 and 30 years of age
89034534|NCT04677179|Experimental|High dose LY3471851|Participants received a subcutaneous injection of high dose LY3471851 every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
89612449|NCT03579615|Experimental|FIASP + closed loop device|Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
89612450|NCT03579615|Active Comparator|Insulin aspart (standard of care insulin) + closed loop device|Subjects randomised to insulin aspart (standard of care insulin) and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using insulin aspart (standard of care insulin) + closed loop intervention for 24 hours.Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
89612451|NCT04367428|Experimental|Probiotics|Patients will receive the previously mentioned combination of probiotics pre- and postoperatively
89612452|NCT04367428|No Intervention|No probiotics|Patients will not receive probiotics
89612453|NCT04367272|Active Comparator|First Knee|The first knee is the knee where the surgery will begin to be applied.
88984391|NCT00433576|Experimental|Treatment (resveratrol, colorectomy)|"STAGE I: Patients undergo an colorectal endoscopy. Patients whose biopsies confirm colorectal adenocarcinoma histology and require surgical resection continue on study stage 2.~STAGE II: Patients receive oral resveratrol on days 1-8. Patients undergo colorectomy on day 9. A tumor biopsy is performed during endoscopy and colorectomy for research purposes."
88984392|NCT00433615|Experimental|1|
88984393|NCT00433615|Experimental|2|
88984394|NCT00433693|Experimental|1|
88984395|NCT00433849|Experimental|1|
88984396|NCT00433849|Experimental|2|
88984397|NCT00098423|Experimental|Treatment (chemotherapy)|"Patients receive induction therapy comprising cytarabine IV continuously on days 1-5 and tanespimycin IV over 1 hour on days 3 and 6.~Patients achieving a morphologic complete response with CRi or partial response may be eligible to receive a second induction course of therapy after day 21 at the discretion of the principal investigator. Patients achieving a CR receive up to 4 courses of consolidation therapy with cytarabine and tanespimycin. Consolidation therapy repeats approximately every 60 days in the absence of disease progression or unacceptable toxicity. Patients who achieve CR and remain in remission for â¥ 6 months may be retreated with cytarabine and tanespimycin (at the current dose level or the MTD) at the time of relapse. Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 months."
88984398|NCT04778085||IMR patients|Patients from outpatient clinics receiving IMR from trained IMR therapists and IMR therapists in training.
88984399|NCT04778085||IMR therapists and other staff|Clinic leaders, IMR therapists and other staff participating in semi-structured individual or group interviews.
88984400|NCT01050790|Experimental|Aza Len Lymphapheresis SCT ALI|Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.
88984401|NCT00433888|Experimental|1|
88984402|NCT00433888|Experimental|2|
88984403|NCT00433927|Active Comparator|Arm A|FOLFIRI plus Cetuximab
88984404|NCT00433927|Active Comparator|Arm B|FOLFIRI plus Bevacizumab
88984405|NCT00131079|Experimental|PEPAF|General Practitioner's assessment of physical activity level and minimal advice in routine clinical practice supplemented by physical activity prescription to those who accepted an additional 15 minutes appointment.
88984406|NCT00131079|Active Comparator|Control|
88984407|NCT04702867||Periodontal bone loss group|The cases with level of alveolar crest more than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
88984408|NCT04702867||Healthy group|The cases with level of alveolar crest equal to or less than 2 mm from the CEJ as measured using CBCT scan on mesial and distal sides of all premolar and molar teeth.
88984409|NCT04702633||Confirmed diagnosis group|Patients with a diagnosis of prostate cancer (metastatic or advanced) before prostatectomy.
89612454|NCT04367272|Experimental|Second Knee|The second knee is the knee where the surgeon will apply secondly.
89612455|NCT04367194|Experimental|BPPV intervention|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
88984410|NCT04702633||Pre-diagnosis group|Patients undergoing prostate biopsy in the context of prostate cancer diagnosis: PSA increases, and / or abnormal digital rectal examination (DRE) and / or an MRI detected signal.
88984411|NCT04762446||SSI group|Participants who developed surgical site infection (SSI) based on the definition of Centre for Disease Control and Prevention.
88984412|NCT04762446||Non-SSI group|Participants who did not develop SSI.
88984413|NCT00098501|Experimental|Arm I|Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.
88984414|NCT04702594|Experimental|UHR and SRH|All patients over the age of 60 present in the UHR and hospitalized in SRH with behavioral disorders in the context of a neurocognitive disorder
88984415|NCT00434005|Experimental|Diesel Exhaust|
88984416|NCT00434005|Sham Comparator|Filtered Air|
88984417|NCT00131547|No Intervention|1|Usual Clinical Care
88984418|NCT00131547|Experimental|2|Behavioral (e.g., Counseling)
89612456|NCT04367194|Experimental|BPPV Epley|Only Epley training.
89612457|NCT04367194|Experimental|BPPV Optocinetic|Only Optocinetic training.
88984419|NCT00098540|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88984420|NCT01050673|Active Comparator|VERSAJET|Excision with VERSAJET™ Hydrosurgery System
88984421|NCT01050673|Active Comparator|Conventional Therapy|Conventional operating room excision will consist of sharp instrumentation and electrocautery techniques, with the use of pulse lavage at the investigator's discretion. The type of sharp instrumentation, together with the brand of pulse lavage will be recorded.
88984422|NCT01050205|Active Comparator|Current Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Current intervention Arm in which case they will receive the intervention immediately."
88984423|NCT01050205|Active Comparator|Delayed Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Delayed Intervention Arm in which case they will receive delayed intervention at 6 months."
88984424|NCT00098579|Experimental|Treatment (chemotherapy)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and alvocidib IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients reaching a cumulative doxorubicin dose of 600 mg/m^2 or experiencing cardiotoxicity may receive alvocidib alone at the discretion of the investigator. Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients receive treatment at the MTD. Patients are followed every 3 months for 1 year.
88984425|NCT00098618|Experimental|Treatment (sorafenib tosylate and recombinant interferon alfa)|Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
88984426|NCT01059448|Experimental|Placebo Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered matching placebo in parent study 20090061 and were administered 210 mg subcutaneous (SC) AMG 827 at Day 1, Week 1, Week 2, and every other week thereafter (Q2WK). Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
88984427|NCT01059448|Experimental|70 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered 70 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2 and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
88984428|NCT01059448|Experimental|140mg AMG 827 Q2WK / 210mg AMG 827 Q2WK|Participants who were administered 140 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2, and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
88984429|NCT01059448|Experimental|210 mg AMG 827 Q2WK / 210 mg AMG 827 Q2WK|Participants who were administered 210 mg AMG 827 in parent study 20090061 and were administered 210 mg SC AMG 827 at Day 1, Week 1, Week 2, and Q2WK thereafter. Participants also continued to receive weekly intramuscular, oral or SC doses of methotrexate and folic acid or folate.
88984430|NCT00098891|Experimental|Treatment (entinostat, isotretinoin)|Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
88984431|NCT01058434|Experimental|TKI258|
88984432|NCT02957617|Experimental|BIIB074|BIIB074 orally twice daily
88984433|NCT04648956||Knee/Hip osteoarthritis|Patients referred for physical therapy rehabilitation
88984434|NCT04702516|Experimental|Semaglutide|Ozempic 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
88984435|NCT04702516|Placebo Comparator|Placebo|Placebo (saline) 1 mg (or highest tolerated dose) s.c. once weekly for 52 weeks (incl. titration)
88984436|NCT04702477|Experimental|Only Arm|This is a single-arm, paired-sample pilot intervention study among participants with pre-diabetes or diabetes. Goal to integrate a MBSR intervention into a group-based, lifestyle intervention among patients with prediabetes or diabetes in the primary care setting
88984437|NCT00099008|Experimental|Arm I|Genistein
88984438|NCT00099008|Placebo Comparator|Arm II|Placebo
89612458|NCT03778515||Cases - Ankylosing Spondylitis Cohort|20 patients with ankylosing spondylitis (AS). Fifteen of these patients will be recruited from the Ankylosing Spondylitis clinic at the University of California, San Francisco. Five patients will be recruited from the Rheumatology clinic at the Cleveland Clinic. Observational with MRI.
88984439|NCT00434239|Experimental|Treatment: Lenalidomide and Ancestim|Drug: Lenalidomide + Ancestim Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
88984440|NCT01057147|Experimental|rebamipide 2% ophthalmic suspension|
88984441|NCT01057147|Placebo Comparator|placebo eye drops|
88984442|NCT01054807|Other|GalyfilconHL/Galyfilcon8.7/Galyfilcon8.3|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)
88984443|NCT01054807|Other|Galyfilcon8.7/Galyfilcon8.3/GalyfilconHL|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
88984444|NCT01054807|Other|GalyfilconHL/Galyfilcon8.3/Galyfilcon8.7|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)
88984445|NCT01054807|Other|Galyfilcon 8.7/Galyfilcon HL/Galyfilcon 8.3|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator) /Galyfilcon A 8.3 BC (Experimental)
88984446|NCT01054807|Other|Galyfilcon8.3/GalyfilconHL/Galyfilcon8.7|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)
89034535|NCT04677179|Experimental|Low dose LY3471851|Participants received a subcutaneous injection of low dose LY3471851 every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
89034536|NCT04677179|Placebo Comparator|Placebo|Participants received a subcutaneous injection of placebo every 2 weeks from weeks 0 to 12. Week 12 responders entered the maintenance period and continued with the same treatment. Week 12 non-responders entered the extension period where they received subcutaneous injection of high dose LY3471851 every 2 weeks up to week 50. At week 26, extension period non-responders were discontinued from treatment. Post-treatment, participants entered follow-up period and were observed for 6 weeks for safety.
89034537|NCT04675827|Experimental|RCB = 0|"Treatment administration: adjuvant pertuzumab + trastuzumab (P+T) fixed dose combination (FDC) SC for 14 cycles.~Sub-study: 121 of the subjects who achieved a pCR (thus assigned to continue treatment with P+T FDC SC) will be randomised at a 1:1 ratio to receive 3 cycles of P+T FDC SC in the hospital, followed by 3 cycles in another setting outside the hospital, or to the same treatment starting with 3 cycles outside the hospital followed by 3 cycles in the hospital (treatment cross-over period). After the first 6 cycles of adjuvant treatment, subjects will be asked to choose between continuing treatment (for the remaining 8 cycles, for a total of 14 cycles) within or outside the hospital, according to their preference (treatment continuation period). Subjects can request to change from outside the hospital to in the hospital administration (and vice-versa) at any moment during the treatment continuation period, but not in the treatment cross-over period."
89034538|NCT04675827|Experimental|RCB > 0|Treatment administration:adjuvant T-DM1 for 14 cycles. In subjects whose residual invasive disease is classified per Residual Cancer Burden (RCB) score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the 14 cycles of T-DM1.
89034539|NCT04675034|Experimental|Cohort 1|Dose A: MEDI7352 Q2W
89034540|NCT04675034|Experimental|Cohort 2|Dose B: MEDI7352 Q2W
89034541|NCT04675034|Experimental|Cohort 3|Dose C: MEDI7352 Q2W
89034542|NCT04675034|Experimental|Cohort 4|Dose D: MEDI7352 Q2W
89034543|NCT04675034|Placebo Comparator|Cohort 5:|Placebo to match MEDI7352 Q2W
89034544|NCT04658641|Active Comparator|Standard clinical pulse shape|Standard clinical pulse shape as used in clinical practice (cathodic stimulation).
89034545|NCT04658641|Experimental|Complex pulse shape|Complex pulse shape (i.e. biphasic pulse shape anode first, biphasic pulse shape cathode first, hyperpolarizing pre-pulse or depolarizing pre-pulse).
89034546|NCT04651816|Active Comparator|Control PSH DPP only|This group will be enrolled the PSH DPP program. There will be two cohorts for this arm.
89034547|NCT04651816|Experimental|Treatment 1 Financial Incentives A|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
89034548|NCT04651816|Experimental|Treatment 2 Financial Incentives B|This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.
89034549|NCT04651816|Experimental|Treatment 3 Motivational Text Messaging|This group will receive text messages with motivational messages while participating in the PSH DPP program. There will be two cohorts for this arm.
89034550|NCT04639141|Active Comparator|Synbiotic|"Dosing: one sachet/dose per day for 12 weeks. The combination includes: Lactobacillus rhamnosus (1x10^10 CFU/dose), Lactobacillus plantarum (4 x 10^9 CFU/dose), Bifidobacterium animalis subsp. lactis (5 x 10^9 CFU/dose), Bifidobacterium longum (1 x 10^9 CFU/dose) + 4g/dose of partially hydrolysed guar gum (PHGG).~Mode of administration: oral."
89034551|NCT04639141|Experimental|Synbiotic + gut-directed hypnotherapy|"Includes the daily oral synbiotic (as pervious described) + a home-based therapy program.~Home-based therapy program: based on the Manchester model of gut-directed hypnotherapy (GDH) adapted for use in children with ASD. The GDH core therapy focus areas will be relaxation, control of gut function and ego-strengthening.~Schedule: daily use of a home-based audio recordings. The program will consist of six (6) therapy sessions/recordings over 12 weeks. Each recording (sessions 1 through 6) is to be used daily for a fortnight. Each session is approximately 15-20 minutes in duration."
89034552|NCT04636814|Experimental|CHF6001 1600µg|
89612459|NCT03778515||Controls - w/o Ankylosing Spondylitis|5 patients without AS and with no history of any arthritis or lower back pain in this study. These 5 patients will make up the control group of the study, which means that they will provide a benchmark of comparison for the results investigators obtain from the active AS group. 2 of these 5 patients will be recruited from Cleveland Clinic, and 3 will be recruited from UCSF. Observational with MRI
89612460|NCT04355416|Experimental|curcumin oral gel|
89612461|NCT04355416|Other|subgingival scaling and root planing|
89612462|NCT02982460|Experimental|Isoinertial + eccentric exercise|The isoinertial training will be based on 4 sets of 8 maximal repetitions using a YoYo-Squat (YoYo Technology AB, Stockholm, Sweden). This exercise device use the inertia of a spinning flywheel (moment inertia = 0.11 kg m-2), offering resistance during coupled concentric and eccentric actions, and allows for high demanding to rotator cuff exercises while offering the possibility to perform with an eccentric overload.Two initial repetitions in any set were aimed at accelerating the flywheel, before executing the subsequent 8 actions at maximal effort. Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder.
89034553|NCT04636814|Experimental|CHF6001 3200µg|
89612463|NCT02982460|Active Comparator|Eccentric exercise|Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
89034554|NCT04636814|Placebo Comparator|Placebo|
89034555|NCT04636814|Active Comparator|Roflumilast|
89034556|NCT04634279|Experimental|Collaborative Care Plus|Intervention is administered to patients in this arm. Care to be delivered via collaborative care. The supplement intervention adds family involvement in care and Caring Contacts, a suicide prevention method.
89034557|NCT04634279|No Intervention|Control|Patients in this arm will receive enhanced usual care.
88984447|NCT01054807|Other|Galyfilcon8.3/Galyfilcon8.7/GalyfilconHL|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
88984448|NCT00099125|Experimental|RT with chemotherapy + post-radiation chemotherapy|Radiation therapy (RT) with concurrent chemotherapy + post-radiation chemotherapy
88984449|NCT01052194|Experimental|25 mg b.i.d. VX-509|
88984450|NCT01052194|Experimental|50 mg b.i.d. VX-509|
88984451|NCT01052194|Experimental|100 mg b.i.d. VX-509|
88984452|NCT01052194|Experimental|150 mg b.i.d. VX-509|
88984453|NCT01052194|Placebo Comparator|Placebo|
88984454|NCT01051414|Experimental|BMS-790052 + BMS-650032|
88984455|NCT00434317|Experimental|ZOL446|
88984456|NCT04621149|Placebo Comparator|placebo|1 liter of filtered water
88984457|NCT04621149|Active Comparator|chlorine dioxide aqueous solution (AS)|1 liter of filtered water with AS
88984458|NCT04621149|Active Comparator|placebo with zinc acetate (ZA)|1 liter of filtered water with ZA
88984459|NCT04621149|Active Comparator|AS with ZA|1 liter of filtered water with AS and ZA
88984460|NCT04621149|Active Comparator|placebo with famotidine, lactoferrin and green tea extract (FLG)|1 liter of filtered water with FLG
88984461|NCT04621149|Active Comparator|AS with FLG|1 liter of filtered water with AS and FLG
88984462|NCT04621149|Active Comparator|placebo with ZA and FLG|1 liter of filtered water with ZA and FLG
88984463|NCT04621149|Active Comparator|AS with ZA and FLG|1 liter of filtered water with AS, ZA, and FLG
88984464|NCT00099203|Experimental|1|
88984465|NCT00099203|Active Comparator|2|
88984466|NCT04728542||Origine|Group of 70 subjects who will undergo a surgery with the ORIGIN PS System
89612464|NCT03777735||human bone graft screw|The patients will receive human bone graft screws surgically.
88984467|NCT04728542||Vanguard|Group of 70 subjects who will undergo a surgery with the VANGUARD System
88984468|NCT00099320|Experimental|Exenatide|After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
88984469|NCT00099320|Placebo Comparator|Placebo|After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.
88984470|NCT04561596|Experimental|Autohypnosis|Use of virtual reality with head mounted display
88984471|NCT04561596|Other|Control|Treatment as usual
88984472|NCT00403650|Experimental|1|
88984473|NCT00403689|Experimental|x|capsules containing beta glycan
88984474|NCT00403689|Placebo Comparator|y|capsules containing placebo (waxy maize starch)
88984475|NCT00099515|Experimental|A|
88984476|NCT00099515|Experimental|B|
88984477|NCT00403806|Active Comparator|1|Intravenous dexamethasone 0.05 mg per kg bodyweight
89612465|NCT04355260|Experimental|Hypertrophic Obstructive Cardiomyopathy|
88984478|NCT00403806|Active Comparator|2|Intravenous dexamethasone 0.15 mg per kg bodyweight
88984479|NCT00403806|Active Comparator|3|Intravenous dexamethasone 0.5 mg per kg bodyweight
88984480|NCT00403806|Placebo Comparator|4|Intravenous saline
88984481|NCT00400595|Experimental|1|Polysporin tRIPLE ointment (topical ointment in widespread use for other skin lesions)
88984482|NCT00400595|Active Comparator|2|Mupirocin
88984483|NCT04464915|Experimental|Isopropyl alcohol swab every 10 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes for a total of one hour.
88984484|NCT04464915|Experimental|Isopropyl alcohol swab every 20 minutes|One deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 20 minutes for a total of one hour.
88984485|NCT04464915|No Intervention|No treatment arm|No intervention administered.
88984486|NCT00400673|Other|Chemotherapy|Risk-oriented chemotherapy for remission induction (application of sequential high-dose cytarabine course to patients unresponsive to standard chemotherapy course 1) and postremission consiolidation(standard risk: blood stem cell supported high-dose cytarabine course [x3]; high risk: allogeneic SCT)
88984487|NCT04728698|Experimental|COVI-MSC|Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)
88984488|NCT04728698|Placebo Comparator|Placebo|Excipient
88984489|NCT00099788|Experimental|1|Ranolazine
88984490|NCT00099788|Placebo Comparator|2|Placebo
88984491|NCT02958449|Experimental|Test - Standard Closure with TissuGlu Surgical Adhesive|Standard closure plus treatment with TissuGlu
88984492|NCT02958449|No Intervention|Control - Standard Closure|Standard closure with no intervention
88984493|NCT00099866|Experimental|Vildagliptin|
88984494|NCT00099866|Active Comparator|Metformin|
88984495|NCT00099944|Experimental|LAF237 50 mg qd + glimepiride 4 mg qd|LAF237 50 mg qd + glimepiride 4 mg qd
88984496|NCT00099944|Experimental|LAF237 50 mg bid + glimepiride 4 mg qd|LAF237 50 mg bid + glimepiride 4 mg qd
88984497|NCT00099944|Placebo Comparator|LAF237 placebo + glimepiride 4 mg qd|LAF237 placebo + glimepiride 4 mg qd
88984498|NCT00100061|Active Comparator|Cranberry Juice|Cranberry Juice provided by Ocean Spray
88984499|NCT00100061|Placebo Comparator|Placebo cranberry juice|Taken orally
88984500|NCT04333914|Experimental|Autophagy inhibitor (GNS651)|
88984501|NCT04333914|Other|Standard of care|
88984502|NCT04333914|Experimental|anti-NKG2A (Monalizumab)|
88984503|NCT04333914|Experimental|anti-C5aR (Avdoralimab)|
88984504|NCT00132249||Head Injured|The Vietnam Head Injured Subjects
88984505|NCT00132249||Head Uninjured|Uninjured Vietnam Veteran Control Subjects
88984506|NCT04307433|Experimental|Arm 1|ST Narrative + mHealth: Storytelling narrative video on tablets
88984507|NCT04307433|Active Comparator|Arm 2|mHealth: a video with a voice over presenting didactic materials on tablets
88984508|NCT04307433|Placebo Comparator|Arm 3|Control: non-narrative educational materials will be read
88984509|NCT00100295|Experimental|A|Herbal treatment
88984510|NCT00100295|Placebo Comparator|B|
89612466|NCT04347304|Experimental|cocoa polyphenols|21 grams of dark chocolate (289 mg polyphenols)
89612467|NCT04347304|Placebo Comparator|polyphenols free|21 grams of white chocolate (0 mg polyphenols)
89034558|NCT04623944|Experimental|NKX101 - CAR NK cell therapy|"All subjects in Part 1 will receive lymphodepletion with fludarabine/cyclophosphamide followed by 3 or 2 (Regimen A or B, respectively) weekly doses of NKX101.~Subjects in Part 2 will receive lymphodepletion with either fludarabine/cyclophosphamide or fludarabine/cytarabine (ara-C), or if the optional arm is opened, lymphodepletion with fludarabine/cyclophosphamide and decitabine, followed by 3 weekly doses of NKX101.~Part 2: unrelated off-the-shelf donor derived NKX101 will be used."
89612468|NCT00928720|Active Comparator|CES device|Participants will use the device for 60 minutes each day for 8 weeks.
89612469|NCT00928720|Sham Comparator|Sham device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
89034561|NCT04590937|Experimental|Cocktail/ Cocktail + BI 730357|Cocktail treatment will be followed by the Test treatment in a fixed sequence. The treatment periods are separated by a wash-out phase of at least 14 days between the two cocktail administrations.
89034562|NCT04581928||COVID-19|Highly educated people Low educated people
89034563|NCT04576897|Experimental|Velacur by Sonic Incytes|Patients with compensated advanced chronic liver disease (cACLD) who have not undergone liver transplantation will be scanned with Velacur.
89034564|NCT04571749|Experimental|Customized Or to ICU handoff protocol|Tailored implementation strategies will be used in 12 ICUs to facilitate the uptake and sustained use of a customized handoff protocol to be used by clinicians at the time of patient care transition from the operating room to the intensive care unit.
89034565|NCT04563923|Experimental|Drug|"Patients in this group will additionally receive 3 s.c. injections of avdoralimab every week during 12 weeks~They receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
89034566|NCT04563923|Other|Conventional therapy|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~Patients of less than 45kg of body weight: 2 tubes of 10g/d~Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesions"
89034567|NCT04562558|Experimental|Arm1-Methotrexate|Patients receive methotrexate intramuscularly（50mg） on Days 1, 3, 5, 7 (4 doses per cycle) with Leucovorin (15mg) on Days 2, 4, 6, 8. Repeat every 14 days. Patients continue on treatment until beta HCG titer is below the institutional normal. Patients then receive 2-3 additional consolidation treatment. If the level of hCG become stationary for at least 2 course of single-agent chemotherapy or rise again, the patient will be referred to multi-course chemotherapy. FAV regimen is preferred, or EMA-CO regimen can also be selected if FAV is unavailable.
89034568|NCT04562558|Experimental|Arm 2-Dactinomycin|Patients will receive IV pulse actinomycin-D (1.25mg/m2，2mg max dos) every 14 days. Patients continue on treatment until beta HCG titer is below the institutional normal. Patients then receive 2-3 additional consolidation treatment.If the level of hCG become stationary for at least 2 course of single-agent chemotherapy or rise again, the patient will be referred to multi-course chemotherapy. FAV regimen is preferred, or EMA-CO regimen can also be selected if FAV is unavailable.
89034569|NCT04560673|Experimental|Group I (neurofeedback training, duloxetine)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks. Patients also receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
89612470|NCT00928720|No Intervention|Usual care alone|No intervention; participants will receive usual medical care
89612471|NCT03776877||Arterial Ischemic Stroke (AIS)|"All patients (prospective and retrospective) included will have to present an Arterial Ischemic Stroke (AIS) from a large cerebral vessel occlusion.~The participation in the study will consist in:~Plasmatic collection at the time of AIS, for study of plasma biomarkers~Additional standardized blinded clinical evaluation at three months after the thrombectomy realized during a phone call, particularly via an assessment of the modified Rankin score."
89612472|NCT00934024|Other|Abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was abstinent after 5 weeks of varenicline treatment.."
89612473|NCT00934024|Other|Non-abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was participants who continued to smoke after 5 weeks of varenicline treatment."
89612474|NCT04360954||Acute COVID infection|Active infection with positive RT-PCR
89612475|NCT04360954||Convalescent COVID|Recent documented infection. Now asymptomatic and RT-PCR negative.
89034570|NCT04560673|Experimental|Group II (neurofeedback training)|Patients receive neurofeedback training over 1 hour 3-5 times weekly for up to 5 weeks.
89612476|NCT04360954||US Controls|Human samples pre-COVID.
89612477|NCT04360954||LMIC Controls|Samples from LMIC pre-COVID.
89034571|NCT04560673|Experimental|Group III (duloxetine)|Patients receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
89034572|NCT04558203||Confirmed COVID19|Confirmed COVID19
89034573|NCT04558203||Not COVID19|Not COVID19
89034574|NCT04545723|No Intervention|Control group|In every cluster designated as a control group, patients aged 65 or older will be selected according to the inclusion criteria. The difference here is that patients will be given the standard opportunistic screening instead: pulse palpation and a 12-lead ECG when an irregular rhythm is found. This is current best practice.
89034575|NCT04545723|Active Comparator|Intervention group|In every cluster designated as an intervention group, patients aged 65 or older will be selected according to the inclusion criteria. Within this group, high-risk patients will be identified using the CHARGE-AF score, and will be prescribed the FibriCheck® app.
89612478|NCT04361032|Experimental|Tocilizumab|ROACTEMRA: (8mg/ kg per day) (1 injection per infusion)
89612479|NCT04361032|Active Comparator|Deferoxamine|DESFERAL: 500 mg, powder, and solvent for IV solution
89612480|NCT04747119|Experimental|study group|received the conventional selected exercise program in addition to muscle energy technique
89034576|NCT04542356|Experimental|experimental group|patients used 6 mg PEG-rhG-CSF prophylactically after chemotherapy
89034577|NCT04542356|Placebo Comparator|control group|patients did not use PEG-rhG-CSF for prevention and were given 5 ug/kg rhG-CSF when ANC<1✕109/L
89034578|NCT04530409|Experimental|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
89034579|NCT04530409|No Intervention|Late CS|Dexamethasone is to be used lately upon the deterioration of cases i.e. sPO2 < 92%
89034580|NCT04528329|Experimental|Early CS|early use of dexamethasone as early as the laboratory confirmation of inflammation.
89034581|NCT04528329|Active Comparator|Late CS|Dexamethasone is to be used lately upon the deterioration of cases
89034582|NCT04527406|Experimental|Early surgical group|The subjects in this group received early surgical treatment, and they are arranged to be admitted to the hospital for surgical treatment after admission. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction.
89034583|NCT04527406|Active Comparator|Traditional surgical treatment|This group of subjects received conservative treatment with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5.
89034584|NCT04526288|Active Comparator|Arm A (alloHCT)|Patients undergo alloHCT.
89034585|NCT04526288|Experimental|Arm B (CPX-351, alloHCT)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment may repeat for an additional cycle for a total of 2 cycles (on days 1 and 3 only of cycle 2) in the absence of disease progression or unacceptable toxicity. Within 60 days after completion of CPX-351, patients undergo alloHCT.
89034586|NCT04524572|Experimental|Individual Challenge|Participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their daily step counts and physical activity expenditure
89034587|NCT04524572|Experimental|friend challenge|Participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their daily step counts and physical activity expenditure in comparison to the group average of all participants randomized to the friend challenge.
89612481|NCT04747119|Experimental|control group|received the conventional selected exercise program
89612482|NCT04360798|Experimental|Unilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will only be applied to the affected lower extremities of the participants.
89612483|NCT04360798|Experimental|Bilateral Exercise Group|The group to which exercise protocol consisting of strengthening, stretching, range of motion, static and dynamic postural control exercises will be applied to the both lower extremities of the participants.
89612484|NCT03552003||Newly diagnosed elderly cHL patients|Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study
89034588|NCT04524572|Experimental|Team challenge|participants will be able to log onto their Tractivity® Online web account at any time during the 4-week intervention phase to track their teams' daily step counts and physical activity expenditure in comparison to the group average of other teams.
89034589|NCT04505371|No Intervention|Control - Standard Care|The control intervention is referral to standard evidence-based cessation services available nationally to Veterans, including the National VA Quitline and SmokefreeVET texting program.
89034590|NCT04505371|Experimental|Intervention - Wellness Intervention for Smokers with HIV|The experimental WISH intervention is an HIV-specific comprehensive wellness program designed to offer integrated phone and text counseling regardless of readiness to quit.
89034591|NCT04505163|Active Comparator|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Standard cryoballoon pulmonary vein isolation alone using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
89034592|NCT04505163|Experimental|Cryoballoon PVI + Posterior Wall Isolation|Cryoballoon pulmonary vein isolation in conjunction with posterior wall isolation using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters
89034593|NCT04505020|Experimental|3D Print + Conventional imaging|Patients in this group allocation will receive a 3D reconstruction of their hip in addition to conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
89034594|NCT04505020|Other|Conventional Imaging|Patients in this group allocation will receive conventional preoperative imaging (X-ray, CT, and MRI) only for the use of pre-operative and intra-operative planning for their hip arthroscopy (FAI) procedure.
89034595|NCT04495608|Experimental|fluconazole|Fluconazole 50mg capsule (1, 2, 3 or 4 pills to take daily during 18 weeks, corresponding respectively to 50, 100, 150 or 200 mg of fluconazole).
89034596|NCT04495608|Placebo Comparator|placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
89034597|NCT04493892|Experimental|Educational Intervention|All participants receive educational information on the potential health risk of endocrine disruptor chemicals in hair care products, specifically phthalates. Provide information on how to reduce exposure.
89034598|NCT04478838|Experimental|Extended Dosing Group|Participants taking olanzapine or risperidone will be switched to an alternate day dosing schedule.
89034599|NCT04478838|No Intervention|Treatment as Usual group|Participants will continue to take their olanzapine or risperidone following the same prescribed daily schedule.
89034600|NCT04460638||Covid+ hospitalization group|Patients hospitalized with SARS-CoV2 infection
89034601|NCT04460638||Covid+ outpatient group|Patients or caregivers followed on an outpatient basis for an SARS-CoV2 infection
89034602|NCT04460638||Covid- group|Caregivers not infected with an SARS-CoV2
89034603|NCT04460638||Non-SARS pathology group|Individuals not infected with SARS-CoV2 but with another acute and/or infectious non-SARS pathology
89057295|NCT04543448|Other|Traditional Rehabilitation|Traditional Rehabilitation program was included strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs in all individuals. Indıvıduals participated in 2 training sessions per week for 4 weeks. Each training session consisted of a 5-minute non-balance coordination exercise, a 30-minute balance and coordination exercise, a 10-minute stretching and strengthing.
89612485|NCT00928954|Active Comparator|Gabapentin|Increasing dose to 300 mg four times per day (total of 1200 mg/day)
89034604|NCT04450628|No Intervention|Surgeon blinded|"During blinded cases no adjustment will be made to the surgical procedure based on EndoFLIP results, as the operating surgeon will not be informed of the measured values.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
89034605|NCT04450628|Experimental|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
89034606|NCT04446416|Experimental|Bevacizumab plus NaviFUS System|"Device: NaviFUS System BBB Disruption by FUS in recurrent GBM Microbubbles (MB) (SonoVue®) 0.1 mL/kg and optimal ultrasound exposure doses (based on the acoustic emission feedback FUS power control algorithm) generated from the NaviFUS System every 2 weeks to transiently open the BBB.~Drug: Bevacizumab 10 mg/kg every 2 weeks for up to 36 weeks or until evidence of progressive disease, unacceptable toxicity, non-compliance with study follow-up, or withdrawal of consent."
89034607|NCT04440930|Experimental|White tea|
89034608|NCT04440930|Active Comparator|Salt water with soda|
89034609|NCT04435496|Other|GYN-CS insertion|GYN-CS device will be inserted in women during their c-section. The study patient can chose between a lifespan of 3 years (GYN-CS 3) and a lifespan of 10 years (GYN-CS 10) of the device.
89034610|NCT04421378|Experimental|Phase 1: Arm A: Selinexor+Radiation Therapy|Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2 and subsequently will continue at 80 mg QW until progressive disease (PD) during adjuvant therapy period.
89034611|NCT04421378|Active Comparator|Arm A Control: Temozolomide+Radiation Therapy|Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m^2) of temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 cycles during adjuvant therapy period.
89034612|NCT04421378|Experimental|Phase 1: Arm B: Selinexor+Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, 2b and 3a and 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 60 mg (dose level 2a) or 80 mg (dose level 2b and 3a) of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2, followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycle 4 to 8 during adjuvant therapy period. Participants will continue selinexor weekly per dose level assigned until PD.
89034613|NCT04421378|Active Comparator|Arm B Control: Temozolomide+Radiation Therapy|Participants with nGBM mMGMT will receive 75 mg/m^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m^2 (started from Cycle 3) and increase to 200 mg/m^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 during adjuvant therapy period.
89034614|NCT04421378|Experimental|Arm C: Selinexor+Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m^2 of lomustine or 150-200 mg/m^2 of carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.
89034615|NCT04421378|Active Comparator|Arm C Control: Lomustine/Carmustine|Participants with rGBM uMGMT or mMGMT will receive 110 mg/m^2 of lomustine or 200 mg/m^2 of Carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle in a 42-day cycle for all cycles.
89612486|NCT00928954|Active Comparator|Memantine|Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).
89612487|NCT04355026|Experimental|hydroxychloroquine and bromhexine|Bromhexine 16 mg TID + hydroxychloroquine 200 mg BID
89612488|NCT04355026|Active Comparator|hydroxychloroquine alone|hydroxychloroquine 200 mg BID
89612489|NCT04762485|Experimental|CD38 positive relapsed or refractory acute leukemia|Biological/Vaccine: Humanized CD7 CAR-T cells Split intravenous infusion of CD7 CAR-T cells [dose escalating infusion of (0.5- 10)x10^6 CD7 CAR-T cells/kg
89612490|NCT04347070||Patients accepted in ICU diagnosed with COVID-19|Patients accepted in ICU diagnosed with COVID-19
89612491|NCT04762173|Experimental|Online self-help intervention|Participants are provided access to two online self-help programs provided by SilverCloud Health. One program is designed to support general stress resilience using principles and techniques from positive psychology and cognitive-behavioral therapy. The other program is designed to support coping with pandemic-related stressors using psychoeducation and cognitive-behavioral therapy and grief therapy principles. Participants have access to both programs and can proceed through them in the order and pace of their choosing. The online self-help intervention is fully self-guided.
89612492|NCT04762173|No Intervention|Care as usual|Participants are provided information about how to contact the counseling center at their college and/or in the local community using the phone number and website of their counseling center (if available), as well as the Substance Abuse and Mental Health Services Administration treatment locator.
89034616|NCT04421378|Experimental|Arm D: Selinexor+Bevacizumab|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and 10 mg/kg of Bevacizumab intravenous (IV) infusion every 2 weeks (Q2W) in 28-day cycle for all cycles.
89034617|NCT04421378|Experimental|Arm E: Selinexor+TTField|Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and will receive scalp application of 200 kilohertz (kHz) of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
89034618|NCT04419077|Other|Virtual reality exposure|Virtual reality exposure just before an oncological procedure (invasive act or a chemotherapy)
89034619|NCT04409600|Active Comparator|Home Based Gait Retraining + Saline Injection|
89034620|NCT04409600|Experimental|Home Based Gait Retraining + Botulinum Toxin Injection|
89034621|NCT04409600|Active Comparator|Supervised Gait Retraining + Saline Injection|
89034622|NCT04409600|Experimental|Supervised Gait Retraining + Botulinum Toxin Injection|
89034623|NCT04384198|Experimental|Sonolysis group|Cerebral hemisphere with sonolysis during MitraClip implantation.
89034624|NCT04384198|No Intervention|Control group|Cerebral hemisphere without sonolysis during MitraClip implantation.
89034625|NCT04373512|Experimental|Low Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermitent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
89612493|NCT04762329|Experimental|Patient group using Manage My Pain (MMP) digital application for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits, on the Manage My Pain (MMP) digital application
89612494|NCT04762329|No Intervention|Patient group using paper format for pain data|Participants completed pain related questionnaires on the following pain related outcomes - anxiety, depression, catastrophizing, disability, patient impression of change, and daily opioid consumption at baseline on initial visit and as a part of the first follow-up clinical visits on paper format or phone interviews.
89612495|NCT04367038|Experimental|Warm Acupressure Procedure Group|"Latent phase Visual Analog Scale and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first warm acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second warm acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
89612496|NCT04367038|Experimental|Cold Acupressure Procedure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase The first cold acupressure procedure was performed for ten minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated three more times at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second cold acupressure procedure was performed three times at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
89612497|NCT04367038|Experimental|Conventional Acupressure Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous blood sample taken Active phase Conventional acupressure was performed for 30 minutes on the Large Intestinal 4 energy meridian zone acupressure point on the non-dominant hand. This process was repeated twice more at one-hour intervals.~Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase The second conventional acupressure procedure was performed twice at one-hour intervals A 30-minute break was given Visual Analog Scale III and Verbal Category Scale III were performed Second venous blood sample taken"
89612498|NCT04367038|No Intervention|Control Group|"Latent phase Visual Analog Scale I and Verbal Category Scale I given as pretest First venous sample taken Active phase~No procedure other than the routine clinical practices were carried out. Visual Analog Scale II and Verbal Category Scale II were measured at the end of the active phase Transition phase No procedure other than the normal clinical routines was conducted Visual Analog Scale III and Verbal Category Scale III were performed. Second venous blood sample taken"
89034626|NCT04373512|Experimental|High Dosage Group|"For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion."
89034627|NCT04342806||HCWs currently working in the US, and their families and communities|"The HERO Registry will include HCWs currently working across the United States, and their families and communities. For the purposes of this study, a healthcare worker is defined as an individual who currently works in a setting where individuals receive healthcare. (Note: individuals do not have to work directly with patients, but may have any role within a setting where individuals receive healthcare, such as housekeeping, food service, etc.)"
89034628|NCT04324892||Treat to target|The study has only 1 cohort with treat-to-target strategy
89612499|NCT04360642|Other|singing arm|"Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities: Newton Abbott and Torquay.~Lung function, frailty and health-related quality of life will be assessed by Spirometry, CRQ (chronic respiratory questionnaire), MRC breathlessness scale, Rockwood frailty and Warwick-Edinburgh Mental Well-being Scale (WEMWBS). Participants will be assessed at baseline and then again at completion of the 12-week course.~Written feedback from participants to capture qualitative experience using narrative and Patient Reported Outcome Measures (PROMs). The attrition and attendance rate will also be recorded for later review."
89612500|NCT04403451|Experimental|Phase 1/Cohort 1|True North Love Notes, Financial Stability, Jobs
89612501|NCT04403451|Experimental|Phase 2/Cohort 2|True North Love Notes, Financial Stability, Jobs
89612502|NCT04403451|Experimental|Phase 3/Cohort 3|True North Love Notes, Financial Stability, Jobs
89612503|NCT04360408|Experimental|Intervention|Participant of the cluster randomised to the intervention group will receive both the usual care from their healthcare providers and EVEREST delivered by the researcher who is a nurse.
89612504|NCT04360408|No Intervention|Control|Participants of the cluster randomised to the control group will receive usual care (standard care with no formalised, structured or tailored interventional to reduce symptom/s) from their healthcare providers
89612505|NCT03548571|Experimental|DC immunization|Leukapheresis before start of radiotherapy. Immunization with DCs starting first week after finalizing radiotherapy (2Gy x 30) and concomitant temozolomide.
89612506|NCT03548571|Active Comparator|Standard therapy|Radiotherapy (2 Gy x30) with concomitant and adjuvant temozolomide.
89612507|NCT00939562|Experimental|doxycycline monohydrate tablet|
89612508|NCT00939562|Active Comparator|doxycycline carragenate tablet|
89612509|NCT04355104|Experimental|Education+standard physical therapy|Consist of 37 patients will take education sessions in addition to standard physical therapy.
89612510|NCT04355104|Active Comparator|Standard physical therapy|Consist of 37 patients take just standard physical therapy.
89612511|NCT04359940||Repaired Tetralogy of Fallot|Patients undergoing routine clinical aand CMR surveillance
89612512|NCT04359862|Experimental|SEVOFLURANE Group|
89612513|NCT04359862|Active Comparator|PROPOFOL Group|
89612514|NCT04354948|Experimental|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 3 min wall squat exercise
89612515|NCT04354948|Placebo Comparator|No pain (Hypotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 3 min wall squat exercise
89612516|NCT03540927|Experimental|PM+ for entrepreneurs|The intervention arm participants will receive a cash transfer to support them in their businesses PLUS 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 discusses problem solving technique.Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
89612517|NCT03540927|Active Comparator|Control|The control arm will receive a cash transfer only to support them in their businesses.
89612518|NCT04354714|Experimental|Ruxolitinib|-Ruxolitinib is an oral medication that will be given twice daily (BID). Dosing on Days 1 through 3 will be 5 mg BID; dosing on Days 4 through 10 will be 10 mg BID.
89612519|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin o.d.|Effects of 40 mg subcutaneous enoxaparin o.d.
88984511|NCT04244058|Active Comparator|NMDA blocker|Comprehensive functional analyses of dynamic [18F]FPEB-PET signal at rest will be carried out in normal volunteers and patients with DOC due to severe brain injury over a 24-month time period. In each study, we will first evaluate mGluR5 occupancy within the frontal cortex, anterior cingulate cortex, insula, striatum and thalamus. Then, a single dose of amantadine (AMT), a compound that blocks NMDA-R and increases glutamate levels at the synaptic cleft, will be given to each subject or patient and at the time corresponding to the peak of the dose, a second [18F]FPEB-PET will be acquired.
88984512|NCT04244058|Experimental|NMDA blocker + L-DOPA|All the patients with DOC that participate in ARM 1 will follow the same methodology of ARM 1: measurement of mGluR5 occupancy at rest and following NMDA-R blockade with AMT by means of [18F]FPEB-PET after premedication with L-DOPA introduced 1 hour prior each [18F]FPEB-PET acquisitions.
88984513|NCT00132444|Active Comparator|1|0.25% gel
88984514|NCT00132444|Active Comparator|2|0.1% gel
88984515|NCT00132444|Placebo Comparator|3|
88984516|NCT00132483|Experimental|Intervention arm|
88984517|NCT00132483|No Intervention|Control|
88984518|NCT00132522|Experimental|Arm 1|
88984519|NCT00100568|Experimental|1|All participants will be given an ARV regimen of lamivudine/zidovudine and efavirenz at study entry. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens.
88984520|NCT04181853|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
88984521|NCT04181853|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
89034629|NCT04322305|Experimental|Pregabalin|Treatment with pregabalin administered in 75 mg and 100 capsules in dosages up to 600 mg per day for up to 8 weeks (including a 3 week titration run up) followed by a one week taper.
89612520|NCT04366960|Active Comparator|40 mg subcutaneous enoxaparin b.i.d|Effects of 40 mg subcutaneous enoxaparin b.i.d
89612521|NCT03539445|Experimental|Butylphthalide|Drug: Butylphthalide Sodium Chloride Injection and Butylphthalide Soft Capsules
89612522|NCT03539445|Placebo Comparator|Placebos|Drug: Butylphthalide Placebo Injection and Butylphthalide Placebo Soft Capsules
89612523|NCT04360876|Experimental|Dexamethasone|Patients assigned to the dexamethasone arm will receive an intravenous dose of 20 mg once daily from day 1 to day 5 which will be reduced to 10mg once daily from day 6 to day 10. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The time from randomization to time for first medication administration will be 4 hours or less. All infusions - dexamethasone and placebo - will be manufactured by the investigational pharmacy at the University of Colorado.
89612524|NCT04360876|Placebo Comparator|Placebo|Participants randomized to the control group will received placebo intravenously for 10 days, one dose per day. Intravenous infusion bags divided into 10 doses will be provided at randomization by the investigational pharmacy. The placebo infusion bags will be as similar as possible to the dexamethasone infusion bags to ensure blinding.
89612525|NCT04359628||BOA|Patients with osteoarthritis registered in the Better BOA register
89612526|NCT04359628||Swedankle|Patients who underwent ankle replacement, fusion or osteotomies and registered in the Swedish ankle registry
89612527|NCT04359628||xBase|Patients with cruciate ligament injuries who received surgical treatment and were registered in the Anterior Cruciate Ligament Register
89612528|NCT04359628||SFR|Patients who received treatment in the Swedish Fracture Register
89612529|NCT04359628||SHAR|Patients who underwent hip replacement therapy and registered in the Swedish Hip Arthroplasty Register
89612530|NCT04359628||SKAR|Patients with knee osteoarthritis and other diagnoses who underwent knee replacement or osteotomies and were registered in the Swedish Knee Arthroplasty Register
89612531|NCT04359628||Bipolär|Patients with Bipolar disorder receiving treatment and were registered in the Swedish National Register for Bipolar Disorder
89612532|NCT04359628||Swedevox|Patients with respiratory failure receiving technical respiratory assistance and were registered in the Swedish National Registry for Respiratory Failure
89612533|NCT04359628||PsoReg|Patients receiving systemic treatment for psoriasis and were registered in the Swedish Registry for Systematic Psoriasis Treatment
89612534|NCT04359628||SRQ|Patients with rheumatic disease receiving medical treatment and rehabilitation and were registered in the Swedish Rheumatology Quality Register
89612535|NCT04359628||SwedeHF|Patients who received treatments of different types in the Swedish Heart Failure Registry
89612536|NCT04359628||Swespine|Patients with spinal stenosis, disc hernia and related diagnoses receiving surgical spine treatment and were registered in the Swedish Spine Register
89612537|NCT04359628||Population health survey|Data of members of the general population who answered population surveys using the EQ-5D-3L instrument
88984522|NCT04181853|No Intervention|No Intervention: Control group|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
89612538|NCT04403529|Experimental|Traditional Chinese Medicine|"60 days of oral Traditional Chinese Medicine (prescription for breast cancer Traditional Chinese Medicine formulation)"
89612539|NCT04403529|Placebo Comparator|Placebo|"60 days of oral placebo (placebo contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler)"
89612540|NCT04403373|Placebo Comparator|Waitlist control group|Participants in this group receive no intervention during the 12-week period.
89612541|NCT04403373|Experimental|Moderate-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a moderate intensity (~3.5 METs). The training will be conducted outdoors. Each training session lasts for 50 minutes.
89612542|NCT04403373|Experimental|Vigorous-intensity walking group|Participants in this group will perform a thrice-a-week walking exercise at a vigorous intensity (~7 METs). The training will be conducted outdoors. Each training session lasts for 25 minutes.
89612543|NCT04354636|Experimental|Silver modified atraumatic restorative treatment|Using silver diamine fluoride incorporated with atraumatic restorative treatment
89612544|NCT04354636|Active Comparator|Atraumatic restorative treatment|Using atraumatic restorative treatment without the application of silver diamine fluoride
88984523|NCT04728659|Experimental|Desogestrel Group|Ovulation inhibition will be performed using Desogestrel (75 mcg) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first
88984524|NCT04728659|Active Comparator|GnRH antagonist|Ovulation inhibition will be performed using ganirelix (Orgalutran, 0.25 mg/die) starting on stimulation day 7 or when the leading follicle will reach 14 mm, whichever comes first.
88984525|NCT04729010|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
88984526|NCT04729010|Active Comparator|Randomized Subjects receive a real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
88984527|NCT00132639|Experimental|1|Preoperative docetaxel-cisplatin combination chemotherapy
88984528|NCT00132639|Active Comparator|2|Preoperative docetaxel monotherapy
88984529|NCT02958371|Experimental|fMRI|The study consists in a fMRI experiment intended to observe the effect of the presence of choice on brain activity following consumption of a fruit-flavored drink, compared to the brain activity when the same drink is consumed without choice.
88984530|NCT04728386|Experimental|curcumin irrigant|final flush root canal irrigation with 5 ml curcumin solution
88984531|NCT04728386|Experimental|sodium hypochlorite|final flush root canal irrigation with 5 ml sodium hypochlorite
88984532|NCT00100646|Experimental|1|Highly active antiretroviral therapy (HAART) consisting of lamivudine, lopinavir/ritonovir, and stavudine for 16 weeks with three structured treatment interruptions for 2, 4, and 8 weeks each; rabies vaccine at Weeks 16, 17, 22 and 92.
88984533|NCT00100646|Active Comparator|2|Continuous HAART consisting of lamivudine, lopinavir/ritonovir, and stavudine throughout the study; rabies vaccine at Weeks 16, 17, 22 and 92.
88984534|NCT00100685|Experimental|Arm 1|Volociximab administered intravenously at a dose of 10 mg/kg qowk
88984535|NCT00100685|Experimental|Arm 2|Volociximab administered intravenously at a dose of 15 mg/kg qwk
88984536|NCT04107558|Experimental|Painful stimuli with Hypnosis and Virtual Reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes. This session takes place under hypnosis
88984537|NCT04107558|No Intervention|Painful stimuli without Hypnosis and Virtual reality|After 5 minutes of rest, we start with painful stimuli during 10 minutes.
89612545|NCT04354090|Experimental|Cohort 0.3-mg|Eligible subjects received 0.3 mg placebo or JY09 on day 1 in this cohort
89612546|NCT04354090|Experimental|Cohort 0.7-mg|Eligible subjects received 0.3 mg placebo or JY09 on days 1, and 0.7 mg placebo or JY09 on days 22
89612547|NCT04354090|Experimental|Cohort 1.5-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.5 mg placebo or JY09 on days 22
89612548|NCT04354090|Experimental|Cohort 3.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 3.0 mg placebo or JY09 on days 22
89612549|NCT04354090|Experimental|Cohort 6.0-mg|Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.0 mg placebo or JY09 on days 15, and 6.0 mg placebo or JY09 on days 30
89612550|NCT04359550|Experimental|treatment group|ZKAB001 injection 10mg/kg once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
89612551|NCT04359550|Placebo Comparator|control group|placebo will given in the same way for once every 3 weeks for 1 cycle (Q3w), up to 16 cycles or 1 year of treatment.
88984538|NCT00100880|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 2-3 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which an estimated 25% of patients experience dose-limiting toxicity."
88984539|NCT00132795|Experimental|1 Therapeutic Phone System|patients assigned to this condition will have unlimited access to the therapeutic telephone system for 4 months.
88984540|NCT00132795|Active Comparator|2 Standard care|Standard post-CBT care (i.e., no formal relapse prevention or professional treatment).
88984541|NCT00403104|Experimental|E|ONO-2506PO in the presence of Riluzole
88984542|NCT00403104|Placebo Comparator|P|Placebo in the presence of Riluzole
88984543|NCT00132834||Asthma/no ICS|Asthmatic children who are not currently taking ICS
88984544|NCT00132834||Asthma/ICS|Asthmatic children on ICS
88984545|NCT00132834||Non-asthmatic children|Children without asthma
88984546|NCT00101075|Experimental|XELOX|"Oxaliplatin 130 mg/m2 day 1 every 3 weeks~Capecitabine 1700 mg/m2/day days 1-14 every 3 weeks. -- Patients will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
88984547|NCT00101114|Experimental|Treatment (sorafenib tosylate, interferon alpha-2b)|Patients receive oral sorafenib twice daily on days 1-28 and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88984548|NCT02964819|Active Comparator|exercise group|Manual cervical traction, Myofascial release of upper trapezius muscle, 3 sets of 1 minute;Sleeper's stretch, during 3 series of 30 seconds,Punch exercise, Knee push-up plus, Prone V-raise exercise (arms abducted at 120°), rotador cuff exercise (internal rotation), rotador cuff exercise (external rotation), Rotation on the wall using a ball (internal rotation), Rotation on the wall using a ball (external rotation).
88984549|NCT02964819|Experimental|exercise + Interferential current group|Addition to the exercise protocol performed in the exercise group the interferential current. Four self-adhesive electrodes (8x5 cm), two upper and two lower ones (forming a square) will be placed around the center of the shoulder. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (swing pattern), 100 Hz Frequency modulation amplitude (AMF), 50 Hz (sweep frequency), automatic vector mode, With intensity at the motor threshold of sensation, with duration of 50 minutes.
88984550|NCT02964819|Placebo Comparator|exercise + US group|In addition to the exercise protocol performed in the exercise group, an ultrasound device will be used. The appliance will be used off, without any individual participant having knowledge. For this, the individual will be asked to position himself in the dorsal position on the stretcher, the therapist will perform the application of the transducer head, with gel on its surface, in the anterolateral region of the affected shoulder.
88984551|NCT00101153|Experimental|Tipifarnib with conventional induction and consolidation|
88984552|NCT00400868|Active Comparator|standard joint protection education|psycho-educational joint protection vs. usual care (standard joint protection education)
88984553|NCT00135408|Active Comparator|A1|
88984554|NCT00135408|Active Comparator|A2|
88984555|NCT00101231|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
88984556|NCT00135447||A|
88984557|NCT00101270|Experimental|Treatment (irinotecan hydrochloride, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
88984558|NCT00133068|Other|1|Control
88984559|NCT00133068|Experimental|2|Reduction of financial barrier
88984560|NCT00133068|Experimental|3|Computer Intervention
88984561|NCT00133068|Experimental|4|Reduction of financial barrier and Computer Intervention
88984562|NCT00101348|Experimental|Treatment (erlotinib hydrochloride, cetuximab, bevacizumab)|"Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1. Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.~Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression."
88984563|NCT00101387|Experimental|Lumbar PENS + exercise|Lumbar PENS twice a week for six weeks combined with general conditioning and aerobic exercise
88984564|NCT00101387|Active Comparator|Lumbar PENS|Lumbar PENS twice a week for 6 weeks
88984565|NCT00101387|Placebo Comparator|Control PENS|Control lumbar PENS twice a week for 6 weeks
89034630|NCT04322305|Placebo Comparator|Placebo|Individuals will receive the placebo capsules that appear identical to the pregabalin capsules and will receive the same number of capsules.
89034631|NCT04307992|Experimental|Intervention|Device: ANEUFIX
89612552|NCT04354480|Experimental|RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1.
89612553|NCT04354480|Placebo Comparator|Placebo|Participants will receive single IM injection in the deltoid muscle of matching placebo on Day 1.
89034632|NCT04305158|Experimental|Nitrous Oxide|Patient receiving Nitrous Oxide are evaluated for success of the procedure
89034633|NCT04305158|Active Comparator|IV Sedation group|In this group a combination of Midazolam and Fentanyl is used per endoscopic discretion
89034634|NCT04301778|Experimental|Durvalumab and SNDX-6352|Participants will receive Durvalumab and SNDX-6352.
89034635|NCT04291209|Active Comparator|Experimental arm with Intratympanic NAC injection|One ear will be randomly chosen for the experimental treatment and receive intratympanic NAC injections 60 minutes prior to their scheduled chemotherapy sessions
89612554|NCT03567525|Active Comparator|Standard surgical approach|standard lymphadenectomy using clips and bipolar cautery to seal lymphatic vessels
89034636|NCT04291209|No Intervention|Control arm with No injection|The control ear will not receive any injections
89034637|NCT04285827|Experimental|CSL889 Cohort A1 (Dose 1)|CSL889 administered as a single IV infusion
89034638|NCT04285827|Experimental|CSL889 Cohort A2 (Dose 2)|CSL889 administered as a single IV infusion
89034639|NCT04285827|Experimental|CSL889 Cohort A3 (Dose 3)|CSL889 administered as a single IV infusion
89034640|NCT04285827|Experimental|CSL889 Cohort A4 (Dose 4)|CSL889 administered as a single IV infusion
89034641|NCT04285827|Experimental|CSL889 Cohort A5 (Dose 5)|CSL889 administered as a single IV infusion
89612555|NCT03567525|Experimental|Experimental approach|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
89612556|NCT02084511|Experimental|BI 1026706 low dose|BI 1026706 low dose
89612557|NCT02084511|Experimental|BI 1026706 high dose|BI 1026706 high dose
89612558|NCT02084511|Experimental|Placebo reference|Placebo reference
89612559|NCT02084511|Experimental|Celecoxib reference|Celecoxib capsule
89034642|NCT04285827|Experimental|CSL889 Cohort A6 (Dose 6)|CSL889 administered as a single IV infusion
89034643|NCT04285827|Experimental|CSL889 Cohort B1 (low dose)|CSL889 administered as a single IV infusion
89034644|NCT04285827|Experimental|CSL889 Cohort B2 (high dose)|CSL889 administered as a single IV infusion
89034645|NCT04267796|Experimental|Group I (lifestyle intervention)|Participants complete lifestyle intervention consisting of 1-3 sets of high-resistance circuit training sessions per week, up to 150 minutes of aerobic training per week, and diet recommendations from a health coach or registered dietitian twice per week for 16 weeks.
89034646|NCT04267796|Active Comparator|Group II (wait-list, lifestyle intervention)|Participants are placed on a wait-list and then complete lifestyle intervention after 4 months.
89034647|NCT04256824|Experimental|Coated Polyglactin 910 with Triclosan|Coated vicryl plus
89612560|NCT00942448|Experimental|Diclofenac HPBCD s.c. 25mg/ml|
89612561|NCT00942448|Experimental|Diclofenac HPBCD s.c. 50mg/ml|
89612562|NCT00942448|Active Comparator|Diclofenac HPBCD s.c. 75mg/ml|
89612563|NCT00942448|Placebo Comparator|Placebo s.c. (1ml)|
89612564|NCT02982148|Experimental|methylene blue intradermal injection|For patients randomized to intradermal injection before surgery began, 0.5ml 0.4% methylene blue(1ml methylene blue mixed up with 1.5ml saline) would be injected sub-areola (12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock) intradermally, 0.1ml respectively, or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
89612565|NCT02982148|Active Comparator|methylene blue subcutaneous injection|For patients randomized to subcutaneous injection before surgery began, 0.5ml 100% methylene blue would be injected sub-areola subcutaneously(12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock), 0.1ml respectively or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
89612566|NCT03562455|Experimental|Virtual Reality Training|Participants will receive virtual reality power wheelchair training using VRSim 3.0 in this group.
89612567|NCT03562455|Active Comparator|In-person Therapist Training|Participants will receive in-person wheelchair training by a therapist in this group.
89612568|NCT04359082|Placebo Comparator|Placebo|Placebo for 8 straight days
89034648|NCT04256824|Active Comparator|Coated Polyglactin 910 without Triclosan|Coated vicryl
89034649|NCT04256213|Experimental|Nivolumab + Ipilimumab|
89034650|NCT04254237|Active Comparator|Intervention group|Infraumbilical Hasson trocar incision.
89034651|NCT04254237|Sham Comparator|Control group|Supraumbilical Hasson trocar incision.
89034652|NCT04248751|Experimental|Graft-Augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin. Then, the graft will be delivered to the subacromial space and positioned over the bursal surface of the suprasinatus tendon, ensuring that the lateral edge of the implant will overlap with the head of the humerus. The graft will be fixed with tendon and bone staples.
89057798|NCT01686399|Experimental|The study has a single arm|The study has one arm The whole population of the campus will be exposed to the intervention. the effectiveness will be assessed using a random selection twice - before and after the intervention
89612569|NCT04359082|Experimental|Bioflavanol|Bioflavanol supplementation for 8 days at 900 mg flavanol per day
89612570|NCT04359316|Experimental|Azithromycin|
89612571|NCT04359316|Active Comparator|Hydroxychloroquine|
88984566|NCT00101387|Active Comparator|Control PENS + exercise|Control PENS twice a week for 6 weeks along with general conditioning and aerobic exercise
89612572|NCT03762135|Experimental|Full version of the LIITah App.|Participants will be given the LIITAH app. which consists of 1) enhanced location identification (ELI), 2) self reported nutrients by annotated photos (SNAP), 3) delivery of individually and culturally tailored point of purchase (POP) prompts along with tailored messages sent at other times of the day, 4) use of app. in connection with parents, 5) goal setting, 6) a point system
89612573|NCT03762135|Active Comparator|Partial App. (ELI and SNAP only)|Participants will be given only the ELI and SNAP components. It will detect their presence in a restaurant and allow users to document their purchases by submitting annotated photos, but it will not deliver any POP prompts encouraging them to make healthy choices, or messages at other times of the day.
89612574|NCT00939796|Experimental|Tympanostomy Tube Delivery System (TTDS)|Tympanostomy tube placement with Acclarent tube delivery system
89612575|NCT00939874|Experimental|Raltegravir|
89612576|NCT04359160|Experimental|Mobile-app follow-up|The mobile app follow-up group will receive an email, to connect into a secure website. They will answer to periodical questions about their condition. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative. All of this information is submitted via the mobile application (Orthense, Digikare Inc. Blagnac, France).The surgeon will have an access to the answer of the patient in real time, and if the patient didn't answer.
89612577|NCT04359160|Active Comparator|Conventional follow-up|Patients in the conventional, questionnaire follow-up group will have the same periodical questions but on paper. They will have to stick personally with the schedule without any reminders. They will have a medical appointment at 6 weeks postoperative and 12 weeks postoperative where they have to bring the questionnaire.
89612578|NCT03557385|Other|aFFR vs cFFR|All subjects will receive Fractional Flow Reserve Measurements with both adenosine (aFFR) and contrast (Iopamidol) (cFFR) using the Navvus® Catheter and CVi® Contrast Delivery System
89612579|NCT03528213|Sham Comparator|Normal saline|at physician discretion
89612580|NCT03528213|Experimental|Sodium lactate light dose|bolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
89612581|NCT03528213|Experimental|Sodium lactate high dose|bolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
89612582|NCT05620030|Experimental|Univentricular Heart|All patients with univentricular hearts
89612583|NCT03758001|Experimental|IBI101|IBI101 will be administrated intravenously. 3+3 dose escalation design will be used with eight dose levels being tested.
89612584|NCT03758001|Experimental|IBI101 in combination with Sintilimab|"IBI101 and Sintilimab will be administrated intravenously. 3+3 dose escalation design will be used with 4 dose levels of IBI101 being tested.~Two dose levels of IBI101 in combination with Sintilimab will be expanded to 10 patients each."
89612585|NCT05346861|Active Comparator|Trastuzumab plus chemotherapy|
89612586|NCT05346861|Experimental|Pyrotinib in combination with Trastuzumab plus chemotherapy|
89612587|NCT04358614|Active Comparator|Case patients|Consecutive patients with COVID moderate pneumonia treated with baricitinib tablets 4 mg/day
89612588|NCT04358614|Other|Controls|Consecutive patients with COVID moderate pneumonia treated with standard therapy before the date of the first baricitinib-treated patient.
89612589|NCT01670409|Experimental|SMART combined with PF chemotherpay|SMART-base IMRT with concurrent and adjuvant chemotherapy(cisplatin and 5-fluorouracil)
89612590|NCT04761705|Experimental|Randomized Part 2, Arm 1|Dose 1 selected in Part I
89612591|NCT04761705|Experimental|Randomized Part 2, Arm 2|Dose 2 selected in Part I
89612592|NCT04761705|Active Comparator|Randomized Part 2, Arm 3|
89612593|NCT04403217|Experimental|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
89612594|NCT04358926|Active Comparator|Hyperbaric oxygen therapy|8 sessions in 4 days hyperbaric oxygen therapy
89612595|NCT04358926|No Intervention|Control|Standard of care
89612596|NCT03520179||SMA TYPE 1|genetically confirmed SMA
89612597|NCT03520179||SMA TYPE 2|genetically confirmed SMA
89612598|NCT03520179||SMA TYPE 3|genetically confirmed SMA, Ambulant and non-ambulant
89612599|NCT04358770|Experimental|Test|Clocortolone Pivalate Cream, 0.1%
89612600|NCT04358770|Active Comparator|Reference|Cloderm® (clocortolone pivalate) Cream, 0.1%
89612601|NCT04402983|Experimental|Telerehabilitation Group|Physiotherapy will be carried out by conducting online conference method. Program content; Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
89612602|NCT04402983|No Intervention|Control group|Information and exercise brochure will be provided
89612603|NCT04564300|Experimental|Oral contraceptive users|
89612604|NCT04564300|Active Comparator|Non-oral contraceptive users|
89612605|NCT04525144|Experimental|Tebonin Forte|Treatment: 120mg, twice a day, 52 weeks
89612606|NCT04525144|No Intervention|Control|No Treatment
88984567|NCT00133146|Experimental|Grass MATA MPL|"300 SU/0.5 mL Grass MATA MPL (Visit 2);~800 SU/0.5 mL Grass MATA MPL (Visit 4);~2000 SU/0.5 mL Grass MATA MPL (Visit 6)"
89612607|NCT05619484|No Intervention|Participant's prescribed ankle-foot orthosis|
89612608|NCT05619484|Experimental|Smart AFO|
89612609|NCT05618470|Experimental|Wumeiwan Jiawei Fang|This group will take Wumei pill granule orally.
89612610|NCT05618470|Active Comparator|botulinum toxin A|In this group, Botulinum toxin type A (Lanzhou Biopharmaceutical Co. LTD.) was injected locally around the eye.
89612611|NCT04358536||COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from COVID-19 patients"
89612612|NCT04358536||Non COVID-19 Patients|"Single posteroanterior (or front-on) X-rays collected from subsets of non COVID-19 patients"
89612613|NCT04358146|Experimental|Test|new thickened infant formula containing fibres
89612614|NCT04358146|Active Comparator|Control|infant formula thickened with locust bean
89034653|NCT04248751|Active Comparator|Non-augmented|Patients randomized to this group will receive a regular rotator cuff repair where the bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin.
89034654|NCT04248322||Subjects who used TTNS|Subjects will have Neurogenic Lower Urinary Tract Dysfunction and will have participated in a study with TTNS. n=20
89034655|NCT04247763|Experimental|Arm 1 (Saturated Fat Meal, Oleic Sunflower Oil Meal)|
89034656|NCT04247763|Active Comparator|Arm 2 (Oleic Sunflower Oil Meal, Saturated Fat Meal)|
89034657|NCT04247074|Experimental|QM1114-DP in the LCL + Placebo in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
89034658|NCT04247074|Placebo Comparator|Placebo in the LCL and GL|"A buffered solution; Mode of administration:~intramuscular injection"
89034659|NCT04247074|Experimental|Placebo in the LCL + QM1114-DP in the GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection
89034660|NCT04247074|Experimental|QM1114-DP in the LCL + GL|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
89034661|NCT04231448|Experimental|CR-CHOP|
89034662|NCT04231448|Placebo Comparator|R-CHOP|
89034663|NCT04224051|Experimental|Metformin target dose of 2g daily|Metformin tablets taken orally with target dose of 2g daily plus standard care
89034664|NCT04224051|Active Comparator|Standard care|Standard care includes help with smoking cessation if applicable; encouragement of physical activity and a healthy diet; blood pressure control; statin and anti-platelet therapy treatment if the patient have clinical manifestations of atherosclerotic disease.
89034665|NCT04216823||Sevoflurane Group|sevoflurane is used for anesthetic induction
89612615|NCT05620498|Experimental|tislelizumab+lenvatinib+GMOX|"tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd, gemcitabine 1g/㎡, D1, D8, Q3W, oxaliplatin 100mg/㎡, D1, Q3W. Imaging evaluation was performed after 3 cycles.~Patients who met surgical criteria will receive R0 resection and adjuvant therapy 4-8 weeks after surgery (tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd) for one year or until disease progression or toxicity became intolerable.~Inoperable patients continue to receive ≤4 cycles of treatment, imaging evaluation every two cycles. Patients will receive R0 resection if meet surgical criteria and adjuvant therapy 4-8 weeks after surgery (Tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd,) for one year or until disease progression or toxicity became intolerable.~Patients still unable to receive surgery, the experimental group will receive tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd for maintained treatment until disease progression or toxicity became intolerable."
89034666|NCT04216823||Propofol Group|intravenous anesthetic propofol is used for anesthetic induction
89034667|NCT04216641|Experimental|Intervention arm|"At each meal: different elements will be presented to the patient (starter / main course / side dish / dessert).~For each of these elements, the patient will be offered 4 versions (a standard version and 3 adapted versions of the same food):~The standard food.~The food refers to a more elaborate texture.~The food refers to a food with a stronger smell.~The food refers to a more important flavor.~The patient will indicate the version of the food that will be preferred."
89034668|NCT04209114|Experimental|Arm A: Combination Therapy|Neoadjuvant (pre-surgical treatment) nivolumab + bempeg, followed by radical cystectomy (RC), followed by adjuvant (post-surgical treatment) nivolumab + bempeg
89034669|NCT04209114|Experimental|Arm B: Monotherapy|Neoadjuvant nivolumab, followed by RC, followed by adjuvant nivolumab
89034670|NCT04209114|Other|Arm C: Standard-of-care|RC alone, without neoadjuvant or adjuvant therapy
89034671|NCT04203797|Experimental|dupilumab|A loading dose at the start of the treatment followed by once every two weeks (Q2W).
89034672|NCT04203797|Experimental|Matching placebo|Matching dupilumab
89034673|NCT04197479|Experimental|Open label: resmetirom|100 mg daily
89034674|NCT04197479|Placebo Comparator|Double blinded: matching placebo|Placebo daily
89034675|NCT04197479|Experimental|Double blinded: resmetirom 80 mg|80 mg daily
89034676|NCT04197479|Experimental|Double blinded: resmetirom 100 mg|100 mg daily
89034677|NCT04191590|Other|Patient with Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of Chronic Rhinosinusitis (CRS)
89034678|NCT04191590|Other|Patient without Chronic Rhinosinusitis (CRS)|Patients with endonasal surgery scheduled under general anesthesia for an indication of endonasal surgery for nasal obstruction or patients requiring an endonasal surgical approach such as pituitary adenomas for example.
89034679|NCT04190212|Experimental|High-intensity interval training|Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).
89034680|NCT04190212|No Intervention|Standard care|Participants will not participate in on-site supervised exercise sessions.
89034681|NCT04176978|Experimental|T2T + statin|Patient in this arm will receive treat-to-target strategy with rousavastin 20mg
89034682|NCT04176978|Active Comparator|T2T only|Patient in this arm will receive treat-to-target strategy only.
89034683|NCT04176965|Experimental|FINEVISION HP|Trifocal FINEVISION HP. Cataractous lens will be removed in the study eyes and the FINEVISION HP will be implanted in the capsular bag.
89034684|NCT04176965|Active Comparator|Control Product|Cataractous lens will be removed in the study eyes and the Alcon AcrySof® SN60AT IOL will be implanted in the capsular bag.
89034685|NCT04175639|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
89034686|NCT04175639|No Intervention|mHealth-Education (mHealth-Ed)|mHealth-Education (mHealth- Ed): Participating in mHealth will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic with a nurse about cancer care.
89034687|NCT04173728|Other|Standardized mixed macronutrients tolerance test|Subjects with different age and BMI will be included. 1) 20 subjects aged 20-29 years with normal body weight (18.5 ≤BMI<24kg/m2); 2) 40 20 subjects aged 30-70 49 years with normal body weight (18.5 ≤ BMI<24kg/m2); 3) 40 20 subjects aged 30-70 49 years with overweight or obesity (BMI<24kg/m2).); 4) 20 subjects aged 50-70 years with normal body weight (18.5 ≤ BMI<24kg/m2); 5) 20 subjects aged 30-49 years with overweight or obesity (BMI<24kg/m2); 6) 20 subjects aged 30-70 years with MetS.
89034688|NCT04166435|Experimental|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
89034689|NCT04156945|Experimental|Intervention I: behavioural intervention|Participants will receive the behavioural Intervention in addition to standard of care.
89034690|NCT04156945|Experimental|Intervention II: home-based testing intervention|Participants will receive the home-based testing intervention in addition to standard of care.
89034691|NCT04156945|Experimental|Intervention III: combined intervention|Participants will receive the behavioural intervention and the home-based testing intervention in addition to standard of care.
89034692|NCT04150900|Experimental|Pembrolizumab + Bavituximab|Pembro and Bavituximab for progressive recurrent/metastatic squamous cell carcinoma of head and neck
89034693|NCT04149730||Patients with primary PEA.|Patients at St. Olavs hospital who suffer cardiac arrest and pulseless electrical activity (PEA) as primary rhythm during 2018-2021. 120 episodes from St. Olavs hospital were collected previously (2010-2013). In addition 200 cases will be available from the hospital of The University of Pennsylvania, Philadelphia, USA.
89034694|NCT04131036||Arm A|Male patients with severe Hemophilia A who use prophylaxis with IV factor VIII concentrate with intended trough >1%.
89034695|NCT04131036||Arm B|Male patients with severe Hemophilia A who use prophylaxis with SQ emicizumab.
89034696|NCT04126798||Healthy adults|Standardization and collecting normative age-related data for cognitive and motor single tasks, as well as cognitive-motor dual-tasks
89034697|NCT04126798||Bilateral vestibulopathy|Validation of cognitive and motor single tasks, as well as cognitive-motor dual-tasks
89612616|NCT05620498|Active Comparator|tislelizumab+GEMOX|"tislelizumab 200mg, Q3W, gemcitabine 1g/㎡, D1, D8, Q3W, oxaliplatin 100mg/㎡, D1, Q3W. Imaging evaluation was performed after 3 cycles.~Patients who met surgical criteria will receive R0 resection and adjuvant therapy 4-8 weeks after surgery (tislelizumab 200mg, Q3W) for one year or until disease progression or toxicity became intolerable.~Inoperable patients continue to receive ≤4 cycles of treatment, imaging evaluation every two cycles. Patients will receive R0 resection if meet surgical criteria and adjuvant therapy 4-8 weeks after surgery (Tislelizumab 200mg, Q3W) for one year or until disease progression or toxicity became intolerable.~Patients still unable to receive surgery, the experimental group will receive tislelizumab 200mg, Q3W for maintained treatment until disease progression or toxicity became intolerable."
89612617|NCT01670565|Experimental|Mycophenolate mofetil + Belimumab|All patients who enroll in this trial will FIRST receive mycophenolate mofetil (MMF, Cellcept), which is a drug commonly given to patients with scleroderma in clinical practice. This drug will be given at no cost to the patient. After the patient has been titrated to 2 grams of MMF per day, the patient will receive EITHER a 10 mg/kg belimumab (Benlysta) intravenous infusion OR a placebo (saline) infusion. This medication and infusion will of course be covered by the study.
89034698|NCT04126798||Unilateral vestibular impairment|Cross-sectional study on cognitive and motor single tasks, as well as cognitive-motor dual-tasks, in persons with unilateral vestibular impairment
89034699|NCT04124965|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
89612618|NCT01670565|Placebo Comparator|Mycophenolate Mofetil + Saline (placebo)|In order to observe the difference between belimumab/MMF compared to MMF alone, half of the patients will receive a normal saline infusion that appears identical to the belimumab infusion.
89612619|NCT03088215|Experimental|A / Shock-waves|Will receive shock-waves
89612620|NCT03088215|No Intervention|B / Nothing|Will not receive shock-waves
89612621|NCT04366804||Patients with neuropsychiatric fluctuations|PD patients with neuropsychiatric fluctuations (≥ 2 positive answers in QUICK test)
89034700|NCT04124965|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.
89612622|NCT04366804||Patients without neuropsychiatric fluctuations|PD patients without neuropsychiatric fluctuations (≤ 1 positive answer in QUICK test)
89612623|NCT01675479|Experimental|wavefront-guided LASIK|
89612624|NCT01678755|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
89612625|NCT01678755|Experimental|ABT-126 High Dose|ABT-126 High Dose
89612626|NCT01678755|Placebo Comparator|Placebo|Placebo
89612627|NCT04358380||Patients without Liver Injury|Hospitalized patients with COVID-19 disease who did not develop liver injury
89034701|NCT04121754|Experimental|Investigational Device|Will walk for 30 minutes at a time, 3 times a week, for 5 weeks using the investigational device.
89034702|NCT04121754|Active Comparator|Active Walking Control|Will walk for 30 minutes at a time, 3 times a week, for 5 weeks using only foot sensors.
89034703|NCT04116073|Experimental|INCMGA00012 (PD-1 antibody)|All participants will receive the interventional study drug; INCMGA00012.
89034704|NCT04067596|Experimental|epiphysiodesis|The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).
89034705|NCT04059640|Experimental|LiquiBand FIX8® OHMF Device|Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.
89034706|NCT04058639|Experimental|felt relief|"custom felt relief"
89034707|NCT04058639|Active Comparator|treatment as usual|standard treatment usually provided by the Surgical Outpatient Clinic
89034708|NCT04049981|Experimental|Facial Engagement|This group will receive a version of Superpower Glass that targets specific areas of social deficits associated with autism.
89034709|NCT04049981|Experimental|Emotion Recognition|This group will receive a version of Superpower Glass that targets different areas of social deficits associated with autism.
89034710|NCT04022967|Experimental|Arm 1 : Dual maintenance therapy DTG+3TC|
89034711|NCT04022967|Experimental|Arm 2 : Dual maintenance therapy ATV/r+3TC|
89034712|NCT04022967|Active Comparator|Arm 3 : Reference triple therapy TDF+3TC+EFV or DTG+3TC+TDF|
89034713|NCT04021862|Experimental|Treatment Arm 1 (bermekimab every week)|"Loading Dose: 400 mg subcutaneous (SC) injection of bermekimab and a SC injection of matching placebo at week 0 (Baseline).~Treatment Dose: 400 mg subcutaneous injection of bermekimab administered weekly (qw) from week 1 through Week 31."
89034714|NCT04021862|Experimental|Treatment Arm 2 (bermekimab every other week)|"Loading Dose: 800 mg SC injection of bermekimab at week 0 (Baseline).~Treatment Dose: 400 mg SC injection of bermekimab administered every other week (q2w) alternating with matching placebo q2w through Week 31."
89034715|NCT04021862|Placebo Comparator|Placebo|"Loading Dose: Placebo matching to bermekimab (4 milliliters [mL]) SC injection at Week 0, (Baseline).~Treatment Dose: SC injection of matching placebo administered once weekly (qw) from week 1 to week 15 during placebo-controlled period. After completion of placebo-controlled period, participants will cross-over and receive bermekimab 400 mg SC injection qw at Week 16 through Week 31."
89034716|NCT04003155|Placebo Comparator|Double-blind Period: Placebo|Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, once daily (QD) up to week 12 during double-blind treatment period.
89034717|NCT04003155|Experimental|Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg|Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 30 mg orally, QD from week 13 up to Week 52 during extension treatment period.
89034718|NCT04003155|Experimental|Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg|Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 45 mg orally, QD from week 13 up to Week 52 during extension treatment period.
89034719|NCT04003155|Experimental|Double-blind Period: Placebo /Extension Period: Fezolinetant 30 mg|Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 30 mg orally, QD from week 13 up to week 52 during extension treatment period.
89034720|NCT04003155|Experimental|Double-blind Period: Placebo /Extension Period: Fezolinetant 45 mg|Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 45 mg orally, QD from week 13 up to week 52 during extension treatment period.
89034721|NCT04003142|Experimental|Double-blind Period: Fezolinetant 30 mg/Extension Period: Fezolinetant 30 mg|Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 30 mg orally, QD from week 13 up to Week 52 during extension treatment period.
89034722|NCT04003142|Experimental|Double-blind Period: Fezolinetant 45 mg/Extension Period: Fezolinetant 45 mg|Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD up to week 12 during double-blind treatment period followed by fezolinetant 45 mg orally, QD from week 13 up to Week 52 during extension treatment period.
89034723|NCT04003142|Placebo Comparator|Double-blind Period: Placebo|Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, once daily (QD) up to week 12 during double-blind treatment period.
89034724|NCT04003142|Experimental|Double-blind Period: Placebo/Extension Period: Fezolinetant 30 mg|Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 30 mg orally, QD from week 13 up to week 52 during extension treatment period.
89034725|NCT04003142|Experimental|Double-blind Period: Placebo/Extension Period: Fezolinetant 45 mg|Participants who received placebo during double-blind treatment period were re-randomized to receive fezolinetant 45 mg orally, QD from week 13 up to week 52 during extension treatment period.
89034726|NCT03998813|Experimental|Locoregional analgesia by femoral triangle catheterization|
89034727|NCT03998813|Active Comparator|Tissue infiltration|
89034728|NCT03991221|Other|Dental exam by orthodontic non-specialists|Detection of the presence of at least one malocclusion by orthodontic non-specialists with the graphic chart
89034729|NCT03991221|Other|Dental exam by orthodontic experts|Detection of the presence of at least one malocclusion by orthodontic experts
89034730|NCT03991091|Experimental|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm
89034731|NCT03991091|Active Comparator|continuation of oxytocin administration|Standard care in France, i.e. when oxytocin is started during the latent phase of the 1st stage, administration of oxytocin is continued during the active 1st stage and during the 2nd stage if the fetal heart rate is reassuring.
89034732|NCT03971422|Experimental|Dosage Regimen 1|Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.
89034733|NCT03971422|Experimental|Dosage Regimen 2|Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during Treatment Period.
89034734|NCT03971422|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo.
89612628|NCT04358380||Patients with Liver Injury|Hospitalized patients with COVID-19 disease who develop liver injury
89612629|NCT04358302|Experimental|Device use|"All participants will be provided with the electronic pill bottle cap called Pillsy to use with their regular HCQ prescription bottles at the start of the study."
89612630|NCT01670799|Experimental|Ketorolac|"All patients will receive a single dose of IV ketorolac for pain management for the indication of post-operative pain control. Patients less than 65 years of age and in otherwise good health will receive a 30mg IV single dose. Patients 65 years of age or greater, or who have mild renal insufficiency or are of low weight (as per section 3.2) will receive a single 15 mg dose IV ketorolac.~In patients who have a clinical pain response and have no contraindications to multi-dose (every 6 hours over 24 hours), additional doses will be given per physician discretion based on clinical indication. Patients receiving 24 hour dosing will be eligible for sample time points after 24 hour dosing."
89612631|NCT02404935|Experimental|Arm A cetuximab|cetuximab 500 mg/m2 (every 2 weeks) until progression
89612632|NCT02404935|Other|Arm B observation|observation until progression
89612633|NCT00943150|Experimental|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
89612634|NCT00943150|Active Comparator|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
89612635|NCT03511131|Other|QSE Resp (Only follow)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to no additional treatment, and then followed for the rest of the study.
89612636|NCT03511131|Other|QSE Resp (KIU at 6-month)|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who responded to QSE, were randomized at month-6 to receive Keep It Up (KIU), and then followed for the rest of the study.
89612637|NCT03511131|Other|QSE Non-Resp, KIU-Control Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), responded to KIU-Control at month-6, and then were followed for the rest of the study.
89612638|NCT03511131|Other|QSE Non-Resp, KIU-Control Non-Resp, KIU|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Keep It Up (KIU). After KIU, they were followed for the rest of the study.
89612639|NCT03511131|Other|QSE Non-Resp, KIU Control Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up-Control (KIU-Control), did not respond to KIU-Control at month-6, and so were randomized into Young Men's Health Project (YMHP). After YMHP, they were followed for the rest of the study.
89612640|NCT03511131|Other|QSE Non-Resp, KIU Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), responded to KIU at month-6, and then were followed for the rest of the study.
89612641|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into no treatment/just follow for the rest of the study.
89612642|NCT03511131|Other|QSE Non-Resp, KIU Non-Resp, YMHP|All participants enter Queer Sex Ed (QSE) and are measured at 0, 3, 6, 9, and 12-months. This arm is comprised of participants who did not respond to QSE, were randomized at month-3 to receive Keep It Up (KIU), did not respond to KIU at month-6, and then were randomized into Young Men's Health Project. After YMHP, they were followed for the rest of the study.
89612643|NCT03509025|Experimental|Long Term Follow-up after Jointstem Transplantation|
89612644|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 20mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).
88984568|NCT00133146|Active Comparator|Grass MATA|"300 SU/0.5 mL Grass MATA (Visit 2);~800 SU/0.5 mL Grass MATA (Visit 4);~2000 SU/0.5 mL Grass MATA (Visit 6);"
88984569|NCT00135603|Active Comparator|A|appendectomy, actual usual treatment
88984570|NCT00135603|Active Comparator|B|antibiotic therapy
88984571|NCT00133224|Experimental|1|
88984572|NCT00133224|Other|2|
88984573|NCT04728464||Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Patients will be treated by Periodontally Accelerated Osteogenic Orthodontics using fixed appliances.
88984574|NCT00133263|Experimental|1|
88984575|NCT00133263|Active Comparator|2|
88984576|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFOX-4|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFOX-4
88984577|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFOX-4|125 mg QD AMG 706 + FOLFOX-4
88984578|NCT00101894|Experimental|50 mg QD AMG706 + panitumumab + FOLFIRI|50 mg QD AMG706 + panitumumab + FOLFIRI
88984579|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFIRI|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFIRI
88984580|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFIRI|100 mg AMG 706 + FOLFIRI
88984581|NCT00101894|Experimental|75 mg QD AMG 706 + panitumumab + FOLFOX-4|75 mg QD AMG 706 + panitumumab + FOLFOX-4
88984582|NCT00101894|Experimental|75 mg BID AMG 706 + panitumumab + FOLFIRI|75 mg BID AMG 706 + panitumumab + FOLFIRI
88984583|NCT00101894|Experimental|125 mg QD AMG 706 + panitumumab + FOLFIRI|125 mg QD AMG 706 + panitumumab + FOLFIRI
88984584|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFIRI|125 mg QD AMG 706 + FOLFIRI
88984585|NCT00101894|Experimental|100 mg QD AMG 706 + panitumumab + FOLFIRI|100 mg QD AMG 706 + panitumumab + FOLFIRI
88984586|NCT00101894|Experimental|75 mg QD AMG 706 + FOLFOX-4|75 mg QD AMG 706 + FOLFOX-4
88984587|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFOX-4|100 mg QD AMG 706 + FOLFOX-4
88984588|NCT00101894|Experimental|50 mg QD AMG 706 + panitumumab + FOLFOX-4|50 mg QD AMG 706 + panitumumab + FOLFOX-4
89612645|NCT04320940|Active Comparator|Phenobarbital Sodium Injection 40mg|Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).
89612646|NCT03422523|Active Comparator|Arm A Control|6 Cycles of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) every 14 days.
89612647|NCT03422523|Experimental|Arm B Experimental|"1 Cycle of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) followed by 5 cycles of R-GemOx with Atezolizumab every 14 days.~Followed by 8 maintenance cycles of Atezolizumab every 21 days."
89612648|NCT03032536|Experimental|Treatments A, B, C|"Part 1: Cross-Over~Treatment A: AL-3778 6 x 100-mg capsules (fasted) once.~Treatment B: AL-3778 2 x 300-mg tablets (fasted) once~Treatment C: AL-3778 2 x 300-mg tablets (high-fat meal) once."
89612649|NCT03032536|Experimental|Treatments D, E, F|"Part 2 (optional): Cross-Over~Treatment D: AL-3778 2×300-mg tablets (fasted) once.~Treatment E: AL-3778 tablet Dose (fasted) once. Dose will match Treatment F dose and will be:~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg~Treatment F: AL-3778 tablet Dose (high-fat meal) once. Dose will match Treatment E dose and will be:~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
88984589|NCT00101894|Experimental|75 mg QD AMG706 + panitumumab + FOLFIRI|75 mg QD AMG706 + panitumumab + FOLFIRI
88984590|NCT00135759|Placebo Comparator|Group 1|Drug
88984591|NCT00135759|Experimental|2|experimental
88984592|NCT00135759|Experimental|3|experimental
88984593|NCT00403923||Patients with known lactose intolerance|
88984594|NCT00135525|Experimental|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
88984595|NCT00135525|Placebo Comparator|Placebo|
88984596|NCT02964468|Experimental|Treatment with IMRT Dose Escalation|Dose Escalation Intensity Modulated Radiotherapy treatment
88984597|NCT02964468|Active Comparator|Treatment with 3DCRT|3DCRT treatment (sequential boost)
88984598|NCT00135954|Other|late intervention|cyclophosphamide and steroids started at time of renal insufficiency
88984599|NCT00135954|Experimental|early intervention|immediate start of cyclophosphamide and steroids
88984600|NCT00102635|Experimental|4-HPR + FTI|SCH66336 daily for 21 days each cycle and with 4-HPR daily on days 1-7 only. On day 1 of cycle 1, 4-HPR only beginning SCH66336 on day 2 of cycle 1.
88984601|NCT00136032|Active Comparator|1|
88984602|NCT00136032|Placebo Comparator|2|
88984603|NCT00133536|Experimental|1|100 subjects 45 mcg of influenza A/H5N1.
88984604|NCT00133536|Placebo Comparator|2|20 subjects saline placebo.
88984605|NCT00136227|Experimental|Lifestyle counseling|Behavioral: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
88984606|NCT04726839||Stroke suspicion|Patients with stroke suspicion within 24 hours of stroke's symptoms
88984607|NCT00102908|Experimental|1|Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
88984608|NCT00102908|Placebo Comparator|2|Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
88984609|NCT00401024|Experimental|Treatment|Imatinib mesylate 600mg orally once a day for seven consecutive days prior to surgery with last dose taken one day prior to surgery
88984610|NCT00401063|Other|Single arm|Acupuncture treatment
88984611|NCT00136305|Experimental|Pictorial Asthma Action Plan|
88984612|NCT00136305|Active Comparator|Written Asthma Action Plan|
88984613|NCT00103220|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88984614|NCT00103337|Experimental|Arm I (500 mg cilengitide)|Patients receive lower dose cilengitide IV over 1 hour twice a week for 6 weeks.
88984615|NCT00103337|Experimental|Arm II (2000 mg cilengitide)|Patients receive higher dose cilengitide IV over 1 hour twice a week for 6 weeks.
88984616|NCT00133770|Experimental|IV pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
88984617|NCT00103454|Experimental|Arm 1|
88984618|NCT00133887|Experimental|1|patients receiving Rapamycin
88984619|NCT00133887|Active Comparator|2|patients receiving anticalcineurin treatment
88984620|NCT00103532|Experimental|Healthy Choices - Motivational Enhancement Intervention|Motivational enhancement intervention
88984621|NCT00103532|Active Comparator|Standard Care|Standard care/individualized referrals
88984622|NCT00136578|Experimental|Subjects receiving carboplatin and SB-715992|Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days.
88984623|NCT00103727|Experimental|talnetant|200mg, 400mg, 600mg) twice a day
88984624|NCT00103727|Placebo Comparator|placebo|placebo
88984625|NCT00103727|Active Comparator|risperidone|3mg twice a day
88984626|NCT00103883||HIV Infected Teens -ATN Clinical Sites|HIV infected teens who are referred to or engaged in care at any of the 15 ATN clinical sites during the course of the study.
88984627|NCT00103883||HIV Positive - ATN Clinical Sites|Youth who test HIV positive at ATN-managed or ATN-affiliated HIV Counseling and Testing Sites (CTS) during the course of the study.
88984628|NCT00103883||HIV Positive - BCHD STD Clinic|Youth who test HIV positive at the BCHD STD Clinic during the course of the study.
88984629|NCT00133965||1|Dignity Psychotherapy
88984630|NCT00133965||2|Supportive Psychotherapy
88984631|NCT00133965||3|Standard Palliative Care
88984632|NCT00103922|Experimental|Arm 1|
89612650|NCT03032536|Experimental|Treatment G|"Part 3: AL-3778 twice daily administered under fasted conditions for 14 days.~Dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
89612651|NCT03032536|Active Comparator|Treatment H|Part 3: Entecavir 0.5 mg once daily administered under fasted conditions for 14 days
89612652|NCT03032536|Experimental|Treatment I|"Part 3: AL-3778 twice daily with entecavir 0.5 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
88984633|NCT00103961||1|Treatment-naive and treatment-experienced HIV-infected adults
88984634|NCT00134160|Active Comparator|1|High-dose ARB monotherapy
88984635|NCT00134160|Active Comparator|2|Combination therapy of ARB with Calcium Channel Blocker
88984636|NCT00136656|Active Comparator|1|cefixime antibiotic treatment by oral route
88984637|NCT00136656|Sham Comparator|2|ceftriaxone antibiotic treatment by venous infusion and cefixime antibiotic treatment by oral route during six days
88984638|NCT04729088|Experimental|Test Drug|Isosorbide 0.5% gel
88984639|NCT00136734|Experimental|1|methylphenidate
88984640|NCT00136734|Placebo Comparator|2|placebo
88984641|NCT00134277|Active Comparator|Infragenual dilatation with stenting|
88984642|NCT00134277|Active Comparator|Infragenual dilatation with cutting balloon|
88984643|NCT00134277|Active Comparator|Laser therapy|
88984644|NCT00134277|Placebo Comparator|Infragenual dilatation|
88984645|NCT00136890|No Intervention|1|Conventional Staging
88984646|NCT00136890|Experimental|2|PET Imaging
88984647|NCT00104312||1|Participants with symptomatic knee osteoarthritis
88984648|NCT00104312||2|Participants without symptomatic knee osteoarthritis, age-matched as controls
88984649|NCT00134355|Experimental|PTK787|"PTK787:~250 mg orally twice daily x 2 wks, then 250 mg orally am, 500 mg orally pm x 1 wk, then 500 mg orally twice daily"
88984650|NCT00104585||1|People with young onset Parkinson's disease and their family members
89612653|NCT03032536|Active Comparator|Treatment J|Part 3: Tenofovir disoproxil fumarate 300 mg once daily administered under fasted conditions for 14 days
89612654|NCT03032536|Experimental|Treatment K|"Part 3: AL-3778 twice daily and tenofovir disoproxil fumarate 300 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
89612655|NCT03032770||placenta accreta|Having at least one sign suggestive of placenta accreta
89612656|NCT03032770||normal placenta|Never having any of the signs suggestive of placenta accreta
88984651|NCT00104702|Experimental|Concentrated and Focalized Radiotherapy|
88984652|NCT00104741|Active Comparator|radiotherapy alone|
88984653|NCT00104741|Experimental|Radiotherapy + androgene deprivation|
88984654|NCT00137202|Active Comparator|2|
88984655|NCT00137241||Group 1|
88984656|NCT04728503|Experimental|5-Minute Mindful Movement Video|5 minute mindful movement video watched in the exam room on an iPad
88984657|NCT04728503|Placebo Comparator|Written Educative Materials|1 page printed written educative material about mindfulness benefits read for 5 minutes in the exam room
88984658|NCT00134628|Active Comparator|A|Hyperbaric Oxygen Therapy
88984659|NCT00134628|Sham Comparator|B|Normal Air
88984660|NCT00105053|Experimental|vaccine group|
88984661|NCT00134745|Active Comparator|4 mg estradiol|
88984662|NCT00134745|Placebo Comparator|2 mg estradiol|
88984663|NCT00134823|Experimental|dosing decision support|weight based dosing decision support
88984664|NCT00134823|No Intervention|no decision support|no weight based dosing decision support
88984665|NCT00105365|Placebo Comparator|walking shoes|walking shoes
88984666|NCT00105365|Experimental|walking shoes + shoe insert|walking shoes + shoe insert
88984667|NCT00137592|Experimental|Lifestyle counseling|Behavioral: small media, group education (multicomponent)
88984668|NCT00105599|Other|Arm 1|
88984669|NCT01058707|Experimental|MLN0128 QD|MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).
88984670|NCT01058707|Experimental|MLN0128 QW|MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).
88984671|NCT01058707|Experimental|MLN0128 QDx3d QW|MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).
88984672|NCT01058707|Experimental|MLN0128 QDx5d QW|MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).
88984673|NCT01058707|Experimental|MLN0128 5 mg QD|MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).
88984674|NCT01058707|Experimental|MLN0128 30 mg QW|MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).
88984675|NCT01058707|Experimental|MLN0128 40 mg QW|MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).
88984676|NCT00105638|Other|Arm 1|
88984677|NCT00105677||Group 1|
88984678|NCT00105716|Other|Arm 1|
88984679|NCT00105755|Other|Arm 1|
88984680|NCT00105794|Other|Arm 1|
88984681|NCT01054144|Experimental|Response Adapted Therapy|Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
88984682|NCT00105833|Experimental|Arm 1|Multifaceted collaborative intervention for depression based in primary care
89612657|NCT03032614|Experimental|Combination of Carboplatin, Eribulin, and Veliparib|Eribulin will be administered intravenously (IV) on days 1 and 8 of each cycle at a dose of 1.1 mg/m2 over a 2-5 minute time period; on cycle day 1. Carboplatin will be administered intravenously at a dose of AUC 5 on day 1 of each cycle, over 30 min, immediately following eribulin infusion, per institutional guidelines. Veliparib will be given at 120 mg bid (two times a day), on days 2-12 for the first cycle of the safety run-in period and thereafter at 240 mg bid.
89612658|NCT04182490|Active Comparator|3000-mg cohort|LMN-101, six 500-mg capsules orally three times daily for 14 days (n=21)
89612659|NCT04182490|Placebo Comparator|Placebo cohort|Placebo, six 500-mg capsules orally three times daily for 14 days (n=21)
89612660|NCT03032458|Active Comparator|Pethidine|Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt)
89612661|NCT03032458|Active Comparator|Ketorolac|Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)
89612662|NCT03032458|Active Comparator|Xylocaine Gel|Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt)
89612663|NCT02245438|Experimental|TPV/RTV low dose|
89612664|NCT02245438|Experimental|TPV/RTV high dose|
89612665|NCT03032146|Experimental|participation in cardiac rehabilitation|Patients with at least a month of cardiac rehabilitation at The Emek Medical Center, Afula. Rehabilitation includes a multidisciplinary program based on physical exercise.
89612666|NCT03032146|No Intervention|control|Patients who chose not to participate in the rehabilitation program, despite being offered the option.
89612667|NCT03087669|Experimental|Observation of hemodynamic parameters|"LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.~MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated."
89612668|NCT00939952|Active Comparator|ertapenem 500 mg IV x1|All patients will receive ertapenem 500 mg IV once.
89612669|NCT02401815|Experimental|Part 1: PLX9486 250 mg QD|Participants will receive PLX9486 250 milligrams (mg) orally once daily (QD) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
89612670|NCT02401815|Experimental|Part 1: PLX9486 350 mg QD|Participants will receive PLX9486 350 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
89612671|NCT02401815|Experimental|Part 1: PLX9486 500 mg QD|Participants will receive PLX9486 500 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
89612672|NCT02401815|Experimental|Part 1: PLX9486 1000 mg QD|Participants will receive PLX9486 1000 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
89612673|NCT02401815|Experimental|Part 1: PLX9486 500 mg BID|Participants will receive PLX9486 500 mg orally twice daily (BID) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
88984683|NCT00105833|No Intervention|Arm 2|Treatment as usual
88984684|NCT00137787|Experimental|1|
88984685|NCT00137787|Active Comparator|2|
88984686|NCT04702048|Experimental|Aflibercept injection|Intravitreal injection of Aflibercept
88984687|NCT04702048|Placebo Comparator|Sham injection|Empty syringe with no needle
88984688|NCT00434551||1|Patients with suspected Crohn's disease
88984689|NCT00105872|Other|Arm 1|
88984690|NCT00105911|Other|Arm 1|
88984691|NCT00434824|Active Comparator|Arm 1|Oral testosterone undecanoate (Andriol)
88984692|NCT00434824|Placebo Comparator|Arm 2|Placebo
88984693|NCT00105950|Experimental|Lapatinib|Single arm study of lapatinib with no comparator arm.
88984694|NCT00434941|Experimental|Radiotherapy + Capecitabine|Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.) Experimental treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.
88984695|NCT00434980|Experimental|Treatment|Participant and family take part in FCA treatment program.
88984696|NCT00135096|Experimental|1|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
88984697|NCT00135096|Experimental|2|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
88984698|NCT00106067|Experimental|Arm 1|In the intervention arm, Patients and their family caregivers have access to a coping and communication support practitioner (CCSP) (see intervention description) in addition to receiving the usual care in the site.
88984699|NCT00106067|No Intervention|Arm 2|In the control arm, Patients are receiving the usual care in the site.
88984700|NCT00135135|Other|1|
88984701|NCT03278080|Other|driving test|
88984702|NCT04702282||unilateral Total knee arthroplasty|Patients receiving unilateral Total knee arthroplasty
88984703|NCT04702282||simultaneous bilateral Total knee arthroplasty|Patients receiving simultaneous bilateral Total knee arthroplasty y
88984704|NCT00435253|Experimental|BLVR Treatment|BLVR Treatment
88984705|NCT00435292|Experimental|flavocoxid 250 mg|flavonoid mixture
88984706|NCT00435292|Active Comparator|flavocoxid 500 mg|flavonoid mixture
88984707|NCT00435292|Active Comparator|naproxen|nonsteroidal antiinflammatory drug
88984708|NCT00435331|Experimental|1|Open Label
88984709|NCT00137865|Experimental|EGEN-001|
88984710|NCT00435643|Active Comparator|A|10 patients with severe OSAS (Apnea Hypopnea Index of more than 30 events per hour of sleep) were treated with nCPAP for three months and all mentioned measurements above were repeated.
88984711|NCT00435760|Active Comparator|Tiotropium|1 puff, 1 day treatment
88984712|NCT00435760|Placebo Comparator|Placebo|Tiotropium or Aclidinium Placebo, 1 day treatment
88984713|NCT00435760|Experimental|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
89612674|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Fasting)|Participants in fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
89612675|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Non-Fasting)|Participants in non-fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
89612676|NCT02401815|Experimental|Part 2e: PLX9486 500 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 500 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
89612677|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
89612678|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 37.5 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 37.5 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
88984714|NCT00435799|Active Comparator|A|
88984715|NCT02957734|Experimental|LAVA Ultimate restorations|For rehabilitation of the severely worn teeth, teeth are prepared (based on Minimal Invasive procedures), scanned using an intra-oral 3D-scanner (TrueDef, 3M), a digital wax-up model is made and finally restorations are milled from a pre polymerized block of resin (LAVA Ultimate). These indirect restorations are then adhesively cemented on the teeth (Relyx Ultimate, 3M). Teeth on which no indirect restoration could be made/designed a direct composite restoration was made using Filtek Supreme XTE in combination with Scotchbond Universal. Furthermore, all anterior veneer restorations are made of direct composite restorations (Filtek Supreme XTE in combination with Scotchbond Universal).
88984716|NCT00142467|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|For cycle 1 (14 days), bevacizumab 10 mg/kg was administered alone on day 1. For cycle 2 and beyond (28 days/cycle), bevacizumab 10 mg/kg was administered on days 1 and 15, gemcitabine 1,000 mg/m2 was administered as a dose rate infusion at 10 mg/m2/min followed by oxaliplatin at 85 mg/m2 on days 2 and 16. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
88984717|NCT02957461||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
88984718|NCT02957461||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
88984719|NCT04702321||Patient cohort|Patients with clinical data and biospecimens
88984720|NCT00436033|Placebo Comparator|Placebo|
88984721|NCT00436033|Experimental|Minalcipran|
88984722|NCT04702399|Experimental|GEL GROUP|Intracavitary application of an anti-adhesion hyaluronic acid gel (HYALOBARRIER® GEL ENDO)
88984723|NCT04702399|No Intervention|CONTROL GROUP|No Intervention
88984724|NCT03276052|Experimental|Aclidinium Bromide 400 μg|One inhalation from the 400 μg Aclidinium Bromide inhaler.
88984725|NCT03273322|Experimental|1: Rivaroxaban 10 mg qd|Rivaroxaban 10 mg, 1 tablet a day, from randomization to Day 90 should be taken between 8 and 10 AM
88984726|NCT03273322|Experimental|2: Rivaroxaban 15 mg qd|"Rivaroxaban 15 mg, 1 tablet a day, from randomization to Day 90~should be taken between 8 and 10 AM"
88984727|NCT03273322|Active Comparator|3: DAPT|Aspirin 75 mg, 1 a day Clopidogrel 75 mg, 1 tablet a day from randomization to Day 90 should be taken between 8 and 10 AM
88984728|NCT04702087|Experimental|OLEP|Omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
88984729|NCT04702087|Placebo Comparator|Placebo|isocaloric formula
88984730|NCT04701970|Other|changes in the occlusal load distribution|A crossover clinical study was carried out with previously constructed and used conventional complete dentures before relining with soft denture liners and then with the same dentures after relining with soft denture liners. patients were comfortably using their relined mandibular complete dentures for at least three months and the retention and stability of the conventional dentures were assessed before second recording of occlusal parameter. The evaluation of occlusal force distribution was carried out with the aid of T-Scan device
88984731|NCT04702009|Active Comparator|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy|Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy
88984732|NCT04702009|Experimental|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy|Anti-PD-1/PD-L1 Antibody, Chemotherapy, and Bronchoscopy-assisted Interventional Therapy
88984733|NCT00106145|Experimental|Part I - Arm 1|
88984734|NCT00106145|Experimental|Part II - Arm 1|
88984735|NCT00106145|Experimental|Part III - Arm 1|
88984736|NCT00106145|Experimental|Part IV - Arm 1|
88984737|NCT00106145|Experimental|Part V - Arm 1|
88984738|NCT04701697|Active Comparator|active comparator：HumanAlbumin|Participants received HumanAlbumin 10g/d
88984739|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 10g|Participants received Recombinant Human Albumin Injection 10g/d
88984740|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 20g|Participants received Recombinant Human Albumin Injection 20g/d
88984741|NCT04701697|Experimental|Experimental:Recombinant Human Albumin Injection 30g|Participants received Recombinant Human Albumin Injection 30g/d
88984742|NCT02957578|Experimental|Solo TTD|Placement of tympanostomy tube with Solo TTD
88984743|NCT04701775|Experimental|Lactobacillus rhamnosus GG Group|Participants received only 1x106 cfu Lactobacillus rhamnosus GG once a day for 8 weeks.
89612679|NCT00947752|Active Comparator|F1 Glatiramer acetate 20mg/1.0ml|
89612680|NCT00947752|Experimental|F2 Glatiramer acetate 20mg/0.5ml|
89612681|NCT03032692|Experimental|SWORD and exercise with biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. During the session, SWORD will be providing real-time audiovisual feedback. The patient has to start in the baseline position and fill the progress bar without violating movement or posture constraints. If the patient does not reach the goal or violates constraints he will receive a negative audio feedback, the progress bar will turn red and be reset. The patient has to return to the baseline position to restart the movement.
89612682|NCT03032692|Active Comparator|SWORD and exercise without biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. The patient will then be instructed to perform as many movements as possible during the allocated time (4 minutes), at a comfortable pace, starting at or below the baseline and trying to reach maximum flexion without significant pain or discomfort. During the session, the SWORD system will be recording the patient´s movement without providing feedback to the patient.
88984744|NCT04701775|Experimental|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis Group|Participants recevied a combined Lactobacillus acidophilus 1x109 cfu and Bifidobacterium animalis subsp.lactis 1x109 cfu once a day for 8 weeks.
88984745|NCT04701775|Placebo Comparator|Placebo|Those participants received placebo capsule once a day for 8 weeks.
88984746|NCT00106223|Experimental|1|Group receiving immediate treatment with cognitive behavioral therapy
88984747|NCT00106223|Active Comparator|2|Waitlist control group to begin CBT 3 months after other CBT group begins treatment
88984748|NCT04701892||Covid-19 infected patients|In this study male and female patients who were previously infected with covid-19 will be included. Patients will only be eligible if they had a positive covid-19 test before inclusion in the study. More specifically, only patients who had a positive COVID-19 test 2 to 8 weeks before study inclusion are eligible.
88984749|NCT00436150|Experimental|A|Participants will receive interpersonal therapy-based treatment
88984750|NCT00436150|Active Comparator|B|Participants will receive standard care
88984751|NCT00142623|Experimental|1|"Use of five tailored take-home DVDs aimed at reducing exposure to ETS"
88984752|NCT00142623|No Intervention|2|Usual care
88984753|NCT03278977|Other|ALTE group|Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
88984754|NCT03278977|Other|iALTE group|Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
88984755|NCT03278275|Experimental|uPAR PET/CT|One injection of the radioligand 68Ga-NOTA-AE105
88984756|NCT00106301|Experimental|FK228 (romidepsin)|romidepsin
88984757|NCT04701736|No Intervention|Routine Care|Routine care consists of an oncology pharmacist counselling the patient on supportive care medications prior to the patient getting his or her prescription dispensed.
88984758|NCT04701736|Active Comparator|Intervention|The intervention group will encompass the oncology pharmacist using the computer system to print a Picture Medication Calendar for the patient and use the calendar to explain supportive medications, in addition to routine care.
88984759|NCT00436306|Experimental|Individualized Intervention: stage-matched/tailored counseling|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
88984760|NCT00436306|Placebo Comparator|Control: Enhanced usual care counseling|The Enhanced Usual Care arm was the control group. It provided computer-based information regarding contraceptive methods, but was not individualized or tailored to the participant stage of change.
88984761|NCT00436423|Experimental|1|Gemcitabine with TS-1
88984762|NCT00436579|Experimental|Arm I (higher-dose enzyme inhibitor therapy)|Patients receive higher-dose oral sorafenib tosylate twice daily on days 15-36.
88984763|NCT00436579|Active Comparator|Arm II (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate three times daily on days 15-36.
88984764|NCT00436579|Active Comparator|Arm III (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate twice daily on days 15-36. (closed to accrual as of 4/29/2009)
88984765|NCT00436657|Experimental|Surgery + CHPP of Escalating Cisplatin|Abdominal Surgery + CHPP of Escalating Cisplatin (Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.)
88984766|NCT00106418|Experimental|Romidepsin|13 mg/m^2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
88984767|NCT00436696||Ancillary-correlative (SNP analysis)|DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
88984768|NCT00436930|Experimental|Arm I|Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
88984769|NCT00436930|Experimental|Arm II|Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
88984770|NCT00437086|Experimental|PS-341|Designed to assess the toxicity and pilot response of PS-341 in patients with advanced myeloproliferative diseases.
88984771|NCT00437320|Experimental|1|
88984772|NCT00437320|Placebo Comparator|2|
89612683|NCT03087747||Group 1|Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
89612684|NCT03087747||Group 2|Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
89612685|NCT03456687|Experimental|Exenatide|This group will receive a weekly Exenatide 2mg injection for one year.
89612686|NCT03497013|Experimental|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
89612687|NCT03497013|Sham Comparator|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
89612688|NCT03495375|Experimental|Treatment with a probiotic|Synbiotic2000Forte (SF) it is composed of 3 LAB species known to have anti-inflammatory effects and restoring the intestinal barrier, and 4 fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch, a formula that is currently produced by Synbiotic AB, Sweden.
89612689|NCT03495375|Placebo Comparator|Treatment with placebo powder|Placebo will be a non-digestable carbohydrate with similar texture and flavor to the SF also provided by Synbiotic AB, Sweden.
89612690|NCT00948298|Placebo Comparator|Placebo|
88984773|NCT00106496|Experimental|1A|
88984774|NCT00106496|Active Comparator|1B|
88984775|NCT00106496|Experimental|2|Open label
88984776|NCT00106496|Experimental|3A|
88984777|NCT00106496|Placebo Comparator|3B|
88984778|NCT00106496|Experimental|4|Open label
88984779|NCT00437359|Other|Fareston|Toremifene citrate: 40-mg tablets by mouth once daily.
88984780|NCT00437359|Other|Arimidex|Anastrozole: 1-mg tablets by mouth once daily.
88984781|NCT00437437|Experimental|1|
88984782|NCT00437476|Experimental|A|LPV/r + selected NRTIs for 26 weeks, followed by LPV/r monotherapy and anti HCV drugs for 48 weeks. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
88984783|NCT00437476|Active Comparator|B|LPV/r+ selected NRTIs for 24 weeks, followed by the same HAART and anti-HCV drugs for 48 weeks. At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decision. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
88984784|NCT00106574|Experimental|1|
88984785|NCT00106574|Placebo Comparator|2|
88984786|NCT02957383|Experimental|wavelength|Wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
88984787|NCT02957383|Experimental|intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2).
88984788|NCT00437632|Experimental|Subjects in Cohort-1 of Section 1|Subjects will be randomized to receive either GSK598809 10 mg or Placebo.
88984789|NCT00437632|Experimental|Subjects in Cohort-2 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
88984790|NCT00437632|Experimental|Subjects in Cohort-3 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
88984791|NCT00437632|Experimental|Subjects in Cohort-4 of Section 1|Subjects will be randomized to receive either GSK598809 40 mg or Placebo.
89612691|NCT00948298|Experimental|Vitamin D|
89612692|NCT05346783|Experimental|TJO-083 [Part 2]|1 drop 3 times a day
88984792|NCT00437632|Experimental|Subjects in Cohort-5 of Section 2|Subjects will be randomized to receive either ascending doses of GSK598809 75, 120 and 175 mg or Placebo. There will be a washout period of 6 days between the doses.
88984793|NCT00437632|Experimental|Subjects in Cohort-6 of Section 3|Subjects will receive caffeine on day -1 and after randomization subject will either receive GSK598809 or Placebo on Day 1. After washout period of 1-week subject will either receive GSK598809 or Placebo for 28 days.
88984794|NCT00437671|Experimental|Entered study|
88984795|NCT00106613|Experimental|FK228 (romidepsin)|13 mg/m2 of romidepsin
88984796|NCT00437749|Active Comparator|CBT-1|
88984797|NCT00437749|Placebo Comparator|Placebo|
88984798|NCT00437827|Active Comparator|1|Each subject in this arm will receive depression therapy similar to that used by the Star*D study - a major depression study conducted in the United States (Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Am J Psychiatry 2006; 163:1905-1917)
88984799|NCT00437827|Experimental|2|Each subject in this arm will receive therapy based upon an individualized rEEG report which provides one or more treatment options with the highest probability of success.
88984800|NCT03273790||NSCLC patients|Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
88984801|NCT03278665|Experimental|4SC-202 + Pembrolizumab|Single arm study of 4SC-202 in combination with Pembrolizumab
88984802|NCT00438022||1|Group 1 will include participants with AD, EH, and recurrent herpes simplex virus (HSV)
88984803|NCT00438022||2|Group 2 will include participants with AD and recurring HSV infections but without EH
88984804|NCT00438022||3|Group 3 will include participants with AD but without EH or HSV infection
88984805|NCT00438022||4|Group 4 will include participants in good general health without AD, EH, or HSV infection
89034735|NCT03952754|Experimental|Group 2: Hip Hop Nutrition-Math Curriculum|The intervention group will receive an tailored program for ten weeks, meeting twice a week.
89612693|NCT05346783|Placebo Comparator|Placebo of TJO-083 [Part 2]|1 drop 6 times a day
89612694|NCT05346783|Active Comparator|Diquas-s Ophthalmic solution 3% 0.4mL [Part 2]|1 drop 6 times a day
89612695|NCT00948610|Placebo Comparator|Placebo|Placebo-participant will receive placebo saline solution via IV route.
89612696|NCT00948610|Active Comparator|Remicade|Remicade-Participant will be given 10 mg/kg of drug via IV route.
89612697|NCT02245750|No Intervention|Routine Invistigations|ICSI with long luteal phase protocol
89612698|NCT02245750|Experimental|Hysteroscopy|hysteroscopy will be done prior to the ICSI cycle
89612699|NCT03032302|Experimental|Multivitamin|Swisse Womens 50+ Ultivite Multivitamin. Once daily.
89612700|NCT03032302|Experimental|Omega-3 Fatty Acids|Holland and Barrett Triple Strength Omega-3 Fish Oils. Once Daily
89612701|NCT03032302|No Intervention|Control|Treatment as usual (cognitive rehabilitation, occupational therapy, physiotherapy; as required)
89612702|NCT04053166|Experimental|Individualized home-based physical activity|The subjects of this arm will have a daily goal in number of steps based on the initial 2 first week evaluation of daily number of steps. They will wear connected wrists, and will be contacted twice a month by phone call by the adapted physical activity trainer to revaluate these goals.
89034736|NCT03952754|Active Comparator|Group 1: Food Explorers Program|The control group will receive the usual care for nutrition program provided by the schools, called Food Explorers. The group will also be conducted ten weeks, meeting twice a week.
89034737|NCT03945656|Experimental|Insulin 287 followed by insulin glargine|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.~After run-in, participants will receive insulin 287 once a week (OW) for 6 weeks.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 12 days."
89034738|NCT03945656|Active Comparator|Insulin glargine followed by insulin 287|"Run-in period (3 to 28 days): Once daily insulin glargine treatment with or without any usual metformin treatment.~After run-in, participants will receive insulin glargine U100 OD for 12 days.~After insulin glargine treatment, participants will receive insulin 287 OW for 6 weeks."
89034739|NCT03942952||CNS demyelinating diagnosis|"Diagnosis of CNS demyelinating disorder: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, anti-MOG antibody, Optic Neuritis.~3T and 7T MRI~Neuropsychological testing~Optical Coherence Tomography~Questionnaires: Quality of Life and Behavior scales~Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one to year and a half year later"
89034740|NCT03942952||Healthy Control|"3T and 7T MRI~Neuropsychological testing~Optical Coherence Tomography~Questionnaires: Quality of Life and Behavior scales~Non invasive clinical assessment : Walking, hand and eye coordination tests Repeat same research activities one year to a year and a half later"
89034741|NCT03903211|Experimental|Cognitively normal individuals|Cognitively normal individualswill receive a single IV injection of [18F]PI-2620.
89612703|NCT04053166|Active Comparator|Control group|The subjects of this arm will not have evaluation of daily steps and recommendations regarding physical activity and sedentary behaviour. They will be asked to live as usual.
89612704|NCT05430958|Experimental|Group 1|Single injection of 0.8 mg of INO-4800 followed by EP administered at Day 0
89612705|NCT05430958|Experimental|Group 2|Single injection of 0.8 mg of INO-4800 plus 0.05 mg of INO-9112 followed by EP administered at Day 0
89612706|NCT05430958|Experimental|Group 3|Single injection of 0.8 mg of INO-4800 plus 0.10 mg of INO-9112 followed by EP administered at Day 0
89612707|NCT05430958|Experimental|Group 4|Single injection of 0.8 mg of INO-4800 plus 0.20 mg of INO-9112 followed by EP administered at Day 0
89612708|NCT05430958|Experimental|Group 5|Two injections of 0.8 mg (1.6 mg total) of INO-4800 followed by EP administered at Day 0
89612709|NCT05430958|Experimental|Group 6|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.05 mg (0.1 mg total) of INO-9112 followed by EP administered at Day 0
89612710|NCT05430958|Experimental|Group 7|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.1 mg (0.20 mg total) of INO-9112 followed by EP administered at Day 0
89612711|NCT05430958|Experimental|Group 8|Two injections of 0.8 mg (1.6 mg total) of INO-4800 + 0.20 mg (0.40 mg total) of INO-9112 followed by EP administered at Day 0
89612712|NCT05428930|Experimental|CKDB-501B|
89612713|NCT05428930|Active Comparator|Botox® 50U|
89612714|NCT02982382|Experimental|Manipulative Treatment|Subjects will receive Manipulative Therapy
89612715|NCT02982382|Sham Comparator|Pain Education|Subjects will receive Pain Education and manual contact over lumbar region
89612716|NCT00944554|Placebo Comparator|Placebo|Group given placebo.
89612717|NCT00944554|Experimental|Varenicline|Experimental group given varenicline dosing.
89612718|NCT03031990|Experimental|Yoga intervention|The participants who elect to include yoga as part of their infertility treatments will self select one of three groups: 1) In person yoga for fertility group; 2) Online yoga for fertility group; 3) In person discussion only group
89034742|NCT03903211|Experimental|Subjects with Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment will receive a single IV injection of [18F]PI-2620.
89034743|NCT03903211|Experimental|Subjects with Alzheimer Disease|Alzheimer Disease Subjects with Alzheimer Disease will receive a single IV injection of [18F]PI-2620.
89034744|NCT03874416|Experimental|Specific rehabilitation of working memory|Specific rehabilitation of working memory according to hierarchized rehabilitation.
89612719|NCT03031990|No Intervention|Control|These are patients that have a history of IVF failure or who are undergoing elective egg freezing who elect to be included in the study but are not interested in including yoga as a part of their treatment.
89612720|NCT03031756|Experimental|test|SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation, glycine powder air-polishing (GPAP) was performed for 10 seconds per surface after the instrumentation (Air-Flows Perio Powder, EMS, Nyon, Switzerland) was applied using a Perio-Flows hand-piece connected to an airflow unit (Air-Flow Masters, EMS).
89612721|NCT03031756|Active Comparator|control|In the control group, SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation.
89612722|NCT00944710|Active Comparator|Intensified treatment|Weekend atropine 1% with plano lens over the sound eye
89612723|NCT00944710|Active Comparator|Control|Weekend atropine 1%
89034745|NCT03874416|Active Comparator|Control group|Non-specific rehabilitation of working memory, usual therapy.
89034746|NCT03866499|Experimental|BPI-7711|180 mg BPI-7711 capsule + 250mg gefitinib placebo tablet, QD
89034747|NCT03866499|Active Comparator|Gefitinib|180 mg BPI-7711 placebo capsule + 250mg gefitinib tablet, QD
89612724|NCT00945100|Active Comparator|Control|2 hours daily patching
89612725|NCT00945100|Active Comparator|Intensified treatment|42 hours per week of patching (averaging 6 hours daily)
89612726|NCT05384236|Experimental|kinesiology taping|Application of a neuromuscular bandage on the plantar fascia
89034748|NCT03861208|Experimental|diet|high fiber high protein foods served in childcare centers are offered for meals and snacks
89034749|NCT03861208|Other|usual diet|foods representing the usual diet in childcare centers are offered for meals and snacks
89034750|NCT03848728|Experimental|Intervention Clinics|SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers
89612727|NCT05384236|Active Comparator|taping or Low-dye taping|Application of a taping on the plantar fascia
89034751|NCT03848728|No Intervention|Control Clinics|Optimized country standard of care
89034752|NCT03848364|Experimental|Hip Hop Stroke 2.0 intervention group|"Students in 4th and 5th grade will receive the intervention, Hip Hop Stroke 2.0, disseminated and implemented by local Stroke Centers - uses a framework of Child-Mediated Health Communication to make children stroke literate and then empower these stroke literate students with the tools required to successfully communicate actionable stroke knowledge (recognition of stroke symptoms and the urgency of calling 911) to their parents and grandparents at home."
89034753|NCT03843775|Experimental|Binimetinib and Encorafenib|Patients will be initially enrolled to the approved dose of encorafenib 450 mg oral QD and binimetinib 45 mg PO BID, dose level 1. If confirmed this dose level is safely tolerated in the study population, we will then escalate treatment to dose level 2 with the novel dosing regimen of encorafenib 450 mg oral QD continuous and binimetinib 60 mg oral BID 21 days on/7 days off.
89034754|NCT03831477|Experimental|80 pin applicator|
89034755|NCT03831477|Active Comparator|160 pin applicator|
89612728|NCT03861130||Kawasaki disease|Kawasaki disease affected children
89612729|NCT03861130||parent of Kawasaki disease affected child|
89612730|NCT03031600|Active Comparator|Radiodilution via Daxor BVA-100|In study arm 1, actual blood volume will be measured using the Daxor Blood Volume Analyzer-100 (BVA-100). In this technique, the subject is injected with 1 ml of human serum albumin labeled with iodine131 (25 microcuries). A small amount of blood is collected from the subject just before injection and at 12, 18, 24, 30, and 36 min after injection.
89612731|NCT03031600|Experimental|Hemodilution via hematocrit measurement|In study arm 2, estimated blood volume will measured via hemodilution. . A blood sample (5 ml) will be drawn for baseline determination of hematocrit via iSTAT and lab measurement from the non-dominant arm. After the baseline hematocrit blood sample is drawn, a volume of normal saline equivalent to 10% of the subject's ideal blood volume will be administered over a 12-minute period through the dominant arm IV catheter. Twelve minutes after the infusion is complete, a second blood sample (5 ml) will be drawn from the non-dominant arm for determination of post-bolus hematocrit via iSTAT and lab. Subjects will then be asked to void into a urinal, and urine output will be measured in ml.
89612732|NCT00949078|Experimental|Open Label Omalizumab Group A|Omalizumab was dosed according to package insert. Patients who have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
89612733|NCT00949078|Experimental|Open Label Omalizumab Group B|Omalizumab was dosed according to package insert. Patients who do not have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
89612734|NCT00945256|Active Comparator|Young Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
89612735|NCT00945256|Active Comparator|Elderly Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
89612736|NCT00945256|Active Comparator|Young Sodium Nitroprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
89612737|NCT00945256|Active Comparator|Elderly Sodium Nitoprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
89612738|NCT00945256|Active Comparator|Elderly Sodium Nitroprusside and Amino Acid Drink|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally
89612739|NCT00940576|Experimental|mare´s milk|oral intake of of 250 ml mare´s milk
89034756|NCT03822962|Other|Standard Tylenol Regimen|"Patient will be given a standard regimen:~Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed."
89034757|NCT03822962|Active Comparator|Ibuprofen 600mg|Tylenol 1000 mg by mouth every 6 hours scheduled and ibuprofen 600 mg tablet by mouth every 8 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
89034758|NCT03785093||Chinese Family|Chinese parents and their offsprings
89034759|NCT03770260|Experimental|Treatment (ixazomib citrate, pevonedistat)|Patients receive ixazomib citrate PO QD on days 1, 8, and 15 of each cycle and pevonedistat IV over 60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89034760|NCT03762850|Experimental|sparsentan|Double-blind: Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400- mg and continue treatment to Week 110.
89034761|NCT03762850|Active Comparator|irbesartan|Double-blind: Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110.
89034762|NCT03762850|Experimental|dapagliflozin + sparsentan (Sub study)|OLE Sub study: Dapagliflozin will be administered daily as a 5-mg oral tablet, in addition to 400-mg of Sparsentan, for a period of 12 weeks.
89034763|NCT03762850|Experimental|sparsentan (Sub Study)|OLE Sub study: Sparsentan will be administered daily as a dose of 400-mg for a period of 12 weeks.
89612740|NCT00940576|Placebo Comparator|placebo drink|oral intake of of 250 ml placebo drink
89612741|NCT05354752|Experimental|VC005 Tablets Dose escalation groups|VC005 Tablets groups Repeat doses
89612742|NCT05354752|Placebo Comparator|VC005 Tablets Placebo groups|VC005 Tablets Placebo groups Repeat doses.
89612743|NCT03854032|Experimental|Arm I (BMS986205, nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD. Beginning week 2, patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days.
89612744|NCT03854032|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days.
88984806|NCT04701541|Other|Obese Patients undergoing Bariatric Surgery|"Obesity is a progressively growing morbid condition in the world, and given the direct relationship between body mass index (BMI) and costs, this has a major impact on economic and health policy. Obese patients undergoing bariatric surgery are at high risk for postoperative respiratory complications. In these patients, postoperative respiratory complications are related to various pathophysiological mechanisms that include: decreased lung volumes, respiratory muscle dysfunction and atelectasis. Demographic (age, gender, BMI) and clinical features of the population included: ASA, comorbidity and pre and postoperative respiratory function [PaO2/FiO2, haemogasanalysis (EGA)]. Ultrasound evaluation of DIA was performed.~T0: preoperative within 24h before surgery: DIA, haemogasanalysis; T1: Post operation: 60 min after extubation: Aldrete Score, DIA, EGA; T2: Post operation: 240 min after extubation: Aldrete, EGA."
88984807|NCT04701463|Experimental|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate supplement|
88984808|NCT04701463|Placebo Comparator|Placebo|
88984809|NCT03279913|Experimental|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
88984810|NCT03279835||Absence of cognitive disorder|
88984811|NCT03279835||Asymptomatic cognitive disorder|
88984812|NCT03279835||Symptomatic cognitive impairment|
88984813|NCT03279835||HIV associated dementia|
88984814|NCT03279757|Experimental|AHES 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 5 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
88984815|NCT03279757|Experimental|AHES 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 15 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
88984816|NCT03279757|Experimental|AHES 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 25 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
88984817|NCT03279757|Experimental|LTC 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 5 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
88984818|NCT03279757|Experimental|LTC 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 15 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
88984819|NCT03279757|Experimental|LTC 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 25 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
88984820|NCT03279757|Other|Unanesthetized skin|A pain stimulus will be given at unanesthetized skin with the fractional CO2 laser, 50 mJ, 5% density
88984821|NCT00438568|Placebo Comparator|1|saline
88984822|NCT00438568|Experimental|2|10 Units
88984823|NCT00438568|Experimental|3|20 Units
88984824|NCT00438607|Other|1|BIIB014 at MTD from Part A
88984825|NCT00438607|Other|2|BIIB014 at dose immediately below MTD from Part A
88984826|NCT00438607|Placebo Comparator|3|
88984827|NCT00438763||1|Subjects using the neoprene splint.
88984828|NCT00438763||2|Subjects using the orthoplast splint.
88984829|NCT00438919|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
88984830|NCT00438958|Active Comparator|Arm I|Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.
88984831|NCT00438958|Experimental|Arm II|Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.
89034764|NCT03759093|Active Comparator|Standard of Care|Dosing of VCD(bortezomib, cyclophosphamide,dexamethasone), VTD (bortezomib,thalidomide, dexamethasone), or VRD (Bortezomib, Lenalidomide, Dexamethasone) combinations according to standard of care
89612745|NCT02982226|Experimental|ReNu Injection|Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
89612746|NCT02982226|Active Comparator|Corticosteroid Injection|Plantar Fascia injection with Corticosteroids.
89612747|NCT03031288|Experimental|"Start feeding with Device A, standard"|Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
88984832|NCT00439036|Experimental|Behavior Therapy: Acceptance and Commitment Therapy|"The Act-ODT intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.~--------------------------------------------------------------------------------"
88984833|NCT00439036|Active Comparator|Drug Counseling|The Drug Counseling intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
88984834|NCT00439075|Experimental|CPAP|positive airway pressure
88984835|NCT00439075|Active Comparator|standard medical therapy|conventional oxygen therapy
88984836|NCT00107081|Active Comparator|Standard|Continued inpatient i.v. antibiotics
88984837|NCT00107081|Experimental|Experimental|Switch to outpatient p.o. antibiotics
88984838|NCT00439348|Experimental|Electronic prescription|Patients receive a prescription for specific over-the-counter medications.
88984839|NCT00439348|Active Comparator|Verbal advice|
88984840|NCT00439426|Experimental|1|
88984841|NCT00439582|Experimental|1|
88984842|NCT00439582|Experimental|2|
88984843|NCT00439621|Experimental|1|
88984844|NCT00439621|Experimental|2|
88984845|NCT00439621|Experimental|3|
88984846|NCT00439621|Placebo Comparator|4|
88984847|NCT00107237|Experimental|AEE788 200 mg + RAD001 5 mg|AEE788 200 mg qd, RAD001 5 mg qd
88984848|NCT00107237|Experimental|AEE788 150 mg + RAD001 5mg|AEE788 150 mg qd, RAD001 5 mg qod
88984849|NCT00439660|Experimental|rotavirus vaccine 116E 1 X 10(4)|vaccine dose of 1 X 10(4) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
88984850|NCT00439660|Experimental|rotavirus vaccine 116E 1 X 10(5)|vaccine dose of 1 X 10(5) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
88984851|NCT00439699|Experimental|Memantine|Tremor reduction
88984852|NCT00439816|Other|Arm 1|
88984853|NCT00439894||blood draw|One time blood draw
88984854|NCT00138177|Experimental|Treatment (vorinostat, mFOLFOX)|"Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD."
88984855|NCT04701229||normal karyotype|control group
88984856|NCT04701229||del5q-RBM22neg-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22, a loss of SLU7.
88984857|NCT04701229||del5q-RBM22neg-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22 but no loss of SLU7
88984858|NCT04701229||del5q-RBM22pos-SLU7neg|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22, but a loss in SLU7
88984859|NCT04701229||del5q-RBM22pos-SLU7pos|this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22 nor SLU7
88984860|NCT03279601|Experimental|A: Capecitabine Combined With Dacarbazine(CAPDTIC)|patients in arm A will receive chemotherapy of CAPDTIC regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
88984861|NCT03279601|Experimental|B: Capecitabine Combined Temozolomide(CAPTEM)|patients in arm B will receive chemotherapy of CAPDTEM regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o.d10-14 q4W
88984862|NCT00105586|Experimental|Escitalopram (1)|Escitalopram
88984863|NCT00105586|Placebo Comparator|Placebo (2)|Placebo
88984864|NCT00107432|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88984865|NCT00439972|Active Comparator|Group 1|Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R)
88984866|NCT00439972|Active Comparator|Group 2|Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
88984867|NCT00439972|Active Comparator|Group 3|Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R)
88984868|NCT00439972|Active Comparator|Group 4|Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R)
88984869|NCT00439972|Active Comparator|Group 5|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
88984870|NCT00439972|Active Comparator|Group 6|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R)
88984871|NCT00142740||1 - HIV Positive|Participant in parent study ATN 024, aged 12-24 years, testing HIV positive. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 024.
88984872|NCT00142740||2 - HIV Negative|Participant in parent study ATN 025, aged 12-24 years and testing negative for HIV infection. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 025.
88984873|NCT00440128|Active Comparator|Docetaxel|Docetaxel
88984874|NCT00440128|Experimental|Docetaxel/Casopitant|Docetaxel/Casopitant
88984875|NCT00440167|Active Comparator|Arm A|
88984876|NCT00440167|Active Comparator|Arm B|
88984877|NCT00107471|Experimental|Dose Level I (0.5 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
89612748|NCT03031288|Experimental|"Start feeding with Device B, vented"|Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
89612749|NCT03031522|Experimental|18F-IRS : EGFR+ Patients|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
89612750|NCT03031522|Experimental|18F-IRS :post-TKI EGFR+ Patients|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study .
89612751|NCT03031522|Experimental|18F-IRS:post-chemo EGFR+|18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
89612752|NCT03031522|Experimental|18F-IRS:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
89612753|NCT03031522|Experimental|18F-IRS:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
89612754|NCT03031522|Experimental|18F-IRS:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
88984878|NCT00107471|Experimental|Dose Level 2 (0.6 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)
88984879|NCT02957266|Active Comparator|Classical treatment|Classical concurrent cisplatin based chemoradiotherapy of cervical cancer. PIK3CA, KRAS, BRAF and RRM1 mutations rates.
88984880|NCT02957266|Experimental|GemInterBraVMAT|"Concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc radiotherapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.~PIK3CA, KRAS, BRAF and RRM1 mutations rates."
88984881|NCT03279562|Experimental|Nalmefene and recovery coaching|Nalmefene prescribed for daily ingestion during the first 3 months of treatment; patients who maintain a successful recovery during the first 3 months of treatment will be offered an option to take Nalmefene on as needed basis, always before encountering situations or circumstances with heightened risk of alcohol or opioid use
88984882|NCT03279523||F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
88984883|NCT00107510|Experimental|docetaxel + carboplatin + pegfilgrastim + surgery|"Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~No more than 6 weeks after completion of chemotherapy, patients undergo definitive surgery.~After completion of study therapy, patients are followed every 6 months until disease progression and then annually for up to 5 years. Patients who do not complete all 4 courses of chemotherapy or do not undergo surgery are followed every 6 months for up to 5 years."
88984884|NCT00440245|Other|salbutamol|There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
88984885|NCT00440323|Experimental|ADBC sequence|In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
88984886|NCT00440323|Experimental|BACD sequence|In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
88984887|NCT00440323|Experimental|CBDA sequence|In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
88984888|NCT00440323|Experimental|DCAB sequence|In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.
88984889|NCT00440362|Active Comparator|T1|
88984890|NCT00440362|Active Comparator|T2|
88984891|NCT00440362|Active Comparator|T3|
88984892|NCT00440362|Active Comparator|T4|
88984893|NCT00440362|Active Comparator|T5|
88984894|NCT00440362|Active Comparator|T6|
88984895|NCT00440362|Active Comparator|T7|
88984896|NCT00440362|Active Comparator|T8|
88984897|NCT00440362|Placebo Comparator|C1|
88984898|NCT00440362|Placebo Comparator|C2|
88984899|NCT00440362|Placebo Comparator|C3|
88984900|NCT00440362|Placebo Comparator|C4|
88984901|NCT00107549|Experimental|1|All participants in this study will receive two injections of the rMVA-HIV vaccine and the rFPV-HIV vaccine
88984902|NCT00440440|Active Comparator|1|testosterone gel
88984903|NCT00440440|Placebo Comparator|2|placebo gel
88984904|NCT00440479||001|Bortezomib dose as determined (observational study) by treating physician
88984905|NCT00107588|Experimental|Reinforcement for homework completion|
88984906|NCT00107588|Active Comparator|Reinforcement for Abstinence|
88984907|NCT00107588|Active Comparator|Case Management|
88984908|NCT00440674|Experimental|1|Direct stenting technique
88984909|NCT00440674|Experimental|2|Conventional stenting with pre-dilatation strategy
88984910|NCT00440752||AL|Cohort of study participants receiving treatment with artemether-lumefantrine
88984911|NCT00107627|Active Comparator|1|Skin staples;
88984912|NCT00107627|Active Comparator|2|Monocryl subcuticular sutures.
88984913|NCT00107627|Active Comparator|3|Caprosyn subcuticular sutures.
88984914|NCT00440869|Experimental|N-acetylcysteine|Active
88984915|NCT00440869|Placebo Comparator|placebo|placebo
88984916|NCT00441025|Active Comparator|1|1 Alemtuzumab
88984917|NCT00441220||A|Patients must have lupus nephritis and previously had therapy with intravenous cyclophosphamide.
88984918|NCT00441220||B|Patients must have lupus nephritis and are currently receiving therapy with intravenous cyclophosphamide.
89034765|NCT03759093|Experimental|CURATE.AI-guided dosing|CURATE.AI optimized modulation of bortezomib and cyclophosphamide dosages in the VCD (bortezomib, cyclophosphamide, dexamethasone), bortezomib and thalidomide in the VTD (bortezomib, thalidomide, dexamethasone) or bortezomib and lenalidomide in the VRD (bortezomib, lenalidomide, dexamethasone) combinations
89034766|NCT03756961|Active Comparator|Control|"Control group: The patients receive the routine based anesthesiological treatment during bariatric surgery (Gastric By-Pass or Sleeve Gastrectomy). It consists of:~General anesthesia induction: TCI Remifentanil Cpt 6 ng/ml/ Cp 3.2 ng/m, Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).~Maintained by Desflurane MAC (0.6-0.8) adjusted via BIS (40-60) and Remifentanil Cp 4-10 ng/ml.~Post-operative pain management: Oxycodone 2.5 mg iv if the pain is rated by patient NRS ≧3. Paracetamol 1 g/6 h and Diclofenac 80 mg/24 h."
89034767|NCT03756961|Experimental|Intervention|"Induction: Dexmedetomidine 0.2 micrograms/kg/h iv 5 min, Esketamine 0.1mg/kg + Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).~Maintained by Desflurane MAC (0.6-0.8) BIS (40-60), Dexmedetomidine 0.2 micrograms/kg/h, Esketamine 0.1-0.3mg/kg/h och 0.1 mg/kg in case of hypertension. At the end of surgery, Lidocaine 1 mg/kg iv (max 4 mg/kg /4 h)~Post-operative: Dexmedetomidine (0.1-0.2 micrograms/kg/h up to 4 h post-operative). If the pain is rated NRS ≧3: Transcutaneous Nerve Stimulation (TENS) with high intensive 40-50 mA for 1 minute, if the patient still NRS ≧3, the TENS treatment is repeated one more time. If pain NRS ≧3 after two treatments with TENS: Esketamine 0.1mg/kg iv + Lidocaine 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS still ≧3 within 30 minutes after both TENS and Esketamine/Lidocaine, 2.5 mg Oxycodone iv, with a 10 minutes intervals until NRS < 3. Perioperative and at discharge, PCC will be used for the the intervention (Phase 2 patients)"
89034768|NCT03749148|Active Comparator|Dupilumab|Dupilumab, s.c. administration 2 injections (600mg) as loading dose, 1 injection (300mg) every 14 days for a total of 16 weeks
89034769|NCT03749148|Placebo Comparator|Placebo|matching Placebo, s.c. administration 2 injections as loading dose, 1 injection every 14 days for a total of 16 weeks
89034770|NCT03737799||Group 1 Age 18-50 at diagnosis|Diagnosed with diabetes within the previous 1 year. Aged between 18 and 50 years at the time of diabetes diagnosis
89034771|NCT03737799||Group 2 Late Onset (insulin)|Diagnosed with diabetes within the previous 1 year. Aged >50 at the time of diabetes diagnosis and treated with insulin therapy
89034772|NCT03737799||Group 3 Late Onset (no insulin)|Diagnosed with diabetes within the previous 1 year. Aged >50 at the time of diabetes diagnosis and treated without insulin
89034773|NCT03737110|Experimental|Rilonacept|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.~RW period: eligible participants randomized to double-blinded administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
89057296|NCT04543448|Experimental|Cervical Mobilization|Cervical Mobilization program, cervical mobilization techniques were applied to the patients for 30 minutes in addition to the traditional program. Cervical mobilization includes suboccipital relaxing techniques, myofascial muscle relaxing techniques for Levator scapula, trapezius, scalenes muscles. These techniques were applied bilaterally.
89057297|NCT01681485||NSCL cancer patients|Surgery, chemotherapy and/or radiation therapy
89612755|NCT03031444|Active Comparator|chemotherapy plus cetuximab|Cetuximab plus FOLFIRI/FOLFOX:FOLFIRI plus cetuximab [Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1;Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1;5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.Repeat every 2 weeks.Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks] or FOLFOX plus Cetuximab [Oxaliplatin 85 mg/m2 IV over 2 hours, day 1 Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks;Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks]
89612756|NCT03031444|Active Comparator|perioperative chemotherapy alone|FOLFIRI/FOLFOX/CapeOX:routine perioperative chemotherapy including FOLFIRI[Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1 5-FU 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks] or FOLFOX[Oxaliplatin 85 mg/m2 IV over 2 hours, day 1;Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks] or CapeOX[Oxaliplatin 130 mg/m2 IV over 2 hours, day 1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks] was adopted in this control arm.
89612757|NCT02980354||Lacunar stroke|Blood samples will be taken from 50 patients who have been diagnosed to have lacunar stroke and are 65 years of age or above.
89612758|NCT02980354||Cortical stroke|Blood samples will be taken from 50 patients who have been diagnosed to have cortical stroke and are 65 years of age or above.
89612759|NCT02980354||Elderly healthy volunteers|Blood samples will be taken from 50 healthy individuals who are 65 years of age or above.
89612760|NCT02980354||Young healthy volunteers|Blood samples will be taken from 50 healthy individuals who are between 18 and 64 years of age.
89612761|NCT05320042|Experimental|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
89612762|NCT05320042|Active Comparator|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
89612763|NCT02982304|Active Comparator|Pallidal (GPi) Deep Brain Stimulation|GPi is the standard target for treating most dystonia. This setting will be the active comparator
89612764|NCT02982304|Experimental|Thalamic (Vim) Deep Brain Stimulation|Vim is the standard target to treat cerebellar dysfunction in movement disorders. It is not routinely used in secondary dystonia
89612765|NCT02982304|Experimental|GPi + Vim (Multi-Target) Deep Brain Stimulation|Combined stimulation of GPi and Vim stimulation (both electrodes ON)
89612766|NCT02980198|Experimental|IFN-Kinoid|IFN-Kinoid + ISA 51
89612767|NCT02980198|Placebo Comparator|Placebo|Placebo + ISA 51
89612768|NCT05258734|Experimental|COVOS app|
88984919|NCT04700995|Experimental|ProTaper rotary NiTi instruments|The ProTaper Universal Retreatment rotary system and ProTaper Gold rotary system were used.
88984920|NCT04700995|Experimental|Hyflex EDM rotary NiTi instruments|Hyflex EDM rotary system was used.
88984921|NCT04700995|Experimental|Reciproc Blue reciprocating NiTi instruments|Reciproc Blue reciprocating system was used.
88984922|NCT04700995|Experimental|Waveone Gold reciprocating NiTi instruments|WaveOne Gold reciprocating system was used.
88984923|NCT00441298|Experimental|1|Tenofovir gel (a reverse transcriptase inhibitor)
88984924|NCT00441298|Placebo Comparator|2|Universal HEC placebo
88984925|NCT00441376|Experimental|ThermoDox + RFA|ThermoDox administered as single dose intravenously over 30 minutes in combination with radiofrequency ablation. Dose is determined by dose cohort patient enters study.
88984926|NCT00441454|Active Comparator|A|Retropubic Tension-free Vaginal Tape (TVT)
88984927|NCT00441454|Active Comparator|B|Transobturator Tension-free Vaginal Tape (TVT-O)
88984928|NCT02964728|Experimental|Botulinum toxin type A|Botulinum neurotoxin injections
88984929|NCT02964728|Placebo Comparator|Placebo|Normal saline solution injections
88984930|NCT00441610|Experimental|Gimatecan|
88984931|NCT00441688|Experimental|GI265235|
88984932|NCT04700683|Active Comparator|Noninvasive Peripheral Nerve Stimulation|NPNS device programmed to deliver active stimulation.
88984933|NCT04700683|Sham Comparator|Sham control|NPNS device programmed to deliver sham stimulation.
88984934|NCT02957344||Text without context|
88984935|NCT02957344||Text with context|
88984936|NCT02957344||Map without context|
88984937|NCT02957344||Map with context|
88984938|NCT03279484|Experimental|NAVIGO 4LV implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
88984939|NCT03279328|Active Comparator|Topical Steroid Ointment|One side of the face will receive a Topical Steroid ointment twice daily for seven days.
88984940|NCT03279328|Active Comparator|Vaseline|One side of the face will receive Vaseline twice daily for seven days.
88984941|NCT03279328|Active Comparator|Skin Barrier Moisturizer|One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.
88984942|NCT03279133|Experimental|LDV/SOF for 12 weeks.|Ledipasvir 90mg/Sofosubvir 400mg fixed-dose combination (FDC) tablet for 12 weeks.
88984943|NCT00441922|Experimental|1|D
89612769|NCT05258734|Active Comparator|Control Group|
88984944|NCT00441922|Experimental|2|V
88984945|NCT00442156||Laser|People with diabetic macular edema involving the center of the macula (OCT central subfield thickness >250 microns), who were already intended to receive focal photocoagulation
88984946|NCT03279055|Experimental|SHUTi|"Participants will be provided with an individual access code for SHUTi~SHUTi is delivered over 6 sessions, each taking 20-30 minutes~SHUTi is delivered by a virtual therapist~Participants will learn about the etiology and maintenance of their insomnia~Participants will learn how to maintain their sleep log~Participants will learn how to address lifestyle barriers that impact their sleep~Participants will be taught stimulus control techniques targeting non-sleep behaviors in the bedroom~Participants will learn a range of cognitive techniques that address the key cognitive factors that perpetuate poor sleep behavior~Participants will be taught how to gradually expand their restricted sleep"
88984947|NCT03278938|Active Comparator|bupropion added to citalopram|patients who did not remit with citalopram will continue at the same dose and have bupropion added
88984948|NCT03278938|Active Comparator|citalopram added to bupropion|Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
88984949|NCT03278860|Experimental|Oxytocin then placebo|Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
88984950|NCT03278860|Experimental|Placebo then oxytocin|Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
88984951|NCT03278743||low to moderate tea consumption|consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
88984952|NCT03278743||High tea consumption|consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
88984953|NCT03278704|Other|RE training only|RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
88984954|NCT03278704|Experimental|Concurrent RE + HIIT|RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
88984955|NCT00442624||1|Patients with chronic insomnia
88984956|NCT00442624||2|age, sex, bmi matched healthy controls
88984957|NCT00108173|Other|Arm 1|
88984958|NCT00442741|Experimental|Patupilone + Midazolam|
89612770|NCT02980432|Experimental|intervention arm|all participants will be assigned to the same arm. Interventions applied include presenting a visual line or a rod with or without a moving (rotating) background while being in different whole-body roll positions. Participants will be asked to adjust the line or the rod along perceived direction of gravity.
88984959|NCT00442741|Experimental|Patupilone + Omeprazole|
88984960|NCT00442780|Placebo Comparator|1|Dose Level A of BIIB014
88984961|NCT00442780|Placebo Comparator|2|Dose Level B of BIIB014
88984962|NCT00442780|Placebo Comparator|3|Dose Level C of BIIB014
88984963|NCT00442780|Placebo Comparator|4|Dose Level D of BIIB014
88984964|NCT00404586|Experimental|Treatment period 1|In treatment period subjects will receive once daily 100 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
88984965|NCT00404586|Experimental|Treatment period 2|In treatment period subjects will receive once daily 200 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
88984966|NCT00404586|Experimental|Treatment period 3|In treatment period subjects will receive once daily 400 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
89057298|NCT04543370|Experimental|Treatment A|2 mg midazolam on Day 1 and 36 mg deflazacort on Day 2.
89612771|NCT03031132|Experimental|HP-Beverage Breakfast|For 7 days, the participants will consume high protein beverage breakfast meals each morning. These meals will consist of shakes and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35g CHO, and 10g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
89612772|NCT03031132|Experimental|HP-Solid Breakfast|For 7 days, the participants will consume high protein solid breakfast meals each morning. These meals will consist of traditional solid breakfast meals and will include commonly consumed breakfast foods (e.g., burritos, waffles, etc.) and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35 g CHO, and 10 g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
89612773|NCT03031132|Experimental|Breakfast Skipping|For 7 days, the participants will skip the morning meal. No food or calorie-containing beverages will be consumed before 12pm on acclimation days and no food consumed until ~5h post habitual breakfast time on testing day 7.
89612774|NCT03031054|Experimental|hyaluronic acid hydrodissection|Ultrasound-guided hydrodissection with 2.5cc hyaluronic acid between carpal tunnel and median nerve.
89612775|NCT03031054|Active Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with 2.5cc normal saline between carpal tunnel and median nerve.
89612776|NCT03031366|Experimental|3D roadmap|TIPS was established using 3d roadmap guidance
89612777|NCT03031366|Active Comparator|conventional TIPS|conventional TIPS procedure using wedged hepatic venography
88984967|NCT00404586|Placebo Comparator|Treatment period 4|In treatment period subjects will receive once daily Placebo and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive Placebo and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
88984968|NCT00108251|Placebo Comparator|1|placebo tablet
88984969|NCT00108251|Experimental|2|eplerenone tablets
88984970|NCT00443014|Experimental|A Cognitive stimulation therapy|Patients with recently diagnosed dementia in five of the study municipality.
88984971|NCT00443014|No Intervention|B Care as usual|
88984972|NCT00443092|Experimental|1|proprietary tart cherry juice blend (8 oz., BID)
88984973|NCT00443092|Placebo Comparator|2|control juice (color matched kool aid blend),(8 oz., BID)
88984974|NCT00443131|Experimental|Group A|
88984975|NCT00443131|Experimental|Group B|
88984976|NCT00443131|Experimental|Group C|
88984977|NCT00443248|Experimental|Vaginal Heat Wash-Out Device|
88984978|NCT04700254||working condition|In order to further explore the differences among working status the data will be categorized into three different groups: suspension of work, employment and unemployment.
88984979|NCT04700254||Family status|In order to xplore the differences among the family status, the data will be categorized into the married and the singles DM patients.
88984980|NCT04700254||BMI status|In order to further explore BMI scale results, we divided the data obtained from the participants into normal (18.50 - 24.99 kg/m2), overweight (25-29.99 kg/m2) and obese (≥30 kg/m2), according to the international classification of the World Health Organisation (WHO).
88984981|NCT04700020|Other|Patients above the age of 18 years|"In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal.~MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland."
88984982|NCT04700332|Experimental|High risk prostate cancer|DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy
88984983|NCT04700332|Experimental|Biochemically recurrent prostate cancer|DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.
88984984|NCT00443365|No Intervention|1|Coronary Artery Bypass Grafting with no Mitral Valve intervention
88984985|NCT00443365|Active Comparator|2|Coronary Artery Bypass Grafting + Mitral Annuloplasty
88984986|NCT00443404|Active Comparator|1|perioperative epidural analgesia
88984987|NCT00443404|Active Comparator|2|Iv PCA Fentanyl preoperative, Epidural analgesia postoperative
88984988|NCT00443404|Active Comparator|3|perioperative IV PCA Fentanyl, epidural anesthesia
88984989|NCT00443404|Active Comparator|4|perioperative IV PCA Fentanyl general anesthesia
88984990|NCT00443404|Placebo Comparator|5|IV PCA with saline 0.9% and sc saline 0.9%in the L3-L4 area. IM meperidine, po codeine/acetaminophen, IV acetaminophen and IV parecoxib
88984991|NCT04700293|Experimental|AYMES AMSTERDAM|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'AMSTERDAM' for a period of > 7 days.
88984992|NCT03278470|Experimental|HL237 50mg|take oral tablet once
88984993|NCT03278470|Experimental|HL237 100mg|take oral tablet once
88984994|NCT03278470|Experimental|HL237 200mg|take oral tablet once
88984995|NCT03278470|Experimental|HL237 400mg|take oral tablet once
88984996|NCT03278470|Experimental|HL237 800mg|take oral tablet once
88984997|NCT03278470|Experimental|HL237 1200mg|take oral tablet once
88984998|NCT03278470|Experimental|HL237 1600mg|take oral tablet once
88984999|NCT00108407|Experimental|1|Integrated Cognitive Behavioral Therapy
88985000|NCT00108407|Experimental|2|Twelve Step Facilitation Therapy
88985001|NCT03278431|Active Comparator|Albendazole triple combi|Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
88985002|NCT03278431|Experimental|Pyrantel pamoate double combi|Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
88985003|NCT03278431|Experimental|Albendazole double combi|Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
88985004|NCT03278431|Experimental|Mebendazole triple combi|Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
88985005|NCT04699825|Active Comparator|study group|new-born infants born from preeclampsia mother
88985006|NCT04699825|Other|control group|new-born infants born from mothers with normal pregnancy matched with the same gestational age, sex and race
88985007|NCT00443638|No Intervention|Control Group|Control Group
89612778|NCT00945334|Experimental|Group 1|Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
89612779|NCT00945334|Experimental|Group 2|Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
89612780|NCT03578224|Experimental|Diagnostic (EUS, FNA, perflubutane microbubble)|Participants undergo standard of care unenhanced endoscopic ultrasound (EUS) and fine needle aspiration (FNA) of identified lymph nodes. Participants then receive perflubutane microbubble peri- or intratumorally and undergo contrast-enhanced EUS followed by FNA of identified lymph nodes.
89612781|NCT03559114|Active Comparator|Anticoagulant|Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
89612782|NCT03559114|Placebo Comparator|Saline|Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.
89612783|NCT03492021|Experimental|Adequate Protein_Carbohydrate Post Therapy|Diet Intervention - Adequate Protein (1.0 g/kg/d) - Carbohydrate Post Therapy [AP-CPT]
89612784|NCT03492021|Experimental|Optimal Protein_Protein Post Therapy|Diet Intervention - Optimal Protein (2.0 g/kg/d) - Protein Post Therapy [OP-PPT]
89612785|NCT05198908|Experimental|VR group|VR (virtual reality glasse) group
89612786|NCT05198908|Experimental|skin to skin group|skin to contact group
88985008|NCT00443638|Experimental|Home visitation through pregnancy|Nurse home visitation through pregnancy
89612787|NCT05198908|No Intervention|Control group-none|Women in this group will not be subjected to any treatment other than the routine hospital protocol. Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary.
89612788|NCT05153590||Reimbursed|The reimbursed cohort includes only patients who received Saxenda® through mandatory basic insurance
89612789|NCT05153590||Non reimbursed|The non reimbursed cohort includes patients who received Saxenda® through additional private insurance or self-pay
88985009|NCT00443638|Experimental|Home visitation through age 2|Nurse home visitation through child age 2.
88985010|NCT00443677|Active Comparator|abvd|
88985011|NCT00443677|Experimental|beacopp|
88985012|NCT00443677|Experimental|coppebvcad|
88985013|NCT00443794|Experimental|1, POLYCAP|Combination of 3 anti hypertensives, lipid lowering agent and anti platelet agent
88985014|NCT00443794|Active Comparator|2 B|Diuretic antihypertensive
88985015|NCT00443794|Active Comparator|3 C|Thiazide plus Angiotensis converting enzyme inhibitor - combination antihypertensive.
88985016|NCT00443794|Active Comparator|4 D|Diuretic with Beta blocker combination antihypertensive
88985017|NCT00443794|Active Comparator|5, E|ACE inhibitor plus Beta blocker combination antihypertensive
88985018|NCT00443794|Active Comparator|6, F|Combination antihypertensive of ACE inhibitor, diuretic and beta blocker
88985019|NCT00443794|Active Comparator|7,G|Combination of ACE inhibitor, betablocker, diuretic and Antiplatelet
88985020|NCT00443794|Active Comparator|8,H|Lipid lowering agent
88985021|NCT00443794|Active Comparator|9,A|Antiplatelet
88985022|NCT00108602|Other|1|
88985023|NCT00138684|Experimental|Venesection therapy|
88985024|NCT00138684|No Intervention|no venesection therapy|
88985025|NCT00444184|Active Comparator|Travoprost/Timolol therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost/timolol drops
88985026|NCT00444184|Active Comparator|Travoprost therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost drops
88985027|NCT00444223|Experimental|fluorine F 18 FEQA + positron emission tomography|
88985028|NCT00444262|Active Comparator|1|conventional treatment
88985029|NCT00444262|Experimental|2|stroke volume optimisation
88985030|NCT03278236|Experimental|TRF|
88985031|NCT03278197|Experimental|1.Patients|"Patients diagnosed with prostate cancer and ex-prostate cancer patients:~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
88985032|NCT03278197|Other|2.Clinicians|"Radiotherapy-oncologists, Urologists, General practitioners, Nurses~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
88985033|NCT03278197|Other|3.Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
88985034|NCT03278158|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
88985035|NCT03278158|Experimental|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
88985036|NCT03278158|Experimental|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet. Discontinued after 2 patients due to good safety. Escalation to higher dose levels in whole study (1, 2 and 4 mg changed to 1, 4 and 8 mg)
88985037|NCT03278158|Experimental|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
88985038|NCT03278158|Experimental|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
88985039|NCT03278041|Experimental|surgical reconstruction with submental flap|surgical reconstruction with submental flap
88985040|NCT03278041|Active Comparator|maxillary obturator|maxillary obturator
88985041|NCT03277963|Active Comparator|Absence of sleep apnea syndrome|Pain perception tests
89612790|NCT03030898|Other|respiratory variation of the right internal jugular vein|
89612791|NCT00089973|Experimental|SB-715992|Females with advanced or metastatic breast cancer were administered Ispinesib
89612792|NCT03030820|Experimental|Dental cleaning|Patients with cirrhosis and healthy controls will undergo dental examination and subsequent dental cleaning if necessary.
89612793|NCT03030742||Post-cesarean delivery|Women who have undergone cesarean delivery
89612794|NCT03030742||Post-vaginal delivery|Women who have undergone vaginal delivery
89612795|NCT04402203|Experimental|Favipiravir + Standard Treatment|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
89612796|NCT04402203|Placebo Comparator|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs & the medication any patient is on due to any concomitant diseases.
89612797|NCT03030976|Experimental|Reduce B cells|Patients receive cyclophosphamide to reduce B cells before CD19-CART infusion. It will also reduce the side effects of cell damage due to antitumor activity.
89612798|NCT03030976|Experimental|Treatment of SLE|Patients receive anti-CD19-CAR-T cells to treatment of SLE. The purpose of this study is to assess the safety and efficacy of CD19 CAR-T cells in the treatment of SLE.
89612799|NCT03454425|Experimental|Exablate Subthalamotomy|Exablate treatment for Parkinson's Disease Motor Features
89612800|NCT03454425|Sham Comparator|Sham ExAblate Subthalamotomy|
89612801|NCT00949234|Other|Open-Label|This was an open-label demonstration project. Therefore, medications were not blinded and participants were made aware of the regimen they received for PEP.
89612802|NCT02984787|Experimental|3D Laparoscopic total gastrectomy|Participants including in the 3D laparoscopic total gastrectomy (3D-LTG) group will undergo 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
89612803|NCT02984787|Active Comparator|2D Laparoscopic total gastrectomy|Participants including in the 2D laparoscopic total gastrectomy (2D-LTG) group will undergo 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
89612804|NCT03090880|No Intervention|Control|usual care,
89612805|NCT03090880|Experimental|Experimental|tinzaparin sodium
88985042|NCT03277963|Experimental|Presence of sleep apnea syndrome|Pain perception tests and for severe sleep apnea syndrome, treatment by positive airway pressure (PPC) ventilation
88985043|NCT03275701|Other|Triumeq|Single Arm, Open Label
88985044|NCT03275467|Experimental|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
88985045|NCT00451165||colon|
88985046|NCT00451165||rectum|
88985047|NCT04698616||Malignant lymphoma patients|Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.
88985048|NCT04698928|Experimental|Theta burst stimulation group|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
88985049|NCT04698772||Survey Packet 1 Group|"Patients who receive Packet 1 will be in group 1, or the treatment group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions [age, sex, race, height, weight, etc.], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2. The physician will be asked to administer a sub-dissociative dose of ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)."
88985050|NCT04698772||Survey Packet 2 Group|"Patients who receive Packet 2 will be in group 2, or the control group. In this packet will be 4 forms: the consent to participate in the study form, a pre-treatment questionnaire (VAS and other demographic information), post-treatment questionnaire (various questions, including demographic questions [age, sex, race, height, weight, etc.], a 10cm (100mm) VAS for pain, a 10cm (100mm) VAS to measure patient satisfaction, and a Likert Scale to measure patient satisfaction), and a form with specific instructions for the physicians to follow that vary depending on whether the instructions are from Packet 1 or Packet 2.The physician will be asked to administer morphine 4 mg IV push over 3-5 minutes for pain control."
88985051|NCT03275428||THRIVE group|Patients receiving non-intubated thoracic surgery for lung nodule resections using intravenous sedation and transnasal humidified rapid-insufflation ventilator exchange
88985052|NCT03275428||Double lumen group|Patients receiving non-intubated thoracic surgery for lung nodule resections using general anesthesia and double lumen endobronchial tube
88985053|NCT00139074|Active Comparator|1|quetiapine fumarate monotherapy
88985054|NCT00139074|Experimental|2|Quetiapine + sodium valproate
88985055|NCT00451867|Active Comparator|A|2000 mg per day of CellCept (MMF) divided into 2 equal doses.
88985056|NCT00451867|Placebo Comparator|B|Placebo
88985057|NCT00143130|Experimental|Single Arm|
89612806|NCT03490695|Experimental|Practice Facilitation Group A|After the first 12 months of usual care (No Practice Facilitation), group A will begin to receive the Practice Facilitation (PF) Strategy at the CHPS compounds in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package.
89612807|NCT03490695|Experimental|Practice Facilitation Group B|"Group B will receive Usual Care (no PF) between 12-24 months which includes Ghana's National Health Insurance, behavioral counseling and referral to care through the usual care system.~After 24 months into the trial, Group B will then receive Practice Facilitation strategy in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package for a duration of another 12 months, as this is a stepped wedge design.~During this 12 months period, practice facilitation will end in the Group A arm."
89612808|NCT03489993||FGF23-Related Hypophosphatemic Diseases|The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
89612809|NCT02245594||Gl motility and sleep pattern|
89612810|NCT00951808|Active Comparator|Blood Transfusion Trial Cohort|Twenty participants will receive a blood transfusion while in the hospital.
89612811|NCT00951808|Active Comparator|Standard Care Trial Cohort|Twenty participants will not receive a blood transfusion and will receive standard care.
89612812|NCT00951808|Active Comparator|Standard Care Observational Cohort|Approximately 300 participants who are ineligible for or decline the blood transfusion part of the study will participate in the observational portion of the study and receive standard care.
89612813|NCT03030508||Group cap|Patients receiving capecitabine chemotherapy after operation
89612814|NCT03030430|Experimental|BAT1706|BAT1706 injection
89612815|NCT03030430|Active Comparator|EU-sourced Avastin|EU-sourced Avastin
89612816|NCT03030430|Active Comparator|US-sourced Avastin|US-sourced Avastin
89612817|NCT03030586||Alzheimer|400 patients in total, with approximately 200 patients with mild Alzheimer's disease and 200 patients with moderate to severe Alzheimer's disease will be recruited for sampling blood, urine (and other peripheral body fluids: tears and saliva as optional) for validation of biomarkers
89612818|NCT03030586||Non-Alzheimer neurodegenerative disease|"200 patients comprising:~75 patients with behavioural variant of Fronto-Temporal Lobe Degeneration (FTD),~50 patients with Parkinson's disease dementia (PDD),~50 patients with Dementia with Lewy Bodies (DLB) and~25 patients with Progressive Supranuclear Palsy (PSP) or cortico-basal degeneration (CBD)"
89612819|NCT03030586||Healthy Controls|200 healthy subjects
89612820|NCT00089661|Experimental|AMG 162 / Denosumab|
89612821|NCT00089661|Placebo Comparator|Placebo|
89612822|NCT00941668|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
89612823|NCT00941668|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
89612824|NCT03488121|Experimental|Poster Only|This arm will only receive motivational posters.
89612825|NCT03488121|Experimental|Thank-you Letter Only|This arm will only receive thank-you letters.
89612826|NCT03488121|Experimental|Double Incentive|This arm will receive both motivational posters and thank-you letters.
88985058|NCT04698733|Experimental|Experimental: BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive 2 treatments a week on nonconsecutive days for 6 weeks in the clinic with an active electrical stimulation device.
88985059|NCT04698694|Experimental|Subjects treated with Cliniporator® using a voltage amplitude of 40 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 40 V.
88985060|NCT04698694|Experimental|Subjects treated with Cliniporator® using a voltage amplitude of 60 V|10 subjects deemed eligible are between 18-55 y of age respected the inclusion and exclusion criteria will be selected in a randomized way (1:1) and treated with a voltage amplitude of 60 V.
88985061|NCT00452218|Experimental|Open|
88985062|NCT03275116|Active Comparator|Twice daily dual bronchodilation|Twice daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg during 4 days
88985063|NCT03275116|Active Comparator|Once daily single bronchodilation|Once daily Tiotropium 'Respimat' 5 mcg during 4 days
88985064|NCT03275077||Controls|Normal Healthy Volunteers
88985065|NCT03275077||ESRD patients|Patients with ESRD who have not received hemodialysis. Patients with known bleeding disorders, coexisting liver diseases, those who were on antiplatelet or anticoagulant therapy and patients who had received red blood cells, fresh frozen plasma or platelet transfusions in the past three months were excluded from the study.
88985066|NCT03275038|No Intervention|Control group|Maintain the original life style
88985067|NCT03275038|Experimental|Tai-Chi exercise group|Receive three one-hour Tai Chi exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
88985068|NCT03275038|Experimental|Aerobic exercise group|Receive three one-hour aerobic exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
88985069|NCT00452257|Experimental|A|
88985070|NCT00452491|Experimental|1|
88985071|NCT00452491|Active Comparator|2|
88985072|NCT00452569|Experimental|A|Oral thalidomide (100mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
88985073|NCT00452569|Experimental|B|Oral thalidomide (200mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
88985074|NCT00452569|Experimental|C|Oral thalidomide (400mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
88985075|NCT00452569|Active Comparator|D|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
88985076|NCT00452608|Placebo Comparator|amido pill|
88985077|NCT00452608|Experimental|atorvastatina|atrovastatina 80 mg/d by mouth for 10 days
88985078|NCT00452803|Active Comparator|study arm|pre-operative chemotherapy (Pac/Cis)
88985079|NCT00452803|Active Comparator|study arm 2|Pre-operative concurrent chemoradiation therapy
88985080|NCT00452881|Experimental|study arm|GemOx
88985081|NCT00452881|Active Comparator|control arm|GemCis
88985082|NCT00453037|Active Comparator|group I (early intervention)|"We refer to the results of the DAFNE-study. This study showed the merits of an educational program in diabetics. In accordance to the protocol of DAFNE, we developed a design as follows: For each participating center patients are randomly assigned to two groups. Group I receives an early educational intervention at time of randomization, which should lead to better control of blood pressure after 6 months compared to the control group. The protocol design was chosen for proving an independent effect of the educational program despite optimal management by the GP. Group II is designated to receive the educational intervention 6 months after enrollment into the study.~for further details please see brief description section"
88985083|NCT00453037|Other|delayed education|"delayed educational intervention~for further details please see brief description section"
88985084|NCT00453076|Experimental|Paclitaxel eluting covered metal stent|Paclitaxel eluting covered metal stent group
88985085|NCT00453076|Active Comparator|Control covered metal stent|Control covered metal stent group
88985086|NCT00453115|Experimental|study arm|GemOx
88985087|NCT03274921||Cardiovascular complication|patients with history of CV complications in the past 4 years had biological determination
88985088|NCT03274921||No cardiovascular complication|patients free of any CV complications had biological determination
88985089|NCT02273557|Experimental|Asasantin ER (new formulation I - low)|
88985090|NCT02273557|Experimental|Asasantin ER (new formulation III - medium)|
88985091|NCT02273557|Experimental|Asasantin ER (new formulation II - high)|
88985092|NCT02273557|Active Comparator|Asasantin ER (present commercial formulation)|
88985093|NCT00109421|Experimental|Experimental arm|In the experimental condition, the intervention group will receive the half-day Project ÒRÉ intervention. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires. A subset of groups will participate in a process evaluation focus group immediately following the program.
88985094|NCT00109421|No Intervention|Attention control group|The attention control group will receive a standard health promotion control program which has been used previously with similar populations. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires.
88985095|NCT00453661||Intervention Group|Patient Navigator (PN) + Educational Materials + Annual Questionnaires
88985096|NCT00453661||Comparison Group|Educational Materials + Exit Questionnaire
88985097|NCT00453700||serological testing|In Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles, serological testing for Trypanosoma cruzi was performed at enrollment.
88985098|NCT00143559|Other|1|
88985099|NCT00453817|Experimental|Study subjects|One-arm observational study
88985100|NCT00143637|Experimental|2|Office dust with added glucan
88985101|NCT00143637|Experimental|1|Clean air exposures in climate chamber
88985102|NCT00109655|Experimental|1|
88985103|NCT03274843|Experimental|Patient with stroke|
88985104|NCT02964429|Experimental|Diacap Pro High-Flux|1.3/ 1.6/ 1.9 sqm
88985105|NCT00454168|Experimental|Arm I|Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
88985106|NCT00454168|Active Comparator|Arm II|Patients receive placebo vaccine and GM-CSF subcutaneously.
88985107|NCT00109811|Experimental|Treatment|Patients receive PSA peptide vaccine (PSA-3A; PSA: 154-163 [155L]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and 18 in the absence of disease progression or unacceptable toxicity.
88985108|NCT02964390|Experimental|Balloon Pulmonary Angioplasty|This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.
88985109|NCT03274765||Women with ovarian stimulation|Women followed in the MAP center of the Rennes University Hospital for ovarian stimulation monitoring Dosage of oestradiol
88985110|NCT03274648|Experimental|vegetarian diet|vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
88985111|NCT03274648|Experimental|Habitual diet + oral butyrate|habitual diet supplemented with 2.4g/day of oral butyrate
88985112|NCT03274648|Active Comparator|Habitual diet|habitual diet without supplementation
88985113|NCT00109889|Other|MRI and PET|Magnetic resonance imaging and positron emission tomography
88985114|NCT00143676|Experimental|Lapaquistat Acetate 50 mg QD + Atorvastatin|
88985115|NCT00143676|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin|
88985116|NCT00143676|Active Comparator|Atorvastatin|
88985117|NCT00454519|Experimental|A|cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.
88985118|NCT00454519|Active Comparator|B|cytoreductive surgery alone, postoperative chemotherapy.
88985119|NCT00112749|Experimental|Study Arm|Please see intervention description
88985120|NCT00454714|Active Comparator|A|Sildenafil arm
88985121|NCT00454714|Placebo Comparator|B|Placebo arm
88985122|NCT00454792|Active Comparator|Exercise and advise to stay active|The exercise group received exercises for the stabilising muscles in the low back and abdomen together with dynamic exercises, exercises for postural instability and light physical fitness training.
88985123|NCT00454792|Experimental|Rest and use of flexible lumbar belt|The rest group was instructed to avoid hard physical activity and to rest twice daily for one hour, by lying down
88985124|NCT00143715|Experimental|1|Low dose oral vitamin K + warfarin cessation
88985125|NCT00143715|Placebo Comparator|2|
88985126|NCT00454831|Active Comparator|HEP 400mg TID|HEP-40 400 mg three times a day
88985127|NCT00454831|Active Comparator|HEP 800mg BID|HEP-40 800 mg twice a day
88985128|NCT00454831|Active Comparator|HEP 800mg TID|HEP-40 800 mg three times a day
88985129|NCT00454831|Active Comparator|HEP 2400mg QD|HEP-40 2400 mg once a day
88985130|NCT00454831|Placebo Comparator|Placebo|Placebo, three times a day
88985131|NCT00455026|Placebo Comparator|1|0 ng/ml target effect site concentration remifentanil
88985132|NCT00455026|Active Comparator|2|2 ng/ml target concentration remifentanil
88985133|NCT00455026|Active Comparator|3|4 ng/ml target effect site concentration remifentanil
88985134|NCT03274609||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being augmented fluoroscopy guided virtual navigation.)"
88985135|NCT03274336|Active Comparator|interview|questionnaire after face-to-face interview
88985136|NCT03274336|Placebo Comparator|brochure|questionnaire interview plus brochure
88985137|NCT03274336|Placebo Comparator|movie|questionnaire interview plus movie
88985138|NCT02273674|Experimental|Left rTMS 5 Hz|This group receive transcranial magnetic stimulation at 5 Hz of frequency over left dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
88985139|NCT02273674|Experimental|Right r TMS 1 Hz|This group receive transcranial magnetic stimulation at 1 Hz of frequency over right dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
88985140|NCT02273713|Experimental|Nab-Paclitaxel|Nab-Paclitaxel added to first line treatment with Oxaliplatin and Capecitabine
89612827|NCT03488121|No Intervention|Control|This arm will not receive any intervention.
89612828|NCT05056792|Experimental|Participants in this group will receive isometric strength training.|Isometric strength training of the quadriceps femoris muscle for 8 weeks.
89612829|NCT05056792|Sham Comparator|Participants in this group will receive plyometric training.|Participants in this group will receive plyometric training for 8 weeks.
89612830|NCT01597414|Active Comparator|Pertuzumab + trastuzumab (PH)|Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1
89612831|NCT01597414|Experimental|PH + metronomic chemotherapy (PHM)|Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1
89612832|NCT04984330|Experimental|selinexor/ dexamethasone (Sd)|"Selinexor • 60mg PO once weekly on days 1, 8, 15, 22 until disease progression or toxicity~Dexamethasone~• 20 mg PO administered 30-60 minutes prior to selinexor on days 1, 2, 8, 9, 15, 16, 22, 23"
89612833|NCT03030352|Experimental|How-to Parenting Program|The How-to Parenting Program consists of seven 2 ½-hour weekly sessions. It is a manual-based program in which participants have their own exercise booklet containing parenting skills and exercises. Groups are led by 2 group leaders and formed of 6 to 10 parents.
89612834|NCT03030352|No Intervention|Wait-list Control Group|Parents assigned to the wait-list control group will receive no intervention for the duration of the trial. The How-to Parenting Program will be delivered to them the following year. This delayed participation is ethically sound, as the program does not target at-risk families.
89612835|NCT04951102|Experimental|Group A Patients who receive SDM intervention|Group A patients will complete a pre-visit electronic Asthma SDM App. They may also receive educational information regarding asthma, medication management, smoking cessation, COVID-19 and COVID-19 vaccines.
89612836|NCT04951102|Active Comparator|Group B Patients who receive standard care|Group B patients will receive standard care.
88985141|NCT02273791||HRT group|Women will be subjected to HRT using Estradiol valerate before FET
88985142|NCT02273791||MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
88985143|NCT00455182|Placebo Comparator|1|Standard medical care
88985144|NCT00455182|Experimental|2|Acupuncture
88985145|NCT00455182|Sham Comparator|3|Sham acupuncture
88985146|NCT00455221|Experimental|Peptide Vaccine|
88985147|NCT00455299|Active Comparator|a|a: suture anchoring + tackers and approximation of defect
88985148|NCT00455299|Active Comparator|b|b: suture anchoring + tackers without approximation of defect
88985149|NCT00455299|Active Comparator|c|c: only tacker fixation and approximation of defect
88985150|NCT00455299|Active Comparator|d|d: only tacker fixation without approximation of defect
88985151|NCT00110279|Experimental|1|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops.
88985152|NCT00110279|Experimental|2|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.
88985153|NCT00455572|Experimental|Cohort 1|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
88985154|NCT00455572|Experimental|Cohort 2|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
88985155|NCT00455572|Experimental|Cohort 3|Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
88985156|NCT00455572|Experimental|Cohort 4|Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.
88985157|NCT00455767|Active Comparator|1|Depelestat
88985158|NCT00455767|Placebo Comparator|2|Placebo
88985159|NCT00455845|Active Comparator|1 levonorgestrel IUD|
88985160|NCT00455845|No Intervention|2 control|
88985161|NCT03274297|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
88985162|NCT03274297|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
88985163|NCT03274297|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment B to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
88985164|NCT03274297|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment A to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
88985165|NCT04698265|Experimental|Human amniotic suspension allograft (ASA), 40 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 1 uses 40 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
88985166|NCT04698265|Experimental|Human amniotic suspension allograft (ASA), 20 mg|Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 2 uses 20 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).
88985167|NCT04698265|Experimental|CellularMatrix (a combination of platelet-rich plasma and hyaluronic acid)|CellularMatrix (RegenLab SA, Switzerland) is composed of sterile and non-pyrogenic tubes allowing the mix of Platelet Rich Plasma (PRP) with Hyaluronic Acid (HA) in the same proportion (2mL of PRP for 2mL of HA).
89612837|NCT04951102|Experimental|Group A Physicians who receive SDM training and electronic Asthma SDM App data|Group A physicians will view an SDM Physician Training Video and receive the patients' reported data from the pre-visit asthma SDM App prior to the patients' visits.
89612838|NCT04951102|Active Comparator|Group B Physicians who provide standard care|Group B physicians will provide standard care.
89612839|NCT03030196|Active Comparator|Denosumab|subcutaneous injection with 60 mg Denosumab once
89612840|NCT03030196|Placebo Comparator|Placebo|subcutaneous injection with NaCl once
89612841|NCT03029962|Experimental|Experimental: Girl2Girl|Girl2Girl is a 7-week teenage pregnancy prevention program delivered daily via text messaging to 14-18 year old females who self-identify as lesbian, bisexual, gay, or other sexual minority. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, Girl2Genie, which shares information about sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
89612842|NCT03029962|No Intervention|No Intervention: Health Lifestyle|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 7-weeks in length (Week 7 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
89612843|NCT03035578|Experimental|Morphine Blood and Saliva sampling|"The infants will receive a 50 mcg/kg loading dose of morphine followed by a constant infusion.Morphine Injection: 10mg/mL, 1mL ampoules.Two strengths of stock syringes:~a)patients <1.5kg, morphine 0.5mg/25mL; b)patients 1.5kg to <5kg, morphine 1mg/25mL.~Time blood samples will be collected for measurement of whole blood concentration of morphine in 24h. Total morphine, morphine-3-glucuronide and morphine-6-glucuronide concentrations; volume of blood required is 0.25 ml. Sparse sampling strategy will be used for those neonates < 1250; total volume of blood required is 0.50 ml. Frequent sampling strategy will be used for those neonates ≥ 1250 gm; total volume of blood required is 0.50 ml.Saliva samples will be collected at 10 and 30 minutes and at 6, 12 and 24h after morphine infusion started.100 uL of saliva, captured using a collection swab."
89612844|NCT04933942|Active Comparator|Control group|Lomustine alone
89612845|NCT04933942|Experimental|Experimental group|Lomustine plus Romiplostim
89612846|NCT00089583|Experimental|2 - 18 yrs old (FPV/RTV BID)|Cohort 1B - 2 - less than 6yrs old (FPV/RTV BID) Cohort 2 - 6 to less than 12 yrs old (FPV/RTV BID) Cohort 3 - 12 - 18 yrs old (FPV/RTV BID) Cohort 4 - 2 - 18 yrs (FPV/RTV BID)
89612847|NCT00089583|Experimental|2 - less than 6yrs old (FPV BID)|Cohort 1A - 2 - less than 6yrs old (FPV BID)
89612848|NCT04902664|Experimental|Intervention Arm|Intervention arm physicians will receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals, along with physician-facing education materials. This email will be sent before each patient study visit for all patients in the study. Participating patients of intervention arm physicians will receive patient education materials one to two days before their study visit.
88985168|NCT04698265|Placebo Comparator|Normal saline|4ml of normal saline
88985169|NCT00456118||repeated miscarriages|60 womens for repeated miscarriages will be included
88985170|NCT00456118||Preeclampsia|70 women for pre-eclampsia will be included
88985171|NCT00456118||intervillites|20 women for intervillites will be included
88985172|NCT00110552|Experimental|1|Sage capsules taken by mouth
88985173|NCT00110552|No Intervention|2|No intervention, no-pill as control
88985174|NCT00456235|Experimental|adjument MMF|adjusting the dose according to the MMF AUC of mycophenolic acid
88985175|NCT00456235|Active Comparator|continued treatment|Continued treatment empirically usual
88985176|NCT00456274|Other|1|
88985177|NCT00456313|Active Comparator|arm 1|
88985178|NCT00113139|Experimental|Telephone-based coping skills|Telephone-based coping skills intervention
88985179|NCT00113139|Active Comparator|Usual Care|
88985180|NCT03274180|Experimental|Nursing consultation|travel preventive consultation was performed by nurse
88985181|NCT03274180|No Intervention|Medical consultation|travel preventive consultation was performed by a doctor
88985182|NCT00110669|Active Comparator|High Dose Prednisone|"Subjects who are randomized to the high-dose prednisone arm of the study will receive the following starting dose:~•Prednisone at 10.0 mg/kg/wk (divided into two doses given on Saturday and Sunday)"
88985183|NCT00110669|Active Comparator|Daily Prednisone|"Subjects who are randomized to the daily prednisone arm of the study will receive the following starting dose:~•Prednisone at 0.75 mg/kg/d"
88985184|NCT00456703|Active Comparator|restriction|In this group, the fluids will be restricted compared to a standard procedure
88985185|NCT00454558|Experimental|Arm 1|
88985186|NCT00456781|Experimental|Augmentation|Rotator Cuff Repair augmented with the Graft Jacket Device
88985187|NCT00456781|Active Comparator|No Augmentation|Rotator Cuff RFepair
88985188|NCT00143988||Treadmill Test exertion females|
88985189|NCT00143988||Treadmill test exertion males|
88985190|NCT00143988||Sexual activity exertion females|
88985191|NCT00143988||Sexual activity exertion males|
88985192|NCT03274141||T2T Patients|RA patients managed with a treat-to-target (T2T) strategy
88985193|NCT03274141||RC Patients|RA patients managed with routine care(RC)
88985194|NCT03274102|Experimental|Group I-EV71 vaccine and EPI vaccines|Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
88985195|NCT03274102|Active Comparator|Group II-EPI vaccine only|Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
88985196|NCT03274102|Active Comparator|Group III-EV71 vaccine only|EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
88985197|NCT00110747|Experimental|S-Caine Peel|
88985198|NCT00110747|Placebo Comparator|Placebo Peel|
89034774|NCT03737110|Placebo Comparator|Placebo|"RI period: single-blind rilonacept 320 mg (or 4.4 mg/kg in pediatric participants) SC, followed by 160 mg (or 2.2 mg/kg in pediatric participants) injections once weekly.~RW period: eligible participants randomized to placebo SC injections once weekly. Participants with pericarditis recurrence who meet the protocol criteria for bailout rilonacept (report at least 1 day with pericarditis pain ≥4 on the 11-point NRS and have 1 CRP value ≥ 1 mg/dL [either on the same day or separated by no more than 7 days]) receive bailout rilonacept (2 open-label injections of 160 mg rilonacept [or 4.4 mg/kg for pediatric participants]) irrespective of randomized treatment assignment and as soon as at least 5 days have passed since the last study drug injection.~LTE period: open-label administration of rilonacept 160 mg (or 2.2 mg/kg in pediatric participants) SC injections once weekly."
89034775|NCT03735901|Active Comparator|Experimental Intervention|White Investigational Medicinal Product (IMP)- capsules of a combination of IMP Levodopa 100mg/Carbidopa 25mg.
89034776|NCT03735901|Placebo Comparator|Control Intervention|Matching placebo, identical in aspect, texture, and taste when compared to the IMP. Procedures regarding route of administration, study treatment duration and treatment phases will be identical in the IMP- and the placebo-group.
89034777|NCT03723590|Experimental|Esterified hyaluronic acid matrix|
89034778|NCT03719144||Patients|Patients registered on ResearchMatch.org with Atrial Fibrillation as a medical condition; or who participate in afib-related social media platforms and confirm a diagnosis of afib, will be invited to participate in this study. Patients will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
89034779|NCT03719144||Providers|Providers who have contributed at least 25 Atrial Fibrillation patients to the Symphony pharmacy claims dataset will be contacted to participate. Interested providers will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
89612849|NCT04902664|Placebo Comparator|Control Arm|Control arm physicians receive an email with information on the general visit preparation tips that their patients will receive. Participating patients of control arm physicians will receive general visit preparation tips one to two days before their study visit.
89612850|NCT03030040|Experimental|MBCT-SH|MBCT-SH will be an unguided, mindfulness-based cognitive therapy, book-based self-help intervention.
89612851|NCT03030040|No Intervention|Control|A wait list control group who will receive no intervention during the 21 weeks of the study. Control participants will be provided with the self-help book that the MBCT-SH group received after week 21.
89612852|NCT03029494|Experimental|Treatment 1: stabilization splint, placebo oral tablet|stabilization splint during night and 1 placebo oral tablet daily, for 6 months
89612853|NCT03029494|Active Comparator|Treatment 2: placebo splint, vitamin C|placebo splint during night and 1000 mg Vitamin C tablet daily, for 6 months
89612854|NCT03029494|No Intervention|Control group|determination of oxidative stress biomarkers and cortisol in saliva of healthy control subjects
89034780|NCT03710122|Experimental|Vancomycin|
89034781|NCT03710122|Placebo Comparator|Placebo|
89034782|NCT03705741|Experimental|Exercise group|Resistance exercise twice a week
89034783|NCT03705741|No Intervention|Control group|
89034784|NCT03698669|Experimental|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
89034785|NCT03698669|Active Comparator|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
89612855|NCT03087279|Experimental|Texas I-CAN Active Math Lessons|Texas I-CAN Active math lesson in academic classroom
89612856|NCT03087279|Experimental|Texas I-CAN Active Language Arts Lessons|Texas I-CAN Active language arts lessons in academic classroom
89612857|NCT03087279|No Intervention|Control|Regular, Sedentary academic lessons in math and language arts
89612858|NCT03035266|Experimental|Blood Flow Restriction (BFR)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation. One week following surgery, subjects randomized to the BFR group will begin combining BFR with all lower extremity strengthening exercises supervised in clinic up to 3 times per week for 12 weeks.
89612859|NCT03035266|Active Comparator|Standard rehabilitation (control group)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation.
89612860|NCT05346705|Experimental|Tongue/soft palate muscle control function training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
89612861|NCT05346705|Experimental|Soft palate muscle group vocal resistance training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
89612862|NCT05346705|Placebo Comparator|Simple tongue extension, cheek drumming/voice training group|In the sleep center, patients undergo a week of upper airway muscle training for 2 hours a day under the guidance of a doctor
89034786|NCT03697304|Experimental|Cohort 1 - Module A|
89034787|NCT03697304|Experimental|Cohort 2 - Module A|
89612863|NCT04832230||Healthy individuals|This group is composed of healthy individuals without previous noise exposure.
89612864|NCT04832230||Acute acoustic trauma patients|This group is composed of patients suffering from acute acoustic trauma.
89612865|NCT03029026||Those patients for TAVR|Those patients who are undergoing TAVR (clinical decision) who are recruited at the Barts Heart Centre will undergo clinical echocardiography, research DPD scintigraphy and clinical TAVR work-up CT (with research post contrast acquisitions at 3-5 minutes), unless already performed prior to recruitment. Those patients undergoing TAVR (clinical decision) who are recruited at the John Radcliffe Hospital will undergo clinical echocardiography and research DPD scintigraphy only. N=150.
89612866|NCT03029026||Those patients for sAVR|Those patients who are undergoing sAVR (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy, research CMR and endomyocardial biopsy at the time of surgery. N=50.
88985199|NCT00457405|Active Comparator|1|first 7 day treatment with dipyridamol and at least two weeks later 7 day treatment with placebo
88985200|NCT00457405|Active Comparator|2|first 7 day treatment with placebo and at least two weeks later 7 day treatment with atorvastatin
88985201|NCT00457756|Active Comparator|I|Cohort I subjects will take supplement for 12 weeks
88985202|NCT00457756|Placebo Comparator|II|Cohort II will take placebo for 12 weeks
88985203|NCT00465712|Experimental|A|Transabdominal amnioinfusion performed before external cephalic version
88985204|NCT00465712|No Intervention|V|Without transabdominal amnioinfusion
88985205|NCT00110942|Active Comparator|Minor sub-study AMG 108|N = 15
88985206|NCT00110942|Placebo Comparator|Minor sub-study placebo|N = 15
88985207|NCT00110942|Active Comparator|Main sub-study AMG 108|N = 73
88985208|NCT00110942|Placebo Comparator|Main sub-study placebo|N = 73
88985209|NCT00465751|Active Comparator|A|chenodeoxycholic acid treatment
88985210|NCT00465751|Placebo Comparator|B|placebo treatment
88985211|NCT00110981|Experimental|Single-arm|
88985212|NCT00465907|Experimental|Paclitaxel, Carboplatin and Irinotecan|Study of Weekly Paclitaxel, Carboplatin and Irinotecan in patients with Non-Small Cell Lung Carcinoma
88985213|NCT00466024|Experimental|1|Health coach and 2 HEPA air cleaners
88985214|NCT00466024|Active Comparator|2|Standard asthma education and 2 HEPA air cleaners
88985215|NCT00466024|Active Comparator|3|Standard asthma education and delayed receipt of 2 HEPA air cleaners
88985216|NCT00111020|Experimental|Arm 1|
88985217|NCT00466063||ICL670|ICL670
88985218|NCT00466102|Active Comparator|1|Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
88985219|NCT00466102|Placebo Comparator|2|Patients with stable disease after 8 week run in receive placebo (blinded)
88985220|NCT00466375||A|Patients with a hemangioma.
88985221|NCT00466375||B.|Patients with a vascular anomaly.
88985222|NCT00111098|Experimental|darbepoetin alfa|
88985223|NCT00347659|Experimental|Single Treatment|Experimental Treatment
88985224|NCT00347737|Experimental|1|Teriparatide
88985225|NCT00111137|Active Comparator|rHuEPO|
88985226|NCT00111137|Experimental|Darbepoetin alfa|
88985227|NCT00347854|Experimental|FID 105783|
88985228|NCT00347854|Active Comparator|Visine|
88985229|NCT00347854|Active Comparator|Refresh Liquigel|
88985230|NCT00347854|Active Comparator|Refresh Plus|
88985231|NCT04714684|Experimental|fitostimoline proctogel|
88985232|NCT04714684|Experimental|fitostimoline proctogel + muscle relaxants|
88985233|NCT04714684|Experimental|muscle relaxants|
88985234|NCT00111176|Other|1|Endovascular Repair
88985235|NCT00111176|Other|2|Surgical
88985236|NCT00144417|Active Comparator|HRZE|isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo
88985237|NCT00144417|Experimental|MRZE|moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo
88985238|NCT00144456|Experimental|1|
88985239|NCT00144456|Active Comparator|2|
88985240|NCT00111254|Experimental|1|In group I, acute effect group, each subject will undergo microdermabrasion of the hip/buttock. Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device). 4mm punch biopsies will be performed in the treated area at 4hrs, 8hrs, and 24hrs post-treatment. In addition, one 4mm punch biopsy will be obtained from adjacent untreated skin.
88985241|NCT00111254|Experimental|2|In group II, chronic effect group, each subject will undergo microdermabrasion of the face at weekly intervals for six weeks. Treatment will consist of 3 passes in different directions with the microdermabrasion handpiece (horizontal, vertical, and oblique). Aluminum oxide abrasion and negative pressure will be increased as tolerated by the patient. Two 2mm punch biopsies will be obtained prior to the first treatment and one week following the sixth treatment.
88985242|NCT00348439|Experimental|Plasmin Injection|human-derived plasmin
88985243|NCT00348439|Placebo Comparator|Vehicle|Plasmin formulation, without active ingredient.
88985244|NCT00348517|Experimental|Systane|
88985245|NCT00348517|Active Comparator|Refresh|
88985246|NCT05595330|Experimental|intervention group|Patients in the intervention group were managed with an upper extremity lymphedema prevention program.
88985247|NCT05595330|No Intervention|control group|The control group received normal perioperative and chemotherapy nursing measures
88985248|NCT00348712|Active Comparator|A|
88985249|NCT00348712|Active Comparator|B|
88985250|NCT02964689|Experimental|Combination of binimetinib, pemetrexed and cisplatin|"The trial consists of two parts:~Part 1: dose escalation based on the 3+3 design with 2 doses of binimetinib~Part 2: expansion cohort at the recommended maximum tolerated dose (MTD) level of binimetinib"
88985251|NCT02959567|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
88985252|NCT00348829|Active Comparator|1|Surgical mitral valve reconstruction
88985253|NCT00348829|No Intervention|2|conservative treatment
88985254|NCT00348868|Experimental|1|enhanced behavioral motivation counseling
88985255|NCT00348868|Active Comparator|2|
88985256|NCT00348907|Active Comparator|1|immediate thermal cure (1st year)
88985257|NCT00348907|Sham Comparator|2|late thermal cure (2 years)
88985258|NCT00348985|Experimental|PXD101 in Combination with Bortezomib (PS-341)|Patients receive PXD101 IV over 30 minutes on days 1-5 and bortezomib IV on days 1, 4, 8, and 11 (2, 5, 8, and 11 during course 1).
89612867|NCT03029026||Those patients for medical management|Those patients who are decided for medical management (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy and any other imaging as per work-up/trial prior to no intervention decision. N=50.
89612868|NCT04402047|Experimental|Electroacupuncture group|
89612869|NCT04402047|Active Comparator|Topical DSG group|
89034788|NCT03697304|Experimental|Cohort 3 - Module A|
89612870|NCT03028714|Experimental|Technology-based nutrition education|Participants will receive access to a website including educational information about nutrition and related topics. Through the website they will be asked to play online quiz-games relevant to the content of the website to improve their knowledge.
89612871|NCT03028714|No Intervention|Control group|Participants in the control group will receive no intervention.
89612872|NCT03028168|Experimental|Intervention Yôga|Active protocol with yôga body movements performed along with respiratory vigorous, without contentions. Two sessions per week, with 45 minutes duration.
89612873|NCT03028168|Experimental|Intervention breathing technique|Passive protocol, seated patient, no significant body movements. Breathing technique, with alternate nostril breathing combined to inspiratory and expiratory retentions.Two sessions per week, with 45 minutes duration
89612874|NCT03028168|Experimental|Control group|Control group (standard pharmacological treatment). Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization.
89612875|NCT03027778|Experimental|Exercise|Participants will engage in pedalling exercise 3 times per week during the first 2 hours of dialysis treatment for the duration of 4 months.
89612876|NCT03027778|No Intervention|Usual care|Participants receive their usual dialysis for the duration of 4 months.
89612877|NCT03035110|Experimental|Dialectical Behavioural Therapy (DBT) skills group|Four group sessions, based on DBT, over two weeks, with a group of four to eight participants in attendance located on the hospital ward where the participant is a patient.
89612878|NCT03017638||Patients receiving QLB and questionaires|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours and 48 hours and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
88985259|NCT05595252||Patients with CIN lésions during pregnancy|
88985260|NCT00349102|Active Comparator|A|Free breathing during conformal radiation
88985261|NCT00349102|Experimental|B|Breath holding during conformal radiation
88985262|NCT00114075|Experimental|Gait analysis|Gait analysis report is available for treatment planning
88985263|NCT00114075|Active Comparator|Control|Subject has gait analysis test, but report is not available for treatment planning
88985264|NCT00421447||Breast Cancer patients|A group of women with breast cancer prescribed Anastrozole
88985265|NCT00421447||Healthy women wit no breast Cancer|A group of healthy women wit no breast cancer prescribed Anastrozole
88985266|NCT04729140|Active Comparator|Ivermectin plus Doxycycline|"Ivermectin 200 mcg/kg on day 1 and day 2-plus doxycycline 100 mg tablets twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
88985267|NCT04729140|Active Comparator|Ivermectin plus Placebo|"Ivermectin 200 mcg/kg on day 1 and day 2-plus placebo tablet twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Ivermectin and Placebo~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
88985268|NCT04729140|Placebo Comparator|Placebo plus Placebo|"Placebo (number of tablets according to weight) plus placebo twice a day for seven days~Body Weight (kg) Single oral Dose number of 3 mg tablets of Placebo~15-24 kg 1 tablet~25-35 kg 2 tablets~36-50 kg 3 tablets~51-65 kg 4 tablets~66-79 kg 5 tablets~80-109 kg 6 tablets~>110 kg 7 tablets"
88985269|NCT00349219|Experimental|1|erlotinib followed at progression by gemcitabine and cisplatin
88985270|NCT00349219|Active Comparator|2|cisplatin and gemcitabine chemotherapy for 6 cycles, followed at progression by erlotinib
88985271|NCT05595174|Active Comparator|group 1|"Patient with self-ligating bracket system split mouth with and without micro-osteoperforations.~Extraction of first premolars were done. A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment."
88985272|NCT05595174|Active Comparator|group 2|"Patient with conventional bracket with split mouth with and without micro-osteoperforations.~Extraction of first premolars were done. A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment."
88985273|NCT00349375|Experimental|1|
88985274|NCT00349375|Experimental|2|
88985275|NCT00349375|Active Comparator|3|
88985276|NCT00349453|Experimental|Deferiprone (L1) monotherapy|Deferiprone (L1) monotherapy
88985277|NCT00349453|Experimental|Combination therapy|Deferiprone (L1) and desferrioxamine combination treatment
88985278|NCT00111527|Active Comparator|1|Normal RV pacing
88985279|NCT00111527|Experimental|2|Echo-guided optimization of pacing
88985280|NCT00349492|Active Comparator|EP|etoposide + cisplatin
88985281|NCT00401739|Experimental|I|Treatment with CSL360
88985282|NCT00111566|Active Comparator|18 Hour infusion|
88985283|NCT00111566|Experimental|4 hour infusion|
88985284|NCT00404703|Experimental|1|
88985285|NCT00349726|Experimental|Inositol low volume|Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes
88985286|NCT00349726|Experimental|Inositol high volume|Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes
88985287|NCT00349726|Placebo Comparator|Placebo low volume|Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.
88985288|NCT00349726|Placebo Comparator|Placebo high volume|Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes
88985289|NCT00111605|Experimental|1|HIV gag DNA vaccine or placebo on Days 0, 28, and 84
89034789|NCT03697304|Experimental|Cohort 1 - Module C|
89034790|NCT03697304|Experimental|Cohort 2 - Module C|
89034791|NCT03697304|Experimental|Cohort 3 - Module C|
89034792|NCT03697304|Experimental|Cohort 4 - Module C|
89034793|NCT03697304|Experimental|Cohort 5 - Module C|
89034794|NCT03691077|Experimental|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
89034795|NCT03682887|Active Comparator|Cryoballoon PV isolation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm cryoballoon catheter will be used.~Cryoablation will be performed for 180 secs at -30 C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and ablation times will be evaluated.~The procedure will be completed without checking any other trigger came from beyond pulmonary vein after the administration of isoproterenol~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
89034796|NCT03682887|Experimental|Cryoballoon PV isolation w/ RA linear ablation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter as the same as cryoballoon PV isolation group.~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~Additional SVC-right atrial septal linear ablation will be performed with a radiofrequency catheter.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local RF ablation will be followed.~The procedure and ablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
89034797|NCT03669926|Other|DBT+SM|Digital Breast Tomosynthesis+synthetic mammography (DBT+SM) All women are screened with DBT+SM. All examinations are independently double read. Consensus used to decide whether or not to recall.
89034798|NCT03662776||retinoblastoma survivors treated with enucleation|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
89034799|NCT03662776||retinoblastoma survivors treated with intra-arteria chemo|MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
89612879|NCT03017638||Historical control|"The control subjects' data will be assessed reviewing patient records. Data will include:~Maximal PACU VAS pain score (per nursing charts)~Overall POD 24 hours and 48 hours and 4 weeks opioid consumption (overall morphine mg/kg equivalent dose)~POD 24 and 48 hours and 4 weeks Respiratory complications"
89612880|NCT03034798||Type 1 Diabetes Exercisers|Participants performed 2 different forms of exercise of identical duration and similar total energy expenditure. One form was purely aerobic in nature and the other was intermittent, high-intensity exercise.
89034800|NCT03625648|Experimental|PTX|Active drug
89034801|NCT03625648|Placebo Comparator|Placebo|Placebo
89034802|NCT03624933|Experimental|28-Day Cannabis Abstinence|The study will assess the changes that occur after a 28-day abstinence period in patients with Major Depressive Disorder (MDD) and comorbid Cannabis Use Disorder (CUD). Patients will be instructed to initiate abstinence 12 hours prior to the baseline session and will come in for weekly visits involving a series of clinical, cognitive, and substance use assessments.
89034803|NCT03623867|Experimental|Secukinumab|Subject will received secukinumab 150mg at week 0-4, and once monthly till week 48
89034804|NCT03623867|Placebo Comparator|Placebo|Subject will received placebo 150mg at week 0-4, and once monthly till week 48
89034805|NCT03616535|Active Comparator|Cognitive training|"Participants randomized to CT will play brain games on a tablet. They will be asked to engage in the activity for a minimum of 30 minutes during each hemodialysis session for 6 months. At each HD session, participants will have 10 different brain games to play and the games will vary for each session."
89034806|NCT03616535|Active Comparator|Exercise training|"Participants randomized to the ET arm will be given a stationary foot peddler and will be asked to engage in the activity for a minimum of 30 minutes at each hemodialysis session for 6 months. ET will start with a 2 minute warm up, then the resistance will be adjusted so that participants are working at perceived exertion of somewhat strong, using the Borg scale (87) (~50 rpm). Resistance will be increased when the rating falls below somewhat hard."
89612881|NCT03017248|Active Comparator|Morphine and Placebo|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an injection of Placebos (0.9% normal saline 0.05ml/kg)
89034807|NCT03616535|Active Comparator|Combined cognitive and exercise training|"Participants in the CT+ET arm will start with 30 minutes of CT (playing brain games on tablet) with a 15-minute break, and then, 30 minutes of ET (stationary foot peddler)."
89034808|NCT03616535|No Intervention|Standard of Care|Participants in this arm will receive standard of care
89612882|NCT03017248|Experimental|Morphine and Ketamine 0.15|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.15mg/kg
89612883|NCT03017248|Experimental|Morphine and Ketamine 0.3|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.3mg/kg
89612884|NCT03035344||ALL paediatric patients|Metabolome study in children diagnosed with ALL after bone marrow biopsy
89057299|NCT04543370|Experimental|Treatment B|2000 mg edasalonexent TID on Day 1 to Day 11 with 2 mg midazolam on Day 10 and with 36 mg deflazacort on Day 11.
89057300|NCT01681524|Experimental|Flurpiridaz F18|Open-label study of a single injection of flurpiridaz F18 for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary cathertization
89057301|NCT04528485|Experimental|Sea swimming|8 sessions over 4 weeks of swimming-based activities in the sea
89057302|NCT04543487|Experimental|Control Group|Group name
89612885|NCT03035344||Healthy matched controls|Metabolome study in healthy children matched for gender and age with the patients group
89612886|NCT03034720|Experimental|Intervention|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
89612887|NCT03034720|No Intervention|Control|Adolescent subjects in the control group will receive care as usual from their health care providers, a standard that is ethically acceptable.
89612888|NCT03034486|Experimental|A single sequence, 3-period|
89612889|NCT00088881|Experimental|Treatment|"R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients with progressive disease go off study.~Zevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Radiation therapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy."
89612890|NCT02981914|Experimental|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Treatment will be administered for up to 24 months, provided that neither disease progression, nor development of a dose-limiting toxicity (DLT), has occurred.
89612891|NCT02981680|Experimental|RIPC|Patients in the remote ischemic preconditioning (RIPC) group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, surgery will be started. The entire pre-conditioning phase will last 30 minutes.
89612892|NCT02981680|Sham Comparator|sham-RIPC|Patients in the sham-RIPC group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the RIPC group, patients in the sham-RIPC group will undergo the same 30 minute delay before starting surgery.
89612893|NCT03026452|Experimental|RFA(radiofrequency ablation)|The investigators used percutaneously US-guided RFA(radiofrequency ablation) for small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
89612894|NCT03025750|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
89612895|NCT03025750|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
89612896|NCT03024892|Experimental|ICG gallbladder|patients who received ICG injection via gallbladder and received fluroscence image guided surgery
89612897|NCT03024892|Experimental|ICG IV|patients who received ICG injection via peripheral vein and received fluroscence image guided surgery
89612898|NCT03024892|Sham Comparator|LC conventional|Patients received conventional laparoscopic cholecystectomy
89612899|NCT03024892|Sham Comparator|LC conventional and IOC|Patients received conventional laparoscopic cholecystectomy + intraoperative cholangiography
89612900|NCT03024658|No Intervention|Zero PEEP|This group of patients did not receive any PEEP at the time of induction of general anesthesia (n= 30)
89612901|NCT03024658|Experimental|PEEP- 10 cm of H2O|This group comprised of patients who received a PEEP of 10 cm H2O at the time of induction of general anesthesia (n= 30)
89612902|NCT00952120|Experimental|GSUC|Gauze-based wall suction negative pressure wound therapy for 4-5 days
89612903|NCT00952120|Active Comparator|Vacuum-assisted closure|Vacuum-assisted closure (VAC) negative pressure wound therapy using commercially available device (KCI, Inc) for 4-5 days
89612904|NCT04353544|Active Comparator|Immediate cord clamping|Immediate cord clamping was defined as clampingwithin 15 seconds of birth
89612905|NCT04353544|Experimental|delayed cord clamping|when the cord stopped pulsing, or five minutes
89612906|NCT03017404|Experimental|treatment group:35 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
88985290|NCT00111605|Experimental|2|HIV gag DNA vaccine plus 100 mcg of IL-12 or placebo on Days 0, 28, and 84
88985291|NCT00111605|Experimental|3|HIV gag DNA vaccine plus 500 mcg of IL-12 or placebo on Days 0, 28, and 84
88985292|NCT00111605|Experimental|4|HIV gag DNA vaccine plus 1,500 mcg of IL-12 or placebo on Days 0, 28, and 84
88985293|NCT00111605|Experimental|5|HIV gag DNA vaccine or placebo on Days 0, 28, 84, 168, and 273
88985294|NCT00111605|Experimental|6|HIV gag DNA vaccine plus IL-12 or placebo on Days 0, 28, and 84 plus CTL MEP/RC529-SE/GM-SCF booster vaccine on Days 168 and 273
88985295|NCT00111605|Experimental|7|HIV gag DNA vaccine plus IL-12 DNA adjuvant or placebo on Days 0 and 84
88985296|NCT00349804|Other|Air cooled (COOL)|Subjects will complete the intermitent exercise protocol with cool dry air blown under the shoulder pads during the rest periods and recovery session
88985297|NCT00404742|Placebo Comparator|Placebo|
88985298|NCT00404742|Active Comparator|LX211, 0.2 mg/kg|
88985299|NCT00404742|Active Comparator|LX211, 0.4 mg/kg|
88985300|NCT00404742|Active Comparator|LX211, 0.6 mg/kg|
88985301|NCT00111644|Experimental|1|
88985302|NCT00111644|Experimental|2|
88985303|NCT00111644|Active Comparator|3|
88985304|NCT00349999||1|18 males and non pregnant females, ages 18-45, with acute cholera.
89210806|NCT01075789|Placebo Comparator|Placebo|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this placebo arm or the treatment arm in a 1:1 ratio. The placebo for swallowing is a viscous, coloured, sucrose-flavoured gel designed to match the appearance of the treatment lignocaine gel to be swallowed by the treatment arm, and normal saline will be delivered to the nasal turbinates and nasopharynx in a similar way to atomised xylocaine in the treatment arm.
89612907|NCT03017404|Experimental|treatment group:40 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
89612908|NCT03017404|Experimental|treatment group:45 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
88985305|NCT00111683|Experimental|MK-0457|Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration
88985306|NCT00350194|Placebo Comparator|1|Omega-3 fatty acid vs. placebo comparator
88985307|NCT00404781|Experimental|optimal antiplatelet|cilostazol in addition to aspirin and clopdidogrel for pts with clopidogrel resistance
88985308|NCT00404781|Active Comparator|standard antiplatelet|aspirin and clopidogrel for all patients
88985309|NCT00350233|Experimental|ExAblate MRgFUS|
88985310|NCT00350350||elderly people|elderly people over 70 years residents of old's people homes with symptoms of dry mouth
88985311|NCT02964611||Alzheimer's disease|Observational Study
88985312|NCT02964611||Parkinson's disease|Observational Study
88985313|NCT02964611||Frontotemporal Lobar Degeneration|Observational Study
88985314|NCT02964611||Healthy Controls|Observational Study
89612909|NCT03017404|Experimental|treatment group:50 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
89612910|NCT00953212|Active Comparator|Group A|Beta Blockers, Ascorbic Acid and Amiodarone
88985315|NCT00350389|Experimental|1|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
88985316|NCT00350389|No Intervention|2|Usual care, updated multifocal glasses if required
88985317|NCT00350506|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed by catheter coronary angiography (CATH).
88985318|NCT00350584|Experimental|Mindfulness Telehealth for PTSD|Participants receive two in-person sessions and 6 sessions over the phone. Participants are introduced to mindfulness concepts. CDs with guided meditation exercises are given to participants and they are asked to practice between sessions.
88985319|NCT00350584|Active Comparator|Psychoeducation Telehealth for PTSD|Participants receive two in-person sessions and six telehealth sessions with education about symptoms of PTSD and coping strategies. In addition, participants are asked to read short homework assignments and think about them during the week; these are discussed in weekly sessions.
88985320|NCT00350662|Experimental|Deferiprone + Desferrioxamine|
88985321|NCT00350662|Experimental|Deferiprone single agent|
88985322|NCT00350662|Active Comparator|Desferrioxamine single agent|
88985323|NCT00350818|Experimental|Azacitidine|Azacitidine after Allogeneic Transplantation
88985324|NCT00350857|Active Comparator|Equetro active|
88985325|NCT00111956|Experimental|Etanercept|
88985326|NCT00111956|Placebo Comparator|Placebo|
88985327|NCT00350935||Healthy volunteers|Healthy controls
88985328|NCT00350935||Patients|Patients with schizophrenia
88985329|NCT00114309|Experimental|1|3 Dose Regimen
88985330|NCT00114309|Experimental|2|6 Dose Regimen
88985331|NCT00350974||End-stage Renal Disease|on maintenance hemodialysis 3 x per week for more than 12 months
88985332|NCT00350974||No kidney disease|eGFR greater than 60 ml/Min
88985333|NCT00350974||Hypertensive group|Blood pressure greater than 130/80
88985334|NCT00351013|Experimental|1|
88985335|NCT00351052|Experimental|1|Pimecrolimus
89612911|NCT00953212|Active Comparator|Group B|Beta Blockers and Ascorbic Acid
89612912|NCT00953212|Active Comparator|Group C|Beta Blockers and Amiodarone
89612913|NCT00953212|Active Comparator|Group D|Beta Blockers alone
89612914|NCT00953290|Experimental|Treated Thigh|The thigh treated with the RF device
88985336|NCT00351052|Placebo Comparator|2|Vehicle
88985337|NCT00114348|Active Comparator|R-Blöcke|Blocktherapie
88985338|NCT00114348|Experimental|Prot-II-Ida|a
88985339|NCT00351325|Experimental|dose escalation|
88985340|NCT00351364|Active Comparator|Montelukast sodium|Drug arm - Montelukast as a single dose 100 mg. To test the hypothesis of leukotriene inhibition.
88985341|NCT00351364|Placebo Comparator|2|No drug given - no placebo available. To compare with active drug.
88985342|NCT00351403|Experimental|Individualized therapy|Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.
88985343|NCT00351403|Other|Historical control|48 week standard therapy
88985344|NCT00351442||1|Inidividuals who have been exposed to HIV but remain uninfected.
88985345|NCT00351442||2|HIV infected regular sexual partners of Group 1 participants.
88985346|NCT00351442||3|HIV uninfected individuals or couples who have not been exposed to HIV.
88985347|NCT05595096|Experimental|spontaneous breathing anesthesia non-intubation group|In this group all the patients with spontaneous breathing anesthesia
88985348|NCT05595096|No Intervention|general anesthesia with double-lumen endotracheal intubation group|In this group all the patients with tradition anesthesia with double-lumen endotracheal intubation
88985349|NCT00112229|Experimental|group 1|Melan-A analog peptide + CpG + Montanide
88985350|NCT00112229|Experimental|group 2|Melan-A natural peptide + CpG + Montanide
88985351|NCT00112229|Experimental|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
88985352|NCT00112229|Experimental|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
89612915|NCT00953290|No Intervention|Untreated Thigh|The untreated thigh
89057303|NCT01681563|Experimental|Pentostatin/Cyclophosphamide/Ofatumumab|Subjects will receive up to 6 cycles of pentostatin, cyclophosphamide, and ofatumumab given every 21 days (+/- 4 days).
89057304|NCT04543292|Experimental|MATFILL|Prosthetic chimney filling with MATFILL prior to other sealing materials to protect the screww head.
88985353|NCT00351598||1|Patients with loco-regional, NSCLC treated by definitive radiotherapy.
88985354|NCT00351715|Experimental|Pharmacokinetic|One episode of breakthrough pain was to be evaluated per patient. Clinical status and bloodwork was evaluated prior to entering into this phase of the trial, and patients were eligible if bloodwork demonstrated a HgB of >90 g/L with no concurrent bleeding. A peripheral intravenous catheter was inserted and saline locked. When breakthrough pain was experienced, methadone was administered, and the patient completed a pain intensity numeric rating scale at time 0 and every 10 minutes for one hour. A 10 cc specimen of blood was collected prior to administration of methadone, and again every 10 minutes for one hour. Blood was collected without anticoagulant, allowed to clot, separated by centrifugation, and serum samples flash frozen. Serum methadone levels were quantified by LC/MS/MS with comparison to isotopically labeled internal standards
88985355|NCT00112346|Active Comparator|A|
88985356|NCT00112346|Active Comparator|B|
88985357|NCT00114465|Experimental|VSL#3|Probiotic
88985358|NCT00114465|Placebo Comparator|Placebo|Placebo
88985359|NCT00352144|Experimental|1|eszopiclone 3 mg tablet
88985360|NCT00352144|Placebo Comparator|2|Placebo tablet
88985361|NCT00352183|Experimental|1|
88985362|NCT00352183|Active Comparator|2|
88985363|NCT04714255|Experimental|TICK-B group as Intervention group|Pediatric patients received TICK-B as a distraction in the TICK-B group Trace Image and Coloring for Kids-Book were conducted on the children undergoing the Cannulation procedure.
88985364|NCT04714255|No Intervention|Standard care provided group as control group|Pediatric patients received standard care (routine care) in the control group.
88985365|NCT00352300|Experimental|Treatment (carboplatin, paclitaxel, pegfilgrastim)|Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
88985366|NCT00112658|Experimental|Folfirinox|
88985367|NCT00112658|Active Comparator|Gemcitabine|
88985368|NCT00352339|Experimental|Aripiprazole|switching group (from risperidone to aripiprazole)
88985369|NCT00352339|Active Comparator|Risperidone|Start with risperidone and keep it through the end of study
88985370|NCT00352339|Active Comparator|Abilify|Start with aripiprazole and keep it through the end of study
88985371|NCT00114543|Active Comparator|Aggressive ELBW|In Aggressive group 1, infants with birth weights 501-750g.
88985372|NCT00114543|Active Comparator|Aggressive VLBW|In the Aggressive group 2, infants with birth weights 751-1000g.
88985373|NCT00114543|Active Comparator|Conservative ELBW|In the Conservative group 1, infants with birth weights 501-750g.
88985374|NCT00114543|Active Comparator|Conservative VLBW|In the Conservative group 2, infants with birth weights 751-1000g.
88985375|NCT00352378|Experimental|Adriamycin plus Cyclophosphamide|Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1.
88985376|NCT00352378|Experimental|Taxotere plus Xeloda|Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
89057305|NCT01681641|Experimental|Lifestyle counseling|Patients and spouses in the intervention group are offered 3 targeted meetings with the DBS nurse, focusing on goal setting for each individual, following DBS, based on patients and spouses own expectations, challenges and goals for everyday life after DBS.
89057306|NCT01681641|No Intervention|Control group|Patients and spouses enrolled in a control group
89612916|NCT03024190|Experimental|with Kinesiotaping|"stretching exercises combined with Kinesiotaping~regular OT rehabilitation program for 3 weeks"
89612917|NCT03024190|Other|control group|"the patients will receive 15-min stretching exercises~regular OT rehabilitation program for 3 weeks"
89612918|NCT03024268|Experimental|A: interventional closure of iASD|Interventional closure of iASD (n=40) with an Figulla Flex Occluder (Occlutech)
89612919|NCT03024268|No Intervention|B: no intervention|Best medical supportive care (n=40)
89612920|NCT03034408|Other|Alcohol Use Disorder|30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20) : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
89612921|NCT03034408|Other|Healthy Control|30 sex and age-matched healthy controls : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
89612922|NCT03017092|Experimental|tablet-guided|Study participants will be administered a brief tobacco intervention by a Salvation Army staff person who is guided by a tablet computer
89612923|NCT03017014||Pediatric participants receiving adalimumab|Pediatric participants receiving adalimumab for CD in real-life conditions.
89612924|NCT03016858|Experimental|NIIASV|undergoing Thoracoscopic Bullectomy Surgery under nonintubated intravenous anesthesia with spontaneous ventilation(NIIASV)
89612925|NCT03016858|Active Comparator|IASLV|undergoing Thoracoscopic Bullectomy Surgery under intubated anesthesia with single-lung mechanical ventilation(IASLV)
89612926|NCT03023020|Other|Abbreviated antiplatelet regimen|"Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)"
89612927|NCT03023020|Other|Prolonged antiplatelet regimen|"Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)"
89612928|NCT00087555|Experimental|2|Sodium oxybate 6.0 g per day.
89612929|NCT00087555|Placebo Comparator|3|Placebo (one of two doses matching active treatment by volume).
89612930|NCT00087555|Experimental|1|Sodium oxybate 4.5 g per day.
89612931|NCT03016780|Active Comparator|Treatment in part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with ulcerative colitis in part 1.
89612932|NCT03016780|Placebo Comparator|Placebo in part 2|The traditional treatments and normal saline will be used in patients with ulcerative colitis in part 2 according to associated guidelines.
89612933|NCT03022318|Experimental|once daily|carbidopa-levodopa 25-100 mg tablets once daily hs for up to 32 days
89612934|NCT03022318|Experimental|3 times daily|carbidopa-levodopa 25-100 mg tablets 3 times daily,in the morning, with supper and hs for up to 32 days
89612935|NCT01677897|Experimental|Metformin|Metformin 2x1000mg orally per day
89612936|NCT03033940||ATTUNE TM subjects|
89612937|NCT03033940||PFC Sigma subjects|
89612938|NCT03483363|Experimental|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure. All groups with receive standard parenteral intravenous (IV) prophylactic antibiotic.
89612939|NCT03483363|Active Comparator|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
89612940|NCT03033628|Experimental|DV group|"Device: injection using DentalVibe comfort system. giving maxillary infiltration dental local anesthesia with the aid of DentalVibe comfort system on one side of the maxillary arch prior extraction of primary molar tooth"
89612941|NCT03033628|Active Comparator|C group|"Device: traditional dental injection giving maxillary infiltration dental local anesthesia without the aid of DentalVibe comfort system on the other side of the maxillary arch prior extraction of primary molar tooth"
89612942|NCT01677975|Experimental|ultrasound, dynamic lymphscintigraphy|
89612943|NCT03016702|Experimental|High Risk Alzheimer's Disease|This group includes subjects with APOEe4 homozygotes, the genetic profile associated with the highest risk for late-onset AD and the next highest-risk group, APOE e3/e4 heterozygotes. To target the highest risk among the APOEe3/e4 heterozygotes in ADPR, the study team will consider TOMM40-'523 variant status. Although there is uncertainty about the independent role of TOMM40 in AD risk-stratification (especially across racial/ethnic groups), this study will use TOMM40-'523 to guide heterozygote selection based on findings that among e3/e4 heterozygotes, longer TOMM40-523 polyT sequences are associated with earlier age of onset for late-onset AD.
89612944|NCT03016702|Experimental|Low Risk Alzheimer Disease|This group includes e2/e2 homozygotes (rare) and e2/e3 heterozygotes. the genetic profile associated with low risk for late-onset development of Alzheimer's disease.
89612945|NCT00956020|Experimental|Treatment|Skin injection with platelet rich fibrin matrix on the inner aspect of the upper arm, with biopsies over a period from 30 minutes to 12 weeks after treatment.
89057307|NCT01681680|Other|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
89057308|NCT04543175||Chemotherapy breast cancer patients|Newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy with the following drugs (Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel were followed until they complete four cycles of chemotherapy.
89034809|NCT03602157|Experimental|ATLCAR.CD30.CCR4 & ATLCAR.CD30|A 3+3 design in adult subjects. Subjects in the first dose level will receive ATLCAR.CD30.CCR4 cells alone, once safety has been established, the initial dose of ATLCAR.CD30.CCR4 will be combined with a fixed dose of ATLCAR.CD30 cells in the next dose level. Every time the dose of ATLCAR.CD30.CCR4 is escalated, subjects in that dose level will receive ATLCAR.CD30.CCR4 alone prior to subsequent dose level enrolling subjects to receive a combination of fixed dose ATLCAR.CD30 and the selected dose level of ATLCAR.CD30.CCR4. The six dose levels will consist of: dose level 1 = 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 2 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 3 = 5 × 10^7/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 4 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 5 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 5 = 1 × 10^8/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 6 = 1 × 108 ATLCAR.CD30 cells/m2 and 1 × 108 ATLCAR.CD30.CCR4 cells/m2.
89034810|NCT03595098|Experimental|FCBT|The Family Based Cognitive Behavioural Therapy (FCBT)
89034811|NCT03595098|Active Comparator|FPRT|Family-based Psychoeducation /Relaxation Training (FPRT)
89034812|NCT03592771|No Intervention|Usual Care|Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.
89034813|NCT03592771|Active Comparator|THRIVE App|Participants use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants receive reminders via text or email to use the app once per week during the 6-month intervention phase. Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.
89034814|NCT03592771|Active Comparator|THRIVE App+Feedback|Participants use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants receive reminders via text or email to use the app once per week during the 6-month intervention phase. In addition, participants in this group will also receive weekly tailored feedback text messages or images during the 6-month intervention phase. Participants use an electronic pill monitoring device with their AET medication and complete a survey at baseline and again after 12 months.
89034815|NCT03587740|Experimental|T-DM1|T-DM1 will be administered every 3 weeks intravenously, with 21 consecutive days defined as a treatment.
89034816|NCT03586999|Experimental|Nivolumab and EPOCH|Patients will all receive nivolumab in combination with standard dose adjusted EPOCH for a planned 6 cycles, unless treatment is stopped early for disease progression or toxicity. Patients that have already received up to 1 cycle of standard of care chemotherapy will receive 5 cycles of experimental nivolumab + DA-EPOCH (dose adjusted, continuous infusion etoposide, prednisone, vincristine, doxorubicin, and bolus dosing of cyclophosphamide) for a total of 6 cycles of chemotherapy.
89034817|NCT03575390|Placebo Comparator|control group|Control group will receive placebo medication therapy
89612946|NCT03086733|Experimental|Metformin|14 to 21 days of pre-operative Metformin tablets First 5 days 850 mg OD v/o 850 mg BID thereafter until 21 days are completed.
89612947|NCT03017170|Experimental|Cranberry|500mg Dried Cranberry
89612948|NCT03017170|Placebo Comparator|Placebo Oral Capsule|Color Matching Placebo
89612949|NCT03033862||Intervention with Bioresorbable Vascular Scaffold|Implant of Abbott Bioresorbable stent
89612950|NCT03033862||Intervention with Drug Eluting Stent|implant of drug eluting stent
89612951|NCT00086619|Experimental|constant dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a constant dose of 30 mcg/day.
89612952|NCT00086619|Experimental|ascending dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a dose that ascends at 6 month intervals (20-30-40 mcg/day).
89612953|NCT00945958|Experimental|SPARC0913|
89612954|NCT00085917|Active Comparator|Standard dose arm|Pegylated interferon alfa -2a STANDARD DOSE Pegasys 180ug/week
89612955|NCT00085917|Experimental|Double dose arm|Double dose pegylated interferon with weight based Ribavirin
89612956|NCT03416283|Experimental|Remote Monitoring (RM)|Remote Monitoring subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence.
89612957|NCT03416283|Experimental|Remote Monitoring + Social Support (RM+SS)|Remote Monitoring + Social Support subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence, as well as a social support partner to provide additional feedback to the participant on their monitoring and adherence practices.
89612958|NCT03416283|No Intervention|Usual Care|Usual care subjects will not receive a blood pressure cuff or bidirectional text messaging. They will be asked to take their medication and monitor BP as usual with no additional contact from study staff until the 4 month study follow-up.
89612959|NCT03416049||High-power PEMF device|20 participants with VSLU will receive PEMF therapy with a high-power PEMF device for 10 minutes twice a day for each VSLU area.
89612960|NCT03416049||Medium-power PEMF device|20 participants with VSLU will receive PEMF therapy with a medium-power PEMF device for 15 minutes twice a day per VSLU area.
89612961|NCT03416049||Low-power PEMF device|20 participants with VSLU will receive PEMF therapy with a low-power PEMF device for 30 minutes twice a day per VSLU area..
89612962|NCT03416049||Sham PEMF device|20 participants with VSLU will receive PEMF therapy with a sham PEMF device identical to the low-power PEMF device and will treat each VSLU area for 15 minutes twice a day.
89612963|NCT00084747|Experimental|bortezomib|
89612964|NCT04402671|Active Comparator|non-crosslinked collagen membrane group|2 patients (1 male, 1 female)
89612965|NCT04402671|Active Comparator|glutaraldehyde cross-linked collagen membrane|2 patients (2 females)
89612966|NCT01678287|Experimental|Arm 1 Non elderly receiving ASP1941|healthy subjects age 18 to 45 years receiving ASP1941
89612967|NCT01678287|Experimental|Arm 2 Non elderly receiving placebo|healthy subjects age 18 to 45 years receiving placebo
89612968|NCT01678287|Experimental|Arm 3 Elderly receiving ASP1941|healthy subjects age ≥ 65 years receiving ASP1941
89612969|NCT01678287|Experimental|Arm 4 Elderly receiving placebo|healthy subjects age ≥ 65 years receiving placebo
89612970|NCT01678365|Experimental|ceftriaxone and metronidazole for complicated appendicitis.|Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.
89612971|NCT01678365|Active Comparator|Ampicillin, gentamicin, and metronidazole|Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole
89034818|NCT03575390|Experimental|test group|pomegranate group will receive oral pomegranate (500 mg, twice per day)
89034819|NCT03564522||Pulmonary Hypertension|Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
89034820|NCT03564522||Heart Transplant|Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
89034821|NCT03537495|No Intervention|Control arm|"Subjects in this arm will only receive high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.~High-dose rifampicin will consist of weight-banded fixed-dose combination (FDC), including rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) according to international guidelines, combined with 900 mg rifampicin (≤37 kg: two 450 mg tablets) or 1200 mg rifampicin (>37 kg: two 600 mg tablets) to reach ~35 mg/kg rifampicin in total."
89034822|NCT03537495|Experimental|Linezolid 600|Subjects in this arm will receive 600 mg linezolid QD along with high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
89034823|NCT03537495|Experimental|Linezolid 1200|Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
89612972|NCT00946270|Experimental|Group 3 CC-4047 + Prednisone|CC-4047 0.5 mg orally daily starting on day 1 through 28. Prednisone given during first 3 cycles of therapy. It will be dosed orally at the dose of 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
89612973|NCT00946270|Experimental|Group 1 CC-4047|CC-4047 3.0 mg orally daily starting on day 1 through 21.
89034824|NCT03534518|Active Comparator|SCI-patients receiving overground training|
89034825|NCT03534518|Active Comparator|SCI-patients receiving treadmill training|
89612974|NCT00946270|Experimental|Group 2 CC-4047|CC-4047 0.5 mg orally daily starting on day 1 through 28.
89612975|NCT03478293|Experimental|iStent inject surgery|Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
89210807|NCT01075789|Active Comparator|Lignocaine|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this treatment placebo arm or the treatment arm in a 1:1 ratio. The children in the treatment arm will receive xylocaine viscous 2% to swallow, and atomised 10% xylocaine to the nasal turbinates and nasopharynx.
89612976|NCT03021850|Active Comparator|Stretching associated with shortwave heating|Applying deep heat through the shortwave equipment for 20 minutes, in coplanar application to the posterior part of the thigh associated with flexibility training of the hamstrings in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles in 10 repetitions of 30 seconds, with a 10 second pause between each repetition.
89612977|NCT03021850|Active Comparator|Stretching associated with cryotherapy|Cryotherapy application for 20 minutes, applied to the posterior part of the thigh associated with flexibility training of the hamstring muscles in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles, in 10 repetitions of 30 seconds , with a 10 second pause between each repetition.
89034826|NCT03525288|Experimental|PSMA-PETgRT|PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.
89034827|NCT03525288|Active Comparator|Standard|Patient's receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.
89034828|NCT03519269|No Intervention|Non robotics-assisted Surgical System|Conventional, non-robotics-assisted total knee surgical system
89612978|NCT03021850|Other|Stretching isolated|The flexibility training of the hamstring muscles will be by passive static stretching of the hamstring muscles in 10 repetitions of 30-second , with a 10-second pause between each repetition.
89612979|NCT03475641|Active Comparator|The current standard anesthesia|Standard treatment during procedure
89612980|NCT03475641|Experimental|Femoral nerve blockade|Femoral nerve blockade added to the standard treatment.
89612981|NCT01678521||Hypercholesterolemic patients|Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment
89612982|NCT03021616|Experimental|Energy drink|Two 16 oz bottles of energy drink will be consumed at baseline.
89612983|NCT03021616|Active Comparator|Moxifloxacin control|32oz of active control drink will contain 400mg moxifloxacin with inactive flavoring ingredients.
89612984|NCT03021616|Placebo Comparator|placebo control|32oz placebo control drink
89612985|NCT03086499||The study population|Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery.
89034829|NCT03519269|Experimental|Navio™ Robotics-assisted Surgical System|Navio™ Robotics-assisted Surgical System
89034830|NCT03518606|Experimental|Breast cancer cohort|Patients presenting advanced refractory breast cancer
89034831|NCT03518606|Experimental|Head and neck cohort|Patients presenting advanced refractory head and neck cancer
89034832|NCT03518606|Experimental|Cervix cohort|Patients presenting advanced refractory cervix cancer
89034833|NCT03518606|Experimental|Prostate cohort|Patients presenting advanced refractory prostate cancer
89034834|NCT03518606|Experimental|Miscellaneous cohort|Patients presenting advanced refractory solid tumour with high mutational load
89034835|NCT03506971|Experimental|Participants|"As part of this research, families will benefit from~pediatric nurse's interventions : home visits by a pediatric nurse who will center around three times: a time of observation of the development and progress of the baby, a time for play with the baby and a time to listening the parents.~psychologist's evaluation and joint home visits : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
89034836|NCT03506971|Other|Control|"psychologist's evaluation : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
89034837|NCT03497299|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
89034838|NCT03497299|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
89034839|NCT03495154|Experimental|Parietene DS Composite Mesh|Patients treated with Parietene DS Composite Mesh
89034840|NCT03486340|Experimental|Cardiological assessment|a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment
89034841|NCT03486340|No Intervention|Standard treatment|Standard chemotherapeutic treatment
89034842|NCT03485326||Safety|Safety
89034843|NCT03480672|Experimental|Pembrolizumab + aRCH|Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
89034844|NCT03480672|Active Comparator|aRCH|adjuvant radio-chemotherapy (aRCH)
89034845|NCT03479255|Experimental|Smartphone-enabled structured exercise therapy (SE-SET)|"This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI.~The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health."
89034846|NCT03479255|Active Comparator|Standard exercise therapy|Self-directed, unsupervised exercise as prescribed by the patient's physician.
89034847|NCT03466918|Experimental|Patients with SAPIEN 3 THV|Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
89034848|NCT03454295|Experimental|Part I|Focus group (Part 1) of four to ten GBM ICs bereaved at least one year to help determine our recruitment strategy. Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received. Should consensus among participants be reached (e.g., if the majority report that being approached at time of their loved one's cancer recurrence would have been the optimal time for enrollment), we will target our enrollment timeline to this point (and this timeline will be reflected in amended inclusion criteria). If no consensus is reached, the study staff will enroll ICs at all points in the caregiving trajectory and revisit the appropriateness of various points of contact during the Part 2 individual interviews.
89612986|NCT03021694|Experimental|Young Males Week 1|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
89612987|NCT03021694|Experimental|Young Males Week 3|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
89612988|NCT03021694|Experimental|Young Males Week 5|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
89612989|NCT03086187|Other|Hephaistos unloading orthosis|Hephaistos unloading orthosis: Calf muscle unloading: The 11 male subjects had to wear a novel orthosis for 8 weeks, which greatly reduces plantarflexor forces during gait.
89612990|NCT02245828|Placebo Comparator|Placebo|Placebo comparator
89612991|NCT02245828|Experimental|QCC374|Single and multiple ascending doses of QCC374
89612992|NCT00956254|Experimental|Fentanyl sublingual spray 100 µg|Participants received a single administration of fentanyl sublingual spray 100 µg sublingually.
89612993|NCT03021148||High-school children|"High-school children, age range from 13 to 18 years, from Liceo Classico and Liceo Artistico Tommaso Fazello of Sciacca, Agrigento, Italy"
89612994|NCT03085953|Experimental|Experimental: Supervisor Intervention|Supervisors in the intervention group will go through the Veteran Supervisor Supportiveness Training.
89612995|NCT03085953|Other|Waitlist Control Group|Supervisors will receive intervention following all measurement points, to serve as a waitlist control comparison group
89612996|NCT03020680|Experimental|ubiquinol|It is the reduced form of coenzyme Q10
89034849|NCT03454295|Experimental|Part II|In Part 2, we will recruit 60 ICs of patients with GBM who will be randomized to receive either MCP-C or EUC. MCP-C will be delivered individually over 7 1-hour-long sessions within 7 - 14 weeks.
89034850|NCT03421691|Other|Excel V laser|excel V Laser Genesis procedure utilizing 1064 nm laser
89034851|NCT03406572|Experimental|HFHO Group|Patients will receive a first NIV session (for 2 hours) with predefined parameters, and ABG will be performed between one and two hours of starting NIV. NIV will be extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require predefined criteria. In-between each NIV session, oxygen will be delivered using a high flow nasal cannula, with a flow of 50-60L/min and a FiO2 set to reach a targeted SpO2: 88%≤SpO2 ≤ 92%. Predefined criteria will be used to resume NIV.
89034852|NCT03406572|Active Comparator|Standard O2 Group|NIV will be initiated based on the same criteria and with the same parameters as the HFHO group. ABG will also be performed between one and two hours and NIV extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require the same predefined criteria as the HFHO group. In-between each NIV session, oxygen will be delivered using standard low flow O2 to reach the same targeted SpO2: 88% ≤SpO2 ≤ 92%. Similar criteria will be used to resume NIV
89034853|NCT03397602|No Intervention|standard care|Participants do not participate in a on site structured exercise training program.
89034854|NCT03397602|Experimental|standard care + MICE|standard care + moderate-intensity continuous exercise training (MICE)
89034855|NCT03397602|Experimental|standard care + HIIT|standard care + high-intensity interval training (HIIT)
89034856|NCT03390296|Experimental|Arm A (anti-OX40 antibody PF-04518600)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89034857|NCT03390296|Experimental|Arm B (azacitidine, venetoclax, GO)|Patients receive azacitidine IV over 10-40 minutes or via injection SC on days 1-7 or 1-5 and 8-9. Patients also receive venetoclax PO on days 1-28 and GO IV over 2 hours on day 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89034858|NCT03390296|Experimental|Arm C (azacitidine, GO, avelumab)|Patients receive azacitidine and GO as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89034859|NCT03390296|Experimental|Arm D (azacitidine, venetoclax, avelumab)|Patients receive azacitidine and venetoclax as in Arm A and avelumab as in Arm C. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89034860|NCT03390296|Experimental|Arm E (azacitidine, avelumab, anti-OX40 antibody PF-04518600)|Patients receive azacitidine and avelumab as in Arm C and anti-OX40 antibody PF-04518600 as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89034861|NCT03390296|Experimental|Arm F (GO, glasdegib)|Patients receive GO IV over 2 hours on days 1, 4, and 7, and glasdegib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89034862|NCT03386240|Experimental|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures|Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.
89034863|NCT03386240|Placebo Comparator|Vicryl, monocryl, PDS (not coated with triclosan)|Use of Monocryl, Vicryl and PDS Suture (equivalent uncoated sutures) will be used exclusively throughout the whole procedure.
89034864|NCT03362801|Other|Sarcopenic|sarcopenic status the day before cystectomy.
89034865|NCT03362801|Other|not sarcopenic|sarcopenic status the day before cystectomy.
89034866|NCT03338387|Experimental|Acipimox|Other Names: Olbetam
89034867|NCT03338387|Placebo Comparator|Placebo|"Other Names:~Placebo (for Olbetam)"
89612997|NCT03020680|Active Comparator|ubiquinone|It is the oxidized form of coenzyme Q10
89612998|NCT01678599|Other|Benznidazol|This is a single arm, open label study; therefore, all subjects enrolled will receive benznidazol.
89612999|NCT03445221|Active Comparator|Group I|Patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
89613000|NCT03445221|Active Comparator|Group II|Patients will continue preoperative oral conventional diet.
89613001|NCT03019822|Other|Placebo, LSD, d-Amphetamine, MDMA|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase
89034868|NCT03334253|Experimental|Atropine Group|0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops
89034869|NCT03334253|Placebo Comparator|Placebo Group|Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops
89034870|NCT03314857|Experimental|Patients with SAPIEN XT THV|Patients will be treated with Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system
89034871|NCT03306264|Experimental|ASTX727|ASTX727 (cedazuridine + decitabine) - Cycle 1 or Cycle 2 (crossover)
89034872|NCT03306264|Active Comparator|IV decitabine|Dacogen (decitabine for injection) - Cycle 1 or Cycle 2 (crossover)
89034873|NCT03304080|Experimental|HR-positive, Her2-positive Metastatic Breast Cancer|Women and men with HR-positive, HER2-positive Metastatic Breast Cancer on trial of anastrozole, palbociclib, trastuzumab and pertuzumab
89034874|NCT03302156|Other|Healthy Control Non-Dosimetry Group|The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6
89613002|NCT03019822|Other|LSD, d-Amphetamine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
89613003|NCT03019822|Other|d-Amphetamine, MDMA, LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
89613004|NCT03019822|Other|MDMA, LSD, Placebo, d-Amphetamine,,|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
89613005|NCT01678677|Experimental|Group A|Subjects in this group will receive formulation 1 of NTHi vaccine.
89034875|NCT03302156|Other|Patient Group|The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40
89034876|NCT03302156|Other|Dosimetry Group|Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6
89057309|NCT01647633|Experimental|Calcium Glycerophosphate Nasal Wash|Nasal spray wash twice daily and up to four additional times per day as needed for nasal allergy symptoms
89057310|NCT04541069|Experimental|Social Communication and Emotional Skill Development (SCESD)|This arm will get the intervention which is the Early Childhood Development (ECD) training.
89057311|NCT04541069|No Intervention|Control|This arm will not get any intervention.
89057312|NCT01647672|Experimental|Abraxane|Abraxane for neoadjuvant chemotherapy
89057799|NCT01686555|Experimental|Single Dose|Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).
89034877|NCT03275506|Experimental|Pembrolizumab + Chemotherapy|"Arm B (n=60): 4 neo-adjuvant cycles of standard 3 weekly Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm B: Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy.~In the arm B, patient will receive Pembrolizumab 200 mg until a maximum of 15 months in total from the beginning of the adjuvant therapy."
89034878|NCT03275506|Active Comparator|Chemotherapy alone|"Arm A (n=30): 4 neo-adjuvant cycles of standard 3 weekly carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm A: carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), q3 weeks +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~- In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy."
89034879|NCT03267680|Experimental|Arm I (IRX-2)|Patients receive cyclophosphamide IV on day 1 and IRX-2 via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
89034880|NCT03267680|Active Comparator|Arm II (placebo)|Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
89034881|NCT03256656|Experimental|Healthy subjects|
89034882|NCT03256656|Active Comparator|Patients with SCI|
89034883|NCT03249870|Experimental|Inotuzumab ozogamicin (INO)|
89034884|NCT03244722|Other|Obese - Very low energy diet (VLED)|Participants will adopt a very-low energy diet
89034885|NCT03244722|Other|Obese - Standard of care (SOC)|Participants will receive the standard of care for obese women looking to become pregnant.
89034886|NCT03244722|Other|Lean - Standard of care (SOC)|Participants will receive the standard of care for lean women looking to become pregnant.
89034887|NCT03240731|Experimental|bone marrow transplant|"All the included patient will receive an haploidentical bone marrow transplant with the following protocol concerning the conditioning and GvHD prevention~Conditioning~THYMOGLOBULINE : 0.5mg/kg at D-9 and 2 mg/kg at D-8 and D-7~THIOTEPA: 10mg/kg/j at D-7~CYCLOPHOSPHAMIDE (Endoxan®):14.5mg/kg/j at D-6 and D-5~FLUDARABINE (Fludara®): 30mg/m2 per Day from D-6 to D-2~TBI : 2GY : D -1 Graft : Injection at D0 of G-CSF-stimulated bone marrow transplant.~Prophylaxis of GvHD~CYCLOPHOSPHAMIDE (Endoxan®): 50mg/Kg per Day from D+3 to D+4~Sirolimus and MycophénolateMofétil (MMP) from D+5. In the absence of acute GvHD (aGvHD), stop of MMP to D35 and pursuit of sirolimus 1 year after the graft."
89034888|NCT03235739|Experimental|Treatment Arm|Naloxegol 25 mg given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
89034889|NCT03235739|Placebo Comparator|Placebo Arm|Matching placebo given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
89034890|NCT03224312||Primary aldosteronism|screened, confirmed and subtyped according to the guidelines.
89034891|NCT03224312||Essential hypertension|screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion
89034892|NCT03210688|Active Comparator|High dose prednisolone|Prednisolone 1 mg/kg/day
89034893|NCT03210688|Experimental|Alfacalcidol and low dose prednisolone|Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day
89034894|NCT03189810|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
89034895|NCT03189810|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
89034896|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Placebo-Controlled Period)|MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
89034897|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Placebo-Controlled Period)|Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
89034898|NCT03176771|Experimental|Placebo (Double-Blind Placebo-Controlled Period)|Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
89034899|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
89057800|NCT01686555|Experimental|Multiple Dose|Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)
89613006|NCT01678677|Experimental|Group B|Subjects in this group will receive formulation 2 of NTHi vaccine.
89034900|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
89613007|NCT01678677|Experimental|Group C|Subjects in this group will receive formulation 3 of NTHi vaccine.
89613008|NCT01678677|Experimental|Group D|Subjects in this group will receive formulation 4 of NTHi vaccine.
89034901|NCT03140748|Other|Patients with fungal peritonitis|
89034902|NCT03140748|Other|Patients with peritonitis without yeast|
89613009|NCT01678677|Experimental|Group E|Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.
89034903|NCT03131921||Colorectal cancer|No intervention. Patients with newly diagnosed stage II-IV colorectal cancer will be enrolled.
89034904|NCT03115788|Active Comparator|No Intervention Game play|The person will be instructed how to hold the iPad and how to play the game.
89034905|NCT03115788|Experimental|Thermal pain and ipad performance|Interventions: Cold induced pain and heat induced pain. The whole group gets thermal heat (n=40) and half (n=20) get cold water foot immersion and half (n=20) get body temperature foot emersion. The person will be instructed how to hold the iPad and how to play the game. The person will then be allowed to play the game until the number of trials is completed or until the person no longer wishes to play.
89034906|NCT03109795|Experimental|Clonidine|To test the magnitude by which short-term (4 weeks) sympathetic nerve activity blockade (clonidine) improves large elastic artery stiffness, vascular inflammation and baroreflex function in subjects with moderate-to-high levels of anxiety
89034907|NCT03109795|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide is a blood pressure-lowering control condition to compare to the effects of clonidine
89034908|NCT03004144|Other|FLOAT-Support|
89034909|NCT02980510|Experimental|A=Experimental group|FOLFIRINOX + Panitumumab oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² given as a 2-hour intravenous (IV) infusion with the addition, after 30 minutes of irinotecan 150 mg/m² given as a 90-minute intravenous infusion through a Y-connector immediately followed by fluorouracil 400 mg/m² IV bolus then 5-fluoruracil (5-FU) 2400 mg/m² over 46 hours continuous infusion.
89034910|NCT02980510|Active Comparator|B=Control group|mFOLFOX6 + Panitumumab mFOLFOX6 every 2 weeks: oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² IV infusion over 2 hours followed by fluorouracil 400 mg/m² IV bolus then 5-FU 2400 mg/m² over 46 hours continuous infusion.
89034911|NCT02971956|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
89034912|NCT02968823|Active Comparator|Licorice|Licorice gargle
89034913|NCT02968823|Placebo Comparator|Sugar water|Sugar gargle
89034914|NCT02967289|Experimental|Arm A|mFOLFIRINOX Folfox Protocol + Irinotecan
89034915|NCT02967289|Active Comparator|Arm B|mFOLFOX 6 Folfox Protocol
89613010|NCT01678677|Experimental|Group F|Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.
89034916|NCT02953301|Experimental|resminostat|3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
89034917|NCT02953301|Placebo Comparator|Placebo|3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
89034918|NCT02941705|Active Comparator|RECIEVED CELLS|this arm will receive the CDCs /CAP 1002 solution
89034919|NCT02941705|Placebo Comparator|CONTROL ARM|this arm will receive a solution during randomization but will not receive the CDCs
89613011|NCT01678677|Experimental|Group G|Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.
89613012|NCT01678677|Experimental|Group H|Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.
89613013|NCT01678677|Placebo Comparator|Group Placebo 1|Subjects in this group will receive placebo.
89613014|NCT01678677|Placebo Comparator|Group Placebo 2|Subjects in this group will receive placebo.
89613015|NCT03443193|Experimental|Linear training|Linear training consists to a progressive improvement of the training load during the 3 month-program.
89613016|NCT03443193|Experimental|Non-linear training|Non-linear training consists to an undulating progressive improvement of the training load during the 3 month-program.
89613017|NCT00946348|Experimental|Dronabinol|Dronabinol 10mg or 15 mg
89613018|NCT00946348|Active Comparator|Cannabis|Cannabis cigarette
89034920|NCT02939742|Experimental|Betamethasone|Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
89034921|NCT02939742|Placebo Comparator|Saline Placebo|Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
89034922|NCT02916966||ALS Patients in Case-Control|ALS patients enrolled by Cleveland Clinic Foundation (CCF)
89034923|NCT02916966||Non-neurodegenerative patients in case control|Non-neurodegenerative patients enrolled by CCF
89034924|NCT02916966||Non-neurodegeneration population in population control|Non-neurodegenerative general population enrolled by ABS mailing system from DHMC
89034925|NCT02916966||ALS Patients in State of OH|ALS registry of all cases in Ohio
89034926|NCT02902484|Experimental|Nintedanib Monotherapy|"One cycle of Nintedanib monotherapy followed by a total of eight cycles of both Nintedanib and the chemotherapeutic agents, or until disease progression, whichever comes first.~Nintedanib dose escalation: 150, 200 mg PO BID~Nab-paclitaxel: 125 mg/m2 day 1,8,15 every 28 days~Gemcitabine: 1000 mg /m2 day 1,8,15 every 28 days"
89613019|NCT00081159|Experimental|HAT, Doxorubicin, Zoledronate + Strontium chloride|Arm I: Hormonal ablative therapy (HAT) comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses; and a single dose of strontium chloride Sr 89 IV over 1-2 minutes on day 1.
89613020|NCT00081159|Experimental|HAT, Doxorubicin + Zoledronate|Arm II: HAT, doxorubicin, and zoledronate as in arm I. HAT comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses.
89613021|NCT03033550|Experimental|single|single arm- behavioral educational intervention of a brief negotiated mobile application
89613022|NCT03033706|Active Comparator|Study group|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation guided fluid therapy): Study group will receive restricted fluid management with 1 ml/Kg/hr with concomitant PPV monitoring. PPV will be measured using invasive blood pressure monitor. Fluid bolus of 3 ml/Kg of ringer solution will be administrated whenever PPV is higher than 13%.
89613023|NCT03033706|Placebo Comparator|Control group|Brain tumor excision under general anesthesia. Intervention (Traditional fluid therapy): Control Group will receive standard fluid management of 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
89613024|NCT03033472|Experimental|Clindamycin|600 mg of Clindamycin orally 30 minutes before root canal treatment
89034929|NCT02798042||Patient population|Patients undergoing bariatric surgery
89034930|NCT02797288||Acute CDI cohort|Hospitalized patients diagnosed with Acute CDI
89034931|NCT02797288||FMT cohort|Patients undergoing FMT for recurrent CDI
89034932|NCT02797288||Past CDI Control Cohort|Hospitalized patients with past CDI diagnosis without recurrence
89034933|NCT02789020|Experimental|Rasagiline|This group will receive a 1 mg rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
89034934|NCT02789020|Placebo Comparator|Placebo|This group will receive a placebo tablet in the same forum as the rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
89034935|NCT02785848||Asthma and/or Sickle Cell Anemia|The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
89034936|NCT02756273|Experimental|no bridge device|After the ileostomy creation, no bridge device was placed.
89034937|NCT02756273|Active Comparator|bridge device|A bridge device was placed after the stoma creation.
89034938|NCT02719314||Rh-GIOP(A)|Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
89034939|NCT02719314||Rh-GIOP(B)|Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
89034940|NCT02719314||Rh-GIOP(C)|Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
89034941|NCT02602769||Cases of ROHHAD syndrome|"Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians.~The investigators will perform transcriptome profiling in this group."
89034942|NCT02602769||Control cohort|Unaffected first degree family members. The investigators will perform transcriptome profiling in this group.
89034943|NCT02598362|Other|intravenous|Participants who are treated with ciprofloxacin intravenously, at discretion of the treating physician.
89613025|NCT03033472|Placebo Comparator|Placebo|placebo 30 minutes Orally before treatment
89613026|NCT01678989||Patient group|Children with BD, (20 children) 12-18 year-old who agreed to participate in the study will be established.
89613027|NCT01678989||Risk group|Twenty healthy children of 12-18 years old who have mothers and/or fathers who previously assessed by an adult psychiatrist and diagnosed as BD according to DSM-IV diagnostic criteria, and who agreed to participate in the study. The age and gender of the groups will be matched.
89034944|NCT02598362|Other|oral|Participants who are treated with ciprofloxacin via the oral route, at discretion of the treating physician.
89034945|NCT02585388|Active Comparator|Vinorelbine|Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
89034946|NCT02585388|Experimental|Vinorelbine+Anastrozole or Letrozole|"Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.~And:~Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity"
89034947|NCT02584465|Active Comparator|A-Tamoxifen|Tamoxifen 40mg/day 2 film-coated tablet containing 20 mg of Tamoxifen/day until progression
89034948|NCT02584465|Experimental|B-Regorafenib|Regorafenib 120mg/day 3 film-coated tablet containing 40 mg of Regorafenib/day, 3 weeks/4 until progression
89034949|NCT02579278||mrEMVI positive rectal tumours|Patients will be registered whose rectal tumours are mrEMVI positive (i.e. EMVI is present in baseline and post-chemoradiotherapy MRI scans).
89034950|NCT02579278||mrEMVI negative rectal tumours|Patients registered who were mrEMVI positive at baseline MRI but have become mrEMVI negative post-chemoradiotherapy.
89034951|NCT02579161|Active Comparator|Antibiotics for a 24 hour period|"Antibiotics for a 24 hour period~Intervention drug to be determined based on patient history etc."
89613028|NCT01678989||Healthy control group|Twenty participants between the ages of 12-18 who agree to participate in the study and whose family members do not have BD. The age and the gender of the groups will be matched.
89613029|NCT01679067||HIV-GALT|
89613030|NCT02981836|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated varicella vaccine;"
89034952|NCT02579161|Active Comparator|Continued antibiotics|"Continued antibiotics until the removal of any external catheters~Intervention drug to be determined based on patient history etc."
89034953|NCT02568124|Experimental|Tranexamic acid|Tranexamic acid 750 mg daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
89034954|NCT02568124|Placebo Comparator|Placebo|Placebo tablet daily until complete radiological resolution of the chronic subdural hematoma or a maximum of 20 weeks.
89034955|NCT02549664||LQT/HCM sedentary patients|LQT/HCM sedentary lifestyle
89034956|NCT02549664||LQT/HCM moderate/vigorous exercise|LQT/HCM participate in moderate or vigorous exercise
89034957|NCT02536170|Experimental|L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
89034958|NCT02536170|Experimental|Loading Dose and L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
89034959|NCT02536170|Placebo Comparator|Placebo|Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
89034960|NCT02535533|Experimental|Study Treatment|"During the Dose-Escalation Part 1, patients will receive SLM twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Expansion Part 2, patients will be treated at the maximum tolerated dose (MTD) of SLM determined as 4000 mcg SLM. SLM will be given orally twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Pilot Phase, dosing will begin at dose level 3 (4000, 5000, or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days. Each cohort will enroll 2 evaluable patients."
89034961|NCT02530983||Esophagectomy/Esophageal Reconstruction/Treatment|Patients who have undergone esophagectomy, esophageal reconstruction, or treatment
89034962|NCT02530983||Upper Digestive Disease|Patients who have an upper digestive disease.
89034963|NCT02524483|Experimental|Therapeutic Challenge Group|The Therapeutic Challenge Group will complete the Therapeutic Challenge Program twice a day, five days each week for 6 weeks.
89034964|NCT02524483|Active Comparator|Therapeutic Exercise Group|The Therapeutic Exercise Group will complete the Therapeutic Exercise Program twice a day, five days each week for 6 weeks.
89034965|NCT02523443|Active Comparator|IV PCA after surgery|general anesthesia with post-operative IV PCA with a standard demand pump
89613031|NCT02981836|Sham Comparator|Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~Intervention: diluent of lyophilized vaccine;"
89613032|NCT03033004|Active Comparator|Conventional Cryolipolysis|Subjects will receive one treatment session of conventional cryolipolisys. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
89613033|NCT03033004|Active Comparator|Contrast Cryolipolysis|Subjects will receive one treatment session of contrast cryolipolisys. Subcutaneous fat tissue will be heated for 10 minutes, cooled for 60 minutes, and heated again for 10 minutes with the cryolipolitic device. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
89613034|NCT03033004|Active Comparator|Reperfusion Cryolipolysis|Subjects will receive one treatment session of Reperfusion Cryolipolysis. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes and heated for 10 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
89613035|NCT03033238||Early or mild knee symptoms|"Existing Cohort study participants (3,026) were enrolled in 2003-2005, Surviving participants without endstage knee osteoarthritis will be asked to participate in the 144-, 152-, 160- and 168-month follow-up contacts [2,660 were enrolled].~New Cohort study participants (1,500) will be recruited and enrolled in 2016-2018 [1,525 were enrolled]."
89613036|NCT03085641|Experimental|Nasal high flow oxygen therapy|"The patient is hospitalized for one night.~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:~Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)~High flow rate: 40-50 L/min without additional oxygen~Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)~High flow rate: 40-50 L/min with FiO2 of 28%"
89613037|NCT03033082||Erectile dysfunction patients|Questionnaire sheets.
89613038|NCT03033082||Normal males|Questionnaire sheets.
89613039|NCT03033160|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
89034966|NCT02523443|Experimental|PCEA during and after surgery|general anesthesia with post-operative thoracic epidural analgesia with a standard demand pump
89613040|NCT03033160|No Intervention|Observation|Observation
89613041|NCT03019354|Experimental|high-flow nasal oxygen|high-flow nasal oxygen was used during intravenous general anesthesia
89057313|NCT04540562|Experimental|Intervention|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
89057314|NCT01681719|Experimental|WBV and resistance|used both interventions
89057315|NCT01681719|Experimental|WBV & resistance sham|used the vibrating platform and sham for resistance training
89057316|NCT01681719|Experimental|Resistance & sham WBV|used resistance exercises and sham for vibrating platform
89613042|NCT03019354|Active Comparator|Oxygen mask|oxygen mask was used during intravenous general anesthesia
89613043|NCT04348539|Experimental|Balance training|The balance training consists of 3 moments: warm up, main and stretch. Warm-up with mobility exercises for major joints and large muscle groups. The main part will have eight exercise stations divided into: a) five balance exercises (dynamic and static with or without object balance) on a varied floor, b) three agility exercises, and a stretching of the worked muscle groups and a final relaxation.
88985377|NCT00352495|Experimental|Vinblastine sulfate and carboplatin|The MTD of vinblastine in combination with a monthly dose of carboplatin will be determined during the first cycle of therapy. Each 4-week cycle will consist of carboplatin once every 4 weeks on day 1. Vinblastine will be given once a week for 3 weeks followed by a one week break. Doses of carboplatin and vinblastine sulfate will be assigned at study enrollment. Patients may receive eleven additional four week cycles, barring tumor progression or unacceptable toxicity. The total duration of therapy will be approximately 48 weeks.
88985378|NCT02964351||High PSA (prostate-specific antigen) levels|
88985379|NCT00112697|Experimental|Arm 1|
89613044|NCT04348539|Experimental|Strength training|Muscle strength training will consist of 3 moments: warm up, main and stretch. Warm up with mobility exercises for the main joints and large muscle groups. The main part will include strength exercises with lower and upper limbs with two sets of 6-12 repetitions according to periodization, and a stretching of the muscle groups worked
89613045|NCT04348539|Experimental|Cardiorespiratory endurance training|The older people walking training consists of 3 moments: warm up, main and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed, then walk according to the training cycle, and then a stretching of the main muscle groups. Will be held, twice a week for 45 minutes each session. The training intensity will follow 60-110% of the volume of the 6-minute Test (6MWT) and the Borg Scale at moderate to difficult intervals. the training
89613046|NCT04348539|No Intervention|Control group|control group: who will receive educational lectures on health, walking and aging.
89613047|NCT00958282|Active Comparator|lisdexamfetamine/Behavior Therapy|lisdexamfetamine 70mg/day plus Behavior Therapy
89613048|NCT00958282|Placebo Comparator|placebo|Placebo Comparator once per day
89613049|NCT02981758||Data Collection Phase 1|All women who had vaginal deliveries between 2010 and 2015 who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x).
89613050|NCT02981758||Data Collection Phase 2|All women who delivered (vaginally) at HackensackUMC who had blood loss and measured quantitatively by Triton and qualitatively (i.e., EBL) by obstetrician.
89613051|NCT03019276|Experimental|TQ-B3101|TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89613052|NCT03032926||Open Trial|N/A - Open Trial
89613053|NCT03033316|Experimental|IV Liposomal Dexamethasone|IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks
89613054|NCT03032848|Active Comparator|Conjugated Estrogen Group|use of 1 gram per day
89613055|NCT03032848|Active Comparator|Promestriene Group|use of 1 gram per day
88985380|NCT00112697|Experimental|Arm 2|
88985381|NCT02959606|Experimental|Sarpogrelate SR 300mg + ASA|"Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Anplone SR"
88985382|NCT02959606|Active Comparator|Clopidogrel + ASA|"Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Plavix"
88985383|NCT00352729|Active Comparator|A|
88985384|NCT00352768|Experimental|F|
89613056|NCT03032848|Active Comparator|Estriol Group|use of 1 gram per day
89613057|NCT03032848|Placebo Comparator|Vaginal Moisturizer Cream|use of 1 gram per day
89613058|NCT00080223|Experimental|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
89613059|NCT03472443|Experimental|Sinew Acupuncture|
88985385|NCT00352768|Placebo Comparator|P|
88985386|NCT00112853|Experimental|Treatment (tipifarnib, etoposide)|"Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD."
88985387|NCT05594901||Retrospective Cohort|
88985388|NCT05594901||Prospective Cohort|
88985389|NCT00353548||1-Anorexia Nervosa|Women ages 16-50 who meet DSM-IV criteria for anorexia nervosa
88985390|NCT00353548||2-Bulimia Nervosa|Women age 16-50 who meet DSM-IV criteria for bulimia nervosa
88985391|NCT00353548||3-Binge Eating Disorder|Women with binge eating disorder
88985392|NCT00353548||4-Healthy Controls|Healthy control subjects ages 16-50 of normal weight
88985393|NCT00353548||5-Obese Controls|Healthy obese control subjects
88985394|NCT00353587|Experimental|MBX-102 200 mg|MBX-102 200 mg once daily for 16 weeks
88985395|NCT00353587|Experimental|MBX-102 400 mg|MBX-102 400 mg once daily for 16 weeks
88985396|NCT00353587|Experimental|MBX-102 600 mg|MBX-102 600 mg once daily for 16 weeks
88985397|NCT00353587|Placebo Comparator|Sugar Pill|Placebo comparator once daily for 16 weeks
88985398|NCT00353587|Active Comparator|Actos|Actos 30 mg once daily for 16 weeks
88985399|NCT00353665|Experimental|1 - active|memantine + riluzole
88985400|NCT00353665|Placebo Comparator|2|riluzole + placebo
88985401|NCT04714606|Experimental|Sibling support group|8 session, tailored support group for siblings of children who have an ASD
88985402|NCT04714606|Active Comparator|Booklet|Control condition in which siblings of children who have an ASD will receive a tailored booklet to complete at home
88985403|NCT04714528|Active Comparator|Physical Exercise Group|45 minutes of aerobic, high intensity group training, three times per week during a 12-week period.
88985404|NCT04714528|Other|Relaxation Group|45 minutes of relaxation therapy once per week for 12 weeks.
88985405|NCT04714489||experimental group|
89613060|NCT03472443|No Intervention|Waitlist|
89613061|NCT01679223||<40 years|subjects aged less than 40 years
88985406|NCT00353743|Active Comparator|1|Patients that receive up to 10 days of doxycycline 200mg/day and metronidazole 500mg/day
88985407|NCT00353743|Placebo Comparator|2|Patients that do not receive antibiotics, only placebo
88985408|NCT00354133|Active Comparator|DBS treatment|Patients in this arm are treated with Deep Brain Stimulation (DBS) of the Nucleus subthalamicus with the device Kinetra and Soletra (neurostimulator, Medtronic) and addtionally get best medical treatment
88985409|NCT00354133|Active Comparator|BMT treatment|Patients in this arm get best medical treatment only.
88985410|NCT00354211||1|FLOTRAC™ SYSTEM
88985411|NCT00354211||2|Control Group
88985412|NCT05594550||28-day survival|Alive 28 days after intensive care admission
88985413|NCT05594550||28-day death|Deceased 28 days after intensive care admission
88985414|NCT00354250|Experimental|Treatment (ispinesib)|Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88985415|NCT04714294|Experimental|SAD: Each volunteer will receive 6 mg, 10mg, 20mg, 40mg(or TBD) of IP once daily for 1 day|Drug: HPP737 or placebo One 1 mg capsule and one 5mg capsule taken orally (by mouth) once daily for SAD arm 1/ Two 5mg capsule taken orally (by mouth) once daily for SAD arm 2/ Four 5mg capsule taken orally (by mouth) once daily for SAD arm 3/ Eight 5mg capsule taken orally (by mouth) once daily for SAD arm 4
88985416|NCT04714294|Experimental|MAD: Each volunteer will receive 10mg, 20mg, 40mg(or TBD) of IP once daily for 7 days|Drug: HPP737 or placebo Two 5mg capsule taken orally (by mouth) once daily for MAD arm 1/ Four 5mg capsule taken orally (by mouth) once daily for MAD arm 2/ Eight 5mg capsule taken orally (by mouth) once daily for MAD arm 3
88985417|NCT00354406|Experimental|A|Patients in Arm A (Early abciximab arm) will receive abciximab at time of STEMI diagnosis, before transfer to the Cath Lab to undergo primary angioplasty.
88985418|NCT00354406|Active Comparator|B|Patients in Arm B (Late abciximab arm) will receive abciximab at time of primary angioplasty, directly in the Cath Lab.
88985419|NCT02965001|Experimental|68Ga-NOTA-AE105|All participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy
88985420|NCT00354523|Experimental|Capecitabine + Dacarbazine + Imatinib|Capecitabine starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle. Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
88985421|NCT00425659|Active Comparator|3|
88985422|NCT00425659|Experimental|1|
88985423|NCT00425659|Other|2|usual practice
88985424|NCT00425776|Active Comparator|Real acupuncture|
88985425|NCT00425776|Sham Comparator|Sham acupuncture|
88985426|NCT00425776|No Intervention|No intervention|
88985427|NCT00425815|Experimental|Org 24448 250 mg|Two capsules (one Org 24448 250 mg capsule and one placebo capsule that is identical to the active treatment) will be ingested orally daily for eight weeks.
88985428|NCT00425815|Experimental|Og 244448 500 mg|Two capsules (two Org 24448 250 mg capsules) will be ingested orally daily for eight weeks.
88985429|NCT00425815|Placebo Comparator|Inactive Capsule|Two capsules (two placebo capsules that are identical to the active treatment) will be ingested orally daily for eight weeks.
88985430|NCT00425893|Active Comparator|1|health education
88985431|NCT00425893|Experimental|2|hand hygiene
88985432|NCT00425893|Experimental|3|masks and hand hygiene
88985433|NCT00425932|No Intervention|Rituximab/Placebo|Patients will be randomized at Baseline to either Placebo or Rituximab. At Week 24 and up to Week 48 if patient DAS28 score is >2.6, patient will be retreated with open label Rituximab.
88985434|NCT00425932|Active Comparator|Open Label|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
88985435|NCT00426010|Active Comparator|1|overt then covert caffeine
88985436|NCT00426010|Active Comparator|2|covert then overt caffeine
88985437|NCT00426010|Active Comparator|3|overt then covert placebo
88985438|NCT00426010|Active Comparator|4|covert then overt placebo
88985439|NCT04705753|Experimental|Cretan IAMA (CAPeo)|All patients are to receive Cretan IAMA (CAPeo) from Day 1.
88985440|NCT04705636|Experimental|Connected device|Connected device for three months period to support children care
88985441|NCT00426166|Experimental|1|Low Level Laser Therapy
88985442|NCT00426166|No Intervention|2|No Laser Therapy. Outcome Measures the same.
88985443|NCT00113633|No Intervention|Control Subjects|These subjects will receive standard discharge instructions that recommend follow-up with a PCP within 3-5 days.
88985444|NCT00113633|Experimental|Intervention Subjects|As part of the intervention, the family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups. For children reporting persistent asthma symptoms, a letter will be given to the family to bring to their PCP stating that screening revealed symptoms that may require further treatment with controller medications. A mailed reminder to schedule a follow-up appointment will be sent to the family.
88985445|NCT00113672|Experimental|A|Increase healthy eating and increase healthy activity
88985446|NCT00113672|Experimental|B|Increase healthy eating and decrease unhealthy activity
88985447|NCT00113672|Experimental|C|Decrease unhealthy eating and increase healthy activity
88985448|NCT00113672|Experimental|D|Decrease unhealthy activity and decrease unhealthy eating
88985449|NCT01059643|Experimental|LY2523355|
88985450|NCT00115128||Filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
88985451|NCT00115167|Experimental|Darbepoetin alfa|
88985452|NCT00115167|Placebo Comparator|Placebo|
88985453|NCT05594316|Other|single group|Trichloroacetic acid
88985454|NCT01059565|Experimental|AZLI|Participants were randomized to receive AZLI for up to 24 weeks and may have continued to receive AZLI during the open-label phase for up to an additional 24 weeks.
88985455|NCT01059565|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match AZLI for up to 24 weeks and may have switched to AZLI during the open-label phase for up to 24 weeks.
88985456|NCT01059526||Patients naive to KALBITOR|HAE patients that have not been treated with KALBITOR (ecallantide) prior to enrollment in the study
88985457|NCT01059526||Patients non- naive to KALBITOR|HAE patients that have been treated with KALBITOR prior to enrollment in the study
89613062|NCT01679223||40-60 years|subjects aged 40-60years
89613063|NCT01679223||> 60 years|subjects aged greater than 60 years
89613064|NCT04402359||Group A|Patients of Group A received meropenem one gram slowly IV infusion every 8 hours for 14 days and gentamicin 7 milligram (mg)/ Kilogram body weight per day slowly IV infusion once daily only for one week after ventilator for 2 weeks
89613065|NCT04402359||Group B|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution). The solution for injection should be administered over 120 minutes.after ventilator for 2 weeks
88985458|NCT00426244|Sham Comparator|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
88985459|NCT00426244|Active Comparator|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
88985460|NCT00426244|No Intervention|Standard Care|Subject only receives care from her OB provider. Subjects were allowed to receive conventional obstetrical care with the exception of OMT, massage therapy, physical therapy, chiropractic manipulation, or therapeutic ultrasound intended to treat musculoskeletal disorders.
88985461|NCT00444379|Active Comparator|PI-based HAART regimen|PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)
88985462|NCT00444379|Active Comparator|non-nucleoside reverse transcriptase inhibitor|non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir)
88985463|NCT00444418|Experimental|1|Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy
88985464|NCT00444418|Experimental|2|Placebo combined with Modified Behavioral Self-Control Psychotherapy
88985465|NCT00444418|Experimental|3|Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy
88985466|NCT00444418|Placebo Comparator|4|Placebo + Brief Behavioral Compliance Enhancement Therapy
89613066|NCT00959764|Experimental|Oral calcitonin and placebo nasal spray|Intervention: Oral calcitonin tablet (along with placebo intranasal spray)
88985467|NCT00444574|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 2.7mg, 41.3mg, 55mg, and 82.5mg patches for 7 weeks
88985468|NCT00444574|Placebo Comparator|Placebo|Placebp matching MTS and Concerta for 7 weeks
88985469|NCT00444574|Active Comparator|Concerta|Methylphenidate HCL 18mg tablet 7 weeks
88985470|NCT00113789|Active Comparator|Pegfilgrastim|
88985471|NCT00113789|Placebo Comparator|Placebo|
88985472|NCT04699903||Positive SARS-Cov-2 cohort|Positive diagnosis of COVID-19 confirmed by a positive EUA SARS-CoV-2 PCR will be stratified in three subgroups 0 - 7 days since onset of symptoms 8 - 14 days since onset of symptoms 15 -90 days since onset of symptoms
88985473|NCT04699903||Negative SARS-Cov-2 cohort|Negative diagnosis of COVID-19 confirmed by a negative, EUA SARS-CoV-2 PCR test within 0-7 days of PCR sample collection will be included in the negative cohort.
88985474|NCT00115323|Active Comparator|1|Problem solving intervention
88985475|NCT00115323|Active Comparator|2|Attention control intervention
88985476|NCT00113828|Experimental|Transplantation|T-cell depleted HLA-matched peripheral blood stem cell transplantation
88985477|NCT00444886|Active Comparator|1|To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
88985478|NCT00444886|Active Comparator|2|To assess the effect of BOTOX injection on numbness and tingling and quality of life.
88985479|NCT05594121|Experimental|Extended-release subcutaneous buprenorphine (SC-BPN-XR)|For eligible patients randomly allocated to SC-BPN-XR, the first dose will be administered at the time of randomization (Day 0). SC-BPN-XR comes in two formulations, 100 mg and 300 mg buprenorphine doses in a pre-filled syringe. SC-BPN-XR administration is by subcutaneous injection in the abdomen. SC-BPN-XR is administered at intervals ≥26 days. For patients randomly allocated to SC-BPN-XR, they will receive the 300 mg dose for the first 2 months, followed by the 100 mg dose every month until the end of the 12-month period. All SC-BPN-XR doses will be administered in clinics by trained personnel. All patients receiving SC-BPN-XR will have their vital signs monitored every 5 minutes for 15 minutes after the injection before leaving the clinic.
89057317|NCT04543058|Experimental|BeatPark Experimental Group|Group of participants who will make its self-rehabilitation in walking program using BeatPark application, delivering synchronized music adapted to the patient walking progression.
89057318|NCT04543058|Active Comparator|Control Group with Music at Random Tempo|Group of participants who will make its self-rehabilitation in walking program using an application delivering music at random tempo.
89057319|NCT04543058|Active Comparator|Control Group without Music|Group of participants who will make its self-rehabilitation in walking program using an application without music.
89057320|NCT01647789|Experimental|CFG920|
89057321|NCT02215031|Experimental|BI 44370|
89057322|NCT02215031|Placebo Comparator|Placebo|
89057323|NCT01681758|Active Comparator|PPV|use PPV to guide fluid therapy
89057324|NCT01681758|Placebo Comparator|standard care|fluids according to standard care
89057325|NCT02215109||BRVO, Retinal vessel diameter|The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.
89057801|NCT01686672|Experimental|Web Intervention|BeInCharge has two components: an electronic diet tracker and a 7 session intervention. The 7 treatment sessions are designed to be completed over a 7 to 10 week period. Each treatment module includes both a nutrition education and child behavior management component. Treatment sessions should be completed every 7 to 10 days, while the electronic diet tracker requires daily input.
89613067|NCT00959764|Active Comparator|Intranasal calcitonin & oral placebo|Intervention: Commercially available, active comparator, intranasal calcitonin-salmon (plus matching oral placebo tablet).
88985480|NCT05594121|Active Comparator|Immediate-release sublingual buprenorphine/naloxone (SL-BPN/NX)|For eligible patients randomly allocated to SL-BPN/NX, the first study dose will be administered at the time of randomization (Day 0) and will match the SL-BPN/NX type (tablet versus film), route (sublingual versus buccal) and dose used for stabilization prior to study enrollment. For the first 2 weeks of the study period, all SL-BPN/NX administration will be directly observed at community pharmacies by trained personnel according to the usual standard of care. Subsequent to this period, healthcare providers and participants will develop a care plan for ongoing directly observed therapy vs unsupervised take-home dosing according to usual standard of care.
88985481|NCT04699669|Other|Cohort 1: CBL-514 2 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
88985482|NCT04699669|Other|Cohort 2: CBL-514 10 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
88985483|NCT04699669|Other|Cohort 3: CBL-514 20 mg, 0.5 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
88985484|NCT04699669|Other|Cohort 4: CBL-514 40 mg, 1.0 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 4 cm^2
88985485|NCT04699669|Other|Cohort 5: CBL-514 40 mg, 2 mg/cm^2|Individual placebo control. CBL-514 will be administrated with the grid spacing of 2 cm^2
88985486|NCT04699669|Experimental|Cohort 6: CBL-514 80 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
88985487|NCT04699669|Experimental|Cohort 7: CBL-514 160 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
88985488|NCT04699669|Experimental|Cohort 8: CBL-514 240 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
88985489|NCT04699669|Experimental|Cohort 9: CBL-514 320 mg, 2 mg/cm^2|CBL-514 only. CBL-514 will be administrated with the grid spacing of 2 cm^2
89613068|NCT00959764|Placebo Comparator|Placebo: tablet & intranasal spray|Intervention: Both oral matching placebo tablets and matching intranasal placebo spray
89613069|NCT01005706|Active Comparator|Tacrolimus Withdrawal Arm|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
88985490|NCT04699708||Preterm infants ≤ 32 weeks|All preterm infants ≤ 32 weeks born in two study centers receiving resuscitative measures at the time of birth either in the form of face mask ventilation or intubation.
88985491|NCT04699552|Experimental|2J 20 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 20Hz
88985492|NCT04699552|Experimental|2J 40 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 40Hz
88985493|NCT04699552|Experimental|2J 60 Hz|The power settings of 2J of energy will be consistent between the three treatment arms. The frequency will be 60Hz
88985494|NCT02956915||patients with severe symptomatic aortic stenosis|Stable patients with severe symptomatic aortic stenosis undergoing planned Transfemoral Transcatheter aortic valve implantation with the SAPIEN-3 prosthesis will be included. TF-TAVI will be done using a minimalist approach of local anesthesia and conscious sedation.
88985495|NCT00445042|Experimental|A|Intrapatient dose escalation study of sorafenib
88985496|NCT00445081|Active Comparator|1|
88985497|NCT00445081|Active Comparator|2|
88985498|NCT02956954|Experimental|Patient treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
88985499|NCT02956954|Sham Comparator|Patient no treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
88985500|NCT02957188||Young|Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
88985501|NCT02957188||Elderly|Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
88985502|NCT02956993|Active Comparator|Vonapanitase|Vonapanitase administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
88985503|NCT02956993|Placebo Comparator|Placebo|Placebo administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
88985504|NCT03277807||Active|pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
88985505|NCT03277807||Inactive|pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
88985506|NCT03277807||risk for hypertensive disorders|pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
88985507|NCT00445120|Experimental|1|
88985508|NCT00445120|Placebo Comparator|2|
88985509|NCT05594004||Oscillating-Rotating electric toothbrush|Twice daily brushing
88985510|NCT05594004||Sonic electric toothbrush|Twice daily brushing
88985511|NCT05594004||Manual toothbrush|Twice daily brushing
88985512|NCT00445471|Other|A|Mifne Approach to PDD
88985513|NCT00445471|Other|B|Treatment as usual
88985514|NCT00115440|Experimental|A|Active treatment arm.
88985515|NCT03277768||Control Group -Patent Ductus Arteriosus Absent|
88985516|NCT03277768||Study Group - Patent Ductus Arteriosus Present|
89034967|NCT02498912|Experimental|Cyclophosphamide followed by Autologous T Cells|Cohorts of 3-6 pts will be infused with escalating doses of modified T cells to establish the MTD of modified T cells. There are 5 planned dose levels: 3 x 10^5, 1 x 10^6, 3 x 10^6, & 1 x 10^7 & 3 x 10^7 4H11-28z/fIL-12/EGFRt+ T cells/kg. Cohort I-IV & VI will be treated escalating dose levels. Once the MTD of T cells is established, the next cohort will receive lymphodepleting cyclophosphamide dose of 750 mg/m^2 or a regimen of cyclophosphamide dose 300 mg/m2 x 3 days concurrent with fludarabine dose 25-30 mg/m2 x 3 days 2-7 days prior to starting the T cell infusion at one dose level below the MTD. If MTD isn't established after Cohort IV, Cohort V will receive conditioning chemotherapy 2-7 days prior to starting the T cell infusion at the same dose as Cohort III. Pts in Cohort V received cyclophosphamide chemotherapy on Day 1 or cyclophosphamide concurrent with fludarabine on Day 1-3, followed 2 to 4 days later by T cell infusion. This cohort is closed to further accrual.
89034968|NCT02431897|Experimental|Estrogen Cream|Conjugated Estrogens cream
89034969|NCT02431897|Placebo Comparator|Placebo Cream|Placebo cream
89034970|NCT02427841|Experimental|Treatment (chemotherapy, chemoradiation therapy, surgery)|"PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.~SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.~POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity."
89034971|NCT02425566|Experimental|Study day with trimethaphan|After baseline measurements, autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min.
89034972|NCT02425566|Experimental|Radionuclide Study day with nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements. Outcome measurements will be repeated within 10 min after the nitroglycerin has dissolved
89034973|NCT02413788|Experimental|combined group (treadmill and resisted)|- 10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) and resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs (36 sessions)
89034974|NCT02413788|Active Comparator|aerobic group (treadmill)|10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) for 36 sessions
89034975|NCT02386735|Experimental|Investigational treatment|Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
89034976|NCT02386735|Active Comparator|Standard treatment|Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.
89613070|NCT01005706|Active Comparator|Tacrolimus Minimization Arm|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
89613071|NCT05346471|Other|Acute posterior fossa lesions|Subjects will receive additional multimodal infratentorial neuromonitoring
89057802|NCT01686672|No Intervention|Usual Care|Participants will receive usual care and be assessed at baseline and week 10 for study outcomes.
89057803|NCT02217371|Experimental|ADHD patient|
89613072|NCT01679379|Active Comparator|Absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture].
89613073|NCT01679379|Active Comparator|Non absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polypropylene non absorbable monofilament suture].
89613074|NCT03085251|Experimental|Blood glucose measurement|
89613075|NCT03085407|Active Comparator|early cholecystectomy|Early cholecystectomy was done within 48 after admission
89613076|NCT03085407|Sham Comparator|delayed cholecystectomy|Delayed cholecystectomy was done after 30 days after randomization.
89613077|NCT01679691|No Intervention|Control group|Control group in whom no epidural anesthesia will be applied
89613078|NCT01679691|Active Comparator|Epidural Anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
89613079|NCT03470805|Experimental|Olaparib|Olaparib orally twice daily at 150 mgs bid continually
89613080|NCT03084549|Experimental|Ropivacaïne|
89613081|NCT03084549|Placebo Comparator|Placebo|
88985517|NCT00446173|Experimental|Busulfan + Cyclophosphamide + G-CSF + GM-CSF|
88985518|NCT05590650|Experimental|SZKJT group|Patients who meet the inclusion criteria and agree to receive concomitant treatment with SZKJT.
88985519|NCT00446212|Active Comparator|1|Propofol based anaesthetic maintenance with propofol effect-site steered target-controlled infusion, in addition to fentanyl and non-opioid analgesics
88985520|NCT00446212|Active Comparator|2|Desflurane based anaesthetic maintenance with manually controlled administration in 100% oxygen in addition to fentanyl and non-opioid analgesics
88985521|NCT00446368|Experimental|RAD001|Subjects will take RAD001 (Everolimus) 10mg by mouth daily.
88985522|NCT00401765|Experimental|Cohort 1A (Docetaxel and CNTO 328)|In cohort 1A, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel every 3 weeks and 6 mg/kg CNTO 328 every 2 weeks will be administered in the treatment phase.
88985523|NCT00401765|Experimental|Cohort 1B (Docetaxel and CNTO 328)|In cohort 1B, 6 mg/kg CNTO 328 will be administered in run-in phase and 75 mg/m2 docetaxel will be administered every 3 weeks plus 6 mg/kg CNTO 328 will be administered every 2 weeks in the treatment phase.
88985524|NCT00401765|Experimental|Cohort 2 (Docetaxel and CNTO 328)|In cohort 2, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel plus 9 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
89613082|NCT03080259|Active Comparator|Stimulant Diversion Prevention|Providers will be trained in methods to prevent or decrease the likelihood of stimulant diversion by their adolescent patients (education and counseling, strategies for use by patients and parents, and treatment adjustments).
89613083|NCT03080259|No Intervention|Treatment As Usual|Standard clinical care
89613084|NCT03081351|Experimental|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
89613085|NCT03081351|Experimental|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
89613086|NCT03084861|Experimental|cord blood eye drops|Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
89613087|NCT03084861|Active Comparator|Conventional treatment|"Conventional treatment:~Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic~Therapeutic Contact lens Description: Air Optix Night&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular"
89057804|NCT02217371|Active Comparator|Healthy volunteers|
89613088|NCT01006252|Experimental|Tasisulam-sodium|Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression.
89613089|NCT01006252|Active Comparator|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m^2) administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
89613090|NCT03081897|Experimental|SPRANC Block group|General anaesthesia and additional regional anaesthesia (cervical plexus block) on the tumor side.
89613091|NCT03081897|Active Comparator|SPRANC Control group|General anaesthesia
89613092|NCT03084705|Experimental|Manumeter with interactive feedback|Study participants will receive an experimental manumeter and interactive feedback from the manumeter to monitor and motivate their upper extremity functional activities.
89613093|NCT03084705|Experimental|Manumeter without interactive feedback|Study participants will receive an experimental manumeter but receive no feedback from the manumeter, and will be given the current standard-of-care for increasing upper extremity exercise booklet to perform at home.
89613094|NCT02245906|Placebo Comparator|Control drink|300 ml control drink containing equal amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
89613095|NCT02245906|Experimental|Brazilian fruit peel|300 ml test drink containing Brazilian fruit peel flour, acute study / one time administration
89613096|NCT02245906|Placebo Comparator|Negative control drink|300 ml control drink without containing amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
89613097|NCT03080649|Active Comparator|Rotary bur|Device rotary bur
89613098|NCT03080649|Experimental|Er:YAG laser|Device Er:YAG laser
89613099|NCT00959842|Experimental|Lovaza|Lovaza was given as the only agent; there was no comparator agent or arm
89613100|NCT03080805|Experimental|Pyrotinib Plus Capecitabine|
89613101|NCT03080805|Active Comparator|Lapatinib Plus Capecitabine|
89613102|NCT00959920|Active Comparator|Indwelling foley catheter|Insertion of an indwelling foley catheter when bladder emptying is necessary. The indwelling catheter will remain in place until the time of delivery.
89613103|NCT00959920|Active Comparator|Intermittent straight catheterization|Intermittent straight catheterization will be performed as needed during labor.
89613104|NCT03018964|Experimental|Solo-SILC|Solo surgery using a laparoscopic camera holder instead of a camera operator in SILC
89613105|NCT03018964|Active Comparator|Ca-SILC|No solo surgery, operation with a camera operator in SILC
88985525|NCT00401765|Experimental|Cohort 3 (Doctaxel and CNTO 328)|In cohort 3, 75 mg/m2 docetaxel will be administered in the run-in phase and 75 mg/m2 docetaxel plus 12 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
88985526|NCT00446407|Experimental|Collaborative Stepped Care|Screening, Antidepressants, Psychosocial interventions (psychoeducation, IPT, adherence management) by Health Counselor, support and supervision by Psychiatrist.
88985527|NCT00446407|Active Comparator|Enhanced Usual Care|
88985528|NCT00446485|Active Comparator|1|Ginkgo Biloba standardized extract 24/6
88985529|NCT00446485|Placebo Comparator|3|placebo
88985530|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg|Valsartan 80 mg or Amlodipine 5 mg ---> Valsartan + Amlodipine 80 / 5 mg
88985531|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg + Diuretic|Valsartan + Amlodipine 80 / 5 mg + Diuretic
88985532|NCT00446602|Experimental|001|Epoetin alfa Type=exact unit=units number=80 000 form=solution for injection route=subcutaneous use once every week or once every 2 weeks.
89613106|NCT03089775|Experimental|BBI-2000|Cohort A
89613107|NCT03089775|Placebo Comparator|Vehicle|Cohort A
89613108|NCT03089775|Other|Multiple treatments|Cohort B
89613109|NCT04401735|Experimental|Polydeoxyribonucleotide|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml
89613110|NCT04401735|Experimental|Polydeoxyribonucleotide, Placebo|Polydeoxyribonucleotide(PDRN) 5.625mg/3ml Placebo (Normal saline)
89613111|NCT04401735|Placebo Comparator|Placebo|Placebo (Normal saline)
89613112|NCT01007110|Active Comparator|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA)
89613113|NCT01007110|Placebo Comparator|Placebo|soy/corn oil placebo
89613114|NCT03019120|Experimental|Active Comparator: Intervention group|Vitamin D supplementation for subjects with below normal levels of this vitamin.
89613115|NCT03080337|No Intervention|Traditional Care|If the participant is randomized to the individual prenatal care model, she will continue to receive individualized care in the prenatal clinic. This includes being seen by both a MFM specialist and possibly an endocrinologist at each prenatal visit. During the prenatal visit, the individual caregivers are responsible for discussing educational topics that they feel are relevant to the patient. Patients are seen every two weeks for Traditional Care.
89613116|NCT03080337|Experimental|Group Care|If the participant is randomized into the group prenatal care model she will be placed in a group of approximately 6-10 women of approximately the same gestational age. These women will then have sessions scheduled at the same intervals they would have had their traditional prenatal visits, every two weeks until 36 weeks and then weekly until delivery, 12 sessions in total. Each session will last between 90-120 minutes. In the group prenatal care model, the entire visit time will be face to face with a provider and the group. Billing will be done through the standard reimbursement system since the program will follow the schedule of prenatal visits recommended by the American Congress of Obstetricians and Gynecologist.
89613117|NCT00960622|Experimental|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
89613118|NCT00960622|Active Comparator|Combivir or Trizivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months or Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
89613119|NCT03430947|Experimental|Treatment|all patients will be treated with Vemurafenib + Cobimetinib
89613120|NCT00960778|Experimental|Women- denicotinized cigarette|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
89613121|NCT00960778|Experimental|Men- denicotinized cigarette|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
89613122|NCT00960778|Experimental|Women -nicotine patch|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
89613123|NCT00960778|Experimental|Men- nicotine patch|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
89613124|NCT03392649|No Intervention|Sham Group|At the end of cardiac surgery, the Parasym alligator clip was placed on the subject's tragus, but the Parasym was not turned on and the subject did not receive any stimulation. The clip was switched to the other ear every 4 hours for a total of 48 hours.
89613125|NCT03392649|Experimental|Stimulation Group|At the end of cardiac surgery, the Parasym alligator clip was placed on the subject's tragus, and the subject received continuous stimulation for 48 hours. The clip was switched to the other ear every 4 hours.
89613126|NCT03019042|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with oral dose of 30 g/day (contain 10.1 herb materials) during entire follow up period (2 years). HGMX is composed of 10 dietary Chinese herbs (including ginseng (Renshen), tuckahoe (Fuling), coixenolide (Yiyiren), Chinese yam (Shanyao), lotus seed (Lianzi), amomum (Sharen), platycodon (Jiegen), white hyacinth bean (Baibiandou), licorice (Gancao), and orange peel (Jupi)), early rice, and oats.
88985533|NCT05589753|Experimental|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during non-rapid eye movement sleep (NREM) sleep.
88985534|NCT05589753|Experimental|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 6 days, While on the medication following studies will be performed - experimental night study, experimental day study, polysomnography night study (PSG).
88985535|NCT00114179|Experimental|Treatment (capecitabine, radiation, bevacizumab, gemcitabine)|"Chemoradiotherapy and bevacizumab: Patients receive oral capecitabine twice daily and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Patients undergo reevaluation 3-4 weeks after completion of chemoradiotherapy and bevacizumab.~Patients with no evidence of disease progression proceed to maintenance therapy. Patients with a marked response may undergo surgery at the discretion of the attending surgeon and then proceed to maintenance therapy approximately 4-8 weeks later.~Maintenance therapy: Beginning within 4-7 weeks after completion of chemoradiotherapy and bevacizumab, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30 minutes on days 1 and 15 provided that blood counts have returned to normal. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
88985536|NCT03277651||liver fibrosis|liver biopsy proved
88985537|NCT03277651||portal hypertension|hepatic venous pressure gradient (HVPG) proved
88985538|NCT00446680|Experimental|1|
88985539|NCT00446680|Placebo Comparator|2|
88985540|NCT00115557|Experimental|1|Performance feedback, academic detailing, practice facilitation, IT support
88985541|NCT00115557|Active Comparator|2|Performance feedback only
88985542|NCT00114257|Experimental|Arm I|"Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide) IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study.~Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
88985543|NCT00446758|Experimental|Zinc|zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children < 12 mo)
88985544|NCT00446758|Placebo Comparator|Placebo|
88985545|NCT03277534|Experimental|Electrical stimulation|
88985546|NCT03277534|Sham Comparator|Control|
88985547|NCT03277456|Experimental|Single intramuscular injection of MVA-NP+M1 vaccine|MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
89034977|NCT02383251|Experimental|Pazopanib/Paclitaxel association|"Arm 1 :~Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Then:~Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity"
89034978|NCT02383251|Active Comparator|Paclitaxel alone|"Arm 2 :~Paclitaxel 80mg/m2 i.v. on days 1, 8, 15~every 28 days until progression of disease or toxicity"
89034979|NCT02348216|Experimental|Axicabtagene Ciloleucel|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, axicabtagene ciloleucel.
89034980|NCT02347683||Benign pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks
89034981|NCT02347683||Malignant pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months
89613127|NCT03019042|Placebo Comparator|placebo|Patients in this arm receive placebo, with oral dose of 30 g/day during entire follow up period (2 years). The placebo is only consist of early rice and oats.
89613128|NCT03080571|Experimental|Stem cell group|autologous BMMNC stem cells with standard care
89613129|NCT03080571|Active Comparator|Control|Patients randomised in this group received standard care only
89613130|NCT00961402|Experimental|Wellness Control|Participants will receive health and wellness information and no exercise information.
89034982|NCT02337647|Other|DCDC app|Subjects will evaluate the DCDC app
89034983|NCT02307331|Other|Optivac and E1|Sirius stem used with Optivac mixed cement - Exceed Cup - E1 PE
89034984|NCT02307331|Other|Optivac and Arcom|Sirius stem used with Optivac mixed cement - Exceed Cup - Arcom PE
89034985|NCT02307331|Other|Optipac and E1|Sirius stem used with Optipac mixed cement - Exceed Cup - E1 PE
89034986|NCT02307331|Other|Optipac and Arcom|Sirius stem used with Optipac mixed cement - Exceed Cup - Arcom PE
89034987|NCT02292641|Other|Patients with pelvic recurrence from primary colorectal cancer|Implementation of imaging assessment proformas describing anatomic pelvic compartments and aetiology of disease recurrence for treatment planning.
89034988|NCT02272309|Experimental|Healthy volunteers|Healthy volunteers
89034989|NCT02272309|Experimental|Patients with LUTS|Patients with LUTS
89034990|NCT02272309|Experimental|Patients with LUTS and treatment|Patients with LUTS and treatment
89034991|NCT02204683|Other|Aflibercept|Subjects who have had a vitrectomy previously
89034992|NCT02204683|Other|Aflibercept in Non-Vitrectomized eyes|Patients who have not had vitrectomy.
89034993|NCT02157532|Active Comparator|Best standard treatment|intravenous r-tPA or any other medical management
89034994|NCT02157532|Active Comparator|Mechanical thrombectomy|Endovascular mechanical thrombectomy with stent-retrievers
89034995|NCT02065921||COPD patients|establishing COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.
89034996|NCT02037529|Experimental|Arm A (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89034997|NCT02037529|Experimental|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89034998|NCT02030028|Other|ACTHAR Gel|Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.
89034999|NCT01956123|Experimental|A|Follitropin Delta (FE 999049) (COS cycle 2)
89035000|NCT01956123|Active Comparator|B|Follitropin Alfa (GONAL-F) (COS cycle 2)
89035001|NCT01956123|Experimental|C|Follitropin Delta (FE 999049) (COS cycle 3)
89035002|NCT01956123|Active Comparator|D|Follitropin Alfa (GONAL-F) (COS cycle 3)
89613131|NCT00961402|Experimental|Exercise Intervention|Intervention will include motivational telephone-based intervention to increase exercise to 5 days per week for 30 minutes or more each session.
89613132|NCT03080181|Experimental|pasireotide|Pasireotide was administered in a 12 months period
89613133|NCT03018886|Other|healthy control subjects|126 healthy controls underwent the GHRH plus arginine stimulations test
89613134|NCT03018886|Experimental|patients with suspected GH deficiency|34 patients with pituitary disease and suspicion of GH deficiency underwent the GHRH plus arginine test
89613135|NCT03080025|Experimental|CBCT® for Couples|"The CBCT® (Cognitively Based Compassion-Training) for couples (CBCT®-fC) consists of a ten-week training program with a 2h group session weekly and daily home practice based on prerecorded guided mediations (Emory University, Atlanta, USA; Ozawa-de Silva & Negi, 2013). The ten weeks start with an overview and a take-home ideas for continuing practice. Furthermore the first and the 3rd module will be repeated once resulting in a total of ten weeks. Further couple- and dyadic exercises are added.~It focuses on six essential key parts for the development of compassion:~Developing attentional stability and clarity of the mind (Mindfulness)~Cultivating insight into the nature of mental experience~Cultivating self-compassion~Developing impartiality~Developing appreciation and affection for others~Developing empathy and realizing engaged compassion"
89613136|NCT03080025|No Intervention|Treatment as usual (TAU)|"Treatment as usual: Primary care according to guidelines from the S3- and national healthcare guideline Unipolar Depression [S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression, Ärztliches Zentrum für Qualität in der Medizin], but excluding current psychotherapy after probatory session."
89613137|NCT03084393||study group|215 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. The investigators do the Mini-Mental score examination (MMSE) and neuropsychological tests 1 day before (baseline) and 1 week after surgery without safety issue. Patients will be divided into POCD and non-POCD groups according to the two times tests.
89613138|NCT03084393||non-surgical group|The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline) and1 week without safety issue. The exclusive purpose of the non-surgical group is to aid in the POCD calculation according to the ISPOCD 1 study definition.
89613139|NCT01007656|Experimental|GD Antrodia camphorata|"GD Antrodia Camphorata is the extract from mycelium of the fungus Antrodia Camphorata which is an endemic species in Taiwan. According to the literatures, mycelium of Antrodia camphorata is beneficial to health. Moreover, the study product GD Antrodia Camphorata has been approved by Department of Health, Taiwan as a health supplement (approval number A00124)."
89613140|NCT03089385|Experimental|Implementation group|This group will have the hypertension tool implemented on them.
89613141|NCT03089385|No Intervention|Control group|This group will not have the tool implemented.
88985548|NCT04699396|Experimental|Mobilisation with Movement 1 (MWM1)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at fibula and talus. Three sets of 10 repetitions of each techniques, were administrated.
88985549|NCT04699396|Experimental|Mobilisation with Movement 2 (MWM2)|Participants received two ankle dorsiflexion MWM techniques, with glides applied at talus and fibula (order of application inverted). Three sets of 10 repetitions of each techniques, were administrated.
88985550|NCT04699396|Placebo Comparator|Placebo|The Placebo group participants performed the same number of sets and repetitions of lean/lunge forward into dorsiflexion, without any glide application, in the same position
88985551|NCT04699396|Experimental|Intervention|The experimental groups (MWM1 and MWM2), were later merged into a single Intervention group.
88985552|NCT03277417||Isolated Oligohydramnios|Fetuses with amniotic fluid index (AFI) equal or less than 5 cm
88985553|NCT03277417||Isolated Polyhydramnios|Fetuses with amniotic fluid index (AFI) more than 25 cm
88985554|NCT03277417||Control Group|Fetuses with normal amount of amniotic fluid
88985555|NCT05582460||PJI|Patients diagnosed with a PJI based on the EBJIS criteria ('Infection confirmed')
88985556|NCT05582460||No PJI|Patients not diagnosed with a PJI based on EBJIS criteria
88985557|NCT04699474|Experimental|Early in-bed leg cycling|
88985558|NCT00115596|Experimental|Intervention Arm|"'Formal Curriculum; Low-Fidelity Simulation'~Residents randomized to the intervention arm will receive the study skills training curriculum (the intervention)."
88985559|NCT00115596|No Intervention|Control|Residents randomized to the control arm will receive standard pediatric training.
88985560|NCT00446836|Other|Single arm|Open label use of Xyotax
88985561|NCT00446875|Experimental|Sucrose|Participants received oral sucrose (0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
88985562|NCT00446875|Placebo Comparator|Placebo|Participants received Placebo (sterile water, 0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
88985563|NCT00446953|Experimental|1|2x 12 mg betamethazone
88985564|NCT00446953|Placebo Comparator|2|no drugs
88985565|NCT00114413|Active Comparator|Reference Strategy|Participants in the reference strategy group will undergo the eNO procedure but will follow NAEPP guidelines alone for asthma treatment without eNO measurements for the rest of the study.
88985566|NCT00114413|Experimental|Biomarker Strategy|Participants in the biomarker strategy group will follow NAEPP treatment guidelines, as well as eNO measurements, to determine asthma treatment at each study visit.
88985567|NCT00447148|No Intervention|1|Paired comparison of 2 angiographic techniques
88985568|NCT00447187|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
88985569|NCT00447187|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
88985570|NCT00447187|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
88985571|NCT00447343||Treatment group|"Patients with cervical myelopathy undergoing decompressive cervical spine surgery will have two scans (pre-operatively and 6 months post-operatively).~A blinded investigator will administer questionnaires at each time point."
88985572|NCT00447343||Control group|"Healthy Volunteers will have two scans 6 months apart.~A blinded investigator will administer questionnaires at each time point."
88985573|NCT00114452|Active Comparator|Provacel: Cohort 1|ex vivo cultured adult mesenchymal stem cells
88985574|NCT00114452|Active Comparator|Provacel: Cohort 2|ex vivo cultured adult mesenchymal stem cells
88985575|NCT00114452|Active Comparator|Provacel: Cohort 3|ex vivo cultured adult mesenchymal stem cells
88985576|NCT00114452|Active Comparator|Provacel: Cohort 4|ex vivo cultured adult mesenchymal stem cells
88985577|NCT00114452|Placebo Comparator|Placebo|ex vivo cultured adult mesenchymal stem cells
88985578|NCT00447577|Experimental|Zylet|Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)
89035003|NCT01906814|Experimental|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
89613142|NCT03089229|Experimental|HAT01H cream|HAT01H medicated cream will come in a blinded tube. This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
88985579|NCT00447577|Active Comparator|Tobradex|Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.
88985580|NCT03276988|Other|Part B - Sequence A|Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection
88985581|NCT03276988|Other|Part B - Sequence B|Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection
88985582|NCT00447733|Experimental|Integrated treatment|Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
88985583|NCT00447733|Active Comparator|Treatment as usual|Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
88985584|NCT03276949||Healthy volunteers|Non-diabetic healthy men/women in between age group 18-80 years (all races and ethnicity) will be included for blood glucose measurements
88815470|NCT03015662|Active Comparator|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
88815471|NCT05592704|Experimental|Intervention group|Individuals participated in the 2-month outpatient aerobic exercise training program, which consisted of 40 training sessions on a cycle ergometer 5 times/week for 40 min. Then during motivational consultation, individuals received recommendations for healthy lifestyle and home-based training. After that, study subjects participated in the 6-month home-based aerobic exercise program using wearable device (heart rate monitor), which was connected to the smartphone via Bluetooth. A special smartphone application enabled participants to keep their training heart rate during home-based exercises (or workouts).
88815472|NCT05592704|No Intervention|Control group|Individuals participated in the 2-month outpatient aerobic exercise training program, which consisted of 40 training sessions on a cycle ergometer 5 times/week for 40 min. Then during motivational consultation, individuals received recommendations for healthy lifestyle and home-based training. After that, study subjects participated in the 6-month home-based aerobic exercise program without wearable devices and smartphone application.
88815473|NCT04400084||Pregnant mothers|Pregnant mothers who have a normal pregnancy
88815474|NCT02169440|Experimental|Group 1|Period 1: BIA 9-1067 + warfarin Period 2: warfarin
88815475|NCT02169440|Active Comparator|Group 2|Period 1: warfarin Period 2: BIA 9-1067 + warfarin
88815476|NCT03015350||two lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
88815477|NCT03015350||one lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
88815478|NCT03015350||two lung ventilation of Desflurane|In GroupSa, 6 % desflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
88815479|NCT03015350||one lung ventilation of desflurane|In GroupSa, 6 % desflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
88815480|NCT03015428|Experimental|Psychoeducation|"Interventions:~Give information Teach and train strategies"
88815481|NCT03015272|Experimental|Auditory-Motor Mapping Training (AMMT)|Auditory-Motor Mapping Training (AMMT) is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention.
88815482|NCT03015272|Active Comparator|Speech-Repetition Therapy (SRT)|Speech-Repetition-Therapy (SRT) is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT
88815483|NCT01054586||HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI|Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.
88815484|NCT01054742||Standard of Care PegIntron Plus Ribavirin [Part 2]|Participants who had relapsed during Part 1 of the study, had detectable HCV-RNA on Day 1 of Part 2 of the study, and who were re-treated during Part 2 of the study with standard of care PegIntron plus ribavirin for 48 weeks.
88815485|NCT01056302||Group 1|15 patients who underwent surgical repair of mandibular fractures at San Francisco VA Medical Center
88815486|NCT05591612|Experimental|MSG (Monosodium Glutamate)|Vegetables and foods prepared with MSG
88815487|NCT05591612|Other|NaCl (sodium chloride/table salt)|Active control/Standard practice Vegetables and foods prepared with table salt
88815488|NCT05591612|Experimental|KCl (potassium chloride/salt substitute)|Vegetables and foods prepared with KCl
88815489|NCT05591456|Experimental|group 1|The first group 50 patient (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week,
88815490|NCT05591456|Active Comparator|group 2|the second group 50 patient (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
88815491|NCT04171466|Active Comparator|Broad Spectrum Antibiotic Therapy + Microbial Consortia|
88815492|NCT04171466|Placebo Comparator|Broad Spectrum Antibiotic Therapy + Placebo|
88815493|NCT04171466|Active Comparator|No Antibiotic Therapy + Microbial Consortia|
88815494|NCT04171466|Placebo Comparator|No Antibiotic Therapy + Placebo|
88815495|NCT05587634|Experimental|Peer Health Coaching Intervention|Intervention Arm - these participants receive individualized peer health coaching (intervention group only) and an adaptive physical activity guide of local resources (both groups)
88815496|NCT05587634|No Intervention|Control|Control arm - these participants receive only an adaptive physical activity local guide including information on local adaptive sports opportunities however no individualized peer health coaching
88815497|NCT02246348|Experimental|Doppler ultrasound|
88815498|NCT02443740|Experimental|Single Ascending Dose-1 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
88815499|NCT02443740|Experimental|Single Ascending Dose-2 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
88815500|NCT02443740|Experimental|Single Dose Cerebrospinal Fluid (Part B)|Single maximum dose from Part A of BIIB118 administered to healthy volunteers to assess the PK of BIIB118 in CSF
88815501|NCT02170376|Experimental|Group 1|Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
88815502|NCT02170376|Experimental|Group 2|25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
89613143|NCT03089229|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
89613144|NCT03089307|Active Comparator|Group A|Patients will receive one session of low intensity extracorporeal shock wave treatment (LI-ESWT) per week for 6 weeks (6 sessions totally).
88985585|NCT04728074|Experimental|Intervention|"The ENtering Employment and SUstaining Work (ENESUW) program consists of 6 main topics which are; self-awareness, occupational self-awareness, taking responsibility, teamwork and labor division, problem identification and problem solving. The entire program adopts a very plain and easy to understand method of information transmission in order to facilitate lossless comprehension and strengthen the trust relationship between the therapists and the participants.~The ENESUW program took 8 weeks in total with twice weekly sessions, making up a total of 16 structured group sessions. The group format enabled the participants to learn through meaningful peer interactions and group activities which were supportive of the main learning goals (i.e. group work, labor division and taking responsibility) of the program. The twice weekly sessions were 45 minutes long in order to keep the participants attentive and active throughout the program."
88985586|NCT04728074|Active Comparator|control|The control group also consisted of individuals with ID. They received face to face, individual vocational based occupational therapy approaches, which were twice a week for 8 weeks (approximately 40-45 minutes)
88985587|NCT00447967|Experimental|1|IOX
88985588|NCT00447967|Experimental|2|FLOX
88985589|NCT00114608|Experimental|1|Electrical foot stimulation
88985590|NCT00401856|Experimental|1|This arm will receive eplerenone
88985591|NCT00401856|Placebo Comparator|2|This group will receive the placebo
88985592|NCT00448045|Experimental|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough peak flow. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough peak flow. Subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
88985593|NCT00448045|Active Comparator|Incentive spirometry|The active control group will consist of individuals assigned to the oximetry with incentive spirometry group. These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
88985594|NCT00448396|Experimental|Patupilone|
88985595|NCT05553678|Experimental|treatment group|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
88985596|NCT05553678|Placebo Comparator|Control group|Normal saline (0.03 ml/kg/30 min) will administered during UIA clipping through microscope.
88985597|NCT00448513|Experimental|catechin|catechin capsule group
88985598|NCT03276910|Experimental|Eprex 20 UI/kg|6 doses at 20 IU/kg in subcutaneous use
88985599|NCT03276910|Experimental|Eprex 50 UI/kg|6 doses at 50 IU/kg in subcutaneous use
88985600|NCT03276910|Placebo Comparator|Placebo|6 injections at 1ml in subcutaneous use of sodium chloride AGUETTANT 0.9%
88985601|NCT03276520|Experimental|ethyl glucuronide|subjects being screened with ethyl glucuronide
88985602|NCT03276520|Active Comparator|ethanol|subjects being screened with ethanol
88985603|NCT00401895|Active Comparator|1|patients treated with 10 mm stent
88985604|NCT00401895|Active Comparator|2|patients treated with 8 mm stent
89613145|NCT03089307|Active Comparator|Group B|Patients will receive two sessions of low intensity extracorporeal wave treatment (LI-ESWT) per week for 6 weeks (12 sessions totally).
88985605|NCT04699318|Experimental|Single Dartos TIP|Single dartos tubularized incised plate urethroplasty
88985606|NCT04699318|Experimental|Double Dartos TIP|Double dartos tubularized incised plate urethroplasty
88985607|NCT00114764|Experimental|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
88985608|NCT00114764|Active Comparator|filgrastim|Filgrastim given daily after induction chemotherapy
88985609|NCT04699513|Experimental|P-SIMV+PS group|The reason behind using P-SIMV+PS as a conventional mode was that it is a pressure controlled mode like APRV.
88985610|NCT04699513|Experimental|APRV group|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
88985611|NCT00448786|Other|Arm C|Arm C - AMG 706 75 mg BID 5-days on and 2-days off
88985612|NCT00448786|Other|Arm B|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
88985613|NCT00448786|Other|Arm A|Arm A = AMG 706 125 mg PO daily continuously
88985614|NCT05543967||Type 2 Diabetes Mellitus|These patients must have a definite diagnosis of type 2 diabetes mellitus (T2DM) according to the American Diabetes Association (ADA) standards. Some of these patients have symptoms of cognitive impairment, while others have normal cognition. All T2DM patients will undergo physical exam, cognitive and olfactory test as well as structural and brain functional MRI at baseline and follow-up time points.
89613146|NCT03088293|Experimental|infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
89613147|NCT03088293|Experimental|cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
88985615|NCT05543967||Healthy Control|These participants have normal glucose tolerance and normal cognition. All HC subjects will undergo physical exam, cognitive and olfactory test as well as structural and brain functional MRI at baseline and follow-up time points.
88985616|NCT04699084|Experimental|Music Group|Patients received music intervention and usual postoperative care.
88985617|NCT04699084|No Intervention|Control Group|Patients received only postoperative usual care.
89613148|NCT03089151|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden, including seeds and transplants, tools, new garden classes and access to master community gardeners in Denver.
89035004|NCT01906814|Active Comparator|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
89035005|NCT01894308|Active Comparator|Forearm dose|Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.
89035006|NCT01894308|Active Comparator|Chest Dose|Half of Ss will receive their dose of Testosterone on the chest.
89035007|NCT01764399|Experimental|Care4U intervention|Care4U intervention with 6 weekly sessions focusing on physical activity, healthy eating, self-management, emotional responses.
89035008|NCT01764399|No Intervention|Information group|The information group receives 6 weekly socialization sessions.
89035009|NCT01762176|Active Comparator|Usual care group|Usual care
89035010|NCT01762176|Active Comparator|Intensive care group|Protocolized intensive treatment
89035011|NCT01705158|Experimental|carboplatin and liposomal doxorubicin|carboplatin and liposomal doxorubicin in ovarian cancer in realapse
89035012|NCT01678157||Documented symptomatic paraesophageal hernia|"Documented symptomatic paraesophageal hernia.~Greater than 5 cm hiatal hernia on upper gastrointestinal study.~Evidence that the stomach or other viscera is present in the hernia and does not spontaneously reduce from the mediastinum.~Significant symptoms or signs of a paraesophageal hernia including but not limited to heartburn,dysphagia, chest pain, shortness of breath, postprandial abdominal pain, early satiety, odynophagia, or chronic anemia.~Consenting adult 19 years of age or older~Must be able to participate in follow-up evaluation.~Free of cognitive impairment"
89613149|NCT03089151|No Intervention|Wait List Control Group|The non-gardening group will remain on the DUG wait lists and will not receive the garden intervention.
89613150|NCT03084003|Experimental|Almond group|2 oz. of almonds everyday for 8 weeks
89613151|NCT03084003|Active Comparator|Control group|Isoenergetic control group 5 graham cracker sheets everyday for 8 weeks
89613152|NCT03703401||Women with recurrent miscarriage and no hydrosalpinx|
89613153|NCT03703401||Women with recurrent miscarriage and concurrent hydrosalpinx|
89613154|NCT03703401||Women with recurrent miscarriage and treated hydrosalpinx|
89035013|NCT01673100|Experimental|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. These messages will be tips to help them engage in physical activity and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
89035014|NCT01673100|No Intervention|Atttention Control|Subjects in the attention control group will receive only general health messages on their study cell phone (not physical activity promoting messages). They also will receive any usual post-PCI procedure care that all get.
89035015|NCT01648088||Pre-op THA and TKA patients|Patients who are scheduled for total joint arthroplasty
89035016|NCT01583322|Experimental|vargatef/Nintedanib|
89613155|NCT01008280|Experimental|Baclofen|baclofen 10 mg po tid
89613156|NCT01008280|Placebo Comparator|Placebo|placebo given tid
89613157|NCT03084159|Experimental|Participatory design and intervention|Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider. They will be asked to complete post intervention surveys (for feasibility and feedback prior to actual trial enrollment). Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
89613158|NCT03084159|Experimental|Intervention Only|This arm include new patients at the initial site that also received the intervention of using an education worksheet during their appointment and filled out post intervention surveys. Some of these providers/staff were not involved in the initial design of the intervention.
89613159|NCT03084159|No Intervention|Usual Care|A second site included usual care, which did not include the intervention. Participants were given post visit surveys similar to those in the two other study / intervention arms. This site served as a usual care comparison.
89035017|NCT01583322|Placebo Comparator|placebo|
89035018|NCT01581047||Amoxicillin/Clavulanic Acid|Patients in the intensive care unit, with an infection which will be treated with Amoxicillin/Clavulanic Acid.
89035019|NCT01581047||Cefuroxime|Patients in the intensive care unit, with an infection which will be treated with Cefuroxime.
89035020|NCT01571037|Other|inhaled nebulized Milrinone|"Drug: Inhaled, nebulized, Milrinone~1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation."
89035021|NCT01558427|Experimental|Active clinical surveillance|Active monitoring of patients with low volume metastases with Prostate Specific Antigen (PSA) and sequential imaging.
89035022|NCT01558427|Experimental|Salvage treatment of metastases|Surgical or radiotherapy treatment of metastases.
89035023|NCT01535248||All ERCP Patients|All patients that will be approached for this study will be undergoing ERCP as part of their medical care.
89035024|NCT01487538|Experimental|intervention group|The intervention will be delivered through action plans, videos, discussion boards and health behavior tracking (weight, calories in and out, pedometer steps) to facilitate health management, resourcefulness and health status.
89613160|NCT04279665|Experimental|Subjects undergoing electrophysiology procedure|Subjects will wear a virtual reality (VR) headset for a total of 40 minutes separated over 2 sessions during an electrophysiology procedure they are already scheduled to undergo.
89035025|NCT01487538|Active Comparator|Standard Advice Group|Standard advice group receives newsletters and health behavior tracking (weight) to initiate, increase, or sustain physical activity for weight maintenance.
89035026|NCT01469650|Active Comparator|400 IU/day vitamin D|Subjects will receive 400 IU/day of vitamin D3, as per current unit policy
89035027|NCT01469650|Experimental|800 IU/day vitamin D3|Subjects will receive 800 IU/day vitamin D3
89035028|NCT01452269|Experimental|Immediate intervention group|This arm will receive the intervention immediately following baseline data collection.
89035029|NCT01452269|Experimental|Delayed intervention group|This arm will receive the intervention one year following the immediate intervention group.
89035030|NCT01397877|Experimental|stratum 1|Patients with low grade disease (grade 1 or 2) with positive or negative mutational status
89035031|NCT01390194||subjects with an underlying liver disease|(1)underlying liver disease; (2) have a lesion on a prior imaging study; (3) must be prior standard MR
89613161|NCT00963430|Experimental|Group 2: 30 mcg H1N1 vaccine|60 subjects to receive 30 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
89613162|NCT00963430|Experimental|Group 1: 15 mcg H1N1 vaccine|60 subjects to receive 15 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
89613163|NCT03083925||Bare metal stent (BMS) TIPS|retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.
89613164|NCT03083925||Regular Viatorr (RV) TIPS|retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.
89613165|NCT03083925||Viatorr Control Expansion (VCX)TIPS|prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.
89613166|NCT03426423|Experimental|Intervention|12 weeks smoking cessation intervention tailored to diabetic and gender specificities, delivered by a study nurse.
89613167|NCT03426423|Active Comparator|Control|Usual care comprising a unique intervention of 5-10 minutes, non tailored smoking cessation intervention, delivered by a study nurse.
89613168|NCT01009762|Placebo Comparator|Saline|Sterile saline for injection is used as placebo arm. It is administered i.m. in the same way as for the active vaccine, week 0, 2, 4, 8.
89613169|NCT01009762|Active Comparator|AFO-18 vaccine|the intervention is injection of the experimental therapeutic peptide vaccine (AFO-18) consisting of 18 peptides in CAF01 adjuvant intra muscularly (i.m.) week 0, 2, 4, 8
89613170|NCT05688813|Experimental|Caudal block group|An echogenic block needle (22 Gauge 50 mm) was then advanced into the sacral canal through the sacrococcygeal membrane while a longitudinal position was used, continuing with the in-plane technique. After ensuring that there is no blood or cerebrospinal fluid with aspiration, 0.5 ml/kg 0.25% bupivacaine was administered while observing caudal epidural space dilation or turbulent flow with Doppler.
89613171|NCT05688813|Experimental|Sacral erector spinae block|Following antiseptic preparation of block site linear ultrasound probe was placed longitudinally to midline just above the sacrum. After the median sacral crests and erector spinae were identified, a 22G, 50 mm block needle was advanced from the cranial to the caudal direction until it touched the top of the 4th median sacral crest with the in-plane technique. After hydrodissection was achieved with 1 ml of saline, 0.5 ml/kg of 0.25% bupivacaine was administered after negative aspiration.
89613172|NCT01009918|Experimental|Arm I lisinopril|Patients receive oral lisinopril once daily.
89613173|NCT01009918|Experimental|Arm II Coreg CR®|Patients receive oral Coreg CR® once daily.
89613174|NCT01009918|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily.
89613175|NCT03088683|Active Comparator|Nathanson Retractor|Nathanson retractor will be used
89613176|NCT03088683|Active Comparator|Reveel Retractor|Reveel retractor will be used
89613177|NCT04401657|Experimental|FFR Measurement|Myocardia ischemia evaluation during adenosine stress testing
89613178|NCT03019198|Experimental|TXA|Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.
89613179|NCT03019198|Placebo Comparator|Control|This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.
89613180|NCT04401501|Experimental|Manual Therapy + Exercise Group|Combination of manual therapy and exercises for cervicogenic headache
89035032|NCT01366911||Stem cell & quanitative computed tomography QCT testing|"The association between bone mineral denity adjacent to acetabular implants, as measured by quanitative computed tomography (QCT), at least 2 years post Total Hip Arthoplasty (THA) surgery and mesechymal stem cell assays, obtained at time of surgery, will evaluate if stem cells can predict orthopaedic surgical outcomes.~Detailed Description:~Subjects who have undergone a THA and who previously consented to Stem Cell Quality Assays: Correlation with Aging/Health study which used excess bone marrow and blood samples to complete stem cell assay labs will be invited back at least 2 years post THA to complete bilateral hip x-rays, if not already completed as part of routine medical follow up plus a QCT bone density testing and to complete a questionnaire regarding smoking, alcohol and exercise history along with recording BMIs."
89613181|NCT04401501|Active Comparator|Exercise Group|Only exercises for cervicogenic headache
89035033|NCT01307644|Experimental|Web-based only (WO) weight intervention|A comprehensive lifestyle modification intervention for healthy eating and activity delivered by web only to facilitate Phase I weight loss (weekly messages baseline to 6 months), Phase 2 guided weight loss and weight maintenance (bi-weekly hot topics news, 6-18 months) and Phase 3 self-managed weight maintenance (6 monthly and 3 bi-monthly new content, 18-30 months).
89035034|NCT01307644|Experimental|WO & peer-led discussion board (WD)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with peer-lead discussion board. A peer leader will facilitate the asynchronous discussion group. The primary purpose of this group is to provide support, increase self-efficacy (role modeling by successful women and leader) and discuss progress toward goals.
89035035|NCT01307644|Experimental|WO & professional email counseling (WE)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with professional email-counseling by experienced counselor who will review women's web-logs of eating, activity, weight and goal-setting on web-site and send e-mail feedback.
89613182|NCT03018808||Subjects met inclusion with at least one exclusion criteria|Subjects who meet all the inclusion criteria, but have at least one exclusion criteria or not agree to participate in the whole study will be invited to sign a special ICF in order to complete a minimal questionnaire.
89035036|NCT01303679|Active Comparator|paclitaxel-bevacizumab|Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15
89035037|NCT01303679|Experimental|exemestane-bevacizumab|exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks
89035038|NCT01298713|Active Comparator|A|Tamoxifen 20mg/d
89035039|NCT01298713|Experimental|B|Tamoxifen 20mg/d + RAD001 10mg/d
89035040|NCT01191697|Experimental|Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine|"Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine for patients with HER2-positive metastatic esophagogastric cancer. Each cycle is 21 days.~Cycle 1, Day 1 Trastuzumab (loading dose) 4mg/kg IV~Cycle 2, Day 1 and all Subsequent Cycles Bevacizumab (7.5mg/kg) IV Trastuzumab (6mg/kg) IV Oxaliplatin (130mg/m2) IV Capecitabine (1200mg/m2) PO (taken Days 1-14 of each cycle)~Patients remained on treatment until disease progression, intercurrent illness that prevented further administration of treatment, unacceptable adverse events, participant decision to withdraw consent or general or specific changes in the participant's condition that rendered the participant unacceptable for further treatment."
89035041|NCT01189643|Experimental|Chemotherapy|This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.
89035042|NCT01187342||Non-striatal lesion group|acute ischemic Stroke in MCA territory of 10-100 cm³ with sparing of striatocapsular structures
89035043|NCT01187342||Striatal lesion group|acute ischemic stroke in MCA/AchA territory with involvement of at least 125 mm³ of striatocapsular structures
89035044|NCT01186042||Aging in HIV|20-40 years of age or older than 50
89035045|NCT01182506|Experimental|Breast cancer survivors|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
89035046|NCT01182506|Experimental|Collateral source|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
89035047|NCT01092884|Active Comparator|Polypodium leucotomos|Subjects randomized to this arm will receive oral supplementation with Polypodium leucotomos extract
89035048|NCT01092884|Placebo Comparator|Sugar pill|Subjects randomized to this arm will receive oral supplementation with placebo
89035049|NCT01044745|Experimental|Treatment (Rituximab and allogeneic HCT transplant)|"CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0."
89035050|NCT00990275|Experimental|Post-alcohol change in airway hyperresponsiveness.|Participants will ingest 3 ounces of vodka mixed with fruit juice within 30 min. Then provocative concentration causing a 20% fall in forced expiratory volume in 1 s (PC20FEV1) will be measured. A one-half concentration difference in the PC20FEV1 will be considered a statistically significant change in airway hyperresponsiveness.
89035051|NCT00876369||Urticaria/Angioedema|Subjects with chronic urticaria and/or angioedema
89035052|NCT00876369||allergy control|Subjects with physician diagnosed allergic rhinitis
89035053|NCT00580385|Experimental|1|
89035054|NCT00570791||Effect of age on intraocular pressure|Correlation between age and IOP with GAT compared to other tonometers.
89035055|NCT00570791||Effect of CCT and IOP|Correlation between CCT and IOP among all tonometers
89035056|NCT00566826|Experimental|1|Patient support treatment sessions
89035057|NCT00566826|Active Comparator|2|Treatment as usual
89035058|NCT00264511|Experimental|Hyperbaric oxygen treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
89035059|NCT00264511|No Intervention|No hyperbaric oxygenation|Patients randomised to this group will receive standard trauma care.
89035060|NCT05291078|Experimental|Experimental Group A|Tinnitus patients(n=12 people)
89035061|NCT05291078|Experimental|Experimental Group B|Tinnitus patients(n=12 people)
89035062|NCT05291078|Sham Comparator|Control Group|Tinnitus patients(n=12 people)
89035063|NCT02941406||Healthy subjects|"Men and Women aged 18 and older~Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant~Normal ophthalmological findings unless the investigator considers an abnormality to be clinically irrelevant"
89035064|NCT02941406||Age-related macular degeneration patients|"Men and Women aged 18 and older~Presence of a macular disease (such as dry or exudative age-related macular degeneration, diabetic maculopathy, epiretinal membrane)"
89035065|NCT02941328|Experimental|Pyridostigmine|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
89035066|NCT02941328|Placebo Comparator|Placebo|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
89035067|NCT02915796|Experimental|G-CSF + CD133(+) cells + PTA|Intramuscular injection of G-CSF along with transarterial infusion of CD133 (+) cells combined with percutaneous transluminal angioplasty
89035068|NCT02915796|Active Comparator|PTA + G-CSF|Percutaneous transluminal angioplasty along with intramuscular injection of G-CSF
89035069|NCT02915796|Placebo Comparator|Only PTA|Only Percutaneous transluminal angioplasty along with placebo infusion of sodium chloride injection
89035070|NCT02941289|Experimental|Alzheimer's patient|Probable diagnosis of Alzheimer's disease with a mild impairment (MMSE 20-26) according to DSM IV diagnosis criteria
89035071|NCT02941289|Active Comparator|Control patient|patient with MMSE score equal or > 27
89035072|NCT02919228|Experimental|Visible light exposure cognitive Red|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to red LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
89035073|NCT02919228|Experimental|Visible light exposure cognitive Orange|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to orange LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
89035074|NCT02919228|Experimental|Visible light exposure cognitive Yellow|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to yellow LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
89035075|NCT02919228|Experimental|Visible light exposure cognitive Green|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to green LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
89035076|NCT02919228|Experimental|Visible light exposure cognitive Cyan|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to cyan LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
89035077|NCT02919228|Experimental|Visible light exposure cognitive Blue|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to blue LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
89035078|NCT02919228|Experimental|Visible light exposure cognitive Violet|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to violet LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
89210808|NCT01075789|Active Comparator|Pre/post intervention evaluation group|This is a contemporaneous arm of children aged 6 years of age and older requiring nasogastric intubation for a clinical reason, who have previously had a nasogastric tube inserted. These children will be ask to rate by recall their previous NGT intubation on a VAS pain scale, and then will perform a post-procedure VAS pain assessment.
89210809|NCT00918437||RAUP treatment|Patients referred to the hospital for a snoring problem
89613183|NCT03018808||Subjects who satisfy all inclusion/exclusion criteria|Subjects who satisfy all inclusion/exclusion criteria and agree to sign the ICF, an interview will be conducted for information regarding medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
89613184|NCT03018808||Spirometry confirmed COPD Subjects|The spirometry confirmed COPD patients will be requested to complete the COPD Assessment Test (CAT), self-administered questionnaire related to quality of life on COPD patients.
89613185|NCT03083613|Experimental|Raltitrexed and Paclitaxel|"All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles~Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,~Eery 3 weeks"
89613186|NCT00963508|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
89613187|NCT00963508|Active Comparator|Nix Crème Rinse|Nix Crème Rinse applied to scalp for 10 minutes
89613188|NCT03088371|Other|Psoas Sciatic blockade|Psoas Sciatic blockade with 20 ml lidocaine 1% and 20 ml bupivacaine 0.25% pajunk needle used for the block and 5 ml Lidocaine 2% used for post-operative pain.
89210810|NCT04515849|Experimental|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
89613189|NCT03088371|Other|Combined spinal epidural|Spinal anaesthesia with 2.5 ml (12.5 mg) of heavy Bupivacaine 0.5%. Epidural for post-operative pain with Bupivacaine 0.125 %in a rate of 7-10 ml/hour Portex combined spinal epidural kit needle through needle.
89613190|NCT01010854|Experimental|VPA FEC100|Valproic Acid with FEC100
89035079|NCT02919228|Experimental|Visible light exposure cognitive White|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to white LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
89613191|NCT05685537||Levosimendan - Interventional|Major patients in heart failure with impaired LVEF (< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at the Nancy University Hospital or at the University Hospital of Rennes, Rouen or Amiens, and who have received Levosimendan preoperatively
89035080|NCT02919150||Myotonometric and isokinetic measurement|"Myotonometric assessment: into the site of the latent medial myofascial trigger point of the soleus muscle and distal to the lateral medial myofascial trigger point of the soleus muscle but into the same taut band.~Isokinetic assessment: triceps surae muscle tone will be quantified by measuring the passive range of motion for ankle dorsiflexion and the resistance to passive ankle dorsiflexion at slow and fast velocity."
89613192|NCT05685537||Non Levosimendan - Control|Major patients in heart failure with impaired LVEF (< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at the Nancy University Hospital or at the University Hospital of Rennes, Rouen or Amiens, and who have not received Levosimendan preoperatively
89035081|NCT02941211|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
89035082|NCT02915484|Experimental|tDCS stimulation A|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
89035083|NCT02915484|Experimental|tDCS stimulation B|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
89035084|NCT02940977||Prostate cancer patients|Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.
89035085|NCT02915328|Experimental|Stent Roadsaver® +Filterwire EZ™|The arm assess the efficacy of the combination of the stent Roadsaver® with the Filterwire EZ™ protection
89035086|NCT02915328|Experimental|Stent Roadsaver® + MO.MA Ultra|The arm assess the efficacy of the combination of the stent Roadsaver® with the MO.MA Ultra protection
89035087|NCT02915328|Experimental|Carotid Wallstent +MO.MA Ultra|The arm assess the efficacy of the combination of the Carotid Wallstent with the MO.MA Ultra protection
89035088|NCT02915328|Experimental|Carotid Wallstent + Filterwire EZ™|The arm assess the efficacy of the combination of the Carotid Wallstent with the Filterwire EZ™ protection
89035089|NCT05238545|Experimental|PD gluten-free diet group|Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day.
89035090|NCT05238545|No Intervention|PD gluten-containing diet group|Subjects with PD on regular, gluten-containing diet, i.e. no restrictions during eating.
89613193|NCT04279509|Experimental|Cancer patient|Histological or cytological diagnosis of head and neck squamous cell carcinoma (HNSCC), colorectal, breast or epithelial ovarian cancer.
89035091|NCT05238545|Experimental|MSA gluten-free diet group|Subjects with PD on gluten-free diet, ie. excluding all gluten-containing food during the day.
89210811|NCT04515849|Experimental|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
89613194|NCT04401189||Breast cancer patients|
89613195|NCT04401189||Healthy controls|
89613196|NCT05685459|Experimental|Intervention|The students involved in the intervention group were divided into subgroups, and the simulation was carried out using standardized patients. Each subgroup consisted of two students. Students were asked to practice supine and lateral recumbent positions in each scenario.
89035092|NCT05238545|No Intervention|MSA gluten-containing diet group|Subjects with MSA on regular gluten-containing diet, i.e. no restrictions during eating.
89035093|NCT02915133||MF-MB|Consecutive participants with high myopic foveoschisis are scheduled to macular buckling (MB) surgery.
89035094|NCT04691336|Experimental|PIMAGroup|All patients were summoned to the care center, being evaluated individually by a nurse, and based on the results, a care plan adapted to the specific needs and objectives was initiated. This care plan involved monitoring using different channels (face-to-face, telephone), with the main objective of monitoring the evolution of compliance, adherence and improving the quality of life of patients. The interventions that were carried out were educational and formative (using counseling communication skills), and technological (using monitoring tools in specific cases). The empowerment program was an educational session in which the nurse discussed content about dyspnea, the benefits of therapy, etc.
89035095|NCT02915250|Experimental|BioChaperone® Combo|Individualised single subcutaneous of BioChaperone® Combo + injection of placebo (0.9% NaCl) to ensure the double dummy
89035096|NCT02915250|Active Comparator|Humalog® Mix25|Individualised single subcutaneous of Humalog® Mix25 + injection of placebo (0.9% NaCl) to ensure the double dummy
89035097|NCT02915250|Active Comparator|Humalog® and Lantus®|Individualised simultaneous subcutaneous injections
89035098|NCT02277041|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
89035099|NCT02277041|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
89035100|NCT02915289|Active Comparator|Povidone Iodine|10% povidone iodine solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to the manufacture guidelines with a minimum of four completed minutes of drying time before placement of surgical drapes. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
89035101|NCT02915289|Active Comparator|Chlorhexidine gluconate|4% chlorhexidine gluconate solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to manufacture guidelines. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
89035102|NCT02939378|Experimental|ketogenic diet group|Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
89035103|NCT02939378|Other|Standard diet group|Standard diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were recorded during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
89035104|NCT02939339|Experimental|real treatment|continuous theta burst stimulation (real) will be delivered
89035105|NCT02939339|Sham Comparator|sham treatment|continuous theta burst stimulation (sham) will be delivered
89035106|NCT02918916|Experimental|Active phototherapy group|"Phototherapy will be applied between sprint and squat training (exactly 10 minutes before squat training).~Active phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin.~The optical power will be calibrated before irradiation in each participant using a Thorlabs thermal power meter (Model S322C, Thorlabs, Newton, New Jersey, USA)."
89035107|NCT02918916|Placebo Comparator|Placebo phototherapy group|"Placebo will be applied between sprint and squat training (exactly 10 minutes before squat training). Placebo phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin. To receive active or placebo phototherapy the participant will be placed in the supine position.~The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled."
89035108|NCT02918916|No Intervention|Control group|Passive recovery will be applied between sprint and squat training (exactly 10 minutes before squat training). During the period when the other groups are receiving recovery strategies, the control group participants will remain seated for passive recovery, supervised by an independent therapist.
89035109|NCT02939417|Experimental|using grape seed extract|Grape seed extract as collagen cross-linking agent
89035110|NCT02939417|Active Comparator|without uing grape seed extract|
89035111|NCT02919033|Placebo Comparator|Usual care (UC)|Patients are managed by their PCPs at the registered CHCs as usual.
89035112|NCT02919033|Experimental|Self-management|"BP tele-monitor & App based self-management supports~Patient proficiency training"
89035113|NCT02919033|Experimental|PCTM intervention|"BP tele-monitor & App-based self-management supports~Patient proficiency training~PCP & cardiologist training of using Web-based analytics~Proactive and interactive care by PCPs and cardiologists"
89035114|NCT02939456|Other|DIR-MRI|Participants will have Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) as well as the standard Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
89035115|NCT02918799|Other|Community cohort|Beirut community will receive the multi-component intervention Mpowerment; the community cohort of YMSM will be used to evaluate the effects of the intervention on the community, as the cohort participants may or may not have participated in the intervention.
89035116|NCT02939261|Active Comparator|Control|Families randomized to control will receive monthly emails containing publicly available handouts on general child health.
89035117|NCT02939261|Experimental|Intervention - 4 Home Visits|Families randomized to the intervention will receive: a) 4 home visits from a health educator, b) weekly e-mails, and c) monthly mailed behavioural supports.
89035118|NCT02918682|Experimental|Exercise Group|The multimodal intervention protocol is described separated by day (1 to 24) and by weeks (1 to 12). Each session was built to last between 50 and 60 minutes.
89035119|NCT02918682|No Intervention|Control Group|Participants from the control group will not perform any kind of physical exercise.
89035120|NCT05018351|Active Comparator|Treatment as Usual-Integrated Care (TAU-IC)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-half of research participants will be randomized to integrated care alone.
89613197|NCT05685459|No Intervention|Control|The students in the control group were divided into subgroups and practised the supine position and the lateral recumbent position with a high-fidelity manikin. Each subgroup consisted of two students. The applications lasted 5-10 minutes for each group, and after the applications, the debriefing phase was conducted, which lasted 20 minutes.
88815503|NCT02170376|Experimental|Group 3|50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
88815504|NCT02170376|Experimental|Group 4|75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
89035121|NCT05018351|Experimental|Peer Navigator Program (PNP)|"Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~scheduling and attending healthcare appointments;~partnering with participant on tasks that arise from appointments;~health-related goal setting; and~taking action-steps toward health-related goals."
89035122|NCT02918643|Active Comparator|Application|7 physicians will receive an application to tablet device with information about potentially inappropriate medications for elderly and access for consultation of the portal of evidence-based health
89035123|NCT02918643|Sham Comparator|Control|7 physicians will receive a tablet with internet access for consultation of the portal of evidence-based health
89035124|NCT05012891||Study Population|Fifty (n=50) consecutive patients with lower-extremity disability or chronic pain (unilateral or bilateral), undergoing a rehabilitation course in a Day-Care Center setting.
89210812|NCT04515849|Experimental|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
89035125|NCT02939027|Experimental|Group 1|For the first 20 patients, a total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days week, 3 weeks or lees at least 2 days apart each fraction.
89035126|NCT02939027|Experimental|Group 2|For the next 20 patients a total dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days week 3 weeks or lees at least 2 days apart each fraction.
89035127|NCT02915172|Experimental|Lenvatinib + Capecitabine|"Phase 1 Study Escalation: Group consists of participants with various solid tumors.~Dose of Lenvatinib received depends on when joining study. First group of participants receive lowest dose level of Lenvatinib. Each new group receives a higher dose of Lenvatinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Lenvatinib found.~All participants receive the same dose of Capecitabine.~Phase 2 Study Expansion: Group consists of participants with advanced breast cancer and any solid tumors with confirmed FGFR abnormalities.~Participants receive Lenvatinib at the highest dose that was tolerated in Dose Escalation Phase.~All participants receive the same dose of Capecitabine."
89035128|NCT02938988|Experimental|Test group|Scaling and root planning and antimicrobial photodynamic therapy with red laser (658nm; 0.1W; 2229J/cm², 10s per point) and methylene blue dye (100μg/ml). Repetition after 3, 7 and 14 days.
89035129|NCT02938988|Active Comparator|Control Group|Scaling and root planning Repetition after 3, 7 and 14 days.
89035130|NCT02918994|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
89035131|NCT02939144|Experimental|Liquorice|Participants of the single-arm study will ingest liquorice candy and their blood, saliva and urine samples will be collected. They will be regularly monitored for any potential side effects.
89035132|NCT02915055||Patients with pain following knee arthroscopic meniscectomy|
89035133|NCT02939222|Other|Routine implant placement|No comparison needed
89035134|NCT02938910||Healthy Volunteers|Healthy volunteers with normal blood pressure
89035135|NCT02938910||Primary Hyperaldosteronism|Subjects with hypertension and high levels of seric aldosterone.
89035136|NCT02938910||Secondary Hyperaldosteronism|Patient with Gitelman syndrome, with normal blood pressure and high level of aldosterone
89035137|NCT02938910||Essential Hypertension|Patient with hypertension without secondary cause of hypertension
89613198|NCT04400721|No Intervention|PCIA arm|Standard post-operative treatment with patient-controlled intravenous analgesia (Piritramide bolus = 2mg, bolus interval = 7 minutes, max 4 hour dose = 30mg)
89035138|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.
89035139|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.
89035140|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)|During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.
89035141|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.
89035142|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.
89035143|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.
89035144|NCT01295827|Experimental|MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
89210813|NCT04515849|Placebo Comparator|Placebo|Placebo administered subcutaneously
89210814|NCT04515849|Active Comparator|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
89210815|NCT03972241|Experimental|Intervention|different interventions including foot insole or kinetic training
89210816|NCT03972241|No Intervention|control|No intervention
89210817|NCT00825968||Data collection group|Patients having procedures done at the electrophysiology Laboratories at the Ross Heart Hospital at The Ohio State University Medical Center.
89210818|NCT04085159|Experimental|CART/CTL/DCvac cells to treat cancer|
89613199|NCT04400721|Active Comparator|ESP block arm|ultrasound guided Erector spinae block (Single shot of 30ml of 0.5% solution of Naropin [Ropivacaine])
89613200|NCT04400721|Active Comparator|IC block arm|3 ml of 0.5% solution of Naropin [Ropivacaine] per intercostal space, up to a maximum of 30ml
89613201|NCT01010932|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
89613202|NCT03018652|Experimental|Intervention group|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
89613203|NCT03018652|Placebo Comparator|Control group|Normal saline (0.9% NaCl) 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
88815505|NCT02170376|Placebo Comparator|Group 5|placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
89613204|NCT04353700|Active Comparator|Yoga group|A certified yoga instructor led the supervised yoga session. An exercise physiologist taught how to record your Rating of Perceived Exertion to monitor their exercise intensity during the in-home yoga intervention. During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks.
89613205|NCT04353700|No Intervention|Control group|If participants were in a CON group, they did not receive the yoga intervention. Instead, they were encouraged to maintain a normal daily lifestyle monitored by the BPAQ at one-month intervals during the 12-week intervention.
89613206|NCT04353466|Experimental|Trial to asses impact of Elelyso on bone involvement in patien|The infusions will be administered at the selected medical center or in the home care setup. The dose of intravenous (IV) infusions of Elelyso will be the same dose of the other ERTs . Bone parameters QCSI and BMD will be assessed at baseline, 12 months and 24 months.
89613207|NCT03018496|Experimental|Older Men|Healthy male adults aged 18-35 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
88985618|NCT03276442|Experimental|Healthy diet|'Low-fat dietary intervention' to be administered to participants
88985619|NCT03276442|Experimental|Unhealthy diet|'High-fat dietary intervention' to be administered to participants
88985620|NCT03276364||Shock|
88985621|NCT00448825|Experimental|Topiramate|Topiramate + Cognitive Behavioral Therapy
88985622|NCT00448825|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
88985623|NCT00448903|Experimental|A|Bemiparin
88985624|NCT00448903|Placebo Comparator|2|Placebo
88985625|NCT00402012|No Intervention|1|
88985626|NCT00402012|Experimental|2|
88985627|NCT03276325|Placebo Comparator|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
88985628|NCT03276325|Active Comparator|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
88985629|NCT00449098|Experimental|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
88985630|NCT00449098|Active Comparator|MMC|Trabeculectomy with MMC
88985631|NCT00449137|Experimental|Single Arm|
88985632|NCT00115791|Experimental|1|
88985633|NCT00115791|Placebo Comparator|2|
88985634|NCT00449293|Active Comparator|1|
88985635|NCT00449293|Active Comparator|2|
89613208|NCT03018496|Experimental|Younger Men|Healthy male adults aged 65-85 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
89613209|NCT03018574||ADHD-patients|The whole blood sample from diagnoses of the children 6-14 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital and Children's Hospital Affiliated to Soochow University according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
88985636|NCT00449488|No Intervention|Control|
88985637|NCT00449488|Active Comparator|Epoetin alfa|i.v bolus 60.000 IU epoetin alfa
88985638|NCT03276247||Asian American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and non-pregnant/non-breastfeeding.
88985639|NCT03276247||African American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and non-pregnant/non-breastfeeding.
88985640|NCT03276247||Hispanic American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and non-pregnant/non-breastfeeding.
88985641|NCT03276247||White non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as white and non-pregnant/non-breastfeeding.
88985642|NCT03276247||Asian American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and pregnant or breastfeeding.
89613210|NCT03018574||Controls-healthy children|The whole blood sample from age- and gender- matched healthy 6-14 years old children
89613211|NCT00966238|Experimental|VAX125|HA1 influenza vaccine
89613212|NCT01012336|Experimental|Aprepitant|
89613213|NCT00966550|Active Comparator|Tomato|Tomato with high carb/fat meal
89613214|NCT00966550|Placebo Comparator|Non-Tomato|Non-tomato with high carb/fat meal
89613215|NCT03387501|Experimental|PRGF|Plasma rich in growth factors (PRGF) administration
88985643|NCT03276247||African American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and pregnant or breastfeeding.
88985644|NCT03276247||Hispanic American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and pregnant or breastfeeding.
88985645|NCT03276247||White pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as White and pregnant or breastfeeding.
88985646|NCT03276208|Experimental|Massage Therapy and Mindfulness|Participants in the intervention group will receive two prenatal massages a week for a three-week period. They will also be enrolled in the mindfulness-based Craving to Quit® tobacco cessation program during this 3-week period.
88985647|NCT03276208|Active Comparator|Mindfulness|Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
88985648|NCT03276169|Experimental|Left atrial appendage closure group|
88985649|NCT03276169|Other|Radiofrequency ablation group|
88985650|NCT03276169|Experimental|LAAC combined with radiofrequency ablation group|
88985651|NCT00449683|Experimental|terazosin|open-label treatment group
88985652|NCT00449839|Other|A, CSII without bolus|Period A: A constant subcutaneous infusion rate of insulin aspart (0.5 U/hr) is given for 8 hours. Following 3 hours of blood sampling.
88985653|NCT00449839|Other|B; CSII with bolus|Period B: A constant subcutaneous infusion of insulin aspart (0.5 U/hr) is given for 8 hours and upon start a s.c.bolus (1.4 U)of insulin aspart is given. Hereafter follows 3 hours of blood sampling.
89613216|NCT01012492|Experimental|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
89035145|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
89035146|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q2W (Part B)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
89035147|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
89035148|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
89035149|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
89035150|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 2 mg/kg Q3W. No participants were enrolled in this arm.
89035151|NCT01295827|Experimental|NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 5 mg/kg Q3W. No participants were enrolled in this arm.
89035152|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 10 mg/kg Q3W. No participants were enrolled in this arm.
89035153|NCT02918838|Experimental|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
89035154|NCT02918838|Experimental|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
89035155|NCT02918838|Active Comparator|Control Group|Participants do not receive a lottery incentive conditional on adherence. Participants will however, continue to receive weekly messaging with airtime top-up contingent on response.
89035156|NCT02918760|Experimental|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
89613217|NCT03016624|Active Comparator|OCT guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
89613218|NCT03016624|Active Comparator|Angiography guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
89613219|NCT03083457|Experimental|PEEP2 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O and scheduled recruiting maneuvers at the beginning of each PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
89613220|NCT03083457|Experimental|PEEP7 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
89613221|NCT03083457|Experimental|PEEP12 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
89613222|NCT03083457|Experimental|PEEP2 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
89035157|NCT02918760|Placebo Comparator|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
89035158|NCT02914743|Experimental|Dental Cleaning and MI Arm|Subjects in this arm will receive a dental cleaning by the hygienist as well as a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
89035159|NCT02914743|Experimental|MI only Arm|Subjects in this arm will not receive a dental cleaning but the hygienist will provide a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
89613223|NCT03083457|Experimental|PEEP7 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
89613224|NCT03083457|Experimental|PEEP12 - RM.|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
89613225|NCT04348227||Before pandemic is declared|Positive endotracheal aspirates addressed from January 1st 2019 to January 1st 2020
89613226|NCT04348227||After pandemic is declared|Positive endotracheal aspirates addressed from February1st 2020 to February 1st 2021
89613227|NCT00967486|Active Comparator|Routine Shunt|These patients are called routine as the routine method of carotid endarterectomy is used.
89613228|NCT00967486|Active Comparator|Selective Shunt|These patients are selectively used for shunting or not shunting based on systolic pressure < 40mmHg. This group is further used as subgroup analysis.
89613229|NCT04348461|No Intervention|Control|Patients receiving regular respiratory distress treatment
89613230|NCT04348461|Experimental|Treatment|Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
89613231|NCT04348617|Experimental|Exercise-Rest|This group will perform the exercise condition at least 1 week after the preliminary visit and will perform the resting condition a minimum of 15 days and a maximum of 2 months after the exercise condition.
89613232|NCT04348617|Experimental|Rest-Exercise|This group will perform the resting condition at least 1 week after the preliminary visit and will perform the exercise condition a minimum of 15 days and a maximum of 2 months after the resting condition.
89613233|NCT01013194|Experimental|Treated patients|Cirrhotic patients treated with Human Fetal Liver Cell Transplantation.
89613234|NCT01013194|No Intervention|Control patients|Cirrhotic patients on Standard therapy.
89613235|NCT04761237|Experimental|Group 1|(H-P) : Pcv-aCO2≥6mmHg between T base and T 0h.;
89613236|NCT04761237|Experimental|Group 2|(L-P) : Pcv-aco2< 6mmHg at T base and≥6mmHg at T 0h
89613237|NCT05684835||Vagus nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the vagus nerve
88985654|NCT00449839|Other|C; CSII with bolus, optional|A constant subcutaneous insulin aspart infusion is given for 8 hours and upon start a bolus of insulin aspart is given. The bolus in arm C is of a different size then arm B. After the 8 hours of constant infusion follows 3 hours of blood sampling. Period C are optional and it is evaluated if it will be conducted after period A and B has been performed.
88985655|NCT00450034|Experimental|1|
88985656|NCT00450229|Experimental|Arm I|Patients receive low-dose, nutritional-grade oral diindolylmethane (DIM) twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
88985657|NCT00450229|Experimental|Arm II|Patients receive high-dose, nutritional-grade oral DIM twice daily as in arm I.
88985658|NCT00450229|Placebo Comparator|Arm III|Patients receive oral placebo twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
88985659|NCT04699279|Experimental|Statin|
88985660|NCT04699279|No Intervention|Blank|
88985661|NCT04698889|Active Comparator|Cow milk|Administration of natural cow whole milk
88985662|NCT04698889|Active Comparator|Human milk|Administration of natural human milk
88985663|NCT04698889|Active Comparator|Modified cow milk - low protein|Administration of modified cow milk at low protein content
88985664|NCT04698889|Active Comparator|Modified cow milk - high protein|Administration of modified cow milk at high protein content
88985665|NCT00450307|Experimental|3F8 and GM-CSF|One cycle has 5 days of 3F8 treatment. Each day, patients receive GM-CSF subcutaneously ~1.5 hr before the start 3F8 infusion. To limit side-effects, patients receive analgesics, antihistamines, and a small dose (IV, over ~5 minutes) of heat-modified 3F8. Cycles can be repeated after a 2-4 week interval, up to a total of two cycles.
88985666|NCT00450541||Fatigue Questionnaire + Interview|
89210819|NCT00928980|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy and withdrawal of antidepressant medication between the 4th and 5th session, patients being off medication until the end of study period (15 months).
89210820|NCT00928980|Experimental|Combination|Mindfulness Based Cognitive Therapy combined with the use of antidepressant medication during the study (15 months).
89613238|NCT05684835||Sympathetic nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the sympathetic nerve
89613239|NCT05684835||Cervical spinal nerve tumor group|patients with neck peripheral nerve sheath tumors originating from the cervical spinal nerve
89613240|NCT04401345|Experimental|Experimental Group (GP)|Patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated at 25mcg/min.
89613241|NCT04401345|Placebo Comparator|Placebo Group(NS)|patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated at 25 mcg/min
89613242|NCT00968344|Experimental|Leucine|3-4 g Leucine added to daily meals during bed rest
88815506|NCT05551988||diabetic foot ulcer patients|Diabetic foot ulcer patients with and without diabetic foot amputation
88815507|NCT02170532|Active Comparator|levalbuterol + saline in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
88815508|NCT02170532|Active Comparator|levalbuterol + ipratroprium in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
89613243|NCT00968344|Placebo Comparator|Placebo|3-4 g Alanine added to daily meals during bed rest
88815509|NCT02170532|Active Comparator|levalbuterol MDI 2 puffs|levalbuterol metered dose inhaler 2 puffs
88815510|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max without pause 2 puffs|levalbuterol MDI + aerochamber max without pause 2 puffs
88985667|NCT03276091|Experimental|COLOFIT+ Study|Personnalized motivational phone call, done by a medical physician
88985668|NCT00115193|Active Comparator|Arm A|Pegfilgrastim
88985669|NCT00115193|Active Comparator|Arm B|Pegfilgrastim
88985670|NCT03276013|Experimental|A|Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W
88985671|NCT03275935||Training Arm|Patients that were given training in regards to proper inhalation technique of Rotahalers
88985672|NCT00450697||observation|
88985673|NCT00450736|Experimental|Single Arm|
88985674|NCT05536362|Experimental|TCI propofol mixed with clonidine and ketamine|Patient group,in which they got intravenous anaesthesia with TCI propofol mixed with clonidine and ketamine
88985675|NCT05536362|Experimental|TCI propofol mixed with a placebo|Control group,in which they received intravenous anaesthesia with TCI propofol mixed with a placebo (NaCl 0.9%)
89613244|NCT03083301||Cardiac insufficiency|Patients with cardiac insufficiency (i.e in NYHA class III or IV) or refractory to optimal medical treatment (155 patients since 2003) in the Brugmann University Hospital, in the cardiac surgery department
89035160|NCT02914743|No Intervention|Control Arm|Subjects in this arm of the study will not receive any oral health intervention while hospitalized. A medical record review will be completed, and patients will be contacted via telephone at 3, 6, and 12 months post-hospitalization to assess their oral health-related quality of life and oral health care-seeking behaviors.
89035161|NCT04983368|Experimental|Xanamem® 5 mg|Oral Xanamem® capsules 5 mg, to be administered once daily
89035162|NCT04983368|Experimental|Xanamem® 10 mg|Oral Xanamem® capsules 10 mg, to be administered once daily
89035163|NCT04983368|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
89035164|NCT02918604|Other|B : veinsite access|infrared technology vein access
89035165|NCT02918604|Active Comparator|A: control group|conventional vein access
89613245|NCT05684679|Experimental|IS Group|"• Patients were instructed to utilize an incentive spirometer in the sitting or half lying position as taught preoperatively.~3 to 5 consecutive breath with the spirometer were interspersed between period of quite breathing.~Duration 10-15 minutes/session."
89035166|NCT01295671|Active Comparator|Sugar-Sweetened Beverages|Provision of beverages: Sugar-sweetened beverages
89035167|NCT01295671|Experimental|Artificially-sweetened Beverages|Provision of beverages: Artificially-sweetened beverages
89035168|NCT01295671|Experimental|Unsweetened Beverages|Provision of beverages: Unsweetened beverages
89035169|NCT02918526|Experimental|Laryngeal Mask|laryngeal mask (LMA)
89035170|NCT02918526|Active Comparator|Oro Tracheal Intubation|oro tracheal intubation
89035171|NCT02938871|Active Comparator|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
89613246|NCT05684679|Experimental|DBE Group|"• Patients were advised to do diaphragmatic breathing exercise in the sitting or half lying position as taught preoperatively.~3 to 5 consecutive deep breath were interspersed between period of quite breathing.~Duration 10-15 minutes/session."
89035172|NCT02938871|Placebo Comparator|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
89035173|NCT01295320|Experimental|GSK1437173A Group|Subjects who received 2 doses of HZ vaccine in the intermediate dose study group in study 108494 (NCT00434577). No treatment was given in this current study (NCT01295320).
89613247|NCT04761003|Active Comparator|Group I (Cryobiopsy group):|patients where patients will be subjected to thoracoscopic cryobiopsy.
89613248|NCT04761003|Active Comparator|Group II (Forceps group)|patients where patients will be subjected to thoracoscopic forceps biopsy.
89613249|NCT01015534|Experimental|Whole brain irradiation plus Temozolomide|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
89613250|NCT01015534|Active Comparator|Whole brain irradiation|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks
89035174|NCT02918448|Experimental|Taining group|training group that performed the resistance program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. Participants of the TG performed 3 sets of 10-15 repetition maximums. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise
89613251|NCT05688033|Experimental|experimental arm|peritoneal space V15<850cc，pelvic bone V10<80% and normal dosimetric limitation
89613252|NCT05688033|No Intervention|control arm|normal dosimetric limitation
89613253|NCT03083145|Active Comparator|Educational Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
89613254|NCT03083145|Active Comparator|No Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
89613255|NCT05683353||Patients with SARS-CoV-2 positive hematologic tumors|Patients with SARS-CoV-2 positive hematologic tumors over 18 years old excluding patients with severe diseases associated with other systems.
89613256|NCT05683353||People with SARS-CoV-2 positive without underlying diseases|People with SARS-CoV-2 positive without underlying diseases over 18 years old excluding people with severe diseases associated with other systems.
88815511|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
89035175|NCT02918448|No Intervention|control group|control group that did not perform any type of physical exercise
89035176|NCT04690517|Other|Tracheal ultrasound|The patients in cardiopulmonary arrest should be performed tracheal ultrasound when tube is passed through the trachea or esophagus.
89035177|NCT01295281|Experimental|LoFric POBE 2.0 - PVC|First period (7 days) use of LoFric POBE 2.0 followed by second period (7 days) use of LoFric PVC
89035178|NCT01295281|Experimental|LoFric PVC - POBE 2.0|First period (7 days) use of LoFric PVC followed by second period (7 days) use of LoFric POBE 2.0.
89035179|NCT02914821|No Intervention|"Business as Usual (No Tax)"|Baseline data where business 'as usual' will be conducted and no price increases will be implemented on SSBs.
89035180|NCT02914821|Experimental|"General Tax (without named beneficiary)"|In the general tax condition investigators will introduce a 3 cent/ounce tax on the five SSB flavors the café offers. An example of this sign would be 'Pepsi, $2.29, includes 60 cent sugary drink surcharge.'
89035181|NCT02914821|Experimental|"Pre-K Tax"|"In the Pre-K tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Pre-K education."
89613257|NCT00968890|Experimental|Pandemrix+Fluarix and Pandemrix+Placebo|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with Fluarix™ on Day 0 and with a placebo on Day 21 intramuscularly in the deltoid region of the dominant arm.
89613258|NCT00968890|Experimental|Pandemrix+Placebo and Pandemrix+Fluarix|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with a placebo on Day 0 and with Fluarix™ on Day 21 intramuscularly in the deltoid region of the dominant arm.
89613259|NCT03082833|Experimental|AZD2014 50mg BD|AZD2014 50mg BD continuous schedule of a 28 day cycle
89613260|NCT03082989||fractional flow reserve performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization
89613261|NCT03082989||fractional flow reserve not performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization
89613262|NCT03017950|Experimental|Part1 (A)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330~IPs for Period 2: CKD-330 + D086"
89613263|NCT03017950|Experimental|Part1 (B)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: CKD-330"
89613264|NCT03017950|Experimental|Part2 (A)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: D086~IPs for Period 2: CKD-330 + D086"
89613265|NCT03017950|Experimental|Part2 (B)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: D086"
89613266|NCT00971620|Experimental|BTX-A|BTX-A intralesional injection
89613267|NCT00971620|Experimental|Placebo/Saline|Saline intralesional injection
89613268|NCT05687565|Placebo Comparator|Control group|Dietary supplementation
89613269|NCT05687565|Experimental|Experimental group 1|1.5 grams once daily during 48 weeks
89613270|NCT05687565|Experimental|Experimental group 2|3 grams once daily during 48 weeks
89613271|NCT01884922|Experimental|Dose escalation|"Nilotinib (Tasigna®): 115 to 350 mg/m2 twice daily (BID) orally given continuously (115 mg/m2 once daily if de-escalation requested~Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle."
89613272|NCT03083223||lung disease|Patients with lung disease
89613273|NCT01610908|Experimental|Schroth exercises|The experimental group receives the Schroth exercises treatment.Patients in this arm receive 5 individual sessions with a Schroth therapist for introduction to the approach. They they receive a home program consisting of 3-4 exercises to do at home everyday for 30-45 minutes. They come to weekly group therapy sessions to where exercise prescription is adjusted.
88985676|NCT00115232||1|Children without family history of early atherosclerosis
88985677|NCT00115232||2|Children with family history of early atherosclerosis.
88985678|NCT00115232||3|Parents of children without family history of early atherosclerosis
88985679|NCT00115232||4|Parents of children with family history of early atherosclerosis
88985680|NCT00450775|Other|1|
88985681|NCT04698577|Experimental|Attention Training|"Engaged in sustained updating by mentally keeping score during an interactive game without written or verbal aids.~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
88985682|NCT04698577|Active Comparator|Active Control|"Played the same interactive game as the attention training group without the requirement of mentally keeping score.~Participants received 15-minute sessions, three times a week for six weeks (18 sessions in total)."
88985683|NCT00450853|Experimental|Granisetron SC-Granisetron IV|Granisetron SC followed by Granisetron IV
88985684|NCT00450892|Other|arm 1|
88985685|NCT00450892|Other|arm 2|
88985686|NCT00450892|Experimental|arm 3|
88985687|NCT05536089||ctDNA positive|Postoperative ctDNA positive
88985688|NCT05536089||ctDNA negative|Postoperative ctDNA negative
88985689|NCT04698655|Active Comparator|Control group|"Asked to read a single-A4 page of brief osteoarthritis information (what is osteoarthritis)"
88985690|NCT04698655|Experimental|Treatment options group|"Asked to read brief osteoarthritis information + two A4 pages of information on treatment options (osteoarthritis treatment options)"
88985691|NCT04698655|Experimental|Treatment options + recommendation group|Asked to read brief osteoarthritis information + information on treatment options + receive hypothetical general practitioner recommendation for exercise
88985692|NCT00451087|Experimental|1|
88985693|NCT00451087|Active Comparator|2|
88985694|NCT05535426|Experimental|Tetranite Stabilized Dental Implants with Provisional Crown|Extraction of maxillary anterior teeth followed by immediate insertion and stabilization of dental implants with Tetranite in otherwise non-stable sites. A provisional crown will also be inserted during this surgery.
88985695|NCT00458029|Experimental|School based intervention|Integration of activities, events, and programs affecting total school food service environment, physical education class, behavior change, promotion, and communications
88985696|NCT00458029|No Intervention|Control|Observational control
88985697|NCT00115388|Other|Deferred screening control group|Samples from women in the control group were stored and tested at the end of the trial
88985698|NCT00458146|Experimental|1|MM-093
88985699|NCT00458146|Placebo Comparator|2|Placebo
88985700|NCT00458224|Experimental|Parental counseling|Life style counseling
88985701|NCT03274063|Active Comparator|Supported self-management|Escalation of urate lowering therapy will be supervised by clinical research team based on results of participant self-testing
88985702|NCT03274063|Sham Comparator|Usual care|Escalation of urate lowering therapy will remain the responsibility of the participants primary care physician.
88985703|NCT00458263|Experimental|single arm|
89613274|NCT01610908|No Intervention|Standard of care|"The Standard of care is a control group that will continue receiving the standard North American treatment prescribed by a surgeon (observation or brace [if meeting SRS criteria]) for of 6 months. After 6 months, the participants will receive the Schroth exercises intervention for 6 months."
89613275|NCT01610908|Active Comparator|Global Postural Re-education (Montréal)|"The active group (in Montréal only) receives the Global Postural Re-Education exercises treatment.Patients in this arm come to weekly individual 1 hour long therapy sessions where exercise prescription is adjusted. Selection of posture exercises is based on scoliosis type, on muscular chain stiffness associated with posture alterations and on position increasing scoliosis or pain (lying, sitting, standing).~They they receive a 15-min home program consisting of 1 to 2 exercises to do at home everyday."
89613276|NCT05687409|Experimental|A 10-g packet of lactulose oral solution and three capsules of probiotics +entecavir group|"10-g packet of lactulose oral solution and three capsules of probiotics +entecavir group:Adults with histologically confirmed stable cirrhosis and BMI < 25 kg m-2 were enrolled and assigned to receive boxes labeled A or B: one for the synbiotic, including a 10-g packet of lactulose oral solution and three capsules of probiotics (each containing > 4.2×106 CFU Clostridium butyricum and > 4.2×105 CFU Bifidobacterium longum infantis). Participants orally administered the contents three times daily after meals.~Entecavir 5mg, once a day. All of the above lasted for six months."
89613277|NCT05687409|Placebo Comparator|A 10-g packet of glucose oral solution and three capsules of starch+entecavir group|"A 10-g packet of glucose oral solution and three capsules of starch+entecavir group:Adults with histologically confirmed stable cirrhosis and BMI < 25 kg m-2 were enrolled and assigned to receive boxes labeled A or B: one for the synbiotic, including a 10-g packet of lactulose oral solution and three capsules of probiotics (each containing > 4.2×106 CFU Clostridium butyricum and > 4.2×105 CFU Bifidobacterium longum infantis). Participants orally administered the contents three times daily after meals.~Entecavir 5mg, once a day. All of the above lasted for six months."
89613278|NCT01016938||Group I|This is a pilot study and there is only one group.
88985704|NCT04728126||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
88985705|NCT00458419|Placebo Comparator|A: naloxone; B: normal saline|Arm A: IV naloxone Arm B: IV normal saline
88985706|NCT00458458|Active Comparator|NA alone|Norethindrone Acetate (NA) 5mg taken 1-3 tabs orally every night for duration of treatment
88985707|NCT00458458|Active Comparator|LD then NA|Lupron Depot(LD) given intramuscularly every 12 weeks for total of 24 weeks then switched to Norethindrone Acetate (NA) taken 1-3 tablets orally every night for remainder of treatment
88985708|NCT00458497|Experimental|1|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
88985709|NCT00458497|Placebo Comparator|2|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric.
88985710|NCT00458575|Experimental|CNTO 2476|Participants 1 to 4: advanced retinitis pigmentosa (RP) with light perception only (LP); Participant 5: combination visual acuity of LP in the treated eye and no better than hand motion (HM) in the fellow eye; and Participants 6 to 9: advanced RP with hand motion (HM) will receive different dose levels of CNTO 2476.
88985711|NCT05525637|Experimental|YZJ-1139 20mg|
88985712|NCT05525637|Experimental|YZJ-1139 40mg|
88985713|NCT05525637|Placebo Comparator|Placebo|
88985714|NCT00115505||Ancillary-Correlative (QOL, employment, informal care cost)|Patients complete the QOL Assessments comprising the Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form; Employment and Informal Care Cost Assessments; and Peripheral Neuropathy of the FACT-NTX subscale at baseline, 29-42 and 57-70 days, and at 9 and 18 months. Patients meeting the cut-off score for peripheral neuropathy on the FACT-NTX subscale at 18 months complete the Symptoms in Relation to Patient Functioning Survey, FACT-NTX subscale, the EORTC QLQ-C30, EORTC QLQ-BR23, and the Medications Used for Treating Peripheral Neuropathy at 24, 36, 48, and 60 months.
88985715|NCT00458731|Experimental|Treatment (cediranib maleate and bevacizumab)|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bevacizumab and cediranib maleate until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
88985716|NCT03274024|Experimental|Tube implant|Ahmed Glaucoma Implant (AGI) surgery
88985717|NCT03274024|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C surgery
88985718|NCT03273985|Experimental|Dry needling|
88985719|NCT03273985|Experimental|Ischemic compression|
88985720|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2
88985721|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2
88985722|NCT00458887||Ancillary/Correlative (ototoxicity assessment)|"Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) for management of therapy complications before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin.~Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests for management of therapy complications before the transplantation and 4 weeks after transplantation."
88985723|NCT00115544|Experimental|1|stannsoporfin 0.75mg/kg
88985724|NCT00115544|Experimental|2|stannsoporfin 1.5mg/kg
88985725|NCT00115544|Placebo Comparator|3|saline injection
88985726|NCT05522049|Experimental|Intervention group|Tracheal intubation facilitated by a hyperangulated videolaryngoscope (C-MAC D-Blade)
89035182|NCT02914821|Experimental|"Childhood Healthy Eating Tax"|"In the Childhood Healthy Eating tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Childhood Healthy Eating education."
89035183|NCT04690712|No Intervention|Socio-Demographic Characteristics of Students|When the socio-demographic characteristics of the students are examined according to the pre-test findings; It was seen that 27% were in the first grade, 20.9% in the second grade, and 25.7% in the third grade. When the age groups were evaluated, it was determined that 47.8% were in the 7-8 age group, 51.5% were in the 9-10 age group and 50% of them were female students and 50% were male students. It was observed that 27.6% of the students had a bad income and 59.3% had a medium level of income. When the father's education status was questioned, it was determined that 17.6% of them did not finish primary school, 55.4% of them were primary school graduates, 2.6% of them were high school graduates. On the other hand, 55% of their mothers did not complete primary school, 43.5% were primary school graduates and 1.5% were secondary school graduates
89035184|NCT04690712|Experimental|Comparison of Students' Pretest and Posttest Development Screening Average|According to the results of height and weight screening at the pre-test stage; the average height of the students is 127.0 ± 9.11; It was determined that the average weight was 26.1 ± 6.19, the average height was 130.61 ± 8.83 and the average weight was 29.92 ± 6.39 in the final test stage. A significant difference was found between pre-test and post-test screening results
89035185|NCT04690712|Experimental|Comparison of Pre-Test and Post-Test Screening Results of Students|In the statistical evaluation, it was found that there was no significant difference between pre-test and post-test screening results
89035186|NCT01294696||All Enrolled Participants|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
89035187|NCT02914704|Experimental|Patients treated with MRI-HIFU|
89035188|NCT04324255||Low ratio|Liver recipient with low preoperative von Willbrand factor-to-protein C ratio
89035189|NCT04324255||High ratio|Liver recipient with high preoperative von Willbrand factor-to-protein C ratio
89035190|NCT04690751|Experimental|Types of Cenobamate|"Treatment A: Oral Dose of cenobamate administered as a single 200 mg tablet under fasted conditions~Treatment B: Oral Dose of cenobamate administered as a single 200 mg/20 mL suspension under fasted conditions~Treatment C: Oral Dose of cenobamate administered at a single 200 mg/20 mL suspension under fed conditions"
89035191|NCT02918487|Experimental|Active|[Formoterol + Fluticasone] Single maintenance and reliever therapy(SMART) and Active polyherbal capsule
89035192|NCT02918487|Placebo Comparator|Placebo|[Formoterol + Fluticasone] conventional along with inert similar looking placebo capsules
89035193|NCT04207606||Epidural Steroid Injection Patients|Patients who are to receive an epidural steroid injection as an outpatient.
89035194|NCT03458078|Placebo Comparator|Group C|Control group
89035195|NCT03458078|Active Comparator|Group Mg|Magnesium sulfate group
89035196|NCT03458078|Active Comparator|Group MDZ|Midazolam group
89035197|NCT02914860|Experimental|Volunteers|Healthy volunteers
89035198|NCT02914860|Active Comparator|PAF|Patients with paroxysmal atrial fibrillation
89035199|NCT02914860|Active Comparator|Pers AF|Patients with persistent atrial fibrillation
89035200|NCT02914860|Active Comparator|L-s Pers AF|Patients with long-standing persistent atrial fibrillation
89035201|NCT04690556|Active Comparator|Lucentis (ranibizumab)|Intravitreal injection
89035202|NCT04690556|Experimental|LUBT010 (proposed ranibizumab biosimilar)|Intravitreal injection
89035203|NCT01294579|Experimental|ofatumumab and bendamustine|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase and 1000 mg IV every 2 months for 2 years.~Bendamustine 90 mg/m2 was given on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)"
89035204|NCT03554655|Experimental|Intervention: Momentum app|Intervention Group will receive treatment as usual together with the Momentum app.
89035205|NCT03554655|No Intervention|Control|Control Group will receive treatment as usual without the Momentum app.
89035206|NCT02938559|Experimental|Cognitive Therapy plus Memory Support|
89035207|NCT02938559|Active Comparator|Cognitive Therapy-as-usual|
89035208|NCT02918214||echocardiography|Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.
89035209|NCT04972331|Active Comparator|CONTROL|Arthroscopic Partial menisectomy
89035210|NCT04972331|Experimental|INTERVENTION|Platet- Rich-Plasma
89035211|NCT02914665|Experimental|20 mg elamipretide|20 mg elamipretide once daily for 7 consecutive days
89035212|NCT02914665|Placebo Comparator|Placebo|Placebo once daily for 7 consecutive days
89035213|NCT04927169|Experimental|CYT107|IM administration of CYT107 / Interleukin-7
89035214|NCT04927169|Placebo Comparator|PLACEBO|IM administration of Saline at the same volume
89035215|NCT02914626|Experimental|Ranibizumab|Standard of care therapy plus intravitreal ranibizumab injections
89035216|NCT02914626|Sham Comparator|Control|Standard of care therapy
89035217|NCT02918331|Experimental|Daratumumab with Lenalidomide and dexamethasone|"Daratumumab (16 milligram per kilogram [mg/kg]) will be administered by intravenous [IV] infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.~Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle.~Participants will receive dexamethasone 40mg weekly, at day 1, 8, 15, 22 of each cycle."
89035218|NCT02918058|Active Comparator|McGill University Health Centre|This arm is defined by the geographic cluster of all eligible participants presenting to the McGill University Health Centre (Montreal, Quebec, Canada) Montreal General Hospital or Royal Victoria Hospital during the study period. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
89035219|NCT02918058|Active Comparator|University Health Network, Toronto|This arm is defined by the geographic cluster of all eligible participants presenting to the University Health Network (Toronto, Ontario, Canada) at the Toronto General Hospital or Toronto Western Hospital. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
89035220|NCT02918058|Active Comparator|University of Ottawa, Ottawa|This arm is defined by the geographic cluster of all eligible participants presenting to the Ottawa Hospital (Ottawa, Ontario, Canada). The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
89035221|NCT03457961||Adjunctive Perampanel|A group of patients who aged 12 years or above and have a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
89035222|NCT02914587|Experimental|ARTAS System|Implantation with the ARTAS System.
89035223|NCT02914587|Active Comparator|Manual Implantation|Implantation manually.
89035224|NCT02938715|Experimental|Feedback group (teledermatology)|
89035225|NCT02938715|No Intervention|Control group (phone only)|
89035226|NCT02914431|Experimental|3D Printing Personalized Titanium Plate|After the LeFort I osteotomy, the intraoperative repositioning and fixation of the maxilla is accomplished using 3D printing personalized titanium plates.
89035227|NCT02914431|No Intervention|CAD/CAM Surgical Splint|After the LeFort I osteotomy, the intraoperative repositioning of the maxilla is accomplished using CAD/CAM surgical splints and the fixation of the maxilla is accomplished using commercialization titanium plates.
89035228|NCT02918136|Experimental|adipose-derived stem cell injection|ultrasound guided injection of 5cc of adipose-derived stem cells (ADSCs)
89035229|NCT02918136|Active Comparator|cortisone injection|ultrasound guided injection of cortisone
89035230|NCT01294462|Experimental|1|Ticagrelor (AZD6140)
89613279|NCT05679063|Experimental|Therapeutic Exercise and Pain Neurophysiology Education|"Therapeutic exercise is the systematic and planned execution of posture movements and physical activities to correct or prevent alterations, improve or enhance physical functioning, and prevent risk factors for solid and optimized overall health status.~Pain Neurophysiology Education:~Education in pain neurophysiology consists in describing to the patient the neurobiology and neurophysiology of his nervous system pain to improve the processing of it and decrease the threatening meaning of pain."
89613280|NCT05679063|Sham Comparator|Sham Comparator|Talks about healthy habits
89613281|NCT02162680|Active Comparator|lidocaine|1% lidocaine intradermal injection
89613282|NCT02162680|Active Comparator|bacteriostatic normal saline (BNS)|bacteriostatic normal saline (BNS) injection
89035231|NCT01294462|Active Comparator|2|Clopidogrel
89035232|NCT02914392||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
89035233|NCT02914392||Matched Controls for fetal congenital heart disease cases|Gravidas without fetal congenital heart disease
89035234|NCT03457922||Group Therapy|Patients in the Stanford Department of Psychiatry and Behavioral Sciences who are enrolling in a trans-diagnostic anxiety therapy group will be invited to participate in research on group processes and outcomes.
89035235|NCT01294423|Experimental|1|Dapagliflozin 5 mg
89035236|NCT01294423|Experimental|2|Dapagliflozin 10 mg
89613283|NCT02162680|No Intervention|no local anesthetic|usual care practice of no local anesthetic administration
89613284|NCT02162992||SLE and Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
89613285|NCT02162992||SLE without Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
89613286|NCT05687331||Patients with hemarthrosis|10 patients that sustained a knee trauma and have hemarthrosis during knee arthrocentesis (red color of the synovial fluid)
89613287|NCT05687331||Patients without hemarthrosis|10 patients that sustained a knee trauma and do not have hemarthrosis during knee arthrocentesis (yellow color of the synovial fluid)
89613288|NCT00972088|Other|capsule endoscopy|patients eligible according to inclusion criteria who underwent a capsule endoscopy
89035237|NCT01294423|Placebo Comparator|3|
89035238|NCT02918175|Other|mHealth Intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected. In addition, they will receive personalized feedback on activity goals based on prior week step counts and participate in coaching sessions using the Pillbox medication tool.
89035239|NCT02918175|No Intervention|No intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected.
89035240|NCT02914353|Experimental|Experimental - EP-7041|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.01 mg/kg to 1.0 mg/kg~Multiple Ascending Dose: 0.01 mg/kg/h - 5 x 24 h continuous infusion up to 0.6 mg/kg/h - 5 x 24 h continuous infusion"
89035241|NCT02914353|Placebo Comparator|Placebo - Sterile Saline|"Single Ascending Dose: Single IV dose for each cohort;~Multiple Ascending Dose: 5 x 24 h continuous infusion for each cohort"
89035242|NCT02938598|Experimental|A|Engagement On - Problem Solving High - Motivation On
89035243|NCT02938598|Experimental|B|Engagement On - Problem Solving Low - Motivation On
89035244|NCT02938598|Experimental|C|Engagement On - Problem Solving High - Motivation Off
89035245|NCT02938598|Experimental|D|Engagement On - Problem Solving Low - Motivation Off
89613289|NCT05677815||patients with COVID-19 infection underwent surgery in 2023|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional
89613290|NCT05677815||patients without COVID-19 infection underwent surgery in 2023|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional
89613291|NCT01017250|Experimental|Stereotactic Radiosurgery|Avastin and Radiosurgery
89613292|NCT03082443|Experimental|Therapeutic group|
89613293|NCT03082443|No Intervention|Control group|
89613294|NCT05687175||Neuropathic pain|Questionnaire administration and socio-demographic data collection
89613295|NCT05687175||Nociceptive pain|Questionnaire administration and socio-demographic data collection
89613296|NCT04746651|Experimental|Guided Self Help|"Four guided self-help booklets were used; Why do I feel so bad? covered formulation/understanding feelings, I can't be bothered doing anything centred on activity scheduling, Why does everything always go wrong? focused on thought-challenging, and How to fix almost everything incorporated problem solving. Linked worksheets were adapted following feedback from Prison Officers."
89613297|NCT02159872|Experimental|Omacetaxine|Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
89613298|NCT00417664||Dexmedetomidine|
89613299|NCT00417664||Propofol|
88985727|NCT05522049|Active Comparator|Control group|Tracheal intubation facilitated by a videolaryngoscope with a Macintosh type blade (C-MAC)
88985728|NCT03273868|Experimental|High velocity low amplitude manipulation|
88985729|NCT03273868|Sham Comparator|Sham manipulation|
88985730|NCT00459160|Experimental|Low MAP Group|Hypotensive Group with a target minimum MAP of 50 mmHg
88985731|NCT00459160|No Intervention|High MAP group|Non experimental group: These patients will have a target minimum MAP of 65 mm Hg
88985732|NCT00459433|Experimental|1|psychosocial intervention
88985733|NCT00459433|Active Comparator|2|Usual care
88985734|NCT00459472|Other|Training|laparoscopic training curriculum: all general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
88985735|NCT05512221|Experimental|Phase I|GBAT+I and GBAT+E groups
88985736|NCT05512221|Experimental|Phase 2a|Watchful Waiting, GBAT+I, and GBAT+E groups
88985737|NCT05512221|Experimental|Phase 2b|GBAT+IE groups
88985738|NCT00459550|Experimental|Part A|Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo. The dose for the first cohort will be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these may be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose will be 20 mg/kg, although the planned top dose is 18 mg/kg
88985739|NCT00459550|Experimental|Part B|"Part B will be a single-blind, repeat dose, placebo controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterise GSK933776 fully.Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo. Dosing in Part B may proceed in parallel with Part A following satisfactory review of minimum data sets as below:~First cohort in Part B: at least 3 weeks' data from the Part A dose that is the same dose level as that planned for Part B Second cohort in Part B: at least 3 weeks PK data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow"
89613300|NCT00417664||Midazolam|
89613301|NCT05687019|Experimental|Patient undergoing prostate enucleation by Holmium Laser|It is based on a pulsed laser at a wavelength of 2140 nm, which penetrates the tissues over a very short distance. The prostate tissue must therefore be in contact with the laser fiber to be cut or vaporized, and hemostasis will take place nearby. The procedure lasts approximately one hour.
89613302|NCT03400059|Experimental|Active Treatment|
88985740|NCT00459589|Experimental|1|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
88985741|NCT00459589|Active Comparator|2|
88985742|NCT00459628|Active Comparator|Conventional radiotherapy|Conventional Long schedule Radiotherapy Arm
88985743|NCT00459628|Experimental|Tomotherapy|Short course schedule by tomotherapy
88985744|NCT04728321|Experimental|AK104|AK104 15mg/kg IV every 3weeks (Q3W)
88985745|NCT04728321|Experimental|AK104 and Lenvatinib|AK104 15 mg/kg IV every 3 weeks (Q3W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
88985746|NCT00459823|Experimental|1|
88985747|NCT04728399|Experimental|Experimental group|2g Soybean peptide, 3g CLA and ng protein.
88985748|NCT04728399|Placebo Comparator|Control group|2g+N protein and 3g Soybean oil.
89613303|NCT03400059|Sham Comparator|Sham Treatment|
89613304|NCT01021306|Active Comparator|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner.
89613305|NCT01021306|Active Comparator|Dental Care & Self Care|Intraoral splints are removable orthopedic appliances fabricated of hard acrylic resin positioned between the remaining teeth of the patient. They are designed in theory to support the function of the TMJ and relieve associated pain. Stabilization splints are believed to function by stabilizing the intracapsular structure of the TMJ, reducing activity of masticatory muscles, distributing occlusal forces, and reducing bruxism (teeth grinding).
89613306|NCT01021306|Sham Comparator|Sham AMCT & Self Care|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except no thrust will be delivered. Self-care only participants successfully completing the 6 month assessment will be given the option for RIST or AMCT for one month.
89613307|NCT01021306|Placebo Comparator|Self-care only group|All patients will be offered the self-care checklist of homecare approaches at baseline. Self-care only participants successfully completing the 6 months assessment will be given the option for RIST or AMCT for one month.
89613308|NCT03082287||IBD|Adult subjects diagnosed with IBD via endoscopy and histological findings.
89613309|NCT03082287||IBS|Adult subjects with IBS as per the Rome IV criteria.
89613310|NCT03082287||Other GI Disorders|Adult subjects with gastrointestinal disorders not meeting the Rome IV criteria or IBD diagnosis.
89613311|NCT03082287||Healthy Subjects|Adult subjects without any gastrointestinal complaints.
89613312|NCT03082365||pre-dialysis|
89613313|NCT03082365||end stage renal disease|
89613314|NCT01021618|Active Comparator|Vasodilator-exercise stress|Four-minute infusion of dipyridamole (0.56 mg/kg) followed by symptom-limited exercise; injection of technetium-99m labeled radiopharmaceutical at peak hyperemia or peak exercise followed by SPECT myocardial perfusion imaging
89613315|NCT01021618|Experimental|Exercise-vasodilator stress|Symptom-limited exercise followed by a bolus intravenous injection of regadenoson (0.4 mg/5 mL) in patients failing to achieve a standard clinical endpoint; injection of technetium-99m labeled radiopharmaceutical 15 seconds after administration of regadenoson (or at peak exercise if regadenoson not administered) followed by SPECT myocardial perfusion imaging.
88985749|NCT00460018|Experimental|Intervention|Women receiving the DEBI Intervention
88985750|NCT00460018|No Intervention|No intervention|Women receiving standard care
88985751|NCT00460057|Placebo Comparator|Alendronate, Placebo|All subjects were given 600 mg of calcium and 400 IU of vitamin D supplements. The subjects were randomized to receive weekly alendronate 20 mg (n = 31) or placebo (n = 32).
88985752|NCT00401921|Placebo Comparator|Minocycline arm|Minocycline 100mg/Placebo 0mg Minocycline 100mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
88985753|NCT00401921|Placebo Comparator|Placebo arm|Placebo 0mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
88985754|NCT00460135|Experimental|RT|resistance training
88985755|NCT00460135|No Intervention|Routine care|General counseling on increasing physical exercise
89613316|NCT03082053|Experimental|Study I|Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors
88985756|NCT00460174|Experimental|Treatment Arm|Concurrent gemcitabine, bevacizumab, and radiation therapy
88985757|NCT00460213|Experimental|Valsartan|
88985758|NCT00460369|Active Comparator|1|sulfadoxine-pyrimethamine
88985759|NCT00460369|Active Comparator|2|artemether-lumefantrine
88985760|NCT00460369|Active Comparator|3|amodiaquine-artesunate coformulation
88985761|NCT04697953|Experimental|brolucizumab 6mg|Open label, brolucizumab 6mg, daily dosing, Treat & Extend regimen by up to 2 week intervals. Dosing intervals as per previous therapy and treatment extension intervals
88985762|NCT00460720||001|
88985763|NCT00460759|Experimental|Moxifloxacin and Rifapentine|
88985764|NCT00460837|Active Comparator|1 A|gastrofin & Picolax
88985765|NCT00460837|Active Comparator|2|senna
88985766|NCT00115856|No Intervention|Subjects studied|Single arm exploratory feasibility safety and efficacy study of MRI to image atherosclerosis in arteries
88985767|NCT02956876|Experimental|Nurse practitioner consultation|standard chemotherapy for colorectal cancer
88985768|NCT02956876|Other|Standard consultation|standard chemotherapy for colorectal cancer
89613317|NCT03082053|Experimental|Study II|Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer
88985769|NCT00115895|Experimental|Radioactive iodine 1,1 GBq|Low activity of radioiodine, 1,1 GBq
88985770|NCT00115895|Other|Radioactive iodine 3,7 GBq|Routine activity of radioiodine, 3,7 GBq
88985771|NCT04728009|Experimental|longan and lingzhi mushroom syrup|All participants (N = 8) were asked to consume 5 mL of longan and lingzhi mushroom syrup as a sweetener daily for 12 weeks.
88985772|NCT00461071|Active Comparator|Internet-based self-help|Internet-based self-help behavioural
88985773|NCT00461071|Active Comparator|Bibliotherapy|bibliotherapy
88985774|NCT00461110|Experimental|1|Active
89613318|NCT01022242|Placebo Comparator|Placebo|Placebo is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
88985775|NCT00461110|Experimental|2|Active
88985776|NCT00461266|Experimental|1|
88985777|NCT00461266|Active Comparator|2|
88985778|NCT04727658|Experimental|Radiosurgical thalamotomy on GammaKnife|
88985779|NCT03273634|Experimental|Active treatment|The treatment will consist of lanzoprazole 30 mg once daily at night time
88985780|NCT03273634|Placebo Comparator|Placebo|A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient
88985781|NCT03273595|Placebo Comparator|Control|
88985782|NCT03273595|Experimental|Experimental group|
88985783|NCT03273556|Experimental|Aliaxin® EV Essential Volume|Comparison within subjects of Aliaxin® EV Essential Volume with and without Lidocaine 0.3%
88985784|NCT04728308|Active Comparator|Experimental group|20ml of 0.5% bupivacaine is infiltrated in the subcutaneous tissue around the incision site
88985785|NCT04728308|Placebo Comparator|Placebo group|20 ml of distill water is infiltrated in the subcutaneous tissue around the incision site
88985786|NCT00461422|Experimental|1|Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
88985787|NCT00461422|No Intervention|2|Standard Flexible antagonist protocol
88985788|NCT04697992|Experimental|group A|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
88985789|NCT04697992|Experimental|group B|one eye was treated with tranexamic acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
89613319|NCT01022242|Experimental|PXL01|PXL01 is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
89613320|NCT03358563|Experimental|Degarelix SC + bicalutamide + docetaxel|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3
89613321|NCT03358563|Experimental|DegarelixSC + bicalutamide + docetaxel + Ferumoxytol enhanced MRI|Degarelix SC monthly x3 + bicalutamide 50mg orally QD x 14 wks + Docetaxel 75mg/m2 IV q 21 days x 3 + Ferumoxytol enhanced MRI within 21 days prior to start of hormonal therapy and second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
89613322|NCT01018420|Experimental|Colchicine|
89613323|NCT01018420|Active Comparator|Moxifloxacin|
89613324|NCT04401033||Endoscopic cohort|Endoscopic examinations: They will be carried out according to the recommendations of the Spanish society for digestive endoscopy (SEED). In summary, the patient will perform a hand wash with hydroalcoholic solution before entering the endoscopy room, and will put on a surgical mask and gloves. Personnel close to the patient will wear an FFP2 mask, exceptionally a surgical mask, a gown (waterproof in high-risk examinations as established in the SEED guidelines), a cap, nitrile gloves and face shield or safety glasses (reusable) and shoe covers. The examinations will be performed by endoscopist-guided sedation in accordance with current clinical guidelines.
89613325|NCT04401033||Ultrasonography cohort|Abdominal ultrasound: They will be carried out according to international clinical guidelines (12). The explorer will wear an FFP2 mask, exceptionally a surgical mask, a gown, a hat, nitrile gloves, and a face shield or safety glasses (reusable) and shoe covers. The gel bottle, transducer, and stretcher will be washed prior to each scan with low-level disinfectant
89613326|NCT04401033||Telephonic cohort|The patient will be telephonically contacted for a medical visit.
89613327|NCT03081975|Active Comparator|HD white light|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
89613328|NCT03081975|Active Comparator|HD narrow band imaging|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
89613329|NCT03082131|Experimental|Group 1|"Order of treatments:~A. Resistant Starch Wheat B. Regular Wheat"
89613330|NCT03082131|Experimental|Group 2|"Order of treatments:~A. Regular Wheat B. Resistant Starch Wheat"
89613331|NCT03081819|Experimental|SH003|Participant will take SH003 for 3 weeks.
89613332|NCT00974350|Experimental|Group 1: SABER-Bupivacaine|2.5 mL SABER-Bupivacaine/Once
88985790|NCT05483634||Genital urinary symptoms of menopause|Menopause for one year, or age above 45 with symptoms of GSM
88985791|NCT04728269|Experimental|Lactibiane topic AD|Cosmetical product Lactibiane Topic AD
88985792|NCT04728269|Placebo Comparator|Placebo|Placebo made with the same base as the cosmetical product
88985793|NCT00461617|Active Comparator|2|Nateglinide 120 mg TID
88985794|NCT04728035|Experimental|Dose escalation (part 1)|Patients will receive irinotecan liposome injection (CSPC) at the initial starting dose until progression or unacceptable toxicity.
88985795|NCT04728035|Experimental|Dose expansion (part 2)|Once the appropriate dose has been established in Part 1, patients will be enrolled into two expansion cohorts according to the sub-type of breast cancer.
88985796|NCT00461695|Other|CMV-seropositive|Cytomegalovirus-seropositive individuals at screening (week 0). Intervention: Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
88985797|NCT00461695|Other|CMV-seronegative|Cytomegalovirus-seronegative individuals at screening (week 0). Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
89613333|NCT00974350|Experimental|Group 2: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
89613334|NCT00974350|Placebo Comparator|Group 3: SABER-Placebo|2.5 mL or 5.0 mL SABER-Placebo/Once
89613335|NCT05633901|Placebo Comparator|Standard of Care|Standard verbal counseling provided to patients by clinic nurse about post-operative expectations
89613336|NCT05633901|Active Comparator|Educational Video|An educational video to aid standard counseling packet on post-operative expectations
89613337|NCT05633511|Experimental|All Participants|Participants will receive the CTG procedure on one side and the PRF procedure on the other. Both are standard of care soft tissue grafting methods and a split mouth design is standard of care.
88985798|NCT03273439|Experimental|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
88985799|NCT03273439|Sham Comparator|Sham rTMS|all procedures were identical except they were the unmagnetized steel cylinders, instead of cylindrical magnets, that were rotated. Participants were, therefore, unable to distinguish between active and sham rTMS.
89035246|NCT02938598|Experimental|E|Engagement Off - Problem Solving High - Motivation On
89035247|NCT02938598|Experimental|F|Engagement Off - Problem Solving Low - Motivation On
89035248|NCT02938598|Experimental|G|Engagement Off - Problem Solving High - Motivation Off
89035249|NCT02938598|Experimental|H|Engagement Off - Problem Solving Low - Motivation Off
89035250|NCT02914197|Experimental|Full information|"The intervention arm will receive full information on the risks and benefits of mammography through:~Decision aid~YouTube video~Group information session"
89613338|NCT05395702|Experimental|Drug: Interferon Gamma|Antibacterial therapy + IFN-G administered intramuscularly 100,000 IU once a day daily for 5 days
89613339|NCT05395702|No Intervention|Control: No intervention|Only antibacterial therapy
89613340|NCT03016546|Experimental|BEST-maCARE|BEST-maCARE intervention will be refined to accommodate our target population using pertinent information attained through interviews conducted with patients representative of the target group and stakeholders from the clinics where the intervention will be pilot tested.
89613341|NCT03016546|Active Comparator|time-matched attention control condition|Participants will be randomly assigned. The control group will receive an intervention that is time and attention equivalent to the experimental condition, though substantively neutral.
89613342|NCT01023178|Active Comparator|Vivelle-Dot|17Beta Estradiol - transdermal
89613343|NCT01023178|Active Comparator|Premarin|Conjugated estrogens
89613344|NCT01023178|Active Comparator|Estrace|17beta Estradiol
89035251|NCT02914197|No Intervention|Control|Standard information leaflet for breast screening from Cancer Care Ontario
89035252|NCT02938832|Active Comparator|Traditional low-fat diet advice|Advice on traditional low-fat diet by dietician
89035253|NCT02938832|Active Comparator|Mediterranean diet advice|Advice on a Mediterranean dietary regime with reduced carbohydrates
89035254|NCT02910570|Experimental|Liraglutide 3 mg|Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
89613345|NCT03373851||Zalviso|Patient willing to participate to the study, and scheduled for major functional surgery (arthroplasty, valgisation osteotomy, DIEP flap surgery, total body lift procedures) will be consented to use the Zalviso device in postoperative period as a main analgesia method.
89035255|NCT02910570|Placebo Comparator|Liraglutide 3 mg placebo|Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
89035256|NCT02910453||VATS group|Pulmonary lobectomy via VATS. VATS starts with a utility incision, approximately 4 cm in length, anterior to the latissimus dorsi muscle at the 4th intercostal space. Muscle fibers are split without cutting and a wound protector is regularly placed in site. The camera port is placed in the 6th or 7th intercostal space at the anterior axillary line and a third 10-mm access is made at the same intercostal space at the posterior axillary line. The hilum is approached anteriorly
89035257|NCT02910453||Open group|Pulmonary lobectomy via posterolateral thoracotomy (PLT). PLT consists in a standard 10-15 muscle-sparing incision at 4th intercostal space, rib divaricators are utilized and the hilum is approached posteriorly as previously described
89035258|NCT02938754|Experimental|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
89035259|NCT02938754|Active Comparator|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
89035260|NCT02938364|Experimental|Earplugs|The participant will be asked to put plastic earplugs in both ears for 10 minutes and then the impression will be made while they are still on.
89035261|NCT02938364|Experimental|Acupressure|The participant will be asked to wear sea bands on P6 points of both hand wrists for 10 minutes and then the impression will be made while they are still on.
89035262|NCT02938364|Placebo Comparator|Placebo|The participant will be asked to wear non pressure bands on both hand wrists for 10 minutes and then the impression will be made while they are still on.
89035263|NCT01294150|Active Comparator|UroLift System|The treatment group subjects underwent the UroLift system procedure. The subject was blinded to his randomization into control or treatment group. Unblinding will occurred at 3 months post procedure after the assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to retreat with the UroLift system if he met the retreatment inclusion and exclusion criteria. Subjects that went on to UL retreatment within the first 12 months started their follow-up schedule over and were considered treatment failures. All UL subjects will be followed a minimum of 5 years.
89613346|NCT03373773|Active Comparator|Home Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter at home."
89613347|NCT03373773|Active Comparator|Office Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter in a medical office."
89613348|NCT01023568|Active Comparator|Macintosh blade|Intubation with Macintosh blade laryngoscope
89613349|NCT01023568|Active Comparator|Glidescope|Intubation with Glidescope laryngoscope
89613350|NCT01023568|Active Comparator|Truview PCD|Intubation with the Truview PCD laryngoscope
89613351|NCT01023724|Active Comparator|bromfenac 0.09%|bromfenac 0.09% drops to be given pre operatively for one day BID, and then postoperatively for 14 days.
89613352|NCT01023724|Active Comparator|Acuvail|Acuvail to be given preoperatively at BID for one day pre op and then post operatively for 14 days.
89035264|NCT01294150|Sham Comparator|Cystoscopy|The control group subjects underwent a cystoscopy procedure. The subject was blinded to his randomization into the control or treatment group. Unblinding will occurred at 3 months post procedure, after follow-up assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
89035265|NCT01294150|Active Comparator|Crossover|Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
89035266|NCT04324216|Experimental|Experimental group|3D virtual reality and hands-on aromatherapy
89613353|NCT03372135||Trendelenburg group|Patients in trendelenburg group take trendelenburg position and have CO2 pneumoperitoneum. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested.
89613354|NCT03372135||Control group|Patients in control group take horizontal position. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested
89035267|NCT04324216|No Intervention|Control group|No intervention
89035268|NCT02938208|Experimental|Jupiter Full Face Mask|Participants to use full face mask in-home for a 14 ± 3 days in-home.
89035269|NCT04832516|Experimental|Individualized exercise group (IND)|Group with adapted and personalized exercises (IND).The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
89035270|NCT04832516|Active Comparator|Traditional exercise group (CLA)|Group with traditional exercise (CLA). The CLA group will perform exercises following WHO (World Health Organization) prescription.
89035271|NCT02910141||CSII (subcutaneous insulin infusion)|People with Type 2 diabetes treated by continuous subcutaneous insulin infusion (CSII)
89035272|NCT02910141||MDI (multiple daily insulin injections)|People with type 2 diabetes treated by multiple daily insulin injections
89035273|NCT04817072|Other|Chronic inflammatory rheumatic disease|Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19
89035274|NCT02910336||Cases|Orofacial Pain patients under went to quantitative sensory test
89035275|NCT02910336||Control|Volunteers and presented neither previous diagnostic of orofacial pain nor generalized pain, under went to quantitative sensory test
89035276|NCT04817033|Active Comparator|High risk OSA Dexmedetomidine|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
89035277|NCT04817033|Active Comparator|High risk OSA Midazolam|High risk OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
89035278|NCT04817033|Active Comparator|Low&Medium OSA Dexmedetomidine|Low&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
89035279|NCT04817033|Active Comparator|Low&Medium OSA Midazolam|Low&Medium OSA defined by STOP BANG questionnaire Intraoperative sedation during spinal anesthesia for transurethral resection of bladder and prostate
89613355|NCT00974818|Experimental|pts getting Mitomycin C (MMC)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of MMC, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
89613356|NCT00974818|Experimental|pts getting Bacillus Calmette-Guerin (BCG)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of either BCG, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
89613357|NCT05395546|Experimental|dCBT-I treatment group|
89613358|NCT00977704|Active Comparator|Restylane and Perlane|Restylane and Perlane administered by injection. Recommended volume of 6.0 mL. Injection on study day 1 with an optional touch up on study day 14.
89613359|NCT05395234|Experimental|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura & McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction & flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
89613360|NCT03371667|Experimental|Methotrexate|"5mg/Kg/day methotrexate for 4 weeks then 3 mg/m2 every two weeks for 12 weeks~2mg/kg/day PO prednisone prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.~10 mg po or iv lederfolin after each MTX administration"
89035280|NCT01292473|Experimental|Placebo|Placebo subcutaneously (sc) every 4 weeks
89035281|NCT01292473|Experimental|Omalizumab 75 mg|Omalizumab 75 mg sc every 4 weeks
89613361|NCT03371667|Placebo Comparator|Placebo|"Once a week placebo for 4 weeks then every two weeks for 12 weeks~2 mg/kg/day PO prednisone (or 1.6 mg/kg/day IV methylprednisolone) once daily.~10 mg po or iv lederfolin after each placebo administration"
89613362|NCT01024738|Placebo Comparator|Fluoride toothpaste|negative control toothpaste
89035282|NCT01292473|Experimental|Omalizumab 150 mg|Omalizumab 150 mg sc every 4 weeks
89613363|NCT01024738|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste (Total toothpaste)
89613364|NCT01024738|Active Comparator|Chlorhexidine Oral Rinse|positive control oral rinse
89613365|NCT04279041|Experimental|Fanta and Zunba rotatory files|Fanta and Zunba rotatory files
89613366|NCT04279041|Active Comparator|manual K-files|manual K-files
89613367|NCT01024972|Experimental|Dantrolene|Dantrolene 1.25mg/kg IV every 6 hours x 7 days
89613368|NCT01024972|Placebo Comparator|Placebo|Equiosmolar volume (5% Mannitol)
89035283|NCT01292473|Experimental|Omalizumab 300 mg|Omalizumab 300 mg sc every 4 weeks.
89035284|NCT03026049|Active Comparator|deep venous stent|Patients will receive deep venous stenting in the iliaco(femoral) region
89035285|NCT03026049|No Intervention|conservative managment|Conservative management of complaints
89035286|NCT03457883|Experimental|group A|accepted herniamesh mesh
89035287|NCT03457883|Experimental|group B|accepted biological graft of cook
89035288|NCT02938247|Experimental|Single-arm study|High caloric, high protein ONS, three portions daily, total dose of 400 kcal/day for 7 consecutive days, oral administration
89035289|NCT02914002|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
89035290|NCT02914002|No Intervention|Usual Food Practices - AC|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
89035291|NCT02914002|No Intervention|Usual Food Practices - NAC|These are participants from a community where the intervention is not active.
89210821|NCT00928980|Active Comparator|Optimal Medical Care|Treatment with optimal medical care: therapeutic dose of antidepressant medication during at least 15 months, administered in accordance with current guidelines.
89210822|NCT03972085|Experimental|Group 1|Patient received neural gliding exercises in addition electrotehrapy sessions.
89210823|NCT03972085|Active Comparator|Group 2|Patient received only electrotherapy sessions
89035292|NCT02938286|Experimental|Fractional CO2 laser at 5% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 5% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied to this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
89035293|NCT02938286|Experimental|Fractional CO2 laser at 15% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
89035294|NCT02938286|Experimental|Fractional Er:YAG laser at 5% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 5% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 5% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
89613369|NCT03370809|Experimental|patients over 75 years old with cancer discovery|Elderly patients with cancer have a 18F-FDG PET whole body performed routinely in the initial assessment . A cerebral recording is added 45 minutes after the 18F-FDG injection and just before the registered whole body
89035295|NCT02938286|Experimental|Fractional Er:YAG laser at 15% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 15% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 15% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
89035296|NCT02914041||Kyphosis group|Subjects are community-dwelling elderly with different degrees of kyphosis, aged at least 60 years with a body mass index between 18.5-29.9 kg/m2 and OWD >0 cm.
89035297|NCT02913963|Active Comparator|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
89613370|NCT05686395|Active Comparator|group 1 Ultrasound-guided Interscalene Block group|In this group, ultrasound-guided ISB will be done using 10 ml of bupivacaine 0.25%.
89613371|NCT05686395|Active Comparator|group 2 Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|, ultrasound-guided SHAC block will be done using 10 ml of bupivacaine 0.25% injected in the interfacial plane between deltoid and subscapular muscle and 10 ml of bupivacaine 0.25% injected in the pericapsular space. Ultrasound-guided SSN block will be done using 10 ml of bupivacaine 0.25% injected at sub omohyoid space.
89613372|NCT01025830|Experimental|Generic|generic fixed dose combination of Stavudine, Lamivudine and Nevirapine (Triomune)
89613373|NCT01025830|Active Comparator|Brand|3 separate single pills of Zerit (Stavudine)Epivir (Lamivudine) Viramune (Nevirapine)
89613374|NCT03081039|Active Comparator|Arm A|Cisplatin or Carboplatin with Gemcitabine for 6 cycles
89613375|NCT03081039|Active Comparator|Arm B|Gemcitabine alone for 6 cycles
89613376|NCT01026844|Experimental|Erlotinib plus hydroxychloroquine|erltoinib 150mg per day plus HCQ in esclating doses of 400mg, 600mg, 800mg and 1000mg per day
89613377|NCT01026844|Experimental|Hydroxychloroqine|hydroxychloroquine given at escalating doses of 400mg, 600mg, 800mg and 1000mg per day
89613378|NCT04278963|Experimental|Yin Hu Qing Wen Decoction Group|Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen Decoction (Granula) for 10 days.
89613379|NCT04278963|Placebo Comparator|Yinhu Qingwen Decoction low-dose group|Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen Decoction (Granula) for 10 days.
89613380|NCT04278963|Active Comparator|Integrated Chinese and Western Medicine group|Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into 3 times(once with 200ml). The Chinese medicine decoction will be given 200ml per time, three times a day for 10 days.
89613381|NCT00979732|Active Comparator|GSE beverage active|grape seed extract beverage 150 mg/BID
89613382|NCT00979732|Placebo Comparator|GSE beverage placebo|grape seed extract placebo beverage 150 mg/BID
89613383|NCT03368781|Experimental|AcQMap Imaging and Mapping|Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.
89613384|NCT03353181|Experimental|Endoscopic scissors|Endoscopic nasobiliary drainage for malignant hilar biliary strictures at first， and application of endoscopic cutting technique followed.
89613385|NCT03353181|Active Comparator|Stent|Standard placement of biliary stent for malignant hilar biliary strictures.
89613386|NCT05686239|Experimental|RL-007 20 mg|oral dosing three times per day (TID)
89613387|NCT05686239|Experimental|RL-007 40 mg|oral dosing three times per day (TID)
89613388|NCT05686239|Placebo Comparator|Placebo|oral dosing three times per day (TID)
89613389|NCT05686161|Experimental|A single 25 μg dose mRNA vaccine SW-BIC-213|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
89613390|NCT05686161|Active Comparator|A third dose of COVID-19 Inactivated vaccine|Intervention Name: COVID-19 Inactivated Vaccine Type : Control Vaccine Dose :Inactive Unit Dose Strength(s) : 0.5ml; Route of Administration: injection Intramuscular
89613391|NCT05686161|Active Comparator|A single 30μg dose mRNA vaccine Pfizer(BNT162b2)|Type :mRNA COVID -19 vaccine - Pfizer(BNT162b2) Dose :Formulation mRNA Unit Dose Strength(s) :30ug; Dosage Level(s) :0.3ml; Route of Administration: injection Intramuscular
89035298|NCT02913963|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
89035299|NCT01292239|Experimental|TMC435 100 mg 12 Wks + PR 24/48|Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
89035300|NCT01292239|Experimental|PBO 12 Wks + PR 48|Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
89035301|NCT02938091|Experimental|High-fat diet|The dietary intervention was designed as a typical Western diet (39% total fat, 14% saturated fat, 12% monounsaturated fat, 9.6% polyunsaturated fat, 42% carbohydrate, 8.8 grams fiber/1000 kcal)
89035302|NCT02938091|Experimental|Low-fat diet|The dietary intervention consisted of a Hispanic diet (20% total fat, 5.5% saturated fat, 9.6% monounsaturated fat, 3.7% polyunsaturated fat, 61% carbohydrate, 13.7 grams fiber/1000 kcal). The diet was comprised of typical foods and recipes resembling a traditional Caribbean Hispanic diet and differed from the Western diet in four primary ways: 1) more fruits and vegetables, 2) more beans (e.g. mixed dishes to reduce serving size of white rice while increasing legumes), 3) emphasis on reduced-fat dairy products (e.g., 1% fat milk), and 4) lower total fat and lower animal and hydrogenated fat.
89613392|NCT03368313|Experimental|Compression arm|The compression arm will receive an adjustable velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
89613393|NCT03368313|No Intervention|Control arm|No compression
89613394|NCT04279821||Colonic diverticulosis and macroscopic signs of inflammation|No interventional study
89613395|NCT04279743|Experimental|ApoE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
89613396|NCT04279743|Experimental|ApoE4 non carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
89613397|NCT03345615|Experimental|Intensive Monitoring|30-day ambulatory cardiac event monitoir
89613398|NCT03345615|No Intervention|Standard Care|Standard Care (no supplemental monitoring)
89035303|NCT01291225|Other|Playground|"The playground arm of the study will consist of playground audits and KAP surveys about playground safety in both Chillicothe and Circleville, Ohio.~The intervention is Playground Safety Renovations and Development."
89035304|NCT01291225|Other|Farms|The Farm Arm will consist of farm audits with safety checklists and KAP surveys about farm safety. The intervention is a Safety Educational Campaign.
89613399|NCT03344913|Active Comparator|Adults with knee Osteoarthritis|walking 30 minutes per day, three days/week for 6 weeks.
89613400|NCT03344913|Active Comparator|Healthy controls|walking 30 minutes per day, three days/week for 6 weeks.
89035305|NCT02909985|Experimental|Visual response to IR|"15 healthy participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source~10 colorblind participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source~For both groups, as intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band Tungsten halogen light with narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see."
89210824|NCT00584909|Experimental|Open Label|
89613401|NCT05685693|Active Comparator|Conventional TKA|Conventional TKA, with no patient-specific instrumentation or robotic assistance
89613402|NCT05685693|Experimental|Robotic-assisted TKA|ROSA Knee System assisted TKA
89613403|NCT01027468|Experimental|group 1|bevacizumab intravitreal injection
89613404|NCT01027780|Active Comparator|Mindfulness-Based Stress Reduction|Participation in the Mindfulness-Based Stress Reduction (MBSR) program following the initial assessment period, just prior to the start of the immunological measures.
89613405|NCT01027780|No Intervention|Wait-list control|Wait-list control participants were offered MBSR training after completion of their primary assessments periods.
89613406|NCT05102799||Anoctaminopathies|Anoctaminopathies including Limb Girdle Muscular Dystrophy R12, Miyoshi distal Muscular Dystrophy type 3 and asymptomatic hyperCKemia
89210825|NCT02551172|Experimental|experimental sequence|Run-in period → Treatment period HGP0816 20mg 1tab HCP1105 4capsues +Placebo of HGP0816
89613407|NCT05395156|Experimental|sham acupoint|Control group: (placebo group) will be consisted of twenty-five females diagnosed with premenstrual syndrome. They will receive TEAS on sham acupoint (the acupoint selection site was 1 inch away from the acupoint selection in the study group) daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles with average of 7 sessions per month for 3 months
89613408|NCT05395156|Experimental|Electroacupuncture|Study group: (Electroacupuncture group) will be consisted of twenty-five females diagnosed with premenstrual syndrome. They will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles with average of 7 sessions per month for 3 months.
89613409|NCT03320343||Patients recruited for pelvic imaging examination|
89613410|NCT05395000|Experimental|"Parents group"|Parent or primary caregiver of a child or adolescent (<18 years old) diagnosed with type 1 diabetes.
89613411|NCT05395000|Experimental|"School workers group"|"Any adult who works or will work in a school or daycare setting who is likely to administer glucagon to a child or adolescent with type 1 diabetes (e.g. teachers, facilitators, teacher candidates, etc.). This individual must not meet the criteria for the parent group."
89613412|NCT04278807|Experimental|PENG-group|Ultrasound-guided PENG-block - 30 patients
89613413|NCT04278807|Experimental|FIB-group|Ultrasound-guided Fascia Iliaca block - 30 patients
89035306|NCT02909985|Experimental|Electroretinography|"5 healthy participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
89035307|NCT02909985|Experimental|Visual Evoke Potential Test|"5 healthy participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
89035308|NCT02937974|Experimental|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
89035309|NCT02937974|Placebo Comparator|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
89035310|NCT05600179||patients with diabetic macular edema|
89035311|NCT05600179||healthy patients|
89035312|NCT01290796|Other|Ajust Adjustable Single-Incision Sling|Urinary incontinence sling
89035313|NCT02937662|Experimental|IAC regimen|Patients receive IAC regimen including idarubicin, cytarabine and cyclophosphamide.
89035314|NCT02937662|Active Comparator|Control Group|Patients receive physician-directed regimens without cyclophosphamide including FLA±G regimen, AAG regimen, decitabine with AA regimen. Physicians can choose one of these regimens based on their experience and patients' condition.
89035315|NCT02909946|Active Comparator|Intervention Arm|NHs randomized to the Intervention Arm will implement a new multi-modal infection control program.
89035316|NCT02909946|No Intervention|Control Arm|NHs randomized to the Control Arm will continue their current standard infection control practices.
89035317|NCT01290757|Experimental|Dabigatran etexilate 150 mg (T)|Capsugel (T), oral administration
89035318|NCT01290757|Experimental|Dabigatran etexilate 150 mg (R)|Qualicaps (R), oral administration
89035319|NCT02937857|Active Comparator|Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
89035320|NCT02937857|Experimental|Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD for 5 days.
89035321|NCT04324060|Active Comparator|TPO treatment group|Danazol 0.2g tid po+rhTPO (recombinant human thrombopoietin injection) 300U/kg/d×14d si every month (stop when PLT≥100×10e9/L or increased more than 50×10e9/L), total course 6 months
89035322|NCT04324060|Placebo Comparator|control|Danazol 0.2g tid po+ control (sodium chloride)×14d si every month, total course 6 months
89035323|NCT01290718|Experimental|Single Arm|
89035324|NCT02937935|Experimental|Protocol Guided-RRT|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
89035325|NCT02937935|Active Comparator|On Demand-RRT|In the protocol guided group patients all patients would be considered for dialysis within 6 hours of randomization After randomization patients would receive dialysis as three sessions per week of at least 4 h with a blood flow >200 mL/min and a dialysate flow >500 mL/min in intermittent group and as 20-25 mL/kg/h of effluent, by filtration and/or diffusion in continuous form until recovery of renal functions
89035326|NCT04688424|Experimental|FES + Cycling|Functional electrical stimulation cycling group
89035327|NCT04688424|Active Comparator|Cycling only|Volitional cycling group (no electrical stimulation)
89035328|NCT04688424|No Intervention|Control|control group
89035329|NCT02937896|Experimental|Ketorolac|30mg ketorolac administrated intravenous and 4 puffs nasal Normal Saline.
89613414|NCT00980278|Active Comparator|sinus lift plus dental implant|"Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: N/A; only sinus augmentation and dental implant"
89035330|NCT02937896|Active Comparator|Desmopressin|40 microgram nasal desmopressin administrated and 1cc Normal Saline intravenous
89035331|NCT02937779|Experimental|HBs Ag positive|"tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for positive Hbe Ag women.~No treatment for negative HBe Ag women"
89035332|NCT04688229|Experimental|Hummingbird intervention group|10 one-hour sessions of focused hand training (affected or dominant hand) using the Hummingbird device in addition to standard of care inpatient rehabilitation
89035333|NCT04688229|Active Comparator|Comparison (sham) group|10 one-hour sessions of activity focused on playing games or puzzles gaged to the ability of the subject in addition to Standard of care inpatient rehabilitation
89035334|NCT04688073|Experimental|Downhill running|Running at 60% VO2max on -15% slope for 30 min on a treadmill
89035335|NCT04688073|Experimental|Level running|Running at 60% VO2max on level surface for 30 min on a treadmill
89035336|NCT04688073|Placebo Comparator|Control|Rest 30 min
89035337|NCT02937428|Experimental|Look away and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look away from the needle during vaccination
89613415|NCT00980278|Experimental|sinus lift plus BRCs and dental implant|"transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant"
89613416|NCT03344211|Experimental|Arm I (enzalutamide, radium 223)|Patients receive enzalutamide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89613417|NCT03344211|Experimental|Arm II (enzalutamide)|Patients receive enzalutamide as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89688399|NCT03404999|Experimental|clinical decision support activated|"TWO MED ASSIST ALERTS~Enter height (when missing)~Repeat BP (when high)~ONE PROVIDER ALERT~BP high & prior BP/BP%s~Defines elev. BP, HTN stage 1-2 with button to enter diagnosis~Link to tailored ordersets~TAILORED ORDERSETS~Elevated BP~Button to schedule f-up <6 m~Button for diet/lifestyle counseling/check-out instructions~HTN stage 1~Buttons to order labs/studies pre-checked for stage 1 recs~Button for nephrology referral~Button to schedule f-up in 1-2 wk/<1 m~Button for diet/lifestyle counseling/check-out instructions~HTN stage 2~Buttons to order labs/studies for stage 2~Button for nephrology referral (pre-checked)~Button to f-up 1 wk~Button for diet/lifestyle counseling/check-out instruction"
89688400|NCT02791906|Experimental|ISMN Only|Patients receive only ISMN
88985800|NCT03273400|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following the intervention all measure lumbar flexion, hamstring extensibility and sEMG activity will be recorded immediately, 5, 10, 15, 20, 30, 60 minutes post application as a single test."
88985801|NCT03273400|No Intervention|Control|All outcome measures (lumbar/hamstring range of motion; EMG activity of the Biceps Femoris and Erector Spinae) will be measured. The control group will then receive no intervention and be asked to lie supine on a plinth for the treatment duration before having the outcome measures reassessed.
88985802|NCT02956720|Experimental|single arm|
88985803|NCT02956681|Active Comparator|Delayed Intervention Group|In this arm of the randomized delayed intervention control trial, participants randomized to delayed intervention control group were sent a brochure with information on hereditary breast and ovarian cancer and the phone number to call a cancer risk program for free genetic counseling.
88985804|NCT02956681|Active Comparator|Intervention Group|In this arm of the randomized delayed intervention control trial, those randomized to the intervention group were told that because of their family history, we were able to offer them a free genetic counseling appointment.
88985805|NCT02956564|Other|exposure group|subjects in this group are those who accept intrauterine intervention
88985806|NCT02956564|No Intervention|control group|subjects in this group are those who do not accept intrauterine intervention
88985807|NCT03273361|Experimental|Seated|Participants completed work tasks while seated.
88985808|NCT03273361|Experimental|Low Intensity Pedaling|Participants completed work tasks while pedaling at a low intensity.
88985809|NCT03273361|Experimental|Low-Moderate Intensity Pedaling|Participants completed work tasks while pedaling at a low-moderate intensity.
88985810|NCT00462007|Experimental|1|Stalevo
88985811|NCT02956252||Spinal anesthesia group|patients underwent laparoscopic cholecystectomy under spinal anesthesia
88985812|NCT02956252||General anesthesia|Patients underwent laparoscopic cholecystectomy under general anesthesia
88985813|NCT00462241|Experimental|chiropractic treatment|Individualised chiropractic treatment, pragmatic approach
88985814|NCT00462241|Sham Comparator|self-management|Self-management: Minimal intervention - practice as usual.
88985815|NCT04726527||Florbetapir F 18 Recipients|Participants in this arm of the study will receive a 10 mCi (370 MBq) bolus injection of florbetapir F 18 and then be scanned in a PET scanner for brain imaging.
88985816|NCT00462358|Experimental|ARRY-520|
88985817|NCT00462358|Experimental|ARRY-520 + G-CSF support|
88985818|NCT00116181|Experimental|continuous therapy|Subjects will receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24.
88985819|NCT00116181|Active Comparator|intermittent therapy|Subjects who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
88985820|NCT00116129|Placebo Comparator|Placebo|Placebo
88985821|NCT00462553|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28. Treatment repeats every 21 days OR every 28 days in the absence of disease progression or unacceptable toxicity.
88985822|NCT00462592|Active Comparator|1|montelukast - montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
88985823|NCT00462592|Active Comparator|2|budesonide - inhaled budesonide turbuhaler 200ug (& matching placebo) taken 1 puff morning & 1 puff evening.
88985824|NCT00462592|Placebo Comparator|3|placebo
88985825|NCT00462592|Active Comparator|4|montelukast budesonide combination - montelukast 5mg ( < 15 years) or 10 mg (& matching placebo)will be taken 1 tab in the evening together with inhaled budesonide turbuhaler 200 ug (& matching placebo) taken 1 puff morning & 1 puff evening.
88985826|NCT00405015|Experimental|1|Placebo first
88985827|NCT00405015|Experimental|2|Rosiglitazone first
88985828|NCT00462631|Experimental|1|paclitaxel eluting balloon followed by bare metal stent
88985829|NCT00462631|Active Comparator|2|Paclitaxel eluting stent
88985830|NCT00462787|Experimental|Clofarabine|This is a single arm phase I clinical trial to assess safety (morbidity and mortality) of a novel leukemia re-induction regimen. The first component of this trial is a phase I dose escalation study to determine the maximum tolerated dose (MTD) of the novel agent Clofarabine, when used in combination with topotecan, vinorelbine, thiotepa and dexamethasone. A total of three dose levels will be explored in this study.
89035338|NCT02937428|Active Comparator|Look at needle and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look at the needle during vaccination
89035339|NCT02937428|Experimental|Look away and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look away from the needle during vaccination
89035340|NCT02937428|Active Comparator|Look at needle and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look at the needle during vaccination
89035341|NCT02909790|Experimental|CURVE LLLT treatment|Up to 20 subjects are randomly selected to receive Curve Low Level Laser Therapy
89035342|NCT02909790|Sham Comparator|SHAM device treatment|Up to 20 subjects assigned to the sham group will be treated with a device that is designed to have the same physical appearance as the treatment group, except that the interlock fuse (grey fuse holder back of device) will be removed prior to treatment. The laser screen will still be active and show to the subject that the treatment time will still be counting down, but will not activate lasers in the treatment paddles
89035343|NCT01290679|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 24 or 48 weeks
89035344|NCT01290679|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 48 weeks
89035345|NCT03457389|Experimental|Experimental group|Serum prolactin level is adjusted to less than 5 ng/mL during cabergoline administration.
89035346|NCT03457389|Active Comparator|Control group|Serum prolactin level is adjusted to normal range during cabergoline administration.
89035347|NCT02937311|Experimental|NMES group|This group of patients received Neuromuscular Electrical Stimulation (NMES) and standardized physiotherapy and rehabilitation protocol
89035348|NCT02937311|Experimental|Kinesiotape Group|This group of patients received standardized physiotherapy and rehabilitation protocol and at the same time kinesiotape was applied to their affected shoulder
89035349|NCT02937311|Experimental|Control|This group of patients received only a standardized physiotherapy and rehabilitation protocol
89613418|NCT05394454|Experimental|Experimental Group|"Breast milk/formula milk/water intake appropriate for the infant's age and weight will be provided 20-30 minutes before collecting the urine sample.~Before the procedure, the infant's heart rate, saturation and Flacc scale score (by the researcher and the observer nurse) will be recorded.~Genital area will be cleaned.~Infants will be held under the armpit by a parent, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~Infants with spontaneous voiding during the period from the beginning of the research procedure until the infant is positioned will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until micturition begins.~After the maneuvers are started, the infants's heart rate and saturation FLACC pain scale score will be recorded at the 1st and 3rd minutes.~The success of the procedure and the duration of the procedure will be recorded"
89613419|NCT05394454|No Intervention|Control Group|"Breast milk/formula milk/water intake appropriate for the infant's age and weight will be provided 20-30 minutes before collecting the urine sample.~Before the procedure, the infant's heart rate, saturation and Flacc scale score (by the researcher and the observer nurse) will be recorded.~Genital area will be cleaned.~Infants will be held under the armpit by a parent, baby boys will be held with their legs hanging down, and baby girls will be held in hip flexion position.~Infants with spontaneous voiding during the period from the beginning of the research procedure until the infant is positioned will be excluded from the study.~Bladder stimulation technique will not be applied.~Infants will be observed for 3 minutes. Infants's heart rate and saturation FLACC pain scale score will be recorded at the 1st and 3rd minutes.~The success of the procedure and the duration of the procedure will be recorded"
89613420|NCT03274401|Active Comparator|Screening Arm|Screening for atrial fibrillation using a hand-held ECG device (Zenicor intermittent ECG) at least twice daily for two weeks. In patients where AF is detected prolonged OAC therapy will be administered.
89613421|NCT03274401|No Intervention|Control Arm|Standard of care
89613422|NCT05086107|Experimental|Group 1|subjects with mild renal impairment (eGFR: 60 to 89 mL/min)
89613423|NCT05086107|Experimental|Group 2|subjects with moderate renal impairment (eGFRr: 30 to 59 mL/min)
89613424|NCT05086107|Experimental|Group 3|subjects with severe renal impairment (eGFR: 15-29 mL/min)
89035350|NCT02890186|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
89035351|NCT02890186|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
89613425|NCT05086107|Experimental|Group 4|subjects with normal renal function (eGFR: ≥ 90 mL/min)
89035352|NCT02909673|Experimental|Fourth R|Fourth R: 27 lesson curriculum addressing youth risk and health promoting behaviors
89035353|NCT02909673|No Intervention|Control|Control: Treatment as usual (standard health class curriculum)
89035354|NCT02937233|Experimental|4 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4
89035355|NCT02937233|Experimental|2 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2
89035356|NCT02937233|Experimental|Single Vaccination Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only
89035357|NCT02909751|Active Comparator|Neoadjuvant chemotherapy|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv"
89210826|NCT02551172|Placebo Comparator|comparative sequence|Run-in period → Treatment period HGP0816 20mg 1tab Placebo of HCP1105 4capsues +HGP0816 20mg
89210827|NCT00147823|Experimental|Vitoss with bone marrow aspirate|Addition of Vitoss to the bone marrow aspirate
89613426|NCT05086107|Experimental|Group 5|subjects with end stage renal disease (ESRD) eGFR: <15 mL/min requiring dialysis (with BV100 dosing and PK during the dialysis-free interval)
89613427|NCT05086107|Experimental|Group 6|subjects with ESRD (eGFRr: <15 mL/min) requiring dialysis (with BV100 dosing and PK on the day of dialysis)
89613428|NCT05085015|Experimental|Functional Exercise Training Group|A program including stretching, aerobics, strengthening and balance training will be implemented under the supervision of a physiotherapist with the instructions of the physiotherapist.They will apply a total of 24 sessions of exercise program for 60-80 minutes, 3 days a week, 8 weeks.
89613429|NCT05085015|Experimental|Home Exercise Training Group|Individuals in the home exercise training program will be asked to follow the program in accordance with the home exercise brochure given for 8 weeks, 3 days a week. The program will include stretching, aerobics, strengthening and balance training. The home exercise program will consist of a brochure prepared from a program similar to a functional exercise program.
89613430|NCT05075109|Experimental|High Frequency TENS|high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
89613431|NCT05075109|Experimental|Low Frequency TENS|low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks with task related training.
89613432|NCT05075109|Active Comparator|Task Related Training|postural control, shoulder mobilization, weight bearing exercises, functional activities that will comprise of simple tasks to more advanced movement patterns
89613433|NCT01029730|Experimental|Bendamustine/Bortezomib/Rituximab|Treatment for all patients will be given in cycles of 28 days (4 weeks). All patients will receive treatment with bendamustine, bortezomib, and rituximab for a maximum of 6 cycles. Rituximab should be administered first.
89613434|NCT05552235|Experimental|Orthosis group|Use of Elbow Soft 300 device during sport practice
89613435|NCT05552235|Other|Control group|No medical device used during sport practice
89613436|NCT05066997|Experimental|Active treatment arm: OCS-01|"In Stage 1: Active treatment arm: OCS-01 - dosing regimen 1 for 6 weeks followed by dosing regimen 2 for 6 weeks.~In Stage 2, subjects will receive the dosing regimen determined from Stage 1 for OCS-01 for 52 weeks."
89613437|NCT05066997|Placebo Comparator|Vehicle placebo arm|"In stage 1: Vehicle: dosing regimen 1 for 6 weeks followed by dosing regimen 2 for 6 weeks.~In Stage 2, subjects will receive the matched dosing regimen for Vehicle for 52 weeks."
89613438|NCT05345535|Experimental|Study group|Participants of study group will perform 45 minutes of trampoline exercises. Evaluations are going to be done immediately before and after trampoline session.
89613439|NCT05345535|Experimental|Control group|Participants of control group will perform 45 minutes of walking. Evaluations are going to be done immediately before and after walking session.
89613440|NCT03273621||Obese|Patients with a body mass index larger than 35 kg/m2
88985831|NCT03273244||Device monitoring|NeuroSense monitoring and ANI monitoring
88985832|NCT02964156|Experimental|Walking test using insoles|Supersole
88985833|NCT02964156|Experimental|Walking test not using insoles|no intervention
88985834|NCT00463294|Active Comparator|On Pump Arm|
88985835|NCT00463294|Experimental|Off Pump Arm|
88985836|NCT00405054|Other|1|continuous infusion every 14 days
88985837|NCT00463450|Experimental|Arm 1|
89613441|NCT05025033|Experimental|PD-1 antibody combined with apatinib and chemotherapy|PD-1 antibody: 200mg intravenous drip every 3 weeks; Apatinib: 250mg/day; Chemotherapy: Irinotecan: 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel: 150mg/m2, intravenous drip once every 3 weeks.
88985838|NCT00463450|Active Comparator|Arm 2|
88985839|NCT00463489|Active Comparator|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
88985840|NCT00463489|Experimental|Individualized Lifestyle Intervention|Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
88985841|NCT00116402|Active Comparator|1|will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
88985842|NCT00116402|Active Comparator|2|salmeterol 50 mcg BID then crossover to combination therapy with fluticasone 220 mcg BID
89613442|NCT00980746|Experimental|ESL 400 mg BID|ESL 400 mg twice daily (BID)
89613443|NCT00980746|Experimental|ESL 800 mg QD|ESL 800 mg once-daily (QD)
89613444|NCT00980746|Experimental|ESL 600 mg BID|Eslicarbazepine 600 mg twice daily
89613445|NCT00980746|Experimental|ESL 1200 mg QD|Eslicarbazepine acetate 1200 mg once daily
89613446|NCT00980746|Experimental|ESL 800 mg BID|Eslicarbazepine acetate 800 mg twice daily
88985843|NCT03273127|Experimental|Abediterol 5 μg|Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
88985844|NCT03273127|Placebo Comparator|Placebo|Out of 12 randomized patients, 3 will receive placebo as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive placebo QD.
88985845|NCT00116376|Experimental|AEE788 + non EIACD|
88985846|NCT00116376|Experimental|AEE788 + EIACD|
89613447|NCT00980746|Placebo Comparator|Placebo|Placebo
89688401|NCT02791906|Experimental|ISMN AND Vitamin C|Patients receive both ISMN and Vitamin C
89688402|NCT03404921|Experimental|ESTD group|Use tunnelling method during ESD operation
89688403|NCT03404921|Other|ESD group|Use traditional method during ESD operation
89688404|NCT01729715|Experimental|Internet|Internet site that offers parents tips on promoting sleep in infants and toddlers
88815512|NCT05551832|Placebo Comparator|Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months|Placebo beginning day of hospital discharge following PPPD for 6 months
88815513|NCT05551832|Experimental|Esmesol 40mg after PPPD for 6 months|Esmesol 40mg beginning day of hospital discharge following PPPD for 6 months
88815514|NCT03014960|Experimental|Experimental Condition|Online Cognitive Behavioral Therapy for Insomnia Intervention
88815515|NCT03014960|No Intervention|Control Condition|No intervention
88815516|NCT04098224|Experimental|Interventional Device - Treated|Subjects connected to the investigational device smART+
88815517|NCT04098224|No Intervention|Control Group|treated according to local Standard of Care.
88815518|NCT05522426|Experimental|SyntrFuge System|Adipose tissue microsized via the SyntrFuge System
88815519|NCT04079582|Experimental|Higher dialysate magnesium|
88815520|NCT04079582|Active Comparator|Lower dialysate magnesium|
88815521|NCT03987854|Experimental|complete diet and lifestyle program|
88815522|NCT02246504|Experimental|HIFU treatment|use of HIFU treatment in patients with non-malignant thyroid nodules
88815523|NCT02175212|Experimental|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
88815524|NCT02175212|Active Comparator|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy"
88815525|NCT01060592|Experimental|Stoma Adjustment at Surgery|The first band adjustment will be made at surgery versus historical controls where the adjustment is not made for 3-4 weeks post-surgery. EndoFLIP device (FDA Device Listing Number : D091203)will be used to make the adjustment.
88815526|NCT01060592|No Intervention|Historic|Weight loss profile over time for 50 patients in the first 12 months after surgery as derived from historic control records. Band adjustments are made in a heuristic fashion during the year after surgery using the experience of surgeon alone
88815527|NCT03014882|Other|Antioxidant treatment|
88815528|NCT02171234|Experimental|Group 1- 200 mg b.i.d. (twice daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
88815529|NCT02171234|Experimental|Group 2 - 400 mg b.i.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
88815530|NCT02171234|Experimental|Group 3- 800 mg o.d. (once daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
88815531|NCT02171234|Experimental|Group 4 - either 800 mg b.i.d or 1200 mg o.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
88815532|NCT01061528|Experimental|New Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
88815533|NCT01061528|Active Comparator|Standard Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
88815534|NCT03016286|Experimental|WBV group|whole-body vibration (WBV) group
88815535|NCT01062074||Korean Participants Vaccinated with GARDASIL|Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.
88815536|NCT01062230|Experimental|All patients|All participants enrolled.
88815537|NCT01062308|Experimental|Taping|The tri-pull method of taping was used.Taping was initiated by first applying three, two-inch wide and approximately ten-inch long, pieces of elastic adhesive tape strips. The first strip was applied from the mid-humerus deltoid tuberosity across the scapula. The second strip was applied from the deltoid tuberosity across the clavicle to the mid-clavicle, but before the supra-sternal notch. The third strip was placed from the deltoid tuberosity over the acromion process to the neck.
88815538|NCT01062308|Active Comparator|Sham Taping|This was done using the same tapes. Three strips of tapes were applied in same position without repositioning the joint. All other Physiotherapy measures like positioning, handling technique and range of motion exercises were equally done for both the groups.
88815539|NCT01063712|Other|Nit-Occlud PDA-R|Interventional, prospective clinical study, non randomized.
88815540|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.005%|bimatoprost ophthalmic sterile solution 0.005%
88815541|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.015%|bimatoprost ophthalmic sterile solution 0.015%
88815542|NCT01064882|Active Comparator|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03%
88815543|NCT01065428||Weaning failure|Weaning failure:(1) failed SBT; (2) reintubation and /or resumption of support following successful extubation; or (3) die 48h following extubation.
88815544|NCT01065428||Weaning successful|Weaning successful:extubation and the absence of ventilatory support 48 h following the extubation
88815545|NCT01065506|Active Comparator|Standard Care plus Wellness Program|
88815546|NCT01065506|Active Comparator|Standard Care plus Exercise Program|
88815547|NCT03817736|Experimental|START-FIT|"Single group assignment combining TACE and SBRT with immune checkpoint inhibitor as treatment in HCC patients.~Procedure of TACE will be standardized.~SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.~An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons."
88815548|NCT01066364|Placebo Comparator|Placebo (sugar) pill|Six tablets per day (identical to colesevelam)
88815549|NCT01066364|Experimental|Colesevelam arm|3.75 grams per day
88815550|NCT01066520|Experimental|Traumeel S ointment|Traumeel S ointment 2 g, 3 times daily topical during 14 days
88815551|NCT01066520|Experimental|Traumeel S gel|Traumeel S gel 2 g, 3 times daily topical during 14 days
89613448|NCT05424783|Experimental|Genomic Prostate Score assay and multi-parametric MRI of the prostate|Men with newly diagnosed NCCN very low to favorable intermediate risk prostate cancer will be enrolled at their post biopsy urologist visit. Once enrolled, participants will have their prostate tissue sent off for their Genomic Prostate Score assay and men will undergo a prostate MRI to evaluate for potentially missed clinically significant prostate cancer. In a subsequent urologist visit, participants will choose their treatment choice. Men who choose active surveillance for their primary treatment choice will be monitored per clinical routine by PSA, digital rectal exam, and active surveillance prostate biopsy in 12-18 months. After month 6, men will be followed through their electronic medical records system to track adherence to their 12-18 month active surveillance prostate biopsy.
89613449|NCT02984631|Other|Preventing pulm HTN during exercise 2nd|Standard of care invasive cardiopulmonary exercise test (CPET) followed by CPET with pre-load control.
89613450|NCT02984631|Other|Preventing pulm HTN during exercise 1st|Pre-load control of invasive cardiopulmonary exercise test (CPET) followed by standard CPET.
89613451|NCT05201157|Active Comparator|Acupressure group|Acupressure will be applied to ST36, LI4 and SP6 points.The Introductory Information Form will be filled in by the researcher and the Visual Similarity Scale for Fatigue will be filled by women once on the post-op 0th day and once on the post-op 2nd day, a total of 2 times.
89613452|NCT05201157|Active Comparator|Control Group|No application will be made to this group, and the Introductory Information Form will be filled in by the researcher and the Visual Similarity Scale for Fatigue will be filled in 2 times in total, once on the post-op 0th day and once on the post-op 2nd day.
89613453|NCT00981214|Experimental|EUR-1008 (APT-1008)|
89613454|NCT03308565|Experimental|Phase I|Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
89613455|NCT01031134|Experimental|Shared Decision Making|1 in person session followed by 2 telephone calls 1 and 2 weeks later.
88985847|NCT04697914|Placebo Comparator|Control Sock|Control comercial Socks (Lurbel Tierra). These socks are designed to perform trekking.
88985848|NCT04697914|Experimental|Experimental Relief Pressure sock|Experimental Socks (Lurbel Tierra based), with a discharge element (in the own fabric and fibres of the sock).
88985849|NCT04697680|Active Comparator|Group 1|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 1) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
88985850|NCT04697680|Active Comparator|Group 2|Subjects randomized into Group 2 will be provided with a sleep schedule each week based on an algorithm (Algorithm 2) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
88985851|NCT04697680|Active Comparator|Group 3|Subjects randomized into Group 1 will be provided with a sleep schedule each week based on an algorithm (Algorithm 3) calculated from sleep diaries and fitbit data. Subjects will complete questionnaires at an initial clinic visit. Subjects will then complete a sleep diary upon waking each day and wear a Fitbit Charge 2 device for sleep monitoring each day for 8 weeks. At the end of the study, subjects will complete follow-up questionnaires at a final clinic visit.
88985852|NCT00116480|Experimental|Misoprostol|three tablets of active misoprostol (600 mcg) given sublingually
88985853|NCT00116480|Placebo Comparator|Placebo|three tablets resembling misoprostol given sublingually
88985854|NCT00116454|Experimental|lipiocis group|intra-arterial hepatic administration, one 2200 MBQ dose, duration of treatment 1 week
88985855|NCT00116454|No Intervention|control group|group untreated
88985856|NCT04697836|Experimental|ST (superficial cervical plexus block combined with Translareyngeal block)|Superficial cervical plexus block combined with Translareyngeal block Group.
88985857|NCT04697836|Active Comparator|S (superficial cervical plexus block)|Superficial cervical plexus block Group
88985858|NCT00464113|Experimental|1|once-weekly dosing
88985859|NCT00464113|Experimental|2|twice-weekly dosing
88985860|NCT03273010|Experimental|Periacryl group|Periacryl, a tissue adhesive, was applied on wound surfaces to achieve haemostasis
88985861|NCT03273010|Active Comparator|Control group|Free gingival graft was harvested from palatal region and left to heal without applying periacryl.
88985862|NCT00464386|No Intervention|POC Glucose Testing|Hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
88985863|NCT00464386|Experimental|Continuous Glucose Monitoring|Continuous arterial glucose monitoring with Guardian sensor + hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
88985864|NCT00116493|Other|1|Standard of care (Iron-folic acid + Deworming)
88985865|NCT00116493|Experimental|2|
88985866|NCT00116493|Experimental|3|
88985867|NCT00116493|Experimental|4|
88985868|NCT00464425|Experimental|Electroacupuncture (EA)|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
88985869|NCT00464425|Sham Comparator|Sham Acupuncture (SA)|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
88985870|NCT00464425|No Intervention|No Acupuncture (NA)|Control
88985871|NCT03272971|Experimental|Radio-frequency Ablation|Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.
88985872|NCT04726488|Experimental|Periareolar Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
89210828|NCT00147823|Active Comparator|Vitoss Alone|vitoss alone
89210829|NCT00929058|Experimental|Bevacizumab|
89613456|NCT01031134|Active Comparator|Usual Care|Physician Usual Care of depressed patients.
89613457|NCT05415657|Experimental|Denosumab|Denosumab 60 mg were injected subcutaneously Q6M on the same day after lumbar fusion surgery, and all patients received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
89613458|NCT05415657|Placebo Comparator|Placebo|Equal volume of saline (0.9%) as placebo were injected subcutaneously Q6M on the same day after lumbar fusion surgery, and all patients received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
89613459|NCT03016234|Active Comparator|Desflurane|inhalation anesthesia administration for maintenance of anesthesia
89613460|NCT03016234|Active Comparator|Propofol|intravenous anesthesia administration for maintenance of anesthesia
89613461|NCT03695679|Experimental|Intervention group|Interactive computer-based intervention
89613462|NCT03695679|No Intervention|Control group|An one-page online information about procedures and tips of condom use with minimal intervention
89613463|NCT04353388||CBC-Diff Monocyte Volume Width Distribution|Monocyte Volume Width Distribution (MDW) is part of the CBC with Differential
89613464|NCT01031914|Experimental|Paced Breathing Sleep/Wake detection|All subjects enrolled will have oobstructive sleep apnea (OSA) and will be current Continuous Positive Airway Pressur (CPAP) users.
89613465|NCT05404893||Fibromyalgia without gastrointestinal symptoms|Patients diagnosed as having Fibromyalgia according to american college of rheumatology 2016 classification criteria, with no abdominal pain, constipation, diarrhea, tenesmus, abdominal cramps
89613466|NCT05404893||Fibromyalgia with gastrointestinal symptoms|Patients diagnosed as having Fibromyalgia according to american college of rheumatology 2016 classification criteria, with abdominal pain and constipation and/or diarrhea and/or tenesmus and/or abdominal cramps
89613467|NCT05404893||Healthy controls|Healthy controls, no gastrointestinal symptoms
89613468|NCT02167204|Experimental|Diagnostic (18F-FLT PET/CT)|Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.
88985873|NCT04726488|Active Comparator|Inframammary Approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
88985874|NCT00464659|Experimental|Effective CPAP treatment|Effective Continuous Positive Airway Pressure treatment (CPAP) applied for 6 weeks
88985875|NCT00464659|Sham Comparator|Sham CPAP treatment|Ineffective Continuous Positive Airway Pressure treatment (sham CPAP) applied for 6 weeks
88985876|NCT00464776|Experimental|1|Various sequences of 3 doses of Aliskiren plus placebo
88985877|NCT00464776|Experimental|2|Various sequences of 3 doses of Aliskiren plus placebo
88985878|NCT00464776|Experimental|3|Various sequences of 3 doses of Aliskiren plus placebo
88985879|NCT00464776|Experimental|4|Various sequences of 3 doses of Aliskiren plus placebo
88985880|NCT03272815|Experimental|PD arm|Patients undergoing assessment of the chest with the percussion device (PD).
88985881|NCT03272815|Active Comparator|US arm|Patients undergoing assessment of the chest with the ultrasound (US).
88985882|NCT00116714||Observation|
88985883|NCT00464893|Active Comparator|catumaxomab arm|Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
88985884|NCT00465049|Experimental|primary closure|suture after I&D
88985885|NCT00465049|Placebo Comparator|SECONDARY CLOSURE|LEAVE TO HEAL BY SECONDARY INTENTIN AFTER I&D
89210830|NCT00925314|Experimental|Transgenic Lymphocyte Immunization|Open Label, Single Arm
89613469|NCT05538585|Experimental|Part 1: Navocaftor with food|Participants will receive navocaftor administered with food
89613470|NCT05538585|Experimental|Part 1: Navocaftor without food|Participants will receive navocaftor administered without food
89613471|NCT05538585|Experimental|Part 2: Galicaftor with food|Participants will receive galicaftor administered with food
89613472|NCT05538585|Experimental|Part 2: Galicaftor without food|Participants will receive galicaftor administered without food
89613473|NCT00982072|Active Comparator|prednisolone|prednisolone tablets
89613474|NCT00982072|Experimental|tacrolimus|tacrolimus tablets
89613475|NCT05343195|Active Comparator|Control group|"Conventional physiotherapy was applied 5 days/ week, 30 min session, in total 18 days.~Exercise program:~1-2 week: 20 min. of active exercise in lying position (e.g.: hip flexion, extension, abduction) with the goal to improve hip range of motions, strengthen muscles. Various equipment was used (slippery base, elastic bands, foam roller, gymnastic ball etc.). + gait training exercise within the bars (10 min);~3 week: 20 min. of active exercise in lying position + stationary bicycle / treadmill (10 min)."
89688405|NCT01729715|Experimental|DVD|DVD that offers parents tips on promoting sleep in infants and toddlers
89688406|NCT01729715|No Intervention|No treatment|
88985886|NCT00465166||1|Patients who had a documented, accidental dural puncture during placement of their labor epidural.
88985887|NCT03272659|Experimental|Blue Light Cystoscopy with Cysview®|"The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy.~Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard."
88985888|NCT00465205|Experimental|I|
88985889|NCT00465244|Experimental|1|Levetiracetam 1 g IV + Lorazepam 2 mg IV
88985890|NCT00465244|Other|2|Placebo + Lorazepam 3 mg IV
88985891|NCT00465283|Active Comparator|Donepezil|
88985892|NCT00465283|Placebo Comparator|placebo|
88985893|NCT04726371|Active Comparator|Generic Best Practices (GBP)|The ~200 group homes randomized into this arm will receive the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consists of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings.
88985894|NCT04726371|Experimental|Tailored Best Practices (TBP)|The ~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents.
89210831|NCT00822146|Experimental|1|
89035358|NCT02909751|Experimental|Neoadjuvant chemotherapy + tocotrienol|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3"
89035359|NCT02936921||Pergravidic maternal infections|proven maternal infections: true seroconversions of profiles of recent infections
89035360|NCT02936921||Subjects free of congenital infection|children who whom all tests performed before birth, at birth and after birth confirmed the absence of congenital toxoplasmosis.
89035361|NCT02936921||Congenitally infected subjects|children for whom at least one test performed before birth, at birth or after birth demonstrated a congenital infection.
89035362|NCT02909829|Experimental|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
89035363|NCT02909829|Experimental|Closed Loop Delivery with Meal Detection Module|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
89035364|NCT02909829|Active Comparator|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate. Participants will eat breakfast and bolus as per usual, then eat lunch and not bolus.
89035365|NCT02909712|Active Comparator|sulfadoxine-pyrimethamine (SP)|"Group 1 (50 CareStart™ RDT-positive women)~Group 2 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy and molecular analysis, and receive SP on day 0. On days 7, 14, 21, and 28 women will provide blood for microscopy and molecular analysis."
89035366|NCT02909712|Experimental|dihydroartemisinin-piperaquine (DHA-PQP)|"Group 3 (50 CareStart™ RDT-positive women)~Group 4 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy, molecular, and PK analysis, and receive DHA-PQP day 0. On day 1, women will receive dose 2. On day 2, women will have an ECG exam, begin Holter monitoring, provide blood for PK analysis, and receive dose 3. Blood for PK analysis will be drawn at 4, 5, and 6 hours following dose 3. An ECG exam will be conducted during this period and, again, on day 7. On days 7, 14, 21, and 28, women will provide blood for microscopy and molecular analysis."
89035367|NCT02937038||Healthy Kids 3-13 y|Healthy boys and girls of 3-13 y of age
89035368|NCT02937038||Parents 20-50 y|One of their Parents 20-50 y of age
89035369|NCT02913885|Active Comparator|Group 2|curodont repair is a biomimetic regeneration scaffold for remineralization
89035370|NCT02913885|Experimental|Group 1|fluoride varnish inhibit progression of white spot lesion
89035371|NCT01290601|Experimental|Cohort 1 Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
89035372|NCT01290601|Active Comparator|Cohort 1-Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
89035373|NCT01290601|Experimental|Cohort 2 Tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
89035374|NCT01290601|Active Comparator|Cohort 2 Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
89035375|NCT02978391|Experimental|UI-EWD Hemostatic system|Patients with upper gastrointestinal bleeding treated with UI-EWD
89035376|NCT02978391|Active Comparator|epinephrine|Patients with upper gastrointestinal bleeding treated with submucosal epinephrine injection
89035377|NCT01290523|Experimental|Yttrium-90 liver radioembolization|Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)
89035378|NCT02936882|Other|Preoperative gastric ultrasonography|
89035379|NCT01290094|Experimental|Single Arm|
89035380|NCT04688346|Placebo Comparator|Control|Saline Pellet
89613476|NCT05343195|Experimental|Task oriented exercise group|"Task oriented exercise program was applied 5 days/ week, 30 min session, in total 18 days.~Exercise program included:~1 week: active exercise in lying position (15 min) + task-oriented exercise (15 min);~2 week: active exercise in lying position (10 min) + task-oriented exercise (20 min);~3 week: stationary bicycle / treadmill (10 min) + task-oriented exercise (20 min).~Task oriented exercise included:~walking backwards, sideways, high kneels (on the instable bases);~walking with alternate speed (physiotherapist give the instruction when to walk faster / slower);~Sit and stand from the chair (standing up to reach for the ball held by the physiotherapist);~step onto the step (after stepping to reach the ball held by the physiotherapist);~walk with the obstacles (obstacle course);~Catch and throw the ball while standing on an unstable base."
89613477|NCT01899053|Experimental|Dose Escalation Treatment Arm A|TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.
89613478|NCT01899053|Experimental|Dose Escalation Treatment Arm B|TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.
89035381|NCT04688346|Experimental|Intervention|Racemic Epinephrine Pellet
89035382|NCT02936765|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
89035383|NCT02936765|Active Comparator|Squale|Patients, who receive Squale (TM) as cervical disc prosthesis after ventral discectomy.
89035384|NCT04324333|Experimental|Using Digital wearable system for fall detection|Digital wearable system (Owlytics Healthcare's app) enables a 24/7 health-tracking service, collecting personal health data from wearable wristbands and insoles. The data is analyzed by machine-learning algorithms that can detect abnormal physiological patterns. This allows the prediction and prevention of potentially harmful health events (such as falls).
89035385|NCT04688268||deep neuromuscular blockade|patients who underwent surgery with deep neuromuscular blockade
89035386|NCT02936726|Active Comparator|Exercise and Health Coaching|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)"
89035387|NCT02936726|Experimental|Exercise, Health Coaching and Meditation|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)~Mindfulness Meditation intervention will incorporate varied types of MBI techniques 3 times per week for 12 weeks, during work hours and/or during their time on campus (after work hours)."
89035388|NCT02913846||Hospital revalidation units|The study will take place within the CHU Brugmann hospital (Brussels) who has 4 revalidation units (104 beds). All patients coming within these units during the study duration will be included.
89035389|NCT04762589|Experimental|RT001|RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
89035390|NCT04762589|Placebo Comparator|Placebo|Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
89035391|NCT01289821|Experimental|Regorafenib + oxaliplatin/folinic acid/5-FU (mFOLFOX6)|On Day 1, participants received 85 mg/m^2 oxaliplatin as a 2-hour intravenous (IV) infusion and folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2-hour IV infusion. Once the initial infusion was completed, participants received 5-FU 400 mg/m^2 IV bolus injection immediately followed by a 5-FU 2400 mg/m^2 IV infusion for 46 hours. The next cycle of mFOLFOX6 was administered on Day 15 to 17. Participants received Regorafenib (Stivarga, BAY73-4506) 160 mg orally (po) once daily (qd) on Days 4 to 10 and Days 18 to 24. One cycle comprised 28 days.
89035392|NCT02913768|Active Comparator|Ondansetron|Intravenous Ondansetron 4 mg diluted in 10 mL of normal saline over 1 min, 5 min before spinal anaesthesia
89035393|NCT02913768|Placebo Comparator|control|Normal Saline 10 mL over 1 min, 5 min before spinal anaesthesia
89035394|NCT03457844|Experimental|Anlotinib|
89035395|NCT03457805|Other|Prostatic Artery Embolization (PAE)|PAE performed under local anesthesia using officially approved microspheres.
89035396|NCT04690283|Placebo Comparator|Placebo-control group|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and placebo treatment twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
89035397|NCT04690283|Experimental|Treatment group I|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Huangqi Guizhi Wuwu granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
89035398|NCT04690283|Experimental|Treatment group II|Subjects will receive FOLFOX4 or mFOLFOX6 or XELOX chemotherapy regimen and orally take Danggui Sini granules twice a day (1/2 bag, morning and evening) for at least three months and one year follow up.
89035399|NCT02936804|Experimental|Screening Arm|Low Dose Computed Tomography (LDCT) was performed at baseline + 2 rounds of biennial repeated LDCT. Management of positive screening test will be carried out by a pre-specified protocol.
89035400|NCT02913807|Placebo Comparator|Traditional Reconstruction|This cohort will be reconstructed using hand contoured osteotomies and reconstruction bars
89035401|NCT02913807|Experimental|Computerized Custom|This cohort will be reconstructed using customized computer-modeled titanium locking customized jigs and plates for the osteotomies.
89035402|NCT02936570|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89035403|NCT01289782|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
89035404|NCT01289782|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks
89035405|NCT02913417|Experimental|hepatic radiation followed by immunotherapy|SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 weeks until progression or 3 years
89035406|NCT02936492|Experimental|BAY1003803|Topical treatment: dose escalating in 9 steps from 0.13 mg to 61.7 mg per subject
89035407|NCT02936492|Placebo Comparator|Placebo|Topical treatment using matching amount of placebo
89035408|NCT02936492|Active Comparator|Clobetasol propionate|Topical treatment using 16.5 mg of clobetasol propionate per subject
89210832|NCT00816998|Other|Early|Participants randomized to this arm will begin physical therapy of their fractured wrist approximately one week following surgery
89613479|NCT01899053|Experimental|Dose Escalation Treatment Arm C|TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.
89613480|NCT01899053|Experimental|Drug-Drug Interaction (DDI) Expansion Cohort|TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.
89613481|NCT01032538||Patients with knee osteoarthritis|Patients with knee osteoarthritis that are about to get an operation with oxford unicondylar knee
89613482|NCT05396235|Experimental|MT-3921|Intravenous (IV)
89613483|NCT05396235|Placebo Comparator|Placebo|Intravenous (IV)
89613484|NCT01032694||Z-max treated group|Patients with Community-Acquired Pneumonia
89035409|NCT02913573|Experimental|GA + Pec Block|Following induction of general anesthesia, the patients in the intervention group will undergo an ultrasound-guided pectoral block. With the patient in proper position, the infraclavicular and axillary regions are prepped with chlorhexidine. An US probe is placed below the third of the clavicle over the pectoralis major muscle. After identifying the appropriate anatomical structures, a 21-gauge echogenic needle is advanced under US visualization to the tissue plane between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie and 15 mL of 0.25% bupivacaine will be deposited. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
89613485|NCT01032694||Amoxiclav treated group|Patients with Community-Acquired Pneumonia
89613486|NCT01032850|Experimental|Arm 1: Sorafenib & Capecitabine|Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400mg) Capecitabine twice a day by mouth (850mg)
89613487|NCT04399707|Active Comparator|Active TENS Unit|
89035410|NCT02913573|No Intervention|GA only|Patients will receive standard general anesthesia.
89035411|NCT01289353|Experimental|ChemoRT|Concurrent Carboplatin and Radiotherapy
89035412|NCT02936531||FXTAS|Patients positive for FMR1 premutation and meet diagnostic criteria for FXTAS
89035413|NCT02936531||FMR1 premutation asymptomatic|Patients positive for FMR1 premutation and do not meet diagnostic criteria for FXTAS
89035414|NCT02913651||Idiopathic hypersomnia|Drug-free patients diagnosed with idiopathic hypersomnia from 01/01/11 to 15/09/15
89035415|NCT02913651||Controls|Patients with no sleep complaints, having a 24-h ambulatory ad libitum polysomnography
89035416|NCT02936414|Experimental|Berberine group|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
89035417|NCT02936414|Placebo Comparator|Placebo group|Accept placebo(300 mg/tid)+SGAs monotherapy.
89035418|NCT02913300|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
89035419|NCT02913300|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
89613488|NCT04399707|Placebo Comparator|Placebo TENS Unit|
89613489|NCT04399707|No Intervention|No TENS Unit|
89613490|NCT05390944|Experimental|IMP4297 first 5*20mg then 10*10mg|Single oral dose of IMP4297 administered under fasting conditions 5*20 mg capsules in first intervention period and 10*10 mg capsules in second intervention period (after washout period: at least 7 days)
89613491|NCT05390944|Experimental|IMP4297 first 10*10mg then 5*20mg|Single oral dose of IMP4297 administered under fasting conditions 10*10 mg capsules in first intervention period and 5*20 mg capsules in second intervention period (after washout period: at least 7 days)
89613492|NCT04911309|Active Comparator|Group 1: 12 weeks functional exercise training followed by standard therapy|"12 weeks functional exercise training twice per week, each session lasting 60 min, additionally to standard therapy. Training sessions will be performed in a group-setting consisting of minimum 4 and maximum 8 participants and coached by experienced sport scientists with the supervision of a medical doctor. The exercises will be individually pants and constantly recorded in order to allow a progression over the course of the 12 week-period. The motor tasks and exercises will be tailored to individual capacity by experienced and trained sport scientists and coaches, therefore insuring the participants' safety and a continuous and progressive monitoring of training load.~After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks."
89613493|NCT04911309|Active Comparator|Group 2: 12 weeks standard therapy / treatment followed by 12 weeks functional exercise training|"12 weeks standard therapy / treatment; the standard therapy group receives no additional exercise sessions. After 12 weeks the groups will switch the intervention method. Group 1 will therefore reassume their standard therapy for 12 weeks.~After 12 weeks the groups will switch the intervention method. Group 2 will perform the same intervention which Group 1 received over the first course of 12 weeks."
89613494|NCT04909437|Experimental|Mycobiotic group|
89613495|NCT04909437|Placebo Comparator|Placebo group|
89613496|NCT01032928|Experimental|Respiratory Phase Training|Chronically dysphagic, medically stable patients at least 6 months post treatment for head and neck cancer with non-optimal respiratory-swallowing patterns participated in up to 8 sessions of respiratory phase training to learn an optimal respiratory - swallow phase pattern
89613497|NCT04278261|Experimental|Focal therapy|Using focal therapy(high-frequency Irreversible electroporation) to treat patients with localized Prostate cancer
89613498|NCT04278261|Active Comparator|Radical prostatectomy|Using laparoscopic radical prostatectomy to treat patients with localized Prostate cancer
89613499|NCT00983242|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
89613500|NCT00983242|Experimental|Colchicine with Verapamil HCl ER|colchicine pharmacokinetics in presence of steady-state verapamil
89613501|NCT04278105|Experimental|HD-tCES & upper extremity rehabilitation|The experiment group will receive HD-tCES combined with upper extremity rehabilitation of affected side.
89613502|NCT04278105|Sham Comparator|Sham HD-tCES & upper extremity rehabilitation|The sham control group will receive sham HD-tCES combined with upper extremity rehabilitation of affected side.
89035420|NCT02936375|Experimental|Iguratimod|Patients will receive iguratimod over the whole follow-up, combined with steroids, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
89035421|NCT02936375|Active Comparator|Cyc+AZA|Patients will receive cyclophosphamide in the first half of study (usually to 24 weeks), followed with azathioprine till the end of follow-up. Patients will also receive steroids as combinational therapy, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
89035422|NCT02913690|Placebo Comparator|Control group|Control group will be supplemented with placebo for 12 months.
89035423|NCT02913690|Active Comparator|Intervention group|The intervention arm will be supplemented with TRF for 12 months.
89035424|NCT01289119|Placebo Comparator|Placebo|Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
89035425|NCT01289119|Experimental|Alogliptin Monotherapy|Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
89035426|NCT01289119|Other|Metformin|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
89613503|NCT04278027|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy. CRT will be based on CIRCuiTS, a computerized program.
89613504|NCT04278027|No Intervention|Treatment as usual|Treatment as usual
89613505|NCT00984334|Placebo Comparator|Capsules with no active drug|Placebo capsules once daily for three weeks then twice daily for three weeks.
89613506|NCT00984334|Active Comparator|Naloxone SR 2.5 mg capsules|Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
89613507|NCT00984334|Experimental|Naloxone SR 10mg capsules|Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
89613508|NCT00984334|Experimental|Naloxone SR 20 mg capsules|Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
89613509|NCT00984334|Experimental|Naloxone SR 5mg capsules|Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
89613510|NCT02168062|Active Comparator|Arm I (standard of care)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
89613511|NCT02168062|Experimental|Arm II (STAND clinic)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
89613512|NCT05334459||Intervention|"Operable, postmenopausal ER/PR positive and Her2 neu (-), oligometastatic dnMBC patients~Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc)~o ER / PR /Her2 /Ki67 study~Collection of CTC.~Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~o Denosumab, Biphosphonate for bone metastasis~RT to metastatic side (if visible). Continue Systemic therapy~12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~ST will be continued until progression and/or unmanageable toxicity.~Radiologic evaluation every 3-6-month based on institutional practice."
89613513|NCT03304587|Experimental|Arm 1: Bright blue-green light|"Bright blue-green light (~515nm; 12,000 lux) for 30 minutes once a day.~For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory~On 2 randomly selected days, the participants will wear a light meter during wake time"
89613514|NCT03304587|Active Comparator|Arm 2: Dim red light|"Dim red light (5 lux) (control group) for 30 minutes once a day.~--For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory --On 2 randomly selected days, the participants will wear a light meter during wake time"
89613515|NCT04352920|Experimental|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
89613516|NCT01888367|Experimental|DFA-02 Antibiotic Gel|Up to 20 mL of DFA-02 antibiotic gel will be placed in the surgical incision after closure of the fascia and before skin closure.
89613517|NCT01888367|Placebo Comparator|DFA-02 Placebo Gel|Up to 20 mL of DFA-02 placebo gel will be placed in the surgical incision after closure of the fascia and before skin closure.
89613518|NCT01888367|No Intervention|Standard of Care|Prior to final closure of the surgical incision, the incision will be irrigated with normal saline and no gel will be applied.
89613519|NCT00988000|Other|Agree to the alternative study invitation|Agree with alternative of telephone consultation (instead of face to face) offered as an initial consultation to new referrals
89613520|NCT00988000|Other|Decline the alternative study invitation|Decline, no respond to the alternative of telephone consultation
89613521|NCT00988000|Other|Comparator|Choose and book
89613522|NCT05343117||Palbociclib based-therapy as initial endocrine therapy|Adult patients with HR+/HER2- advanced breast cancer who received palbociclib based-therapy as initial endocrine therapy from August 1, 2018 to December 31, 2023.
89613523|NCT05343117||Palbociclib based-therapy after chemotherapy|Adult patients with HR+/HER2- advanced breast cancer who received palbociclib based-therapy after chemotherapy from August 1, 2018 to December 31, 2023.
89613524|NCT01898195|Active Comparator|Standard Care|Participants in this arm will receive varenicline for smoking cessation.
89613525|NCT01898195|Experimental|Standard Care + Text message|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.
89613526|NCT01898195|Experimental|Standard Care + Text Message + ABT|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions
89613527|NCT04348071|Experimental|Ruxolitinib|This study is an Adaptive Phase 2/3 trial designed to test the safety (Phase 2) and efficacy (Phase 2 and 3) of ruxolitinib to treat COVID-19. Phase 2 consists of a single-arm, open-label assignment of 20 participants receiving 10 mg ruxolitinib twice daily for 14 days. Phase 3 consists of a single-arm, open-label assignment of 60 additional participants receiving ruxolitinib at the same dose. In both phases, participants will be monitored daily while hospitalized for 29 days, or until discharge, whichever occurs first. Participants who are discharged will be followed up with via phone on Day 15 and Day 29.
89613528|NCT05242666|Other|DCM1: MRI Spinal Cord|3T MR Imaging of the cervical spinal cord, before and at 3-6 months after surgery.
89613529|NCT05242666|Other|DCM2: MRI Brain and Spinal Cord|3T MR Imaging of the brain and cervical spinal cord, before and at 3-6 months after surgery. A subset will also be invited to undergo 7T MRI Brain and Spinal Cord Imaging.
89035427|NCT01289119|Experimental|Metformin + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
89035428|NCT01289119|Other|Pioglitazone|Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
89035429|NCT01289119|Experimental|Pioglitazone + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
89035430|NCT02936336|No Intervention|Control|without exercise intervention
89035431|NCT02936336|Experimental|Exercise|Subjects with circuit exercise, aerobic dance, or Tai Chi exercise intervention.
89035432|NCT02913378|Experimental|Locking plate|Surgical treatment with open reduction and osteosynthesis with locking plate
89035433|NCT02913378|Active Comparator|Conservative|Conservative treatment with sling and rehabilitation
89035434|NCT02936141|Experimental|Group psychotherapy|Group psychotherapy sessions includes the following: training of social skills (such as communication, social interaction and assertive behaviors), cognitive stimulation and training of activities of daily living (such as personal hygiene, hygiene of spaces and standardized mealtimes)
89035435|NCT02913339|Experimental|Intervention|Community health workers (CHWs) will conduct screening for CVD risk using a mobile phone application to assess risk and to schedule appointments at primary care centers (PCCs). The screening process will be non-invasive and no surgical, pharmaceutical, or other testing procedures will be utilized for screening of CVD risk by CHWs. If the CHW calculates the risk of CVD to be > 10%, s/he will schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment. An automatic reminder messaging system will send reminder messages about upcoming appointments to the participants.
89035436|NCT02913339|Active Comparator|Control|"The protocol will be identical to that implemented in the intervention arm with the following difference:~If the CHW calculates the risk of CVD to be > 10%, s/he will verbally advise the study participant of her/his increased risk and recommend that s/he schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment."
89035437|NCT02936180|Active Comparator|Standard dose influenza vaccine|Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
89035438|NCT02936180|Active Comparator|High dose influenza vaccine|Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
89035439|NCT01289041|Experimental|All Patients|
89035440|NCT02913183|Experimental|young Fresh Frozen Plasma|"Drug: young plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~Drug: young plasma exchange over a course of 3 consecutive days after stroke onset."
89613530|NCT05242666|Other|DCM3: [11C]-PIB MR/PET Cervical Spinal Cord|[11C]PIB PET/MR Imaging of the cervical spinal cord, before and at 3-6 months after surgery.
89613531|NCT05242666|Other|Healthy Volunteer: MRI Brain and Spinal Cord|Age-Matched Healthy Controls will undergo MRI Brain and Spinal Cord. A subset will also be invited to undergo interval imaging at 3-6 months.
89613532|NCT03696927|Experimental|User Focus Group Participants|Target user population will be human subjects with spinal cord injury at levels C3 to C5, and ASIA Impairment Scale (AIS) A, B, or C.
89613533|NCT01897727|Active Comparator|Spironolactone|Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP > 140/90 mm Hg throughout the 3 month study.
89035441|NCT02913183|Placebo Comparator|old Fresh Frozen Plasma|"Old plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~Old plasma exchange over a course of 3 consecutive days after stroke onset.~Patients will receive usual care and drug use in hospital."
89035442|NCT01288729|Experimental|Group 1 - Steel Cathetar, then Teflon|Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.
89035443|NCT01288729|Experimental|Group 2 - Teflon Cathetar, the Steel|Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
89035444|NCT02936258|Other|MRI|Men in Arm A will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI. The unbiopsied men will have a repeat MRI at 2 years.
89035445|NCT02936258|Active Comparator|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
89035446|NCT01288612|Active Comparator|Sedated Endoscopy|Sedated esophagogastroduodenoscopy with biopsy
89035447|NCT01288612|Active Comparator|Transnasal Endoscopy at Hospital Unit|Unsedated transnasal endoscopy at hospital unit.
89035448|NCT01288612|Active Comparator|Transnasal Endoscopy at Mobile Unit|Unsedated transnasal endoscopy in mobile research van
89035449|NCT02913027|No Intervention|Observational|ARM: Normal Pelvic Exam Exposures: External Exam followed by speculum exam, followed by bimanual exam
89035450|NCT02913027|Active Comparator|Experimental Pelvic Exam|Arm: Changing the order of Pelvic Exam Intervention: External exam, Bimanual Exam, Speculum Exam
89613534|NCT01897727|Sham Comparator|Standard of care BP treatment|Antihypertensive medication added and/or uptitrated to keep BP < 140/90 mm Hg throughout the study.
89613535|NCT04352998|Active Comparator|One dose pre-workout supplement condition|One dose/serving of a multi-ingredient pre-workout supplement was administered to the subjects.
89613536|NCT04352998|Active Comparator|Two dose pre-workout supplement condition|Two doses/servings of a multi-ingredient pre-workout supplement was administered to the subjects.
89613537|NCT04352998|Placebo Comparator|Placebo condition|One dose/serving of a placebo was administered to the subjects.
89613538|NCT05593744||Thyroid dysfunction|Patients had thyroid dysfunction during anti-PD-1 therapy.
89613539|NCT05593744||No thyroid dysfunction|Patients didn't have thyroid dysfunction during anti-PD-1 therapy.
89035451|NCT04323982|Experimental|New Cataract Surgery|Traditional surgery combined triamcinolone staining of the anterior vitreous (TA)
89613540|NCT01897493|Active Comparator|Digoxin|0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1
89210833|NCT00816998|Other|Delayed|Participants randomized to this group will begin physical therapy of their fractured wrist approximately 6 weeks from their surgery. This is the approximate time frame in which therapy begins for patients not involved in the study. The term Delayed refers to therapy being delayed in starting from those in the study who begin therapy at one week post-operatively, not a delay in current care practice.
89613541|NCT01897493|Experimental|Evacetrapib + Digoxin|130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15
89613542|NCT04353076|Experimental|Young adults|Young adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
89613543|NCT04353076|Experimental|Older adults (no cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity)
89613544|NCT04353076|Experimental|Older adults (cooling)|Older adults exposed to a 9-hour simulated heatwave (40°C, 15% relative humidity) with ambient cooling intervention (i.e., exposure to an air-conditioned room) for hours 5-6.
89613545|NCT03264027|Experimental|Carbon dioxide|Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
89613546|NCT03264027|Active Comparator|Ambient air|Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
89613547|NCT04415411|No Intervention|Control group|Routine nursing care
89613548|NCT04415411|Experimental|Intervention group|Nursing care based on the Theory of Human Caring
89613549|NCT01887353|Active Comparator|Ranolazine|
89613550|NCT01887353|Placebo Comparator|Placebo|
89613551|NCT00988156|Active Comparator|Eslicarbazepine acetate|To receive Eslicarbazepine acetate in addition to concomitant therapy
89613552|NCT00988156|Placebo Comparator|Placebo|To receive placebo in addition to concomitant therapy
89613553|NCT02160730|Experimental|R-roscovitine|• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.
89613554|NCT01896869|Experimental|Ipilimumab + Vaccine (Arm A)|Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks.
89613555|NCT01896869|Experimental|FOLFIRINOX (Arm B)|Administered every 14 days (one cycle)
89613556|NCT03329001|Experimental|Stage 1: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase
89613557|NCT03329001|Experimental|Stage 1: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
89613558|NCT03329001|Experimental|Stage 2: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase.
89613559|NCT03329001|Experimental|Stage 2: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
89613560|NCT03329001|Experimental|Stage 3: High fat meal-fasted sequence|Single dose niraparib tablet with a high fat meal followed by single dose of niraparib tablet in a fasted state.
89613561|NCT03329001|Experimental|Stage 3: Fasted-high fat meal sequence|Single dose niraparib tablet in a fasted state followed by single dose Niraparib tablet with a high fat meal.
89613562|NCT04872465|Active Comparator|Experimental|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
89210834|NCT00907452|Active Comparator|melphalan-prednisone-thalidomide|
89210835|NCT00907452|Active Comparator|lenalidomide-dexamethasone|
89613563|NCT04872465|Placebo Comparator|Sham Comparator|Participants will receive sham (placebo) TBS treatment the same as experimental group
89613564|NCT01896557|Experimental|omeprazole|Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
89613565|NCT01896557|Experimental|ranitidine|Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.
89613566|NCT02160808|Active Comparator|Secretin|Stimulate pancreatic secretion
89613567|NCT02160808|Placebo Comparator|Saline|Placebo should not stimulate the pancreas to release its fluids
89613568|NCT01886105|Experimental|SmEDTMP/Autologous Stem Cell Infusion/RT|"DAY 1 Tracer dose 153Sm-EDTMP administration (1 mCi/kg) SPECT/High-resolution CT at 4 hours. SPECT/CT (low resolution) at 24 and 48 hrs~DAY 7 Individualized treatment dose 153Sm-EDTMP administration (max 30 mCi/kg) SPECT scans at 4, 24 and 48 hours~DAY 21 (2 weeks following treatment dose) Auto-Stem cell infusion~DAY 40 (approx. two weeks after stem cell rescue) Initiate EBT upon count recovery~1 MONTH following completion of all therapy Response assessment with repeat imaging (CT/MRI, Tc-99m bone scan) 18F-MISO/FDG PET"
88815552|NCT01066520|Active Comparator|Diclofenac gel|Diclofenac gel 2 g, 3 times daily topical during 14 days
89210836|NCT00822224|Experimental|1|Use of MEOPA during the painful care
89210837|NCT00907530|Active Comparator|MULTIHANCE|gadobenate dimeglumine
89613569|NCT03327909|Experimental|TAKE|Participants in TAKE units will be advised to take all antihypertensive medications as prescribed, including on the morning of dialysis.
89613570|NCT03327909|Experimental|HOLD|Participants in the HOLD units will advised to hold the dose of the antihypertensive medications prior to the dialysis session on the morning of the dialysis days. Participants can choose whether they wish to take the antihypertensive medication that was held at any time after the dialysis session has ended.
89613571|NCT00989014|Experimental|CD07805/47 0.5% Topical Gel|0.5% Topical Gel
89613572|NCT00989014|Experimental|CD07805/47 0.18% Topical Gel|0.18% Topical Gel
89613573|NCT00989014|Experimental|CD07805/47 0.07% Topical Gel|0.07% Topical Gel
89613574|NCT00989014|Placebo Comparator|CD07805/47 Vehicle Topical Gel|Vehicle Topical Gel
89035452|NCT04323982|Active Comparator|Traditional Cataract Surgery|For patients younger than 2 years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + A-vit) For patients older than 2years of age: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + primary intraocular lens implantation + anterior vitrectomy (ACCC+ I/A + PCCC + IOL + A-vit)
89035453|NCT02936297|Placebo Comparator|Lactose free placebo|Lactose free placebo pill
89035454|NCT02936297|Active Comparator|Low dose Gluten (0.5g)|Low dose gluten pill
89035455|NCT02936297|Active Comparator|High Dose Gluten (2.0g)|High dose gluten pill
89035456|NCT01287832|Active Comparator|High dose vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
89035457|NCT01287832|Experimental|High-dose daptomycin|Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
89035458|NCT02913066|Experimental|Single drug|S-1 concurrent Radiotherapy
89035459|NCT02913066|Active Comparator|Double drug|S-1 plus cisplatin concurrent Radiotherapy
89035460|NCT00623701|Placebo Comparator|1|sublingual placebo preparation
89035461|NCT00623701|Experimental|2|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose
89035462|NCT02936063|Experimental|Surgical staples|Skin closure with surgical staples
89035463|NCT02936063|Experimental|Sutures|Skin closure with subcuticular sutures
89035464|NCT01287754|Experimental|Single Arm|
89035465|NCT02912832|Experimental|TBDx|"All samples were tested with TBDx and compared with smear microscopy and Xpert MTB/RIF using solid and liquid culture as gold standard.~Operators were blinded to all other results for a sample upon data entry."
89035466|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
89035467|NCT02912793|Active Comparator|Hydroxy-propyl-beta-cyclodextrin IV 2000 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
89035468|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
89035469|NCT02912871|Experimental|MRIgHIFU unilateral subthalamotomy|Unilateral Subthalamotomy performed by MRI guided High intensity focused ultrasound in a single session.
89613575|NCT05095012|Other|Clinical Pathway Participation|Patients that are seen in an emergency department participating in the clinical pathway will not be aware of any changes, other than be given a specific education handout at discharge and be advised to visit the recoverconcussion.ca web portal. Specialty referrals for high risk patients will automatically be made during the emergency visit, through the clinical pathway.
89613576|NCT03262779|Experimental|combination nivolumab and ipilimumab - primary|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks in patients with primary resistance.
89613577|NCT03262779|Experimental|combination nivolumab and ipilimumab - acquired|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, and ipilimumab 1 mg/kg administered IV every 6 weeks in patients with acquired resistance.
89613578|NCT05593120||CT-FFR|All patients will be assessed and managed according to the results of CT-FFR test, assuming they have no prespecified contraindications to CT coronary angiography. The result of the CT-FFR will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
89613579|NCT05593120||Routine care|All patients will be assessed and managed exactly as they are usually treated by the investigator and the institution's heart team according to routine practice in Wuhan Asia Heart Hospital.
89613580|NCT03299751|Experimental|NICU newborns of at least 7 days of life with suggestive signs|
89613581|NCT05031754||Infants with atopic dermatitis|Infants with atopic dermatitis
89035470|NCT02935790|Experimental|ACY-241 combo with Ipi and Nivo|ACY-241 in Combination with Ipilimumab and Nivolumab
89035471|NCT02912637||CF patients|Hyperpolarized Xenon MRI
89035472|NCT02912637||Healthy volunteers|Hyperpolarized Xenon MRI
89035473|NCT02912910||Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
89035474|NCT02912910||Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
89035475|NCT02935829|Experimental|Glucose as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89035476|NCT02935829|Experimental|Carob preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
89035477|NCT02935829|Experimental|White bread as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89210838|NCT00907530|Active Comparator|GADOVIST|gadobutrol
89210839|NCT05331885|Experimental|AR-320 (Suvratoxumab)|Participants will receive a single intravenous (IV) dose of suvratoxumab on Day 0 of the study.
89210840|NCT05331885|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo to survatoxumab on Day 0 of the study.
89613582|NCT05031754||Infants without atopic dermatitis|Infants without atopic dermatitis
89035478|NCT02935829|Experimental|Carob snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89035479|NCT02935829|Experimental|Chocolate cookie snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89035480|NCT02935829|Experimental|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
89035481|NCT02912598|Active Comparator|Mallinckrodt™ Endobronchial Tube|Usage of a left-sided Mallinckrodt™ double-lumen tube (DLT) to achieve lung isolation and one lung ventilation.
89613583|NCT05022394|Experimental|Treatment (sapanisertib, nivolumab)|Patients receive PO QD on days 1, 8, 15, and 22 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89613584|NCT01895777|Experimental|dabigatran etexilate|Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months
89613585|NCT01895777|Active Comparator|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
89035482|NCT02912598|Active Comparator|Fuji Uniblocker™|Usage of a Fuji Uniblocker™ in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
89035483|NCT02912598|Experimental|ETView VivaSight™-SL+EB|Usage of a ETView VivaSight™-EB endobronchial blocker in a ETView VivaSight™-SL single-lumen tube to achieve lung isolation and one lung ventilation.
89035484|NCT02912598|Active Comparator|COOK© Arndt Endobronchial Blocker|Usage of a COOK© Arndt Endobronchial Blocker in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
89035485|NCT02935712|Experimental|Part A|Three cohorts with 9 subjects and each cohort received 2 treatments (AZD8601+Placebo/ Placebo+Placebo)
89035486|NCT02935712|Experimental|Part B|Subjects received 2 treatments (AZD8601+Placebo)
89035487|NCT02912754|Experimental|Ibrutinib plus Ruxolitinib|Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
89035488|NCT02912754|No Intervention|Ibrutinib alone|Patients will continue to take Ibrutinib for the equivalent period of time.
89035489|NCT02935868||Test group|Patients with Type 1 diabetes mellitus
89035490|NCT02935868||Control Group|Patients without systemic diseases
89035491|NCT02912676|Experimental|6TG/6MP/MTX|Single arm feasibility study aiming to demonstrate the applicability of combining incremental doses of oral 6-Thioguanine with oral daily 6-Mercaptopurine and oral weekly Methotrexate in order to achieve mean levels of DNA-TG above 500 fmol/mikrogram DNA.
89035492|NCT02912403||Postpartum Cesarean Section|We will be including postpartum women as this study idea is pertaining to recent pregnancy
89035493|NCT02912481|Experimental|Posterior tibial artery|real time ultrasound guided arterial catheterization on the posterior tibial artery
89035494|NCT02912481|Active Comparator|Radial artery|real time ultrasound guided arterial catheterization on the radial artery
89035495|NCT02912481|Active Comparator|Dorsalis pedis artery|real time ultrasound guided arterial catheterization on the dorsalis pedis artery
89035496|NCT02935985||Adults with sICH less than 8h|"Adult patients presenting in one of the study locations and being diagnosed with intracerebral hemorrhage. The onset of the conditions is establised as sonner than 8h.~Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
89035497|NCT02912442||Infertile women study 1|
89613586|NCT05005936||Ancillary-Correlative (ABUS, WBUS)|Patients undergo ABUS over 15 minutes followed by WBUS over 30 minutes at baseline, mid-treatment and pre-surgery (end of treatment).
89035498|NCT02912442||Infertile women study 2|
89035499|NCT02912442||Repeated pregnancy loss|
89035500|NCT02935439|Active Comparator|Cell-Phone Intervention Arm|A standard cell phone system sent web-browser messages daily to ask about their weight and symptoms of heart failure. Participants received up to 3 daily messages 15 minutes apart at a time of their choosing for 90 days. Participants were given a mobile phone for the 90 day period and a weight scale.
89035501|NCT02935439|No Intervention|Usual Care|Usual Care participants continued to receive care in the Heart Failure Clinic. All subjects were enrolled in the study for 90 days. Participants were given a weight scale.
89035502|NCT02912169|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF infusion) intravenous (IV) and Intranasal.
89035503|NCT02912520||Patients with antibiotic therapy|Patients with antibiotic therapy for 2 weeks.
89035504|NCT02912520||Patients without antibiotic therapy|Patients without any antibiotic therapy in the last 3 months.
89035505|NCT02935166|Placebo Comparator|Uncharged|Respiratory muscle training: placebo General High Intensity Training (30 minutes in cycle ergometer) and placebo respiratory muscle training: This training group performed with the valve Orygen® uncharged (placebo effect). Performing 10 consecutive inspirations (5 series) two times a day during 3 weeks.
89613587|NCT03291951|Experimental|Resistance training group|Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.
89035506|NCT02935166|Active Comparator|Inspiratory|Respiratory muscle training: Inspiratory General Training (30 minutes in cycle ergometer) and high intensity inspiratory muscle training: The inspiratory training was conducted with the Orygen® valve. Inspiratory training load was defined as maximum and patient tolerance that would perform 10 consecutive inspirations (5 series) two times a day, during 3 weeks.
89035507|NCT02935166|Active Comparator|Inspiratory and expiratory|Respiratory muscle training: Inspiratory and expiratory General High Intensity Training (30 minutes in cycle ergometer) and inspiratory and expiratory training: The inspiratory and expiratory training was conducted with the Orygen® valve. Loading inspiratory and expiratory training was defined as maximum and patient tolerance. This was the optimal load that would allow the patient to perform 10 consecutive inspirations (5 sessions) 2 times a day,during 3 weeks.
89035508|NCT02935959|Active Comparator|nebulized ketamine|patients will be premedicated with nebulized ketamine solution (2 mg/kg)
89035509|NCT02935959|Active Comparator|nebulized dexmedetomidine|patients will be premedicated with nebulized dexmedetomidine solution (2 μg/kg)
89035510|NCT02935959|Active Comparator|nebulized midazolam|patients will be premedicated with midazolam (0.2 mg/kg) nebulized solution
89035511|NCT02935127|Experimental|Absorbable Group|In this group of patients absorbable sutures will be used for vascular anastomoses.
89035512|NCT02935127|Experimental|Non-Absorbable Group|In this group of patients non-absorbable sutures will be used for vascular anastomoses.
89613588|NCT03291951|No Intervention|Usual care group|Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.
89613589|NCT00992602|Experimental|Treatment (liposomal cytarabine, high-dose methotrexate)|See Detailed Description
89613590|NCT00993226|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
89613591|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
89035513|NCT02912286|Active Comparator|conventional needle irrigation|side-vented needle used for endodontic irrigation
89035514|NCT02912286|Experimental|passive ultrasonic irrigation|IrriSafe ultrasonic tip used for irrigation agitation in endodontic treatment
89613592|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
89613593|NCT00993226|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
89613594|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
89613595|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
89613596|NCT04889248|Experimental|Intervention|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual
89613597|NCT04889248|No Intervention|Control|Without inspiratory muscle training. Treatment as usual.
89613598|NCT01885559|Placebo Comparator|ACE-I + placebo|Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg
89613599|NCT01885559|Active Comparator|ACE-I + ARB|Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.
89613600|NCT01884545|Active Comparator|Standard Risk Assessment (SRA)|Subjects will receive a standard risk assessment only for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
89613601|NCT01884545|Experimental|SRA plus Health Coaching (HC)|In addition to the standard risk assessment for CHD and T2D subjects will receive health coaching intervention for 6 months
89613602|NCT01884545|Experimental|SRA plus Genetic Risk Counseling (GRC)|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
89613603|NCT01884545|Experimental|SRA+HC+GRC|In addition to the standard risk assessment for CHD and T2D subjects will receive genetic risk counseling and health coaching intervention for 6 months.
89613604|NCT01895543|Experimental|EBX10|Elobixibat 10 mg
89613605|NCT00994318|Experimental|FCM (high ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
89613606|NCT00994318|Experimental|FCM (low ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
89035515|NCT02912286|Experimental|sonic irrigation|Vibringe is a sonic irrigation system used to irrigate and activate the irrigant at same time
89035516|NCT02912325|Other|FaseMetS ® a food supplement|Daily administration: 2 tablets FaseMETS a day
89035517|NCT02935322|Active Comparator|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|A mouthrinse combining chlorhexidine and NaF
89035518|NCT02935322|Active Comparator|0.2 % NaF mouthrinse|A mouthrinse containing NaF
89035519|NCT02935322|Active Comparator|0.12% chlorhexidine mouthrinse|A mouthrinse containing chlorhexidine
89613607|NCT00994318|Active Comparator|Oral Iron|Ferrous sulphate 100 mg iron twice daily, continuous
89613608|NCT04695808|Experimental|intervention group|Yoga practice will be done two days a week for 10 weeks.
89613609|NCT04695808|No Intervention|control group|no intervention
89613610|NCT04525456|Experimental|Reduxium|1 oral drop (0.05ml) per 10kg of body weight (max 8 drops), every 8 hours (3 times a day) for 14 days
89613611|NCT00995722|Experimental|Prednisone + Pyridostigmine|Corticosteroid
89613612|NCT00995722|Placebo Comparator|Placebo + Pyridostigmine|Matched, inactive substance
89613613|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 1|"Arm 1, Level 1: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 15 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
89613614|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 2|"Arm 1, Level 2: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 20 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
89613615|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 2, Level 1|"Arm 1, Level 2: Irinotecan intravenously at 50 mg/m2 + Temsirolimus intravenously at 25 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
89613616|NCT03016468|Experimental|Parenteral Remodulin then Oral Treprostinil|
89613617|NCT00997204|Experimental|Icatibant- Naive Treatment Phase|Single subcutaneous injection of icatibant, 30 mg
89613618|NCT00997204|Experimental|icatibant- Self administration Phase|Single subcutaneous injection of icatibant, 30 mg
89613619|NCT00997516|Experimental|SILS appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
89613620|NCT00997516|Active Comparator|Conventional laparoscopic appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
89613621|NCT04263610|Experimental|Non-Germany: Dimethyl fumarate standard scheme|"Part 1: Participants will receive Dimethyl fumarate (DMF) standard scheme from baseline to Week 16.~Part 2: Participants achieving a Psoriasis Area and Severity Index (PASI) 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
89613622|NCT04263610|Experimental|Germany: Dimethyl fumarate standard scheme|Part 1: Participants will receive DMF standard scheme from Baseline to Week 16. Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40.
89613623|NCT04263610|Experimental|Germany: Dimethyl fumarate simplified scheme|"Part 1: Participants will receive DMF simplified scheme from Baseline to Week 16.~Part 2: Participants achieving a PASI 75 response (responders) and participants failing to achieve a PASI 75 response but having achieved a PASI 50 response (partial responders) at Week 16 will continue with DMF treatment until Week 40. Participants failing to achieve a PASI 50 response (non-responders) at Week 16 will be treated with Tildrakizumab until Week 40."
89613624|NCT00997594|Active Comparator|Adrenal radiofrquency (RF) ablation|Patients who wll receive adrenal RF ablation.
89035520|NCT02935322|Placebo Comparator|Placebo mouthrinse|A mouthrinse containing all basic ingredients as the other three mouth rinses compared but without chlorhexidine and fluoride
89035521|NCT02912130|No Intervention|Control|No Intervention
89035522|NCT02912130|Experimental|Exercise|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~Resistance Exercise i.e. 60 minutes per week of progressive resistance training"
89613625|NCT00997594|Active Comparator|Abdominal RF ablation other than adrenal gland|Patients who will receive abdominal radiofrequency ablation other than adrenal gland.
89613626|NCT04225390|Experimental|Dacarbazine|Dacarbazine (day1 and day21) 850 mg/m² i.v. followed by re-exposure to the previous immunotherapy
89035523|NCT02912130|Experimental|Exercise+Nutrition|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day"
89035524|NCT02912130|Experimental|Nutrition|Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day
89035525|NCT02934893|Experimental|Intervention Group|Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
89613627|NCT00997672|Experimental|Lithium CARBONATE 150 and/or 300 mg|
89613628|NCT00997672|Placebo Comparator|Placebo|Placebo comparator
89613629|NCT05495776||Patients with colorectal cancer|Patients with colon adenocarcinoma who have not previously received antitumor treatment (chemo/radiation therapy) for a currently detected tumor
89613630|NCT04160650|Experimental|Educational nursing intervention|"Patients in experimental group receive standard care and one-hour educational session. Patients are provided knowledge of~healthy diet~malnutrition, its prevalence and consequences for patients with CRC undergoing CT~side effects impairing nutrition intake during CT treatment.~prevention and self-care methods of the side effects Teach-back is used to verify participants' understanding. Empowering effect is confirmed by using active listening and asking patients' individual side effects, self-care strategies and need of additional knowledge in the beginning of the session and supporting patients' self-care methods when they have been applicable and effective. Additional knowledge of each theme is offered. To reinforce the intervention effect patients receive after the first CT a self-monitoring diary including assessment of side effects prevalence and intensity (NRS 0-10) before and after the self-care strategies. They return diaries by the 5th cycle of CT."
89688407|NCT04466293|No Intervention|Standard of care study arm|"Providers will receive training on benefits, indications, and contra-indications for TPT. Providers will use the standard approach of the default being to not prescribe. Only if providers specifically write for TPT will it be dispensed by a pharmacy or the provider."
89035526|NCT02934893|Active Comparator|Standard Diabetes Management|Patient in standard diabetes management in the Medication Management Clinic
89035527|NCT02934893|No Intervention|Primary Care|Matched cohort managed through their primary care physician (PCP) and standard of care.
89035528|NCT02935647|Experimental|Propofol|Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.
89035529|NCT02934815|Experimental|Intervention group - SEGT|16 weekly sessions, 90 min of Supportive-expressive group therapy
89035530|NCT02934815|No Intervention|Control group|No intervention
89035531|NCT02912247|Experimental|monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection 40mg administered subcutaneously once
89613631|NCT04160650|No Intervention|Standard care|"Patients in control group receive standard care, information of~general CT induced side effects and their self-care; nausea, diarrhoea, obstipation and sores in the mouth, peripheral neuropathy symptoms, local venous irritation, heart symptoms, mucous and skin irritation~side-effects' self-monitoring, fluid intake, medication dose changes, effect of CT~weight control~taste alteration~cold sensitivity~variable diet~dietary supplements~available dietitian services~They receive a self-monitoring diary, which includes only side effects and their intensity (NRS 0-10)."
89613632|NCT00998374||Pyloric-sparing vs. non-pyloric sparing|Pyloric: SG & DS Non-pyloric: RYGB
89613633|NCT04828161|Experimental|Phase 2 / Part A, ensovibep active treatment arm 1|Phase 2 / Part A: ensovibep active treatment arm 1
89613634|NCT04828161|Experimental|Phase 2 / Part A, ensovibep active treatment arm 2|Phase 2 / Part A: ensovibep active treatment arm 2
89613635|NCT04828161|Experimental|Phase 2 / Part A, ensovibep active treatment arm 3|Phase 2 / Part A: ensovibep active treatment arm 3
89613636|NCT04828161|Placebo Comparator|Phase 2 / Part A, Placebo|Phase 2 / Part A: Placebo
89613637|NCT04828161|Experimental|Phase 3/ Part B, ensovibep active treatment arm 4|Phase 3/ Part B: ensovibep active treatment. Part B was not initiated.
89613638|NCT04828161|Placebo Comparator|Phase 3/ Part B, Placebo arm|Phase 3/ Part B: Placebo. Part B was not initiated.
89613639|NCT01000324|Experimental|Twinrix Group|Pooled group of subjects from groups who were vaccinated with either Lot 1, Lot 2 or Lot 3 of Twinrix in the primary study according to a 0, 1, 6-Month schedule
89613640|NCT04399629|Active Comparator|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
89613641|NCT04399629|Experimental|Parenting Wisely|Online parenting training
89613642|NCT04606797|Experimental|Nicotine Replacement Therapy|
89613643|NCT04606797|No Intervention|Control|
89613644|NCT02164240|Experimental|Sunitinib alternated with Regorafenib|The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
89613645|NCT02164396|Active Comparator|Spectacles Lens|Participant will discontinue soft contact lens wear and wear spectacles only. Spectacle lens refers to the habitual prescription glasses that the participant arrives to the testing center with; they are NOT prescribed or given to the participant by the investigator as part of the study protocol.
89613646|NCT02164396|Active Comparator|Habitual Soft Contact Lens|Participant will continue to wear their habitual soft contact lenses. Habitual lenses are the contact lenses used by the subjects prior to participating in the clinical trial. Various types/brands are used by subjects prior to participation.
89613647|NCT02164396|Experimental|Test Lens|Participants will be dispensed senofilcon A or narafilcon A depending on their habitual modality (reusable or daily disposable)
89613648|NCT02169466|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
89613649|NCT02169466|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
89613650|NCT02169466|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
89613651|NCT02169466|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
89613652|NCT05440396||Patient|"Patients will be recruited independently in each of the centers participating in the study, according to the specific organization of each service (hospital and home). Patients will be selected based on the study inclusion/non-inclusion criteria. The included patients will receive oral information about the study. The informed consent will be obtained before any investigation.~Each photograph will focus on the intravascular catheter. The investigators will respect the main non-inclusion criterion: not to show any peripheral identification sign close to the insertion point of the catheter that cannot be masked when the photograph is taken. In this context, jewellery, clothing, tattoos, scars, and birthmarks represent identifying features. Individual access accounts with secure, randomly generated passwords will be provided to investigators.~The photographs will be anonymous, and any identification of the person concerned will be impossible."
89613653|NCT01001806|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
89035532|NCT02912247|Active Comparator|adalimumab|adalimumab 40mg administered subcutaneously once
89035533|NCT02934971||Supervised cohort of 200 chemo-treated patients|cohort of 200 patients undergoing a chemo therapy accordingly to the inclusion criteria patients
89035534|NCT02934971||Age matched control group of 200 normal subjects|200 age matched control group of subjects from the outpatient clinic who are not chemo-treated and who fit the inclusion and exclusion criteria
89035535|NCT02934971||A:machine learning approach (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
89035536|NCT02934971||B: conventional echocardiographic parameters (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
89035537|NCT02935491||Transcatheter Aortic Valve Implantation|Lyon and Paris cohorts : 900 patients will be used to test the prognostic value of aortic calcifications and to propose a risk score Clermont and Rouen cohorts (700 patients) will be used to test in an independent group, the predictive value of the risk score
89035538|NCT02935010|Experimental|Tailored therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
89035539|NCT02935010|Active Comparator|Empiric therapy|give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, amoxicillin 1000mg tid and metronidazole 400mg tid for 14 days
89035540|NCT02912013|Experimental|Me mini|Subjects treated with Me mini device
89035541|NCT02934776|Experimental|DTI acquisition|Addition of up to 10 minutes in MRI machine purpose of acquiring additional DTI images
89035542|NCT02911974|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
89035543|NCT02911974|Active Comparator|Expect EUS Aspiration Needle|All patients will undergo sampling of pancreatic masses using the Expect EUS Aspiration Needle. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types
89035544|NCT04690088||Manual infusion (control) group|
89035545|NCT04690088||TCI (case) group|
89035546|NCT04690244|Experimental|Tai Chi Chuan group|"Fifteen healthy elderly subjects participated in 10 weeks of Tai Chi Chuan practice. Inclusion criteria were:~aged 60 years and older;~sedentary behavior for at least 6 months;~no previous experience of Tai Chi Chuan practice;~good physical health determined by Physical Activity Readiness Questionnaire as - confirmed by medical history;~no cognitive impairments determined by baseline Mini-Mental State Examination score of ≥ 45.~All participants were asked to not perform any sports activities while the research was ongoing."
89613654|NCT01001806|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
89613655|NCT01001806|Active Comparator|Nevanac|One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
89613656|NCT04021264|Active Comparator|PRE-GA|14 mL injection of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil before the start of surgery and 14 ml of 5% dextrose at the end of surgery into the epidural catheter
89613657|NCT04021264|Sham Comparator|POST-GA|14 mL injection of 5% dextrose before the start of surgery and 14 ml of a solution containing 0.125% bupivacaine and 2 mcg/ml sufentanil at the end of surgery into the epidural catheter
89613658|NCT01002118|Placebo Comparator|Placebo|4 capsules inert oil Placebo each day for 16 weeks
89613659|NCT01002118|Active Comparator|Omega-3 Fatty Acid Ethyl Esters|4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks
89035547|NCT04690244|No Intervention|Control group|In the control group, fifteen subjects also had to meet the same criteria and did not perform any exercises or make changes in their daily living life.
89035548|NCT02935569|Experimental|Compression Headband|a compression headband, placed only at the time of irradiation
89035549|NCT04690166||Cancer Patients|"In outpatients clinic, the first group consists of 60 head and neck cancer patients who were treated by ours. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
89035550|NCT04690166||Healty Control|"In outpatients clinic, the control group consists of 60 patients who have not speech and hear impairments. The participants will given the document consists that bit, bet, but words and also a brief part of Diyet passage who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely."
89035551|NCT02935530|Experimental|s-LMWH|2125 I.U. subcutaneous injection for 5-10 days
89035552|NCT02935530|Active Comparator|LMWH|4250 I.U. subcutaneous injection for 5-10 days
89035553|NCT02935530|Experimental|Argatroban|20mg, injection for 5-10 days
89035554|NCT02935608|Experimental|BIIB074 high dose|Administered twice daily (BID)
89035555|NCT02935608|Experimental|BIIB074 low dose|Administered BID
89035556|NCT02935608|Placebo Comparator|Placebo|Placebo administered BID
89035557|NCT02935803|Other|Modified TVM operation|Modified Trans-vaginal Mesh operation (mTVM): polypropylene monofilament meshes produced by Aspide® fixed up to the mid urethra by a resolvable suture. 76 participants will be involved.
89035558|NCT02935803|Other|Control group|76 Participants as control group undergo a traditional Trans-vaginal Mesh operation (TVM) with polypropylene monofilament meshes produced by Aspide® . (Sergent et al.)
89613660|NCT05311839|Experimental|Thera band exercises group|received graded Thera band exercises for 5 days per week for eight weeks in addition to the conventional physical therapy program.
89035559|NCT02934386|Experimental|WinMedical WinPack device|50 volunteers undergoing experimental protocol according to IEEE 1708:2014 standard
89035560|NCT02912052|Experimental|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.
89035561|NCT02912052|Active Comparator|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.
89035562|NCT02934620|Experimental|CSD500 Condom|Receive CSD500 condoms with condom counseling to use them for sexual pleasure.
89035563|NCT02934620|Active Comparator|Standard Condom|Receive the standard condom with condom counseling to use them for pregnancy and disease prevention.
89035564|NCT02935881|Active Comparator|RFA (Stretta Procedure)|Radio Frequency Ablation (RFA) using a Stretta device.
89613661|NCT05311839|Experimental|conventional physiotherapy program group|received a conventional physical therapy program.
89035565|NCT02935881|Sham Comparator|Placebo Arm|Stretta device used but RFA will not be generated.
89035566|NCT02934464|Experimental|ARM A|"RAMUCIRUMAB 8 mg/kg on Days 1 and 15 of every 28-day cycle~PACLITAXEL 80 mg/m2 on Days 1, 8, and 15 of every 28-day cycle until progressive disease, unacceptable toxicity, informed consent withdrawal or patient's death."
89035567|NCT02934464|Active Comparator|ARM B|"FOLFOX4: Oxaliplatin 85 mg/m2 + l-Leucovorin 100 mg/m2 + 5-fluorouracil 400/600 mg/m2. Cycle length is 2 weeks +/- 3 days.~mFOLFOX6: Oxaliplatin a 85 mg/m2+ l-Leucovorin 200 mg/m2 + 5-fluorouracil 400 mg/m2 and 2400 mg/m2 46-hours continous infusion. Cycle length is 2 weeks +/- 3 days.~XELOX:Oxaliplatin130 mg/m2 + Capecitabine will be 2000 mg/m2 for 14 days. Cycle length is 3 weeks +/- 3 days."
89035568|NCT02934542|No Intervention|Control Group|Patients in this group will undergo an elective standard laparoscopic procedure with a designated OR staff to maneuver the laparoscopic camera. The procedures will be performed according to the hospital and OR routine procedure.
89035569|NCT02934542|Experimental|AutoLap Group|Patients in this group will undergo a laparoscopic procedure using the AutoLap system. In this group the surgeon will use the AutoLap system to hold and control the movements of the laparoscopic camera.
89035570|NCT02935413|Active Comparator|tDCS|group receiving complete treatment of transcranial direct current stimulation
89035571|NCT02935413|Active Comparator|Standard rehabilitation|Standard rehabilitation procedures
89035572|NCT02934425|Placebo Comparator|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast
89035573|NCT02934425|Experimental|High pork protein breakfast|High pork protein breakfast
89035574|NCT02935218|Other|Parenting Skills for Mothers with BPD|single-arm study
89035575|NCT02934308|Experimental|ICU patients|
89035576|NCT02934269|Experimental|CC-90006; Dose Level 1|CC-90006 will be administered by subcutaneous injection in the abdomen
89035577|NCT02934269|Experimental|CC-90006; Dose Level 2|CC-90006 will be administered by subcutaneous injection in the abdomen
89035578|NCT02934269|Experimental|CC-90006; Dose Level 3|CC-90006 will be administered by subcutaneous injection in the abdomen
89613662|NCT01003288|Experimental|Pandemic influenza H1N1 vaccine|Influenza vaccine
89613663|NCT04759365|Experimental|ASN51|ASN51 will be administered as an oral capsule
89613664|NCT04759365|Placebo Comparator|Placebo|Placebo will be administered as an oral capsule
89035579|NCT02934269|Experimental|CC-90006; Dose Level 4|CC-90006 will be administered by subcutaneous injection in the abdomen
89035580|NCT02934269|Experimental|CC-90006; Dose Level 5|CC-90006 will be administered by subcutaneous injection in the abdomen
89035581|NCT02934269|Experimental|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
89035582|NCT02934035||Placebo|The placebo group includes participants in eligible clinical trials who have been assigned to placebo medication.
89035583|NCT02934035||Antidepressant|The antidepressant group includes participants in eligible clinical trials who have been assigned to antidepressant medication.
89035584|NCT02911740|Experimental|Urine LAM Ag test|Patients will be enrolled prospectively and tested for TB using the urine LAM Ag test
89035585|NCT02911740|No Intervention|Retrospective arm|Charts of retrospectively selected patients from the Hospital Santo Tomas database who presented within the last five years meeting inclusion criteria will be used as controls
89035586|NCT02934152|Experimental|Early eradication|Group A (H pylori eradication timing: early eradication, n=100): Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.
89035587|NCT02934152|Experimental|Late eradication|Group B (H pylori eradication timing: late eradication, n=100): PPI with rabeprazole 20 mg qd for 4 weeks, followed by H pylori eradication with triple therapy for two weeks
89613665|NCT05364112|Experimental|Compreflex|Patients recruited for the study will be given one unit of Compreflex (study device) to be worn on the studied leg with a venous ulcer. Once the wound is covered by dressing, the subjects were instructed to wear the study device for 24 hours over the study period. Subjects were allowed to take off the study device during a shower. Subjects were asked to visit the clinic for follow-up purposes at 3 assessment time points after being recruited at the first visit: V2 (3-week), V3 (12-week) and V4 (26-week). Subjects' wound area, leg circumferences were measured and calculated. Patient-centred questionnaires were given to the subjects to assess their compliance and satisfaction with the study device.
89613666|NCT03232593||Participants who Receive Atezolizumab|Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.
89035588|NCT02934152|Active Comparator|Negative Hp|For patients with negative H. p infection documented by UBT (Group C, n=200), No H pylori eradication treatment will be given but PPI with rabeprazole 20 mg qd will be given for 8 weeks.
89035589|NCT02935296|No Intervention|Control|Standard of Care
89613667|NCT02162446|Experimental|68Ga-OPS202|Satoreotide trizoxetan will be administered in two sequentially ascending peptide doses
89035590|NCT02935296|Experimental|Integrated Intervention|Standard of care plus an integrated system of psychosocial counseling and systems navigation for HIV treatment and Substance Use treatment
89035591|NCT02934074||Unilateral Lower Limb Loss|Individuals with unilateral lower limb loss will be participants of the group.
89035592|NCT02911779|Other|change of medilateral angle line|change of medilateral angle line during crowning of the head
89035593|NCT02934113|No Intervention|Control|
89035594|NCT02934113|Experimental|iOTA and HWPP|
89035595|NCT02934113|Experimental|HWPP|
89035596|NCT02935335||Menopur® HP-hMG|Treatment according to routine clinical practice.
89035597|NCT02933996|Experimental|TEAS+GA group|"The patients of TEAS+GA group will receive TEAS therapy in perioperative period.~GA: general anesthesia"
89035598|NCT02933996|Sham Comparator|Sham TEAS+GA group|The patients of Sham TEAS+GA will receive none TEAS in perioperative period.
89613668|NCT01895309|Experimental|SB4 (proposed biosimilar to etanercept)|SB4 50 mg/week via subcutaneous injection
89035599|NCT02934230|Experimental|Prehabilitation Group|The intervention will be a home-based total-body exercise training program (prehabilitation) based on a protocol with proven efficacy in improving the function of non-frail surgical patients in less than 4 weeks of preoperative utilization.Prehabilitation will consist of 3 components: 1) strength training; 2) aerobic exercise and 3) flexibility. Prehabilitation will be prescribed as 1-hour sessions performed a minimum of 3 times per week. Intervention group patients will also be provided with nutritional advice. In addition to paper-based materials outlining the prehabilitation program, weekly prehabilitation teaching sessions will be held at our Cancer Centre for patients randomized to the intervention group, and activity logs and weekly phone calls will be used to measure compliance and to answer questions. During the final week of the program, patients will also participate in a brief qualitative interview over the phone to explore their experience with the program.
89035600|NCT02934230|No Intervention|Control Group|Patients randomized to the control group will be provided standard perioperative care as per our institutional standards. They will receive the World Health Organization (WHO) Global Recommendations for Physical Activity for Health for people 60 years and above pamphlet, as well as Canada's Food Guide. In-hospital perioperative care, and postoperative care, will be at the discretion of each patient's surgeon and anesthesiologist.
89035601|NCT02933840|Experimental|AlertWatch|Patients will receive standard monitoring and in addition the AlertWatch software will alert the intensive care physician if there is a value that meets criteria for alerting. The care team will be the orthopedic surgery team in addition to the intensive care physician being involved as a consultant if he/she receives an alert.
89035602|NCT02933840|No Intervention|No AlertWatch|Patients will receive standard monitoring without the AlertWatch software. The care team will be the orthopedic surgery team without the intensive care physician being involved as a consultant.
89613669|NCT01895309|Active Comparator|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
89613670|NCT01884311|Experimental|Subgam-VF|Subgam-VF is a 16% IgG and will be administered weekly, by subcutaneous infusion. The total duration of treatment will be for 26 weeks.
89613671|NCT01004770|Experimental|1 (AH113111 Injection)|
89613672|NCT01004770|Active Comparator|2 (Visipaque Injection)|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
89613673|NCT04399317|Experimental|Group A|This is the treatment group. Patients will be ventilated using the new device (Evone) applying flow controlled ventilation for 48 hours. Ventilation parameters will be assessed every 6-8 hours. All other treatment will be unchanged and according to institutional standards.
89613674|NCT04399317|No Intervention|Group B|These patients will be treated according to institutional standards. Only data will be collected. This is the control group.
89613675|NCT03230877|Experimental|Group A|"Participants will be randomized to receive either the Improved Seal or Normal Seal Toffee full face mask for a total of 7 ± 4 days from visit 1. At visit 2 they will return the first mask and be switched to the remaining mask for a total of 7 ± 4 days from visit 2."
89613676|NCT03230877|Experimental|Group B|"Participants will be randomized to receive either the Improved Seal or Normal Seal Toffee full face mask for a total of 7 ± 4 days from visit 1. At visit 2 they will return the first mask and be switched to the remaining mask for a total of 7 ± 4 days from visit 2."
89613677|NCT04469374|Experimental|Jumping exercise|10 rest-inserted jumps performed three times per week
89613678|NCT04469374|Sham Comparator|Balance exercise|Single-leg balances for 60 seconds on each leg
89613679|NCT01884077|Active Comparator|Reverse Shoulder Arthroplasty|Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
89613680|NCT01884077|Active Comparator|Total Shoulder Arthroplasty|Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint
89613681|NCT03922204|Experimental|MCLA-145|In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 ( every 2 weeks ) until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 at the recommended phase II dose every 2 weeks. The duration of each treatment cycle is 28 days
89613682|NCT04717791|Other|Procedure|Subjects will be followed from the Vivaer® treatment date out to 24 months post index procedure.
89613683|NCT04713579||Premature infants|Infants born prematurely requiring a stoma for condition such as necrotizing enterocolitis (NEC) or spontaneous intestinal perforation (SIP).
89613684|NCT04713579||Term Infants|Infants born closer to term requiring a stoma e.g. for congenital causes of bowel obstruction such as intestinal atresia, gastroschisis or meconium ileus
89613685|NCT04579029|Experimental|Surgical Cohort|"Patients randomised to the surgical group will undergo near infrared spectroscopy imaging to assess suitability and plan the surgical procedure.~Limb measurements with perometry and bio-impedance spectroscopy will be performed at baseline. Under general anaesthetic multiple LVA bypass procedures will be performed on the affected arm. Near infrared spectroscopy imaging will be used throughout. One week after discharge the patient will return for the bandages to be removed and the wounds inspected for any evidence of infection before renewing the bandage. Again, two weeks after surgery, the patient will return for inspection of wound and removal of sutures. It is at this point that the surgical patients will be returned into a standard lymphoedema compression garment, fitted by the research nurse. Thereafter, standard follow up (Bilateral) measurements and checks will be done at 1 month, 3 months, 6 months and 1 year."
89613686|NCT04579029|No Intervention|Non-surgical cohort|"The main intervention for the non-surgical group largely encompasses limb measurements with perometry and bio-impedance spectroscopy at baseline before a compression garment is applied. The compression garments will be measured and fitted by a trained lymphoedema specialist and will be given the standard advice as is best practice for such patients currently. This cohort will likewise be followed up at 1 month, 3 months, 6 months and 1 year and undergo perometry readings and measurements with comparable collection of data.~For patients in both surgical and non-surgical groups, the compression garments will be measured and fitted by a trained lymphoedema specialist and they will be given the standard advice as is best practice for such patients currently. For each patient key details of the surgical technique, garment specification, imaging results and perometry/BIS measurements will be recorded on a study specific form for subsequent entry onto the database."
89035603|NCT02911662|Experimental|3-day treatment|Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
89613687|NCT04705545|No Intervention|molar block|No additional anchorage reinforcements besides the banding first and second molar with and tying them together at the buccal tubes (also known as molar block)
89613688|NCT04705545|Experimental|TPA group|Bands are selected and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a transpalatal archwire.
89613689|NCT04705545|Experimental|Nance button group|Bands are selected and an alginate impression taken over the bands. Bands are replaced on the tooth and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a Nance button
89613690|NCT05066698|Experimental|ST266|Topical ocular application: one drop in the study eye four times a day for 8 weeks
89613691|NCT05066698|Placebo Comparator|Placebo|Topical ocular application: one drop in the study eye four times a day for 8 weeks
89613692|NCT04277793|Experimental|Monitored self-guided problem solving intervention|Monitored self-guided problem solving intervention
89613693|NCT05058742|Experimental|Nervus vagus stimulation|Non-invasive Nervus vagus stimulation called AuriStim Intermittent stimluation cycle of three hours of activity and three hours of rest, equating to four cycles of three hours of Stimulation in 24 hours) is performed. The stimulation is performed until the patient's condition is better and he or she isdischarged from OCU or transferred to normal ward or dies.
89613694|NCT05058742|No Intervention|Control|There is no Nervus vagus stimulation.
89613695|NCT03832101|Experimental|Difficult face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Thereafter, participants in the Difficult group will undergo training involving discriminations between highly similar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
89613696|NCT03832101|Experimental|Easy face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Easy group will discriminate between dissimilar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
89613697|NCT03832101|Active Comparator|Control|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Control group will perform a simple face-matching exercise. This training will last for approximately 30 minutes. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
89613698|NCT03707860||head and neck radiotherapy patients|(Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app.
89613699|NCT03685318|Active Comparator|Conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo for two weeks. The conventional mouthguard is designed with the palatal margin at 6 mm from the cervical line.
89613700|NCT03685318|Active Comparator|Shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo for two weeks. The shortened mouthguard is designed with the palatal margin at 2 mm from the cervical line.
89035604|NCT02911662|Active Comparator|7-day treatment|Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
89035605|NCT02933723|Experimental|Blood draw- adjuvanted TIV|individuals who received adjuvanted trivalent influenza vaccine (aTIV, Fluad) and consent to a blood draw
89035606|NCT02933723|Active Comparator|Blood draw - nonadjuvanted TIV|individuals who received nonadjuvanted trivalent influenza vaccine and consent to a blood draw
89035607|NCT02911623|Experimental|Lithoplasty Treatment|Patients in this group will receive treatment with the Shockwave Lithoplasty® System which uses lithotripsy-enhanced, low-pressure balloon dilation of calcified stenotic peripheral arteries.
89035608|NCT02935101|Experimental|Prednisolon|Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).
89035609|NCT02935101|Placebo Comparator|Placebo|Identical looking capsules like the IMP containing placebo (without active component) for oral administration.
89035610|NCT04689971|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily (experimental group).
89035611|NCT04689971|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
89035612|NCT02934945|Other|patients with CVA(CVA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
89035613|NCT02934945|Other|patients with TA(TA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
89035614|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])|Healthy elderly participants will receive single dose of 30mg JNJ-54175446.
89035615|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 100mg)|Healthy elderly participants will receive single dose of 100mg JNJ-54175446.
89035616|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 300mg)|Healthy elderly participants will receive single dose of 300mg JNJ-54175446.
89613701|NCT03617302|Experimental|Beetroot juice|10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.
89613702|NCT03617302|Placebo Comparator|Placebo Beetroot juice|10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.
89613703|NCT04334980|Experimental|bacTRL-Spike|"Group 1 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. longum);~Group 2 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. longum;~Group 3 (n=3; Sentinel +2): Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. longum;~Group 4 (n=3): Single Data and Safety Monitoring Board (DSMB)-defined dose of bacTRL-Spike among subjects 56 years of age and older.~Group 5 (n=12): DSMB-defined prime and boost doses of bacTRL-Spike delivered with a 28-day intervening interval."
89613704|NCT05003908|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
89613705|NCT04323748|Experimental|rituximab|All patients enrolled will receive the dose dense administration of rituximab. Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
89613706|NCT03015298||Gastric cancer|Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
89613707|NCT04296838|Experimental|refractory UME patients treated with Conbercept|patients in this arm should meet the inclusion criteria and the definition of refractory UME
89613708|NCT03258177|Experimental|Virtual Visit Group|Participants assigned to the virtual visit group will receive a virtual visit as their postoperative follow-up visit.
89613709|NCT03258177|No Intervention|Standard In-person Group|Participants assigned to the standard in-person group will receive an in-person follow-up visit as their postoperative follow-up visit.
89613710|NCT03015064||Myocardial Infarction|Patients with first myocardial Infarction
89613711|NCT03187054|Active Comparator|POPQ-based surgery|will undergo anterior or posterior colporrhaphy for all of anterior or posterior vaginal prolapse stage 2 or greater (i.e. point Ba or Bp ≥-1 on the POPQ examination)
89613712|NCT03187054|Experimental|Simulated apical support-based surgery|will undergo anterior or posterior colporrhaphy only for the prolapse unresolved under simulated apical support (i.e. point Ba or Bp ≥-1 under simulated apical support)
89613713|NCT04760457|Active Comparator|IL-FLS|Immediate loading (IL) and Flapless surgery (FLS)
89613714|NCT04760457|Active Comparator|IL-FPS|Immediate loading (IL) and Flapped surgery (FPS)
89613715|NCT04760457|Active Comparator|DL-FLS|Delayed loading (DL) and Flapless surgery (FLS)
89613716|NCT04760457|Active Comparator|DL-FPS|Delayed loading (DL) and Flapped surgery (FPS)
89613717|NCT02991586|Experimental|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral treatment that was originally developed to treat chronically suicidal individuals diagnosed with borderline personality disorder (BPD) and it is now recognized as the gold standard psychological treatment for this population. In addition, research has shown that it is effective in treating a wide range of other disorders such as substance dependence, depression, post-traumatic stress disorder (PTSD), and eating disorders. In this research DBT skills will be taught to parents of adolescents with high emotional instability
89613718|NCT02991586|No Intervention|Control|"Control: The No intervention arm in this research is defined as follow:, sons and daughters are in their respective treatment but parents are nor receiving any DBT intervention"
89613719|NCT04898296||Patients over 55 Years with coronary heart disease|Questionnaire and semistructured Interview 45 -60 minutes
89613720|NCT04898296||physical therapists working with patients with coronary heart disease|Focus group 60 -90 minutes
89613721|NCT04550013|Active Comparator|Heavy-Slow Resistance training|Heavy-Slow Resistance training. Three times weekly for 12 weeks.
89613722|NCT04550013|Experimental|Low-Load Blood Flow Restriction training|Low-Load Blood Flow Restriction training. Three times weekly for 12 weeks
89035617|NCT02933762|Experimental|Part 1: Cohort A1 (Placebo)|Healthy elderly participants will receive single dose of placebo.
89035618|NCT02933762|Experimental|Part 1: Cohort A2 (JNJ-54175446 D1 mg)|Healthy elderly participants will receive an additional dose D1 mg [less than or equal to (<=) 600 mg] of JNJ-54175446, to be determined.
89613723|NCT04894162|Other|Sequential recruitment of all inpatients|"Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a questionnaire about research preferences.~This is not part of standard care and results do not contribute to usual care - thus is an 'interventional' study."
89613724|NCT04134520||Generally healthy subjects with no known cancer disorder|
89613725|NCT04134520||Subjects with a pathological diagnosis of cancer|
89613726|NCT02808364|Experimental|Personalized cellular vaccine|Subjects will undergo tumor resection. They will receive biweekly cellular vaccines consisting of mRNA tumor antigen pulsed autologous DCs.
89613727|NCT04683393||Healthy Subjects|To compare the markers of frailty (MoF) in patients with multiple myeloma (MM) with the healthy subjects.
89035619|NCT02933762|Experimental|Part 1: Cohort A3 (JNJ-54175446 D2 mg)|Healthy young participants will receive a single dose D2 mg (<= 600 mg) of JNJ-54175446, to be determined.
89035620|NCT02933762|Experimental|Part 1: Cohort A3 (Placebo)|Healthy young participants will receive a single dose of placebo.
89035621|NCT02933762|Experimental|Part 2: Cohort B1 (JNJ-54175446 D3 mg)|Healthy elderly participants will receive multiple dose levels D3 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
89035622|NCT02933762|Experimental|Part 2: Cohort B1 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1.
89035623|NCT02933762|Experimental|Part 2: Cohort B2 (JNJ-54175446 D4 mg)|Healthy elderly participants will receive multiple dose levels D4 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
89035624|NCT02933762|Experimental|Part 2: Cohort B2 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
89613728|NCT04683393||MM Patients|Patients with multiple myeloma (MM), the aim is to assess if any of the proposed parameters and markers of frailty (e.g. biomarkers of cellular senescence and organ damage, inflammatory markers, physical tests such as gait speed and hand grip test) are associated with frailty status, defined according to the GA, at baseline.
89613729|NCT02709616|Experimental|Personalized cellular vaccine|DC based cellular vaccine
89613730|NCT02468752|Sham Comparator|Air|Normobaric air breathing
89613731|NCT02468752|Experimental|Oxygen|Normobaric oxygen breathing
89613732|NCT04672239|Experimental|SiS|"Participants will be onboarded (remotely) to the smartphone app Smiling instead of Smoking (SiS), and will be asked to use it for 7 weeks while they quit smoking."
89613733|NCT04672239|Active Comparator|QG|"Participants will be onboarded (remotely) to the smartphone app QuitGuide (QG), and will be asked to use it for 7 weeks while they quit smoking."
89613734|NCT04672239|Other|CTA|"Participants will be onboarded (remotely) to the NCI brochure Clearing the Air (CTA), and will be asked to use it for 7 weeks while they quit smoking."
89613735|NCT01894919|Experimental|2H3H511_V|In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.
89613736|NCT01894919|No Intervention|2H3H511_NV|In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
89035625|NCT02933762|Experimental|Part 2: Cohort B3 (JNJ-54175446 D5 mg)|Healthy elderly participants will receive multiple dose levels D5 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
89035626|NCT02933762|Experimental|Part 2: Cohort B3 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
89613737|NCT01894919|Experimental|3H5_11_V|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
89613738|NCT01894919|No Intervention|3H5_11_NV|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
89613739|NCT01894919|Experimental|68_11_V|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
89613740|NCT01894919|No Intervention|68_11_NV|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
89613741|NCT01894919|Experimental|02_2_5_V|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
89613742|NCT01894919|No Intervention|02_2_5_NV|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
89613743|NCT01894919|Experimental|02_6_10_V|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
89613744|NCT01894919|No Intervention|02_6_10_NV|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
89613745|NCT01894919|Experimental|NAIVE 123|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
89035627|NCT02933645|Active Comparator|Insulin nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain fast-acting human insulin Actrapid (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
89210841|NCT00717197|Experimental|Capecitabine|Capecitabine (1,000-1,250 mg/m2) taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
89210842|NCT00929136|Experimental|Endotoxin|
89210843|NCT00925392|Experimental|Doripenem 500 mg|
89210844|NCT00925392|Experimental|Doripenem 1000 mg|
89613746|NCT01894919|Experimental|NAIVE_4A|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
89613747|NCT01894919|Experimental|NAIVE_4B|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
89613748|NCT04418206|Other|Samples With DNA|Nasopharyngal swab and blood samples
89613749|NCT04130698|Experimental|Distress Tolerance|"Treatment rationale: RAs will explain that there are 3 (not 2 as in the control) key factors that maintain smoking behavior and excess weight: 1) learned habits, 2) the addictive properties of smoking and food, and 3) a way to manage distress. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address all 3 key factors. This condition includes both key factors in the control but introduces the third key factor distress tolerance (DT). Toward that end, modules will include: a values discussion; experiential avoidance; distress tolerance; and mindfulness-based ways to manage distress.~Module 1: Orientation & ACT; Module 2: Avoidance; Module 3: Cognitive Fusion vs. Defusion; Module 4: Self-As-Context; Module 5: Present-Moment-Awareness; and Module 6: Values and Committed Action."
89035628|NCT02933645|Placebo Comparator|Placebo nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd,Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd,Denmark) over 15 min.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
89613750|NCT04130698|Active Comparator|Active Health Control|"Treatment rationale: RAs will explain that there are 2 key factors that maintain smoking behavior and excess weight: 1) learned habits and 2) the addictive properties of smoking and food. Therefore, to be effective, an intervention designed to simultaneously treat smoking cessation and weight loss must address both key factors. Toward that end, modules will include standard treatment on: the dangers of smoking, excess weight, unhealthy diets and sedentariness; the importance of healthy behaviors; and relaxation exercises to manage stress. These are all key aspects of standard treatment for smoking cessation and weight loss.~Module 1: Orientation and Health; Module 2: Game Plan; Module 3: Stress and Coping Strategies; Module 4: Physical Activity; Module 5: Changes in Activities, Habits and Lifestyle; and Module 6: Long-Term Rewards."
89035629|NCT02933567|Experimental|CSC OnDemand Pilo|Pilot Intervention
89613751|NCT05306223|Experimental|Bedaquiline-containing Short-course Regimen (SCR)|Participants will receive an oral dose of bedaquiline 400 milligrams (mg) once daily for first 2 weeks followed by bedaquiline 200 mg thrice a week for 22 weeks (with at least 48 hours between doses) in combination with oral doses of levofloxacin (LFX) up to 1000 mg (weight-based), cycloserine (CS) up to 750 mg (weight-based), clofazimine (CFZ) 100 mg daily for 40 weeks and linezolid [LZD] 600 mg daily for at least 24 weeks . If a participant is still sputum culture-positive for Mycobacterium tuberculosis by Week 16, bedaquiline treatment will be extended from Week 24 to Week 40.
89035630|NCT02933684|Experimental|DCS|Participants will receive 50mg of Seromycin (aka D-cycloserine) in conjunction with virtual reality exposure therapy once a week for 4 weeks.
89035631|NCT02933684|Placebo Comparator|Placebo|Participants will receive a placebo in conjunction with virtual reality exposure therapy once a week for 4 weeks.
89035632|NCT02934867|Experimental|CONTARM|Protocol phone advice
89035633|NCT02934867|Other|CONTHAB|Usual phone advice
89035634|NCT02933333|Experimental|GM-CSF|Eligible patients received subcutaneous GM-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
89035635|NCT02933333|Experimental|G-CSF|Eligible patients received subcutaneous G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. G-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
89210845|NCT05315271|Active Comparator|Group 1|All patients will be randomly allocated into two equal groups: each group will contain 30patients:
89210846|NCT05315271|Active Comparator|Group 2|All patients will be randomly allocated into two equal groups: each group will contain 30patients:
89613752|NCT05306223|Experimental|Non-bedaquiline-containing Short-course Regimen (SCR)|Participants will receive oral doses of LFX up to 1000 mg (weight-based), CS up to 750 mg (weight-based), CFZ 100 mg, Pyrazinamide (PZA) up to 2000 mg (weight-based), Protionamide (PTO) up to 800 mg (weight-based) daily for first 16 weeks and LZD 600 mg daily for at least 24 weeks.
89613753|NCT03016000|Experimental|Thalidomide|Thalidomide 50mg daily by mouth( increase 50mg after 2 weeks if tolerated until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if the patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/day, thalidomide discontinuation was allowed.
89613754|NCT03016000|Other|Observation|Observation
89613755|NCT04130152|Experimental|Palbociclib + Letrozole|"Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.~If the patient is pre-menopausal, ovarian suppression with luteinizing hormone-releasing hormone (LHRH) analogues (ie, triptorelin 3.75 mg intra-muscular (IM) or Goserelin 3,6 mg SC) must be initiated at least 2 weeks before palbociclib plus letrozole administration."
89613756|NCT03224481|Experimental|Receive electronic reminder|Participants in the intervention group will receive tailored electronic reminders. The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
89613757|NCT03224481|No Intervention|Control group|Participants in the control group will not receive additional reminders.
89613758|NCT01894841|Experimental|CLASP Intervention|A 6 month adjunctive intervention consisting of 3 individual meetings, one family session, and 11 brief phone contacts with patient and identified significant other.
89613759|NCT01894841|Other|Safety Assessment and follow up Evaluation|Treatment as usual plus enhanced monitoring.
89613760|NCT04106674|No Intervention|Non-surgical|No surgery
89613761|NCT04106674|Active Comparator|Surgical|Surgeons preference
89613762|NCT03254589|Experimental|Group 1|Newly diagnosed RA patients started on subcutaneous MTX - open randomisation vs. sulfasalazine. In this group, use of NSAIDs, steroids, and/or other DMARDs, is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice .
89613763|NCT03254589|Active Comparator|Group 2|Newly diagnosed RA patients started on sulfasalazine - open randomisation vs. subcutaneous MTX. In this group, use of NSAIDs, steroids, and/or other DMARDs (except MTX), is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
89613764|NCT03254589|Experimental|Group 3|RA patients on long-term treatment (> 1 year) with oral MTX, with or without other DMARDs, NSAIDs and/or steroids, switched to subcutaneous MTX (same dose). In these patients, treatment with other DMARDs, NSAIDs and/or steroids will continue. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
89613765|NCT03254589|Active Comparator|Group 4|RA patients on stable treatment (> 1 year) with other (non-MTX) DMARDs, with or without NSAIDs and/or steroids, and continued on the same treatment. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
89613766|NCT01894607|Experimental|Contrast Enhanced Intraoperative Ultrasound|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.~Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having."
89613767|NCT04399395|Active Comparator|Lifestyle and naltrexone/bupropion|
89613768|NCT04399395|Other|Lifestyle|
89613769|NCT01883453|Placebo Comparator|Saline+glucose nasal spray|A nasal spray with isotone saline + 5% glucose, dosing one puff 5 times daily in each nostril at the first treatment day and thereafter trice daily for a total of one week
89613770|NCT01883453|Active Comparator|Nasal spray with glucose oxidase+glucose|A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.
89613771|NCT02000596|Experimental|Cohort 1: T+P|Trastuzumab plus Pertuzumab as first line treatment for HER2 overexpressed Metastatic Breast Cancer (without hormonal therapy or chemotherapy)
89613772|NCT02000596|Experimental|Cohort 2 - Arm A|Hormonal Therapy with Anastrozole and Fulvestrant in addition Trastuzumab plus Pertuzumab for women who progressed on T+P alone, and who are ER/PR +
89613773|NCT02000596|Experimental|Cohort 2 - Arm B|Chemotherapy with Eribulin in addition to Trastuzumab plus Pertuzumab for women who progressed on T+P alone and who are ER/PR -
89613774|NCT03223779|Experimental|TAS-102|"Photon treatments will be performed on a linear accelerator~Photon SBRT will be given during TAS-102 dosing~TAS-102 dosing occurs on days 1 through 5 and 8 through 12~TAS-102 tablets should be taken twice a day orally"
88985895|NCT03272425|Experimental|Sequence ABBA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
88985896|NCT03272425|Experimental|Sequence BABA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
88985897|NCT03272425|Experimental|Sequence ABAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
88985898|NCT03272425|Experimental|Sequence BAAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
88985899|NCT03272542|Experimental|Prebiotic: soluble corn fiber|SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate & Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber). Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
88985900|NCT03272542|Placebo Comparator|Placebo|The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
88985901|NCT03272503|Experimental|Group 1 Pimozide 2 mg (current) or 4 mg/day (study initiation)|Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.
88985902|NCT03272503|Placebo Comparator|Group 2 Placebo|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
88985903|NCT00116987|Other|1|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
88985904|NCT00116987|Other|2|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
88985905|NCT00116727||Drug|etanercept 50 mg/wk SC
88985906|NCT00465556|Experimental|1|Dove Intervention
88985907|NCT00465556|Active Comparator|2|Intimate Partner Violence (IPV) Protocol
89210847|NCT00147745|Experimental|1|colesevelam 3.8g administered daily for 12 weeks
89210848|NCT00147745|Placebo Comparator|2|Colesevelam matching placebo for 12 weeks
89210849|NCT00147745|Active Comparator|3|open-label Insulin Glargine for 12 weeks
89613775|NCT04613297|Other|COVID-19 uninfected patients|Patient with negative PCR result
89613776|NCT04613297|Other|non-hospitalized COVID-19 infected patients|Patient with positive PCR result who does not require hospitalization for COVID-19
89613777|NCT04613297|Other|hospitalized COVID-19 infected patients|Patient with positive PCR who require hospitalization for COVID-19
89613778|NCT02165722|Experimental|Intervention: Toolkit|4 Pillars Toolkit
89613779|NCT02165722|No Intervention|No Intervention: Standard practice|11 Clinical Practices [control sites]
89613780|NCT04654143|Experimental|Single Ascending Dose (SAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo.
89613781|NCT04654143|Experimental|Multiple Ascending Dose (MAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo.
89035636|NCT02933333|Experimental|G-CSF + GM-CSF|Eligible patients received subcutaneous a combination of GM-CSF 5 μg/kg per day and G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF and G-CSF are given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
89035637|NCT02911584|Active Comparator|Sacral colpopexy|Laparoscopic procedure
89035638|NCT02911584|Active Comparator|POPS|Laparoscopic procedure: Pelvic Organs Prolapse Suspension
89035639|NCT02933294|Active Comparator|Triportal pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
89035640|NCT02933294|Active Comparator|Uniportal pulmonary resection surgery|Treated by minimally invasive video assisted thoracoscopic single-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
89035641|NCT02934828|Experimental|Neoadjuvant chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year. RECIST is used once every 2 cycles. Patients will finish 6 cycles preoperative chemotherapy when CR/partial response(PR)/stable disease(SD) by RECIST without serious adverse events.
89613782|NCT04654143|Experimental|Food Effect|This cohort has 6 subjects randomized to BVL-GSK098 and 2 subjects randomized to placebo. Each participant will receive a single oral dose of BVL-GSK098 or placebo administered after the participant eats a high-fat, high calorie breakfast.
89613783|NCT01882985|Experimental|Treatment (docetaxel and lycopene)|Patients receive docetaxel IV over 1 hour on day 2 and lycopene PO once daily on days 1-21. Treatment repeats every 21days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
89613784|NCT04648761|Experimental|OPTIMAL group|This group will have their anti IL 5 biologics titrated by OPTIMAL algorithm
89035642|NCT02934828|Active Comparator|postoperative chemotherapy|Postoperative Chemotherapy:Standard chemotherapy regiments according to risk of recurrence: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
89035643|NCT02933216||VR|The CSD patients are received treatment of vaginal repair.
89613785|NCT04648761|No Intervention|Control group|This group will continue their treatment with anti IL 5 biologics unchanged
89613786|NCT04277481||Group 1 (10 minute cold pack)|10 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
89035644|NCT02933216||hysteroscope + laparoscope|The CSD patients are received treatment of hysteroscopic combined with laparoscopic excision.
89035645|NCT02670252|Experimental|BUCY|For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
89035646|NCT02670252|Active Comparator|TBICY|For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.
89035647|NCT02933177|Experimental|2 months control condition - 4 months chariot-flash|"200 patient , in 15 nursing homes randomly will be exposed two months in the control condition (usual intervention) and 4 months in the experimental condition (chariot-flash intervention). The experimental condition is to propose the chariot-flash in emergency during the emergence or increase of productive symptoms."
89035648|NCT02933177|Experimental|4 months control condition-2 months chariot flash|200 patient, in 14 other nursing homes will be exposed 4 months in the control condition and 2 months in the experimental condition
89035649|NCT02911467|Experimental|MR imaging with hyperpolarized 13C pyruvate of men with CRPC|75 men with castration-resistant prostate cancer (CRPC) will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at baseline and after 1 month of treatment with an androgen signaling inhibitor. Patients with CRPC that is not primarily refractory (defined as disease progression by PCWG2 criteria within 6 months of treatment initiation) to Androgen Signaling Inhibitors (ASI) treatment will undergo a third metabolic MR scan at the time of disease progression. Patients may undergo optional MR- or CT-guided tumor biopsies at baseline and at the time of disease progression.
89613787|NCT04277481||Group 2 (12 minute cold pack)|12 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
89613788|NCT04277481||Group 3 (15 minute cold pack)|15 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
89035650|NCT02934789|Active Comparator|Study group: surgical arm|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
89035651|NCT02934789|Active Comparator|Control group: medical arm|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids
89035652|NCT02933099|Experimental|Aprepitant arm|Aprepitant+palonosetron+dexamethasone
89035653|NCT02933099|Active Comparator|Control arm|palonosetron+dexamethasone
89035654|NCT02935023|Experimental|CIRT with systemic therapy arm|Carbon ion radiotherapy combined with systemic therapy
89035655|NCT02934906||Control Group|Pregnant women with anti-HPA antibody negative from the same hospital, the same race, and the same gravidity and parity, who are admitted at the same time.
89035656|NCT02934906||Experimental Group|pregnant women with anti-HPA antibody positive
89613789|NCT04277481||Group 4 (20 minute cold pack)|20 min, s package (35 * 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
89613790|NCT02166346|Experimental|Dalfampridine then Placebo|All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
89613791|NCT02166346|Experimental|Placebo the Dalfampridine|All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
89613792|NCT01893905|Experimental|CS+SG|Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks
89613793|NCT01893905|Placebo Comparator|Placebo|Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks
89613794|NCT04460235|Other|Vaccination|All patients will be vaccinated according to national guidelines
89613795|NCT01050946|Other|Haploidentical/cord transplant|Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
89035657|NCT02911350|Experimental|Hormone Suppressors, Paclitaxel & Radiation therapy|"Hormone Suppressors: Patients may take any of the following combinations for a period of 6 months:~Lupron / Flutamide~Zoladex/ Flutamide~Lupron/ Casodex~Zoladex/ Casodex~Paclitaxel: 30 mg/m2 twice a week administered as a one hour infusion either Monday & Wednesday or Tuesday & Thursday for eight consecutive weeks will be started within the first week of radiation therapy. Following the first 3 dose levels, the dose of Paclitaxel will be escalated to 35 mg/m2 (dose level IV), 40 mg/m2 (dose level V) & 45 mg/m2 (dose level VI).~Radiation Therapy: 5 days a week for 8 weeks to a total dose of 66.6 to 73.8 Gray depending on when patient enter the study."
89035658|NCT04623983|Experimental|resilient bonding tray|Patients receiving resilient orthodontic bonding trays
89035659|NCT04623983|Experimental|rigid bonding tray|Patients receiving rigid orthodontic bonding trays
89035660|NCT02911428||dosages of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.25 ml, during the study under Protocol 02-E-2015 in October-November 2015.
89035661|NCT02911428||dosages of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.
89035662|NCT02911389|Active Comparator|Home PT via web-based platform|unsupervised, home rehabilitation delivered by a web-based platform
89035663|NCT02911389|Active Comparator|Home PT via paper manual|unsupervised, home rehabilitation delivered by a paper manual
89613796|NCT03677661|Active Comparator|Conventional approach|Graded aerobic exercise and advice for graded cognitive stimulation approach based on the 2016 Berlin consensus
89613797|NCT03677661|Experimental|Personalized rehabilitation program|Cervico-vestibular rehabilitation personalized patient-centered clinical program combined with the exercise and advice of the conventional approach
89613798|NCT03015922|Experimental|Lenalidomide or pomalidomide, plus REOLYSIN|"Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.~Plus (all patients):~REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles."
89613799|NCT01893827|Active Comparator|XR-NTX|Xr-NTX 380mg IM injection monthly x 6 months
89613800|NCT01893827|Active Comparator|Oral Naltrexone|Oral naltrexone 50mg/day x 6 months
89613801|NCT03015766|Experimental|Auricular acupressure therapy|Participants in the treatment group will received AAT on five active acupoints including Acup.1. Shen Men (Spiritual Gate, TF4), Acup.2. Jiao Gan (Sympathetic autonomic, AH6a), Acup.3. Xin (Heart, CO15), Acup.4. Pi Zhi Xia (Subcortex, AT4), Acup.5. Nei Fen Mi (Endocrine, CO18)
89613802|NCT03015766|Sham Comparator|sham auricular acupressure therapy|Participants in the control group (SAA group) will receive auricular acupressure on five Helix points (HX 5-9), which were clearly remote from the inner ear area. These points have no evidence for insomnia management.
89613803|NCT03222843|Experimental|Arm 1|oral hetrombopag at an initial dose of 2.5 mg once daily
89613804|NCT03222843|Experimental|Arm 2|oral hetrombopag at an initial dose of 5 mg once daily
89613805|NCT03222843|Placebo Comparator|Arm 3|oral placebo at an initial dose of 2.5 mg once daily
89613806|NCT03222843|Placebo Comparator|Arm 4|oral placebo at an initial dose of 5 mg once daily
89613807|NCT03015688||knee OA|OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons Participants who met the following criteria were excluded：the knee OA concomitant with hip OA, suppurative and rheumatoid arthritis, gout patients, patients who underwent knee arthroscopy surgery within 6 months, bilateral or unilateral knee replacements, the knee joint trauma patients, histories of glucocorticoid and/or sterol hormones.
89613808|NCT03015688||Control|"no often have pain, aching or stiffness in your Left/right knee during last month,no Left/right knee trauma history,no histories of glucocorticoid and/or sterol hormones normal knee X-ray images,"
89613809|NCT01882907|Experimental|vildagliptin|vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
89613810|NCT01882907|Active Comparator|pioglitazone|Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
89613811|NCT04073823|Active Comparator|Flexitouch Plus|
89613812|NCT04073823|Experimental|Flexitouch Plus with SW|
89613813|NCT04049955|Experimental|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
89035664|NCT02911389|Active Comparator|outpatient PT|outpatient physical therapy
89035665|NCT02933138||Multifactorial Chylomicronemia|no intervention, phenotypic and genotypic study
89613814|NCT01051570|Experimental|Carboplatin, RAD 001 & Prednisone|"Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle~RAD 001: 5 mg Orally daily, starting from Day 2 continuously~Prednisone 5 mg Orally twice daily, continuously"
89613815|NCT04046601|Experimental|Impedance|every resected tissue will measured by an impedance probe
89613816|NCT01893281|Experimental|Topical Testosterone Solution|Topical Testosterone Solution 30 milligrams up to 120 milligrams per day (mg/day) administered topically to axillae titrated based on testosterone levels.
89035666|NCT02933021||All participants|Nurse visit for blood sample, questionnaire and phone call
89613817|NCT01893203|Other|BF-200 ALA vs MAL|BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design
89613818|NCT04023435|Experimental|PNE education|All subjects will be tested before and after receiving PNE education
89613819|NCT05263947|Experimental|Arm A|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Icotinib 250 mg tablets shall be administered orally 3 times every day at least one hour before or two hours after the ingestion of food.
89035667|NCT02934750|Experimental|Pursed lip breathing|In this arm, patients will be asked to perform a six-minute walking test while continuously using the pursed lip breathing technique.
89613820|NCT04415567||lenvatinib|high-risk patients with HBV-related HCC who took lenvatinib as adjuvant therapy after liver transplantation
89613821|NCT04415567||control|high-risk patients with HBV-related HCC who received routine treatment and follow-up after liver transplantation
89613822|NCT04723576|Experimental|Stress First Aid|"The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. SFA sites will implement SFA through a train-the-trainer model."
89613823|NCT04723576|No Intervention|Usual Care|The cRCT will be comprised of three cohorts of matched pairs representing approximately 40 diverse sites (12-15 pairs of hospitals hospitals and 5-7 pairs of clinics/practices) to determine whether SFA for frontline HCWs improves mental and physical well-being compared to Usual Care (UC). Each pair will be assigned to either SFA or UC using a simple 1:1 randomization. UC sites will not implement SFA during the study period but will be given full access to all implementation materials following the conclusion of their participation.
89613824|NCT03280251|Experimental|Methylphenidate and structured cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
89613825|NCT03280251|Experimental|Placebo and structured cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
89613826|NCT03280251|Experimental|Methylphenidate and pseudo cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
89613827|NCT03280251|Experimental|Placebo and pseudo cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
89613828|NCT01882829|Experimental|Nuedexta (dextromethorphan/quinidine)|45/10 mg every 12 hours x 8 weeks
89613829|NCT04399005|Experimental|daily room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
89613830|NCT04399005|Experimental|after-each-case room disinfection|Room disinfection was defined as the cleansing and disinfection of the surface of the facility, endoscopist's gown, and air in the endoscopy room after the examination. Specifically, sanitizing wipes wiped the surface of the facility one by one, containing quaternary ammonium salt, alcohol, and interfacial activator; the air disinfection machine continued for 30min of air disinfection. After-each-case room disinfection was defined as after completing each case.
89613831|NCT04760301|Experimental|local tranexamic acid injection to cervix|1 gr of Tranexamic acid diluted in 10 ml saline
89613832|NCT04760301|Placebo Comparator|local normal saline injection to cervix|20 ml of saline
89613833|NCT04760301|Experimental|IV 1 g tranexamic acid|1 gr of Tranexamic acid diluted in 100 ml saline- IV
89613834|NCT04760301|Placebo Comparator|IV 1 g normal saline|100 ml saline- IV
89613835|NCT02170870|Experimental|Healthy Controls Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
89613836|NCT02170870|Placebo Comparator|Healthy Controls Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
89613837|NCT02170870|Experimental|Diabetics Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
89613838|NCT02170870|Placebo Comparator|Diabetics Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
89035668|NCT02934750|No Intervention|Usual breathing|In this control arm, patients will be asked to perform a six-minute walking test while breathing normally.
89035669|NCT02932709||Patients admitted of Psychiatry|Only patients who had a suicide attempt admitted to the Department of Emergency Psychiatry.
89035670|NCT02932514|Experimental|Eversense (Senseonics) CGM System|
89035671|NCT02911311|Experimental|IVC group|intravitreal injection of conbercept (IVC) group：all study eyes randomised to receive conbercept will receive an intravitreal injection of conbercept 2 mg/ 0.05 mL at baseline and at 1 and 2 moths. Further treatment since months 3 is determined by the degree of regression of neovascularization (NV) of disc and elsewhere on clinical examination
89035672|NCT02911311|Active Comparator|PRP group|panretinal photocoagulation (PRP) group:all study eyes randomised to receive PRP will receive an fill-in PRP in 1-2 two weekly sessions as per routine clinical practice with emphasis on targeting retinal nonperfusion areas
89613839|NCT02170870|Experimental|Functional Dyspepsia Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
89035673|NCT02932631|Active Comparator|CONVENTIONAL PHYSICAL THERAPY group|"physical exercises divided into three phases:~stretching, strengthening and/or mobilization;~functional training of the affected muscles;~functional training of the paretic limb."
89613840|NCT02170870|Placebo Comparator|Functional Dyspepsia Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
89613841|NCT04400097|Experimental|hidden-knot group|
89613842|NCT04400097|Active Comparator|two-knot group|
89613843|NCT04400097|Active Comparator|multi-knot group|
89613844|NCT04678648|Experimental|RSC-1255 Treatment|Single Arm Study. All study participants receive RSC-1255.
89613845|NCT03014986||Patients who receive HCV treatment|HSCT patients with HCV who are receiving (or has recently received) HCV treatment
89613846|NCT03014986||Patients who do not receive HCV treatment|HSCT patients with HCV who have not received treatment
89613847|NCT03015454|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the UCSF electronic health record.
89613848|NCT03015454|Active Comparator|Without InSight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the UCSF electronic health record.
89613849|NCT04760379|Active Comparator|Conventional Therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
89613850|NCT04760379|Experimental|Vibration Therapy|Focal muscle vibrator (FMV) (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
89613851|NCT03014908||NMR-T1DM|type 1 diabetic children and adolescents
89613852|NCT03014908||NMR-C|non-diabetic children and adolescents
89613853|NCT01054768|Experimental|alpha-lipoic acid and acetyl-L-carnitine|alpha-lipoic acid and acetyl-L-carnitine1400 mg tablet twice a day for 6 months.
89613854|NCT01054768|Placebo Comparator|Placebo|1400 mg placebo tablet twice a day for 6 months.
89613855|NCT04387617|Experimental|CBD Oil Group|
89613856|NCT04387617|Placebo Comparator|Control Group|
89613857|NCT03014830|Active Comparator|Alirocumab|Subjects will receive alirocumab for 6 weeks.
89613858|NCT03014830|Placebo Comparator|Placebos|Subjects will receive placebo for 6 weeks.
89613859|NCT05237193||malignant biliary obstruction|Pre-surgery patients with malignant biliary obstruction will be the experimental group to determine the sensitivity and specificity of UCAD analysis, the result will be compared with cytology.
89035674|NCT02932631|Experimental|containment therapy induced|healthy side is restricted with splinting and exercises in hemiparetic member: carry out functional tasks individually. Each task will be held for 5 minutes, totaling 60 minutes of service
89035675|NCT02932358|Active Comparator|Flexible Family Visitation Model (FFVM)|In the FFVM, two or fewer family members will be allowed to visit the patient for up to 12 consecutive hours each day. In addition to family visitation, patients will be allowed to receive social visits in specific time intervals (according local ICU regulation). To have access to the FFVM, family members of ICU patients will have to attend a structured meeting at ICU in which they will receive orientations about the ICU environment, common ICU treatments, rehabilitation and basic infection control practices, multidisciplinary work at ICU and palliative treatment. Social visitors will not be required to attend the structured meeting.
89613860|NCT05237193||Benign biliary obstruction|Patients being treated for other biliary diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UCAD analysis.
89613861|NCT04277403|Experimental|HA-WBRT+SIB|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a simultaneously integrated boost (SIB) to each brain metastasis
89613862|NCT04277403|Active Comparator|SRS|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases
89613863|NCT03014596|Experimental|Intervention|The Assert-method will be used in the counselling of adolescents with mental health problems
89613864|NCT03014596|No Intervention|Control|Treatment as usual, i.e. tha Assert-method will not be used in the counselling
89613865|NCT04365465|Experimental|Active device|Participants in this arm will receive an active NSS-Bridge device placed immediately following their cesarean section.
89613866|NCT04365465|Sham Comparator|Placebo device|Participants in this arm will receive an inactive (sham) NSS-Bridge device placed immediately following their cesarean section.
89613867|NCT04365465|Active Comparator|Active Control|Participants in this arm will receive no device, only the standard postpartum pain control.
89613868|NCT04398615|Experimental|Intervention|Single arm, receiving the experimental device
89613869|NCT01055704|Experimental|Methylnaltrexone|
89613870|NCT01055704|Experimental|Codeine|
89613871|NCT01055704|Experimental|Methylnaltrexone + codeine|
89613872|NCT01055704|Placebo Comparator|Placebo|
89613873|NCT03280017|Experimental|Ketamine|Participant allocated to this arm will receive intravenous ketamine infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
89613874|NCT03280017|Placebo Comparator|Normal saline|Participant allocated to this arm will receive intravenous normal saline solution infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
89613875|NCT01882439|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
89613876|NCT01882439|Experimental|Treatment Sequence B|Tofacitinib 10 mg BID for 6 months
89613877|NCT01882439|Placebo Comparator|Treatment Sequence C|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
89613878|NCT01882439|Placebo Comparator|Treatment Sequence D|Placebo for 3 months then tofacitinib 10 mg BID for 3 months
89613879|NCT05236491|Active Comparator|Trajectory A|"Participants who have received 3 doses of an mRNA vaccine, will be offered a choice between a fourth dose of an mRNA vaccine and a dose of a protein subunit vaccine (PSV) (Novavax NUVAXOVID)~For the Moderna SPIKEVAX Bivalent Original/Omicron BA.4/5: participants will receive one (1) intramuscular injection of 0.5 mL (50 mcg).~For the Novavax Nuvaxovid vaccine: participants will receive one (1) intramuscular injection of 0.5 mL (5 mcg) of Novavax Nuvaxovid."
89613880|NCT05236491|No Intervention|Trajectory B|Participants who have already received a 4 doses or more of COVID-19 vaccine in the community at inclusion and do not wish to receive a 5th dose of vaccine in the study.
89210850|NCT04542486|Experimental|The conventional approach:|Gingivoplasties and removal of excess gingival tissues through the conventional scalpel technique using a reverse bevel.
89613881|NCT05236491|Active Comparator|Trajectory B5|"Participants who have received 4 doses of an mRNA vaccine at inclusion and wish to receive a dose of a protein subunit vaccine (PSV) (Novavax NUVAXOVID) as a fifth dose.~For the Novavax Nuvaxovid vaccine: participants will receive one (1) intramuscular injection of 0.5 mL (5 mcg) of Novavax Nuvaxovid."
89613882|NCT02246686|Experimental|STW5-II|Half of study population, assigned randomly
89613883|NCT02246686|Placebo Comparator|Placebo|Half of study population, assigned randomly
89613884|NCT04400019|No Intervention|Tracking control|"According to the randomization process described, those nursing homes assigned to the control arm of the trial will receive the same treatment as those assigned to the intervention group, except for the medication, which will be a masked placebo.~The study is triple blind, so neither the professionals who carry out the follow-up, nor the patients, nor the person in charge of analyzing the data, know to which group each nursing home belongs."
89613885|NCT04400019|Experimental|Intervention|The dose to be used as chemoprophylaxis will be 800mg of Hydroxychloroquine (HCQ) on the first day and 400mg during the subsequent four days. Participating subjects will be followed up at 6, 14 and 28 days.
89613886|NCT01055782|Experimental|With endoguide|Colonoscopy completed with endoguide
89613887|NCT01055782|No Intervention|Without endoguide|Colonoscopy completed without endoguide
89613888|NCT05225805|Experimental|Group A|Group A will receive one dose of 150 mg lefamulin IV followed by one dose of 600 mg lefamulin oral
89613889|NCT05225805|Experimental|Group B|Group B will receive one dose of 600 mg lefamulin oral followed by one dose of 150 mg lefamulin IV
89613890|NCT01056016|No Intervention|Wait-list control|Wait-list control group
89613891|NCT01056016|Experimental|ADHD Collaborative Intervention|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a Diagnostic and Statistical Manual-IV (DSM-IV) based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales. The intervention lasts for 6 months.
89613892|NCT01056328|Experimental|St. Jude Medical Cardiac Ablation System|
89210851|NCT04542486|Active Comparator|The intervention approach:|"Gingivoplasties and elimination of excess gingival tissues through the use of Soft tissue trimmer."
89613893|NCT01056328|Active Comparator|FDA approved Open Irrigated Radio Frequency Ablation System|
89613894|NCT04358913|Experimental|MR Imaging on the Alberta linac-MR P3 system|All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.
89613895|NCT01892657|Experimental|Facial Moisturizer with SPF 50+|All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
89613896|NCT04351581|Experimental|A: COVID+ Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose. The clinicians will be encouraged to continue the medication throughout the hospital admission but it will be permissable for the clinician to stop treatment if necessary e.g. due to hypotension.
89613897|NCT04351581|Experimental|B: Covid+ Discontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during hospital admission the clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during hospital admission. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
89613898|NCT04351581|Experimental|C: COVID% Continuation|The enrolled patients will continue their prescribed ACEi/ARB in the same dose.
89613899|NCT04351581|Experimental|D: COVID% DIscontinuation|The enrolled patients will discontinue their prescribed ACEi/ARB. If hypertensive treatment is necessary during the study period clinicians will first be encouraged to start non-ACEi/non-ARB treatment; however, if needed it will be possible to start ACEi/ARB again during the study period. After study completion (30 days from randomization) the patients will be reminded to seek their generel practitioner to reinitiate ACEi/ARB treatment.
89613900|NCT01057888|Experimental|Autodialer|Autodialer reminder/recall
89613901|NCT01057888|Experimental|Letters|Mailed reminder letters
89613902|NCT01057888|No Intervention|Controls|Controls
89210852|NCT00929292|Experimental|Modilac Dahlia 1|Formula enriched with alpha-lactalbumin and containing a probiotic
89613903|NCT01881737|Experimental|Pregnenolone|Pregnenolone up to 500 mg per day
89613904|NCT01109056|Experimental|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
89613905|NCT01109056|Placebo Comparator|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
89613906|NCT04760145|Experimental|Intervention Group|Multicomponent exercise with blood flow restriction
89613907|NCT04760145|Active Comparator|Control Group|Multicomponent exercise without blood flow restriction
89613908|NCT03870399|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
89613909|NCT01109602|Experimental|Arm 1: Yoga Group|"Yoga Group, 8 week bi-weekly in-person yoga training focused on strength, flexibility, and balance~Yoga focused on strength, flexibility, and balance"
89210853|NCT00929292|Placebo Comparator|Modilac 1|Regular milk
89210854|NCT05632965||Healthy preterm infants|Thyroid function in Preterm infants not needing hospital admission will be estimated at day 3 and day 10 of life.
89210855|NCT05632965||Sick preterm infants|Thyroid function in sick preterm infants admitted to NICU will be estimated at day 3 and day 10 of life .
89210856|NCT01326169|Active Comparator|Standard care|No intervention
89210857|NCT01326169|Experimental|Counseling|Telephone-delivered counseling
89210858|NCT00642902|Experimental|Atacicept 25 mg|
89210859|NCT00642902|Experimental|Atacicept 75 mg|
89210860|NCT00642902|Experimental|Atacicept 150 mg|
89210861|NCT00642902|Placebo Comparator|Placebo|
89210862|NCT00925470||1|
89613910|NCT01109602|Experimental|Arm 2: Yoga Group Plus|"Yoga Group Plus: 8 week, bi-weekly in-person yoga training focused on strength, flexibility, and balance paired with almost daily at home yoga focused on breathing and relaxation.~Yoga focused on strength, flexibility, and balance~Data for both yoga groups were combined for analyses as there were not any differences between these two groups."
89613911|NCT01109602|No Intervention|Arm 3: Wait list control group|wait-list control: will be assessed before and after 8 weeks. Will then be offered the 8 week yoga intervention.
89613912|NCT02175472|Active Comparator|Spectramax light therapy device|Light therapy device which emits a specific bandwidth combination and intensity of light.
89613913|NCT02175472|Sham Comparator|Control light device|Light therapy device, identical in appearance and operation to the Spectramax device, except that it produces a different bandwidth and intensity, which is not believed to produce a therapeutic response.
89613914|NCT03014752|Active Comparator|Classical ketogenic diet|The classical ketogenic diet with 4:1 ketogenic ratio, each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced.
89613915|NCT03014752|Active Comparator|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
89613916|NCT01892501|Other|hypermetabolic mediastinal lymph nodes in PET,|hypermetabolic mediastinal lymph nodes in PET,in a context of New cancer or cancer recurrence.
89613917|NCT04333407|Experimental|Active Arm|
89613918|NCT04333407|No Intervention|Control Arm|
89613919|NCT04398225|Experimental|Cohort 1 (9-12 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
89613920|NCT04398225|Experimental|Cohort 2 (9-12 y)|Centanafadine extended release capsule; 200 mg adult equivalent; twice daily for 14 days
89613921|NCT04398225|Experimental|Cohort 3 (9-12 y)|Centanafadine extended release capsule; 400 mg adult equivalent; twice daily for 14 days
89613922|NCT04398225|Experimental|Cohort 4 (6-8 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
89613923|NCT04398225|Experimental|Cohort 5 (4-5 y)|Centanafadine extended release capsule; 100 mg adult equivalent; twice daily for 14 days
89613924|NCT04398147|Experimental|phase ⅠLow single dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
89613925|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (18-<55)|6 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
89613926|NCT04398147|Experimental|phase ⅠLow 2 dose (18-<55)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
89613927|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (18-<55)|6 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
89613928|NCT04398147|Experimental|phase ⅠLow single dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
89613929|NCT04398147|Placebo Comparator|phase ⅠPlacebo low single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
89613930|NCT04398147|Experimental|phase ⅠLow 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
89613931|NCT04398147|Placebo Comparator|phase ⅠPlacebo low 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
89613932|NCT04398147|Experimental|phase ⅠMedium single dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
89613933|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium single dose (65-<85)|3 subjects, Placebo containing 0 vp, single dose, Intramuscular administration
89613934|NCT04398147|Experimental|phase ⅠMedium 2 dose (65-<85)|12 subjects, Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
89613935|NCT04398147|Placebo Comparator|phase ⅠPlacebo medium 2 dose (65-<85)|3 subjects, Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
89613936|NCT04398147|Experimental|Phase II Low single dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
89613937|NCT04398147|Placebo Comparator|Phase II placebo low single dose (18-<55)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
89613938|NCT04398147|Experimental|Phase II Low 2 dose (18-<55)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
89613939|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (18-<55)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
88985908|NCT00473551|Experimental|Anti-Third Party T Lymphocytes + Nonmyeloablative SCT|"Anti-Third Party CTL (Cytolytic T-lymphocytes) with Nonmyeloablative SCT (Stem Cell Transplantation)~Rituximab 375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8; + Cyclophosphamide 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine; + Fludarabine 40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6; + Radiation 2Gy Total body radiation day before transplantation + Stem Cell Transplantation + Intravenous infusion of Anti-third Party CTLs."
88985909|NCT00473863|Experimental|intervention|Receives CCTA
88985910|NCT00473863|No Intervention|Control|
88985911|NCT00117026|Experimental|Benfotiamine|Benfotiamine 300mg/day
88985912|NCT00117026|Placebo Comparator|Placebo|Placebo for benfotiamine
88985913|NCT00473980|Experimental|Drug|Treatment with indomethacin or celecoxib
88985914|NCT00473980|Sham Comparator|SHAM|Sham treatment
88985915|NCT05396313||Zhongshan Hospital cohort|Patients receiving CIED implantation at Zhongshan Hospital
88985916|NCT05396313||Fuwai Hospital cohort|Patients receiving CIED implantation at Fuwai Hospital
88985917|NCT05396313||Shanghai Chest Hospital cohort|Patients receiving CIED implantation at Shanghai Chest Hospital
88985918|NCT00474019|Experimental|1|Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg
88985919|NCT00474136|Experimental|1|
88985920|NCT00474136|Experimental|2|
88985921|NCT00474136|Active Comparator|3|
88985922|NCT03270709|Experimental|HIV+ smokers|Vitamin D3 450,000 IU orally
89613940|NCT04398147|Experimental|Phase II Low single dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, single dose, Intramuscular administration
89613941|NCT04398147|Placebo Comparator|Phase II placebo low single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
89613942|NCT04398147|Experimental|Phase II Low 2 dose (55-<85)|50 subjects, Ad5-nCoV containing 5E10 vp, 2 dose 56 days apart, Intramuscular administration
89613943|NCT04398147|Placebo Comparator|Phase II placebo low 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
89613944|NCT04398147|Experimental|Phase II medium single dose (55-<85)|50 subjects, Ad5-nCoV containing 10E10 vp, single dose, Intramuscular administration
89613945|NCT04398147|Placebo Comparator|Phase II placebo medium single dose (55-<85)|10 subjects，Placebo containing 0 vp, single dose, Intramuscular administration
89613946|NCT04398147|Experimental|Phase II medium 2 dose (55-<85)|50 subjects，Ad5-nCoV containing 10E10 vp, 2 dose 56 days apart, Intramuscular administration
89613947|NCT04398147|Placebo Comparator|Phase II placebo medium 2 dose (55-<85)|10 subjects，Placebo containing 0 vp, 2 dose 56 days apart, Intramuscular administration
89613948|NCT04398147|Experimental|Phase II Low 1 or 2 dose (18-<55)|100 subjects，Ad5-nCoV containing 5E10 vp, 1or2 dose, Intramuscular administration ，according to the Previous trial results
89613949|NCT04398147|Placebo Comparator|Phase II placebo 1 or 2 dose (18-<55)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
89613950|NCT04398147|Experimental|Phase II Low or medium dosage 1 or 2 dose (55-<85)|100 subjects，Ad5-nCoV containing 5E10 vp or 10E10vp, 1or2 dose, Intramuscular administration，according to the Previous trial results
89613951|NCT04398147|Placebo Comparator|Phase II placebo Low or medium,1 or 2 dose (55-<85)|20 subjects，placebo containing 0 vp, 1or2 dose, Intramuscular administration
89613952|NCT04398927|Experimental|Folfirinox plus PD1|Patients treated with systemic chemotherapy(regimen: Folfirinox) plus PD1
89613953|NCT03203889|Experimental|CRAFT-AI|Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided. A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use. The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities. In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use. The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
89613954|NCT03203889|Active Comparator|12-step facilitation for loved ones|12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions. There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease. The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP. The CSO works to decrease enabling behaviors. Counselors will help the CSO to work the program of Nar/Al-Anon.
89613955|NCT03203187|Placebo Comparator|No mango intake|No mango intake for two weeks
89613956|NCT03203187|Experimental|330 grams of daily mango intake|330 grams (2 cups) of daily mango intake for two weeks
89613957|NCT05194059|Experimental|Experimental Group|Participants will follow a personalized activity pacing program for 16 weeks with the support of a heath band and a mobile application for tablet
88985923|NCT03270709|Active Comparator|HIV- non-smokers|Vitamin D3 450,000 IU orally
88985924|NCT03270709|Active Comparator|HIV+ non-smokers|Vitamin D3 450,000 IU orally
88985925|NCT03270709|Active Comparator|HIV- smokers|Vitamin D3 450,000 IU orally
88985926|NCT04727892||complications after epilepsy surgery|Group A with no complication; Group B with complications
88985927|NCT03270592|Other|Service dogs|Single arm study using a before after design where Before represent having a regular companion dog and after represent having a certified service dog
88985928|NCT03270553|Experimental|Sequence 1|In Period 1, subjects receive metformin alone; in Period 2, subjects receive metformin + plazomicin
88985929|NCT03270553|Experimental|Sequence 2|In Period 1, subjects receive metformin + plazomicin; in Period 2, subjects receive metformin alone
88985930|NCT03270202|Experimental|PAI group|Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.
89613958|NCT05194059|No Intervention|Control Group|Participants will follow a personalized activity pacing program for 16 weeks without any other support
89613959|NCT01059682|Experimental|Dalcetrapib|
89613960|NCT01059682|Placebo Comparator|Placebo|
89613961|NCT04398693|No Intervention|Normotensive Patients|40 normotensive patients with systolic BP (SBP) < 140 mmHg and diastolic BP (DBP) < 90 mmHg at the office, without the use of antihypertensive drugs and evaluated through ambulatory blood pressure monitoring (ABPM) to confirm normotension (BP < 130/80 mmHg) and the exclusion of possible masked hypertension.
89613962|NCT04398693|No Intervention|Controlled Hypertensive Patients|40 controlled hypertensive patients using up to three antihypertensive drugs with SBP < 130 mmHg and DBP < 80 mmHg evaluated through 24 hours ambulatory blood pressure monitoring (ABPM).
89613963|NCT04398693|Active Comparator|Resistant Hypertensive Patients|The study will be double-blinded, randomized, placebo-controlled crossover Initially, 20 individuals of the resistant hypertensive group will take prebiotic for 4 weeks, while other 20 individuals this group will use placebo. After a washout period of 4 weeks, the study protocol will be repeated in the other arm.
89613964|NCT04399083|Experimental|Single Arm|
89613965|NCT01892345|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction Period: Participants received eculizumab (900 milligrams [mg]) via intravenous (IV) infusion once a week (every 7 ± 2 days) for 4 weeks followed by eculizumab 1200 mg for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received eculizumab (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
89613966|NCT01892345|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (900 mg) via IV infusion once a week (every 7 ± 2 days) for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received matching placebo (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
89613967|NCT01059760|Other|Fasting Day First|28±4 hours of water-only fasting followed by 28±4 hours fed
89613968|NCT01059760|Other|Fed Day First|28± 4 hours fed followed by 28± 4 hours of fasting
89613969|NCT04399785|Experimental|Arm 1|
89613970|NCT01059994|Placebo Comparator|placebo sildenafil young|Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.
89613971|NCT01059994|Experimental|sildenafil young|Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.
89613972|NCT01059994|Placebo Comparator|placebo sildenafil older|Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.
89613973|NCT01059994|Experimental|sildenafil older|Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.
89613974|NCT01061476|Other|Single arm - Sleep apnea|"Participants with sleep apnea will be recruited for the study. Each participant will undergo 3 sleep studies to assess the effect of the Provent™ device. Participants will only use the device while they are in the sleep laboratory. They will not use the device at home between sleep studies .~Baseline sleep study (No device) - Assess the effects of no Provent™ on sleep apnea severity.~Treatment sleep study (Provent™ device used) - Assess the effects of Provent™ on sleep apnea severity~Physiology sleep study (Provent™ on/off) - Assess the physiological effects of the Provent™ device on breathing during sleep."
89613975|NCT01111162|Experimental|Vaccine|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
89613976|NCT04398303|Experimental|ACT-20-MSC in ACT-20-CM|Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously
89613977|NCT04398303|Experimental|ACT-20-CM|Conventional treatment plus ACT-20-CM administered intravenously
89613978|NCT04398303|Placebo Comparator|Placebo|Conventional treatment plus placebo (MEM-α) administered intravenously
89613979|NCT03784287|Experimental|AX 250|All subjects will receive AX 250 at the MTTD established in 250-201, 300mg administered weekly by ICV infusion that will continue for up to 240 weeks.
89613980|NCT03772743|Other|Culprit-only revascularization|All patients randomized to culprit only revascularization must not undergo percutaneous coronary intervention (PCI) any lesion except from the culprit lesion already treated at the moment of the randomization. Staged procedures are considered protocol violation.
89613981|NCT03772743|Other|Complete functionally-guided revascularization|Patients who are randomized to this strategy will receive revascularization of the culprit lesion and guided by functional assessment on all non-culprit lesions. Functional evaluation is mandatory for all stenosis with diameter stenosis % between 50 and 90% at visual estimation. Revascularization must be guided by functional assessment on all vessels. The system utilized to obtain functional evaluation is left to Operator's discretion. PCI is allowed only if functional evaluation is positive according to the threshold of the chosen functional system. It is suggested to achieve functional complete revascularization within the index procedure, while it is mandatory to obtain it within the index hospitalization.
89613982|NCT01111318|Experimental|BI 10773|50 mg single dose
89613983|NCT04760067||Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
89613984|NCT04760067||Artificial Turf|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
89613985|NCT04760067||Wood Parquet|After obtaining the demographic information of the athletes participating in our study, information about injury anxiety and injury anxiety will be collected with the Sports Injury Anxiety Scale.
89613986|NCT03571048|Active Comparator|Reduced Calorie Diet (RCD)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
89613987|NCT03571048|Experimental|Time Restricted Feeding (TRF)|Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.
88985931|NCT03270202|Active Comparator|Usual care|Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
88985932|NCT00116883|Experimental|Arm 1|
88985933|NCT03270397|Experimental|Active participants|"The first 20 students who signed up for the course: The group- theory and practice were included. No exclusion criteria were used. Full attendance in the course which includes 13 sessions was mandatory. In each session, students were assigned to different body image tasks that were discussed in the coming session. All students completed a self-report questionnaire at baseline and conclusion of the course."
88985934|NCT03270397|No Intervention|Controls|All the other students, that requested to sign up for the course but did not have a place, served as control group. All students completed a self-report questionnaire at baseline and conclusion of the course.
88985935|NCT03270280|Placebo Comparator|Normal Saline|The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo
88985936|NCT03270280|Experimental|Nigella Sativa|The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention
89035676|NCT02932358|Active Comparator|Restrictive Family Visitation Model (RFVM)|In the RFVM, patients will be allowed to receive restricted visits according routine ICU practices, but respecting the maximum limit of 4.5 hours of visitation per day. Visitors will not be required to attend the structured meeting. The length of ICU visits will be similar to those of social visits in the FFVM.
89035677|NCT04690257|Experimental|TICK-B group as Intervention group|"Experimental: TICK-B group~-Pediatric patients received TICK-B as a distraction in the TICK-B group"
89035678|NCT04690257|No Intervention|Standard care provided group as control group|-Pediatric patients received standard care (routine care) in the control group.
89035679|NCT02932397|Active Comparator|Propofol|Active drug given to patients as an intravenous dose of 0.5 mg/kg of propofol
89035680|NCT02932397|Placebo Comparator|Saline solution|Placebo drug given to patients as an intravenous dose of 0.05 mL/kg of saline solution (NaCl 0.9%)
89035681|NCT02932319|Active Comparator|Foley catheter|The patient will have an induction at home after 60 mn of fetal heart rate monitoring.
89035682|NCT02932319|Sham Comparator|Expectative|The patient in this arm will have the actual care (expectative until the next day befor starting the induction)
89035683|NCT02911272|Active Comparator|2-hour group|Augmentation of labour at 2-hour action line on the labour partograph
89035684|NCT02911272|Experimental|4-hour group|Augmentation of labour at 4-hour action line on the labour partograph
89613988|NCT01892189|Experimental|Sequence 1: Placebo + TAK-063 3 mg + TAK-063 30 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 milligram (mg), orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
89613989|NCT01892189|Experimental|Sequence 2: TAK-063 3 mg + TAK-063 30 mg + Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
89613990|NCT01892189|Experimental|Sequence 3: TAK-063 30 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
89613991|NCT01892189|Experimental|Sequence 4: Placebo + TAK-063 3 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
89035685|NCT02932241|Experimental|Computerized DBT skills training|The Computerized Dialectical Behavior Therapy Skills Training (cDBT) intervention includes 4 mindfulness, 6 emotion regulations, 2 distress tolerance, and 4 addiction skills. cDBT will retain the essence of DBT skills by being didactically focused, having a predetermined agenda driven by skills to be taught, emphasizing modeling through video vignettes, incorporating in session practice of skills whenever feasible, reviewing homework at beginning of sessions before teaching new skills, and assigning practice between sessions.
89035686|NCT02932241|No Intervention|Waitlist|A waitlist (WL) control condition was chosen considering the pilot nature of the study, feasibility, and the overall goal of assessing treatment's promise. Participants will be assessed for drinking and suicidal urges in the same manner as in the cDBT condition. After 8 weeks, subjects will be able to enroll in the intervention.
89035687|NCT02911194|Experimental|Treatment|a2 milk intervention period
89035688|NCT02911194|Placebo Comparator|Control|a1 containing milk (normal) intervention period
89035689|NCT02932436|Experimental|Empagliflozin|10 mg Empagliflozin daily per os for 12 weeks
89035690|NCT02932436|Experimental|Placebo|amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks
89035691|NCT02911155||US Nuclear Medicine Technologist|radiologic technologists certified in nuclear medicine
89035692|NCT02932670|Active Comparator|costoclavicular inflaclavicular block|costoclavicular block with similar volume
89035693|NCT02932670|Experimental|costoclavicular block|costoclavicular block with decreasing volume
89035694|NCT02910960|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
89035695|NCT02910960|Active Comparator|SharkCore Biopsy System|All patients will undergo sampling of pancreatic masses using the SharkCore Biopsy System. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
89035696|NCT02932124||1|manual chest compressions
89035697|NCT02932124||2|mechanical chest compression
89035698|NCT02932007|Experimental|Chloroquine Phosphate|Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.
89035699|NCT02932085|Active Comparator|rTMS + Wash-out period + Sham|"Five consecutive daily repetitive transcranial magnetic stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~Two weeks wash-out period~Five consecutive daily sham stimulation sessions"
89035700|NCT02932085|Sham Comparator|Sham + Wash-out period + rTMS|"Five consecutive daily sham stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~Two weeks wash-out period~Five consecutive daily repetitive transcranial magnetic stimulation sessions"
89035701|NCT02910882|Experimental|Single Arm|"Cohort I (PEGPH20 Dose Escalation + Gemcitabine and Concurrent Radiotherapy), First 3 Patients:~An abbreviated sequential dose escalation schema for the first 3 patients (each subsequent patient will be accrued only after no dose limiting toxicities are found in the first 2 weeks of concurrent therapy for the previous patient).~Intravenous (IV) PEGPH20, per dose escalation guidelines for first 3 patients; Intravenous (IV) Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);~Cohort II (PEGPH20 + Gemcitabine and Concurrent Radiotherapy), Patients 4 - 10:~IV PEGPH20, per dosing level determined in dose escalation (Cohort I); IV Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);"
89613992|NCT01892189|Experimental|Sequence 5: TAK-063 3 mg + TAK-063 300 mg+ Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period"
89613993|NCT01892189|Experimental|Sequence 6: TAK-063 300 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
89613994|NCT01892189|Experimental|Sequence 7: Placebo + TAK-063 30 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight:~Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period"
89613995|NCT01892189|Experimental|Sequence 8: TAK-063 30 mg + TAK-063 300 mg + Placebo|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
89613996|NCT01892189|Experimental|Sequence 9: TAK-063 300 mg + Placebo + TAK-063 30 mg|Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight. Period 1 & 2 are followed by 7 day washout period
89613997|NCT03750201|Experimental|Direct Selective Trabeculoplasty|Treatment by the investigational device.
89613998|NCT03750201|Active Comparator|Selective Trabeculoplasty|Treatment by the comparator device.
89613999|NCT01062568|Experimental|Obese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
89614000|NCT01062568|Experimental|Nonobese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
89614001|NCT03739281|Other|Nuclear medicine imaging|Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
89614002|NCT03014518||Suicide Attempt Study Group|Adolescents admitted to the Cleveland Clinic inpatient child and adolescent psychiatry unit after suicide attempt. Clinical assessments and blood samples; follow-up for 12 mos.
89614003|NCT03014518||Healthy Control Group|Healthy adolescents with no history of suicide attempt. Clinical assessments and blood samples; no 12mo follow-up.
89035702|NCT02931968||Monolithic zirconia prosthesis|Subjects previously treated with at least one arch (maxilla/mandible) of dental implants restored with a full-arch monolithic zirconia implant supported fixed dental prosthesis will be recalled for clinical and radiographic examination.
89035703|NCT02934438|Active Comparator|Neo40 Supplement|Utilizing intellectual property developed out of the University of Texas Health Science Center in Houston, Neo40 is a GMP certified, over the counter, all natural formulation that provides a system for generating NO in an endothelium-dependent and independent manner. The NEO40™ Daily™ product ingredients list and packaging was submitted to FDA Office of Compliance by Neogenis Labs, Inc. for use as a dietary supplement. It is made up of Beet root extract, hawthorne berry, Vitamin C, L-citrulline and sodium nitrite. The lozenges utilize natural product chemistry activated by the saliva to generate authentic NO gas in the oral cavity through the one-electron reduction of nitrite. This product's formulation was designed to be a quick dissolve that melts in the mouth within four to five minutes.
89035704|NCT02934438|Placebo Comparator|Placebo|A placebo product has been manufactured that looks, tastes and feels like the Neo40 active lozenge without the active ingredients
89035705|NCT02932046||Standardized noon meal|"Patients with anorexia nervosa during in-patient treatment are rating hunger and satiety on a visual analogue scale before and after a standardized and supervised meal. The meal is treatment as usual in a specialized ward. A patient may participate several times, if readmitted."
89614004|NCT05155137|Experimental|Riskometer + Polypill|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
89614005|NCT05155137|Placebo Comparator|Riskometer + Placebo|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use placebo polypill
89614006|NCT05155137|Experimental|No Riskometer + Polypill|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
89614007|NCT05155137|No Intervention|No Riskometer + Placebo (Usual Care)|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the placebo polypill = usual care
89035706|NCT02934516|Experimental|Disimpaction with lower uterine support|Cesarean section with support of the lower uterine segment
89035707|NCT02934516|Active Comparator|Classic push method|Cesarean section with push method
89035708|NCT02932202|Experimental|Longitudinal Nutritional Counseling|The intervention group will be contacted every 2 weeks by medical students over the phone to provide nutrition counseling and complete a verbal survey. During the phone calls, participants will be asked a series of questions regarding their dietary intake over the course of the last 2 weeks. If any deficiencies are identified, participants will be counseled on those topics
89035709|NCT02932202|Placebo Comparator|Standard Care Counseling|Participants in the control group will receive standard counseling, which includes weights at every visit, and counseling on weight gain goals as perceived necessary by the provider.
89035710|NCT02934594||Group A|Motor function intact group: received palliative decompression
89035711|NCT02934594||Group B1|motor deficit group: received palliative decompression within 48 hours after symptoms occured
89035712|NCT02934594||Group B2|motor deficit group: received palliative decompression 48 hours after symptoms occured
89614008|NCT01881425|Experimental|InnFocus MicroShunt|InnFocus MicroShunt
89614009|NCT01881425|Active Comparator|Trabeculectomy|glaucoma surgery to reduce IOP
89614010|NCT04165473||Intervention Group|Study participants having finished the following course in the past will be assigned to the intervention group: During a 6-module course, with four 3-day modules and two 5-day modules in the timeframe of one year, participants learn ways to strengthen their personal resources to establish effective social relationships and to develop skills as a social being. In between the module courses, the participants take 5 single sessions with an instructed trainer and document 10 conversations/social situations where they successfully applied the new skills.
89614011|NCT04165473||Control Group|Individuals without intervention
89035713|NCT02931929|Other|68Ga-NeoBOMB1|68Ga-NeoBOMB1, 2-vial kit for radiolabelling. I.v. Administration after radiolabelling
89035714|NCT02910804|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
89035715|NCT02931734|Active Comparator|Resin modified glass ionomer (RMGI)|Resin modified glass ionomer; an application every 48 hours; 4 sessions.
89035716|NCT02931734|Active Comparator|Potassium Nitrate 2% (KF)|Potassium Nitrate and Sodium fluoride 2%; an application every 48 hours; 4 sessions.
89035717|NCT02931734|Active Comparator|Low level laser therapy - GaAlAs (LLLT)|Low level laser therapy - GaAlAs; an application every 48 hours; 4 sessions.
89035718|NCT02931734|Active Comparator|RMGI and KF|Resin modified glass ionomer and potassium nitrate and sodium fluoride 2%; an application of the two associated products, every 48 hours; 4 sessions.
89035719|NCT02931734|Active Comparator|RMGI and LLLT|Resin modified glass ionomer and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
89035720|NCT02931734|Active Comparator|KF and LLLT|Potassium Nitrate and Sodium fluoride 2% and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
89210863|NCT05313477|Active Comparator|Supplement group|"Vitamin D2 supplement based on initial vitamin D level~≥ 20ng/mL -> vitamin D2 20,000unit/week~10-19.9ng/mL -> vitamin D2 40,000unit/week~<10ng/mL -> vitamin D2 60,000unit/week Calcium carbonate 1000mg/day"
89614012|NCT01064284|Active Comparator|PLASMA DERIVED Factor VIII|Plasma-derived vWF/FVIII
89614013|NCT01064284|Active Comparator|rFVIII|Recombinant FVIII
89614014|NCT04611815|Active Comparator|Robotic-assisted total knee arthroplasty|Patients undergoing robotic-assisted total knee arthroplasty with use of Journey II BCS implants
89614015|NCT04611815|Active Comparator|Conventional total knee arthroplasty|Patients undergoing conventional total knee arthroplasty with use of Journey II BCS implants
89614016|NCT01891721|Experimental|Specific Perceptual Training - Brain Fitness Program (BFP)|In each session, participants will work on 4 of the 6 BFP exercises (15 min per exercise). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
89614017|NCT01891721|Experimental|Broad Cognitive Training - Cognitive Package (Cogpack)|In each session, participants will work on a different subset of 4 to 6 Cogpack exercises. Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
89614018|NCT01891721|Active Comparator|Control Treatment - Commercial Computer Games (Sporcle)|In each session, participants will play between 8 and 16 games (1 to 15 min per game). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
89614019|NCT01064362||Prophylaxis following major orthopedic surgery|Patients age 18 years and older in the PHARMO RLS database treated with either fondaparinux sodium or LMWH for thromboprophylaxis following hip fracture and/or hip/knee replacement surgery.
89614020|NCT03013738|Experimental|Growing Pro-Social (GPS) program|"The Growing Pro-Social (GPS) program is a cognitive-behavioral group program for offenders. GPS is based on schema therapy, which conceptualizes aggressiveness as a result of a distorted view of the self and of the others. The ultimate goal of the GPS is to promote change in dysfunctional core beliefs about the self and the others.~GPS consists of 40 sessions, each lasting about 90 minutes. Sessions must be carried out by two therapists who should be skillful in schema therapy. Sessions are grouped into five modules: (1) human communication, (2) interpersonal relationships, (3) cognitive distortions, (4) function and meaning of emotions, and (5) early maladaptive schemas.~The treatment group attended the GPS program in addition to the Treatment AsUsual (TAU) delivered at Portuguese prisons."
89614021|NCT03013738|Other|Treatment As Usual|Subjects in this group received Treatment As Usual in Portuguese prisons (supervision of school frequency, occupational and job-related tasks and sentence planning supervision over time) and did not attend the GPS program or any other structured program during the research period.
89614022|NCT01880957|Other|Lithium|Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs. Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2 mEq/l. Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode
89614023|NCT01880957|Other|Lamotrigine|Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine. Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.
89614024|NCT04152837|Experimental|Lixivaptan|Lixivaptan oral capsules, 100-200 mg twice daily
89614025|NCT01064830|Active Comparator|topical cyclosporine suspension|apply 2 drops to 2 target nails under occlusion daily for 20 weeks
89614026|NCT01064830|Placebo Comparator|vehicle|apply to target nails daily under occlusion daily for 20 weeks
89614027|NCT01879553|Experimental|TIV (18 to ≤ 60 years)|Adult subjects 18 to ≤60 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
89614028|NCT01879553|Experimental|TIV (≥ 61 years)|Adult subjects ≥61 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
89614029|NCT01115452|Experimental|5% KNO3 solution|Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
89614030|NCT01115452|Experimental|2.5% KNO3 solution|Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
89614031|NCT01115452|Placebo Comparator|Sterile Water|Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period.
89614032|NCT04126551||Lean, healthy control|Lean, healthy control subjects. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
89614033|NCT04126551||Overweight/obese nondiabetic|Overweight/Obese nondiabetic subjects. Overweight and obesity will be defined using the standard body mass index cutoffs. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
89614034|NCT04126551||Type 2 diabetes|Participants with type 2 diabetes will be diagnosed accordingly to ADA criteria. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
89614035|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Fasting|lisdexamfetamine dimesylate 70 mg capsule administered under fasted conditions
89614036|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Vanilla Yogurt|Lisdexamfetamine Dimesylate 70mg capsule mixed into vanilla yogurt
89614037|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Orange Juice|Lisdexamfetamine Dimesylate 70mg capsule mixed into orange juice
89035721|NCT02931734|Active Comparator|RMGI, KF, LLLT|Resin modified glass ionomer, potassium nitrate and sodium fluoride 2% and Low level laser therapy - GaAlAs ; an application of the three associated products, every 48 hours; 4 sessions.
89614038|NCT03571971|Experimental|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
89614039|NCT03571971|Active Comparator|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
89614040|NCT03564015|Experimental|Smartphone app|The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
89035722|NCT02931656|Experimental|GDM aquatic exercise|GDM Diagnosis criteria accordance with to IADPSG / WHO
89614041|NCT03564015|Active Comparator|Paper handout|The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 3, 5, 7, 10, 12, and 14.
89614042|NCT04616651|Active Comparator|Pre-Chatbot survey arm|Participants will take the self-appraisal survey prior to interacting with the O2O program via the online Chatbot.
89614043|NCT04616651|Experimental|Post-Chatbot survey arm|Participants will take the self-appraisal survey after interacting with the O2O program via the online Chatbot. (This arm will also answer additional questions regarding participants' satisfaction with the O2O Chatbot.)
89614044|NCT01066624|Active Comparator|0.9% Sodium Chloride irrigation solution|Standard of care for prevention and management of oral mucositis (0.9% Sodium Chloride irrigation solution): Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study.
89614045|NCT01066624|Active Comparator|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion. After patients are done with the cryotherapy they will follow the standard of care for prevention and management of oral mucositis until the end of the study.
89614046|NCT01066624|Active Comparator|Calcium phosphate (Caphosol) mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
89614047|NCT01878383||Non-pregnant women/active HSV lesions|Women presenting to local health department
89614048|NCT01878383||Pregnant women/no active HSV lesions|Women presenting in active labor
89614049|NCT04123197|Other|Young Participants with Prior MI|Participants aged 60 or less who experienced a MI within the last 8 months will undergo a stress challenge to assess MSI and will then be followed for 3 years.
89614050|NCT05132907|Experimental|Cohort 1 (previously vaccinated, two dose recipients)|Cohort 1 will include individuals with vaccination against COVID-19 who will receive a two-dose schedule of HDT-301 56 days apart. Dose will be escalated from low to mid to high according to predefined safety parameters.
89614051|NCT05132907|Experimental|Cohort 2 (previously vaccinated, single dose recipients)|Cohort 2 will include individuals with vaccination against COVID-19 who will receive a one-dose schedule of HDT-301. Dose will be escalated from low to mid to high according to predefined safety parameters.
89614052|NCT05132907|Experimental|Cohort 3 (previously unvaccinated)|Cohort 3 will include 21 individuals with no history of vaccination against COVID-19 who will receive a two-dose schedule of HDT-301 56 days apart. Dose will be escalated from low to mid to high according to predefined safety parameters.
89614053|NCT04398771||Treatment|Rovatitan 5/80mg (Rosuvastatin 5mg/Valsartan 80mg) Rovatitan 5/160mg (Rosuvastatin 5mg/Valsartan 160mg) Rovatitan 10/80mg (Rosuvastatin 10mg/Valsartan 80mg) Rovatitan 10/160mg (Rosuvastatin 10mg/Valsartan 160mg) Rovatitan 20/80mg (Rosuvastatin 20mg/Valsartan 80mg) Rovatitan 20/160mg (Rosuvastatin 20mg/Valsartan 160mg)
89614054|NCT01878149||VEO® Lateral Access and Interbody Fusion System|
89614055|NCT01878149||eXtreme Lumbar Interbody Fusion (XLIF®)|
89614056|NCT01067716|Experimental|Refractive Error|
89614057|NCT01863953|Experimental|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
89614058|NCT01863953|Active Comparator|Bimatoprost Ophthalmic Solution 0.01% and Vehicle|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
89614059|NCT01863953|Active Comparator|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
89614060|NCT01068964|Experimental|0.03% Bimatoprost/0.5% Timolol in Same Bottle|Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
89614061|NCT01068964|Active Comparator|0.03% Bimatoprost and 0.5% Timolol in Separate Bottles|Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
89614062|NCT03217162|Experimental|surfactant combined with mechanical ventilation|surfactant is given to the infant with ARDS.
89614063|NCT03217162|Active Comparator|mechanical ventilation|mechanical ventilation is given to the infant with ARDS.
89614064|NCT00768274|Experimental|Arm A|Low-dose apabetalone (RVX000222) or placebo
89614065|NCT00768274|Experimental|Arm B|apabetalone (RVX000222) Dose-escalation or placebo
89035723|NCT02931656|Active Comparator|Control Group aquatic exercise|No change in blood glucose levels Group, investigated between 24-28 weeks of gestation.
89614066|NCT00768274|Experimental|Arm C|high-dose apabetalone (RVX000222) or placebo
89614067|NCT01116466|Experimental|ActiGait|Receiving ActiGait - implantable drop foot stimulator
89614068|NCT04352842||Non-survivors|Patients deceased during the study period
89614069|NCT04352842||Survivors|Patients survived during the study period
89614070|NCT01116934||PLS patients|Eight PLS patients (one female) from 6 families.
89614071|NCT01116934||Healthy controls|Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.
89614072|NCT02984475|Active Comparator|treatment arm|30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).
89614073|NCT02984475|No Intervention|control arm|30 patients receiving blood transfusion and taking iron-chelating therapy.
89614074|NCT01069354|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
89035724|NCT02910765|Active Comparator|M methylene blue and ozone|intravenous methylene blue and blood mixed with ozone ozone injection in early sepsis patients
89035725|NCT02910765|Placebo Comparator|P Placebo|saline and oxygen mixed blood injection in early sepsis patients
89614075|NCT01069354|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
89614076|NCT01069510|Placebo Comparator|Placebo|Patients will receive placebo
89614077|NCT01069510|Experimental|Spironolactone|Spironolactone 25 mg daily
89614078|NCT04398069|No Intervention|Standard Group|standard hemodynamic goals and catecholamin infusion to achieve: mean arterial pressure > or equal to 65 mmHg and diastolic arterial pressure > ou equal to 50 mmHg within the first 60 minutes.
89614079|NCT04398069|Experimental|personalized hemodynamic goals Group|Personalized hemodynamic goals and catecholamin infusion to achieve normal cerebral perfusion assessed by transcranial doppler: PI < 1,2.
89614080|NCT03013660|No Intervention|Comparison|Participants will be provided with standard information about the benefits of STSC and breastfeeding and will be encouraged to come into the NICU every day for at least 1 hour of STSC. To facilitate increased let down of breast milk, all participants will be provided a hospital grade breast pump free of charge during the stay of their babies in the NICU and assistance will be provided to the mothers in procuring a Medicaid covered breast pump to keep when the baby leaves the NICU. The hospital grade breast pump will be provided to her as soon as she enrolls into the study and will remain with her until her baby is discharged or transferred.
89614081|NCT03013660|Experimental|Treatment: Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment. The participants selected for the intervention arm will be asked not to discuss the payment with any other study participants (such as the members of any other families they may see at the NICU) or other health care staff at the NICU. Participants will also receive everything that the Comparison group receives.
89614082|NCT04746261|Experimental|ASSIP plus treatment as usual|ASSIP according to manual. Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
89614083|NCT04746261|Active Comparator|Treatment as usual|Treatment as usual will be multidisciplinary and combine psychotherapy, pharmacotherapy and other treatments as well as referral to specialist psychiatry or primary care as required.
89614084|NCT04278495|Active Comparator|Losartan|"to receive the medication Cozaar (Losartan Potassium 25mg Merck Sharp & Dohme-UK),"
89614085|NCT04278495|Placebo Comparator|Placebo|to receive either placebo
89614086|NCT04276545|Experimental|IV administration of dexmedetomidine|IV administration of a single loading dose DEX (0.5μg/kg)
89614087|NCT04276545|Active Comparator|IV administration of midazolam|IV administration of midazolam (0.05mg/kg)
89614088|NCT01117948|Experimental|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
89614089|NCT01117948|Placebo Comparator|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
89614090|NCT02445027|Experimental|MGH OCT Imaging Capsule|Subject will swallow the OCT capsule and images will be acquired using the OCT Imaging system.
89614091|NCT01118338|Experimental|Redesigned Purevision Contact Lens|Redesigned Bausch & Lomb PureVision contact lens
88985937|NCT03270319||ICU patient|"Critically ill patients in our adult intensive care unit with the following characteristics:~advanced hemodynamic monitoring in place including pulmonary artery catheter and arterial catheter~intubated or tracheostomy in place~echocardiography requested by the treating physician~intervention of interest: hemodynamic assessment done by echocardiography and thermodilution (pulmonary artery catheter)"
88985938|NCT00116922|Active Comparator|A|Avandamet [ Rosuglitazone 2 and Metformin 500]
89210864|NCT05313477|No Intervention|No supplement group|no medication supplement
89210865|NCT02531815|Experimental|Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo|
89614092|NCT01118338|Active Comparator|PureVision Contact Lens|Bausch & Lomb PureVision contact lens
89614093|NCT03013036|Other|Group I|Patients between 1 and 2 years
89614094|NCT03013036|Other|Group II|patients between 3 and 5 years
89614095|NCT03013036|Other|Group III|patients between 6 and 8 years
89614096|NCT01071538|Experimental|Buprenorphine|Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
89614097|NCT01072006||Control Group|Control group without traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD)
89614098|NCT01072006||PTSD Group|PTSD (not TBI)
89614099|NCT01072006||TBI Group|TBI (no PTSD)
89614100|NCT01072006||TBI+PTSD Group|Combined TBI history and PTSD
89614101|NCT03346395|Experimental|Problem solving based intervention|The problem solving based intervention contains a problem solving process and cooperation between the person on sick leave, his/her employer and health care professionals. The intervention consists of five steps: 1) Making an inventory of problems and/or opportunities related to return to work; 2) brainstorming about solutions; 3) writing down solutions, identifying the support needed to implement the solutions; 4) a three-party meeting with the person on sick leave, his/her employer and the rehabilitation coordinator; 5) evaluation of the action plan and implementation of solutions, relapse prevention. The intervention takes the form of two to five consultations. The first and fourth steps are key elements.
89614102|NCT03346395|Active Comparator|Care as usual|Medical treatment, or behavioral therapy or in combination. Meeting with a rehabilitation coordinator if that is a part or care as usual within primary health care.
89614103|NCT04352686|Active Comparator|Buspirone|Buspirone 20 mg per oral
89614104|NCT04352686|Placebo Comparator|Placebo|Placebo
89614105|NCT03146091|Experimental|Outpatient nonantibiotic treatment|
89614106|NCT03146091|Active Comparator|Outpatient antibiotic treatment|
89614107|NCT01119040|Experimental|NOTES PEG Rescue|A new way of performing surgery is called Natural Orifice Translumenal Endoscopic Surgery, or NOTES, for short. NOTES may allow surgeons to perform abdominal surgery without any skin incisions. By using natural openings in the body, like the mouth, surgeons can enter the stomach with a tube instead of the traditional method of making an incision in the skin of the abdomen.
89614108|NCT04275687|Experimental|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4~7 daily fractions as a boost. Concurrent chemotherapy consists of weekly docetaxel and nedaplatin."
89614109|NCT02172742|Experimental|BIA 2-093|"BIA 2-093 1200 mg (2 tablets 600 mg) ESL, Eslicarbazepine acetate~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
89614110|NCT02172742|Placebo Comparator|Placebo|"Placebo (2 tablets matching BIA 2-093 600 mg tablets) PLC, Placebo~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
89614111|NCT03831633|Experimental|AKYNZEO|
89614112|NCT03831633|Active Comparator|Standard of Care|
89614113|NCT04396509||women giving birth by normal vaginal delivery|100 women delivered vaginally. . They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
89614114|NCT04396509||women giving birth by c-section|100 delivered with cesarean section. They were examined three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken. Women aged 18 to 45 years who delivered at term and had natural pregnancy (without any ART method),
89614115|NCT02216175|Experimental|SLIT followed by Conventional OIT|Participants will receive up to 7 months of SLIT followed by 6 months conventional OIT to cow's milk
89614116|NCT02216175|Active Comparator|Conventional OIT|Participants will receive up to 7 months of low dose OIT, followed by 6 months conventional OIT to cow's milk
89614117|NCT02216175|Placebo Comparator|Delayed start OIT|Participants will receive up to 7 months placebo, followed by 6 months conventional OIT to cow's milk
89614118|NCT03145857|Experimental|[68]Ga-HA-DOTATATE|All participants will be imaged with [68]Ga-HA-DOTATATE PET/CT or PET/MRI for uptake by somatostatin receptor positive tumours. Up to seven [68]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.
89614119|NCT02172820|Experimental|Financial incentives|Participants receive financial incentives for completing exercise sessions.
89614120|NCT02172820|No Intervention|Control|Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.
89614121|NCT03086889|Experimental|The intervention group|The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
89614122|NCT03086889|Other|The control group|The control group will receive for traditional rehabilitation training for 3 weeks.
89614123|NCT02393079|Experimental|Active helmet LED|Description of the intervention: 18 patients will undergo 18 sessions of transcranial LED therapy (ACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
89614124|NCT02393079|Sham Comparator|Sham group|Description of the intervention: 18 patients will undergo 18 sessions of transcranial LED therapy (INACTIVE HELMET) with 30 minutes duration each. The sessions take place over 6 weeks. The therapy will be performed with a helmet that covers the frontal and parietal region.
89614125|NCT01074034|Experimental|AV Therapy Assessment group|appropriate system performance of the atrial and ventricular tachyarrhythmia therapies in the ASSURE device
89614126|NCT02173522|Experimental|Prostate artery embolization (PAE)|10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
89614127|NCT02173522|No Intervention|Control|10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.
89614128|NCT01075204||Clarithromycin modified release|Patients with upper or lower respiratory tract infection were administered clarithromycin modified release 500 mg once daily for 7 days and then followed for a further 3 days, per routine clinical practice.
89614129|NCT01120834|Experimental|all subjects|
89614130|NCT01120990|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
89614131|NCT04346836|Experimental|Metabolic Syndrome|"Elderly women with Metabolic Syndrome~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
89614132|NCT04346836|Experimental|Non-Metabolic Syndrome|"Elderly women without Metabolic Syndrome.~24 sessions of low-intensity exercise and psychoeducation, twice a week over 12 weeks."
89614133|NCT02798224|Experimental|e-assist: Colon Health (treatment arm)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
89614134|NCT02798224|Active Comparator|Healthwise Educational Program (active control)|Eligible patients identified will receive a prompt (via email) to log into portal for an important health message. Once eligible patient initiates portal session, continuing past IRB consent screen, patient is enrolled.
89614135|NCT02798224|No Intervention|Usual care control (observational only)|There will be no participant contact in this arm. We will use existing data sources only (e.g., EHRs) to obtain information on participants in this arm (i.e., an observational data review only).
89614136|NCT01122160|Placebo Comparator|placebo|Placebo with berries (blackberries + strawberries)
89614137|NCT01122160|Experimental|omeprazole|Prilosec (omeprazole) 20.6 mg tablet with berries (blackberries + strawberries)
89614138|NCT02623816|No Intervention|Sub-optimal dosing|No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 6 weeks.
89614139|NCT02623816|Experimental|Optimal dosing|Patients will be administered optimal dosing regimen of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.
89614140|NCT02180230|Other|Shorty implants|Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
89210866|NCT02531815|Experimental|Cohort 2 (SC) PF-06741086, Placebo|
89210867|NCT02531815|Experimental|Cohort 3 (SC) PF-06741086, Placebo|
89614141|NCT03012958||Health control group|"Who are 18 years or older, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
89614142|NCT03012958||Deployment-related lung disease|"Defined as the presence of unexplained chest symptoms in a deployer who, on surgical lung biopsy is found to have bronchiolitis or granulomatous pneumonitis without other known causes.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
89614143|NCT01122238|Experimental|1, Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
89614144|NCT01122238|Experimental|2, Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
89614145|NCT01122238|Experimental|3, Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
89614146|NCT01122238|Experimental|4, Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
89614147|NCT01122238|Experimental|5, Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
89614148|NCT01122238|Experimental|6, Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
89614149|NCT01122238|Experimental|7, Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
89614150|NCT01122238|Experimental|8, Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
89614151|NCT01122238|Experimental|9, No Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
89614152|NCT01122238|Experimental|10, No Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
89614153|NCT01122238|Experimental|11, No Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
88985939|NCT03270475|Experimental|Exercise|12-15 training sessions of 30 min over 4-5 weeks
88985940|NCT00474799|Experimental|A|MNS075 7.5mg q1h
88985941|NCT00474799|Experimental|B|MNS075 15mg q3h
88985942|NCT00474838|Active Comparator|Oral AntiDiabetic Drug|glimepiride and metformin and/or once daily glargine
88985943|NCT00474838|Experimental|intensive insulin group|insulin glargine insulin glulisine
88985944|NCT04727918|Active Comparator|Cold biopsy forceps (CBF)|Patients will be allocated to the CBF arm after randomization (1:1)
89614154|NCT01122238|Experimental|12, No Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
89614155|NCT01122238|Experimental|13, No Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
89614156|NCT01122238|Experimental|14, No Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
89614157|NCT01122238|Experimental|15, No Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
88985945|NCT04727918|Active Comparator|Cold snare polypectomy (CSP)|Patients will be allocated to the CSP arm after randomization (1:1)
88985946|NCT00474916|Experimental|KRN5500|KRN5500 escalating dose of .6, 1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
88985947|NCT00474916|Placebo Comparator|Normal Saline|Placebo consists of IV infusion of normal saline
88985948|NCT00475072|Experimental|1|
88985949|NCT00475111|Experimental|1|People in Group 1 will participate in CBT for Pain (CBT-P), which will focus on altering thought processes as a way to cope more effectively with pain.
88985950|NCT00475111|Experimental|2|People in Group 2 will participate in Mindfulness Medication for Emotion Regulation (MM-ER), a type of CBT that focuses on being more aware of one's emotions and regulating them.
88985951|NCT00475111|Experimental|3|Group 3 participants will serve as controls and receive educational information on the causes of, course of, and treatment for RA.
88985952|NCT00117299|Experimental|A|PTK/ZK o.d. 1250 mg p.o.
88985953|NCT02956369|Placebo Comparator|Control|10 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups. The control granulates consists of maize starch and long-chain fatty acids with powder.
89614158|NCT01122238|Experimental|16, No Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
89614159|NCT01122316|Experimental|Metformin|
89614160|NCT01076452|Active Comparator|STN|Participants were randomized to receive deep brain stimulation on STN (Subthalamic Nucleus) target.
89614161|NCT01076452|Active Comparator|GPi|Participants were randomized to receive deep brain stimulation on GPi (Globus Pallidus) target.
89614162|NCT01076686||Bupivacaine and low dose SKY0402|
89614163|NCT01076686||Bupivacaine and high dose SKY0402|
89614164|NCT01076686||Bupivacaine|
89614165|NCT01076686||High dose SKY0402|
89614166|NCT03049449|Experimental|Chimeric Antigen Receptor (CAR)+ T cells|All patients will be receiving starting dose: 0.3x10^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0 and Cyclophosphamide: 300 or 500 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
89614167|NCT04396431|Other|2|The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy.
89614168|NCT02399943|Experimental|Trametinib and Panitumumab|"Trametinib: 2 mg QD, orally, continuously.~Panitumumab: 6 mg/kg, intravenously, Q2W"
89614169|NCT03186027|Active Comparator|Active supplement (CoQ10 plus NADH)|"CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.~Active supplement based on Coenzyme Q10 plus NADH"
89614170|NCT03186027|Placebo Comparator|Phosphoserine plus vitamin C|"CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.~Placebo: phosphoserine plus vitamin C"
89614171|NCT04397913||Treatment(paracetamol or ibuprofen)|Paracetamol and ibuprofen are administered at standard dose for children with PDA.
89614172|NCT04397523|Other|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
89614173|NCT02176408|Experimental|Behavioral Activation plus Exercise|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the exercise intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
89614174|NCT02176408|Active Comparator|Behavioral Activation plus Stretching|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the stretching intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
89614175|NCT02176486|Experimental|Cohort A: Ixazomib 0.5 milligram (mg)|Ixazomib 0.5 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
89210868|NCT02531815|Experimental|Cohort 4 (Intravenous [IV]) PF-06741086, Placebo|
89210869|NCT02531815|Experimental|Cohort 5 (IV) PF-06741086, Placebo|
89614176|NCT02176486|Experimental|Cohort B: Ixazomib 2 mg|Ixazomib 2 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
89614177|NCT02176486|Experimental|Cohort C: Ixazomib 3 mg|Ixazomib 3 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
89614178|NCT02176486|Experimental|Cohort D: Ixazomib 4 mg|Ixazomib 4 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
89614179|NCT02176486|Placebo Comparator|Cohorts A through D: Placebo|Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in 28-day cycle, Cycles 1 through 3.
89614180|NCT01124188|Experimental|Study Intervention Arm|Higher-dose venlafaxine and Problem Solving Therapy for Depression and Pain (PST-DP)
89614181|NCT01124188|Active Comparator|Active Control|Higher-dose venlafaxine and supportive management (SM)
89614182|NCT02220478|Active Comparator|Signature Cutting Guides|Patients indicated for a Posterior Lateral THA utilizing non implantable Signature Cutting Guides during surgery.
89614183|NCT02220478|Active Comparator|Conventional Instrumentation|Patients indicated for a Posterior Lateral THA utilizing non implantable Conventional Instrumentation during surgery.
89614184|NCT01125202|Experimental|SCT-based behavioral intervention|Intervention participants continue to receive routine dialysis care, as well as a 16 week dietary counseling intervention based on Social Cognitive Theory. Dietary counseling is paired with Personal Digital Assistant-based dietary self-monitoring.
89614185|NCT01125202|Active Comparator|Attention control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
89614186|NCT03013114|Experimental|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
89614187|NCT01077310|Active Comparator|Intramuscular naltrexone|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
89614188|NCT01077310|Placebo Comparator|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
89614189|NCT01078246||Raltegravir Cohort Only|Participants with HIV-1 infection who received raltegravir (RAL) on or after 12 October 2007 (the market authorization date in the United States) (Raltegravir Cohort). These participants contributed data to the Raltegravir Cohort only.
89614190|NCT01078246||Historical and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received RAL on or after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Historical and Raltegravir Cohorts only.
89035726|NCT02931773||Control|Probands having normal fasting glucose and having a head up tilt test with Task Force® Monitor.
89035727|NCT02931773||Pre-Diabetes|Patients having normal fasting glucose and abnormal Oral Glucose tolerance test and having a head up tilt test with Task Force® Monitor.
89614191|NCT01078246||Historical Cohort Only|Participants with HIV-1 infection who received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort). These participants contributed data to the Historical Cohort only.
89614192|NCT01078246||Historical and Concurrent Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Historical and Concurrent Cohorts only.
89614193|NCT01078246||Concurrent Cohort Only|Participants with HIV-1 infection who received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Concurrent Cohort only.
89614194|NCT01078246||Concurrent and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 2) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Concurrent and Raltegravir Cohorts only.
89614195|NCT01078246||Historical, Concurrent and Raltegravir Cohorts|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), 2) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 3) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to all three cohorts.
89614196|NCT01078402||Single patients group: RA, PsA and AS|Single patients group with: Active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)
89614197|NCT02989857|Active Comparator|AG-120|Participants received AG-120 500 mg, tablet, orally, once a day (QD) in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.
89614198|NCT02989857|Placebo Comparator|Placebo|Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.
89035728|NCT02931773||Recently diagnosed Diabetic patients|Patients being diagnosed as Diabetics type in the recent five years and having a head up tilt test with Task Force® Monitor
89614199|NCT02989857|Experimental|After Cross over to AG-120|Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle for up to approximately 32 months.
89614200|NCT02393937|Experimental|Test: Metronidazole Gel 1%|Metronidazole Gel 1% once daily for 70 days.
89614201|NCT02393937|Active Comparator|Reference: Metronidazole Gel 1%|Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.
89614202|NCT02393937|Placebo Comparator|Placebo|Placebo Gel once daily for 70 days.
89614203|NCT01877915|Experimental|Rivaroxaban 2.5 mg|Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
89614204|NCT01877915|Placebo Comparator|Placebo|Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
89614205|NCT01876979|Active Comparator|IMF Screws|Use of IMF screws as a means to wire the jaws.
89614206|NCT01876979|Active Comparator|Erich Arch Bars|Use of Erich Arch bars in the wiring of the jaws.
89614207|NCT04397601||A|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
89614208|NCT04397601||B|mCRC RAS mutated patients progressing to first-line chemotherapy with fluoropyrimidines, oxaliplatin and bevacizumab.
89614209|NCT01860989|Experimental|Cohort 1|6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
89035729|NCT02934633|Experimental|Keeping Baby Safe|Keeping Baby Safe 2-DVD package, designed for parents of children from birth to 24 months. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
89614210|NCT01860989|Experimental|Cohort 2|6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose
89614211|NCT01860989|Experimental|Cohort 3|6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose
89035730|NCT02934633|Active Comparator|AAP TIPP Sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets that parents would typically receive from their pediatrician or general practitioner at well-baby visits.
89614212|NCT01860989|Experimental|Cohort4|6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose
89035731|NCT02931617|Active Comparator|Physiotherapy w/Positive end expiratory pressure training|Chest Physiotherapy w/Positive end expiratory pressure training; post therapy lung volume measurements
89035732|NCT02931617|Experimental|Physiotherapy w/Inspiratory force training|Chest Physiotherapy w/Inspiratory force training; post therapy lung volume measurements
89035733|NCT02925026|Experimental|Lactoferrin+Lysozyme|lactoferrin and lysozyme in rice flour
89035734|NCT02925026|Placebo Comparator|Placebo|rice flour
89035735|NCT02925065|Experimental|Early-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 1-6 of the study.
89614213|NCT02906241|Experimental|Patients--Intervention|Patients are randomized to an intervention group. They participate in all aspects of the study and also receive the intervention, which consists of a booklet.
89614214|NCT02906241|No Intervention|Patients--Usual Care|Patients are randomized to the standard of care arm and participate in all aspects of the study but receive no intervention.
89614215|NCT02906241|Other|Physicians|Physicians receive the intervention approximately halfway through data collection for a within subjects, pre-post intervention comparison
89614216|NCT01860677|Active Comparator|Active stimulation|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies. The device has been designated by the FDA to be minimally invasive and has FDA approval to be used to reduce symptoms associated with anxiety, depression, pain and insomnia. The unit is locked at the factory to deliver a maximal output of 4 mA of current and has a timer that prevents it from staying on longer than 20 minutes. Current will be limited to a maximum of 2 mA.
89614217|NCT01860677|Placebo Comparator|Sham stimulation|Participants are outfitted with a device that is identical to the Fisher Wallace Cranial Stimulator in appearance but does not deliver any current.
88985954|NCT02956369|Active Comparator|SATIOSTAT|10 obese, non-diabetic candidates will ingest SATIOSTAT as meal replacement at lunch and as first course at dinner over a period of 6 weeks. The SATIOSTAT granulates consists of hydrocolloids (fibers) and long-chain fatty acids with powder.
88985955|NCT02956408|Active Comparator|Conventional|Patients in this arm will be prescribed Vitamin D3 2000 IU once a day
88985956|NCT02956408|Experimental|High Dose|Patients in this arm will be prescribed Vitamin D3 6000 IU once a day
88985957|NCT00475189|Active Comparator|1|
88985958|NCT00475189|Active Comparator|II|loestrin 1/20 given 1 tab 21/7
88985959|NCT00117377|Experimental|1|Pimecrolimus
88985960|NCT00117377|Placebo Comparator|2|Placebo control twice daily application
88985961|NCT02964195|Experimental|Rifaximin Group|Rifaximin 400 mg bid for 2 month,
88985962|NCT02964195|No Intervention|Control|Routine endoscopic treatment without prophylactic use of antibiotics
88985963|NCT00475618|Experimental|Fluoride Varnish|Professional cleaning + education + fluoride vanish
88985964|NCT00475618|Active Comparator|Fluoride Toothpaste 500 ppm|Professional cleaning + education + fluoride toothpaste 500 ppm
88985965|NCT00475618|Active Comparator|No fluoride toothpaste|Professional cleaning + education + no fluoride toothpaste
88985966|NCT03270007|Experimental|Chemotherapy|
88985967|NCT03270007|No Intervention|Control|
88985968|NCT00402038|Experimental|Arm 1|
88985969|NCT00402038|Placebo Comparator|Arm 2|
88985970|NCT00475930|Experimental|1|2% chlorhexidine gluconate impregnated cloths, self applied three times weekly
89614218|NCT02870829|Experimental|Vitamin K2|Vitamin K comes in various isoforms and we have elected to use the K2 isoform - menaquinone-7. We have chosen a dose of 360mcg 3x/week as previous studies using menaquinone-7 demonstrated an increasing dose efficacy relationship up to this strength. Vitamin K2 is manufactured by Nattopharma
89614219|NCT02870829|No Intervention|Standard Therapy|Subjects randomised to standard therapy will continue to receive dialysis and chronic kidney disease-metabolic bone disease (CKD-MBD) management in accordance to current best practise guidelines
89614220|NCT02861391|Experimental|CO2 AcuPulse Laser treatment|Subjects with USI as diagnosed by cough test intended to receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
89614221|NCT02861391|Sham Comparator|Sham laser treatment|Subjects with USI as diagnosed by cough test intended to receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
89614222|NCT02014389||Healthy subjects|Healthy subjects will be used as control group
89614223|NCT02014389||Patients|Patients with Glaucoma , Patients with retinal dystrophy
88985971|NCT00475930|Placebo Comparator|2|Comfort Bath cloths, self applied three times weekly
88985972|NCT05376306|Experimental|MBSR - STEM|STEM MAJOR in COLLEGE randomized to receive Mindfulness-based Stress Reduction intervention
88985973|NCT05376306|Experimental|MBSR - non-STEM|Non-STEM MAJOR in COLLEGE randomized to receive Mindfulness-based Stress Reduction intervention
88985974|NCT05376306|Experimental|PMR - STEM|STEM MAJOR in COLLEGE randomized to receive Progressive Muscle Relaxation intervention
88985975|NCT05376306|Experimental|PMR - Non-STEM|Non-STEM MAJOR in COLLEGE randomized to receive Progressive Muscle Relaxation intervention
88985976|NCT04727840|Other|Intervention|All 20 CKD patients will be receiving a potassium binder while consuming a tailored diet of non-potassium restricted foods
88985977|NCT00476164|Experimental|Rituximab|Infusion of 2 x 1g of rituximab, 14 days apart
88985978|NCT00476164|Sham Comparator|2|
88985979|NCT00476203|Experimental|1|Immediate yoga classes offered
88985980|NCT00476203|Other|2|Delayed yoga classes (after 6 months) offered [wait list control group]
88985981|NCT00476281|Other|abnormal glucose tolerance|abnormal glucose tolerance
88985982|NCT00402077|Experimental|1|
88985983|NCT00402077|Experimental|2|
88985984|NCT00402077|Experimental|3|
88985985|NCT00402077|Placebo Comparator|4|
88985986|NCT00476359|Other|double-boosted PI|double-boosted protease inhibitor combination
88985987|NCT00476398|No Intervention|Diagnostic capsule endoscopy|Patient with non-cardiac chest pain will undergo capsule endoscopy
88985988|NCT03270046|Placebo Comparator|No enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy without water enema.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication. The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale for evaluation of side effect, complication during PEG ingestion, enema and colonoscopy, and participant satisfactory."
89210870|NCT02531815|Experimental|Cohort 6 (IV) PF-06741086, Placebo|
89614224|NCT01876901|Experimental|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|Patients treated with 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) in centers who routinely performing this intervention.
89614225|NCT01876901|Experimental|Colo-anal anastomosis (CAA)|Patients operated with colo-anal anastomosis (CAA) in centers who routinely performing this intervention.
89614226|NCT01876823|Experimental|es-citalopram and Memantine Treatment|concurrent es-citalopram plus memantine were administered for 48 weeks.
89614227|NCT01876511|Experimental|Cohort A: MSI Positive Colorectal Cancer|
89614228|NCT01876511|Experimental|Cohort B: MSI Negative Colorectal Cancer|
89614229|NCT01876511|Experimental|Cohort C: MSI Positive Non-Colorectal Cancer|
89614230|NCT01993719|Experimental|Arm 1N -Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Standard Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants without prior treatment pembrolizumab or nivolumab Standard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)"
89614231|NCT01993719|Experimental|Arm 1P - Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Standard Chemo Prep Regimen Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2, Standard Chemo Preparative Regimen in participants previously treated with pembrolizumab or nivolumab.~Standard preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days Cyclophosphamide: 60 mg/kg/day X 2 days intravenous (IV) Young TIL: Day 0: Cells will be infused intravenously (IV)"
89614232|NCT01993719|Experimental|Arm 2/Foll By Arm 1P-Low dose Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|Decreased Chemo Prep Regimen+Retreat. Young TIL+High Dose Interleukin-2, Decreased Chemo Preparative Regimen. Young TIL+High Dose Interleukin-2, Standard Chemo (Retreat). Lower dose preparative regimen + Young TIL Cells. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days. Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 300 mg/m^2 IV over 60 minutes. Young TIL: Day 0: Cells will be infused IV. Retreatment: Standard Chemo Prep Regimen. Aldesleukin: 720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine: 25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide: 60 mg/kg/day X 2 days IV. Young TIL: Day 0: Cells will be infused IV.
89614233|NCT01993719|Experimental|Arm 2- Low Dose Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|"Decreased Chemo Prep Regimen. Young Tumor Infiltrating Lymphocytes (TIL) Plus High Dose Interleukin-2 Lower Dose preparative regimen + Young Tumor Infiltrating Lymphocytes (TIL) Cells Aldesleukin: 720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).~Fludarabine: 30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days Cyclophosphamide: Days -5 to -3 (low-dose arm): Cyclophosphamide 30 mg/kg IV over 60 minutes for 2 days.~Young TIL: Day 0: Cells will be infused intravenously (IV)"
89614234|NCT01993719|Experimental|Arm 1P/Foll By Arm-1P/R-Standard Chemotherapy Preparative Regimen + TIL + 720,000 IU/kg Aldesleukin|Standard Chemo Prep Regimen(SCPR)+Retreat. Young TIL+High Dose(HD) Interleukin-2, SCPR. Young TIL+HD Interleukin-2, SC(Retreat). SCPR+Young TIL Cells retreatment with SCPR+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kgIV every eight hours (+/-1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m^2/day intravenous piggy-back(IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL:Day 0: Cells will be infused IV. Retreatment with standard preparative regimen+Young TIL Cells+pembrolizumab. Aldesleukin:720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses). Fludarabine:25 mg/m^2/day intravenous piggy-back (IVPB) daily for 5 days. Cyclophosphamide:60 mg/kg/day X 2 days IV. Young TIL: Day 0:Cells will be infused IV. Pembrolizumab:2 mg/kg IV on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
89614235|NCT00638235||Phase I (IntePro, US only)|AMS Apogee™ with IntePro(Began May 2006 - Closed)
89614236|NCT00638235||Phase I (InteXen LP, US only)|AMS Apogee™ with InteXen LP (Began May 2006 - Closed)
89614237|NCT00638235||Phase II (France only)|AMS Perigee™ with IntePro (Began February 2007 - Closed)
89614238|NCT00638235||Phase III/IV (Perigee IntePro Lite, US only)|AMS Perigee™ with IntePro Lite (Began April 2007 - Closed)
89614239|NCT00638235||Phase III/IV (Apogee IntePro Lite, US only)|AMS Apogee™ with IntePro Lite (Began April 2007 - Closed)
89614240|NCT00638235||Phase V (Elevate Posterior IntePro Lite, US & EU)|AMS Elevate™ Apical & Posteiror with IntePro Lite (Began April 2008 - Closed)
89035736|NCT02925065|Experimental|Delayed-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 8-13 of the study.
89614241|NCT00638235||Phase V (Elevate Posterior InteXen, US only)|AMS Elevate™ Apical & Posteiror with IntXen LP (Began April 2008 - Closed)
89614242|NCT00638235||Phase VI (Elevate Anterior Gen 1, For Study Use Only, EU only)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 1, For Study Use Only, Began October 2008 - Closed)
89614243|NCT00638235||Phase VII (Elevate Anterior Gen 2, US & EU)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 2, Began April 2009 - Closed)
89035737|NCT02925182|Experimental|test|Recurrent Aphthous Stomatitis were irradiated with Er,Cr:YSGG laser (Waterlase MD, Biolase, Irvine, CA, USA) on hard tissue mode with a mg6 sapphire tip (600 µm diameter, 6 mm length) using non-contact mode at an energy level of 0.25W and a repetition rate of 20 kHz and pulse duration of 140 µs, 0% water and 10% air at 5 J/cm2 energy density. The treatment time was 20 s per surface by scanning the Recurrent Aphthous Stomatitis area.
89035738|NCT02925182|Placebo Comparator|Control|In the placebo group, the same Er,Cr:YSGG laser without laser emission was used.
89614244|NCT01848171|Active Comparator|L-thyroxine|Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period
89614245|NCT01848171|No Intervention|blank|No intervention
89614246|NCT02758665|Experimental|Obinutuzumab, Ibrutinib, Venetoclax|Obinutuzumab i.v.: Cycle 1 (3000 mg), Cycle 2-6 (1000 mg) Ibrutinib (tablet): Cycle 1-15 (420 mg daily) Venetoclax (tablet): Cycle 1 (last 7 days 20 mg daily), Cycle 2 (ramp up 50 mg to 400 mg) Cycle 3-12 (400 mg daily)
89614247|NCT03182673|Experimental|SHR7390, SHR-1210 and SHR3162|"Total 60-100 subjects with advanced solid tumors~In the two-drug combination therapy,subjects were received single oral doses of SHR7390，then accepted two drug combination therapy, SHR7390 is administered multiple daily oral doses of SHR7390 for 28 days for a treatment cycle. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose.~In the second study part, subjects accepted three drug combination therapy, SHR7390 is administered orally for 21 days and discontinued for 7 days in a 28-day treatment cycle,SHR3162 was administered orally twice a day for 28 days at a fixed dose of 100 mg. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose"
89614248|NCT00638157|Active Comparator|Daptomycin Alone|daptomycin 6 mg/kg q24h for treatment of right-sided infective endocarditis
89614249|NCT00638157|Experimental|Daptomycin plus gentamicin|daptomycin 6 mg/kg q24h with concomitant initial gentamicin dosed for the first 2 days of therapy for the treatment of right-sided infective endocarditis
89614250|NCT00637377|Active Comparator|Ranibizumab 0.5mg Q4|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
89614251|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
89614252|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
89614253|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
89614254|NCT00636987|Other|Implanted with Biocor or Biocor Supra Valves|
89614255|NCT01078558||Patients with rheumatic disease|Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
89614256|NCT01475110||Study cohort group|"Adult patients with Imatinib resistant (failure + suboptimal) or intolerant chronic myeloid leukaemia in all phases, who started treatment with Nilotinib between January 2005 and December 2012 in Italy.~Adult pts treated with Nilotinib as second line therapy after Dasatinib."
89614257|NCT01080118|Other|control group|Control group, taught with a standard Macintosh laryngoscope
89614258|NCT01080118|Experimental|Study group|Study group taught with the Airtraq video laryngoscope
89614259|NCT01080976||Primary Care Physicians|
89210871|NCT02531815|Experimental|Cohort 7 (IV) PF-06741086, Placebo|
89614260|NCT01080976||Diabetologists|
89614261|NCT03013582|Experimental|Amnion wrapping + Tenolysis|Standard surgical tenolysis + wrapping of the released tendon with amnion.
89614262|NCT03013582|Placebo Comparator|Tenolysis control|Standard surgical tenolysis alone
89614263|NCT05307718||The basic cohort|The subjects with the newly indicated indication for use: NOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins
89614264|NCT05307718||Cases|"Cases will be subjects who have observed ADRs during follow-up: bleeding that meets the criteria of major or non-major, clinically relevant bleeding (for anticoagulants and platelet aggregation inhibitors); muscle or liver lesions (for statins); any other serious ADR."
89614265|NCT05307718||Controls|Controls will be subjects in whom no ADRs were observed during the study
89614266|NCT05307484|Experimental|Serious game group|Participants in the intervention group installed a mobile application, 'Sam's Mozzie Adventure'. This is a locally designed serious game which was co-created between SingHealth Polyclinics and AI Innovation Labs (AI2 Labs) Private Limited, specifically for this study. The principal investigator reviewed existing publicly available information on dengue prevention, including those on the National Environmental Agency (NEA) 'Stop Dengue' website, and provided the relevant content and pedagogical knowledge to the team of app developers from AI2 Labs. After creating the syllabus, the developers deployed their technological knowledge to integrate the dengue prevention information into the serious game. The participants were instructed to complete playing this serious game within 2 weeks.
89614267|NCT05307484|Active Comparator|Dengue prevention website group|The control group accessed the NEA 'Stop Dengue' website which contained dengue prevention information in the forms of online articles, posters and video. The participants were instructed to complete reading the online resources within 2 weeks.
89614268|NCT01376596|Experimental|CBT-based Intervention|Contrast the impact of a CBT intervention for the treatment of social anxiety in schizophrenia with standard care (care as usual)
89614269|NCT01376596|Active Comparator|Treatment as usual|Usual care received by patients at clinic/hospital - randomized to a wait list to receive the CBT intervention at the end of the group that received the intervention immediately
89614270|NCT01033864|Experimental|MMF, Prednisone|Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
89614271|NCT01033864|Active Comparator|EC-MPS|Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.
89614272|NCT05307016||MAP patients|All pregnancies complicated with any degree of Placenta previa anterior, posterior or centralis undergoing pre-labor CS at gestational age (36+0 to 40+0)
89210872|NCT02531815|Experimental|Cohort 8 (subcutaneous [SC]) PF-06741086|
89210873|NCT00826124|Active Comparator|I|Two epidural steroid injections two weeks apart based on history and physical exam alone
89210874|NCT00826124|Active Comparator|II|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
89614273|NCT01082380|Experimental|1|
89614274|NCT01083628|Experimental|Group CBT for Depression with MoodText'|Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content
89614275|NCT01083628|Active Comparator|Group CBT for Depression|Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression
89614276|NCT01083706|Experimental|Treatment (chemotherapy)|Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89614277|NCT03014128||Inspection and Packaging|self-descriptive
89614278|NCT03014128||Grinding, Polishing and Matting|self-descriptive
89614279|NCT03014128||All other employees at Aesculap (not in first 2 groups)|including administration and offices as well as all other mechanical workplaces
89614280|NCT01035346|Experimental|A|
89614281|NCT01035346|Placebo Comparator|B|
89614282|NCT03186729|Experimental|Antithrombotic treatment|For patients with vascular disease and indication for antiplatelet drugs: Antiplatelet drugs; For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs
89614283|NCT03186729|No Intervention|No antithrombotic treatment|For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.
89614284|NCT05306392|Experimental|Moderate Hypothermia|Patients with acute respiratory distress syndrome treated with venovenous ECMO to a strategy of moderate hypothermia during 48 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
89614285|NCT05306392|Sham Comparator|Control - Normothermia|Patients with acute respiratory distress syndrome treated with venovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
89614286|NCT05306314||TREATAPROST 0 mL( BID- 10mL*2) PO|Treataprost 10 mL ( 5 mL 2*1- PO ) 42 days Generic Name : Treatarost Advance Dosage Form: Suspension, vials of 250 mL Dosage : 250 mL Frequency : 2*1 (BID) Duration: 42 days (6 weeks) Administration:Oral administration before meals 30 minutes as 20 mL(10mL*2)
89614287|NCT05306314||Antibiotic Treatment (1*1) PO + NSAID (PRN) PO ya da SUPP|"Levolon 500 mg ( 1*1 -PO) 28 daANTIBIOTIC TREATMENT Levolon 500 mg ( 1*1 - PO) 28 days (4 weeks) Dosage Form:Film-coated tablet Dosage : 500 mg Frequency : 1*1 Duration: 28 days (4 weeks) Administration:It should be taken orally, without chewing, with a sufficient amount of water. The tablets can be taken during or between meals.~NSAID Diclomec 75 mg ( PRN- PO )- 28 days (4 weeks) Dosage Form:Tablet Dosage : 75 mg Frequency : PRN Duration: 28 days (4 weeks as per needed) Administration:It should be taken orally, without chewing, with a sufficient amount of water. The tablets can be taken during or between meals."
89614288|NCT01085344|Experimental|Factor VIII|escalating dose Factor VIII
89614289|NCT01085500|Experimental|Simulation Curriculum|General surgery residents will undergo a simulation-based educational curriculum (Mastery Learning TEP Curriculum) on TEP hernia repair
89614290|NCT01085500|Other|Current Practice|General surgery residents will undergo current practice of learning how to perform the TEP repair in the operating room under direct supervision of the staff surgeon without any simulation pre-training.
89614291|NCT01035658|Experimental|Dose Level 1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
89614292|NCT01035658|Experimental|Dose Level -1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
89614293|NCT01035658|Experimental|Dose Level 1 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
89614294|NCT01035658|Experimental|Dose Level 2 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
89614295|NCT05306236|Experimental|LLL therapy and postural correction ex (study group)|study group will be treated by low level laser therapy and postural correction exercises
89614296|NCT05306236|Experimental|postural correction ex (control group)|control group will be treated by postural correction exercises only
89614297|NCT01037452|Experimental|Combination product|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet
89614298|NCT01037452|Active Comparator|PPI alone|Lansoprazole
89614299|NCT01037452|Active Comparator|Antacid alone|Calcium carbonate/magnesium hydroxide
89614300|NCT01037452|Placebo Comparator|Placebo|Placebo
89614301|NCT03012646|Experimental|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
89614302|NCT01085968|Experimental|PD Subjects|PD subjects who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
89614303|NCT01085968|Active Comparator|Control Subjects|Age matched controls who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
89614304|NCT01087918|Experimental|First RAGT, then strength training|16 sessions of 45 minutes of robot-assisted gait training 4 times a week in first intervention period and 16 sessions of 45 minutes of strength training 4 times a week in second intervention period.
89614305|NCT01087918|Experimental|First strength training, then RAGT|16 sessions of 45 minutes of strength training 4 times a week in first intervention period and 16 sessions of 45 minutes of robot-assisted gait training 4 times a week in second intervention period.
89614306|NCT00636441|Active Comparator|Guided Arm|"Genomically-guided treatment allocation.~This arm has the following cohorts:~AC sensitive patients [>60% probability of response to AC]~TC sensitive patients [>60% probability of response to TC]~Patients sensitive to neither AC nor TC; randomized to AC or TC"
89614307|NCT00636441|Active Comparator|Non-Guided Arm|"Non-genomically-guided treatment allocation.~This arm has the following cohorts:~In patients randomly assigned to AC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC~In patients randomly assigned to TC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC"
89614308|NCT01087996|Experimental|Auto-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.
89614309|NCT01087996|Experimental|Allo-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells.
89614310|NCT00636363|Experimental|Multipurpose Solution - Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
89614311|NCT00636363|Experimental|Multipurpose Solution - No Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
89614312|NCT00636363|Active Comparator|Ciba Vision Aquify Multipurpose Solution|Ciba Vision Aquify Multipurpose Solution for use with contact lens care
89614313|NCT02984397|Experimental|KF group|In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)
89614314|NCT02984397|Placebo Comparator|Placebo group|Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.
89614315|NCT02984397|Active Comparator|SOC|Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study
89614316|NCT01600131|Experimental|Caregiver education and support|problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.cidrr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
89614317|NCT01600131|Other|Standard Care|Caregivers receiving standard of care
89614318|NCT01588119||Dabigatran|in atrial fibrillation
89614319|NCT01588119||Rivaroxaban|in atrial fibrillation and VTE
89614320|NCT01588119||Apixaban|in atrial fibrillation and VTE
89614321|NCT01588119||Edoxaban|in atrial fibrillation and VTE
89614322|NCT01088464|Experimental|Cohort 1|
89614323|NCT01088464|Experimental|Cohort 2|
89614324|NCT01088464|Experimental|Cohort 3|
89614325|NCT01090180|Experimental|Arm 1: Dexamethasone|Dexamethasone (oral)
89614326|NCT01090180|Placebo Comparator|Arm 2: Placebo|Placebo (inactive)
88985989|NCT03270046|Active Comparator|Water enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy and enema with sterile water until stool was clear or patient felt discomfort but not exceed 3 liter, before colonoscopy.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication.The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale."
89614327|NCT00636207|Experimental|Montelukast 0.1 mg|"Participants receive Montelukast inhalation powder, 0.1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
89614328|NCT00636207|Experimental|Montelukast 0.3 mg|"Participants receive Montelukast inhalation powder, 0.3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
89614329|NCT00636207|Experimental|Montelukast 1 mg|"Participants receive Montelukast inhalation powder, 1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period."
89614330|NCT00636207|Experimental|Montelukast 3 mg|"Participants receive Montelukast inhalation powder, 3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
89614331|NCT00636207|Experimental|Montelukast 10 mg|"Participants receive Montelukast inhalation powder, 10 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
89614332|NCT00636207|Placebo Comparator|Placebo|"Participants receive Placebo to Montelukast inhalation powder.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
88985990|NCT00117195||PD/PS|
89614333|NCT01922505||PPI triple therapy|7-day PPI triple therapy regimen: PPI (esomeprazole 40 mg or omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg or rabeprazole 20 mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
89614334|NCT04395885||study group|health care staff, regardless of gender, who is actively working during the outbreak
89614335|NCT04395885||control group|age matched group of non-health worker individuals.
89614336|NCT01091116|Experimental|Double dose MEN16132 0.125 mg|Intra-articular administration of two 0.125 mg doses of MEN16132 at 2-week interval.
89614337|NCT01091116|Experimental|Double dose MEN16132 0.25 mg|Intra-articular administration of two 0.25 mg doses of MEN16132 at 2-week interval.
88985991|NCT00117611|Active Comparator|1|Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
89614338|NCT01091116|Experimental|Double dose MEN16132 0.5 mg|Intra-articular administration of two 0.5 mg doses of MEN16132 at 2-week interval.
89614339|NCT01091116|Experimental|Single dose MEN16132 0.5 mg|Intra-articular administration of one 0.5 mg dose of MEN16132 followed by one intra-articular injection of placebo at 2-week interval.
89614340|NCT01091116|Placebo Comparator|Placebo|Intra-articular administration of two doses of Placebo at 2-week interval.
89614341|NCT03013426|Experimental|NVX-508|Administration of 1, 2 or 4 doses of NVX-508 at three dose levels; 0.05ml/kg. 0.1ml/kg and 0.17ml/kg in a 3 + 3 design.
89614342|NCT01092364|Experimental|Cell phone intervention|Behavioral lifestyle intervention for weight loss, delivered by cell phone.
89614343|NCT01092364|Experimental|Personal counseling intervention|Behavioral lifestyle intervention for weight loss, delivered by personal counseling.
89614344|NCT01092364|No Intervention|Advice only|Advice only control group.
89614345|NCT01092442||Retrospective Patients|Retrospective Patients: The patient group who had the CryoValve SG Pulmonary Human Heart Valve implanted prior to the February 2008 clearance of the valve.
89614346|NCT01092442||Prospective Patients|Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.
89614347|NCT01092676|Active Comparator|Regular Ibuprofen Dosing|Regular Ibuprofen Dosing throughout 4 days of study
89614348|NCT01092676|Active Comparator|PRN Ibuprofen dosing|As needed Ibuprofen dosing
89614349|NCT01092910|Experimental|Esteem Implant|Subjects are implanted with the Esteem Totally Implantable Hearing System
89614350|NCT05289622|Experimental|Polyurethane expandable valve stent implant surgery|Valve stent implantation will be performed under general anesthesia with transesophageal echocardiography monitoring, with thoracotomy approach median and circulation aid extracorporeal.
89614351|NCT05271994||Endoscopic biliary drainage|Patients with distal malignant biliary obstruction, who need endoscopic biliary drainage
89614352|NCT05190640|Experimental|Intervention arm|The dietary supplement (Asystems) is designed, and marketed commercially to be taken in servings of one gummy: one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies.
89614353|NCT03013972||Colorectal cancer patients|Colorectal cancer patients during adjuvant chemotherapy
89614354|NCT05106244|Experimental|family self-nursing mode|
89614355|NCT05106244|No Intervention|hospital nursing mode|
89614356|NCT05088148||Group 1: FGR group|Estimated fetal weight <10th percentile
89614357|NCT05088148||Group 2: Control group|Healthy pregnants who will give birth 37th and after gestational week
89614358|NCT01039792|Placebo Comparator|Placebo|Placebo
89614359|NCT01039792|Experimental|Active|Active Methyl B12
89614360|NCT03013816|Experimental|Testimonial Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
89614361|NCT03013816|Experimental|Informational Messaging|This video mirrors common educational campaigns and included segments of HRSA's animated video, Organ Donation and Transplantation: How Does it Work? The IM video presents facts about donation, including the current supply-demand problem in transplantation, common reasons for/against donor designation, donation myths, and the importance of communicating with parents about donation. Information about how to register as a donor is also included. The video contains no personal testimonials.
89614362|NCT03013816|Experimental|Blended Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
88985992|NCT00117611|Placebo Comparator|2|placebo administered subcutaneously once or twice monthly
88985993|NCT05374239|Other|Hospital 1|First hospital in the allocation sequence to cross from control to intervention arm.
88985994|NCT05374239|Other|Hospital 2|Second hospital in the allocation sequence to cross from control to intervention arm.
88985995|NCT05374239|Other|Hospital 3|Third hospital in the allocation sequence to cross from control to intervention arm.
88985996|NCT05374239|Other|Hospital 4|Fourth hospital in the allocation sequence to cross from control to intervention arm.
88985997|NCT03277261|Experimental|Ublituximab + Oral Placebo|Participants were administered ublituximab 150 milligrams (mg), intravenous (IV) infusion over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo once daily (QD) from Day 1 up to the last day of Week 95.
88985998|NCT03277261|Active Comparator|Teriflunomide + IV Placebo|Participants were administered teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
88985999|NCT05373147|Experimental|CAR T cells therapy|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10^5 CAR+ T cells/kg, 3×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 3×10^6 CAR+ T cells/kg.
88986000|NCT04727957||Dataset for development and testing|
88986001|NCT04727957||Dataset for external validation|
88986002|NCT02273947|Experimental|Arm 1 (ABDC): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
88986003|NCT02273947|Experimental|Arm 2 (BCAD): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
88986004|NCT02273947|Experimental|Arm 3 (CDBA): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
88986005|NCT02273947|Experimental|Arm 4 (DACB): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
88986006|NCT02273947|Experimental|Arm 5 (EFHG): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
88986007|NCT02273947|Experimental|Arm 6 (FGEH): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
89035739|NCT02924987|Other|Aflibercept injection|Not applicable. There will be no randomization nor stratification to any to study arms or groups.
89035740|NCT04687995|Active Comparator|Tragal preichondrium graft|Tragal perichodrium graft for endoscopic myringoplasty as a reference graft
89614363|NCT03012724|Active Comparator|H1-Coil|Device: Brainsway H1-Coil Deep TMS System. An FDA cleared deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the lateral prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
89614364|NCT03012724|Experimental|H7-Coil|Device: Brainsway H7-Coil Deep TMS System. A deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the medial prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
89614365|NCT05023720||Regorafenib group|Patients were given only regorafenib orally
89614366|NCT05023720||Joint group|The patient was treated with regorafenib orally and in combination with other medications
89614367|NCT01041274|Experimental|Citalopram|Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.
89614368|NCT01041274|Placebo Comparator|Placebo|Participants will receive a daily dose of placebo for 12 months.
89614369|NCT00635427|Experimental|VPRIV 60 U/kg(VPRIV Parent Study 45 or 60 U/kg- TKT032,GCB039)|"This arm is the Overall velaglucerase alfa (VPRIV) 60 U/kg and includes patients from the following groups:~VPRIV 45 U/kg or 60 U/kg, IV, EOW for 51 weeks in parent study TKT032 (NCT00430625) and switched to 60 U/kg in HGT-GCB-044 to maintain blindness or 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)"
89614370|NCT00635427|Experimental|VPRIV 60 U/kg (Parent study-imiglucerase(60 U/kg) HGT-GCB-039)|imiglucerase 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)and switched 60 U/kg VPRIV in HGT-GCB-044
89614371|NCT00635427|Experimental|VPRIV 15-60 U/kg (Parent study VPRIV (15-60 U/kg) TKT034)|VPRIV 15- 60 U/kg, IV, EOW for 51 weeks in parent study TKT034 (NCT00478647) and continued in HGT-GCB-044 at the same dose as prescribed in TKT034
89614372|NCT00635349|Active Comparator|Non-steroidal Anti-inflammatory Drug (NSAIDs)|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numeric rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of NSAIDs to receive either meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 29 to Day 85.
89614373|NCT00635349|Experimental|Tramadol Hydrochloride Plus Acetaminophen|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numerical rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
89614374|NCT00634803|Experimental|CBT for POD|Integrated cognitive behavioral therapy for chronic pain and opioid dependence
89614375|NCT00634803|Active Comparator|Educational Counseling for POD|Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
89614376|NCT00634803|Active Comparator|Physician Management|PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
89614377|NCT01401699|Experimental|Optical Frequency Domain imaging System|Optical Frequency Domain Imaging (OFDI) balloon based imaging
89614378|NCT01042288|Experimental|Carboplatin/Pemetrexed/Panitumumab|Systemic Therapy
89614379|NCT01217385|Experimental|DOSI Pre-Surgery|Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.
89614380|NCT01042366|Experimental|Vaccine co-cultured with melanoma cells|Dendritic Cells co-cultured with melanoma cells injected as a vaccine intra/peri-nodally under ultrasound guidance
89614381|NCT01042366|Experimental|Vaccine pulsed with tumor cell lysates|Dendritic Cells pulsed with tumor cell lysates were injected as a vaccine intra/peri-nodally under ultrasound guidance
89614382|NCT01042366|Experimental|Vaccine fused with tumor cells|Dendritic Cells fused with tumor cells were injected as a vaccine intra/peri-nodally under ultrasound guidance
89035741|NCT04687995|Active Comparator|pretragal ( SMAS) fascia graft|pretragal ( SMAS) fascia graft for endoscopic myringoplasty as a new graft
89035742|NCT02925104|Experimental|INC280|
89035743|NCT02910687||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
89035744|NCT02924909|Experimental|induction carboplatin paclitaxel|carboplatin AUC=6 21 day cycle for 2 cycles paclitaxel 175 mg/m2 21 day cycle for 2 cycles radiotherapy 4500 cGy in 25 fractions carboplatin AUC=2 in a week regimen during radiotherapy paclitaxel 50 mg/m2 in a week regimen during radiotherapy Minimal Invasive Surgery
89035745|NCT02934360||Non-small cell Lung Cancer|Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time
89035746|NCT02934360||Breast Cancer|Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.
89035747|NCT02924948|No Intervention|Conventional insertion|EUS will be inserted with conventional method.
89035748|NCT02924948|Experimental|Balloon inflated insertion|EUS will be inserted with balloon inflated method
89035749|NCT02934321|Active Comparator|Aspartame Sweetened Beverage|Volunteers will consume a low-calorie, aspartame sweetened beverage (185 mg aspartame in water) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
89210875|NCT00224107|Experimental|Silodosin|Silodosin 8 mg once daily with food
89210876|NCT00224107|Placebo Comparator|placebo|Matching Placebo capsule once daily with food
89614383|NCT01043146|Active Comparator|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
89614384|NCT01043146|Placebo Comparator|placebo|intravenous 0.9 % NaCl
89614385|NCT04906018||volunteer group - BMI less than 30|Each subject with a BMI less than 30 will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
89614386|NCT04906018||volunteer group - BMI of 30 and above|Each subject with a BMI of 30 and above will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
89614387|NCT04880668|No Intervention|Control - No aerosol box|Participants will perform the AGMP without an aerosol box
89614388|NCT04880668|Experimental|Intervention - Aerosol box|Participants will perform the AGMP with an aerosol box
89614389|NCT01043926|Experimental|Participants with Moderate Hepatic Insufficiency (Part I)|Participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
89614390|NCT01043926|Experimental|Healthy Participants (Part I)|Healthy participants matched to participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
89614391|NCT01043926|Experimental|Participants with Mild Hepatic Insufficiency (Part II)|Participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
89614392|NCT01043926|Experimental|Healthy Participants (Part II)|Healthy participants matched to participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
89614393|NCT04801810|Experimental|Normobaric hypoxia (NH)|8 weeks of overnight exposure (8 hrs/night) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
89614394|NCT04801810|Sham Comparator|Normobaric normoxia (NN)|8 weeks of overnight exposure (8 hrs/night) to NN conditions (~21% oxygen; sea level) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
89614395|NCT01044706|Experimental|Bicalutamide 50 mg Tablet|Bicalutamide 50 mg Tablet
89614396|NCT01044706|Active Comparator|Casodex® 50 mg Tablet|Casodex® 50 mg Tablet
89614397|NCT04447534|Experimental|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine alone
89614398|NCT04447534|Experimental|Chloroquine or hydroxychloroquine with zinc|Chloroquine or hydroxychloroquine with zinc
89614399|NCT03014050|Experimental|EH: Stimulation of Head Point|Electrical stimulation of the head point of the hand (EH, experimental stimulation); intervention with e-Tapper TT-R1
89614400|NCT03014050|Active Comparator|CS: Control Stimulation|Electrical stimulation of the leg point of the hand (CS, control stimulation); intervention with e-Tapper TT-R1
89210877|NCT00822302|Placebo Comparator|1.Saline Infusion|Patients randomised to this arm will receive an infusion of saline
89614401|NCT01044862|Active Comparator|Aromatase Inhibitors (AI)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
88986008|NCT02273947|Experimental|Arm 7 (GHFE): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
88986009|NCT02273947|Experimental|Arm 8 (HEGF): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
88986010|NCT02273947|Experimental|Arm 9 (IJK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986011|NCT02273947|Experimental|Arm 10 (JKI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986012|NCT02273947|Experimental|Arm 11 (KIJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986013|NCT02273947|Experimental|Arm 12 (IKJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986014|NCT02273947|Experimental|Arm 13 (JIK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986015|NCT02273947|Experimental|Arm 14 (KJI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986016|NCT02273947|Experimental|Arm 15 (LMN): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986017|NCT02273947|Experimental|Arm 16 (OPQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986018|NCT02273947|Experimental|Arm 17 (PQO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
89210878|NCT00822302|Active Comparator|2.recHDL|Patients randomised to the active comparator arm of the study will receive 40mg/kg reconstituted High density lipoproteins (lot nos 05422-00006) over a period of 4 hours, 24 hours prior to carotid endarterectomy.
89210879|NCT04004871|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive induction chemotherapy with Nab-paclitaxel, cisplatin and fluorouracil every three weeks for three cycles before radiotherapy, and then receive concurrent chemoradiotherapy.
89210880|NCT00826358|Experimental|A|ABT-143 capsules 5/45mg
89210881|NCT00826358|Active Comparator|B|ABT-335 45mg and rosuvastatin 5mg
89614402|NCT01044862|Active Comparator|Clomiphene Citrate (CC)|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
89614403|NCT01044862|Active Comparator|Follicle Stimulating Hormone (FSH)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
89614404|NCT01045174|Active Comparator|Breath-Actuated Nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer.
89614405|NCT01045174|Active Comparator|Conventional continuous-ouput nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer
89614406|NCT04365478|Experimental|rSWT group|Radial Extracorporeal Shock Wave Therapy on spastic muscles of upper limb
89614407|NCT04365478|Active Comparator|Control group|conventional physiotherapy
89614408|NCT04361656||Current standard of care preparation|Current Standard of Care for inpatient colonoscopy: The dose of PEG-ELS will be large-volume (4-Liter) administered as either single-dose if colonoscopy is scheduled BEFORE 11 a.m. (250 mL orally every 15 minutes between 6 p.m. and midnight the day prior to procedure), or split-dose if the colonoscopy is scheduled AT or AFTER 11 a.m. (First dose: 2-Liters; 250 mL orally every 15 minutes between 6-8 p.m. the day prior to procedure. Second dose: 2-Liters; 250 mL orally every 15 minutes to be completed 5 hours before the scheduled time of the procedure).
89614409|NCT04361656||Lubiprostone Intervention|"The study entails giving two doses of Lubiprostone in addition to the standard large-volume polythene glycol-electrolytes solution (PEG-ELS) according to the time of the procedure as follow: If the colonoscopy is scheduled BEFORE 11a.m. the patient will receive in addition to the PEG-ELS: Lubiprostone 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy.~If the colonoscopy is scheduled AT or AFTER 11a.m. the patient will receive in addition to PEG-ELS: Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS"
89614410|NCT04242394||Chronic gallbladder diseases|Routine ERCP participants with chronic gallbladder diseases
89614411|NCT04242394||Without Chronic gallbladder disease|Routine ERCP participants without chronic gallbladder diseases
89614412|NCT04238338||high MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
89614413|NCT04238338||low MLR group|"Divided into high MLR group and low MLR group according to the median of monocyte / lymphocyte ratio(MLR).~Patients undergo peritoneal dialysis 3, 4 or 5 times per day, with a daily peritoneal dialysate dose of approximately 6000-10000 ml. The glucose concentration of peritoneal dialysate varies depending on the specific requirements of the individual patient for ultrafiltration volume. Three concentrations of glucose peritoneal dialysis solution are available for peritoneal dialysis patients. The low concentration is 1.5% or 2.5% and the high concentration is 4.25%. In principle, a 1.5% glucose peritoneal dialysis solution is first applied, or a high concentration of 4.25% glucose peritoneal dialysis solution can be appropriately applied according to the actual situation. Other drugs continued to be used in patients with other diseases."
89614414|NCT01047358||ajuvant group|adjuvant setting after two to three years of tamoxifen
89614415|NCT01047358||palliative group|palliative setting after progression of disease with anti-estrogen therapy
89614416|NCT01048606|Active Comparator|Placeco + exercise|Placebo (no phytoestrogen): Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) Exercise (three 1h-sessions/week)
89614417|NCT01048606|Active Comparator|Phytoestrogens without exercise|Phytoestrogens (70mg/day of soy isoflavone) Without exercise (no structured exercise session)
89614418|NCT01048606|Experimental|Phytoestrogens + exercise|Phytoestrogens (70 mg/day soy isoflavone) Exercise (1h-sessions 3 times/week)
89614419|NCT01048606|No Intervention|Placebo without exercise|Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) No exercise
89614420|NCT04224766|Experimental|suprascapular nerve block with costoclavicular infraclavicular|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL bupivacaine 0.5%, then single shot US-guided costoclavicular block (CCB) with 10 ml bupivacaine 0.5%.
89614421|NCT04224766|Active Comparator|Interscalene brachial plexus block|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL bupivacaine 0.5%.
89614422|NCT04210882|Experimental|12-week Moderate-Intensity Exercise Program|"Exercise intervention: Participants will complete 57 total sessions of moderate-intensity exercise (walking while tracking heart rate) over 12 weeks. Exercise intensity, frequency, and session duration will increase during the first 4 weeks of the intervention until participants are completing five (5) sessions weekly and walking for 30 min each session at 60-75% of Heart Rate Reserve (HRR) (moderate-intensity exercise), as follows:~Week 1: Three sessions, lasting ≥ 15 minutes, at 50-75% of HRR; Week 2: Four sessions, lasting ≥ 20 minutes, at 50-75% of HRR; Week 3: Five sessions, lasting ≥ 30 minutes, at 50-75% of HRR; Weeks 4-12: Five sessions, lasting ≥ 30 minutes, at 60-75% of HRR"
89614423|NCT03012256|Experimental|Cardio-respiratory management model|Additional home care management includes medication reconciliation, self-care education, advanced care planning, as well as physician communication and transfer protocols
89614424|NCT03012256|No Intervention|Control|Home care (standard of care)
88986019|NCT02273947|Experimental|Arm 18 (QOP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
89210882|NCT03972007|Experimental|Immediate LEDT Group|The 940nm LED blanket will be positioned across the full length of the biceps brachii muscle in the dominant limb immediately before the muscle fatigue protocol.
88986020|NCT02273947|Experimental|Arm 19 (OQP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986021|NCT02273947|Experimental|Arm 20 (POQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986022|NCT02273947|Experimental|Arm 21 (QPO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
88986023|NCT00476632||Control|Person with no history of cancer.
88986024|NCT00117689|Experimental|1|Standard (tacrolimus based standard therapy without induction)
88986025|NCT00117689|Active Comparator|2 Standard of Care|Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy
88986026|NCT00476671||1|HIV infected adults with viral load < 50 copies/ml on NNRTI based HAART
88986027|NCT00117273|Experimental|1|
88986028|NCT00117273|Active Comparator|2|
89614425|NCT04128514||Enrolled subjects|"Subjects ≥40 years of age presenting for cataract surgery who are interested in reducing their dependence on spectacles at all distances, and who are appropriate candidates for multifocal lens implantation.~The Acrysof (R) Panoptix (R) Toric intraocular lens will be implanted in both eyes of subjects."
89614426|NCT01049776|Experimental|Pazapanib (GW786034)|
89614427|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 1.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 1.0 milligrams per kilogram (mg/kg) once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or investigational medicinal product (IMP) occurs.
89614428|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 3.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 3.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614429|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 10.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614430|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 20.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 20.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614431|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once weekly for the first 12 weeks and once every 2 weeks starting Week 13 in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
88986029|NCT00117273|Active Comparator|3|
88986030|NCT00476710||Normal Glucose Metabolism|Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
88986031|NCT00476710||Impaired Glucose Tolerance|Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
88986032|NCT00476710||Frank type 2 diabetes|Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl
88986033|NCT05358678||cases with cs niche|133 cases with cs niche undergoing ART will be included. Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
88986034|NCT05358678||cases without cs niche|133 cases without cs niche undergoing ART will be included. Pituitary suppression will be achieved by long or antagonist protocol. For long protocol, GnRH agonist will be administered for 10-14 days starting from mid-luteal phase of preceding cycle. After confirmation of down regulation, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). Gonadotropins therapy will be tailored according to age, BMI, antral follicle count, antimullerian hormone and previous response. In antagonist protocol, gonadotropins will be given from second or third day of cycle in a daily dose of (150-300 IU). GnRH antagonist will be adjusted according to patient response. On the 5th -6th day of stimulation, sonography will be performed and repeated every 1-3 days with regular estradiol assessment. When at least 3 follicles reach ≥ 17 mm in mean diameter, trigger will be given. Oocytes pick up will be performed 34-36 hour after triggering.
88986035|NCT00117767|Experimental|1|Terbinafine
88986036|NCT00117767|Active Comparator|2|Griseofulvin
88986037|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 1|Diclofenac sodium 1 topical patches will be compared against placebo patches.
88986038|NCT03277066|Experimental|Diclofenac Sodium Active Topical Patch 2|Diclofenac sodium 2 topical patches will be compared against placebo patches.
88986039|NCT05357157||Electroacupuncture|All subjects will be administered electroacupuncture sessions Acupoints that will be used: Baihui, Yin tang, BL-10, GB21, SI13, BL-60, ST-36, LV-3, LV8, Spl 6, LI-4, LI11, Kid 3, Ren 6, Heart 7
88986040|NCT05357157||Electroacupuncture, Nutrition and Dietary supplement|All subjects will be administered electroacupuncture sessions Acupoints that will be used: Baihui, Yin tang, BL-10, GB21, SI13, BL-60, ST-36, LV-3, LV8, Spl 6, LI-4, LI11, Kid 3, Ren 6, Heart 7. Patients will be presented with the option to be prescribed a dietary supplement containing vitamin B complex, Mg, Zn, superoxide dismutase, Alpha Lipoic Acid and PalmitoylethanolamideAdditionally they will be given a specific anti-intiflamatory dietary regimen to follow.
88986041|NCT00118235|Experimental|Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)|Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88986042|NCT03277690|Experimental|Levoketoconazole|Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo
89614432|NCT01772004|Experimental|Primary Expansion Cohort: NSCLC, Post-platinum Doublet|Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614433|NCT01772004|Experimental|Primary Expansion Cohort: NSCLC, First Line|Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614434|NCT01772004|Experimental|Primary Expansion Cohort: Metastatic Breast Cancer|Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614435|NCT01772004|Experimental|Primary Expansion Cohort: GC/GEJC Progressed|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who progressed on or after first line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614436|NCT01772004|Experimental|Primary Expansion Cohort: GC/GEJC Non Progressed|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614437|NCT01772004|Experimental|Secondary Expansion Cohort: Colorectal Cancer|Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614438|NCT01772004|Experimental|Secondary Expansion Cohort: Castrate-resistant Prostate Cancer|Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614439|NCT01772004|Experimental|Secondary Expansion Cohort: Adrenocortical Carcinoma|Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614440|NCT01772004|Experimental|Secondary Expansion Cohort: Melanoma|Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614441|NCT01772004|Experimental|Secondary Expansion Cohort: Mesothelioma|Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
88986043|NCT03277690|Placebo Comparator|Placebo|Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole
88986044|NCT03271021|Experimental|FMX101, 4% minocycline foam|FMX101, 4% minocycline foam applied topically once daily for 12 weeks
88986045|NCT03271021|Placebo Comparator|Vehicle foam|Vehicle foam applied topically once daily for 12 weeks
88986046|NCT03279640|Experimental|Dual-mode stimulation|"rTMS on ipsilesional M1 + tDCS on contralesional M1~10 Hz of rTMS was applied over the ipsilesional M1 for 20 minutes with simultaneous application of cathodal tDCS on the contralesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
88986047|NCT03279640|Experimental|Single stimulation|"rTMS on ipsilesional M1~10 Hz of rTMS over the ipsilesional M1 was applied for 20 minutes.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
88986048|NCT02273986|Experimental|Digoxin|Digoxin
88986049|NCT02273986|Experimental|Digoxin with K-877|Digoxin with K-877
88986050|NCT00118508|Placebo Comparator|A|Group A will receive active study drug
88986051|NCT00476905||Spectral-Diagnosis|Method for noninvasive detection of cutaneous malignancies
88986052|NCT00476983|Experimental|1|SQV/r 1500/100 mg OD + Truvada OD
88986053|NCT00118547|Other|1|
88986054|NCT00477178||chronic non-malignant pain codeine|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - on long-term codeine therapy
88986055|NCT00477178||chronic non-malignant pain|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - NOT on long-term codeine therapy
88986056|NCT00477178||healthy|healthy controls
88986057|NCT00477217|Other|1|
88986058|NCT03279367||Hearing Impaired|Participants will be asked to wear an electro-encephalography (EEG) cap for measurement of brain activity whilst listening to speech stimuli. The speech stimuli will be presented through a loudspeaker positioned 1 meter in front of the participant. Participants will be asked to listen to the speech stimuli when using and without using their hearing aid. They will be asked to pay attention to the speech stimuli. This will be assured by asking them to answer questions related to the speech stimulus at random intervals. Subjects will also go through standard clinical procedures for assessing their hearing function and hearing aid setup.
88986059|NCT00477256||Child|Children between 6 and 17 years diagnosed with, and treated for, any type of cancer.
88986060|NCT00477256||Parent|Parent(s) or caregiver(s) of children with cancer.
88986061|NCT00477256||Medical Staff|Medical staff (i.e., physicians, nurse practitioners) involved in the children's medical decision-making.
88986062|NCT00477373|Experimental|1|If the daily dose does not exceed 1000 mg, Depakine CHRONO can be administered once a day. If the dose is greater than 1000 mg/day, Depakine CHRONO will be administered in a bid regimen: one tablet in the morning and one tablet in the evening.
88986063|NCT00477646|Experimental|Prevention Care Management|Telephone support over 18 months from trained Prevention Care Managers, to help women overcome barriers to colon, breast, and cervical cancer screening
88986064|NCT00477646|No Intervention|Usual Care|Usual Care. A sample of patients receive a single telephone call to validate claims data and collect basic demographic information.
88986065|NCT00477763|Active Comparator|1|
88986066|NCT00477763|Placebo Comparator|2|
89614442|NCT01772004|Experimental|Secondary Expansion Cohort: Urothelial Carcinoma|Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614443|NCT01772004|Experimental|Secondary Expansion Cohort: Ovarian Cancer|Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614444|NCT01772004|Experimental|Secondary Expansion Cohort: Renal Cell Carcinoma (First Line)|Participants with Renal cell carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a first-line therapy in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614445|NCT01772004|Experimental|Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)|Participants with Renal cell carcinoma who failed 1 prior systemic first-line regimen received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a second line treatment in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614446|NCT01772004|Experimental|Efficacy Expansion Cohort: Ovarian Cancer|Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614447|NCT01772004|Experimental|Efficacy Expansion Cohort: Urothelial Carcinoma|Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
88986067|NCT00477802|Experimental|Botox|Randomized into receiving Botox first. At cross-over, patients will receive placebo.
88986068|NCT00477802|Placebo Comparator|Placebo|Randomized to receive placebo first. At cross-over, patients will receive the active Botox.
88986069|NCT00477880|Experimental|Cetuximab|Cetuximab lV weekly at an initial loading dose of 400 ml/m2, followed by three weekly maintenance doses of 250 mg/m2. Four infusions of C225 will be defined as a course of therapy.
88986070|NCT00477919||Weekly assessment by E-MOSAIC|Patients complete a weekly assessment comprising visual analogue scales (VAS) of pain, fatigue, drowsiness, nausea, anxiety, depression, shortness of breath, loss of appetite, and overall well-being; up to 3 optional symptoms selected by the patient; and an estimated nutritional intake using an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC). Nurses record the patient's weight, KPS score, body mass index, and assessment of current medication for pain (i.e., morphine-equivalent daily dose), fatigue, and anorexia/cachexia syndromes weekly. A Longitudinal Monitoring Sheet (LoMoS) is printed (comprising VAS of pain, pain medication, fatigue, KPS, medication for fatigue [i.e., methylphenidate hydrochloride or epoetin alfa], anorexia, weight change, nutritional intake, medication, supplements, counseling for anorexia, VAS of individually selected symptoms) and stored.
88986071|NCT00477919||Palm-based monitoring tool|Patients complete a weekly symptom assessment and nutritional intake using a Palm-based monitoring tool. Nurses record weight and Karnofsky performance status (KPS) scores weekly. A proof of electronic transfer sheet is printed and stored.
88986072|NCT00477997|Placebo Comparator|1|Saline bolus + OGTT
88986073|NCT00477997|Other|2|GH-bolus and OGTT
88986074|NCT00477997|Other|3|GH-bolus
88986075|NCT00478114|Experimental|1|Sorafenib
88986076|NCT00478270|Experimental|1|
88986077|NCT00478309|No Intervention|Arm I|Participants receive standard primary care.
88986078|NCT00478309|Experimental|Arm II|Participants receive standard primary care followed by the Genetic Epidemiology and Risk Assessment (GERA) intervention. Participants also participate in a discussion session regarding the GERA including the rationale behind methylenetetrahydrofolate reductase mutation detection and folate assessment and its relationship to colorectal cancer risk.
88986079|NCT00478348|Other|Drain|
88986080|NCT00478348|Other|No drain|
88986081|NCT04727801||Febrile (n=50)|Febrile is defined as having sublingual temperatures of 37.5 °C or above. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
88986082|NCT04727801||Afebrile (n=50)|Afebrile is defined as having sublingual temperatures of less than 37.5 °C. All subjects will wear the Verily Patch in the axillary region for up to 8 days. In addition, subjects will measure oral and axillary temperatures using a commercially available thermometer.
88986083|NCT00478504|Active Comparator|Clomiphene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
88986084|NCT00478504|Active Comparator|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
88986085|NCT00117468|Experimental|1|
88986086|NCT00117468|Active Comparator|2|
88986087|NCT03271879|Active Comparator|Empagliflozin at a dose of 10 mg/day|Patients will be treated with 10mg Empagliflozin once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
88986088|NCT03271879|Placebo Comparator|Placebo|Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
88986089|NCT00478543|Experimental|Diuretic|Furosemide
88986090|NCT00118937|Placebo Comparator|1|Single-blind placebo run-in period. Duration one month.
88986091|NCT00118937|Active Comparator|2|Metformin 2000 mg, double-masked randomized during 12 months.
88986092|NCT00118937|Placebo Comparator|3|Placebo, double-masked randomized during 12 months.
88986093|NCT00478621|Experimental|Group A|
88986094|NCT00478621|Experimental|Group B|
88986095|NCT00478621|Experimental|Group C|
88986096|NCT00478621|Experimental|Group D|
88986097|NCT00478621|Experimental|Group E|
88986098|NCT00478621|Active Comparator|Group F|
88986099|NCT05292807|Experimental|Imaginal exposure for memories|A behavioral intervention in imagery for memories
89035750|NCT02934321|Experimental|Erythritol Sweetened Beverage|Volunteers will consume an isosweet, compared to aspartame, high osmolar, low-calorie erythritol sweetened beverage (50.8 g erythritol in water, 1.66 Molar) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
89614448|NCT01772004|Experimental|Efficacy Expansion Cohort: GC/ GEJC, Third Line|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614449|NCT01772004|Experimental|Efficacy Expansion Cohort: HNSCC|Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
89614450|NCT02930044|Experimental|Early glargine dose|Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion.
89614451|NCT02930044|Placebo Comparator|Standard therapy|Retrospective arm that received standard insulin therapy for treatment of DKA
89614452|NCT02181400|Active Comparator|NIR Laser Treatment 25 miiliwatts (mW)/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
89614453|NCT02181400|Active Comparator|NIR laser treatment 100mW/cm2 dose|The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
89614454|NCT02181400|Active Comparator|NIR laser treatment 200mW/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
89614455|NCT04352218|Active Comparator|PTA Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty of internal jugular vein non-thrombotic stenosis in patients with chronic headache
89614456|NCT04352218|Experimental|"PTA + Stenting using Petalo stent"|Percutaneous Transluminal Angioplasty + Stenting of internal jugular vein non-thrombotic stenosis in patients with chronic headache
89614457|NCT03012178||Mitral Valve Surgery|Patients undergoing ACC/AHA guideline directed mitral valve surgery for mitral insufficiency.
89614458|NCT03012412|Experimental|Mindfulness Based Program for Infertility|"Behavioral: MBPI~The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 15 participants)."
89614459|NCT03012412|No Intervention|Treatment As Usual (TAU)|Standard infertility medical treatment provided by IVF clinics (public and private) - no psychological intervention being pursued.
89614460|NCT02666638|Active Comparator|Control Volunteers|MRI on up to a 7T scanner without contrast.
89614461|NCT02666638|Experimental|Clinical Patients|MRI on up to a 7T scanner without contrast.+ 10 minutes of research development imaging added onto their clinical MRI scans.
89614462|NCT03683524|Experimental|Experimental group|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
89614463|NCT03683524|Active Comparator|Control group|continuation of their current stable ART
89614464|NCT02246842|Experimental|D-Gam®|D-Gam® (human anti-D immunoglobulin)
89614465|NCT02246842|Active Comparator|Rhophylac®|Human Anti-D Immunoglobulin
89614466|NCT02617342|Experimental|Robot-mediated Intervention|Families assigned to the robot condition will be asked to complete pre-test assessments and post testing as well as to participate in the robot intervention. The intervention will last for a 8-14 week period in which families will bring their child in 2-3 times a week on average for approximately 30 minutes until 24 treatment sessions have been completed. Children will receive one-on-one intervention with an interventionist facilitating the child's interactions with the robot.
89614467|NCT02617342|No Intervention|Treatment as Usual|Families assigned to the TAU condition will be asked to complete pre-test assessments and approximately 8-14 weeks later return to complete post-test assessments where the social emotions activity will be retested. During the 8-14 weeks between the testing assessments, families in the TAU condition will also receive a weekly email asking about their child's media use.
89614468|NCT02550886||Patient/Caregiver Dyad|
89614469|NCT02249650|Experimental|TSB-9-W1 cohort|TSB-9-W1 200 mg/day (Cohort 1) TSB-9-W1 400 mg/day (Cohort 2) TSB-9-W1 600 mg/day (Cohort 3) TSB-9-W1 800 mg/day (Cohort 4) TSB-9-W1 1000 mg/day (Cohort 5)
89614470|NCT02182492|Experimental|Glucocorticoid|Fluticasone propionate nasal spray
89035751|NCT02924831|Experimental|Moxibustion group|drug:moxa Moxibustion was to stimulate acupoints of Guanyuan(RN4)and the Zusanli(ST36) with burned moxa.
89614471|NCT02182492|Experimental|Clarithromycin|Clarithromycin tablet
89614472|NCT02182804|Experimental|Study|probe-based confocal laser endomicroscopy narrow band imaging with magnification
89614473|NCT03010306|No Intervention|Nutrition only|Monthly food baskets were provided to the nutrition only group. Food baskets included basic foods to sustain a family of three over one month's time, such as rice and evaporated milk. Food baskets were valued at approximately $28 US Dollars per basket.
89614474|NCT03010306|Active Comparator|Nutrition + CASITA|The CASITA intervention was given by a community health worker (CHW) and involves individual and group modalities. HOME-CASITA took place at the dyad's place of residence, and the GROUP-CASITA at a local community center. All CASITA participants received 12 weekly sessions over 3 months. Interventions retain core elements of the SPARK approach: coaching parents on child development stimulation and providing social support and encouragement. Each session is as follows: 1) Child observation & knowledge sharing about child development; 2) Practice of reciprocal attention focusing and social interaction activities; 3) Parent encouragement on behavior and developmental interactions; and 4) Parent social support through referral assistance, reassurance, and validation of parent's concerns.
89035752|NCT02924831|Experimental|Acupuncture group|material: stainless steel needle In acupuncture treatment, needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),with manipulations to get Deqi sensation.
89614475|NCT03010384|Active Comparator|Intervention|Consultation with a physician specialized in social medicine. The consultation lasted about one hour. Together with the patient a return-to-work (RTW) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. If relevant, patients were offered up till 5 sessions with a psychologist.
89614476|NCT03010384|No Intervention|Control|Standard treatment from the Department of Rheumatology
89614477|NCT01163656|Active Comparator|Direct Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Miller Laryngoscope.
89614478|NCT01163656|Active Comparator|Glidescope Cobalt Video Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Glidescope Cobalt Video Laryngoscope.
89614479|NCT01129804|Experimental|Network Support|Network Support treatment is aimed at helping patients change their social support network so that it supports abstinence. In this treatment patients will be encouraged to attend AA meetings and engage in other activities that would involve non-drinkers. These activities would be determined by the patient, with help from the therapist. Patients would learn about methods of avoiding drinking, making new friends, and getting enjoyment from activities other than drinking. In addition patients will learn specific skills intended to help them make new acquaintances and change their circle of friends.
89614480|NCT01129804|Active Comparator|Packaged Cognitive-Behavioral Treatment|The purpose of Packaged Cognitive-Behavioral Treatment (PCBT) is to train patients in a variety of skills that they can use to keep themselves from drinking.
89614481|NCT01165840|Experimental|Dapsone|Dapsone 100 mg PO x 1 dose
89614482|NCT01166230||Patients with Ta/T1, randomized to white light cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
89614483|NCT01166230||Patients with Ta/T1 randomized to Hexvix cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
89614484|NCT04351854||Patients with SARS-CoV-2-infection|Patients with clinical suspicion or evidence of SARS-CoV-2-infection on presentation in the ED
89614485|NCT04351854||Control group|Particularly, controls will be identified retrospectively at the same hospitals based on matching of demographics, underlying diseases and duration of hospital stay (i.e. one control per case, both in the same hospital). Moreover, the mere suspicion of SARS-CoV-2-infection on admission in the ED is sufficient for enrolment. A considerable portion of these patients are actually not infected and serve as internal control.
89614486|NCT01168024|Experimental|CINCOR™ System Treatment|Use of the CINCOR™ System and CCS-1 device during the pericutanous coronary intervention (PCI) procedure plus Standard of Care peri-procedural hydration for the prevention of contrast induced nephropathy (CIN).
89614487|NCT01168024|Other|Standard of Care|The control group will receive a peri and post-procedural hydration rate.
89614488|NCT05389566||Type 1 diabetes|People with type 1 diabetes above 40 years
89614489|NCT05389566||People with type 2 diabetes|People with type 2 diabetes above 50 years
89614490|NCT05389566||Healthy controls|Healthy controls without diabetes
89614491|NCT01168726|Experimental|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
89614492|NCT01168726|Experimental|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
89614493|NCT01168726|Active Comparator|Alcohol Education|Educational information about harms associated with heavy drinking.
89614494|NCT01170754|Experimental|PEG-3350 and Gatorade|255 miralax with 64 oz gatorade.
89614495|NCT01170754|Active Comparator|Golytely 4 Liters|Golytely 4 Liters
89614496|NCT02522832|Experimental|Titre 1|Low infectious titre of innoculum
89614497|NCT02522832|Experimental|Titre 2|Medium infectious titre of innoculum
89614498|NCT02522832|Experimental|Titre 3|High infectious titre of innoculum
89614499|NCT05166330|Active Comparator|ketofol 1:1|0.15-0.2 mL/kg from of 5 mg/mL propofol and 5 mg/mL ketamine mixture
89614500|NCT05166330|Active Comparator|ketofol 1:3|0.15-0.2 mL/kg from of 7.5 mg/mL propofol and 2.5 mg/mL ketamine mixture
88986100|NCT05292807|Experimental|Imaginal exposure for future events|A behavioral intervention in imagery for future events
88986101|NCT05292807|Experimental|Imagery rescripting for memories|A different behavioral intervention in imagery for memories
88986102|NCT05292807|Experimental|Imagery rescripting for future events|A different behavioral intervention in imagery for future events
88986103|NCT00402155||1|Normal subjects
88986104|NCT00402155||2|Reading discomfort subjects
88986105|NCT00478699|Active Comparator|1|
88986106|NCT00478699|Experimental|2|
88986107|NCT00478816|Active Comparator|Group 1|Primed subject with pandemic Vaccine
88986108|NCT00478816|Active Comparator|Group 2|Non Primed subject with pandemic Vaccine
88986109|NCT00119054|Other|Arm 1|
88986110|NCT02956174|Experimental|Co-Cr single crown|Co-Cr single crown
88986111|NCT02956174|Active Comparator|Contralateral sound tooth|Contralateral sound tooth
88986112|NCT02956213|Experimental|ARM 1 MERV17 first|"This group will receive a portable HEPA air filtering device with MERV17 air filter for the first part of the study. At cross over, this group will receive the placebo or no high-efficiency filter."
88986113|NCT02956213|Active Comparator|ARM 2 MERV17 second|This group will receive a HEPA portable air filter with no high efficiency air filter for the first part of the study. At cross over, this group will receive the high-efficiency MERV17 air filter.
88986114|NCT00479245|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
88986115|NCT05279781|Active Comparator|Root canal treatment group|This group will receive complete root canal therapy
88986116|NCT05279781|Active Comparator|Pulpotomy group|This group will receive full pulpotomy
88986117|NCT02274064|Experimental|Intervention|Donors randomly assigned to this group will receive a motivational interview and implementation intention intervention telephone call.
89614501|NCT01378104|Experimental|80% dosage group of peginterferon alfa 2a|This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
89614502|NCT01378104|Active Comparator|100% dosage group of peginterferon alfa 2a|These group patients would be treated with standard dose 180 ug/week for 48 weeks.
89614503|NCT03344250|Experimental|Main Study|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. Participants will receive the first and second infusions of EGFR BATs on days 14 and 21 after finishing concurrent RT and TMZ and then receive an infusion on day 21 of the first six cycles of TMZ.
89614504|NCT03344250|Experimental|Subcohort for MGMT unmethylated patients|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. About 4 weeks after completion of RT/TMZ, participants will receive 8 weekly doses of EGFR BATs.
89614505|NCT01130740|No Intervention|Arm 1|usual care
89614506|NCT01130740|Experimental|Arm 2|Osteoarthritis Intervention - Primary care providers receive patient-specific osteoarthritis information and treatment recommendations approximately one week prior to the patient's first post-enrollment routine appointment with PCP; patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
89614507|NCT05397288|Experimental|Resistance-Aerobic-Education (RAE)|"Participants first receive 6 months of resistance exercise, then 6 months of aerobic exercise, and finally 6 months of education program on healthy lifestyle.~Behavioral: Resistance exercise (R) Behavioral: Aerobic exercise (A) Behavioral: Healthy lifestyle education (E)"
89614508|NCT05397288|Experimental|Aerobic-Resistance-Education (ARE)|"Participants first receive 6 months of aerobic exercise, then 6 months of resistance exercise, and finally 6 months of education program on healthy lifestyle.~Behavioral: Aerobic exercise (A) Behavioral: Resistance exercise (R) Behavioral: Healthy lifestyle education (E)"
89614509|NCT05397288|Experimental|Education-Resistance-Aerobic (ERA)|"Participants first receive 6 months of education program on healthy lifestyle, then 6 months of resistance exercise, and finally 6 months of aerobic exercise.~Behavioral: Healthy lifestyle education (E) Behavioral: Resistance exercise (R) Behavioral: Aerobic exercise (A)"
89614510|NCT04453644|Experimental|Group A (Hamstrings)|Hamstring stretching would be done then isometric strength would be measured.
89614511|NCT04453644|Experimental|Group B (Calf)|Calf stretching would be done then isometric strength would be measured.
88986118|NCT02274064|No Intervention|Control|Donors randomly assigned to this group will receive a standard donor recruitment telephone call.
88986119|NCT00479323|Other|1|Immunize healthy volunteers with pneumococcal vaccine (Pneumovax 23) to obtain a pool of hyperimmune sera in a quantity sufficient to generate reference sera.
88986120|NCT00479362|Experimental|1 Warfarin Uninterrupted|Warfarin therapy is continued without interruption prior to cardiac pacing device implantation
88986121|NCT00479362|Active Comparator|2 Warfarin Interrupted|Warfarin therapy is discontinued 2 days prior to cardiac pacing device implantation
88986122|NCT00479362|Sham Comparator|3 Aspirin Group|Patients with aspirin therapy during implantation
88986123|NCT00479362|Other|4 No Antithrombotic Group|No antithrombotic treatment during operations
88986124|NCT00479479|Experimental|Cobalamin|An intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
88986125|NCT00479479|No Intervention|No intervention|No intervention
88986126|NCT00119210|Placebo Comparator|Placebo|Sugar pill
88986127|NCT00119210|Experimental|Bupropion SR|
88986128|NCT00479752|Active Comparator|A|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m²."
88986129|NCT00479752|Active Comparator|B|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
88986130|NCT00119249|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89614512|NCT01130896||MRI and Cardiac Devices|Clinically indicated MRI (all types) in patients with implanted pacemakers and ICD
89614513|NCT05166174||Pregnant women who underwent previous cesarean section with barbed suture|"This group includes pregnant women, who underwent a previous cesarean section. During the previous surgical procedure, the hysterotomy was closed by using barbed suture (Fish-bone suture)."
89614514|NCT05166174||Pregnant women who underwent previous cesarean section with conventional smooth suture|This group includes pregnant women, who underwent a previous cesarean section. During the previous surgical procedure, the hysterotomy was closed conventional smooth suture.
89614515|NCT05396976|Experimental|Yoga Group|Yoga practice will be done two days a week for 10 weeks.
89614516|NCT05396976|No Intervention|control group|no intervention
89614517|NCT05396976|Experimental|Muscle Relaxation Exercise Practices Group|Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
89614518|NCT05396976|Experimental|Yoga and Muscle Relaxation Exercise Practices Group|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
88986131|NCT00479830||Group 1|South Asian, Subgroup: Asian Indian, population in the Greater Houston area.
88986132|NCT00479830||Group 2|South Asian, Subgroup: Bangladeshi, population in the Greater Houston area.
88986133|NCT00479830||Group 3|South Asian, Subgroup: Pakistani, population in the Greater Houston area.
88986134|NCT00479830||Group 4|South Asian, Subgroup: Sri Lankan, population in the Greater Houston area.
88986135|NCT00479986|Experimental|Pioglitazone|
88986136|NCT00479986|Active Comparator|placebo|
88986137|NCT00119444|Other|periacetabular osteotomy|
88986138|NCT00480181|Experimental|Active|
88986139|NCT00480181|Placebo Comparator|placebo|
89035753|NCT02924831|Placebo Comparator|Placebo group|material: stainless steel needle Needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),but without any manipulations and Deqi sensation.
89035754|NCT02924831|Experimental|Zusanli（ST36)-acupuncture group|material: stainless steel needle Stimulating acupoints of Zusanli(ST36) with acupuncture.
89035755|NCT02924831|Experimental|Guanyuan(RN4)-acupuncture group|material: stainless steel needle. Stimulating acupoint of Guanyuan(RN4) with acupuncture.
89614519|NCT01131052|Active Comparator|BASAL PLUS|Diabetic subjects receive insulin glargine once daily plus corrective doses of insulin glulisine before meals and bedtime as needed
89614520|NCT01131052|Active Comparator|sliding scale regular insulin (SSRI)|Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed
89614521|NCT03687138||Control 1|This is the control LES population. The analysis will be done with a 24h urin sample. We will compare this population with the other control population and the study population.
89614522|NCT03687138||Study population|This is the study population. The analysis will be done with a 24h urin sample. We will compare this population with the controls populations.
89614523|NCT01132144|Experimental|Endometrial injury group|Endometrial biopsy was performed once with a pipelle de Cornier® in the month before initiating controlled ovarian stimulation.
89614524|NCT01132144|Sham Comparator|Control group|Introduction of the speculum and wiping of the cervix with gaze for 30 seconds.
89614525|NCT01379274|Experimental|lenalidomide and azacitidine combination|Lenalidomide and azacitidine combination to be utilized in patients who did not respond to 3 months of lenalidomide monotherapy.
89614526|NCT01171690|Experimental|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
89614527|NCT02522988|Experimental|Group 1a|During the first 3-week period of the study, Group 1 will serve as the experimental arm and will receive the open-label placebo intervention. Group 1 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
89614528|NCT02522988|No Intervention|Group 2a|During the first 3-week period of the study, Group 2 will serve as the comparator arm.
89614529|NCT02522988|No Intervention|Group 1b|During the last 3-week period of the study, Group 1 will serve as the comparator arm.
89614530|NCT02522988|Experimental|Group 2b|During the last 3-week period of the study, Group 2 will serve as the experimental arm and will receive the open-label placebo intervention.Group 2 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
89035756|NCT02934126||breast cancer patients|breast cancer patients who have faced a decision on different types of radiotherapy or to leave radiotherapy out of the treatment
89035757|NCT02924753|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
89035758|NCT04673136|Experimental|Colonoscopy assisted by GI-GENIUS|
89614531|NCT01171924|Experimental|Arm A: 5 days/week schedule|
89614532|NCT01171924|Experimental|Arm B: 3 days/week schedule|
89614533|NCT05396664|Experimental|Intervention|The ATWA LSE program will be implemented following a joint curricula development process with approval from the government in each of the three countries. The 'dose' of the intervention are once-weekly hour-long sessions for both in-school adolescents (session facilitated by teachers) and out-of-school adolescents (sessions facilitated by community leaders) over the course of the academic year (roughly 9 months), or roughly 30 sessions of exposure to the in-depth LSE curriculum.
89614534|NCT05396664|No Intervention|Control|"Control groups are comprised of adolescents (10-19) attending schools where the ATWA Life Skills Education (LSE) program has not been implemented, as well as out-of-school adolescents (10-19) who have not received the ATWA LSE program in their communities. Control groups receive standard of care educational opportunities. Standard of care in the case of this trial translate to the provision of standard Ministry of Education-sanctioned sexuality education, as already available in the adolescents' schools and communities."
89614535|NCT05389254|Experimental|real-time CGM group|Participants in this group will be implanted with sensors of SISENSING® GS1 continuous glucose monitoring system in their left upper arm within 24 hours after hospitalization. According to the real-time CGM blood glucose data and clinical needs, researchers will carry out individualized in-hospital blood glucose standard management.
89035759|NCT04673136|Placebo Comparator|Standard colonoscopy|
89035760|NCT02924792||Reinfusion - Fast1|Case: Autologous reinfusion through Fast1 sternal needle. (Pyng Medical) CE marked/FDA Approved
89035761|NCT02924792||Reinfusion - T.A.L.O.N|Case: Autologous reinfusion through T.A.L.O.N sternal needle. (Vidacare) CE Marked/FDA approved
89035762|NCT02924792||Reinfusion - Intravenous line|Control: Autologous reinfusion through standard intravenous line
89035763|NCT02910375|Other|Cohort A|Patients starting golimumab therapy Week 0: 200 mg Week 2: 100 mg Week 6, 10, 14, and 18: 50 mg (<80 kg) or 100mg (>80 kg body weight)
89035764|NCT02910375|Other|Cohort B|Patients already on golimumab therapy will continue their actual treatment 50 mg every 4 weeks (<80 kg) or 100mg every 4 weeks (>80 kg body weight)
89035765|NCT02924675|Experimental|pregabalin group|
89035766|NCT02924675|Placebo Comparator|Placebo group|
89035767|NCT02910609||Management at PN 3-7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
89035768|NCT02910609||Management after PN 7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life
89614536|NCT05389254|Other|Capillary blood glucose monitoring group|Participants in this group will be implanted with sensors of SISENSING® GS1 continuous glucose monitoring system in their left upper arm within 24 hours after hospitalization. But these patients will be blind to the CGM data. They'll receive 8-point capillary blood glucose monitoring simultaneously, which are 6am, 9am, 11am, 1pm, 4pm, 7pm, 9pm, 2am. According to the 8-point glucose data and clinical needs, researchers will carry out individualized in-hospital blood glucose standard management.
89614537|NCT01132378|Active Comparator|Mini-midvastus approach|Mini Midvastus approach with skin incision less than 13 cm long and vastus medialis obliquus dissection not more than 3 cm from the patellar margin was used to perform total knee arthroplasty in 40 patients.
89035769|NCT02924597|Experimental|Robot-assisted laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
89035770|NCT02924597|Active Comparator|Robot-Assisted laparoscopic partial nephrectomy|The tumor then will be laparoscopic enucleation without hilar clamping.
89614538|NCT01132378|Active Comparator|Medial Parapatellar Approach|Mini Medial Parapatellar approach with skin incision less than 13 cm. The extension into quadriceps tendon did not exceed 3 cm.Mini medial parapatellar approach was used to perform total knee arthroplasty.
89614539|NCT05389176|Experimental|Group A|Esmolol is used 6 to 24 hours after onset of septic shock in patients with fluid optimization to control heart beats between 70-100bpm.
89614540|NCT05389176|Experimental|Group B|Esmolol is used 24 hours after onset of septic shock in patients to control heart beats between 70-100bpm.
89035771|NCT02924558|Experimental|Egg protein/unsaturated fatty acid|8% higher protein energy (from egg protein) and 8% higher fat energy (from unsaturated fatty acids); approximately 42/23/35% kcal from carbohydrate/protein/fat, respectively
89035772|NCT02924558|Placebo Comparator|Control|16% higher carbohydrate energy; approximately 58/15/27% kcal from carbohydrate/protein/fat, respectively
89614541|NCT05389176|No Intervention|Group C|patients received conventional therapy in accordance with septic shock guidelines 2021
89614542|NCT05396508|Active Comparator|physical therapy|physical therapy
89614543|NCT05396508|Active Comparator|physical therapy + interfacial injection|physical therapy + interfascial injection
89035773|NCT03847545|Experimental|Intervention|The participants receive Fampridine treatment (10 mg x 2 daily) for 14 days. They are testet prior to treatment and following the 14 days of treatment.
89614544|NCT01132690|Experimental|30 units/kg|
89614545|NCT01132690|Experimental|60 units/kg|
89035774|NCT02924285|Active Comparator|Procedure|Radiofrequency catheter ablation
89035775|NCT02924285|Active Comparator|Antiarrhythmic Drug|Amiodarone
89614546|NCT05380830|No Intervention|Control|The group will be only submitted to evaluations (body composition, hematological, lipid and cytokines profile, food intake, and maximal effort under treadmill and deep-water running) at the beginning and the end of the study.
89614547|NCT05380830|Experimental|Group Hypoxia|During the intervention of 8 weeks the participants will have the deep-water running training under normoxia, but during the rest they will be under hypoxia (FiO2=13%).
89614548|NCT05380830|Placebo Comparator|Group Normoxia|During the intervention of 8 weeks the participants will have the deep-water running training under normoxia, and during the rest they will keep under normoxia (FiO2=20%).
89614549|NCT05396274|Active Comparator|standard nasal therapy|"nasal oxygen was applied for procedure~%40 inspired oxygen fraction five minutes preoxygenation"
89614550|NCT05396274|Active Comparator|high flow nasal cannula|"High Flow Nasal Oxygen was applied for procedure~%40 inspired oxygen fraction five minutes preoxygenation"
89614551|NCT04454034||Group1|The refractory elbow RA who undergo arthroscopic synovectomy
89614552|NCT01132846|Active Comparator|Low dose Dopamine|"Drug: Dopamine~Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study"
89614553|NCT01132846|Placebo Comparator|Placebo|Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
89614554|NCT01132846|Active Comparator|Low Dose Nesiritide|Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
89614555|NCT03130608|Experimental|Inspiratory Muscle Training|"The experimental group will perform Inspiratory Muscle Training (IMT) using a THRESHOLD device, a simple hand held one way valve.~In addition, the experimental group will gradually increase their activity as part of their usual care post-transplant."
89614556|NCT03130608|No Intervention|Usual Care|Receive the usual post-liver transplant care of gradually increase their activity.
89614557|NCT05396196|Active Comparator|Pre-Tape|
89035776|NCT02933931||vaccinated with 5 x 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV
89035777|NCT02933931||vaccinated with 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV
89035778|NCT02933931||vaccinated with 3 x 10E5 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV
89035779|NCT02924363||Single arm (cardiac MRI & hematocrit blood sample)|Patients will undergo a pre- & post- MitraClip procedure cardiac magnetic resonance imaging (CMR) scan with an FDA cleared MRI scanner and with or without an FDA approved contrast dye. The scan and the blood draw to assess the hematocrit is research, the MitraClip procedure is standard of care for these patients.
89035780|NCT02934048|Experimental|7-day triple regimen|Patients in this group received a 7-day triple regimen to eradicate H. pylori. The triple therapy contains proton pump inhibitor (PPI)-clarithromycin plus a susceptible antibiotics will be involved in the study.
89035781|NCT02934048|Experimental|10-day triple regimen|Patients in this group received a 10-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
89035782|NCT02934048|Experimental|14-day triple regimen|Patients in this group received a 14-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
89035783|NCT02924207|Experimental|Intervention|Path Electronic decision support arm
89035784|NCT02934087|Active Comparator|Retrograde Gate Cannulation|All patients undergoing elective EVAR with a standard commercially available stent graft will be randomized after informed consent obtained; gate cannulation method will be attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (snare) will be attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
89057326|NCT01681914||Anemia|Ambulatory, HIV-infected adult patients with hemoglobin <10 g/dL will be evaluated and managed in accordance with Mozambique's new anemia guideline for non-physician clinicians. The basic steps recommended by the guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral blood smear) and treat if indicated; evaluate for adverse drug reactions and manage per Mozambican national guidelines; consider nutritional deficiencies and intestinal parasites; evaluate response to therapy at <=1 month.
89614558|NCT05396196|Experimental|With Tape 1|
89614559|NCT05396196|Experimental|With Tape 2|
89614560|NCT05396196|Experimental|Post-Tape|
89614561|NCT01173016|Experimental|Laronidase After Transplantation|Patients with Mucopolysaccharidosis type IH (MPS I, Hurler syndrome) treated with a prior allogeneic transplant >2 years previously and treated with Laronidase weekly for 2 years after transplant.
89614562|NCT05165784|Active Comparator|V technique|Researcher will perform the V tecnique on the patient's inguinal area
89614563|NCT05165784|Active Comparator|palpation tecnique|Researcher will perform the V tecnique on the patient's inguinal area
89614564|NCT04215900|Experimental|High-Speed Multi-Directional Yoga|The duration of the intervention is 18 weeks, with 16 weeks of training.
89614565|NCT04215900|No Intervention|Waitlist control|During the course of the 18 week study this arm will receive no intervention. Participants will be encouraged to maintain their daily schedules.Following the completion of the study the participants will be offered eight yoga sessions over a one month period.
89614566|NCT01133158|Experimental|R-BMD|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years
89614567|NCT03109626|Active Comparator|DHA administration|DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind
89614568|NCT03109626|Placebo Comparator|placebo administration|placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.
89614569|NCT01133860|Experimental|eltrombopag|
89614570|NCT04455516||repair group|The first operation in these patients was meniscus repair
89614571|NCT04455516||nonfailure group|These patients had a successful first operation
89614572|NCT04455516||failure group|In these patients, the first meniscus repair operation failed
89614573|NCT02184208||Device utlization following extubation|
89614574|NCT02184208||Pulmonary mechanics|
89614575|NCT05372406||training group|elderly patients (aged ≥ 65 years) elderly patients undergo surgeries
89614576|NCT05372406||external validation group|elderly patients (aged ≥ 65 years) elderly patients undergo surgeries
89614577|NCT01134016|Experimental|Antroquinonol|"6 dose levels, Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~A maximum of 36 patients were planned based on a criteria of a maximum of 6 patients per cohort: 1 to 6 patients were planned for each dose group in the accelerated phase; 3 to 6 patients for each dose group in the standard phase .~The method of dose escalation in the accelerated titration phase continued to the next higher dose level until a patient experienced MT or a DLT. Standard titration phase start with 3+3 patients. Dose escalation proceeded sequentially between cohorts."
89614578|NCT04819074||Patients with unruptured brain aneurysms|"We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.~No intervention."
89614579|NCT01173874|Experimental|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
89614580|NCT01173874|No Intervention|Cognitive activity control group|This is a non-specific mental activity control condition, conducted two times per week for a total of 30 sessions.
89614581|NCT04815798|Experimental|Bacteriophage-loaded Microcapsule Spray with Standard of Care|Phage therapy (Bacteriophage-loaded Microcapsule Spray) will be administered topically in conjunction with standard of care for pressure ulcers.
89614582|NCT04815798|Placebo Comparator|Placebo with Standard of Care|Placebo, analogous to the experimental arm, will be administered topically in conjunction with standard of care for pressure ulcers.
89614583|NCT01174030|Experimental|CD07805/47 Gel 0.5% QD|
89614584|NCT01174030|Experimental|CD07805/47 Gel 0.18% QD|
89614585|NCT01174030|Experimental|CD07805/47 Gel 0.18% BID|
88986140|NCT00480220|Experimental|1|Specific Intervention as Global care and support program
88986141|NCT00480220|No Intervention|2|'No specific intervention'
88986142|NCT00480259|Active Comparator|Standard Nutrition|
88986143|NCT00480259|Experimental|Hyperprotein Nutrition|
88986144|NCT00119522||Group 1|cohort is of individuals with a spinal cord injury who use a wheelchair as their primary means of mobility
88986145|NCT05244876|Experimental|Experimental group|Intervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
88986146|NCT05244876|No Intervention|Control group|I declare that I will not change my lifestyle during the study process.
88986147|NCT02274103|Active Comparator|Clinic|BFST delivered to youth with poorly controlled diabetes and their families in the clinic, face-to-face.
88986148|NCT02274103|Active Comparator|Skype|BFST delivered to youth with poorly controlled diabetes and their families using Skype.
88986149|NCT00119561|Experimental|Arm 1|Telephone support groups
88986150|NCT00119561|No Intervention|Arm 2|Usual VA care
88986151|NCT01240018|Placebo Comparator|Placebo|
88986152|NCT01240018|Active Comparator|High dose Lb. casei|
88986153|NCT00480454|Active Comparator|1|Stage 1 would require 12 per group low dose and 12 per group high dose (total 72)
88986154|NCT00480454|Active Comparator|2|Stage 2 would require 48 per group (total 144)
88986155|NCT00480571|Experimental|1|BL 1020 low dose
88986156|NCT00480571|Experimental|2|BL 1020 High Dose
88986157|NCT00480610|Experimental|1|
88986158|NCT00480610|Placebo Comparator|2|
88986159|NCT00117741|Experimental|Dialectical Behavior Therapy|Participants receive standard dialectical behavior therapy and suboxone
88986160|NCT00117741|Active Comparator|Drug Counseling|Participants receive standard individual and group counseling and suboxone.
89614586|NCT01174030|Placebo Comparator|Vehicle Gel QD|
89614587|NCT01174030|Placebo Comparator|Vehicle Gel BID|
89614588|NCT01174576|Experimental|caffeinated coffee|200 mL caffeinated coffee with 3 mg caffeine per kg body weight
89614589|NCT01174576|Experimental|decaffeinated coffee|200 mL decaffeinated coffee, same amount as caffeinated coffee
89614590|NCT01174576|Experimental|Water|200 mL, control intervention
89614591|NCT04641936||Cohort A|Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
89614592|NCT04641936||Cohort B|Validation cohort will be recruited in the next 36 months of the study period.
89614593|NCT01134328|Experimental|AC-150 Combo|
89614594|NCT01134328|Active Comparator|AC-150A 0.1%|
89614595|NCT01134328|Active Comparator|AC-150B 0.005%|
89614596|NCT01134328|Other|Vehicle|
89614597|NCT05165004|Experimental|Kangaroo Mother Care|Researchers contacted the mother a day before applying KMC, and advised her to take shower and abstain from using perfumes before attending to the NICU. On days of KMC application, the researchers asked the mother to remove the upper clothes in a private room and put on an open-front gown and mask. The mother was assisted to sit in a comfortable chair with a soft backrest and footrest to prevent fatigue. Then, the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation. The mother was instructed to support the neonate's bottom with the right hand while supporting the head and neck with the other hand.
89614598|NCT05165004|Experimental|Hammock Positioning|Researchers made a hammock by using a rectangular cotton cloth with ropes that passed through the circular openings of the incubator and tied on the upper part of it. After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed.
89614599|NCT05165004|Active Comparator|NICU Routine Care|The preterm neonates in the control group received the routine care of the NICU, which entails; encircling the neonate in a fetal position using rolled towel inside the incubator.
89614600|NCT04622124|Placebo Comparator|Part 1 Single Ascending Dose (SAD) study|The single ascending dose trial set up 7 dose groups of 2.5, 5, 10, 20, 40, 60 and 80 mg. The 2.5 mg dose group was the exploratory part with open label, while the other dose groups were double-blind. 8 subjects were randomly enrolled in each dose group, 6 of whom received FCN-207 tablets and 2 of whom received placebo. This part of the study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic studies of single dose FCN-207 tablets in healthy volunteers.
89614601|NCT04622124|Experimental|Part 2 Food-effect study|Twelve subjects were enrolled and randomly divided into two groups. The subjects were given FCN-207 tablets after fasting and high-fat diet with double Cross experiment , and feces samples were collected for metabolism/excretion characteristics study.
89614602|NCT04622124|Placebo Comparator|Part 3 Multiple Ascending Dose (MAD) study|A total of 16 subjects were randomly assigned to each dose group for multiple dose study , including 12 who received FCN-207 tablets and 4 who received placebo for a 10-day administration cycle. The dosage of multiple administration was based on the results of single ascending dose study results , and the method of drug administration refers to the results of the food influence test.
89614603|NCT01134952|Experimental|Mycophenolate to sirolimus switch|Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF
89614604|NCT04590222||Female, BMI≥30, mild|"Females:~Obese BMI≥30 With Mild infection n = 10"
89614605|NCT04590222||Female, BMI≥30, severe|"Females:~Obese BMI≥30 With severe infection n = 10"
89614606|NCT04590222||Female, BMI<30, mild|"Females:~Non-Obese BMI<30 With Mild infection n = 10"
89614607|NCT04590222||Female, BMI<30, severe|"Females:~Non-Obese BMI<30 With severe infection n = 10"
89614608|NCT04590222||male, BMI≥30, mild|males: Obese BMI≥30 With Mild infection n = 10
89614609|NCT04590222||male, BMI≥30, severe|males: Obese BMI≥30 With severe infection n = 10
89614610|NCT04590222||male, BMI<30, mild|males: Non-Obese BMI<30 With Mild infection n = 10
89614611|NCT04590222||male, BMI<30, severe|males: Non-Obese BMI<30 With severe infection n = 10
89614612|NCT04590222||Healthy donors from the EFS (Etablissement Français du Sang, St Louis)|Healthy donors from the EFS (Etablissement Français du Sang, St Louis) including 5 men and 5 women
89614613|NCT01175434|Experimental|School-Based Medication Group|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse will begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
89614614|NCT01175434|No Intervention|Usual Care Group|Children in the Usual Care group will not receive preventive medications delivered at school. These children will continue to receive all of their asthma care from their parents and primary care physicians.
88986161|NCT00480649|Active Comparator|Sal/FP 50/250mcg|SERETIDE 50/250
89614615|NCT01175902|Active Comparator|Arm 1|Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
89614616|NCT01175902|Active Comparator|Arm 2|Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day
89614617|NCT05384730|Experimental|Intervention Arm|This group will receive the weekly group exercise and nutrition support which will be delivered online by trained volunteers. The duration of the intervention is 12 weeks.
88815553|NCT01067456|No Intervention|Dedicated CT arm|Subjects in this arm will continue to receive standard of care - that is the dedicated CT protocol to rule out either aortic dissection or acute coronary syndrome or pulmonary embolism.
88986162|NCT00480649|Active Comparator|Sal/FP 50/500mcg|SERETIDE 50/500
88986163|NCT00119639|Experimental|Arm 1|
89614618|NCT01135186|Other|Sapropterin|open label study of sapropterin dihydrochloride
89614619|NCT05379114|Experimental|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
89614620|NCT05379114|Active Comparator|COMPARATOR DEVICE|dimethicone based head lice treatment (medical device class 1) already in market in europe: Pouxit ®
89614621|NCT05164848|Experimental|Cohort A|"JMT101 combined with two dose levels of afatinib will be tested according to the 3 + 3 dose-escalation design. The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
89614622|NCT05164848|Experimental|Dose Expansion Cohort|Once the safe and effective dose has been determined, an expansion cohort will be recruited to further evaluate the efficacy and safety of the selected dose.
89614623|NCT05164770|Experimental|Zanubrutinib+R+chemotherapy|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
89614624|NCT05164770|Active Comparator|R+chemotherapy|R-CHOP; R-DA-EPOCH; R-HD MTX
89614625|NCT05374668|Experimental|Video-based Yoga|video-based yoga (n=40) given for patients in post-covid-19 status for 8 weeks
89614626|NCT05374668|Experimental|Home-based postur exercises|Home exzercises were given for 8 weeks
89614627|NCT05164692|Placebo Comparator|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test.~Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
89614628|NCT05164692|Experimental|Navax|"Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billions CFU/5 mL (LiveSpo®️ Navax):~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test.~Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
89614629|NCT01922583|Experimental|Vial|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
89614630|NCT01922661|Experimental|Cohort 1|Dose 1 of REGN1908-1909 or placebo
89614631|NCT01922661|Experimental|Cohort 2|Dose 2 of REGN1908-1909 or placebo
89614632|NCT01922661|Experimental|Cohort 3|Dose 3 of REGN1908-1909 or placebo
89614633|NCT05090982||Patients with Atopic dermatitis|150 patients with Atopic dermatitis
89614634|NCT05370222|Experimental|Experimental group|
89614635|NCT00634569|Experimental|Flebogamma 5% DIF|
89614636|NCT04396353||Physically active|Those who receive regular amounts of physical activity. Those who participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen as recommended by the health organizations. Additionally, a person who spend less time sitting (i.e. watching television, surfing the web, playing video games).
89614637|NCT04396353||Sedentary|Those who do not receive regular amounts of physical activity. Where physical inactivity is considered the failure to meet the recommendations of the health organizations, stating that an individual should participate in a minimum of 150 minutes of moderate exercise, or 75 minutes of a more vigorous regimen. Sitting about 70-85% of the time (i.e. watching television, surfing the web, playing video games) is also considered a person living a sedentary lifestyle.
88986164|NCT00480727|Placebo Comparator|Control|No fortnightly re-tensioning. Placebo treatment utilises the re-tensioning procedure, pt experiences clicking sensation, however, the pin is not tightened.
88986165|NCT00480727|Experimental|Treatment (Re-tensioning) Group|Pins are re-tensioned fortnightly back to initial fitting tension of 8lb/inch.
88986166|NCT05238792|Experimental|Arm A for patients age ≥18 years and <70 years|Arm A will enroll patients age ≥18 years and <70 years. TAA-T product will first be administered to patients as monotherapy at dose level 1 to determine safety. Following demonstration of safety in dose level 1, lymphodepleting chemotherapy will be administered prior to the first dose of TAA-Ts on the dose escalation phase (dose levels 2 and 3). The TAA-T product will be assessed for safety and anti-tumor activity.
89614638|NCT01175980|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88986167|NCT05238792|Experimental|Arm B for patients age ≥6 years and <18 years|Arm B will enroll patients age ≥6 years and <18 years. TAA-T product will first be administered to patients as monotherapy at dose level 1 to determine safety. Following demonstration of safety in dose level 1, lymphodepleting chemotherapy will be administered prior to the first dose of TAA-Ts on the dose escalation phase (dose levels 2 and 3). The TAA-T product will be assessed for safety and anti-tumor activity.
88986168|NCT00480844|Experimental|Sertindole|
88986169|NCT00480844|Active Comparator|Risperidone|
88986170|NCT00119717|Experimental|1|
88986171|NCT00119717|Active Comparator|2|
88986172|NCT00480883|Active Comparator|1|injection meglumine antimoniate 20 mg/kg/day/intramuscular for 21 days.
89614639|NCT04246554|Experimental|Control|Patients receive oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for pain following ACL reconstruction surgery
89614640|NCT04246554|Experimental|Ketorolac|Patients receive IV ketorolac followed by ketorolac 10 mg every 6 hours for 3 days following ACL reconstruction surgery. Patients are additionally discharged with oxycodone- acetaminophen (5mg-325mg) 28 tablets PRN for additional pain control
88986173|NCT00480883|Experimental|2|injection meglumine antimoniate 10 mg/kg/day/intramuscular plus tablet allopurinol 1200 mg/day/6hourly divided doses.
88986174|NCT00480922|Experimental|1|A low glycemic load diet
88986175|NCT00480922|Active Comparator|2|Low fat diet
89614641|NCT01922817|Active Comparator|Saxagliptin|5mg once daily in addition to insulin therapy
89614642|NCT01922817|Placebo Comparator|Placebo|Crossover Placebo once daily
89614643|NCT04275765|No Intervention|Arm 1: Routine Care|Participants will undergo routine care but take part in assessments.
89614644|NCT04275765|Active Comparator|Arm 2:Behavioral Intervention with nudges & Facebook|Participants will receive nudges and be enrolled in social media platform.
89035785|NCT02934087|Active Comparator|Snare Technique|"All patients undergoing elective EVAR with a standard commercially available stent graft were randomized after informed consent obtained; gate cannulation method was attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (retrograde gate cannulation) was attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.~Antegrade or crossover cannulation involves passing a guidewire from the ipsilateral limb to the contralateral limb gate of the endograft, which can be accomplished with a curved catheter. The wire may be retrieved on the contralateral limb using a snare device."
89035786|NCT01287520|Experimental|LY2090314/pemetrexed/carboplatin|"Part A, Cycle 1 (28 days): Intravenous doses of LY2090314 starting at 10 milligram (mg) were given on Day 1 followed by 10 mg LY2090314, 500 milligram per square meter (mg/m^2) pemetrexed (intravenous dose), and 5 or 6 area under the concentration-time curve (AUC) intravenous dose of carboplatin on Day 8.~Part A, Cycle 2 (21 days): Pemetrexed and carboplatin given on Day 1 at the same dose administered in Cycle 1.~Part A, Cycle 3 (21 days) and beyond: LY2090314, Pemetrexed and carboplatin were given on Day 1 at the same dose administered in Cycle 1. LY2090314 doses were escalated until the maximum tolerated dose (MTD) was reached.~Part B: Dose determined in Part A was administered. Participants were allowed to continue the combination treatment if they were receiving therapeutic benefit until they fulfilled one of the criteria for discontinuation."
89614645|NCT04275765|Active Comparator|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
89614646|NCT05697432|Experimental|Education|The children with special needs will receive a complete oral examination and then their parent/guardian will be subjected to education about oral hygiene, brushing and dietary guidance.
89614647|NCT01176448|Experimental|Fractionated laser|This Arm is the section of scar that will be treated with Fractionated Laser
89614648|NCT01176448|Active Comparator|Dermabrasion|Dermabrasion is the gold standard for scar resurfacing and will be used as the control against which Fractionated Laser is compared.
89614649|NCT04275609|Experimental|Artificial Intelligence generating endoscopic report|In this group, the endoscopic report was generated by artificial intelligence (AI) based on the structured diagnostic report generation system.
89614650|NCT04275609|Active Comparator|Physicians writing endoscopic report|In this group, the endoscopic report was writing by physicians.
89614651|NCT04275921|Experimental|Study participants cohort I|3 stage III NSCLC patients receiving radiotherapy will be imaged, each for a single MRI session using TWIST and HASTE sequences.
89614652|NCT04275921|Experimental|Study participants cohort II|12 patients will be imaged, each for two MRI sessions taking place during the radiotherapy schedule and separated by at least a week.
89614653|NCT04397289|Experimental|Heparin group|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation. Warfarin 1.25-2.5 mg po qd, 30 days after operation. PT/INR was kept at 1.25-1.5.
89614654|NCT04397289|Experimental|Rivaroxaban group|Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation. PT/INR was kept at 1.25-1.5.
89614655|NCT04397289|Sham Comparator|Control group|No preventive intervention measures.
89614656|NCT01135420|Active Comparator|Usual Care|Psychiatry inpatient usual care
89614657|NCT01135420|Experimental|Telephone Monitoring|Patients in the TM condition will receive an in-person session while in treatment, followed by monitoring over the telephone for three months after discharge. The intervention will incorporate motivational interviewing to monitor patients' substance use, facilitate entry into outpatient treatment, and encourage 12-step self-help group participation.
89614658|NCT04396275|Experimental|Cooked whole navy beans|A meal consisting of cooked navy beans
89614659|NCT04396275|Experimental|Cooked whole yellow split peas|A meal consisting of cooked yellow peas
89614660|NCT04396275|Experimental|Cooked rice (control)|A meal consisting of cooked rice
89614661|NCT05697354|Experimental|Tablet group|The Tablet group will carry out the exercises using the Khymeia VRRS Home Tablet.
89035787|NCT02924246|Placebo Comparator|Control group|Regular cholera vaccination
89035788|NCT02924246|Active Comparator|Raw milk|Cholera vaccination - raw milk
89035789|NCT02924246|Active Comparator|Pasteurized milk|Cholera vaccination - pasteurized milk
89035790|NCT02924246|Active Comparator|UHT milk|Cholera vaccination - UHT milk
89614662|NCT05697354|Experimental|App group|The App group will perform the exercises on their smartphone using the Khymeia Medico Amico App.
89614663|NCT01137370||Patients with TB|
89614664|NCT01137370||People without TB|
89614665|NCT00634179|Experimental|Treatment (VR-CHOP regimen)|"INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression.~MAINTENANCE: Patients achieving complete response (CR) receive rituximab IV once every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or partial response (PR) receive rituximab IV and bortezomib once weekly for 4 weeks every 6 months for up to 2 years in the absence of disease progression or unacceptable toxicity."
89035791|NCT04323865||Study 2. Repeatability of FHRV|
89035792|NCT00623740|Experimental|1: hydrocortisone|1: active arm treated with low doses of HC during the first 10 days of life
89614666|NCT01178944|Experimental|Treatment (pralatrexate, oxaliplatin)|Patients receive pralatrexate IV over 3-5 minutes and oxaliplatin IV over 2 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Oxaliplatin will be discontinued after 12 courses.
89614667|NCT03011788|Active Comparator|Single day|Single day Golytely purge 4L purge
89614668|NCT03011788|Active Comparator|2 day colon purge|Two days of Golytely purge 8L purge
89614669|NCT01179490|Experimental|SyB L-0501 + prednisolone|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.
89210883|NCT03972007|Experimental|LEDT Group 15Min|The 940nm LED blanket will be positioned across the length of the biceps brachii muscle in the dominant limb 15 minutes before the muscle fatigue protocol.
89210884|NCT03972007|Sham Comparator|Immediate Sham Group|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, immediately prior to the muscle fatigue protocol.
89614670|NCT01179568|Active Comparator|CGT with Citalopram|Targeted psychotherapy for complicated grief will be combined with SSRI medication.
89614671|NCT01179568|Active Comparator|Citalopram|Citalopram is an Selective Serotonin Reuptake Inhibitor (SSRI) medication. It will be combined with grief-focused clinical management.
89614672|NCT01179568|Placebo Comparator|Placebo (Sugar pill)|Inactive medication. It will be combined with grief-focused clinical management.
89614673|NCT01179568|Active Comparator|CGT with Placebo|The targeted psychotherapy for complicated grief will be combined with inactive medication.
89614674|NCT01180036|Active Comparator|Rituximab Treatment Arm|Patients randomized to the RTX arm will receive 1000 mg IV on Days 1 and 15. Patients who achieve complete remission at 6 months will not be retreated. A second course of RTX 1000 mg IV will be administered at study month 6 for individuals who have not achieved a complete remission, but have achieved a minimum of >25% reduction in Time 0 proteinuria. Dosing at study month 6 will be independent of cluster of differentiation (CD) 19+ B cell count.
89614675|NCT01180036|Active Comparator|Cyclosporine Treatment Arm|Patients randomized to the Cyclosporine arm will be started at a dose of CsA = 3.5 mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Target trough CsA blood levels are 125 to 175 ng/ml. Patients will have their doses adjusted according to their blood levels of CSA as monitored every 2 weeks until the target trough level is reached. If a complete remission is achieved by 6 months, CSA will be tapered and discontinued over a three-month period. If after 6 months there has not been a reduction in proteinuria of at least 25% of baseline values, the drug will also be discontinued. If there has been a >25% reduction in baseline proteinuria (but not complete remission) the CSA will be continued for an additional 6 months.
89614676|NCT01180894|Active Comparator|Iron sucrose|100 mg IV TIW
89614677|NCT01180894|Placebo Comparator|Placebo|Pacebo - Normal Saline
89614678|NCT01181050|Experimental|4.0 mg/kg|Subjects received a single dose of 4 mg/kg NNC0142-0002
89614679|NCT01181050|Placebo Comparator|Placebo|Subjects received a single dose of placebo
89614680|NCT03011944||Quality Improvement Program|This group will consist of hospitalized and SNF, at-risk/malnourished patients being discharged to home health and outpatients at-risk/malnourished patients enrolled in home health.
89614681|NCT03011944||Control|This group will consist of historical controls, concurrent controls, and matched concurrent controls across other sites within the health system.
89614682|NCT01181596||Arm 1: observational ultrasound|Collection of image data with the ultrasound probe.
89614683|NCT01181674|Experimental|Group 1 (short)|
89614684|NCT01181674|Experimental|Group 2 (long)|
89614685|NCT01181674|Other|Standard care|
89614686|NCT01182376|Placebo Comparator|Placebo|Half of the patients will be assigned placebo.
89614687|NCT01182376|Experimental|Multaq® (dronedarone)|Half of the patients will be prescribed dronedarone.
89614688|NCT01183312|Experimental|Placebo, then Flumazenil|Subjects in this arm will first receive a day of placebo, then a day of sublingual flumazenil
89614689|NCT01183312|Experimental|Flumazenil, then Placebo|Subjects in this group will first receive a day of sublingual flumazenil, then a day of placebo.
89614690|NCT05219136|Active Comparator|Conventional Fasting Group|In this parallel group, subjects are performed a conventional fasting protocol which requires 6-8h fasting for solid, 2h for clear liquids.
89614691|NCT05219136|Experimental|Modified Fasting Group|"In this test group, a new protocol of 4h fasting for rice porridge, 2h for clear liquids is applied to subjects.~The rice porridge is commercially available (New Rice Porridge®, Charm Kitchen Food Co., Ltd., Q/NBBD0001S). The volume is 300ml, with the energy as 105kJ per 100g, and it can be eaten after being heated or at room temperature."
89614692|NCT03188172|Experimental|Trial Treatment|"Induction:~Cyclophosphamide 500mg, days 1, 8 Bortezomib 1.3mg/m2, days 1, 4, 8, 11 Lenalidomide 25mg, days 1-14 Daratumumab 16mg/kg, days 1, 8, 15 (cycles 1& 2), day 1 only from cycle 3 Dexamethasone 20-40mg, days 1, 4, 8, 11~ASCT stem cell harvest:~with Bortezomib 1.3mg/m2, (12 hours post melphalan) Bortezomib 1.3mg/m2, day +5, +14, weekly~Consolidation part 1:~Bortezomib 1.3mg/m2 days 1, 8, 15, 22 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1 Dexamethasone 20-40mg days 1, 8, 15, 22~Consolidation part 2:~Bortezomib 1.3mg/m2 days 1, 8, 15 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1~Maintenance:~Lenalidomide 10mg days 1-21 Daratumumab 16mg/kg day 1"
89614693|NCT01183546||Wheelchair Users with Spinal Cord Injury|wheelchair users with spinal cord injury
88986176|NCT00481000|No Intervention|1|Waitlist; Treatment as usual
88986177|NCT05236998|Experimental|Sequence A|Period 1: Dapagliflozin and Sitagliptin / Period 2: SID1903 (FDC)
88986178|NCT05236998|Experimental|Sequence B|Period 1: SID1903 (FDC) / Period 2: Dapagliflozin and Sitagliptin
88986179|NCT01240096|Active Comparator|Mirtazapine|mirtazapine 15 mg daily
88986180|NCT01240096|Placebo Comparator|Placebo|Placebo once daily
88986181|NCT01240174|Other|Intervention Arm|Single arm in the study of doctors receiving feedback about their antibiotic prescribing rate for acute bronchitis.
88986182|NCT01240252|Experimental|Type 2 Diabetes Mellitus Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
88986183|NCT01240252|Experimental|Overweight or Obese Subjects with Normal Glucose Tolerance|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
88986184|NCT01240252|Placebo Comparator|Non-Obese Control Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
88986185|NCT01240291|Experimental|alanyl-glutamine|Intravenous alanyl-glutamine (0.5 g/kg body weight/day)
88986186|NCT01240291|Placebo Comparator|normal saline|Intravenous placebo (normal saline; 0.9 %)
89614694|NCT05340036|Active Comparator|Group I (Conventional plates)|"Digital intermediate and final interocclusal wafer splints will be designed to guide the maxilla and mandible in the desired position using CAD software (3-matic 11.0; Materialise NV, Leuven, Belgium).~The designed splints will be then exported in stereolithography (STL) file format to the additive CAM machine (FORMIGA P 110 printer; EOS e-manufacturing solutions, Munich, Germany) and manufactured in white polyamide (PA2200; EOS e-manufacturing solutions, Munich, Germany) using fused deposition modelling (FDM) technology.The splints will be cold sterilized by overnight immersion in 2% glutaraldehyde.~2.0 conventional mini plates will be used for fixation of maxilla and mandible in the new position."
89035793|NCT00623740|Placebo Comparator|2: Placebo|2:placebo arm treated with placebo at the same conditions than active arm
89614695|NCT05340036|Experimental|Group II (Patient specific plates)|"The cutting guides will be designed on the maxilla and mandible to orient the osteotomy and mark reference holes to be used later for the repositioning/ fixation plate, using CAD software.~The designed guide will be then exported in stereolithography (STL) file format to the additive CAM machine and manufactured in white polyamide using fused deposition modelling (FDM) technology. No finishing or polishing was done in order to maintain accuracy. The guides will be cold sterilized by overnight immersion in 2% glutaraldehyde.~The patient-specific osteosynthesis plates will be designed to fix the maxilla and mandible in the desired position making use of the previously established reference holes. The designed plates will be exported in STL file format to be manufactured in grade 5 titanium alloy utilizing selective laser sintering (SLS) technology on an additive CAM machine."
89614696|NCT01184014|Experimental|Experimental group|a study-specific steroid (NPH) dosing algorithm plus standard recommended care. The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).
89614697|NCT01184014|Active Comparator|Control group|the standard recommended care (Methodist Hospital Complete Insulin Orders)
89614698|NCT03130140|Active Comparator|Macroscopic on-site evaluation|EUS-FNA perform with a 19-gauge needle with macroscopic on-site evaluation.
89614699|NCT03130140|Sham Comparator|Control|EUS-FNA perform with a 19-gauge needle with conventional techniques.
89614700|NCT01185028|Experimental|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
89614701|NCT03011866|Experimental|Experimental|"Loading dose: 100ml 0.9% normal saline(NS) intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 5ml/hr 0.9% NS intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 500mg TXA in 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
89035794|NCT01287403|Placebo Comparator|Refined wheat flour|A negative control flour to serve as a reference.
89035795|NCT01287403|Active Comparator|Esterase wholegrain wheat flour|Wholegrain wheat flour treated with esterases to release phenolics (positive control for phenolic acids)
89614702|NCT03011866|Other|Control|"Loading dose: 10mg/kg tranexamic acid(TXA) in 100ml 0.9% NS intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 1mg/kg/hr TXA intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
89614703|NCT05263596|Other|No Sarcopenia (Control Group)|healthy participants
89614704|NCT05263596|Other|Sarcopenia is probable|"Low muscle strength (in accordance with the guidlines of The European Working Group on Sarcopenia in Older People 2 (EWGSOP2))"
89614705|NCT05263596|Other|Sarcopenia is confirmed|"Low muscle strength + low muscle quantity (in accordance with the guidlines of The European Working Group on Sarcopenia in Older People 2 (EWGSOP2))"
89614706|NCT05199168|No Intervention|Thoracoscopic esophagectomy without IONM|
89614707|NCT05199168|Experimental|Thoracoscopic esophagectomy with IONM|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
89614708|NCT01143142|Experimental|Tailoring|Individuals assigned to the experimental group will receive a two-page brochure tailored based on their responses to the survey.
89614709|NCT01143142|Active Comparator|Untailored information|Individuals assigned to the control group will receive the CDC vaccine information sheet that is standardly provided.
89614710|NCT02186938|No Intervention|Usual Care|Arterial line (radial, femoral, dorsalis pedis, or brachial), central line for access when needed, intubation vs tracheostomy, general anesthesia. We currently use stroke-volume variability monitoring (FloTrac) in all patients using the arterial line placed for blood pressure monitoring.
89614711|NCT02186938|Experimental|Treatment|The study will use a treatment algorithm for patients in the treatment group. This algorithm will aim to maintain a near-normal blood pressure and use goal directed therapy to achieve this. Currently the standard of care is to use IV fluid exclusively in these patients and anesthesia providers everywhere have been challenging that treatment plan. Our algorithm has an iterative approach assessing volume status, cardiac output and vascular tone in order, with interventions specified for each. Individual treatments have been proven safe and effective in this population, we believe this sequence may be the best current management system. By avoiding excessive fluid administration we expect to decrease ICU length of stay due to the comorbidities caused (pulmonary edema, bowl edema, glycocalyx damage).
89614712|NCT05190822||Students|
89614713|NCT02187016|Experimental|AirFloss + BreathRx|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
89035796|NCT01287403|Experimental|Wholegrain wheat flour|Flour with unknown response
89035797|NCT01287403|Experimental|Liquid whole grain wheat flour|Test flour with unknown response.
89035798|NCT01287403|Experimental|Wholegrain barley flour|Test flour with unknown response.
89035799|NCT01287403|Experimental|Liquid wholegrain barley flour|Test flour with unknown response.
89035800|NCT02924168|Experimental|Active Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, at 3.5 to 4 bar air pressure (resulting in an energy flux density [EFD] of approximately 0.07 mJ/mm2) and at 15Hz frequency. A total of 4 sessions will be performed.
89035801|NCT02924168|Sham Comparator|Sham Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, without air pressure (resulting in no EFD) and at 15Hz frequency. A total of 4 sessions will be performed.
89035802|NCT01287364|Experimental|ciclesonide HFA followed by mometasone|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily in first intervention period, followed by a 7-14 day washout period, after which the second intervention of mometasone nasal inhalation 200 μg once daily will be administered.
89614714|NCT02187016|Experimental|AirFloss + Listerine|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with Listerine Cool Mint rinse once a day.
89614715|NCT02187016|Experimental|Dental Floss|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device once a day.
89614716|NCT02187016|Active Comparator|Manual Toothbrush|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute
89614717|NCT05439798|Active Comparator|Group OD (Group ondansetron+dexamethasone)|The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg-1).
89614718|NCT05439798|Active Comparator|Group PD (Group palonosetron+dexamethasone)|The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).
89614719|NCT05439798|Placebo Comparator|Group D (Group Dexamethasone)|The patients in Group D (Group Dexamethasone) will be given intravenous (iv) dexamethasone (0.5 mg.kg-1).
89614720|NCT02188576|Experimental|high dose TXA|"High dose TXA is the intervention.~A higher dose of tranexamic acid will be given to this arm as follows:~50 mg/kg loading dose and 5 mg/kg/h infusion"
89614721|NCT02188576|Experimental|Low Dose TXA|"Low dose TXA is the intervention.~A lower dose of TXa will be given as follows:~10 mg/kg loading dose and 5 mg/kg/h infusion"
89614722|NCT05439720|Experimental|Exercise and ketone|Ketone ester is provided
89614723|NCT05439720|Placebo Comparator|Exercise and placebo|Placebo is provided
89614724|NCT05439720|Placebo Comparator|Non-exercise and placebo|Placebo is provided
89035803|NCT01287364|Active Comparator|mometasone followed by ciclesonide HFA|mometasone nasal inhalation 200 μg once daily in first intervention period followed by a 7-14 day washout period after which the second intervention of ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily will be administered
89614725|NCT05439642|Other|Hemophilia|Evaluation of quality of life of children with hemophilia in Turkey
89614726|NCT02189122|Active Comparator|Group 1:Aspirin/placebo|Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
89035804|NCT02924012|Experimental|active video game|An active game session lasting 40 minutes
89035805|NCT02924012|Other|sedentary video game|An sedentary game session lasting 40 minutes
89614727|NCT02189122|Active Comparator|Group 2:NHP-544C/placebo|Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
89614728|NCT05309460|Active Comparator|Nifedipine|Patients randomized to Nifedipine will be started on Nifedipine XR 30mg BID. Escalation in therapy to be determined by primary provider. Maximum dose of Nifedipine is 120mg daily. All patients will be monitored for signs and symptoms of hypotension or medication side effect- severe HA, orthostasis, syncope.
89614729|NCT05309460|Active Comparator|Labetalol|Patients randomized to Labetalol will be started on 200mg TID. Escalation in therapy to be determined by primary provider. Maximum dose is 2400mg in a day. All patients will be monitored for signs and symptoms of hypotension or medication side effect- orthostasis, syncope, bradycardia.
89614730|NCT03261804||Group I:internal vaginal douching users|
89614731|NCT03261804||Group II: none internal vaginal douching users|
89614732|NCT01093690|Experimental|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg orally four times a day on day 2-5
89614733|NCT01093690|Placebo Comparator|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
89614734|NCT05301426|Experimental|Passive hamstring stretch.|Manual stretching of the hamstring muscles using the technique proposed by Henri Neiger.
89614735|NCT05301426|Experimental|Longitudinal slippage of the sciatic nerve.|Neurodynamic technique described by David Butler and Michael Shacklock.
89614736|NCT05301426|Active Comparator|Passive upper limb mobilisations.|Control group. Passive mobilisation of the upper limbs.
89614737|NCT04455360|Experimental|EMDR R-TEP intervention|Participants will receive a minimum of 2 and a maximum of 8 online EMDR R-TEP sessions, starting within 3-months of hospital discharge. Sessions will be delivered online by experienced, suitably trained and registered psychological practitioners.
89614738|NCT04455360|No Intervention|Standard care|Patients will receive standard post-hospital discharge care.
89614739|NCT01143610|Experimental|Newly forming bone|Miller class I or II deep recessions treated by the newly forming bone technique.
89614740|NCT01143610|Active Comparator|Subepithelial connective tissue graft|Miller class I or II deep recessions treated by subepithelial connective tissue graft.
89614741|NCT03130530||ALF-X|all patient underwent robotic colorectal surgery using ALF-X system
89614742|NCT05439486|Active Comparator|100% oxygen|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
89614743|NCT05439486|Placebo Comparator|ordinary room oxygen|ED patients in this group exposed to normal air oxygen concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
89614744|NCT01143688|Active Comparator|albuterol inhaler|albuterol
89614745|NCT01143688|Placebo Comparator|placebo inhaler|placebo
89614746|NCT01143688|Placebo Comparator|placebo acupuncture|placebo
89614747|NCT04455594|Experimental|Almonertinib|Almonertinib 110mg QD
89614748|NCT04455594|Active Comparator|Investigator-choice therapy (Erlotinib or Chemotherapy)|Erlotinib 150mg QD or Cisplatin(75mg/m2) or Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
89614749|NCT05439408|Experimental|XS004 - Period 1|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
89614750|NCT05439408|Active Comparator|SPRYCEL - Period 1|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
89614751|NCT05439408|Experimental|XS004 - Period 2|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
89614752|NCT05439408|Active Comparator|SPRYCEL - Period 2|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
89614753|NCT05439408|Experimental|XS004 - Period 3|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
89614754|NCT05439408|Active Comparator|SPRYCEL - Period 3|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
89614755|NCT05439408|Experimental|XS004 - Period 4|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 100 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel and in accordance with the randomization schedule.
89614756|NCT05439408|Active Comparator|SPRYCEL - Period 4|At the clinic, after an overnight fast of at least 10 hours, a single oral dose of 140 mg tablet was administered to each participant in a sitting posture with about 240 mL of drinking water in the presence of the principal investigator and quality assurance personnel, and in accordance with the randomization schedule.
89614757|NCT05261880|Experimental|Neural mobilization|Neural mobilization will be given for 15 minutes with 3 repetitions. After mobilization, Kinesio taping will be applied and it will bandage till the next session.
89614758|NCT05261880|Experimental|Scaphoid, hamate mobilization|Scaphoid and hamate mobilization for 20 minutes, at the end of session kinesio taping will bandage till the next session.
89035806|NCT02924012|Other|walking|An walking lasting 40 minutes
89614759|NCT01187914||Open Irrigation|Those individuals who had an ablation using open irrigation cooled-tip RF ablation.
89614760|NCT04453800|Experimental|Group A ：low dose sofadil|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
89614761|NCT04453800|Experimental|Group B: Medium dose group|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
89614762|NCT04453800|Experimental|Group C: high dose group|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
89614763|NCT04453800|Placebo Comparator|Group D: placebo group|Saline was administered intravenously
89614764|NCT01188460|Placebo Comparator|Control Group|Receive one weekly telephone follow-up call per week to monitor sleep progress, complete 7 weeks of sleep diaries only (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), complete questionnaires at three study timepoints
89614765|NCT01188460|Experimental|Experimental Group|Receive one weekly telephone call to monitor sleep progress, complete 7 weeks of sleep diaries (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), implement one chapter per week of self-help manual for insomnia over 7 weeks at home, complete questionnaires at three study timepoints
89614766|NCT03011476|Active Comparator|Donepezil|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
89614767|NCT03011476|Placebo Comparator|Placebos|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
89035807|NCT02889757|Experimental|NAC 1200 mg|patients with add NAC (600) 1# bid use per day during the study period
89035808|NCT02889757|Experimental|NAC 2400 mg|patients with add NAC (600) 2# bid use per day during the study period
89035809|NCT02889757|Placebo Comparator|NAC 0 mg|patients with add NAC (600) 0# (placebo) use per day during the study period
89614768|NCT05438784|Active Comparator|Group A (patient specific titanium implant)|(reconstruction with patient specific titanium implant)
89614769|NCT05438784|Active Comparator|Group B (preformed plate bended on stereolithographic model)|(reconstruction with preformed titanium plate preoperatively bended on stereolithographic model)
89614770|NCT02522754|Placebo Comparator|Placebo|Placebo
89614771|NCT02522754|Experimental|Protesomal Vaccine 1 x 30 µg|Protesomal Vaccine 1 x 30 µg
89614772|NCT02522754|Experimental|Protesomal Vaccine 2 x 30 µg|Protesomal Vaccine 2 x 30 µg
89614773|NCT02522754|Experimental|Protesomal Vaccine 2 x 15 µg|Protesomal Vaccine 2 x 15 µg
89614774|NCT01188694|Experimental|Psychotherapy plus Methylene Blue, USP|
89614775|NCT01188694|Placebo Comparator|Psychotherapy Plus Placebo|
89614776|NCT01188694|Other|Delayed Psychotherapy|
89614777|NCT04453566||Elite Athletes|Elite Athletes
89614778|NCT04454112|Experimental|24-hour esophageal pH monitoring|24-hour esophageal pH monitoring was conducted using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands). This system consists of a portable data logger (MMS Investigation and Diagnostic Software®) and a disposable catheter which contains two pH electrodes (Unisensor, Attikon, Switzerland). Before recording, the pH electrode was calibrated in the special buffer solutions at pH values of 1 and 2.
89614779|NCT04454268|Other|hydatid cyst|
89035810|NCT02889952||NIR-|All consecutive patients (n=174) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only- by surgeon 1, from January 2015 to January 2016 (period 1)
89614780|NCT01188928|Experimental|LEO 80185|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension
89614781|NCT01188928|Active Comparator|Betamethasone|Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle
89614782|NCT01188928|Active Comparator|Calcipotriol|Calcipotriol 50 mcg/g in the topical suspension vehicle
89614783|NCT01188928|Placebo Comparator|Topical suspension vehicle|The topical suspension vehicle alone
89614784|NCT05438706|Experimental|Arm 1|chidamide in combination with camrelizumab and capecitabine
89614785|NCT05438706|Experimental|Arm 2|chidamide in combination with camrelizumab and carboplatin
89614786|NCT05438472||healthcare professionals with COVID-19 mRNA vaccine booster|Consecutive individuals that received a COVID-19 mRNA vaccine booster and undergo a systematic approach to detect myocarditis at the University Hospital Basel. The project population includes mainly healthcare workers, aged between 16-65, most of them with presumable no comorbidities. Baseline characteristics include age, divided in several groups (16-20 years, 21-25 years, 26-30 years, 31-35 years, 36-40 years, 41-45 years, 46-50 years, 51-55 years, 56-60 years, 61-65 years).
89614787|NCT05167344|Experimental|Healthy Relationships Program-Enhanced (HRP-E)|Youth participating in the HRP-E and facilitators delivering in the program
89614788|NCT01189240|Experimental|Phase I Dose Finding|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
89614789|NCT01189240|Experimental|Phase II Stage I|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
89614790|NCT01189240|Experimental|Phase II Stage II Arm 1|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
89614791|NCT01189240|Active Comparator|Phase II Stage II Arm 2|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
89614792|NCT01189240|Experimental|Phase I Dose Finding - Level 1 5mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
89614793|NCT01189240|Experimental|Phase I Dose Finding - Level 2 10mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
89614794|NCT01189240|Experimental|Phase I Dose Finding - Level 3 20mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
89614795|NCT03467490|Experimental|Treatment|65 participants will be invited to receive a one-day educational intervention (first study visit) at the Ivey Eye Institute. The educational intervention includes watching a short video series and receiving educational handouts which summarize the content of the videos. Participants will have access to the educational handbook for reference. At two months post-intervention, participants will be invited back to St. Joseph's Hospital to complete the second administration of the heiQ and OSDI. Participants will have an opportunity to ask the ophthalmologist any question during the question and answer period. Participants will then be asked to provide feedback on the video series using a participation satisfaction survey and will be given an educational handbook which may be used to as a reference/guide on how to self-manage
89035811|NCT02889952||NIR|All consecutive patients (n=63) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with intraoperative use of NIR - surgical field was examined with NIR before any thyroid dissection- by surgeon 1, from February 2016 to May 2016 (period 2)
89035812|NCT02889952||Control1|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by another surgeon in the unit (surgeon 2), during period 1.
89035813|NCT02889952||Control2|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by surgeon 2, during period 2.
89614796|NCT03467490|No Intervention|Control|Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
89614797|NCT03462264|No Intervention|Control Group / Group 1|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic.
89035814|NCT02889835|Active Comparator|Universal Composite|Supreme Universal Restorative
89035815|NCT02889835|Experimental|Flowable Composite|Supreme Flowable Restorative
89035816|NCT02889835|Experimental|Bulk Fill Flowable Composite|Bulk Fill Flowable Restorative
89035817|NCT02923973|Experimental|TVU CL screening|TVU CL screening: serial TVU CL scan from 16 0/7 to 24 6/7 every week, for a total of nine scans Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
89614798|NCT03462264|Experimental|Group 2|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a pre-formatted diary for them to fill out.
89614799|NCT03462264|Experimental|Group 3|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a link to download the free ScolioGold App on to their mobile from the clinic.
89614800|NCT03013348||Adults (22-99),|Male or female subject between the ages of 22-99, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
89614801|NCT03013348||Adolescents (13-21)|Male or female subject between the ages of 13-21, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
89614802|NCT03013348||Children (2-12)|Male or female subject between the ages of 2-12, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
89614803|NCT03467334|Experimental|B. breve|Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.
89614804|NCT03467334|Experimental|B. breve plus L. fermentum|Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.
89614805|NCT03467334|Active Comparator|Simethicone 20 mg|Control group that will receive simethicone 4 times (10 drops) a day.
89614806|NCT02880384|Experimental|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing.
89614807|NCT03462186|Experimental|Intervention|Invitation to use healthfinder website
89614808|NCT03462186|No Intervention|Control|No intervention
89614809|NCT02874144|Experimental|AZ Compound|40 mg 12 weeks TID po
89614810|NCT02874144|Placebo Comparator|Placebo|40 mg 12 weeks TID po
89614811|NCT03467178|Experimental|Decitabine plus Carboplatin|Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
89614812|NCT03467178|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
89614813|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Adult|1 doses of 1 ml of Rotavirus vaccine per oral
89614814|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Children|1 doses of 1 ml of Rotavirus vaccine per oral
89614815|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Neonates|3 doses of 1 ml of Rotavirus vaccine per oral
89614816|NCT03462108|Placebo Comparator|Placebo-Neonates|3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral
89614817|NCT03467100|Experimental|XEN901|Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort
89614818|NCT03467100|Placebo Comparator|Placebo|Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort
89614819|NCT05434182|Experimental|Intradermal Suture Group|Vascular surgery patients undergoing a femoral approach surgery and randomized to this group will have their skin closed with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
89614820|NCT05434182|Active Comparator|Metallic Staples|Vascular surgery patients undergoing a femoral approach surgery and randomized to this group will have their skin closed with metallic stapling using Visistat® (Weck®) 35W skin stapler.
89614821|NCT02847078|Experimental|Smart phone app|The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
89614822|NCT02847078|Other|Control group|Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.
89614823|NCT02835534|Experimental|rhTNK-tPA|rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
89614824|NCT02835534|Active Comparator|rt-PA|Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
89614825|NCT02722200|Experimental|Intravenous glucocorticoids|Subjects in the glucocorticoids arm will receive an infusion of hydrocortisone overnight in the research unit prior to fMRI testing on either the first or second visit.
89614826|NCT02722200|Placebo Comparator|Intravenous saline|Subjects in the saline arm will receive an infusion of saline overnight in the research unit prior to fMRI testing on either the first or second visit.
89614827|NCT04066218||age 15-19|The investigators plan to complete 24 interviews with 12 in the age 15-19 cohort.The investigators will also ensure that at least 8 people from each sex are included in this study.
89614828|NCT04066218||age 20-24|The investigators plan to complete 24 interviews with 12 in the age 20-24 cohort. The investigators will also ensure that at least 8 people from each sex are included in this study.
89614829|NCT04453176||"operating block admission on foot"|Patient going to the oparating block on foot
89614830|NCT04453176||standard operating block admission|Patient going to the operating room in a conventional way (stretcher)
89614831|NCT01094548|Experimental|Tecemotide (L-BLP25) plus single low dose cyclophosphamide|
89614832|NCT01094548|Experimental|Tecemotide (L-BLP25) plus multiple low dose cyclophosphamide|
89614833|NCT01094704|Experimental|Hypertonic Saline - 1 hour|sodium chloride (7%); mucociliary clearance measured 1 hour post dose
89614834|NCT01094704|Experimental|Hypertonic Saline - 4 hours|sodium chloride (7%); mucociliary clearance measured four hours post-dose.
89614835|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 108 mg SC|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
89614836|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 300 mg IV|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.
89614837|NCT02611830|Experimental|Maintenance Phase: Induction IV + Placebo|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.
89614838|NCT03461874|Active Comparator|Treatment as usual|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Calcium channel blockers
89614839|NCT03461874|Experimental|Treatment as usual + ACT|"Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and eight group sessions of 90 minutes of ACT.~The ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program."
88986187|NCT00119795|Active Comparator|Health education control|This is an education program for older adults entitles, successful aging.
88986188|NCT00119795|Experimental|Exercise Only|Structured exercise 150 min/wk
88986189|NCT00119795|Experimental|Weight Loss|Behavioral weight loss; goal of 7%
88986190|NCT00481039||1|Patients diagnosed as having abnormal hemoglobin like hemoglobin S and thalassemia in a bedouin village
88986191|NCT00481156|Experimental|Patients: Cognitive Remediation|Patients in the cognitive REM condition attended up to 25 h of training in small groups over 4-6 weeks based on the approach to cognitive remediation described by Wexler and Bell (2005). Patients performed tasks designed to train attention and memory from the battery available within a computerized software package (CogPack Marker Software). This training protocol has been shown to improve memory and executive functioning in patients with schizophrenia (Sartory et al, 2005) and tasks chosen were designed to produce improved working memory and attention capacity in the treated group. In addition, patients in the REM group trained on the word N-back one to two times a week and on N-back tasks using a variety of other stimuli (such as faces) one to two times a week to support the generalization of working memory improvements.
88986192|NCT00481156|Active Comparator|Patients: Cognitive-Behavioral Social Skills Training|Patients in the CBSST group also attended up to 25 h of treatment but followed a manualized group therapy protocol (Granholm et al, 2005) using cognitive and behavioral therapy methods to increase patients' skills in symptom recognition, communication, problem solving, and relapse prevention. In both conditions, the facilitators interacted with the clients throughout small group (B4 patients) sessions: in the REM group, this mostly involved brief one-on-one discussions regarding task performance; in the CBSST condition, this interaction was in the context of the group milieu.
88986193|NCT00481156|Other|Controls: Retest control group|Estimate of normal brain functioning and retest effects
88986194|NCT01240369||VEGF-C low|
88986195|NCT01240369||VEGF-C high|
88986196|NCT01240369||miR-326 low|
88986197|NCT01240369||miR-326 high|
88986198|NCT01240408|Experimental|Treatment group 1|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
88986199|NCT01240408|Experimental|Treatment group 2|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
88986200|NCT05232786||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
88986201|NCT05232786||Health Care Professionals (HCPs)|HCPs treating people who have obesity
88986202|NCT01240447|Other|Best support treatment|
88986203|NCT01240447|Experimental|Racotumomab vaccine|
88986204|NCT00481312|Active Comparator|1|Dexmedetomidine
88986205|NCT00481312|Active Comparator|2|Midazolam
88986206|NCT00481390||HIV-1 infected adults|HIV-1 infected adults
88986207|NCT00481429||1|Rosiglitazone
88986208|NCT00481429||2|Diet control +/- metformin
88986209|NCT00481624|Experimental|Epoetin Alfa plus Iron|
88986210|NCT00481663|Experimental|Sitagliptin 25 mg once daily|Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
88986211|NCT00481663|Experimental|Sitagliptin 50 mg once daily|Sitagliptin, 50 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
88986212|NCT00481663|Experimental|Sitaglipin 100 mg once daily|Sitagliptin, 100 mg, once daily for 158 weeks, orally
88986213|NCT00481663|Experimental|Sitagliptin 50 mg twice daily|Sitagliptin 50 mg, twice daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
89035818|NCT02923973|No Intervention|No TVU CL screening|no screening Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
89035819|NCT01287013|Other|Cone Beam CT|Procedure performed with Xperguide cone-beam Computed Tomography (CT) navigation
89614840|NCT03461718|Experimental|Ketamine|Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
89614841|NCT03461718|Active Comparator|Control|This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.
88986214|NCT00481663|Placebo Comparator|Placebo to Sitagliptin → Metformin|Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.
88986215|NCT05220423|Other|Reminders Group|This group will receive 6 reminders (sms/emails) on top of the National annual communication campaign organized by the French Health System authorities
88986216|NCT05220423|Other|No reminders group|This group will receive no reminders on top of the National annual communication campaign organized by the French Health System authorities
88986217|NCT00120068|Other|Arm 1|
88986218|NCT00481819|Experimental|1|In combination with MMF and steroids
88986219|NCT00481819|Active Comparator|2|In combination with MMF and steroids
88986220|NCT02958228|Experimental|Positive Mental Imagery Training (PMIT)|Computerized Positive Mental Imagery Training (PMIT), a form of mental imagery-based cognitive bias modification adapted from previous experimental (e.g. Holmes, Lang, & Shah, 2009) and clinical (e.g. Blackwell & Holmes, 2010) work. The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
88986221|NCT02958228|Active Comparator|Cognitive Control Training (CCT)|An adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015). The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
88986222|NCT02958228|Active Comparator|Treatment as Usual|Participants will receive their treatment as usual (TAU) within the inpatient setting, which may include group/individual psychological therapy, a range of therapeutic activities, and pharmacological treatment.
88986223|NCT02958059|Experimental|Treatment|The intervention group
88986224|NCT02958059|Placebo Comparator|Comparator|The comparator group
88986225|NCT01240525|Other|CD4 DLI|Patients will receive trial product manipulated CD4 DLI post transplant as trial treatment.
88986226|NCT01240525|Other|No DLI|Patients will receive no DLI post transplant as trial treatment.
88986227|NCT00482209|Active Comparator|1|200mg mifepristone followed by 400mcg misoprostol
88986228|NCT00482209|Active Comparator|2|200mg mifepristone followed by 800mcg misoprostol
88986229|NCT00117936|Experimental|1|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - high dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
88986230|NCT00117936|Experimental|2|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
88986231|NCT00117936|Placebo Comparator|3|Placebo solution void (not containing) Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141), given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
88986232|NCT01240642|Experimental|ASA404|
88986233|NCT05202054|Experimental|The Effect of mindfulness stress reduction program on slepness and quality of life|Groups of 20 will be formed for the implementation of the mindfulness stress reduction program in the experimental group. The BFSAP day and time will be determined by taking into account the time zones where women are available. 150 minutes of BFSAP will be applied to the women in the experimental group once a week, lasting 8 weeks and consisting of 8 times in total. The women will then be given a midterm test. After the midterm, women will be asked to individually repeat the BFSAP application in their own home for 8 weeks (weeks 8-16).
88986234|NCT05202054|No Intervention|control group|THESE PARTICIPANTS HAVE NOT BEEN APPLIED
88986235|NCT01240681|Other|FLT PET and BOLD MRI scan|All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy
88986236|NCT00482287|Other|1|Dose level 0.3 mg/kg with 6 active and 2 placebo
88986237|NCT00482287|Other|2|Dose level 0.6 mg/kg 6 patients active and 2 placebo
88986238|NCT00482287|Other|3|Dose level 1.2 mg/kg 6 active and 2 placebo
88986239|NCT00482287|Other|4|Dose level 2.4 mg/kg 6 active and 2 placebo
88986240|NCT00482443|Experimental|1|To assess the efficacy of a Diabetes Interactive Diary in Diabetes Management.
88986241|NCT00482443|Active Comparator|2|Control Arm. Patients will receive standard education programme.
88986242|NCT00482482|Experimental|Yoga|Yoga was offered twice a week for 8 weeks, 1.5 hours per session
88986243|NCT00482482|Active Comparator|Psychoeducation|Psychoeducation was offered twice a week for 8 weeks, 1.5 hours per session
88986244|NCT00482521|Experimental|CC-4047|
88986245|NCT00482599|Active Comparator|Normal renal function|Org 25969 given to subjects with normal renal function
88986246|NCT00482599|Experimental|Impaired renal function|Org 25969 given to subjects with impaired renal function
88986247|NCT00120302|Experimental|1|Pimecrolimus
88986248|NCT00120302|Placebo Comparator|2|Vehicle
88986249|NCT01240720|Experimental|I131-F16SIP|"Phase I: Multicentre, open-label, two-step singlearm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-F16SIP, given at the RD of 55.5 mCi/m2, as determined in phase I."
88986250|NCT00482989|Experimental|1|MEDI-545
88986251|NCT00482989|Other|2|Placebo
88986252|NCT00120380|Active Comparator|Aerosolized Iloprost|
88986253|NCT00120380|Placebo Comparator|Bosentan monotherapy|
88986254|NCT01240798||Depression, anxiety|
89614842|NCT02522364|Active Comparator|BioMonitor|Participants randomized for this arm will be implanted with a BioMonitor device an implantable loop recorder inserted under the skin in the region of the thorax. It continuously records heart rhythm for a period of up to 7 years. The device will be interrogated at 1 month intervals. All arrhythmic events and conductive disturbances will be noted. In addition will be followed as specified in the standard arm
89614843|NCT02522364|Active Comparator|Standard|Participants randomized for this arm will be followed by biannual office visits initialing clinical evaluation, review of clinical events, review and update of medical therapy. Participants will undergo ECG holter examination at 3 and 6 months after discharge
88986255|NCT01240837|Active Comparator|glucose|
88986256|NCT01240837|Active Comparator|sucrose|
88986257|NCT01240837|Experimental|palm sugar|
88986258|NCT01240954|Active Comparator|OSIRIS|
88986259|NCT01240954|Experimental|OSIRIS other concentration 1|
88986260|NCT01240954|Experimental|OSIRIS other concentration 2|
88986261|NCT01240993|Active Comparator|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will also provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed specifically for this study.
88986262|NCT01240993|Experimental|Mothers and Toddlers Program|This intervention is an introductory, short-term, supportive, psychodynamic therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing. Mothers meet with an individual, MBT-trained psychodynamically-oriented therapist for 12 sessions. The intervention is conducted a clinic where mothers are enrolled in treatment for their substance abuse.
88986263|NCT01241032|Experimental|Udenafil|Udenafil 200mg
88986264|NCT01241032|Active Comparator|Udenafil + Alcohol|Udenafil 200mg + Alcohol
88986265|NCT00120458|Experimental|1|Anxiolytic Therapy
88986266|NCT00120458|Placebo Comparator|2|Anxiolytic Therapy
88986267|NCT00483067|Experimental|2-CdA + Ara-C + G-CSF|2-CdA 12 mg/m^2/day by vein (IV) Continuous Infusion and Ara-C 1 gm/m^2/day IV for 5 Days with G-CSF 5 mcg/kg/day subcutaneously starting Day 9
88986268|NCT00483106|Active Comparator|Ritalin|
88986269|NCT00483106|Placebo Comparator|Placebo|
88986270|NCT00118170|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib once on day 1 and then once daily, twice daily, or every other day beginning on day 8 and continuing for 3 months. Patients are re-evaluated at 3 months. Patients with responding disease may continue study treatment in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients (per treatment cohort) receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
88986271|NCT00483145|Active Comparator|1|Long-pulsed dye laser (Candela)
88986272|NCT00483145|Active Comparator|2|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
88986273|NCT00483535|Experimental|Sequence ABC|All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
88986274|NCT01241071|Experimental|Myofascial treatment|Myofascial release techniques of different muscles implicated in low back pain
88986275|NCT01241071|Placebo Comparator|Placebo|
88986276|NCT04727489||Autism Spectrum Disorder|Probands with Autism Spectrum Disorder, (N=700), Diagnosis of ASD according to DSM-V criteria For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
88986277|NCT04727489||Control without Autism Spectrum Disorder|Controls without Austim Spectrum Disorder, aged 6 to 40, N=2100 (300 adultes, 300 children) Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
88986278|NCT04727489||Relatives of probands with Autism Spectrum Disorder|"Relatives of probands with Autism Spectrum Disorder (N=1200 parents, N=600 siblings, N=300 other relatives)~Without Autism Spectrum Disorder diagnosis according to DSM-V,~With Autism Spectrum Disorder diagnosis according to DSM-V, and using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders"
88986279|NCT04727489||Relatives of controls|Relatives of controls without Autism Spectrum Disorder, N=400 first degree relatives
88986280|NCT00483808|Experimental|Denervation|Renal denervation using the Symplicty Catheter
88986281|NCT00483886|Active Comparator|1|Prucalopride 2 mg
88986282|NCT00483886|Placebo Comparator|3|Placebo
88986283|NCT00483886|Active Comparator|2|Prucalopride 4 mg
88986284|NCT00483964|Experimental|A|The group getting the study drugs, Bacopa monnieri and Nardostachys jatamansi
88986285|NCT00483964|Active Comparator|B|The group getting Olanzapine
88986286|NCT01241110|Active Comparator|azitromicin,PID treatment,ofluxacin|
88986287|NCT01241149|Active Comparator|Normal pH, abnormal Impedance|After 24hr pH-metry and impedance, those patients with normal pH (i.e. DeMeester score <14.7) but with abnormal impedance scores will be offered anti-reflux surgery
88986288|NCT01241149|Placebo Comparator|Abnormal pH|After 24hr pH-metry and impedance, those with abnormal pH scores (i.e. DeMeester score >14.7)will be offered anti-reflux surgery
88986289|NCT01241188|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
89614844|NCT03461640|Experimental|Community-based doula support for labour|"Women will receive support from a Community-based doula (CBD) plus standard labour support. Women will meet twice with the CBD prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. The CBD will then stay with her throughout her labour and birth and support her with interpretation/Communication with the staff and emotional and instrumental support. The CBD-support will be in addition to any other support people she may have, such as her partner.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.~CBDs will be recruited, trained and employed by non-profit organization MIRA, using well-tested processes."
89614845|NCT03461640|Active Comparator|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
89614846|NCT03466788|Other|Patients treated with chemotherapy|
89614847|NCT03466788|Other|Patients not treated with chemotherapy|
89614848|NCT03466710|Active Comparator|Colposcopy arm|Patients received colposcopy as per standard of care
89614849|NCT03466710|Experimental|Pap arm|Patients received a Pap test only
89614850|NCT03466710|Experimental|HPV arm|Patients received an HPV test only
89614851|NCT03466632|Active Comparator|• Propofol Group|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..
89614852|NCT03466632|Active Comparator|• Dexmedetomidine Group|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
89614853|NCT03466554|Experimental|hyperbaric oxygen therapy (HBOT) active treatment|60 daily HBOT sessions will be administrated 5 days per week. Comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
89614854|NCT03466554|No Intervention|Control-follow up|"The standard of care of psychological and mediational support .~After 3 months of follow up, participants will be re-evaluated. The individuals in the control group will then be offered to receive the treatment and to be re-reevaluated after the treatment is over (3 months)."
89614855|NCT03461562|Experimental|Experimental|
89614856|NCT03461562|Active Comparator|Control|
89614857|NCT05348928||With oral ascorbic acid|1 g ascorbic acid orally
89614858|NCT05348928||Without oral ascorbic acid|No oral ascorbic acid is taken
88986290|NCT01241188|Active Comparator|2 TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
88986291|NCT05138211|Experimental|Hemiparetic patients|Patients with hemiparetic gait who will be assisted by the exoskeleton action
88986292|NCT00484120|Experimental|1|3% Diclofenac NE cream
88986293|NCT00484120|Placebo Comparator|2|
88986294|NCT00484276|Experimental|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every 3 weeks or weekly
88986295|NCT00484432|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
88986296|NCT00484510|Experimental|Ascorbic Acid|
88986297|NCT00484510|Placebo Comparator|Placebo|
88986298|NCT05130723||Patients|Pediatric patients aged 2-18 years administered with fluconazole for the treatment or prophylaxis of invasive fungal infections.
88986299|NCT00484705|Experimental|Low-frequency electro-acupuncture|
88986300|NCT00484705|Experimental|Physical exercise|
88986301|NCT00484705|Active Comparator|Untreated control|
88986302|NCT00484744|Experimental|Acetaminophen|
88986303|NCT00484744|Experimental|Ibuprofen|
88986304|NCT00484744|Placebo Comparator|Avicel|
88986305|NCT05128656|Other|Cases|SARS-Cov-2 asymptomatic nursing homes employees
88986306|NCT05128656|Other|Controls|cohort of patients with a symptomatic COVID-19, preferably recruited in nursing homes or in case of difficulties in the virology service of COCHIN Hospital.
88986307|NCT00484783|Experimental|Prospective|Subjects scheduled to receive procedure
88986308|NCT00484783|Other|Historical|Chart review control group
88986309|NCT00484822|Experimental|1|Brazo 1: Bemiparina Sódica 3.500 UI/día.
88986310|NCT00484822|Placebo Comparator|2|Brazo 2: Heparina Cálcica 10.000 UI/día.
89614859|NCT01144624|Experimental|1|"AZD9773 250 units/kg (1 infusion) + 50 units/kg (9 infusions) (Dose Cohort 1):~AZD9773 500 units/kg (1 infusion) + 100 units/kg (9 infusions) (Dose Cohort 2)"
89614860|NCT01144624|Placebo Comparator|2|
88986311|NCT01241266||1|Target subject population are the consecutive patients hospitalized due to peptic ulcer bleeding. Subjects should be: ≥18 years; admitted to the hospital with an overt upper GI bleed (hematemesis/coffee ground vomiting, melena, hematochezia and other clin
89614861|NCT05339334|Experimental|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days to adult Chinese healthy volunteers
89614862|NCT01096810|Experimental|TBL 12|TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression
89614863|NCT03461328|Experimental|Mg-group|10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
89614864|NCT03461328|No Intervention|Control group|In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.
89614865|NCT02455284|Experimental|Healthy subjects|MRI and neuropsychological evaluation
89614866|NCT03466398|Experimental|Intervention Arm|Patients will use the Vivify Health RPM protocol as part of their diabetes management. They required to complete the Care Plan questions on a daily basis, and will upload blood glucose readings directly to the tablet twice a day. They will also have scheduled video conferences with study team physicians or advanced practice nurses on a weekly basis, to discuss ongoing diabetes management and educational objectives.
89614867|NCT03466398|No Intervention|Control Arm|Patients in this arm will manage their diabetes at home per normal standard of care, without any extra intervention from the study investigators.
89614868|NCT04453254|Active Comparator|Whole Food Meal|A whole meal consisting of 1 cup 2% milk, 1 cup Kashi Go Lean Original cereal, ¼ cup of almonds, ¼ cup of strawberries, and ¼ cup of raspberries.
89614869|NCT04453254|Active Comparator|Supplement Food Meal|A supplemental meal equivalent consisting of 1 cup 2% milk, 20 g whey protein, ½ EAS Myoplex bar, and ½ Balance bar.
89614870|NCT01145638|Experimental|iron isomaltoside 1000|Iron isomaltoside intravenously as bolus or infusion
89614871|NCT01145638|Active Comparator|iron sulphate|oral iron sulphate twice a day
89614872|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T7-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -9, -8 and -7.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 7 days (T7) after the end of the preconditioning regimen"
89614873|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
89614874|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL2|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 2: 3x108 NKR-2 (adjusted at 4.6x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
89614875|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL3|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 3: 1x109 NKR-2 (adjusted at 1.5x107 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
88986312|NCT01241383|Experimental|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
88986313|NCT00485017|Experimental|1|THR-4109: 115 mg orally in am, 115 mg orally in pm for 24 weeks
88986314|NCT00485017|Experimental|2|THR-4109: 100 mg orally in am, 100 mg orally in pm for 24 weeks
88986315|NCT00485017|Experimental|3|THR-4109: 15 mg orally in am, 15 mg orally in pm for 24 weeks
88986316|NCT00485017|Placebo Comparator|4|
88986317|NCT00485056|Placebo Comparator|Placebo|Crossover arm
88986318|NCT00485056|Active Comparator|Pioglitazone|Pioglitazone 45mgs daily
88986319|NCT00118560|Experimental|1|treadmill walking and calf exercise
89210885|NCT03972007|Sham Comparator|Sham Group 15Min|The 940nm LED blanket will be positioned throughout the biceps brachii muscle in the dominant limb, however, it will not be ligated, with no light emission, 15 minutes before the protocol of muscle fatigue.
89210886|NCT00987909|Placebo Comparator|Placebo|Solution resembling the active solutions, but without allergen extract
89614876|NCT03466320|Experimental|Phase I Dose Escalation - extension|This extension segment will enroll more patients (to reach 9 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
89614877|NCT03466320|Experimental|Phase II Segment 1|This extension segment will enroll more patients (to reach 13 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
89614878|NCT03466320|Experimental|Phase II Segment 2|Enrollment in the Phase II part of the study will be divided in 2 consecutive segments, with 13 patients in total in the segment 1 and 30 new patients in segment 2 (43 patients in total) if the study is not terminated due to futility, according a Simon's two-stage optimal design
89614879|NCT03466242|Experimental|Intranasal Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine (1-2ug/kg)
89614880|NCT03466242|Active Comparator|IV Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine (1mg/kg)
89614881|NCT03013270|Experimental|ARIS group|Aerobic-Resistance-Inspiratory
88986320|NCT00485251|Active Comparator|1|hand assisted right hemicolectomy
88986321|NCT00485251|Active Comparator|2|laparoscopic right hemicolectomy
88986322|NCT00118638|Experimental|Darbepoetin alfa 500 mcg - Group A|
89614882|NCT03013270|Active Comparator|AT/RT group|Aerobic-Resistance
89614883|NCT03013270|Active Comparator|AT/IMT group|Aerobic-Inspiratory
89614884|NCT03013270|Active Comparator|AT group|Aerobic Training
89614885|NCT03461250||HCV serology negative in HD|Risk factors
89614886|NCT03461250||HCV serology positive in HD|Risk factors HCV viral load HCV genotype Liver elastography by Fibroscan
88986323|NCT00118638|Active Comparator|Darbepoetin alfa 2.25 mcg/kg - Group B|
88986324|NCT00485329|Experimental|Low dose papain|Ratio of drug to placebo treated patients will be 4:1
88986325|NCT00485329|Experimental|Medium dose papain|Ratio of drug to placebo treated patients will be 4:1
88986326|NCT00485329|Experimental|High dose papain|Ratio of drug to placebo treated patients will be 4:1
88986327|NCT01241500|Experimental|ON 01910.Na + best supportive care (BSC)|Patients will receive ON 01910.Na 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards and best supportive care (BSC).
88986328|NCT01241500|No Intervention|Best supportive care (BSC)|Patients will receive best supportive care (BSC).
88986329|NCT00120965|Experimental|1|Autopulse device
88986330|NCT00120965|Active Comparator|2|Manual CPR
88986331|NCT01241578|Experimental|Mobile Phone Intervention|Participants receive a behavioral intervention via mobile phone and brief in-person counseling sessions.
88986332|NCT01241617|Active Comparator|Duet TRS|Endo GIA with integrated Duet TRS
88986333|NCT01241617|Active Comparator|Endo GIA|Endo GIA stapler with Single Use Loading units
89210887|NCT00987909|Experimental|Cat hair allergen extract, dose group 1|
89210888|NCT00987909|Experimental|Cat hair allergen extract, dose group 2|
89614887|NCT03461172||patients operated for breast cancer|patients operated for histologically proven breast cancer
89614888|NCT03466164|Experimental|Behavioral: Mindfulness Based Stress Reduction Program|Mindfulness-Based Stress Reduction MZ: identical (monozygotic; MZ) twins are tested in a pre-post manner, with only one twin randomly assigned to MT in between the two testing sessions
89614889|NCT03466164|No Intervention|Control MZ|Control MZ twin will complete 2 testing sessions without intervention.
89614890|NCT02980120||Anorexia Nervosa Group|n=50 female patients with Anorexia Nervosa (AN) who fulfill the criteria for DSM-IV, BMI z-scores will be used for age and sex specific cut-off points that are extrapolated from the adult BMI cut-off <17.5 Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
89614891|NCT02980120||Bulimia Nervosa Group|n=30 female patients with Bulimia Nervosa (BN) who have BMI z-scores from the adult range <17.5-25.0 (this reflects the lower prevalence rates of BN compared to AN) Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
89614892|NCT02980120||Healthy Control Group|n=30 healthy females who have BMI z-scores from the adult range from 19.0-25.0 and who do not fulfill diagnostic criteria for any psychiatric disorder.Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
89614893|NCT03466008|Experimental|Whole body cryotherapy arm|intervention consisted of 10 sessions of WBC (three minutes for each session) which were performed in addition to usual care in a standard cryotherapy room over a duration of 8 days.
89614894|NCT03466008|No Intervention|Usual treatment arm|usual care
89614895|NCT05324280|Experimental|Acupuncture Group|"Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture. The needles will be stimulated manually and will remain for 20 minutes.~Body acupuncture needles (diameter 0.3mm, length 30 mm) will be placed on the following positions:~On the lower abdomen and back within Th11 and L1~Kidney 13 and 14; alternately unilaterally~Ren2 and 3 (midline) On classical acupuncture points on the extremities and the head~Stomach 36, Spleen 6; bilaterally~Large intestine 4, Liver 3; Bladder 60 bilaterally~Du 20 (midline)~Ear acupuncture:~Ear acupuncture needles (diameter 0,2 mm, length 20mm) will be used:~Veg. I (Sympathetic), lower pelvis, hypogastric plexus, Heart,Thalamus, genital system (combining Chinese and French ear acupuncture)~For point detection an electric potentiometer will be used. Ear points are punctured according to their generally accepted positions."
89614896|NCT05324280|No Intervention|Waiting list Group|Participants allocated to the waiting list control group may continue previously initiated standard therapy, but must not initiate any new treatment. They will be asked not to undergo acupuncture treatment for any condition within the next 3 months. After this period they are offered 10 acupuncture treatments over a period of 3 months.
89614897|NCT02522052|Experimental|Blue mussel diet|5 meals a week including blue mussels
89614898|NCT02522052|Active Comparator|Meat/control diet|5 meals a week including meat
89614899|NCT01190878|Experimental|ISV-303 BID|
88986334|NCT02274181|Experimental|25 mg (approximately equivalent to [(~]) 500 nanocurie|A single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal
89614900|NCT01190878|Experimental|ISV-303 QD|
89614901|NCT01190878|Active Comparator|Xibrom BID|
89614902|NCT01190878|Placebo Comparator|DuraSite Vehicle BID|
89614903|NCT03465930||Patients with lymphedema|Patients affected by primary or secondary lymphedema. The intervention will consist in supermicrosurgical lymphatico-venous anastomoses (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia. It requires an accurate visualization of the lymphatic vessels that are still functional.
88986335|NCT01241422|Experimental|Treatment A: JNJ 40929837|
88986336|NCT01241422|Placebo Comparator|Treatment B: Placebo|
88986337|NCT01241422|Other|Treatment C: Montelukast|
89614904|NCT01146496|Active Comparator|Storage container|Ultraviolet light resistant plastic in-ground pesticide storage container
89614905|NCT01146496|No Intervention|Control|
89614906|NCT01146808|Experimental|ADV plus hepatitis B vaccination|Adefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.
89614907|NCT02522130|Active Comparator|lidocaine group|Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,
89614908|NCT02522130|Active Comparator|misoprostol group|Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion
89614909|NCT02522130|Active Comparator|non steroid group|Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion
89614910|NCT02522130|Placebo Comparator|placebo group|group D will receive placebo tablets.
89614911|NCT03461016|Experimental|Smartphone-Based Exposure Therapy|Participants assigned to the Smartphone-Based Exposure Therapy group will receive two weeks of exposure therapy via their smartphone. Participants will have the opportunity to receive up to 50 minutes of exposure video intervention daily for the two weeks.
89614912|NCT03461016|No Intervention|Waitlist Control|Participants who have been randomly assigned to participate in the Waitlist Control group will not receive treatment; however, after the two weeks of no intervention, participants in this condition will be offered the same treatment as the treatment condition.
89614913|NCT01148524|Other|rMenB06|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 6 months) and placebo (at 1 and 2 months) in V72P10 study had a blood draw.
89614914|NCT01148524|Other|rMenB0|Subjects who had received 1 dose of rMenB+OMV-NZ (at 0 month) and 3 doses of placebo (at 1, 2 and 6 months) in V72P10 study had a blood draw.
89614915|NCT01148524|Other|rMenB016|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 6 months) and 1 dose of placebo (at 2 months) in V72P10 study had a blood draw.
88986338|NCT02274220|Experimental|Rapid Advancement of Feeds|Postoperative feeds are initiated on first postoperative day and rapidly advanced over 27 hours.
88986339|NCT02274220|Experimental|Average feeding protocol|Postoperative feeds are initiated on first postoperative day and advanced in using a standardized protocol that best-reflects current feeding practice. Maximum feeding volume is reached at 60 hours.
89614916|NCT01148524|Other|rMenB01|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 1 month) and placebo (at 2 and 6 months) in V72P10 study had a blood draw.
89614917|NCT01148524|Other|rMenB026|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 2 and 6 months) and 1 dose of placebo (at 1 month) in V72P10 study had a blood draw.
89614918|NCT01148524|Other|rMenB02|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 2 months) and placebo (at 1 and 6 months) in V72P10 study had a blood draw.
89614919|NCT01148524|Other|rMenB012|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 2 months) and 1 dose of placebo (at 6 months) in V72P10 study had a blood draw.
89614920|NCT01148524|Other|rMenB6|Subjects who had received 1 dose of rMenB+OMV-NZ (at 6 months) and 3 doses of placebo (at 0, 1 and 2 months) in V72P10 study had a blood draw.
89614921|NCT01148524|Other|Naive|An additional study group of naïve subjects that served as a baseline comparator for assessing antibody persistence in the vaccine groups and had blood draw for serological analyses at the time of enrollment.
89614922|NCT03460938|Experimental|RIPC|
89614923|NCT03460938|No Intervention|Control|
89614924|NCT03460860|Experimental|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|
89614925|NCT03460860|Placebo Comparator|Placebo|
89614926|NCT01191736|Experimental|No training, assessed within 60 mins|Subjects receive no training
89614927|NCT01191736|Experimental|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
89614928|NCT01191736|Experimental|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
89614929|NCT01191736|Experimental|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
89614930|NCT01191736|Experimental|Ultra-brief video; assessed at 2 months|
89614931|NCT01191736|Experimental|Brief video; assessed 2 months later|
89614932|NCT01191736|Experimental|Brief video + hands-on; ass'd 2 ms later|
89614933|NCT01192282||Genital Warts|All female patients with Genital Warts presenting to Groote Schuur Hospital
89614934|NCT04607382||Low-dose estrogen progestin products (LEP)|The patients in the LEP cohort should not have taken LEP in the last 2 months before the enrollment in the study, and will take LEP during the study period.
89614935|NCT04607382||Non-LEP|Those patients in the Non-LEP cohort should not have taken LEP in the last 2 months before the enrollment and will take NSAIDs and/or Chinese medicine (CM) during the study period.
89614936|NCT01192828|Experimental|Taurine|Treatment with Taurine
89614937|NCT01099618|Active Comparator|Metformin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
89614938|NCT01099618|Active Comparator|Sitagliptin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
89614939|NCT01099618|Placebo Comparator|Placebo|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg(n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
89614940|NCT01099774|Experimental|Bimatoprost 0.03% Formulation B Ophthalmic Solution|Bimatoprost 0.03% Formulation B Ophthalmic Solution
89614941|NCT01099774|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% Ophthalmic Solution
89614942|NCT03013192|No Intervention|Control|No text message reminders, usual patient protocol
89614943|NCT03013192|Experimental|Intervention (text messaging)|Text message reminders for PT
89614944|NCT01328574|Experimental|Single Arm - TRC105 in Urothelial Carcinoma|TRC105 15 mg/kg/dose every two weeks
89614945|NCT03460626|Placebo Comparator|Group-I (Control group)|This group will be administered a placebo that is an odorless oil without any therapeutic effect)
89614946|NCT03460626|Experimental|Group-II (Treated group)|This group will be administered lavender oil.
89614947|NCT03460626|No Intervention|Group-III (Untreated group)|No intervention will be provided in this group.
89614948|NCT04453488|Experimental|RUTI® vaccine|Participants will receive two dose of RUTI® vaccine at the baseline visit and after 2 weeks +/- 3 days, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in an injection volume of 0.3 mL.
89614949|NCT04453488|Placebo Comparator|Placebo|Participants will receive two dose of physiological serum will be administered subcutaneously in the deltoid region at the baseline visit and after 2 weeks +/- 3 days.
89035820|NCT01287013|Other|Conventional CT|Procedure performed with Conventional Computed Tomography (CT) image guidance
89614950|NCT01100242|Experimental|Arm 1: VELCADE and Sorafenib|Patients will be given VELCADE® (bortezomib) 1mg/m2 intravenously on days 1,4,8 & 11 and sorafenib at a dosage of 200 mg orally twice per day. One full course is comprised of 21 days.
89614951|NCT01148836|Experimental|Coenzyme Q 10 and Pulmonary Hypertension|PAH subjects to take Co-Q daily for three months
89614952|NCT01148836|Experimental|Coenzyme Q 10 and Normal Controls|Normal controls to take Co-Q daily for three months
89614953|NCT03460548|Experimental|Remogen|
89614954|NCT03460548|Active Comparator|Cationorm|
89614955|NCT05115006||Cohort 1|Participants diagnosed with stage II and stage III melanoma who have undergone surgery
89614956|NCT01149616|Active Comparator|Intervention|Dexamethasone 8mg iv x 1
89614957|NCT01149616|Placebo Comparator|Placebo|placebo
89614958|NCT03465462|Active Comparator|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
89614959|NCT03465462|Active Comparator|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
89614960|NCT03465462|Active Comparator|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
89614961|NCT03460470|Active Comparator|Sildenafil 40mgx3 daily|Sildenafil 40mgx3 daily for 6 months
89614962|NCT03460470|Placebo Comparator|Placebo tablet x3 daily|Placebo for Sildenafil 40mgx3 daily for 6 months
89614963|NCT03465306|Experimental|Intensive digital CBT|
89614964|NCT03465306|Active Comparator|Standard digital CBT|
89614965|NCT01101100|Experimental|AMG 827|AMG 827
89614966|NCT03460392||Neurological and behavioral disorders|Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
89614967|NCT03460392||Subjects affected by bone diseases|Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
89614968|NCT03460392||Dysmetabolic and/or endocrine disorders|Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
89614969|NCT03460392||Subjects performing agonistic activity|Subjects performing physical activity at agonistic level are enrolled.
89614970|NCT03460392||Gastroenteric disorders|Subjects affected by gastric and/or enteric disorders are enrolled.
89614971|NCT03460392||Prolonged antibiotic therapy|Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
89614972|NCT03460392||Healthy subjects|Subjects without any known ongoing disease are enrolled.
89614973|NCT01149772|Experimental|ACCESS|Medically ill patients received six-sessions of cognitive behavioral therapy tailored to their unique needs. Patients received 2 core modules and 3 elective modules. Elective modules focused on physical health, cognitive restructuring, behavioral activation, and relaxation. The six session was a wrap up that everyone received. Patients also had the option to receive 2 follow-up booster sessions to aid in maintenance of skills learned.
89614974|NCT01149772|No Intervention|Enhanced Usual Care|Patients in this arm received feedback about their physical and emotional health functioning and were still able to receive usual primary care services.
89614975|NCT05201118|Experimental|CT103A combined with Selinexor|All subjects will be assigned to two Selinexor dose groups of 20 mg/week and 40 mg/week after receiving a single dose infusion of CT103A.
89614976|NCT05012436|Experimental|YHD1119 75mg, 150mg NF|CLcr (mL/min/1.73m2) >= 60 Period 1 : YHD1119 75 mg Period 2 : YHD1119 150 mg NF
89614977|NCT05012436|Experimental|YHD1119 75mg|60 > CLcr (mL/min/1.73m2) >= 30 Period 1 : YHD1119 75 mg Period 2 : NA
89614978|NCT01101880|Experimental|Treatment (chemotherapy and colony stimulating factor)|"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.~CONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.~Treatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity."
89614979|NCT03460080||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
89614980|NCT03460080||Hepatic hemangioma patients|
89614981|NCT04989972|Experimental|Intervention arm|participants will take the active intervention PSIL428
89614982|NCT04989972|Experimental|placebo arm|participants will take the intervention 1 mg Oyster mushrooms
89614983|NCT04989972|Experimental|open label|all participants will take the active intervention PSIL428
89614984|NCT01101958|Other|Chartis System-EBV Treatment|Subjects with heterogeneous emphysema, had their collateral ventilation status in the target treatment lobe assessed using the Chartis System (CV- or CV+) and underwent endobronchial lung volume reduction (ELVR) with endobronchial valves (EBV).
89614985|NCT04978038|Experimental|Pfizer-BioNtech mRNA- COVID-19|Eligible participants will be vaccinated with the Pfizer-BioNtech mRNA- COVID-19. A 0.3ml dose of the vaccine will be administered intramuscularly.
89614986|NCT04978038|Active Comparator|Pneumococcal Prevnar-13|Eligible participants will be vaccinated with Pfizer Prevar-13 (pneumococcal vaccine) in a blinded manner such that the vaccination with Pfizer-BioNtech mRNA- COVID-19 will be mimicked. That is, a 0.5ml dose of the vaccine will be administered intramuscularly. After completion of the study participants in the control arm will be given a fourth dose of Pfizer-BioNtech mRNA- COVID-19.
89614987|NCT01194466|Active Comparator|Active TENS|Active high frequency TENS will be use for Active TENS.
89614988|NCT01194466|Experimental|Placebo (low intensity) TENS|Placebo TENS will be applied for one arm of the study
89614989|NCT01194466|Sham Comparator|No Treatment|TENS unit in place but not turned on
89614990|NCT03011632|Experimental|mometasone nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months,
89614991|NCT03011632|Placebo Comparator|placebo mometasone|a group of children without immunoglobulin E (IgE) - dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
89614992|NCT01102270|Active Comparator|Eszopiclone|Eszopiclone 3mg prior to sleep (1 night)
89614993|NCT01102270|Placebo Comparator|Sugar Pill|Sugar Pill (placebo) prior to sleep (1 night)
89614994|NCT01102738||Premature babies (<32 weeks)|All premature babies born at less than 32 completed weeks gestation who are admitted to an Imperial College NHS Healthcare Trust Neonatal Intensive Care Unit (St. Mary's Hospital or Queen Charlotte's & Chelsea Hospital), and whose parents/guardians have given their consent will be eligible to enter the study.
89614995|NCT01102894|Experimental|Low fiber and High Fiber|Subjects consume a low fiber cereal and swallow the SmartPill device that measures gastrointestinal transit time Subjects consume a high fiber cereal along with swallowing the SmartPill device that measures gastrointestinal transit time
89614996|NCT01103440|Other|Conventional Strategy|Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure
89614997|NCT01103440|Active Comparator|Aggressive Strategy|Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally
89614998|NCT03011554|Experimental|Implantable Miniature Telescope (IMT)|Intervention: Implanting the Implantable Miniature Telescope (IMT) in pseudophakic eyes of patients suffering from binocular end-stage AMD.
89614999|NCT01152112|Experimental|Treatment, Office Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in an office setting
89615000|NCT01152112|Experimental|Treatment, Hospital Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in a hospital setting
89615001|NCT04352374|Experimental|Aerobic exercise group|"The therapist advised all participants of this group to drink a plenty of water before and after the exercise session to avoid excessive loss of body water during the session. Pregnant women were instructed to have a light meal about one hour before the performance of exercise and to wear comfortable clothes.~Participants in this group were given a Low-Intensity Aerobic Exercise with Borg scale RPE at 11. Participants were asked to maintain this intensity of rate of perceived exertion throughout the 45 minutes' duration of the aerobic training.~During the training session, the therapist stood near the patient to observe and detect signs of stopping the exercise. The therapist continuously asked the patient if she felt pain, dizzy or shortens of breath.~No complications were observed during physical exercise sessions, for example, hypertensive crisis, hypotension, hyperthermia, musculoskeletal lesions, or other complications identified that demanded interruption of the exercise."
89615002|NCT04352374|Active Comparator|Device guided breathing group|"At the beginning the researcher explained the device and study procedures to every participant of this group .The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.~The participant is instructed to alter their breathing rate, aiming for up to 10 breaths per minute, in response to a melody played to them via the asked to use the device for at least 40 min per week, with each session lasting at least 10 min"
89615003|NCT01105312|Experimental|panobinostat (LBH589) and letrozole|Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks. There are two phases of the study. The first phase determines the maximum tolerated dose for LBH589 in combination with letrozole. The second phase is to assess and confirm the response rate and safety profile of LBH589 in combination with letrozole.
89615004|NCT01328496|Other|Research Arm|"Participant with high-risk hematologic malignancies undergoing Hematopoietic Cell Transplantation, who do not have a suitable Human Leukocyte Antigen -matched related/sibling donor, Matched Unrelated Donor or Killer immunoglobulin receptors ligand mismatched haploidentical donor identified, will receive a single UCB unit.~Intervention: Preparative Regimen"
89615005|NCT01328496|Other|Observation Arm|"Patients requiring two UCB units will be eligible for UCBT01 on the observational arm.~Intervention: Preparative Regimen"
89615006|NCT04488978|Experimental|Irbesartan low/Amlodipine low|Irbesartan low & Amlodipine low, once daily for 8 weeks
89615007|NCT04488978|Experimental|Irbesartan low/Amlodipine high|Irbesartan low & Amlodipine high, once daily for 8 weeks
89615008|NCT04488978|Experimental|Irbesartan high/Amlodipine low|Irbesartan high & Amlodipine low, once daily for 8 weeks
89615009|NCT04488978|Experimental|Irbesartan high/Amlodipine high|Irbesartan high & Amlodipine high, once daily for 8 weeks
89615010|NCT04488978|Active Comparator|Amlodipine low|Amlodipine low, once daily for 8 weeks
89615011|NCT04488978|Active Comparator|Amlodipine high|Amlodipine high, once daily for 8 weeks
89615012|NCT04488978|Active Comparator|Irbesartan low|Irbesartan low, once daily for 8 weeks
89615013|NCT04488978|Active Comparator|Irbesartan high|Irbesartan high, once daily for 8 weeks
89615014|NCT04464486|Experimental|COVID-19 Symptom Augmented SCH Intervention|The SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants receive automated self-management support messages for symptoms reported and a Nurse Practitioner monitors and responds to alerts for COVID-19 symptoms and poorly controlled or worsening cancer symptoms. Participants in this group complete baseline and monthly measures.
89615015|NCT04464486|No Intervention|Enhanced Usual Care|Participants in the control group are given information by research staff reviewing COVID-19 symptoms, home precautions, and instructions on what to do to address concerns that arise. Participants in this group complete baseline and monthly measures.
89035821|NCT02934243||easy Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven easy
88815554|NCT01067456|Experimental|Comprehensive Cardiothoracic CT arm|The intervention consisted in a change of the routine CT protocol (as in dedicated CT protocol) to a comprehensive cardiothoracic CT protocol which includes changes in contrast injection and coverage to enable evaluation of the presence of acute coronary syndrome/aortic dissection/pulmonary embolism in a single scan.
88815555|NCT01067768|Experimental|Daily review|In the intervention group a nurse reviewed daily, by using a checklist designed for this study, the indications and pertinence of the catheter. If it was not indicated she asked the doctor to order the removal of the catheter, but the doctor would make the final decision.
88815556|NCT01067768|No Intervention|Routine care|In the control group, the attending team would remove the catheter as routine, without any suggestion by the research protocol.
88815557|NCT01068548|No Intervention|Arm 1|pre-implementation of computer based intervention
88815558|NCT01068548|Experimental|Arm 2|post-implementation of computer based length of stay clinical reminder
88815559|NCT05239130|Experimental|Auralya 1|Sixteen patients will be administered Auralya® 1 (Cross-linked Hyaluronic Acid) for the treatment of minor facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
89615016|NCT03465228|Experimental|Training group|This group will do the Deep Water Running, with intervals and continuous training twice a week, and before each session, will be applied the LED equipment. The training will be thirty minutes and will be controlled by heart rate, 70% to 80% maximum heart rate in continuous training, and maximum heart rate in intervals training.
89615017|NCT03465228|Experimental|Training and LED group|This group will receive the photobiomodulation treatment and the same training model of training group.
89035822|NCT02934243||difficult Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven difficult
89035823|NCT02924090|Active Comparator|ECT with Etomidate|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose.
89615018|NCT03465228|Experimental|LED group|This group will receive only the photobiomodulation treatment with 30 seconds of light emitting in four points of lumbar region.
89615019|NCT03460002|Experimental|Measles vaccine|In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.
89615020|NCT03460002|Experimental|Oral polio vaccine|In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.
89615021|NCT03460002|No Intervention|Weighing-MV|In control villages children aged 9-59 months acting as controls to the MV-intervention arm will be weighed only.
89615022|NCT03460002|No Intervention|Weighing-OPV|In control villages children aged 0-8 months acting as controls to the OPV-intervention arm will be weighed only.
89615023|NCT01105702|Experimental|TBL/RT|"Cycle 1(One 42-day cycle)~Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment~Radiation within 3-5 weeks of surgery~Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks~Treatment Cycles 2-7 (28 days per cycle)~Temozolomide at a dose of 150 mg/m^2 on Days 1-7~Bevacizumab 10 mg/kg on Day 8 and Day 22~Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L."
89615024|NCT01197898|Experimental|Collagenase Santyl|Ointment applied once daily
89615025|NCT01197898|Placebo Comparator|Vehicle Base|Applied once daily
89615026|NCT03468582|Experimental|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
89615027|NCT03458754||Patients|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
89615028|NCT03458754||Healthy controls|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
89615029|NCT04453332|Active Comparator|Oral hormone therapy|Estradiol 1mg and micronized natural progesterone 200mg 14 days a month (oral)
89035824|NCT02924090|Active Comparator|ECT with Ketamine|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose.
89035825|NCT02924090|Active Comparator|ECT with Etomidate and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
89615030|NCT04453332|Active Comparator|Non-oral hormone therapy|Percutaneous estradiol gel 1.5mg and micronized progesterone 200mg vaginal 14 days a month (non-oral)
89035826|NCT02924090|Active Comparator|ECT with Ketamine and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
89035827|NCT01286779|Experimental|BAX 326|
89035828|NCT02934165|Experimental|Family Safety 123|Parents viewed a website with videos on child injury prevention strategies and received emails for 30 days inviting them to view additional videos.
89035829|NCT02934165|Active Comparator|AAP TIPP sheets|Parents viewed online injury prevention materials developed by the American Academy of Pediatrics and had continuing access to these materials for 30 days.
89035830|NCT04137770|No Intervention|control|Patients will receive routine post-operative analgesics
89615031|NCT03464994|Other|ichthyosis patients|patients presenting an Hereditary ichthyosis, whatever form or ongoing therapy will have an ophthalmological examination.
89615032|NCT03464994|Other|control population|patient without ichthyosis disease and consulting an ophthalmologist for refractive surgery screening or systematic eye examination will have an ophthalmological examination
89615033|NCT03458286|No Intervention|Control group|The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment.
89035831|NCT04137770|Experimental|intervention|Patients will receive routine post-operative analgesics plus scheduled ketorolac and surgical site ice packs
89035832|NCT05594797|Experimental|Human BCMA Targeted T Cells Injection|Single administration：6.0×10^6 CAR+T/kg
89035833|NCT01286740|Experimental|FTC/RPV/TDF|Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.
89210889|NCT00987909|Experimental|Cat hair allergen extract, dose group 3|
89210890|NCT00822380|Experimental|Anemic children|
89615034|NCT03458286|Experimental|Experimental Arm|A device- BRH-A2 wound healing device will provide Combined ultrasound and electric current stimulation (CUSECS) treatment which is the intervention for this arm. Participants in this group will receive an adjunctive combined ultrasound and electric current stimulation (CUSECS) treatment along their usual treatment for their diabetic ulcer twice weekly for 8 weeks using the BRH-A2 wound healing device. They will also have a follow up appointment 4 weeks after completion of treatment.
89615035|NCT03468504|Experimental|Mirror Therapy & Treadmill Training|"Mirror Therapy: Participants view a mirror reflection of their non-affected limb which is placed in their mid-sagittal plane for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
89615036|NCT03468504|Placebo Comparator|Placebo Mirror & Treadmill Training|"Placebo Mirror Therapy: Participants view a mirror which is placed forward/ahead of them in their mid-sagittal plane, and cannot see a reflection of any lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
88986340|NCT02274220|No Intervention|Feeds not affected|Postoperative feeds for patients not eligible for randomization are initiated by the treating clinical team and increased as per clinical team's preference.
88986341|NCT02274298|Active Comparator|CKD feedback and tools|Physicians in these clinics/clusters will receive feedback on their performance for screening and managing CKD quality indicators as well as EMR tools to aid in their performance
88986342|NCT02274298|No Intervention|No Intervention|Physicians in these clinics/clusters will not receive CKD feedback or tools
88986343|NCT02274337|Experimental|AC0010|patients receiving avitinib treatment Qd, at different dose stages
88986344|NCT05004441|Experimental|First-line treatment|"First-line treatment: Fruquintinib Combined With mFOLFOX6/FOLFIRI for twelve cycles.~Maintenance treatment: Fruquintinib and Capecitabine"
88986345|NCT00485719|Experimental|1|Twice daily (bid) dosing
88986346|NCT00485719|Experimental|2|Once daily (qd) dosing
88986347|NCT01241656|Experimental|Mail DVD|
88986348|NCT01241656|Experimental|Invite to SMA to view and discuss DESI|
88986349|NCT01241656|Experimental|SMA and DVD|
88986350|NCT01241656|No Intervention|Encouraged to talk to physician|
88986351|NCT01241695|Experimental|Test|Diben DRINK (200 ml) / a diabetes-specific oral nutritional supplement
88986352|NCT01241695|Placebo Comparator|Control|Fresubin(R) energy fibre DRINK / an isoenergetic standard oral nutritional supplement
88986353|NCT01241773|Experimental|001|TMC435 Two 75 mg capsules once daily for 14 days
88986354|NCT01241773|Experimental|002|efavirenz One 600 mg tablet once daily for 14 days
88986355|NCT01241773|Experimental|003|TMC435 + efavirenz Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet once daily for 14 days
88986356|NCT01241773|Experimental|004|TMC435 Two 75 mg capsules once daily for 7 days
88986357|NCT01241773|Experimental|005|raltegravir One 400 mg tablet twice daily for 7 days
88986358|NCT01241773|Experimental|006|TMC435 + raltegravir Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
88986359|NCT01241812|Experimental|A.|10 weeks of partially supervised lower limb muscle strengthening targeting the following muscles groups: quadriceps, hamstrings, hip abductors.
88986360|NCT01241812|No Intervention|B|
88986361|NCT01241851|Active Comparator|Aerobic exercise|
88986362|NCT01241851|Active Comparator|Resistance exercise|
88986363|NCT01241851|No Intervention|Control|
88986364|NCT01241890||Children with Cystic Fibrosis, care as usual|Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
88986365|NCT00121277|Experimental|SAHA (Suberoylanilide Acid) with Capecitabine|
88986366|NCT00118872|Active Comparator|LGG yogurt|Lactobacillus (LGG) containing yogurt
88986367|NCT00118872|Placebo Comparator|Placebo yogurt|Regular yogurt, NOT containing LGG
88986368|NCT00485914|Experimental|On-site work evaluation|Participants will receive one-to-one contact with an occupational therapist and an individualized work plan
88986369|NCT00485914|Active Comparator|Educational material|Participants will receive educational materials to develop strategies to compensate for limitations caused by their condition
88986370|NCT01241968|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
88986371|NCT01241968|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
88986372|NCT00121316|Experimental|1|Pimecrolimus
88986373|NCT00121316|Placebo Comparator|2|Matching vehicle cream (placebo)
88986374|NCT00118950|Active Comparator|4|Metformin plus placebo-Repgalinide. Double-masked, randomized. Duration: Four months.
88986375|NCT00118950|Active Comparator|2|Repaglinide plus Placebo-Metformin. Double-masked, randomized. Duration: Four months.
88986376|NCT00118950|Other|1|Run-in period: Treatment: Diet-only. Duration: One month.
88986377|NCT00118950|Other|3|Wash-out period: Treatment: Diet-only: Duration: One month.
88986378|NCT00486148|No Intervention|"group S"|Breast milk
88986379|NCT00486148|No Intervention|"group A"|Control Infant formula
88986380|NCT00486148|Experimental|"group B"|Infant formula supplemented with 0.4 g/100 ml of oligosaccharides
88986381|NCT00118989|Placebo Comparator|PLACEBO|placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
88986382|NCT00118989|Experimental|Curcuminoids C3 Complex® to be taken orally via caps|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
88986383|NCT00486187|Experimental|1|"Treatment-naive subjects randomly assigned to rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking metformin before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking glyburide before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day)."
89615037|NCT04906434|Experimental|ABSK011 60mg cohort|60mg cohort：1 patient will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, the patient will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.
89615038|NCT04906434|Experimental|ABSK011 120mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
88986384|NCT00486187|Active Comparator|2|"Treatment-naive subjects randomly assigned to metformin (250 mg twice per day [BID] titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%).~Subjects taking metformin before randomization were randomly assigned to the addition of glyburide (2.5 mg BID titrated to 5 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 5 mg BID titrated to 10 mg BID if baseline A1C >8.0%).~Subjects taking glyburide before randomization were randomly assigned to the addition of metformin (250 mg BID titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0% or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%)."
88986385|NCT00486304|Experimental|Antioxidant-deficient diet (ADD)|
88986386|NCT00486304|Placebo Comparator|Placebo|
88986387|NCT00121394|Experimental|Chlorhexidine|
88986388|NCT00486343|Experimental|1|Zileuton CR
88986389|NCT00486343|Placebo Comparator|2|Placebo
88986390|NCT00119028|Other|Arm 1|Non-experimental QI intervention - No comparator
88986391|NCT00486421|Experimental|PRED & RITUX|
88986392|NCT00486577|Experimental|1|
88986393|NCT00486577|Experimental|2|
88986394|NCT00119067|Active Comparator|AVA 8-SQ|receive 8 injections of AVA SQ
88986395|NCT00119067|Experimental|AVA 8-IM|receive 8 injections of AVA IM
88986396|NCT00119067|Experimental|AVA 7-IM|receive 7 injections of AVA IM
88986397|NCT00119067|Experimental|AVA 5-IM|receive 5 injections of AVA IM
88986398|NCT00119067|Experimental|AVA 4-IM|receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42
88986399|NCT00119067|Placebo Comparator|Saline placebo IM or SQ|
88986400|NCT00486733|No Intervention|Standard of Care|Standard of Care Treatment; no study treatment
88986401|NCT00486733|Experimental|Standard of Care plus Study Treatment|Standard of Care Treatment plus study treatment
88986402|NCT00121550|Experimental|Clarithromycin|Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.
88986403|NCT00121550|Placebo Comparator|Placebo|Placebo comparator
88986404|NCT01242046|Experimental|Caffeine|Participants will ingest a tablet with 400 mg caffeine
88986405|NCT01242046|Placebo Comparator|Placebo|Participants will ingest an inert placebo tablet
88986406|NCT01242124|Experimental|side-to-side stapled esophagogastric anastomosis arm|
88986407|NCT01242124|Active Comparator|circular-stapled esophagogastric anastomosis arm|
88986408|NCT01242202|Experimental|ASP group|Concomitant administration of ASP1941 and α- glucosidase inhibitor
88986409|NCT00486928||AVR|All consecutive patients in the study period
89615039|NCT04906434|Experimental|ABSK011 180mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
88986410|NCT00486967||Heart Failure|CHF patients were identified from inpatients as well as patients attending outpatient clinics and from the general practice in the community. Diagnosis of CHF was based on the European Society of Cardiology guidelines for CHF. All patients with stable CHF were included in the study. Inpatients with CHF who were hospitalized were also included, except patients with acutely decompensated CHF requiring intravenous therapy. CHF patients with a previous diagnosis of diabetes mellitus were excluded from the study.
88986411|NCT00486967||Controls|A group of healthy subjects were also studied. They were recruited from the community and were clinically healthy based on history, physical examination, and blood laboratory results and were not taking any medication.
88986412|NCT00487006|Active Comparator|At risk for CIH/with CIH|In hyperglycemic patients who will be starting insulin infusions to control hyperglycemia, blood will be drawn just prior to initiation of insulin infusion for the following levels: insulin, glucose, and C-peptide. These levels will be re-drawn upon achieving euglycemia, at 24 hours following that, then every three days. Levels will be again drawn once the insulin infusion is stopped/when CIH has resolved, and 24 hours following discontinuation of insulin infusion. At each timepoint the patient's clinical status will be documented and significant interval changes (intubation/extubation, change in pressor need), amount of dextrose (mg/kg/hour) supplied, and other concurrent medicines and doses will be recorded.
88986413|NCT00487006|Active Comparator|At risk for CIH/without CIH|"For comparative controls, insulin, C-peptide, and glucose levels will be drawn from ICU patients aged 2-12 years at similar risk (mechanical ventilation or vasoactive medications) but without CIH. The above labs will be drawn and data gathered near the time of risk, 24 hours later, then in 3 days following, for a total of three timepoints."
88986414|NCT00487006|Active Comparator|Not at risk for CIH/without CIH|"In addition, other ICU patients aged 2-12 years that are deemed NOT at risk for critical illness hyperglycemia will also be evaluated to serve as a group not at risk but admitted to the PICU as a further control population. Like Group B, the above labs will be drawn and data gathered at the time consent is obtained, 24 hours later, then in 3 days following, for a total of three timepoints"
88986415|NCT04710797|Experimental|No Lymphadenectomy|Comprehensive staging surgery with no Lymphadenectomy
88986416|NCT04710797|Active Comparator|Lymphadenectomy|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
89615040|NCT04906434|Experimental|ABSK011 240mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
89615041|NCT04906434|Experimental|ABSK011 320mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
89615042|NCT04906434|Experimental|ABSK011 400mg cohort|"all patients will first receive a single dose ABSK-011 (run-in period) at Day -2 and be followed by a 1-day off (2 days in all for run-in period) to access the PK of single-dose. Then, patients will continuously receive ABSK-011 once daily (QD) in repeated 28-day cycles.~Dose escalation will employ a 3+3 design except for the patient in the accelerated titration cohort."
89615043|NCT04904250|Experimental|Emboshield NAV6|using Emboshield NAV6 distal embolism protection device during CAS
89615044|NCT04904250|Active Comparator|SpiderFX|using SpiderFX distal protection device during CAS
89615045|NCT04348422||Symptomatic|COVID-19 RT-PCR positive patients with reported symptoms
89615046|NCT04348422||Asymptomatic|COVID-19 RT-PCR positive patients without presenting any symptoms
89615047|NCT04453098|Experimental|Re group|high-Resistance-moderate-endurance, participants performed 10 repetitions at 70% of one maximal repetition in resistance and 30% of VO2-peak for endurance training
89615048|NCT04453098|Experimental|rE group|moderate-resistance (30%) - high-Endurance (70%)
89615049|NCT04453098|Experimental|re group|moderate-resistance (30%) - moderate-endurance (30%).
89615050|NCT04453098|No Intervention|control group|no intervention
89615051|NCT03456570|Active Comparator|progesterone|these patients will be offered Dydrogesterone 10 mg twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
89615052|NCT03456570|Placebo Comparator|placebo|those patients will be offered placebo tablets twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
89615053|NCT05203224|Experimental|Intravenous Dornase alfa (DNase)|Patients will receive a single intravenous dose of dornase alfa (at either 0.125mg/kg, 0.25mg/kg, or 0.5mg/kg in escalating tiers), administered as a bolus over ~30 seconds.
89615054|NCT03464838|Experimental|Real Stimulation tDCS with CBT|16 participants will attend to one weekly tDCS stimulation session with intensity 1.8 milliamps for 8 consecutive weeks. Following the tDCS session, participants will attend to a cognitive behavioural therapy (CBT) session. One tDCS + CBT session per week (Total: 8 sessions).
89615055|NCT03464838|Sham Comparator|Sham tDCS with CBT|16 participants will attend to one weekly Sham tDCS session with intensity 0 milliamps for 8 consecutive weeks. Following the Sham tDCS session, participants will attend to a CBT session. One Sham tDCS + CBT session per week (Total: 8 sessions).
89615056|NCT04870554|No Intervention|Continuous Feeding|Enteric feeding will be given continuously.
89615057|NCT04870554|Experimental|Timed Feeding|Enteric feeding will be given four times per day, approximating breakfast, lunch, a snack, and dinner.
89615058|NCT03456180||Haemoadsorption with Cytosorb cartridge|patients with septic shock and acute renal failure requiring renal replacement therapy with the haemoadsorption cartridge Cytosorb
89615059|NCT03468348|Placebo Comparator|placebo group|
89615060|NCT03468348|Active Comparator|duloxetine 30|
89210891|NCT00720083|Active Comparator|RT + Cisplatin|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
89615061|NCT03468348|Active Comparator|duloxetine 60|
89615062|NCT03468348|Active Comparator|duloxetine 90|
89615063|NCT03464682|Experimental|HS-25 10mg|HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
89615064|NCT03464682|Experimental|HS-25 20mg|HS-25 10mg 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
89615065|NCT03464682|Experimental|HS-25 10mg combination with Atorvastatin|HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily, 12 weeks
89615066|NCT03464682|Experimental|HS-25 20mg combination with Atorvastatin|HS-25 20mg, Aorvastatin 10mg, oral once daily, 12 weeks
89615067|NCT03464682|Active Comparator|Aorvastatin 10mg|Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily, 12 weeks
89615068|NCT03464682|Placebo Comparator|Placebo of HS-25 and Aorvastatin|Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12 weeks
89615069|NCT03454152||patients|pediatric patients with diabetic ketoacidosis come to Assuit University Children Hospital within one year. Electrocardiogram and echocardiography will be done to all patient with diabetic ketoacidosis
89615070|NCT03464526|Active Comparator|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
89615071|NCT03464526|Active Comparator|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
89615072|NCT03464526|Active Comparator|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
88986417|NCT00487045|Experimental|1|Hem-Avert Perianal Stabilizer, single use, disposable, sterile, individually packaged instrument
88986418|NCT00487045|No Intervention|2|
88986419|NCT00119184|Experimental|External cephalic version with spinal anesthesia|External cephalic version with spinal anesthesia
88986420|NCT00119184|Active Comparator|External cephalic version without spinal anesthesia|External cephalic version without spinal anesthesia
88986421|NCT02274376||Cohort|
88986422|NCT00487357||MATCh Parents' Supplemental Survey|Parent/Guardian Survey
88986423|NCT00487474||Sculptra|
88986424|NCT00487591||Simva+Omacor|
88986425|NCT00487591||Simva + Placebo|
88986426|NCT04706156||Vaccinated Healthcare Workers (CZ)|Czech healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
89615073|NCT03464526|Placebo Comparator|Placebo|Placebo tablet, once daily for 12 weeks
89210892|NCT00720083|Experimental|RT + Cisplatin + Vandetanib|Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
89210893|NCT00826436||8 subjects for Cohort 1|
89210894|NCT00826436||8 subjects for Cohort 2|
89210895|NCT00209131|Experimental|Flomax|Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
89615074|NCT03468192|Experimental|non-precaution group|Study Group: Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed.
89615075|NCT03468192|No Intervention|precaution group|Control Group: the precaution group (PG) had standard postoperative hip precautions included limited flexion of the hip to 90° (avoid reaching down to toes or bringing knee up beyond 90°) and limited adduction of the hip (avoid sleeping on side and avoid crossing legs at knees or ankles). The mandatory assistive equipment to use for at least 3 months were reacher and stocking application aid. The patients were instructed only to use elevated chair, bed and toilet in order not to flex more than 90° in the hip. For the same reason a brace over the knee was prescribed for 6 weeks, particularly in patients with cognitive limitations.
89615076|NCT02522598|Experimental|VVZ-149 injection|VVZ-149 Injections will be mixed with saline,then intravenous infusion for 8hr. The drug product will be administered with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 7.5 hours.
89615077|NCT02522598|Placebo Comparator|Placebo|placebo group will receive an water for injection the same volume and period of experimental group.
89615078|NCT03464370|Experimental|TLE-AE Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
89615079|NCT03464370|Active Comparator|Non AE epileptic Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
89615080|NCT03464370|Active Comparator|Extra-temporal epilepsy Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors and then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
89615081|NCT03464370|Active Comparator|Healthy volunteers Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors
89615082|NCT04862052|Active Comparator|Xience chromium-cobalt everolimus eluting stent|The Xience chromium-cobalt everolimus eluting stent will be evaluated in prior implanted coronary drug eluting stent restenosis.
89615083|NCT04862052|Experimental|Emperor paclitaxel coated balloon|The Emperor paclitaxel coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
89615084|NCT04862052|Experimental|Magic Touch sirolimus coated balloon|The Magic Touch sirolimus coated balloon will be evaluated in prior implanted coronary drug eluting stent restenosis.
89615085|NCT03453918|Experimental|Polyphenols|patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.
89615086|NCT03453918|Experimental|Placebo|patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.
88815560|NCT05239130|Experimental|Auralya 2|Sixteen patients will be administered Auralya® 2 (Cross-linked Hyaluronic Acid) for the treatment of medium-sized facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
88815561|NCT05239130|Experimental|Auralya 3|Sixteen patients will be administered Auralya® 3 (Cross-linked Hyaluronic Acid) for the treatment of major facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
88815562|NCT05227898|Active Comparator|Attune™|Attune™ is a completely digital therapeutic intervention.
88815563|NCT05227898|Active Comparator|Cerena™|Cerena™ is a completely digital therapeutic intervention.
88815564|NCT03014804|Experimental|Group I (DCVax-L)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine ID on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.
88815565|NCT03014804|Experimental|Group II (DCVax-L, nivolumab)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine as in Group I, and nivolumab IV over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.
88815566|NCT05224388||Critically ill, prophylactic dose regimen|Prophylaxis of deep vein trombosis in critically ill patients
88815567|NCT05224388||Critically ill, therapeutic dose regimen|Therapeutic anticoagulation for tromboembolic pathology in critically ill patients
88815568|NCT05224388||Covid, prophylactic dose regimen|Prophylaxis of deep vein trombosis in Covid patients
88815569|NCT05224388||Covid, therapeutic dose regimen|Therapeutic anticoagulation for tromboembolic pathology in Covid patients
88815570|NCT03558464|Experimental|Intervention|"Intervention (agriculture-focused package~+ nutrition-sensitive and nutrition-specific interventions=integrated package)"
89210896|NCT00209131|Placebo Comparator|Sugar pill|Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.
88815571|NCT03558464|Active Comparator|Control|(agriculture-focused package)
89210897|NCT00925626|Experimental|Sub - Vastus arthrotomy|Sub-vastus arthrotomy
89035834|NCT02934009|Experimental|Dialysis patients|In this group dialysis patients are measured by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) during their routine dialysis sessions. After a 5 min rest period the arm of the patients is placed onto the NMR-Mouse and measured before the beginning of dialysis. The arm examined is not the shunt arm. The area selected should not display any signs of skin disease or scars from previous surgeries. After the dialysis the same area is measured again in a second measurement. The measurement will be repeated on three different days with each patient.
89035835|NCT02934009|Experimental|Healthy volunteers|"In this group kidney-healthy volunteers will be examined by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) at three different days. The right/left arm or leg will be used for repeated measurement. Altogether 2 measurements per day are reformed in order to evaluate the reproducibility and variability."
89035836|NCT01286311|Experimental|Direct-to-patient tailored cardiovascular risk message system|Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.
89035837|NCT01286311|No Intervention|Control|
89035838|NCT02923856|Experimental|Clarithromycin resistance group|Patients who are resistant to clarithromycin in susceptibility test were classified into clarithromycin resistance group.
89615087|NCT03468114|Experimental|Intervention|Participant households will receive 4 visits by health extension workers delivering intervention
89615088|NCT03468114|Active Comparator|Control|Participant households will receive 4 visits by health extension workers delivering standard care
89615089|NCT03452982|Experimental|Patients with ovarian cancer|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection
89615090|NCT03468036||Extubation with 100% O2|for further information please refer to study protocol
89615091|NCT03468036||Extubation with 35% O2|for further information please refer to study protocol
89615092|NCT04803786||Transition from Xyrem to Xywav|
89615093|NCT03464214|Active Comparator|Vibration Group|Local vibration on neck muscles
89615094|NCT03464214|Active Comparator|Stabilization Group|Cervical stabilization exercises on cervical region
89615095|NCT03464214|No Intervention|Control Group|Individuals performed only daily living activities
89615096|NCT03464058|Experimental|Part 1: Regimen A|Participants will be treated with a BOS172767 200 milligram (mg) spray dried dispersion tablet (2 × 100 mg tablets) in the fasted state on Day 1.
89615097|NCT03464058|Experimental|Part 1: Regimen B|Participants will be treated with a BOS172767 200 mg lipid capsule (2 × 100 mg capsules) in the fasted state on Day 1.
89615098|NCT03464058|Experimental|Part 1: Regimen C|Participants will be treated with a BOS172767 200 mg micronized capsule (2 × 100 mg capsules) in the fasted state on Day 1.
89035839|NCT02923856|Experimental|7 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 7days standardized treatment.
89210898|NCT00925626|Active Comparator|Mid-Vastus arthrotomy|Mid-vastus arthrotomy
89615099|NCT03464058|Experimental|Part 1: Regimen D|Participants will be treated with a BOS172767 200 mg immediate release reference capsule formulation (2 × 100 mg capsules) in the fasted state on Day 1.
89615100|NCT03464058|Experimental|Part 1: Regimen E|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fasted state on Day 1.
89615101|NCT03464058|Experimental|Part 1: Regimen F|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fed state on Day 1.
89615102|NCT03464058|Experimental|Part 2: Regimen G|Participants will be treated with 400 mg of the selected BOS172767 prototype in the fasted state on Day 1.
89615103|NCT03464058|Experimental|Part 2: Regimen H|Participants will be treated with 600 mg of the selected BOS172767 prototype in the fasted state on Day 1.
89615104|NCT03464058|Experimental|Part 2: Regimen I|Participants will be treated with 800 mg of the selected BOS172767 prototype in the fasted state on Day 1.
89615105|NCT03464058|Experimental|Part 2: Regimen J|Participants will be treated with rabeprazole on Days -3 to -1, and a selected dose of the BOS172767 prototype in the fasted state on Day 1.
89615106|NCT03464058|Experimental|Part 3: Regimen K|Participants will be treated with 400 mg of a BOS172767 prototype or matching placebo once daily (QD) or twice daily (BID) for 14 days (Days 1 to 14).
89615107|NCT03464058|Experimental|Part 3: Regimen L|Participants will be treated with 600 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
89615108|NCT03464058|Experimental|Part 3: Regimen M|Participants will be treated with 800 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
89615109|NCT05163444|Experimental|Rolling can|Gait analysis with rolling cane
89615110|NCT05163444|Active Comparator|Quadripod can|Gait analysis with quadripod cane
89615111|NCT03451734||treatment cohort|in sub-project 1, participants are randomized into olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups, we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
89615112|NCT03451734||adjunctive group|Patients who do not have an ideal response to antipsychotics treatment (reduction rate of Positive and Negative Symptom Scale (PANSS) score less than 25%) in sub-project 2 are recruited in this trial. They are randomly assigned to antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups, and the antipsychotic drugs used at this stage are still consistent with the first trial of sub-project 2. At baseline, 4 weeks and 8 weeks after treatment, all participants receive evaluations.
89615113|NCT03451734||metformin and lifestyle intervention for MetS|Participants who develop MetS at the last visit in sub-project 1 and sub-project 2 are recruited in this trial. Patients are randomized into low-dose metformin (1000 mg/d), high-dose metformin (1500 mg/d), low dose metformin plus lifestyle intervention group (1000 mg/d), high dose metformin plus lifestyle intervention (1500 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
88815572|NCT03833336|Placebo Comparator|Placebo|normal saline solution plus oral lactose capsules
88815573|NCT03833336|Active Comparator|Intravenous ferric carboxymaltose|Ferric carboxymaltose 500-1000 mg at 0,6,12,24 weeks ( adjusted by protocol)
89615114|NCT03451734||metformin and lifestyle prevention for high risk of MetS|Participants who are at a high risk of MetS are recruited in this trial. Participants are randomized into low dose metformin (750 mg/d), high dose metformin (1000 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
89615115|NCT03451734||validation cohort|in sub-project 2, there are1,800 first-episode schizophrenia patients recruited from 19 hospitals, and six groups as with sub-project 1. The assessments (timepoint and content) are conducted as in sub-project 1.
89615116|NCT03129984||The study population|The study population is comprised of all patients included in the Brizzy register, Belgium.
89615117|NCT03467880||Healthy subjects|Healthy subjects.
89615118|NCT03467880||Chronic obstructive pulmonary disease|Patience with chronic obstructive pulmonary disease.
89615119|NCT03467880||Asthma|Patience with asthma.
89615120|NCT03467880||Interstitial lung disease|Patience with interstitial lung disease.
89615121|NCT03467880||Upper airway obstruction|Patience with upper airway obstruction.
89615122|NCT03451344|Experimental|Integrated rehabilitation group|Participants will receive the standardized community-based rehabilitation and simultaneously receive a 6-month integrated rehabilitation based on the Community-based Addiction Rehabilitation Electronic System.
89615123|NCT03451344|Active Comparator|Community-based rehabilitation group|Participants will receive the standardized community-based rehabilitation.
89615124|NCT01198366|Placebo Comparator|Dose Finding Gr 1 placebo x 2|Subjects received two doses (x2) of placebo (sterile buffer) on study days 0 and 28.
89615125|NCT01198366|Experimental|Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2|Subjects received two doses (x2) of AERAS-402 (1.5 x 10^10 vp) on study days 0 and 28.
89615126|NCT01198366|Experimental|Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2|Subjects received two doses (x2) of AERAS-402 (3.0 x 10^10 vp) on study days 0 and 28.
89615127|NCT01198366|Experimental|Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2|Subjects received two doses (x2) of AERAS-402 (1.0 x 10^11 vp) on study days 0 and 28.
89615128|NCT01198366|Experimental|Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3|Subjects received 3 doses (x3) of AERAS-402 (1.0 X 10^11 vp) on days 0, 28 and 280.
89615129|NCT01198366|Placebo Comparator|Expanded Safety Phase Gr 5 Placebo x3|Subjects received 3 doses (x3) of placebo (sterile buffer) on days 0, 28 and 280.
89615130|NCT03130218|No Intervention|Control|Patients in the control group will not receive peppermint oil aromatherapy as a primary intervention for postoperative nausea and vomiting. Primary therapy for postoperative nausea and vomiting would entail standard antiemetic drug therapies. Patient monitoring and documentation would include the following: Patients in the control group will be assessed every 4 hours and as needed for nausea. All aspects of care from physician, nursing and all disciplines will be consistent with current practices in care of postoperative bariatric surgical patients.
89615131|NCT03130218|Experimental|Intervention|Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
89615132|NCT03129906|Active Comparator|Gluten|Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
89615133|NCT03129906|Placebo Comparator|Rice protein|Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
88986427|NCT04706156||Vaccinated Healthcare Workers (DE)|German healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
88986428|NCT04706156||Vaccinated Healthcare Workers (SK)|Slovak healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
88986429|NCT04706156||Vaccinated Healthcare Workers (TR)|Turkish healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)
88986430|NCT01242280|Active Comparator|Self-expandable esophageal stent|"The patient will receive a self-expandable esophageal stent (SX-Ella-Danis) without endoscopical guidance but under slight sedation. An immediate X-ray will be done to assess the correct placement of the stent.~After a maximum of 7 days, the stent will be removed by using the specifically designed devices."
88986431|NCT01242280|Active Comparator|Sengstaken-Blakemore tube|The esophageal tamponade will be done as described elsewhere. The gastric content will be checked hourly and the correct placement of the tube will be checked by an immediate X-ray. The esophageal balloon will be inflated a maximum of 24 hours.
88986432|NCT01242319||Multi-modal practice intervention|15 intervention practices receive academic detailing, patient activation computer kiosk, decision supported PDA, and coronary risk factor management toolbox
88986433|NCT01242319||Usual care|15 practices receive academic detailing reviewing the ATP III cholesterol management guidelines
88986434|NCT01242358|Experimental|Capnography|Arm with capnographic monitoring
88986435|NCT01242358|Placebo Comparator|Standard monitoring|Standard monitoring
88986436|NCT04706117|Other|Canalicular obstruction|
88986437|NCT00487708|Experimental|1|ACZ885
88986438|NCT00487786|Experimental|A|Each patient receives OGX-427
88986439|NCT04705922|Experimental|Sequence 1 [TT-00420 tablet, fed; TT-00420 tablet, fasted; TT-00420 capsule, fasted]|Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.
88986440|NCT04705922|Experimental|Sequence 2 [TT-00420 tablet, fasted; TT-00420 capsule, fed; TT-00420 tablet, fed]|Participants will receive a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions. There will be at least a 14-day wash-out period between each dose.
89035840|NCT02923856|Experimental|7 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 7days standardized treatment.
89035841|NCT02923856|Experimental|10 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 10days standardized treatment.
89035842|NCT02923856|Experimental|10 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 10days standardized treatment.
89035843|NCT02923856|Experimental|14 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 14days standardized treatment.
89035844|NCT02923856|Experimental|14 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 14days standardized treatment.
89035845|NCT02934204|Experimental|MTX and Temozolomide|"Induction therapy:~Methotrexate 3.5g/m2 ivgtt d1 2weeks/cycle，total 8 cycles Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 4 cycles~Consolidation therapy:~PCNSL patients achieve CR,Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 12 cycles"
89035846|NCT01286077|Experimental|bortezomib|bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
89615134|NCT03011320|Experimental|Cohort 1|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at <8 hours prior to surgery"
89035847|NCT01286077|No Intervention|Non-treated control|no treatment, observation only
89035848|NCT03749655|No Intervention|PR+CBT|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy
89035849|NCT03749655|Experimental|PR+CBT+PA Promotion.|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy and physical activity promotion.
89035850|NCT05590936|Active Comparator|Dimenydrinate|Preoperative per os administration of 50 mg dimenydrinate
89035851|NCT05590936|Other|Ondasentron|Intraoperative intravenous administration of 4 mg ondansetron
89035852|NCT04689464||mild covid|
89615135|NCT03011320|Experimental|Cohort 2|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at 48±4 hours prior to surgery"
89615136|NCT03011320|Experimental|Cohort 3|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at <8 hours prior to surgery"
89615137|NCT03011320|Experimental|Cohort 4|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at 48±4 hours prior to surgery"
89615138|NCT03463746|Experimental|Experimental group (EG)|Subacute stroke patients will get standard individual physical therapy 2x/week, 45min and electromechanical-assisted gait training on LYRA® gait trainer 3x/week, 45min.
89615139|NCT03463746|Active Comparator|Comparator group (CG)|The CG will get standard individual physical therapy 5x/week, 45min without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
89615140|NCT03451266|Experimental|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (vitamin C arm).
89615141|NCT03451266|Placebo Comparator|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (placebo arm).
89615142|NCT05322486||Primary tumour resection group.|Surgical resection of the primary tumour followed by chemotherapy +/- targeted therapy regime.
89615143|NCT05322486||Chemotherapy group.|Chemotherapy +/- targeted therapy alone.
89615144|NCT03463668||symptomatic non-covered duodenal prosthesis|Any symptomatic duodenal stenosis with symptomatic duodenal duodenal prosthesis between 2010 and 2017.
89615145|NCT03467646|Active Comparator|Sleeve Gastrectomy|Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure
89615146|NCT03467646|Active Comparator|Roux-en-Y gastric bypass|Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure
89615147|NCT03467646|Experimental|One-Anastomosis gastric bypass|Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure
88815574|NCT03833336|Active Comparator|Oral iron A: ferroglycine sulfate|oral capsules of ferroglycine sulfate iron until week 24
88815575|NCT03833336|Active Comparator|Oral iron B: sucrosomial iron|oral capsules of sucrosomial iron until week 24
89035853|NCT04689464||moderate covid|
89035854|NCT04689464||severe covid|
89035855|NCT01285960|Experimental|ExAblate treatment UF V2|ExAblate MRgFUS Treatment
89035856|NCT02933814|No Intervention|Control Group|Patients in Group 1 (Plain Bupivacaine) will be treated intra-operatively with injections of 0.25% bupivacaine, with 10 mL (25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the surgical procedure.
89035857|NCT02933814|Experimental|Experimental Group|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
89035858|NCT04323826|Experimental|salads with olive oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water mixture will be provided to consume.
89035859|NCT04323826|Experimental|salads with olive oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g olive oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
89210899|NCT04044950|Experimental|Arm 1|Approximately 3x10^8 E7 TCR T cells (based on the number of disease sites the patient has) will be injected on day 0.
89210900|NCT00907608|Experimental|1|Receive Darbepoetin alfa
89615148|NCT01199146|Experimental|Abiraterone acetate|
89615149|NCT01199848|Placebo Comparator|Placebo|Pbo
89615150|NCT01199848|Experimental|10G STRB powder|Dose 1
89615151|NCT01199848|Experimental|20G STRB powder|Dose 2
89615152|NCT01199848|Experimental|40G STRB powder|Dose 3
89615153|NCT01199848|Placebo Comparator|PlacebonoFiber|Placebo without fiber
89615154|NCT03467568|Active Comparator|Sodium chloride / Water|The sodium chloride / water arm involves 300mg sodium chloride being consumed in a capsule and on two occasions 150ml of water being drunk
89615155|NCT03467568|Active Comparator|Sodium chloride / no water|A capsule containing 300mg of sodium chloride will be consumed but no water will be drunk over the morning
89615156|NCT03467568|Active Comparator|Placebo / water|A capsule containing a placebo will be consumed and on two occasions 150ml of water will be drunk
89615157|NCT03467568|Placebo Comparator|Placebo / no water|A capsule containing a placebo will be consumed but no water will be drunk over the morning
89615158|NCT01199926|Experimental|Vitamin D|Participants in this arm consumed a 4000 IU vitamin D supplement daily for 12 weeks while participating in a resistance exercise training program.
89615159|NCT01199926|Placebo Comparator|Placebo|Participants in this arm consumed a placebo (microcrystalline cellulose) daily for 12 weeks while participating in a resistance exercise training program.
89615160|NCT03463590|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.
89615161|NCT01106326|Experimental|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
89615162|NCT03463434|Experimental|Air Fluidized Therapy|Patients will be placed on the Envella AFT bed
89615163|NCT03463434|Active Comparator|Continuous Low Pressure-LAL|Patients will receive a Continuous low pressure mattress with low air loss
89615164|NCT03463356|Experimental|Shame Intervention|Participants will complete a two shame intervention sessions approximately one week apart.
89035860|NCT04323826|Experimental|salads with coconut oil-water emulsion|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water emulsion (4% whey protein isolate as emulsifier) will be provided to consume.
89615165|NCT03463278||0-4 blastocysts|group A: cumulative pregnancy rate of 0-4 blastocysts vitrified
89615166|NCT03463278||5-7 blastocysts|group B: cumulative pregnancy rate of 5-7 blastocysts vitrified
89615167|NCT03463278||>7 blastocysts|group C: cumulative pregnancy rate of >7 blastocysts vitrified
89615168|NCT03463200|No Intervention|Control group|It will not apply any tape.
89615169|NCT03463200|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
89615170|NCT03463200|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
89615171|NCT03463200|Experimental|Experimental group 3|Apply Micropore tape in the erector spine muscles.
89615172|NCT04212780|Active Comparator|Treatment Naive|Participants receiving Long-term stimulation of the thalamus via dual leads for Essential Tremor
89615173|NCT04212780|Active Comparator|Refractory Participants|Patients with recurrent, debilitating intention tremor despite ongoing, optimized VIM DBS therapy
89615174|NCT01106950|Experimental|Treated Patients|Patients are treated with donor natural killer cells, fludarabine, cyclophosphamide, Denileukin diftitox, Donor lymphapheresis and IL-2.
89615175|NCT01107730|Active Comparator|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
88815576|NCT01069562|Active Comparator|MANUAL|In the manual group isoflurane was administered using Tech 7 vapouriser. The dial setting was controlled by the anesthesiologist to achieve and maintain a BIS of 50 during anesthesia.
89035861|NCT04323826|Experimental|salads with coconut oil-water mixture|Vegetable salads (100g tomatoes, 62g carrots, 70g spinach, 25g lettuce and 5g wolfberry) with 56g coconut oil-water mixture will be provided to consume.
89210901|NCT00907608|No Intervention|2|
89615176|NCT01107730|Active Comparator|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
89615177|NCT01107730|Active Comparator|Placebo|
89615178|NCT03463122|Other|Training first|This group completed 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy followed by four weeks of conventional therapy
89615179|NCT03463122|Other|Waiting first|This group completed four weeks of conventional therapy followed by 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy.
89615180|NCT03011164||WV 1|The condition of this group will be set as participants walking at 3.5km/h
89615181|NCT03011164||WV 2|The condition of this group will be set as participants walking at 4.0km/h
89615182|NCT03011164||RV 1|The condition of this group will be set as participants running at 3.5km/h
89615183|NCT03011164||RV 2|The condition of this group will be set as participants running at 4.0km/h
89615184|NCT03463044|Placebo Comparator|Placebo|
89615185|NCT03463044|Experimental|MOTREM 1|
89615186|NCT03463044|Experimental|MOTREM 2|
89615187|NCT03463044|Experimental|MOTREM 3|
89615188|NCT03463044|Experimental|MOTREM 4|
89615189|NCT03463044|Experimental|MOTREM 5|
89615190|NCT03463044|Experimental|MOTREM 6|
89615191|NCT03463044|Experimental|MOTREM 7|
89615192|NCT03463044|Experimental|MOTREM 8|
89615193|NCT02522208|Experimental|BiDil Extended Release (XR)|BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
89615194|NCT02522208|Active Comparator|BiDil Immediate Release (IR)|BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
89615195|NCT01107964|Active Comparator|Omega-3-acid ethyl esters|
89615196|NCT01107964|Placebo Comparator|Corn oil capsule|
89615197|NCT05684172|Active Comparator|endovascular thrombectomy|For patients randomized to the control group, EVT has to be completed within 24 hours of stroke onset. The choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
89035862|NCT05578183|Experimental|high dose TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
89035863|NCT05578183|Experimental|low dose TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
89035864|NCT05578183|Sham Comparator|high dose sham TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
89615198|NCT05684172|Experimental|endovascular thrombectomy+intra-arterial tenecteplase|For patients randomized to the endovascular treatment arm, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the lenticulostriates branches. The administration of TNK will be infused for 15 seconds.
89035865|NCT05578183|Sham Comparator|low dose sham TBS group|parameters: pattern: intermittent TBS (iTBS; 2 seconds of TBS are delivered every 10 seconds), TBS consists of pulses applied in bursts of 3 at 50 Hz with an interburst interval at 5 Hz
89035866|NCT02923817|Experimental|Treatment|
89035867|NCT02933775|Experimental|CAR-CD19 T cells|Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -9 - Day -4.
89035868|NCT02923700|Experimental|Leukocyte-rich PRP group|Three weekly knee intra-articular injections of leukocyte-rich PRP
89035869|NCT02923700|Experimental|Leukocyte-poor PRP group|Three weekly knee intra-articular injections of leukocyte-poor PRP
89035870|NCT02923622||Traditional Chinese and Western medicine combined group|
89035871|NCT02923622||Traditional Chinese medicine group|
89035872|NCT02923622||Western medicine group|
89035873|NCT02923583|Experimental|M834|M834 (abatacept biosimilar candidate)
89615199|NCT03011242||Longitudinal Cohort: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis starting standard of care treatment with a TNFi or non-biologic DMARD.
89615200|NCT03011242||Assay Development: Healthy or Psoriatic Arthritis|Individuals that are healthy or with a diagnosis of Psoriatic Arthritis will be enrolled for blood draws for assay development and/or for an ultrasound for development of techniques and scoring system validation.
89035874|NCT02923583|Active Comparator|US Orencia®|US-sourced Orencia® (abatacept)
89035875|NCT02923583|Active Comparator|EU Orencia®|EU-sourced Orencia® (abatacept)
89035876|NCT02933580|Experimental|Cohort A: JNJ-56136379 (25 mg) or Placebo|Participants will receive a single oral dose of 25 milligram (mg) of JNJ-56136379 (1*25-mg tablet) or placebo on Day 1, fasted conditions.
89035877|NCT02933580|Experimental|Cohort B: JNJ-56136379 (150 mg) or Placebo|Participants will receive a single oral dose of 150 mg of JNJ-56136379 (2* 25-mg tablet and 1*100-mg tablet) or placebo on Day 1, fasted conditions.
89035878|NCT02933580|Experimental|Cohort C: JNJ-56136379 (300 mg) or Placebo|Participants will receive a single oral dose of 300 mg of JNJ-56136379 (3*100-mg tablet) or placebo on Day 1, fasted conditions.
89035879|NCT02933580|Experimental|Cohort D: JNJ-56136379 (600 mg) or Placebo|Participants will receive a single oral dose of 600 mg of JNJ-56136379 (6*100-mg tablet) or placebo on Day 1, fasted conditions.
89035880|NCT02923388|Active Comparator|Experimental|"Intervention: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks."
89035881|NCT02923388|Placebo Comparator|Placebo|"Intervention: Injection normal saline (1 ml) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Oral placebo pill 2 tablets thrice daily for 5 weeks."
89035882|NCT02933658|Experimental|Reference1|single(Reference1) -> combination(Reference1+Reference2)
89035883|NCT02933658|Experimental|Reference2|single(Reference2) -> combination(Reference1+Reference2)
89035884|NCT02923661|Experimental|CM LOC attachment group|this group will receive CM LOC attachment and lower overdenture attached to it
89615201|NCT03011242||Cross-Sectional: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis in good disease state on stable non-biologic DMARDS or on stable TNFi.
89615202|NCT01200160||Lipid abnormalities|Niacin
89615203|NCT01201486||Pregnant women|Pregnant females in the 2nd trimester.
89615204|NCT04452786|Other|Endoscopic sleeve gastroplasity operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
89615205|NCT04452786|Other|Laparoscopic sleeve gastrectomy operated patients|Four test days, two days before surgery, one test day three months after surgery and one test day one year after surgery
89615206|NCT01153672|Experimental|Treatment (enzyme inhibitor therapy, AI sensitization therapy)|Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
89615207|NCT03010072|Active Comparator|low-dose sucroferric oxyhydroxide|Low dose 250 mg sucroferric oxyhydroxide (PA21) per day (1x 250mg tablets/day) for 14 days.
89615208|NCT03010072|Active Comparator|high-dose sucroferric oxyhydroxide|Uniform dose 2000 mg of sucroferric oxyhydroxide (PA21) per day (4x 500mg tablets/day) for 14 days
89035885|NCT02923661|Active Comparator|Ball attachment|this group will receive Ball attachment and lower overdenture attached to it
89035886|NCT02933853|Experimental|Faster Aspart|
89035887|NCT02933853|Active Comparator|Insulin Aspart|
89035888|NCT02923505||SDB+COPD|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease
89035889|NCT02923505||SDB+HF|Patients with sleep-disordered breathing and concomitant heart failure
89035890|NCT02923505||SDB+COPD+HF|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease and heart failure
89035891|NCT02923310|Experimental|Osteoarthrits G II and III|Group of treatment
89035892|NCT02923310|Experimental|Osteoarthrits GIV|Group of treatment
89615209|NCT03011086||oral sub mucous fibrosis|patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination
89035893|NCT00532194|Placebo Comparator|A (reference)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.
89035894|NCT00532194|Active Comparator|B (concurrent cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.
89035895|NCT00532194|Active Comparator|C (concurrent and maintenance cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.
89615210|NCT03011086||control group|patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity
89615211|NCT02734212|Experimental|Ending Self-Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
89615212|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
89615213|NCT01202578|Experimental|tympanostomy tube|performance and safety of tympanostomy tube delivery system
89615214|NCT01202656|Experimental|G-CSF then Saline|G-CSF (Granulocyte colony stimulating factor)
89615215|NCT01202656|Placebo Comparator|Saline then G-CSF|Normal Saline
89615216|NCT03462732|Active Comparator|Group I|Endotracheal tube plus Nelaton catheter
89035896|NCT02933268|Active Comparator|Ad libitum water intake|Ad libitum water intake, defined as intake guided by thirst to achieve a target urine osmolality > 300 mOsmo/kg
89615217|NCT03462732|Active Comparator|Group II|Endotracheal tube
89615218|NCT01219738|Experimental|budesonide 360ug|asthmatic subject received different doses of inhaled budesonide in random other
89615219|NCT01219738|Experimental|budesonide 720ug|asthmatic subject received different doses of inhaled budesonide in random other
89615220|NCT01219738|Experimental|budesonide 1440ug|asthmatic subject received different doses of inhaled budesonide in random other
89615221|NCT01219738|Placebo Comparator|placebo|asthmatic subject received inhaled placebo
89615222|NCT01219738|Experimental|Budesonide720ug 4 times|asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.
89615223|NCT04639752|Experimental|Mom´s Supporting Mom (MSM)|A preventive intervention that involves psychoeducation and peer techniques described in study detailed description.
89615224|NCT04639752|Active Comparator|Enhanced Treatment as Usual|Referral to treatment in the community and monitoring
89615225|NCT03848754|Experimental|Pracinostat 45 mg with Gemtuzumab Ozogamicin|"Gemtuzumab Ozogamicin Induction: GO 3 mg/m^2 on Day 1, 4, and 7~Pracinostat Induction: 45 mg administered orally 3 days a week with 48 hours between dosing for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles. We will utilize a 3+3 design to determine the safe dose of pracinostat in combination with fixed dose GO. If there are no DLTs in the first three patients, the dose of pracinostat will be escalated to 60mg. Escalation to the next dose level will be done only after the third patient on the previous dose level has been observed for 28 days, and no DLTs were noticed. If there is 1 DLT, an additional 3 patients will be tested at same dose level. If there are ≥ 2 DLTs in 3 or 6 patients, the study will be placed on hold. If there is < 2 DLTs in the first 3 or 6 patients, the dose of pracinostat will be escalated to 60mg. If there are no DLTs in the first 3 patients at 60 mg, an additional 3 patients will be enrolled to ensure 6 patients are treated at the MTD."
89035897|NCT02933268|Active Comparator|High water intake|Personalised daily water intake prescription to achieve target urine osmolality < 270 mOsm/kg.
89035898|NCT02923154|Experimental|MT-3995|
89035899|NCT02923154|Placebo Comparator|Placebo|
89035900|NCT02665143|Experimental|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .
89035901|NCT00532272|Experimental|letrozole|letrozole(2.5mg orally daily)
89035902|NCT00532272|Active Comparator|goserelin plus letrozole|goserelin (3.6mg subcutaneously every 28 days) plus letrozole(2.5mg orally daily)
89035903|NCT02922920|Experimental|Tart cherry juice|Participants consumed 16 fl. oz of tart cherry juice daily for 12 weeks.
89035904|NCT02922920|Placebo Comparator|Placebo juice|Participants consumed 16 fl. oz of placebo daily for 12 weeks.
89035905|NCT03292419|Other|Topography guided LASI|
89035906|NCT02933385|Experimental|Full lifestyle program|Participants receive all the intervention tools that aimed to enhance lifestyle profile.
89035907|NCT02933385|Experimental|High lifestyle program|Participants receive most of the intervention tools that aimed to enhance lifestyle profile.
89035908|NCT02933385|Experimental|Moderate lifestyle program|Participants receive some intervention tools that aimed to enhance lifestyle profile.
89035909|NCT02933385|Experimental|Light lifestyle program|Participants receive little intervention tools that aimed to enhance lifestyle profile.
89035910|NCT02933385|No Intervention|Control group|Participants receive none of the intervention tools that aimed to enhance lifestyle profile.
89035911|NCT02922842|Active Comparator|Tibial Nerve|Transcutaneous electrical stimulation will be placed on the posterior tibial nerve.
89035912|NCT02922842|Active Comparator|Parasacral|Transcutaneous electrical stimulation will be placed on the lower back near the s3 foramina.
89035913|NCT02922842|Sham Comparator|Shoulder|Transcutaneous electrical stimulation will be placed on the shoulder.
89035914|NCT02933190|Other|CSP；transvaginal surgery；UAE and D&C|Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar
89035915|NCT02923076|Experimental|Study treatment|Allogeneic transplantation with CCR5 delta32/delta32 hematopoietic cells from cord blood.
89035916|NCT02923037|Experimental|Supportive Care (Yoga)|Patients undergo an initial yoga evaluation for 60 minutes. Patients then undergo their first guided yoga practice session for 30-60 minutes and subsequent guided yoga sessions for 30-90 minutes 3 times a week for 4 weeks, and twice a week for an additional 4 weeks. Patients are also encouraged to complete home yoga practice for 30 to 90 minutes every day for 8 weeks. They will have tape measurement of arms and ldex measurement of arms. Quality-of-Life Assessment will also be made.
89615226|NCT03848754|Experimental|Pracinostat 60 mg with Gemtuzumab Ozogamicin|"Gemtuzumab Ozogamicin Induction: GO 3 mg/m^2 on Day 1, 4, and 7~Pracinostat: 60 mg administered orally 3 days a week with 48 hours between dosing for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.~We will utilize a 3+3 design to determine the safe dose of pracinostat in combination with fixed dose GO. If there are no DLTs in the first three patients, the dose of pracinostat will be escalated to 60mg. Escalation to the next dose level will be done only after the third patient on the previous dose level has been observed for 28 days, and no DLTs were noticed. If there is 1 DLT, an additional 3 patients will be tested at same dose level. If there are ≥ 2 DLTs in 3 or 6 patients, the study will be placed on hold. If there is < 2 DLTs in the first 3 or 6 patients, the dose of pracinostat will be escalated to 60mg. If there are no DLTs in the first 3 patients at 60 mg, an additional 3 patients will be enrolled to ensure 6 patients are treated at the MTD."
89035917|NCT02933229|Experimental|H. pylori eradication cohort|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
89615227|NCT03848754|Experimental|Gemtuzumab Ozogamicin Monotherapy Maintenance|"Response will be assessed through bone marrow biopsy on Day 28. Patients achieving at least a partial remission marrow will be offered up to 5 cycles of maintenance therapy. Maintenance should begin no later than 42 days after initial induction.~**Gemtuzumab Ozogamicin Maintenance: 2 mg/m^2 intravenous administration on day 1, in a 28-day cycle."
89615228|NCT03848754|Experimental|Pracinostat with Gemtuzumab Ozogamicin Maintenance|"Response will be assessed through bone marrow biopsy on Day 28. Patients achieving at least a partial remission marrow will be offered up to 5 cycles of maintenance therapy. Maintenance should begin no later than 42 days after initial induction.~Gemtuzumab Ozogamicin Maintenance: 2 mg/m^2 intravenous administration on day 1, in a 28-day cycle.~Pracinostat Maintenance: (In addition to GO, only if induction dose escalation occurs) 45 mg orally 3 days a week with 48 hours between dosing, for three consecutive weeks, followed by 1 week of rest, in a 28-day cycle."
89615229|NCT01155154|Active Comparator|clindamycin|clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
89615230|NCT01155154|Active Comparator|cepahlexin|
89615231|NCT01155154|Placebo Comparator|Placebo|
89615232|NCT02521896|Experimental|Steerable sheath for intracardiac access|Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation
89615233|NCT03786432|Experimental|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
89615234|NCT04614714|Experimental|NR First|Mothers will receive NR during the first 7 days of intervention, then placebo for the 7 days following washout.
89615235|NCT04614714|Experimental|Placebo First|Mothers will receive placebo during the first 7 days of intervention, then NR for the 7 days following washout.
89615236|NCT01221298|Experimental|ABT-450/r and ABT-072, plus ribavirin (RBV)|ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.
89615237|NCT01222234|Experimental|Group 1: Cholecalciferol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
89615238|NCT01222234|Experimental|Group 2: Calcitriol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered calcitriol 0.25mcg daily for 8 weeks.
89615239|NCT01222234|Experimental|Group 3: Cholecalciferol - non-CKD|Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
89615240|NCT01203046|Active Comparator|GROUP A: 7 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the during the next 7 days after surgery.
89615241|NCT01203046|Experimental|GROUP B - 3 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and during the next 3 days after surgery.
89615242|NCT04604184|Experimental|BI 764198 treatment group|
89615243|NCT04604184|Placebo Comparator|Placebo|
89615244|NCT04604106||Patient group|Infant aged 12 months (± four weeks) with a history of general anesthesia exposure
89035918|NCT02922803|Active Comparator|Vitamin D insufficient|Subjects with Vitamin D level in blood > 25 nmool/L < 50 nmol/L will be treated with 1 combination tablet of Vitamin D3/calcium per day
89035919|NCT02922803|Active Comparator|Vitamin D deficient|Subjects with Vitamin D level in blood < 25 nmol/L (25-OHD) will be treated with 2 combination tablets of Vitamin D3/calcium per day
89035920|NCT02933424|No Intervention|Control beverage with no protein powder|Standard breakfast drink with no protein powder added
89035921|NCT02933424|Experimental|Beverage with Rice protein powder 25 grams|Standard breakfast drink with 25 grams of rice protein powder.
89035922|NCT02933424|Experimental|Beverage with Pea protein powder 25 grams|Standard breakfast drink with 25 grams of pea protein powder.
89035923|NCT02933424|Experimental|Beverage with Oats protein powder 25 grams|Standard breakfast drink with 25 grams of Oats protein powder.
89615245|NCT04604106||Healthy subject group|Infant aged 12 months (± four weeks) without a history of general anesthesia
89615246|NCT04549272||Patients with Patent Foramen Ovale|
89615247|NCT03462420|Experimental|PT+ walking|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. In addition, participants will be asked to perform free walking at their own pace for 30-45 min, 5 days per week for 6 consecutive weeks and to record their walking date/time on a diary form provided by the research team before commencing the study. Participants in PT+ group will also be provided with accelerometer to accurately estimate their physical activity level.
89615248|NCT03462420|Active Comparator|Regular PT|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. Participants in this group will not be notified about the walking program.
89615249|NCT03449394|Active Comparator|Delusions (Tx)|
89615250|NCT03449394|No Intervention|Delusions (TAU)|
89615251|NCT03449394|Active Comparator|Depression (Tx)|
89615252|NCT03449394|No Intervention|Depression (TAU)|
89615253|NCT05320848|Experimental|Treatment group|the patients treated with cardiac rehabilitation intervention.
89615254|NCT05320848|No Intervention|Control group|the patients treated without cardiac rehabilitation intervention.
89615255|NCT03449316|Experimental|Inhaler technique education|This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator.
89615256|NCT03449316|No Intervention|Usual Care|"This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.~If any adjustments are made in drug classes or device types in every participants, this information will be recorded."
89615257|NCT05320536|Experimental|Experimental group|Guilingji capsule Take 2 tablets orally, once before breakfast and dinner, and take them with saline. The total treatment period is 90 days.
89615258|NCT05320536|Placebo Comparator|Control group|Placebo Take 2 tablets orally, once before breakfast and dinner, and take them with saline. The total treatment period is 90 days
89615259|NCT02460588|Placebo Comparator|Corticosteroid with placebo|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid."
89615260|NCT02460588|Experimental|Corticosteroid associated with Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
89615261|NCT03641430|Experimental|Supportive care with Over-the-Counter (OCT) product|Participants will apply over-the-counter product for a certain period with or without light challenge
88986441|NCT04705922|Experimental|Sequence 3 [TT-00420 capsule, fasted; TT-00420 tablet, fed; TT-00420 tablet, fasted]|Participants will receive a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions. There will be at least a 14-day wash-out period between each dose.
88986442|NCT00488137|Active Comparator|1|Prucalopride 2 mg
88986443|NCT00488137|Placebo Comparator|3|Placebo
88986444|NCT00488137|Active Comparator|2|Prucalopride 4 mg
88986445|NCT00488176|Active Comparator|1|monteluksat sodium
88986446|NCT00488176|Active Comparator|2|cetirizine
88986447|NCT00488176|Active Comparator|3|montelukast sodium and cetirizine
88986448|NCT00488176|Placebo Comparator|4|placebo
88986449|NCT00488215|Active Comparator|1|Prucalopride
88986450|NCT00488215|Placebo Comparator|2|Placebo
88986451|NCT00488332||OCT + FS + Questionnaire|Optical Coherence Tomography (OCT) + Fluorescence Spectroscopy (FS) and Questionnaire
88986452|NCT04710758|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D2 lymphadenectomy for patients enrolled in this group.
88986453|NCT04710758|Active Comparator|Open total gastrectomy|The surgeon will perform OTG with D2 lymphadenectomy for patients enrolled in this group.
88986454|NCT00488527|Experimental|1|
88986455|NCT00488566|Other|Part 1|Single dose escalation
88986456|NCT00488566|Other|Part 2|Pharmacodynamic assessment
88986457|NCT00121745|Experimental|1|
88986458|NCT00121745|Experimental|2|
88986459|NCT00121745|Experimental|3|
88986460|NCT00121745|Experimental|4|
88986461|NCT00145197|Experimental|Improving the Delivery of Effective Care to Minorities|
88986462|NCT00121784|Experimental|1|1
88986463|NCT01242397|Other|CRT ON|After implant, patients will be randomized to CRT pacing ON vs OFF in crossover fashion with 3 months in each period
88986464|NCT01242397|Other|CRT- OFF|After implant, patients will be randomized to CRT pacing OFF vs ON in crossover fashion with 3 months in each period
89615262|NCT04369638|Experimental|3D NAM|
89615263|NCT04369638|Active Comparator|Traditional NAM|
89615264|NCT05320458|Experimental|Pulmonary Rehabilitation|Pulmonary rehabilitation program will be applied 3 days a week at 40-60% of submaximal heart rate for a total of 8 weeks. Diaphragmatic breathing, pursed lips and segmental breathing exercises will be applied to the patients in the presence of a physiotherapist. Walking and aerobic exercise training will be given.
89615265|NCT05320224|Other|Patient-Oriented Music Intervention (POMI) followed by No Music - Sequence AB|Patient participants will first receive 20-30 minutes of the patient-oriented music intervention (POMI) first, followed by no music, with a minimal washout period of four hours
89615266|NCT05320224|Other|No Music followed by Patient-Oriented Music Intervention (POMI) - Sequence BA|Patient participants will first receive no music first, followed by 20-30 minutes of the patient-oriented music intervention (POMI), with a minimal washout period of four hours
89615267|NCT03449160|Active Comparator|Physical Therapy|Receive standard physical therapy
89615268|NCT03449160|Experimental|posture training device|Receive a posture training device in addition to standard physical therapy
89615269|NCT03449082|Experimental|High concentration of Allo-ASC group|High concentration of Allo-ASC 0.5cc (Total: 10 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
89615270|NCT03449082|Experimental|Low concentration of Allo-ASC group|Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
89615271|NCT03449082|Placebo Comparator|Placebo Comparator (Fibrin) group|Normal saline 0.5cc & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
89615272|NCT05308134|Active Comparator|Standard fortification|
89615273|NCT05308134|Experimental|Target fortification|
89615274|NCT05308134|Experimental|BUN adjustable fortification|
89615275|NCT03130062|Experimental|Exercise|Volunteers underwent a supervised resistance exercise program for 16 weeks. The subjects performed 10 exercises with 3 sets of 10 maximum repetitions in each. The training sessions were held twice a week.
89615276|NCT03130062|No Intervention|Control|Volunteers in this group were instructed not to perform systematic physical exercises for 16 weeks (the same period of the GEX group training program), and only the SSP medication treatment was maintained, and they were followed up during the study period.
89615277|NCT03413202|Experimental|butylphthalide(NBP)|Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
89615278|NCT03413202|Placebo Comparator|placebo|Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo
89615279|NCT02521818|Experimental|Modified Atkins Diet|modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
89615280|NCT02521818|Active Comparator|NIA Diet for Seniors|Diet recommended by NIA for seniors
89615281|NCT04169100|Experimental|Prednisone Group|These patients have CTD and QTc over 500 msec. Prednisone is administered as a preventative measure against arrhythmia via QTc shortening.
89615282|NCT03698448|Placebo Comparator|Placebo DPI|Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID
89615283|NCT03698448|Active Comparator|Low dose OligoG DPI|17.5 mg OligoG dry powder for inhalation. 10 capsules, BID
89615284|NCT03698448|Active Comparator|medium dose OligoG DPI|27.5 mg OligoG dry powder for inhalation. 10 capsules, BID
89615285|NCT03698448|Active Comparator|High dose OligoG DPI|37.5 mg OligoG dry powder for inhalation. 10 capsules, BID
88986465|NCT01242475|Experimental|0.1µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
88986466|NCT01242475|Active Comparator|2TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
88986467|NCT01242553||Normal|Normal results from clinical exam and free of ocular pathology.
88986468|NCT01242553||Retina|Clinical exam results consistent with retina pathology
88986469|NCT01242553||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
88986470|NCT01242553||Cornea|Clinical exam results consistent with cornea pathology.
88986471|NCT01242592|Experimental|Homeopathy|
88986472|NCT01242592|Placebo Comparator|Placebo|
88986473|NCT00489034||Index Participants|HIV-infected females, ages 13- 23 years, recruited from ATN sites in New York, Chicago, Miami, Los Angeles, and New Orleans will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic and/or gender interviewing.
88986474|NCT00489034||Network Participants|Closest friends of index participants s and parents/guardians of index participants who know the index participant's HIV status will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic interviewing.
88986475|NCT00145314|Active Comparator|A|FLOX: 5-fluorouracil/folinic acid/oxaliplatin; Nordic Regimen; given continuosly
88986476|NCT00145314|Experimental|B|FLOX: 5-fluorouracil/folinic acid/oxaliplatin and cetuximab
88986477|NCT00145314|Experimental|C|FLOX given intermittently and maintenance cetuximab
88986478|NCT04727372||Islamabad Group|Individuals residing and surveyed in Islamabad
88986479|NCT04727372||Lahore Group|Individuals residing and surveyed in Lahore
89615286|NCT04155996||data collection|20 patients
89615287|NCT05239806|Experimental|SCTV01C|Participants will receive one dose of SCTV01C on Day 0 and one dose of SCTV01E on Day 180.
89615288|NCT05239806|Experimental|SCTV01E|Participants will receive one dose of SCTV01E on Day 0 and one dose of SCTV01E on Day 180.
89615289|NCT05239806|Active Comparator|Sinopharm inactivated COVID-19 vaccine|Participants will receive one dose of Sinopharm inactivated COVID-19 vaccine on Day 0 and one dose of SCTV01E on Day 180.
89615290|NCT05239806|Active Comparator|Comirnaty|Participants will receive one dose of Comirnaty on Day 0 and one dose of SCTV01E on Day 180.
89615291|NCT01155778|Experimental|10 mg rhHNS|10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
89615292|NCT01155778|Experimental|45 mg rhHNS|45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
89615293|NCT01155778|Experimental|90 mg rhHNS|Given IDDD as a 45 mg dose every 14 [±2 days] for a monthly total of 90 mg for 6 months
89615294|NCT04155840|Experimental|Treatment (copanlisib, rituximab, bendamustine)|Patients receive copanlisib IV over 1 hour on days 1, 8 and 15 or days 1 and 15 (depending on dose level). Patients also receive rituximab IV on day 1 and bendamustine IV on days 1 and 2 of cycles 1-4. Patients who achieve at least a partial response (MRD-positive) continue on treatment for 2 additional cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 7, patients receive copanlisib IV over 1 hour on days 1 and 15 for an additional 6 cycles in the absence of disease progression or unacceptable toxicity.
89615295|NCT03448848|Experimental|study|
89615296|NCT03448848|Placebo Comparator|control|
89615297|NCT05086770|Experimental|Test group|The test group will be administered 300-500 ㎛ range of Gelatin microsphere (Nexsphere™). A suspension in which a contrast medium and physiological saline are mixed will be administered until the embolization is sufficiently achieved.
89615298|NCT05086770|Active Comparator|Control group|The control group will be administered 500-700 ㎛ of Embospheres until sufficient embolization is achieved.
89615299|NCT03448770|Active Comparator|Lactulsoe|Lactulose : 20-30gm 2-3 doses per day
89615300|NCT03448770|Experimental|Polyethlene Glycol|PEG (Polyethlene Glycol)- 17 gm sachet 3-4 times per day
88986480|NCT04727372||Faisalabad Group|Individuals residing and surveyed in Faisalabad
88986481|NCT04727372||Bahawalpur Group|Individuals residing and surveyed in Bahawalpur
88986482|NCT01242631|Experimental|Everolimus 10 mg daily|
88986483|NCT00486382|Experimental|Low dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
88986484|NCT00486382|Experimental|Medium dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
89615301|NCT03443778|Active Comparator|Nacl 0,9% (Control) group|Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
89615302|NCT03443778|Active Comparator|Bupivacaine 0,5%|Bupivacaine 0.5% 1 mg/kg with in Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
89615303|NCT03443778|Active Comparator|Bupivacaine 0,5% , Dexamethasone|Bupivacaine 0,5% 1 mg/kg,dexamethasone 0.5 mg/kg (max dosage 8mg) 3-5 ml separately two part for each tonsil before surgery
89615304|NCT03443622|Experimental|SC-43 100 mg/day|SC-43 Oral Solution (100 mg/ml), 1 ml by mouth, q.d. for 28 days
89615305|NCT03443622|Experimental|SC-43 200 mg/day|SC-43 Oral Solution (100 mg/ml), 2 ml by mouth, q.d. for 28 days
89615306|NCT03443622|Experimental|SC-43 400 mg/day|SC-43 Oral Solution (100 mg/ml), 4 ml by mouth, q.d. for 28 days
89615307|NCT03443622|Experimental|SC-43 600 mg/day|SC-43 Oral Solution (100 mg/ml), 6 ml by mouth, q.d. for 28 days
89615308|NCT03443622|Experimental|SC-43 900 mg/day|SC-43 Oral Solution (100 mg/ml), 9 ml by mouth, q.d. for 28 days
89615309|NCT03443622|Experimental|SC-43 1200 mg/day|SC-43 Oral Solution (100 mg/ml), 12 ml by mouth, q.d. for 28 days
89615310|NCT01872312|Other|treatment|Loading IBV® Valve System
89615311|NCT03443544||Intestinal origin|Either perianal abcess or rectal carcinoma
89615312|NCT03443544||Testicular Origin|Complicated epididymitis with fascitis,
89615313|NCT03443544||Urinary Origin|From urinary tract infection or fistulae from urethral trauma
89615314|NCT03443544||Cutaneous Origin|mostly folliculitis, and skin infections
89615315|NCT02948712|Experimental|Survivor Distress|This intervention will use the NCCN Distress Screening Thermometer to score each participant on their level of distress. Depending on the score the intervention will be tailored to the participant based on the Overview of Evaluation and Treatment Schema DIS-4 per the NCCN Distress Guidelines V1.0, 2016.
89615316|NCT03443466|Experimental|Epidural electrical stimulation (EES)|n=20
89615317|NCT03443466|Active Comparator|Loss of resistance (LOR)|n=20
89615318|NCT03448380||SMBG and FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
89615319|NCT03443388|Active Comparator|Part 2: Helmet|"After a screening period, 10 patients with drug resistant epilepsy will first be assigned to wear one Hövding inflatable helmet in their daily lives. Subjects will fill out questionnaires about their seizures, injuries, and the circumstances of inflation when it occurs. After experiencing a seizure resulting in a fall or any helmet deployment, patients will crossover to the no helmet group. If no seizure resulting in fall occurs in 3 months, participation will end."
89615320|NCT03443388|No Intervention|Part 2: No Helmet|"After a screening period, 10 subjects with drug resistant epilepsy will first be assigned to not wear an inflatable helmet. Subjects will fill out questionnaires about their seizures and injuries. After approximately 3 months, patients will crossover to the helmet group."
88986485|NCT00486382|Experimental|High dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
88986486|NCT00487318|Experimental|Arm 1 Plus statin|The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.
88986487|NCT00487318|Active Comparator|2|Administration of the standard of care for hepatitis C of peginterferon and ribavirin.
88986488|NCT01242670|Experimental|Ross River Virus Vaccine|Subjects will be randomized in equal numbers (1:1:1) to receive one of three different lots of the vaccine on Day 1, Day 22 and Day 181. (The study is blinded with regard to which vaccine lot is administered to a subject but all subjects will receive 3 injections with a 2.5 µg aluminum hydroxide adjuvanted dose of RRV vaccine.)
88986489|NCT01242826|Experimental|A|
88986490|NCT01242865|Other|Attention and Interpretation Therapy|
88986491|NCT01242904|Experimental|bimodal solution|200 mls of 30% glucose in sterile water is added by the patient to the usual icodextrin day dwell, to create the bimodal solution intraperitoneally
88986492|NCT01242904|Active Comparator|icodextrin|200 mls of icodextrin is added by the patient to the usual icodextrin day dwell
88986493|NCT00121940|Experimental|Guided Care|
88986494|NCT00121940|No Intervention|Usual Care|
89615321|NCT03448302||Patients with colorectal adenocarcinoma|The patients will undergo computed tomography perfusion
89615322|NCT03443310|Other|Ultrasound assessment of DVT|DVT ultrasound vs Clinical assessment in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
89615323|NCT03955614|Experimental|St Marys Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
89615324|NCT03955614|Experimental|University College Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
89615325|NCT03955614|Experimental|Chelsea and Westminster Hospital|25 cases will be observed before the intervention and then 25 cases will be observed with the intervention
89615326|NCT01203826|Experimental|asfotase alfa|asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection
89615327|NCT03943836|Experimental|Music Group|Patients listen to music
89615328|NCT03943836|No Intervention|No Music group|Patients do not listen to music
89615329|NCT03448146|Experimental|Para-Toluenesulfonamide|".The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.~. In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient."
89615330|NCT03011008|Experimental|Liraglutide + insulin|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
89615331|NCT03011008|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
89615332|NCT03443232|Experimental|Cryoballoon ablation group|Persistens atrial fibrillation in Cryoballoon ablation group will apply cryoablation
89615333|NCT03443232|Other|Radiofrequency ablation group|Persistens atrial fibrillation in Radiofrequency ablation group will apply Radiofrequency ablation
89615334|NCT04983732|Experimental|FL-101-IV|FL-101 single IV infusion over 60-minutes
89615335|NCT04983732|Experimental|FL-101-SC|FL-101 single SC injection
89615336|NCT04452552|Experimental|ultra-sound cavitation|cavitation40 KHz applied for 30 min, once time weekly for 8 weeks.
88986495|NCT01242943|Experimental|L19SIP I131|"Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I."
88986496|NCT01242982|Experimental|Operation|Closed reduction and operated for fixation with 2 antegrade intramedullary Kirschner wires.
88986497|NCT01242982|Active Comparator|Conservative treatment|Treated conservatively with reduction and then Plaster of Paris.
88986498|NCT00122018|Experimental|NAC|N-acetylcysteine started day prior to surgery, continued through night of surgery
88986499|NCT00122018|Experimental|fenoldopam|fenoldopam started at surgery continued for 24 hours
88986500|NCT00122018|Experimental|NAC and fenoldopam|Both N-acetylcysteine and fenoldopam as above
88986501|NCT00122018|Placebo Comparator|Control|Placebo
88986502|NCT00489697|Experimental|1 (single arm)|patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy
88986503|NCT00489814||1|Patients who are planned to undergo local proton radiotherapy for biopsy-proven, untreated, prostate adenocarcinoma.
88986504|NCT04866888|Experimental|pregnant women with placenta accreta spectrum|"Bladder will be dissected and mobilized down to the vagina after skeletonization and securing of bridging vessels either by electro-coagulation or ligation. Uterus will be incised 5mm above the placenta bulge, delivering the fetus followed by Carbetocin 100 microgram /1 ml intravascular. Repair of the uterine wall defect will be done. If extrauterine bleeding is excessive we may revert to internal iliac artery ligation followed by insertion of intra-peritoneal drain and regular abdominal wall closure.~After 3 months from delivery, ultrasound with different modalities will be done to all patients and outpatient hysteroscopy if symptomatic patients or with abnormal sonography."
88986505|NCT00490087|Experimental|Hysteroscopic resection plus IUD|
88986506|NCT00490087|No Intervention|Hysteroscopic resection without IUD|
88986507|NCT01243060|Experimental|Almorexant 100mg|Subjects will receive a one-time dose of Almorexant 100mg.
88986508|NCT01243060|Experimental|Almorexant 200mg|Subjects will receive a one-time dose of Almorexant 200mg.
88986509|NCT01243060|Active Comparator|Zolpidem|Subjects will receive a one-time dose of Zolpidem 10mg.
88986510|NCT01243060|Placebo Comparator|Placebo|Subjects will receive a one-time dose of Placebo.
88986511|NCT04848909|Experimental|Men with prostate cancer post-prostatectomy|Men with localized prostate cancer who are considered candidates for post-prostatectomy radiation.
88986512|NCT04727450|Active Comparator|1. Integrated format|Integrated or Combination of ABC of A: cognitive training. B: physical training and C: Combined Cognitive and Physical Training (CCPT).
88986513|NCT04727450|Active Comparator|2. Cognitive training + Physical Training (A+B)|Intervention of A & B treatments.
88986514|NCT04727450|Active Comparator|3. Physical training + CCPT (B+C)|Intervention of B & C treatments.
88986515|NCT04727450|Active Comparator|4. CCPT + Cognitive training (C+A)|Intervention of C & A treatments.
88986516|NCT04727450|No Intervention|5. Control group|No intervention
88986517|NCT01243099||In-stent (BMS) restenosis|
88986518|NCT01243099||De-novo coronary lesion|
88986519|NCT00490126||Laparoscopic Surgery Database|
88986520|NCT00122174|Other|Arm 1|
88986521|NCT00490516|Experimental|1|
88986522|NCT00490516|Experimental|2|
88986523|NCT00490516|Placebo Comparator|3|
88986524|NCT00490633|Experimental|Facemask and hand hygiene|Facemask and hand hygiene provided for participants.
88986525|NCT00490633|Experimental|Facemask only|Facemask only provided for participants.
88986526|NCT00490633|No Intervention|Control|Control, no intervention.
89035924|NCT03194568|Experimental|Anterior Vertebral Tethering|Subjects receiving Anterior Vertebral Tethering intervention.
89615337|NCT04452552|Experimental|radiofrequency|radiofrequency multi-polar 5MHZ applied for 30 min, once time weekly for 8 weeks
89615338|NCT01157416|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
89615339|NCT01157416|Placebo Comparator|Placebo plus CBT|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
89035925|NCT02922569|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training and mindfulness training requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
89035926|NCT02922569|Active Comparator|Active Comparator|Commercially available computerized training and traumatic brain injury information session requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
89035927|NCT02834559|Active Comparator|Adjuvant therapy with 5-FU and LMWH|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
89035928|NCT02834559|Placebo Comparator|Standard of care|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
89035929|NCT02933307|No Intervention|Control group|Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
89615340|NCT01206478|Experimental|Amitriptyline plus Megestrol|Amitriptyline once daily at bedtime plus megestrol starting at visit 2
89615341|NCT01206478|Active Comparator|Placebo plus Megestrol|Matching placebo once daily at bedtime plus megestrol starting at visit 2
89615342|NCT04963530|Experimental|Wear of antagonist teeth to monolithic zirconia restorations|Evaluate enamel wear antagonist to monolithic zirconia restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
89615343|NCT04963530|Experimental|Wear of antagonist teeth to lithium disilicate restorations|Evaluate enamel wear antagonist to lithium disilicate restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
89615344|NCT04963530|Experimental|Wear of antagonist teeth to metalceramic restorations|Evaluate enamel wear antagonist to metal ceramic restorations monitoring the short and medium-term volume loss and assessing the factors that may influence this wear.
89615345|NCT04963530|Experimental|Wear of natural enamel|Evaluate physiological enamel wear (control group) monitoring the short short and medium-term volume loss and assessing the factors that may influence this wear.
89615346|NCT01158820|Placebo Comparator|Placebo|midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand
89615347|NCT01158820|Active Comparator|dexmedetomidine and ketamine|dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand
89615348|NCT03707028|Experimental|Rivoceranib with Paclitaxel|Participants will receive oral daily doses of rivoceranib per 28-day cycle (as its mesylate salt) with a fixed dose of paclitaxel given intravenously on Day 1, Day 8, and Day 15 of the 28-day cycle.
89615349|NCT03447756|Experimental|ABX-1431|One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of ABX-1431 HCl with the daily dose between 8 mg and 24 mg of ABX-1431. Each patients dose will be determined by the Investigator based on assessment of adverse events.
89615350|NCT03447756|Placebo Comparator|Placebo oral capsule|One or more oral capsules containing placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of placebo. Each patients dose will be determined by the Investigator based on assessment of adverse events.
89615351|NCT01207570|Experimental|Endermotherapy|The subjects in the experimental group will receive a single session (5 minutes) of endermotherapy) applied to the gastrocnemius/soleus muscle group in the more affected side. The treatment will b e carried out by a qualified physiotherapist.
89615352|NCT01207570|Active Comparator|Passive stretching|The subjects in this group will receive a single session of passive stretching of the gastrocnemius/soleus muscle for 5 minutes.
89615353|NCT03447678|Experimental|Pembrolizumab|subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC
89035930|NCT02933307|Experimental|HealthPatch (Intervention)|Patients with HealthPatch and regular MEWS measurements
89615354|NCT01207648||Retrospective Cohort|Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events were observed in this retrospective cohort study. In this study, medical records of participants evaluated between 1997 to 2009 were reviewed. The observation period started with the first medical record available on site till last medical record available on site or the end of the observation period (31 December 2009), whichever occurred first.
89615355|NCT01225354|Experimental|Calcium hydroxylapatite|Subject will be treated at baseline and, if needed, at 2 weeks.
89615356|NCT04937790|Experimental|Core stabilization group (CSG)|This arm consists core stabilization exercises including abdominal hallowing, supine bride, bride dog, side plank, curl-up and modified push up exercise. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
89035931|NCT02933307|Experimental|ViSi Mobile (Intervention)|Patients with ViSi Mobile and regular MEWS measurements
89035932|NCT02922686|Active Comparator|flucloxacillin + phenoxymethylpenicillin|Flucloxacillin 500 mg four times daily + Phenoxymethylpenicillin 500 mg four times daily for 7 days.
89035933|NCT02922686|Placebo Comparator|flucloxacillin + placebo|Flucloxacillin 500 mg four times daily + Placebo four times daily for 7 days.
89035934|NCT02784366||Cancer immunotherapy patients - no GI side effect|Cancer immunotherapy patients who do not develop GI side effects.
89035935|NCT02784366||Cancer immunotherapy patients - develop GI side effects|Cancer immunotherapy patients who develop GI side effects
89615357|NCT04937790|Experimental|Wobble board group ( WBG)|This arm consists balance training exercises which performed on computerized wobble board for primarily lower limb and anti- gravity muscle. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
89615358|NCT04937790|No Intervention|Control group (CG)|This arm was planned as a control group. Therefore, any intervention will not be performed. Patients in this arm going to participate only one session of patient education at the beginning of the program
89615359|NCT02521662|Active Comparator|Patch|21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
89615360|NCT02521662|Active Comparator|Patch and nicotine-free e-cigarette|21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
89615361|NCT02521662|Active Comparator|Patch and nicotine e-cigarette|21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
89615362|NCT01226914|Placebo Comparator|Placebo|For subjects in the placebo group, saline was drawn into the applicator and aerosolized in a similar fashion; it was allowed to remain in the wound during closure.
89615363|NCT01226914|Experimental|Evicel|For subjects in the treatment group, Evicel was applied in the usual manner by study personnel, with 5mL of each component drawn into a two-barrel syringe device and aerosolized using a pedal-controlled inert gas supply.
89615364|NCT01158976|Experimental|DHA supplementation|
89615365|NCT01158976|Placebo Comparator|Soybean Oil|
89615366|NCT04937556|Active Comparator|Probiotic: Lactobacillus salivarius + Vit D + Zinc|Lactobacillus strain during 28 days, approximately 1*10E9 colony forming unit (CFU) of L. salivarius in 1 capsule per day.
89615367|NCT04937556|Placebo Comparator|Placebo|Placebo supplement in 1 capsule per day during 28 days.
89615368|NCT01227382|Other|ERCP with Cholangiopancreatoscopy|The subjects who have been scheduled for an Endoscopic Retrograde Cholangiopancreatography (ERCP) with Cholangiopancreatoscopy for evaluation of a bile duct or pancreatic duct stricture sampling.
89615369|NCT05183880|Active Comparator|Crystalline vitamin C supplementation|1000 mg of vitamin C ingested in crystalline form
89615370|NCT05183880|Experimental|Phosphatidylcholine-lipid encapsulated vitamin C supplementation|1000 mg of vitamin C ingested in phosphatidylcholine-lipid encapsulated form
89615371|NCT01159054|Experimental|This study has only one arm.|Blood sample and scan results to be compared before and after intervention in each subject.
89615372|NCT05175846||Normal volunteers|Participants with negative COVID-19 test
89615373|NCT05175846||COVID-19|Participants with positive COVID-19 test and severe symptoms of disease
89615374|NCT04451694||Covid-19 unit outgoing patients|nutritional evaluation and intervention
89615375|NCT01209442|Experimental|RT with Temozolomide and Bevacizumab|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily TMZ at 75 mg/m2 qd concurrent with IMRT (including weekends and holidays). Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Day 1 and the 1st Fx of IMRT must start on the same day. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab therapy, patients will have a brain MRI and if there is no evidence of disease progression, patients will receive 6 cycles of Bevacizumab and TMZ. Beginning a minimum of 28 days after the last radiation treatment the bevacizumab will be dosed at 10 mg/kg on day 1 and day 15 of each cycle. TMZ will be given at 150-200 mg/m2 qd on days 1-5 of each cycle. Each cycle is 28 days.
89615376|NCT04451928||Preterm delivery|Pregnant women who give birth before 37th gestational week
89615377|NCT04451928||Term delivery|Pregnant women who will give birth 37th and after gestational week
89615378|NCT04452006|Experimental|Part A (SAD) - A1, ACT-541478 10 mg fasted|SAD = single ascending dose
89615379|NCT04452006|Experimental|Part A (SAD) - A2, ACT-541478 30 mg fasted|SAD = single ascending dose
89615380|NCT04452006|Experimental|Part A (SAD) - A3 (Period 1), ACT-541478 100 mg fasted|SAD = single ascending dose
89615381|NCT04452006|Experimental|Part A (SAD) - A3 (Period 2), ACT-541478 100 mg fed|SAD = single ascending dose
89615382|NCT04452006|Experimental|Part A (SAD) - A4, ACT-541478 300 mg fasted|SAD = single ascending dose
89615383|NCT04452006|Experimental|Part A (SAD) - A5, ACT-541478 1000 mg fasted|SAD = single ascending dose
88986527|NCT00490672|Other|Control Arm|Conventional Patient Management on Hypertension, Diabetes Mellitus and Hyperlipidaemia by Malaysian GP
88986528|NCT00490672|Active Comparator|CORFIS Arm|Community based Multiple Risk Factor Intervention Strategies
89615384|NCT04452006|Experimental|Part B - B1-3, ACT-541478 low or high dose|
89615385|NCT04452006|Experimental|Part C (MAD) - C1, ACT-541478 30 mg, fasted|MAD = multiple ascending dose
89615386|NCT04452006|Experimental|Part C (MAD) - C2, ACT-541478 100 mg, fasted|MAD = multiple ascending dose
89615387|NCT04452006|Experimental|Part C (MAD) - C3, ACT-541478 300 mg, fasted|MAD = multiple ascending dose
89615388|NCT04452006|Experimental|Part C (Elderly) E1, ACT-541478, fasted|
89615389|NCT01160380|Experimental|Armodafinil|The patients receive armodafinil for all 56 days of the study.
89615390|NCT01160380|Placebo Comparator|Placebo-First|These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
89615391|NCT03071328|Experimental|Bone metastatic site|
89615392|NCT03071328|Experimental|Liver metastatic site|
89615393|NCT03071328|Experimental|Lymph node metastatic site|
89615394|NCT03071328|Experimental|Soft tissue metastatic site|
89615395|NCT03447600|Experimental|Alternate day fasting|Participants randomised to Alternate Day Fasting weight loss intervention. One day fasting of 25% total energy requirements alternated with one day ad libitum intake until study completion at >/=5% weight loss which is an average of 12 weeks.
89615396|NCT03447600|Active Comparator|Continuous caloric restriction|Participants randomised to continuous caloric restriction weight loss intervention. Every day intake of 75% total energy requirements until study completion at >/=5% weight loss which is an average of 12 weeks.
89615397|NCT03447444|Other|music and physical activity|An intervention consisting of physical activity, music and walking, was systematically implemented for eight weeks
89615398|NCT04956042|Experimental|Cohort 1 - Fosciclopirox only|An initial 14 study participants will be enrolled in Cohort 1a and will be treated with fosciclopirox. If there is a disease response, an additional 14 study participants will be enrolled into Cohort 1 (Cohort 1b).
89615399|NCT04956042|Experimental|Cohort 2 - Fosciclopirox + Cytarabine|To be implemented if a disease response is not seen in Cohort 1a. Cohort 2a will have an initial 14 study participants treated with fosciclopirox and cytarabine. If a disease response is seen, an additional 14 study participants will be enrolled (Cohort 2b).
89615400|NCT03442998|Other|Suburban|Study participants will wall on a suburban sidewalk setting for 50 minutes.
89615401|NCT03442998|Other|Nature|Study participants will wall on a nature path setting for 50 minutes.
89615402|NCT01228084|Experimental|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
89615403|NCT03009994|Other|Exteriorization group|After delivery of the fetus and placenta, the surgeon bring uterus yet out from peritoneal cavity by manual handling of the uterus uterus from fundus and extracted out of the abdominal cavity before starting to close it. After repair of the uterus , uterus returned to abdominal cavity and repair anterior abdominal wall as following.
89615404|NCT03009994|Other|Non exteriorization group|Uterine incision will be repaired intra abdominally
89615405|NCT03442920|Experimental|Obese women|Obese women who participated exercise programme.
89615406|NCT03442920|No Intervention|Normal weighted|Normal weighted women with non-periodontitis
89615407|NCT03010696||Healthy subjects|Normal kidney function
89615408|NCT03010696||ESRD patients|Diagnosed as ESRD with hemodialysis
89615409|NCT04923984|Experimental|Embolization of Middle Meningeal Artery for Subdural Hematoma|All patients with CSDH will undergo embolization of Middle Meningeal artery
89615410|NCT03447366|Experimental|Mitral doppler|Mitral doppler before and after vascular filling
89615411|NCT01229410|Experimental|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
89615412|NCT01229410|Experimental|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
89615413|NCT02521740||caregivers|someone who takes care and lives with a disabled elderly
89615414|NCT02521740||controls|someone who lives with an healthy elderly
89615415|NCT01212172|Active Comparator|Soprano/SHR|Alma Soprano/SHR 810 nm Diode Laser
89615416|NCT01212172|Active Comparator|LightSheer|LightSheer Duet 810 nm diode laser
89615417|NCT03442686|Experimental|Spring 2018 Compass Course Group|Two groups of up to 15 participants (30 total) will receive the study intervention during Spring 2018. All participants will complete study questionnaires before and after the Spring sessions.
89615418|NCT03442686|No Intervention|Spring 2018 Comparison Group|Two groups of up to 15 participants will receive the study intervention in Fall 2018. All participants will complete study questionnaires before and after the Spring sessions. Those who enroll in the study and agree to participate in the Fall sessions will serve as a no-treatment comparison group.
89615419|NCT03447054|Experimental|Combined TDCS active and ICT active|Five consecutive days: Twenty minutes of TDCS on the right dorsolateral prefrontal cortex while performing an alcohol-cue inhibitory control training consisting to systematically paired go responses with non-alcohol pictures and no-go responses with alcohol-related pictures.
89615420|NCT03447054|Active Comparator|Combined TDCS sham and ICT active|Five consecutive days: Twenty minutes of sham TDCS on the right dorsolateral prefrontal cortex, while performing a no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
89615421|NCT03447054|Active Comparator|Combined TDCS active and ICT inactive|Five consecutive days: Twenty minutes of active TDCS in association with no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
89615422|NCT03447054|Sham Comparator|Combined Sham TDCS and inactive ICT|Five consecutive days: Twenty minutes of Inactive TDCS combined with an non alcohol-cue inhibitory control training consisting to carry out a go/no-go paradigm with no alcohol-related content.
89615423|NCT01160458|Experimental|IMC-A12 Monotherapy in Patients|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
89615424|NCT03109704|Experimental|Supine thrust manipulation|The supine upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
89615425|NCT03109704|Experimental|Seated thrust manipulation|The seated upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
89615426|NCT03109704|Sham Comparator|Sham manipulation|The sham manipulation will be performed two times.
89615427|NCT01212484|Experimental|Placebo (first), Carbidopa (second)|Crossover design Placebo first followed by carbidopa
89615428|NCT01212484|Experimental|Carbidopa (first), Placebo (second)|Crossover design carbidopa first followed by placebo
89615429|NCT03446976|Experimental|CT-P13 SC Auto-injector|CT-P13 SC Auto-injector
89615430|NCT03446976|Experimental|CT-P13 SC Pre-filled Syringe|CT-P13 SC Pre-filled Syringe
89615431|NCT01212874|Active Comparator|Nitroglycerin|nitroglycerin titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
89615432|NCT01212874|Active Comparator|Esmolol|esmolol titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
89615433|NCT03446898||Adults Living at Qinghai-Tibet Plateau for Work Purpose|Qinghai-Tibet Plateau is a high altitude area in which human would be exposed in chronic hypoxia environment.
89615434|NCT03442608|Experimental|mild hypothermia|Device: Zoll 2000 and/or CureWrap 3500 cooling system,lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
89615435|NCT03442608|Placebo Comparator|northermia|normal physical cooling methods,like ice bag, conditionally required.
89615436|NCT03446820|Other|Sleep participants|Crossover from standard sheets to hygro cotton sheets
89035936|NCT02922530|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session
89615437|NCT03446742||Cardiovascular rehabilitation group|Initially all patients will have their charts analyzed, from which data will be extracted for characterization of the population, and anthropometric data will be measured for calculation of body mass index. Afterwards, patients will have their clinical, physical and biochemical parameters. They will be followed up for a period of 2 months during the routines of the cardiovascular rehabilitation sessions for assessment of signs and symptoms. In the second stage the patients will perform the normal routines of their cardiovascular rehabilitation program for a period of 6 months. In the third stage, patients will have their clinical, physical and biochemical parameters and then followed up for another 2 months during the routines of the sessions of the cardiovascular rehabilitation program to evaluate signs and symptoms, which will allow to evaluate if gains/losses in the physical parameters can exert influences in the appearance of signs and symptoms during the sessions.
89615438|NCT03129438|Experimental|continuous EEG (cEEG)|Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
89035937|NCT02922530|Active Comparator|Active Comparator|Commercially available computerized training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session.
89615439|NCT03129438|Active Comparator|routine EEG (rEEG)|Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
89615440|NCT03442530|Active Comparator|Tobacco Treatment As Usual (TTAU)|Eligible women assigned to the control group will be informed of the risks of tobacco use and benefits of quitting using the ACOG 5A's approach by their healthcare provider.5 This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The study coordinator will invite participants to complete the tobacco use questionnaires (TUQ),urine cotinine validation, and Expired Air Carbon Monoxide (EACO) analysis to assess ongoing tobacco use at the designated time points.
89615441|NCT03442530|Experimental|ToPIC|Eligible women assigned to the intervention will receive TTAU plus ToPIC administered by the CTTS. At least once monthly, at routinely scheduled prenatal visits or through telephone, the CTTS will provide cessation counseling. The CTTS will invite participants to complete TUQs,urine cotinine validation and EACO analysis to assess ongoing tobacco use at the designated time points.
89615442|NCT03442452|Other|Electronic Decision Aid|For this study, we will be testing a novel electronic decision aid to improve Acute Myeloid Leukemia patients' understanding of their illness, prognosis, and treatment options.
89615443|NCT04900584|Experimental|Intervention group|The intervention group is managed by applying all three types of intervention.
89615444|NCT04900584|No Intervention|non-Intervention group|Non-intervention group is managed by conventional heart failure treatment.
89615445|NCT03442218|Experimental|Clorhexidine|Vaginal wash with clorhexidine solution
89615446|NCT03442218|Placebo Comparator|Saline solution|Vaginal wash with saline solution
89615447|NCT01859741|Experimental|OMP-59R5 Combination with Etoposide and Cisplatin|
89615448|NCT01859741|Experimental|Etoposide and Cisplatin plus Placebo|
89035938|NCT02922452|Experimental|BMS-986141 and Dilitazem|
89035939|NCT02922374|Experimental|CS|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
89035940|NCT02933151|Other|Usual Care Protocol|Facility randomized to follow the usual care nutritional supplement protocol
89035941|NCT02933151|Other|Intensive Protocol|Facility randomized to follow the intensive nutritional supplement protocol
89035942|NCT02922491|Experimental|Group 1|"400 mg Vitamin E of synthetic source~1 once daily during 2 months"
89035943|NCT02922491|Experimental|Group 2|"400 mg Vitamin E of natural source~1 once daily during 2 months"
89035944|NCT02922491|Placebo Comparator|Group control|"400 mg of starch~1 once daily during 2 months"
89035945|NCT02922491|No Intervention|No intervention|Without intervention
89035946|NCT04687722|Experimental|High Intensity Aerobic Training Group.|The experimental group will receive High Intensity Aerobic Training at 80-90% of Heart Rate Maximum calculated using karvonen rule.
89035947|NCT04687722|Active Comparator|Control Group|The control group will receive routine low Intensity aerobic Training at 40-60% of Heart Rate Maximum calculated using karvonen rule.
89057327|NCT01681914||Fever or History of Fever|Ambulatory, HIV-infected adult patients with measured axillary temperature >=37.5 C or history of fever within the past 24 hours will be evaluated and managed in accordance with Mozambique's new fever guideline for non-physician clinicians. The basic steps of the fever guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral smear) and treat if indicated; treat any other cause of fever identified through history and physical examination; re-evaluate at next scheduled clinical visit (sooner if worse or if not improving within 48 hours of initiating treatment). Although blood cultures are seldom performed in Mozambican health centers, venipuncture specimens will also be cultured for bacterial pathogens at the first study visit.
89615449|NCT01212952|Experimental|Arm I|Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89615450|NCT05161182|Experimental|High fat, low carbohydrate diet|
89615451|NCT05161182|Experimental|Low fat, high carbohydrate diet|
89615452|NCT04609865|Experimental|Lidocaine 2%|The lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours,and then 0.6mg/kg/h for 14 days or until extubation.
89615453|NCT04609865|Placebo Comparator|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
89615454|NCT04608695|No Intervention|Control ovary|
89615455|NCT04608695|Experimental|Punctured ovary|
89615456|NCT01229722|Active Comparator|Beeper|Patients randomized to the control arm (Beeper) will receive the standard of care at each clinic visit. The subjects will bring their HIV medications every 3 weeks (MEMS measure, pill count) and questioned on their adherence to antiretroviral therapy (ART) in the past 7 days. They will not receive any text messages addressing their adherence to ART between each study visit. Their providers will not be receiving any adherence reports but will be asked to assess their adherence at at the start of the trial (Time 1 or T1) and at subsequent clinic visit scheduled according to a frequency defined by standard of care.
89615457|NCT01229722|Experimental|Cell Phone|Participants will receive a text message reminder via ARemind at scheduled intervals, with varying frequency. They will also be subject to a remote adherence assessment, over text messages, interactive voice response (IVR), or a remote pill count with assistance over the phone from a counselor. Those who demonstrate lower adherence rates may receive a call from a counselor.
89615458|NCT01859507|Experimental|BOTOX group|Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.
89615459|NCT01140594|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
89615460|NCT01140594|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
89615461|NCT03442140|Experimental|Experimental|Patients who completed the Baylor Martha Foster Lung Center Pulmonary Rehabilitation Program at least six months ago will participate in the 12-week harmonica program
89615462|NCT04608227||Third trimester pregnant women undergoing ceasarean section|
88986529|NCT01243216|Experimental|Ultrasound Group|Patients in the Ultrasound Group will have a pre-procedure ultrasound of the spine prior to needle placement
88986530|NCT01243216|No Intervention|No Ultrasound Group|Patients in the No Ultrasound Group will not have a pre-procedure ultrasound of the spine performed prior to needle placement.
88986531|NCT00490750|Active Comparator|Laparoscopic Dor fundoplication|Heller myotomy followed by Dor fundoplication
88986532|NCT00490750|Active Comparator|Laparoscopic Toupet fundoplication|Heller myotomy followed by Toupet fundoplication
88986533|NCT00490828|Placebo Comparator|A|
88986534|NCT00490828|Active Comparator|B|Stress doses of hydrocortisone
88986535|NCT00490906||1|Patients receive Copaxone
88986536|NCT00490906||2|Patients receive interferons
88986537|NCT00491062|Active Comparator|Control|
88986538|NCT00491062|Experimental|Parkinson stade 1|
88986539|NCT00491062|Experimental|Parkinson stade2|
88986540|NCT00491062|Experimental|Parkinson stade 3|
88986541|NCT00122408|Active Comparator|1|
88986542|NCT00122408|Placebo Comparator|2|
88986543|NCT00491101||1|Children with asthma, both genders, from 7-18 years old.
88986544|NCT00491140||Observation|Colorectal cancer patients
88986545|NCT00491257|Experimental|Study Group 1|Participants aged 18 to 60 years at enrollment
88986546|NCT00491257|Experimental|Study Group 2|Participants aged 61 years or older at enrollment.
88986547|NCT04809753|Experimental|Eustachian tube dilation|Eustachian tube dilation with an endovascular balloon
88986548|NCT01243255||1|Patients with hypercholesterolemia on lipid lowering pharmacological treatment
88986549|NCT01243372||Correlative (BRAF V600E mutation analysis)|Previously collected formalin-fixed and paraffin-embedded baseline tumor samples are analyzed for BRAF V600E mutation. Mutation status is correlated with clinical response and outcome data from patients enrolled on CALGB-C80405.
88986550|NCT01243489|Other|patient diary|compliance supporting measure: patients uses patient diary from month 6 to 12
88986551|NCT01243489|Other|"Information service Leben mit CML"|"compliance supporting measure: patient uses the Information service Leben mit CML"
88986552|NCT00491803|Active Comparator|1|Sildenafil 20mg
88986553|NCT00491803|Active Comparator|2|Sildenafil 40mg
88986554|NCT00122603|Experimental|Group 1|Atazanavir + Fosamprenavir + ritonavir
88986555|NCT00122603|Experimental|group 2|Atazanavir + saquinavir + ritonavir
88986556|NCT00145743|Experimental|1|Patient's reported questionaire, profile in 10 dimensions (EORTC) and referees' report with treatment recommendations
88986557|NCT00145743|Experimental|2|Patient's reported questionaire; no recommendations given
88986558|NCT00491998|Experimental|2-hourly dosing|6 Doses of IMP at 2-hourly intervals
88986559|NCT00491998|Experimental|3-hourly dosing|4 doses of IMP at 3-hourly intervals
88986560|NCT00491998|Active Comparator|3-hourly dosing plus Entacapone|4 doses of IMP plus Entacapone at 3-hourly intervals
88986561|NCT00122642|Experimental|1|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes for patients not in the hospital.
89615463|NCT03442062|Experimental|AFIX|Clinics randomly assigned to this arm will receive an Assessment Feedback Incentives and eXchange (AFIX) consultation delivered in-person by a state health department immunization specialist.This arm includes ~ 90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
89615464|NCT03442062|Experimental|Physician-to-physician engagement|Clinics randomly assigned to this arm will receive physician-to-physician (P2P) consultations delivered remotely to providers by physician educators. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
89615465|NCT03442062|Experimental|AFIX + P2P|Clinics randomly assigned to this arm will receive both an Assessment Feedback Incentives and eXchange (AFIX) consultation and a physician-to-physician (P2P) consultation.This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
89615466|NCT03442062|Other|Active Intervention Control|Clinics randomly assigned to this arm will receive a brief non-HPV vaccine related quality improvement consultation. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
89615467|NCT01876043|Experimental|plitidepsin|plitidepsin
89615468|NCT01875731|Experimental|BPS (Bacterial Pneumonia Score)|Strategy based on BPS guided antibiotic use
89615469|NCT01875731|Active Comparator|Guideline|Strategy based on enforced guideline guided antibiotic use
89615470|NCT03129204|Experimental|SAF-T Intervention Group|The SĀF-T intervention includes coaching from SĀF-T trained research staff on awareness of biological sensations associated with events in the ICU that are perceived stressful. The research staff member will sit across from the participant and ask them to use their eyes to follow hand movements that will induce lateral left-right (saccadic) eye movements to elicit an orienting response that activates an investigatory reflex in which first, an alert response occurs and then, a reflexive pause produces decreased arousal in the face of no threat, which elicits a calming response that rapidly eliminates negative biological sensations of stress.
89615471|NCT03129204|No Intervention|Control Group|The control group will not receive the SAF-T intervention.
89615472|NCT03441828|Experimental|Group DNMB|"Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block by infusion of rocuronium at the starting dose of 0.3-0.6 mg / kg / h, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
89615473|NCT03441828|Active Comparator|Group MNMB|"Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block. neuromuscular blockade will be maintained with intravenous bolus of rocuronium (0.15-0.25 mg/kg) titrated to obtain a TOF count of 1-3.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
89615474|NCT03446430|Experimental|Hypertensives|PWV measurement by LDV
89615475|NCT04891614|Experimental|Treatment|Subjects diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training.
89615476|NCT01873859|Active Comparator|On-metformin|Diabetic patients receiving contrast media without discontinuing metformin.
89615477|NCT01873859|No Intervention|Off-metformin|Diabetic patients receiving contrast media with discontinuation of metformin.
89615478|NCT00493896|Experimental|Fondaparinux|Fondaparinux treatment - one standard of care option
89615479|NCT00493896|Active Comparator|2|Enoxaparin
89615480|NCT00388908|Experimental|A|Multifaceted intervention
89615481|NCT00388908|Active Comparator|B|Usual Care
89615482|NCT04288674||Leptospirosis group|Patients with cultural, serological, molecular or histological evidence and clinical evidence of invasive leptospirosis disease.
89615483|NCT04288674||Control group|Controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital)
89615484|NCT03450486|Experimental|affected limb|measurements of balance from the affected side of individuals with unilateral knee osteoarthritis following an exercise session
89615485|NCT03450486|Active Comparator|unaffected limb|measurements of balance from the unaffected side of individuals with unilateral knee osteoarthritis following an exercise session
89615486|NCT03441672|Experimental|Intervention|Participants in the intervention group interact with the game technology to learn about prenatal screening, in addition to usual care provided in the clinic.
89615487|NCT03441672|No Intervention|Control|Participants in the control group learn about prenatal screening through usual care in the clinic.
89615488|NCT03449940|Active Comparator|Immediate repair (group 1)|"Penile explorations were done within 24 hours of presentation, under general or spinal anaesthesia.~1g Ceftriaxone IV was given.~Incision-- Subcoronal, circumferential & degloving.~Repair-- Continuous technique with inverted knots using 3-0 polyglactin suture.~All patients were discharged from hospital within 24 hours."
89615489|NCT03449940|Active Comparator|Delayed repair (group 2)|"Patients were not admitted; instead they were discharged from hospital and given an elective surgery date. Oral Diclofenac Sodium 50mg was prescribed to be taken as needed and instructions to abstain from any sexual activity.~In an ambulatory setting, surgery was done 7 - 10 days later.~1g Ceftriaxone IV was given.~Local anaesthesia (dorsal penile nerve block): 1% Lidocaine 10cc was given.~Incision--- 2 - 3cm localized incision over the site of the rolling sign.~Repair--- Continuous technique with inverted knots using 3-0 polyglactin suture."
89210902|NCT00224029|Experimental|Oxybutynin transdermal system|Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing
89210903|NCT00826592|Experimental|Video-based education arm|Subjects receiving the video-based educational material
89615490|NCT03449862|Experimental|LEGAL-COST|Clinicians were first presented malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan) then patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test)
89615491|NCT03449862|Active Comparator|COST-LEGAL|Clinicians were first presented with patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test) then malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan)
89035948|NCT03457454||Primary Care Provider/Staff Participants Interviews|"Up to two primary care providers and at least one staff person at each of the 16 clinics, with approximately 5 interviewees per clinic. Eligible providers and staff include physicians, nurse practitioners, nurses, case managers, medical assistants, administrative staff, or other employees of the clinic involved in the cancer screening and follow-up process.~If the participant verbally consents, the research team member will conduct an interview with the provider to learn about the current processes used to support and monitor colorectal cancer screening (CRC) from screening initiation through follow-up; assess capacity and interest in implementing Evidence Based Practices for supporting and monitoring CRC screening, including any ideas interviewees have or find appealing; and engage the organizations as partners to build interest, capacity, and infrastructure for future intervention trial and other future studies."
89035949|NCT03457454||Patient Participants Interviews|"10 patients across 5 clinics will be recruited for interviews, which will address the patient experience with screening and follow-up.~If the participant verbally consents, the research team member will conduct an interview with the patient participant to gain a deeper understanding of the CRC screening process from the patient's perspective; the gaps, challenges, or road blocks/speed bumps to completing CRC screening steps; and what organizations can do better or differently to help people complete the CRC screening process."
89035950|NCT03457454||Patient Participants Anonymous Survey|-Patient participants will be recruited to take an anonymous mailed survey, which will address patient level barriers to screening and follow-up focusing on out of pocket costs.
89057328|NCT01681914||Anemia and Fever/History of Fever|Patients who meet eligibility criteria for both the anemia and fever arms will be evaluated and managed using both the new Mozambican anemia guideline and the new Mozambican fever guideline, as above.
89210904|NCT00826592|Active Comparator|Written education arm:|Subjects receiving the written educational material
89615492|NCT03446196|Experimental|MOSTCARE UP|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
89615493|NCT03446196|No Intervention|CLINICIAN EXPERIENCE|Fluid replacement will be made based on clinician experience
89615494|NCT03441516|Experimental|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400mg bid + Donepezil 10mg qd for 24 weeks
89615495|NCT03441516|Active Comparator|Aripezil® Tab.|Donepezil 10mg qd for 24 weeks
89615496|NCT03445962||Down Syndrome (DS)|Assessment of OSAS predictive factors in Down Syndrome without or without OSAS
89615497|NCT03445884|Experimental|Acute myocardial infarctions group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. three times. 1-3 days after intervention, 7-10 days after intervention and 30-35 days after intervention.
89615498|NCT03445884|Active Comparator|Control group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. one time.
89615499|NCT03449550|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
89615500|NCT03449550|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
89615501|NCT03441438|Active Comparator|Control|Patients without asthma or aspirin intolerance who may or may not react to alcoholic beverages
89615502|NCT03441438|Active Comparator|Aspirin Tolerant Asthma|Patients with asthma who are tolerant to aspirin and/or other NSAIDs and note sensitivity to alcoholic beverages
89615503|NCT03441438|Active Comparator|Aspirin Intolerant Asthma / AERD|Patients with AERD who note sensitivity to alcoholic beverages
89615504|NCT01857869|Experimental|GSK257049-0,1,7M Group|Subjects receiving 2 doses of GSK257049 vaccine given at 0 and 1 months and followed 6 months later (At Month 7) by another dose of GSK257049 vaccine.
89615505|NCT01857869|Experimental|GSK257049-0,1,2M Group|Subjects receiving 3 doses of GSK257049 vaccine given one month apart (0,1 and 2 months).
89615506|NCT01857869|Experimental|Infectivity Control Group|Volunteers who did not receive any immunization but underwent sporozoite challenge
89615507|NCT01230424|Experimental|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
89615508|NCT01230424|Placebo Comparator|Sodium Chloride|0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
89615509|NCT01230502|Active Comparator|Group 3: Donor Specific Regulation (DSR) -, standard of care|Subjects who test Donor Specific Regulation (DSR) negative will not be randomized to possible tacrolimus withdrawal, and will remain on standard of care immunosuppression.
89615510|NCT01230502|Active Comparator|Group 2 Donor Specific Regulation (DSR) +; standard of care|Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 2 will remain on standard of care immunosuppression.
89615511|NCT01230502|Experimental|Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy|"Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy:~Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 1 will begin a taper off tacrolimus for 6 months, after repeat DSR testing at 6 months subject will either discontinue tacrolimus if they remain DSR negative or remain at reduced dose if converted to DSR positive"
89615512|NCT03438240|Active Comparator|Group BF|Bupivacaine plus Fentanyl
89615513|NCT03438240|Active Comparator|Group BD|Bupivacaine plus Dexmedetomidine
89615514|NCT01160848|Other|Part 1|Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application
89615515|NCT01160848|Other|Part 2|For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)
89615516|NCT03445572|Experimental|Group I (MSB)|Participants are instructed on the MSB technique and then perform MSB over 15 minutes BID for 28 days.
89615517|NCT03445572|Experimental|Group II (IK meditation)|Participants are instructed on the 3 steps of IK meditation and then perform IK meditation over 15 minutes BID for 28 days.
89615518|NCT03445572|Active Comparator|Group III (waitlist)|Participants are placed on a waitlist and receive standard supportive care for 28 days. After 28 days, participants may crossover to Group II.
89035951|NCT03457454||Colonoscopy Provider/Staff Participants Interviews|"Colonoscopy providers and a staff or mid-level provider in each office will be recruited for interviews.~If the participant consents, the research team member will conduct an interview to learn about current processes used to support and monitor colorectal cancer screening from the perspective of gastroenterology/colonoscopy sites and to learn about how gastroenterology/colonoscopy sites communicate and coordinate care with other healthcare organizations and patients to support and monitor colorectal cancer screening."
89035952|NCT02933112|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
89035953|NCT02922140|No Intervention|control group|will receive standard care by physician in attendance
89035954|NCT02922140|Active Comparator|intervention group|will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
89035955|NCT02932917|Experimental|MapMySmoke|All patients in the study will use the MapMySmoke app to document their smoking and craving behavior
89615519|NCT01213576|Active Comparator|albendazole 400mg and ivermectin 200mcg/kg|Annual treatment
89615520|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg/kg|Annual treatment
89615521|NCT01213576|Active Comparator|Albendazole 400mg and ivermectin 200mcg/kg|albendazole 400mg and ivermectin 200mcg/kg given twice a year
89615522|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg /kg bi-annually|Albendazole 800mg and ivermectin 400mcg/kg given twice a year
89615523|NCT03445416|Experimental|Intervention: POL arm|POL intervention. Enrolled POLs will be randomized at their intake visit; those randomized to the intervention arm will attend the popular opinion leader training (developed in Aim 1) and will be asked to diffuse the intervention messages to their network recruits.
89615524|NCT03445416|Active Comparator|Comparison group|POLs who are randomized to the comparison arm will receive an abbreviated version of the POL training that includes general health messaging, but does not incorporate medical mistrust, stigma or specific vaccination messaging.
89615525|NCT05088408|Active Comparator|Control|Bowel preparation as usual. Colonoscopy.
89615526|NCT05088408|Experimental|Dietary supplement|"Bowel preparation as usual plus two bottles of the dietary supplement Resource® Energy Apricot.~Colonoscopy."
89615527|NCT03010774|Experimental|Intervention - Risk Stratification|Study participants will be risk stratified according to the eCART scoring algorithm each night. If they are stratified as low risk, they will not receive routine nighttime spot-check vital signs unless indicated by a change in patient status or monitor alarm.
89615528|NCT03010774|Active Comparator|Control - Usual Care|Study participants will be woken at night for routine nighttime spot-check vital signs regardless of patient disease severity or risk.
89615529|NCT04452630||Covid 19 Patients|patients having presented an episode of Covid-19 diagnosed by at least one positive nasopharyngeal RT-PCR test for SARS-Cov-2 and considered recovered.
89615530|NCT04452318|Experimental|REGN10933 + REGN10987|
89615531|NCT04452318|Placebo Comparator|Placebo|
89615532|NCT01161160|Experimental|AREPANRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
89615533|NCT01161160|Experimental|PANDEMRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Pandemrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
89615534|NCT01161160|Experimental|AREPANRIX GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
89035956|NCT02922179||Diabetes Type 1|Individuals diagnosed with type 1 diabetes exposed to Long- and intermediate- acting insulins
89035957|NCT02922179||Diabetes Type 2|Individuals diagnosed with type 2 diabetes exposed to Long- and intermediate- acting insulins
89615535|NCT04621578|Experimental|Transcutaneous electrical acupoint stimulation arm|Patients will be given TEAS treatment at the maximum tolerable intensity at a frequency of 2 Hertz (Hz) after surgery in postanesthesia care unit (PACU), and after returning to the ward.
89615536|NCT04621578|Sham Comparator|Sham stimulation arm|Patients will use the same device, same stimulation site, and be treated at the same time points, but the lead of the device was damaged. Therefore, although the patients can see the stimulator running, there is actually no current passing through.
89615537|NCT04573764|Active Comparator|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|
89615538|NCT04573764|Placebo Comparator|Placebo|
89615539|NCT04571190|Experimental|Prenatal MBSR|The prenatal MBSR program consists of nine two-hour sessions including teachings in mindfulness meditation and yoga. The program is taught by an experienced MBSR instructor with relevant clinical expertise.
89615540|NCT04571190|No Intervention|Usual care|Standard clinical practice, usual care (TAU), imply routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Usual care include a multidisciplinary approach involving preventive counselling by midwifes, physicians and social workers throughout the pregnancy and follow-up until the early post-partum period.
89615541|NCT03010618|Other|Study Group|
89035958|NCT02922062|Experimental|Low Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO (protein):CHO (carbohydrate):FAT, 18:8:74). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
89057329|NCT04540679|Active Comparator|Inpatient - Standard Care Delayed Platform|Patient will receive standard inpatient care and provided access to the platform 6 weeks after inpatient discharge with support provided by the VIP coach.
89615542|NCT03438162|No Intervention|Control group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications.
89615543|NCT03438162|Experimental|Intervention group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications. Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
89615544|NCT03010852|No Intervention|Standard of care incentive spirometer|Patients in the SOC cohort will not receive the preoperative education and only one postoperative visit per day to collect their self-reported use of IS, if prescribed, and respiratory symptoms but avoiding increasing their awareness of POH, O2 therapy and IS.
89615545|NCT03010852|Experimental|Focused incentive spirometer education and monitoring|One of the study investigators will meet eligible patients in the preoperative visit to the UCH Weight Loss Surgery clinic, inform and consent the patient and introduce the first education on IS therapy, highlighting its possible benefits and the importance of compliance (patient's inspiratory effort and frequency). This IS education will be repeated in the preoperative area immediately before surgery. The site will then follow the patient postoperatively. The site will directly check on the patient in the PACU and later in his/her hospital room at least 3 times a day during the first 3 days or sooner if their O2 therapy is discontinued for 2h. During these PO check ups The site will reinforce the IS use, monitor the patient's performance of IS and ask him/her about other respiratory symptoms.
89615546|NCT03438084|Experimental|Interesterified|Commercially available interesterifed fat spread. 50g fat.
89615547|NCT03438084|Active Comparator|Non- interesterified|Commercially available non-interesterified fat. 50g fat.
89615548|NCT03438084|Active Comparator|Control|Rapeseed oil. 50 g fat.
89615549|NCT03438084|Active Comparator|Saturated fat control|Butter. 50g fat
89615550|NCT01161862|Experimental|Bi-hormonal with meal-priming bolus|The first meal-priming bolus was solely based on weight (0.05 U/kg), after which meal-priming boluses were automatically adapted by the control system online targeting 75% of the anticipated insulin needed in the first four hours after the start of the meal
89615551|NCT01161862|Experimental|Bi-hormonal without meal-priming bolus|The insulin controller was entirely reactive to CGMG; there were no meal priming boluses and no meal announcements
89615552|NCT01214356|Placebo Comparator|Lower Dose Vitamin D|Vitamin D3 supplementation of 400 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
89615553|NCT01214356|Active Comparator|Higher Dose Vitamin D|Vitamin D3 supplementation of 4000 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
89615554|NCT03437850||South African cohort|
89615555|NCT03437850||Swedish Cohort|
89615556|NCT03437772||CBT with mindfulness|
89615557|NCT03437772||Treatment as Usual: Barkley therapy|
89615558|NCT01214980|Experimental|MIST Therapy in conjunction with SOC|Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
89615559|NCT01214980|Active Comparator|Control arm|Standard of care treatment
89615560|NCT03445338|Experimental|Cohort 1|
89615561|NCT03445338|Experimental|Cohort 2|
89615562|NCT03445338|Experimental|Cohort 3|
89615563|NCT03445260|Placebo Comparator|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
88986562|NCT00122642|Placebo Comparator|2|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
88986563|NCT04790565|Experimental|Fecal microbiota transplantation (FMT)|Patients will be given capsulized FMT, 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Patients will continue fasting for 2 hours after the intervention. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
88986564|NCT00492076|Active Comparator|1|Pangramin Plus Dermatophagoides pteronyssinus 100%
88986565|NCT00492076|Placebo Comparator|2|Pangramin Plus placebo
88986566|NCT00402272|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
88986567|NCT00492271|Experimental|1|Experimental arm with increasing dosage
88986568|NCT00492310|Experimental|1|Cognitive-behavioral smoking cessation with yoga
88986569|NCT00492310|Active Comparator|2|smoking cessation with twice weekly wellness program
88986570|NCT00492388|Experimental|A|PMI-150 (intranasal ketamine)
88986571|NCT00492388|Placebo Comparator|B|placebo
88986572|NCT01243528||Patients in neurological rehabilitation|Patients suffering from a neurological disease
88986573|NCT01243684|Active Comparator|Healty volunteers|
88986574|NCT01243684|Experimental|Patients|
88986575|NCT00492427|Active Comparator|2|
88986576|NCT00492427|Experimental|1|
88986577|NCT00492466|Experimental|1|
88986578|NCT00492661|Experimental|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression (drug which suppresses the body's immune response, used in transplantation and diseases caused by disordered immunity) will be provided with intensive dietary advice and supervised progressive resistance training (PRT) for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
88986579|NCT00492739|Other|Varicella vaccine|2-3 doses of Varicella vaccine to seronegative patients two months apart
88986580|NCT04781712|Experimental|Self-management using mHealth|Self-management (physical activity, sleep, exercise, education, etc.) using mHealth
88986581|NCT04781712|No Intervention|Exercise using brochure|Only exercise using brochure
88986582|NCT00402350|Placebo Comparator|Placebo|Subjects (2) from each of the 4 dose escalation arms
88986583|NCT00402350|Experimental|25 mcg IV and Inhaled Crossover|Single dose crossover (IV vs Inhaled)
89615564|NCT03445260|Experimental|Nutritional Supplements|carbohydrate loading, immunonutrition (formulated liquid diet), protein supplement
89615565|NCT01232920|Active Comparator|Methotrexate|
89615566|NCT01232920|Active Comparator|Mycophenolate mofetil|
89615567|NCT03445182|Active Comparator|Control group|Local anaesthesia with conventional syringe
89615568|NCT03445182|Active Comparator|DentalVibe group|Local anaesthesia with conventional syringe + DentalVibe
89615569|NCT03010540|Experimental|Morphine Plus Fentanyl|
89615570|NCT03010540|Active Comparator|Fentanyl only|
89615571|NCT03445104|Experimental|Huperzine A|Huperzine A will be provided in the form of a single capsule for oral ingestion.
89615572|NCT03445104|Placebo Comparator|Rice Flour|Placebo will be provided in the form of a single capsule for oral ingestion.
89615573|NCT01234714||Major liver resection|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonant Imaging (MRI) and underwent major liver resection (>=3 segments).
89615574|NCT03440580|Active Comparator|Intervention|The intervention school will receive the BOOSTH intervention: Boosth activity tracker, Boosth sync app, Boosht game app
89615575|NCT03440580|No Intervention|control group|The control school will receive the standard curriculum. After the study is finished the children of the control school will receive the Boosth product
89615576|NCT03440502||control group.|Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
89615577|NCT03440502||study group|The same as control group but with DM or gestational diabetes Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
89615578|NCT01162096|Experimental|Transplantation|
89615579|NCT03437538|Active Comparator|First MCO-HD, then High-flux-HDF|Participants with ongoing HDF-treatments will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF
89615580|NCT03437538|Active Comparator|First High-flux-HDF, then MCO-HD|Participants with ongoing HDF-treatments will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD
89615581|NCT04801290||TIPS insertion|
89615582|NCT01234870|Experimental|Ischemic heart disease patients|Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
89615583|NCT05665686|Experimental|Device Group|Sexual Information and Advice to Individuals Individuals in both groups will be given training on sexuality. Male and female sexual situation, orgasm, male and female anatomical structures will be explained. At the same time, information will be given about the pelvic floor muscles, their function and their importance in sexual life.
89615584|NCT05665686|Active Comparator|home exercise|A home exercise program including pelvic floor relaxation exercises in different positions will be created for individuals in both groups and self-myofascial massages will be taught. At the same time, information will be given about the pelvic floor muscles, their function and their importance in sexual life.
89615585|NCT03437460|Active Comparator|Ibuprofen 600mg|Treatment group participants receive a single 600 mg of over-the-counter ibuprofen.
89615586|NCT03437460|Placebo Comparator|Prenatal vitamins|The placebo group participants receive a single dose of a pre-natal multivitamin.
89615587|NCT03437460|No Intervention|Control group|Control-group participants are not provided with any treatment and they are fully informed regarding their treatment status.
89615588|NCT03444792|Experimental|Group I (dilation group)|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure. - If failed we will use artery forceps to dilate cervix
89615589|NCT03444792|No Intervention|Group II (non dilatation group)|the surgeon will perform cesarian section without attempting cervical dilatation
89615590|NCT03444636|Experimental|Ropivacaine/Fentanyl|
89615591|NCT03444636|Active Comparator|Bupivacaine/Fentanyl|
89615592|NCT01215292|Placebo Comparator|Acyline & T Gel & Placebo Ketoconazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10
89615593|NCT01215292|Experimental|Acyline & T Gel & Ketoconazole 400|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10
88986584|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 2|Inhaled Staccato fentanyl, 25 mcg x 2
88986585|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 4|Inhaled Staccato fentanyl, 25 mcg x 4
88986586|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 6|Inhaled Staccato fentanyl, 25 mcg x 6
88986587|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 12|Inhaled Staccato fentanyl, 25 mcg x 12
88986588|NCT04777149|Experimental|transcranial Random Noise Stimulation (tRNS)|Participants in this group will receive a combined intervention (3 days of tRNS during functional task practice and 3 days of sham-stimulation during functional task practice).
88986589|NCT04777149|Active Comparator|transcranial Direct Current Stimulation (tDCS)|Participants in this group will receive a combined intervention (3 days of tDCS during functional task practice and 3 days of sham-stimulation during functional task practice).
88986590|NCT00402389|Experimental|1|Participants assigned to take omega-3 fatty acids
88986591|NCT00402389|Placebo Comparator|2|Participants assigned to take placebo
88986592|NCT04766970|Active Comparator|Standardized assessment|
89615594|NCT01215292|Experimental|Acyline & T gel & Ketoconazole 800|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10
89615595|NCT01215292|Experimental|Acyline & T gel & Dutasteride|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10
89615596|NCT01215292|Experimental|Group 5: anastrazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10
88986593|NCT04766970|Experimental|Telehealth assessment|
88986594|NCT00492895|Other|A|one arm only. Crossover study
89615597|NCT04796454|Active Comparator|CisGem/GemOx|"Cisplatin/Gemcitabine (3-week cycle):~Cisplatin IV 25 mg/m² d1 and day8~Gemcitabine 1000 mg/m² d1 and d8~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years.~In case of unacceptable toxicity the CisGem regimen can also be switched to a GemOx regimen (4-week cycle):~Oxaliplatin IV 100 mg/m² d1 and day15~Gemcitabine 1000 mg/m² d1 and d15"
89035959|NCT02922062|Active Comparator|High Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO:CHO:FAT, 18:60:22). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
89035960|NCT02922101|Experimental|Audit and Feedback with toolbox|Access to an online dashboard that provides insight into clinical performance on quality indicators for pain management; including a quality improvement toolbox to facilitate planning and executing actions. Participating ICUs will receive one educational outreach visit and brief monthly telephone calls.
89035961|NCT02922101|Active Comparator|Audit and Feedback without toolbox|Same intervention, but without access to the quality improvement toolbox.
89035962|NCT02932839|Experimental|Intervention|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
89035963|NCT02922218||Enzalutamide|Enzalutamide 160 mg/day c/24h
89615598|NCT04796454|Experimental|PamTMZ|"Pamiparib + temozolomide (4-week cycle):~Pamiparib 60 mg PO twice a day d1-d28 Temozolomide 60 mg PO daily d1-d7~This treatment regimen will be given until documented disease progression, unacceptable toxicity, or patient refusal, for a maximum of 2 years."
89035964|NCT02932800|Active Comparator|"Ballerina associated with flap fixation"|"The catheter is anchored to the skin begins by a point U around the catheter insertion site and followed by a series of woven points around the catheter , commonly referred to as  node dancer  to pass the wires on each side of the orifices located at the catheter distal flaps and hold three consecutive nodes . Then, the clamping is carried out of the catheter to the skin by means of a simple point and hold three consecutive nodes in each lateral hole of the fastening flap while leaving, between the fastening flap and the puncture site a space 2 cm distance for viewing the ostium ."
89615599|NCT03437382|Other|RFA + radioembolization|Quirem Medical Holmium-166 radioembolization microspheres
89615600|NCT05113680|Experimental|compassion|compassion focused group based on CFT
89615601|NCT05113680|Active Comparator|emotional competencies|emotional competencies group (based on emotional intelligence)
89615602|NCT05113680|No Intervention|control|control group
89615603|NCT02521506|Experimental|Verio Pattern Alert® activated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends.
89615604|NCT02521506|Active Comparator|Verio Pattern Alert® deactivated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer.
89615605|NCT02189668|Experimental|Non-operative Management|Non-operative management with antibiotics only Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
89615606|NCT02189668|No Intervention|Surgery|Usual care with urgent appendectomy
89615607|NCT03437304|Experimental|Immunose™ FLU 1%|Immunose™ FLU 1%. QIV, 30 μg HA/strain and 1% Endocine™ 200 μl for intranasal administration, 2 dosing occasions.
89615608|NCT03437304|Experimental|Immunose™ FLU 2%, 200 μl|Immunose™ FLU 2%. QIV, 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration, 2 dosing occasions.
89615609|NCT03437304|Experimental|Immunose™ FLU 2%, 300 μl|Immunose™ FLU 2%, 300 μl. QIV, 30 μg HA/strain and 2% Endocine™, 300 μl for intranasal administration, 2 dosing occasions.
89615610|NCT03437304|Experimental|Influenza antigen|Influenza antigen. QIV, 30 μg HA/strain, 200 μl for intranasal administrations, 2 dosing occasions.
89615611|NCT03437304|Placebo Comparator|Placebo|Placebo. Saline (NaCl), 200 μl for intranasal administration, 2 dosing occasions.
89615612|NCT03437304|Experimental|i.m comparator and Immunose™ FLU 2%|i.m comparator: QIV 15 μg HA/strain, 500 µl for a single intramuscular administration, and Immunose FLU 2%: QIV 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration. A second dose of Immunose FLU 2% will be administered 3 weeks later.
89615613|NCT03437304|Active Comparator|i.m comparator|i.m comparator. QIV 15 μg HA/strain, 500 µl for a single intramuscular administration.
89615614|NCT02981290|Experimental|Renodapt Then Mycept Then Cellmune Then CellCept|Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
89615615|NCT02981290|Experimental|Mycept Then CellCept Then Renodapt Then Cellmune|Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period.
89035965|NCT02932800|Active Comparator|the usual fixation technique|The catheter is attached to the skin with a simple point and holding three we row on each side hole fixing fin while leaving, between the fastening flap and the puncture site , an area of 2 cm away for viewing ostium . The catheter is anchored to the skin by a simple point and holding three consecutive us in each hole of the side flap in the distal region.
89615616|NCT02981290|Experimental|Cellmune Then Renodapt Then CellCept Then Mycept|Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
89615617|NCT02981290|Experimental|CellCept Then Cellmune Then Mycept Then Renodapt|Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period.
89615618|NCT03437226|Experimental|Levosimendan Arm|Patients receive 6 or 24 hours infusion depending on the site. Levosimendan 2.5 MG/M 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Levosimendan 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Levosimendan
89615619|NCT03437226|Placebo Comparator|Placebo Arm|Patients receive 6 or 24 hours infusion depending on the site. 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Placebo 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Placebo
89615620|NCT03444558|Experimental|Dietary Supplement|50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
89615621|NCT03444558|Placebo Comparator|Placebo|50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
89615622|NCT01236196|Experimental|Arm 1 - Telephone CBT|telephone cognitive behavior therapy for pain management
89615623|NCT01236196|Active Comparator|Arm 2 - telephone education|telephone pain education
89615624|NCT03444480|Experimental|Remimazolam Tosylate 1|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start， 0.5 mg Flumazenil is administered
89615625|NCT03444480|Experimental|Remimazolam Tosylate 2|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered
89615626|NCT01236742|Experimental|single-vision glasses and ortho-k lenses|Children who are currently wearing ortho-k lenses at night for correction of refractive errors will be switched to wear single-vision glasses for the first 7 months and then switched back to ortho-k lenses for the next 7 months
89615627|NCT01236742|Active Comparator|ortho-k lenses|Children who are currently wearing ortho-k lenses at night for the correction of refractive errors will continue with the current treatment and serve as the first control group
89615628|NCT01236742|Other|single-vision glasses|Children who are currently wearing single-vision spectacles in the daytime for correcting their refractive errors will continue with the current treatment and serve as the second control group
89615629|NCT04788420||Sorafenib group|Patients assigned to this group received sorafenib post-transplantation.
89615630|NCT04788420||Control group|Patients assigned to this group did not receive sorafenib or any other FLT3 inhibitor post-transplantation until reaching the primary outcome.
89615631|NCT01282138|Experimental|Patanol|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
89615632|NCT01282138|Placebo Comparator|Tears Naturale II|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
89615633|NCT01922973||normal men and women|normal volunteers: young and older men and women studied under fed and fasting (62.5h) conditions with frequent blood sampling for ghrelin and related hormones
89615634|NCT03440346|Experimental|Few-foods diet intervention|
89615635|NCT03444402|Experimental|Group A|Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)
89615636|NCT03444402|Experimental|Group B|Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)
89615637|NCT03444402|Experimental|Group C|Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)
89615638|NCT01238536|Experimental|Epidural Steroid injection|"Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.~Intervention: Epidural steroid with local anesthetic injection~2cc of .25 - 1% lidocaine and glucocorticoid (Kenalog 40-120 mg, depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg)"
89615639|NCT01238536|Active Comparator|Epidural local anesthetic injection|Intervention: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
89615640|NCT03437070|Experimental|TDO Dose Level|Trabectedin [T], Doxorubicin [D], and Olaratumab [O]
89615641|NCT04346446|Experimental|Convalescent Plasma+Supportive Care|Convalescent Plasma+Supportive Care Convalescent plasma from recovered COVID-19 patients will be transfused to severely sick COVID-19 infected patients
89615642|NCT04346446|Active Comparator|Random Donor Plasma+Supportive Care|Random Donor Plasma+Supportive Care
89615643|NCT00634101|Active Comparator|nefilcon A|Subjects randomized to this arm received the nelfilcon A lens throughout the entire duration of the study.
89615644|NCT00634101|Experimental|narafilcon A|Subjects randomized to this arm received the narafilcon A lens throughout the entire duration of the study.
89615645|NCT04478058|Experimental|e-CBT|Weekly e-CBT sessions will occur through Online Psychotherapy Tool (OPTT) and consist of slides and interactive therapist videos. Content and format mirrors live CBT. Slides will highlight a different topic each week and include general information, overview of skills, and homework. Homework will be submitted through OPTT and reviewed by administrators with personalized feedback within three days. Weekly homework submission will be mandatory before beginning the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment. After each cycle of e-CBT, patients and healthcare providers involved in e-CBT will be recruited for focus groups once they have completed their 12-week program. Qualitative data will be gathered through 10 focus groups. The focus group prompts will pertain to experience and expectations of service. Patients will be contacted six months after treatment to complete DASS 21 and Q-LES-Q-SF questionnaires.
88986595|NCT00492934|Active Comparator|1|Daily injections with a small dose of gonadotrophins from day 2 of the cycle
89035966|NCT02932995||DXR stent group|Patients who undergo coronary intervention with DXR stent
89615646|NCT04478058|Active Comparator|Live CBT|The content and format of live CBT will be mirrored by the e-CBT group over the course of 12 weeks. The sessions will highlight a different topic each week and include general information, an overview of skills, and homework on that topic. Live CBT homework will be reviewed by the CBT group organizer and provided at the beginning of the next CBT session. Weekly homework submission for feedback will be mandatory before being eligible for the next session. DASS 21 and Q-LES-Q-SF questionnaires will be completed at the beginning and end of treatment for both live and e-CBT. All live and e-CBT patients will be contacted six months after the completion of their CBT to complete final DASS 21 and Q-LES-Q-SF questionnaires. This will allow for the examination of the longevity of e-CBT compared to live CBT.
89615647|NCT01284244|Experimental|Uresta|
89615648|NCT01284244|Sham Comparator|Silastic vaginal ring|
89615649|NCT04469088|Experimental|Dry Needling Group|
89615650|NCT04469088|Active Comparator|Manual Therapy Treatment|
89615651|NCT03129048|Experimental|MedDiet-WL|MedDiet-WL group, advice and exchange lists will be designed to promote a 1-2 lb. per week weight loss (approximately 30% caloric restriction or a reduction of about 600 calories per day) for an end goal of a 7% weight loss from baseline.
89615652|NCT03129048|Experimental|MedDiet-A|For the MedDiet-A group, dietary advice and corresponding exchange lists will be given within the context of promoting weight stability.
89615653|NCT03129048|Other|Typical Diet Control (TDC)|Typical Diet Control (TDC) will maintain current eating and activity patterns and weight over 14 months.
89615654|NCT04450290|Experimental|single arm - treatment|All subjects will be implanted with the investigational device.
89615655|NCT00633477|Experimental|Resatorvid 2.4 mg/kg/day|
89615656|NCT00633477|Placebo Comparator|Placebo|
89615657|NCT03128970|No Intervention|frozen/thawed|blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing.
89615658|NCT03128970|Experimental|synchronized frozen/thawed hatching blastocysts|blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage
89615659|NCT03128736|Experimental|dexlansoprazole group|dexlansoprazole 60mg
89615660|NCT03128736|Experimental|esomeprazole group|esomeprazole 40mg
89615661|NCT01923207|Experimental|DX-2930|DX-2930 administered by subcutaneous route
89615662|NCT01923207|Placebo Comparator|placebo|inactive formulation of DX-2930
89615663|NCT01218958|Experimental|Medisorb naltrexone 190 mg|
89615664|NCT01218958|Experimental|Medisorb naltrexone 380 mg|
89615665|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 190 mg|
89615666|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 380 mg|
89615667|NCT00340899||Pregnant women|Pregnant women with gestational age between 6 and 22 weeks
89615668|NCT03444246|Experimental|Iodine free diet group|The arm with non iodized salt，the subject in the non iodized salt group used the iodized salt for the first three months, and the iodized salt was changed after three months.
89615669|NCT03444246|Active Comparator|Normal iodine diet group|The arm with iodized salt，the subject in the control group were consumed with iodized salt within six months.
89615670|NCT04377360|Experimental|Diffusing Alpha-emitter Radiation Therapy (DaRT)|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. Tumor response to DaRT will be assessed periodically 3 months after removal.
89615671|NCT04752228|Experimental|ACE Screen|"At the initial visit, the Philadelphia ACE Survey, a validated ACE questionnaire, will be administered by a research coordinator. A Lifestyle Assessment package will also be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire. Patients who test positive for ACE will receive a 3-page printed ACE Resource Pack.~At 3 months, the Lifestyle Assessment will be administered again.~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
88986596|NCT00492934|No Intervention|2|No daily injections with hormones
88986597|NCT01243723|Experimental|Eductyl suppository|
88986598|NCT01243723|Placebo Comparator|Placebo suppository|
88986599|NCT02274454|Active Comparator|1.25mM Calcium-NO oxytocin pretreatment|
88986600|NCT02274454|Active Comparator|2.5mM Calcium-NO oxytocin pretreatment|
88986601|NCT02274454|Active Comparator|5.0mM Calcium-NO oxytocin pretreatment|
88986602|NCT02274454|Active Comparator|1.25mM Calcium-WITH oxytocin pretreatment|
88986603|NCT02274454|Active Comparator|2.5mM Calcium-WITH oxytocin pretreatment|
88986604|NCT02274454|Active Comparator|5.0mM Calcium-WITH oxytocin pretreatment|
88986605|NCT04760730|Experimental|Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29|Subjects will receive 1 intramuscular (IM) injection of 5 × 10^10 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 29
88986606|NCT04760730|Experimental|Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29|Subjects will receive 1 intramuscular (IM) injection of rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 1 followed by AZD1222 5 × 10^10 vp (nominal) on Day 29.
88986607|NCT00493051|Other|1|Standardized Wound Care
88986608|NCT00493051|Placebo Comparator|2|Placebo 1 dose
88986609|NCT00493051|Placebo Comparator|3|Placebo 2 doses
88986610|NCT00493051|Active Comparator|4|Active 1 dose
88986611|NCT00493051|Active Comparator|5|Active 2 doses
88986612|NCT00493129|Experimental|Ontak|Ontak administered intravenously on Days 1-5 at the dose of 9 µg/kg/day, with a rest period from Days 6-21.
88986613|NCT04750044|Experimental|early refeeding group|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed.
89035967|NCT02921984|Experimental|Docetaxel arm|Concurrent chemotherapy with Docetaxel if genetic testing show that the patient should be sensitive to this drug.
89035968|NCT02921984|Experimental|Pemetrexed arm|Concurrent chemotherapy with Pemetrexed if genetic testing show that the patient should be sensitive to this drug.
89035969|NCT02921984|Experimental|Cisplatin arm|Concurrent chemotherapy with Cisplatin if genetic testing show that the patient was nor sensitive to neither Pemetrexed nor Docetaxel
89615672|NCT04752228|Other|Lifestyle Assessment|"At the initial visit, no Philadelphia ACE Survey will be administered. The Lifestyle Assessment packaged will be provided for self-completion, featuring General Demographics, Cardiovascular and Medication History, Health Behaviours, the Short Form (36) Health Survey, the Patient Health Questionnaire-9, the General Anxiety Disorder-7 questionnaire, the Seattle Angina Questionnaire-7, and the modified Perceived Need for Card Questionnaire.~At 3 months, the Lifestyle Assessment will be administered again.~At 6 months, the Philadelphia ACE survey, Lifestyle Assessment, as well as a scale assessing their comfort level in being screened for ACE, disclosing their ACE status to their clinicians, and their confidence level in their clinicians' ability to help them manage their ACEs will be administered."
89615673|NCT03440268|Experimental|N Acetyl Cysteine|NAC in pre operatory 150mg/kg infusion in 2 hours. NAC during the surgery 50mg/kg in 6 hours. The influence of NAC will be assess in post operatory moment with routine exams
89615674|NCT03440268|Placebo Comparator|Placebos|Saline solution in pre operatory. Saline Solution duing the surgery. The post operatory datas of both groups will be compare
89615675|NCT04369014|Experimental|etomidate|
89615676|NCT04369014|Experimental|propofol|
89615677|NCT03436914|Experimental|PPI|Esomezol®
89615678|NCT03436836|Experimental|Group N|"group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline.~Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study"
89615679|NCT03436836|Active Comparator|Group C|Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline
89615680|NCT00331773|Active Comparator|Conventional 3D-CRT|Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
89615681|NCT00331773|Experimental|Hypofractionated 3D-CRT|Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions
89615682|NCT03440034|Experimental|Pioglitazone|All subjects will be provided Pioglitazone 15mg tablets, total dose of 45mg (3 tablets) for oral administration once daily. 32-week treatment period.
89615683|NCT04708938|Experimental|Treatment group|High voltage electrical stimulation + exercise therapy
89615684|NCT04708938|Active Comparator|Control group|Exercise therapy
89615685|NCT03436524||Training cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the development of the risk stratification model
89615686|NCT03436524||Validation cohorts|Cohorts of chronic lymphocytic leukemia patients at Binet A stage for the validation of the risk stratification model
89615687|NCT03436446||Orthopedic Patients|Orthopedic patients will undergo an interview with the research team regarding the framing of various social incentives to promote increased response rates for patient reported outcome measures post-operatively.
89615688|NCT03439956||Transvaginal specimen extraction (cases)|Pregnant women that underwent previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
89615689|NCT03439956||Controls|Pregnant women that did not undergo previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
89615690|NCT03439878|Experimental|Galactose|Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
89615691|NCT03439878|Active Comparator|Glucose|Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
89035970|NCT02921867|Experimental|Intervention group|Simulation-based training in nine modules with optional training times and ending with an obligatory certification test before traditional training is started. Traditional training time unaltered: six weeks.
89035971|NCT02921867|No Intervention|Traditional training|Six weeks focused stay at an ultrasound ward with day to day one-on-one supervision (current practise)
89035972|NCT05467566|Experimental|Stimulation + exercise group|30-minute exercise program (based on Pilates method) combined with active transcranial direct current stimulation.
89035973|NCT05467566|Sham Comparator|Sham stimulation + exercise group|This arm will perform the same procedures of experimental group but the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
89035974|NCT02921945|Experimental|SCT800|
89035975|NCT04689230|Active Comparator|upper eyelid blepharoplasty|"traditional upper eyelid blepharoplasty : upper eyelid entire length incision followed by proper dissection medially to medial pad fat.~medial pad fat identification and excision. closure of the wound with subcuticular 6/0 vicryl suture"
89057330|NCT04540679|Active Comparator|Inpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the inpatient program
89615692|NCT04327518|Experimental|TECNIS® Toric II|Subjects will be implanted in one or both eyes with the study lens
89615693|NCT03439800|Experimental|Mental and Physical Practice|"Action observation: is defined as the observation of the motor action, in this study, through a video.~Mental Practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical Practice: is the execution of the motor action."
89615694|NCT03439800|Active Comparator|Physical Practice|Physical Practice: is the execution of the motor action.
89615695|NCT04760223|Experimental|Video intervention 1|We presented a 100-second video to study participants to reduce stigma towards depression (a boy presenter). The protagonist discussed his own depression and how getting help assist him.
89615696|NCT04760223|Experimental|Video intervention 2|We presented a 100-second video to study participants to reduce stigma towards depression (a girl presenter). The protagonist discussed his own depression and how getting help assist her.
89615697|NCT04760223|Placebo Comparator|control video 1|A 100-second video presenting a boy without depression
89615698|NCT04760223|Placebo Comparator|control video 2|A 100-second video presenting a girl without depression
89615699|NCT03439722||Patients|Episodic cluster headache patients will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
89615700|NCT03439722||Controls|Controls will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
89615701|NCT00244101|Active Comparator|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
89615702|NCT00244101|Experimental|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
89615703|NCT00244101|Experimental|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
89615704|NCT04959708|Active Comparator|Control group|Participants in the control group will have the same exposure in time as the intervention group and will be asked to maintain their lifestyle during the whole study and to refrain from starting any new regular physical activity. In case they can not maintain the same lifestyle during the study period, they will be asked to inform the researchers at any of the assessments.
89615705|NCT04959708|Experimental|Intervention group|The intervention group will consist of the Ínsula method. Insula method will be developed twice a week for 12 weeks online form through videoconference platform. The intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
89615706|NCT03436212|Other|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device for 14 days
89615707|NCT02337465|Experimental|Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)|Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
89615708|NCT03436134|Active Comparator|Plasma Exchange Group|Patients receiving Exchange plasma as a treatment of chronic antibody mediated rejection.
89615709|NCT03436134|Experimental|Double filtration PlasmaPheresis Group|Patients receiving double filtration plasmapheresis as a treatment of chronic antibody mediated rejection.
89615710|NCT00633243|Experimental|Modified Directly Observed Therapy (mDOT)|Hepatitis C Virus (HCV) Treatment in Modified Directly Observed Therapy (mDOT) in Methadone Maintenance Treatment (MMT)
89615711|NCT00633243|Active Comparator|Self-Administered Therapy at Liver Specialty Clinic (SAT)|Hepatitis C virus (HCV) at a liver specialty clinic as self-administered therapy
89615712|NCT03439566||Total hip arthroplasty|No intervention will take place. Only registration and data collection of patient´s care and treatment will take place. There will be no changes in patient´s treatment.
89615713|NCT04759677|Active Comparator|the situation where the accelerometer is placed on the wrist during active video games playing|In one session the accelerometer will place on the dominant wrist Individuals will instructed not to remove and instruct them to wear the device during the session.
89615714|NCT04759677|Active Comparator|the situation where the accelerometer is placed on the hip during active video games playing|"In one session the accelerometer will place on a flexible belt by attaching to the hip area at the intersection of the dominant wrist and axillary line.~Individuals will instructed not to remove and instruct them to wear the device during the session."
89615715|NCT04451382||OnabotulinumtoxinA (BoNTA)|DRUG: OnabotulinumtoxinA (BoNTA) is an injection into the bladder which blocks the presynaptic release of acetylcholine. BoNTA was approved for the treatment of OAB by the FDA in 2013.
89615716|NCT04451382||Percutaneous tibial nerve stimulation (PTNS)|DEVICE: PTNS involves needle stimulation of the posterior tibial nerve and is typically performed with weekly 30 minute sessions for a 12 week treatment course.
89615717|NCT04276389|Active Comparator|OCT-guided arm|
89615718|NCT04276389|Placebo Comparator|Angiography-guided arm|
88986614|NCT04750044|Active Comparator|delayed refeeding group|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2.
88986615|NCT00126542|Experimental|Treatment (bevacizumab, erlotinib hydrochloride)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral erlotinib once daily on days 1-21. Treatment repeats every 21 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to 1 of the study drugs may continue treatment with the remaining study drug alone in the absence of disease progression or unacceptable toxicity.
88986616|NCT00493324|Experimental|1|
88986617|NCT01243801|Active Comparator|Epidural ketamine|"Bolus of epidural ketamine during the induction of anesthesia~Epidural infusion of ketamine during the first 48 h after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
88986618|NCT01243801|Active Comparator|Intravenous ketamine|"Bolus of intravenous ketamine administered during the induction of anesthesia~Intravenous infusion during the first 48 hours after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine plus fentanyl"
88986619|NCT01243801|Placebo Comparator|Placebo|"Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
88986620|NCT00126620|Experimental|OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)|Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.
88986621|NCT01243879|Active Comparator|Fasting with stimuli|Fasting in the presence of food-related stimuli
88986622|NCT01243879|Sham Comparator|Fasting without stimuli|Fasting in the absence of food-related stimuli
88986623|NCT01243918|Experimental|VNI/Optiflow, Immunodeficient patients|VNI = non invasive ventilation
88986624|NCT01243918|Experimental|Optiflow/VNI, Immunodeficient patients|VNI = non invasive ventilation
88986625|NCT01243918|Experimental|Ospal/Optiflow, Immunocompetent patients|
88986626|NCT01243918|Experimental|Optiflow/Ospal, Immunocompetent patients|
88986627|NCT00493363|Experimental|arm 1|
88986628|NCT00493363|Active Comparator|arm 2|
88986629|NCT00493402|Experimental|combined chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, with particle embolization.
89035976|NCT04689230|Experimental|small incision technique|"medial upper eyelid 4 mm length incision followed by proper dissection medially to medial pad fat.~medial pad fat identification and excision. closure of the wound with interrupted 6/0 vicryl sutures"
89615719|NCT03128658||Trauma patients|Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.
89615720|NCT01923441||Highschool athletes|
89035977|NCT04689269|Active Comparator|McGrath-King Vision|The participants will attempt double-lumen tube intubation using the McGrath (X-blade) laryngoscope then they will use the King Vision (channelled blade size 3) in the same order.
89035978|NCT04689269|Active Comparator|King Vision-McGrath|The participants will attempt double-lumen tube intubation using the King Vision (channelled blade size 3) then they will use the McGrath (X-blade) laryngoscope in the same order.
89615721|NCT01923441||midschool athletes|
89615722|NCT03128814||Elite (pre)adolescent tennis players|
89615723|NCT03128814||Age- and gender-matched controls|
89615724|NCT03128619|Experimental|Arm A (copanlisib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression, or unacceptable toxicity.
89615725|NCT03128619|Experimental|Arm B (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive copanlisib (MTD) IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89615726|NCT03128619|Experimental|Arm C (copanlisib, palbociclib, letrozole)|PHASE II: Patients receive palbociclib PO QD for days 1-14 of course 1 and letrozole PO continuously on days 1-14. Patients then undergo biopsy. Patients then receive copanlisib IV over 1 hour on days 1, 8, and 15 and letrozole PO continuously on days 1-28. Treatment with copanlisib (MTD) and letrozole repeats every 28 days for up to 3.5 courses in the absence of disease progression or unacceptable toxicity.
89615727|NCT03128619|Experimental|Phase Ib (copanlisib, palbociclib, letrozole)|PHASE Ib: Patients with metastatic breast cancer receive copanlisib IV over 1 hour on days 1, 8, and 15, palbociclib PO QD on days 1-21, and letrozole PO continuously on days 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89615728|NCT04451616||Group A - study group - patients with metabolic syndrome|"Patients with metabolic syndrome will be included.~Procedures:~blood sample collection~hair sample collection~urine sample collection~body composition analysis~questionnaires~blood pressure, pulse and blood oxygen saturation measurement"
89615729|NCT04451616||Group B - control group - patients without metabolic syndrome|"Patients without metabolic syndrome will be included.~blood sample collection~hair sample collection~urine sample collection~body composition analysis~questionnaires~blood pressure, pulse and blood oxygen saturation measurement"
89615730|NCT03433092||Jing Huang et. al, 2017|
89615731|NCT03433092||Max Leenders et. al,2014|
89615732|NCT03433092||Yusuke Okuyama et. al,2014|
89615733|NCT03433092||GC Kabat et. al,2012|
89615734|NCT03433092||Christina Persson et. al,2008|
89615735|NCT03433092||M Jenab et. al,2006|
89615736|NCT03433092||Kenji Wakai et. al,2005|
89615737|NCT03433092||Christian C. Abnet et. al,2003|
89615738|NCT03433092||N Malila et. al,2002|
89615739|NCT03433092||G Pappalardo et. al,1997|
89615740|NCT04451538|Experimental|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g [12 spoon, 500 kcal]/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g [12 spoon, 440 kcal]/day, twice a day).
89615741|NCT04451538|Placebo Comparator|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
89035979|NCT01285609|Experimental|Ipilimumab + Paclitaxel and Carboplatin|"Ipilimumab + Active Chemo Backbone~Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
89615742|NCT03433014|Active Comparator|0.5% Levobupivacaine|The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision.
89615743|NCT03433014|Other|Control|The control group will not receive any local infiltrative agent.
89615744|NCT01872689|Placebo Comparator|Monotherapy (Cohort A): Placebo|Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
89615745|NCT01872689|Experimental|Monotherapy (Cohort A): Lebrikizumab|Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
89615746|NCT01872689|Placebo Comparator|Combination Therapy (Cohort B): Placebo + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
89035980|NCT01285609|Placebo Comparator|Placebo + Paclitaxel and Carboplatin|"Placebo + Active Chemo Backbone~Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
89615747|NCT01872689|Experimental|Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
89615748|NCT04678908|Experimental|HB0025|HB0025 IV every 2 weeks (q2w)
89615749|NCT03999606|Active Comparator|Mindfulness Training|Participants in the control group will be assigned to a online based mindfulness training.
89615750|NCT03999606|Experimental|Music Training|Participants in the experimental group will be assigned to a online based choir program.
89615751|NCT03435978||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
89615752|NCT03435978||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
89615753|NCT03435900|Experimental|Intervention group|
89615754|NCT03435900|Active Comparator|Control group|
89615755|NCT00632931|Experimental|A|Arm A: Drug/Placebo
89615756|NCT00632931|Experimental|B|Arm B: Placebo/Drug
89615757|NCT04666974|Experimental|Phase 3: iCBT + Treatment As Usual|CWs in the iCBT group, will be assigned to one the six therapy modules, based on their gender and diagnosis (i.e. Female/Male * GAD, MDD or PTSD). Each CW will be assigned a specific clinician (a trained psychiatrist/psychologist/ social worker) who would be their care liaison through the study. Each week, the clinician would send one session of the 12-session curriculum to the CW on a pre-determined day of the week. Each weekly session consists of 20-30 slides followed by a homework assignment. It usually takes 40-60 minutes for a participant to complete one weekly session which they have to complete by a specific day of the week. The clinician will review the CW's assignments and provide feedback on their performance. The clinician feedback is structured and takes approximately 15 minutes to complete. The clinician will then send the content for the next session along with the feedback.
89615758|NCT04666974|No Intervention|Phase 3: Treatment as Usual|Participants will complete clincally validated questionnaires to measure symptoms while continuing with their regular daily activities and treatments (if any) (i.e., exercise, diet, medications, etc.)
89615759|NCT04666974|Experimental|Phase 4: iCBT + Treatment as Usual|Participants will be randomly assigned to this group and take part in the iCBT module program from phase 3.
89615760|NCT04666974|Active Comparator|Phase 4: In-Person CBT + Treatment as Usual|Participants will be randomly assigned to this group and complete in-person CBT with similar content, homework, and feedback as in the iCBT + TAU group. All in-person CBT will be delivered by a trained professional and each session will take approximately 60-75 minutes.
89615761|NCT01857323|Experimental|Albuterol Spiromax®|The approximate 50-day treatment period consisted of 180 mcg (90 mcg/dose cycle, 2 dose cycles) twice daily study medication administration with Albuterol Spiromax with dose-counter.
89615762|NCT03439488|Experimental|Part 1 (Healthy Participants): Single Ascending Dose (SAD)|Participants in Cohorts 1 to 5 and 3 optional cohorts (Cohorts 6, 7 and 10) will receive a single dose of JNJ-440/placebo on Day 1. Two cohorts will receive a second dose of JNJ-440/placebo in a fed state (participants from Cohort 3 will also participate in Cohort 8) or as an alternative JNJ-440 formulation (participants from Cohort 2 will also participate in optional Cohort 9) after a washout window of at least 10 days. In Cohorts 1 to 4, study drug will be administered under fasted conditions; in the remaining cohorts, study drug will be administered under fasted/fed conditions depending on the results of the food effect evaluation.
89615763|NCT03439488|Experimental|Part 2 (Healthy Participants): Multiple Ascending Dose (MAD)|Participants in Cohorts 1 and 2 will receive a once daily dose of JNJ-440/placebo for the duration of 7 days under fasted or fed conditions. Participants in an optional cohort (Cohort 3) may receive a once daily or twice daily dose of JNJ-440/placebo for the duration of 7 or 14 days under fasted or fed conditions. The starting dose for Cohort 1 in Part 2 will be determined by the Sponsor in consultation with the Principal Investigator based on the data from Part 1. Dose escalation will be performed only after review of safety and pharmacokinetic (PK) data after a minimum of 7 days of study drug administration.
89615764|NCT03439488|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD|Participants in Cohorts 1 and 2 and 3 optional cohorts (Cohorts 3, 4, and 5) will receive multiple ascending doses of JNJ-440/placebo once daily or twice daily for 28 days under fed or fasted conditions. The starting dose and formulation for Cohort 1 will be determined based on the review of available data in healthy participants from Part 1 (SAD) and Part 2 (MAD). Dose escalation will be performed only after review of safety, tolerability, and PK data after a minimum of 14 days of study drug administration from at least 8 CHB participants.
89615765|NCT03435822|Other|asthma action plan management group|Patients in this group will be provided both written asthma action plan and mobile-based APP to remind them take medicine regularly and direct them what to do when asthma get worse.
89615766|NCT03435822|Other|conventional management group|Patients in this group will be provided conventional management method with prescriptions and asthma diaries.
89035981|NCT02921672|Active Comparator|Cognitively Normal|Persons who are considered to have normal cognitive function. A registered dietician will meet with each person to discuss the Mediterranean Diet.
89615767|NCT03104439|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously 3 times per cycle~Ipilimumab will be administered intravenously once per cycle~Radiation Therapy will be administered per hospital standard"
89615768|NCT03432780|Experimental|Docetaxel, hormone and radiation therapy|Radiation therapy combined with weekly docetaxel (20 mg/m2) and hormone therapy.
89615769|NCT03432780|Active Comparator|Hormone and radiation therapy|Radiation therapy and hormone therapy
89035982|NCT02921672|Active Comparator|Mild Cognitive Impairment|Persons diagnosed mild cognitive impairment (MCI). A registered dietician will meet with each person to discuss the Mediterranean Diet.
89615770|NCT00055731|Experimental|Chemotherapy|
89615771|NCT00055731|Active Comparator|Without Chemotherapy|
89615772|NCT03432702|Active Comparator|Alveolar ridge augmentation without ABG|Horizontal ridge augmentation using guided bone regeneration without autogenous block graft (ABG)
89615773|NCT03432702|Experimental|Alveolar ridge augmentation with ABG|Horizontal ridge augmentation using guided bone regeneration with autogenous block graft (ABG).
89615774|NCT03435744|Experimental|Simvastatin with TAU|Participants will receive Simvastatin 20 mg added to TAU for 3 months
89615775|NCT03435744|Placebo Comparator|Placebo Oral Tablet with TAU|Participants will receive placebo added to TAU for 3 months
89615776|NCT03975504|Other|LDCT Screening|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
89615777|NCT03439410||Internal Medicine ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
89615778|NCT03439410||Subacute ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
89615779|NCT03435666|Experimental|Capecitabine|Capecitabine is the test product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) Capecitabine.
89615780|NCT03435666|Active Comparator|XELODA|XELODA is the reference product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) XELODA.
89615781|NCT00632541|Experimental|Single Arm A|Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle
89615782|NCT01872611|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
89615783|NCT01872611|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
89210905|NCT04085081|Experimental|Supportive care (coaching call, motivational messages)|Patients and family caregivers complete comprehensive geriatric and functional assessments before surgery. This information is used to develop a personalized walking program plus simple lower extremity strength exercises. The intervention is administered by trained coaches with physical and occupational therapy background. The sessions are delivered by telephone before surgery (30-60 minutes), and on days 2, 7, 14, and 21 after hospital discharge (20-50 minutes). Participants will also receive brief motivational text or email messages (4 times per week between telephone sessions) to provide support, promote physical activity behavior change, and to sustain participant engagement.
89210906|NCT00907686||LBWIs of CMV-positive mother|LBWIs born to CMV-positive mothers
89210907|NCT00907686||CMV Sero-negative & Sero-postive LBWIs|LBWIs of CMV sero-negative & sero-positive mothers
89615784|NCT04451148||Obese subjects|Subjects with obesity
89615785|NCT04451148||Obese plus metabolic syndrome subjects|Subjects with obesity and metabolic syndrome
89615786|NCT04451148||Healthy controls|Otherwise healthy subjects
89615787|NCT03432624||Experiment Subgroup, Group One|Experiment Subgroup, Group One consists of pancreatic cancer patients, in which 120 are operable, and 120 are not operable.
89615788|NCT03432624||Control Subgroup, Group One|Control Subgroup, Group One consists of 150 patients, in which 30 are of gallbladder carcinoma, 60 are of biliary tract lower segment carcinoma, 60 are of gastrointestinal carcinoma.
89615789|NCT03432624||Interference Subgroup, Group One|Interference Subgroup, Group One consists of 150 patients, in which 60 are of chronic pancreatitis, 90 are of other types of pancreatic tumor, in which 30 are of IPMN (intraductal papillary mucinous neoplasm), 30 are of SPT (solid pseudopapillary tumor of pancreas), and 30 pancreatic cystic adenoma.
89615790|NCT03432624||Experiment Subgroup, Group Two|Group Two consists of 210 patients selected from Group One, of which the Experiment Subgroup, Group Two consists of the 120 operable pancreatic cancer patients who have had successful surgery.
89615791|NCT03432624||Control Subgroup, Group Two|Control Subgroup, Group Two consists of 90 patients of other cancers who have had successful surgery, in which 30 are of gallbladder carcinoma, and 60 are of biliary tract lower segment carcinoma.
89615792|NCT04607681|Experimental|1 GROUP|"Patients who agree to participate in the study will be informed about the study and their written and verbal consent will be obtained. At this stage, which will last 6 weeks for each patient;~On the first day, the patients will be evaluated first by filling the Individual Descriptive Features Form, Information Need Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices,~In order for the patients in the intervention group to use the web-based asthma education program, a web-based asthma education program will be introduced by giving their username and password.~After 6 weeks of training, second data will be collected on the web in the intervention group."
89615793|NCT04607681|No Intervention|2 GROUP|"Written and verbal consents will be obtained from patients who agree to participate in the study by providing information about the study.~At this stage, which will take 6 weeks for each patient; On the first day, the patients will first be evaluated by filling the Individual Descriptive Characteristics Form, Information Requirement Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices, Second data after 6 weeks will be collected in the control group via Google form or phone call"
89615794|NCT03089853|Experimental|Intervention Arm|Subjects randomized to intervention arm will have a device applied to their thigh on either side, and subject to neuromuscular electrical stimulation for 30 minutes daily for 2 weeks, followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
89615795|NCT03089853|No Intervention|Usual Care Arm|Usual care will consist of a protocolized regimen of 5 days of systemic steroids, unless the treating physician determines a different regimen, in which case the change will be documented.
89615796|NCT03439176|Experimental|Test of new adhesive strips|"The subjects will test adhesives strips made of 4 different adhesives:~Standard adhesive 1 Standard adhesive 2 PL4 PL16-L"
89615797|NCT03432468|Active Comparator|postmenopausal hypertensive women|
89615798|NCT03432468|Placebo Comparator|age-matched hypertensive male patients|
89615799|NCT03086967|Active Comparator|Six Hour|Placement of foley catheter and extrusion after 6 hours followed by induction.
89035983|NCT02921672|Experimental|Mild to Moderate Alzheimer's Disease|Persons diagnosed with mild to moderate Alzheimer's disease (AD). A registered dietician will meet with each person to discuss the Mediterranean Diet.
89615800|NCT03086967|Active Comparator|Twelve Hour|Placement of foley catheter and extrusion after 12 hours followed by induction.
89615801|NCT03435588|Active Comparator|EUS-FNA with ROSE|EUS-FNA with ROSE is performed with a 22 or 25 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.
89615802|NCT03435588|Experimental|EUS-FNB alone|EUS-FNB is performed with a 22 or 25 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. The biopsied samples are then expressed using a stylet into a jar filled with 10% formalin. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist.
89615803|NCT01856543|Placebo Comparator|Eucerin|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Pts should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
89615804|NCT01856543|Experimental|Mometasone Furoate 0.1%|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Patients should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
89615805|NCT03435432|Active Comparator|Glucose|50 grams of glucose in 50 ml water
89615806|NCT03435432|Placebo Comparator|Water|50 ml water
89615807|NCT03439098|Experimental|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg/day
89615808|NCT03439098|Experimental|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg/day
89615809|NCT03439098|Placebo Comparator|Placebo|Placebo
89615810|NCT03439020|Experimental|FCSEMS + Plastic|"Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture and insert an additional plastic stent to anchor the metal stent.~(Plastic stent anchoring)"
89615811|NCT03439020|Active Comparator|FCSEMS|Insert only a fully covered self expandable metal stent (FCSEMS) without a plastic stent for malignant biliary stricture.
89615812|NCT03432312|Experimental|Nicotine 4 mg mint lozenges|
89615813|NCT03432312|Active Comparator|NiQuitin 4 mg mint lozenges|
89615814|NCT03438942|Experimental|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
89615815|NCT03438942|Active Comparator|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
89615816|NCT03438864|Experimental|10 Hz|Interferential current, entry frequency 4000 Hz and 4010 Hz, beat frequency 10 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
89615817|NCT03438864|Experimental|100 Hz|Interferential current, entry frequency 4000 Hz and 4100 Hz, beat frequency 100 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
89615818|NCT03438864|Sham Comparator|Placebo-Sham Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
89615819|NCT03432234||COPD and frequent exacerbation|Patient with COPD diagnosis and at least two exacerbations by year (FE)
89615820|NCT03432234||COPD no frequent exacerbation|Patient with COPD diagnosis with no frequent exacerbation, less than 2 by year (NE).
89615821|NCT03432234||Healthy (control)|Healthy volunteers patients (H)
89615822|NCT03432156|Experimental|Experimental group|subjects who are treated with autologous Tcm cells immunotherapy
89615823|NCT03432156|No Intervention|No intervention group|subjects who are treated without autologous Tcm cells immunotherapy
89035984|NCT04689984|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and astaxanthin 6 mg tablet once daily (experimental group).
89035985|NCT04689984|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline.
89035986|NCT02921711||LVIS®|
89035987|NCT05467254|Experimental|CLL1+CD33 CAR-T|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
89035988|NCT03981341|Experimental|Post menopausal sleep apnea|Post menopausal women with severe sleep apnea
89035989|NCT03981341|Experimental|Post menopausal non sleep apnea|Post menopausal women without sleep apnea
89035990|NCT04620057|Experimental|Butyrate + standard care for pediatric obesity|standard care for pediatric obesity + sodium butyrate (20 mg/kg body weight/day)
89035991|NCT04620057|Placebo Comparator|placebo + standard care for pediatric obesity|standard care for pediatric obesity + placebo (cornstarch)
89615824|NCT04451070||Family Medicine resident physicians|Family Medicine resident physicians at David Grant Medical Center who started their Family Medicine residency at David Grant Medical Center between June 2018 - June 2019 and are scheduled to graduate from Family Medicine residency between June 2021 - June 2022.
89615825|NCT03438786|Experimental|group A|Patients undergoing trans-inguinal pre-peritoneal (TIPP) hernioplasty
89615826|NCT03438786|Experimental|group B|Patients undergoing lichtnestein's hernioplasty
89615827|NCT03438708|Experimental|Axitinib Oral Tablet [Inlyta]|Axitinib 5 mg PO BID for 8-10 weeks
89210908|NCT05613309||patients with acute varicose hemorrhage in Renmin Hospital of Wuhan University in recent 10 years|In this study, patients with liver cirrhosis and acute variceal bleeding in Renmin Hospital of Wuhan University in the past 10 years will be selected as the research objects. Patients will be divided into survival and death groups according to whether they died 6 hours after admission. The differences in clinical data between the two groups will be compared and analyzed to decide the risk factors for early death and establish a mortality risk prediction model.
89615828|NCT00632463|Experimental|1|Dose regimen 1
89615829|NCT00632463|Experimental|2|Dose regimen 2
89615830|NCT00632463|Placebo Comparator|3|Placebo
89615831|NCT03435276|Experimental|Cohort 1|Randomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7
89615832|NCT03435276|Experimental|Cohort 2|Randomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
89615833|NCT03435276|Experimental|Cohort 3|Randomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
89615834|NCT01923597|Active Comparator|Green tea extract|Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
89615835|NCT01923597|Placebo Comparator|Placebo (celulose)|Patients will receive four capsules of placebo (celulose) daily for 3 months.
89615836|NCT00632229|Experimental|Paliperidone|Recieves study medication called paliperidone
89615837|NCT00632229|Placebo Comparator|Pill placebo|Placebo comparator
89615838|NCT03435120||Breakthrough Cancer Pain|No intervention (Non Interventional Study)
89615839|NCT01923675|Experimental|color blocking tint|Spectacles with red-blocking tint subjects will wear glasses daily for 6 months and have
89615840|NCT01923675|Other|holographic diffuser|Spectacles with color neutral tint subjects will wear glasses daily for 6 months and have
89615841|NCT01923675|Other|diffuser & color blocking tint|Spectacles with holographic diffuser and red-blocking tint subjects will wear glasses daily for 6 months and have
89615842|NCT01923675|Other|holographic diffuser and neutral tint|Spectacles with holographic diffuser and color neutral tint subjects will wear glasses daily for 6 months and have
89615843|NCT03431922|Experimental|endovascular denervation|endovascular denervation
89615844|NCT03128502||healthy control|Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.
89615845|NCT03128502||plaque induced gingivitis|Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.
89615846|NCT03128502||chronic periodontitis|Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.
89615847|NCT03128502||aggressive periodontitis|Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL >5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).
89615848|NCT01923753|Experimental|Aerosure 15 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure. Order of presentation is randomised."
89615849|NCT01923753|Active Comparator|Aerosure 25 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
89615850|NCT01923753|Sham Comparator|Aerosure sham|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
89615851|NCT00631137|Placebo Comparator|Arm 1: Control Group|whey protein powder
89035992|NCT01285492|Experimental|QVA149|QVA149 110/50 μg once a day (o.d)
89035993|NCT01285492|Active Comparator|Tiotropium|tiotropium 18 μg o.d.
89035994|NCT02889991|Experimental|High Intensity Dry Needling|Maneuver of Input-Output with the acupuncture needle, until the disappearance of local twitch responses or patient tolerance.
89035995|NCT02889991|Experimental|Low Intensity Dry Needling|Maximum 10 input-output maneuvers with acupuncture needle or maximum 3 local twitch responses or patient tolerance.
89035996|NCT02889991|Experimental|Fascial mechanotransduction Dry needling|Maneuver of input, screwing and pulling out of the needle acupuncture.
89035997|NCT02889991|Sham Comparator|Placebo Dry Needling Technique|"Technique is performed with the Park´s Sham device."
89035998|NCT04615143|Experimental|Tislelizumab|Tislelizumab is one kind of PD-1 inhibitors. Patients enrolled will receive Tislelizumab as neoadjuvant treatment before surgery (200mg q3w*2 cycles) and as adjuvant treatment after surgery for 1 year
89520269|NCT04436445|Active Comparator|Life style modification|"lifestyle modifications in the form of dietary recommendations, exercises and sleep quality improvement for 8 weeks.The life style modification followed in the treatment: Avoid consumption of all kinds of alcohol beverages. Avoid consumption of spicy foods, pepper, chili and coffee Follow a correct diet assuming each day 50% carbohydrates,30% fats and 20% proteins Increase your intake of fruits, vegetables and foods rich of natural fibers (dark bred, vegetables, spinaches).~8 hour sleep at night 40 minutes of walking 3time per week."
89520270|NCT05283161|Placebo Comparator|Placebo|10 participants will receive placebo (vehicle). The placebo will match the study drug in odor, taste, color and appearance. The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
89615852|NCT00631137|Active Comparator|ARM 2 : Treatment Group|Testosterone Gel (10g pouch/day) applied to skin
89615853|NCT03428880|Active Comparator|spinal morphine|intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.
89615854|NCT03428880|Active Comparator|quadratus lumborum block|"intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline.~Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side."
89615855|NCT01923831|Experimental|Magnesium group|
89615856|NCT01923831|Active Comparator|Dexamethasone group|
89615857|NCT01923909|Active Comparator|Intra-articular corticosteroid|Intra-articular corticosteroid injections Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
89615858|NCT01923909|Experimental|Intra-articular platelet-rich plasma|IA PRP procedure This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the suprapatellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
89615859|NCT03434886|Experimental|CF View|
89615860|NCT03434886|Active Comparator|CF Educational videos|
89615861|NCT03434886|Active Comparator|CF View and videos|
89615862|NCT03434886|No Intervention|Usual standard of care|
89615863|NCT03428724|Active Comparator|standard group|standard polyethylene glycol preparation for colonoscopy
89615864|NCT03428724|Experimental|individualized group|either a low or a high volume bowel preparation according to patient characteristics
89615865|NCT04450602|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR (Patent Pending) active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
89615866|NCT04450602|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
89615867|NCT04892940|Experimental|Virtual Reality group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
89615868|NCT04892940|Active Comparator|Control group|Adolescents aged 13 to 18 years who have undergone scoliosis surgery
89615869|NCT03305250|Active Comparator|Interventional Arm|Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
89615870|NCT03305250|No Intervention|Standard of Care Arm|The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
89615871|NCT03085563|Active Comparator|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method.
89615872|NCT03085563|Active Comparator|Intranasal Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.
89615873|NCT03431766|Placebo Comparator|control group A|on this group a placebo gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment.
89615874|NCT03431766|Experimental|test group B|on this group a 0.20% chlorhexidine gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment described on the study protocol.
89615875|NCT04450446||cerebral hemorrhage|
88986630|NCT00493402|Experimental|combined chemotherapy without embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, without particle embolization.
89520271|NCT05283161|Experimental|cannabidiol and tetrahydrocannabinol 1:1 (0.1 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (0.1 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
89520272|NCT05283161|Experimental|cannabidiol and tetrahydrocannabinol 1:1 (1.0 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (1.0 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
89615876|NCT04450446||thromboembolism|
89615877|NCT04450446||no thromboembolism and cerebral hemorrhage|
89615878|NCT03274752|Experimental|Paroxetine|Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week
89615879|NCT03274752|Placebo Comparator|Placebo|Placebo oral capsule QD per os for 13 weeks
89615880|NCT03428568|Experimental|Herbal Melanin|Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)
89615881|NCT03428568|Active Comparator|Nexium|omeprazole 40 mg once per day for one month.
89615882|NCT03428568|Experimental|H-Pylori infected : Herbal Melanin|Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)
89615883|NCT03428568|Active Comparator|nexium+ amoxil+clarithromycin|"omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.~Omeprazole+Amoxil+clarithromycin is the standard triple therapy given"
89615884|NCT03428568|Experimental|nexium +Herbal melanin|omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested
89615885|NCT03428568|Experimental|Herbal melanin+amoxil+ clarithromycin|Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested
89615886|NCT03431688|Active Comparator|PAM|treatment with PPI, metonidazole, amoxicillin
89615887|NCT03431688|Active Comparator|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
89615888|NCT00630825|Experimental|1.0/2.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks
89615889|NCT00630825|Experimental|1.0/1.0 milligram (mg) LY2189265|LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks
89615890|NCT00630825|Experimental|0.5/1.0 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks
89615891|NCT00630825|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks
89615892|NCT03431610|Experimental|SB414 2%|SB414 2% topically twice daily
89615893|NCT03431610|Experimental|SB414 6%|SB414 6% topically twice daily
89615894|NCT03431610|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
89615895|NCT03434574|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
89615896|NCT03434574|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
89615897|NCT03434496|Experimental|Experimental group|The investigators will enroll 30 patients with PD, randomly divided into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The 15 patients in the experimental group will perform training by means of the device Gait Trainer 3 (Biodex), where they will train on a tredmill equipped with music. They will walk following specific musical beets and rhythms so to entrain their own internal rhythm. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
89615898|NCT03434496|Active Comparator|Control Group|The control group will perform only conventional gait treadmill training, besides physical exercises to improve muscle force and tone. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
89615899|NCT03434340|Experimental|Granisetron & Dexamethasone & Peppermint essential oil|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn followed by Peppermint essential oil 2 drops on nasal strip applied for 6 hours
89615900|NCT03434340|Active Comparator|Granisetron & Dexamethasone|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn
89615901|NCT03431454|Active Comparator|home-based vision orthoptic therapy (HBVOT) group|In the home-based vision orthoptic therapy (HBVOT) group, patients were trained to do the pencil push-ups procedure 15 minutes per day, five days a week
89615902|NCT03431454|Active Comparator|office-based vision orthoptic therapy (OBVOT) group|In the office-based vision orthoptic therapy (OBVOT) group, 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed
89615903|NCT03431454|Active Comparator|augmented office-based vision orthoptic therapy (AOBVOT) group|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
89615904|NCT01923987|Experimental|SCRT/ChemoTx with Delayed Surgery|Short course radiotherapy (25 Gy in 5 fractions) followed by intensive chemotherapy, compromising of FOLFOX of FOLFIRI (+-Bevacizumab or Cetuximab), with delayed surgery for rectal cancer with synchronous distant metastasis
89615905|NCT02521350||Control|- older than 40 years patients with no specific gender, who will stay at least one night in hospital will be included into our study. And cardiovascular, urological surgery patients and patients with known renal insufficiency will be excluded.
89035999|NCT04615143|Experimental|Tislelizumab Combined Lenvatinib|Patients enrolled will receive Tislelizumab combined Lenvatinibas neoadjuvant treatment before surgery (Tislelizumab: 200mg q3w*2 cycles+Lenvatinib 8/12mg qd*4weeks) and as adjuvant treatment after surgery for 1 year
89210909|NCT03969979||testis with epididymo-orchitis|The patients' previously inflamed testis with epididymo-orchitis
89210910|NCT03969979||healthy testis|The patients' non inflamed testis
89615906|NCT03101163|Experimental|Intervention|Subjects randomized to the intervention group will undergo subchondral drilling surgery according to standard protocol, and will also receive a regimen of PBSC and HA intra-articular injections and postoperative physiotherapy.
89615907|NCT03101163|Active Comparator|Standard treatment|Subjects randomized to the standard treatment-controlled parallel group will receive intra-articular HA injections and a physiotherapy regimen.
89615908|NCT02521194|Experimental|Caregiver Questionnaire|Questionnaire completion regarding opinion on the inpatient occupational therapy session person being cared for received.
89615909|NCT02521194|Experimental|Patient Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
89615910|NCT01924065|Active Comparator|Transesophageal Echocardiography group|This arm includes the patients with atrial fibrillation who undergo transesophageal echocardiography-guided cardioversion
89615911|NCT01924065|Active Comparator|Oral anticoagulant Group|This arm includes the patients with atrial fibrillation who take warfarin or new oral anticoagulant agents three weeks before electrical cardioversion.
89615912|NCT03428412|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
89615913|NCT03428412|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
89036000|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard XP|The new Vanguard XP Total knee arthroplasty system is a further development of the Vanguard TKA. The new Vanguard XP system both cruciate ligaments are preserved.
89036001|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard CR|Total knee arthroplasty system without preservation of the anterior cruciate ligament
89036002|NCT05467137|Experimental|Standard of care + MSOT|Standard of care + MSOT
89036003|NCT02933463|Experimental|embrace wetbond sealant|moisture tolerant resin based, have same properties of other sealant
89615914|NCT03431298|Experimental|Aerobic exercise & movement control|"The duration of intervention is 8 weeks.~Individualized functional movement control training is 60 min/week~Aerobic exercise is 60 min/week"
89615915|NCT03431298|Active Comparator|Aerobic exercise|"The duration of intervention is 8 weeks.~Frequency: 2 times/ week~Duration: 60min/ time"
89615916|NCT00638703|Experimental|I|Size 2 enteric coated capsule containg lyophilized Oxalobacter formigenes
89615917|NCT00638703|Placebo Comparator|II|Size 2 enteric coated capsule containg placebo
89615918|NCT03431220|Experimental|RENASYS TOUCH NPWT System|Negative Pressure Wound Therapy (NPWT)
89615919|NCT01924143|Experimental|TD-9855|
89615920|NCT03434106|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
89615921|NCT03434106|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
89615922|NCT03434106|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
89615923|NCT03434106|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
89615924|NCT01924377|Other|standard circumferential pulmonary vein isolation (CPVI)|standard circumferential pulmonary vein isolation by radiofrequenvy ablation
89615925|NCT01924377|Experimental|CPVI + Rotor|standard circumferential pulmonary vein isolation + rotors' identification and ablation'
89615926|NCT03428334|Experimental|Oral roflumilast|oral roflumilast 500 microgram daily for 4 weeks
89615927|NCT01924611|Active Comparator|Control Group|Atraumatic Restorative Technique using cotton rolls.
89615928|NCT01924611|Experimental|Experimental Group|Atraumatic Restorative Technique using rubber dam.
89615929|NCT01241344|Active Comparator|Brincidofovir|"Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
89615930|NCT01241344|Placebo Comparator|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
89615931|NCT01925001|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
89615932|NCT01925001|Active Comparator|Sodium chloride solution|Normal saline (0.9% Sodium Chloride Injection USP)administered intravenously
89036004|NCT02933463|Active Comparator|clinpro sealant|is a dental resin, with low viscosity , fluoride releasing with a unique patented color change.
89036005|NCT02921633|Experimental|Intervention letter|Centrally-sent behavioural-insight informed invitation letter.
89036006|NCT02921633|No Intervention|Control|No centrally-sent invitation letter.
89036007|NCT01284634|Experimental|GWP42003 200 milligrams (mg)/day Dose|Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
89036008|NCT01284634|Experimental|GWP42003 400 mg/day Dose|Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
89036009|NCT01284634|Experimental|GWP42003 800 mg/day Dose|Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
89036010|NCT01284634|Experimental|Placebo|Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.
89615933|NCT03128580||Natural Cycle|The patient will not undergo hyperstimulation rather a natural cycle
89615934|NCT03128580||Stimulated Cycle|The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.
89615935|NCT03009682|Other|Olaparib 300 mg|Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days
89615936|NCT03431142|Experimental|Clopidogrel monotherapy|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.
89615937|NCT03431142|Active Comparator|Clopidogrel plus aspirin|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.
89615938|NCT02521272|Experimental|air pocket|Breathing in the simulated avalanche snow.
89615939|NCT03831321|Active Comparator|Diclofenac group|The group who are 50 mg Diclofenac Sodium and lubricant gel administered one hour before cystoscopy and local
89615940|NCT03831321|Placebo Comparator|Placebo|The group who are not administered 50 mg Diclofenac Sodium before cystoscopy and administered lubricant gel just before local cystoscopy
89615941|NCT01285024|No Intervention|Control|No Vitagel used during total hip arthroplasty
89615942|NCT01285024|Experimental|Vitagel|Vitagel applied just prior to closure during total hip arthroplasty
89615943|NCT03430908||Participants with an endotracheal tube|Participants undergoing general anesthesia with an endotracheal tube will have a gastric tube blindly inserted by an anesthesia provider.
89036011|NCT02932722|Sham Comparator|Control|Patients in the control group will be receive remote ischemic preconditioning before anesthetic induction (before exposure to any anesthetic).
89615944|NCT01925079|Experimental|Intensive Educational Group|The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.
89615945|NCT01925079|Sham Comparator|Control Group|The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.
89615946|NCT03156582||"all participants included Milan criteria  and AFP score"|"The first arm is made of liver recipients or dropped off list patients at the time of the Milan criteria (fixed until 2013/06/01 for transplanted patients because mandatory three months reevaluation of patients obliged the various teams to respect the criteria at this time, but until 2013/03/01 for dropped off patients because we did not want to count dropped of because of the AFP score in this arm).~The second arm is made of liver recipients or dropped off list patients at the time of the AFP score (fixed after 2013/06/01)for transplanted patients and after 2013/03/01 for dropped off patients)"
89615947|NCT04450134|Placebo Comparator|Placebo|6 weeks high-intensity interval training + placebo intake
89615948|NCT04450134|Experimental|Blockade|6 weeks high-intensity interval training + histamine H1/H2 receptor blockade
89615949|NCT01286818|Experimental|FOLFIRI plus Ramucirumab (IMC-1121B)|
89615950|NCT03113292|Experimental|Pilates Method|Mat Pilates Program, 2x/week, for 6 weeks, supervised by a Physiotherapist. Sessions will last forty five min, with 4 individuals per session. On average, 10 to 15 exercises will be performed per session, with repetitions ranging from 10 to 20 times, according subject's limitations. If necessary, the exercises will be adapted individually for the three levels of difficulty: basic, intermediate and advanced. Progress will be dependent on the absence of postural compensations when performing the repetitions of the exercises.
89615951|NCT03113292|Active Comparator|Home Exercise Prescription|Composed by two familiarization sessions, supervised by a Physiotherapist. The protocol include postural reeducation exercises, stretching and muscle strengthening, stabilization and mobilization of the spine. Subsequently, participants will receive an educational booklet containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. Also, it will include a booklet with the prescription of therapeutic home exercises to be performed during the next 6 weeks. It will be recommended that the participants perform the exercises 2x/week. Participants will also be contacted weekly by email and/or telephone, for remote supervision and for checking the prescribed exercises.
89615952|NCT04450056||Mother-infant pairs|Mothers with a term-born (>37 weeks gestation) infant whom they are exclusively or predominantly breastfeeding at 1 month postpartum. Mothers must be enrolled in the MaPPS Trial (ClinicalTrials.gov Identifier: NCT03287882).
89615953|NCT01925157|Experimental|LY3090106 (Healthy)|Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).
89615954|NCT01925157|Placebo Comparator|Placebo (Healthy)|Healthy participants will receive a single dose of placebo matching LY3090106 SQ.
89615955|NCT01925157|Experimental|LY3090106 (RA)|Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).
89615956|NCT01925157|Placebo Comparator|Placebo (RA)|Participants with RA will receive a single dose of placebo matching LY3090106 SQ.
88986631|NCT00493402|Experimental|single agent chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
88986632|NCT00493480|Active Comparator|carvedilol|
88986633|NCT00493480|Active Comparator|propranolol|Cirrhotic patients treated with propranolol
88986634|NCT01243996|Experimental|Infant treated with high dose ibuprofen|
88986635|NCT01244074|Experimental|biofeedback|
88986636|NCT01244152|Experimental|Intervention|
88986637|NCT01244152|Active Comparator|Control Group|
88986638|NCT00493714||Arm 1 (Patient)|Cancer patient who recently experienced confusion or restlessness.
88986639|NCT00493714||Arm 2 (Caregiver)|Caregivers of cancer patients who recently experienced confusion or restlessness.
88986640|NCT00493909|Active Comparator|1|thoracic epidural analgesia
88986641|NCT00493909|Active Comparator|2|intrathecal opioids and thoracic paravertebral analgesia
88986642|NCT00493987|Active Comparator|Testosterone enanthate|
88986643|NCT00493987|Placebo Comparator|Duatesteride|Duatesteride
88986644|NCT00494065|Experimental|1|Chiropractic Spinal Manipulative Therapy + Home exercise
88986645|NCT00494065|Active Comparator|2|Home exercise
88986646|NCT00494104|Active Comparator|200 IU/day Vitamin D|200 IU/day Vitamin D
88986647|NCT00494104|Experimental|400 IU/day Vitamin D|400 IU/day Vitamin D
88986648|NCT00494104|Experimental|600 IU/day Vitamin D|600 IU/day Vitamin D
88986649|NCT00494104|Experimental|800 IU/day Vitamin D|800 IU/day Vitamin D
88986650|NCT00405366|Other|Single Arm Study|
88986651|NCT00494260|Experimental|Social learning and cognitive behavioral therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques.
89036012|NCT02932722|Active Comparator|Propofol|Patients in the propofol groups will be receive remote ischemic preconditioning after anesthetic induction using propofol, as a main anesthetic.
89036013|NCT02932722|Active Comparator|Sevoflurane|Patients in the sevoflurane groups will be receive remote ischemic preconditioning after anesthetic induction using sevoflurane, as a main anesthetic.
89615957|NCT01243294|Active Comparator|SenSura|"CE marked and launched (The letters CE do not represent any specific words, though may have initially stood for Communauté Européenne (European Community) or Conformité Européenne (European Conformity). By affixing the CE marking to a product, the manufacturer declares that it meets EU safety and health and environmental requirements."
89615958|NCT01243294|Active Comparator|New ostomy appliance (SS)|SS = New ostomy appliance. Due to company confidentiality the product is just called SS and this is not short for any other names.
89615959|NCT03428256|Active Comparator|Pre-oxygenation with a standard anaesthetic face mask|Pre-oxygenation delivered in the standard way; 3 minutes, Fraction of inspired oxygen (FiO2) 1.0, 8 vital capacity breaths in the last minute
89615960|NCT03428256|Experimental|Pre-oxygenation using Optiflow and THRIVE technique|Pre-oxygenation delivered via nasal high flow humidified oxygen (Optiflow) and THRIVE technique. Gradually increased to 70 litres/minute, mouth closed, 8 vital capacity breaths in the last minute
89615961|NCT00635505|Experimental|T|albuterol HFA 180 mcg QID
89615962|NCT00635505|Active Comparator|R|180 mcg QID 12 weeks
89615963|NCT00635505|Placebo Comparator|P|2 actuations QID 12 weeks or until use of rescue drug
89615964|NCT03428178|Experimental|rAAV2-ND4|A Single IVT of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
89615965|NCT01243450|Active Comparator|Active generic|Treatment of acne for 12 weeks with generic tretinoin
89615966|NCT01243450|Placebo Comparator|Placebo|Treatment of acne for 12 weeks with Placebo
89615967|NCT01243450|Active Comparator|Brand|Treatment of acne over 12 weeks with tretinoin Brand
89615968|NCT01925313|Experimental|CJ-30044|
89615969|NCT01925313|Active Comparator|TALION TAB. 10mg|
89615970|NCT03433872|Other|Caregivers|"Caregiver refers to teachers and child care providers in infant and toddler classrooms in center-based or FCC settings. All caregivers in the study will be assigned to the intervention. The PD providers supporting these caregivers will be trained in the We Grow Together: The Q-CCIIT Professional Development System."
89615971|NCT05249751||mild-moderate|Cases classified as mild-moderate fulfilled the following criteria: fever and respiratory symptoms, CORAD 1-5, and oxygen saturation (SpO2 92 percent),
89615972|NCT05249751||Severe|severe cases met the following criteria: fever and respiratory symptoms, CORAD 4-5, and oxygen saturation (SpO2 92 percent).
89615973|NCT03430830|Experimental|GROUP 1|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.
89615974|NCT03430830|Experimental|GROUP 2|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
89615975|NCT03430830|Experimental|GROUP 3|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
89036014|NCT02921516|Experimental|N'ap Grandi|Both Adolescent and Caregiver participate in assessment and intervention groups. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
89036015|NCT02921516|Active Comparator|N'ap Grandi - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
89615976|NCT03430830|Experimental|GROUP 4|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
89615977|NCT03430830|Experimental|GROUP 5|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
89615978|NCT03430830|Experimental|GROUP 6|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
89615979|NCT02197078||Glitazones|
89615980|NCT02197078||Linagliptin|
89615981|NCT02197078||Sulfonylurea|
89615982|NCT02197078||Within-class comparators|
89615983|NCT00635193|Other|Cohort 1|Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk
89615984|NCT00635193|Other|Cohort 2|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk
89615985|NCT00635193|Other|Group A|liposomal doxorubicin, 40 mg/m2 q4wk
89615986|NCT00635193|Other|Group B|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule)
89615987|NCT00635193|Other|Group C|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule)
89615988|NCT01925391|Active Comparator|Sevoflurane, oxygen, intraocular pressure|Intraocular measurements under induction with Sevoflurane in oxygen
89615989|NCT01925391|Active Comparator|Nitrous oxide/O2/tetracaine|intraocular pressures in children undergoing inhalation induction with nitrous oxide in oxygen
89615990|NCT00633789|Experimental|1|
89615991|NCT00633789|Placebo Comparator|2|
89036016|NCT02921516|Placebo Comparator|Health Promotion - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
89036017|NCT01284361|Experimental|30 cm Intermittent Catheter|Intervention was the test of a 30 cm catheter compared to standard commercial 40 cm catheter in a cross-over design.
89036018|NCT01284361|Active Comparator|40 cm Intermittent Catheter|Active comparator 40 cm commercial catheter was compared to experimental 30 cm catheter in a cross-over design.
89615992|NCT01287208|Active Comparator|Unblinded activity monitor|Subjects wear the activity device and can see the data on the device and on a website where the data is uploaded.
89615993|NCT01287208|Placebo Comparator|Blinded activity monitor|Subjects wear a blinded activity device and cannot see the activity on the device and cannot log on to the website where the data gets uploaded.
89615994|NCT00630201|Experimental|Probuphine|buprenorphine implant
89615995|NCT04396197||COVID-19|Observations taken of standard physiotherapy practice. All patients are assessed daily and receive respiratory care and rehabilitation as deemed appropriate by the treating therapist
89615996|NCT05241483||fever|Remote patient monitoring. fever values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
89615997|NCT05241483||pulse|Remote patient monitoring. pulse values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
89615998|NCT05241483||blood pressure|Remote patient monitoring. Blood pressure values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
89615999|NCT05241483||oxygen saturation|Remote patient monitoring. oxygen saturationvalues recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
89616000|NCT05241483||glucose|Remote patient monitoring. glucose values recorded by the patient in the system. Validation of pre-diagnosis results of AI systems to detect fever-related diseases.
89616001|NCT01288534|Experimental|Radiation Treatment|
89616002|NCT01925547|Experimental|Micellar curcumin|Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.
89616003|NCT01925547|Placebo Comparator|Placebo|Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.
89616004|NCT04395807|Active Comparator|Helmet CPAP|Helmet Continuous Positive Airway Pressure (CaStar hood for CPAP therapy by Starmed/Intersurgical) driven by high-flow blender (Bio-Med Devices).
89616005|NCT04395807|Active Comparator|HFNC|High-Flow Nasal Cannula (OptiflowTM nasal high-flow interface) driven by AIRVO 2 humidification system (Fisher and Paykel)
89036019|NCT01284127||Deferiprone|All patients must have MRI evidence of superficial siderosis and be treated with deferiprone according to standard of care guidelines.
89036020|NCT02921438||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
89036021|NCT02932761|Experimental|VR + GnRHa|CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection (abbreviated as VR + GnRHa). In the group of VR + GnRHa, 2 doses of GnRHa were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
89616006|NCT03122301|Active Comparator|Bupivicaine|Stellate Ganglion Block Injection with bupivicaine
89616007|NCT03122301|Sham Comparator|Saline|Saline injection
89616008|NCT01920087|Experimental|ATNC05|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
89616009|NCT01920087|Placebo Comparator|Placebo|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
89616010|NCT01920243|Experimental|Health Mechanics- New Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals with new-onset traumatic spinal cord injuries are eligible for this group.
89616011|NCT01920243|No Intervention|Usual Care- New Injuries|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with new-onset traumatic spinal cord injuries.
89616012|NCT01920243|Experimental|Health Mechanics- Chronic Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals who have had traumatic spinal cord injuries for at least one year are eligible for this group.
89616013|NCT01920243|No Intervention|Usual Care- Chronics|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with who have had traumatic spinal cord injuries for at least one year.
89616014|NCT01925859|Experimental|EryDex System|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
89616015|NCT04347837|Experimental|Investigational device|The investigational device will be used for all participants
89616016|NCT01920321|Experimental|Endoscopic lung volume reduction|After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.
89616017|NCT03435627||Norditropin® (naïve participants)|The treatment period of Norditropin® for naïve participants will be up to 208 weeks.
89616018|NCT03435627||Norditropin® (non-naïve participants)|The treatment period of Norditropin® for non-naïve participants will be up to 442 weeks.
89616019|NCT01920399|Placebo Comparator|Placebo|IV infusions of 0.9% normal saline
89616020|NCT01920399|Experimental|CAZ-AVI|IV infusion of AVI 500 mg + CAZ 2000 mg.
89616021|NCT01920633||People with Down syndrome|
89616022|NCT01926171|Experimental|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus concurrent icotinib, which was administered orally three times per day.
89616023|NCT01926327|Active Comparator|platelet reach plasma|The patients with osteoarthritis who underwent PRP injection.
89616024|NCT01926327|Placebo Comparator|placebo|The patients with osteoarthritis who underwent Normal Saline injection.
89616025|NCT03092037||All participants|All participants will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. Genotyping data will be analyzed for associations with serum ENG concentrations.
89616026|NCT03092037||All participants (side-effects)|All participants will have their blood drawn and complete a brief questionnaire regarding bleeding patterns and side-effects. DNA will be extracted from whole blood and genotyping data will be analyzed for associations with specific bleeding patterns and side-effects.
89616027|NCT05247723|Experimental|SIVCA|Aspirating testicular tissue using a standard IV cannula with applied negative pressure.
89616028|NCT05247723|Active Comparator|Micro-TESE|Extracting testicular tissue surgically
89616029|NCT01926405|Other|Subjects with narcolepsy or with idiopathic hypersomnia|
89616030|NCT01926405|Other|Control patients with no sleeping disorder|
89616031|NCT01920945|Experimental|OnabotulinumtoxinA|
89616032|NCT01926483|Experimental|Neoadjuvant Treatment|Neoadjuvant Chemoradiotherapy
89616033|NCT01926639|Experimental|Radiotherapy , rituximab and DC|Treatment repeated 3 times and targeting different lymph nodes
89616034|NCT01926717||Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy|
89036022|NCT02932761|Placebo Comparator|VR|CSD patients were treated with vaginal repair of CSD in combination with 0.01 ml saline as a subcutaneous injection (abbreviated as VR). In the group of VR, 2 doses of saline were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
89616035|NCT01926717||Pancreaticoduodenectomy|
89616036|NCT01926795|Active Comparator|Short Leg Cast|Patient will be placed in a short leg cast for approximately 3 weeks or until radiographic union
89616037|NCT01926795|Experimental|No immobilization|No cast or splint will be applied to the injured extremity
89616038|NCT01926795|Other|Observational|Patient will be treated based on the parents comfort. This arm will consist of individuals in which the parent/guardian did not agree to randomization, but did consent for observational follow-up regardless of treatment.
89616039|NCT02199496|Experimental|Cohort 1: Ustekinumab-Single-dose Phase 1, Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously then re-enrolled into the multi-dose phase. In multi-dose phase, subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
89616040|NCT02199496|Experimental|Cohort 2: Ustekinumab-Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
89616041|NCT01926873||Healthy volunteers|
89616042|NCT04395417|Experimental|Hyaluronic acid injection group|This is the study group in whom Hyaluronic acid injection was injected at lateral epicondylitis site.
89616043|NCT04395417|Active Comparator|Prolotherapy injection group|This is the control group in whom prolotherapy injection was given at lateral epicondyle site.
89616044|NCT02199574|Experimental|EXPAREL|Single administration of EXPAREL 133 mg (10 mL).
89616045|NCT03088527|Experimental|RAD140 Part A and Part B|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.~Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose."
89616046|NCT01926951|Experimental|Renal Denervation|Renal Denervation using the Kona Surround Sound Externally Focused Therapeutic Ultrasound therapy.
89616047|NCT02199652|Placebo Comparator|placebo|placebo pill
89616048|NCT02199652|Experimental|prazosin|prazosin pill
89616049|NCT05241561|Experimental|Cabozantinib|
89616050|NCT03009916|Other|Healthy controls|Healthy controls found according to the protocol
89616051|NCT03009916|Other|Patients with BAM|Patients with bile acid malabsorption found according to the protocol
89616052|NCT01921491|Other|Standard of Care|Surgical debridement of DFU, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice Offloading. Reassessment weekly at office visit.
89616053|NCT01921491|Active Comparator|Other Commercially Available Product|Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
89616054|NCT01921491|Experimental|dHACM|Application of dHACM with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of dHACM will be applied weekly at weeks 2-11.
89616055|NCT01921569|Experimental|dHACM|Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
89616056|NCT01921569|Placebo Comparator|Saline Injection|Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
89616057|NCT01289080|Active Comparator|Group 1|subjects with normal renal function
89616058|NCT01289080|Active Comparator|Group 2|severely renally impaired subjects
89616059|NCT01927029|Experimental|Progesterone|Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.
89616060|NCT01927029|Placebo Comparator|Placebo|Placebo Gel, for daily use from 18 weeks to 34 weeks.
88986652|NCT00494260|Active Comparator|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
88986653|NCT00494416|No Intervention|ANC approach|Passive health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
89616061|NCT01921647|Experimental|YH4808, amoxicillin, clarithromycin|single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin
89616062|NCT01921647|Experimental|YH4808, amoxicillin and clarithromycin|7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication
89616063|NCT01921647|Experimental|YH4808 and amoxicillin|7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication
89616064|NCT01921647|Active Comparator|nexium, amoxicillin and clarithromycin|BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication
89616065|NCT01246258||Test group|Standard tests of balance function
89616066|NCT01927107|Active Comparator|Probiotic mixture|Probiotic mixture including Lactobacillus acidophilus (4.3x108CFU/per sachet), Lactobacillus rhamnosus (4.3x108CFU/ per sachet), Bifidobacterium bifidum (4.3x108CFU/ per sachet), Bifidobacterium longum (4.3x108CFU/ per sachet), Enterococcus faecium (8.2x108CFU/ per sachet, per oral daily for 30 days in addition to standard approach
89616067|NCT01927107|Active Comparator|Control|Standard diet therapy
89616068|NCT03087591|Experimental|Treatment (APN401)|Patients receive siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes on days 1, 29, and 57 in the absence of disease progression or unacceptable toxicity.
89616069|NCT03087357||Low Risk|The Low Risk group will consist of 2,400 pregnancies with no high risk findings (e.g., abnormal ultrasound, positive serum screen) who are undergoing initial clinical cfDNA screening. To simulate a general pregnancy population, approximately 20% of these women will be age 35 and older. An estimated 2% (48) of these LR women will have a failed/no call cfDNA test. Consenting women will provide samples for SmartNIPT testing.
89616070|NCT03087357||High Risk|The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
88986654|NCT00494416|Other|advanced strategies SP|Joint with advanced strategies delivery approach (JAS). In addition to passive delivery of IPT/sulphadoxine pyrimethamine (SP) at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages, such as immunization, health promotion, and even ANC visits.
88986655|NCT00494416|Other|Community based|Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs). Each approach will be implemented in a zone constituted by the catchment area of a number of health centres to achieve the required sample size. The zones will be randomly assigned to a delivery approach. The main outcomes to be measured are: a) the coverage of IPT, b) compliance, c) infection prevalence, d) Hb level, e) difficulties and constraints of each approach, f) the acceptability to population and health staff and g) the performance of each approach to deliver IPT /SP. Coverage by 10%, each group should be composed of n = 3841 pregnant women.
88986656|NCT00494455|Active Comparator|1|Continuous subcutaneous glucose monitoring in patients without shock
88986657|NCT00494455|Active Comparator|2|continuous subcutaneous glucose monitoring in patients with shock
88986658|NCT01244230|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old - Type: Experimental
88986659|NCT01244230|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
88986660|NCT01244230|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
88986661|NCT01244269|Experimental|Methylphenidate 10|Methylphenidate 10mg three times daily for a total of 7 doses.
88986662|NCT01244269|Placebo Comparator|Placebo 10|Placebo capsule three times daily for a total of 7 doses.
88986663|NCT01244269|Experimental|Methylpheindate 20|Methylphenidate 20mg three times daily for a total of 7 doses.
88986664|NCT01244269|Placebo Comparator|Placebo 20|Placebo capsule three times daily for a total of 7 doses.
88986665|NCT02958189|Experimental|Group 1: Tweet4Wellness+Self-monitoring|This group will receive the Tweet4Wellness intervention: daily theory-based peer-to-peer discussion prompt within the private Twitter-based support group for the entire 6 months of the study. They will also receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component).
88986666|NCT02958189|Active Comparator|Group 2: Self-monitoring|This group will receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component) for the first 3 months. For the second three months of the study, they will receive the Tweet4Wellness intervention in addition to their Fitbit self-monitoring.
88986667|NCT00494572|Sham Comparator|Sterile Water|Sterile water
88986668|NCT00494572|Active Comparator|Montelukast|10mg rapid dissolving granules in sterile water orally once
88986669|NCT00494650|Experimental|1|Participants will receive cognitive behavioral therapy.
89616071|NCT01339858|Experimental|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 600 mg of NAC. Dosing will begin at 600 mg/d and titrated up over 5 weeks until a maximum dose of 3600 mg/d is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose.
89616072|NCT01339858|Placebo Comparator|Sugar Pill|matched placebo
89616073|NCT03831555|Active Comparator|PREP-C|The research assistant will complete the abbreviated PREP-C survey with the study participants either before or after their medical appointment. The PREP-C tool is accessed online at https://prepc.org/.
89616074|NCT03831555|No Intervention|Standard of care|Participants will receive the standard of care (usual care) for chronic HCV infection.
89616075|NCT03087123|Active Comparator|2-Week Baseline|Families will be randomized to a 2-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
89616076|NCT03087123|Active Comparator|4-Week Baseline|Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
89616077|NCT03087123|Active Comparator|6-Week Baseline|Families will be randomized to a 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
89616078|NCT04275453|Experimental|Ketogenic diet - 24 hours|Subjects will undergo FDG PET/CT after 1 day of dietary modification (ketogenic diet for at least 3 meals) and 12 hours of fasting prior to FDG injection.
89616079|NCT04275453|Experimental|Ketogenic diet - 72 hours|Subjects will then undergo FDG PET/CT after 3 day of dietary modification (ketogenic diet for at least 9 meals) and 12 hours of fasting prior to FDG injection.
89616080|NCT04275453|Experimental|Exogenous ketone ester|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants. The KE drink will be administered approximately 45 minutes prior to FDG injection as concentrations of ~3 mmol/L are reached within 60 minutes . By way of comparison, website marketing of the commercial drink recommends ingestion 30 minutes prior to athletic performance. We will also perform echocardiography immediately before and 30 minutes after the drink.
89616081|NCT01339936|Experimental|Investigational eye drop|Formulation 1: Carboxymethylcellulose sodium, glycerin and polysorbate 80 based eye drops formulated for the relief of ocular surface irritation and symptoms of dryness
89616082|NCT05246865|Experimental|Women with PCOS|Women with polycystic ovary syndrome
89616083|NCT05246865|Experimental|Age and BMI-matched healthy volunteers|Otherwise healthy women without PCOS but matching in age and body mass index to the above group
89616084|NCT01289392|Active Comparator|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard treatment
89616085|NCT01289392|Active Comparator|Oral Appliance|Alternative treatment for obstructive sleep apnea patients
89616086|NCT01289392|Active Comparator|Physical Exercise|Aerobic and resistance physical exercises
89616087|NCT01921725|Experimental|Hydrophilic-based dressing (KoCarbonTM)|The wound is first cleansed with normal saline, and then applied with hydrophilic-based dressing (KoCarbonTM) and covered by sterile gauze. The frequency of dressing chang is depend on the amount of exudate.
89616088|NCT03111537|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered alternative nicotine products and instructed for partial or complete substitution of cigarettes (subject's choice);
89616089|NCT03111537|Experimental|Complete Substitution E-Cigarette|Complete substitution (i.e., no smoking) with e-cigarette use
89616090|NCT03111537|Experimental|Partial Substitution E-Cigarette|Partial substitution, encouraged to use e-cigarettes instead of smoking usual cigarettes
89616091|NCT03111537|Experimental|Complete Substitution Nic Gum or Lozenge|Complete substitution (i.e., no smoking) to nicotine gum or lozenge use
89616092|NCT01289548|No Intervention|control|patients (both donors and recipients) had a deflated cuff placed on the left lower limb for 30 min
89616093|NCT01289548|Experimental|donor|Donors receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; recipients only have a deflated blood pressure cuff around their leg for 30 minutes.
88986670|NCT00494650|Active Comparator|2|Participants will receive brief PTSD treatment.
88986671|NCT04737681||Normal BMI|BMI 18.5-24.9 kg/m2
88986672|NCT04737681||Obese BMI|BMI ≥ 30 kg/m2
88986673|NCT00494767|Experimental|GW869682 1000 mg thrice daily (TID)|Subjects will be randomized to receive GW869682 1000 mg TID
88986674|NCT00494767|Experimental|GSK189075 250 mg TID|Subjects will be randomized to receive GSK189075 250 mg TID
88986675|NCT00494767|Placebo Comparator|GW869682-Placebo TID|Subjects will be randomized to receive Placebo matching GW869682 for TID
88986676|NCT00494767|Placebo Comparator|GSK189075-Placebo TID|Subjects will be randomized to receive Placebo matching GSK189075 for TID
88986677|NCT00494845|Experimental|Intervention|8-week Mindfulness Program for chronic low back pain
88986678|NCT00494845|Active Comparator|Comparison|8-week health education program
88986679|NCT01244464|Experimental|Study Group|
88986680|NCT01244542|Experimental|Patients with schizophrenia|
88986681|NCT01244542|Active Comparator|Healthy controls|controls matched with patients on age, sex and education level
88986682|NCT02957877|Experimental|LMWH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using low-molecular weight heparin (nadroparin) as anticoagulation
88986683|NCT02957877|Active Comparator|UFH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using unfractionated heparin as anticoagulation
88986684|NCT01244581|Experimental|Amoxicillin-clavulanate|Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
89036023|NCT01283971|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg intravenous (IV) every 4 weeks + Placebo to adalimumab subcutaneous (SC) every 2 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
89036024|NCT01283971|Active Comparator|Adalimumab + Methotrexate|Adalimumab 40 mg SC every 2 weeks + Placebo to tocilizumab IV every 4 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
89036025|NCT05466981|Experimental|Current smokers with an HCV infection|Persons who currently smoke cigarettes and are also HCV RNA+
89036026|NCT02921360|Experimental|12 hours|Non-contrast CT and CT-angiography are performed in 11 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 12 hours after thrombolysis
89036027|NCT02921360|No Intervention|24 hours|Non-contrast CT and CT-angiography are performed in 23 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 24 hours after thrombolysis
89036028|NCT02932605|Experimental|Cannabidiol|Patients will be treated with 600mg CBD daily for 4 weeks (28 days)
89036029|NCT02932605|Placebo Comparator|Placebo|Patients will be treated with placebo daily for 4 weeks (28 days)
89036030|NCT02921243||Stool Sample Collection|
89036031|NCT02921243||Prebiotic|
89036032|NCT02921204||Vitamin D status|Subjects are recruited to asses Vitamin D status with no interventions
89036033|NCT01283581|Experimental|Delafloxacin|300 mg IV (intravenous) every 12 hours for 5-14 days
89036034|NCT01283581|Active Comparator|Vancomycin|15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas
89036035|NCT01283581|Active Comparator|Linezolid|600 mg IV every 12 hours for 5-14 days
89036036|NCT05466903|No Intervention|Control arm|patients were given a liquid diet 6 hours after the operation
89036037|NCT05466903|Experimental|Experimental arm|patients were given a liquid diet 2 hours after the operation
89036038|NCT02921399||early eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
89036039|NCT02921399||late eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
89036040|NCT01283542|Experimental|Pasireotide LAR|All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks
89036041|NCT05466864|Experimental|TMU Hospital|Potential participants with suspected OSA will be identified from the schedule of the TMU sleep labs. Those subjects who satisfy the study conclusion and exclusion criteria will be approached and invited to participate in the study.
89036042|NCT02921048||omega-3|individuals voluntarily taking at least 3 g/wk of EPA and DHA from dietary sources including fish oil supplements and ocean fish/shellfish consumption for a period of at least 6 months prior to enrollment in the study
89036043|NCT02921048||control|individuals who have consumed no more than 1 serving size (4-6 oz)/month of ocean fish/shellfish, or no more than 1 pill/month of fish oil supplement during the 6 month period preceding enrollment
89036044|NCT02932488|Experimental|Sumatriptan|"In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects."
89036045|NCT02921165|Active Comparator|Group 1|Non hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
89036046|NCT02921165|Experimental|Group 2|Hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
89036047|NCT02921165|Experimental|Group 3|Non Hypertensive Intervention: On normal saline rinses.
89036048|NCT01283386|Experimental|FCR-lite|Rituximab, fludarabine, and cyclophosphamide
89036049|NCT01283386|Active Comparator|LR Therapy|Rituximab and chlorambucile
89036050|NCT05466786||Experimental ARM|All patients received standard care for postoperative management.
89036051|NCT02920931|Experimental|A|"st period: Tenofovir disoproxil fumarate~nd period: Tenofovir Disoproxil"
89036052|NCT02920931|Active Comparator|B|"st period: Tenofovir disoproxil~nd period: Tenofovir Disoproxil fumarate"
89036053|NCT01283152|Active Comparator|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|
89036054|NCT01283152|Other|Lactulose|Per standard of care
89036055|NCT02932527|Experimental|infertile men exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
89036056|NCT02932527|Other|infertile men not exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) not exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
89036057|NCT02921126||High Dose Group|Apixaban - 10 mg/day Rivaroxaban - 20 mg/day Dabigatran - 300 mg/day
89036058|NCT02921126||Low Dose Group|Apixaban - 5 mg/day Rivaroxaban - 15 mg/day Dabigatran - 220 mg/day
89036059|NCT02921126||Other Dose Group|Invalid Doses / Off-Label
89036060|NCT01283035|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 will be taken PO once a week for four weeks (one cycle). Treatment will continue for as long as a subject is benefiting from the study drug.
89036061|NCT02920853|Experimental|BT-CPR|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback training to provide pain relief when relaxation is achieved.
89616094|NCT01289548|Experimental|recipient|recipients receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; donors only have a deflated blood pressure cuff around their leg for 30 minutes.
89616095|NCT01927263|Experimental|NI-071|
89616096|NCT01927263|Active Comparator|Infliximab|
89616097|NCT01921881|Experimental|St John's wort|"Subjects will undergo 3 oral glucose tolerance tests:~Without taking any St John's wort~After 3 weeks pretreatment with St John's wort~Minimum 6 weeks after last St John's wort ingestion"
89616098|NCT01341730|Active Comparator|Atorvastatin 20 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg group is to take atorvastatin 20 mg and take follow up PET CT in 3 months"
89616099|NCT01341730|Experimental|Atorvastatin 20 mg + Pioglitazone 30 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg + Pioglitazone 30 mg group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months"
89616100|NCT01921959||Partners of intervention women|Partners of women randomized to intervention
89616101|NCT01921959||Partners of no intervention women|Partners of women randomized to control
89616102|NCT01927653||The patients with amnestic MCI|"The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:~memory complaint~normal general cognition~normal activities of daily living~not demented"
89616103|NCT01927653||The patients with dysexecutive MCI|"The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:~relatively focal executive dysfunction~Within reference range on tests of memory, language and visuospatial skills~normal general cognition~normal activities of daily living~not demented"
88986685|NCT01244581|Placebo Comparator|Placebo|
88986686|NCT01244659|Experimental|Tacrolimus from EMS|Group 1: Tacrolimus from EMS + Myfortic® + Steroids
88986687|NCT01244659|Active Comparator|Prograf|Group 2: Prograf® + Myfortic® + Steroids
88986688|NCT01244698|Other|Antibiotics until Drain Removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
88986689|NCT01244698|Experimental|Early discontinuation of antibiotics|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.
88986690|NCT00495196|Experimental|1|
88986691|NCT00495196|Active Comparator|2|
88986692|NCT00495235||Endometrial Cancer Group|Participants who have had endometrial cancer (cases).
88986693|NCT00495235||Control Group|Participants who have not had endometrial cancer (controls).
88986694|NCT00495274|Experimental|Healthy male subjects|In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.
88986695|NCT00495313|Active Comparator|Cohort 1: doxycycline|Vibramycin plus metronidazole
88986696|NCT00495313|Active Comparator|Cohort 2|Oracea® delayed release plus metronidazole
88986697|NCT01244776|Experimental|Acellular corneal matrix|
88986698|NCT00495352|Active Comparator|High-dose NRT, Low-dose NRT, bupropion|
88986699|NCT00495664|Experimental|TITANOX|Titanium-nitride-oxide coated stent
88986700|NCT00495664|Active Comparator|PES|Paclitaxel-eluting stent
88986701|NCT00495703|Experimental|1|Exercise
88986702|NCT00495703|Active Comparator|2|Usual Care
88986703|NCT00495859|Active Comparator|1|Study group will receive formula enriched with arginine, ω-3 fatty acids, and nucleotides once daily
88986704|NCT00495859|Active Comparator|2|controls receive an isocaloric isonitrogenous non-specific nutritional support
88986705|NCT00405405|Experimental|Treatment|A combination of Cisplatin, Docetaxel, Bevacizumab, Erlotinib, and Radiotherapy
88986706|NCT00495898|Experimental|1|CYPHER sirolimus-eluting stent
88986707|NCT00495898|Active Comparator|2|uncoated Bx VELOCITY balloon-expandable stent
88986708|NCT00496093|Experimental|Pneumococcal Vaccine, Polyvalent (23-valent)|Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1.
88986709|NCT00496288|Experimental|prophylactic irradiation|prophylactic contralateral breast irradiation
88986710|NCT00496288|No Intervention|controls|Those that do not opt for prophylactic irradiation or mastectomy
88986711|NCT00496327|Experimental|1|Open label
88986712|NCT00496444|Experimental|Azacitidine + Valproic Acid|
88986713|NCT00496561|Active Comparator|1|subcutaneous immunotherapy (House Dust Mites)
88986714|NCT00496561|Placebo Comparator|2|placebo of subcutaneous immunotherapy (House Dust Mites)
88986715|NCT00146250|Experimental|Nitrous oxide|Nitrous oxide 70% as balance gas in inspired mixture
88986716|NCT00146250|Experimental|Nitrogen|Nitrogen instead of nitrous oxide 70% as balance gas in inspired mixture
88986717|NCT00496678|Experimental|Navigation|Navigation through the cancer care system is the intervention
88986718|NCT00496678|Active Comparator|Standard of Care|Cancer patient receives standard of care.
89616104|NCT01927653||The healthy volunteers|"The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:~Age and gender matched healthy subjects without significant neuropsychiatric disorder~Able to understand and provide signed informed consent"
89616105|NCT01247272|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
89616106|NCT01247272|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
88986719|NCT00496717||1|There is only one arm and all patients will have their aortic calcium scoring by CT scan.
88986720|NCT00496990|Active Comparator|control|Participants in this group receive the opportunity to attend a support group
88986721|NCT00496990|Experimental|Enhanced care|Participants in this arm receive the opportunity to have detoxification or methadone treatment as well as receive vouchers contingent upon drug free urine samples and individualized counseling
88986722|NCT00497068|Experimental|tobacco abstinent contingent voucher|Tobacco abstinent contingent voucher condition
88986723|NCT00497068|Experimental|non-contingent|Participants receive vouchers non-contingent upon tobacco use status
88986724|NCT00497068|Other|no voucher|This is the standard care intervention
88986725|NCT02958098||Myocardial infarction|Individuals with myocardial infarction before age 50 years.
88986726|NCT02958098||Stroke|Individuals with stroke before age 50 years
88986727|NCT02958098||Aortic dissection|Individuals with aortic dissection before age 50 years
88986728|NCT02958098||Systolic heart failure|Individuals with systolic heart failure/dilated cardiomyopathy before age 50 years.
88986729|NCT02958098||Atrial fibrillation|Individuals with atrial fibrillation before age 50 years
88986730|NCT00497107|Active Comparator|1|The Control Group (UFT + Calcium Folinate)
88986731|NCT00497107|Experimental|2|The PSK Group (UFT + Calcium Folinate + PSK)
89616107|NCT03430089|Experimental|Group 1: 6 to 35 months|Shz QIV 0.25 mL, 2 doses
89616108|NCT03430089|Experimental|Group 2: 3 to 8 years|Shz QIV 0.5 mL, 2 doses
89616109|NCT03430089|Experimental|Group 3: 9 to 17 years|Shz QIV 0.5 mL, single dose
89616110|NCT03430089|Experimental|Group 4: 18 to 60 years|Shz QIV 0.5 mL, single dose
89616111|NCT03430089|Experimental|Group 5: 61 years and older|Shz QIV 0.5 mL, single dose
89616112|NCT01290484|Experimental|Open Label|Sildenafil oral tablet three times daily
88986732|NCT04696978||PND group|patients occur neurocognitive disorders according to scores in this group
88986733|NCT04696978||NO PND group|patients do not occur neurocognitive disorders according to scores in this group
88986734|NCT04727216|Active Comparator|Continuous DRG-S Dosing|2 week stimulation program using continuous DRG-S dosing at standard stimulation parameters
88986735|NCT04727216|Experimental|1 minute on: 1 minute off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 1 minute off intermittent DRG-S dosing at standard stimulation parameters
88986736|NCT04727216|Experimental|1 minute on: 2 minutes off Intermittent DRG-S Dosing|2 week stimulation program using 1 minute on: 2 minutes off intermittent DRG-S dosing at standard stimulation parameters
88986737|NCT01244854|Other|Arm 1|Enhanced Usual Care; patients receive care as usual, with additional mailings on wellness newsletter topics
88986738|NCT01244971|Active Comparator|Acarbose|
88986739|NCT01244971|Active Comparator|Exercise|
88986740|NCT01244971|Experimental|Exercise + Acarbose|
88986741|NCT04599894|Sham Comparator|control group|Oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
88986742|NCT04599894|Experimental|study group|Oral administration of Pregabalin (37.5mg) at 8 am and 18 pm 1 d before operation; oral administration of Pregabalin (75mg) 2h before operation; and oral administration of Pregabalin (75mg) at 18 pm from the first day after operation to discharge.
88986743|NCT01245010|Experimental|Water|Water and education provision
88986744|NCT01245010|Active Comparator|Control|Education only
88986745|NCT00497185|Other|A|Mindfulness-Based Cognitive Therapy
88986746|NCT00497185|No Intervention|B|Shared care: Treatment as usual augmented by psychiatric consultation intervention to optimise treatment in the present health care system.
88986747|NCT00497224|Experimental|Erlotinib|Eligible patients will receive erlotinib 150mg PO daily, with dose escalation occurring as tolerated.
88986748|NCT04726982|Experimental|Low dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
88986749|NCT04726982|Experimental|High dose acetazolamide|Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
88986750|NCT04726982|Placebo Comparator|Placebo|Matching placebo tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
89616113|NCT01247428|Experimental|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
89616114|NCT04397055|Experimental|Cottonseed Oil|Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance
89616115|NCT04397055|Active Comparator|Olive Oil|Participants are given foods enriched with olive oil and instructed on how to substitute study foods into their diet to maintain caloric balance
89616116|NCT04396743|Active Comparator|Periapical surgery with placement of prf high clots|Patients will undergo periapical surgery and PRF-high clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
89616117|NCT04396743|Active Comparator|Periapical surgery with placement of prf medium clots|Patients will undergo periapical surgery and PRF-medium clot and membrane will be placed inside the bonycrypt and over the denuded root surface respectively before closure of the flap.
89616118|NCT03518619|Experimental|PFIcope+EMI|This will include: 1) an in-person personalized feedback session to present normative information and feedback on problems associated with drinking to cope, to discuss the individual's use of alcohol to cope, and to generate relapse prevention coping skills messages to be used in the EMI text intervention; 2) EMA to monitor affect and intention to drink after discharge; 3) tailored text messages (EMI) based on EMA responses (i.e., individualized coping skills messages when individuals report negative affect and intention to drink); and 4) additional EMA to monitor coping skills usage, alcohol use, and drinking to cope.
89616119|NCT01928043|Experimental|adjunctive curcumin|Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.
89616120|NCT01342666|Experimental|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
89616121|NCT01342666|Placebo Comparator|Cucumber consumption|Daily consumption of 300g of cucumber.
89616122|NCT02979886|Experimental|triptorelin|GnRH-a will be given everyday to the patient undergoing IVF treatment from middle luteal phase to the day of HCG. After 14 days of injection, serum FSH/LH/E2 will be checked. Then ovarian stimulation will be started by giving daily subcutaneous injection of recombinant FSH 150~300 IU. An appropriate dose of HMG (75~150 IU) will be added when follicles are larger than 12~14mm in diameter. When one leading follicle is >18mm in diameter, or two follicles are >17mm in diameter, or three follicles are >16mm in diameter, final ovulation will be triggered by a single injection of HCG 4,000~10,000 IU or Ovidrel® 250μg (equivalent to HCG 6,500 IU)
89616123|NCT01928121|Experimental|AF expert program|Care provided by the interdisciplinary, nurse-coordinated AF expert program
89616124|NCT01928121|No Intervention|Usual care|
89616125|NCT01290640||TC3 TKA|Subjects implanted with a DePuy fixed-bearing Total Condylar III (TC3) TKA
89616126|NCT01290640||PFC RP TC3 TKA|Subjects implanted with a DePuy PFC Rotating Platform TC3 TKA
89616127|NCT01929369||CONTROL GROUP|Control group: index intervention guided by DSA; IVUS post-intervention only (50 patients)
88986751|NCT04555941|Experimental|active iTBS|The patient is treated with iTBS stimulation according to protocol with an active coil.
88986752|NCT04555941|Sham Comparator|Sham iTBS|The patient is treated with Sham-iTBS stimulation according to protocol with an inactive coil.
88986753|NCT00497302|Experimental|1|receives housing based on drug abstinence
88986754|NCT00497302|Active Comparator|2|Usual care treatment at the Center for Addiction and Pregnancy
88986755|NCT00497341|Experimental|1|antibiotic is given before tourniquet inflation and before tourniquet release
88986756|NCT00497341|Placebo Comparator|2|antibiotic is given before tourniquet inflation
88986757|NCT00497380|Experimental|Arginine enriched nutrition|
88986758|NCT00497380|Placebo Comparator|Nutrition|
88986759|NCT00127829|Experimental|1|Gefitinib (IRESSA®)
88986760|NCT00497458|Placebo Comparator|Arimidex|Arimidex 1 mg plus placebo
88986761|NCT00497458|Active Comparator|Arimidex test 40mg|Arimidex 1mg and testosterone 40mg
88986762|NCT00497458|Active Comparator|Arimidex plus test 80mg|Arimidex 1mg and testosterone 80mg
88986763|NCT00497497|Experimental|1|
88986764|NCT00497497|Experimental|2|
88986765|NCT01245088|Experimental|chondroitin sulfate|400 mg (one table) TID
88986766|NCT00127868|Active Comparator|1|oral griseofulvin and selenium sulfide shampoo 1%
89616128|NCT01929369||TEST GROUP|Test group: index intervention guided by IVUS + DSA (50 patients
89616129|NCT01928277||ICU-patients|ICU-patients weaning form mechanical ventilation
89616130|NCT01928355||metabolically healthy|
89616131|NCT01928355||Unhealthy|
89616132|NCT01928511|Active Comparator|Continued oral nucleos(t)ide therapy|Patients assigned to this arm will continue their nucleos(t) analogue
89616133|NCT01928511|Experimental|Add on peg-interferon|Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
88986767|NCT00127868|Active Comparator|2|oral griseofulvin and ciclopirox shampoo
88986768|NCT00127868|Active Comparator|3|oral griseofulvin and ketoconazole shampoo 2%
88986769|NCT00127868|Placebo Comparator|4|oral griseofulvin and baby shampoo
88986770|NCT00497536|Active Comparator|1|≈ bolus protocol.
88986771|NCT00497536|Active Comparator|2|≈ CSII protocol
88986772|NCT00497536|Active Comparator|3|≈ CIII protocol.
88986773|NCT00497614|Other|No arm|
88986774|NCT00497653|Experimental|DCI|
88986775|NCT00497653|Placebo Comparator|Placebo|
88986776|NCT00497809|Experimental|1|AVI-014 2.5mcg/kg
88986777|NCT00497809|Experimental|2|AVI-014 5.0 mcg/kg
88986778|NCT00497809|Experimental|3|AVI014 10.0 mcg/kg
88986779|NCT00497809|Active Comparator|4|Filgrastim 5.0 mcg/kg
88986780|NCT00497848|Active Comparator|motivational interviewing|
88986781|NCT00497848|Experimental|The System Orientated Intervention|
88986782|NCT00146523|Experimental|mifepristone 600 mg|
88986783|NCT00146523|Placebo Comparator|matching placebo|
88986784|NCT00498043|Experimental|R-CHOP-14|R-CHOP14 induction regimen
88986785|NCT00498043|Experimental|R-ACVBP14|R-ACVBP14 induction regimen
88986786|NCT00402623|Placebo Comparator|1|placebo
88986787|NCT00402623|Active Comparator|2|quercetin (food supplement)
88986788|NCT00498121||VAP patient|
88986789|NCT00498277||Spinal MRI|
89036062|NCT02920853|Active Comparator|Biofeedback-Only|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback.
89036063|NCT02932371|Experimental|Cardiac Surgery|
89036064|NCT01283464|Active Comparator|Retinol|Retinol 1.0% cream
89036065|NCT01283464|Active Comparator|Tretinoin|Tretinoin 0.02% cream
89616134|NCT01928511|Experimental|switch to peg-interferon|Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly
89616135|NCT05241327|Active Comparator|Active|Beetroot Juice (Nitrate, 400 mg)
89616136|NCT05241327|Placebo Comparator|Placebo|Beetroot Juice (Nitrate, 0 mg)
89616137|NCT01929525||Silver Nitrate|Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form.
89616138|NCT05241171|Experimental|Fitbit plus Feedback Intervention|Participants who were randomized to the provider-feedback intervention arm received goal setting, and feedback graphs and charts,
89616139|NCT05241171|Active Comparator|Fitbit alone|Participants in self-managed control group were provided access to the Fitbit website or app but did not receive any feedback on their activity level from the study team.
89616140|NCT03430752||Survivors of Childhood Solid Tumors|Survivors of Childhood Solid Tumors were invited to fill in a set of questionnaires.
89616141|NCT03430752||Survivors of Childhood Leukemia|Survivors of Childhood Leukemia were invited to fill in a set of questionnaires.
89616142|NCT01928667||Microscopic Colitis|Group consists of subjects diagnosed with either collagenous of lymphocytic colitis between January 1, 2000 and December 31, 2012
89616143|NCT01928667||Healthy Controls|Control group consists of subjects with no history of microscopic colitis. Group is age and sex matched with the case-group
89616144|NCT01928745||CABG patients|15 patient who underwent a CABG will be submitted in this study
89616145|NCT01928745||Sepsis patients|15 patients with a severe sepsis will be admitted in this study
89616146|NCT03433716|Experimental|PNM group|Subjects were treated for 3 weeks, once a week. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol by Valera and Minaya. The subjects were seated while their arms were supported by an arm rest, forearms pronated and elbows moderately flexed. The radial nerve was located at 4cm proximal to the tip of the lateral epicondyle of humerus using an ultrasound machine (cross-section), subsequently, an acupuncture needle (0.30mm x 30mm) was inserted in a short axis approach, perpendicular to the surface of the skin, until the perineurium of the radial nerve (in close proximity).
89616147|NCT03433716|No Intervention|Control group|the subects of the control group received no any treatment
89616148|NCT01928823|Experimental|D-Cycloserine + CBT|Patients receiving CBT (cognitive behavioral therapy) and D-Cycloserine (3 times, 50 mg, oral) directly after an exposure
89616149|NCT01928823|Placebo Comparator|Placebo + CBT|Patients receiving CBT (cognitive behavioral therapy) and a placebo pill (3 times, looking identical to the DCS pill) directly after an exposure
89616150|NCT01290874|Experimental|Tiotropium|Tiotropium bromide will be evaluated as a treatment for asthma.
89616151|NCT01290874|Active Comparator|Salmeterol or Formoterol|Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
89616152|NCT02977494|Experimental|Daratumumab Bortezomib|
89616153|NCT01929603|Experimental|Olaparib alone, olaparib+rifampicin|Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
89616154|NCT04217850|Experimental|500 kcal Energy Deficit|The goal of the nutrition and exercise intervention will be to induce an energy deficit of approximately 500 kcals/day over the 12-week period in order to induce an approximate 5% weight loss in all participants.
89616155|NCT04178460|Experimental|Assigned Interventions|Niraparib combined with MGD013
89616156|NCT01344616|No Intervention|usual clinical care|usual clinical care with no intervention
89616157|NCT01344616|Experimental|lifestyle counseling|computer-based clinical support to patient
89616158|NCT01929837|Experimental|E-fied navigated rTMS|Electrical field navigated transcranial magnetic stimulation
89616159|NCT01929837|Sham Comparator|sham E-field navigated rTMS|Sham electrical field navigated rTMS
88986790|NCT00498316|Other|Cord Blood Infusion|"Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.~Fludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.~Rituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.~Cyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
88986791|NCT01245166|Active Comparator|Acarbose|
88986792|NCT01245166|Experimental|Metformin/Acarbose|
88986793|NCT00402701|Experimental|1|Students in school with active walk-to-school promotion programs.
88986794|NCT00402701|No Intervention|2|Students in schools with access to standard school district transportation resources.
88986795|NCT00498472|Active Comparator|A|Pre-discharge NT-ProBNP based
88986796|NCT00498472|No Intervention|B|Discharge date and treatment not based on the knowledge of pre-discharge NT-proBNP levels
88986797|NCT00498589|Placebo Comparator|1|Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks
88986798|NCT00498589|Placebo Comparator|2|1 IM or SC of placebo per week during 24 weeks
88986799|NCT00498667||PET/CT|all patients with aggressive lymphoma who had a baseline and interim pet/ct study
89616160|NCT01929837|Experimental|non-navigated rTMS|non-navigated rTMS
89616161|NCT01929837|Experimental|Experimental, Navigated rTMS|Navigated rTMS,
89616162|NCT01928901|Experimental|administration of Bronchipret|7 days of administration of Bronchipret, 2 FCT t.i.d
89616163|NCT01928901|Experimental|administration of Sinupret|7 days of administration of Sinupret, 2 CT t.i.d
89616164|NCT01928901|Placebo Comparator|administration of Bronchipret Placebo|7 days of administration of Bronchipret Placebo, 2 FCT t.i.d
89616165|NCT01928901|Placebo Comparator|administration of Sinupret Placebo|7 days of administration of Sinupret Placebo, 2 CT t.i.d
89616166|NCT03433560||Korean female breast cancer patients|
89616167|NCT01290952|Experimental|Off-pump bypass surgery|Off-pump coronary artery bypass graft (OPCAB) using mandatory a stabilization device and advisable, but not mandatory, a heart positioner
89616168|NCT01290952|Active Comparator|On-pump bypass surgery|coronary artery bypass graft with cardiopulmonary bypass (CPB/CAB)
89036066|NCT01282801|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
89616169|NCT03008902||Non-patients|Non-patients, who have not had vertebral fractures or hyperkyphosis, and have not been seen at BIDMC, will be recruited from the community as described in section B3C and B6 below. The non-patient group will consist of 16 healthy adults ages 18-40.
89616170|NCT03008902||Patients|Patients, who have been seen at BIDMC for vertebral fractures or hyperkyphosis, will be identified by review of medical records as described in B3C and B6 below. The patient group will consist of 32 adults ages 75 and older who have previously been diagnosed with a thoracic vertebral fracture at BIDMC.
89616171|NCT01928979||Group 1|
89616172|NCT04075734|Experimental|Intervention|The intervention consists of (1) online self-management educational modules and (2) weekly peer mentor calls to facilitate engagement with the modules and offer specialized support over approximately six weeks.
89616173|NCT04075734|No Intervention|Usual Care|Participants are not receiving the tested intervention. They continue to receive standard or routine psychosocial or transition care available to them as part of the normal practice
89616174|NCT05240859||Geleli|RA patients treated with Geleli
89616175|NCT01926249||Individuals at high risk of developing Alzheimer's dementia|"2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.~300 participants with an isolated cognitive complaint and an age of 60 years or more."
89616176|NCT04395105|Experimental|High dose Dexamethasone|Intravenous Dexamethasone 16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10
89616177|NCT04395105|No Intervention|Usual care - low dose Dexamethasone|Intravenous Dexamethasone 6 mg qd for 10 days based on RECOVERY trial
89616178|NCT04072770|Experimental|Pea|Mashed potatoes meal containing pea protein isolate intrinsically labelled with 15N and 2H
89616179|NCT04072770|Active Comparator|Casein|Mashed potatoes meal containing casein isolate intrinsically labelled with 15N and 2H
89616180|NCT01291108|Experimental|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.
89616181|NCT01291108|Experimental|AGN-210669 + bimatoprost|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.
89616182|NCT01291108|Experimental|AGN-210669 + bimatoprost vehicle|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
89616183|NCT01291108|Active Comparator|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.
89616184|NCT01291108|Experimental|bimatoprost + AGN-210669|bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.
89616185|NCT01291108|Other|bimatoprost + bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
89616186|NCT01920789|Experimental|Stereotactic radiotherapy|Arm A: Stereotactic radiotherapy to a dose of 66 Gy at the isocenter with 22 Gy per fraction in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour. A heterogeneous dose distribution is used so 45 Gy will cover the PTV.
89616187|NCT01920789|Active Comparator|Conventionally fractionated radiotherapy|Arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour.
89616188|NCT01929213|Experimental|Udenafil|
89616189|NCT01929213|Experimental|Bosentan|
89616190|NCT01929213|Experimental|Udenafil/Bosentan|
89616191|NCT01291498|Other|HIFU Treatment|High Intensity Focused Ultrasound. This is not a comparative study
88986800|NCT00498784|Experimental|Arm 1|
88986801|NCT00127946|Active Comparator|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
88986802|NCT00127946|No Intervention|placebo|This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
88986803|NCT00498979|Experimental|recombinant interferon alfa-2b|recombinant interferon alfa-2b
88986804|NCT01245205|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive Akt inhibitor MK2206 PO QOD for 28 days (35 days for course 1) and lapatinib ditosylate PO QD or BID on days 1-28 (days 9-35 for course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88986805|NCT01245244|Experimental|Morphine|
88986806|NCT01245244|Placebo Comparator|Placebo|
88986807|NCT00499018|Experimental|1|R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
88986808|NCT00499018|Experimental|1 BIS|R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
88986809|NCT00499018|Experimental|2|R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2
88986810|NCT00499018|Experimental|2 BIS|R-CHOP14 x 4 Restaging + R-CHOP14 x 4
88986811|NCT00127985|Experimental|Active|IV 6-methyl-prednisolone
88986812|NCT00127985|Placebo Comparator|Comparator|IV Placebo
88986813|NCT00499057|Other|single arm study|single arm study
88986814|NCT00424164|Experimental|Tamoxifen-lapatinib|Tamoxifen alone at cycle 1 and as of cycle 2 in combination with Lapatinib.
88986815|NCT00424164|Experimental|Lapatinib-tamoxifen|Lapatinib will be given alone for 2 weeks during cycle 1. As of cycle 2, you will receive the combined treatment Lapatinib and Tamoxifen
88986816|NCT00128024|Active Comparator|Statins|
88986817|NCT00128024|No Intervention|No statins|
88986818|NCT00499135|Experimental|Schedule A|Patients receive sunitinib malate PO QD in weeks 1-4. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
89036067|NCT01282801|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
89036068|NCT02920814|Experimental|Time Intensive CBT for SPOV|Time intensive CBT for SPOV involving 6 weekly sessions and 2 intensive days of 4 hours each (over 8 weeks in total).
89036069|NCT00532350|Experimental|1|QAT370
89036070|NCT00532350|Placebo Comparator|2|Placebo
89036071|NCT00532350|Active Comparator|3|Tiotropium
89036072|NCT02920775||Pain|
89036073|NCT02920775||PCP|
89036074|NCT02920775||Dentist|
89036075|NCT02920775||Surgery|
89036076|NCT02920775||Emergency Medicine|
89036077|NCT02920775||Oncology|
89036078|NCT02920775||Hospice and Palliative Medicine|
89616192|NCT02984085|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene 7) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
89616193|NCT03726060|Other|splint therapy|"Alginate impressions will be taken and the plaster models of the dental arches will be made.~The splint will be subsequently delivered to the patient with the relative indications of use.~The splint therapy consist in the use of neuromuscoral splint every the night for 6 months."
89616194|NCT03726060|Other|physical therapy with splint therapy|"The treatment consists of a series of interventions: advice on self-treatment techniques to be performed at home and administering manual therapy techniques addressed to: temporomandibular district, cervical and cervico-thoracic junction.~Each session will be carried out individually and will last for 45 minutes. This duration will be divided as follows: 25 minutes dedicated to the temporomandibular district, 15 minutes to the cervical and cervico-thoracic junction, 5 minutes to teaching self-treatment techniques to be carried out at home and to verify the correct way of performing them.~The cycle will consist of 10 sessions distributed over 3 months."
89616195|NCT05604651||dry eye disease|Dry eye disease was diagnosed according to the Tear Film and Ocular Surface Society (TFOS) DEWS II criteria: (1) Ocular Surface Disease Index (OSDI) score ≥ 13 and (2) one of these signs; fluorescein tear breakup time (TBUT) <10 sec; abnormal ocular surface staining (>5 corneal spots or > 9 conjunctival spots).
89616196|NCT05604651||control|The controll group enrolled healthy participants without ocular and systemic diseases.
89616197|NCT03430518|Experimental|Her2-negative Metastatic Breast Ca and Recurrent Ovarian Ca|Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian cancer
89616198|NCT02938806||Obese/overweight children with T1D|No intervention
89616199|NCT02938806||Normal weight children with T1D|No intervention
89616200|NCT02938806||Obese/overweight children, no diabetes|No intervention
89616201|NCT02938806||Healthy, normal weight children|No intervention
89616202|NCT03430440|Experimental|CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button.
89616203|NCT03430440|Active Comparator|Conventional mode|The conventional mode in which only the basal infusion rate is set to be fixed.
89036079|NCT02920775||Anesthesiology|
89036080|NCT02920775||Neurology|
89036081|NCT02920775||Nurse Practitioners|
89036082|NCT02920775||Pediatrics|
89036083|NCT02920775||Physical Medicine & Rehabilitation|
89036084|NCT02920775||Physician Assistant|
89036085|NCT02920775||Rheumatology|
89036086|NCT02920775||All Other Specialties|
89036087|NCT02932566|Active Comparator|Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
89036088|NCT02932566|Placebo Comparator|Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
89036089|NCT02920736||sepsis with acute renal injury group|Based on definition of sepsis with Sepsis 3.0 and AKI was defined using KDIGO（Kidney Disease: Improving Global Outcomes） consensus definition of AKI.The group was the secondary AKI in sepsis patients
89036090|NCT02920736||sepsis non-acute renal injury group|The group was the non-AKI in sepsis patients
89036091|NCT02920736||control group|Approximately 110 persons(18-80years) with healthy physical examination and without liver and kidney dysfunction
89036092|NCT01282372||Participants with moderate to severe rheumatic disease|Participants with moderate to severe rheumatic disease (RA, PsA, or AS), who received adalimumab in accordance with approved label
89036093|NCT00532389|Experimental|Panobinostat (LBH589)|
89036094|NCT02920580|Active Comparator|Extubation|Extubation by removal of endotracheal tube.
89036095|NCT02920580|Active Comparator|Usual care|The usual clinical practice is removal of the endotracheal tube (extubation), or insertion of tracheostomy, timed according to physicians' discretion
89036096|NCT02932644||Rheumatoid arthritis patients|Participants in the original, parental trial
89036097|NCT02920697|Experimental|B-cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)|
89036098|NCT02920697|Experimental|Chronic Lymphocytic Leukaemia (CLL)|
89036099|NCT05466708|Experimental|Esketamine combined with dexmedetomidine|Esticketamine was administered at 1mg/kg, IVP, then intravenously pumped at 0.25-1.5mg/ kg (kg×h) in combination with dexmedetomidine 1.0μg/kg for 20 min, followed by continuous intravenously pumped at 0.2-0.7mg/ kg (kg×h), maintaining a RASS score of -2-0.
89036100|NCT05466708|Active Comparator|Dexmedetomidine|Dexmedetomidine was administered at 1.0μg/kg for 20 min, followed by continuous intravenous pumping at 0.2-0.7mg/ kg×h to maintain a RASS score of -2-0
89036101|NCT02920541|Experimental|S 055746|
89036102|NCT01282294||ETN PROtect|There is only 1 cohort in this case series
89616204|NCT01920867|Active Comparator|RB, ST, IV|Injections of BMSC retrobulbar (RB), subtenon (ST) and intravenous (IV)
89616205|NCT01920867|Active Comparator|RB, ST, IV, IVIT|Injections of BMSC retrobulbar, subtenon, intravenous and intravitreal ( IVIT )
89616206|NCT01920867|Active Comparator|RB, ST, IV, IO|Injection of BMSC retrobulbar, subtenon, intravenous and intraocular (IO) with vitrectomy
89036103|NCT02932293|Experimental|SOF+DCV+SMV 3-4 wks|Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is <500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is >500 IU/ml.
89036104|NCT02932293|Experimental|SOF+DCV+SMV 6-8 wks|Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is <500 IU/ml or (b) 8 weeks if HCV VL on day 2 is >500 IU/ml.
89036105|NCT02920502|Placebo Comparator|Arm 1: Placebo|Normal Healthy Volunteers without any skin pathology, will receive placebo
89616207|NCT03128424|Experimental|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is intended for patients with atherosclerotic lesions of the SFA
89616208|NCT01925937|Experimental|Coenzyme Q10 & Atorvastatin|10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
89616209|NCT01925937|Active Comparator|Atorvastatin & placebo|10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
89616210|NCT03430362|Active Comparator|Hyoscine group|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
89616211|NCT03430362|Placebo Comparator|Control group|Group B, will receive 2 ml of normal saline single intravenous dose
89616212|NCT05240079|Experimental|Patients|
89616213|NCT03430284|Experimental|Integrated Treatment|
89036106|NCT02920502|Experimental|Arm 2: cholecalciferol: 50,000 IU|Normal healthy Volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 50,000 IU.
89616214|NCT03430284|Other|General Treatment|
89616215|NCT03057639||Observational (questionnaires)|Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
89616216|NCT01346488||Adalimumab|Participants with RA treated with adalimumab who are either engaged in paid work for more than 35 hours per week (paid workers) or those who are either engaged in paid work for less than 35 hours per week or who perform basic activities of daily life other than paid work (home workers).
89616217|NCT03428022|Experimental|Apatinib combined with EGFR-TKI|Apatinib（Tablet（Tab. ）500millgram（mg）/day（d）） combined with EGFR-TKI（as previously）
89616218|NCT05076396|Experimental|PM14|Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
89616219|NCT00986661|Experimental|PV-10 Injection (Intralesional)|Subjects in each of three cohorts will receive a single dose of PV-10 to one Target Lesion.
89616220|NCT03128112|No Intervention|Exam room without poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms without posters will be ask to fill out a second short questionnaire after seeing their physician that will ask parents whether they discussed their child's weight status with their physician and whether they believe their own child is: very overweight, overweight, healthy weight, underweight, or very underweight.
89616221|NCT03128112|Active Comparator|Exam room with poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms with posters will be directed to read the poster on the exam room wall. After viewing the poster and after seeing their physician, parents will be ask to fill out a second short questionnaire that will ask parents whether they discussed their child's weight status with their physician, whether this conversation was prompted by the poster, and whether they believe their own child is very overweight, overweight, healthy weight, underweight, or very underweight.
89616222|NCT00989781|Experimental|PCOS women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
89036107|NCT02920502|Experimental|Arm 3: cholecalciferol: 100,000 IU|Normal healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 100,000 IU.
89036108|NCT02920502|Experimental|Arm 4: cholecalciferol: 200,000 IU|Normal Healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 200,000 IU.
89036109|NCT01282216|Active Comparator|Donor PCV13|Donors receive PCV13 prior to bone marrow donation.
89036110|NCT01282216|Active Comparator|Donor Havrix|Donors receive Havrix prior to bone marrow donation.
89616223|NCT00989781|Experimental|Normal women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
89616224|NCT01292746|Experimental|Erchonia ML Scanner (MLS)|Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light
89616225|NCT03430128|Experimental|Oral IMPACT|"Perioperative immunonutrition will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.~The recommended dose for IMPACT immunotherapy is one packet, to be taken three times a day."
89616226|NCT03430128|Active Comparator|Standard Nutrition (ENSURE)|Standard nutritional supplementation will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
89616227|NCT03427944|Active Comparator|Calcium Dobesilate group|Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group
89616228|NCT03427944|Placebo Comparator|Conventional Treatment group|conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)
89616229|NCT03050463||breast cancer with bilateral mastectomy|This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
89616230|NCT03050463||breast cancer without bilateral mastectomy|This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
89616231|NCT03050463||healthy subjects|Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
89616232|NCT01922193|Experimental|Test Group|
89616233|NCT01922193|Active Comparator|Control Group|
89616234|NCT03429972|Experimental|Paclitaxel and Elasto-Gel™ Cryotherapy|Cryotherapy will be applied using Elasto-Gel™ hypothermia mitts and slippers for 15 minutes before, during and 15 minutes after each paclitaxel infusion.
89616235|NCT03429972|Other|Paclitaxel alone|Paclitaxel will be administered without cryotherapy.
89616236|NCT03423576|Experimental|Intervention|comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.
89616237|NCT03423576|No Intervention|Control|Standard care
89616238|NCT01347034|Active Comparator|External Beam Radiation Therapy (RT)|Arm A - University of Florida - External Beam Radiation Therapy (RT) - As outlined in Intervention Description
89616239|NCT01347034|Experimental|External Beam RT + DC Injection|Arm B - Moffitt Cancer Center - External Beam RT + Autologous Dendritic Cells (DC) Injection - As outlined in Intervention Description
88986819|NCT00499135|Experimental|Schedule B|Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
88986820|NCT01245361|Experimental|Infliximab|Group I: Infliximab 3 mg/kg wk 0,2,6
88986821|NCT01245361|Placebo Comparator|sodium chloride|RA 1 solution for infusion, intravenous use Sterile normal saline 0.9% sodium chloride
88986822|NCT01245400|Experimental|Z-Lig|Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) graft implantation performed under anesthesia during an arthroscopic procedure.
88986823|NCT01245400|Active Comparator|Allograft|Allograft bone/tendon graft implantation performed under anesthesia during an arthroscopic procedure.
88986824|NCT00424203|Experimental|Myocet, Endoxan|
88986825|NCT01245556|Experimental|BMS-908662 or Ipilimumab (A)|
88986826|NCT01245556|Experimental|BMS-908662 or Ipilimumab (B)|
88986827|NCT02274532|Experimental|Patient|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 5 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability, with the option with patients for a 1-week period of take-home testing and associated pre- and post-assessments.
88986828|NCT02274532|Other|Control|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 4 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability. Control subjects will participate in two sessions, including a pre- and post-training assessments.
88986829|NCT00128141|No Intervention|1|
88986830|NCT00128141|Experimental|2|tactile stimulus
88986831|NCT00499525|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour once weekly for 3 weeks. Patients also receive oral sorafenib tosylate twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88986832|NCT00499525|Active Comparator|Arm II|Patients receive paclitaxel as in arm I and oral placebo twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
88986833|NCT01245790|Experimental|1|Healthy subjects (Stage 1)
88986834|NCT01245790|Experimental|2|Mild renal impairment (Stage 2)
88986835|NCT01245790|Experimental|3|Moderate renal impairment (Stage 2)
88986836|NCT01245790|Experimental|4|Severe renal impairment (Stage 2)
88986837|NCT01245790|Experimental|5|End stage renal disease (Stage 1)
88986838|NCT01245829|Placebo Comparator|Matt|A standard non antimicrobial laminated chart which will form the control group (group 1).
88986839|NCT01245829|Experimental|Cellomed|Observation charts coated in a laminate with antimicrobial properties (Cellomed) will form group 2.
88986840|NCT00128258|Experimental|open|open treatment
88986841|NCT00146679|Placebo Comparator|Usual Care (UC)|Usual Care provided by providers
88986842|NCT00146679|Active Comparator|Psychoeducational Telephone CounselingTC|Education and Counseling for ICD patients provided through Telephone Contact
89616240|NCT03423498|Experimental|groups with toe-spread-out exercise|This arm included individuals with hallux valgus (research group A) and without deformation (research group B), who were patients of Department of Rehabilitation, Poznan University of Medical Sciences. They performed the toe-spread-out exercises for 14 days and were examined twice: before and after exercises. The examination of participants included a surface electromyography, electroneurography and goniometer tests to measure the range of motion in the hallux joints.
89616241|NCT03423498|No Intervention|control group|This arm included individuals with hallux valgus deformity from the control group which did not undergo any therapy of hallux. They were patients of Department of Rehabilitation as well. These participants were examined twice at an interval of 14 days in the same way as the patients from experimental arm.
89616242|NCT04351282|Experimental|SBRT|4-6 cycles of chemotherapy±immunotherapy and radical radiotherapy for nasopharyngeal tumors were given. SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
89616243|NCT03427710|Experimental|Cohort A1|CiVi007 dose 1
89616244|NCT03427710|Experimental|Cohort A2|CiVi007 dose 2
89616245|NCT03427710|Experimental|Cohort A3|CiVi007 dose 3
89616246|NCT03427710|Experimental|Cohort A4|CiVi007 dose 4
89616247|NCT03427710|Experimental|Cohort A5|CiVi007 dose 5
89616248|NCT03427710|Placebo Comparator|Combined placebo group|group response from placebo subsets of dosing cohorts
89616249|NCT01349140|Experimental|Nerve Block|The dominant side (left or right) will be randomized to one of two treatment groups: the higher or lower concentration of the local anesthetic EXPAREL. The non-dominant contralateral side will receive the other possible treatment. The volume of each and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve blocks is 30-40 mL).3 Since volume will remain constant, we will vary the dose of EXPAREL by varying concentration (volume x concentration = dose). Of note, EXPAREL may be mixed with normal saline to vary the concentration. Randomization will be based on computer-generated codes. Randomization will be in blocks of two, and stratified by sex.
89616250|NCT05248113|Experimental|Intraoperative electrical stimulation of cochlear nerve|Electrical stimulation of the cochlear nerve will be tested intraoperatively in patients undergoing vestibular schwannoma resection.
89616251|NCT03079167|Experimental|Erythropoietin|Erythropoietin (epoetin alfa) 1000 IU/kg birth weight (capped at 4000IU daily) IV infusion, on Days 1, 2, 3, 5 and 7 of age
89616252|NCT03079167|Placebo Comparator|Placebo|IV normal saline (equiv. volume), on Days 1, 2, 3, 5 and 7 of age
89616253|NCT04449900||The exudative CCH group|Treatment naïve patients with exudative CCH which caused subfoveal retinal detachment and/or intraretinal fluid
89616254|NCT04449900||The healthy eye control group|In the healthy eye control group, all eyes should have no ocular diseases and the best-corrected visual acuity (BCVA) should be 20/20 or better.
89616255|NCT03427632||percutaneous Vertebroplasty|patients meet the inclusion and exclusion criteria will be subjected to percutaneous vertebroplasty receiving bone cement (Polymethyl methacrylate)
89616256|NCT03427554|Experimental|Tretinoin cream 0.1%|Once daily at home, to apply the entire affected areas of the face.
89616257|NCT03427554|Active Comparator|RETIN-A® Cream|Once daily at home, to apply the entire affected areas of the face.
89616258|NCT03427554|Placebo Comparator|Vehicle of the test product|Once daily at home, to apply the entire affected areas of the face.
88986843|NCT00146679|Active Comparator|Psychoeducation through Groups (SG)|Education and Counseling for ICD patients provided in a group setting with other ICD Patients
88986844|NCT00499798||patients on temozolimide for brain cancer|
88986845|NCT00499837|Experimental|80 mg/kg AAT inhaled|80 mg/kg AAT inhaled
88986846|NCT00499837|Placebo Comparator|Placebo inhaled|Placebo inhaled
88986847|NCT00499876|Active Comparator|A|
88986848|NCT00499876|Placebo Comparator|B|
88986849|NCT05562401|Experimental|Coconut Water|To determine if Coconut Water is more effective on hydration status than Sport Drink in adolescents who perform physical exercise.
88986850|NCT05562401|Active Comparator|Sport Drink|To determine if Coconut Water is more effective on hydration status than Sport Drink in adolescents who perform physical exercise.
88986851|NCT00500032|Experimental|Arm 1|Active Comparator for all subjects enrolled in 6108A1-500
89616259|NCT03128190|No Intervention|Control group|In the control period, patients were given intravenous fluids at the discretion of the anesthesiologist based on institutional protocol using 250ml of crystalloids or 100ml of colloids based on central venous pressure (CVP) and mean arterial pressure (MAP) measurements. The aim was to keep the CVP ≥ 8mmHg and MAP ≥ 65mmHg. Fluid boluses were administered up to a total of 1000ml, if patients did not attain a MAP of >65 mmHg, a vasopressor drug was administered.
89616260|NCT03128190|Experimental|PPV group|intraoperative fluid management was titrated to maintain PPV< 10%. fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
89616261|NCT01349920||Infliximab 5 mg/kg|Infliximab treatment and endoscopy.
89616262|NCT03128346|Experimental|The nerve block group|TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen)
89616263|NCT03128346|Active Comparator|The standard of care group|Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen.
89616264|NCT03423108|No Intervention|Control|Participants randomized to this group will perform monthly cohabitation meetings.
89616265|NCT03423108|Experimental|G150|Participants randomized to this group will be enrolled to a 150 min/week structured and supervised exercise training. The program consists of 3 sessions in a week, each of these lasting 50 minutes. The session will be composed of aerobic training (25 minutes at 60-75% of HRmax) and strength training (25 minutes, 8 whole-body exercises at up to 8-12 maximal repetitions).
89616266|NCT03423108|Experimental|G300|Participants randomized to this group will be enrolled to the same structural settings of G150 group (type of exercise, exercise intensity and weekly frequency). They will receive twice the G150 group dose's. To do so, each session will last 100 minutes (50 minutes of aerobic exercise training and 50 minutes of strength training).
89616267|NCT02521116|Other|Healthy subjects|healthy study subjects, age 18-80 years
89616268|NCT03427476|Experimental|Metastatic RCC (> 3 lesions)|Patients with metastatic renal cell carcinoma and planned biopsy of a metastatic lesion (N = 5)
89616269|NCT03427476|Experimental|RCC patients with primary lesions > 7 mm in diameter|Cohort B: Patients with evidence of primary renal cell carcinoma and lesions > 7 cm (may also have metastatic disease) (N = 5)
89616270|NCT03423030|Experimental|Panel A - Active|N = 6, 10 mg then 40 mg of PBTZ169 Formulation
89616271|NCT03423030|Placebo Comparator|Panel A - Placebo|N = 2, 10 mg then 40 mg of matching placebo
89616272|NCT03423030|Experimental|Panel B - Active|N = 6, 20 mg then 80 mg of PBTZ169 Formulation
89616273|NCT03423030|Placebo Comparator|Panel B - Placebo|N = 2, 20 mg then 80 mg of matching placebo
89616274|NCT03423030|Experimental|Panel C - Active|N = 6, First dosing of Panel C with 160 mg PBTZ169 Formulation then Second dosing of Panel C with 160 mg PBTZ169 Native Crystalline Powder (NCP)
89616275|NCT03423030|Active Comparator|Panel C - Placebo|N = 2, 160 mg of matching placebo for the two interventions
89616276|NCT03423030|Experimental|Panel D - Active|N = 6, First dosing of Panel D with 320 mg PBTZ169 Formulation then Second dosing of Panel D with 320 mg PBTZ169 Native Crystalline Powder (NCP)
89616277|NCT03423030|Active Comparator|Panel D - Placebo|N = 2, 320 mg of matching placebo for the two interventions
89616278|NCT03427242|Experimental|treatment arm|oral apatinib
89616279|NCT01252732|Experimental|Single-Dose IV Oritavancin Diphosphate|
89616280|NCT01252732|Active Comparator|IV Vancomycin|
89616281|NCT02854644|Experimental|glioma|1 additional blood sample for patients with glioma and without treatment
89616282|NCT02854644|Experimental|breast cancer|2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
89616283|NCT02854644|Experimental|breast cancer HER2+|1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
89616284|NCT02854644|Experimental|Breast Cancer HER 2+ or HER2 triple -|1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
89616285|NCT00989235|Active Comparator|Abatacept (10 mg/Kg)|
89616286|NCT00989235|Active Comparator|Abatacept (5 mg/Kg)|
89616287|NCT06154122|Experimental|Virtual Reality Plus Treatment As Usual|"3 sessions of virtual reality upper limb treatment for up to 30 minutes each will be administered each week for 12 weeks.~Participants randomised to the VR treatment arm will also receive treatment as usual for their upper limbs (see Treatment As Usual)."
89616288|NCT06154122|Active Comparator|Treatment As Usual|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
89616289|NCT06154109|Experimental|Xiaopi granules plus neoadjuvant chemotherapy|Xiaopi granules have a dosage of 18 g per bag, 18 g per administration, twice daily, for a total of 8 days per treatment course. The duration of the treatment course will align with that of the chemotherapy regimen. The neoadjuvant chemotherapy is developed based on the National Comprehensive Cancer Network (NCCN) guidelines. Different treatments and doses are according to the standard recommendations outlined in the guidelines. Treatment options may include AC-T, ECT, EC, TC, AC, TAC, TP, etc.
88986852|NCT00500188|Experimental|7 Days|Imatinib Mesylate 300 mg orally twice daily starting 7 days before surgery.
88986853|NCT00500188|Experimental|5 Days|Imatinib Mesylate 300 mg orally twice daily starting 5 days before surgery.
89616290|NCT06154109|Experimental|Xiaopi decoction plus neoadjuvant chemotherapy|Xiaopi decoction has a dosage of 18 g per bag, 18 g per administration, twice daily, for a total of 8 days per treatment course. The duration of the treatment course will align with that of the chemotherapy regimen. The neoadjuvant chemotherapy is developed based on the National Comprehensive Cancer Network (NCCN) guidelines. Different treatments and doses are according to the standard recommendations outlined in the guidelines. Treatment options may include AC-T, ECT, EC, TC, AC, TAC, TP, etc.
89616291|NCT06154109|Placebo Comparator|Placebo plus neoadjuvant chemotherapy|The placebo is a look-alike substance that contains no active drug and has a placebo inspection report. The dosage of 18g per bag, 18g per administration, twice daily, for a total of 8 days per treatment course. The duration of the treatment course will align with that of the chemotherapy regimen. The neoadjuvant chemotherapy is developed based on the National Comprehensive Cancer Network (NCCN) guidelines. Different treatments and doses are according to the standard recommendations outlined in the guidelines. Treatment options may include AC-T, ECT, EC, TC, AC, TAC, TP, etc.
89616292|NCT06154096||Healthy volunteer|Subject without MASLD or metabolic-associated disease
89616293|NCT06154096||MASLD|Subject with MASLD
89616294|NCT06154044|Experimental|Treatment Arm|After successful LVAD implantation, patients will be enrolled and followed for 2 months to allow for postoperative rehabilitation and heart failure medical therapy and LVAD support optimization. All patients will then undergo autologous CD34+ cell therapy which will be delivered via intracoronary route. All patients will be followed for 6 months after cell therapy. At baseline, and at 1, 3 and 6 months after cell therapy, we will perform comprehensive clinical evaluation. Clinical, biochemical, biomarker-related, imaging and myocardial histology data will be transferred to a secured central database.
89616295|NCT06154031|Experimental|stroke survivors|
89616296|NCT06154018|Active Comparator|0.8:1|This arm will receive an initial administration of 0.8mg of protamine per 100IU of totally given heparin.
89616297|NCT06154018|Active Comparator|0.6:1|This arm will receive an initial administration of 0.6mg of protamine per 100IU of totally given heparin.
89616298|NCT06153992|Active Comparator|Control group|The control group received exercise therapy (once a day, 40min/ times, 5 times/week), occupational therapy (once a day, 30min/ times, 5 times/week), low-frequency electricity (once a day, 20min/ times, 5 times/week), acupuncture therapy (once a day, 20min/ times, 5 times/week) .
89616299|NCT06153992|Active Comparator|Traditional isokinetic treatment group|The treatment machine adopts the traditional isokinetic training machine, the treatment items and the treatment parameters are the same as the intelligent isokinetic treatment group.
89616300|NCT06153992|Experimental|Intelligent isokinetic treatment group|"In the intelligent isokinetic treatment group, isokinetic muscle strength training of hemiplegic lower limb flexion muscle group and knee extension muscle group was added to the treatment of the control group.~Intelligent isokinetic treatment to increase the above treatment hemiplegic lower limb flexion, knee extension muscle isokinetic strength training. The patient's seat back was adjusted to 85° and fixed with a belt and shoulder cross-strap. The thigh of the subject was fixed with a nylon buckle, the lateral condyle of the femur was the axis, the lever arm length was scale 12, and the distal leg was fixed above the ankle. Passive joint activities were performed on the knee and ankle before training. Avoid joint damage and perform three low-resistance warm-up exercises. Choose 60°/s, 90°/s, 120°/s angular speed isokinetic training according to the patient's specific conditions. Each angular speed training is 10 times, the interval rest is 15s.ect."
89616301|NCT06153953|Active Comparator|group A|
89616302|NCT06153953|Active Comparator|group B|
89616303|NCT06153927||Patients with CCTA and FFR assessment|Patients with CAD who underwent CCTA, invasive coronary angiography, and FFR measurement will be included in this study.
89616304|NCT06153914|Experimental|Surgical group|This study intends to select patients with decompensated hepatitis B cirrhosis who meet the enrollment criteria and perform sequential adult left lateral lobe liver transplantation.
89616305|NCT06153901|Experimental|endoloop mediated cardioplication (ECLC)|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
89616306|NCT06153862|Active Comparator|Malaria patients|Malaria patients
89616307|NCT06153862|Active Comparator|Non malaria donors|Healthy individuals (donors; controls)
89616308|NCT06153849||BCG instillation patient|Patients with pathology-confirmed median to high risk urothelial carcinoma defined by 2023 EAU guideline, underwent transurethral resection of bladder tumor and receiving BCG instillation therapy.
89616309|NCT06153823|Experimental|virtual reality glasses|
89616310|NCT06153823|Active Comparator|show-tell-do technique.|
89616311|NCT06153784|Experimental|Combination of hydroxyurea and thalidomide|Hydroxyurea was continued at a dose of 10-20 mg/kg/day for 6 months and then thalidomide was added orally at a dose of 2-5mg/kg/day.
89616312|NCT06153771||Extremely premature newborn|(born before 32 weeks' gestation)
89616313|NCT06153706|Experimental|L-PFR loaded with medical grade metronidazole|
89616314|NCT06153706|Active Comparator|L-PFR|
89616315|NCT06153680|Experimental|One medical device as investigational device|
88986854|NCT00500188|Experimental|3 Days|Imatinib Mesylate 300 mg orally twice daily starting 3 days before surgery.
88986855|NCT04710914|Experimental|sedation by inhaled isoflurane|sedation by midazolam with the MIRUS device
88986856|NCT04710914|Active Comparator|sedation with intravenous midazolam|continuation of sedation with intravenous midazolam
89616316|NCT06153654||Obese|Obese participants with BMI >30
88986857|NCT00500344|Other|1|
88986858|NCT00146835||Cohort A|The primary study cohort includes all infants from SCKP who have begun their primary course of vaccine with PEDIARIX co-administered with Prevnar and for whom at least one dose of PEDIARIX was administered prior to the infant's 9-month birthday and safety follow-up information is available.
88986859|NCT00146835||Cohort B|This Historical cohort includes age-, gender- and area-matched infants who received at least one dose of DTaP vaccine co-administered with 7Pn between 1 January 2002 and 29 April 2003.
89616317|NCT06153654||Lean|Lean participants with a BMI <25
89616318|NCT06153654||Bariatric|Participants with scheduled bariatric surgery.
89616319|NCT06153628|Experimental|Virtual reality glasses|"First of all, the State Anxiety Inventory will be applied to all women (60 women).Then, milk will be expressed from both breasts once a day (10:00) for the first 3 days and the amount of milk expressed will be recorded in the Breast Milk Amount Tracking Form. After the first 3 days, all women will be relaxed by watching virtual reality glasses (10 minutes) once a day (10:00 in the morning) for 3 days, and the State Anxiety Inventory will be applied at the end of the video. Then, milk will be expressed from both breasts and recorded in the Breast Milk Amount Tracking Form."
89616320|NCT06153615|Experimental|Idiopathic Hypersomnia|
88986860|NCT00146835||Cohort C|"This delayed Pediarix use clinics cohort includes all infants who, during the enrollment period for Cohort A, begin their primary course of vaccination with a DTaP vaccine co-administered with 7Pn. It is age-, gender-, and area-matched in a similar manner to Cohort B."
88986861|NCT01245868|Experimental|Bupivacaine|Bupivacaine as used routinely
88986862|NCT01245868|Placebo Comparator|Lidocaine added to bupivacaine|lidocaine is added to bupivacaine
88986863|NCT05562362|Experimental|Fasted State|Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will be randomized to 1 of 3 dose levels (200mg, 400mg and 800 mg) and will receive a single dose of sparsentan in the fasted state on Period 1, Day 1 (Study Day 1)
88986864|NCT05562362|Experimental|Fed State|Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will have a single dose of sparsentan (200mg, 400mg and 800 mg) in the fed state (high-fat breakfast) on Period 2, Day 1 (Study Day 8)
88986865|NCT05562362|Experimental|Fed State - Multiple|Sparsentan will be administered in 3-dose level in healthy subjects. Subjects will have multiple doses of sparsentan (200mg, 400mg and 800 mg) in the fed state on Period 3, Days 1 to 14 (Study days 12 to 25)
88986866|NCT00500422|Experimental|Doxil + Gemcitabine + Velcade|Doxil Starting dose of 20 mg/m^2 intravenous (IV) over 2 hours on Day 1 and Gemcitabine 500 mg/m^2 IV over 30 minutes on Days 1 and 8; Velcade Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles.
89036111|NCT01282216|Active Comparator|Recipient vaccine|Recipients receive Havrix and PCV13 post bone marrow transplant.
89616321|NCT06153615|Active Comparator|Narcolepsy type 1|
89616322|NCT06153615|Active Comparator|Healthy subject|
89036112|NCT04323709||levosimendan group|All patients undergoing VA-ECMO from January 2012 to December 2018 and treated with levosimendan were eligible.
89036113|NCT04323709||group control|All patients undergoing VA-ECMO from January 2012 to December 2018 but not treated with levosimendan were eligible.
89036114|NCT02920463||Critically ill patients with infection|Critically ill adult patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
89036115|NCT01281865|Experimental|Treatment (everolimus and imatinib mesylate)|Patients receive everolimus PO once daily and imatinib mesylate PO once daily on days 1-28. Course repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and tumor tissue sample collection at baseline and periodically during study for correlative biomarker and protein expression studies.
89616323|NCT06153602|Experimental|Nalbuphine group|0.5% Hyperbaric Spinal Bupivacaine 5-15 mg (1-3 ml) + Nalbuphine(10mg/ml) 0.8 mg intrathecal
89616324|NCT06153602|Placebo Comparator|Control group|0.5% Hyperbaric Spinal Bupivacaine 5-15 mg (1-3 ml) + 0.9% Sodium chloride 0.08 ml intrathecal
89616325|NCT06153589|Experimental|Musicotherapy + debridement and usual analgesic protocol|Patients in the experimental arm will receive classic debridement care and usual use of analgesic treatment, accompanied by a musicotherapy session respecting the standardized method of the U-shaped sequence.
89616326|NCT06153589|No Intervention|Debridement and usual analgesic protocol|Patients in the experimental arm will receive classic debridement care and usual use of analgesic treatment.
89616327|NCT06153524|Experimental|Physical Activity|The PA group will be guided by sports scientists to progressively build up to 60-minutes of daily moderate-vigorous exercise. The goals will be tailored to existing activity levels so as not to increase physical activity too quickly and will be set out in an action plan to be handed out at the beginning of the intervention. For the autonomous PA plan, participants from the PA group will be given Fitbits and a comprehensive manual of instructions to help them build their own weekly plan, and they will participate in weekly online meetings. The manual is structured with four main sections: 1. General information on training, 2. Moderate activity, 3. Vigorous activity, 4. Training agenda. The latter is for the participants to fill in after every training session. This information is then cross-checked by the PA specialists with the comments gathered during the weekly meetings.
89616328|NCT06153524|Experimental|Smartphone|The ST group will be guided by psychologists/psychotherapists to reduce their average daily phone use by 50% over the first two months of the intervention and to maintain this for the final month, and this will be measured using a screen time recording application. This intervention group will receive a list of nudge strategies (adapted from Olson et al., 2022) to add small barriers which guide them into reducing their phone use (e.g. disabling notifications, not using phone in bed). Participants will select three strategies (minimum) to try in the first month, then an additional two (minimum) for the second month. They will also receive a list of potential replacement activities to do instead of using their phone and are asked to choose which activities they want to try and/or list their own ideas. How easy/difficult each strategy is, how enjoyable the replacement activities are, and whether they want to change will be discussed in the meetings.
89036116|NCT02932683|Experimental|MedNav assisted resuscitators|MedNav will be used to perform neonatal resuscitation on a mannequin and assessed after teaching and 7 weeks after intervention, following this a small group will be used as a cross over study.
89036117|NCT02932683|No Intervention|No MedNav resuscitators|Neonatal resuscitation will be performed on a mannequin (without the use of MedNav) and assessed after teaching and 7 weeks after intervention.
89616329|NCT06153524|No Intervention|Control|The control group will receive basic written explanatory information on the study and will then simply record all their physical activity and screen time, without being set specific goals. This group will receive a list of mental health resources, all materials for increasing physical activity and reducing screen time and will be invited to a psychoeducation talk at the end of the study.
89616330|NCT06153511|Experimental|Patient with spinal condition who requires a transpedicular fixation intervention.|Patient with spinal condition (vertebral fractures, spinal stenosis, kyphosis, among others) who requires a intervention for spinal fusion with pedicle screws.
89616331|NCT06153472|Experimental|VR-based sensory stimulation|Participants in the experimental group will receive VR-based sensory stimulation.
89616332|NCT06153472|No Intervention|Usual care|Participants in the control group will receive usual care.
89616333|NCT06153433|Active Comparator|Rosuvastatin IR Tablet|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
89616334|NCT06153433|Experimental|SUVARO®OD Tablet|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
89616335|NCT06153342|Active Comparator|TL-925 Arm|Subjects will be dosed in clinic on days of dosing.
89616336|NCT06153342|Placebo Comparator|Placebo Arm|Subjects will be dosed in clinic on days of dosing.
89616337|NCT06153329|Experimental|THDB0206 injection|
89616338|NCT06153329|Active Comparator|Humalog®|
89616339|NCT06153329|Active Comparator|BC222insulin lispro injection|
89616340|NCT06153316||Exposure Schools|From the dataset that matches study criteria, randomly select three K-12 schools that have recently experienced mass violence or attempted mass violence (< two years prior) and three K-12 schools that have experienced mass violence or attempted mass violence less recently (> two years ago). Students, teachers and principals of these schools will be eligible to participate.
89036118|NCT02920658|Experimental|NAVS Naphthalan|NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
89036119|NCT02920658|Active Comparator|0.05% Betamethasone dipropionate|0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; 0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
89036120|NCT02889679|Experimental|Underwater resection|All eligible lesion identified in a patient will be resected by the underwater technique. Excluded lesions will be resected by standard polypectomy.
89616341|NCT06153316||Non-exposure schools|For the study, the non-exposure schools will be matched to exposure schools on five key variables: state, urban/non-urban, school type (public/private), school level (elementary/middle/high), and school size, and selected from the complete database of K-12 schools across the United states. Students, teachers and principals of these schools will be eligible to participate.
89616342|NCT06153186|Experimental|Flunarizine|Flunarizine 5 mg capsules will be administered once a day at night. If the 5mg/day dose is tolerated by any given participant, the dose will be escalated to 10mg/day taken as two 5mg capsules at night
89616343|NCT06153160|Experimental|Patients with HemaShock device|"12 patients in cardiac arrest will receive HemaShock device during resuscitation.~All other interventions will be made following guidelines."
89616344|NCT06153160|No Intervention|Patients with-out HemaShock device|"12 patients in cardiac arrest will not receive HemaShock device during resuscitation.~All other interventions will be made following guidelines."
89616345|NCT06153147||Late effects after nephrotoxic chemotherapies.|3 and 5 year kidney and blood pressure effects after cancer therapy.
89616346|NCT06153134|Active Comparator|Curcuma xanthorriza Roxb.|"Fifteen patients will apply 10% Curcuma xanthorriza Roxb. cream topically at the half of the face, once daily in night, for 2 months.~Along with study drug or positive control, patients will receive standard uniform sunscreen and face wash."
89616347|NCT06153134|Active Comparator|Kojic acid|"Fifteen patients will apply 2% kojic acid cream topically at the half of the face, once daily in night, for 2 months.~Along with study drug or positive control, patients will receive standard uniform sunscreen and face wash."
89616348|NCT06153121||Adult tennis players|tennis players between the age of 18 and 35
89616349|NCT06153121||Adult swimmers|swimmers between the age of 18 and 35
89616350|NCT06153121||Adolescent tennis players|tennis players between the age of 12 and 18
89616351|NCT06153121||Adolescent swimmers|swimmers between the age of 12 and 18
89616352|NCT06153082|Experimental|ROTEM Group|In ROTEM group if CT EXTEM >80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM <35 and MCF FIBTEM <8 CRYO or Fibrinogen concentrate, if MCF EXTEM<35 and MCF FIBTEM >8 Platelet, CL LY>50 Trenaxemic acid.
89616353|NCT06153082|Active Comparator|THROMBOELASTOGRAPHY|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°
89616354|NCT06153030||Patient with right colonic diverticulitis|
89616355|NCT06152991|Experimental|Test Group|Oral administration of 2 capsules of Godex® three times a day (tid) for 96 weeks
89616356|NCT06152991|Placebo Comparator|Control Group|Oral administration of 2 placebo capsules three times a day (tid) for 96 weeks
89616357|NCT06152978|Experimental|Sintilimab plus chemotherapy|Sintilimab: 200mg; cisplatin: 75mg/m2, d1, routine hydration for 3 days; nab-paclitaxel: 260mg/m2, d1, every 3 weeks, 2-3 cycles.
89616358|NCT06152978|Active Comparator|Chemotherapy|Cisplatin: 75mg/m2, d1, routine hydration for 3 days; nab-paclitaxel: 260mg/m2, d1, every 3 weeks, 2-3 cycles.
89616359|NCT06152939||1|patients with acute anterior ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention .
89616360|NCT06152939||2|patients with acute anterior ST segment elevation myocardial infarction have thrombolytic therapy .
89616361|NCT06152900|Experimental|Treatment Arm|All subjects enrolled in the study will be placed into the treatment arm of the study, to be treated by the Accufit device.
89616362|NCT06152887|Active Comparator|Active tDCs|Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. An anodal electrode is placed above the primary motor cortex, M1, while a cathode is placed above the contralateral supraorbital area.
89616363|NCT06152887|Sham Comparator|Sham tDCS|Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 30 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
89616364|NCT06152848||Patients affected by malnutrition|Patients affected by malnutrition due to deficiency or excess
89616365|NCT06152848||Sex- and age- matched healthy controls|Sex- and age- matched healthy controls not affected by any pathology and/or malnutrition due to deficiency or excess
89616366|NCT06152822|Experimental|treatment group|pyrotinib+capecitabine+bevacizumab
89616367|NCT06152796|Experimental|Paracetamol|preterms receive oral/iv paracetamol at the dose of 15 mg/kg every 6 h for 3 days.
89616368|NCT06152796|Experimental|Ibuprofen|preterms receive oral ibuprofen at the initial dose 10 mg/kg, followed by 5 mg/kg after 24 and 48 h
89616369|NCT06152783||A group|The sequence of endoscopy in group A was as follows: white light endoscopy, ME-NBI endoscopy,Confocal laser endomicroscopy.
89616370|NCT06152783||B group|The sequence of endoscopy in group B was as follows: white light endoscopy, Confocal laser endomicroscopy, ME-NBI endoscopy.
89616371|NCT06152757|Experimental|BGT007H injection|Intravenous infusion
89616372|NCT06152705|Experimental|fMRI guided iTBS targetting|The target selected is based on functional connectivity determined from the MRI scan.
89616373|NCT06152705|Active Comparator|Neuronavigation guided iTBS targetting|A technique for treatment location targeting, based on structural images of the brain using standard coordinates.
89616374|NCT06152692|Experimental|OSA + CPAP|OSA + CPAP
89616375|NCT06152692|Placebo Comparator|OSA + sham CPAP|OSA + sham CPAP
89616376|NCT06152692|No Intervention|Control|Control
89616377|NCT06152679||Patients|Patients who have undergone day-case bladder tumour resection or bladder outflow obstruction surgery (prostate resection or enucleation) within the past 6 weeks.
89616378|NCT06152666||Staff|Members of healthcare teams involved in the delivery of day-case endourology operations.
89616379|NCT06152640|Experimental|dTMS treatment group|dTMS treatment group has 40 patients with dTMS intervention using real coils, targeting ACC, given 5 times a week for 6 weeks, with a total of 30 treatments.
89616380|NCT06152640|Sham Comparator|pseudo-stimulation group|Pseudo-stimulation group has 40 patients with dTMS intervention using sham coils (with the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field). It is given 5 times a week for 6 weeks, with a total of 30 treatments.
89036121|NCT02889679|Active Comparator|Conventional resection|All eligible lesion identified in a patient will be resected by the conventional (gas distended colon) resection techniques. Excluded lesions will be resected by standard polypectomy.
89036122|NCT02890030||Case-Control|Patients with testicular germ cell tumor who were treated with surgery and not cisplatin-based chemotherapy
89036123|NCT01281202|Active Comparator|CPP-109 Vigabatrin Tablets|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received 3 CPP-109 Vigabatrin 500 mg Tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Individual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
89036124|NCT01281202|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received Vigabatrin matching placebo tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Indivdiual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
89036125|NCT02889718|Experimental|anaesthesia with CONCERT-CL® station|During the surgery, 3 drugs usually used for anaesthesia will be administered by the CONCERT-CL® station
89036126|NCT02932215|Experimental|All participants|All participants will receive open label lorcaserin
89616381|NCT06150794|Active Comparator|MTX alone (arm 1)|"Participants will receive intra-matrical methotrexate injection in the affected fingers of both hands, once a month for 3 months.~Comparison arms represent right hand (MTX+EL) and left hand (MTX alone) in the same participants."
89036127|NCT01281124|Experimental|Treatment (azacitidine)|Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89616382|NCT06150794|Active Comparator|MTX + EL (arm 2)|"Participants will receive excimer laser treatment in the affected fingers of the right hand only, in addition to treatment with methotrexate injection the same participants are receiving in the same hand.~Excimer laser will be applied twice weekly for 3 months.~Comparison arms represent right hand (MTX+EL) and left hand (MTX alone) in the same participants."
89616383|NCT06150040|Experimental|Refractory Acute Myeloid Leukemia|Patients who meet primary refractory disease definition according to ELN criteria after 2 cycles of standard [AZACITIDINE +VENETOCLAX] (i.e: patients who have failed to have a complete remission (with complete (CR) or incomplete hematologic recovery (CRi))
89616384|NCT06149208||Year 1 - Treatment Change|This group will receive the new treatment standard
89616385|NCT06149208||Year 2 - Sustainability|This group will be used to measure sustainability of the new treatment standard
89616386|NCT06145776|Experimental|dual-task group|Dual-Task Training Protocol (DTTP) The dual-task training protocol (DT) will consist in cognitive exercise categories: verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks, which will be associated to treadmill gait training (Sousa et al., 2016). Verbal commands will focus on the following: (1) large strides; (2) heel strike; (3) raising the knees while walking (Kelly et al., 2012).
89036128|NCT00623857|Active Comparator|1|Zinc
89036129|NCT00623857|Active Comparator|2|Vitamins and minerals other than zinc
89036130|NCT00623857|Active Comparator|3|Vitamins plus zinc and other minerals
89036131|NCT00623857|Placebo Comparator|4|Placebo for all vitamins and minerals
89036132|NCT05466435|Experimental|Heavy Slow Resistance group|Heavy slow resistance exercise will be given along with traditional physical therapy program
89036133|NCT05466435|Placebo Comparator|Control group|Traditional physical therapy program will be given to the control group
89036134|NCT02920424|Experimental|Part A: JNJ-56022473 or Placebo (4:1)|Subjects will receive 3 subcutaneous (SC) administrations of the same dose level of JNJ-56022473 Dose 1, Dose 2, or Dose 3 or placebo every 2 weeks (in the ratio of 4:1 [4 active: 1 placebo]).
89036135|NCT02920424|Experimental|Part B: JNJ-56022473 or Placebo (5:1)|Subjects will receive 3 SC administrations of the same dose level of JNJ-56022473 or placebo every 2 weeks (in the ratio of 5:1 [5 active: 1 placebo]). The dose level(s) will be based upon an interim analysis (IA) of the Part A data.
89036136|NCT01280968|Experimental|NIC002 Vaccine in Aluminum hydroxide|4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
89616387|NCT06145776|Active Comparator|control group|The participants will perform 21 min treadmill gait training associated to tDCS active in F3 for 20 min, 3 times a week for 4 weeks.
89616388|NCT06145594|Experimental|EMA+Maintenance TMS|Weekly EMA monitoring and a cluster of 5 maintenance sessions scheduled if/when PHQ9 scores reach threshold, per algorithm. Participants continue other concurrent treatment as usual (TAU) with medications, psychotherapy, etc per outpatient clinicians.
89616389|NCT06145594|Active Comparator|EMA only|Weekly EMA monitoring without scheduled maintenance TMS. Participants in this arm may get TMS retreatment according to current standard of care (i.e., through their insurance coverage). Participants continue other concurrent treatment as usual (TAU) with medications, psychotherapy, etc per outpatient clinicians.
89616390|NCT06143371|Experimental|CAN10 single ascending dose|A single dose of CAN10 will be administered intravenously (IV) to healthy subjects.
89616391|NCT06143371|Placebo Comparator|CAN10 single ascending dose - placebo|A single dose of matching placebo will be administered intravenously (IV) to healthy subjects.
89616392|NCT06143371|Experimental|CAN10 multiple ascending dose|Multiple doses of CAN10 will be administered subcutaneously (SC) to subjects with mild to moderate plaque psoriasis
89616393|NCT06143371|Placebo Comparator|CAN10 multiple ascending dose - placebo|Multiple doses of matching placebo will be administered subcutaneously (SC) to subjects with mild to moderate plaque psoriasis
89616394|NCT06141317|Experimental|PASC transplantation (25 million PASCs/patient)|Pluripotent Adipose-Derived Stem Cells will be delivered intravenously
89616395|NCT06141317|Placebo Comparator|Control|Saline solution will be delivered intravenously
89616396|NCT06140901|Active Comparator|Arm non PIBO|children hospitalized for adenovirus or rhinovirus infection with non progressing to PIBO
89616397|NCT06140901|Active Comparator|Arm PIBO|Children hospitalized for adenovirus or rhinovirus infection with progressing to PIBO in evolution.
89616398|NCT06139874|Experimental|THRIVE Coached|Thrive is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention. It will be delivered by school social workers/counselors. Following training in THRIVE, school therapists in this condition will receive ongoing weekly group supervision over the life of the study.
89616399|NCT06139874|Experimental|THRIVE Low Coached|Thrive is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention. It will be delivered by school social workers/counselors. Following training in THRIVE, school therapists in this condition will receive weekly group supervision only during thier first THRIVE case.
89616400|NCT06139874|Active Comparator|Parenting Wisely|Online asynchronous parenting training that parents will complete independently.
89616401|NCT06137911|Experimental|Group A:JYP0061 15mg|Experimental: JYP0061 Single ascending dose
89616402|NCT06137911|Placebo Comparator|Group B:JYP0061 placebo comparator 15mg|Placebo comparator: JYP0061 placebo comparator Single ascending dose
89616403|NCT06137911|Experimental|Group C:JYP0061 food influence group 15mg|Food influence group
89616404|NCT06137911|Experimental|Group D:JYP0061 multiple ascending doses 30mg|Multiple ascending doses
89616405|NCT06137911|Placebo Comparator|Group E:JYP0061 placebo comparator food influence group 30mg|Food influence group
89616406|NCT06137911|Placebo Comparator|Group F:JYP0061 placebo comparator multiple ascending doses 30mg|Multiple ascending doses
89616407|NCT06128291||Posterior colporrhaphy|Medical records of women received concomitant posterior colporrhaphy for their pelvic organ prolapse repairs. Comparison will be made to compare preoperative and postoperative conditions.
89616408|NCT06122103||Clareon Monofocal|
89616409|NCT06122103||Light-Adjustable Lens|
89616410|NCT06121024||Simple Tracheal Stenosis|Simple stenosis was defined as lesions with a vertical extension <1 cm (short segment) with endoluminal occlusion, without tracheomalacia or loss of cartilage support.
88986867|NCT00500461|Experimental|Subjects receiving GSK233705|Each subject will receive one or more ascending doses given as a constant rate IV infusion over 30 minutes and a single oral dose of 250 microgram GSK233705 solution. IV doses will include 30, 70, 110 microgram of GSK233705 at specified time points.
88986868|NCT05562284|Experimental|IAT combined with conservative therapies|IAT (Drug: 50 mg Alteplase)+conservative treatments
88986869|NCT05562284|Other|Conservative therapies|conservative treatments including traditional ones and hyperbaric oxygen therapy
88986870|NCT00500617||segment 1|Gene discovery blood draw
88986871|NCT00500617||sement 2|Assay development blood draw
88986872|NCT00500617||segment 3|Assay validation blood draw
88986873|NCT00500617||segment 4|Additional assay testing blood draw (Note: post discovery diabetic subjects assigned to this group)
88986874|NCT00500695|Experimental|Motivational Interviewing|Motivational Interviewing
88986875|NCT00500695|Active Comparator|Psychoeducation|Psychoeducation
89616411|NCT06121024||Complex Tracheal Stenosis|Complex stenosis were defined as lesions ≥1 cm and varying degrees of cartilage involvement or circumferential contractile scar or tracheal stenosis associated with malacia and inflammation.
88986876|NCT00500734||Heart Disease Patients|
88986877|NCT00500851|Active Comparator|1|In case of meeting clinical criteria for jejunal feeding, tubes are placed using CORTRAK (electromagnetic imaging).
88986878|NCT00500851|Active Comparator|2|Endoscopic placement of jejunal feeding tubes fulfilling clinical indication for jejunal feeding.
88986879|NCT01245946|Experimental|Photodynamic therapy|
89616412|NCT06115525||Survivors|Patients admitted to the intensive care unit due to respiratory failure with no mortality in the 3-month follow-up period
89616413|NCT06115525||Nonsurvivors|Patients who were admitted to the intensive care unit due to respiratory failure and mortality was observed in the 3-month follow-up period
89616414|NCT06110637|Experimental|Hard shoes runners|Half-marathon runners with hard shoes preceded and followed by assessment of neuromuscular fatigue.
89616415|NCT06110637|Active Comparator|Soft shoes runners|Half-marathon runners with soft shoes preceded and followed by assessment of neuromuscular fatigue.
89616416|NCT06109233||MRD negativity|NDMM patients who obtained MRD negativity after induction and consolidation therapy
89616417|NCT06109233||MRD positivity|NDMM patients who MRD positivity after induction and consolidation therapy and agree to adjust the treatment regimen
89616418|NCT06108375|Other|Live then recording|During the first visit music will be played live, during the second visit a recording will play.
89616419|NCT06108375|Other|Recording then live|During the first visit a recording will play, during the second visit music will be played live.
89616420|NCT06105788|Experimental|Exercise|Arm 1: All participants, knee OA and pain-free individuals, will undergo a single exercise of arm exercise using an arm ergometer and;
89616421|NCT06105788|Active Comparator|Lower Body Exercise|Arm 2: All participants, knee OA and pain-free individuals, will undergo a single exercise of leg exercise using a cycling ergometer.
89616422|NCT06100120|Experimental|Hybrid implants|Hybrid implants will be placed in this group
89616423|NCT06100120|Active Comparator|Fully etched implants|Fully etched implants will be placed in this group
89616424|NCT06090344|No Intervention|Usual care|Usual care from healthcare providers
89616425|NCT06090344|Experimental|Traditional video format|Multimedia videos formatted as traditionally found online
89616426|NCT06090344|Experimental|Evidence-informed video format|Multimedia videos formatted as per evidence advice
89616427|NCT06082882|Experimental|In-Person Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker delivered behavioral education and referrals to low-cost services. Delivered in person to participants in community and clinic settings. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
89616428|NCT06082882|Experimental|Telephone Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker delivered behavioral education and referrals to low-cost services. Delivered by telephone to individual participants. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
88986880|NCT01245946|Experimental|Conventional therapy|
89616429|NCT06082882|Experimental|Zoom Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker delivered behavioral education and referrals to low-cost services. Delivered by Zoom to individual participants. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
89616430|NCT06082505|Experimental|In-Person Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker deliver behavioral education and referrals to low-cost services. Deliver in person to participants in community and clinic settings. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
88986881|NCT05562206|Experimental|Study group|All subjects using the study device
88986882|NCT01245985|Experimental|treatment arm|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
89616431|NCT06082505|Experimental|Telephone Delivered Breast and Cervical Cancer Behavioral Intervention|Community health worker deliver behavioral education and referrals to low-cost services. Participants are followed up by health coach navigators to address barriers and connect to safety-net clinics.
88986883|NCT01246024|Experimental|Hypoxia|
88986884|NCT00500968|Active Comparator|Stent|
88986885|NCT00500968|Active Comparator|conventional distal pancreatectomy|
88986886|NCT05562050||Control|
88986887|NCT05562050||COVID-19 related anosmia|
88986888|NCT05562050||Head-trauma related anosmia|
88986889|NCT00501241|Placebo Comparator|1|placebo twice daily
88986890|NCT00501241|Experimental|2|20 mg ATI-7505, BID for 4 weeks
88986891|NCT00501241|Experimental|3|40 mg ATI, BID, 4 weeks
88986892|NCT00501241|Experimental|4|80 mg ATI-4505, BID for 4 weeks
88986893|NCT00501241|Experimental|5|120 mg ATI-7505, BID for 4 weeks
88986894|NCT01246102|Experimental|1|starting at 20 mg/m2
88986895|NCT00501280||MSF Women + their children|Blood and urine samples and interviews of Migrant or seasonal farmworker (MSF) woman + their children
88986896|NCT00501280||Non-MSF Women + their Children|Blood and urine samples and interviews of non-MSF women (women who have never worked in agriculture) and their children
88986897|NCT01246141||Repair group|patients in repair group underwent tricuspid repair for functional tricuspid regurgitation.
88986898|NCT01246141||replacement group|In this group, patients underwent tricuspid valve replacement for functional tricuspid regurgitation.
88986899|NCT01246219|Experimental|GH treatment|4 years of GH treatment
88986900|NCT01246219|Placebo Comparator|Placebo|1 year treatment with placebo followed by optional 3 years of GH treatment
88986901|NCT01246219|No Intervention|Non treatment group|
88986902|NCT02274610|Experimental|Group A|Period 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere
88986903|NCT02274610|Experimental|Group B|Period 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP
88986904|NCT01246336||Patients with parkinsonism|Patients suffering from Parkinson's disease or parkinsonism
88986905|NCT01246336||Healthy controls|Patients not suffering from Parkinson's disease or any other neurological disorder
88986906|NCT00501670||Group A|Collection of lesion samples and blood sampling from subjects aged >=50 years with clinically diagnosed herpes zoster
88986907|NCT04697134|Experimental|Conscious Discipline Intervention Group|Participants in this group received one-on-one Conscious Discipline classes with a Roving Caregiver. These classes consisted of the dissemination of Conscious Discipline Skills and fun songs, games, and activities to foster connections between the infant and caregiver. Both the infant and caregiver received the intervention simultaneously.
88986908|NCT04697134|No Intervention|Control|Participants in this group did not receive the intervention.
88986909|NCT00501748|Experimental|Rituximab|
88986910|NCT00501787|Active Comparator|Group B|Non-tailoring
88986911|NCT00501787|Active Comparator|Group A|Tailoring
88986912|NCT05561699|Experimental|Penpulimab Combined With Chemoradiotherapy(CRT)|
88986913|NCT00501865|Experimental|Sequence AB|Subjects will be randomized to sequence AB, where A represents fasted state and B represents fed state. Subjects will be administered a single oral dose of GW273225 50 milligrams (mg) in the fasted state in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 2. There will be at least 21 days between doses for the fasted and fed treatment phases of the study.
88986914|NCT00501865|Experimental|Sequence BA|Subjects will be randomized to sequence BA, where A represents fasted state and B represents fed state. Subjects will be orally administered a single dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg in the fasted state in dosing period 2. There will be at least 21 days between doses for the fed and fasted treatment phases of the study.
88986915|NCT00501904|Active Comparator|Group A|Short protocol
88986916|NCT00501904|Active Comparator|Group B|Long protocol
88986917|NCT00501982|No Intervention|1|N Cpap in delivery room and than rescue curosurf in case of need
89616432|NCT06080217|Experimental|study group|"The patients were lying in the lithotomy position with the streTched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average."
89616433|NCT06080217|Sham Comparator|placebo group|"The patients were lying in the lithotomy position with the streched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe) . A capacitive probe in the free treatment / power control program was used, with NO electricity was released to the bladder for 20 minutes"
89616434|NCT06058936|Experimental|virtual reality|"The patients in this group are under exercise training and pneumatic pressure followed by Pablo©Handle training for 45 minutes per week for 8 week~-Pablo©Handle training One-dimensional therapy games using five games are available for Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Apple hunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week"
89616435|NCT06058936|Active Comparator|regular exercises|"The patients in this group will receive exercise training and pneumatic pressure only for 30 min3 times per week for 8 week~Exercise training will be done by the following exercise for 15 min3 times per week for 8 week~Intermittent Compression Therapy Parameters: using the (Care Pump expert 8)~Pressure. 60 mmHg, Direction. Distal to proximal, Speed 4 to 5, for 15 min /3 times per week for 8 week"
89616436|NCT06054061|Experimental|TAU + Wellbeing promotion group (Think and Cope Positively) Intervention|In addition to their usual treatment, participants form the experimental arm will receive 15 weekly intervention sessions, where aspects related to subjective wellbeing, life plans, alliance with the therapist or family and social relationships will be worked on.
89616437|NCT06054061|Other|TAU + waiting list|The control group will continue to receive the treatment as usual in their intervention resources. At the end of the 15-week control period they will receive the intervention.
89616438|NCT06051188|Experimental|FCV-PCV|90 minutes of flow-controlled ventilation followed by 90 minutes of pressure-controlled ventilation.
89616439|NCT06051188|Experimental|PCV-FCV|90 minutes of pressure-controlled ventilation followed by 90 minutes of flow-controlled ventilation.
89616440|NCT06045793|Experimental|TNX-1300|A single IV 200 mg injection of TNX-1300
89616441|NCT06045793|Placebo Comparator|Placebo|A single IV injection of placebo with UC
89616442|NCT06036446|Experimental|Cerclage|Cervical cerclage placement with removal during the 36th week of gestation or earlier if clinically indicated.
89616443|NCT06036446|Other|Control|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
89616444|NCT06029049|Experimental|Modified Time Principle Induction (MTPI) with rocuronium|
89616445|NCT06029049|Active Comparator|RSI with succinylcholine|
89616446|NCT06028620|Experimental|Maltreated children|"The Maltreated Children group was assessed before and after a psychological intervention using clinical scales (anxiety, depression, post-traumatic stress disorder and Callous unemotional traits) and an emotion paradigm through functional magnetic resonance imaging (fMRI). The psychological intervention implemented with the maltreated group was the Trauma Focused-Cognitive Behavior Therapy.~For this study, 12 to 16 sessions of 60-90 min each, were implemented once a week for 4 months. 14 out of 15 maltreated children completed the TF-CBT units and one week after that, they underwent the post-treatment assessment."
88986918|NCT00501982|Experimental|2|Poractant alfa (Curosurf) + N Cpap in delivery room
88986919|NCT00502021|Experimental|1|Supplement of flaxseed powder (60 g/day)during 12 weeks
88986920|NCT00502021|Placebo Comparator|2|Placebo powder supplement 60 g/day during 12 weeks
89616447|NCT06028620|No Intervention|Healthy Control group|This group did not have any records of maltreatment. They were assessed using clinical scales (anxiety, depression, post-traumatic stress disorder and Callous unemotional traits) and an emotion paradigm through functional magnetic resonance imaging (fMRI). Their scores and brain images were compared with the maltreatment group before this group underwent psychological treatment.
89616448|NCT06023290|Other|Study population (single arm)|
89616449|NCT06020937||Control|Healthy patients
89616450|NCT06020937||Multiple Sclerosis 1|Patients with multiple Sclerosis and Trigeminal disorders
89616451|NCT06020937||Multiple Sclerosis 2|Patients with Multiple Sclerosis without trigeminal concerns
89616452|NCT06018493|Experimental|intervention group|In intervention group, participants will receive the whole peri-renal fat modification therapy (including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting and initiating) Intervention: Device: focused power ultrasound mediate inferior perirenal adipose tissue modification
89616453|NCT06018493|Sham Comparator|sham-control group|"In sham control group, participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.~Intervention: Device: sham-control group"
88986921|NCT00502021|Experimental|3|Flaxseed oil 30 ml/day (10 g ALA)during 12 weeks
88986922|NCT00502021|Placebo Comparator|4|Safflower oil 30 ml/day (no ALA) during 12 weeks
88986923|NCT00147303|Experimental|group L|25mg sarpogrelate
88986924|NCT00147303|Experimental|group M|50mg sarpogrelate
88986925|NCT00147303|Experimental|group H|100mg sarpogrelate
88986926|NCT00502099|Active Comparator|1|Pegylated interferon alpha 2a plus ribavirin
88986927|NCT00502099|Active Comparator|2|Pegylated interferon alpha 2b plus ribavirin
89616454|NCT06002191|Experimental|Flourish + Questionnaires|Participants will be onboarded to Flourish by a research study clinician, following which they will receive a text messaging program for 4 weeks as well as an accompanying resources website. As part of the text messaging program, participants will receive brief questionnaires evaluating their online experiences once every 3 days.
89616455|NCT06002191|Active Comparator|Questionnaires Alone|Participants will be onboarded to a text message program that solely will send participants brief questionnaires evaluating their online experiences once every 3 days.
89616456|NCT06001853|Active Comparator|Arm A Treatment|Participants in Arm A will be scheduled for a single set of intra-articular injections of allogeneic, culture-expanded BM-MSCs at the dose 10 x106 in 1 ml per facet joint, for a total of 2 joints to be injected. BM-MSC injections will be performed using fluoroscopic guidance.
89616457|NCT06001853|Placebo Comparator|Arm B: DMSO Crossover|Participants in Arm B will receive a DMSO injection. Following the BM-MSC or DMSO injection, each subject will be followed for study endpoints using a predetermined protocol. A final visit for evaluation and imaging will be conducted at the end of the study.
89616458|NCT05999812|Experimental|Treatment Arm|"ATRA orally 45 mg/m2 daily in 2 divided doses days 1-7, repeat every 14 days~Atezolizumab IV D1, 840 mg every 14 days~Bevacizumab IV D1, 10 mg/kg every 14 days"
89616459|NCT05998837|Active Comparator|Type 2 Diabetes Dapagliflozin 10 mg|Patients with Type 2 Diabetes allocated to Dapagliflozin 10 mg
89616460|NCT05998837|Placebo Comparator|Type 2 Diabetes Placebo|Patients with Type 2 Diabetes allocated to Placebo
88986928|NCT00502138|Experimental|A|Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion
88986929|NCT02958137||Isolated CMC|Arthroscopic Resection Arthroplasty of isolated CMC joint OA. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
88986930|NCT02958137||Pantrapezial|Arthroscopic Resection Arthroplasty of simultaneous ARA of both the CMC and the STT joints. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
88986931|NCT00502177||Quality of Life Questionnaire|Patients undergoing continuous hyperthermic peritoneal perfusion with cisplatin and their parents/caregivers.
88986932|NCT00502255|Experimental|telemonitoring|Health Buddy in patients home situation
88986933|NCT00502255|Experimental|usual care|patients receive care as usual
88986934|NCT04375917|Active Comparator|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
88986935|NCT04375917|No Intervention|control|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
88986936|NCT00502372|Experimental|Enriched product, dietary supplement|Subjects receiving enriched product compared to an unenriched product
88986937|NCT00502372|Active Comparator|1|Subjects not receiving enriched product
88986938|NCT00502411|Experimental|Doxorubicin + Radiation Therapy|Doxorubicin 17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4. Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
88986939|NCT00502528|Placebo Comparator|1|Placebo
88986940|NCT00502528|Active Comparator|2|BQ-123
88986941|NCT01246414||Allergic asthma|Patients with allergic asthma
88986942|NCT01246414||Non-allergic asthma|Patients with non-allergic asthma
88986943|NCT01246414||Non-asthmatic controls|Non-asthmatic controls
88986944|NCT02955901|Active Comparator|3-day low residue diet|Group A - 3 day low residue diet prior to the colonoscopy
88986945|NCT02955901|Placebo Comparator|1-day low residue diet|Group B - 1 day low residue diet prior to the colonoscopy
88986946|NCT02956096|Active Comparator|tDCS device and Treatmill|The stimulation is accomplished with a direct current-tDCS Stimulator Plus device, via two surface electrodes sponge (non-metallic) 5-7 cm2 in saline moistened with a 2mA current during 20 minutes after hemodinamic analysis is performed for 15 minutes and then made only training treadmill for 20 minutes. Placebo tDCS will follow the same procedures, but the tDCS device will only be switched on for 20 seconds. The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve (MACKO , 2005).
88986947|NCT02956096|Sham Comparator|1- tDCS|1. Who received stimulation transcranial direct current active will receive Sham stimulation and who received the placebo stimulation receive active stimulation and then the two groups will do the workout on the treadmill
88986948|NCT05561465|Experimental|Pterygomaxillary disjunction|
89616461|NCT05998837|Active Comparator|Without Diabetes Dapagliflozin 10 mg|Patients without Type 2 Diabetes allocated to Dapagliflozin 10 mg
89616462|NCT05998837|Placebo Comparator|Without Diabetes Placebo|Patients without Type 2 Diabetes allocated to Placebo
89616463|NCT05992571|Placebo Comparator|Placebo|Single dose of a taste-matched calorie-free placebo
89616464|NCT05992571|Experimental|β-OHB|Single dose of a ketone monoester ([R]-3-hydroxybutyl [R]-3-hydroxybutyrate; 0.6 g β-OHB/kg body weight)
89616465|NCT05989100|Experimental|Favourate taste stimulation|The swab will be immersed in sugar, salt, citric acid, or paprika mixed with water, and be placed in -18℃ refrigerator. Select the swabs of the participant favourate taste to brush oral cavity and tounge. The stimulation will last two to three minutes one time, and twice for a rehabilitation session, once per day and six days every week, three weeks totally. Swallowing rehabilitation also include standard training that carried out in the department.
89616466|NCT05989100|Active Comparator|Sour stimulation|Using sour swab to brush oral cavity and tounge of the participant. The treatment duration and other training method is as same as mentioned above.
89616467|NCT05989100|Placebo Comparator|Thermal stimulation|Only ice-water swab to brush oral cavity and tounge. The treatment duration and other training method is as same as mentioned above.
89616468|NCT05985395|Experimental|HEART Camp Connect|Participants will have access to a virtual exercise platform or membership to a medical exercise facility. Participants will meet with a virtual exercise coach via Zoom on a weekly basis.
89616469|NCT05985395|No Intervention|Usual Care|Participants will have access to a virtual exercise platform or membership to a medical exercise facility.
89616470|NCT05982665|Experimental|Molecular hydrogen|Molecular hydrogen inhalation for 60 min at 48 h, 24 h, and 60 min pre-exercise and for 30 min post-exercise and 24 h post exercise.
89616471|NCT05982665|Placebo Comparator|Placebo|Placebo inhalation for 60 min at 48 h, 24 h, and 60 min pre-exercise and for 30 min post-exercise and 24 h post exercise.
89616472|NCT05977530|Experimental|self-rescue training|children will receive self-rescue training from a certified instructor
89616473|NCT05972265|Experimental|Acute Exercise Moderate first|Day 1 Assessments, Day 8 Moderate Intensity Exercise (followed by symptom measures and neuropsychological tests), Day 15 Light Intensity Exercise (symptom measures and neuropsychological tests)
89616474|NCT05972265|Active Comparator|Acute Exercise Light first|Control Day 1 Assessments (symptom measures, neuropsychological tests, and cognitive complaints interview), Day 8 Light Intensity Exercise (followed by symptom measures and neuropsychological tests), Day 15 Moderate Intensity Exercise (symptom measures and neuropsychological tests)
89616475|NCT05972265|Experimental|Chronic Exercise Moderate|9-weeks Moderate Intensity Exercise Day 36 (at 3 weeks) Assessments Day 57 (at 6 weeks) Assessments Day 78 (at 9 weeks) Assessments
89616476|NCT05972265|No Intervention|Activity as Usual|9-week activity as usual Day 36 (at 3 weeks) Assessments Day 57 (at 6 weeks) Assessments Day 78 (at 9 weeks) Assessments
89616477|NCT05970406|Experimental|Active Participants in high intensity dysphagia therapy|Participants with acute dysphagia who will receive high intensity dysphagia therapy during stay in inpatient rehab facility
89616478|NCT05970224|Experimental|Ir-CPI|Ir-CPI will be administered on top of standard of care
89616479|NCT05970224|No Intervention|Standard care|Only standard of care
89616480|NCT05968170|Experimental|Patients receiving allogeneic hematopoietic stem cell transplants|"The test product is an αβ+/CD19+ T-cell depleted stem cell product using the CliniMACS system. The test product is given intravenously over a period of time as dictated by the final volume of the infused product (5mL/kg/hour).~The target dose of CD34+ cells is 20-40 x 10^6/kg, but a minimum of 5 x 10^6/kg is required. The target dose of TCRαβ+ T-cells and CD19+/CD20+ T-cells is ≤ 1 x 10^5/kg."
89616481|NCT05961215|Experimental|Penguin Cold Cap|Patients will receive Penguin cold cap: 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
89616482|NCT05954741|Active Comparator|Group 1|Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset < 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.
89616483|NCT05954741|Active Comparator|Group 2|Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset < 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.
89616484|NCT05954741|Active Comparator|Group 3|Patients with Neurocognitive Disorder with Clinical Dementia Rating Scale score between 0.5 and 1, due to vascular disease or due to multiple etiology), symptoms onset < 12 months, age between 65 and 80 years of age, and signed informed consent to participate in the study.
89616485|NCT05934994|Experimental|Patients with undetermined solitary bone lesions|All patients with indeterminate solitary bone lesions undetermined on conventional imaging for whom a biopsy or excision is scheduled, will be able to participate in the study.
89616486|NCT05930756|Active Comparator|Three-target GNRFA technique (T1)|Radiofrequency ablation will target three of the genicular nerves: the superolateral genicular nerve, the superomedial genicular nerve, and the inferomedial genicular nerve.
89616487|NCT05930756|Active Comparator|Six-target GNRFA technique (T2)|Radiofrequency ablation will target six of the genicular nerves: the superolateral genicular nerve, the superomedial genicular nerve, the inferomedial genicular nerve, two branches from the nerve of vastus intermedius, and the recurrent fibular nerve
89616488|NCT05925868|Experimental|Mobile app|Parents will be given access the Headspace, a mobile mindfulness app, and instructed to use it at least 4 days a week for a minimum of 10 minutes
89616489|NCT05925634|Active Comparator|RPE (usual care)|Participants randomized to usual care (RPE) will not complete a GXT. They will instead be scheduled for an approximately 5-minute educational session (i.e., time/attention-matched control condition) where they will receive information about heart-healthy nutrition. This is standard care at both sites. Patients in the control group will follow standard exercise prescription protocols in CR. This will include a baseline exercise assessment on exercise equipment in the gym (e.g., treadmill, elliptical, rower, NuStep, and/or stationary bicycle) as appropriate. Based on exercise levels achieved on the first day, patients will be given exercise recommendations for their 2nd session of CR and so forth. Participants will be asked to exercise at a moderate intensity RPE level at both sites. As the patients progress in CR, patients will increase their time, intensity, and mode of exercise guided by RPE and clinical assessment.
89616490|NCT05925634|Experimental|GXT+ THHR (intervention)|Patients assigned to the intervention group will complete a GXT approximately one week later and ideally prior to the 4th cardiac rehabilitation session. Resting and peak heart rate from the GXT will be recorded and used to calculate a target heart rate range (THRR) using the Karvonen formula (60-85% Heart rate reserve). After the test, they will receive psychoeducational feedback (PF) about their test results and exercise performance. After the PF, we will discuss the THRR and how it will be used to guide exercise intensity in CR. Patients in the intervention group will use their THHR to adjust their exercise intensity. For the first 6 cardiac rehabilitation sessions, patients will receive feedback about heart rate from the PolarHR monitor, research staff and CR staff when available. The goal is for patients to exercise in THRR for the majority of each exercise session.
89616491|NCT05918952||Testing Group|1-health COVID-19 test and Video
88986949|NCT00147381|Experimental|Campath-1H 20 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 20 mg IV infusion over 3-6 hours.~Day 1: Same protocol of Campath-1H and methylprednisolone as on Day 0.~Day 2: No treatment~Day 3: Initial dose of Tacrolimus 0,1 mg/kg/d (0,05 mg/kg/bid)~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
89036137|NCT01280968|Placebo Comparator|Placebo Vaccine - Aluminum hydroxide|4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
89616492|NCT05918952||Non-Testing Group|
89616493|NCT05917626|Experimental|Digital SPA|A psychological intervention for chronic pain in adolescents administered using an app co-created with patients.
89616494|NCT05917626|No Intervention|Usual Care|Participants assigned to this arm will receive usual care from their hospital.
89616495|NCT05909553|Experimental|Venetoclax Sequence 1|Participants will receive whole venetoclax, followed by crushed venetoclax, and completed with ground venetoclax for a 15 day period.
89616496|NCT05909553|Experimental|Venetoclax Sequence 2|Participants will receive crushed venetoclax, followed by ground venetoclax, and completed with whole venetoclax for a 15 day period.
89616497|NCT05909553|Experimental|Venetoclax Sequence 3|Participants will receive ground venetoclax, followed by whole venetoclax, and completed with crushed venetoclax for a 15 day period.
89616498|NCT05896436|Experimental|Emotion Focused Therapy|Participants will receive 12 weekly 1-hour sessions of Emotion Focused Therapy with a trained student therapist.
89616499|NCT05896436|No Intervention|Wait list control|No intervention; waitlist control group will receive intervention once the data collection during the intervention period has concluded.
89616500|NCT05891158|Experimental|Arm 1, Mild HI: Fazirsiran 200 mg|Participants with mild hepatic impairment (HI) will receive fazirsiran 200 milligrams (mg) subcutaneous (SC) injection on Day 1.
89616501|NCT05891158|Experimental|Arm 2, Moderate HI: Fazirsiran 200 mg|Participants with moderate HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety, and PK data by the sponsor study team in consultation with the investigator.
89616502|NCT05891158|Experimental|Arm 3, Severe HI: Fazirsiran 200 mg|Participants with severe HI will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety, and PK data by the sponsor study team in consultation with the investigator.
89616503|NCT05891158|Experimental|Arm 4, Normal Hepatic Function: Fazirsiran 200 mg|Participants with normal hepatic function will receive fazirsiran 200 mg SC injection on Day 1. The dose may be modified after review of available safety, and PK data by the sponsor study team in consultation with the investigator.
89616504|NCT05890794|Experimental|0.8 mg/kg ilofotase alfa|Single dose administered intravenously over 1 hour
89616505|NCT05890794|Experimental|3.2 mg/kg ilofotase alfa|Single dose administered intravenously over 1 hour
89616506|NCT05889221|Experimental|Combination isatuximab SC, lenalidomide, bortezomib and dexamethasone|
89616507|NCT05873556|Experimental|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|Participants randomized to the Lab-based Cue Reactivity PFI condition will receive a link to the personalized feedback in the lab after completing the cue reactivity protocol. Participants view the feedback on their own during the lab session. The personalized feedback is delivered online and contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
89616508|NCT05873556|No Intervention|Assessment-only control|Participants randomized to the control group will not receive any intervention. They complete all the survey assessments and the lab-based cue reactivity protocol without ever receiving any personalized feedback.
89616509|NCT05872789|Experimental|Diazepam 1% Oral gel|Patients were treated with Diazepam 1% oral gel.
88986950|NCT00147381|Active Comparator|Tacrolimus|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
89616510|NCT05872789|Placebo Comparator|Placebo|Patients treated with a placebo gel control.
88986951|NCT00147381|Experimental|Campath-1H 30 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment.~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
88986952|NCT00502606||patients with provisional crowns|the same patient would serve as control and test
89616511|NCT05870033||Men group|Muscle activity amongst men with KOA
89616512|NCT05870033||Women group|Muscle activity amongst women with KOA
89616513|NCT05856513|Experimental|Child-Pugh A|8 participants with mild hepatic impairment (Child-Pugh A) will be given 600mg of ZSP1273.
89616514|NCT05856513|Experimental|Child-Pugh B|8 participants with moderate hepatic impairment (Child-Pugh B) will be given 600mg of ZSP1273.
89616515|NCT05856513|Experimental|Normal hepatic function|8 participants with normal hepatic function will be given 600mg of ZSP1273.
88986953|NCT05561231|Active Comparator|Group C|Group of patients intubated with C blade of CMAC videolaryngoscopes
89616516|NCT05847322|Other|Contact|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A 3 day course of Azithromycin will be administered on week 6 if colonised.
89616517|NCT05847322|Experimental|Challenge|Challenge volunteers will receive a nasal inoculation containing Bordetella pertussis on Day 0. They will return to the Clinical Research Facility weekly to monitor safety, colonisation and immune responses. A 3 day course of Azithromycin will be administered on week 6 if colonised.
89616518|NCT05844280|Active Comparator|Control Group|receiving physical therapy with BFR+NMES devices used at sub-therapeutic levels
89616519|NCT05844280|Experimental|Treatment Group|receiving physical therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic
89616520|NCT05838131|Experimental|CAR-T cells Infusion|Biological: CART cells chimeric antigen receptor T cells
89616521|NCT05833880||Atopic dermatitis patients|
89616522|NCT05829031|Experimental|Music listening vs. No music listening|Every participant will be randomly assigned (50:50) to one of the following two conditions: Music listening after a stressful and/or discriminatory event (i.e., intervention condition) or no music listening after a stressful and/or discriminatory event (i.e., control condition).
89616523|NCT05826951|Experimental|Alcohol-alcohol|Both conversation partners receive alcohol
89616524|NCT05826951|Placebo Comparator|placebo-placebo|Both conversation partners receive placebo
89616525|NCT05826951|Experimental|alcohol-placebo|participant receives alcohol and conversation partner receives placebo
89616526|NCT05826951|Experimental|placebo-alcohol|participant receives placebo and conversation partner receives alcohol
89616527|NCT05806177|Experimental|AD16|AD16 tablets should be administered only in the morning on the day of the first dose and on the ninth day after the first dose. Fasting is required for at least 10 h before administration.Two dosing cohorts received AD16 From the third day to the eighth day, the medicine was administered twice a day, 1 h before breakfast, 1 h before dinner or 2 h after dinner, with a 12 h interval (time window ±1 h).The duration of oral AD16 tablets was nine days.
89616528|NCT05806177|Placebo Comparator|AD16 placebo|AD16 placebo tablets should be administered only in the morning on the day of the first dose and on the ninth day after the first dose. Fasting is required for at least 10 h before administration.Two dosing cohorts received AD16 placebo From the third day to the eighth day, the medicine was administered twice a day, 1 h before breakfast, 1 h before dinner or 2 h after dinner, with a 12 h interval (time window ±1 h).The duration of oral AD16 placebo tablets was nine days.
89616529|NCT05802056|Experimental|Treatment (aldesleukin, nivolumab, chemotherapy)|Patients receive aldesleukin IP on study. Patients also receive standard of care nivolumab IV, leucovorin calcium IV, fluorouracil IV, and oxaliplatin IV on study. Patients also undergo diagnostic laparoscopy with biopsy, PET/CT or PET/MRI, and collection of blood and tissue samples throughout the trial.
89616530|NCT05795842||AFib monitoring learning algorithms|Participants will wear a prescribed (standard of care) ambulatory ECG monitoring (Biotel Patch or LINQ insertable cardiac monitor) and a MOTO 360 smartwatch, fitted with a proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting.
89616531|NCT05792787||Apical Periodontitis|"Patients with radiographic signs of Apical Periodontitis. The inclusion criteria of the study are healthy patients older than 40 years old, the presence of at least 24 teeth and the ability and willingness to give informed consent. Participants affected by any systemic disease or being administered either antibiotics in the last 6 months or antiaggregant, antiplatelet and antihypertensive medications are excluded from this study.~The atherosclerosis risk factors excluded in our study are signs of CVD, smoking habits, diabetes , obesity, arterial hypertension, dyslipidemia. Patients with periodontal disease and lesions other than endodontic etiology in maxilla/mandible will be also excluded from this study ). Participants that were pregnant or lactating females, non-Italian or only English speaking will also also excluded from the study, as well as those who were unable or unwilling to give informed consent."
89616532|NCT05792787||Control|"healthy individual free from clinical and radiographic evidence of AP. The inclusion criteria of the study are healthy patients older than 40 years old, the presence of at least 24 teeth and the ability and willingness to give informed consent. Participants affected by any systemic disease or being administered either antibiotics in the last 6 months or antiaggregant, antiplatelet and antihypertensive medications are excluded from this study.~The atherosclerosis risk factors excluded in our study are signs of CVD, smoking habits, diabetes , obesity, arterial hypertension, dyslipidemia. Patients with periodontal disease and lesions other than endodontic etiology in maxilla/mandible will be also excluded from this study ). Participants that were pregnant or lactating females, non-Italian or only English speaking will also also excluded from the study, as well as those who were unable or unwilling to give informed consent."
89616533|NCT05791695||Study Patients|Patients ≥ 18 years who have received one or more injections of aflibercept during the study period
89616534|NCT05787743|Active Comparator|Facial cream with 2% palm tocotrienols extract|Facial cream with 2% palm tocotrienols extract
89616535|NCT05787743|Placebo Comparator|Base cream (no active)|Base cream (no active)
88986954|NCT05561231|Active Comparator|Group D|Group of patients intubated with D blade of CMAC videolaryngoscope
88986955|NCT00502684|Experimental|1|Peri-operative etodolac and propranolol as described in protocol
88986956|NCT00502684|Placebo Comparator|2|peri-operative placebo as described in protocol
88986957|NCT00502723|Active Comparator|2|Radical laparoscopy prostatectomy
88986958|NCT00502723|Experimental|1|Radical retropubic prostatectomy
88986959|NCT01246492|Placebo Comparator|45g glucose|glucose water
88986960|NCT01246492|Active Comparator|45g glucose + 150mg aspartame|glucose water aspartame
88986961|NCT01246492|Active Comparator|45g glucose + 20 mg saccharin|glucose water saccharin
88986962|NCT01246492|Active Comparator|45g glucose + 85mg asculfame - K|glucose water aseulfame- k
88986963|NCT05561192|Experimental|diaphragmatic breathing exercises group|Intervention with diaphragmatic breathing exercises will take place in the last 15 minutes of Physical Education classes, focusing on diaphragmatic breathing. This breathing is also characterized by reducing the respiratory cycle or rate, and it can use the count of seconds in a progressive way, either in the inhalation through the nose while the abdomen expands, in the support or blockage or also called pause, and finally in the expiration, also performed by the nostrils. The creation of an inhalation and exhalation pattern becomes important as it has a direct relationship with the reduction of the activities of the sympathetic nervous system and the increase of the activity of the parasympathetic nervous system, also influencing the motor activities, the brain mass, the quality of the sleep and the attenuation of stressors.
89036138|NCT02920385|Experimental|Levothyroxine/SNAC/Placebo/Semaglutide|
89616536|NCT05787041|Experimental|High-fat diet group|A single dose of AD16 tablets was taken orally after a high fat diet
89616537|NCT05787041|Experimental|Fasting group|A single dose of AD16 tablets was taken orally under fasting conditions
89616538|NCT05787028|Experimental|AD16|The experimental group received AD16, which was a tablet with a dosage form of 10mg/tablet. Take warm water orally on an empty stomach in the morning, once a day.7 dosing cohorts will receive a single oral dose of AD16.
89616539|NCT05787028|Placebo Comparator|placebo|"The placebo group received AD16 placebo, which was a tablet with a dosage form of 10mg/tablet. Take warm water orally on an empty stomach in the morning, once a day.~7 dosing cohorts will receive a single oral dose of AD16 placebo."
89036139|NCT01280812|Experimental|PA intervention and Maintenance plus|3-month physical activity intervention and 6-month maintenance intervention-Plus program
89036140|NCT01280812|Experimental|PA intervention and Maintenance regular|3-month physical activity intervention and 6-month maintenance - Regular program
89036141|NCT01280812|Active Comparator|Pedometer|Non-intervention group
89036142|NCT02932020|Experimental|Group A|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection of (a) 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI~Visit: 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
89036143|NCT02932020|Other|Group B|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection 2mL 0.5% marcaine and 1mL and 1mL steroid (depomedrol 80mg/ml).~Visit 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
89616540|NCT05785806|Experimental|Skin to skin contact and co-parenting theory course|"Skin to skin contact and co-parenting theory course~Skin to skin contact instruction manual and co-parenting theory brochure~Daily face-to-face skin to skin contact guidance during hospitalization~Online punching skin to skin contact"
89616541|NCT05785806|Other|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
89616542|NCT05778994|Experimental|EXPERIMENTAL|Group that performs therapy with intorus
89616543|NCT05778994|No Intervention|CONTROL|Group without intervention
89616544|NCT05777031|Experimental|Collagenase Clostridium Histolyticum (CCH) Group|There will be 8 total treatments. These will follow the manufacturer protocol of 2 injections 24-72 hours apart (one cycle), followed by a 6-week break. This will total a maximum of 4 cycles.
89616545|NCT05768841||endurance athletes|participants that have or are participating in endurance sports
89616546|NCT05768087|Experimental|Escalated proton therapy|
89616547|NCT05761860|Active Comparator|Oral oxycodone (5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin.
89616548|NCT05761860|Active Comparator|Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)|Combined effects of oxycodone and oxytocin.
89616549|NCT05761860|Active Comparator|Oral placebo + intranasal oxytocin (48 IU)|Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
89616550|NCT05761860|Active Comparator|Oral oxycodone (5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
89616551|NCT05761860|Active Comparator|Oral oxycodone (2.5mg) + intranasal placebo|Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.
89616552|NCT05761860|Sham Comparator|Oral placebo + intranasal placebo|Serves as the control.
89616553|NCT05759299||Patients undergoing anesthesia in operating room and outside operating room|Patients undergoing elective or emergency tracheal intubation to receive general anesthesia for surgery in operating room or outside operating room (e.g. endoscopy and radiology unit, cardiology lab cath)
89616554|NCT05759052||Cohort of adult survivors having been treated by vincristine|Cohort of adult survivors having been treated by vincristine for a childhood leukemia
89616555|NCT05753800|Experimental|Experimental group|This group receives motor intervention sessions with the Intorus device
89616556|NCT05753800|No Intervention|Control group|This group receives no motor intervention sessions with the Intorus device
89616557|NCT05744323|Experimental|Experimental group|The experimental group will engage in functional training
89036144|NCT02932098|Experimental|App Notifications|The web-based app will be used to remind patients of discharge instructions, ask questions related to current prescription pain medication use, new symptoms, or changes in the severity of symptoms. Patients will receive reminders via text or email to use the app. Daily reminders will be sent in Week 1, every other day in Week 2, and once per week for Weeks 3-4. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
89036145|NCT02932098|Active Comparator|Usual Care|Patients will have access to the web-based app, but will not receive reminders to use it. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
89036146|NCT05466396||Smokers with Pre-COPD|Smoking history ≥ 10 pack-years 0.7≤ FEV1/FVC<0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
89036147|NCT05466396||Smokers with Mild-COPD|Smoking history ≥ 10 pack-years FEV1/FVC<0.7 and FEV1%pred ≥ 80% (post-bronchodilator)
89036148|NCT05466396||Non-Smokers with Pre-COPD|Smoking history < 10 pack-years or never-smokers 0.7≤ FEV1/FVC<0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
89036149|NCT05466396||Non-Smokers with Mild-COPD|Smoking history < 10 pack-years or never-smokers FEV1/FVC<0.7 and FEV1%pred ≥ 80% (post-bronchodilator)
89616558|NCT05744323|No Intervention|Control group|the control group will follow the state-mandated physical education curriculum.
89616559|NCT05743582||COPD patients|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
89616560|NCT05743582||Healthy controls - smokers|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
89616561|NCT05743582||Healthy controls - non-smokers|Bronchoscopy to retrieve bronchoalveolar lavage fluid for isolation of immune cells, and phlebotomy for blood sample collection.
89616562|NCT05741034|Experimental|JUVÉDERM® VOLITE™|"Participants will receive VOLITE for initial treatment and exit the study at month 12 after last treatment.~Participants may have the opportunity to receive optional touch-up treatment of VOLITE during the follow-up duration period."
89616563|NCT05741034|Other|Control - No Treatment|Participants in the control group will receive no treatment. At Month 2, these participants will have the option to receive VOLITE treatment and exit the study at month 9 after last treatment.
89616564|NCT05740046|Experimental|experimental group|Group that will receive the intervention sessions using the Intorus tool
89616565|NCT05740046|No Intervention|control group|Group that will receive the intervention sessions without using the Intorus tool
88986964|NCT05561192|Experimental|Cardiorespiratory and strength exercise group|"Intervention with cardiorespiratory and strength physical exercises will always occur in the first 15 minutes of each class. Cardiorespiratory exercises and localized muscular resistance will be developed involving all muscle groups, adapted to the materials and school equipment available. The exercises developed will be primarily calisthenics, to facilitate a possible replication within the school environment. A circuit with 4 stations will be elaborated, where one station will offer a cardiorespiratory stimulus, containing the following exercises: jumping jacks, jumping rope, stationary running, going up and down steps and burpees. The other three stations will be composed of localized muscular resistance exercises, involving lower limbs (squat, lunge and isometric chair), upper limbs (flexion) and trunk (abdominal).~The time of execution of the exercises in each station will be of 1 minute."
88986965|NCT05561192|Experimental|Cooperative sports activities group|The intervention of cooperative sports activities that will integrate the physical education class will be based on the cooperative learning model and elaborated through the aforementioned points. Intervention sessions will last 20 minutes, being held during the main part of the class. Activities will be planned that prioritize reflection, thinking and sharing of ideas among students, by proposing challenges within the sport. For example, how to get out of a certain type of marking within a game, or in the case of cooperative games, with the principle that students cooperate with each other to solve a proposed challenge (for example, how long a team can remain dominating the volleyball without it falling to the ground?).
89616566|NCT05733377||Pregnant|Pregnant >36 weeks gestation, 20 to 40 years old, without significant lumbar pathology, or intense labor pain, or percentile p>97 or <p3, or with a result of delivery-cesarean section due to risk of loss of fetal well-being
89616567|NCT05726539|Active Comparator|Intervention|participants receive group-based peer support
89616568|NCT05726539|No Intervention|Waitlist|participants wait to receive peer support until pre and post assessments are complete with their matched intervention group
89616569|NCT05724784|Experimental|Flourish|Participants will be onboarded to Flourish by a research study clinician, following which they will receive a text messaging program for 4 weeks as well as an accompanying resources website.
89616570|NCT05714527|Experimental|Close-loop FiO2 Controller|Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
89036150|NCT05466396||Healthy Controls|Healthy volunteers without smoking history FEV1/FVC ≥ 0.8 and FEV1%pred ≥ 80% (post-bronchodilator)
89616571|NCT05714527|Active Comparator|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
89616572|NCT05709002|Experimental|MASP+ app & NRT|"MASP+ is an intervention designed to assist Black smokers with HIV who experience elevated anxiety sensitivity to quit smoking through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress and nicotine withdrawal.~Nicotine patches will be made available to provide adjunctive support."
89616573|NCT05709002|Active Comparator|QuitGuide app + NRT|"The QuitGuide app is a standard-of-care app that allows users to track nicotine cravings and provides motivational messages.~Nicotine patches will be made available to provide adjunctive support."
89616574|NCT05698940|Active Comparator|Infundibulotomy|Infundibulotomy on one side of sinuses
89616575|NCT05698940|Sham Comparator|No Infundibultomty|No Intervention on other side of sinuses
89616576|NCT05694312|Experimental|Ibrutinib|Patients will receive ibrutinib 420 mg/day orally for up to 12 cycles of 28 days.
89616577|NCT05693545|Experimental|Oral Pencillin|Oral phenoxymethyl penicillin (Pen V) prophylaxis 250mg twice daily.
89616578|NCT05693545|Active Comparator|IM Penicillin|Intramuscular benzathine benzylpenicillin G (BPG) prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days
89616579|NCT05685316|Experimental|COPLA® cartilage implant|The potential subjects will be screened against inclusion and exclusion criteria. If deemed eligible, they will be consented and enrolled. The enrolled subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery with bone marrow stimulation.
89616580|NCT05682339|Active Comparator|Quinine only|In this arm, participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of control for L-isoleucine.
89616581|NCT05682339|Active Comparator|L-isoleucine only|In this arm, participants will receive a 10 ml intragastric bolus of control for quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-isoleucine.
89616582|NCT05682339|Active Comparator|Quinine + L-isoleucine|In this arm participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-isoleucine.
89616583|NCT05682339|Placebo Comparator|Control|In this arm, participants will receive a 10 ml intragastric bolus of control solution followed 30 min later by 100 ml intragastric bolus of control solution.
89036151|NCT02920307|Experimental|TEP without fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair without mesh fixation
89036152|NCT02920307|Active Comparator|TEP with fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair
89036153|NCT02920307|Experimental|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) hernia repair without mesh fixation
89616584|NCT05676502|Active Comparator|Nasal High Flow with Optiflow M cannula|Nasal high flow treatment 35L/min with the standard symmetric nasal cannula (Optiflow M)
89616585|NCT05676502|Active Comparator|Nasal High Flow with Optiflow Duet Cannula|Nasal high flow treatment 35L/min with the asymmetric nasal cannula (Optiflow Duet)
89616586|NCT05676463|Experimental|Treatment (MRI-guided IMRT, ADT)|Patients undergo MRI-guided IMRT on study and receive SOC ADT throughout the trial. Patients may also undergo PSMA PET, CT, MRI, and bone scans at screening and undergo collection of blood samples throughout the trial.
89616587|NCT05665491|Experimental|Interpretation bias manipulation|The primary component of the interpretation bias manipulation is the Word Sentence Association Paradigm (WSAP) delivered by the HabitWorks smartphone app. Users complete 50 trials in each exercise (approximately 5 min) and are prompted to complete 3 exercises per week (12 total over 4 weeks). The WSAP incorporates repetitive and quick practice, increasing individuals' awareness of their cognitive biases and shifting of their automatic responses.
89616588|NCT05665491|Placebo Comparator|Self-Assessment|Parents will complete the same repeated assessments, including EMA of parent behavior and weekly symptom surveys, but they will not complete the WSAP.
89616589|NCT05662592|Experimental|Treatment Arm|Broadband light treatment will be provided on pigmented skin lesions
89616590|NCT05660109|Experimental|TPM502|
89616591|NCT05660109|Placebo Comparator|placebo|
88986966|NCT05561192|Active Comparator|Comparator Group|The classes that will form the comparator group will carry out the Physical Education classes according to the planning previously prepared by the professors of the discipline and that are already part of the syllabus of the semester and/or the school year of the classes. These contents, within the proposal of the two schools, are already consolidated and are centered on the teaching of sport through methodologies aimed at a pedagogical proposal mostly analytical, partial or characterized by the traditional model (technicist model). In these classes, the activities are practiced through the model of direct instruction of teaching, where the teacher acts as the main figure of the teaching-learning process.
88986967|NCT00502918||1|
88986968|NCT00503074|Experimental|1|Parents receive tailored health-behavior change messages designed to reduce their child's exposure to televised food commercials. Intervention is delivered by a case manager, by a website, and by periodic newsletters.
89616592|NCT05659160||Endovascular therapy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombus aspiration, others, or combination methods.
89616593|NCT05659160||Best medical management|Patients enrolled in this group received the best medical management.
89616594|NCT05652270|Active Comparator|Goal Attainment Intervention|
89616595|NCT05652270|Active Comparator|Goal Development Intervention|
89616596|NCT05652270|Active Comparator|Goal Development and Tracking Intervention|
88986969|NCT00503074|Active Comparator|Control|Parents of children ages 2-5 receive behavioral-change counseling around toddler & preschooler safety and injury prevention.
88986970|NCT00503152|Experimental|benazepril|
88986971|NCT00503152|Experimental|valsartan|
88986972|NCT00503152|Experimental|benazepril/valsartan|
88986973|NCT00147459|Active Comparator|booster|no antibody and boosted
88986974|NCT00503191|Experimental|Intention-based therapy treatment for autism|NeuroModulation Technique
88986975|NCT00503230|Active Comparator|Standard Care Intervention (SCI)|
89616597|NCT05636397|Experimental|BPD±PH|"Arm 1: BPD±PH~Total of 12-24 infants; 6-12 at each dose level of oral dosage form of L-Citrulline. (300 or 500 mg/kg/day divided q6 hours).~Dose Level 1 = 300 mg/kg/day Dose Level 2 = 500 mg/kg/day"
89616598|NCT05636397|Experimental|Surgical NEC|"Arm 2: sNEC~A total of 18-36 infants with Stage III NEC; 6-12 at each dose level of oral dosage form of L-Citrulline. (75, 150 or 225 mg/kg/day divided q6 hours)~Dose Level 1 = 75 mg/kg/day Dose Level 2 = 150 mg/kg/day Dose Level 3 = 225 mg/kg/day"
89616599|NCT05635344|No Intervention|Second evacuation only|Patients that are randomised onto this arm of the study will be treated by second evacuation ALONE.
89616600|NCT05635344|Experimental|Pembrolizumab and second evacuation|Patients that are randomised onto this arm will be given a single dose of Pembrolizumab in a neoadjuvant setting followed by second evacuation
89616601|NCT05630521|Experimental|Telehealth Intervention Group|"The intervention components are: 1) educational modules and 2) bi-weekly telehealth visits for managed problem solving for 12 weeks.~All intervention participants will be provided four educational modules, electronically and in print form. The modules are adapted from evidence-based materials developed by the American Heart Association, American College of Cardiology, and Centers for Disease Control and Prevention and cover (1) the causes of HTN, (2) how HTN raises risks for other chronic conditions, (3) medications for effectively managing high BP, and (4) how to manage barriers to medication adherence.~Telehealth visits will supplement and reinforce the educational modules, addressing participants' specific knowledge needs and enhancing self-efficacy."
89616602|NCT05630521|No Intervention|Control|The study will use a usual-care control group. The standard of care for this patient population does not involve any type of medication adherence intervention or monitoring beyond regular clinic follow-up visits with their health care provider. Control group participants will be given printed handouts on the American Heart Association's Life's Simple 7 lifestyle changes for reducing cardiovascular risk, along with the instructions for using the MEMS cap. If control group participants ask about their antihypertensive medications during the study, they will be referred to their prescribing provider or pharmacist for any information that could not be obtained from the medication label or pharmacy packaging.
88986976|NCT00503230|Active Comparator|Culturally Tailored Intervention (CTI)|
88986977|NCT00503347|Experimental|1|0.3 mg/kg
88986978|NCT00503347|Experimental|2|1 mg/kg
88986979|NCT00503347|Experimental|3|3 mg/kg
88986980|NCT00503347|Experimental|4|6 mg/kg
88986981|NCT00503542|Experimental|Intervention|Patients primarily with itching or irritation are treated for candidal vaginitis. Patients primarily with vaginal odor are treated for bacterial vaginosis. Patients who did not fit either of the previous groups are treated for both candidal vaginitis and bacterial vaginosis.
88986982|NCT00503542|Active Comparator|Control|Patient are examined and a wet mount is prepared. If a definitive diagnosis is made patient is treated for the condition diagnosed. If no diagnosis is made the clinician has the option of either foregoing treatment (watchful waiting) or following the protocol in the experimental group
88986983|NCT01246531||Urolithiasis|Case arm: men above fifty years-old with urolithiasis
88986984|NCT01246531||Control|Control arm: men above fifty years-old without urolithiasis
88986985|NCT01246648|Active Comparator|chronic periodontitis|
88986986|NCT01246648|Active Comparator|agressive periodontitis|
88986987|NCT01246648|Active Comparator|healthy patients|
88986988|NCT05561036|Experimental|Liposome doxorubicin|Liposome doxorubicin (50mg/m2) with a treatment cycle of once every 28 days
88986989|NCT05561036|Placebo Comparator|intravenous placebo|saline solution
89616603|NCT05630183|Experimental|Part 1: Combination (Safety Lead-in Phase)|Participants will receive botensilimab in combination with standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
89616604|NCT05630183|Experimental|Part 2: Combination|Participants will receive botensilimab in combination standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
89616605|NCT05630183|Active Comparator|Part 2: Standard of Care|Participants will receive standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
89616606|NCT05619458|Experimental|Mindfulness intervention|The intervention will consist of 6 one-hour sessions delivered once per week in a classroom at an alternative high school during normal school hours.
89616607|NCT05606276|Active Comparator|Cycling exercise|Cycling on a cycle ergometer instead of doing the experimental eccentric exercise.
89616608|NCT05606276|Experimental|Eccentric exercise|Perform 2 sets of maximal eccentric contractions as the single session exercise intervention.
89616609|NCT05599750|Active Comparator|Hernia repair with mesh (Control arm)|Participants will undergo incisional hernia repair with prolene mesh in the retrorectus position with at least 4cm of overlap.
89616610|NCT05599750|Active Comparator|Primary closure (Intervention arm)|Participants will undergo incisional hernia repair with suture alone using modern surgical techniques.
89616611|NCT05599685||Participants with metastatic NSCLC initiated on 1L treatment with NIVO/IPI/PBC|
89616612|NCT05586360|Experimental|Simvastatin|Patients randomized to the statin group will receive 40 mg oral simvastatin QD for eight weeks prior to prostatectomy, including the day of surgery.
89616613|NCT05586360|No Intervention|Control|Patients randomized to the control group receive no intervention prior to prostatectomy.
89616614|NCT05584397||Tenofovir-containing ART|Cohort 1: Tenofovir-containing ART (tenofovir disoproxil fumarate [TDF] OR tenofovir alafenamide [TAF] PLUS any other ART drugs) prescribed for daily use by participants' primary care providers.
89616615|NCT05584397||NRTI-sparing ART|Cohort 2: NRTI-sparing ART (specifically: rilpivirine PLUS dolutegravir OR rilpivirine PLUS cabotegravir) prescribed for daily use by participants' primary care providers.
89616616|NCT05573178|Experimental|Ablation of left atrial ganglion plexus|In this arm, ablation of GPs will only performed in the left atrium, including ablation of right anterior ganglion plexus (RAGP)，left superior ganglion plexus (LSGP)，left ganglion plexus (LLGP), left interior ganglion plexus (LIGP) and right interior ganglion plexus（RIGP).
89616617|NCT05573178|Experimental|combined ablation of left and right atrial ganglion plexus|In the arm the, ablation of GPs will perform in both atrium, including ablation of right anterior ganglion plexus (RAGP)，left superior ganglion plexus (LSGP)，left ganglion plexus (LLGP), left interior ganglion plexus (LIGP), right interior ganglion plexus (RIGP), and superior vena cava ganglion plexus (SVCGP). SVCGP were ablated in the right atrium，the left GPs were ablated through the left atrium
89616618|NCT05572879|Experimental|Test group(EuCorVac-19) - Cohort A|Cohort A - Immunogenicity cohort
89616619|NCT05572879|Active Comparator|Comparator group(ChAdOx1) - Cohort A|Cohort A - Immunogenicity cohort
89616620|NCT05572879|Experimental|Test group(EuCorVac-19) - Cohort B|Cohort B - Safety cohort
89616621|NCT05572879|Active Comparator|Comparator group(ChAdOx1) - Cohort B|Cohort B - Safety cohort
89616622|NCT05570812|Experimental|Placebo|"Participants will be on the following dosage schedule:~50 mg daily for 2 weeks, THEN 100 mg daily for 1 week, THEN 250 mg daily for 1 week, THEN 500 mg daily for 4 weeks"
89616623|NCT05570812|Experimental|Pregnenolone|"Participants will be on the following dosage schedule:~50 mg daily for 2 weeks, THEN 100 mg daily for 1 week, THEN 250 mg daily for 1 week, THEN 500 mg daily for 4 weeks"
89616624|NCT05568056|Experimental|ASD-EXP and NT-EXP|Autistic children and Neurotypical children who receive intervention between pre and post testing
89616625|NCT05568056|No Intervention|ASD-WLC and NT|Autistic children who receive intervention only after their pre and post testing and Neurotypical children who do not receive any intervention
89616626|NCT05555173|Experimental|Buzzy|Buzzy will be applied 5 to 10 cm proximal (toward the subject's head) to the dorsum of the hand site immediately prior and throughout the intravenous catheter insertion attempt.
89616627|NCT05555173|No Intervention|No Buzzy|Subjects will have a 20g intravenous catheter inserted either in the left or right dorsum side of the hand without the Buzzy device.
89616628|NCT05555056|Active Comparator|Active Stimulation|MxN-9 HD-tES Stimulator (Soterix Inc.) will be used to deliver direct current (High-Definition Transcranial Direct Current Stimulation) to the target brain areas via electrodes and conducive gels. A constant current will be applied for 20 minutes with peak current of 2 mA. The 9 electrodes (8 channels + 1 ground) positions and current intensity have been determined based on computer simulation using HDTargets software (Soterix Inc.) that results in maximum focal current on the left VLPFC (x=-50, y=+26, z=+8) and the PCC (x=1, y=-61, z=38) with inward field orientation.
89616629|NCT05555056|Sham Comparator|Inactive Stimulation|The current will be applied for 30 seconds ramp-up followed by 30 seconds ramp-down, and thus no active stimulation will be administered except for the initial and last 1 minutes of 20 minute stimulation duration.
89616630|NCT05552716||Case Schools|All Schools identified with all incidents in which a gun is fired, or a bullet hits school property for any reason, regardless of the number of victims, time, day of the week.
89036154|NCT02920307|Active Comparator|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) hernia repair
89616631|NCT05552716||Control Schools|A random sample of schools that have not experienced any incidents in which a gun is fired, or a bullet hits school property for any reason, regardless of the number of victims, time, day of the week matched with a case school based on geographic state, urban/non-urban status, and elementary/middle/high school status.
89616632|NCT05551936|Experimental|Investigational Group|"Phase 1:~90 mg/m^2 of bendamustine by IV on Day 1 and 2 of a 28 day cycle (up to 3 Cycles)~375 mg/m^2 of rituximab by IV on Day 1 of a 28 day cycle (up to 3 Cycles)~Participants enrolled in this phase will be given one of 3 different dose levels of tazemetostat along with the drugs above (for up to 3 Cycles). 3 patients will be assigned to the lowest dose level and if the dose is tolerated, 3 more patients will be enrolled one dose level higher. Up to 18 participants being enrolled.~Dose Level 1: 400 mg of tazemetostat orally twice daily~Dose Level 2: 600 mg of tazemetostat orally twice daily~Dose Level 3: 800 mg of tazemetostat orally twice daily~Phase 2:~6 patients from Phase 1 who were treated at the recommended Phase 2 dose will be added to 21 additional patients.~375 mg/m^2 of rituximab through IV on Day 1 of a 28 day cycle (Cycles 1-6)~Tazemetostat orally twice daily of a 28 day cycle (Cycles 1-6)"
89616633|NCT05550675||Double incontinence|
89616634|NCT05550675||faecal incontinence|
89616635|NCT05550675||controls|
89616636|NCT05540613|Sham Comparator|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
89616637|NCT05540613|Active Comparator|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
89616638|NCT05540613|Experimental|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
89616639|NCT05537389|No Intervention|Control|Patients with central venous access (central umbilical venous catheter or epicutaneous cava catheter)
89616640|NCT05537389|Experimental|Filter|Patients with central venous access and in-line filters (central umbilical venous catheter or epicutaneous cava catheter)
89616641|NCT05535075|Active Comparator|Standard of Care Vancomycin treatment|Vancomycin standard-of-care dosing and therapeutic drug monitoring (TDM), according to institutional guidelines during 20 day study period
89616642|NCT05535075|Experimental|Vancomycin model-informed precision dosing|Area Under the Concentration-time curve ((AUC)/Minimal Inhibitory Concentration (MIC)-based model-informed precision dosing of vancomycin using a dosing calculator during 20 day study period
89616643|NCT05532891||Pre-pandemic|Patients that underwent elective bariatric surgery in a control period prior to the pandemic (one year from 1st September 2018).
89616644|NCT05532891||Pandemic|Patients that underwent elective bariatric surgery during the pandemic (one year from 1st April 2020)
89616645|NCT05524493||Healthy participants|
89616646|NCT05524493||Patients with migraine|
89616647|NCT05524493||Patients with drug resistent epilepsy|
89616648|NCT05524480|Experimental|Salud en Mis Manos - Dissemination and Implementation Assistance|The multi-component and multi-faceted implementation strategy SEMM-DIA
89616649|NCT05524480|Active Comparator|Salud en Mis Manos - Usual Implementation Practice|The SEMM-Usual Implementation Practice arm includes all existing SEMM program materials.
89616650|NCT05523609|Experimental|Control Group|20 patients will receive Letrozole only for 12 weeks.
89616651|NCT05523609|Experimental|VitD/Ca group|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 and 1000 mg of calcium per day for 12 weeks.
89616652|NCT05518435||Work package 1 (WP1) - survey|"WP1 aims to recruit a minimum of 252 survey respondents, providing a minimum of six responses for each of the 42 Integrated Care Systems (ICSs) in England. The aim will be to gather responses from as many respondents as possible, to provide as much information as possible on primary care provision across over >1200 PCNs in England. This will provide the first national overview of prescribing practice and the availability of health care for young people with ADHD through primary care in England. The inclusion of three stakeholder groups (health professional, service users, and commissioners/providers) will ensure that the survey includes reports from a balance of perspectives and provide the opportunity to compare data between groups and locations.~The sampling frame for WP1 includes all stakeholders aged 16 or over with an interest in providing or receiving health care for young people with ADHD, as well as those involved in providing/commissioning local primary care provision."
89616653|NCT05518435||Work package 2 (WP2) - qualitative study|"WP2 aims to recruit between 20 and 30 participants, consisting of 10-15 young people (aged 16-25) with ADHD and their parent carers and 10-15 health professionals and commissioners/providers. Participants will be recruited from between three and six geographic locations (e.g., PCNs), dependent on findings from WP1. This sample size will enable qualitative data to be collected from approximately five participants per location.~The sampling frame for WP2 consists of a purposive selection of stakeholders."
89616654|NCT05518435||Work package 3 (WP3) - co-production of guidance|"WP3 aims to recruit between six and 16 participants, consisting of 2-6 young people (aged 16-25) with ADHD and/or their parents/carers, 2-6 health professional and/or commissioners/providers, and between 1 and 4 members of the research team. The sample will be sufficient to include perspectives from identified key stakeholders, while the relatively small group size will support close group work. The small sample size will also enable delivery of key features of co-production research such as building strong relationships and providing opportunities for growth and development of participants.~The sampling frame for WP3 consists of a purposive selection of key stakeholders. In addition to the key stakeholder groups outlined above, co-production activities will also involve MAP study researchers."
89616655|NCT05505344||Validation lab study|All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
89616656|NCT05493033|Experimental|Intracorporeal anastomotic after LRC|
89616657|NCT05493033|Active Comparator|Extracorporeal anastomotic after LRC|
89616658|NCT05489237|Experimental|Dose Escalation (Phase I)|Participants should have advanced (metastatic and/or surgically unresectable) GIST, following failure of at least prior imatinib therapy due to progression of GIST.
89616659|NCT05489237|Experimental|(Phase 1b) Cohort 1 - Participants with GIST progression after first-line imatinib therapy|Participants with advanced GIST who have had GIST progression only after first-line imatinib only (second line therapy setting).
89616660|NCT05489237|Experimental|(Phase 1b): Cohort 2 - Participants with GIST progression after 2nd OR 3rd line TKI therapy|Participants with metastatic and/or surgically unresectable GIST following progression EITHER after sequential imatinib then sunitinib (third-line therapy setting) OR after imatinib, sunitinib, and then an additional TKI agent (i.e., regorafenib or ripretinib) (fourth-line therapy setting).
89616661|NCT05489237|Experimental|(Phase 1b): Cohort 3 - Participants with GIST progression after 4th or greater lines of TKI therapy|Participants with advanced GIST who have had GIST progression after 4th line or greater lines of TKI therapy (failure due to progression of all available agents (imatinib, sunitinib, regorafenib, ripretinib, and possibly others (> 5th line therapy setting)
89616662|NCT05487846|Experimental|Arm I (peer navigation)|Patients receive assistance from a peer navigator during genetic evaluation processes. Peer navigators help patients schedule counseling appointments, discuss questions and concerns about testing, assist in sample collection, schedule a post-test disclosure visit, and do a results and recommendations debrief.
89616663|NCT05487846|Active Comparator|Arm II (best practice)|Patients receive standard care during genetic evaluation processes. Patients receive genetic counseling, undergo genetic testing, schedule a post-test disclosure visit, and receive their genetic test results and recommendations per standard care.
89616664|NCT05482646|Experimental|Tai Chi|This group will perform 3 months of Tai Chi training
89616665|NCT05482646|Active Comparator|Conventional exercise|This group will perform 3 months of conventional exercise training
89036155|NCT01280656||Conventional Interferon Plus Ribavirin|Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
89616666|NCT05482646|Other|Health Education Control|This group will participate in a 3-month health education program
89616667|NCT05481437||Brentuximab Vedotin|Participants will receive Brentuximab Vedotin injection 50 mg once every 2 weeks and AVD treatment (doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine).
89036156|NCT01280656||Peginterferon Alfa-2a Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
89616668|NCT05481359||EGF-Guided Ablation Therapy|Subjects will be treated with cardiac ablation guided by the Ablamap Electrographic Flow (EGF) Mapping System.
89036157|NCT01280656||Peginterferon Alfa-2b Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
89616669|NCT05475678|Experimental|（Carrelizumab + TCb） regimen|The experimental group received 6 cycles of TCb+carrelizumab (docetaxel 75mg/m2 on the first day + carboplatin AUC=6, on the first day; camrelizumab 200mg on the third day) regimen neoadjuvant chemotherapy, every 21 days is a cycle.
89616670|NCT05475678|Placebo Comparator|TCb regimen|The control group received 6 cycles of TCb (docetaxel 75mg/m2 on the first day + carboplatin AUC=6 on the first day) regimen neoadjuvant chemotherapy, every 21 days as a cycle.
89616671|NCT05470036|Other|Educational intervention|In-clinic or virtual educational session on germline testing in prostate cancer with a trained educator.
89616672|NCT05468203|Experimental|Dapagliflozin|Dapaliflozin 10mg tablet administered once daily while in ICU for up to 30 days
89616673|NCT05468203|Placebo Comparator|Matched Placebo|Matched placebo tablet administered once daily while in ICU for up to 30 days
89616674|NCT05466331|Experimental|Mobile Tele-HCV Care|Direct Acting Antiviral (DAA) treatment for HCV on a mobile van via telemedicine
89616675|NCT05466331|Active Comparator|Enhanced Usual Care|Referral with care navigation to a local or regional HCV treatment provider
89036158|NCT05466162|Experimental|Soft tissue mobilization + joint and nerve Mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
89036159|NCT05466162|Active Comparator|joint and nerve mobilizations|"Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
89036160|NCT03741530|Experimental|Glibenclamide group|Giving standard management for ICH plus glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
89036161|NCT03741530|Placebo Comparator|Control group|Giving standard management for ICH
89036162|NCT01280617|Experimental|Thymoglobulin 1.25mg/kg dose|The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.
89036163|NCT01280617|Experimental|Thymoglobulin 0.75mg/kg dose|The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.
89036164|NCT02920268|Experimental|Intervention|Intervention with dance and yoga sessions, two times a week in 8 months.
89036165|NCT02920268|No Intervention|Controls|No intervention
89036166|NCT02932137|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
89036167|NCT02932137|No Intervention|Traditional therapy|Treat activated SLE with glucocorticoid or immunosuppressor.
89036168|NCT02889484||Disc hernia patients treated in Sweden|Individuals undergoing lumbar disc hernia surgery and included in the Swespine register
89036169|NCT02889484||Disc hernia patients treated in Norway|Individuals undergoing lumbar disc hernia surgery and included in the NORspine register
89036170|NCT02889484||Disc hernia patients treated in Denmark|Individuals undergoing lumbar disc hernia surgery and included in the Danespine register
89616676|NCT05458934||Lung-/Airway diseases|Patients with lung-/airway diseases
89616677|NCT05458934||Controls|Participants without lung-/airway disease
89616678|NCT05450770|Active Comparator|HIV+ GROUP|"Subjects included in the ANRS EP 46 NOVAA trial:~• 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 > 350/mm3 and a viral load <50 copies / mL for at least 6 months)."
89616679|NCT05450770|Other|HIV- GROUP|"Subjects included in the ANRS EP 46 NOVAA trial:~• 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals."
89036171|NCT02889328|Experimental|regorafenib|regorafenib 100 mg po od daily, every 4 weeks (28 day)
89036172|NCT02932059|Experimental|Adult schizophrenic patients (18-45 years)|4 groups formed by the case-control study in two age strata
89036173|NCT02932059|Experimental|Aged patients with schizophrenia (≥ 55 years)|4 groups formed by the case-control study in two age strata
89616680|NCT05446324|Experimental|68Ga-tilmanocept PET/CT|All participants receive 68Ga-tilmanocept PET/CT imaging in adjunct to standard-of-care (SLN mapping with intraoperative ICG).
89616681|NCT05442437|Experimental|Low-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 2.5×10^7 cells.
88986990|NCT01246687|Experimental|e-Intervention group|Receive stage-specific dietary intervention via the website & standard care at the outpatient clinic.
88986991|NCT01246687|No Intervention|Control group|Continue with the standard diabetes care at the outpatient clinic without getting access to the web-based intervention.
88986992|NCT01246804|Experimental|ginkgo biloba + raltegravir|15 days ginkgo biloba 120mg BID + raltegravir 400mg SD
88986993|NCT01246804|Active Comparator|raltegravir|single dose raltegravir 400mg
88986994|NCT01246843||metastatic Renal Cell Carcinoma without treatment|patients with metastasized RCC who did not receive treatment
88986995|NCT01246843||mRCC with treatment|"patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for~≥ 8 weeks"
88986996|NCT05560997||biopsy-proved NAFLD cohort|NAFLD is defined as the presence of at least 5% steatosis based on histological examination.
88986997|NCT05560997||longitudinal physical examination cohort|The diagnosis of NAFLD was based on imaging evaluation.
88986998|NCT01246882|Experimental|Augmented activity feedback|Feedback three times per week about 10-m walking speed, plus amount and types of physical activity measured using wireless bilateral ankle sensors that detect bouts of walking and cycling speed, duration, and distance.
88986999|NCT01246882|Active Comparator|speed-only feedback|Feedback three times per week about overground walking speed over 10 meters.
88987000|NCT01246921|Active Comparator|fluticasone proprionate 0.05 %|Group reveiving 12 months NB-UVB phototherapy twice a week in combination with fluticasone proprionate 0.05 % cream in an intermittent scheme
88987001|NCT01246921|No Intervention|no intervention|Group receiving 12 months NB-UVB phototherapy twice weekly, without any topical treatment
88987002|NCT04696939|Experimental|Atezolizumab + Carboplatin +Etoposide +surgery|"Neoadjuvant therapy: Atezolizumab, 1200 milligrams(mg) on Day 1 of every 21-day cycle, 2 cycles; Carboplatin, 75 mg per square meter(mg/m^2) on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m^2 on Day 1 of every 3-day cycle, 2 cycles.~Surgery: patients will receive surgery."
88987003|NCT04696939|Active Comparator|Carboplatin +Etoposide +surgery|"Neoadjuvant therapy: Carboplatin, 75 mg/m^2 on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m^2 on Day 1 of every 3-day cycle, 2 cycles.~Surgery: patients will receive surgery."
88987004|NCT05560919|Experimental|Group 1|Six participants were bonded with 0.022 × 0.028 inch slot brackets (Ortho Smile) using pre-adjusted edgewise appliance with 0.022 MBT prescriptions. Local periodontal injection of 1,25 DHC at weekly interval (3 times). The gingival fluid volume will measured befor and after 1-1.5 hours after first injection. the same is done visit at the second and third visits. Pain during injection and treatment will be assessed using the FLACC scale and face scale
88987005|NCT05560919|Experimental|Group 2|Six participants were bonded with 0.022 × 0.028 inch slot brackets (Ortho Smile) using pre-adjusted edgewise appliance with 0.022 MBT prescriptions. Local periodontal injection of dimethylsulfoxide at weekly interval (3 times). The gingival fluid volume will measured befor and after 1-1.5 hours after first injection. the same is done visit at the second and third visits. Pain during injection and treatment will be assessed using the FLACC scale and face scale.
88987006|NCT05560919|Experimental|Group 3|Six participants were bonded with 0.022 × 0.028 inch slot brackets (Ortho Smile) using pre-adjusted edgewise appliance with 0.022 MBT prescriptions. ocal periodontal injection of serum at weekly interval (3 times). The gingival fluid volume will measured once. Pain during treatment will be assessed using the FLACC scale and face scale.
88987007|NCT00503659|Active Comparator|A|Methacholine challenge, five-breath dosimeter protocol
88987008|NCT00503659|Active Comparator|B|Methacholine challenge five incremental dosages protocol
88987009|NCT00503737|Active Comparator|Colorectal Cancer Screening Toolkit|Toolbox includes tools and guides designed increase screening by primary care physicians
88987010|NCT00503737|No Intervention|Standard of Care Colorectal Cancer Screening|Primary Care physician will screen for colorectal cancer as per his/her standard practice
88987011|NCT04063163|Experimental|A|HLX 10+chemotherapy (Carboplatin-Etoposide)
88987012|NCT04063163|Placebo Comparator|B|Placebo+chemotherapy (Carboplatin-Etoposide)
88987013|NCT01247038|Experimental|Metal on ceramic articulation|The arm consists of patients with Ceramic femoral heads articulating with metal acetabular cups
88987014|NCT01247038|Active Comparator|Metal-on-metal|The arm consists of patients with Metal femoral heads articulating with metal acetabular cups
88987015|NCT01247077|Active Comparator|placebo|Placebo and thyroxin + methimazole
88987016|NCT01247077|Placebo Comparator|selenium|selenium + methimazole + thyroxin
88987017|NCT00501319||1|Patients with Non-Small Cell Lung Cancer.
88987018|NCT04011566||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
88987019|NCT01247155||first day review|
88987020|NCT01247155||non-first day review|
88987021|NCT00147732|Active Comparator|1|Accelerated radiotherapy
88987022|NCT00147732|Experimental|2|ARCON
88987023|NCT00503854||Observational (questionnaire)|Patients complete a questionnaire on days 1, 2, and 6 regarding fatigue, sleep disturbance, depression, and other symptoms.
88987024|NCT03990467|Experimental|Patients treated by amikacin and piperacillin|ICU patient with a sepsis treated by amikacin and piperacillin/tazobactam
88987025|NCT00503893||Wilm's Tumor PO1|Familial and Sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia.
88987026|NCT01247311|Active Comparator|1.|"1,25 Vitamin D (0.50ug *3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
88987027|NCT01247311|Active Comparator|2.|"25 Vitamin D (5000IU * 3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
88987028|NCT01247311|Placebo Comparator|3.|Placebo given orally 3xweek for six months
88987029|NCT00147771|Experimental|1|
89616682|NCT05442437|Experimental|medium-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 5.0×10^7 cells.
89616683|NCT05442437|Experimental|High-dose group|100mL human umbilical cord mesenchymal stem cell preparation, containing 1.0×10^8 cells.
89616684|NCT05440890|Active Comparator|Control group|Standard protocol rehabilitation programme for an anterior cruciate ligament repair based on VAN MELICK N, et al 2016.
89616685|NCT05440890|Experimental|Cross-education group|"Standard protocol rehabilitation programme for an anterior cruciate ligament repair based on VAN MELICK N, et al 2016.~Additionally a contralateral lower limb strength training."
89616686|NCT05415488|Active Comparator|IBS dietary advice according to the NICE guidelines|The traditional dietary advice according to the NICE guidelines and the systematic reviews performed by the British dietetic association (BDA) include having regular meals and to take time to eat, not to skip meals or eat too much at ones. The diet also limits intake of known trigger foods, such as coffee, alcohol, fizzy drinks, spicy foods, fatty foods etc. People who experience loose stools are recommended to avoid sweeteners (-ol), and people with wind/bloating are recommended to eat soluble fibers such as oats and flaxseeds.
89616687|NCT05415488|Sham Comparator|A healthy diet according to the Swedish dietary guidelines|This diet includes eating 500 grams of vegetables and fruits/day, fish approximately 3 times/week, 70 grams of wholegrain/day and to limit intake of red meat.
89616688|NCT05406635|No Intervention|Standard imaging monitored treatment|Standard care + biomarkers, which are blinded until end of study.
89616689|NCT05406635|Experimental|Intervention biomarker monitored treatment|biomarker monitored treatment + imaging, which is blinded until end of study
89616690|NCT05405881|Other|Children with upper motor neuron lesions|With the Proprioception Measurement Tool (PROMT) following modalities are assessed: joint movement sense, joint position sense, and active position sense. The child has to wear on each leg two Shimmer Sensors on the lower limb and the foot. The child sits on a table or bench, and the feet are free-hanging. A table is positioned in front of the child to place the smartphone or convertible notebook at a distance where the child can press the digital button. The table with an additional U-table platform prevents the child's view towards the legs. The duration of these three tests is 20 minutes. The comparator assessments on each level of the ICF-CY are conducted, and a feasibility questionnaire (detailed described under chapter outcome measures)
89616691|NCT05405881|Other|Children without UMN lesions (developing typically)|With the Proprioception Measurement Tool (PROMT) following modalities are assessed: joint movement sense, joint position sense, and active position sense. The child has to wear on each leg two Shimmer Sensors on the lower limb and the foot. The child sits on a table or bench, and the feet are free-hanging. A table is positioned in front of the child to place the smartphone or convertible notebook at a distance where the child can press the digital button. The table with an additional U-table platform prevents the child's view towards the legs. The duration of these three tests is 20 minutes. A feasibility questionnaire (detailed described under chapter outcome measures)
89616692|NCT05403359||Ward (e.g., pulmonology ward, COVID-unit, etc.),|"WP1A: Patients with WHO clinical progression scale class 4-5 (i.e., no oxygen therapy) admitted to the ward with laboratory-confirmed COVID-19.~WP1B: Adult patients admitted to the ward with laboratory-confirmed COVID-19 and on at least oxygen therapy."
89616693|NCT05403359||Intensive Care Unit|Adult patients (≥18 years) admitted to the ICU with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) according to the Berlin definition criteria (i.e., receiving invasive mechanical ventilation).
89616694|NCT05402566||Healhy volunteers|Repeated MRI and DMI for simplification of protocols. Repeated within 6 +/- 2 weeks.
89616695|NCT05402566||Alzheimer's disease patients|MRI and DMI to assess cerebral glucose metabolism. Single examination. Compared with PET.
89616696|NCT05402566||Healthy controls|MRI and DMI for comparison with AD patients.
89616697|NCT05398354|Experimental|Active Retirement - intervention|The duration of the program is 24-weeks, 2-times a week, for up to 50 minutes per session. The sessions will be divided into three phases: the initial phase (10 minutes) will consist of a 5-minute walk followed by a joint warm-up; fundamental phase (25 minutes) will work in an exercise circuit, this circuit will consist of 4 cycles, with 8 exercises each, with a duration of 50 seconds and a rest of 15 seconds, for the exchange of exercise; and return to calm (10 minutes), where we will perform muscle stretching.
89616698|NCT05398354|No Intervention|Active Retirement - control|The control group will only carry out the assessments and will be offered the same intervention as the intervention group at the end of the intervention.
89616699|NCT05390567||Standard of Care in-clinic Pap-Test|Participant cervical cancer screening method of choice: Standard of Care Pap-Test
89616700|NCT05390567||HPV Self-Test|Participant cervical cancer screening method of choice: HPV Self-Test
89616701|NCT05362968|No Intervention|Control arm|Each participants on usual diet and lifestyle for 12 weeks
88987030|NCT01247389|Active Comparator|midline incision|
88987031|NCT01247389|Active Comparator|transverse incision|
88987032|NCT03987659|Active Comparator|Root Canal Treatment without dECMs release|Two visit non-surgical root canal therapy with conventional irrigation protocols
88987033|NCT03987659|Experimental|Root Canal Treatment with dECMs release|Two visit non-surgical root canal treatment with irrigation protocols that optimise release of soluble dentine extracellular matrix components (dEMCs)
88987034|NCT01247467||Breast Tumor|Breast Tumor Blocks
88987035|NCT01247506||1|tumor tissues of HCC patients
88987036|NCT01247506||2|paired nontumor tissues of HCC patients
88987037|NCT01247545|Placebo Comparator|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
88987038|NCT01247545|Active Comparator|Remote ischaemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
88987039|NCT01247662||ASD group|
88987040|NCT01247662||ADHD group|
88987041|NCT01247662||Normally developing control group|
89616702|NCT05362968|Experimental|Strawberry intervention|Each participants will consume freeze-dried strawberry powder (32g/day) for 12 weeks
89616703|NCT05359185|Experimental|Treatment-only|Participants in the this group will receive core Relationship Education programming, which consists of six weekly 2.5-hour Family Wellness Workshops.
89616704|NCT05359185|Experimental|Treatment-Plus|Participants in this group will receive an enhanced model that includes the core RE programming, and adds economic-focused services which include two 2.5-hour workshops (one on financial planning and one on career coaching), as well as individual financial planning and career coaching services ongoing for up to one year.
89616705|NCT05352958||Patients with Amyotrophic Lateral Sclerosis|"ALS~certain or probable according to the revised Escorial criteria~no indication for non-invasive ventilation"
88987042|NCT01247740|Experimental|1|three chamber bag for parenteral nutrition containing lipids, glucose, amino acids and electrolytes
88987043|NCT01247740|Active Comparator|2|compounded monobag including lipids, glucose, amino acids and electrolytes
88987044|NCT01247779|Active Comparator|Standard Coelioscopy|gynecologic surgery - standard coelioscopy
88987045|NCT01247779|Experimental|Robot-assisted coelioscopy|gynecologic surgery - robot assisted coelioscopy
88987046|NCT01247818|Experimental|PH-10 Treatment (High Dose Cohort)|
88987047|NCT01247818|Experimental|PH-10 Treatment (Mid Dose Cohort)|
88987048|NCT01247818|Experimental|PH-10 Treatment (Low Dose Cohort)|
88987049|NCT01247818|Placebo Comparator|Vehicle Control|
88987050|NCT00503932|Experimental|Proton Therapy + Capecitabine|Capecitabine 825 mg/m^2 by mouth twice daily on Proton Therapy (radiation) days.
88987051|NCT03981146|Experimental|Nivolumab|Patients will receive 480mg of Nivolumab on a four weekly cycle for a maximum of two years.
88987052|NCT01247857|Active Comparator|Preoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity before surgery
88987053|NCT01247857|Active Comparator|Postoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity after surgery
88987054|NCT01247857|Placebo Comparator|Control|Nebulization of normal saline 3 ml before and after surgery
88987055|NCT04331730|Experimental|AKST4290 (800 mg) + Aflibercept|Subjects will receive 400 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
88987056|NCT04331730|Experimental|AKST4290 (1600 mg) + Aflibercept|Subjects will receive 800 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment
88987057|NCT04331730|Placebo Comparator|Placebo + Aflibercept|Subjects will receive placebo for 36 weeks, in combination with intravitreal aflibercept injection treatment
88987058|NCT01248052|Experimental|LY2979165 (Part A)|single oral doses at dose levels ranging from 20 to 1000 mg
88987059|NCT01248052|Placebo Comparator|Placebo (Part A)|single oral dose
88987060|NCT01248052|Experimental|LY2979165 - low dose (Part B)|single oral low dose of LY297165 (dose to be determined by Part A)
88987061|NCT01248052|Experimental|LY2979165 - high dose (Part B)|single oral high dose of LY2979165 (dose determined from Part A)
88987062|NCT01248052|Placebo Comparator|Placebo - Part B|single oral dose
88987063|NCT01248091|Placebo Comparator|Placebo gel|
88987064|NCT01248091|Experimental|Nitroprusside Gel|
88987065|NCT01248169||Hydralazine|This group will receive administration of the antihypertensive Hydralazine for the attempted control of their blood pressure and stabilization of their hemodynamic state.
88987066|NCT01248169||Labetalol|This group will receive administration of the antihypertensive Labetalol for the attempted control of their blood pressure and stabilization of their hemodynamic state.
88987067|NCT01248208|Experimental|FluMist (LAIV) group|FluMist influenza vaccine 0.2 mL intranasal vaccine once
88987068|NCT01248208|Active Comparator|Flu shot (TIV) group|"Patients 6 months to 2 yrs or > 49 years or WITH a history of asthma symptoms / treatment within the past 12 months will receive intramuscular influenza vaccination. History/Treatment of asthma in the past 12 months is defined as follows:~wheezing in the past 12 months~use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist (LABA), or oral steroid in the past 12 months~emergency room or acute care visit or hospitalization for asthma or wheezing in the past 12 months."
88987069|NCT00503971|Experimental|Vorinostat plus erlotinib|Vorinostat plus erlotinib
88987070|NCT04311450|Experimental|Behavioral Weight Loss|Behavioral: Participants randomized assigned to this arm will received 12 weeks of Behavioral Weight Loss (BWL) counseling.
88987071|NCT04311450|No Intervention|Waitlist Control|Waitlist Control: Participants assigned to this arm will attend follow-up visits to control for the effect of time. Following completion of post-treatment assessment participants in the waitlist control group will be offered an abbreviated BWL treatment.
88987072|NCT00504010|Active Comparator|1|arnica containing cream
88987073|NCT00504010|Placebo Comparator|2|carrier cream without arnica
88987074|NCT01248325|Experimental|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
88987075|NCT01248325|Active Comparator|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
88987076|NCT02274883|Experimental|Enriched Protein Fractions|This group is given Infant formula with enriched protein fractions.
88987077|NCT02274883|Active Comparator|Protein Fractions|This group is given Infant formula with protein fractions.
88987078|NCT02274961|Experimental|S-pantoprazole 10mg|S-pantoprazole 10mg Tablet once daily for 4 weeks
88987079|NCT02274961|Placebo Comparator|Placebo|Placebo tablet for the test drug
88987080|NCT02275000|Experimental|Intervention|5 Day physiotherapy programme at the National Hospital for Neurology and Neurosurgery, Queen Square, London UK.
88987081|NCT02275000|Active Comparator|Treatment as usual|Participants are referred to their local neuro-physiotherapy service and if appropriate placed on a waiting list for inpatient rehabilitation.
89616706|NCT05350462||Agboville, Côte d'Ivoire|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
89616707|NCT05350462||Bangolo, Côte d'Ivoire|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
89616708|NCT05350462||Man, Côte d'Ivoire|"was a phase III clinical trial site for Levo-Praziquantel in 2021~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
89616709|NCT05350462||Homa Bay, Kenya|"was a phase III clinical trial site for Levo-Praziquantel in 2021~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
89616710|NCT05350462||Kwale, Kenya|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
89616711|NCT05350462||Hoima, Uganda|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
89616712|NCT05350462||Bugiri, Uganda|"Drug naive region~Parents/guardians of pre-school aged children Primary healthcare personnel Community stakeholders (e.g. political/administrative leaders, religious leaders, traditional healers, civil society, non-governmental organizations, key health system representatives, schistosomiasis control officers, community drug distributers)"
89616713|NCT05330780|Experimental|All participants|The study will be single arm with intervention provided to all participants
89616714|NCT05313516|Experimental|OKKO Health app|Use of OKKO Health app for home monitoring.
89616715|NCT05304052|Experimental|Mindfulness meditation intervention|Half of the subjects will be randomly assigned to participate in the mindfulness meditation intervention. This class will meet once a week, for two hours, over the course of six weeks.
89616716|NCT05304052|No Intervention|Wait list control|Half of the subjects will be randomly assigned to be in the wait-list control group. These subjects will not be asked to do anything during the six weeks while the mindfulness meditation group takes place, other than to not enroll in a meditation class.
89616717|NCT05289076|Experimental|Colorectal liver metastsis, single arm|Tumour tissue from patients operated for colorectal liver metastases. A cubic centimeter of tumour tissue will be processed and implanted in zebra fish embryos. Tissue in zebrafish embryos will treated with different combinations of chemotherapy. Chemocombination of best effect will be offered patients in the third phase of the trial
89616718|NCT05282485|Experimental|Synbiotic Group|A synbiotic combining 2'-Fucosyllactose (2'-FL) human milk oligosaccharides (HMO) with B.infantis (probiotic) will be administered to infants from 4 to 24 weeks of age.
89616719|NCT05282485|Placebo Comparator|Placebo Group|Maltodextrin will be administered to infants from 4 to 24 weeks of age.
89616720|NCT05280275|Experimental|Part 1: Dose Finding|"Belantamab mafodotin will be administered as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose:~Cohort 1: 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle~Cohort 2: 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle~Administration schedule for daratumumab 1800mg SC (fixed dose):~Cycles 1-2: days 1, 8, 15, 22 Cycles 3-6: days 1, 15 Cycles 7+: day 1~Lenalidomide: 25 mg/d on day 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants < 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years"
89616721|NCT05278065|Experimental|Electronic cigarette|Participants in this experimental condition will be provided with a 4th generation electronic cigarette device and disposable cartridges.
89616722|NCT05278065|No Intervention|Smoking As Usual|Participants in this assessment-only condition will continue smoking as usual.
89616723|NCT05244226|Active Comparator|Short acting opioids: Fentanyl, Hydromorphone|
89616724|NCT05244226|Active Comparator|Long Acting Opioid: Methadone|
89616725|NCT05237869|Sham Comparator|Physical Therapy|For patients enrolled in the control group, the participants will undergo calibration of the Delfi Personalized Tourniquet System to measure limb occlusion pressure and will wear the cuff during completion of the exercises with minimal inflation (approximately 5%), to hold the cuff in place during treatment. This will act as a sham.
89616726|NCT05237869|Active Comparator|Blood Flow Restricted Physical Therapy|Physical therapy assisted by blood flow restriction per standard physical therapy protocol.
89616727|NCT05232643||Cohort 1|Non-valvular atrial fibrillation (NVAF) participants administered oral anticoagulants (OAs)
89616728|NCT05232643||Cohort 2|Non-valvular atrial fibrillation (NVAF) participants not administered oral anticoagulants
89036174|NCT02932059|Experimental|Adults controls (18-45 years)|4 groups formed by the case-control study in two age strata
89616729|NCT05224986|No Intervention|Variable Schedule|Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks.
89616730|NCT05224986|Experimental|Fixed Schedule|Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks.
89616731|NCT05213273|Experimental|Group A: Fresh/frozen fish|Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish), excluding the consumption of canned fish.
89036175|NCT02932059|Experimental|Aged Controls (≥ 55 years)|4 groups formed by the case-control study in two age strata
89036176|NCT01280266|Experimental|Amlodipine-Udenafil (AU) arm|Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks
89036177|NCT01280266|Experimental|Udenafil-Amlodipine (UA) arm|Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks
89616732|NCT05213273|Experimental|Group B: Canned fish|Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish where at least 1-2 servings will be in the form of canned fish). A selection of canned fish (tuna, sardine, salmon and mackerel) will be administered to each volunteer for the duration of the study.
89616733|NCT05194124|Experimental|Setmelanotide subcutaneous injection Weekly 20 mg|Patients on 2mg setmelanotide daily will be randomized 1:1 to receive setmelanotide either QD or QW during the double blind period, and all will be assigned to this arm in the open label period.
89616734|NCT05194124|Experimental|Setmelanotide subcutaneous injection Weekly 30 mg|Patients on 3mg setmelanotide daily will be randomized 1:1 to receive setmelanotide either QD or QW during the double blind period, and all will be assigned to this arm in the open label period.
89036178|NCT01279447|Sham Comparator|Placebo|A sham infrapatellar block performed under US guidance with normal saline
89616735|NCT05194124|Experimental|Setmelanotide subcutaneous injection Daily 2 mg|Patients on 2mg setmelanotide daily will be randomized 1:1 to receive setmelanotide either QD or QW during the double blind period.
89036179|NCT01279447|Experimental|Infrapatellar nerve block|An infrapatellar nerve block performed under US guidance with 0.25% bupivacaine
89036180|NCT05466045|Experimental|experimental group|Experimental group received olive oil application
89036181|NCT05466045|Placebo Comparator|control group|Control group received normal saline application
89036182|NCT02920034|Active Comparator|Radiofrequency main renal artery|Renal sympathetic denervation of the main renal artery using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
89036183|NCT02920034|Experimental|Radiofrequency main and branches|Renal sympathetic denervation of the main renal artery, its branches and accessories using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
89036184|NCT02920034|Experimental|Ultrasound main renal artery|Renal sympathetic denervation of the main renal artery using the ultrasound-based Paradise™ catheter (ReCor, CA, USA)
89616736|NCT05194124|Experimental|Setmelanotide subcutaneous injection Daily 3 mg|Patients on 3mg setmelanotide daily will be randomized 1:1 to receive setmelanotide either QD or QW during the double blind period.
89616737|NCT05194124|Placebo Comparator|Placebo subcutaneous injection Daily|Patients will be randomized 1:1 to receive either QD or QW placebo during the double blind period (and setmelanotide in the other formulation).
89616738|NCT05194124|Placebo Comparator|Placebo subcutaneous injection Weekly|Patients will be randomized 1:1 to receive either QD or QW placebo during the double blind period (and setmelanotide in the other formulation).
89616739|NCT05157464|Experimental|Losartan Group|
89616740|NCT05157464|No Intervention|Control Group|No additional steps in management are required for the control arm of the study.
89616741|NCT05154318|Experimental|Pericapsular Nerve Group Block|30ml 0.3% Ropivacaine will be injected between psoas muscle and iliopubic eminence.
89036185|NCT02920151|Experimental|BALANCE EXERCISES CIRCUIT|balance exercises circuit for three months, twice weekly, 50 minutes per day.
89036186|NCT02920151|No Intervention|CONTROL GROUP|usual routine
89036187|NCT02932254|Active Comparator|Magnesium Sulfate|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution)."
89036188|NCT02932254|Placebo Comparator|Saline Solution|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously 100 mL saline solution over 10 minutes."
89036189|NCT02920112|Experimental|One year post-op Tele-CBT|This group will receive Telephone based Cognitive Behavioral Therapy (Tele-CBT) one year after bariatric surgery.
89036190|NCT02920190|Experimental|Liraglutide Group|Participants in this group will receive the Liraglutide intervention for 12 months
89036191|NCT05465850|Active Comparator|Filtek Z350XT|
89036192|NCT05465850|Experimental|Essentia universal shade, GC composite|
89036193|NCT05465850|Experimental|Omnichroma composite|
89036194|NCT02919878|Experimental|pre-op Gemcitabine & XRT|"Pre-op chemo: Gemcitabine will be administered as continuous infusion IV over 24 hrs (100 mg/m2) weekly for 6 wks starting on day 1 of Radiotherapy (XRT).~XRT/ Intensity modulated radiotherapy(IMRT): 1.8 Gy/fx, 5 fractions/wk will be delivered. Pelvis will receive 45 Gy/25 fractions/5 wks with a boost dose of 5.4 Gy for T3 and 9 Gy for T4 to a cone down volume. The total tumor dose= 50.4 -54 Gy.~Post-op chemo: Standard 6 cycles of adjuvant Capecitabine (1250 mg/m2) PO twice per day on days 1-14 each cycle, (every 21 days) in patients who have a complete resection of rectal cancer and negative surgical margins."
89036195|NCT02931786|Active Comparator|propofol|body core temperature was measured from tympanic membrane after 1 mg/kg propofol administration, before and after magnetic resonance imaging
89616742|NCT05154318|Active Comparator|Fascia iliaca compartment block|30ml 0.3% Ropivacaine will be injected into fascia iliaca compartment.
89616743|NCT05153863|Experimental|Single Arm C-Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
89616744|NCT05130229|Experimental|Sleep Well Bee Well|Sleep program to help toddlers sleep better
89616745|NCT05130229|Placebo Comparator|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
89616746|NCT05126862|Experimental|MindTrails pilot|This intervention involves completion of five, 20-minute MindTrails online training sessions over five weeks.
89616747|NCT05117632|Experimental|ALTO-100|ALTO-100 PO tablet, daily dosing 8 weeks
89616748|NCT05116241|Experimental|BPZE1 intranasal and Placebo intramuscular|Individual will receive an intranasal dose of BPZE1 via the mucosal atomization device and a dose of intramuscular placebo.
89616749|NCT05116241|Experimental|BPZE1 intranasal and Boostrix intramuscular|Individual will receive an intranasal dose of BPZE1 via the mucosal atomization device and a dose of intramuscular Boostrix (acellular pertussis [aP] vaccine).
89616750|NCT05116241|Active Comparator|Placebo intranasal and Boostrix intramuscular|Individual will receive an intranasal dose of placebo via the mucosal atomization device and a dose of intramuscular Boostrix (aP vaccine comparator).
89616751|NCT05113641|Experimental|Alkalizing Fruit and Vegetables|Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format. Participants will receive a 1-hour dietary counseling session in the first week from a registered dietitian (RD), either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet. Intervention will last 12 months.
89616752|NCT05113641|Active Comparator|Sodium Bicarbonate|Participants randomized to the alkali therapy will receive oral sodium bicarbonate 500mg tablets three times a day, reflecting a common starting dose at clinical practice. Thereafter, decisions around dose titration for the sodium bicarbonate will then be transferred to the participant's nephrologist who will be responsible for monitoring the participants serum bicarbonate concentration with a goal of maintaining a serum bicarbonate level >22 mEq/L. Participants will receive counselling from a registered dietician (RD) as part of the standard care. Intervention will last 12 months.
88987082|NCT02275039|Experimental|Treatment (MVA-p53 vaccine and gemcitabine hydrochloride)|Patients receive modified vaccinia virus ankara vaccine expressing p53 SC on day 15 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
88987083|NCT02275078|Other|Interventional|The program consists of 3 components: 1) COPD self-management using an Action Plan; 2) Telesystem-Phone self-assessment/reporting system; and 3) Nurse case manager support.
88987084|NCT01248403|Active Comparator|paclitaxel + placebo|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ Placebo (2 tablets / day) d1-d28"
88987085|NCT01248403|Experimental|paclitaxel + RAD001|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ RAD001 10mg (2 x5 mg tablets / day) d1-d28"
88987086|NCT01248442|Experimental|Cholecalciferol|
88987087|NCT01248442|Placebo Comparator|Placebo|
88987088|NCT01248481||Group 1|
88987089|NCT02957838|Experimental|Non-diabetics|Non-diabetic volunteers with HbA1c < 6.5%. Subjects will be treated with C18:0 supplementation or mock.
88987090|NCT02957838|Experimental|Type 2 Diabetics|Type 2 Diabetes according to common definitions, but we exclude insulin-treated Type 2 diabetics because nutritional intervention is more difficult/risky. Subjects will be treated with C18:0 supplementation or mock.
88987091|NCT02955667|Experimental|invivo microscopy group|patients receive invivo micro-colposcopy examination and do not have to receive the biopsies
88987092|NCT02955667|Other|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
88987093|NCT01248520|Placebo Comparator|General health information|Pregnant women receiving text messages containing general health messages without including information regarding the importance of the influenza vaccination
88987094|NCT01248520|Active Comparator|Influenza and general health information|Pregnant women receiving text messages with influenza facts and the importance of the influenza vaccination, as well as general health messages Intervention: Text messages with influenza facts
88987095|NCT01248637||Pimonidazole hydrochloride|Oral pimonidazole is administered at a dose of 0.5gm/m2 once approximately 24 hrs prior to surgery
88987096|NCT04186923|Experimental|Intervention group (IG)|Families receive permanent contact persons to support in the organisation of everyday life, financial applications, during emotional coping with illness and open communication within the family.
88987097|NCT04186923|No Intervention|Control Group|In the control group the families are treated according to the standard of care.
88987098|NCT01248754|Experimental|18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
88987099|NCT01248832|Experimental|Telephone Counseling|Telephone Counseling
88987100|NCT01248832|Active Comparator|Self-help Materials|Self-help Materials
88987101|NCT03929939|Experimental|Lifestyle Modification Group|
88987102|NCT03929939|No Intervention|Control Group|
88987103|NCT04183140|Active Comparator|Transradial|Transradial intervention
88987104|NCT04183140|Active Comparator|Transulnar|Transulnar intervention
88987105|NCT01248910|Experimental|Alpine Skiing|
88987106|NCT01248910|No Intervention|Control group|
88987107|NCT01248988||Synflorix Group|Infants and children who received at least one dose of Synflorix™ as a part of routine practice at a private clinic or hospital
88987108|NCT01247194|Active Comparator|Cohort A|"PPI-461 50 mg~or placebo"
88987109|NCT01247194|Active Comparator|Cohort B|"PPI-461 100 mg~or placebo"
88987110|NCT01247194|Active Comparator|Cohort C|"PPI-461 200 mg~or placebo"
88987111|NCT01249105|Experimental|Part 1|Patients with recurrent glioblastoma multiforme (GBM) who require reoperation.
88987112|NCT01249105|Experimental|Part 2|Participants with GBM and with anaplastic glioma
88987113|NCT02957955|Experimental|Interventional|Group 1. Usual care + High-Intensity Interval Training, Nutritional Workshop, Stress Management Course.
89036196|NCT02931786|Active Comparator|ketofol|body core temperature was measured from tympanic membrane after 0,1 ml/kg administration of ketamine propofol mixture of 10 mg/ml both, before and after magnetic resonance imaging
89036197|NCT02931747|Placebo Comparator|Placebo|Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
89036198|NCT02931747|Active Comparator|Bacopa Monnieri 300 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
89036199|NCT02931747|Active Comparator|Bacopa Monnieri 600 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
89036200|NCT02919605|Experimental|Single dose of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg will be included, in a single dose.
89036201|NCT02919605|Experimental|Two doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during two weeks.
89616753|NCT05098444|Experimental|Cognitive behavioral psychotherapy|"Internet-based CBT for patients with endometriosis:~The experimental group has access to an online training consisting of 8 modules, one per week.~Modules comprise of 1) psychoeducation (e.g., information about endometriosis and its treatment); 2) & 3) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions); 4&5) pain and stress management (e.g. activity plans, relaxation techniques); 6) emotion regulation strategies (e.g. recognition and acceptance of emotions); 7) communication training (e.g. detection and communication of needs); 8) prophylaxis (e.g. summary of intervention, plans for the future).~Participants are in weekly written contact with their assigned therapist via the news function of the training platform, receiving feedback on the content or getting answers to open questions."
89616754|NCT05098444|Other|Waiting list|During the waiting period, patients receive no treatment. After a waiting time of 5 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
89616755|NCT05090865|Other|Liberalized dietary potassium and then restricted potassium via fruit and vegetables|Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2-week run-in and liberalized potassium treatment period, then cross-over to the restricted potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional Coronavirus disease (COVID)-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet.
89616756|NCT05090865|Other|Restricted dietary potassium and then liberalized potassium via fruit and vegetables|Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2 week run-in and then start receiving a restricted potassium treatment period, then cross-over to the liberalized potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional COVID-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet
89616757|NCT05080296||All patients underwent DaTSCAN SPECT scans|
89616758|NCT05079620|Experimental|Antibiotics|"5 days of empiric antibiotics selected from a guideline-appropriate regimen. Alternate agents may be selected by the treating team if allergies or other patient factors mandate, but are still recommended for a 5 day course. Supportive care including oxygen and ventilation can be offered ad libitum.~Options include ceftriaxone, Augmentin, cefepime, vancomycin, levofloxacin."
89616759|NCT05079620|No Intervention|Control|No initial antibiotic therapy unless clinical picture changes or worsens. Supportive care including oxygen and ventilation can be offered ad libitum.
89616760|NCT05079321|Experimental|Coated Scleral Lens|Participants wear a lens coated with Hydra-PEG.
89616761|NCT05079321|Placebo Comparator|Uncoated Scleral Lens|Participants wear an uncoated (control) lens.
89036202|NCT02919605|Experimental|Three doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during three weeks.
89036203|NCT02931708|Experimental|DFES group|"Diaphragm Functional Electrical Stimulation:~Each session will last 30 minutes. The parameters selected in the stimulator will be: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance.~The patient will be positioned supine, headboard 30º, knees extended. Furthermore, the electrodes used to perform the electrical stimulation will be adhesive, disposable and hypoallergenic. These will be placed at sixth, seventh and eighth intercostal spaces, axiliar medium line and paraxiphoid both chest sides."
89036204|NCT02919800|Experimental|MOD-5014|MOD-5014 longevity is the result of fusion of three consecutive C-terminal peptide (CTP) domains to the C-terminus of FVII. CTP technology is based on a natural peptide, the C-terminal peptide of the beta chain of human chorionic gonadotropin (hCG), which provides hCG with the required longevity to maintain pregnancy (initial half-life [t1/2] ~10 h, terminal t1/2 ~37 h). The beta chain of luteinizing hormone (LH), a gonadotropin that triggers ovulation, is almost identical to hCG but does not include the CTP. As a result, LH has a significantly shorter half-life in blood (initial t1/2 ~1 h, terminal t1/2 ~10 h) (Fares et al., 1992).
89036205|NCT02919800|Placebo Comparator|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
89036206|NCT04687605|Experimental|Optimum duration of hypercapnia|Daily serial measurement of 2 hours under target hypercapnia of pCO2 50 - 55 mmHg by changes of respirator settings once per day
89036207|NCT02931630|Experimental|HP/HF|Whey protein powder / High fiber bread
89036208|NCT02931630|Experimental|HP/LF|Whey protein powder / Low fiber bread
89036209|NCT02931630|Experimental|LP/HF|Maltodextrin powder / High fiber bread
89036210|NCT02931630|Experimental|LP/LF|Maltodextrin powder / Low fiber bread
89036211|NCT02931669||Adult AAC users|Will be accessed via online forums to fill in online anonymous survey link
89036212|NCT02931669||Children who use AAC|Parents at local special schools will be given the opportunity for their child to participate in a face to face symbol based interview. They will give written consent and children's assent will also be obtained.
89616762|NCT05068869|Other|Dignio Digital Remote Care intervention group|Participants will receive the MyDignio app for individualized follow-up for 6 months.
89616763|NCT05068869|Other|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
89616764|NCT05049850|Experimental|Imlifidase|Imlifidase is administered intravenously as one dose of 0.25 mg/kg over 15 minutes within the 24-hour period prior to transplantation. (A second dose may be given if the crossmatch test at 4 hours after the first dose remains positive.)
89616765|NCT05037461|Experimental|High-dose-high precision MR-guided radiotherapy|"Radiotherapy for pancreatic NET will be delivered in an image-guided, hypofractionated scheme of 5 fractions of 8 Gy, prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days 2 or 3 times a week with a maximum overall treatment time of 14 days on the 1.5T MR-Linac (Elekta Unity MR-Linac).~The Gross Tumor Volume (GTV) is defines as the pNET visible on pre-treatment CT and MRI scan. No clinical target volume (CTV) is used. The PTV is made by adding a 3mm margin to the GTV.~The treatment plan is a 9-14 field intensity modulated radiotherapy (IMRT) plan with dose prescribed to 95% of the PTV. While respecting the dose constraints to adjacent tissues"
89616766|NCT05036655|Active Comparator|Intervention: PGMP|Sites will implement a perioperative glycemic management pathway based on national guidelines and current evidence, with support of an implementation scientist team.
89616767|NCT05036655|Active Comparator|Non-intervention: usual care|Sites will perform usual perioperative glycemic management.
89616768|NCT05033002|No Intervention|Treatment as Usual Group|This group will receive treatment as usual which means that no formal stigma reduction intervention will be provided. At the end of the follow-up period, this group will be invited to view the Labda Siku Moja stigma reduction intervention without follow-up.
89616769|NCT05033002|Experimental|Stigma Intervention Group|This group will participate in a 5 week intervention. Each week, intervention group participants will watch one ethnodrama segment of the Labda Siku Moja stigma reduction intervention followed by a guided debrief using motivational interviewing.
89616770|NCT05026827|Experimental|Iyengar Yoga|Participants will engage in 10 weekly IY classes
89616771|NCT05026827|Active Comparator|Socialization Control|Participants will engage in 10 weekly socialization control group sessions
89616772|NCT05026827|No Intervention|Healthy Comparison Group|A group of participants will also be followed for 10 weeks
89616773|NCT05019170|Experimental|Best Practices + Incentives group|Participants assigned to this condition will receive the best practices treatment plus the financial incentives intervention.
89616774|NCT05019170|Active Comparator|Best Practices|Participants assigned to this condition will receive the best practices treatment alone.
89616775|NCT05003518|Experimental|Condition 1: Low Personalisation+Low Frequency|The intervention will have low levels of personalisation and one message a day will be sent to participants.
89616776|NCT05003518|Experimental|Condition 2: High Personalisation+Low Frequency|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname) and one message a day will be sent to participants.
89616777|NCT05003518|Experimental|Condition 3: Low Personalisation+High Frequency|The intervention will have low levels of personalisation and three messages a day will be sent to participants.
89616778|NCT05003518|Experimental|Condition 4: High Personalisation+High Frequency|The intervention will have high levels of personalisation and three messages a day will be sent to participants.
89616779|NCT05003518|Experimental|Condition 5: High Personalisation+Low Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
89616780|NCT05003518|Experimental|Condition 6: Low Personalisation+High Frequency+Gamification|The intervention will have low levels of personalisation, contains gamified progress updates, and three messages a day will be sent to participants.
89616781|NCT05003518|Experimental|Condition 7: High Personalisation+High Frequency+Gamification|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and three message a day will be sent to participants.
89616782|NCT05003518|Experimental|Condition 8: Low Personalisation+Low Frequency+Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and one message a day will be sent to participants.
89616783|NCT05003518|Experimental|Condition 9: High Personalisation+Low Frequency+Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and one message a day will be sent to participants.
89616784|NCT05003518|Experimental|Condition 10: Low Personalisation + High Frequency + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages, and three message a day will be sent to participants.
89616785|NCT05003518|Experimental|Condition 11: High Personalisation + High Frequency + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages, and three message a day will be sent to participants.
89036213|NCT02931669||Family members|The paper version of the survey will be distributed among parents at local special schools for them to fill in at home with their families. Online groups of families will also be sent the online survey link.
89036214|NCT02931669||Teachers|Teachers at local special schools will be given the paper survey forms. Online groups of teachers will receive the online link.
89036215|NCT02931669||Health Professionals|Online groups of health professionals will receive the online link
89616786|NCT05003518|Experimental|Condition 12: Low Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation, contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
89616787|NCT05003518|Experimental|Condition 13: High Personalisation + Low Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent one message a day.
89036216|NCT02919722|Experimental|Music interventions|Live music will be provided on the patient's neglected side and patients will be encouraged to play music interactively with a focus towards that side whenever possible
89036217|NCT02931864|No Intervention|Usual care group|Usual care is meant the routine medical and health care services at the hospital.
89036218|NCT02931864|Experimental|Experimental group|Five weekly sessions of online symptom management + mindfulness training programme + usual care
89616788|NCT05003518|Experimental|Condition 14: Low Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three message a day.
89616789|NCT05003518|Experimental|Condition 15: High Personalisation + High Frequency + Gamification + Gender Targeting|The intervention will have high levels of personalisation (utilise the user's nickname and their child's nickname), contains gender targeted messages and gamified progress updates. Participants will be sent three messages a day.
89616790|NCT05003518|Experimental|Condition 16: Low Personalisation+Low Frequency+Gamification|The intervention will have low levels of personalisation (utilise the user's nickname and their child's nickname), contains gamified progress updates, and one message a day will be sent to participants.
89616791|NCT04986241||Sedentary Heart Failure with Reduced Ejection Fraction Without Statin|Sedentary Heart Failure with Reduced Ejection Fraction determined by echocardiogram; Without statin in the last 6 months.
89616792|NCT04986241||Sedentary Heart Failure with Reduced Ejection Fraction With Statin|Sedentary Heart Failure with Reduced Ejection Fraction determined by echocardiogram; With current use of statin.
89616793|NCT04986241||Physically active Heart Failure with Reduced Ejection Fraction Without Statin|Physically active Heart Failure with Reduced Ejection Fraction determined by echocardiogram; Without statin in the last 6 months.
89616794|NCT04986241||Physically active Heart Failure with Reduced Ejection Fraction With Statin|Physically active Heart Failure with Reduced Ejection Fraction determined by echocardiogram; With current use of statin.
89616795|NCT04986241||Healthy sedentary Without Statin|Sedentary and healthy participant without use of statin; Without statin in the last 6 months.
89616796|NCT04986241||Healthy sedentary With Statin|Participant with dyslipidemia and sedentary with current use of statin.
89616797|NCT04986241||Healthy physically active Without Statin|Healthy, physically active participant without use of statin; Without statin in the last 6 months.
89616798|NCT04986241||Healthy physically active With Statin|Participant with dyslipidemia and physically active with current use of statin.
89616799|NCT04982497|Experimental|Video game based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 70 (±25) minutes long that will be administered at a rate of 1 per week with between-session homework.
89616800|NCT04982497|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
89616801|NCT04977999|Active Comparator|Eccentric training|Eccentron (BTE Technologies, Inc.) training
89616802|NCT04977999|Experimental|Aquatic training|Hydroworks aquatic training
89616803|NCT04969198|Experimental|Nicotine Patch + Nicotine Mini Lozenge|"No medication for 1 Week after Target Quit Day (TQD). Medication started 1 Week after TQD.~Patches (Nicotine): 14 mg Patches for 4 weeks postquit (Week 1-5), then 7 mg patches for 4 weeks (Week 6-9)~Mini Lozenge (Nicotine): 2 mg Mini Lozenges 5x per day (up to 20x day max) for 8 weeks post quit (Week 1-9)"
89616804|NCT04968405|Other|Single Arm|Intervention with a 510k cleared shoulder arthroplasty device
89616805|NCT04965012|Experimental|CBT with MET treatment group|Participants in this arm will be provided with an MET-therapist guided introduction, in addition to the online CBT treatment.
89616806|NCT04965012|Experimental|CBT without MET treatment group|Participants in this arm will be provided with a brief non-MET research assistant-led welcome to the program, in addition to the online CBT treatment.
89616807|NCT04965012|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about cannabis and wellbeing.
89036219|NCT02931864|Active Comparator|Comparison group 1|Five weekly sessions of online symptom management programme + usual care
89616808|NCT04960605|Other|Test group|Patients with Primary Sjögren Syndrom
89036220|NCT02931864|Active Comparator|Comparison group 2|Five weekly sessions of online mindfulness training programme and usual care
89036221|NCT00532428|Active Comparator|1|
89036222|NCT00532428|Active Comparator|2|
89036223|NCT00532428|Placebo Comparator|3|
89616809|NCT04960605|Other|Control group|Patients with Primary Sjögren Syndrom, matched to the test group
89616810|NCT04948853|No Intervention|Treatment as usual|Treatment as usual, with respect to employment, for individuals on probation typically entails the probation officer informing the probationer that probationer is responsible for obtaining employment or could entail a referral from a probation officer to an employment or job assistance service, such as vocational rehabilitation. The probationer is responsible for follow up with that service.
89616811|NCT04948853|Experimental|Intervention - Individual Placement Support-Supported Employment|Subjects in this condition will receive services from a 1.5 FTE IPS-SE team that will work to provide one-on-one person-centered services to help obtain employment, including but not limited to career profiling, resume assistance, job placement, training and other activities.
89616812|NCT04943900|Experimental|Part 1A: Monotherapy (BMS-986416)|
89616813|NCT04943900|Experimental|Part 1B: Combination Therapy (BMS-986416 + Nivolumab)|
89036224|NCT02919527|Experimental|Self-Myofascial-Release|Two 60 seconds bouts of Self-Myofascial-Release performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
89036225|NCT02919527|Active Comparator|Stretching|Two 60 seconds bouts of static stretching performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
89036226|NCT02919527|No Intervention|Control|No Intervention
89036227|NCT02919644|Experimental|vaccine + Interleukin -2 (IL2)|autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)
89036228|NCT05465733|Experimental|Envafolimab|
89036229|NCT02919488|Experimental|Exercise Condition|
89036230|NCT02919488|Active Comparator|Control Condition|
89036231|NCT00533286|Placebo Comparator|A|placebo (2 tablets daily)
89616814|NCT04943861|Active Comparator|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
89616815|NCT04943861|Other|Usual Care|There is no peer navigation within usual care.
89616816|NCT04941300|Other|Mailed FIT Outreach|Primer, FIT Kit, Reminders, Abnormal FIT Follow-up
89616817|NCT04941300|No Intervention|Usual Care|
89616818|NCT04939402|Other|General|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
89616819|NCT04939220|Active Comparator|Control Group|Deep sedation with propofol and natural airway
89616820|NCT04939220|Experimental|Experimental Group|SGA Placement and maintenance with inhalational anesthetic or propofol
89616821|NCT04935034|Experimental|Vitamin D enriched mixed micelles dairy drink|20ug vitamin D in pre-formed mixed micelle dairy drink
89616822|NCT04935034|Active Comparator|Vitamin D enriched olive oil dairy drink|20ug vitamin D in olive oil dairy drink
89616823|NCT04935034|Active Comparator|Vitamin D enriched fish oil dairy drink|20ug vitamin D in fish oil dairy drink
89616824|NCT04935034|Active Comparator|Vitamin D enriched fat-free dairy drink|20ug vitamin D in fat-free dairy drink
89616825|NCT04928664|Active Comparator|Liposoaml Bupivacaine (LB) Group|Intervention group
89616826|NCT04928664|Experimental|Standard Bupivacaine (SB) Group|Control group
89616827|NCT04928261|Experimental|De-escalated HER2 targeted treatment|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery.
89616828|NCT04916392||liposomal bupivacaine|Nerve block will be preformed using 5ml of 1.33% liposomal bupivacaine with 5ml of 0.9% normal saline.
89616829|NCT04908384|Experimental|IMPACT Intervention|IMPACT health application and wearable device
89616830|NCT04908384|No Intervention|Usual care control|Usual care control.
89036232|NCT00533286|Experimental|B|diazepam (2 x 5 mg)
89036233|NCT03680456|Active Comparator|Intervention|due to postoperative Hemoglobin Level intravenous iron Ferriccarboxymaltose is Infuses, dosage is based on the Ganzoni-Algorithm
89616831|NCT04902352|Experimental|Periadventitial dissection|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process."
89616832|NCT04902352|Active Comparator|NO periadventitial dissection|For patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact
89616833|NCT04887454|Experimental|Once-Weekly HIIT|Once-weekly HIIT for 16 weeks, led by certified athletic coaches
89616834|NCT04887454|Experimental|Thrice-Weekly HIIT|Thrice-weekly HIIT for 16 weeks, led by certified athletic coaches
89616835|NCT04887454|Other|Usual Care|Bi-weekly health education, led by research personnel
89616836|NCT04884334||VAC-Stent® treatment|spontaneous, iatrogenic or postoperative leakage of the oesophagus or colon
89616837|NCT04879706||AKI necessitating KRT|Patients with AKI necessitating KRT
89616838|NCT04868695|Experimental|Bilateral Spheno-Ethmoidectomy:|
89616839|NCT04868695|Experimental|Bilateral Fronto-Spheno-Ethmoidectomy + Draf 2b|
89616840|NCT04868695|Experimental|Draf Typ 3|
89616841|NCT04866251|Active Comparator|Healthy young subject|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
89616842|NCT04866251|Active Comparator|Healthy older subjects|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
89036234|NCT03680456|Placebo Comparator|Placebo|Natriumchlorid is the placebo
89036235|NCT03673787|Experimental|Phase I|Increasing doses of ipatasertib in combination with a fixed dose of atezolizumab to establish the recommended phase II dose.
89036236|NCT03673787|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose of ipatasertib identified in Phase I, in combination with atezolizumab, in six patient cohorts: patients with solid tumours who have hyperactivation of the PI3K pathway; patients with castrate-resistant prostate cancer with PTEN loss; patients with glioblastoma; patients with melanoma; patients solid tumour types refractory to immune-checkpoint inhibitors; patients with gynaecological cancers.
89036237|NCT05465694|Active Comparator|2-minute-time interval of per oral 24% sucrose|For infants in the 2-minute-time interval of per oral 24% sucrose was given prior to the heel lance intervention.
89036238|NCT05465694|Active Comparator|no time interval of per oral 24% sucrose|In no time interval of sucrose was given immediately prior to heel lance intervention.
89616843|NCT04866251|Active Comparator|Acute stroke patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
89616844|NCT04866251|Active Comparator|Patients with Parkinson´s Disease|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
89616845|NCT04866251|Active Comparator|Patients with Multiple Sclerosis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
89616846|NCT04866251|Active Comparator|Patients with Myasthenia gravis|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
89616847|NCT04866251|Active Comparator|Geriatric patients|Testing of gag reflex in different oral areas (tongue, velum, pharyngeal wall) and evaluation of present reactions. The Mallampati score is assessed in order to evaluate the feasibility of gag reflex test in case of higher Mallampati scores.
89616848|NCT04859725|Experimental|Hyperspectral Imaging with Snapscan camera|"Included patients will undergo a resection of the low grade glioma as standard-of-care. Hyperspectral imaging data will be acquired by the SnapScan HSI camera mounted on the (standard) surgical microscope.~As such, the surgical procedure does not deviate from the common, standard-of-care surgical procedures, apart from the acquisition of intraoperative scanning images using the SnapScan HSI camera on the microscope. The objective of this all is to get an initial high quality in vivo dataset to start exploring the potential of the technology."
89616849|NCT04854668|Experimental|Anlotinib + CapeOx|Anlotinib combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Anlotinib combined with Capecitabine.
89616850|NCT04854668|Active Comparator|Bevacizumab + CapeOx|Bevacizumab combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Bevacizumab combined with Capecitabine.
89616851|NCT04842084||healthy volunteers|Healthy volunteers both sex aged between 18 and 50 without personal or family history of hemorrhage, thrombosis before 45 years old,
89616852|NCT04836312|No Intervention|Attention Control|Patients will be instructed via text message and email to fast at least 16 hours per day every day. For the next 18 weeks, they will receive a daily text message via the Way to Health platform asking if they fasted for at least 16 hours over the past 24 hours. If they fail to respond, reminder text messages will be sent. Once per week, they will receive a text message asking them to weigh themselves and check their blood pressure, and reply with the results via text message
89616853|NCT04836312|Experimental|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
89616854|NCT04830488|Experimental|Body Image after Head and Neck Cancer Treatment|
89616855|NCT04830410|Experimental|Fructan powder|2 g of fructan powder 3 times per day for 7 days
89616856|NCT04830410|Placebo Comparator|Placebo|2g of placebo (maltodextrin) 3 times per day for 7 days.
89616857|NCT04804605|Experimental|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
88987114|NCT02957955|No Intervention|Non interventional|Group 2. Usual care. Patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
88987115|NCT01249144|Active Comparator|Tecnis Z9002 Intraocular Lens (IOL)|
89616858|NCT04788264|Experimental|Arm I (exercise training, behavior modification)|Beginning 1 week prior to start of intervention, patients receive a Fitbit to monitor physical activity for 13 weeks. Patients receive consultation and personalized exercise prescription from a physical therapist at baseline, and attend exercise training sessions with a physical therapist during weeks 1, 3, 6, 9, and 12. Patients also attend behavior modification sessions with a behavioral therapist that focus on goal setting and healthy behavior changes during weeks 2, 4, 5, 7, 8, 10, and 11.
89616859|NCT04788264|Active Comparator|Arm II (Fitbit, consultation)|Patients receive a Fitbit to monitor physical activity for 12 weeks. Patients also receive consultation from a physical therapist to assess physical performance at weeks 1, 6, and 12.
89616860|NCT04786093|Active Comparator|Stereotactic Ablative Radiotherapy (SAbR) Arm plus Durvalumab arm|SAbR with each radiation treatment fraction delivered every other day
88987116|NCT01249144|Active Comparator|Softec HD Intraocular Lens (IOL)|
88987117|NCT01249183|Experimental|1- VAXIGRIP and REPEVAX concomitantly|
88987118|NCT01249183|Active Comparator|2-REPEVAX 28 days after VAXIGRIP|
88987119|NCT01249222|No Intervention|conventional treatment|
88987120|NCT01249222|Experimental|Plasmapheresis|
88987121|NCT01249300||Dysphagia|Patients with CVA which causes dysphagia
88987122|NCT01249339|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes.
89616861|NCT04786093|Experimental|Personalized Ultra-fractionated Stereotactic Radiotherapy (PULSAR) plus Durvalumab arm|PULSAR with each radiation treatment fraction delivered every 4 weeks
89616862|NCT04785976||Surgical clipping|
89616863|NCT04785976||Endovascular coiling|
89616864|NCT04779684|Experimental|ACP by proxy pilot intervention group|All participants are included in the intervention group
89616865|NCT04778709|Experimental|Bone Graft A|Bone Graft A: Mixture of 25% small-particle cortical, 25% large particle cortical, 25% small particle cancellous, 25% large particle cancellous allograft
89616866|NCT04778709|Active Comparator|Bone Graft B|Bone Graft B: 100% large particle cancellous allograft
89616867|NCT04778059|Experimental|USB002|
89616868|NCT04778059|Placebo Comparator|Placebo|
89616869|NCT04773470|Experimental|Spinal Muscle Atrophy|All patients with Spinal Muscle Atrophy type 1 to 4
88987123|NCT01249339|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
88987124|NCT01249339|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes.
88987125|NCT01249339|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
88987126|NCT03809429|Experimental|FE 999049 + GnRH agonist (GONAPEPTYL)|
88987127|NCT03809429|Experimental|FE 999049 + GnRH antagonist (CETROTIDE)|
89036239|NCT03615248|Experimental|Primary Arm -|"30 Subjects will be approached in Asthma Clinics at the Janeway Children's Health and Rehabilitation Centre by the research nurse, and if selected to the study, will use the BreatheSuite device for 3-6 months.~Inclusion criteria: Age 10-18, diagnosis of asthma by the pediatrician, regular access to a smartphone, parental consent, ongoing need for regular use of a medication delivered by metered dose inhaler as deemed by the pediatrician, ability to demonstrate proper technique of metered dose inhaler use in the clinic while supervised by research nurse or pediatrician without parent or caregiver intervention;"
89036240|NCT04805112|Experimental|Provision of multiple self-tests|Participants randomized to the intervention group will be given 2-3 HIV oral self-tests to offer to their sexual partner(s). The participant will be instructed to encourage their partner to test himself alone [partner testing] or with the participant [couple testing]; the partner will also be given a card with information on testing and a list of facilities where he can go for confirmatory testing. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
89036241|NCT04805112|No Intervention|Referral vouchers for clinic testing|Participants randomized to the control group will be given multiple referral coupons for HIV testing at pre-selected HIV testing services (HTS) sites. The participant will be instructed to give the coupon to their sexual partner(s) and encourage him to go for HIV testing at pre-selected HTS sites, either alone [partner testing] or together with the participant [couple testing]. The coupon will also have information on testing and a list of facilities where he can go for HTS. All participants will be encouraged to call a study helpline/hotline in the event of any adverse events that they or their sexual partners experience or if they need further instructions or information
89036242|NCT03571802|Experimental|intervention arm|simvastatin 20mg once
89616870|NCT04765033|Active Comparator|5% Hypertonic saline|5% hypertonic saline nebuliser 4 mls twice in a day for 3 months
89036243|NCT04799652||Doctors within Belgian Hospitals|
89036244|NCT02919332||Diagnostic (18F-FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
89616871|NCT04765033|Placebo Comparator|Placebo|0.9% saline nebuliser 4 mls twice in a day for 3 months
89616872|NCT04726150||Mildly of Asymptomatic COVID|Athletes with prior COVID-19 that had a mildly or asymptomatic course
89616873|NCT04726150||Moderate to Severe Symptoms, Cardiac Symptoms|Athletes with prior COVID-19 that had a moderate to severely symptomatic course, or who experience(d) cardiac symptoms
89616874|NCT04726150||Hospitalized for|Athletes that were hospitalized for COVID-19
89616875|NCT04723784|Experimental|Person with disability|"Initial assessment.~Implementation of AT in the daily life of participants~Application of outcome measures and analysis of the data"
89616876|NCT04690049|Experimental|Neuromuscular resistance exercise group|Subjects will develop an innovator program consisting in the performance of exercises of increasing difficulty, with movements based on functional tests to analyze the subjects' neuromuscular capacities. Participants will attend to 80 individual, face-to-face physiotherapy sessions, including both supervised and semi-supervised monitoring. From the total, a minimum of 15 sessions will be supervised, including 6 sessions to teach and monitor the exercises, and 9 sessions to perform the tests in order to quantify the load; 37 sessions will be semi-supervised, where subjects will perform the exercises independently, but with the presence of an instructor; additionally, the remaining 28 sessions will consist in non-supervised aerobic work at a 70-80% from maximum heart rate, obtained according to the methodology of Tanaka et al.
89616877|NCT04690049|Active Comparator|Control exercise group|This program will be based on a home exercise protocol considering painful sensation and self-perceived stability as progression criteria: regarding pain management, exercises will be planned in a way that increased pain after their performance reverts to before-exercise levels prior to the next session; regarding self-perceived stability, participants will be asked to maintain a constant sensation of joint stability and control during the execution of the exercises. Participants will perform shoulder rotations (external and internal) and abduction up to 30º by using elastic bands. The resistance of the band will be adjusted by the physiotherapist so that participants perceive the exercises as demanding enough but not too unpleasant, being able to complete the 10 repetitions before taking the rest. Likewise, exercises will progress until a maximum of 90º of shoulder abduction.
89616878|NCT04621266|Experimental|Online Home-based peer support intervention|Participants will receive intervention on top of standard usual care.
89616879|NCT04621266|No Intervention|Standard usual care|Participants will receive standard usual care.
89036245|NCT05465577|Experimental|Financial Navigation- Patients Only|Patients only participated in financial navigation program.
89036246|NCT05465577|Experimental|Financial Navigation- Patient and Caregiver|Patients and their caregivers participated as a dyad in financial navigation program.
89616880|NCT04621227|Other|Period 1|Participants will receive the following treatments in this sequence : (i)Rosuvastatin alone (one dose of 10 mg), (ii) Midazolam alone (one dose of 2mg), (iii) PF 06882961 alone (120 mg twice daily), (iv) PF 06882961 (120 mg twice daily) + Rosuvastatin (one dose of 10mg), (v) PF 06882961 (120 mg) + Midazolam (one dose of 2 mg), (vi) PF 06882961 (200 mg) alone, (vii) PF 06882961 (200 mg) + Rosuvastatin (one dose of 10 mg), (viii) PF 06882961 (200 mg)+ Midazolam (one dose of 2 mg) in the study.
89616881|NCT04597918|Experimental|Faricimab|Participants will receive 6 doses (one 6 mg faricimab intravitreal [IVT] injection every 28 days [Q4W]) starting at Day 1 and ending on the Day 140 visit. Participants will return for a safety follow-up visit (SFV) after ≥28 days and within <35 days following their last study treatment.
89616882|NCT04592549|Experimental|Cohort 1: 150 mg IM injection of active drug or placebo|"Subjects in cohort 1 will receive a 150 mg dose IM injection of either active drug or placebo.~Cohort 1 will dose 8 subjects to active drug and 2 subject to placebo"
89616883|NCT04592549|Experimental|Cohort 2: 300 mg IM injection of active drug or placebo|"Subjects in cohort 2 will receive 300 mg IM injection of either active drug or placebo.~Cohort 2 will dose 8 subjects to active drug and 2 subject to placebo."
89036247|NCT02919254|Active Comparator|High Dosage|Subjects will receive approximately 8 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
89616884|NCT04592549|Experimental|Cohort 3: 300 mg IM injection of active drug or placebo|"Subjects in cohort 3 will receive 300 mg IM injection of either active drug or placebo.~Cohort 3 will dose 8 subjects to active drug and 2 subject to placebo"
89616885|NCT04592549|Experimental|Cohort 4: 300 mg IM injection of active drug or placebo|"Subjects in cohort 4 will receive 300 mg IM injection of either active drug or placebo.~Cohort 4 will dose 8 subjects to active drug and 2 subject to placebo"
89616886|NCT04592549|Experimental|Cohort 5: 600 mg IM injection of active drug or placebo|"Subjects in cohort 5 will receive 600 mg IM injection of either active drug or placebo.~Cohort 5 will dose 8 subjects to active drug and 2 subject to placebo"
89616887|NCT04591990|Experimental|AVP + placebo hydrocortisone|REVERPLEG® 40 IU/2mL+ Placebo of hydrocortisone.
89616888|NCT04591990|Experimental|placebo AVP + hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
89616889|NCT04591990|Experimental|AVP + hydrocortisone|REVERPLEG® 40 IU/2mL + Hydrocortisone 100mg UPJOHN®.
89616890|NCT04591990|Experimental|placebo AVP + placebo hydrocortisone|Placebo of REVERPLEG® 40 IU/2mL + placebo of hydrocortisone
89616891|NCT04583033|Experimental|Cognitive Behavioral Therapy (CBT) Group|Participants will receive CBT intervention bi-weekly for total of six (6) sessions.
88987128|NCT04697251|Other|FOT measurements|FOT measurements in newborns and small infants
89616892|NCT04583033|No Intervention|Control Group|Participants will not receive any intervention as part of the study.
89616893|NCT04553185||Parkinson's disease patients|Patients with idiopathic or familial Parkinson's disease
88987129|NCT04151004|Experimental|Patient group|Incremental cycling test to volitional exhaustion. Constant load cycling test to volitional exhaustion. Respiratory and leg muscle endurance test to volitional exhaustion. Three respiratory muscle training interventions.
88987130|NCT04151004|Active Comparator|Control group|The control group executes the same tests as the patient group.
88987131|NCT00504127|Experimental|naproxcinod 375 mg bid|
88987132|NCT00504127|Experimental|naproxcinod 750 mg bid|
88987133|NCT00504127|Active Comparator|naproxen 500 mg bid|
88987134|NCT00504127|Placebo Comparator|placebo|
88987135|NCT01249456||Femara(Letrozole)|
88987136|NCT03755999|Experimental|PIOMI treat group|Preterm infant receive oral massage using the premature infant oral motor intervention (PIOMI)
89616894|NCT04547634|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
89616895|NCT04547634|No Intervention|Control|Subjects will be told to continue with their normal activity of daily living. After the intervention in the experimental group, the control group will be offered intervention.
89616896|NCT04546126|Experimental|Dexamethasone (Group 2)|"Participants will undergo an FNP-59 scan on day 0 in the am. Participants will then take~1 mg dexamethasone 2x a day for 3 days to suppress cortisol production. Participants will then have a second FNP-59 scan on day 4 in the am."
89616897|NCT04546126|Experimental|Cosyntropin (Group 3)|Participants will undergo an FNP-59 scan on day 0 in the am. On day 4 the participant will arrive for imaging. Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
89616898|NCT04546126|Experimental|Adrenal pathology (Group 4)|Whole-body PET/CT scans will be done on 4 patients at 1 hr and the other 4 patients at 6 hours. All the patients will have a whole-body PET/CT scan at 3 hours.
89616899|NCT04533672|Experimental|Single study arm|
89616900|NCT04531917|Experimental|Pain Neuroscience Education + Behavioural Graded Activity|Patients allocated to the intervention group will receive a 12-week treatment program that consists of 6 sessions, in which 'Pain Neuroscience Education' and 'Behavioural Graded Activity' will be integrated.
89616901|NCT04531917|Active Comparator|Usual care|"Patients allocated to the control group will receive an information leaflet from Kom op tegen kanker regarding Pain in and after cancer."
89616902|NCT04484142|Experimental|DS-1062a 6.0 mg/kg|Participants will receive 6.0 mg/kg of DS-1062a
89616903|NCT04466683|Experimental|Low radiation arm|A single dose of 35 cGY delivered to the whole thorax
88987137|NCT03755999|No Intervention|Routine care group|Preterm infant receive routine care of neonatal intensive care unit(NICU)
88987138|NCT01249534||Patients after gastroesophageal cancer surgery|
88987139|NCT01249573|Experimental|fascia therapy|arm where fascia therapy is used as a treatment for an acute ankle distortion
88987140|NCT01249573|Experimental|transcutaneous fibrolysis|arm where transcutaneous fibrolysis is used as a treatment for an acute ankle distortion
88987141|NCT01249573|Placebo Comparator|placebo|arm where placebo therapy is used as a treatment for an acute ankle distortion
88987142|NCT01249612|Placebo Comparator|Control treatment|Elbow joint icing using two plastic bags with crushed ice
88987143|NCT01249612|Active Comparator|Active treatment|Knee joint icing using two plastic bags with crushed ice
88987144|NCT01249690|Experimental|PAD|
88987145|NCT01249690|Experimental|TAD|
88987146|NCT03712826|Experimental|anti TNF|Crohn patient with antiTNF treatment
88987147|NCT03712826|Experimental|Ustekinumab|Crohn disease with ustekinumab treatment
88987148|NCT01249768||Cohort|The cohort will consist of 150 patients with a hypokinetic rigid syndrome and a disease duration of maximum 36 months
88987149|NCT01249807||1|Patients, Family, Community member
88987150|NCT01249846|Experimental|Arm 1|Each one of the two selected periodontal pockets (target pockets) will be randomized to the Frequent PerioChip® treatment or to the Routine PerioChip®.
88987151|NCT01249846|Placebo Comparator|Arm 2|Each one of the two selected target pockets will be randomized to the Frequent PerioChip® treatment or to the Frequent Placebo Chip treatment.
88987152|NCT00405444|Experimental|1|
88987153|NCT00405444|Placebo Comparator|2|
88987154|NCT00504322|Placebo Comparator|placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
89036248|NCT02919254|Active Comparator|Moderate Dosage|Subjects will receive approximately 0.5 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
89036249|NCT02919254|Placebo Comparator|Placebo|Subjects will receive a placebo beverage containing negligible nitrate for 7 days.
89616904|NCT04466683|Experimental|High radiation arm|A single dose of 100 cGY delivered to the whole thorax
89616905|NCT04466683|No Intervention|Control arm|Patients will receive no radiation therapy but will have research samples collected and best supportive care
89616906|NCT04451863|Placebo Comparator|Placebo|0 mg THC, 0 mg myrcene, 0 mg BCP
89616907|NCT04451863|Active Comparator|Low strength THC|5 mg THC, 0 mg myrcene, 0 mg BCP
89616908|NCT04451863|Active Comparator|Higher strength THC|15 mg THC, 0 mg myrcene, 0 mg BCP
89616909|NCT04451863|Active Comparator|Low strength myrcene|0 mg THC, 0.5 mg myrcene, 0 mg BCP
89616910|NCT04451863|Active Comparator|High strength myrcene|0 mg THC, 12.0 mg myrcene, 0 mg BCP
89616911|NCT04451863|Active Comparator|Low strength BCP|0 mg THC, 0 mg myrcene, 0.5 mg BCP
89616912|NCT04451863|Active Comparator|High strength BCP|15 mg THC, 0 mg myrcene, 7.5 mg BCP
89616913|NCT04451863|Active Comparator|Low THC + Low myrcene|5 mg THC, 0.5 mg myrcene, 0 mg BCP
89616914|NCT04451863|Active Comparator|Low THC + High myrcene|5 mg THC, 12.0 mg myrcene, 0 mg BCP
89616915|NCT04451863|Active Comparator|High THC + Low myrcerne|15 mg THC, 0.5 mg myrcene, 0 mg BCP
89616916|NCT04451863|Active Comparator|High THC + High myrcene|15 mg THC, 12.0 mg myrcene, 0 mg BCP
89616917|NCT04451863|Active Comparator|Low THC + Low BCP|5 mg THC, 0 mg myrcene, 0.5 mg BCP
89616918|NCT04451863|Active Comparator|Low THC + High BCP|5 mg THC, 0 mg myrcene, 7.5 mg BCP
89616919|NCT04451863|Active Comparator|High THC + Low BCP|15 mg THC, 0 mg myrcene, 0.5 mg BCP
89616920|NCT04451863|Active Comparator|High THC + High BCP|15 mg THC, 0 mg myrcene, 7.5 mg BCP
89616921|NCT04398706|Experimental|Group 1|One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
89616922|NCT04398706|Experimental|Group 2|One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
89616923|NCT04398706|Experimental|Group 3|One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
89616924|NCT04398706|Active Comparator|Group 4|One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
88987155|NCT00504322|Active Comparator|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
88987156|NCT03679130|Experimental|Structured exercise training (EXE)|Structured supervised exercise training (EXE) contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
88987157|NCT03679130|Experimental|Motivational counseling (MOT)|Motivational counseling supported by health technology (MOT) contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
88987158|NCT03679130|No Intervention|Control group (CON)|Control group receiving standard treatment.
89616925|NCT04398706|Experimental|Group 5|Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
89616926|NCT04398706|Experimental|Group 6|Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
89616927|NCT04398706|Experimental|Group 7|Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
89616928|NCT04398706|Active Comparator|Group 8|Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
89616929|NCT04353739|Experimental|Immediate Treatment (IT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
89616930|NCT04353739|Active Comparator|Delay Treatment (DT)|This small RCT will contain two arms, with participants randomly assigned to either the immediate treatment group (IT Group) or the delayed treatment group (DT Group).
89616931|NCT04351906|Other|ECCO2R|ECCO2R in patients with mild to moderate ARDS with/without AKI requiring dialysis.
89616932|NCT04334759|Experimental|Experimental Arm: Durvalumab + Chemotherapy, then Durvalumab Maintenance|Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab
88987159|NCT00504361||1: Lung Disease|Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination
88987160|NCT00504361||2: Normal Control|Individuals without a history of lung disease.
88987161|NCT00504400|Experimental|A|
89616933|NCT04334759|Active Comparator|Control Arm: Chemotherapy, then Observation|Standard Chemotherapy for 4 to 6 cycles, followed by Observation
89616934|NCT04334759|Active Comparator|Control Arm: Ipilimumab and Nivolumab|Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.
89616935|NCT04324437|Other|eRAPID online symptom monitoring in lung cancer|Two groups of patients with differing internet access: access from home or access in clinic only
89616936|NCT04317586|Other|Trident II Tritanium Acetabular Shell for Revision|
89616937|NCT04270123||Group 1|Group 1 consists of breast cancer patients with local or locally advanced disease. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. A subgroup of participants within this group (those who have changed disease or treatment status) will be asked to complete the above questionnaires again, three months later (+-1 week). They will also complete an anchor question. Completing twice is for the responsiveness to change analysis.
89616938|NCT04270123||Group 2|Group 2 consists of metastatic breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires at one time point only.
89616939|NCT04270123||Group 3 - follow up|Group 3 consists of follow up breast cancer patients. All participants will complete the EORTC QLQ-C30 and BR-45 questionnaires. One-to two weeks later, a subgroup of participants in this group (with no evidence of disease and /or change in health status) will complete the above questionnaires, as well as an anchor question. Completing twice is for the test-retest analysis.
89616940|NCT04267874|Experimental|Arm I (BRB nectar, placebo, biospecimen collection)|Patients receive BRB nectar PO BID for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
89616941|NCT04267874|Experimental|Arm II (placebo, BRB nectar, biospecimen collection)|Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.
89616942|NCT04219020||Children with a CP diagnosis|"Children younger than 18 years with a CP diagnosis. Intervention will be determined later based on baseline results. Self- and/or proxy-reported survey and/or participation in interviews.~Parents of all participants will provide proxy report. Children with CP > 8 years of age and cognitively able (approx. 50%) will provide self-report."
89616943|NCT04219020||Controls|Siblings (12-17 years) of children with cerebral palsy. No intervention, self-reported survey.
89036250|NCT02919293|Experimental|Adjuvant-Free MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant-free MenAC-Hib conjugate vaccine.
89036251|NCT02919293|Active Comparator|Adjuvant MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant MenAC-Hib conjugate vaccine.
89036252|NCT05463315|Experimental|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
89036253|NCT02919371|Experimental|Sunitinib and Bevacizumab Arm|Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab
89616944|NCT04219020||Health Care Professionals|Health Care Professionals identified as providers of pain care. No intervention, interview participants
89616945|NCT04214184|Experimental|Increased Sleep Duration Intervention|Following baseline assessments, participants will complete a 4-week increased sleep duration intervention followed by one night of sleep in the lab on this increased sleep duration schedule. In the morning, participants will have blood collected for metabolomics analyses and complete oral glucose tolerance testing
89616946|NCT04210713|Active Comparator|AUD-Minocycline|Participants diagnosed with alcohol use disorder will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
89616947|NCT04210713|Placebo Comparator|AUD-Placebo|Participants diagnosed with alcohol use disorder will be randomly assigned to take placebo for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
89616948|NCT04210713|Active Comparator|Healthy Control-Minocycline|Healthy control participants will be randomly assigned to take minocycline for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
89616949|NCT04210713|Placebo Comparator|Healthy Control-Placebo|Healthy control participants will be randomly assigned to take placebo for 4 weeks. The randomization is double-blinded and will alternate between minocycline and placebo.
89616950|NCT04198779|Experimental|APPLI|Care support with implementation of the application
89616951|NCT04198779|No Intervention|CONTROL|Conventional care support
89616952|NCT04192071|Active Comparator|high interactive virtual human administered nutrition module|The virtual health assistant will interactively collect nutrition information (alcohol, red meat, and processed meat intake) and report risk information back to users in visual and audio format
89616953|NCT04192071|Active Comparator|low interactive virtual human module|Complete the current intervention module that includes items assessing alcohol and meat intake.
89616954|NCT04192071|Sham Comparator|attention control module|The attention control group, will complete a related module not related to colorectal cancer or nutrition
89616955|NCT04185415|Experimental|bepranemab|Subjects will be randomized to receive bepranemab.
89616956|NCT04185415|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo.
89616957|NCT04151264|No Intervention|Control Arm|blinded HPI monitoring
89036254|NCT05460819|Experimental|Treatment group A|Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment.
89036255|NCT05460819|Sham Comparator|Treatment group B|Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week).
89616958|NCT04151264|Active Comparator|Intervention Arm|HPI monitoring to predict hypotension
89616959|NCT04149314|Active Comparator|Interventional|Interventional group (hemodynamic optimization based on HPI).
89616960|NCT04149314|No Intervention|Control|Control group (blinded HPI monitoring, standard anesthesia care).
89616961|NCT04145024||Pulmonary arterial hypertension|Group 1 PH
89616962|NCT04145024||Pulmonary hypertension due to left heart disease|Group 2 PH
89616963|NCT04145024||Pulmonary hypertension due to lung disease|Group 3 PH
89616964|NCT04145024||Chronic thromboembolic pulmonary hypertension|Group 4 PH
89616965|NCT04145024||Miscellaneous|Group 5 PH
89616966|NCT04145024||Exclusion PH|Patient with invasively excluded PH
89616967|NCT04141839|Other|Control|Delayed intervention: baseline and 3-month assessment prior to receiving the Safer Bars training.
89616968|NCT04141839|Experimental|Intervention|This arm with consist of bars randomized to have the Safer Bars training on their premises attended by all their liquor serving staff with assessment directly before and after training (pre/post), and at 3 and 6 months post-training follow-up.
89616969|NCT04133376|Experimental|e-hookah vaping with nicotine|"Participants were invited to vape a 30-minute electronic hookah with nicotine vaping session, followed by a 30-minute electronic hookah without nicotine vaping session.~To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days."
89616970|NCT04133376|Experimental|e-hookah vaping without nicotine|"Participants were invited to vape a 30-minute electronic hookah without nicotine vaping session, followed by a 30-minute electronic hookah with nicotine vaping session.~To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days."
89616971|NCT04121221|Experimental|GA Depot|Monthly IM injection
89616972|NCT04121221|Placebo Comparator|Placebo|Monthly IM injection
89616973|NCT04117334||Bracing AIS patients|These are patients undergoing brace treatment for AIS
89616974|NCT04116658|Experimental|Cohort 1|Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab
89616975|NCT04116658|Experimental|Cohort 2|Multiple dose of EO2041 in combination with nivolumab
89616976|NCT04116658|Experimental|Cohort 3|Multiple dose of EO2041 in combination with nivolumab and bevacizumab
89616977|NCT04102930||Retrospective|A patient who has a diagnosis of GCA or PMR
89616978|NCT04102930||Prospective|Patient with suspected GCA and PMR
89616979|NCT04083170|Experimental|Regimen A (fludarabine, cyclophosphamide, TBI, dilanubcel)|Patients receive fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6, and undergo TBI BID on days -4 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
89616980|NCT04083170|Experimental|Regimen B (anticancer drugs, TBI, dilanubicel)|Patients receive fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo TBI QD on days -2 to -1. Patients then undergo umbilical cord blood transplant on day 0. Between 4-24 hours after transplant completion, patients receive dilanubicel IV over 5-10 minutes in the absence of disease progression or unacceptable toxicity.
89616981|NCT04056910|Experimental|Concurrent dosing of ivosidenib and nivolumab|Ivosidenib will be administered concurrently with nivolumab on a Q28 day schedule.
89616982|NCT04048278|Experimental|Lidocaine Hydrochloride|The IV bolus and infusions of lidocaine to those patients assigned to the lidocaine group will be started in the operating room and will continue until 24 h later. The group receiving the lidocaine infusion will first be administered a 1.0 - 1.5 mg/kg loading infusion over 5 minutes followed by a 1.0 - 1.5 mg/kg/h infusion for 24 h
89616983|NCT04048278|Placebo Comparator|Saline Solution for Injection|The group receiving the saline infusion will be administered an equivalent volume of saline infused over 5 min followed by a saline infusion at the same flow rate as that used in the lidocaine group for 24 h (1.0 - 1.5 mg/kg/hr)
89616984|NCT04047368|Active Comparator|Rotablation|
89616985|NCT04047368|Experimental|Coronary Lithoplasty|
89616986|NCT04045717|Experimental|Hypo-FLAME 2.0|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
89616987|NCT04024020||Individuals with insomnia|Men and women with chronic insomnia (>5 years duration)
89616988|NCT04024020||Good sleepers|Men and women with a longstanding pattern of good sleep
89616989|NCT04004065|Experimental|Part A: Vesleteplirsen|Participants received escalating dose levels of vesleteplirsen, every 4 weeks, via intravenous (IV) infusion for up to 75 weeks during Part A. Once the doses have been selected for Part B, all participants who have completed Part A will transition to Part B.
89616990|NCT04004065|Experimental|Part B: Vesleteplirsen|Participants will receive vesleteplirsen at the doses selected based on data from Part A every 4 weeks, via IV infusion, for up to 5 years. This includes the participants who rollover from Part A, as well as the additional participants who will be enrolled at the beginning of Part B.
89616991|NCT04003506|Experimental|Group LB|local infiltration of analgesia (LIA) with adductor canal block (ACB) will be given using 10ml of 1.33% liposomal bupivacaine with 10ml 0.5% standard bupivacaine
89616992|NCT04003506|Active Comparator|group SB|LIA with ACB will be given using 20ml 0.5%standard bupivacaine
89616993|NCT03998501|Experimental|Active|5-week CBTm
89616994|NCT03998501|No Intervention|Waitlisted|Waitlisted (will receive 5-week CBTm 3 months after).
89616995|NCT03980457|Experimental|Exo-group|Standard rehabilitation plus use of Exoskeleton
89616996|NCT03980457|Placebo Comparator|Control-Group|Standard rehabilitation
89616997|NCT03974711||All study subjects|"Note: No interventions are administered under this evaluation.~This is a real-world population. The determination to undergo a lateral lumbar interbody fusion procedure is made outside of this evaluation and is a standard of care, on-label procedure."
89616998|NCT03965299|Experimental|VERUM transcutaneous tibial nerve stimulation (TTNS)|
89616999|NCT03965299|Sham Comparator|SHAM transcutaneous tibial nerve stimulation (TTNS)|
89617000|NCT03964493|Experimental|TNP-2092|TNP-2092 300 mg intravenous every 12 hours
89617001|NCT03964493|Active Comparator|Vancomycin|vancomycin 1 g intravenous every 12 hours
89617002|NCT03951909|Experimental|Active intervention|Either Physiotherapy activity and awareness intervention (PAAI) or Teaching recovery techniques (TRT)
89617003|NCT03951909|Experimental|Waiting list|The same interventions as above will be hold for waiting lists participants, but after 6 to 8 weeks
89617004|NCT03939026|Experimental|ALLO-647, ALLO-501|
89617005|NCT03926767|Experimental|Pain Neuroscience Education + orofacial and neck exercises|All participants in this arm will initially receive two additional sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
89617006|NCT03926767|Active Comparator|Orofacial and neck exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
89617007|NCT03915574|Experimental|Dural Puncture Epidural|Participants will receive a dural puncture epidural block with a 25 gauge spinal needle followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
89617008|NCT03915574|Active Comparator|Standard Epidural|Participants will have standard epidural infusion followed by a standard epidural infusion (0.0625% bupivacaine + 2mcg/ml fentanyl)
89617009|NCT03912272|Placebo Comparator|Usual Care Control|Subjects in the usual care control group will receive a health education program. This program includes 12-month twice-a-month sessions (70 minutes each session) for obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation. The class will be conducted in small group setting (4-8 participants each group). The same health information will be delivered to the subjects in the HIIT group throughout the 12-month intervention period. Subjects will be asked to attend >70% of the classes.
89617010|NCT03912272|Experimental|High-intensity Interval Training Group|HIIT will be prescribed once weekly under the supervision of certified athletics coaches for 12 months. HIIT training will be performed in a small group setting (4-8 participants each group) in laboratories. In each session, subjects will run for four 4-minute intervals at 85%-95% of the peak heart rate (HRpeak) with a 3-minute active recovery at 50%-70% of the HRpeak between each interval. A 5-minute jog at an intensity of 70% of the HRpeak will be included for warm-up and cool-down before and after, respectively. Subjects will be asked to attend >70% of the classes.
89617011|NCT03902912|Experimental|prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH plus 7. Women will be then given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
89617012|NCT03887481|Experimental|Active HD-tDCS + Language/Cognitive Intervention(s) first|Participants will receive active HD-tDCS + Language/Cognitive Intervention(s) first and then receive Sham + Language/Cognitive Intervention(s) after a three-month washout period.
89617013|NCT03887481|Experimental|Sham + Language/Cognitive Intervention(s) first|Participants will receive Sham + Language/Cognitive Intervention(s) first and then receive active HD-tDCS + Language/Cognitive Intervention(s) after a three-month washout period.
89617014|NCT03879096|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
88987162|NCT00504439|Experimental|Cohort 1|Subjects in Cohort 1 will receive 20 milligrams (mg) of SB-656933-AAA once daily or matching placebo once daily for 14 days.
88987163|NCT00504439|Experimental|Cohort 2|Subjects will be administered 40 mg simvastatin on day 1 followed by a washout period of two days. From day 3, the subjects will receive 50 mg of SB-656933-AAA once daily or matching placebo once daily for 14 days. On day 17, subjects will be administered 40 mg simvastatin along with SB-656933-AAA to assess statin interaction.
88987164|NCT00504439|Experimental|Cohort 3|Subjects will be administered 100 mg SB-656933-AAA/ day or matching placebo for 14 days. Dosing will initiate after cohort I and II have completed dosing.
88987165|NCT04054830|Experimental|Topical, preservative-free NSAID|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
88987166|NCT04054830|Active Comparator|Topical, preservative-free steroid|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
88987167|NCT04054830|Experimental|Topical, preservative-free NSAID (Voltaren Ophtha 1 mg/ml, GSK|Topical medication are to be used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per wee
88987168|NCT01249924|Other|CPAP Group|CPAP Treatment
89617015|NCT03864406|Experimental|Pharmacokinetic study in healthy volunteers|Healthy participants received a single dose of rivaroxaban 10 mg orally on day 1 (phase 1) followed by cobicistat 150 mg once daily from days 2 - 7 and a single dose of rivaroxaban 10 mg on day 7 (phase 2). Participants received darunavir /cobicistat 800/150 mg once daily from days 8 - 13 followed by a single dose of rivaroxaban 10mg on day 13 (phase 3). Serial blood sampling was done on days 1, 7, and 13.
88987169|NCT01249924|Other|Control Group|Routine care
88987170|NCT01249963|Experimental|Experimental Group|Patients of this group will receive 400 ml per day of T-Diet plus Atémpero product during 28 days.
88987171|NCT01249963|Active Comparator|Control Diet|Patients of this group will receive 2 packets (76 g) per day of AlitraQ (Abbott) product during 28 days.
88987172|NCT01249651|Other|1|One arm: esomeprazole 40 mg
88987173|NCT03999723|Experimental|Vitamin C|Oral vitamin C (ascorbic acid) will be given in a dose of 1000 mg daily (two capsules of 500 mg once daily) starting day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier.
89617016|NCT03853122|Active Comparator|Best current practice exercise programme|"Therapeutic physical exercise, best current practice:~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group)."
89617017|NCT03853122|Experimental|Experimental exercise programme|"Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages):~Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly"
89617018|NCT03846804|Experimental|Karius Test|Participants will have additional blood drawn for the purposes of analysis with the Karius test.
89617019|NCT03840941||Frail patients with COPD|No intervention
89617020|NCT03840941||Non-frail patients with COPD|No intervention
89617021|NCT03832686|Experimental|Virtual Coach App|Participants in the experimental arm (Group A) will receive a comprehensive swallowing rehabilitation app. This study seeks to determine if a mobile application may enhance adherence to swallowing therapy in patients undergoing radiation therapy for head and neck cancer. No devices - outside of the Smartphone already owned by the participant - will be used in this study. Similarly, no drugs, biological materials, or other substances will be used.
89617022|NCT03832686|No Intervention|Standard of Care|The paper group (Group B) will be given paper exercise logs to fill out Participants will be educated regarding potential radiation-related side effects and trained in the same series of swallowing exercises by the SLP. The paper log treatment group will serve as a standard treatment group. As adherence is a primary goal of the target intervention, paper logging will be necessary to determine relative adherence while minimizing reporting bias.
89617023|NCT03823534|Experimental|Experimental Arm|For the first 24 hours following surgery, patients younger than 65 years old will be administered a maximum of 120 mg/day bolus IV ketorolac (30 mg every 6 hours). Patients older than 65 years old or with history of advanced renal impairment will receive a maximum of 60 mg/day bolus IV ketorolac (15 mg every 6 hours). All patients may also be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate- severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. At discharge, they will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours, quantity 50. Those with preexisting liver disease will be prescribed the equivalent in oxycodone and will not receive acetaminophen for mild pain.
89617024|NCT03823534|Placebo Comparator|Control|Following surgery, patients will be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate-severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. They will also be given a placebo injection of normal saline every 6 hours for the first 24 hours following surgery. At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours PRN quantity 50, unless they have preexisting liver disease, in which case they will be prescribed the equivalent in oxycodone. They will not receive a nerve block.
89617025|NCT03807440||Subjects with Diabetes Mellitus, Type 2|
89617026|NCT03799874|Experimental|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 3 days.
89617027|NCT03799874|Placebo Comparator|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
88987174|NCT03999723|Placebo Comparator|Placebo|Placebo will be administered orally as two capsules once daily that look and taste identical to the capsules containing vitamin C. Treatment will start day 1 in the 1st azacitidine (AZA) cycle (D1/C1) and continuing until discontinuation of AZA or end of study, whichever occurs earlier. The content of the placebo capsules is glucose monohydrate, potato starch, gelatin, magnesium stearate and talc.
88987175|NCT03567707|Experimental|C-section -Vaginal seeding|"Pregnant women who undergo C-section and (neonate) vaginal seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with gauze containing their mother's vaginal microbiota just after delivery."
88987176|NCT03567707|Experimental|C-section - Placebo Seeding|"Pregnant women who undergo C-section and (neonate) placebo seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with sterile gauze (placebo)."
88987177|NCT03567707|Active Comparator|standard care|"Pregnant women who undergo spontaneous vaginal delivery (of neonate) .~Pregnant women who undergo spontaneous vaginal delivery and (neonate) receives standard care."
88987178|NCT03988062|Experimental|TrelliX Embolic Coil System|
88987179|NCT01249417|Experimental|Dysport 10 U/Kg|10 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
89617028|NCT03783403|Experimental|CC-95251|
89617029|NCT03783403|Experimental|CC-95251 in combination with rituximab|
89617030|NCT03783403|Experimental|CC-95251 in combination with cetuximab|
89617031|NCT03774849|Experimental|Picoway™ 532nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 532nm fractional handpiece
88987180|NCT01249417|Experimental|Dysport 15 U/Kg|15 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
88987181|NCT01249417|Placebo Comparator|Placebo|Total volume to be injected per lower limb - 2ml. Either one or both lower limbs can be treated.
88987182|NCT04725747|Experimental|Midazolam/Ketamine Melt|One Midazolam/Ketamine 3mg/50mg melt administered sublingually
88987183|NCT04725747|Active Comparator|Midazolam Melt|Midazolam 3mg melt administered sublingually
88987184|NCT04725747|Active Comparator|Ketamine Melt|Ketamine 50mg melt administered sublingually
88987185|NCT03544853|Experimental|Prosthetic socket evaluation|Intervention: Prosthetic socket for transtibial amputee. A subject's conventional prosthetic socket is compared to a novel prosthetic socket designed as part of the research. For standing and walking exercises the following will be assessed. 1) local skin contact pressures, 2) metabolic power, 3) gait parameters (symmetry indices for joint angles, positions, torques, and also ground reaction forces), and 4) the socket evaluation questionnaire.
89617032|NCT03774849|Experimental|PicoWay™ 730nm wavelength|PicoWay™ 730nm wavelength. Subjects will receive up to four study treatments with the PicoWay™ 730nm wavelength.
89617033|NCT03774849|Experimental|PicoWay ™1064nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 1064nm fractional handpiece
89617034|NCT03770338|No Intervention|Control|Recruitment for fusion surgery as usual
89617035|NCT03770338|Experimental|Teriparatide|Preoperative 1 month use of teriparatide, before lumbar fusion surgery
89617036|NCT03767231|Experimental|HCV POC VL Group|This group will receive the POC HCV viral load testing via fingerstick using the novel Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
89617037|NCT03767231|No Intervention|Reference Group|This group will receive the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing only. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
89617038|NCT03761706|Experimental|Intervention Cohort|This is a one-arm intervention study that includes assessments and questionnaires at several time points as early stage breast cancer patients undergo chemotherapy and at 6 months post-chemotherapy. Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits to evaluate engagement in physical activity. Study participants will complete questionnaires, an exercise log, and submit blood samples as multiple time points.
89617039|NCT03746522|Experimental|Setmelanotide (Double-Blind)|Participants received once daily SC injection of setmelanotide for 14 weeks in a double-blind placebo-controlled treatment period (Period 1). Participants ≥16 years of age started on setmelanotide 2.0 mg with dose escalation to 3.0 mg. Participants <16 years of age started on setmelanotide 1.0 mg with dose escalation to 3.0 mg.
89617040|NCT03746522|Placebo Comparator|Placebo (Double-Blind)|Participants received once daily SC injection of placebo (matching setmelanotide) for 14 weeks in a double-blind placebo-controlled treatment period (Period 1).
89617041|NCT03746522|Experimental|Setmelanotide (Open-label)|After the initial 14-week double-blind treatment period, all participants immediately transitioned to open-label setmelanotide once daily SC injection for 38 weeks (Period 2) and then continued to receive setmelanotide in the 14-week open-label treatment period (Period 3).
89617042|NCT03715712|Experimental|Standard|Standardized blood pressure management with a target of mean blood pressure greater than 65mmHg and systolic blood pressure lower than 160mmHg
88987186|NCT01249261|Placebo Comparator|Placebo/Risedronate|Placebo years 1-5, Risedronate 5mg/day years 6 & 7, no drug year 8
88987187|NCT01249261|Active Comparator|Risedronate|Risedronate 5mg years 1-7, no drug year 8
88987188|NCT03463694|Experimental|Hypertonic Saline ~2.6% NaCl|3 drops each nostril of Hypertonic Saline (HS) at least 4 times a day until asymptomatic or maximum of 28 days
88987189|NCT03463694|No Intervention|Standard Care|Control arm of standard symptomatic care only
88987190|NCT03890952|Experimental|Arm B Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients not undergoing salvage surgery
88987191|NCT03890952|Experimental|Arm A Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients undergoing salvage surgery
88987192|NCT03285893||Native Hawaiian cigarette smokers|oral cell DNA adducts
88987193|NCT03285893||White (European Americans) cigarette smokers|oral cell DNA adducts
88987194|NCT03285893||Japanese American cigarette smokers|oral cell DNA adducts
88987195|NCT03868722|Experimental|Treatment arm|Treatment with Acalabrutinib and Venetoclax is initiated within 14 days after randomization.
89617043|NCT03715712|Active Comparator|Individualized|Individualized blood pressure management of 20% within the preoperative ward blood pressure
89617044|NCT03710161|Experimental|4000 IU Vitamin D|4000 IU Vitamin D taken daily for six months
89617045|NCT03710161|Active Comparator|800 IU Vitamin D|800 IU Vitamin D taken daily for six months
89617046|NCT03709667|Experimental|EX|Participants in this arm of the study will be randomized in to the exercise intervention.
89617047|NCT03709667|Placebo Comparator|CON|The control condition is a health-education intervention.
89617048|NCT03709277|Experimental|Pharmacist-Driven Intervention|The study group will receive a patient-tailored, pharmacist-driven intervention(s) to overcome patient-specific barriers to adherence. Each patient in the study group will be intervened upon using a protocol that is based on their reason for non-adherence.
89617049|NCT03709277|No Intervention|Standard of Care|The usual care group will receive the standard of care provided to all patients that utilize Vanderbilt Specialty Pharmacy.
89617050|NCT03692494|Experimental|Unilateral vocal fold paralysis standard of care voice therapy|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques.
89617051|NCT03692494|Experimental|Unilateral paralysis standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
88987196|NCT03868722|No Intervention|Observation arm|Observation period is initiated within 14 days after randomization.
88987197|NCT03833778|Other|Intervention group|Answering disease related questions during playing a tablet game
88987198|NCT03833778|No Intervention|control group|
89036256|NCT05460819|No Intervention|control|The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy.
89617052|NCT03692494|Experimental|Parkinson's disease standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
89617053|NCT03689049|Experimental|SPIDER|QI Learning Collaboratives.
89617054|NCT03689049|Placebo Comparator|Usual Care|Standard primary care.
89617055|NCT03682536|Experimental|Luspatercept|
89617056|NCT03682536|Active Comparator|Epoetin alfa|
89617057|NCT03670316|Experimental|Algorithm Treatment plus referral to quitline (AT)|will be assigned a pharmacotherapy treatment regimen recommended to their provider.
89617058|NCT03670316|Active Comparator|Quitline (eTAU)|will be referred to quitlines, telephone-based tobacco cessation services.
89617059|NCT03596801|Experimental|Group 1: RSV 6120/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^6.0 plaque-forming units (PFUs) of RSV 6120/∆NS1 vaccine at Day 0.
89617060|NCT03596801|Experimental|Group 1: RSV 6120/F1/G2/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^5.8 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
89617061|NCT03596801|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of placebo at Day 0.
89617062|NCT03596801|Experimental|Group 2: RSV 6120/∆NS1 Vaccine|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS1 vaccine at Day 0.
89617063|NCT03596801|Experimental|Group 2: RSV 6120/F1/G2/∆NS1|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
89617064|NCT03596801|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of placebo at Day 0.
89617065|NCT03498378|Experimental|Avelumab, Palbociclib, and Cetuximab|Identify the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for the combination of palbociclib, avelumab, and cetuximab
89617066|NCT03478956|Experimental|Etrolizumab Q4W|Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
89617067|NCT03478956|Experimental|Etrolizumab Q8W|Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
89617068|NCT03477110|Experimental|Treatment (temozolomide, radiation, NovoTTF-200A device)|Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-200A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89617069|NCT03475043|Experimental|Auditory training: temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in a temporal (timing/duration) cue for 9, 1-hour training sessions and will receive correct-answer feedback.~Aim 2: Listeners will hear sentences that vary in speech rate for 6, 1-hour training sessions and will receive correct-answer feedback."
89617070|NCT03475043|Active Comparator|Auditory training: non-temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in either stimulus intensity or stimulus frequency during 9, 1-hour training sessions and will receive correct-answer feedback.~Aim 2: Listeners will hear speech in varying levels of noise during 6, 1-hour training sessions and will receive correct-answer feedback."
89617071|NCT03475043|No Intervention|Passive control group (Aims 1 and 2)|Listeners will be evaluated on pre-training and post-training tests, but will receive no training at all.
89617072|NCT03467113|Experimental|ZX008 0.2 to 0.8 mg/kg/day|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (flexible dosing 0.2 mg/kg/day to 0.8 mg/kg/day)
89617073|NCT03415828|Experimental|Ethanol gel|CE-marked medical device used according to its instructions for use: GELSCOM® Single injection in the selected disc(s) of 0.6 to 2.2 ml
89617074|NCT03415828|Active Comparator|Steroid infiltration|Authorized drug used according to its summary product characteristics: HYDROCORTANCYL 2,5 POUR CENT Single injection in the selected disc(s) of 0.2 to 2.0 ml
89036257|NCT02919410|Active Comparator|Surgery performed using iodophor-impregnated adhesive drapes|
89036258|NCT02919410|Other|Surgery performed without iodophor-impregnated adhesive drapes|
89617075|NCT03389399||Brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days|This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.
89617076|NCT03356886|Experimental|Spinal Manipulative Technique (SMT)|This protocol of combined manipulation and mobilization techniques was adopted in view of the previous findings of a systematic review in which the combination of thrust mobilization and non-thrust techniques showed greater (moderate) evidence for chronic low back pain when compared to each technique alone (limited evidence). In addition, the thrust manipulation will be administered at the thoracic spine considering that a previous study found no differences in pain intensity after lumbar spine high-velocity manipulation versus non-region-specific manipulation in patients with chronic low back pain.
89617077|NCT03356886|Active Comparator|SMT + Pain Neuroscience Education|Content: 1) Contextualization on the importance of the program; 2) Initial concepts on neuroscience and pain, 3) How context can influence pain perception; 5) human beings as a multisensory complex; 6) Pain and memory; 7) Nociception and nociceptors; 8) The incorrect concepts on pain; 9) Concepts on pain neurophysiology; 10) Types of sensitization; 11) Descending inhibitory system; 12) The danger message and the brain processing; 13) The sensitized brain and its relationship to chronic pain; 14) The contribution of other systems to pain experience; 15) How bone, muscles and nerves send sensory information all the time; 16) Fear avoidance model revisited; 17) Encouragement to change; 18) How to develop positive attitudes and 19) Concepts of gradual exposition and gradual activity
89617078|NCT03347110|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 2 years.
89617079|NCT03343236||Patients with head and neck cancer|All patients with newly diagnosed and untreated head and neck cancer. Exclusion criteria: previous treatment for malignant disorder except for skin cancer, severe alcohol abuse, psychiatric disorder, inability to understand Swedish
89617080|NCT03332303|Experimental|Experimental: Estradiol Vaginal Cream, USP, 0.01% (Prasco LLC)|"Estradiol Vaginal Cream, USP, 0.01%, administered once daily for 7 days.~Intervention: Drug: Estradiol Vaginal Cream, USP, 0.01%"
89617081|NCT03332303|Active Comparator|Active Comparator: Estrace® Cream|"Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%), administered once daily for 7 days.~Intervention: Drug: Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%)"
89617082|NCT03332303|Placebo Comparator|Placebo Comparator: Placebo (Test vehicle cream) Vaginal Cream|"Placebo (Test vehicle cream) Vaginal Cream, administered once daily for 7 days.~Intervention: Drug: Placebo (Test vehicle cream) Vaginal Cream"
89617083|NCT03306615|Experimental|Treatment Arm|Hyaluronidase plus saline
89617084|NCT03306615|Placebo Comparator|Control Arm|Normal Saline
89617085|NCT03278730|Active Comparator|Para-Tyrosine intervention|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Tyrosine. Strength 500 mg. Oral dose form: hard capsule. Number of Dispensed at frequency of 3x2 g daily. Duration of administration: 4 to 7 days."
89617086|NCT03278730|Placebo Comparator|Placebo|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Placebo.. Strength N/A. Oral dose form: capsule matching to Tyrosine capsule. Number of Dispnsed an frequency 3x2 g daily. Duration of administration: 4 to 7 days."
89617087|NCT03261505|Experimental|VGAIT|
89617088|NCT03261505|Sham Comparator|VGAIT Control|
89617089|NCT03261505|Active Comparator|Real Acupuncture|
89617090|NCT03261505|Placebo Comparator|Sham Acupuncture|
89617091|NCT03240965||Volunteers <60 years|Volunteers, who are able to consent to participation in the study, as control.
89617092|NCT03240965||Volunteers >60 years|Volunteers, who are able to consent to participation in the study, as control.
89036259|NCT02919215|Experimental|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
89036260|NCT02919215|No Intervention|Wait-list Control|These participants will not receive access to the Teacher Help intervention until September of the following academic year. Teachers, students, guardians, and collaborating psychologists are free to access and/or provide usual services. The psychologists will provide Teacher Help access codes to the Wait-list group in September of the following academic year:
89617093|NCT03240965||Stroke patients|Stroke patients with supratentorial stroke, who are able to consent to participation in the study.
89617094|NCT03206801|Experimental|Intervention|Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.
89617095|NCT03206801|No Intervention|Control|Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.
89617096|NCT03137355||Leigh syndrome|All people diagnosed with Leigh syndrome.
89036261|NCT04748016|Experimental|3D-printed models plus CT imaging|Fracture repair surgery using sterilized 3DP models, CT-MPR and CT-3DR for planning and intraoperative visualization
89036262|NCT04748016|Active Comparator|CT imaging alone|Fracture repair surgery using CT-MPR and CT-3DR for planning and intraoperative visualization
89036263|NCT04736901||Group 1|Enoxaparin therapeutic dose
89036264|NCT04736901||Group 2|Enoxaparin prophylactic dose
89036265|NCT04736901||Group 3|Rivaroxaban therapeutic dose
89036266|NCT04736901||Group 4|Rivaroxaban prophylactic dose
89036267|NCT04736901||Group 5|Apixaban therapeutic dose
89036268|NCT04736901||Group 6|Apixaban prophylactic dose
89036269|NCT02919176|Active Comparator|Mirabegron|Mirabegron 50 mg/day
89036270|NCT02919176|Active Comparator|Pioglitazone|Pioglitazone 30 mg/day
89036271|NCT02919176|Experimental|Mirabegron and Pioglitazone|Combination of Mirabegron 50 mg/day and Pioglitazone 30 mg/day
89036272|NCT04734678||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with tocilizumab in addition to standard management.
89036273|NCT04734678||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with infliximab and tocilizumab in addition to standard management.
89036274|NCT02919059|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg once daily during 24 weeks
89036275|NCT02919059|Active Comparator|Glimepiride 4 mg|Glimepiride 4 mg once daily during 24 weeks
89036276|NCT05421507||Patients with head and neck tumors with local recurrence or metastasis|"The patients in the group were treated with routine clinical treatment: 3D-PCT combined with CT-guided I-125 seeds implantation in the treatment of head and neck malignant tumors.~The prescription dose is given 110-150Gy according to tumor pathological type, tumor volume, history of previous radiotherapy and different surrounding normal tissues according to experience and routine diagnosis and treatment."
89617097|NCT03093909|Experimental|Aerosol Gemcitabine (GCB)|"Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).~Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.~Participants may continue to receive the study drug for up to 12 cycles per decision of doctor."
89617098|NCT03089320|No Intervention|Treatment As Usual (TAU)|"We have elected to compare the CM plus stepped care condition to TAU to test its efficacy against a real world control and because CM plus stepped care is a comprehensive stand alone intervention that would substitute for TAU. While annual AUDIT-C screening is mandatory at the 7 sites, providing interventions for patients with unhealthy alcohol use is a matter of physician judgment and individual clinical practice with wide practice variation. HIV clinicians will not receive knowledge of the results of follow-up research assessments. We will conduct a Treatment Services Review at each follow-up to assess for receipt of addiction treatment services received since the last assessment and assess for contamination."
89617099|NCT03089320|Experimental|Contingency Management plus Stepped Care (Step 2)|"Step 1: Contingency management; Step 2: Addiction physician management and motivational enhancement therapy~Consistent with tenets of stepped care designs we provide a priori intervals and criteria (drinking targets) that dictate increasing the intensity of treatment (stepping up) based on research and standards in the field. All CM plus stepped care subjects will undergo PEth testing at 3 months to determine the efficacy of Step 1. Patients with a PEth > 8 ng/ml will continue on to Step 2."
89617100|NCT03083431|Experimental|Propranolol|Oral propranolol (1.6 mg propranolol-HCl/kg/d in 3-4 divided dosages) given for a maximum of 10 weeks (depending on postmenstrual gestational age at birth)
89036277|NCT02918786|Active Comparator|Continuous positive airway pressure|After extubation, patients will receive continuous positive airway pressure (CPAP) delivered by the variable generator WhisperFlow System (control) Intervention:Device : CPAP of 5 cmH2O delivered by the variable generator WhisperFlow System for 48 hours
89036278|NCT02918786|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention) Intervention: Device: Nasal high-flow
89617101|NCT03083431|Placebo Comparator|Placebo|Placebo (same duration as oral propranolol solution)
89036279|NCT04731753||Group treated with study product|Subjects will undergo one mechanical debridement procedure with Cutimed DebriClean
89617102|NCT03077399|Experimental|stroke|stroke patients, application of SCALA
89617103|NCT03077399|Experimental|control|Healthy individuals (patients without stroke), application of SCALA
89036280|NCT02918981|Active Comparator|Whey protein|After resistance exercise, participants aged 50-79 years will consume 14g Whey protein dissolved in 200 mL of water
89036281|NCT02918981|Experimental|Whey + Leucine|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine dissolved in 200 mL of water
89036282|NCT02918981|Experimental|Whey + Leucine + Whey peptides|After resistance exercise, participants aged 50-79 years will consume 4 g Whey protein + 1.25 g Leucine + 2.6 g Whey peptides dissolved in 200 mL of water
89036283|NCT02918981|Experimental|Whey + Leucine + Citrulline|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine + 0.8 g Citrulline dissolved in 200 mL of water
89036284|NCT02918981|Sham Comparator|Water|After resistance exercise, participants aged either 20-30 or 50-79 years old will consume 200 mL water
89036285|NCT04727775||Complications|Evaluathion
89036286|NCT04727775||Oxygen status|Evaluathion
89036287|NCT04727775||Oxugen support|Evaluathion
89036288|NCT02918825|Experimental|Paliperidone|Drug: Paliperidone, 75-150mg/month, once a month, 12 weeks
89036289|NCT02918825|Active Comparator|Olanzapine|Drug: Olanzapine, 20mg/day, twice a day, 12 weeks
89036290|NCT05420376|Active Comparator|Whole Mesh|For the patients in the first group, the whole patch will be laid on the area without being fixed.
89036291|NCT05420376|Active Comparator|Split Mesh|The patients in the second group will be given a patch of the same size, but partially divided horizontally and wrapped around the spermatic cord.
89036292|NCT02919020|Experimental|Proprioceptive neuromuscular facilitation (PNF);|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
89036293|NCT02919020|Experimental|resistance exercise|Resistance exercise to strengthen lower limbs
89036294|NCT04724070||NGS and PDO/PDX establishment|
89617104|NCT03050931||Epilepsy with intracranial electrodes|Electrical Impedance Tomography with depth electrodes or intracranial electrode mats
89617105|NCT03050931||Epilepsy with scalp electrodes|Electrical Impedance Tomography with scalp electrodes
89617106|NCT03025334|Sham Comparator|Sham tDCS|sham tDCS (30sec ramp-up and 3sec ramp-down)
88987199|NCT03789201|Experimental|Healthy Volunteers|thematic permission to use non-invasive techniques regarded as having minimal risk in healthy individuals, such as, MRI, EEG, EMG, low-frequency stimulation (= 1 Hz), electrical stimulation of the skin to mimic the somatosensory artifact of TMS, and behavioral tests
88987200|NCT00139113|Experimental|HAVRIX 6 and 12 mos; mother antibody pos|HAVRIX administered to infants born to anti-HAV positive mothers at ages 6 and 12 months
88987201|NCT00139113|Active Comparator|HAVRIX age 6, 12 mos; mom antibody neg|HAVRIX administered to infants born to anti-HAV negative mothers at ages 6 and 12 months
88987202|NCT00139113|Experimental|HAVRIX ages 12, 15 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 12 and 15 months
88987203|NCT00139113|Active Comparator|HAVRIX ages 12, 15 mos; mom antibody-|HAVRIX administered to infants born to anti-HAV negative mothers at ages 12 and 15 months
88987204|NCT00139113|Experimental|HAVRIX ages 15,21 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 15 and 21 months
88987205|NCT00139113|Active Comparator|HAVRIX ages 15,21 mos; mom antibody -|HAVRIX administered to infants born to anti-HAV negative mothers at ages 15 and 21 months
88987206|NCT02952092|Experimental|ASP1517 Group|Subjects will take the study drug at two- or three-day intervals.
88987207|NCT02952092|Experimental|Darbepoetin alfa Group|Subjects will take the study drug once a week.
88987208|NCT00139152|Placebo Comparator|Placebo|Saline placebo
88987209|NCT00139152|Experimental|Xolair|Xolair treatment
88987210|NCT02824523||High-dose aspirin|
88987211|NCT02736422|Other|hyperpolarised xenon|evaluating the sensitivity of pulse sequences for 129Xe magnetic resonance imaging in the lungs, heart and brain and monitoring the transient changes in vital signs during and following the gas inhalation
88987212|NCT03733509|Experimental|Intraoperative Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of Bupivacaine 0.25%.~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml of saline solution (NaCl 0.9%)."
88987213|NCT03733509|Active Comparator|Ultrasound Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of of saline solution (NaCl 0.9%).~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml Bupivacaine 0.25%."
88987214|NCT02714387||ICU patients|Patients with Non Traumatic Neuro-Vascular Diseases. Medical data concerning ICU stay will be collected.
89617107|NCT03025334|Active Comparator|Real tDCS right|Real anodal tDCS (right DLPFC)
89617108|NCT02974881|Experimental|transcatheter mitral valve replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools. The HighLife Valve is a 31 mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI).
89617109|NCT02972788|Experimental|Experimental Group|Group will receive enamel matrix protein derivative treatment along with scaling and root planing.
89617110|NCT02972788|Sham Comparator|Control Group|Group will receive placebo (saline) treatment along with scaling and root planing.
89617111|NCT02927769|Experimental|Nivolumab + brentuximab vedotin|
89617112|NCT02927769|Experimental|brentuximab vedotin + bendamustine|
89617113|NCT02878174|Active Comparator|conventional ultrasound (US)-guided group|internal jugular vein catheterization using conventional US-guided internal jugular vein (IJV) cannulation
89617114|NCT02878174|Experimental|rotational Prelocation group|internal jugular vein catheterization using landmark approach based on the rotation-adjusted US screen
89617115|NCT02874040|Experimental|Experimental|endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar
88987215|NCT03682029|Experimental|Vitamin C|Vitamin C (ascorbic acid) 500 mg/capsule. Ingestion of 2 capsules (1000 mg) daily for 12 months.
88987216|NCT03682029|Placebo Comparator|Placebo|Placebo capsule. Ingestion of 2 capsules daily for 12 months. Placebo will be prepared as capsules that look and taste identical to the vitamin C supplement capsules. The content of the placebo is lactose, potato starch, gelatin, magnesium stearate, and talc.
88987217|NCT02426255||ICU patients|Patients with severe trauma (with or without brain injury) or Patients with hemorrhagic shock Data concerning the ICU stay will be collected for these patients
88987218|NCT02087072||Recently discharged homebound patients|
88987219|NCT02065154|Experimental|Cyclophosphamide (Cytoxan)|Cyclophosphamide (Cytoxan)
88987220|NCT00139386|Active Comparator|Candesratan|
88987221|NCT00139386|No Intervention|Non-candesartan|
88987222|NCT00403520|Experimental|Experimental 1|
88987223|NCT00403520|Placebo Comparator|Placebo Comparator|
88987224|NCT00139542|Active Comparator|CONTROL|AED Treatment protocol following AHA Guidelines 2000 recommendations for cardiac arrest resuscitation.
88987225|NCT00139542|Experimental|STUDY|AED treatment protocol with prolonged CPR intervals, single shocks, fewer rhythm analysis and pulse checks.
88987226|NCT03510078|Experimental|Intensive glycemic control|With a target of blood glucose range of 130 mg/dL or less
88987227|NCT03510078|Experimental|Conventional glycemic control|With a target of blood glucose range of 130-180 mg/dL
88987228|NCT00139581|Experimental|1|Pimecrolimus b.i.d.
88987229|NCT00139581|Experimental|2|Pimecrolimus o.d. and placebo o.d.
88987230|NCT03500913||Adults with growth hormone deficiency|Subjects who present to the neuroendocrine unit at Columbia University Irving Medical Center (CUIMC) for therapy of GH deficiency or who are followed in the unit and have active GH deficiency and are planning to initiate a therapy.
88987231|NCT03500913||Control group|Healthy subjects matched to the GH deficiency subjects for age (+/- 5 years), gender and total fat mass (+/- 4%).
89617116|NCT02864563|Experimental|Prospective cohort|Experimental arm, prospective cohort
89617117|NCT02851992|Other|GTS cementless stem|Total Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)
89617118|NCT02827435|Experimental|Rocuronium bolus|rocuronium bromide 1st bolus 0.1mg/kg, rocuronium bromide 2nd bolus 0.4mg/kg
89617119|NCT02824991|Experimental|Deep Dry Needling|"Deep Dry Needling (DN) with the purpose of obtaining local twitch responses (LTRs). Description: Latent MTrPs were identified in both MG using according the presence of a palpable taut band and hypersensitive spot in the palpable taut band as diagnostic criteria.~The deep DN was administered by a physical therapist with three years of experience in the technique. The ultrasound video (SonoSite Titan; Sonosite, Bothell, WA, USA) was recorded at 60 frames per second captured through an external capture device from Epiphan Systems Inc. (Ottawa, Ontario, Canada). According to the perception of the physical therapist and the ultrasound assessment, the filament needle was inserted into the MTrP to achieve three LTRs. Posterior to DN application, the ROMs of the MG and HA were measured"
89617120|NCT02788773|Experimental|Arm A - Durvalumab plus Tremelimumab|Durvalumab-IV for 60 minutes day 1 every 4 weeks Tremelimumab-IV every 60 minutes day 1, cycles 1-4
89617121|NCT02788773|Experimental|Arm B - Durvalumab alone|Durvalumab-IV for 60 minutes day 1 every 4 weeks
89617122|NCT02754544|Experimental|Diagnostic (electrocorticography)|Patients undergo tumor resection. During surgery, patients also undergo electrocorticography with either the CorTec high resolution hybrid grid, the PMT high-resolution grid, or the Ad-Tech grid followed by direct electrocortical stimulation.
89617123|NCT02688400|Experimental|Diacerein|One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).
89617124|NCT02688400|Active Comparator|Celecoxib|One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).
89617125|NCT02637583|Active Comparator|Sequential vaccination PCV13 and PPV23|PCV13 0.5 ml intramuscular injection once on day 0 PPV23 0.5 ml intramuscular injection once 6 months later
89617126|NCT02637583|Experimental|Simultaneous vaccination PCV13 and PPV23|PCV13 0.5ml intramuscular injection once on day 0 followed by PPV23 0.5ml intramuscular injection on day 0
89617127|NCT02637583|Active Comparator|Single vaccinationPPV23|PPV23 0.5ml intramuscular injection on day 0
89617128|NCT02626455|Experimental|Copanlisib + R-B or R-CHOP / Arm 1|Combination of copanlisib with standard immunochemotherapy (rituximab and bendamustine) [R-B] or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP] (safety run-in and phase III)
89617129|NCT02626455|Placebo Comparator|Placebo + R-B or R-CHOP / Arm 2|Combination of placebo and R-B or R-CHOP (phase III only)
89617130|NCT02492932|Experimental|IJV_2nd|Ultrasonography examination of the patients who are assumed to take second attempt of internal jugular venous catheterization
88987232|NCT00740753|Other|Treatment|yttrium 90 (TheraSphere) administration
88987233|NCT03497481||Neopterin Dosage|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
88987234|NCT00130598|Active Comparator|1|control group: patients receive a preventive hydration with 154mEq/l saline at an ongoing rate of 1ml/kg per hour of at least 12 hours prior and after the procedure.
88987235|NCT00130598|Active Comparator|2|7h-sodium bicarbonate (according to the regimen used in a recently published study (slightly modified)14): before contrast a bolus of 3ml/kg NaHCO3 166mEq/l for one hour, followed by an infusion of NaHCO3 166mEq/l with a rate of 1ml/kg per hour until 6h after contrast.
88987236|NCT00130598|Active Comparator|3|short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg; patients with a body weight above 100kg 300ml) as a bolus 20 minutes before contrast; additionally ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl of San Pellegrino® non-sparkling mineral water at the start of the infusion. Ingestion of 500ml San Pellegrino® non-sparkling mineral water in the first 6 hours after contrast.
88987237|NCT00130676|Experimental|mifepristone 600 mg|
88987238|NCT00130676|Placebo Comparator|matching placebo|
88987239|NCT00404274|Experimental|Treatment regimen A|In treatment regimen A subject will co-administer casopitant and warfarin over three-day period (Day 1 150 milligram per day [mg/day], Day 2 50 mg/day, Day 3 50 mg/day) and from Days 4 to 10 subject will administer only warfarin.
88987240|NCT00404274|Experimental|Treatment regimen B|In treatment regimen B subject will co-administer casopitant 60 mg/day and warfarin for 14 days.
89617131|NCT02433197|Experimental|Aerobic program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
89617132|NCT02433197|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 8-week intervention.
89617133|NCT02352896|Experimental|EPI-743|Participants will receive EPI-743 at a dose of 15 milligrams/kilogram (mg/kg) up to a total 200 mg 3 times daily (TID) orally with meal or by using nasogastric (NG) or gastrostomy feeding tubes with liquid food for at least 36 months.
89617134|NCT02320136||epilepsy|epilepsy patients
88987241|NCT00404274|Experimental|Treatment regimen C|In treatment regimen C subject will co-administer warfarin and casopitant 30 mg/day for 14 days.
88987242|NCT00130754|Experimental|1|Thymo
88987243|NCT00130754|No Intervention|2|
88987244|NCT00404313|Experimental|1|MK0633 10 mg
88987245|NCT00404313|Experimental|2|MK0633 50 mg
88987246|NCT00404313|Experimental|3|MK0633 100 mg
88987247|NCT00404313|Placebo Comparator|4|placebo
88987248|NCT00130910|Experimental|1|Albendazole
88987249|NCT00130910|Placebo Comparator|2|
88987250|NCT04710953|Experimental|CPAP arm|In addition to standard of care, CPAP will be provided at high altitude posts where Gamow bag is not available and all patients of HAPE will be given CPAP when evacuation/descent is either not possible or delayed due to weather conditions.
89617135|NCT02320136||tumor with epilepsy|tumor patients with epileptic seizures
89617136|NCT02320136||tumor without epilepsy|tumor patients without epileptic seizures
88987251|NCT04710953|No Intervention|Gamow bag arm/hyperbaric chamber|Posts where Gamow bag would be available, the patients of HAPE will be given standard of care and will be asked to lie inside Gamow bag inflated at 2 Psi for several hours to simulate a descent of 1500 meters when evacuation/descent is either not possible or delayed due to weather conditions.
89617137|NCT02242266|Experimental|Tiotropium low dose|oral inhalation via the blue HandiHaler®
89617138|NCT02242266|Experimental|Tiotropium medium dose|oral inhalation via the blue HandiHaler®
88987252|NCT03226821|Experimental|Tesamorelin|Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.
88987253|NCT00139815|Active Comparator|Enoxaparin|
88987254|NCT00139815|Experimental|Fondaparinux|
89617139|NCT02242266|Active Comparator|Spiriva® HandiHaler® high dose|oral inhalation via the grey HandiHaler®
89617140|NCT02242266|Placebo Comparator|Placebo|
89617141|NCT02193347|Experimental|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.
89617142|NCT02176434|Experimental|Tolerance|Combined kidney and hematopoietic stem cell transplantation from the same donor.
89617143|NCT02045381||MRI group|Patient receives one research MRI prior to radiation treatment.
89617144|NCT02039843|Active Comparator|Emotional Support Dogs|"Participants paired with Emotional Support Dogs~Emotional Support Dogs were required to pass the American Kennel Club Canine Good Citizen and the American Kennel Club Community Canine tests and be well-behaved and well-socialized."
89617145|NCT02039843|Active Comparator|Service Dogs|"Participants paired with Service Dogs~Service Dogs were required to pass the American Kennel Club Canine Good Citizen and the Assistance Dogs International Public Access tests and trained to complete five PTSD-specific tasks (lights, sweep, bring, block, & behind)."
89617146|NCT02004275|Experimental|Arm I (pomalidomide, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
89617147|NCT02004275|Experimental|Arm II (pomalidomide, dexamethasone, ixazomib)|Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89617148|NCT02003170||Neurodevelopmental Disorders|Children who present to various Arkansas Children's Hospital clinics for standard care related to neurodevelopmental disorders.
89617149|NCT02000284||General ASD|150 general ASD children
89617150|NCT02000284||ASD/MD|50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder
89617151|NCT02000284||ASD/noMD|50 children with ASD that have been r/o as having a mitochondrial disorder
89617152|NCT02000284||MD/noASD|50 children with a mitochondrial disorder and without an ASD
88987255|NCT00131027|Experimental|A|HD-MTX
88987256|NCT00131027|Active Comparator|B|ID-MTX
88987257|NCT00405483|Active Comparator|Minimally invasive exposure|Surgical technique, minimal incision
88987258|NCT00405483|Active Comparator|Standard exposure|Standard Incision
88987259|NCT00405561|Experimental|AMT2003|
89617153|NCT02000284||Developmental Delay|50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays
89617154|NCT02000284||Typically Developing|100 children with no history of medical, behavioral, or immunological disorders
89617155|NCT01911013|Active Comparator|Cage and Plate|anterior cervical discectomy and fusion surgery at one segment is performed using cervical cage and plate system
88987260|NCT00131144|Experimental|Octreotide Acetate in Microspheres 20 mg|20 mg will be administered im once every 4 weeks
89617156|NCT01911013|Experimental|Cage alone|anterior cervical discectomy and fusion surgery at one segment is performed using only cervical cage without plate
89617157|NCT01731444|Experimental|Phenylephrine|20 ug/cc
89617158|NCT01731444|Active Comparator|Epinephrine|1:1000000
89617159|NCT01630785||IONM patients|all patients where surgery requires IONM
89617160|NCT01559129|Placebo Comparator|Placebo|
89617161|NCT01559129|Experimental|Pomalidomide|Participants received 1 mg pomalidomide orally once a day for 52 weeks during the treatment phase and for up to 2 years during the open-label extension phase.
89617162|NCT01488240|Active Comparator|Proximal|part of scar proximal to heart
89617163|NCT01488240|Active Comparator|Distal|part of scar distal to heart
89617164|NCT01005303|Placebo Comparator|Placebo|
88987261|NCT00131144|Experimental|Octreotide Acetate in Microspheres 30 mg|30 mg will be administered im once every 4 weeks
88987262|NCT00131144|Placebo Comparator|Placebo|
88987263|NCT00140010|Experimental|A|30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient
88987264|NCT00131495|Placebo Comparator|1|Placebo patch
88987265|NCT00131495|Experimental|2|Testosterone patch (300mcg/day, changed twice a week for one year
88987266|NCT03128268|Experimental|All Enrollees|"Intervention: Diagnostic test~All enrollees will receive a 4D MRI as a research intervention using imaging software for 4 dimensional images for Cardiac MRI"
89617165|NCT01005303|Active Comparator|Micronutrient|
89617166|NCT01003028|Experimental|Limited|Limit the maximum plasma concentration target to 9.8 ng/ml
89617167|NCT01003028|Active Comparator|Control|Use 20 ng/ml as max plasma concentration
89617168|NCT00355238|Experimental|1|no comparator to brivanib
89617169|NCT00303303|Experimental|Fab initial and maintenance therapy|Active Fab Antivenom initial therapy followed by active Fab antivenom maintenance therapy
89617170|NCT00303303|Experimental|Fab initial therapy; placebo maintenance|Active initial Fab antivenom therapy followed by placebo maintenance therapy.
89617171|NCT00303303|Placebo Comparator|Placebo initial and maintenance therapy|Placebo initial and maintenance therapy.
89210911|NCT00817154|Experimental|Hopes-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
88987267|NCT04726631|Other|Basal insulin analogue and premeal rapid acting insulin|
89520273|NCT05283161|Experimental|cannabidiol and tetrahydrocannabinol 1:1 (10.0 mg/ml)|10 participants will receive CBD and THC in the same concentration (1:1) (10.0 mg/ml). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days.
89520274|NCT03843489|Experimental|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
88987268|NCT04726631|Other|Neutral Protamine Hagedorn with regular insulin|
88987269|NCT03117309|Experimental|PART A: Nivolumab|Nivolumab 240mg; Nivolumab 360mg
88987270|NCT03117309|Experimental|PART B: Nivolumab + Ipilimumab|Nivolumab 3mg/kg and Ipilimumab 1mg/kg; Nivolumab 360mg
88987271|NCT03095274|Experimental|Durvalumab|"Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) for 12 months in patients ≥ 30kg.~Weight-based dosing should be used for patients <30 kg: durvalumab 20 mg/kg."
89520275|NCT03843489|Sham Comparator|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
89520276|NCT03691311|Experimental|Denosumab|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
89520277|NCT03691311|No Intervention|Control|Control group
89520278|NCT03448835|Experimental|atezolizumab and chemotherapy|1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel
89520279|NCT03690453|Experimental|Healthy volunteer for Clinical Trial|
89520280|NCT03690453|No Intervention|Healthy volunteer for blood donor|
89520281|NCT03487575|Experimental|Open trial|
89520282|NCT03464409|Active Comparator|SCI Patient - Nerve Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking nerve transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
89520283|NCT03464409|Active Comparator|SCI Patient - Tendon Transfer Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury seeking tendon transfer surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline (pre-operatively), Early Followup (1 month post-operatively) and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
89520284|NCT03464409|Active Comparator|SCI Patient - No Surgery|Patients aged 18 to 80 with a mid cervical level spinal cord injury who did not chose to have surgery to improve hand and arm function. Participants will be assessed at 3 time points: Baseline, Early Followup (1 month later), and Late Followup (6-24 months later). Assessments will include the Spinal Cord Independence Measure (SCIM-SR), the 36-Item Short Form Health Survey (SF-36), and a semi-structured interview to be conducted by a study team member.
89520285|NCT03448523|Experimental|Right To Play's Positive Child and Youth Development program|Behavioural intervention
89520286|NCT03448523|No Intervention|Control|No intervention; intervention to be offered after end line assessment
89520287|NCT03439527|Experimental|MPC-group|All patients are treated by the same product: Autologous MPCs
89520288|NCT03439527|Other|NMES+MPC-group|After treatment, the patients will be randomized 1:1 in the MPC-group or NMES+MPC-group to investigate the benefits of an additional physiotherapy (Neuromuscular Electromagnetic Stimulation, NMES)
89520289|NCT05104905|Experimental|Renal cell intervention 1.0 mg/kg|
89520290|NCT05104905|Experimental|Renal cell intervention 3.0 mg/kg|
89520291|NCT05104905|Experimental|Renal cell intervention 10 mg/kg|
89520292|NCT05104905|No Intervention|Renal cell Observation|
89520293|NCT05104905|Experimental|Colon cancer intervention 1.0 mg/kg|
89520294|NCT05104905|Experimental|Colon cancer intervention 3.0 mg/kg|
89520295|NCT05104905|Experimental|Colon cancer intervention 10 mg/kg|
89520296|NCT05104905|No Intervention|Colon cancer Observation|
89520297|NCT05108727|Active Comparator|Active Diode Laser Therapy+ Modified Widman Flap|Diode laser with a wavelength of 810±5 nm and a power of 1 watt in continuous mode was applied to the Modified Widman Flap at the test sites
89520298|NCT05108727|Sham Comparator|Sham Diode Laser Therapy+ Modified Widman Flap|Control sites were treated with MWF alone
89520299|NCT05102331|Experimental|Lavender Oil Aromatherapy Treatment Arm (LOA)|"Participants will complete baseline assessments including 20 minutes of questionnaires and vitals assessment, including EEG activity (baseline measured with Bispectral Index (BIS) device). Participants will be given a dental bib with three lavender oil drops and instructed to relax for 20 minutes. BP and a brief self-report measure will be obtained. BIS recordings will be collected continuously during study and biopsy.~At procedure, participants will continue to wear bib with drops. BIS machine will stay attached and recording. Participants will be asked to verbally report pain and anxiety on visual analogue scale between the bone marrow aspirate and biopsy. EEG and heart rate (HR) will be collected continuously. An event marker and notation will indicate times when participant does something that may influence EEG activity (e.g. speak, move, etc.) or diagnostic images are taken. At procedure end, BIS device will be removed, final questionnaires administered, and vitals measured."
89617172|NCT03422874|Experimental|Nelfinavir plus MLN9708|"Both Nelfinavir and MLN9708 will be given orally (by mouth). MLN9708 will be given as 3 mg orally twice weekly. Study drugs will be administered on 21-day treatment cycles. All cycles are 21 days.~During the first cycle of MLN9708 only will initially be administered orally at a fixed dose of 3mg twice weekly for 2 weeks, on Mondays and Thursdays during this treatment cycle. During the third week there will be no study combination drug therapy(for Cycle 1 only). During Cycles 2 and 3, MLN9708 administered twice weekly on Mondays and Thursdays for the first 2 weeks of Cycles 2 and 3. Nelfinavir (escalating cohorts [1250mg, 1875mg, 2500mg, 3125mg]) will be administered orally twice daily in the dose cohorts listed."
88987272|NCT03095274|Experimental|Tremelimumab|"Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients ≥ 30kg.~Weight-based dosing should be used for patients <30 kg: tremelimumab 1 mg/kg Q4."
89617173|NCT01253824|Experimental|NPC-01|1mg norethisterone and 0.02mg ethinyl estradiol
89617174|NCT01253824|Active Comparator|IKH-01|1mg norethisterone and 0.35mg ethinyl estradiol
88987273|NCT01248949|Experimental|MEDI3617 SINGLE AGENT TOTAL|Participants will receive MEDI3617 via intravenous (IV) infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
89617175|NCT03422796|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
89617176|NCT03422796|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb
89617177|NCT04396977|Other|Histamine and placebo skin pricks|Each subject will receive the same histamine (10 mg/ml) and control (saline) skin prick on the right and left forearm on both study visits, to allow an intra-individual comparison
89617178|NCT03429738|Experimental|Experimental Drug|Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours
89617179|NCT03429738|Active Comparator|Active Comparator|Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours
89617180|NCT05242185||COVID-19 survivors|All patients age 18years and more who have SARS-CoV-2 infection confirmed by reverse-transcriptase polymerase-chain-reaction assay (RT-PCR) following their discharge from Dhaka hospital or outpatient clinic or inpatient wards of BSMMU
89617181|NCT03429660||Cohort|"Data to be collected are :~- Medical information on Immune Thrombocytopenia treatment"
89617182|NCT01253902|Active Comparator|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.
89617183|NCT01253902|Active Comparator|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.
89617184|NCT01253902|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.
89617185|NCT02843100|Experimental|Group 1|Modified Exclusive Enteral Nutrition including two weeks of Exclusive Enteral Nutrition (EEN) using Modulen followed by Partial Enteral Nutrition (PEN) along with the Crohn's Disease Exclusion Diet (CDED) phases 2 & 3 for 24 weeks
89617186|NCT02843100|Active Comparator|Group 2|Standard Exclusive Enteral Nutrition for 8 weeks using Modulen, followed by free diet with gradual reduction of Modulen to 25% of energy needs by week 24.
89617187|NCT05601609||young colorectal cancer (yCRC)|"histologically confirmed cases of adenocarcinoma in the colon and rectum~the age at the time of diagnosis should be ≤ 40 years"
88987274|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q3W ESCALATION|Participants will receive MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
88987275|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q2W TOTAL|Participants will receive MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
88987276|NCT01248949|Experimental|MEDI3617 + PACLITAXEL TOTAL|Participants will receive MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
88987277|NCT01248949|Experimental|MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL|Participants will receive MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
88987278|NCT02275234||Retrospective|Patients who survived cardiac arrest >3 months prior to the start of the study and a close family/friend,will be invited to attend an outpatient clinic
88987279|NCT02275234||Prospective- psychological intervention|In patients who survived cardiac arrest and a close family/friend,will be invited to attend an outpatient clinic
89617188|NCT05601609||elderly colorectal cancer (eCRC)|"histologically confirmed cases of adenocarcinoma in the colon and rectum~the age at the time of diagnosis should be ≥ 70 years"
89617189|NCT01253980|Active Comparator|Amoxicillin|Amoxicillin
89617190|NCT01253980|Placebo Comparator|Placebo suspension|Placebo
88987280|NCT03030495||Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve<2 & Index of microvascular resistance>25U
88987281|NCT03030495||No Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve>2 & Index of microvascular resistance<25U
88987282|NCT00504478|Experimental|1|8-weeks of high complex carbohydrate diet
88987283|NCT00504478|Experimental|2|omega-3 fatty acids supplements
88987284|NCT04696666|Experimental|Patients assigned in a single group and treated with 6 instillations of INSTYLAN for 6 weeks|Single Group Assignment
88987285|NCT01248793|Experimental|Placebo|
88987286|NCT01248793|Experimental|Golimumab|
88987287|NCT00403676|Experimental|Follow up by nurse|Patient randomized for follow-up by a nurse
88987288|NCT00403676|Experimental|follow up by medical doctor|Patients randomized for follow up by a medical doctor
89617191|NCT04449354|Other|Quality of Life assessment|HidraWear AX Garment
89617192|NCT00988533|Experimental|0.5% Ivermectin Cream|
89617193|NCT01254214|Experimental|tMBSR|telephone-adapted Mindfulness Based Stress Reduction (tMBSR) is an 8-week program of training in mindfulness meditation consisting of two in-person group meetings and 6 conference calls, led by a trained meditation teacher.
89617194|NCT01254214|Active Comparator|Support Group|The Support Group is a group intervention led by a trained facilitator and designed to match the intervention for time, attention and social support
89617195|NCT03048669|Experimental|Continuous quality improvement (CQI)|Quality improvement initiatives implemented at facility level using participatory data-driven approaches and on-site monitoring and supervisory support
89617196|NCT03048669|No Intervention|Standard of care|In health districts randomized to standard of care, the same strengthening of the data collection system for the monitoring of indicators as in the intervention group will be implemented. At least once a month, a study staff will visit each clinics irrespective of their randomization to extract information for the mother-infant register into an electronic database. No report on indicators will be produced for those clinic for the duration of the study. Staff from clinics and health district bureau in the standard of care group will not be associated with the quarterly review of the indicators. The study will not influence with any other HIV service provision activity in the standard of care group.
89617197|NCT01254760|Other|Investigational multifocal / Commercial multifocal|Investigational multifocal contact lenses worn first, with commercial multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
89617198|NCT01254760|Other|Commercial multifocal / Investigational multifocal|Commercial multifocal contact lenses worn first, with investigational multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
89617199|NCT05601375||Pregnancy with a healthy fetus|3 times echocardiography in pregnancy once echocardiography after birth
89617200|NCT05601375||Pregnancy with a fetus with a structural heart disease|3 times echocardiography in pregnancy once echocardiography after birth
89617201|NCT05601375||Pregnancy with a fetus with a fetal growth restriction|3 times echocardiography in pregnancy once echocardiography after birth
89617202|NCT02984007|Experimental|Motivational Interviewing|Educational session based on the motivational interviewing
89617203|NCT02984007|Other|Information flyer|Information flyer on childhood vaccines
89617204|NCT01350388|Active Comparator|Febuxostat|80 mg/day of febuxostat for 24 weeks
89617205|NCT01350388|Placebo Comparator|Placebo|1 placebo tablet per day for 24 weeks
89617206|NCT03154749|Experimental|DCb|Docetaxel (75 mg/m2 administered intravenously every 3 weeks) and carboplatin (area under the concentration-time curve [AUC] 6, intravenously every 3 weeks) for six cycles
89617207|NCT03154749|Active Comparator|EC-D|Epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles
89617208|NCT03633396|Placebo Comparator|Placebo|Participants will receive placebo administered by subcutaneous injection on Day 1 followed by monthly doses of placebo by subcutaneous injection on Days 29, 57, and 85.
89617209|NCT03633396|Experimental|imsidolimab|Participants will receive 200 mg imsidolimab by subcutaneous injection on Day 1 followed by monthly doses of 100 mg imsidolimab by subcutaneous injection on Days 29, 57, and 85.
89617210|NCT03422718|Experimental|Arm 1|No healthy behavior texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
89617211|NCT03422718|Experimental|Arm 2|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
88987289|NCT01248364|Experimental|BI 10773 Arm|BI 10773 high dose once daily
88987290|NCT00131846|Active Comparator|1|Diuretics use
88987291|NCT00131846|Active Comparator|2|No diuretics use
88987292|NCT01248130|Active Comparator|Omega-3 Fatty Acid Treatment|
88987293|NCT01248130|Placebo Comparator|Placebo (Sugar Pill)|
88987294|NCT02830620|Other|groupe1|cancer of the pancreas WITH syndrome of anorexia-cachexie Dosage of chimiokines
88987295|NCT02830620|Other|groupe2|cancer of the pancreas WITHOUT syndrome of anorexia-cachexie Dosage of chimiokines
88987296|NCT02830620|Other|groupe3|pure food limitation typifies restrictive anorexia nervosa Dosage of chimiokines
89617212|NCT03422718|Experimental|Arm 3|No healthy behavior texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
89617213|NCT03422718|Experimental|Arm 4|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
89617214|NCT03422718|Experimental|Arm 5|No healthy behavior texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
89617215|NCT03422718|Experimental|Arm 6|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
89617216|NCT03422718|Experimental|Arm 7|No healthy behavior texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
89617217|NCT03422718|Experimental|Arm 8|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
89617218|NCT00988065|Experimental|Sugammadex 4 mg/kg|Participants were to receive one dose of sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
89617219|NCT00988065|Experimental|Sugammadex 16 mg/kg|Participants were to receive one dose of sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
89617220|NCT00988065|Placebo Comparator|Placebo|Participants were to receive one dose of placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
88987297|NCT02830620|Other|groupe4|unhurt individual of any appetite-suppressing evolutionary disease and cachectisante Dosage of chimiokines
88987298|NCT02955550|Experimental|PNK-007 and rhIL-2|Melphalan per institutional practices (within Day -5 to 01), ASCT (Day 0), PNK-007 at varying dose levels (within Day 7 to Day 14) and rhIL-2 every other day starting day of PNK-007 administration.
89617221|NCT03422640|Experimental|Treatment arm with apremilast|Open label arm treating frontal fibrosing alopecia with apremilast
89036295|NCT02918903|Experimental|Minimal caries removal|the patients in this group will be treated by minimal caries removal technique, where only caries at lateral walls of cavity is removed, stainless steel crown preparation is performed and then stainless steel crown is placed as final restoration.
89036296|NCT02918903|Active Comparator|Complete caries removal|patients in this group will be treated by complete caries removal technique, where all caries will be removed, a base of resin modified glass ionomer is placed and then stainless steel crown is placed as final restoration.
89036297|NCT05407935|Experimental|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
89036298|NCT05407935|Active Comparator|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
89036299|NCT02918747|Experimental|P-Gemoxd|"Pegaspargase+Gemcitabine+Oxaliplatin+Dexamethasone (PEG-ASP+Gemoxd): Patients received the P-Gemoxd chemotherapy regimen every 3 weeks.~Pegaspargase 2000U/m2 im day 1, Gemcitabine 800mg/m2 ivdrip 30min day 1 and day 5, Oxaliplatin 85mg/m2 ivdrip day 1, Dexamethasone 15 mg ivdrip, QD, day 1 to day 5.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions."
89036300|NCT02918747|Active Comparator|P-CHOP|"Pegaspargase+Cyclophosphamide+Doxorubicin+Vincristine +Prednisone (P-CHOP)：Patients received the P-CHOP chemotherapy regimen every 3 weeks. Cyclophosphamide 750 mg/m2，ivdrip day 1； doxorubicin 50mg/m 2，ivdrip day 1；vincristine 1.4 mg/m 2(≤2mg），ivdrip day 1; Pegaspargase 2000U/m2 im，day 2 and prednisone (60 mg/m 2 /day) on days 1 to 5 orally.~IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50-56 grays (Gy) in 25-28 fractions."
89036301|NCT02918708|Active Comparator|group 2 (Synflorix then Prevenar13)|PCV10 given at 2 and 4 months of age, PCV13 given at 12 months of age
89036302|NCT02918708|Active Comparator|group 1 (Prevenar13 only)|PCV13 given at 2,4 and 13 months of age
89036303|NCT02918591|Experimental|Empagliflozine|All type 2 diabetic participant will be treated during 2 month with Empagliflozine 10 to 25 mg daily during 2 month.
89036304|NCT02918513|Experimental|Wellness Intervention|WILD 5 Wellness is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
89036305|NCT02918240|Experimental|4 week interval|Patients will be seen every 4 weeks to adjust their orthodontic braces
89036306|NCT02918240|Experimental|6 week interval|Patients will be seen every 6 weeks to adjust their orthodontic braces
89036307|NCT02918240|Experimental|8 week interval|Patients will be seen every 8 weeks to adjust their orthodontic braces
89617222|NCT03427164|Experimental|TIPS|Participants will have measurements taken of spleen stiffness before and after TIPS. Participation will last about 12 months, with visits at 1-2 weeks post-TIPS, 3 months, 6 months, and 12 months.
89617223|NCT02055222||Lung disease (IPF) and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
89617224|NCT02055222||Lung disease COPD and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
89617225|NCT02055222||Normal Volunteers- Non-smokers, and Smokers|50 smoking and 30 non-smoking controls
89617226|NCT01351090|Experimental|Ketorolac tromethamine (5%)|
89617227|NCT01351090|Experimental|Ketorolac tromethamine (15%)|
89617228|NCT01351090|Placebo Comparator|Placebo|
89617229|NCT01918644|Experimental|Treatment (SBRT, capecitabine, and surgery)|Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
89617230|NCT00987831|Experimental|Blood drawing only Group C|Healthy controls, age, sex and ethnicity matched to the active study participants were recruited for two time blood donation as controls for the biomarker studies
89036308|NCT02918240|Experimental|10 week interval|Patients will be seen every 10 weeks to adjust their orthodontic braces
89617231|NCT00987831|Experimental|Group A SLE prospective study|In Group A SLE patients enter with active disease. Any immune suppressant (e.g. methotrexate, azathioprine or mmf) is withdrawn and after blood drawing, depomedrol up to 160 mg IM is given. This may be repeated for a maximum of 160mg up to four times total in the first two weeks. Depomedrol is expected to last 1-3 months, serial biomarkers will be drawn until time of flare, at which time biomarkers will be drawn, patient is defined as meeting endpoint and new treatment initiated. Patients may elect to continue to donate blood samples per protocol up to one year.
89036309|NCT02918045|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
89036310|NCT02918045|Active Comparator|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions involves the placement of an absorbable oxidized cellulose gauze Surgicel (Ethicon, Inc, San Angelo, TX) into the extraction socket. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard local hemostatic care for oral surgery subjects.
89617232|NCT00987831|Experimental|Group B SLE one blood donation|SLE patients who meet the same entry criteria as Group A could elect to donate blood one time and not to continue in the prospective protocol. No extra intervention was performed other than blood draw and medical records review. This allowed an extension of cross sectional comparisons between biomarker changes related to background treatments by combining Group A baseline data with Group B data.
89617233|NCT03608358|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg and dapagliflozin 5 mg placebo to match added to saxagliptin 5 mg and metformin
89617234|NCT03608358|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
89617235|NCT03608358|Placebo Comparator|Placebo|Dapagliflozin 5 mg placebo to match and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
89617236|NCT04274907|Experimental|Dose Escalation Phase: Venetoclax + Pembrolizumab|Participants will receive escalating doses of venetoclax in combination with pembrolizumab Dose A.
89617237|NCT04274907|Experimental|Randomization Phase: Venetoclax + Pembrolizumab|Participants will receive venetoclax at dose levels determined in the dose escalation phase in combination with pembrolizumab Dose A.
89617238|NCT04274907|Active Comparator|Randomization Phase: Pembrolizumab Monotherapy|Participants will receive pembrolizumab Dose A
89617239|NCT01256164|Experimental|Fibrocaps + Gelfoam|After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.
89617240|NCT01256164|Active Comparator|Gelfoam|Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
89617241|NCT03422484||People with at least one medication error|People with at least one medication error at hospital admission
89617242|NCT03422484||People without medication error at hospital admission|People without medication error at hospital admission
89617243|NCT03427086|Active Comparator|Interventional|Patient will received high dose of biotin (300 mg/day)
89617244|NCT03427086|Placebo Comparator|Placebo|Patients will receive placebo
89617245|NCT01256944||Control|The normal reproductive-aged women
89617246|NCT01256944||PCOS|"Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:~Oligo- or anovulation~Clinical and/or biochemical signs of hyperandrogenism~Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)"
89617247|NCT03148665||Control population|Control population (n=150): absence of current or prior oropharyngeal carcinoma, no active cancer diagnosis. Control population includes at least 50 subjects who have smoked at least 100 cigarettes during lifetime OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as a one-time test for control subjects
89617248|NCT03148665||Cancer population|Cancer population (n=150): patients with previously untreated oral cavity or oropharynx squamous cell carcinoma with absence of distant metastasis OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
88987299|NCT00131963||Regimen 1|Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
88987300|NCT00131963||Regimen 2|Patients receive doxorubicin and cyclophosphamide as in regimen 1. Patients then receive paclitaxel IV over 1 hour once weekly for 12 weeks.
89617249|NCT03427008|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressive medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth app.
89617250|NCT03427008|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the mHealth app and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
89617251|NCT00986973|Experimental|Sapropterin (KUVAN)|All subjects will receive Sapropterin (KUVAN) therapy at a dose of 20/mk/kg/day for four months.
88987301|NCT00132080|Placebo Comparator|1|Patients with acute Kawasaki disease
88987302|NCT00132119|Experimental|1|Nalmefene HCl 20 mg
88987303|NCT00132119|Experimental|2|Nalmefene HCl 40 mg
89617252|NCT01887522|Experimental|VINILO|"VINILO-arm: Vinblastine and nilotinib given in combination at the RD defined in the Phase I part:~Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28 Recommended doses of the drug combination will be reconsidered at an interim stage of the phase II trial after the analysis of the delayed toxicity encountered in the first 20 patients treated at the initial RD (adaptive design)."
89617253|NCT01887522|Active Comparator|Control Vinblastine only|"Control Vinblastine only arm:~· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Each 28-day cycle is repeated on Day 29/Day 1.~In both treatment groups, dose reductions and/or administration delays will be performed in case of severe hematological and/or non hematological toxicities while on treatment.~Vinblastine will be temporarily stopped in case of neutropenia <1 x109/L or thrombopenia <75 x 109/L. It could be re-started at a reduced dose after complete recovery.~Patients benefiting from study treatment may continue up to 12 cycles as long as the toxicity-benefit ratio is adequate."
89617254|NCT03422406||HH group|Group (participants) with pre-gestational history of undergoing hysterosalpingography (HSG) using an oil-soluble iodinated contrast medium
89617255|NCT03422406||Non-HH group|Group (participants) without pre-gestational history of undergoing hysterosalpingography (HSG)
89617256|NCT03426930|Active Comparator|The reference treatment of dysmorphophobia used|
88987304|NCT00132119|Placebo Comparator|3|Placebo
88987305|NCT00132158|Other|1|
88987306|NCT01247350|Experimental|2 mg LY3009104 (Cohort 1)|2mg administered once on day 1 (single dose)
88987307|NCT01247350|Experimental|5 mg LY3009104 (Cohort 2)|5mg administered once on day 1 (single dose)
88987308|NCT01247350|Experimental|10 mg LY3009104 (Cohort 3)|10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
88987309|NCT01247350|Experimental|14 mg LY3009104 (Cohort 4 )|14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
89617257|NCT03426930|Experimental|The reference treatment with the virtual reality|
89617258|NCT00986427|Active Comparator|1|Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
89617259|NCT00986427|Placebo Comparator|2|Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
89617260|NCT03429504||Obese breast cancer patients|Response to treatment and progression free survival in obese breast cancer patients
89617261|NCT03429504||non obese breast cancer patients|Response to treatment and progression free survival in non obese breast cancer patients
89617262|NCT05245461||Anterior Cruciate Ligament Reconstruction|Patients who had remnant-preserving anterior cruciate ligament reconstruction
89036311|NCT02918123|Experimental|Treatment|"FURESTEM-CD Inj. 5.0x10^7 cells~FURESTEM-CD Inj. 1.0x10^7 cells~FURESTEM-CD Inj. 2.0x10^8 cells"
89617263|NCT05245461||Healthy Group|People who had no knee surgery or injury
89617264|NCT03426852||Study group|Individuals with lumbar back pain plus sacroiliac disc herniation
89617265|NCT03426852||Control Group|Individuals with lumbar back pain
89617266|NCT03527394||Families|"We plan to recruit a sample of 100 families (dyads) for this study, which will include 100 youth and 100 parents.~Note: For the sake of transparency, this sample size differs from the original estimate (n=250 families; see Ball et al., BMC Health Serv Res, 2017;17:261). A recent systematic review (Park et al., Int J Nurs Stud, 2018;79:58-69) suggested that sample size estimates for studies that evaluate test-retest reliability (a key psychometric property we will examine) should include ~5 participants for every survey item. Given the design of the interview, and in light of current patient volumes at the clinical recruitment sites, we are confident that a sample of 100 families will be both achievable and satisfactory for psychometric analyses."
89036312|NCT05400096|Experimental|CFT based online group intervention|The group will consist of 12 weekly 1.15h long online sessions.
89617267|NCT05601063||Psychiatric patient group|"Current diagnosis in the medical chart of any of the following. The patient may be in partial but not full remission. Comorbidity among these disorders and other unlisted disorders is expected and allowable.~Schizophrenia-spectrum disorder - schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder, brief psychotic disorder, or unspecified psychotic disorder~Bipolar spectrum disorder - bipolar I or II disorder, cyclothymia, unspecified or other specified bipolar disorder~(Unipolar) Depressive disorder - major depressive disorder, dysthymia, unspecified and other specified depressive disorder~Anxiety disorder - obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, post-traumatic stress disorder~Personality disorder - borderline personality disorder~Attention-Deficit Hyperactivity Disorder"
89036313|NCT02917850|Active Comparator|Isokinetic|Patients who benefit from the hip flexors isokinetic strengthening rehabilitation program
89617268|NCT05601063||Healthy controls|Healthy comparison subjects with no known psychiatric diagnosis
89617269|NCT03426774|Experimental|YG ( 25-59yrs) -GJogger|Gentle Jogger applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
89617270|NCT03426774|Experimental|OG (Greater than 60 yrs)-GJogger|Gentle Jogger applied to each individual in (1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
89617271|NCT03426774|Experimental|YG ( 25-59yrs) -GJumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
89036314|NCT02917850|Active Comparator|Control|Patients who benefit from a conventional rehabilitation program
89617272|NCT03426774|Experimental|OG (Greater than 60 yrs)-Gjumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
89617273|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJogger Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
89617274|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)- GJogger-Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
89617275|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJumper- Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
89617276|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)-GJumper Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
89617277|NCT02842320|Experimental|Additional biological samples|Bone marrow sample and blood collected at J0 (screening visit), and at 3, 6, 12, 18 and 24 months and at each additional consultations (relapse ...)
89617278|NCT00986349|Experimental|Diabetes|Single Arm
89617279|NCT03426696||Thyroid Related Eye Disease|Survey about the psychological condition would done with the patients of Thyroid Related Eye Disease
89617280|NCT03429426||Rheumatoid arthritis|"Patients with Rheumatoid arthritis ≥5 years according to the ACR/EULAR 2010 classification criteria or the American Rheumatism Association 1987 revised criteria.~ICD-10: M059 Seropositive rheumatoid arthritis UNS, M060 Seronegative rheumatoid arthritis, M069 Rheumatoid arthritis UNS."
89036315|NCT03825575|Experimental|Incontinence and low level laser therapy|Intervention: Low level laser therapy (sacral neuromodulation or photobiomodulation) will be administered to patients with fecal incontinence
89036316|NCT00532545|Experimental|A|Teriparatide
89036317|NCT03819062|Experimental|Refractory Constipation with LLLT|Low level laser therapy (LLLT) will be administered to patients with severe refractory chronic constipation
89036318|NCT04674111|Experimental|Vortex Feasibility Study (Vortex FIH)|Vortex - First in Human Study to Evaluate the Feasibility, Safety, Clinical and Technical Success of the Vortex Temporary Percutaneous, Transvalvular Circulatory Support System (Vortex System)
89036319|NCT03792737|Experimental|Investigational group 1|Investigational group 1: Use the study device Spiral PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and MONOCRYL Plus for continuous subcuticular suture.
89036320|NCT03792737|Experimental|Investigational group 2|Investigational group 2: Use PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the study device Spiral MONOCRYL Plus for continuous subcuticular suture.
89036321|NCT03792737|Active Comparator|Control group|Control group: Use the control device PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the control device MONOCRYL Plus continuous subcuticular suture.
89617281|NCT03429426||Pre-Rheumatoid arthritis|Patients with joint pain, but no swelling and Anti-CCP 3 times above the upper limit.
89617282|NCT03429426||Healthy Subjects|Healthy age- and sex-matched Individuals are recruited, as a control group.
89617283|NCT03426618||Pediatric participants with Hepatitis B Virus (HBV)|All participants who received at least 1 dose of Baraclude.
89617284|NCT03429192||N2 non-small cell lung cancer|Chinese patients with N2 non-small cell lung cancer
89617285|NCT03426540|Experimental|Conbercept|intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery
89617286|NCT03426540|No Intervention|control group|Pars plana vitrectomy alone
89617287|NCT03426462|Experimental|Age 1-6 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
89617288|NCT03426462|Experimental|Age 8-13 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
89617289|NCT03421938|Experimental|Group 1 (Downhill Exercise Group)|This group will have downhill walking exercises with %10 slope.
89617290|NCT03421938|Experimental|Group 2 ( Uphill Exercise Group)|This group will have uphill walking exercises on the treadmill with %10 slope.
89617291|NCT03421860|Active Comparator|ephedrine|will receive ephedrine :a bolus of 9 mg after SA once intervention: will receive complementary doses of ephedrine 6 mgto maintain systolic blood pressure above 80 % of baseline
89617292|NCT03421860|Active Comparator|phenylephrine|will receive Phenylephrine : a bolus of 100 mcg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
89036322|NCT04686942||Before sonazoid|US detection liver metastases before sonazoid
89036323|NCT04686942||After sonazoid|US detection liver metastases after sonazoid
89036324|NCT03782519|Experimental|Incremental hemodialysis|Patients who will begin HD with two treatment sessions per week
89036325|NCT03782519|Active Comparator|Conventional hemodialysis|Patients who will begin HD three times a week
89617293|NCT03421860|Active Comparator|ondansetron|will receive ondansetron: a bolus of 8 mg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
89617294|NCT03421860|Active Comparator|norepinephrine|will receive noradrenaline (norepinephrine) a bolus of 0,25 mcg/kg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
89617295|NCT03426384|Active Comparator|Intervention Group|"The Intervention Group will enter daily tasks into the Mymee app. After the first intake session, the subject will participate in weekly 20-30-minute coaching sessions with the Health Coach. At the second session, the Health Coach will review the symptoms and the free text entered by the subject to determine which dietary and environmental factors will be monitored in the Mymee app.~Each subsequent week, the Health Coach will review and discuss with the subject the food diary and the data entered into the Mymee app during the previous week. Based on this discussion and the subject's medical records, the Health Coach will determine or revise which symptoms will continue to be monitored using the Mymee App."
89617296|NCT03426384|No Intervention|Control Group|The Control Group subjects will receive no training, coaching, or other intervention services from Mymee. The Control Group subjects will complete the same battery of assessments at the same intervals as the Intervention Group subjects.
89617297|NCT04448730||Group 1 (normal weight with PCOS )|35 cases
89617298|NCT04448730||overweight PCOS|38 cases
89617299|NCT03421626||Primary Enrollment|Initial enrollment of patients with history of CML
89617300|NCT04449120|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one-month. Three visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
89036326|NCT05381883|Other|Epidemiology|"Participants will answer sociodemographic questions, questions about the experience of potentially traumatic lifelong events, the presence of a known psychological or medical disorder and the taking of drug treatment.~These questionnaires will make it possible to detect the main psychological disorders (post-traumatic stress disorder, depression, panic disorder, generalized anxiety disorder), to evaluate coping strategies, the presence of professional exhaustion (burnout), the consumption of psychoactive substances and quality of life."
89036327|NCT03756155|Experimental|Group 1|Group 1 will complete a protocol with 10 sets of 10 second isometric holds followed by 10 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30%-40% value.
89036328|NCT03756155|Experimental|Group 2|Group 2 will complete a protocol with 5 sets of 20 second isometric holds followed by 20 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30% value.
89036329|NCT00533520|Active Comparator|0.5mg ranibizumab|Subjects will be treated with 0.5mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
89036330|NCT00533520|Active Comparator|1.0mg ranibizumab|Subjects will be treated with 1.0mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
89036331|NCT00533520|Active Comparator|2.0mg ranibizumab|Subjects will be treated with 2.0 mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
89036332|NCT00533559|Experimental|buphenyl|
89036333|NCT00533559|Placebo Comparator|Placebo|
89036334|NCT03685253|Placebo Comparator|Placebo|Participants randomized to placebo will take 2 capsules by mouth twice a day for 6 months. The placebo capsules are matched to the NR capsules.
89617301|NCT04449120|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group received the written nutrition educational information as well as four online cooking classes (one cooking class per week) during the one-month intervention period. Three visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the program´s beginning (T2); and (3) after three months of follow-up period. In all time-points, questionnaires will be registered and at T2 and T3 blood samples will be collected.~Participants will attend 4 culinary workshops between visit 2 and 3. Volunteers will be contacted by phone after 1 month and 6 months of the end of the intervention to collect information about food and culinary habits."
89617302|NCT03421548|Experimental|BKpro I with EyeMate|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
89617303|NCT03421548|No Intervention|BKpro I|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
89617304|NCT04448652||+NSAIDs|Patients undergoing elective colorectal cancer resection before april 1st 2016 were treated with paracetamol tablets 1000 mg and ibuprofen tablets 400 mg four times a day from the day of the operation and until discharge.
89617305|NCT04448652||-NSAIDs|Patients undergoing elective colorectal cancer resection from april 1st 2016 were only treated with paracetamol tablets 1000 mg four times a day from the day of the operation and until discharge.
89617306|NCT03483324|Experimental|Experimental|Unmanipulated umbilical cord blood plus AB-110
89617307|NCT03426150|Experimental|CPP-ACP|Tooth mousse (GC, Japan) application on the specimen surface for 3 min.
89617308|NCT03426150|Placebo Comparator|Deionized water|Deionized water application on the specimen surface for 3 min
89617309|NCT02053584|Experimental|Dario BGMS|
89617310|NCT03417258||Patients with polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
89617311|NCT03417258||Patients without polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
89617312|NCT03127878|Active Comparator|Active-control|High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
88987310|NCT01247350|Placebo Comparator|Placebo|administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
88987311|NCT04710849||Treatment Failure Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. Definition of systemic glucocorticoid treatment failure during hospitalization is (Reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): The following occurs from the 2nd to the 7th day after admission Situation: ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
88987312|NCT04710849||Treatment Success Group|The diagnostic criteria of AECOPD is defined in global initiative for chronic obstructive lung disease (GOLD 2016). According to the efficacy of systemic hormone therapy during hospitalization, they were divided into treatment success group and treatment failure group. The treatment success group was defined as not meeting any of the following conditions for failure of systemic hormone therapy during hospitalization (reference: Crisafulli E, Torres A, Huerta A, et al. COPD, 2016, 13(1): 82-92): ①Need to receive mechanical ventilation treatment or need to be admitted to the ICU due to illness; ②72 hours after the initial anti-infective treatment, clinical signs of infection persist and need to change antibiotic treatment; ③Death from any cause.
88987313|NCT01246999|Active Comparator|Live Attenuated Influenza vaccine|LAIV 0.2 ml will be given intranasally followed by LAIV 0.2 mg given intranasally 28 days later
88987314|NCT01246999|Active Comparator|Trivalent Influenza Vaccine 2010-2011|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 8 years intramuscularly followed by a second dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly 28 days later
88987315|NCT01246999|Active Comparator|TIV followed by LAIV|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly followed by LAIV given in a dose of .2 ml intranasally 28 days later
88987316|NCT01246999|Active Comparator|LAIV followed by TIV|LAIV will be given in a dose of .2 ml intranasally followed by a dose of TIV given in a dose of .25 ml 2 years to 36 months or .5 ml 37 months to 9 years intramuscularly 28 days later
88987317|NCT00132353||Healthy volunteers|For normative data
88987318|NCT00132353||Patients with neurological disorders|For teaching fellows electrodiagnostic techniques
88987319|NCT04696783|Experimental|Drug Group|Esomeprazole Magnesium Enteric-coated Tablets and lifestyle adjustment
88987320|NCT04696783|Placebo Comparator|non-Drug Group|Only lifestyle adjustment
88987321|NCT00132509|Experimental|DFIL|
88987322|NCT00132509|Active Comparator|NINDS|
88987323|NCT00140712|Experimental|Ropinirole|single dose .25mg of IR formulation, .05mg of RLS controlled release
88987324|NCT00140751|Experimental|Simplification|The patients included in this arm are on Monotherapy of Kaletra (Lopinavir/ritonavir)during 48 weeks
89617313|NCT03127878|Experimental|Upper-limb additional training|High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
89617314|NCT03421314|Experimental|Zinc|Participants in this arm will take a daily 30 mg dose of zinc gluconate during 6 months
89617315|NCT03421314|Experimental|Selenium|Participants in this arm will take a daily 200 mcg of selenium yeast during 6 months
89617316|NCT03421314|Experimental|Zinc + Selenium|Participants in this arm will take a daily 30 mg dose of zinc gluconate + 200 mcg of selenium yeast during 6 months
89617317|NCT03421314|No Intervention|Control|Participants in this arm will not take supplementation as a control.
89617318|NCT03421236|Experimental|non muscle invasive bladder cancer patient|intravesical instillation of Ty21a in patients not requiring BCG
89617319|NCT03425994||Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) tablet by mouth, once daily for 48 weeks
89617320|NCT03421158|No Intervention|Control|Newborns received no pain interventions during the procedure
89617321|NCT03421158|Experimental|Breastfeeding|Newborns were breastfed during the procedure
89617322|NCT03421158|Experimental|Oral Sucrose|Newborns were given oral sucrose during the procedure
89617323|NCT03421158|Experimental|Skin to skin contact|Newborns were placed in direct contact with their mothers during the procedure
89617324|NCT03421158|Experimental|Non-nutritive sucking|Newborns were given a pacifier to suck on during the procedure
89617325|NCT03421080|Active Comparator|MoodGYM Only|The MoodGYM only Internet intervention will consist of a popular, automated, self-help cognitive behavioral therapy program for depression comprising five modules to be completed over five weeks and an online workbook incorporating 29 exercises. A series of published research trials has shown MoodGYM to be effective in reducing depressive symptoms in users in a range of settings (e.g., schools, universities, Lifeline suicide prevention, U.K. NHS Choices online), for different aspects of the mental health service spectrum (e.g., prevention vs treatment), and different age groups (adults, adolescents).
89617326|NCT03421080|Experimental|MoodGYM + CYD|The MoodGYM + CYD intervention condition will consist of the MoodGYM only intervention and an online intervention providing feedback on quantity and frequency of drinking, severity of hazardous drinking, and provides recommendations for safe levels of alcohol consumption (Check Your Drinking - CYD). The CYD Final Report will be provided as part of the participant's MoodDYM dashboard.
89617327|NCT03416712|No Intervention|Control|"To obtain baseline socioeconomic data on all children (intervention and control), study participants will utilize the Children's HealthWatch Survey (www.childrenshealthwatch.org), which is a standardized, validated survey designed to collect demographics and information on child health and development, parental health, and socioeconomic factors income, education level, financial literacy, childcare, and government assistance).~The control group will not complete the WE CARE HOUSTON survey and will not receive any referrals to community resources from the study team at the time of enrollment (they may be referred to resources by their medical/clinical team as per standard of care during their hospitalization at Texas Children's Hospital). The study investigators will offer control participants information on community resources at the end of the study. Study participants will be called for a 6 month follow up structure telephone survey."
89617328|NCT03416712|Experimental|Intervention|The intervention group will complete a short survey called the WE CARE HOUSTON survey. The WE CARE HOUSTON survey has been designed to quickly assess patient need for local services that address the social determinants of health. The WE CARE HOUSTON survey will be administered on paper or verbally if family is not able to read. Based on the parent's responses to the screening survey, the study investigators will use an algorithm to direct families to appropriate services and community resources. Families who screen positive for social needs will receive a handout on resources. For the families that screen positive for depression/ mental health needs, domestic violence, or alcohol and drug abuse, the study investigators will notify the medical/clinical team and recommend an inpatient social work prior to discharge. Intervention participants will be called 1 week-2 months after enrollment to follow up on resources and will be called for a 6 month follow up structured telephone survey.
89617329|NCT03425916||Primiparous women|Women after normal, not operative, vaginal one-child delivery
89617330|NCT03425916||Nulliparous women|Women without any child or pregnancy, age-matched
89617331|NCT03416634|Active Comparator|App Alone|Participants randomized to use the Microsoft Band app to track daily activity
89617332|NCT03416634|Experimental|App Plus Automated Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive automated, motivational text messages
89617333|NCT03416634|Experimental|App Plus Personalized Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive personalized, motivational text messages
89617334|NCT03416634|Active Comparator|Wearable Device Alone|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity
89617335|NCT03416634|Experimental|Wearable Device Plus Automated Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive automated, motivational text messages
89617336|NCT03416634|Experimental|Wearable Device Plus Personalized Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive personalized, motivational text messages
89617337|NCT03421002|Experimental|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour. Micafungin will be administered for a minimum of 14 days until 1 of the following conditions applied: •Negative results (absence of Candida growth) from at least 2 consecutive blood cultures and/or resolution of clinical and laboratory symptoms and reduction of mannan antigen blood level (< 125 pg/mL) are obtained. •In case of meningitis, hydrocephalus and external ventricular derivation, negative results (absence of Candida growth) from at least 2 consecutive cerebral spinal fluid (CSF) cultures associated with resolution of clinical and laboratory symptoms. •Interruption (including addition or switch to another antifungal agent or dosage change of micafungin) due to demonstration of therapy failure.
89617338|NCT03420924|Experimental|Thermal suit|
89617339|NCT03420924|Active Comparator|Conventional hospital clothes|
89617340|NCT03420846|Experimental|OCT Mapped arm|OCT is used to map the tumour margins as the first stage MMS estimate
89617341|NCT03420846|No Intervention|Control arm|Standard MMS is performed
89617342|NCT03416556|Experimental|Mobilization to the glenohumeral joint|This condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder
89617343|NCT03416556|Sham Comparator|The manual contact condition|In this condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition.
89617344|NCT03416556|No Intervention|No-contact condition|There was no manual contact between the therapist and the participant
89617345|NCT03416478||ctDNA test group|
89036335|NCT03685253|Experimental|Niagen®|Participants randomized to Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will take 250 mg capsules. Participants will take 2 capsules by mouth twice a day (1000 mg) for 6 months
89036336|NCT04673604|Placebo Comparator|Triple preservative-free therapy with placebo in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use placebo (artificial tears) in the evening (21:00) for 6 months. At the end of this period patients will be crossed over to the other therapy (cyclosporine 0.1% in the evening)
89617346|NCT03416400||Immature oocytes vitrified before In Vitro Maturation|Immature oocytes were vitrified using closed system vitrification. After warming, they were cultured during 36 hours in IVM medium and fixed for cellular analysis
89036337|NCT04673604|Active Comparator|Triple preservative-free therapy with cyclosporine 0.1% in the evening|In this arm subjects will be randomized to topical therapy comprising preservative-free tafluprost drops dosed in the evening (20:30) and dorzolamide/timolol fixed combination drops administered twice daily (8:00 and 20:00). Patients will use cyclosporine 0.1% drops in the evening (21:00) for 6 months. At the end of this period all patients will be crossed over to the other therapy (placebo in the evening)
89036338|NCT04602819|Experimental|Experimental|
89036339|NCT05348109||well fininshed cases|
89036340|NCT00532220|Active Comparator|A|
89617347|NCT03416400||Immature oocytes cultured in vitro before vitrification|Immature oocytes were cultured in vitro in IVM medium during 36 hours. After IVM, they were vitrified. After warming, they were fixed for cellular analysis.
89617348|NCT03416400||Fresh oocytes|Immature oocytes were cultured in vitro in IVM medium during 36 hours and subsequently, fixed for cellular analysis.
89617349|NCT00985959|Experimental|Phase I: JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
89617350|NCT00985959|Experimental|Phase I: JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
89617351|NCT00985959|Experimental|Phase I: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
89617352|NCT00985959|Experimental|Phase II: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
89617353|NCT05607849|Experimental|Decisional aid for organised cancer screening|Eligible women will receive an invitation letter for a mammography accompanied by a leaflet mentioning the existence of the DA and encouraging them to consult their GP to initiate the DMP. The GPs will receive a letter informing them of the letter sent to their patients inviting them to make use of the DA, of the DA itself, and presenting the different stages in the DMP with encouragement to implement it.
89617354|NCT05607849|No Intervention|Standard organised cancer screening|Eligible women will receive only invitation letters, in line with national standard practice
89617355|NCT00985725|Experimental|Active|SPD489
89617356|NCT00985725|Placebo Comparator|Placebo|Placebo
89617357|NCT01294306|Experimental|Treatment (Akt inhibitor MK2206, erlotinib hydrochloride)|Patients receive Akt inhibitor MK2206 PO QOD of a 28-day course, and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89617358|NCT00985491|Experimental|Device|All patients will be implanted with the Endobarrier Liner device.
89617359|NCT01351480|Other|abatacept|open label use of abatacept for 12 months
89617360|NCT03416829|Experimental|100% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (100% frequency - vibrotactile cueing every time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
89617361|NCT03416829|Experimental|25% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (25% frequency - vibrotactile cueing every 4th time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
89036341|NCT00532220|Placebo Comparator|B|
89036342|NCT00532584|Experimental|treatment with inhaled beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
89036343|NCT00532584|No Intervention|Control - healthy smokers|Group B will act as control and include healthy smokers who receive no treatment.
89036344|NCT00532584|No Intervention|control - healthy non-smokers|Group C will act as control and include healthy non-smokers who receive no treatment.
89036345|NCT03457259|Active Comparator|Midline|Pt. will receive midline catheters. The outcomes will be registered and some patients will be examined once weekly for thrombosis with ultrasound.
89036346|NCT03457259|Active Comparator|Conventional|Pt. will receive the conventional treatment (PVC and/or PICCline/CVC). The outcomes will be registered.
89036347|NCT04687332|Experimental|plasma exchange|patients were treated with plasma exchange
89036348|NCT04687332|Experimental|immunadsorption|patients were treated with immunadsorption
89036349|NCT05467709|Experimental|CTP-543|Subjects will receive a single 2 mg dose of midazolam on Day 1. Starting on Day 3, 12 mg dose of CTP-543 will be administered (q12 hrs) for 14 consecutive days (up to Day 16). On Day 16, subjects will be co-administered a single 2 mg midazolam dose along with the morning dose of CTP-543. The second dose of CTP-543 will be administered as scheduled on Day 16.
89036350|NCT00532623|Active Comparator|Combination|
89617362|NCT03416829|Experimental|Summary feedback|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (summary - no cueing, statistics shown every 2 minutes of voicing). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
89617363|NCT04348149|Experimental|Intervention group|
89617364|NCT04348149|No Intervention|Wait-list|
89617365|NCT05607693|Experimental|SHR3680|
89617366|NCT01352182|Experimental|Pioglitazone hydrochloride|Pioglitazone hydrochloride treatment group
89617367|NCT01352182|No Intervention|Normal standard care|Normal standard care control group
89617368|NCT00984867|Active Comparator|1|Dapagliflozin 10 mg tablet
89617369|NCT00984867|Placebo Comparator|2|Matching placebo tablet
89617370|NCT01294384|Experimental|New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
89617371|NCT01294384|Experimental|New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
88987325|NCT00140751|No Intervention|Continued|The patients included in this arm continue their treatment without any changes
88987326|NCT00140790|Active Comparator|Valsartan 40mg|Standard Dose valsartan
88987327|NCT00140790|Active Comparator|Valsartan 160mg|High Dose valsartan
88987328|NCT01245751|Experimental|Group 1: Booster Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
88987329|NCT01245751|Experimental|Group 2: First Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
88987330|NCT01245751|Experimental|Group 3: First Dose Participants ≥60 and <70 years of age|Herpes zoster history-negative participants ≥60 and <70 years of age who have never received Zoster Vaccine, Live
88987331|NCT01245751|Experimental|Group 4: First Dose Participants ≥50 and <60 years of age|Herpes zoster history-negative participants ≥50 and <60 years of age who have never received Zoster Vaccine, Live
88987332|NCT00132665|Active Comparator|1|Procedure/Surgery: A: Radiotherapy alone
88987333|NCT00132665|Experimental|2|Drug: B: CBDCA and Radiotherapy
88987334|NCT01245673|Experimental|Prevnar, T Cells, Lenalidomide, MAGE A-3|All patients will receive a priming immunization with a MAGE-A3/GM-CSF vaccine with adjuvant Hiltonol® (Poly-ICLC) along with the pneumococcal conjugate vaccine/PCV control vaccine about 10 days before a steady-state mononuclear cell apheresis. Patients will then undergo hematopoietic stem cell mobilization. All patients will receive high-dose melphalan followed by hematopoietic stem cells on day 0. On day +2, patients will receive anti-CD3/anti-CD28-costimulated autologous T cells. At days 14, 42, and 90, patients will receive MAGEA3/GM-CSF (+Hiltonol® Poly-ICLC) and PCV booster immunizations followed by restaging studies and immune assessments at day +100. At day 100, after immunizations and restaging, patients will start Revlamid® (Lenalidomide) maintenance therapy followed by 2 additional MAGE-A3 and PCV immunizations at days 120 and 150.
88987335|NCT01245283|Active Comparator|Wait-list Non-exercise Control (CON)|Subjects will continue to participate in their normal activities and clinical care during the four month study period if assigned to this group.
88987336|NCT01245283|Active Comparator|Concentric Focused RX (CRX)|Training protocol for 1 set of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
88987337|NCT01245283|Active Comparator|Eccentric Focused RX (ERX)|"The Human Dynamics Laboratory features prototype equipment that increases resistance loads during the eccentric phase of the contraction while assistance is provided by the machine during the concentric phase. One set of each exercise - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press."
88987338|NCT02261415|Experimental|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
88987339|NCT02261415|Placebo Comparator|Normal saline (0.9% sodium chloride)|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
88987340|NCT00132704||A|The experiments in Group A will be conducted in order to determine if human tumor microvascular endothelium displays similar dose parameters as mouse tumor endothelium, and if the microvascular endothelium of tumors of different types behaves in a similar fashion in its response to IR.
88987341|NCT00132704||B|The experiments in Group B will be conducted in order to determine if tumor endothelium isolated to near homogeneity demonstrates dose parameters similar to those used in single dose radiotherapy of brain tumors.
89617372|NCT01294384|Active Comparator|Refresh Tears®|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
89617373|NCT04759521||Group 1|Inactive HBsAg carriers were patients with HBsAg positivity for more than 6 months
89617374|NCT04759521||Group 2|Patients diagnosed with chronic hepatitis B were patients with HBsAg positivity for more than 6 months
89617375|NCT04759521||Group 3|The control group was composed of healthy individuals who were not infected with hepatitis B virus and did not fit any exclusion criteria.
89617376|NCT01257802|Active Comparator|LUPRON|Monthly depot leuprolide acetate 3.75 mg injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
89617377|NCT01257802|Placebo Comparator|Placebo|Monthly placebo injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses.
89617378|NCT05607303||Cases|MTF youth who will begin taking estrogen clinically in < 6 months with or without headache
89617379|NCT05607303||Controls|Cisgender males with or without headache
89617380|NCT01257880||Control (absence of PFO)|Persons who have migraine aura and no evidence of PFO, based on transcranial Doppler evaluation.
89617381|NCT01257880||Large PFO|Persons who have migraine aura and large PFO, as assessed by transcranial Doppler evaluation.
89617382|NCT02979964|Experimental|Arm 1, Positive Framing|All metrics in the audit and feedback practice reports presented with 'positive' framing, where the proportion of patients safe from risk (i.e., appropriate/desirable prescribing behaviours) is described.
89617383|NCT02979964|Experimental|Arm 2, Negative Framing|All metrics in the audit and feedback practice reports presented with 'negative' framing, where the proportion of patients at risk (i.e., due to inappropriate/undesirable prescribing behaviours) is described.
89617384|NCT02979964|Experimental|Arm 3, Top Quartile Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the 75th percentile for performance by physicians working in nursing homes in the province for each metric.
89617385|NCT02979964|Experimental|Arm 4, Average Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the average performance by physicians working in nursing homes in the province for each metric.
89617386|NCT00984009|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
89617387|NCT00984009|Experimental|Colchicine with Grapefruit Juice|colchicine pharmacokinetics in presence of grapefruit juice
89617388|NCT00983931|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
88987342|NCT01245049|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
88987343|NCT01245049|Active Comparator|REPEVAX GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Repevax™ vaccine co-administered with Priorix™ vaccine at Day 0. Repevax™ vaccine was administered intramuscularly in the deltoid muscle of the arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arn or as an intramuscular injection into the deltoid muscle of the right arm.
88987344|NCT00132743|Active Comparator|1|Optimal Medical Care
88987345|NCT00132743|Active Comparator|2|Optimal Medical Care and Supervised Exercise
88987346|NCT00132743|Active Comparator|3|Optimal Medical Care and Stent
88987347|NCT02087592|No Intervention|Control|Usual standard of care
88987348|NCT02087592|Experimental|Intervention|Usual standard of care plus structured physical exercise training plus mediterranean-style diet
88987349|NCT01244893|Other|Acuvue Advance Plus prePQ/Acuvue Advance Plus postPQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification will be worn first and Acuvue AdvancePlus silicone hydrogel contact lens manufactured after process qualification will be worn second.
88987350|NCT01244893|Other|Acuvue Advance Plus postPQ/Acuvue Advance Plus prePQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification worn first and Acuvue Advance Plus silicone hydrogel contact lens manufactured after process qualification worn second.
88987351|NCT00132821|Active Comparator|A|Bupropion
88987352|NCT00132821|Active Comparator|B|Transdermal nicotine patch
88987353|NCT00132821|Placebo Comparator|C|
88987354|NCT00132821|Placebo Comparator|D|
88987355|NCT01244815|Experimental|Asenapine 2.5 mg twice daily (BID)|Participants receive asenapine 2.5 mg BID for 21 days.
88987356|NCT01244815|Experimental|Asenapine 5.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive asenapine 5.0 mg BID for the remainder of the 21-day treatment period.
88987357|NCT01244815|Experimental|Asenapine 10.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. On Day 5 and 6 participants receive asenapine 5.0 mg BID. On Day 7 participants receive asenapine 5.0 mg in the morning and 10.0 mg in the evening. Participants receive asenapine 10.0 mg BID for the remainder of the 21-day treatment period.
88987358|NCT01244815|Placebo Comparator|Placebo|Participants receive placebo BID for 21 days.
88987359|NCT00132899|Active Comparator|Methotrexate|Methotrexate and infliximab combination
88987360|NCT00132899|Placebo Comparator|Placebo|Placebo plus infliximab combination
88987361|NCT02955706|Experimental|Active|Acetyl-L-carnitine (DongA ST)
88987362|NCT02955706|Placebo Comparator|placebo|Placebo of Acetyl-L-carnitine (DongA ST)
88987363|NCT00141024|Experimental|1|Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
89617389|NCT00983931|Experimental|Colchicine with Cyclosporine|-colchicine pharmacokinetics in presence of cyclosporine
89617390|NCT05606211||Long COVID|Individuals who have been infected with the corona virus and developed Long COVID
89617391|NCT05606211||No Long COVID|Individuals who have been infected with the corona virus and fully recovered.
89617392|NCT05604573||pancreatic cancer|patients with pancreatic cancer
89617393|NCT05604573||control|patients without any malignancy
89617394|NCT02984319|Active Comparator|Cherry|Cherry concentrate
89617395|NCT02984319|Placebo Comparator|Placebo|Placebo concentrate
89617396|NCT05604495||Adult patients with bronchiectasis (unknown cause)|Diagnosis of bronchiectasis was performed using chest HRCT scans in suspected patients with coughing and expectoration, or long durations of hemoptysis. High-resolution images were obtained during full inspiration at 1-mm collimation and 10-mm intervals from the apex to the base of the lungs. The presence of bronchiectasis was confirmed based on the following criteria: 1) lack of tapering in the bronchi; 2) dilation of the bronchi where the internal diameter was larger than that of the adjacent pulmonary artery; or 3) visualization of the peripheral bronchi within 1 cm of the costal pleural surface or the adjacent mediastinal pleural surface.
89617397|NCT00983853|Experimental|Part A|The dose of ribavirin used (fixed versus weight-based) is region dependent
89617398|NCT00983853|Experimental|Part B|The dose of ribavirin used (fixed versus weight-based) is region dependent
89617399|NCT05604261|Experimental|Anaprazole sodium 40 mg QD|
88987364|NCT00141024|Experimental|2|Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
88987365|NCT00141024|Experimental|3|In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
88987366|NCT00141024|Experimental|4|In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6.
88987367|NCT00141024|Experimental|5|In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
88987368|NCT01244425|Experimental|FS VH S/D 500 s-apr|Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), not to exceed 20mL per participant. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
88987369|NCT01244425|Active Comparator|Manual compression - Control|A dry surgical gauze swab will be used to apply by hand an even light pressure onto the oozing resection surface of the liver. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
88987370|NCT00133055|Experimental|Treatment booklet and telephone coaching|
88987371|NCT00133055|Other|Usual Care|
88987372|NCT00133094|Other|Arm 1|
88987373|NCT01154439|Experimental|Everolimus|Everolimus mice-regimen
88987374|NCT00133172|Experimental|1|Steroid rapid 5-day withdrawal
88987375|NCT00133172|Active Comparator|2|Standard steroid maintenance
88987376|NCT00133211|Active Comparator|1|Antiarrythmic drug treatment
88987377|NCT00133211|Experimental|2|
88987378|NCT00133250|Experimental|A|Abciximab
88987379|NCT00133250|Placebo Comparator|B|Heparin Sodium
88987380|NCT00144495|Experimental|1|patient whose ΔHb is less than 1.0g/dL on the day of 7th administration
88987381|NCT00144495|Experimental|2|patient whose ΔHb is 1.0g/dL or above on the day of 7th administration
88987382|NCT00144534|Experimental|1|
88987383|NCT00133406|Experimental|a|oral glutamine with juice for 10 days
88987384|NCT00133406|Experimental|b|PO vit A q 4 mo for 1 year plus zinc placebo
88987385|NCT00133406|Active Comparator|c|Zinc 40 mg twice weekly Plus Vitamin A Placebo for one year
88987386|NCT00133406|Placebo Comparator|d|oral glycine with juice daily for 10 days
88987387|NCT00133406|Placebo Comparator|e|Vitamin A Placebo plus Zinc Placebo for one year
88987388|NCT00133406|Experimental|f|Vitamin A q 4 months and PO Zinc for 1 year
88987389|NCT00133445|Experimental|Group A|Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
88987390|NCT00133445|Active Comparator|Group B|Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
88987391|NCT00144612|Experimental|1|
88987392|NCT00133523|Placebo Comparator|Group 4: Placebo: Intramuscular|N=165 subjects administered placebo intramuscularly.
88987393|NCT00133523|Placebo Comparator|Group 3: Placebo: Nasal|N=165 subjects administered placebo intranasally.
88987394|NCT00133523|Experimental|Group 1: FluMist™|N=825 subjects administered live attenuated vaccine intranasally.
88987395|NCT00133523|Experimental|Group 2: Fluzone®/Fluvirin|N=825 subjects administered inactivated vaccine intramuscularly.
88987396|NCT00144651|Experimental|1|
88987397|NCT00404391|Experimental|Arm 1: hydrocodone/acetaminophen extended release|
88987398|NCT00404391|Experimental|Arm 2: hydrocodone/acetaminophen extended release|
88987399|NCT00404391|Placebo Comparator|placebo|
88987400|NCT04726904|Other|Conventional lead placement|The cadaver is placed in the prone position. The exact location for insertion of the needle is defined with the conventional technique.
88987401|NCT00404469|Active Comparator|CORT|Peritendinous corticosteroid injections at 0 and 4 weeks. 12 weeks total
88987402|NCT00404469|Experimental|ECC|12 weeks of eccentric unilateral decline squats
88987403|NCT00404469|Experimental|HSR|Heavy slow resistance training. 3/week. 12 weeks
88987404|NCT00133601|Experimental|1|CBT-1
88987405|NCT00133601|No Intervention|2|Control Group
88987406|NCT00144807|Experimental|R-AC|rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation
88987407|NCT04726917||Patients with COPD|Patients qualified for 3-week in-hospital pulmonary rehabilitation
88987408|NCT00133718|Other|Structured multi intervention|Structured multi intervention to reach predefined glycemic and blood pressure goals as well as activity and weight goal
88987409|NCT00133718|Other|Standard of care|Standard care with or without structured care according to national guidelines
88987410|NCT01244191|Experimental|Tivantinib and erlotinib|Tivantinib 720 mg daily (360 mg twice a day) in combination with 150 mg of erlotinib, given once a day
88987411|NCT01244191|Active Comparator|Placebo and erlotinib|Tivantinib placebo given twice a day in combination with 150 mg of erlotinib, given once a day
88987412|NCT00144846|Other|Arm 1|
88987413|NCT00133796|Experimental|Heceptin|Herceptin administered to enrolled subjects
88987414|NCT00144885|No Intervention|1|
88987415|NCT00133913||Cohort|Patients with measurable metastatic colorectal cancer about to start a new line of chemotherapy.
88987416|NCT00141531|Active Comparator|Apaziquone|
88987417|NCT01244035|Experimental|Part I - Sequence ABC|Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3
88987418|NCT01244035|Experimental|Part I - Sequence ACB|Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3
88987419|NCT01244035|Experimental|Part I - Sequence BCA|Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3
88987420|NCT01244035|Experimental|Part I - Sequence BAC|Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3
88987421|NCT01244035|Experimental|Part I - Sequence CAB|Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3
88987422|NCT01244035|Experimental|Part I - Sequence CBA|Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3
89617400|NCT05604261|Experimental|Anaprazole sodium 60 mg QD|
89617401|NCT05604261|Active Comparator|Rabeprazole sodium 20 mg QD|
89617402|NCT05604105||Sample of the Egyptian population|"Participants of Giza residents.~Inclusion criteria:~• Adult individuals (Age>18 years).~Exclusion criteria:~Dental students or dental practitioners; as awareness of the disease is an integral part of their profession.~Oral cancer patients: Individuals who experience currently or previously having oral cancer.~Individuals with mental or communication disabilities."
89617403|NCT04759287|Active Comparator|VS group|include patients undergoing awake intubation using the C-MAC VS
89617404|NCT04759287|Placebo Comparator|FOB group|will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
89617405|NCT05603013|Experimental|Vinorelbine Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2
89617406|NCT00983073|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
89617407|NCT05602857|Experimental|Balance Training|Participants will follow a home-based BT intervention specifically designed by the investigators to improve postural control and balance in children. The BT program will consist of training sessions every other day (3 days a week) and a total of up to 45 minutes of balance exercises per week (15 minutes or less per session), addressing static balance (i.e., standing on one foot) and dynamic balance (i.e., balancing a book on your head while walking).
89617408|NCT05602857|Active Comparator|Music Training|Participants will follow a home-based MT intervention designed to provide enjoyable experiences to the child participants. The sessions will occur every other day (3 days a week) for a total of up to 45 minutes per week (15 minutes or less per session) for 12 weeks. The MT program will consist of a different selection of music videos each week, including a mix of familiar and new tunes.
89617409|NCT05602857|No Intervention|Business as usual|Children assigned to this control group will follow their usual activities during the 12 weeks between initial assessment and the second assessment.
89617410|NCT00982137|Experimental|ChimeriVax™-JE then STAMARIL®|Participants will receive ChimeriVax™-JE on Day 0 and STAMARIL® on Day 30
89617411|NCT00982137|Experimental|STAMARIL® then ChimeriVax™-JE|Participants will receive STAMARIL® on Day 0 and ChimeriVax™-JE on Day 30
89617412|NCT00982137|Experimental|ChimeriVax™-JE and STAMARIL®, then Diluent|Participants will receive ChimeriVax™-JE and STAMARIL® on Day 0 and diluent on Day 30.
89617413|NCT00982137|Experimental|Diluent then ChimeriVax™-JE and STAMARIL®|Participants will receive Diluent on Day 0 and ChimeriVax™-JE and STAMARIL® on Day 30.
89617414|NCT05603715|Other|Pyridostigmine Bromide|Open Label
89617415|NCT04394793|Experimental|Study Arm|
89617416|NCT03047031||Group A|Patients who started treatment with nintedanib after 23rd January, 2017 and have permanently discontinued the drug (as decided by the investigator) at the time of participation in the active surveillance.
89617417|NCT03047031||Group B|Patients who started treatment with nintedanib after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance.
89617418|NCT03047031||Group C|Patients who have been newly prescribed nintedanib at the time of participation in the active surveillance
89617419|NCT00981747|Experimental|All study participants|Study participants are patients that have been diagnosed with idiopathic pulmonary fibrosis (IPF).
89617420|NCT05602545|Experimental|Test-1|patients with peri-implantitis
89617421|NCT05602545|Experimental|Test-2|patients with peri-implant mucositis
89617422|NCT05602545|Other|control|patients with peri-implant health
89617423|NCT04394403|Experimental|immediate guided self-help|In this condition, individuals will be given access to material and exercises based on CBT to reduce their stress
89617424|NCT04394403|No Intervention|waitlist|Individuals in this condition will wait 6 weeks before they are provided access to the guided self-help program
88987423|NCT01244035|Experimental|Part II - Sequence DEF|Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3
89617425|NCT03030183|Experimental|Zilucoplan (RA101495)|Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
89617426|NCT03029169|Active Comparator|Propafenone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 35-70 mg intravenous propafenone followed by continuous infusion of 400-840 mg/24h."
89617427|NCT03029169|Active Comparator|Amiodarone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 150-300 mg of intravenous amiodarone followed by continuous infusion of 600-1800 mg/24h."
89617428|NCT04275219|Experimental|Tong-Fu-Xing-Shen herbal formula|Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12days.
89617429|NCT04275219|Placebo Comparator|The Placebo of Tong-Fu-Xing-Shen herbal formula|The Placebo of Tong-Fu-Xing-Shen herbal formula prescription (0.4g*36 capsules/bottle，1-4 capsules each time, three times a day.) for 10-12 days.
89617430|NCT05609955|Experimental|MgSO4|The treatment group received intravenous magnesium sulfate therapy with a 20% magnesium sulfate regimen, 39mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously.
89617431|NCT05609955|Placebo Comparator|Placebo|The treatment group who received intravenous placebo therapy with a regimen of 100 ml NaCl in 1 hour intravenous
89617432|NCT04129905|Experimental|Symptomatic HCM patients|30 subjects (25-26 sarcomeric, 4-5 Fabry).
89617433|NCT04129905|Active Comparator|Healthy controls subjects|10 subjects (matched in age and sex to HCM patients) to obtain reference values of endothelial dysfunction.
89617434|NCT01295710|Active Comparator|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
89617435|NCT01295710|Placebo Comparator|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
88987424|NCT01244035|Experimental|Part II - Sequence DFE|Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3
89617436|NCT01258504||CYP2C9 wild type|"CYP2C9 wild type =extensive metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
89617437|NCT01258504||CYP2C9 mutant|"CYP2C9 *2/*2 or 2*/*3 or *3/*3 = poor metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
89617438|NCT01258582|Experimental|Oral HIV testing|
88987425|NCT01244035|Experimental|Part II - Sequence EFD|Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3
88987426|NCT01244035|Experimental|Part II - Sequence EDF|Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3
88987427|NCT01244035|Experimental|Part II - Sequence FDE|Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3
88987428|NCT01244035|Experimental|Part II -Sequence FED|Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3
88987429|NCT00134069|Experimental|Treatment (sorafenib, irinotecan, cetuximab)|Patients will receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 8 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 3-6. Patients will then receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 6 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 1-4. Treatment may repeat every 6 weeks for as long as benefit is shown.
88987430|NCT00405600|Active Comparator|Device|Device used in surgery with or without instrumentation
88987431|NCT00141648|Experimental|1|Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
89617439|NCT01258582|Active Comparator|Fingerstick HIV testing|
89617440|NCT04351828||Celiac patients compliant to gluten-free diet (GFD)|People with celiac disease who compliant to gluten-free diet (GFD) when they accepted in the study
89617441|NCT04351828||Celiac patients non-compliant to gluten-free diet(NGFD)|People with celiac disease who noncompliant to the gluten-free diet (NGFD) group when they accepted in the study
89617442|NCT01259128|Experimental|SER120 500 ng/day|SER120 Level 1 (500 ng/day)
89617443|NCT01259128|Experimental|SER120 750 ng/day|SER120 Level 2 (750 ng/day)
89617444|NCT01353196||stenosis|carotid stenosis
89617445|NCT01353196||no stenosis|no stenosis
89617446|NCT01353976|Experimental|Econazole Nitrate Foam 1%|Study medication
89617447|NCT01353976|Placebo Comparator|Vehicle Foam|Placebo medication
89617448|NCT01354444|Active Comparator|Carvedilol|Carvedilol is a is a beta-blocker. Beta-blockers are generally used to reduce the workload on the heart and help it to beat more regularly.
89617449|NCT01354444|Placebo Comparator|Placebo|Non active substance
89617450|NCT01259440|Active Comparator|Video Teleconferencing Care|Video teleconferencing care
89617451|NCT01259440|Placebo Comparator|Usual Care|Usual Care
89617452|NCT03009526|Active Comparator|Sulfadoxine-pyrimethamine|Intermittent preventive treatment with Sulfadoxine-pyrimethamine: Monthly dose of 3 co-formulated tablets containing 500 mg sulfadoxine and 25 mg pyrimethamine
89617453|NCT03009526|Experimental|dihydroartemisinin-piperaquine|"Intermittent preventive treatment with dihydroartemisinin-piperaquine: Monthly course of daily doses of co-formulated DP tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine, dosed based on the woman's weight, for 3 days:~24-35.9 kg: Two tablets~36-59.9 kg: Three tablets~60-79.9 kg: Four tablets~≥80 kg: Five tablets"
89617454|NCT01259596|Active Comparator|Cognitive behavioral therapy|Cognitive-behavioral therapy consists of psychoeducation, relaxation techniques, cognitive therapy, problem-solving, thought stopping, behavioral activation, exposure, coping with pain, sleep, and relapse prevention
89617455|NCT01259596|Active Comparator|Nondirective supportive therapy|Nondirective supportive therapy consists of providing a warm and accepting environment in which a person can reflect on their experiences, thoughts, and feelings
89617456|NCT01354990||Participants treated with sitagliptin|
89617457|NCT01355224|No Intervention|No risk feedback|No obesity risk information given (control)
89617458|NCT01355224|Experimental|Genetic risk feedback|Only personal genetic risk information provided
88987432|NCT00405678|Experimental|1|Subjects receiving chemo and exercise training
89617459|NCT01355224|Experimental|Lifestyle risk feedback|Only personal lifestyle risk information provided
89617460|NCT01355224|Experimental|Both genetic or lifestyle risk feedback|Personal genetic and lifestyle information provided
89617461|NCT01260454|Experimental|Qutenza patch|All participants actively treated with Qutenza
89617462|NCT01296646|Active Comparator|Arm 1|Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
89617463|NCT01296646|Active Comparator|Arm 2|Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
89617464|NCT01296646|Active Comparator|Arm 3|Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions
88987433|NCT00405678|Experimental|2|Subjects receiving chemo only
88987434|NCT00141687|Experimental|Early External Cephalic Version Group|Early external cephalic version (ECV) procedure performed between 34 weeks and 0/7 days and 35 weeks and 6/7 days of gestation
88987435|NCT00141687|Active Comparator|Delayed External Cephalic Version Group|Delayed external cephalic version (ECV) procedure performed at or after 37 weeks and 0/7 days of gestation
89617465|NCT01296646|Active Comparator|Arm 4|Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions
89617466|NCT01297348||Lybrel®|Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism [VTE] and women not diagnosed with VTE).
89617467|NCT01297348||Other OCs containing 20μg of ethinyl estradiol|Current users of oral contraceptives containing 20μg of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)
89617468|NCT01856309|Experimental|Sirukumab 100 mg|
89617469|NCT01856309|Experimental|Sirukumab 50 mg / placebo|
89617470|NCT01260688|Experimental|Arm I|Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89617471|NCT01260688|Experimental|Arm II|Patients receive cediranib maleate as in arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89617472|NCT01355458|Experimental|CD07805/47 gel|
89617473|NCT01355458|Placebo Comparator|Placebo|
89617474|NCT01298128|Experimental|NuvaRing|NuvaRing for IVF pre-treatment
89617475|NCT01298128|Active Comparator|Combined oral contraceptive pill|OCP for IVF pre-treatment
89617476|NCT01298752|Experimental|Mapracorat|Mapracorat ophthalmic suspension
89617477|NCT01298752|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
89617478|NCT02199964|Experimental|Cyclosporin 0.05% emulsion|used in the eye 4 times a day
89617479|NCT02199964|Active Comparator|Endura Refresh, Artificial Tears|Over the Counter artificial tears used in the eye 4 times a day
89617480|NCT01299454|Active Comparator|Normal|
89617481|NCT01299454|Active Comparator|Mild|
89617482|NCT01299454|Active Comparator|Moderate|
89617483|NCT01299454|Active Comparator|Severe|
89617484|NCT02323048|Experimental|Paired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
89617485|NCT02323048|Experimental|Paired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
89617486|NCT02323048|Experimental|Paired no reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
89617487|NCT02323048|Experimental|Unpaired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
89617488|NCT02323048|Experimental|Unpaired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
89617489|NCT01265446|Experimental|Lidocaine 8mg +CPC 2mg|one single dose
89617490|NCT01265446|Active Comparator|Lidocaine 1mg + CPC 2mg|one single dose
89617491|NCT01265524|Active Comparator|CLP|Investigational drug: 15 g CLP per day given as capsules
89617492|NCT01265524|Placebo Comparator|Placebo|Placebo, capsules
89617493|NCT01299610|Experimental|GW870086 2.0% &amp; 0.2%|GW870086 2.0%, GW870086 0.2% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
89617494|NCT01299610|Experimental|GW870086 2.0% & FP 0.05%|GW870086 2.0%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
89617495|NCT01299610|Experimental|GW870086 0.2% & FP 0.05%|GW870086 0.2%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
89617496|NCT01300624|Experimental|Verb Network Strengthening Treatment|Verb Network Strengthening Treatment (VNeST) tasks involve the retrieval of nouns related to a target verb. For example, for the verb measure, participants would come up with people who measure and what they measure (e.g., carpenter/lumber, chef/sugar). They would then answer questions related to why, where, and when these things might occur (e.g., for carpenter/measure, they might say to get the right length of board, (why) at a construction site, (where) and when building a house (where). Cues and assistance are provided to the participants when they are unable to complete any given task. As the participants improve, cues are reduced.
89617497|NCT04352062|Experimental|Treatment Group|Melatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)
89617498|NCT04352062|Placebo Comparator|Placebo|1 tablet twice daily (period 6 months)
89617499|NCT04352062|Other|Helicobacter pylori infected group|Pantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
89617500|NCT01302808|Experimental|Cohort 1 (Erlotinib plus Romidepsin (8 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
89617501|NCT01302808|Experimental|Cohort 2 (Erlotinib plus Romidepsin (10 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
89617502|NCT01302808|Experimental|Cohort 3 (Erlotinib plus Romidepsin (10 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
89617503|NCT01302808|Experimental|Cohort 4 (Erlotinib plus Romidepsin (8 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
88987436|NCT04710810|Experimental|Experimental|Patients receive group and rhesus compatible UCB cells through intravenous bolus injections (4 injections at 2-week intervals) after pre-medication with Clemastine (0.025 mg/kg body weight, intravenously). One dose is 250±10 x 10⁶ viable cells per sample.
88987437|NCT04710810|No Intervention|Control|Patients receives standard therapy (applied behavioral analysis, speech therapy).
88987438|NCT00134420|Active Comparator|Growth Hormone Treatment|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done 1st for eligibility and this group received GH (growth hormone) (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)immediately after randomization
88987439|NCT00134420|Other|GH treatment delayed by one year|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done first for eligibility and this group received growth hormone (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)after one year of observation
89617504|NCT01267240|Experimental|Arm I (capecitabine, vorinostat)|Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89617505|NCT01357564|Experimental|Tailored Activity Program|Occupational therapists assess the person's home environment, preserved capabilities, daily routines, interests and the caregiver's readiness and ability to use activities. Activities are developed that reflect the Veteran's previous or current interests and are modified to match their preserved capabilities without taxing the most impaired areas of cognition (e.g., memory, new learning). TAP-VA provides caregivers with the knowledge and skills to use activities. The overall goal is to provide predictability, familiarity, and structure in the daily life of the Veteran and establish a level of environmental stimulation appropriate to that person's abilities.
89617506|NCT01357564|Active Comparator|Attention Control|Caregivers in this group receive bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers are provided important information about dementia and strategies for disease management. Each telephone contact begins with a brief overview of the specific purpose of the session, followed by a description of the key facts about the session topic, and concludes with a question and answer period. The attention control group intervention is delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
88987440|NCT00152256|Experimental|1|
88987441|NCT00152256|Experimental|2|
89617507|NCT01855919|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for first 3 days and 20 mg for last 4 days of week.
89617508|NCT01855919|Placebo Comparator|Placebo|Placebo administered orally once every day for 15 weeks.
89617509|NCT01357720|Experimental|Quinvaxem|
89617510|NCT01357720|Active Comparator|Tritanrix Hib/HepB + Quinvaxem|
89617511|NCT01871519|Other|Balloon Kyphoplasty|This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.
88987442|NCT00152256|Placebo Comparator|3|
88987443|NCT00134537|Experimental|1|Interspinous process and dynamic stabilization
88987444|NCT00134537|Active Comparator|2|Conservative Care
88987445|NCT00152295|Experimental|1|
88987446|NCT00134615|Experimental|RQP-MH|These participants receive the RQP-MH intervention
89617512|NCT01871285|Experimental|MSE Dose Group 1|Morning and evening dose of buprenorphine HCl buccal film (300 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
88987447|NCT00134654|Active Comparator|Group A|Premarin once a day
89617513|NCT01871285|Experimental|MSE Dose Group 2|Morning and evening dose of buprenorphine HCl buccal film (450 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
89617514|NCT01358266|Active Comparator|Ophthalmic solution low dose|
89617515|NCT01358266|Active Comparator|Ophthalmic solution medium dose|
89617516|NCT01358266|Active Comparator|Ophthalmic solution high dose|
89617517|NCT01870973|Experimental|root canal treatment|root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin, if allergic 300 mg clindamycin)
89617518|NCT01870973|Active Comparator|no root canal treatment|no root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin if allergic 300 mg clindamycin)
89617519|NCT01267864|Active Comparator|Metoclopramide|Metoclopramide 10mg IVSS
89617520|NCT01267864|Active Comparator|Ketorolac|Ketorolac 30mg IV
89617521|NCT01267864|Active Comparator|Valproate|1gm IV
89617522|NCT01854827|Experimental|IVIG active treatment|Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE
89617523|NCT04415255|Experimental|EPABI & IABPI|extrapleural autologous blood injection (EPABI) along with intraparenchymal autologous blood patch injection (IABPI)
88987448|NCT00134654|Active Comparator|Group B|Premarin 3 times a day
88987449|NCT02964455|Experimental|Docetaxel + Nedaplatin + Radiotherapy|Docetaxel and nedaplatin 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation.
88987450|NCT00134966|Experimental|1|
88987451|NCT00134966|Active Comparator|2|
88987452|NCT00152568|Experimental|Child Passenger Safety Technician services|
88987453|NCT00135005|Experimental|AMN107 + STI571|
88987454|NCT00142233|Experimental|ANTOX (vers.)1.2|"Adults and children aged 10+ will take two ANTOX (vers)1.2 tablets three times per day. (Antioxidant treatment: daily: 300 μg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine) plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one ANTOX (vers)1.2 tablet three times daily (Antioxidant treatment: daily: 150 μg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine) plus one placebo Magnesiocard (2.5 mmol) tablet three times a day."
88987455|NCT00142233|Experimental|Magnesium|"Adults and children aged 10+ will take two Magnesiocard (2.5 mmol) tablets three times per day (total dose: 15 mmol = 365 mg per day) plus two placebo ANTOX (vers)1.2 tablets three times a day.~Children aged five to nine years of age will take one Magnesiocard (2.5 mmol) tablet three times a day (total dose: 7.5 mmol = 182 mg per day) plus one placebo ANTOX (vers)1.2 tablet three times a day."
88987456|NCT00142233|Placebo Comparator|Placebo|"Adults and children aged 10+ will take two placebo ANTOX (vers)1.2 tablets three times a day, plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one placebo ANTOX (vers)1.2 tablet three times a day, plus one placebo Magnesiocard (2.5 mmol) tablet three times per day."
88987457|NCT00135083|Experimental|1|"Once daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch"
88987458|NCT00135083|Experimental|2|"Twice daily:~Insulin glulisine Dosing: Supper & Lunch, Lunch & Breakfast, Breakfast & Supper~Monitoring Needed at: Bedtime & Pre-Supper, Pre-Supper & Pre-Lunch, Pre-Lunch & Bedtime"
88987459|NCT00135083|Experimental|3|"Twice daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch"
88987460|NCT04725357|Experimental|Arthroscopic Labral Repair + postoperative Meloxicam|After surgery participants will receive a prescription of 20 pills of 15 mg Meloxicam
88987461|NCT04725357|Active Comparator|Arthroscopic Labral Repair without Meloxicam|After surgery participants will receive a prescription of 20 pills of 5/300 mg vicodin (hydrocodone/acetaminophen)
88987462|NCT00135122|Placebo Comparator|2|Placebo in six days
88987463|NCT00135278|Other|CSF Drainage|
88987464|NCT00135278|Other|No CSF Drainage|
88987465|NCT00142428|Experimental|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
89617524|NCT04415255|Active Comparator|IABPI-alone|intraparenchymal autologous blood patch injection (IABPI)
89617525|NCT04414709|Experimental|Two short implants|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
89617526|NCT04414709|Active Comparator|Single short implant|DENTIUM superline implant fixture is characterized by sandblasted with large grits and acid etched surface treatment (S.L.A). SLA surface allows good bone-implant contact with good clinical performance, maintaining crestal bone margin. Short Implants of 7.0 mm length and 4.5 mm diameter are to be used. The Short Implants are characterized by 1.5mm supra-bony smooth collar, and 5.5mm infra-bony surface treated double threaded titanium.
89617527|NCT02196688|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
89617528|NCT02196688|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
89617529|NCT01359748|Other|Wrist Size <= 14.25 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
89617530|NCT01359748|Other|Wrist Size >=14.26 <16.50 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
89617531|NCT01359748|Other|Wrist size >=16.5 <17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
89617532|NCT01359748|Other|Wrist Size >=17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
89617533|NCT03009448||Late onset depression|
89617534|NCT01360450|Experimental|Treatment|Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
89617535|NCT01360450|Placebo Comparator|Control|Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally
89617536|NCT03009214|Experimental|AMC303|"cohorts will receive ascending doses of AMC303 as intravenous infusion~Planned doses are:~0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg"
89617537|NCT01268644|Experimental|active open label Leptin|Active open label Leptin for type 1 Diabetes
89617538|NCT01303744|Experimental|CHF 5074 1x|oral tablet, multidose
89617539|NCT01303744|Experimental|CHF 5074 2x|oral tablet, multidose
89617540|NCT01303744|Experimental|CHF 5074 3x|oral tablet, multidose
89617541|NCT01303744|Placebo Comparator|Placebo|placebo, oral tablet, multidose
89617542|NCT01361620|Other|Aspirin|All subjects took 7-10 days of 81 mg aspirin
88987466|NCT00135551|Active Comparator|angiotensin receptor blockers|benidipine+angiotensin receptor blockers, titlation scheme
88987467|NCT00135551|Active Comparator|β-blockers|benidipie+β-blockers, titlation scheme
88987468|NCT00135551|Active Comparator|thiazide diuretics|benidipine+thiazide diuretics, titlation scheme
88987469|NCT00135590|Experimental|1|Protein pulse-feeding
88987470|NCT00135590|Active Comparator|2|Spread diet
88987471|NCT00135785|Active Comparator|1|Bupropion
88987472|NCT00135785|Placebo Comparator|2|Placebo
88987473|NCT00159081|Experimental|1|Maintenance antipsychotic treatment with risperidone
88987474|NCT00159081|Active Comparator|2|Maintenance antipsychotic treatment with haloperidol in low-dose
88987475|NCT00159120|Active Comparator|1|further maintenance antipsychotic treatment and prodrome-based early intervention
88987476|NCT00159120|Experimental|2|stepwise drug discontinuation (after 1 year maintenance antipsychotic treatment) and prodrome-based early intervention
88987477|NCT00135902|Active Comparator|17P plus Omega-3 Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus Omega 3 supplements, 4 capsules per day for up to 5 weeks. Each capsule contained 200 mg of docosahexaenoic acid (DHA) and 300 mg of eicosapentaenoic acid (EPA).
88987478|NCT00135902|Placebo Comparator|17P plus Placebo Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus placebo capsules, 4 capsules per day for up to 5 weeks
88987479|NCT00159198||1|Patients with frontotemporal dementia and amyotrophic lateral sclerosis
88987480|NCT00159198||2|Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis
88987481|NCT04726670||A Comparison of Pain Levels|A Comparison of Pain Levels at different time intervals according to the Irrigation Activation Protocols
89617543|NCT01361854|Experimental|polysomnography for suspicion of SDB|adults, suspects of suffering from sleep disordered-breathing, who must undergo a diagnostic polysomnography
89617544|NCT01269736|Experimental|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
89617545|NCT01269736|No Intervention|Control|Usual in-service education for nurses
89617546|NCT01305772|Experimental|Surgery|Patients who underwent surgery after research PET/CT scans and subsequent radiation therapy with panitumumab administration
89617547|NCT01305772|Active Comparator|Radiation Therapy|Patients who underwent radiation therapy only, in conjunction with panitumumab therapy.
89617548|NCT01270126|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
89617549|NCT01270126|No Intervention|Sham stimulation (placebo condition)|A clicking sound was presented and the same electrode montage set-up was used during rtACS- and placebo-stimulation, except that placebo patients received no current (stimulator turned off)
89617550|NCT01270516|Placebo Comparator|Control, to be given saline solution|Intervention: This group will be given saline (30 ml every 12 hours) for 10 days
89617551|NCT01270516|Experimental|EPA, eicosapentaenoic acid|This group will be given 1000 mg EPA every 12 hours for 10 days
89617552|NCT01270516|Experimental|HMB, hydroxymethylbutyrate|This arm will be given HMB (1500 mg) every 12 hours for 10 days.
89617553|NCT01270516|Experimental|EPA and HMB|Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.
89617554|NCT01271452|Active Comparator|Vistabel®|botulinum toxin type A (Vistabel®)
88987482|NCT04726670||The evaluation of postoperative pain (Mean Rank) within the group according to time periods|The evaluation of postoperative pain (Mean Rank) within the group according to time periods
88987483|NCT00135941|Experimental|1|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
89617555|NCT01271452|Active Comparator|Bocouture®|botulinum toxin type A (Bocouture®)
89617556|NCT01271686|Experimental|0.01% bimatoprost|bimatoprost 0.01% one time per day at bedtime for 4 weeks.
89617557|NCT01362946|Experimental|Reward-Emphasized treatment|This treatment consisted of behavior therapy modified to match the unique learning styles of children with CPCU. This was accomplished by emphasizing rewards and de-emphasizing punishments. This treatment was administered using a summer treatment program.
89617558|NCT01362946|Active Comparator|Standard treatment|This treatment consisted of standard behavior therapy, in which reward and punishment components were used in a balanced manner, as is typically done in outpatient settings. This treatment was administered using a summer treatment program.
89617559|NCT01854047|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
89617560|NCT01854047|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
89617561|NCT01854047|Experimental|Dupilumab 300 mg q4w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
89617562|NCT01854047|Experimental|Dupilumab 200 mg q4w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
89617563|NCT01854047|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
89617564|NCT01363258|Experimental|Care-resistant mouth care (MOUTh)|These nursing home residents with dementia receive mouth care from study personnel who use strategies to reduce care-resistant behavior (Managing Oral Hygiene Using Threat Reduction or MOUTh) while providing evidence-based mouth care.
89617565|NCT01363258|Active Comparator|Evidence Base Mouth Care|Nursing home residents with dementia received mouth care from study personnel who were trained in evidence-based mouth care only.
89617566|NCT01363492|Experimental|Replagal 0.2 mg/kg every other week (EOW)|
89617567|NCT01307098|Experimental|Sebelipase alfa 0.35 mg/kg|Cohort 1: Participants were administered once weekly (qw) infusions of 0.35 mg/kg sebelipase alfa.
89617568|NCT01307098|Experimental|Sebelipase alfa 1 mg/kg|Cohort 2: Participants were administered qw infusions of 1 mg/kg sebelipase alfa.
89617569|NCT01307098|Experimental|Sebelipase alfa 3 mg/kg|Cohort 3: Participants were administered qw infusions of 3 mg/kg sebelipase alfa.
89617570|NCT01272076||Dry AMD and geographic atrophy|Patients diagnosed with dry AMD and geographic atrophy
89617571|NCT01870739|Experimental|sacubitril/valsartan (LCZ696)|"Single drug treatment period: Patients received LCZ696 200mg once daily (q.d.) + placebo to 20 mg olmesartan q.d for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (400 mg qd LCZ696 + placebo to 40 mg qd olmesartan) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
89036351|NCT00532623|Active Comparator|Seqeuntial|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
89036352|NCT04687488|Other|Fluorescein|"Fluorescein dye and ultraviolet (UV) light are used to assess the aerosol contamination during endonasal investigations. We will dilute medical fluorescein vials (FLUORESCEINE 10% Faure; SERB, 40 Avenue George V, 75008 Paris, France) to a concentration of 1% fluorescein in 10ml of normal saline solution. Next, we swab the nasal cavity with a compress soaked (15 droplets with a pipette) in fluorescein and we apply 5 droplets into the nasal cavity and nasopharynx at the beginning of the investigation.~After coating the nose with fluorescein, the patient will wear a surgical nose-mouth mask and will be positioned in the bed used for HRiM or MII-pH probe insertion. As the MII-pH probe is removed 24h after placement of the probe, prior to this activity the same fluorescein application method (fluorescein drops and a cotton swab) will be used."
89036353|NCT00532662|Experimental|1|epidural s(+)-ketamine for supplementation of caudal anesthesia
89036354|NCT00532662|Active Comparator|2|intravenous ketamine for supplementation of caudal anesthesia
89036355|NCT00532337|Placebo Comparator|P|
89036356|NCT00532337|Experimental|E1|
89036357|NCT00532337|Experimental|E2|
89036358|NCT00532337|Experimental|E3|
89036359|NCT00532337|Active Comparator|A|
89036360|NCT05467436|Experimental|Experimental group|"Subject will receive standard prescription for local anesthetics, IV sedation drugs and analgesics at the time of first surgery.~Subject will receive individually tailored-prescription for local anesthetics, IV sedation drugs and analgesics, based upon pharmacogenomic assessment at the time of second surgery."
89617572|NCT01870739|Active Comparator|olmesartan|"Single drug treatment period: Patients received 20 mg olmesartan q.d + placebo to LCZ696 200mg once daily (q.d.) for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (40 mg olmesartan q.d + placebo to 400 mg qd LCZ696) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
89617573|NCT01272388|Active Comparator|Tadalafil|
89617574|NCT01272388|Placebo Comparator|Placebo|
89617575|NCT01613417|Active Comparator|MRI with Gadoteridol|MRI after 0.1 mmol/kg IV ProHance, then with 0.1 mmol/kg Gadovist/Gadavist. MRI performed after both agents with identical sequences.
89617576|NCT01613417|Active Comparator|MRI with Gadobutrol|MRI after 0.1 mmol/kg IV Gadovist/Gadavist, then with 0.1 mmol/kg ProHance. MRI performed after both agents with identical sequences.
89617577|NCT01364740|Experimental|PMP-300E, In-Lab PSG|PMP-300E, A 7-channel (nasal pressure, effort, snoring, SpO2, pulse rate, body position and movement) Level 3 portable monitor (11.2 x 3.3 x 5.5cm, 80g, Pacific Medico Co., LTD) to measure sleep-related breathing will be tested against conventional gold-standard In-Lab Polysomnography (sleep study)
89617578|NCT04414865||single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
89617579|NCT01364896||Inflammatory bowel disease, Immunosuppressive agent|Men and women 18 years + with a histological diagnosis of IBD (ulcerative colitis or Crohn's disease) who are undergoing a colonoscopy prior to starting a non-corticosteroid immunosuppressive agent
89617580|NCT01870583|Active Comparator|Combination iodine and chlorhexidine|The combincation skin preparation will utilize the iodine based preparation first followed by the chlorhexidine based skin preparation prior to cesarean delivery.
89036361|NCT05467319|Experimental|Ferric derisomaltose|1000mg of intravenous Ferric derisomaltose/Iron isomaltoside in 100mL of normal saline will be administered 21-90 days prior to planned surgery for gynecologic malignancy as a single dose.
89036362|NCT05467319|Placebo Comparator|Placebo|100mL of normal saline will be administered 21-90 days prior to planned surgery for gynecologic malignancy as a single dose.
89036363|NCT04590300|Other|Schizophrenia|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
89036364|NCT04590300|Other|Bipolar disorder|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
89617581|NCT01870583|Active Comparator|Chlorhexidine|Chlorhexidine based skin preparation solution applied to skin prior to cesarean delivery
89617582|NCT01870583|Active Comparator|Iodine povidone|Iodine povidone based skin preparation solution applied to skin prior to cesarean delivery
89036365|NCT05467241|Experimental|Self-induced therapeutic tremor (SITT) combined with mindfulness|"This arm will consist of self-induced therapeutic tremor (SITT) training combined with mindfulness training that is performed during a 60 minute session, 2 times per week, for 4 weeks.~Self-induced therapeutic tremor (SITT) combined with mindfulness: SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. During SITT muscles will gently shake, and release built up stress. This shaking of muscles lets the participant's body physically let go of tension and stress. Mindfulness is the ability to be fully present in a moment so that the participant can focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them. Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed."
89036366|NCT00533715||>100|"The study included healthy children (2.5-6.5 years old) from a number of public kindergartens. An initial screening questionnaire based on the ATA-DLD-78-A for adults, adapted for children and translated into Hebrew, concerning the child's birth, past and present health status, was completed by the parents.~Exclusion criteria: Previous symptoms or treatment for asthma, current respiratory symptoms or other present respiratory diseases."
89617583|NCT04351594|Experimental|Topical analgesia (+Menthol)|Biofreeze Topical Gel with active ingredient (Menthol 4%)
89617584|NCT04351594|Placebo Comparator|Topical analgesia (-Menthol)|Biofreeze Topical Gel with no active ingredient (Menthol 0%)
89617585|NCT04603469||Trisomy 21 patients|Children <18 years old requiring general anesthesia with inhalation induction Down syndrome ASA physical classification 1-3
89617586|NCT01308814|Placebo Comparator|Placebo|Placebo patches for 12 months and placebo pills for 12 days every 2 months.
89617587|NCT01308814|Experimental|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.
89617588|NCT03009760|Experimental|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
89617589|NCT03009760|Experimental|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
89617590|NCT03009760|Experimental|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
89617591|NCT03009760|Experimental|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
89617592|NCT03009604|Experimental|Simethicone|women take 6 tablets (2 tablets after each meal) and to fast overnight before the operation
89617593|NCT03009604|Active Comparator|Enema|women take 3 rectal Enema (8:00 pm, 12:00 am & 8:00 am) and to fast over night before the operation.
89617594|NCT01275586|Experimental|Tasigna|Following enrollment each subject will initially receive the drug Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated. Subjects will have his/her dose increased as tolerated dose during the first three months of therapy. The maximum targeted dose is 400mg twice daily.
89617595|NCT01275664|Experimental|Treatment (granisetron, dexamethasone, aprepitant)|Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.
89617596|NCT02193490|Active Comparator|DNase|DNase 0.1% eye drops four times a day for 8 weeks
89617597|NCT02193490|Placebo Comparator|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
89617598|NCT01367080|Experimental|A Group|"1st administration - DWETR10~2nd administration - DWETR25"
89617599|NCT01367080|Experimental|B Group|"1st administration - DWETR25~2nd administration - DWETR10"
89617600|NCT01367860|Active Comparator|OMicro|This group will be formed by randomization, which gets out surgery to open microdiscectomy
89617601|NCT01367860|Experimental|SJet|This group will be formed by randomization, and receive the discectomy procedure addressed by the technique of Percutaneous Diskectomy SpineJet
89617602|NCT01869959|Placebo Comparator|Placebo|Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.
89617603|NCT01869959|Experimental|3 mg LY2405319|Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days.
89617604|NCT01869959|Experimental|10 mg LY2405319|Participants received 10 mg LY2405319 injected SC once daily for 28 days.
89617605|NCT01869959|Experimental|20 mg LY2405319|Participants received 20 mg LY2405319 injected SC once daily for 28 days.
89617606|NCT01368874|Active Comparator|Group A|Ulthera® System treatment of the submental and submandibular regions at two treatment depths, and the lower neck region at one treatment depth.
89617607|NCT01368874|Active Comparator|Group B|Ulthera® System treatment of skin above the jawline, as well as the submental, submandibular and lower neck regions.
89617608|NCT01368874|Active Comparator|Group C|Ulthera® System treatment of the submental, submandibular, and the lower neck regions at two treatment depths.
89617609|NCT01369030||Deplin®|Subjects with depression who have been prescribed Deplin® daily.
89617610|NCT01613027||Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
89617611|NCT01369108|Experimental|Flowable composite|Flowable composite
89617612|NCT01369108|Active Comparator|Conventional composite|Highly filled conventional composite restorative
89617613|NCT04595045|Experimental|patients with spastic lower limb paresis|patients with spastic lower limb paresis secondary to Multiple Sclerosis
89617614|NCT01369732|Placebo Comparator|Saline group|We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.
89617615|NCT01369732|Experimental|erythropoietin group|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
89617616|NCT01869725|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.
89617617|NCT01309360|Active Comparator|group A : 40ml Prilocaine 1%|40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block
89617618|NCT01309360|Active Comparator|group B : 30ml Prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
89617619|NCT01309360|Active Comparator|group C : 20ml Prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
89617620|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological and GI) + Omeprazole|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
89617621|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological) + Omeprazole|The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
89617622|NCT01851863|Active Comparator|Flupentixol-Melitracen(without explanation) + Omeprazole|In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
89617623|NCT01851863|Active Comparator|proton pump inhibitor|Prescribe Omeprazole.
89617624|NCT01369888|Experimental|IL-15 following Young TIL (0.25 mcg)|0.25 mcg/kg/day x 10
89617625|NCT01369888|Experimental|IL-15 following Young TIL (0.50 mcg)|0.50 mcg/kg/day x 10
89617626|NCT01369888|Experimental|IL-15 Following Young TIL (1 mcg)|1 mcg/kg/day x 10
89617627|NCT01369888|Experimental|IL-15 Following Young TIL (2 mcg)|2 mcg/kg/day x 10
89617628|NCT01850615|Experimental|FIAsp and basal insulin + metformin|Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
88987484|NCT00135941|Experimental|2|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
88987485|NCT00136175|Experimental|Arm I|Patients with clinical stage T2 with hydronephrosis or T3 bladder cancer will receive 3 cycles of chemotherapy (200mg/m^2 paclitaxel on day 1, carboplatin on day 1, and 800 mg/m^2 gemcitabine on days 1 and 8 of each 21 day cycle).
88987486|NCT00136175|Experimental|Arm II|Patients with T4 or lymph node positive disease will receive up to 6 cycles of paclitaxel, carboplatin, and gemcitabine.
88987487|NCT00136370|Experimental|1|Chlorhexidine Vaginal Wipe
88987488|NCT00136370|Placebo Comparator|2|Sterile water external genital wipe
88987489|NCT00159510|No Intervention|Control|The control group with neither nitric oxide nor methylene blue used
88987490|NCT00159510|Active Comparator|MB alone|Single methylene blue used
88987491|NCT00159510|Active Comparator|NO alone|Nitric oxide alone used
88987492|NCT00159510|Active Comparator|MB+NO|Both nitric oxide and methylene blue used
88987493|NCT00136409|Experimental|Mono-Therapy Gleevec|Gleevec administered orally at a pre-determined dose once daily.
88987494|NCT00136565|Experimental|Experimental|Velcade, Doxorubicine, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
88987495|NCT00153231|Experimental|Infracoccygeal sacropexy|Intervention: IVS
88987496|NCT00153231|Active Comparator|Sacrospinofixation|Intervention: Sacrospinofixation
88987497|NCT00136682|Active Comparator|(PCEA)|patient-controlled epidural analgesia PCEA involves having an epidural catheter placed before surgery.The epidural catheter will be used during surgery to give drugs, such as morphine and a local anesthetic bupivacaine, which will help control pain. After surgery, a constant flow of pain-reducing medicine, such as morphine, will be given through the catheter. This is controlled by the patient.
88987498|NCT00136682|Active Comparator|PCA|patient-controlled intravenous analgesia (PCA) PCA involves placing a tube into the patient's vein after surgery. The tube is connected to a pump that is controlled by the patient. The pump holds a medicine, such as morphine, that eases pain.
88987499|NCT00153426|Experimental|lifestyle counseling|Women assigned to lifestyle change intervention arm for nutrition and physical activity with print-based tailored health communications and a computer-based interactive nutrition program targeting health behaviors of diet and physical activity. Women in a control group did not receive the intervention.
88987500|NCT04724538|Experimental|Healthy volunteers|CT-scans for exclusion of pneumonia. Accumulated absorbed dose calculation of volunteers' lungs after inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 833 MBq of 99mTc-pertechnetate.
88987501|NCT04724538|Experimental|Patient with COVID-19 pneumonia|Inhalation of 99mTc-pertechnetate aerosol from commercial gas generator which was loaded by 4165 MBq of 99mTc-pertechnetate. CT scans a day before, 7 and 14 days after inhalation procedure. Blood tests a day before, 1, 3 and 7 days after inhalation procedure.
88987502|NCT04724538|No Intervention|Patient with COVID-19 pneumonia without intervention|Blood tests at 1, 3 and 7 days.
88987503|NCT00137189|Experimental|Music therapy|See published study protocol
88987504|NCT00137189|Other|Standard care|See published study protocol
88987505|NCT00159939|Active Comparator|prone position|prone positioning
88987506|NCT00159939|No Intervention|supine position|
88987507|NCT00137306|Other|Arm 1|
88987508|NCT00160017||Collaborative group|Participants (i.e. profesionals) participate in a Breakthrough Collaborative intervention to improve diabetes care so that patients are provided more often with diabetes care as described in guidelines
88987509|NCT00160017||usual care group|Participants are offered no intervention and care is provided as usual
88987510|NCT00153504|Experimental|Housing and Health Study housing rental assistance|
88987511|NCT00153504|Active Comparator|Standard local practice housing assistance|
88987512|NCT00137501|Other|A|High dose Nifedpine arm
88987513|NCT00137501|Other|B|Low dose Nifedipine arm
88987514|NCT00160056|Other|Hypoglycemia|Intrerfvention is a hypoglycemic stimulus
88987515|NCT00153660|Active Comparator|NSAID #1|Celecoxib and Naproxen Placebo
88987516|NCT00153660|Active Comparator|NSAID #2|Naproxen and Celecoxib Placebo
88987517|NCT00160290|Experimental|A|Lactulose Group
88987518|NCT00160290|Active Comparator|B|Plantago Group
88987519|NCT00137735|Active Comparator|1|Gabapentin
88987520|NCT00137735|Placebo Comparator|2|Placebo
88987521|NCT00137852|Experimental|Cisplatin/CPT-11/Celecoxib/XRT/Surgery|Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
88987522|NCT00153894|Active Comparator|Group A|Immediate Exercise
88987523|NCT00153894|Active Comparator|Group B|Delayed Exercise (delay by 16 weeks)
88987524|NCT00138008|Active Comparator|1|Drug: endocrine therapy
88987525|NCT00138008|Experimental|2|Procedure/Surgery: radiotherapy
88987526|NCT00160446|Experimental|1|
88987527|NCT00160446|Experimental|2|
88987528|NCT00160446|Experimental|3|
88987529|NCT00160446|Placebo Comparator|4|
88987530|NCT00153933|Experimental|CC-5013 in combination with bortezomib|Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.
88987531|NCT00153972|Active Comparator|Levodopa|Levodopa 300 mg per day orally.
88987532|NCT00153972|Active Comparator|Cabergoline|Cabergoline 3 mg per day orally.
88987533|NCT00404144|Experimental|Drug Eluting Balloon|treatment of small vessel with drug eluting balloon
88987534|NCT00160485|Experimental|1|Glyburide,gestational diabetes, maternal complications, neonatal complications
88987535|NCT00160485|Active Comparator|2|Insulin, gestational diabetes, maternal complications, neonatal outcomes
88987536|NCT00404183|Experimental|hydrocodone/acetaminophen extended release|
88987537|NCT00404183|Placebo Comparator|Placebo|
88987538|NCT00404222|Experimental|hydrocodone / acetaminophen extended release|
88987539|NCT00404222|Active Comparator|Hydrocodone/Acetaminophen Immediate Release (Norco ®)|
89617629|NCT01850615|Active Comparator|Basal insulin + metformin|Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
89617630|NCT02196766|Active Comparator|Bioclean First Care EX combo, then Aosept Clearcare combo|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
89617631|NCT02196766|Active Comparator|Aosept Clearcare combo, then Bioclean First Care EX combo|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
89617632|NCT01309906|Experimental|Investigational lens|Bausch & Lomb investigational silicone hydrogel lens
89617633|NCT01309906|Active Comparator|Air Optix Aqua lens|Ciba Vision Air Optix Aqua contact lens
89617634|NCT04415099|Experimental|One group|Only one group was assessed before and after performing muscle fatigue protocol.
89617635|NCT01372462|Experimental|NIOV - Room air|Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
89617636|NCT01372462|Experimental|NIOV - Oxygen|Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
89617637|NCT01372462|Active Comparator|Nasal Cannula Oxygen|Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
89617638|NCT01372462|No Intervention|No treatment|Control arm. Subjects exercise without using supplemental oxygen or NIOV.
89617639|NCT01373242|Experimental|Peanut ( liquid peanut extract) SLIT|All subjects will receive peanut SLIT upon enrollment for at least the first 48 months. After the desensitization DBPCFC after at least 48 months of treatment, subjects will be randomized off treatment from 1 to 17 weeks. Subjects will then undergo another DBPCFC.
89617640|NCT01279564|Experimental|ETview|ETview TVT endotracheal tube
89617641|NCT01279564|Sham Comparator|Control|Endotracheal tube
89617642|NCT01280110|Active Comparator|Preserved (BAK 0.006%) lubricating drop|One group will receive preserved lubricating drops 4 times a day for 1 month.
88987540|NCT00404222|Placebo Comparator|Placebo|
88987541|NCT00154089|Experimental|EM-1421|"Administration of EM-1421 intravaginally once per week for 3 weeks~Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)"
88987542|NCT00138437||Leprosy Patients (Group 1)|All leprosy patients
88987543|NCT00138437||Household Contacts (Group 2)|Household contacts with known contact with leprosy patients
88987544|NCT00138437||Healthy Individuals (Group 3)|Healthy persons with no known contact with leprosy patients
88987545|NCT00138476|Experimental|Group 4: 0.48 RT-PCR units or Placebo|Group 4: dosage group of 10 subjects will receive 0.48 RT-PCR units of Lot 42399 NV or placebo control (8 subjects will receive NV and 2 subjects will receive placebo control).
88987546|NCT00138476|Experimental|Group 3: 4.8 RT-PCR units or Placebo|Group 3: dosage group of 12 subjects will receive 4.8 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
88987547|NCT00138476|Experimental|Group 2: 48 RT-PCR units or Placebo|Group 2: dosage group of 12 subjects will receive 48 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
88987548|NCT00138476|Experimental|Group 1: 4800 RT-PCR units or Placebo|Group 1: dosage group of 11 subjects will receive 4800 reverse transcription polymerase chain reaction (RT-PCR) units of Lot 42399 Norwalk Virus (NV) or placebo control (9 subjects will receive NV and 2 subjects will receive placebo control).
88987549|NCT00138476|Experimental|Validation Group: 4.8 and 0.48 RT-PCR units|Validation Group: dosage group of 12 subjects, 4 will receive 4.8 RT-PCR units and 8 will receive 0.48 RT-PCR units of Lot 42399 NV. No placebo control.
88987550|NCT00138554|Experimental|vildagliptin 50 mg qd + pioglitazone 45 mg qd|vildagliptin 50 mg qd + pioglitazone 45 mg qd for 28 weeks
88987551|NCT00138554|Experimental|vildagliptin 50 mg bd+ pioglitazone 45 mg qd|vildagliptin 50 mg bd + pioglitazone 45 mg qd for 28 weeks
89617643|NCT01280110|Active Comparator|Preservative-free lubricating drops|The second group will receive preservative-free lubricating drops 4 times a day for 1 month.
88987552|NCT00138632|Experimental|1|
88987553|NCT00138632|Experimental|2|
88987554|NCT00138632|Placebo Comparator|3|
88987555|NCT00160875|Experimental|Cisplatin, Irinotecan|
89617644|NCT03009136|Experimental|SCRT group|3g, three times a day, each taken before or between meals
89617645|NCT03009136|Placebo Comparator|placebo group|3g, three times a day, each taken before or between meals
89617646|NCT01403584|Experimental|AutoVPAP with addition of AutoEPAP|This arm will receive conventional device modified to enable algorithm for automatically applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
89617647|NCT01403584|Active Comparator|AutoVPAP without addition of AutoEPAP|This arm will receive conventionally applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
89617648|NCT01374490|Experimental|Crofelemer|
89617649|NCT01374802|Experimental|BI 201335|capsule for oral administration
89617650|NCT01374802|Experimental|Darunavir 400 mg|tablet for oral administration
89617651|NCT01374802|Experimental|Ritonavir 100 mg|tablet for oral administration
89617652|NCT01375660|Placebo Comparator|Arm 1|Placebo: One capsule weekly
89617653|NCT01375660|Experimental|Arm 2|50K vitamin D2: One capsule weekly
89617654|NCT01868477|Experimental|Erythropoietin alpha|Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.
89617655|NCT01868477|Experimental|Deferasirox + Erythropoietin alpha|Patients will receive deferasirox dispersible tablet (DT) 10 mg/kg/day or deferasirox film-coated tablet (FCT) 7 mg/kg/day in combination with erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, erythropoietin dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be discontinued from the study. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study. Patients will continue deferasirox treatment.
89617656|NCT01849289|Experimental|Insulin Degludec|
89617657|NCT01849289|Experimental|Insulin Glargine|
89617658|NCT01868243|Experimental|Dabigatran|Dabigatran 110 mg BID
89617659|NCT01868243|Active Comparator|Warfarin|Warfarin adjusted-dose
89617660|NCT01611935|Active Comparator|Vasopressin|Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
89617661|NCT01611935|Placebo Comparator|Normal Saline|An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.
89617662|NCT01868165||Cohort of older adults taking antihypertensives|Adults aged 80 and over treated with antihypertensive drugs
89617663|NCT02201056|Experimental|Cohort 1: TAK-935 15 mg|TAK-935 15 mg solution, orally, once, on Day 1.
89617664|NCT02201056|Experimental|Cohort 2: TAK-935 50 mg|TAK-935 50 mg solution, orally, once, on Day 1.
89617665|NCT02201056|Experimental|Cohort 3: TAK-935 200 mg|TAK-935 200 mg solution, orally, once, on Day 1.
89617666|NCT02201056|Experimental|Cohort 4: TAK-935 600 mg|TAK-935 600 mg solution, orally, once, on Day 1.
89617667|NCT02201056|Experimental|Cohort 5: TAK-935 900 mg|TAK-935 900 mg solution, orally, once, on Day 1.
89617668|NCT02201056|Experimental|Cohort 6: TAK-935 1350 mg|TAK-935 1350 mg solution, orally, once, on Day 1.
89617669|NCT02201056|Placebo Comparator|Cohorts 1-6: Placebo|TAK-935 placebo-matching solution, orally, once, on Day 1.
89617670|NCT01868009|Experimental|ELLIPTA Period 1 and DISKUS Period 2 Arm|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.
89617671|NCT01868009|Experimental|DISKUS Period 1 and ELLIPTA Period 2 Arm|Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
89617672|NCT02201212|Experimental|Everolimus|"Everolimus~Fixed doses orally once a day per each 28 day cycle~Participants will stay on study as long as they do not progress for a maximum of 24 months.~Tumor assessments will be performed after every 2 cycles for as long as they are on study."
89617673|NCT01376050|Active Comparator|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 milliWatts (mW) 635 nanometer (nm) light emitting diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center, and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
88987556|NCT01243762|Experimental|Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg|Participants in Part 1 of the study receive dalotuzumab 7.5 mg/kg intravenously (IV) weekly + MK-0752 1800 mg orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy.
88987557|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-0752 1800 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-0752 1800 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
88987558|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 90 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-2206 90 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
89617674|NCT01376050|Placebo Comparator|Placebo Laser|Placebo Laser has the same appearance and application as the Erchonia MLS but does not emit an therapeutic output.
88987559|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 135 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 135 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
89617675|NCT01376362|Experimental|Interferon gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
89617676|NCT03009292|Experimental|24 mg lenvatinib|Participants will receive once daily oral dosing of lenvatinib 24 milligrams (mg)
89617677|NCT01312948|Experimental|Prototype mask|
89617678|NCT04346680|Experimental|Experimental group|
89617679|NCT01962792|Experimental|Phase 1 - Dose Finding|Ibrutinib PO 560mg + Carfilzomib IV 20/27mg/m2 + Dexamethasone PO 20mg
88987560|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 150 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 150 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
88987561|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 200 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 200 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
89617680|NCT01962792|Experimental|Phase 2b - Main Study|Ibrutinib PO 560mg + Carfilzomib IV 20/36mg/m2 + Dexamethasone PO 20mg
89617681|NCT01962792|Experimental|Phase 2b - Sub-study|Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg
89617682|NCT01849055|Placebo Comparator|Placebo|Placebo matching LY3023703 administered orally, once daily (QD), for 28 days
89617683|NCT01849055|Experimental|LY3023703|Escalating doses (2.5 milligram [mg] up to 30 mg) of LY3023703 administered orally, QD, for 28 days
89617684|NCT01849055|Active Comparator|Celecoxib|400 mg celecoxib administered orally, QD, for 28 days. (Positive control.)
89617685|NCT03420690||Family of patient|
89617686|NCT01848353|Active Comparator|Standard payment, phase 1|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
89617687|NCT01848353|Active Comparator|Standard payment, phase 2|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
89617688|NCT01848353|Active Comparator|Ramp-down payment, phase 3|All participants will perform exercise training. This phase will last from weeks 33-48 (phase 3). Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes, but the value of the payments will decrease weekly (ramp-down) until reaching zero in week 41. All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
89617689|NCT01848353|Experimental|Incentivized payment, phase 1|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they increase exercise frequency (number of days) during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
89617690|NCT01848353|Experimental|Incentivized payment, phase 2|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they exercise for longer than 20 minutes per session during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
89617691|NCT01848353|Experimental|Raffle payment, phase 3|All participants will perform exercise training. In weeks 33-48 (phase 3)participants in this arm will receive fewer financial incentives than in the prior 32 weeks but they will be delivered through a raffle system to utilize a variable reinforcement approach. All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior.
89617692|NCT01848353|No Intervention|Normal weight, low activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have low physical activity and fitness like the intervention group. Therefore differences in their results with the intervention group will reflect the effects of overweight/obesity on the variables of interest.
89617693|NCT01848353|No Intervention|Normal weight, high activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have higher physical activity and fitness than the intervention group. They will therefore serve as a healthy reference group and differences in their results with the intervention group will reflect the effects of both overweight/obesity and physical activity on the variables of interest.
89617694|NCT03420612||training|The training cohort was used to determine the influencing factors of the pain during the colonoscopy and establish the intubation discomfort score (IDS)
89617695|NCT03420612||validation|The validation cohort was used to verify the IDS
89617696|NCT02418390|No Intervention|No prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, without prophylactic central lymph node dissection
89617697|NCT02418390|Active Comparator|Prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, with prophylactic central lymph node dissection
89617698|NCT03420534|Experimental|iloperidone in fasting|iloperidone 1mg by mouth once for 6 days in the first cycle or the second cycle
89617699|NCT03420534|Active Comparator|placebo tablets in fasting|placebo mimic iloperidone 1mg by mouth once for 6 days in the second cycle or the first cycle
89617700|NCT03420534|Active Comparator|placebo tablets in postprandial|placebo mimic iloperidone 1mg by mouth once for 6 days
89617701|NCT03420534|Experimental|iloperidone in postprandial|iloperidone 1mg by mouth once for 6 days
89617702|NCT03416322|No Intervention|Second Examination of the right colon|Second forward view examination of the right colon once the right colon (cecum to hepatic flexure) has been examined
89617703|NCT03416322|Experimental|Water exchange|"Water infusion during colonoscope insertion in the right colon (from hepatic flexure to cecum) and remove water during withdrawn (Exchange method)."
89617704|NCT01313494|Experimental|Roflumilast|Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
89617705|NCT01313494|Placebo Comparator|Placebo|Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
89617706|NCT01847885|Experimental|Smartpatch Treatment Group|Subjects in the Treatment Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
89617707|NCT01847885|Sham Comparator|Smartpatch Control Group|Subjects in the Control Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, but will not receive any electrical stimulation.
89617708|NCT01314742|Experimental|Biotene OralBalance® gel Arm|Biotene OralBalance® gel contains antibacterial active ingredients: lactoperoxidase, lysozyme and lactoferrin. These enzymes occur naturally in the human milk and colostrum and have mimicking properties of the human saliva activity in vivo.
89617709|NCT01314742|Placebo Comparator|Sterile Water Arm|Sterile Water moisten cotton tipped applicator
89617710|NCT01407094|Active Comparator|Sertraline|SSRI monotherapy
89617711|NCT01407094|Placebo Comparator|Placebo|Placebo control
88987562|NCT01243762|Experimental|Dalotuzumab + Ridaforolimus|Participants in Part 2 of the study receive dalotuzumab 10 mg/kg IV weekly + ridaforolimus 20 mg PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy.
88987563|NCT04696705|Experimental|Allogeneic γδT cell immunotherapy|Patients will receive 2 cycles of ex-vivo expanded allogeneic γδT cells treatments, at 14 days' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
88987564|NCT04696588|Experimental|Kinesiotherapy group|This is the group (n=59) receives treatment i.e complex set of neck exercises and massage
89617712|NCT01407094|Active Comparator|Bupropion|BupropionXL
89617713|NCT01867307|Experimental|Healthy Controls|healthy controls
89617714|NCT01867307|Experimental|Patients|patients with type 2 diabetes mellitus
88987565|NCT04696588|No Intervention|Waiting List group|Individuals registered in the waiting list for receiving the treatment specified for kinesiotherapy group (n=59).These patients receive no treatment for tinnitus.
88987566|NCT01243411|Experimental|AA4500|collagenase clostridium histolyticum
88987567|NCT02964533|Experimental|TFM|thunder-fire moxibustion therapy
88987568|NCT02964533|Active Comparator|MSM|common moxa-stick moxibustion therapy
89617715|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin, fed|3 single tablets under fed conditions
89617716|NCT01845077|Experimental|5 mg Linagliptin/1500 mg Metformin FDC|2 FDC tablets under fasted conditions
89617717|NCT01845077|Active Comparator|5 mg Linagliptin/1500 mg Metformin|4 single tablets under fasted conditions
89617718|NCT01845077|Experimental|5 mg Linagliptin/1000 mg Metformin FDC|1 fixed dose combination(FDC) tablet under fasted conditions
89617719|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin|3 single tablets under fasted conditions
89617720|NCT01845077|Experimental|5mg Linagliptin/1000mg Metformin, FDCfed|1 FDC tablet under fed conditions
89617721|NCT01866917|Experimental|TAP|Patients will receive Ropivicaine 0.5% 20cc injectate from a study labeled syringe
89617722|NCT01866917|Placebo Comparator|Saline|Patients will receive Normal saline 20cc injectate from a study labeled syringe
89617723|NCT01407952|Other|HydroCoil Embolic System|Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
89617724|NCT01407952|Other|Control|Aneurysm treatment using bare platinum coil(s)
89617725|NCT01316302|Experimental|Pristiq|Flexible dose, 50-100mg QD
89617726|NCT01316302|Placebo Comparator|Placebo|Matching placebo
89617727|NCT01410058||Nevirapine|HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
89617728|NCT01410058||Efavirenz|HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
89617729|NCT01380106|Active Comparator|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
89617730|NCT01380106|Active Comparator|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle
89617731|NCT01381120|Experimental|VESIcare + Narcotic Painkiller|VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
89617732|NCT01381120|Active Comparator|Narcotic Painkiller|Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
89617733|NCT03009370||Recurrent miscarriage|RM is defined as three or more pregnancy losses at< 20 weeks of gestation.
89617734|NCT01316770|Placebo Comparator|Placebo Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with saline (placebo). { UPDATE: drug(generic) was administered at what time pt, dose of drug, route administration, frequency}
89617735|NCT01316770|Experimental|Dexamethasone Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with dexamethasone {UPDATE: drug (generic) was administered at what time pt, dose of drug, route administration, frequency}
89617736|NCT01316926|Active Comparator|Paxil CR Reference|Reference drug administration followed by test drug administration
89617737|NCT01316926|Active Comparator|Paxil CR Test|Test drug administration followed by Reference drug administration
89617738|NCT01318018||Magnetic Seizure Therapy Group|Patients receiving magnetic seizure therapy for depression
89617739|NCT01318018||Electroconvulsive Therapy Group|Patients receiving electroconvulsive therapy for depression
89617740|NCT01318408|Experimental|Levetiracetam|Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.
89617741|NCT01319110|Experimental|CoenzymeQ10|Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
89617742|NCT01319110|Placebo Comparator|Placebo|Patients will receive 20 ml chocolate Ensure (as a placebo) three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). Placebo will be given through pre-existing NG or OG tube.
89617743|NCT01383616|Active Comparator|Unipedicular kyphoplasty|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm only vertebral body pedicle was entered to deliver bone cement.
89617744|NCT01383616|Active Comparator|Bipedicular Kyphoplasty group|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm two pedicles were entered to deliver bone cement.
89617745|NCT03008512|Experimental|Genexol-PM|Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
89617746|NCT04351516|Experimental|hydroxychloroquine|
88987569|NCT00138944|Placebo Comparator|1|Placebo
88987570|NCT00138944|Active Comparator|2|Eplerenone
88987571|NCT01243177|Experimental|Lacosamide|
88987572|NCT01243177|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|
88987573|NCT00161187|Experimental|Treatment|Biological/Vaccine: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
88987574|NCT04705584|Active Comparator|Topical steroids|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by 4 times daily for 2 weeks, then twice daily for 2 weeks and finally once daily for 2 weeks.
88987575|NCT04705584|Experimental|Topical Cyclosporine A|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Cyclosporine A 2% Topical eye drops 2 times per day for 6 weeks.
88987576|NCT04705584|Experimental|Topical Tacrolimus|Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by Topical Tacrolimus A 0.3% Topical eye drops 2 times per day for 6 weeks.
88987577|NCT00139256|Experimental|Betamethasone|Betamethasone injection
88987578|NCT00139256|Placebo Comparator|Placebo|Placebo injection
89617747|NCT04351516|Placebo Comparator|Placebo|
89617748|NCT01411696||All Participants|Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.
89617749|NCT01319500||Yasmin|"Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC Yasmin"
89617750|NCT01319500||Other OCs|"Users of OCs except Yasmin (Other OCs)"
89617751|NCT01412086||All Participants|Healthy volunteers. No treatment (intervention) was received.
89617752|NCT01844765|Experimental|Newly diagnosed and untreated Ph+ CML in first CP|Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
89617753|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in CP|Resistant or Intolerant to either imatinib or dasatinib
89617754|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in AP|Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.
89617755|NCT01412164|Experimental|Firehawk|Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
89617756|NCT04346758|Other|Modified Shamrock approach|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
89617757|NCT01866293|Experimental|Cabozantinib (XL184)|Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
89617758|NCT01844687|Other|Active marijuana (MJ) with 0 mg CBD|Active MJ cigarettes contain 5.30% THC
89617759|NCT01844687|Other|Active MJ with 200 mg CBD|Active MJ cigarettes contain 5.30% THC
88987579|NCT00161265||1|women with breast cancer
88987580|NCT00161304|Active Comparator|Testosterone Enanthate|Testosterone
88987581|NCT00161304|Placebo Comparator|Placebo|Placebo
88987582|NCT04705389|Other|Case group|Intervention only includes additional blood sampling at baseline and during follow up (5 samplings).
88987583|NCT01242748|Experimental|Degarelix 240 mg/480 mg|
89617760|NCT01844687|Other|Active MJ with 400 mg CBD|Active MJ cigarettes contain 5.30% THC
89617761|NCT01844687|Other|Active MJ with 800 mg CBD|Active MJ cigarettes contain 5.30% THC
89617762|NCT01844687|Other|Inactive MJ with 0 mg CBD|Inactive MJ cigarettes contain 0.01% THC
89617763|NCT01844687|Other|Inactive MJ with 200 mg CBD|Inactive MJ cigarettes contain 0.01% THC
89617764|NCT01844687|Other|Inactive MJ with 400 mg CBD|Inactive MJ cigarettes contain 0.01% THC
89617765|NCT01844687|Other|Inactive MJ with 800 mg CBD|Inactive MJ cigarettes contain 0.01% THC
89617766|NCT01844531|Experimental|FDC empagliflozin dose 1 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
89617767|NCT01844531|Active Comparator|empagliflozin dose 1 + metformin tablets|single tablets after intake of a high fat, high caloric meal
89617768|NCT01844531|Experimental|FDC empagliflozin dose 2 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
89617769|NCT01844531|Active Comparator|empagliflozin dose 2 + metformin tablets|single tablets after intake of a high fat, high caloric meal
89617770|NCT01844375|Experimental|Carbohydrate group|The carbohydrate (CHO) group will be given the carbohydrate drink (12.5% carbohydrates, 50 kcal/100 ml, 240 mOsmol/l, pH 5.0) 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except the carbohydrate drink. The pharmacy department is responsible for preparing the carbohydrate drink.
89617771|NCT01844375|Active Comparator|Control group|The control group will be given pure water 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except pure water.
88987584|NCT01242748|Active Comparator|Goserelin acetate|
88987585|NCT00139451|Active Comparator|Nutrition and Growth Hormone|
88987586|NCT00139451|Active Comparator|Observation and Growth Hormone|
88987587|NCT00161343|Experimental|1|Small interactive groups on preventing HIV infections using an Information-Behavioral Skills-Motivational model
88987588|NCT00161343|Placebo Comparator|2|Small interactive groups on general health-promotion topics using an Information-Behavioral Skills-Motivational model
88987589|NCT04705740||September 2013 to August 2015|5 endoscopists
88987590|NCT04705740||September 2015 to December 2017|4 endoscopists
88987591|NCT04705740||January 2018 to June 2020|3 endoscopists
88987592|NCT00139490|Experimental|A|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
88987593|NCT00139490|Active Comparator|B|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
88987594|NCT00139490|Placebo Comparator|C|Usual Care group
88987595|NCT00139529|Experimental|1|Participants will receive an educational intervention during pregnancy combined with a motivational interviewing program using telephone counseling to prevent postpartum relapse to tobacco use.
88987596|NCT00139529|Active Comparator|2|Participants will receive an educational intervention during pregnancy.
89617772|NCT02367456|Experimental|Arm A|MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
89036367|NCT05467202|Experimental|Treatment group|"Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg，6 ×10e6/kg，9×10e6/kg.~Dose Expansion:Participants receive a single dose (at the MTD determined)."
89036368|NCT05338788||Patient Group|"Thirty-two 32 patients with cervical disk herniation related chronic neck pain participated in this cross-sectional controlled study. Patients who aged 18-64 years, had neck pain for at least 12 weeks, no tumor, trauma, fracture pathology in the spinal region and no history of spine surgery were included.~The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System (BBS; Biodex Medical Systems, Shirley, New York, USA) was used to assess postural control. The evaluated parameters of this system are presented below: modified clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task. Dual-task interference (DTI) was assessed."
89036369|NCT05338788||Control Group|"Twenty-three 23 age and sex-matched asymptomatic controls participated in this cross-sectional controlled study.~The Biodex Balance System (BBS; Biodex Medical Systems, Shirley, New York, USA) was used to assess postural control.The evaluated parameters of this system are presented below: modified clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task. Dual-task interference (DTI)was assessed."
89617773|NCT02367456|Experimental|Arm B|AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
89617774|NCT03420456|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and the light energy may activate under-stimulated brain regions.
89036370|NCT05466968|Experimental|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days
89617775|NCT03420378|Experimental|Interventional Arm|Patients with vitamin D deficiency will receive vitamin D replacement therapy. Before and after therapy, cutaneous silent period will be measured from each upper extremity and latencies will be recorded. Their LANSS scores and Notthingham Health Profile will be recorded before and after treatment.
89617776|NCT03425682||Cervical Fusion - ACDF|Up to 50 patients undergoing anterior cervical discectomy and fusion (ACDF) using ViBone will be enrolled.
89617777|NCT03425682||Lumbar Interbody Fusion|Up to 50 patients undergoing lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone will also be enrolled.
89617778|NCT03415932|Experimental|Health education|Assessment of healt care Contacts Before and after intervention
89617779|NCT03425604||Endometriosis I y II, according to ASRM classification|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
89617780|NCT03425604||patients without endometriosis|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
89617781|NCT03425448|Active Comparator|Heparin group|
89617782|NCT03425448|Experimental|Neotrolin Group|
89617783|NCT03419988|Experimental|Exercise Intervention|8-weeks exercise intervention: 3-days per week for 45-55 minutes per session
89617784|NCT03419988|No Intervention|Control|8-weeks control: asked not to change anything or start exercising.
89617785|NCT03425370|Experimental|Wound Side A: buried sutures, Wound Side B: tissue adhesive|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
89617786|NCT03425370|Experimental|Wound Side A: tissue adhesive, Wound Side B: buried sutures|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
89617787|NCT03415698|Active Comparator|Standard Medical Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required)
89617788|NCT03415698|Active Comparator|G-CSF + Standard Medical Therapy|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
89617789|NCT03425214|Experimental|NC with RBD|fMRI and video polysmnography
89617790|NCT03425214|Experimental|NC without RBD|fMRI and video polysomnography
89617791|NCT03425214|Experimental|control group (healthy subjects)|fMRI
89617792|NCT03419910|Experimental|BMS-986165 and cyclosporine|BMS-986165 and cyclosporine administered orally
89617793|NCT03419754|Experimental|Glucose and Fidgetting|75 g of glucose will be given at the beginning of the study day (days one with glucose+fidgeting )
89617794|NCT03419754|Placebo Comparator|Fidgetting|Subjects will fidget their legs in an up and down motion for 2.5 min on and then 2.5 min off for the duration of the study.
89036371|NCT05466968|Placebo Comparator|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days
89036372|NCT05466812|Experimental|Sr-89 treated group|Sr-89 treatment
89617795|NCT03415542|Other|Exercise Intervention|Participants receive a print-based exercise promotion program across 12 weeks and are asked to monitor their exercise behavior using an app on their cell phone.
89617796|NCT03425136|Experimental|SAIA (Systems Analysis & Improvement)|Intervention is a five-step package of industrial engineering methods known as SAIA (the systems analysis and improvement approach) delivered by district maternal and child health managers to subordinate health facilities that provide prevention of mother-to-child HIV services.
89617797|NCT03425136|No Intervention|Control|Routine provision of prevention of mother-to-child HIV transmission services and routine support from district maternal and child health managers to subordinate facilities.
89036373|NCT05466773|Experimental|CN group|Giving nutrition education for nurse, but not for patients
89617798|NCT01319812|Experimental|Astron Stent Group|"Participants indicated for stenting in iliac atherosclerotic lesions.~Intervention: Device: Astron Stents"
89617799|NCT01319812|Experimental|Pulsar Stent Group|"Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.~Intervention: Device: Pulsar Stents"
89617800|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)|
89617801|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid|
88987597|NCT00161421|Experimental|1|Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, & 10.
88987598|NCT00161460|Active Comparator|1|Study nurse contacts subjects who enroll in the intervention to provide detailed education about screening tests, to assess their risk for colorectal cancer, and to facilitate screening.
88987599|NCT00161460|No Intervention|2|Patients who do not enroll receive usual care from their primary care providers.
89617802|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)|
89617803|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid|
89617804|NCT03415230|Experimental|Therapeutic massage|Women will undertake sessions of therapeutic massage
88987600|NCT04726943|Experimental|RF Energy|RF delivery targeting the atrial side of a significant residual leak in patients with acute and chronic evidence of incomplete percutaneous LAA occlusion
88987601|NCT00161577|Other|A|Group A = Ketorolac
88987602|NCT00161577|Placebo Comparator|B|
88987603|NCT00404261|Other|Arm 1|Fluticasone/Salmeterol HFA MDI without counter
88987604|NCT00404261|Other|Arm 2|Fluticasone/Salmeterol HFA MDI with counter
88987605|NCT00139841|Experimental|1|bendamustine
89617805|NCT03415230|Sham Comparator|Sham massage|Women will undertake sessions of sham massage
89617806|NCT01865747|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily.
89617807|NCT01865747|Active Comparator|Everolimus (Afinitor)|Everolimus (Afinitor) 10 mg tablet once daily.
89617808|NCT03424980||Tyrosine kinase inhibitors|Diagnosed patients with advanced non-small cell lung cancer (NSCLC) with brain metastases who were administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors
89617809|NCT03424902||group1|patients with no or mild paravalular leakage
89617810|NCT03424902||group 2|patients with moderate or or severe paravalvular leakage
89617811|NCT03415074|Active Comparator|Supplemented low protein diet (sLPD)|Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)
89617812|NCT03415074|Active Comparator|Mild protein restriction diet (MPD)|Mild restriction in dietary protein intake (0.8 g/kg-day)
89617813|NCT01385644|Experimental|1*10^6 MSC / kg|Placental MSC
89617814|NCT01385644|Experimental|2*10^6 MSC / kg|Placental MSC
88987606|NCT04724187|Experimental|intrauterine misoprostol and oxytocin|there will be added effect of misoprostol to stimulate uterine contraction along with oxytocin
88987607|NCT04724187|Active Comparator|oxytocin|only oxytocin will stimulate uterine contraction
88987608|NCT04727021|Experimental|Treatment A: Single oral dose of a 20 mg tablet rivaroxaban|"2-way crossover: The subjects will receive the following treatments in a randomized order:~Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions~Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
88987609|NCT04727021|Experimental|Treatment B: Single oral dose of 20 mg rivaroxaban, granules|"2-way crossover: The subjects will receive the following treatments in a randomized order:~Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions~Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions."
88987610|NCT04724226|Experimental|C-couple|Camrelizumab and Apatinib after Cryoablation
88987611|NCT00139958||1|
88987612|NCT00139958||2|
89617815|NCT03424746|Experimental|Open label EDTA chelation|EDTA-based chelation therapy plus vitamins in diabetic patients with severe peripheral artery disease presenting with impending amputation and determine if there is an improvement in outcomes and a delay or reduction of amputations.
89617816|NCT03414918|Experimental|Clarithromycin|250 mg clarithromycin diluted in 250 ml saline will be administered as a slow infusion (45 min) in a peripheral vein during AVS. This dose of clarithromycin should yield peak plasma concentrations of 2.78 mcg/mL (on average)13, which are higher than the IC50 measured in vitro (0.53-1.29 mcg/mL).
89617817|NCT04448496|Experimental|Arms|Diabetic macular edema Dexamethasone 0.7mg is injected into the vitreous cavity. Center-involved macular edema secondary to diabetic retinopathy for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
89617818|NCT01387672|Active Comparator|Nitrol|Nitroglycerin Ointment 2% USP
89617819|NCT01387672|Active Comparator|Nitro-Dur|Nitroglycerin Extended Release Patch 160mg
89617820|NCT01387672|Active Comparator|Nitrostat 1|Nitroglycerin 0.3mg Sublingual Tablet
89617821|NCT01387672|Active Comparator|Nitrostat 2|Nitroglycerin 0.6mg Sublingual Tablet
89617822|NCT01387672|Active Comparator|ISMO|Isosorbide Mononitrate 20mg Oral Tablet
89617823|NCT01387672|Placebo Comparator|Placebo|Placebo Ointment
89617824|NCT03419520|Experimental|Intervention group|Schools receive healthy actions aimed to reduce the risk of developing obesity, along the study
89617825|NCT03419520|No Intervention|Control group|Schools monitored along the study but won't receive any healthy action.
89617826|NCT01843673|Experimental|in-room imaging systems|Patients undergo FBCT once before treatment and once weekly for a total of 6-7 scans, dual CBCT up to 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian kV OBI 5 times weekly for a total of 33-35 scans, 2-D x-ray with Brain Lab ExacTrac 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian MV OBI once weekly for a total of 6-7 scans, and EPID imaging up to 5 times weekly for a total of 33-35 scans while undergoing IGART.
88987613|NCT00140075|Experimental|B|"ET (8 cycles)~T = docetaxel or paclitaxel"
88987614|NCT00140075|Experimental|A|"EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles~T = docetaxel or paclitaxel"
89617827|NCT01412554||Longitudinal Insulin Sensitivity|The participants were examined using the hyperinsulinaemic isoglycaemic glucose clamp technique which is the gold standard to assess insulin sensitivity.
89617828|NCT03419442||Ra-223 therapy before chemotherapy|Treatment sequence 1 will include all mCRPC patients who received Ra-223 alone or in combination with abiraterone or enzalutamide and subsequently received chemotherapy
89617829|NCT03419442||Ra-223 after chemotherapy|Treatment sequence 2 includes all mCRPC patients who received chemotherapy before Radium 223 therapy
89617830|NCT01412710|Experimental|4000 IU group|This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.
88987615|NCT00140114|Other|A|A: Vaginal misoprostol (cytotec)
88987616|NCT00140114|Other|B|Sublingual misoprostol (Cytotec)
89617831|NCT01412710|Experimental|6000 IU group|This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.
89617832|NCT01843205|Placebo Comparator|Placebo|Subjects will be maintained on placebo.
89617833|NCT01843205|Experimental|Buspirone|Subjects will be maintained on buspirone.
89617834|NCT03419286||EGFR MUTATED|patient with lung cancer with EGFR mutation before transformation into small cell lung cancer
89617835|NCT03419286||EGFR NON MUTATED|patient with lung cancer without driver oncogenic before transformation into small cell lung cancer
89617836|NCT01412866|Experimental|EDSS with CO monitor|Web-based electronic decision support system (EDSS) with carbon monoxide (CO) monitor and health-checklist
89617837|NCT01412866|Active Comparator|EDSS without CO monitor|Web-based electronic decision support system (EDSS) with health-checklist only
89617838|NCT03419208|Experimental|SPIN-HAND Program|Offered the SPIN-HAND program
89617839|NCT03419208|No Intervention|Treatment as usual|Not offered SPIN-HAND program, treatment as usual
89617840|NCT03419130|Experimental|Cohort I (pembrolizumab, hypofractionated RT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hypofractionated RT over 5 fractions for 14 days.
88987617|NCT01242514|Experimental|A|Oral treatment
88987618|NCT01242514|Experimental|B|Oral treatment
88987619|NCT01242514|Experimental|C|Oral treatment
88987620|NCT04710966|Experimental|debridement group|For the debridement group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic debridement will be performed.
88987621|NCT04710966|Experimental|repair group|For the repair group, if the tear type is confirmed to be bursal-side Ellman grade II during the operation, arthroscopic repair will be performed.
88987622|NCT01242085|Active Comparator|control group|control group will have standard instrumentation of their knee replacement
88987623|NCT01242085|Experimental|trumatch group|the trumatch patient will have custom instruments made from preop CT scans
89617841|NCT03419130|Experimental|Cohort II (pembrolizumab, conventionally fractionated RT)|Patients receive pembrolizumab as in Cohort I. Patients also receive conventionally fractionated RT over 30 fractions for 52 weeks.
89617842|NCT01320826||Physician colonoscopists|"All primary care physicians (family physicians and general internists) who perform colonoscopies were approached to voluntarily participate in the APC-Endo study.~All patients having a colonoscopy done by an APC-Endo study physician endoscopist were approached at the time of their endoscopy to consent to the post procedure telephone survey."
89617843|NCT01414036|Active Comparator|Enhanced Traditional Care control|This arm will receive a low literacy smoking cessation educational brochure, a list of hospital and community resources for smoking cessation, in addition to usual care.
89617844|NCT01414036|Experimental|Patient Navigation|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of hospital and community resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
89617845|NCT03424590|Active Comparator|COTS|Volunteers will be provided with Clearblue connected Ovulation test system to use during the study period, accortding to the instructions for use.
89617846|NCT03424590|No Intervention|Control|Volunteers will not be provided with Clearblue Connected Ovulation Test System and will be instructed not to use any other ovulation predictions tests during the study period.
89617847|NCT04351672|Experimental|Early Time-Restricted Feeding|
89617848|NCT04351672|Experimental|Late Time-Restricted Feeding|
89617849|NCT03424434||Medical staff of an UHC, practitioners and residents|The target population is practitioners and residents who works at hospital in an UHC, they are also specialists, surgeons, dental surgeons.
89617850|NCT01414426|Experimental|Arm I (chemoprevention)|Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
89617851|NCT01414426|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
89617852|NCT03418974|Experimental|Pitavastatin treatment|The drug pitavastatin is given to the patient according to the doctor's order and restricted to BangZhi produced by Jiangsu Wanbang Medicine Marketing Co., Ltd..
89617853|NCT03418974|Experimental|Atorvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
88987624|NCT01241461|Experimental|LY2584702|
88987625|NCT01240135|Other|FID 114576A / renu fresh|FID 114675A used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after which renu fresh used for contact lens care for an additional 14 days.
88987626|NCT01240135|Other|renu fresh / FID 114675A|Renu fresh used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after FID 114675A used for contact lens care for an additional 14 days.
88987627|NCT01245634|Experimental|A|
88987628|NCT01245634|Placebo Comparator|B|
88987629|NCT01240876|Experimental|CEP-37247|
88987630|NCT01240876|Placebo Comparator|Matching placebo|
88987631|NCT01240759|Experimental|S-707106 Dose A|One S-707106 A tablet + 3 Placebo A tablets
88987632|NCT01240759|Experimental|S-707106 Dose B|One S-707106 B tablet + 3 Placebo A tablets
89617854|NCT03418974|Experimental|Rosuvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
89533126|NCT05465174|Experimental|Group 2, Arm A: Neoadjuvant nivolumab|Participants with recurrent craniopharyngioma will receive one (1) dose of nivolumab within 14 days - 5 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent. If participants are eligible based on archival tissue alone, these participants will go directly on to receive combination therapy only.
89617855|NCT03424356|Experimental|lma with rocuronium bromide|In study group, 2-3 mg/kg propofol, 1mcg/kg fentanyl and 0.15 mg/kg rocuronium bromide will be administered during lma insertion in cystoscopy procedure.
89617856|NCT03424356|Active Comparator|lma with saline solution|In control group, 2-3 mg/kg propofol, 1 mcg/kg fentanyl and saline(no rocuronium) will be administered during lma insertion in cystoscopy procedure.
89617857|NCT03127410|Experimental|Traction|Intermittent lumbar traction will be performed in the prone position for 3 x 15-minute sessions at 40% of the participants body weight and will be adjusted based on the participants response.
89617858|NCT03414528||Patients with PID|
89617859|NCT03414450|Experimental|Dose Escalation (Phase 1A)|An adaptive design using the ordinal Continual Reassessment Method (oCRM) will be used to determine the MTD and RD of ETC-1907206 in combination with dasatinib.
89617860|NCT03414450|Experimental|Dose Expansion (Phase 1B)|Once the MTD and/or RD has been determined in Phase 1A, an expansion cohort will be enrolled in order to characterize the safety, PK and preliminary clinical activity of ETC-1907206 in combination with dasatinib. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, withdrawal of consent or it is judged not to be in the patient's interest to continue on the study.
89617861|NCT03414294|Experimental|K-755 Part A (SAD)|
89617862|NCT03414294|Placebo Comparator|Placebo Part A (SAD)|
89617863|NCT03414294|Experimental|K-755 Part B (MAD)|
89617864|NCT03414294|Placebo Comparator|Placebo Part B (MAD)|
89617865|NCT03414294|Experimental|K-755 Part C (FE)|
89617866|NCT03414294|Experimental|K-755 Part D (FE)|
89617867|NCT03414294|Experimental|K-755 Part E (MAD)|
89617868|NCT03414294|Placebo Comparator|Placebo Part E (MAD)|
89617869|NCT01389076|Experimental|Treatment arm|Low dose methotrexate and Bexxar
89617870|NCT02948478||Precarious patients|Precarious patients - exposed - will be those identified as precarious by at least one of the three scores (EPICES, Pascal, European Deprivation Index)
89617871|NCT02948478||Non precarious patients|Non precarious patient - non exposed - will be all the patients identified as non-precarious by the three scores (EPICES, Pascal, European Deprivation Index)
89617872|NCT02813226|Other|Imaging|Molecular Imaging
89617873|NCT03414216|Experimental|Group1 - early off-loading surgery|"Within 1 week of randomization, offloading surgery:~Tip of toe ulcers will be treated by percutaneous tenotomy. Ulcers under metatarsal heads will be offloaded with minimally invasive floating metatarsal osteotomy.~Ulcers plantar to the interphalangeal joint of the hallux will be treated by a modified Keller resection arthroplasty."
89617874|NCT03414216|Active Comparator|Group 2 - off-loading in fiberglass cast|"Tip of toe ulcers and ulcers plantar to the interphalangeal joint of the big toe will be casted in a fiberglass cast with a heel, ending under the metatarsal heads, leaving the toes in the air.~Ulcers under metatarsal heads will be casted in a full foot fiberglass cast with a heel with a window below the ulcer designed to relieve pressure under the metatarsal heads."
89617875|NCT03127800|Experimental|Morphine sulphate|Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness
89617876|NCT01389856|Experimental|1|Bosentan
89617877|NCT01389856|Placebo Comparator|2|Matching placebo
89617878|NCT04448964|Experimental|Part 1: Treatment Sequence ABC|Participants will receive a single dose of JNJ-70033093 spray-dried dispersion (SDD) tablet under fasted conditions (Treatment A) in Treatment Period 1, followed by JNJ-70033093 SDD tablet in fed conditions (Treatment B) in Treatment Period 2, and then JNJ-70033093 SDD granule capsule under fasted conditions (Treatment C) in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
89617879|NCT04448964|Experimental|Part 1: Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
89617880|NCT04448964|Experimental|Part 1: Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
89617881|NCT04448964|Experimental|Part 1: Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, and then Treatment B in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
89617882|NCT04448964|Experimental|Part 1: Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, and then Treatment C in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
89617883|NCT04448964|Experimental|Part 1: Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, and then Treatment A in Treatment Period 3 on Day 1 of each Period during Part 1. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
89617884|NCT04448964|Experimental|Part 2: Treatment Sequence DE|Participants will receive Treatment D (single dose of JNJ-70033093 SDD tablet in fed conditions) in Treatment Period 1, and then Treatment E (single dose of JNJ-70033093 SDD granule capsule under fasted conditions) in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
89617885|NCT04448964|Experimental|Part 2: Treatment Sequence ED|Participants will receive Treatment E in Treatment Period 1, and then Treatment D in Treatment Period 2 on Day 1 of each Period during Part 2. There will be a wash-out period of at least 5 days and up to 2 weeks between Day 1 of each treatment period.
89617886|NCT03423966|Experimental|Self Objective Mobility Evaluation|Usual Care Plus a Smartphone pedometer App
89617887|NCT03423966|No Intervention|Usual Care (UC)|Usual Care of obesity
89617888|NCT03418896|Experimental|human chorion gonadotropin|Pregnyl, hCG, 5000 IU times one im.
89617889|NCT03414138|Experimental|Mindfulness Meditation Group|"Research volunteers will participate in four sessions (20 min/session) of mindfulness training. Participants are taught that perceived sensory events are momentary and fleeting, requiring no further evaluation. They will be asked to close their eyes, relax and focus on the flow of their breathing by simply letting go of discursive thoughts."
88815577|NCT01069562|Experimental|IAADS group|In this group, liquid isoflurane was injected into the circuit using a syringe pump controlled by the IAADS system.The IAADS system has the algorithm to regulate the rate of infusion of isoflurane such that BIS is achieved and maintained at 50 during anesthesia.
88815578|NCT02416908|Experimental|Phase I Schedule A (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, and 12 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
88815579|NCT02416908|Experimental|Phase I Schedule B (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, 12, 17, and 19 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
88815580|NCT02416908|Experimental|Phase II (selinexor)|"Selinexor will be given at the schedule as determined in Phase 1.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
88815581|NCT05187962||Women receiving epidural analgesia for labor|Sensory block level check Patients will have their sensory block level checked using 3 modalities: ice, pin prick and soft touch (cotton ball).
88815582|NCT01070810|Placebo Comparator|1|50 ml D5W
88815583|NCT01070810|Experimental|2|200mg Thiamine in 50ml D5W
88815584|NCT01071044|Active Comparator|Lisdexamfetamine Dimesylate|Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
88815585|NCT01071044|Placebo Comparator|Sugar pill|"Matching Placebo 30, 50 or 70 mg"
88815586|NCT05150756|Active Comparator|Group Lidocaine|At induction of anesthesia, patients will receive a loading dose of intravenous (IV) 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% via infusion pump. The infusion will be continued till the end of surgery.
88815587|NCT05150756|Active Comparator|Group Morphine|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
88815588|NCT01071356|Experimental|Intensive MI|9 hours of Motivational Interviewing + outpatient substance abuse treatment
88815589|NCT01071356|Active Comparator|Single session MI|1.5 hours of Motivational Interviewing + 8 hours of time equivalent nutrition classes +outpatient substance abuse treatment
88815590|NCT04352582||1|Survey respondants
88815591|NCT03364400|Experimental|VT1021|Escalating doses of VT1021 to determine RP2D
88815592|NCT03359252|Active Comparator|non-stent assisted coiling|patients treated with non-stent assisted coiling of unruptured intracranial aneurysms
88815593|NCT03359252|Experimental|stent assisted coiling|patients treated with stent assisted coiling of unruptured intracranial aneurysm
88815594|NCT01072136|Placebo Comparator|Placebo|Placebo.
88815595|NCT01072136|Experimental|Azithromycin/Cefixime|A single dose of cefixime 400 mg (1 tablet oral at 400 mg) and azithromycin 1 gram (2 tablets oral at 500 mg each).
88815596|NCT05135858|Experimental|CPG2|6 infusions of glucarpidase
88815597|NCT05116904|Other|Children with Smith Magenis Syndrome|
88815598|NCT01074164|Placebo Comparator|Control group|This group of subjects will serve as the control group and will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids.
88815599|NCT01074164|Experimental|Accu-patch pellet|This group of subjects will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids. Additionally, they will use a titanium pellet (accu-patch pellet) to self-apply pressure at the LI11 acupuncture pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times weekly for 1 month.
88815600|NCT03014102|Experimental|TPOqd|Recombinant Human Thrombopoietin 300U/kg/d ih quaque die, day-3/-2/-1 before mobilization
88815601|NCT03014102|Active Comparator|TPOqod|Recombinant Human Thrombopoietin 300U/kg/d ih qua altera die, day-3/-1/+2 before mobilization
88815602|NCT03041324|Experimental|Cohort 1 SB-913 Starting Dose 5.00E+12 vg/kg|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
88815603|NCT03041324|Experimental|Cohort 2 SB-913 at Next Ascending Dose 1.00E+13 vg/kg|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
88815604|NCT03041324|Experimental|Cohort 3 SB-913 at Next Ascending Dose 5.00E+13 vg/kg|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
88815605|NCT05017532|Experimental|Intervention|Intervention with RC2S+ that consists of 24 biweekly sessions
88815606|NCT03005444|Experimental|Anticoagulation|Rivaroxaban：10mg/d for 2 years
88815607|NCT03005444|No Intervention|Non-anticoagulated|No anticoagulants will be used.
88815608|NCT01076270|Experimental|Filgrastim and plerixafor for PBSC mobilization|"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.~After completion of study treatment, donors are followed up 1 day after the last stem cell donation."
88815609|NCT04937192||Kidney stone former|
88815610|NCT01076504|Experimental|Amrubicin/Carboplatin with Pegfilgrastim|Systemic therapy
88815611|NCT02453256|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
88815612|NCT02453256|Experimental|Double-Blind Tocilizumab|Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
88815613|NCT04912050||Tablo Hemodialysis System|Hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy > 12 hours on the Tablo Hemodialysis System
88815614|NCT02442804|Experimental|Stroke - POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
88815615|NCT02442804|Placebo Comparator|Stroke - Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
88815616|NCT01076972||Lopinavir/ritonavir group|All patients in this non-interventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
88815617|NCT02174198|Experimental|BioOss Collagen|Intervention: BioOss Collagen at the time of implant placement
88815618|NCT02174198|No Intervention|No Bone Graft|No placement of BioOss at the time of implant placement
88815619|NCT02174432|Experimental|nalbuphine HCl ER|nalbuphine HCl ER
88815620|NCT02176382|Active Comparator|Standard dose teriparatide|teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
88815621|NCT02176382|Active Comparator|High dose teriparatide|teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
88815622|NCT01077596||New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006|All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription.
88815623|NCT03013712|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen by infusion.
88815624|NCT02740868|Active Comparator|Healthy|Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
88815625|NCT02740868|Active Comparator|Cystic Fibrisos|Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
88815626|NCT02740868|Active Comparator|Asthma|Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
88815627|NCT04352894|Experimental|fluorescence guided peritoneal exploration|Indocyanine green (ICG) intravenous injection and peritoneal exploration with technology able to detect fluorescence generated by ICG
88815628|NCT02414958|Experimental|Empagliflozin low dose|Empagliflozin tablets once daily
88815629|NCT02414958|Experimental|Empagliflozin high dose|Empagliflozin tablets once daily
88815630|NCT02414958|Placebo Comparator|Placebo|Placebo tablets matching empagliflozin once daily
88815631|NCT03016208||Misoprostol vaginal insert for max. 24hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 24 hours
88815632|NCT03016208||Misoprostol vaginal insert for max. 10hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 10 hours
88815633|NCT01078220||3-Dose Safety Population (Primary)|Females between ages 9 to 26 at receipt of the first dose of GARDASIL who are members of the participating MCOs and have completed the 3-dose regimen of GARDSIL vaccination with 12 months.
88815634|NCT01078220||Pregnancy Safety Population|Females who received at least one dose of GARDASIL during pregnancy.
88815635|NCT01078220||Autoimmune Safety Population|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
88815636|NCT01078220||Any Dose Safety Population (Secondary)|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
88815637|NCT03013790|Active Comparator|Melatonin 5mg|This arm will be given 5mg tablets of Melatonin nightly for the duration of their hospital stay
88815638|NCT03013790|Active Comparator|Melatonin 3mg|This arm will be given 3mg tablets of Melatonin nightly for the duration of their hospital stay
89036374|NCT05466773|Experimental|CP group|Giving nutrition education for patients, but not for nurses
89617890|NCT03414138|Active Comparator|Book Listening Control|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 4 session sequence is meant to match features of the experimental meditation sessions, including attention to the recording, room setting, social support, conditioning, and time elapsed during the sessions. We do not expect that this group will demonstrate significant blood oxygenation changes as a function of the intervention.
89617891|NCT01323010|Experimental|Albuterol - Experimental|Albuterol dosages during the first hour include 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
89617892|NCT01323010|Active Comparator|Albuterol - Control|Albuterol dosages during the first hour include either 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg).
89036375|NCT05466773|Experimental|CNP group|Giving nutrition education for both patients and nurses
89036376|NCT05466773|No Intervention|NC group|No nutrition education for patients and nurses
89036377|NCT00533793|Active Comparator|SoC|Standard of Care
89617893|NCT03127176||BD with cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) and cognitive impairment.~Intervention: Genome sequencing of fecal samples"
89617894|NCT03127176||BD without cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) without cognitive impairment.~Intervention: Genome sequencing of fecal samples"
89617895|NCT03127176||Control group|This group will include healthy volunteers. Intervention: Genome sequencing of fecal samples
89036378|NCT00533793|Active Comparator|SoC plus 0.133 mg/mL|
89036379|NCT00533793|Active Comparator|SoC plus 0.4 mg/mL|
89036380|NCT00533793|Active Comparator|SoC plus 1.0 mg/mL|
89036381|NCT00533832|Active Comparator|1|Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)
89036382|NCT00533832|Placebo Comparator|2|Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS
89036383|NCT05466617|Experimental|PuzzleWalk|"PuzzleWalk incorporates behavior change techniques (BCTs), a theory-based method of promoting healthy behavior change by leveraging psychological determinants. The example techniques included in PuzzleWalk are a comprehensive, visualized user guide, self-monitoring of target performance, contingent rewards, and goal setting.~It is a spot the difference puzzle game comprising 660 major city images around the world. This format was chosen because it is easy to understand the purpose of the game, and it can quickly capture the user's interests without a complex comprehension process. Moreover, this visual image-based game facilitates visual interaction, which is a unique strength of individuals with ASD. The most unique design element of PuzzleWalk is the conversion algorithm between steps and game-solving time. Specifically, the user's accumulated steps are directly converted to game-solving time to motivate PA participation."
89617896|NCT03423810|Experimental|Group 1: Hydralazine|Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.
89617897|NCT01835015|Experimental|CLG561, Concentration Level A|Single 50 μL intravitreal injection of CLG561, Dose Level A
89617898|NCT01835015|Experimental|CLG561, Concentration Level B|Single 50 μL intravitreal injection of CLG561, Dose Level B
89617899|NCT01835015|Experimental|CLG561, Concentration Level C|Single 50 μL intravitreal injection of CLG561, Dose Level C
89617900|NCT01835015|Experimental|CLG561, Concentration Level D|Single 50 μL intravitreal injection of CLG561, Dose Level D
89617901|NCT01835015|Experimental|CLG561, Concentration Level E|Single 100 μL intravitreal injection of CLG561, Dose Level E
89617902|NCT03414060|Experimental|Intervention (Menstrual Cup)|The menstrual cup is a 100% silicone, flexible reservoir cup that, when inserted correctly in the vagina, is sanitary and efficacious in preventing leakage of menstrual blood and in eliminating odor.
89617903|NCT03413904|Experimental|transanal TME|Study procedure will consist in 2-team (combined) LAR with transanal TME using laparoscopic abdominal assistance.Transanal TME is performed either at the same time or following the above steps. Transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or using a Pfannenstiel incision followed by colorectal anastomosis, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
89617904|NCT03413904|Active Comparator|laparoscopic TME|Procedure will consist in 1 team performing laparoscopic TME. Following stapled closure of the rectum below the tumor, and complete mobilization of the rectosigmoid, the specimen is extracted using a Pfannenstiel incision . A stapled (knight-Griffen) colorectal anastomosis or coloanal anastomosis will be created and a temporary diverting stoma will be fashioned which is standard of care following surgery for this type of cancer.
88815639|NCT03013790|Placebo Comparator|Placebo|This arm will be given a Sucrose tablet nightly for the duration of their hospital stay
89036384|NCT05466617|Experimental|Google Fit|Google Fit (Google LLC) is a PA-tracking platform developed by Google for Android and Apple iOS. The app uses a sensor built into a smartphone device to automatically track PA, including steps and active minutes. It also allows users to journal and record a variety of forms of PA (eg, cycling, weightlifting, and yoga) by manually setting the activity tracking mode. Google Fit uses a heart point-based reward system as a gamification strategy to provide users with individualized exercise tips incorporated with PA recommendations outlined by the American Heart Association. The number of heart points received based on active minutes is the app's primary gamification strategy.
89036385|NCT00533871||Normotensive|Pregnant women in the third trimester with normal blood pressure this pregnancy and no history of HTN or pre-eclampsia in a previous pregnancy
89036386|NCT00533871||Chronic Hypertensive|Pregnant women in their third trimester with known hypertension prior to the current pregnancy
89036387|NCT00533871||Pre-eclampsia|Pregnant women in their third trimester who meet ACOG diagnostic criteria for pre-eclampsia
89036388|NCT04484610|Experimental|Appropriate Opioid Quantities|Pharmacists in the intervention regions are invited to complete an eLearning program to promote the practice change intervention of assessing and dispensing appropriate quantities of opioids prescribed for acute pain.
89617905|NCT01390246|Active Comparator|Bupropion SR + cessation counseling|"Bupropion SR and smoking cessation counseling Subjects received Bupropion SR 150 mg tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (bupropion SR 150 mg orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose Bupropion SR 150 mg tablet orally BID for a total medication treatment of 12 full weeks.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
89617906|NCT01390246|Placebo Comparator|Placebo + cessation counseling|"Placebo and smoking cessation counseling Subjects received matching Bupropion SR placebo tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (matched placebo tablets orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose matching Bupropion SR placebo tablet orally BID for a total medication treatment of 12 full weeks of therapy.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
89617907|NCT03418584|Experimental|HybridAPC|The patient with Barrett's esophagus is treatment by HybridAPC.
89617908|NCT01390870||Patient Survey|Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
89617909|NCT03127254|Experimental|Video Narrative with surveys|Participants will be asked to create a 10-15 minute video narrative on their experiences after being diagnosed with cancer. Participants will also be asked to complete surveys including pediatric quality of life (PedsQL), Ten Item Personality Inventory (TIPI), Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test, and The Cognitive Log (Cog-Log)
89617910|NCT03008668|Experimental|experimental group: Acupuncture|acupuncture on 5 most sensitized points/ acupoints
89617911|NCT03008668|Active Comparator|Control group: Acupuncture|acupuncture on 5 least low/non-sensitized points
89617912|NCT03423732|Active Comparator|Active Group|Patients randomized to the active treatment group will receive CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin); 15 000 000 via common femoral artery injection and 15 000 000 via intramuscular injections above the knee (ATK, 6 injection sites) and below the knee (BTK, 6 injection sites).
89617913|NCT03423732|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) injections in the same manner.
89617914|NCT04631952|Experimental|Online exercise|SMS messages on encouraging active lifestyle plus an online exercise video
89617915|NCT04631952|Active Comparator|SMS message|SMS messages on encouraging active lifestyle
89617916|NCT02231814|Experimental|Group 1|Crohn's Disease Exclusion Diet+Partial Enteral Nutrition (PEN): Crohns Disease Exclusion Diet + PEN
89617917|NCT02231814|Experimental|Group 2|Crohn's Disease Exclusion Diet alone with a calcium supplement
89617918|NCT03413826|Experimental|6 Days per week|This group will exercise 6 days per week and expend 3,000 kcal per week for 12 weeks
89617919|NCT03413826|Experimental|2 Days per week|This group will exercise 2 days per week and expend 3,000 kcal per week for 12 weeks
89617920|NCT03413826|No Intervention|control|This group will remain sedentary for 12 weeks
89036389|NCT04484610|No Intervention|Usual Practice|Pharmacists in the comparison regions are not targeted for the practice change intervention (they are not invited nor provided access to the eLearning program).
89036390|NCT04687670|Experimental|Intervention group(pET)|Personalized embryo transfer of a single vitrified blastocyst in a HRT cycle according to the ERA test results.
89617921|NCT03413748|Active Comparator|Peritoneal irrigation|Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
89617922|NCT03413748|Active Comparator|Non peritoneal irrigation|No Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
89617923|NCT03418506|Experimental|Intervention|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
89617924|NCT03418506|No Intervention|Control|No specific education will be given to the control group.
89617925|NCT03418428||Test group|Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
89617926|NCT03418428||Control group 1|Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
89617927|NCT03418428||Control group 2|In-house relatives of Test group and Control group 1 participants
89617928|NCT03418428||Control group 3|Patients with long-term history of proton pump inhibitor usage
89617929|NCT01842581|Experimental|Rifaximin 550 mg BID|Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
89617930|NCT01842581|Experimental|Rifaximin 550 mg BID + Lactulose|Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.
89617931|NCT04448028|Placebo Comparator|Intervention group|Patients randomized to the intervention group discontinue their pre-existing PPI treatment and replace it with placebo (day 15 to 360). During the first 14 days (dose tapering phase) patients in the intervention group will receive placebo on day 1, 3, 5, 7, 9, 10, 12, 13 and esomeprazole 20mg on day 2, 4, 6, 8, 11, 14, to minimize the risk for gastric acid rebound symptoms.
89036391|NCT04687670|Active Comparator|Control group(FET)|Frozen embryo transfer of a single vitrified blastocyst in a HRT cycle according to the clinical standard practice.
89036392|NCT05466266|Experimental|ICE group|ICE group without TEE detection before procedure
89036393|NCT05466266|Active Comparator|TEE group|TEE group with non-ICE usage at the entire procedure
89617932|NCT04448028|Active Comparator|Control group|Patients randomized to the control group continue their pre-existing PPI therapy with esomeprazole 20mg/day (day 15 to 360). During the first 14 days (dose tapering phase) patients in the control group receive esomeprazole 20mg/day on day 1 to 14.
89617933|NCT04447950|Experimental|Study group|Posterior QL block with 20-40 cc of Bupivocaine in posterior border of Quadratum Lumborum muscle at the end of the operation.
89617934|NCT04447950|Placebo Comparator|Placebo group|Posterior QL block with 40 cc of Saline in posterior border of Quadratum Lumborum muscle at the end of the operation.
89617935|NCT05169996|Experimental|Real Food|Participants are exposed to a tangram game with puzzle pieces from chocolate.
89617936|NCT05169996|Experimental|Real Nonfood|Participants are exposed to a tangram game with puzzle pieces from wood.
89617937|NCT05169996|Experimental|Virtual reality Food|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) chocolate.
89617938|NCT05169996|Experimental|Virtual reality Nonfood|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) wood.
89617939|NCT05169996|Experimental|Virtual reality Food Branded|Participants are exposed to a virtual reality experience with a tangram game with puzzle pieces from (virtual) chocolate. In the background of the puzzle, a brand is shown.
89617940|NCT03418194|Experimental|TAES group|Patients in group TAES group received transcutaneous acupoint electrical stimulation (disperse-dense waves, frequency 4/20Hz) at the points of PC6 (Neiguan) and PC4 (Ximen) from 30 min before anesthesia induction to the end of surgery,
89617941|NCT03418194|Placebo Comparator|control group|Patients in group C received electrode plate atthe points of PC6 (Neiguan) and PC4 (Ximen) without any electrical stimulation.
89617942|NCT03413514|Experimental|experiment group|Neoadjuvant chemotherapy(NACT) are performed for locally advanced gastric cancer. The clinical response is evaluated by MRI and enhanced CT. The cycle of neoadjuvant chemotherapy is decided by the doctor and the patents together with shared decision making(SDM). Radical gastrectomy with D2 lymph node dissection are performed after neoadjuvant chemotherapy. Adjuvant chemotherapy(ACT) are preformed after surgery. Questionnaires are preformed to evaluate the involvement emotion and reason for the decision of stopping neoadjuvant chemotherapy.
89617943|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
89617944|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
89617945|NCT03413436|Experimental|Lobaplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Lobaplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
89617946|NCT03413436|Active Comparator|Cisplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Cisplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
89617947|NCT01833455|Placebo Comparator|PVC Suppression then Placebo|This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
89617948|NCT01833455|Placebo Comparator|Placebo then PVC Suppression|This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
89617949|NCT03418116|Experimental|Argus II|"Implantation of the Argus II Retinal Prosthesis in patients with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius. The array will be placed parafoveally, adjacent to the preserved central visual field (i.e., tunnel vision) in these subjects."
89617950|NCT03413358|Experimental|Treatment group|Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid.
89617951|NCT03413358|Experimental|Control group|Blank control and Platinum-based two medicine (carboplatin / cisplatin) .
89617952|NCT01833143|Experimental|Bortezomib|Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment ± 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 2 weeks, or at the discretion of the treating physician or patient.
89617953|NCT05169528|Other|Colorectal Cancer Prehabilitation Program|This is a before-after trial. The same group of participants will have a series of outcome measures taken at baseline, which will then be compared to these same outcome measures when repeated after undergoing prehabilitation and at 3 months' post-operatively
89617954|NCT01841567|Other|dressing|
89617955|NCT03413280|Experimental|preoperative Rectus sheath block: group Pre|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml Before surgical incision
89617956|NCT03413280|Active Comparator|postoperative Rectus sheath block: group Post|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml After surgical incision
89617957|NCT05169450|Experimental|Diterpene ginkgolides meglumine injection|The intervention group received daily single infusions of 25 mg diterpene ginkgolides meglumine injection (DGMI) diluted with 250 ml of 0.9% sodium chloride injection for 14 days.
89617958|NCT05169450|Active Comparator|Ginaton|The control group received once or twice a day infusion of 35-60mg Ginaton diluted with 250 ml of 0.9% sodium chloride injection for 14 days.
89617959|NCT03411174|Experimental|HF-PBI|Hypofractionated partial breast irradiation was delivered to the tumor bed areas for low recurrence risk breast cancer patients, with prescription dose 40Gy in 15 fractions in 3 weeks.
88815640|NCT01078376|Experimental|Cohort 1: Healthy Adults (18 years to 45 years old)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
88987633|NCT01240759|Experimental|S-707106 Dose C|S-707106 Dose C = Four S-707106 B tablets
89617960|NCT04448340||Parkinson Disease Dementia|the PDD group comprised of 58 patients fulfilling the Criteria for probable PDD of the Movement Disorders Society
89617961|NCT04448340||Dementia with Lewy Bodies|the DLB group comprised of 40 patients, according to the recent revised criteria for probable DLB
89617962|NCT03417648|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
89617963|NCT03417648|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
89617964|NCT03411018||Conventional respiratory managed group.|Preterm infants born with less than 32 weeks gestational age (wGA) that entered in the neonatal Intensive care unit (NICU) from January 1 2012 to December 31 2013. These preterm infants were managed according to prior ventilatory protocol: Prophylactic Continuous positive airway pressure (CPAP) in delivery room, early surfactant administration by INSURE technique and volume target mechanical ventilation with rescue high frequency ventilation when needed. Mechanical ventilation exposure will be analyzed
89617965|NCT03411018||Less invasive managed group|Preterm Infants born with less than 32wGA that entered the NICU from January 1 2014 to December 31 2017. This infants are managed according to the actual ventilatory protocol. Prophylactic CPAP in delivery room, early surfactant administration by less invasive technique, nasal Synchronized positive pressure ventilation for CPAP failure and early rescue high frequency ventilation with minimally target volume.Mechanical ventilation exposure will be analyzed
89617966|NCT01833065|Experimental|EBX 10|Elobixibat 10 mg/day
89617967|NCT01833065|Experimental|EBX 5|Elobixibat 5 mg/day
89617968|NCT01833065|Placebo Comparator|PLCBO|Placebo
89617969|NCT03413124|Active Comparator|Capsule then Tablet|MGL-3196 Capsule on Day 1 followed by MGL-3196 Tablet on Day 5
89617970|NCT03413124|Active Comparator|Tablet then Capsule|MGL-3196 Tablet on Day 1 followed by MGL-3196 Capsule on Day 5
89617971|NCT03410940||Subjects who received a CLS Brevius Kinectiv stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and received the CLS Brevius Kinectiv stem.
89617972|NCT03417414||B-CLL|Patients with B-Cell CLL
89617973|NCT03417414||B-NHL|Patients with B-Cell NHL
89617974|NCT04860102|Experimental|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
89617975|NCT04860102|No Intervention|hands off|standard of care
89617976|NCT03413046||ALL|30 children with a recent diagnosis of PreB ALL
89617977|NCT03413046||Control|30 healthy children
89617978|NCT02520804|Active Comparator|normal saline|normal saline for fluid resuscitation and maintenance for 72 hours
89617979|NCT02520804|Experimental|sterofundin|sterofundin for fluid resuscitation and maintenance for 72 hours
89617980|NCT03412968|Experimental|Polysulfone Filter Group|The purpose of the research is to determine whether, by controlling the patient's hemodilution level and, therefore, the acute anaemia caused by the Cardiopulmonary Bypass (CPB) priming fluid, continuous conventional ultrafiltration (CUF) can decrease serum lactate levels during normothermic CPB by increasing the haematocrit and, consequently, the supply of oxygen to the tissues, and whether the haemofiltration membrane can remove lactate molecules in situations of hyperlactataemia in CPB.
89617981|NCT03412968|Active Comparator|Control Group|The purpose of the research is to determine serum lactate levels during normothermic cardiopulmonary bypass procedure (CPB) without continuous hemofiltration of the patient during the CPB.
89617982|NCT02520882|Experimental|68Ga-NOTA-Aca-BBN(7-14) PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-Aca-BBN(7-14) in one dose intravenously and underwent PET/CT scan 30 min later.
89617983|NCT01831817|Experimental|5% calcium sodium phosphosilicate/ sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
89617984|NCT01831817|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
89617985|NCT01831817|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
89617986|NCT01831817|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
89617987|NCT04839744|Experimental|TG103 produced by the modified manufacturing process|A single dose of TG103 (15mg) produced by the modified manufacturing process will be administered subcutaneously (SC) in healthy male subjects.
89617988|NCT04839744|Active Comparator|TG103 produced by the original manufacturing process original manufacturing process|A single dose of TG103 (15mg) produced by the original manufacturing process will be administered subcutaneously (SC) in healthy male subjects.
89617989|NCT03397836|Experimental|Health TAPESTRY Intervention|This patient group will begin receiving the TAPESTRY interventions from time zero
89617990|NCT03397836|Active Comparator|Usual Care|This patient group will receive the intervention after a 6 month waiting period. In the first 6 months they will receive usual care and they will be used as a comparison group.
89617991|NCT03397758|Experimental|Study population|They were treated with AGNES micro-insulated needles with RF applicators in two separate sessions, at intervals of four weeks.
89617992|NCT05169294|Experimental|Intervention|
89617993|NCT05169294|Active Comparator|Control|
88987634|NCT01240759|Active Comparator|Metformin|The standard of care dose of metformin for the individual patient + 3 Placebo A tablets
88987635|NCT02955784|Experimental|Sinasprite Mobile App|Mobile App
88987636|NCT02955862|Other|Assigned Interventions Antifungals Patients with symptoms|"Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.~For CrAg-positive patients, the initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months."
88987637|NCT01244386||Inflammatory bowel disease|Patients with inflammatory bowel disease requiring CT for clinical purposes will be studied.
88987638|NCT00504634|Experimental|Bortezomib|1 mg/m^2 intravenous (IV) Days 1, 4, 8, and 11.
88987639|NCT00140465|Active Comparator|1|75 mg Clopidogrel Maintenance Doses
89617994|NCT02520648|Active Comparator|Neuro-lymphatic treatment|Participants were positioned in prone, with the head in neutral position and the arms beside the body. They were asked to perform conscious breathing. The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement. Neuro-lymphatic reflexes as referred to applied kinesiology, are locations on the body that are believed to affect a specific muscle and organ. Duration of the treatment is 15 minutes.
89617995|NCT02520648|Experimental|Articulatory spinal manual therapy.|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached. Three repetitions are performed at each vertebral level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize possible slight dysfunctions of the spine, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
89617996|NCT02520648|Experimental|Articulatory costal Manual therapy.|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier. Three repetitions are performed at each costal level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize the mobility of the ribs, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
89617997|NCT03410550|Experimental|Exoskeleton Training|Twenty men with complete and incomplete SCI will be enrolled in the trial.
89617998|NCT03412656|Experimental|Patient|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing the subjects' own prosthetic sockets. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
88987640|NCT00140465|Active Comparator|2|150 mg Clopidogrel Maintenance Doses
88987641|NCT01245517|Experimental|Dietary Phosphorus Education Program|
88815641|NCT01078376|Experimental|Cohort 1: Adolescents (≥12 to <17 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
88815642|NCT01078376|Experimental|Cohort 2: Children (≥6 to <12 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
88815643|NCT01078376|Experimental|Cohort 3: Children (≥1 to <6 years old)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
88815644|NCT02485184|Active Comparator|TIPS group|Transjugular intrahepatic portosystemic shunt
88815645|NCT02485184|Active Comparator|ET & drugs groups|"Endoscopic therapy.~Non-selective beta blockers.~Anticoagulation therapy."
88815646|NCT03015818|Experimental|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|
88815647|NCT01079390|Experimental|High dose acupuncture|six needle applied during acupuncture
88815648|NCT01079390|Experimental|Low dose acupuncture|two needles will be applied.
88815649|NCT01079390|Placebo Comparator|placebo acupuncture|sham acupuncture treatment will be applied
88815650|NCT01080248|Experimental|Arm 1 (gemcitabine & pazopanib)|"Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.~Pazopanib 800 mg PO daily of each 28 day cycle."
88815651|NCT01080794|Active Comparator|Double rTMS|High frequency rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
88815652|NCT01080794|Active Comparator|M1 Active rTMS + DLPFC Sham rTMS|High frequency stimulation of the primary motor cortex (M1) and sham stimulation of the dorsolateral prefrontal cortex (DLPFC).
88815653|NCT01080794|Active Comparator|DLPFC Active rTMS + M1 Sham rTMS|High frequency stimulation of the dorsolateral prefrontal cortex (DLPFC) and sham stimulation of the primary motor cortex (M1).
88815654|NCT01080794|Sham Comparator|Double Sham rTMS|Sham rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
88815655|NCT02452476|Experimental|CHF5633|Single dose within 24 hours from birth
88815656|NCT02452476|Active Comparator|Poractant alfa|Single dose within 24 hours from birth
88815657|NCT01082588|Active Comparator|pravastatin|pravastatin 40mg, once a day, shortly after baseline for 12 consecutive weeks
88815658|NCT01082588|Placebo Comparator|Placebo|placebo, once a day, shortly after baseline for 12 consecutive weeks
88815659|NCT02442336|Experimental|My Journey AHead|Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy.
88815660|NCT02119988|Experimental|TIPS combined with variceal embolization|"The covered stents will be used for TIPS~The gastroesophageal collaterals will be embolized during the procedure of TIPS"
88815661|NCT02119988|Active Comparator|TIPS alone|"The covered stents will be used for TIPS~No embolization of any collateral will be performed during TIPS"
88815662|NCT03016052|Experimental|ABMT|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
88815663|NCT02452398|Experimental|Treatment Group|Hair removal treatment using Venus Versa IPL energy
88815664|NCT02452398|Placebo Comparator|No intervention|Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.
89617999|NCT03412656|Other|Control|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing an adapter simulating a prosthetic socket. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
89618000|NCT03412500|Active Comparator|Vancomycin trough concentration method|vancomycin dosage will be adjusted by the trough concentration method
89618001|NCT03412500|Experimental|Vancomycin equation-based method|vancomycin dosage will be adjusted by the equation-based method
89618002|NCT01417780|Active Comparator|AB103 0.25 mg/kg|
89618003|NCT01417780|Active Comparator|AB103 0.5 mg/kg|
89618004|NCT01417780|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride)
89036394|NCT05307354|Experimental|Nerve Mobilization Group|Tibial nerve mobilization in addition to foot-ankle joint range of motion exercises
89036395|NCT05307354|Active Comparator|Control group|Only joint range of motion exercises
89618005|NCT01840943|Experimental|CAELYX|Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.
89618006|NCT01840943|Active Comparator|Topotecan hydrochloride (HCl)|Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
89618007|NCT03397524|Experimental|optima4BP|optima4BP will receive several types of data to personalize the participant's medication treatment. The data include: remotely measured blood pressure (BP), and information on current medication treatment as well as health updates posted in Epic Electronic Record.
89618008|NCT03397524|No Intervention|Standard of Care|The participants randomized to the Standard of Care will follow usual care, as currently followed at the University of California San Francisco.
89618009|NCT03127020|Experimental|PQR309|PQR309 being taken continuously on daily basis (60,80mg) or intermittent (120mg, 140mg, 160mg) dosing
89618010|NCT03412422||Acute circulatory failure|Mechanically ventilated patients with acute circulatory failure, monitored with PiCCO method, who need fluid responsiveness assessment.
89618011|NCT01840163|Other|CanSORT Online Tool|Comprehensive decision tool
89618012|NCT01840163|Other|Static version of CanSORT tool|Static version (non-interactive) version of CanSORT decision tool
89036396|NCT05466227|Experimental|Implementing Modified Valsalva|Implementing Modified Valsalva
89036397|NCT04472793||Full-Time CCHMC Employees|
89618013|NCT05171400|Sham Comparator|Control Group (CG)|The palatal wound area will not receive any treatment
89618014|NCT05171400|Experimental|Blank Film Group (BF)|The palatal wound area will receive silk fibroin film as a dressing
89036398|NCT05466149|Experimental|Furmonertinib 240mg QD|Treating patients of locally advanced or metastatic NSCLC with EGFR exon 20 insertions who have progressed during or after platinum-based chemotherapy.
89036399|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
89036400|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
89036401|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 24 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
89036402|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 48 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
89036403|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 24 weeks|Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR
89036404|NCT01276639|Experimental|Active Treatment 10 mg BID|
89618015|NCT05171400|Experimental|Insulin-loaded film (IF)|The palatal wound area will receive an insulin-loaded silk fibroin film as a drug delivery system
89036405|NCT01276639|Experimental|ActiveTreatment 5 mg BID|
89036406|NCT01276639|Placebo Comparator|Placebo Treatment|
89036407|NCT05465915|Active Comparator|Blue|"Session - Titration with 0.30ms pulse width~Session - Titration with 0.15ms pulse width~Session and further - continue with 0.15ms pulse width"
89618016|NCT02203630|Active Comparator|Phenylephrine|Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
89618017|NCT02203630|Active Comparator|Norepinephrine|Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
89618018|NCT05169138|Placebo Comparator|massage group with lavender essential oil|Pregnant women (n:37) who participated in this group were given an intense massage for at least 10 minutes in each phase during the first phase of labor. Visual Analog Pain Scale and McGill Melzack Pain Questionnaire were applied before and after the application, and the process was completed with a total of 6 measurements.
88815665|NCT01605266||Nephrotic Syndrome|The cohort includes all children diagnosed with nephrotic syndrome between ages 1-18. Children and their caregiver must be willing to provide informed consent, complete questionnaires, and provide biospecimens of the child. Those with secondary causes of nephrotic syndrome and/or systemic disease are excluded.
89036408|NCT05465915|Active Comparator|Red|"Session - Titration with 0.15ms pulse width~Session - Titration with 0.3ms pulse width~Session and further - continue with 0.3ms pulse width"
89036409|NCT05465837||Non covid Tracheostomy Patients|Adult patients (>18 years) who underwent tracheostomy without having the covid-19 infection
89036410|NCT05465837||Covid-19 Tracheostomy Patients|Adult patients (>18 years) who underwent tracheostomy had the covid-19 infection
89036411|NCT00532415|Experimental|Triamcinolone|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
89618019|NCT05169138|Placebo Comparator|group of inhalations with lavender essential oil|Pregnant women (n:44) who participated in this group were administered inhalation with lavender oil at an intensity of at least 10 minutes in each phase during the first phase of labor. Visual Analog Pain Scale and McGill Melzack Pain Questionnaire were applied before and after the application, and the process was completed with a total of 6 measurements.
89618020|NCT05169138|No Intervention|control group|No application was made to the pregnant women (n:40) who participated in this group in each phase of the first phase of labor. Despite this, the Visual Analog Pain Scale and McGill Melzack Pain Questionnaire, which were applied at the beginning of each phase in order to increase the reliability of the results, were re-evaluated 30 minutes after the measurements, even though there was no application, and the process was completed with a total of 6 measurements.
89618021|NCT03397446|Experimental|Lisdexamfetamine dimesylate|A central nervous system stimulant, specifically, a prodrug of dextro-amphetamine
89618022|NCT04447482|Experimental|Treatment Group|4D electromagnetic navigation bronchoscopy (4D-ENB) for lung biopsy. Guidance based on tip tracked surgical tools and images calculated from CT.
89618023|NCT04447482|Active Comparator|Control Group|Bronchoscopic lung biopsy taken while using X-ray fluoroscopy.
89618024|NCT02196922|Active Comparator|Standard of Care|Patients in the control group will receive standard of care at a Heart Failure clinic (primary and cardiac care as reimbursed by Medicare or sliding scale/uncompensated care). Standard of care patients will be contacted on a weekly basis in order to maintain comparable frequency of contact.
89618025|NCT02196922|Experimental|Telehealth Self Management (TSM)|TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
89618026|NCT03127098|Experimental|ETBX-011 in combination with ALT-803|A combination of agents will be administered to subjects in this dose-escalation study
89618027|NCT05168436||Cohort 1|Participants with renal cell carcinoma (RCC) treated with nivolumab
89618028|NCT05168436||Cohort 2|Oncologists with expertise in renal cancer from Spain and Portugal
89618029|NCT03410472|Experimental|Web based diet application|This arm entails the subject to record their diet into an online web program to monitor calories. The calorie goal will be given to the subjects in this group prior to the study based on dual x-ray absorptiometry test that will test resting metabolic rate.
89618030|NCT03410472|No Intervention|Control|This group will have body composition tested at week 1 and then repeat this test at 8 weeks having no intervention.
89618031|NCT04681794|Experimental|MayoP4 Group|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, hopping/jumping, and movement-based mindfulness.
89210912|NCT02591381|Experimental|STANDARD AUS Placement|Standard placement of an artificial urinary sphincter involves a small incision made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void.
89210913|NCT02591381|Experimental|TRANSCORPORAL AUS Placement|Transcorporal placement has been introduced as a way to reduce risk of erosion and involves tunneling the cuff through the erectile bodies. The same incision is made as for the standard approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.
89210914|NCT00929370|Experimental|GSK1018921|Glycine Transporter-1 inhibitor to modulate the NMDA receptor.
89210915|NCT00817232|Experimental|Treatment 1|50 microamp amplitude
89618032|NCT04681794|No Intervention|Control Group|No intervention
89618033|NCT04667442||EUA RT-PCR positive|
89618034|NCT04667442||EUA RT-PCR negative|
89618035|NCT03410316||Participants of the NEO study|Men and women aged 45 oy 65 years, with an oversampling of individuals with a BMI of 27 kg/m2 or higher
89618036|NCT03397290|Experimental|Ultrasound Imaging|A Single Ultrasound Imaging to diagnose of pneumothorax post transthoracic lung biopsy.
89618037|NCT03410238|Experimental|Treatment|Participants receive Saferteens Brief Intervention and a brochure containing psycho-education and resources.
89210916|NCT00817232|Experimental|Treatment 2|500 microamp amplitude
89210917|NCT03967795|Other|All patients|"Citrulline genration test before starting enteral nutrition~At ICU admission, a blood sample is collected (i) before and (ii) 90 minutes after N2-L-Alanyl-L-Glutamine administration"
89618038|NCT03410238|No Intervention|Control|Participants receive a brochure containing psycho-education and resources only.
89618039|NCT04656522|Experimental|Participatory Comic Intervention|This is a pre-test/post-test trial, therefore all participants will participate in the participatory comic intervention.
89618040|NCT03397212|Experimental|NADA and Clonidine|NADA acupuncture and treatment with tbl Clonidine
89618041|NCT03397212|Sham Comparator|Sham acupuncture and Clonidine|Sham ear acupuncture and treatment with tbl Clonidine
89618042|NCT01417936|Experimental|Sym004|
89618043|NCT05170932|No Intervention|open flap + mechanical debridement|This group included 10 patients with periodontitis stage 2 or 3, grade A infra-bony defect sites (Caton, 2018) that had undergone proper curettage ensuring complete removal of all granulation tissue present within the defect by scaling and root planning then open flap debridement only.
89618044|NCT05170932|Experimental|open flap +CHX gel 2 % + 24% EDTA|This group included 10 patients with periodontitis stage 2 or 3, grade A infra-bony defect sites (Caton, 2018) that had undergone proper curettage ensuring complete removal of all granulation tissue present within the defect by scaling and root planning then open flap debridement before treating root and bony walls of the pocket surfaces by application of 24% EDTA etching and washing with saline, then application of 2% chlorhexidine gel on root surface.
89618045|NCT01418482|Experimental|Mepilex Border Ag|Mepilex Border Ag, a silver dressing will be used
89618046|NCT05168358|No Intervention|Control group|This arm will include 55 patients, their parents will be taught the timed voiding regimen every 2 hours.
89618047|NCT05168358|Experimental|OCD group|This arm will include 55 patients, their parents will be taught the timed voiding regimen every 2 hours, in addition to placing an overnight catheter to drain the urinary bladder during night.
89618048|NCT01419028||Patients with perinatal and/or infantile onset HPP|Patients with a confirmed diagnosis of perinatal or infantile onset hypophosphatasia (HPP)
89618049|NCT03410160||High frequency of adrenal crisis|Patients with a high frequency of adrenal crisis in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
89618050|NCT03410160||Low frequency of adrenal crisis|Patients with no adrenal crisis or a low frequency of AC in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
89618051|NCT01393132|Experimental|Thymosin Beta 4 eye drops|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
89618052|NCT01393132|Placebo Comparator|Vehicle Control|It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.
89618053|NCT05170620|Experimental|Patients|Patients with squamous intraepithelial lesions of the lower anogenital tracts will receive laser ablation.
89618054|NCT01324882|Experimental|Study Arm|This is the group who will have a colonoscopy with the Olympus Technically Improved Colonoscope.
89618055|NCT01324882|Active Comparator|Control|This is the group who will have a colonoscopy with the traditional colonoscope Olympus CF-H180.
89618056|NCT03397056||The study population|"The target population corresponds to patients with a respiratory disease already included in a biomedical research protocol.~Intervention: Questionnaire"
89618057|NCT02520570||general department|Patients using ulinastatin in department beyond ICU would be labelled as general department group.
89618058|NCT02520570||ICU|Patients using ulinastatin in ICU would be labelled as ICU group.
89618059|NCT03396978|Experimental|GnRHag|Participants will undergo 6 months of gonadotropin releasing hormone agonist (GnRHag) therapy (intramuscular injection of leuprolide acetate 3.75 mg for depot suspension; Lupron; TAP Pharmaceutical Products, Inc.; Lake Forest, IL) to chronically suppress ovarian hormones. A single injection of leuprolide acetate produces an initial stimulation (for up to 3 wk) followed by a prolonged suppression of pituitary gonadotropins and ovarian hormones. Repeated monthly dosing suppresses ovarian hormone secretion.
89618060|NCT02201446||ARDS patients|Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
89618061|NCT02201446||Healthy volunteers|Fifty-eight healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
88815666|NCT04922346||Healthy Pregnant|All volunteer pregnant women who were in the 2nd and 3rd trimesters (between 14-40 weeks) and who met the inclusion criteria in the study
88815667|NCT02413398|Experimental|Dapagliflozin|10 mg Tablets, Oral, Once daily, 24 weeks
88815668|NCT02413398|Placebo Comparator|Placebo|Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
88815669|NCT04926168||Adjuvant TMZ (Treatment group):|"Adjuvant TMZ (temozolomide) will be given to patients as standard of Care (SOC) treatment is administered on an outpatient basis.~Patients will be provided with medication diaries and instructed in their use. TMZ will be dispensed as SOC."
88815670|NCT04926168||Delay TMZ (Observation group):|"Patients in this cohort will have their TMZ in the adjuvant setting delayed and they will be observed with SOC procedures. Once the patient recurs, will be off observation and will be able to either have TMZ prescribed or something other."
88815671|NCT02441946|Experimental|Abemaciclib + Anastrozole|"Abemaciclib (150 milligrams [mg]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
88815672|NCT02441946|Experimental|Abemaciclib|"Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
88815673|NCT02441946|Active Comparator|Anastrozole|"Anastrozole (1 mg) is given orally QD for 2 weeks.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks."
88815674|NCT01083368|Experimental|Arm 1: Combination of temsirolimus and AVASTIN|Patients receive temsirolimus IV over 30-60 minutes once weekly and bevacizumab IV over 30-90 minutes once every two weeks . Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
88815675|NCT01083758|Other|LEO 80185 (Taclonex® Scalp topical suspension/ Xamiol® gel)|
88815676|NCT02387580|Active Comparator|Regimen A: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
88815677|NCT02387580|Experimental|Regimen B: OZ439 Prototype 1 and PQP - 110mL|800 mg OZ439 Prototype 1 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
88815678|NCT02387580|Experimental|Regimen C: OZ439 Prototype 3 and PQP - 110mL|800 mg OZ439 Prototype 3 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
88815679|NCT02387580|Active Comparator|Regimen D: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
88815680|NCT02387580|Experimental|Regimen E: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
88815681|NCT02387580|Experimental|Regimen F: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
89618062|NCT04632966|Experimental|PTP-001 - Low Dose (100 mg)|intra-articular injection of 100 mg PTP-001 resuspended with 4 mL of normal saline
89618063|NCT04632966|Experimental|PTP-001 - High Dose (200 mg)|intra-articular injection of 200 mg PTP-001 resuspended with 4 mL of normal saline
89618064|NCT03396900|Active Comparator|RhBMP-2 Protein, Recombinant|15 subjects treated with corticotomy with rhBMP-2 (C+BMP)
89618065|NCT03396900|Experimental|Conventional Corticotomy|15 subjects treated with conventional corticotomy (C) as in the PAOO protocol
89618066|NCT03412032|Other|ERC|Assessment as used by the European Resuscitation Council
89618067|NCT03412032|Other|AHA|Assessment as used by the American Heart Association
89618068|NCT03410082|Active Comparator|OAA/S|The patients in the control group will receive MAC titrated according to observer's assessment of anesthesia/sedation(OAA/S) score.
89618069|NCT03410082|Active Comparator|BIS|The patients in the control group will receive MAC titrated according to bispectral index(BIS).
89618070|NCT03411954||HP-RT|Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues
89618071|NCT03411876|Experimental|First ESWT with Oxymizer, second ESWT with CNC|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the Oxymizer and the second ESWT with a conventional nasal cannula (CNC).
89618072|NCT03411876|Experimental|First ESWT with CNC, second ESWT with Oxymizer|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the CNC and the second ESWT with the Oxymizer.
89618073|NCT03410004|Experimental|Experimental|Drug: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
88987642|NCT02955628|Experimental|Ibrutinib-RICE|Patients not achieving a complete remission at time of PET-2 will receive ibrutinib and proceed on to autologous transplant if at least a partial remission is achieved. After transplantation, ibrutinib will be continued for up to 1 year. Autologous transplantation will be with BEAM conditioning.
88987643|NCT00140504|Experimental|MedCheck|Electronic medication safety queries via PatientSite portal
88987644|NCT00140504|No Intervention|Usual care|No electronic medication safety messages via PatientSite portal
88987645|NCT01247701|Experimental|Umbilical Cord Blood Transplant|Busulfan,Cyclophosphamide, Fludarabine, Cord Blood Stem Cell Infusion
88987646|NCT00140582|Experimental|A : rituximab maintenance|Maintenance with rituximab for 2 years
88987647|NCT00140582|No Intervention|B : no maintenance|No further treatment
89618074|NCT03396744|Active Comparator|Morning group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention
89618075|NCT03396744|Active Comparator|Mid-day group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention.
89618076|NCT03411798|Experimental|Experimental|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI<4) maintenance.
88987648|NCT00140660|Experimental|R-ACVBP|addition of rituximab to standard ACVBP chemotherapy
88987649|NCT00140660|No Intervention|ACVBP|standard ACVBP chemotherapy
88987650|NCT00140738|Experimental|Group A|"Patients receive study vaccinations in 3 consecutive cycles:~In Cycle 1 each patients will receive six vaccinations at two-week intervals followed by evaluation.~In Cycle 2, subjects will patients six vaccinations at two-week intervals followed by evaluation.~In Cycle 3, subjects will patients six vaccinations at three-week intervals."
88987651|NCT00140738|Experimental|Group B|Patients receive study vaccinations as second-line therapy
88987652|NCT02964572|Active Comparator|Glimepiride|Glimepiride (anti-diabetic drug) as a comparison group
88987653|NCT02964572|Experimental|Empagliflozin|Empagliflozin (anti-diabetic drug) as a study group
88987654|NCT00162201|Experimental|1|
89618077|NCT03409536||SSEP Monitoring|participants will receive a brachial plexus block for their surgery and will be monitored for brachial plexus injury using the automated SSEP monitor.
88987655|NCT01248247|Experimental|Group 1 - Erlotinib|Erlotinib 150 mg by mouth each day of a 28 day cycle.
88987656|NCT01248247|Experimental|Group 2 - Erlotinib + MK-2206|"Erlotinib 150 mg by mouth each day of a 28 day cycle.~MK-2206 135 mg by mouth every week of a 28 day cycle."
89618078|NCT03408756|Active Comparator|Oral Methotrexate|Participants will receive methotrexate through oral route of administration
89618079|NCT03408756|Active Comparator|Subcutaneous Methotrexate|Participants will receive methotrexate through subcutaneous route of administration
89618080|NCT03406806|Experimental|GaitBox|
89618081|NCT03406806|Active Comparator|Sprint System device|
89618082|NCT03406806|Active Comparator|NIH Toolbox 4 meter test|
89618083|NCT01328158||Lopinavir/Ritonavir|Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated
89618084|NCT03411720|Experimental|FES-row-training|Subjects will perform 4 months of FES-row-raining
89618085|NCT03411720|Other|Wait-list time control|Subjects will wait 4 months before performing being allowed to engage in 4 months of FES-row-training
89618086|NCT03411720|Active Comparator|Arms-only-row-training|Subjects will perform 4 months of arms-only row training before being allowed to engage in 4 months of FES-row-training
89618087|NCT03411564|Experimental|Group 1|Students enrolled in one or two targeted secondary schools in each city who are going to receive the intervention (workshop)
89618088|NCT03411564|No Intervention|Grup 0|Students from other centers with similar socioeconomic characteristics (relating to social characteristics and school location) to the centers.
89618089|NCT01394614||Narcoleptics exposed to A/H1N1 vaccine|Adjuvanted (ASO3) A/H1N1 pandemic vaccine
89618090|NCT01394614||Narcoleptics unexposed to A/H1N1 vaccine|Narcoleptic subjects who were unexposed (non-vaccinated or vaccinated after onset) to adjuvanted (ASO3) A/H1N1 pandemic vaccine.
89618091|NCT04588818|Experimental|Adalimumab plus Methotrexate|
89618092|NCT03406494|Experimental|intervention group|Early multicomponent physical therapy program plus sepsis standard therapy
89618093|NCT03406494|No Intervention|control group|Sepsis standard therapy, including early initiation of intravenous antibiotics, infection source debriding, appropriate fluid therapy, minimum sedation, protocolized weaning procedure, blood glucose control and early enteral feeding, etc.
89036412|NCT04448145||COVID-19 Positive|Participants who have been diagnosed with COVID-19 or experienced symptoms of COVID-19.
89036413|NCT04448145||COVID-19 Negative|Participants who have never tested positive for COVID-19.
89036414|NCT00532454|Other|tamoxifen|observation for clinical efficacy on tamoxifen according to CYP2D6 genotype
89036415|NCT01275625|Experimental|Treatment|Single arm study of combivir and maraviroc for 48 weeks
89036416|NCT05465720|Active Comparator|motor|
89618094|NCT01394692|Active Comparator|intraoperative MRI|tumor resection with intraoperative MRI-guidance
89618095|NCT01394692|Active Comparator|conventional group|standard microsurgical tumor resection
89618096|NCT01422070||Patients admitted to the Study Units|Consecutive adult patients consecutively admitted to the Study Units during one month (either from 7th November to 4th December 2010, or from 16th January to 12th February 2012)
89618097|NCT01422226|Experimental|Experimental active comparator|"Drug: Misoprostol~Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion"
89618098|NCT01422226|Placebo Comparator|Placebo comparator|"Other: Placebo~Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion"
89618099|NCT01423162|Experimental|Drink with Vit C then drink without Vit C|Fortified oat drink with vitamin C on day 1 followed by fortified oat drink without vitamin C on day 2
89618100|NCT01423162|Experimental|Drink without Vit C then drink with Vit C|Fortified oat drink without vitamin C on day 1 followed by fortified oat drink with vitamin C on day 2
89618101|NCT05170542|Experimental|Camrelizumab+S-1|
89618102|NCT01328782|Active Comparator|The group receiving oral pain medicine|This group will receive Oxycodone with Acetaminophen orally
89036417|NCT05465720|Experimental|sensory|
89036418|NCT05465720|Experimental|cognitive|
89036419|NCT05463458|Placebo Comparator|control|included 51 patients who will receive Standard of nutrition Care (2.0 g/kg body weight/day(A I) Calories should be in range of 25-30 Kcal/kg body weight/day.
89618103|NCT01328782|Active Comparator|The group receiving bupivacaine and oral pain medicine|This group will receive an intra-articular shot during surgery and will then be sent to the recovery room to receive pain medication as needed.
89618104|NCT01328782|Active Comparator|The group receiving ropivacaine and oral pain medicine|This group will receive an intra-articular shot of ropivacaine during surgery and will be sent to the recovery room to receive pain medicine as needed.
89618105|NCT04447326|Experimental|IC＋CCRT＋Toripalimab＋Endostar|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w; Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles; Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles.
89618106|NCT04447326|Active Comparator|IC＋CCRT|Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg/m2 d1,8; DDP 80mg/m2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg/m2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy/30-33f, 5d/w, 6-7 w.
89618107|NCT01426360|Experimental|strontium chloride/potassium nitrate dentifrice|
89618108|NCT01426360|Placebo Comparator|control dentifrice|
89618109|NCT03411330|Active Comparator|Group H (Hyaluronidase added to local anaesthetics)|"group H scalp block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg , Hyaluronidase will be added in in a dose of 1500 IU . The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block and not just a ring block. At the end of the scalp block further local anesthetic can be infiltrated locally to the pin sites and 7 nernes supraorbital nerve, a branch of the trigeminal nerve,supratrochlear nerve, a branch of the trigeminal nerve.~zygomaticotemporal nerve,auriculotemporal nerve, lesser occipital nerve, greater occipital nerve and greater auricular nerve"
89618110|NCT03411330|Active Comparator|Group A (local anaesthetics alone)|"Group A :scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum dose of 175 mg The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block, and not just a ring block. At the end of the scalp block; further local anesthetic can be infiltrated locally to the pin sites and 7 nernes Supraorbital nerve, a branch of the trigeminal nerve.~supratrochlear nerve, a branch of the trigeminal nerve. zygomaticotemporal nerve, auriculotemporal nerve, lesser occipital nerve, greater occipital nerve, greater auricular nerve"
89618111|NCT05167890|Active Comparator|Coffee Arm|Patients in coffee arm receive 1 cup of coffee 3 times per day (150 mL at 8:00 AM, 12:00 PM, and5:00 PM), in addition to the regular infusion therapy and/or alimentation starting the first day postoperatively till the end of the 3 postoperative day.
89036420|NCT05463458|Experimental|case|included 51 patients who will receive adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) and anti-oxidants.
89036421|NCT05459792|Experimental|ultrasound guided median nerve block|A linear transducer will be placed on the ventral aspect of the mid-forearm, where the median nerve is visible in the fascial plane between the flexor digitorum superficialis and flexor digitorum profundus after raising a skin wheal using local anesthetic, the needle will be introduced in-plane view from lateral to medial and aimed at the fascial plane adjacent to the median nerve.
89036422|NCT05459792|Experimental|ultrasound guided radial nerve block|A linear transducer will be placed on the forearm: at the elbow (the radial nerve between the brachioradialis and the biceps muscle). the preferred approach is to start proximally above the elbow and identify the radial nerve as a triangular hyperechoic structure coming off the distal humerus. then following this distally to the antecubital fossa, where the nerve will branch into its superficial and deep branches. the needle will be introduced in-plane view from lateral to medial aimed at the fascial plane adjacent to the radial nerve.
89036423|NCT05459792|Placebo Comparator|local infiltration|Intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle.
89036424|NCT04686825|Experimental|T1|DA-8010 2.5 mg (Fasting)
89036425|NCT04686825|Experimental|T2|DA-8010 2.5 mg (Fed)
89036426|NCT04686825|Experimental|T3|DA-8010 5 mg (Fasting)
89036427|NCT04686825|Experimental|T4|DA-8010 5 mg (Fed)
89618112|NCT05167890|Active Comparator|Orange Arm|Patients in orange arm receive 1 cup of orange juice 3 times per day (150 mL at 8:00 AM, 12:00 PM, and5:00 PM), in addition to the regular infusion therapy and/or alimentation starting the first day postoperatively till the end of the 3 postoperative day.
89618113|NCT03411252|Experimental|Mirabegron|Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
89618114|NCT03411252|Placebo Comparator|Placebo|Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.
89618115|NCT03394170||Osteoarthritis|Participants who are undergoing unicompartmental knee replacement will be considered OA status
89618116|NCT03394170||Non-Osteoarthritis|"Participants with an acute injury (occurring no more than 90 days prior to surgery) with no history of knee injury or surgery, will be considered Non-OA status"
89618117|NCT03396354|Experimental|Integrated robotic surgery|
89618118|NCT03396354|Active Comparator|Conventional laparoscopic surgery|
89618119|NCT05167812||Prospective cohort of couples with RPL|
89618120|NCT05167812||Retrospective cohort op couples with RPL|
89618121|NCT04390620||MUCODA|DAFILON - sterile, monofilament, non-absorbable surgical suture material produced from Polyamide
89618122|NCT01831427|Experimental|Andecaliximab 0.3 mg/kg IV single ascending dose (SAD)|Participants will receive andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.
89618123|NCT01831427|Experimental|Andecaliximab 1.0 mg/kg IV (SAD)|Participants will receive andecaliximab 1.0 mg/kg on Day 1.
89618124|NCT01831427|Experimental|Andecaliximab 2.5 mg/kg IV (SAD)|Participants will receive andecaliximab 2.5 mg/kg on Day 1.
89618125|NCT01831427|Experimental|Andecaliximab 5.0 mg/kg IV (SAD)|Participants will receive andecaliximab 5.0 mg/kg on Day 1.
89618126|NCT01831427|Placebo Comparator|Placebo Pooled (SAD)|Participants will receive placebo on Day 1.
89618127|NCT01831427|Experimental|Andecaliximab 0.3 mg/kg IV multiple ascending doses (MAD)|Participants will receive andecaliximab 0.3 mg/kg on Days 1, 15, and 29.
89618128|NCT01831427|Experimental|Andecaliximab 1.0 mg/kg IV (MAD)|Participants will receive andecaliximab 1.0 mg/kg on Days 1, 15, and 29.
89618129|NCT01831427|Experimental|Andecaliximab 2.5 mg/kg IV (MAD)|Participants will receive andecaliximab 2.5 mg/kg on Days 1, 15, and 29.
89618130|NCT01831427|Experimental|Andecaliximab 5.0 mg/kg IV (MAD)|Participants will receive andecaliximab 5.0 mg/kg on Days 1, 15, and 29.
88987657|NCT01248247|Experimental|Group 3 - AZD6244 + MK-2206|AZD6244 100 mg by mouth daily of a 28 day cycle. MK-2206 100 mg by mouth every week of a 28 day cycle.
88987658|NCT01248247|Experimental|Group 4 - Sorafenib|Sorafenib 400 mg by mouth twice a day for a 28 day cycle.
88987659|NCT04518241|Experimental|Condition 1|Core, fixed compensation, TMQQ, MI sessions
88987660|NCT04518241|Experimental|Condition 2|Core, lottery prize, TMQQ, MI sessions
88987661|NCT04518241|Experimental|Condition 3|Core, fixed compensation, MI sessions
88987662|NCT04518241|Experimental|Condition 4|Core, lottery prize, MI sessions
88987663|NCT04518241|Experimental|Condition 5|Core, fixed compensation, TMQQ
89618131|NCT01831427|Experimental|Andecaliximab 150 mg SC (Adaptive MAD)|Participants will receive andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.
89618132|NCT01831427|Placebo Comparator|Placebo Pooled (MAD)|Participants will receive placebo on Days 1, 15, and 29.
89618133|NCT01426828|Other|Arm A|"Arm A will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of KLH only vaccine."
89618134|NCT01426828|Other|Arm B|Arm B will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of ID-KLH Vaccine Myeloma Immunoglobulin Idiotype Vaccine (id-KLH vaccine)
89618135|NCT03126474||Delphi panel|Group of expert surgeons who have experience dealing with distal radius fractures No intervention will be performed on a patient. Participants will discuss and aim to obtain agreement about best treatment options for a variety of cases
88987664|NCT04518241|Experimental|Condition 6|Core, lottery prize, TMQQ
88987665|NCT04518241|Experimental|Condition 7|Core, fixed compensation
88987666|NCT04518241|Experimental|Condition 8|Core, lottery prize
88987667|NCT00504790|Experimental|GSK923295|anti-mitotic compound under study
88987668|NCT02275429|Other|Runners|Each year, about 1,200 runners residing on Reunion Island take the start of the Madmen's Diagonal ultramarathon. Among those, 500 runners will be selected at random and will receive a letter informing them of the study and requesting their participation. Those who accept are to contact the study team. Among those volunteers, 100 runners will be selected randomly and included in the study. They will undergo a blood test the day before the race starts (day 0, when they retrieve their race number), upon completion of the race, and upon days 7 and 28.
88987669|NCT02483260|Other|10-day course of treatment|10-day course of treatment with follow-up 14 ± 2 days after first dose
89618136|NCT01830881|Placebo Comparator|placebo-cherry syrup and ibuprofen|5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
89618137|NCT01830881|Active Comparator|Midazolam and ibuprofen|5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
89618138|NCT03404700|Experimental|Group 1:Test breakfast A and B|"*Please note: Part I of the study does not have separate groups. All subjects will undergo RFPM. The description of groups presented below is for part II of the study.~Subjects will have egg breakfast(test breakfast A) and egg breakfast with high saturated fat (test breakfast B) in any order."
89618139|NCT03404700|Experimental|Group 2:Test breakfast A and C|Subjects will have egg breakfast and (test breakfast A) and cereal breakfast (test breakfast C) in any order.
89618140|NCT03404700|Experimental|Group 3:Test breakfast A and D|Subjects will have egg breakfast (test breakfast A) and cereal breakfast (test breakfast C) in any order.
89618141|NCT03404700|Experimental|Group 4:Test breakfast B and C|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast (test breakfast C) in any order.
89618142|NCT03404700|Experimental|Group 5:Test breakfast B and D|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast with high saturated fat (test breakfast D) in any order.
89618143|NCT03404700|Experimental|Group 6:Test breakfast C and D|Subjects will have cereal breakfast (test breakfast C) and cereal breakfast with high saturated fat (test breakfast D) in any order
89618144|NCT01396486|Active Comparator|Omega-3/Placebo|Combination Omega-3 and Placebo treatment.
89618145|NCT01396486|Active Comparator|Placebo/Inositol|Combination Placebo and Inositol treatment.
89618146|NCT01396486|Active Comparator|Omega-3/Inositol|Combination Omega-3 and Inositol treatment.
89618147|NCT05215002|Experimental|Telephone call|Patient will receive a telephone call in the evening of the day of the surgery or one day after surgery
89618148|NCT05215002|Experimental|No telephone call|Patient will not receive a telephone call in the evening of the day of the surgery or one day after surgery
89618149|NCT03395964|Active Comparator|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
89618150|NCT03395964|Experimental|Hybrid Dyna-CT guided localization|Patients will be brought into the Hybrid OR, and placed in the lateral decubitus position. A C-arm CT scan of the pre-determined ﬁeld of view that included the nodule position will be acquired during an end-inspiratory hold maneuver using a 5 sec scan protocol with 0.36mGy/projection and 248 projections acquired over 200°. The radiologist reviewed the C-arm CT scan to localize the nodule and plan trajectories for percutaneous hook-wire placement using Syngo iGuide needle guidance software. The planned needle pathways will be integrated into the C-arm fluoroscopic imaging system, which provided laser crossbar and guidance markers on fluoroscopy images to direct the needle pathway for hook wire placement.
89618151|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for 7 days|Participant will received 7-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal.
89618152|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for14 days|Pparticipant will received 14-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal
89618153|NCT01397656|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations followed by cross-over to CPR with Continuous Compressions
89618154|NCT01397656|Active Comparator|CPR with Continuous Compressions|Continuous Chest Compressions without ventilation followed by CPR 30:2 (30 chest compressions to 2 ventilations)
89618155|NCT01330420|Experimental|Relaxation Response Resiliency Program for Depression|"The Relaxation Response Resiliency Program for Depression (3RP-D) is a low-cost, easily replicable, 6-session, 1.5 hour, mind body intervention.~The 3RP-D was designed to promote resiliency by reducing the harmful effects of stress through the elicitation of the relaxation response, and through skill training to enhance positive attitudes and beliefs, nutrition, exercise, recuperative sleep, social support, and coping. Specific interventions include: cognitive behavioral therapy (CBT), enhancing social support (SS), cultivating positive attitudes and beliefs (CPE), and promoting Healthy Lifestyle Habits(HL). The 3RP-D program has been manualized for use by group facilitators and health center patients."
89618156|NCT03126942|Experimental|Novaloc, then Locator|Participants will receive the Novaloc attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Locator attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
89618157|NCT03126942|Active Comparator|Locator, then Novaloc|Participants will receive the Locator attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Novaloc attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
89618158|NCT01838681|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
89618159|NCT01838681|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available ADT
89618160|NCT03404544|Active Comparator|Carbetocin bolus|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 3 ml syringe over 2 sec and the 10 ml syringe will contain only normal saline given as infusion over 10 min.
89618161|NCT03404544|Experimental|Carbetocin infusion|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 10 ml syringe as an infusion over 10min and the 3 ml syringe will contain only normal saline given iv over 2 sec as a bolus.
89618162|NCT01398280|Experimental|Aminocaproic Acid (ACA)|Subjects will treat their facial skin twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
88987670|NCT04515628|Experimental|Period A: Rosuvastatin|
88987671|NCT04515628|Experimental|Period B: Branebrutinib|
88987672|NCT04515628|Experimental|Period C: Branebrutinib + Rosuvastatin and Branebrutinib|
88987673|NCT04515628|Experimental|Period D: Branebrutinib|
88987674|NCT00141011|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
88987675|NCT00141011|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
88987676|NCT04517734||Pregnant Adolescents|
88987677|NCT04517734||Pregnant Women Carrying Multiple Fetuses|
88987678|NCT00504907|Experimental|Cohort A|Placebo or BTA9881 -10mg
88987679|NCT00504907|Experimental|Cohort B|Placebo or BTA9881 - 10mg
88987680|NCT00504907|Experimental|Cohort C|Placebo or BTA9881 - 25mg
88987681|NCT00504907|Experimental|Cohort D|Placebo or BTA9881 - 50mg
88987682|NCT00504907|Experimental|Cohort E|Placebo or BTA9881 - 100mg
89618163|NCT01398280|Placebo Comparator|Vehicle cream|Subjects will apply vehicle twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
89618164|NCT03403842|Active Comparator|PERIDURAL|Peridural catheter positioning with a continuous infusion of ropivacaine 0,2% 99 ml+ sufentanil 50 mcg at an infusion rate of 4-6 ml/h
89618165|NCT03403842|Active Comparator|PCA MORPHINE|Patient controlled analgesia of endovenous morphine, injection dose 1 mg, lock-out time 10 minutes, maximum dosage for hour 4 mg
89618166|NCT03403842|Experimental|SSTS|Patients controlled analgesia of sublingual sufentanil tablet system, 15 mcg sufentanil tablets, lock out time 20 minutes
89618167|NCT01398982|Placebo Comparator|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
89618168|NCT01398982|Experimental|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
89618169|NCT03394092||STEMI|The study population consists of 50 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
89618170|NCT03394092||Control|50 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as control group.Quantitative changes of IgG glycosylation be measured only once on admission.
89618171|NCT02203162|Experimental|cough reflex sensitivity|electronic cigarette exposure
89618172|NCT04589897|Experimental|Experimental|Manuka honey sinus rinse
89618173|NCT04589897|Active Comparator|Standard|Standard sinus rinse
89618174|NCT04290000||hematological malignancies|hematological malignancies treated with CAR-T Cells
89618175|NCT04447560|Experimental|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol before and after the plane block and two researchers will measure the radius and area of those vessels separately.
89618176|NCT03394014|Active Comparator|popliteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) once circumferentially around the sciatic nerve at the popliteal fossa using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA)
89618177|NCT03394014|Active Comparator|subgluteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) circumferentially around the sciatic nerve at the subgluteal region using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA).
89618178|NCT03401970|Active Comparator|Acellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.
89618179|NCT03401970|Experimental|Cellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
89618180|NCT03401970|Experimental|Low-carbohydrate high-fat diet|Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.
89618181|NCT01427296|Active Comparator|OsmoPrep Tablets|
89618182|NCT01427296|Active Comparator|HalfLytely and Bisacodyl Tablet|
89618183|NCT03126240||sleeve Gastrectomy|This is a five-trocar technique. The abdominal cavity is accessed through a 1cm supraumbilical incision using an optical trocar. The operating ports are inserted under direct vision. The gastroesophageal (GE) junction is exposed. A point on the greater curvature approximately 3-6cm to the pylorus is identified as the distal extent of the resection. Ultrasonic shears are used to divide the vessels long the greater curve up to the angle of His. Linear cutting staplers are used to vertically transect the stomach, creating a narrow gastric tube with. A 19Fr drain is placed in the subhepatic space near the staple line. The resected portion of the stomach is extracted through one of the working ports.
89618184|NCT03126162|Experimental|Bladder Backfilled group|Subjects randomized to the bladder backfilled group (Group A) will have 200 mL of normal saline instilled into their bladders prior to removal of the foley catheter. The foley catheter will subsequently be removed
88987683|NCT00504907|Experimental|Cohort F|Placebo or BTA9881 - 200mg
88987684|NCT00504907|Experimental|Cohort G|Placebo or BTA9881 - 400mg
88987685|NCT00504946|Active Comparator|I|
88987686|NCT00504946|Active Comparator|II|
88987687|NCT00504946|Placebo Comparator|III|
88987688|NCT00504946|Active Comparator|A|
88987689|NCT00504946|Placebo Comparator|B|
88987690|NCT00505024|Experimental|IVRS Only|
89618185|NCT03126162|Placebo Comparator|Control group|Subjects randomized to the control group (Group B) will just have their foley catheters removed at the end of the surgery. This is routinely done post-operatively after routine gynecologic surgery.
89618186|NCT03401736|Experimental|Group M：received midazolam|Patients who requires the mechanical ventilation allocated to the midazolam group (group M) were treated with an infusion bolus of 0.05 mg/kg and continuous infusion of 0.04 to 0.20 mg/kg/hour, with the dosage adjusted to achieve the desired level of sedation.
89618187|NCT03401736|Active Comparator|Group D: received dexmedetomidine|Patients who requires the mechanical ventilation allocated to the dexmedetomidine group (group D) received an infusion bolus of 1 ug/kg within 10 minutes and continuous infusion of 0.25 to 0.75 ug/kg/hour, with the dosage adjusted to achieve the desired level of sedation.All patients maintained BIS between 65~85 and the Ramsay score was 3 to 4.
89618188|NCT02203786|Active Comparator|Haloperidol|"Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
89618189|NCT02203786|Active Comparator|Fluphenazine|"Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
89618190|NCT03009058|Experimental|IMM-101 + Gem panc ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
89618191|NCT03009058|Experimental|IMM-101+Gem/nab-paclitaxel panc ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
89618192|NCT03009058|Experimental|IMM-101+Gem+capecitabine panc ca|"IMM-101 will be given in combination with gemcitabine +capecitabine combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
89618193|NCT03009058|Experimental|IMM-101 + FOLFIRINOX panc ca|"IMM-101 will be given in combination with standard FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan and OXaliplatin) treatment.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
89618194|NCT03009058|Experimental|IMM-101+FOLFOX colorectal cancer|"IMM-101 will be given in combination with standard FOLFOX (FOLinic acid, Fluorouracil and OXaliplatin) treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
89618195|NCT03009058|Experimental|IMM-101+FOLFIRI+CETUXIMAB CRC|"IMM-101 will be given in combination with standard FOLFIRI (FOLinic acid, Fluorouracil and IRInotecan) + cetuximab combination treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
89618196|NCT03009058|Experimental|IMM-101+Gem cholangio|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
89618197|NCT03009058|Experimental|IMM-101+Gem lung ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter
89618198|NCT03009058|Experimental|IMM-101+Gem + nab-paclitaxel lung ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
88987691|NCT00505024|Experimental|IVRS + Symptoms Report|
88987692|NCT04511416|Active Comparator|Intervention|Metformin
88987693|NCT04511416|Placebo Comparator|Placebo|Placebo
88987694|NCT04517695||COVID-19 ICU Patients|Patients who are admitted to the ICU with a confirmed SARS-CoV-2 infection
88987695|NCT04517695||ICU Patients with bacterial infection|"Patients who are admitted to the ICU with a confirmed bacterial infection.~Bacterial infection is defined as the clinical suspicion of a bacterial infection with the presence of two or more clinical markers of infection:~abnormal body temperature (>38C or <36C)~increased heart rate (>90 b/min),~increased respiratory rate > 20/min or a decreased arterial CO2: PaCO2 < 32 mmHg~Abnormal white blood cell count: < 4000 mm3 or > 12,000 /mm3 or > 10% immature cells~OR~The presence of a positive (blood) culture with bacterial growth."
88987696|NCT00407082|Experimental|Fluocinolone acetonide 0.59mg|Fluocinolone acetonide ocular implant 0.59mg
88987697|NCT00407082|Experimental|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
88987698|NCT00407082|No Intervention|No intervention|Fellow eye
89618199|NCT03009058|Experimental|IMM-101+anti-PD1 lung ca|"IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab.~In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen."
89618200|NCT03009058|Experimental|IMM-101+Gem melanoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
89618201|NCT03009058|Experimental|IMM-101+anti-PD1 melanoma|IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab. The first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
89618202|NCT03009058|Experimental|IMM-101+ anti-CTLA-4 melanoma|IMM-101 will be given in combination with standard treatment with ipilimumab. In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the ipilimumab cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
89618203|NCT03009058|Experimental|IMM-101+Gem breast cancer|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
89618204|NCT03009058|Experimental|IMM-101+Gem/ nab-paclitaxel breast|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
89618205|NCT03009058|Experimental|IMM-101 + Gem sarcoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
89618206|NCT03009058|Experimental|IMM-101+cyclophosphamide|"IMM-101 will be given in combination with low dose cyclophosphamide (300mg/m2 in patients with solid malignancies.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
89618207|NCT01611857|Experimental|Maximum Tolerated Dose|Phase I trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors followed by a Phase II portion for patients with first-line metastatic GE cancer.
89618208|NCT03393702|Experimental|Gabapentin|"Single dose preoperative gabapentin.~After surgery gabapentin 2 times per day for 3 days."
89618209|NCT03393702|Placebo Comparator|Placebo Control|"Single dose preoperative placebo control.~After surgery placebo 2 times per day for 3 days."
89618210|NCT03393624||Cases: patients with dark circles|Patients who believe they have periorbicular hyperchromia and have a confirmatory physical examination performed by a dermatologist.
89618211|NCT03393624||Controls: patients without dark circles|Patients who believe that they do not have periorbicular hyperchromia under their eyes and have physical examination that excludes dark circles carried out by a dermatologist.
89618212|NCT02204176|Sham Comparator|Exercise info only|"Participants in the exercise information only group will engage in a group discussion with the principal investigator to discuss what constitutes regular physical activity and benefits of exercise and basic tips on the activity itself. Guidelines for prescribing suggested exercises will be based on recommendations from the U.S. Department of Health and Human Services (USDHHS, 2008) as well as risks associated with exercise and how they can be reduced."
89618213|NCT02204176|Experimental|Exercise info + implementation intentions|"Participants in the exercise information plus implementation intentions group will engage in a group discussion with the principal investigator to discuss all of the components from the exercise information only approach, but with more emphasis on how to create implementation intentions. Discussions will revolve around possible barriers to exercise plans and how to overcome/address those barriers by making specific plans of when and where to exercise, along with designating which types of exercises they will perform and for how long (or how many repetitions)."
89618214|NCT02204176|Experimental|Exercise info + implementation intentions + industriousness|"Participants in the exercise information plus implementation intentions plus industriousness training group will engage in a group discussion with the principal investigator to discuss all of the components from the second approach as well as include findings linking industriousness and exercise behavior. Participants will be directed to think about and generate solutions to how they can become more industrious and monitor their efforts despite the difficulties they may face and relate these solutions to help them engage in more exercise behavior."
89618215|NCT03399864|Experimental|Experimental group|Apart from receiving scheduled medical follow-up, the subjects in the experimental group will receive a weekly 45-minute lesson on musical training for 52 weeks. The musical training will be conducted by the Music Children Foundation and be implemented in a ratio of one subject to one qualified orchestral performer at the subjects' homes. A musical instrument will be assigned to each subject based on their interests and the results of the prior assessment of subjects' expiratory function and fine motor skills. The musical training will start at the lowest level, such as hitting simple notes and end at the highest level, such as playing an entire song.
89618216|NCT03399864|Other|Control group|The subjects will receive usual care, such as medical follow-up according to the schedule of the oncology units.
89618217|NCT01829477|Experimental|TAK-875 50 mg|TAK-875 50 mg tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
89618218|NCT01829477|Placebo Comparator|Placebo|TAK-875 placebo-matching tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
89618219|NCT02204566|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
89618220|NCT03126864|Experimental|CD33-CAR-T cells - Adult Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
89036428|NCT05455892||Elder patients hospitalized for COVID-19 in geriatric short stay units.|All patients over 70 years of age, with a positive Polymerase Chain Reaction or a high presumption of COVID-19, hospitalized in short geriatric units in University Hospital of Lyon, who agree with retrospective collection of their clinical datas.
89618221|NCT03126864|Experimental|CD33-CAR-T cells - Pediatric Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
89036429|NCT05454800|Experimental|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Individuals with AIS in this group, in accordance with the Schroth classification, individually planned, aimed at correcting and stabilizing the spine in three dimensions, an exercise program will be applied in 45-60 minutes sessions, 2 days a week, for 8 weeks, a total of 16 sessions. In addition to corrective exercises specific to scoliosis, physical activity counseling will also be given.
89618222|NCT03399630|Active Comparator|Injection of Autologous Adipose Tissue|Treatment knee receives injection of 1.5 cc's of adipose tissue mixed with 1.5 cc's of Lactated Ringers
89618223|NCT03399630|Placebo Comparator|Injection of Lactated Ringers|Placebo control group receives injection of 3 cc's of Lactated Ringers with no adipose tissue
89618224|NCT03395730|Experimental|"• Group (A) Study Group 1:"|"In the labor room women in Group A (n = 50):~Clamping and cutting the placental cord after delivery of the baby.~Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution"
89618225|NCT03395730|Experimental|"• Group (B) Study Group 2:"|"In the labor room women in Group B (n = 50):~Clamping and cutting the placental cord after delivery of the baby.~Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes."
89618226|NCT03395730|Active Comparator|"• Group (C) Control Group:"|"In the labor room women in Group C (n = 50):~Clamping and cutting the placental cord after 2 minutes of delivery of the baby.~Placenta will be delivered spontaneously after appearance of clinical signs of placental separation"
89618227|NCT01334086|Experimental|Aprepitant|
89618228|NCT03399474|Active Comparator|Lidocaine only|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline for intravenous regional anesthesia.
89618229|NCT03399474|Experimental|0.5 ug/kg dexmedetomidine|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.5 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min for intravenous regional anesthesia.
89036430|NCT05454800|Experimental|Scoliosis Specific Corrective Exercises|Individuals with AIS in this group, in accordance with the Schroth classification, individually planned, aimed at correcting and stabilizing the spine in three dimensions, an exercise program will be applied in 45-60 minutes sessions, 2 days a week, for 8 weeks, a total of 16 sessions.
89036431|NCT04686552|Experimental|cinnamon|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served with 6 g of ground cinnamon.
89036432|NCT04686552|No Intervention|control|The test meal consisted of ½ cup dry instant oatmeal, prepared with 1 cup of 2% milk served without 6 g of ground cinnamon
89036433|NCT00533988|No Intervention|5592|Standard triple lumen catheter
89036434|NCT00533988|Active Comparator|5593|Antimicrobial impregnated catheter (chlorhexidine silver-sulfadiazine)
89036435|NCT05285748|Experimental|Self-Paced Intensity Physical Activity|
89036436|NCT05285748|Active Comparator|Prescribed Moderate Intensity Physical Activity|
89036437|NCT05424887|Experimental|100 mg AK3280|After the 4-week screening period, Eligible subjects will be administered daily 100 mg AK3280 b.i.d. for 24weeks
89036438|NCT05424887|Experimental|200 mg AK3280|After the 4-week screening period, Eligible subjects will be administered daily 200 mg AK3280 b.i.d. for 24weeks
89036439|NCT05424887|Placebo Comparator|placebo|There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.
89036440|NCT05424887|Experimental|Extension Study Cohort|The extension study includes a 24-week medication observation period and a 4-week safety follow-up period. Subjects who meet the requirements will enter the extension study after 24 weeks of treatment in the main study. Subjects entering the extension study will continue to orally take AK3280 200 mg for 24 weeks.
89036441|NCT00533637|Experimental|1|NLA Nasal Spray
89036442|NCT00533637|Active Comparator|2|
89618230|NCT03399474|Experimental|0.25 ug/kg dexmedetomidine|1 Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.25 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min. for intravenous regional anesthesia.
89618231|NCT01611155|Experimental|Arm I (management of therapy complications)|Patients receive venlafaxine PO BID beginning on day 1 of and continuing through completion of FOLFOX.
89618232|NCT01611155|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID beginning on day 1 of and continuing through completion of FOLFOX.
89036443|NCT00533637|Placebo Comparator|3|
89618233|NCT01430182|Experimental|Methadone 0.2 mg/kg|0.2 mg/kg methadone by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
89618234|NCT01430182|Active Comparator|Morphine 0.2 mg/kg|0.2 mg/kg morphine by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
89618235|NCT05166408|Other|Buccinator myomucosal flap for primary cleft repair|Study group
89618236|NCT05166408|Other|Bardach two flap palatoplasty for primary cleft repair|Control group
89618237|NCT05097768|Active Comparator|Dexamethasone|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive Dexamethasone 0.5 mg.
89618238|NCT05097768|Active Comparator|Ketorolac|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive ketorolac 10 mg.
89618239|NCT05097768|Active Comparator|Meloxicam|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive meloxicam 7.5 mg.
89618240|NCT05097768|Active Comparator|Ibuprofen|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive ibuprofen 600 mg.
89618241|NCT05097768|Placebo Comparator|Placebo|Before the inferior alveolar nerve block injection by 60 minutes, the patient will receive placebo.
89618242|NCT01829243|Experimental|Milnacipran|Eligible subjects will receive milnacipran (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
89618243|NCT01829243|Placebo Comparator|Placebo|Eligible subjects will receive placebo (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
89618244|NCT03393312|Experimental|Bifrontal tDCS|"20 minutes of 2 mA transcranial direct current stimulation (tDCS), with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively).~The stimulation will be applied before or during task performance, depending on the condition assignment."
89618245|NCT03393312|Sham Comparator|Sham tDCS|"Participants receive 20 minutes of sham tDCS, with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively). In sham tDCS, stimulation starts with 8s fade in followed by 30s direct current followed by 5s fade out followed by 870s without any stimulation.~The stimulation will be applied before or during task performance, depending on the condition assignment."
89618246|NCT01838447|No Intervention|Usual care group|This group will receive daily cholecalciferol (vitamin D3) based on the Adequate Intake (AI) for infants and the Recommended Dietary Allowance (RDA) for children over 1 year. Specific dose amounts are 400 IU per day for infants (0-1 year), and 600 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a placebo solution.
89618247|NCT01838447|Experimental|High Dose Group|This group will receive cholecalciferol (vitamin D3) based on the age-specific tolerable daily upper intake level (UL). Specific dose amounts are 1600 IU per day for infants (0-1 year), and 2400 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a dose of 1200 IU per day to account for vitamin D in formula.
89618248|NCT03395574|Experimental|terlipressin group|group will receive terlipressin infusion one mg in 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of 160 μg per hour (8 ml/h).
89618249|NCT03395574|Placebo Comparator|saline (control) group|group will receive normal saline infusion 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of (8 ml/h).
89618250|NCT03395496|Experimental|Biodentine|Dental materials
89618251|NCT03395496|Experimental|ProRoot MTA|Dental Materials
89618252|NCT03399240|Experimental|Vitastiq device|Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.
89618253|NCT01829165|Experimental|rTMS Treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own fMRI images. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
89036444|NCT05466695|Experimental|tadalfil group|Patients will use daily tadalafil 5 mg for 2 months
89036445|NCT05466695|Experimental|sildenafil group|Patients will use daily sildenafil 25 mg for 2 months
89036446|NCT05284500||Pediatric cardiac surgery patients|Patients undergoing pediatric cardiac surgery with cardiopulmonary bypass between 2008 and 2018 at our institution.
89036447|NCT05423639|Experimental|Control group 1|Testing Palodent sectional matrix system only when placing Class II resin composite restorations is to increase proximal contact tightness.
89036448|NCT05423639|Active Comparator|Intervention group 2|A pre-contoured instrument called Optra contact (Ivoclar, Vivadent) will be used with group 2. For testing palodent matrix systems with Optracontact when placing Class II resin composite restorations is to increase proximal contact tightness with adjacent teeth when compared with group 1.
89036449|NCT05281185|Active Comparator|Severe haemophilia A patients with weight-based prophylaxis|Severe haemophilia A patients with low-dose standard half-life concentrates weight-based prophylaxis
89036450|NCT05281185|Experimental|Severe haemophilia A patients with low dose extended half-life PK-guided prophylaxis|Severe haemophilia A patients with low-dose extended half-life concentrates PK-guided prophylaxis
89036451|NCT00532532|Experimental|1|AV650 low dose
89036452|NCT00532532|Experimental|2|AV650 high dose
89036453|NCT00532532|Experimental|3|Placebo
89036454|NCT04393935|Experimental|Pharmacy delivered PrEP Intervention|Customers of the study pharmacies who participate in the intervention to receive PrEP through the pharmacy.
89036455|NCT05405036||Students|60 second-year students studying at the Department of Physiotherapy and Rehabilitation at University are planned to attend.
89036456|NCT05354297|Experimental|Cecelia Health|Access to live Cecelia health coach on the telephone for 1 year plus access to Cecelia health coach by text messaging (via the OneTouch Reveal mobile diabetes app). Subjects will be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) diabetes app.
89036457|NCT05354297|Experimental|Fitbit|Fitbit Inspire 2 wearable plus 1 year subscription to premium Fitbit application. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
89036458|NCT05354297|Experimental|Noom|Noom behavioural weight loss program subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
89036459|NCT05354297|Experimental|Welldoc|Multi-condition support program from Welldoc subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter.
89036460|NCT05276544|Experimental|phone counseling|dietary intervention via phone counseling
89618254|NCT01829165|Sham Comparator|Sham Treatment|"rTMS will be delivered for 20 sessions over 4 weeks. Placebo 10Hz rTMS will be delivered through sham stimulation electrodes. The rTMS coil will be positioned using neuro-navigation based on participants' own fMRI images, mimicking active rTMS treatment. Daily treatment regiments will last 36.5minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sham sessions for adverse events and/or side effects.~Upon completing the sham 20 sessions participants are unblinded and offered 20 further treatments of guaranteed open-label treatment. The open-label treatment would follow the active rTMS treatment protocol."
89618255|NCT04982172|Experimental|Interventional arm|Model-informed precision dosing of infliximab (intravenously administered) using a Bayesian forecasting software tool. Doses and dosing intervals will be derived from the software tool, aiming to maintain adequate exposure (trough concentration target 5 mg/L).
89036461|NCT05276544|Experimental|video counseling|dietary intervention via video counseling
89036462|NCT05276544|Experimental|Traditional follow up|dietary intervention via traditional follow up
89036463|NCT05346614|Experimental|Active lifestyle intervention|Individuals in the active intervention group will undergo diabetyping (diabetes type 2 phenotyping: glucose, and C-peptide responses to a glucose challenge). Based on the diabetype, individuals will receive recommendations to follow either a calorie-restricted (500kcal deficit minimum) low carbohydrate or a modified Mediterranean diet for a period of 18 weeks (total intervention is 24 weeks). Secondly, individuals will follow a personalized exercise program. Guidance and coaching (individual and small group) will be given via mobile app and digital platform. Individuals will receive real-time feedback based on their diet, exercise, and glucose levels (via continuous glucose monitoring for 4 weeks). Medications will be slowly withdrawn over the intervention period, with a focus on the first phase of the intervention.
89036464|NCT05346614|No Intervention|Usual care group|Individuals in the usual care group will receive standard diabetes care.
89036465|NCT04322565|Experimental|Colchicine|Administration of Colchicine 1mg (or 0.5 mg in CKD)/day + standard of care for COVID-19 pneumonia
89036466|NCT04322565|No Intervention|Standard of care|Standard of care for COVID-19 pneumonia
89036467|NCT04687826||Pancreaticoduodenectomy in 2015|Patients who underwent pancreaticoduodenectomy in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique. Most of the patients spent the first postoperative night in ICU where the monitoring of urine output and fluid balance are more specific than in a normal ward.
89036468|NCT04687826||Pancreaticoduodenectomy in 2017|Patients who underwent pancreaticoduodenectomy in 2017 got liberal intraoperative fluid therapy and most of the patients spent the first postoperative night in a regular ward.
89036469|NCT05267691||sun-protected|All patients with basal cell carcinoma in a sun protected body site
89036470|NCT05267691||sun-exposed|All patients with basal cell carcinoma in a sun exposed body site
89036471|NCT05342285||normal FMD|SLE femals patientd with normal flow mediated whose ages from 18 to 45yrs
89036472|NCT05342285||abnormal FMD|SLE femals with abnormal flow mediated dikation ages between 18 to 45yrs old
89036473|NCT05342285||Normal female|normal femals whise ages from 18 to 45yrs old
89036474|NCT05259189|Experimental|NBL-012 Injection|Two subjects will be enrolled in the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of NBL-012 Injection for subsequent dose cohorts
89036475|NCT05259189|Placebo Comparator|Placebo|2 out of 10 healthy subjects will be randomized to receive a single dose of placebo.
89036476|NCT05333354|Experimental|Experimental(simulation education group)|The experimental group (simulation teaching group), the content of simulation teaching is based on the simulation model, and includes five important elements: Instructor, student, educational practice, simulation situation design and characteristics, and result that design covering the four stages of learning, concrete experience, reflective observation, abstract conceptualization and action experience, and design lesson plans, which include delirium assessment and delirium risk factor detection. Delirium prevention and management (PADIS guidelines). The main objectives of the teaching plan design of the experimental group are: to be able to confirm delirium by assessment of the Delirium Assessment Scale; to confirm the risk factors by the history taking; to propose treatment and measures according to the assessment results. Secondary goals: Be able to perform handovers.
89036477|NCT05333354|No Intervention|Control(traditional group)|Nurses in the control group did not receive simulated situational teaching, but received classroom teaching 3 times (once every other week) (delirium assessment, risk factor assessment; PADIS treatment), each session of about 2 hours. In order to avoid inconsistent teaching content, the control group and the experimental group are not to be together in classroom.
89036478|NCT00532688|Experimental|1|5 patients: 28 days of n-acetylcysteine (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period.
89036479|NCT00532688|Placebo Comparator|2|28 days of oral distilled water (5ml) (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to intervention (N-acetylcysteine 500mg oral bd) for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
89036480|NCT00534066||Admitted|Patients presenting to the ED with acute exacerbation of CHF who require admission to the hospital directly from the ED
89036481|NCT00534066||Observational|Patients who present to the ED for acute exacerbation of CHF who are transferred to the Observation Unit from the ED for up to 24 hours.
89036482|NCT00534144|Active Comparator|Iron Sucrose|
89036483|NCT00534144|Active Comparator|Ferric Gluconate|
89036484|NCT00534183|Experimental|1|Olanzapine
89036485|NCT00534183|Active Comparator|2|Risperidone
89036486|NCT00534183|Active Comparator|3|haloperidol
89036487|NCT05303714|Active Comparator|Arm A (FOLFOX)|Patients randomized in the Arm A will undergo to 6 courses of systemic chemotherapy according to FOLFOX regimen, after these six courses of chemotherapy, radiologic restaging (CT scan) as well as a second staging laparoscopy will be performed. If a Progression Disease will be detected, the patient will end the trial and will undergo to II line chemotherapy regimen. If a stable disease or a partial response will be documented, after a multidisciplinary discussion, patient will undergo to either further 6 courses of chemotherapy or to cytoreductive surgery plus HIPEC.
89036488|NCT05303714|Experimental|Arm B (FOLFOX and PIPAC)|Patients randomized in the ARM B will undergo to 6 courses of systemic chemotherapy (FOLFOX regimen) plus PIPAC every two cycles of chemo (Fig.1). At least seven days should last between each PIPAC and the next chemotherapy course, and at least 14 days should last between the chemotherapy course and the next PIPAC. After six courses of chemotherapy and 3 PIPACs procedure, a radiologic restaging (CT scan) as well as a laparoscopic reassessment will be performed. If a Progression Disease will be detected, the patient will end the trial and will undergo to II line chemotherapy regimen. If a stable disease or a partial response will be documented, patient will be treated with cytoreductive surgery plus HIPEC.
89036489|NCT00534222||Quetiapine|
89036490|NCT00534222||Olanzapine|
89036491|NCT00534222||Risperidone|
89036492|NCT05296928|Experimental|umbilical incision|Placing the laparoscopic trocar by cutting the umbilicus directly at the entrance to the abdomen
89036493|NCT05296928|Active Comparator|subumbilical incision|Placing a laparoscopic trocar by making a sub-umbilicus incision at the entrance to the abdomen
89036494|NCT05223387|Experimental|Study Group|Anthogyr Axiom TL REG and corresponding Multi-Unit abutments
89036495|NCT05223387|Active Comparator|Control Group|Anthogyr Axiom BL REG and corresponding Multi-Unit abutment
89036496|NCT00532727|Experimental|Arm A|Carboplatin
89036497|NCT00532727|Active Comparator|Arm B|Docetaxel
89618256|NCT04982172|Active Comparator|Historical control arm|The treating physician adjusted the intravenously administered infliximab doses and dosing intervals without being guided by a model-informed precision dosing software tool. The primary objective was to extend the dosing interval. Therefore, dose de-escalation (interval extension with/without dose adjustment) were performed following a scheme at the treating physician's discretion.
89618257|NCT04592471||Orthosis Group 1|Use of kneeMID500 device
89036498|NCT04261218|Experimental|Group 1 - Dose Finding|The first 3 patients enrolled in Group 1 will receive tomivosertib at a dose of 100 mg orally twice daily (BID), under fasting conditions, and will be assessed for dose limiting toxicities (DLTs) during this 'run-in' period. They will also receive the first cycle of tomivosertib IN COMBINATION with weekly paclitaxel in the 'post run-in' period. Depending on the occurrence/absence of DLTs, this first group of 3 patients may need to be expanded (up to 9 patients) or the trial may proceed to start enrollment in Group 2 (detailed in the arm below).
89036499|NCT04261218|Experimental|Group 2 - Dose Expansion|It is anticipated that Group 2 patients will receive tomivosertib at a dose of 100 mg orally twice daily (BID) during the 'run-in' period, which is taken in combination with weekly paclitaxel (according to market label) during the 'post run-in' period.
89036500|NCT05274620|Other|IntelliCare|8 weeks of IntelliCare
89036501|NCT05262998|Active Comparator|CONTROL|Plate fixation
89036502|NCT05262998|Experimental|INTERVENTION|Intramedullary Screw
89618258|NCT04592471||Control Group 1|Control Group of the kneeMID500 Orthosis Group - No use of the device
89618259|NCT04592471||Orthosis Group 2|Use of kneeSTRONG700 device
89618260|NCT04592471||Control Group 2|Control Group of the kneeSTRONG700 Orthosis Group - No use of the device
89036503|NCT04687410|Active Comparator|FNA|
89036504|NCT04687410|Experimental|FNB|
89036505|NCT00532766|Experimental|2|Jusline Humulin
89036506|NCT04687449|Active Comparator|Active Comparator: Curcumin therapy added to standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
89036507|NCT04687449|Active Comparator|Active Comparator: Placebo with Standard COPD care|Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.
89036508|NCT04221009|Experimental|Intervention (single arm)|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
89618261|NCT04944186|Active Comparator|Intervention Group|Patients in the experimental group will receive structured pressure injury patient education. It is consists of 2 sessions followed by biweekly follow-up for 8-week. The first session lasts for two days; the duration is 80 minutes (40 minutes /day for two days). Method of delivery is face to face, one to one with the aid of PowerPoint presentation and booklet. In the second session, the duration remains the same (80 minutes; 40 minutes/day for 2 days). The method of delivery also the same but teaching aid video presentation will be used. Three videos with a duration of approximately 2 - 3 minutes. In the second session, participants will be given a task to perform and document in the booklet given to monitoring its adherence. Upon completion of the two sessions, the patient will be follow-up biweekly and monitored their progress.
89618262|NCT04944186|Other|Control group|Patients in this group shall continue with the standard patient education in the ward. Standard patient education routinely delivers through an informal verbal method after wound dressing is done.
89618263|NCT03393234|Experimental|A group|Patients who receive interphincteric resection (ISR) in this group will be given extra intraoperative radiation by INTRBEAM using low energy X-ray.
89618264|NCT03393234|No Intervention|B group|Patients who only receive interphincteric resection (ISR) in this group without intraoperative radiation.
89618265|NCT01837823|Experimental|rosuvastatin|All subjects will receive rosuvastatin 40mg/day
89618266|NCT03393156|Experimental|Internet-based metracognitive therapy|"The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book Metacognitive therapy for depression and anxiety by Adrian Wells (2011)."
89618267|NCT03393156|No Intervention|Wait-list|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.
89618268|NCT03395262|Experimental|Active with caffeine|Novel formula with caffeine
89618269|NCT03395262|Active Comparator|Active without caffeine|Novel formula without caffeine
89618270|NCT03395262|Placebo Comparator|Placebo|Dextrose
89618271|NCT03852888|Experimental|mtugroup|All patients managed for rheumatoid arthritis (according to the ACR / EULAR 2010 criteria) in the Rheumatology Department of the University Hospital of Reims and treated with methotrexate monotherapy.
89618272|NCT03399162|Experimental|PREHAB Group|"Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.~Patients in this group will also complete an 8-week PREHAB exercise program, with weekly exercise classes and a list of exercises to complete at home."
89036509|NCT04200924||Children with idiopathic toe walking|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
89057331|NCT04540679|Active Comparator|Outpatient - Platform Access|Patient will be provided access to the platform within 2 weeks of admission to the outpatient program. If patient is transitioning from the inpatient program, their access to the platform will be guided by which group they were originally assigned to (i.e. if a 6 week delay is applicable).
89618273|NCT03399162|Active Comparator|Standard of care group|Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
89618274|NCT04755972|Active Comparator|N-acetylcysteine|Inhalation of 5 ml-s of N-acetylcysteine every 12 hours.
89618275|NCT04755972|Active Comparator|Hypertonic saline|Inhalation of 5 ml-s of 5% sodium chloride every 12 hours.
89618276|NCT04755972|Active Comparator|Bicarbonate|Inhalation of 5 ml-s 8.4% sodium bicarbonate every 12 hours.
89618277|NCT04755972|No Intervention|Control group|No preventive inhalation.
89618278|NCT01828073||Cohort 1: Full term infants exposed in utero to maternal RAL|Infants, who were expected to be ≥2000 grams at birth (i.e. full-term) at time of enrollment, born to women with HIV-1 infection who received RAL 400 mg twice daily for at least two weeks prior to delivery and continued to receive ARVs during labor. The group also includes the mothers of these infants.
89618279|NCT01828073||Cohort 2: LBW infants exposed in utero to maternal RAL|Infants, who were expected to be ≤2500 grams at birth (i.e. LBW) at time of enrollment, born to women with HIV-1 infection who received at least one dose of RAL 400 mg within 2 to 24 hours prior to delivery. The group also includes the mothers of these infants.
89618280|NCT04697693|Experimental|Treatment with escitalopram or duloxetine|Participant will be begun on either escitalopram 10mg or duloxetine 30mg. The default medication will be escitalopram. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the Hamilton Rating Score for Depression (HRSD) >7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study. Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg of duloxetine for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study
89618281|NCT03819114|Experimental|A: LNG 1.5 mg among participants on EFV-based ART (randomized)|Participants received 1.5 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
89618282|NCT03819114|Experimental|B: LNG 3.0 mg among participants on EFV-based ART (randomized)|Participants received 3mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
89618283|NCT03819114|Experimental|C: LNG 1.5 mg among participants on DTG-based ART (assigned)|Participants received 1.5 mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
89618284|NCT03819114|Experimental|D: LNG 3.0 mg among participants on RIF-INH TB Therapy (assigned)|Participants received 3mg of LNG once orally on Day 0 and were followed post-treatment for 4 weeks.
89618285|NCT01827839|Experimental|HZ Group|Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.
89618286|NCT03399084|Experimental|Ferric carboxymaltose (test)|Patients will receive a single dose of Ferric carboxymaltose
89036510|NCT04200924||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
89036511|NCT05230979|Experimental|Normal weight|People with normal weight will consume 40 g of common bean baked snack, cooked beans or white bread for a single occasion.
89618287|NCT03399084|Active Comparator|Ferric carboxymaltose (reference)|Patients will receive a single dose of Ferric carboxymaltose
89618288|NCT05239416|Experimental|Fat grafting combined with compression therapy|"Fat grafting + compression bandages/stockings~Fat grafting:~For the purposes of this study, the standard technique will be used for all patients~General or local anaesthesia.~Performed under the supervision of a plastic surgeon.~Harvest site will be either abdomen or lower limb.~After harvesting fat by liposuction, the lipoaspirate (which contains the ASCs) will be injected at the base of the healed venous ulcer within the same aseptic operative setting.~Compression therapy:~compression bandages / stockings as per routine practice"
89036512|NCT05230979|Experimental|Overweight|People with overweight will consume 40 g of common bean baked snack, cooked beans or white bread for a single occasion.
89036513|NCT05230979|Experimental|Glycemic index|Determination of glycemic index under the ISO 26642:2010.
89036514|NCT00532818|Placebo Comparator|1|
89618289|NCT05239416|No Intervention|Compression therapy only|"Compression therapy:~compression bandages / stockings as per routine practice"
89618290|NCT04722120|Active Comparator|Conventional liver CT|Underwent conventional liver CT on HCC high-risk patient
89618291|NCT04722120|Experimental|Double low dose CT|Underwent double low dose liver CT with 30% lower radiation dose and 20% contrast media on HCC high-risk patient
89618292|NCT04709250|Active Comparator|group A: receive ultrasound-guided interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine consistent with the overall local anaesthetic dosing of less than 2.5 mg/kg. will be injected with low pressures to avoid intraneural injection.
89618293|NCT04709250|Active Comparator|group B: receive ultrasound-guided selective nerve block|The patient will be put in the sitting position, a linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to obtain a view of the suprascapular nerve a 22 G, 8 cm needle will be advanced in-plane and a total of 5-8 mL of 0.25% bupivacaine is injected then the arm adducted the linear probe will be placed at the junction of the pectoralis major muscle and the biceps muscle such that the axillary artery will be visualized in cross-section The probe will be moved towards the biceps muscle (laterally) until the musculocutaneous nerve is visualized and8 ml of 0.25% bupivacaine will be injected
89036515|NCT00532818|Experimental|2|
89036516|NCT04687397||Disorders of consciousness|Patients diagnosed as either in a Vegetative State or in a Minimally Conscious State
89618294|NCT01827371|Experimental|Arm C|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 22.
89618295|NCT01827371|Experimental|Arm B|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 15.
89618296|NCT01827371|Experimental|Arm A|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 29.
89618297|NCT01827371|Experimental|Arm D|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via Stratis™ on Days 1 and 29.
89618298|NCT03399006||preeclampsia|women who developed preeclampsia. Preeclampsia was defined as a blood pressure 140/90 mmHg and proteinuria of 300 mg in 24 hours, or two readings of at least 2+ on dipstick analysis of midstream urine specimens if no 24-hour urine collection was available in absence of urinary tract infection
89618299|NCT03399006||Normal pregnancy|women with normal blood presure
89036517|NCT05209035|Active Comparator|Trazodone|
89036518|NCT05209035|Placebo Comparator|Placebo|
89036519|NCT04687202||Patients developing CA|Including patients developing intraoperative cardiac arrest during transcatheter aortic valve implantation from January 2014 to May 2019
89036520|NCT00534261|Experimental|1|patients received Avonex IM injections and be evaluated for quality of life criteria
89036521|NCT04686708||Pre-pandemic period|Patients managed in the pre-pandemic period
89036522|NCT04686708||Pandemic period|Patients managed in the pandemic period
89036523|NCT00534300|Experimental|A|
89036524|NCT00534300|Placebo Comparator|B|
89036525|NCT05202405|Experimental|Sequence A|Period 1 : Reference Drug(AD-221A and AD-221B) Period 2 : Test Drug(AD-221)
89036526|NCT05202405|Experimental|Sequence B|Period 1 : Test Drug(AD-221) Period 2 : Reference Drug(AD-221A and AD-221B)
89036527|NCT00532857|Experimental|Paclitaxel/Gemcitabine/Trastuzumab|
89036528|NCT05200377||Cerebral small vessel disease group|Patients with clinically and radiologically evidenced cerebral small vessel disease. Patients are grouped by severity of cerebral small vessel disease assessed by comprehensive MRI findings.
89036529|NCT00532896||bariatric surgery|patients with morbid obesity undergoing a bariatric surgery
89036530|NCT00532896||No bariatric surgery|patients with morbid obesity on a waiting list for a bariatric surgery but who will have their surgery in more than one year.
89036531|NCT05190458|Other|Non-invasive mechanical ventilation (group A)|Patients will be Randomized into 2 subgroups by (1:1) crossover:- Group A will be put on NIMV Group B will be put on HVNI
89036532|NCT05190458|Other|High Velocity Nasal Insufflation (group B)|Patients will be Randomized into 2 subgroups by (1:1) crossover:- Group A will be put on NIMV Group B will be put on HVNI
89036533|NCT04169334|No Intervention|Control group|Group receiving care as usual
89036534|NCT04169334|Experimental|Intervention group|Intervention group receiving a standardized preventive program (5 days at the Obstetric department)
89036535|NCT05180903|Experimental|Bulk Fill resin composite restorations reinforced by ultra high molecular weight polyethylene.|Bulk Fill resin composite restorations (X-tra base & GrandioSO, Voco, Cuxhaven, Germany) reinforced by ultra high molecular weight polyethylene. (Ribbond THM, Ribbond Inc, Seattle, WA, USA)
89618300|NCT03392922|Experimental|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery
89618301|NCT03392922|Experimental|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
89618302|NCT05056116|Experimental|Biliary Tract Cancer|Surufatinib 250mg/Toripalimab 240mg
89618303|NCT03126318|Active Comparator|COR-001|COR-001 5, 15, 50, or 100 mg dose (depending on dose cohort assigned to patient) given by subcutaneous injection one time only
89618304|NCT03126318|Placebo Comparator|Placebo|Placebo at pH 6.0will be given in a volume to match the volume of COR-001 being given for the dose cohort by subcutaneous injection one time only
89618305|NCT02520258|Experimental|Aspartame Consumers - Cohort 1|"Experimental Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - (If OGTT results are abnormal, participants will be invited to participate in Phase II) Five (5) week study phase with Prudent Metabolic Diet and Intervention of diet soda containing aspartame only; Week 1: Prudent Metabolic Diet and 36oz diet soda po daily, Week 2-4: Prudent Metabolic Diet and no diet soda, Week 5: Prudent Metabolic Diet and 36 oz diet soda po daily."
89618306|NCT02520258|Active Comparator|Aspartame Naive Participants - Cohort 2|"Control Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - Not applicable for this cohort."
89618307|NCT03392844|Experimental|Intervention: Bed after 7 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 7 days after initiating daily diary/actigraph procedures.
89618308|NCT03392844|Experimental|Wait-list: Bed after 14 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 14 days after initiating daily diary/actigraph procedures.
89618309|NCT01401166|Experimental|Cohort 1: SC (SID) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
89618310|NCT01401166|Experimental|Cohort 1: IV then SC (SID) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
89618311|NCT01401166|Experimental|Cohort 2: SC (Vial) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
89618312|NCT01401166|Experimental|Cohort 2: IV then SC (Vial) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
89618313|NCT05238402||on statins|patients who received a statin
88987699|NCT04517617||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
89036536|NCT05180903|Active Comparator|Bulk Fill resin composite restorations|Bulk Fill resin composite restorations (X-tra base & GrandioSO, Voco, Cuxhaven, Germany)
89036537|NCT05191251||Full-term pregnant women with HEMSTOP|"Full-term pregnant women who have given birth vaginally or by cesarean section. Patients for whom a HEMSTOP questionnaire could be carried out in prepartum, during the pre-delivery anesthesia consultation.~Patients who received follow-up during pregnancy as recommended. Age over 18"
89036538|NCT04686513||Obese young adult|
89036539|NCT04686513||Non Obese young adult|
89036540|NCT05152004|Experimental|High dose dual therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 750 mg q.i.d for 14 days
89036541|NCT05152004|Active Comparator|Hybrid therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 1 g b.i.d. for 7 days, followed by rabeprazole (Pariet) 20 mg, amoxicillin(Amolin)1 g, clarithromycin (Klaricid) 500 mg, and metronidazole (Flagyl) 500 mg b.i.d. for 7 days
89036542|NCT05132153|Active Comparator|(Group A) will receive milrinone|Patients will receive milrinone 50 microgram/kg in 5ml volume, over 5 min by nebulization
89036543|NCT05132153|Placebo Comparator|(Group B) will receive normal saline|Patients will receive 5 ml saline by nebulization over 5 min
89036544|NCT00534378|No Intervention|1|
89036545|NCT05131997|Experimental|AD-221|AD-221, Placebo of AD-221A, AD-221B and AD-221C
89036546|NCT05131997|Experimental|AD-221A|AD-221A, Placebo of AD-221, AD-221B and AD-221C
89036547|NCT05131997|Active Comparator|AD-221B|AD-221B, Placebo of AD-221, AD-221A and AD-221C
89036548|NCT05131997|Active Comparator|AD-221C|AD-221C, Placebo of AD-221, AD-221A and AD-221B
89036549|NCT05186961||caregivers|Person who provided primary care for children younger than 18 years with swallowing disorders.
89036550|NCT00534456|Experimental|Active|
89036551|NCT00534456|Placebo Comparator|Placebo|
89036552|NCT00532922||1|Chinese asthma patient prescribed Symbicort® Turbuhaler®
89057332|NCT01647867|Experimental|Met analysis|Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
88987700|NCT00407160||Group 1 Standard Immunosuppression|"Anti-thymocyte Globulin (Rabbit)] ,tacrolimus, mycophenolate mofetil and prednisone~Patients with End Stage Renal Disease (ESRD) and high Panel Reactive Antibody (PRA) who randomize to the control group. These patients will get induction therapy prior to transplant with Thymoglobulin 1.5 mg/kg/day for 4 days to a total dose of 6mg/kg.~They will receive maintenance immunosuppression with three drugs : tacrolimus, cellcept and prednisone."
88987701|NCT00407160||Group 2 Campath Immunosuppression|"Alemtuzumab,tacrolimus~Patients with ESRD and high PRA who randomize to the study group. These patients will get induction therapy prior to reperfusion of the kidney, during the transplant operation, with Campath (Alemtuzumab) 30mg, one dose. They will receive maintenance immunosuppression with tacrolimus alone (monotherapy)."
88987702|NCT00155259|Experimental|A|
88987703|NCT04519216|Active Comparator|Traditional education|Participants in the control group will complete an online unfolding case scenario. Then these same participants will participate in a videoconferencing case based lecture with the academic pediatric fellow
88987704|NCT04519216|Experimental|Telesimulation|Participants in the intervention group will complete an online unfolding case scenario. Then these participants will complete a telesimulation case with a standardized patient via video conferencing.
88987705|NCT00505102|Active Comparator|A|
88987706|NCT00404378|Experimental|Cohort 1 Treatment Period 1|Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.
88987707|NCT00404378|Experimental|Cohort 1 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
88987708|NCT00404378|Experimental|Cohort 2 Treatment Period 1|Subjects will receive single oral dose of 50 mg of Casopitant. There will be wash out period of 7 days.
88987709|NCT00404378|Experimental|Cohort 2 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.
88987710|NCT04511728|Experimental|HSK3486|
88987711|NCT04511728|Active Comparator|Propofol|
88987712|NCT04510987|Experimental|Experimental: Treatment 1|Participants in Groups 1-4 and Group 6 will receive a single dose of BAY2433334 on one occasion. Participants in Group 5 will receive a single dose of BAY2433334 on a dialysis-free day.
88987713|NCT04510987|Experimental|Experimental: Treatment 2|Participants in Group 5 will receive a single dose of BAY2433334 on a day with dialysis treatment.
88987714|NCT04519996|Experimental|US Internal Jugular Vein Collapsibility Index|The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility.
88987715|NCT04519996|Experimental|US Inferior Vena Cava Collapsibility Index|The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration.
88987716|NCT00162318|Experimental|A|
88987717|NCT00404417|Experimental|1|Botox/Placebo
88987718|NCT00404417|Experimental|2|Botox/Botox
88987719|NCT00404417|Experimental|3|Placebo/Botox
88987720|NCT00404417|Placebo Comparator|4|Placebo/Placebo
88987721|NCT04519918|No Intervention|Standard ICSI procedure|a single spermatozoon was injected into the ooplasm.
88987722|NCT04519918|Experimental|Chemical oocyte activation|After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
88987723|NCT04519918|Experimental|Mechanical oocyte activation|Mechanical stimulation was done before standard ICSI procedure, then the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.
88987724|NCT04519606||One-lung ventilation|During one-lung ventilation, the dependent lung (non-operation lung) will be mechanically ventilated with a fixed positive end-expiratory pressure (PEEP) of 4 cmH2O and the peak pressure below 30 cmH2O. Tidal volumes will be titrated from the initial 4 ml/kg predicted body weight (PBW) to 7 ml/kg PBW. Optimal lung compliance is determined by the levels of upper reflection point of the pressure-volume loop closed to 30 cmH2O. Chest tomography will be undertaken with the optimal tidal volume during OLV phase and when the independent lung is completely recruited using the stepwise PEEP increase method.
88987725|NCT04519762|Sham Comparator|Control group|Management of sepsis/ septic shock via fluids, antibiotics, vasopressors and inotropes.
88987726|NCT04519762|Active Comparator|Study group|Management of sepsis/ septic shock in addition to management of hypophosphatemia.
88987727|NCT04519723|Other|Alma Harmony Laser System|There is only one arm. Three hand modules; Dye-VL 500-600nm, High Power QSW 1064nm, and High power Pixel ER:YAG 2940nm laser module with rollers will be utilized in combination in a series of treatments intended to improve skin color, tone, texture and laxity. Subjects will receive up to four treatments administered in intervals of 28 +/- 2 days. Treatment duration of approximately 60 minutes.
88987728|NCT02275468|Placebo Comparator|Control Group|Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90~110g/L.
88987729|NCT02275468|Experimental|Fu-zheng-qu-zhuo oral liquid Group|Patients of FZQZ Group received Fu-zheng-qu-zhuo (FZQZ) oral liquid 20ml every time, and three times a day combined with integrated therapy. The integrated therapy was same to Control Group.
89618314|NCT05238402||not on statins|patients who not received a statin
89618315|NCT03395106|Experimental|Parent source + intuitive story content|
89618316|NCT03395106|Experimental|Doctor source + intuitive story content|
89618317|NCT03395106|Experimental|Parent source + deliberative content|
89618318|NCT03395106|Experimental|Doctor source + deliberative content|
89618319|NCT03394950|Experimental|rtPA combined with Butyphthalide|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
89618320|NCT03394950|Active Comparator|rtPA compared with placebo|Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
89618321|NCT01473160|Experimental|delefilcon A|Delefilcon A randomly assigned to one eye, with narafilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
89618322|NCT01473160|Active Comparator|narafilcon A|Narafilcon A randomly assigned to one eye, with delefilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
89618323|NCT03394872||Drainage group|Patients under mechanical ventilator support due to acute respiratory failure who had significant pleural effusion and drainage plan according to the intensive Care Unit (ICU) protocols decided by primary physician
89618324|NCT03392766|Experimental|Single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and brochial blocker
89618325|NCT03392766|Experimental|Double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube
89618326|NCT03392688|Experimental|Patellofemoral pain group|"Diagnosis of PFP was established based on symptoms, physical examination performed by an orthopedic surgeon. Patients were also screened through physical examination to rule out ligamentous or meniscal injuries, patellar tendinitis and knee joint effusion by an orthopedic surgeon. All patients also underwent a radiologic examination consisting of AP, lateral and tangential radiograms.~Surface EMG, Kujala patellofemoral pain scale, Q angle measurement were administered to the PFP group."
89618327|NCT03392688|Active Comparator|Control Group|"Control group had similar demographic characteristics with PFP group, and neither one of the controls had any knee pathology or current knee pain or effusion that would effect the gait.~Surface EMG, Q angle measurement were administered to the control group."
89618328|NCT03392610||Bronchial endoscopy|Compare quality procedures performed with reusable versus disposable bronchoscopes in respiratory endoscopy unit
89618329|NCT03392610||Critical care unit|Compare quality procedures performed with reusable versus disposable bronchoscopes in critical care unit
89618330|NCT03392610||Anesthesia department|Compare quality procedures performed with reusable versus disposable bronchoscopes in anesthesia department
89618331|NCT04586634|Active Comparator|Peristeen|Subjects to use newly developed Peristeen cone catherter device
89618332|NCT04586634|No Intervention|Standard of care|subjects continue with their standard of care treatment
89618333|NCT04567992|Experimental|SCPB|
89618334|NCT04567992|Placebo Comparator|Control|
89618335|NCT01335724|Experimental|Diclofenac diethylamine 1.16% gel|
88987730|NCT04519450||ICU patients without an with chronic respiratory diseases|The group will consist of >50 patients admitted to the intensive care unit, of which at least 20 with chronic respiratory diseases. Patients of both sexes, patients with and without chronic respiratory diseases, and also patients requiring mechanical ventilation were included and their demographic characteristics and outcomes registered. All patients will sign an informed consent form before inclusion in the prospective observational study.
88987731|NCT00404534|Experimental|1|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
88987732|NCT00404534|Placebo Comparator|2|Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
88987733|NCT04519060|No Intervention|No eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care.
88987734|NCT04519060|Experimental|Eye shields after dilated eye exam|Eye dilation for scheduled exam will be followed by routine clinical care and the application of eye shields. They will be worn until four (4) hours after the last dose of dilating eye drops.
88987735|NCT02955472|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
88987736|NCT02955472|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: ComparGLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
88987737|NCT00505297||A|Subjects with potentiall rapidl progressing OA
88987738|NCT00505297||B|Age-matched healthy subjects with no knee pain
88987739|NCT04519333|Other|Compare to sistemic treatment and mesotherapy.|This is a prospective parallel randomized controlled trial conducted with patients admitted to our emergency department with neck pain related to cervical disc herniation
88987740|NCT00141440|Experimental|1|COPD patients
88987741|NCT04518904||Group of poor prognosis|In this group,the patients had suffered from systemic infection,pulmonary complications or died.
88987742|NCT04518904||Group of good prognosis|In this group,the patients were safely discharged without complications.
88987743|NCT04518826||FFR|In FFR group, FFR at maximum hyperemia will be measured after pretreatment of DES-ISR lesion by balloons(non-compliant balloon, cutting balloon or scoring balloon). If FFR <0.9, the operator will dilate the DES-ISR lesion again before another FFR is measured. If FFR>=0.9, DEB will be used and final FFR will be measured at the end of the procedure.
88987744|NCT04518826||CAG|In angiography group, the operator will treat the DES-ISR lesion with balloons(non-compliant balloon, cutting balloon or scoring balloon), and then DEB without FFR guidance.
88987745|NCT02955589|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
89618336|NCT01335724|Placebo Comparator|placebo gel|
89618337|NCT01476202|Experimental|Nicotine mouth strip|single dose
89618338|NCT01476202|Active Comparator|nicotine lozenge|single dose
89618339|NCT01476202|Active Comparator|nicotine gum|single dose
89618340|NCT01539694|Experimental|LD118033 contact lens|Investigational LD118033 multifocal low add soft contact lenses, to be worn on a daily wear basis.
89618341|NCT01539694|Active Comparator|PureVision multifocal contact lens|PureVision multifocal low add soft contact lens, to be worn on a daily wear basis.
89618342|NCT01476748|Active Comparator|Ethicon Xcel Trocars|Ethicon Xcel trocars will be used in this arm with Laprostop device
89618343|NCT01476748|Active Comparator|Covidien Veraport Trocars|Covidien Veraport Trocars will be used in this arm with the Laprostop device
88987746|NCT00162435|Experimental|Genetic|
89618344|NCT01476748|Active Comparator|Storz Reusable Trocars|Storz Reusable Trocars will be used in this arm with the Laprostop device
89618345|NCT01477450|Active Comparator|1 L/min ; 16 mL|Cylinder oxygen delivery (1 L/min) followed by pulse-dose oxygen by concentrator (16 mL)
89618346|NCT01477450|Active Comparator|2 L/min ; 32 mL|Cylinder oxygen delivery (2 L/min) followed by pulse-dose oxygen by concentrator (32 mL)
89618347|NCT01477450|Active Comparator|3 L/min ; 48 mL|Cylinder oxygen delivery (3 L/min) followed by pulse-dose oxygen by concentrator (48 mL)
89618348|NCT01477762|Active Comparator|PTSD Negative|Participants who do not have PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
89618349|NCT01477762|Experimental|PTSD Positive|Participants with PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
89618350|NCT01478854|Experimental|Neural Progenitor Cell Sparing Radiation with Temozolomide|All subjects are treated with neural progenitor cell sparing radiation to 60 Gy in 2 Gy per day, 30 fractions Concurrent and adjuvant temozolomide chemotherapy
88987747|NCT00162435|Experimental|Control|
88987748|NCT04518709|Experimental|Posterior Annulus Elevation Technique Group|In patients who were determined in the treatment group, after the conventional procedure for mitral valve repair was completed, a posterior mitral valve elevation technique will be performed.
88987749|NCT04518709|Placebo Comparator|Without Posterior Annulus Elevation Technique Group|No additional procedure will be done after conventional mitral valve repair
88987750|NCT04518865|Experimental|pre-pubertal group.|The patients were allocated into the pre-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS II and CVMS III
88987751|NCT04518865|Experimental|post-pubertal group|The patients were allocated into the post-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS V and CVMS IV
88987752|NCT04518982|Experimental|The experimental group|
88987753|NCT04518982|Placebo Comparator|The control group|
88987754|NCT04518631|Experimental|8-week mindfulness program|8-week .b Foundations course
88987755|NCT04518631|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
88987756|NCT00141557|Experimental|1|
89618351|NCT01434472|Experimental|Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)|Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).
88987757|NCT00141557|Active Comparator|2|
88987758|NCT00162474|Experimental|Warfarin|
89618352|NCT01435174|Experimental|Ranolazine|End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
89618353|NCT01540162||Group I|Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.
89618354|NCT01540162||Group II|Patients of group II remain unexposed to the probiotic Mutaflor.
89618355|NCT01436266|Active Comparator|Misoprostol|400 mcg buccally 2 hours prior to procedure
89618356|NCT01436266|Placebo Comparator|Placebo (Folic acid)|Two 1-mg tablets buccally 2 hours prior to procedure
89618357|NCT01542502|Experimental|Anakinra|Treatment with daily subcutaneous injections of Anakinra 100 mg
89618358|NCT01542502|Placebo Comparator|Placebo|Treatment with daily subcutaneous injection of placebo
89618359|NCT01437124||Ceramic on metal THA|Those who have received a ceramic on metal total hip replacement
89618360|NCT01439620|Experimental|OFDI imaging|Subject will swallow an OFDI capsule and images will be obtained using MGH Optical Frequency Domain Imaging (OFDI) imaging system.
89618361|NCT01439854|Placebo Comparator|Placebo|this arm is control
89618362|NCT01439854|Experimental|Dapagliflozin|Interventional arm
89618363|NCT01479478|Active Comparator|Probiotic dietary supplement|Probiotic dietary supplement one capsule once per day until delivery.
89618364|NCT01479478|Placebo Comparator|Placebo|Placebo capsule, one daily until delivery.
88987759|NCT04518553|Active Comparator|active control|antiviraltherapy using HA using antiviralHA drugs of HA to decrease HBV-DNA load. In this group, patients with chronic hepatitis B just take antiviral drug of HAs to control hepatitis B viral without active interference.
88987760|NCT04518553|Experimental|active interference|HA+plasma purification as active interference. HA antiviral therapy using HA plus plasma purification every three months.DFT as plasma purification mode will be used. DFT therapy time lasts 2.5-3 hours each time.After three months, DFT therapy will be used if patients' HBV-DNA loads are higher than cut-off normal level.
88987761|NCT00505336|Experimental|1|Eplerenone
88987762|NCT00505336|Active Comparator|3|no additional treatment
88987763|NCT00505336|Experimental|2|Atorvastatin
88987764|NCT04518514|Experimental|Preoperative evaluation and risk assessment via telemedicine|
89618365|NCT04409262|Experimental|Remdesivir + Tocilizumab (RDV+TCZ)|Participants assigned to the RDV+TCZ arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ on Day 1.
89618366|NCT04409262|Active Comparator|Remdesivir + Placebo (RDV+Placebo)|Participants assigned to the RDV+ placebo arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ-placebo on Day 1.
89618367|NCT01481740|Experimental|Phenylephrine bolus|
89618368|NCT01481740|Experimental|Phenylephrine infusion|
89618369|NCT01544062|Experimental|IV acetaminophen|Study subjects receiving IV acetaminophen
89618370|NCT01544062|Placebo Comparator|Normal saline|Study subjects receiving placebo
89618371|NCT04331964|Active Comparator|Mineral Trioxide Aggregate (MTA)|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The exposed pulp tissues will be directly capped with a 3mm of MTA (Pro Root MTA) layer.
89618372|NCT04331964|Experimental|MTA with platelet rich fibrin (PRF).|A standardized partial pulpotomy procedure will be performed after administration of local anesthesia. The PRF membrane obtained after centrifugation of the patient's own blood is going to be placed over the exposed pulp. Then, a 3mm of MTA (Pro Root MTA) will be placed over the PRF membrane.
89618373|NCT03126084|Active Comparator|TAP|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive transversus abdominis plane block with 20 ml of 0.25% bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
89618374|NCT03126084|Active Comparator|QLB2|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive quadratus lumborum type 2 block with 20 ml of %0.25 bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
89618375|NCT03126084|Active Comparator|CONT|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
89618376|NCT03126396|Experimental|Urgo 310 3166 dressing|Urgo 310 3166 dressing
89618377|NCT03126006|Experimental|NSPT plus oral hygiene|It includes pregnant women (with periodontal disease) who will be subjected to one episode of non-surgical periodontal therapy under local anesthesia during pregnancy. they will receive oral hygiene instruction also.
89618378|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
89618379|NCT01483378|Other|Subjects who received the vaccine|Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
89618380|NCT01483378|No Intervention|Subjects who declined the vaccine|
89618381|NCT03392298|Experimental|CCA group|Participants in CCA group will be treated with 15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd)， once daily for 4 weeks.
89618382|NCT03392298|No Intervention|Control group|Participants in Control group will be treated with nothing, but followed up for 4 weeks.
89618383|NCT01440634|Other|supervised exercise|It consists of six months of supervised, intermittent track walking to near maximal leg pain or discomfort three days per week. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month.
89618384|NCT01440634|No Intervention|Standard of Care|Patients will be observed during the time of the study, no intervention will be applied. Patients are allowed to do their regular activity at home.
89618385|NCT03392220|Experimental|undergo unilateral (affected side) neck dissection (II-IV)|patient undergo affected side neck dissection, along with the excision of the laryngeal primary tumor
89618386|NCT03392220|Experimental|undergo bilateral neck dissection (II-IV)|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
89618387|NCT03008356|Experimental|L-carnitine|Oral L-carnitine 1000mg twice daily
89618388|NCT03008356|Experimental|L-carnitine + health coaching|Oral L-carnitine 1000mg twice daily and weekly 10-15 minute health coaching calls
89618389|NCT03008356|Placebo Comparator|Placebo|Placebo capsules twice daily
89618390|NCT04305912|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to verofilcon A daily disposable lenses for one week.
89618391|NCT04305912|Active Comparator|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
89618392|NCT01544998|Experimental|Tadalafil plus Placebo, then Tadalafil plus Nesiritide|First intervention period: oral Tadalafil; after 1 hour, subcutaneous (sc) placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
88987765|NCT04518202|Experimental|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
88987766|NCT04518202|Placebo Comparator|Sham patch|Sham patch applied at 6 hours before the scheduled office hysteroscopy.
88987767|NCT04517890|Experimental|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
88987768|NCT04517890|Placebo Comparator|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
89057333|NCT04540367|No Intervention|No Intervention: Control|Participants in this group performed the exercises without the blood flow restriction therapy cuff
89618393|NCT01544998|Experimental|Tadalafil plus Nesiritide, then Tadalafil plus Placebo|First intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
89618394|NCT03391830|Active Comparator|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
89618395|NCT03391830|Placebo Comparator|Placebo|Placebo
89618396|NCT04033770|Active Comparator|Air-charged measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS but using an air-charged instead of a water-filled measurement system."
89618397|NCT04033770|Active Comparator|Water-perfused measurement system|"UDI (same session repeat filling cystometry and pressure flow study) according to Good Urodynamic Practice recommended by the ICS."
89618398|NCT01441492|Experimental|No Drains|Patients who will not receive intraperitoneal drainage following pancreas resection.
89618399|NCT01441492|Experimental|Drains|Patients who will receive drains, the standard of care treatment, following pancreas resection.
89618400|NCT01441570|Active Comparator|Nebivolol|
89618401|NCT01441570|Active Comparator|Metoprolol Succinate|
89618402|NCT03394794|Active Comparator|Kegel exercises|Pelvic floor exercises designed in the 1950s' by Arnold Kegel.
89618403|NCT03394794|Experimental|biofeedback|Biofeeback therapy to improve neuromuscular coordination and strengthen sphincter contractility.
89618404|NCT03394794|Experimental|electrostimulation|Administration of electric current with a specific device (stimulator) and through a vaginal prove, in order to improve pelvic floor contractility.
89618405|NCT03394794|Experimental|transcutaneous neuromodulation|Stimulation of tibial nerve with a specific electric current through a stimulator and surface electrodes
89618406|NCT05238012|Experimental|Xuezhikang Capsule|Experimental drug: Xuezhikang Capsule, specification: 300mg / capsule.
89618407|NCT05238012|Active Comparator|Atorvastatin Calcium Tablets|Control drug: Atorvastatin Calcium Tablets, specification: 20mg / tablet.
89618408|NCT01441882|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89618409|NCT03394716||Patient brain tumor treated with fractionated radiotherapy|
89618410|NCT01484626|Experimental|Bendamustine|Bendamustine is combined with standard chemotherapy.
89618411|NCT04446936||Propeller flaps|Patients who undergone propeller flap surgery
89618412|NCT04446936||Random flaps|Patients who undergone random flap surgery
89618413|NCT03394638|Active Comparator|Conventional group|"Treatment includes:~10 individual and 3 group consultations at the outpatient department by several disciplines in the first postoperative year.~Additional visits if necessary~No further access to the BePATIENT website"
89618414|NCT03394638|Experimental|Online group|"Treatment includes:~Added to conventional group: Continuation of access to the BePATIENT website with:~eLearning programs~Informative videos~Patient network~Video consulting"
89618415|NCT03394638|Experimental|Device group|"Added to Online group:Four wireless devices, which are~Weight Scale~Blood Pressure~Oximeter~Activity Tracker"
89618416|NCT03394560|Experimental|high-frequency rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
89618417|NCT03394560|Sham Comparator|sham rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
89618418|NCT03394482|Experimental|Lu AF35700 5 mg clinical formulation|
89618419|NCT03394482|Experimental|Lu AF35700 5 mg commercial formulation|
89618420|NCT03394482|Experimental|Lu AF35700 10 mg clinical formulation|
89618421|NCT03394482|Experimental|Lu AF35700 10 mg commercial formulation|
88987769|NCT04517812|Experimental|Intervention group|The intervention group will carry out a 12-week exercise-based intervention delivered via the VirtualRehab platform. The exercise-games have been designed from conventional physiotherapy exercises for stroke rehabilitation. A personalised training programme will be created for individual participants by a qualified physiotherapist member of the research team. Each participant will be asked to undertake their set exercise-based training programme for one hour a day, six days a week for 12 weeks.
88987770|NCT04517812|No Intervention|Control group|The control group will undertake the measurement battery and provide the demographic details.
88987771|NCT04517968|Experimental|immediate implant with customized healing abutment|
88987772|NCT02275507||Women Undergoing Scheduled Cesarean Delivery|We will be recruiting women who are scheduled for an elective repeat or primary cesarean delivery.
89618422|NCT03394482|Experimental|Lu AF35700 20 mg clinical formulation|
89618423|NCT03394482|Experimental|Lu AF35700 20 mg commercial formulation|
89618424|NCT01545232|Active Comparator|1:1:1 Blood Transfusion Ratio|
89618425|NCT01545232|Active Comparator|1:1:2 Blood Transfusion Ratio|
89618426|NCT03394404|Experimental|ECG-I mapping and PVI|ECG-I mapping and PVI
89618427|NCT05237778|Experimental|TMR group|Patients will receive a sound while they generate a positive outcome of imagery rehearsal therapy (IRT). They will also receive the sound during REM sleep.
89618428|NCT05237778|Active Comparator|Control group|Patients will not receive a sound while they generate a positive outcome of imagery rehearsal therapy (IRT). They will receive the same sound as the experimental group during REM sleep under the same conditions.
89618429|NCT05237700||Trendelenburg with lithotomy positioning on the operating table.|The patient is positioned in Trendelenburg with lithotomy positioning on the operating table.
89618430|NCT05237700||Trendelenburg without lithotomy positioning on the operating table.|The patient is positioned in Trendelenburg without lithotomy positioning on the operating table.
89618431|NCT05237544||leftover dried blood spot material|All samples used will be leftover dried blood spot material from the Newborn Screening Lab at Great Ormond Street Hospital.
89618432|NCT05237544||anonymous known SMA positive blood spots|The anonymous known SMA positive blood spots will be provided by an external company (Biogen),
89618433|NCT01545700|Placebo Comparator|Control, saline 0-4 hours|2 cc of saline
89618434|NCT01545700|Active Comparator|Dexamethasone 4 mg, 0-4 hours|Dexamethasone 4 mg administered intraoperatively
89618435|NCT01545700|Active Comparator|Dexamethasone 8 mg, 0-4 hours|Dexamethasone 8 mg administered intraoperatively
89618436|NCT01545700|Placebo Comparator|Placebo Comparator saline 8-24 hours|placebo, 2 cc saline
89618437|NCT01545700|Active Comparator|Dexamethasone 4 mg, 8-24 hours|Dexamethasone 4 mg administered intraoperatively
89618438|NCT01545700|Active Comparator|Dexamethasone 8 mg, 8-24 hours|Dexamethasone 8 mg administered intraoperatively
89618439|NCT02520336|Experimental|active management|Laboratoy test request given postpartum with phone reminder prior to test
89618440|NCT02520336|No Intervention|Routine care|
89618441|NCT04006002||Endoscopic Sleeve Gastrectomy|This group includes all patient who undergo Endoscopic Sleeve Gastrectomy for weight loss
89618442|NCT04006002||Laproscopic Sleeve Gastrectomy|This group includes all patient who undergo Laproscopic Sleeve Gastrectomy for weight loss
89618443|NCT01486810|Experimental|Lisdexamfetamine and medication management|Patients will be titrated to the tolerated dose of Lisdexamfetamine over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks. All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
89618444|NCT04446780||Women who underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery with mediolateral episiotomy
89618445|NCT04446780||Women who did not underwent an episiotomy|Nulliparous women who underwent an instrumental vaginal delivery without mediolateral episiotomy
89618446|NCT04446546||Cold Stored Allograft Vascular Access|
89618447|NCT01487668|No Intervention|Arm 1 - Usual Care|Usual care will include standard mental health and medical care available in the VA clinics but with no active management by the LGCC health specialist.
89618448|NCT01487668|Experimental|Arm 2 - Life Goals Collaborative Care|
89618449|NCT03398772|Experimental|Experiment|Comprehensive Health Coaching Program
89618450|NCT03398772|No Intervention|Control|Guideline-based usual care
89618451|NCT04446624|No Intervention|Treatment as usual (TAU)|Patients in the TAU group will receive the treatment routinely offered to patients undergoing RT for breast cancer.
89618452|NCT04446624|Experimental|Music therapy intervention (PSY)|Patients in the PSY group will participate to a short-term group psychotherapy with elements of music therapy; meetings will be 1 / week, for a total of 6 weeks. Beginning of psychotherapy intervention will be 1-2 weeks after recruitment at T0 and will therefore cover the entire duration of the RT cycle.
89618453|NCT01443442|Active Comparator|Bepreve|1.5% bepotastine besilate, drops, twice per day, for two weeks
89618454|NCT01443442|Active Comparator|Alrex|treatment with 0.2 % loteprednol etabonate, drops, four times per day
89618455|NCT03389646|Active Comparator|Treated with Device: Including sham|"Treated with CERAMENTTM|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum."
88987773|NCT02275585||Cirrhosis|Patients with cirrhosis will be followed looking about the event of portal vein thrombosis
89057334|NCT04540367|Experimental|Experimental: BFR|Participants in this group performed the exercises with the blood flow restriction therapy cuff
89057335|NCT01682070|Placebo Comparator|SUBLIVAC FIX Phleum prat. 0 AUN/ml|
89618456|NCT03389646|No Intervention|Control|Control without CERAMENT device
89618457|NCT01444924|Experimental|Bupivicaine|TAP block with bupivicaine/epinephrine placed prior to surgery.
89057336|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 3,333 AUN/ml|
89057337|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 10,000 AUN/ml|
89618458|NCT01444924|Placebo Comparator|Placebo|TAP block with placebo placed prior to surgery
89618459|NCT03389568|Experimental|Intervention for caregivers of ICU patients|
89618460|NCT01546402|Experimental|Phacoemulsification with IOL implant|This group (Group B) includes patients who will undergo phacoemulsification with intraocular lens implantation. The dexamethasone implant will not be injected at the beginning of cataract surgery. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
89618461|NCT01546402|Experimental|Phacoemulsification with Ozurdex|This group (Group A) includes patients who will undergo phacoemulsification with intraocular lens implantation with intraoperative long acting steroid injection (Ozurdex ®). The dexamethasone implant will be injected at the beginning of cataract surgery, 4mm from the limbus using the specially designed injector. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
89618462|NCT03389490|Experimental|Active|Insulin glargine 300U/ml
89618463|NCT03389490|Active Comparator|Control|Neutral Protamine Hagedorn insulin
89618464|NCT01546636|Placebo Comparator|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
89618465|NCT01546636|Active Comparator|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
89618466|NCT03391752||Royal Alexandria|Administrative records
89618467|NCT03391752||Pasqua Regional hospital|Administrative records
89618468|NCT03391752||Concordia Hospital|Administrative records
89618469|NCT03391752||Niagara General Hospital|Administrative records
89618470|NCT03391752||Hospital 6|Administrative Records
89618471|NCT03391752||Hospital 7|Administrative Records
89618472|NCT03391752||Hospital 8|Administrative Records
89618473|NCT03391752||Hospital 9|Administrative Records
89618474|NCT03391752||Hospital 10|Administrative records
89618475|NCT03391674|Experimental|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
89618476|NCT03391674|No Intervention|Observational|Observational
89618477|NCT01547806|Experimental|Hematopoietic Progenitor Cells (HPC)|Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.
89618478|NCT03391596|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 12-week Internet-based, acceptance and commitment therapy intervention"
89618479|NCT03391596|Active Comparator|Standardized rehabilitation|"Group Standardized rehabilitation will receive a standardized rehabilitation program in the rehabilitation center"
89618480|NCT03391596|Other|Support by caregiver associations|"Group Support by voluntary caregiver associations will receive support given by caregiver associations"
89618481|NCT01445626||All participants|Patients who received at least two OZURDEX® (dexamethasone intravitreal implant) injections.
89618482|NCT03398460|Other|Health Care Providers|Bellevue hospital Medical Intensive Care Unit; 30 Nurses and 50 physcians
89618483|NCT02744742|Experimental|G-CSF + Decitabine + BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
89618484|NCT02744742|Active Comparator|BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
89618485|NCT01548040|Experimental|quadriceps NMES using Kneehab XP|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation (NMES) using Kneehab XP on the affected leg, 20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
88987774|NCT02275663|Experimental|Azacytidine plus FLAG|"Azacytidine 75 mg/m2 = mg IV in 100 ml Normal Saline (NS) over 30 minutes on days -5 t0 -1~G-CSF 5 mcg/kg subcut on days 0 to + 6~Fludarabine 30mg/m² in 100ml NS IV daily over 30min., on Days +1 to +5~Cytarabine 2gm/m² = 500ml NS IV daily over 4h, on Days +1 to +5 Start 4h after completion of fludarabine infusion."
88987775|NCT02275702|Placebo Comparator|Group 1|saline solution IV, bolus
88987776|NCT02275702|Active Comparator|Group 2|0,1mg/kg systemic dose of dexamethasone, bolus
88987777|NCT04517773||study group|Oncological patients
88987778|NCT04518163|Experimental|study group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus 1gm tranexamic acid by intravenous infusion
88987779|NCT04518163|Active Comparator|control group|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus saline by intravenous infusion
88987780|NCT04517227|Experimental|single arm|All patients enrolled with receive the sequential therapy of TACE, ablation and durvalumab.
88987781|NCT00141713|Experimental|1|etanercept treatment for GVHD
88987782|NCT04517188|Experimental|Halodine Nasal Antiseptic|"Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP~Single topical administration"
88987783|NCT04516837|Experimental|eltrombopag plus rhTPO|Combination of eltrombopag and rhTPO
88987784|NCT04516837|Active Comparator|eltrombopag|Eltrombopag monotherapy
88987785|NCT00155454|Experimental|Study group|Group 1 had intravitreal long acting gas (10% C3F8) injection in the vitreous cavity at the end of surgery
89618486|NCT01548040|Sham Comparator|quadriceps TENS|The sham device will look identical to the Kneehab XP device. All subjects in the control group will receive quadriceps Transcutaneous Electrical Nerve Stimulation (TENS) at a minimal sensory input using Kneehab XP on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
89618487|NCT03389334|Experimental|massage group|Subjects will complete the SF-36, ODI, demographics surveys and then will receive pre-treatment range of motion, muscle strength and visual analogue pain scale prior to massage. Then will have a 45-minute myofascial release massage. Then they will fill out the visual analogue pain scale again. (Approximately 90-minutes) The second and third visits: visual analogue scale prior to the treatment; 45-minute massage, by the same therapist who treated them during the initial visit, and will fill out a second visual analog pain scale following the treatment. (Approximately 60-minutes) The fourth visit: visual analogue pain scale and 45-minute massage; post-treatment SF-36, ODI surveys, visual analogue pain scale, post-treatment range of motion and muscle strength.
89618488|NCT01548742|Experimental|Arm 1: Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR)
89618489|NCT01548742|Active Comparator|Arm 2: Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT)
89618490|NCT03125772|Experimental|TAXUS Element™ Paclitaxel-Eluting System|The TAXUS® Element™ stent system is a multifunctional device providing a mechanical structure for vascular lumen support and a pharmacological agent targeted toward reducing or preventing the incidence of restenosis. The TAXUS Element™ stent is a balloon expandable, stainless steel platinum alloy stent, coated with paclitaxel in a slow-release system, pre-mounted on a high-pressure Monorail delivery catheter and is intended for use in the treatment of coronary artery disease. The pharmacological agent, paclitaxel, is incorporated into a triblock polymer matrix and applied to the surface of the stent. The polymer matrix provides controlled release of available paclitaxel. The TAXUS Element™ stent design is built upon the TAXUS Express and TAXUS Liberte design experience, but incorporates several improved stent design characteristics. The TAXUS Element™ stent also has a smaller tip profile, designed to enhance the ability to cross tighter and/or more complex lesions.
89618491|NCT03125772|Active Comparator|XIENCE PRIME™ ™ Everolimus-Eluting Stent System|The everolimus-eluting stent (EES, manufactured and distributed by Abbott Vascular, Santa Clara, CA, as XIENCE PRIME™ ) is a balloon expandable stent manufactured from a flexible cobalt chromium alloy with a multicellular design and 0.0032-in strut thickness which is coated with a thin (7.8 μm) nonadhesive, durable, biocompatible acrylic polymer and fluorinated copolymer releasing everolimus. Everolimus [40-O-(2-hydroxyethyl)- rapamycin], a semisynthetic macrolide immunosuppressant, inhibits growth factor-stimulated cell proliferation by causing cell-cycle arrest in the late G1 stage, thereby suppressing neointimal formation. Comparative analysis in an in vivo rabbit aortoiliac model has shown more rapid endothelialization with the EES compared to SES, PES, and ZES.
89618492|NCT03391440|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
89618493|NCT01447888|Experimental|150% Oral Morphine Equivalent (OME)|Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients
89618494|NCT01447888|Active Comparator|Control|Standard perioperative dosing, which does not currently account for patients' baseline opiate use.
89618495|NCT03398382|Placebo Comparator|Magnesium citrate tablet group|In this group patients will take magnesium citrate tablets 3 days postoperatively, so 400 mg magnesium citrate tbl (Solgar) /per day will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
89618496|NCT03398382|Placebo Comparator|Placebo tablet group|"In this group patients will take placebo tablets 3 days postoperatively, so 400 mg /per day placebo tbl will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.~Placebo tablets will be identical to the right drug (Magnesium citrate tbl.Solgar)"
89618497|NCT03398382|Placebo Comparator|Magnesium citrate lozenge group|In this group patients will take 100 mg. magnesium citrate lozenge (Diasporal) 30 min. before the procedure and continue to take up to 4 lozenges per day over the next 3 days in the same time intervals as it was on the day of surgery.
89618498|NCT03398382|Placebo Comparator|Placebo lozenge group|"In this group patients will take 100 mg. placebo lozenge 30 min. before the procedure and continue to take up to 4 pastilles per day over the next 3 days in the same time intervals as it was on the day of surgery.~Placebo lozenges will be identical to the right drug (Magnesium citrate tbl.(Diasporal)"
89618499|NCT03391206||presence of BCRL|presence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
89618500|NCT03391206||absence of BCRL|absence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
89618501|NCT03389256|Experimental|apatinib combine with EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
89618502|NCT03389256|Active Comparator|EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
89618503|NCT03398226||Control group|
89618504|NCT03398226||Distal Gastrectomy (DG) group|38 patients planing distal gastrectomy due to gastric cancer
89618505|NCT03398226||Total Gastrectomy (TG) group|38 patients planing total gastrectomy due to gastric cancer
89618506|NCT01490788|Experimental|Treatment A|1 x TNX-102 2.4 mg gelcap under fasting conditions
89618507|NCT01490788|Experimental|Treatment B|1 x cyclobenzaprine 5 mg immediate release (IR) tablet under fasting conditions
89618508|NCT01490788|Active Comparator|Treatment C|1 x TNX-102 2.4 mg gelcap under fed conditions
89036553|NCT05163990|Experimental|TEAS group|10 minutes before intraspinal anesthesia, bilateral Neiguan points and Zusanli points are given dense wave transcutaneous acupoint electrical stimulation with the frequency of 10/50Hz. The intensity is based on the maximum tolerance of the participant, and the stimulation last until 30 minutes after subarachnoid administration.
89036554|NCT05163990|No Intervention|Control group|Electrodes are connected at bilateral Neiguan points and Zusanli points 10 minutes before intraspinal anesthesia, but no transcutaneous acupoint electrical stimulation is given, the duration is the same as that of the TEAS group.
89036555|NCT05077631|Experimental|ACD856|
89036556|NCT05077631|Placebo Comparator|Placebo|
89036557|NCT00532961|Experimental|Zylet|Zylet (loteprednol etabonate and tobramycin)
89036558|NCT00532961|Active Comparator|Tobradex|TobraDex (dexamethasone and tobramycin)
89618509|NCT03389178||stress group (SG)|"We will identify prospective subjects according with the inclusion criteria of the study, consistent on singleton pregnant women between 18 to 45 years of age in their third trimester (at least 28 weeks gestation). Upon acceptance participants will enter to Phase I-IV.~Women and participants will be categorized as stressed or controls after scoring the Cohen Perceived Stress Scale-10 (PSS-10). The PSS-10 has been validated in German speaking populations and will be a quick tool for screening stress among prospective subjects. For the purposes of the current study, a participant with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
89618510|NCT03389178||control group (CG)|"For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control.~Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
89618511|NCT02559726|Experimental|O-HCM|20 patients with Hypertrophic Cardiomyopathy with outflow-tract obstruction
89618512|NCT02559726|Experimental|NO-HCM|20 patients with Hypertrophic Cardiomyopathy without outflow-tract obstruction
89618513|NCT02559726|Other|healthy volunteers|20 healthy volunteers
89618514|NCT02559024|Experimental|21 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 21 days prior to surgery
89618515|NCT02559024|Experimental|14 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 14 days prior to surgery
89618516|NCT02559024|Experimental|7 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 7 days prior to surgery
89618517|NCT01822470||Study group|a. Study Subjects will be recruited from patients who are already undergoing upper enteroscopy and aspiration for diagnosis of SIBO.
89618518|NCT01822470||Control group|b. Control Subjects will be recruited from patients who are already undergoing a double balloon enteroscopy or upper enteroscopy for another medical reason
89618519|NCT03391050|Experimental|APR-246 + Dabrafenib|
89618520|NCT03397992|Active Comparator|Group A|Treatment with high dialysate temperature first followed by low dialysate temperature and alternating thereafter.
89618521|NCT03397992|Active Comparator|Group B|Treatment with low dialysate temperature first followed by high dialysate temperature and alternating thereafter
89618522|NCT03390972|Experimental|Dexmedetomidine|Volunteers are given an intravenous infusion with dexmedetomidine, with an effect-site target concentration of 0.6 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests the effect-site target concentration is raised to 1.2 ng/ml and the swallowing series is repeated.
89618523|NCT03390972|Placebo Comparator|Placebo|Volunteers are given an intravenous infusion with saline 0,9% with target controlled infusion pump in corresponding doses as in the dexmedetomidine arm.
89618524|NCT01550224|Active Comparator|Participant Group 1 (methylated MGMT promoter)|Participants with methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have no expression of MGMT protein, will be assigned into Group 1, and will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
89618525|NCT01550224|Active Comparator|Participant Group 2 (non-methylated MGMT promoter)|Participants with non-methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have expression MGMT protein, will be assigned to into Group 2, and will initially receive daily, low doses (protracted dose schedule) of temozolomide (100 mg/m2) for 14 days in an attempt to inactivate MGMT activity. Following the protracted dose schedule, participants will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
89618526|NCT01254474|Experimental|MAP 4 procedure|Assess MAP 4 mapping capabilities in cardiac chambers in patients suffering from regular or fibrillating tachycardia's
89618527|NCT01491022|Experimental|Ampyra|Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
89210918|NCT04086251|Experimental|Gaido Intervention|All patients enrolled in the study will participate in the Gaido Intervention, which entails wearing the Biovotion Everion continuously and take blood pressure and oral temperature spot checks per clinician orders. Patients will also be responsible for filling out PRO surveys and any surveys that trigger as a result of their vital signs falling outside of tailored thresholds.
89618528|NCT01491022|Sham Comparator|Placebo|placebo 4 weeks followed by Ampyra 10 mg po BID
89618529|NCT00782184|Experimental|ezetimibe/simvastatin 10/40|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
89618530|NCT00782184|Active Comparator|atorvastatin 40 mg|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period
89618531|NCT02979808|Experimental|Navina Smart|Navina Smart will be used during 12 months for transanal irrigation (TAI).
89618532|NCT01448356|Experimental|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~25°C and 45% humidity;~25°C and 65% humidity;~30°C and 45% humidity;~30°C and 65% humidity"
89618533|NCT03390816||Transversal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital
89618534|NCT03390816||Longitudinal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital Forward-looking follow-up of 6 months of a sub-sample during the first year
89618535|NCT03397914|Experimental|Group A Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 2.5 mg/kg of colistimethate sodium intravenous as loading dose followed by 1.25 mg/kg every 12 hours as maintenance dose
89618536|NCT03397914|Experimental|Group B Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 5 mg/kg of colistimethate sodium intravenous as loading dose followed by 2.5 mg/kg every 12 hours as maintenance dose
89618537|NCT02214238|Active Comparator|Market released PAP device|Use of a market released PAP device
89618538|NCT02214238|Experimental|Modified PAP device|Us of the modified PAP device
89618539|NCT03126708|Experimental|chemotherapy (cisplatin plus paclitaxel) and cetuximab|
89618540|NCT03126708|Active Comparator|chemotherapy (cisplatin plus paclitaxel)|
89618541|NCT03390738|Experimental|Intravenous nivolumab 240mg|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal.
89618542|NCT03390660||birth cohorts|born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014
89618543|NCT03385434|Experimental|Endorings-assisted screening colonoscopy|146 patients with an indication for screening endoscopy will receive an Endorings-2-assisted colonoscopy.
89618544|NCT03385434|No Intervention|Standard screening colonoscopy|146 patients with an indication for screening endoscopy will receive a standard colonoscopy.
89618545|NCT03390582||Hashimoto's thyroiditis|Hashimoto's thyroiditis (HT) is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers.
89618546|NCT03390582||healthy controls|healthy controls are all from normal volunteers
89036559|NCT04138524|Experimental|interventional|All the participants will received the full SAFIR. SAFIR is composed with 5 core components: 1) assessment of the family, 2) emotional support, 3) information, 4) family engagement, 5) care coordination. Each family will participate in 3 structured family meetings, with a follow-up at 30 days. During each meeting, every core component will be delivered but their dose will be adapted following the priorities of the families.
89036560|NCT05121792|Experimental|Therapist online training in Prolonged Grief Disorder Therapy|Participants will be given access to an online 10-module interactive tutorial about Prolonged Grief Disorder Therapy.
89520300|NCT05102331|Placebo Comparator|Placebo Aromatherapy Control Arm (PA)|Participants assigned to PA Clinic staff will have the same procedures as listed in LOA arm except the oil used will be a refined jojoba oil which has no color or smell. The BMAB procedure will follow the SOC provided by the clinic. This includes warning participants of upcoming stimuli, encouraging patients to remain calm, and generally expressing empathy to participants. Participants in this group will receive the same collection of questionnaires before, during, and after the procedure as the LOA group. BP, HR, and EEG measurements will similarly be collected continuously before, during, and after the procedure.
89520301|NCT04808193|Experimental|Brugada Survey|Survey will be answered by all participants
89057338|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml by an independent safety committee
89210919|NCT00907764|Experimental|Regadenoson alone|
89210920|NCT00907764|Experimental|Regadenoson with exercise|
89520302|NCT05058573|Experimental|Myofascial relaxation technique + Temporomandibular joint release techniques group (n=22)|medical treatment + temporomandibular joint relaxation (temporalis, masseter, and suboccipital muscles) + myofasial release/trigger points (trapezius, rhomboideus, and levator scapulae, sternocleidomastoideus muscles),
89520303|NCT05058573|Experimental|Temporomandibular joint release techniques group (n=22)|only temporomandibular joint relaxation will be performed in this group (temporalis, masseter, and suboccipital muscles).
89520304|NCT05058573|Experimental|Control group (n=22)|only medication treatment will be applied
89520305|NCT02734433|Experimental|Pexidartinib|Pexidartinib capsules administered twice daily in the morning and evening. Each cycle of treatment is 28 days in duration. The cycle of treatment is continued until disease progression, unacceptable toxicity, or consent withdrawal.
89520306|NCT04741659|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their actual low oxygen flow
89520307|NCT04741659|Active Comparator|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe with HFNC of 40 L/min
89520308|NCT04741659|Active Comparator|Helmet CPAP|the patients will be asked to breathe with the Helmet CPAP
89520309|NCT04741659|Active Comparator|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
89520310|NCT04451759|Active Comparator|healthy controls|
89520311|NCT04451759|Experimental|Anorexia|
89520312|NCT04451759|Experimental|Obesity|
89520313|NCT03129191|Active Comparator|AB arm|"Sequence:~Aided with non-invasive bone conduction hearing aid A~Aided with non-invasive bone conduction hearing aid B"
89520314|NCT03129191|Active Comparator|BA arm|"Sequence:~Aided with non-invasive bone conduction hearing aid B~Aided with non-invasive bone conduction hearing aid A"
89520315|NCT04696419|Other|ANIMAL CONTACT 1|Only one arm - within-subject design
89520316|NCT03448445||High-risk MCI|This cohort will include participants with high-risk mild cognitive impairment (MCI).
89520317|NCT03448445||Low-risk MCI|This cohort will include participants with low-risk MCI.
89520318|NCT04583319||SARS-CoV-2 Positive|patients tested positive for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
89520319|NCT04583319||SARS-CoV-2 Negative|participants tested negative for SARS-CoV-2 by routine Turkish MOH and FDA approved RT-PCR IVD test.
89520320|NCT03443609|Other|68Ga-HBED-CC-PSMA PET / CT|"Patients will receive 68Ga-HBED-CC-PSMA PET / CT imaging for the detection of prostate cancer recurrence sites. This determination will be made at the patient and lesion level by reference to the gold standard (or truth standard) that will be obtained from the histology data and / or from an imaging and evolution follow-up. PSA over a period of at least 6 months (RECIST 1.1 criteria)."
89520321|NCT04583163||Neuro-critical Care Patients|"Up to 12 subjects will be recruited over a 1 year period. Patients enrolled in the study are recruited from the pool of neuro-critical care patients admitted to the surgical intensive care unit (SICU).~To meet study inclusion, transcranial Doppler (TCD) testing will be ordered as part of the standard of care for these patients. The test will not be ordered solely for research purposes. There are no known side effects from the non-invasive measurement of cerebral blood flow using ultrasound.~Three different TCD technicians will perform triplicate readings on 3 consecutive days on up to 12 patients already undergoing TCD as ordered by their treating team. Standard of care on specific neuro critical care patients (such as cerebral aneurysms) is to undergo daily TCD monitoring to assess for possible vasospasm. Patients will be in the supine position while measurements are obtained. The probe will be placed in the preauricular region of the temporal window."
89520322|NCT03448367||SMBG/FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
89520323|NCT04562181|Experimental|Interventions|Anesthesia will be induced with bolus infusion using propofol, sufentanil and cis-atracurium intravenously. The patients will be intubated subsequently. TOF (T4/T1) will be calculated continuously using muscle relaxation monitoring. Anesthesia are maintained with a combination of sevoflurane, propofol, sufentanil and cis-atracurium. Anti-emetic and opioids will be routinely administrated prior to abdominal closure. Neostigmine will be administrated for reversing the residual neuromuscular blockade after the patient get his breath. Tracheal extubating is indicated by a TOF value above 70% in addition to other physical signs.
89520324|NCT03443531|Experimental|TCM|Patients in this group will receive two types of TCM treatment, which are Bufei Huatan granule, Yifei Qinghua granule. The herbal extract twice daily for 24 weeks for lower dosage. The two granules are corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
89618547|NCT03390582||treatment_naive GD|GD is primarily a humoral disease where autoantibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism.
89618548|NCT03390582||treated GD|GD patients treated by Methimazole Pill
89618549|NCT03385356|Active Comparator|1000 IU of vitamin D per day|Half of randomized patients will receive 1000 IU of vitamin D per day
89618550|NCT03385356|Active Comparator|4000 IU of vitamin D per day|Half of randomized patients will receive 4000 IU of vitamin D per day
89618551|NCT03385278|Experimental|real-sham|the group first received real rTMS,then sham one.
89618552|NCT03385278|Experimental|sham-real|the group first received sham rTMS,then real one.
89618553|NCT01913574|Experimental|Acupuncture & NCPB|The NCPB will be administered once at the start of the trial and the acupuncture will be performed 3 times per week for 2 weeks (6 times in total).
89618554|NCT01913574|Active Comparator|NCPB|The NCPB alone will be applied to the patients in this group, once at the start of the trial.
89618555|NCT03125850|Experimental|day-ward group|
89618556|NCT03125850|Active Comparator|inpatient group|
89618557|NCT03388866|Active Comparator|Mite extract sublingual immunotherapy|"Use of mite extract sublingual immunotherapy (SLIT) with increasing weekly doses of extracts of mite Dermatophagoides pteronyssinus, as represented below:~Weekly dose schedule Monday Wednesday Friday~st week 1 drop 2 drops 4 drops~nd week 6 drops 8 drops 8 drops~Monthly Dilution Schedule Dilution of mite extract~1st and 2nd weeks (1st month) 1: 1000000 v: v 3rd and 4th weeks (1st month) 1: 100000 v: v~1st and 2nd weeks (2nd month)1: 10000 v: v 3rd and 4th weeks (2nd month) 1:1000 v: v~1st and 2nd weeks (3rd month) 1: 100 v:v 3rd and 4th weeks (3rd month) 1:10 v:v 3rd to 18th month 1:10 v: v"
89618558|NCT03388866|Placebo Comparator|SLIT placebo|"Patients in the control group will be submitted to the same administration schedule, but with allergen extract diluent (doubly distilled water solution and glycerin), as described below:~Weekly dose schedule Monday Wednesday Friday~st week 1 drop 2 drops 4 drops~nd week 6 drops 8 drops 8 drops~Intervention: Placebo - Immunotherapy allergen diluent"
89618559|NCT01873170||Combined Oral Contraceptive pills|Levonorgestrel/ethinyl estradiol 0.15mg/30mcg daily oral tabs x21 then 7 inert tabs
89618560|NCT01873170||depot medroxyprogesterone acetate|150mg DMPA intramuscular injection once every 3 months
89618561|NCT01873170||Levonorgestrel-intrauterine device|52mg levonorgestrel intrauterine device
89618562|NCT01873170||Copper intrauterine device|Copper T380A intrauterine device
89618563|NCT01873170||Etonogestrel contraceptive implant|68mg etonogestrel subdermal implant
89618564|NCT01873170||Control|Low risk of pregnancy due to sterilization, heterosexual abstinence, or consistent condom use
89618565|NCT01856868|Experimental|Treatment with Epicatechin|Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
89618566|NCT03390270||Patients with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
89618567|NCT03125694|Active Comparator|Sitagliptin|
89618568|NCT03125694|Active Comparator|Pioglitazone|
89618569|NCT03385200|Active Comparator|A|Application and measurement of tumor size using contrast agent-enhanced diagnostic and therapy supporting (with SonoVue®) ultrasound
89618570|NCT03385200|No Intervention|B|Application and measurement of tumor size using contrast agent-enhanced diagnostic ultrasound
89618571|NCT02731638|Experimental|Intrastromal voriconazole plus natamycin|Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis
89618572|NCT02731638|Active Comparator|Natamycin alone|Standard of care topical treatment for fungal keratitis
89618573|NCT01451632|Experimental|Part 1: MM-121 + cetuximab|increasing doses of weekly MM-121 + weekly cetuximab
89618574|NCT01451632|Experimental|Part 2: MM-121 + cetuximab + irinotecan|increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
89618575|NCT03390192|Experimental|Dual-mode stimulation|"Dual-mode stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and active tDCS. 1 Hz of rTMS is applied over the contralesional M1 for 20 minutes with simultaneous application of anodal tDCS on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
89618576|NCT03390192|Active Comparator|Single sham stimulation|"Single sham stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and sham tDCS. 1 Hz of rTMS over the contralesional M1 was applied for 20 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
89618577|NCT01491490|Active Comparator|GWP42003 : GWP42004 (40:1)|
89618578|NCT01491490|Placebo Comparator|Placebo|
89618579|NCT03008200||RDS +|postpartum RDS developed group
89618580|NCT03008200||RDS -|postpartum RDS undeveloped group
89618581|NCT03812016|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device. Test the device one time ( duration: 30-120 mins/each time) and 3 times within 3 months.~Intervention: using the magnetic device"
89618582|NCT02520492|Experimental|noninvasive method of ICP measurements|"Patients will receive a noninvasive measurement of ICP variations during each of their follow up consultation. These measurements will last until 30 minutes for the first consultation (parameters to determine) and 10 minutes for the others. A postural test will be performed during the ICP measurements when the patient condition will make it possible to do.~Measurements will be performed by a device with noninvasive acoustic probes placed in the ear, and in case of electrophysiological test, regular electrodes on the brow."
89618583|NCT01491958|Experimental|Donor|Related donors will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines. Peripheral blood stem cells will not be manipulated or T-depleted prior to administration.
89618584|NCT01491958|Experimental|Patient|Patients will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first. Standard post transplant care will be administered.
89618585|NCT01492582|Experimental|Prevention (vaccine therapy)|Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
89618586|NCT01493596|Other|CPP-115 Dose 1|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
89618587|NCT01493596|Other|CPP-115 Dose 2|2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
89618588|NCT01493596|Other|CPP-115 Dose 3|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
89618589|NCT01493596|Other|CPP-115 Dose 4|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
89618590|NCT01493596|Other|CPP-115 Dose 5|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
89618591|NCT01493596|Other|CPP-115 Dose 6|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
89618592|NCT01552876|Other|etafilcon A / nelfilcon A / Filcon II 3|etafilcon A worn first then nelfilcon A worn second with Filcon II 3 worn third.
89618593|NCT01552876|Other|nelfilcon A / etafilcon A / Filcon II 3|nelfilcon A worn first then etafilcon A worn second with Filcon II 3 worn third.
89618594|NCT01495858|Experimental|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|
89618595|NCT01495858|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
89618596|NCT01495858|Active Comparator|DPH 50 mg|
89618597|NCT01496248|Experimental|Korean Red Ginseng|Extract of Korean red ginseng was administrated to subjects through capsule form.
89618598|NCT01497496|Experimental|Immunotherapy|Combination regimen consisting of high dose methylprednisolone combined with ofatumumab, followed by consolidative therapy with lenalidomide in combination with ofatumumab.
89618599|NCT02208310|Active Comparator|Low Dose Vitamin D|Patients will be given 400 IU cholecalciferol once daily for 30 days. <-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
89618600|NCT02208310|Experimental|High Dose Vitamin D|Patients will be given cholecalciferol 10,000 IU daily for 30 days. <-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if <50 ng/ml, a 30 day course will be administered.
89618601|NCT01453894|Experimental|Reminder and Outreach Intervention|Participants randomized to this arm will receive the Reminder and Outreach intervention.
89618602|NCT01453894|No Intervention|Usual Care Control Group|Patients assigned to this arm will receive usual care.
89618603|NCT01454362|Experimental|Electronic cigarette|We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.
89618604|NCT01454362|Active Comparator|Nicotine Inhalator|The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.
89618605|NCT01455064||Type 1 or 2 diabetes, MDI or pump|
89618606|NCT01456000|Experimental|EAS-AC (HeartLight)|Treatment with the EAS-AC.
89210921|NCT00907764|Experimental|Regadenoson with contrast agent|
89618607|NCT01456000|Active Comparator|Control Arm Ablation|Treatment with standard ablation.
89618608|NCT01554982|Other|Ferric Citrate|Open label extension of those completing study KRX-0304
89618609|NCT01497808|Experimental|Ipilimumab and Radiotherapy (8 Gy x 2)|
89618610|NCT01497808|Experimental|Ipilimumab and Radiotherapy (8 Gy x 3)|
89618611|NCT01497808|Experimental|Ipilimumab and Radiotherapy (6 Gy x 2)|
89618612|NCT01497808|Experimental|Ipilimumab and Radiotherapy (6 Gy x 3)|
89618613|NCT01498588|Experimental|Eribulin+Doxorubicin+Cyclophosphamide|"Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide~Eribulin Day 1 and Day 8 of a 21 day cycle x 4 cycles:~Day 1: Eribulin 1.4mg/m² IV~Day 8: Eribulin 1.4mg/m² IV~Dose-dense doxorubicin and cyclophosphamide every 14 days x 4 cycles:~Day 1: Doxorubicin 60mg/m² IV~Day 1: Cyclophosphamide 600mg/m² IV~Day 2: Pegfilgrastim support 6mg sc at least 24 hours after chemotherapy at the discretion of the investigator."
89210922|NCT00907764|Experimental|Regadenoson with contrast agent (perfusion)|
89618614|NCT01498744|Experimental|5 days postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
89618615|NCT01498744|Experimental|1 day postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
89618616|NCT01498978|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression then receive maintenance ipilimumab IV once every 3 months for 4 additional doses.
89618617|NCT01458418|Experimental|Montelukast 10 mg/day|Subjects will receive two 5mg tablets of Montelukast/day.
89618618|NCT01458418|Experimental|Montelukast 5mg/day|Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
89618619|NCT01458418|Placebo Comparator|placebo|Subjects will receive two placebo tablets per day.
89618620|NCT01557322||Biologic|
89618621|NCT01557322||non-biologic DMARD|
89618622|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
89618623|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
89618624|NCT01459588|Active Comparator|Carboxymethylcellulose Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
89618625|NCT01459588|Active Comparator|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
89618626|NCT01501162|Placebo Comparator|alcohol, hepatitis, Placebo|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
89618627|NCT01501162|Active Comparator|hepatitis, alcohol, probiotics|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
89618628|NCT01502332|Experimental|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways.
89618629|NCT01502332|Active Comparator|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways.
89618630|NCT01504672|Experimental|Medication review|
89618631|NCT01504672|No Intervention|Usual care|
89618632|NCT01557790|Experimental|Proton RT|Subjects receive proton radiation for seminoma
89618633|NCT01557868|Active Comparator|Synvisc (hylan G-F 20)|
89618634|NCT01557868|Active Comparator|Euflexxa (1% sodium hyaluronate)|
89618635|NCT01559506|No Intervention|No device|Subject does not receive ABS system
89618636|NCT01559506|Experimental|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
89618637|NCT02208466|Experimental|Active rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
89618638|NCT02208466|Experimental|Sham rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
89618639|NCT02208466|Experimental|Sham rTMS/placebo fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.
89618640|NCT02209948|Experimental|Temozolomide|Those patients will take 6 additional Temozolomide cycles
89618641|NCT02209948|No Intervention|Without treatment|
89618642|NCT02981212|Experimental|Mycophenolate Mofetil|MYREPT® capsule(CKDpharm, KOREA) and corticosteroid
89618643|NCT02981212|Active Comparator|Conservative treatment|maintain conservative treatment (ACE inhibitor or ARB)
89618644|NCT01560286|Experimental|Group 1|4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
89618645|NCT01505764|Experimental|Arm 1 (Anamorelin HCl)|Anamorelin HCl
89618646|NCT01505764|Placebo Comparator|Arm 2 (Placebo)|Placebo
89618647|NCT01464190|Experimental|PA21|
89618648|NCT01464190|Active Comparator|Sevelamer carbonate|
89618649|NCT01466764|Active Comparator|Anakinra|Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
89618650|NCT01466764|Placebo Comparator|Saline injection|Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
89618651|NCT01563406|Experimental|Alcohol with 5 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
89618652|NCT01563406|Experimental|Alcohol with 15 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
89618653|NCT01563406|Experimental|Chlorhexidine with 5 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
89618654|NCT01563406|Experimental|Chlorhexidine with 15 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
89618655|NCT01467934||Trivalent inactivated influenza vaccine|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1
89618656|NCT01467934||TIV and PCV13 together|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
89618657|NCT01467934||13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
89618658|NCT01468012|Experimental|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
89618659|NCT01468012|Placebo Comparator|Placebo|placebo
89618660|NCT01468558|Other|All subjects|Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).
89618661|NCT03730662|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
89618662|NCT03730662|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
89618663|NCT03730662|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
89618664|NCT03730662|Active Comparator|Insulin Glargine|"Insulin glargine administered SC once a day. Doses were individualized and titrated according to protocol-defined targets.~The starting dose of insulin glargine was 10 IU/day at bedtime, titrated to a FBG <100 mg/dL, following a treat-to-target (TTT) algorithm."
89618665|NCT01509040|Active Comparator|Control|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
89618666|NCT01509040|Experimental|Low Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/h, ultrafiltration 45 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
89618667|NCT01509040|Experimental|High Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/kg/h, ultrafiltration 90 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
89618668|NCT01470118|Active Comparator|LASTACAFT® (alcaftadine 0.25%)|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
89618669|NCT01470118|Active Comparator|Pataday™ (olopatadine 0.2%)|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
89618670|NCT01470118|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of placebo instilled in each eye at Day 0 and Day 14.
89618671|NCT03388554|Active Comparator|Active tDCS|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
89618672|NCT03388554|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
89618673|NCT03388320|Experimental|Participants receiving A-CHESS|Participants will be provided access to the smartphone application A-CHESS (intervention) that will be downloaded to their phone.
88987786|NCT00155454|Sham Comparator|Control group|Group 2 did not receive intravitreal long acting gas (10% C3F8)
88987787|NCT04516954|Experimental|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
88987788|NCT02955238|Experimental|Special Intervention|The Special Intervention (SI) is designed to modify multiple, modifiable CVD risk factors that affect atherosclerosis and can be measured by sonography of the carotid intimal thickness. The SI is designed to address multiple, modifiable CVD risk factors that involve medication therapy, including hypertension, diabetes, and dyslipidemia.
88987789|NCT02955238|No Intervention|Usual Care|Usual care (UC) reflects current practices by the primary care providers in the adult medicine department. Participants randomized into the UC group will continue with their regular medical visits and referrals to the health educator as they were before randomization.
88987790|NCT00162552|Active Comparator|1|Patients with severe cirrhosis treated with Pentoxifylline
88987791|NCT00162552|Placebo Comparator|2|Patients with severe cirrhosis treated with a placebo
88987792|NCT04516681|Experimental|Combined Ascorbic Acid with chemotherapy group|Ascorbic Acid with FOLFOXIRI with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks
88987793|NCT04516681|Active Comparator|Chemotherapy alone group|standard FOLFOXIRI treatment
88987794|NCT04516330|Active Comparator|unifocal breast cancer|patients having unifocal breast cancer
88987795|NCT04516330|Active Comparator|multicentric breast cancer|patients having multicentric breast cancer
88987796|NCT04516603|Experimental|Fampridine SR|"Single oral administration of a tablet fampridine (10 mg) formulated for oral administration taken once in the morning without food. Tablets must be administered whole.~The single intake is followed by a washout period of at least 7 days equalling over 40 half-lives of the active substance fampridine (t½ = 3.61 h) between experimental and control intervention."
88987797|NCT04516603|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of the identical additives formulated for oral administration.
89036561|NCT00534534|Active Comparator|1|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. In addition, they also will undergo repeated similar interventions at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
89036562|NCT00534534|No Intervention|Standard|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
89618674|NCT01470196|Experimental|Treatment Arm|Carfilzomib, dexamethasone, rituximab
89618675|NCT03389880|Active Comparator|Patellar denervation|
89036563|NCT05062070|Active Comparator|5 Percent TolaSure Topical Gel|5% (w/w) TolaSure Gel
89618676|NCT03389880|Experimental|Non-patellar denervation|
89618677|NCT04446234|Experimental|Risperidone|Risperidone tablet
89618678|NCT04446234|Experimental|Aripiprazole|Aripiprazole tablet
89618679|NCT04446234|Experimental|Ziprasidone|Ziprasidone tablet
89618680|NCT04446234|Experimental|Amisulpride|Amisulpride tablet
89618681|NCT04446234|Experimental|Quetiapine|Quetiapine tablet
89618682|NCT01510834|Experimental|All STR2IVE Participants|All participants who met study criteria, consented and were enrolled, were asked to complete online assessments at three timepoints(baseline, 1-month, and 3-months) and complete 2 or more behavioral programs each month. Behavioral programs and assessments were provided online via the Multibehavioral, Computerized Tailored Intervention STR2IVE.
89618683|NCT03385044|Active Comparator|Cuff sealing by MOVT|MOVT (minimal occlusive volume technique). The cuff sealing will be confirmed with MOVT, then the intracuff pressure will be measured.
89618684|NCT03385044|Active Comparator|Cuff sealing by VE/VI ratio|VE/VI ratio of Spirometer. The cuff sealing will be confirmed with VE/VI ratio of a spirometer, then the intracuff pressure will be measured.
89618685|NCT03388086||Onabotulinum 300 units|
89618686|NCT03388086||Onabotulinum 200 units|
89618687|NCT03613506|Experimental|Peripheral blood TGF-β content before and after radiotherapy|
89618688|NCT01565902|Experimental|Mild hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
89618689|NCT01565902|Experimental|Moderate hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
89618690|NCT01565902|Experimental|Severe hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
89618691|NCT01565902|Experimental|Matched healthy subjects|Treatment with a single oral dose of 0.25 mg BAF312
89036564|NCT05062070|Placebo Comparator|Topical Vehicle Gel|TolaSure Vehicle Gel
89036565|NCT00534573|Active Comparator|Moclobemide,|treatment during 2 weeks
89618692|NCT01566448|Experimental|Ketamine|Ketamine oral mouthwash 20mg/5ml swish and spit four times daily
89618693|NCT05565976|Experimental|Dapagliflozin|10mg PO q24h for 12 months plus standard treatment with statins, platelet antiaggregant, and hypoglycemic medications.
89618694|NCT05565976|Active Comparator|Standard treatment|Standard treatment with statins, platelet antiaggregant, and hypoglycemic medications.
89618695|NCT01566526||Patients Previously Treated with OZURDEX®|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
89618696|NCT01566682||Indeterminate Pulmonary Lesions|Patients with Pulmonary Lesions as seen by CT
89618697|NCT03185832||CRT-D Cohort|Number of participants with first appropriately treated ventricular arrhythmia
89618698|NCT03185832||ICD Cohort|Number of participants with first appropriately treated ventricular arrhythmia
89618699|NCT03185832||Pacing (PM / CRT-P) Cohort|All cause mortality
89618700|NCT03185832||Non-device Cohort|All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors
89618701|NCT01566838|Active Comparator|On-q pump|Patients in this arm will receive the standard acute pain management regimen during hospital admission and will be sent home after discharge with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
89618702|NCT01566838|Active Comparator|Standard of care|"Patients in this arm will not receive a pain catheter in addition to the standard of care for pain management. Standard of care will consist of a standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and maintained on a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures. Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV once, neuromuscular reversal agents, and an antiemetic (ondansetron 4mg). Patients will also be given additional narcotics (fentanyl) upon emergence, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will also be provided. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
89618703|NCT02930538||Children undergoing surgery|Children ages 3-18 undergoing a surgical procedure at Nationwide Children's Hosp.
89036566|NCT00534573|Active Comparator|Amisulpride|Comparison
89036567|NCT04686890|Active Comparator|postoperative opiod (morphine) consumption|patient-controlled analgesia (15 minutes. lock time, 2 ml bolus= total 1 mg morphine intravenously, limited to maximum 4 bolus / per hour )
89618704|NCT03384888|Experimental|ano-M1-cat-SO5 tDCS|Participants will receive active transcranial direct current stimulation (tDCS) (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 5 consecutive days.
89618705|NCT03384888|Experimental|ano-M1-cat-SO10 tDCS|Participants will receive active transcranial direct current stimulation (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 10 consecutive days.
89618706|NCT03384888|Sham Comparator|Sham tDCS|Participants who receive stimulation of the simulated type (sham tDCS), following the protocol of the ano-M1-cat-SO5 group.
89618707|NCT01567150|Active Comparator|novel dressing|Treatment with novel dressing
89618708|NCT01567150|No Intervention|Control|Control is treatment without novel dressing
89618709|NCT03125616|Active Comparator|Standard UK 4CMenB vaccine|4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .
89618710|NCT03125616|Experimental|Additional 4CMenB Vaccine|4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.
89618711|NCT03380832||Type 2 diabetes for at least 10 years|This is an observational study in which we will quantify vestibular thresholds in individuals who have had type 2 diabetes for at least 10 years. Normative data has recently been published and subjects with diabetes will be compared to a model that includes age effects.
89618712|NCT01568008||All participants|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.
89618713|NCT03387930||Low back pain group|Participants will be followed up over 2 years to monitor the course of low back pain
89618714|NCT03387930||Asymptomatic group|Participants will be followed up over 2 years to monitor the incidence and course of low back pain
89618715|NCT05565508|Experimental|new laparoscopic access technique|in which we used our new laparoscopic access
89618716|NCT05565508|Experimental|Hasson's technique|in which we used the well-known Hasson's technique for primary laparoscopic access
89618717|NCT01514734|Experimental|AZARGA|Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks
89618718|NCT03380754|Experimental|Carbohydrate Rich Drink|Group A will receive the carbohydrate rich drink, Nutricia preOp. This is the intervention group.
89618719|NCT03380754|Placebo Comparator|Placebo Drink|Group B will receive placebo, Nestle Splash Lemon Flavor Water (Placebo) (similarly flavored and appearing water, however with no calorie, carbohydrate or nutritional content).
89618720|NCT03380754|No Intervention|No Drink|Group C will not receive any drink. This group will follow normal protocol.
89618721|NCT01515046|Experimental|Gemcitabine with escalating IV ascorbate|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off.~Ascorbate (vitamin C) given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbate / infusion for two infusions. Doses are then escalated in 25 gram increments until therapeutic window is achieved (350 mg/dL or above). Dose is then held at that level for the full cycle."
89618722|NCT03380676||Oromandibular dystonia group|Patients with idiopathic oromandibular dystonia, either focal or associated to other dystonic features including generalized dystonia
89618723|NCT03380676||Healthy subjects|Healthy subjects (normal neurological examination), each being age-matched to a subjet of the oromandibular dystonia group
89618724|NCT03384576|Experimental|Music intervention|Participants listen to music in the waiting room
89618725|NCT03384576|Active Comparator|No music|Participants will not have music in the waiting room
89618726|NCT01568944|Experimental|Oral Antibiotic and Oral Rinse|Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
89618727|NCT01568944|Other|Standard Treatment|Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
89618728|NCT03380598|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 6 months.
89618729|NCT03380598|Active Comparator|CLOSS|Usual care plus using a web based support system for self-monitoring weight at physical activity.
89618730|NCT05565274|Experimental|Tramadol plus Paracetamol|2ml of 100mg of intramuscular tramadol plus 2ml of 600mg of intramuscular paracetamol unlabeled
89618731|NCT05565274|Active Comparator|Pentazocine plus placebo|2ml of 30mg of pentazocine plus 2 ml of water for injection will be administered intramuscularly during labour
89618732|NCT03380520|Experimental|Ferric carboxymaltose|Ferric carboxymaltose according to SmPC
89618733|NCT03380520|Placebo Comparator|Placebo|Normal saline (0.9%)
89618734|NCT03387540||Myocarditis induced by Immune check point inhibitor|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by ICI, with a chronology compatible with the drug toxicity
89618735|NCT05173662|Experimental|Intervention Group|"To the mothers in this group; At least 12 hours before the heel blood collection (guthrie screening test), training was given, lasting 25 minutes, on average, through the training brochure on non-pharmacological pain management prepared by the researcher. The training was carried out in a language that the mother could understand, in the form of direct lectures and questions and answers, using the visuals in the brochure. In the training content; There are five non-pharmacological methods. These;~Expressed breast milk~Wrapping~Skin-to-skin contact~Cuddling~They are methods of making calming sounds."
89618736|NCT05173662|No Intervention|Control Group|In the control group, as in the clinical routine, the heel stick procedure was performed in the newborn's own bed next to his mother. No other action has been applied.
89618737|NCT05173584|Experimental|Levalbuterol Arm|
89618738|NCT05173584|Active Comparator|Albuterol Arm|
89618739|NCT03387306||Patient group|This grup included 38 patients with NTG.
89618740|NCT03387306||Control group|This group included 38 healthy controls.
89618741|NCT04671030|Experimental|Treatment group|Subjects are screened by criteria, intravenous and transdermal iontophoresis then undergo the study during which they will be administered the placebo alternating with real drug without being aware of which is being given.
89618742|NCT04671030|Placebo Comparator|Placebo group|Placebo will be given without the subject being aware of the time in advance.
89618743|NCT04660890|Experimental|Treatment Arm (ABC)|"Treatment Sequence ABC - Participants will receive all 3 doses of ALXN2050 in a multiple-ascending fashion over 3 periods:~Treatment A (Period 1): ALXN2050 Dose 120 milligrams (mg) and moxifloxacin-matching placebo.~Treatment B (Period 2): ALXN2050 Dose 240 mg and moxifloxacin-matching placebo.~Treatment C (Period 3): ALXN2050 Dose 360 mg and moxifloxacin-matching placebo."
89618744|NCT04660890|Placebo Comparator|Control Arm (DEF)|"Treatment Sequence DEF - Participants will receive ALXN2050-matching placebo over 3 periods:~Treatment D (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.~Treatment E (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin.~Treatment F (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin-matching placebo."
89618745|NCT04660890|Placebo Comparator|Control Arm (GHI)|"Treatment Sequence GHI - Participants will receive ALXN2050-matching placebo over 3 periods:~Treatment G (Period 1): 120 mg ALXN2050-matching placebo and moxifloxacin.~Treatment H (Period 2): 240 mg ALXN2050-matching placebo and moxifloxacin-matching placebo.~Treatment I (Period 3): 360 mg ALXN2050-matching placebo and moxifloxacin."
89618746|NCT04632264|Experimental|Pre-placental group|"Oxytocin will be initiated immediately after delivery of the neonatal anterior shoulder (within 15 seconds). This is our intervention group. Saline placebo will be initiated post placenta delivery (within 15 seconds)."
89618747|NCT04632264|Other|Post-placental group|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds). Oxytocin will be initiated immediately after placenta delivery (within 15 seconds).
89618748|NCT04607928|Placebo Comparator|Placebo|No anti-fibrotic treatment. Patients in placebo and treatment arm may be on corticosteroid treatment
89618749|NCT04607928|Experimental|Treatment|Pirfenidone
89618750|NCT03610386|Active Comparator|Control|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours and then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes .
89618751|NCT03610386|Experimental|Treatment with menthoxypropanediol|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. Thy will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …).One of two biopsies will be left in culture for 24 hours. Then the menthoxypropanediol (200 µM) will be applied topically on this explant and left for 6 hours. Then the biopsy will be cut in half: half will be used for immunohistochemical analyzes, the second half for transcriptomic analyzes.
89618752|NCT03384420|Experimental|Intervention CD34+ cells enriched with MNV-BLD|Intervention CD34+ cells enriched with MNV-BLD
89618753|NCT03387228|Experimental|Pain education group (PEG)|Pain education based on Explain Pain developed by Moseley and Butler in 2003.
89618754|NCT03387228|Active Comparator|Control group (CG)|Evidence based physiotherapy care brief education, superficial heat, massage, and exercise.
89618755|NCT04569786|Experimental|V590 5.00x10^5 pfu (Panel A)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel A) will receive a single dose of V590 5.00x10^5 pfu or placebo on Day 1.
89618756|NCT04569786|Experimental|V590 2.40x10^6 pfu (Panel B)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel B) will receive a single dose of 2.40x10^6 pfu or placebo on Day 1.
89618757|NCT04569786|Experimental|V590 1.15x10^7 pfu (Panel C)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel C) will receive a single dose of 1.15x10^7 pfu or placebo on Day 1.
89618758|NCT04569786|Experimental|V590 5.55x10^7 pfu (Panel D)|Participants in this 18 to 54-year-old SARS-CoV-2 seronegative cohort (Panel D) will receive a single dose of V590 5.55x10^7 pfu or placebo on Day 1.
89618759|NCT04569786|Experimental|Part 2: 5.00x10^5 pfu (Panel E)|Participants in this ≥ 55 years old SARS CoV-2 seronegative cohort (Panel E) will receive a single dose of V590 5.00x10^5 pfu or placebo on Day 1.
89618760|NCT04569786|Experimental|Part 2: 2.40x10^6 pfu (Panel F)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel F) will receive a single dose of 2.40x10^6 pfu or placebo on Day 1.
89618761|NCT04569786|Experimental|Part 2: 1.15x10^7 pfu (Panel G)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel G) will receive a single dose of V590 1.15x10^7 pfu or placebo on Day 1
89618762|NCT04569786|Experimental|Part 2: 5.55x10^7 pfu (Panel H)|Participants in this ≥ 55 years old SARS-CoV-2 seronegative cohort (Panel H) will receive a single dose of V590 5.55x10^7 pfu or placebo on Day 1.
89618763|NCT04569786|Experimental|Part 3: 5.55x10^7 pfu (Panel I)|Participants in this 18 to 54-year-old SARS-CoV-2 seropositive cohort (Panel I) will receive a single dose of V590 5.55x10^7 pfu or placebo on Day 1.
89618764|NCT04485624||Attendees at Paediatric Emergency Department 1 (PED1)|"These participants will be recruited from the children and young people (under the age of 16) attending the PED of a large district general hospital.~There was going to be a second group recruited but COVID meant that the site was not able to support non-COVID studies by the time the necessary approvals were in place."
89618765|NCT04447170||Laparoscopic repair|Patients undergoing laparoscopic treatment
89618766|NCT04447170||Open repair|Patients undergoing open treatment
89618767|NCT05172804|Experimental|Nursing students receiving progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement [11].
89618768|NCT05172804|Experimental|Nursing students receiving guided imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin [11].
89036568|NCT04686890|Active Comparator|peroperative continuous opioid (remifentanil) consumption|continuous remifentanil infusion was given during the whole procedure
89036569|NCT04686890|Active Comparator|postoperative numerated rating scale|at the 1, 3, 6, 12 and 24 th hour postoperatively - numerated rating scale score was evaluated and recoded as 0= no pain (better), 10: unbearable pain (worse)
89036570|NCT00533000|Experimental|A|Smoking cessation
89036571|NCT00533000|No Intervention|B|
89036572|NCT00534612|Experimental|1|fine needle aspiration biopsy of the parotid gland mass
89036573|NCT00533039|Placebo Comparator|Control|Subjects take 2 tablets BID. Placebo tablets are identical to active medication.
89036574|NCT00533039|Experimental|Varespladib (A-002)|Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
89036575|NCT05103306||Triple OADs failure|Inadequatelly controlled type 2 diabetes patients despite triple combination therapy with metformin, glimepiride, and DPP-4 inhibitor
89618769|NCT05172804|Experimental|Nursing student receiving mindfulness meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting) [11]."
89618770|NCT05172804|Active Comparator|control Group|Participants in the control condition will be instructed to sit with their eyes closed during the intervention periods. Participants in the control group will follow an identical time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
89618771|NCT03380442|Experimental|Psilocybin group|This group will receive a single oral 25mg dose of psilocybin under surveilled and safe conditions.
89618772|NCT03380442|Active Comparator|Ketamine group|This group will receive a single intranasal 125mg dose of ketamine under surveilled and safe conditions.
89618773|NCT03380442|No Intervention|No-treatment group|This group will be included in the study as a no-treatment group, so that natural time-dependent changes in depressive symptoms can be controlled for and thus the antidepressive effects of ketamine and psilocybin treatment can be verified
89618774|NCT03380364|Experimental|Group Undergoing Hysterosopy|This group will include 75 women with unexplained infertility. 5 mm rigid sheath Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.
89618775|NCT03558360||Bariatric surger|Bariatric surgery and impedance measurement
89618776|NCT03387072||Patients affected with CIQTP|Patients affected with catecholamine-induced QT prolongation (CIQTP)
89618777|NCT03387072||Healthy relatives of patients affected with CIQTP|Healthy relatives of patients affected with CIQTP identified during the familial screening
89036576|NCT05042999|Experimental|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
89036577|NCT05042999|No Intervention|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
89036578|NCT05102097|Experimental|Experimental Group|Treadmill walk: i- warm up ( 5 minutes ) II- Main exercise (30 minutes) III- cool down (5 minutes) IV- Standard of care (10minutes)
89036579|NCT05102097|Active Comparator|Control group|Standard of care (10 minutes)
89036580|NCT05007002|Experimental|Robot-based therapy|Chronic stroke patients receiving robot-based therapy
89036581|NCT04106037||Legionnaires' disease|All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years: from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre Hospital and the UZ Brussel Hospital.
89618778|NCT03386916||Patient with a CT scan guide percutaneous biopsy of lytic bone|Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
89618779|NCT03380286||Coronary Stenosis|
89618780|NCT02519868|Experimental|Experimental arm|Patients will have both interventions: electrical stimulation followed by chemical stimulation
89036582|NCT04980443|Experimental|FIT positive individuals|FIT-positive individuals of whom we will collect blood samples and who will undergo a colonoscopy after blood sampling.
89036583|NCT04971980|Experimental|hUC-MSC infusion (BC-U001)|Cohort 1: Low-dose BC-U001 Cohort 2: Medium-dose BC-U001 Cohort 3: High-dose BC-U001
89036584|NCT04965779|Experimental|Intervention group (Abdominal binder)|The abdominal binder is applied after the women come to the clinic (postpartum 1st hour) following cesarean delivery and removed after the postpartum 48th hour. Postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided together with the application of the abdominal binder.
89036585|NCT04965779|Active Comparator|Control group (No abdominal binder)|Only postpartum nursing care in line with a follow-up protocol that was created based on the Republic of Turkey Ministry of Health's Postpartum Care Management Guide (2018) is provided with no abdominal binder or similar application.
89036586|NCT04960241|Active Comparator|Homebased telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
89057339|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 40,000 AUN/ml|Start of SUBLIVAC FIX Phleum prat. 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml arm evaluated by an independent safety committee
89618781|NCT03380130|Experimental|SIRT and Nivolumab|SIRT (selective internal radiation therapy) will be performed in a single session using SIR-Spheres resin microspheres. After 3 weeks, nivolumab 240 mg every 2 weeks will be initiated
89618782|NCT03386838|Experimental|Nivolumab and BMS-986205|Nivolumab administered in combination with BMS-986205
89618783|NCT03386838|Active Comparator|EXTREME study regimen|Cetuximab + Cisplatin/Carboplatin + Fluorouracil
89618784|NCT03386760|Experimental|A- Ultra-Speed Picosecond laser|Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation
89618785|NCT03386760|Active Comparator|B- Nanosecond laser|Utilisation of Nanosecond laser for tattoo depigmentation
89618786|NCT03384342|Experimental|Experimental group|"For a total period of 12 months, perform Narrow-band UV-B therapy treatment once a month.~At this time, the dose of Narrow-band UV-B therapy therapy is based on the 50% of the maximum dose that the patient received for the treatment."
89618787|NCT03384342|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
89618788|NCT03386682|Experimental|ESTYME MATRIX|Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s)
89618789|NCT03384264|Experimental|TG|
89618790|NCT03384264|No Intervention|CG|the CG maintained their normal physical activity habits over the study
89618791|NCT03384186|Experimental|Danicopan Modified Release Prototype Tablets|"Participants received danicopan once each period as a single oral dose as follows:~Period 1: Danicopan Modified Release Prototype 1 under fasted conditions. Period 2: Danicopan Modified Release Prototype 2 under fasted conditions. Period 3: Danicopan Modified Release Prototype 3 under fasted conditions. Period 4: Danicopan Modified Release Prototype 2 under fed conditions.~There was a washout period of at least 14 days between each danicopan dosing."
89618792|NCT03379974|Experimental|ARM A: DDAVP followed by exercise|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise intervention"
89618793|NCT03379974|Active Comparator|ARM B: DDAVP alone|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
89618794|NCT03379974|Experimental|ARM C: Exercise intervention|"Intervention #1: Exercise intervention~Intervention #2: no further intervention (rest)"
89618795|NCT03379974|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise intervention~Intervention #2: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
89618796|NCT03384030|Experimental|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
89618797|NCT03379896||Sepsis|Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).
89618798|NCT03379896||Control|Age-matched healthy control
89618799|NCT03379818|Experimental|Specific word training intervention|This training programme will be similar to a typical word learning intervention. Infants will be introduced to 28 real objects and their names (e.g. biscuit, trousers). These objects will be divided into 7 sets of four words, and during each session, infants will be presented with one of this sets. Each session will consist of a 15 min play session in which each object will be presented at least 10 times and each object name will be mentioned at least 10 times. Additionally, techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
89618800|NCT03379818|Experimental|Shape training intervention|In the shape training intervention, infants will be presented with four novel words paired with four novel sets of objects. Each set consists of two exemplars with the same shape but with different colors and textures, and a contrasting object. Each set will be presented in a play session, and the name of the objects will be mentioned at least 10 times. The other three sets of exemplars will be presented in the same way. Each session will last 15 minutes. This intervention is based on a study conducted by Smith and colleagues (2002), where they found that typically developing infants that are taught to attend to shape at 17 months old, can enhance significantly their word learning.
89618801|NCT03386370|Other|"Treatment by Indigo mechanical thrombectomy system"|Acute or Chronic clot: if chronic (> 14 days) no intervention given via Indigo
89618802|NCT03383952|Experimental|ICAR19 CAR-T cells|Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 CAR-T cells and the investigators will determine the safety and therapeutic effects of these cells.
89618803|NCT03383796|Experimental|3D approach|Three dimensional laparoscopic resection for pCCA
89618804|NCT03383796|Experimental|open approach|Open resection for pCCA
89036587|NCT04960241|Active Comparator|Homebased rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
89618805|NCT01570036|Experimental|Herceptin + NeuVax vaccine|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion, but may be delayed to the fourth or fifth Herceptin infusion with prior approval from the PI. Patients will be blinded regarding assigned arm. After completion of primary vaccine series, patients will receive 4 NeuVax vaccine booster inoculations to be administered every 6 months x 4 for total treatment duration of 30 months.
89618806|NCT01570036|Active Comparator|Herceptin + GM-CSF only|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive inoculations of GM-CSF only (250mcg) administered intradermally every 3 weeks for 6 total inoculations, 30-120 minutes after completion of Herceptin infusion. The GM-CSF only inoculation series will begin immediately after completion of the third Herceptin infusion. Patients will be blinded as to whether they are receiving NeuVax vaccine or GM-CSF only. After completion of six-inoculation primary vaccine series, patients will then receive a total of four GM-CSF only booster inoculations to be administered at 12, 18, 24, and 30 months from the date of the first Herceptin infusion.
89618807|NCT03386136|Experimental|Hospitalized Ileus or Pseudo-Obstruction Patient|Hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction [clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm] provided with 100% oxygen via non-rebreather face mask, for 6 hours
89618808|NCT03379584|Experimental|SGN-CD48A|SGN-CD48A
89618809|NCT03386058|Experimental|Intervention|Temporary device deactivation
89618810|NCT03383718||DSE+/FFR+|Patients with positive Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve Revascularisation
89618811|NCT03383718||DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-|"Patients with positive Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Optimal Medical Treatment/OMT"
89618812|NCT01516684|Experimental|Arm I (EMLA)|Patients receive topical EMLA cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
89618813|NCT01516684|Active Comparator|Arm II (placebo)|Patients receive topical placebo cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
89618814|NCT03383640|No Intervention|Control|Control Group: Standardized post operative rehabilitation, where active exercises of the replanted digits is postponed until radiologic healing of the amputated bone.
89618815|NCT03383640|Other|Intervention|Intervention Group: Early active exercises of the replanted digits started between day 5 and 7 after surgery, as instructed by hand therapist
89618816|NCT04316754|No Intervention|Control group|No music will be played to the control group.
89618817|NCT04316754|Active Comparator|Intervention 1|During angiography, the Intervention-1 group will listen to the music that the child wants to listen.
89618818|NCT04316754|Active Comparator|Intervention-2|"The Intervention-2 group will listen to the music which determined by the researchers. The music which determined by the researchers is The art of fugue by Johann Sebastian Bach. The music to be played has been decided by examining the literature. (DOI: 10.4274/jpr.24892)"
89618819|NCT03383562||morning group|patients in the morning group are operated during 8:30 a.m. to 2:00 p.m.
89618820|NCT03383562||afternoon group|patients in the morning group are operated during 2:00 p.m. to 8:00 p.m.
89618821|NCT03383562||night group|patients in the morning group are operated during 8:00 p.m. to 12:00 p.m.
89618822|NCT01517074|Experimental|Sirolimus|Participants will receive a15 μL (660 μg) subconjunctival injection of sirolimus in the study eye at baseline if a single quadrant or two adjacent quadrants are involved. If greater than two quadrants are involved (i.e., 3 or 4 quadrant involvement) or two non-adjacent quadrants are involved, two 15 μL (660 μg) injections will be given in two quadrants 180 degrees apart (total dose of 30 μL or 1,320 μg). Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period).
88987798|NCT00505492|Experimental|Radiation + Chemotherapy|Radiation with weekly Cisplatin 40 mg/m^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m^2 IV) Chemotherapy every 28 days
88987799|NCT04516174|Experimental|Dex+TAPB group|Patients in Dex+TAPB group will receive the bilateral transversus abdominis plane block with 0.25% ropivacaine 20ml each side before anesthesia and combined with continuous infusion of dexmedetomidine during operation.
88987800|NCT04516174|Placebo Comparator|Control group|Patients in control group will receive the bilateral transversus abdominis plane block with saline 20ml each side before anesthesia and don't receive the infusion of dexmedetomidine during operation.
88987801|NCT04516213|Experimental|Enteral formula tube feeding|Enterally fed children, ages 1-4, with established enteral feeding access
88987802|NCT04515979|Experimental|vactosertib+Pembrolizumab|Vactosertib (5days on and 2days off) Pembrolizumab 200mg Q3Weeks
88987803|NCT04696510||Chronic migraineurs|This group includes patients with chronic migraine.
88987804|NCT04696510||Control group|This group includes healthy subjects.
88987805|NCT04696510||Episodic migraineurs|This group includes patients with episodic migraine
88987806|NCT04515706|Experimental|Iguratimod|Iguratimod 25 twice a day (bid) on Week 1-48.
89618823|NCT03379350|Experimental|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
89618824|NCT03379350|No Intervention|control group|Patients in control group are managed with gravity drainage (water seal only, without suction) all the time after operation.
89618825|NCT01570348|Experimental|Treatment (allogeneic BMT)|"CONDITIONING THERAPY: Patients receive fludarabine phosphate IV over 30-60 minutes QD on days -6 to -2 and cyclophosphamide IV over 1-2 hours QD on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo donor BMT on day 0.~IMMUNOSUPPRESSIVE THERAPY: Patients receive high-dose cyclophosphamide IV over 1-2 hours QD on days 3-4, tacrolimus IV daily or PO BID on days 5-180 with taper to day 365, and mycophenolate acid enteric coated or mycophenolate mofetil PO TID on days 0-35."
89618826|NCT03383484|No Intervention|No intervention|No OMT, yoga, acupuncture, or other interventions.
89618827|NCT03383484|Experimental|OMT intervention|Weekly OMT for 3 months
88987807|NCT04515706|Placebo Comparator|Placebo|Placebo twice a day (bid) on Week 1-24, and Iguratimod 25 twice a day (bid) on Week 25-48.
88987808|NCT00505531||Tramadol ER- 200mg|Tramadol Extended Release capsules Weeks 1 & 6- 100 mg/day Weeks 2-5- 200 mg/day
88987809|NCT00505531||Tramadol ER- 300mg|Tramadol Extended Release capsules Weeks 1 & 7- 100 mg/day Weeks 2 & 6- 200 mg/day Weeks 3-5- 300 mg/day
88987810|NCT00505531||Placebo|Diphenhydramine capsules Weeks 1-6- 25 mg/day
88987811|NCT00505570|No Intervention|Medical Management|
88987812|NCT00505570|Experimental|PFO Closure|
88987813|NCT02964299||Standard|Standard bite block
88987814|NCT02964299||Mandibular advancement bite block|Mandibular advancement by 3 mm, 6 mm or 9 mm from neutral position
88987815|NCT04515355|Experimental|People with MS (PwMS)|People with MS recruited to take part and will be randomised to receive the intervention of online programme of support.
88987816|NCT04515355|No Intervention|People with MS (PwMS) - standard care|People with MS recruited to take part and will be randomised to receive the usual standard of care.
88987817|NCT04515277|Active Comparator|40 g (D1)|40 g gum acacia powder (D1). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
88987818|NCT04515277|Active Comparator|20 g (D2)|20 g gum acacia powder (D2). Treatment type is applied with the standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
88987819|NCT04515277|Other|No treatment (NT)|0 g gum acacia powder. Standardized breakfast (in 300 mL orange juice) on the test days (V2, V3 or V4).
88987820|NCT00141908|Placebo Comparator|Placebo progesterone injection|Placebo IM injections
88987821|NCT00141908|Active Comparator|Progesterone injections|17-hydroxyprogesterone caproate weekly injections
88987822|NCT04515043|Experimental|INVAC-1|All patients have been treated by INVAC-1 vaccine during the previous phase 1 NCT02301754. No new treatment injection is required in this study.
88987823|NCT04514614|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
88987824|NCT04724889||Patients with underlying AF|Patients that will have AF detected by ILR will be compared with patients without AF.
88987825|NCT04724889||Patients without AF|Patients that will have AF detected by ILR will be compared with patients without AF.
88987826|NCT04514770|Active Comparator|early amniotomy|"Group A:~Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.~Early amniotomy was performed for the participant of the first group at 3 cementer cervical dilatation with Kocher's forceps provided the head is well fitted to the cervix."
88987827|NCT04514770|Active Comparator|Late amniotomy|"Group B:~Pregnant women had taken misoprostol (vagiprost vaginal tablet; Adwia Pharmaceutical Company) vaginally as 25 micro gram of misoprostol. It was repeated every 6 hours until three or more uterine contractions of 40 second duration occur over 10 minutes, or when reaching four doses maximum (i.e. 100 micro gram) is reached.~late amniotomy was performed for the participant of the second group at 7 cementer cervical dilatation."
88987828|NCT04514809|Experimental|Experimental|It consists of 15 mothers who meet the inclusion criteria
88987829|NCT04514809|Experimental|Control Groups|It consists of 15 mothers who meet the inclusion criteria
88987830|NCT02955433|Experimental|Rideshare|The intervention arm will receive an appointment reminder and free transportation for one appointment to travel between the patient's home and primary care clinic using a rideshare-based transportation service.
88987831|NCT02955433|No Intervention|Control|The control arm will receive an appointment reminder, but no free transportation offer.
88987832|NCT00141986|Experimental|Vitamin D-higher dose|Vitamin D 2000 IU per os once daily
88987833|NCT00141986|Active Comparator|Vitamin D-lower dose|Vitamin D 400 IU per os once daily
88987834|NCT04514731|Experimental|Group M|Patients in the magnesium sulfate group received magnesium sulfate 50 mg/kg for 15 minutes after spinal anesthesia and then 15 mg/kg/hour by continuous intravenous infusion until the end of surgery
88987835|NCT04514731|Placebo Comparator|Group S|Patients in the saline group received the same volume of isotonic saline over the same period with magnesium infusion protocol
88987836|NCT04514419|Experimental|Trastuzumab + HS627 + Docetaxel|Trastuzumab HS627 Docetaxel
88987837|NCT04514419|Experimental|Trastuzumab + Pertuzumab + Docetaxel|Trastuzumab Pertuzumab Docetaxel
88987838|NCT04514380||Group C|Patients drank carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon A.
88987839|NCT04514380||Group N|Patients did not drink carbohydrate fluid 2 hours prior to surgery according to the routine fasting protocol by surgeon B.
89057340|NCT04542941|Active Comparator|Intervention arm|The participants will receive COVID Convalescent Plasma in addition to the standard of care received by all COVID 19 patients
89618828|NCT03383484|Experimental|Yoga intervention|Yoga 3 times per week for 3 months
89618829|NCT03383406|Experimental|I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)|
89618830|NCT05564884||Unvaccinated, Prior natural COVID-19 infection|Unvaccinated, Prior natural COVID-19 infection
89618831|NCT05564884||Vaccinated, No prior natural COVID-19 infection|Vaccinated, No prior natural COVID-19 infection
89057341|NCT04542941|No Intervention|Control arm|The participants under this arm will receive the COVID 19 standard of care
89618832|NCT05564884||Vaccinated, Prior natural COVID-19 infection|Vaccinated, Prior natural COVID-19 infection
89618833|NCT04445922|Experimental|test-anastrozole tablet|1 mg anastrozole was produced and provided by Salutas Pharma GmbH
89618834|NCT04445922|Experimental|reference-anastrozole tablet|1 mg anastrozole was produced by AstraZeneca Pharmaceuticals LP.
89618835|NCT01572298|Active Comparator|allograft alone|guided bone regeneration with allograft alone (includes tenting screws and overlying allograft membrane material)
89618836|NCT01572298|Experimental|allograft with autograft|guided bone regeneration with allograft and autograft combined (includes tenting screws and overlying allograft membrane material)
89618837|NCT01518868|Experimental|Investigational contact lens|multifocal high add soft contact lens
89618838|NCT01518868|Active Comparator|PureVision contact lens|Multi-focal contact lens
89618839|NCT04287348|Other|Beovu (Brolucizumab)|Prospective, one-treatment-arm, monocentre study
89210923|NCT02550314|Experimental|NPC-18,FBG-18|"Intervention drug:~NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue~Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane"
89210924|NCT00987987|Experimental|1|1
89618840|NCT03383328|Active Comparator|NSAID + prednisolone, preoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
89618841|NCT03383328|Active Comparator|NSAID + prednisolone, postoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
89618842|NCT03383328|Experimental|NSAID, preoperative|"NSAID eye drops as monotherapy. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
89618843|NCT03383328|Experimental|NSAID, postoperative|"NSAID eye drops as monotherapy. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
89618844|NCT03383328|Experimental|Drop-less surgery|"A depot of dexamethasone is administered subtenonally during surgery.~Dexamethason Krka 4 mg/ml solution for injection/infusion. 0,5 ml equivalent to 2 mg of dexamethasone is administered once."
89618845|NCT04445376|Experimental|Intervention Group (Ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
89618846|NCT04445376|Experimental|Intervention (Non ventilatory)|Breathing Exercise and Aerobic Training will be provided to all the patients.The training session will be given 3 days a week.
89618847|NCT01573702|Other|Stereotactic Radiosurgery Followed by Erlotinib|Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib
89618848|NCT04445298||Pregnant women with expected delivery in the fall or winter|We will enroll up to 40 women who are expected to deliver in the fall (September, October, November) and winter (December, January, February). We will then follow their infant offspring.
89618849|NCT04445298||Pregnant women with expected delivery in the spring or summer|We will enroll up to 40 women who are expected to deliver in the spring (March, April, May) and summer (June, July, August). We will then follow their infant offspring.
89618850|NCT04445298||Infants born in the fall or winter|The infants born to the enrolled mothers will be followed. These are infants born in the fall (September, October, November) or winter (December, January, February).
89618851|NCT04445298||Infants born in the spring or summer|The infants born to the enrolled mothers will be followed. These are infants born in the spring (March, April, May) or summer (June, July, August).
89618852|NCT03379038|Experimental|Progressive Physical Therapy (PPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions.~Total 42 sessions were performed in 6 weeks (7 days/week). Intensity: The aim of the PPT was to improve the patient's level of spasticity, strength and activity level."
89618853|NCT03379038|Placebo Comparator|Maintenance Physical Therapy (MPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions. Total 42 sessions were performed in 6 weeks (7 days/week).~Intensity:The aim of the MPT was to maintain the patient's current level of spasticity, strength and activity level."
89618854|NCT03093246|Placebo Comparator|Control group|In this group (n = 19), patients will take placebo pills and full-mouth ultrasonic debridement will be performed to treat diseased sites.
89618855|NCT03093246|Experimental|Test Group|In this group (n = 19), patients will take 3 g of omega-3 polyunsaturated fatty acids and 100 mg of aspirin daily over a period of 180 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
89618856|NCT03000426|Sham Comparator|Free gingival graft + PBM Sham|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which do not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications.
89057342|NCT01647984|Placebo Comparator|Placebo|Inert Placebo - Vitamin B complex + diet
89618857|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 60|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 60 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 60 Joules/cm2 and a time of 56 seconds per point (1,68 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
89618858|NCT03000426|Experimental|Free gingival graft + GaAlAs Laser 15|The irradiation will be performed with a GaAlAs diode laser that continuously emits a wavelength of 660 nm with a power of 30 milliwatts (mW). The patients allocated for the group 15 will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 Joules/cm2 and a time of 14 seconds per point (0,42 Joules/cm2 per point). During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by four more applications performed every other day, with a total of 5 laser applications. The power of the equipment will be calibrated prior to each application.
89618859|NCT05171634|Experimental|Colonoscopy assisted by DiscoveryTM|
89618860|NCT05171634|Active Comparator|Virtual Colonoscopy with iSCAN|
89618861|NCT03125460||Initial Enrollment|Initial enrollment of patients with history of bladder cancer
89618862|NCT03125460||Longitudinal Cohort|Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
89618863|NCT02969928|Active Comparator|Amoxicillin and Metronidazole|In this group (n = 23), patients will take Amoxicillin 500 mg tid for 7 days and Metronidazole 400 mg tid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
89618864|NCT02969928|Experimental|Clarithromycin|In this group (n = 23), patients will take Clarithromycin 500 mg bid for 7 days and full-mouth ultrasonic debridement will be performed to treat diseased sites.
89618865|NCT05171556||RV4942A arm|RV4942A study product is applied twice a day (morning and evening) on the face, neck and eye contour during the whole study.
89618866|NCT02968446|Placebo Comparator|Group 1: 4 placebo - 0 Vitamin D with Valchlor|Participants will be given 4 placebo capsules and 0 cholecalciferol (Vitamin D) capsules after being treated with Valchlor.
89618867|NCT02968446|Experimental|Group 2: 0 placebo - 4 Vitamin D with mechloroethamine|Participants will be given 0 placebo capsules and 4 cholecalciferol capsules to total 200,000 IU of cholecalciferol (Vitamin D) after being treated with Valchlor.
89618868|NCT03125382|Active Comparator|In office standard visit-New|Patients with new implants who do not perform device data transmission through Carelink system
89618869|NCT03125382|Active Comparator|In office standard visit-Previous|Patients with previous implants who do not perform device data transmission through Carelink system
89618870|NCT03125382|Experimental|Carelink - New Implants|Patients with new implants who perform device data transmission through Carelink system
89618871|NCT03125382|Experimental|Carelink - Previous Implants|Patients with previous implants who perform device data transmission through Carelink system
89618872|NCT03383250|Experimental|Meal ingestion|
89618873|NCT03378960|Other|omeprazole|omeprazole 20 mg
89618874|NCT02907996||Sofosbuvir|Adult Korean participants with genotype 1, 2, 3, and 4 chronic HCV infection and pediatric Korean participants aged 12 to <18 years with genotype 2 and 3 chronic HCV infection who are initiating commercial Sovaldi regimens
89618875|NCT03383172|Experimental|ICPS with internal school facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by the early educator of the class, who is part of the school personnel.This internal facilitator will be trained in the program. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
89618876|NCT03383172|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
89618877|NCT03383172|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
89618878|NCT03378804|Experimental|PIEB-PCEA|"Programmed intermittent epidural bolus (PIEB) application of ropivacaine 0.2% with patient-controlled epidural analgesia:~The background rate is set at 6ml per hour. The patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min."
89618879|NCT03378804|Active Comparator|CEI-PCEA|"Continous epidural analgesia with patient-controlled analgesia using ropivacaine 0.2%:~The background rate is set at 6 ml / h continuously. The patient-controlled bolus function is programmed in with 4ml at a lock-out interval of 30min."
89618880|NCT03385824|Experimental|Self-Advocacy for Independent Life (SAIL)|10 week treatment program to improve self-advocacy skills. Includes 4 in-person group sessions (3 hours per session) and two supportive phone calls; workbook and home assignments.
89618881|NCT03385824|No Intervention|Control|SAIL workbook provided at the conclusion of the study.
89618882|NCT03385746|Experimental|polyamide|metal reinforced polyamide denture base material
89036588|NCT04960241|Active Comparator|No physical rehabilitation|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
89036589|NCT05080959|Experimental|CPL-01|CPL-01 200mg, 400mg, 600mg
89618883|NCT03385746|Active Comparator|heat cured acrylic resin|conventional heat cured acrylic resin denture base
89618884|NCT03378726|Experimental|Standard Counseling and Micronutrients|Participants will receive standard services provided by the Ministry of Health, including powder micronutrients. Children receive 1 gram of powdered micronutrientes for 60 days between 6 and 12 months of age, and 60 daily packets per year from the time they are 1 year old until 5 years old.
89618885|NCT03378726|Experimental|SPOON Group Counseling with SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group counseling, which is a new form of social communication in which participants will learn relevant lessons in a group format. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
89618886|NCT03378726|Experimental|Group, Interpersonal Counseling, SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group and interpersonal counseling, which will consist of both participants learning relevant lessons in group format as well as in formats in which participants will work one-on-one with an instructor. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
89618887|NCT03378648|Experimental|CHF6366 active|
89618888|NCT03378648|Placebo Comparator|CHF6366|
89618889|NCT03378648|Active Comparator|Comparator|
89618890|NCT04039542|Experimental|Compassion focused therapy (CFT)|A group programme of CFT running for 10 sessions lasting 90 minutes per session.
89618891|NCT02792790||Patients with carpal tunnel syndrome.|Patients undergoing carpal tunnel release surgery.
89618892|NCT01519414|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89618893|NCT01519414|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
89618894|NCT01519570|Experimental|An informational packet regarding shingles and the HZV|
89618895|NCT01519570|No Intervention|Standard medical care from their primary care physician|
89618896|NCT01519648||Acute leukemia patients|Patients with de novo or relapsed acute myeloid and lymphoid leukemia
89618897|NCT01519648||Allo- or auto- transplant recipients|
89618898|NCT01575106|Experimental|Arm 1|There is only one cohort in this study. All subjects receive the same intervention, the application of heat pain using TSA or CHEPS.
89618899|NCT01519882|Placebo Comparator|Placebo|Placebo Transdermal Patches
89618900|NCT01519882|Experimental|Rotigotine|Rotigotine Transdermal Patches
89618901|NCT05562856|Experimental|surface pre-reacted glass filler coating material|surface pre-reacted glass filler coating material used to remineralize WSLs
89618902|NCT05562856|Active Comparator|micro-invasive resin infiltration technique (Icon)|micro-invasive resin infiltration technique (Icon) in the ability to improve caries lesion state (LF scores) and making the WSLs
89618903|NCT05562856|Experimental|Permaseal resin|Permaseal composite resin sealant as micro-invasive resin infiltration technique in the ability to improve caries lesion state (LF scores) and making the WSLs
89618904|NCT05562856|Experimental|Optiguard resin|Optiguardcomposite resin sealant as micro-invasive resin infiltration technique in the ability to improve caries lesion state (LF scores) and making the WSLs
89618905|NCT01576120|Experimental|bowel prep regimen first boost 6 oz. and second boost 3 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 6 oz. SuPrep administered and 3hrs later 3 oz. SuPrep was administered if needed depends on the capsule progress in the GI
89618906|NCT01576120|Experimental|bowel prep regimen first boost 3 oz. and second boost 6 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 3 oz. SuPrep administered and 3hrs later 6 oz. SuPrep was administered if needed depends on the capsule progress in the GI
89618907|NCT03008044|Experimental|Device: FiberSense system|10 subjects will wear 2 FiberSense system in abdomen and upper arm respectively and Dexcom G4 Platinum CGM sensor for 1 day.
89618908|NCT03008044|Experimental|Extension Phase|2 subjects will extend the wearing of the sensors up to 14 days (2 FiberSense systems to Day 14 and Dexcom sensor to Day 7±1) after the glucose clamp study.
89618909|NCT01576276|Experimental|Morphine condition|
89036590|NCT05080959|Experimental|Naropin|150mg
89036591|NCT05080959|Experimental|Placebo|30mL normal saline (0.9%)
89036592|NCT00533078|Other|1|
89036593|NCT05064267||CKD stage 3|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 3 from a non-inflammatory etiology.
89036594|NCT05064267||CKD stage 4|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 4 from a non-inflammatory etiology.
89618910|NCT01576276|Experimental|Ketorolac condition|
89618911|NCT01576588|Experimental|R-HDMP|"Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).~Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion."
89618912|NCT01826981|Experimental|Cohort 1,Group 1: LDV/SOF + RBV 12 wk (GT1 SOF retreatment)|LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study
89618913|NCT01826981|Experimental|Cohort 1,Group 2:SOF+Peg-IFN+RBV 12 wk (GT2,3 SOF retreatment)|SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
89618914|NCT01826981|Experimental|Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, liver disease)|LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
89618915|NCT01826981|Experimental|Cohort 2,Group 2: LDV/SOF+GS-9669 12wk (GT1 TE, liver disease)|LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
89618916|NCT01826981|Experimental|Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)|LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection
89618917|NCT01826981|Experimental|Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)|LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection
89618918|NCT01826981|Experimental|Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)|LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection
89618919|NCT01826981|Experimental|Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)|LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection
89618920|NCT01826981|Experimental|Cohort 3,Group 1: LDV/SOF 12 wk (GT1 cirrhotic CPT B)|LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis
89618921|NCT01826981|Experimental|Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
89618922|NCT01826981|Experimental|Cohort 4,Group 2:SOF+VEL 25mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
89618923|NCT01826981|Experimental|Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
89618924|NCT01826981|Experimental|Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
89618925|NCT01826981|Experimental|Cohort 5,Group 1: LDV/SOF + RBV 24 wk (SOF retreatment)|LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
89618926|NCT01826981|Experimental|Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HBV coinfection)|LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection
89618927|NCT02247154|Experimental|Vigam® Liquid|
89618928|NCT01522924|Experimental|Counseling practice sessions|Dental students will be administered the first questionnaire before receiving a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients, and debriefing session.
89618929|NCT01522924|No Intervention|Lecture only|Students will receive the first questionnaire before the lecture and the second questionnaire after the lecture
89618930|NCT01523704|Experimental|Home Monitoring(HM)|Patients assigned to HM Group(HM follow-up ONLY) will have Home Monitoring programmed ON. They will be seen in the office for device interrogations at the 3-month follow-up, and at 27 month follow-up. In the meanwhile the device status will be evaluated using HM only for the 9, 15 and 21 month scheduled follow-up. Patients will visit the hospital for device interrogation on 27 month final follow-up.
88987840|NCT00505609|Experimental|A|The Institute for Reproductive Health trained health providers in teaching the Standard Days Method to study subjects and in study procedures. Providers counseled study participants in method use. Participants were followed for up to 13 cycles of method use.
88987841|NCT04514263||Oral Biopsy|Patients with oral lesions undergoing diagnostic or therapeutic biopsies either for benign lesions or potentially malignant disorders or malignant lesions or salivary glands diseases.
88987842|NCT04514536|Experimental|Health monitoring|Subjects have to monitor their health autonomously using the monitoring platform (connected health devices and app on the touchpad).
88987843|NCT02275858|Experimental|Stiffening wire first|This arm will use the stiffening wire first followed by the placebo wire
88987844|NCT02275858|Placebo Comparator|Placebo wire first|This arm will use the placebo wire first followed by the stiffening wire
88987845|NCT02275897|Experimental|Slow Speed|Slow group patients will receive spinal injection over 60 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
88987846|NCT02275897|Experimental|Fast Speed|Fast group patients will receive spinal injection over 15 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
88987847|NCT04514185|Experimental|With exoskeleton|The experimental trial will be performed with exoskeleton.
88987848|NCT04514185|Experimental|Without exoskeleton|The experimental protocol will be performed without exoskeleton.
88987849|NCT04514068|Experimental|Unilateral electroacupuncture of p6 acupoint|
88987850|NCT04514068|Experimental|Bilateral electroacupuncture of p6 acupoint|
88987851|NCT04514068|Sham Comparator|Sham acupuncture of p6 acupoint|
88987852|NCT00142103|Experimental|CPG10101|
88987853|NCT00142103|Experimental|CPG10101 + pegylated interferon|
88987854|NCT00142103|Experimental|CPG10101 + ribavirin|
88987855|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin|
88987856|NCT00142103|Active Comparator|Pegylated inteferon + ribavirin|
88987857|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
88987858|NCT04513873|Experimental|Equipment Intervention Group|"The intervention group had equipment that looks like a blood tube in front of them during the blood collection process to divert their attention from the blood collection process to the equipment. This equipment was with a fixed arm on the right and a moving arm on the left with a total height of 80 cm as well as a red light-emitting diode(LED) to stimulate the blood collection. It had some answers to common questions of parents as well as the key concerns of the children like  Will it hurt me?. The equipment was made a musical device by loading the most popular children's songs into its database."
89618931|NCT01523704|Active Comparator|Control|Patients assigned to Control Group (HM + Conventional In-office follow-up - Control group) will have HM programmed ON. In addition to HM, these patients will visit the hospital for device interrogation at 3, 9, 15, 21 and 27 month follow-ups.
88987859|NCT04513873|No Intervention|No Intervention Group|Standard blood collection procedures were applied to the control group.
88987860|NCT00505726||Confocal Microscopy|
88987861|NCT00142181|Experimental|Campath-1H|30 mg IV three times a week, 6-12 weeks.
89036595|NCT05064267||CKD stage 5|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 5 from a non-inflammatory etiology.
89036596|NCT04942730|Experimental|FluBuBe|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days; Days -7 through -6: Bendamustine 130 mg/m2 iv x 2 days; Days -5 through -3: Busulfan 1 mg/kg po qid x 3 days; Days +3 through +4: Cyclophosphamide 50 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
89036597|NCT04068402|Experimental|Treatment|
89036598|NCT04909190|No Intervention|1xIFU|Subjects in this arm are randomized to have a saline flush volume according to the IFU of the used device.
89036599|NCT04909190|Experimental|4xIFU|Subjects in this arm are randomized to have a saline flush volume of 4x of what is stated in the IFU of the used device.
89036600|NCT04034901|Experimental|Monitoring of cardiorespiratory parameters|Monitoring of cardiorespiratory parameters with BORA Band
89688408|NCT04466293|Experimental|Choice Architecture study arm|"Clinic staff will be responsible for strategy delivery for all patient interactions. Research staff will provide training and guidance for the choice architecture arm. Research staff will also work with the clinics to develop appropriate clinical stationary, ink stamps, stickers, or EMR modifications for prescribing, and reminder systems (e.g. written by pharmacy in clinic file, post-it on clinic file, post-it on lab results). The goal of this approach is for TPT prescribing to occur routinely and as part of ART prescribing. This is in contrast to considering prescribing only at the end of a long algorithm that includes TB and other assessments. With this approach, a patient will automatically be prescribed TPT unless the clinician specifically decides patients are not candidates due to active TB treatment or other clinical reasons."
89036601|NCT04903964|Experimental|oral nutrition only group that received nutrition education|This group consists of children who are fed orally according to their chronological age. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the hospitalized child after the operation will be determined and the measurements will be checked.
89036602|NCT04903964|Experimental|group that received nutrition education and fed with nutritional support|This group consists of children who receive nutritional support provided by oral food supplements, oral food supplements, enteral tube feeding and / or parenteral nutrition. The questionnaire form developed by the researcher and the parameters used in the evaluation of growth (height, head and chest circumference measurement) and Ankara Development Screening Inventory (AGTE) will be applied to the child and his / her family included in the specified group. Nutrition education prepared by the researcher will be given to the mothers of the children included in this group. After the nutrition training given to their mothers, the growth and development monitoring parameters of the child, body weight, height, head and chest circumference, will be repeated at regular intervals. Ankara Development Screening Inventory (AGTE) will be applied. The follow-up frequency of the child hospitalized after the operation will be determined and the measurements will be checked.
89036603|NCT04903964|No Intervention|control group|While collecting research data on the specified dates; Comparison group (KG) will be selected as many as the number of volunteers who want to participate in the research. No nutritional attempt will be made to the child included in this group. The parameters used in the evaluation of growth (height, head and chest circumference measurement) and the Ankara Development Screening Inventory (AGTE) will be applied to children aged 0-3 who are followed up due to congenital heart disease.
89036604|NCT00534690|Other|1|
89036605|NCT00534690|Other|2|
89036606|NCT04901936|Experimental|Pegcetacoplan|
89036607|NCT01272193|Experimental|IDegAsp OD|
89036608|NCT01272193|Active Comparator|IGlar OD|
89036609|NCT04899206||ARBs only|Hypertensive patients under pharmacological treatment with ARBs
89036610|NCT04899206||ACEIs only|Hypertensive patients under pharmacological treatment with ACEIs
89036611|NCT04899206||ARBs + ACEIs|Hypertensive patients under pharmacological treatment with ARBs and ACEIs
89036612|NCT04899206||Other Antihypertensive Drugs|Hypertensive patients under pharmacological treatment with non-angiotensin agents (diuretics, calcium channel blockers and/or β-blockers alone or combined among them)
89036613|NCT04899206||Angiotensin Agents and Other Antihypertensive Drugs|Hypertensive patients under combined pharmacological treatment with Angiotensin Agents (ACEIs and/or ARBs) and Other Antihypertensives (non-angiotensin agents)
89036614|NCT04019613|Experimental|Subjects undergoing clinical invasive hemodynamic stress test|Subjects scheduled for standard-of-care, clinically indicated, invasive hemodynamic stress test will undergo lung ultrasound and assessment of extravascular lung water by pulmonary thermodilution technique.
89036615|NCT04687163|Experimental|OXA 130|Patients received sorafenib or lenvatinib Plus HAIC of 130 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
89036616|NCT04687163|Active Comparator|OXA 85|Patients received sorafenib or lenvatinib Plus HAIC of 85 mg/m² oxaliplatin, and 2400 mg/m² 5-fu
89036617|NCT04017117|Experimental|Custom Made Poly Ether Ether Ketone Mesh|Applying Poly Ether Ether Ketone mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
89036618|NCT04017117|Active Comparator|Conventional Titanium mesh|Applying Titanium mesh with mix of autogenous bone graft and bone substitute in posterior atrophic mandible for augmentation
89036619|NCT04686812|Experimental|Worksite health promotion program|Participants had a baseline health risk assessment (HRA) after which they were invited to participate in a workplace health promotion program. The intervention lasted six months and included the following components: nutrition counseling, physical activity, and stress management. HRAs were performed 6 and 12 months after intervention onset.
89036620|NCT04686812|No Intervention|Control|Participants only had a baseline and follow-up health risk assessments at 6 and 12 months.
89036621|NCT01270828|Experimental|Pregablain CR tablet 82.5 to 660mg|
89036622|NCT01270828|Placebo Comparator|Placebo|
89618932|NCT02728752|Placebo Comparator|Placebo|Subjects randomized to placebo will receive 4 infusions of placebo every 4 weeks during the blinded First Period (16 weeks). If confirmed deterioration (deterioration at 2 consecutive visits) during the First Period, subjects will be switched to Octagam 10%. After response assessment at Week 16, all subjects with no confirmed deterioration and subjects switched to Octagam 10% due to confirmed deterioration but without further confirmed deterioration during the First Period will continue to receive 2.0 g/kg of Octagam 10% every 4 weeks during the subsequent 6-months open-label Extension Period. At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator. Subjects randomized to placebo and switched to Octagam 10% due to confirmed deterioration, who deteriorate also during Octagam 10% treatment at 2 consecutive visits will drop-out after response assessment at Week 16 and will not enter the Extension Period.
89618933|NCT02728752|Experimental|Octagam10%|Subjects randomized to Octagam will receive 4 infusions of 2.0 g/kg Octagam 10% every 4 weeks during the blinded First Period (16 weeks). If confirmed deterioration (deterioration at 2 consecutive visits) during the First Period, subjects will be switched to the alternate treatment. After response assessment at Week 16, all subjects with no confirmed deterioration during the First Period will continue receiving 2.0 g/kg of Octagam 10% every 4 weeks during the subsequent 6-months open-label Extension Period. At Week 28, subjects who are stable on 2.0 g/kg Octagam 10% can be switched to 1.0 g/kg Octagam 10%, at the discretion of the investigator. Subjects randomized to Octagam and switched to the alternate treatment due to confirmed deterioration will drop-out after response assessment at Week 16 and will not enter the Extension Period.
89618934|NCT03007810|Experimental|Hemay005|Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
89618935|NCT03007810|Placebo Comparator|Placebo|Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
89618936|NCT01578772|Experimental|Telmisartan|Open label
89618937|NCT02691624||sentinel lymph node biopsy|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive sentinel lymph node biopsy
89618938|NCT02691624||axillary lymph node dissection|Patients of the group is diagnosed with breast cancer and receive lymphoscintigraphy before operation, and will receive axillary lymph node dissection
89618939|NCT03007576|Experimental|RegStem|Autologous MSC, 5×10^7 cells, one injection
89618940|NCT01804049|Placebo Comparator|Placebo|60 participants will be randomized to placebo pills.
89618941|NCT01804049|Active Comparator|Metformin|60 enrolled participants will be randomized to metformin.
89618942|NCT02383992|Active Comparator|Hydrogen Peroxide|Post-operative wound will be treated with 3% H2O2 solution, Subjects will also clean the sutured wounds with 3% H2O2 solution or twice daily then dress the wounds with petroleum jelly and a bandage.
89618943|NCT02383992|Active Comparator|Saline|Post-operative wound will be treated with 0.9% normal saline. Subjects will also clean the sutured wounds with normal saline twice daily then dress the wounds with petroleum jelly and a bandage.
89618944|NCT02346630|Active Comparator|Levodopa / Carbidopa + Armeo|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
89618945|NCT02346630|Placebo Comparator|Placebo + Armeo|Placebo capsules daily for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
89618946|NCT01826825||Clock in the box|Those patients with and without probable cognitive impairment based on the Clock-in-the-box assessment.
89618947|NCT01826825||Mini-Cog|Those patients with and without probable cognitive impairment based on the Mini-Cog assessment.
89618948|NCT03385668|Experimental|Pirfenidone|All patients will receive Pirfenidone
89618949|NCT01803737|Active Comparator|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
89618950|NCT01803737|Experimental|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
89618951|NCT03994848|No Intervention|Control|
88987862|NCT04513756|Experimental|Active Treatment Group|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques.
89618952|NCT03994848|Experimental|Spirometry Group|
89618953|NCT03378492|Active Comparator|Standard Epidural|Participants in this group will have epidurals placed using standard practice.
89618954|NCT03378492|Experimental|Ultrasound Guided Epidural|Participants in this group will have epidurals placed using standard practice with the assistance of ultrasound.
89618955|NCT03378024||diabetic mellitus patients|"Measure the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) of pre-exercise and post-exercise by the oscillometric (Omron Colin co.).~And follow up for 3 years to identify of the correlation with PAD outcome."
89618956|NCT01826201|Experimental|10% MOL4239 ointment & placebo ointment|10% MOL4239 ointment to one target lesion and placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
89618957|NCT03385590|Experimental|Soy-fiber-maize|Complementary food composed of soybean, soy fiber and maize flours.
89618958|NCT03385590|Active Comparator|Maize|Complementary food composed of maize flour.
89618959|NCT04947072|Experimental|Erector Spinae Plane Block|Patient will receive single-shot ultrasound-guided erector spinae plane block at the level of T9 on the side which will be operated on.
89618960|NCT04947072|Active Comparator|Spinal Anesthesia|Patient will receive spinal anesthesia at the level of L3-L4 or L4-L5
89057343|NCT01647984|Active Comparator|Ritmonutra|Omega-3 polyunsaturated fatty acids, Hawthorn, Astaxanthin, Vitamin E, Vitamin B complex + diet
89618961|NCT04942158|Experimental|CTZ group|Non-instrumentation endodontic treatment and use of a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste)
89618962|NCT04942158|Active Comparator|ZOE group|Endodontic treatment with instrumentation and filling with Zinc Oxide and Eugenol paste (ZOE paste)
89618963|NCT03382704||Patients undergoing biopsy|Patients undergoing biopsy (incisional or excisional) of peri-ocular lesions. Pre-operative examination for presence or absence of lanugo hairs
89618964|NCT03382626|Active Comparator|tDCS plus Computer-assisted training|Patients will receive 10 sessions of active anodal tDCS on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for electroencephalogram (EEG) electrode placement) plus Computer-assisted cognitive training (games to improve working memory, attention, and executive function).
89618965|NCT03382626|Sham Comparator|tDCS sham plus Computer-assisted training|Patients will receive 10 sessions of sham anodal tDCS on the left prefrontal cortex dorsolateral plus Computer-assisted cognitive training (games to improve working memory, attention and executive function).
89618966|NCT03375450||Observation|Cohort of patients with COPD
89618967|NCT03375372|Active Comparator|Group 1 (Treatment Group)|Subjects receive intervention of Scaling and Root Planing (S&RP) procedure under local anesthesia, plus a specified Oral Hygiene Regimen (OHR)
89618968|NCT03375372|No Intervention|Group 2 (Delayed treatment)|Subjects have delayed treatment scaling and root planing procedure and OHR at 36 weeks (Final visit) These subjects are not followed beyond completion of the treatment.
89618969|NCT03377946|Experimental|probiotics on type 2 diabetes|take probiotics
89618970|NCT03377946|Experimental|probiotics on pre-diabetes|take probiotics
89618971|NCT03377946|Placebo Comparator|placebo on type 2 diabetes|take placebo
89618972|NCT03377946|Placebo Comparator|placebo on pre-diabetes|take placebo
89618973|NCT03125538|Experimental|Motor Imagery|Participants from the experimental group will perform MIP concomitantly with usual physical rehabilitation program.
89618974|NCT03125538|Active Comparator|Control task|Concomitantly with usual physical rehabilitation program, participants from the control group will perform a cognitive task that has no impact on motor rehabilitation (word scramble game).
89618975|NCT03377868|Other|Patients with Amyotrophic lateral sclerosis|Patients diagnosed with amyotrophic lateral sclerosis
89618976|NCT03377868|Other|Control|Parallel cohort of healthy age and sex matched subjects
89618977|NCT03377712||Brachial Plexus Injury group|Patients who will be submitted to the surgical procedure and monitored for the repercussions of the surgery. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation, functional capacity, pain evaluation, function and quality of life
89618978|NCT03377712||Paired group|Healthy individuals who will be matched by sex and age with the group of patients who will effectively undergo the surgical process. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation and functional capacity.
89618979|NCT03947112||Norwegian population with Duchenne Muscular Dystrophy (DMD)|Boys with DMD.
89618980|NCT03396666|Experimental|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
89618981|NCT03396666|No Intervention|No intervention|Regular follow-up with advice on physical activity and nutrition
89618982|NCT03387774|Experimental|Concurrent chemoradiotherapy and ulinastatin|"Concurrent chemoradiotherapy (CCRT) and intravenous drip of ulinastatin, the details are as follows:~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT;~Ulinastatin through intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline, 3 times every radiation day, until the end of radiotherapy."
89618983|NCT03387774|Active Comparator|Concurrent chemoradiotherapy|"Concurrent chemoradiotherapy (CCRT) alone:~Intensity modulated radiation therapy combined with concurrent chemotherapy of cisplatin 100mg/m2 on day 1 and day 22 of RT."
89618984|NCT03382392||ALS|
89618985|NCT03382392||control 1|
89618986|NCT03382392||control 2|
89618987|NCT03124290|Other|CPR with attention distraction first|First, they perform two-minute chest compressions with conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions without conducting the PASAT.
89618988|NCT03124290|Other|CPR without attention distraction first|First, they perform two-minute chest compressions without conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions with conducting the PASAT.
89618989|NCT03382314|Experimental|HDDO-1614|Bazedoxifene + Cholecalciferol combination drug
89618990|NCT03382314|Active Comparator|Bazedoxifene + Cholecalciferol|Co-administration of Bazedoxifene and Cholecalciferol
89618991|NCT01523782|Experimental|GRASPA 50 IU/kg|Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
89618992|NCT01523782|Experimental|GRASPA 100 IU/kg|Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
89618993|NCT01523782|Experimental|GRASPA 150 IU/kg|Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
89618994|NCT03124524|No Intervention|Control group|33 healthy controls
89618995|NCT03124524|Active Comparator|Qlarista Group|group who were administered estradiol valerate/dienogest
89618996|NCT03124524|Active Comparator|Yasmin Group|group who were administered ethinylestradiol and drospirenone
89618997|NCT03377400|Experimental|study arm|Concurrent radiotherapy with chemotherapy (5FU/CDDP) and immune checkpoint inhibitors (durvalumab/tremelimumab), and followed by consolidation immune checkpoint inhibitors
89618998|NCT01525420|Experimental|ACT|ACT: This is the experimental arm of the study. This included 5 weekly sessions of ACT therapy via telephone.
89618999|NCT01525420|Active Comparator|CBT|CBT: This is the control arm of the study. This included 5 weekly sessions of CBT therapy via telephone.
89619000|NCT03377322|Active Comparator|Treatment|Probiotics capsules
89619001|NCT03377322|Placebo Comparator|Placebo|Placebo capsules containing maltodextrin
89619002|NCT03382236|Experimental|Real osteopathy|
89619003|NCT03382236|Placebo Comparator|Sham osteopathy|
89619004|NCT01803269|Active Comparator|Arm A (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89619005|NCT01803269|Experimental|Arm B (CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX10 cyclodextr1 IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89619006|NCT03382080|Experimental|Dream School Program (DSP)|The Dream School Program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
89619007|NCT03382080|Experimental|DSP and Mental Health Support Team|"A combination of the universal Dream Schoop Program (see description above) and the selective/indicative intervention Mental Health Support Team which is aimed at specific students at risk of dropping out of upper secondary school. It is a systematization of the student services through~Co-location of services and staff working in services~One open door to increase accessibility to the services and staff for students~Focus on the transition from lower to upper secondary school~Close follow-up of students at risk to ensure tailored help to each student~Early intervention and follow up when students starts being absent from school"
89619008|NCT03382080|No Intervention|Control|The control group are upper secondary schools who run classes and the school as usual, and do not introduce new programs similar to the Dream School or Mental Health Support Team during the project period.
88987863|NCT04513756|No Intervention|Treatment As Usual Group|CRA comprising of nine sessions will not be provided to this group. However, patients who will be already receiving treatment from any psychiatric or some other rehabilitation facility will be advised to continue their routine treatment.
88987864|NCT02954926|Experimental|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
89619009|NCT03377166|Active Comparator|Vertigo|Participants with vestibular disorder
88987865|NCT02954926|No Intervention|Control|No intervention
88987866|NCT02955121|Active Comparator|Pharmacogenetic Results Available to Provider|Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
88987867|NCT02955121|No Intervention|Control Arm|No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.
88987868|NCT00505804|Experimental|1|
88987869|NCT00505804|Active Comparator|2|
88987870|NCT04724850||COVID-19 patients|All patients diagnosed with COVID-19 in the community of Extremadura from the beginning of the epidemic to its ending in Spain.
88987871|NCT04513093|Experimental|İntervention Group|"The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.~The Bristol Stool Scale and Constipation Severity Scale were re-applied to the individuals in the intervention before, during the second week of practice and at the end of practice (fourth week)."
88987872|NCT04513093|No Intervention|Control Group|"No application was applied to the individuals in the control group. Bristol Stool Scale and Constipation Severity Scale were applied to the individuals in the control group at the same time as (at the beginning, second week and fourth week) the intervention group."
89619010|NCT03377166|Active Comparator|Control|Participants without vestibular disorder
88987873|NCT04512898|Experimental|Patient with IBS|Patients with IBS and positive H. pylori.
88987874|NCT00505843|Other|1|7mg MK0657 capsules + >/=1.0 mg/kg/hr dose of levodopa.
88987875|NCT00505843|Other|2|7mg MK0657 Pbo capsules + >/=1.0 mg/kg/hr dose of levodopa.
88987876|NCT00505882|Active Comparator|Insulin|
88987877|NCT00505882|Experimental|Pramlintide|
88987878|NCT00505960|Experimental|1|
88987879|NCT00505999||Questionnaire|Patients diagnosed with Multiple Myeloma and healthy controls.
88987880|NCT04512859|Experimental|Stellate Ganglion Block|"Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.~Patients were then assessed using transcranial Doppler"
88987881|NCT04512859|Placebo Comparator|No Stellate Ganglion Block|"patients will receive a stellate ganglion block with 0.9% saline 10mL on the same side of vasospasm at the level of the sixth cervical vertebrae (C6) before surgery.~Patients were then assessed using transcranial Doppler"
88987882|NCT04512508|Other|Group 1, HIV negative patients.|Only HIV negative patients
88987883|NCT04512508|Other|Group 2, HIV positive patients|Only HIV positive patients
88987884|NCT04512625|No Intervention|Control group|Sensitivity level scores were evaluated on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation.
88987885|NCT04512625|Experimental|Group GL (Gluma desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
89057344|NCT04540328|Other|Non-surgical peridontal treatment|Patients with chronic periodontitis received non-surgical periodontal treatment, including scaling and root planing and polishing within 14 days under local anesthesia with manual and ultrasonic devices and standardized oral hygiene instructions including methods of tooth-brushing and interdental cleaning were also given to each one. A professional supragingival plaque control was applied on a regular basis every month.
89619011|NCT01802879|Experimental|Panobinostat - 10 to 40 mg/day TIW QoW|10 to 40mg/day TIW QoW (3 times/week every other week) as per parent protocol design
89619012|NCT03145038|Experimental|Treatment A|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fed, American breakfast
89036623|NCT00533195|Active Comparator|0|5-MOP photochemotherapy. Intake of Geralen capsules (1.2 mg/kg) 2 hours before irradiation. Determination of the minimal phototoxic dose (MPD) and Geralen serum level prior to treatment. Start with 70 % of the MPD, no dose increments in the first treatment week. From the second week increments of the UVA dose by 20 % in the absence of an erythemal reaction, respectively by 10 % in cases of a barely perceptible erythemal response. Increments of the UVA dose at the earliest 96 hours after the last increments. Treatment frequency 3 x week for 5 weeks (=15 exposures). No maintenance therapy except emollients.
89036624|NCT00533195|Experimental|1|UVA1 phototherapy. Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability. No maintenance therapy except emollients.
89619013|NCT03145038|Experimental|Treatment B|Single oral dose of 20 x 0.5 mg vericiguat high-dose pediatric formulation, fasted
89619014|NCT03145038|Experimental|Treatment C|Single oral dose of 25 x 0.1 mg vericiguat high-dose pediatric formulation, fed, American breakfast
89619015|NCT03145038|Active Comparator|Treatment D|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, American breakfast
89619016|NCT03145038|Experimental|Treatment E|Single oral dose of 10 mg vericiguat crushed IR tablet, adult formulation, fed, American breakfast
89619017|NCT03145038|Experimental|Treatment F|Single oral dose of 10 mg vericiguat intact IR tablet, adult formulation, fed, continental breakfast
89619018|NCT01825577|Experimental|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
89619019|NCT03375138|Experimental|Process E PPQ belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
89619020|NCT03375138|Experimental|Process C belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
89619021|NCT03124914|Active Comparator|Patients considered physically active|Measures of strength and determination of neuromuscular fatigue
89619022|NCT03124914|Active Comparator|Patients considered physically inactive|Measures of strength and determination of neuromuscular fatigue
89619023|NCT03381924|Experimental|Intervention group|Neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
89619024|NCT03381924|Placebo Comparator|Control group|Routine clinical practice
89619025|NCT03124680|Active Comparator|opioid free group|Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4
89619026|NCT03124680|Placebo Comparator|Opioid group|Opioid group using sufentanil, lidocaine, clonidine
89619027|NCT03124446|Experimental|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
89619028|NCT03124446|Active Comparator|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
89619029|NCT01802411|Active Comparator|EXPAREL 266 mg|Intercostal nerve block using single total administration of 20 mL EXPAREL (bupivacaine liposome injectable suspension) 266 mg (approximately 88 mg [6.6 mL] to each of three nerve segments)
89619030|NCT01802411|Placebo Comparator|Placebo|Intercostal nerve block using single total administration of 20 mL normal saline (6.6 mL to each of three nerve segments)
89619031|NCT03381846|Experimental|MOHS treatment arm|Patients who have their dermatofibrosarcoma protuberans excised with MOHS surgery.
89619032|NCT03374904|Active Comparator|Control Group|Patients in control group will attend to four session of Play Therapy plus inpatient treatment as usual during four weeks
89036625|NCT03987165|Experimental|Music Therapy|Music therapy by a certified music therapist will be delivered to infants over a period of 5 days. There will be two periods of data collection each day, one in the morning and one in the afternoon. Each baby will receive music therapy during one of these time points, with each baby serving as their own control during the second timepoint.
89036626|NCT03987165|No Intervention|Control|
89036627|NCT03982407|Experimental|Ga68 PSMA PET-MR|68Ga labeled PSMA -11 (or PSMA-HBED_CC) PET/MRI scan
89036628|NCT04687124|Active Comparator|Fish oil|dietary counselling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
89036629|NCT04687124|Placebo Comparator|standard care|The departmental usual procedure with the possibility of requiring of a dietician when needed
89619033|NCT03374904|Experimental|Video Feedback|Once a week, after play therapy, individual or group video feedback session will be done.
89619034|NCT03381768|Experimental|Study group|3 vaccines of PD-L2 peptide followed by 12 vaccines of PD-L2 and PD-L1 peptide, over the course of one year.
89619035|NCT03377010||Hematopoietic Stem Cell Transplant (HSCT) Survivor|Study participants will be administered a Dietary Intake - Food Frequency Questionnaire and a Receptivity to Participating in Diet Interventions Questionnaire.
89619036|NCT03381690||Epidural (ED) emergent C-sec|
89619037|NCT03381690||Non-ED emergent C-sec|
89619038|NCT03381690||Non-ED elective C-sec|
89619039|NCT01579084|Experimental|AGN-199201 Formulation A and B|AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.
89619040|NCT01579084|Experimental|AGN-199201 Formulation B and C|AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.
89619041|NCT01579084|Experimental|AGN-199201 Formulation C and A|AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.
89619042|NCT01579084|Other|AGN-199201 Formulation A and Vehicle|AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
89619043|NCT01579084|Other|AGN-199201 Formulation B and Vehicle|AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
89619044|NCT01579084|Other|AGN-199201 Formulation C and Vehicle|AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
89619045|NCT01579084|Experimental|AGN-199201 Formulation A|AGN-199201 Formulation A applied to both sides of the face twice daily.
89619046|NCT01579084|Experimental|AGN-199201 Formulation B|AGN-199201 Formulation B applied to both sides of the face twice daily.
89619047|NCT01579084|Experimental|AGN-199201 Formulation C|AGN-199201 Formulation C applied to both sides of the face twice daily.
89619048|NCT01579084|Placebo Comparator|AGN-199201 Vehicle|AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.
89619049|NCT02963610|Experimental|Pembrolizumab, Lenalidomide|"Phase I The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. The dose of lenalidomide will depend upon the patient cohort. Cohort 1 will receive 10mg, Cohort II will receive 15mg and cohort 3 will receive 20mg of lenalidomide.~Phase II The treatment will be given on a 21-day cycle, with a dose of pembrolizumab given on day1(IV) and doses of lenalidomide given on day 1-14 (orally). The dose of pembrolizumab will be fixed at 200 mg. Maximum Tolerated Dose (MTD) of lenalidomide as determined by the Phase I study will be given in Phase II study."
89619050|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (100/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FF/UMEC/VI (100/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol metered dose inhalers (MDIs) as a rescue medication throughout the study.
89619051|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (200/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FF/UMEC/VI (200/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
89619052|NCT03376932|Active Comparator|Subjects receiving FP/SAL(250/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FP/SAL (250/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
89619053|NCT03376932|Active Comparator|Subjects receiving FP/SAL(500/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FP/SAL (500/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily given in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
89619054|NCT03007342|Experimental|Experimental group|Oral tablet 1000 mg of Amoxicillin/ clavulanic acid combination every 12 hours for five days.
89619055|NCT03007342|Placebo Comparator|control group|Oral tablet placebo every 12 hours for five days.
89619056|NCT03376854|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
89619057|NCT03376854|Active Comparator|Standard of care|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
89619058|NCT01579162|Experimental|Healthy Controls|Healthy controls will be recruited to have approximately equal numbers of men and women. Controls will be of healthy weight as defined by a BMI 18-25 and without liver disease or risk factors for liver disease.
89619059|NCT01579162|Experimental|chronic HCV patients with F0-F2 fibrosis|
89619060|NCT01579162|Experimental|chronic HCV patients with F3-F4 fibrosis|
89619061|NCT01579162|Experimental|NASH patients with F0-F2 fibrosis|
89619062|NCT01579162|Experimental|NASH patients with F3-F4 fibrosis|
88987886|NCT04512625|Experimental|Group SF (SheildForce desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
89036630|NCT01269385|Experimental|Arm I|Patients receive PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity.
89619063|NCT01580098|No Intervention|Control group|treatment as usual
89619064|NCT01580098|Experimental|Self-monitoring for patients with Diabetes mellitus type 2|Patients are self-monitoring and submitting their vital parameters.
89619065|NCT01580098|Experimental|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are measuring and entering the vital parameters of the patients.
89619066|NCT03376776||Eyes with epiretinal proliferation|The eyes with epiretinal proliferation around the macular hole detected with optical coherence tomography
89619067|NCT03376776||Eyes without epiretinal proliferation|The eyes without epiretinal proliferation around the macular hole detected with optical coherence tomography
89619068|NCT03381534|Placebo Comparator|stent assisted angioplasty|patient randomly assigned to this group would be undergone stenting of vertebral artery origin without embolic protection device
89619069|NCT03381534|Experimental|stenting with EPD|patient randomly assigned to this group would be undergone stenting of vertebral artery origin with embolic protection device
89619070|NCT03007654|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around surgery area
89619071|NCT03007654|No Intervention|No treatment|standard treatment for surgery
89619072|NCT03007654|Active Comparator|Adept|adhesion barrier, Adept, to apply medical device fully around surgery area
89619073|NCT03007264|Experimental|CAP treated|volar arm will be treated with cold atmospheric plasma.
89619074|NCT03007264|Experimental|CAP on bacteria|volar arm with bacteria will be treated with cold atmospheric plasma.
89619075|NCT03007264|No Intervention|no CAP on bacteria|volar arm with bacteria will not be treated with cold atmospheric plasma. Sham comparator for measurements of skin parameters TEWL, temperature and bacterial load.
89619076|NCT03376620|Sham Comparator|10% Urea cream|Opposite breast scars treated OD at hs simultaneously using sham 10% Urea cream
89619077|NCT03376620|Active Comparator|Active cream with 1,4 diaminobutane|Other breast scar treated daily with active cream with 1,4 diaminobutane topically OD at hs
89619078|NCT03374514|Experimental|DEX|Topical dexamethasone will be placed at a concentration of 20mg / ml in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy in the cochlear implant surgery, paying special attention to the round window membrane completely submerged in the liquid, to the insertion of the electrode assembly
89619079|NCT03374514|Placebo Comparator|SF|Sterile isotonic saline solution will be placed in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy during cochlear implant surgery, paying special attention to the fact that the round window membrane is completely submerged in the liquid, prior to insertion of the electrode array
89619080|NCT03381456|Experimental|Healthy subject|LICI
89619081|NCT03381456|Experimental|Dystonic subject|LICI
89619082|NCT03374436|Experimental|High-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals)
89619083|NCT03374436|Experimental|High-Carbohydrate Active|"Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals) but will complete 8 stair climbing sprint snacks once per hour involving ascending 3 flights of stairs at a vigorous pace (~20 seconds each)."
89619084|NCT03374436|Active Comparator|Low-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a low-carbohydrate diet (3 meals)
89619085|NCT01526356|Placebo Comparator|Placebo|Cream only
89619086|NCT01526356|Active Comparator|0.1 % Rapamycin|0.1% Rapamycin cream
89619087|NCT01526356|Active Comparator|1% Rapamycin|1% Rapamycin cream
89619088|NCT03812094|Active Comparator|Basic Bladder advice|Basic bladder advice as given from a pre-specified document, study nurse
89619089|NCT03812094|Active Comparator|Alarm|Alarm Enurad 400
89619090|NCT03812094|No Intervention|No treatment|No treatment during study period.
89619091|NCT04838964|Experimental|MRG003|MRG003 will be administrated via IV infusion at 2.0 mg/kg on Day 1 of every 3 weeks (21-day cycle).
89619092|NCT01526902|Active Comparator|omafilcon A / PC 1-D MF|"omafilcon A (PC 1-D MF) / lotrafilcon B (AIR OPTIX MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
89619093|NCT01526902|Active Comparator|lotrafilcon B / Air Optix MF|"lotrafilcon B (AIR OPTIX MF) / omafilcon A (PC 1-D MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
89619094|NCT03376542|Experimental|Cardiopulmonary exercise testing|All patients included in the study will perform cardiopulmonary exercise testing prior to surgery
89619095|NCT02519946|Experimental|On-Line Diet and Exercise Intervention|
89619096|NCT01528150||Accent MRI System|Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads
89619097|NCT03376464|Experimental|single injection technique (SIT)|40 U of Xeomin Cosmetic delivered directly into the region where the three masseter heads overlap.
89619098|NCT03376464|Experimental|multi-injection technique (MIT)|A distribution of 40 U (8 U distributed in 5 different areas) of Xeomin Cosmetic over the width of the masseter while respecting the upper limit of the anterior border of the masseter and the inferior insertion of the masseter. The injections are separated by a 1cm distance and the dose is equally distributed across these sites.
89619099|NCT01528228|Active Comparator|Structured TENS Therapy|This group will be given an active TENS unit to use.
89619100|NCT01528228|Sham Comparator|Sham TENS Therapy|This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
89619101|NCT03376386|Other|HNSCC receiving (chemo)radiotherapy|Imaging
89619102|NCT03376308||Group 1|"Venous diameter measurements were made via the USG in the hand dorsum. Transverse venous diameter ≤2mm was defined group 1.~Anesthesia induction drugs were all treated in the same order and dose. Pain score, withdrawal movement score and hemodynamic response was recorded."
89619103|NCT03376308||Group 2|"Venous diameter measurements were made via the USG in the hand dorsum.Transverse venous diameter >2mm was defined group 2.Anesthesia induction drugs were all treated in the same order and dose.~Pain score, withdrawal movement score and hemodynamic response was recorded."
89619104|NCT03381144|Experimental|Part 1: GDC-0334|Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.
89619105|NCT03381144|Placebo Comparator|Part 1: Placebo|Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.
89619106|NCT03381144|Experimental|Part 2: GDC-0334|Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.
89619107|NCT03381144|Placebo Comparator|Part 2: Placebo|Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.
89619108|NCT03381144|Experimental|Part 3: GDC-0334|Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.
89619109|NCT03381144|Placebo Comparator|Part 3: Placebo|Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.
89619110|NCT03374280|Experimental|pemetrexed/cisplatin intercalating gefitinib|"pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 ;gefitinib 250mg d3-20d, to 4 cycles.~pemetrexed 500mg/m2 d1; gefitinib 250mg d2-20d to disease progression or untolerable"
89619111|NCT03374280|Active Comparator|pemetrexed/cisplatin|pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 to 4 cycles. pemetrexed 500mg/m2 d1 to disease progression or untolerable
89619112|NCT03376230||Control patients|
89619113|NCT03376230||Crohn's disease patients|
89619114|NCT03376230||Ulcerative colitis patients|
89619115|NCT03381066|Experimental|Intercalating arm|gefitinib, pemetrexed,cisplatin
89619116|NCT03381066|Active Comparator|chemotherapy alone arm|Vinorelbine, cisplatin
89619117|NCT03374124||postoperational CRS|observe the symptoms and endoscopic appearance
89619118|NCT03380988|Experimental|Fiber-enriched buckwheat pasta|Acute test meal
89619119|NCT03380988|Active Comparator|Corn pasta|Acute test meal
89619120|NCT03374046|No Intervention|Control Group|Standard care
89619121|NCT03374046|Experimental|Apneic Oxygenation Group|"During apneic period of intubation attempt, patient will be placed on nasal cannula~If 0-2 years: 3L/min NC of 100% FiO2~If > or = to 2 through17 years: 5L/min NC of 100% FiO2"
89619122|NCT03380910|Experimental|Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
89619123|NCT03380910|Other|Not Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are not ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
89619124|NCT02814786|Experimental|Equinus cohort|"15 childrens who have a fixed equinus defined as a fixed limitation of dorsiflexion inferior to 0°.~Interventions: MRI scanner and gait analysis"
89619125|NCT02814786|Experimental|Control cohort|"In this cohort, there will be 15 childrens with age and gender matched to equinus cohort and with no history of lower limb musculo-skeletal injury in past 6 months.~Interventions: MRI scanner and gait analysis"
88987887|NCT04512625|Experimental|Group TS (Telio CS desensitizer)|In desensitizer groups, respective desensitizer application was done following the manufacturer's directions immediately after tooth preparation before final impressions were made (first visit), before metal try-in (second visit) and before final cementation (third visit). Sensitivity level scores were evaluated, before the desensitizer application, on the Visual Analogue Scale using cold stimuli (Cold Test) and electrical stimuli (Electric Pulp Test) at all the 3-time intervals, i. e first, second, and the third visit and then telephonically two weeks after the final cementation. The data were statistically analyzed using one-way ANOVA followed by post-hoc Bonferroni and unpaired t-test.
88987888|NCT04512664|Active Comparator|short term group|cold treatment for 4 hours
88987889|NCT04512664|Experimental|long term group|cold treatment for 48 hours
89619126|NCT04764552|Experimental|Yeahhh Baby Ointment|Ointment will be applied per instructions twice daily during treatment with a two week washout period between arms.
89619127|NCT04764552|Placebo Comparator|Placebo Ointment|Ointment will be applied per instructions twice daily during treatment with a two week washout period between arms.
89619128|NCT02647242|Experimental|Patients with parkinson's disease|Patients with parkinson's disease
89619129|NCT03376074|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 2 hours
89619130|NCT03376074|Active Comparator|Conventional cold storage|
89619131|NCT02520024|Experimental|Self-directed Care|"Individuals in the experimental condition will work with a specially trained certified peer specialists (CPS) who will serve as recovery coaches to develop an individualized recovery plan that describes their goals and desires. They will then work with the team to select both the behavioral health treatment and rehabilitation services, and the non-behavioral health materials and resources they believe are necessary to achieve their goals."
89619132|NCT02520024|No Intervention|Treatment as usual|Participants in the control condition will receive services as usual.
88987890|NCT04512391||Erector Spinae|patients who are administered ultrasound guided ESPB at T4 vertebrae level with long acting local anesthetic (%0,25 bupivacaine) and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
88987891|NCT04512391||Control|patients who are not administered any regional analgesic technique and followed up with patient controlled analgesia device and all records about aforementioned data is completely available.
89619133|NCT03370146||TKA patients - Experimental Group|
89619134|NCT03370146||TKA patients - Control Group 1|
89619135|NCT03370146||Healthy subjects - Control Group 2|
89619136|NCT03375996||FLACS group|Patient presenting cataract and scheduled for laser-assisted cataract surgery
89619137|NCT01580410|Experimental|Arm I (mitomycin C)|Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC.
89619138|NCT01580410|Experimental|Arm II (oxaliplatin)|Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC.
89619139|NCT03373812|Active Comparator|anterior approach|patients having involutional ptosis undergoing anterior approach surgical ptosis repair (Levator advancement)
89619140|NCT03373812|Active Comparator|posterior approach|patients having involutional ptosis undergoing posterior approach surgical ptosis repair (mullerectomy)
89619141|NCT01581658|Experimental|BI10773 medium dose group 1|BI10773 medium dose tablet single dose group 1
89619142|NCT01581658|Experimental|BI10773 medium dose group 2|BI10773 medium dose tablet single dose group 2
89619143|NCT01581658|Experimental|BI10773 Medium dose group 3|BI10773 medium dose tablet single dose group 3
89619144|NCT01581658|Experimental|BI10773 Medium dose group 4|BI10773 medium dose tablet single dose group 4
89619145|NCT03370068|Experimental|ICSI|All the oocytes in this group (from one ovary) will undergo insemination by ICSI.
89619146|NCT03370068|Active Comparator|Conventional IVF|All the oocytes in this group (from the other ovary) will undergo insemination by conventional IVF.
89619147|NCT01530178|Active Comparator|Part A|Sitagliptin 25mg
89619148|NCT01530178|Active Comparator|Part B|Sitagliptin 50mg
89619149|NCT01530178|Active Comparator|Part C|Sitagliptin 100mg
89619150|NCT01530178|Placebo Comparator|Part D|Placebo oral tablet
89619151|NCT03369990|Experimental|Botulinum toxin type A|DWP450
89619152|NCT03369990|Placebo Comparator|Placebo|Normal Saline
89619153|NCT03375840|Experimental|Text-only PWL, immediate post|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
89619154|NCT03375840|Experimental|Text-only PWL, delay posttest|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
89619155|NCT03375840|Experimental|Low-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
89619156|NCT03375840|Experimental|Low-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
89619157|NCT03375840|Experimental|High-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
88987892|NCT04512313|Active Comparator|Group receiving rocuronium 0,3 mg/kg|Rocuronium 0,3 mg/kg at induction
88987893|NCT04512313|Active Comparator|Group receiving rocuronium 0,9 mg/kg|Rocuronium 0,9 mg/kg at induction
88987894|NCT00142493|Experimental|1|
88987895|NCT00142493|Experimental|2|
88987896|NCT00142493|Experimental|3|
88987897|NCT00142493|Experimental|4|
88987898|NCT00142493|Placebo Comparator|5|
88987899|NCT04512352|Experimental|Treatment group|Online curriculum has been delivered to this group of participants on an Internet-based platform
88987900|NCT04512352|No Intervention|Wait-list control group|Participants in wait-list control group would not have access to the online curriculum until the intervention process for treatment group is finished.
88987901|NCT04511689||test group|bone grafting with gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
89619158|NCT03375840|Experimental|High-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
89619159|NCT03006874|Experimental|CJ-12420 50mg QD|CJ-12420 50mg tablet, once daily, oral administration for up to 8 weeks.
88987902|NCT04511689||control group|bone grafting with xenogenic deproteinized bone matrix mixed with autobone
88987903|NCT00142532|Experimental|1|At the time of pre-op preparation, 18 semi-permanent intradermal acupuncture studs will be placed at acupuncture points in the back, two will be placed in the legs and two in the ear. All studs will be replaced when the epidural is removed or, for patients without epidurals, shortly before discharge. The new leg and auricular studs will then be removed at eleven days; the new back studs will be removed at the three week post-discharge consult.
89619160|NCT03006874|Experimental|CJ-12420 100mg QD|CJ-12420 100mg tablet, once daily, oral administration for up to 8 weeks.
89619161|NCT03006874|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg, tablet. once daily, oral administration for up to 8 weeks.
89619162|NCT03369912|Experimental|Active|CSJ148
89619163|NCT03369912|Placebo Comparator|Placebo|5% dextrose
89619164|NCT03375684|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
89619165|NCT03375684|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
89619166|NCT03373578|Active Comparator|earmuffs|Preterm newborns with earmuffs during the Quiet time
89619167|NCT03373578|No Intervention|control|Preterm newborns without earmuffs during de Quiet time
88987904|NCT00142532|Placebo Comparator|2|"The treatment is the same as for the true acupuncture group, with the following exceptions. The studs in the back will be dummy studs have no needle and that have been used in previous research at MSKCC. The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.~Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
88987905|NCT04511923|No Intervention|Standard Care|Standard care
88987906|NCT04511923|Experimental|Heparin|Standard care plus nebulised unfractionated heparin 25000 units every 6 hours for 10 days
88987907|NCT04511611|Experimental|Test A: 10 mg ODT with water, then 10 mg film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
88987908|NCT04511611|Experimental|Test A: 10 mg film-coated tablet, then 10 mg ODT with water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) with water in the fasted state
88987909|NCT04511611|Experimental|Test B: 10 mg ODT without water, then 10 film-coated tablet|Participants received one single dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban film-coated tablet in the fasted state
88987910|NCT04511611|Experimental|Test B: 10 mg film-coated tablet, then 10 mg ODT without water|Participants received one single dose of 10 mg rivaroxaban film-coated tablet in the fasted state. After a washing period of 5 days, participants received one single oral dose of 10 mg rivaroxaban orally disintegrating tablet (ODT) without water in the fasted state
88987911|NCT04511260|Experimental|VRF Treatment|"A treatment of the vaginal canal using the NuEra Tight VRF small area handpiece. A treatment of the introitus and vestibule using the NuEra Tight VRF small area hand piece (optional).~Following screening visit, eligible subjects will be enrolled into the study. Each subject will receive 3 treatments, 4 weeks apart and 2 Follow Up (FU) visits, at 1, and 3 months following the last treatment."
88987912|NCT04511299|Experimental|Fish oil-enriched intravenous lipid emulsion|SMOFlipid 20%, given for 3 consecutive days with 1-4 g/kg/day.
88987913|NCT04511299|Active Comparator|Standard intavenous lipid emulsion|Lipofundin 20%, given for 3 consecutive days with 1-4 g/kg/day.
88987914|NCT04511221|Placebo Comparator|Placebo|15 mg capsule containing rice maltodextrin and medium chain coconut triglycerides
88987915|NCT04511221|Active Comparator|Bifidobacterium animals subsp. lactis BL04|15 mg capsule containing 1x 10^9 CFU Bifidobacterium animals subsp. lactis BL04 with rice maltodextrin and medium chain coconut triglycerides as a filler material
88987916|NCT04511221|Experimental|Bifidobacterium animals subsp. lactis BL04+PreforPro|15 mg capsule containing 1x 10^9 CFU Bifidobacterium animals subsp. lactis BL04 and 1x10^6 PFU of PreforPro (Commercial phage preparation) with rice maltodextrin and medium chain coconut triglycerides as a filler material
88987917|NCT04511182|Experimental|exercise intervention group|Patients will receive standard medications plus EBCR 。Education covering topics related to AMI and exercise for AMI will be implemented and any consultations on exercise prescription and disease management will be explained by a cardiac rehabilitation team consisting of cardiologists, cardiology nurses and physiotherapists.
88987918|NCT04511182|No Intervention|Usual care group（control）|Patients will receive standard medications according to national guidelines, as well as education and consultations as intervention group. However，no exercise prescription is given,
88987919|NCT04511104|Active Comparator|Standard of Care|"Standard of care treatment:~- including passive / assisted / active movements, stretching, functional exercise, scar treatment~Duration: up to 8 weeks"
88987920|NCT04511104|Experimental|Exercise|"Standard of care + added exercises~Exercise type: resistance and aerobic exercise~Resistance Exercise: 3x / week (manual resistance, free weights, machines) Aerobic exercise: 2x / week (cycle ergometer, treadmill)~Duration: up to 8 weeks"
88987921|NCT00142610|Experimental|vitamin|500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks
88987922|NCT00142610|Placebo Comparator|Placebo|
88987923|NCT04510870|Experimental|Experimental group|"infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)~infusion is NaCl"
88987924|NCT04510870|Experimental|NaCl infusion group|"infusion is NaCl~infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)"
88987925|NCT00406536|Active Comparator|1|
88987926|NCT00406536|Placebo Comparator|2|
88987927|NCT02955160|Experimental|Multivalent|Pneumococcal conjugate vaccine
88987928|NCT02955160|Active Comparator|Tdap|Tetanus, diphtheria, and pertussis vaccine
88987929|NCT02954965|Experimental|Reward|A brief, phone-administered intervention designed to help graduate students increase the number of pleasant and rewarding activities in their daily lives.
88987930|NCT02954965|Experimental|Approach|A brief, phone-administered intervention designed to help graduate students block procrastination and avoidance and to approach important activities they are currently avoiding.
88987931|NCT02954965|No Intervention|Monitoring|Participants will monitor their current behaviors, mood, and burnout with no directed intervention to change behavior
88987932|NCT00142688|Experimental|1|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
88987933|NCT00142688|Active Comparator|2|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
88987934|NCT02275936|Experimental|Group 1 - 50 mg|Every 12 hour oral dosing of N91115 for 28 days
88987935|NCT02275936|Experimental|Group 2 - 100 mg|Every 12 hour oral dosing of N91115 for 28 days
88987936|NCT02275936|Experimental|Group 3 - 200 mg|Every 12 hour oral dosing of N91115 for 28 days
88987937|NCT02275936|Placebo Comparator|Group 4 - Placebo|Every 12 hour oral dosing of placebo comparator for 28 days
88987938|NCT00406575|Placebo Comparator|Placebo|Participants receive diluent via continuous IV infusion for 48 hours.
88987939|NCT00406575|Experimental|Low Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 100 µg/kg/day (corresponding to a dose of 4.2 µg/kg/hr).
88987940|NCT00406575|Experimental|High Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 500 µg/kg/day (corresponding to a dose of 21.0 µg/kg/hr).
88987941|NCT02275975|Experimental|K-877|K-877
88987942|NCT02275975|Experimental|K-877 with Fluconazole|K-877 with Fluconazole
88987943|NCT02276092||intervention|exposure to antimicrobial stewardship intervention
88987944|NCT02276092||control|usual care with no exposure to antimicrobial stewardship
88987945|NCT02276131|Experimental|Usability testing|Patients will participate in summative human factors testing of the Vigilant Diabetes Management Application in a controlled environment and during home use testing. Clinicians will participate in summative human factors testing in a controlled environment.
88987946|NCT04510402|Experimental|Safety Analysis|Evaluate safety of PVP-I nasal swabs single daily application
88987947|NCT04510402|Experimental|Tolerability analysis|Investigate the dosing of PVP-I nasal swabs daily single dosing versus double dosing
89210925|NCT01073527|Active Comparator|Hypertonic saline-salbutamol combination|NaCl 5% - 4cc (with standard treatment - salbutamol 0.5cc)
89210926|NCT01073527|Placebo Comparator|normal saline-salbutamol combination|Standard treatment normal saline 4cc with salbutamol 0.5cc
89619168|NCT01581970|Experimental|Cetuximab/low dose Cyclophosphamide|Safety population as defined by all patients receiving at least one treatment with cyclophosphamide on Day 1.
89619169|NCT01583452|Experimental|Chewing Gum Group|Group of patients given chewing gum as part of the treatment for prevention of post-operative ileus right after surgery, besides the standard pharmacologic treatment and post-operative care.
89619170|NCT01583452|No Intervention|No intervention|By observing the clinical evolution of the participants not given chewing gum as a prevention for post-operative ileus, and just given the standard pharmacologic treatment and post-operative care.
89619171|NCT01531738||Control|Normal weight healthy volunteers
89619172|NCT01531738||Bariatric Surgery|obese patients due to undergo gastric bypass or gastric banding
89619173|NCT01583686|Experimental|1/Phase I|Non-myeloablative but lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) plus low dose aldesleukin.
89619174|NCT01583686|Experimental|2/Phase II|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) + low-dose aldesleukin
89619175|NCT01532128|Experimental|Group 1|Period 1: rasagiline 1 mg Period 2: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 3: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg
89619176|NCT01532128|Experimental|Group 2|Period 1: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 2: rasagiline 1 mg Period 3: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg
89619177|NCT01532128|Experimental|Group 3|Period 1: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 2: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 3: rasagiline 1 mg
89619178|NCT01584388|Experimental|Rituximab|
89619179|NCT03007108|Experimental|healthy infants|
89619180|NCT01584544|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-25 combined with concurrent radiotherapy will be given to enrolled patients.
89619181|NCT01584544|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
89619182|NCT01584544|Experimental|1350mg|capecitabine 1300mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
89619183|NCT01584544|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
89619184|NCT01584544|Experimental|1650mg|capecitabine 1650mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
88987948|NCT00506194|Experimental|Insulin|Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard. Two third of daily dose was administered before breakfast and the other was administered at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre-breakfast dose was titrated base on pre-supper blood glucose.
88987949|NCT00506194|Active Comparator|OAD|Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was <70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose >160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.
88987950|NCT00506233||Chronic Graft-Versus Host Disease (GvHD)|Participants with chronic graft-versus host disease (GvHD)
88987951|NCT00506272|Experimental|Standard care|Patients admitted for elective surgery will receive standard diabetes care, including but not limited to finger stick blood glucose determinations, and insulin injections delivered by the nursing staff.
88987952|NCT00506272|Experimental|Patient administered care|Patients will self-monitor and record finger-stick blood glucose measurements, and self administer insulin at doses agreed upon with the consulting endocrinology in-patient service.
88987953|NCT00506311|Experimental|Fibrin Sealant|
88987954|NCT00506311|No Intervention|No Fibrin Sealant|
88987955|NCT04513327|Experimental|Digital Healthcare System Rehabilitation|
89619185|NCT03006796||group 1 (AZL/C)|Group 1 - patients receiving azilsartan medoxomil/chlorthalidone 40/12.5 mg or 40/25 mg per os once a day for 6 months.
89619186|NCT03006796||group 2 (IRB/H)|Group 2 - patients receiving irbesartan/hydrochlorothiazide 150/12.5 mg or 300/25 mg per once a day for 6 months.
89619187|NCT03006952|Active Comparator|pentoxifylline & losartan|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
89619188|NCT03006952|Active Comparator|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
89619189|NCT01532830|Experimental|Active|n-VNS active therapy
89619190|NCT01802333|Experimental|Arm I (standard dose cytarabine, daunorubicin hydrochloride)|"INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
89619191|NCT01802333|Experimental|Arm II (high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
88987956|NCT04513327|Active Comparator|Conventional Rehabilitation|
88987957|NCT04511377|Experimental|Digital Healthcare System Rehabilitation|Rehabilitation using Uincare Homeplus
88987958|NCT04511377|Active Comparator|Conventional Rehabilitation|Rehabilitation using Brochure
89619192|NCT01802333|Experimental|Arm III (vorinostat, high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat."
89619193|NCT03007186||Case group|The oral glucose tolerance test that these women undergo in pregnancy between 24+0 and 28+0 showed pathological measurements.
89619194|NCT03007186||Control group|The oral glucose tolerance test of these women showed no pathological measurements.
89619195|NCT01585324|Experimental|Single Arm|
89619196|NCT01586026||Group A|Maintenance flushes at days 1-28
89619197|NCT01586026||Group B|Maintenance flushes at days 29-56
89619198|NCT01586026||Group C|Maintenance flushes at days 57+
89619199|NCT03006484||Before Period|Patients who developed in-hosptial cardiac arrest before the implementation of new legislation on life-sustaining treatments
89619200|NCT03006484||After Period|Patients who developed in-hosptial cardiac arrest after the implementation of new legislation on life-sustaining treatments
89619201|NCT03006640|Placebo Comparator|Control group|
89619202|NCT03006640|Active Comparator|NTG group|
89619203|NCT01586962|Experimental|Upper Respiratory Infections|
89619204|NCT01588444|Experimental|cancellous FDBA (LifeNet)|grafting with cancellous mineralized freeze-dried bone allograft (LifeNet Health)
89619205|NCT01588444|Experimental|cortical FDBA (LifeNet)|CORTICAL FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
88987959|NCT02276248|Experimental|radiotherapy+chemotherapy|Radiotherapy technique: Intensity-modulated radiation therapy total dose: 50 to 56 grays per fraction: 2 grays GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
88987960|NCT00406614|Experimental|1|Literacy-focused high blood pressure intervention. The intervention group will receive the health literacy -focused hypertension management intervention that will be delivered through 6 weeks of highly interactive group sessions in a classroom setting, followed by telephone counseling once a month for 12 months. Also, the intervention group will concurrently use home blood pressure monitoring with telephone transmission for 12 months.
88987961|NCT00406614|Active Comparator|2|Wait-list control group will initially receive usual care from a regular medical provider. Participants in the control group will take part in the intervention once the study has been completed.
88987962|NCT04516018|Experimental|Cold acclimation arm|An oral glucose tolerance test will be performed on day 1 of the study. The next day (day 2), subjects will be exposed to shivering thermogenesis for at least 1 hour. The day after, an oral glucose tolerance test will be performed (day 3). The following 9 days, subjects will be exposed daily to shivering thermogenesis for at least 1 hour (day 4-12). On the last day (day 13), an oral glucose tolerance test will be performed.
88987963|NCT00142805|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
88987964|NCT00142805|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
89619206|NCT03006250|Experimental|Desflurane|Desflurane group: The rule of 24 will be applied, which means that the fresh gas flow (l/ min) multiplied by volume percent of desflurane must not exceed 24. Therefore, once the patients return of spontaneous ventilation, an anesthesiologist turns on oxygen 1 l/ min, nitrous oxide 1 l/ min, and desflurane 12 vol% for 1-2 minutes. When the end-tidal desflurane reaches 3-3.5% (approximately 0.5 MAC), the anesthesiologist will decrease oxygen and nitrous oxide to each 0.5 l/ min and desflurane to 6 vol% (1 MAC). Desflurane concentration will be adjusted to maintain the end-tidal desflurane around 3-6% (0.5-1 MAC).
89619207|NCT03006250|Active Comparator|Sevoflurane|Sevoflurane group: The oxygen and nitrous oxide each 1 l/min will be turned on with sevoflurane 4 vol% for 1-2 minutes or until the end-tidal sevoflurane reach 1-1.2% (approximately 0.5 MAC). After that, the flow of oxygen and nitrous oxide is reduced to each 0.5 l/ min and concentration dial of sevoflurane is set to 2 vol% (1 MAC). During the operation, sevoflurane concentration will be adjusted to maintain the end-tidal sevoflurane around 1-2% (0.5-1 MAC)
89619208|NCT03006406|Active Comparator|Long term GnRH-a for 1 month|patient in this group only receive GnRH-a 3.75 for 1 month
89619209|NCT03006406|Experimental|patient in this group only receive GnRH-a 3.75 for 2 month|patient in this group only receive GnRH-a 3.75 for 2 month
88987965|NCT04510831|Experimental|Refined maize|Two portions of porridge prepared with refined maize flour with extrinsic addition of labelled FeSO4 (isotopic iron 54)
88987966|NCT04510831|Experimental|T.molitor native chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) native chitin and extrinsic addition FeSO4 (isotopic iron 58)
88987967|NCT04510831|Experimental|T.molitor reduced chitin|Two portions of porridge prepared with refined maize flour mixed with dried intrinsically labelled Tenebrio molitor (isotopic iron 57) reduced chitin and extrinsic addition FeSO4 (isotopic iron 58)
88987968|NCT00142844|Experimental|Naltrexone|Naltrexone
88987969|NCT00142844|Experimental|Disulfiram|Disulfiram
88987970|NCT00142844|Experimental|Naltrexone and Disulfiram|Naltrexone and Disulfiram
88987971|NCT00142844|Placebo Comparator|Placebo|Placebo
89619210|NCT00980655|Experimental|1|
89619211|NCT04129437|Active Comparator|NSAID|Ibuprofen, 800 mg, one time dose
89619212|NCT04129437|Active Comparator|OMT/NSAID|Ibuprofen, 800 mg, one time dose
89619213|NCT04129437|Active Comparator|OMT alone|low velocity osteopathic manipulative medicine
89619214|NCT05609799|Other|Healthy females|One blood sample is collected on healthy females in reproductive age. The sample will be analyzed for volumen of leucocyte subsets.
89619215|NCT01535014|Experimental|Dietressa (2 tablets 3 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (2 tablets 3 times daily) for 24 weeks.
89619216|NCT01535014|Experimental|Dietressa (1 tablet 6 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (1 tablet 6 times daily) for 24 weeks.
89619217|NCT01535014|Placebo Comparator|Placebo (2 tablets 3 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (2 tablets 3 times daily) for 24 weeks.
89619218|NCT01535014|Placebo Comparator|Placebo (1 tablet 6 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (1 tablet 6 times daily) for 24 weeks.
89619219|NCT05609721||Patients with antithromotic therapy|Data from medical records and radiology registry with mTBI in Sundsvall hospital between 2018-2020 in Sundsvall identified 2044 patients. Demographic data, pre-injury medications with antithrombotic treatment, state of consciousness at admission and the results of CT-scans of brain was investigated.
89619220|NCT05609721||Patients without antothrombotic therapy|Data from medical records and radiology registry with mTBI in Sundsvall hospital between 2018-2020 in Sundsvall identified 2044 patients. Demographic data, pre-injury medications with antithrombotic treatment, state of consciousness at admission and the results of CT-scans of brain was investigated.
89619221|NCT01535326|Placebo Comparator|air insufflation|Use air insufflation during colonoscopy
89619222|NCT01535326|Active Comparator|water immersion|infuse water during insertion, remove water during withdrawal of colonoscopy
89619223|NCT01535326|Active Comparator|water exchange|infuse and remove water during insertion phase of colonoscopy
89619224|NCT01801865|Experimental|MRI for Neonates|All participants will receive an MRI in the NICU scanner in the GE OPTIMA 1.5T MRI at CCHMC.
89619225|NCT01590238|Experimental|Treatment with PRFM|Subjects treated monthly 3 times with intradermal injections of PRFM into bald/balding scalp. Post-treatment hair density index measured and compared to hair density index measured prior to treatment for each subject.
89619226|NCT00980343|Experimental|Arm I (pre-surgery vismodegib)|"Patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily for 7 days before therapeutic conventional surgery. Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis"
89619227|NCT00980343|Experimental|Arm II (no vismodegib pre-surgery)|"Patients do not receive treatment before therapeutic conventional surgery.~Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
89619228|NCT01801475|Active Comparator|Pregnant women|Full term pregnant women scheduled for Cesarean section and will be given Ondansetron as standard-of-care prior to surgery.
89619229|NCT01801475|Active Comparator|Non-pregnant women|Non-pregnant women scheduled for surgery at Stanford who will be given Ondansetron prior to their surgery as standard-of-care.
89619230|NCT01801475|No Intervention|Neonates|"Babies of the pregnant women enrolled in the study; no ondansetron is given to babies in this Aim 1 of the study."
89619231|NCT01536184|Experimental|Receives COS Intervention|Circle of Security (COS) Family Intervention (B. Marvin model) is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour. The protocol itself involves a series of activities and repeated videotaped interactions between the child and their caregiver which are reviewed by the therapist who has established themselves with the caregiver as a secure base from which the attachment relationship may be explored.
89619232|NCT01536184|No Intervention|Control Group-Regular FASD Services|Regular FASD Services include general information on Fetal Alcohol Spectrum Disorder (FASD) with general behavioural management strategies and parental supports.
89619233|NCT03063021|Experimental|Experimental Arm (carbonyl content >0.6, GSH/GSSG <3)|Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) in the aqueous.
89619234|NCT03063021|Experimental|Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3)|Subjects with RP who don't have a high carbonyl content (>0.6) and a reduced GSH/GSSG ratio (<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.
89619235|NCT01536496|Active Comparator|Control (INR, PTT, fibrinogen, D-dimer)|Patients randomized to the Control Group will receive blood component therapy guided by conventional coagulation tests per usual clinical practice. The control arm involves the use of conventional coagulation tests (aPTT, INR, fibrinogen level, D-dimer) to diagnose and describe post-injury coagulopathy and to guide blood product replacement. In the Control Group, blood will be drawn for conventional coagulation testing (aPTT, INR, platelet count, fibrinogen level, D-dimer) at Baseline (as defined above), then twice more during the first six hours at the discretion of the treating team, then again at 12 hours and at 24 hours post-injury. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
89619236|NCT01536496|Active Comparator|Test (r-TEG)|Patients randomized to the r-TEG guided haemostatic resuscitation group (Test Group) will receive blood component therapy per usual clinical practice. The test arm involves the use of rapid-TEG to diagnose and describe post-injury coagulopathy and to guide blood product replacement per institutional algorithm. In the Test Group, blood for r-TEG will be collected on admission, or upon entering the operating room, depending on the acuity of the injury (Baseline), and this will be followed by two additional r-TEG analyses during the first six hours at the discretion of the treating team (attending surgeon, anesthesiologist) and then two further r-TEG analyses at 12 hours and at 24 hours post-injury respectively. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
89619237|NCT02337933|Experimental|Ursolic acid|Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
89619238|NCT02337933|Placebo Comparator|Placebo|Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks
89619239|NCT03062943|Experimental|Nintedanib 150mg BID|nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
89619240|NCT01536886|Placebo Comparator|LEO 90100 vehicle|Aerosol foam with no active ingredient
89619241|NCT01536886|Active Comparator|Betamethasone plus calcipotriol|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) ointment
89619242|NCT01536886|Experimental|LEO 90100|LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
89619243|NCT01536886|Placebo Comparator|Ointment vehicle|Ointment with no active ingredients
89619244|NCT01822925|Experimental|DA-9801 300mg|DA-9801 will be administered in tablet form, 100mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
89619245|NCT01822925|Experimental|DA-9801 600mg|DA-9801 will be administered in tablet form, 200 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
89619246|NCT01822925|Experimental|DA-9801 900mg|DA-9801 will be administered in tablet form, 300 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
89619247|NCT01822925|Placebo Comparator|Placebo|Placebo (same formulation as DA-9801 but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 12 weeks.
89619248|NCT02247310||Cohort 1|Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome and be on treatment with Betaferon using the BETACONNECT auto-injector device.
89619249|NCT03041415|Active Comparator|ALED Alone Physical Activity Program|"The Active Living Every Day (ALED) comprehensive 12-week PA training and support program is appropriate for delivery by trained instructors from diverse backgrounds.~Participants are taught self-regulatory skills aimed at increasing and sustaining regular physical activities such as walking."
89619250|NCT03041415|Experimental|ALED + Our Voice PA Program|"The ALED physical activity program is combined with the Our Voice citizen science engagement program, which teaches participants how to assess the barriers and enablers of neighborhood physical activity using a simple mobile app.~Residents then share their data and build consensus around major barriers and potential solutions, which they share with local decision makers."
89619251|NCT00989001|Experimental|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
89619252|NCT00989001|Placebo Comparator|Placebo|Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant
88987972|NCT00163137|Experimental|Lasofoxifene 0.25 mg|lasofoxifene 0.25 mg/day
88987973|NCT00163137|Active Comparator|raloxifene|raloxifene 60 mg/day
88987974|NCT00163137|Placebo Comparator|Placebo|Placebo
88987975|NCT04516096|Experimental|AMX-0035 long term treatment extension|AMX0035 administered twice daily p.o.
88987976|NCT00142883|Active Comparator|pregabalin|pregabalin compared to placebo
88987977|NCT00142883|Placebo Comparator|Placebo|Placebo compared to pregabalin
88987978|NCT04512196|Experimental|Super-oxidised Solution|Peritoneal lavage with super-oxidised solution of at least 10 cc/kg and wound lavage with super-oxidised solution 1 cc/kg
88987979|NCT04512196|Placebo Comparator|Normal Saline|Peritoneal lavage with normal saline 0.9% of at least 10 cc/kg and wound lavage with normal saline 0.9% 1 cc/kg
88987980|NCT00142922|Experimental|1|Attended Breaking Down Barriers program
88987981|NCT00142922|Active Comparator|2|Attention control group
88987982|NCT00142922|Active Comparator|3|Indivdual attention control group
88987983|NCT00142961|Experimental|1|Atomoxetine prescribed daily
88987984|NCT00142961|Placebo Comparator|2|placebo controlled arm
88987985|NCT00506467||VRI System|Vibration Response Imaging (VRI) System
88987986|NCT04512937|Experimental|All patients|All patients will be subjects to the intervention of computer navigation-assisted surgery
88987987|NCT00143039||NIH/SSIUGR fetuses|Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.
88987988|NCT00143039||Control-Normal fetus|Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.
88987989|NCT04515433|Experimental|real tACS|Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
88987990|NCT04515433|Placebo Comparator|sham tACS|Single session of sham tACS over the superior parietal cortex (Precuneus)
88987991|NCT04514575||High-FFP|Patients transfused with an FFP:RBC ratio of 2:3 to 3:3 (0.7 - 1.0)
88987992|NCT04514575||Low-FFP|Patients transfused with an FFP:RBC ratio at or below 1:3 (0.0 - 0.3).
88987993|NCT04510909|Experimental|Pilot arm|Mixed methods, acceptability and feasibility pilot of the COMMIT mHealth application
88987994|NCT00404612|Placebo Comparator|Placebo|
88987995|NCT00404612|Active Comparator|LX211, 0.2 mg/kg|
88987996|NCT00404612|Active Comparator|LX211, 0.4 mg/kg|
88987997|NCT00404612|Active Comparator|LX211, 0.6 mg/kg|
89619253|NCT03061539|Experimental|Nivolumab & Ipilimumab - Cohort 1|Patients will receive Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses followed by a 6 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
89619254|NCT03061539|Experimental|Nivolumab & Ipilimumab - Cohort 2|Patients will receive Nivolumab 3 mg/kg + ipilimumab 1 mg/kg every three weeks for a maximum of 4 doses followed by a 3 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
89619255|NCT01590550||Single arm|Single arm for all patient receiving inpatient HD
89619256|NCT05609253|Active Comparator|Itraconazole in capsule form|Participants in this arm will receive the capsule form of itraconazole
89619257|NCT05609253|Active Comparator|Itraconazole in solution form|Participants in this arm will receive the solution form of itraconazole
89619258|NCT01591018|Experimental|cardiac surgery with sonolysis|cardiac surgery (CABG or heart valve surgery) with sonolysis (continual transcranial Doppler monitoring)
89619259|NCT01591018|Placebo Comparator|cardiac surgery without sonolysis|cardiac surgery (CABG or heart valve surgery) without sonolysis (continual transcranial Doppler monitoring)
89619260|NCT05609097|Experimental|PRIME + COMBO|PRIME training (Phase 1), followed by 8 weeks of progressive whole-body COMBO training.
89619261|NCT05609097|Other|COMBO only|4 weeks of standard progressive whole-body aerobic plus resistance training (COMBO) followed by 8 weeks continued COMBO training.
89619262|NCT01801007|Other|Flow Re-Direction Endoluminal Device|
89619263|NCT05609019|Experimental|SYHX2005|"Stage1 dose-escalation: Patients with advanced solid tumors will receive escalating doses of SYHX2005 as monotherapy.~Stage2 dose-expansion: Patients with advanced solid tumors will receive SYHX2005 monotherapy at recommended dose (1 or 2 ) in Stage 1 (dose escalation) to evaluate the preliminary antitumor activity of SYHX2005."
89619264|NCT04120545|Experimental|Microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
89619265|NCT04120545|Placebo Comparator|Placebo microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
89619266|NCT01822691|Experimental|INCB024360 Treatment|Participants were treated with 600 mg orally, twice a day for 16 weeks, unless clear evidence of disease progression or toxicity was evident.
89619267|NCT01822535|No Intervention|No Drug: Tetraplegia|"Tetraplegia: Lesion level T1 and above, American Spinal Injury Association (ASIA) impairment levels A and B, ages 18-68 years.~Exposure of up to 2 hours in a cool room."
89619268|NCT01822535|No Intervention|No Drug: AB Controls|AB Controls: Matched for age and gender to subjects with tetraplegia. Exposure of up to 2 hours in a cool room.
89619269|NCT01822535|Experimental|Drug (midodrine): Tetraplegia|Persons with tetraplegia who completed Visit 1 (no drug). Participants are administered midodrine hydrochloride (10 mg tablet) by a physician before exposure of up to 2 hours in a cool room. (Visit 2)
89619270|NCT01537666|Experimental|Aerovanc 16 mg in healthy volunteers|
89619271|NCT01537666|Experimental|AeroVanc 32 mg in healthy volunteers|
89619272|NCT01537666|Experimental|AeroVanc 80 mg in healthy volunteers|
89619273|NCT01537666|Active Comparator|IV vancomycin in healthy volunteers|
89619274|NCT01537666|Experimental|AeroVanc 32 mg in CF patients|
89619275|NCT01537666|Experimental|AeroVanc 80 mg in CF patients|
89619276|NCT01537900|Experimental|Grazoprevir 100 mg|Participants received GZR 100 mg once daily (q.d.) for 7 days. Liver FNA was performed on Day 7.
89619277|NCT03005938|Experimental|Spinal manipulation|Spinal manipulation
89619278|NCT03005938|Sham Comparator|Imitation of the spinal manipulation|Imitation of the spinal manipulation
89619279|NCT01591408|Experimental|EEG biofeedback|Subjects will receive EEG biofeedback according to their own brain rhythms
89619280|NCT01591408|Sham Comparator|sham EEG biofeedback|Subjects will receive feedback according to someone else's brain rhythms collected during a different session.
89619281|NCT01539070|Experimental|Eating and physical activity counseling|Participants randomized to intervention received a 6 week curriculum focused on obesity awareness and prevention. A trained nutritionist led diet, healthy growth and physical activity workshops, while a health educator led workshops on instilling healthy habits and routines in childhood. The nurse provided child care and developed relevant games and activities for children while parents attended the workshops.
89619282|NCT01539070|No Intervention|Usual care|According to the existing clinical practice guide within IMSS, obese children may be referred to a nutritionist if the physician considers it necessary, given general dietary advice by the attending physician, or, if necessary, sent for laboratory analyses of blood lipids and glucose. We gave the parents the height and weight results from the measurement of their child and recommended they share results with their physician in their next medical consultation.
89619283|NCT01592500|Experimental|MOD-4023 low dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
89619284|NCT01592500|Experimental|MOD-4023 middle dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
89619285|NCT01592500|Experimental|MOD-4023 high dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
89619286|NCT01592500|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
89619287|NCT02212834||Mammograms|Surveillance mammograms in women with a personal history of breast cancer
89619288|NCT02212834||Breast MRI|Surveillance breast Magnetic Resonance Imaging (MRI) in women with a personal history of breast cancer
89619289|NCT03002116|Active Comparator|Group N|Healthy volunteers without peripheral arterial disease according to clinical examination and Duplex ultrasound
89619290|NCT03002116|Experimental|Group DN|Patients suffering from diabetes and diabetic foot without vascular compromise according to clinical assessment continuous-wave Doppler and Duplex ultrasound
89619291|NCT03002116|Experimental|Group DC|Diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
89619292|NCT03002116|Experimental|Group NDC|Non diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
89619293|NCT01799993|Experimental|Amikacin inhale (BAY41-6551)|Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10.
89619294|NCT01799993|Placebo Comparator|Placebo|Participants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10.
89619295|NCT01593592|Experimental|Lactobacillus reuteri group|The active group that will receive the standard triple therapy and Lactobacillus reuteri
89619296|NCT01593592|Placebo Comparator|Control group|The control group that will receive the standard triple therapy and placebo
89619297|NCT03001960|Experimental|Group 1- PREloading BEFORE TAVI|"Aspirin 100 mg loading orally 6-12 hours before TAVI and~Clopidogrel 600mg loading 6-12 before TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
89619298|NCT03001960|Experimental|Group 2 - POSTLoading AFTER TAVI|"Aspirin 100 mg loading orally 6-12 hours after TAVI and~Clopidogrel 600mg loading 6-12 hours after TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
89619299|NCT01822223|Experimental|Laser-ablated dental implant-abutments|Laser-ablated dental implant abutments will be attached to surgically placed dental implants.
89619300|NCT01822223|Active Comparator|Smooth implant-abutments|Smooth dental implant-abutments will be attached to surgically placed dental implants.
89619301|NCT01593670|Experimental|Patients With High Risk MDS|Patients who received treatment for high risk myelodysplastic syndromes (MDS). Treatment Received: Decitabine 10 mg/m^2/day intravenous (IV) over 1 hour days 1-5; Vorinostat 200 mg by mouth (PO) twice a day days 6-15; Il-2 activated donor natural killer cells (NK) infusion IV over 15 to 60 minutes day 17; Interleukin-2 6 million units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17. Repeat treatment course 6 to 8 weeks after cycle 1 start date.
89619302|NCT01593748|Experimental|Experimental|Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.
89619303|NCT01593748|Active Comparator|Standard of Care|Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).
89619304|NCT01594294|Experimental|AOSEPT Plus|AOSEPT® Plus contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
89619305|NCT01594294|Active Comparator|ReNu MultiPlus|ReNu MultiPlus® contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
89619306|NCT01594294|Other|Complete MPS Easy Rub|COMPLETE® MPS Easy Rub® Formula contact lens solution used with etafilcon A contact lenses (14 days) or lotrafilcon B contact lenses (30 days), Screening Phase
89619307|NCT01594528|Experimental|SC|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with schizophrenia
89619308|NCT01594528|Experimental|controls|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects without any psychiatric trouble
89619309|NCT01594528|Experimental|MD|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with major depression
89619310|NCT03005704|Experimental|Antiplatelet Treatment|Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
89619311|NCT03005704|No Intervention|Control|Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.
89619312|NCT03001648||PGS|Patients with RIF scheduled for PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridation (aCGH) underwent one or more stimulation cycles. If euploid blastocysts were available, patients underwent frozen embryo transfer/s.
88987998|NCT04513990|Experimental|Diagnostic (biospecimen collection)|Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical provider and self-collection of oral, saliva, and nasal samples.
88987999|NCT02955199|Experimental|Mothering From the Inside Out|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
88988000|NCT02955199|Active Comparator|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
89619313|NCT03001648||Standard IVF|Patients with RIF scheduled for standard IVF (In Vitro Fertilization) underwent a single stimulation cycle with the fresh embryo transfer and the subsequent frozen embryo transfers if there were surplus frozen embryos and the fresh embryo transfer was unsuccessful.
89619314|NCT01595386|Placebo Comparator|Normal Saline|The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
89619315|NCT01595386|Experimental|Hydrocortisone|Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.
89619316|NCT01595854|Experimental|Test 2 (part 3)|low dose dabigatran + high dose ticagrelor
89619317|NCT01595854|Active Comparator|Test 1 (part 1 + 2)|high dose ticagrelor
89619318|NCT01595854|Experimental|Reference 1 (part 1 + 2)|medium dose dabigatran
89619319|NCT01595854|Experimental|Reference 2 (part 3)|low dose dabigatran
89619320|NCT01596088|Experimental|Drug: Dexrazoxane|"Dexrazoxane should be given once daily for 3 consecutive days. The dose is:~Day 1: 1000 mg/m2, Day 2: 1000 mg/m2, Day 3: 500 mg/m2 (body surface area)"
89619321|NCT02228382|Experimental|Bosutinib|
89619322|NCT02216422|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir with RBV|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) co-administered with weight-based Ribavirin (RBV; twice daily) for 12 weeks
89688409|NCT03404765|Experimental|Tai Chi group|The Tai Chi group (i.e. the intervention group) received a 16-week Tai Chi program, of 32 sessions (2 sessions per week), each being one hour long.
88988001|NCT00404690|Active Comparator|1|Operative attempt at closure
88988002|NCT00404690|Experimental|2|bedside silo
88988003|NCT00506506|Experimental|1|N-acetylcysteine 1200 mg twice daily x 48 hours
88988004|NCT00506506|Placebo Comparator|2|
89619323|NCT03001570|Experimental|Arm 1|"Radiotherapy treatment associated with concurrent Cetuximab administration.~Patients candidate to curative concurrent Cetuximab and Radiotherapy are eligible for this study. After expressing written informed consent, patients will perform CT simulation. Then an IMRT-SIB (Simultaneous Integrated Boost) treatment plan will be elaborated and deliver the following Cetuximab pharmacokinetic:~Length: 6 weeks; 1 fraction daily (From Monday to Friday) 30 Total Fractions (5 per week, 6 weeks of treatment). Cetuximab will be administered weekly from a week before starting radiotherapy until the end of treatment for 7 subsequent administration accordingly to the standard schedule (1 before and 6 during radiotherapy)."
89619324|NCT03005548|Experimental|Active tDCS|Experimental: Transcranial direct current stimulation (tDCS). Patients assigned to the active treatment group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by tDCS (20 minutes of 2 milliamperes (mA) anodal tDCS over the ipsilateral cortex for 5days/week).
89619325|NCT03005548|Sham Comparator|Sham tDCS|Sham Control Group: Patients assigned to the control group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by sham tDCS stimulation (30 sec over the ipsilateral cortex, 5 days/week).
89619326|NCT03373500|Experimental|Low Salt Diet|Dietary salt reduction: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
89619327|NCT03373500|No Intervention|Standard Treatment|Patients will be instructed to continue with their usual diet, therefore no advice will be given about salt reduction.
89619328|NCT03005392|Experimental|Evaluate physical fitness|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
89619329|NCT03005392|Experimental|Evaluate Cardiological changes|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
89619330|NCT03005392|Experimental|Evaluate activity physical|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
88988005|NCT02597803|Experimental|High Dose RGN-259|High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
88988006|NCT02597803|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
88988007|NCT02597803|Experimental|Low Dose RGN-259|Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
88988008|NCT02594254|Experimental|Study Arm 1|Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.
89619331|NCT03005392|No Intervention|control grup|The control group will be recommended to maintain a level of physical activity they would routinely and habitually have during the 4 months that the study will last.
89619332|NCT03369834|No Intervention|Control Group|the volunteers of this group will not be submitted to the intervention.
88988009|NCT02594254|Experimental|Study Arm 2|Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
88988010|NCT02594254|Experimental|Study Arm 3|Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
88988011|NCT02594254|Experimental|Study Arm 4|Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
88988012|NCT02594254|Experimental|Study Arm 5|Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
88988013|NCT02594254|Experimental|Study Arm 6|If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
88988014|NCT02594254|Experimental|Study Arm 7|If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.
88988015|NCT00163449|Active Comparator|1|Ciclesonide 40 µg
88988016|NCT00163449|Active Comparator|2|Ciclesonide 80 µg
89619333|NCT03369834|Experimental|Red LED group|in the volunteers of this group will be applied Red Light-emitting diode device with the length 620nm wave along the entire tibialis anterior muscle and bilateral sural triceps.
88988017|NCT00163449|Active Comparator|3|Ciclesonide 160 µg
88988018|NCT00163449|Placebo Comparator|4|Placebo
88988019|NCT00143273|Experimental|Lasofoxifene Dose 1|0.05 mg
88988020|NCT00143273|Experimental|Lasofoxifene Dose 2|0.25 mg
88988021|NCT00143273|Experimental|Lasofoxifene Dose 3|0.5 mg
88988022|NCT00143273|Placebo Comparator|Placebo|0 mg
88988023|NCT02598583|Experimental|Cohort 1|"Participants were administered ALXN1210 900 mg.~In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period."
89619334|NCT03369834|Active Comparator|LED group infrared|in the volunteers of this group will be applied Infrared Light-emitting diode device with the wavelength of 940nm throughout the tibialis anterior muscle and bilateral sural triceps.
89619335|NCT03369834|Active Comparator|LED group mixed|in the volunteers of this group will be applied Infrared and Red Light-emitting diode device with the wavelength of 940nm and 620nm throughout the tibialis anterior muscle and bilateral sural triceps.
89619336|NCT03369834|Placebo Comparator|Sham Group|LED device off.
89619337|NCT03005470|Experimental|TELEM group|Participants in the telemonitoring home blood pressure group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
89619338|NCT03005470|Experimental|TELEMEV group|In the telemonitoring of lifestyle group, participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent to the smarphones on four of the five days of the week at random times using a software developed for this study.
89619339|NCT03005470|Experimental|TELEM-TELEMEV group|Participants in the telemonitoring home blood pressure plus telemonitoring of lifestyle group (TELEM-TELEMEV) will receive both interventions as previously described.
89619340|NCT03005470|Active Comparator|Usual clinical treatment (UCT)|Participants in the control group will be under antihypertensive treatment, chosen at the discretion of the assistant physician. Participants will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
89619341|NCT03373422|Experimental|BAY1128688 (dose 1)|One BAY1128688 tablet (lowest dose) in the morning, one placebo tablet in the evening
89619342|NCT03373422|Experimental|BAY1128688 (dose 2)|One BAY1128688 tablet (first intermediate dose) in the morning, one placebo tablet in the evening
89619343|NCT03373422|Experimental|BAY1128688 (dose 3)|One BAY1128688 tablet (second intermediate dose) in the morning, one placebo tablet in the evening
89619344|NCT03373422|Experimental|BAY1128688 (dose 4)|One BAY1128688 tablet (second intermediate dose) in the morning and one in the evening
89619345|NCT03373422|Experimental|BAY1128688 (dose 5)|One BAY1128688 tablet (highest dose) in the morning and one in the evening
89619346|NCT03373422|Placebo Comparator|Placebo|One placebo tablet in the morning and one in the evening
89619347|NCT03375606|Experimental|CSL730|
89619348|NCT03375606|Placebo Comparator|Placebo|
89619349|NCT03375528|Experimental|coronary artery disease patients|To define the Matrix metalloproteinases expression level in the neointimal hyperplasia induced by DES implantation
88988024|NCT02598583|Experimental|Cohort 2|"Participants were administered ALXN1210 1800 mg.~In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period."
88988025|NCT00163644|Active Comparator|Aerobic exercise plus resistance|Aerobic exercise plus resistance exercise for 6 weeks
88988026|NCT00163644|Active Comparator|Aerobic exercise|Aerobic exercise for 6 weeks
88988027|NCT00163644|Other|Control|No formal exercise and weekly phone calls
88988028|NCT02598895|Experimental|Treatment (docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 courses in the absence of disease progression or unacceptable toxicity.
88988029|NCT00143468|Experimental|1|ALI/ARDS patients and healthy subjects
89619350|NCT03363750|Experimental|mind-body-skills intervention|mind-body-skills group intervention offered weekly for 10 weeks
89619351|NCT03373344|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
89619352|NCT03373344|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer."
89619353|NCT03369522||Construction|100 recordings that will be used for the algorithm development
89619354|NCT03369522||Validation|100 recordings for the validation of the algorithm
89619355|NCT03373266|Active Comparator|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
89619356|NCT03373266|Active Comparator|isoflurane|anesthesia was maintained with isoflurane 1-2%.
89619357|NCT03363672||Patients receiving surgery|No intervention will be administered. Patients included will be asked to return a questionnaire regarding chronic postoperative pain via app.
89619358|NCT03369366|Experimental|Reconstruction and Dental Rehabilitation|Placement of NobelActive dental implants (minimum of three) using integrated osteotomy and implant placement guide.Placement of provisional screw-retained prosthesis (all while flap is still pedicled to vascular supply). Inset of flap/implant/prosthesis/custom plate construct (KLS Martin Mandibular Reconstruction Implant).
89619359|NCT03363594||1|Diabetes Mellitus
89619360|NCT02217904|Experimental|Islatravir 1 mg|Single oral dose of islatravir 1 mg
89619361|NCT02217904|Experimental|Islatravir 2 mg|Single oral dose of islatravir 2 mg
89619362|NCT02217904|Experimental|Islatravir 10 mg|Single oral dose of islatravir 10 mg
89619363|NCT02217904|Experimental|Islatravir 30 mg|Single oral dose of islatravir 30 mg
89619364|NCT02217904|Experimental|Islatravir 0.5 mg|Single oral dose of islatravir 0.5 mg
89619365|NCT02217904|Experimental|Islatravir 0.25 mg|Single oral dose of islatravir 0.25 mg
89619366|NCT02217904|Experimental|Islatravir 30 mg Extended Observation|Single oral dose of 30 mg islatravir administered following >8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
89619367|NCT02981134||bioabsorbable scaffold|Patients with BVS(bioabsorbable scaffold) for coronary stenosis
89619368|NCT03363516||Cases|Glucose normotolerant subjects with 1-h post-load plasma glucose >155 mg/dL
89619369|NCT03363516||Controls|Glucose normotolerant subjects with 1-h post-load plasma glucose <155 mg/dL
89619370|NCT02980822||Sweden, Denmark, Norway|"Group: Degenerative lumbar disc disease patients treated in Sweden and included in the Swespine register~Group: Degenerative lumbar disc disease patients treated in Norway and included in the NORspine register~Group: Degenerative lumbar disc disease patients treated in Denmark and included in the DaneSpine register"
89619371|NCT03363438||martinique|
89619372|NCT03363438||guadeloupe|
89619373|NCT02980900|Placebo Comparator|Placebo supplement|Post exercise placebo supplement Pre bed placebo supplement
89619374|NCT02980900|Active Comparator|Post exercise supplement|Post exercise protein-polyphenol supplement Pre bed placebo supplement
89619375|NCT02980900|Active Comparator|Pre bed supplement|Post exercise placebo supplement Pre bed protein-polyphenol supplement
89619376|NCT02980900|Active Comparator|Post exercise + pre bed supplement|Post exercise protein-polyphenol supplement Pre bed protein-polyphenol supplement
89619377|NCT03372876|Experimental|Protein-carbohydrate (PC) (protein intake after exercise)|ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon. The resistance exercise was performed equally by both groups.
89619378|NCT03372876|Placebo Comparator|Carbohydrate-protein (CP) (protein intake far to exercise)|ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. The resistance exercise was performed equally by both groups.
89619379|NCT03369132|Experimental|Angiflash|
89619380|NCT03369132|Placebo Comparator|Placebo|
89619381|NCT05488600||Team Sports|30 elite athletes between the ages of 20-30 who are interested in team sports
89619382|NCT05488600||Individual Sports|30 elite athletes between the ages of 20-30 who are interested in individual sports
89619383|NCT05488600||Control Group|30 healthy individuals between the ages of 20-30 who are not interested in sports
89619384|NCT03005158|Other|Validation Phase|All six hospital sites currently use the ARCHITECT STAT high- sensitive troponin I assay in the assessment of patients with suspected acute coronary syndrome and use sex-specific thresholds upper reference limits (99th centile) to rule out myocardial infarction. This validation phase of up to 10 months will provide baseline information for each site on patients with suspected acute coronary syndrome in whom myocardial infarction is ruled out.
88988030|NCT05148286|Active Comparator|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1~2h for initial fluid resuscitation.
88988031|NCT05148286|Placebo Comparator|Control|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice.
88988032|NCT05147779|Experimental|Treatment Group (AlloRx)|intravenous and intracavernosal or interstitial delivery (total dose of 100 million cells)
88988033|NCT00506545|Experimental|SCH 619734|
89619385|NCT03005158|Other|Randomization Phase|Participating centres will be randomized to implement the HighSTEACS pathway (intervention). The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
89619386|NCT03005158|Active Comparator|Implementation Phase|A final phase of up to 10 months after implementation of the HighSTEACS pathway will be matched by calendar month in each site to that of the validation phase, allowing each participating centre to act as its own control and to adjust for seasonal differences in the incidence of myocardial infarction and mortality.
88988034|NCT00506545|Placebo Comparator|Placebo|
88988035|NCT02964143|Experimental|Experimental group|Patients from this group will be treated with a combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) prepared with the Cellular Matrix / A-CP HA medical device
88988036|NCT02964143|Active Comparator|Control group 1|Patients from this group will be treated with a well-recognized hyaluronic acid named Ostenil® Plus
88988037|NCT02964143|Active Comparator|Control group 2|Patients from this group will be treated with PRP alone, prepared with RegenKit-BCT-1
88988038|NCT05144581||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County 2013-2017, identified by ICD-code K.58.
88988039|NCT05144074||Non-filtered platelet concentrates (NF-PC group).|In NF-PC group, 90 whole blood units were collected with Tripple blood bags, Six NF-PCs were pooled together and stored in a horizonal shaker at 20 ± 2C for 5 days .
88988040|NCT05144074||leukocyte-depleted platelet concentrates (LD-PC group).|In LD-PC group, another 90 whole blood units were collected using Whole Blood Filter Saving Platelets (WB-SP) bags with an integrated leukoreduction filter
88988041|NCT04696627||Dural puncture|Patients with well-documented recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019.
88988042|NCT04696627||Dural puncture with blood patch|Patients with well-documented recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019 that were treated with an epidural blood patch.
88988043|NCT04696627||No dural puncture|Patients who did not have recognized unintentional dural punctures during their labor epidural insertion at Mount Sinai Hospital from January 2015 to December 2019.
88988044|NCT04696393|Experimental|Treatment Sequence 1: AB|Participants will receive Treatment A (mitapivat 100 milligram [mg] tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
89619387|NCT01900002|Experimental|Treatment (sorafenib tosylate, TheraSphere)|Patients receive sorafenib tosylate PO BID. After 4 weeks, patients receive yttrium Y 90 glass microspheres IA. Courses of sorafenib tosylate repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89619388|NCT03005314|Other|Surgery|Postoperative chemotherapy group
89619389|NCT03005314|Other|Chemotherapy|Preoperative chemotherapy group
89619390|NCT03005002|Experimental|Treatment (durvalumab, tremelimumab)|Patients receive durvalumab IV over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning at week 17, patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
89619391|NCT03123510|Experimental|Synbiotic supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides
89619392|NCT03123510|Placebo Comparator|placebo|sugar pills
89619393|NCT02247856|Active Comparator|Control Group|Noninvasive ventilation+ jet nebulizer
89619394|NCT02247856|Experimental|Experimental Group|Noninvasive ventilation+ Vibrating Mesh Nebulizer (VMN)
89619395|NCT04526964|Other|Intervention Group (IGr)|Participants of the intervention group (IGr) receive self-management support and skills training based on the modular self-management curriculum during the inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up and a supplementary app.
89619396|NCT04526964|No Intervention|Control Group (CGr)|Participants in the control group (CGr) receive the standard follow-up procedures (care as usual).
89619397|NCT03001102|Sham Comparator|Bathing with 4% Chlorhexidine gluconate|Two baths with chlorhexidine using precise methods, including to scrubb the whole body with 50mL of undiluted solution, at night before surgery and the morning of surgery.
89619398|NCT03001102|Experimental|Bathing with10% PVPI degermante|Two baths with PVPI using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
89619399|NCT03001102|Active Comparator|Bathing with soap without antiseptic.|Two baths with soap using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
89619400|NCT02519556|Experimental|Probiatop|Probiotic comprising the mixture of strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus paracasei and Bifidobacterium lactis, at a dose of 1 gram sachet, once a day for 6 months
89619401|NCT02519556|Placebo Comparator|Placebo|Placebo of Maltodextrin in sachet
89619402|NCT03000946|Experimental|Somatostatin|Continuous intravenous infusion of somatostatin-14, 6 mg per day during 6.5 days
89619403|NCT03000946|Active Comparator|Octreotide|Subcutaneous octreotide 100 μg 3 times a day for 6.5 days.
89619404|NCT03363282|Experimental|Mini-SLET|Simple Limbal Epithelial Transplantation
89619405|NCT03363282|Experimental|Limbal-Conjunctival Autograft|Patients treated with limbal-conjunctival autograft
89619406|NCT03006718|Experimental|Patients|"Participants must have SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSβ+ thalassemia, HbSOArab), within the age range of 8 - 21 years, and be admitted to the hospital for vaso-occlusive crisis (VOE)-related pain. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study.~All participants will use the PROMIS for Pain Management App over 5 consecutive weeks (starting at hospital discharge)."
88988045|NCT04696393|Experimental|Treatment Sequence 1: BA|Participants will receive Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment A (mitapivat 100 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
88988046|NCT05143723|Experimental|agonist group|Patients of the first group received GNRH-a for LPS at a dose of 0.2 mg, subdermally, daily from the second day after TVOP till 8 weeks of pregnancy.
88988047|NCT05143723|Active Comparator|group of progesterone and estradiol|The second group of patients received progesterone as LPS at a dosage of 30 mg per day, per os, and estradiol at a dosage of 3 mg per day, transdermally starting from the second day after TVOP till 8 weeks of pregnancy
88988048|NCT00143624|Experimental|1|The first group will receive 8 mg of the study drug (rosiglitazone).
88988049|NCT00143624|Placebo Comparator|2|The second group will be given a placebo.
88988050|NCT05143528|Placebo Comparator|Arm A: Placebo|425 subjects will be randomized to the placebo group.
88988051|NCT05143528|Active Comparator|Arm B: Experimental Low Dose|425 subjects to each of the Nilotinib BE, 84mg.
88988052|NCT05143528|Active Comparator|Arm C: Experimental High Dose|425 subjects to each of the Nilotinib BE, 112mg.
89619407|NCT03004768|Experimental|Single dose of radiolabeled BMS-986165|
89619408|NCT03369054|Experimental|Minority Stress|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
89619409|NCT03369054|Active Comparator|Treatment as Usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
88988053|NCT05143060|Experimental|Cereal fiber powder|Cereal fiber powder
88988054|NCT05143060|Placebo Comparator|Pure glucose powder|Pure glucose powder
88988055|NCT05142982|Experimental|Radiotherapy|Patients randomized to the test arm will undergo radiotherapy to the residual mass. Patients will be stratified by the size of the residual mass in shortest dimension being <3 cm or > 3 cm.A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
88988056|NCT05142982|No Intervention|Observation|Patients randomized to the standard arm will be observed and the status of residual mass monitored with an FDG PETCT scan done at three to six monthly intervals.
88988057|NCT00143663|Experimental|Lapaquistat Acetate 100 mg QD|
88988058|NCT00143663|Placebo Comparator|Placebo QD|
88988059|NCT05142865|Experimental|Camrelizumab+ Chemotherapy+Apatinib|Induction stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1) or Cisplatin(25mg/m2，continuously on Day 1, 2 and 3) Q3W for 4-6 cycles; Maintenance stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally, once daily in 21-day cycle .
88988060|NCT00506584|Experimental|Group 1, arm 1|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day, where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
89619410|NCT03005236|Experimental|Envarsus|Basiliximab induction with maintenance therapy of Envarsus, mycophenolate mofetil and corticosteroids. Envarsus constitutes the experimental component of immunosuppression in older kidney transplant recipients.
89619411|NCT03005236|Active Comparator|Standard twice daily tacrolimus|Basiliximab induction with maintenance therapy of standard tacrolimus, mycophenolate mofetil and corticosteroids. Standard tacrolimus constitutes the control component of immunosuppression in older kidney transplant recipients.
89619412|NCT03363204|Experimental|BRUXENSE|Patients corresponding to selection criteria will use the BRUXENSE occlusal splint for 10 consecutive nights.
89619413|NCT03004690|Experimental|Performance temperature 22°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 22°C.
89619414|NCT03004690|Experimental|Performance temperature 28°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 28°C.
89619415|NCT02519010|Experimental|A Test|Test drug (Amlodipine/Valsartan) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
89619416|NCT02519010|Active Comparator|B Reference|Reference drug (Exforge) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
89619417|NCT03372642||Subtalar endorthesis|Patients who underwent subtalar endorthesis for flexible pediatric flatfoot
89619418|NCT03004456|Experimental|Distraction|"Patients randomized to the Distraction group will be permitted to choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw."
89619419|NCT03004456|No Intervention|Standard of care|"Patients randomized to the Standard of Care group will not be provided with an iPad."
89619420|NCT03368976||Interscalene|
89619421|NCT03368976||Supraclavicular|
89619422|NCT03368976||Infraclavicular|
89619423|NCT03368976||Transversus Abdominus Plane|
89619424|NCT03368976||Paravertebral Space|
88988061|NCT00506584|Experimental|Group1, Arm 2|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 40 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
88988062|NCT00506584|Active Comparator|Group 1, Arm 3|Human breast milk + bovine-based human milk fortifier (initiated when nutrition volume reaches 100 mL/kg/day) + pre-term formula (as needed)
88988063|NCT00506584|Experimental|Group 2, Arm 1|Prolact20/Neo20 + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
88988064|NCT00506584|Active Comparator|Group 2, Arm 2|Pre-term/term formula (minimum 20 cal/oz)
88988065|NCT05142592|Experimental|Cohort 1|1~6 subjects in this cohort will receive IPG7236 50 mg bid orally.
88988066|NCT05142592|Experimental|Cohort 2|3~6 subjects in this cohort will receive IPG7236 100 mg bid orally.
88988067|NCT05142592|Experimental|Cohort 3|3~6 subjects in this cohort will receive IPG7236 150 mg bid orally.
88988068|NCT05142592|Experimental|Cohort 4|3~6 subjects in this cohort will receive IPG7236 200 mg bid orally.
88988069|NCT05142592|Experimental|Cohort 5|3~6 subjects in this cohort will receive IPG7236 250 mg bid orally.
88988070|NCT05142592|Experimental|Cohort 6|3~6 subjects in this cohort will receive IPG7236 300 mg bid orally.
88988071|NCT05146531|Active Comparator|McCoy group|Patients were intubated with McCoy laryngoscope.
88988072|NCT05146531|Experimental|C-MAC group|Patients were intubated with C-MAC D-blade video laryngoscope.
88988073|NCT05146492|Active Comparator|Patient with acute myocardial infarction without pericardial effusion|
88988074|NCT05146492|Experimental|Patient with acute myocardial infarction and pericardial effusion|
88988075|NCT00143741|Other|Lipitor|
88988076|NCT00156156|Experimental|1|
88988077|NCT00156156|Experimental|2|
88988078|NCT05146102|Experimental|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method~Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
89619425|NCT03368976||Fascia Iliaca|
89619426|NCT03368976||Femoral Nerve|
89619427|NCT03368976||Saphenous Nerve via Adductor Canal|
89619428|NCT03368976||Popliteal Sciatic Nerve|
89619429|NCT03004612|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 24 months Linagliptin 2.5mg + metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
89619430|NCT03004612|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 24 months Metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
89619431|NCT04525560|Experimental|PEG-ELS-S|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
89619432|NCT04525560|Active Comparator|PEG-ELS-L|The dosage of PEG-ELS is given according to body weight: 10-15 kg, PEG-ELS 0.75 L; 15-22.5 kg, PEG-ELS 1.5 L; 22.5-30 kg, PEG-ELS 2.25 L; more than 30 kg, PEG-ELS 3 L.
89619433|NCT03363048|Experimental|Restricted|
89619434|NCT03363048|Experimental|Restriction plus Incentive|
89619435|NCT03363048|No Intervention|Control|
89619436|NCT03000868|Experimental|Cold EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare without electrocautery.
89619437|NCT03000868|Active Comparator|Hot EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare with the use of electrocautery.
89619438|NCT03000790|Experimental|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior arch will make the Ring around the tongue"
89619439|NCT03372486|Active Comparator|Bupivacaine plus naloxone|Patients will receive brachial plexus block using bupivacaine plus naloxone.
89619440|NCT03372486|Placebo Comparator|Bupivacaine|Patients will receive brachial plexus block using bupivacaine.
89619441|NCT05064670|Experimental|Exercise|The intervention group will, in addition to routine clinical care according to (inter-) national guidelines, receive an exercise program of resistance and aerobic exercise delivered live online by an upskilled exercise professional in group exercise classes twice weekly for 3 months
89619442|NCT05064670|No Intervention|Control|The control group will receive routine clinical care according to (inter-) national guidelines
89619443|NCT03372330||Sepsis with PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index < 0.9 or vascular Duplex confirmed peripheral artery disease.~* Standard care for sepsis and PAD"
89619444|NCT03372330||Sepsis without PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index >= 0.9 or vascular Duplex found no evidence of peripheral artery disease.~* Standard care for sepsis"
89619445|NCT04525482|No Intervention|Control Group|No intervention was implemented
89619446|NCT04525482|Experimental|Intervention Group|Early goal-directed sedation programs was implemented
89619447|NCT05035888|Active Comparator|Phenylephrine group|Prophylactic phenylephrine bolus simultaneous with spinal anesthesia
89619448|NCT05035888|Experimental|Norepinephrine group|Prophylactic norepinephrine bolus simultaneous with spinal anesthesia
89619449|NCT03000712|Experimental|Autologous Adipose Tissue derived MSCs|Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)
89619450|NCT03000712|No Intervention|No treatment|No treatment (after high tibial osteotomy)
89619451|NCT03372252|Experimental|Successful weaning|Patients extubated after the success of the breathing test in spontaneous ventilation under artificial nose and always extubated after seven days.
89619452|NCT03372252|Experimental|Failure to wean|Patients who failed the breathing test in spontaneous ventilation under artificial nose and not extubated or patients extubated after the success of the weaning test in spontaneous ventilation under artificial nose but reintubated within seven days.
89619453|NCT03000478|Active Comparator|Prolonged Exposure|12 sessions of PE as per protocol
89619454|NCT03000478|Experimental|VRET|12 sessions of Virtual Reality Exposure Therapy
89619455|NCT03372018|Experimental|Promotora-led intervention (PLI)|PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
89619456|NCT03372018|Active Comparator|Usual care (UC)|UC participants will receive standard educational materials in Spanish discussing mental health and diabetes prevention. UC participants will be encouraged to continue all routine medical care during the study.
89619457|NCT03004300|Active Comparator|group 1|Patients with atresic maxilla without upper airway obstruction submitted to rapid maxillary expansion
88988079|NCT05146102|No Intervention|No organized ethics communication in group|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They have not being educated in the one to five-step method and organized interprofessional sessions are not planned at the wards."
88988080|NCT05146063||Polycystic ovary syndrome patients with insulin resistance|
88988081|NCT05146063||Polycystic ovary syndrome patients without insulin resistance|
88988082|NCT00156195|Experimental|1|
89619458|NCT03004300|Experimental|group 2|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion before adenotonsillectomy
89619459|NCT03004300|Experimental|group 3|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion after adenotonsillectomy
89619460|NCT03362814|Experimental|Experimental Group|Ravidasvir + Danoprevir + Ritonavir + Ribavirin
89619461|NCT03362814|Placebo Comparator|Placebo Group|Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo
88988083|NCT00156195|Experimental|2|
88988084|NCT05145946|Experimental|Video Game Training Group 1 - High Frequency Hearing Loss|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have high frequency hearing loss.
88988085|NCT05145946|Active Comparator|Video Game Training Group 1 - Normal Hearing|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have normal hearing.
89619462|NCT05004454|Experimental|Bacillus subtilis BS50|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
89619463|NCT05004454|Placebo Comparator|Placebo|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
89619464|NCT03004222|Experimental|Local anesthetic (Bupivicaine)|The experimental arm intervention is 75 subjects will receive the study agent (20 mL of 0.5% bupivacaine) to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
89619465|NCT03004222|Placebo Comparator|Placebo 20 ml|75 subjects will be treated with normal saline/placebo to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
89619466|NCT03000634|Experimental|Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD|Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15
89619467|NCT03000634|Other|VRD-bortezomib, lenalidomide, dexamethasone|Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22
89619468|NCT02518776|Other|Neuropsychological tests|
89619469|NCT03000400|Experimental|Intervention group|Patient and family members receiving the 8 week family centered intervention, The Traumatic Brain Injury Family System Intervention.
89619470|NCT03000400|Active Comparator|Control group|Family members attend one ongoing psycho-educational group session provided by Oslo University Hospital (OUH).
89619471|NCT02520102|Experimental|sargramostim|Sargramostim is administered daily until the absolute neutrophil count (ANC) equals or exceeds 1500/mm^3 for 3 consecutive measurements or up to 42 days post-induction chemotherapy.
89619472|NCT03000556|Experimental|experience|
89619473|NCT03000556|No Intervention|control|
89619474|NCT03371940|Experimental|Talk therapy (CBT)|"Participants randomized the talk therapy arm received 10 weeks of CBT or talk therapy. The goal of CBT was to provide individuals with skills and concepts that they may use to: 1) manage and reduce depressive symptoms; 2) prevent the onset and severity of future depressive episodes; and 3) generalize these skills to diabetes management.~CBT interventionists facilitated patient management of depressive symptoms by providing participants with:~Education about depression and the cognitive-behavioral therapy model;~A safe relationship for participants to explore their symptom patterns and try to new tools to address them;~Coaching as participants fully engage emotional and behavioral strategies."
89619475|NCT03371940|Experimental|Exercise (EXER)|Participants randomized to the exercise arm were enrolled in a 12-week physical activity intervention designed to increase aerobic physical activity. Participants were asked to complete 100 minutes of aerobic activity in Week 1, 125 minutes in Week 2, and 150 minutes per week of physical activity in Weeks 3-12. In addition, participants received 6 exercise training classes in which safe exercise practices were introduced and practiced, free access to a local exercise facility, use of a pedometer, completion of activity logs each week, and received an exercise workbook that addressed social and motivational aspects of physical activity.
89619476|NCT03371940|Experimental|Talk therapy + exercise (CBT+EXER)|Participants randomized to the combination therapy received both talk therapy and exercise as detailed above.
89619477|NCT03371940|Placebo Comparator|Usual care (UC)|Participants randomized to usual care received no study intervention.
89619478|NCT03368508|Experimental|Experimental group|the real-object rotatable 3D images were used in demonstrating these three techniques. The photogrammetry technique was used to produce the 3D images.
89619479|NCT03368508|Active Comparator|Control group|The control group received similar materials, but the only difference was that all the images were two-dimensional.
89619480|NCT03000322|Experimental|Cooling Vest|During the four-week Treatment Period, participants should use the Cooling Vest two times per day (once in the morning for one hour and once in the evening for one hour.)
89619481|NCT03371862|Experimental|Test group|
88988086|NCT05145946|Sham Comparator|Video Game Training Group 2 - High Frequency Hearing Loss|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have high frequency hearing loss.
88988087|NCT05145946|Sham Comparator|Video Game Training Group 2 - Normal Hearing|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have normal hearing.
88988088|NCT02276365|Experimental|Sequence ABC|"Treatment A: 50 mg BI 10773 once daily from day 1 to 5~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7~Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out"
88988089|NCT02276365|Experimental|Sequence CAB|"Treatment C: 45 mg pioglitazone once daily from day 1 to 7~Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7"
88988090|NCT05145712|Experimental|Bowel readiness|
88988091|NCT05145673|Placebo Comparator|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) .
88988092|NCT05145673|Experimental|Cinnamon (OGTT plus aqueous cinnamon extract)|The Experimental group was given an glucose solution to oral glucose tolerance test (OGTT) followed by aqueous cinnamon extract.
88988093|NCT05145634|Experimental|Educational group|The interventions administered to the experimental group were one-on-one instruction and Health Brief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards.
88988094|NCT05145634|No Intervention|Control group|Patients in the control group only received brochure and medication cards.
88988095|NCT00143936|Active Comparator|Low Carb|Low Cabohydrate Diet: 20 week of weekly group behavior modification, 20 weekly bi-weekly, bi-monthly to finish
88988096|NCT00143936|Active Comparator|Low Calorie|Low Calorie Diet: 20 weeks of weekly behavior modification, 20 weekly of bi-weekly, bimonthly to finish 2 years
88988097|NCT05145244||Patients with newly diagnosed non-small cell lung cancer|"Approximately 1800 patients who are initiating~Standard of care, including targeted therapy based on PD-L1 status, EGFR, ALK or ROS1 (routine biomarkers)~Active clinical trials in the clinics after informed consent"
88988098|NCT05145244||Patients with metastatic breast cancer|"Approximately 600 patients who are initiating~Standard of care, including targeted therapy based on HER2 status and ER status (routine biomarkers)~Active clinical trials in the clinics after informed consent"
88988099|NCT05145205||LSG|
88988100|NCT05145205||RYGB|
88988101|NCT05145088|No Intervention|Control Group|The participants in this group are under control and not perfoming any exercise, and their life style is NOT consistent with any kind of submaximal exercise training designed as per protocol.
89619482|NCT03362580||Group A|Patients diagnosed with diabetes mellitus, type 1 or type 2, aged 15 years or older
89619483|NCT03362580||Group B|Patients non-diagnosed with diabetes mellitus, aged 15 years or older
89619484|NCT03368430|Experimental|Melatonin|10 mg melatonin capsule was given to participants in the test group once per day for only 2 months after performing scaling and root planing (SRP) during the whole 6- month period of the study.
89619485|NCT03368430|Placebo Comparator|Placebo|Matching placebo capsule was given to the control group once daily for 2 months after receiving scaling and root planing (SRP) during the whole 6- month period of the study.
89619486|NCT03371784|Active Comparator|Hydrocortisone|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to i.v hydrocortisone administration.
89619487|NCT03371784|Placebo Comparator|Placebo|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to placebo (sodium chloride 0.9%).
89619488|NCT03003832|Experimental|Intervention|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
89619489|NCT03003832|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
89619490|NCT02247934||Concept elicitation interviews (Step I)|Approximately 20 participants will be included.
89619491|NCT02247934||Cognitive interviews (Step II)|Approximately 30 participants will be included.
89619492|NCT03368352|No Intervention|Normoxia|Sleep in normal room air with no drug
89619493|NCT03368352|Placebo Comparator|Hypoxia with Placebo|Sleep in hypoxic tent after taking Placebo 1 hour before bed.
89619494|NCT03368352|Experimental|Hypoxia with Melatonin|Sleep in hypoxic tent after taking 5 mg Melatonin before bed.
89619495|NCT02248012|Experimental|Everolimus/temozolomide|Everolimus 10 mg daily, temozolomide 150 mg/m2 for 7 days every 2 weeks.
89619496|NCT03371628|Experimental|Group VNI 1h|Intervention: Non invasive ventilation, applied for 1 hour
89619497|NCT03371628|No Intervention|Group O2|Oxygen therapy
89619498|NCT03003988|Experimental|Creatine monohydrate|Creatine monohydrate (6.0 g.) + dextrose (0.5 g.)
89619499|NCT03003988|Active Comparator|Creatine nitrate|Creatine nitrate (5.0 g. creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio).
89619500|NCT03003988|Placebo Comparator|Placebo|6.5 g. dextrose
89619501|NCT03003910|Experimental|Best Possible Self|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
89619502|NCT03003910|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts occurred in the past 24 hours.
89619503|NCT03362346||Neurocritical patients|Patients with brain injury from trauma, ischemic stroke, hemorrhage stroke (intracerebral hemorrhage, subarachnoid hemorrhage), brain tumor with increased intracranial pressure, brain infection, hydrocephalus, among others.
89619504|NCT03362268|Experimental|Ilaprazole|
89619505|NCT03362268|Active Comparator|omeprazole|
89619506|NCT04901962|Experimental|JOBST® Confidence compression garments|The CE-marked class I medical devices JOBST® Confidence compression garments for lower and upper extremities will be tested under routine conditions according to their selected intended use. Subjects will be treated with either thigh-high compression stockings (AG) or arm compression garments without hand part (CG1), depending on their indication.
89619507|NCT04523844|Active Comparator|Brinzolamide-brimonidine fixed combination|One drop of the brinzolamide-brimonidine fixed combination is instilled in the eyes of patients two hours before the intravitreal injection
89619508|NCT04523844|No Intervention|No topical IOP-lowering medication|No IOP-lowering drops are instilled before the intravitreal injections
89619509|NCT02248090|Experimental|AZD9496|AZD9496 dose escalation and expansion(s)
89619510|NCT03362034|Active Comparator|single transfer tray|
89619511|NCT03362034|Experimental|double transfer trays|
89619512|NCT03003754|Experimental|High Intensity Training (HIT) + Resistance Training (RT)|"To HIT program will be use cycle ergometers adapted for children (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Each participant performed a range of 8 to 14 cycling intervals during the intervention period. The time of each work interval cycling will be increased progressively weekly, and ranged between 40-60 s (40 s weeks 1-2; 50 s weeks 3-5; 60 s week 6), with 120 s of passive rest (over the bicycle without movement) between each interval of work.~The RT will consist in voluntary concentric/eccentric exercise during 1 minute until to get a high subjective effort perception (i.e., between 8-10 points based on the modified and subjective Borg scale of 1 to 10 points. Subjects will perform 4 exercises (biceps curl, leg-extension, shoulders press, and upper row exercise) during 6-weeks."
89619513|NCT03003754|Active Comparator|Control group|We will compare within each group (G)-1, G-2, and G-3 sub-group according to both RT and HIT intervention both pre-post changes as well as if are there some anthropometric, cardiovascular, and performance variable predicting changes in homeostasis model assessment (HOMA-IR).
89619514|NCT03361878|Active Comparator|Metformin Tolerant|
89619515|NCT03361878|Active Comparator|Metformin Intolerant|
89619516|NCT02518854||study|children aged 6-18 years with pre-metabolic syndrome
89619517|NCT02518854||control|children aged 6-18 years without pre-metabolic syndrome
89619518|NCT04523532|Experimental|Group 1: Folate + hazelnut oil|Group 1 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of vegetables rich in folate - 191µg and additionally received 01 capsule containing 25 mg hazelnut oil per day.
89619519|NCT04523532|Placebo Comparator|Group 2: Folate|Group 2 = in this group, the individuals received, during the period of 08 weeks daily, daily dietary intervention with, 300 g of folate-rich vegetables - 191 µg and 01 placebo capsule.
89619520|NCT04523532|Experimental|Group 3: Moderate folate + hazelnut oil|Group 3 = in this group, individuals received, during the period of 08 weeks daily, with 300 g of vegetables containing 94 µg of folate and 01 capsule containing 25 mg of hazelnut oil per day.
89619521|NCT04523532|No Intervention|Group 4: Control|Group 4 = in this group, individuals received weekly visits during the 08 week period to maintain their eating habits.
89619522|NCT02995642|Experimental|18F-FPPRGD2|Subjects (with either carotid atherosclerosis stenosis or AAA) will receive a single intravenous injection of 10mCi of 18F-FPPRGD2 and will undergo positron emission tomography/computed tomography (PET/CT) or PET/MRI (PET/magnetic resonance imaging) imaging 45-60 minutes after injection.
89619523|NCT02518932|Experimental|Drug GLP-1 (32-36) Amide|To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp
89619524|NCT02518932|Placebo Comparator|Placebo|To examine the effect of saline on glucose uptake
89619525|NCT02998606|Experimental|Study Group|MOVANTIK™ (Naloxegol) 25 mg oral capsule, daily
89619526|NCT02998606|Placebo Comparator|Control Group|Placebo Oral Capsule 25 mg, daily
89619527|NCT04636528|Experimental|Digital Rehabilitation|Home-based 8-week rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist
89619528|NCT04636528|Active Comparator|Conventional Rehabilitation|Outpatient clinic-based 8 week rehabilitation program with face-to-face PT sessions
89619529|NCT05365438|Experimental|Atmeg with Omethyl Cutielet|Atmeg: 2 capsules daily (1 capsule containes atorvastatin 10 mg and Omega-3 1000 mg) Omethyl Cutielet: Omega-3 2000mg (920mg as EPA ethyl ester, 760mg as DHA ethyl ester) once daily
89619530|NCT05365438|Active Comparator|Atmeg|Atmeg: 2 capsules daily (1 capsule containes atorvastatin 10 mg and Omega-3 1000 mg)
89619531|NCT05365438|Active Comparator|ezetimibe/atorvastatin 10/20|1 tablet once daily (atorvastatin 20mg with ezetimibe 10mg)
89619532|NCT05290558|Placebo Comparator|Placebo|Patients in this arm will be given a placebo pill that resembles the actual Bu Shen Yi Jing Pill.
89619533|NCT05290558|Active Comparator|Bu Shen Yi Jing Pill|Patients in this arm will be given the BSYJ Pill.
89619534|NCT02997670|Experimental|Main patient cohort|Algorithmic Cardiac Resynchronisation Therapy Optimisation; Patients requiring CRT-D enrolled to receive algorithmic CRT optimisation at their device implantation. They will then be programmed to standard CRT settings for 12 weeks. Assessments will be performed and they will again undergo CRT optimisation using the specified algorithm. This time, they will be programmed to the settings giving maximal cardiac output on echocardiography, as assessed by LVOT VTI. After a further 12 weeks, they will again undergo assessment and the study will terminate.
89619535|NCT05132998|Experimental|Cardiac Rehabilitation Program (CRP) Group|"Baseline consultation with physiatrist specialized in CRP - addressing CVRF control, comorbidities and disabilities; case-by-case discussion with a cardiologist specialized in CR will be undertaken, for tailoring exercise prescription. Nutritional individualized plan addressing dietary goals. Psychological management addressing psychosocial outcomes and motivation for healthy lifestyle habits~Multidisciplinary team educational meeting: periodic group sessions with health education purposes~Exercise intervention - 2 times/week sessions at CR facilities, supervised by a physiatrist, conducted by physiotherapist. Heart rate (HR) continuously monitored during each session by remote electrocardiographic monitoring or HR monitor. Exercise intensity estimated according to CR guidelines, determined after CV risk stratification, using CPET results."
89619536|NCT05132998|Active Comparator|Community Exercise Group|"a) Besides standard medical and supportive care, psychological and nutritional individual support will be offered on demand, in hospital setting, according to the attending physician standard clinical assessment and usual care.~Exercise intervention - Performed at a community-based facility, comprising 2 sessions/week, prescribed according to current physical activity guidelines for cancer survivors. Exercise intervention will be conducted by an exercise physiologist, internationally certified in exercise for cancer patients"
89619537|NCT05672914|Experimental|Tablet-based Sustained Care|Intervention to support sustained smoking cessation.
89619538|NCT05672914|No Intervention|Usual Care|Standard hospital care: : A brief (5-10 min.) tobacco education session from a hospital nurse, along with educational materials about quitting and a quitline brochure.
89619539|NCT03003364|Experimental|XCEL-UMC-BETA/placebo|Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)
89619540|NCT03003364|Placebo Comparator|Placebo/XCEL-UMC-BETA|Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)
89619541|NCT03003598|Active Comparator|Videolaryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
89619542|NCT03003598|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
89619543|NCT02981056|Active Comparator|Wash + Lotion regimen|"Johnson's Baby Top-To-Toe Wash (Ideally 7 times a week, at least 5 times a week) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
89619544|NCT02981056|Active Comparator|Water + Lotion regimen|"Water (in lieu of bathing products) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
89619545|NCT02981056|Active Comparator|Water only|Water (in lieu of bathing products) only. The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso.
89619546|NCT03003286|Experimental|UOT Students and Parents|Unstuck and on Target (UOT) provided in the classroom for students at Title 1 schools
89619547|NCT03003286|Experimental|PATSS Students and Parents|Parents and Teachers Supporting Students (PATSS) provided in the classroom for students at Title 1 schools
89619548|NCT03003442|Experimental|Supradyn® Energy 3RDA|Supradyn® Energy 3RDA, 1 multivitamin/mineral tablet administered by mouth daily for 28 days
89619549|NCT03003442|Placebo Comparator|Placebo|Placebo, 1 tablet administered by mouth daily for 28 days
89619550|NCT03003208|Other|Pulmonary rehabilitation|
89619551|NCT03002896|Experimental|Pep-Pal + Treatment as Usual|If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.
89619552|NCT03002896|Active Comparator|Treatment as Usual|Treatment as usual provides voluntary (at the caregiver's discretion) support services for the caregivers which is rarely used by the caregivers.
89619553|NCT02248168||Idiopathic Parkinson's disease patients|
89619554|NCT03002740||NVAF patients newly prescribed apixaban|
89619555|NCT03002740||NVAF patients newly prescribed rivaroxaban|
89619556|NCT03002740||NVAF patients newly prescribed dabigatran|
89619557|NCT03002740||NVAF patients newly prescribed VKA|
89619558|NCT02248402|Experimental|Vax-DC/MM|
89619559|NCT05672446|Experimental|Experimental|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients.
89619560|NCT05672446|No Intervention|Control|No attempt was made to the students in the control group.
89619561|NCT05672290|Experimental|Group 1|Group 1 will be applied external electric stimulation three days per week
89619562|NCT05672290|Active Comparator|Group 2|Group 2 will be applied external electric stimulation one day per week
89619563|NCT02997124|Experimental|Local Infiltration with TAP block|Ultrasound guided Transversus Abdominis Plane block is administered intraoperatively using 0.2% Ropivacaine.
89619564|NCT02997124|Experimental|Local Infiltration only|Local Infiltration with 0.2% Ropivacaine.
89619565|NCT03002428|Experimental|Teriparatide (PF708)|PF708 20 mcg once-daily subcutaneous injection for 24 weeks
89619566|NCT03002428|Active Comparator|Teriparatide (Forteo)|Forteo 20 mcg once-daily subcutaneous injection for 24 weeks
89619567|NCT03002584||IBS & general population|"The participants will be given the IGQ questionnaire to complete as well as other self-reported questionnaires.~Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale."
89619568|NCT03002662||BMI <18.5 underweight (Group 1)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMI <18.5 underweight (Group 1)
89619569|NCT03002662||BMİ: 18.5 - 24.9 normal weight (Group 2)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 18.5 - 24.9 normal weight (Group 2)
89619570|NCT03002662||BMİ: 25- 29.9 overweight (Group 3)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 25- 29.9 overweight (Group 3)
89619571|NCT03002662||BMİ>30 obese (Group 4)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ>30 obese (Group 4)
89619572|NCT02224612|Active Comparator|Children 4-5 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
88988102|NCT05145088|Experimental|Experimental group|"the particpants are made to perform submaximal exercise testing according to ACSM guidelines for 03 weeks.~For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate.~The data will be calculated at two times in the form of pre and post testing."
88988103|NCT00506701|Experimental|Tadalafil treatment 40 mg|
88988104|NCT05147857|Active Comparator|Mesotac in mid trimester|Prostaglandin
88988105|NCT05147857|Active Comparator|Dilapan s in mid trimester|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
88988106|NCT05147740|Experimental|B/F/TAF|B/F/TAF for 48 weeks
88988107|NCT05147623||Principal cohort|All patients recruited in one week who underwent to any surgical procedure that meet inclusion criteria of the study.
89619573|NCT02224612|Active Comparator|Children 6-9 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
89619574|NCT02224612|Active Comparator|Children 10-12 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
88988108|NCT05147194|No Intervention|Control group|Blank group
88988109|NCT05147194|Experimental|Trimetazidine group|The participates received treatments of trimetazidine
88988110|NCT05147155||Severe asthma patients|The sample will consist of 40 patients between 18 and 82 years of age with uncontrolled severe eosinophilic asthma despite receiving high dose ICS/LABA combination therapy who will receive mepolizumab, which will be administered as a 100-mg subcutaneous dose every four weeks
88988111|NCT05147155||Control group 1|Control group 1 will be a set of 50 healthy individuals matched for age and gender
88988112|NCT05147155||Control group 2|Control group 2 will be a set of 40 patients with severe well-controlled asthma requiring high dose ICS/LABA combination therapy from becoming uncontrolled, as previously defined, matched for age and gender.
88988113|NCT04696276|Experimental|A-ERAS|will receive ERAS pathways care
88988114|NCT04696276|No Intervention|B-nonERAS|will receive traditional non ERAS care
89619575|NCT02225080||Duragen Secure|Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
89619576|NCT02225860|Active Comparator|Diet and Water adjustment|Reduction in dietary salt and protein intake
89619577|NCT02225860|No Intervention|Control|Continue with usual diet
89619578|NCT01377012|Experimental|AIN457 10mg/kg-75mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
89619579|NCT01377012|Experimental|AIN457 10mg/kg-150mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
89619580|NCT01377012|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24
89619581|NCT05672056|Experimental|Intervention|The intervention will be modifying stock reconstruction plates to mimic patient specific plates in mandibular reconstruction with free fibula flaps
89619582|NCT03371550|Experimental|Radiochemotherapy|Induction chemotherapy with docetaxel and cisplatine and concomitant radiotherapy
89619583|NCT05671744|Other|Blood samples from pregnant women|Samples of peripheral blood collected from pregnant women undergoing CVS or genetic amniocentesis
89619584|NCT03371472|Other|VALE - PVL leak sizing balloon - mitral|Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in mitral position - Balton developed investigational balloon
89619585|NCT03371472|Other|VALE - PVL leak sizing balloon - aortic|'Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in aortic position - Balton developed investigational balloon
89619586|NCT03371394||median 1|
89619587|NCT03371394||median 2|
89619588|NCT02324920|Experimental|DDD+CLS|The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
89619589|NCT02324920|Placebo Comparator|ODO|The pacemaker will be programmed in ODO mode.
89619590|NCT03371316|Experimental|Hemicraniectomy Surgery with Viashield|All patients requiring a hemicraniectomy surgery will receive the anti-adhesion barrier of amnion patch.
89619591|NCT03371238|Experimental|Floorball|
89619592|NCT03371238|No Intervention|Control|
89619593|NCT05671666|Other|Healthy controls|
89619594|NCT04527120|Other|Model A first and then B|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
89619595|NCT04527120|Other|Model B first and then A|Model A and B would be randomly allotted to commercial model and IDUP. Intervention limb would involve performing on sequentially on the commercial and IDUP, following which a feed back of the candidates would be recorded about their performance on the same with respect to sonological appearance, tactile feedback, artefacts and ease of performing the procedure. Set time points (time to needle tip visualisation, time to puncture) and no of attempts before successful cannulation would be recorded by an assessor on a pre set proforma.
89619596|NCT05670028|Experimental|CA-guided BP|The upper and lower limits of autoregulation determined by ICM+ software are used to guide the range of blood pressure control, but no more than 40% above or below the usual BP. From when the upper or lower limit of autoregulation appeared in ICM+ software to 48h after revascularization, the total time of actual BP beyond the CA range will be no more than two hours through drug intervention.
89619597|NCT05670028|Active Comparator|Fixed target BP|After randomization to 48h after endovascular therapy, the target of BP was determined by clinicians according to current guidelines, i.e. <180/105mmHg.
89619598|NCT03004378|No Intervention|Control|Participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
89619599|NCT03004378|Experimental|Intervention|Fitbit (activity tracker) + participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
89619600|NCT03123900|Experimental|Physical exercise (n= 40)|Walking program up to 45 minutes, 5 times a week for 3 months.
89619601|NCT03123900|Experimental|Cognitive training (n=40)|Computerized cognitive training up to 45 minutes, 5 times a week for 3 months.
89619602|NCT03123900|Experimental|Combined training (n=40)|Exercise and cognitive training up to 90 minutes, 5 times a week for 3 months.
89619603|NCT03123900|No Intervention|Control group (n=20)|Waiting list group.They receive no intervention during this waiting period. At the end of this period our training programs are available to them.
89619604|NCT05669872|Experimental|patient blood management group|"before surgery (within 2-6 weeks before surgery)~- 7 ≤ Hb < 12 g/dL : ferric carboxymaltose 1000mg~during surgery~- In case of hemodynamically unstable, transfusion according to the judgment of the operating surgeon and anesthesiologist~after surgery (POD #1)~7 ≤ Hb < 12 g/dL : ferric carboxymaltose 1000mg~Hb <7 g/dL : pRBC 2 packs transfusion"
89619605|NCT05669872|Active Comparator|conventional management group|"before surgery (within 2-6 weeks before surgery)~8 ≤ Hb < 10 g/dL: pRBC 1 pack transfusion~Hb < 8 g/dL: pRBC 2 packs transfusion * Use of oral iron supplements, EPO, in control patients is permitted. (no IV iron supplements)~during surgery~- In case of hemodynamically unstable, transfusion according to the judgment of the operating surgeon and anesthesiologist~after surgery (POD #1)~8 ≤ Hb < 10 g/dL: pRBC 1 pack transfusion~Hb < 8 g/dL: pRBC 2 packs transfusion * Use of oral iron supplements, EPO, in control patients is permitted. (no IV iron supplements)"
89619606|NCT04861948|Experimental|Cohort A|
89619607|NCT04861948|Experimental|Cohort B|
89619608|NCT04861948|Experimental|Cohort C|
89619609|NCT04861948|Experimental|Cohort D|
89619610|NCT04526496|Experimental|Single Ascending Doses|50mg-600mg
89619611|NCT04526496|Experimental|Multiple Ascending Doses|dose to be determined
89619612|NCT04856956|Experimental|Intervention (Use of diagnostic decision support software)|Trainee or nurse practitioner sees patient and uses diagnostic decision support software in developing their differential diagnosis and plan
89619613|NCT04856956|No Intervention|Control (Current process)|Trainee or nurse practitioner sees patient but doesn't use diagnostic decision support software in developing their differential diagnosis and plan
89619614|NCT04526262|Experimental|BBB disruption|All participant in this arm will undergo 2 sessions of transcranial magnetic resonance guided focused ultrasound blood brain barrier disruption every 3 months.
89619615|NCT04526028||Palbociclib combined with Fulvestrant|
89619616|NCT04526028||Fulvestrant|
89619617|NCT04812184|Experimental|Surgical Tape to bridge of nose|placed a piece of tape to the bridge of the nose, adhering a face mask to the patient's face
89619618|NCT04812184|No Intervention|Standard of care|Patients given a mask with no intervention to the mask
89619619|NCT02518698||Cohort 1 / Treatment patterns|Patients with castrated resistant prostate cancer and bone metastases
89619620|NCT04143490|Experimental|UC Patients|Patient group
89619621|NCT04143490|Active Comparator|Healthy controls|Control group
89619622|NCT03368274|Experimental|Signal arm study|Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.
89619623|NCT03361644|Experimental|High-Intensity Interval Training|Brief periods of vigorous physical activity separated by short periods of rest.
89619624|NCT03361644|Active Comparator|Moderate-Intensity Continuous Training|Physical activity at a sustained moderate heart rate.
89619625|NCT04765462|Experimental|Allogeneic γδ T cell Group|Enrolled patients will be administered allogeneic γδ T cells with or without the combinations of traditional therapies, including chemotherapy, targeted therapy, radiotherapy, immune checkpoint inhibitors and others.
89619626|NCT03361566|Experimental|low energy flux at ad libitum energy intake|physical activity: inactive energy intake: ad libitum
89619627|NCT03361566|Experimental|medium energy flux at ad libitum energy intake|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: ad libitum
89619628|NCT03361566|Experimental|high energy flux at ad libitum energy intake|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: ad libitum
89619629|NCT03361566|Experimental|Low energy flux at energy balance|physical activity: inactive energy intake: individual energy balance
89619630|NCT03361566|Experimental|medium energy flux at energy balance|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: individual energy balance
89619631|NCT03361566|Experimental|high energy flux at energy balance|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: individual energy balance
89619632|NCT03361566|Experimental|low energy flux at caloric restriction|physical activity: inactive energy intake: caloric restriction -25%
89619633|NCT03361566|Experimental|medium energy flux at caloric restriction|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
89619634|NCT03361566|Experimental|high energy flux at caloric restriction|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
89619635|NCT03361566|Experimental|low energy flux at overfeeding|physical activity: inactive energy intake: overfeeding +25%
89619636|NCT03361566|Experimental|medium energy flux at overfeeding|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: overfeeding +25%
89619637|NCT03361566|Experimental|high energy flux at overfeeding|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: overfeeding +25%
89619638|NCT04666558|No Intervention|Standard Care|The standard of care response to COVID. Educational materials will be provided to patients via email. The package will include a combination of personalized exercises, and nutrition information for healthy eating. Participants will also receive a Garmin watch to track their activity over the intervention.
89619639|NCT04666558|Experimental|App-Based, Personnel-Light Care|"An app-based, personnel-light approach to virtual care with a focus on support through group-based interactions with the Trainers, Dietitians and other participants. The patient's personalized 12-week home based exercise program will be enabled in the app after a baseline exercise specialist appointment. The 10-week nutrition program will be enabled at week 3 after a virtual dietitian assessment in week 2 (~1 hour). The home programs will auto-progress. Participants will also receive a Garmin watch to track their activity over the intervention."
89619640|NCT04666558|Experimental|App-Based, Personnel-Intensive Care|"An app-based, personnel-intensive approach to virtual care with support through a combination of group-based interactions with Trainers, Dietitians and other participants, as well as one-on-one support with Exercise Trainers and Dietitians. In addition to Group 2 features, patient interaction with Trainers will be via live group classes AND 1-to-1 sessions: up to seven 1-to-1 consultations with an exercise specialist and three 1-to-1 consultations with a dietitian to review progress and goals and make any necessary modifications to programming. Participants will also receive a Garmin watch to track their activity over the intervention."
89619641|NCT03361488|Experimental|Trained anesthesiologist|Patient interview by anesthesiologists having obtained training to optimize structured communication
89619642|NCT03361488|No Intervention|Control anesthesiologist|Patient interview by control anesthesiologists
89619643|NCT02247544|Experimental|Trabectedin|"Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1).~Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response."
88988115|NCT05149924|Experimental|QL1012，Recombinant Human Follicle Stimulating Hormone for Injection|
88988116|NCT05149924|Active Comparator|Gonal-f ®|
89619644|NCT03370848|Experimental|Psyllium plus Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER~Psyllium 1.7gm wafers - take 2 wafers (3.4 grams total) along with aspirin 30 minutes prior to niacin ER"
88988118|NCT05149729|Experimental|Crowe type 3 and 4 patients undergoing shortened hip replacement|Clinical and radiological results of Crowe type 3 and 4 patients who underwent shortened hip prosthesis at 12 and 24 months
88988119|NCT05149612|Experimental|Heat Therapy Group|The patients in the intervention group will be treated with hot water bags twice, for 20 minutes in the morning and 20 minutes in the evening, to the shoulder area, starting four hours after the operation, until the patient is discharged.
89619645|NCT03370848|Active Comparator|Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER"
89619646|NCT03367884|Experimental|Neck dissection group|Neck dissection followed by radiotherapy(50Gy) according to risk factors
89619647|NCT03367884|Active Comparator|Radiotherapy group|Definitive radiotherapy (70Gy)
89619648|NCT03123432|Experimental|immunomodulating nutrients enriched diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, enteral nutrition (EN) was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the interventional diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
89619649|NCT03123432|Active Comparator|standard diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
89619650|NCT02248792|Experimental|Group A|Methotrexate 10mg orally once weekly
89619651|NCT02248792|Active Comparator|Group B|Methotrexate 25mg orally once weekly
89619652|NCT03367728|Placebo Comparator|TAP and Rectus Sheath Normal Saline|TAP and Rectus Sheath Block of 60 mL Normal Saline divided into 4 injections administered as in Experimental Arm.
89619653|NCT03367728|Experimental|TAP and Rectus Sheath ropivacaine|The block will be administered in the anterior abdominal wall. For the TAP block, the standard technique will be followed- at the anterior axillary line midway between the subcostal margin and iliac crest. For the rectus sheath block, a bilateral sub-xiphoid approach will be used. There will be 4 injection sites in total and the size of the needle will be standardized to an 18g spinal needle 10cms. Using laparoscopic visualization, the transversus abdominis muscles were identified lateral to the semilunar line. Ropivacaine to be infiltrated will be divided into 4 equal amounts. The procedure is then repeated 2 times in the transversus abdominis plane (20mL each) and 2 times as a Rectus Sheath Block (10mL each) with a total amount of 60 mL.
89619654|NCT03361332||Healthy subjects|
89619655|NCT03361332||Patients with Gilles de la Tourette Syndrome|
89619656|NCT02519634|Other|Group 1|Patients in Group 1 undergo Super-Mini Percutaneous Nephrolithotomy
89619657|NCT02519634|Other|Group 2|Patients in Group 2 undergo Retrograde Intrarenal Surgery
89619658|NCT02248870|Placebo Comparator|Saline|Bupivacaine with adrenaline with 2 ml. of Saline added
89619659|NCT02248870|Experimental|Dexamethasone|Bupivacaine with adrenaline with 2 ml. of Dexamethasone added
89619660|NCT03367650|Other|ALS's patients in Guadeloupe and Martinique|"We shall determine:~Impact of ALS in Guadeloupe and Martinique~Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study~The distribution of ALS various phenotypes in our population of patients.~We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.~Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease~Search for possible environmental factors"
89619661|NCT02993380|Experimental|Stir-fried olive oil group|olive oil in heated under 150 degrees
89619662|NCT02993380|Experimental|Natural olive oil group|olive oil in without heated
89619663|NCT04073056|Active Comparator|Quadratus Lumborum II Group|The QL 2 group will receive 15 mL bupivacaine 0.25% on both sides for a total of 30 mL once the surgery is done but prior to extubation under ultrasound guidance.
89619664|NCT04073056|Active Comparator|Conventional Therapy|Conventional therapy consists of the injection of 30 mL of bupivacaine 0.25% directly into the incision sites by the surgeon at the end of the procedure.
89619665|NCT03361098|Experimental|SGLT2 inhibitor + GLP-1 receptor agonist|dapagliflozin 10 mg tablet /day and exenatide twice daily subcutaneous injection (week 1-4; 5 microgram, week 5 -16; 10 microgram)
89619666|NCT03361098|Active Comparator|GLP-1 receptor agonist (exenatide) and placebo|GLP-1 receptor agonist exenatide twice daily in combination with placebo dapagliflozin
89619667|NCT03361098|Active Comparator|SGLT2 inhibitor (dapagliflozin) and placebo|SGLT2 inhibitor dapagliflozin 10 mg tablet /day in combination with placebo GLP-1 receptor agonist exenatide twice daily
89619668|NCT03361098|Placebo Comparator|double placebo|placebo dapagliflozin and placebo exenatide twice daily
89619669|NCT03367494|Other|Subjects with Cystic Fibrosis|Diagnostic
89619670|NCT03367494|Other|Healthy Volunteers|Diagnostic
89619671|NCT03370458|Experimental|Lactobacillus plantarum DR7|"Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks.~Intervention: Dietary Supplement: Lactobacillus plantarum DR7"
89619672|NCT03370458|Placebo Comparator|Placebo|"Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.~Intervention: Dietary Supplement: Placebo"
89619673|NCT02519478|Experimental|Helmetless Tackling Training (HuTT)|The HuTT program is modeled after a tackling drill progression common to the sports of rugby and American football, but participants do not wear helmets or should pads as they normally would in football. Drills will be executed at 50%-75% effort. The goal of the contact is to execute proper technique. Drills will be supervised at all times and feedback will be provided to confirm proper technique and correct improper technique. The HuTT drill will be completed in two phases and takes approximately 6-10 minutes per session. A research assistant will ensure adherence and standardization of the treatment throughout the season. Subjects in the intervention group will participate in HuTT 4 times per week throughout the 2 weeks of pre-season and 2 times a week during in-season.
89619674|NCT02519478|No Intervention|Control|Control group subjects participate in normal football activities as they would normally have during a football season
89619675|NCT05594290|Experimental|Preoperative arm|"Patients will be treated with one cycle of chemo-immunotherapy with retifanlimab (500 mg day 1), cisplatin (25 mg/sqm i.v. day 1, 2 ) or carboplatin (AUC 4 i.v., day 1 - in patients unsuited or unfit for cisplatin) and etoposide (100 mg/sqm iv. day 1, 2, 3).~After receiving the short-course preoperative chemo-immunotherapy study regimen, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant radiation therapy if indicated"
89619676|NCT03360864|Experimental|Therapeutic Education Program|"Patient randomized in this arm will attend a 1 day long validated Therapeutic Education Program.~This program will take place within 6 months after biologic treatment initiation."
89619677|NCT03360864|No Intervention|No therapeutic Education Program|Patient randomized in this arm will not attend a Therapeutic Education Program within 12 months after biologic treatment initiation.
89619678|NCT03367416||Intervention|This study will test the NIATx model, an evidence-based behavioral intervention for implementing organizational change and quality improvement in community based health settings with a high proportion of underserved individuals. The goal of the study will be to use the model to identify and implement organizational changes in dental practices that will improve the no-show rate in underserved populations.
89619679|NCT04525170|Experimental|HPT treated|daily wear Hexafocon A rigid contact lens treated with Hydra PEG surface coating
89619680|NCT04525170|Experimental|untreated|daily wear Hexafocon A rigid contact lens
89619681|NCT03360786|Experimental|Specific Protocol|The intervention group will work with the study physiotherapist and perform a 10-20 minute progressive exercises twice per week. The intervention will include a series of exercises including dynamic balance, adaptation, cervical spine strength, cervical spine neuromotor control and divided attention exercises. Exercises will begin at a lower level and progress to increasingly difficult levels of each exercise type over the course of the intervention. Concussion education and injury identification will also be completed.
89619682|NCT03360786|Active Comparator|Control Protocol|The control group will continue with their standard warm up and practice schedule but have the addition of contact time with the study physiotherapist for education regarding concussion education and injury identification.
89619683|NCT03367338|Active Comparator|Group A|Participants in group A consumed a 2-day very low-phosphate diet with PPR of 8 mg/g, followed by a 5-day washout period in which they adhered to usual diets, and then consumed a 2-day low-phosphate diet with PPR of 10 mg/g.
89619684|NCT03367338|Active Comparator|Group B|Compared with group A, the opposite order of low-phosphate diets will be prescribed in group B.
89619685|NCT04523610|Experimental|Program Users - Quantitative|The Telehealth Intervention Program (TIP-OA) for older adults was created during the COVID-19 pandemic to support the health of older adults who are isolated or have mental health/cognitive issues. Within the TIP-OA program, trained volunteers provide friendly phone calls once a week to older adults (age 60+). 200 participants will be recruited for the quantitative component of the study.
89619686|NCT04523610|Other|Program Users - Qualitative|Interviews will be conducted with 25 participants regarding their perceptions and experiences in the TIP-OA program.
89619687|NCT04523610|Other|Volunteers - Qualitative|15 volunteers taking part in the semi-structured interviews and 16 volunteers participating in the focus groups. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
89619688|NCT04523610|Other|Stakeholders - Qualitative|18 stakeholders (clinicians, community partners, TIP-OA team members) will participate in focus groups and interviews. Specifically, 10 clinicians will participate in one focus group and 8 community partners/team members will participate in interviews. The interviews and focus groups will evaluate their roles, experiences, and challenges volunteering with the TIP-OA program.
89619689|NCT02995174|Experimental|Intervention (dichoptic video game play)|Mild amblyopic subjects will be asked to play dichoptic video game in an i-Pod touch device for 1 hour per day in 6 weeks.
89619690|NCT02995174|Placebo Comparator|Control (video game play)|Mild amblyopic subjects will be asked to play video game in an i-Pod touch device for 1 hour per day in 6 weeks.
89619691|NCT03965104|Experimental|Intervention pharmacists|Will receive the HC-PCP prior to starting enrollment, and then will provide care to their patients, which will include risk assessment, prescribing of antihypertensive medications, and follow-up monthly according to the Hypertension Canada Guidelines.
89619692|NCT03965104|No Intervention|Control pharmacists|Will provide usual pharmacist care. All patients with blood pressure above target will be entered into the study database and serve as the control group. No specific interventions or follow-up will be mandated other than usual pharmacist care, although all patients will be assessed at 3 months to determine change in BP since enrollment (the primary outcome).
89619693|NCT03358446||A group|"Based on the presence of non-overlapping range between femoral artery and vein from the initial observation, the patients were divided into following two groups.~A group is the patients with non-overlapping range"
89619694|NCT03358446||S group|S group is the patients without non-overlapping range
89619695|NCT03360552|Experimental|the multidimensional score of fragility (RAI CA)|A general practitioner (MG) management strategy guided by a multidimensional evaluation (RAI-CA) on the multidimensional score of fragility (RAI-HC) of patients with mild to moderately severe dementia.
89619696|NCT03360552|Placebo Comparator|Usual care|support for patients without multidimensional evaluation (RAI-CA)
89619697|NCT04525248|Active Comparator|High resection|Laparoscopic total colectomy + High resection of rectum
89619698|NCT04525248|Experimental|Low resection|Laparoscopic total colectomy + Low resection of rectum
89619699|NCT03367182||Weekly paclitaxel + bevacizumab|
89619700|NCT03367182||Topotecan + bevacizumab|
89619701|NCT03367182||Pegylated liposomal doxorubicin + bevacizumab|
89619702|NCT03360474|Experimental|Intervention|Patients will be placed on the delirium screening intervention protocol arm. They will be screened for delirium twice per day. If positive, they will follow the treatment algorithm and assessed at 4 hour intervals until they reach 4 negative screens. Once 4 negative screens have been reached, they will be assessed twice daily.
89619703|NCT05561764|Experimental|Imipenem/cilastatin/relebactam|Adult participants will receive intravenous imipenem/cilastatin/relebactam at a dosing regimen consistent with the current prescribing information and according to estimated renal function. Adolescent participants will receive intravenous imipenem/cilastatin/relebactam at a dosing regimen consistent with Phase I data [37.5 (15/15/7.5) mg/kg, up to a maximum dose of 1.25g]. Each dose will be infused over 30 minutes.
89619704|NCT03358212||denosumab used postoperatively|the postoperative denosumab group, including patients receiving denosumab after piecemeal intralesional curettage aided by digital subtraction angiography(DSA) and balloon occlusion of abdominal aorta;
89619705|NCT04521816|Experimental|Intervention--PACT Intensive Management|"The intervention is the PACT Intensive Management Program (PIM) provides a standardized menu of services, ranging from chart review assessment or in-home assessment, to a time limited intensive care management intervention. The following PIM features are standardized across the PIM demonstration sites:~A) Chart review assessment template in the EMR; B) Comprehensive assessment template of unmet needs and modifiable risk factors in EMR; C) Transitions in care process (eligibility criteria, clinical protocols); D) Diagnostic home visits process (eligibility criteria, clinical protocols); E) Core risk stratification/Triage process; F) Discharge criteria and note template in EMR; G) Standardized interdisciplinary team (IDT) meeting note procedure and template in EMR."
89619706|NCT04521816|No Intervention|Usual care|High-Risk patients receiving care in PACT.
89619707|NCT03358134|Experimental|Secukinumab|All patients will be treated with active treatment. (anti-IL17)
89619708|NCT03360318|Active Comparator|Elbow cast|Device: Elbow cast
89619709|NCT03360318|Experimental|Removable elbow brace|Device: Removable elbow brace
89619710|NCT03360240||Cases|Cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
89619711|NCT03360240||controls|Are patients with pregnancy that starts before the age of 19 that without develops (preeclampsia mild), severe preeclampsia, gestational hypertension or eclampsia) that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
89619712|NCT03124134|Experimental|A) Gelesis200, 50 g carbs|4.20 g of Gelesis200 before a 50 g carbohydrate breakfast
89619713|NCT03124134|Experimental|B) Gelesis200, 100 g carbs|4.20 g of Gelesis200 before a 100 g carbohydrate breakfast
89619714|NCT03124134|Placebo Comparator|C) Water, 50 g carbs|300 mL water before a 50 g carbohydrate breakfast
89619715|NCT03124134|Placebo Comparator|D) Water, 100 g carbs|300 mL water before a 100 g carbohydrate breakfast
89619716|NCT03124134|Experimental|E) Gelesis200, TBD carbs|up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
89619717|NCT03124134|Placebo Comparator|F) Water, TBD carbs|300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
89619718|NCT04256980|Experimental|Pemigatinib in patients with advanced/metastatic or surgically|Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma
89619719|NCT04222270|Experimental|Intervention|Caregiver peer support from Champion caregivers (Peer mentors) to caregivers of unsuppressed children living with HIV (CLHIV) on child care and medication adherence strategies to enhance achievement of viral suppression: Champion Caregivers (Peer Mentors) will be assigned to the intervention arm and will be trained to support 10-15 caregivers for 18 months post enrollment. Champion Caregivers (CCs) be trained using an adapted Mentor-Mother Peer Support curriculum and topics will include pediatric treatment gaps, ARV formulations/dosing, adherence counseling, and virological failure/suppression. Champion caregivers will conduct monthly-to-quarterly 30 min to 1 hr clinic-aligned caregiver group training sessions and home visits at least once quarterly, targeting Child living with HIV (CLHIV) adherence, age-appropriate disclosure, and keeping clinic appointments. The intervention arm will in addition to peer support intervention, receive routine standard of care at the health facility.
89619720|NCT04222270|No Intervention|Control|Unsuppressed Children living with HIV and their caregivers recruited in the control arm will receive no champion caregiver peer support intervention but will continue to receive the standard of care at their health facilities which include routine care, including age-appropriate antiretroviral therapy and clinic appointments (typically every 2-3 months). Routine, albeit brief (5-10 min) adherence counselling is provided to CLHIV/caregivers by trained healthcare workers (HCWs) at every visit. In Nigeria, routine VL is done at 6 months post-ART initiation and repeated 12 months post- initiation 20. VL is done yearly thereafter for suppressed clients. Those unsuppressed receive 3-months' enhanced adherence counselling (EAC) (15-30 min) by Healthcare workers, with intensified appointment schedules and repeat VL upon EAC completion. This rigorous intervention continues until viral suppression is achieved or ART is switched; drug resistance testing (DRT) is not routine.
89619721|NCT04522128|Active Comparator|Feedback Intervention|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.~Participants randomly allocated to the feedback intervention will then be provided with graphs showing WHOQOL COMBI facet scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important."
89210927|NCT00822458|Experimental|Arm I|"Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1 and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue samples are collected and analyzed for the expression of genes that activate the SHH (e.g., Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in situ hybridization and reverse transcriptase real time-PCR."
88988120|NCT05149612|No Intervention|Control group|When the individuals in the control group have pain, analgesic drug treatment will be applied at the request of the physician, and no other intervention will be applied.
89210928|NCT00223795|Active Comparator|Single point cane|People with knee osteoarthritis underwent gait analysis with a cane
89210929|NCT00223795|No Intervention|No cane|Patients with knee osteoarthritis undergo gait analysis without a cane
89619722|NCT04522128|Experimental|Extended Intervention|"All participants will complete an online questionnaire (as described above).~Participants randomly allocated to the extended intervention will then be provided with graphs to highlight differences between their actual WHOQoL COMBI scores and their perceived importance ratings. The graphs will highlight where quality of life might be poor but important to the participant. Participants will be asked three questions (i.e. how could your QoL in this domain be improved, what resources would you need to make this change, what practical actions are needed to address the discrepancies in your QoL?) to help them plan how they might be able to improve quality of life currently rated as poor but important.~Participants will then receive an online intervention that will provide them with behaviour change techniques to help them address the discrepancies in the relevant quality of life domains."
89619723|NCT04522128|Other|Waitlist Control|"All participants will complete an online questionnaire. This will include demographic information, social distancing/isolation history, The Lubben Social Network Scale, The 6-item Loneliness Scale, Ten-Item Personality Scale, Spontaneous Self-affirmation Scale, Brief Illness Perception Questionnaire and the WHOQoL COMBI plus importance of QOL facet questions.~Participants randomly allocated to the waitlist control group will then receive their WHOQoL COMBI scores only, with no information about differences between quality of life and importance or intervention materials."
89619724|NCT04190680|Experimental|Kokkerelli Learning Street|The classes included in this group will participate in the Kokkerelli Learning Street; a school-based nutrition education programme included classroom-based lessons, a visit to a grower's farm and a cooking workshop.
89619725|NCT04190680|No Intervention|Control group|The classes included in this group will not participate in the Kokkerelli Learning Street and will continue with their regular curriculum.
89619726|NCT03358056|Experimental|Mindfulness-based Cognitive Therapy|
89619727|NCT02993458|Experimental|DASH diet-Low Na diet|DASH style diet, low sodium (1500 mg/d).
89619728|NCT02993458|Active Comparator|DASH diet-High Na diet|DASH style diet, high sodium (3500 mg/d).
89619729|NCT02993458|Active Comparator|Usual diet-Low Na diet|Diet reflecting typical dietary pattern of American adolescents, low sodium (1500 mg/d).
89619730|NCT02993458|Active Comparator|Usual diet-High Na diet|Diet reflecting typical dietary pattern of American adolescents, high sodium (3500 mg/d).
89619731|NCT03123666|Experimental|Granulocyte/macrophage colony-stimulating factor (GM-CSF)|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer OR Placebo for 7 days. Both the groups will receive standard medical care
89619732|NCT03123666|Placebo Comparator|Placebo|Placebo will be given identical to the interventional
89619733|NCT04160806|Active Comparator|Active Group|Left anodal/right anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
89619734|NCT04160806|Sham Comparator|Sham Group|Sham transcranial direct current stimulation over the dorsolateral prefrontal cortex
89619735|NCT03357978|Other|A-T patients|"A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution~bioelectrical impedance Analysis~blood draw~transient elastography (FibroScan)~ataxia score~Five-Times-Sit-to-Stand Test"
89619736|NCT03109392|Experimental|Nebulized lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
89619737|NCT03109392|Experimental|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
89619738|NCT03109392|Active Comparator|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
89619739|NCT03357900|Experimental|Orthotopic liver transplantation|
89619740|NCT03360006|Experimental|ABBV-744 Dose Escalation|ABBV-744 will be administered at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
89619741|NCT03360006|Experimental|ABBV-744 Dose Expansion|ABBV-744 will be administered at the recommended Phase 2 dose determined during the Dose Escalation phase.
89619742|NCT04525326|Experimental|standard chemotherapy plus Cetuximab|
89619743|NCT04525326|Experimental|standard chemotherapy plus Bevacizumab|
89619744|NCT02247622||Healthy control|
89619745|NCT02247622||IBD|patients with inflammatory bowel disease, study group
89619746|NCT02247622||PSC|patients with primary sclerosing cholangitis, study group
89619747|NCT03367104||Normal healthy controls|
89619748|NCT03367104||Heart failure patients|
89619749|NCT03359928|Experimental|Boxing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Non-contact boxing involves boxing punch pads that will be held by the one of the researchers, while wearing protective boxing gloves. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
89210930|NCT02538432|Experimental|RQ-00000007 Alone|RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
88988121|NCT05149339|No Intervention|Case subgroup with deficient Vitamin D|Group with deficient Vitamin D < 20 ng/mL No treatment for the Vitamin D deficiency
89210931|NCT02538432|Active Comparator|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
89210932|NCT00817310||Severe IVH|Infants born at less than 1500g with diagnosis of Grade II or IV IVH
89210933|NCT00817310||control|infants born at less than 1500g without IVH on HUS
89210934|NCT01563627|Experimental|Antiepileptic Drug resistant|Adult patients suffering from epilepsy drug-resistant and potentially surgical candidates
89210935|NCT01563627|Experimental|Antiepileptic drug Controlled group|epilepsy well controlled by antiepileptic drugs
89210936|NCT02538276||Group carotid endarterectomy (CEA)|Patients submitted to carotid endarterectomy
89619750|NCT03359928|Experimental|Stair stepping|Participants will complete 3 sessions of exercise. In each of the three sessions a different exercise modality will be conducted in a randomised sequence. Stair stepping involves stepping on to and off a 35 cm Reebok exercise bench, repeatedly. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed.
89619751|NCT03359928|Experimental|Stair climbing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Stair climbing involves continuously ascending the stairs located in a public access staircase. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest).~During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
89619752|NCT03357822|Experimental|Sequential combination therapy group|Patients are treated with pegylated Interferon (180ug, subcutaneously, once a week) plus entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 48/72/96 weeks
89619753|NCT03357822|Active Comparator|Nucleoside therapy group|Patients are treated with entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 96 weeks
89619754|NCT03367026|Active Comparator|Ivabradine oral product|Patients in the ivabradine treatment arm receive interventions:an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.
89619755|NCT03367026|No Intervention|control group|All patients receive established medical therapy according to current guidelines and therapeutic standards.
89619756|NCT05445934|Experimental|FB2001 group|FB2001 will be administered by IV infusion twice daily (BID) for up to 5 days, plus SOC.
89619757|NCT05445934|Placebo Comparator|Placebo group|Placebo will be administered by IV infusion twice daily (BID) for up to 5 days, plus SOC.
89619758|NCT03359772|No Intervention|Group 1|Exercise Only Group
89619759|NCT03359772|Active Comparator|Group 2|Kinesthetic Ability Trainer Group
89619760|NCT03542500|No Intervention|Control|Youth randomized into the control arm of this study will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline, 3-months, 12-months). Due to access to funding and feasibility, youth in the control arm and EPP-only arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. Youth will also be compensated for their participation in our quantitative assessments.
89619761|NCT03542500|Experimental|Entrepreneurship Training|Youth randomized into the Entrepreneurship Training-only arm will receive GIZ's employment programming approximately three months after the completion of the baseline assessments. The GIZ-supported Entrepreneurship Training program includes six training modules, delivered over three weeks, to include skills development, financial literacy, and other skills necessary to secure employment or engage in livelihood activities.
89619762|NCT03542500|Experimental|YRI+Entrepreneurship Training|Youth randomized into the YRI+Entrepreneurship Training arm will begin the YRI module within two weeks after the completion of baseline assessments. The YRI curriculum (12 modules), will be delivered in 12 weekly 90-minute sessions, with additional time taken as needed. These weekly sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention (3-months) quantitative assessment. Following the completion of the quantitative assessments, youth will receive the Entrepreneurship Training.
89619763|NCT03366870|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
89210937|NCT02538276||Group carotid stenting (CAS)|Patients submitted to carotid artery stenting
89210938|NCT00826670|Experimental|Topical decolonization|
89210939|NCT00826670|Placebo Comparator|Placebo|
89210940|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI|"Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months.~Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy."
89210941|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI/ATG|Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months
89619764|NCT03366870|Experimental|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
89619765|NCT02248948|Placebo Comparator|Medium Chain Triglycerides Supplement|Medium Chain Triglycerides Oil with 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
89619766|NCT02248948|Experimental|Omega-3 Fatty Acids Supplement|The Omega-3 Fatty Acid supplement provides 540 mg of eicosapentaenoic acid (EPA), 340 mg of docosahexaenoic acid (DHA), 60 mg of gamma linolenic acid (GLA/Omega-6), 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
89619767|NCT03359694|Experimental|DT group|Pegylated liposomal doxorubicin and Docetaxel Treatment group Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
89619768|NCT03359694|Active Comparator|ET group|Conventional doxorubicin and Docetaxel Treatment group Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
89619769|NCT03359694|Experimental|NX group|Navelbine and Xeloda treatment group in group of Non-pCR patients Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d×4
89619770|NCT03359694|No Intervention|Control group|"no treatment group of Non-pCR patients after DT or ET neoadjuvant chemotherapy.~No drugs treatment in this group."
89210942|NCT02549612|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed with a higher pressure balloon. If no effect is noticed, (the child should experience clicking sound in one or both ears) after day 3, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.
89619771|NCT03407716|Experimental|Group I (North American ginseng extract AFX-2)|Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89619772|NCT03407716|Placebo Comparator|GROUP II (placebo)|Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
89619773|NCT03359616|Experimental|transanal total mesorectal excision|Transanally, the rectum is mobilized through the mesorectal plane according to the TME principles, assisted by the transanal surgical platform (Transanally curable surgical resection).
89619774|NCT03359616|Active Comparator|laparoscopic total mesorectal excision|By standard laparoscopic techniques, the rectal cancer will be resected by the conventional laparoscopic TME (LaTME).
89619775|NCT02227810|Experimental|electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle for 20 min/session, twice daily for 10 days
89619776|NCT02227810|Sham Comparator|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
89619777|NCT03357666|Experimental|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Glucose 200mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
89619778|NCT03357666|Experimental|HUDC_VT(Glucose 400mg/Sodium chloride 200mg)|Glucose 400mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
89619779|NCT03357666|Experimental|HUDC_VT(Glucose 400mg)|Glucose 400mg, once a day, two tablets at a time for 7 days
89619780|NCT03357666|Experimental|HUDC_VT(Sodium chloride 200mg)|Sodium chloride 200mg, once a day, two tablets at a time for 7 days
89619781|NCT03357666|Placebo Comparator|Placebo|Placebo, once a day, two tablets at a time for 7 days
89619782|NCT03366714|Experimental|RAM cannula|nasal CPAP support with RAM cannula
89619783|NCT03366714|Active Comparator|Hudson cannula (short binasal cannula)|nasal CPAP support with Hudson cannula
89619784|NCT03357432|Experimental|effects of gelatin, collagen on PINP levels|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subs
89619785|NCT03357354|Experimental|Obese Children in precarious situations|
89619786|NCT03350620|Experimental|NVK-002 Concentration 1|"Stage 1: Subjects will be randomized to NVK-002 Concentration 1~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
89619787|NCT03350620|Experimental|NVK-002 Concentration 2|"Stage 1: Subjects will be randomized to NVK-002 Concentration 2~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
89619788|NCT03350620|Placebo Comparator|Vehicle (Placebo)|"Stage 1: Subjects will be randomized to Vehicle (Placebo)~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms"
89619789|NCT03123276|Experimental|gemcitabine + pembrolizumab|First cohort of 6 patients may receive Gemcitabine 800 mg/m2 + Pembrolizumab 200 mg. After safety data review, if no DLTs then dose for Gemcitabine will be increased to 1000 and further 1200 mg/m2.
89619790|NCT03366558||PD patients: early stage|Parkinson Disease patients with early stage of the disease: potentially hypokinesia, but no dyskinesia and motor fluctuations
89619791|NCT03366558||PD patients: developed stage|"PD patients having dyskinesia and motor fluctuations (described as developed stage of the disease)"
89619792|NCT03366558||No PD|Subjects not having diagnosed Parkinson Disease
89210943|NCT02549612|No Intervention|Control|No intervention is used in this group.
89210944|NCT03775239|Other|Treatment-as-usual|Those who are randomly selected to treatment-as-usual will receive a minimum of 6 sessions at Sexological Clinic.
89210945|NCT03775239|Other|Treatment-as-usual + MSIR|Those who are randomly selected to receive Mindfulness in Sex Therapy and Intimate Relationships (MSIR) will first receive 6 weeks of mindfulness followed by treatment-as-usual. The intervention will take place at Sexological Clinic.
89619793|NCT03359382|No Intervention|control|
89619794|NCT03359382|Experimental|exercise|
89619795|NCT03855904|Experimental|TC-325|The intervention (experimental) arm patients are treated initially with TC-325 alone. Treatment failure for TC-325 is defined as endoscopists cannot achieve hemostasis with 1 syringe (20gm) of TC-325.
89619796|NCT03855904|Active Comparator|Traditional treatment (Control group)|Control group patients initially receive usual standard of (traditional) endoscopic treatment (SET) as defined by injection therapy with another modality or sole/combination use of thermal or mechanical modalities. Crossovers to either treatment arm are permitted if immediate haemostasis does not achieved with standard endoscopic or TC-325 application.Treatment failure of SET is defined as endoscopists cannot achieve hemostasis by selected SET.
89619797|NCT03357276|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89619798|NCT03357276|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89619799|NCT04524936||obese patient with non-alcoholic fatty liver disease|
89619800|NCT04524936||obese patient without non-alcoholic fatty liver disease|
89619801|NCT04524936||control group|
89619802|NCT04524780|Experimental|left atrial appendage radiography|
89619803|NCT04524780|Experimental|intracardiac echocardiography guidance|
89619804|NCT03359226|Experimental|Submandibular gland biopsy|No treatment is being used in this study. Study participants will have bilateral submandibular gland biopsies.
89619805|NCT02247700||Mechanical Ventilation|Infants and Children requiring mechanical ventilation
89619806|NCT03359148||Disposable ventilator system|The experimental study group will be assigned to a disposable ventilator system combined with an auto-filled heated humidifier (HH), a closed suction catheter, and a closed aerosol therapy procedure with a valved T-adaptor.
89619807|NCT03359148||Conventional reused ventilator system|According to clinical commonly used system, the control study group will be assigned to use with conventional reused ventilator system, combined with a manually filled HH, an open suction catheter, and a conventional aerosol therapy procedure.
89619808|NCT04521660|Experimental|Intervention group|Patients in the intervention group will wear virtual reality glasses during coronary angiography.
89619809|NCT04521660|No Intervention|Control group|Patients in the control group will not wear virtual reality glasses. They will be given standard care and treatment during the procedure.
89619810|NCT02249026|Experimental|BZDs + opiate exposure treated with BPN|In-utero opiate and BZD exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
89619811|NCT02249026|Active Comparator|Opiates exposure treated with BPN|In-utero opiate exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
88988122|NCT05149339|Experimental|Case subgroup with deficient Vitamin D + Vitamin D supplementation|Group with deficient Vitamin D + Daily oral dose of Cholecalciferol for 28 days for correcting the deficiency
88988123|NCT05149339|No Intervention|Case subgroup with normal Vitamin D|Group with normal Vitamin D level > 20 ng/mL
88988124|NCT05149261||Acute aortic syndrome|"patients admitted to the Georges Pompidou European Hospital via the SOS aorta network"
88988125|NCT05149183|Experimental|cervical stability training|cervical stability training will be received three times a week for eight weeks
88988126|NCT05149183|Active Comparator|traditional treatment|traditional treatment will be received three times a week for eight weeks
88988127|NCT05149066|Experimental|Experimental group|"The experimental group was administered a 9-sessions weekly programme in the school context.~It completed three assessment moments: pre-intervention, post-intervention and a 3-months after the intervention follow-up."
88988128|NCT05149066|No Intervention|Control group|The control group did not receive any intervention. It completed three assessment moments: pre-intervention, post-intervention and a 3-months after the intervention follow-up.
88988129|NCT00506740|Active Comparator|Electrocautery|Elesurgical instruments are used to cut and coagulate tissue using alternatig electric current focusing intense heat at the surgical site. In electrosurgery, the patient is included in the circuit and current enters the patient's body.
88988130|NCT02276404|Experimental|relaxation training|Each participant of the experimental group 1 receives 2 one-hour sessions of guided relaxation training prior to surgery.
89619812|NCT04521504|Experimental|Biofeedback|Patients were treated with an experimental rehabilitation protocol, based on shoulder kinematic biofeedback.
89619813|NCT04521504|No Intervention|Control|Patients were treated with a standard rehabilitation protocol, based on hospital guidelines.
89619814|NCT03357198||cough peak flow measurement|All enrolled patients will undergo measurement of cough peak flow by two methods, i.e. using a handheld electronic spirometer, and using the ventilator flowmeter, in a randomized order.
89619815|NCT03366402||Influenza A|
89619816|NCT03366402||Influenza B|
89619817|NCT03366324|Experimental|Combination of CAR-T therapy and HSCT|After patients achieve MRD- remissions through Second generation CAR-T cells, they will subsequently receive hematological stem cell transplantations within 30 days.
89619818|NCT03133156|Experimental|Moderate Intensity Training-Healthy Lean|Eligible subjects will undergo a 10-week moderate intensity exercise program.
88988131|NCT02276404|Experimental|acupuncture|Each participant of the experimental group 2 receives 3 acupuncture treatments with a semi-standardized acupoint scheme: once a week over 2 weeks and the day before surgery.
88988132|NCT02276404|Experimental|relaxation training and acupuncture|Each patient of the experimental group 3 receives 3 acupuncture treatments with a semi-standardized acupoint scheme and 2 one-hour sessions of guided relaxation training prior to surgery.
88988133|NCT02276404|No Intervention|usual care|Patients receive usual senological treatment
88988134|NCT05149027|Experimental|HBM4003+Toripalimap|HBM4003 combined with toripalimab in patients with advanced HCC and other solid tumors
88988135|NCT05148988||AAA patients|The entire cohort consists of patients with an abdominal aortic aneurysm eligible for endovascular repair using an Endurant II device.
88988136|NCT00156507|Experimental|1|Parents of children in the experimental group receive asthma education prior to NICU discharge.
89619819|NCT03133156|Experimental|Moderate Intensity Training-Healthy Overweight/Obese|Eligible subjects will undergo a 10-week moderate intensity exercise program.
89619820|NCT03133156|Experimental|Moderate Intensity Training-Overweight/Obese Type 2 Diabetes|Eligible subjects will undergo a 10-week moderate intensity exercise program.
89619821|NCT03133156|Experimental|High Intensity Training-Healthy Lean.|Eligible subjects will undergo a 10-week high intensity exercise program
89619822|NCT04521192|Experimental|TR sequence group|
89619823|NCT04521192|Experimental|RT sequence group|
89619824|NCT02995876|No Intervention|Zirconia and E-max Press|The first design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press.
89210946|NCT00907842|Experimental|mesh placement|
89210947|NCT00822536|Active Comparator|1|Bi therapy : aspirin/ clopidogrel
89210948|NCT00822536|Active Comparator|2|Monotherapy: aspirin
89520325|NCT03443531|Placebo Comparator|placebo TCM|Patients in this group will be given two placebo TCM treatment, which are which are placebo Bufei Huatan granule, placebo Yifei Qinghua granule, corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
89520326|NCT04561245|Experimental|ALT-801 (Part 1)|Escalating doses of ALT-801 administered once
89520327|NCT04561245|Placebo Comparator|Placebo (Part 1)|Placebo administered once
89520328|NCT04561245|Experimental|ALT-801 (Part 2)|Escalating doses of ALT-801 administered once weekly for 12 weeks
89520329|NCT04561245|Placebo Comparator|Placebo (Part 2)|Placebo administered once weekly for 12 weeks
89520330|NCT03448289|No Intervention|Control|This group will not receive the RLPT.
89520331|NCT03448289|Experimental|Intervention|This group will receive the RLPT.
89520332|NCT03443453|Experimental|MIV-711 ABCD|Subjects will first receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B). Thereafter they will receive the capsule formulation under fasted conditions (C) followed by the capsule formulation administered under fed conditions (D).
89520333|NCT03443453|Experimental|MIV-711 CDAB|Subjects will first receive the capsule formulation under fasted conditions (C)followed by the capsule formulation administered under fed conditions (D). Thereafter they will receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B).
89520334|NCT03448211|Experimental|Para-toluenesulfonamide Injection (PTS)|Investigational product
89520335|NCT03448133|Experimental|rTMS treatment group|The participants will be devided into rTMS treatment and sham treatment by means of randomized methods.The protocol of treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
89520336|NCT03448133|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
89520337|NCT05069805|Active Comparator|PECS II block group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanyl
89520338|NCT05069805|Active Comparator|ESP block group|Patients in ESP group will receive general balanced inhaled anesthesia with sevoflurane and fentanyl
89520339|NCT03443375|Experimental|Nonperiodized resistance training|The Nonperiodized group performed was an intervention based on resistance exercise program with a constant intensity.
89520340|NCT03443375|Experimental|Daily undulating periodized|The Daily undulating periodized program was an intervention based on daily alterations on exercise load. .
89520341|NCT03443375|No Intervention|Control group|The control group remained their regular habits of life during all study period, without engaging in physical exercise programs.
89520342|NCT05066529|Experimental|dry-needling group|"32 participants in this group Dry-needling treatment will be applied once a week for three weeks. Servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.)~All participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups."
89520343|NCT05066529|Other|exercise group|"32 participants in this group Servical stretching exercises are given to all participants. (20 repetitions in one session and 2 sessions in a day, three days a week.)~All participants will be evaluated before treatment, after treatment (at 3rd week) and at 3 month follow-ups."
89520344|NCT03448055|Other|Interventional|Immunocal 20gm daily
89520345|NCT05059665||HCC Subjects|"All subjects will be recently diagnosed with hepatocellular carcinoma as defined by at least one of the following criteria:~Subject has a ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance by MRI and/or CT.~Subject has a lesion of any size indicated to be HCC due to capsule appearance by 4 phase CT scan and/or multiphase contrast enhanced MRI.~Subjects with a suspicious lesion of less than 2 cm must have HCC confirmed by both MRI and CT.~Subject has a biopsy that is positive for HCC.~Diagnostic imaging by multiphasic MRI or CT indicates a suspicious lesion on the liver, which is subsequently confirmed to be HCC by another method (biopsy, or surgical pathology)."
89520346|NCT05059665||Surveillance Subjects|At-risk subjects with chronic liver disease undergoing routine imaging surveillance for HCC.
89520347|NCT03447977|Experimental|cervical group|cervical spinal mobilizations, exercises, 2 session for 6 weeks
89520348|NCT03447977|Experimental|thoracic group|cervical and thoracic spinal mobilizations, exercises, 2 session for 6 weeks
89520349|NCT03447977|Experimental|exercise group|exercises, 2 session for 6 weeks
89520350|NCT04909905|Experimental|Group EN (standard enteral nutrition)|Patients receive standard enteral nutrition according to ICU nutrition protocol during 7days from admission
89520351|NCT04909905|Experimental|Group GN (glutamine supplemented enteral nutrition)|Patients receive intravenous glutamine supplementation to enteral nutrition in a dose of glutamine of 0.4 g/kg/day during 7 days from admission.
89520352|NCT03443297|Experimental|Early Feeding group|Active ingredient: maternal expressed breast milk Time of initiation of first feeding: 24 to 48 hours of age. Doses: Initially 4 hourly feeding will be started with 0.5 ml and 1 ml expressed breast milk in babies with birth weight <1200 grams and >1200 grams respectively. On the following day 3 hourly, thereafter 2 hourly feeding will be provided in both groups. Gradually amount of feeding will be increased after reaching 2 hourly feeding at the rate of 10 ml/kg/day for initial 10 days then 20ml/kg/day in 2 aliquots till full feeding(150ml/kg/day).For babies with birth weight <1200 gram, rate of feeding advancement 10 ml/kg/day till full feeds. Time of starting first feeding and time to reach full feeding, both will be documented in a questionnaire for each patient.
89520353|NCT03443297|No Intervention|Late Feeding group|Feeding with maternal breast milk will be given in conventional way
89520354|NCT01709123|Placebo Comparator|placebo|Placebo supplementation in pill form for 3 months following randomization after a placebo run-in period.
89520355|NCT01709123|Experimental|chromium niacinate|Chromium niacinate supplementation (200ug or 500ug/day) in pill form for 3 months following randomization after a placebo run-in period
88988137|NCT02954731|Experimental|UP-CBT|"The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is one of the most widely studied transdiagnostic manuals. Here, the investigators apply a group manual that has been modified from the published UP for individual therapy based on recommendations on group delivery from the UP Institute (personal communications) and integrations modifications necessary for the delivery in the Mental Health Service. Group UP-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions."
88988138|NCT02954731|Active Comparator|Standard-CBT|Group CBT following Danish versions of diagnosis specific manuals (Social Anxiety Disorder (SAD) Group; Depression (DEP) Group; Agoraphobia/Panic Disorder (Ag/PD) (standard-CBT). The original elements of psychoeducation, cognitive restructuring, and exposure/activity scheduling are present in the applied manuals. Standard-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions.
88988139|NCT02954692|Experimental|Insulin glargine (U300)|Insulin glargine (U300) will be administered daily through subcutaneous injection, and thereafter, dose will be titrated weekly (preferably 3-4 days) as needed. Background non-insulin anti-diabetic drugs approved for use in combination with insulin according to local labelling, will be permitted, with the exception of Thiazolidinediones (TZDs), which must be stopped at the time of basal insulin initiation.
88988140|NCT00506818|Active Comparator|2|Intensive risk factor intervention
88988141|NCT00506896|Active Comparator|1|
88988142|NCT00506935|Experimental|1|GVG
88988143|NCT00506935|Placebo Comparator|2|placebo
88988144|NCT00507013|Other|2|
88988145|NCT00507091|Experimental|ZD6474 (vandetanib) 100mg|
88988146|NCT00507091|Experimental|ZD6474 (vandetanib) 300mg|
88988147|NCT05148910|Active Comparator|Copper IUD (TCu380A)|Women receiving an intrauterine device (IUD) containing 380mm² of copper.
88988148|NCT05148910|Experimental|Silver and copper IUD (TCu380Ag)|Women receiving an intrauterine device (IUD) containing 380mm² of copper with a silver core.
88988149|NCT04726436|Experimental|Dextrose 5%|100 mL/ hour of dextrose 5% were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon to assess the timing and dosing of dextrose solution effect on PONV.
88988150|NCT04726436|Experimental|Dextrose 10%|100 mL/ hour of dextrose 10% were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon
88988151|NCT04726436|Placebo Comparator|Saline placebo|100 mL/ hour of normal saline were given starting 1 hour before operation and continue till approximately middle of surgery by communicating with surgeon
88988152|NCT05148520|Other|5A's model|The practice guideline emphasizes on the use of '5A's' model that contains five major steps in providing smoking cessation counselling. Specifically, our counsellors will take the following steps to provide telephone counselling for youth smokers who are ready to quit smoking
89520356|NCT03443219|Experimental|Spritztube®|The patients were randomly allocated to two groups by using computer-generated numbers.In Spritztube® group, Spritztube® was inserted into each patient after anesthesia induction.
88988153|NCT05148403|Experimental|Experimental group|Glibenclamide was given orally or through nasogastric tube, 1.25 mg every 8 hours for 7 days
89520357|NCT03443219|Active Comparator|LMA Supreme™|The patients were randomly allocated to two groups by using computer-generated numbers.In vgroup, LMA Supreme™was inserted into each patient after anesthesia induction.
89520358|NCT01301807|Experimental|Treatment (carfilzomib, panobinostat)|Participants receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 and panobinostat PO QD on days 1, 3, 5, 8, 10, and 12 of each course. Courses repeat every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After 8 courses, participants may continue carfilzomib IV on days 1, 2, 15, and 16, and panobinostat PO on days 1, 3, 5, 8, 10, and 12 of each course. If the disease becomes worse, participants can receive carfilzomib on the original dosing schedule (days 1, 2, 8, 9, 15, and 16 of each course).
89520359|NCT04962893|Experimental|VLP-Wuhan group (Group V1)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
89520360|NCT04962893|Experimental|VLP-Alpha (British) variant group (Group V2)|110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.
89520361|NCT04962893|Experimental|VLP-Wuhan+Alpha group (Group V3)|"110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan and Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.~Initial vaccination with Wuhan followed by a booster of Alpha variant."
89520362|NCT02521571|Experimental|Intervention Group|
89520363|NCT02521571|Placebo Comparator|Control Group|
89520364|NCT03443141|Experimental|Vitamin E dressing|Patients will receive a Vitamin E-containing dressing over the wound
89520365|NCT03443141|Sham Comparator|Standard dressing|Patients will receive a standard dressing over the wound
89520366|NCT04937543|No Intervention|No intervation|patients receiving standart of care
89520367|NCT04937543|Active Comparator|Experimental intervation one|patients receiving standart of care + inhaled beclometasone
89520368|NCT04937543|Active Comparator|Experimental intervation two|patients receiving standart of care + inhaled beclometasone/ formoterol / glycopyrronium
89520369|NCT03442907|Experimental|Study group|"The intraoperative blood pressure target for all patients in the study group is the mean arterial pressure (+ 10mmHg maximum) derived from the prior 24-hour blood pressure measurement.~To achieve the blood pressure target, fluid or vasoactive substances will be used."
89520370|NCT03442907|Active Comparator|Control group|Study patients of the control group are treated according to the standard operating procedures (SOP) of the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf.
89520371|NCT03447899|Experimental|ABC Intervention|"The investigators will deliver the Attachment and Biobehavioral Catch-up (ABC) in the home weekly using live, in-room coaching, to give caregivers feedback as they use targeted skills during interactions with the child. The intervention will last 10 sessions. Study participants in both groups will complete study measures at baseline, 1 month, 3 months, post-intervention, 6 months, and 12 months."
89520372|NCT03447899|No Intervention|Standard of Care|"Subjects will receive normal standard of care without the Attachment and Biobehavioral Catch-up (ABC)."
89520373|NCT04928105|Experimental|CD7 CAR-T|
89619825|NCT02995876|Experimental|Zirconia and E-max Press and Glaze|The second design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with a glaze layer to improve adhesion.
89619826|NCT02995876|Experimental|Zirconia and E-max Press twice|The third design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with an E-max Press layer to improve adhesion.
89619827|NCT03359070|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
89619828|NCT03359070|Active Comparator|Group 2 - miconazole cream 2%|Topical application of miconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
89619829|NCT03366246|Active Comparator|lidocaine / prilocaine cream|according to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy.
89619830|NCT03366246|Placebo Comparator|placebo|according to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy.
89619831|NCT01623466|Experimental|AG890-6.5|Evaluate levonorgestrel delivery in AG890-6.5
89619832|NCT01623466|Experimental|AG890-12.5|Evaluate levonorgestrel delivery in AG890-12.5
89619833|NCT04521036|Experimental|Convalescent plasma|Standard of care plus 500 mL of convalescent plasma from COVID-19 recovered donors
89619834|NCT04521036|No Intervention|Standard of care|Standard of care (Supportive care, oxygen, antibiotics, no convalescent plasma)
89619835|NCT04524624|Experimental|AI-based CDSS|"Automatically identifying acute ischemic stroke lesions on DWI.~Classification of stroke subtypes and mechanisms.~Evidence-based alerts and guidelines for early stroke management.~Guideline-recommended secondary stroke prevention strategies."
89619836|NCT04524624|No Intervention|Usual Care|Usual Care
89619837|NCT03366090||IBD patients|Biopsies for immunological analyses
89619838|NCT03366090||healthy controls|Biopsies for immunological analyses
89619839|NCT01624168|Placebo Comparator|Anxiety Management Education|
89210949|NCT04015752||diabetics|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present, medication used, controlled or not.~Complete physical examination with special attention to :~Vital signs ( MAP, pulse, temp, RR). Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).~Laboratory investigations includes :~CBC , Liver and kidney functions → baseline and follow up. Arterial Blood Gases (ABG). Lactic acid level. HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
89619840|NCT01624168|Experimental|10 week tai chi intervention|10 week course in Evidence Based Tai Chi meeting 2 times per week
89619841|NCT01624168|Experimental|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
89619842|NCT03358914||Adolescents with psoriasis|No assigned intervention: completion of PsoTeenQOL and other instruments for assessment of psychometric properties and further refinement of the PsoTeenQOL.
89619843|NCT03358914||Parents of adolescents with psoriasis|No assigned intervention: completion of proxy-version of the PsoTeenQOL for validation purposes
89619844|NCT03358914||Adolescents without psoriasis|No assigned intervention: completion of non-psoriasis control-version of the PsoTeenQOL for validation purposes
88988154|NCT05148403|No Intervention|Control group|No glibenclamide treatment
88988155|NCT05148208|Placebo Comparator|Placebo|Supplementation of water
88988156|NCT05148208|Active Comparator|Creatine 0.5 mM|Supplementation of creatine dissolved in water to a final concentration of 0.5 mM of creatine in the dialysate
88988157|NCT05148208|Active Comparator|Creatine 1 mM|Supplementation of creatine dissolved in water to a final concentration of 1 mM of creatine in the dialysate
88988158|NCT05148208|Active Comparator|Creatine 1.5 mM|Supplementation of creatine dissolved in water to a final concentration of 1.5 mM of creatine in the dialysate
88988159|NCT05148208|Active Comparator|Creatine 2.0 mM|Supplementation of creatine dissolved in water to a final concentration of 2 mM of creatine in the dialysate
89619845|NCT03365856||RA patients|As routinary clinical practice and observational study
89619846|NCT03642574|Experimental|PIMT methylation|Subjects will have blastocyst biopsy and whole genome DNA methylation sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. Only embryos with euploid chromosome will be transfered to the uterus. The outcome of all euploids transfers within 1 year will be followed up. During study, every subject will have at most one live birth.
89619847|NCT03358836||Group A|Episodic treatment with FIX concentrates for bleeding episodes
89619848|NCT03358836||Group B|Prophylaxis using any FIX concentrate with an intended trough of 1-5%
89619849|NCT03358836||Group C|Prophylaxis with an extended half-life (EHL) FIX with an intended trough of >10%
89619850|NCT04520958|Experimental|Mindfulness of Breath|
89619851|NCT04520958|Experimental|Mindfulness of Pain|
89619852|NCT04520958|Active Comparator|Cognitive-Behaviorally Based Pain Psychoeducation|
89619853|NCT04520646|Experimental|empagliflozin|empagliflozin is added on the basis of the original treatment
89619854|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|Patients with an invasive breast cancer on neoadjuvant chemotherapy (with the exception of cT2cN0 tumors) are preselected before the surgical procedure. They are definitely included during the post-surgery visit following the analysis of the surgical specimen (only patients whose tumor did not achieve a complete pathological response are included).
89619855|NCT03365700|Active Comparator|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line.
89619856|NCT03365700|Active Comparator|Radiofrequency Ablation|Contact force-sensing radiofrequency left atrial ablation with 3D mapping system.
89210950|NCT04015752||non diabetics|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present medication used, controlled or not.~Complete physical examination with special attention to :~Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, JV canula,..).~Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
89520374|NCT03447665|No Intervention|Control|Infant sleep monitoring and parental surveys only
89520375|NCT03447665|Experimental|Intervention (Bedtime only)|Infant behavioral sleep intervention implemented at bedtime only. Parents are instructed to soothe/help their infant back to sleep after night wakings. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
89520376|NCT03447665|Experimental|Intervention (All night)|Infant behavioral sleep intervention implemented at bedtime and after each subsequent infant night waking. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
89520377|NCT04923737|Active Comparator|Dexmedetomidine group|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
89520378|NCT04923737|Placebo Comparator|Control group|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
89520379|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 1)|"Open-label, sequential PLX3397 dose escalation with a fixed dose of pembrolizumab in approximately 24 patients with advanced solid tumors.~(Enrollment complete- 33 enrolled)"
89520380|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 2)|"Extension cohort at the RP2D of PLX3397 in combination with pembrolizumab in approximately 376 patients with advanced solid tumors~(Enrollment Complete- 45 enrolled)"
89520381|NCT04915859|Active Comparator|Active Cooling|Participants will be actively cooled during rest breaks
89520382|NCT04915859|Placebo Comparator|No Intervention|"Participants will participate in passive cooling where they sit in a chair during rest"
89520383|NCT04904471|Experimental|Experimental|Three doses of recombinant SARS-CoV-2 vaccine (Sf9 Cell) on Day 0, Day 21and Day 42.
89520384|NCT04904471|Placebo Comparator|Placebo Comparator|Three doses of placebo on Day 0, Day 21and Day 42.
89520385|NCT04926662||Aim 1: Focus Groups|Focus groups will be conducted in 2 New Hampshire and 2 Vermont towns to better understand patient knowledge, attitudes, and preferences regarding access to lung cancer screening.
89520386|NCT04926662||Aim 2: Cross Sectional Survey|Based on focus group feedback, the investigators will visit each proposed site to survey on 2 separate dates to confirm days and times of high traffic. The investigators will also survey patrons at the proposed locations to further determine prospective patient mobile screening preferences and evaluate willingness to participate in screening.
89520387|NCT04926662||Aim 3: Survey with follow up data|The investigators will pilot mobile lung cancer screening clinics at each chosen location using the knowledge acquired from focus group experience and local patient survey. Surveys will be conducted at these clinics, and patients will be followed for up to 5 years.
89520388|NCT02419508|Experimental|SIMBRINZA + PGA|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
89520389|NCT02419508|Other|Vehicle + PGA|Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
89520390|NCT01328249|Experimental|Doxorubicin and cyclophosphamide followed by eribulin mesylate|
89520391|NCT03128801|Experimental|Global Stretching Program (GSP)|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active).
89520392|NCT03128801|Active Comparator|Stabilization Exercises|A exercise protocol will be administered and the criteria to increase exercise progression was previously described by Hicks et al (2005).
89520393|NCT01651052|Experimental|Aortic Bioprosthesis, Model 11000|Aortic valve replacement therapy
89520394|NCT05188157|Other|control group|conventional physiotherapy
89520395|NCT05188157|Experimental|mirror therapy group|conventional physiotherapy and mirror therapy
89520396|NCT03447587|Experimental|Electroacupuncture|Subjects will receive 4 weeks of acupuncture following with a semi-standardized protocol.
89520397|NCT03447587|Placebo Comparator|Sham acupuncture group|Subjects will receive sham acupuncture with the same sterilization procedure as traditional acupuncture group.
89520398|NCT02388074|Experimental|CyPath® Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
89520399|NCT03442517|Experimental|Group-based phone counseling (GBPC)|Participants will take part in weekly group-based phone counseling sessions for 6 weeks starting between 16-30 weeks of pregnancy.
89520400|NCT03442517|Active Comparator|Usual prenatal care|Participants will continue their usual prenatal care.
89520401|NCT03447431||MSI colon tumours|MSI colon tumours (as compared to MSS CRCs and matching normal colonic mucosa) Identification of exon/intron sites affected by aberrant splicing events due to MSI in CRC
89520402|NCT03442439|Active Comparator|Nutrition and Play Intervention (NPI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
89520403|NCT03442439|Experimental|Family Nurture Intervention (FNI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
89520404|NCT03442361||Intralipid|Standard soybean oil-based therapy
89520405|NCT03442361||Clinoleic|Olive oil based therapy
89520406|NCT03442283||Supplementation|
89520407|NCT03442283||No Supplementation|
89520408|NCT01602549|Experimental|Cohort|1:2 ratio, placebo, 50 mg administered orally once daily for 7-9 days
89520409|NCT03447275||Controls|Apparently healthy subjects without type 2 diabetes
88988160|NCT05148169|Active Comparator|SSRI group|One SSRI is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
89520410|NCT03447275||Patients with type 2 diabetes|type 2 Diabetes since 5 years or longer
89520411|NCT03442205|Experimental|Group A|
89520412|NCT03442205|Experimental|Group B|
89520413|NCT03442205|Experimental|Group C|
89520414|NCT03447197|Active Comparator|On-Pump|Use of extracorporeal circulation
89520415|NCT03447197|No Intervention|Off-Pump|
89520416|NCT03442127|Other|Patient Group|Program users
89520417|NCT02521805|Sham Comparator|PA|Animal protein and no fiber (control)
89520418|NCT02521805|Experimental|PAF|Animal protein added fiber
89520419|NCT02521805|Experimental|PVF|Vegetable protein naturally containing dietary fiber
89520420|NCT02521805|Experimental|PAVM|Animal protein and dietary fiber in meal
89520421|NCT02521883|Active Comparator|Device: Sooma tDCS|The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.
89520422|NCT02521883|Placebo Comparator|Device: Sham tDCS|The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.
89520423|NCT03442049|Experimental|Study group|Spinal stabilization exercises in addition to home exercise program
89520424|NCT03442049|Active Comparator|Control Group|Home exercise program
89520425|NCT03441815|Experimental|XC8 2 mg|Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
89520426|NCT03441815|Experimental|XC8 10 mg|Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
89520427|NCT03441815|Experimental|XC8 50 mg|Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
89520428|NCT03441815|Experimental|XC8 200 mg|Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).
89520429|NCT03441815|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).
89520430|NCT03446963|Experimental|Single arm: Groups 4 Health|Social group intervention. The aim is to practice participating in a social group within a safe environment; to identify groups and social networks which are meaningful for the person; and to understand any barriers people may have to engaging with these groups/networks.
89520431|NCT02427464|Experimental|Engensis (VM202)|"Subjects randomized to the Engensis (VM202) treatment arm received the following intramuscular injections in each calf:~Day 0 - 16 injections of 0.5mL of VM202 / calf~Day 14 - 16 injections of 0.5mL of VM202 / calf~Day 90 - 16 injections of 0.5mL of VM202 / calf~Day 104 - 16 injections of 0.5mL of VM202 / calf"
89520432|NCT02427464|Placebo Comparator|Placebo|"Subjects in the placebo control group received the following intramuscular injections in each calf:~Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf"
89520433|NCT02426918|Experimental|Debio 1450 320/480 mg|After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
89520434|NCT02426918|Experimental|Debio 1450 160/240 mg|After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
89520435|NCT02426918|Placebo Comparator|Placebo|After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
89520436|NCT02387840|Experimental|NF1-associated Optic Pathway Glioma (OPG)|Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
89520437|NCT02387840|Experimental|NF1 without brain tumor|Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
89520438|NCT02387840|Experimental|Without NF1 and with brain tumor exposed to therapy|Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
89520439|NCT02387840|Experimental|Without NF1 and with untreated low grade brain tumors|Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
89520440|NCT02387840|Experimental|Without NF1 and without brain tumors|Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
89520441|NCT02387840|Experimental|Brain tumors of assorted pathology|Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
89520442|NCT02387762|Experimental|ACP-196 + Methotrexate|Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week
89520443|NCT02387762|Placebo Comparator|Placebo + Methotrexate|Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week
89520444|NCT02418182|Placebo Comparator|Control|Control group participants will receive unlabelled 2 non-active placebo tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
89520445|NCT02418182|Experimental|Experimental|Experimental group participants will receive 2 acetaminophen 500mg tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
89520446|NCT04884191|Experimental|Pacritinib 100 mg QD|
89520447|NCT04884191|Experimental|Pacritinib 100 mg BID|
89520448|NCT04884191|Experimental|Pacritinib 200 mg BID|
89520449|NCT03446729|Experimental|Memory Self Monitoring (MSM)|"Intervention: Guided self-help Behavioral Weight Loss. The MSM group is assigned to self-monitor in habit books what they consume in their previous meal immediately prior to each meal, similar to other studies exploring the effect of episodic meal memory on food intake."
89520450|NCT03446729|Active Comparator|Caloric Self Monitoring (CSM)|"Intervention: Guided self-help Behavioral Weight Loss. The CSM group is assigned to self-monitor what food they consume, and the associated caloric content after each meal in their habit books in line with traditional BWL self-monitoring."
89520451|NCT05164835|Experimental|Experimental|
89520452|NCT02387372|Experimental|Mechanically Ventilated|"Participants with proven or suspected pneumonia, undergoing mechanical ventilation will receive 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~Those with Creatinine clearance (CLCR) > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~Those with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~Those with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
89520453|NCT02387372|Experimental|Critically Ill|Critically ill participants with CLCR ≥180 mL/min (as calculated by the Cockcroft-Gault equation) will receive a single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion.
89520454|NCT05156567||routine physicians|
89520455|NCT05156567||DLS|
89520456|NCT05370170|No Intervention|Routine antenatal care|the control group will receive routine antenatal care and will not receive the guidelines group included 30 cases
89520457|NCT05370170|Experimental|Ottawa guidelines|study group will receive routine antenatal care in addition to the Ottawa nutritional guidelines group included 30 cases
89520458|NCT02426138|Experimental|Med. Tailored Meal Delivery, Usual Care + Choose Myplate|Participants will receive 12 weeks of medically tailored meal delivery, comprising approximately half of their weekly caloric intake and consisting of foods prepared under the supervision of a registered dietitian to be compatible with a diabetes diet. They will also receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
89520459|NCT02426138|Active Comparator|Usual Care + Choose Myplate, Med. Tailored Meal Delivery|Participants will receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
89520460|NCT04881149|Experimental|All Study Participants|The TempSure will be used on the flanks during this study. Subjects will receive 1 biopsy in the treatment area on the flank. Subjects will also receive 1 biopsy sample on the contralateral side, where they did not receive treatment. Each subject had 1 control sample (tissue that was taken from an area where no treatment was received), and 1 treatment sample (tissue taken from an area that had been subjected to the treatment).
89520461|NCT03446495||Trabectedin + PLD|Trabectedin + PLD according to SmPC
89520462|NCT03441425|No Intervention|Control|The control group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin returns to spontaneous circulation at the end of the scenario. They will then complete a retention simulation session three months later.
89520463|NCT03441425|Experimental|Unexpected death|The experimental group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin unexpectedly dies at the end of the scenario. They will then complete a retention simulation session three months later.
89520464|NCT03441347|Experimental|Specific rehabilitation program|Specific, personalized, multidisciplinary rehabilitation program consisting of physical- and occupational therapy.
89520465|NCT03441347|Other|Usual Care|Usual care for people with neuralgic amyotrophy, may vary per individual
89520466|NCT03446261|Experimental|Rosuvamibe® Tab|Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks
89520467|NCT03446261|Active Comparator|Monorova® Tab|Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks
89520468|NCT03441191|Experimental|Active AVS|Active AVS consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
89520469|NCT03441191|Placebo Comparator|Placebo Control AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
89520470|NCT05116397|Experimental|4% CO2|Inspired gas containing 4% CO2, 21% O2, balance N2
89520471|NCT05116397|Experimental|2% CO2|Inspired gas containing 2% CO2, 21% O2, balance N2
89520472|NCT05116397|Sham Comparator|0% CO2|Inspired gas containing 0% CO2, 21% O2, balance N2
89520473|NCT03441035||Adults, uncomplicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
89520474|NCT03441035||Adults, complicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until hospital discharge or postoperative day 21. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points. A infusion of deuterium labeled phenylalanine will be given in the ICU at 1-3 occasions to determine the synthesis rate of albumin.
89520475|NCT03441035||Children|Children undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. P-albumin and B-Hb is only taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
89520476|NCT03440645|Experimental|Family or Household Members|
89520477|NCT04552275|Other|HALT Cohort|Patients who develop HALT
89520478|NCT04552275|Other|Control Group|Patients who do not develop HALT
89520479|NCT04807673|Experimental|Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)|"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), paclitaxel 135mg/m^2 IV on Day 2 Q3W, and cisplatin 80 mg/m^2 IV on Day 2 Q3W, a total of three cycles. All treatments will be beginning on Day 1 of each 3-week dosing cycle. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment. After surgery, pembrolizumab 200 mg IV on Day 1 Q3W lasting one year.~Surgery: McKeown esophagectomy"
89520480|NCT04807673|Experimental|neoadjuvant chemoradiotherapy+ Surgery (114)|"neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m^2 on D1 and Cisplatin 25mg/m^2 D1, repeated every week. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment.~Surgery: McKeown esophagectomy"
89036631|NCT02715635|Active Comparator|Nitrate-rich beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml containing ~8 mmol of inorganic nitrate"
89036632|NCT02715635|Placebo Comparator|Nitrate-deplete beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml which is nitrate-depleted"
89036633|NCT04685954|Experimental|Bulk-Fill|Filtek™ Bulk Fill Posterior, 3M ESPE, St. Paul MN, USA (FB)
89036634|NCT04685954|Experimental|Incremental|Filtek Ultimate Universal, 3M ESPE, St. Paul MN, USA (FU)
89036635|NCT02506946||PCOS subjects|Forty adolescents and young adults between the ages of 14 and 25 years with Polycystic Ovary Syndrome (PCOS) at least two years past menarche.
89036636|NCT02506946||Control subjects|Forty unaffected adolescents and young adults between the ages of 14 and 25 years at least two years past menarche.
89036637|NCT00533013|Active Comparator|Usual care|Management of heart failure is provided by primary practitioners and consultant cardiologists
89036638|NCT00533013|Experimental|Disease Management|Disease management led by nurse specialists in regional Heart Failure Clinics and a national Call Center. Tele-Monitoring of body weight, pulse rate and blood pressure is performed at participants' homes.
89036639|NCT02071862|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
89036640|NCT02071862|Experimental|Pac-CB|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity
89036641|NCT02071862|Experimental|CBE|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity
89036642|NCT02071862|Experimental|CB-Erl|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity
89036643|NCT02071862|Experimental|CBD|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity
89619857|NCT01624948|Experimental|Everolimus+Tacrolimus/Prednisone|This arm (group 1) will undergo mycophenolic acid (MPA) discontinuation with the addition of Zortress (everolimus) to their current regimen of tacrolimus and prednisone; All patients in group 1 will receive Zortress (everolimus) at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
89619858|NCT01624948|Active Comparator|Standard of care: 50% reduction of MPA|This arm (group 2) patients will continue with tacrolimus (target trough level of 6-10 ng/mL), prednisone, and undergo a 50% reduction of the MPA dose, which is the standard immunosuppression treatment for renal transplant recipients with evidence of BKV infection. At months 1, 2, and 3 post-randomization urine and plasma BKV levels will be re-checked. Renal allograft biopsies will be done for cause as clinically indicated.
89619859|NCT03357042|Experimental|Persistent post-concussive symptoms|Participants who report post-concussive symptoms. 20 participants will receive the aerobic exercise and balance training intervention, 20 participants will receive standard of care treatment for concussions.
89619860|NCT03357042|Active Comparator|Healthy control|Persons without post-concussive symptoms. No intervention.
89619861|NCT04520568|Active Comparator|HFNC group|For HFNC group, F&P AIRVOTM 2 will be adjusted to give the patients the oxygen flow at 50L/min and the FiO2 at 1.0.Then after three minutes of preoxygenation, sedation will be conducted by giving 25 µg fentanyl and a bolus of 1 mg/kg propofol followed by continuous infusion of propofol using a target-controlled infusion system (TCI pump TE371; Terumo Corporation, TokyoJapan).
89036644|NCT02071862|Experimental|CB-Cabo|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity
89036645|NCT00535691|Active Comparator|1|Tacrolimus ointment 0.03% once daily, placebo once daily
89619862|NCT04520568|Placebo Comparator|control group|induction of general anaesthesia will be done using 2 mg/kg propofol and 1 µg/kg fentanyl. Double lumen tube will be facilitated by cisatracurium 0.2 mg/kg. Anaesthesia will be maintained with isoflurane 0.8 %-1% in 100% oxygen and maintenance dose of cisatracurium 0.02 mg/kg when needed. At the end of surgery, residual neuromuscular paralysis will be antagonized with neostigmine 0.05 mg/kg and atropine 0.01 mg/kg.
89036646|NCT00535691|Active Comparator|2|Tacrolimus ointment 0.03% twice daily
89036647|NCT05051085|Experimental|"Internet-delivered treatment: SpilleFri."|"All participants receive the internet-delivered therapist-assisted 8-modules treatment program SpilleFri."
89036648|NCT01268683|Experimental|Glyburide for Injection|This arm is administered a glyburide bolus followed by continuous infusion of glyburide for 72 hours
89036649|NCT05037201|No Intervention|Usual care|The control arm will receive usual health system messaging about the importance and deadlines for receiving COVID-19 vaccination.
89036650|NCT05037201|Experimental|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
89036651|NCT02021474|Experimental|AGX-201|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis.
89036652|NCT02021474|Placebo Comparator|Evan's solution = phenol 0.4%, isotonic sodium chloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis.
89036653|NCT01268566|Experimental|MEDI-575, 25 mg/kg|MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.
89619863|NCT03358602|Experimental|Radiotherapy|Radiotherapy & open partial supraglottic laryngectomy(primary tumor)
89619864|NCT03358602|Active Comparator|Elective neck dissection|Elective neck dissection & open partial supraglottic laryngectomy(primary tumor)
89619865|NCT01625104|Experimental|Group 1: Aggressive Intervention Strategy|"Hospitals were randomized to an aggressive intervention strategy or to business as usual. The hospitals randomized to the aggressive intervention strategy underwent the following:~Grand Rounds conducted by physician and nurse from the Coordinating Center. This included a formal presentation on the evidence supporting rapid time to treatment in STEMI patients and evidence based strategies for reducing treatment delays.~Discussion with staff regarding perceived barriers to treatment and suggestions/ideas for strategies to overcome these barriers~Follow-up monthly phone conferences to continue to discuss strategies and ideas sharing~Written plan from sites detailing plans to change processes of care."
89619866|NCT01625104|Placebo Comparator|Group 2: Control Strategy|"Hospitals randomized to the control group were instructed to conduct business as usual."
89619867|NCT04445142||epiretinal membrane group|Patients developed secondary fovea epiretinal membrane
89619868|NCT03365544|Experimental|6am-2pm eating window|4 weeks of time restricted eating between 6am-2pm.
89619869|NCT03365544|Experimental|2pm-10pm eating window|4 weeks of time restricted eating between 2pm-10pm.
89619870|NCT01625416|Experimental|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
89619871|NCT01625416|No Intervention|Usual Care|Usual care control patients will be given a list of available community resources and encouraged to proceed using all resources available to them.
89619872|NCT04520880||Critically ill SARS-Cov2 patients|Critically ill patients with acute hypoxemic respiratory failure defined as those admitted to ICU and receiving mechanical ventilation (invasive or non-invasive) or high-level supplemental oxygen (via a high-flow nasal cannula or non-rebreathing face mask at a flow rate of 15 L per min or greater), at or during hospitalization
89619873|NCT04520880||Hospitalized non-critically ill SARS-Cov2 symptomatic patients|Hospitalized non-critically ill SARS-Cov2 symptomatic patients
89619874|NCT04520724|Experimental|Study group|"30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (ca. 300 kcal; no less than 12 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a higher fiber content twice daily (12 g of fiber/per roll) for 8 weeks.~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
89619875|NCT04520724|Placebo Comparator|Placebo group|"30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (ca. 300 kcal; no less than 6 g of fiber) for 8 weeks.30 patients with NAFLD which consumes rolls with a lower fiber content twice daily (6 g of fiber/per roll) for 8 weeks.~Rolls should be eaten for 1st and 2nd breakfast. Before starting the study, patients will receive nutritional guidelines how compose a meal that the caloric content does not exceed 400 kcal per breakfast. At the beginning patients will be trained by licensed dietitians on the principles of diet in NAFLD. During 8 weeks of intervention, patients will have telephone access to consultations with a dietitian."
89619876|NCT03477604|Experimental|MicroStent and Standard PTA|Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.
89619877|NCT03477604|Active Comparator|Standard PTA|
89619878|NCT04520802||POCD|Patients with postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
89619879|NCT04520802||no POCD|Patients without postoperative cognitive decline (POCD) after coronary artery bypass grafting (CABG) surgery
89619880|NCT03365466||Group A|Patients who received a daily dose of 75mg LDA per day after menstruation prior to ET.
89619881|NCT03365466||Group B|Patients who received a daily dose of 5000u LMWH after menstruation prior to ET.
89619882|NCT03365466||Group C|Patients who received a daily dose of 75 mg LDA plus 5000u LMWH after menstruation prior to ET.
89619883|NCT03365466||Group D|Patients who did not receive any treatment.
89619884|NCT03833284|Experimental|Participant Barriers to TVU Screening|Patients with a history of pre-term birth will be identified through a review of their medical history. Patients will then be asked to complete a survey assessing their knowledge of transvaginal ultrasound screening. Patients will then be asked to attend in-person or online workshops designed to increase patient knowledge of TVU screening guidelines and benefits. Finally, patients will complete exit surveys to determine whether their attitudes and beliefs towards screening have changed over time.
89036654|NCT05010291|Experimental|Standard of Care (SOC) messaging|Participants randomized into this arm will receive standard voice call reminders + the Standard of Care (SOC) text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include the SOC text
89036655|NCT05010291|Experimental|Loss aversion messaging|Participants randomized into this arm will receive standard voice call reminders + loss aversion text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include loss aversion framing.
89036656|NCT05010291|Experimental|Social norms messaging|Participants randomized into this arm will receive standard voice call reminders + social norms text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include social norms framing.
89036657|NCT05010291|Experimental|Altruism messaging|Participants randomized into this arm will receive standard voice call reminders + altruism text message reminders. The study team will send these one-way text messages to recipients of care as a reminder 1) approximately 3-7 days in advance of a clinic appointment, or 2) to follow-up approximately 24 hours after a missed clinic appointment. These text messages will include altruism framing.
89619885|NCT03833284|Experimental|Provider Barriers to TVU Screening|Obstetric and Gynecologic Providers will be identified based on prior working relationships with the University of Kentucky outreach programs. Chosen providers will be asked to complete a survey assessing their attitudes towards TVU screening. Following completion, providers will be asked to attend either in-person or online workshops designed to increase provider knowledge of TVU screening guidelines and benefits. Finally, providers will complete exit surveys to determine whether their attitudes and beliefs toward screening have changed over time.
89036658|NCT01268488|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using a Ninja 2 investigational blood glucose meter and the Contour® sensor. This BG monitoring system will not proceed to marketed product.
89619886|NCT03356964|Active Comparator|Control group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (13). The stimulation dosage will remain unchanged until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
89619887|NCT03356964|Experimental|Study group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (LaMarca et al.). As soon as ≥ 3 follicle of a size of 14mm are seen, the stimulation dosage will be reduced daily by 12.5 IU recFSH until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
89619888|NCT03346252|Experimental|Botulinum Toxin type A|Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.
89619889|NCT04522752||Gastric Polyp|The included subjects were patients with benign epithelial gastric polyps confirmed by gastroscopy and biopsy pathology. The size and pathology type of polyps were identified. Gastroscopy and biopsy were followed up six, twelve and eighteen months later to observe the relationship between the size, pathology types of polyps and the development of gastric polyps. Other factors including the relationship between helicobacter pylori infection and polyp type were also observed.
89619890|NCT04522830|Experimental|BTL-TML-COVID|BTL-TML-COVID
89619891|NCT04522830|Placebo Comparator|Placebo|Placebo
89619892|NCT03365388|Experimental|Sodium Hyaluronate group|Treatment of periarthritis of shoulder with Sodium Hyaluronate
89619893|NCT03365388|Active Comparator|Aerzhi group|Treatment of periarthritis of shoulder with Aerzhi
89619894|NCT03365310|Experimental|Intervention Group|Participants will receive turmeric and tulsi capsule with milk(100 ml) along with standard of care treatment as determined by research physician...Each participants has to take two capsules of turmeric formula and tulsi twice daily for the study period of 3 months
89619895|NCT03365310|Active Comparator|Standard Care Group|Participants will only receive the standard of care treatment as determined by research physician
89619896|NCT03356808|Experimental|Lung cancer-specific T cells|Peripheral blood mononuclear cells (PBMCs) of patients, who have cancer antigen identified lung cancer, will be obtained through apheresis, and T cells will be activated and ex vivo engineered.
89619897|NCT04522986|Experimental|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
89619898|NCT03123744|Experimental|Palbociclib 125 mg|Palbociclib is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study measurements will be obtained at baseline and about every 8 weeks thereafter. Subjects will continue study drug until disease progression or unacceptable toxicity.
89619899|NCT04522362|Sham Comparator|Control task-|The Control Task was implemented to ensure the specificity of the psychological stress effects had on study outcomes. Therefore, the Control Task had a similar procedure and the same duration of the TSST, lacking except for only the psychologically stressful component. The control task consisted of (a) Participants had a 5-min a preparation section and anticipation phase (5 min ), (b) a reading task where they had to. Then, all participants had to be read a simple text in a low voice (5 min), and (c) an arithmetic section where they were asked to perform an easy mathematical calculation (5 mins).
89036659|NCT04686071|Experimental|PNF method|
89688410|NCT03404765|No Intervention|Ususal care group|The control group received the usual care offered by the respective centers. No intervention had been arranged for the control group during the study period. Participants in the control group were advised to attend different kinds of recreational activities provided by their community centers and to continue with their daily activities, including their usual general physical mobility and social activities.
89688411|NCT01723319|Experimental|1|deep TMS treatment
89036660|NCT04686071|Other|standard rehabilitation|
89036661|NCT01268098|Experimental|25 µg dose|25 µg
89036662|NCT01268098|Experimental|50 µg dose|50 µg
89036663|NCT00533052|Experimental|Affective and Cognitive Skills Training|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training
89036664|NCT01674803|Active Comparator|Orsiro|
89036665|NCT01674803|Active Comparator|Synergy|
89036666|NCT01674803|Active Comparator|Resolute Integrity|
89036667|NCT04959825|Active Comparator|melatonin group|Melatonin group (group M )will receive melatonin as a premedication 1 hour before surgery in a dose of 5 mg
89036668|NCT04959825|Placebo Comparator|control group|15 patients will be enrolled for open nephrectomy will receive sugar-coated tablets. Control group(group C)
89036669|NCT05471453|Sham Comparator|DHEA group|75 mg DHEA supplementation per day for 3 months before IVF
89036670|NCT05471453|Experimental|DHEA+CoQ10+Tocotrienol group|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
89036671|NCT05471453|No Intervention|Control group|No supplementation before IVF
89036672|NCT04949607|Experimental|Chronic Traumatic Brain Injury|Subjects aged 18-70 years with chronic traumatic brain injury receiving Inulin treatment.
89036673|NCT04949607|Experimental|Healthy Controls|Healthy subjects aged 18-70 years receiving Inulin treatment.
89619900|NCT04522362|Experimental|Experimental Task- Trier Social Stress Task|"The Trier Social Stress Task (TSST) is a standardized, 15-minute laboratory task designed to induce psychological stress in laboratory settings (Kirschbaum, Pirke, & Hellhammer, 1993). The TSST consists of three continuously successive phases: (a) an anticipation period (5 min); (b) a free speech task (5 min); and (c) a mental arithmetic task (5 min). As is standard in the TSST procedure, participants were told by a research staff member that they would provide a brief speech about their dream job in front of a critical audience. At the end of the speech, a member of the audience instructed the participant to conduct serial subtractions as accurately and quickly as possible."
89619901|NCT03358524|Experimental|Vitamin E 400 IU|Vitamin-E Capsule (alpha-tocopherol) 400 IU once per day orally for 8 weeks
89619902|NCT03358524|Placebo Comparator|Placebo|Placebo capsule once per day orally for 8 weeks
89619903|NCT03365232|Experimental|non custom base attachment|
89619904|NCT03365232|Active Comparator|custom base attachment|
89619905|NCT04444986|Experimental|FAVIR then AVIGAN|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
89619906|NCT04444986|Experimental|AVIGAN then FAVIR|Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
89619907|NCT04444596|Other|Swab|Conjunctival swab and nasopharyngeal swab for SARS-COV 2
89619908|NCT04444674|Experimental|Group 1- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
89619909|NCT04444674|Placebo Comparator|Group 1- placebo|Participants (HIV-negative) will receive two doses of Normal saline (0.9%) in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
89619910|NCT04444674|Experimental|Group 2a- IP|Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
89619911|NCT04444674|Placebo Comparator|Group 2a- placebo|Participants (HIV-negative) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 7 (1-dose) or 9 (2 doses) routine visits over a 12 month period.
89619912|NCT04444674|Experimental|Group 2b- IP|Participants will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
89619913|NCT04444674|Placebo Comparator|Group 2b- placebo|Participants will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 5 (1-dose) or 6 (2 doses) routine visits over a 12 month period.
89619914|NCT04444674|Experimental|Group 3- IP|Participants (HIV-positive) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
89619915|NCT04444674|Placebo Comparator|Group 3- placebo|Participants (HIV-positive) will receive two doses of placebo in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month period.
89619916|NCT03365076|Experimental|Physical aerobic intervention|The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
89036674|NCT03457233|Active Comparator|Normal weight|18.5- 24.9 kg/m2
89619917|NCT03365076|No Intervention|Controls|These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.
89619918|NCT02519166|Other|Patients with chronic wounds|
89619919|NCT03356730|Experimental|Arm vitamin D|Vitamin D 5.000 IU a day for 2 months (10 drops after lunch)
89619920|NCT03356730|Placebo Comparator|Arm placebo|Placebo for 2 months (10 drops after lunch)
89619921|NCT03354702|Experimental|Group aerobic activity (experimental)|Group aerobic exercise (experimental). Patients perform aerobic exercise per 30 minutes (moderate intensity: 70% to 85% of estimated maximum heart rate), more 10 minutes stretching, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions.
89688412|NCT01723319|Sham Comparator|2|inactive treatment
89036675|NCT03457233|Active Comparator|Overweight|BMI 25-29.9 kg/m2
89036676|NCT03457233|Active Comparator|Obese|BMI ≥ 30 kg/m2
89036677|NCT00535808|Experimental|1|Administration of nitroprusside
89036678|NCT00535808|Experimental|2|Administration of nitroglycerine
89036679|NCT00535808|Experimental|3|Administration of sevoflurane
89036680|NCT04920903|Experimental|COR588|
89036681|NCT04920903|Placebo Comparator|Placebo|
89036682|NCT05471063|Experimental|ABCD treatment|In this single-arm research, patients were treated with ABCD 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) combined with flucytosine 100 mg/kg/d for induction therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks. Then, patients were treated with Fluconazole (400-600 mg/d) ± flucytosine (100 mg/kg/d) for consolidation therapy for at least 6 weeks.
89520481|NCT04803383|Experimental|Tele-Yoga Group|Patients in the tele-yoga group will participate in tele-yoga sessions with a maximum of 5 people in each group by video-conference method for 8 weeks, 3 days a week. Assessments will perform just before starting to study and after the 8-week tele-yoga program
89520482|NCT04803383|No Intervention|Control group|Patients in the waiting list control group will be asked to continue their normal physical activities during the 8-week study, not to start a new exercise program, and to report any changes in the drug or dosage used. Control group's assessments will be performed when they are included in the study and at the end of 8 weeks. After these assessments, patients who wish will participate in the tele-yoga program.
89520483|NCT04453215|Experimental|test group|SLE patients treated with infrared laser irradiation
89520484|NCT04453215|Placebo Comparator|placebo group|SLE patients treated with red laser irradiation
88988161|NCT05148169|Experimental|SSRI plus Sulforaphane group|"One SSRI is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
89520485|NCT04453215|No Intervention|control group|no therapy group
89520486|NCT03446183||Smoking cessation prospective|Smoking cessation workshops
89520487|NCT03446183||Smoking cessation retrospective|File review of former workshop participants
89520488|NCT02426684|Experimental|IdeS®|Twenty patients will receive 0.24mg/kg (n=20)
89520489|NCT05084105||Cannabis Group|A total of 30 older (age 50-80 years) men and women who are using cannabis.
89520490|NCT05084105||Control Group|A total of 30 older (age 50-80 years) men and women who are not using cannabis.
89520491|NCT03446105|Experimental|App-based behavioral intervention|Participants randomized to this study arm will take part in the Achieving Wellness After Kancer in Early life (AWAKE) behavioral intervention for 8 weeks.
89520492|NCT03446105|Active Comparator|Attention control group|Participants randomized to this study arm will take part in a behavioral intervention and coaching for 8 weeks.
89520493|NCT05060055|Experimental|Test Group|Customized healing abutment inserted in immediate implant placement in association with the use of a connective tissue graft.
89520494|NCT05060055|Active Comparator|Control Group|Customized healing abutment inserted in immediate implant placement.
89520495|NCT03445871|Active Comparator|Patients with active rheumatoid arthritis|Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
89520496|NCT03445871|Active Comparator|Patients with rheumatoid arthritis into remission|Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
89520497|NCT03445715|Experimental|Cohort I|Single intra-articular injection ART-I02: 2.4x10E12 vg / wrist joint
89520498|NCT03445715|Experimental|Cohort II|Single intra-articular injection of ART-I02: 2.4x10E13 vg / wrist joint
89520499|NCT03445715|Experimental|Cohort III|Single intra-articular injection in the wrist joint of ART-I02 Maximum Tolerated Dose (MTD) as assessed in cohorts I and II:
89520500|NCT03440489|Other|six-minute walking test|physical performance of the muscle: measured by Gait speed test, Timed up and go test, six-minute walking test , 30 seconds chair stand test
89520501|NCT03129035|Active Comparator|internal iliac artery ligation|women undergo bilateral internal iliac artery ligation after fetal extraction and before proceeding in cesarean hysterectomy
89520502|NCT03129035|Active Comparator|No internal iliac artery ligation|Women undergo cesarean hysterectomy after fetal extraction
89520503|NCT02656173|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day along with tamsulosin 0.2 mg for 12 weeks
89520504|NCT02656173|Experimental|Placebo|Participants who received matching placebo once a day along with tamsulosin 0.2 mg for 12 weeks.
89520505|NCT03445403|Experimental|Chronic pain disorders|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
89520506|NCT03445403|Active Comparator|Healthy controls|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
89520507|NCT03440255|Experimental|Transcutaneous Vagus Nerve Stimulation|TaVNS 8 sessions, 30 min, 4 weeks GAD: 20 Hertz (Hz) - 80 microseconds (µs) CP: 5Hz-200µs IBS: 3Hz-250µs
89520508|NCT04452071||prepubertal|patients born in 2012-2011
89520509|NCT04452071||pubertal|patients born in 2010-2009-2008-2007
89520510|NCT04452071||postpubertal|patients born in 2006-2005-2004-2003
89520511|NCT03445247|Sham Comparator|Control|No intervention, no placebo, but do the same blood tests and examinations as experiment group at the same time points
89520512|NCT03445247|Experimental|Extracorporeal low-intensity shockwave group|with 12 times extracorporeal low intensity shockwave therapy and do the blood test and assessments at baseline, 3, 6, 12 m after initiation of therapy.
89520513|NCT04418895|Experimental|Single Arm: Standard of Care|Investigator's choice of total neoadjuvant therapy (TNT) comprised of neoadjuvant chemotherapy and chemoradiation followed by surgical resection; or neoadjuvant chemoradiation followed by surgical resection and then adjuvant chemotherapy.
89520514|NCT04715633|Experimental|PD-1 inhibitors plus VEGF inhibitors|Patients will be given 4 cycles of Camrelizumab (200mg iv every 3 weeks) plus Apatinib (250mg QD day1-14) before being evaluated for response.
89520515|NCT04236999|Experimental|YSLQQ group|"This group will receive the prevention program during the academic year in school hours. The prevention program is called Unplugged in its original name, but the adaptation made by the research team for Chile is called Yo Sé Lo Que Quiero (YSLQQ). 12 one-hour sessions taught once a week by class teachers, previously trained in a 3-day course. Each session will be delivered during the time of Orientation lessons."
89520516|NCT04236999|No Intervention|Control group|The control group will receive the usual teaching activities regarding substance use prevention.
89688413|NCT01729793|Active Comparator|Digestive Enzyme #2|A proprietary blend of dietary supplement enzymes in a capsule
88988162|NCT05148169|No Intervention|Healthy control group|No intervention is given.
88988163|NCT05148130||the gestational diabetes pregnant women group|The diagnosis of GDM was established following the International Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criteria. GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l, 1-hour plasma glucose ≥10.0 mmol/l, and 2-hour plasma glucose of 8.5-11.0 mmol/l. Women diagnosed with DM or prediabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
88988164|NCT05148130||the healthy pregnant control group|the control group was pregnant women who delivered a single fetus at full term without complications and complications during pregnancy
89520517|NCT03445091|Experimental|Patients using investigational product|Open-label use of SANKOM Patent Socks
89520518|NCT04152915|Experimental|DV3396|Semaglutide administered with the DV3396 pen-injector (semaglutide D, test formulation)
89520519|NCT04152915|Experimental|PDS290|Semaglutide administered with the PDS290 pen-injector (semaglutide reference formulation)
89520520|NCT03109457||Oral squamous cell carcinoma|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
88988165|NCT00144482|Experimental|1|
88988166|NCT00144482|Placebo Comparator|2|
88988167|NCT02276599||Cardiac catheterization|Patients with a diagnosis of atrial septal defect who are having a cardiac catheterization.
88988168|NCT05148754|Experimental|Elsulfavirin 400 mg.|Cohort I (N = 3). Single oral dose of 400 mg.
88988169|NCT05148754|Experimental|Elsulfavirin 800 mg.|Cohort II (N = 3). Single oral dose of 800 mg.
88988170|NCT05148754|Experimental|Elsulfavirin 1 200 mg.|Cohort III (N = 3). Single oral administration at a dose of 1200 mg.
88988171|NCT05148754|Experimental|Elsulfavirin 1 200 mg*9|Cohort IV (N = 6). A single 1200 mg oral dose followed by 200 mg daily for 9 days.
88988172|NCT00404729|Other|Citicoline treatment|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
88988173|NCT05146687||Aflibercept|Patients/patient eyes who were treated only with aflibercept in 2019
88988174|NCT05146687||Ranibizumab|Patients/patient eyes who were treated only with ranibizumab in 2019
88988175|NCT05146687||Bevacizumab|Patients/patient eyes who were treated only with bevacizumab in 2019
88988176|NCT05146687||≥2 Different Anti- VEFGFs|Patients/patient eyes who were treated with ≥2 different anti-VEGFs in 2019
88988177|NCT05141929|Experimental|intervention group|web based education and routine clinical procedure
88988178|NCT05141929|No Intervention|control group|only routine clinical procedure
88988179|NCT05141578|Experimental|Luci Intervention|Participants enrolled in this group will receive the Luci intervention for a 24-week period.
88988180|NCT05141578|No Intervention|Wait-list Control|Participants in the waiting-list control group will not receive any intervention during the study. They will be invited to participate to the program at the end of the trial.
88988181|NCT05144659|Active Comparator|Double faced transverse preputial onlay island flap (group A)|Thirty-four patients undergo double faced transverse preputial onlay island flap are categorized as (group A)
89520521|NCT03109457||Control|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
89520522|NCT03440021|Experimental|High-dosage (60mg) ORM-12741|6 x 10 mg ORM-12741 immediate release capsules in a single dose
89520523|NCT03440021|Experimental|Low-dosage (10mg) ORM-12741|1 x 10 mg ORM-12741 immediate release capsules and 5 x placebo capsules in a single dose
89520524|NCT03440021|Placebo Comparator|Placebo|6 x placebo capsules in a single dose
89520525|NCT03445013|Experimental|SB414 6%|SB414 6% topically twice daily
89520526|NCT03445013|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
89520527|NCT03444935|Experimental|Intervention|Participants randomized to the intervention group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the control group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
89520528|NCT03444935|Other|Control|Participants randomized to the control group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the intervention group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
89520529|NCT03439943|Experimental|Lixisenatide|Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
89520530|NCT03439943|Placebo Comparator|Placebo|Placebo: once daily subcutaneous injection
89520531|NCT03439787|Active Comparator|Active Popliteal Plexus Block|10 ml Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
89520532|NCT03439787|Placebo Comparator|Placebo Popliteal Plexus Block|10 ml Sodium Chloride 0.9 %
89520533|NCT03444857|Experimental|CPAP treatment|Continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) plus standard care (according to current STEMI guidelines) for 3 months after pPCI
89520534|NCT03444857|No Intervention|Control|Standard care (according to current STEMI guidelines) for 3 months after PPCI with no intervention for OSA
89036683|NCT04920396|Experimental|IRPL|Three treatments with IRPL (manufacturer: E-Swin, France) on days 0, 15 and 45
89619922|NCT03354702|Active Comparator|Group stretching (control)|Group stretching (control). Patients perform stretching per 30 minutes, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions
89619923|NCT03364998|Experimental|BAY94-9027 and Elocta|Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment
89619924|NCT03364998|Experimental|Elocta and BAY94-9027|Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment
89619925|NCT03356418|Experimental|WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session
89619926|NCT03356418|Sham Comparator|Sham WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
89619927|NCT04520022|Experimental|FURESTEM-CD Inj|
89619928|NCT03364920||normal level of serum maresin-1|
89619929|NCT03364920||abnormal level of serum maresin-1|
89619930|NCT04520334|Other|Zhineng Qigong|Zhineng Qigong intervention
89619931|NCT04508946|Active Comparator|Hydrocortisone Monotherapy|Hydrocortisone Monotherapy
89619932|NCT04508946|Experimental|triple therapy regimen (vitamin c - thiamine- hydrocortisone)|triple therapy regimen (vitamin c - thiamine- hydrocortisone)
89619933|NCT03364842|Experimental|F group|Furosemide group
89619934|NCT03364842|No Intervention|C group|Control group
89619935|NCT04443972|Experimental|PD VitalOs cement® alone|class II furcation defects that will be treated with PD VitalOs cement® alone
89619936|NCT04443972|Experimental|PD VitalOs cement® plus Bone graft and membrane|PD VitalOs cement® and Hydroxyapatite bone graft and biodegradable collagen membrane in the treatment of class II furcation defects.
89619937|NCT03356184|Experimental|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
89619938|NCT03356184|Active Comparator|The Earlysense System Device Group|The reference device -EarlySense System and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
89036684|NCT04920396|Active Comparator|Warm compress|Daily use of a warm compress (manufacturer: The Eye Doctor, UK) with Sterileyes® twice a day for 5 minutes
89036685|NCT05471024|Active Comparator|Digitized Mounted Articulator Scan|"Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
89619939|NCT03364764|Experimental|efficiency of sirolimus on PRCA|A prospective research of the sirolimus efficiency on refractory PRCA patients On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
89619940|NCT02519400|Experimental|Amitriptyline|Single oral dose of amitriptyline, 25 mg
89619941|NCT02518542|Active Comparator|Per oral endoscopic therapy A|Per oral endoscopic myotomy
89619942|NCT02518542|Active Comparator|Per oral endoscopic therapy B|Prolonged dilatation by implantation of large diameter stents.
88988182|NCT05144659|Active Comparator|transverse inner preputial onlay island flap (control group) (group B)|Another thirty-four patients undergo transverse inner preputial onlay island flap are categorized as the control group = (group B)
89036686|NCT05471024|Experimental|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
89036687|NCT05471024|Experimental|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
89036688|NCT04912206|Experimental|Intervention|Point-of-Care Ultrasound on top of diagnosis work-up
89619943|NCT02518542|Active Comparator|Per oral endoscopic therapy C|Dilatation
89619944|NCT02518542|Active Comparator|Laparoscopic surgery|Laparoscopic Heller myotomy
89619945|NCT04518696|Experimental|suprachoroidal buckling treatment group|suprachoroidal buckling for therapy of rhegmatogenous retinal detachment
89619946|NCT04509258|Placebo Comparator|control group|this group will have the standard and routine therapy of treatment of acute Aluminium Phosphide poisoning immediately after admission according to PCCA guidelines
89619947|NCT04509258|Active Comparator|N- acetyl cysteine grouo|N-acetyl cysteine will be given at dose of 300mg/kg/d IV in the first day then 150 mg/kg/d IV in addition to standard of care according to PCCA guidelines
89619948|NCT04509258|Active Comparator|Acetyl L-carnitine group|Acetyl L-carnitine will be given at dose of 50 mg/kg IV once to be followed by additional doses of 15 mg/kg IV q4hr infused over 30 min. standard of care according to PCCA guidelines will also be provided
89688414|NCT01729793|Placebo Comparator|Placebo|Capsule identical to active arm containing only microcrystalline cellulose
88988183|NCT05141422|Experimental|Treatment group|SHR2150+ efavirenz
88988184|NCT00156663|Other|Arm 1|
88988185|NCT05141461|Sham Comparator|Group C|The patients will be received an ultrasound-guided interscalene brachial plexus block with 15 mL bupivacaine 0.5%.
88988186|NCT05141461|Experimental|Group Dex|The patients will be received an ultrasound-guided interscalene brachial plexus block with 15 mL bupivacaine 0.5% and 5 mg intravenous dexamethasone.
89619949|NCT04509258|Active Comparator|Medicated paraffin oil group|Gastric decontamination with sodium bicarbonate (NaHCO3; 44 mEq, orally) and medicated paraffin oil (200 mL) will be administered in addition to standard of care according to PCCA guidelines
89619950|NCT03354624|Experimental|Nerve growth factor group|Three injections of sterile solutions of recombinant human nerve growth factor (NGF) will be performed in the right extensor carpi radialis muscle to induce muscle hyperalgesia.
89619951|NCT03354624|Experimental|Nerve growth factor group + delayed onset muscle soreness|Injections of nerve growth factor and eccentric exercise of the extensor carpi radialis muscle will be performed to induce muscle hyperalgesia.
89619952|NCT03354546||Elective noncardiac surgery|Individuals having major noncardiac surgery following an elective hospital admission
89619953|NCT03354546||Emergency general surgery|Individuals having general surgery following an urgent hospital admission
89619954|NCT03354468||fall prevention program time 1|orthopedic department in Kristiansund hospital before implementation of a fall prevention program
89619955|NCT03354468||no fall prevention program time 1|orthopedic department in Ålesund hospital without fall prevention program
89619956|NCT03354468||fall prevention program time 2|orthopedic department in Kristiansund hospital after implementation of a fall prevention program
89619957|NCT03354468||no fall prevention program time 2|orthopedic department in Ålesund hospital without fall prevention program
89619958|NCT03355950|Active Comparator|TEP group|Patients who undergo totally extraperitoneal hernia repair, TEP Repair.
88988187|NCT05140135|Experimental|Recovery Oriented Cognitive Therapy (CT-R)|Therapists implement CT-R in weekly sessions for approximately 9 months while supported by a clinical supervisor. Therapists will have completed a supervised CT-R training case prior to the initiation of the randomized controlled trial. CT-R will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. The therapist will use techniques to engage the patient in the adaptive mode, which involves activating cognitions, affects, motivation, and behaviors by engaging the individual in personally meaningful activities.
88988188|NCT05140135|Active Comparator|Continued Usual Care|
88988189|NCT00404885|Placebo Comparator|Placebo|
88988190|NCT00404885|Active Comparator|LX211, 0.2 mg/kg|
88988191|NCT00404885|Active Comparator|LX211, 0.4 mg/kg|
88988192|NCT00404885|Active Comparator|LX211, 0.6 mg/kg|
88988193|NCT05148832|Experimental|Cortocosteroid|ageusia and anosmia were recruited (that their covid infection was confirmed by using PCR). 10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery. All data were recorded and then analyzed.
88988194|NCT05145985||Women over 60|Women aged over 60 years. Participants were allowed to participate in the study if they were able to walk independently and their health condition allowed them to perform the indicated fitness tests.
88988195|NCT00148239|Experimental|Caregiver Only|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
88988196|NCT00148239|Experimental|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
88988197|NCT00148239|Active Comparator|Control|Participants are provided with written materials at beginning of study; nothing thereafter
88988198|NCT05140213||Group 1 : Before|"Before phase including 186 patients patients included before the implementation of the prescription support tool"
88988199|NCT05140213||Group 2 : After|"After phase including 185 patients patients included after the implementation of the prescription support tool"
88988200|NCT05595005||Stroke|Stroke patients (ischemic or hemorrhagic) in the chronic phase (> 6 months)
88988201|NCT05595005||Healthy controls|Healthy adult controls
88988202|NCT00156702|Active Comparator|1|
88988203|NCT00156702|No Intervention|2|
88988204|NCT05142943|Experimental|Visual Illusion (VI and therapeutic exercise program (EP)|"the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes. Then a physical exercise program for the upper extremities will be carried out:~General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~Gross mobility and coordination: ball games.~Fine mobility and coordination: writing tasks, puzzles, abacus ...~Strength exercises: shoulder, elbow, wrist, fingers.~Stretching."
89619959|NCT03355950|Active Comparator|Lichtenstein group|Patients who undergo Lichtenstein repair.
89619960|NCT03364374||Stroke survivors|Individuals that experienced uni-hemispheric ischemic or hemorrhagic stroke
89619961|NCT03364374||Controls|Healthy controls with no history of stroke
89619962|NCT03364218|Experimental|Treatment Group|Subjects will receive N-Acetyl Cysteine (NAC) nebulized 2 mL of 10% NAC solution every 12 hours during their stay in the Pediatric Intensive Care Unit.
89619963|NCT03364218|No Intervention|Control Group|Subjects will not receive NAC, but will receive standard care for acute bronchiolitis.
89619964|NCT04444284|Experimental|Dosage Group 1: RSV Vaccine Dosage 1|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 1.
88988205|NCT05142943|Sham Comparator|VI sham and EP|the configuration of the work table will be the same as in real IV, although videos of landscapes will be projected on them without any type of human or animal movement appearing on them. This program will last 10 minutes. Afterwards, a physical exercise program for the upper extremities will be carried out, detailed in Arm I.
88988206|NCT05142943|Experimental|VI|only the visual illusion program will be carried out, detailed in Arm I.
88988207|NCT05142943|Sham Comparator|VI sham|
88988208|NCT05594966||Cerebral Small Vessel Disease|In this group, patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI.
89619965|NCT04444284|Placebo Comparator|Dosage Group 1: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
89619966|NCT04444284|Experimental|Dosage Group 2: RSV Vaccine Dosage 2|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 2.
89619967|NCT04444284|Placebo Comparator|Dosage Group 2: Placebo|Participants in this arm will receive a single intranasal dose of placebo.
89619968|NCT04444284|Experimental|Dosage Group 3: RSV Vaccine Dosage 3|Participants in this arm will receive a single intranasal dose of the investigational RSV vaccine at Dosage 3.
89619969|NCT03354312|Experimental|Lidocaine/Articaine|Lidocaine Hydrochloride 1% Gel anesthesia / Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia
89619970|NCT03354312|Experimental|Articaine/Lidocaine|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia / Lidocaine Hydrochloride 1% Gel anesthesia
89619971|NCT03354234|Experimental|Stimuli of slowly increasing intensities|"300-s check before the stimuli~LBNP is applied stepwise with 11.1 mmHg/15 s decrement to -100 mmHg, and then this value is sustained for 120 s~180-second phase of rest between stimuli~75°-HUT (5°/s) for 120 s after a 15-s reversing of the gravity vector (-30°)~180-second phase of rest between stimuli~75°-HUT (5°/s) accompanied by an exposure to an LBNP of -60 mmHg increased linearly by -4 mmHg/s, and then this value is sustained for 120 s during HUT~120-s check after the stimuli"
89619972|NCT03354234|Experimental|Stimuli of rapidly increasing intensities|"120-s check before the stimuli~75°-HUT (45°/s) for 60 s after a 3-s reversing of the gravity vector (-30°)~180-second phase of rest between stimuli~LBNP decreases linearly by -20 mmHg/s to -100 mmHg, and then this value is sustained for 60 s.~180 second phase of rest between stimuli~push-pull, i.e., 3 x 75°-HUT (45°/s) preceded by -30°-HDT (45°/s) and accompanied by an exposure to an LBNP of -60 mmHg decreased linearly by -20 mmHg/s, and then this value is sustained for 30 s during HUT~120-s check after the stimuli"
89619973|NCT03364062||cemented shoulder replacement patients|A total of 350 cases of proximal humeral fracture receiving cemented shoulder replacement in Department of Orthopedics and Trauma
89619974|NCT03363984|Experimental|Midazolam & ID-082|Single oral administration of 2 mg midazolam on Day 1, Day 2, and Day 11. Administration of ID-082 from Day 2 through Day 11.
89619975|NCT03363828||Normal microbiota|Based on qPCR and Next gen sequencing
89619976|NCT03363828||Abnormal microbiota|Based on qPCR and Next gen sequencing
89619977|NCT04508868|Experimental|Brief Behavioral Activation with Mental Imagery|Four weekly sessions of Brief Behavioral Activation with Mental Imagery.
89619978|NCT04508868|Placebo Comparator|Minimal Attention Control Intervention|Four weeks with weekly follow-up calls.
89619979|NCT04524468||hemodialysis patients|end-stage renal disease patients on hemodialysis
89619980|NCT04524468||peritoneal dialysis patients|end-stage renal disease patients on peritoneal dialysis
89619981|NCT03354156||High-LDL|patients with LDL cholesterol levels of >4.9 mmo/l, who have not been treated with statins in the past years, and who have an indication for treatment with statins.
89619982|NCT03354156||Control|control subjects with an LDL cholesterol level of <3.5 mmol/l
88988209|NCT05594966||non-Cerebral Small Vessel Disease|In this group, cerebral small vessel disease is ruled out by preoperative multimodal MRI.
88988210|NCT05148637|Active Comparator|Group I|anesthesia maintained by sevoflurane
88988211|NCT05148637|Active Comparator|Group II|anesthesia maintained by desflurane
88988212|NCT05148637|Active Comparator|Group III|anesthesia maintained by TIVA
88988213|NCT00148278|Experimental|1|norepinephrine plus dobutamine
88988214|NCT00148278|Active Comparator|2|epinephrine
88988215|NCT05143333||Post acute COVID-19|Severity of COVID-19 will be determined based on patient classification within the PACT (Johns Hopkins Post-acute COVID-19 Team) clinic. Specifically, patients followed in the PACT-ICU clinic required ICU stays of ≥48 hours and high-flow nasal cannula/non-invasive ventilation or mechanical ventilation. Those followed in the PACT-Base clinic have less severe disease that does not necessitate ≥48 hours in the ICU but does qualify for PACT clinic referral based on either (1) ongoing pulmonary and/or rehabilitation needs at the time of hospital discharge, or (2) persistent pulmonary or functional deficits at 4-6 weeks post infection without hospitalization.
88988216|NCT00507247|Experimental|Daptomycin|6mg/kg/day intravenous (IV) for 10 days
88988217|NCT05143762|Active Comparator|group (A)|will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day).
88988218|NCT05143762|Active Comparator|group (B)|will receive dexamethasone 0.5mg/kg IV.
88988219|NCT05143762|Placebo Comparator|group(C)|will received placebo 10 ml normal saline IV.
88988220|NCT05143450|Experimental|Experimental Group|Before the procedure, manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher.
88988221|NCT05143450|No Intervention|Control Group|No intervention will perform to reduce pain in the control group.
88988222|NCT00148356|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
88988223|NCT00148356|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
88988224|NCT02954770||Fitbit® challenger|The residents who participated a Fitbit® challenge study about one year ago
88988225|NCT02954614|Experimental|Intervention group|Active play in after school programs (ASP). Training program for ASP staff.
88988226|NCT02954614|No Intervention|Control group|ASP as usual.
88988227|NCT02954809|Experimental|Experimental|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
89619983|NCT03519438||Lateral 3/4 of treatment field|placement of Mepitel on the lateral ¾ of the treatment field
89619984|NCT03519438||Medial 3/4 of treatment field|placement of Mepitel on the medial ¾ of the treatment field
89619985|NCT04444206|Experimental|CL and CCI screening|The Cervical lenght (CL) and the Consistence Cervix Index (CCI) will be evaluated by transvaginal ultrasound. CL and CCI measurements will be expected in the first trimester, between 11 and 13 weeks + 6 days, in the second trimester, between 19 and 22 weeks and in the third trimester between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy, in accordance with current national guidelines.
89619986|NCT04444206|No Intervention|No CL and CCI screening|The investigators collect data of these pregnant women without any additional ultrasound examination
89619987|NCT04524078|Experimental|Intensive integrated intervention care program|intensive integrated intervention care program [ICP] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
89619988|NCT04524078|No Intervention|Non intensive integrated intervention care program|
89520535|NCT05082155|Experimental|Right sided catheter bupivacaine 0.25% and left sided catheter normal saline|This is a split body study. Bilateral erector spinae plane catheters will be inserted and study fluid is administered bilaterally. Bupivacaine 0.25 will be administered through the right-sided catheter while normal saline will be administered through the left-sided catheter. Both infusion pumps will be programmed to deliver a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
89520536|NCT05082155|Experimental|Right sided catheter normal saline and left sided catheter bupivacaine 0.25%|This is a split body study. Bilateral erector spinae plane catheters will be inserted and study fluid is administered bilaterally. Normal saline will be administered through the right-sided catheter while bupivacaine 0.25% will be administered through the left-sided catheter. Both infusion pumps will be programmed to deliver a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
89520537|NCT02656017|Experimental|Metformin|"Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations:~Increase to 500mg twice daily at week 2~Increase to 1000mg qAM, 500mg qPM at week 4~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~Increased titrations based on tolerability"
89520538|NCT02656017|Placebo Comparator|Placebo|"Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations:~Increase to 500mg twice daily at week 2~Increase to 1000mg qAM, 500mg qPM at week 4~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~Increased titrations based on tolerability"
89520539|NCT03439709|Experimental|intervention|Gamma knife radiosurgery (Leksell Gamma Knife, Elekta AB, Stockholm, Sweden) is used for intervention. Administration of standard medical therapy using Lanreotide 60 mg concurrently starts with radiosurgery
88988228|NCT02954809|Active Comparator|Attention Control|Exposure to dim light delivered with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
88988229|NCT05140993|Experimental|extended support|providing extended emotional and orientation support
88988230|NCT05140993|No Intervention|common practice|The hospital routine clinical standard- not providing extended emotional and orientation support
88988231|NCT05145751||COVID-19 infection|Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection
89036689|NCT04912206|No Intervention|Control|Usual diagnosis work-up without Point-of-Care Ultrasound
89036690|NCT05470946|Other|Enteroscopy|Double balloon enteroscopy
89036691|NCT04910100|Experimental|Nebivolol Ophthalmic Suspension 1 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
89036692|NCT04910100|Experimental|Nebivolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
89520540|NCT03439709|Active Comparator|control|Without radiosurgery, standard medical therapy (Lanreotide 60Mg Solution for Injection) same with interventional group is applied
89520541|NCT03439553|Experimental|Intervention|People shown ads with referral to target websites.
89520542|NCT03439553|Active Comparator|Intervention with control websites|People shown ads with referral to control websites.
89520543|NCT03439553|No Intervention|Control|People who make target queries, but are not shown the ads.
89520544|NCT04561401|Experimental|rTMS + IPRP|25 youth aged 10-18 years with severe chronic pain will be invited to partake in the Intensive Pain Rehabilitation Program, where they will receive Repeated Transcranial Magnetic Stimulation as one of their treatment interventions.
89520545|NCT04561401|Active Comparator|IPRP|Youth within this arm will not be receiving the rTMS intervention. Rather, they will only be enrolled within the IPRP.
89520546|NCT04706039|Experimental|Outpatients without hospitalisation criteria|Symptomatic and asymptomatic outpatient without hospitalisation criteria presenting in a COVID-19 screening centre of the Hospices Civils de Lyon
89520547|NCT04451369|No Intervention|Control group|Group without prehabilitation program before surgery
89520548|NCT04451369|Experimental|Prehabilitation group|Group will follows a prehabilitation program before surgery
89520549|NCT04402515||Tiotropium plus Olodaterol treatment regimen|
89520550|NCT04402515||Inhaled corticosteroids-containing treatment regimen|
89520551|NCT04451447|Experimental|white test arm|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
89520552|NCT04451447|Other|Saline test arm|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
89520553|NCT04516941|Active Comparator|Edoxaban|Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or <50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).
89520554|NCT04516941|Active Comparator|Colchicine|Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days).
89520555|NCT04516941|No Intervention|No Edoxaban and No Colchicine|No intervention
89520556|NCT04516941|Active Comparator|Edoxaban and Colchicine|"Edoxaban 60 mg q.d., or 30 mg q.d. in patients with CrCl = or <50 ml/min or body weight equal or less than 60 kg from randomization to end of study visit at day 25 (+/-3).~Colchicine at 0.5 mg per os (PO) twice daily for the first 3 days and then once daily from randomization to day 14 (+/-3) days. Treatment could be continued to day 25 (+3/-3 days)."
89520557|NCT03444467|Experimental|NNC9204-1513|Participants will receive increasing doses of NNC9204-1513.
89520558|NCT03444467|Active Comparator|Glucagon|Participants will receive a single fixed dose of glucagon.
89520559|NCT02657343|Experimental|Cohort A: Ribociclib + T-DM1 [3+3 Design]|"Ribociclib will be given orally once day (day 5-18) at a pre-determine dose for two weeks of a 21 day cycle. During dose escalation, patients received doses of ribociclib of Period 1: 300 mg (n = 3), Period 2: 400 mg (n = 3), Period 3: 500 mg (n = 3), and Period 4: 600 mg (n = 3). Maximum dose-escalation of Ribociclib will be up to 600 mg. Dose-escalation will stop if DLT exceed limit.~T-DM1 will be given as IV infusions on Day 1 of a 3 week cycle at a pre-determined dose over pre-determined period of time."
89036693|NCT04910100|Experimental|Timolol Ophthalmic Suspension 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
89036694|NCT04910100|Active Comparator|Timolol Ophthalmic Solution 0.5 Percent|Administered twice daily to both eyes for 84 days (12 weeks)
89036695|NCT04686149||Neo CCRT+Neo CTx +/- cystectomy|Patients receive neoadjuvant CCRT and neoadjuvant CTx. Radical cystectomy is performed depending on pathologic response. The patients showing clinical complete response after neoadjuvant CCRT and initially stage T2N0M0 are not treated with neoadjuvant chemotherapy.
89036696|NCT01268059|Active Comparator|Carboplatin/Paclitaxel|Carboplatin/paclitaxel regimen (carboplatin area under the plasma concentration-time curve [AUC] of 6 milligram per milliliter into minute [mg/mL*min], and paclitaxel 200 milligram per square meter [mg/m^2]) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal. Subjects were enrolled from North America/European Union (EU) and Japan regions.
89619989|NCT03355716|Placebo Comparator|Group A (placebo):|instillation of bupivacaine alone: Bupivacaine 25 ml (0.25%) after surgery completion
89619990|NCT03355716|Active Comparator|Group B|Instillation of bupivacaine and morphine: Bupivacaine 25 ml (0.25%) + Morphine (3.0 mg)
89619991|NCT03355716|Active Comparator|Group C|Instillation of bupivacaine and fentanyl: Bupivacaine25 ml (0.25%) + fentanyl (30.0 Mc)
89619992|NCT03355716|Active Comparator|Group D|Instillation of bupivacaine and Ketamine: Bupivacaine25 ml (0.25%) + ketamine (0.5 mg/kg).
89619993|NCT04524312|Active Comparator|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
89619994|NCT04524312|Active Comparator|K-Mod|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Bioimplanti K-MOD prosthesis
89619995|NCT04524156|Active Comparator|COVIS 19 positive|
89619996|NCT04524156|Sham Comparator|COVID 19 negative|
89619997|NCT03355638|Active Comparator|aflibercept monotherapy|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
89619998|NCT03355638|Experimental|aflibercept plus pranoprofen|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of pranoprofen (Pranoflog; Sifi SpA, Aci Sant'Antonio, CT, Italy) three times a day for 12 months. All patients were followed up for 12 months.
89619999|NCT03355638|Experimental|aflibercept plus nutraceutical|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients were given daily tablets of Omega-3 supplementation (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
89620000|NCT03350646|Other|Low volume (20-25 μl)|Low volume (20-25 μl)
89036697|NCT01268059|Experimental|Carboplatin/Paclitaxel + MEDI-575|Carboplatin/paclitaxel regimen (carboplatin AUC = 6 mg/mL*min, and paclitaxel 200 mg/m^2) followed by MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575. Subjects were enrolled from North America/European Union (EU) and Japan regions.
89036698|NCT00535886|Active Comparator|Elaidic Acid|
89036699|NCT00535886|Experimental|Vaccenic Acid|
89036700|NCT00535886|Placebo Comparator|Oleic Acid|
89620001|NCT03350646|Other|High volume (40-45 μl)|High volume (40-45 μl)
89036701|NCT01267825|Experimental|CT-guided intervention|CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care
89036702|NCT01267825|Active Comparator|Standard medical care|
89036703|NCT02889406|Experimental|Motivational intervention|"Following the motivational interviewing schema, structured in 2 phases of treatment (motivational and intervention) and organised in 11 visits (one each month). The first and last visits will be performed in consultations of endocrinology unit from referral hospitals; the other visits will be held in paediatric primary care setting. Visits will be scheduled monthly and each one will last between 15 and 20 minutes.~In addition to individualized visits, three group workshops focused in nutrition education for families will be organized. Each workshop will last 45 minutes and will target parents/mothers and obese children, separately."
89620002|NCT03354078|Active Comparator|interrupted sutures group|This group in which closure of the subcutaneous layer is closed by interrupted sutures
89620003|NCT03354078|Active Comparator|Continous sutures group|subcutanous tissue layer is closed by continous sutures in this group
89620004|NCT01626664|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
89620005|NCT01626664|Active Comparator|investigator's choice|Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
89620006|NCT04515966|Active Comparator|Ultrasound-guided steroid injection|Participants with CTS who meet the inclusion criteria are randomized to two groups. One group (or arm) will receive an ultrasound-guided steroid injection in the vicinity of the median nerve within the carpal tunnel. A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine is injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
89620007|NCT04515966|Active Comparator|Wrist splint|Participants in this arm are treated with a wrist splint.
89620008|NCT03350490|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89620009|NCT03350490|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89688415|NCT02793154|Experimental|Part A: Exenatide|Part A is a single arm design and all subjects will receive 10 mcg subcutaneous injection (SC) of exenatide twice daily for 5 days
89036704|NCT02889406|No Intervention|Control group|Children who are assigned to the control group will follow the usual treatment performed in paediatrics, what is following the Clinical Practice Guideline on the prevention and treatment of child and adolescent obesity. Monthly visits will be conducted in which weight, height and waist circumference will be measured and compliance with the initial advice will be reviewed.
89036705|NCT00593242|Experimental|infusions|infants who arrive at the study site within the first 14 postnatal days and had a history of moderate to severe hypoxic ischemic encephalopathy, and have cells available for infusion that pass Carolinas Cord Blood Bank Quality checks Outcomes will be measured at 22-26 months fby neurodevelopment assessment
89036706|NCT00593242|Other|historical control|Infants who had moderate to severe hypoxic ischemic encephalopathy in the neonatal period but did not receive autologous cord blood cells.
89036707|NCT05470829|Experimental|Part 1 75mg ZM-H1505R or placebo|"75 mg was selected for PK bridging.Twelve healthy subjects were enrolled,of which 8 subjects received ZM-H1505R and 4 subjects received placebo.~Subjects were administrated in the morning under fasting conditions on Day 1 and afterwards Day 4 - Day 14 once daily,i.e. after 3-day washout period and followed by 11-day consecutive administration.Safety and tolerability evaluation was performed on Day 3,Day 6,Day 10 and Day 17 after the initial administration.~Two sentinel subjects (one male and one female) were enrolled to reveived ZM-H1505R.When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects,and study drug concentration of sentinel subjects after the initial administration had been analysed so that PK sampling timepoints for the remaining subjects was determined, the remaining 10 subjects were enrolled to receive ZM-H1505R or placebo at a 3:2 ratio in a randomized manner."
89036708|NCT05470829|Experimental|Cohort 1 of Part 2 50mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 50 mg dose group (cohort 1). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated.~Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
89036709|NCT05470829|Experimental|Cohort 2 of Part 2 100mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 100 mg dose group (cohort 2). Dose ascending was continued when safety evaluation on Day 8 showed that the lower dose could be tolerated.~Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
89057345|NCT01648062|Active Comparator|Arousal reduction using guided imagery|Sleep Self-Regulation Using Mental Imagery: Participants in the arousal reduction condition were instructed to imagine wearing a backpack loaded with their worries, then putting the heavy backpack down, and then experiencing the relief and freedom from tension.
89520560|NCT02657343|Experimental|Cohort B: Ribociclib + Trastuzumab [Phase 1b/2 Study]|"Ribociclib will be given orally once day (400 mg per day on a continuous schedule) for a 21-day cycle of treatment.~Trastuzumab will be given as IV infusions over 6 mg/kg every 3 weeks."
89520561|NCT02657343|Experimental|Cohort C: Ribociclib + Trastuzumab + Fulvestrant [Phase 1b/2 Study]|"Ribociclib will be given orally once a day continuously for a 28-day cycle of treatment (except at Dose Level -1, when Ribociclib is given Days 1-21 of a 28 day cycle).~Trastuzumab will be given as IV infusions over a pre-determined period of time and dose. Fulvestrant will be dosed approximately every 28 days as per standard of care."
89520562|NCT03445169|Experimental|Fasting|Belzutifan tablets taken after fasting
89520563|NCT03445169|Experimental|Non-Fasting|Belzutifan taken after eating a high calorie meal
89520564|NCT04524585|Experimental|Partial NMB|
89520565|NCT04019145|Experimental|Fiber Reinforced bulk fill resin composite|Fiber reinforced bulk fill resin composite dentine substitute, capped occlusally and proximally (closed centripetal technique) by nanohybrid resin composite.
89520566|NCT04019145|Active Comparator|nanohybrid resin composite incrementation|Nanohybrid resin composite layering to fill the whole cavity, using closed centripetal technique.
89520567|NCT03444389||Study group|Patients with hemorrhoids
89520568|NCT03444389||Control group|Healthy participants without hemorrhoids
89520569|NCT03966495||PRisM program|"Pluriprofessional primary care offices with the PRiSM RM program:~Nine of the pluriprofessional primary care offices which implemented the RM program tested in the PRiSM study (2015-2017). The program consisted in: 1) Training on RM in the context of primary care; 2) The appointment of a RM referent in the office; 3) The conduct of six incident review meetings.~All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.~All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
89520570|NCT03966495||Control|"Pluriprofessional primary care offices without the PRiSM RM program:~Nine of the offices pluriprofessional primary care offices which didn't implement the RM program tested in the PRiSM study (2015-2017). They belonged to the PRisM study control group.~All participating offices had to declare adverse events that occurred during the time frame of the PRiSM study.~All participating offices had to fill in the safety climate survey MOSPS at the beginning and at the end of the PRiSM study."
89520571|NCT03444311|Active Comparator|A: 1 dosis|1 dosis (3E+09 cfu/day + 6 g of fiber/day)
89520572|NCT03444311|Active Comparator|B: 2 dosis|2 dosis (3E+09 cfu/day + 12 g of fiber/day)
89520573|NCT04663529||CLADE|contact lens wearers with DED
89520574|NCT04663529||non-CLADE|DED without contact lens wear
89520575|NCT04663529||NC|normal control
89520576|NCT05073731|Experimental|Synchronized Telerehabilitation|Physical activity training aiming to increase hand/arm function and fine motor function will be applied via videoconference for 8 weeks, 2 days a week, in 45-60 minute sessions.
89520577|NCT05073731|Active Comparator|Asynchronous Telerehabilitation|Exercise videos and exercise tracking form will be sent.
88988232|NCT05142631|Experimental|Fruquintinib in soft tissue sarcoma|Fruquintinib : 5mg, once a day (QD), oral on an empty stomach or after a meal, taken with 100 ~ 200ml drinking water for 3 weeks and stopped for 1 week.
88988233|NCT05146960|Experimental|Temporal summation|"Temporal summation will be evoked in ECRL muscle origin, ECRB muscle belly, Brachioradialis. Pressure pain thresholds (PPTs) will be identified two times with a 30 s interval for each predetermined area. The average of two measurements will be used as a PPTs value. Temporal summation was induced two minutes after last PPTs was recorded. To evoke temporal summation at the lateral elbow, the probe will be applied with the pressure of the predefined PPT threshold at the rate of approximately 2 kg/s where it will be maintained for 1 s before being released with a 1 s interstimulus interval (ISI). This procedure will be repeated 10 times in each predetermined area. Pain intensity will be asked to participants at first, fifth and tenth pulse using a Visual Analog Scale range from 0 indicate no pain to 10 most painful"
88988234|NCT05146960|Placebo Comparator|Placebo|pressure pain threshold will be evaluated once in each predetermined region with a 30 second interval.
89520578|NCT03439397|Experimental|Ballon Technique group|Intervention：Ballon Technique
89520579|NCT03439397|Active Comparator|SOAI group|Intervention：Selective Ophthalmic Artery Infusion
89520580|NCT03439241|Experimental|Silent arm|The participants test the new Coloplast ostomy device use the product as they usually would.
89520581|NCT03439241|Experimental|Active arm|The participants test the tnew Coloplast ostomy device and are guided by the measuring device
89520582|NCT02655237|Experimental|Relugolix 40 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by relugolix 40 mg, tablets, orally, once daily and leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 24 weeks in treatment period.
89520583|NCT02655237|Active Comparator|Leuprorelin 1.88 mg or 3.75 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by leuprorelin acetate 1.88 mg or 3.75 mg, injection, SC, once in 4 weeks and relugolix placebo matching tablets, orally, once daily for 24 weeks in treatment period.
89520584|NCT03444233|Experimental|low f1 diet|low fructose diet week 1
89520585|NCT03444233|Experimental|fruit rich diet|fruit rich diet week 2
89520586|NCT03444233|Experimental|low f2 diet|low fructose diet week 3
89520587|NCT03444233|Experimental|HFCS rich diet|HFCS rich diet week 4
89520588|NCT03439163||PD patients|the entire group underwent MRI scan
89520589|NCT03444077|Active Comparator|Control group|The patients allocated in the control group will be managed as recommended in the local guidelines and protocols. As the trial involves participating centers with different prehospital and hospital realities and local practices, the control group will reflect a wide panel of levels of care and will not be limited to a unique approach.
89520590|NCT03444077|Experimental|Intervention group|"Patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS < 10 will be classified as not in need for DCR.~TICCS < 10 This subgroup will be considered without a need for DCR and without coagulopathy. There will not be any activation of the DCR components (no phone contact to the blood bank, to the surgical team, no prehospital transfusion). There will be any prehospital treatment/prevention of the hyperfibrinolysis using Tranexamic acid (TXA). Crystalloids infusion will be allowed.~TICCS ≥ 10 This subgroup will be considered with a need for DCR and with coagulopathy. They will be treated using the STTTOPPP the bleeding protocol."
89520591|NCT03439007||Hypotensive|A group of pediatric patients who showed hypotension during induction of anesthesia
89520592|NCT03439007||Normotensive|A group of pediatric patients who did not show hypotension during induction of anesthesia
89520593|NCT03890133|Experimental|Ba-Duan-Jin group|The participants will be guided by a research staff to do the Ba-Duan-Jin therapy for 50 minutes twice weekly for 12 weeks, in the outpatient section of the hospital; Pregabalin placebo treatment will be administered at bedtime once a day, starting at 150 mg for the first week, and increase to the dose of 300 mg from the second week. After one week, if 300 mg dose is tolerable, then maintain it for 10 additional weeks, if not, then go back to the 150 mg dose for 10 additional weeks.
89520594|NCT03890133|Active Comparator|Pregabalin group|"Wellness education and muscle relaxation exercise program: This program will be held for 50 minutes twice weekly for twelve weeks, containing 10-minute wellness education, 10-minute doctor-patient discussion, and 30-minute guided muscle relaxation exercise.~Active pregabalin capsules: As same usage as the placebo pregabalin capsules."
89520595|NCT03890133|No Intervention|Healthy control group|
89520596|NCT03871647||POAF group|Patients who will experience AF at any time during the first six days after the operation.
89520597|NCT03871647||Non POAF group|Patients with a sinus rhythm during the first six days after the operation.
89520598|NCT03443921|Experimental|Surgery Group|In Surgery Group, an artery divestment combined pancreatectomy will be performed if no pre-operative contra-indication or intra-operative metastasis were revealed. Post-operative adjuvant chemotherapies were prescribed according to performance status.
89520599|NCT03443921|Active Comparator|NeoChemo Group|In NeoChemo (Neoadjuvant Chemotherapy) Group, neoadjuvant chemotherapy will be utilized. After 2 circles of neoadjuvant chemotherapies, patients will be reevaluated and curative operation would be attempted if without disease progression.
89520600|NCT03781245|Experimental|Early|Intervention is administered for cycle 1 and 2 with researchers and following this the company continues intervention independently.
89520601|NCT03781245|Active Comparator|Lagged|Intervention is not administered for cycle 1; researchers administer intervention in cycle 2 and following this the company continues intervention independently.
89520602|NCT03438851|Experimental|Full-time Cognitive Rehabilitation Program|Participants in full-time program will be asked to complete 4 experimental sessions with the NeuroCatch Platform™ over the course of 3 months (i.e. one session/ month).
89520603|NCT03438851|Experimental|Part-time Cognitive Rehabilitation Program|Participants in the part-time program will be asked to complete 3 experimental sessions with the NeuroCatch Platform™ over 3 months (i.e. one session/1.5 months).
89520604|NCT04304703||Internal Medicine resident subjects|Subjects who are categorical Internal Medicine residents at Penn State Hershey Medical Center (PGY1-PGY3), and meet inclusion/exclusion criteria, will be enrolled in this study and wear the WHOOP strap 3.0 for real-time measurement of physiologic metrics.
88988235|NCT02964260|Experimental|TAE combined ablation simultaneously|TAE simultaneously combined with ablation.The treatment interval is 1-3 days between two procedures. TAE using embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
88988236|NCT02964260|Other|TACE combined ablation sequentially|TACE sequentially combined thermal ablation.The treatment interval is 1 month between two procedures. TACE using chemotherapy drug(Doxorubicin/platinum agents) and embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
88988237|NCT05149105|Experimental|APC intervention|"In addition to multidisciplinary care (standard care), patients benefit from an Argon Plasma Coagulation (APC) intervention at D0.~The APC intervention should be repeted at Month 2 and Month 4."
88988238|NCT05149105|No Intervention|Control|Patients are treated according to standard care (multidisciplinary care).
88988239|NCT02276677|Experimental|Oxytocin|Oxytocin 24 IU x 1
88988240|NCT02276677|Placebo Comparator|Placebo|Placebo 24 IU x 1
88988241|NCT02276716|Experimental|Phosphatidylserine|"Phosphatidylserine titration from 300, 600 and 800 mg/day~duration: 6 months"
88988242|NCT05144113||Current FES-Row Subjects|To determine user needs we will survey 10 subjects that are currently participating in FES-row training to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.
88988243|NCT05144113||Non-FES-Row Subjects|To determine user needs we will survey 10 subjects that have never participated in FES-row training to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.
88988244|NCT05594537||ZXR00+ZXR00 emmetropia group|The bilateral implantation of ZXR00 IOLs，and emmetropia was considered as the target refraction for both eyes.
89210951|NCT04015752||patients devoloped hyperglycemia in ICU only|"Full history with special attention to:~Causes of admission to ICU . Duration of DM when present medication used, controlled or not. 2. Complete physical examination with special attention to : Vital signs ( MAP, pulse, temp, RR) Signs of shock (cold clammy skin , oliguria, altered mental status ) Consciousness level. Source of infection (chest , abdomen ,catheter, CVP,..). 3. Laboratory investigations CBC , Liver and kidney functions → baseline and follow up HBA1C. ESR, CRP →baseline and follow up.~Culture :~On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections."
89210952|NCT00826826|Active Comparator|Amiodarone|
89210953|NCT00826826|Placebo Comparator|Placebo|
89210954|NCT00925860|Experimental|non invasive ventilation approach|pure hypoxemic patients admitted to ICU treated by non-positive pressure mechanical ventilation
89520605|NCT03443843|Experimental|Sequence 1|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
89520606|NCT03443843|Experimental|Sequence 2|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
89520607|NCT03443843|Experimental|Sequence 3|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
89520608|NCT03443843|Experimental|Sequence 4|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
89520609|NCT04240587|Active Comparator|TrueTear™ intranasal neurostimulator (ITN) Active Arm|TrueTear™ intranasal neurostimulator (ITN) with active tips - The tips carry the current from the base to the nasociliary nerve.
89520610|NCT04240587|Placebo Comparator|TrueTear™ intranasal neurostimulator (ITN) Placebo/Sham Arm|"TrueTear™ intranasal neurostimulator (ITN) with sham tips - The sham tips and do not properly carry the current."
89520611|NCT03756753|Experimental|Intervention group- results known|Providers of patients enrolled in this arm of the study will be notified of the point of care respiratory testing results
89520612|NCT03756753|No Intervention|Control group- results not known|Providers of patients enrolled in the study will not be notified of the point of care respiratory testing results
89520613|NCT03438305||Group D|
89520614|NCT03438305||Group N|
89520615|NCT03438227|Experimental|Intravenous iron dextran infusion|Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor & Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
89520616|NCT03438227|Active Comparator|Oral ferrous sulfate supplementation|Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.
89520617|NCT03714633|Experimental|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Home-based post-discharge intervention for extreme premature babies and their parents. The intervention consists of one hospital visit, nine home-visits and two telephone calls during the first year corrected age, specifically from one week before discharge to 12 months corrected age. The intervention is strengths-based working with the infant-parent interaction, supporting infant development and strengthening the parent in his/her role.
89520618|NCT03714633|No Intervention|Control|The participants of the Control Group receives treatment as usual, which consists of a regular follow-up program with neurodevelopmental assessment at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 66 months corrected age. Compared to children not participating in the study, the control group will receive an extended follow-up program, with assessment and questionnaires at term age, 3 months corrected age, 12 months corrected age, 24 months corrected age and 36 months corrected age. Participants in the control group will be referred to specialized care when needed.
89520619|NCT03438695|Experimental|Motorized Spiral Enteroscopy|Patients with indication for total enteroscopy. day1: anterograde motorized spiral enteroscopy, day 2: retrograde motorized spiral enteroscopy
89520620|NCT04318197|Active Comparator|Global rehabilitation|2 hours of daily rehabilitation, 3 days per week during 4 weeks
89210955|NCT00925860|No Intervention|conventionally ventilated|pure hypoxemic patients treated by conventional ventilatory support
88988245|NCT05594537||ZXR00+ZXR00 micromonovision group|The bilateral implantation of ZXR00 IOLs，and the ZXR00 IOLs power calculations were performed using a micro-monovision approach aiming for minimal residual myopia (≈ -0.50 D) in the nondominant eye and emmetropia in the dominant eye.
88988246|NCT05594537||ZXR00ZMB00 group|The blended implantation of bifocal IOLs (ZMB00) and ZXR IOLs.
88988247|NCT04696003|No Intervention|control|The patients with classic PPROM between 22/0-26/0 weeks' gestation with oligo/anhydramnion with standard conservative treatment (7 days Amoxicillin/Clarithromycin therapy or 7 days Amoxicillin and once Azithromycin 1 g per os, and corticosteroids like Celestan®, Essex Pharma, Munich, Germany) as RDS prophylaxis will represent the control group (DGGG Guideline AWMF 015-025, February 2019, Version 1.0). The diagnosis of the PPROM must be not early than 20/0 weeks' gestation.
88988248|NCT04696003|Active Comparator|Amnion Flush group (continuous amnioinfusion)|"In the Amnion Flush group additionally to the standard treatment the amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intra-amniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. Amnion Flush Solution (CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h (2400 ml/d) under periodic ultrasound using the standard i.v. pump. The deepest pool of amniotic ﬂuid should be stabilized by about 4 cm. The ultrasound control will be performed daily. Induction of the labour or c-section at 34/0 week of gestation or earlier if indicated."
88988249|NCT05141344|Active Comparator|melatonin group|patients in this group will be premedicated One hour before the start of surgery by receiving 0.5mg/kg orally of melatonin (Melatonin 3 mg ), (the tablet will be dissolved in 5 ml of water, to be given by syringe 5ml) in the preoperative unit
89210956|NCT00817388||1|patients will be asked to provide a urine specimen and complete a questionnaire.
89210957|NCT05013996|Experimental|Intervention|Patients randomized to the experimental (MIDSA groupe) will be treated according to the usual methods of each of the centers (CMP / CRIAVS / private practitioners, etc.) completed with the Multidimensional Inventory of Development, Sex, and Aggression-MIDSA groupe Multidimensional Inventory of Development, Sex, and Aggression-inventory tool.
89210958|NCT05013996|Active Comparator|Control|Patients randomized to the control group will be treated according to the usual methods of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
89210959|NCT00822614|Active Comparator|Active Comparator|Current BTP Medication
89210960|NCT00822614|Experimental|Fentanyl TAIFUN|Titration for dose confirmation followed by observation period
89520621|NCT04318197|Experimental|Personalized rehabilitation|2 hours of daily rehabilitation including at least 2 times 20 minutes of electrostimulation on atrophied muscles, 3 days per week during 4 weeks
89520622|NCT04318197|No Intervention|Classic rehabilitation|40 minutes of rehabilitation, once a week during 4 weeks.
89520623|NCT03438617|Experimental|Peer Support Intervention|9 CHCs will receive the peer support intervention for the full duration of the study period (12 months). Baseline assessment, 12-month and 18-month evaluation to assess the effectiveness and sustainability of the intervention.
89520624|NCT04006509|Experimental|Antenatal Education Group|Patients will receive a prenatally delivered lactation educational program.
89520625|NCT04006509|No Intervention|Standard of Care Group|Patients will receive standard of care and not a prenatally delivered lactation educational program.
89520626|NCT03944811|Active Comparator|Transcrestal sinus floor elevation using Summers technique|
89520627|NCT03944811|Experimental|Transcrestal sinus floor elevation using piezoelectric surgery|
89520628|NCT03438461|Experimental|Part 1|In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram [mg]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.
89520629|NCT03438461|Experimental|Part 2 (Optional)|Optional Part 2 will only be performed if considered to be warranted by the sponsor based on the preliminary pharmacokinetic (PK) analysis of the results from Part 1. Participants will receive a single oral dose of seltorexant (20 mg) as 3 different formulations assigned to one of the either 6 or 4 treatment sequences under fasted or semi-fasted conditions. The treatment will be assigned in 1 of the 6 or 4 assigned sequences per treatment period that is either Period 1 to 6 or Period 1 to 4).
89520630|NCT03433391|Other|Surgery Plus Oxiplex|Oxiplex will be applied after hemostasis is achieved and prior to closure, in adult patients undergoing single level partial discectomy.
89520631|NCT03433391|Other|Surgery Only|Standard of care procedures for adult patients undergoing single level partial discectomy will be followed.
89520632|NCT04512339|Active Comparator|Dupilumab|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive dupilumab injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
89520633|NCT04512339|Placebo Comparator|Placebo|Patients with severe hand eczema with an inadequate response or intolerance to alitretinoin. This group will receive placebo injections (600mg subcutaneously as a loading dose, followed by 300mg subcutaneously once every two weeks).
89520634|NCT03835923|Experimental|lifestyle intervention|Telemedicine-supported lifestyle intervention trough individual structured exercise training (endurance and strength training), increase in daily physical activity, and individual nutritional recommendations
89520635|NCT03835923|Active Comparator|usual care|general exercise and nutritional recommendations according to current guidelines
89520636|NCT03433235|Experimental|Early edoxaban initiation group|Low dose of edoxaban (15 or 30 mg) once daily from Day 2, then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
89520637|NCT03433235|Active Comparator|Conventional edoxaban initiation group|No antithrombotic treatment† -- then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
89520638|NCT03438071||Control group|
89520639|NCT03438071||Videoconference group|
88988250|NCT05141344|Placebo Comparator|placebo group|patients in group P (n =25 ) will receive a placebo( sugary tablets dissolved in 5ml of water by syringe 5 ml) one hour before the start of surgery.
88988251|NCT03456271||fracture group|
88988252|NCT03456271||non-fracture group|
88988253|NCT03450733||Previously Implanted (Group 1)|Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
88988254|NCT03450733||Control (Group 2)|Control, non-implanted subjects
88988255|NCT05594498|Experimental|StrataXRT Arm|This is a single-arm trial where all patients will receive the intervention of StrataXRT.
88988256|NCT03451825|Experimental|Phase 1: Avelumab|
88988257|NCT03451825|Experimental|Phase 2, Cohort 1: Avelumab|
88988258|NCT03451825|Experimental|Phase 2, Cohort 2: Avelumab|
88988259|NCT03450187|Active Comparator|Cohort A|50 mg TP-271 q24 (n=6), a novel, broad-spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
88988260|NCT03450187|Active Comparator|Cohort B|100 mg TLP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
88988261|NCT03450187|Active Comparator|Cohort C|200 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
88988262|NCT03450187|Active Comparator|Cohort D|300 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
88988263|NCT03450187|Active Comparator|Cohort E|400 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
88988264|NCT03459859|Experimental|Pevonedistat 10 LDAC 20|Dose Level -1: Pevonedistat 10 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
88988265|NCT03459859|Experimental|Pevonedistat 15 LDAC 20|Dose Level 1 (Starting Dose): Pevonedistat 15 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
88988266|NCT03459859|Experimental|Pevonedistat 20 LDAC 20|Dose Level 2: Pevonedistat 20 mg/m2, low dose Cytarabine 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
88988267|NCT03459859|Experimental|Pevonedistat 25 LDAC 20|Dose Level 3: Pevonedistat 25 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
88988268|NCT05594459|Active Comparator|Opioids|
88988269|NCT05594459|Experimental|Mini invasive|
88988270|NCT00507403|Active Comparator|Infliximab|Infliximab
88988271|NCT00507403|Experimental|Infliximab +methotrexate|Infliximab +methotrexate
88988272|NCT05594420||MVR through Median sternotomy|
88988273|NCT05594420||MVR through Minimally invasive approach|
88988274|NCT03457792||Abatacept for Rheumatoid Arthritis (RA)|Participants diagnosed with moderate to severe active RA within the last 24 months and initiated treatment with Abatacept
88988275|NCT03451162|Experimental|Dose Escalation Cohort: DHES0815A|Participants will receive DHES0815A in escalating doses in the dose-escalation cohort of the study. Participants will receive additional infusions of DHES0815A on Day 1 of subsequent cycles provided that they meet the protocol specified criteria for acceptable toxicity and ongoing clinical benefit.
88988276|NCT03451162|Experimental|Dose Expansion Cohort: DHES0815A|Participants will be treated at or below the Maximum Tolerated Dose (MTD) of DHES0815A (based on the review of the totality of the data) to obtain additional safety, tolerability, PK, and anti-tumor activity data.
88988277|NCT02955043|Experimental|Behavioral intervention|Participants will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. The intervention will be delivered in three 45-60 minute face-to-face sessions at approximately 3-4, 8, and 12 weeks post-HSCT with brief telephone coaching calls scheduled between sessions. Participants will be encouraged to use the behavioral strategies from hospital discharge through 18 weeks post-HSCT. Participants will be asked to complete a daily checklist indicating which intervention strategies they used. Participants will also receive standard medical care following HSCT.
88988278|NCT02955043|No Intervention|Usual care|Participants will receive standard medical care following HSCT.
88988279|NCT02954419||IgA nephropathy group|Eligible biopsy-proven primary IgA nephropathy patients.
88988280|NCT05594381|Experimental|Neoadjuvant Sintilimab plus SOX therapy|"All enrolled subjects were treated with Sintilimab combined with SOX regimen (Oxaliplatin plus Tegafur) for 3 cycles and then underwent radical surgery.~Peripheral blood from all patients will be collected at the following 5 time points: before neoadjuvant therapy (within 3 days before the first dose); before the start of the third cycle of neoadjuvant therapy (within 3 days); before surgery (within 7 days) and after surgery (within 3-7 days). Plasma was tested for ctDNA. All subjects were further stratified according to the detection results of ctDNA and their changes during the neoadjuvant treatment period.~After operation, sintilimab combined with SOX therapy was continued for 5 cycles according to the original plan (if the preoperative treatment did not reach 3 cycles, it should be supplemented to 8 cycles)"
88988281|NCT00507637|Experimental|NT 201 (IncobotulinumtoxinA/Xeomin®)|
88988282|NCT05594342|Experimental|Ivabradine+ dobutamine infusion|Patients will receive ivabradine 7.5 mg twice daily via oral route after starting dobutamine infusion by 30 minutes.
88988283|NCT05594342|Active Comparator|Dobutamine infusion only|Patient will receive dobutamine infusion only for cardiogenic shock
88988284|NCT00507676||Group 1|One hundred and sixty healthy infants between 1 and 24 months of age will be evaluated. Subjects will be recruited so that there are 40 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. The ethnic composition will be approximately 80% Caucasian and 20% African-American in each of the four groups, which represents the distribution within the cities where infants will be evaluated. Subjects will be excluded if they were born prematurely (<37 weeks gestation), have a history of congenital cardio-respiratory disease, or have history of lower respiratory illness.
88988285|NCT00507676||Group 2|Eighty infants between 1 and 24 months of age scheduled for CT scans of the abdomen or chest will be evaluated. Subjects will be excluded if they are born prematurely (<37 weeks gestation), have history of congenital cardio-respiratory disease, or have history of recurrent wheezing.
89620010|NCT03350490|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89620011|NCT03350490|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89620012|NCT03355404|Experimental|"Standing Patient"|
89620013|NCT03355404|No Intervention|"Standardized management in stretcher"|
89620014|NCT01626820|Experimental|Fluviral Adults Group|Subjects 18-60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
89620015|NCT01626820|Experimental|Fluviral Elderly Group|Subjects above 60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
89620016|NCT04504656||1|open surgery
89620017|NCT04504656||2|minimally invasive surgery
89620018|NCT04507932|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
89620019|NCT04504110|Experimental|Epithelial ovarian cancer|68Ga-FAPI-04 and 18F-FDG PET/CT
88988286|NCT00507676||Group 3|Eighty infants with recurrent wheezing between 1 and 24 months of age will be evaluated when they are not acutely symptomatic for at least 3 weeks. Subjects will be recruited so that there are 20 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. Subjects will be excluded if they were born prematurely (<37 weeks gestation) or have history of congenital cardio -respiratory disease.
88988287|NCT00507715|Experimental|1|Plantago ovata husk
88988288|NCT00507715|Placebo Comparator|2|hemicellulose crystalline
88988289|NCT00507754||Latent Tuberculosis Infection|Patients with cancer at risk for developing active tuberculosis (TB).
88988290|NCT05594303|Experimental|Bronchial basal cells|Treatment by autologous bronchial basal cells.
88988291|NCT05594303|No Intervention|Control|No interventon.
88988292|NCT00507832|Active Comparator|I|"Interindividual design:~active and comparator (one side each) applied twice daily"
88988293|NCT00507832|Active Comparator|II Hydrocortisone|Hydrocortisone, twice daily
88988294|NCT00507949|Experimental|1|Megestrol acetate: sachets of granulated 160 mg. Dose: 160 mg/b.i.d. Duration 8 weeks
88988295|NCT00507949|Placebo Comparator|2|The placebo is the excipient of the experimental drug.
88988296|NCT02954263|Experimental|TD-1439|Capsule formulation
88988297|NCT02954263|Placebo Comparator|Placebo|Capsule formulation
88988298|NCT02954302|Experimental|PrPD with RGA|Patients who will undergo PrPD with proximal Roux-en-y gastrojejunal anastomosis.
88988299|NCT02954302|Experimental|conventional PrPD|Patients who will undergo conventional PrPD.
88988300|NCT02954185|Experimental|WellClub Device|Hand held device that patients use for home therapy
88988301|NCT02954185|Active Comparator|Standard Therapy|Standard care therapy for should pain
88988302|NCT05594186|Active Comparator|Tranexamic acid|Patients in group A, received Tranexamic acid 1300 mg (2 tablets of 650 mg) three times daily for 5 days starting from the first day of menses for 12 months.
88988303|NCT05594186|Active Comparator|Combined oral contraceptive pill|Patients in group B, received combined oral contraceptive pill (OCP) once daily for 21 days (Desogestrel 150 micrograms/ Ethinylestradiol 30 micrograms, tablets), starting from the first day of menses, then to have a one-week pill free period to allow for a withdrawal bleed, and that was repeated for 12 cycles.
88988304|NCT05594186|Active Comparator|Tranexamic acid plus Combined oral contraceptive pill|Patients in group C, received a combination of Tranexamic acid 1300 mg three times daily for 5 days, and a combined oral contraceptive pill once daily for 21 days (Desogestrel 150 micrograms/ Ethinylestradiol 30 micrograms, tablets), both starting from the first day of menses for 12 consecutive cycles.
88988305|NCT05594186|Active Comparator|Levonorgestrel-releasing intrauterine system|Patients in group D, had the levonorgestrel-releasing intrauterine system inserted into the uterine cavity. The insertion was done by a skilled gynecologist as an outpatient procedure without anesthesia.
88988306|NCT02954380|Experimental|ZIO/ILR|THe Zio ILR arm will already have an ILR implanted for standard of care and will receive the Zio patch
88988307|NCT00507988|Experimental|A|Complex Problem Solving Training
88988308|NCT00507988|Active Comparator|B|Basic Cognitive Training
89620020|NCT03353844|Experimental|Intradialytic exercise group|These patients will get intradialytic exercise every sessions of hemodiafiltration
89620021|NCT03353844|No Intervention|Standard dialysis group|regular and standard of care in every hemodiafiltration sessions (as usual) without intradialytic exercise.
89620022|NCT03355248|Active Comparator|Control Group - 28|The control group (post-operative cesarean section) will be prescribed 28 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
89620023|NCT03355248|Experimental|Experimental - 20|The experimental group (post-operative cesarean section) will be prescribed 20 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
89620024|NCT03350334|Active Comparator|Duloxetine|The patients who will be given 60 mg duloxetine 2 hours before surgery and 24 hours after surgery.
89620025|NCT03350334|Placebo Comparator|Placebo Control|The patients who will be given 60 mg placebo 2 hours before surgery and 24 hours after surgery.
89620026|NCT04515108||Group 1 (Pregnants with COVID-19)|Study group included pregnant women with clinically confirmed COVID-19.
89620027|NCT04515108||Group 2 (Pregnants without COVID-19)|Control group consisted of healthy pregnant women in the same number and same gestational week with the Study group.
89533127|NCT05465174|Experimental|Group 2, Arm B: Neoadjuvant Tovorafenib|Participants with recurrent craniopharyngioma will receive one (1) dose of Tovorafenib within 7 days +/- 2 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent.
89620028|NCT04513470|Experimental|COVID-19|Five subjects, male or female > 18 and < 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
89620029|NCT03353766|Experimental|Early crossbite correction|Early crossbite correction with Q-H Device
89620030|NCT03353766|No Intervention|Crossbite correction in mixed dentition|Later crossbite correction, during mixed dentition
89620031|NCT03353610||Patient-reported PSVT.|Participants who recorded a PSVT diagnosis.
89620032|NCT03353610||Suspected PSVT.|Participants who do not record a PSVT diagnosis.
89620033|NCT03353610||Other subgroups.|Subgroups also may be examined ( PSVT-episode characteristics, use of a self-management technique for PSVT at home (on their own) to return heart rate back to normal).The sample size, however, may limit the extent of any subgroup analyses.
89620034|NCT01627288|Experimental|Boost Radiation: Dose Level 1|2.4 Gy X 25 fractions = 60 Gy
89620035|NCT01627288|Experimental|Boost Radiation: Dose level 2|2.6 Gy X 25 fractions = 65 Gy
89620036|NCT01627288|Experimental|Boost Radiation: Dose level 3|2.8 Gy x 25 fractions = 70 Gy
89620037|NCT01627288|Experimental|Experimental: Boost Radiation Dose Level 0|"If the 2 dose limiting toxicities are documented at dose level 1, therapy will be de-escalated to Dose level 0 defined below.~Dose level 0: 2.2 Gy X 25 fractions = 55 Gy"
89620038|NCT03350178|Experimental|treated patients|Treated wit FMT
89620039|NCT04513392|Active Comparator|KTP laser treatment|All participants will complete a paper Voice Handicap Index-10 (VHI-10) questionnaire and laryngeal stroboscopy examination at baseline. Local anesthesia will be administered as per standard of care for in-office laryngeal procedures. KTP laser will be utilized to ablate the lesion of interest. Immediately following the procedure, participants will complete a VAS pain scale on paper. Participants will be asked to exercise 3 days of absolute voice rest following the procedure. All patients will have follow-up clinic appointments on POD 7, POD 30, and POD 90 after surgery. At each of the follow-up visit, the patients will fill out a paper VHI-10 questionnaire and undergo stroboscopic examination to assess vocal fold vibratory properties and closure, as well as residual lesions. During the first week post procedure, the participants will continue to complete a daily VAS at home for pain assessment.
89620040|NCT04513392|Experimental|BL laser treatment|The only difference in study procedures between the experimental arm and the control arm is that the experimental arm will use the BL laser. The post-operative instructions and follow-up schedule are identical.
89620041|NCT01628614||POAG or OHT|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
89620042|NCT03353532||Cohort|Adult patients with SSI after any surgical procedure.
89620043|NCT03353532||Case-Control|"Cases: Patients establishing S. aureus SSI Controls: Patients from the same center who did not undergo S. aureus SSI, matched by the following criteria~Type of procedure~Age~ASA score~BMI~Duration of procedure (as percentile for this procedure)~Diabetes~Sex"
89620044|NCT03350100|Experimental|Birhi date cultivar|A 48.46 g of freeze dried powder of Birhi date Cultivar which is equivalent to a 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 162.8 mg/100 g of GAE. and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
89620045|NCT03350100|Experimental|Khassab date cultivar|A 34.5 g of freeze dried powder of Khassab date Cultivar which is equivalent to A 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 91.52 mg/100 g of GAE. and 0.80 g of fibres,will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
89620046|NCT03350100|Placebo Comparator|placebo|A 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
89688416|NCT02793154|Experimental|Part B: Albiglutide|In Part B, half of the subjects will be randomized to receive albiglutide: On Day 1: Once weekly SC injection at 30 mg for 4 weeks From Week 5, Day 1: Dose will be increased to 50 mg once weekly SC injection for 4 weeks
89533128|NCT05465174|Experimental|Group 2, Arm C: Neoadjuvant combination nivolumab and Tovorafenib|Participants with recurrent craniopharyngioma will receive one (1) dose of nivolumab (14 days -5 days prior) and one (1) dose of Tovorafenib (7 days +/- 2 days) prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent.
88988309|NCT02954107||Absence epilepsy|Children aged 6-12 years of age primarily presenting with episodes of brief loss of consciousness (absences) in an otherwise normal child in the previous 2 years. With an EEG showing 3 Hz (2.5-4.5 Hz) generalized rhythmic spike-and-wave complexes with a discharge duration of at least 3 seconds on a present or former EEG.
88988310|NCT02954107||Controls|Overall healthy children aged 6-12 years of age following a regular school without major problems.
88988311|NCT05594108|Experimental|Experimental Group|Ultrasound guided IUD insertion
88988312|NCT05594108|No Intervention|Control Group|Non ultrasound guided IUD insertion
88988313|NCT02953951||Stored Blood Cells|"Blood transfusion:~Stored blood cells transfused patients"
88988314|NCT02953951||Autologous Salvaged Blood|"Blood transfusion:~Autologous salvaged blood transfused patients"
88988315|NCT02953951||Control|"Blood transfusion:~No transfusion patients"
88988316|NCT02953912|Experimental|Reciproc single-file.|The Reciproc is a single-file nickel-titanium systems used in reciprocating motion, made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue .
89620047|NCT03122964||Patients with gross or microscopic hematuria|This study aims to prospectively enroll a minimum of 700 subjects, with gross or microscopic hematuria. Each site will target enrollment of 100 subjects and patient samples will be collected from consecutive patients meeting the inclusion criteria outlined below. The total study duration is expected to be 24 months.
89620048|NCT02528500|Experimental|TAMBE Device|Study designed to assess the feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of patients with aortic aneurysms involving the visceral branch vessels. Patients with thoracoabdominal or pararenal abdominal aortic aneurysms are eligible for screening for participation in the study. The particular characteristics of the patient's aneurysm and anatomy will determine ultimate eligibility for enrollment. Only patients who meet all of the eligibility criteria will be enrolled.
89620049|NCT04512612|Active Comparator|Dye based Chromoendoscopy|The patients enrolled in this group will undergo pan-colonic chromoendoscopy evaluation.
89620050|NCT04512612|Active Comparator|High Definition White Light Endoscopy|The patients enrolled in this group will undergo high definition white light endoscopy based evaluation
89620051|NCT04513158|Experimental|Treatment Arm|Study is single arm all patients hospitalized meeting inclusion/exclusion criteria and providing informed consent to receive one unit (approximately 200 mL) of convalescent plasma with data collected daily on routine (non-research) clinical assessments/physical exams and lab results.
89620052|NCT01629784|Other|CLE and sun counseling|
89620053|NCT03350022|Experimental|Sham Feeding|
89620054|NCT03355092|Experimental|vBloc Therapy + Usual Care for Type 2 Diabetes|
89620055|NCT03355092|No Intervention|Usual Care for Type 2 Diabetes|
89620056|NCT02230696|Experimental|Test Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Perrigo
89620057|NCT02230696|Active Comparator|Reference Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Meda
89620058|NCT02230696|Placebo Comparator|Placebo Product|Placebo nasal spray
89620059|NCT03353454|Experimental|Maralixibat (SHP625)|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
89620060|NCT03353454|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
89620061|NCT03353376|Experimental|group care with empowerment model|4 group visits a year according to empowerment model in a tertiary diabetes clinic
88988317|NCT02953912|Active Comparator|One Shape single-file .|One Shape is single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue. with electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
88988318|NCT02954146|Active Comparator|CBT only|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT only) sessions for anger management.
88988319|NCT02954146|Experimental|CBT + Connectd mobile health app|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT) sessions for anger management. In addition, veterans in this group will also receive instructions for using Connectd mobile health app with a family member or friend that will provide data for the CBT clinician.
88988320|NCT00148590|Active Comparator|Memantine plus Risperidone|6 weeks 20 mg Memantine as add-on treatment to Risperidone
88988321|NCT00148590|Placebo Comparator|Placebo plus Risperidone|6 weeks 20 mg Placebo as add-on treatment to Risperidone
88988322|NCT02954068|Active Comparator|IV Infusion|Oxytocin 10 IU, 500 ml IV infusion within 40 minutes + intra muscular injection of placebo, 10 IU
88988323|NCT02954068|Active Comparator|IM administration|Oxytocin 10 IU via intra muscular injection + Intravenously administered placebo, 10 IU, 500ml
88988324|NCT00508339||1|Patients with a diagnosis of soft tissue sarcoma.
88988325|NCT00157131|Experimental|FS 4IU VH S/D|"FS 4IU VH S/D was administered intraoperatively to the wound bed by spray application using the TISSOMAT and Spray Set. Only the DUPLOJECTvii system and Spray Set (connection tube with sterile filter and spray head) device was used for simultaneous spray application of the study product. A thin layer of FS 4IU VH S/D was applied to the wound bed using a painting motion from side to side to achieve coverage. The recommended dosing volume was 2.0 to 4.0 mL/100 cm2. One 2-mL pack (4 mL total volume) of FS 4IU VH S/D applied using the TISSOMAT and Spray Set was sufficient to coat a wound bed of 100-200 cm2."
88988326|NCT00157131|Active Comparator|Staples|Staples are the current standard of care in burn surgery and are well accepted as the control in this type of study.
88988327|NCT00508378||Interview & Questionnaires|
88988328|NCT02954029|Experimental|Study group (transradial cohort)|device-assisted compression with ezClot pad
88988329|NCT02954029|Experimental|Study group (transfemoral cohort)|manual compression with ezClot pad
88988330|NCT02954029|Active Comparator|Control group (transradial cohort)|Rotary compression device
88988331|NCT02954029|Active Comparator|Control group (transfemoral cohort)|manual compression with BloodSTOP ix pad
88988332|NCT02957721|Other|Behavioral self-management|Eligible patients who are registered on the practice EHR linked portal will be invited to join the study. Following informed consent, enrollment and randomization, participants in the treatment group will receive the type 2 diabetes behavioral self-management education intervention; comprised of 9 modules derived from Medline Plus.
89620062|NCT03353376|Active Comparator|individual usual care|individual visits according to disponibility in the diabetes clinic and needs of the patients
88988333|NCT02957721|No Intervention|Usual Care|Usual care includes whatever care and services the patient's clinical provides as well as generic type 2 diabetes education built into the patient's EHR linked portal.
88988334|NCT00508456|Experimental|Hominex®-2 + Temodar®|Dietary Methionine Restriction (Hominex®-2) Days 1-7 and 15-21 + Temodar® 150 mg/m^2 orally Days 8-15
88988335|NCT00508495|Experimental|Test drug|
88988336|NCT00508495|Active Comparator|Reference drug|
88988337|NCT00508495|Placebo Comparator|Placebo|
89620063|NCT04507620||cervical neck collar|
89620064|NCT04507620||head blocks strapped on the backboard|
89620065|NCT03355014|Experimental|Gemigliptin+Metformin combination therapy group|"Part I (Fasted) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day~Part II (High fat diet) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day"
89620066|NCT03355014|Experimental|Gemigliptin and Metformin coadministration therapy group|"Part I (Fasted) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg~Part II (High fat diet) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg"
89620067|NCT03349944|Active Comparator|Moderate intensity training|Moderate continuous exercise three times pr. week for 50 min.
89620068|NCT03349944|Experimental|High intensity training|High intensity interval training three times pr. week for 15 min.
89620069|NCT02231086|Active Comparator|Standard adjuvant systemic chemotherapy|Standard adjuvant systemic chemotherapy according to the Dutch colon cancer guideline, using a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) schedule. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
89620070|NCT02231086|Experimental|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
89620071|NCT03353298|Active Comparator|Arm A|Allopurinol 300 mg
89620072|NCT03353298|Placebo Comparator|Arm B|Placebo Oral tablets
89620073|NCT03187210|Experimental|Dosis finding (Phase I)|Brentuximab Vedotin at day -8 together with standard BeEAM (Bendamustine, Cytarabine, Etoposide and Melphalan) chemotherapy at days -7 to -1 followed by reinfusion of autologous stem cells at day 0
89620074|NCT03187210|Active Comparator|Arm A (Phase II)|"BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; Etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
89620075|NCT03187210|Experimental|Arm B (Phase II)|"Brentuximab Vedotin 1.8 mg/kg at day -8 together with standard BeEAM chemotherapy at days -7 to -1~BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
89620076|NCT03349866|Experimental|apatinib XELOX and radiotherapy|apatinib：250mg qd po XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
89620077|NCT03349866|Active Comparator|XELOX and radiotherapy|XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
89620078|NCT03354000|Placebo Comparator|Take-home online training|Participants received a link to access the online tutorial videos on their own.
89620079|NCT03354000|Active Comparator|In-person online training|Participants received an in-person tutorial of how to use the patient portal website with a trained research assistant.
89620080|NCT04503798|Experimental|Online Goal Management Training (GMT)|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
89620081|NCT04503798|No Intervention|Treatment-as-usual control group|Participants randomized to this arm will receive no additional information or access to the intervention program. They will continue to receive treatment-as-usual from their care providers.
89620082|NCT01629862|Active Comparator|Active CPAP|Therapeutic continuous positive airway pressure (CPAP).
89620083|NCT01629862|Placebo Comparator|Sham CPAP|Sham (non-therapeutic) continuous positive airway pressure.
89620084|NCT03354858||Follicular flushing|One ovary will be aspirated using follicular flushing (up to 5 times per follicle).
89620085|NCT03354858||No flushing|One ovary will be aspirated using direct aspiration (no flushing).
89620086|NCT03354780||endometriosis|Survey on first pregnancy after endometriosis diagnosis
88988338|NCT00508573||Lynch Syndrome Registry|Patient that has or is at risk for Lynch Syndrome.
89620087|NCT03354780||non endometriosis|Survey on first pregnancy
89620088|NCT04443894|Active Comparator|PECS block|
89620089|NCT04443894|Active Comparator|local infiltration|
89620090|NCT03353142|Experimental|Equal Breathing|
89620091|NCT01631110|Experimental|Elderly subjects aged over 60 years|
89620092|NCT01631110|Experimental|Adults from 18 to 60 years old inclusive|
89620093|NCT04507698|Experimental|Supervised Exercise Arm|If participants are placed in the Supervised Exercise Group, they will attend supervised group exercise sessions, which are individually tailored to the participants physical condition, at least once a week, every week for the first year of the study. They will be asked to exercise 3 times a week.
88988339|NCT00508612|Active Comparator|1|The 12-lesson Williams LifeSkills anger and stress management workshop (WLS) enhances awareness of thoughts and feelings in stressful situations, and provides training in evaluation, deflection, problem-solving, assertion, saying no, speaking, listening, empathy, and emphasizing positives.
88988340|NCT00508612|Placebo Comparator|2|Control group (will attend regular high school classes)
88988341|NCT00508690|Active Comparator|IV|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
88988342|NCT00508690|Active Comparator|Oral/IV|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
88988343|NCT02953756||Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery (GKRS)
88988344|NCT02953522|Other|191 mcg/day of Folate|Diet with 191 mcg/day of Folate
88988345|NCT02953522|Other|90 mcg/day of Folate|Diet with 90 mcg/day of Folate
88988346|NCT02953483|Experimental|Acellular first|Lung preservative solution without red blood cells will be used for perfusion in the initial 2 hours followed by addition of red blood cells for the next two hours
89533129|NCT05465174|Experimental|Group 2, Arm D: Non-biopsy/resection participants|Non-biopsy/resection participants with recurrent disease will receive combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent.
89533130|NCT05457790|Active Comparator|1/Immediate Intervention Group|1-week baseline data collection period followed by an 8-week ACT intervention period focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
89533131|NCT05457790|Active Comparator|2/Waitlist Control Group|1-week baseline data collection period followed by 8 weeks of maintaining usual routine followed by an 8-week intervention focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
89533132|NCT05445882|Experimental|Arm 1|N-803 + BN-Brachyury (+ bintrafusp alfa if progression beyond 12 weeks)
89533133|NCT05445882|Experimental|Arm 2|N-803 (+ BN-Brachyury + bintrafusp alfa if progression beyond 12 weeks)
89533134|NCT05445882|Experimental|Arm 3|N-803 + bintrafusp alfa (+ BN-Brachyury if progression beyond 12 weeks)
89533135|NCT05445778|Experimental|Arm 1|Mirvetuximab Soravtansine (MIRV) plus Bevacizumab
89533136|NCT05445778|Active Comparator|Arm 2|Bevacizumab monotherapy
89533137|NCT05440344|Experimental|Imlunestrant (Mild Hepatic Impairment)|Imlunestrant administered orally.
89533138|NCT05440344|Experimental|Imlunestrant (Moderate Hepatic Impairment)|Imlunestrant administered orally.
89533139|NCT05440344|Experimental|Imlunestrant (Severe Hepatic Impairment)|Imlunestrant administered orally.
89533140|NCT05440344|Experimental|Imlunestrant (Normal Hepatic Function)|Imlunestrant administered orally.
89533141|NCT05438719|Experimental|MOTUS|All subjects will be treated with the MOTUS Total Joint Replacement
89533142|NCT05438576|Experimental|Intervention|Participants will have ECGs analyzed with artificial intelligence for cardiomyopathy detection.
89533143|NCT05438576|No Intervention|Control|Participants will have standard clinical ECGs acquired.
89533144|NCT05416333|Experimental|azelaic acid treatment|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
88988347|NCT02953483|Experimental|Cellular first|Lung preservative solution will contain red blood cells for the first two hours followed by acellular perfusate for the next two hours
88988348|NCT05572541||Patients with traumatic brain injury|Temporomandibular joint range of motion, Fonseca questionnaire, facial asymmetry, and massater and temporal pain threshold will be evaluated by measuring both TBI patients and healthy individuals. In addition, post-injury dietary intake and dominant chewing side will be questioned in TBI patients. Temporomandibular movements will be measured with a disposable cardboard ruler.
88988349|NCT05572541||healthy volunteers|Temporomandibular joint range of motion, Fonseca questionnaire, facial asymmetry, and massater and temporal pain threshold will be evaluated by measuring both TBI patients and healthy individuals. Temporomandibular movements will be measured with a disposable cardboard ruler.
88988350|NCT02953600|Experimental|Standard Dose Spirulina Platensis|Spirulina platensis pill/500mg, 3 pills before each meal /6 pills per day
88988351|NCT02953600|Active Comparator|Zero Spirulina Platensis|Spirulina platensis pill/500mg, 6 pills before each meal /12 pills per day
88988352|NCT02953600|Active Comparator|Double Dose Spirulina Platensis|same as usual, non pill taken
88988353|NCT02953444|No Intervention|Wait List Control|Participants receive daily email surveys for two weeks before being given access to the brief-mindfulness-practice training materials.
88988354|NCT02953444|Experimental|Thirty-Second Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a thirty-second mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
89533145|NCT05416333|Sham Comparator|control (no additional treatment)|Subjects will continue to use their current primary provider prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
89533146|NCT05409066|Experimental|Epcoritamab Dose A in Combination With R2|Participants will receive epcoritamab Dose A in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).
89533147|NCT05409066|Experimental|Epcoritamab Dose B in Combination With R2|Participants will receive epcoritamab Dose B in combination with lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days). Enrollment is closed for this arm.
89533148|NCT05409066|Active Comparator|Lenalidomide and Rituximab (R2)|Participants will receive lenalidomide and rituximab (R2) for 12 cycles (each cycle is 28 days).
89533149|NCT05407961|Experimental|LY3532226 + Dulaglutide (Part A)|LY3532226 administered subcutaneously (SC) followed by dulaglutide administered SC.
89533150|NCT05407961|Placebo Comparator|Placebo + Dulaglutide (Part A)|Placebo administered SC followed by dulaglutide administered SC.
89533151|NCT05407961|Active Comparator|Dulaglutide + Placebo (Part B)|Dulaglutide administered SC in combination with placebo given SC.
89533152|NCT05407961|Experimental|LY3532226 + Dulaglutide (Part B)|LY3532226 administered SC in combination with Dulaglutide given SC.
89533153|NCT05407961|Experimental|LY3532226 + Placebo (Part B)|LY3532226 administered SC in combination with placebo given SC.
89533154|NCT05406700|Experimental|Arm A Treatment with Niraparib|Patients randomized to arm A will receive niraparib daily and undergo tumor resection after 28 days (+/- 7 days) of treatment. The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery . Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent
89620094|NCT04507698|No Intervention|Self-Directed Exercise Arm|If Participants are placed in the Self-directed Exercise Group, they will receive usual medical care (standard of care) and be asked to follow their usual exercise and lifestyle routine. They will receive supportive care in the form of newsletters, covering a variety of topics including pain management, bone health, goal setting, taking control of life, and more.
89620095|NCT03353064|Active Comparator|Vivify + EMS|This arm will have the Telemedicine kits and get scheduled EMS home visits. The subjects will complete daily biometrics / surveys / care plans through the telemedicine kit, as specified in the activity schedule Apart from the tablet device, EMS home visits will be scheduled on Day 7, Day 21 and Day 42 from discharge. During these home visits, the EM personnel will perform a check of the NIV/NIPPV device. They are able to adjust pressures according to your Pulmonologist / Sleep doctor's prescription, and troubleshoot any issues with the mask, the humidifier, etc. They will also measure End-tidal CO2 via nasal cannula.
89620096|NCT03353064|Active Comparator|Vivify Only|"This group will receive the telemedicine tablet and kit, with the same protocol as defined above.~No EMS home visits will be set up"
89620097|NCT01631656|Experimental|Azelaic Acid plus Laser|Azelaic acid 15% twice daily on half the face for 6 weeks, plus laser treatment with Nd:Yag laser once at 2 weeks.
89620098|NCT01631656|Active Comparator|Laser only|laser treatment on all face once at 2 weeks with no azelaic acid on one side of the face
89620099|NCT04503876|Active Comparator|Decremental PEEP titration following an ARM|PEEP will be titrated in a stepwise decremental fashion following a standardized alveolar recruitment maneuver (ARM). The ARM is a progressive increase of intra-thoracic pressure (pressure controlled mode), with a constant driving pressure of 10 cmH2O and PEEP steps (10-15-20-25-30-35 and 40 cmH2O), reaching a maximum pressure of 50 cmH2O, allowing full recruitment. PEEP steps will be conducted every 2 cmH2O (from 20 to 6 cmH2O), every 5 minutes.
89620100|NCT04503876|Active Comparator|Incremental PEEP titration without any previous ARM|PEEP will be titrated in a stepwise incremental fashion without any previous alveolar recruitment maneuver (ARM). PEEP steps will be conducted every 2 cmH2O (from 6 to 20 cmH2O), every 5 minutes.
89620101|NCT04507542|Experimental|Enriched Music-Supported Therapy group|Participants in the eMST-group will follow a 10-week program of Enriched Music-Supported Therapy. The program comprises 3 individual self-training sessions and 1 group session per week (total program duration: 40 hours).
89620102|NCT04507542|Active Comparator|Control group|Participants in the control intervention group will follow the Graded Repetitive Arm Supplementary Program (GRASP, Harris et al., 2009). They will be asked to complete 4 weekly one-hour session for 10 weeks (total program duration: 40 hours).
88988355|NCT02953444|Active Comparator|Three-Minute Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a three minute mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
88988356|NCT03272152||Inflamed CD group|Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients
88988357|NCT03272152||Non-inflamed CD group|Non-inflamed ileal mucosa was obtained from normal sites of active CD patients
88988358|NCT03272152||Control group|Control ileal mucosa was obtained from healthy patients
88988359|NCT03272230|Experimental|bvFTD|"Initially especially patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
88988360|NCT03272230|Experimental|Healthy control|"Healthy age, sex and education matched controls~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
88988361|NCT03272230|Experimental|Parkinson's disease without Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
88988362|NCT03272230|Experimental|Depression|"Initially especially patients diagnosed with depression (Major Depressive Disorder, DSM-IV).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
88988363|NCT03272230|Experimental|Parkinson's disease with Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992). ICDs are closely related to use of dopaminergic medications.~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
88988364|NCT03272386||Observational study|Observational study with patients over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included.
88988365|NCT00466492|Other|No sedatation intervention|The intervention group is the normal care in our institution, the control group is the golden standard
88988366|NCT04726202||Control arm|standard procedure of coding at hospital
88988367|NCT04726202||Precoding arm|Coding of the standard procedure will be reviewed and corrected
88988368|NCT00466609|Experimental|Quetiapine (fluoxetine plus quetiapine)|fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks
88988369|NCT00466609|Active Comparator|Clomipramine (fluoxetine plus clomipramine)|Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks
88988370|NCT00466609|Placebo Comparator|Placebo (fluoxetine plus placebo)|Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks
88988371|NCT00466804||Heart Transplant Recipients|People who will have a heart transplant
88988372|NCT00466843|Experimental|1|Participants will be treated with ATG
88988373|NCT00466882||Inamed Lap-Band System|The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning. The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years.
89057805|NCT05393596|Experimental|Experimental Group (Incluyete VR Software)|Through virtual reality headsets, the software Inclúyete VR will be used, in which situations related to stigma in Severe Mental Disorder are recreated. Specifically, its purpose is to put the participant in a virtual world that shows how the stigma towards people with severe mental health problems is and also to experience situations of rehabilitation and social inclusion, thus giving a more real and closer image of what can be the current treatment in mental health. The approximate duration is 15 minutes.
89620103|NCT01632202|Active Comparator|Seprafilm Slurry|The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
89620104|NCT01632202|Placebo Comparator|Placebo|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
89620105|NCT02985190|Experimental|Azacitidine 75mg/m²/day|"Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles~in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles~in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria"
89620106|NCT01634620||FeNO|Participants with chronic obstructive pulmonary disease (COPD) will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
89620107|NCT01635244|Active Comparator|Freestyle|Aortic valve replacement will be performed with a Freestyle stentless aortic bioprosthesis (Medtronic Cardiovascular; Minneapolis, MN).
89620108|NCT01635244|Active Comparator|Magna Ease|Aortic valve replacement will be performed with a Magna Ease aortic bioprosthesis (Edwards Lifesciences; Irvine, CA).
89620109|NCT01635244|Active Comparator|Trifecta|Aortic valve replacement will be performed with a Trifecta aortic bioprosthesis (St. Jude Medical; St. Paul, MN).
89620110|NCT01636102|Experimental|Arm 1|
89620111|NCT01376310|Experimental|Cohort A|Subjects on GSK1120212 Monotherapy who have been treated less than 24 weeks in their parent study.
89620112|NCT01376310|Experimental|Cohort B|Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial.
89620113|NCT01949506|Other|Stereotactic Body Radiation Therapy|Arms: Stereotactic Body Radiation Therapy (SBRT) with Adaptive Radiation Therapy (ART) for all patients. A non-randomized study. Patients must have 1-5 pulmonary metastases all less than 5 cm in size. Pathologic confirmation of primary soft tissue sarcoma. All lesions to receive 3-5 fractions to each tumor. Treatments delivered with > 10 Gy per fraction will have a minimum of 48 hour interfraction interval. For treatments with ≤ 10 Gy per fraction will have a minimum 24 hour interfraction interval. Treatments will be ideally completed over 14 days for 3 fraction treatments and over 21 days for >5 fraction treatment schedules.
89620114|NCT03349788|Experimental|LCA-nP|The group underwent laparoscopic radical rectectomy without preserving left colic artery. In IMA group, the dissecting based on TME is performed without preserving left colic artery. Surgeon should dissect the lymph nodes and ligated the vessel in the root of inferior mesenteric artery.
89620115|NCT03349788|Active Comparator|LCA-P|The group underwent laparoscopic radical rectectomy with preserving left colic artery. In LCA group, the dissecting based on TME is performed with preserving left colic artery. The relationship of inferior mesenteric artery, inferior mesenteric vein and LCA should be identified and ligated separately without LCA.
89620116|NCT01829386||Non heme iron levels on MRI|"Intervention: MRI scans To develop a reliable MR based measurement of Non-heme iron in brain tissue of patients with hemorrhagic stroke : on day 1, 14 and 30 after stroke to assess the non heme iron levels on MRI.~To evaluate the role of iron chelators following a hemorrhagic stroke/parenchymal hemorrhage."
89620117|NCT04507386|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
89620118|NCT04507386|No Intervention|Control|The control group will receive regular medical care and advice on healthy lifestyle, including physical activity and healthy eating recommendations
89620119|NCT03349554|Experimental|"standardized meditation technique body-scan"|
89620120|NCT04506996|Experimental|Intervention Group - Receiving Text Messages|"The 16-weeks text-messaging intervention centered around 8 goal topics: eating only when hungry, increasing PA, eating a lower fat diet, eating less sugar and reducing calories from beverages, exercising more, eating a balance diet, portion control, and making healthier food choices in social situations.~Messaging~Sun evening: asked to pick 1 of 3 goal topics~Mon morning: received a goal to focus on for the week~Mon evening: asked whether plans were made to reach the goal~Wed morning: received a tip to help reach goal~Wed evening: reminded that if having cravings, text tip to automatically receive a tip~Fri morning: received end of the week congratulations, encouragement to keep goals in mind over the weekend~Fri evening: asked for weight, congratulated if lost weight, or encouraged if no weight lost"
89620121|NCT04506996|Active Comparator|Control Group - Written Messages|"Participants in the control group, received a printed copy of the same messages that the intervention group received. However, the first eight-weeks' worth of messages and craving tips were given after the baseline assessment, and the rest were given after the first follow-up assessment (~ 8 weeks post randomization).~The messages for each week were clearly laid out and labeled. Participants were given spaces to record their answers (i.e. to which goal they were selecting for each week). The study staff reviewed the first week's messages together with the study participants to get the participants comfortable with the format that the printed messages were presented in."
89620122|NCT04509882|Experimental|bear bile pill|Patients randomized to the bear bile pill arm will receive treatment with 15 pills, three times daily of bear bile pill (1350mg per day) plus on-going antidepressant therapy (SSRI/SNRI).
89057806|NCT05393596|Active Comparator|Control Group (Welcome Oculus Software)|Participants will use the default virtual reality headset welcome game, unrelated to mental health. It presents an interactive virtual environment, with various playful interfaces and instructions for use. The duration is approximately 15 minutes.
89620123|NCT04509882|Placebo Comparator|placebo|Patients randomized to the placebo arm will receive 15 pills, three times daily of placebo plus on-going antidepressant therapy (SSRI/SNRI).
89620124|NCT04509960|No Intervention|proseal laryngeal mask insertion|no intervention
89620125|NCT04509960|Experimental|proseal laryngeal mask insertion with laryngoscope|with the help of direct laryngoscopy
89620126|NCT03352986||osteonecrosis|Sickle cell patients with osteonecrosis as a vascular main complication
89620127|NCT03352986||leg ulcer|Sickle cell patients with leg ulcer as a vascular main complication
89620128|NCT03352986||microalbuminuria|Sickle cell patients with microalbuminuria as a vascular main complication
89620129|NCT03352986||pulmonary hypertension|Sickle cell patients with pulmonary hypertension as a vascular main complication
89620130|NCT03352986||stroke|Sickle cell patients with strocke as a vascular main complication
89620131|NCT03352986||priapism|Sickle cell patients with priapism as a vascular main complication
89620132|NCT03349398|Active Comparator|the group of Roux-en-Y|
89620133|NCT03349398|Experimental|the group of Uncut Roux-en-Y|
89620134|NCT01585402|Experimental|Etidronate Treatment for Arterial Calcifications due to Deficiency in CD73 (ACDC)|Participants diagnosed with Arterial Calcifications due to Deficiency in CD73 (ACDC) will receive Etidronate. Etidronate will be administered orally at total dose of 20mg/kg daily x 14 days, followed by 10 weeks off study drug (12 weeks = one cycle). Participants may receive up to 12 cycles of etidronate.
89620135|NCT03352908||YSP|The Yale Swallow Protocol (YSP) consists of a brief cognitive screen, a brief oral motor exam, and a 3oz water challenge (subjects instructed to drink 3oz of water without stopping). Pass/fail is determined based on the subjects ability to drink the 3oz of water uninterrupted without immediate cough.
89620136|NCT03352908||FEES|Flexible Endoscopic Evaluation of Swallowing (FEES) uses a flexible endoscope that will be passed transnasally into the pharynx by a speech pathologist specializing in dysphagia management. FEES will be treated as a placebo comparator.
89620137|NCT01636414|Active Comparator|Hemovac drain|
89620138|NCT01636414|Active Comparator|Re-infusion drain|
89620139|NCT01636414|Active Comparator|Tranexamic drain|
89620140|NCT03352830|No Intervention|Control|All individuals in each arm will receive a new LPG cookstove. The control arm will receive an orientation for safe operation of the new LPG stove. Participants in the control arm will, however, receive no other intervention.
89620141|NCT03352830|Experimental|No Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
88988374|NCT03272113|No Intervention|Control|"Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support.~Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week."
89057807|NCT02217488|Experimental|DG3173|
89057808|NCT02217488|Placebo Comparator|Vehicle|
89057809|NCT04536740|Other|PDL-treated PWS|PWS treated with PDL before will be treated with PDT
89620142|NCT03352830|Experimental|Delivery, No Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand.
89620143|NCT03352830|Experimental|Agent Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand. Participants in this arm also receive a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
89620144|NCT02518308|Experimental|Arm I (MBSR intervention)|Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.
89620145|NCT02518308|No Intervention|Arm II (control)|Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.
89620146|NCT01636882|Experimental|CVA21|Dose of CAVATAK up to 3 x 10⁸ TCID50 for an additional 9 treatments at 3-week intervals
89620147|NCT03352752|Experimental|Possess HTC Vive before the operation|The experimental group was wearing VR helmet before operation, and the immersion experience was selected from the video content library pre-selected. After 3 minutes of the VR experience, the surgeon started the fractional laser operation (Notify the patient). The operating area is continuous 10 maximum square spot areas.The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
88988375|NCT03272113|Experimental|Intervention|Women will receive usual care as described above plus the SKIP-IT intervention
88988376|NCT00466999|Active Comparator|surgery|standard surgical treatment (either dilation and curettage or manual vacuum aspiration)
88988377|NCT00466999|Active Comparator|misoprostol|400 mcg misoprostol
88988378|NCT02956330||CLS1003-201|Those subjects whose parent study primary investigator has access to their medical records, following exit from CLS1003-201.
88988379|NCT00467116|Experimental|Therapeutic Intervention|
88988380|NCT03272074|Experimental|Egg Group (Group A)|Participants will consume one large egg per day for 12 weeks
88988381|NCT03272074|Active Comparator|Egg White Group (Group B)|Participants will consume equivalent amounts of egg whites for 12 weeks
89620148|NCT03352752|Experimental|Without HTC Vive before the operation|The control group was wearing a blindfold before operation. The operating area is continuous 10 maximum square spot areas. The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
89620149|NCT01638052|No Intervention|0.25% Bupivacaine|This is our standard of care concentration
89036710|NCT05470829|Experimental|Cohort 3 of Part 2 200mg ZM-H1505R or placebo|"Subjects were enrolled in sequence from 200 mg dose group (cohort 3). Ten chronic hepatitis B virus-infected patients were enrolled in each cohort to receive ZM-H1505R (n=8) or placebo (n=2).~Subjects in all cohorts were administrated on Day 1 - Day 28 once daily (consecutive 28-day administration) in the morning under fasting conditions.~Two sentinel subjects were enrolled in each cohort to reveived ZM-H1505R. When safety evaluation on Day 3 showed that ZM-H1505R could be tolerated by sentinel subjects, the remaining 8 subjects including HBeAg-positive and HBeAg-negative patients at a ratio of 4:4 were enrolled to receive ZM-H1505R or placebo at a 3:1 ratio in a randomized manner."
89620150|NCT01638052|Experimental|0.25% Bupivacaine + Clonidine|These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.
89620151|NCT02518152|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating periodontal defect
89620152|NCT02518152|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating periodontal defect
89620153|NCT02518152|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating periodontal defect
89620154|NCT01229878|Active Comparator|Arm 1|Hemodialysis Patients randomized to take Vitamin D supplements
89620155|NCT01229878|Placebo Comparator|Arm 2|Hemodialysis Patients randomized to take placebo pills
89620156|NCT03352674|Experimental|Insulin Glargine Ezelin|Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
89620157|NCT03352674|Active Comparator|Insulin Glargine Lantus|Insulin Glargine Pen Injector [Lantus]
89620158|NCT02249260|Experimental|Behavioral|Group-based high intensity interval training and lifestyle counseling
89620159|NCT02518074|Other|HEARING AND VESTIBULAR INTERACTIONS|Hearing and Vestibular Interactions during two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
89620160|NCT03352596|Experimental|intervention group|Eight weeks of low fructose diet with a maximum of 12 g of fructose
89620161|NCT03352596|No Intervention|control group|Eight weeks of regular diabetic diet with a 15%pro 30%fat 55%CHO
89620162|NCT01639222|Experimental|Calcium 500 mg and Vitamin D3 800 IU|"Period 1: Low calcium meals for up to 3 days.~Period 2: Calcium 500 mg and Vitamin D3 800 IU chewable tablets, orally, once daily for up to 3 days with low calcium meals."
89620163|NCT03352518|Experimental|IMD data collection|Subjects will intensively collect spectral raman data in a home-based setting for 5 days using WM3.4NR and comparators.
89620164|NCT03349086|Active Comparator|Voice Exercise|Randomized participants in this group will undergo 45 minutes of voice exercise, including sustained pitches and pitch glides on a variety of different vocal facilitators.
89620165|NCT03349086|No Intervention|Voice Rest|Randomized participants in this group will undergo 45 minutes of voice rest.
89036711|NCT00593281|No Intervention|1|IV Morphine
89036712|NCT00593281|Experimental|2|SC Morphine with Hylenex
89036713|NCT00593281|Active Comparator|3|SC Morphine with Saline
89620166|NCT01640548||Cohort|
89620167|NCT04502628|Experimental|HBOT group|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished.
89036714|NCT00593359||A|Lactated Ringer's replacement for blood loss and placebo eye drops
89036715|NCT00593359||B|Lactated Ringer's replacement for blood loss and brimonidine eye drops
89620168|NCT05473338||CRPS (Complex Regional Pain Syndrome)|Participants with CRPS (Complex Regional Pain Syndrome))
89620169|NCT05473338||Healthy|Healthy individuals
89620170|NCT04443270|Experimental|Chloroquine phosphate prophylactic group|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
89620171|NCT04443270|No Intervention|Control group|Health personnel who want to be included voluntary in the study and meet the inclusion criteria without Chloroquine use.
89620172|NCT01598194|Experimental|Novel 22-gauge Core Biopsy Needle Standard Biopsy Needle|The 22-gauge core biopsy needle with reverse bevel design (EchoTip® Procore™) will be compared prospectively to the standard straight hollow-core 22-gauge or 25-gauge FNA needle already used in our clinical practice for the diagnosis of solid pancreatic lesions.
89620173|NCT03349008|Placebo Comparator|Control group|Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo
89620174|NCT03349008|Experimental|Experimental group|Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate
89620175|NCT01598350|Experimental|Orthotic|Orthotic Use
89620176|NCT01598428|Other|cataract|
89620177|NCT03352440|Experimental|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
89036716|NCT00593359||C|Albumin replacement for blood loss and placebo eye drops;
89036717|NCT00593359||D|Albumin replacement for blood loss and brimonidine eye drops
89057810|NCT04536740|Experimental|without treatment PWS|PWS without treatment before will be treated with PDT
89620178|NCT03352440|Experimental|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
89620179|NCT03352440|Active Comparator|Control Group - Kinect|Group with typical development that will perform the task on Kinect
89620180|NCT03352440|Active Comparator|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
89620181|NCT03352362|Experimental|caldolor|intravenous caldolor injection during intraoperative period
89620182|NCT03352362|Active Comparator|denogan|intravenous denogan injection during intraoperative period
89620183|NCT03352362|Experimental|combination|intravenous denogan and caldolor injection during intraoperative period
89620184|NCT03348852|Active Comparator|Active tDCS|Active transcranial direct current stimulation
89620185|NCT03348852|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
89620186|NCT01598740|Experimental|CLP with spironolactone|
89620187|NCT01598740|Experimental|CLP without spironolactone|
89620188|NCT03352284|Experimental|Straumann Pure Ceramic Implant|Replacement of single tooth gaps with a Zirconia implant
89620189|NCT01599286|Experimental|Active Comparator|Parallel Trial Comparing NCG + Standard of Care Treatment
89036718|NCT04327102|Experimental|Experimental : intervention group|Combination of health education tools and health literacy intervention: on the basis of the control group, the hypertension health education tools are used as the education media to encourage patients to find out the elements of the tool chart, use the picture content to guide the topic development, encourage patients to discuss with each other, realize heuristic questions, rather than a single indoctrination, so as to deepen the understanding and memory of patients. At the end of the course, patients are encouraged to set short-term goals to encourage behaviors that continue to achieve larger goals. At the same time, health literacy lectures were organized during the hospitalization. Health literacy lecture is mainly to learn the information that hypertension needs to pay attention to in order to improve the health literacy of hypertension patients and other indicators.
89036719|NCT04327102|No Intervention|No intervention:The control group|No intervention except conventional care were performed for the control group
89036720|NCT00536003|Experimental|1|
89036721|NCT00536003|Placebo Comparator|2|
89036722|NCT00593437||1|diagnosed with normal bone density by Norland Excel
89620190|NCT01599286|Active Comparator|Placebo Comparator|Placebo and Standard of Care Therapy
89620191|NCT04503642||Intervention Group|The intervention consisted in the closure of the abdominal wall and skin by a second surgical team which included a board-certified surgeon and a resident.
89620192|NCT04503642||Baseline Group|During the baseline period, closure of the abdominal wall was performed by the main surgical team, the same team that performed the whole surgery.
89620193|NCT01599832|Experimental|Treatment (pazopanib hydrochloride, DCE-MRI)|Patients receive pazopanib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline, day 8, and prior to courses 3, 5, and 7.
89620194|NCT01600222|Experimental|LEO 90100|
89620195|NCT05062096|Other|Group 1: BRAF-mutated metastatic patients treated with 1st line targeted therapy|BRAF-mutated metastatic patients treated with 1st line targeted therapy
89620196|NCT05062096|Other|Group 2: Metastatic patients treated with 1st line immunotherapy|Metastatic patients treated with 1st line immunotherapy
89620197|NCT05062096|Other|Group 3: BRAF-mutated patients treated with adjuvant targeted therapy|BRAF-mutated patients treated with adjuvant targeted therapy
89620198|NCT05062096|Other|Group 4: Patients treated with adjuvant immunotherapy|Patients treated with adjuvant immunotherapy
89620199|NCT00709098|Active Comparator|iloprost power 6|iloprost power 15
89620200|NCT00709098|Experimental|iloprost power 15|iloprost power 15
89036723|NCT00593437||2|diagnosed with osteopenia by Norland Excel densitometer
89036724|NCT00593437||3|diagnosed with osteoporosis by Norland Excel densitometer
89036725|NCT00593476|Active Comparator|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
89036726|NCT00593476|Active Comparator|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
89036727|NCT00593515|Experimental|1|Family CBT
89036728|NCT00593515|Active Comparator|2|Child-focused CBT
89620201|NCT03348696|Active Comparator|dexamethasone tapering dose|standard dexamethasone pre-medication (8mg B.I.D x 3 days commencing the day before chemotherapy) then 4mg 1x/d for 2 days followed by 2mg 1x/d for 2 days
89620202|NCT03348696|Active Comparator|dexamethasone physician choice|standard dexamethasone pre-medication (i.e. 8mg B.I.D x 3 days commencing the day before chemotherapy) then physician choice interventions
89036729|NCT00533091|Active Comparator|1|MEDI-545
89620203|NCT04506450|Active Comparator|Peripheral nerve block|The participant will receive a combination of lumbar plexus block, sciatic nerve block, lateral femoral cutaneous nerve block and lateral branch of iliohypogastric nerve block
89036730|NCT00533091|Other|2|Placebo
89036731|NCT00536042|Experimental|minocycline|addition of minocycline to standard asthma care as add-on therapy: 150 mg bid to 250 mg bid for up to one year
89036732|NCT01606384|Placebo Comparator|Placebo|Twice daily
89036733|NCT01606384|Experimental|SSR149415 - 100mg|Twice daily
89036734|NCT01606384|Experimental|SSR149415 - 250mg|Twice daily
89620204|NCT04506450|Active Comparator|Spinal anesthesia|The participant will receive a combination of spinal anesthesia and lumbar plexus block
89620205|NCT03348618|Experimental|IVIG|IVIG dose at 1 g/Kg/body weight
89620206|NCT03352206||2-Drug Treated Communities|"Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
89620207|NCT03352206||3-Drug Treated Communities|"Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
89620208|NCT03352128|Experimental|Creatine supplementation|7-day creatine supplementation
89620209|NCT03352128|Placebo Comparator|Placebo supplementation|7-day calcium lactate supplementation
89036735|NCT01606423|Placebo Comparator|Placebo|Administered once, orally
89036736|NCT01606423|Experimental|10 mg LY2409021|10 mg LY2409021 administered once, orally
89036737|NCT01606423|Experimental|22.5 mg LY2409021|22.5 mg LY2409021 administered once, orally
89036738|NCT01606423|Experimental|60 mg LY2409021|60 mg LY2409021 administered once, orally
89036739|NCT01606423|Experimental|200 mg LY2409021|200 mg LY2409021 administered once, orally
89036740|NCT01606423|Experimental|500 mg LY2409021|500 mg LY2409021 administered once, orally
89036741|NCT01606462|Experimental|Oxytocin|one application of 24 IU oxytocin per volunteer
89036742|NCT01606462|Placebo Comparator|Placebo|sodium chloride solution, intranasal application, 3 puffs per nostril one application per volunteer
89036743|NCT00533130||1|Pediatric patients under 16 years old with long bones fractures
89620210|NCT03122730|Experimental|VentaProst|VentaProst (epoprostenol solution for inhalation via custom drug delivery system)
89620211|NCT05281692||Positive|Enhanced Preservation Media (EPM-IX)
89620212|NCT05281692||Control|Med Schenker's STM viral media
89036744|NCT01606501||Limb Salvage patients|Patients undergoing limb salvage following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
89036745|NCT01606501||Transtibial Amputation patients|Patients undergoing transtibial amputation following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
89036746|NCT01606540|Experimental|Reposition and immobilism|"The patient are under sedation before reposition. The patient will be injected with 8-10 ml 1% Lidocain.~After reposition the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after reposition."
89036747|NCT01606540|Active Comparator|Surgery|"The method of surgery is type bridging.~After surgery the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after operation."
89036748|NCT01606579|Experimental|Part I|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Acute Group patients. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
89036749|NCT01606579|Experimental|Part II|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Non-Acute Group patients. Dosing will begin 2 dose levels below the Part I MTD. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
89620213|NCT04505904|Experimental|Syntocinon First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received syntocinon at visit one and placebo at visit two. Syntocinon is 24 IU dose administered intranasally in spray form.
89620214|NCT04505904|Placebo Comparator|Placebo First|Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received placebo at visit one, and syntocinon at visit two.
89620215|NCT04505982||Tocilizumab intravenous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, intravenous
89620216|NCT04505982||Tocilizumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with tocilizumab, subcutaneous
89620217|NCT04505982||Sarilumab subcutaneous|Patients followed in the CHU Brugmann Hospital for a rheumatoid polyarthritis and treated according to standard of care with sarilumab, subcutaneous
89620218|NCT03348462|Experimental|ethosomal anthralin|Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
89620219|NCT03348462|Active Comparator|liposomal anthralin|Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
89620220|NCT04505514|Experimental|Intravenous Iron Group|
89620221|NCT04505514|Active Comparator|Oral Iron Group|
89620222|NCT03352050|Active Comparator|ground beef|ground beef instead of mushrooms
89620223|NCT03352050|Active Comparator|Mushroom|2 servings of mushrooms
89620224|NCT05256732|Experimental|AT-527|
89620225|NCT05256732|Placebo Comparator|Placebo|
89036750|NCT01606579|Experimental|Part III Arm A|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with low dose ara-C therapy (20 mg SC BID × 10d q 28d) for AML patients ≥ 65 years of age."
89036751|NCT01606579|Experimental|Part III Arm B|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with dasatinib (140 mg PO daily) to Acute Group patients with CML-AP or BC."
89036752|NCT01606579|Experimental|Part III Arm C|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 1 dose level below the Part II MTD will be administered in combination with dasatinib (100 mg PO daily) to Non-Acute Group patients with CML-CP."
89620226|NCT05256732|Experimental|AT-527 BID|
89620227|NCT05256732|Experimental|AT-527 single dose fasted/fed|
89620228|NCT05208918|Active Comparator|Epidural steroid group|Transforaminal steroid application to the dorsal root ganglion of the affected dermatome of herpes zoster related pain in affected patients
89620229|NCT05208918|Active Comparator|PRF plus steroids group|Pulsed radiofrequency plus Depo-Medrol (steroid) application to the dorsal root ganglion of the affected dermatome of herpes zoster related pain in affected patients
89620230|NCT03348384|Experimental|Cocaine use disorders|PET scan
89620231|NCT03348384|Experimental|Controls|PET scan
89620232|NCT02517762|Experimental|Stay active|Receive the advice by the physician to stay as active as possible in spite of the pain experienced
89620233|NCT02517762|Experimental|Adjust activity|Receive the advice by the physician to adjust the activity according to the pain, i.e. to avoid activities, movements or positions that cause or worsen the pain
89620234|NCT03346980||Familial adenomatous polyposis|The Danish Polyposis Register is sited at Copenhagen University Hospital Hvidovre. From this registry consecutive familial adenomatous polyposis patients referred for esophagogastroduodenoscopy (EGD) will prospectively be enrolled in this single-center study. Both patients referred for endoscopic surveillance and interventional endoscopy are eligible.
89620235|NCT04505748|Experimental|Self-transfusion group|Patients to whom a self-transfusion device has been used after total knee arthroplasty.
89620236|NCT04505748|No Intervention|Control group|Patients to whom conventional drains have been used after total knee arthroplasty.
89620237|NCT03351972|Active Comparator|Bowel Prep routine|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the routine guidance of taking the contents the day before their capsule endoscopy
89620238|NCT03351972|Active Comparator|Bowel Prep Split|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the guidance stating to take the first dose the day before the capsule endoscopy and the second dose the morning of the capsule endoscopy
89036753|NCT00533169|Experimental|ZD6474 + Retinoic Acid|Part A = ZD6474 Alone, Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = ZD6474 + Retinoic Acid 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
89620239|NCT03351972|Experimental|No bowel prep|Participants randomised to this arm will be advised to drink clear liquids only ahead of their capsule endoscopy procedure
89620240|NCT04503330|Experimental|Patients with iatrogenic PUJO|patients with iatrogenic PUJO or long segment ureteric stricture disease for safety and efficacy of using buccal graft for repair
89620241|NCT05585424|Experimental|Experimental Group|Patients in the experimental group were paired so that each patient with MCI faced a patient with ModCI. During the sessions, two therapists performed the upper limb activities that only the MCI patients could see and they performed them by imitation
89620242|NCT05585424|No Intervention|Control group|The CG was assessed at baseline and after one month and continued with their usual activities in the nursing home.
89620243|NCT03122340|Placebo Comparator|Placebo Group|Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
89620244|NCT03122340|Experimental|Polyprenol Group|Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
89620245|NCT03351894|Placebo Comparator|Conventional|Conventional phacoemulsification surgery
89620246|NCT03351894|Active Comparator|Femtosecond laser|Ziemer femtosecond laser assisted cataract surgery Intervention: Ziemer femtosecond laser assisted cataract surgery
89620247|NCT03351816|Experimental|Cardioversion group|Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
89620248|NCT03351816|Experimental|Ablation group|Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
89620249|NCT04505202|Experimental|Experimental group|0.12% chlorhexidine gluconate
89620250|NCT04505202|Placebo Comparator|Placebo group|sodium bicarbonate
89620251|NCT04505124|Experimental|FutureMe|"Participants use the FutureMe app for 12 weeks. The app has the following functionality:~Opportunity to personalize one's avatar~Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)~Feedback on health behaviors represented through a Future-self avatar (consequential and visual feedback)~Individualized shopping tipps"
89620252|NCT04505124|Active Comparator|Control|"Participants use the a control app for 12 weeks. The control app has the following functionality:~Tracking of PA (steps) and nutrition (purchasing behavior at food retailers)~Feedback on health behaviors represented through conventional dashboards (numeric & text feedback)~Individualized shopping tipps"
89620253|NCT04504890||Adults - Diagnosis|Adults seeking treatment for an attention-related disorder
89620254|NCT04504890||Adults - Prescribed|Adults who have been diagnosed with ADHD and prescribed medication treatment for the disorder
89620255|NCT04504890||Children - Diagnosis|Children seeking treatment for an attention-related disorder
89620256|NCT04504890||Children - Prescribed|Children who have been diagnosed with ADHD and prescribed medication treatment for the disorder
89620257|NCT03348072||Jehovah's witnesses|Jehovah's witnesses having undergone cardiac surgery between 1991 till 2012. Blood perfusions refused.
89036754|NCT01606618||Spina bifida aperta|
89036755|NCT01606618||Acquired traumatic spinal cord injury|
89036756|NCT01606696|Experimental|HIIT|Higher intensity interval training.
89036757|NCT01606696|Active Comparator|Standard intensity non-interval training|Standard intensity non-interval training
89620258|NCT03348072||Control|Paired control group, twice as big as the experimental group. Pairing criteria: age, sex, type of surgery performed. The control group must accept blood transfusions.
89620259|NCT03346746|Experimental|Low GI diet|This diet contained three Low GI meals. This was the Low Glycaemic Diet intervention.
89620260|NCT03346746|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
89620261|NCT03122028|Experimental|LAmbre closure system|
89620262|NCT03351582|Experimental|Grief and Communication One Session|Group one will meet with a family therapist for one 90 minute session where the main focus will be on providing psychoeducation on grief and communication to both children and parents. This arm receives only the first session of the grief and communication family intervention.
89620263|NCT03351582|Experimental|Grief and Communication Three Sessions|Thie Group will receive all three sessions of the grief and communication family intervention.
89620264|NCT03351582|No Intervention|Control|Group three will be the control group and will not receive the grief and communication family intervention.
89620265|NCT05098704|Experimental|clopidogrel|
89620266|NCT05098704|Placebo Comparator|placebo|
89620267|NCT05585268|Active Comparator|MedSafer-supplemented medication reconciliation|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
89620268|NCT05585268|No Intervention|Standard of care medication reconciliation|This unit will serve as the control unit where standard of care will be provided and no deprescribing reports nor brochures will be delivered. MedSafer reports will be generated but withheld from the clinical team. This will serve as a comparator to determine if the intervention unit was more successful in deprescribing compared to this control unit.
89620269|NCT05584956|Active Comparator|Group 1|n=22): Patients will receive traditional treatment and L- carnitine 50mg/kg/day orally (maximum dose 3g per day)
89620270|NCT05584956|Active Comparator|Group 2|n=22): Patients will receive traditional treatment and Sildenafil 0.25mg/kg/dose every 6 h orally (maximum dose 60 mg per day)
89620271|NCT04502004|No Intervention|Control Group (CG)|"Receive the recommendations of the Clinical Practice Guidelines which consist of: advice on smoking cessation smoking, leaflet with information (tobacco components, treatments to reduce withdrawal syndrome).~Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
89036758|NCT00593632|Experimental|High Fiber Intake|Two 3/4 Cup servings of high fiber Uncle Sam cereal daily
89036759|NCT00593671|Active Comparator|PGS group|
89036760|NCT00593671|No Intervention|control group|
89057811|NCT01686789|Active Comparator|Pegylated interferon alpha-2a plus standard dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus standard dose ribavirin 100-1200 mg/day for 48 weeks
88988382|NCT00467194|Experimental|Phase I study of rapamycin and bevacizumab|"Rapamycin (available as 1mg per tablet; Wyeth) will be given orally once in the morning before meal. The starting dose of rapamycin will be 1mg administered once daily. All doses of rapamycin will be preceded by an oral loading dose three times the maintenance dose on day 1. The dose of rapamycin will be increased at each dose level.~Bevacizumab (100mg/4ml; Roche) will start concurrently with rapamycin. It will be diluted in a total of 100ml of 0.9% sodium chloride given via intravenous injection. The first dose will be infused over 90 minutes. If the first infusion is tolerated without any adverse infusion-related events (fever and/or chills), the second infusion may be delivered over 60 minutes. If the 60- minute infusion is well tolerated, the subsequent doses may be delivered over 30 minutes."
88988383|NCT00148902|Experimental|All treated subjects|All subjects received Lapatinib in Combination with Docetaxel (Taxotere)
88988384|NCT05507645|Experimental|rhPro-UK (35mg)|rhPro-UK: 35 mg (5 mg per vial, 7 vials in total) Dissolve 15mg (3 vials) of rhPro-UK in 10ml of saline and intravenous bolus within 3 minutes, and dissolve the remaining 20mg (4 vials) in 90ml of saline and intravenous drip within 30 minutes. (Note: after adding saline, overturn it gently once to twice, do not shake vigorously, so as to avoid foaming of the rhPro-UK solution and reduce the efficacy).
88988385|NCT05507645|Active Comparator|standard medical treatment|Standard antiplatelet or anticoagulant treatment at the discretion of local investigators according to the 'Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018'.
88988386|NCT03271918|Experimental|Study Group|This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.
88988387|NCT03271918|No Intervention|Control Group|This group was followed, with clinical visits in same frequency of study group, but without intervention.
88988388|NCT05497310|Experimental|Induction with attenuated ATO plus low-dose ATRA|Remission induction therapy will be administrated as ATRA 25/mg/m2/day for 28 continuous days without interruption if APL is suspected. ATO 0.3mg/kg/day for days 1-5 (5 doses) and then 0.25 mg/kg/day every other day twice a week for the next 3 weeks (6 doses).
88988389|NCT00467974|Experimental|1|TEA with LEM
88988390|NCT00467974|Active Comparator|2|TACE
88988391|NCT05486273|Experimental|Groupe OC (Onco-Coaching)|"You will be offered 6 coaching sessions at a rate of one session per month. The first session will take place in the month following your inclusion in the study.~The study also includes the evaluation, by quality of life questionnaires, of the well-being variables (Self-efficacy, Capabilities, PANAS and Life Satisfaction, Hope, Anxiety and Depression in hospital, Subjective well-being and Health benefit).~They should be completed at the time of inclusion in the protocol at 1, 3, 6, 9 and 12 months after inclusion. The purpose of these interviews is to ask more specific questions about the impact of the program."
88988392|NCT05486273|Active Comparator|Groupe C (Contrôle)|the patient will have standard management including also questionnaires and semi-structured interviews within the same time frame as the experimental arm.
88988393|NCT00468013|Experimental|1|Computer-based exercises to be executed at home.
88988394|NCT00468013|Sham Comparator|2|Computer-based exercises to be executed at home.
88988395|NCT00468091|Placebo Comparator|saline-saline|"saline IV~+ saline IV"
88988396|NCT00468091|Active Comparator|saline-exendin(9-39)amide|"saline IV~+ exendin(9-39)amide IV"
88988397|NCT00468091|Active Comparator|saline-atropine|"saline IV~+ atropine IV"
88988398|NCT00468091|Active Comparator|exendin(9-39)amide-atropine|"exendin(9-39)amide IV~+ atropine IV"
89533155|NCT05406700|Active Comparator|Arm B No Treatment with Niraparib|Subjects in arm B will not receive niraparib prior to surgery. The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery . Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent.
89533156|NCT05400512|Experimental|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
89533157|NCT05400512|Experimental|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
88988399|NCT00468247|Active Comparator|1|Device , Navigator used for guiding haemodynamic care
88988400|NCT00468247|Placebo Comparator|2|Conventional care
88988401|NCT00468325|Active Comparator|Multi-slice Computed Tomography|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to a multi-slice computed tomography arm where they will receive a CT scan of their heart.
88988402|NCT00468325|Active Comparator|Standard of Care|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to the Standard of Care arm and receive rest-stress nuclear myocardial perfusion imaging test.
89533158|NCT05400109|Experimental|UF-KURE19 CAR-T cell infusion|"The safety and manufacturing feasability of UF-KURE19 will be determined with up to 10 patients being enrolled. Lymphodepleting therapy will begin on Days -4 to -2 with each weight category of participants receiving 30mg/m2/IV of Fludarabine and 500mg/m2/IV of Cyclophosphamide regardless of the level of UF-KURE19 CAR-T cell dosing.~Dosing:~Participants greater than or equal to 50 kg:~Level -1: 8.5 x 10^6 UF-KURE19 CAR-T Cell Dose (CAR positive cells)~Level 1 : 17.5 x 10^6 UF-KURE19 CAR-T Cell Dose~Participants less than 50 kg:~Level -1: 5.5 x 10^6 UF-KURE19 CAR-T Cell Dose~Level 1: 11.5 x 10^6 UF-KURE19 CAR-T Cell Dose"
89533159|NCT05391178|Active Comparator|Psoriasis|Psoriasis participants will be provided sleeves made from the Lumiton yarn to cover their arms. The participants will be instructed to wear the sleeves made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
89533160|NCT05391178|Active Comparator|Alopecia Areata|Alopecia areata participants will be provided a hat made from the Lumiton yarn. The participants will be instructed to wear the hat made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
89533161|NCT05391178|Active Comparator|Polymorphous Light Eruption|Polymorphous light eruption participants will be provided a shirt made from the Lumiton yarn. The participants will be instructed to wear the shirt made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
89533162|NCT05388877|Experimental|Treatment (E6201, dabrafenib)|Patients receive MEK-1/MEKK-1 inhibitor E6201 IV over 2 hours on days 1, 4, 8, 11, 15, and 18, and dabrafenib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89533163|NCT05376267|Experimental|Cooling 0 hours|Participants will be kept at a normal temperature for the whole 5 days.
89620272|NCT04502004|Experimental|Experimental Group (EG)|"Receive codes to download the App NoFumo+ . Is a mHealth that offer a CBT program. Follow-up after discharge by the hospital tabacco service: at one month, at three months, at six months and at one year."
89620273|NCT03351504|No Intervention|Control (usual lighting)|Participants will continue to use their usual lighting sources.
89620274|NCT03351504|Experimental|Intervention (solar lighting)|Participants will receive an indoor solar lighting system
89620275|NCT03351426|Active Comparator|Active tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will consist of 20 minutes stimulation at 2mA. Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
89620276|NCT03351426|Sham Comparator|Sham tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will be sham stimulation (30-second ramp up and down). Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
89620277|NCT01376700|Experimental|ADVATE - Prophylactic Regimen|Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.
89620278|NCT04504578|Experimental|patients with progressive keratoconus with thin corneas|patients with progressive keratoconus with thin corneas , with thickness less than 400 micron ,will do conventional cross linking but with putting contact lens over the cornea ( will receive Contact lens assisted corneal cross liking )
89620279|NCT01797965|Experimental|BIIB019|BIIB019 150 mg subcutaneous (SC) every 4 weeks
89620280|NCT01601236|Experimental|Acthar 8 U (0.1 mL) daily|Repository Corticotropin Injection
89620281|NCT01601236|Placebo Comparator|Placebo (0.1 mL) daily|Placebo
89620282|NCT01601236|Experimental|Acthar 16 U (0.2 mL) daily|Repository Corticotropin Injection
89620283|NCT01601236|Placebo Comparator|Placebo (0.2 mL) daily|Placebo
89620284|NCT01601236|Experimental|Acthar 32 U (0.4 mL) daily|Repository Corticotropin Injection
89620285|NCT01601236|Placebo Comparator|Placebo (0.4 mL) daily|Placebo
89620286|NCT05584878|Experimental|Group I|
89620287|NCT05584878|Experimental|Group II|
89620288|NCT05584878|Active Comparator|Group III|
89620289|NCT01601782|Experimental|Volume Imaging scan|New type of ultrasound scan using General Electric US scanner, Model is a GE Logiq E9.
88988403|NCT03271801|Active Comparator|Child Health Education|The child health education condition will participate in a family-based obesity treatment program for the first 40 minutes of each session, followed by 20 minutes designated to education about a child health topic. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time.
88988404|NCT03271801|Experimental|Skills Training|The skills training condition will participate in a family-based obesity treatment program for the first 40 minutes of each session followed by 20 minutes of experiential learning about meal stimulus control strategies. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time. In addition they will self-monitor the use the following stimulus control strategies: portion control, energy density and variety.
88988405|NCT00405002||1|ALI/ARDS patients
88988406|NCT03271450||Continuer at 90 Days: Dabigatran|
88988407|NCT03271450||Continuer at 180 Days: Dabigatran|
88988408|NCT03271450||Continuer at 270 Days: Dabigatran|
88988409|NCT03271450||Continuer at 90 Days: Apixaban|
89620290|NCT01601860|Active Comparator|Control|Active Comparator: Control Group Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
89620291|NCT01601860|Experimental|Intervention Group|Experimental: Intervention Group Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: Walking (with cervical dilation between 4 and 5 cm) Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm) Shower (with dilation> 7 cm);
89620292|NCT01376388|Experimental|GSK573719/GW642444|125/25mcg
89620293|NCT01643902|Experimental|IV tPA|Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria
89620294|NCT03347994|Experimental|Minnelide 0.40 (Dose Level -1)|"Dose Level -1: 25% decrease from prior dose level~- 0.40 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
89620295|NCT03347994|Experimental|Minnelide 0.53 (Dose Level 1)|"Starting Dose Level 1:~0.53 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
89620296|NCT03347994|Experimental|Minnelide 0.67 (Dose Level 2)|"Dose Level 2: 25% increase from Dose Level 1~- 0.67 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
89620297|NCT03347994|Experimental|Minnelide 0.80 (Dose Level 3)|"Dose Level 3: 25% increase from Dose Level 2~- 0.80 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
89620298|NCT01644058|Experimental|Immediate loading|Immediate loading of 2 endo-osseous mandibular implants
89620299|NCT04966338|Experimental|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
89620300|NCT04966338|Active Comparator|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.
89620301|NCT03347916|Placebo Comparator|Control group|patients received strawberry juice 5 ml volume, one hour before induction.
89620302|NCT03347916|Active Comparator|Gabapentin group|patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
89620303|NCT03350958|Experimental|Group 1|Participants received experimental test meal first and placebo comparator meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
89620304|NCT03350958|Placebo Comparator|Group 2|Participants received placebo comparator meal first and experimental test meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
89620305|NCT03350802||procalcitonin pneumonia cohort|Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort.
89620306|NCT01821677|Experimental|Low Dose Danazol|Capsules, 0.5 mg/BMI Danazol with dose determined by subject's BMI at baseline, 2 capsules (5 mg, 7.5 mg, or 10 mg) twice daily, for 12 weeks.
89620307|NCT01821677|Experimental|High Dose Danazol|Capsules, 1.0 mg/BMI Danazol with dose determined by subject's BMI at baseline, 2 capsules (5 mg, 7.5 mg, or 10 mg) twice daily, for 12 weeks.
89620308|NCT01821677|Placebo Comparator|Placebo|Gelatin capsules, identical in appearance to the active capsules, filled with pharmaceutical grade lactose and magnesium stearate.
89620309|NCT01797731|Active Comparator|Conventional System|Conventional tibial extramedullary alignment system used by surgeon during surgery.
89620310|NCT01797731|Experimental|KneeAlign System|Digital hand-held surgical navigation system for tibial component placement used by surgeon during surgery.
89620311|NCT05651958|Experimental|Pranayma Breathing Technique|Pranayma Breathing Technique protocol includes 15 breaths in the morning and 15 breaths in evening for atleast weeks.
89620312|NCT05651958|Active Comparator|Conventional Treatment|Long-acting beta-2 agonist, nebulizers and long acting anti-mucosic drugs.
89620313|NCT03062280|Experimental|Chronocort®|Chronocort® modified release hydrocortisone
89620314|NCT00709722|Experimental|1|NKT-01
89620315|NCT03121872|Experimental|Root Coverage Surgery with T-PRF|"Multiple gingival recessions were treated by Titanium prepared PRF (T-PRF) in 16 patients.~The T-PRF membrane that was procured was placed in the defect area 1 mm beyond the enamel-cement border.. The T-PRF was fixed in the receiver area by a mattress stitch through the apical aspect using 5-0 monofilament absorbable sutures. The flap was stitched in a manner that completely covered the graft in the coronal aspect. Thereafter, the graft was fixed to the flap on the coronal aspect with horizontal mattress sutures. Compression was applied to the receiver area with serum-impregnated sterile gauze for approximately 5 minutes, and then periodontal paste was placed onto the surgery site."
89620316|NCT03121872|Active Comparator|Root Coverage Surgery with CTG|"Multiple gingival recessions were treated by Connective Tissue Graft (CTG)in 18 patients.The CTG width was measured to include 1 mm beyond the root surface defects in the receiver area. Following anaesthesia of the palate, the borders of the start and finish incisions were marked. Subepithelial connective tissue that was 1.5-2 mm thick and excluded the periosteum was removed and maintained in physiological saline. The palate was stitched with 4-0 absorbable sutures (Pegalak, Doğsan, Turkey) and covered with a periodontal paste.~Before placing the connective tissue in the receiver area, the fat and glandular tissues and the band-shaped epithelium on the connective tissue were removed using scissors."
89620317|NCT01645306|Placebo Comparator|Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol|Placebo control with PBS, 1% sucrose and 4% mannitol
89620318|NCT01645306|Active Comparator|40 mg Revacept|low dose Revacept 40mg in PBS, 1% sucrose, 4% mannitol
89620319|NCT01645306|Active Comparator|120 mg Revacept|high dose revacept 120mg in PBS, 1% sucrose, 4% mannitol
89620320|NCT05584488||Inherited diseases of allergic inflammation or immune dysregulation|Patients and blood relatives with disorders of allergic inflammation and immune dysregulation.
89620321|NCT01820585|Placebo Comparator|Placebo|Tablets
88988410|NCT03271450||Continuer at 180 Days: Apixaban|
88988411|NCT03271450||Continuer at 270 Days: Apixaban|
88988412|NCT03271450||Continuer at 90 Days: Rivaroxaban|
89620322|NCT01820585|Active Comparator|ESL 400 mg|Eslicarbazepine acetate (BIA 2-093) tablets
88988413|NCT03271450||Continuer at 180 Days: Rivaroxaban|
88988414|NCT03271450||Continuer at 270 Days: Rivaroxaban|
88988415|NCT03271450||Continuer at 90 Days: Edoxaban|
88988416|NCT03271450||Continuer at 180 Days: Edoxaban|
88988417|NCT03271450||Continuer at 270 Days: Edoxaban|
88988418|NCT03271450||Continuer at 90 Days: Warfarin|
88988419|NCT03271450||Continuer at 180 Days: Warfarin|
88988420|NCT03271450||Continuer at 270 Days: Warfarin|
88988421|NCT03271450||Discontinuer at 90 Days: Dabigatran|
88988422|NCT03271450||Discontinuer at 180 Days: Dabigatran|
88988423|NCT03271450||Discontinuer at 270 Days: Dabigatran|
88988424|NCT03271450||Discontinuer at 90 Days: Apixaban|
88988425|NCT03271450||Discontinuer at 180 Days: Apixaban|
88988426|NCT03271450||Discontinuer at 270 Days: Apixaban|
88988427|NCT03271450||Discontinuer at 90 Days: Rivaroxaban|
88988428|NCT03271450||Discontinuer at 180 Days: Rivaroxaban|
88988429|NCT03271450||Discontinuer at 270 Days: Rivaroxaban|
88988430|NCT03271450||Discontinuer at 90 Days: Edoxaban|
88988431|NCT03271450||Discontinuer at 180 Days: Edoxaban|
88988432|NCT03271450||Discontinuer at 270 Days: Edoxaban|
88988433|NCT03271450||Discontinuer at 90 Days: Warfarin|
88988434|NCT03271450||Discontinuer at 180 Days: Warfarin|
88988435|NCT03271450||Discontinuer at 270 Days: Warfarin|
88988436|NCT03271606|Experimental|ERAS group|The patients in this group receive enhanced measures perioperatively
88988437|NCT03271606|Active Comparator|Traditional group|The patients in this group receive traditional measures perioperatively
88988438|NCT00405041|Experimental|A|
88988439|NCT00468754|Experimental|A|
88988440|NCT00468754|Experimental|B|
88988441|NCT00468793|Active Comparator|2|Fluid therapy guided by blood pressure and urine production
88988442|NCT00468793|Experimental|1|ScvO2 guided fluid therapy
88988443|NCT00468832||Ongoing Duchenne Muscular Dystrophy (DMD) Cohort|340 patients currently enrolled participants with DMD.
89620323|NCT01820585|Active Comparator|ESL 800 mg|Eslicarbazepine acetate (BIA 2-093) tablets
89620324|NCT01820585|Active Comparator|ESL 1200 mg|Eslicarbazepine acetate (BIA 2-093) tablets
89620325|NCT02593188||HYQVIA- Epoch 1|Participants receiving HYQVIA
89620326|NCT02593188||HYQVIA- Epoch 2|Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)
89620327|NCT01797263|Experimental|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
89620328|NCT01797263|Active Comparator|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
89620329|NCT01602172|Experimental|Brief Alcohol Intervention (BI)|The 3-part Brief Intervention (BI) consists of . Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
89620330|NCT01602172|Active Comparator|Attention Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity. Two weeks later, the Research Assistant calls subjects in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. This intervention is designed to provide all the information and assessments that that Brief Intervention participants as well as all the alcohol consumption and motivation to change measures-- it is designed to control for the attention that the BI participants receive w/o the motivational interventions
89620331|NCT01602172|Active Comparator|Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. Subjects complete only drinking quantity measures at baseline and 6 months post baseline. The inclusion of this group tests whether completing more extensive questionnaires (in comparison the Attention Control group) decreases alcohol consumption.
89620332|NCT02253108|Experimental|SYNERGY drug eluting stent|Everolimus eluting bioresorbable polymer stent
89620333|NCT02253108|Experimental|Biomatrix NeoFlex drug eluting stent|Biolimus eluting bioresorbable polymer stent
89620334|NCT04500990||Single agent PD-1/PD-L1 inhibitor|Patients will receive single agent PD-1/PD-L1 inhibitor in a predefined group.
89620335|NCT04500990||Combined immunotherapy|Patients will receive combined immunotherapy in a predefined group. PD-1/PD-L1 inhibitor will be combined with target therapy, such as lenvatinib, enrotinib, herceptin et al.
89620336|NCT01603420|Active Comparator|Radiation + 24mo luteinizing hormone-releasing hormone (LHRH)|Conformal RT 79.2 Gy(RBE) total dose + 24 months LHRH agonist (androgen suppression).
89620337|NCT01603420|Experimental|Radiation + Chemo + 6mo luteinizing hormone-releasing hormone|Conformal RT 79.2 Gy(RBE) total dose + Chemotherapy: Docetaxel 20mg/m2 x every 7 days x 8 weeks followed by 6 months LHRH (androgen suppression).
88988444|NCT00468832||New Young Duchenne Muscular Dystrophy (DMD) Cohort|Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.
88988445|NCT00468832||Typically Developing Control Cohort|Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.
88988446|NCT00468871|Experimental|Fluocinolone acetonide|Intravitreal fluocinolone acetonide implant
88988447|NCT00468871|Active Comparator|Standard care|Standard of Care
88988448|NCT00468949||1|Patients undergoing excision surgery for their dupuytren's contracture
88988449|NCT00468949||2|Patients not undergoing surgery for their excision surgery
88988450|NCT00469027|Experimental|eNOS transfected EPCs|eNOS transfected EPCs will be delivered by injection via a PA line, incremental doses over three days
88988451|NCT00469105|Active Comparator|Control|Control Arm receives standard diabetes disease management
88988452|NCT00469105|Experimental|Intervention Arm|Receives numeracy/literacy sensitive diabetes management
88988453|NCT00469261|Experimental|Doxycycline|Active drug 100 mg bid for seven days in pts with AMI treated with Primary PCI and current medical therapy
88988454|NCT00469261|Active Comparator|Standard Therapy|Pts with AMI treated with Primary PCI and current medical therapy
88988455|NCT04697446||Patients from the BLU-667-1101 (ARROW) study|Patients with Non-Small Cell Lung Cancer (NSCLC) who received treatment with pralsetinib as part of the BLU-667-1101 (ARROW) study
88988456|NCT04697446||External Control Group|Patients with Non-Small Cell Lung Cancer (NSCLC) that received best available therapy
88988457|NCT05457140|Experimental|Enrollees - WGS|These participants will be subject to whole genome sequencing and Phage ImmunoPrecipiation sequencing (PhIP-Seq) to identify genetic changes and novel antibodies associated with psychosis.
88988458|NCT00469378|Experimental|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
88988459|NCT00149175||Neurodegenerative disorders with cognitive impairment|
88988460|NCT00149175||Control|
88988461|NCT00149175||At risk reactive|
89036761|NCT02892721|No Intervention|Control group|The control group will not receive the one-day training course or access to the online educational module. Test sets will be administered in the same manner as for the intervention group, but the control group will not receive any feedback on performance during the 12 month assessment phase. Feedback on test performance will only be provided after the 12 month period has ended.
89036762|NCT02892721|Other|Training with feedback|See intervention description
89036763|NCT00593710|Experimental|1|Losartan
89036764|NCT00593710|Active Comparator|2|Atenolol
89036765|NCT04885686|Experimental|Endomethasone N RCS|Endomethasone N RCS is used in combination with gutta percha points for the permanent obturation of root canals.
89620338|NCT02064036|Experimental|Single|Neoadjuvant Androgen Blockade (Casodex) Followed by: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade (Casodex and Leuprolide) to Whole Pelvis, Prostate, and Seminal VesiclesFollowed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance Followed by: Adjuvant Androgen Blockade (Casodex)
89036766|NCT04885686|Active Comparator|Endomethasone SP RCS|Endomethasone SP RCS is used in combination with gutta percha points for the permanent obturation of root canals.
89036767|NCT00593749|Active Comparator|HCS|Intervention group
89620339|NCT05645484||18F-PFPN PET imaging|For clinically suspected or confirmed melanoma patients, targeted melanin-specific imaging 18F-PFPN PET/MR was performed. CT was instead when MRI was contraindicated. PET images, clinical characteristics, and follow-up information will be collected for prognostic analyses.
89620340|NCT05645484||18F-FDG PET imaging|For clinically suspected or confirmed melanoma patients, general metabolic imaging 18F-FDG PET PET/CT was performed. PET images, clinical characteristics, and follow-up information will be collected for prognostic analyses.
89620341|NCT03347682||Test group: Transtibial amputees|After translation/retranslation of the Prosthesis donning and doffing questionnaire, transtibial amputees will be asked to complete a quality of life evaluation Nottingham Health Profile-NHP, a satisfaction evaluation Satisfaction with Prosthesis -SATPRO and the Turkish version of the Prosthesis donning and doffing questionnaire twice (1-3 days apart).
89620342|NCT04551300|Experimental|VS-505 500mg|VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.
89620343|NCT04551300|Experimental|VS-505 750mg|VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.
89620344|NCT04551300|Experimental|VS-505 1500mg|VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.
89620345|NCT04551300|Experimental|VS-505 2250mg|VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.
89620346|NCT04551300|Active Comparator|Sevelamer Carbonate 1600mg|Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.
89036768|NCT00593749|Placebo Comparator|Control|Control
89620347|NCT02232022|Experimental|NonCryptogenic Ischemic Stroke Patients|Patients with non-cryptogenic ischemic stroke will be enrolled within 10 days of stroke onset
89620348|NCT04437186|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
89036769|NCT00593788||1|Normal-hearing adults between 18 and 31 years of age.
89036770|NCT00536081|Active Comparator|A|Pegfilgrastim during all 6 cycles of chemotherapy
89036771|NCT00536081|Experimental|B|Pegfilgrastim during the first two cycles of chemotherapy
89036772|NCT02892643|Experimental|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
89620349|NCT04437186|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
89620350|NCT04974580|Experimental|CoachingOnlyArm|Phone Coaching; no Digital Coaching, no NRT: This arm will receive only the two phone counseling calls which all other arms will receive.
89620351|NCT04974580|Experimental|DigitalArm|Phone Coaching + Digital Coaching; no NRT: This arm will receive digital content (text messages with links to online materials) in addition to to the two phone counseling calls which all arms will receive.
89620352|NCT04974580|Experimental|CoachingNRTArm|Phone Coaching + NRT; no Digital Coaching: This arm will receive Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
89036773|NCT02892643|Active Comparator|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
89036774|NCT00593944|Experimental|1|Patients will receive active MDX-1342.
89620353|NCT04974580|Experimental|DigitalNRTArm|This arm will receive digital content (text messages with links to online materials) AND Nicotine Replacement Therapy (NRT) in addition to the two phone counseling calls which all arms will receive.
89620354|NCT01605292|Active Comparator|Palpation|Manual palpation of radial pulse, as sole guide to needle cannulation.
89620355|NCT01605292|Experimental|Ultrasound|Real-time ultrasound guidance to facilitate needle cannulation of artery.
89036775|NCT00536159|Active Comparator|Community Care|Medicaid eligible/insured pregnant women and their infants are eligible for risk assessment and up to 18 home visits (9/pregnancy and 9/infancy) from community professional providers as part of a state-sponsored enhanced prenatal and postnatal Medicaid program.
89036776|NCT00536159|Experimental|Nurse-CHW Team|Nurse-CHW team provided both nursing care, with additional focus on mental health and stress, and intensive relationship-based support from a CHW similar in characteristics to women served in the context of state-sponsored Medicaid program.
89036777|NCT00594139|Experimental|1|Receipt of autologous neo-bladder construct
89620356|NCT03121794||Low BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 18.5 - 25 kg/m2
89620357|NCT03121794||Moderate BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 30-35 kg/m2 will receive ultrasound exam.
89620358|NCT03121794||High BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI > 40 kg/m2 will receive ultrasound exam.
89620359|NCT01797185|Experimental|SPARC1104 group 1|
89620360|NCT01797185|Experimental|SPARC1104 group 2|
89620361|NCT01797185|Experimental|SPARC1104 group 3|
89620362|NCT04501770|Experimental|M802|Subjects who meet the enrollment criteria will enter the core treatment period and receive a cycle of treatment with M802 (once weekly for 4 weeks) via intravenous infusion. And eligible subjects who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
89620363|NCT01691326|Experimental|6 months to < 36 months of age group|Participants at 6 months to < 36 months of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone® (Pediatric Dose).
89620364|NCT01691326|Experimental|3 years to < 9 years of age group|Participants at 3 years to < 9 years of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone®.
89620365|NCT04501692|Experimental|VivaSight|Intubated with a VivaSight-SL endotracheal tube.
89620366|NCT04501692|Active Comparator|Conventional|Intubated by videolaryngoscopy.
89620367|NCT04501068||Ambu AuraGain|Ambu® AuraGainTM Patients undergoing anesthesia in which airway management includes a Ambu® AuraGainTM supraglottic airway and fulfill the inclusion criteria of the study.
89620368|NCT01606852|No Intervention|usual sedative practice|"Subjects will have usual care sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration."
89620369|NCT01606852|Experimental|Patient controlled sedation|Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.
88988462|NCT04697641|Experimental|Helicobacter pylori eradication therapy Group|Patients with Functional Dyspepsia receiving two week course of triple drug regimen for H pylori eradication followed by six weeks of proton pump inhibitors
89620370|NCT02517840||Nonagenarian CLI|Patients suffering from Critical Limb Ischemia aged 90 year-old or above who undergo limb revascularization by means of open surgery or endovascular revascularization
89620371|NCT01691560|Experimental|5% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
89620372|NCT01691560|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
89620373|NCT01691560|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
89620374|NCT01691560|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
89620375|NCT02517606|Experimental|Conventional physical therapy plus HPCS|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization) plus the addition of hip posterolateral complex strengthening (HPCS)
89620376|NCT02517606|Active Comparator|Conventional physical therapy|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization)
89620377|NCT03346278|No Intervention|No Text Message Intervention|Participants will receive usual care of information on CR and clinical referral to CR.
89620378|NCT03346278|Experimental|Text Message Intervention|Participants randomized to the intervention will receive usual care plus a text messaging intervention.
89620379|NCT03346200|Active Comparator|20 mg tamoxifen|
89620380|NCT03346200|Experimental|10 mg tamoxifen|
89620381|NCT03346200|Experimental|5 mg tamoxifen|
89620382|NCT03346200|Experimental|2.5 mg tamoxifen|
89620383|NCT03346200|Experimental|1 mg tamoxifen|
89620384|NCT03346200|Placebo Comparator|0 mg tamoxifen|
89620385|NCT01691950||Reconstruction|Those who have undergone limb reconstruction following lower limb trauma
88988463|NCT04697641|Active Comparator|Symptomatic treatment group|Patients with Functional Dyspepsia receiving symptomatic therapy with proton pump inhibitors or gastric prokinetics
88988464|NCT00469573|Other|1.|
88988465|NCT00469651|Experimental|1|15 microgramme candidate vaccine
88988466|NCT00469651|Active Comparator|2|Hepatitis B vaccine
88988467|NCT00469651|Experimental|3|30 microgramme MSP3 candidate malaria vaccine
89620386|NCT01691950||Healthy volunteers|Healthy volunteers for control
89620387|NCT04501458|Experimental|Functional community health units|Community health units with active community health workers.
89620388|NCT04501458|No Intervention|Non functional community health units|Community health units without active community health workers.
89620389|NCT04501458|Experimental|Health facilities with oxygen capacity|Health facility with regular oxygen capacity.
89620390|NCT04501458|No Intervention|Health facilities without oxygen capacity|
89620391|NCT01819727|Active Comparator|BMN 165, 20mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
89620392|NCT01819727|Active Comparator|BMN 165, 40mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
89620393|NCT01649362|No Intervention|Control group|"No prefeeding oral stimulation~Infants in the control group received neither oral stimulation nor a pacifier before or during gavage feeding."
89620394|NCT01649362|Experimental|Oral stimulation, interventional group|"Infants in the interventional group received pre-feeding oral stimulation. The intervention started on infants born within 32 gestational weeks when the patients were stable and tube-fed, receiving more than 100 ml/kg/day of milk. On infants born after 32 weeks, the intervention started immediately after clinical stability was achieved.~The pre-feeding oral stimulation program consisted of a 15-minute stimulation program delivered by one of the eight trained nurses or one trained member from the medical staff in accordance with the stimulation program proposed by Fucile, Gisel and Lau.~The stimulation program was administered 15 to 30 minutes prior to tube feeding, once daily for at least 10 days. The program was stopped when the infants attained more than three oral feedings per day. The program was interrupted if the infants were medically unstable and/or had episodes of desaturation, apnoea and/or bradycardia during the intervention"
89620395|NCT05584020|Experimental|ACL Repair|Patients under surgical anterior cruciate ligament repair
89620396|NCT05584020|Other|ACL Reconstruction|Patients under surgical anterior cruciate ligament reconstruction
89620397|NCT03346590|Active Comparator|16 patients with active RA|"Women over 18 years old with proven active (DAS28 >3.2) RA, diagnosed based on ACR/EULAR 2010 criteria, receiving biological anti-TNF treatment for the first time.~Covered by social security. Capable of giving informed consent and acceding to the requirements of the study. For high-resolution echocardiography: no hypertension, diabetes or history of cardiovascular disorders."
89620398|NCT03346590|Sham Comparator|8 Healthy volunteers (control group)|Healthy volunteers (control group) The healthy female controls will be enrolled from the Centre de Recherche en Nutrition Humaine (CRNH) list of volunteers and matched to the RA patients according to age ±5 years and BMI class (<25; 25-30; >30).
89620399|NCT01692340|Experimental|Isotopically labeled lycopene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
89620400|NCT01692340|Experimental|Isotopically labeled phytoene|We will administer 3.2 mg isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
89620401|NCT01692340|Experimental|Isotopically labeled phytofluene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
89620402|NCT03346512||Cardiac surgery|Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015
89620403|NCT02517450|Experimental|experimental group|The subjects had to participate an adventure-based training programme.
89620404|NCT02517450|Placebo Comparator|placebo control group|The subjects had to participate a placebo control programme
89620405|NCT02517372|Active Comparator|Cohorte 1|"Low dose pemirolast sodium (CRD007) given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
89620406|NCT02517372|Active Comparator|Cohorte 2|"Medium dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
88988468|NCT00469651|Active Comparator|4|Hepatitis B control vaccine
88988469|NCT00469690|Other|1|
88988470|NCT00469690|Other|2|
88988471|NCT00469729|Experimental|StemEx|
88988472|NCT00469768|Experimental|A|
88988473|NCT00469768|Experimental|B|
88988474|NCT00469768|Placebo Comparator|C|
88988475|NCT06183736|Experimental|Single-arm|This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency.All patients will be given CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
88988476|NCT06183710|No Intervention|Integrated care only (control group)|The integrated care comprises of standard treatment offered at the Integrated Treatment Clinic at King's College Hospital and includes addiction and liver follow-up as well as facilitation of psychosocial sessions
88988477|NCT06183710|Experimental|Integrated care + CM|The integrated care comprises of standard treatment offered at the Integrated Treatment Clinic at King's College Hospital and includes addiction and liver follow-up as well as facilitation of psychosocial sessions. The adjunctive CM aims to reinforce attendance to integrated alcohol and liver care services from KCH over the course of 3 months
88988478|NCT06183632||Healthy donor|All healthy volunteers are eligible to donate according to EFS criteria.
88988479|NCT06183580|Experimental|dACC Arm|Participants assigned to the Neurofeedback from the dorsal anterior cingulate cortex
88988480|NCT06183580|Experimental|rAMY Arm|Participants assigned to the Neurofeedback from the amygdala
88988481|NCT06183567|Active Comparator|Sedoanalgesia (SA) group|The aim was to achieve a moderate level of sedoanalgesia (previously called conscious sedation) that would reduce agitation, anxiety and mobility but allow communication with the patient. Sedation was maintained at a level where cardiovascular function was preserved and no intervention was required to protect the airway in spontaneous breathing. Fentanyl iv 25-50 µg bolus was administered to each patient undergoing sedoanalgesia. For maintenance of sedoanalgesia, propofol iv infusion was started at doses of 1-2 mg kg-1 hour. It was titrated according to BIS level. In case of patient noncompliance, propofol iv 0.5 mg kg-1 was intervened.
88988482|NCT06183567|Active Comparator|General anesthesia (GA) group|Anesthesia induction was performed with lidocaine iv 0.5 mg kg-1, propofol iv 1-2 mg kg-1, fentanyl iv 25-50 µg. After providing adequate ventilation with a mask, rocuronium iv 0.45-0.6 mg kg-1 is administered and endotracheal intubation is performed. After intubation is confirmed with end-tidal CO2 monitoring, tidal volume is set to 6-8 ml kg-1 and respiratory frequency to 12/min in CMV mode. In order to maintain cerebral perfusion, PaCO2: 35-40 mmHg is aimed to be maintained. Sevoflurane MAC 0.8 and remifentanil infusion 0.03 µg kg-1 min iv were used for maintenance of anesthesia. At the end of the procedure, sugammadex iv 2mg kg-1 was administered for extubation.
89036778|NCT04882449|Experimental|Bodyport Scale|All subjects will be given the Bodyport scale to use
89620407|NCT02517372|Active Comparator|Cohorte 3|"High dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
89620408|NCT01692496|Experimental|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
89620409|NCT05583240|Experimental|Essential Oils|
89620410|NCT01692964||InflammaDry|Patients suspected of having dry eye will be tested with the InflammaDry.
89620411|NCT02517216|Other|parabolic flight and MRI scans|
89620412|NCT01649596|Active Comparator|Warming Gown|Comparison of two types of warming processes prior to, during, and after the surgery procedure.
89620413|NCT01649596|Other|Standard of Care Warming|Standard of care warming with hospital-issued blankets.
89620414|NCT03346122|Experimental|Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)|Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
89620415|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
89620416|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
89620417|NCT03346122|Experimental|Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)|Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
89620418|NCT03346122|Experimental|Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
89620419|NCT03346122|Experimental|Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
89620420|NCT03346122|Experimental|Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
89620421|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
89620422|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
89620423|NCT03346122|Experimental|Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
89620424|NCT02516826|Experimental|Rosuvastatin Arm|Rosuvastatin 10mg in combination with placebo of Olmesartan 20mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
89620425|NCT02516826|Experimental|Olmesartan Arm|Olmesartan 20mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
89620426|NCT02516826|Experimental|Combination Arm|Olmesartan/Rosuvastatin(Combination) 20/10mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan 20mg
89620427|NCT01650298|No Intervention|Control|Remote transmissions were scheduled per each institution's device monitoring protocol. Anticoagulation was initiated/discontinued based on standard of care/guidelines as prescribed by doctor
89688417|NCT02793154|Active Comparator|Part B: Exenatide|"In Part B, half of the subjects will be randomized to receive exenatide: On Day 1: Twice daily SC injection at 5 mcg for 4 weeks.~From Week 5, Day 1: Dose will be uptitrated to 10 mcg twice daily SC injection for 4 weeks"
88988483|NCT06183541|Active Comparator|PENG Block group|PENG block group; USG probe is placed on the transverse plane medial to the anterior inferior iliac spine (AIIS), the medial end of the probe is placed on the superior pubic It is rotated approximately 45° counterclockwise to align it with the ramus. For the PENG block, an 80 mm block needle is placed in the fascial plane between the psoas tendon and pubic ramus and 20 ml of 0.5% bupivacaine is administered after spinal anesthesia,
88988484|NCT06183541|Other|Control group|Control group; 10 ml 0.5% bupivacaine + 10 ml 2% lidocaine is infiltrated into the surgical area by the surgical team at the end of surgery
88988485|NCT06183528|Active Comparator|PENG group|PENG block was placed in the fascial plane between the pseudotendon and pubic ramus with USG in-plane technique, 20 ml of 0.5% bupivacaine was administered after spinal anaesthesia.
88988486|NCT06183528|Placebo Comparator|non-PENG group|group non-PENG, surgery was started without PENG block after spinal anaesthesia.
88988487|NCT06183515|Placebo Comparator|non-CPAP (Control)|The non-CPAP group received Fi02:0.6, and oxygen support was provided at a rate of 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a tracheostomy cannula.
88988488|NCT06183515|Active Comparator|CPAP group|During the postoperative period, the CPAP group received Fi02:0.6 and 8 to 12 mmHg of nasal CPAP, or CPAP was initiated through the tracheostomy cannula.
88988489|NCT06183476|Experimental|Intervention|Amplify-RHYTHM will consist of two main components: 1) timed light exposure, 2) weekly remote coaching session.
88988490|NCT06183450||hearing subject|Adult normal hearing subjects, evaluated annually for 5 years,
88988491|NCT06183424|Active Comparator|Interventional|Active tDCS stimulation will be applied over the scalp for 20 minutes at an intensity of 2 mA. Stimulation will be given for 5 days. The application will be made to the patient who has had 30 Covid and has cognition complaints in a randomized manner.
88988492|NCT06183424|Placebo Comparator|Sham|For the pseudo-stimulation to be applied to the sham group, the electrodes will be placed on the scalp in exactly the same way as the experimental group. For all stimulations, the reference electrode will be placed in the right orbital region and given once for 15 seconds, so that the participant will feel a slight tingling, but no real stimulation will be given.
88988493|NCT06183411|Other|Children with DCD|
88988494|NCT06183385|Other|Saliva|"Collection of two saliva samples (approx. 1.5 to 2 mL each) by passive drooling in healthy volunteers~These samples will be centrifuged and the supernatant collected."
89036779|NCT00594217|Experimental|Progesterone|oral micronized progesterone suspension, single 100 mg oral dose
89620428|NCT01650298|Experimental|Tailored Anticoagulation (TAC)|"Anticoagulation was initiated or discontinued based on atrial tachycardia / atrial fibrillation (AT/AF) burden as assessed through frequent remote transmissions via Merlin.net.~Patients sent in biweekly remote transmissions, automatic alert-triggered transmissions for AT/AF burden above a set threshold, and unscheduled patient-activated transmissions as needed"
89620429|NCT01795937|Experimental|Part 1: Faldaprevir + Itraconazole|Interaction of Faldaprevir and Itraconazole
89620430|NCT01795937|Experimental|Part 2:Faldaprevir+Rosuvastatin+Atorvast|Interaction of Faldaprevir, Rosuvastatin and Atorvastatin
89620431|NCT04139382|Experimental|Intervention|Telephone Consultation for women requesting abortion
89620432|NCT04139382|Active Comparator|Control|Face-to-face consultation for women requesting abortion
89620433|NCT01608100|Experimental|ARCHITECT STAT High Sensitive Troponin I Assay testing|All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.
89620434|NCT05581368||Chronic Cannabis Cohort|"For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria:~age: 19 to 80~males and females~all ethnicities~cannabis use at least 3-4 times per week or more in the past 6 months (50 volunteers, experimental group)~no history of cardiovascular disease~For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude cannabis users:~that ingest cannabis containing cannabidiol (CBD)~that are unable to provide a receipt for the cannabis product(s) they ingest~that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments."
89620435|NCT05581368||Control Cohort|"For investigations on the effects of cannabis on the cardiovascular system, the investigators would like to recruit 50 participants with the following inclusion criteria:~age: 19 to 80~males and females~all ethnicities~patients who do not use cannabis~no history of cardiovascular disease~For investigations on the effects of cannabis on the cardiovascular system, the investigators will exclude participants:~that ingest cannabis~that are unwilling to stop consuming soy products and/or genistein 48 hours prior to appointments."
89620436|NCT04501224|Experimental|switch to tenofovir alafenamide fumarate|Patients will switch to tenofovir alafenamide fumarate treatment, 25mg，once a day
89620437|NCT04501224|Active Comparator|Continue with the original regimen|Patients will continue with the original regimen treatment, entecavir, 0.5mg once a day, or tenofovir disoproxil fumarate 300mg once a day
89620438|NCT02517060||Healthy participants|Male or female healthy participants
89620439|NCT01817777|Experimental|Metformin Small Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
89036780|NCT00594217|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
89036781|NCT01606774|Experimental|Low risk patients|Patients who agreed to 4 telemedicine obstetrical visits
89036782|NCT01606813|Active Comparator|Brief physician counseling (BPC) + Usual care (UC)|The participant will receive standard care. They will receive BPC from their PCP on weight loss by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss.
89036783|NCT01606813|Experimental|BPC + Internet Weight Control Program (IWCP)|The participant will receive BPC from their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program.
89036784|NCT01606813|Experimental|BPC + IWCP + Follow up email notes from PCP|The participant will receive BPC form their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program. And they will receive brief follow up email notes from PCPs on how their weight loss is going (from data collected from the weight loss website).
89036785|NCT04874376|Experimental|IOL retrospective data collection|Experimental arm: Premium Monofocal intraocular lens.
89036786|NCT01260181|Experimental|Erlotinib|Participants will receive erlotinib 150 millgrams (mg) orally daily until disease progression.
89036787|NCT02892565|Experimental|Cases|Patients with SLE and/or APL and first vein thrombosis episode
89036788|NCT02892565|Other|Controls|age-matched; Patients with SLE and/or APL
89036789|NCT00594373|Experimental|1|Application of 1% tenofovir gel for 14 consecutive days between menses
89036790|NCT00594373|Placebo Comparator|2|Application of 1% tenofovir placebo gel for 14 consecutive days between menses
89036791|NCT02892799|Active Comparator|Standard of Care|Patients randomized to the usual care arm will be treated almost the same as if they do not enroll in the study. They will be managed in accordance with best ICU (intensive care unit) practices, with treatment decisions made by the treating team. Often this will include blood draws (often 2 teaspoons once or twice per day, but sometimes exceeding this), assessments of cardiac function, assessments of fluid status, and other measures as dictated by the presenting illness (this is broad and will include antibiotics, diuretics, cardiac medications, ventilator and oxygen management, etc.). Patients in the usual care arm will not have diuresis managed by NICOM.
89057812|NCT01686789|Experimental|Pegylated interferon alpha-2a 180 mcgs adjusted dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus adjusted dose ribavirin for 48 weeks
89688418|NCT03404687||Patients with adnexal masses|
89688419|NCT01729949|Active Comparator|Active Treatment Beverage|Strawberry powder and Blackcurrent extract
89688420|NCT01729949|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
89688421|NCT03404531|Experimental|Social Media Messages Intervention Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website and theoretically-grounded social media messages.
89688422|NCT03404531|Active Comparator|Website Only Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website only.
89688423|NCT01723553|Experimental|PiB positron emission tomography (PET)|All subjects will receive PET imaging with C-11 PiB on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
89620440|NCT01817777|Experimental|Metformin Large Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
89620441|NCT05576844|Experimental|Interpersonal and social rhythm intervention|
89620442|NCT05576844|Active Comparator|Controlled group|
89620443|NCT05617170||Group 1 experimental group will subject to implanted rehabilitation programme|50 case of acute cerebrovascular stroke patients will subject to implanted rehabilitation programme based on telemedicine if avilable .
89620444|NCT05617170||Group 2 control group will subject to ordinary rehabilitation techniques|50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques .
89620445|NCT01693900|Experimental|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under an ultrasound guidance device with an in-plane technique by a single study investigator, in the preoperative area.
89620446|NCT01693900|Active Comparator|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room.
89620447|NCT01650844|Experimental|School-based Telemedicine Enhanced Asthma Mangement Group|We will use a web-based system to assess asthma severity or control and will send a symptom report to the child's primary care physician (PCP). Children randomized to the SB-TEAM group, will receive a telemedicine visit in the school health office at the start of the school year to provide an initial asthma assessment. The telemedicine provider will deliver brief asthma education and referrals to community resources, and will send a guideline-based preventive medication prescription electronically to a local pharmacy. The pharmacy will deliver the medications to home and school, and the school nurse will administer the medication as directly observed therapy throughout the school year. Follow-up telemedicine assessments will occur twice during the study period. These follow-up visits will focus on assessment of control, assessment of ongoing triggers or co-morbid conditions, and brief asthma education.
89688424|NCT03404453||Paediatric patients at preanaesthetic visi|Difficult airway incidence and prediction:Paediatric patients at preanaesthetic visit scheduled for surgery under general anaesthesia
88988495|NCT06183385|Other|Vaginal secretions|In order to be as close as possible to real life, two vaginal swabs (introduced through the vaginal orifice over a length of 2 to 3 cm) will be taken with a sterile dry swab during the gynecological examination (prior to endovaginal ultrasound or any other endovaginal procedure) of patients included in the Reproductive Medicine Service.
88988496|NCT06183372|Experimental|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules
88988497|NCT06183372|Placebo Comparator|Placebo|300mg Maltodextrin capsules
88988498|NCT06183346||Main Cohort (Single Cohort)|The main cohort consists of all patients who will undergo either emergency/urgent/delayed/elective cholecystectomy in all participating hospitals in Indonesia. Inclusion/exclusion criteria will be applied.
88988499|NCT06183333|Experimental|Intervention group|Web-based emotion regulation intervention
88988500|NCT06183333|No Intervention|Waitlist control group|Eight-week waiting period
88988501|NCT06183294||: adult subjects who underwent a clinically indicated invasive coronary angiography|"adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions.~Interventions:~Other: Collecting invasive FFR measurements."
88988502|NCT06183281|Experimental|Intervention|The INSPIRE chronic pain management system has three primary components: 1) a patient facing smartphone app that collects and interprets a comprehensive intake and patient reported outcomes (PROs), provides health education, and a tailored, modular self-management program that includes cognitive-behavioral therapy (CBT), physical therapy (PT), and mindfulness-based interventions (MBI), 2) a weekly telehealth visit with a pain coach that uses the PRO data and module engagement measures to guide the visit, and 3) enhanced primary care coordination achieved through pain coaching notes and alerts integrated into the electronic health record (EHR).
88988503|NCT06183281|No Intervention|Control|Control participants will receive educational materials about chronic pain and full workbook with non-pharmacologic strategies.
88988504|NCT06183255||Infertile men|Men with a diagnosis of pure Male Factor Infertility, as for WHO criteria
88988505|NCT06183255||Fertile men|Fathers with at least one child, spontaneously conceived, with a time-to-pregnancy within 12 months, as for WHO criteria
88988506|NCT06183242|Experimental|Group I-1|Intake of REMAXA, enteric-coated tablets, 2 tablets 3 times a day for 10 days
88988507|NCT06183242|Experimental|Group I-2|Intake of REMAXA, enteric-coated tablets, 2 tablets 2 times a day for 10 days
88988508|NCT06183242|Experimental|Group I-3|Intake of REMAXA, enteric-coated tablets, 2 tablets once a day for 10 days
88988509|NCT06183242|Active Comparator|Group I-4|Infusions of REMAXOL, solution for infusion, by intravenous drip, 400 ml once a day for 10 days.
89057813|NCT02217605|Experimental|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) followed by 75 minutes 31P MRS
88988510|NCT06183242|Experimental|Group II-1|Intake of REMAXA, enteric-coated tablets, during 10 days according to optimal dosing regimen established during stage I.
88988511|NCT06183242|Active Comparator|Group II-2|Infusions of REMAXOL, solution for infusion, by intravenous drip, 400 ml once a day for 10 days.
88988512|NCT06183242|Placebo Comparator|Group II-3|Intake of Placebo, enteric-coated tablets, during 10 days, analogous to dosing regimen in Group II-1
88988513|NCT06183216|Experimental|Infants aged 2 months in experimental group|35 participants aged 2 months will be randomized to receive Sinovac PCV13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.
88988514|NCT06183216|Active Comparator|Infants aged 2 months in control group|35 participants aged 2 months will be randomized to receive PREVNAR 13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.
89620448|NCT01650844|Active Comparator|Enhanced Usual Care Group|Children randomized to the enhanced usual care group will receive a symptom assessment using national care guidelines, a recommendation for appropriate preventive medications, and asthma education materials. We will use the web-based system to send a symptom report to the child's PCP with guideline-based recommendations for preventive care. We will provide systematic feedback to the family and providers at the same intervals as in the SB-TEAM group's telemedicine visits, by prompting providers to use care guidelines, and caregivers to schedule recommended follow-up visits with the PCP.
89620449|NCT01795547|Experimental|Aripiprazole and aripiprazole once-monthly|
89620450|NCT01795547|Active Comparator|Paliperidone and paliperidone palmitate|
89620451|NCT01695304|Experimental|Intervention Arm|Households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water.
88988515|NCT06183216|Experimental|Children aged 2-5 years in experimental group|35 children aged 2-5 years will be randomized to receive Sinovac PCV13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old.
89620452|NCT01695304|No Intervention|Control Arm|Households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
89620453|NCT01651078||Main cohort|Patients with radiographic evidence of lesion regrowth following prior treatment with stereotactic radiosurgery (regardless of the process being suspected recurrent or progressive brain metastasis versus radiation necrosis) and who already scheduled for NeuroBlate procedure.
89620454|NCT03920826|Experimental|tACS stimulation group|NEXALIN ADI transcranial alternating current stimulator
89620455|NCT03920826|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
89620456|NCT01794923|Experimental|Ibuprofen 5% topical gel BID|IBU BID (Treatment A)
89620457|NCT01794923|Placebo Comparator|Placebo topical gel BID|Placebo BID (Treatment B)
89620458|NCT01794923|Experimental|Ibuprofen 5% topical gel TID|IBU TID (Treatment C)
89620459|NCT01794923|Placebo Comparator|Placebo topical gel TID|Placebo TID (Treatment D)
89620460|NCT02517138|Other|Measurements of eye movements and perception|
88988516|NCT06183216|Active Comparator|Children aged 2-5 years in control group|35 children aged 2-5 years will be randomized to receive PREVNAR 13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old.
88988517|NCT06183190||Autoimmune Liver Disease|Autoimmune Liver Disease
88988518|NCT06183190||Wilsons Disease|Wilsons Disease
88988519|NCT06183190||Healthy Control|Healthy Control
88988520|NCT06183151||Participants|All participants to undergo the same study method. Where all participants are to donate capillary blood to complete 2 tests on the investigational system and the remnant blood sample from routine CBC testing will also be tested on the investigational system. The routine CBC results will be compared to the results obtained by the investigational system.
89620461|NCT02516514|Experimental|Multi-sampling strategy|2 or 3 blood cultures in 24 hours worked at ½ hour intervals with seeding at least a pair of flasks, aerobic and anaerobic, by blood culture.
89620462|NCT02516514|Active Comparator|Single-sampling strategy|1 single dose of venous blood 30ml ± 10ml with seeding 4 blood culture bottles (aerobic and anaerobic 2 2).
88988521|NCT06183086||Linovera|Apply Linovera under clinical routine practice
88988522|NCT06183073|Active Comparator|Caudal block with bupivacaine and dexmedetomidine|Caudal block with bupivacaine 0.25% in a dose of (1 ml / kg) and dexmedetomidine 1μg/ kg.
88988523|NCT06183073|Active Comparator|TAP block with bupivacaine|TAP block with bupivacaine 0.25% in a dose of (0.5 ml / kg).
88988524|NCT06183060||difficult laryngoscopy group|Cormack-Lehane (C-L) scale: class III-IV
88988525|NCT06183060||easy laryngoscopy group|Cormack-Lehane (C-L) scale: class I-II
88988526|NCT06183047||patients with neuroendocrine tumours|We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
88988527|NCT06183021|Experimental|Total pulpotomy with cryotherapy|Total coronal amputation will be performed using vital pulp cryotherapy
88988528|NCT06183021|No Intervention|Total pulpotomy|Total coronal amputation will be performed.
88988529|NCT06183021|Experimental|Root canal treatment with cryotherapy|Orthograde root canal treatment will be performed with intracanal cryotherapy.
88988530|NCT06183021|No Intervention|Root canal treatment|Orthograde root canal treatment will be performed.
88988531|NCT06183008|Experimental|Intravenous Immunoglobulin|3 courses Intravenous immunoglobulin, Infusion solution, 100mg/ml, 2g/kg over 3 days
88988532|NCT06183008|Placebo Comparator|Placebo|3 courses Saline infusion solution 0,9%, same volume as IVIG over 3 days
88988533|NCT06182982|Experimental|Auricolotherapy|Preoperative positioning of magnetic ball plasters for auricolotherpy.
88988534|NCT06182982|Sham Comparator|Control|Ears will be covered by a band-aid (after a simulation of auricolotherapy)
88988535|NCT06182969|Experimental|APG-2575|Dose escalation
89620463|NCT02516904|Experimental|CD101 IV|single intravenous infusion ascending dose
89620464|NCT02516904|Placebo Comparator|Placebo|normal saline
89620465|NCT03346044|Active Comparator|Carpentier-Edwards SAV bioprostheses|
89620466|NCT03346044|Active Comparator|Medtronic Mosaic bioprostheses|
89620467|NCT04502940||Mild pancreatitis|Patients with mild acute biliary pancreatitis according to Atlanta classification
89620468|NCT04502940||Moderate Pancreatitis|Patients with moderate acute biliary pancreatitis according to Atlanta classification
89620469|NCT04502940||Severe pancreatitis|Patients with severe acute biliary pancreatitis according to Atlanta classification
89620470|NCT04502940||Control|Healthy volunteers
89620471|NCT03347604||Patients with abdominal obesity|Enrolling patients with abdominal obesity as defined by WHO to have waist to hop ratio of > 0.85 in women, or > 0.9 in men.
89620472|NCT01794845|Experimental|Erbitux, Taxotere, LD Fractionated RT|Erbitux, Taxotere and Low Dose Fractionated Radiation Therapy (LDFRT)
89620473|NCT01794689|Experimental|Morphine US then Morphine FA|Participants randomized to receive Morphine and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
89620474|NCT01794689|Placebo Comparator|Placebo US then Placebo FA|Participants randomized to receive the saline placebo and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
89620475|NCT01794689|Experimental|Morphine FA then Morphine US|Participants randomized to receive Morphine and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
89620476|NCT01794689|Placebo Comparator|Placebo FA then Placebo US|Participants randomized to receive the saline placebo and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
89620477|NCT01794299|Experimental|ATIR|
89620478|NCT01817075|Experimental|Arm I (CHG cleansing wipe)|Patients receive CHG cleansing with topical skin wipes QD for 90 days.
89620479|NCT01817075|Active Comparator|Arm II (control)|Patients receive control cleansing with topical skin wipes QD for 90 days.
89620480|NCT01816763|Experimental|tablet based NRS pain one week, followed by nurse pain screen|tablet-based patient self-report of the 'NRS pain one week'
89620481|NCT01816763|Experimental|tablet based PEG, followed by nurse pain screen|tablet-based enhanced pain screening with the PEG (pain intensity, emotional, and functional pain interference)
89620482|NCT01816763|Experimental|DVPRS, followed by nurse pain screen|Defense Veterans Pain Rating Scale on tablet followed by usual nursing staff documented pain screening with NRS pain now
89620483|NCT04578353|Experimental|AquaPass System|Participants will undergo 3 procedures (each procedure up to 3 (±1) hours operation) using the AquaPass System, with 4-10 days between each procedure.
89620484|NCT01816685|Experimental|CPAP|Patients in the CPAP group will be instructed to wear an autotitrating positive airway pressure (APAP) device any time they sleep prior to surgery and on postoperative days 0, 1, and 2.
89620485|NCT01816685|No Intervention|Routine Care|
89620486|NCT01653028|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88988536|NCT06182969|Placebo Comparator|Placebo|
88988537|NCT06182956|Experimental|NIV + CPAP + HFO|The patient will be placed under noninvasive mechanical ventilation during 30 min, then continuous positive airway pressure during 30 min and then nasal high-flow oxygen during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
88988538|NCT06182956|Experimental|NIV + HFO + CPAP|The patient will be placed under noninvasive mechanical ventilation during 30 min, then nasal high-flow oxygen during 30 min and then continuous positive airway pressure during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
88988539|NCT06182956|Experimental|CPAP + NIV + HFO|The patient will be placed under continuous positive airway pressure during 30 min, then noninvasive mechanical ventilation during 30 min and then nasal high-flow oxygen during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
88988540|NCT06182956|Experimental|CPAP + HFO + NIV|The patient will be placed under continuous positive airway pressure during 30 min, then nasal high-flow oxygen during 30 min and then noninvasive mechanical ventilation during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
88988541|NCT06182956|Experimental|HFO + CPAP + NIV|The patient will be placed under nasal high-flow oxygen during 30 min, then continuous positive airway pressure during 30 min and then noninvasive mechanical ventilation during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
88988542|NCT06182956|Experimental|HFO + NIV + CPAP|The patient will be placed under nasal high-flow oxygen during 30 min, then noninvasive mechanical ventilation during 30 min and then continuous positive airway pressure during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.
88988543|NCT06182943|Experimental|electroacupuncture group|electroacupuncture combined with surrounding acupuncture
88988544|NCT06182943|Sham Comparator|sham electroacupuncture group|sham electroacupuncture
88988545|NCT06182943|Placebo Comparator|ice compress combined with brake rest group|ice compress combined with brake rest
89620487|NCT00708552|Experimental|SB-742457 - 15mg|SB-742457 - 15mg
89620488|NCT00708552|Placebo Comparator|Placebo|
89620489|NCT00708552|Experimental|SB-742457 - 35mg|SB-742457 - 35mg
89620490|NCT00708552|Active Comparator|Donepezil|
89620491|NCT02516436|Experimental|BEMA Buprenorphine NX|Buprenorphine with naloxone in a buccal film
89620492|NCT02516436|Active Comparator|Buprenorphine|Buprenorphine in a buccal film
89620493|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin|
89620494|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1 mg/mL|
89620495|NCT03347526|Active Comparator|Vigabatrin|
89620496|NCT03742752|Experimental|Enteral Nutrition (EN)|"To demonstrate the superiority of EN versus TPN in the treatment of postoperative upper GI anastomotic leak (PUGIAL) after upper GI surgery (including esophageal, gastric, duodenal, pancreatic and obesity surgery).~Patients will be randomized to receive EN through jejunostomy or nasojejunal tube until oral diet covering at least 60% of their daily requirement"
89620497|NCT03742752|Active Comparator|Parenteral Nutrition (TPN)|Patients will be randomized to receive TPN through central venous access, piccline or totally implantable venous access port tube until oral diet covering at least 60% of their daily requirement
89620498|NCT02516280|Experimental|Hyperbaric gaseous cryotherapy group|Conventional rehabilitation with Cryoton ™ hyperbaric cryotherapy
89620499|NCT02516280|Active Comparator|Control ice bag group|Conventional rehabilitation with ice bag cryotherapy. Application of a bag of crushed ice directly on the anterior aspect of the knee.
89620500|NCT03347370||SC Peginterferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
89620501|NCT03347370||SC interferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
89620502|NCT03347370||SC interferon beta-1b|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
89620503|NCT02516124||NISSC|Autologous HSCT
89620504|NCT02515968|Active Comparator|Desflurane|Anesthesia is maintained with desflurane during surgery.
89620505|NCT02515968|Experimental|Propofol|Anesthesia is maintained with propofol during surgery.
89620506|NCT03347214||1|People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study
88988546|NCT06182930|Experimental|Experimental|Within the scope of the research, caregivers will be given face-to-face training in 2 sessions, 15 days apart.
89620507|NCT03345966|Experimental|Immunohistochemistry|"In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used.~The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units."
89620508|NCT03345966|Experimental|Polymerase Chain Reaction PCR|"Calculation of Relative Quantification (RQ) (relative expression):~After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows:~Finally, RQ was calculated according to the following equation:~∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene~∆∆ Ct = ∆ Ct sample - Ct control gene~RQ = 2-(∆∆Ct)"
89620509|NCT03345888||resuscitation time line group|The ETCO2 will be arrange in resuscitation time line.
89620510|NCT03345888||ETCO2 time line group|The ETCO2 will be arrange in time line which the beginning time is the time of starting to show stable ETCO2 wave.
89620511|NCT03347136|Active Comparator|Newborns with CPAP support|Newborn with mild to moderate respiratory distress randomly allocated to CPAP arm. CPAP started with Positive End Expiatory Pressure(PEEEP) 05 and increased up to PEEP 09 according to the severity of baby's condition.
89620512|NCT03347136|Experimental|Newborns with NIPPV support|Newborn with mild to moderate respiratory distress randomly allocated to NIPPV arm. NIPPV started with Intermittent Mandatory Ventilation rate 30, Peak Inspiratory Pressure 20 and PEEP 5.Increased the settings according to the severity of baby's condition
89620513|NCT03346356|Experimental|Teenagers as cross-age teachers|After the initial training, the teenage teachers facilitated the curricula associated with the SHCP, Discovering Healthy Choices and Cooking Up Healthy Choices, approximately twice a month. The curricula can be viewed at http://cns.ucdavis.edu/programs/shcp/curriculum.html. Each activity provided step-by-step instructions that the teenage teachers were asked to follow. Younger youth served as participants for the classroom and garden-based activities.
89620514|NCT03346356|No Intervention|Comparison group|Youth of similar ages to the intervention group completed the same assessments, but did not receive the intervention.
88988547|NCT06182930|No Intervention|Control|They will receive routine home health care follow-up.
88988548|NCT06182917||ctDNA alternation during the treatment of Ovarian cancer|Tumor samples of included patients were detected by WES, and 16 major clonal mutation sites were screened for the personalized monitoring panel. All patients received blood ctDNA detection to monitor the major clonal alternation after 3 cycels treatment or 3 months after therapy, at the same time, the detection of serum tumor markers (CA125) and imaging examination were carried out, in order to evaluate the MRD detection efficiency.
89620515|NCT03122574|Experimental|Treatment|Pure (100%) lavender aromatherapy
89620516|NCT03122574|Placebo Comparator|Placebo Control|Pure (100%) jojoba aromatherapy
89620517|NCT03122574|No Intervention|Standard of care Control|No aromatherapy control group
89620518|NCT02507700|Active Comparator|popliteal block|Popliteal block will be performed with a single dose of 0.3 ml·kg(-1) of 0.25% bupivacaine.
89620519|NCT02507700|Sham Comparator|Plaster cover|Only plaster cover will be applied without nerve block for sham procedure.
89620520|NCT02513004|Experimental|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose.Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
89620521|NCT02513004|Active Comparator|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
89620522|NCT04500522|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide (INH) 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
89620523|NCT04500522|Placebo Comparator|Placebo Comparator|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
89620524|NCT02507310|Active Comparator|Control|The room will be kept at 18-20 degrees Celsius. This is within the human thermoneutral zone. It will serve as the control condition.
89620525|NCT02507310|Experimental|Warm Environment|The room will be kept at 25-27 degrees Celsius. This is above the human thermoneutral zone. This will serve as the experimental condition.
89620526|NCT02513082|Experimental|Femoral nerve block|Femoral nerve block will be performed just one time after total knee arthroplasty in general anesthesia state
89620527|NCT02513082|Active Comparator|Adductor canal block|Adductor canal block will be performed just one time after total knee arthroplasty in general anesthesia state
89620528|NCT02507232|Active Comparator|Arm A|NovoTTF-200A
89620529|NCT02507232|Active Comparator|Arm B|NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)
89620530|NCT02506998|Experimental|DLE plus standard medications|"DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks"
89620531|NCT01608490|Experimental|RePneu Lung Volume Reduction Coil System|The RePneu Lung Volume Reduction Coil System is an implantable device, delivered through a fiber-optic bronchoscope. This is a two part system that consists of 1) sterile Nitinol Coils and 2) a sterile, disposable, single-use (single-patient) Delivery System consisting of a Guidewire, Catheter, Cartridge, and Forceps.
89620532|NCT01608490|No Intervention|Control arm is standard medical care|The Control Group will not undergo any bronchoscopies for Coil placement and will not receive prophylactic antibiotics or steroids before and after 'treatment' or chest x-rays in connection with the 'treatment' visits. The frequency of visits to the Study Doctor or designee will be similar to the LVRC Group.
89620533|NCT04500444|Experimental|Blood-Flow Restriction Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The blood flow restriction protocol will be applied to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. Before the first application, patients will be evaluated by a specialist physician using ultrasonography and it will be ensured that the arterial blood flow is not restricted as the blood flow restriction restricts only venous blood flow. The pressure threshold at this point is the level to be used in subsequent training sessions and the same person (physician) will be bandaging in the same way during all subsequent training sessions.
89620534|NCT04500444|Sham Comparator|Control Group|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes. The sham blood flow restriction protocol will be applied which consists of loose bandaging to both lower extremities at the crotch level with 10 cm wide elastic bandages before warming up. The same person (physician) will be bandaging in the same way during all subsequent training sessions. The pressure feeling of the patient must correspond to level 0 -not tight at all- before starting the exercise training.
89620535|NCT04498338|Experimental|Neural mobilization and conventional physical therapy|Neural mobilization combined with conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) were performed three times/week for 6 successive weeks.
89620536|NCT04498338|Active Comparator|Conventional physical therapy program|Conventional physical therapy program (Transcutaneous electrical nerve stimulation (TENs) and exercise program) was performed three times/week for 6 successive weeks.
89620537|NCT02507076|Experimental|Treatment (ILP with melphalan)|Patients undergo ILP with melphalan IV over 60 minutes.
89620538|NCT01609348|Active Comparator|Venlafaxine|225 mg daily over 12 weeks
89620539|NCT01609348|Placebo Comparator|Sugar pill|
89620540|NCT04500678|Experimental|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
89620541|NCT04500678|No Intervention|Observation|Observed without metformin
89620542|NCT02992366|Experimental|socket shield (A)|"Following local anesthetic infiltration opposite to the root to be extracted the root is sectioned in a mesiodistal direction along its long axis as far apical as possible.~After sectioning the root into labial and palatal halves, the palatal half is removed with preservation of the labial root section.~The labial half is prepared to be Flushing or 1mm above the labial alveolar crest. Then thinned slightly to a concave contour in an apico-coronal and mesiodistal direction.~The implant will be inserted in place of the palatal half with the labial surface of the implant facing the labial root shield (root-implant interface)~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
89620543|NCT02992366|Active Comparator|conventional immediate implant (B)|"Following local anesthetic infiltration opposite to the root to be extracted non traumatic extraction of the tooth or remaining root by periotome.~The implant fixture will be inserted in the empty socket by conventional manner.~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
89620544|NCT02515812|Experimental|Adrenergic Function Explorations with CZT camera|I-123-MIBG and CZT Camera (D-SPECT)
89620545|NCT02515812|Active Comparator|Adrenergic Function Explorations with Anger camera|I-123-MIBG and Anger Camera
89620546|NCT02512848||endometrial neoplasms|patients with risk of endometrial cancer in the postmenopausal period
88988549|NCT06247449|Experimental|Screening MRI|One-time brain magnetic resonance (or computed tomography when magnetic resonance is contraindicated), plus circulating tumor DNA analysis, plus Testing Morbidity Index (TMI)
88988550|NCT06247436|Experimental|Branch Chained Amino Acids-4mg|4g BCAA, solved in water, twice daily
88988551|NCT06247436|No Intervention|Control|no consumption
88988552|NCT06247423|Experimental|10kHz|Alternating current stimulation with a 10kHz frequency with a transcutaneous approach, 20 minutes for each intervention.
88988553|NCT06247423|Sham Comparator|Sham stimulation|Sham stimulation via transcutaneous approach will be delivered only for the first 30 seconds, following the same procedures as the 10kHz group.
89620547|NCT02512770|Experimental|dilatation|esaphageal dilatation group
89620548|NCT02512770|No Intervention|control|control group ( only endoscopy for control)
89620549|NCT02506920|Active Comparator|Pack butter|Oral fat tolerance test contains: Cream, lactic acid culture, salt. Fat contents in grams: Saturated fat (SFA) 52, monounsaturated fat (MUFA) 19.1, polyunsaturated fat (PUFA) 1.6
89620550|NCT02506920|Active Comparator|Kjaergaarden blend butter|Oral fat tolerance test contains:Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 37.4, MUFA 27.3, PUFA 1.8
89620551|NCT02506920|Active Comparator|Blend butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 23.7, MUFA 23.2, PUFA 7.8
89620552|NCT02506920|Active Comparator|Fish oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, fish oil, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 0.7
89620553|NCT02506920|Active Comparator|Olive oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, olive oil, lactic acid culture, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 5.7
89620554|NCT02506920|Active Comparator|Low saturated fat butter|Oral fat tolerance test contains: Butter, lactic acid culture, salt. Fat contents in grams: SFA14.9, MUFA16, PUFA 5.6
89620555|NCT02512458|Experimental|Cabazitaxel|Patient will be treated with iv cabazitaxel 25mg/m2 q 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).
89620556|NCT02515578|Active Comparator|Standard practice transformation support|Primary care practices will receive a cardiovascular care toolkit, practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions
89620557|NCT02515578|Experimental|Enhanced practice transformation support|Primary care practices will receive practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions PLUS patient advisory council support and a modified cardiovascular care toolkit based on combined practice and patient input regarding the local context.
89620558|NCT02507154|Experimental|Cetuximab + NK cells|During cycle 1, patient will receive intravenous cetuximab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, with subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo. Following NK cell infusion, cetuximab will be administered weekly for another 2 weeks. During cycle 2 and 3, one cycle of cetuximab monotherapy will be administered 3 weeks apart. Patients who demonstrate objective tumor response or stable disease after cycle 3 will receive a second infusion of NK cells along with cetuximab during cycle 4 therapy at the same dose and schedule as in cycle 1. This will be followed by 2 additional cycles of cetuximab monotherapy (3 weeks apart).
89620559|NCT02515734|Active Comparator|FOLFOXIRI+Bmab|Patients in the FOLFOXIRI + Bmab group receive until 12 cycles of FOLFOXIRI plus bevacizumab, consisting of a 30-minute infusion of bevacizumab at a dose of 5 mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and bevacizumab every 14 days until disease progression.
88988554|NCT06247410|Other|Sequence: Reference-Test-Reference-Test (RTRT)|"Once daily patch application of one patch of Test or Reference over 4 days, i.e. a total of 4 alternating applications with RTRT sequence. Each patch remains applied for 24 h. Treatments may be directly switched without washout phase.~Period 1: Reference: Neupro® 8 mg/24 h, 40 cm2 transdermal system containing 18 mg rotigotine (UCB Pharma GmbH, Germany), dermal application~Period 2: Test: ROT-TDS (8 mg/24 h) 36.8 cm2 transdermal system containing 14.72 mg rotigotine (Luye Pharma AG, Germany), dermal application~Period 3: Reference: Neupro® 8 mg/24 h, 40 cm2 transdermal system containing 18 mg rotigotine (UCB Pharma GmbH, Germany), dermal application~Period 4: Test: ROT-TDS (8 mg/24 h) 36.8 cm2 transdermal system containing 14.72 mg rotigotine (Luye Pharma AG, Germany), dermal application"
88988555|NCT06247410|Other|Sequence: Test-Refrence-Test-Reference|"Once daily patch application of one patch of Test or Reference over 4 days, i.e. a total of 4 alternating applications with TRTR sequence. Each patch remains applied for 24 h. Treatments may be directly switched without washout phase.~Period 1: Test: ROT-TDS (8 mg/24 h) 36.8 cm2 transdermal system containing 14.72 mg rotigotine (Luye Pharma AG, Germany), dermal application~Period 2: Reference: Neupro® 8 mg/24 h, 40 cm2 transdermal system containing 18 mg rotigotine (UCB Pharma GmbH, Germany), dermal application~Period 3: Test: ROT-TDS (8 mg/24 h) 36.8 cm2 transdermal system containing 14.72 mg rotigotine (Luye Pharma AG, Germany), dermal application~Period 4: Reference: Neupro® 8 mg/24 h, 40 cm2 transdermal system containing 18 mg rotigotine (UCB Pharma GmbH, Germany), dermal application"
88988556|NCT06247397|Experimental|High-flow oxygen therapy|Intervention arm
88988557|NCT06247397|Active Comparator|Low-flow oxygen therapy|Comparison arm
88988558|NCT06247384|No Intervention|Group A - FloTrac group|Patients receiving standard therapy with the arterial pressure cardiac output hemodynamic monitoring
88988559|NCT06247384|Experimental|Group B - HPI - Hypotension Prediction Index group|Patients receiving therapy according to the hypotension prediction index hemodynamic monitoring.
88988560|NCT06247319||Participants Treated with Risankizumab|Participants with a recent diagnosis of moderate plaque PsO (defined as ≤24 months since the first diagnosis of moderate PsO), and naïve to advanced treatments (biologics, apremilast, and deucravacitinib) will receive risankizumab as prescribed by their physician according to local label.
88988561|NCT06247306|Experimental|real-time fMRI neurofeedback (of the ACC)|Participants are instructed to reduce their stress-response by attempts to upregulate the ACC activity contigent on real-time feedback.
88988562|NCT06247306|Sham Comparator|Yoke-control group|Participants receive previously recorded feedback signal from other participants&#39; ACC activity instead of their own live ACC activity.
88988563|NCT06247293||Surgical resection combined with intraperitoneal hyperthermic perfusion chemotherapy|Surgical resection combined with intraperitoneal hyperthermic perfusion chemotherapy
89620560|NCT02515734|Experimental|FOLFOXIRI+Cmab|Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.
89620561|NCT02506608|Experimental|Operation of sensorized hand prosthesis|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in amputees:~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~TIME 4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~Sensorized hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~Prosthetics sensorized hand for amputees DLR / HIT Hand II (Wessling Robotics)~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand"
89620562|NCT02512536|Experimental|Experimental|"Intervention:~Subjects receiving a single ultrasound scan guided injection of Botulinum Toxin type A into the supraspinatus muscle belly.~Drug: Dysport 300 units im. One single injection over course of study."
89620563|NCT02506842|Experimental|nab-paclitaxel + gemcitabine (AG)|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
89620564|NCT02506842|Experimental|oxaliplatin + folinic acid + fluorouracil (OFF)|oxaliplatin at 85mg/m^2 on days 8 and 22, folinic acid at 200mg/m^2 on days 1,8,15 and 22, fluorouracil at 2000mg/m^2 on days 1,8,15 and 22.
89620565|NCT02512614|No Intervention|Comparison|Hand hygiene education.
89620566|NCT02512614|Experimental|Intervention|Hand hygiene education and 4 antimicrobial hand towels
89620567|NCT04500054|Experimental|Music Intervention Group|The music intervention group listened to the music by the researchers for the duration of 15 minutes one hour before the surgery as well as the standard care.
89620568|NCT04500054|No Intervention|No Intervention Group|The control group patients received standard care only.
88988564|NCT06247293||simple surgical resection|Control group: simple surgical resection
88988565|NCT06247293||other|imple interventional hemostasis group
88988566|NCT06247267||Primary/Secondary Untreated Hypogonadism|Subjects in group 1 will take clinically indicated testosterone replacement therapy (Fortesta-injection, gel and transdermal) for 12 months with titration for a serum total T level between 300-600 ng/dL.
88988567|NCT06247267||Male-to-Female (MTF)|Subjects in group 2 will take clinically indicated estrogen therapy (Estradiol-orally and transdermal and/or spironolactone-orally) for 12 months for hormonal transition period.
88988568|NCT06247267||Female-to-Male (FTM)|Subjects in group 3 will take clinically indicated testoserone replacement therapy (Fortesta-injection, gel and transdermal) for 12 months for hormonal transition period.
88988569|NCT06247254|Experimental|Intensive Tailored Telehealth Management (ITTM)|The ITTM intervention involves a comprehensive, multi-dimensional approach to using real-time BP data to manage BP after stroke. ITTM includes an in-person visit during which participants will complete a series of questionnaires within the COMPASS-CP® web application and will receive a COMPASS-BP Action Plan home safety checklist, Blood Pressure (BP) Matters documents, and referrals to local resources, as needed.
88988570|NCT06247254|Other|Intensive Clinic Management (ICM)|The ICM arm includes BP management at in-person follow-up visits occurring every 2 months when BPs are at target and if not in target, monthly visits. Medications will be adjusted to lower BP to the target using evidence-based guidelines and in the context of whether the participant can effectively manage their medications and BP. ICM participants will receive a COMPASS Care plan, which will evaluate social and functional factors for managing stroke recovery.
88988571|NCT06247241|Experimental|VMB-100 administration|intrasphincteric injection of VMB-100 in the urethra sphincter
88988572|NCT06247228|Experimental|Experimental group|Experimental group will receive the Click2Move intervention for one year, including a wearable (provided by the research group) and mobile phone application downloaded in the participants own mobile phone. Click2Move intervention comprises elements at three levels: environmental (activity tracking and app provision, reminders, cooperative challenges, and social chat), organisational level (organisational support and motivational messages), and at individual level (educational materials, self-monitoring, feedback provision, demonstration videos and a list of strategies).
88988573|NCT06247228|No Intervention|Control group|Participants in the control arm will be asked to complete the same study measurements as those in the intervention arms, at the same time points. The control arm participants will not receive any device, nor will they have to download the mobile phone application. After the year of the intervention, they will be able to receive the intervention if they agree.
88988574|NCT06247215|Experimental|Experimental|Participants will evaluate the culturally-tailored resilience-building intervention prototype
88988575|NCT06247202|Experimental|Intervention group|Participants in the intervention group will receive smart phone delivered health education in the form of text messages through WhatsApp.
88988576|NCT06247202|Active Comparator|Control group|Participants in the control group will receive paper delivered health education in the form of a one time handout.
89620569|NCT03345498||ETV 0.5 mg|Group of study participants who were started on 0.5 mg/day of entecavir
89620570|NCT03345498||ETV 1.0 mg|Group of study participants who were started on 1.0 mg/day of entecavir
89620571|NCT04497558|Experimental|ERA group|In the experimental group, those patients undergo endometrial receptivity array. According to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out.
88988577|NCT06247189|Experimental|ICOPE Monitor Program|Evaluation at inclusion and re-evaluation monthly.
88988578|NCT06247176|Experimental|Autism Spectrum Disorder Habituation Group|This will be the group of subjects with Autism and sensory over-responsivity. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.
89620572|NCT04497558|No Intervention|Control group|In the control group, those patients do not receive any treatment before next cycle of transfer. In the control group, no intervention will be performed.
89620573|NCT03121638|Active Comparator|VARIVAX|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm
89620574|NCT03121638|Active Comparator|ZOSTAVAX|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
89620575|NCT03121638|Experimental|NBP6081|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
89620576|NCT03121638|Experimental|NBP6082|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
89620577|NCT03121638|Experimental|NBP6083|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
89620578|NCT02506686|Experimental|Meropenem|Meropenem i.v.
89620579|NCT02515500|Active Comparator|Gradual Cessation|
89620580|NCT02515500|Experimental|Gradual Cessation w/ Quitbit|
89620581|NCT02512380|Experimental|SLOT group|4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。
89620582|NCT02512380|Active Comparator|SOX group|3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1
89620583|NCT02512146||Irritable bowel syndrome|Patients meeting Rome III criteria of irritable bowel syndrome. Intervention: colonoscopy.
89620584|NCT02512146||Normal controls|"Asymptomatic individuals for health surveillance or patients for follow up after polypectomy.~Intervention: colonoscopy."
89620585|NCT04497792|Experimental|Treatment group|The treatment group are patients with stable coronary artery disease before planned percutaneous coronary intervention. All of them will receive empagliflozin additionally to previously taken hypoglycemic treatment.
89620586|NCT04497792|Other|Control group|patients continue previously prescribed medication intake
89620587|NCT02506530|Active Comparator|intensive decongestive treatment (IDT)|Patients will receive an intensive decongestive treatment for 5 days
89620588|NCT02506530|Experimental|IDT + Cellu M6|Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days
89620589|NCT02506530|Active Comparator|Cellu M6 + bandages|Patients will receive an bandages + Cellu M6 for 5 days
88988579|NCT06247176|Active Comparator|Neurotypical Habitation Group|This will be the group of subjects who are neurotypical peers. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.
88988580|NCT06247150|Other|Patients with cGVHD|
88988581|NCT06247150|Other|Patients without cGVHD|
88988582|NCT06247137|Active Comparator|Dietary supplement|
88988583|NCT06247137|Placebo Comparator|Placebo|
89620590|NCT03345030||Unexplained infertile group|Patients diagnosed as unexplained infertility (UI) were recruited to the study. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. If the results of all this tests were normal, patients were accepted as UI.
89620591|NCT03345030||Control group|The control group received in vitro fertilization (IVF) for tubal factor and included only those women who had salpingectomy for ectopic pregnancy or proximal tubal obstruction because of low-grade infection or fimbrial occlusion with or without mild peritubal adhesions. Tubal infertility associated with hydrosalpinx, severe pelvic adhesions, endometriosis or pelvic inflammatory disease were excluded. Patients with male factor except oligoasthenospermia were also recruited for the study.
88988584|NCT06247111|Placebo Comparator|Usual Care|Participants receive usual care from providers to manage their blood pressure
88988585|NCT06247111|Active Comparator|Remote Blood Pressure Monitoring + Telehealth|Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
88988586|NCT06247085|Experimental|pegtibatinase|
88988587|NCT06247085|Placebo Comparator|placebo|
88988588|NCT06247072||low IOP|having low IOP in one eye
88988589|NCT06247072||intermediate IOP|having intermediate IOP in one eye
89620592|NCT02511990|Experimental|Group 1A|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~3 mg/kg, single dose IV administration of 10-1074"
89620593|NCT02511990|Experimental|Group 1B|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~10 mg/kg, single dose IV administration of 10-1074"
89620594|NCT02511990|Experimental|Group 1C|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
89620595|NCT02511990|Experimental|Group 1D|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
89620596|NCT02511990|Experimental|Group 2A|"HIV-uninfected individuals~3 mg/kg, single dose IV administration of 10-1074"
89620597|NCT02511990|Experimental|Group 2B|"HIV-uninfected individuals~10 mg/kg, single dose IV administration of 10-1074"
89620598|NCT02511990|Experimental|Group 2C|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
89620599|NCT02511990|Experimental|Group 2D|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
89620600|NCT02506218|Experimental|10 + 20 g protein consumption|10 g breakfast followed by the consumption of a 20g whey protein shake
89620601|NCT02506218|Active Comparator|30 g protein breakfast|
89620602|NCT02506218|Active Comparator|10 g protein breakfast|
89620603|NCT03345264|Experimental|Cancer patients, survivors, and partners|
88988590|NCT06247072||high IOP|having high IOP in one eye
88988591|NCT06247059|Experimental|Box Fan|Classrooms receive box fans equipped with a filter.
88988592|NCT06247059|Experimental|UV Germicidal Irradiation Lamp Unit|Classrooms receive UV germicidal irradiation lamp unit(s).
88988593|NCT06247059|Experimental|Combined: Box Fan and UV Germicidal Irradiation Lamp Units|Classrooms receive box fans equipped with a filter and UV germicidal irradiation lamp unit(s).
88988594|NCT06247059|No Intervention|Non-Interventional Control|Classrooms receive no intervention to their standard classroom setup.
89620604|NCT02511834|Experimental|VEST supported|Vein graft supported by VEST
89620605|NCT02511834|Active Comparator|Control|Vein grafts unsupported by VEST
89620606|NCT02511912|Experimental|V-Wave|"This is a single arm study, all eligible patients will receive the V-Wave implantable shunt.~The V-Wave device is implanted via standard femoral venous access and inter-atrial septal puncture intervention and is placed through the Fossa Ovalis."
89620607|NCT04497714||Cervical lymph nodes tuberculosis|The patients with Cervical lymph nodes tuberculosis
89620608|NCT04497714||Cervical lymphoma|The patients with
89620609|NCT04497714||Cervical lymph node metastasis|The patients with
89620610|NCT04497714||Cervical Reactive hyperplasia|The patients with
89620611|NCT02511756|Other|Perfusion-computed tomography (CTP)|Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
89620612|NCT02506452|Active Comparator|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading device
89620613|NCT02506452|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading device
89620614|NCT02515422|Active Comparator|Group 1, Ketamine|Ketamine, 1 mg/kg (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA) was administered subcutaneously before the closure of pfannenstiel incision.
89620615|NCT02515422|Active Comparator|Group 2, Bupivacaine|Bupivacaine 0.5% 20 mL (100 mg) (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company, Turkey) was administered subcutaneously before the closure of pfannenstiel incision.
89620616|NCT02515422|Active Comparator|Group 3, Ketamine+Bupivacaine|Ketamine 1 mg/kg (Ketalar®) and bupivacaine 0.5% (100 mg) (Marcaine®) were administered subcutaneously before the closure of pfannenstiel incision.
89620617|NCT02515422|Placebo Comparator|Group 4, Placebo|Placebo (0.9% saline solution) was administered subcutaneously before the closure of pfannenstiel incision.
89620618|NCT02515344|Experimental|A: nominative list|"Providing a list of patients not compliant with CRC sreening~General Practitioners allocated to the intervention group (A) will receive:~a nominative list of their patients who were not compliant to colorectal cancer screening.~a document providing general information about colorectal cancer screening"
89620619|NCT02515344|Active Comparator|B: general information|"Providing general information about CRC screening~General Practitioners allocated to group (B) will receive:~- a document providing general information about colorectal cancer screening (but will not receive the nominative list of patients non compliant to colorectal cancer screening)"
89620620|NCT02515344|No Intervention|C: usual practice|General Practitioners allocated to group (C) will not receive any information (as in usual practice)
89620621|NCT02506296|Other|Insulin treated T2D diagnosed >=35yrs|"split by presence or absence of severe endogenous insulin deficiency:~Severe deficiency = fasting blood C-peptide ≤0.08nmol/L or stimulated C-peptide ≤0.2nmol/L or post meal urine C-peptide creatinine ratio ≤0.2nmol/mmol~Retained endogenous insulin secretion = fasting blood C-peptide ≥0.25nmol/L or stimulated C-peptide ≥0.6nmol/L or post meal urine C-peptide creatinine ratio ≥0.6nmol/mmol~Groups will be compared for:~glucose variability (via Continuous Glucose Monitoring System (CGM)) and hypoglycaemia risk (via hypoglycaemia questionnaire)~glycaemic response to standard DPPIV inhibitor therapy"
89620622|NCT02506140|Experimental|Ticagrelor/ASA|Drugs: Ticagrelor and Acetylsalicylic acid.
89620623|NCT02506140|Active Comparator|Clopidogrel/ASA|Drugs: Clopidogrel and Acetylsalicylic acid.
89620624|NCT02515188|Experimental|propacetamol group|
89620625|NCT02515188|Placebo Comparator|placebo group|
89620626|NCT02506062|Experimental|Active Arm - 200 mmHg|Patients who start in the active arm of the study will receive ischemic preconditioning (IPC) treatment consisting of applying the blood pressure cuff to a pressure of 200 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week. Patients may choose to treat at home with a portable manual blood pressure machine or may be treated in clinic by research staff. Patients will receive treatment for two weeks followed by a wash-out period (no treatment) of two weeks. Patients will then receive the placebo treatment. This completes their participation in the study.
89620627|NCT02506062|Placebo Comparator|Placebo Arm - 60 mmHg|Patients who start in the placebo arm will receive placebo treatment, consisting of applying the blood pressure cuff to a pressure of 60 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week for two weeks followed by a two week wash-out and then two weeks in the active treatment phase, thus completing their participation in the study.
89620628|NCT02505672||Study group|Patients older than 18 who are planned to undergo chemoradiotherapy for nasopharyngeal carcinoma.
89620629|NCT01696084|Experimental|Arm A (CPX-351)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
89620630|NCT01696084|Active Comparator|Arm B (7+3)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
89620631|NCT02515032|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
89533164|NCT05376267|Experimental|Cooling 12 hours|The participant will be cooled to 33°Celsius (C) for 12 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
89620632|NCT02515032|Placebo Comparator|Placebo|An isocaloric placebo comparator
89533165|NCT05376267|Experimental|Cooling 18 hours|The participant will be cooled to 33°C for 18 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
89533166|NCT05376267|Experimental|Cooling 24 hours|The participant will be cooled to 33°C for 24 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
89620633|NCT02514876|Experimental|Single arm- Foresight ICE System|This open label feasibility study will evaluate the Foresight ICE system for imaging chambers of the heart and guiding transseptal puncture during an atrial fibrillation (AF) ablation procedure.
89620634|NCT02511600|Experimental|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
89620635|NCT02511600|Active Comparator|Standard of Care|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
89620636|NCT02228824|Experimental|Very low nicotine content cigarettes|
89620637|NCT02228824|Active Comparator|Normal nicotine content cigarettes|
89620638|NCT02505828|Other|Septic arthritis|with bacteriological identification
89620639|NCT02505828|Other|Juvenile idiopathic arthritis|beyond the ILAR (International League of Associations for Rheumatology) definition
89620640|NCT02511366|Experimental|ileal infusion of casein|Ileal infusion of casein
89620641|NCT02511366|Placebo Comparator|ileal infusion of tap water|ileal infusion of tap water
89620642|NCT02230540|Experimental|Sequence A|"Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product A in different positions. Measurement of residual urine at different positions."
89620643|NCT02230540|Experimental|Sequence B|"Based on results from sequence A, sequence B may or may not be initiated.~Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product B in different positions. Measurement of residual urine at different positions."
89620644|NCT02514954|Experimental|BioChaperone® Combo|1 single dose 400 U/mL
89620645|NCT02514954|Active Comparator|Humalog® Mix25|1 single dose 100 U/mL
89620646|NCT04443036|Experimental|Albumin-bound Paclitaxel Combined With Toripalimab|"Albumin-bound Paclitaxel：125mg/m2 IV d1、8，Q3W~Toripalimab：240 mg，IV d1，Q3W~until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration of Toripalimab is 24 months"
89620647|NCT02514720|Other|Fast Nicotine Metabolizers|Those in the upper tertile of NMR for cigarette/nicotine metabolism.
89620648|NCT02514720|Other|Slow Nicotine Metabolizers|Those in the lower tertile of NMR for cigarette/nicotine metabolism
89620649|NCT01653418|Experimental|V-BEAM + Stem Cell Infusion|Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
89620650|NCT02514642|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients withStable Coronary Artery Disease
89620651|NCT02514642|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
89620652|NCT02511210|Active Comparator|regional anesthesia|spinal anesthesia or peripheral nerve block
89620653|NCT02511210|Active Comparator|general anesthesia|intubated patients
89620654|NCT01653964|Experimental|Molecular breast imaging|Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
89620655|NCT03344874|Experimental|Stethee (new stethoscope)|"Test 1: Use Stethee® to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use 3MTM Littmann® Classic IIITM to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
89620656|NCT03344874|Active Comparator|Littmann (conventional stethoscope)|"Test 1: Use 3MTM Littmann® Classic IIITM to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use Stethee® to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
88988597|NCT06247033|Active Comparator|Active TNS - Chronic stroke patients with urgency symptoms, followed with PFTE, BT, TNS|Study group was followed with tibial nerve stimulation for 6 weeks, 2 sessions in a week, for 30 minutes. Stimulation was performed with TENS device, with settings of 10 Hz frequency, 200 msn wavelenght, continuous symetrical biphasic current. Amptlitude was increased just below the motor range that cause flexion in toes. All patiens were followed for PFTE and BT according to standard schedule.
88988598|NCT06247033|Sham Comparator|Sham TNS - Chronic stroke patients with urgency symptoms, followed with PFTE, BT, Sham TNS|Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut down. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
89533167|NCT05376267|Experimental|Cooling 36 hours|The participant will be cooled to 33°C for 36 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
89620657|NCT02505438|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
89533168|NCT05376267|Experimental|Cooling 48 hours|The participant will be cooled to 33°C for 48 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
89533169|NCT05376267|Experimental|Cooling 60 hours|The participant will be cooled to 33°C for 60 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
89533170|NCT05376267|Experimental|Cooling 72 hours|The participant will be cooled to 33°C for 72 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
89533171|NCT05376267|Experimental|Cooling 84 hours|The participant will be cooled to 33°C for 84 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
89620658|NCT02505438|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
89620659|NCT02505438|Experimental|Old Unilateral Exercise and HMB|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with HMB (beta-hydroxy-beta-methylbutyrate) supplementation
89620660|NCT02505438|Experimental|Old Unilateral Exercise and Omega 3|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with Omega 3 supplementation
89620661|NCT02237950|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
89620662|NCT02237950|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
89620663|NCT02505594||OSA Group|Apnea-hypopnea index (AHI) ≥ 15 events/h
89620664|NCT02505594||Control Group|Apnea-hypopnea index (AHI) < 5 events/h
89620665|NCT02511288||Cohort 1|Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis
89620666|NCT02511288||Cohort 2|Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis
89620667|NCT02511288||Cohort 3|Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)
89620668|NCT04497480|Experimental|experimental group|
89620669|NCT04497480|No Intervention|controlled group|
89620670|NCT02238028|Experimental|Wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
89620671|NCT02238028|No Intervention|Not wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
89620672|NCT02511054|Experimental|1a|Arm 1a (n=2), the pilot phase, is designed to examinethat the dosing of PYR on 2, 3 days post DVI with Sanaria PfSPZ Challenge while under CQ prophylaxis does not result in subpatent parasitemia (positive qRT-PCR result defined as two consecutive samples > 20 parasites/uL or a single positive qRTPCR (Bullet) 100) or a single episode of patent parasitemia (positive blood smear defined as two unambiguous parasites in a thicksmear) in (Bullet)1/2 subjects. Subjects will considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
89620673|NCT02511054|Experimental|2|Arm 2 (n=12) will receive the selected regimen of pyrimethamine, on 2, 3 days (unless another Arm other than Arm 1a is determined from the pilot phase) post Sanaria PfSPZ Challenge via DVI while under CQprophylaxis. These subjects will be considered enrolledinto the study upon receipt of the loading dose of CQ(2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
89620674|NCT02511054|Experimental|3|Arm 3 (n=6) will receive Sanaria PfSPZ Challenge DVI while under CQ prophylaxis without PYR treatment. These subjects will be considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
89620675|NCT02511054|Experimental|4|Arm 4 (n=5) will only receive one dose of Sanaria PfSPZ Challenge at CHMI as a positive control for thestudy. Subjects in Arm 4 will be considered enrolledon the day of Sanaria PfSPZ Challenge via DVI.
89620676|NCT04499118|Experimental|Arm a(HR+/HER2-,HRD-）|Participants receive AT regimen for neoadjuvant therapy
89620677|NCT04499118|Experimental|Arm b(TNBC, HRD-)|Participants receive TP regimen for neoadjuvant therapy
89620678|NCT04499118|Experimental|Arm c(HER2-,HRD+)|Participants receive AT regimen for neoadjuvant therapy
89620679|NCT04499118|Experimental|Arm d(HER2-, HRD+)|Participants receive TP regimen for neoadjuvant therapy
89620680|NCT01612546|Experimental|Treatment (cyclodextrin-based polymer-camptothecin CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX101 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the completion of 6 courses, patients achieving stable disease or better may receive treatment for an additional 6 months.
89620681|NCT01698502||Trained|Healthy, Endurance trained (Maximal oxygen uptake (VO2max), ml*min-1*kg-1>60), 20-30 year, BMI: 18,5-25kg/m2, males.
89620682|NCT01698502||Untrained|Healthy, sedentary (Maximal oxygen uptake (VO2max), ml*min-1*kg-1<50), 20-30 year, BMI: 18,5-25kg/m2, males.
89620683|NCT02514564||2x/wk|This group will be consisted of patients that will perform exercise two times a week.
89620684|NCT02514564||3x/wk|This group will be consisted of patients that will perform exercise three times a week.
89620685|NCT02514564||Control|This group will not perform exercise.
89620686|NCT04499898|Experimental|carvedilol|Carvedilol
89620687|NCT04499898|Active Comparator|Band Ligation|Band Ligation
89620688|NCT01613014|Placebo Comparator|Sugar Pill|Matched Placebo sugar pill - target dose 2 pills BID
89620689|NCT01613014|Active Comparator|ABT-436|ABT-436 Target dose of 400 mg BID
89620690|NCT02514330|Experimental|Interval Training at 1% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 1% incline, Final Drop Jump (20;30;40 cm)
89620691|NCT02514330|Experimental|Interval Training at 10% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 10% incline, Final Drop Jump (20;30;40 cm)
89620692|NCT02514330|No Intervention|Control|Procedure: Initial Drop Jump (20;30;40 cm), 20 min Rest, Final Drop Jump (20;30;40 cm)
89620693|NCT02510976|Active Comparator|Prucalopride|Prucalopride tablet 2 mg
89620694|NCT02510976|Placebo Comparator|Placebo|matching placebo tablet
89620695|NCT02505516|Placebo Comparator|metformin|metformin 500mg
89620696|NCT02505516|No Intervention|not on metformin|
89620697|NCT02510898|Experimental|Intervention Arm|All subjects enrolled in the study will receive the intervention. This is a one-arm study.
89620698|NCT02514408||Ancillary-Correlative (collection of blood samples)|Patients undergo placement of a central line via the right femoral vein and undergo ORC. Blood samples are collected and analyzed for CTCs pre-surgery, at 30 minutes and 1 hour once ORC begins, post-surgery, and 7 days after surgery.
89620699|NCT02505360|Other|nasal and ear cartilage taken from the newborn|to compare biochemical and histological characteristics of both nasal and ear cartilage taken from the newborn at the time of surgical time cheilorhinoplasty
89620700|NCT04499586|Experimental|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Administration of Raltitrexed and Irinotecan weekly followed by a 2 week 'rest' period with no drug given. Raltitrexed is given by IV infusion at a dose of 3mg/m2. Irinotecan is given by IV infusion at a dose of 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7).Radiation: 45-55Gy/25-30Fx
89620701|NCT01656460|Experimental|Stereotactic radiation Arm 1|"Dose Levels/total Dose~1 16 Gy"
89620702|NCT01656460|Experimental|Stereotactic radiation Arm 2|2 20 Gy
89620703|NCT01656460|Experimental|Stereotactic radiation Arm 3|3 24 Gy
89620704|NCT01656460|Experimental|Stereotactic radiation Arm 4|4 28 Gy
89620705|NCT02505282||Orthostatic Hypotension|>20mmHg systolic BP drop or >10mmHg diastolic BP drop on standing, and syncopal symptoms on standing
89620706|NCT02505282||Control|No fall in BP or <20mmHg systolic BP drop and <10mmHg diastolic BP drop on standing, and no syncopal symptoms on standing
89620707|NCT03343938|Experimental|Closed Station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
89620708|NCT03343938|No Intervention|Open flow cabinet|Embryo handling is performed inside a conventional open flow cabinet without a controlled environment.
89620709|NCT01656772|Active Comparator|Manual Lasso navigation|Use of conventional manual navigation techniques with the Lasso catheter
89620710|NCT01656772|Experimental|Vdrive Lasso navigation|Use of the Vdrive to remotely and robotically control the manipulation of a Lasso catheter
89620711|NCT01816295|Placebo Comparator|Placebo Solution|Placebo Solution applied topically once daily for 12 weeks.
89620712|NCT01816295|Experimental|Testosterone Solution|Testosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.
89620713|NCT02514018|Other|Immediate Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 Plaque-forming unit - PFU) administered as a single-dose at day 0
89620714|NCT02514018|Other|Delayed Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 PFU) administered as a single-dose at day 84 (+/- 3 days)
89620715|NCT02513862|Experimental|APRP group|APRP group is performed autologous platelet-rich plasma harvest technique before administration of heparin to the patient,the red blood cell(RBC) component is retransfused to the patient when the RBC transfusion protocol is reached,and the autologous platelet-rich plasma is transfused to the patient immediately after heparin is neutralized with protamine.
89620716|NCT02513862|No Intervention|control group|APRP group receive no autologous platelet-rich plasma harvest technique.
89620717|NCT01659268|Experimental|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
89620718|NCT01659268|Other|Exhibition-dialogued class|Students will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, each subgroup composed of 4-5 students will go to the and practical activity in skill lab using the low-fidelity mannequin for 35 minutes.
89620719|NCT02510586|Experimental|Sevo_postconditioning|Patients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.
89620720|NCT02510586|No Intervention|Non_postconditioning|Patients not receiving sevoflurane postconditioning after revascularization completed
89620721|NCT01704196|Active Comparator|Nepicastat|Nepicastat 120mg and 100mg riboflavin (once per day) for 11 weeks
89620722|NCT01704196|Placebo Comparator|Placebo|Placebo capsule containing 100mg riboflavin (once per day) for 11 weeks.
89210961|NCT00907920||Correlative studies|"Tumor DNA samples are examined by mutation analysis for germline and somatic mutations in the ALK tyrosine kinase domain. Samples are analyzed by whole genome amplification using polymerase chain reaction and then sequenced for DNA alterations in the entire ALK coding sequence. Samples are also examined for SNPs by polymorphism analysis. Exploratory multivariable analysis is performed to test for the prognostic ability of ALK mutations in the presence of other known prognostic variables (i.e., age, International Neuroblastoma Staging System stage, MYCN status, International Neuroblastoma Pathology Classification, and diploidy).~A subset of tumor DNA samples from high-risk patients will be resequenced for DNA alterations to determine whether or not additional regions in ALK, outside of the tyrosine kinase domain, are prone to mutations and should be sequenced in a larger panel."
89620723|NCT01610297|Experimental|ICL670|Oral dose of ICL670 at 10 mg/kg daily
89620724|NCT03343782|Experimental|Stem cell transplantation|Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval
89620725|NCT02510352||Rotator cuff tear|patients with a symptomatic rotator cuff tear treated without surgical repair
89620726|NCT01660672|Other|LEVETIRACETAM|Open label, dose escalation to optimal dose.
89620727|NCT02505048|Experimental|rucaparib|"Tablets 200 mg and 300 mg per os : 600 mg / bid every day in continuous.~Patients will be treated with rucaparib Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks (RECIST 1.1) Safety will be assessed continuously"
89620728|NCT01793051|Experimental|Minocycline|"Minocycline 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance chemotherapy for MM.~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
89620729|NCT01793051|Placebo Comparator|Placebo|"Placebo 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
89688425|NCT02907268|Active Comparator|Treatment Arm A|The first treatment group received onabotulinumtoxinA (Botox) on the right side of their face and abobotulinumtoxinA (Dysport) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
89210962|NCT04087967|Experimental|Decitabine combined with HAAG|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
89210963|NCT04087967|Active Comparator|IA Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed AML patients younger than 60.
89533172|NCT05376267|Experimental|Cooling 96 hours|The participant will be cooled to 33°C for 96 hours, slowly rewarmed over approximately 16 hours, and then will be kept at a normal temperature (36.8°C or 98.6°F) until the end of the 5th day.
88988599|NCT06247020|Experimental|Oral sodium-butyrrate supplementation|Participants consumed 8 capsules of sodium butyrate per day for a week. The capsules were consumed with main meals (2 for breakfast, 2 for lunch and 2 for dinner). Each capsule contained 200 mg of sodium butyrate, for a total of 1.6 grams of sodium butyrate per day.
88988600|NCT06247020|Placebo Comparator|Placebo|Participants consumed 8 capsules of placebo. The capsules were consumed with main meals (2 for breakfast, 2 for lunch and 2 for dinner). Each capsule contained cornstarch
88988601|NCT06247007|Experimental|EA (electroacupuncture)|Individuals who underwent electroacupuncture addition to non-surgical periodontal therapy
88988602|NCT06247007|No Intervention|Control|Individuals who have non-surgical periodontal therapy only
89533173|NCT05372627||1|Adults undergoing clinically-indicated contrast-enhanced time-resolved cardiac CT for suspected structural heart disease
89533174|NCT05371496|Active Comparator|Semaglutide Treatment|Subjects will receive Semaglutide once weekly in addition to counselling on healthy lifestyle intervention
89533175|NCT05371496|Placebo Comparator|Placebo Treatment|Subjects will receive matching placebo once weekly in addition to counselling on healthy lifestyle intervention
89533176|NCT05369611||SELF|1,668 current members of the SELF cohort: African American women between the ages of 23-35 at enrollment in SELF who have not previously withdrawn from SELF and are not known to have died.
89533177|NCT05352022|Experimental|Monthly Unconditional Financial Incentive|Individuals assigned to this group will receive diabetes education and a monthly incentive to supplement income and enhance ability to purchase healthy food options.
89533178|NCT05352022|Experimental|Monthly Unconditional Plus Healthy Food Purchasing Financial Incentive|Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, and an additional weekly incentive if receipt for purchase of healthy food items from a grocery store is provided.
89533179|NCT05352022|Experimental|Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial Incentive|Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, an additional weekly incentive if receipt for purchase of healthy food items from a grocery store is provided, and an incentive at the end of the study based on absolute drop in HbA1c.
89533180|NCT05338749|Experimental|Cognitive Training|Participants in this condition will received game-based cognitive training.
89533181|NCT05335889||Type 2 Diabetes group|Participants with Type 2 Diabetes will wear eButton and Continuous Glucose Monitoring (CGM) for 2 weeks and complete food diaries to record carb grams.
89533182|NCT05331365|Experimental|Group of the construction of the composite Ankle go score and internal validations|50 patients will be include for the construction of the composite score and its internal validations. They will complete questionnaires (FAAM, ALR-RSI) and undergo tests (SLSTS, SHTS, SEBT and Figure of 8) 4 months after ankle's surgery (visit 1), 6 months after surgery (visit 2) and 12 months post surgery
89533183|NCT05331365|Experimental|group of the external validation stage of the composite score|50 additional patients for the external validation stage of the composite score. They will complete questionnaires (FAAM, ALR-RSI) and undergo tests (SLSTS, SHTS, SEBT and Figure of 8) 4 months after ankle's surgery (visit 1) and 6 months after surgery (visit 2)
89533184|NCT05331365|No Intervention|Group allowing the assessment of the score's ability to discriminate|30 healthy volunteers (who did not undergone an ankle's surgery) will be included in the study to analyze the ability of composite score to discriminate. The healthy population will perform the same physical and psychological tests as Group allowing the construction of the composite Ankle go score and internal validations
89533185|NCT05326412|Experimental|Itepekimab|"This arm includes participants from 3 populations: Part A-former smokers, Part B-former smokers and Part B-current smokers.~Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 12 weeks"
89533186|NCT05322850|Experimental|Orca-Q|
89533187|NCT05307692|Experimental|Seltorexant|Participants will receive single oral dose of seltorexant 20 milligrams (mg) tablet once daily from Day 1 to Day 42.
89533188|NCT05307692|Placebo Comparator|Placebo|Participants will receive single oral dose of matching placebo tablet once daily from Day 1 to Day 42.
89533189|NCT05289492|Experimental|A: Participants will receive EOS884448|EOS884448 will be administered
89533190|NCT05289492|Experimental|B: Participants will receive EOS884448 and iberdomide|EOS884448 and iberdomide will be administered
89533191|NCT05289492|Experimental|C: Participants will receive EOS884448, iberdomide and dexamethasone|EOS884448, iberdomide and dexamethasone will be administered
89533192|NCT05286281|Experimental|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
89533193|NCT05282186|Experimental|Cognitive Enhancement Therapy|CET is a comprehensive manualized cognitive remediation program designed to maximize gains in social functioning by integrating computer-based training to enhance neurocognition with group-based exercises to improve social cognition.
89533194|NCT05282186|Active Comparator|Social Skills Training|The HOPES social rehabilitation program uses the principles of SST (modeling, role playing, positive and corrective feedback, homework assignments, in vivo skills practice), designed to improve both psychosocial functioning and preventive health.
89533195|NCT05279300|Experimental|Dose escalation|
89533196|NCT05279300|Experimental|Dose expansion|
89533197|NCT05277571|Experimental|UCB1381 dosing regime 1 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
89533198|NCT05277571|Experimental|UCB1381 dosing regime 2 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
89620730|NCT02510508|Experimental|Group CRAFT|"All CSO's who are allocated to CRAFT group condition will be offered seven sessions of a CRAFT Group format. Each group will meet for 90 minutes weekly and will be completed within 2 months. The group content is based on the CRAFT techniques described by a training manual written by Roozen, Smith and Meyers (2015). Furthermore the CSOs in this condition will also receive a Dutch version of the CRAFT self-help book (Self Directed CRAFT Delivery), Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). Groups will engage in a combination of didactic teaching, role-play of new communication styles and discuss their experiences utilizing CRAFT skills."
89620731|NCT02510508|Active Comparator|Self-Directed CRAFT Delivery|"CSO's allocated to the Self- Directed CRAFT Delivery will receive the Dutch version of the CRAFT self-help book, Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). The book helps CSO's how to utilize the CRAFT model in their daily lives. It includes guidelines for responding to IP behavior, improving positive communication skills, improving the CSO's own well-being and explains how to engage the IP into treatment."
89620732|NCT02510508|No Intervention|Non-intervention|Participants assigned to the non-intervention condition will be placed on a Group CRAFT waiting list.
89620733|NCT01661764|Active Comparator|rs174535 (GG), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
89620734|NCT01661764|Placebo Comparator|rs174535 (GG), placebo|Oleic Acid
89620735|NCT01661764|Active Comparator|rs174535 (GT), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
89620736|NCT01661764|Placebo Comparator|rs174535 (GT), placebo|Oleic Acid
89620737|NCT01661764|Active Comparator|rs174535 (TT), fish oil supplement|Eicosapentanoic acid and docosahexanoic acid
89620738|NCT01661764|Placebo Comparator|rs174535 (TT), placebo|Oleic Acid
89620739|NCT02510430|Experimental|Reducing Sitting Time Group|This group will be asked to reduce overall accumulated sitting time by 2 hours per day.
89620740|NCT02510430|Experimental|Re-Patterning Sitting Time Group|This group will be asked to use standing breaks to interrupt long bouts of sitting time.
89620741|NCT02510430|Placebo Comparator|Usual Care|This is an attention control group and is not asked to make changes to sitting time.
89620742|NCT01816061|Experimental|Experimental - COMPASS|Goal-setting sessions
89620743|NCT01816061|Active Comparator|Control - COMPASS|Informative phone calls
89620744|NCT02510274|Experimental|Part1, ASP3325 Tablet A|ASP3325 tablets A will be orally administered with 150 mL of water in fasting condition on non-dialysis day in Day 1
89620745|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 1|ASP3325 tablets B will be orally administered t.i.d. 30 minutes before each meal for 2 weeks
89620746|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 2|ASP3325 tablets B will be orally administered t.i.d. 30 minutes just after each meal for 2 weeks
89620747|NCT03121482|Active Comparator|HFNC alone|Control group
89620748|NCT03121482|Experimental|HFNC and NIV|
89620749|NCT01662778|Active Comparator|Monodisperse FP 1.5um|50 mg of monodisperse Fluticasone Propionate delivered as 1.5 microns aerosol followed by AMP PC20 challenge test
89620750|NCT01662778|Active Comparator|Monodisperse FP 6.0um|50 mg of monodisperse Fluticasone Propionate delivered as 6.0 microns aerosol followed by AMP PC20 challenge test
89620751|NCT01662778|Placebo Comparator|Placebo STAG|No active drug, just solvent delivered from STAG followed by AMP PC20 challenge test
89620752|NCT01662778|Active Comparator|MDI FP|Fluticasone Propionate , Metered dose inhaler, 250 mg dose followed by AMP PC20 challenge test
89620753|NCT03121560|Active Comparator|Hysteroscopy|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
89620754|NCT03121560|Experimental|Hysterosonography|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
89620755|NCT02510196|Active Comparator|reminder|participants in this group will be reminded to use ultrasound for neuraxial anesthesia on a regular basis
89620756|NCT02510196|No Intervention|control|participants in this group will not be reminded to use ultrasound for neuraxial anesthesia
89620757|NCT01792115|Active Comparator|Vit E 200 IU/d|Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
89620758|NCT01792115|Active Comparator|Vitamin E 400|Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
89620759|NCT01792115|Active Comparator|Vitamin E 800|Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
89620760|NCT02504814|Experimental|ventilatory effects|measuring mean airway pressure, breathing volumes and decrease in hypercapnia
89620761|NCT01791803|Experimental|Hypnotherapy|Patients admitted with a cardiopulmonary illness received a 90 minute free hypnotherapy session within 2 weeks of discharge, and a standardized tape for smoking cessation and relaxation for continued use after the session. They also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after discharge.
89210964|NCT02549456|Experimental|Natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer with natural orifice specimen extraction
89620762|NCT01791803|Experimental|Nicotine Replacement Therapy|Patients recieved a free one month supply of Nicotine replacement therapy to include patches and Gum, lozenges or sprays. Patients also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after hospitalization.
89620763|NCT01791803|Experimental|Hypnotherapy and Nicotine replacement|The group received similar hypnotherapy session and tape, similar brochure and counseling protocol, as well as free nicotine replacement supplies for a month after discharge.
89620764|NCT01791803|No Intervention|Self-Quit group|Patients were given brief counseling during hospitalization and will not be contacted until 26 weeks after hospitalization.
89620765|NCT01662856|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
89036792|NCT02892799|Experimental|NICOM-Guided Diuresis|"Within 4 hours, patients will have their blood pressure obtained, a NICOM-based assessment of PLR (passive leg raise)-induced change in cardiac index, hourly urinary output, and quantization of the total input and output from the beginning of the morning shift (7 am). This will allow determination of the fluid goal over the next 4 hours. Patients will receive furosemide to achieve the goal fluid balance, if needed as described in the accompanying protocol. Monitoring of electrolytes and renal function will be at the discretion of the treating physician.~Following the initial evaluation, at set times spaced every 4 hours apart, patients will have an ongoing evaluation of the day's fluid balance, hourly urinary output, and PLR/NICOM values. This diuresis protocol will continue for a total of seven 24-hour periods or until the primary means of oxygenation/ventilation has been withdrawn, whichever occurs first. Patients will be followed for a total of 60 days to evaluate outcome data."
89036793|NCT05470166|Experimental|infusion of intraoperative lidocaine to patients undergoing whipple surgery|lidocaine 1.5mg/kg infused as bolus, then 2mg/kg/hr through the operation
89036794|NCT05470166|Experimental|saline infusion of same volume of lidocaine|same amount of normal saline infused as bolus and infusion
89036795|NCT00594451||I Multicenter Veteran's Affairs Rheumatoid Arthritis (VARA) registry|multicenter Veteran Affairs Rheumatoid Arthritis (VARA) registry
89620766|NCT01662856|Active Comparator|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
89620767|NCT02504970||Anesthesia Group Type|AQI collects data from anesthesia groups. The groups are classified according to practice type
89620768|NCT01791725|Experimental|ELND005 BID|ELND005 250 mg BID
89620769|NCT01791725|Experimental|ELND005 QD|ELND005 250 mg QD
89620770|NCT01791725|Placebo Comparator|Placebo|Placebo BID
89620771|NCT04499976|Experimental|INH|3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily dose, 900 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
89620772|NCT04499976|Placebo Comparator|Placebo Comparator|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
89620773|NCT02504658|Experimental|Text Message Group|Subjects will set 2 lifestyle goals (exercise and nutrition) and receive health tips and goal status check in messages over 1 month.
89620774|NCT02504658|Active Comparator|Control Group|"The control subjects will set 2 lifestyle goals and receive a educational booklet to review.They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over. The approximate procedure time will be 20-25 minutes."
89620775|NCT01791413|Active Comparator|depot medroxyprogesterone acetate|
89036796|NCT00594451||II NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)|NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)
89036797|NCT00594490||Silicone|patients undergoing placement of silicone breast prosthetics
89036798|NCT00594529|Other|1|
89036799|NCT05470127|Experimental|SUREcore biopsy needle|The SUREcore needle will be used to collect up to 10 tissue samples
89036800|NCT05470127|Active Comparator|Standard of Care biopsy needle|The urologist will use his/her standard biopsy needle to collect up to 15 tissue samples
89036801|NCT05470049|Experimental|Treatment group A: SHR8554 Injection and SHR0410 Injection|
89036802|NCT05470049|Experimental|Treatment group B: SHR8554 Injection and SHR0410 Injection|
89036803|NCT05470049|Placebo Comparator|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection|
89036804|NCT02412579||Hepatocellular Carcinoma with Cirrhosis|Subjects with hepatocellular carcinoma and cirrhosis.
89036805|NCT02412579||Cirrhosis without Hepatocellular Carcinoma|Subjects with only cirrhosis.
89036806|NCT01260142|Experimental|Arm 1|
89620776|NCT01791413|No Intervention|No depot medroxyprogesterone acetate|
89620777|NCT02513316||Study I (AF)|Prospective cohort study of patients anticoagulated after cardioembolic stroke started on best practice oral anticoagulant (without prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up for the occurrence of ICH, ischaemic stroke and cognitive function for an average of two years. Our main baseline exposures (risk factors of interest) are the presence of CMBs on MRI, and genetic polymorphisms in candidate genes with potential functional relevance to ICH risk.
89620778|NCT02513316||Study II (ICH)|Observational and genetics study of intracerebral haemorrhage Patients with ICH (non anticoagulant-related ICH cases and anticoagulant-related ICH cases).
89620779|NCT01614574|Experimental|Investigational|velaglucerase alfa
89620780|NCT01610063|Experimental|Guided|A pharmacogenomic algorithm (GeneSight) guided treatment decisions for antidepressant medication selection and appropriate dosing.
89620781|NCT01610063|No Intervention|Unguided|Treatment as usual
89620782|NCT04499040|Experimental|patients with SD/THE|
89620783|NCT04499040|Placebo Comparator|control group|
89620784|NCT02510118|Experimental|conventional chemotherapy + placebo ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the placebo ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency.
89036807|NCT01260142|Experimental|Arm 2|
89036808|NCT01260142|Experimental|Arm 3|
89036809|NCT01259869|Experimental|PX-866|
89036810|NCT05469932|Active Comparator|Treatment|"Pre-treatment medical examination by an ophthalmologist and self-filled questionnaire.~Four treatment sessions. Each session includes 20 minutes with the instrument active at power level 4. Post-treatment medical examination by an ophthalmologist and self-filled questionnaire."
89036811|NCT05469932|Placebo Comparator|Placebo|"Pre-treatment medical examination by an ophthalmologist and self-filled questionnaire.~Four treatment sessions. Each session includes 20 minutes with the instrument active at power level 0. Post-treatment medical examination by an ophthalmologist and self-filled questionnaire."
89036812|NCT00594607|Active Comparator|1: AN69ST|Hemodialysis sessions with use of the dialysis filter AN69ST.
89036813|NCT00594607|Active Comparator|2:Fx8|Hemodialysis sessions with use of the dialysis filter Fx8
89036814|NCT05469776|Experimental|bicruciate-retaining total knee arthroplasty|The prosthesis is minimally constrained and allows the preservation of both cruciate ligaments. All implants are cemented.
89036815|NCT05469776|Active Comparator|posterior-stabilized total knee arthroplasty|The prosthesis requires the excision of both cruciate ligaments
89620785|NCT02510118|Experimental|conventional chemotherapy + ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency, a herbal extract twice daily for 26 weeks for lower dosage.
89620786|NCT02509806|Experimental|Apatinib Maintenance Therapy After First-line Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
89620787|NCT02509806|No Intervention|No Intervention After First-line Chemotherapy|No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
89620788|NCT01813721||Group 1|All patients enrolled
89620789|NCT02509728|Active Comparator|standard nutrition|standard nutrition
89620790|NCT02509728|Experimental|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
89620791|NCT02509728|Experimental|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
89620792|NCT02509728|Experimental|choline and DHA supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride and 60mg/kg of DHA for 10 days
89620793|NCT02509338|Experimental|Electrode deep brain stimulation|Monocontact electrode deep brain stimulation
89620794|NCT02501616|Active Comparator|Metformin first|"Metformin first 8 wks --> Dapagliflozin 8wks.~Metformin for initial 8 weeks. During that period, metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' dapagliflozin is followed. During that period, dose of dapagliflozin is maintained 10mg/day."
89620795|NCT02501616|Active Comparator|Dapagliflozin first|"Dapagliflozin first 8 wks --> Metformin 8wks.~Dapagliflozin for initial 8 weeks. After 1 weeks of washout period, 8 weeks' metformin is followed."
89620796|NCT02501460|Active Comparator|Supplement Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and dietary supplementation. Adherence will be assured as described below.
89620797|NCT02501460|Placebo Comparator|Placebo Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and placebo. Adherence will be assured as described below.
89620798|NCT01790633|Active Comparator|Standard testing with ELISA|HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
89620799|NCT01790633|Experimental|Rapid testing|HBV, HCV, and HIV infection status determined by a rapid test
89620800|NCT02504190||lymphoma patients eligible for TEAM conditioning|Lymphoma Patients who are eligible will be included. Patients will undergo TEAM conditioning regimen followed by autologous haematopoietic stem cells transplantation according to standard practice of the centre and drugs label in France.
89620801|NCT02501070||Pre-PROGALIAM|Patients treated for myocardial infarction before the implementation of the network for acute myocardial infarction care (2001 to 2005).
89620802|NCT02501070||PROGALIAM|Patients treated for myocardial infarction after the implementation of the network for acute myocardial infarction care (2005 to 2011).
89620803|NCT01788215|Active Comparator|Doxycycline|Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
89620804|NCT01788215|Placebo Comparator|Sugar Pill|The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
89620805|NCT02503956|Experimental|Treated group|Patients treated with perforated punctal plugs
89620806|NCT02503956|Active Comparator|Comparison group|Comparison group treated with standard of care - Lacrimal intubation with Crawford lacrimal tube
89036816|NCT05469659|Experimental|Tofogliflozin|
89036817|NCT05469659|Active Comparator|Metformin|
89036818|NCT04686006||Graves disease|
89036819|NCT05469620|No Intervention|Control|Receive usual care.
89036820|NCT05469620|Experimental|Education|Receive nutrition education.
89036821|NCT05469620|Experimental|Meal|Receive meal kit.
89036822|NCT05469620|Experimental|Education and Meal|Receive both nutrition education and meal kit.
89036823|NCT00535704|Experimental|1|The Strong AFrican American FAmilies-Teen program is a five part educational program has been designed to help teens and their parents create successful futures and avoid the risky behaviors that sometimes keep teens from reaching their goals.
89210965|NCT02549456|Experimental|Laparoendoscopic resection|Laparoscopic assisted transanal endoscopic resection of rectal cancer
89210966|NCT00929448||Immunoglobulin|
89620807|NCT01787825|Other|PillCam SB2 then CapsoCam SV-1|PillCam SB2 capsule then CapsoCam SV-1 capsule
89620808|NCT01787825|Other|CapsoCam SV-1 then PillCam SB2|CapsoCam SV-1 capsule then PillCam SB2 capsule
89620809|NCT03343314||Hospitalized patients due to a severe, symptomatic aortic sten|Patients who agreed to participate in the study, aged ≥75 years, with severe and symptomatic aortic stenosis, and hospitalized in one of the medical and surgical centers participating in the study
89620810|NCT03344484|Experimental|Midline Approach|A midline surgical approach will be used for the exposure required to complete the lumbar fusion.
89620811|NCT03344484|Experimental|Paramedian Approach|A paramedian (i.e. Wiltse) surgical approach will be used for the exposure required to complete the lumbar fusion.
89620812|NCT02503800||subjects undergoing venom immunotherapy|The study group will include all the subjects receiving routine venom immunotherapy at the Meir Medical Center Allergy Clinic.
89620813|NCT01813019|Experimental|AFQ056|"Following baseline, approximately 60 patients who are considered eligible will be randomized to AFQ056 arm and will receive the dosing regimen of 4 weeks AFQ056 b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks AFQ056 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg AFQ056 b.i.d)~*patients that do not tolerate 200 mg b.i.d may be down-titrated to 150 mg b.i.d."
89620814|NCT01813019|Placebo Comparator|Placebo|Following baseline, approximately 60 patients who are considered eligible will be randomized to Placebo arm and will receive the dosing regimen of 4 weeks Placebo b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks Placebo 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg Placebo b.i.d) *patients that do not tolerate 200 matching placebo AFQ056 mg b.i.d may be down-titrated to 150 mg b.i.d.
89620815|NCT02509572|Experimental|Decision Support Arm|Patients randomized to the intervention will complete a sexual health screen (SHS). The results of the SHS will provide decision support for STI testing by risk stratifying patients with screening recommendations to the clinician based on risk.
89620816|NCT02509572|No Intervention|Usual Care Arm|Patients randomized to the usual care arm will complete the sexual health screen (SHS). However these results and the STI testing decision support will not be shared with the clinician.
89620817|NCT01787591|Experimental|Acute Fat-Free Milk Ingestion|Participants will ingest 1 cup of fat-free milk with 15 mg deuterium-labeled alpha-tocopherol.
89620818|NCT01787591|Experimental|Acute Low-Fat Milk Ingestion|Participants will ingest 1 cup of low-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
89620819|NCT01787591|Experimental|Acute Full-Fat Milk Ingestion|Participants will ingest 1 cup of full-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
89620820|NCT01787591|Experimental|Acute Soy Milk Ingestion|Participants will ingest 1 cup of soy milk with 15 mg deuterium-labeled alpha-tocopherol.
89620821|NCT02504034|Experimental|Transhepatic portosystemic shunt|Patients with cavernous transformation of portal vein undergo transhepatic portalsystemic shunt and other interventional radiology treatment
89620822|NCT02503644|Active Comparator|IVA337 800mg|Patients receive twice daily 400mg IVA337.
89620823|NCT02503644|Active Comparator|IVA337 1200mg|Patients receive twice daily 600mg IVA337.
89620824|NCT02503644|Placebo Comparator|Placebo|Patients receive twice daily placebo.
89620825|NCT01812707|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
89620826|NCT01812707|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
88988603|NCT06246929|Experimental|Mindfulness-Based Cognitive Therapy With Walking (MBCT+w)|MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
88988604|NCT06246929|Active Comparator|Active Living Every Day (ALED)|ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
88988605|NCT06246916|Experimental|fianlimab+cemiplimab|Randomized 1:1
88988606|NCT06246916|Active Comparator|relatlimab+nivolumab|Randomized 1:1
88988607|NCT06246903||suspicious nevus/nevi|
89620827|NCT01812707|Experimental|Alirocumab 75 mg Q2W|Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
89620828|NCT01812707|Placebo Comparator|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
89620829|NCT02509182|Active Comparator|100% FiO2|100% oxygen administered during pulmonary lobectomy surgery.
89620830|NCT02509182|Experimental|60% FiO2|60% oxygen administered during pulmonary lobectomy surgery.
89620831|NCT04497090|Active Comparator|Fixed-EPAP|EPAP was kept fixed at the prescribed level throughout the night
89620832|NCT04497090|Experimental|Auto-EPAP|EPAP was continuously adjusted using the experimental approach aimed at abolishing tidal expiratory flow limitation
89620833|NCT01787279|Experimental|Peginterferon alpha-2a, 180 mcg/48 weeks|Eligible participants with HI3vAg (a type of Hepatitis B surface antigen) negative chronic hepatitis B will be administered peginterferon alpha-2a (PEGASYS), 40kD, 180 micrograms (mcg) subcutaneously once weekly for 48 weeks. The untreated Follow-up will be for 24 weeks.
89620834|NCT02728206|Experimental|SOF/VEL|SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant
88988608|NCT06246890||Screening + Autism ALERT|Families with children under 54 months, without a medical ASD diagnosis, who are referred by an autism clinic or primary care provider to Autism ALERT
88988609|NCT06246851|Experimental|Group A: 2-8 x 10^5 cfu intradermal BCG (non-type 2 diabetic group)|12 historically BCG-vaccinated volunteers without type 2 diabetes will receive 2-8 X 10^5 cfu intradermally injected BCG. All Group A volunteers will have a bronchoscopy 14 days post challenge.
88988610|NCT06246851|Experimental|Group B: 2-8 x 10^6 cfu aerosol inhaled BCG (non-type 2 diabetic group)|12 historically BCG-vaccinated volunteers without type 2 diabetes will receive 2-8 X 10^6 cfu aerosol inhaled BCG. All Group B volunteers will have a bronchoscopy 14 days post challenge.
89210967|NCT04087577|Experimental|experimental group|conventional physical therapy with mirror therapy
89210968|NCT04087577|Active Comparator|control group|conventional physical therapy
89210969|NCT04196751|Experimental|Clinical Supervision Intervention|All the enrolled participants will be undergoing Clinical Supervision sessions with their selected supervisors for pre-identified objectives for their skill and knowledge development.
89210970|NCT00926016|Active Comparator|pioglitazone|Treatment with pioglitazone 45 mg a day for 3 months
89036824|NCT00535704|Other|2|The FUEL program is a family-based adaptation of a curriculum designed to assist teens to develop lifestyles that prevent health problems such as heart disease, diabetes, and being overweight. This program deals with diet and exercise, the influence of TV and magazines on eating habits, and handling stress.
89036825|NCT01808820|Experimental|Safety Pilot: DC Vaccine/Lysate|Participants in this group will undergo leukapheresis after standard of care surgical tumor resection. Leukapheresis will be used to obtain peripheral blood mononuclear cells (PBMC) from which the dendritic cells (DC) will be obtained. Retrieved DC will be used as a vaccine once weekly on Weeks 1-4 within 3 weeks from end of leukapheresis. Participants will also receive Imiquimod, which will be applied one evening prior to DC dose for 8 hours then for 8 hours each of the next two evenings. Enrollment of participants in the Pilot group will be staggered until the second participant has no treatment limiting toxicities. For the first five subjects to be enrolled in the pilot, the administration of DC to each subject will be delayed until the prior subject has received the second administration of DC. Participants will also receive Lysate of tumor administered every 4 weeks + 3 days on Weeks 8, 12, 16 and 28 (+ / - 3 days).
89057814|NCT01686867|Experimental|Commercially-made followed by locally-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. Four months later the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
89620835|NCT04576793|Experimental|Cognitive impairment|"Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties~Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties~Amnestic Alzheimer's disease - a typical version of Alzheimer's disease with memory difficulties"
89620836|NCT04576793|Active Comparator|No cognitive impairment|Healthy controls
89620837|NCT02500992||Transrectal sigmoidectomy|Patients undergoing transrectal NOTES sigmoidectomy
89620838|NCT02500992||Laparoscopic-assisted sigmoidectomy|Patients undergoing laparoscopic-assisted sigmoidectomy
89620839|NCT01811225|Experimental|Low-Dose Contraceptive, then High-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.~Participants in this arm will begin with the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the high dose progesterone, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM)."
89620840|NCT01811225|Experimental|High-Dose Contraceptive, then Low-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.~Participants in this arm will begin with the high progesterone dose, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM)."
89620841|NCT02503566|Experimental|All patients|Optical coherence tomography will be performed in all patients
89620842|NCT01809197|Experimental|Air Optix/OFPM|Lotrafilcon B contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with OPTI-FREE MPDS lens care system
89620843|NCT01809197|Active Comparator|Acuvue Oasys/Habitual MPS|Senofilcon A contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with habitual MPS lens care system
89620844|NCT02508870|Experimental|Cohort A: Atezolizumab - HMA R/R MDS|Participants with MDS who are HMA R/R will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (Q3W) (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a partial response (PR) or hematological improvement (HI) after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
89620845|NCT02508870|Experimental|Cohort B: Atezolizumab+Azacitidine - HMA R/R MDS|Induction: Participants with MDS who are HMA R/R will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) on Days 1 to 7 of 28-day cycle, for 6 cycles. Maintenance: Participants who complete induction treatment will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
89620846|NCT02508870|Experimental|Cohort C1: Atezolizumab+Azacitidine - HMA-Naive MDS|Participants with MDS who are HMA-naive will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
89620847|NCT02508870|Experimental|Cohort C2: Atezolizumab+Azacitidine - HMA-Naive MDS|If the participants enrolled in Cohort C1 fulfil the dose limiting toxicity (DLT) criteria, then additional participants with MDS who are HMA-naïve will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
89210971|NCT00926016|No Intervention|No intervention|Monitoring period without pioglitazone for 3 months
89210972|NCT04017104||18F-FDG PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-FDG PET/CT procedure.~18FFDG is considered standard care and has been approved by Health Canada."
89620848|NCT02508870|Experimental|Cohort A2: Atezolizumab - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a PR or HI after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
89620849|NCT02508870|Experimental|Cohort B2: Atezolizumab+Azacitidine - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, for 6 cycles during induction. Participants who complete induction treatment will receive maintenance atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
89620850|NCT02508792|Active Comparator|LASER|"Subject will receive application of LASER before muscle fatigue protocol.~Note: this is a crossover study."
89620851|NCT02508792|Placebo Comparator|LASER PLACEBO|"Subject will receive application of LASER (now deactivated) before muscle fatigue protocol.~Note: this is a crossover study."
89620852|NCT01786109|Experimental|Dronabinol 2.5 mg|One dose of dronabinol 2.5 mg was taken orally with water.
89620853|NCT01786109|Experimental|Dronabinol 5 mg|One dose of dronabinol 5 mg was taken orally with water.
88988611|NCT06246851|Experimental|Group C: 2-8 x 10^5 cfu intradermal BCG (type 2 diabetic group)|12 historically BCG-vaccinated volunteers with confirmed type 2 diabetes will receive 2-8 X 10^5 cfu intradermally injected BCG. All Group C volunteers will not have a bronchoscopy.
88988612|NCT06246825||PARABOLA cohort|Patients with paroxysmal or persistent atrial fibrillation and a high likelihood of obstructive sleep apnea
88988613|NCT06246799|Experimental|Group IC|Tirzepatide starting at 2.5mg weekly titrated to 15mg weekly (2.5 month 1, 5mg month 2, 10mg month 3 and 15mg at month 4) with Pioglitazone beginning at 15mg daily and ending at 45mg daily (15mg month 1, 30mg month 2 and 45mg at month 3 onwards).
88988614|NCT06246799|Active Comparator|Group II|Metformin starting at 1000mg XR daily and Sitagliptin 100mg daily at week 4, Metformin will be increased to 200mg.
88988615|NCT06246799|Active Comparator|Group IA|Tirzepatide will be started at 2.5mg and increased to 15mg by month 4. At month 6, Pioglitazone will be added to the Tirzepatide, 15 mg daily.
88988616|NCT06246799|Active Comparator|Group 1B|Pioglitazone will be started at 15mg and increased to 45 mg by month 3. At month 6, tirzepatide 2.5mg will be started and increased weekly as tolerated.
88988617|NCT06246786|Experimental|Cyclosporin A|Patients with newly diagnosed triple negative breast cancer with low or negative RAD51 (A protein coding gene that provides instructions for making a protein that is essential for repairing damaged DNA)
88988618|NCT06246773|Experimental|Positive Parenting Program|
88988619|NCT06246773|Active Comparator|Usual Care|
88988620|NCT06246760|Experimental|Incremental exercise test|Maximal incremental exercise test on a treadmill or a cycle ergometer until volitional exhaustion
88988621|NCT06246695|Experimental|Inhibitor group|Jaktinib 100mg, once daily on the 1st and 9th days before meal; Itraconazole 200mg, once daily from the 4th day to the 12th day.
88988622|NCT06246695|Experimental|Inducer group|"Jaktinib 100mg, once daily on the 1st and 12th days before meal, Rifampicin 600mg, once daily from the 4th day to the 14th day.~Rifampicin 600mg, once daily from the 1th day to the 11th day, Jaktinib 100mg, once daily on the 9st and 25th days before meal."
88988623|NCT06246682|Other|cholesteatoma removal by otoendoscope|removal of the cholesteatoma in atticoantral region by otoendoscope
88988624|NCT06246669|Experimental|Moderate Intensity|Treadmill walking at a rating of perceived exertion (RPE) of 13.
88988625|NCT06246669|Experimental|Light Intensity|Treadmill walking at a rating of perceived exertion (RPE) of 9.
88988626|NCT06246656|Active Comparator|CAD/CAM milled TAD guides|The position guides for orthodontic Temporary Anchorage Devices (TAD) will be produced by CAD/CAM milling.
88988627|NCT06246656|Active Comparator|3D printed guides|The position guides for orthodontic Temporary Anchorage Devices (TAD) will be produced by 3D printing technology.
88988628|NCT06246643|Experimental|Regorafenib|Adult and pediatric patients from completed Bayer-sponsored regorafenib trials who are benefiting from regorafenib treatment.
88988629|NCT06246630|Experimental|Organoid-Guided therapy|All patients will be included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation and drug sensitivity tests.
88988630|NCT06246617|Experimental|Arm 1|Subjects who have received or plan to receive pulmonary lobectomy/segmentectomy, mediastinal tumor resection (including thymectomy), radical resection of esophagus cancer or other surgeries with the SP single-port robot.
89057815|NCT01686867|Experimental|Locally-made followed by commercially-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. Four months later the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
89057816|NCT02217644|Experimental|BI 653048 H3PO4 solution|single rising doses
89057817|NCT02217644|Experimental|BI 653048 H3PO4 low dose capsule|
89057818|NCT02217644|Experimental|BI 653048 H3PO4 high dose capsule|
89057819|NCT02217644|Placebo Comparator|Placebo|
89620854|NCT01786109|Placebo Comparator|Placebo|One dose of placebo was taken orally with water.
89620855|NCT02509104|Experimental|Cohort 1 Fasted condition|Each subject will receive both treatments A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fasting conditions.
89620856|NCT02509104|Experimental|Cohort 2 Fed condition|Each subject will receive both treatment A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fed (high fat breakfast) conditions.
89620857|NCT02500914|Experimental|SC-002|"Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability.~Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent."
89620858|NCT02503488|Experimental|Program Group|The treatment arm will consist of 20 randomly selected participants who will receive Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) for their traumatic symptomology, aggression, and depression. FORNET consists of a guided exposure of the participant's traumatic experiences in chronological order and integrating them into a coherent biographical memory.The intervention addresses the participant's positive, negative, and violent memories of events that have taken place during their lifetime, and also provides participants an opportunity to asses their current situation and future plans. FORNET can be completed in six sessions and each session lasts 90 minutes on average.
89620859|NCT02503488|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive group and individual psycho-social support from trained peer-support workers, with 10 sessions occurring throughout the course of the intervention for each participant. In addition, there will be sensitisation trainings as well as mentoring for establishing greater financial independence. Last, TAU will include one-day events promoting social cohesion and peace.
89620860|NCT02500680|Experimental|Group 1 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 1µg (Standard Dose) Single Dose
89620861|NCT02500680|Experimental|Group 2 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 3µg (Standard Dose) Single Dose
89620862|NCT02500680|Experimental|Group 3 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 5µg (Standard Dose) Single Dose
89620863|NCT02500680|Experimental|Group 4 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg (Standard Dose) Single Dose
89620864|NCT02500680|Active Comparator|Group 5A (Phase 1A)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 15µg (Standard Dose) Single Dose
89620865|NCT02500680|Active Comparator|Group 5B (Phase 1B)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
89620866|NCT02500680|Experimental|Group 6 (Phase 1B)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) Optimal Vaccine Dose from Phase 1A (9µg) (Standard Dose) Single Dose
89620867|NCT02500680|Experimental|Group 7A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose
89620868|NCT02500680|Active Comparator|Group 7B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
89620869|NCT02500680|Experimental|Group 8A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 15µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose (as 2 x 0.25 mL in each arm)
89620870|NCT02500680|Active Comparator|Group 8B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose (0.5 mL) in one arm and 0.5 mL of PBS in the other arm
89620871|NCT04496778|Active Comparator|low level laser plus exercise|acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
89620872|NCT04496778|Placebo Comparator|sham laser plus exercise|placebo acupuncture low level laser combined with nasal laser irradiation in addition to aerobic exercise 3 times per week for 3 months
89620873|NCT02500446|Active Comparator|Intensification|Oral dolutegravir 50 mg once daily for 8 weeks added to their current ART regimen.
89620874|NCT02500446|Placebo Comparator|Placebo|Oral placebo once daily for 8 weeks added to their current ART regimen.
89620875|NCT02500524|Experimental|10% Cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
89620876|NCT02500524|Active Comparator|1% permethrin creme rinse|1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.
89620877|NCT02508714|Active Comparator|Orsiro DES (Biotronik)|The ORSIRO hybrid coating DES (Biotronik, Switzerland) is a device which includes a modern, highly flexible, thin-strut stent platform, eluting sirolimus from a thin biodegradable BIO-lute coating grom PLLA (poly(L-lactic acid)) which is located mainly on the abluminal side.
89620878|NCT02508714|Active Comparator|RESOLUTE ONYX DES (Medtronic)|The RESOLUTE ONYX is a permanent polymer DES that uses a novel highly flexible metallic stent backbone with increased radiographic visibility eluting the drug zotarolimus from the BioLinx durable polymer coating. The stent platform uses corewire technology that allows the stent to have a denser core metal surrounded by outer layer of cobalt-chromium.
89620879|NCT02508558|Other|Measurements under different gravity states|motion perception and locomotor operation performance under different gravity states
89620880|NCT02503098|Experimental|Recovery Record adaptive smartphone application (RR-A)|Participants will have access to all Recovery Record standard functions and will additionally receive tailored, algorithm-generated content targeting cognitive distortions.
89620881|NCT02503098|Active Comparator|Recovery Record standard smartphone application (RR-S)|Participants will have access to all Recovery Record standard functions, including meal monitoring, motivational enhancement, social support, and coping skill strategies.
89620882|NCT04498962|Experimental|chronic stable angina|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with chronic stable angina will be treated by Danzhu Fuyuan Granule in addtion to routine care
89620883|NCT04498962|Experimental|Vascular Dementia|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Vascular Dementia will be treated by Danzhu Fuyuan Granule in addtion to routine care
89620884|NCT04498962|Experimental|Idiopathic Membranous Nephropathy|Experimental: the patient who have the syndrome of intermingled phlegm and blood stasis with Idiopathic Membranous Nephropathy will be treated by Danzhu Fuyuan Granule in addtion to routine care
89620885|NCT04498962|No Intervention|Healthy population|Comparator: Healthy population with no treatment
89620886|NCT02508402|Active Comparator|dexamethasone group|The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).
89620887|NCT02508402|Placebo Comparator|Placebo group|and the participants of placebo Group will not receive Dexamethasone or any other cervical ripening agent.II.two milliliters of normal saline given.
89620888|NCT02500134||Normal|Healthy volunteer control without ocular surface disease or prior ophthalmic surgery history
89620889|NCT02500212|Experimental|ENVARSUS tablets|"Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.~Envarsus® tablets will be administered orally once daily in the morning"
89620890|NCT02500212|Active Comparator|ADVAGRAF capsules|"Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths.~Advagraf® capsules will be administered orally once daily in the morning"
89620891|NCT01615120|Experimental|GTx-758 125mg|one GTx-758 tablet orally administered daily
89620892|NCT01615120|Experimental|GTx-758 250 mg|two GTx-758 tablets orally administered daily
89620893|NCT02500290||Acute coronary syndrome|
89620894|NCT04496934|Experimental|Intervention|Exercise intervention
89620895|NCT04496934|Active Comparator|Control|The control group is a waiting list group. The participants will receive exercise intervention after twelve weeks of treatment as usual.
89620896|NCT02508168|Experimental|Sequence I: AB|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by alogliptin 12.5 mg tablets and metformin 1000 mg tablets, orally, once, on Day 1 of Period 2.
89620897|NCT02508168|Experimental|Sequence II: BA|Alogliptin 12.5 mg tablets, orally and metformin 1000 mg tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 2.
89620898|NCT01616056|Experimental|Bandage Contact Lenses|Patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.
89620899|NCT02503176|Experimental|KCT-0809|
89620900|NCT02508246|Experimental|Treatment (WEE1 inhibitor MK-1, cisplatin, docetaxel, surgery)|Patients receive WEE1 inhibitor MK-1775 PO BID on days 2-4, 9-11, and 16-18, and day -7 prior to course 1, day 1 for PD assessment. Patients also receive cisplatin IV on days 1 (or up to two days after last dose of WEE1 inhibitor MK-1775 lead-in is completed), 8 (or 7 days after first chemotherapy dose), and 15, and docetaxel IV on days 1, 8, and 15. Patients experiencing progressive disease undergo surgical resection. Patients not deemed surgically resectable proceed to chemoradiation as clinically indicated. Patients experiencing stable disease or partial response may receive 2 additional courses of treatment every 28 days in the absence of disease progression or unacceptable toxicity.
89620901|NCT01617148|Experimental|Treatment with Aflibercept|Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
89620902|NCT02508090||Study Population|Participants who previously received 12 weeks of miravirsen monotherapy in Study SPC3649-207 will complete up to 36 months of safety and efficacy follow-up without investigational treatment.
89620903|NCT01618240||Long term ventilated subjects|Muscle Strength Measurement, ventilator
89620904|NCT03344406||Subjects with asthma|Subjects with moderate to severe asthma will be interviewed via telephone. Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
89620905|NCT02249338|Experimental|BIIL 284 BS|
89620906|NCT02249338|Placebo Comparator|Placebo|
89620907|NCT02503020|Active Comparator|Group A|Preterm infants formula A Pretarm infants were fed on formula with Arachidonic acid (0.6%) and Docosahexaenoic acid (0.3%)
89620908|NCT02503020|Active Comparator|Group B|Preterm infants formula B Pretarm infants were fed on formula with Arachidonic acid (0.3%) and Docosahexaenoic acid (0.3%)
89620909|NCT01618942|Experimental|male subjects|grouped by gender and applied pressure pain test
88988631|NCT06246604|Experimental|Screening|"Patients will receive an ultrasound screening for DVT between 48 to 96 hours after the admission to the intensive care. In case of negative ultrasound:~if the pharmacological thromboprophylaxis is NOT possible, ultrasound is repeated after 48-96 hours;~if the pharmacological thromboprophylaxis is possible, re-evaluation is warrant only in case of clinical changes.~In case of positive ultrasound:~if the DVT is proximal, it must be treated according to guidelines. Re-evaluation is warranted only in case of clinical changes;~if the DVT is distal and a full or intermediate anti-thrombotic treatment is possible, re-evaluation is warrant only in case of clinical changes;~if the DVT is distal and a full or intermediate anti-thrombotic treatment is NOT possible, the ultrasound is repeated after 48-96 hours."
88988632|NCT06246604|Active Comparator|Standard-of-care|Ultrasound examination are performed according to clinical risk of DVT
88988633|NCT06246591|Active Comparator|Extracorporeal Shockwave Therapy (Group A)|Patients of this group were invited to our department's outpatient clinics on a weekly basis, for a total of five sessions (5 weeks), lasting approximately 20 minutes each. Treatment energy and frequency were established following the recommendations and guidelines of the International Society for Medical Shockwave Treatment (ISMST).
88988634|NCT06246591|Active Comparator|Mesotherapy (Group B)|Patients in this group underwent mesotherapy treatment at our outpatient clinics with Thiocolchicoside fl 4mg/2ml and Mepivacaine fl 10mg/1ml, once a week, for a total of five sessions (5 weeks), lasting about 15 minutes each.
88988635|NCT06246513|Experimental|SRP-9003|Participants will receive a single intravenous (IV) infusion of SRP-9003.
88988636|NCT06246487|Experimental|Intervention|Occupational Therapy Intervention
88988637|NCT06246487|No Intervention|Control|No intervention
89620910|NCT01618942|Experimental|female subjects|grouped by gender and applied pressure pain test
89620911|NCT02499978|Experimental|DRV/COBI, DTG Immediate switch|DARUNAVIR/COBICISTAT (800mg/150MG), DOLUTEGRAVIR 50MG DAILY at randomization and follow through week 48.
89620912|NCT02499978|Active Comparator|DRV/COBI, DTG Delayed Switch|DARUNAVIR/COBICISTAT (800MG150MG), DOLUTEGRAVIR 50MG DAILY at week 24 and follow through week 48.
89620913|NCT02502942|Experimental|Untreated OSA Muscle Exercise Group|Patients who were previously diagnosed of obstructive sleep apnea (OSA) with apnea hypopnea index (AHI) > 10 events/hr and have previously failed or refused PAP therapy. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
89620914|NCT02502942|Experimental|PAP Therapy Muscle Exercise Group|OSA patients who are currently treated with PAP for their OSA (with AHI of previous sleep study > 10 events/hr). In this group, patients will learn and practice upper airway muscle exercise for six weeks.
89620915|NCT02502942|Experimental|Oral Appliance Muscle Exercise Group|OSA patients who are currently treated with an oral appliance with residual AHI > 10 events/hr. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
89620916|NCT02502942|Active Comparator|Normal Control Sham Exercise Group|Patients of untreated OSA group, PAP therapy group, and oral appliance group are randomized to upper airway muscle exercise versus sham exercise.
89620917|NCT01620190|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle formula)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89620918|NCT03121170|Experimental|ESWT during PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2bar and total 5000 frequencies approximately. The time is menstrual cycle first one and third day, and the therapy divide into two times.
89620919|NCT03121170|Experimental|ESWT before PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2 bar and total 5000 frequencies approximately. The time start from the 5th and 7th day before the estimated first day of menstrual cycle and all therapy time consuming need 15 minutes.
89620920|NCT03121170|Placebo Comparator|hot compress paste|In hot compress paste group , the women with primary dysmenorrhea stick the hot compress paste on their belly autonomously.
89620921|NCT04496856|Experimental|Collagen|Participants of this arm are going to consume 30 g of collagen peptides daily for 30 days
89620922|NCT04496856|Experimental|Whey Protein|Participants of this arm are going to consume 30 g of whey protein daily for 30 days
89620923|NCT04498884|Experimental|Rinsulin® mix 30/70|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
88988638|NCT06246474|No Intervention|control group (A)|Adolescents in control group (A) will received a designed physical therapy program for the treatment of thoracic kyphosis
88988639|NCT06246474|Experimental|group (B)|Adolescents in study group (B) will received the same designed physical therapy program for the control group in addition to Kinesio taping.
88988640|NCT06246461|Experimental|the control group: a total daily dose of 2,500 mg/m2|The control group was treated with capecitabine at a conventional dose: 1,250 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 2,500 mg/m2). Treatment was given for 2 weeks, followed by a 1 week of discontinuation, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
88988641|NCT06246461|Active Comparator|the medium-dose group: a total daily dose of 2,000 mg/m2|The medium-dose group was treated with medium-dose capecitabine: 1,000 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 2,000 mg/m2). Treatment was given for 2 weeks, followed by a 1 week of discontinuation, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
88988642|NCT06246461|Active Comparator|the low-dose group: a total daily dose of 1,500 mg/m2|The low-dose group was treated with low-dose capecitabine: 750 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 1,500 mg/m2). Treatment was given for 3 weeks per cycle, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
88988643|NCT06246448|Experimental|Robotic-assisted radical cholecystectomy|
88988644|NCT06246448|Active Comparator|Open radical cholecystectomy|
88988645|NCT06246435||Prediabetic group|The prediabetic group (HbA1c ≤ 6.5, n = 25)
89620924|NCT04498884|Active Comparator|Humulin® M3|Single subcutaneous administration of Insulin at a dose 0.4 IU / kg
89620925|NCT04498494||myocarditis|The diagnosis of acute myocarditis was confirmed by a recent history of gastrointestinal/upper respiratory tract infection and/or complaints of cardiac symptoms and increasing cardiac markers and/or presentation with a new abnormality of the 12-lead ECGcombined with at least one of the following: ⅰ) Active or borderline biopsy according to the Dallas criteria (13); ⅱ) positive infectious origin of ventricular dysfunction; ⅲ) delayed enhancement on cardiac MRI consistent with myocarditis; or ⅳ) serological tests, ECGs, ultrasonic cardiogram (UCG), coronary angiography and ventriculography to exclude acute myocardial infarction (AMI), stress cardiomyopathy, congenital heart disease, myocarditis secondary to sepsis, valve disease, hyperthyroidism, autoimmune disease and rheumatic fever
89620926|NCT04498494||fulminant myocarditis|In patients with acute myocarditis, a diagnosis of FM was determined upon identification of one or more of the following: Haemodynamic instability due to cardiogenic shock or arrhythmia; left ventricular dysfunction and low cardiac output syndrome requiring inotropes or mechanical circulatory support; mechanical ventilation; and/or cardiac arrest (CA)
88988646|NCT06246435||T2MD group|(HbA1c ≥ 6.5, n = 25).
88988647|NCT06246422|Experimental|group A|after careful hemostasis for the bleeding points in the liver bed received 500 mg of Tranexamic acid dissolved in 20 ml normal saline locally in the liver bed through the right port, then introduction of a piece of gauze to keep the drug in place for about 3 minutes and then remove it and inserting a drain and close it for one hour after finishing the operation.
88988648|NCT06246422|Experimental|group B|they also underwent the same procedure with routine care for hemostasis until there was no significant bleeding and then instillation of 20 ml normal saline in the gallbladder bed , then drain was inserted and closed for 1 hour the sameway as group A.
88988649|NCT06246409|Active Comparator|Arm 1: Existing patient instructions|
88988650|NCT06246409|Experimental|Arm 2: Modernized patient instructions|
88988651|NCT06246383|Active Comparator|QActin|Cucumber extract
89036826|NCT01808820|Experimental|Expansion Cohort: DC Vaccine/Lysate|Participants in this group will undergo leukapheresis within after standard of care surgical tumor resection. Leukapheresis will be used to obtain peripheral blood mononuclear cells (PBMC) from which the dendritic cells (DC) will be obtained. Retrieved DC will be used as a vaccine once weekly on Weeks 1-4 within 3 weeks from end of pheresis. Participants will also receive Imiquimod, which will be applied one evening prior to DC dose for 8 hours then for 8 hours each of the next two evenings. Participants will also receive Lysate of tumor administered every 4 weeks + 3 days on Weeks 8, 12, 16 and 28 (+ / - 3 days).
89036827|NCT05469386|Placebo Comparator|Placebo|Placebo capsule administered in the morning
89036828|NCT05469386|Experimental|Methylphenidate ER (.3 mg/kg dose)|Methylphenidate ER (.3 mg/kg dose)administered in the morning
89036829|NCT05469386|Active Comparator|General Classroom|General classroom procedures
89620927|NCT01621672|Experimental|Revlimid|Revlimid dosing will be in the morning at the same time each day
89620928|NCT01621672|No Intervention|No further treatment|No treatment control.
89620929|NCT02499822|Experimental|Nifedipine GITS 30 mg slow release|Nifedipine GITS 30 mg slow release in tablets.
89620930|NCT02499822|Experimental|Ramipril 10 mg|Ramipril 10 mg in tablets.
89620931|NCT01663012|Experimental|Drug: Etirinotecan pegol|145 mg/m2 dose
89620932|NCT02499744|Active Comparator|HHFNC|HHFNC is provided nasal cannula. Ventilator settings:fraction of inspired oxygen (FiO2):21-40%,flow:2-8(litre,L)/min,to maintain arterial blood hemoglobin oxygen saturation ( SaO2) at 90-95% The weaning process is left to the discretion of the attending physician.,when FiO2: 25%,flow:2(litre,L)/min.
89620933|NCT02499744|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP):6cm H2O,R:30 per minute .
89620934|NCT01704976|Experimental|Intervention|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (5 Hz, noise 4) - T1
89620935|NCT01704976|Sham Comparator|Sham group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (1 Hz, noise 1) - T1
89620936|NCT02502552||Inflammatory Bowel Disease|Inflammatory Bowel Disease patients followed in Saint-Etienne Hospital since 3 years or more. Blood specimen 3 years after a first blood specimen
89036830|NCT05469386|Experimental|Positive Behavior Support Classroom|Positive Behavior Support Classroom procedures
89036831|NCT05469386|Experimental|Academic accommodations|Academic accommodations are used during seat work and quiz
89036832|NCT01462890|Other|Control Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.
89036833|NCT01462890|Experimental|Research Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.
89620937|NCT02499510|Experimental|GoldenFlow stent|Titanium nitrite coated woven nitinol stent
89620938|NCT04496622|Experimental|Whole Body Vibration Technique|WBV training with the frequency of 16-25 Hz along with conventional treatment.
89620939|NCT04496622|Active Comparator|WBV Technique|WBV training with the frequency of 26-35 Hz along with conventional treatment.
89620940|NCT02499432|Experimental|Motivational Enhancement|Motivational Interviewing/Enhancement is a form of collaborative discussion for strengthening motivation and commitment to change.
88988652|NCT06246383|Placebo Comparator|placebo|Placebo capsule
88988653|NCT06246370||COPD group|patients with COPD aged 40 years and above.
89036834|NCT05469152|Experimental|ds-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically controlled capsule endoscopy (ds-MCE) first, followed by EGD within 48 hours.
89036835|NCT05469113|Experimental|Repaglinide - Period 1|Single dose of repaglinide administered orally.
89036836|NCT05469113|Experimental|Selpercatinib and repaglinide - Period 2|"Multiple doses of selpercatinib along with single dose of repaglinide administered orally.~There will be a 24-hour washout period between Period 1 and 2."
89533199|NCT05277571|Experimental|UCB1381 dosing regime 3 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
89533200|NCT05277571|Experimental|UCB1381 dosing regime 4 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
89533201|NCT05277571|Experimental|UCB1381 dosing regime 5 in Part A|Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
89533202|NCT05277571|Experimental|UCB1381 dosing regime 6 in Part A|Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
88988654|NCT06246370||control group|aged matced healty patients
88988655|NCT06246344||LCCRT|"Radiotherapy: The pelvic lymph node drainage area (CTV) is targeted with a dose of 45-50 Gy delivered in 25 fractions.~Concurrent Chemotherapy: During radiotherapy, concurrent administration of capecitabine at a dose of 825 mg/m2, twice daily.~Consolidation Chemotherapy Phase: On Day 1, two cycles of the CAPEOX regimen are administered (capecitabine 1.0 g/m2 po bid d1-14 + oxaliplatin 130 mg/m2, q3w). Initiated 7-10 days after completion of LCCRT.~Surgical Phase: Commencing on Day 1, the patient undergoes Total Mesorectal Excision (TME) following consolidation chemotherapy."
89533203|NCT05277571|Experimental|UCB1381 dosing regime 7 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
89533204|NCT05277571|Experimental|UCB1381 dosing regime 8 in Part A|Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
89533205|NCT05277571|Experimental|UCB1381 dosing regime 9 in Part B|Participants will be randomized to receive repeated doses UCB1381 intravenously (iv).
89533206|NCT05277571|Placebo Comparator|Placebo iv Arm Part A|Participants will be randomized to receive a single dose of placebo iv to maintain the blinding.
89620941|NCT02499432|No Intervention|Standard training|Training as usual
89620942|NCT02502474|Experimental|Patients undergoing a colonoscopy|Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin
89036837|NCT01259713|Experimental|Liposomal amphotericin B|Liposomal amphotericin B 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
89036838|NCT01259713|Placebo Comparator|Placebo|Placebo to match liposomal amphotericin B twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
89036839|NCT00594724|Experimental|1|
89620943|NCT02499276|Experimental|PSV, PAV, NAVA, Variable-PSV|This is a crossover study in which each patient will be ventilated in the following modes of mechanical ventilation: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilator Assist (NAVA), Proportional assist ventilation (NAVA) and variable Pressure Support Ventilation (Variable-PSV), in a randomised order.
89620944|NCT04496700|Experimental|Group 1 - Shooting test|All participants in this group were tested for shooting abilities before and after blood donation. No variation within the group.
89620945|NCT04496700|Experimental|Group 2 - VO2max|"All participants in this group were tested for physical abilities before and after blood donation. Method: Bruce protocol.~No variation of protocol within the group."
89620946|NCT04496700|Experimental|Group 3 - Feasability|"All participants in this group were tested for feasability before and after blood donation. Method: Hiking uphill with 20 kg backpack.~No variation of method within the group."
89620947|NCT04495140|Experimental|Oral [14C]PF-06882961, 50 mg|In this arm, a single oral dose of [14C]PF-06882961, 50 mg will be administered as a liquid formulation.
89620948|NCT04495140|Experimental|Oral PF-06882961 50 mg and intravenous [14C]PF-06882961 100 ug|In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of [14C]PF-06882961, 100 ug, will be administered via intravenous infusion.
89620949|NCT03343548|Active Comparator|Group I|magnesium group (Mg)
89620950|NCT03343548|Placebo Comparator|Group II|control group (C)
89620951|NCT02507934|Experimental|Lubricin|Lubricin 150 μg/ml eye drops solution
89620952|NCT02507934|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
89620953|NCT02234128|Experimental|EVLP Double Lung Group|Toronto EVLP System™ administered to double lungs.
89620954|NCT02234128|Experimental|EVLP Single Lung Group|Toronto EVLP System™ administered to single lungs.
89620955|NCT02234128|No Intervention|Control Group|Those patients receiving a single or double lung via conventional transplant.
89620956|NCT02504112||X-Ray PSI Group|Male or female patients, over 18 years old and with indication of total knee arthroplasty
89620957|NCT01622296|Active Comparator|Sodium Bicarbonate with Lidocaine|
89036840|NCT00622882|Active Comparator|ID|Patients receiving an early Infectious disease consultation ( within first 48 hours of a positive blood culture)
89620958|NCT01622296|Placebo Comparator|Lidocaine with no buffer|
89620959|NCT01705288|Active Comparator|Control Group (Standard Laparotomy)|Patients undergoing standard anesthesia and standard exploratory laparotomy. Treatment will be per your surgeon's routine standards.
89620960|NCT01705288|Experimental|Rapid Recovery Group|"Protocol for rapid recovery laparotomy procedure involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), post-operative use of non-steroidal anti-inflammatory drugs, early eating after surgery, early walking, and certain goals for discharge from the hospital."
89620961|NCT02507778|Other|biopsy|needle will be inserted before and after biopsy and will measure circulating tumor cells.
89036841|NCT00622882|No Intervention|NO ID|Includes those patients who do not receive an Infectious disease consultation in the first 48 hours
89620962|NCT01707238|Experimental|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
89620963|NCT01707238|Active Comparator|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
89620964|NCT02507622|Other|gas concentration|Gaz concentration of C02, CO and NH4, 3 exhaled in weightlessness and normal gravity.
89620965|NCT02507466|Experimental|Variable high-intensity Training|high intensity variable stepping exercise on a treadmill and overground
89620966|NCT02507466|Active Comparator|Variable low-intensity training|low intensity variable stepping exercise on a treadmill and overground
89620967|NCT02507466|Active Comparator|Constant High Intensity Training|high intensity constant (forward) stepping exercise on a treadmill and overground
89620968|NCT03343002|Experimental|fentanyl at 10-15 min before end of surgery|
89620969|NCT03343002|Active Comparator|fentanyl at end of surgery|
89620970|NCT03120936|Other|Main|Emtricitabine / Tenofovir Disoproxil Oral Tablet and PrEP support.
89036842|NCT01052727|Other|overnight stay group|Group of patients who rests at least one night in Hospital
89036843|NCT01052727|Other|day-care Group|Group of patients who is discharged tha same day of operation
89036844|NCT00622921|Other|1|Couples-based behavioral psychotherapy
89036845|NCT05469035|Experimental|Experimental|Nurses in the experimental group participated in mobile-based video learning.
89036846|NCT05469035|Active Comparator|Control|Nurses in the experimental group participated in face-to-face learning.
89036847|NCT02892526||Vital wounds|from abdominoplasty of alive persons
89036848|NCT02892526||Post-mortem wounds|from autopsy of deceased persons
89036849|NCT00594763||TS|Women with Turner syndrome
89036850|NCT00594802||CHART REVIEW ONLY|CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
89036851|NCT01259401|Experimental|SIP group|The Sleep Intervention Program group received a sleep education program based on behavioral principles, delivered in 4 individual sessions carried out within the Adult Day Health Care program.
89620971|NCT03121092|No Intervention|Discontinue ACEI or ARB|Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
89620972|NCT03121092|Active Comparator|Continue ACEI or ARB|Patients in this group will take an ACE or ARB on the day of surgery.
89620973|NCT02234752|Experimental|Galantamine ER, Memantine XR|Week 1, Galantamine ER 8 mg HS & Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS & Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS & Memantine XR 21 mg HS
89620974|NCT04496388|Experimental|Aerobic exercise|Aerobic exercise is lasting for nearly 50 minutes each time, including warm-up and stretching for 10 minutes after exercise.
89036852|NCT01259401|Active Comparator|Control group|The Control group received basic sleep education, delivered in 4 individual sessions carried out within the Adult Day Health Care
89620975|NCT04496388|Experimental|Aerobic exercise combined with resistance exercise|Aerobic exercise is lasting for nearly 20 minutes each time, and add resistance exercise for 20 minutes. Additional warm-up 10 minutes and stretching for 5 minutes.
89620976|NCT04496388|Experimental|Aerobic exercise combined with interval training|Aerobic exercise is lasting for nearly 20 minutes each time, and add moderal intensity interval training for 10 minutes. Additional warm-up 10 minutes and stretching for 15 minutes.
89620977|NCT04496388|Placebo Comparator|Placebo|No exercise intervention.
89620978|NCT02502084|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
89620979|NCT01664806|No Intervention|Coag mode 30 Watts Power|Elective laparoscopic cholecystectomy will be performed with 30 Watts power coag mode which is current standard of care.
89620980|NCT01664806|Experimental|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform Elective laparoscopic cholecystectomy. which is the experimental arm of the study's mode.
89620981|NCT02498886|Experimental|Iron deficient anaemic: IDA|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
89620982|NCT02498886|Experimental|Iron sufficient: non-IDA|"Women that are not anaemic or iron deficient.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
89620983|NCT02498886|Experimental|Iron deficient anaemic (IDA): IHAT new manufacture|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT new manufacture- iron hydroxide adipate tartrate: an analogue of natural food iron.~Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
89620984|NCT02499042|Experimental|Oxygen reduction|post-ROSC oxygen reduced to 2L per minute then delivered to maintain oxygen saturation 90-94% to hospital
89620985|NCT02499042|Active Comparator|Standard Care|post-ROSC oxygen maintained ≥10L per minute to hospital
89620986|NCT01665040|Experimental|Neurostimulation for chronic pain|Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.
89620987|NCT04494984|Active Comparator|Active|Subjects will receive a 1st intravenous dose of 4 mg/kg INM005 (Anti-SARS-CoV-2 hyperimmune equine immunoglobulin F[ab']2 fragments) and a 2nd intravenous dose of 4 mg/kg of INM005. Each dose will be separated by 48 h (± 2 h).
89620988|NCT04494984|Placebo Comparator|Placebo|Subjects will receive a 1st intravenous dose of Placebo and a 2nd intravenous dose of Placebo. Each dose will be separated by 48 h (± 2 h).
89620989|NCT01665508|Experimental|Nebivolol|Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
89620990|NCT02498808||Healthy controls|Staff or patients attending hospital or visitors attending with patients. They should not have vasculitis or inflammatory arthritis
89620991|NCT02498808||Early rheumatoid arthritis|Newly diagnosed patients with rheumatoid arthritis attending hospital, prior to use of biologic therapies
89620992|NCT02498808||New or relapsing ANCA vasculitis|Newly diagnosed or flaring patients with anti-neutrophil cytoplasm antibody associated systemic vasculitis attending hospital
89620993|NCT02498808||Newly diagnosed giant cell arteritis|Newly diagnosed patients with giant cell arteritis attending hospital
89620994|NCT02507544|Experimental|TRX-818|
89620995|NCT03344094||MS-ocrelizumab treated|ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start
89620996|NCT03344094||MS untreated|age- and sex-matched untreated MS controls
89620997|NCT03344094||Healthy control|age- and sex-matched untreated healthy controls
89620998|NCT03344094||MS interferon-treated|MS with ongoing interferon-beta therapy
89036853|NCT00536315||COPD|Patients with cough and/or shortness of breath who may have windpipe collapse.
89036854|NCT00536315||Healthy adults|Subjects without symptoms for comparison.
89036855|NCT00536315||Tracheomalacia|Patients with cough and/or shortness of breath who may have windpipe collapse.
89036856|NCT05471466|Active Comparator|Diathermy- Electrosurgical Unit Cutting Settings|One half of the neck incision in each participant was made using diathermy (electrosurgical unit cutting settings at 15 watts Blend One mode).
89036857|NCT05471466|Active Comparator|Scalpel- Surgical Blade|One half of the neck incision in each participant was made using a scalpel (size 10 surgical blade).
89036858|NCT00594841|Active Comparator|1|Conservative (nonoperative) management of the AC joint dislocation.
89036859|NCT00594841|Experimental|2|Operative fixation (i.e., ORIF) of the dislocation with a hook plate and screws.
89036860|NCT00594919||AKI group|Acute kidney injury group after cardiac surgery.
89036861|NCT00594919||NKF group|Normal kidney function group after cardiac surgery
89036862|NCT05468879|Experimental|Glimepiride 3 mg Tablet|Participants received Glimepiride 3 mg Tablet with 240 mL of 20% glucose solution
89036863|NCT05468879|Active Comparator|Amaryl® 3 mg tablet|Participants received Amaryl® 3 mg tablet (Glimepiride 3 mg) with 240 mL of 20% glucose solution
89620999|NCT03343392|Experimental|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
89036864|NCT04320433|Experimental|Experimental|Participants will undergo two trials visit (with a week of separation). During the visits they will ingest an oral glucose load solution (oral glucose tolerance test) and gas exchange will be measured over the following 3-hours. The glucose levels will be monitored through a Glucose meter in different time frames.
89036865|NCT05471388|Active Comparator|case|
89036866|NCT05471388|Active Comparator|control|
89036867|NCT04326907|Experimental|CAT injection group|After fistulectomy for complex anal fistula, CAT (harvested from abdominal subcutaneous adipose tissue by Coleman's procedure) was injected into the tissue surrounding the internal opening, and inside the perianal wound obtained after fistulectomy.
89036868|NCT04326907|No Intervention|No CAT injection group|Patients of this group were treated with anal fistulectomy without CAT injection.
89036869|NCT05468801|Experimental|Individualized Homeopathic Remedy plus Standard Pharmacologic Treatment|Each subject receives an individually selected homeopathic remedy (individualized homeopathic remedy) as an add on to the conventional standardized pharmacological treatment he/she is receiving prior and during study. Standardized pharmacological treatment will be monitored and approved at first hospital neurological visit and as a requirement needs to be unchanged within 3 months prior inclusion and throughout the study.
89036870|NCT05468801|Placebo Comparator|Placebo plus Standard Pharmacologic Treatment|Subjects receive an indistinguishable placebo plus the conventional standardized pharmacological treatment he/she is receiving prior and during study. Standardized pharmacological treatment will be monitored and approved at first hospital neurological visit and as a requirement needs to be unchanged within 3 months prior inclusion and throughout the study.
89036871|NCT04326985|Experimental|Autologous Mesenchymal Stem Cells Treatment (MSCs)|"The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.~The treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.~T0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
89621000|NCT03343392|Placebo Comparator|Placebo group|One hour before in-office bleaching patients received either placebo.
89621001|NCT03344016|No Intervention|Standard care follow-up group|Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.
89621002|NCT03344016|Active Comparator|Special care follow-up group|In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.
89621003|NCT03342924|Experimental|Flanker test and physical fitness test|Participants performed a computer-based Flanker Task measuring cognitive control and physical fitness tests: two-minute walk, vertical jump, one-minute curl-ups, and handgrip strength. Body composition variables included: body mass index, percent body fat, waist circumference, and sagittal abdominal height. General linear models were performed to evaluate impacts of physical fitness and body composition on cognition, adjusting for age and sex.
89621004|NCT02498496|Experimental|Magnesium Sulfate|Administration of a bolus dose of 2 g of MgSO4 in 100 mL of Normal Saline IV, in 20 min.
89621005|NCT02498496|Placebo Comparator|Placebo|Administration of a bolus dose of 100 mL of Normal Saline, in 20 min.
89621006|NCT02502708|Experimental|Group 1 (CLOSED)|"Core Regimen: Dose-escalation of indoximod, in combination with temozolomide, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
89621007|NCT02502708|Experimental|Group 2 (CLOSED)|"Expansion cohorts: Indoximod therapy at the pediatric recommended phase 2 dose (RP2D) determined by Group 1, in combination with temozolomide.~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
89621008|NCT02502708|Experimental|Group 3 (CLOSED)|"Dose-escalation of indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
89621009|NCT02502708|Experimental|Group 3b|"Indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with newly diagnosed treatment-naive diffuse intrinsic pontine glioma (DIPG).~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
89621010|NCT02502708|Experimental|Group 4|"Continued access to indoximod in combination with low-dose oral cyclophosphamide and etoposide for patients with progressive disease after treatment with indoximod plus temozolomide.~Indoximod will be administered at 32 mg/kg/dose divided twice daily.~Cyclophosphamide to be given at 2.5 mg/kg/dose daily~Etoposide to be given at 50 mg/m2/dose daily"
89621011|NCT02498574|Experimental|Group 1|Non-invasive brain stimulation protocol expected to improve performance, with cognitively challenging game
89621012|NCT02498574|Placebo Comparator|Group 2|Non-invasive brain stimulation protocol not expected to improve performance, with cognitively challenging game
89036872|NCT04326985|Active Comparator|Hyaluronic acid (HA)|"The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.~T0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
89036873|NCT00536393|Active Comparator|Doxorubicine|CHOP 8 courses every 21 days
89036874|NCT00536393|Experimental|Doxorubicine pegylated|CLOP 8 courses every 21 days
89036875|NCT04324684||Covid19 pneumonia with comorbidities|"Patients with pneumonia from Covid 19 with at least one of the following comorbidities:~Hypertension~Obesity and/or type 2 diabetes~Cardiovascular disease~Chronic obstructive lung disease"
89036876|NCT04324684||Covid2 pneumonia without comorbidities|Without any of the following comorbidities
89621013|NCT02728596|Active Comparator|Clinic group 1 (clinics with existing automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on existing automated system recommendations: CSF is recommended for drugs with high risk of FN; CSF is not recommended for drugs with low risk of FN.
89621014|NCT02728596|Active Comparator|Clinic group 2 (clinics with no automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on existing clinical practice guidelines.
89621015|NCT02728596|Experimental|Clinic group 3 (clinics with automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drugs with intermediate or high risk of FN; CSF is not recommended for drugs with low risk of FN.
89621016|NCT02728596|Experimental|Clinic group 4 (clinics with automated system for CSF prescribing)|CSF prescribing for patients taking anti-cancer drugs is based on automated system recommendations: CSF is recommended for drug with high risk of FN; CSF is not recommended for drugs with intermediate or low risk of FN.
89621017|NCT01707472|Experimental|Simtuzumab in HIV Patients|HIV-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
89621018|NCT01707472|Experimental|Simtuzumab in HCV Patients|HCV-infected participants will receive simtuzumab every 2 weeks for 24 weeks.
89621019|NCT01707472|Experimental|Simtuzumab in HIV/HCV Co-Infected Patients|HIV/HCV co-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
89621020|NCT01666210|Active Comparator|Dexamethasone Punctum Plug|Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
89621021|NCT01666210|Placebo Comparator|Placebo Vehicle Punctum Plug|Placebo punctum plug insertion
89621022|NCT01666912|Active Comparator|6 week postpartum contraceptive implant|randomized to receive contraceptive implant at normal 6 week postpartum visit
89621023|NCT01666912|Experimental|Immediate postpartum contraceptive implant|randomized to receive contraceptive implant prior to leaving the hospital postpartum
89621024|NCT03341988|Other|Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily|Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week
89036877|NCT00595387|Active Comparator|1|Participants receiving supportive psychotherapy
89621025|NCT02501850|Experimental|Group A|Type 2 diabetic patients whom were prescribed GLP-1R agonists by the endocrinologist, according to usual clinical practice (liraglutide, exenatide, lixisenatide). The intervention is the prescription of an GLP-1R agonist (liraglutide, exenatide, lixisenatide)
89621026|NCT02501850|Active Comparator|Group B|Type 2 diabetic patients whom were prescribed metformin and/or sulphonilurea, according to usual clinical practice.
89621027|NCT01709032|Experimental|Deferasirox and deferiprone|
89621028|NCT02498340|Experimental|Diet challenge|The patients will have a single blood test after dietetic challenge, they will be subjected to eat non- fava beans diet at doses of 10 -30 gm of 3 different types of non- fava beans( each one will be given once daily for 3 days).
89036878|NCT00595387|Experimental|2|Participants receiving cognitive behavioral therapy
89036879|NCT00595543|Active Comparator|1|
89036880|NCT00595543|Active Comparator|2|
89036881|NCT00595543|Active Comparator|3|
89036882|NCT05519098||Inclusion group|"Patients referred for colonoscopy:~≥18 years old~Consenting to participate~Exclusion criteria:~Endoscopists~Employment or family member employed at Augere Medical AS~Patients:~Severe comorbidity, NYHA III-IV~Pregnancy~Hospitalized patients~Active inflammatory bowel disease~Poor bowel preparation defined as Boston Bowel Preparation Score as ≤1 in any segment~Absence or unable to provide consent~Cecum not reached"
89621029|NCT01667536|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
89036883|NCT00595660|Active Comparator|1|Needle 21 for FNA
89036884|NCT00595660|Active Comparator|2|22 needle for FNA
89036885|NCT00595660|Active Comparator|3|23 needle for FNA
89036886|NCT00595660|Active Comparator|4|24 needle for FNA
89036887|NCT05504746|Experimental|SHEN26 capsule (SAD and FE part)|SHEN26 capsule 50mg, 200mg, 400mg, 800mg, and 1200mg dose groups
89036888|NCT05504746|Experimental|SHEN26 capsule (MAD part)|SHEN26 capsule 200mg, 400mg, and 600mg dose groups
89036889|NCT05504746|Placebo Comparator|SHEN26 placebo (SAD and FE part)|SHEN26 placebo 50mg, 200mg, 400mg, 800mg, and 1200mg dose groups
89036890|NCT05504746|Placebo Comparator|SHEN26 placebo (MAD part)|SHEN26 placebo 200mg, 400mg, and 600mg dose groups
89036891|NCT02892370|Experimental|SHR0302 fasted to fed|SHR0302 tablets (10 mg) administered on day 1 fasting, and day 7 with high fat, high calorie breakfast
89036892|NCT02892370|Experimental|SHR0302 fed to fasted|SHR0302 tablets (10 mg) administered on day 1 with high fat, high calorie breakfast, and day 7 fasting
89036893|NCT04326868|Active Comparator|Albendazole|ABZ (400mg)
89036894|NCT04326868|Experimental|Albendazole and Mebendazole|ABZ 400mg + 1 tablet of MBZ (500mg)
89036895|NCT04326868|Experimental|Albendazole and Pyrantel|ABZ (400mg) + Pyr (125 mg)
89036896|NCT00595738||Heart Failure Patients|Patients admitted with advanced heart failure for tailoring of heart failure therapy via placement of a pulmonary artery (PA) catheter. In our study, the patients will already have a PA catheter placed for clinical/treatment reasons when we approach them for the study.
89036897|NCT00595777|No Intervention|1. Comparison|The centres allocated to the comparison group will continue to provide usual care only.
89036898|NCT00595777|Experimental|2. Experimental|The EPAT package consists of an educational programme, which deals with the common barriers to effective cancer pain control and the bedside pain tool.
89036899|NCT00595816|Experimental|1|Active treatment: physical training and counselling
89036900|NCT00595855|Active Comparator|TE|trabeculectomy
89036901|NCT00595855|Experimental|DS|deep sclerectomy
89036902|NCT00595894||1 CLEAR participants - African Americans with early rheumatoid arthritis|CLEAR enrollees include African American patients with early rheumatoid arthritis, as defined using ACR criteria
89036903|NCT00595894||2 VARA participants - male veterans with established rheumatoid arthritis|VARA enrollees will include male veterans with established RA diagnosed using ACR criteria
89036904|NCT00595972|Experimental|A|patients will be treated by ECF regimen (epirubicin, cisplatin plus 5-FU) combined with endostar
89036905|NCT00596050|Active Comparator|ketamine and midazolam|ketamine and midazolam
89621030|NCT02496078|Active Comparator|Active dual arm|"Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 24 week and follow up to week 48"
89621031|NCT02496078|Placebo Comparator|Placebo arm|"Daclatasvir placebo in tablet form QD and Asunaprevir placebo in soft capsule form BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 36 week and follow up to week 60"
89621032|NCT01667848|Experimental|group B: Insufflation with warm gas|Insufflation with warmed, humidified carbon dioxide insufflation during laparoscopic cholecystectomy using the optitherm® device attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
89621033|NCT01667848|Experimental|group A: Insufflation with cold gas|group A: Insufflation with cold gas during laparoscopic cholecystectomy, the use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A
89621034|NCT02495922|Active Comparator|A1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
89621035|NCT02495922|Experimental|A2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
89621036|NCT02495922|Experimental|B1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab , 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
89621037|NCT02495922|Experimental|B2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
89621038|NCT01668628||Incident PD patients|First treatment for end stage of renal disease (ESRD) by any peritoneal dialysis modality within 30 days prior to or following enrollment (patients may be enrolled prior to commencing first treatment if there is clear indication that the treatment modality is continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dilaysis (APD) and they consent in advance to enter the study) and patients who don't have any experience of dialysis treatment before this study
89621039|NCT01668628||Prevalent PD patients|Prevalent peritoneal dialysis(PD) patients who are under peritoneal dialysis treatment more than 6 months
89621040|NCT01668628||Prevalent HD patients|Prevalent hemodialysis(HD) patients who are under hemodialysis treatment more than 6 months
89621041|NCT01669096|Experimental|GSK 692342 Group|Healthy male and female subjects, between and including 18 to 50 years of age, who received 2 doses of GSK 692342 vaccine administered intramuscularly in the deltoid region of the arm, at Days 0 and 30.
89036906|NCT00596050|Active Comparator|etomidate and fentanyl and lidocaine|etomidate and fentanyl and lidocaine
89036907|NCT05468684||Neck Pain-Associated Disorders|neck pain without an acceleration-deceleration mechanism
89036908|NCT05468684||Whiplash-Associated Disorders|neck pain resulting from a traumatic acceleration-deceleration mechanism and classified as WAD Grade I-III on the modified Quebec Task Force Scale
89036909|NCT02888899|Experimental|Standard treatment|
89036910|NCT02888899|Experimental|PTNS in addition to standard treatment|
89036911|NCT00596089||1|Men and women 60 years and older
89036912|NCT00596089||2|Men and women 20-30 years of age
89036913|NCT05470959|Other|ACTIVA bioactive|bioactive ionic resin composite
89036914|NCT05470959|Other|Riva LC|Resin-modifed glass ionomer
89036915|NCT00624091|Experimental|1|Early-surgery, within 48 hours from randomization
89036916|NCT00624091|Active Comparator|2|State-to-the-art group. Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
89036917|NCT00596128|No Intervention|1|Blood sugar monitoring and intervention as clinical routine, no SOP defined and implemented
89036918|NCT00596128|Experimental|2|Blood sugar monitoring after implementation of SOP
89036919|NCT00596206|Experimental|1|100 mg of leflunomide
89036920|NCT00596206|Active Comparator|2|20 mg of leflunomide
89036921|NCT00596245|Experimental|1|MT 400, naproxen sodium 550mg
89036922|NCT00596284|Experimental|CBT-AD|Participants will receive Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
89036923|NCT00596284|Active Comparator|EUC|EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a half-day Cognitive Behavior Workshop.
89036924|NCT05468528|Experimental|linear ablation group|The linear ablation is performed on the basis of Ω-type linear ablation. Further stepwise ablation of the left atrial anterior wall increases the blockage of the LA roof and the MVA isthmus. Ablation in CS or ethanol ablation of vein of Marshall. Also, epicardial ablation on the roof or rigid between LAA-LPVs may be applied if necessary.
89036925|NCT05468528|Other|PVI group|pulmonary vein isolation ablation alone
89036926|NCT05427448|Experimental|Prospective multisite clinical trial with consecutive recruitment.|Patients consulting in memory clinics from Montpellier, Nîmes, or Perpignan. CSF AD biomarkers performed for diagnostic purpose in clinical routine practice
89036927|NCT00624130|Experimental|Arm 1|
89036928|NCT00624130|Active Comparator|Arm 2|
89036929|NCT05468450|Active Comparator|Ultrasound-guided-foam sclerotherapy (UGFS)|Injection of Polidocanol foam into SSV
89036930|NCT05468450|Active Comparator|Endovenous Laser Ablation (EVLA)|Ablation of SSV using laser energy
89036931|NCT04686123|Experimental|Group A|Group A performed active Stretching of Pectoralis Minor (PMi) muscle along with the strengthening of Lower Trapezius muscle under the supervision of a physiotherapist
89036932|NCT04686123|Active Comparator|Group B|Group B performed active Stretching of the Pectoralis Minor (PMi) muscle only under the supervision of a physiotherapist.
89036933|NCT04320355|Experimental|Soft tissue manual therapy|The researcher student will place the gloves with the force sensor on the thumb of her right and left hand. She will evaluate the Caesarean section scar and identify the most rigid scar areas when compression is applied. On these identified areas, the researcher student will apply the manual therapy procedure described in the independent variable (compression + shear) section. This procedure will be applied to all identified rigid areas of the Caesarean section scar.This procedure will last 10 minutes (approximately 2 minutes per rigid area). After this time, the researcher-student will remove the force sensor and leave the room.
89036934|NCT00535860|Experimental|50 mcg|ViaDerm transdermal delivery
89036935|NCT00535860|Experimental|80 mcg|Add Via-Derm transdermal delivery
89621042|NCT01709422|Active Comparator|Propofol|both midazolam (1mg if aged <= 70 years or 0.5mg in age >70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.
89621043|NCT01709422|Active Comparator|Conventional|both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.
89621044|NCT01669642|Experimental|Ketamine|participants who get the ketamine sedation will be enrolled. there is no control or comparison group.
89621045|NCT01669720|Experimental|Aflibercept|Patients will be randomized 2:1, to receive Aflibercept,4mg/kg IV q2weeks until progression for a maximum of 2 years
89621046|NCT01669720|No Intervention|Observation|Patients will be randomized 2:1 to receive Aflibercept. Patients who are randomized to observation will be followed per the study table, but will receive no intervention.
89621047|NCT01670110|Active Comparator|Pasireotide LAR (SOM230)|Active Pasireotide LAR
89621048|NCT01670110|Placebo Comparator|placebo injection|
89621049|NCT01672996|Experimental|Arm 1 - Ioforminol 160mgI/mL|Single administration of Ioforminol 160mgI/mL given to the subject.
89621050|NCT01672996|Experimental|Arm 2 - Ioforminol 200mgI/mL|Given as a single administration to the subject
89621051|NCT01672996|Active Comparator|Arm 3 - Iopamidol 300mgI/mL|Given as a single administration to the subject
89621052|NCT01674478|Experimental|Microlipid with fish oil group|This group will be given early enteral lipid supplementation with Microlipid and fish oil.
89621053|NCT01674478|Active Comparator|Microlipid group|This group will be given early enteral lipid supplementation only with Microlipid.
89621054|NCT02245360|Experimental|Grass tablet 75,000 SQ-T|Grass tablet 75,000 Standardized Quality units Tablet (SQ-T)
89036936|NCT00535860|Active Comparator|20 mcg|Subcutaneous injection
89036937|NCT05388721||GDM group|Pregnant women with positive OGTT results at 24-28 gestational weeks
89036938|NCT05388721||Control group|Pregnant women with negative OGTT results at 24-28 gestational weeks, and had baseline data that matched those in the GDM group
89036939|NCT02892331|No Intervention|Control|This group does not change physical activity during the intervention period, but will receive exercise training after the study is complete
89036940|NCT02892331|Experimental|MOD-INT|The Moderate intensity exercise training (MOD-INT) group will exercise at a moderate aerobic exercise intensity for 24 weeks
89036941|NCT02892331|Experimental|HIGH-INT|High Intensity exercise training (HI-INT) group will exercise at a high aerobic intensity for 24 weeks
89036942|NCT00536549|Experimental|A|Guardina RT monitoring
89036943|NCT00536549|Active Comparator|B|
89036944|NCT04208074|Experimental|Exercise|Four months of muscle resistance training (exercise) designed to increase muscle mass and strength. The exercise protocol includes four different lifts with weights including, squats, bench press, dead lift and overhead press. The weights for each lift will be optimized for each participant and increased as the participant adapts to the exercise routine.
89036945|NCT05387668|Experimental|Part A: Japanese cohort|Three ascending dose levels of either BGB-23339 or placebo.
89036946|NCT05387668|Experimental|Part B: Caucasian cohort|One dose level of either BGB-23339 or placebo based on data collected in Part A.
89036947|NCT04207957|Other|IV|2 h IV infusion (Groups A/B)
89036948|NCT04207957|Other|oral (fasted)|30 mg tablets given after an overnight fast (Groups A/B)
89036949|NCT04207957|Other|oral (fed)|30 mg tablets given after a high fat breakfast (Groups A/B)
89036950|NCT04207957|Other|oral (intact tablet)|30 mg tablets (Group C)
89036951|NCT04207957|Other|oral (NG tube)|30 mg tablets in water via NG tube (Group C)
89036952|NCT05383339||Patients|Patients with autoimmune diseases, vasculitis and autoinflammatory diseases
89036953|NCT00535977|Experimental|1|Dietary intervention of ITC-enriched broccoli
89036954|NCT00535977|Experimental|2|Dietary intervention of frozen peas
89036955|NCT00596518|Experimental|PF-00734200|
89036956|NCT00596557|Experimental|Everolimus, Immunosupression|everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
89036957|NCT04326556|Experimental|Prospective cohort for etiological and prognostic purposes|
89036958|NCT00596596|Active Comparator|1|0,5 mg prucalopride
89036959|NCT00596596|Active Comparator|2|1 mg prucalopride
89036960|NCT00596596|Active Comparator|3|2 mg prucalopride
89621055|NCT02245360|Placebo Comparator|Placebo|Placebo
89621056|NCT02245516|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
89621057|NCT02245516|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|KPI-121 1.0% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
89621058|NCT01677286|Experimental|doxycycline 100 mg po bid x 12 months|Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
89621059|NCT02246062|No Intervention|Control group|in which the relative receive only conventional verbal information one day before the procedure at ward.
89621060|NCT02246062|Active Comparator|info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery at ward.
89036961|NCT00596596|Placebo Comparator|5|Placebo arm
89036962|NCT00596596|Active Comparator|4|4 mg prucalopride
89036963|NCT05468294|Experimental|Ph I: F16IL2 + Nivolumab|"Patients will receive a fixed dose of Nivolumab and the following increasing dose levels of F16IL2: 15, 30, 50 and 70 Mio IU.~Once the RD is established, 17 patients will receive a fixed dose of Nivolumab and F16IL2 at the RD, established during the Phase I part of the study."
89036964|NCT00596674|Experimental|Lifestyle Counts Intervention|A wellness intervention that includes 8 weeks of behavior change classes focused on acquiring the skills and knowledge to improve health behaviors (e.g., exercise, stress management), followed by 3 months of phone support.
89036965|NCT00596674|Placebo Comparator|Attention Countrol|8 weeks of general health classes followed by phone calls for 3 months
89036966|NCT00596713||1|Both genders aged 20 to 80 years and living in private households in the city of São Paulo. Pregnant or lactating women, people with physical or mental impairment and workers in night shifts are not part of the population of interest.
89036967|NCT00536588|Experimental|SCH 721015 with SCH 209702|
89036968|NCT00596791|Other|1 arm|Open-lable study with one arm.
89621061|NCT02246062|Active Comparator|smartphone group|in which the relative received only conventional verbal information one day before the procedure and the child received smartphone application immediately before entering the operating room
89621062|NCT02246062|Active Comparator|smartphone and info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery and the child received smartphone application immediately before entering the operating room.
89621063|NCT05147038|Experimental|Intervention group|Participants allocated into the intervention group will be coached for 12 weeks by a tele-coaching mobile App containing tips for PA increase and for number of steps recording (visual feedback for the patient).
89621064|NCT05147038|No Intervention|Control group|Participants in the control group will receive usual care (including regular visits) together with the educational information.
89621065|NCT01678846|Experimental|Good School Toolkit|Schools in the intervention arm will receive the Good Schools Toolkit materials and implementation support.
89036969|NCT05312866|Active Comparator|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
89036970|NCT05312866|Active Comparator|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
89621066|NCT01678846|No Intervention|Control|Schools in this arm will receive the Good Schools Toolkit materials and some implementation support after the end of the trial.
89621067|NCT02502630|Experimental|Treated with microwave ablation|Patients undergoing MWA for pulmonary metastases from colorectal cancer.
89621068|NCT04498260|Experimental|Local steroid-triamcinolone acetonide|Local steroid (triamcinolone acetonide) injection to the ulcer immediately after ESD. Total amount of injected triamcinolone is 100 mg.
89621069|NCT04498260|Active Comparator|Oral steroid-predonisolone|(predonisolone) administration three days after ESD. Predonisolone is administered over 8 weeks, started at 30 mg/day and tapered 30, 30, 25, 25, 20, 15, 10 and 5 every 7 days, totaling 8 weeks of treatment.
89621070|NCT05341336|Experimental|Surgical excision|complete surgical excision of the scalp AVMs after identifying feeding arteries, vein and high flew shunts to perform a complete devascularization of the AVM.
89036971|NCT05470803|Experimental|Cohort A: 03 doses Pfizer/Wyeth|Group 1: AstraZeneca/Fiocruz Group 2: Pfizer/Wyeth Group 3: Clover SCB-2019
89036972|NCT05470803|Experimental|Cohort B: 03 doses AstraZeneca/Fiocruz|Group 4: AstraZeneca/Fiocruz Group 5: Pfizer/Wyeth Group 6: Clover SCB-2019
89036973|NCT05470803|Experimental|Cohort C: 03 doses Sinovac/Butantan or 02 doses and 01 dose AstraZeneca/Fiocruz|Group 7: AstraZeneca/Fiocruz Group 8: Pfizer/Wyeth Group 9: Clover SCB-2019
89036974|NCT05470803|Experimental|Cohort D: 02 doses AstraZeneca/Fiocruz and 01 dose Alum/CpG adjuvanted 9 or 30 µg Clover SCB-2019|Group 10: Clover SCB-2019
89036975|NCT00622960|Experimental|High MUFA diet|Those subjects assigned to a high monounsaturated fat diet
89036976|NCT00622960|Active Comparator|High CHO diet|Those subjects assigned to a high carbohydrate diet
89057820|NCT04536311|Experimental|Paravertebral block in surgical stabilization of rib fractures under awake or appropriate sedation|patients receive internal fixation for multiple rib fractures using paravertebral nerve block anesthesia in awareness status and keep spontaneous breath
89621071|NCT01679314|Active Comparator|Active AlphaCore device|AlphaCore active stimulation treatment
89621072|NCT01679314|Sham Comparator|Sham AlphaCore device|AlphaCore sham device
89621073|NCT01680172|Experimental|Ketamine|Single dose of ketamine (0.5 mg/kg)
89621074|NCT01680172|Placebo Comparator|Placebo|Single dose of placebo
89036977|NCT05468255|Experimental|Metabolic|Metabolic: Participants will have their blood glucose levels measured via continuous glucose monitoring for 3 days while participating in their normal exercise routines (EX). Participants will also have their blood glucose levels measured for 3 days while not exercising (NOEX), following immediately by 3 days of a return to normal activity(REX). Participants will be randomized to participate in the EX or NOEX/REX phases first. The EX and NOEX/REX phases will be separated by at least 1 week
89036978|NCT05468255|Experimental|Vascular|Vascular: Participants will have their blood vessel health measured while performing their normal exercise routines (EX) and while undergoing 1, 3, 5 days of no exercise (NOEX) followed immediately by 1 and 3 days of return to exercise (REX).
89036979|NCT00596908||1|Subjects with Parkinsonian Tremor (PT)
89621075|NCT01680328|Other|Different injection speed and volume combinations|The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.
89621076|NCT02235064|Experimental|Sertraline|Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
89621077|NCT02235064|Placebo Comparator|Placebo|Identical appearing capsule daily containing color-matched cellulose only
89621078|NCT05710588|Experimental|M-DTT group|This group has motor-motor dual task training-balance related tasks as primary task (e.g. marching, stepping) and motor tasks as secondary task (e.g. touching wall, popping a fidget toy).
89621079|NCT05710588|Experimental|C-DTT group|This group has motor-cognitive dual-task training-balance related tasks as primary task (e.g. marching, stepping) and cognitive tasks as secondary task (e.g. repeating tongue twisters, counting backwards from 100).
89621080|NCT01680640|Active Comparator|Synbiotic|Fructo-oligosacharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis (BB-12) as minimum of 10 billion colony forming unit (CFU)/day (1 capsule a day).
89621081|NCT01680640|Placebo Comparator|Maltodextrin|4 grams of maltodextrin daily.
89621082|NCT02249806||PH target therapy|Patients receiving PH target therapy
89621083|NCT05710510|Active Comparator|Local Care + Model|Quarterly clinic visits with a local primary care provider
89621084|NCT05710510|Active Comparator|Team Care Model|An intensive group lifestyle intervention led by a lifestyle coach via Zoom, paired with quarterly clinic visits with a local primary care provider and the lifestyle coach, the coach joining via telemedicine.
89621085|NCT05710432|Experimental|Quasi-Isometric Neck Flexion|"On minimal mechanical ventilation support (unassisted/assisted spontaneous breathing) via tracheostomy.~Quasi-Isometric Neck Flexion will be performed during mechanical ventilation. Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction. 30% will be the target intensity level for neck flexion. The patient will perform 2 sets of 6-10 quasi-isometric neck flexions."
89621086|NCT05710432|Experimental|Inspiratory Muscle Training|Perform 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load). The training device will be set at 30% of the highest value of three MIP maneuvers. A two-minute rest period with MV support will be provided between each set.
89036980|NCT00596908||2|Subjects with non Parkinsonian Tremor (nPT)
89036981|NCT04326790|Experimental|Intervention|Colchicine, on top of standard treatment
89036982|NCT04326790|Active Comparator|Control|Standard treatment, including all medications recommedned by the National Public Health Organization
89036983|NCT05468177|Experimental|neoadjuvant chemotherapy|Cetuximab+ mFOLFOX+ Anti-PD-1+Surgery
89036984|NCT00596986|Active Comparator|AD|Antidepressant Duloxetine
89036985|NCT00596986|Active Comparator|PT|Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy
89036986|NCT00597025|Active Comparator|Group A|Center Hemodialysis patients
89036987|NCT00597025|Active Comparator|Group B|Center hemodialysis patients
89036988|NCT00597025|No Intervention|Group C|Center Hemodialysis Patients
89036989|NCT00597025|Active Comparator|Group D|Peritoneal dialysis patients
89621087|NCT02246608|Active Comparator|Routine NPWT Standard of Care|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, standard of care dressing will be placed.
89621088|NCT02246608|Experimental|NPWT Standard of Care plus Oasis wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, Oasis wound product will be applied in addition to standard of care dressing.
89621089|NCT02237092|Experimental|Measurement of IAP|The data obtained are in inches of water column were translated in millimeters of mercury.
89621090|NCT01681030|Experimental|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
89621091|NCT01681030|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
89621092|NCT01681030|Active Comparator|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
89621093|NCT01681810|Experimental|14Nitrogen sodium nitrite|sodium nitrite 40 mg three times a day for 12 weeks
89621094|NCT01683526|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy
89621095|NCT01683526|Active Comparator|Video laryngoscopy|Intubation will be done using video laryngoscopy
89621096|NCT02249416|Experimental|TPV/RTV low + ZDV|
89621097|NCT02249416|Experimental|TPV/RTV high + ZDV|
89621098|NCT01685242|Experimental|AC-170 0.24%|
89621099|NCT01685242|Placebo Comparator|AC-170 0%|
89621100|NCT01685320|Active Comparator|Direct laryngoscope|Includes cases in which the forces applied by Macintosh direct laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
89621101|NCT01685320|Active Comparator|Indirect laryngoscope|Includes cases in which the forces applied by GlideScope indirect laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
89621102|NCT04937296|Placebo Comparator|Usual care|
89621103|NCT04937296|Experimental|Physical activity|
89036990|NCT00597025|No Intervention|Group E|Peritoneal dialysis patients
89621104|NCT00708162|Experimental|Elvitegravir|"EVG 85 mg or 150 mg + RAL placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg; all other participants will receive EVG 150 mg."
89621105|NCT00708162|Active Comparator|Raltegravir|"RAL 800 mg (400 mg twice daily) + EVG placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving LPV/r or ATV/r as part of their background regimen in the Open-Label Phase will receive EVG 85 mg; all other participants will receive EVG 150 mg."
89621106|NCT04930042|Experimental|AVT04 45 mg SC|Test Product: AVT04 (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
89621107|NCT04930042|Active Comparator|EU Stelara 45 mg SC|Comparator ref product: EU Stelara (ustekinumab) Initial loading dose of 45 mg followed by 45 mg SC once every 12 weeks starting 4 weeks after the initial loading dose administered SC. Injected as subcutaneous in thigh and abdomen.
89621108|NCT04898920|Placebo Comparator|Control Group|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
89621109|NCT04898920|Experimental|Dexamethasone Group|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
89621110|NCT02249884|Experimental|Urea Dose A|Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.
89621111|NCT02249884|Experimental|Urea Dose B|Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.
89621112|NCT02249884|Experimental|Urea Dose C|Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.
89621113|NCT02249884|Experimental|Chamomile Dose A|Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.
89621114|NCT02249884|Experimental|Chamomile Dose B|Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.
89621115|NCT02249884|Experimental|Chamomile Dose C|Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.
89621116|NCT03342846|Active Comparator|High Frequency rTMS in PD|The first group received 20 Hz rTMS on M1 daily for 10 days 5 sessions every week.
89621117|NCT03342846|Active Comparator|Low Frequency rTMS in PD|The second group received 1 Hz rTMS on M1 daily for 10 days 5 sessions every week.
89621118|NCT01686646|Active Comparator|highest dose Paracetamol + caffeine|highest dose of Paracetamol and caffeine
89621119|NCT01686646|Active Comparator|low-dose Paracetamol + caffeine|lowest dose of Paracetamol and caffeine
89621120|NCT01686646|Active Comparator|high dose paracetamol|highest dose paracetamol
89621121|NCT01686646|Active Comparator|low dose paracetamol|lowest dose paracetamol
89621122|NCT02498262|Experimental|Virtual Reality Training System|
89621123|NCT02501772|Experimental|Sanyinjiao acupressor group|In addition to maintain current treatment included oral anti-hyperglycemia agent and ACEI(angiotensin-converting enzyme inhibitor ) or ARB, subjects should wear ankle band at Sanyinjiao point ( calf , ankle on the foot tip 3 inch ), with the thumb pressing daily five minutes later and carry more than four hours for 8 weeks
89621124|NCT02501772|Sham Comparator|Control Group|In the control group, ankle band was place as same as the those for the SA(Sanyinjiao acupressor) group, but was wearing at the acupoint of Sanyinjiao with anti- surface without pressure. It was applied four hours per day for 8 weeks
89621125|NCT02495688|Experimental|Regional anesthesia|Patients are anesthezised with local aneshtetics administered with ultrasound guidance in the nerval plexus of the arm.
89621126|NCT02495688|Active Comparator|General anesthesia|Patients are anesthezised with general anesthesia and orotrachial airway. Local anesthetics (Chirocaine 5 mg/ml, 10 ml) is administered in the surgical wound during surgery.
89621127|NCT01687036|Other|Cryoablation|Cryoablation
89621128|NCT02325856|Active Comparator|Study group|Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
89621129|NCT02325856|Placebo Comparator|Control group|Dry weight determined by clinical symptoms
89621130|NCT02495766|Experimental|Treatment A: XCEL-MC-ALPHA/Placebo|Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.
89621131|NCT02495766|Experimental|Treatment B: Placebo/XCEL-MC-ALPHA|Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6.
89036991|NCT04326517||Emphysematous pyelonephritis|This is a single-group cohort study. A sub-classification will be used in order to differentiate patients that did not require intensive care, the ones who admitted to intensive care and mortality.
89036992|NCT00536627|Experimental|1|Patients will receive 5 injections of DNA vaccine at weeks 0, 8, 16, 40, 44.
89621132|NCT01687114|Experimental|cranberry juice|27% cranberry juice
89621133|NCT03342768|Experimental|TID|Messages will be sent 1-2 times per week containing information that aims to denormalise the tobacco industry.
89621134|NCT03342768|Other|Sugar sweetened beverages|Messages will be sent 1-2 times per week containing information on the adverse health effects of sugar sweetened beverages.
89621135|NCT05709730||Women aged 26-80 with atypical glandular cell (AGC) cytology result|Women in the capital region of Sweden with AGC, a concomitant human papillomavirus (HPV) analysis, and a histopathology.
89621136|NCT04495920|Experimental|Test product|
89621137|NCT01687972|Active Comparator|Sutures|
89621138|NCT01687972|Active Comparator|Insorb Staples|
89621139|NCT02501382||Patients with NSTI treated with HBOT|NSTI definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection causing necrosis in subcutis, muscle and/or fascia.
89621140|NCT03342612|Experimental|Brain Magnetic Resonance Imaging (MRI)|Neuroimaging protocol to assess brain changes after minor head trauma and over the time.
89036993|NCT00536627|No Intervention|2|
89621141|NCT01688596|No Intervention|No Treatment|"The No Treatment group includes patients undergoing laparoscopic hysterectomy without local infiltration of bupivacaine."
89621142|NCT01688596|Active Comparator|Bupivacaine|"The Bupivacaine Arm includes all patients who will receive bupivacaine injection on their trocar sites after the laparoscopic hysterectomy is completed. Bupivacaine (0.25%) will be injected through the closed incisions ensuring subcutaneous tissue, fascia, muscle and pre-peritoneal space of the trocar incision sites are infiltrated. All incisions 8 mm and greater are injected with 10 cc while all incisions 5 mm or less are infiltrated with 5 cc."
89621143|NCT02495532|Active Comparator|Colon Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
89621144|NCT02495532|Active Comparator|Rectal Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
89621145|NCT02498184|Experimental|real acupuncture|traditional chinese acupuncture
89621146|NCT02498184|Sham Comparator|sham acupuncture|non effective acupuncture
89621147|NCT04869592|Experimental|Phase 1 low-dose group|
89621148|NCT04869592|Experimental|Phase 1 high-dose group|
89621149|NCT04869592|Placebo Comparator|Phase 1 placebo group|
89621150|NCT04869592|Experimental|Phase 2 low-dose group A|
89621151|NCT04869592|Experimental|Phase 2 low-dose group B|
89621152|NCT04869592|Experimental|Phase 2 low-dose group C|
89621153|NCT04869592|Experimental|Phase 2 low-dose group D|
89621154|NCT04869592|Experimental|Phase 2 high-dose group A|
89621155|NCT04869592|Experimental|Phase 2 high-dose group B|
89621156|NCT04869592|Experimental|Phase 2 high-dose group C|
89621157|NCT04869592|Experimental|Phase 2 high-dose group D|
89621158|NCT04869592|Placebo Comparator|Phase 2 placebo group A|
89621159|NCT04869592|Placebo Comparator|Phase 2 placebo group B|
89621160|NCT04869592|Placebo Comparator|Phase 2 placebo group C|
89621161|NCT04869592|Placebo Comparator|Phase 2 placebo group D|
89621162|NCT02498028||Cervical Fusion|patients with anterior cerivical decompression and fusion
89621163|NCT02498028||Cervical Disc Prostheses|patients with cervical total disc replacement
89621164|NCT02249962||Overall cohort: HIV+ women on Option B+ and their infants|Women (n=8000) visiting an antenatal clinic for care who will be followed prospectively for Malawi standard treatment outcomes and pregnancy outcomes as patients on Option B+
89621165|NCT02249962||Sub-cohort A: first HIV diagnosis|Women (n=300) who present to the antenatal care clinic and are diagnosed for the first time with HIV. These women will be started on Option B+ as anti-retroviral treatment, per Malawi Ministry of Health standard of care.
89621166|NCT02249962||Sub-cohort B: subsequent pregnancies failing 1st line ART|Women (n=150) who have failed first-line treatment (TDF/3TC/EFV) based on HIV RNA levels and CD4 count. These women will be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
89621167|NCT02249962||Sub-cohort C: subsequent pregnancies who default from 1st line|Women (n=150) who are HIV+ and have a subsequent pregnancy who have not been adherent to first-line (Option B+: TDF/3TC/EFV). These women will be re-initiated on first-line treatment for 3 months, then evaluated to assess whether continuation on first-line treatment is sufficient, or if they need to be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
89621168|NCT04495842|Experimental|Intervention|Participants receive an active essential oil blend to inhale for 15 minutes. The blend contains plant based oils sourced from flowers and citrus plants.
89621169|NCT04495842|Placebo Comparator|Control|Participants receive an inert comparison to inhale for 15 minutes.
89210973|NCT04017104||68Ga-DOTATOC PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 68Ga-DOTATOC PET/CT procedure.~The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
89621170|NCT03336996|Experimental|evaluation|To characterize and evaluate functional and anatomical changes of nerve fiber injuries after umbilical cord mesenchymal stem cells transplantation with BOLD drived-DTI
89621171|NCT03336996|Experimental|BOLD-fMRI and DTI|To determine the therapeutic efficiency of umbilical cord mesenchymal stem cells and also the utility of the integration of BOLD-fMRI and DTI.
89621172|NCT03336996|Experimental|correlate the imaging results|To correlate the imaging results with the electrophysiology outcomes
89210974|NCT04017104||18F-DCFPyL PET/CT Diagnostic Imaging|"Participants that have been chosen and consented to participate in the optional DWB PET/CT scan sub-study will undergo an extra 18F-DCFPyL PET/CT procedure.~The 18F-DCFPyL radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada."
89621173|NCT02495298|Experimental|Treatment Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
89621174|NCT02495298|Sham Comparator|Placebo Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Sham Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
89621175|NCT01690000|Active Comparator|Melatonin1|1 mg melatonin nightly
89621176|NCT01690000|Active Comparator|Melatonin3|3 mg melatonin given nightly
89621177|NCT01690000|Active Comparator|Placebo|Identical placebo given nightly
89621178|NCT02495220|Experimental|subtenon block Group (SB)|received SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
89621179|NCT02495220|Experimental|intravenous dexmedetomidine Group(IV)|received 1µ/kg IV dexmedetomidine after induction of anesthesia
89621180|NCT01690546|Experimental|BUP/VLNXT to VIVITROL|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
89621181|NCT02495376|Active Comparator|Group A|Group A participates in the first available MBSR course.
89210975|NCT04015206|Experimental|IPT-G+UCT|10 sessions of Group Interpersonal therapy added to pharmacotherapy + clinical management plus one individual session pre-group and one session pos-group
89621182|NCT02495376|Active Comparator|Group B|Group B waits 16 weeks before participating in the MBSR course.
89621183|NCT05709418|Experimental|Mathematics intervention|Low-performing children get targeted support with a scripted intervention
89621184|NCT05709418|No Intervention|Control group|Business as usual
89621185|NCT02498106|Active Comparator|nutritional supplement|2 Orthica Soft Multi Mini capsules and 1 Orthica Fish EPA Mini capsule per day; duration: 6 months
89621186|NCT02498106|Placebo Comparator|placebo|During 6 months one group receives 3 placebo supplements daily with identical look and feel to Orthica Soft Multi Mini and Orthica Fish EPA Mini
89621187|NCT03120390|Experimental|Group I (PCT)|Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
89621188|NCT03120390|Experimental|Group II (PAT)|Patients undergo supervised exercise sessions comprising of AE over 45-60 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
89621189|NCT03120390|Active Comparator|Group III (usual care)|Patients undergo usual care. Beginning 24 weeks, patients may undergo supervised exercise sessions comprising of AE and RE as in Group I.
89621190|NCT03276286|Experimental|Nativis Voyager|Nativis Voyager combined with SOC Radiotherapy and temozolomide
89621191|NCT03336918||Bipolar Disorder I or II Depressed|DSM-V Bipolar I or II Depressed treated with lithium
89621192|NCT03336918||Healthy Controls|Healthy Controls with no psychiatric history
89621193|NCT02494830|Experimental|ketamine 5 mg intravenous|
89621194|NCT02494830|Experimental|ketamine 10 mg oral|
89621195|NCT02494830|Experimental|ketamine 20 mg oral|
89621196|NCT02494830|Experimental|ketamine 40 mg oral|
89621197|NCT02494830|Experimental|ketamine 80 mg oral|
89621198|NCT03215836|Other|Obese Asthmatics|BMI >/= 30 and without metabolic syndrome
89621199|NCT03215836|Other|Obese Astmatics|BMI >/= 30 and with metabolic syndrome
89621200|NCT03215836|Other|Obese non-asthmatics|BMI >/= 30
89621201|NCT03215836|Other|Non - obese asthmatics|BMI: lean > 20; Normal >/= 20 to <25; overweight </= 25 to < 30;
89621202|NCT03341832|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
89621203|NCT03341832|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
89621204|NCT03341832|Placebo Comparator|Placebo|NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose
89621205|NCT05484180|Experimental|experimental group|As a nursing initiative to the experimental group in the research; Training and consultancy supported guided imagery application based on the health promotion model was applied.
89621206|NCT05484180|No Intervention|control group|No attempt will be made on individuals in the control group during the research process. After the research process is over; After the training booklet, Mp3 player loaded with directed imagery recording and exercise materials are delivered, guided imagery application based on the Health Promotion Model will be supported by training and counseling.
89621207|NCT02239744|Experimental|True air purification|One group of subjects used an intervention of true air purifiers placed in the center of the room.
89621208|NCT02239744|Sham Comparator|Sham air purification|This group of subjects used an intervention of sham air purifiers under the same conditions with true purifiers with the only difference being removal of the filter gauze in the sham purifiers.
89621209|NCT04351048|Experimental|SW|stepwise excavation
89621210|NCT04351048|Experimental|OneS|one step excavation
89621211|NCT03336840|Experimental|Metformin|
89621212|NCT03336840|Experimental|Probiotics|
89210976|NCT04015206|Active Comparator|Usual treatment (UCT)|Pharmacotherapy + Clinical management once a month
89210977|NCT04799223|Experimental|Group receiving the 4 designed foods|The experimental group consumes the 4 foods designed for the study and will follow healthy eating guidelines.
89210978|NCT04799223|Active Comparator|Group with no designed foods|The control group follows healthy eating guidelines.
89621213|NCT03336840|Experimental|Metformin and Probiotics|
89621214|NCT03336684|Experimental|Patient Education Group|Patients will be provided with disease education literature
89621215|NCT03336684|No Intervention|Normal Group|Patients will not be provided with disease education literature
89621216|NCT02497872|Experimental|Early Precut Sphincterectomy|Biliary stone removal using early precut: Patients enrolled in this arm received biliary drainage through a small incision on the papilla with an endoscopic needle-knife - a technique called precut sphincterotomy.
89621217|NCT02497872|Active Comparator|Pancreatic Duct Stent|Biliary stone removal using persistence of cannulation and a later pancreatic duct stent placement: Patients enrolled in this arm received conventional biliary drainage through persistent biliary cannulation. After completion of biliary drainage, a prophylactic pancreatic duct stent was placed.
89621218|NCT02497638|Experimental|Metformin and Atorvastatin|Atorvastatin 20 mg once daily until progression with one month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
89621219|NCT02497638|Placebo Comparator|Placebo|One placebo tablet (corresponding to atorvastatin) once daily until progression, with one month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
89621220|NCT02495064|Experimental|Mometasone Furoate Cream(MF)|"participants will be given conventional Chemoradiotherapy and MF.~MF Brief introduction:~Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.~Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.~It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."
89621221|NCT02495064|No Intervention|Chemoradiotherapy|conventional Chemoradiotherapy only
89621222|NCT02494908|Active Comparator|Healthy controls|Healthy controls with no known neurological disease matched for sex and age with the patients group
89621223|NCT02494908|Active Comparator|IPD patients|Men and women diagnosed with idiopathic parkinson's disease
89621224|NCT02494752|Experimental|Stem cell enriched|Fat graft will be enriched with ex vivo expanded stem cells
89621225|NCT02494752|Active Comparator|Non stem cell enriched|Fat graft will not be enriched with ex vivo expanded stem cells
89621226|NCT02494674|Experimental|Bite Counter tracking|Study participants will be asked to track their energy intake via a wearable device called the Bite Counter. Participants will attend weekly meetings to provide feedback on the Bite Counter.
89621227|NCT02493192|Active Comparator|Meperidine|Use pethidine and haloperidol injection as a pain relief.
89621228|NCT02493192|Experimental|birth ball|Use birth ball as a pain relief.
89621229|NCT02749084|Experimental|T reg DLI|"This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS.~The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.~The study is single center single arm open label and includes a DOSE ESCALATION phase followed by an EXTENDED PHASE with the MAXIMUM TOLERATED DOSE (MTD).~During the dose escalation phase each patient will receive three doses of purified donor T reg cells each administered intravenously 1 month apart. Dose levels of purified Tregs will be 5x10e5/kg, 1x10e6/kg and 2x10e6/kg, resulting in three doses of 1.7x10e5/kg, 3.3x10e5/kg and 6.6x10e5/kg, respectively.~In the dose escalation study at least 9 patients will be required depending on the occurrence of adverse events during the study).~Patients in the MTD study should be about 10, according to Fleming."
89621230|NCT03341754|Experimental|Group 1 (D/ChAd63-CA)|"(2-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A at 2 mg total (1 mg per construct) per dose as two 1 mL IM injections of the blended D-CA, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A boost, at a total dose of 1 x 1011 virus particles (vp) (5 x 1010 vp/construct) as a single IM injection of 0.65mL, using a needle and syringe.~Week 0 = Prime with D-CA Week 4 = Prime with D-CA Week 8 = Prime with D-CA Week 24 = Boost with ChAd63-CA Week 28 = Controlled Human Malaria Infection (CHMI)"
89621231|NCT03341754|Experimental|Group 2 (D/ChAd63-CAT)|"(3-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A + D-T at 3 mg total (1 mg per construct) per dose as two 1 mL intramuscular (IM) injections of the blended D-CAT, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A + ChAd63-T boost, at a total dose of 1.5 x 1011 vp (5 x 1010 vp/construct) as a single IM injection of 1.0mL, using a needle and syringe.~Week 0 = Prime with D-CAT Week 4 = Prime with D-CAT Week 8 = Prime with D-CAT Week 24 = Boost with ChAd63-CAT Week 28 = Controlled Human Malaria Infection (CHMI)"
89621232|NCT03341754|Active Comparator|Infectivity Control (IC)|"Subjects will be exposed to the bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.~Week 28 = Controlled Human Malaria Infection (CHMI)"
89621233|NCT05705752|Experimental|Balance|Balance training group.
89621234|NCT05705752|Active Comparator|Pilates|Pilates group.
89621235|NCT03341598|Active Comparator|CAF+R|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M- St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures will be placed to stabilize the flap in a coronal position 2 mm above the cementoenamel junction (CEJ), followed by interrupted sutures to close the releasing incisions.
89621236|NCT03341598|Experimental|CAF+R+MC|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M - St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Geistlich) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
89036994|NCT00597103||1|Prevalent patients who have been receiving more frequent dialysis.
89621237|NCT02497716|Experimental|Rivaroxaban|Single arm, open label study
89621238|NCT02238808|Experimental|Estradiol treatment|Estradiol 6 mg daily for 7-14 days
89621239|NCT02497794|Active Comparator|postoperative chew gum|The patients in the study group will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours.
89621240|NCT02497794|Placebo Comparator|without postoperative chew gum|The control group will be followed without chew gum.
89621241|NCT01483612|Experimental|Lifestyle counseling|
89621242|NCT01483612|No Intervention|control|
89621243|NCT02497560|Active Comparator|Treatment|all natural dietary supplement
89621244|NCT02497560|Other|Treatment + Omega-3s|all natural dietary supplement + omega-3s
89621245|NCT02497560|Placebo Comparator|Placebo|vegetable oil
89621246|NCT03336294|Other|Old group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
89036995|NCT00597103||2|Incident patients new to more frequent dialysis
89036996|NCT00597103||3|Patients who switch from one more frequent hemodialysis treatment regimen to another more frequent dialysis regimen.
89036997|NCT00597142|Experimental|1|
89036998|NCT02909595|Experimental|Balloon catheter group|Bile duct stones extraction was carried out with a balloon catheter.
89036999|NCT02909595|Active Comparator|Basket catheter group|Bile duct stones extraction was carried out with a basket catheter.
89037000|NCT04326712||Group 1|Unilateral transtibial amputees using conventinional manufactured socket
89037001|NCT04326712||Group 2|Unilateral transtibial amputees using 3D manufactured socket
89621247|NCT03336294|Other|Young group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
89621248|NCT02497326|Active Comparator|Polyfax & Lignocain gel or silvazine cream|Polyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash
89621249|NCT02497326|Experimental|Topical heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval."
89621250|NCT02497170|Other|Life style changes|Pre and post after education intervention Education program
89621251|NCT03341442|Experimental|No hip precautions|No hip precautions practiced after THA surgery
89621252|NCT03341442|No Intervention|Hip precautions|Hip precautions practiced per standard of care after THA surgery
89621253|NCT02245672|Experimental|MGR001|MGR001 administered two times per day by inhalation throughout the study
89621254|NCT02245672|Active Comparator|Advair Diskus|Advair Diskus administered two times per day by inhalation throughout the study
89621255|NCT02245672|Placebo Comparator|Placebo|Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study
89621256|NCT03336138|Active Comparator|AMA group|Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
89621257|NCT03336138|No Intervention|Control group|Patient with standard follow-up with no specific assistance for ambulatory patients
89621258|NCT03341286|Experimental|TK3|This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day
89621259|NCT03341286|Placebo Comparator|Placebo|Placebo orally, to be taken three times a day
89621260|NCT04500106||Participants With Nurse Support, Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, using video devices.
89621261|NCT04500106||Participants With Nurse Support, Not Using Video Devices|Participants treated with Levodopa Carbidopa Intestinal Gel (LCIG) in accordance with approved label who are provided AbbVie Duodopa Specialist (ADS) nurse support, not using video devices.
89621262|NCT03336060||Healthy Control|Age matched healthy subjects. Inclusion criteria for healthy controls are: male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication
89621263|NCT03336060||Subjects with ACL reconstruction|"Unilateral, primary anterior cruciate ligament tear and reconstruction (1 to 10 years ago); no serious concomitant injuries, e.g. unhappy triad); no kinesiophobia; symmetric single leg jump performance (>85 %); male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication"
89621264|NCT04461418|Active Comparator|Dexamethasone|Dose starting at 4 mg daily (for patients randomized to the Dexamethasone arm).
89621265|NCT04461418|Active Comparator|Prednisone|Dose starting at 25 mg/day (a calculation of equipotent steroid equivalencies will be used).
89621266|NCT02497092|Active Comparator|Slow angled injection|Slow and angled insertion of the needle through the sclera
89621267|NCT02497092|Active Comparator|Slow straight injection|Slow and straight insertion of the needle through the sclera
89037002|NCT04326595|Active Comparator|surgical termination|
89621268|NCT02497092|Active Comparator|Fast angled injection|fast and angled insertion of the needle through the sclera
89621269|NCT02497092|Active Comparator|Fast straight injection|fast and straight insertion of the needle through the sclera
89621270|NCT05667610|Experimental|Intervention group (immune-supportive diet)|"Immune-supportive diet (for 4 months) on top of peanut and/or nut free diet~Feasibility of adherence to the Immune-supportive diet (intervention group only) and dietary compliance by Likert scale after 2,5 and 4 months of dietary intervention (2x)"
89621271|NCT05667610|Active Comparator|Control group|- Peanut and/or nut free diet only
89621272|NCT02497014|Experimental|1 Stent|Patients who are going to receive 1 stent in the main vessel and the side vessel will be treated with kissing ballon inflation
89621273|NCT02497014|Experimental|2 Stents|Patients who are going to receive 2 stents in both vessels
89621274|NCT05654428|Experimental|Experimental Group|"55 patients~Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes~New Intervention:~Mckenzie Extension~Prone press-ups~Head life in prone~Prone on elbow~Prone on hands~Prone on pillow"
89621275|NCT05654428|Active Comparator|Control Group|"55 patients~Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes Standard treatment:~TENS (4-pole) + Hot pack for 15 minutes~New Intervention:~William Flexion~Single knee to chest~Double knee to chest~Straight Leg Raise~Bridging~Pelvic tilt"
89621276|NCT05641792|Experimental|CGM pre-, intra- and postoperatively|Patients will have a Dexcom G6 system placed on admission on outer part of the arm, glycaemia will be monitored for 10 consecutive days
89621277|NCT03335982|Other|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia. The feasibility, safety, success rate, and satisfaction with TET placement were evaluated for enteral nutrition or fecal microbiota transplantation.
89621278|NCT03335904|Placebo Comparator|Placebo|Participants will ingest microcrystalline cellulose by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
89621279|NCT03335904|Experimental|Losartan|Participants will ingest 50 mg of losartan, an angiotensin receptor blocker, by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
89037003|NCT04326595|Active Comparator|medical termination|
89210979|NCT00826904||Lean|Healthy, pregnant women with BMI of 20 - 26 kg/m2
89621280|NCT05233020|Experimental|Robotic|Fifteen patients undergo rVHR operation.
89621281|NCT05233020|Experimental|hybrid|Fifteen patients undergo hybrid operation.
89621282|NCT03335826|Experimental|Combined epidural-general anesthesia|Patients assigned to this group receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
89621283|NCT03335826|Active Comparator|General anesthesia|Patients assigned to this group receive general anesthesia and postoperative patient-controlled intravenous analgesia.
89621284|NCT02496858||Early-onset CAD|The anticipated 2000 young CAD patients who aged ≤45years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
89621285|NCT02496858||Late-onset CAD|The anticipated 2000 old CAD patients aged≥65years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
89621286|NCT02496858||Age-matched controls|The anticipated 2000 control subjects without obvious coronary stenosis aged≤45years or ≥65years will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
89621287|NCT03335748|Active Comparator|active control group|The program for the active control group is the same as for the experimental group, except that the degree of difficulty of the exercises remains low and invariable across trials, with three items needing to be recalled throughout.
89621288|NCT03335748|Experimental|the Cogmed program|12 exercises proposed in the Cogmed program. Eight of these target visuospatial WM and four target verbal WM. Eight exercises are preprogrammed for each session, for a total of 90 trials (Pearsons, 2014). The degree of difficulty of the trials increases as a function of the participant's performance. For each trial, the participant receives feedback on their performance.
89621289|NCT01711294|Active Comparator|19 G Flex Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)
89621290|NCT01711294|Active Comparator|22 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)
89621291|NCT01711294|Active Comparator|19 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)
89621292|NCT03340818|Experimental|Bone Marrow Concentrate|Patients in this group will receive injection of autologous bone marrow concentrate into the suspected painful intervertebral discs.
89621293|NCT03340818|Sham Comparator|Placebo Group|Patients in this group will receive an injection of normal saline dorsal to the transverse process. The bone marrow aspiration will be simulated for these patients.
89621294|NCT05622760|Experimental|Audiovisual information|Group of participants to whom the information is given through an audiovisual medium.
89621295|NCT05622760|Placebo Comparator|Written information|Group of participants to whom the information is given through the writing that is available on the website of the health organization.
89621296|NCT03340740|Experimental|Cetirizine|Cetirizine 10mg (10ml) (patients age 12-17) or cetirizine 5mg (5ml) (patients age 6-11) x 1 dose at beginning of course in emergency department.
89621297|NCT03340740|Placebo Comparator|Placebo|Placebo 10ml (patients age 12-17) or 5ml (patients age 6-11) x 1 dose at beginning of course in the emergency department.
89621298|NCT01711372|Placebo Comparator|Controls who played Groundskeeper game|Controls played a go/no go task on Sifteo cubes to asses for attentional capabilities.
89621299|NCT01711372|Active Comparator|Probands played groundskeeper game|Patients with ADHD played a go/no go task on Sifteo cubes to asses for attentional capabilities
89621300|NCT03340662|Experimental|CC-122 Alone under fasted conditions|Single oral dose of 3 mg CC-122 administered alone under fasted conditions
89621301|NCT03340662|Experimental|CC-122 plus Itraconazole|Single oral dose of 3 mg CC-122 alone and with multiple doses of itraconazole.
89621302|NCT03340662|Experimental|CC-122 plus Fluvoxamine|Single oral dose of 3 mg CC-122 alone and with multiple doses of fluvoxamine.
89621303|NCT03340662|Experimental|CC-122 plus Rifampin|Single oral dose of 3 mg CC-122 alone and with multiple doses of rifampin
89621304|NCT03342300|Experimental|Arm A|participants will recieve pegylated liposomal doxorubicin (50 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
89621305|NCT03342300|Placebo Comparator|Arm B|participants will recieve pirarubicin (60 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
89621306|NCT01711918|Experimental|Domperidone|Participants will received domperidone at a dose of 10mg given up to three times per day
89621307|NCT03120468|Experimental|Topiramate and N-Acetyl Cysteine|Drug: Topiramate and N-Acetyl Cysteine Other Name for Topiramate: Topamax
89621308|NCT03120468|Experimental|Topiramate and Placebo|Drug: Topiramate and Placebo Other Name for Topiramate: Topamax Other Name for Placebo: Sugar Pill
89621309|NCT02493270|Experimental|Adjunctive smoking cessation|non-surgical periodontal therapy and concurrent smoking cessation therapy
89621310|NCT01712230|Placebo Comparator|Placebo|Monthly placebo injections for 6 months
89037004|NCT00597181|Active Comparator|1|Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes
89037005|NCT00597181|Active Comparator|2|Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes
89621311|NCT01712230|Active Comparator|GnRH agonist|Monthly GnRH agonist injections for 6 months
89037006|NCT00597220|Experimental|1|Omega 3
89621312|NCT01712230|Active Comparator|GnRH agonist + exercise|Monthly GnRH agonist injections for 6 months plus supervised cardiovascular exercise intervention
89621313|NCT03335514||STEMI|The study population consists of 20 patients with ST-elevated acute myocardial infarction (STEMI,n = 20) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
89037007|NCT00597220|Placebo Comparator|2|
89621314|NCT03335514||NSTE-ACS|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTE-ACS,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
89621315|NCT03335514||SAP|The study population consists of 30 patients with stable angina pectoris (SAP, n = 30). The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies,chronic or acute infections, severe heart failure (NYHA class 3and 4) and advanced liver or renal diseases are excluded.
89621316|NCT03335514||CONTROL|20 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group
89621317|NCT01712776|Active Comparator|Vapocoolant (Pain Ease Medium Stream )|Application of Vapocoolant (Pain Ease Medium Stream) for 4-10 seconds onto venipuncture site.
89621318|NCT01712776|Placebo Comparator|Nature's Tears Sterile Water|Application of sterile water stream (nature's tears) for 4-10 seconds onto the venipuncture site.
89621319|NCT02496390|Placebo Comparator|Autologous|"Patients will be randomized to receive a fecal transplant using their own microbes/Feces (autologous - 9 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
89621320|NCT02496390|Active Comparator|Allogenic|"Patients will be randomized to receive a fecal transplant of feces/microbiome from the healthy donor (allogeneic - 12 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
89621321|NCT03342222|Experimental|PEEK Interference Screws|PEEK Interference Screws provided by Ruijin Hangzhou Martins Medical Equipment Co., Ltd.
89621322|NCT03342222|Active Comparator|Biosure PK interference screw|Biosure PK interference screw from Smith & Nephew plc.
89621323|NCT03340584|Experimental|The intervention group|The intervention group will be received the Nine Castle Net Format taping and the traditional rehabilitation throughout all hospitalization period.We will exchange the new taping for Every two days.
89621324|NCT03340584|Other|The control group|The control group will be received the traditional rehabilitation during the hospitalization period.The traditional rehabilitation included occupational therapy and physical therapy.
89621325|NCT03335436|Experimental|Gabapentin|Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
89621326|NCT03335436|Placebo Comparator|Placebo|Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
89621327|NCT02494284|Experimental|Short term dual therapy|
89621328|NCT02494284|Active Comparator|Long term dual therapy|
89621329|NCT01713400|Experimental|Ustekinumab|Ustekinumab, Tacrolimus and Sirolimus. Ustekinumab: 45 mg for adults who weight 100 kg or less; 90 mg for adults who weight greater than 100 kg. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
89621330|NCT01713400|Placebo Comparator|Placebo|Placebo, Tacrolimus, and Sirolimus. Placebo: Identical volume to that of ustekinumab. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
89621331|NCT03342066||A|Cariogram
89621332|NCT03342066||B|CAMBRA
89621333|NCT04226872|Experimental|Intervention|"The intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet."
89621334|NCT04226872|No Intervention|Control|"The control group will not receive the intervention (i.e. they will not access My Tools for Care - In Care). They will receive a copy of the Alzheimer Society's The Progression Of Alzheimer's Disease - Overview Booklet. Data collection for outcome variables will be the same as participants in the intervention group."
89621335|NCT02496312|Experimental|ECOCAPTURE|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
89621336|NCT03335358|Experimental|Positive Psychology Intervention|Participants complete baseline assessments and receive a 20min training on the positive psychology activities. They are instructed to engage in at least 2 positive psychology activities alone and at least 2 as a couple each week for 8 weeks. Self-administered activities include expressing gratitude, practicing acts of kindness, focusing on the positive, fostering relationships, working toward a goal, spirituality, savoring. Post-intervention and 3-month follow-up assessments are completed.
89621337|NCT03335358|Other|Waitlist control|Participants complete a baseline assessment and are waitlisted for 4-6 weeks. They then complete another assessment, receive the 20min training on activities, and then complete the 8-week self-administered intervention (same as the experimental arm). Post-intervention and 3-month follow up assessments are also completed.
89621338|NCT02248246|Other|Colectomy with Harmonic ACE®+7 Shears|Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection
89621339|NCT02496468||new-onset wheeze/asthma|children with inhaled or systemic corticosteroid-/leukotriene receptor antagonist-naïve wheeze/asthma, will undergo follow-up after initial recruitment
89621340|NCT02496468||wheeze/asthma under controller therapy|children with wheeze/asthma, already under controller (inhaled or systemic corticosteroids or leukotriene receptor antagonist) therapy, will undergo follow-up after initial recruitment
89621341|NCT02496468||healthy controls|healthy age- and sex-matched controls, will not undergo follow-up after initial recruitment
89621342|NCT03335280||Positive for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
89621343|NCT03335280||Negative for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
89621344|NCT04494828|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/ kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
89037008|NCT02892097|Active Comparator|Parietal tDCS plus RTP|Single session of bilateral parietal tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP).
89210980|NCT00826904||Obese|Healthy, obese pregnant women with BMI 30 - 38 kg/m2
89621345|NCT04494828|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
89621346|NCT01713868|Other|Safe Sleep Edu and Breastfeeding mHealth|Participants will receive Safe Sleep Nursery Education and Breastfeeding Mobile Health messaging
89621347|NCT01713868|Other|Breastfeeding Edu and Safe Sleep mHealth|Participants will receive the Breastfeeding Nursery Education and the Safe Sleep Mobile Health messaging
88988656|NCT06246344||MRIg-LCCRT|"Radiotherapy (SIB): Targeting the rectal tumor (GTVp) and regional metastatic lymph nodes (GTVn) with a dose of 60-65 Gy delivered in 25 fractions; the pelvic lymph node drainage area (CTV) receives a dose of 45-50 Gy delivered in 25 fractions.~Concurrent Chemotherapy: During radiotherapy, concurrent administration of capecitabine at a dose of 825 mg/m2, twice daily.~Consolidation Chemotherapy Phase: On Day 1, two cycles of the CAPEOX regimen are administered (capecitabine 1.0 g/m2 po bid d1-14 + oxaliplatin 130 mg/m2, q3w). Initiated 7-10 days after completion of LCCRT.~Surgical Phase: Commencing on Day 1, the patient undergoes Total Mesorectal Excision (TME) following consolidation chemotherapy."
89621348|NCT01713868|Other|Safe Sleep Edu and Safe Sleep mHealth|Participants will receive Safe Sleep Nursery Education and Safe Sleep Mobile Health messaging
89621349|NCT01713868|Other|Breastfeed Edu and Breastfeed mHealth|Participants will receive Breastfeeding Nursery Education and Breastfeeding Mobile Health messaging
89621350|NCT04494906|Experimental|Interactive stepping exercise group|Participants will execute interactive stepping exercise 2 times per week for 8 weeks (16 sessions).
89621351|NCT04494906|Active Comparator|Square stepping exercise group|Participants will execute square stepping exercise 2 times per week for 8 weeks (16 sessions).
89621352|NCT01714024|Experimental|Healthy Volunteers|Subjects who are non-diabetic, with no history of smoking within the past two years and no metabolic bone disease diagnosis.
89621353|NCT01714024|Experimental|Diabetic Subjects|Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin.
89621354|NCT01714024|Experimental|Osteopenic Subjects|Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates
89621355|NCT01714336|Placebo Comparator|placebo|Normal saline will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
89621356|NCT01714336|Active Comparator|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
89621357|NCT01714492||Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|subjects implanted with the Sigma Posterior Stabilizing Rotating Platform TKA including a polyethylene insert with 4 beads
88988657|NCT06246318|Experimental|virtual reality plus conventional occupational therapy|"Virtual reality will be given to the study group in addition to the conventional occupational therapy program.~Nintendo Wii Fit Plus will be used as the virtual reality method in the research."
88988658|NCT06246318|Other|conventional occupational therapy|This is a control group. Sensory integration and gross motor training approaches are used in the conventional occupational therapy program.
88988659|NCT06246305|Active Comparator|Conventional physical therapy|The conventional therapy rehabilitation program is divided into three phases: on-brace, off-brace, and active mobilization. The on-brace phase (post-op 0-6 weeks) mainly consists of low-intensity whole-body exercises with shoulder girdle, elbow, and hand mobilization exercises on the affected side. In this phase, exercises are done of three sets with 10 repetitions per day. The off-brace phase (post-op 6-9 weeks) consists of passive shoulder ROM exercises using an exercise stick and an early scapular stabilization exercise. The active mobilization phase (post-op 9-12 weeks) consists of both active and passive shoulder ROM , strengthening exercise with progressive resistance using TheraBand, and scapular stabilization exercises. During the off-brace and active mobilization phases, exercises are done of 3-5 sets of exercises with 10 repetitions per day.
88988660|NCT06246305|Experimental|Virtual reality (VR)|During the on-brace phase(0-6 weeks), participants in this group will use the program as performed in the control group. During the off-brace (6-9 weeks post-op) and active mobilization phases (9-12 weeks post-op), participants will use the Virtual Reality machine. This program includes warming and cooling periods with posterior, anterior and inferior capsule stretching and pectoral muscle stretching. Exercise training includes bilateral shoulder elevation, boxing, bowling and tennis games accompanied by avatar. Resistance training is progressed in the active mobilization phase using TheraBand.
89057821|NCT02217683|No Intervention|Young blood transfusion|The first group of patients (n=30) will be randomized to receive leukoreduced blood transfusion stored for less than 10 days
89621358|NCT01714804|Experimental|Prospective|Accell Evo3
89621359|NCT01716208|Experimental|Ofatumumab + Fresh Frozen Plasma|Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).
89621360|NCT00706992|Experimental|Arm I - Adj-4 A2 F5 cells|Patients receive anti-MART-1 F5 TCR-transduced peripheral blood lymphocytes (PBLs) intravenously (IV) over 20-30 minutes on day 0. 1 x 10e9 to 5 x 10e10 IV.
89621361|NCT00706992|Experimental|Arm II-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on days 0 and 30. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously.
89621362|NCT00706992|Experimental|Arm III-Adj-4 A2 F5 cells + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
89621363|NCT00706992|Experimental|Arm IV-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide+SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I, MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 as in arm II, and aldesleukin as in arm III. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
89621364|NCT00706992|Experimental|Arm V-Adj-4 A2 F5 cells + ALVAC MART-1:26-35(27L) Vaccine|Patients receive anti-MART-1 F5 TCR-transduced PBLs IV over 20-30 minutes on day 0, and ALVAC-MART-1 vaccine SC on days 0 and 14. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
89621365|NCT00706992|Experimental|Arm VI-Adj-4 A2 F5 cells + ALVAC MART-1 VAccine + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs and ALVAC-MART-1 vaccine as in arm V, and low-dose aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL)+ 125,000 IU/kg/day subcutaneously.
89621366|NCT00706992|Experimental|Arm VII-Adj-4 A2 ALVAC MART-1:26-35(27L) Vaccine|Patients receive ALVAC-MART-1 vaccine SC on days 0 and 14. ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
89621367|NCT02249728|Experimental|Absolute Bioavailability|IV PBT2 microtracer and oral PBT2 single dose
89037009|NCT02892097|Active Comparator|Primary motor cortex tDCS plus RTP|Single session of bilateral primary motor cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
89037010|NCT02892097|Sham Comparator|Sham tDCS plus RTP|Single session of sham tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
89037011|NCT00597259|Experimental|A|
89037012|NCT00597259|Active Comparator|B|Entecavir Alone
89037013|NCT05468060|Experimental|PA1010 5mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 5 mg of PA1010 tablets or 5mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
89621368|NCT02249728|Experimental|Radiolabelled AME|oral 14C PBT2
89621369|NCT03335202||cf patients at the cf centre Kiel|microbiome of cf patients at the cf centre Kiel will be analyzed and correlated to standard cf care.
89621370|NCT03340194||Systemic sclerosis patients|
89621371|NCT03335124|Experimental|Active substances|"Vitamin C: Vitamin C will be mixed as 1500 mg vitamin C in 50ml container, which will then be infused over 30 minutes to 1 hour. The bag will be labeled by the pharmacy as Vitamin C. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.~Hydrocortisone: Hydrocortisone will be mixed as 50 mg of Hydrocortisone in 50 ml of 0.9 % Sodium Chloride. Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.~Thiamine: Intravenous thiamine will be given in a dose of 200mg q 12 hourly for 4 days or until ICU discharge."
89621372|NCT03335124|Placebo Comparator|Control|Vitamin C placebo will consist of an identical container of 50cc normal saline (0.9% Sodium Chloride Injection) (but with no vitamin C) and will be labelled vitamin C. Placebo will be infused over 30-60 minutes as per the infusion instructions of the active vitamin. Hydrocortisone placebo will be provided in an identical 50 ml bag of 0.9% Sodium Chloride Injection. Placebo patients will receive a matching vial of 0.9% Sodium Chloride Injection.
89621373|NCT04072744||Participants|General Study Participants
89621374|NCT03340116||Pre-operative cohort|This cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 prior to any surgical intervention
89621375|NCT03340116||Post-operative cohort|This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.
89621376|NCT03340038|Active Comparator|Specialty Ward|Patients who have been randomized into receiving post-operative care at the Non-ICU Specialty ward (intervention) after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
89621377|NCT03340038|No Intervention|Intensive Care Unit (ICU)|Patients who have been randomized into receiving post-operative care at the intensive care unit after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
89621378|NCT03339960|Active Comparator|Robotic camera controlled|
89621379|NCT03339960|Active Comparator|Human camera controlled|
89621380|NCT02248558|Active Comparator|Conventional video|This arm will receive a one-minute conventional video promoting HIV test uptake.
89621381|NCT02248558|Experimental|Crowdsourced video|This arm will receive a one-minute crowdsourced video promoting HIV test uptake.
89621382|NCT03339882|Experimental|Remifemin intervention|Using Remifemin during LHRH-a treatment in breast cancer
89621383|NCT03339882|No Intervention|Control|No intervention during LHRH-a treatment in breast cancer
89621384|NCT03339804|Experimental|Chemotherapy|Infusion of doxorubicin and cyclophosphamide
89621385|NCT02248636|Experimental|Real discontinuation|This group is tapered off their previous cholinesterase inhibitor medication.
89621386|NCT02248636|Sham Comparator|Sham discontinuation|This group receives their previous cholinesterase inhibitor medication, but in in placebo form.
89621387|NCT02494362|Experimental|Experimental Group|Computer gaming hand exercise regimen.
89037014|NCT05468060|Experimental|PA1010 10mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 10mg of PA1010 tablets or 10mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
89037015|NCT05468060|Experimental|PA1010 20mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 20mg of PA1010 tablets or 20mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
89037016|NCT05468060|Experimental|PA1010 30mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 30mg of PA1010 tablets or 30mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
89037017|NCT05468060|Experimental|PA1010 45mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 45mg of PA1010 tablets or 45mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
89037018|NCT05468060|Experimental|PA1010 60mg|Ten subjects will be randomly assigned in a ratio of 4:1 to receive 60mg of PA1010 tablets or 60mg of PA1010 placebo tablets. They will be administered a single dose and observed for four days.
89037019|NCT05468060|Experimental|PA1010 10mg before and after meals|Ten subjects will be administered 10mg PA1010 after overnight fasting for 10 hours in the first cycle, and then will be administered 10mg PA1010 within 30 minutes after high-fat meal in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.
89210981|NCT04765449|Experimental|ARM A: Covid-19 Patients Receiving CTLs|Patients who have an HLA antigen in common with COVID-19 fighting T cells will receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells, and then if there are no serious side effects, the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested, and each patient will complete a 14 day monitoring period before the next patient can be treated.
89533207|NCT05277571|Placebo Comparator|Placebo sc Arm Part A|Participants will be randomized to receive a single dose of placebo sc to maintain the blinding.
89533208|NCT05277571|Placebo Comparator|Placebo iv Arm Part B|Participants will be randomized to receive repeated doses of placebo iv to maintain the blinding.
89533209|NCT05276050|Experimental|Study group|Participants in this group will receive active F8-coil delivered rTMS.
89533210|NCT05276050|Active Comparator|Active control group|Participants in this group will receive active H-coil delivered rTMS.
89533211|NCT05272046|Active Comparator|Monopolar Electrocautery tool|Patients randomized into this group will receive the standard of care monopolar tool for their POEM procedure.
89533212|NCT05272046|Experimental|Bipolar Electrocautery tool|Patients randomized into this group will receive the standard of care bipolar tool for their POEM procedure.
89533213|NCT05269355|Experimental|Unesbulin and Dacarbazine|Participants will receive unesbulin 300 milligrams (mg) tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/meter squared (m^2) intravenously (IV) once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
89533214|NCT05269355|Placebo Comparator|Placebo and Dacarbazine|Participants will receive placebo matching to unesbulin tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/m^2 IV once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
89533215|NCT05268614|Experimental|Chemo-radiotherapy|Participants will receive chemo-radiotherapy.
89533216|NCT05264974|Experimental|mRNA-nanoparticle (mRNA-NP) vaccine|
89533217|NCT05256810|Experimental|Part A: ALN-XDH|A single dose of ALN-XDH administered by subcutaneous (SC) injection.
89533218|NCT05256810|Placebo Comparator|Part A: Placebo|A single dose of placebo administered by SC injection.
89533219|NCT05256810|Experimental|Part B: ALN-XDH Single Dose|A single dose of ALN-XDH administered by SC injection.
89533220|NCT05256810|Experimental|Part B: ALN-XDH Multiple Dose|Multiple doses of ALN-XDH administered by SC injection.
89533221|NCT05256810|Placebo Comparator|Part B: Placebo|Multiple doses of placebo administered by SC injection.
89533222|NCT05256810|Experimental|Part C: ALN-XDH|A single dose of ALN-XDH administered by SC injection.
89533223|NCT05256810|Placebo Comparator|Part C: Placebo|A single dose of placebo administered by SC injection.
89533224|NCT05254379|Experimental|Transcranial Direct-Current Stimulation (tDCS)|Participants will be assigned to tDCS intervention. Starting Day 1 of EHVP-IOP, remote-based tDCS will be administered with a constant current intensity for 20 min per session for up to 10 sessions over 2 weeks (one session per day) using a Soterix 1x1 tDCS mini-CT Stimulator with headgear and saline-soaked surface sponge electrodes. Therapy sessions will be performed over Zoom. With the exception of day one when the session will occur on its own, the sessions will occur within one hour of the start of the daily therapy session.
89533225|NCT05251415||patients suffering from autoimmune disease|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity.
89533226|NCT05247580||Hospital staff caregivers|Necker - Enfants Malades hospital' nurses, nurses' aides, residents and, doctors of medicine.
89533227|NCT05237986||Cohort 1|Participants with relapsed/refractory leukemias or lymphomas, scheduled to receive CAR T-cell therapy.
89533228|NCT05237986||Cohort 2|Caregivers (informants)
89533229|NCT05233306||GTS patient group|Cohort of adult GTS patients, males and females, age range 18 to 50 years
89533230|NCT05233306||Control group|Cohort of healthy control subjects, males and females, age range 18 to 50 years
89533231|NCT05232253|Experimental|Neurogenic Bladder Patient|Patients with neurogenic bladder
89533232|NCT05218499|Experimental|Brigimadlin (BI 907828) low dose|Phase II
89533233|NCT05218499|Experimental|Brigimadlin (BI 907828) high dose|Phase II
89533234|NCT05218499|Experimental|Brigimadlin (BI 907828) arm|Phase III
89533235|NCT05218499|Active Comparator|Doxorubicin arm|Phase II/III
89533236|NCT05216042|Experimental|Experimental: Low NP Genotype Group|150 healthy adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
89533237|NCT05216042|Experimental|Active Comparator: High NP Genotype Group|50 healthy adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
89533238|NCT05200403|Experimental|Crisaborole 2%|Adult caregivers of children participants will be asked to apply a thin even-layer of Crisaborole (2%) twice daily for 2 weeks.
89533239|NCT05200403|Active Comparator|Vehicle Arm|Adult caregivers of children participants will be asked to apply a thin even-layer of vehicle treatment twice daily for 2 weeks.
89533240|NCT05200117||Nulliparous cohort|Cervical stiffness will be measured in the same subject sequentially between days and during the same day and at different gestational ages.
89533241|NCT05200117||Multiparous cohort|Cervical stiffness will be measured in the same subject sequentially between days and during the same day and at different gestational ages.
89533242|NCT05192382|Experimental|Paltusotine|
89533243|NCT05192382|Placebo Comparator|Placebo|
89037020|NCT05468060|Experimental|PA1010 10mg after and before meals|Ten subjects will be administered 10mg PA1010 within 30 minutes after the high-fat meal in the first cycle, and then will be administered 10mg PA1010 after overnight fasting 10 hours in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is 10 days.
89037021|NCT02892253|Experimental|NIR+ group|"Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND).~Parathyroid identification was done with the use of NIR (intervention group, NIR+ group)"
89037022|NCT02892253|No Intervention|NIR- group|Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only (no intervention group, NIR- group)
89037023|NCT05470764|Experimental|PERINDOPRES® TRIO (Test)|A single oral dose of the test product PERINDOPRES® TRIO 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets.
89037024|NCT05470764|Active Comparator|TRIPLIXAM® 10 mg /2.5 mg/10 mg|A single oral dose of the reference product TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets.
89037025|NCT00597298|Active Comparator|1|inspiratory muscle training program using a pressure threshold device
89037026|NCT00597298|Sham Comparator|2|
89037027|NCT04320550||abdominal pain|one group of children complaining of recurrent abdominal pain
89037028|NCT05271019|No Intervention|Control group: Conventional Rehabilitation Program|"Standard rehabilitation program for 3 months, starting in the early phase in the ICU. A daily session from monday to friday. It includes breathing and secretions management exercises, building upper and lower extremity range of motion. Exercise progression should gradually incorporate aerobic exercises (treadmill, cycloergometer and upper and lower limb strength exercises) and limb strength training.~Aerobic exercise at moderate intensity (no more than 3-4/10 on the modified Borg scale). Aerobic exercise starting with 20 minutes and gradually increasing up to 30 minutes.~Limb strength training from 1 to 3 sets of 8-10 repetitions at moderate intensity."
89037029|NCT05271019|Experimental|Experimental group: Conventional Rehabilitation Program + Inspiratory Muscle Training (IMT)|"Standard rehabilitation program for 3 months, starting in the early phase in the ICU. A daily session from monday to friday. It includes breathing and secretions management exercises, building upper and lower extremity range of motion. Exercise progression should gradually incorporate aerobic exercises (treadmill, cycloergometer and upper and lower limb strength exercises) and limb strength training.~Aerobic exercise at moderate intensity (no more than 3-4/10 on the modified Borg scale). Aerobic exercise starting with 20 minutes and gradually increasing up to 30 minutes.~Limb strength training from 1 to 3 sets of 8-10 repetitions at moderate intensity."
89037030|NCT04326634|Experimental|Controlled exercises Group|
89037031|NCT04326634|Experimental|Non controlled exercises Group|
89037032|NCT00597337|Experimental|1|Receiving FearNot
89037033|NCT00597337|No Intervention|2|Control: Treatment as usual (normal curriculum)
89037034|NCT00597415|Placebo Comparator|A 1|A 1=placebo
89621388|NCT03339648|Experimental|Professional Development Enhancement|"During the measurement period, this group will receive the intervention, described below:~Content using three of UF Lastinger Center's innovations for cost-effective teaching and learning - e-Content Clinics, Coaching, and Communities of Practice. Elements of the professional development model are as follows:~E-Content Clinics- Content Clinics are offered online using digital video technology.~Coaching- Coaching develops strong cadres of leaders that have profound expertise and substantial success in advancing teaching and learning outcomes. This approach uses existing personnel to reinforce and deepen learning through online professional development by embedding it in day-to-day activities.~Online Community of Practice- This scalable online platform allows users to create virtual communities of practice designed to strengthen the learning and collaboration network."
89621389|NCT03339648|Active Comparator|Control- Delayed Intervention|This arm will continue business as usual during the measurement period. They will receive the exact same intervention described above once data collection is complete.
89621390|NCT02248714|Experimental|Study arm|Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)
89621391|NCT02248714|No Intervention|Control arm|Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.
89037035|NCT00597415|Active Comparator|A 2|A 2=celecoxib
89037036|NCT00597454|Experimental|1|
89037037|NCT04686110|Other|Patients Amyotrophic Lateral Sclerosis|
89037038|NCT04686110|Other|Control subjects|
89037039|NCT00597532|Experimental|1|soy (soy protein supplementation 50 grams/day)
89037040|NCT00597532|Placebo Comparator|2|milk protein supplementation 50 grams/day
89037041|NCT00597610|Experimental|1|
89037042|NCT00597649|Experimental|1|Bicifadine 800 mg/day for a year
89037043|NCT00597649|Experimental|2|Bicifadine 1200 mg/day for a year
89621392|NCT02494128|Active Comparator|Intervention group|Education in group leadership
89621393|NCT02494128|No Intervention|Control group|This group fills in the questionnaire. No intervention given.
89621394|NCT03331224|Experimental|OTSC|Initial treatment with the OTSC for non-variceal upper GI-bleedings with high risk of recurrency.
89621395|NCT03331224|Active Comparator|Standard therapy|Endoscopic standard therapy (two techniques e.g. clip and injection)
89037044|NCT04686032|Experimental|Advanced Rehab Group|The experimental group will receive early physical therapy interventions including patient education, ambulation, in-bed exercises, deep breathing exercises, connective tissue manipulation and TENS during the first 3 post-operative days following abdominal hysterectomy
89037045|NCT04686032|Active Comparator|Early ambulation Group|Participants of this group will receive patient education and early ambulation during the first 3 post-operative days following abdominal hysterectomy
89037046|NCT00597688|Active Comparator|1|Chlorhexidine gel
89037047|NCT00597688|Placebo Comparator|2|Placebo gel
89037048|NCT00597844|Experimental|1|voice evaluation and fMRI prior to surgical rehabilitation of UVCP
89037049|NCT00597844|Other|2|Healthy volunteers-voice evaluation and fMRI
89621396|NCT03331146|Placebo Comparator|Control group|saline infusion will be administered after induction of general anesthesia
89621397|NCT03331146|Active Comparator|Sodium Nitrite|sodium nitrite will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
89621398|NCT02491866|Other|psychiatric patients|patients with schizophrenia, bipolar disorder or depression according DSM V criteria
89621399|NCT03331068||Patients with prostate cancer|online questionnaire of MAX-PC
89621400|NCT02491554|Active Comparator|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based DBS implantation in the thalamic/subthalamic region (Vim-cZI) starting as awake surgery with a brief general anesthesia for stimulator implantation at the end of surgery.
89621401|NCT02491554|Experimental|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided DBS implantation in the dentato-rubro-thalamic bundle (DRT) in general anesthesia.
89621402|NCT02491320|Experimental|Pre-treatment acupuncture + letrozole|A 16 week acupuncture pretreatment followed by letrozole(LE). Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. All subjects will be requested to use contraception during the 16 week acupuncture pretreatment. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks. After 16 weeks of acupuncture treatment, LE will start on day 2-3 after a spontaneous period or after a withdrawal bleeding after progestin administration. The subjects will be instructed to have intercourse on a regular basis during the cycles.
89621403|NCT02491320|Active Comparator|Letrozole|LE alone. LE will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. The subjects will be instructed to have intercourse on a regular basis during the cycles.
88988661|NCT06246292|Experimental|landmark guided ESPB technique|The ESPB was performed using the landmarks described by Vadera et al. (5). Before initiating the block procedure, the spinous process of the T4 vertebra and a point situated 3 cm to its side are marked at the appropriate level. The needle was inserted perpendicularly to the skin and advanced in all planes until it contacts the vertebra's transverse process. The depth at which the thoracic vertebra's transverse process lies from the skin can vary, ranging from 2 to 4 cm, contingent upon the individual's physique. The needle tip was positioned between the erector spinae muscle and the transverse process. The volume of local anesthetics was injected in this plane.
88988662|NCT06246292|Active Comparator|ultrasound-guided ESPB technique|The block was performed based on the original description by Forero et al. (2). A high-frequency linear transducer (MyLab 70 Xvision, Esaote SpA, Florence, Italy) was positioned in the parasagittal plane 2 cm lateral to the T4 vertebra. Once the transverse process and the overlying erector spinae muscle were visible on the ultrasound, the needle was introduced using the in-plane technique. The needle was inserted in the cranial-to-caudal direction until it reached the tip of the transverse process. Following a negative aspiration and a successful hydro dissection, the local anesthetic solution was injected beneath the erector spinae muscle's fascia.
88988663|NCT06246266|Experimental|Helfer Skin Tap Technique group|Mechanical stimulation given with the Helfer Skin Tap technique during intramuscular vaccine administration will distract the baby's attention.
88988664|NCT06246266|Experimental|ShotBlocker Technique group|"During intramuscular vaccine administration to babies, the injection ShotBlocker Technique will be applied using the ShotBlocker tool (a tool with a U appearance, with blunt but not pointed protrusions)."
88988665|NCT06246240|No Intervention|Control group|The Personal Information Form will be applied to the control group without any intervention and they will be asked to score the VAS Scale at the time the nausea begins and the retests at 60 and 120 minutes. After the interview with the pregnant women, all pregnant women will be called 24-48 hours later and data will be collected by questioning the 60th and 120th minute VAS scores of nausea severity.
88988666|NCT06246240|Experimental|Intervention group|After obtaining the consent of the pregnant women, the Personal Information Form and VAS scale were applied. The experimental group was asked to score the VAS scale as soon as nausea started and was practiced chewing vitamin C gum for 30-60 minutes. Pregnant women in the experimental group were asked to score the VAS scale at 60 and 120 minutes after chewing gum.
88988667|NCT06246214|Active Comparator|BlueLT|Participants with depressive and/or anxiety symptoms that will receive the interventional light (BlueLT)
88988668|NCT06246214|Sham Comparator|ControlLT|Participants with depressive and/or anxiety symptoms that will receive the placebo light (ControlLT)
88988669|NCT06246214|No Intervention|Healthy control|Participants without depressive and/or anxiety symptoms
88988670|NCT06246162|Experimental|Lipo-MIT combination regimen group|"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."
88988671|NCT06246149|Experimental|Tebentafusp|Participants will receive tebentafusp 20 mcg on week 1, 30 mcg on week 2, 68 mcg on week 3, and 68 mcg weekly thereafter for 6 months i.e., maximum 26 infusions.
88988672|NCT06246149|No Intervention|Observation|
88988673|NCT06246136|Active Comparator|Arm 1|ELIOS
88988674|NCT06246136|Active Comparator|Arm 2|iStent inject® W
88988675|NCT06246123||All Participants|Korean participants who are prescribed with Jyseleca (Filgotinib Maleate) tablet 100 mg and 200 mg per approved prescribing information of Filgotinib Maleate in the post marketing setting will be enrolled and observed for up to 24 weeks or until discontinuation of treatment due to AEs or any other reason, whichever occurs first.
88988676|NCT06246097||group 1|early loading of dental implants within a month
89621404|NCT03330990|Other|Entrectinib / Midazolam|
89621405|NCT03335046|Experimental|Intervention|The intervention arm will receive the home visit intervention, consisting of 2 visits to the home by a team consisting of a pediatric medical provider and a school teacher or school support staff member. This team will evaluate the child's home environment to assess for potential asthma triggers that may lead to school absenteeism, and provide strategies and material goods to help reduce those triggers.
89621406|NCT03335046|Other|Wait-List Control|The control group will receive standard interventions carried out by the school system for students at risk for chronic absenteeism. Following the study observation period, this control group will then receive the home visits performed for the intervention group.
89621407|NCT03330912|Experimental|Seat Height Intervention|"Randomly assigned 5 wheelchair seat heights ranging from very low (2 below) to very high (2 above) the lower leg length of the participant."
89621408|NCT03339336|Experimental|BIIB074 350 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 350 mg tablets orally BID Double-Blind Treatment Period.
89621409|NCT03339336|Experimental|BIIB074 200 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 200 mg tablets orally BID Double-Blind Treatment Period.
89621410|NCT03339336|Placebo Comparator|Placebo|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 placebo-matching tablets orally BID Double-Blind Treatment Period.
89621411|NCT01785875|Experimental|Etelcalcetide|Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.
89621412|NCT02496546|Experimental|LEO 32731 cream|Topical application
89621413|NCT02496546|Placebo Comparator|LEO 32731 cream vehicle|Topical application
89621414|NCT03334968||Patient group|Acute ischemic stroke patients
89621415|NCT03334968||Control group|Those served as control group
88988677|NCT06246097||group 2|delayed loading of dental implants within 3 months
88988678|NCT06246084|Experimental|Group A: Endocrine Therapy Education Intervention|"Participants will complete:~Baseline visit.~Educational video once a week for 6 weeks.~6-week survey.~3-month survey."
88988679|NCT06246084|No Intervention|Group B: Wait-List Control Group|"Participants will complete:~Baseline visit.~6-week survey.~3-month survey.~Access to intervention educational videos.~2-week post video survey."
88988680|NCT06246071|Experimental|TYK-00540|"Escalation stage: Multiple doses of TYK-00540 tablets as monotherapy for oral administration to find the maximum tolerated dose. The administration frequency will be twice daily (BID), every 28 days as a cycle.~Expansion stage: an optimal dose of TYK-00540 tablets for cohort expansion. The administration frequency will be twice daily (BID), every 28 days as a cycle."
88988681|NCT06246045|Experimental|Algorithm-driven|
88988682|NCT06246045|Active Comparator|PERT-driven|
88988683|NCT06246032|Experimental|Modified feeding Protocol|Prospective
88988684|NCT06246032|No Intervention|Current feeding Protocol|"Retrospective data will be collected from medical record of patients undergo the current feeding protocol as follow~Initiation of feeding (average):~8.7cc/kg (6-12cc/kg)~Advancement based on birthweight (average):~<750g: 20cc/kg/d (17-24cc/kg/d) 750-999g: 29cc/kg/d (25-34cc/kg/d) 1000-1249g: 22cc/kg/d (20-24cc/kg/d) 1250-1499g: 24cc/kg/d (21-25cc/kg/d) 1500-1749g: 20cc/kg/d (18-21cc/kg/d) 1750-2000g: 34cc/kg/d (32-36cc/kg/d)~Starting Human milk fortification when feed reach at 120cc/kg/d"
88988685|NCT06246006||Patients with suspected MPN|
88988686|NCT06245993||Diaphyseal femoral fracture treated children|
88988687|NCT06245967|Experimental|Experimental|True FSM (Concussion protocol) with symptom management medication
88988688|NCT06245967|Sham Comparator|Sham-control|Sham FSM (no protocol) with symptom management medication
88988689|NCT06245954|Experimental|Standardized training group|The bronchoscopists in this group will accept simulation training by means of simulators and extracorporeal lungs
88988690|NCT06245954|Other|Traditional teaching model group|The bronchoscopists in this group will accept traditional lectures, hands-on demonstrations and so on to learn TBLC
88988691|NCT06245941|Experimental|TQB3909 Tablets|TQB3909 Tablets, orally administered. 28 days as a treatment cycle.
88988692|NCT06245941|Experimental|TQ05105 Tablets combined with TQB3909 Tablets|TQ05105 Tablets combined with TQB3909 Tablets, orally administered. 28 days as a treatment cycle.
88988693|NCT06245928|Experimental|Experimental Group|The individuals in the experimental group will be trained with an individualized respiratory exercise device for 5 days a week for 8 weeks. The initial pressure load will be set to the resistance level corresponding to 40% of the maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurements. Participants will be asked to rest following 6 breathing cycles and repeat a total of 36 breathing cycles (6 sets) in each session. Participants will be able to practice both inspiratory and expiratory respiratory muscle training in one breathing cycle. Progression will be increased by 5-10% weekly, with the perceived exertion level being in the range of 4-6 according to the Modified Borg Scale. In addition, physical activity will be recommended.
88988694|NCT06245928|Active Comparator|Control Group|The individuals in the control group will be trained with Threshold® IMT + Threshold™ PEP training for 5 days a week for 8 weeks. Respiratory muscle training will be performed with Threshold® IMT and Threshold™ PEP devices. The training intensity will be set to 40% of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurements in the first week. Participants will be asked to perform 6 sets of 6 repetitions for inspiratory and expiratory muscle training separately for a total of 36 repetitions each. Progression will be increased by 5-10% weekly so that the perceived exertion level will be in the range of 4-6 according to the Modified Borg Scale. If the training threshold exceeds the upper-pressure limits of the Threshold® IMT + Threshold™ PEP devices, the training intensity will be continued at the highest limit. In addition, physical activity will be recommended.
88988695|NCT06245902|Experimental|Naltrexone and Acetaminophen|Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
89057822|NCT02217683|No Intervention|Old blood transfusion|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days
89621416|NCT03339102||Participants who received Humira®|Non-infectious intermediate, posterior, or panuveitis patients who received Humira®
89621417|NCT03330756|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
89621418|NCT03330756|Experimental|Laparoscopic Mini Gastric Bypass|laparoscopic Mini gastric bypass
89037050|NCT05467982|Experimental|Integrated Illness Management and Recovery (I-IMR) PLUS COVID-19 ENHANCEMENT:|In addition to the primary intervention (Integrated Illness Management and Recovery), participants received 3 additional COVID-19 related educational/skills training sessions provided individually, remotely by I-IMR Specialists.
89037051|NCT05467982|Experimental|Stanford Chronic Disease Self-Management Program (CDSMP) ONLY:|No additional COVID-19 intervention was provided to this group. These participants only received the primary disease management intervention (CDSMP)
89037052|NCT05470530|Active Comparator|IT group|Participants were received normal saline 2 mL intravenously with intrathecal injection of heavy bupivacaine 0.5% 2 mL (10mg) plus 0.5 mL (2mg) dexamethasone diluted in 0.5 ml of 0.9% saline, overall 3 ml volume intrathecally. The dose of 2mg of dexamethasone was demonstrated by Amer (2018) to be the least effective intrathecal dose.
89037053|NCT05470530|Active Comparator|IV group|Participants were received dexamethasone 2 mL (8mg) intravenously with intrathecal injection of heavy bupivacaine 0.5% 2 mL plus 1 mL of 0.9% saline
89037054|NCT00597922||1|2,000 women between the ages of 18 and 55 years who are hospitalized with a heart attack
89037055|NCT00597922||2|1,000 men between the ages of 18 and 55 years who are hospitalized with a heart attack
89037056|NCT00598000||1|Determine the impact, in terms of quality of life (QOL), of minimally invasive, video-assisted thoracic surgery (VATS)
89037057|NCT00598000||2|Determine the impact, in terms of quality of life (QOL), in traditional thoracotomy and anatomic lung resection in early stage lung cancer.
89037058|NCT02909517||Choroidal nevus|Requires distinction from melanoma through diagnostic testing (low-risk features)
89037059|NCT02909517||Choroidal indeterminate melanocytic lesion|Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features)
89037060|NCT02909517||Choroidal melanoma|Requires confirmation of diagnosis and evaluation for potential metatstases
89037061|NCT02909517||Suspected metastatic tumour|Requires identification of primary tumour (ie, primary tumour elsewhere)
89037062|NCT02909517||Locally treated ocular tumour|Requires followup to evaluate response to treatment and potential change or repeat therapy
89621419|NCT03330678|Experimental|Probiotic (VSL#3)|Probiotics will be given to women included in study arm
89037063|NCT00598117||1|Group 1 (newly diagnosed patients) Initial assessment → first post op visit → 6 and 12 months post surgery
89037064|NCT00598117||2|Group 2 (post-treatment patients) A one-time assessment will be conducted at least 18 months following treatment
89037065|NCT02891980|Experimental|Group 2|MVA-BN®-Filo Day 1, Ad26.ZEBOV Day 29 and MVA-BN®-Filo Day 366
89037066|NCT02891980|Experimental|Group 3|Ad26.ZEBOV Day 1, MVA-BN®-Filo Day 29 and MVA-BN®-Filo Day 366
89037067|NCT02891980|Experimental|Group 4|Ad26.ZEBOV Day 1, Ad26.ZEBOV Day 29
89037068|NCT02891980|Experimental|Group1|MVA-BN®-Filo Day 1 and MVA-BN®-Filo Day 29
89621420|NCT03330600|Experimental|aquatic physicotherapy group|For the experimental group, we will associate kinesiotherapy with immersion in water.
89621421|NCT03330600|Placebo Comparator|immersion group|The control group will be submitted to immersion in the water, contained in flexion with the towel and maintaining the same care as the experimental one.
89037069|NCT04130347||Pancreatic resection|
89037070|NCT04130347||Liver resection|
89037071|NCT04130347||HIPEC surgery|
89037072|NCT04130347||Gynecological debulking surgery|
89037073|NCT00536666|Other|1|Iron oligosaccharide
89037074|NCT04207762||PET/CT Diagnostic Imaging|Each subject will have a PET/CT scan, using 18F-AmBF3-TATE. 18F-AmBF3-TATE radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada.
89037075|NCT04128631||PET/CT|group of patients will do F-18FDG PET/CT scan after negative whole body scan with elevated serum thyroglobulin Antibody or Thyroglobulin levels.
89037076|NCT05467826|Experimental|Arm 1|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
89621422|NCT04576559|Experimental|Modified dental visual aids|
89037077|NCT05467826|Experimental|Arm 2|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
89037078|NCT04128241||Panel of Spanish consumers|A panel of Spanish consumers recruited from various audited and validated internet databases.
89037079|NCT00598156|Experimental|1|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
89037080|NCT00598156|Experimental|2|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression
89037081|NCT00598195|No Intervention|Ketamine Pharmacokinetics|The pharmacokinetic action of Ketamine used in Children having heart surgery.
89037082|NCT00598234|Active Comparator|1|Celecoxib (Celebrex)
89037083|NCT00598234|Placebo Comparator|2|Placebo
89037084|NCT04326205|Experimental|Dual-aided|active tDCS to the ipsilesional primary motor cortex (M1lesioned) followed by FES to the paretic hand during MT
89037085|NCT04326205|Active Comparator|FES-alone|sham tDCS to the M1lesioned followed by FES to the paretic hand during MT
89037086|NCT04326205|Active Comparator|tDCS-alone|active tDCS to the M1lesioned followed by sham FES to the paretic hand during MT
89037087|NCT04326205|Placebo Comparator|Dual-sham|sham tDCS to the M1lesioned followed by sham FES to the paretic hand during M
89037088|NCT00598429|Active Comparator|High dose|PGE1 300 ng/kg/min via nebulizer over a 72-hour period
89037089|NCT00598429|Active Comparator|Low dose|PGE1 150 ng/kg/min via nebulizer over a 72-hour period
89037090|NCT00598429|Placebo Comparator|Placebo|Normal saline, the diluent for the drug, via nebulizer over a 72-hour period
89037091|NCT05470452|Experimental|Physician AI-assisted diagnosis group|
89037092|NCT05470452|Sham Comparator|Physician Independent Diagnostic Group|
89037093|NCT00598546||1|
89037094|NCT00598624|Experimental|A|
89621423|NCT04576559|Active Comparator|Regular dental visual aids|
89621424|NCT03330522|Experimental|Intervention|"The active intervention is Love, Sex, & Choices, a 12-episode, online HIV prevention intervention video series accessed on study provided smartphones. Each episode is up to 20 minutes in length. Study participants receive one episode per week for 12 weeks on study provided smartphones."
89037095|NCT02891941||Mild Traumatic Brain Injury|This cohort will have sustained a closed head injury, defined as externally inflicted trauma without skull fracture within the last month.
89037096|NCT02891785|Experimental|ANtiPain intervention|ANtiPain is a cancer pain self-management support intervention administered by nurses in an intervention session while the patient is still hospitalized and via phone calls after discharge. ANtiPain is based on three key strategies: information, skill building and nurse coaching.
89621425|NCT03330522|Active Comparator|Control Comparison Group|The control comparison intervention is twelve messages in text that promote HIV prevention behaviors and open communication with male sex partners. Study participants receive one message per week for 12 weeks on study provided smartphones.
89621426|NCT03339024|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30:Self-administered intranasal spray as needed, max thrice daily"
89621427|NCT03339024|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
89621428|NCT06038526|Experimental|Prevention (canakinumab, bronchoscopy)|Patients undergo bronchoscopy over 30-60 minutes and receive canakinumab SC 60 minutes and 2 weeks after the initial bronchoscopy. Patients undergo an additional bronchoscopy on day 77. Patients undergo buccal, nasal, and blood sample collection and CO testing on study.
89621429|NCT06038461|Experimental|Surufatinib Combined With Temozolomide and S-1|"Patients will receive surufatinib combined with temozolomide and S-1 once every three weeks as the second-line treatment until disease progression or intolerable toxicity or patients withdrawal of consent.~Phase I: DLTs of surufatinib combined with temozolomide and S-1 will be evaluated based on NCI CTCAE v 5.0 in the first cycle."
89621430|NCT06038422|Experimental|GTP regimen treated patients|R/R HLH patients treated with GTP regimen
89621431|NCT06038409||Chronic Pain|The use of ketamine in chronic pain
89621432|NCT06038409||Depressive Disorders|The use of ketamine in depressive disorders
89621433|NCT06038409||Anxiety Disorders|The use of ketamine in anxiety disorders
89621434|NCT06038409||Chronic Condtions|The use of ketamine in chronic conditions
89621435|NCT06038383|Experimental|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that enrolled the intervention with VR during hemodialysis.
89037097|NCT02891785|No Intervention|standard care|Standard care will be described as part of the study.
89037098|NCT00536094|Experimental|1|Participants will receive cognitive behavioral therapy for anxiety that includes exposure
89621436|NCT06038383|Active Comparator|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that enrolled the intervention with SB during hemodialysis.
89621437|NCT06038383|Experimental|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that enrolled the intervention with SB during hemodialysis, after the period of washout.
89621438|NCT06038383|Active Comparator|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that enrolled the intervention with VR during hemodialysis, after the period of washout.
89621439|NCT06038370|Experimental|Self-induced cognitive trance|
89037099|NCT00536094|Active Comparator|2|Participants will receive treatment as usual as delivered by school-based clinicians
89037100|NCT05466344|Active Comparator|Herbst Group|Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the type IV Herbst appliance (mini plate anchored appliance). The age of patients will be (18-20y).
89037101|NCT05466344|Active Comparator|TFBC Group|Include ten young adult orthodontic patients who are treated by using fixed orthodontic appliances followed by the Twin Force Bite Corrector appliance (dentally anchored appliance). The age of patients will be (18-20y).
89037102|NCT02891746||Premature infants|premature infants ≤ 34 weeks of gestation
89037103|NCT02891746||Term infants|neonates ≥ 37 weeks gestation
89621440|NCT06038357|Experimental|CBITS|Cognitive Behavioral Intervention for Trauma in Schools (CBITS)
89621441|NCT06038357|Active Comparator|Treatment as usual (TAU+)|Enhanced Treatment as Usual means regular care in child welfare program and mental health care. They also receive feedback on their assessments and a treatment recommendation.
89621442|NCT06038279|Experimental|Arm 1 (SAD)- INI-2004 Dose Cohort 1|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
89037104|NCT00598741|Experimental|1|
89621443|NCT06038279|Experimental|Arm 2 (SAD)- INI-2004 Dose Cohort 2|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
89621444|NCT06038279|Experimental|Arm 3 (SAD)- INI-2004 Dose Cohort 3|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
89621445|NCT06038279|Experimental|Arm 4 (SAD)- INI-2004 Dose Cohort 4|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
89621446|NCT06038279|Placebo Comparator|Placebo|Healthy Participants will be enrolled and randomised to receive a single dose of INI-2004 or placebo intranasally (ratio 3:1 active: placebo).
89621447|NCT06038279|Experimental|Arm 1 (MAD) - INI-2004 Dose Cohort 1|Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.
89621448|NCT06038279|Experimental|Arm 2 (MAD) -INI-2004 Dose Cohort 2|Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.
89621449|NCT06038279|Experimental|Arm 3 (MAD) - INI-2004 Dose Cohort 3|Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.
89037105|NCT00598780||1|Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
89037106|NCT00598858|Experimental|Treatment (docetaxel and prednisone)|Patients receive docetaxel IV over 60 minutes on days 1 and 2 and prednisone PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89037107|NCT02909166|Active Comparator|aliskiren|Aliskiren 300 once a day (q.d)
89037108|NCT02909166|Placebo Comparator|placebo|Placebo once a day (q.d)
89037109|NCT05466305|Placebo Comparator|Maxillary complete denture reinforced by chrome cobalt alloy|Completely edentulous patients treated by maxillary complete denture reinforced by chrome cobalt alloy
89037110|NCT05466305|Experimental|Maxillary complete denture reinforced by gold plated chrome cobalt alloy|Completely edentulous patients treated by maxillary complete denture reinforced by gold plated chrome cobalt alloy
89037111|NCT00622999||All|All patients
89037112|NCT04207684|Experimental|Testosterone|Subjects receive a single-dose treatment. Urine samples will be collected until 5 days after administration (6 fractions: 0-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h post-administration).
89037113|NCT02909400|Experimental|Treatment A|Oral administration of 100 mg KH176 twice daily
89621450|NCT06038279|Placebo Comparator|Placebo (MAD)|Participants with allergic rhinitis will be enrolled and randomised (ratio 3:1 active:placebo) to receive INI-2004 or placebo intranasally once per week for a total of 4 weeks.
89621451|NCT06038097|Experimental|Early intervention arm|Radiofrequency Pallidotomy at earliest available date
89621452|NCT06038097|No Intervention|Delayed intervention arm|Radiofrequency pallidotomy offered at 12 weeks following agreeing to participate in the study
89621453|NCT06038084|Experimental|Bronpass Tab.|
89621454|NCT06038084|Active Comparator|Erdos capsule|
89621455|NCT06038058|Experimental|BRY812|
89621456|NCT06038019||Group 1|Patients with suspected or confirmed food allergy
89621457|NCT06038006|Experimental|Participants|The only arm containing participants of this study.
89621458|NCT06037954|Experimental|Open Door for Cancer (OD-C)|OD-C includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded.
89621459|NCT06037954|Active Comparator|Usual Care|Participants assigned to Usual Care (n=50) will receive standard care. MSK's current usual care for distress screening is that all patients are screened for distress when they initiate care at MSK. Additional distress screening is conducted based on the determination of the oncology team. In addition, patients are referred to social work, psychology, and/or psychiatry based on the judgment of the oncology team.
89621460|NCT06037941|Experimental|E-Nose Technology|Patients will undergo E-Nose testing at baseline (before any treatment is administered) and at three points after treatment (1, 3, and 6 months). Patients will undergo E-Nose testing in a presurgical or interventional radiology suite.
89621461|NCT06037902|Experimental|CPAP|patients will undergo simulation twice, with and without CPAP
89621462|NCT06037850|Experimental|Treatment|Randomized to Treatment
89621463|NCT06037850|Active Comparator|Control|Randomized to Control
89037114|NCT02909400|Placebo Comparator|Treatment B|Oral administration of matching placebo twice daily
89037115|NCT05604950||S group|underwent surgical treatment.
89037116|NCT05604950||NS group|underwent non-surgical treatment with RT and/or chemoradiotherapy.
89037117|NCT04321564||Nullipar pregnant women|
89621464|NCT06037837||Robotic surgeons|Participants will be robotic surgeons in urologic, gynecologic, colorectal, hepatobiliary, gastric, and thoracic surgery
89621465|NCT06037824|Experimental|Experimental Group|"This group received classic rehabilitation* + compressive cryotherapy~* classic rehabilitation include passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
89621466|NCT06037824|Active Comparator|Control Group|"This group received classic rehabilitation* + classic cryotherapy~*classic rehabilitation include passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
89621467|NCT06037785|Experimental|SPSM intervention|Heart rate self monitoring Online shock management modules
89037118|NCT04321564||multipar pregnant women|
89037119|NCT03135067|Experimental|Provision of multiple self-tests|Participants in intervention clusters will be given multiple HIV self-test kits, testing instructions, and advice to use their discretion when offering self-tests to selected sexual partners. Participants will be encouraged to offer self-tests primarily to current and potential partners with whom unprotected sex is likely. All participants will be encouraged to use condoms with sexual partners. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering self-tests to partners. Participants will have opportunities to obtain additional HIV self-test kits on a monthly basis.
89037120|NCT03135067|No Intervention|Referral vouchers for VCT|Participants will be given a multiple referral vouchers for HIV testing to distribute to their sexual partners. All participants will be encouraged to use condoms with sexual partners. These referral vouchers will encourage the partners to seek HIV counseling & testing services in local clinics. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering referral vouchers to partners. Participants will have opportunities to obtain additional referral vouchers on a monthly basis.
89037121|NCT00536133|Experimental|Zinc group|children with recurrent acute lower respiratory infections receiving zinc supplementation
89037122|NCT00536133|Placebo Comparator|Placebo group|children with recurrent acute lower respiratory infections receiving placebo syrup
89037123|NCT05603858||Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
89621468|NCT06037785|No Intervention|usual care|standard observation and post-ICD shock care at each clinic that includes ICD interrogations monitored in-person or via home monitor
89037124|NCT02909478|Experimental|Aprepitant arm|Aprepitant + Tropisetron
89037125|NCT02909478|Active Comparator|Control arm|Dexamethasone+ Tropisetron
89037126|NCT03005626|Experimental|Therapeutic education|Structured therapeutic education programs
89037127|NCT03005626|Active Comparator|Control group|standard outpatient follow-up
89037128|NCT00536211|Experimental|1|Exercise
89037129|NCT00536211|Active Comparator|2|Metformin
89037130|NCT02914873|Active Comparator|Current practice for active surveillance|In this arm, patients are monitored according to current practice for active surveillance at the trial centre. Repeat biopsies (and/or other examinations) and curative treatment are performed according to the urologist's judgement.
89037131|NCT02914873|Experimental|Standardized triggers for treatment|In this arm, patients are monitored according to a standardized active surveillance protocol with specific triggers for treatment. Repeat biopsies and curative treatment are only initiated if/when specific criteria are fulfilled.
89037132|NCT00624208|Active Comparator|1|Intravenous injection of droperidol 20 mcg.kg-1 and saline (group 1)
89037133|NCT00624208|Active Comparator|2|Intravenous injection of ondansetron 0.1 mg.kg-1 and saline (group 2
89037134|NCT00624208|Active Comparator|3|Intravenous injection of droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1 (group 3)
89037135|NCT00624208|Placebo Comparator|4|Intravenous injection of saline and saline (group 4)
89037136|NCT00624247|Other|Immediate|Individuals assigned to be approached for routine HIV testing immediately upon admission to the jail.
89037137|NCT00624247|Other|Following Day|Individuals assigned to be approached for routine HIV testing the day following admission to the jail.
89037138|NCT00624247|Other|Delayed|Individuals assigned to be approached for routine HIV testing several days following admission to the jail.
89037139|NCT00536289|Active Comparator|1|Sharp needles
89037140|NCT00536289|Experimental|2|Blunt tipped needles
89621469|NCT06037772|Experimental|Subcutaneous injection practice game|After the subcutaneous injection was explained to the experimental group, the digital game developed for subcutaneous injection was explained and they were allowed to play the game for a week. Afterwards, the experimental group was shown the subcutaneous injection application on a low-reality model of the abdomen, and the students were allowed to practice the skill.
89621470|NCT06037772|Active Comparator|Traditional education|The students in the control group were given the traditional education method (subcutaneous injection application on a low-reality abdominal model after the completion of the theoretical course on the subject of subcutaneous injection).
89621471|NCT06037655|Experimental|Experimental|NeoAdjuvant Therapy with Adebrelimab plus Mecapegfilgrastim and Gemcitabine/cisplatin followed by the operation
89621472|NCT06037642|Experimental|Intervention group|
89621473|NCT06037642|Active Comparator|Control group|
89621474|NCT06037629||Preterm neonates in intensive care|Preterm neonates born <36 completed weeks of gestation with postmenstrual age <36 weeks
89621475|NCT06037577|Experimental|Anti-human CCL24 monoclonal antibody (CM-101)|Single 5 mg/kg of CM-101, Subcutaneous administration
89621476|NCT06037577|Placebo Comparator|Placebo|Placebo : Subcutaneous administration
89621477|NCT06037551|Experimental|Subject glucometer measurement|Blood glucose measurement BGM for personal use
89621478|NCT06037538|Experimental|Subject glucometer measurement|Blood glucose measurement BGM for personal use
89621479|NCT06037512|Experimental|Subject glucometer measurement|Blood glucose measurement BGM for personal use
89621480|NCT06037499|Experimental|Subject glucometer measurement|
89621481|NCT06037486|Experimental|Subject glucometer measurement|
89621482|NCT06037473||growth hormone deficiency(GHD)|Growth hormone deficiency (GHD) is a rare and treatable condition that causes short height in children and metabolic issues in adults.
89621483|NCT06037473||Idiopathic short stature (ISS)|Idiopathic short stature is a condition in which the height of the individual is more than 2 SD below the corresponding mean height for a given age, sex and population, in whom no identifiable disorder is present.
89037141|NCT05601791|Active Comparator|Discoradicular contact+ESI TF|Patients with discorradicular contact who underwent ESI TF
89037142|NCT05601791|Active Comparator|Discoradicular contact+PLDD|Patients with discorradicular contact who underwent PLDD
89037143|NCT05601791|Active Comparator|Without discoradicular contact+ESI TF|Patients without discorradicular contact who underwent ESI TF
89037144|NCT05601791|Active Comparator|Without discoradicular contact+PLDD|Patients without discorradicular contact who underwent PLDD
89037145|NCT05470062|Experimental|experimental group|wear the insoles for at least 4-h every day for 1-month
89037146|NCT05470062|No Intervention|control group|not wear insoles for at least 4-h every day for 1-month
89037147|NCT04685642|No Intervention|non-drug|
89037148|NCT04685642|Active Comparator|Aspirin|
89037149|NCT04685642|Active Comparator|Statin|
89037150|NCT02909244||Patients with PID|Biological sampling: collection of feces. In case of blood samples availability in hospital biobank : analyzes of these samples in the frame of this research
89037151|NCT02909244||Control patients, with no PID|Biological sampling: collection of feces.
89037152|NCT04685564|Experimental|RBD1016 experiment group|Subjects in experiment groups will receive a single subcutaneous injection of RBD1016.
89037153|NCT04685564|Placebo Comparator|placebo gruop|Subjects in placebo groups will receive a single subcutaneous injection of placebo.
89037154|NCT02909283||Sickle cell disease patients|Physical exams and blood analyzes
89057823|NCT02217683|Active Comparator|Old blood transfusion and Nitric Oxide|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days while breathing nitric oxide (80 part per million) and oxygen
89057824|NCT04536233|Placebo Comparator|control group|
89621484|NCT06037473||small for gestational age (SGA)|Small for gestational age (SGA) is defined as a birth weight of less than 10th percentile for gestational age.
89621485|NCT06037473||Turner Syndrome (TS)|Turner syndrome, a condition that affects only females, results when one of the X chromosomes (sex chromosomes) is missing or partially missing.
89621486|NCT06037473||others|others who with the height of the individual is more than 2 SD below the corresponding mean height for a given age, sex and population.
89621487|NCT06037395|Experimental|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
89621488|NCT06037395|Active Comparator|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
89621489|NCT06037356|Experimental|Prostatic Urethral Lift|Prostatic urethral lift implants will be placed in patients under local anesthesia or monitored anesthetic care. The number of implants used will depend on intra-operative findings, ranging from 2 to 8 implants per patient.
89621490|NCT06037356|Active Comparator|TURP|Transurethral resection of prostate (TURP) will be performed under spinal or general anesthesia as per usual care.
89621491|NCT06037291|Experimental|Coriander Seed Oil|Dietary supplement - Coriander Seed Oil
89621492|NCT06037291|Placebo Comparator|Placebo|Dietary supplement - Placebo
89621493|NCT06037278|Other|MyPAO use|SIngle arm study, use of device
89621494|NCT06037265|Other|Total Sample Size|The total sample size will be up to 40 subjects that complete the full intended implant durations of either 7 days (n=up to 10) or60 days (n=up to 30). Group 1 patients will be enrolled first and at least 5 patients will complete the 7-day implant duration before Group 2 patients begin enrollment. Group 1 and Group 2 subjects can be screened in parallel. Group 2 enrollment will start immediately after at least 5 subjects in Group 1 have successfully completed the 7-day implantation period. Study subjects will have the PortIO device implanted by a qualified physician (Table 5) and then undergo prescribed, standard of care infusion regimen as determined by their treating physician over either the 7-day or the 60-day period. After the intended implant duration and use during the implant period, the device will then be removed and the subject will be followed for safety at 30 days after explant.
89621495|NCT06037239|Experimental|Linperlisib + Chidamide|Linperlisib combined with chidamide
89621496|NCT06037200||Patients with suspected DOAC intake|Stroke patients with safe or suspected intake of direct oral anticoagulants
89621497|NCT06037200||Patients without DOAC intake|Stroke patients without intake of direct oral anticoagulants
89621498|NCT06037161|Experimental|GPST + CTG|Gingival Pedicle Split Thickness + Connective Tissue Graft procedure
89621499|NCT06037161|Active Comparator|CAF + CTG|Coronally Advanced Flap + Connective Tissue Graft procedure
89621500|NCT06037122||group R-BID|rabeprazole 10mg, amoxicillin 1000 mg, clarithromycin 500 mg, bismuth pectin 200 mg or bismuth potassium citrate 220mg twice daily, all drugs given for 14 days
89621501|NCT06037122||group V-BID|vonoprazan 20mg, amoxicillin 1000 mg, clarithromycin 500 mg, bismuth pectin 200 mg or bismuth potassium citrate 220mg twice daily, all drugs given for 14 days
89621502|NCT06037122||group V-QD|vonoprazan 20mg once daily, amoxicillin 1000 mg, clarithromycin 500 mg, bismuth pectin 200 mg or bismuth potassium citrate 220mg twice daily, all drugs given for 14 days
89621503|NCT06037096|Experimental|Attend-PE|
89621504|NCT06037083||20 extremely low birth weight infants|In addition to the standard care, all participants will be monitored using an extra oxygen saturation probe, two near infrared spectroscopy sensors, and an electrical impedance tomography belt. Data will be continuously collected from extubation to 168 hours postextubation
89621505|NCT06037044|Experimental|Sensory integration therapy for balance and gait|Sensory integration walking pathway with obstacles x 10 and standing on one leg with eyes open and eyes closed 5-10 sec
89621506|NCT06037044|Active Comparator|Traditional Physiotherapy for balance and gait|Walking pathway with obstacles x 10 and standing on one leg with eyes open 5-10 sec
89621507|NCT06037018|Experimental|CC312|
89621508|NCT06036979|Active Comparator|Paravertebral Block Group|This group will receive combined general anaesthesia with preoperative ultrasound guide paravertebral plane block
88988696|NCT06245902|Experimental|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
89621509|NCT06036979|Active Comparator|Erector Spinae Block Group|This group will receive combined general anaesthesia with preoperative ultrasound guided erector spinae plane block
89621510|NCT06036979|No Intervention|Control Group|This group will receive balanced general anesthesia using intravenous (0.1mg/kg) morphine, 30 mg ketorlac and 1 gm paracetamol).
89621511|NCT06036966|Experimental|Hetrombopag|single-arm
89621512|NCT06036953|No Intervention|No EMS|
89621513|NCT06036953|Experimental|EMS|
89621514|NCT06036940|No Intervention|First Control Group|The children in the first control group were given pre-operative patient education by the service nurse.
88988697|NCT06245902|Active Comparator|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
88988698|NCT06245902|Active Comparator|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
88988699|NCT06245902|Placebo Comparator|Placebo Capsules|Patient take two capsule containing placebo together for a qualifying migraine
88988700|NCT06245824|Experimental|All the subjects enrolled will receive the experimental intervention|Participants will receive 5.4 mg/kg of T-DXd as IV infusion q3w, along with pyrotinib 400mg or 320mg (depend on recommended dose) orally once a day within 30 minutes after breakfast for a 21-day cycle.
88988701|NCT06245798||liver resection|
88988702|NCT06245798||transarterial chemoembolisation|
88988703|NCT06245785||liver resection|
88988704|NCT06245785||transarterial chemoembolisation|
89621515|NCT06036940|Experimental|Second Experimental Group|The children in the second experimental group were given pre-operative patient education by the service nurse, also patient visits were provided by the operating room nurse and the operating room environment was explained through play.
89621516|NCT06036940|Experimental|Third Experimental Group|The children in the third experimental group were given pre-operative patient education by the service nurse, and then the mother's voice recording was played until they went to the operating room.
89621517|NCT06036888||thoracobrachial outlet syndrome|"Patient :~adult~with thoraco-brachial outlet syndrome~who has participated to DEFILE-QoL study in 2016~who accept to participate and is able to complete questionaries"
89621518|NCT06036875||Health Services Research|Patients complete a survey and may participate in an interview on study.
89621519|NCT06036862|Experimental|Patients with severe rectal anastomotic stenosis|Focusing on Patients with severe rectal anastomotic stenosis, espically long length and ultra lower firbrotic stenosis
89621520|NCT06036797|Experimental|Group 1|Group 1 will be administered with 15 ug/ml hydromorphone and 0.08% ropivacaine
89621521|NCT06036797|Experimental|Group 2|Group 2 will be administered with 17.5 ug/ml hydromorphone and 0.08% ropivacaine
89621522|NCT06036797|Experimental|Group 3|Group 3 will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine
89621523|NCT06036797|Active Comparator|Group 4|Group 4 will be administered with 0.4 ug/ml sufentanil and 0.08% ropivacaine
89621524|NCT06036771|Experimental|Voice-activated Intelligent Personal Assistant (VIPA) intervention|"IG participants will receive~The developed VIPA user protocol~30-minute training session on day 1~Weekly technical tele-support~Dosage of the intervention: PWP are encouraged to perform 10 voice commands/ day during the 8-week intervention period, self-reported usage will be documented by participants in a progress note."
89621525|NCT06036771|No Intervention|Usual care, no intervention provided|CG participants will be placed under usual care, no intervention will be provided and PWP will continue their daily life during the intervention period
89621526|NCT06036706|Other|"Cohort IMRT:"|Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy…)
89621527|NCT06036706|Other|"Cohort SRT"|Patients receiving hypo-fractionated stereotactic brain irradiation
89621528|NCT06036706|Other|"Cohort PRT"|Patients receiving normo-fractionated proton therapy brain irradiation
89621529|NCT06036706|Other|Control cohort|Participants without any meningioma, cancer history or neurological comorbidities
89621530|NCT06036680||Endoscopic balloon dilatation (EBD) treated CD patients|
89621531|NCT06036680||Self-expandable metal stent (SEMS) treated CD patients|
89621532|NCT06036654|Experimental|Local Hyperthermia for the Treatment of Onychomycosis|(1) In months 0-2, local hyperthermia treatment was given once a week for 20 minutes each time, for a total of 9 times; (2) In months 2-4, at the same target lesion, once every 2 weeks, for a total of 4 times; (3) In months 4-6, once every 4 weeks, for a total of 2 times. The frequency of this course of treatment was 15 times lasting for 6 months, and follow-up ended 12 months from the first treatment.
89621533|NCT06036615|Experimental|Group A|Exercise Group, 6- month combined aerobic, strengthening, mobility- flexibility exercise intervention, 4- month de-training period
89621534|NCT06036615|No Intervention|Group B|Control Group, 10- month normal physical activity, without participating in organized sports activities, no intervention
89621535|NCT06036589|Experimental|CA application + BAM8-22|
88988705|NCT06245759||the U.S. National Cancer Center SEER database|The Chinese NMIBC cohort includes patients from January 1996 to December 2019 at 15 institutions.
89621536|NCT06036589|Experimental|CA application and vehicle|
89621537|NCT06036576|Active Comparator|Thyroid Stimulating Hormone 2.5-4 mU/L|This arm consists of participants who have experienced recurrent pregnancy loss in the first trimester and have TSH levels ranging between 2.5 mU/L and 4 mU/L. These participants will receive levothyroxine treatment of 1.6 micrograms per kg per day
89621538|NCT06036576|Active Comparator|Thyroid Stimulating Hormone more than 4 mU/L|This arm consists of participants who have experienced recurrent pregnancy loss in the first trimester and have TSH levels more than 4 mU/L. These participants will receive levothyroxine treatment of 1.6 micrograms per kg per day
89621539|NCT06036537||rheumatoid arthritis|
89621540|NCT06036498||Preoperative Assessment of Trail Group|
89621541|NCT06036498||Post-Anaesthetic Induction Assessment of Trial Groups|
89621542|NCT06036498||After Pneumoperitoneum Assessment of Trial Groups|
89621543|NCT06036498||Within Head-up Tilt Position Assessment of Trial Groups|
89621544|NCT06036498||Neuralized Position Assessment of Trial Groups|
89621545|NCT06036498||Within Deflation of Abdomen Assessment of Trial Groups|
89621546|NCT06036498||Awaking Period from Anaesthesia Assessment of Trial Groups|
89621547|NCT06036485|Experimental|Kerecis Omega 3|
89621548|NCT06036485|Active Comparator|Surgical debridement|
89621549|NCT06036056||Acute Respiratory Distress Syndrome|Mild Acute Respiratory Distress Syndrome
89621550|NCT06036056||Healthy|Healthy volunteer
89621551|NCT06034431|Experimental|Ride Share Participants|"Investigators will recruit Black men with intermediate or high-risk PC who are seeking definitive treatment at Mass General Brigham Prostate Cancer Outreach Clinic, as Black men are more likely to report travel burden when accessing care and, therefore, most likely to benefit from ridesharing services.~Investigators will implement a pre/post-evaluation design with matched historical controls to estimate the impact of rideshares on reducing missed appointments. Historical controls will be sampled from the pre-intervention period of April 2022 to September 2024 and the post-intervention period between October 2024 and November 2025, where October 2024 represents the initiation of the intervention. Participants who identify as Black, reside in a census tract in Massachusetts, and have been recognized as having a high travel burden based on results from Aim 1 will be eligible to receive the rideshare intervention"
89621552|NCT06034197|Experimental|VGT-309|Subjects will receive an IV infusion of 0.32 mg/kg VGT-309 12 to 36 hours before a standard of care endoscopy procedure.
89621553|NCT06034171|Experimental|Group A|Implant with phosphate surface device in the right side of the lower jawbone, and the hydroxylapatite surface treatment implant is placed in the left side of the lower jaw.
88988706|NCT06245759||the Chinese Bladder Cancer Alliance CBCC database|SEER*Stat software (version 8.4.1.1) collected 17 registries cohort data on NMIBC patients diagnosed between 2000 and 2020.
88988707|NCT06245733|Experimental|Experimental Group|Participants who will receive the training
88988708|NCT06245733|No Intervention|Control Group|participants who will not be interfered with
88988709|NCT06245720||AKI group|AKI is then defined as an increase in serum creatinine (SCr) of at least 26.4 μmol/L over 48 hours, or an increase in SCr greater than 1.5 times baseline over 7 days, or a urine output of less than 0.5 mL/kg per hour for more than 6 hours, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
89621554|NCT06034171|Experimental|Group B|Implant with phosphate surface device for the lower jaw on the left side, and the implant with hydroxylapatite surface treatment is inserted into the right side of the jawbone.
88988710|NCT06245720||Non-AKI group|According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, patients do not develop acute kidney injury.
89621555|NCT06034145||Asthma|Asthma according to Gina Guidelines
89621556|NCT06034132|Experimental|Test group|
89621557|NCT06034132|Active Comparator|Control group|
89621558|NCT06034119|Experimental|Stroke participants|Researchers will assess muscle control in participants post-stroke during different types of walking modifications
89621559|NCT06034119|Active Comparator|Neurotypical participants|Researchers will compare muscle control to neurotypical participants during the same types of walking modifications to assess stroke-induced changes in muscle control vs. intervention-induced changes in muscle control
89621560|NCT06034106|Experimental|Pomegranate (P. granatum) peel compress group|36 g of pomegranate peel powder was given to the patient in a closed container. A teaspoon (approximately 2-3 g) of powder was mixed with water from the storage container and applied to the patient's knee by making a paste, and then the knee was wrapped with a bandage. It was kept for 20 minutes by placing a hot thermophore (approximately 40-45 C) on it. This application was carried out 3 days a week.
89621561|NCT06034106|Placebo Comparator|Hot compress|In the hot compress group, the knee was wrapped with a bandage and the hot thermophor (approximately 40-45 °C) was placed on the knee. The hot thermoform was applied to the patient 3 days a week by keeping it for 20 minutes.
89621562|NCT06034106|No Intervention|Control Group|Patients in the control group did not receive any additional intervention.
89621563|NCT06034080|Active Comparator|Health System Level (HSL) Intervention|"The HSL Intervention is based on the CDC Core Elements of Stewardship and the HSL intervention is recommended by national guidelines. Sites randomized to this arm will require:~A change in their Electronic Health Record to their prescription fields to align with national guidelines~Individualized feedback report to their clinicians and clinic overall~And virtual learning sessions and continuing medical education credits for clinicians."
89621564|NCT06034080|Experimental|Hybrid Intervention|"The Hybrid Intervention will be comprised of Shared Decision-Making (SDM) and the HSL Intervention. A previously validated SDM aid for ear infection care will be implemented. The aid was developed using the International Patient Decision Aid Standards and is freely available. Sites randomized to this arm will require all of the HSL components as well as:~Use of the Shared-Decision Aide~Clinician Education on SDM"
89621565|NCT06034054|Experimental|Nursing counseling|The individuals included in nursing counseling group were given counseling by the research nurse for 6 months.
89621566|NCT06034054|No Intervention|Control|Individuals included in control group were followed up routinely in the outpatient clinic for 6 months.
89621567|NCT06034041|Experimental|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
89621568|NCT06034041|Placebo Comparator|Control|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
89621569|NCT06034015|Active Comparator|Part A|
89621570|NCT06034015|Active Comparator|Part B|
89621571|NCT06033989|Experimental|Hyaluronic acids|Hyaluronic acid has a huge potential to speed up the healing process and increase implant stability by enhancing bone/implant interaction and new bone formation.
89621572|NCT06033989|Active Comparator|Sandblasting acid etched|"Sandblasting and acid etching is the most commonly used basic method for modifying the surface of dental implants . the sandblasting procedure roughs up the outer layer of the implant , creating a surface that is easier for the bone to grip as the implant heals."
89621573|NCT06033937||Migraine Medication Group|
89621574|NCT06033937||PFO Occlusion Group|
89621575|NCT06033924|Experimental|Internet-based Walking Program|Internet pages allow participants to see step-count goals, progress over time and access to walking tips
89621576|NCT06033924|Experimental|Telehealth Counseling Walking Program|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator
89621577|NCT06033846|Experimental|Experimental: Treatment group|Drug: Minocyclin 200 mg oral minocycline for a total of 30 days
89621578|NCT06033846|No Intervention|Control group|first/second-line drugs for autoimmune encephalitis
89621579|NCT06033794|Experimental|Laparoscopic No. 253 lymph node dissection and preserving the LCA under fluorescence guidance.|Preoperatively, indoycine green fluorescent dye was injected into the anus to trace the No. 253 lymph nodes, and intraoperatively, arterial branching of the mesentery was performed by intravenous injection of fluorescent dye to preserve the left colic artery.
89621580|NCT06033794|Active Comparator|Performing laparoscopic No. 253 lymph node dissection and preserving the LCA.|Conventional laparoscopic approach for dissection of the No. 253 lymph nodes and preservation of the left colic artery.
89621581|NCT06033755|Other|Participants with EILO were recruited and given treatment (i.e. one arm?)|Only participants with EILO were recruited and given treatment as usual.
89621582|NCT06033742|Experimental|HS-10374|Single and multiple ascending doses of HS-10374 orally
89621583|NCT06033742|Placebo Comparator|Placebo|Single and multiple ascending doses of HS-10374-matched placebo orally
89621584|NCT06033729|Experimental|"Group 1 REMIFENTANIL TCI (Experimental Group)"|the patients performed the EBUS-TBNA procedure under conscious sedation with infusion of Remifentanil TCI with a target between 3 and 6 ng/ml;
89621585|NCT06033729|Active Comparator|"Group 2 STANDARD (Control Group)"|the patients performed the EBUS-TBNA procedure in conscious sedation with the association of midazolam and/or fentanyl and/or propofol in refracted boluses based on clinical needs (agitation, unsatisfactory level of sedation or not collaborative patient) and according to the anesthesiologist's clinical judgement.
89621586|NCT06033690|Experimental|multidisciplinary guide|Consultation and multidisciplinary guide with guidance on physical activity and healthy eating.
89621587|NCT06033690|No Intervention|Control|Consultations with a multidisciplinary team
89621588|NCT06033651||Only 1 arm for the study|All participants shall receive the same treatment.
89621589|NCT06033612|Experimental|Part A Single Ascending Dose (SAD) - RV299/Placebo|Participants will receive RV299 or placebo as a single dose on Day 1. Sentinel dosing will be used (one on RV299 and one on placebo) before the rest of the cohort are dosed together.
88988711|NCT06245707|Experimental|Ponticelli group|Patients with idiopathic membranous nephropathy were treated with Ponticelli protocol,that is alternating prednisone or methylprednisone -cyclophosphamide every other month
89057825|NCT04536233|Experimental|experimental group|
89621590|NCT06033612|Experimental|Part B Multiple Ascending Dose (MAD) - RV299/Placebo|"Participants will receive RV299 or placebo twice daily on Day 1-4 and a single dose on Day 5. Participants in each cohort will receive ascending doses of RV299, depending on emerging safety and PK data.~Part B, Cohort 3 will investigate interaction between midazolam and RV299. Participants will receive a single dose of midazolam on Day 1 and Day 7, and receive RV299 twice daily on Days 2 - 6"
88988712|NCT06245707|Experimental|Rituximab group|Patients with idiopathic membranous nephropathy were treated with Rituximab.The specific dosage of rituximab depends on the guidance of peripheral blood B cells.
88988713|NCT06245681||Transgender women|Transgender individuals assigned male at birth undergoing estrogen and antiandrogen hormone therapy
88988714|NCT06245681||Transgender men|Transgender individuals assigned female at birth undergoing testosterone hormone therapy
88988715|NCT06245668|Active Comparator|SaCoVLM™ video laryngeal mask|SaCoVLM™ video laryngeal mask
88988716|NCT06245668|Active Comparator|LMA Supreme|LMA Supreme
88988717|NCT06245642|Placebo Comparator|Positive control group|Guipi Granule + compound Xiwujia granule simulator
88988718|NCT06245642|Experimental|Experimental group|Compound Xiwujia granule + Guipi granule simulator
88988719|NCT06245629||Bortezomib-bendamustine-melphalan|Myeloma patients receiving bortezomib-bendamustine-melphalan at autologous hematopoietic stem cell transplantation first relapse.
88988720|NCT06245629||high-dose melphalan|Myeloma patients receiving high-dose melphalan at autologous hematopoietic stem cell transplantation at first relapse.
88988721|NCT06245616|Experimental|Pomace olive oil group|The arm receives a breakfast with pomace olive oil as main fat source.
88988722|NCT06245616|Active Comparator|High-oleic sunflower oil group|The arm receives a breakfast with high-oleic sunflower oil as main fat source.
88988723|NCT06245603|Experimental|Arm A (interventional arm)|patients receive Hydeal Cyst intravesical instillations during the BCG or MMC therapy period.
88988724|NCT06245603|No Intervention|Arm B (control arm)|patients receive only standard therapy (BCG or MMC).
89533244|NCT05185024|Experimental|Ferrous Sulfate Capsules|30 mg of elemental iron and 60 mg of vitamin C per capsule.
89533245|NCT05185024|Experimental|>Your< Iron Forte Capsules|30 mg of elemental iron and 60 mg of vitamin C per capsule.
89533246|NCT05185024|Experimental|>Your< Iron Forte Liquid|35 mg of elemental iron, 0.7 mg vitamin B6 and 1.25 mcg vitamin B12 per one dosing (5 ml).
89533247|NCT05181072|Experimental|Enhanced in-person peer-motivation|This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
89533248|NCT05181072|Experimental|Virtual peer-motivation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual.
89533249|NCT05181072|No Intervention|Self-help/Control|The participants in the control group will receive the services already in place, including a brief motivation enhancement session.
89533250|NCT05180864|Active Comparator|Complete omentectomy|Gastrectomy with complete omentectomy
89533251|NCT05180864|Experimental|Omentum presevation|Gastrectomy with preservation of the omentum distal to the gastroepiploic vessels
89533252|NCT05170958|Experimental|LBL-024|LBL-024 injection; Initial dose - MTD; Q3W
89533253|NCT05164601||AMI Patients Cohort|
89533254|NCT05164575|Experimental|eRP-LOw Intensity (eRP-LO)|an 8-week intervention that includes FOUR virtual visits with a physiotherapist
89533255|NCT05164575|Experimental|eRP-HIgh Intensity (eRP-HI)|an 8-week intervention that includes EIGHT virtual visits with a physiotherapist
89533256|NCT05164133|Experimental|All Participants|Participants who are hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation will receive a single dose of TCZ on Day 1, with the option to receive a second dose 8-24 hours later if clinically indicated.
89533257|NCT05144542|Experimental|E-Cigarettes|Participants vape e-cigarettes for 26 weeks. Participants use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day for up to 182 days. Participants complete questionnaires over 50 minutes and undergo collection of urine sample at 0, 1, 7, 13, and 27 weeks, and collection of blood samples at 6, 12, and 26 weeks. Participants may also undergo measurement of CO levels at 1, 6, 12, and 26 weeks.
89533258|NCT05139836||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe atopic dermatitis.
89533259|NCT05126693|Experimental|Intervention group|The children in the intervention group will receive BoNT injections in the medial gastrocnemius and/or the semitendinosus muscle(s). As part of the standard treatment approach of the CP Reference Centre of the University Hospitals Leuven, the injections are followed by a period of bilateral stretching casts if indicated (below the knee walking casts and removable knee extension casts when necessary) and all children will receive intensive physical therapy and application of ankle foot orthoses following BoNT injections. The follow-up period for the current study is 8-10 weeks. During this intensive physical therapy period post-BoNT, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (that is scheduled prior to the BoNT injections).
89533260|NCT05126693|No Intervention|Control group|This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic management during a period of 8-10 weeks.
89533261|NCT05112900|No Intervention|Usual Care|Participants will only receive public service announcement-type messaging on COVID-19 testing every 3 weeks such as recommendation to obtain COVID-19 testing if exposed or experience symptoms and information on testing options through the school or district.
89533262|NCT05112900|Experimental|Text Messaging (TM)|This arm consists of a text message (TM) prompt asking if a participant has COVID-19 symptoms or if a participant has been exposed to a person who has tested positive for COVID-19. If a participant responds yes, they will receive a TM prompt for immediate testing and to re-test. Participants will be provided with information on testing options. After 24 hours, the participant will receive another TM that asks if they tested and what their results are. After 3 days, participants will be prompted to re-test.
89621591|NCT06033612|Experimental|Part C Food Effect (FE)- RV299|Participants will receive RV299 as a single dose on Day 1 and Day 5; treatment will be administered in the first treatment period fasted and the second treatment period fed (or vice versa).
89621592|NCT06033599|Experimental|MORE and MI|
89621593|NCT06033599|Experimental|MORE and No MI|
89621594|NCT06033599|Active Comparator|Support Group and MI|
89621595|NCT06033599|Active Comparator|Support Group and No MI|
89621596|NCT06033573|Experimental|Contrast-enhanced spectral mammography arm|Subjects receiving contrast-enhanced spectral mammography (CESM) 4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductography
89621597|NCT06033560||Full analysis|All eligible patients.
89621598|NCT06033560||P/F ratio subgroups|Patients with a P/F ratio split in groups of <=100; 100-150; 150-200
89621599|NCT06033560||Respiratory rate subgroups|Patients with a respiratory rate split in groups of <=25; >25 breaths/min
89621600|NCT06033560||Body mass index (BMI) subgroups|Patients with BMI split in groups of <=25; 25-30; 30-35; >35 kg/m^2
89621601|NCT06033560||Immunocompromised subgroups|Immunocompromised patients due to medication or an underlined condition.
88988725|NCT06245590|Experimental|Albumin + Midodrine|Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (>75 mm and <90).
88988726|NCT06245590|Active Comparator|Midodrine +standard of care|Midodrine alone titrated based on MAP.
88988727|NCT06245551|Experimental|A/B - Treatment with PT027 (BUDESONIDE/ALBUTEROL) 160/180 μg followed by treatment with Placebo|Subjects randomized to receive a single dose of PT027 160/180 μg in treatment Period 1, and a single dose of Placebo in treatment Period 2.
88988728|NCT06245551|Experimental|B/A - Treatment with Placebo followed by treatment with PT027 (BUDESONIDE/ALBUTEROL) 160/180 μg|Subjects randomized to receive a single dose of Placebo in treatment Period 1, and a single dose of PT027 160/180 in treatment Period 2.
88988729|NCT06245538|Experimental|Seated rest|Participants will be resting while seated on a comfortable chair for 20 minutes
88988730|NCT06245538|Experimental|Exercise at moderate intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
88988731|NCT06245538|Experimental|Exercise at vigorous intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)
88988732|NCT06245512||With endometriosis|Women affected by endometriosis
88988733|NCT06245512||Without endometriosis|Women without any clinical sign of endometriosis
88988734|NCT06245486|Experimental|Probiotic Young Group (Women aged 18-29 years)|Participants in this group will take probiotic Crispact® (20 Bld CFU/Stick of Lactobacillus crispatus M247) as 1 oral sachet per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
88988735|NCT06245486|Active Comparator|Control Young Group (Women aged 18-29 years)|Participants in this group will take Placebo as 1 oral sachet per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
88988736|NCT06245486|Experimental|Probiotic Lady Group (Women aged 30-64 years)|Participants in this group will take probiotic Crispact® (20 Bld CFU/Stick of Lactobacillus crispatus M247) as 1 sachet oral per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
88988737|NCT06245486|Active Comparator|Control Lady Group (Women aged 18-29 years)|Participants in this group will take Placebo as 1 oral sachet per day for four months and 1 sachet in vaginal lavage for the first 10 days of treatment.
88988738|NCT06245447||CASPR2- Patients|
88988739|NCT06245447||Patients affected by autoimmune encephalitis with antibodies against CASPR2|
88988740|NCT06245434|Experimental|Main group with acute brain injury and initial Disorders of consciousness|50 patients in the initial phase of acute brain injury with disturbed consciousness, hospitalized in the Neurological Intensive Care Unit and at risk of delayed awakening
89621602|NCT06033560||Intensive care unit (ICU) subgroup|Only patients eligible within 24 hours of ICU admission.
89621603|NCT06033469||IBD group|Pediatric patients with IBD
89621604|NCT06033456|Experimental|Radiofrequency stellate ganglion block using ultrasound guidance (SGB)|"Visualization of the C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex.~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning ."
89621605|NCT06033456|Experimental|Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance|Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
88988741|NCT06245434|Active Comparator|Comparative group with acute brain injury without Disorders of consciousness|20 patients in the initial phase of brain damage WITHOUT disturbance of consciousness, hospitalized in the Neurological Intensive Care Unit and presenting similar causes of brain damage.
88988742|NCT06245434|Active Comparator|Comparative group with post-acute Disorders of consciousness|20 patients in the sub-acute or chronic phase of a consciousness disorder and admitted to the Post-Resuscitation Rehabilitation Service.
88988743|NCT06245408|Experimental|Dazodalibep Dose 1|Participants will be administered dose 1 of dazodalibep by intravenous (IV) infusion.
88988744|NCT06245408|Experimental|Dazodalibep Dose 2|Participants will be administered dose 2 of dazodalibep by IV infusion.
88988745|NCT06245408|Placebo Comparator|Placebo|Participants will be administered placebo by IV infusion.
89037155|NCT02908932|Experimental|Phospholipid-bound omega-3 supplement|2.3g/d omega-3 HUFAs (with the EPA to DHA ratio of approximately 2:1), delivered in 8 capsules/day in Krill oil concentrates (Aker BioMarine Antarctic AS, Norway). Participants will receive supplements for the duration of IBOLC (19 weeks) and up until entry in Ranger. Time between completion of IBOLC and entry in Ranger is variable, ranging from 1 weeks to 10 weeks (4 weeks typical). Total duration on supplement thus ranges from 20 to 30 weeks.
89037156|NCT02908932|Placebo Comparator|Placebo supplement|Matching placebo capsules, substituting macadamia nut oil and appropriate colorant for krill oil. Macadamia nut oil has not been associated with psychological, cognitive, or health benefits. Furthermore, it is not typically consumed in large quantities and is therefore useful in tracking blood serum levels to assess compliance within the placebo arm. Placebo capsules have been produced by Aker Biomarine. As with the experimental arm, participants will take 8 capsules daily for the duration of the study (20-30 weeks).
89621606|NCT06033456|Experimental|Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block|Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
89621607|NCT06033443|Experimental|Experiment group|The experimental group will be given collaborative learning-based nursing education for twelve weeks.
89621608|NCT06033365|Experimental|Intervention|Dedicated care navigator to address social support needs
89621609|NCT06033365|No Intervention|Usual care|Standard of care.
89621610|NCT06033339|Other|Blood Sampling|"Collection of 10 ml of blood on EDTA tube during:~Standard check-up visit as a part of the standard monitoring of the disorder for homozygous and symptomatic heterozygous patients~Specific study visit for asymptomatic heterozygous patients~Presurgery blood test for control subjects"
89621611|NCT06033313|Experimental|Positively framed text messages|Positively framed text messages
89621612|NCT06033313|Experimental|Negatively frame text messages|Negatively framed text messages
89621613|NCT06033300|Experimental|suspected heparin-induced thrombocytopenia:|
89621614|NCT06033287||CDK4/6 inhibitors treatment|All HR+/HER2- metastatic breast cancer patients using CDK4/6 inhibitors
89621615|NCT06033274||Patients with Tricuspid Regurgitation undergoing Transcatheter Tricuspid Valve Replacement|Patients having clinically significant tricuspid regurgitation, defined according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease, requiring transcatheter tricuspid valve replacement
89621616|NCT06033248||patients diagnosed with NSCLC|In phase I, the researchers will assess the ability of a rat-based ABP to detect the presence or absence of NSCLC-specific VOCs in urine samples from subjects with and without NSCLC. In phase II, the researchers will assess the ability of the ABP to detect the presence of NSCLC-specific VOCs in urine samples from subjects with suspected but undiagnosed NSCLC (clinical stage I to IIIA). Urine samples will be collected from 50 patients diagnosed with NSCLC and from 50 subjects without NSCLC for phase I and from 110 patients with suspected but undiagnosed NSCLC for phase II (total number of subjects = 210).
89621617|NCT06033183|Experimental|Radiosensitivity|Patients who agree to participate in this research study will have blood sample collected to perform the RadioDtect test
89621618|NCT06033170|Experimental|Insertion of CELOX™ PPH trans-vaginally for bleeding control|There is only one group.
89621619|NCT06033144||"Non Tapia group"|Patients without Tapia's syndrome
89621620|NCT06033144||"Tapia group"|Patient with Tapia's syndrome
89621621|NCT06033118|Experimental|Gemox combined with Anlotinib and Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
89621622|NCT06033105||Group A|35 OLP patients
89621623|NCT06033105||Group B|35 healthy controls.
89621624|NCT06033053|Experimental|Experimental|The experimental group will learn how to modulate the vmPFC-amygdala functional connectivity while being presented with pictures inducing fear.
89621625|NCT06033053|Sham Comparator|Sham|The sham group will learn how to modulate the functional connectivity of sham ROIs while being presented with pictures inducing fear.
89621626|NCT06032988|Active Comparator|LactoLevure|The probiotic capsule LactoLevure^R will be given once a day
89621627|NCT06032988|Placebo Comparator|Placebo|Placebo capsules will consist of identical to the LactoLevure^R capsules of powdered glucose polymer, and will be given once a day
89621628|NCT06032962|Experimental|non-gynecologic surgery|Female candidates for non-gynecologic abdominal surgery
89621629|NCT06032936|Experimental|BBP-398 + Osimertinib|"Phase Ia (Dose Escalation):~Dose level 1: (starting dose level) The one lower dose level than RP2D of BBP-398 monotherapy in Chinese patients (RP2D -1) with Osimertinib 80 mg Dose level 2: RP2D The same dose level to RP2D of BBP-398 monotherapy in Chinese patients with Osimertinib 80 mg Note: The dosing interval and regimen might be changed based on emerging data of Study NAV-1001, LB1002-101 and this study. The proposed new dosing regimen will be submitted in a memo to EC for approval before execution.~Phase Ib (Efficacy Expansion):~Osimertinib 80mg QD + BBP-398 RP2D QD"
89621630|NCT06032897|No Intervention|control group|The control group who participated in routine activities
89057826|NCT02217722|Experimental|Ulcerative Colitis Diet counseling|Patients will receive a structured novel diet termed the UCD for 6 weeks. . patients that completed induction phase with remission(PUCAI<10) will be asked if they are willing to adhere to the UCD for an additional 20 weeks.
89621631|NCT06032897|Experimental|experimental group|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The individualized music listening were performed twice a week for four weeks, for a total of eight times.
89621632|NCT06032884|Experimental|IHD Group|A central venous access (uncuffed nontunneled catheter, preferentially in the right jugular vein or femoral vein), a biocompatible membrane and bicarbonate dialysate will be used. The investigators will plan at least 3 sessions of 4 to 6 hours each per week with blood flow > 200ml/min, dialysate flow>500ml/min, high sodium concentration (>145 mmol/L) and low temperature (35°C) in the dialysate. the investigators will recommend urea reduction ratio > 65% for each session.
89621633|NCT06032884|Experimental|CRRT group|A central venous access (uncuffed nontunneled catheter, preferentially in the right jugular vein or femoral vein) and a biocompatible membrane will be used with a change of membrane every 72 hours (unless clotting occurs before). Choice between continuous veno-venous hemodialysis (CVVHD), continuous veno-venous hemofiltration (CVVHF), or continuous veno-venous hemodiafiltration (CVVHDF) will be left at physician discretion. The investigators will recommend a minimum delivered dose of dialysis of 20-25 ml/Kg/h of effluent by filtration and/or diffusion.
89621634|NCT06032871|Experimental|Chest physiotherapy|Patients receive airway clearance by chest physiotherapy for 30 minutes twice a day.
89621635|NCT06032858|Experimental|Apremilast 30 mg twice daily|
89621636|NCT06032845|Experimental|Cryoablation combined with Tislelizumab and lenvatinib|Cryoablation treatment starts at day 0. Tislelizumab and Lenvatinib will be initiated on day 1 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89621637|NCT06032832|Experimental|Soy protein concentrate meat analog|Meat analog made from soy protein concentrate contains 57Fe as ferrous sulfate. All participants will consume this test meal.
88988746|NCT06245343|Experimental|Functional inspiratory muscle training group|Patients in the training group will be performed functional inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure.
88988747|NCT06245343|Sham Comparator|Control group|The control group will not be given any training during the study period.
88988748|NCT06245330|Experimental|Dose escalation phase|AST-001 (5.0 mg/m^2 to 40.0 mg/m^2) will be administered by IV infusion on Days 1, 8 and 15 of each 28-day cycle to determine the MTD and RP2D with a BOIN design.
88988749|NCT06245330|Experimental|phase II pancreatic cancer|AST-001 (RP2D) will be administered by IV infusion on Days 1, 8 and 15 of each 28-day cycle
88988750|NCT06245317|Active Comparator|Pressure control ventilation-volume guarantee (PCV-VG) group|In the PCV-VG group the tidal volume will be set to 8-10ml/kg and the respiratory rate will be adjusted according to oxygen saturation and end-tidal CO¬2.
88988751|NCT06245317|Active Comparator|Pressure control ventilation (PCV) group|In the PCV group peak inspiratory pressure will be set to 10-15 cm H2O titrated to achieve 8-10 ml/kg and the respiratory rate will be adjusted according to oxygen saturation and end-tidal Co2
88988752|NCT06245317|Active Comparator|Volume control ventilation (VCV) group|In the VCV group tidal volume will be set to 8-10 ml/kg and the respiratory rate will be adjusted according to oxygen saturation and end-tidal CO2,
88988753|NCT06245304|Other|DDD-50 followed by AAI-DDD 50|Patients will be programmed to DDD-50 first. After 3 months, patients will be programmed to AAI-DDD 50.
88988754|NCT06245304|Other|AAI-DDD 50 followed by DDD-50|Patients will be programmed to AAI-DDD-50 first. After 3 months, patients will be programmed to DDD 50.
88988755|NCT06245291|Experimental|Cohort A|Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at early and mid-treatment period timepoints
88988756|NCT06245291|Experimental|Cohort B|Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at mid and late-treatment period timepoints
88988757|NCT06245291|Experimental|Cohort C|Imdusiran 60 mg SC Q8 weeks + nucleos(t)ide analog for 48 weeks + durvalumab at 2 late treatment period timepoints
88988758|NCT06245278|Experimental|Clinical Healthy|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum will be taken from all individuals at the beginning of the study. TIM-3 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the clinically healthy group.
88988759|NCT06245278|Experimental|Periodontitis|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. TIM-3 analysis will be performed by ELISA in saliva and serum of individuals. TIM-3 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
88988760|NCT06245278|Experimental|Periodontitis with İnflammatory Bowel Disease|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. TIM-3 analysis will be performed by ELISA in saliva and serum of individuals. TIM-3 levels will be examined to evaluate before and after treatment in periodontitis with İnflammatory Bowel Disease. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
88988761|NCT06245278|Experimental|Healthy individuals with İnflammatory Bowel Disease|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum will be taken from all individuals at the beginning of the study. TIM-3 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the healthy individuals with İnflammatory Bowel Disease group.
88988762|NCT06245265|Experimental|Clinical Healthy|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum will be taken from all individuals at the beginning of the study. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the clinically healthy group.
89057827|NCT02217722|Experimental|Antibiotic Treatment|Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.
89057828|NCT01686945|Experimental|Healthy - 20 mg|
89621638|NCT06032832|Experimental|Soy protein concentrate meat analog without phytic acid|Meat analog made from soy protein concentrate that was removed phytic acid (dephytinization) contains 58Fe as ferrous sulfate. All participants will consume this test meal.
89621639|NCT06032832|Experimental|Farinata_chickpea flour|Farinata (thin pancake) made from chickpea flour contains 57Fe as ferrous sulfate. All participants will consume this test meal.
89621640|NCT06032832|Experimental|Farinata_chickpea flour without phytic acid|Farinata (thin pancake) made from chickpea flour that was removed phytic acid (dephytinization) contains 58Fe as ferrous sulfate. All participants will consume this test meal.
89621641|NCT06032819||hemorrhage|The result of the Intracranial hyper-density on CT images is determined by dual-energy CT or follow-up images: hyper-density can be seen on the virtual non-contrasted image of dual-energy CT, or high density persist longer than 48 hours.
89621642|NCT06032819||simple contrast extravasation|There is no Intracranial hyper-density on the virtual non-contrast images of dual-energy CT, or the follow-up CT show that the hyper-density is absorbed within 48 hours.
89621643|NCT06032793|Experimental|Deep breathing exercise|"This group will perform following exercises:~Pursed lip breathing, Diaphragmatic breathing and powered breathing for 3-4 times a day for 6 weeks."
89621644|NCT06032793|No Intervention|No Intervention|This group will not perform any exercise.
89621645|NCT06032741||mechanical ventilation group|Patients with Guillain-Barré Syndrome require mechanical ventilation during hospitalization
89621646|NCT06032741||no mechanical ventilation group|Patients with Guillain-Barré Syndrome do not require mechanical ventilation during hospitalization
89621647|NCT06032728|Experimental|A|sunitinib 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
89621648|NCT06032728|No Intervention|B|Patients with radical nephrectomy are observed without intervention
89621649|NCT06032702|Experimental|3 week interval|3 week orthodontic interappointment interval
89621650|NCT06032702|Experimental|6 week interval|6 week orthodontic interappointment interval
89621651|NCT06032689|Active Comparator|Xtra-fill|Bulk-fill high-viscosity methacrylate-based resin composites.
89621652|NCT06032689|Active Comparator|X-base|Bulk-fill low-viscosity methacrylate-based resin composites.
89621653|NCT06032689|Active Comparator|Admira fusion x-tra|Bulk-fill high-viscosity ormocer-based resin composites.
89621654|NCT06032689|Active Comparator|Admira fusion x-base|Bulk-fill low-viscosity ormocer-based resin composites.
89621655|NCT06032663|Experimental|PET-MRI within 1 week of planning scan.|Patients would not normally have a PET-MRI as well as planning scan. In this experimental arm, patients will be given a PET-MRI within 1 week of the planning scan.
89621656|NCT06032624|Active Comparator|Ketamine group (group K)|Ketamine group (group K):40 ml 0.5%bupivacaine and 0.5 mg\kg ketamine.
88988763|NCT06245265|Experimental|Periodontitis|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. ANGPTL-4 analysis will be performed by ELISA in saliva and serum of individuals. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
89621657|NCT06032624|Active Comparator|Dexmedetomidine group (group D)|Dexmedetomidine group (group D) 40 ml 0.5% bupivacaine and 50µg\kg dexmedetomidine.
89621658|NCT06032611|Experimental|Intervention|Participants will complete a number of cognitive and fine motor tests on a touch-sensitive tablet. They will also be asked to complete a questionnaire on their habits and medical history. They will also be asked to wear a smartwatch for 7 days.
89621659|NCT06032572|Experimental|VRS100 robotic-assisted PCI|VRS100 robotic-assisted PCI
89621660|NCT06032572|Active Comparator|Manual PCI|Manual PCI
89621661|NCT06032559|Experimental|MORE|Eight group sessions of Mindfulness-Oriented Recovery Enhancement plus methadone treatment as usual (TAU)
89621662|NCT06032559|Active Comparator|Scripted Mindfulness Practice (SMP)|Eight group sessions of scripted mindfulness practice plus TAU.
89621663|NCT06032559|Active Comparator|Treatment-as-Usual|Methadone treatment as usual.
89621664|NCT06032520||Forensic Outpatient Systemic Therapy (FAST)|FAST is a promising treatment for juveniles showing severe antisocial behavior, including aggression, (domestic) violence, and delinquent behavior. FAST has a flexible intensity and length, addresses individual and systemic risk and protective factors, and is responsive to the abilities of the client (system), intervention characteristics all considered crucial for effective treatment.
89621665|NCT06032507|Experimental|Pulsed lavagegroup|Bone cementation with previous high-pressure pulsatile lavage
89621666|NCT06032507|Experimental|Non-pulsed lavage group|Bone cementation with previous manual rinsing lavage
89621667|NCT06032442|Experimental|ARTNEO|1 capsule 1 time per day for 6 months
89621668|NCT06032442|Active Comparator|Artra|1 tablet 2 times per day for 6 months
89621669|NCT06032429|Experimental|Shared Medical Appointments|This strategy is conducted by groups of patients meeting over time for comprehensive care, usually involving a practitioner with prescribing privileges, for a defining chronic condition or health care state. Meanwhile, this model often use educational and/or self-management enhancement strategies, paired with medication management, in an effort to achieve improved disease outcomes.
89621670|NCT06032429|No Intervention|Standard care|Routine health education without more advanced illustration
89621671|NCT06032403|No Intervention|Control group|Consists of 100 participants followed for one year
89621672|NCT06032403|Other|Intervention group|Consists of 100 participants followed for one year
88988764|NCT06245265|Experimental|Periodontitis with rheumatoid arthritis|Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. ANGPTL-4 analysis will be performed by ELISA in saliva and serum of individuals. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontitis with rheumatoid arthritis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
89057829|NCT01686945|Experimental|Healthy - 40 mg|
89037157|NCT05595785|Experimental|Physical-Based Yoga Practice|"Participants attended two 50-minute class sessions per week during the four week intervention phase.~The physical-based yoga practice was Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis. The yoga class sessions included the physical postures of yoga with an emphasis on alignment, holding postures, and breathing normally.~Each yoga class session sequentially included the following physical postures of yoga: (1) standing in stillness; (2) pranayama deep breathing and warm up; (3) standing series- balance postures, wide leg postures; (4) transition from the standing postures to the floor postures with tree pose; (5) floor series - wind removing, sit up movements, cobra posture, kneeling postures; (6) cool down-stretching, spine twist, Kapalbhati breathing, and Savasana."
89037158|NCT05595785|Experimental|Mindfulness-Based Yoga Practice|"Participants attended two 50-minute class sessions per week during the four week intervention phase.~The mindfulness-based yoga practice included all elements of the physical-based yoga class sessions with the addition of mindfulness cues.~The mindfulness cues included body scan, mindful movement, and yoga nidra. Beyond verbal physical cues on how to control breathing and perform precise body movements during the yoga postures, verbal mindfulness cues asked participants to focus on the sensations of their breathing and body awareness non judgmentally, e.g. Feel your breathe move in through your nose and fill your lungs from bottom to top. Feel your breath exit the nose and empty lungs from top to bottom. Keep your attention on your breath and your body."
89037159|NCT02909205|Other|control|First phase : before training / sensitization / booklet delivery
89037160|NCT02909205|Other|post intervention|Second phase : after training / sensitization / booklet delivery
89037161|NCT05312346||responsiveness to erythropoietin stimulating agent|we evolute responsiveness of patients on hemodialysis for erythropoietin stimulating agents or not and factors effecting this response
89037162|NCT05568563|Experimental|Ethyl chloride|
89037163|NCT05568563|Experimental|Honey|
89037164|NCT05568563|No Intervention|Control|
89037165|NCT00536861|Experimental|1|
89037166|NCT05469984|Active Comparator|women with term prolonged>18h rupture of membrane|women with term prolonged >18 h prom or in preterm delivery will be treated with IV ampicillin 2 gr every 6 hours until delivery
89037167|NCT05469984|Active Comparator|women with preterm labor|women with term prolonged >18 h prom or in preterm delivery will be treated with IV ampicillin 2 gr every 6 hours until delivery plus IV gentamicin 5 mg/kg every 24 hours
89037168|NCT00536900|Experimental|1|Advisor-Teller Money Manager
89037169|NCT00536900|Active Comparator|2|FIT (finance instruction therapy)
89037170|NCT05312190|Experimental|Zhenqi Buxue Oral Liquid|Zhenqi Buxue Oral Liquid, 10 ml each time, 2 times a day for 3 menstrual cycles, orally
89037171|NCT05312190|Experimental|Zhenqi Buxue Oral Liquid and Progesterone Capsules|Zhenqi Buxue Oral Liquid was taken orally, 10 ml at a time, twice a day for 3 menstrual cycles + orally from the second half of menstrual cycle, Progesterone Capsules 200mg, once a day for 10 days for 3 menstrual cycles
89037172|NCT05312190|Active Comparator|Progesterone Capsules|Progesterone Capsules 200mg, qd*10 days*3 menstrual cycles, orally
89037173|NCT00537173||Arm 1|Paclitaxel 90 mg/m2 IV D1, 8, and 15 + Avastin 10 mg/kg IV, day 1 and 15
89037174|NCT05469906||interventional group|kidney graft preserved with M101
89037175|NCT05469906||control group|kidney graft preserved in standard condition (without M101)
89037176|NCT00537212|Active Comparator|1|"Subjects will receive phototherapy and dietary counselling consistent with The South Beach diet."
89037177|NCT00537212|Active Comparator|2|"Subjects will receive phototherapy and dietary counselling consistent with The Ornish Diet."
89037178|NCT00537212|Sham Comparator|3|Subjects will receive phototherapy alone, without dietary counselling.
89037179|NCT02503839|Experimental|Arm#1|"arm#1 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days.~Step-wise inclusion starting with arm#1,arm#2 and arm#3 (first group) randomized (2:2:1) and if safety data are satisfactory proceeding with arm #4 and the rest of arm#3 randomized (2:2:1)."
89037180|NCT02503839|Experimental|Arm#2|arm#2 (n=10) receiving H56:IC31 vaccine at day 84 and 140 and no etoricoxib.
89037181|NCT02503839|No Intervention|Arm#3|arm#3 (n=10), the first group (n=5) serving as control to arm#1 and arm#2, the next group (n=5) serving as control to arm#4.
89037182|NCT02503839|Experimental|Arm#4|arm#4 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days and H56:IC31 vaccine at day 84 and 140.
89037183|NCT05469750|Experimental|Dalpiciclib+ letrozole +capecitabine|"Dalpiciclib 150 mg was given orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~letrozole 2.5mg po qd capecitabine 1000mg/m2 po bid"
89037184|NCT05530109||Patients with idiopathic generalised epilepsy|
89621673|NCT06032390|Experimental|Intervention arm|AI assisted mammography screening interpretation
89037185|NCT05530109||healthy controls|age- and sex-matched healthy controls
89037186|NCT05469594||Termination of pregnancy between 12-14 weeks of gestation|
89037187|NCT05469594||Termination of pregnancy between 14-16 weeks of gestation|
89037188|NCT05469516|Experimental|Ultherapy and Radiesse|"Delivered to the lower face areas as drawn using a single transducer with a focal depth of 1.5mm (following a previously published paper (Lowe, 2021) but with extension of the lower treatment area to the two-ruler width (Ulthera marking ruler) as treatment zones. Application will be delivered through a cross-hatching technique.~Immediately following MFU-V or up to a week after, diluted CaHA will be administered following the Global Consensus Guidelines published in 2018 by de Almeida et al as follows 1) 1 syringe or 1.5ml of CaHA diluted 1:1 with saline for a total of 3ml of solution or 1.5 diluted CaHA per side will be injected in the subdermal plane with a cannula using a retrograde fanning technique."
89037189|NCT03457181|Active Comparator|music group|in music group, patient was asked to choose one music genres from 5 different music genres according to his/her preference. Patient selected music was delivered by an iPhone 6 and Music app (Apple Inc., USA) through the iPhone's headphones.
89037190|NCT03457181|Active Comparator|operating room noise group|in operating room noise group, operating room noise was delivered by an iPhone and Microphone App (Free version, Von Bruno). This application allows the iPhone to be used as a live microphone.
89037191|NCT05311410|Active Comparator|Control group|
89037192|NCT05311410|Active Comparator|Study group|
89057830|NCT01686945|Experimental|Healthy - 60 mg|
89057831|NCT01686945|Experimental|T2D - 20/40/60 mg|
88988765|NCT06245265|Experimental|Healthy individuals with RA|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum fluid will be taken from all individuals at the beginning of the study. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the healthy individuals with RA group.
88988766|NCT06245252|Experimental|group (A)|treated by 40-minute passive stretching exercises,three times per week for 12 weeks
88988767|NCT06245252|Experimental|group (B)|treated by 30 minutes electrical stimulation three times per week for 12 weeks
88988768|NCT06245239||group I|children aged < 3years undergoing hypospadias repair surgery.
88988769|NCT06245226||Fibromyalgia group|50 female fibromyalgia patients
88988770|NCT06245226||Control group|50 pain-free female volunteers
88988771|NCT06245174||Parkinson's disease (PD)|Individuals with mild to severe movement disorder symptoms of Parkinson's disease
88988772|NCT06245161|Experimental|• Group IA|15 maxillary quadrants each have at least one primary molar indicated for restorative treatment or vital pulp therapy, allocated to Intra-osseous Anesthesia by QuickSleeper5.
88988773|NCT06245161|Active Comparator|• Group IB|15 maxillary quadrants each have at least one primary molar indicated for restorative treatment or vital pulp therapy, allocated to infiltration anesthesia
89533263|NCT05112900|Experimental|Text Messaging + Health Navigator (TM + HN)|This arm consists of continued text messages (TM) about COVID-19 testing options with the addition of a brief telephone call from a health navigator (HN). These calls will be conducted using Motivation and Problem Solving (MAPS). MAPS is an empirically validated proactive coaching approach used to address barriers and motivate participants to utilize testing options if they are experiencing COVID-19 symptoms or have been exposed to someone that has tested positive for COVID-19.
88988774|NCT06245161|Experimental|• Group IC|15 Mandibular quadrants each have at least one primary molar indicated for restorative treatment or vital pulp therapy, allocated to Intra-osseous Anesthesia by QuickSleeper5.
88988775|NCT06245161|Active Comparator|• Group ID|15 mandibular quadrants each have at least one primary molar indicated for restorative treatment or vital pulp therapy, allocated to inferior alveolar nerve block (IANB) anesthesia
88988776|NCT06245161|Experimental|• Group IIA|15 maxillary primary molars indicated for extraction allocated to Intra-osseous Anesthesia by QuickSleeper5
89533264|NCT05109234|Experimental|Brivaracetam arm|Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
89533265|NCT05109117|Experimental|Test Arm|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter^2) of ChapStick Active Performance (CAP) Unscented will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
89533266|NCT05109117|No Intervention|Control Arm|No treatment will be applied to the assigned control site.
89533267|NCT05103384||PD Virtual Reality Cohort|
89533268|NCT05093296|Experimental|Oxytocin + Naltrexone|"All patients will receive 50mg Naltrexone daily (NTX, oral tablet) in the course of standard in-patient treatment. In the experimental group, patients will receive a single dose of 24 I.U. oxytocin nasal spray at two study visits during in-patient treatment:~Visit 2 - First Application of Oxytocin 40 minutes prior to a combined stress- and alcohol cue-exposure during visit 2~Visit 3 - Second Application of Oxytocin 40 minutes prior to an fMRI-based assessment of alcohol cue-reactivity"
89533269|NCT05093296|Active Comparator|Placebo + Naltrexone|"All patients will receive 50mg Naltrexone daily (NTX, oral tablet) in the course of standard in-patient treatment. In the comparator group, patients will receive a placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin) at two study visits during in-patient treatment:~Visit 2 - First Application of Placebo 40 minutes prior to a combined stress- and alcohol cue-exposure during visit 2~Visit 3 - Second Application of Placebo 40 minutes prior to an fMRI-based assessment of alcohol cue-reactivity"
89533270|NCT05086692|Experimental|MDNA11|"MDNA11 is a long-acting beta-only recombinant interleukin-2 (rIL-2) albumin fusion"
89533271|NCT05081882|Experimental|Kava Intervention|
89533272|NCT05081882|Placebo Comparator|Placebo Control|
89533273|NCT05078385|Experimental|AGLE-102|AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
89533274|NCT05076617|Experimental|Staccato alprazolam|Participants will receive Staccato alprazolam by inhalation.
89533275|NCT05076175|Experimental|Ozanimod High Dose|
89533276|NCT05076175|Experimental|Ozanimod Low Dose|
89533277|NCT05075980|Experimental|Arm A (IMPT, cisplatin)|Patients who already underwent surgical resection undergo IMPT for 18 sessions (Monday-Friday) over 24 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care.
89533278|NCT05075980|Experimental|Arm B (IMPT, cisplatin)|Patients undergo surgical resection and then IMPT for 15 sessions (Monday-Friday) over 19 days in the absence of disease progression or unacceptable toxicity. Patients may receive cisplatin IV over 1-2 hours per standard of care.
89533279|NCT05074290|Experimental|Epidiferphane + taxane chemotherapy|
89533280|NCT05069545||Tresiba + Fiasp using NovoPen 6 per local label|Participants will use Tresiba® and Fiasp® in NovoPen® 6 as prescribed to participants by the study doctor
89533281|NCT05065866|Experimental|Dose Escalation|Dose escalation to determine the maximum tolerated dose (MTD) of BMS-986345 in combination with Duvelisib in patients with lymphoid malignancy. Patients will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 6 dose levels will be used.
89533282|NCT05064800|Active Comparator|Treatment A|Dabigatran only
89533283|NCT05064800|Experimental|Treatment B|PF-07321332/ritonavir + Dabigatran
89533284|NCT05064800|Active Comparator|Treatment C|Ritonavir + Dabigatran
89533285|NCT05064540|Experimental|Alto Abdominal Stent Graft System|Subjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.
89533286|NCT05064540|Active Comparator|Comparators|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.
89533287|NCT05063162|Experimental|Rozanolixizumab Arm|Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints.
88988777|NCT06245161|Active Comparator|• Group IIB|15 maxillary primary molars indicated for extraction allocated to Infiltration anesthesia
88988778|NCT06245161|Experimental|• Group IIC|15 Mandibular primary molars indicated for extraction, allocated to Intra-osseous Anesthesia by QuickSleeper5
88988779|NCT06245161|Active Comparator|• Group IID|15 Mandibular primary molars indicated for extraction, allocated to inferior alveolar nerve block (IANB) anesthesia.
88988780|NCT06245135|Experimental|TIME at Home|TIME at Home is a virtual, group, task-oriented exercise program targeting balance and mobility. A community organization delivers two 1.5-hour sessions per week, for 8 weeks using Zoom.
88988781|NCT06245135|No Intervention|Waitlist|Individuals in the waitlist control group will receive the TIME at Home program following the final 5-month evaluation.
88988782|NCT06245122|Experimental|Dose escalation|"Single ascending dose (SAD): Participants will receive CS23546 once on the first day (D1).~Multiple ascending dose (MAD): Participants will receive CS23546 once daily from the 7th day (C1D1)."
88988783|NCT06245122|Experimental|Dose expansion|Dose expansion is planned to begin when the recommended Phase 2 dose (RP2D) will be determined.
88988784|NCT06245109|Active Comparator|Duloxetine|Duloxetine 60mg tablet, daily (with an initial and final 7-day titration at 30 mg, daily)
88988785|NCT06245109|Active Comparator|Celecoxib|Celecoxib 200 mg tablet, daily
88988786|NCT06245109|Placebo Comparator|Placebo|Matching placebo tablet, daily
88988787|NCT06245096|Active Comparator|Cognitive Behavioral Therapy|Over 8 sessions, clients learn techniques to challenge and change maladaptive thought and behavioral patterns
88988788|NCT06245096|Active Comparator|Acceptance and Commitment Therapy|Over 8 sessions, clients learn techniques to accept their negative internal experiences and commit to action in line with their values
88988789|NCT06245044|Experimental|No MI Help|No MI help will be presented during the verification tasks
88988790|NCT06245044|Experimental|Scenario #1|MI help will be presented in the form of a pop-up message the participant's decision differs from the MI's determination.
88988791|NCT06245044|Experimental|Scenario #2|MI help will be displayed concurrently with the filled and reference images.
88988792|NCT06245018|Experimental|iNK Injection|Cohort1:Low dose iNK injection; Cohort2:Mid dose iNK injection; Cohort3:High dose iNK injection;
88988793|NCT06245005||OPAC|Feasibility to conduct brain exercise gameplay on a portable electronic device at Ohio State Preoperative Assessment Clinic (OPAC)
88988794|NCT06245005||PREOP|Feasibility to conduct brain exercise gameplay on a portable electronic device at The Wexner Medical Center Preoperative Holding Areas.
88988795|NCT06244407|Experimental|Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated tablet|Participants first received Vildagliptin and metformin HCl 50/1000 mg 1 tablet (Test product) in a fasting state. After a washout period of 7 days, they then recieved Galvus Met® 1 tablet (Reference product) in a fed state.
88988796|NCT06244407|Active Comparator|Galvus Met®|Participants first received Galvus Met® 1 tablet (Reference product) in a fed state. After a washout period of 7 days, they then recieved Vildagliptin and metformin HCl 50/1000 mg (Test product) in a fed state.
88988797|NCT06244017|Experimental|EEG Spectrogram-guided|The general anesthesia administration is guided by using the EEG spectrogram in this group. Other perioperative care protocols are the same between the two study group.
89057832|NCT04536506|Experimental|Treatment group|Bobath group received 45 min of sessions three times weekly for 12 weeks.
89533288|NCT05063162|Placebo Comparator|Placebo Arm|Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding.
89533289|NCT05058287|Experimental|Group 1: Topical Steroid|
89533290|NCT05058287|Placebo Comparator|Group 2: Topical Normal Saline|
89533291|NCT05041387||Neuromuscular disorders|Patients with neuromuscular disorders, no specific diagnosis
89533292|NCT05039840|Experimental|SAR441344|SAR441344 intravenous (IV) loading dose followed by subcutaneous (SC) doses, 24 weeks
89533293|NCT05039840|Placebo Comparator|Placebo|Placebo IV loading dose followed by SC, 24 weeks
89533294|NCT05035082|Experimental|oral semaglutide|All participants are given tablets used in addition to metformin.
89533295|NCT05035082|Active Comparator|other oral glucose lowering medication|All participants are given tablets used in addition to metformin.
89533296|NCT05031507||1|Subjects with rare skeletal disorders
89533297|NCT05027958|Other|1|TST+ IGRA+
89533298|NCT05027958|Other|2|TST- IGRA-
89533299|NCT05023551|Experimental|Single arm DSP-0390|Arm Description [*] DSP-0390 by oral administration
89533300|NCT05012111||Cohort 1|Severe Aplastic Anemia(SAA): Age 2 and older; Previous diagnosis of bone marrow failure
89533301|NCT05012111||Cohort 2|Other Marrow Failure: Age 2 and older; Previous diagnosis of bone marrow failure;
89533302|NCT05012111||Cohort 3|Telomere Biology Disorders(TBD): Age 2 and older; Previous diagnosis of bone marrow failure
89533303|NCT05012111||Cohort 4|Inherited Bone Marrow Failure(IBMF)Syndromes: Age 2 and older; Previous diagnosis of bone marrow failure
89533304|NCT05012111||Cohort 5|Family Screening: Age 2 and older; First degree family member with a known or suspected inherited bone marrow failure syndrome
89533305|NCT05006443|Other|Moderate or severe tricuspid regurgitation|40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.
89533306|NCT04985604|Experimental|Arm #1 (Closed to Enrollment)|Tovorafenib monotherapy
89533307|NCT04985604|Experimental|Arm #2|Tovorafenib plus pimasertib
89533308|NCT04982094|Experimental|Mental Health First Aid and Relationship Building Training (MHFA+RBT)|Mental Health First Aid training in conjunction with Relationship Building Training.
89533309|NCT04982094|Active Comparator|Mental Health First Aid (MHFA only)|Mental Health First Aid training alone.
89533310|NCT04975607|Experimental|Music Therapy Group|
89533311|NCT04975607|No Intervention|Control Group|
89621674|NCT06032390|Active Comparator|Control arm|Standard mammography screening interpretation (standard procedure)
89621675|NCT06032325||Neutrophil Gelatinase Associated Lipocalin and Kidney Injury Molecule-1|
89621676|NCT06032312||1|metabolic healthy obese
89621677|NCT06032312||2|metabolic unhealthy obese
89621678|NCT06031597|Experimental|Cohort A: concurrent chemoradiotherapy combined with ICIs|For performance status (PS)=0-1 and both lungs V20≤20%, mean lung dose (MLD)≤11 gray(Gy), then the patient should be treated with concurrent chemo-radiotherapy and immunotherapy, and immunotherapy should be given after chemo-radiotherapy to maintain up to 1 year. Participants eligible for enrollment will receive radiotherapy within 8 weeks of the end of chemotherapy combined with Immune checkpoint inhibitors (ICIs) at a radical prescribed dose of 60 Gy ± 10% at 2 Gy once daily for 5 days per week. The chemotherapy regimen will be cisplatin at a dose of 25 mg/m2 once a week for 5-6 cycles. Marketed programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors are chosen as immunotherapy agents. Immunotherapy will be given every 3 weeks, with no more than 3 cycles of immunotherapy during radiotherapy. The dosage is recommended according to the drug insert.
89621679|NCT06031597|Experimental|Cohort B: concurrent radiotherapy combined with ICIs|For PS=0-1 and 20%<both lungs V20≤25% or 11Gy<MLD≤13Gy, radiotherapy alone combined with concurrent immunotherapy, followed by immunotherapy up to 1 year. Participants eligible for enrollment will receive radiotherapy within 8 weeks of the end of chemotherapy combined with ICIs at a radical prescribed dose of 60 Gy ± 10% at 2 Gy once daily for 5 days per week. Marketed PD-1 or PD-L1 inhibitors are chosen as immunotherapy agents. Immunotherapy will be given every 3 weeks, with no more than 3 cycles of immunotherapy during radiotherapy. The dosage is recommended according to the drug insert.
89621680|NCT06031597|Experimental|Cohort C: radiotherapy|For PS=2 or 25%<both lungs V20≤30% or 13Gy<MLD≤17Gy, radiotherapy alone, followed by immunotherapy for up to 1 year. Participants eligible for enrollment will receive radiotherapy within 8 weeks of the end of chemotherapy combined with ICIs at a radical prescribed dose of 60 Gy ± 10% at 2 Gy once daily for 5 days per week. Marketed PD-1 or PD-L1 inhibitors are chosen as immunotherapy agents. The dosage is recommended according to the drug insert.
89621681|NCT06031571|Experimental|group A|group A (will receive cupping massage technique in addition to traditional exercises)
89621682|NCT06031571|Experimental|Group B|group B (will receive myofascial release technique in addition to traditional exercises)
89621683|NCT06031571|Active Comparator|Group C|group C control group (will receive traditional exercises only)
89621684|NCT06031467|Active Comparator|Non-surgical mechanical therapy|Titanium curettes were used for non-surgical mechanical therapy in both groups under local anesthesia. The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt. The control group received mechanical therapy alone.
89621685|NCT06031467|Active Comparator|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|Titanium curettes were used for non-surgical mechanical therapy in both groups under local anesthesia. The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt. The laser group received mechanical therapy followed by Er;Cr;YSGG laser.
89621686|NCT06030778||intervention group|The descriptive characteristics form and the attitude scale of healthcare professionals towards their patients with chronic pain were administered to 205 students from the departments of medicine, physical therapy and rehabilitation, and nursing who agreed to participate in the study. The attitude scale of the health professionals towards their chronic pain patients was applied to 29 randomly selected students among these 205 students 15 days later.
89621687|NCT06030362|Active Comparator|Probiotic|
89621688|NCT06030362|Placebo Comparator|Placebo|
89621689|NCT06030024|Experimental|Active rTMS|Participants in this one and only arm in the current study received active repetitive transcranial magnetic stimulation.
89621690|NCT06029556|Active Comparator|Mobility out of Bed|
89621691|NCT06029556|Experimental|Ergometry in Bed|
89621692|NCT06028880|Experimental|Experimental group|1 pre-session + 12 sessions
89621693|NCT06028607|Other|Study Population|"Participants will be recruited and consented as part of routine care. All will trial supplement initially and have standard and additional measures taken. they will be followed up at month 1 and 2 collecting the primary outcomes (acceptability/palatability and dietary intake) and all initial measures repeated at month 3.~Each participant will receive 3 months supply of gels to consume 2 per day."
89621694|NCT06028568||Elderly patients undergoing surgery|Older than or equal to 65 years of age; patients who intend to undergo major abdominal surgery under general anesthesia (grade 3-4 surgery based on surgical grade)
89621695|NCT06028568||Elderly healthy volunteers|Age-and sex-matched community population
89621696|NCT06028126|Experimental|0.2% ropivacaine|Intermittent superficial parasternal intercostal plane block via ultrasound-guided catheter placement. Initial bolus dosing of 20 milliliter (mL) of 0.2% ropivacaine per side at the time of catheter placement, followed by intermittent boluses of 10 mL 0.2% ropivacaine per side.
88988798|NCT06244017|Active Comparator|Bispectral index-guided|The general anesthesia administration is guided by using the processed EEG index, namely the bispectral index (BIS) in this group. Other perioperative care protocols are the same between the two study group.
88988799|NCT06243809|Experimental|Linagliptin 5 mg, Then Trajenta 5 mg|Participants first received Linagliptin 5 mg tablet 1 tablet (Test product) in a fasting state. After a washout period of 1 week, they then received Trajecta 5 mg tablet (Reference product) in a fasting state.
88988800|NCT06243809|Active Comparator|Trajenta 5 mg, Then Linagliptin 5 mg|Participants first received Trajenta 5 mg tablet 1 tablet (Reference product) in a fasting state. After a washout period of 1 week, they then recieved Linagliptin 5 mg tablet (Test product) in a fasting state
88988801|NCT06243796|Experimental|Flap fixation|After completing the modified radical mastectomy procedure, the researcher will use absorbable suture (vicryl), multiple alternating stitches 2.5 cm apart between the subcutaneous tissues of the skin flaps and the underlying muscles at various parts of the flap and also, at the wound edge.
88988802|NCT06243796|No Intervention|Non flap fixation|After mastectomy, the researcher will close the wound in the conventional method.
89057833|NCT04536506|Active Comparator|Control group|Vojta group received the following three times weekly for 12 weeks.
89621697|NCT06028126|Sham Comparator|0.9% saline|Intermitted superficial parasternal intercostal plane block via ultrasound-guided catheter placement. Initial bolus of 20 mL of 0.9% saline per side at the time of catheter placement, followed by intermitted boluses of 10 ml of 0.9% saline per side.
89621698|NCT06027931|Experimental|Conservative Access Opening|Root canal treatment using Conservative Access Opening type.
89621699|NCT06027931|Experimental|Traditional Access Opening|Root canal treatment using Traditional Access Opening type.
89621700|NCT06027645|Experimental|Crawli Group|Participants from the Crawli Group will benefit from the crawling stimulation intervention with a mini-skateboard (i.e. the crawliskate) in addition to usual care
89621701|NCT06027645|No Intervention|Control Group|Control group infants benefit from usual care
89621702|NCT06027359|Experimental|Therapeutic game to reduce fear of hospital and ambulance|therapeutic play was applied to 5 groups every day of the week and was completed in 4 weeks.
89621703|NCT06027359|Experimental|Therapeutic game to reduce fear of injectors and eye drops|therapeutic play was applied to 5 groups every day of the week and was completed in 4 weeks.
89621704|NCT06027359|Experimental|Therapeutic play to reduce fear of intrauterine and serum|therapeutic play was applied to 5 groups every day of the week and was completed in 4 weeks.
89621705|NCT06027359|Experimental|Therapeutic play to reduce fear of EKG and EMG|therapeutic play was applied to 5 groups every day of the week and was completed in 4 weeks.
89621706|NCT06026267|Experimental|High Dose Arm|Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg body weight (Maximum 100g)on day 3 along with standard medical therapy.
89621707|NCT06026267|Active Comparator|Reduced Dose Albumin+Standard Medical therapy|Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.
89621708|NCT06025760|Active Comparator|Interventional group|Mechanically ventilated patients will receive a nutritional caloric intake of 25-30 kcal/kg/day with a high protein dose of 2 gm protein /kg/day within 24 hours of ICU admission.
89621709|NCT06025760|Placebo Comparator|Control group|patients will receive a nutritional caloric intake of 25-30 kcal/kg/day with a standard protein dose of 1.2 gm protein /kg/day within 24 hours of ICU admission.
89621710|NCT06024980|Active Comparator|Supraglottic and glottic T2 laryngeal carcinoma|The open partial horizontal laryngectomy was underwent in patients with supraglottic or glottic laryngeal carcinoma in T2
89621711|NCT06024980|Active Comparator|Supraglottic and glottic T1 laryngeal carcinoma|The transoral endoscopic laser cordectomy was underwent in patients with supraglottic or glottic laryngeal carcinoma in T1
89621712|NCT06024876|Experimental|CS-101|CS-101: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
89621713|NCT06023537|Experimental|Behavioral Weight Loss Intervention|
89621714|NCT06023173||Training Cohort|This cohort was derived from Arm A (treated with FOLFOX + bevacizumab) of the BECOME studyand was used for model construction.
89621715|NCT06023173||Negative Validation Cohort|The cohort was derived from Arm B (treated with FOLFOX) of the BECOME study , which demonstrated that the model specifically predicted the efficacy of bevacizumab.
89621716|NCT06023173||Internal Validation Cohort|The cohort was derived from an independent Zhongshan Hospital cohort with the same treatment team and imaging instrumentation as the BECOME study, differing only in patient period, and was used for internal validation of the model.
89621717|NCT06023173||External Validation Cohort|The cohort was obtained from the Zhongshan Hospital - Xiamenand the First Affiliated Hospital of Wenzhou Medical University for external validation of the model.
89621718|NCT06022809|Active Comparator|Individual-level intervention|Virtual one-on-one session
89621719|NCT06022809|Experimental|Group-level intervention|Virtual group sessions
88988803|NCT06243523|Other|Action group|The action intervention of this research is the implementation of a stress management psychoeducation program based on Neuman's Systems Model for the spouses of patients hospitalized in the intensive care unit.
88988804|NCT06243354|Experimental|Test product-HYP-2090PTSA|
88988805|NCT06243276|Active Comparator|Diabetic patients|
89057834|NCT01686984|Experimental|Altered breath|The group where the investigators alter the inspiratory and expiratory aspects of a ventilated breath.
89057835|NCT02217839|Experimental|DG3173|
89621720|NCT06016205|Active Comparator|Morphine group (n= 25):|
89621721|NCT06016205|Active Comparator|PECS group (n= 25):|
89621722|NCT06015204|Active Comparator|C5-C6 group|The C5-to-C6 nerve roots and supraclavicular nerves are blocked with 25 ml of 0.75% ropivacaine under ultrasound guidance.
89621723|NCT06015204|Experimental|C5-C8 group|The C5-to-C8 nerve roots and supraclavicular nerves are blocked with 25 ml of 0.75% ropivacaine under ultrasound guidance.
89688426|NCT02907268|Active Comparator|Treatment Arm B|The second treatment group received abobotulinumtoxinA (Dysport) on the right side of their face and onabotulinumtoxinA (Botox) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
88988806|NCT06243276|Active Comparator|Healthy patient|
88988807|NCT06243003|Experimental|HA-WBRT with SRS|hippocampal-sparing WBRT combined with SRS will be used to treat SCLC patients with baseline brain metastases during standard first-line chemotherapy combined with immunotherapy.
88988808|NCT06242808|Active Comparator|Usual free community food market services|Usual free community food market services
88988809|NCT06242808|Experimental|Medically tailored groceries and food resource coaching|Medically tailored groceries and food resource coaching
88988810|NCT06242600|Experimental|CytaCoat LIP Foley catheter|CytaCoat LIP Foley catheters will be randomized 1:1 (15 patients in each arm), to patients in need of catheterization for up to 24 hrs.
88988811|NCT06242600|Other|Uncoated silicone Foley catheter|Uncoated silicone Foley catheter will be randomized 1:1 (15 patients in each arm), to patients in need of catheterization for up to 24 hrs.
89037193|NCT05469399|Experimental|GBVRLPCA|Students in the experimental group will be given a knowledge test, an objectively structured clinical exam for skill assessment, theoretical lectures, and a game practice for a week. One week later, students will be given a knowledge test, an objectively structured clinical exam for skill evaluation, and an evaluation form for game practice.
89037194|NCT05469399|Active Comparator|Control Group|The students in the control group will be given a knowledge test, an objectively structured clinical exam for skill assessment, theoretical lessons, and no application will be made for a week. After one week, students will be given a knowledge test and an objective structured clinical exam for skill assessment.
89037195|NCT03457064|No Intervention|Physical Activity (PA)|Physical activity (PA) involved a program of physical exercise alone.
89037196|NCT03457064|Active Comparator|PA+Social Adherence Intervention(PASAI)|PA+Social Adherence Intervention(PASAI) involved a program of physical exercise combined with a social adherence intervention.
89037197|NCT05433740|Experimental|Group I: Adjustable ligament|In the adjustable ligament method, binding tape with a button at one end and button holes along the band was wrapped around the outer end of the bite-block section of the device. The ends of the tape were then passed over the outer end of the bite block between two tubes and adjusted at or above the ear level (except neck veins), and fixed by inserting the button through the appropriate hole.
89037198|NCT05433740|No Intervention|Group II: Adhesive tape|The laryngeal mask was fixed using the standard method using adhesive tape.
89037199|NCT05294133|No Intervention|control group|no intervention
89621724|NCT06013826|Experimental|Experimental|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated. D-FISQ was repeated to the patients when they came to the hospital for control.
89621725|NCT06013826|No Intervention|Control|Patients who were randomly assigned to the control group were informed about the method of the study. Telehealth service in the control group was not applied. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. D-FISQ was repeated to the patients when they came to the hospital for control.
89621726|NCT06009263|Sham Comparator|Control|The participants will receive conventional treatment in the form of TENS and Ultrasound.
89621727|NCT06009263|Experimental|Intervention 1|"The participants will receive open chain segmental control exercises plus conventional treatment in the form of TENS and Ultrasound."
89621728|NCT06009263|Experimental|Intervention 2|"The participants will receive closed chain segmental control exercises plus conventional treatment in the form of TENS and Ultrasound."
89621729|NCT06008379|Experimental|dose escalation and dose expansion|all subjects enrolled in the part of dose escalation and dose expansion will receive 7MW3711 by introvenous infusion
89621730|NCT06008379|Experimental|cohort expansion|all subjects enrolled in the part of cohort expansion will be treated by 7MW3711 will receive 7MW3711 by introvenous infusion
89621731|NCT06008366|Experimental|Dose escalation and dose expansion|All subjects enrolled in the part of dose escalation and dose expansion will receive 7MW3711 by introvenous infusion
89621732|NCT06008366|Experimental|Cohort expansion|All subjects enrolled in the part of cohort expansion will be treated by 7MW3711 will receive 7MW3711 by introvenous infusion
89037200|NCT05294133|Experimental|physical activity|
89037201|NCT05399342||LAAOS III Extended Follow-Up Cohort|Patients randomized into the LAAOS III trial who have consented to longer term observational follow-up. There is no intervention in this study.
89037202|NCT00536367||Patients seen for ADHF at OSUMC|
89037203|NCT05468775|Experimental|intervention group|
89037204|NCT05468775|No Intervention|control group|
89037205|NCT05384717|Experimental|Fidget group|Participants in the experimental fidget group select a fidget from 4 options: fidget spinner, stress ball, pop-it, or fidget cube
89037206|NCT05384717|Placebo Comparator|Control group|No fidget choice provided
89037207|NCT05468658|Experimental|Experimental Group (A): Feng Shui Birth Unit|"The cabinets will be painted using salmon and pastel green.~It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~Live nature videos and sounds will be projected onto the wall.~Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~Natural plants will be placed.~Lighting will be used.~Bed linen will be designed according to the Feng Shui.~Wooden bell will be used.~Turtle, elephant and Wu Lou objects will be placed.~The Bagua mirror will be placed.~Crystals will be placed.~Natural stones will be placed.~The fountain will be placed in the east compass direction of the unit.~Straw bamboo separator will be used."
89037208|NCT05468658|No Intervention|Control Group (B): Routine Birth Unit|The delivery unit of the institution consists of a small corridor, a labor room, a delivery room and a baby room. In the small corridor, there is a desk, document cabinets, vaccine cabinet and medicine cabinet for the midwife to work. The institution's routine delivery unit is equipped with standard medical devices and supplies. However, there are medical devices that are not used in the unit. White bed linens designed with the standard hospital logo are used in the unit. However, the curtains are plain cream, the walls are light blue, and the ceilings are white.
89037209|NCT04319926|Experimental|Lidocaine Patch (Sequence T1T2)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 1, lidocaine 1.8% topical systems are applied in Period 1, and the generic lidocaine 5% patches are applied in Period 2.
89037210|NCT04319926|Experimental|Lidocaine Patch (Sequence T2T1)|Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 2, generic lidocaine 5% patches are applied in Period 1, and the lidocaine 1.8% topical systems are applied in Period 2.
89057836|NCT02217839|Experimental|DG3173+Octreotide|
89057837|NCT01687023||Tai Chi|Healthy Tai Chi practitioners
89621733|NCT06005961|Active Comparator|MBP intervention arm|The MBP intervention has two modules: the core and the tailor-made modules. The core module focuses on emotional management, while the five tailor-made modules include anxiety management, mood and depression management, anger management, sleeping well, and managing self-expectation and compassion.
89621734|NCT06005961|Other|Waitlist control arm|Participants allocated to the waitlist control group will wait for 6 plus 4 weeks before receiving the MBP intervention.
89621735|NCT06001567|Experimental|Avatrombopag|Patients receive avatrombopag treatment 5-10 days.
89621736|NCT06000579|Experimental|Experimental Group|EFT will be applied to individuals with premenstrual syndrome.
89621737|NCT06000579|No Intervention|Control Group|Individuals in the control group will not be interfered with.
89621738|NCT06000462|Experimental|Dapagliflozin arm|10 mg strength will be used in this study. The drug is usually taken orally once a day, preferably in the morning. The participants will be using the medication for 32 weeks only, then continue follow up for another 16 weeks (off drug therapy) with behavior weight management program only. The patients will be informed from the beginning of the study with the general side effects of medication (patient information sheet) that should be reported if experienced.
89621739|NCT06000462|Active Comparator|Metformin arm|1000 mg strength will be used once daily dose. Medication will be provided randomly to the patient according to the corresponding number. The patients are informed to declare any experienced side effects that has been stated in the patient information sheet without informing the name of drugs.
89621740|NCT06000462|Placebo Comparator|Placebo arm|receive a harmless substance or treatment that has no therapeutic effect, once daily.
89533312|NCT04971720|Experimental|Sacubitril/Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
88988814|NCT06242080|Active Comparator|"MTIA intervention"|"The Mindfulness Training Instructor Administered (MTIA) intervention will incorporate the following elements: training in an 8-week, 90-minute per week, modified mindfulness program, which places additional emphasis on training which is feasible and relevant to race/ethnic groups, including: a) didactics on relevance to stress, coping and resilience, b) mindful compassion for self and others; c) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking. The MTIA will be instructor led, internet-delivered (via Zoom), interactive, group-based mindfulness training intervention that will incorporate the training for approximately 9 persons in a group format, with outside-of session assignments."
88988815|NCT06242080|Active Comparator|"MAPP intervention"|"The MindfulnessAPP (MAPP) is a self-administered intervention developed by the SMILE study team. The MAPP is for individual use, with eight MAPP sessions composed of mindfulness exercises and didactics that correspond to the MTIA sessions. As the MTIA weekly class will be 90 minutes in length, the MAPP assignments will recommend spending approximately 90 minutes per week covering the assigned lesson, but in a flexible format convenient for the participant. In addition, each session will contain mindfulness-based practice assignments generally ranging from 10 to 30 minutes per day. The total number of suggested days for completion will be 49 days, comparable to the time from start to finish of a traditional 8 week MTIA session; however, there will be flexibility within this individualized program."
88988816|NCT06242080|No Intervention|Wait-list Control|The Wait-list Control (WLC) group will participate in all research assessment sessions, but will not be offered the Mindfulness intervention until after their role in the research is complete.
88988817|NCT06241807|Experimental|Camrelizumab Plus Chemotherapy Arm|Patients were assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed (for adenocarcinoma), 500mg/m2 plus platinum [cisplatin, 75 mg/m2; carboplatin, area under the curve, 5])
88988818|NCT06241781|Experimental|GT101 injection treatment group|
88988819|NCT06241781|Active Comparator|Gemcitabine injection treatment group|
88988820|NCT06241768|Experimental|Text message 1|Version 1 of the text message invitation to use the cloud-based colorectal cancer screening program
88988821|NCT06241768|Experimental|Text message 2|Version 2 of the text message invitation to use the cloud-based colorectal cancer screening program
88988822|NCT06241768|Experimental|Text message 3|Version 3 of the text message invitation to use the cloud-based colorectal cancer screening program
88988823|NCT06241768|Experimental|Text message 4|Version 4 of the text message invitation to use the cloud-based colorectal cancer screening program
88988824|NCT06241729||Patients with diffuse large-cell B lymphoma|Patients with diffuse large-cell B lymphoma in a single-centre cohort at Grand Hôpital de Charleroi
88988825|NCT06241456|Experimental|Regimen A: FT825|Participants with advanced HER2-expressing solid tumors receive FT825 following chemotherapy in Cycle 1 (each cycle is approximately 61 days). Based on the safety, tolerability, and radiographically confirmed clinical benefit to treatment in Cycle 1, participants may be considered for an additional treatment cycle (Cycle 2 retreatment).
88988826|NCT06241456|Experimental|Regimen B: FT825 + Cetuximab|Participants with advanced epidermal growth factor receptor (EGFR)-expressing solid tumors receive FT825 in combination with cetuximab following chemotherapy in Cycle 1 (each cycle is approximately 61 days). Based on the safety, tolerability, and radiographically confirmed clinical benefit to treatment in Cycle 1, participants may be considered for an additional treatment cycle (Cycle 2 retreatment).
88988827|NCT06241261|Experimental|Silver diamine fluoride gel|38% silver diamine fluoride gel
88988828|NCT06241261|Active Comparator|Silver diamine fluoride solution|38% silver diamine fluoride solution
88999218|NCT03004404|Experimental|BA Part: R/T1/T2|"Participants were orally administered 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~Followed by 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
89057838|NCT02217917|Experimental|Cohort 1|Single ascending dose in 3 period cross-over design (with optional 4th period)
89621741|NCT06000085|Experimental|Flowable Giomer Beautifil flow plus x|injectable flowable restorative material
89621742|NCT06000085|Active Comparator|Glass-hybrid-added HVGIC Equia Forte|Glass-hybrid-added Highly viscous glass ionomer cement
88988829|NCT06239779|Experimental|Education Group|"The Education Group is comprised of study participants who receive an educational intervention aimed at enhancing their understanding and management of fibromyalgia. This group is designed to assess the impact of fibromyalgia education on various aspects of participants' well-being, including pain levels, quality of life, smart phone addiction, and daily activities.~Participants in the Education Group will attend a brief educational session. The educational content covers the following key topics: an overview of fibromyalgia, coping strategies and potential harmful effects of smart phone addiction on fibromyalgia.~The primary objective of the Education Group is to evaluate the influence of fibromyalgia education on pain levels, quality of life and physical function (measured using the FIQR) and smart phone addiction (measured using the SAS-SV) and socialization frequency, exercise frequency, sleep quality and daily screen time based on participant diaries."
88988830|NCT06239779|No Intervention|Control Group|"The Control Group is a vital component of this study, serving as a reference group for evaluating the impact of the Education Group's intervention. Participants in this group do not receive the structured educational intervention. Instead they follow their usual routines and receive standard care for fibromyalgia, which may include any recommendations typically offered by their healthcare providers but they are monitored similarly to the participants in the Education Group.~The primary objective of the Control Group is to provide a baseline against which the effects of the educational intervention received by the Education Group can be compared. By not receiving the intervention, this group helps assess whether the educational program has a measurable impact on various aspects of participants' well-being when compared to standard care."
88988831|NCT06238609|Active Comparator|Intervention Group|Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
88988832|NCT06238609|Sham Comparator|Control group|Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
88988833|NCT06237387||Group A|Patients with Allen-Smith acne score 0 and 2 (Mild lesions)
88988834|NCT06237387||Group B|Patients with Allen-Smith acne score 4 (Moderate lesions)
88988835|NCT06237387||Group C|Patients with Allen-Smith acne score 6 and 8 (Severe lesions)
88988836|NCT06236568|Experimental|Machine perfusion|The liver graft to be transplanted is treated with 90 minutes of D-HOPE machine perfusion
88988837|NCT06236568|Active Comparator|No machine perfusion|Standard liver transplantation
88988838|NCT06236035||Group Control|
88988839|NCT06236035||Group ANI|
88988840|NCT06235593|Experimental|Intervention Group|The intervention will be a combination of interviews and face-to-face follow-ups, with teleconsultations, based on other observational and experimental studies. The intervention program includes monitoring for 9 months
88988841|NCT06233825|Experimental|Nutritional Intervention|5 g omega-3 fatty acids (3.75 g eicosapentaenoic acid [EPA] + 1.25 g docosahexaenoic acid [DHA]) per day for 6 weeks, starting 4 weeks before and continuing 2 weeks after surgery, plus 40 g (2 x 20 g) of EAA per day, starting 1 week before and continuing 2 weeks after surgery.
88988842|NCT06233825|Placebo Comparator|Placebo Control|5 g safflower oil per day for 6 weeks, starting 4 weeks before and continuing 2 weeks after surgery, plus 40 g (2 x 20 g) of NEAA per day, starting 1 week before and continuing 2 weeks after surgery.
88988843|NCT06231212|Experimental|ECa groups|Intervention group takes capsules containing of ECa 233, an active substance composed of Madecassoside and Asiaticoside
88988844|NCT06231212|Active Comparator|NSAID group|Active-controlled group was given capsules containing 200 mg of ibuprofen
88988845|NCT06231212|Placebo Comparator|Placebo group|Placebo-controlled group received capsules containing 250 mg of lactose
88988846|NCT06230900|Experimental|Experimental group|14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion (test period)
88988847|NCT06230705|Experimental|Guided management|"The intervention will be comprised of four broad components (described below). The focus groups will inform these components and therefore, we propose a community-responsive and ultimately, community-driven intervention.~Component on reducing barriers to health care access~Nutritional component~Activity component~CVD risk factor education component"
88988848|NCT06230705|Active Comparator|Self-managed|Self-managed (control group): For participants randomized to the self-managed group, we will employ the standard of care that is currently used by the Strong Heart Study (SHS) and other large cohorts, which is based on a referral program for risk factor control and dissemination of educational pamphlets. Therefore, the risk factor control and education for this group will be self-managed.
89621743|NCT06000007|Active Comparator|Treatment as usual|Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
89621744|NCT06000007|Active Comparator|Intervention arm|Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
88988849|NCT06230172|Experimental|Prospective group (>1600 grams)|The prospective group is weaned from incubator to crib at a postnatal weight of >1600 grams following consent process.
89037211|NCT04320043||Anterior cervical decompression surgery|Adult patients who underwent anterior cervical decompression surgery for radiculopathy and/or myelopathy due to cervical degenerative disc disease. Patients underwent one of the following interventions: ACD, ACDF, ACDF with plating or corpectomy.
89621745|NCT05997641|Experimental|DF-003 (Single Ascending Dose, Part 1)|Participants will receive a single oral dose of 3 mg DF-003 (1 mg x 3).
89621746|NCT05997641|Placebo Comparator|Placebo (Single Ascending Dose, Part 1)|Visually matching 0 mg DF-003 capsules.
89621747|NCT05997641|Experimental|DF-003 (Multiple Ascending Doses, Part 2)|Participants will receive DF-003 once daily by oral administration for 14 days. The specific doses given will be based on data collected in Part 1 of the study. This part of the study may include 1 mg, 5 mg, or 25 mg capsules.
89621748|NCT05997641|Placebo Comparator|Placebo (Multiple Ascending Doses, Part 2)|Visually matching 0 mg DF-003 capsules.
89621749|NCT05994859|Experimental|SIRT|Treatment with SIRT.
89037212|NCT05382416|Experimental|Peer Toolkit Training|Participants assigned to this arm will attend online or in-person trainings on the SHARE! Peer Toolkit, which requires 60 hours of time to be completed over 10 weeks.
89037213|NCT05382416|No Intervention|Wait-list Control|The wait-list control will continue practice as usual and not receive peer toolkit training until after the follow-up data collection.
89037214|NCT05194579|Other|PF-06881894 by on-body injector (OBI)|PF-06881894 given by on-body injector (OBI) as test arm, 6 mg administered as a single SC injection
89037215|NCT05194579|Other|PF-06881894 by prefilled syringe (PFS)|PF-06881894 given by prefilled syringe (PFS) as reference arm, 6 mg administered as a single SC injection
89037216|NCT04320472||Follow up|Follow up of all included patients up to 3 months after enrollement
89037217|NCT05378594|Experimental|House dust mite nasal allergen challenge|House dust mite allergic patients to undergo nasal allergen challenge with house dust mite extract
89037218|NCT05378594|Experimental|Silver birch pollen nasal allergen challenge|Silver birch pollen allergic patients to undergo nasal allergen challenge with silver birch pollen extract
89037219|NCT04206943|Experimental|A Low Dose|4 x 10^6 Car-T cell/ kg
89037220|NCT04206943|Experimental|B High Dose|6 x 10^6 Car-T cell/ kg
89037221|NCT01313923|Experimental|Sirolimus (formerly known as Rapamycin)|Subjects with stable pemphigus vulgaris already on treatment with prednisone will be enrolled. Subjects will start taking oral sirolimus and have it up-titrated while decreasing the prednisone dosage. Their disease state will be monitored during this time.
89037222|NCT01313884|Experimental|Combination Therapy|"Regimen A alternating with Regimen B every 21 days~Regimen A:~Cytoxan 1200mg/m2~Doxorubicin, starting dose 75 mg/m2 to a maximum of 450mg/m2~Vincristine, starting dose 2 mg/m2 to a maximum of 2 mg~Pegfilgrastim, 6 mg subcutaneous within 24 to 48 hours after each cycle~Regimen B:~Irinotecan 50 mg/m2/day x 5 days~Temozolomide 100 mg/m2/day x 5 days followed by 2 weeks treatment-free"
89621750|NCT05994183|Experimental|Dexamethasone Administration|Dexamethasone will be given orally to all consented participants. Two doses will be administered within 12-48 hours, with at least the 1st dose administered during the bronchiolitis hospitalization. If the participant is discharged before the 2nd dose, it will be administered at home.
89037223|NCT05352659|Experimental|Face-to-face and online LGBTQ training+|The Study Intervention arm receives the organization-level LGBTQ climate assessment and technical assistance, the provider-level face-to-face LGBTQ training along with links to publicly available on-line training.
89037224|NCT05352659|Other|On-line resources|The Comparison Intervention arm receives only links to publicly available on-line resources.
89037225|NCT01158664|Experimental|0.6 mm tread pitch implant|
89037226|NCT01158664|Experimental|0.1 mm tread pitch implant|
89621751|NCT05992740|Active Comparator|bronchial wash group|the patients will undergo bronchoscope then pre-biopsy bronchial wash, biopsy, post-biopsy bronchial wash will be obtained
89037227|NCT00537524|Experimental|Arm 1|0.5mL of H5N1 vaccine 7.5ug
89037228|NCT00537524|Active Comparator|Arm 2|0.25 or 0.5mL of H5N1 vaccine
89037229|NCT05193240|Experimental|preliminary swallowing test|compared as nasofibroscopy and ultrasound examination of vocal cords
89037230|NCT00536406|Experimental|A|Participants will receive the BE-ACTIV treatment
89037231|NCT00536406|Active Comparator|B|Participants will receive treatment as usual
89037232|NCT01135459|Experimental|CEP-33457|Participants will receive CEP-33457 200 mcg SC every 4 weeks for 20 weeks (Day 1, Weeks 4, 8, 12, 16, and 20).
89037233|NCT01135459|Placebo Comparator|Placebo|Participants will receive placebo matching to CEP-33457 SC every 4 weeks for 20 weeks (Day 1, Weeks 4, 8, 12, 16, and 20).
89037234|NCT00537602|Experimental|A|Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
89037235|NCT00537602|Placebo Comparator|B|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
89037236|NCT05178667|Experimental|High dose|4 capsules with 1.6g of active product per day: 2 at breakfast and 2 at dinner
89037237|NCT05178667|Active Comparator|Low dose|4 capsules with 0.8g of active product per day: 2 at breakfast and 2 at dinner
89037238|NCT05178667|Placebo Comparator|Maltodextrin|4 placebo capsules (maltodextrin) per day: 2 at breakfast and 2 at dinner
89037239|NCT01259284|Experimental|Atorvastatin|1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
89037240|NCT01259284|Experimental|Fish Oil Supplement|3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
89037241|NCT01259284|Placebo Comparator|Placebo|4 capsules orally every morning and 3 every evening for 5 days pre-surgery.
89037242|NCT03457025|Active Comparator|Standard of Care Therapy|Reference Therapy
89037243|NCT03457025|Experimental|Standard of Care + HOTB|Reference therapy in addition to Hyperbaric Oxygen Therapy
89037244|NCT01259245|Experimental|Tai chi + PRP|Tai chi elements in incorporated into the exercise component of standard pulmonary rehabilitation program. The exercise content was totally identical to the PRP group except 15 minutes of Tai Chi exercises was substituted to 15 minutes of relaxation exercise. The 5 forms of Sun Style of Tai Chi were taught.
89037245|NCT01259245|Active Comparator|PRP|PRP is a formal pulmonary rehabilitation program consisted of physical training including warm up and cool down exercise and aerobic exercises in addition to breathing control exercises, safety precautions for physical training, Thera-Band strengthening exercises and overview of COPD management.
89037246|NCT00537719|Active Comparator|GSK716155|albiglutide subcutaneous injection
89037247|NCT00537719|Placebo Comparator|placebo|placebo injection
89037248|NCT04685603|Experimental|AV-COVID-19 (0.1 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
89037249|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 0 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
89037250|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 0 mcg GMCSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 0 mcg GM-CSF
89037251|NCT04685603|Experimental|Experimental: AV-COVID-19 (0.1 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
89037252|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
89037253|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 250 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 250 mcg GM-CSF
89037254|NCT04685603|Experimental|AV-COVID-19 (0.1 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.1 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
89037255|NCT04685603|Experimental|AV-COVID-19 (0.33 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 0.33 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
89037256|NCT04685603|Experimental|AV-COVID-19 (1.0 mg antigen, 500 mcg GM-CSF)|Autologous dendritic cells previously loaded with 1.0 mg SARS-CoV-2 spike protein, admixed with 500 mcg GM-CSF
89037257|NCT00536523||Patients Receiving Chemotherapy|Patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer for which 6 cycles of a taxane and platinum containing regimen is planned
89037258|NCT04685837|Experimental|Tele-rehabilitation group|The participants randomly assigned to the tele-rehabilitation group will use a computer application to know and execute the exercise protocol. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the application works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
89621752|NCT05992740|Active Comparator|bronchial brush|the patients will undergo bronchoscope then pre-biopsy bronchial brush, biopsy, post-biopsy bronchial brush will be obtained
89621753|NCT05992584|Experimental|Len-Sin-SIRT|Lenvatinib, sintilimab plus SIRT
89037259|NCT04685837|Experimental|Face to face group|Participants randomly assigned to the face-to-face group will use the physical therapy clinic to do the exercises controlled by the principal investigator. Before starting the protocol, each participant will be assessed by the principal investigator. He will explain how the protocol works. They will perform 2 sessions of therapeutic exercise for 8 weeks. At the end of the protocol, they will be re-evaluated by the principal investigator.
89037260|NCT00536562|No Intervention|Usual Care|Usual Care as provided through the Stroke Prevention Clinic
89037261|NCT00536562|Active Comparator|Cardiac Rehabilitation|Usual Care plus Comprehensive Cardiac Rehabilitation Program
89037262|NCT00537758|Experimental|1|Cognitive Behavior Therapy
89037263|NCT00537758|Experimental|2|Behavioral Weight Loss Treatment
89037264|NCT00537758|Experimental|3|CBT + BWL
89037265|NCT04685096||Asian skin|Twice-daily application for 55 Days
89037266|NCT04685096||African-American skin|Twice-daily application for 55 Days
89037267|NCT00537797|Experimental|Arm 1|"18-FDG-PET exam with SUV determination~Thyroid operation to remove nodule~Pathologic confirmation of nodule histology~Determine sensitivity and specificity of FDG-PET, correlative studies"
89621754|NCT05991739|Experimental|Treatment|Participants in the treatment arm will begin the FIESTA intervention immediately (Time 1).
89621755|NCT05991739|Other|Waitlist-Control|Participants in the waitlist-control arm will wait approximately three months for the FIESTA intervention (Time 2).
89621756|NCT05989490|Experimental|Static stretching to the point of pain|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of pain.
89621757|NCT05989490|Experimental|Static stretching to the point of discomfort|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort.
89037268|NCT00537836|Experimental|ZK 283197, 3 mg|Postmenopausal women with hot flushes received 3 mg (3 x 1 mg tablets) ZK 283197, administered orally once daily over 8 weeks
89037269|NCT00537836|Placebo Comparator|Matching placebo|Postmenopausal women with hot flushes received placebo (3 tablets) orally once daily over 8 weeks
89037270|NCT00537836|Experimental|ZK 283197, 2 mg|Postmenopausal women with hot flushes received 2 mg (2 x 1 mg tablet) ZK 283197 plus 1 placebo tablet, once daily orally over 8 weeks
89621758|NCT05986825||Experimental|Patients with Verneuil disease
89621759|NCT05981443|Experimental|Active Comparator: Dermabond|The surgical wound over one eyebrow will be closed with Dermabond.
89621760|NCT05981443|Active Comparator|Active Comparator: Non-Absorbable Sutures|The surgical wound over one eyebrow will be closed with non-absorbable sutures.
89621761|NCT05981274||Systematic joint and bone health assessments before and after enrollment|"Haemophilia Early Arthropathy Detection :HEAD-US, HJHS, and DEXA scan~serum markers : CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)~Quality of life assessments (Haem-A-QoL, EQ-5D)"
89037271|NCT00537836|Active Comparator|17ß-estradiol|Postmenopausal women with hot flushes received 1 mg (2 x 0.5 mg tablet) 17ß-estradiol plus 1 placebo tablet, once daily orally over 8 weeks
89037272|NCT05468268|Experimental|20 Hz rTMS|"rTMS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode.~Stimulation parameters will be rTMS delivery of 1600 pulses divided into blocks: 20 Hz for 2 seconds (40 pulses) followed by 28 seconds of pause, with a stimulation intensity equal to 100% of the motor threshold value at rest."
89037273|NCT05468268|Sham Comparator|Sham rTMS|"Sham rTMS will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during stimulation, and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation. This 30 mm distance is adequate to ensure that the magnetic pulse does not reach the cortex."
89037274|NCT02277171|Experimental|Nitric oxide impregnated catheter|
89037275|NCT00537875|Active Comparator|1|
89037276|NCT00537875|Placebo Comparator|2|
89037277|NCT00551564|Experimental|Subjects in healthy normal and overweight control arm|Subjects in the Healthy Normal or Overweight Control Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
89037278|NCT00551564|Experimental|Subjects in healthy obese with T2DM arm|Subjects who are in the Healthy Obese or T2DM Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
89037279|NCT05105061|Experimental|Ketamine (1) then Placebo (2)|Participants will receive an intramuscular injection of racemic ketamine, followed the next day by an intramuscular injection of saline (placebo)
88988850|NCT06227429||Full Analysis Set (FAS)|The Full Analysis Set (FAS) will include all patients with a confirmed HT-1 diagnosis on Nitisinone treatment in routine clinical care, who provide signed informed consent. Patients must be either on treatment with Nitisinone at study entry or they must have been prescribed Nitisinone at enrollment. No specific exclusion criteria from the analysis set will be applied. The FAS will be used for all analyses.
88988851|NCT06221306|Experimental|Narrow diameter implant placement (NDI) (3.3)|
88988852|NCT06221306|Active Comparator|Standard diameter implant (SDI) placement (4.1) with simultaneous bone augmentation.|
88988853|NCT06221085||normal BMI|30 female students who have normal BMI <25kg/m2.
88988854|NCT06221085||overweight|30 female students who are overweight and their BMI 25 - 30 kg/m2
88988855|NCT06221085||obese|30 female students who are obese and their BMI > 30 kg/m2.
88988856|NCT06217562|Active Comparator|Septic shock treatment strategy involving a lower threshold for vasopressin initiation|Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.1 micrograms/kilogram/minute (mcg/kg/min). Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.
88988857|NCT06217562|Active Comparator|Septic shock treatment strategy involving a higher threshold for vasopressin initiation|Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.4 mcg/kg/min. Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.
88988858|NCT06216028|No Intervention|Standard of Care|Standard of care IA injection may include cortisone or hyaluronic acid (HA) as per discretion of the Principal Investigator
88988859|NCT06216028|Experimental|Bone Marrow Aspirate Concentrate (BMAC)|Cell suspension for infusion. 50 mL of Bone Marrow Aspirate collected, and 10-15 mL BMAC injected to knee(s)
88988860|NCT06212076|Experimental|Cohort 1 (200 mg BID)|Starting at 200mg BID cohort, 3 subjects will be enrolled. After 3 subjects completed DLT evaluation, the Safety Monitoring Committee (SMC) will review all available safety and PK/PD data from all treated subjects (DLT evaluable and non-DLT evaluable subjects), taking into consideration the dose-assignment recommendation based on 3+3 decision rule , to make the recommendation on the conduct of the study including the dose level and dose schedule for subsequent subjects.
88988861|NCT06212076|Experimental|Cohort 2 (250 mg BID)|Starting at 250 mg BID cohort, 3 subjects will be enrolled. After 3 subjects completed DLT evaluation, the Safety Monitoring Committee (SMC) will review all available safety and PK/PD data from all treated subjects (DLT evaluable and non-DLT evaluable subjects), taking into consideration the dose-assignment recommendation based on 3+3 decision rule , to make the recommendation on the conduct of the study including the dose level and dose schedule for subsequent subjects.
88988862|NCT06212076|Experimental|Cohort 3 (NSCLC)|Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with non small cell lung cancer (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
89621762|NCT05979948|Experimental|zanubrutinib combined with BR regimen|Drug: zanubrutinib,160 mg oral capsules twice daily for 12 months Drug: Bendamustine,70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles. Drug: Rituximab,375 mg/m2 intravenously on day 0 of each cycle for 6 cycles.
89621763|NCT05975671|Other|PICU Clinicians and Sepsis stakeholders|"Clinicians and sepsis stakeholders in the participating sites will be primarily recruited via email. During the course of this multifaceted intervention:~All the PICU (Pediatric Intensive Care Unit) prescribing clinicians and sepsis stakeholders in the participating sites will receive clinical guidelines, unit-level feedback reports, and education on Vancomycin use during the intervention.~Investigators will perform semi-structured interviews with 90 PICU clinicians and sepsis stakeholders.~Surveys will be sent to all eligible clinicians, estimated to be up to 2500 individuals across the 4 sites. These structured surveys will be done at baseline and at 9 months post-implementation."
88988863|NCT06212076|Experimental|Cohort 4 (TNBC)|Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with triple-negative breast cancer (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
89037280|NCT05105061|Placebo Comparator|Placebo (1) then Ketamine (2)|Participants will receive an intramuscular injection of saline (placebo), followed the next day by an intramuscular injection of racemic ketamine
89621764|NCT05975671|No Intervention|PICU Patients with suspected sepsis|Research procedures involving patients will be limited to medical record review. This medical record review will help inform the intervention directed at PICU clinicians/stakeholders and the assessment of study outcomes. Approximately 50,000 patients will participate in the study. Data elements will be collected at each site and stored as password-protected Comma-separated values (CSV) files. These files will not contain any direct Protected Health Information (PHI) but will contain elements of date (e.g., date of admission, date of suspected sepsis episode). The study Identification (ID) number will be used to identify each unique patient. Each site will collect and store data in compliance with the Children's Hospital of Philadelphia (CHOP) and local Institutional Review Board (IRB) policies.
89621765|NCT05967741|Experimental|Erythritol-sweetened beverage|1-gram erythritol/kg body weight/day, divided into three beverage servings and fruit-flavored with Kool-Aid® unsweetened drink mix.
89037281|NCT04870463|Active Comparator|Gold Standard Group|Patients treated with multi-braces fixed appliances and a conventional sequence of aligning and levelling arches (Ni-Ti arches with the same force in all sections)
89057839|NCT02217917|Experimental|Cohort 2|Multiple ascending dose
89621766|NCT05967741|Placebo Comparator|Aspartame-sweetened beverage|Control beverages will be made from a noncaloric aspartame-sweetened, fruit-flavored drink mix at the concentration needed to match the sweetness (~3 mg aspartame/kg/day) and flavoring of the erythritol beverages on a per volume basis.
89621767|NCT05966285||suture group|Patients ≥65 years who underwent urgent surgical groin hernia repair from January 2015 to June 2022 were included.
89621768|NCT05966285||mesh repair|Patients ≥65 years who underwent urgent surgical groin hernia repair from January 2015 to June 2022 were included.
89621769|NCT05966259|Other|Intervention Group- Intensive Multilevel Intervention|Intervention Group: intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
89621770|NCT05966259|Other|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
89621771|NCT05965219|Experimental|Part A: Emraclidine Followed by Itraconazole + Emraclidine|Participants will receive a single oral dose of emraclidine 10 milligrams (mg) on Day 1 in Treatment Period (TP) 1 followed by itraconazole 200 mg, orally, twice daily (BID) on Day 1 and once daily (QD) from Days 2 to 14, with a single oral dose of emraclidine 10 mg co-administered on Day 5 in TP 2.
89621772|NCT05965219|Experimental|Part B: Emraclidine Followed by Carbamazepine + Emraclidine|Participants will receive a single oral dose of emraclidine 30 mg on Day 1 in TP 1 followed by carbamazepine 100 mg BID from Days 1 to 3, 200 mg BID from Days 4 to 6, and 300 mg BID from Days 7 to 19, orally, with a single oral dose of emraclidine 30 mg on Day 16 in TP 2.
89621773|NCT05965219|Experimental|Part C: Metformin Followed by Emraclidine + Metformin|Participants will receive a single oral dose of metformin 850 mg on Day 1 in TP 1 followed by emraclidine 30 mg, orally, QD for Days 1 to 10, with a single oral dose of metformin 850 mg co-administered on Day 8 in TP 2.
89621774|NCT05963451||Chronic Low Back Pain (CLBP) group|Participants who will took part in our study are people living with CLBP who will undergo facet thermal ablation treatment
89621775|NCT05957809|Experimental|1. Structured exercise group|This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks.
89621776|NCT05957809|No Intervention|2. Control group|This group will be assessed at the beginning, 8. and 24. weeks.
89621777|NCT05957484|Active Comparator|Active Treatment|Study participants will receive ~18-minute active stimulation twice daily over 4 weeks, using a non-invasive brainstem modulation device.
89621778|NCT05957484|Placebo Comparator|Sham Treatment|Study participants will receive ~18-minute of sham stimulation twice daily over 4 weeks using a non-invasive brainstem modulation device.
89621779|NCT05957484|Experimental|Open Label|After completion of sham or active stimulation over 4 weeks, participants can choose to receive ~18-minute active stimulation twice daily for up to 12 weeks.
89621780|NCT05953012|Experimental|PART 1- SAD|"The SAD part of the study will be conducted in a step-wise manner for a total of 4 dose levels of PMC-403.~Dose level 1: 0.7 mg/eye, baseline(Day 0)~Dose level 2: 2 mg/eye, baseline(Day 0)~Dose level 3: 3 mg/eye, baseline(Day 0)~Dose level 4: 4 mg/eye, baseline(Day 0)"
89621781|NCT05953012|Experimental|PART 2- MAD|"Upon the end of the SAD part of the study, the MAD part is planned to be conducted in a step-wise manner for a total of 2 dose levels.~Dose level 1: 3 mg/eye, baseline(Day 0), Week 4(Day 28), Week 8(Day 56)~Dose level 2: 4 mg/eye, baseline(Day 0), Week 4(Day 28), Week 8(Day 56)"
89621782|NCT05947474|Experimental|Dose Escalation ORB-011|ORB-011 Dose Escalation Participants will be administered study drug at dose levels corresponding to their Cohort. Cohort 1 will be treated with the lowest dose, and the dose will be escalated for future cohorts once the previous dose has been observed not to be associated with DLTs. Up to 7 dose cohorts have been pre-specified. Doses from the escalation arms will be selected as RP2D candidates.
89621783|NCT05946798|Placebo Comparator|local lactated Ringer's perfusion|lactated Ringer's is perfused through the microdialysis fiber to serve as the vehicle control
89621784|NCT05946798|Experimental|local apocynin perfusion|local apocynin is perfused through the microdialysis fiber to serve as the NADPH oxidase inhibited experimental treatment
89621785|NCT05946798|Experimental|local L-NAME perfusion|local L-NAME is perfused through the microdialysis fiber to inhibit nitric oxide synthase
89621786|NCT05946798|Experimental|local apocynin + L-NAME perfusion|local apocynin and L-NAME are perfused through the microdialysis fiber for dual inhibition of NADPH oxidase and nitric oxide synthase
89621787|NCT05946785|Placebo Comparator|local lactated Ringer's perfusion|lactated Ringer's is perfused through the microdialysis fiber to serve as the vehicle control
89621788|NCT05946785|Experimental|local ascorbate perfusion|local ascorbate is perfused through the microdialysis fiber to serve as the antioxidant experimental treatment
89621789|NCT05946785|Experimental|local L-NAME perfusion|local L-NAME is perfused through the microdialysis fiber to inhibit nitric oxide synthase
89621790|NCT05945719||Adult chronic pain patients|Adult chronic pain patients who sexually harass pain clinic staff
89037282|NCT04870463|Experimental|Intervention Group|Patients treated with multi-braces fixed appliances and a different sequence of aligning and levelling arches (some arches provide individual forces for each group of teeth (incisors, premolars and molars))
89621791|NCT05945394||Patients with suspected CHD who experienced CAG|Patients with suspected coronary heart disease who experienced coronary angiography
89621792|NCT05944978|Experimental|Study treatment|Participants receive GNC-035 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89621793|NCT05941819|Experimental|All participants|All participants will be provided with the ARC-IM Thoracic System (implantable and non-implantable parts)
89057840|NCT02217917|Experimental|Cohort 3|Multiple ascending dose
89057841|NCT01687062|Active Comparator|FeSO4 + high phytate|injera test meal 1 labeled with a 4 mg staple iron isotope tag
89057842|NCT01687062|Experimental|FeSO4 + medium phytate|injera test meal 2 labeled with a 4 mg staple iron isotope tag
89533313|NCT04971720|Experimental|Sacubitril/Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
89621794|NCT05940961|Experimental|Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL|intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
89621795|NCT05939518|Experimental|Liberal Lactated Ringer Fluid Protocol with Ephedrine and Phenylephrine Boluses|IV Infusion of 500 ml of lactated Ringer's (RL) solution during the induction of anesthesia followed by an infusion of RL at a rate of 8.0 ml/kg/h throughout the maintenance phase of anesthesia. The anesthesia care provider will be allowed free use of IV boluses of ephedrine or phenylephrine to target a mean arterial blood pressure of >60 mmHg.
89621796|NCT05939518|Active Comparator|Restrictive Lactated Ringer Fluid Protocol with Noradrenaline Infusion|IV Infusion of 200 ml of lactated Ringer's (RL) solution during the induction of anesthesia followed by an infusion of RL at a rate of 2.0 ml/kg/h + an infusion of noradrenaline throughout the maintenance phase of anesthesia, through a large peripheral vein. The noradrenaline infusion rate will be titrated after an initial bolus of 10 μg, from an initial rate of 2.0 μg/kg/h, which may be raised up to 8.0 μg/kg/h, to target a mean arterial blood pressure (MBP) of >60 mmHg. If the MBP target is still not achieved, the RL infusion rate may be increased up to 4.0 ml/kg/h.
89621797|NCT05934500|No Intervention|Standard of Care|Opioid standard of care: Percocet (oxycodone 5mg-acetaminophen 325 mg) every 4 hours PRN postoperatively for 7 days
89621798|NCT05934500|Experimental|Cannabidiol Oil 100 mg/day|CDB 100mg PO liquid suspension QD starting 30 days prior to surgery and finishing 30 days post-operatively
89621799|NCT05934500|Experimental|Cannabidiol Oil 200 mg/day|CBD 200mg PO liquid suspension QD starting 30 days prior to surgery and finishing 30 days post-operatively.
89621800|NCT05934019|Experimental|EMPATIA|Participants in this group will access the online prevention program EMPATIA as a self-help online program during eight weeks.
89621801|NCT05934019|No Intervention|Care As Usual|Participants in this group will gain access to the online prevention program EMPATIA after 12 months. All other kinds of interventions during participation are allowed and will be recorded using the Client Sociodemographic and Service Receipt Inventory
89621802|NCT05930925|Experimental|[phenyl-14C]ARV-471|[phenyl-14C]ARV-471 is administered as a single dose
89621803|NCT05930925|Experimental|[oxoisoindolin-14C]ARV-471|[oxoisoindolin-14C]ARV-471 is administered as a single dose
89621804|NCT05926947|Experimental|Verum A|
89621805|NCT05926947|Experimental|Verum B|
89621806|NCT05926947|Placebo Comparator|Placebo|
89621807|NCT05923788|Other|Fabry disease|
89621808|NCT05923788|Other|Patients undergoing renal functional exploration|Patients undergoing renal functional exploration for a reason other than Fabry disease, amyloidosis, hemochromatosis
89621809|NCT05920863|Experimental|Experimental|"TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.~Tislelizumab: 200mg, cycle 3 week.~Lenvatinib: weight <60kg, 8mg/day; weight ≥60kg, 12mg/day."
89621810|NCT05919368|Experimental|Yam pill|It consists of sweet potato, white art and ginseng
89621811|NCT05919368|Placebo Comparator|placebo group|It consists of corn starch and dextrin
89621812|NCT05917587|Active Comparator|metformin|
89621813|NCT05917587|Placebo Comparator|placebo|
89621814|NCT05914116|Experimental|DB-1311 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 1 on Day 1 of each cycle Q3W
89621815|NCT05914116|Experimental|DB-1311 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 2 on Day 1 of each cycle Q3W
89621816|NCT05914116|Experimental|DB-1311 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 3 on Day 1 of each cycle Q3W
89621817|NCT05914116|Experimental|DB-1311 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 4 on Day 1 of each cycle Q3W
88988864|NCT06212076|Experimental|Cohort 5 (head and neck cancer)|Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with head and neck cancer (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
88988865|NCT06212076|Experimental|Cohort 6 (brain glioma)|Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with brain glioma (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
88988866|NCT06210854|Experimental|Tropis Experimental|Will receive study drug using the Tropis device
88988867|NCT06210854|Experimental|Stratis Experimental|Will receive study drug using the Stratis device
88988868|NCT06210854|Placebo Comparator|Tropis Placebo|Will receive placebo using the Tropis device
88988869|NCT06210854|Placebo Comparator|Stratis Placebo|Will receive placebo using the Stratis device
89533314|NCT04971720|Active Comparator|Valsartan Morning Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
89621818|NCT05914116|Experimental|DB-1311 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1311 at Dose Level 5 on Day 1 of each cycle Q3W
89621819|NCT05914116|Experimental|DB-1311 Dose Expansion 1|Subjects with advanced/unresectable, or metastatic SCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
89621820|NCT05914116|Experimental|DB-1311 Dose Expansion 2|Subjects with advanced/unresectable, or metastatic NSCLC who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
89621821|NCT05914116|Experimental|DB-1311 Dose Expansion 3|Subjects with advanced/unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
89621822|NCT05914116|Experimental|DB-1311 Dose Expansion 4|Subjects with advanced/unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
89621823|NCT05914116|Experimental|DB-1311 Dose Expansion 5|Subjects with advanced/unresectable, or metastatic melanoma who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
89621824|NCT05914116|Experimental|DB-1311 Dose Expansion 6|Subjects with other advanced or metastatic solid tumors who have progressed on or after standard systemic treatments, a 21-day treatment cycle (i.e., once every 3 weeks) via intravenous infusion will be used for DB-1311.
89621825|NCT05908799||Pembrolizumab + Chemotherapy|Exposure Group
89621826|NCT05908799||Chemotherapy|Reference Group
89621827|NCT05907824||Parenchyma-sparing Resections|Parenchyma-sparing resections, including open, laparoscopic, or robotic pancreatic enucleation, duodenum-preserving pancreatic head resection, middle segment pancreatectomy, and spleen-preserving distal pancreatectomy, without standard lymph node dissection.
89621828|NCT05907824||Oncologic Resections|Oncologic resections, including open, laparoscopic, or robotic pancreaticoduodenectomy or distal pancreatectomy, with standard lymph node dissection.
89621829|NCT05906303|Experimental|Caffeine and sodium benzoate|Patients will received 250 mg IV caffeine and sodium benzoate (125 mg each) dissolved in 500 cc normal saline which will be administered over the course of two hours upon determination the patient is 10 cm in cervical dilation.
89621830|NCT05906303|Placebo Comparator|Placebo|Patients will received 500 cc normal saline which will be administered over the course of two hours upon determination the patient is 10 cm in cervical dilation.
89621831|NCT05905718||Spinomed orthosis group|
89621832|NCT05905718||Biofeedback orthosis group|
89621833|NCT05903053|Experimental|Telehealth Intervention|"A multiple baseline design across subjects will be used with varying introduction of treatment elements. Baseline periods will be 3, 5, and 7 sessions with the baseline period of 3 and 5 sessions repeated twice for subsequent participants. An intense intervention phase will follow the baseline phase in which 45-60 minute treatment sessions will occur twice per week over the course of 4-6 weeks for a total of 8 sessions. Each week during the intense intervention phase, caregiver coaches will introduce a new treatment technique to the caregiver and allow for caregiver practice with immediate feedback. At the conclusion of the intense intervention phase, coaches will provide booster sessions with the caregivers once weekly for 1 month (4 sessions total)."
89621834|NCT05900427|Experimental|Liposomal Bupivacaine Group|10 mL (133 mg) Liposomal bupivacaine and 20 mL (50 mg) 0.25% bupivacaine and 6 mL of saline (183 mg)
89621835|NCT05900427|Other|Plain Bupivacaine Group|36 mL (180 mg) 0.5% bupivacaine
89621836|NCT05897840|Experimental|Continuous measurement of central venous oxygen saturation|"The measurement of SvcO2 is performed by spectrophotometry which is a quantitative measurement of wavelength transmission.~For this, a fiber optic probe, CeVOX probe, is used."
89621837|NCT05897307|Placebo Comparator|Group (C)|will not receive any regional anesthesia and only will receive fentanyl 1μg/kg/hr.
89621838|NCT05897307|Active Comparator|Group (R)|will receive 30 ml of 0.25% of plain ropivacaine for each side.
89621839|NCT05897307|Active Comparator|Group (DR)|will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
89621840|NCT05897086|No Intervention|Control (No Intervention)|For the control groups, epineural repair will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon.
89621841|NCT05897086|Experimental|Experimental|For the experimental group, after obtaining hemostasis, prior to neurorrhaphy, the operative field will be irrigated with calcium-free Plasmalyte A® (Baxter: Deerfield, IL) throughout the neurorrhaphy. At this point, the nerves will be repaired using standard suture neurorrhaphy techniques. Subsequently, approximately 1 or 2 drops of 5mg/ml (0.5%) methylene blue in sterile water solution are applied to the trimmed nerve endings. Then, approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water will be irrigated onto the neurorrhaphy site and the surgeon will wait one minute prior to continuing. Following this, the repaired nerve will be irrigated with calcium-containing Lactated Ringers (Hospira; Lake Forest, IL).
89621842|NCT05896683|Experimental|Part 1: Sequence AB|Participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention period 1. After washout period of 14 to 21 days, participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention period 2.
89621843|NCT05896683|Experimental|Part 1: Sequence BA|Participants will receive intervention B (lazertinib test formulation) on Day 1 of intervention period 1. After washout period of 14 to 21 days, participants will receive intervention A (lazertinib reference formulation) on Day 1 of intervention period 2.
89621844|NCT05896683|Experimental|Part 2: Sequence CD|Participants will receive Intervention C (lazertinib reference formulation) on Day 1 of intervention period 1. After washout period of 14 to 21 days, participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention period 2.
88988870|NCT06210074|Experimental|Main Study Arm|Women attending for routine colposcopy clinics as part of standard of care will be provided with the opportunity to participate and get tested with the Daye Diagnostic Tampon. Initial notice of the study will be via a patient information sheet sent with the colposcopy invitation
88988871|NCT06209112||Conventional group' (Group C)|The 'conventional' group (Group C): FGF will be set to 6 L/min and the FVS 3% at Tzero. The FGF will be reduced to 0.5 L/min upon reaching FAS 2%. Hereafter, the FVS will be set to 4% and maintained till 15 min (T15) from Tzero.
89621845|NCT05896683|Experimental|Part 2: Sequence DC|Participants will receive intervention D (lazertinib test formulation) on Day 1 of intervention period 1. After washout period of 14 to 21 days, participants will receive intervention C (lazertinib reference formulation) on Day 1 of intervention period 2.
89037283|NCT00551603|Experimental|1|Group Epo will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-weekly SC epoetinum beta during the first phase, then will be switched to receive SC once-fortnightly darbepoetinum. Anaemia treatment schedule will continue according to the Romanian Best Practice Guidelines recommendations, with the same dose. A conversion factor of 1:200 will be used.
89037284|NCT00551603|Active Comparator|2|Subjects in the Darbepo Group will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-fortnightly or once-monthly darbepoetin SC administration, continuing their previous schedule and will continue their previous schedule of anaemia treatment during the second phase of the study
89037285|NCT05093712||Phase I (survey)|Patients complete surveys over 10 minutes on their background, health literacy level, barriers to cancer care, and knowledge of cervical cancer and its treatment.
89037286|NCT05093712||Phase II (survey, educational video)|Patients watch educational video on cervical cancer. Patients also complete surveys over 5-10 minutes at baseline and after watching educational video.
89037287|NCT04864262|Experimental|Photovoice|
89037288|NCT04853264|Experimental|Experimental: intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
89037289|NCT04853264|Active Comparator|Control group|Conventional peripheral venipuncture performed by a registered nurse.
89037290|NCT05075811|Experimental|Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC)|Direct injection of vertebral bone marrow derived mesenchymal stem cells at a dose of 100 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
89037291|NCT05075811|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of vertebral allogeneic bone marrow derived mesenchymal stem cells at a dose of 100 million cells into ileal pouch fistula(s).
89621846|NCT05894772|Experimental|Intervention arm|Power over Pain Portal
89037292|NCT04806191|Experimental|Intervention|Patients will be assessed by GPs who have attended an outreach workshop and trained at using an evidence based strategy for shoulder examination and treatment. GPs will have access to a decision support tool and patients is offered a tailored information package for self management.
89037293|NCT04806191|Active Comparator|Treatment as usual (TAU)|The participants enrolled in the control period will receive treatment as offered in general practice.
89037294|NCT00551681|Active Comparator|1|Epicardial left ventricular lead placement
89037295|NCT00551681|Active Comparator|2|transvenous left ventricular lead
89037296|NCT00551720|Experimental|Standard Care|
89037297|NCT00551720|Experimental|Motivational Enhancement|
89621847|NCT05887102|Experimental|PACHA program group|Pharmacists and women in the PACHA program group will receive the PACHA program component's.
89621848|NCT05887102|No Intervention|Usual care group|Pharmacists and women in the Usual care group will provide/receive usual care.
89037298|NCT04686201|Experimental|intervention group|
89037299|NCT04686201|No Intervention|control group|
89037300|NCT05056584|Experimental|Healthy control subjects|Healthy control subjects, matched for age, sex and BMI
89037301|NCT05056584|Experimental|Patients with End-stage Renal Disease|Patients with hemodialysis-treated ESRD.
89037302|NCT05056584|Experimental|Patients with liver cirrhosis|Patients with Child-Pugh A or B Cirrhosis
89037303|NCT00551915|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
89621849|NCT05884619|Experimental|Dual-target deep brain stimulation|This is a single arm, prospective, open label clinical study, participants who fit inclusion and don't fit exclusion criteria, completed physical anti-addiction treatments and surgical implantation standard will start DBS system stimulation and adjust parameters after 10-14 days of implantation. Then after stimulation for 9-32 weeks, they will be evaluated for treatment efficacies. This study is extendable, with agreements from participants, long term efficacy and safety follow-up study will be performed after 32 weeks ± 7 days of following, once every 2-3 months.
89621850|NCT05875025|Experimental|Test Propellant|Placebo HFA-152a propellant
89621851|NCT05875025|Placebo Comparator|Reference Propellant|Placebo HFA-134a propellant
89621852|NCT05869760||Observational Group|Children will be followed from 4-24 months of age.
89037304|NCT00551915|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
89037305|NCT00551915|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
89037306|NCT00551915|Active Comparator|PENTACEL™ + RECOMBIVAX HB™|Participants were vaccinated with 0.5 ml each of PENTACEL™ + RECOMBIVAX HB™ via intramuscular injection as a primary series at 2, 4, and 6 months of age, and with 0.5 ml PENTACEL™ as a booster at 12 to 14 months of age.
89037307|NCT00551954|Experimental|1|20 weeks of treatment with acarbose (100 mg t.i.d.)
89037308|NCT00551954|Placebo Comparator|2|20 weeks of treatment with placebo (one tablet t.i.d.)
89621853|NCT05868863||osteoporotic fractures or neoplastic lesions of the bony pelvis|"Patient aged 80 and over suffering from osteoporotic fractures or neoplastic lesions of the bony pelvis treated by percutaneous cementoplasty with or without screw fixation at university hospital center of Saint-Etienne between January 1st 2012 and February 28th 2023 will be included.~Analysis datas of medical record."
89621854|NCT05856539|Experimental|ESP Block|"Patients assigned to the ESP Block arm will receive an ESP block prior to the surgery."
89621855|NCT05856539|No Intervention|Control|"Patients assigned to the Control group will not receive an ESP block prior to the surgery."
89621856|NCT05839808|Other|Individuals who have had a stroke|To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
89621857|NCT05839795|Other|Caregivers of Rehabilitation Patients|Caregivers of rehabilitation patients, such as those with neurological, pediatric, and orthopedic disorders
89621858|NCT05829629|Experimental|FluBHPVE6E7|intracervical and intramuscular 0.5 ml per dose 3 doses (12 weeks)
89621859|NCT05829629|Placebo Comparator|Placebo|intracervical and intramuscular 0.5 ml per dose 3 doses (12 weeks)
88988872|NCT06209112||Over-pressure group' (Group OP)|"The 'over-pressure' group (Group OP): FGF will be set to 0.5 L/min and FVS 8% at Tzero.~Subsequently, the FVS will be set to 4% upon reaching FAS 2% and maintained till 15 min (T15) from Tzero."
88988873|NCT06207552|Experimental|Arm of BBM-F101 injection|The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
88988874|NCT06204588|Experimental|Test group-1|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
88988875|NCT06204588|Experimental|Test group-2|Single flap approach along with diode laser (SFA+LLLT).
88988876|NCT06204588|Experimental|Control group|using single flap approach only
88988877|NCT06204016||premenopausal women|naturally cycling women without hormonal contraception
88988878|NCT06204016||postmenopausal women|women after menopause (min. 12 months no menstrual bleeding)
88988879|NCT06203483|Active Comparator|Adductor canal block|Adductor canal block will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
88988880|NCT06203483|Active Comparator|PENG block|PENG Block will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
88988881|NCT06201000||Heart Failure Patients with reduced or preserved Ejection Fraction|Patients with reduced or preserved ejection fraction that have received the Guided Therapy (β-blockers, Diuretics, Angiotensin-converting enzyme (ACE) inhibitors or Angiotensin receptor blockers (ARBs) or Angiotensin Receptor-Neprilysin Inhibitor (ARNi) and Mineralocorticoid receptor antagonists (MRAs) then Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) (10 mg of dapagliflozin or empagliflozin) will be added at the study entry.
88988882|NCT06198725|Experimental|High fiber intervention group|Participants in the high fiber intervention group take high fiber dietary products (28g dietary fiber per day) for 12 weeks, and at the same time, follow the doctor's advice to use subcutaneous insulin injection for treatment.
88988883|NCT06198725|No Intervention|Usual treatment group|Participants in the usual treatment group received routine diet education for diabetes and were treated with subcutaneous insulin injection according to the doctor's advice
88988884|NCT06198335|Active Comparator|Group M-TAPA (Modified Perichondral Approach Thoracoabdominal Nerve block group)|Patients will be performed to block at the end of the surgery. Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
88988885|NCT06198335|Active Comparator|Group TAP (Transversus Abdominal Plane block group)|Patients will be performed to block at the end of the surgery. Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
88988886|NCT06191094|Experimental|Faricimab injection|Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The 6-mg dose of faricimab will be administered by IVT at the study site to patients. A specified filter needle must be used for each dose preparation of faricimab according to the instructions provided in the Investigator's Brochure and package insert. No other material than specified should be used. Vials of faricimab drug product are for a single-dose only (one injection preparation per patient per eye). Vials used for one patient must not be used for any other patient. Partially used vials, remaining faricimab drug product, as well as administration material must not be reused.
89037309|NCT00551993|Active Comparator|2|Robotic Sacral Colpopexy
89037310|NCT00551993|Active Comparator|1|Laparoscopic Sacral Colpopexy
89037311|NCT00552149|Active Comparator|1|GEMOX
89037312|NCT00552149|Experimental|2|GEMOX + CETUXIMAB
89037313|NCT05467878||Group I|Patients undergoing regional anesthesia were studied. It can be in the form of combined spinal epidural or epidural anesthesia.
89037314|NCT05467878||Group 2|Patients in whom general anesthesia and iv analgesic methods are preferred are in this group.
89621860|NCT05829525|Other|Healthy young adults group|Face-to-face assessment study
89621861|NCT05825742|Experimental|Lumoral Treatment (Study group)|"Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.~Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines."
89621862|NCT05825742|Other|Standard of care (Control group)|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
89621863|NCT05824208|Experimental|Bi-weekly pregnancy yoga-based sessions for 8 weeks|
89621864|NCT05823623|Experimental|Inetetamab combined with Pyrotinib plus Oral Vinorelbine|Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, intravenous, every 3 weeks for one cycle. Pyrotinib: 400mg, oral, every day. Vinorelbine: 60mg/m2, oral, every week.
89621865|NCT05822856||Patients with RA without inflammation with persistent chronic pain|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
89621866|NCT05822856||Patients with an active RA (in inflammatory flare)|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
89621867|NCT05822856||Patients with RA in remission without pain|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
89037315|NCT05467878||Group 3|Patients who prefer peripheral block under general anesthesia and ultrasound are in this group.
89037316|NCT03455699||Experimental: VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
89037317|NCT03455699||Active Comparator: RFA|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
89037318|NCT03455699||Experimental: Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
89037319|NCT00536640|Experimental|Arm A (Erlotinib, Bevacizumab)|
89037320|NCT00536640|Active Comparator|Arm B (Gemcitabine, Cisplatin, Bevacizumab)|
89037321|NCT00552227|Experimental|1|
89037322|NCT00552227|Placebo Comparator|2|
89037323|NCT00536679|Experimental|Sequence ABC|Subjects will be randomized to sequence ABC, where A=1 milligram (mg) GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
89037324|NCT00536679|Experimental|Sequence ACB|Subjects will be randomized to sequence ACB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
89037325|NCT00536679|Experimental|Sequence BAC|Subjects will be randomized to sequence BAC, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
89037326|NCT00536679|Experimental|Sequence BCA|Subjects will be randomized to sequence BCA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
89037327|NCT00536679|Experimental|Sequence CAB|Subjects will be randomized to sequence CAB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
89037328|NCT00536679|Experimental|Sequence CBA|Subjects will be randomized to sequence CBA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
89037329|NCT04793477|Experimental|K files (Dentsply Caulk, Milfors, DE, USA)|Instrumentation with manual files shall be performed with balanced forces (Roane) technique consist of placing the instrument as apically as it can go and then turning it clockwise (less than 180º). This is followed by a counterclockwise rotation (of at least 120º) with slight apical pressure. This is repeated until the desired working length is obtained.
89037330|NCT04793477|Experimental|VDW.ROTATE (VDW, Munich, Germany).|Instrumentation with VDW.ROTATE files shall be performed with a glide path to WL using VDW.ROTATETM 15.04 until reaching working length (1.3cNm and 300-400 rpm), the next instrument in the sequence is VDW.ROTATETM 20.05 until reaching working length (2.1cNm and 300-400rpm). and finally instrument with VDW.ROTATETM 25.04 (2.3cNm and 300-400rpm)
89621868|NCT05822856||fibromyalgia patients|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
89621869|NCT05822856||Control subjects: healthy volunteers|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
89621870|NCT05821699|Experimental|In Person LCS Intervention- With Opioid Risk Education|Patients will receive opioid education and Naloxone education. Therapeutic Intervention will include education on implementing mindfulness practices into postoperative recovery, known as the Community Resiliency Model CRM). Clinical Pain Coordination will include directed referrals for complex needs, including mental health and substance use disorders, as needed. All participants in the LCS intervention arm will also receive the current standard-of-care. The Community Resiliency Model (CRM) is a noncognitive variant of mindfulness, emphasizing attunement to interoceptive and exteroceptive signaling cues for regulation of autonomic responses to stress. CRM skills are introduced over a sixty-to-ninety-minute session, allowing for a brief introduction and application of skills by participants. These will be in person.
89621871|NCT05821699|Experimental|Virtual LCS Intervention-With Opioid Risk Education|Participants will receive opioid education, and Naloxone education. Therapeutic Intervention will include education on implementing mindfulness practices into postoperative recovery, known as the Community Resiliency Model CRM). Clinical Pain Coordination will include directed referrals for complex needs, including mental health and substance use disorders, as needed. All participants in the LCS intervention arm will also receive the current standard-of-care. The Community Resiliency Model (CRM) is a noncognitive variant of mindfulness, emphasizing attunement to interoceptive and exteroceptive signaling cues for regulation of autonomic responses to stress. CRM skills are introduced over a sixty-to-ninety-minute session, allowing for a brief introduction and application of skills by participants. These will be in performed virtually via a digital conferencing platform
89621872|NCT05821699|Active Comparator|No LCS intervention|Patients will receive the current standard-of-care for pain management in the aftermath of surgery, which includes: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
89037331|NCT04793477|Experimental|Reciproc® blue (RCP, VDW, Munich, Germany)|Instrumentation with Reciproc blue files shall be performed with only one file and move it in a pecking motion (the amplitude will not exceed 3mm). All the instruments shall be cleaned after 3 pecks.
89037332|NCT04974801|Other|Provox Life HMEs followed by Usual Care HMEs|Use of Provox Life devices during a period of six weeks followed by use of Usual Care devices during a period of six weeks.
89037333|NCT04974801|Other|Usual Care HMEs followed by Provox Life HMEs|Use of Usual Care devices during a period of six weeks followed by use of Provox Life devices during a period of six weeks.
89037334|NCT04967430|Experimental|Treatment|To receive a dose of peginterferon lambda 180mcg SC at baseline (Day 0).
89037335|NCT04967430|Placebo Comparator|Placebo|"Patients in this arm will receive a single SC dose of 0.9% sodium chloride (normal saline) solution at baseline (Day 0).~A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse."
89037336|NCT04783103|Active Comparator|Active adTMS|Subjects in the treatment arm receive 20 sessions of real adTMS . The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
89037337|NCT04783103|Sham Comparator|Sham adTMS|Subject in the control/Placebo/Sham arm receive 20 sessions of sham adTMS. The sessions will be spread over the four succeeding days (5 sessions daily on Tuesday, Wednesday, Thursday and Friday).
89037338|NCT01259089|Experimental|Arm I|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89037339|NCT05467839|Experimental|vitillgo patients|
89037340|NCT05142436|Experimental|Cohort 1: Non-combusted cigarette variant 42001402 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
89037341|NCT05142436|Experimental|Cohort 2: Non-combusted cigarette variant 42001399 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
89037342|NCT05142436|Experimental|Cohort 3: Non-combusted cigarette variant 42001401 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
89037343|NCT05142436|Experimental|Cohort 4: Non-combusted cigarette variant 40007386 and product use mode B|Subjects randomized to use of a non-combusted cigarette variant and product use mode B
89037344|NCT05142436|Experimental|Cohort 5: Non-combusted cigarette variant 42001402 and product use mode A|Subjects randomized to use of a non-combusted cigarette variant and product use mode A
89037345|NCT05142436|No Intervention|Cohort 6: Usual Brand Cigarettes|Subjects randomized to continue to smoke usual brand cigarettes
89621873|NCT05816915|Experimental|Professional lifestyle modification counselling (behavioral therapy)|Lifestyle intervention will be based on CBT (cognitive behavioral therapy) and mindfulness, especially mindful eating by professional organisation STOB.
89621874|NCT05816915|No Intervention|standard care|Patients will have standard care with regular visits at an outpatient Department of Hepatology. Standard recommendations of lifestyle change and weight reduction will be given by hepatologists.
89037346|NCT05142436|No Intervention|Cohort 7: Assisted Smoking Cessation|Subjects assigned to assisted smoking cessation
89037347|NCT05142436|No Intervention|Cohort 8: Never-Smokers|Never-smokers
89037348|NCT04960176|Active Comparator|Acupuncture Group|Acupuncture will be administered to 5 different reel acupoints. The acupoints are Du20 in head, LI4 bilateral in hands and ST36 bilateral in legs.
89037349|NCT04960176|Sham Comparator|Non-Invasive Sham Acupuncture Group|Non-invasive sham acupuncture using a blunted needle will be administered to 5 different reel acupoints. The acupoints are Du20 in head, LI4 bilateral in hands and ST36 bilateral in legs.
89037350|NCT05466513|Experimental|Experimental Group|Facial tactile stimulation was applied for 2 minutes.
89037351|NCT05466513|No Intervention|Control Group|No intervention was applied.
89037352|NCT04943757|Experimental|PTBCy graft-versus-host disease prophylaxis|Days +3 through +4: Bendamustine 50 mg/m2 iv x 2 days; Days +3 through +4: Cyclophosphamide 25 mg/kg iv x 2 days; Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 3 g/day, iv or po x 30 days; Days +5 through +100: Tacrolimus 0.03 mg/kg/day with further correction by concentration
89037353|NCT00552500|Active Comparator|Schizophrenics|i) meets DSM-IV criteria for schizophrenia, any type, treated with atypical or high potency typical neuroleptics for at least 3 months; ii) aged 18 to 60 years; iii) able to give informed consent; iv) no antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.
89037354|NCT05465265|Active Comparator|Intervention and control group|To establish the effect of navigation on PrEP uptake, adherence and retention among PWID.
89037355|NCT05465265|Placebo Comparator|Control group|To establish the effect of providing PrEP information through pamphlets on PrEP uptake, adherence and retention among PWID.
89621875|NCT05814497|Experimental|Healthy Controls|Healthy controls with no history of chronic pain.
89621876|NCT05814497|Experimental|Headache and Migraine|Individuals who have migraine with headaches.
89621877|NCT05814497|Experimental|Functional Abdominal Pain Disorder (FAPD)|Individuals who have functional abdominal pain disorder.
89621878|NCT05814497|Experimental|Localized and Diffuse/Widespread Musculoskeletal Pain (MSK)|Individuals with chronic musculoskeletal pain.
89621879|NCT05814497|Experimental|Complex Regional Pain Syndrome (CRPS)|Individuals with complex regional pain syndrome.
89621880|NCT05805306|Experimental|PrEP Promotion|
89621881|NCT05805306|Placebo Comparator|Vaccine Promotion|
89621882|NCT05799183|Experimental|Pre-test: ARM A|SHR-1210 before process changes 20 mg
89621883|NCT05799183|Experimental|Pre-test: ARM B|SHR-1210 after process changes 20 mg
89621884|NCT05799183|Experimental|Formal Test: ARM A|SHR-1210 before process changes 20 mg
89621885|NCT05799183|Experimental|Formal Test: ARM B|SHR-1210 after process changes 20 mg
89621886|NCT05797025|Other|Individuals with neck pain|To assess pressure pain threshold and pinch grip strengths.
89621887|NCT05797025|Other|Healthy group|To assess pressure pain threshold and pinch grip strengths.
89621888|NCT05797012|Other|Individuals with migraine|To assess headache severity, head posture, cervical muscle endurance and neck disorders.
88988887|NCT06191094|Sham Comparator|Sham injection|Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The sham procedure mimics an intravitreal injection of faricimab except that the blunt end of an empty syringe is pressed against an anesthetized eye instead of a needle attached to a faricimab-filled syringe.
88988888|NCT06188832|Experimental|Fiber Supplementation|The active powder contained 1g glucomannan, 1g inulin, and 3g psyllium per bag.
88988889|NCT06188832|Placebo Comparator|Placebo group|The placebo powder composed of maltodextrin and rice flour, carefully selected to mimic the texture and volume of the active powder without providing any active dietary fiber
88988890|NCT06184607||Maxillary anterior interdental papilla|Presence or loss of interdental papilla with intact maxillary central incisors in systemically healthy patients
88988891|NCT06181656||Group 1|30 participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer. This group will be subdivided into Group 1A, which will comprise 15 participants treated with proton therapy, and Group 1B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
88988892|NCT06181656||Group 2|30 participants currently receiving, planning to receive, or recently completed chemoradiation for hepatocellular carcinoma. This group will be subdivided into Group 2A, which will comprise 15 participants treated with proton therapy, and Group 2B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).
88988893|NCT06181656||Group 3|20 Healthy Volunteers.
88988894|NCT06181591|Experimental|Hibero SR (Mirabegron) 50 mg|Subjects aged between 5 and 18 years will receive a daily dose of IP orally starting from baseline to week 8.
88988895|NCT06181591|Active Comparator|Ditropan (Oxybutynin Chloride) 10 mg|Subjects aged between 5 and 18 years will receive a daily dose of active comparator orally starting from baseline to week 8.
88988896|NCT06181110|Experimental|TranS-C Group|TranS-C is a personalized, non-pharmacological transdiagnostic intervention that addresses psychosocial, behavioural, and cognitive contributors to sleep and circadian dysfunction. It references the sleep health framework and integrates evidence-based elements, including CBT for insomnia, interpersonal and social rhythm therapy (IPSRT), chronotherapy, and motivation enhancement.
88988897|NCT06181110|No Intervention|Care-As-Usual Group|The participants in this group will not receive the TranS-C treatment but will have access to usual care based on their needs and preferences, including but not limited to pharmacological interventions, psychological interventions, and complementary and alternative medicine. A treatment tracking log will be used to monitor the care the participants receive during the study period. The CAU group will receive self-help TranS-C materials after completing all of the assessments. We will monitor the participants' weekly depression severity using PHQ-9 and refer those who have serious suicidal risk to the PI for further assessment and professional mental health services if deemed necessary.
88988898|NCT06178991|Experimental|Cohort 1 Arm A: Influenza and COVID-19 Combination A and Placebo|Cohort 1 Arm A: Influenza and COVID-19 combination A vaccine and Placebo
88988899|NCT06178991|Active Comparator|Cohort 1 Arm B: COVID-19 vaccine and licensed influenza vaccine concomitant administration group|Cohort 1 Arm B: COVID-19 vaccine and licensed influenza vaccine concomitant administration group
88988900|NCT06178991|Experimental|Cohort 2 Arm C:Influenza and COVID-19 Combination B and Placebo|Cohort 2 Arm C: Influenza and COVID-19 Combination B vaccine and Placebo
88988901|NCT06178991|Active Comparator|Cohort 2 Arm D: COVID-19 vaccine and licensed influenza vaccine concomitant administration group|Cohort 2 Arm D: COVID-19 vaccine and licensed influenza vaccine concomitant administration group
88988902|NCT06178796|Active Comparator|With graft|
88988903|NCT06178796|Active Comparator|Without graft|
88988904|NCT06178796|Active Comparator|Delayed healing site|
88988905|NCT06177834|Active Comparator|Classical dorsal slit circumcision technique|In this group, the patients who will operated with dorsal sleeve slit circumcision technique.
88988906|NCT06177834|Experimental|Alisklamp|In this group, the patients who will operated with Alisklamp technique.
88988907|NCT06176625|No Intervention|Delirium & Sensory Loss|The observational portion of the study, during which participants are screened for delirium. Consented individuals also complete bedside hearing and vision screenings, and provide information regarding care on patient satisfaction questionnaires.
88988908|NCT06176625|No Intervention|Baseline Delirium Prevalence|This arm of the interventional portion of the study will be used as baseline comparison data to determine whether implementation of the intervention impacted delirium outcomes. Baseline data collection will be collected for each of the units prior to implementation of the intervention.
88988909|NCT06176625|Active Comparator|Communication Signage|For patients who report a little or moderate trouble hearing following the implementation of the intervention, a pink sign will be posted to prompt use of effective communication strategies by nursing staff.
88988910|NCT06176625|Active Comparator|Amplifier|For patients who report a lot of trouble hearing following the implementation of the intervention, a blue sign will be posted to prompt nursing staff to remind patient to make use of amplifier provided as part of the study.
88988911|NCT06169943|Other|Control|Participants in the control group will receive the same mobile app as the intervention group but with limited function.
88988912|NCT06169943|Experimental|Intervention|Participants in the intervention group will receive the mHealth social support program.
88988913|NCT06168058|Sham Comparator|Transcatheter Venography|
88988914|NCT06168058|Experimental|Bilateral Ovarian Vein Embolization|Transcatheter Venography plus Bilateral Ovarian Vein Embolization.
88988915|NCT06158451|Experimental|Zinc-oxide Propolis (Zno-P)|Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed and added after minimal instrumentation until size 20 to remove all the accessible necrotic pulp and placed on the pulpal floor and intracanal.
88988916|NCT06158451|Active Comparator|Modified triple antibiotic paste|Metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt) will be mixed and added after minimal instrumentation until size 20 to remove all the accessible necrotic pulp and placed on the pulpal floor and intracanal.
89037356|NCT00552539|Experimental|1|pre test survey, educational video, post test survey
89037357|NCT00552539|No Intervention|2|no intervention
89621889|NCT05795309|Experimental|Hybrid Automated Insulin Delivery|The intervention is the Medtronic 780G Hybrid Automated Insulin Delivery system
89621890|NCT05795309|No Intervention|Standard care|The control is Standard Care with real-time CGM
88988917|NCT06157515|Experimental|continuous vibrating mesh nebulization (cVMN)|Participants will inhale 2.5 mg salbutamol (from a 0.5 unit dose vial of Saldolin Inhalation Solution, Taiwan FDA approval number 043572) via the commercially available vibrating mesh nebulizer (Microbase, model number MBPN002). The device continuously generates aerosol throughout the respiratory cycle. Participants are encouraged to breathe with normal tidal breathing for up to 5 minutes until no aerosol is visually seen. No repeat or additional dosing is utilized.
88988918|NCT06157515|Experimental|Breath-actuated vibrating mesh nebulizer (bVMN)|Participants will inhale 2.5 mg salbutamol (from a 0.5 unit dose vial of Saldolin Inhalation Solution, Taiwan FDA approval number 043572) via the commercially available vibrating mesh nebulizer (Microbase, model number MBPN002) with trigger module attachment. This device utilizes a microphone and algorithm to detect the inspiration to activate aerosol generation during period of inspiration only. Participants are encouraged to breathe with normal tidal breathing for up to 5 minutes until no aerosol is visually seen. No repeat or additional dosing is utilized.
88988919|NCT06157463||observation|Ga-68 FAPI study before and during TNT
88988920|NCT06154889|Active Comparator|Convention readaptation protocol|Patients have a conventional re-education after surgery for anterior shoulder dislocation (Latarjet procedure)
88988921|NCT06154889|Experimental|Readaptation protocol with psychologic intervention|Patient have a conventional re-education after surgery for anterior shoulder dislocation (Latarjet procedure) with addition of 4 consultations with a sports psychologist
88988922|NCT06153173|Experimental|Mirdametinib|Mirdametinib will be dosed by mouth twice a day at a dose of 2 mg/m2 BID with a max of 4 mg BID (8 mg per day max).
88988923|NCT06148987||Questionnaire group|"This study will be conducted in Turkey between January and August Ferbruary 2024, and it aims to investigate the Turkish translation, reliability, and validity of the AAE-A survey. All participants must meet the following inclusion criteria: (i) be 18 years old or older, (ii) use smart devices and tools, and (iii) provide written consent to participate. Participants with specific abnormalities such as cognitive or neurological disorders, upper extremity pain, functional limitations, or cognitive impairments will be excluded from the study to ensure the accuracy of the norms. It is estimated that a sample size of 270 individuals, with 10 individuals per item, will be needed for the sample size of this study."
88988924|NCT06146634|Experimental|Hazard Perception Training|
88988925|NCT06146634|Placebo Comparator|Vehicle Maintenance Training|
88988926|NCT06146218|Experimental|Contemplative-Based Resilience Training (CBRT)|The intervention group will undergo a 10-week program addressing mindfulness, compassion, social-emotional self-care, exposing stress-reactive habits, self-awareness, visualization, and deep breathing.
88988927|NCT06145646|Experimental|Muscle temperature|Heating the vastus lateralis of the right quadriceps using microwaves
88988928|NCT06145503|Experimental|Dance Intervention Group|"Patients within the dance intervention group (n=20) were initially required to complete a Patient Information Form and provide written informed consent following an explanation of the study. Over the course of 12 weeks, these patients (n=20) received a 60-minute dance intervention three times a week, led by a dance instructor. Assessments, including the MoCA and SS-QOL, were conducted three times: before the dance intervention (pre-test/0th week), at the 6th week (interim measurement), and after completing the 12-week study (post-test/12th week)."
88988929|NCT06145503|No Intervention|Control Group|"The control group did not receive any intervention beyond participating in data collection. Patients in this group underwent assessments with the MoCA and SS-QOL before the study (pre-test/0th week), at the 6th week of the study (interim measurement), and after the completion of the 12-week study (post-test/12th week)."
88988930|NCT06139757||Euploid embryo transfer group|Participants will wear the Oura Ring continuously for data collection starting in the month prior to their embryo transfer date. They will wear the Oura Ring throughout the preparation, embryo transfer, and post-transfer until either a negative pregnancy test or, if positive, until 8 weeks gestation. The study time for each participant will thus extend from either 5 weeks for negative pregnancy tests, to 10 weeks for normally continuing pregnancies.
88988931|NCT06138925|Active Comparator|healthy children|
88988932|NCT06138925|Experimental|hildren with cerebral palsy|
89621891|NCT05794633|Experimental|Acupuncture Group|"The patients will be recieved two days a week for 8 sessions with sterile 25*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
89621892|NCT05794633|Placebo Comparator|Placebo Acupuncture Group|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the Placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
89621893|NCT05794308|Active Comparator|Non-Relational Chatbot Physical Activity Intervention|Participants are randomly assigned to a non-relational chatbot in a mobile app. The chatbot will provide physical activity education sessions. The chatbot will not engage in relational conversation behaviors.
89621894|NCT05794308|Experimental|Relational Chatbot Physical Activity Intervention|Participants are randomly assigned to a relational chatbot in a mobile app. The chatbot will provide physical activity education sessions. The chatbot will engage in relational conversation behaviors.
89621895|NCT05794295|Active Comparator|Acoustic Stimulation (AS)|Participants in this arm will be exposed to acoustic stimulation while they sleep during a night of monitoring in the UC Davis Epilepsy Monitoring Unit (EMU).
89621896|NCT05794295|Sham Comparator|SHAM Stimulation|Participants in this arm will not be exposed to any stimulation while they have their sleep monitored for one night in the UC Davis Epilepsy Monitoring Unit (EMU).
89621897|NCT05782868|Experimental|TNB Identity Affirmation (IA) Condition|Participants in the IA only intervention condition will receive the same prompt for all four days of writing, a design used in expressive writing interventions to allow for deeper and continued reflection into specific thoughts and emotions.
89621898|NCT05782868|Experimental|IA + Strengthening Social Connections (SSC) Condition|For participants in the IA+SSC condition, participants will complete the IA intervention on the first three days. On the fourth day, participants will be directed to compose a brief letter.
89621899|NCT05782868|Experimental|Control Condition|Expressive writing assignment, without prompts.
89621900|NCT05781347|Active Comparator|Obese patients receiving Stretta|
89621901|NCT05781347|No Intervention|Obese patients receiving Conservative therapy/PPI|
89621902|NCT05781347|Active Comparator|Non-obese patients receiving Stretta|
89621903|NCT05781347|No Intervention|Non-obese patients receiving Conservative treatment/PPI|
89621904|NCT05778812|Experimental|Full Sleep|"With Full Sleep, the app provides daily lessons about sleep and skills that can help with sleep. In the app, participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they additionally complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach. The intent of coach access is for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST (Radar Enabled Sensing Technology) device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
89621905|NCT05778812|Active Comparator|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
89621906|NCT05773118|Experimental|orthokeratology lens|The subjects will wear an orthokeratology lens with 3-zone reverse geometry design. The subjects are instructed to wear the lenses for at least eight hours every night and are removed during daytime hours.
89621907|NCT05773118|Experimental|multifocal soft contact lens|The subjects will wear a multifocal soft contact lens during daytime hours and remove the lens at night
89621908|NCT05773118|Active Comparator|single vision spectacle|The subjects will wear single vision spectacle lens as control.
89621909|NCT05771909|Experimental|NeurodigitX|"After randomization, the NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day).~At this visit and at the 1/2/3 and 6 month visits, staff will complete the following scales and questionnaires (15 minutes in length): Visual Anxiety Analog Scale (VAS), Spielberger Anxiety Scale - State (STAI form Y-A) and SF-12 Quality of Life Questionnaire.~All participants will be called in at 3 months for a visit to measure HRV via the app."
88988933|NCT06136468|Experimental|Experimental|"Exercise program using the virtual coach projected through head-mounted display"
88988934|NCT06136468|No Intervention|No Intervention|Usual exercise program
88988935|NCT06134453|Experimental|Reiki|According to randomization, patients in the reiki group will be taken to a quiet single room and reiki will be applied for approximately 25-30 minutes. Reiki practice will be applied by a researcher who has been trained at the Reiki Master level.
88988936|NCT06134453|Sham Comparator|Sham Reiki|According to randomization, the patients in the sham reiki group were taken to a quiet single room and sham reiki was applied for approximately 25-30 minutes. will be applied. According to random distribution, patients in the sham reiki group will be taken to a quiet single room and sham reiki will be applied for approximately 25-30 minutes. Sham Reiki will be administered by a healthcare professional who has not received Reiki training. Their hands will remain in the same position and for the same duration as if they were actually doing Reiki, but Reiki energy will not be given to the patient.
88988937|NCT06134453|No Intervention|Control Group|The control group will be given routine care in the pre-operative waiting room without any intervention, and the data collection tools will be applied at the same time as the experimental group, twice at 30-minute intervals.
89037358|NCT00552539|Experimental|3|educational video and post test survey
89621910|NCT05771909|Other|Control|"After randomization, the Control Group does not receive the NeurodigitX application.~At this visit and at the 1/2/3 and 6 month visits, staff will complete the following scales and questionnaires (15 minutes in length): Visual Anxiety Analog Scale (VAS), Spielberger Anxiety Scale - State (STAI form Y-A) and SF-12 Quality of Life Questionnaire.~All participants will be called in at 3 months for a visit to measure HRV via the app."
89621911|NCT05771896|Experimental|Darolutamide with Radium-223|"Darolutamide:~Dosage:600mg Route: By mouth (PO) Frequency: Twice a day, throughout the duration of the study~Radium-223:~Dosage: 55 kBq/kg body weight or 1.49 microcurie/kg body weight Route: IV Frequency: Every 28+/-7 days, a maximum of 6 cycles"
89621912|NCT05771896|Placebo Comparator|Darolutamide with Placebo|"Darolutamide:~Dosage:600mg Route: By mouth (PO) Frequency: Twice a day, throughout the duration of the study~Placebo:~Dosage: 55 kBq/kg body weight or 1.49 microcurie/kg body weight Route: IV Frequency: Every 28+/-7 days, a maximum of 6 cycles"
89621913|NCT05769465||Patients treated with nusinersen|
89621914|NCT05769465||Patients treated with risdiplam|
89621915|NCT05769465||Patients treated with onasemnogene abeparvovec|
89621916|NCT05769465||Patients naive from disease modifying treatments|
89621917|NCT05767567|Experimental|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
89621918|NCT05767567|No Intervention|Control|
89688427|NCT04376957|Active Comparator|Counselled with Current Standard Care|Standard of care consists of standard counselling and written materials provided by the oncologist or pharmacy (e.g. instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered).
89621919|NCT05764863|Experimental|young healthy adults|Participants need to complete three experimental conditions associated with fMRI recording of brain activity. In condition A (Visual Spatial), participants will see the sequences presented from left to right; in condition B (Visual No Spatial), participants will see sequences of items presented in the middle of the screen; and in condition C (Auditory), the sequences will be presented in an auditory format.
89621920|NCT05764642|Experimental|Chronic Kidney Disease Group|Subjects with Chronic Kidney Disease (CKD) with clinically indicated renal biopsy will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.
89621921|NCT05764642|Active Comparator|Healthy Control Group|Healthy volunteers with normal eGFR will have microvessel images obtained by Super-Resolution Ultrasound Imaging (SRUI) using Definity ultrasound contrast agent.
89621922|NCT05763914|Experimental|Group 1: Picture-based prevention education and an educational course|The participants will have access to picture-based prevention education, and at the same time, they will participate in an educational course.
89621923|NCT05763914|Experimental|Group 2: Picture-based prevention education only (no educational course)|The participants will only have access to picture-based prevention education and will not participate in any educational course.
89621924|NCT05763914|Placebo Comparator|Group 3: Placebo (control)|The participants will not have access to picture-based prevention education and do not participate in any educational course.
89621925|NCT05756465|Experimental|SVR group|Participant in the intervention arm will receive immersive virtual reality intervention in the form of VR box (Shinecon 6.0 VR Box Virtual Reality Glasses with headphones). SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) which attached to the head of cancer patient during chemotherapy, by displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical audio instruments (non-copyright).
89621926|NCT05756465|No Intervention|Control group|In the control group, participants will be given standard care in the form of guided imagery leaflets. It is an information sheets in the form of leaflets about the meaning, benefits, and ways of doing guided imagery relaxation therapy for cancer patient during chemotherapy. RA will guide the participants to practice the guided imagery relaxation therapy listed on the leaflet for ± 10 minutes.
89621927|NCT05755217|Active Comparator|Dark chocolate|Single dose of 1g/kg of dark chocolate (70% cocoa, Lindt Excellence)
89621928|NCT05755217|Placebo Comparator|White chocolate|Single dose of 1g/kg of white chocolate (4% cocoa, Nestle Galak).
89621929|NCT05750030|Experimental|FMT combined with Atezolizumab plus Bevacizumab|
89621930|NCT05742958|Experimental|Intrathecal morphine (Group ITM)|12.5-15 mg hyperbaric 0.5% bupivacaine + 0.1 mg (0.1 mL) morphine with a single dose intrathecal injection through the L4-L5 interval (spinal anesthesia) + placebo adductor canal block (with 30 mL saline) will be administered.
89621931|NCT05742958|Experimental|Adductor canal block (Group ACB)|Spinal anesthesia from L4-L5 interval with 12.5-15 mg hyperbaric 0.5% bupivacaine + adductor canal block (30 mL 0.25% bupivacaine) will be applied.
89621932|NCT05742672|Experimental|Massage|In the experimental group, twice a day, in the morning and evening, and 30 minutes after the meal, for 15 minutes. Effusion, petrissage and vibration massage movements will be applied by the researcher for a certain period of time in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.
89621933|NCT05736068|Experimental|Non-surgical|No reduction. Application of a cast.
89621934|NCT05736068|Active Comparator|Surgical|Closed reduction under general anesthesia with or without additional pin fixation of surgeons' choice followed by cast immobilization.
89621935|NCT05735561||Proximal Humerus Fracture Anterior Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is anterior to the glenoid.
89621936|NCT05735561||Proximal Humerus Fracture Posterior Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is posterior to the glenoid.
89621937|NCT05735561||Proximal Humerus Fracture Varus Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is in varus compared to the glenoid.
89621938|NCT05735561||Proximal Humerus Fracture Valgus Dislocation|The study doesn't provide any intervention. This group is defined as having a dislocation that is in valgus compared to the gelnoid.
88988938|NCT06133062|Experimental|Atezolizumab and bevacizumab with proton radiotherapy|Patients undergo Atezolizumab and Bevacizumab with proton radiotherapy.
88988939|NCT06126185|Experimental|Synbiotic treatment|12-week course of synbiotic
88988940|NCT06122116|Active Comparator|Physical Therapy (PT) Only|All participants will complete a standard of care PT program addressing individual strength, mobility, and flexibility deficits in both proximal and distal muscle groups. The provider may also use other modalities to address distal issues. If a participant has not been placed on profile at the time of consent, a profile may be written by the study medical provider to ensure limitation of activities, as appropriate.
88988941|NCT06122116|Active Comparator|PT + Platelet-Rich Plasma (PRP)|"PRP Preparation: The PRP will be prepared following standard technique by drawing 60cc blood from the participant through venipuncture and spinning the blood sample in a centrifuge (for approximately 17 minutes), adjusting for leukocyte poor-platelet rich plasma (LP-PRP). This sample will be prepared by the study provider. Any leftover blood will be safely discarded per standard protocols.~A small portion of the pre-spin whole blood (approximately 1 cc) and post-spin injectant PRP (approximately 1 cc) will be sent to MAMC Department of Pathology and Laboratory Services (DPALS) for complete blood count (CBC) cytology to monitor standardization and reproducibility. This portion will be labeled by participant ID and study. De-identified hardcopy results will be obtained from MAMC DPALS, and CBC results will be reported on Appendix G (CBC Results CRF). Post-procedural instructions will be provided in a participant handout."
89037359|NCT00552539|No Intervention|4|post test survey
89037360|NCT04917783|Other|Standard of Care|Caregivers in the standard of care-arm will receive immediate verbal feedback by a psychologist on their neurocognitive testing results, recommendations, and guidance for implementing recommendations (e.g., sending a 504 Plan request to the school). This report will contain information regarding background, test results, a summary and impressions, and bullet-pointed recommendations.
89057843|NCT01687062|Experimental|FeSO4 + low phytate|injera test meal 3 labeled with a 4 mg staple iron isotope tag
89621939|NCT05735535|Experimental|3TC/DTG|·To evaluate efficacy of switching to a two-drug one-pill regimen with DTG/3TC
89621940|NCT05735535|Active Comparator|TDF Regimen|comparision arm to maintaining the three-drugs regimen in women currently receiving any three-drug regimen containing Tenovofir (TAF or TDF) (e.g. TAF/F/E/C; TAF/F/RPV; TDF/F/RPV; TAF/F+PI/C; TAF/F+PI/r; TDF/F/PI/r; TAF/F+DTG; TDF/F/DTG; TAF/F+RTG; TDF/F/RTG; TAF/F/BIC) who are virologically suppressed.
89621941|NCT05732285|Experimental|CRT plus CBT and Lifestyle modifications|
89621942|NCT05732285|Active Comparator|Usual care|
89621943|NCT05730855||Oral Lichen Planus|
89621944|NCT05730855||Leukoplakia|
89621945|NCT05730855||Healthy control|
89621946|NCT05727774|Experimental|Hot water condition|Participants do the water biking training for two weeks, 1 hour a day, in hot water temperature (35°C)
89621947|NCT05727774|Sham Comparator|Neutral water condition|Participants do the water biking training for two weeks, 1 hour a day, in neutral water temperature (25°C)
89621948|NCT05720715|Active Comparator|group A|receive cyclosporine eye drops together with prednisolone eye drops.
89621949|NCT05720715|Placebo Comparator|group B|receive topical prednisolone with placebo eye drops (tear replacement).
89621950|NCT05718895|Experimental|ATG-022|"Dose Escalation Phase:~for subjects with solid tumors,approximately 16-36 subjects will be enrolled .~Dose Expansion Phase:~The tumor types in the Dose Expansion Phase may involve other tumor types based on the signals from the Dose Escalation Phase. The total number of patients in dose expansion will be up to approximately 120 patients."
89621951|NCT05711537|Experimental|Intervention Auricular Acupressure (AA) Group|Participants will participate in the Auricular Acupressure intervention over 3 days in addition to the Standard of Care treatment for Chronic Pain and complete questionnaires
89621952|NCT05710484||Inferior alveolar nerve block anesthesia cohort|This group will consist of participants who are undergoing procedures that require mandibular anesthesia as routine part of care. Participants in this group will have voice recordings taken before and after the administration of anesthesia. The aim is to assess any changes in voice characteristics attributable to the effect of the anesthesia.
89621953|NCT05709496|Experimental|De-escalated radiotherapy to the prostate|De-escalated radiotherapy to the prostate with an intra-prostatic boost to the dominant .
89621954|NCT05698173|Experimental|Systemic Lupus Erythematosus|Diagnosis of systemic lupus erythematosus according to American College of Rheumatology (ACR) or SLICC criteria
89621955|NCT05698173|Other|Controls|Healthy controls
89621956|NCT05681741|Sham Comparator|current pump flow (between 2 and 2.4 l/min/m²)|the pump flow will be constant during this randomized phase
89621957|NCT05681741|Active Comparator|high pump flow (between 2.6 and 3 l/min/m²)|the pump flow will be constant during this randomized phase
89621958|NCT05681065|No Intervention|Control group|Standard practice. Patients will receive the usual clinical care based on the transmission of information and advice, and review according to the Clinical Practice Guidelines corresponding to the various chronic diseases presented by the patient.
89621959|NCT05681065|Experimental|Intervention Group|Standard practice. Patients will receive the usual clinical care based on the transmission of information and advice, and review according to the Clinical Practice Guidelines corresponding to the various chronic diseases presented by the patient. In addition, these participants will be provided with the TeNDER technological tool. The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of the biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of health professionals.
89621960|NCT05680792|Other|Administration of nitazoxanide alone|Participants in this arm will receive 1000 mg of nitazoxanide tablets alone
89621961|NCT05680792|Other|Administration of nitazoxanide plus atazanavir/ritonavir|Participants in this arm will receive 1000 mg of nitazoxanide tablets twice daily together with one tablet of atazanavir/ritonavir (300 mg/100 mg) once daily in the morning.
89621962|NCT05677880||Non-Carrier Cohort|About 100 participants who are at-risk, healthy family members with No NOTCH3 Mutation and no symptoms or signs of cognitive decline.
89621963|NCT05677880||Pre-Symptomatic NOTCH3 Cohort|About 133 participants who are pre-symptomatic, at-risk, and healthy (with verified NOTCH3 mutation) family members with no symptoms.
89621964|NCT05677880||Symptomatic NOTCH3 Cohort - No Functional Decline|About 134 participants who are symptomatic (with verified NOTCH3 mutation) family members and no functional decline (e.g., mild cognitive impairment (MCI) with premorbid functional levels maintained).
89621965|NCT05677880||Symptomatic NOTCH3 Cohort - Functional Decline|About 133 participants who are symptomatic family members with a verified NOTCH3 CADASIL mutation and evidence of functional decline consistent with early dementia.
89621966|NCT05676814|Active Comparator|Pecto-intercostal Fascial Block (PIFB)|Subjects in this arm receive standard of care PIFB after surgery
89621967|NCT05676814|Experimental|PIFB with adjuvants|Subjects in this arm receive standard of care PIFB with additional medications after surgery
89037361|NCT04917783|Experimental|Health Literacy|"Participants randomized to the experimental health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations of their neurocognitive testing results along with the full written report. The domains listed as either satisfactory or needing help listed on the passport card will directly correspond to those listed on the full report."
89037362|NCT02277314|Other|Low Cost Treatment for Cataracts|Low cost, manual small incision cataract surgery performed in an educational environment. All costs covered by subjects.
89621968|NCT05669404|No Intervention|Control Group (CG)|Patients continued to consume their usual diet for 3 months
89621969|NCT05669404|Experimental|Salt Restriction Group (SRG)|Patients continued to consume their usual diet, but they restricted sodium intake to 2,000 mg/ day for 3 months.
89621970|NCT05669404|Experimental|DASH Diet combined with salt restriction Group (DDG)|Patients consumed the DASH diet for 3 months.
89621971|NCT05669404|Experimental|Mediterranean Diet combined with salt restriction Group (MDG)|Patients consumed the MedDiet diet for 3 months.
89688428|NCT04376957|Experimental|Counselled with MASCC Oral agent Teaching Tool (MOATT)|This group will receive counselling using the MASCC Oral Agent Teaching Tool and be compared with the standard of care counselling.
89688429|NCT02907814|Experimental|Uveitis and Cataract Imaging Group|Subjects will undergo up to three optical coherence tomography scans.
89037363|NCT04756388|Active Comparator|Executive Training|The Executive Training (ET) condition will consist of the ET intervention that Dr. Best previously developed and evaluated. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, at home between sessions. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
89037364|NCT04756388|Experimental|Strategy Development only|In Strategy Development only participants will engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life. Between sessions, participants will be encouraged to practice their cognitive strategies in their daily life and track their strategies using the strategy worksheet. There will be no computerized cognitive training in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
89037365|NCT04756388|Experimental|Computerized Cognitive Training only|In Computerized Cognitive Training only participants will spend the entire one-hour session practicing computerized training exercises. Between sessions participants will be encouraged to practice the computerized exercises at home for 40 minutes per day. There will be no strategy development in this condition. All interventions will be delivered virtually in the participant's home and group sessions will be conducted using the online platform Zoom.
89037366|NCT01258738|Active Comparator|etanercept|In Period 1 : Subjects will receive via a prefilled syringe an active dose equivalent to 1.0ml of Etanercept solution once weekly SC once weekly. Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
89057844|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:1) + high phytate|injera test meal 4 labeled with a 4 mg staple iron isotope tag
89057845|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:3) + high phytate|injera test meal 5 labeled with a 4 mg staple iron isotope tag
89621972|NCT05669222|Experimental|FAST Guided Strategy (μQFR+RWS)|"μQFR is measured in all non-infarct related arteries containing any non-culprit lesion with visually-assessed DS% ≥50% and ≤90% with RVD ≥2.5 mm.~μQFR ≤0.80: PCI~RWS ≥13%: PCI~μQFR >0.80 and RWS <13%: Deferral~DS% >90%: PCI without the need of μQFR or RWS~For all patients undergoing PCI, post-PCI μQFR measurement is recommended; if μQFR <0.90, if the reason is obvious post-dilation with a non-compliant balloon or bail-out stenting should be considered; if the reason is not obvious intravascular imaging should be considered."
89621973|NCT05669222|Sham Comparator|Standard Treatment Strategy|"PCI should be performed of all non-culprit lesions with visual DS% ≥70% in all non-infarct related arteries with RVD ≥2.5 mm;~For a non-culprit lesion with visually DS% 50-70%, PCI can be performed if FFR ≤0.80 or iFR ≤0.89."
89621974|NCT05664867|Experimental|MGT (Mainstream Genetic Testing) Model|The mainstream genetic testing (MGT) model of cancer genetic services involves a non-genetics healthcare provider, such as the primary care provider, who engages patients in the counseling, consenting, and ordering of genetic testing. The provider/care team discloses the genetic test results and refers patients for genetic counseling only when genetic test results are abnormal. By eliminating the pre- and post-test counseling visits with a genetics provider, the MGT model has the potential to provide scalable access to genetic services.
89621975|NCT05664867|Active Comparator|SOC (Standard of Care) Model|The enhanced standard of care model (SOC+) is the current referral model of cancer genetic services delivery with an enhancement to include screening for and resources to address health literacy. This model begins with a health care provider's recognition, identification and then referral of a patient to a genetic counselor where genetic testing takes place if appropriate. This model is time- and resource- intensive and may not be scalable.
89621976|NCT05660863|Experimental|cohort 1：MN-08 24 mg/day|2 x 6 mg MN-08 tablets for a total dose of 12 mg or 2 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
89621977|NCT05660863|Experimental|cohort 2：MN-08 60 mg/day|5 x 6 mg MN-08 tablets for a total dose of 30 mg or 5 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
89621978|NCT05655598|Experimental|Level 0 Starting Palbociclib with TAS-116|
89621979|NCT05655598|Experimental|Level -1 Palbociclib with TAS-116|
89621980|NCT05655598|Experimental|Level -2 Palbociclib with TAS-116|
89621981|NCT05655234|Experimental|Participants receiving the MB programme|"Participants receiving the MB programme:~meditative breathing; breathing while listening to music; drawing of a mental image while breathing; and processing and sharing of the experience. home practice"
89621982|NCT05655234|Placebo Comparator|Participants receiving the control condition|"Mental health education programme:~breathing exercise; stress reduction talk"
89621983|NCT05651867|Experimental|Interventional arm|Patients treated by percutaneous CT-guided procedures in the lung with the EPIONE® device
89621984|NCT05646472||≥ 65 Community-dwelling older adults|
89621985|NCT05644132|Experimental|Thumb base joint prosthesis|
89621986|NCT05643027|Other|INTERVENTION FOR AVOIDANCE-RELATED OPIOID MISUSE|Participants will participate in a six-session behavioral intervention, delivered by a licensed clinical psychologist.
89621987|NCT05639270|Experimental|low back pain|"The experimental intervention consists of vagal stimulation using the Tens Eco device with an auricular electrode and conductive gel.~The stimulation will have an intensity of 25 Hz, lasting 30 minutes, once a day, for 3 months.~An evaluation of the pain will be done every week by phone for the first month and then in consultation at one month and at 3 months."
89621988|NCT05629780|Experimental|Conservative|Resuscitation fluids were only given under certain pre-defined criteria
89621989|NCT05629780|No Intervention|Traditional (liberal)|Patients were treated with standard of care for each site with regards to recuscitation fluids.
89688430|NCT02907814|Experimental|Control|Control subjects will undergo a brief, non-contact eye exam and then undergo up to three optical coherence tomography scans.
89688431|NCT02909140|Experimental|Topical Mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
89621990|NCT05621044|Experimental|FitBrothers smartphone active app|"Participants will be expected to engage with the FitBrothers app on a daily basis. Daily alerts and notifications will engage users in daily use of the app and provide up-to-date information on users' progress. Participant responses will also be used to evaluate additional or on-going support of users' needs (e.g., increase/ decrease prompts based on user preferences, tailored messages around a set goal, etc.). To protect privacy and to ensure that the participant is the person completing the app activities, KB will uniquely identify the user's smartphone based off the device's hardware footprint. The app will upload all app activity data to the KB secured web server database."
89621991|NCT05621044|Active Comparator|Comparator app|Nike Training Club is a free app available on iOS and Android platforms. The app is designed to increase fitness in users through a variety of mechanisms. Similar to FitBrothers, men will be able to track and monitor their physical activity level, set goals, engage in competitions, and upload activity data from a wearable. They will also be provided with preset workouts, receive guidance from an expert, and receive personalized plans that automatically adapt to user behavior. Unlike the FitBrothers app, the Nike Training Club app was not developed with input from African American men, does not track health information (e.g. blood pressure, blood glucose), does not have a theoretical basis, and does not have specific strategies for maintenance.
89621992|NCT05617742|Experimental|68Ga-FAPI-46 PET Scan|A single-center prospective interventional single-arm clinical trial. All patients will undergo whole-body 68Ga-FAPI-46 PET scan within two weeks before or after 18F-FDG-PET. Injected activity of 68Ga-FAPI-46 is limited to 100-250 MBq per examination.
89621993|NCT05616832||Veterans with upper extremity impairment after stroke|Veterans with upper extremity impairment after stroke will be recruited for this study.
89621994|NCT05605288|Experimental|Distal transradial artery access|Vascular access after cannulation of distal transradial artery through anatomical snuffbox for coronary angiography and interventions
89621995|NCT05605288|Active Comparator|Conventional transradial artery access|Vascular access after puncturing on the conventional transradial artery for performing coronary angiography and interventions
89621996|NCT05604040|Experimental|Self-monitoring and education program for lifestyle changes|Participants will send self-reports of their home BPs, diet, physical activity and emotions while attending a 6-week education program of lifestyle changes and coping skills. Participants will get summary reports of their home BP and lifestyle monitoring. Participants primary care physicians will be notified of persisting high BPs and final average home BP levels. Researchers will monitor home BP levels and change in hypertension control state
89621997|NCT05601869|Experimental|Intervention|Participants in this arm receive a new prosthesis system designed to improve footwear options.
89621998|NCT05598580|Experimental|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy. After that, participants will be monitored for another 24 weeks.
89621999|NCT05598580|Experimental|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy. After that, participants will be monitored for another 24 weeks.
89622000|NCT05598580|No Intervention|Control|Participants will continue to receive antiretroviral therapy without other intervention and be monitored for 48 weeks.
89622001|NCT05597280|Experimental|BE-PEP|"Intervention arm in which BE-PEP will be provided to all persons residing within 100 meters of an index case, to be repeated after four weeks for household contacts.~BE-PEP: bedaquiline (400 or 800 mg depending on weight band) combined with rifampicin (10 mg/kg) will be provided as post-exposure prophylaxis~Both arms will target anyone living within 100 meters of an index case or the entire village if more than 50% are eligible. The dosage form of rifampicine is 150 mg and 300 mg, for bedaquiline it's 20 mg or 100 mg."
89622002|NCT05597280|Active Comparator|SDR PEP|"WHO recommended standard PEP will be provided, i.e. 10 mg/kg of rifampicin in a single dose. In both arms anyone living within 100 meters of an index case will be targeted or the entire village if more than 50% are eligible.~The dosage form of rifampicine is 150 mg and 300 mg."
89622003|NCT05596175|No Intervention|Usual Care|Patients will continue Usual Care, which will include having medication optimised for adequate heart-rate control, anti-arrhythmic therapy, and anti-coagulation (for stroke-risk) instituted by their treating Cardiologist if indicated by their CHA₂DS₂-VASc Score. Patients who remain significantly symptomatic despite attempts to optimise medical therapy may be referred for further rhythm management strategies, including cardioversion(s) and/or ablation(s) - as per current standard clinical practice. The Cardiologist will also provide routine, verbal one-off lifestyle advice in line with guidance.
88988942|NCT06122116|Active Comparator|PT + Photobiomodulation Treatment (PBMT)|"In addition to SOC PT, the PBMT group will receive PBM treatment, as outlined below.~PBM treatments will occur 3 times each week, for 3 weeks. A member of the study team will measure the treatment area according to a standard protocol and calculate the treatment time (approximately 5-20 minutes). PBMT will be delivered at 6 J/cm2 and 25W and applied in a serpentine pattern to the knee area. Participants will be asked to refrain from using perfumes or plant extracts (e.g., St. John's Wort) in the treatment area(s), as this can increase skin photosensitivity."
88988943|NCT06122116|Active Comparator|PT + PRP + PBMT|"In addition to SOC PT, the PRP and PBMT group will receive PRP treatment and PBMT treatments.~Participants in this group will start PBMT treatments on the same day after receiving the study PRP injection. On the day of the PRP injection, the participant will be instructed to rest for 5-10 minutes prior to the PBMT application and team member will ensure the participant is comfortable not in pain. Immediately following the study injection, the team member will take care not to provide the PBMT over the injected area; however, all subsequent PBMT treatments will be delivered to the knee where the PRP was injected."
88988944|NCT06120972|Experimental|Olaparib (maintenance)|300 mg Olaparib (tablets) will be taken orally, twice a day (approximately every twelve hours)
88988945|NCT06120075|Experimental|Dose Escalation Cohort 1 - AB801 Dose Level 1|Participants will receive AB801 orally daily
88988946|NCT06120075|Experimental|Dose Escalation Cohort 2 - AB801 Dose Level 2|Participants will receive AB801 orally daily
88988947|NCT06120075|Experimental|Dose Escalation Cohort 3 - AB801 Dose Level 3|Participants will receive AB801 orally daily
88988948|NCT06120075|Experimental|Dose Escalation Cohort 4 - AB801 Dose Level 4|Participants will receive AB801 orally daily
89622004|NCT05596175|Experimental|Super Rehab plus Usual Care|12-month Super Rehab programme involving supervised dietary review sessions, 1-to-1 high-intensity exercise sessions and 3-monthly clinical review of AF risk factors, alongside Usual Care (defined above)
89622005|NCT05593965|Experimental|TMS to lateral prefrontal cortex followed by TMS to medial prefrontal cortex|Participants will receive TMS while performing a reward-based decision-making task. In the first stimulation session, the TMS coil will be placed over the lateral prefrontal cortex on the scalp. In the second session, the TMS coil will be placed over the medial prefrontal cortex on the scalp. during every session, subjects receive Delta-beta patterned TMS, Theta-gamma patterned TMS, and Arrhythmic TMS.
89622006|NCT05593965|Experimental|TMS to medial prefrontal cortex followed by TMS to lateral prefrontal cortex|Participants will receive TMS while performing a reward-based decision-making task. In the first stimulation session, the TMS coil will be placed over the medial prefrontal cortex on the scalp. In the second session, the TMS coil will be placed over the lateral prefrontal cortex on the scalp. during every session, subjects receive Delta-beta patterned TMS, Theta-gamma patterned TMS, and Arrhythmic TMS.
89622007|NCT05593757|Experimental|Quinidine in period A, verapamil in period B|For this arm, patients will be treated with quinidine 200 mg thrice daily during period A. During period B, patients will be treated with verapamil 320-480mg daily during period B. The duration of the periods is different for each patient and depends on the time of inclusion.
89622008|NCT05593757|Experimental|Verapamil in period A, quinidine in period B|For this arm, patients will be treated with verapamil 320-480mg daily during period A. During period B, patients will be treated with quinidine 200 mg thrice daily during period A. The duration of the periods is different for each patient and depends on the time of inclusion.
89622009|NCT05586451|Other|Resistance Trained|Resistance-trained individuals are considered those who report performing structured moderate to intense resistance exercise for at least three days per week for at least 2 years prior to study start.
89622010|NCT05586451|Other|Untrained|Untrained individuals are considered those that report less than two days per week of structured (> 30 minutes) moderate to vigorous-intensity aerobic exercise and less than two days per week of structured resistance training for the 3 months prior to study start.
89622011|NCT05586087|Experimental|Experimental group|Participants perform a 16-week of High-Speed Resistance Training program.
89622012|NCT05586087|No Intervention|Control group|Participantes continued their usual activity without engaging in any strength training or beginning a new exercise program during the study.
88988949|NCT06120075|Experimental|Dose Escalation Cohort 5 - AB801 Dose Level 5|Participants will receive AB801 orally daily
88988950|NCT06120075|Experimental|Dose Escalation Cohort 6 - AB801 Dose Level 6|Participants will receive AB801 orally daily
88988951|NCT06120075|Experimental|Dose Expansion Cohort 1- AB801 + Zimberelimab + Docetaxel|Participants with NSCLC with known mutation or deletion of serine/threonine kinase 11 gene will receive AB801 orally in combination with zimberelimab and docetaxel administered via intravenous (IV) infusion
88988952|NCT06120075|Experimental|Dose Expansion Cohort 2 - AB801 + Docetaxel|Participants with NSCLC will receive AB801 orally in combination with docetaxel IV infusion
88988953|NCT06116617|Experimental|SRSD107|SRSD107 for subcutaneous (s.c.) injection Group A1, 15mg, single dose Group A2, 45mg, single dose Group A3, 120mg, single dose Group A4, 240mg, single dose Group A5, 450mg, single dose Group B1, 45mg per dose, 90mg multi dose Group B2, 120mg per dose, 240mg multi dose Group B3, 225mg per dose, 450mg multi dose
88988954|NCT06116617|Placebo Comparator|Placebo|Sodium chloride for subcutaneous (s.c.) injection
88988955|NCT06112496||smart phone addict|
88988956|NCT06112496||smart phone non addict|
88988957|NCT06110325|Experimental|Cawthorne and Cooksey exercise program|The exercise program will span one month and will center on the Cawthorne and Cooksey exercises targeting the vestibular system. Each session will be conducted individually and last for twenty minutes. The program will take place three times a week, with the initial session held in person and the subsequent two via video assistance from their homes
88988958|NCT06110325|Active Comparator|Control group|Information/Education on Fall Prevention and Promoting an Active, Healthy Lifestyle through Informational Leaflets.
88988959|NCT06107231|Experimental|Honey alone and honey with almonds, then sucrose alone and sucrose with almonds|Participants will be provided honey alone once each day for 3 days, then honey plus almonds for an additional 3 days while wearing a continuous glucose monitor. After a 14 day wash-out, participants will be provided sucrose alone once each day for 3 days, then sucrose plus almonds for an additional 3 days while wearing a continuous glucose monitor.
88988960|NCT06107231|Experimental|Sucrose alone and sucrose with almonds, then honey alone and honey with almonds|Participants will be provided sucrose alone once each day for 3 days, then sucrose plus almonds for an additional 3 days while wearing a continuous glucose monitor. After a 14 day wash-out, participants will be provided honey alone once each day for 3 days, then honey plus almonds for an additional 3 days while wearing a continuous glucose monitor.
88988961|NCT06097390|Experimental|Sequence 1: Semaglutide J then Semaglutide K|Oral semaglutide J will be administered in treatment period 1 followed by semaglutide K in treatment period 2.
88988962|NCT06097390|Experimental|Sequence 2: Semagultide K then Semaglutide J|Oral semaglutide K will be administered in treatment period 1 followed by semaglutide J in treatment period 2.
88988963|NCT06096467|Experimental|Comprehension exercise training combined with protein supplementation (CET+PS)|CET+PS: the comprehension exercise training combined with protein supplementation
88988964|NCT06096467|Placebo Comparator|Comprehension exercise training combined with placebo milk (CET+PC)|CET+PC: the comprehension exercise training combined with placebo milk
88988965|NCT06095583|Experimental|Experimental group A|Tifcemalimab (200 mg intravenous infusion [IV]) and toripalimab (240 mg IV)
88988966|NCT06095583|Experimental|Experimental group B|Placebo for tifcemalimab (IV) and toripalimab (240 mg IV)
88988967|NCT06095583|Placebo Comparator|Placebo group C|Placebos for both tifcemalimab and toripalimab (IV)
89037367|NCT01258738|Placebo Comparator|PLACEBO|In Period 1: Subjects will receive in a prefilled syringe with a PLACEBO dose equivalent to 1.0 ml of placebo solution once weekly SC Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
89037368|NCT04900077|Experimental|treatment group|treated by Carriere® Motion™ Appliance
89037369|NCT04900077|No Intervention|control group|no treatment
89037370|NCT00552656||1|the group of patients with angiographic results of complex coronary lesions(refer to the definition of protocol)are enrolled and given a clinical follow up and angiographic follow up during the following one year.
89622013|NCT05569941|Experimental|Part A: SAD Cohorts 1-5 ABI-4334 Tablet|A single dose of ABI-4334 will be administered on Day 1 in dose-escalation cohorts with a starting dose of 30 mg. The doses for subsequent cohorts will be determined by evaluation of safety and PK data from previous cohorts.
89622014|NCT05569941|Placebo Comparator|Part A: SAD Cohorts 1-5 ABI-4334 Placebo Tablet|A single dose of placebo matching ABI-4334 will be administered on Day 1.
89622015|NCT05569941|Experimental|Part A: SAD Fed Cohorts 6-7 ABI-4334 Tablet|A single dose of ABI-4334 will be administered after a high-fat meal on Day 1 in cohort 6. A single dose of ABI-4334 will be administered on two separate occasions, once fasted and once after a high-fat meal in cohort 7. The dose administered will be determined after evaluation of cumulative safety and PK data from cohorts 1-5.
89622016|NCT05569941|Placebo Comparator|Part A: SAD Fed Cohorts 6 ABI-4334 Placebo Tablet|A single dose of placebo matching ABI-4334 will be administered on Day 1 after a high-fat meal on Day 1 in cohort 6.
89622017|NCT05569941|Experimental|Part B: MAD Cohorts 1-2 ABI-4334 Tablet|Once-daily doses of ABI-4334 will be administered from Day 1 to Day 8. Cohort B1 will receive a dose determined from evaluation of the data from the SAD cohorts. The doses for the subsequent cohort will be determined by evaluation of safety and PK data from previous cohorts.
89622018|NCT05569941|Placebo Comparator|Part B: MAD Cohorts 1-2 ABI-4334 Placebo Tablet|Once-daily doses of placebo matching ABI-4334 will be administered from Day 1 to Day 8.
89622019|NCT05567393|Placebo Comparator|Part 1 (SRD): Pooled Placebo|TAK-951 placebo-matching, single dose, subcutaneous (SC) injection, on Day 1 in fasted healthy participants in the single-rising dose (SRD) period.
89622020|NCT05567393|Experimental|Part 1 (SRD): Cohort 2: TAK-951 Dose 1|TAK-951 Dose 1, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622021|NCT05567393|Experimental|Part 1 (SRD): Cohort 1: TAK-951 Dose 2|TAK-951 Dose 2, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622022|NCT05567393|Experimental|Part 1 (SRD): Cohort 15: TAK-951 Dose 2|TAK-951 Dose 2, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622023|NCT05567393|Experimental|Part 1 (SRD): Cohort 3: TAK-951 Dose 3|TAK-951 Dose 3, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622024|NCT05567393|Experimental|Part 1 (SRD): Cohort 4: TAK-951 Dose 4|TAK-951 Dose 4, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622025|NCT05567393|Experimental|Part 1 (SRD): Cohort 5: TAK-951 Dose 5|TAK-951 Dose 5, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622026|NCT05567393|Experimental|Part 1 (SRD): Cohort 6: TAK-951 Dose 6|TAK-951 Dose 6, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622027|NCT05567393|Experimental|Part 1 (SRD): Cohort 13: TAK-951 Dose 7|TAK-951 Dose 7, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622028|NCT05567393|Experimental|Part 1 (SRD): Cohort 14: TAK-951 Dose 8|TAK-951 Dose 8, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622029|NCT05567393|Experimental|Part 1 (SRD): Cohort 16: TAK-951 Dose 9|TAK-951 Dose 9, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622030|NCT05567393|Experimental|Part 1 (SRD): Cohort 17: TAK-951 Dose 10|TAK-951 Dose 10, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622031|NCT05567393|Experimental|Part 1 (SRD): Cohort 18: TAK-951 Dose 11|TAK-951 Dose 11, single dose, SC injection, on Day 1 in fasted healthy participants in the SRD period.
89622032|NCT05567393|Placebo Comparator|Part 3 (MRD): Pooled Placebo|TAK-951 placebo-matching, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the multiple-rising dose (MRD) period.
89622033|NCT05567393|Experimental|Part 3 (MRD): Cohort 10: TAK-951 Dose 1A|TAK-951 Dose 1A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
89622034|NCT05567393|Experimental|Part 3 (MRD): Cohort 11: TAK-951 Dose 2A|TAK-951 Dose 2A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
89622035|NCT05567393|Experimental|Part 3 (MRD): Cohort 12: TAK-951 Dose 3A|TAK-951 Dose 3A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
89622036|NCT05567393|Experimental|Part 3 (MRD): Cohort 20: TAK-951 Dose 4A|TAK-951 Dose 4A, SC injection, for 5 days from Days 1 to 5 in fasted healthy participants in the MRD period.
89622037|NCT05563181|Placebo Comparator|Control bar code|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
89622038|NCT05563181|Experimental|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
89622039|NCT05563181|Experimental|Control bar code + informational campaign about warning labels|Viewing an informational campaign about warning labels followed by viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
89622040|NCT05563181|Experimental|Warning label + informational campaign about warning labels|"Viewing an informational campaign about warning labels followed by viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
89037371|NCT01824537|Active Comparator|HPV vaccine, Gardasil 9|HPV vaccine intervention: The intervention vaccine will be Gardasil 9, a 9-valent vaccine by Merck. This vaccine was chosen because it allows for the observation of 9 HPV outcomes (HPV 6, 11, 16 and 18) (the other available vaccine, Cervarix, protects against HPVs 16 and 18, only).
89057846|NCT02217956|Experimental|HCIP + bevacizumab|"4 dose level of cisplatin are planned: Level 1 : 50 mg/m2 (start level) Level 2 : 60 mg/m2 Level 3 : 70 mg/m2 Level 4 : 80 mg/m2 Level -1: 40 mg/m2 (in case of DLT at level 1)~bevacizumab: Treatment starts between week 10 and 14 after HCIP. Dosage: 15 mg/kg for a total of 22 injections every 3 weeks for 15 months"
89622041|NCT05562310|Experimental|Phenylalanine, methionine, histidine requirement|
89622042|NCT05561790|Experimental|Intervention|Administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy.
89622043|NCT05561790|No Intervention|Control|Waitlist control (sleep diary only); access to treatment after final measurement
89622044|NCT05560113|Experimental|cTBS: Inhibitory Transcranial magnetic stimulation (TMS) to sensory Cortex|Participants will undergo a Functional magnetic resonance imaging (fMRI) scan while performing a fear conditioning/extinction task at the Center for Systems Imaging- Emory University Hospital (CSI-EUH) and then either stay at CSI-EUH or relocate to the Neural Plasticity Research Laboratory at Emory Rehabilitation Hospital. Participants will then be randomly assigned to either receive active or sham continuous theta burst stimulation (cTBS) to transiently disrupt neural activity in the targeted sensory cortex region specifically during the sensory memory consolidation window.
89622045|NCT05560113|Placebo Comparator|Sham cTBS|Participants will undergo a Functional magnetic resonance imaging (fMRI) scan while performing a fear conditioning/extinction task at CSI-EUH and then either stay at CSI-EUH or relocate to the Neural Plasticity Research Laboratory at Emory Rehabilitation Hospital. Participants will then be randomly assigned to either receive active or sham continuous theta burst stimulation (cTBS) to transiently disrupt neural activity in the targeted sensory cortex region specifically during the sensory memory consolidation window.
89622046|NCT05556434||patients with postoperative complications|Patients who experienced postoperative complications were divided into the first group. The complications were defined according to the Clavien-Dindo classification system.
89622047|NCT05556434||patients without postoperative complications|Patients who didn't experience postoperative complications were divided into the second group.
89622048|NCT05548283|Other|β-lactam Only (Non-AG)|Participants randomized to this arm will be prescribed a standard of care intravenous (IV) β-lactam as selected by their treating physician. Treatment must not include an IV aminoglycoside.
89622049|NCT05548283|Other|β-lactam and Aminoglycoside (AG)|Participants randomized to this arm will be prescribed a standard of care intravenous (IV) β-lactam and aminoglycoside selected by their treating physician.
89622050|NCT05547672|Experimental|UroMems artificial urinary sphincter|"Male adults (18+) with urinary incontinence with reduced outlet resistance due to intrinsic sphincter deficiency.~Intervention: device (UroMems artificial urinary sphincter)"
89622051|NCT05540210|Experimental|PSP sample|
89622052|NCT05539196||Post Exablate Neuro Pallidotomy for Parkinson's Disease with Motor Complications|The population enrolled in this registry will be comprised of male and female patients that plan to be treated using the Exablate Neuro system for advanced, idiopathic Parkinson's disease with medication-refractory moderate to severe motor complications. No intervention is performed under this registry protocol.
89622053|NCT05532618|Active Comparator|Levobupivacaine|Intervention group; 10 ml of Levobupivacaine 0.25% will be added in the adductor canal using ultrasound
89622054|NCT05532618|Placebo Comparator|Placebo|Control group; 10 ml of sodium chloride 0.9% will be added in the adductor canal using ultrasound
89622055|NCT05527704|Active Comparator|CPAP+Salbutamol|All patients will receive nCPAP at 5-6 cm H2O pressure with an oxygen concentration of 21% or more to maintain preductal saturation between 90% and 95%. Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulised salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
89622056|NCT05527704|Placebo Comparator|CPAP+Placebo|Patients in the placebo group will also receive nCPAP at 5-6 cm H2O pressure with an oxygen concentration of 21% or more to maintain preductal saturation between 90% and 95%. In addition, patients will receive 3 mL nebulised 0.9% NaCl administered for 30 min. as a placebo
89622057|NCT05526222|Experimental|Jaktinib low dose|Low dose
89622058|NCT05526222|Experimental|Jaktinib high dose|High dose
89622059|NCT05526222|Placebo Comparator|Placebo|Placebo
89622060|NCT05523856||New Treatment Modalities Cohort|A consecutive sample of clinically localized prostate cancer patients treated with active surveillance, robot-assisted radical prostatectomy, intensity-modulated radiotherapy, or real-time brachytherapy in 18 Spanish hospitals.
89622061|NCT05520476||20 patients with at least two seizures per week.|The device collects vital signs and EEG data as well as caregiver information associated with seizure episodes.
88988968|NCT06095011|Experimental|normal conservative management + posture training|Participants will receive normal conservative management as well as posture training via the UpRight Go posture trainer. The device will be provided to participants with all supplies and instructions that come from the original manufacturer and will be walked through how to install and use the necessary smartphone application as well as wear the posture trainer. Participants will be asked to wear the device daily for six weeks with goals for the amount of time spent wearing the sensor each day provided by the smartphone app. Participants will return to clinic in six weeks to return the device and submit usage data, or will mail back the device. Devices will be cleaned with disinfectant wipes before use by future participants.
88988969|NCT06095011|No Intervention|normal conservative management only (standard of care)|Participants will receive conservative management.only: standard of care for initial treatment of cubital tunnel syndrome
88988970|NCT06094608|Experimental|Morning light treatment|A 1 hour per day morning light treatment starting at average wake time, or up to 1 hour earlier to accommodate the morning schedule. The daily treatment continues for 4 weeks.
88988971|NCT06094608|Active Comparator|Treatment-as-usual|Participants will be instructed to continue to follow their usual sleep schedule for 4 weeks.
88988972|NCT06093217||Prospective Cohort: 'Live' Introduction of AI technology|Consecutive CTPAs, for patients with suspected acute PE, which have their imaging interpreted 'live' by AI technology. The radiologist will have ultimate responsibility for the report generated.
88988973|NCT06093217||Comparator Cohort: Standard Radiology reporting|"Retrospective CTPAs, for patients with suspected acute PE, which have been reported by a human radiologist only.~These CTPAs will not be interpreted by AI technology 'live' BUT undergo analysis to help assess the sensitivity, specificity, false negative, false positive rates of AI technology."
88988974|NCT06092710||study group with PSG and sleep survey|the study group will be recruited after their polysomnography but before its results, so patients and investigators will not have any data about Apnea Hypopnea Index (AHI) and sleep survey. they will experiment their subjective perception of air flow through their airways with the guidance of a manual therapist during a 15 minutes protocol
88988975|NCT06092710||control group with sleep survey|the control group will be recruited after a sleep survey with no sleep disorder. they will experiment their subjective perception of air flow through their airways with the guidance of a manual therapist during a 15 minutes protocol
89057847|NCT01687140|Placebo Comparator|Placebo|Participant takes one pill of placebo a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
89057848|NCT01687140|Active Comparator|DCS|Participant takes one pill of D-Cycloserine a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
89622062|NCT05518669||Peripheral Pulmonary Nodules|Patients with peripheral pulmonary nodules on chest computed tomography suspicion of malignancy who are scheduled to reach the target lesion for diagnosis by mobile cone-beam CT combined with electromagnetic navigation bronchoscopy.
89622063|NCT05517837|Experimental|BMS-986421 Under Fasted Conditions|
89622064|NCT05517837|Placebo Comparator|Placebo|
89622065|NCT05517707||Nasogastric tube group|Neonates age 0-18 weeks post-partum at enrollment with gestational age > 28 weeks will have the Gravitas Feeding Tube placed using standard technique. Tube placement will be verified by the institution standard of care. Study tubes are to remain in place up to 30 days.
89622066|NCT05514964|Experimental|Intervention Arm|The experimental arm were provided an intervention program based on John Forsyth & Georg Eifert (2016) The Mindfulness & Acceptance Workbook for Anxiety: A Guide to Breaking Free from Anxiety, Phobias & Worry Using Acceptance & Commitment Therapy, New Harbinger Publications. However, the initial treatment was adapted for the LGBT community using the suggestions from APA Guidelines for Psychological Practice With Lesbian, Gay and Bisexual Clients (2012) and Pachankis, J. E. (2014). Uncovering Clinical Principles and Techniques to Address Minority Stress, Mental Health, and Related Health Risks Among Gay and Bisexual Men. Clinical Psychology: Science and Practice, 21(4), 313-330. doi:10.1111/cpsp.12078.
89622067|NCT05503134|Experimental|Treatment|"Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2000 mg/ m2/day (days -6 to day -2)~Six doses of universal donor IL-21 expanded NK cells (UD-NK) given thrice weekly for two weeks starting on day 0. Days may vary and NK cells can be given from days 0 to 21. Patients may receive up to 2 cycles of fludarabine/cytarabine (FLA) + NK cells (up to 12 NK cell infusions) if they do not achieve CR after cycle 1 or if necessary to bridge to transplant."
88988976|NCT06091930|Experimental|Part I: BI 765049|BI 765049 monotherapy - dose escalation
88988977|NCT06091930|Experimental|Part II: BI 765049|BI 765049 monotherapy - dose expansion
88988978|NCT06091930|Experimental|Part III: BI 765049 + ezabenlimab|BI 765049 + ezabenlimab combination therapy - dose escalation
88988979|NCT06091930|Experimental|Part IV: BI 765049 + ezabenlimab|BI 765049 + ezabenlimab combination therapy - dose expansion
88988980|NCT06088602|Experimental|Cryo-group|Postoperative cryoneurolysis of the superficial genicular nerves, i.e., the infrapatellar branches of the saphenous nerve (ISN) and the anterior femoral cutaneous nerve (AFCN).
88988981|NCT06088602|Sham Comparator|Sham-group|Postoperative sham cryoneurolysis of the lower extremity.
88988982|NCT06086457|Active Comparator|PD-1 inhibitor plus chemotherapy arm|"Drugs: TP or PF regimen depended on investigator's choice. A maximum of six cycles was recommended for chemotherapy.~Biological: PD-1 inhibitor (Camrelizumab)."
88988983|NCT06086457|Experimental|Radiotherapy arm|"Radiation: Intensity-modulated Radiation Therapy/Volumetric Modulated Arc Therapy (IMRT/VMAT) technique. Patients will receive radiotherapy between the first and third cycle of chemotherapy.~Drugs: TP or PF regimen depended on investigator's choice. Biological: PD-1 inhibitor (Camrelizumab)."
88988984|NCT06085781|Other|Cohort A|Participants who are to receive standard of care radiotherapy will have one biopsy and MRI scan before starting radiotherapy and during week two of radiotherapy. Participants will also have an the option to consent to an additional biopsy and MRI scan during week 4 of radiotherapy. Oral pimonidazole will be taken the night before each biopsy.
88988985|NCT06085781|Other|Cohort B|Participants who are to receive standard of care curative surgery will have an MRI scan within one week prior to surgery. Tumor tissue from the surgery will also be collected for research. Oral pimonidazole will be taken the night before surgery.
88988986|NCT06084403|Active Comparator|20 ml volume adductor canal block|ACB will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
88988987|NCT06084403|Active Comparator|30 ml volume adductor canal block|ACB will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
88988988|NCT06084403|Active Comparator|40 ml volume adductor canal block|ACB will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
88988989|NCT06081426|Experimental|1st phase Non-ketogenic Diet / 2nd phase Ketogenic Diet|Participants with Bipolar Disorder will consume a non-ketogenic diet for the first phase of the study and then a ketogenic diet for the second phase of the study
88988990|NCT06081426|Experimental|1st phase Ketogenic Diet / 2nd phase Non-ketogenic Diet|Participants with Bipolar Disorder will consume a ketogenic diet for the first phase of the study and then a non-ketogenic diet for the second phase of the study
88988991|NCT06081426|Other|No diet|Participants without Bipolar Disorder will not participate in the diet phases of the study
88988992|NCT06074068|Experimental|Fathers for Change|Defining features of F4C include: 1) focus on the fathering role to facilitate engagement, 2) focus on RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 60 minutes per week over 18 weeks.
89622068|NCT05497349|Experimental|Leukocyte Rich-PRP Injection|"Three infiltrations of Leukocyte Rich Platelet Rich Plasma~1 infiltration weekly, for 3 weeks"
89622069|NCT05497349|Active Comparator|Leukocyte Poor- PRP Injection|"Three infiltrations of Leukocyte Poor-Platelet Rich Plasma~1 infiltration weekly, for 3 weeks."
89622070|NCT05495854|No Intervention|National Health Authority (HAS) strategy control|
89622071|NCT05495854|Experimental|new strategy experimental|
89622072|NCT05494424|Experimental|Goal Management Training (GMT)|Internet-delivered group-based GMT to groups of six participants in six two-hour sessions delivered weekly (five weeks). Manualized intervention.
89622073|NCT05494424|No Intervention|Wait list|Wait list control condition
89622074|NCT05491447|Active Comparator|Study Drug Treated, BMX-010 0.5%|n=72
89622075|NCT05491447|Active Comparator|Study Drug Treated, BMX-010 0.1%|n=72
89622076|NCT05491447|Placebo Comparator|Placebo Treated|n=72
89622077|NCT05491031|Experimental|Multiple sclerosis|
89622078|NCT05490043|Experimental|ATG-101|"Dose Escalation Phase:~Will be conducted with an enhanced PDx cohort.~Dose Expansion Phase:~Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled."
89622079|NCT05482815|Experimental|Voice Prosthesis|Subjects receive a Voice prosthesis using the Provox Puncture Set, then undergo an articulation training program (3 weeks). The voice prosthesis is replaced after 3 months and 6 months.
89622080|NCT05480683|Experimental|Targeted CT of pelvis with specific penile anatomical positioning for Peyronie Disease|Subject presenting with Peyronie disease signs or symptoms to Mayo Clinic Florida Department of Urology will undergo a targeted noncontrast CT of the pelvis with specific penile anatomical positioning
89622081|NCT05465954|Experimental|Treatment (efineptakin alfa, pembrolizumab)|"BEFORE SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1. Patients then undergo surgery 1 week later.~AFTER SURGERY: Patients receive pembrolizumab IV over 30 minutes and efineptakin alfa IM on day 1 of each cycle. Cycles repeat every 42 days for 2 years in the absence of disease progression or unacceptable toxicity."
89622082|NCT05464199|Experimental|Participants receiving neurofeedback intervention|Self administered neurofeedback training - Use of Headset and tablet with software App for playing a selected neurofeedback game. The EEG headset and tablet-based application is designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own EEG signals associated with activity in brain networks related to pain perception and pain modulation.
89622083|NCT05455671||Cohort 1 - Healthy Controls|Persons, male or female, between the ages of 3 and 21 (inclusive) with healthy lungs, defined by no known or suspected chronic or temporary lung disease. A single study visit
89622084|NCT05455671||Cohort 2 - CF Longitudinal|Persons, male or female, with CF, defined by two known disease-causing mutations and/or a sweat chloride value of >60mmol/L, between the ages of 3 and 21 (inclusive).
89622085|NCT05455671||Cohort 3 - CF Exacerbation|Persons, male or female, with CF, defined by two known disease-causing mutations and/or a sweat chloride value of >60mmol/L, between the ages of 3 and 21 (inclusive), experiencing a pulmonary exacerbation requiring antibiotics.
89622086|NCT05454358|Experimental|Letrozole|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
89622087|NCT05454358|No Intervention|Observation|Observation alone without any other therapy after postoperative adjuvant therapy
89622088|NCT05453721|Experimental|Indocyanine green fluorescence imaging method group|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
89622089|NCT05453721|Active Comparator|Modified inflation-deflation method group|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
89622090|NCT05450887|Experimental|OCA 5 mg titrated to 10 mg ± UDCA|"OCA 5 mg once daily for 3 months and then titrating up to 10 mg based on tolerability and response.~Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA."
89622091|NCT05450887|Placebo Comparator|Placebo ± UDCA|Placebo once daily. Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA.
89622092|NCT05444634|Experimental|distraction card|Immediately before the procedure, the child will be asked questions about the distraction cards. Questions about the cards will continue to be asked immediately after the intramuscular injection is finished.
89622093|NCT05444634|Experimental|Stress Ball|The child will be informed about the stress ball and asked to play continuously
89057849|NCT04535960|Experimental|Liraglutide|Liraglutide Subcutaneous Total Dose 1.8mg daily for 6 weeks
89622094|NCT05444634|No Intervention|Control|
89057850|NCT04535960|Experimental|Empagliflozin|Empagliflozin Tablets Total Dose 25mg daily for 6 weeks
89622095|NCT05443230||patients with sarcopenia|
89622096|NCT05443230||patients without sarcopenia|
89622097|NCT05443217||patients with response to systemic therapies|
89622098|NCT05443217||patients with no response to systemic therapies|
89622099|NCT05431101|Active Comparator|Absorbable sutures|Absorbable sutures Vicryl rapide or Safil quick
89622100|NCT05431101|Active Comparator|Non-absorbable sutures|Non-absorbable sutures Ethilon or Flexocrin
89622101|NCT05426902|Experimental|SLE@Duke|Clinic providers in Duke Rheumatology outside of the Duke Lupus Clinic are eligible to participate in the SLE@Duke intervention. Participants complete a baseline survey and training in the Type 1 & 2 SLE Model. They are asked to perform the intervention for all eligible patients over 4 weeks. Patients complete a survey at the end of their clinic visit, and providers complete a survey at the end of the 4 week intervention period. All participating providers were invited to an in-depth interview at the end of the intervention period.
89622102|NCT05426746|Experimental|ALT-100|"one of 4 ascending dose levels of ALT-100 administered as a single intravenous infusion with a staggered dose for sentinels followed by the rest of the cohort.~cohort 1: 0.1 mg/kg cohort 2: 0.4 mg/kg cohort 3: 1.0 mg/kg cohort 4: 4.0 mg/kg"
89622103|NCT05426746|Placebo Comparator|Saline|normal sterile saline (0.9% sodium chloride) administered as a single intravenous infusion at a constant infusion rate in a total volume and appearance matched to the active comparator, with a staggered dose for sentinels followed by the rest of the cohort
88988993|NCT06074068|Active Comparator|Duluth BIP|The BIP is a psychoeducational intervention that will be delivered in 60- minute individual weekly sessions over 18 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including video vignettes and role plays to teach anger management skills.
88988994|NCT06073717|Experimental|Exercise Intervention|This arm will receive a 5-month (20 weeks) supervised exercise program based on aerobic and resistance/strength training together with a weekly calorie or step challenge.
88988995|NCT06073717|Experimental|Dual Motor-Cognitive Intervention|This arm will receive a 5-month (20 weeks) supervised and simultaneous dual-task program based on aerobic, resistance, and cognitive stimulation training together with a weekly calorie or step challenge
88988996|NCT06073717|Active Comparator|Health and Wellness Intervention|This arm will receive a 5-month health and wellness program.
88988997|NCT06073444|No Intervention|Standard care|Participants assigned to this group will be screened for neonatal jaundice with the current used method consisting in visual assessment
88988998|NCT06073444|Experimental|Standard care + Picterus JP|Participants assigned to this group will be screened for neonatal jaundice with the current used method consisting in visual assessment and the smartphone app Picterus JP
88988999|NCT06072131|Active Comparator|Group 1a|Group 1a Belinostat 600 mg/m2 + CHOP
88989000|NCT06072131|Active Comparator|Group 1b|Group 1b Belinostat 1000 mg/m2 + CHOP
88989001|NCT06072131|Active Comparator|Group 2a|Group 2a Pralatrexate 20 mg/m2 + COP
88989002|NCT06072131|Active Comparator|Group 2b|Group 2b Pralatrexate 30 mg/m2 + COP
88989003|NCT06072131|Active Comparator|Group 3|CHOP
88989004|NCT06063135|No Intervention|Control|Single life-style coaching session
88989005|NCT06063135|Experimental|Exercise Time 1|Physical exercise intervention taking place at one time of the day
88989006|NCT06063135|Experimental|Exercise Time 2|Physical exercise intervention taking place at another time of day
88989007|NCT06061614|Experimental|Dose level 1|Dose level 1 will be administered
88989008|NCT06061614|Experimental|Dose level 2|Dose level 2 will be administered
88989009|NCT06061614|Experimental|Dose level 3|Dose level 3 will be administered
88989010|NCT06059846|Experimental|TBP-PI-HBr 600 mg + Dummy Infusion|Participants will receive TBP-PI-HBr 600 mg, orally and dummy infusion IV, every 6 hours from Days 1 through 10.
88989011|NCT06059846|Active Comparator|Imipenem-cilastatin 500 mg + Dummy Tablets|Participants will receive imipenem-cilastatin 500 mg, IV and matched dummy tablets, orally, every 6 hours from Days 1 through 10.
88989012|NCT06058910||Newborn|This study will include newborn pediatric patients under 2-weeks of age who are necessary to conduct this study and are representative of the target population for use with this device.
88989013|NCT06057805|Experimental|Blinded CGM|Blinded continuous glucose monitor Dexcom G7
88989014|NCT06053242|Experimental|Low Dose|Subjects in the low dose arm will receive a single administration of either 6x10^6 cells (n=8) or a placebo injection (n=2). Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
88989015|NCT06053242|Experimental|Medium Dose|Subjects in the medium dose arm will receive a single administration of either 12x10^6 cells (n=8) or a placebo injection (n=2). Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
88989016|NCT06053242|Experimental|High Dose|Subjects in the high dose arm will receive a single administration of either 24x10^6 cells (n=8) or a placebo injection (n=2). Each subject will receive six paraspinal intramuscular injections (three injections per side) of either CELZ-201-DDT or placebo into the lumbar musculature under direct ultrasound guidance.
88989017|NCT06052839|Experimental|Pembrolizumab + Carboplatin with Paclitaxel|"Pembrolizumab: Administer 200 mg intravenously (IV) every 3 weeks (q3w); maintenance will be continued at 400 mg IV q6w for 12 cycles for a total of 2 years of therapy~Carboplatin: Started with cycle 2 (C2) of pembrolizumab and continued thereafter every 3rd cycle of pembrolizumab for a total of 4 cycles with paclitaxel; carboplatin will be given at C2, C5, C8, and C11 of pembrolizumab.~Paclitaxel: Started with cycle 2 (C2) of pembrolizumab and continued thereafter every 3rd cycle of pembrolizumab for a total of 4 cycles with carboplatin."
88989018|NCT06052475|Experimental|Physiological Pacing (Conduction System Pacing or Biventricular Pacing)|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
88989019|NCT06052475|Active Comparator|Right Ventricular Pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice)
88989020|NCT06051721|Experimental|Arm A: Active|Arm A participants will receive a full dose of CYB004 in 2 of 2 medicine sessions, approximately three weeks apart. All participants will receive supportive EMBARK psychotherapy throughout the study.
88989021|NCT06051721|Active Comparator|Arm B: Control|Arm B participants will receive a low dose of CYB004 in 2 of 2 medicine sessions, approximately three weeks apart. All participants will receive supportive EMBARK psychotherapy throughout the study.
88989022|NCT06049615|Experimental|CLAAS|Subjects to be implanted with the CLAAS device.
88989023|NCT06047678|Experimental|Normotension group|Participants with normotension Adult: 40 - 63 years old Physically active - no professional sportsman
88989024|NCT06047678|Experimental|Hypertension Stage 1 group|Participants with Hypertension Stage 1 Adult: 40 - 63 years old Physically active - no professional sportsman.
88989025|NCT06043791|Experimental|Treatment|Patients will be imaged with standard of care MRI shoulder arthrogram on a 1.5 T magnet and additionally with non-contrast MRI of the shoulder on a 3 T magnet. All patients will be dually imaged. Initial imaging will utilize the standard of care, and, subsequently, patients will be brought back within 2 weeks, for non-contrast MRI as part of the study protocol
88989026|NCT06042920|Experimental|Deucravacitinib|
88989027|NCT06042920|Placebo Comparator|Placebo followed by Deucravacitinib|
88989028|NCT06040905|Experimental|Coenzyme Q10|Coenzyme Q10 300 mg/day (150 mg/b.i.d.)
88989029|NCT06040905|Placebo Comparator|Placebo|Placebo (dextrin)
89057851|NCT02270463|Experimental|SL-401|
89622104|NCT05404022|Experimental|Intervention arm|12 weeks home based tailored nutrition and physical activity (PA) programme Participants will have an appointment (face-to-face if possible) with the study physiotherapist and dietitian for delivery of the PA (including breathlessness management) and nutrition intervention components. Participants will receive study equipment at these appointments (or by post) including paper-based tracking diary, resistance bands for strength exercises, a Fitbit activity monitor to track steps and aerobic activity during the study period, nutritional supplements (if prescribed), and printed study materials (if preferred over pdf emails; e.g. cooking tips, recipes). A video/telephone follow-up call (10-15 minutes) will be conducted by the research team with the participant at weeks 2,3,4,5 and 6 and then at weeks 8,10 and 12 to review and adjust their programme (with input from the physiotherapist and dietitian if required).
89622105|NCT05404022|No Intervention|Usual care arm|The usual cancer care will include usual patient management and care prior, during and after cancer treatment - medication, symptom control, cancer advice and support from routine medical and nursing input with access to Allied Health Professionals (AHPs) such as physiotherapists and dietitians as clinically indicated. As part of this, it is common for older adults with cancer to be prescribed high protein supplementation. Control participants will receive a general information leaflet regarding activity and nutrition.
89622106|NCT05393765|Experimental|experimental|"Experimental: Intervention group Yönetebilirim Before the initiation of the program, patients who visit the outpatient clinic will be evaluated according to the inclusion-exclusion criteria, their consent will be obtained, and pre-tests will be administered. Then, randomization will be performed and participants will be assigned to the experimental and control groups. Participants in the experimental group will be registered on the web-based program. The individuals in the experimental group will use Yönetebilirim for 8 weeks as of the time the program is put into use. Yönetebilirim consists of modules and consultancy services. Participants will be able to watch informative videos as much as they want for 8 weeks and receive consultancy service if they wish."
89622107|NCT05393765|No Intervention|Control|The control group will receive standard care without any intervention. The group will not receive any other intervention.
89622108|NCT05373121|Experimental|Intervention condition - signposting to online peer support|The intervention group will be sent a list of online peer support signposting groups and forums to engage with, which will be adapted depending on what health conditions their child has. They will be asked to keep a weekly engagement log for three months.
89622109|NCT05373121|No Intervention|Waitlist condition|The waitlist group will be informed that they will be contacted again in three months, after which, the waitlist will be sent the signposting resources.
89622110|NCT05371509|Experimental|Myofunctional therapy (MT) nozzle|Subjects diagnosed with mild to moderate obstructive sleep apnea will receive a water bottle with a myofunctional therapy (MT) nozzle to use daily
89622111|NCT05371509|Placebo Comparator|Placebo nozzle|Subjects diagnosed with mild to moderate obstructive sleep apnea will receive a water bottle with a placebo nozzle to use daily
89622112|NCT05370430|Experimental|B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T cells]|BAFFR-CAR T cells in participants with r/r B-NHL
89622113|NCT05364190|Experimental|Group A(Intervention group)|patients will receive 100 mg canagliflozin initiated within 24 hours from patients hospital admission due to signs of hypervolemic state. All patients also will be prescribed the conventional diuretic therapy and other medications such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI) and mineralocorticoid receptor antagonists (MRAs). Canagliflozin will be continued for 90 days after hospital discharge
89622114|NCT05364190|Active Comparator|Group B|patients will receive 10 mg Empagliflozin initiated within 24 hours from patients hospital admission due to signs of a hypervolemic state.All patients also will be prescribed conventional diuretic therapy and other medications including ACEIs, ARBs, beta-blockers, ARNI, and MRAs.Empagliflozin will be continued for 90 days after hospital discharge
89622115|NCT05363930|Active Comparator|Single balloon enteroscopy|Patients with suspected Crohn's disease requiring small bowel enteroscopy based on clinical features, laboratory investigation and in cross-sectional imaging (computed tomography/magnetic resonance enterography or enteroclysis/ video capsule endoscopy
89622116|NCT05363930|Active Comparator|Novel Motorized Spiral Enteroscopy|Patients with suspected Crohn's disease requiring small bowel enteroscopy based on clinical features, laboratory investigation and in cross-sectional imaging (computed tomography/magnetic resonance enterography or enteroclysis/ video capsule endoscopy
89622117|NCT05352893|Experimental|IV high dose Imsidolimab, other name ANB019|ANB019 Biological Humanized Monoclonal Antibody High Dose
89622118|NCT05352893|Experimental|IV low dose Imsidolimab, other name ANB019|ANB019 Biological Humanized Monoclonal Antibody Low Dose
89622119|NCT05352893|Placebo Comparator|IV Placebo|Placebo Solution
89622120|NCT05349617|Experimental|Group 1 - PXVX0317|
89622121|NCT05349617|Placebo Comparator|Group 2 - Placebo|
88989030|NCT06038435|Experimental|Cognitive Orientation Approach + Ayres Sensory Integration Therapy|Cognitive Orientation Approach on Daily Occupational Performance (CO-OP) and Ayres Sensory Integration (ASI) Therapy will be applied together
88989031|NCT06038435|Active Comparator|Ayres Sensory Integration Therapy Only|Only Ayres Sensory Integration (ASI) Therapy will be applied
88989032|NCT06036121|Experimental|Phase 1a Dose Escalation|Increasing doses of ADRX-0706 will be administered to identify the maximum tolerated dose (MTD) and the recommended dose to be used in the Phase 1b part.
88989033|NCT06036121|Experimental|Phase 1b Dose Expansion|ADRX-0706 will be initially administered at the dose recommended from the Phase 1a part in 3 disease-specific cohorts.
88989034|NCT06034990||Survey participants|Participants in this cross-sectional survey will be physicians with specialty in Anesthesiology, Surgery, Critical care medicine, Pulmonology, Nephrology, General Medicine currently working in Surgical or Medical ICU in Southeast Asia in year 2023-2024
89622122|NCT05341921|Active Comparator|Alternate Nostril Breathing Phase I|Alternate nostril breathing for normotensive women in 3rd trimester of pregnancy
88989035|NCT06030843|Experimental|Empagliflozin|Empagliflozin 10 mg po OD
88989036|NCT06030843|Placebo Comparator|Placebo|Matching placebo
88989037|NCT06022107|Experimental|LDART|Participants will be asked to log onto the LDART website each night for a month.
89622123|NCT05341921|Active Comparator|Bhramari Breathing Phase I|Bhramari breathing for normotensive women in 3rd trimester of pregnancy
89622124|NCT05341921|Active Comparator|Sheetali Breathing Phase I|Sheetali breathing for normotensive women in 3rd trimester of pregnancy
89622125|NCT05341921|Active Comparator|Alternate Nostril Breathing Phase II|Alternate nostril breathing for hypertensive women in 3rd trimester of pregnancy
89622126|NCT05341921|Active Comparator|Bhramari Breathing Phase II|Bhramari breathing for hypertensive women in 3rd trimester of pregnancy
89622127|NCT05341921|Active Comparator|Sheetali Breathing Phase II|Sheetali breathing for hypertensive women in 3rd trimester of pregnancy
89622128|NCT05337150|Experimental|Lifestyle Modification with a Balanced Calorie Deficit Diet|Lifestyle modification intervention with a balanced calorie deficit diet (i.e., participants will be prescribed a calorie goal and will track their dietary intake in order to meet this goal).
88989038|NCT06021106|Experimental|Experimental group|Breathing exercises were applied to the experimental group with virtual reality glasses. Each application consists of 20 minutes. The exercises were performed 3 days a week for eight weeks, a total of 24 sessions.
88989039|NCT06021106|Active Comparator|Control group|In the control group, routine treatment and care continued and no additional intervention was made.
88989040|NCT06020599||Children who need general anesthesia for surgery|Children who need general anesthesia for surgery (ENT, dentistry) at Louis Mourier Hospital.
88989041|NCT06019494|Experimental|Low aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary with an aspiration flow rate of 0.42ml/sec.
88989042|NCT06019494|Experimental|High aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary with an aspiration flow rate of 0.62ml/sec.
88989043|NCT06017219|Experimental|within subject control 20mg|spermidine
88989044|NCT06017219|Experimental|within subject control 40mg|spermidine
88989045|NCT06016257|Experimental|VirtuaCare Group|"For the subjects in Group 1, the physical therapist will set up the patients within the VirtuaCare™ system and build their treatment plan.~Each time a patient in the VirtuaCare returns for a clinic visit, the physical therapist will review their VirtuaCare™ patient report displaying information such as exercises completed along with their measured form, pace, range of motion, and exertion. From the review, they will help the patient understand any corrections they need to make in the following week when at home. The therapist can add or adjust any exercises they deem necessary for the next phase of the patient's rehabilitation."
88989046|NCT06016257|No Intervention|Usual and Customary Group|This study involves a medical record review for the control group. Data will be abstracted from closed medical records after completion of shoulder physical therapy.
88989047|NCT06015867|Active Comparator|Control Bread: Wholemeal Yeast Bread|Wholemeal bread, containing mainly of wholemeal flour, water and bakers' yeast will be used as the control test bread.
88989048|NCT06015867|Active Comparator|Wholemeal Sourdough Bread|Wholemeal sourdough bread, containing mainly of wholemeal flour, water and added sourdough co-culture (consisting of W.anom.+ C.crust strain).
88989049|NCT06015165|Experimental|Anes Group|In Anes Group, the anesthesiologist routinely works in the operating room, and will communicate with anorectal physicians through bedside visits, video telephone calls, and a hospital-wide electronic medical record system in the operating room. Anesthesiologists will evaluate the patient's pain degree and symptoms perioperatively at bedside, and will administer opioids or non-opioids at the optimal interval and standard dose until discharge. The anesthesiologist and the surgeon will jointly formulate the discharge medication plan and give the patient guidance on analgesic treatment.
88989050|NCT06015165|Active Comparator|Surg. group|According to the current perioperative management mode, patients in the surgeon-led group (Surg. group) will be given local anesthesia during the operation, and will receive routine ambulatory surgery anesthesia plan, and routine postoperative analgesia plan in the ward will be given to the patients, under the guidance of the department of pharmacy. The patients will receive rescue opioids and standardized NSAIDs until discharge.
88989051|NCT06014593|Other|Heart failure patients|Stable or relapsing heart failure patients aged between 25 and 85, diagnosed by a cardiologist and requiring respiratory and cardiac investigations at the Montpellier University Hospital.
88989052|NCT06014593|Other|Healthy voluntary|Volunteers Aged 25 to 85 with no previous cardiorespiratory history or treatment.
88989053|NCT06012266|Active Comparator|Group A: Dapagliflozin first, Empagliflozin second|"Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~On the day of Visit 3, they will switch to Empagliflozin once daily, to be continued up to the day preceding Visit 4."
88989054|NCT06012266|Active Comparator|Group B: Empagliflozin first, Dapagliflozin second|"Patients randomized to Group B will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~On the day of Visit 3, they will switch to Dapagliflozin once daily, to be continued up to the day preceding Visit 4."
88989055|NCT06006065|Experimental|Intervention group|Upper limb somatosensory discrimination therapy (Sense for Kids therapy)
88989056|NCT06006065|Active Comparator|Active control group|Upper limb motor therapy
88989057|NCT06003387|Experimental|CSL222|Participants will receive CSL222 as a single intravenous (IV) infusion of 2 × 10^13 genome copies per kilogram (gc/kg) on Day D.
89622129|NCT05337150|Experimental|Lifestyle Modification with an Ad Libitum Whole Food Plant-Based Eating Plan|Lifestyle modification intervention with an ad libitum whole food plant-based diet (i.e., participants will eat, ad libitum, fruits, vegetables, starches, legumes, and whole grains, and will avoid eating processed foods, refined oils, and animal products)
89622130|NCT05330897|Experimental|Treatment arm|Implantation of an eCLIPs™ device
89622131|NCT05325723||Intervention group|"30 second audio phonocardiogram (PCG) recordings at each of the five standard cardiac auscultatory positions using an Apple iPhone®.~the assessment of VHD by echocardiogram, as reported by the echocardiography laboratory."
89622132|NCT05322928|Experimental|Engagement in daily occupations|The experimental contents will include 1-hour video appointments with an occupational therapist a week in four weeks and a maintenance phase of similar session format every second week in two months.
89622133|NCT05320237|Experimental|Virtual Reality Intervention|Eight weeks of two 30 minute sessions using virtual reality with the upper limb exercise games.
89622134|NCT05320237|No Intervention|Control Group|Participants will be asked to continue with their usual care independent of this study.
89622135|NCT05319236|Other|Gabi System|Subjects will wear the Gabi system each time they go to sleep or are resting, to measure and record their SpO2, pulse rate, respiratory rate and movements.
89622136|NCT05316727||Vaping|At least weekly vape use over the past 3 months of the subjects unspecified product
89622137|NCT05316727||Non vapers|No previous history of vape use and no current history of smoking tobacco for controls
89622138|NCT05315479|Experimental|N1539|N1539 (Meloxicam IV) 0.6 mg/kg (maximum 30 mg) Q24H
89622139|NCT05315206|Experimental|Citicoline Treated Group, TC Group|In a group of patients with open angle glaucoma (OAG), Citicoline in oral solution (10 ml / day) will be administered for 12 months (Citicoline Treated Group, TC Group)
89622140|NCT05315206|Placebo Comparator|Placebo Treated Group, TP Group|in another group of patients with open angle glaucoma (OAG) will be administered Placebo (Containing all excipients of Citicoline in oral solution) (10 ml / day) for 12 months (Placebo Treated Group, TP Group)
89622141|NCT05311254|Experimental|Fosfomycin|Drug: Fosfomycin: oral capsules containing 700 mg of calcium fosfomycin, equivalent to 500 mg of active drug.
89622142|NCT05311254|Active Comparator|Ciprofloxacin|Oral ciprofloxacin, tablets containing 500 mg of active drug.
89622143|NCT05308355||OFA : Opioid Free Anesthesia|Opioid-free surgery. Analgesia provided by attenuation analgesic 1, dexmedetomidine, ketamine and general anesthesia by propofol. Regional loco anesthesia is performed in the OFA group and possible in the OBA group. It's local service protocol used since 1 year.
89622144|NCT05308355||OBA : Opioid Based Anesthesia|Conventional anesthesia with Propofol and Sufentanil boli with the possibility of regional loco anesthesia.
89622145|NCT05303376|Experimental|Active|
89622146|NCT05303376|Placebo Comparator|Placebo|
89622147|NCT05302583|Other|SOC only then SOC plus Aromatherapy Inhaler|"Participant will receive standard of care pharmacological intervention (SOC) as needed throughout the day.~Participants will complete the Standard of Care Pharmacological Intervention Use Log.~At between 1300 and 1500 hours, study personnel will administer the NCCN Distress Thermometer and Problem List."
89622148|NCT05302583|Other|SOC and Aromatherapy Inhaler then SOC only|"Participant will use the aromatherapy inhaler as needed for up to two (2) hours in the morning and complete the Aromatherapy Inhaler Use Log.~At between 1300 and 1500 hours, study personnel will administer the NCCN Distress Thermometer and Problem List."
89622149|NCT05300633|Experimental|Intervention arm|Family member/concerned significant other
89622150|NCT05299580|Experimental|single arm|Patients will be treated with Dabrafenib 150 mg bid and Trametinib 2mg qd. Each cycle is 28 days and the treatment will be continued until documented disease progression, unacceptable toxicity, intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, or administrative reasons.
89622151|NCT05294757|No Intervention|Hospital control|Hospital control cohort: Participants will be consecutively recruited from the scheduled patient list of the frailty unit, day hospital, and the outpatient clinic of the Geriatrics Department of Hospital 2. After obtaining informed consent, baseline study variables will be collected. Patients will be followed-up for a 16-week period, under usual care. After the follow-up period, baseline evaluation will be repeated.
89622152|NCT05294757|Experimental|Exercise|Elderly people without muscle problems participating in the exercise program to see improvements in their muscle mass levels and quality
89622153|NCT05294757|No Intervention|Primary care Control|Primary care cohort: Participants will be consecutively recruited from the scheduled patient list of the Primary Care Units. After informed consent acquisition, baseline study variables will be collected. Patients will be followed-up during one year, under usual care. After the one-year follow-up, the baseline evaluation will be repeated.
89622154|NCT05289557|Active Comparator|Bonjesta|On Day 1, one tablet will be taken orally at bedtime. If this dose adequately controls symptoms (i.e., PUQE = 3), the participant will be directed to continue taking one tablet daily at bedtime only. However, on Day 2, if symptoms of nausea, retching and/or vomiting persist (i.e., PUQE score >3), the participant will be directed to take her usual dose of 1 tablet at bedtime and an additional tablet the next morning on Day 3. The minimum dosage prescribed will be 1 tablet daily at bedtime, increasing, when indicated, to the maximal dosage of 2 tablets per day (one tablet in the morning and one tablet at bedtime) starting Day 3 and will continue through Day 14.
89622155|NCT05289557|Placebo Comparator|Placebo|On Day 1, one tablet will be taken orally at bedtime. If this dose adequately controls symptoms (i.e., PUQE = 3), the participant will be directed to continue taking one tablet daily at bedtime only. However, on Day 2, if symptoms of nausea, retching and/or vomiting persist (i.e., PUQE score >3), the participant will be directed to take her usual dose of 1 tablet at bedtime and an additional tablet the next morning on Day 3. The minimum dosage prescribed will be 1 tablet daily at bedtime, increasing, when indicated, to the maximal dosage of 2 tablets per day (one tablet in the morning and one tablet at bedtime) starting Day 3 and will continue through Day 14.
89622156|NCT05283187|Experimental|MBCT|Mindfulness Based Cognitive Therapy
89622157|NCT05283187|No Intervention|Control Group|No intervention
89622158|NCT05278676|Experimental|Cohort A Single Dose: Dotinurad|Participants will receive dotinurad 1 milligram (mg) (1*1 mg tablet) as a single oral dose after 10-hour fasting on Day 1 in the morning.
89622159|NCT05278676|Experimental|Cohort B Multiple Dose: Dotinurad|Participants will receive dotinurad 4 mg (2*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning. A washout period of 3 days will be maintained after single dose on Day 1 and then participants will receive dotinurad 4 mg (2*2 mg tablets) after 10-hour fasting from Day 4 to Day 10 once daily in the morning.
89037372|NCT01824537|Placebo Comparator|Hepatitis A vaccine|"The placebo comparator will be Avaxim, by Sanofi Pasteur. This control vaccine was chosen because hepatitis A immunization provides a similar health prevention incentive as HPV vaccination to study participants while preserving the scientific cogency of a placebo comparator. Gardasil 9 requires administration of 3 doses, while Avaxim only requires 2 doses. For this reason, a placebo injection (saline solution) will be added in between the Avaxim vaccination regimen. Consequently, both treatment and control vaccines will have similar regimens, i.e., study entry, 2 months, and 6 months."
89037373|NCT04863339|Experimental|Tranexamic Acid|Participants in the Tranexamic Acid arm will receive a dose of Tranexamic Acid.
89037374|NCT04863339|Placebo Comparator|Placebo|Patients in the placebo arm will receive a saline placebo.
89622160|NCT05278676|Experimental|Cohort C Single Dose: Dotinurad|Participants will receive dotinurad 10 mg (5*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning.
89622161|NCT05277831|Experimental|Guided Imagery Intervention|Guided Imagery Intervention
89622162|NCT05277831|Active Comparator|Standard Behavioral Control|Standard Behavioral Control
89622163|NCT05276947|Experimental|Peanut ball intervention|The experimental group. In the active phase of the labor (cervical dilatation = 5 cm), the peanut ball, which has a cover provided by the researcher and changed in each patient, will be placed between the knees of the participant for at least 30 minutes every hour, and a position change will be provided with the peanut ball in each time. The positions to be given with the peanut ball, semi sitting lunge, side lying, tucked, leaning forward, pushing and sitting position.
89622164|NCT05276947|No Intervention|Control group|Standard care will be given to the control group without positioning with a peanut ball.
89622165|NCT05272956|No Intervention|control group|Enteral feeding is carried out with a syringe pump
89622166|NCT05272956|Experimental|intervention group|the first enteral feeding is pushed with a syringe by the nurse. Following enteral feeding attempts are pushed with a syringe by the parents. Bolus feeding speed is at the discretion of the person pushing the syringe (nurse or parent) and is adjusted to the child's signs of discomfort. When the parents are absent, enteral feeding is carried out with a syringe pump
89622167|NCT05249868||SARS-CoV-2 Infection|"Confirmed SARS-CoV-2 infection diagnosed after 11 May 2020 and registered in electronic health records.~(positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for <5 days is positive on a PRAg test)"
89622168|NCT05249868||NO SARS-CoV-2 Infection|No confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.
89622169|NCT05245032||Feasibility testing|During the screening visit, blood and/or a bone marrow sample will be obtained for the patient's standard clinical evaluation. An aliquot of the blood and/or marrow sample will be obtained for ex vivo drug sensitivity assay
89622170|NCT05244486|Experimental|Treatment Arm|Men will begin utilizing PTT 30-60 minutes daily for 5-7 days weekly beginning 1 month post-prostatectomy until 6 months. After 6 months, they will have the option to continue to use the therapy for 3 additional months or discontinue at their discretion.
89622171|NCT05244486|Active Comparator|Control|Men will not utilize PTT for the first 6 months post-prostatectomy. Beginning at 6 months, they may utilize PTT if they desire (open label) until 9 months post-prostatectomy.
89622172|NCT05237440|Other|All patients|Metabolic, hormonal and psychometric evaluations will be carried out during or after hospitalization inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out
89622173|NCT05231187||Prospective Arm|Subjects has had a diagnostic blood culture ordered per routine standard of care.
89037375|NCT04684277|Experimental|antidepressant treatment|recieve antidepressant treatment
89037376|NCT04684277|Experimental|antidepressant treatment combined with Internet-based interventions|recieve antidepressant treatment combined with Internet-based interventions
89037377|NCT05604183|Experimental|Subjects|"On all subjects included in the study (see inclusion / exclusion criteria and informed consent) both procedures will be performed.~The result of these procedures (retinal scan, result from cognitive test and blood sample) will be used to build diagnostic classification models."
89622174|NCT05231187||Contrived Arm|Samples of healthy whole blood spiked with bacterial strains harboring the resistance gene targets on the T2Resistance Panel.
89622175|NCT05231187||Healthy Donor Arm|Healthy donor subjects.
89622176|NCT05230576||Deep learning training cohort|2/3 of the enrolled patients and their corresponding carotid artery dynamic scan images and expert diagnosis results were randomly selected as the training cohort for deep learning.
89622177|NCT05230576||Deep learning validation cohort|The carotid artery dynamic scan images and expert diagnosis results of the remaining 1/3 patients were used as a validation cohort to evaluate the overall diagnostic accuracy of the deep learning model.
89622178|NCT05227599|Other|Daily Diary Method Cohort|"Participants will be asked to complete a self-report questionnaire that has been validated to assess daily affect. There are 5 items assessing positive affect (joyful, cheerful, happy, lively, proud) and 5 items assessing negative affect (miserable, mad, afraid, scared sad). The respondent is asked to rate these 10 different feelings on a 5-point Likert scale from 1, not much or not at all to 5, a lot."
89622179|NCT05226260|Experimental|Intervention|Intervention clinics receiving fully functional Epic order panel with set default [short] duration by diagnosis: for cellulitis and drained abscess, 5 days. For impetigo and undrained abscess, 7 days.
89622180|NCT05226260|No Intervention|Control|Control clinics receiving basic Epic order panel with antibiotic doses by diagnosis but duration free text (must be entered manually by clinician prescriber).
89622181|NCT05222438|Experimental|Loncastuximab tesirine|Patients will start loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles). Patients will receive IV infusion of loncastuximab tesirine 150 μg/kg at Q3W for the first 2 cycles followed by 75 μg/kg at Q3W for the remaining 6 cycles.
89622182|NCT05205616|Placebo Comparator|Reciprocating saw|The traditional surgical instrument used for cutting bilateral sagittal split osteotomies
89622183|NCT05205616|Active Comparator|Sonopet ultrasonic saw|This instrument is being compared to the reciprocating saw
89622184|NCT05199870||Echo FX Stem with RingLoc Bipolar Acetabular Cup and Femoral Head|Patients that have been implanted with a Echo FX stem with RingLoc Bipolar acetabular cup and femoral head to repair hip malfunction/disease/injury.
89622185|NCT05199012|Placebo Comparator|Placebo|Placebo is maltodextrin, delivered as 2 capsules.
89622186|NCT05199012|Active Comparator|Active|The active comparator is black pepper extract, delivered as 2 capsules.
89057852|NCT04536428|Experimental|ClearEndoclip|This arm is a group in whom ClearEndoclip would be used for the treatment of bleeding.
89057853|NCT04536428|Active Comparator|EZ clip|This arm is a group in whom EZ clip would be used for the treatment of bleeding.
89057854|NCT01687374|Placebo Comparator|Placebo|
88989058|NCT06002789|Experimental|MSI-H/MSS (dMMR/pMMR) mixed sMPCC or all-MSI-H (dMMR) sMPCC|"MSI-H/MSS (dMMR/pMMR) mixed sMPCC: Synchronous multiple primary colorectal cancer consist of MSI/dMMR and MSS/pMMR tumors at the same time~all-MSI-H (dMMR) sMPCC: Synchronous multiple primary colorectal cancer with all MSI/dMMR tumors"
88989059|NCT05995860|No Intervention|Control group triads|
88989060|NCT05995860|Experimental|Intervention group triads|
88989061|NCT05995470|Experimental|DBT-ST group|Participants in the intervention group will receive the DBT-ST by means of a free video-communication app. Over the next 13 weeks from the baseline, the intervention group will receive a weekly 120-minute internet-based DBT-ST focusing on the four modules of DBT-ST.
88989062|NCT05995470|Other|TAU group|Participants in the wait list control group will receive a monthly health education for three months that provides general health information and sharing sessions, which is one of the routine care for drinkers during the first 3-4 months after they seek help for drinking problem (waiting period for further intervention).
88989063|NCT05994716|No Intervention|Observation group|
88989064|NCT05994716|Experimental|Telemonitoring|
88989065|NCT05989698|Experimental|C-mo System|
88989066|NCT05988684|Experimental|Metformin|Metformin group will be instructed to take metformin
88989067|NCT05988684|No Intervention|control|Standard treatment and Follow-up, no metformin
88989068|NCT05986422|Active Comparator|Methylprednisolone|"Tested IMP: Methylprednisolone (film-coated tablet). Authorization status: Not authorized in this targeted therapeutic indication; methylprednisolone is authorized for treatment of multiple autoimmune diseases. The tablets being administered in this trial are an official trade product provided by the marketing authorization holder JenaPharm.~Administration: Tablet containing 16 mg/tablet will be administered orally and according to bodyweight groups. Treatment period comprises 6 weeks of blinded daily IMP (investigational medicinal product) intake (verum or placebo) and 6 weeks of unblinded daily intake of Methylprednisolone. The general IMP titration regimen was investigated and proven to be safe in patients with cerebral vasculitis (Schirmer et al., 2020)."
88989069|NCT05986422|Placebo Comparator|Placebo|"Comparator IMP: Placebo (film-coated tablet). Authorization status: Not authorized. To ensure identical conditions with the verum (Methylprednisolone), we will use placebo tablets of the same color and size in identical tablet packages for both the verum and placebo.~Administration: Tablets (7 mm) will be administered orally and according to bodyweight groups. To achieve consistent conditions with the verum, titration will be conducted in a manner similar to the tested IMP (Methylprednisolone). Treatment period comprises 6 weeks of blinded daily IMP intake (placebo or verum) and 6 weeks of unblinded daily intake of Methylprednisolone."
88989070|NCT05982353|Sham Comparator|PTFE application with immediate implantation|this group received PTFE membranes during immediate implantation as the gold standard
88989071|NCT05982353|Experimental|Gelatin Sponge application with immediate implantation|this group received gelatin sponges during immediate implant placement
88989072|NCT05982171|Experimental|Exoskeleton+Transcutaneous Spinal Cord Stimulation|Treatment in this group will involve walking overground using the assistance of an exoskeleton while receiving a therapeutic level of transcutaneous spinal cord stimulation (TSCS) thoracolumbar spinal cord areas. Focus will be on stepping at a high intensity throughout the session as measured by heart rate.
88989073|NCT05982171|Sham Comparator|Exoskeleton+Sham Stimluation|Treatment in this group will involve walking overground using the assistance of an exoskeleton while receiving a non-therapeutic level of stimulation (considered to be a sham). Focus will be on stepping at a high intensity throughout the session as measured by heart rate.
88989074|NCT05980689|Experimental|Treatment Arm|A total of 33 pMMR/MSS LARC patients will receive long-course chemoradiotherapy plus 2 cycles of AK104, followed by another 3 cycles of AK104, finally received clinical routine manage.
88989075|NCT05977088|Experimental|Interventional|"Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken i in the Faraday cage."
88989076|NCT05977088|Sham Comparator|Sham|The same treatment procedures will be applied to the control group with a sham coil.
88989077|NCT05976009|Experimental|active rTMS treatment|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
88989078|NCT05975697|Experimental|Experimental group to be applied FES|FES treatment to the deltoid, triceps, extensor carpi radialis muscles for a total of 10 sessions, 30 minutes twice a day (in the morning and in the evening), for 5 days after the first 24th hour after the thrombectomy procedure in the experimental group patients (Program duration is 15 minutes and resting time is 15 minutes). minutes) will be applied.
88989079|NCT05975697|No Intervention|control group|In the control group patients; From the first 24 hours after the thrombectomy procedure, the routine of the clinic (such as not performing a non-pharmacological procedure) is applied for 5 days, and no other procedure will be performed.
88989080|NCT05974904||Non-MAFLD group|controlled attenuation parameter<274 dB/m
88989081|NCT05974904||MAFLD group|controlled attenuation parameter ≥ 274 dB/m
88989082|NCT05974904||Non-fibrosis group|liver stiffness measurement < 8.2 kPa
88989083|NCT05974904||Fibrosis group|liver stiffness measurement ≥ 8.2 kPa
88989084|NCT05974358|Experimental|Kono-S group|Kono-S group, in which ileocolonic anastomosis will be performed following the technique described by Kono et al.
88989085|NCT05974358|Other|Control group|Conventional side-to-side ileocolonic anastomosis
88989086|NCT05970328||Arrhythmia Participant|Non-critical adult (21 years and older) participants that are suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour Holter monitor.
88989087|NCT05968911||Trauma brain injury|Patients with acquired brain injury of traumatic etiology.
88989088|NCT05968911||Non-trauma brain injury|Patients with acquired brain injury of non-traumatic etiology.
88989089|NCT05967299|Placebo Comparator|Placebo|Placebo for ZMA001 is supplied in a single-use 10 mL glass vial. Each vial contains 30 mg/mL of sucrose.Placebo drug is manufactured using the same ingredients as active drug (20 mM histidine-HCl buffer [pH 5.6], 30 mg/mL sucrose, 0.070 w/v% polysorbate 80) excluding ZMA001 antibody and is packed in the same vial.
89057855|NCT01687374|Experimental|Parathyroid hormone|
89622187|NCT05197998|Experimental|Color Brave Program|The experimental group will be asked to download and complete a 6-week multi-module mobile app program designed to enhance and encourage critical conversations about race and racism among parents and their young children.
89622188|NCT05197998|Other|Wait-list Control|The wait-list control group will be placed on the wait-list for the first 6-weeks, the period in which the experimental group will complete the intervention program. Following the 6-week wait-list period they will receive the color brave program.
89622189|NCT05197972|Experimental|Experimental group|Classic management of the preoperative period with a cardiac coherence program coupled with hypnosis.
89622190|NCT05197972|No Intervention|Control group|Classic management of the preoperative period
89622191|NCT05197075|Experimental|Darunavir/Cobicistat (DRV/COBI) Fixed Dose Combination (FDC)|Participants will receive the DRV/COBI FDC tablet for oral use, dispersed in water on Day 1.
89622192|NCT05195398|Experimental|A-tDCS|Participants randomized to tDCS will undergo 15- 30 minute sessions over 5 weeks of A-tDCS to the ipsilesional frontoparietal cortex while participating in computerized cognitive therapy (CCT).
89622193|NCT05195398|Active Comparator|Sham Intervention|Participants randomized to sham will undergo 15- 30 minute sessions over 5 weeks of a sham-intervention, also applied to the ipsilesional frontoparietal cortex, while participating in computerized cognitive therapy (CCT).
89622194|NCT05187013|Experimental|Hypertension-Specific Education|6 months of mHealth HTN management support via SMS texts including reminders for medication adherence, appointment attendance, and HTN-specific health education and support. Texts will be delivered to support medication adherence and lifestyle changes, and participants will receive appointment reminders before each appointments with a follow-up text and robocall if the appointment is missed.
89622195|NCT05187013|Other|General Health Education|6 months of mHealth including basic healthcare and general health promotion via SMS texts. Blood pressure measurements and adherence assessments will be collected at every shelter visit.
89622196|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 30 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
89622197|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 30 seconds + GLS-5310 IN|GLS-5310 ID + GeneDerm + GLS-5310 IN administered at Visit 1
89622198|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 65 kPa, 15 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
89622199|NCT05182567|Experimental|GLS-5310 ID + GeneDerm 80 kPa, 30 seconds|GLS-5310 ID + GeneDerm administered at Visit 1
89622200|NCT05178498||Observational (physical exam, questionnaire)|Patients complete physical measurements every 6 months and complete questionnaires annually for 5 years. Patients are followed up annually in years 5-10.
88989090|NCT05967299|Experimental|ZMA001 (BC-NKA-20008)|ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
88989091|NCT05964829|Experimental|Control|Participants will follow the walking program.
88989092|NCT05964829|Experimental|Functional electrical stimulation|Participants will follow the walking program and receive stimulation assistance during the walking sessions.
88989093|NCT05964036|Experimental|active TMS|active iTBS coupled with medical therapy
88989094|NCT05964036|Sham Comparator|sham TMS|Sham iTBS coupled with medical therapy
88989095|NCT05964010|Active Comparator|SBIRT-A-Standard|Standard adolescent-only approach to screening, brief intervention, and referral to treatment for adolescent substance use.
88989096|NCT05964010|Experimental|SBIRT-A-Family|Family-based approach to screening, brief intervention, and referral to treatment for adolescent substance use in which caregivers are systematically included in screening, intervention, and referral activities.
88989097|NCT05962996||Amines|Sedated and intubated patients requiring a deep venous catheter, unable to communicate their level of pain, and treated with aminergic drugs (no curare) Assessment of pain levels by pupillometry during the placement of the deep venous catheter
88989098|NCT05962996||Curares|Sedated and intubated patients requiring a deep venous catheter, unable to communicate their level of pain, and treated with curares (no aminergic drug) Assessment of pain levels by pupillometry during the placement of the deep venous catheter
88989099|NCT05962996||Sedation alone|Sedated and intubated patients requiring a deep venous catheter, unable to communicate their level of pain, without any aminergic drug nor curare Assessment of pain levels by pupillometry during the placement of the deep venous catheter
88989100|NCT05956899|Experimental|Group A|Group A will receive a stat dose of IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia.
88989101|NCT05956899|Active Comparator|Group B|Group B will receive a stat dose of IV ondansetron 0.15mg/kg at the start of wound closure.
88989102|NCT05955066|Experimental|Baricitinib|Patients randomized into JAKi group will receive one capsule of baricitinib (4mg) daily for 24 weeks.
88989103|NCT05955066|Placebo Comparator|Placebo|Patients randomized into placebo group will receive one capsule of placebo daily for 24 weeks.
88989104|NCT05953662|Experimental|Reduced-port laparoscopic surgery|locations of trocars: A 10mm trocar is placed in the supraumbilical or subumbilicus as an observation port, and the surgeon inserts a 10mm trocar and a 5mm trocar on the ipsilateral side of the patient according to the intraoperative situation, as the main operation port and the secondary operation port, and the positions of the trocars follow the principle that the lesion is located at the triangular apex of the two trocars.
88989105|NCT05953662|Active Comparator|conventional laparoscopic surgery|locations of trocars: A 10mm trocar is placed in the supraumbilicus or subumbilicus as an observation port, and the surgeon inserts a 10mm trocar and a 5mm trocar in a suitable position according to the intraoperative situation as the main operation port and the secondary operation port. The assistant places two 5mm trocars in the appropriate position as the assistant operation port.
88989107|NCT05946213|Experimental|Arm I (SBRT)|Patients undergo SBRT for a total of 5 treatments over 2 weeks.
88989108|NCT05946213|Active Comparator|Arm II (EBRT)|Patients undergo EBRT for 20 to 45 treatments over 4 to 9 weeks.
88989109|NCT05944692||Pediatric patients|pediatric patients with epilepsy
88989110|NCT05944692||Adult patients|Adult patients with epilepsy
88989111|NCT05943444|Active Comparator|Parks technique|patients receive coloanal anastomosis operation
89622201|NCT05169697|Experimental|YH002 in combination with YH001|Dose escalation:A traditional 3+3 dose escalation algorithm will be utilized to identify MTD and/or RP2D Dose expansion:One selected dose after the escalation stage will be expanded to enroll additional 20 subjects. The subjects will be divided into two groups：A and B.
89622202|NCT05168735|Experimental|Intravenous Ketamine + Mindfulness Exercises|
89622203|NCT05168735|Active Comparator|Intravenous Ketamine + Academic Exercises|
89622204|NCT05164822||Necrotizing Vasculitis|"Patient with an initial diagnosis or a relapse of :~- Systemic Vasculitic Neuropathy (SVN): Primary Necrotizing Vasculitis answering the Chapel Hill Consensus Conference criteria associated with a symptomatic Vasculitic Peripheral Neuropathy~Or~- Non Systemic Vasculitic Neuropathy (NSVN): pure symptomatic peripheral neurological impairment without systemic visceral impairment"
89622205|NCT05163782|Experimental|People with foot drop|People with left or right foot drop
89622206|NCT05163288|Experimental|N-acetyl-L-leucine (IB1001)|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients <13 will receive weight-tiered doses.
88989112|NCT05943444|Experimental|Bacon technique|patients receive coloanal pull-out anastomosis operation
88989113|NCT05938075|Experimental|VXC0-100 at Dose level 1|Participants will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 1 on Month 6.
88989114|NCT05938075|Experimental|VXC0-100 at Dose level 2|Participants will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 2 on Month 6.
88989115|NCT05938075|Experimental|VXC0-100 at Dose level 3|Participants will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 3 on Month 6.
88989116|NCT05938075|Experimental|COVID-19 mRNA vaccine|Participants will receive a COVID-19 mRNA vaccine on Day 1 and then a boost with the same COVID-19 mRNA vaccine at Day 21.
88989117|NCT05934292|Experimental|Panel A: Moderate Renal Impairment (RI)|Period 1 Day 1: Participants receive MK-0616 20 mg tablet single dose orally (Period 1 = 15 days)
88989118|NCT05934292|Experimental|Panel B: Severe RI|Period 1 Day 1: Participants receive MK-0616 20 mg tablet single dose orally (Period 1 = 15 days)
88989119|NCT05934292|Experimental|Panel C: End-Stage Renal Disease (ESRD) on Hemodialysis (HD)|Period 1 Day 1: Participants receive MK-0616 20 mg tablet single dose orally (Period 1 = 15 days). Period 2 Day 1: Participants receive MK-0616 20 mg tablet single dose orally (Period 2 = 15 days). A washout period of 14 days will separate Period 1 and Period 2.
88989120|NCT05934292|Experimental|Panel D: Healthy|Period 1 Day 1: Participants receive MK-0616 20 mg tablet single dose orally (Period 1 = 15 days)
88989121|NCT05932966||Patients with type 1 Diabetes equipped with control-IQ closed loop system|Patients with type 1 Diabetes equipped with control-IQ closed loop system
88989122|NCT05932966||Patients with type 1 diabetes equipped with Smart GUARD closed loop system|Patients with type 1 diabetes equipped with Smart GUARD closed loop system
88989123|NCT05930496|Experimental|Arm A (exercise intervention)|Patients receive the supervised exercise intervention over 8 weeks on study. Patients also undergo collection of blood samples at baseline and week 8.
88989124|NCT05930496|Active Comparator|Arm B (waitlist control)|Patients receive health-related information for 8 weeks on study. Patients are then offered a session of supervised exercise followed by 7 weeks of tele-coaching sessions. Patients also undergo collection of blood samples at baseline and week 8.
88989125|NCT05930418|Experimental|Cardiac MRI after sepsis|Participants who meet the eligibility criteria of severe sepsis.
88989126|NCT05929820|Experimental|Protect Your Colon™ (Intervention)|Patients randomized to Protect Your Colon™ will be directed to go through the website at least 2 days before their clinic appointment. Those who finish the decision aid will then review their personalized report which details their priorities in selecting a screening test as well as the test that best matches their values. Patients will also be encouraged to bring their personalized report with them to the visit to discuss with their doctor. All intervention participants will also receive a reminder via email one day before their scheduled clinic visit. They will be reminded to go through the Protect Your Colon™ website before the clinic visit and to bring their personalized report with them to the visit.
88989127|NCT05929820|No Intervention|Usual Care (Control)|The usual care group will be managed according to the providers' customary practices: CRC screening discussions, if any, are at the discretion of the provider as Cedars-Sinai does not employ a standardized approach. Patients randomized to the control arm will not be sent any materials before their clinic appointment.
88989128|NCT05927363|No Intervention|Controls|Patients in Phase 3 of cardiac rehabilitation, undergoing the usual care provided.
88989129|NCT05927363|Experimental|Experimental Group|"Patients in Phase 3 of cardiovascular rehabilitation, following a therapeutic educational program for consolidation (patient partner and a caregiver) as well as the usual care provided."
88989130|NCT05927207|Experimental|TRIP App|Both groups will be assessed at baseline on the outcome measurements, after which the immediate intervention group will begin the 6-week intervention
88989131|NCT05927207|No Intervention|Waitlist control|Both groups will be assessed at baseline on the outcome measurements, after which the the waitlist control group will receive usual care in the following six weeks. Afterwards, the waitlist control group will complete outcome assessment once again, before receiving the 6-week intervention
88989132|NCT05927116|Experimental|Immediate intervention|Both groups will be assessed at baseline on the outcome measurements, after which the immediate intervention group will begin the 6-week intervention
88989133|NCT05927116|No Intervention|Waitlist control|Both groups will be assessed at baseline on the outcome measurements, after which the the waitlist control group will receive usual care in the following six weeks. Afterwards, the waitlist control group will complete outcome assessment once again, before receiving the 6-week intervention
88989134|NCT05925881|Active Comparator|Lower Trapezius Tendon Transfer|The lower trapezius tendon transfer arm will consist of patients randomized to this surgical procedure. This is an arthroscopically assisted open procedure that involves harvesting of the lower trapezius muscle tendon and re-grafting it onto to shoulder to repair massive rotator cuff tears.
89622207|NCT05163288|Placebo Comparator|Placebo comparator|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients <13 will receive weight-tiered doses.
89622208|NCT05156853|Experimental|Insect-based menu|Replacement of meat proteins with insect-based alternatives at main meals 3 times weekly.
89622209|NCT05156853|Active Comparator|Plant-based menu|Replacement of meat proteins with plant-based alternatives at main meals 3 times weekly.
89622210|NCT05154006|Active Comparator|Active Control (Information only)|Women in the active control group receive instruction on safe carrying behaviors (reduce carried weight & use safe lifting techniques) and information about benefits when performing the behavior and reducing strain on the pelvic floor.
89622211|NCT05154006|Experimental|Individual promotion of self-efficacy|"The group Individual promotion of self-efficacy receives the same instructions and information on safe carrying behavior as the control group.~Additionally, this group will receive behavior change techniques (Michie et al., 2013) to increase self-efficacy (psychological activities to increase self-confidence / belief in own capability to reduce risks of carrying loads with own behavior)."
89622212|NCT05154006|Experimental|Promotion of self-efficacy + social support|"The group Promotion of self-efficacy + social support receives the same instructions for safe carrying behavior as the control group. The intervention will also include the same behavior change techniques to promote self-efficacy.~Additionally, a social partner from the same or neighboring household will be involved in the intervention activities. The partner will participate in the intervention activities and will be instructed to provide emotional, practical and informational social support."
89622213|NCT05148338|Experimental|Risk intervention group|Comprehensive risk factor management at specialized AF outpatient clinic concerning blood pressure, cholesterol, glycaemic control, physical inactivity, weight control, smoking, alcohol intake and sleep apnea.
89622214|NCT05148338|Active Comparator|Control group|Standard of care. Treatment by cardiologist conform existing guidelines.
89622215|NCT05147532|Other|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714
89622216|NCT05135819|Experimental|Intergenerational educational program|
89622217|NCT05111405|Other|Trapezial excision with or without soft tissue interposition and /or ligament reconstruction|The participating surgeon will perform their usual version of a trapeziectomy and thumb metacarpal using either FCR tendon or abductor hallucis longs (APL) tendon. Tendon interposition will be left to the surgeon's discretion.
89622218|NCT05111405|Other|Suture button suspension arthroplasty (SBS)|Dorso-radial incision, capsulotomy between extensor pollicis brevis (EPB) and APL protecting the radial artery. A second incision is made on dorsum of hand between the 2nd and 3rd MCs. A cannulated drill with suture passer is passed from base of 1st MC to mid 2nd MC. The TightropeTM is passed from 1st to second MC with one button on the base of the 1st MC. Trapeziectomy is then performed using a cruciate osteotomy and rongeurs. The thumb is adducted against index MC to avoid excessive tightening and the suture is tied over a second button on the 2nd MC. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
89622219|NCT05104645|Experimental|Patients after a Stroke|
89622220|NCT05104645|Active Comparator|Healthy Volunteering|
89622221|NCT05086705|Experimental|Arm A (EMBr Wave)|Patients utilize the EMBr Wave device for 4 weeks, then crossover to arm B for 4 weeks.
89622222|NCT05086705|Active Comparator|Arm B (crossover)|Patients receive no treatment for 4 weeks, then crossover to arm A for 4 weeks.
89622223|NCT05084924|Experimental|Delta-beta tACS|The study is investigating the use of transcranial alternating current stimulation (tACS). The stimulation is delivered at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. For the experimental arm, the tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
89622224|NCT05084924|Active Comparator|Theta-gamma tACS|This arm serves as an active control where tACS will be delivered using the cross-frequency stimulation waveform theta-gamma (5-50Hz).
89622225|NCT05084924|Sham Comparator|Active-sham tACS|For active sham stimulation, either delta-beta or theta-gamma stimulation is delivered for 10 seconds and then returns to baseline. This is intended to mimic the skin sensations (e.g., itching, burning, tingling) that are experienced at the onset of stimulation, assisting with blinding the participant's assignment.
89622226|NCT05070104|Experimental|Single Arm|CPI-613 mFFX Bevacizumab
89622227|NCT05066854|Experimental|Integron research|"Empirical antibiotic treatment chosen based on the results of the integron search:~when PCR is negative, patients will receive SXT (30 mg/kg/j of sulfamethoxazole and 6 mg/kg/j of trimethoprim)~when PCR is positive or uninterpretable for integrons, patients will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
89622228|NCT05066854|Other|Usual practice|Empirical antibiotic treatment based on the usual practice of each center according to the GPIG guidelines.
89622229|NCT05064150||NET patient observational cohort|Patients diagnosed with lung or gastrointestinal neuroendocrine tumors
89622230|NCT05063513|Experimental|Transplant arm|Experimental arm will undergo mobilisation with cyclophosphamide (CY) 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
89622231|NCT05063513|Active Comparator|Rituximab arm|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
88989135|NCT05925881|Active Comparator|Bridging Reconstruction Repair|"The bridging reconstruction repair arm will consist of patients randomized to this surgical procedure. This operation is arthroscopic, and involves the insertion of a human dermal allograft to the rotator cuff, sutured and anchored in a bridging fashion to repair massive rotator cuff tears."
88989136|NCT05924802|Placebo Comparator|Placebo|Placebo given that mimics taste, weight, and size of the interventional supplement mirroring the same time points as the ketone ester supplement group. Mirrored imaging with MRI as well.
88989137|NCT05924802|Experimental|Ketone ester supplement|Ketone ester given daily for 12 weeks and scanned before and after intervention with MRI.
89037378|NCT05603871||ligamentoplasty of ligamentum teres|"The patients will be examined for:~Length of both lower limbs in relation to each other.~Length of both lower limbs according to patient age.~Presence of hump related to the outer surface of the hip~Presence of pain, abnormal gait, Trendlenburg test.~An addition to the steps of the open reduction, the following were done:~Identification of ligamentum teres~Ligamentoplasty of ligamentum teres"
89037379|NCT04651985||Injured Achilles tendon participants who have an Achilles tendinopathy|They will do the eccentric exercise protocol and go through a series of ultrasound examination.
89037380|NCT04651985||Healthy Achilles tendon (contralateral) of participants who have an Achilles tendinopathy|They will do the eccentric exercise protocol and go through a series of ultrasound examination.
89037381|NCT04647968|Other|Primary closure of tracheo-cutaneous fistula|This group will undergo a protocoled primary closure of their tracheotomy.
89037382|NCT04647968|Other|Secondary closure of tracheo-cutaneous fistula|This group will undergo a protocoled secondary closure of their tracheotomy.
89037383|NCT04630184|Experimental|Virtual reality and exercice|This group will receive the exposure intervention in virtual reality and physical activity during 12 weeks
89037384|NCT04630184|Placebo Comparator|Placebo and exercice|This group will receive the placebo intervention (relaxation) and physical activity during 12 weeks
89037385|NCT04630184|No Intervention|waiting list|This group will receive no intervention during 12 weeks, then will be randomized in the experimental or placebo group
89037386|NCT00552734||Control|The other half of the patients were randomized to the control group who were followed for their routine diabetes care and had to visit the clinic on the same schedule as the experimental group.
89037387|NCT00552734||Experimental|Half of the subjects were randomized to this group using insulin guidance software on a PDA to adjust their insulin dose at home based on the prescription provided by the provider.
89037388|NCT00552773|Experimental|Cyclamen Europaeum|
89037389|NCT00552773|Placebo Comparator|Placebo|
89037390|NCT04831164||Case|Patients with MRI confirmed rotator cuff tears
89037391|NCT04831164||Control|Patients without rotator cuff tears
89037392|NCT04816617|Experimental|Aerobic Exercise|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
89622232|NCT05048810|Experimental|68Ga-DOTA-NT-20.3|Subjects will undergo PET imaging using 68Ga-DOTA-NT-20.3.
89622233|NCT05045677|Experimental|Digital DBT intervention group|Digital intervention group plus standard care
89037393|NCT04816617|Placebo Comparator|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
89037394|NCT04543682|Experimental|First intervention group (0.125 ng/kg/min Iloprost)|The first intervention group will receive open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.125 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. The catheter will be inserted during the surgical procedure. Infusion of Iloprost will start 24hrs post-operatively and the dose will be delivered over 24h.
89622234|NCT05045677|Active Comparator|Standard care|Standard care alone
89622235|NCT05043675|Experimental|[18F]APN-1607|For the injection, subjects will receive a target dose of 0.1~0.15mCi/Kg [18F]APN-1607 as a bolus injection.
89622236|NCT05037656|No Intervention|Control|Students in the control group will receive the standard health education curriculum.
89622237|NCT05037656|Experimental|Experimental|Students in the treatment group will receive the school-based classroom curriculum.
89057856|NCT04530188|Experimental|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
89622238|NCT05016219|Active Comparator|Active Intervention plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
89622239|NCT05016219|Active Comparator|Active Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
89622240|NCT05016219|Active Comparator|Placebo Light plus Active Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
89622241|NCT05016219|Placebo Comparator|Placebo Light plus Placebo Rhythm|The device will set on a tabletop in a room where the participant spends at least 2 hours in the morning. Using a timer, it will automatically turn on at preferred wakeup times (but no later than 09:00 am) chosen by the participant. Lights will remain on for at least 2 hours and participants will be asked to remain the space that lights are being applied for that period of time.
89622242|NCT05012176|Experimental|Arm I (EFT)|Patients participate in EFT over 12 weeks, in which they will receive prompts via a guided smartphone application to engage in EFT in their daily lives. Patients are asked to recall future positive experiences to create text cues which vividly describes these experiences.
89057857|NCT04530188|Active Comparator|intravenous sedation with propofol|intravenous sedation with propofol, as already used in our ICU
89057858|NCT01687452|Experimental|Groupe A|Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load > 1000 copies / ml
89622243|NCT05012176|Active Comparator|Arm II (ERT)|Patients participate in ERT over 12 weeks, in which they will receive prompts via a guided smartphone application to engage in ERT in their daily lives. Patients are asked to recall past positive experiences to create text cues which vividly describes these experiences.
89622244|NCT05001516|Experimental|LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~first dose: 0.2mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=1;"
89622245|NCT05001516|Experimental|LM302 Dose Escalation Level 2, 0.4 mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~second dose: 0.4mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=3;"
89622246|NCT05001516|Experimental|LM302 Dose Escalation Level 3, 0.8 mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~third dose: 0.8mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;"
89622247|NCT05001516|Experimental|LM302 Dose Escalation Level 4, 1.6mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fourth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;"
89622248|NCT05001516|Experimental|LM302 Dose Escalation Level 5, 2.4mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~fifth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=9;"
89622249|NCT05001516|Experimental|LM302 Dose Escalation Level 6, 2.8mg/kg|"The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.~sixth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=12;"
89622250|NCT05000827|Experimental|PSMA PET/CT based indication for ePLND:|"Node-negative PSMA PET/CT [N0] and M0: do not perform ePLND~Node-positive PSMA PET/CT [N1] and M0: perform ePLND"
89622251|NCT05000827|Active Comparator|Nomogram-based indication for ePLND (standard of care)|Nomogram-based indication for ePLND (conform current EAU guidelines)
89622252|NCT04990726||Observational (assessment, blood collection, questionnaire)|Patients undergo medical assessments and blood sample collection and complete questionnaires at baseline, 1, 3, 6, 12, 18, and 24 months.
89622253|NCT04990726||Treatment (assessment, blood collection, questionnaire)|Patients undergo medical assessments and blood sample collection and complete questionnaires at baseline (prior to C1 infusion), 2, 4, 7 infusion, at end of treatment, and 18 and 24 months after completion of treatment.
89622254|NCT04989790|No Intervention|Baseline/Pre-implementation|Usual PICU care
89622255|NCT04989790|Active Comparator|Intervention/Post-implementation|PICU Up! is a multifaceted, inter-professional pathway that is integrated into routine PICU practice to safely optimize early and progressive patient mobility.
89622256|NCT04973085|Experimental|Cold circulated water|Cold water circulated through an adhesive wrap applied to the front of the neck.
89622257|NCT04973085|Active Comparator|Body-temperature circulated water|Body-temperature water circulated through an adhesive wrap applied to the front of the neck.
89622258|NCT04973007|Active Comparator|Gadoxetate disodium exam first|The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly.
89622259|NCT04973007|Active Comparator|Gadobenate Dimeglumine exam first|The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly.
89622260|NCT04963673||DFG> 40 ml / min|Kidney transplant population followed at CHU Amiens (group 1 ⇾ DFG> 40 ml / min).
89622261|NCT04963673||DFG < 40 ml / min|Kidney transplant population followed at CHU Amiens (group 2 ⇾ DFG < 40 ml / min).
88989138|NCT05924022|Experimental|Full treatment|Participants are administered 100% oxygen in the HBOT chamber at 2.0 ATA
88989139|NCT05924022|Sham Comparator|Partial treatment|Participants are administered 21% oxygen in the HBOT chamber at <1.3 ATA.
88989140|NCT05923567||CA19-9<385 & FE-1>100|
88989141|NCT05923567||CA19-9<385 and FE-1>100|
88989142|NCT05923567||CA19-9>385 & FE-1>100|
88989143|NCT05923567||CA19-9>385 & FE-1<100|
88989144|NCT05922709|Experimental|CS12192 Cohort 1|Subjects receive a single dose of 50 mg CS12192 or matching placebo.
88989145|NCT05922709|Experimental|CS12192 Cohort 2|Subjects receive a single dose of 150 mg CS12192 or matching placebo.
88989146|NCT05922709|Experimental|CS12192 Cohort 3|Subjects receive a single dose of 200 mg CS12192 or matching placebo.
88989147|NCT05922709|Experimental|CS12192 Cohort 4|Subjects receive a single dose of 300 mg CS12192 or matching placebo.
88989148|NCT05922709|Experimental|CS12192 Cohort 5|Subjects receive a single dose of 400 mg CS12192 or matching placebo.
88989149|NCT05922709|Experimental|CS12192 Cohort 6|Subjects receive 200 mg CS12192 or matching placebo for 7 days, twice daily (every 12 h) from Day 1 to Day 6, and once on Day 7.
88989150|NCT05922709|Experimental|CS12192 Cohort 7|Subjects receive 300 mg CS12192 or matching placebo, twice daily (every 12 h) from Day 1 to Day 6, and once on Day 7.
88989151|NCT05922709|Experimental|CS12192 Cohort 8|Subjects receive 400 mg CS12192 or matching placebo for 7 days, twice daily (every 12 h) from Day 1 to Day 6, and once on Day 7.
88989152|NCT05922709|Experimental|CS12192 Cohort 9|Subjects receive a single dose 400 mg CS12192 in either the fasted or fed state for two periods.
88989153|NCT05922709|Experimental|CS12192 Cohort 10|Subjects receive a single dose of 600 mg CS12192 or matching placebo.
88989154|NCT05922332|Experimental|Rich medium chain fatty acid milk powder group|This group will be fed milk powder rich in medium-chain fatty acids. The MCT content of formula milk is 39%, and the total energy is 68kcal/100ml.
88989155|NCT05922332|Active Comparator|Regular milk powder group|This group will be fed regular milk powder.The MCT content of formula milk is less than 30%, and the total energy is 67kcal/100ml.
88989156|NCT05922046|Experimental|Subjects with Parkinson's Disease over 65 years of age|Individuals diagnosed with Parkinson's disease who are at least 65 years old on the date of initial assessment will be selected.
89622262|NCT04962009|Experimental|Travoprost Evolute® (Travoprost Punctal Plug Delivery System, T-PPDS), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
89622263|NCT04954599|Experimental|Module 1A Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 monotherapy in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
89622264|NCT04954599|Experimental|Module 1B Monotherapy Dose Expansion Cohort|Expansion cohort dosing CP-506 monotherapy in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
89622265|NCT04954599|Experimental|Module 2A Combination with carboplatin Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with carboplatin in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
89622266|NCT04954599|Experimental|Module 2B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with carboplatin in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
89622267|NCT04954599|Experimental|Module 3A Combination with Immune Checkpoint Inhibitor Multiple Ascending Dose|Multiple ascending dose cohorts dosing CP-506 in combination with Immune Checkpoint Inhibitor in all patients up to a maximally tolerated or maximally feasible dose Intervention: Drug: CP-506
89622268|NCT04954599|Experimental|Module 3B Combination with carboplatin Dose Expansion Cohort|Expansion cohort dosing CP-506 in combination with Immune Checkpoint Inhibitor in patients at recommended phase 2 dose (RP2D) Intervention: Drug: CP-506
89622269|NCT04943523|Placebo Comparator|Placebo|vegetable oil 4g/day
89622270|NCT04943523|Active Comparator|Krill Oil|Krill Oil 4g/day
89622271|NCT04932265|Active Comparator|Red ginseng HRG80|16 subjects will receive 200 mg of red ginseng preparation HRG80 in one capsule
89622272|NCT04932265|Experimental|Red ginseng HRG80 incorporated in gamma-cyclodextrin|16 subjects will receive 200 mg of red ginseng preparation HRG80 incorporated in gamma-cyclodextrin in two chewable tablets
89622273|NCT04926545|Experimental|Irinotecan naive cohort|"This cohort will enroll 6 postmenopausal female patients who have never received irinotecan treatment before. Patients in irinotecan naive cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 4 rounds of pharmacokinetic studies will be conducted.~Round 0 (before chemotherapy): pharmacokinetic testing (raloxifene 60mg as probe) before XCHT administration, then XCHT for 4 days with pharmacokinetic testing (raloxifene 60mg as probe) on the 4th day of XCHT administration.~Round 1(1st cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (without raloxifene) on day 4.~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3.~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
89622274|NCT04926545|Experimental|Irinotecan used cohort|"This cohort will recruit 18 patients who were treated with irinotecan previously and have at least one diarrhea episode with a severity of more than grade 2. Patients in irinotecan used cohort will receive 3 cycles of FOLFIRI chemotherapy, during which 3 rounds of pharmacokinetic studies will be conducted.~Round 1(1st cycle of chemotherapy): FOLFIRI, with pharmacokinetic testing (raloxifene 60mg as probe) on the first day of chemotherapy.~Round 2 (2nd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 4.~Round 3 (3rd cycle of chemotherapy): XCHT for 5 days and FOLFIRI on day 4, with pharmacokinetic testing (raloxifene 60mg as probe) on day 3."
89622275|NCT04916548|Experimental|Intravenous Ketamine|Open-label ketamine infusion
89622276|NCT04886011|Placebo Comparator|placebo gel|Methylcellulose gel was applied to the ulcer till complete healing
89622277|NCT04886011|Experimental|camel whey protein gel|camel whey protein dissolved in methycellulose gel was applied to the ulcer till complete healing
89622278|NCT04881656|Experimental|HIIYH|Help is in Your Hands is a series of online modules for parents with narrated videos of specific interactive strategies for supporting toddlers' communication development.
89622279|NCT04881656|No Intervention|Comparison|No additional materials
89622280|NCT04874870|Active Comparator|No Splint Group|This group will receive Xiaflex injection only
89622281|NCT04874870|Active Comparator|Splint Group|This group will receive Xiaflex injection and hand-based custom orthosis to maintain finger extension
89622282|NCT04860297|Experimental|mRNA-1273|"Part A: All participants (healthy participants and SOT participants) who were unvaccinated prior to enrollment will receive 2 intramuscular (IM) injections of 100 microgram (µg) mRNA-1273 on Day 1 and Day 29.~All SOT participants who were unvaccinated prior to enrollment will be offered the opportunity to receive a third primary dose of mRNA-1273 at Day 85 as per the emergency use authorization (EUA) Fact Sheet available at the time of protocol finalization.~SOT participants who were previously vaccinated with 2 doses of Moderna COVID-19 vaccine under the EUA prior to enrollment will receive Dose 3 on Day 1.~Part B: All eligible participants from Part A will be offered to receive a 100 µg booster dose of mRNA-1273 who are at least 4 months from the last dose. SOT recipients who completed primary COVID-19 vaccination series under EUA (outside of the mRNA-1273-P304 study) will receive a 100 µg booster dose on booster dose Day 1."
89622283|NCT04857372|Experimental|Group 1|Malignant pleural mesothelioma
89622284|NCT04857372|Experimental|Group 2|NF2 truncating mutations or deletions
89622285|NCT04857372|Experimental|Group 3|Solid tumors with functional YAP/TAZ fusions
89622286|NCT04857372|Experimental|Group 4|Non-pleural mesothelioma
89622287|NCT04851509|Active Comparator|Dynamic rotational locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance less than 25mm. The compression nut will be used to compress the fracture. The screw will be rotationally locked by using the 5mm hex flexible screwdriver by advancing the set screw until it stops completely. The screw will then be turned counterclockwise by a ½ turn.
88989157|NCT05922046|Experimental|Subjects with Parkinson's disease under 65 years|Individuals diagnosed with Parkinson's disease aged between 18 and 64 years on the date of the initial assessment will be selected.
89622288|NCT04851509|Experimental|Static locking|Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance of less than 25mm. The compression nut will be used to compress the fracture. The screw will then be statically locked using the 6Nm torque-limiting blue handle with 6mm hex coupling to completely lock the set screw down on the helical screw.
89622289|NCT04848480|Experimental|Insulin icodec + insulin aspart|insulin icodec once a week in combination with 2-4 times daily injections of insulin aspart at meal times.
89622290|NCT04848480|Active Comparator|Insulin degludec + insulin aspart|insulin degludec once a day in combination with 2-4 times daily injections of insulin aspart at meal times.
89622291|NCT04848389|Experimental|Skin adhesive|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
89622292|NCT04848389|Other|Standard suture|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed with the same thread with a subcutaneous stitch.
89622293|NCT04843436|Experimental|Robotic Assisted Microsurgery|Patients who meet the eligibility criteria for the study and undergo a microsurgical reconstruction using the Symani System according to its indications for use.
89622294|NCT04841018|Experimental|Control|Higher dose of dexamethasone (0.5mg/kg) that is known to enhance the analgesic quality of caudal block from previous study
89622295|NCT04841018|Experimental|Dexamethasone|Lower, antiemetic dose of dexamethasone (0.15mg/kg)
89622296|NCT04837859|Experimental|Arm A age 18-60|Patients at the age of 18-60 years at enrollment will receive 2 initial doses of 200 mg tislelizumab in 21-day intervals followed by an interim positron emission tomography (PET-2). Following a PET-guided approach, patients with a negative PET-2 (i.e. Deauville score 1-3) according to central review will continue receiving tislelizumab for another 4 doses of 300 mg in 28-day intervals. Patients with a positive PET-2 (i.e. Deauville score >3) will receive 4 cycles of combined 300 mg tislelizumab on day 1 and AVD chemotherapy on day 1 and 15 in 28-day cycles (4x T-AVD). For all patients, 30 Gy involved-site radiotherapy (IS-RT) will only be applied in case of PET positivity after completion of (chemo-) immunotherapy.
89622297|NCT04837859|Experimental|Arm B Age 60+|Patients above the age of 60 years will be enrolled in a separate, exploratory cohort and receive PET-guided treatment with tislelizumab or T-AVD as described above. However, all patients in the exploratory cohort for older patients will receive consolidating 30 Gy IS-RT.
89622298|NCT04833855|Active Comparator|Group 1: Omalizumab|Participants naive to anti-IgE therapies will receive omalizumab.
89622299|NCT04833855|Placebo Comparator|Group 2: Placebo|Participants naive to anti-IgE therapies will receive a placebo.
89622300|NCT04833855|Experimental|Group 3: Tezepelumab Dose 1|Participants naive to anti-IgE therapies will receive tezepelumab.
89622301|NCT04833855|Experimental|Group 4: Tezepelumab Dose 2|Participants naive to anti-IgE therapies will receive tezepelumab.
89622302|NCT04833855|Placebo Comparator|Group 5: Placebo|Participants previously treated with anti-IgE therapies will receive a placebo.
89622303|NCT04833855|Experimental|Group 6: Tezepelumab Dose 1|Participants previously treated with anti-IgE therapies will receive tezepelumab.
89622304|NCT04833855|Experimental|Group 7: Tezepelumab Dose 2|Participants previously treated with anti-IgE therapies will receive tezepelumab.
89622305|NCT04827355|Sham Comparator|Control|Participants allocated to the control arm will be fit with the UES Compression Device at a pressure known not to provide intervention.
89622306|NCT04827355|Experimental|Experimental|Participants allocated to the experimental arm will be fit with the UES Compression Device according to manufacturer guidelines.
89622307|NCT04805489|Experimental|stress test with masks|Within the framework of this research, an additional stress test is performed. This stress test, consisting of 3 periods, will follow a cardiovascular assessment requested as part of a health check-up, a license application, for risk factor assessment.
89622308|NCT04799886||Child and adolescent psychiatrist|
89622309|NCT04795401|Experimental|FRAME Group|"Patients will be enrolled during their hospitalization/consultation in vascular surgery department. After asking questions, his given free, informed and written consent will be collected, and recorded in his medical file by the investigator.~During this hospitalization, the pre-procedure forming part of the usual care is carried out. The specific acts of research are: Cardiac echocardiography and Quality of life survey SF-36 The plication procedure will be performed according to the FRAME FR. All pre-, peri-, and post- operative routine patient management will be carried out as usual.~Follow up visits will be held at 6, 12 months post procedure. All follow up visits will include the assessments as usual.~The specific acts of research are as follows: Cardiac echocardiography at 12 months and quality of life survey SF-36."
88989158|NCT05919160|Experimental|Neuronal Recording and Behavioral Testing|Neuronal Recording and Behavioral Testing
88989159|NCT05916911|Experimental|Glizigen Group|Patients will receive combined treatment with Glizigen® oral solution and Glizigen® vaginal gel for 2 months.
88989160|NCT05916911|Placebo Comparator|Placebo Group|Patients will receive combined treatment with Placebo oral solution and Placebo vaginal gel for 2 months.
88989161|NCT05915169|Experimental|topical haemoglobin spray care group|Patients with stage 2 pressure ulcers in the sacrum area will be treated with topical haemoglobin spray every 3 days for 2 months.
88989162|NCT05915169|No Intervention|group of gas dressings with saline solution|Patients with stage 2 pressure ulcers in the sacrum area will receive routine saline gas dressing for 2 months.
88989163|NCT05913284|Experimental|Methadone group|Upon induction of anaesthesia, intravenous methadone 0.2mg/kg (maximum dose 20mg) in blind labelling will be administered by infusion over 30 minutes. No further morphine will be given throughout the operation, but administration of Intraoperative fentanyl will be left to the discretion of the attending anaesthesiologists
89037395|NCT04543682|Experimental|Second intervention group (0.25 ng/kg/min Iloprost)|The second intervention group will also receive open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.25 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. Infusion will start 24hrs post-operatively and the dose will be delivered over 24h.
89622310|NCT04795401|No Intervention|Control Group|"Control group corresponds to the historical patients over a period of time sufficient to have at least 20 patients according to inclusion criteria. The information form will be sent to each patient eligible for the study by post. Without any feedback from him within 30 days, it is considered that the patient does not object to the use of its data.~As part of this research, no additional examination will be performed. The data used correspond to the data collected in the usual care of patients."
89622311|NCT04795284||Patients with symptomatic lumbar spinal stenosis|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
89037396|NCT04543682|Other|Control intervention group|Control intervention: Patients will receive the standard of care procedure for such fractures, i.e. standard of care open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes).
89037397|NCT05603676|Experimental|Hypertensive IHHC|Hypertensive participants who performed IHHC
89037398|NCT05603676|Placebo Comparator|Hypertensive placebo|Hypertensive participants who performed placebo intervention
89037399|NCT05603676|Active Comparator|Healthy IHHC|Healthy participants who performed IHHC
89037400|NCT05603676|Sham Comparator|Healthy Placebo|Healthy participants who performed placebo intervention
89037401|NCT04802616|Experimental|Polyvalent mechanical bacterial lysate|Treatment over 3 successive months with one daily sublingual tablet (7 mg of bacterial lysate) over 10 days followed by 20 days of rest.
89037402|NCT04802616|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily sublingual tablet over 10 days followed by 20 days of rest.
89037403|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
89037404|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
89037405|NCT04772274|Experimental|SB17|SB17 (proposed ustekinumab biosimilar)
89037406|NCT04772274|Active Comparator|EU Stelara|EU sourced Stelara (ustekinumab)
89037407|NCT04772274|Active Comparator|US Stelara|US sourced Stelara (ustekinumab)
89037408|NCT04398797|Experimental|Intervention|Use of notification algorithm and nurse follow-up
89037409|NCT04398797|No Intervention|Control|Standard regime (usual care)
89037410|NCT00536796||Patients at very high risk|
89037411|NCT00536796||Patients at high risk|
89622312|NCT04795284||Healthy elderly|30-meter walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30-meter walking task twice. Inertial sensors are put on each participant foot.
89622313|NCT04790201|Experimental|Friendship Bench Delivered by Professional Counselor|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a professional counselor. Individuals enrolled in this arm will receive 6 weekly counseling sessions per the adapted FB protocol (Aim 1).
89622314|NCT04790201|Experimental|Friendship Bench Delivered by Lay Counselor|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a trained lay counselor. Individuals enrolled in this arm arm will receive 6 weekly counselling sessions per the adapted FB protocol (Aim 1).
89622315|NCT04790201|Active Comparator|Enhanced Usual Care|25 participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Enhanced usual care will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care.
89622316|NCT04788823|No Intervention|Control|Group 1 will represent controls and will not receive prednisone in the 3-year post-op period.
89622317|NCT04788823|Experimental|Prednisone Monthly - Scheduled|Group 2 will receive 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be given at the beginning of months 0, 2, and 4 and will be self-administered.
89037412|NCT00536796||Patients at medium risk|
89037413|NCT00536796||Patients at low risk|
89037414|NCT03457311|Other|OGSP measurement|For the OGSP measurement, subjects will be orally administered with 1.25 ml/kg G.S.P. oral solution (400 mg/ml of galactose). At least 20 ml water will be given to subjects after drinking G.S.P. oral solution within 3 to 5 minutes. Sixty minutes after oral G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of OGSP value.
89037415|NCT04370327|Active Comparator|Pain Free Exercise (PF)|Patients will be randomised to twice weekly for 24 weeks of pain free exercise in a supervised exercise programme
89037416|NCT04370327|Active Comparator|Moderate Claudication Pain Exercise (MOD-P)|Patients will be randomised to twice weekly for 24 weeks of moderate claudication pain exercise in a supervised exercise programme
89037417|NCT04370327|Active Comparator|Maximal Claudication Pain Exercise (MAX-P)|Patients will be randomised to twice weekly for 24 weeks of maximal claudication pain exercise in a supervised exercise programme
89037418|NCT00536835|Experimental|Stage A|Stage A will identify maximum tolerated doses for either Schedule 1 - GSK461364 given once weekly on Day 1, 8 and 15 every 28 days; Schedule 2 - GSK 461364 given twice weekly Days 1, 2, 8, 9, 15 and 16; Schedule 3 Daily on Day 1 to Day 15 every 21 days.
89037419|NCT00536835|Experimental|Stage B|Evaluate safety, PK, pharmacodynamic (PD) & tumor response in expanded cohorts at the MTD for at least one schedule from Stage A.
89622318|NCT04788823|Experimental|Prednisone Monthly - As Needed|Group 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered.
89622319|NCT04788823|Experimental|Prednisone Every Other Week|Group 4 will receive alternating 1 week dosages of prednisone (1 week on, 1 week off - 5 mg daily only) for a total of 24 weeks
89622320|NCT04786106|Active Comparator|CCH+PTT|Men will receive two injections of CCH administered 1-3 days apart, followed by manual modeling and PTT 30-60 min/day as outlined in our prior publication. Approximately 6 weeks later, the next round of injections will be performed until a maximum of 8 injections in total has been administered. PTT will be continued until the 3-month post-treatment visit.
89622321|NCT04786106|Active Comparator|Surgery+PTT|Men will undergo either penile plication or I&G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit.
89622322|NCT04782479||in the air|the position of the practitioner's hand holding the tube was placed in the air while the assistant pulling back the stylet.
89622323|NCT04782479||on the cheek of a manikin|the position of the practitioner's hand holding the tube was placed on the cheek of a manikin while the assistant pulling back the stylet.
89622324|NCT04765943||Study population|Patients with LVEF equal to or less than 40% determined by echocardiogram on the 4th day after acute myocardial infarction.
89622325|NCT04762277|Experimental|Spesolimab|
89622326|NCT04762277|Placebo Comparator|Placebo|
89622327|NCT04751552|Active Comparator|Levobupivacaine group|Patients receive an ESPB with the local anaesthetic levobupivacaine
89622328|NCT04751552|Placebo Comparator|Placebo group|Patients receive an ESPB with 0,9% saline
89622329|NCT04751396||Part A (Interview)|Participants navigate the educational tool over 30-45 minutes then participate in an interview about their thoughts and opinions about the content, ease of use, and format of the tool over 45 minutes.
89622330|NCT04751396||Part B Group I (standard information)|Patients receive standard educational information during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
89622331|NCT04751396||Part B Group II (educational tool)|Patients navigate educational tool over 20 minutes during their clinician encounter. Patients also complete questionnaires over 30-45 minutes at baseline within a week prior to their clinician encounter, immediately after the encounter, and at 3 months.
89622332|NCT04747496||NVAF patients|NVAF adult patients with one or more risk factors treated with edoxaban.
89622333|NCT04747145|Experimental|Pulsed reduced dose-rate radiotherapy|Chemoradiation, adjuvant chemotherapy.
89622334|NCT04736654||Patients group|Individuals with headache
89622335|NCT04729205|Experimental|Promitil 1.6 mg/kg|PROMITIL (1.6 mg/kg body weight) will be intravenously (IV) administered on the first day of three 28-day cycles. On days 1 and 15 of each PROMITIL cycle, patients will be treated with the mFOLFOX6 regimen, which includes concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h
89622336|NCT04729205|Experimental|Promitil 2.0 mg/kg|PROMITIL (2.0 mg/kg body weight) will be intravenously (IV) administered on the first day of three 28-day cycles. On days 1 and 15 of each PROMITIL cycle, patients will be treated with the mFOLFOX6 regimen, which includes concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h
89037420|NCT04362527|Experimental|Milrinone|The patients randomized to this arm will have Milrinone (Laboratoires STRAGEN, France)
89037421|NCT04362527|Placebo Comparator|Placebo|The patients randomized to this arm will have Saline solution
89037422|NCT05579145|Experimental|5-Second Expiratory Pause|Closed system aspiration following by expiratory pause with mechanical ventilator for 5 seconds.
89037423|NCT05579145|Experimental|10-Second Expiratory Pause|Closed system aspiration following by expiratory pause with mechanical ventilator for 10 seconds.
89057859|NCT01687452|Experimental|group B|Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load > 40 copies / ml
89057860|NCT01687452|Placebo Comparator|group C|Healthy volunteers
89622337|NCT04723446|Experimental|Group 1 (test group; n= up to 10 patients) - 0.2 % Chlorhexidine digluconate|Participants will be instructed to rinse their mouth with 10 ml of Corsodyl® Alcohol free mouthwash for 1 minute.
89622338|NCT04723446|Experimental|Group 2 (test group; n= up to 10 patients) - 1.5% Hydrogen peroxide|Participants will be instructed to rinse their mouth with 10 ml of Colgate® Peroxyl mouthwash for 1 minute.
89622339|NCT04723446|Experimental|Group 3 (test group; n= up to 10 patients) - Cetylpyridinium chloride|Participants will be instructed to rinse their mouth with 10 ml of Oral-B® Gum & Enamel Care mouthwashes for 1 minute.
89622340|NCT04723446|Experimental|Group 4 (control group; n= up to 10 patients) - No rinsing|Patients will be instructed to not rinse their mouth with any solution, not even water.
89622341|NCT04721860|Experimental|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 4 weeks.
89622342|NCT04721860|Sham Comparator|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 4 weeks.
89622343|NCT04717570|Experimental|TRIA Mitral Valve|Patients receiving the Foldax Mitral Valve
89622344|NCT04710862|Active Comparator|Breathing training with a device|Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will perform exhalation exercises through a breathing device. Homework activities will be assigned. Post-training testing sessions will also be conducted.
89037424|NCT04755114|Experimental|Turkish Music Group|After the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min). Immediately after the pre-test evaluations, the music group will be played to the music desired by the patient for 30 minutes. Immediately after the interventions, pain level, vital signs will be evaluated and saliva sample will be taken as a final test (30 minutes). The same procedures will be repeated in the 60th minute after the intervention to determine the duration of the interventions applied.
89622345|NCT04710862|Active Comparator|Breathing training without a device|Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will receive training on the use of breathing techniques without a device, but with visual feedback throughout training. Homework activities will be assigned. Post-training testing sessions will also be conducted.
89622346|NCT04695171||Prior Primary Large Hiatal Hernia with LINX Placement MSA|Patients who were previously implanted with the LINX device during repair of a hiatal hernia >3 cm >2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at 3 and 5 years to determine recurrence of hiatal hernia.
89622347|NCT04695171||Prior Primary Large Hiatal Hernia with Fundoplication|Patients who previously underwent lower esophageal sphincter reconstruction by fundoplication during repair of a hiatal hernia >3 cm >2 years prior will be asked to complete a quality of life questionnaire at about 3 years and 5 years post procedure. Each participant will complete a barium swallow at about 3 and 5 years to determine recurrence of hiatal hernia.
89622348|NCT04683172|Experimental|Active tDCS|Active tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
89622349|NCT04683172|Sham Comparator|Sham tDCS|Sham tDCS will be delivered daily for 5 consecutive days with the patient either sitting or lying down.A tDCS session generally lasts 20 minutes.
89622350|NCT04677374|Placebo Comparator|Standard of care|Participants in this arm will be offered Standard of Care (SOC) referral process for voluntary medical male circumcision (VMMC) services
89622351|NCT04677374|Experimental|Block 1 (intensified health education)|Participants in this arm will be offered intensified health education
89622352|NCT04677374|Experimental|Block 2 (intensified health education and SMS/telephonic tracing)|Participants in this arm will be offered intensified health education and SMS/telephonic tracing
89622353|NCT04677374|Experimental|Block 3 (intensified health education, SMS/telephonic tracing and transport reimbursement)|Participants in this arm will be offered intensified health education, SMS/telephonic tracing and transport reimbursement
89622354|NCT04671797|Experimental|Early Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at an early dinner time (DLMO-3h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
89622355|NCT04671797|Experimental|Late Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
89622356|NCT04671797|Experimental|Late Dinner + Late Sleep first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by delayed bedtime (DLMO+6h). This arm will cross-over to the other 2 arms in random order.
89622357|NCT04665648|Experimental|Treatment arm|Patients who received intravenous nicorandil before and after reperfusion with primary percutaneous coronary intervention
89622358|NCT04665648|Placebo Comparator|Placebo arm|Patients who received intravenous placebo before and after reperfusion with primary primary percutaneous coronary intervention
89622359|NCT04637594|Active Comparator|Arm A (immune checkpoint inhibitor)|"CONTINUATION OF ICI TREATMENT:~Patients receive either pembrolizumab intravenously (IV) over 30 minutes on day 1, nivolumab IV over 30 minutes on days 1 and 15, atezolizumab IV over 30-60 minutes on day 1, durvalumab IV over 60 minutes on days 1 and 15, or avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 21 or 42 days for pembrolizumab, every 21 days for atezolizumab, and 28 days for nivolumab, durvalumab, and avelumab in the absence of disease progression or unacceptable toxicity."
89622360|NCT04637594|Experimental|Arm B (immune checkpoint inhibitor)|"DISCONTINUATION OF ICI TREATMENT:~Patients receiving ICI treatment will discontinue ICI treatment within 1 cycle length after randomization. Cycle length is determined by the ICI regimen the patient is receiving at randomization. At disease progression patients may restart the same ICI treatment they were receiving upon randomization at physician discretion."
89622361|NCT04635111||Symptomatic TGCT Participants|Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience moderate or severe hepatotoxicity due to use of TURALIO™ (pexidartinib).
89622362|NCT04633057|Experimental|TJ101|TJ101 1.2 mg/kg once a week for 52weeks
89622363|NCT04633057|Active Comparator|NordiFlex|NordiFlex Injection 0.034 mg/kg once a day for 52 weeks
89622364|NCT04627493|No Intervention|Waitlist (Control)|Usual care
89622365|NCT04627493|Experimental|Exercise|Online exercise program
89622366|NCT04625751||T2DM +CAN|
89622367|NCT04625751||T2DM -CAN|
89622368|NCT04625751||Healthy control|
89622369|NCT04623099|Other|Standard dosing|Patients randomized to standard dosing (std) will initiate escitalopram at 5 mg daily and will then increase to 20 mg/day at week 4.
89622370|NCT04623099|Experimental|Pharmacogenetically-guided escitalopram dosing|Patients randomized to PGx-guided treatment, escitalopram titration will be based on CYP2C19 phenotype and predicted escitalopram exposure. In poor metabolizers (PM), escitalopram will be initiated at 5 mg daily and increased to 10 mg daily at week 4.
89057861|NCT02216162|Experimental|A: Interventional adapted physical activity + enhanced geriatr|Geriatric (functionality, gait, nutrition) follow-up, biological tests, anti-aromatase agents blood dosing, clinical assessment. Weekly Taï-Chi exercises.
89057862|NCT02216162|Other|Arm B: control|Clinical follow-up according to the Guidelines, annual geriatric and nutritional assessment
89057863|NCT01687491|Active Comparator|Enoxa|ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
89057864|NCT01687491|Active Comparator|Lovenox|LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
89037425|NCT04755114|Experimental|Comedy Film Group|fter the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min). Immediately after the pre-test evaluations,the Comedy film group will watch a comedy movie video. Immediately after the interventions, pain level, vital signs will be evaluated and saliva sample will be taken as a final test (30 minutes). The same procedures will be repeated in the 60th minute after the intervention to determine the duration of the interventions applied.
89037426|NCT04755114|No Intervention|Control group|"After the patient introduction form is filled, pain level, blood pressure, pulse and respiratory rate will be evaluated, saliva sample will be taken to determine the cortisol level and pre-test data will be collected (0 min).~Pain level and vital signs will be evaluated and saliva sample will be taken for the final test (30th minute) and follow-up (60th minute) simultaneously with the administration group without any intervention."
89037427|NCT04748952||Adult with horizontal bone defect|"30 implants will be placed in osteotomy sites prepared by osseodensification for patients with horizontal bone deficiency based on radiographic findings (CBCT).~Alveolar ridge width will be measured intraoperatively before and after osteotomy site preparation to assess the amount of ridge expansion. Implant stability will be measured immediately after implant installation and 16 weeks later."
89037428|NCT00552851|Other|Pegvisomant|patients with active acromegaly and impaired cardiac function
89037429|NCT01614171|Experimental|Growth hormone therapy|Growth hormone treatment for 6 months
89037430|NCT05567367|Experimental|RT234 0.2 mg, Single Ascending Dose (SAD)|Part 1, SAD Cohort 1A
89037431|NCT05567367|Experimental|RT234 0.6 mg followed by oral vardenafil 20mg on day 3, SAD|Part 1, SAD Cohort 2A1
89037432|NCT05567367|Experimental|Oral vardenafil 20mg followed by RT234 0.6 mg on day 3, SAD|Part 1, SAD Cohort 2A2
89037433|NCT05567367|Experimental|RT234 1.2 mg, SAD|Part 1, SAD Cohort 3A
89037434|NCT05567367|Experimental|RT234 2.4 mg, SAD|Part 1, SAD Cohort 4A
89037435|NCT05567367|Experimental|RT234 2.4 mg, Multiple Ascending Dose (MAD)|Part 2, MAD Cohort 1B
89037436|NCT05562024|Experimental|T cell injection targeting TAA06 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 2.0 × 10^6, 4.0 × 10^6 and 8.0 × 10^6 CAR-T/kg groups in order of sequence.
89037437|NCT00536952|Experimental|Arm 1|Pulmozyme
89037438|NCT00536952|Placebo Comparator|Arm 2|Placebo
89037439|NCT04684004||TTC patients with hyperglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by higher blood glucose values at admission, and so defined as hyperglycemics.
89037440|NCT04684004||TTC patients with normoglycemia|These patients will be hospitalized for TTC acute event. These patients will be characterized by normal blood glucose values at admission, and so defined as normoglycemics.
89037441|NCT04675632||The intervention group|the tibial run off would be treated through endovascular therapy
89037442|NCT04675632||the non-intervention group|the tibial run off would not be treated through endovascular therapy
89037443|NCT04282616|Experimental|Home-based unstructured physical activity program|According to each patient's baseline physical activity level, the facilitator will advise patients to start or to increase their spontaneous activity by giving counselling on total exercise time, mode, intensity and frequency as suggested by the American College of Sport Medicine guidelines. Every patient will be provided with a log-book and a wearable physical activity monitor, which has to be returned in the subsequent controls, to favor adherence and objectively measure the exercise activities
89037444|NCT04282616|Experimental|Home-based structured low-intensity physical activity program|According to each patient's baseline physical activity level, a semi-personalized walking program, will be provided. This program, derived from previous experience on renal patients, includes a 10-min session/day of intermittent walking (1- or 2-min work and 1-min seated rest) to be performed at home at prescribed speed. The speed, converted into walking cadence and followed by a metronome, is weekly increased. Patients will be provided with a daily log containing the detailed exercise prescription and spaces to give a feedback on training execution and related symptoms.
89037445|NCT04282616|Experimental|In-hospital structured supervised physical activity program|"Patients will join the room properly equipped for the exercise program in groups of maximum four subjects for a 2-time/week thirty minutes training sessions, to be performed for dialysis patients immediately before or after the dialysis treatment, or in non-dialysis according to their preferences.~Each sessions will include low-intensity walking exercises (similar to the structured home-based training), resistance and power exercises with elastic bands and light weights. Each sessions will begin and end with a warm-up and cool-down period of stretching. The total duration of the session will be about 30 minutes. Rate of perceived exertion will be collected and the training intensity will be set according to the patient's baseline capacity and weekly increased."
89037446|NCT04282616|No Intervention|No-training|Patients choosing this option will not start any physical activity program, but they will perform the outcome measures, acting as a control group.
89037447|NCT00537147|Experimental|1|1 vaccination of a 10^4 plaque-forming units (PFU) dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
89037448|NCT00537147|Experimental|2|1 vaccination of a 10^5 PFU dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
89037449|NCT00537147|Placebo Comparator|3|1 vaccination of a placebo administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
89057346|NCT01648062|Active Comparator|Mental simulation of sleep behavior|Sleep Self-Regulation Using Mental Imagery: Participants in this condition received instructions to visualize a specific behavioral plan designed to meet the goal of obtaining quality sleep each night through the practice of certain behaviors. To form the behavioral plan, participants visualised changing into comfortable clothes and taking time to relax prior to going to bed, the time they planned to go to sleep, where they planned to sleep, and the bedtime routine they follow to help them to get to sleep. At bedtime, they were instructed to mentally run through a checklist of these behaviors and then do any behaviors that they had not yet completed.
89622371|NCT04619680|Experimental|Nintedanib|150 mg PO twice a day, taken with food, (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
89622372|NCT04619680|Placebo Comparator|Placebo|placebo equivalent 150mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
89622373|NCT04614571|Other|Gluten Challenge|
89622374|NCT04613778|Experimental|Laser acupuncture|Laser acupuncture with knee-chest position
89622375|NCT04613778|No Intervention|No intervention|usual care with knee-chest position
89622376|NCT04590547|Experimental|GLS-1027 120 mg|One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily
89622377|NCT04590547|Experimental|GLS-1027 360 mg|Three 120 mg pills of GLS-1027 given by mouth once daily
89622378|NCT04590547|Placebo Comparator|Placebo|Three Placebo pills given by mouth once daily
89622379|NCT04587752|Experimental|CBT for Weight Bullying|Cognitive-Behavioral Therapy (CBT) for children who have experienced weight-related bullying
89622380|NCT04579367||Bempedoic acid and/or fixed-dose combination with ezetimibe|Participants with primary hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe.
89622381|NCT04572256|Experimental|Montelukast|Patients will receive oral montelukast (10 mg) daily for 6 months after surgery.
89622382|NCT04572256|Placebo Comparator|Placebo|Patients will receive an oral placebo daily for 6 months after surgery.
89622383|NCT04571580|Placebo Comparator|placebo|intracoronary infusion with saline
89622384|NCT04571580|Experimental|reteplase 9mg|intracoronary infusion with reteplase 9mg
89622385|NCT04571580|Experimental|reteplase 18mg|intracoronary infusion with reteplase 18mg
89622386|NCT04567108|Active Comparator|Maintain SSBs (Control)|Instruction to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)
89622387|NCT04567108|Experimental|Substitute Aspartame ASBs (participants randomized through 8/31/2023)|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with aspartame (months 0-6); then switch to water only (months 6-12)
89622388|NCT04567108|Experimental|Substitute Sucralose ASBs (participants randomized through 8/31/2023)|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with sucralose (months 0-6); then switch to water only (months 6-12)
89622389|NCT04567108|Experimental|Substitute Water|Instruction/guidelines to eliminate SSBs and replace with water (months 0-12)
89622390|NCT04567108|Experimental|Substitute ASBs (participants randomized on or after 9/1/2023)|Instruction/guidelines to eliminate SSBs and replace, where possible with beverages artificially sweetened with choice of non-nutritive sweeteners such as sucralose or aspartame
89622391|NCT04557748||Prospective Observational Cohort Study|Men and women with lower urinary tract symptoms.
89622392|NCT04557748||Prospective Observational Cohort Study Controls|Men and women who do not have urinary dysfunction.
89622393|NCT04557748||Central Sensitization Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
89622394|NCT04557748||Central Sensitization Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
89622395|NCT04557748||Physical Activity and Sleep Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency.
89622396|NCT04557748||Physical Activity and Sleep Study Controls|Men and women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency.
89622397|NCT04557748||Organ-Based Study|Women enrolled in the Prospective Observational Cohort Study with urinary urgency, with and without urgency incontinence.
89622398|NCT04557748||Organ-Based Study Controls|Women enrolled in the Prospective Observational Cohort Study with no symptoms of urinary urgency pr urgency incontinence.
89622399|NCT04557748||Qualitative Assessment of Patients with Urinary Urgency Study|Men and women enrolled in the Prospective Observational Cohort Study with urinary urgency who have treatment plans prescribed at the baseline visit.
89622400|NCT04556513||Patient|Patient hospitalized in ICU for PCR-proven SARS-COV-2 infection
89622401|NCT04553198|Experimental|Backward Locomotion Treadmill Training (BLTT)|Participants train on a reverse treadmill (no bodyweight support), three times per week x 3 weeks.
89622402|NCT04553198|Sham Comparator|Forward Locomotion Treadmill Training (FLTT)|Participants train on a treadmill (no bodyweight support), three times per week x 3 weeks.
89622403|NCT04550741|Experimental|Telerehabilitation|Experimental group of 100 patients using the M-Réhab BPCO telerehabilitation solution. The solution will be provided during the fourth and final week of RR's stay during which patients will be trained to use all of the solution's features. Patients will carry out the entire post-rehabilitation using the remote rehabilitation solution and will benefit from medical assessments by teleconsultation at 1, 3, 6 and 12 months as well as assessments at 3, 6 and 12 months by filling. electronic auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
89622404|NCT04550741|No Intervention|Standard chronic care|following usual standard chronic care. Patients will receive during the last week of stay in the center, the usual advice to continue physical activity and nutritional advice at home. The evaluations at 3, 6 and 12 months will be done by electronic filling of auto-questionnaires followed by a telephone quality control if necessary. A final evaluation at 12 months, by videoconference, will be carried out at the patient's home.
89622405|NCT04542070|Experimental|Participants receiving CAB LA + RPV LA regimen|Participants will be offered the option to start with a month long oral lead in or to start long acting intramuscular (IM) injections (oral lead in [OLI] or direct to injection [D2I]). On Day 1, participants who choose to participate in OLI will be administered CAB + RPV orally for one month. At the Month 1 visit, last dose of oral CAB + RPV will be given followed by the first CAB LA + RPV LA IM injection. The second IM injection with CAB LA and RPV LA will be administered at Month 2 followed by the same administered every 2 months (Q2M) until Month 12. In D2I, at Day 1, eligible participants will receive the first injection of CAB LA + RPV LA as initial loading dose. The second and third injections (CAB LA + RPV LA) will be administered at Month 1 and Month 3 followed by the same Q2M until Month 11.
89622406|NCT04542070|Active Comparator|Participants receiving BIK|"Participants will receive BIK, that is a combination of Bictegravir (BIC) + Emtricitabine (FTC)~+ Tenofovir alafenamide (TAF) orally, administered until Month 12."
89622407|NCT04538950|Other|Checkpoint Inhibitor (ICI)|Subjects diagnosed with cancer and will be receiving immune checkpoint inhibitors as treatment standard of care will have a PET/CT scan before and after therapy. PET/CT scan is done for study purposes only.
89622408|NCT04522388|Experimental|Treatment|Nutritional shakes, Ensure Enlive, twice per day orally in patients awaiting lung transplant
89622409|NCT04513951|Experimental|mFOLFOXIRI + Cetuximab + Avelumab|"Avelumab, 800 mg intravenous [IV] dose over 60 minutes, day 1, followed by~Cetuximab, 500 mg/m2 IV dose over 2 hours at cycle 1 (if well tolerated, it is administered over 90 minutes at cycle 2 and over 60 minutes by cycle 3), day 1, followed by~Irinotecan 150 mg/ m2 IV dose over 60 minutes day 1, followed by~Oxaliplatin 85 mg/m2 IV dose over 2 hours, day 1 in two-way with~L-Leucovorin 200 mg/ m2 IV dose over 2 hours, day 1 followed by~5-fluoruracil 2400 mg/m2 IV dose 48 h-continuous infusion, starting on day 1; to be repeated every 14 days for a maximum of 12 cycles. If no progression occurs during the induction treatment, patients will receive maintenance with 5-FU/LV plus cetuximab and avelumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus cetuximab and avelumab will be repeated biweekly until disease progression, unacceptable toxicity, patient's refusal or consent withdrawal."
89622410|NCT04510558|Experimental|Intervention (mesh)|Insertion of a non-resorbable mesh in the subway position.
89622411|NCT04510558|Sham Comparator|Control (no mesh)|No insertion of mesh.
89037450|NCT04656951|Experimental|Daratumumab added to VCd in induction, Vd in maintenance and Rd at relapse|"Daratumumab at standard dose of 1800 mg will be administered subcutaneously at weekly intervals in cycles 1-2 and every 2 weeks in cycles 3-6 and every 4 weeks in cycles 7-8 together with VCD using bortezomib weekly s.c. for 8 cycles of 28 days each, cyclophosphamide i.v. at 500 mg/m2 on d1 of every cycle and dexamethasone p.o. at 20 mg per week.~Maintenance will be daratumumab subcutaneously every 4 weeks with bortezomib s.c. and dexamethasone 20 mg every 2 weeks until progression or intolerance.~At relapse/progression treatment will be daratumumab 1800 mg subcutaneously weekly during cycle 1-2, every 2 weeks in cycle 3-6 and every 4 weeks thereafter together with lenalidomide 25 mg p.o. day 1-21 and dexamethasone 20-40 mg weekly."
89037451|NCT04268147||Spinocerebellar Ataxia-1|individuals with a genetically confirmed diagnosis of SCA-1
89037452|NCT04268147||Spinocerebellar Ataxia-2|individuals with a genetically confirmed diagnosis of SCA-2
89037453|NCT04268147||Spinocerebellar Ataxia-3|individuals with a genetically confirmed diagnosis of SCA-3
89037454|NCT04268147||Spinocerebellar Ataxia-6|individuals with a genetically confirmed diagnosis of SCA-6
89037455|NCT04268147||Freidreich's Ataxia|individuals with a genetically confirmed diagnosis of FA
89622412|NCT04509596|Experimental|daily dose of DZD1516|daily dose of DZD1516
89037456|NCT04268147||FA Controls|Healthy, age-matched controls
89037457|NCT04268147||SCA Controls|Healthy, age-matched controls
89037458|NCT00537186|Other|1|Iron oligosaccharide
89037459|NCT04251260|Experimental|Positioning in flexion|Intervention: Positioning of body in flexion and aligment towards midline with Snuggle up (Philips, USA)
89037460|NCT04251260|No Intervention|Control group|No intervention
89037461|NCT04244786|Active Comparator|active anodal tDCS to ventrolateral prefrontal cortex (VLPFC)|1.5 milliamp (mA) anodal tDCS over right ventrolateral prefrontal cortex; 20-minutes, 6-sessions
89037462|NCT04244786|Sham Comparator|sham anodal tDCS to VLPFC|Identical electrode montage, sham tDCS over 6 sessions.
89037463|NCT04642014|Experimental|Hospitalized patients with SARS CoV-2 infection|Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma
89037464|NCT04234334|Experimental|Egg intake|Consumption of 2 eggs with spinach daily for breakfast for 4 weeks
89037465|NCT04234334|Experimental|Egg Subsitute|Consumption of 2 egg substitutes daily for breakfast for 4 weeks
89037466|NCT00552890|Experimental|ATK|modified Atkins diet
89037467|NCT00552890|Experimental|ADA|subjects assigned to follow ADA recommended diet for 1 year
89037468|NCT04200755|Experimental|Dupilumab|30 patients; Dupilumab s.c. injection; 2 ready-to-use syringes (600 mg) initial (V1), 1 ready-to-use syringe (300 mg) every 14 days (V2- V13) Dupilumab s.c. injection in healthy skin, 24 weeks
89037469|NCT04200755|Placebo Comparator|Placebo|15 patients; placebo s.c. injection; 2 ready-to-use syringes initial (V1), 1 ready-to-use syringe every 14 days (V2-V13) placebo s.c. injection in healthy skin, 24 weeks
89037470|NCT04173533|Placebo Comparator|Control Group|Oral azacitidine (CC-486) matched placebo once daily for first 14 days of each 28 day cycle
89037471|NCT04173533|Experimental|Experimental Group|Oral azacitidine (CC-486) 200 mg once daily for first 14 days of each 28 day cycle
89037472|NCT05544591|Experimental|611 Q2W|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 1, followed by two 150 mg injections (for a total of 300 mg) q2w from Week 2 to Week 14 (7 cycles).
89037473|NCT05544591|Experimental|611 Q4W|Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on week 0 Day 1, followed by two 150 mg injections (for a total of 300 mg) q4w on week 4, 8, 12 and two injections of placebo on week 2, 6, 10, 14.
89037474|NCT05544591|Placebo Comparator|placebo|Four subcutaneous injections of placebo as a loading dose on week 0 Day 1, followed by two injections q2w from Week 2 to Week 14 (7 cycles).
89037475|NCT01534065|Experimental|Barricaid|CE Marked Device
89037476|NCT01258348|Experimental|LY573636 +sunitinib|
89037477|NCT01258075|Experimental|Colesevelam|High-dose colesevelam suspended in a drink for oral administration once daily with dinner
89037478|NCT01258075|Experimental|Placebo proxy|Low-dose colesevelam suspended in a drink for oral administration once daily with dinner
89037479|NCT01257568|Other|Rejuvenate Modular Hip System|Rejuvenate Modular Hip
89037480|NCT04687878|Experimental|Insulin|Regular Insulin, 20 IU twice a day, intranasally, every day for 12 weeks
89037481|NCT04687878|Placebo Comparator|Placebo|Normal saline, twice a day, intranasally, every day for 12 weeks
89037482|NCT04687839|Experimental|Healthy adult subjects|"It's a randomized intra-individual comparative study with two injured study areas (treated and untreated) for each subject.~The randomization will determine the application side on which the tested product will be applied (RIGHT or LEFT forearm).~Twice daily application on the treated area."
89037483|NCT01256788|Experimental|Viscosupplementation|Hyaluronic acid injection
89037484|NCT01256788|Placebo Comparator|Saline injection|
89037485|NCT01256671|Experimental|DHEA|0.5% DHEA (intravaginal)
89622413|NCT04499235|Experimental|Mometasone furoate + AKST4290|Subjects will receive mometasone furoate concurrently with AKST4290, 400 mg twice daily, until disease control is reached.
89622414|NCT04499235|Placebo Comparator|Mometasone furoate + Placebo|Subjects will receive mometasone furoate concurrently with placebo until disease control is reached.
89622415|NCT04487548|No Intervention|Control group|The control group will have their preadmission clinic telephone call as normal and may be given advice to quit smoking and information about available smoking cessation resources over the phone.
89622416|NCT04487548|Experimental|Intervention group|The intervention group will be emailed (or postal mailed) the smoking cessation bundle with educational video, brochure, referral to the Smokers' Helpline and direct referral to an online pharmacy for nicotine replacement.
89622417|NCT04476446|Experimental|Intranasal Esketamine|Induction Phase: Participants will self-administer esketamine intranasally 56 milligram (mg) on Day 1 followed by 56 mg or 84 mg (as a flexible dose regimen) twice per week for 4 weeks. Participants greater than or equal to (>=) 65 years old will start at a dose of 28 mg on Day 1. Maintenance Phase: Participants will self-administer esketamine 56 mg or 84 mg intranasally once per week from Week 5 to Week 9. Subsequently from Week 9, based on the investigator's clinical judgment, participants will self-administer esketamine 56 mg or 84 mg intranasally once or twice a week.
89622418|NCT04465344|Experimental|IOL implantation experimental|Experimental arm: Trifocal intraocular lens Isatis TF
89622419|NCT04465344|Active Comparator|IOL implantation active comparator|Comparator arm: Monofocal intraocular lens Isatis
89622420|NCT04465071|No Intervention|Standard Treatment|Post-Cataract surgery standard treatment of Maxidex 0.1% QDS for 4 weeks, and Chloramphenicol drops QDS for 2 weeks
89622421|NCT04465071|Other|Standard Treatment plus lubricating drops|Lubricant eye-drops (0.3% cross linked sodium hyaluronate, AEONTM Protect Plus and phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vita-mins A and E (AEONTM Repair) for 6 weeks post-Cataract surgery, in addition to the standard treatment of Maxidex 0.1% QDS for 4 weeks, and Chloramphenicol drops QDS for 2 weeks
89622422|NCT04445688|Experimental|AD036|AD036 oral capsule administered before sleep
89622423|NCT04445688|Active Comparator|Atomoxetine|Atomoxetine oral capsule administered before sleep
89622424|NCT04445688|Placebo Comparator|Placebo|Placebo oral capsule administered before sleep
89622425|NCT04442737|Experimental|D/C/F/TAF FDC Arm (Immediate Switch)|Participants will be immediately switched to a regimen of darunavir 800 milligram (mg)/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily for 48 weeks.
89622426|NCT04442737|Active Comparator|INI + TAF/FTC Arm (Delayed Switch)|Participants will continue to receive current baseline integrase (INI)-based regimen plus Tenofovir Alafenamide/Emtricitabine (TAF/FTC) antiretroviral (ARV) regimen for 24 weeks. After 24 weeks participants will switch to a regimen of D/C/F/TAF FDC once daily for an additional 24 weeks.
89622427|NCT04439643||Development / training|Selected by stratified partitioning
89622428|NCT04439643||Sequestered / test|Selected by stratified partitioning
89622429|NCT04437862|Experimental|Q Revascularization System|
89622430|NCT04436250|Active Comparator|Placebo|Clonidine at a dose of 1 microg/kg Magnesium sulfate at a dose of 40 mg/kg
89622431|NCT04436250|Experimental|S-Ketamine Low dose|S-Ketamine at a dose of 0.2 mg/kg
89622432|NCT04436250|Experimental|S-ketamine High dose|S-ketamine at a dose of 0.4 mg/kg
89622433|NCT04433910|Experimental|Convalescent plasma|Convalescent plasma transfusion on day 1, 3 and 5.
89622434|NCT04433910|No Intervention|Best supportive care|Best supportive care, cross over for patients with progressive disease on day 14 with convalescent plasma transfusion on day 15, 17 and 19.
89622435|NCT04423484||Children with Nephroblastoma|All children coming into the participating units with suspected Nephroblastoma.
89622436|NCT04414046|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
89622437|NCT04382755|Active Comparator|Group A (active)|Standard of Care (SoC) + subcutaneous Zilucoplan® + prophylactic antibiotics until 14 days after last Zilucoplan®
89622438|NCT04382755|Placebo Comparator|Group B (control)|Standard of Care (SoC) + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
89622439|NCT04365556|Experimental|TASC Intervention|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
89622440|NCT04365556|No Intervention|Treatment as Usual|Participants will not receive any intervention.
89037486|NCT04687566|Experimental|dextromethorphan|Dextromethorphan, 60 mg per day, once daily, for 12 weeks
89622441|NCT04356469|Experimental|TCR alpha beta T cell depletion|The leukapheresis product will undergo TCR alpha beta negative selection following a standardized protocol
89622442|NCT04355832|Placebo Comparator|Placebo 1|The participants will be randomized to placebo infusion.
89622443|NCT04355832|Placebo Comparator|Placebo 2|The participants will be randomized to placebo infusion.
89622444|NCT04355832|Experimental|GLP-1|The participants will be randomized to Glucagon-like peptide-1 infusion.
89622445|NCT04322539|Experimental|Fruquintinib Plus Best Supportive Care (BSC) Group|Participants will be orally administered Fruquintinib 5 mg in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break (with each cycle length of 28 days).
89037487|NCT04687566|Experimental|memantine|Memantine, 5 mg per day, once daily, for 12 weeks
89037488|NCT04687566|Experimental|dextromethorphan and memantine|Dextromethorphan (60mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks
89037489|NCT04687566|Placebo Comparator|placebo|placebo, once daily, for 12 weeks
89037490|NCT04683809|Experimental|Exercise group|Patients in this group will attend telerehabilitation sessions.
89622446|NCT04322539|Placebo Comparator|Placebo Plus BSC Group|Participants will be orally administered Placebo 5 mg in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break (with each cycle length of 28 days).
89622447|NCT04307862|Experimental|ZEP-3Na 0.1%|The ZEP-3Na 0.1% cream will be applied topically twice daily
89622448|NCT04307862|Experimental|ZEP-3Na 1%|The ZEP-3Na 1% cream will be applied topically twice daily
89622449|NCT04307862|Placebo Comparator|Vehicle Control|The Vehicle Control cream will be applied topically twice daily
89622450|NCT04270422|Experimental|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial, twice a week, 12 sessions
89037491|NCT04683809|No Intervention|Control group|Patients in this arm will be subject to routine follow up.
89037492|NCT01256476|Experimental|pitavastatin 4 mg once daily (QD)|
89037493|NCT01256476|Active Comparator|pravastatin 40 mg once daily (QD)|
89037494|NCT05507892|Experimental|Treatment|Participants who will receive 100 mg of canagliflozin daily for six (6) months in addition to standard of care.
89037495|NCT04128371|Experimental|1|Subjects will receive mepolizumab 700 mg IV x 3 doses at approximately one month intervals, at predicted eosinophil nadir (2-3 weeks after peak), at study visits 4, 6, and 7.
89037496|NCT04684043||Post PCI state|The study population of this study underwent percutaneous coronary intervention(PCI) with drug-eluting stent (DES) and measured fractional flow reserve after PCI.
89037497|NCT04684082||Single Group Assignment|Patients will receive colonic irrigation as bowel preparation prior to colonoscopy.
89037498|NCT04683887|Experimental|Tape application|
89037499|NCT04683887|No Intervention|No tape application|
89037500|NCT05506956|Experimental|Flotetuzumab Following Allogeneic Transplant|All participants will receive one cycle (28 days) of flotetuzumab. After one cycle, all participants will undergo a bone marrow biopsy to assess response and based on the response, may receive additional cycles up to a total cycle of six cycles.
89037501|NCT05506722|Active Comparator|Testes shocker|This device is working and giving the electrical shocks regularly.
89037502|NCT05506722|Placebo Comparator|Fake Testes shocker|This device is not giving electricity but it is working with a red light, so the participants cannot suspect it.
89037503|NCT05504616|Experimental|Intervention Group|"Participants randomized to the intervention group will receive an initial electronic communication (i.e. email) that includes:~Link to physical activity education. This will be an educational module based on Phase 1 results and evidence-based literature regarding the benefits of physical activity in the general population and specific to axSpA.~One week after receiving the physical activity educational module, participants will receive access to the ADAS application and an .ics file for each 3-week cycle of electronic calendar reminders to engage in physical activity."
89037504|NCT05504616|No Intervention|Control Group|Participants randomized to the control group will receive usual care, which includes standard rheumatology care and access to educational materials on the importance of exercise and physical activity available through the TWH Spondylitis Program and through the public domain. They will receive a link to the physical activity educational module at baseline. They also have access to the program physiotherapist for a single one-hour individualized exercise consultation as requested by either the patient or the treating rheumatologist.
89622451|NCT04270422|Active Comparator|Usual physiotherapy|Usual evidence based physiotherapy, twice a week, 12 sessions
89622452|NCT04257929|Active Comparator|Double-Blind Treatment Phase Lower Dose Pitolisant|"Pediatric patients (6 to less than 12 years of age):~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 8.9 mg pitolisant administered once daily in the morning.~Adolescent patients (12 to less than 18 years of age):~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 13.35 mg pitolisant administered once daily in the morning.~Adult patients (18 to 65 years of age):~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning."
89037505|NCT04108364|Experimental|VoiceAdapt Intervention|PWA who train with VoiceAdapt app
89037506|NCT04108364|No Intervention|No Intervention|PWA who are on the waitlist and not training with VoiceAdapt app
89037507|NCT05502276|Active Comparator|Endoscopic Submucosal Dissection (ESD)|The Endoscopic Submucosal Dissection (ESD) procedures will be performed with the devices commonly used at the Services of Endoscopy of the Centers participating in the study. There are several models of knives on the market, produced by different companies, all considered equally effective by international guidelines.
89037508|NCT05502276|Experimental|Endoscopic Full-Thickness Resection (EFTR)|"The FTRD® (Full Thickness Resection Device; Ovesco Endoscopy, Tübingen, Germany) is the only over-the-scope device designed to undergo Endoscopic Full-Thickness Resection (EFTR) using a clip-and-cut technique. It consists of a 14 mm modified over-the-scope-clip (OTSC) mounted on the outside of a 23 mm cap, which has a preloaded 13 mm monofilament loop at the end. This device received the CE mark for the lower digestive tract in September 2014 and its efficacy and safety have been evaluated in preclinical studies and clinical trials."
89037509|NCT04106999|Placebo Comparator|Placebo|Normal Saline will be infused as per the protocol
89037510|NCT04106999|Experimental|Intervention group|Dexmedetomidine will be infused as per the protocol
89037511|NCT05003089|Experimental|BAY1834845 arm|BAY1834845 will be administered twice daily for 7 consecutive days (Days 1 - 7).
89037512|NCT05003089|Experimental|BAY1830839 arm|BAY1830839 will be administered twice daily for 7 consecutive days (Days 1 - 7).
89037513|NCT05003089|Active Comparator|Prednisolone arm|Prednisolone will be administered twice daily for 7 consecutive days (Days 1 - 7).
89037514|NCT05003089|Placebo Comparator|Placebo arm|Placebo will be administered twice daily for 7 consecutive days (Days 1 - 7).
89037515|NCT01256008|Placebo Comparator|stage 1 Clinical Management|The group will receive clinical management treatment only each session.
89037516|NCT01256008|Experimental|stage1 CBT|The experimental group will receive CBT
89037517|NCT01256008|No Intervention|stage1 Control group|Participants with breast cancer in the control group received standard medical care, but don't receive any other interventions.
89037518|NCT04976101|Experimental|Sinusoidal Galvanic Vestibular Stimulation|"Treatment:~1. Stimulation of the vestibular nerves with 0.025 Hz, 2 mA sinusoidal galvanic vestibular stimulation Depending on initial results, changes in frequency may range up to 0.1 Hz."
89037519|NCT04976101|Placebo Comparator|Placebo|"Treatment:~1. Placebo (sham) (no current given however the electrodes and devise is placed and computer keys pressed). Depending on initial results, changes in frequency may range up to 0.1 Hz."
89037520|NCT04206826|Experimental|PREDELFI Film|
89037521|NCT04206826|Placebo Comparator|CONTROL Film|
89622453|NCT04257929|Active Comparator|Double-Blind Treatment Phase Higher Dose Pitolisant|"Pediatric patients (6 to less than 12 years of age):~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning.~Adolescent patients (12 to less than 18 years of age):~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 26.7 mg pitolisant administered once daily in the morning.~Adult patients (18 to 65 years of age):~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
89622454|NCT04257929|Placebo Comparator|Double-Blind Treatment Phase Placebo|"Pediatric patients (6 to less than 12 years of age):~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets~Adolescent patients (12 to less than 18 years of age):~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets~Adult patients (18 to 65 years of age):~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
89622455|NCT04257929|Other|Open-Label Pitolisant|"Age-based dosing (prior to implementation of amendment 6) with maximum once daily doses of 17.8 mg for pediatric patients (6 to <12 years), 26.7 mg for adolescent patients (12 to <18 years), or 35.6 mg for adult patients (18 to 65 years).~Weight-based dosing (after implementation of amendment 6) with maximum once daily doses of 17.8 mg for patients ≤40 kg, 35.6 mg for patients >40 to ≤80 kg, and 44.5 mg for patients >80 kg."
89622456|NCT04257695|Experimental|TapPro|Biweekly telephone and in-person visits with a clinician over three months. At each visit, a protocol adapted from the Prescription Opioid Taper Study will be provided to participants, who will learn about pain coping, distraction techniques, diaphragmatic breathing, sleep techniques, and progressive muscle relaxation techniques. All are specifically designed for patients with chronic pain on chronic opioid therapy. During visits, taper parameters will be discussed and the provider will work through a dose reduction schedule, if participants are in agreement. Additionally, urine drug screens will be obtained.
89622457|NCT04257695|No Intervention|Usual Care|Participants randomized to the usual care arm will continue seeing their primary care providers as indicated.
89622458|NCT04255810||Women with breast implants and self-reported symptoms of BII|Women undergoing elective breast implant removal without replacement who self-report systemic symptons associated with BII
89622459|NCT04255810||Women with breast implants and no self-reported BII|Women undergoing elective breast implant exchange or removal without self-reported symptoms of BII
89622460|NCT04255810||Women undergoing elective mastopexy (breast lift)|Women undergoing an elective mastopexy (breast lift) without breast implants or soft tissue support
89622461|NCT04249882|Placebo Comparator|Placebo|Matched to active medications
89622462|NCT04249882|Active Comparator|Varenicline|1 mg twice a day
89622463|NCT04249882|Active Comparator|Naltrexone|50 mg once a day
89622464|NCT04249401||Reduced dose NOAC|Participants with NVAF initiating treatment with reduced doses of individual non-vitamin K antagonist oral anticoagulants (NOACs)
89622465|NCT04249401||Vitamin K antagonists (VKA)|Participants with NVAF initiating treatment with vitamin K antagonists (VKA)
89622466|NCT04245748|Active Comparator|Escitalopram|Adaptively randomized, double-blind treatment with escitalopram for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with escitalopram or citalopram for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
89622467|NCT04245748|Active Comparator|Duloxetine|Adaptively randomized, double-blind treatment with duloxetine for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with duloxetine for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
89622468|NCT04245436|Active Comparator|Duloxetine|Patients randomized to duloxetine, treatment will be initiated at 30 mg qAM through Week 4 (V5) (consistent with the registration trial for duloxetine in pediatric patients with generalized anxiety disorder). Then, duloxetine will be increased to 60 mg qAM at Week 4 (V5) and will be continued at this dose until Week 6 (V6) or the end of the acute phase of the study. Beginning at Week 6 (V6), duloxetine may be increased to 90 mg daily and at Week 8 (V7), may be increased to 120 mg daily.
89622469|NCT04245436|Active Comparator|Escitalopram|Patients randomized to escitalopram, will initiate treatment at 5 mg qAM for 1 week and then 10 mg qAM (the recommended starting dose for adolescents 12-17 years and the dose used in the pediatric registration trials). After Week 4 (V5), escitalopram will be increased to 15 mg and this dose will be continued until either Week 6 (V6) or the end of the acute phase of the study; however, at Week 6 (V6), escitalopram may be increased to 20 mg qAM based on efficacy.
89622470|NCT04241848|Experimental|Powered Orthotic Exoskeleton Training Group|Participant in 36 session ambulation training using a powered orthotic exoskeleton.
89622471|NCT04241848|Active Comparator|Control Group|Participant in 36 session ambulation training without using a powered orthotic exoskeleton.
89622472|NCT04241419|Experimental|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
89622473|NCT04233970|Experimental|Intervention group|Participants randomized to the intervention group will receive access to the multi-component, web-based intervention programme. The intervention programme will be developed in line with principles of patient empowerment and based on the Theory of Planned Behaviour.
89622474|NCT04233970|Active Comparator|Control group|Participants randomized to the control group will receive access to the web-based control programme with optimized standard care.
89622475|NCT04221997|Experimental|sertraline|90 patients will be randomized to sertraline
89622476|NCT04221997|Placebo Comparator|Placebo|30 patient will be randomized to placebo
89622477|NCT04221997|No Intervention|Healthy Control|30 healthy comparison subjects will be followed over the course of 12 weeks
89037522|NCT04207021|Experimental|intervention|"the study involves the intake of two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks of a nutritional supplement~INTERVENTION CAPSULE COMPOSITION active substances for 2 capsules Bio Curcumin 400 mg Polydatin 00 mg Beta-Caryophyllene 48 mg"
89622478|NCT04208919|Experimental|DCreg Prior to Weaning|Regulatory dendritic cells that were derived from the recipient's liver donor will be infused into the recipient one week prior to the initiation of immunosuppression weaning.
89622479|NCT04194554|Experimental|Niraparid Dose Escalation|"Dose Level 1: 100 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT~Dose Level 2: 200 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT~Dose Level 3: 200 mg PO daily of Niraparib without breaks during SBRT until completion of 6 cycles."
89622480|NCT04193605|Active Comparator|Mindfulness Based Stress Reduction|MBSR sessions received by the treatment group will include an orientation, approximately 8 intervention sessions, and an exit interview.
89622481|NCT04193605|No Intervention|Standard of Care|The control condition will continue receiving usual care or standard of care.
89622482|NCT04191889|Experimental|TRIPLET|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
89622483|NCT04181255|Experimental|Curosurf|
89622484|NCT04181255|Placebo Comparator|Sham (air)|
89622485|NCT04170894|Experimental|Apnea|Patients will undergo an atrial fibrillation ablation and will have induced periods of apnea throughout the procedure.
89622486|NCT04170894|Active Comparator|Control|Patients who choose not to participate in the apnea arm will have the opportunity to consent to the control arm. These patients will undergo an atrial fibrillation ablation per standard of care without periods of apnea throughout the procedure. This data will be collected to use as a comparator to the apnea arm.
89622487|NCT04165291|Experimental|F4C|Participants randomized to the Fathers for Change (F4C) program.
89622488|NCT04165291|Active Comparator|BIP|Participants randomized to the Batterer Intervention Program (BIP).
89622489|NCT04153760|Active Comparator|Aspirin|Aspirin 81 mg daily for six weeks post-randomization (postpartum)
89622490|NCT04153760|Placebo Comparator|Placebo|Placebo daily for six weeks post-randomization (postpartum)
89622491|NCT04128709|Experimental|Neurogenic Bladder Patient|Patients with neurogenic bladder
89622492|NCT04125862|Other|Fibrous Dysplasia/McCune-Albright Syndrome|20, Fibrous Dysplasia/McCune-Albright Syndrome Patients with or without pain
89622493|NCT04125862|Other|Healthy Controls|20, matched healthy controls
89622494|NCT04125017|Other|effect of using LASER pulse|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
89622495|NCT04125017|Other|Micro-needle Technique|effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts as a previous step before vitrification in regarding their effect on embryo viability
89622496|NCT04097717|Experimental|Decision Aid Arm|Participants will use the web-based decision aid plus usual medical care.
89622497|NCT04097717|Other|Usual Care Arm|Participants will receive usual medical care.
89037523|NCT04207021|Placebo Comparator|placebo|particpants included in the placebo group will take two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
89037524|NCT03457272|Experimental|New risk assessment|New risk assesment
89037525|NCT03457272|No Intervention|Standard|Standard risk assessment
89037526|NCT05467683|Other|Open Exposure-Based Therapy (EBT)|All participants will receive a well-established psychological treatment.
89622498|NCT04085094||1. Healthy and pre-menopausal women without CKD|"A total of 45 healthy and pre-menopausal women (<50 years old) will be recruited. Thirty of them are not on oral anticonception; 15 will be examined at each visit during their follicular phase, 15 during their luteal phase. Fifteen are on oral contraception.~Three visits will take place:~V1: after 5 days of a high salt diet (adding 6g of salt/day on top of regular diet), patients will undergo renal ultrasound (Doppler and CEUS), renal functional MRI (BOLD and phase contrast) and Na23 muscle and skin MRI.~V2: after 5 days of low salt diet (dietary instructions), the same exams mentioned above will be repeated~V3: renal CEUS will be performed before and after an oral protein load (1g/kg) or after SL nitroglycerin (0.2mg).~The day before each visit, a 24h urine collection will be performed in order to measure renal salt excretion."
89622499|NCT04085094||2. Pre-menopausal women with CKD|A total of 30 women with CKD will be recruited and undergo the same visits as outlined above
89622500|NCT04085094||3. Post-menopausal women without CKD|Fifteen post-menopausal women will undergo the same exams as outlined above
89622501|NCT04085094||4. Healthy men|A total of thirty age-and sex-matched men (15 below and 15 above 50 years old) will undergo the same exams as above.
89622502|NCT04085094||5.Men with CKD|Fifteen men with CKD will undergo the same exams as outlined above
89622503|NCT04082312||Group 1|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + with KDIGO stage 3 AKI
89622504|NCT04082312||Group 2|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + without KDIGO stage 3 AKI and alive at D10
89622505|NCT04082312||Group 3|Patients admitted in the surgical intensive care unit in post-operative of cardiac surgery between January 2013 and December 2016 + Assisted by VA-ECMO + died before D10 without KDIGO stage 3 AKI
89622506|NCT04081805|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
89622507|NCT04081805|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcroablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
89037527|NCT01255423|Experimental|Diclofenac sodium topical gel 1%|
89037528|NCT01255423|Placebo Comparator|Placebo|
89037529|NCT01255306||NO IOP|Patients without raised IOP
89037530|NCT01255306||RAISED IOP|Patients with raised IOP
89037531|NCT04006964||Identification Group|Subjects >= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
89037532|NCT04006964||Validation Group|Subjects >= 3 years old will measure as a minimum FOT and spirometry. Final diagnosis will be made by the physician as per current guidelines.
89622508|NCT04081805|Active Comparator|Promestriene|The patient will use intravaginal promestriene, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the promestriene tube to verify the correct use.
89622509|NCT04075656|Experimental|UrApp|Participants randomized to this study arm will use the UrApp mobile application for one year, in addition to receiving the standard of care.
89622510|NCT04075656|Active Comparator|Standard of Care|Participants randomized to this study arm will use receive the standard of care for one year.
89622511|NCT04070534|Other|PALS intervention|This arm will influence the development of a patient-directed education module using the Patient Activated Learning System (PALS)
89622512|NCT04068922|Experimental|Resilience Intervention|Participants will initially complete a baseline assessment assessing study eligibility. The Resilience intervention consists of seven weekly 1.5-hour group sessions guided by trained clinicians. Due to the COVID-19 pandemic, these group session may be conducted through Zoom. Skills and content will be directed toward improving pain management by enhancing positive emotions, setting goals, learning to live a life according to one's values, and boosting self-confidence in one's ability to manage pain. Self-administered activities include the identification of personal strengths, pleasant activity scheduling, expressing gratitude, values clarification, mindfulness practice, goal setting, positive reappraisal, and noting positive events.
89622513|NCT04066517|Experimental|Open Label|Non-randomized, open label clinical trial that intends to treat with SBRT 15 patients with refractory VT.
89622514|NCT04051866|Other|Control|Usual care (provided in Primary Health Care Centres) Oral hygiene instructions
89622515|NCT04051866|Experimental|Intervention|Usual care (provided in Primary Health Care Centres) Non-surgical periodontal treatment: Scaling and root planing (SRP) Oral hygiene instructions
89622516|NCT04045379|Active Comparator|LASER|The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 (carbon dioxide)LASER, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
89622517|NCT04045379|Active Comparator|Micro Ablative Radiofrequency|The patients will receive 3 consecutive applications of intravaginal and vulvar MIcro ablative radiofrequency, according to the manufacturer protocol for vaginal atrophy. The applications will be separated by the interval of 30 days
89622518|NCT04045379|Active Comparator|Estriol|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.
89622519|NCT04045067||Group 1|A group of patients who have pulmonary vein isolation alone, without low-voltage areas identified.
89622520|NCT04045067||Group 2|A group of patients who have pulmonary veins isolation alone, with low-voltage areas identified but the complementary defragmentation will not be carried out.
89622521|NCT04045067||Group 3|A group of patients who have pulmonary veins isolation, with low-voltage areas identified and the complementary defragmentation will be carried out.
89622522|NCT04031521||Sickle cell pain crisis|
89622523|NCT04031521||Sickle cell steady-state|
89622524|NCT04018651|Experimental|PrEP Master Adherence Intervention|The intervention consists of an introductory session and 4 individual sessions led by the PrEP Master, over an 8 week period. Between the sessions, the PrEP Master will conduct weekly check-in calls to participants to encourage adherence and assist with difficulties. During the weekly check-in, side effects and their impact will be assessed using assessment measures.
89622525|NCT04015167||T2 Alpha Tibia|Subjects in the clinical investigation will undergo placement of the Tibial Nail of the T2 Alpha Tibia Nailing System, according to the approved Instructions for Use and Operative Technique Manual.
89622526|NCT04015154||T2 Alpha Femoral Nail PF|Subjects in the clinical investigation will undergo placement of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the piriformis fossa, according to the Instructions for Use and Operative Technique Manual
89037533|NCT01254721|Experimental|1|Seroquel XR tablet
89037534|NCT01254721|Active Comparator|2|Seroquel XR + lithium
89037535|NCT04519671|Experimental|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
89622527|NCT04006613|Experimental|Circuit Training|Structured intervention to improve aerobic capacity, balance and strength
89622528|NCT04006613|Active Comparator|Usual Care|Unstructured intervention to improve mobility and balance
89037536|NCT04519671|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)
89037537|NCT04207099||ARM 1|Patients receive standard of care treatment for their diabetic foot ulcer
89037538|NCT04207099||ARM 2|Patients receive MolecuLight i:X guided treatment for their diabetic foot ulcer
89037539|NCT05575258|Active Comparator|Sequence 1: Agro (Green) - Conventional (Yellow)|"First, the agro-ecological sourced diet will be consumed.~Secondly, the conventional sourced diet will be consumed."
89622529|NCT04002115|Experimental|Clofarabine 30 mg/m^2|Day -14 through Day -10 Clofarabine 30 mg/m^2, Day - 9 Day of rest, Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 5 Fludarabine 40 mg/m^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 4 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 3 Fludarabine 40 mg/m^2 IV(Regimen A, Fludarabine 24 mg/m^2 IV for Regimen B), Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +1 Day of rest, Day +2 Day of rest, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF.
89622530|NCT03999021|Experimental|Experimental Arm|All participants to receive study intervention.
89037540|NCT05575258|Active Comparator|Sequence 2: Conventional (Yellow) - Agro (Green)|"First, the conventional sourced diet will be consumed.~Secondly, the agro-ecological sourced diet will be consumed."
89037541|NCT04862533|Experimental|Beta-alanine + PFMT|Participants will ingest an active supplement containing beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
89037542|NCT04862533|Experimental|Placebo + PFMT|Participants will ingest a placebo supplement containing no beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
89622531|NCT03996499|Experimental|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
89622532|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts A|BI 765063 (SIRPα inhibitor) alone in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
89622533|NCT03990233|Experimental|Step 1 (Dose escalation) : Cohorts B|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumours
89622534|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C1|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with metastatic colorectal cancer
89622535|NCT03990233|Experimental|Step 2 (Expansion Cohorts) : Cohort C2|BI 765063 (SIRPα inhibitor) in combination with BI 754091 (PD-1 inhibitor) in V1/V1 homozygous patients with metastatic endometrium cancer
89622536|NCT03981289||CAPN3 (LGMD2A)|Clinical Assessments, Biomarkers
89622537|NCT03981289||DYSF (LGMD2B)|Clinical Assessments, Biomarkers
89622538|NCT03981289||ANO5 (LGMD2L)|Clinical Assessments, Biomarkers
89622539|NCT03981289||DNAJB6 (LGMD1D)|Clinical Assessments, Biomarkers
89622540|NCT03981289||Sarcoglycan (LGMD2D) (LGMD2E) (LGMD2C) (LGMD2F)|Clinical assessments
89622541|NCT03976544|No Intervention|Natural cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH), on the first or second day of the menstrual cycle. If these serum hormonal values are considered basal for the beginning of the follicular phase, patients are asked to come back on day 10 to 12 of the cycle for blood sample and transvaginal ultrasound scan in order to assess follicular growth.~The timing of ovulation is determined based on a combination of ultrasonography features (the presence of a dominant follicle and adequate endometrium) and endocrine hormonal values in serum blood samples. Ovulation is generally defined as an, at least, 180% increase of LH compared to the mean level in the previous 24h.~Frozen-warmed blastocyst transfer will take place six days following the spontaneous LH surge."
89622542|NCT03976544|Experimental|Hormone replacement therapy cycle|"Patients are asked to perform a blood sample, with evaluation of serum estradiol (E2), progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) on the first or second day of the menstrual cycle. If these values are considered basal for the beginning of the follicular phase, estrogen supplementation (Estradiol valerate, Progynova® 3x2mg/day) is started to induce proliferation of the endometrium. Blood sample and transvaginal ultrasound are thereafter performed ten to fourteen days later. If the endometrium is considered adequate (generally considered if triple line and above 6,5 mm thickness), embryo transfer is scheduled on the sixth day of progesterone (vaginal micronized progesterone, Utrogestan® 2x200mg twice a day) supplementation.~In case of escape spontaneous ovulation embryo transfer will be performed considering the presumable time of ovulation."
89622543|NCT03971656|No Intervention|Control|Standard care
89622544|NCT03971656|Experimental|Intervention|Three-Fold Nutritional Intervention
89622545|NCT03968172|Experimental|EBBC programme|Participants in the intervention group will receive access to evidence-based patient information (EBPI) about lifestyle factors in MS combined with a complex behaviour change programme (EBBC programme), an online tool that was developed in line with principles of patient empowerment and cognitive behavioural therapy (CBT) approaches, including acceptance and mindfulness oriented techniques.
89622546|NCT03968172|Active Comparator|Control group programme|Participants randomized to the active control group will receive access to an information platform with optimized standard care consisting of information compiled from the German Multiple Sclerosis Society (DMSG) information material to reflect current practice.
89622547|NCT03964415|Experimental|Group1:Ad26.Mos4.HIV,Clade C and Mosaic gp140 bivalent vaccine|Participants will receive adenovirus serotype 26.Mosaic 4.human immunodeficiency virus (Ad26.Mos4.HIV) via intramuscular (IM) injection into the deltoid muscle at months 0 (Day 1) and 3 (preferably the deltoid of the non-dominant upper arm) and, Ad26.Mos4.HIV together with Clade C and Mosaic gp140 HIV bivalent vaccine IM into the deltoid muscle at Months 6 and 12 (different deltoid for each injection).
89622548|NCT03964415|Placebo Comparator|Group 2: Placebo|Participants will receive placebo into the deltoid muscle on Months 0 (Day 1), 3 (1 injection), 6 and 12 (2 injections).
89622549|NCT03960866|Experimental|Nyxol Ophthalmic Solution 1%|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
89622550|NCT03960866|Placebo Comparator|Nyxol Ophthalmic Solution Vehicle|1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days
89037543|NCT05570656|Active Comparator|AS patients|Evaluation of kinematic parameters by wearing X-Sens sensors in different movements (flexion and extension of the spine, tying shoelaces, picking up an object on the ground, walking, etc.)
89037544|NCT05570656|Active Comparator|healthy volunteers|Evaluation of kinematic parameters by wearing X-Sens sensors in different movements (flexion and extension of the spine, tying shoelaces, picking up an object on the ground, walking, etc.)
89037545|NCT04853095|Experimental|Intervention group (PerFix)|Peritoneal fixation technique
89037546|NCT04853095|Active Comparator|Control group (no PerFix)|Standard of care (i.e. no fixation)
89037547|NCT04785469|Experimental|Eccentric training group|
89037548|NCT04785469|Active Comparator|Control group|
89037549|NCT01254643|Experimental|All Enrolled|9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.
89037550|NCT04491825||Mycosis fungoides (MF)|
89037551|NCT04491825||Eczema (Atopic Dermatitis)|
89037552|NCT04491825||Chronic Plaque-Psoriasis|
89037553|NCT04491825||Healthy Control Skin|
89037554|NCT01254604|Experimental|Tafluprost|One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
89037555|NCT01254604|Active Comparator|Timolol|One drop of preservative-free timolol maleate (0.05%) per eye twice daily (morning and evening) for four weeks.
89037556|NCT03980093|Experimental|Education plus Values|
89037557|NCT03980093|Active Comparator|Education|
89037558|NCT00537264|Experimental|Computer|Health-related quality of life questionnaires will be administered using a computerised multimedia touchscreen system.
89037559|NCT00537264|Experimental|Interviewer|Health-related quality of life questionnaire will be administered via face-to-face interviews.
89037560|NCT03945734|Experimental|Expressive Helping|Participants complete four 20-minute writing/voice-recording sessions spaced one week apart. During the first week, the instructions will explain that cancer patients and survivors benefit from learning about other cancer survivors' experiences. They are told that the first three weeks of writing/voice-recording (writing/talking about their stress and coping at Week 1, deepest emotions about cancer at Week 2, self-affirmation and benefit finding at Week 3) are exercises designed to help them think about their cancer experiences and to prepare them to write/record the narrative they would share on Week 4. During Week 4, they are asked to write/record a narrative as if they are speaking to another Chinese person with cancer, adding advice and encouragements, and reminded that their writing/recording would be shared with other Chinese American cancer patients and survivors.
89037561|NCT04473768||NTS bloodstream infection|growth of NTS in blood culture
89037562|NCT04473768||NTS/Pf malaria co-infection|concurrence of current Pf malaria infection and NTS bloodstream infection
89622551|NCT03959826|Active Comparator|Job activity contracting|Standard services plus job activity contracting
89622552|NCT03959826|Experimental|Reinforcement for completing activities|Standard services plus job activity contracting plus reinforcement for completing job-related activities
89622553|NCT03953833|Experimental|recombinant anti-HER2 humanized monoclonal antibody conjugate|Drug Name : Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection R & D code: B003 Drug Type : Biological Products
89622554|NCT03949465|Experimental|Open label iTBS rTMS|Participants will receive repetitive transcranial magnetic stimulation (rTMS) as a treatment for depression
89622555|NCT03944512|Experimental|Pravastatin|20 mg pravastatin daily
89622556|NCT03944512|Placebo Comparator|Placebo|Identical appearing daily placebo
89622557|NCT03930797|Experimental|Intimacy Enhancement|Participants attend four sessions (60-75 minutes) consisting of education and skills training to enhance physical and emotional intimacy.
89622558|NCT03930797|Active Comparator|Living Healthy Together|Participants attend four sessions (60-75 minutes) consisting of information and support across a range of breast cancer-related topics.
89622559|NCT03928418|Experimental|Live Phone Call Booster Arm|The live phone call arm will include in-person counseling during 2 quarterly clinic visits plus live booster phone calls every three weeks in the interim.
89622560|NCT03928418|Experimental|Technology Booster Arm|The technology booster arm will include in-person counseling during 2 quarterly clinic visits plus tech (choice of SMS or IVR) boosters once to twice weekly in the interim.
89622561|NCT03928418|No Intervention|Standard of Care (SOC) Arm|The standard of care (SOC) control (brief unstructured advice, with a wait-listed intervention).
89622562|NCT03926572|Other|Patients with Pulmonary arterial hypertension|Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
89622563|NCT03908567|Placebo Comparator|Placebo|Nasal spray solution without active ingredient
89622564|NCT03908567|Experimental|1 mg AM-125|Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.
89622565|NCT03908567|Experimental|10 mg AM-125|Nasal spray solution with 50 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 30 mg betahistine dihydrochloride.
89037563|NCT04473768||Other pathogen bloodstream infections|growth of a pathogen other than NTS in blood culture
89037564|NCT04473768||Severe Pf malaria mono-infection|defined according to WHO-criteria
89037565|NCT04473768||Other causes of febrile illness requiring hospital admission|"Current Pf malaria infection: see above~Recent Pf malaria infection: see above~Non-confirmed bloodstream infection without Pf malaria: no growth in blood culture and negative results in all Pf malaria tests~If feasible, severe bacterial localized infections such as pneumonia, meningitis, osteomyelitis, complicated urinary tract infection, abscess, skin/soft tissue infection or abdominal infection, will be assessed and clinically defined"
89622566|NCT03908567|Experimental|20 mg AM-125|Nasal spray solution with 100 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 60 mg betahistine dihydrochloride.
89037566|NCT03939065|Experimental|Insulin Pump and CGM|
89037567|NCT03939065|Other|Standard of Care and CGM|
89037568|NCT01254565|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
89037569|NCT01254565|Placebo Comparator|Placebo|Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).
89037570|NCT04772053|Experimental|Participants undergoing tumor biopsy|
89037571|NCT01254409|Experimental|PRM-151|PRM-151 administered at escalating doses of 1, 5, and 10 mg/kg by 30 minute intravenous (IV) infusion days 1, 3, 5, 8 and 15.
89037572|NCT01254409|Placebo Comparator|Placebo|0.9% saline administered by 30 minute IV infusion Days 1, 3, 5, 8, and 15.
89037573|NCT04684160|Active Comparator|Fixed-bearing group|
89037574|NCT04684160|Experimental|Mobile-bearing group|
89037575|NCT04390698|Experimental|nerve block+opioid-free general anesthesia|Paravertebral block with an ultrasound-guided technique; opioid-free general anesthesia
89037576|NCT04390698|Sham Comparator|sham bock+opioid general anesthesia|Sham block by local infiltration at the same site of paravertebral block; opioid based general aneshesia
89037577|NCT01254331|Experimental|Single arm|
89037578|NCT04673578|Experimental|Celecoxib|Celecoxib 50 mg orally twice daily (if weight 10-25 kg) or 100 mg orally twice daily (if weight > 25 kg) for 12 weeks. Used as adjunct to treatment-as-usual.
89037579|NCT04673578|Placebo Comparator|Placebo (microcrystalline cellulose)|Placebo capsules identical to celecoxib. One capsule orally twice daily for 12 weeks. Used as adjunct to treatment-as-usual.
89037580|NCT05414058|Experimental|Apo-Methylphenidate ER arm|Apo-Methylphenidate ER, 36 mg, oral, once a day, every morning, 4 weeks duration. Methylphenidate ER will be started at 18 mg to test tolerability and will be titrated at day 7 to a dose of 36 mg.
89037581|NCT05414058|No Intervention|Treatment as usual arm|Participants in the treatment as usual arm will continue with their current treatment as decided by their treatment team.
89037582|NCT03757403|Experimental|RDD1609 followed by Placebo|Application on the perianal area BID
89622567|NCT03908567|Experimental|Oral 16 mg betahistine|Tablets containing betahistine dihydrochloride. Administered three times daily as 1 tablet per time. Total daily dose is 48 mg oral betahistine dihydrochloride.
89622568|NCT03898661|Experimental|local collagenase|Patients receiving local injection of collagenase (0.9 mg XiapexR) into the esophageals stricture
89622569|NCT03884855|Active Comparator|Classical Cardiac Rehabilitation|Patients benefit from a classic cardiac rehabilitation cycle during 3 months.
89622570|NCT03884855|Experimental|Karate Rehabilitation|Patients benefit from cardiac rehabilitation cycle with traditional karate during 3 months.
89622571|NCT04208516|Active Comparator|Continuous nerve blocks|A total of 30 subjects equally distributed to either continuous Erector Spinae Plane block for unilateral thoracic surgery , or continuous Quadratus Lumborum block for major abdominal surgery. Patients in this group will receive 20ml 0.5% ropivacaine per block performed after positioning of the needle followed by continuous perineural infusion of 0.25% lidocaine (10ml/hr) beginning in the post-anesthesia care unit (PACU) and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
89622572|NCT04208516|Experimental|Single nerve blocks plus IV lidocaine infusion|A total of 30 subjects equally distributed to either Erector Spinae Plane block for unilateral thoracic surgery, or Quadratus Lumborum block for major abdominal surgery, will be included . Patients in this group will receive 20ml 0.5% ropivacaine, 4mg dexamethasone, and 20mcg dexmedetomidine (30mcg if only one block is performed) per block after proper positioning of the Tuohy needle. Upon patient arrival in the recovery room a continuous infusion of IV lidocaine 50 mg /hr will be started and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
89622573|NCT03860207|Experimental|Hu3F8-BsAb|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle. In cycle 1, blood is drawn for PK studies.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
89622574|NCT03851068|Experimental|Tria Aortic Valve|Patients receiving the Foldax Tria Aortic Valve
89037583|NCT03757403|Experimental|Placebo followed by RDD1609|Application on the perianal area BID
89037584|NCT04381923|Active Comparator|Helmet Continuous Positive Airway Pressure (CPAP)|When a patient has an Sp02 < 92% on ≥ 6 LPM NC, helmet CPAP will be applied unless a specific contraindication is present.
89037585|NCT04381923|Active Comparator|High Flow Nasal Oxygen (HFNO)|When a patient has an Sp02 < 92% on ≥ 6 LPM NC , HFNO (≥ 40 LPM) will be applied unless a specific contraindication is present
89037586|NCT00537342|Experimental|A|Biological Vaccine
89037587|NCT00537342|Placebo Comparator|B|
89037588|NCT03720860||Sepsis|Patients admitted to the intensive care unit with sepsis
89037589|NCT03720860||Surgery|Patinets subjected to major surgery and then admitted to the intensive care unit
89037590|NCT03720860||Non-inflamed|Otherwise healthy patients admitted to the intensive care unit because of intoxication.
89622575|NCT03827967|Experimental|1x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
89622576|NCT03827967|Experimental|2x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
89037591|NCT04338516|Active Comparator|Bio-Oss® Collagen,|subjects treated with Bio-Oss® Collagen, (Geistlich, Inc.)
89037592|NCT04338516|Experimental|Ossix™ Bone|subjects treated with Ossix™ Bone (Datum Dental Ltd)
89037593|NCT05399511||Practising GPs|GPs working in primary care setting.
89037594|NCT00537420|Placebo Comparator|1|Nasal Placebo
89037595|NCT00537420|Placebo Comparator|2|Capsule Placebo
89037596|NCT00537420|Experimental|3|Nasal PYY3-36 200 ug
89037597|NCT00537420|Experimental|4|Nasal PYY3-36 400 ug
89037598|NCT00537420|Experimental|5|Nasal PYY3-36 600 ug
89037599|NCT00537420|Active Comparator|6|Sibutramine 10 mg
89037600|NCT04295889|Active Comparator|Group A|"Group A will receive an invitation for home based albuminuria screening using a more conventional urine collection device (known as Peespot Test)."
89037601|NCT04295889|Active Comparator|Group B|"Group B will receive an invitation for home based albuminuria screening using an app (internet application) and an ACR dipstick test (known as ACR| EU Test)."
89037602|NCT03504215|Experimental|young adults|Both young adults born preterm (n=60) and term (n=30) will undergo the exercise intervention.
89037603|NCT03457038|Experimental|Patient with Septic Shock|Patient Hospitalized in Intensive Care Unit for sepsis of any etiology. The number of follow-up visits will not be changed compared to usual patient follow-up hospitalized in the intensive care unit but there will be blood testing more frequently
89037604|NCT04218279|Experimental|Sleep Health Education|At baseline, the experimental group will have immediate access to 10 brief education modules focused on diverse elements of sleep health and fatigue.
89037605|NCT04218279|Active Comparator|Wait List Control|At 3 months after baseline, the wait-list control group will be provided access to the 10 education modules focused on diverse elements of sleep health and fatigue..
89037606|NCT04183374|Experimental|Intervention|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
89037607|NCT01254292|Experimental|LCS12 (Skyla, BAY86-5028)|Participants received LCS12 (low dose levonorgestrel [LNG] intrauterine delivery system [IUS]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months
89622577|NCT03827967|Experimental|4x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
89622578|NCT03827967|Experimental|8x10^8 particles of PalloV-CC|Intradermal injection of PalloV-CC weekly x 4 weekly
89037608|NCT01254292|Active Comparator|EE30/DRSP (Yasmin, BAY86-5131)|Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles
89037609|NCT04178538|Experimental|25 years and older- ACL recon with DBM, Internal brace|Patients in this arm will be 25 years of age and over and receive ACL reconstruction augmented with demineralized bone matrix, bone marrow, and internal brace
89037610|NCT04178538|Active Comparator|25 years and older- Standard ACL reconstruction|Patients in this arm will be 25 years of age and over will receive an allograft All-Inside ACL reconstruction
89037611|NCT04178538|Experimental|24 years and younger- ACL recon with DBM, Internal brace|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft augmented with demineralized bone matrix, bone marrow, and internal brace
89037612|NCT04178538|Active Comparator|24 years and younger- Standard ACL reconstruction|In this arm patients 24 years and under that are skeletally mature, will receive ACL reconstruction with a quad tendon autograft standard all inside technique
89037613|NCT04075383|Other|immediate dental implant|The implant is installed immediately after tooth extraction.
89037614|NCT04075383|Other|immediate-delayed dental implant|The implant is installed 8 weeks after tooth extraction.
89037615|NCT04683770||HR + / HER2 - advanced breast cancer|
89037616|NCT00537498|Experimental|1|Interventional group
89037617|NCT01254019|Experimental|GSK2402968|6mg/kg
89037618|NCT01254019|Experimental|Placebo|dose-matched
89037619|NCT04687644|Experimental|Online Education|The education program developed within the scope of the research consists of five modules. In order to use the question and answer method in education, to make the education interactive and to receive feedback, 4 separate training groups of 7 people will be formed. The training will take place on the online platform, not face to face. Midwives will be contacted by phone and / or e-mail and the researcher will give a brief information about the research after introducing himself. A social media group will be created for each training group in order to communicate, announce trainings and inform changes.
89037620|NCT04687644|Active Comparator|Control|Midwives who attend the online forms of study will complete the survey. In the survey there are demographic and their view about woman centred care question forms. There are also Patient Centred Care Competency Scale and Minnesota Job Satisfaction Questionnaire. They will complete the survey.
89037621|NCT03055871|No Intervention|Standard education control group|The control group package will consist of Canada's PA guidelines recommending 180 min per week for young children, transitioning to 60 minutes of activity a day for children at five and a breakdown of ways for the parent to help their child achieve this PA (unstructured, endurance, strength, activities) commensurate with this guide. The guide also contains arguments and information about the benefits of PA.
89037622|NCT03055871|Other|Physical activity planning intervention|The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercise for children where they list physical activities that they have found fun in the past, as well as activities that they would find enjoyable to do as a family.
89037623|NCT03055871|Other|Habit formation intervention|The habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines, or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
89037624|NCT04683458||Paclitaxel-coated devices|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any drug-coated medical device (e.g., drug-eluting stent, drug-coated balloon).
89037625|NCT04683458||Controlls|Patients with symptomatic peripheral arterial occlusive disease or diabetic foot syndrome with chronic limb-threatening ischaemia who underwent endovascular revascularisation of the peripheral arteries in the lower limbs with any medical device except drug-coated techniques (e.g., drug-eluting stent, drug-coated balloon).
89037626|NCT04319497|Other|Refraction reproducibility and agreement|Subjective and objective refraction will be performed in all patients
89622579|NCT03807479|Experimental|Ponatinib|Patients in this treatment arm receive Ponatinib: starting dose 30 mg once-daily. Doses may be increased in case of inappropriate response and reduced to manage drug-related adverse events (AEs) and may be re-escalated once events resolve.
89622580|NCT03782558||Patients with CTS|Surgical transection of transverse ligament
89622581|NCT03782545|Experimental|Treatment with the truSculpt RF device|Subjects will be treated with the truSculpt RF device
89622582|NCT03780842|Experimental|Invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in intubated newborns
89622583|NCT03780842|Experimental|Non-invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in newborns with non-invasive NAVA ventilation (= with a nasal interface).
89622584|NCT03763032|Experimental|Stepped Interventions|Patient navigation intervention, plus various psychosocial interventions
89622585|NCT03757130|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses.
89037627|NCT01253317|Experimental|rhIGF-1|Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the OLE.
89037628|NCT00537537|Active Comparator|1|Telbivudine
89037629|NCT00537537|Active Comparator|2|Telbivudine
89622586|NCT03757130|Active Comparator|Placebo + Liraglutide|Participants received placebo subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.
89622587|NCT03757130|Experimental|AMG 598 70 mg|Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses.
89037630|NCT00537537|Active Comparator|3|Telbivudine
89037631|NCT02863874|Active Comparator|Vicryl®|The vaginal or and perineal tear is sutured continuously with Vicryl®. The instruments for suturing and the bedcover are clean whereas the gloves are sterile.
89037632|NCT02863874|Active Comparator|VicrylPlus®|The vaginal or and perineal tear is sutured continuously with VicrylPlus®. The instruments for suturing and bedcover are clean whereas the gloves are sterile.
89037633|NCT04319770|Active Comparator|periodontal regenerative surgery + EMD (control)|periodontal regenerative surgery with enamel matrix derivative
89037634|NCT04319770|Experimental|periodontal regenerative surgery + HA (test)|periodontal regenerative surgery with hyaluronic acid
89037635|NCT04073472|Experimental|mesenchymal stem cells (MSCs)|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells (MSC) into ileal pouch fistula at baseline and possibly again after 3 months if not completely healed.
89037636|NCT01253200|Experimental|Blazer® Open-Irrigated Ablation Catheter|Patients treated with the Blazer® Open-Irrigated Ablation Catheter
89037637|NCT01253200|Active Comparator|Control Catheter|Patients treated with an open-irrigated radiofrequency ablation catheter that has received FDA market approval for the treatment of type 1 atrial flutter( Biosense Webster ThermoCool® ablation catheters (NaviStar™, EZ Steer, or SF) or St. Jude Medical ablation catheters (Therapy™ Cool Path™ or Safire BLU™),
89622588|NCT03757130|Experimental|AMG 598 70 mg + Liraglutide|Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.
89037638|NCT00553046||family burden|chronich respiratory failure home ventilated patients
89622589|NCT03757130|Experimental|AMG 598 210 mg|Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.
89622590|NCT03757130|Experimental|AMG 598 210 mg + Liraglutide|Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.
89622591|NCT03757130|Experimental|AMG 598 420 mg|Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.
89037639|NCT04515901|Experimental|SPGB|Via a soft tip 20-gauge long IV catheter attached to a 3 mL syringe will be filled with 2 mL of 2% viscous lidocaine. The 2% viscous lidocaine will be administered according to the method of Barre.
89037640|NCT04515901|Placebo Comparator|Placebo|It will be adminstered the same as the experimental arm but with methylcellulose and cherry flavouring to match odour and taste.
89037641|NCT01253044|Experimental|Acceptance and Commitment Therapy|12 weeks of individually delivered Acceptance and Commitment Therapy
89037642|NCT01253044|Active Comparator|Present Centered Therapy|12 weeks of individually delivered Present Centered Therapy
89037643|NCT02646527|Experimental|DT+|Dignity Therapy is conducted with patients and partners
89037644|NCT02646527|Experimental|DT|Dignity Therapy is conducted only with patients
89037645|NCT02646527|No Intervention|SPC|standard palliative care
89037646|NCT04685889|Active Comparator|Icon Group|Icon® resin infiltration treatment was performed on 58 permanent central teeth with MIH and evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
89037647|NCT04685889|No Intervention|Control Group|No treatment was performed on healthy teeth. However, similar to the treated teeth, 58 healthy permanent central teeth of the same individuals were evaluated before; immediately after; and 1, 3, and 6 months after the procedure.
89037648|NCT04206514|Experimental|Peer Counselor|Participants receive personalized text messages and phone calls from a peer counselor- a women who had an abortion and was trained in post abortion care and PCC
89037649|NCT04206514|Experimental|Nurse|Participants receive personalized text messages and phone calls from a nurse trained in post abortion care and PCC
89037650|NCT04206514|No Intervention|control|Participants receive the standard of care for post-abortion patients in Kenya.
89037651|NCT04001556|Experimental|Patients reporting subjective sicca symptoms|HAQ(Health Assessment Questionnaire) Score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
89037652|NCT04001556|Experimental|Patients without subjective sicca symptoms|HAQ(Health Assessment Questionnaire) score, bilateral schirmer 's test, unstimulated whole salivary flow rate, blood sample for immunologic evaluation
89622592|NCT03757130|Experimental|AMG 598 420 mg + Liraglutide|Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.
89622593|NCT03743142||Patients with AAA|Patients with AAA are eligible for participation and study screening. They will receive, once included, an endovascular repair of the AAA
89622594|NCT03719807|Active Comparator|Control Group|Usual Care No routine outpatient physiotherapy following discharge home post-operatively in line with standard care.
89622595|NCT03719807|Experimental|Intervention Group|12 x Exercise//Rehabilitation sessions Begin at 6 weeks. 6 x weekly sessions Followed by 6 x bi-weekly sessions In line with Accelerated Rehabilitation protocol
89037653|NCT04320589|Active Comparator|General Anesthesia|Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ & β-adrenergic blockers [Prazosin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day &/or Labetalol (Trandate)200-600 mg/day, Angiotensin Converting enzyme inhibitors ( ACE inhibitors ) & Angiotensin II receptor blockers ARBs e.g. Tritace 2.5-10 mg/day & Atacand 4-16 mg/day]
89037654|NCT04320589|Active Comparator|Dexmedetomidine|Dexmedetomidine-Magnesium Sulfate (Dex-MgSo₄) group: in which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement & a bolus of 40 mg/kg MgSo₄ is given I.V. & may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached. Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
89037655|NCT04319458|Experimental|Fotonovela|Fotonovela mental health literacy intervention: Secret Feelings/Sentimientos Secretos
89037656|NCT04319458|Active Comparator|Control|Control mental health literacy intervention: NIH publication - Depression: What You Need to Know
89037657|NCT01252966|Experimental|Cognitive Training|Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
89037658|NCT01252966|Placebo Comparator|Control Training|Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
89037659|NCT02582957|Experimental|Sigh breaths|Sigh breaths consisting of a Tidal volume (VT) that produces a plateau pressure (Pplat) of 35 cmH2O (or 40 cmH2O in patients with BMIs > 35 or in patients with moderate or severe abdominal distension from ascites, blood and/or ileum, or prone patients). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
89037660|NCT02582957|No Intervention|Usual Care|Usual care, meaning that the treating physician will be free to treat the patient in any way he or she sees fit, including utilizing invasive mechanical ventilation as they wish.
89037661|NCT03990909|Experimental|BCAAs|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
89622596|NCT03712202|Experimental|Group I Arm A (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
89622597|NCT03712202|Experimental|Group I Arm B (ABVD, nivolumab)|Patients receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89622598|NCT03712202|Experimental|Group II (AVD, brentuximab vedotin, nivolumab)|Patients receive doxorubicin IV, vinblastine IV, dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients that are PET/CT negative receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89622599|NCT03692065|Active Comparator|Apixaban film coated tablets 2.5 mg|Patients randomized in the apixaban reduced dose group will receive an apixaban 2.5 mg tablet and a placebo of apixaban 5 mg tablet, twice daily for 12 months.
89622600|NCT03692065|Active Comparator|Apixaban film coated tablets 5 mg|Patients randomized in the apixaban full dose group will receive a placebo of apixaban 2.5 mg tablet and an apixaban 5 mg tablet, twice daily for 12 months.
89622601|NCT03682068|Experimental|Durvalumab in Combination with SoC Chemotherapy|"Durvalumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks.~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
89622602|NCT03682068|Experimental|Durvalumab in Combination with Tremelimumab+SoC Chemotherapy|"Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks~Tremelimumab will be provided for 4 cycles.~All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
89622603|NCT03682068|Active Comparator|SoC Chemotherapy|"Patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles:~cisplatin+ gemcitabine~If the patient is cisplatin-ineligible, carboplatin + gemcitabine"
89622604|NCT03667573|Experimental|tsDCS Dosage A and textured insoles|"tsDCS dosage A and textured shoe insoles"
89622605|NCT03667573|Experimental|tsDCS Dosage B and textured insoles|"tsDCS dosage B and textured shoe insoles"
89622606|NCT03667573|Experimental|tsDCS Dosage A and smooth insoles|"tsDCS dosage A and smooth shoe insoles"
89622607|NCT03667573|Experimental|tsDCS Dosage B and smooth insoles|"tsDCS dosage B and smooth shoe insoles"
89622608|NCT03661528|Experimental|andexanet alfa|Patients will receive one of two dosing regimens of andexanet alfa based on which FXa inhibitor they received and the amount and timing of the most recent dose.
89622609|NCT03661528|Other|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
89622610|NCT03660046||Depot medroxyprogesterone acetate (DMPA)|This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.
89622611|NCT03660046||Etonogestrel implant (Eng-Implant)|This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.
89622612|NCT03660046||Levonorgestrel IUD (Lng-IUD)|This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.
89622613|NCT03656601||Vaginal delivery|Women that had only vaginal delivery
89622614|NCT03656601||Cesarean-section|Women that had only cesarean-section
89622615|NCT03656601||Nulliparous|Women without delivery
89622616|NCT03650673|Other|Diagnostic Test: Identification of subgroups of patients with|
89622617|NCT03643198|Sham Comparator|CONTROL|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
89037662|NCT03990909|Placebo Comparator|Rice Protein|Rice protein control group: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
89622618|NCT03643198|Active Comparator|TREATMENT|In the study group, patients will receive oral treatment with Ciprofloxacin at a dose of 500 mg every 12 hours and Metronidazole 500 mg every 8 hours for a period of 7 days.
89622619|NCT03641469|Experimental|Green Sun Dynamic Brace|Historical measures of brace effectiveness (in- and out-of-brace Cobb angles), wear time, and brace-related quality of life will be compared to those measured after the subject is fit with a Green Sun dynamic brace.
89037663|NCT03990909|Placebo Comparator|Microcrystalline Cellulose|Placebo control group: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
89037664|NCT01252810|Experimental|GE 145 320mg I/ml injection|
89037665|NCT01252810|Active Comparator|Iopamidol 370mg I/ml injection|
89037666|NCT04206709|Experimental|aerobic effort|Active upper limbs pedaling
89037667|NCT04206709|Sham Comparator|passive pedaling|passive pedaling
89037668|NCT00537654|Experimental|Fasted state|Subjects will be required to fast overnight. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
89037669|NCT00537654|Experimental|Fed state|Subjects will be served high fat breakfast 30 minutes prior to dosing. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
89037670|NCT04397692|Experimental|Inhaled NO delivered using LungFit™ in addition to SST|Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.
89622620|NCT03621956|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
89622621|NCT03621956|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
89622622|NCT03598842|Experimental|Malnourished without lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan.The consented household contact will also receive a daily multivitamin.
89622623|NCT03598842|Experimental|Malnourished with lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
89622624|NCT03598842|Active Comparator|Well-nourished with lung parasites|These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
89622625|NCT03598842|No Intervention|Well-nourished without lung parasites|These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.
89622626|NCT03581136|Experimental|Prescription Isodose Surface Coverage|"The dose fractionation to the CTV (1cm expansion on cavity) will be 40Gy/ 5 fractions and the PTV (3 mm expansion of CTV) will be a minimum dose of 30Gy/5 fractions.~If PTV >100cc or if dose constraints cannot be met on higher dose prescribe CTV (1.0cm) to 35Gy/5 fractions and PTV (3mm) to 30Gy/5 fractions. This is to potentially reduce risk of fat necrosis."
89622627|NCT03574103|Active Comparator|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction as dietary weight loss strategy.
89622628|NCT03574103|Experimental|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
89622629|NCT03574103|Experimental|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
89622630|NCT03570372|Experimental|Intervention group|18 week internet-based CBT with therapist support. Regular online group discussions.
89622631|NCT03570372|Active Comparator|Control group|Reads 2 books about Autism Spectrum Disorder (ASD)
89622632|NCT03562273||GammaPod Quality of Life Evaluations|This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
89037671|NCT04397692|No Intervention|Standard of care|Control - Standard of care
89622633|NCT03555565||Alogliptin and Metformin hydrochloride|Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
89622634|NCT03519386|Experimental|Implant Group 1|G2-TR intraocular implant containing travoprost 75 mcg with high elution rate, plus postoperative placebo eye drops.
89622635|NCT03519386|Experimental|Implant Group 2|G2-TR intraocular implant containing travoprost 75 mcg with low elution rate, plus postoperative placebo eye drops.
89622636|NCT03519386|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
89037672|NCT01252186|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy in each 91-day cycle for a total of two 91-day cycles.
89057865|NCT01687530|Experimental|AMCA bone membrane|AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.
89622637|NCT03508648|Placebo Comparator|Matching Placebo|Subjects previously enrolled in the placebo arm of study G201002.
89622638|NCT03508648|Active Comparator|1 mg GTx-024|Subjects previously enrolled in the 1 mg GTx-024 arm of study G201002.
89622639|NCT03508648|Active Comparator|3 mg GTx-024|Subjects previously enrolled in the 3 mg GTx-024 arm of study G201002.
89622640|NCT03487185|Experimental|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
89622641|NCT03487185|Other|Sleep Advice Control|Initial sleep advice counseling alone
89622642|NCT03474159|Other|patients|patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Echocardiography, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF
89622643|NCT03463798||Patients|Patients with a suspicion of diaphragmatic dysfunction
89622644|NCT03463798||Healthy volunteers|Subjects without any medical condition
89622645|NCT03456089|Other|Neurogenic Bladder Patients|Patients with neurogenic bladder undergoing urodynamics testing
89622646|NCT03454204||Pharmacokinetic|Establish a pharmacokinetic relationship between plasma concentration and the effect of norepinephrine in patients under concentration-target intravenous anesthesia by identifying significant covariates during general anesthesia.
89622647|NCT03452332|Experimental|Treatment (tremelimumab, durvalumab, SABR)|Participants receive tremelimumab IV over 1 hour followed by durvalumab IV over 1 hour on day 1 of each cycle. Participants also undergo SABR over 30-45 minutes on days 8, 10, and 12 of cycle 1. Treatment with tremelimumab repeats every 4 weeks for up to 4 cycles, and treatment with durvalumab repeats every 4 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89622648|NCT03431090|Experimental|CliniMACS Isolation|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
89622649|NCT03424148|Other|Excel V™ Laser & Micro-Lens Array Attachment|Treatment with Excel V™ Laser and a Micro-Lens Array Attachment for skin quality
89622650|NCT03405792|Experimental|Optune System combined with Temozolomide (TMZ) + Pembrolizumab|Patients with newly-diagnosed GBM who undergo maximal safe resection (biopsy alone is eligible) followed by chemoradiation consisting of concomitant TMZ daily and radiation therapy (RT) with minimal RT will be eligible for this trial. Four to six weeks after finishing chemoradiation, patients will start monthly cycles of adjuvant TMZ. Treatment with Optune will start at approximately the same time as the first cycle of adjuvant TMZ and continue until second disease progression or a maximum of 2 years. Within one week after starting Cycle 2 of adjuvant TMZ and Optune therapy, patients will begin open-label treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
89622651|NCT03405792|Other|Historical Control|Historical control data of patients treated with Optune System combined with Temozolomide alone will be compared with the Optune System combined with Temozolomide (TMZ) + Pembrolizumab arm.
89622652|NCT03391973|Experimental|Arm 1 - Pembrolizumab|Arm 1 - Pembrolizumab injection dosed at 200 mg given Q3 weeks by IV infusion on Day 1 of each 3 week cycle.
89622653|NCT03369665|Experimental|Mavenclad®|
89622654|NCT03353870||qualitative interview|This study has only one arm
89622655|NCT03333590|Experimental|Cohort 1 (Minimal Efficacious Dose) rAAVrh74.MCK.GALGT2|N = 3 [2.5 x E13 vg/kg per leg, delivered bilaterally (total 5.0 x E13 vg/kg)]
89622656|NCT03333590|Experimental|Cohort 2 (Dose Escalation) rAAVrh74.MCK.GALGT2|N=3 [5 x E13 vg/kg per leg, delivered bilaterally (total 1.0 x E14 vg/kg)]
89622657|NCT03323112||Influenza vaccine recipients|Health care workers vaccinated by their occupational health care according to the routine praxis.
89622658|NCT03311503|Experimental|Treatment arm|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
89622659|NCT03304249|Experimental|iAmHealthy|Participants randomized to this arm receive the iAmHealthy Healthy Lifestyles Program.
89622660|NCT03304249|Active Comparator|Control|Participants randomized to this group receive comparable content delivered via a newsletter.
89622661|NCT03279887||Post operative respiratory failure|"Patients with acute respiratory failure (ARF) less than 72 hours after a major cardiac surgery with cardiopulmonary bypass~ARF was defined as one of the following conditions:~If mechanical ventilation, a partial pressure of oxygen/ inspired oxygen fraction ratio (PaO2/FiO2) < 200, or failure of weaning (failure of spontaneous ventilation test, re-intubation in the first 24 hours), or need for non-invasive ventilation immediately after extubation,~If spontaneous ventilation: clinical signs of acute respiratory distress (dyspnea at least exertion, cyanosis, polypnea> 25/min, upper or intercostal swallowing, abdominal swing ...), pulse oximetry (SpO2) < 90% or PaO2 <60 mmHg despite oxygen therapy ≥ 3 L/min."
89622662|NCT03278912||IBD|-Patients with IBD without a diagnosed PIDD.-First- or second-degree relatives of patients with a PIDD of interest who do not have a PIDD themselves, but have diagnosed or suspected IBD.
89037673|NCT01252186|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received 21 days of active combination tablets containing 150 µg LNG/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
89622663|NCT03278912||Non-PIDD/non-IBD (healthy volunteers)|healthy volunteers
89622664|NCT03278912||PIDD|CGD cohort; IPEX syndrome cohort; CTLA4 haploinsufficiency cohort; LRBA deficiency and hypomorphic RAG deficiency cohorts
89622665|NCT03278847||Enteral nutrition comparison|This comparison refers to differences in enteral nutrition during therapeutic hypothermia
89622666|NCT03278847||Parenteral nutrition comparison|This comparison refers to differences in parenteral nutrition during therapeutic hypothermia
89622667|NCT03259620|Experimental|CLS006|Furosemide Topical Gel, 0.125%
89622668|NCT03259620|Experimental|CLS006 Vehicle|Vehicle Topical Gel
89622669|NCT03253341|Experimental|Smart Aging Program|Participants will be enrolled into the Smart Aging Program.
89622670|NCT03253341|Active Comparator|Control Group|Participants will be enrolled into group that receives educational materials that reflect the current standard of care.
89622671|NCT03226522|Experimental|AXS-05|AXS-05 tablets taken by mouth for 5 weeks.
89622672|NCT03226522|Active Comparator|Bupropion|Bupropion tablets taken by mouth for 5 weeks.
89622673|NCT03226522|Placebo Comparator|Placebo|Placebo tablets taken by mouth for 5 weeks.
89622674|NCT03225677||Patients with Cirrhosis|Patients with a diagnosis of cirrhosis will have a blood draw and muscle biopsy will be performed.
89622675|NCT03225677||controls|control group should have serum ALT and AST within normal range and a blood draw and muscle biopsy will be performed
89622676|NCT03225508||Phase 1|"The first phase will be to evaluate a new lung ultrasound technique to measure diaphragmatic excursion using a linear probe in the mid-axillary line. This will involve scanning 75 healthy patients undergoing elective surgery to determine normal reference values in men and women.~The following interventions will be carried out:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe on both sides of the chest (ii) Measurement of diaphragmatic movement with a curved ultrasound probe on both sides of the chest"
89622677|NCT03225508||Phase 2|"This will involve patients undergoing an interscalene / supraclavicular brachial plexus block for their routine care, it will examine the reduction in diaphragmatic motion due to phrenic nerve palsy.~Interventions:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe bilaterally.~(ii) Measurement of diaphragmatic movement with a curved ultrasound probe bilaterally.~(iii) Pulmonary function tests prior to the brachial plexus block (iv) Planned supraclavicular / interscalene block by the clinical team. (v) Repeat measurement of diaphragmatic movement with linear ultrasound, only on the side of the brachial plexus block.~(vi) Repeat measurement of diaphragmatic movement with curved ultrasound, only on the side of the brachial plexus block."
89622678|NCT03224949||Healthy controls|
89622679|NCT03224949||Alcoholic hepatitis|
89622680|NCT03224949||Alcoholic steatosis|
89622681|NCT03224949||Alcoholic cirrhosis without HCC|
89622682|NCT03224949||Nonalcoholic steatohepatitis (NASH)|
89622683|NCT03224949||Alcoholic cirrhosis with HCC|
89622684|NCT03212976|Other|Study Phase 1|Patients with an intracranial pressure monitor will undergo phase contrast magnetic resonance imaging to measure their ICP.
89622685|NCT03212976|Other|Study Phase 2|Patients with shunts or CSF access devices such as Ommaya reservoir, etc will undergo phase contrast magnetic resonance imaging
89622686|NCT03201757|Experimental|ALKS 3831|Coated bilayer tablet
89622687|NCT03189706|Experimental|Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS)|Each cycle consists of four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF.
89622688|NCT03181893|Placebo Comparator|Placebo ARM|
89622689|NCT03181893|Experimental|PF-06823859 ARM high|
89622690|NCT03181893|Experimental|PF-06823859 ARM low|
89622691|NCT03180840|Experimental|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg intravenous infusion every 4 weeks
89622692|NCT03139227|Experimental|Supportive Care (celery-banana bread)|Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7, and then consume one serving of higher dose apigenin celery-banana bread on days 8-14. Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion, on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.
89622693|NCT03135327|Experimental|Interventional Phase - Ocufolin Group|Participants in this group will receive the Ocufolin medical food for 6 months.
89622694|NCT03135327|No Intervention|Observational Phase Group|Participants in this group will be studied and followed up for 1-2 years.
89622695|NCT03128879|Experimental|Treatment (venetoclax, ibrutinib, acalabarutinib)|Patients receive venetoclax PO QD and ibrutinib PO QD and acalabrutinib PO BID. Treatment repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unaccepted toxicity.
89622696|NCT03124160|Experimental|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.
89622697|NCT03124160|Active Comparator|ParaGard® CuT380A|ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.
89622698|NCT03077243|Experimental|≤ 10 pack years smoking history|
89622699|NCT03077243|Experimental|> 10 py smoking history, no p53 mutation|
89622700|NCT03077243|Active Comparator|> 10 py smoking history, p53 mutation|
89622701|NCT03066596|Experimental|PRAGMATIC|Intervention practices will receive guideline information and assess children's asthma severity and control. For children with persistent/uncontrolled asthma, academic detailing and prompt in EHR following asthma guidelines will guide asthma management; outreach worker will follow up with patients referred to the by providers to receive care coordination to assure that provider management plan is followed by patient at home.
89622702|NCT03064035|Experimental|Fixed dose 4FPCC|"Incorporating a fixed dose of 1500 IU.~If the patient receiving the 1500 IU fixed dose remains in a bleeding state and the INR remains above goal, an additional 500 IU may be administered at the physician's discretion to minimize bleeding and attempt to achieve hemostasis."
89622703|NCT03064035|Active Comparator|Variable dose 4FPCC|"The FDA-approved variable dosing algorithm is as follows:~initial INR 2-3.9: 25 IU/kg (maximum dose 2500 IU), initial INR 4-6: 35 IU/kg (maximum dose 3500 IU), and initial INR >6: 50 IU/kg (maximum dose 5000 IU). The patient weight will be obtained using a scale and documented by the treating registered nurse"
89622704|NCT03054181||HyQvia|Recombinant human hyaluronidase and normal immunoglobulin 10%
89622705|NCT03018730|Experimental|PRX-102|PRX-102 infusion every 2 weeks
89622706|NCT03012022||Healthy Volunteers|Volunteers without known cardiomyopathy or heart failure
89622707|NCT02971891|Experimental|CLS006 (Furosemide)|CLS006 (Furosemide) Topical Gel, 0.125%
89622708|NCT02971891|Placebo Comparator|Vehicle|Vehicle Topical Gel
89622709|NCT02953717|Active Comparator|Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery
89622710|NCT02953717|Active Comparator|Whole Brain Radiation Therapy (WBRT)|Whole Brain Radiation Therapy
89622711|NCT02918474|Experimental|Supportive care (decision making tool)|Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
89622712|NCT02889978||Cancer arm|Participants with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.
89622713|NCT02889978||Non-cancer arm|Participants with no known diagnosis or past history of cancer from which a blood sample will be collected.
89037674|NCT01252186|Active Comparator|28-day Desogestrel Oral Contraceptive|Participants received 21 days of active combination tablets (containing 150 µg desogestrel (DSG)/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
89622714|NCT02881814|Experimental|Lung ultrasound and clinical decision|Clinical assessment and choice of chest physiotherapy treatmetn performed by the clinical physiotherapist, followed by a comprehensive lung and diaphragm ultrasonography. After ultrasonography, the clinical physiotherapist is asked what CPT treatment he was going finally to implement, and explain the reasons for change, if any.
89622715|NCT02881814|Experimental|Mechanically ventilated patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
89622716|NCT02872025|Experimental|CLOSED:Pembrolizumab intralesionally (IL) x 2 doses (Escalation Phase)|Participants, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The participant will then undergo the surgical treatment as determined by the surgeon and the participant (partial mastectomy or mastectomy).
89622717|NCT02872025|Experimental|CLOSED:Pembrolizumab IL x 4 doses (Expansion Phase)|Participants, upon diagnosis with high risk DCIS, will be offered 4 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 4th dose. The participant will then undergo the surgical treatment as determined by the surgeon and the participant (partial mastectomy or mastectomy).
89622718|NCT02872025|Experimental|CLOSED:Pembrolizumab IL x 2 doses + mRNA 2752 IL x 2-4 doses (Expansion Phase)|Participants, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab and intralesional mRNA 2752 injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The participant will then undergo the surgical treatment as determined by the surgeon and the participant (partial mastectomy or mastectomy).
89622719|NCT02872025|Experimental|mRNA-2752 Monotherapy x 2-4 doses (Escalation Cohort)|Participants will be offered up to 4 doses of mRNA-2752 injected intralesionally (IL) 3 weeks apart (+/- 1) week) with surgery or core biopsy 3 weeks (+/-1 week). The participants will proceed to biopsy, either image guided or excisional or partial mastectomy
89622720|NCT02872025|Experimental|mRNA-2752 x 2-4 doses with or without immune checkpoint inhibitor (Expansion Cohort)|Participants will be will be offered injections of mRNA-2752 given on up to 4 occasions, 3 weeks apart (+/- 1 week) or a combination mRNA-2752 and immune checkpoint inhibitor will be given up to 4 occasions, 3 weeks apart (+/- 1 week). The participants will proceed to biopsy, either image guided or excisional or partial mastectomy.
89622721|NCT02872025|No Intervention|No active treatment|The control group will proceed to surgery alone within a 4 month timeframe following the diagnosis of high risk DCIS.
89622722|NCT02824029|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89622723|NCT02822573|Active Comparator|Donepezil|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5 mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
89622724|NCT02822573|Placebo Comparator|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
89622725|NCT02795676|Experimental|PRX-102 (pegunigalsidase alfa)|PRX-102 infusion every 2 weeks
89622726|NCT02795676|Active Comparator|agalsidase beta|agalsidase beta infusion every 2 weeks
89622727|NCT02784535|Placebo Comparator|placebo|placebo capsules
89622728|NCT02784535|Active Comparator|atomoxetine|atomoxetine capsules 10 mg or 18 mg
89622729|NCT02750072|Active Comparator|Infrapatellar approach|Infrapatellar approach using the surgeon's incision of choice (i.e., patellar tendon split, tendon retraction medial, tendon retraction lateral).
89622730|NCT02750072|Experimental|Semi-extended suprapatellar approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed suprapatellar percutaneous instrumentation (patellofemoral protection sleeve).
89037675|NCT03988335|Experimental|RIST4721|RIST4721 as once-daily 300mg oral solution for 28 days.
89622731|NCT02723409|Active Comparator|Round Procedure|umbilicoplasty technique
89622732|NCT02723409|Active Comparator|"Scarless round procedure"|umbilicoplasty technique
89622733|NCT02723409|Active Comparator|"Inverted U procedure"|umbilicoplasty technique
89622734|NCT02723409|Active Comparator|"Inverted V procedure"|umbilicoplasty technique
89622735|NCT02723409|Active Comparator|"Y deepithelialized procedure"|umbilicoplasty technique
89622736|NCT02708836|Active Comparator|ETT only|Endotracheal tube intubation after induction of anesthesia. Ventilation with ETT until emergence.
89622737|NCT02708836|Experimental|Combined ETT/LMA technique|Placement of LMA after induction of anesthesia. Intubation of trachea with ETT via LMA with fiberoptic bronchoscope. Ventilation with ETT throughout case. Removal of ETT while deeply anesthetized. Ventilation with LMA until emergence.
89037676|NCT03988335|Placebo Comparator|Placebo|Placebo as once-daily 300mg oral solution for 28 days.
89037677|NCT00537693|Active Comparator|1|CRRT via Convection
89622738|NCT02690545|Experimental|ATLCAR.CD30 cells|"Phase Ib: In adults, and separately, in children, two doses will be investigated 1x10^8 cells/m2 and 2x10^8 cells/m^2. The study team will run two independent dose-escalation sequences, one for adults and another one for children. The study team plans to use the 3+3 design and start with a low dose of 1x10^8 cells/m2. If there are no DLT in first 3 patients, the study team will go up to the dose of 2 x 10^8 cells/m2. If there is toxicity in 1/3 patients in the initial cohort, the study team would expand to enroll up to 6 patients. If there are dose limiting toxicities (DLT) at the dose of 2 x 10^8 cells/m^2, the study team will initially decrease the dose to an intermediate dose of 1.5 x 10^8 cells/m^.~Phase II: The study team planning to enroll 31 patients to contribute data. Sequential boundary will be used to monitor DLT rate."
89037678|NCT00537693|Active Comparator|2|CRRT via Diffusion
89622739|NCT02643069|Experimental|Intervention Geriatric Program|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, according to the treating physicians (s) surgeon and the performance of a geriatrician . This management will consist of the therapeutic plan, access to geriatric levels of care, coordination with primary and social care, rehabilitation, and discharge plan.
89622740|NCT02643069|No Intervention|Usual clinical practice|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, agreed with the treating physicians (s) surgeon.
89622741|NCT02617511|Experimental|Omega-3 Supplementation|This groups will supplement their regular diet with 2.97 grams of combined omega-3 fatty acid (EPA/DHA) supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
89622742|NCT02617511|Placebo Comparator|Placebo|This group will supplement their regular diet with 3.0 grams of a combined omega-3-6-9 supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
89622743|NCT02587234|Experimental|Active|2 hours of active peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
89622744|NCT02587234|Sham Comparator|Sham PNS|2 hours of sham peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
89622745|NCT02561091|Placebo Comparator|Placebo|Placebo gel for intratympanic use
89622746|NCT02561091|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
89622747|NCT02561091|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
89622748|NCT02489604|Experimental|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE 25.9 GBq activity. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
89622749|NCT02489604|Experimental|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE 18.5 GBq activity. Total activity of 18.5 GBq 100 mCi for 5 cycles, every 6 ± 2 weeks (500 mCi)
89622750|NCT02473276|Active Comparator|EPID PFM|"The group EPID PFM will receive 3 mg (6 ml) of preservative-free morphine, followed by 3 ml of sterile normal saline, to be administered through the epidural catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
89622751|NCT02473276|Sham Comparator|EPID SAL|"The placebo group, EPID NS, will receive 6 ml of sterile normal saline via the epidural catheter followed by another 3 ml NS. Sixteen to 24 hours after receiving the first study drug,the patient will then receive the identical study drug (for a total of two doses)."
89622752|NCT02473276|Active Comparator|IT PFM|"The group, IT PFM will receive 200 micrograms (mcg) (0.4 ml) of preservative-free morphine via the intrathecal catheter, followed by a flush of the catheter with 2 ml of sterile saline.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
89622753|NCT02473276|Sham Comparator|IT SAL|The placebo group IT SAL will receive 0.4 ml and then 2 ml of sterile normal saline through the intrathecal catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses).
89622754|NCT02451423|Experimental|Cohort A1: Atezolizumab Monotherapy (Closed to enrollment)|Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 1 cycle (1200mg x 1 dose)
89622755|NCT02451423|Experimental|Cohort A2: Atezolizumab Monotherapy (Closed to enrollment|Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 2 cycles (1200 mg x 2 doses)
89622756|NCT02451423|Experimental|Cohort A3: Atezolizumab Monotherapy|Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 3 cycles (1200 mg x 3 doses)
89622757|NCT02444442|Active Comparator|Renal Denervation|participants randomised to undergo renal denervation
89622758|NCT02444442|Sham Comparator|Sham control|participants randomised to undergo sham procedure
89622759|NCT02411773|Active Comparator|Exercise Training plus Sodium Bicarbonate|Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.
89622760|NCT02411773|Active Comparator|Exercise Training plus Placebo|Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
89622761|NCT02411773|Active Comparator|Control to Exercise (Stretching) plus Sodium Bicarbonate|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.
89622762|NCT02411773|Placebo Comparator|Control to Exercise (Stretching) plus Placebo|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
89057347|NCT01648062|Active Comparator|Combination|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to practice a combination of the guided imagery (for relaxation) and mental simulation imagery for sleep-related behaviour
89057348|NCT01648062|Sham Comparator|Control|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to imagine a typical post work activity
89622763|NCT02411773|No Intervention|Healthy Control|Healthy subjects without CKD will not receive any interventions.
89622764|NCT02378428|Experimental|MIBG|Research participants with MIBG avid tumors
89622765|NCT02366039||EMR|patients undergoing clinically indicated endoscopic mucosal resection as standard of care will be asked to participate for this observational study
89622766|NCT02328599||Surgical|Prior Bariatric surgery
89622767|NCT02328599||Non-surgical|Medical / Lifestyle management
89622768|NCT02315027|Experimental|1 dose of 1 × 10(7) MSCs|Group 1: Participants will receive a single intrathecal dose of 1 × 10(7) mesenchymal stem cells (MSCs)
89622769|NCT02315027|Experimental|2 doses of 5 × 10(7) MSCs|Group 2: Participants will receive one intrathecal dose of 5 × 10(7) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 5 × 10(7) MSCs approximately one month later
89037679|NCT04320316|Experimental|Crysvita (burosumab-twza) Treatment|"The starting dose will be 0.3 mg/kg to be given every 2 weeks. If required dose may be titrated with increments of 0.1 mg/kg/dose every 4 weeks up to a maximum of dose of 2.0mg/kg (not to exceed 90mg per dose) until phosphorus level is WNL.~Patient will receive study drug via SC injection to the abdomen, upper arms, thighs, or buttocks; the injection site will be rotated with each injection. If the dose level exceeds 1.5 mL in volume, the dose should be administered at two injection sites.~Duration of treatment is 52 weeks. Subjects that complete treatment through week 52 may have the option to continue KRN23 treatment. If this is warranted based on preliminary efficacy, the current protocol will be amended to allow for an extension."
89037680|NCT01731782|Active Comparator|bupivacaine|bupivacaine-0.5ml/kg of 25% bupivacaine for maximum of 30ml
89037681|NCT01731782|Placebo Comparator|normal saline|Normal saline placebo-0.5ml/kg of 0.9% normal saline (max of 30ml)to mimic bupivacaine
89037682|NCT02889211|Active Comparator|Metabolically Healthy - Non-depressed|Overweight individuals without metabolic syndrome and free of psychiatric illness
89037683|NCT02889211|Experimental|Metabolically Healthy - Depressed|Overweight individuals without metabolic syndrome and with active major depression
89037684|NCT02889211|Experimental|Insulin Resistant - Depressed|Overweight individuals with metabolic syndrome and active major depression
89037685|NCT02889211|Experimental|Insulin Resistant - Non-depressed|Overweight individuals with metabolic syndrome and free of psychiatric illness
89037686|NCT01251952|Experimental|Denileukin Diftitox (Ontak)|Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
89037687|NCT04356430|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before robotic assisted radical prostatectomy
89037688|NCT04356430|Experimental|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robotic assisted radical prostatectomy. Goserelin 10.8 mg will be administered once per 12 weeks.
89037689|NCT01352195|Active Comparator|Usual Care (UC)|This condition will comprise a single, high quality booklet that is currently in dissemination: NCI's Clearing the Air (NCI, 2003).
89037690|NCT01352195|Active Comparator|Standard Repeated Mailings (Stand-RM)|Stand-RM will be the same 8 Forever Free booklets (edited for cessation) distributed over 12 months as in our preliminary studies.
89037691|NCT01352195|Active Comparator|Intensive Repeated Mailings (Inten-RM)|Inten-RM will add two additional booklets to extend the intervention out to 18 months, plus additional monthly contacts.
89037692|NCT04321135|Experimental|Guided Lifestyle Program|The Intervention will be conducted in a cohort of 20 (anticipated) and is designed to increase self-efficacy, social support and perceived access to healthy eating and exercise resources and promote weight loss. Participants assigned to the Guided Lifestyle Program will participate in twice weekly sessions - the first weekly session will be 120 minutes in length with the first hour addressing lifestyle change education and strategies. The second hour will be supervised exercise including aerobics and resistance training. The second weekly session will be a one-hour supervised exercise session. Participants will also receive 2-3 text messages weekly.They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.The Guided Lifestyle program is four months long (16 weeks). Please note, the Guided Lifestyle program participants will be offered a booster session off-study.
89037693|NCT04321135|Active Comparator|Self-Guided Lifestyle Program|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging. The study team will call these participants once a month to check in.
89037694|NCT04320238|Experimental|low-risk group|medical staff work in non-isolated general wards or laboratories, not directly contact with COVID-19 patients.
89037695|NCT04320238|Experimental|high-risk group|doctors and nurses work in isolated ward, directly contact with COVID-19 patients.
89622770|NCT02315027|Experimental|2 doses of 1 × 10(8) MSCs|Group 3: Participants will receive one intrathecal dose of 1 × 10(8) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 1 × 10(8) MSCs approximately one month later
89622771|NCT02315027|Experimental|10 doses of 5 x 10(7) (±20%) MSCs|Group 4: Participants will receive up to 10 doses of 5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
89622772|NCT02315027|Experimental|10 doses of 2.5 x 10(7) (±20%) MSCs|Group 5: Participants will receive up to 10 doses of 2.5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
89622773|NCT02297256|Active Comparator|BMAC & Allograft|Subjects will be treated with bone marrow aspirate concentrate (BMAC) and allograft during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, 12 teaspoons of bone marrow will be taken (aspirated) from one side of hip bone. This may be repeated on the other side of hip bone for a total of 12, 24, or 36 teaspoons of bone marrow total taken from your hip bone depending on the decision made by the surgeon. The bone marrow will then be concentrated with a machine for 15 minutes to a final volume of 2, 4, or 6 teaspoons of BMAC. BMAC will be combined with packed allograft bone chips using another machine to produce two or three constructed bone logs. The bone logs will be laid along the backside of the spine and between each vertebral body.
89037696|NCT04320121|Experimental|Nelutri™ group|This group takes Nelutri™ for 12 weeks
89037697|NCT04320121|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
89037698|NCT04320004|No Intervention|Baseline|"Participating clinics will enter a baseline period where no interventions are used, but survey collection of baseline information about patient storage and disposal is collected. The baseline period varies depending on the cohort timing for each clinic but will last a minimum of one month for each clinic. In order to generate a survey list, the investigators will institute a silent best practice alert (BPA) in these clinics. This Silent BPA is not seen by providers, but a silent report is generated for reporting purposes, and for the study team to generate the baseline survey list."
89057349|NCT04540640|Experimental|Subnormothermic Perfusion|Kidneys retrieved for transplantation will undergo subnormothermic oxygenated perfusion using the study device and perfusion solution for at least 1 hour prior to transplantation into the recipient.
89037699|NCT04320004|Active Comparator|Education Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose. Between 30-45 days following the new opioid prescription, the survey call center will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, and mailed educational material.
89037700|NCT04320004|Active Comparator|Education Intervention with Reminder|This arm will follow the Education Intervention arm (BPA, provider education, mailed education and follow up survey) Approximately 50% of patients in the Education Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
89037701|NCT04320004|Active Comparator|Education + Disposal Bag Intervention|If a patient meets study criteria, an alert will fire in the EHR to remind the provider to discuss proper storage and disposal of the opioid medication with the subject. Following the subject's visit, participants will be mailed an education packet consisting of a cover letter and a flyer detailing the importance of medication disposal of unused opioids and instructing how to properly dispose plus a postage paid medication disposal mail bag and instructions for use. Between 30-45 days following the new opioid prescription, the survey unit will contact subjects by telephone to interview them regarding opioid prescription disposition and actions taken to disposal of any leftover medications, household information, their satisfaction with interventions, including provider-based education, mailed educational material and mail-back bags.
89037702|NCT04320004|Active Comparator|Education + Disposal Bag Intervention with Reminder|This arm will follow the Education+ Disposal Bag Intervention arm (BPA, provider education, mailed education+ disposal bag and follow up survey) Approximately 50% of patients in the Education + Disposal Bag Intervention arm will be randomized to receive an interactive voice response (IVR) telephone call approximately 14 calendar days following receipt of his/her new opioid prescription. The IVR is intended to remind patients/caregivers to properly dispose of any unused medication and gather information from the patient on any disposal actions the patient has taken.
89037703|NCT01229072|Experimental|1|Heparin Blausiegel
89037704|NCT01229072|Active Comparator|2|Liquemine
89037705|NCT04685733||Group 1|Comparison of blood pressure, LVET and CO/SV measures with respective Gold Standards
89622774|NCT02297256|Active Comparator|Iliac Crest Bone Graft|Subjects who are in the Iliac Crest Bone Graft arm will be treated with Iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, the surgeon will make an incision to expose the iliac crest (hip bone), and cutting out the segments of the bone that will be needed, based on the decision of the surgeon. The bone chips will be laid along the backside of the spine and also between each vertebral body where the bone will fuse into place. When the bone becomes solid/fused, there is no movement in the fused spine.
89622775|NCT02278666||upper mini-sternotomy|aortic valve replacement surgery via upper J or T sternotomy (ministernotomy)
89037706|NCT04685733||Group 2|Comparison of blood pressure and HRV measures with respective Gold Standards
89622776|NCT02278666||right mini thoracotomy|aortic valve replacement/repair surgery via right mini thoracotomy
89622777|NCT02278666||conventional sternotomy|aortic valve replacement surgery via conventional full sternotomy
89622778|NCT02184195|Experimental|Olaparib|Olaparib tablets po. 300 mg twice daily
89622779|NCT02184195|Placebo Comparator|Placebo|Placebo tablets twice daily
89622780|NCT02181413|Experimental|Ixazomib Citrate|Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons. Participants who have had any dose reductions due to adverse events (AEs) would not be dose escalated.
89622781|NCT02181413|Placebo Comparator|Placebo|Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons.
89037707|NCT04685733||Group 3|Comparison of blood pressure and CO/SV measures with respective Gold Standards
89037708|NCT01228643|Experimental|Norzyme®|
89622782|NCT02151981|Experimental|Osimertinib|Osimertinib 80 mg, orally, once daily
89622783|NCT02151981|Active Comparator|Platinum-based doublet chemotherapy|pemetrexed 500mg/m2 + carboplatin AUC5 or pemetrexed 500mg/m2 + cisplatin 75mg/m2
89622784|NCT02138617|Experimental|*1/*1 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 310 mg/m2,(IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
89622785|NCT02138617|Experimental|*1/*28 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 260 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
89622786|NCT02138617|Experimental|*28/*28|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 180 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
89622787|NCT02118584|Experimental|Part 1: Open-label Extension|Participants with moderate to severe UC who were enrolled in the Phase II OLE study or the Phase III studies, and who meet the eligibility criteria for enrollment will receive open-label etrolizumab in Part 1 (OLE).
89622788|NCT02118584|No Intervention|Part 2: Safety Monitoring|All participants from Part 1 (OLE), participants whose PML follow-up is not completed within the Phase II OLE study, and participants transferring from the Phase III double-blind studies after the 12-week safety follow-up will be monitored for PML (92 weeks).
89622789|NCT02069756||Duchenne and Becker Muscular Dystrophy|Patients with Duchenne or Becker Muscular Dystrophy, as well as carrier females.
89037709|NCT01228643|Active Comparator|Creon®|
89622790|NCT02040207|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
89622791|NCT02040194|Experimental|AM-101 injection|AM-101
89622792|NCT02040194|Placebo Comparator|Placebo injection|Placebo
89622793|NCT02021019|Experimental|Renal Denervation|Renal denervation using a catheter-based Radio-frequency approach
89622794|NCT02021019|No Intervention|Usual Care|Usual care
89622795|NCT02000895||Preterm infants|>24 weeks <37 weeks gestational age
89622796|NCT02000895||Term infants|>37 weeks' gestational age
89622797|NCT02000895||Follow-up at 6 Years|Children enrolled from the birth cohort(s) to be followed at 6 to 10 years of age.
89622798|NCT01996605|Experimental|Oxytocin 15 mcg|Oxytocin 15 mcg injected spinally
89622799|NCT01996605|Experimental|Oxytocin 150 mcg|Oxytocin 150 mcg injected spinally
89622800|NCT01996605|Active Comparator|Placebo|Preservative free normal saline injected spinally
89622801|NCT01981720|Experimental|PRX-102 (pegunigalsidase alfa)|PRX-102 (pegunigalsidase alfa) 1.0 mg/kg IV every 2 weeks (+/- 3 days)
89622802|NCT01974440|Placebo Comparator|Treatment Arm A|Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab [BR] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for 6 cycles + placebo.
89622803|NCT01974440|Experimental|Treatment Arm B|Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).
89622804|NCT01921166|Active Comparator|clomiphene plus gonadotropins|clomiphene plus gonadotropins
89622805|NCT01921166|Active Comparator|Leuprolide flare|Leuprolide flare
89622806|NCT01906970|Experimental|ClampArt|ClampArt
89622807|NCT01855477|Other|Histological biopsy procedure|This is a multicenter study combining histological biopsy of tumor material with DNA sequencing using Next Generation Sequencing (NGS) platform. The study aims to obtain a more accurate pre-treatment stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing to obtain a mutational profile.
89622808|NCT01836744|Active Comparator|survival rate autologous bone|dental implant placement in the previous sinus lift side with autologous bone; dental implant placement in the previous sinus lift side with xenograft material side;
89622809|NCT01836744|Active Comparator|survival rate axenograft material|dental implant placement in the previous sinus lift side with xenograft material side;
89622810|NCT01805076|Other|Arm 1 (control)|Patients undergo a clinical breast examination and mammography with ultrasound of the breast and regional nodes followed by breast conserving surgery.
89622811|NCT01805076|Experimental|Arm 2 (experimental)|Patients undergo a clinical breast examination, mammography with ultrasound of breast and regional nodes and breast MRI followed by breast conserving surgery or mastectomy.
89622812|NCT01802281|Active Comparator|Hysteropexy|Uphold® LITE
89622813|NCT01802281|Active Comparator|Hysterectomy and USLS|Vaginal hysterectomy and uterosacral ligament suspension (USLS)
89622814|NCT01796795|Placebo Comparator|vehicle gel|The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
89622815|NCT01796795|Active Comparator|SR-T100 gel with 1.0% of SM|SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
89622816|NCT01796795|Active Comparator|SR-T100 gel with 2.3% of SM|SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
89622817|NCT01755650|Experimental|D-18F FPM|
89622818|NCT01755650|Experimental|L-18F FPM|
89622819|NCT01696461|Experimental|Related donors receiving plerixafor|"Collection of sufficient CD34+ cells using plerixafor as the mobilizing agent.~Eligible donors determined according to institutional standards~18-65 years of age~6/6 HLA-matched sibling~Fulfill individual Transplant Center criteria to serve as a mobilized blood cell donor~Serum creatinine <1.5 x institution upper limit of normal (ULN) or estimated creatinine clearance (CLCR) >50 mL/min~Treatment Description:~Receive subcutaneous plerixafor at 240 μg/kg and commence leukapheresis approximately 4 hours later.~Leukapheresis will be performed up to two consecutive days. The target CD34+ cell dose is > 4.0 x 106/kg with a minimum of > 2.0 x 106/kg."
89622820|NCT01696461|No Intervention|Recipients, myeloablative regimen|"Patients undergoing conditioning under a myeloablative regimen~Myeloablative (one of four general regimens):~Busulfan (> 9 mg/kg po or iv total) with fludarabine Busulfan (> 9 mg/kg po or iv total) with cyclophosphamide Total body irradiation (> 1000 cGy) plus etoposide Total body irradiation (> 500 cGy) plus cyclophosphamide"
89622821|NCT01696461|No Intervention|Recipients, reduced intensity conditioning regimen.|"Patients undergoing conditioning using a reduced intensity conditioning regimen.~Reduced Intensity (one of three general regimens):~Busulfan (< 9 mg/kg po or iv total) plus fludarabine Melphalan (100-140 mg/m2 iv total) plus fludarabine Fludarabine plus cyclophosphamide (> 2000 mg/m2 total)"
89622822|NCT01688492|Experimental|ipilimumab|This multi-institution open label study has a Phase 1 and Phase 2 component. The Phase 1 dose escalation stage is to establish the tolerability of ipilimumab to be used in combination with the standard clinical dose of abiraterone acetate plus prednisone in chemotherapy and immunotherapy-naïve patients with progressive metastatic CRPC. Due to the overlapping potential hepatic toxicity between abiraterone and ipilimumab, a Lead in Therapy with abiraterone plus prednisone for 2 cycles will assess for adverse events related to the abiraterone plus prednisone. Patients, who tolerate well the Lead in therapy as defined by Grade 1 or less AEs, will pursue Combination Therapy. Patients with AEs Grade ≥ 2 after Lead in Therapy will be excluded and replaced. The Phase 2 stage will assess efficacy and confirm an acceptable safety profile of the recommended dose.
89622823|NCT01678898|Experimental|0.2 mg/kg|PRX-102 0.2 mg/kg every 2 weeks
89622824|NCT01678898|Experimental|1 mg/kg|PRX-102 1 mg/kg every 2 weeks
89622825|NCT01678898|Experimental|2 mg/kg|PRX-102 2 mg/kg every 2 weeks
89037710|NCT04685460|Experimental|3D-printed bolus|
89037711|NCT04685460|No Intervention|Conventional bolus|
89037712|NCT01199978|Other|Fractionated Proton Radiation|Single arm study, delivering fractionated radiation with a technique (proton therapy) that may be associated with reduced side effects
89622826|NCT01606098|Active Comparator|Systemic treatment|First-line fluoropyrimidine-based chemotherapy with bevacizumab initiated within 4 weeks of randomization, followed by salvage therapy upon progression at the discretion of the local investigator. Surgery of primary tumour will be performed only when indicated by local signs or symptoms.
89622827|NCT01606098|Experimental|Surgery followed by systemic treatment|Surgery within 4 weeks of randomization followed by fluoropyrimidine-based chemotherapy with bevacizumab until progression or unacceptable toxicity, followed by salvage therapy upon progression at the discretion of the local investigator
89622828|NCT01508221|Experimental|Trental + Vitamin E|Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment
89622829|NCT01493219||Epilepsy|Blood and urine sample collection, pre and post op
89622830|NCT01493219||Glioma|Blood and urine sample collection, pre and post op
89622831|NCT01485861|Experimental|Phase Ib: Ipatasertib 400 mg + abiraterone|Participants will receive ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
89622832|NCT01485861|Experimental|Phase Ib: Apitolisib 30 mg + abiraterone|Participants will receive apitolisib 30 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
89622833|NCT01485861|Experimental|Phase II: Ipatasertib 400 mg + abiraterone|Participants will receive Ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
89622834|NCT01485861|Experimental|Phase II: Ipatasertib 200 mg + abiraterone|Participants will receive Ipatasertib 200 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
89622835|NCT01485861|Placebo Comparator|Phase II: Placebo + abiraterone|Participants will receive placebo (for Ipatasertib) once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
89622836|NCT01485861|Experimental|Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone|Participants will receive ipatasertib 400 mg orally once daily and/or prednisone/prednisolone 5 mg orally once daily or bid and/or abiraterone 1000 mg orally once daily according to the following schedule: ipatasertib in the morning during Cycle 1, Days 1-7; ipatasertib in the morning plus prednisone/prednisolone once at night during Cycle 1, Day 8; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) during Cycle 1, Days 9-11; ipatasertib in the morning plus prednisone/prednisolone bid (morning and night) and abiraterone in the morning during Cycle 1, Days 12-18; ipatasertib in the evening plus prednisone/prednisolone bid (morning and night) and abiraterone at the same time as ipatasertib during Cycle 1, Days 19-25; Cycle 2 and beyond ipatasertib once daily in the morning or evening, abiraterone at the same time as ipatasertib, and prednisone/prednisolone bid.
89622837|NCT01452503|Active Comparator|PATH Women's Condom|PATH Women's Condom
89622838|NCT01452503|Active Comparator|FC2 female condom|Female Health Company's FC2 female condom
89622839|NCT01452503|Active Comparator|Reddy 6 female condom (V-Amour)|Reddy 6 female condom (Commercially known as the V-Amour female condom)
89622840|NCT01241734|Experimental|Revlimid (Lenalidomide) in Combination|Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation
89622841|NCT01220674||community dwelling older adults, normal controls|men and women 55 years of age or older who are cognitively intact.
89622842|NCT01220674||community dwelling older adults, mild cognitive impairment|men and women 55 years of age or older who have minimal cognitive decline (MMSE 20-24).
89622843|NCT01101438|Experimental|Arm I|Patients receive oral metformin hydrochloride twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
89622844|NCT01101438|Placebo Comparator|Arm II|Patients receive oral placebo twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
89622845|NCT01094769|Experimental|Moxonidine|
89622846|NCT01094769|Placebo Comparator|Placebo|
89622847|NCT01088633|Other|Exhaled particle analysis|
89622848|NCT01007773|Experimental|Dexmedetomidine|In conjunction with conventional sedative and analgesic agents.
89622849|NCT01007773|Active Comparator|Standard of Care|Patients randomized to conventional sedation will have as the main pharmacologic agents to achieve sedation and analgesia propofol and fentanyl, respectively.
89622850|NCT01004640||Group 1|"Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.~Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis."
89037713|NCT00532116|Active Comparator|A|EMSAM 6mg
89622851|NCT00966979|Other|Triathlon PKR|All subjects enrolled will receive the Triathlon PKR device.
89622852|NCT00936663|Experimental|Sitagliptin 100 mg daily|sitagliptin 100 mg daily
89037714|NCT00532116|Active Comparator|B|EMSAM (Selegiline Transdermal System) 12mg
89037715|NCT04283513|Experimental|Efficacy of IV Ribavirin|The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
89037716|NCT01251367|Experimental|Dysport®|Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.
89037717|NCT03910998|Active Comparator|"Group M for Moderate muscle relaxation, low doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.~Rocuronium IV bolus guided by TOF that must remain between 1-3 / 4 during surgery."
89037718|NCT03910998|Experimental|"Group D for Deep muscle relaxation, high doses rocuronium"|"A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia.~Bolus of rocuronium 0.1 mg/kg IV will be given during surgery to keep the TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes)."
89037719|NCT04263389||control group|control group is a normal matched group.
89622853|NCT00936663|Placebo Comparator|placebo|placebo
89037720|NCT04263389||study group|study group is a group of chronic mechanical cervical pain
89037721|NCT04685148|Experimental|Intervention|Estradiol patches (200 μg per day) 0-3 weeks postpartum.
89622854|NCT00931606|Experimental|Sotatercept 0.1 mg/kg|Participants will receive sotatercept 0.1 mg/kg subcutaneously every 28 days up to 4 doses.
89622855|NCT00931606|Experimental|Sotatercept 0.3 mg/kg|Participants will receive sotatercept 0.3 mg/kg subcutaneously every 28 days up to 4 doses.
89622856|NCT00931606|Experimental|Sotatercept 0.5 mg/kg|Participants will receive sotatercept 0.5 mg/kg subcutaneously every 28 days up to 4 doses.
89622857|NCT00931606|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously every 28 days up to 4 doses.
89622858|NCT00924300||patients|children and/or adolescents with psychiatric disorder
89622859|NCT00924300||controls|typically-developing children/adolescents
89622860|NCT00836563||Forearm Arteriovenous Loop Graft|Participants with planned forearm loop arteriovenous graft placement for hemodialysis or forearm loop arteriovenous graft placed within the previous 7 days will have the upper arm vessels assessed following forearm loop arteriovenous graft placement for size changes and timing of changes.
89622861|NCT00776035||heart failure|Obesity related Heart failure population
89622862|NCT00681343|Experimental|A|Thymoglobulin Induction
89622863|NCT00681343|Experimental|B|Campath-1H Induction
89622864|NCT00681343|Experimental|C|Daclizumab Induction
89622865|NCT00665457|Experimental|Celecoxib|"•Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15, oral capecitabine twice daily on days 1-14, and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1, oral celecoxib twice daily on days 1-14, and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.~•Surgery: Patients undergo definitive surgery (either modified radical mastectomy or lumpectomy combined with axillary node dissection). Patients may also undergo adjuvant radiotherapy and hormonal therapy at the discretion of multidisciplinary breast team."
89622866|NCT00613041||1|Patients with one or more pulmonary nodules 5-15 mm in diameter.
89622867|NCT00597870|Experimental|Treatment of Thoracic Lesions|Endoluminal treatment of thoracic lesions
89622868|NCT00591279||A|Barium enema and colonoscopy at one and three years after entry.
89622869|NCT00591279||B|Barium enema and colonoscopy at three years only after entry.
89622870|NCT00579228||1 Cardiovascular disease (CVD) in Participants without diabetes|Progression of cardiovascular disease (CVD) in participants without diabetes
89037722|NCT04685148|Placebo Comparator|Placebo|Placebo patches (Coloplast Comfeel) for 0-3 weeks postpartum
89037723|NCT04258358|Experimental|People living with dementia intervention group|"Long term care and support are provided in a dementia care friendly environment with emphasis on 'the person's home'. Each resident's home carries a registered address to symbolise the person's home. Based on needs and strengths, people living with dementia and their families are supported to choose the technology to enable the person's independence plus developing new and maintaining existing skills. Examples of supportive and assistive technology include mobile devices, memory clocks, gas and flood detectors, sensor mats and global positioning system trackers or safe return ornaments. Routine care follows a holistic integrated health and social care plan tailored to the needs of the person living with dementia.~Respite care provided in guesthouse facilities embody a similar approach only for a shorter period of time without assigning registered home addresses."
89037724|NCT04258358|No Intervention|People living with dementia control group|"People living with dementia in need of long-term rehabilitation or recovery for at least eight months; and people living with dementia in need of respite care for up to 14 days~People living with dementia will continue to use standard care. Standard care in this respect constitutes usual health and social care or any other nationally acceptable form of therapy that people living with dementia would seek to use."
89037725|NCT04249453||Chronic low back pain with high disability|Veterans with chronic, non-specific LBP and a Roland-Morris Disability Questionnaire (RMDQ) score of >12 (gender-balanced, n1=18)
89037726|NCT04249453||Chronic low back pain with low disability|Veterans with chronic, non-specific LBP and a RMDQ score of 12 (gender-balanced, n2=18)
89037727|NCT04249453||Controls|Asymptomatic veterans with no recent history of LBP (gender-balanced, n3=18)
89037728|NCT02888548|Experimental|Arm cross over 1|botulinum toxins alone then botulinum toxins + orthos
89622871|NCT00579228||2 Cardiovascular disease (CVD) in participants with type 2 Diabetes|Progression of cardiovascular disease (CVD) in participants with type 2 Diabetes with good control
89622872|NCT00579228||3 Cardiovascular disease (CVD) in participants with type 1 diabetes|Progression of cardiovascular disease (CVD) in participants with type 1 diabetes with good control
89622873|NCT00574730|Experimental|Arm 1|Participants will receive 6 cycles of combination chemotherapy with the standard CHOP regimen given in conjunction with rituximab. Cycles are repeated at 21-day intervals for six to eight cycles. Participants achieving at least a partial response to chemotherapy will begin PEG Intron at a dose of 2g/kg/week subcutaneously. PEG Intron treatment will be continued for 12 months in the absence of signs of progressive/recurrent disease, or unacceptable toxicity/intolerance of therapy.
89622874|NCT00518167|Experimental|1|Intensive lifestyle intervention
89622875|NCT00518167|No Intervention|2|Standard counselling at baseline
89622876|NCT00503269|Active Comparator|1|30 ml of 1% Lignocaine with 1:10,000 Adrenaline
89622877|NCT00503269|Active Comparator|2|Standard General anaesthesia with Enflurane and Propofol.
89037729|NCT02888548|Experimental|Arm cross over 2|botulinum toxins + orthosis then botulinum toxins alone
89037730|NCT03888222|Placebo Comparator|Placebo|"Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) capsule orally once daily for 3 months (90 days)."
89037731|NCT03888222|Active Comparator|100 mg of Bosutinib|Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 2 will receive the 100 mg of Bosutinib one (1) capsule orally once daily for 3 months (90 days).
89037732|NCT01250509|Experimental|CALMM|Participants receiving the 'Craving and Lifestyle Management through Mindfulness' intervention, i.e. program that combines stress reduction with mindful eating practices.
89037733|NCT01250509|No Intervention|Waitlist Control|Participants were waitlisted for the intervention during the experimental phase.
89037734|NCT03883893|Active Comparator|IV Tylenol|Participants will receive IV acetaminophen 15mg/kg in the OR.
89037735|NCT03883893|Placebo Comparator|Normal Saline|Participants will receive 0.9% normal saline in the OR. The amount received will be equivalent of what would be given if they were receiving IV acetaminophen.
89037736|NCT04319575|Experimental|Chitosan calcium hyroxide paste|after the access preparation and cleaning and shaping, chitosan calcium hydroxide paste will be placed in the canal and kept for 4 weeks.
89037737|NCT04319575|Active Comparator|triple antibiotic paste|after the access preparation and cleaning and shaping, ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.
89037738|NCT00537732|Active Comparator|control group|3 tablets, only 20 mg omeprazole, genotype independent
89037739|NCT00537732|Active Comparator|intervention group|20 vs. 60 mg daily, genotype dependent
89037740|NCT04180436|Experimental|morbidly obese patients with BMI ≥ 40|Morbidly obese patients with BMI ≥ 40
89037741|NCT04180436|Experimental|Patients operated by gastric bypass|Patients operated by gastric bypass for over a year and with stable weight
89037742|NCT04180436|Experimental|Patients operated by sleeve gastrectomy|Patients operated by sleeve gastrectomy for over a year and with stable weight
89037743|NCT04180436|Experimental|Control group: non-operated subjects|Control group: non-operated subjects but with an age and a BMI corresponding to those of the patients of the 2 operated groups.
89037744|NCT00537927|Active Comparator|0|fixation of mesh with a single crown of tacks and absorbable sutures
89622878|NCT00496756|Other|Sorafenib|"The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the table below, providing no dose limiting toxicity (Grade 3 or 4) is observed. If grade 3 or 4 toxicity is observed, delay and dose modification will occur as defined in protocol. Once dose level 3 is reached, the patient will remain at that dose as defined in following section.~Dose Level 1 Day 1-28 400 mg b.i.d. Dose Level 2 Day 29-56 600 mg b.i.d. Dose Level 3 Day 57- 800 mg b.i.d.~A treatment cycle will be 4 weeks.~Two 4-week cycles will be administered. At the completion of two cycles (week 8), restaging will occur. Patients will continue on therapy per study protocol."
89622879|NCT00483561|Experimental|Gefitinib plus Etoposide|"Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.~Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple)."
89037745|NCT00537927|Active Comparator|1|fixation of mesh with a double crown of tacks and no sutures
89622880|NCT00483366|Other|Imatinib/Gemcitabine/Capecitabine|"Patients will be accrued on cohorts of three per dose level starting at dose level 0. Accrual to higher dose levels will depend on toxicity occurrence.~Dose limiting toxicity (DLT) will be determined after cycle two for each patient.~Schema: Imatinib days 1 - 5 and days 8 - 12 Gemcitabine on days 3 and 10 Capecitabine on days 1 - 14~Doses: Imatinib 400 mg/d fixed dose Gemcitabine 450 mg/m2; 550 mg/m2; 675 mg/m2; 825 mg/m2; 1000 mg/m2 Capecitabine 500 mg/m2; 600 mg/m2 bid; 725 mg/m2; 850 mg/m2~Treatment cycle: 21-days~Treatment duration: Until disease progression or unacceptable toxicity defined in protocol."
89622881|NCT00114881||Inner-city children with asthma|Children at high risk for developing allergic diseases and asthma, on the basis of a parental history of asthma, allergic rhinitis or atopic dermatitis, and residence in the inner city
89037746|NCT00537927|Active Comparator|2|fixation of mesh with a single crown of tacks and non-absorbable sutures
89037747|NCT01250119|Experimental|Single Arm|
89037748|NCT04682444|Experimental|Group 1 - Active Treatment|Patient who were randomized into Group 1 ingested Amizon tablets 0.5 g (2 tablets) after a meal, 3 times a day, for 7 days; each tablet contains 0.25 g of enisamium iodide.
89037749|NCT04682444|Placebo Comparator|Group 2 - Placebo|Patient who were randomized into Group 2 ingested placebo tablets after a meal, at the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
89037750|NCT04320277|Experimental|Patients|All patients received baricitinib combined to antiviral therapy lopinavir/ritonavir for 2 weeks.
89037751|NCT04320277|Active Comparator|Controls|All consecutive patients with mild to moderate COVID-19 infection, older than 18, a during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine.
89037752|NCT05300529|Experimental|Vestibular Rehabilitation Exercises|Vestibular Rehabilitation Exercises focused on eye stabilization and Vestibulo-Oculo Reflex (VOR). Two sessions/week supervised by researcher (40 min) and conducting exercises at home 2 times/day, 5 days/week. (15-20 min)
89037753|NCT05300529|Sham Comparator|Conventional Rehabilitation exercises|Conventional rehabilitation exercises: stretching and walking. Two sessions/week supervised by researcher (40 min) and conducting exercises at home 2 times/day, 5 days/week. (15-20 min)
89057350|NCT01648179|Experimental|GSK1322322 IV formulation|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via IV formulation
89057351|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fasted)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fasted)
89057352|NCT01648179|Experimental|GSK1322322 Oral mesylate salt solution|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Oral mesylate salt solution
89622882|NCT03338946||CIED subjects|CIED interrogation
89622883|NCT03338868||Patients with MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
89037754|NCT04163549|Experimental|Safe at Home Cycle 1|The experimental arm will receive the Safe at Home program which is a community-based discussion group series aiming to prevent and respond to intimate partner violence and child maltreatment in conflict-affected communities. It includes once weekly, single-sex discussion groups with coupled men and women and once monthly family discussion groups with couples and children. During the weekly sessions men and women reflect critically and engage in dialogue related to gender, power, and privilege, learn about the causes and consequence of violence against women and children and gain skills in stress management, psychosocial support and positive parenting strategies. Family sessions focus on improving relationship quality and shared decision-making among partners and participation of children in family decision-making.
89037755|NCT04163549|No Intervention|Safe at Home Cycle 2|During the period of the study, this group will not receive an intervention. Rather, this arm will receive the Safe at Home program after endline data collection is completed for a waitlisted group.
89622884|NCT03338868||Patients without MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
89622885|NCT04494204|Experimental|Intervention|2 tablets Immunofree 500 mg tablets thrice a day for 10 days and 1 capsule Reginmune 750 mg twice a day for 10 days
89622886|NCT04494204|Active Comparator|Comparator Agent|As per standard National Clinical Management Protocol for COVID-19 by Government of India, Ministry of Health and Family Welfare, Directorate General of Health Services, (EMR Division), Version 3, 13.06.20
89622887|NCT03330444||LD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota mainly composed of different species of the genus Lactobacillus, determined by NGS sequencing.
89622888|NCT03330444||NLD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota composed of different pathogenic bacteria such as Streptococcus and Gardnerella, or not dominated by bacteria of the genus Lactobacillus, determined by NGS sequencing.
89622889|NCT03330366|Experimental|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
89622890|NCT03330366|Placebo Comparator|Placebo|take two capsules per day for 8 weeks
89622891|NCT03338634||Children 6 to 10|Children must be between the ages of 6-10 years-old at the time they participate. All children will be physically healthy and without diagnosed learning disorders. A parent or legal guardian must be able to accompany the child.
89622892|NCT03334578|Experimental|Drug: Gastrografin|"Patient will receive 30ml of Gastrografin (diluted at 1:3 ratio with water) as recommended by the manufacturer for a single dose in our population. The dose will be given via the nasogastric tube, which will then be clamped for 1 hour. Gastrografin will only be given if there is evidence of a bowel obstruction. Additionally, Gastrografin will only be given when the patient is hemodynamically stable, not receiving any inotropes, and off of invasive respiratory support. Once administered the patient will receive an x-ray at 48 hours. If Gastrografin can be viewed past the obstruction than another dose of Gastrografin (30ml at 1:3 dilution ratio with water via NG tube) can be given. If gastrografin is not viewed past the obstruction than another dose will not be given.~Generic name: Diatrizoate Meglumine, Diatrizoate Sodium"
89622893|NCT03334578|No Intervention|Control: Standard care|This group will be recruited from an ongoing observational study at our centre. The patients in this group have all received the standard care for treating gastroschisis and any potentially associated bowel obstruction. They have not received Gastrografin. They will be recruited between May 2010 and May 2019.
89622894|NCT02493972|Experimental|manual exploration by GelPort|manual exploration in supplement of coelioscopy before laparotomy
89622895|NCT03338478|Experimental|Epilepsy Patients|Patients being tapered off of levetiracetam or lamotrigine monotherapy during epilepsy video monitoring. Patients will receive the Wii Balance Board and computerized reaction time testing.
89622896|NCT03338478|Experimental|Healthy Control Group|Patients without a diagnosis of epilepsy. Control participants will receive the Wii Balance Board and computerized reaction time testing.
89622897|NCT02492412|Experimental|HE10|Drug: HE10 1~2 drops b.i.d at 12 hour interval for 12 weeks
89037756|NCT01250002|Active Comparator|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
89037757|NCT01250002|Placebo Comparator|Placebo|Placebo will receive the same volume of saline infusion.
89037758|NCT05491876|Experimental|Chest physiotherapy with breathing exercises and ACBT|Group A will recieve chest physiotherapy with breathing exercises and ACBT.
89622898|NCT02492412|Active Comparator|Restasis|Drug: Restasis(Cyclosporine 0.05%) 1~2 drops b.i.d at 12 hour interval for 12 weeks
89622899|NCT03330054||Group A|50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope
89622900|NCT03330054||Group B|25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope
89622901|NCT03330054||Group C|25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope
89622902|NCT03329898|Experimental|dried biological amnion graft|dried biological amnion graft patients, who are with IUA, treated by uterine application of dried biological amnion graft + disposable balloon uterine stent + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
89622903|NCT03329898|Sham Comparator|disposable balloon uterine stent only|disposable balloon uterine stent patients, who are with IUA, treated by uterine application of disposable balloon uterine stent only + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
89622904|NCT03334110|Experimental|LIMA-GSV-SCVBG Group|Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.
89622905|NCT03334110|Other|BIMA-SCVBG Group|The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.
89037759|NCT05491876|Experimental|Chest physiotherapy with breathing exercises|Group B will receive chest physiotherapy with breathing exercises.
89037760|NCT04157153|Experimental|Treatment|All subjects will be implanted with the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) and followed up until 60 months.
89037761|NCT04119596||Diagnosed Parkinson's disease|Patients with incident Parkinson's disease
88989164|NCT05913284|Active Comparator|Morphine group|Upon induction of anaesthesia, intravenous morphine that is of equipotent dose as 0.2mg/kg methadone or 20mg methadone if maximum dose of interventional drug is reached) in blind labelling will be administered by infusion over 30 minutes. No further morphine will be given throughout the operation, but administration of Intraoperative fentanyl will be left to the discretion of the attending anaesthesiologists
88989165|NCT05911243|Experimental|Arm I (acupressure therapy)|Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.
88989166|NCT05911243|Active Comparator|Arm II (usual care)|Patients receive usual care on study. Patients also undergo collection of blood samples on study.
88989167|NCT05903339|Experimental|Group 1: Low dose V3G CH848 Pr-NP1 with 3M-052-AF + Alum|3 doses of V3G CH848 Pr-NP1 (60 mcg) combined with 3M-052-AF (5 mcg) and Alum (500 mcg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit
88989168|NCT05903339|Experimental|Group 2: Low dose V3G CH848 Pr-NP1 with ACU-026-001-1|3 doses of V3G CH848 Pr-NP1 (60 mcg) combined with ACU-026-001-1 (2.0 mg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit
88989169|NCT05903339|Experimental|Group 3: V3G CH848 Pr-NP1 with 3M-052-AF + Alum|3 doses of V3G CH848 Pr-NP1 (100 mcg) combined with 3M-052-AF (5 mcg) and Alum (500 mcg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit
88989170|NCT05903339|Experimental|Group 4: V3G CH848 Pr-NP1 with ACU-026-001-1|3 doses of V3G CH848 Pr-NP1 (100 mcg) combined with ACU-026-001-1 (2.0 mg) at the month 0, 2, and 6 visits, followed by 1 dose of V3G CH848 mRNA-Tr2 (50 mcg) at the month 10 visit
88989171|NCT05903235|Experimental|Virtual Reality-based Mirror Therapy (VR+MT)|In each therapy session, the patients will execute 2 upper-limb functional tasks, starting with easy then more complex tasks.
88989172|NCT05903235|Experimental|Mixed Reality-based Mirror Therapy (MR+MT)|The patients will execute 2 upper-limb functional tasks in each session.
88989173|NCT05903235|Active Comparator|Traditional Mirror Therapy (MT)|The patients will execute 2 to 3 categories of activities per training session: (1) active range of motion exercises, (2) reaching movement or object manipulation, and (3) upper-limb functional tasks.
88989174|NCT05898932||Medical Management|Participants will be managing condition with medication
88989175|NCT05898932||Surgical Management|Participants will be managing condition with a surgery
88989176|NCT05898243||Humeral anterior dislocation|Patients presenting a first episode of humeral anterior dislocation and who are over 40 years old.
88989177|NCT05896137|Experimental|2mg CS0159|QD for 12 weeks
88989178|NCT05896137|Experimental|4mg CS0159|QD for 12 weeks
88989179|NCT05896137|Experimental|Placebo|QD for 12 weeks
88989180|NCT05896124|Experimental|2mg CS0159|QD for 12 weeks
88989181|NCT05896124|Experimental|4mg CS0159|QD for 12 weeks
88989182|NCT05896124|Experimental|Placebo|QD for 12 weeks
88989183|NCT05894109|Placebo Comparator|OnabotulinumtoxinA without Zinc Supplementation|Given placebo
88989184|NCT05894109|Experimental|OnabotulinumtoxinA with Zinc Supplementation|Given 50 mg of zinc citrate
88989185|NCT05891171|Experimental|Dose Escalation Cohort 1|Participants will receive AB598 intravenous (IV) infusion once every 3 weeks
88989186|NCT05891171|Experimental|Dose Escalation Cohort 2|Participants will receive AB598 IV infusion once every 3 weeks
88989187|NCT05891171|Experimental|Dose Escalation Cohort 3|Participants will receive AB598 IV infusion once every 3 weeks
88989188|NCT05891171|Experimental|Dose Escalation Cohort 4|Participants will receive AB598 IV infusion once every 3 weeks
88989189|NCT05891171|Experimental|Dose Expansion Cohort 1 NSCLC|Participants will receive AB598 IV infusion in combination with zimberelimab and carboplatin/pemetrexed once every 3 weeks, for up to 2 years
88989190|NCT05891171|Experimental|Dose Expansion Cohort 2 Gastric/GEJ Cancer|Participants will receive AB598 IV infusion every 2 weeks in combination with zimberelimab once every 4 weeks, and FOLFOX (oxaliplatin, leucovorin, fluorouracil) every 2 weeks, for up to 2 years
88989191|NCT05888389|Active Comparator|GA|The GA group will receive general anesthesia.
88989192|NCT05888389|Experimental|CNB-D|The CNB-D group will receive cranial nerve block anesthesia combined with sedative anesthesia
88989193|NCT05887817|Experimental|Finerenone|Kerendia® tablets
88989194|NCT05887817|Placebo Comparator|Placebo|Placebo tablets
88989195|NCT05886972||Patients aware about propofol injection induced pain|Patients who will be informed about the possibility of incidence of propofol injection pain
88989196|NCT05886972||Patients not aware about propofol injection induced pain|Patients will not be informed about the possibility of incidence of propofol injection pain
88989197|NCT05885529||consecutive participants in the 15 centers|adult patients with mild traumatic brain injury admitted within 12 hours after the trauma. No interventions, observational study
88989198|NCT05878522|Experimental|Treatment A|6 capsules of sisunatovir administered Q12 hours for 5 doses
88989199|NCT05878522|Placebo Comparator|Treatment B|6 capsules of placebo administered Q12 hours for 5 doses
88989200|NCT05878522|Active Comparator|Treatment C|6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
88989201|NCT05878522|Experimental|Treatment D|7 capsules of sisunatovir administered Q12 hours for 5 doses
88989202|NCT05876572|Other|healthy volunteer adults|
88989203|NCT05874973|Experimental|Time-Controlled Adaptative Ventilation (TCAV)|"APRV mode set with:~a Phigh at Plateau Pressure of the VCV mode~a Tlow set to terminate the expiration at 75% of the maximal expiratory flow~a Plow set at 0 cmH2O.~a Thigh set to achieve adequate decarboxylation."
88989204|NCT05874973|Active Comparator|Volume Control Ventilation (VCV)|"Ventilation with the VCV mode set with:~a tidal volume (VT) at or below 6 ml/kg of predicted body weight~a positive end-expiratory pressure (PEEP) set at least at 5 cmH2O~a driving pressure lower than 15 cmH2O."
88989205|NCT05872269|Experimental|Saroglitazar 4 mg tablets|Oral (once daily ) during 364 days/52 weeks of treatment period.
88989206|NCT05869929|Experimental|Vegetables|4-5 servings of vegetables daily, per USDA definition.
88989207|NCT05869929|No Intervention|Normal diet|Participant maintains normal diet, no intervention
88989208|NCT05869136|Experimental|Test group|Microneedling along with hyaluronic acid in thin gingival phenotype
89622906|NCT03329820||1 Uncomplicated CHB|Patients with chronic CHB infections but normal liver function and without cirrhosis or hepatocellular carcinoma
89622907|NCT03329820||2 CHB with impaired liver function (LF) or CC w/o tx|CHB with impaired liver function or compensated cirrhosis, not on anti-viral treatment
89622908|NCT03329820||3 CHB with impaired LF or CC with tx|CHB with impaired liver function or compensated cirrhosis, on anti-viral treatment.
89622909|NCT03329820||4 Decompensated cirrhosis|Patients with CHB infection and cirrhosis complicated by one or more of the following: variceal bleeding, hepatic encephalopathy or ascites.
89622910|NCT03329820||5 Hepatocellular carcinoma|Patients with confirmed diagnosis of hepatocellular carcinoma
89622911|NCT03329742|Placebo Comparator|Control protein diet arm|20% protein content
89622912|NCT03329742|Experimental|Low protein diet arm|10% protein content
89622913|NCT03329664|Experimental|CIK Intervention plus routine treatment|Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
89622914|NCT03329664|Active Comparator|Control|Patients who receive routine treatments only (chemotherapy, radiation therapy)
89622915|NCT03338322|Experimental|Twisted file adaptive|Files that are used in root canal preparation in adaptive motion
89622916|NCT03338322|Active Comparator|Reciproc|Reciproc files are used in root canal preparation with reciprocation motion
89622917|NCT02493816|Experimental|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
89622918|NCT02492568|Experimental|SBRT + Pembrolizumab|Stereotactic Body Radiation Therapy (SBRT) followed by pembrolizumab treatment within 7 days of completion. SBRT: 3 x 8 Gy, given 1-2 weeks prior to start of pembrolizumab. Dose of pembrolizumab is 200 mg, every 3 weeks. Patients can continue the pembrolizumab treatment for maximal 2 years.
89622919|NCT02492568|Active Comparator|Pembrolizumab alone|Dose of pembrolizumab is 200 mg, every 3 weeks.Patients can continue the pembrolizumab treatment for maximal 2 years.
89622920|NCT03329586|Experimental|Training|
89622921|NCT03334032||Inpatient treatment for Anorexia nervosa|"Adolescents with anorexia nervosa assessed~at baseline: on admission to inpatient treatment~at follow-up: 6 months after admission on outpatient basis"
88989209|NCT05869136|Active Comparator|Control group|Microneedling in thin gingival phenotype
88989210|NCT05867251|Experimental|Phase 1, Part 1a: Cohort 1A|Once daily (QD), oral doses of ARTS-021 until intolerable toxicities to determine the MTD/RP2D. Each cycle is 28 days.
88989211|NCT05867251|Experimental|Phase 1, Part 1b: Cohort 1B|Once daily oral doses of ARTS-021 at 1 to 2 dose levels below the MTD/RP2D (starting dose [DL 0]) followed by dose escalation to the MTD/RP2D (DL 1) or dose de-escalation to 2 to 3 dose levels below the MTD/RP2D in combination with either palbociclib plus letrozole or palbociclib plus letrozole. Each cycle is 28 days for ARTS-021.
88989212|NCT05867251|Experimental|Phase 1, Part 1a: Cohort 1C|Once daily oral doses of ARTS-021 at 1 to 2 dose levels below MTD/RP2D determined in Part 1a (starting dose [DL 0]) followed by dose escalation to the MTD/RP2D (DL 1) or dose de-escalation to 2 or 3 dose levels below the MTD/RP2D in combination with carboplatin. Each cycle is 28 days for ARTS-021.
88989213|NCT05867251|Experimental|Phase 2, Part 2a: Cohort 2A|Once daily oral doses of ARTS-021 at the MTD/RP2D until disease progression or toxicity.
88989214|NCT05867251|Experimental|Phase 2, Part 2b: Cohort 2B|Once daily oral doses of ARTS-021 at the RP2D in combination with either palbociclib plus fulvestrant or palbociclib plus letrozole until disease progression or toxicity.
88989215|NCT05867251|Experimental|Phase 2, Part 2b: Cohort 2C|Once daily oral doses of ARTS-021 at the RP2D in combination with carboplatin until disease progression or toxicity.
88989216|NCT05864365|Experimental|ATH434|
88989217|NCT05862688||Infection|patients with infection
88989218|NCT05862688||non-infection|patients without infection
88989219|NCT05857696|Other|neurostimulation|3 months of tonic stimutaltion + 3 weeks with random stimulation mode between microburst, High frequency, stopped stimulation (Off) then stimulation with the more efficient mode (according the patient) until 6 monthe after implantation.
88989220|NCT05851963|Experimental|Group using sonic toothbrush|Patients will be asked to use a sonic toothbrush for 24 months
88989221|NCT05851963|Experimental|Group using hydrosonic toothbrush|Patients will be asked to use a hydrosonic toothbrush for 24 months
88989222|NCT05851963|Placebo Comparator|Group using manual toothbrush|Patients will be asked to use a manual toothbrush for 24 months
88989223|NCT05851963|Experimental|Group using manual toothbrush with 5460 strands|Patients will be asked to use a manual toothbrush with 5460 strands for 24 months
89622922|NCT03334032||Controls|Adolescent healthy and normal weight controls (matched for gender and age), assessed at one point of time
89622923|NCT01722292|Experimental|Phase 1b: LY2940680 + C + E|"Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams [mg] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve [AUC] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle.~Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
89622924|NCT01722292|Placebo Comparator|Phase 2: Placebo + C + E|"Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
89622925|NCT01722292|Experimental|Phase 2: LY2940680 + C+ E|"Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily."
89622926|NCT03329430|Experimental|Foot orthoses|Customize foot orthoses
89622927|NCT02494050|Experimental|Behavioral Activation-Full|Twelve weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
89622928|NCT02494050|Experimental|Behavioral Activation-Short|Eight weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
89622929|NCT02494050|Active Comparator|Bipolar Disorder Collaborative Care|Twelve weekly sessions of phone therapy using BDCC manual adapted for anhedonia.
89622930|NCT02249494|Experimental|Smartphone (mobile app) & telehealth|Participants will install and use a mobile application designed to provide nutritional recommendations for hypertensive patients. These recommendations will be based on the DASH diet guidelines appropriate to patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call center when they have questions about diagnosis and management of their patients.
89622931|NCT02249494|Placebo Comparator|nutritional counseling & telehealth|Physicians who are enrolled for this group will continue performing routine nutritional counseling in their clinical practice. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call service when they have questions about diagnosis and management of their patients.
89622932|NCT02493894|Experimental|PEG & Cefazolin|patients firstly get liquid diet for 24 hours. After that they get PEG solution (80gr/1Litr) each 8 hours for 24 hours. After 48 hours, cefazolin 1gram, every 6hours for 2 days
89622933|NCT02493894|Sham Comparator|placebo & cefazolin|placebo for PEG and cefazolin 1gram, every 6hours for 2 days
89622934|NCT03338166||Group A|Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
89622935|NCT03338166||Group B|Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
89622936|NCT03338166||Group C|Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
89622937|NCT03338166||Group D|Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months
88989224|NCT05847530|Experimental|Group A|This group is Potenza treatments only.
88989225|NCT05847530|Experimental|Group B|This group is Potenza and Icon treatments.
88989226|NCT05846087|Experimental|Treatment|Three weeks of sleep retraining therapy - behavioral component of cognitive behavioral therapy for insomnia. This will be self-delivered by participants digitally using the smart phone App 'SleepFix'.
88989227|NCT05846087|Active Comparator|Control|Sleep health education modules delivered each week for three weeks. Modules contain information about sleep and insomnia; how insomnia affects other aspects of life; what activities influence health sleep (sleep hygiene) and information designed to dispel false beliefs about sleep
88989228|NCT05840783|Experimental|Group A - Open-ended needle|Open ended needle group. Irrigation in this group shall be done using a conventional open-ended needle during root canal therapy
88989229|NCT05840783|Experimental|Group B- side-vented needle|Side vented needle group. Irrigation in this group shall be done using a 30G side-vented needle during root canal therapy
88989230|NCT05840783|Experimental|Group C- Endoactivator|Sonic activation group. In this group, final irrigation during endodontic therapy shall be done using a sonic activation device (Endoactivator)
88989231|NCT05837325||Study Group|
88989232|NCT05837325||Out of Study Group|
88989233|NCT05835154|Experimental|Supportive Care (advanced care planning checklist)|FIELD TEST: Participants complete the Advance Care Planning (ACP) Mobility Checklist on study. Participants complete questionnaires at baseline and after completing the checklist intervention and undergo interview on study. Participants medical records are also reviewed.
88989234|NCT05832801|Other|Group ( Traditional dietary advice)|Each patient will follow traditional dietary advice only for 8 weeks. Compliance of the patient to the diet will be assessed using regular telephone calls.
88989235|NCT05832801|Experimental|Group (Pilates and traditional dietary advice )|Patients in this group will participate in an 8-week Pilates exercise program, 2 times per week for 16 sessions, and will follow traditional dietary advice. Warming up and cooling down stretches for 5 minutes will be considered before and after exercise for the safety of the patients.
88989236|NCT05831540|Experimental|Group I (staff focus group)|Staff participate in facilitated planning discussions to develop CDS tools on study.
88989237|NCT05831540|Experimental|Group II (staff CDS tool utilization)|Staff receives CDS tools training and implements CDS tools to facilitate HPV vaccination on study.
88989238|NCT05831540|Experimental|Group III (parent survey)|Parents complete survey post-intervention on study.
88989239|NCT05831085|Experimental|Imaging- and Physiology-Guided State-of-the-Art Percutaneous Coronary Intervention|
88989240|NCT05831085|Active Comparator|Coronary-Artery Bypass Grafting|
88989241|NCT05828147|Experimental|Rituximab group|Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
88989242|NCT05825482|Active Comparator|Arm 1|Partial mastectomy with Savi Scout® localization and routine cavity shave margins
88989243|NCT05825482|Active Comparator|Arm 2|Partial mastectomy with Savi Scout® localization and selective shave margins.
88989244|NCT05822362|Active Comparator|Full Spectrum Cannabidiol|200mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
89037762|NCT04119596||Control|Volunteers without diagnosed Parkinson's disease not meeting the exclusion criteria
89037763|NCT04107389|Active Comparator|Intervention Group|Receives Art Therapy assessment and intervention
89037764|NCT04107389|Active Comparator|Wait List Control Group|Added to wait list to receive intervention at a later date, participant is made aware of this
89037765|NCT05329116|Active Comparator|Intra-articular PRP|For PRP treatment, 8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection. Patients will receive a single session of PRP treatment.
89622938|NCT02493738|Experimental|Lozanoc 50mg|Lozanoc 50mg, oral administration
89622939|NCT02493738|Active Comparator|Sporanox 100mg|Sporanox 100mg, oral administration
89622940|NCT03333798|Experimental|Cognitive-Behavioral Intervention|Cognitive-Behavioral Intervention with community worker support.
89622941|NCT03333798|Active Comparator|Standard psychosocial care|Standard psychosocial care delivered by health services.
89622942|NCT02493582|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.
89622943|NCT02493582|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
89622944|NCT05560360|Experimental|healthy subjects|
89622945|NCT03329118|Experimental|SHR3824 1Omg,Simavastatin 40mg|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
89622946|NCT03333720|Experimental|Intervention|Intervention is phenylalanine-free protein substitute. Following a 7 day baseline period, all recruits will receive the new phenylalanine-free protein substitute daily for 28 days in addition to routine nutritional management. The study product prescription will be specified on an individual basis by the metabolic Dietitian responsible for the patient's nutritional management and will be dependent on age, bodyweight and medical condition of the patient, but will wholly replace their currently prescribed tablet protein substitute and multivitamin supplements.
89622947|NCT01723384|Active Comparator|Naltrexone|Intermittent oral naltrexone to be taken on an as-needed basis for 8 weeks.
89622948|NCT01723384|Placebo Comparator|Placebo|Intermittent oral placebo to be taken on an as-needed basis for 8 weeks
89622949|NCT03329040||Primipara mothers|Infant to primipara mothers, i.e. the first infant to the mother - No intervention
89622950|NCT03329040||Multipara mothers|Infant to multipara mothers, i.e. not the first infant to the mother - No intervention
89622951|NCT02492490|Experimental|SVF(Stromal Vascular Fraction) derived MSC transprlantation|"transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF~SVF will be cultured to abstain MSC~The abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD."
89622952|NCT02492490|Active Comparator|Basiliximab|induction with Basiliximab during kidney transplantation from DCD
89622953|NCT03328962|No Intervention|Control group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/17 to 15/3/18. Their smoking status will be observed over a period of six months.
89622954|NCT03328962|Experimental|Intervention group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/18 to 15/3/19. The intervention group will receive structured smoking cessation counselling based on MI and adapted for the cancer setting combined with provision of smoking cessation medication (nicotine replacement therapy) while in the control group there will be standard care which may vary from hospital to hospital. Their smoking status will be observed over a period of six months.
89622955|NCT03333642|Experimental|Duodenal Ileal interposition|Duodenal Ileal Interposition with Sleeve Gastrectomy.
89622956|NCT03333564|Experimental|VD3 group|treated with 50,000 IU VD3 / week
89622957|NCT03333564|Experimental|omega3-FA group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
89057353|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fed)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fed)
89057354|NCT02215382|Active Comparator|sugammadex|
89622958|NCT03333564|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3FA) once daily
89622959|NCT03333564|Other|Control group|No intervention was given
89622960|NCT05464446||Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy (DMD) between the ages of 5 and 18 who were diagnosed with DMD by a specialist physician as a result of gene analysis and/or muscle biopsy and their families were included in the study.
89622961|NCT02493504|Experimental|Heparin|75 patients were randomly assigned to receive 100units/kg of heparin after dissection prior to anastomosis.
89622962|NCT02493504|No Intervention|Control|75 received no intraoperative heparin injection.
89622963|NCT03333330|Experimental|Carotid imaging with Visipaque 320 and SonoVue|"Patients undergo to brain MRI, carotid contrast-enhanced CTA, duplex ultrasound, CEUS, blood sampling, clinical structured interview.~Intervention is related to the administration of contrast agents:~Visipaque 320 for contrast-enhanced CTA, and SonoVue for CEUS"
89622964|NCT00706914|Experimental|Once-daily aclidinium/formoterol|Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
89622965|NCT00706914|Experimental|Morning aclidinium/formoterol plus evening formoterol|Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
89622966|NCT00706914|Active Comparator|Formoterol BID|Formoterol fumarate 12 µg twice-daily (BID)
89622967|NCT03337776|Active Comparator|WhatsApp message|WhatsApp messages will be sent to invite subjects to participate CRC screening
89622968|NCT03337776|Active Comparator|Telephone call|Telephone call will be made to invite subjects to participate CRC screening
89622969|NCT03328728|Experimental|Cellular Matrix / A-CP HA Kit|One intra-articular injection of a combination of PRP and non-crosslinked HA
89622970|NCT03328728|Active Comparator|Synvisc-One|One intra-articular injection of a crosslinked HA
89622971|NCT03333174|Experimental|Servo-controlled Oxygen Environment|Oxygen will be provided by servo-controlled oxygen environment with adjustment of oxygen concentration (FiO2) to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
89622972|NCT03333174|Active Comparator|Nasal Cannula Oxygen|Oxygen will be provided by nasal cannula with adjustment of flow rate and FiO2 to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
89622973|NCT03328572|Active Comparator|E-max Endocrowns|all patients in this arm will receive e-max endocrowns
89622974|NCT03328572|Experimental|Cerasmart Endocrowns|all patients in this arm will receive Cerasmart endocrowns
89622975|NCT03328494|Experimental|Part A: Monotherapy (BOS172722)|BOS172722 will be administered on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies.
89622976|NCT03328494|Experimental|Part A: Combination therapy (BOS172722 + Paclitaxel)|BOS172722 will be administered on Cycle 0 Day 1 and on Days 1, 2, 8, 9, 15, and 16 in Cycle 1 and subsequent 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies. The participants will also receive 80 milligrams per meters squared (mg/m^2) paclitaxel as an intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. During dose escalation, further exploration of the treatment schedule for the BOS172722-paclitaxel combination will be initiated. In such combination cohorts, BOS172722 will be administered with paclitaxel on Days 1, 8, and 15 only of each treatment cycle (except for Cycle 2 Day1), and will not be administered on Day 2, 9, and 16. These alternative schedules will be explored to further characterize the pharmacokinetics and tolerability of such a dosing regimen.
89622977|NCT03328494|Experimental|Part B: Combination therapy (BOS172722 + Paclitaxel)|Participants with triple-negative breast cancer will be treated with oral BOS172722 at the recommended Phase 2 dose (RP2D) established in Part A on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle and IV paclitaxel at 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
89622978|NCT02491398||First-line|Previously untreated CLL requiring therapy according to the NCI criteria and treated with at least one cycle of BR as first-line treatment.
89622979|NCT02491398||Second-line|CLL that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the NCI criteria and treated with at least one cycle of BR.
89622980|NCT03337464|Experimental|Parkinson's disease|Subjects with Parkinson's disease
89622981|NCT03337464|Active Comparator|Control|Subjects without Parkinson's disease
89622982|NCT03333096|Other|Glaucoma and mild cognitive impairment|"Device: Ocusweep test battery Neuropsychological test battery~Ocusweep system compared to neuropsychological testing"
89622983|NCT02492256|Active Comparator|PVI group|Conventional PVI by circumferential antral ablation according to standard procedures.
89622984|NCT02492256|Experimental|PVI+GP guided by SUMO technology group|Conventional PVI by circumferential antral ablation according to standard procedures and atrial ganglionated plexi ablation guided by the SUMO technology.
89622985|NCT03337386|Experimental|Inferior Vena Cava Collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
89622986|NCT03337386|Experimental|Subclavian Vein Collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
89622987|NCT03337386|Active Comparator|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
89622988|NCT03328416|Experimental|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
88989245|NCT05822362|Active Comparator|Broad Spectrum Cannabidiol|200mg/day of broad-spectrum cannabidiol, containing 0.0% THC.
88989246|NCT05822362|Placebo Comparator|Hemp Seed Oil|200mg/day of hemp seed oil with no cannabinoids present.
88989247|NCT05812898|Sham Comparator|control group|The control group received selective exercises therapy in the form of strengthening and stretching exercises for selective muscles of hip and knee
88989248|NCT05812898|Experimental|study group|The study group received selective exercises therapy in the form of strengthening and stretching exercises for selective muscles of hip and knee, plus myofascial release technique of the deep front line.
88989249|NCT05808920||Group 1|Participants with previous diagnosis of H&N SCC treated with radiotherapy. Recurrent, residual, or new primary SCC of the oropharynx, oral cavity, larynx, and hypopharynx treated with salvage surgery
88989250|NCT05806554||T1DM|Participants with type 1 diabetes mellitus
88989251|NCT05806554||T2DM|Participants with type 2 diabetes mellitus
88989252|NCT05799768|Experimental|Ketogenic diet plan|Subjects will be provided extensive educational and ongoing support on the KD, including personalized coaching with the ability to text a dietitian at any time and expect a response within 12 hours. Diet adherence and progress will be assessed daily using at-home whole capillary blood ketone/glucose monitors, along with diet records. We will assess adherence based on days in ketosis following these parameters: (BHB ≥ 0.5mM). Adherence will be defined as > 80% of days in ketosis.
88989253|NCT05794048|Experimental|Hepatocellular carcinoma|Patients with hepatocellular carcinoma
89622989|NCT03333018||Aclidinium bromide monotherapy|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
89622990|NCT03333018||Aclidinium bromide and formoterol|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
89622991|NCT03333018||New users of other COPD medication|New users of other COPD medications (tiotropium, other LAMAs, LABA, LABA/ICS, LAMA/LABA), prescribed as recorded in the database.
89622992|NCT03328260|Experimental|Treatment|
89622993|NCT03332940|Experimental|Tc99m-sulfur colloid + Tc99m-tilmanocept|All subjects will receive a single IV injection of unfiltered sulfur colloid radiolabeled with 8 mCi Tc99m on study day 0. All subjects will receive a single IV injection of 200 mcg tilmanocept radiolabeled with 8 mCi Tc99m on study day 3.
89622994|NCT03332862|Experimental|Discontinuous ablation|perform discontinuous ablation of ipsilateral pulmunary veins.
89622995|NCT03332862|Active Comparator|Continuous ablation|perform continuous ablation of ipsilateral pulmunary veins.
89622996|NCT03327948|Experimental|Treatment group|Urinary Urgency Incontinence
89622997|NCT03337230|Experimental|Physical Activity + Diet + Social media|Educational materials for the proposed study will be delivered via a secret social media Facebook group. These materials will promote simple, attainable forms of Physical Activity and lasting diet changes. A study moderator will deliver weekly communications to the Facebook group providing intervention content including social support, social competition and comparison, and social rewards
89622998|NCT02493348|Experimental|Continuous 40 Hz Rhythmic Sensory Stimulation|The intervention consists of Rhythmic Sensory Stimulation of a continuous sine wave single-frequency stimulation (40 Hz). The treatment prescription is 30 minutes daily 40 Hz Rhythmic Sensory Stimulation, 5 days per week, for five weeks of treatment, for a total of 25 sessions.
89622999|NCT02493348|Active Comparator|Intermittent Rhythmic Sensory Stimulation|The stimulation consists of random and intermittent complex wave gamma-range RSS with peaks at 45 Hz and 95 Hz, for 30 minutes daily stimulation, 5 days per week, for a total of five weeks of treatment.
89623000|NCT03337074||Sperm Epigenome arm/healthy men|Men with no significant health problems.
89623001|NCT03337074||Sperm Epigenome arm/cholestatic men|Men with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.
89623002|NCT03337074||Outcomes arm/Cholestatic fathers|Fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after the conception of their child who is now aged 16 - 25 years of age.
89623003|NCT03337074||Outcomes arm/Children of cholestatic fathers|16 - 25 years-old children of fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after their conception.
89623004|NCT01723696|Placebo Comparator|placebo tablet+prenatal vitamin|A daily placebo tablet
89623005|NCT01723696|Active Comparator|Vitamin C +prenatal vitamin|500 mg vitamin C /day
89623006|NCT03332706||SG|Study Group is the group where the patients during observation suffer from spontaneous abortion or missed abortion,
88989254|NCT05794048|Experimental|Pancreatic adenocarcinoma|Patients with pancreatic adenocarcinoma
88989255|NCT05794048|Experimental|Pancreatic neuroendocrine tumor|Patients with pancreatic neuroendocrine tumor
88989256|NCT05793879|Experimental|Video 360|"Patients will watch spherical videos displaying everyday actions towards objects; an audio is embedded describing the action and the object represented (i.e. I'm cutting the potatoes)."
89057355|NCT02215382|Active Comparator|neostigmine + atropine|
89623007|NCT03332706||CG|Control Group is where the patients carry the normal live fetal for at least 8 weeks
89623008|NCT01726036|Active Comparator|Gomco Circumcision Clamp|Gomco circumcision clamp used for neonatal circumcision.
89623009|NCT01726036|Active Comparator|Mogen Circumcision Clamp|Mogen circumcision clamp used for neonatal circumcision.
89623010|NCT03327870||1|Sjogren's Syndrome
89623011|NCT03327870||2|Sicca
89623012|NCT03327870||3|Incomplete Sjogren's Syndrome
89623013|NCT03327870||4|Healthy Volunteers
89623014|NCT03327870||5|Excluded by 2016 ACR/EULAR Classificastion Criteria
89623015|NCT03327558|Experimental|Apriso 0.375G ER CAP|Apriso 0.375G ER Cap
89623016|NCT03327558|Active Comparator|APRISO 375 mg extended-release capsules|APRISO 375 mg ER cap
89623017|NCT02492646|Experimental|Saline group|In the saline group, disposable endotracheal tube was immersed in the 1 liter of sterile 0.9% sodium chloride irrigation solution before anesthetic induction.
89623018|NCT02492646|Experimental|Dry group|In the dry group, endotracheal tube was peeled off from sterile packing just before orotracheal intubation.
88989257|NCT05793879|Active Comparator|Standard video|"Patients will watch standard videos displaying everyday actions towards objects; an audio is embedded describing the action and the object represented (i.e. I'm cutting the potatoes)"
88989258|NCT05791201|Experimental|VX-264|
88989259|NCT05788536|Experimental|DB-OTO - Dose Escalation|Unilateral intracochlear dosing
88989260|NCT05788536|Experimental|DB-OTO - Dose Expansion|Bilateral intracochlear dosing using the dose selected based on safety and efficacy data from the Dose Escalation phase (Part A).
88989261|NCT05785130|Experimental|background noise group|Background noise at bedtime.
88989262|NCT05785130|No Intervention|conventional treatment group|Treatment as usual.
88989263|NCT05782725||1|PCOS and SCH
88989264|NCT05782725||2|PCOH without SCH
88989265|NCT05782725||3|HPOD and SCH
88989266|NCT05782725||4|HPOD without SCH
88989267|NCT05780619||Patients with abnormal vasoreactivity|
88989268|NCT05780619||Patients with normal vasoreactivity|
89623019|NCT01726504|Experimental|electro-acupuncture|"The electric stimulator is applied to bilateral ST25andSP14 with dilatational wave10/50 Hz and electric current0.1-1.0mA.They are given acupuncture with 0.3×50mm or 0.35×75mm needles by inserting30-70mm and twirling lifting andthrusting 3 times.Dosage:The needle arrives the abdominal muscle layer(patients feel painful and acupuncturists feel touching hard).~Bilateral ST37 are given conventional acupuncture with 0.30mm×40mm needles by inserting 25-30mm and twirling lifting and thrusting for 3.Dosage:Local sour and heavy feeling is the appropriate dose.~Every session lasts for 30min/day.The participants are treated continuously for 8 weeks.During 8-week treatment the first 2 weeks,5 sessions per week,and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total."
89037766|NCT05329116|Active Comparator|Intra-articular PRP + periarticular mesotherapy|"In addition to single session PRP treatment, patients will receive 3 weeks of mesotherapy treatment once a week (the first session will be with PRP treatment).~Sterile and disposable needle tip (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used in mesotherapy. Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used."
89037767|NCT04107116|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
89037768|NCT04107116|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by their local oncologists.
89623020|NCT01726504|Sham Comparator|sham electro-acupuncture|"The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave, 10/50 Hz and electric current 0.5mA. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. The needle is inserted by 3mm-5mm (the needle can be vertically fixed on the skin).~Bilateral ST37 are given acupuncture with 3mm-5mm (the needle can be vertically fixed on the skin).~Length of Treatment and the treatment sessions are the same as treatment group."
89623021|NCT03332472|Experimental|Telemedicine group|Telematics visit in front of the conventional visit face to face
89623022|NCT03332472|Placebo Comparator|Conventional group|Group with conventional medical visit
89623023|NCT02242630|Active Comparator|Methylprednisolone, 20 mg|Methylprednisolone, 20 mg, will be injected
89037769|NCT04105595||ASD patients|
89037770|NCT04105595||PFO patients|
89037771|NCT04069637||Early onset Scoliosis|Patients with early onset scoliosis treated with growth-sparing instrumentation (TGR, MCGR, and, VEPTR).
89037772|NCT04069637||Control group|Patients with operative fractures.
89037773|NCT03995771||Children and adolescents with knee pain|Children and adolescents (8-19 years old) presenting to general practice for knee pain
89037774|NCT05307510|Active Comparator|Intervention A - prefabricated splint|A prefabricated splint is provided to the client
89037775|NCT05307510|Experimental|Intervention B - custom orthosis|a custom orthosis (wrist splint with thumb spica) is fabricated by an occupational therapist
89037776|NCT05264142|Experimental|CYP2C19 Rapid Metabolizers (RM)|CYP2C19 rapid metabolizers (RM) are characterized by one normal function allele and one increased function allele
89037777|NCT05264142|Experimental|CYP2C19 Normal metabolizers (NM)|CYP2C19 normal metabolizers (NMs) harboring two normal function alleles defined by the lack of any characterized polymorphisms.
89037778|NCT05264142|Experimental|CYP2C19 Intermediate metabolizers (IM)|CYP2C19 intermediate metabolizers (IMs) are characterized by the presence of one normal function allele and one no function allele or one no function allele and one increased function allele.
89037779|NCT01246960|Experimental|Ramucirumab|"Oxaliplatin 85 milligrams per square meter (mg/m^2) given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-Fluorouracil (5-FU) 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Ramucirumab 8 milligrams per kilogram (mg/kg) given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
89037780|NCT01246960|Placebo Comparator|Placebo|"Oxaliplatin 85 mg/m^2 given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-FU 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Placebo given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
89037781|NCT03870269|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
89037782|NCT03870269|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
89037783|NCT01244620|Experimental|Treatment A|sitaxsentan 100 mg QD for 6 days (Treatment A)
89623024|NCT02242630|Active Comparator|Methylprednisolone, 40 mg|Methylprednisolone, 40 mg, will be injected
89623025|NCT02242630|Active Comparator|Triamcinolone, 20 mg|Triamcinolone, 20 mg, will be injected
89623026|NCT02242630|Active Comparator|Triamcinolone, 40 mg|Triamcinolone, 40 mg, will be injected
89623027|NCT03327480|Experimental|neoprene CMC orthosis|We will prescribe a neopren CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
89623028|NCT03327480|Experimental|thermoplastic CMC orthosis|We will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
89623029|NCT02980744|Experimental|STUFFS|Participants will undergo a sedentary behaviour intervention which includes breaking up prolonged sitting by standing and walking around for 5 minutes every half-hour, standing and walking during television commercial breaks, doing 2 sets of 10 sit-to-stand transitions three times per day, and going to the kitchen to grab some drink every hour. A wrist-worn Misfit activity monitor - a motivational tool that will track adherence to the intervention will be used throughout the intervention period (i.e. 8 weeks). This device which is commercially available provides activity feedback for the user in real time.
89623030|NCT03109158|Experimental|NC-6004 and 5-FU|"Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.~In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.~Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.~In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1."
89623031|NCT03324906|Active Comparator|tDCS active Prader-Willi Syndrome|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
89623032|NCT03324906|Active Comparator|tDCS active Obese Subjects|The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation). The start ramp, when the current will be changed from zero to 2mA (two milli amps), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes.
89623033|NCT03332394||Healthcare Professionals|Includes nurses, physicians, and allied health professionals who care for patients on the 6NW (Respirology ward) of the General campus at TOH who have implemented and worked with the COPD care pathway during the study duration.
89623034|NCT03332394||COPD Patients|Adult patients admitted to the 6NW (Respirology ward) of the General campus at TOH with a primary diagnosis of acute exacerbation of COPD (AECOPD). The diagnosis is based on the admitting physician's assessment of the patient in the emergency room.
89623035|NCT03324828|Active Comparator|Hydroxyzine+no clowns|Patients will receive hydroxyzine solution and no additional intervention
89623036|NCT03324828|Experimental|Hydroxyzine+clowns|Patients will receive hydroxyzine solution and clowns intervention
89623037|NCT03324828|Active Comparator|Placebo+clowns|Patients will receive placebo solution and clowns intervention
89623038|NCT03324828|No Intervention|Placebo+no clowns|Patients will receive placebo solution and no additional intervention
89623039|NCT03324594|Active Comparator|Group A|Participants will be first given (1) WONDALEAF-CAP, followed by (2) WONDALEAF-ON-MEN, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
89623040|NCT03324594|Active Comparator|Group B|Participants will be first given (1) WONDALEAF-CAP, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
89623041|NCT03324594|Active Comparator|Group C|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
89623042|NCT03324594|Active Comparator|Group D|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) WONDALEAF-CAP, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
89623043|NCT03324594|Active Comparator|Group E|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-ON-MEN, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
89623044|NCT03324594|Active Comparator|Group F|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-CAP, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
89623045|NCT03327246|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients who are plan to undergo a major elective surgery in Assuta Ashdod and are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community for two periods of time: (1) Pre habilitation plan for a month prior to surgery (2) a period of 3 months post discharge.
89623046|NCT03327246|No Intervention|No Intervention: Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
89623047|NCT03327168|Active Comparator|Adenosine|Perfusion is measured using PET/CT during intravenous infusion (0.14 mg/kg/min) of adenosine.
89623048|NCT03327168|No Intervention|Room temperature|Perfusion and A2A receptor density is measured using PET/CT in resting room temperature conditions.
89623049|NCT03327168|Experimental|Cold exposure|Perfusion and A2A receptor density is measured using PET/CT during controlled cold exposure.
89037784|NCT01244620|Experimental|Treatment B|tadalafil 40 mg QD for 6 days
88989269|NCT05780034|Experimental|AC676 Dose Escalation|Participants will receive an assigned dose of AC676 in a 28-days cycle.
88989270|NCT05776329|Experimental|Low-inflammatory and environmentally friendly dietary strategy (AIA-D)|The environmentally friendly dietary strategy (AIA-D) designed based on the planetary health diet recommendations translated to the regional context and includes nutrients related to anti-inflammatory responses
88989271|NCT05776329|Active Comparator|General healthy diet recommendations (CONV-D).|The active comparator CONV-D is based on the general healthy diet recommendations
88989272|NCT05775822|Other|Single arm study|After signing the informed consent form, patients who meet all eligibility criteria will be enrolled in the Study. After execution of the CT scan the patient will be contacted to discuss the CT scan result. In case of high calcium score values, patients will be performing a cardiological medical examination, ECG, and further diagnostic investigations, as clinically indicated
88989273|NCT05774314|Experimental|Community Health Worker Intervention|
88989274|NCT05774314|No Intervention|No Community Health Worker Intervention|
88989275|NCT05770544|Experimental|Treatment Arm 03|This entrectinib treatment arm is for adult, teenage/young adult (TYA) and paediatric participants with ROS1 gene fusion-positive malignancies.
89533315|NCT04971720|Active Comparator|Valsartan Evening Dose|We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
89533316|NCT04970459||Patients with Marfan syndrome or related syndromes|Children aged at least 3 years old or adult with Marfan syndrome or related syndromes
89533317|NCT04969770|Experimental|Neuromuscular scoliosis|Minor patients with neuromuscular scoliosis and followed at Necker Hospital
88989279|NCT05765214|Experimental|Intervention Group (IG)|Participants randomized to the IG will receive a customized patient-centered, culturally appropriate education program. Patients randomized to the IG will participate in eight (8) education sessions. A booklet with colorectal cancer education and nutrition education will be developed and print materials given to the participants to use as a workbook.
88989280|NCT05765214|No Intervention|Usual Care (UC)|Patients randomized to UC group will continue to receive care at the clinic without any intervention from the study team.
88989281|NCT05761886|Experimental|telehealth-based clinical pharmacy intervention|will involve a pharmacist identifying and addressing medication-related problems (e.g., inappropriate dosage or indications, drug interactions, and therapeutic duplication); optimizing medication regimens (discontinuing if appropriate, providing subsidized and generic options, and reducing medication complexity); and providing T2D education and self-management support
88989282|NCT05761886|No Intervention|usual care|will involve routine physician office visits every 3 (for those with HbA1c outside goal) - or every 6 months (for those with HbA1c within goal). Medication regimens are usually managed by physicians, nurse practitioners, and physician assistants, and Patients have access to centralized chronic disease management programs.
88989283|NCT05754866|Experimental|Transbronchial lung cryobiopsy|
88989284|NCT05754866|Active Comparator|Transbronchial lung biopsy|
89037785|NCT01244620|Experimental|Treatment C|sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days
89037786|NCT01244620|Experimental|Treatment D|sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days
89533318|NCT04969770|Other|Neuromuscular pathologies without instrumented scoliosis|Minor patients with neuromuscular pathology without instrumented scoliosis and followed at Necker Hospital
89533319|NCT04969770|Other|Controls|Minor patients without neuromuscular pathology or scoliosis and followed at Necker Hospital
89533320|NCT04964934|Experimental|AZD9833 + palbociclib, abemaciclib or ribociclib|The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily)
89533321|NCT04964934|Active Comparator|Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib|The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)
89533322|NCT04955990|Experimental|Participants with PAH|Participants with pulmonary arterial hypertension (PAH) who newly initiate any PAH therapy(ies) at the index date (date when a participant starts the first new PAH therapy after baseline assessments) in a routine clinical setting, either as first-line therapy, as replacement therapies, as concomitant with other PAH therapies, or have already been receiving macitentan 10 milligrams (mg) for at least 3 months prior to the index date. The primary data source for this study will be the medical records of each participant.
89533323|NCT04942535|Experimental|Social Incentive Gamification|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive the Social Incentive Gamification intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
89533324|NCT04942535|Experimental|Social Goals through Incentives to Charity|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive the Social Goals through Incentives to Charity intervention during the 12 month intervention and Daily Performance Feedback during the 6 month follow up."
89533325|NCT04942535|Active Comparator|Control|"Each participant is enrolled as part of a family team. Each participant wears a Fitbit every day and strives to achieve their daily step goal.~Participants in this arm receive Daily Performance Feedback during the 12 month intervention and 6 month follow up."
89533326|NCT04941274|Experimental|1/Dose Determination/De-Escalation|Abemaciclib (de-escalating dose)
89533327|NCT04941274|Experimental|2/Dose Expansion: Group 2a|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 15 participants previously treated with at least 1 line of systemic therapy.
88989285|NCT05753111|Placebo Comparator|Placebo|Participants receive placebo supplements on two separate occasions in a randomized order. The placebo supplements contain 350 mg of maltodextrine. Placebo supplements are packaged in non-see-through hard capsules to assure that there are no differences in appearance or taste. Participants are instructed to ingest their supplement twice a day (in the morning and one hour before bedtime) for 6 consecutive days starting after collection of baseline measures.
88989286|NCT05753111|Experimental|Palmitoylethanolamide (PEA) supplementation|Participants receive PEA supplements on two separate occasions in a randomized order. The PEA supplements contain 350 mg of Levagen+ (315 mg of PEA and 35 mg of excipients). Levagen+ consists for 90% of palmitoylethanolamide and for 10% of a mixture of coconut oil (fractionated), polyglycerol polyricinoleate, citrus oil, olive oil, lecithin, dl-alpha tocopheryl acetate, and silicon dioxide to improve the bioavailability of PEA. Both PEA supplements are packaged in non-see-through hard capsules to assure that there are no differences in appearance or taste. Participants are instructed to ingest their supplement twice a day (in the morning and one hour before bedtime) for 6 consecutive days starting after collection of baseline measures.
89037787|NCT04682717||PI group|A cut-off value of baseline PI below which hypotension at 5 min post induction could be predicted will be the primary outcome, while positive and negative predictive values at 15 minutes will be secondary outcomes.
89037788|NCT04319692|Experimental|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks.
89623050|NCT01726738|Experimental|BRAF (dabrafenib) and MEK (trametinib) inhibitors|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
89623051|NCT02492178|Experimental|IR artesunate + IV artesunate|Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
89623052|NCT02492178|Experimental|IV artesunate + IR artesunate|Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
89623053|NCT03327090|Experimental|Experimental Kinesio Tape|"The Kinesio Tape original brand was used in this study (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque). The application of the experimental Kinesio Tape was as Dr. Kenzo Kase demonstration for muscle facilitation (Kase. et al., 2003):~Gluteal maximus muscle.~Quadriceps muscle.~Gastrocnemius muscle and soleus muscle (triceps surae).~The tape was in tension (15%- 35%) and the muscles were stretched during the application."
89623054|NCT03327090|Sham Comparator|Sham Kinesio Tape|"Same tape brand was used, but different application techniques were utilized for the three muscles.~Gluteal maximus muscle.~Quadriceps muscle.~Gastrocnemius muscle and soleus muscle (triceps surae).~There were no tension on the tape and no muscle stretching during the application."
89623055|NCT03699280|Experimental|Virtual Reality|VR video to be played during the procedure
89623056|NCT03699280|No Intervention|Standard Procedure|Routine protocol outpatient hysteroscopy
89623057|NCT03324516|Experimental|Experimental Group|Patients included in this arm will undergo a traditional bony pterional approach for their craniotomy. A superior cuff of temporal muscle will be left attached to the temporal bone.
89623058|NCT03324516|Active Comparator|Control|Patients included into this arm will receive a traditional pterional approach for their craniotomy. The temporal muscle will be detached in its entirety.
89623059|NCT05542576|Experimental|AMDX2011P 25mg|25mg (1ml) single bolus injection intravenous for diagnostic review
89623060|NCT05542576|Experimental|AMDX2011P 50mg|AMDX2011P 50mg (2ml) single bolus injection intravenous for diagnostic review
89623061|NCT05542576|Experimental|AMDX2011P 100mg|AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review
89623062|NCT05542576|Experimental|AMDX2011P 200mg|AMDX2011P 200mg (6-8ml) single bolus injection intravenous for diagnostic review
89623063|NCT03332082|Experimental|Tooth positioner treatment group|The participants that meet the inclusion criteria will be treated with tooth positioner.
89623064|NCT03327012|Experimental|Treatment of Panlongqi Tablet|Patients were treated with Panlongqi Tablet.
89623065|NCT03327012|Placebo Comparator|Treatment of Panlongqi Placebo|Patients were treated with Panlongqi Placebo Tablet.
89623066|NCT03683992||cemented and cementless Triathlon group|cemented group are patients who get randomized to receive cemented knee implant and Patient randomized to receiving cement less knee implant.
89623067|NCT03326934|Sham Comparator|Milk Chocolate|Each subject consumes a Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
89623068|NCT03326934|Experimental|Dark Chocolate|Each subject consumes a Trader Joe's 72% Cacao Dark Chocolate bar: 47g, 34g cacao, total flavanols: 316.3 mg.
89623069|NCT03326778||AVR + CABG|Patient receiving AVR combined with CABG
89623070|NCT03332004|Experimental|Indocyanine Green arm|All the enrolled patients met the inclusion criteria. No patients have been excluded from the study. All patient have been subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions have been described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green were administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision has been made, in order to identify the fluorescent lesions. All the lesions has been described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged
89623071|NCT03324204|Experimental|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis is placed on proper knee alignment during exercise. Most of the women exhibit excessive medial rotation and adduction of the femur, resulting in knee valgus. The women will be instructed how to correct their abnormalities using mirrors as visual feedback. All exercises will be completed without pain. If the exercises are too easy, the level of difficulty will be increased individually in accordance with the rehabilitation protocol
89623072|NCT03324204|Active Comparator|Shock Wave Therapy|The ESWT group will will meet the therapist twice in the first week, and once a week after it. ESWT will be applied to the iliotibial band and tensor fascia latae with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session.
89623073|NCT02490618|Experimental|Test|Probiotic tablet
89623074|NCT02490618|Placebo Comparator|Control|Control tablet
89623075|NCT05464290|Experimental|Nanofat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels.
89623076|NCT03331848|Placebo Comparator|PLACEBO|
89623077|NCT03331848|Experimental|PXT002331 - 20mg|
89623078|NCT01728844|Active Comparator|beta-tricalcium phosphate alone|beta-tricalcium phosphate alone
89623079|NCT01728844|Experimental|GFeBGS 0.1%|GFeBGS consisting of beta-tricalcium phosphate + 0.1% recombinant human basic fibroblast growth factor (rh-bFGF)
89623080|NCT01728844|Experimental|GFeBGS 0.3%|GFeBGS consisting of beta-tricalcium phosphate + 0.3% rh-bFGF
89623081|NCT01728844|Experimental|GFeGBS 0.4%|GFeBGS consisting of beta-tricalcium phosphate + 0.4% rh-bFGF
89623082|NCT04494126|Experimental|Tranexamic acid|Experimental: TXA Group One gram of intravenous tranexamic acid (TXA) in normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
89623083|NCT04494126|Placebo Comparator|Placebo|Placebo Comparator: Control Group Intravenous normal saline (50cc) given over 15 minutes starting just prior to skin incision, and repeated 6 hours later in the postoperative period.
89623084|NCT05517694|Experimental|pelvic floor exercises, behavioral therapy and respiratory exercises group|Interventions of this group include pelvic floor exercises and behavioral therapy plus respiratory exercises for 8 weeks.
89623085|NCT05517694|Active Comparator|pelvic floor exercises and behavioral therapy group|Interventions of this group include pelvic floor exercises and behavioral therapy for 8 weeks.
89623086|NCT03324126||Targeted fortification|In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day.
89623087|NCT03324126||Adjustable fortification|"In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was < 5 mg/dL, the amount of protein fortification was gradually increased to an estimated maximum level of 4.5 g/kg/day"
89623088|NCT03324048|Other|Patients anxious|Patients anxious will be perform relaxation session.
89623089|NCT05503966|Experimental|Positive ABM|The ABM intervention will be initiated two weeks after antidepressant treatment started (baseline) and continues with two daily sessions for two weeks.
89623090|NCT05503966|Active Comparator|No ABM|This group will in addition to TAU complete the schedule of intermediate assessments as in the ABM group, but no ABM , thus controlling for the aspects of the ABM group that are additional to TAU (increased engagement in cognitive activity and repeated assessment over time), but not including the training component itself (SSRI Active comparison group).
89623091|NCT05503966|No Intervention|TAU|Patients allocated to this group will be assessed at baseline and at the primary end-point as well after 12 weeks and 6 months follow-up. They will not complete any instruments during the intervention period to prevent the effect of some cognitive activity and provide a more ecologically valid version of TAU as it happens in primary care.
89623092|NCT02492022|Experimental|Probiotic L008-1|Encapsuled combinaison of 2 probiotics
89623093|NCT02492022|Experimental|Probiotic L008-2|Encapsuled combinaison of 2 probiotics
89623094|NCT02492022|Placebo Comparator|Placebo|Encapsuled non active ingredients
89623095|NCT03323970||Physicians|
89623096|NCT01730872|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
89623097|NCT01730872|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
89623098|NCT02491086|Experimental|Intervention|The intervention group will receive a free pack of one-week NRT. The nurse will help the subject to decide which NRT product (patch, gum and lozenge) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption, followed by the delivery of the sampling, instructions of using the NRT sampling, an education card about NRT and a 12-page smoking cessation booklet (Figure 1). Based on the experience in the previous trials, the choice of NRT (either patch, lozenge or gum) will be made according to subject's preference, and the counsellors will provide medication counselling [25-27]. If the subject is willing to continue the counselling at recruitment, the ambassador will further introduce the NRT's side effects, adherence and effectiveness (Table 1). Otherwise, the ambassador will contact the subject for providing these details and enquiring the usage through telephone within 2 days.
89623099|NCT02491086|Active Comparator|Control|The control group subjects will only be advised by the ambassador to purchase the NRT on their own, but will not be given the sampling. The same education card and the 12-page smoking cessation booklet will be provided.
89623100|NCT02491710|Experimental|Low-cost box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a low-cost tablet-based box trainer.
89623101|NCT02491710|Active Comparator|Standard box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a standard box trainer
89623102|NCT03469492|Active Comparator|type 2 diabetes mellitus|Subjects with type 2 diabetes on insulin.
89623103|NCT03469492|Active Comparator|type 1 diabetes mellitus|Subjects with type 1 diabetes on insulin.
89623104|NCT02490696|Experimental|Miso|In this arm two PET scans wiil be realized. The first one will be made with F-Miso tracer. 24 hours later the FAZA PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
89623105|NCT02490696|Experimental|FAZA|In this arm two PET scans wiil be realized. The first one will be made with FAZA tracer. 24 hours later the F-Miso PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
89623106|NCT03331770|Experimental|BAK-free latanoprost ophthalmic emulsion|Patients with primary open-angle glaucoma who were using BAK-containing latanoprost ophthalmic solution for ≥ 6 months (baseline), switched to a new formulation of latanoprost ophthalmic product
89623107|NCT03323814||short-sleepers|subset of participants will be recruited who report less than typical work/ weekday sleep in order to examine whether enhancing sleep with stimulation will reduce the amount of extra sleep subjects usually get on the weekends.
89623108|NCT03323814||shift-workers|An additional subset of participants will be recruited who work evening shifts to see if enhanced sleep can counteract some of the effects of schedule shifting.
89623109|NCT03323814||normal-sleepers|The first cohort will be used to optimize the the type and duration of sensory stimuli that will optimally enhance slow-waves.
89623110|NCT02491164|Experimental|BAC TWO administration|All participants in this clinical study will be dosed on one occasion with BAC TWO. The final dosage will be 80 µg (± 25%).
89623111|NCT04851496||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89623112|NCT04851496||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89623113|NCT04851496||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89623114|NCT04851496||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89623115|NCT03326700|Active Comparator|Laparoscopic hernia repair.|Intervention: inguinal hernia repair.
89623116|NCT03326700|Active Comparator|Open hernia repair.|Intervention: inguinal hernia repair.
89623117|NCT03331692|Other|TIVA group|"The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under totally intravenous anesthesia.~During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed."
89623118|NCT03331692|Other|VA group|The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under volatile anesthesia. During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed.
89037789|NCT04319692|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks.
89037790|NCT05238480|Active Comparator|XC-XP-XP-XC Sequence|Use of the Xtreme Conventional mouthguard (XC) while playing rugby for first and fourth weeks and the Xtreme Pro mouthguard (XP) for the second and third weeks.
89037791|NCT05238480|Active Comparator|XP-XC-XC-XP Sequence|Use of the Xtreme Pro mouthguard (XP) while playing rugby for first and fourth weeks and the Xtreme Conventional mouthguard (XC) for the second and third weeks.
89037792|NCT04682327||Responder group|"After the 4 cycles of anti-PD-1/PD-L1 mAbs treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .~Responders are defined as complete remission, partial remission, or stable disease."
89037793|NCT04682327||Nonresponder group|"After the 4 cycles of anti-PD-1/PD-L1 treatment, the investigators evaluated the subjects' response to anti-PD-1/PD-L1, according to the Response Evaluation Criteria In Solid Tumors (RECIST V1.1) or Modified RECIST 1.1 for immune based therapeutics (iRECIST) .~Nonresponders are defined as disease progression."
89623119|NCT05317156|Experimental|Prone position-Cold vapor group|Cold vapor will be applied to the prone position experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtimeun600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
89623120|NCT05317156|Experimental|Supine position-Cold vapor group|Cold vapor will be applied to the supine position experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtimeun600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
89623121|NCT05317156|No Intervention|Prone position-Control group|Patients in the prone position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
89037794|NCT02889640|No Intervention|Control group|These youth will receive standard mathematics instruction and support (including possibly other tutoring interventions), but not the daily, intensive, during-the-school-day math tutoring provided by SAGA.
89688432|NCT02909140|Experimental|Intracameral Mydriasis|Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
89037795|NCT02889640|Experimental|Scale-up SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with scale-up tutors. Tutors will be hired using the randomization process, and will be randomly assigned to youth.
89037796|NCT02889640|Experimental|Standard SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with tutors hired via SAGA's standard process, which does not involve randomization. Tutors will be randomly assigned to youth.
89037797|NCT01267201|Experimental|POS formulation #1|
89037798|NCT01267201|Experimental|POS formulation #2|
89037799|NCT01267201|Active Comparator|commercial tablet|
89037800|NCT04323514|Experimental|Patients with COVID-19 pneumonia|Consecutive patients with COVID-19 pneumonia admitted to ARNAS Civico-Di Cristina-Benfratelli, Palermo
89037801|NCT00545220|Experimental|1|PST
89037802|NCT00545220|Sham Comparator|2|Attention Control
89037803|NCT03755492||Group 1 (Provided absorbent pads)|Patients will receive a 6 month supply (as needed) of absorbent pads for urinary incontinence.
89037804|NCT03755492||Group 2 (not provided absorbent pads)|Patients enrolled in the control arm will not receive absorbent pads.
89037805|NCT05175573|Experimental|SuperNO2VA Et|Continuous positive airway pressure with end-tidal CO2 monitoring
89037806|NCT05175573|Active Comparator|Supplemental Oxygen Face Mask|
89623122|NCT05317156|No Intervention|Supine position-Control Group|Patients in the supine position control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia when they come to the recovery room and at the 6th,12th, and 24th hours after the surgery in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
89037807|NCT03736616|Experimental|Cohort A: Transplant eligible|"Patients receive RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin area under curve (AUC) 5 IV d2, Etoposide (VP16) 100mg/m2 IV d1-3 & Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~BEAM chemotherapy & autoHSCT: BEAM given as Carmustine (BCNU) 300mg/m2 IV day -6 respective to stem cell infusion, VP16 200mg/m2 IV BID day -5 to day-2, Cytarabine (Ara-C) 200mg/m2 IV BID day -5 to day -2, and Melphalan 140mg/m2 IV day -1. Autologous hematopoietic stem cell infusion on day 0. Only patients with CR/PR after RICE acalabrutinib will undergo BEAM and autoHSCT~Maintenance therapy: Post autoHSCT patients will receive Acalabrutinib 100mg oral BID starting on day +30 for 12 consecutive months or until progression or intolerance if occurs within those 12 months."
89037808|NCT03736616|Experimental|Cohort B: Transplant ineligible|"Patients receive RICE chemoimmunotherapy + Acalabrutinib Salvage therapy: RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin AUC 5 IV d2, Etoposide 100mg/m2 IV d1-3. Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~Maintenance therapy: Patients will receive Acalabrutinib 100mg oral BID for 12 consecutive months or until progression or intolerance if occurs within those 12 months. Maintenance therapy will only be given to patients with stable disease or better response after 3 cycles of RICE+ acalabrutinib"
89037809|NCT04684680|Experimental|zamzam water|patient will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
89037810|NCT04684680|Active Comparator|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
89037811|NCT03718403|Experimental|Single arm open labeled intervention study|Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.
89037812|NCT00545259|Experimental|1|AEB071
89037813|NCT00537966|No Intervention|Control|Patients with primary HIV-1 infection who do not want to undergo early combination antiretroviral treatment
89037814|NCT00537966|Active Comparator|Intervention|In this arm patients with primary HIV-1 infection will receive early combination antiretroviral therapy with standard drugs approved by Swiss Medic.
89037815|NCT03456492||case|Hyponatremic elderly patients (>70 years) with hip fractures
89623123|NCT03331614|No Intervention|Control Group|This group will continue with their current treatment regimen during the course of the study. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
89623124|NCT03331614|Active Comparator|Active Treatment Group|This group will continue with their current treatment regimen during the course of the study. In addition they will be given an active intervention with the Flowaid FA-100 SCCD device to utilize at home daily. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
89037816|NCT03456492||control|Normonatremic elderly patients(>70 years) undergoing joint replacement
89037817|NCT01266967|Experimental|Single Arm|Single arm with 2 cohorts; Cohort A no previous brain therapy and Cohort B previous brain therapy
89037818|NCT03456414|Experimental|Virtual reality during hemodialysis|During 12 weeks subjects will exercise during hemodialysis. The intervention will be virtual reality exercise during hemodialysis.
89037819|NCT03456414|No Intervention|Control period - no exercise|During 12 weeks subjects will not exercise during hemodialysis
89037820|NCT03610412|Active Comparator|Cinnamomum Cassia|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.
89037821|NCT03610412|Placebo Comparator|Placebo|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.
89037822|NCT00538044|Experimental|1simvastatin group|before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
89037823|NCT00538044|No Intervention|2contral group|just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group
89037824|NCT00538083|Experimental|1, 2|acute phase, solid dark chocolate, placebo
89037825|NCT00538083|Experimental|3, 4, 5|acute phase, sugared cocoa, sugar-free cocoa, placebo
89037826|NCT00538083|Experimental|6, 7, 8|sustained phase, sugared cocoa, sugar-free cocoa, placebo
89037827|NCT01266850|Active Comparator|Group 1, RotaTeq® x 3|2, 4 and 6 months of age: RotaTeq®
89037828|NCT01266850|Experimental|Group 5, Rotarix®, RotaTeq® x2|2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®
89037829|NCT01266850|Active Comparator|Group 4, Rotarix® x 2|2 and 4 months of age: Rotarix®
89037830|NCT01266850|Experimental|Group 2, RotaTeq®, Rotarix® x 2|2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®
89037831|NCT01266850|Experimental|Group 3, RotaTeq® x 2, Rotarix®|2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®
89037832|NCT00538122||Thioridazine Group|Patients must have been treated with (Mellaril) thioridazine at least three months at time of enrollment.
89037833|NCT03431480|Experimental|hCBMNC|Autologous human placental cord blood mononuclear cells (buffy coat fraction)
89623125|NCT03326622|Experimental|moderate exercise + standard care|This group performed a moderate exercise protocol with training zone determined by Cardiopulmonary Exercise testing added to standard care program based on American Academy of Neurology guidelines.
89623126|NCT03326622|Active Comparator|Standard care|This group performed a standard care program based on American Academy of Neurology guidelines, without exercise intensity control.
89623127|NCT02491008|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
89623128|NCT02491008|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
89623129|NCT05316844||Office Employees Group|Office Employees with neck pain
89623130|NCT03331536||Roux en Y Gastric Bypass Pre-menopausal|Pre-menopausal women undergoing Roux en Y Gastric Bypass
89623131|NCT03331536||Roux en Y Gastric Bypass Post-menopausal|Post-menopausal women undergoing Roux en Y Gastric Bypass
89623132|NCT03331536||Sleeve Gastrectomy Pre-menopausal|Pre-menopausal women undergoing Sleeve Gastrectomy
89623133|NCT03331536||Sleeve Gastrectomy Post-menopausal|Post-menopausal women undergoing Gastric Sleeve
89623134|NCT03331458|Experimental|subjects with prostate cancer|
89623135|NCT04826692|Experimental|Metformin|Therapeutic group: Biguanidines (antidiabetic) Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
89623136|NCT04826692|Placebo Comparator|Placebo|Therapeutic group: NA Administration way: Oral Initial dose: 425 mg twice daily Maximum dose: 850 mg, twice daily Treatment duration: 12 months
89623137|NCT03326544|Experimental|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
89623138|NCT03326544|Experimental|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
89623139|NCT02490930|Experimental|Experimental|Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy. Fingolimod will be administered at 0.5 mg every day for the first two weeks. Beginning the third week, they will take fingolimod on Monday, Wednesday and Friday until the end of radiotherapy or until the 28th dose, whichever comes first.
89037834|NCT00545376|No Intervention|1|This group will leave after the first visit without additional instruction and will be asked to return in two weeks for a follow up lung assessment.
89623140|NCT04825990|Experimental|Single Arm Treatment|Patients will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week dosing cycle (Q3W) and olaparib 300 mg capsules twice a day (BID) every day starting from Day 1 of Cycle 1. Treatment with protocol therapy will continue until objective disease progression, any prohibitive toxicity or until a maximum of 35 treatment cycles (up to 2 years).
89623141|NCT03326466||Patients with SAP|
89623142|NCT03326466||Healthy Controls|
89037835|NCT00545376|Experimental|2|This group, at the first visit, will be taught three home OMT techniques that a family member or friend can administer to them. They will be asked to do these techniques at least 4 times a week, up to every day, for two weeks before returning for a follow up lung assessment.
89037836|NCT00545376|Experimental|3|This arm is the physicians that I will recruit participants through. They will be exposed to education about the use of OMT for asthma.
89037837|NCT00538161|Experimental|Low tidal volume arm|
89037838|NCT00538161|Active Comparator|Conventional tidal volume arm|
89037839|NCT00545415|Experimental|1|
89037840|NCT00545415|Experimental|2|
89037841|NCT00545415|Experimental|3|
89037842|NCT00545415|Experimental|4|
89037843|NCT00545415|Experimental|5|
89037844|NCT00545415|Experimental|6|
89037845|NCT00545493|Experimental|Group 1|"Tacrolimus capsules (Prograf; dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter)"
89037846|NCT00545493|Experimental|Group 2|"Intravenous immunoglobulins (IVIG) infusions (Octagam; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months)."
89037847|NCT01266460|Experimental|Treatment (ADXS11-001)|Patients receive live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001 IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89623143|NCT04816474|Experimental|Education and Phone Counseling Service|Patients in this group will be trained online for 6 weeks. After the online training is over, a telephone consultation service will be provided once a week for 6 weeks.
89623144|NCT04816474|No Intervention|Control|No application will be made to patients in this group for 12 weeks. Pre-test and post-test will be applied.
89623145|NCT03323424|Experimental|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice, but also a Stereotactic Body Radio-Therapy (SBRT).
89623146|NCT03323424|Active Comparator|Systemic treatment|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice.
89623147|NCT04809298|Other|Free-hand lumbar punction|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the free-hand method.
89623148|NCT04809298|Active Comparator|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
89623149|NCT03331302|Active Comparator|COPD patients - Xe-133|COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
89623150|NCT03331302|Experimental|COPD patients - Hyperpolarized Xe-129|COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
89623151|NCT01738672|Experimental|Nitrous Oxide|Parturients who request labor analgesia will be offered inhaled nitrous oxide for labor analgesia.
89623152|NCT02488512|Experimental|90Y-DOTATOC|90Y-DOTATOC
89623153|NCT03323190|Experimental|Inpatient COPD patient|All COPD patients meeting the inclusion criteria of this study will be exposed to inpatient COPD education and tested at a later date to determine if knowledge on COPD was gained.
89623154|NCT04790578|Experimental|ZoeInsights Application Arm|Participants will receive free access to the ZI app for the 12-week intervention. After completing initial set-up, participants will be asked to record physical activity and symptoms regularly via scheduled in-app routines. Further use of ZI (eg. Custom daily routines, additional graphing, medication tracking, accessing linked health resources) during the intervention will be possible ad libitum. After the initial 12-weeks of the EXCEL+ZI intervention, participants have continued free access to the ZI app for up to 1 year.
89623155|NCT04790578|Active Comparator|Waitlist control|During the 12-week intervention the participants will only take part in an online delivered EXCEL exercise class and will not have access to the ZI app. After completion of the 24-week test, the participants will be granted access to the ZI app.
89623156|NCT03326232|Experimental|Blinded continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter).
89623157|NCT03326232|Experimental|Real time continuous glucose monitoring|The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
89623158|NCT05316454|Experimental|Experimental|Patients with hypertension benefit from self-efficacy support in terms of medication adherence and self-efficacy.
89623159|NCT05316454|No Intervention|Control|No change.
89623160|NCT01808651|Experimental|Fluoxetine|Flexible dosing of 20 to 40 milligrams (mg) administered orally, once daily, for approximately 52 weeks
89623161|NCT02488590||CHRONIC OBSTRUCTIVE PULMONARY DISEASE|"Patients with an obstructive spirometry and characteristics of chronic obstructive pulmonary disease~Clinical intervention:~Long acting B agonist (LABA) + Long acting muscarinic receptor antagonist (LAMA) inhaled therapy"
88989287|NCT05751785|Active Comparator|Physical Therapy (PT) Only|"Participants in the PT only arm will follow the PT program outlined above. Twice a week for three weeks, a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the study team member will also ensure the participant is keeping their activity/medication/pain log; the study team member will also deliver the DVPRS with supplemental questions. (See Appendix F for Check-in Data Collection CRF). These check-ins may occur virtually or in person.~In Part 1, the physical therapy only arm requires 8 visits. The participants will complete 2 check-in visits each week (remote or in person), for three weeks. Follow-up data will be collected at 6 weeks (virtual or in-person) and at 3 months (in-person)."
88989288|NCT05751785|Active Comparator|PT + Photobiomodulation Therapy (PBMT)|"The physical therapy + photobiomodulation therapy arm will receive PBMT twice a week, for three weeks, in addition to the PT treatment described above.~A member of the study team will measure the treatment area according to a standard protocol (Appendix N PBM Dose Calculations), to calculate and determine the treatment time, approximately 5-20 minutes. PBMT will be delivered at 25W."
89037848|NCT01266265||Tyvaso|The Tyvaso group will consist of patients receiving Tyvaso and may be receiving another FDA approved PAH therapy as part of routine care.
89037849|NCT01266265||Control|The control group will consist of patients with no previous Tyvaso exposure and not taking Tyvaso at the time of the Baseline visit, but receiving any other FDA approved PAH therapy as part of routine care.
89037850|NCT00545610||Test 1 (n=50)|1 x 10^5 (+/-10%) CD34+ cells/kg of body weight
89623162|NCT02488590||ASTHMA|"patients with asthma and a normal spirometry~Clinical intervention: Inhaled corticosteroids (ICS)"
89623163|NCT02488590||ASTHMA COPD OVERLAP SYNDROME|"patients with an obstructive spirometry and characteristics of both COPD and Asthma~Clinical Intervention: LABA + LAMA + ICS"
89623164|NCT02488590||OBSTRUCTIVE ASTHMA|"patients with an obstructive spirometry and characteristics of asthma~Clinical Intervention: LABA + ICS inhaled therapy"
89623165|NCT02488590||OTHER|"patients with another diagnosis or healthy persons~clinical Intervention: undefined - according to diagnosis"
89623166|NCT01738750|Experimental|Cost Information Included|Group of patients that will receive cost information for both the laparoscopic and open surgical procedures prior to choice of procedure.
89623167|NCT01738750|No Intervention|No Cost Information Included|Group of patients that will not receive cost information for the laparoscopic and open surgical procedures prior to choice of procedure.
89623168|NCT02488668|Experimental|Surface Electrical Stimulation|Please see information under 'Detailed description'
89623169|NCT05316376|Experimental|dd-nabTC|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5, day 1, every 4 weeks)
89623170|NCT05316376|Active Comparator|CONTROL|paclitaxel (175 mg/m2, day 1, every 4 weeks) combined with carboplatin (AUC=6, day1, every 4 weeks)
89623171|NCT03326076||Primary donor-derived cell-free DNA|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
89037851|NCT00545610||Test 2 (n=50)|5 x 10^5 (+/-10%) CD34+ cells/kg of body weight
89037852|NCT00545610||Placebo (n=50)|Saline plus 5% autologous plasma
89037853|NCT00538200|Other|1|Dietary Advice
89037854|NCT00538200|Other|2|Supplements
89037855|NCT00545649|Experimental|1|Exercise and education
89623172|NCT03326076||Control|A matched control cohort of 1000 patients with planned renal surveillance biopsies at 12 months post-transplantation but were not managed with donor-derived cell-free DNA (AlloSure®) or KidneyCare will be retrospectively selected
89623173|NCT03326076||Secondary donor-derived cell-free DNA|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
89623174|NCT03326076||Primary KidneyCare®|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
89623175|NCT03326076||Secondary KidneyCare®|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
89623176|NCT01743976|Experimental|Donepezil|donepezil 5 mg every day
89623177|NCT01743976|Placebo Comparator|Placebo|Placebo (sugar pill) every day
89623178|NCT05316064|Experimental|probiotic 9 log CFU/day|Intervention consists of daily oral administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
89623179|NCT05316064|Placebo Comparator|placebo|placebo contains primarily carrier without probiotic and it is identical in taste and appearance and appear as light-yellow powder. It is also taken by the participants for 12 weeks.
89623180|NCT05315986|Experimental|Group 1: Sleep intervention (ESE) & Saffron (food supplement)|"Saffron: Dietary supplement consists of a gummy sweet (Saffr'Inside; 30mg). Ingest one gummy per day for a duration of 4 weeks total.~Enhanced Sleep Education (ESE): Receive a psycho-education based multi-component sleep intervention consisting of: Sleep education, Sleep hygiene, mindfulness and sleep behavioural recommendations adapted from the validated Brief Behaviour Treatment for Insomnia (BBTi) intervention.The intervention is presented to participants via a pre-recorded presentation, lasting approximately 15 minutes. Participants will also receive some personalized feedback from their objective sleep measurements, collected from their EEG data to help them better understand their sleep patterns."
89623181|NCT05315986|Experimental|Group 2: Sleep intervention (ESE) & No Saffron (placebo food supplement)|"Placebo (no Saffron): Placebo food supplement identical looking (gummy sweet) to experimental food supplement. Ingestion of one gummy per day for a duration of 4 weeks total.~Enhanced Sleep Education (ESE): Receive a psycho-education based multi-component sleep intervention consisting of: Sleep education, Sleep hygiene, mindfulness and sleep behavioural recommendations adapted from the validated Brief Behaviour Treatment for Insomnia (BBTi) intervention.The intervention is presented to participants via a pre-recorded presentation, lasting approximately 15 minutes. Participants will also receive some personalized feedback from their objective sleep measurements, collected from their EEG data to help them better understand their sleep patterns."
89623182|NCT05315986|Experimental|Group 3: No sleep intervention (Control ESE) & Saffron (food supplement)|"Saffron: Dietary supplement consists of a gummy sweet (Saffr'Inside; 30mg). Ingest one gummy per day for a duration of 4 weeks total.~No Psycho-education (ESE) intervention. Control."
89037856|NCT00545649|Active Comparator|2|Education only
89623183|NCT05315986|Placebo Comparator|Group 4: No sleep intervention (Control ESE) & No Saffron (placebo food supplement)|"Placebo (no Saffron): Placebo food supplement identical looking (gummy sweet) to experimental food supplement. Ingestion of one gummy per day for a duration of 4 weeks total.~No Psycho-education (ESE) intervention. Control."
89623184|NCT05464212|Active Comparator|USG Guided Greater Occipital Nerve Block (GONB)|
89623185|NCT05464212|Active Comparator|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency (GONB+PRF)|
89037857|NCT01266148|Experimental|Everolimus|Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
89037858|NCT01266148|Experimental|Control|Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.
89037859|NCT00538239|Experimental|Ridaforolimus|
89037860|NCT00538239|Placebo Comparator|Placebo|
89037861|NCT03263897|Experimental|Active|Receiving insufflation during an acute episode of migraine in both visits
89037862|NCT03263897|Sham Comparator|Sham|Receiving placebo insufflation during an acute episode of migraine in the first visit and receiving insufflation during an acute episode in the second visit
89037863|NCT00545727|Other|HGI|High/standard glycemic index diet
89623186|NCT05315830|Experimental|HER2 Vaccine alone|0.6 μg HER2 Vaccine
89623187|NCT05315830|Experimental|HER2 Vaccine plus Standard of Care Chemotherapy|0.6 μg HER2 Vaccine plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or other Standard of Care Chemotherapy
89623188|NCT05464056|Experimental|BUILT Study|One group receives the intervention.
89623189|NCT03322956|Experimental|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
89037864|NCT00545727|Experimental|LGI|Low glycemic index diet
89037865|NCT01266070|Experimental|Dovitinib|500 mg/day on a 5 day on, 2 day off schedule
89037866|NCT05270148|Experimental|HIIT Group|Participants are enrolled in a high-intensity interval training exercise program
89037867|NCT05270148|Active Comparator|FatMax Group|Participants who are enrolled in a moderate-intensity continuous training exercise program
89037868|NCT05270148|No Intervention|Control|Participants who do not receive an exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
89037869|NCT01265992||Paricalcitol capsules|Patients with secondary hyperparathyroidism associated with Stage 3 - 5 CKD and not yet on dialysis and prescribed paricalcitol capsules in accordance with the terms of the marketing authorization in Sweden.
89037870|NCT00538317|Experimental|1|tirofiban bolus + perfusion started at the site of caring
89037871|NCT00538317|Active Comparator|2|tirofiban bolus + perfusion started at the beginning of coronarography (usual use of tirofiban)
89037872|NCT03228563|Experimental|Probiotics|Taking two capsules of probiotics twice daily for 12 months.
88989289|NCT05751785|Active Comparator|PT + Shockwave Therapy (SWT)|"The physical therapy + shockwave therapy arm will receive SWT once a week for three weeks in addition to the PT treatment described above. Twice a week, for three weeks, a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the study team member will also ensure the participant is keeping their activity/medication/pain log; the study team member will also deliver the DVPRS with supplemental questions. (See Appendix F for Check- in Data Collection CRF). The first check-in of the week will occur in-person after the SWT, if, however, this is not feasible, it may be conducted virtually; the second check-in of the week may occur virtually or in-person.~In total, participants will receive one SWT treatment each week (in person) and complete two check-ins each week (remote or in person), for three weeks. The SWT will take approximately 5-20 minutes."
88989290|NCT05751785|Active Comparator|PT + SWT and PBMT|"The PT + SWT + PBMT arm will receive both SWT and PBMT treatments in addition to PT treatment described above. Participants will receive PBMT twice a week and SWT once a week, for three weeks. The SWT visit may be combined with a PBMT visit in the same week. Up to two times each week after a treatment visit (for three weeks), a team member will check-in with the participants to ensure physical therapy exercise adherence, and response to treatment. During the second check-in of the week, the team member will also ensure the participant is keeping their activity/medication/pain log; the team member will also deliver the DVPRS with supplemental questions. When/if needed, these check-ins may occur virtually. (See Appendix F for check-in data collection CRF).~In Part 1, the PT+ SWT + PBMT treatment arm requires 8 visits: 3 for PBMT alone with check- ins (in person), 3 for PBMT & SWT with check-ins (in person), 6-week follow-up (virtual or in-person), and 3-month follow-up (in person)."
88989291|NCT05750537|Experimental|EMPACT-Us|An innovative suite of tobacco cessation services designed in partnership with patients, providers, and other community stakeholders during a pilot study.
88989292|NCT05750537|No Intervention|Newly-enhanced usual care (EUC)|Newly-enhanced usual care (EUC)
88989293|NCT05750433|Experimental|PreforPro+B. subtilis DE111 probiotics|PreforPro is a prebiotic which is a bacteriophage-based product. This prebiotic was used in combination with Bacillus subtilis probiotics.
88989294|NCT05750433|Placebo Comparator|Placebo(maltodextrin)|Maltodextrin was used as a placebo.
88989295|NCT05750433|Active Comparator|B. subtilis DE111 alone|Bacillus subtilis probiotics was used in this arm alone to compare with the experimental arm.
88989296|NCT05747469|Other|Adipose Allograft Matrix (AAM)|Using fluoroscopic guidance (X-ray), a needle will be injected into the joint space. 1 cc of Leneva (adipose allograft matrix, MTF Biologics) will be injected into the joint.
88989297|NCT05740059|No Intervention|Control|Patients assigned to the Control group will be transfused if hemoglobin (Hb) concentration is lower than 9 g/d.
88989298|NCT05740059|Active Comparator|Adjusted transfusion|Patients assigned to the SvO2 group will be transfused if Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65%.
88989299|NCT05737576|Experimental|Cohort 1|HR011408 injection + NovoRapid®
88989300|NCT05737576|Experimental|Cohort 2|NovoRapid® + HR011408 injection
88989301|NCT05737576|Experimental|Cohort 3|HR011408 injection + NovoRapid®
88989302|NCT05737576|Experimental|Cohort 4|NovoRapid® + HR011408 injection
88989303|NCT05737576|Experimental|Cohort 5|
88989304|NCT05737576|Experimental|Cohort 6|
88989305|NCT05736562|Experimental|Ritual Epre|This group will receive 2 Ritual Epre multivitamin-mineral supplement pills daily.
89623190|NCT03322956|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
89623191|NCT04442568|Active Comparator|ERAS|all patients in this group will be performed LSG under a specified anesthesia protocol. This protocol includes non-opioid analgesia and sedation. Also short-acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the second hour postoperatively, also will be started oral intake between second and fourth hours.
89623192|NCT04442568|No Intervention|no ERAS|all patients in this group will be performed LSG under a conventional anesthesia protocol which is depended on the anesthesiologist . This protocol includes opioid analgesia and sedation. Also short and long acting anesthetic drugs will be used in this arm. The patients in this arm will be mobilized in the fourth hour postoperatively, also will be started oral intake in the next day morning after surgery.
89623193|NCT04716322|Other|Adapted Physical Activity|A 16-week health-adapted physical activity program and 5-year follow-up
89623194|NCT03109236|Experimental|Treatment|"Patient will undergo CD133+ cells transplantation at stable compensated state.~5 dose GCSF will be administered 5 days consecutively before bone marrow harvesting.~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system.~Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins."
89623195|NCT03109236|Active Comparator|Control|"Non-Transplant Arm:~Patients will receive 5 doses of GCSF"
89623196|NCT05463822|Experimental|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
89623197|NCT04639960|Experimental|Risperidone|
88989306|NCT05736562|Placebo Comparator|Control|This group will receive a blank placebo.
88989307|NCT05736237||Families with optic disc drusen|
88989308|NCT05734352||Intervention|Completion of questionnaire
89623198|NCT04639960|Placebo Comparator|Placebo|
89623199|NCT03320616|Experimental|Sequence 1|4 single doses of EYP001a: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed
89037873|NCT03228563|No Intervention|Healthy control|Healthy volunteers were: no hypertension (Blood pressure<140/90mmHg), no diabetes (Glucose AC 70~100mg/dl), no hyperlipidemia (Cholesterol Total 130~200mg/dL、Triglyceride<150mg/dL), no urinary protein (-) and normal renal function (eGFR>90), after signing the consent form, the stool samples will be collected.
89623200|NCT03320616|Experimental|Sequence 2|4 single doses of EYP001a: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed
88989309|NCT05731856|Experimental|Apollo Intervention Arm|Eligible UPMC Physicians and Residents who consent to be part of this study will use an Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology that can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable), as this is where the TVS seems most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature. The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.
88989310|NCT05730088|Experimental|intervention group|"Within the scope of the pre-test, the researcher to the patients who will explain the purpose of the research and agree to participate in the research; Inclusion Criteria Form; Socio-Demographic Information Form; Patient Descriptive Information Form, Modified British Medical Research Council (MRC) Questionnaire, St George Respiratory Questionnaire (Quality of Life Scale) will be used to evaluate patients' symptoms. In addition, the patients in the intervention group will be educated with the training booklet Educational Guide for COPD Patients prepared by the researcher by scanning the literature."
88989311|NCT05730088|No Intervention|Not intervention group|The control group will be subjected to the standard COPD training given in the hospital and no intervention will be made by the researcher. After the trials of the experimental group are completed, the control group will be given a home visit, a COPD training booklet, and audio-visual materials.
88989312|NCT05726318|Other|Culture-directed antibiotic|Participants will be directed to refrain from taking antibiotics until results of urine culture are reported, which is expected within 48-72h.
88989313|NCT05726318|Active Comparator|Empiric antibiotic|Antibiotic Protocol. For participants in the empiric Rx arm, we will choose an antibiotic with consideration of patient reported allergies, current medications and current IDSA guidelines. If there is a contraindication to the first antibiotic on the list they will progress to the next option until a suitable selection is achieved.
88989314|NCT05719064|Experimental|Adaptive Cell Phone Support|Computer-delivered cell phone support (reminders, problem-solving, referrals to resources) and responsive human coaching (phone calls, test messages, in-app messaging) to improved medication adherence.
88989315|NCT05719064|Experimental|Computer-Delivered Cell Phone Support|Computer-delivered cell phone support (reminders, problem-solving, referrals to resources)
88989316|NCT05719064|Active Comparator|Automated Text Reminders|Scheduled one-way text automated message reminders to take medication
88989317|NCT05718778|Experimental|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
88989318|NCT05715528|Experimental|Obeldesivir|Participants will receive obeldesivir 350 mg twice daily for 5 days.
89623201|NCT03320616|Experimental|Sequence 3|4 single doses of EYP001a: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted
89623202|NCT03320616|Experimental|Sequence 4|4 single doses of EYP001a: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted
89623203|NCT04597996|Experimental|Web Based Education|A pre-test will be applied. Web-based education will be conducted. The post-test will be applied twice, the first one to be performed 4 weeks after Web-based education is completed and the second one 3 months after Web-based education is completed.
89623204|NCT04597996|No Intervention|No Intervention Group|The control group will not have any intervention during the study.
89623205|NCT03109314|Active Comparator|Single-letter training group|Subjects will be trained on a low-contrast single-letter task. The task is to identify a faint letter (low-contrast). Performance will be measured as correct or incorrect. Training will consist of identifying these low-contrast letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
89623206|NCT03109314|Active Comparator|Uncrowd training group|Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
89623207|NCT04566016|Experimental|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1).
89623208|NCT04566016|Active Comparator|General anesthesia|Patients scheduled for lower limb arterial bypass surgery and allocated for treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
88989319|NCT05715528|Placebo Comparator|Obeldesivir Placebo|Participants will receive obeldesivir placebo twice daily for 5 days.
88989320|NCT05713877|Experimental|Enteral melatonin 9 mg|Melatonin 9 mg from a 1 mg/mL oral suspension of melatonin in ORA-BLEND SF® (sugar-free flavoured suspending vehicle). Final volume in the oral syringe will be 9 mL.
88989321|NCT05713877|Placebo Comparator|Enteral placebo|ORA-BLEND SF® (sugar-free flavoured suspending vehicle). Final volume in the oral syringe will be 9 mL.
88989322|NCT05713071|Experimental|BEAM Treatment Patients|Subjects having esophagogastroduodenoscopy (EGD) with Bariatric Endoscopic Antral Myotomy (BEAM) with standard of care lifestyle modification therapy.
88989323|NCT05713071|No Intervention|Lifestyle Modification Control Group|Standard of care lifestyle modification therapy only.
89037874|NCT01265953|Experimental|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of sulforaphane (SFN) daily, 2 capsules (1 capsule B.I.D.) daily
89037875|NCT01265953|Placebo Comparator|Placebo capsules|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
89037876|NCT01265875|Other|human secretin|intravenous secretin administration in escalating doses three times daily for three days. After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
89037877|NCT00545805|Experimental|OM group|
89037878|NCT00545805|Active Comparator|CT group|Control group
89037879|NCT01265797|Active Comparator|Cranial Electrostimulator|wears active cranial electrostimulation device for 20 minutes daily for 28 days
89037880|NCT01265797|Sham Comparator|Sham device|wears sham device for 20 minutes daily for 28 days
89037881|NCT00538356|Experimental|Home Monitoring|ICD or CRT-D with Home Monitoring feature activated Home Monitoring data will be analyzed regularly and patients will be contacted and scheduled for additional follow-up after predefined events
89037882|NCT00538356|Active Comparator|Control|ICD or CRT-D with Home Monitoring feature deactivated Patients will be treated as per standard of care in each participating clinic
89037883|NCT01265719||Latanoprost-treatment group|
89037884|NCT01265719||Non-topical prostaglandin analogue treatment group|
89037885|NCT03148496|Experimental|Biologic Mesh and Small Bites|Biologic mesh placement and small bites used for suturing.
89037886|NCT03148496|Experimental|Small Bites and No Biologic Mesh|Small bites used for suturing with no placement of biologic mesh
89037887|NCT03148496|Experimental|Biologic mesh and Large Bites|Biologic mesh placement and large bites used for suturing
89037888|NCT03148496|Active Comparator|Large Bites and no biologic mesh|Large bites used for suturing and no placement of biologic mesh.
89037889|NCT01265563|Placebo Comparator|NAC placebo and Silibin placebo|Drug: N-acetylcysteine placebo and Drug: Silibin placebo
89037890|NCT01265563|Experimental|NAC active and Silibin placebo|Drug: N-acetylcysteine and Drug: Silibin placebo
89037891|NCT01265563|Experimental|NAC placebo and Silibin active|Drug: N-acetylcysteine placebo and Drug: Silibin active
89623209|NCT03320538|Experimental|Hou Gu Mi Xi|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
89623210|NCT03320538|Experimental|Hou Gu Mi Xi + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (once 10 mg, once a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
89037892|NCT01265563|Experimental|NAC active and Silibin active|Drug: N-acetylcysteine active and Drug: Silibin active
89037893|NCT01265563|Experimental|NAC active and High-dose Silibin active|Drug: N-acetylcysteine active and Drug: Silibin higher dose active
89037894|NCT03025139|Active Comparator|Arm A (MAPs)|Patients attend a mindfulness meditation class over 2 hours once weekly for 6 weeks. Patients then attend in person booster sessions that include guided meditation, questions, and discussion of how to maintain a mindfulness practice over 1 hour once monthly for 2 months.
89037895|NCT03025139|Active Comparator|Arm B (SE)|Patients attend a survivorship education class over 2 hours once weekly for 6 weeks. Patients also receive monthly electronic newsletters with tailored information about topics of interest to younger survivors, including cancer-related events in the community and tips about following through on recommendations for healthy living.
89037896|NCT03025139|Active Comparator|Arm C (USUAL CARE/DELAYED TREATMENT CONTROL GROUP)|Patients receive usual care for 9 months. Patients are then offered a choice of participating in Arm A or Arm B.
89037897|NCT00545922|Experimental|A|7 weekly sessions of group cognitive behavioral therapy
89037898|NCT00545922|Active Comparator|B|Minimal Telephone Contact
89037899|NCT01265056|Placebo Comparator|Sugar Pill|Placebo
89037900|NCT01265056|Experimental|Gabapentin|Gabapentin
89037901|NCT05656651|Experimental|Cancer patients|Single exercise intervention following a HIIT protocol, duration ~20 mins
89037902|NCT05656651|Active Comparator|Healthy adults|Single exercise intervention following a HIIT protocol, duration ~20 mins
89037903|NCT02942498|Experimental|Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg|Vitamin C and Vitamin E supplementation 10 mg/kg/ day
89037904|NCT02942498|Placebo Comparator|Placebo|Placebo solution
89037905|NCT00545961|Placebo Comparator|1|placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
89037906|NCT00545961|Active Comparator|2|amoxicillin-clavulanate acid
89037907|NCT02935517|Experimental|Group 1: 4.0 x 10^10 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
89623211|NCT03320538|Placebo Comparator|Placebo + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Placebo of Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (10 mg/d, qd).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
89623212|NCT03320538|Placebo Comparator|Placebo|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive placebo of Hou Gu Mi Xi (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
89623213|NCT03322878|Experimental|Intravenous magnesium group (Group IV)|Group IV (n=30) will receive intravenous (IV) 20 ml magnesium SO4 (50 mg/ kg 10% MgSO4(magnesium sulphate) diluted in normal saline to a total volume of 20 ml(milliliter) ) and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg) .
89623214|NCT03322878|Active Comparator|Caudal magnesium group (Group CA)|Group CA (n=30) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% and 50 mg Magnesium SO4 diluted in normal saline with total volume of 1mL/kg).
89623215|NCT03322878|Placebo Comparator|Placebo group (Group P)|Group P (n=30) ) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg).
89623216|NCT03322800|Experimental|AK0529 100 mg, Pilot|This is an open pilot arm and male subjects enrolled into this arm will be only administered with an oral single dose of 100 mg AK0529. The dose group begins treatment on Day 1.
89623217|NCT03322800|Experimental|AK0529 100 mg|Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.
89623218|NCT03322800|Experimental|AK0529 300 mg, food effect|A 3x3 cross-over study is designed in this group to evaluate the food effect following a standard Chinese meal or a high fat meal in the same subjects, comparing with the PK profile of AK0529 under fasted condition. Subjects will be administered with an oral dose of 300 mg AK0529 or placebo on Day 1 of each cycle.
89623219|NCT03322800|Experimental|AK0529 600 mg|Subjects will be administered with an oral single dose of 600 mg AK0529 or placebo. The dose group begins treatment on Day 1.
89623220|NCT03322800|Experimental|AK0529 300 mg, MAD|Subjects will be administered with the multiple doses of 300 mg AK0529 or placebo on Day 1-7.
89623221|NCT03322800|Other|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose group (except the pilot group). The placebo is administered at the same time (and of the same dosage) as the AK0529 subjects.
89623222|NCT03325998|Experimental|Gait training group|"Gait training with Samsung Hip Assist v1~All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions."
89623223|NCT03325920|Experimental|Sleep bruxism group|25 sleep bruxism subjects wear the DIABRUX for five consecutive nights.
89623224|NCT03325920|Experimental|non-sleep bruxism group|25 non-sleep bruxism subjects wear the DIABRUX for five consecutive nights.
89623225|NCT03320460|Experimental|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ =660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
89623226|NCT03320460|Active Comparator|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
89623227|NCT03325764|Other|sleeve gastrectomy|Assessment before and after sleeve gastrectomy
89623228|NCT02488434|Active Comparator|fertile chip|sperm selection by using fertile chip and conventional methods
89623229|NCT02488434|No Intervention|classical ICSI procedure|unexplained infertile couples who will be undertaken intracytoplasmic sperm injection (ICSI) for fertilisation
89623230|NCT01746784|Experimental|N6022|Subjects randomized to study drug will receive N6022 by intravenous infusion once per day for 7 days
89623231|NCT01746784|Placebo Comparator|Normal saline|Subjects randomized to placebo will receive normal saline administered intravenously using the same volume as the active drug group
89623232|NCT04513678|Experimental|ImmunOncoTool Condition|The ImmunOncoTool condition includes access to the web-based platform, routine monitoring of irAEs every week for twelve weeks and then bi-weekly for an additional eight weeks, and messages to healthcare providers and patients if a reported irAE is deemed severe enough that it warrants provider attention.
89623233|NCT04513678|No Intervention|Control|Participants in the control condition are not assigned an intervention. They receive standard of care.
89623234|NCT00706134|Placebo Comparator|Placebo|
89623235|NCT00706134|Experimental|Aliskiren 75 mg|
89623236|NCT00706134|Experimental|Aliskiren 150 mg|
89623237|NCT00706134|Experimental|Aliskiren 300 mg|
89623238|NCT04471714|Experimental|Control|Control participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
89623239|NCT04471714|Experimental|Spinal Cord Injury|Participants with a spinal cord injury will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other.
89623240|NCT03322644|Experimental|Internet-based CBT intervention|In addition to standard medical care, participants in the Internet-based CBT group will receive access to the Pancreatitis Pain Course and will be asked to complete all online modules over 2 months using their own smartphone or computer. A coach will guide participants through the weekly lessons.
89623241|NCT03322644|No Intervention|Wait list control group|Participants assigned to the Wait list control group will be asked to continue with any recommendations made by their clinic provider and will not be offered any internet-based content until after they complete the 5 month assessments (i.e. Months 5-7).
89623242|NCT05405790||Patients receiving TEVAR|
89623243|NCT05315284|Other|Patients with fresh non-comminuted fracture mid-shaft clavicle|
89623244|NCT02488278|No Intervention|Self-Monitoring of Glucose Blood Measurements|Self-Monitoring of Glucose Blood Measurements using the GlucoMe Glucose Monitoring Device and App
89623245|NCT02488356|Experimental|Litramine|Patented fibre complex from Opuntia ficus-indica (Litramine)
89623246|NCT02488356|Placebo Comparator|Placebo|Inert fillers that is manufactured to look and taste the same as verum
89623247|NCT03325686|Experimental|vitamin D supplement|D
89623248|NCT03325686|Placebo Comparator|control|P
89623249|NCT05315128|Active Comparator|Intralesional methotrexate|Group A 30 patients received intralesional injection of MTX with an insulin syringe into the tumor at a dose ranging between 12.5 mg to 25 mg according to the tumor size every week until complete improvement or for a maximum of 8 sessions.
89623250|NCT05315128|Active Comparator|Intramuscular methotrexate|Group B 30 patients received systemic MTX (SC, or IM) was injected at a dose of 25 mg every week until clearance or for a maximum of 8 sessions.
89623251|NCT03322488|Experimental|Patients with Crohn's Disease|20 patients with Crohn's Disease. Intervention: Fistulodesis
89623252|NCT03322488|Experimental|Patients without IBD|20 patients without underlying Inflammatory Bowel Disease. Intervention: Fistulodesis
89623253|NCT05315050|Experimental|Educational session and Informational Pamphlet|
89623254|NCT05315050|Active Comparator|Informational Pamphlet|
89623255|NCT05314504|Experimental|Test group|Treatment administration to subjects
89623256|NCT05314504|No Intervention|Control group|After primary endpoint evaluation, eligible subjects will receive treatment at Week 12
89623257|NCT03322410|Experimental|Patients|
89623258|NCT05300308||transperitoneal pelvic lymph node dissection for treatment of urogenital cancer|patients planned for transperitoneal pelvic lymph node dissection for treatment of urogenital cancer (including prostate or bladder cancer)
89623259|NCT03325530||Focus Group|
89623260|NCT03320148|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
89623261|NCT03320148|Active Comparator|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, and prescribe medications and/or refer based on their assessment findings and patient preferences.
89623262|NCT03325374||BLB patients|Patients admitted for urgent MRI with possible cauda equina syndrome will be consented for questionnaires and examination.
89623263|NCT03325296|Experimental|LEO 124249 ointment 30 mg/g|Ointment to be applied on the eyebrow twice daily.
89623264|NCT03325296|Placebo Comparator|LEO 124249 ointment vehicle|Ointment to be applied on the eyebrow twice daily.
89623265|NCT01808573|Experimental|neratinib plus capecitabine|neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
89623266|NCT01808573|Active Comparator|lapatinib plus capecitabine|lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
89623267|NCT03322332||NonDM-0|Nondiabetics without significant stenoses (> 50%) in the coronary arteries
89623268|NCT03322332||NonDM-L|Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)
89623269|NCT03322332||NonDM-R|Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
89623270|NCT03322332||NonDM-LR|Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
89623271|NCT03322332||DM-0|Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries
89623272|NCT03322332||DM-L|T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA
89623273|NCT03322332||DM-R|T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
89623274|NCT03322332||DM-LR|T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
89688433|NCT02909140|Experimental|Topical + Intracameral mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
89688434|NCT01723631|Other|Relapsing Multiple Sclerosis- group 1|Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.
89623275|NCT01746940|Placebo Comparator|Group 1, Placebo Topical Solution|Group 1: Placebo group -Placebo solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . All placebo subjects, regardless of Von Frey filament test results, will undergo Phase 1 recovery (i.e. at least 90 minutes after cotton pledget removal) and associated required study procedures (including the final 12 lead ECG). After a minimum of 24 hours from the time of study drug pledget removal, the subject may continue the procedure, and the treatment reverts to standard anesthetic management (suitable products at the discretion of the investigator). Alternatively, at the investigator's discretion, the diagnostic procedure or surgery may be delayed until study termination.
89623276|NCT01746940|Active Comparator|Group 2, Cocaine HCl 4% Topical Solution|Group 2: Cocaine HCI 4% Group - Cocaine HCl 4% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total amount of Cocaine HCl 4% topical solution used will be recorded.
89623277|NCT01746940|Active Comparator|Group 3, Cocaine HCl 10% Topical Solution|Group 3: Cocaine HCI 10% Group - Cocaine HCl 10% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total amount of Cocaine HCl 10% topical solution used will be recorded.
89623278|NCT03325218||Questionnaire Set A|
89623279|NCT03325218||Questionnaire Set B|
89623280|NCT01747330|Experimental|Creon micro, minimicrospheres|
89623281|NCT03319992|No Intervention|Conventional treatment|The conventional treatment arm was conducted according to a set of exercises that were specifically designed in order to match the robotic treatment. Patients received both physical therapy (PT) and occupational therapy (OT) session, administered by the physiotherapists of the hospital. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals.
89623282|NCT03319992|Experimental|Robotic treatment|The patients enrolled in the robotic arm are going to be undergone a series of passive, assisted and active mobilization in upper limb task-oriented exercises implemented in 3d virtual environments. Briefly speaking, these tasks promote the upper arm multi-joints coordination during the execution of reaching movements and grasping actions of fixed virtual objects displaced in the space.
89623283|NCT04493580|Experimental|iDBT Treatments|15 weekly DBT sessions. During each session, participants will be sent 30-40 PowerPoint slides including general information on particular topic, overview of skills, and homework sheets to be completed and returned to therapists. Therapists involved will be a psychiatry resident, a psychologist, and a registered nurse who will also facilitate the in-person groups. The content and format of the online program will directly corresponded with that of the in-person group. Participants will be asked to send their homework sheets back to therapists by a specific day each week. The following day, the therapist will email feedback regarding the homework submitted and send next week's PowerPoint slides, information sheets, and homework. In order to be eligible to receive the materials, participants are required to send in homework prior to deadline. If homework was not returned, reminder email will be sent. If more than two sessions are missed, participants are excluded from the program.
89623284|NCT04493580|Active Comparator|In-Person DBT Treatments|Weekly skills-building groups titled Managing Powerful Emotions (MPE) includes Mindfulness, Distress Tolerance, Emotion Regulation, and Interpersonal Effectiveness. Personality Disorders Service offers more advanced therapy groups for individuals who have successfully completed MPE and wish to continue seeking treatment modalities. Chrysalis Day Treatment Program (CDTP) is for an individual who has progress through two prior phases. In phase one, individuals will participate in a DBT-informed skill-building group (MPE). Once completed, the individual will progress to phase two which includes attending a psychotherapy group, incorporating DBT skills-building. Finally, in phase three, individuals who wish to participate in a more advanced and complex psychological treatment program, apply to participate in CDTP. The CDTP is an intensive day treatment program integrating DBT skills-building, psychodynamic psychotherapy, and a range of other group therapy modalities.
89623285|NCT04769128|Active Comparator|Group (A) (control group)(traditional physical therapy programme)|Group (A) (control group): Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training. 3 sessions/ week for 12 weeks.
89688435|NCT01723631|Other|Relapsing Multiple Sclerosis- group 2|Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.
89688436|NCT01723631|Other|secondary progressive multiple sclerosis- Group 3|Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis
88989324|NCT05708443|Active Comparator|lower limbs (LL) group|These patients will participate in a pulmonary rehabilitation program (usual training) on lower limbs
88989325|NCT05708443|Experimental|lower plus upper limbs (L+UL) group|These patients will attend a rehabilitation program combining upper and lower extremity training
89037908|NCT02935517|Experimental|Group 2: 1.2 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
89037909|NCT02935517|Experimental|Group 3: 3.6 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
89037910|NCT02935517|Experimental|Group 3a: 3.6 x 10^11 vg/mL of AGTC-402|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
89037911|NCT02935517|Experimental|Group 4: 1.1 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
89037912|NCT02935517|Experimental|Group 4a: 1.1 x 10^12 vg/mL of AGTC-402|Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
89037913|NCT02935517|Experimental|Group 5: 3.2 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
89037914|NCT02935517|Experimental|Group 6: MTD of AGTC-402|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGA3 study drug determined by Groups 1-5.
89037915|NCT01264939|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
89037916|NCT01264939|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
89037917|NCT00538668|Experimental|1|20 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
89037918|NCT00538668|Experimental|2|25 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
89037919|NCT00538668|Experimental|3|30 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
89623286|NCT04769128|Experimental|Group (B) (experimental or manipulative group)|"Fifteen patients with CRPS I received traditional physical therapy program in the form of transcutaneous electrical neuromuscular stimulation (TENS), mirror therapy, and exercises for upper limb exercises in the form of gradual weight-bearing exercises by using different equipment such as balls, balloons, or silk-like cloths, combined with different positions of the patient (i.e. lying, sitting, or standing), range of motion exercises (active and self-Assisted), resisting exercises (manual and mechanical), stretching exercises (manual and self-stretching) and fine motor control training in addition to T3-T4 thoracic manipulation (Maitland screw technique grade V) 3 sessions/ week for 12 weeks."
89623287|NCT03319914||ST-003 Observational|Calciphylaxis patients who participated in the ST-001 CALISTA
89623288|NCT05253274|Experimental|Virtual Reality application group|VR application will be applied to the experimental group during the emergency surgical intervention under local anesthesia.
89623289|NCT05253274|No Intervention|Control|The patients in the control group routinely receives standard care in the emergency service. No application will be made to the control group.
89623290|NCT04442958|Experimental|Convalescent Plasma Therapy Group|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
89623291|NCT04442958|No Intervention|Non-Plasma Therapy Group|Standart critical care treatment group
89623292|NCT02990962|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (5cc) between carpal tunnel and median nerve.
89623293|NCT02990962|Active Comparator|Perineural injection with steroid|Ultrasound-guided perineural injection with 1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and median nerve.
89623294|NCT04443114|Other|Early Arm|The early arm will receive the experimental organ donation workshop first, followed by the control workshop on end-of-life care.
89623295|NCT04443114|Other|Late Arm|The late arm will receive the control workshop on end-of-life care first, followed by the experimental organ donation workshop.
89623296|NCT02246530|Active Comparator|PRP injection into PTRCT|Treatment - PRP injection
89037920|NCT00538668|Experimental|4|35 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
89037921|NCT00538668|Experimental|5|40 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
89037922|NCT00538668|Experimental|6|45 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
89623297|NCT02246530|Active Comparator|Subacromial steroid bursal injection|Current standard of care for treatment of resistant partial thickness rotator cuff tears
89623298|NCT03319836||Pre-very high protein enteral nutrition|20 enterally fed critically ill adult patients prior to the introduction of a very high protein enteral nutrition formula [2015].
89623299|NCT03319836||Post-very high protein enteral nutrition|20 enterally fed critically ill adult patients post the introduction of a very high protein enteral nutrition formula [2016].
89623300|NCT03319758|Experimental|thin or dehiscences buccal plate|Immediate implant placement used bone augmentation in combination with an absorbable collagen membrane with thin or dehiscences buccal plate.
89623301|NCT03322098|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
89623302|NCT03322098|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
89623303|NCT04400578|Experimental|TRICIN|"If a patient is eligible~local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application~Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application~Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application"
89037923|NCT00538668|Experimental|7|50 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
89037924|NCT00538668|Experimental|8|55 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
89037925|NCT00538668|Experimental|9|25 mCi/m2 of 177Lu-J591 will be given every 2 weeks.
89037926|NCT02889367|Experimental|Treatment A|Participants will receive odalasvir 100 milligram (mg) or odalasvir matching placebo once on Day 1.
89037927|NCT02889367|Experimental|Treatment B|Participants will receive odalasvir 500 mg or odalasvir matching placebo once on Day 1.
89037928|NCT02889367|Experimental|Treatment C|Participants will receive odalasvir (dose to be determined based on pharmacokinetic data from treatment A and B but no more than 1000 mg) or odalasvir matching placebo once on Day 1.
89037929|NCT02922647|Experimental|suprapubic catheterization|Intervention:suprapubic catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
89037930|NCT02922647|Active Comparator|transurethral catheterization|Intervention:transurethral catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
89037931|NCT00546039|Active Comparator|1|
89037932|NCT00546039|Placebo Comparator|2|
89623304|NCT03319680|Active Comparator|Citrate dialysate|Hemodialysis with citrate dialysate during 16 weeks
89623305|NCT03319680|No Intervention|Acetate dialysate|Hemodialysis with acetate dialysate during 16 weeks
89623306|NCT03322020|Experimental|CK 18 Gy|Patients who receive Cyberknife boost dose of 18 Gy in 3 fractions
89623307|NCT03322020|Experimental|CK 21 Gy|Patients who receive Cyberknife boost dose of 21 Gy in 3 fractions
89623308|NCT01808339|Experimental|FF AM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the morning (approximately 09:00) and placebo in the evening (approximately 21:00) for 14 days (+/- 2 days).
89623309|NCT01808339|Experimental|FF PM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the evening (approximately 21:00) and placebo in the morning (approximately 09:00) for 14 days (+/-2 days).
89623310|NCT01808339|Placebo Comparator|Placebo|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects in this arm will receive Placebo in the evening and morning (at approximately 09:00 and 21:00) for 14 days (+/- 2 days).
89623311|NCT03316404||Cohort 1|Cohort 1 of the study will collect blood samples from participants in various states of the disease. After qualification and informed consent, accepted participants will be sent a blood collection kit and will be asked to complete a study-related questionnaire.
89623312|NCT03316404||Cohort 2|Cohort 2 may be conducted at selected clinical sites where MS treatment-naïve patients who are entering a new treatment paradigm will be sought. At the clinical site, patients will be qualified, consented, and a small amount (up to 1mL) of blood will be collected. Between approximately 1 week and 6 months of treatment on the new drug, the participant will be sent another blood collection kit for microsample collection and a brief questionnaire at home. A final sample will be collected between 3 and 6 months after the start of treatment. Within 6 months of initiating treatment, the site will be asked to provide information regarding the health and treatment status of the participant.
89623313|NCT01749904|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
89623314|NCT01749904|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
89623315|NCT02484846|Experimental|60% TIB|Participants were to spend 60% of their normal time in bed on the night prior to the second visit.
89623316|NCT02484846|Experimental|70% TIB|Participants were to spend 70% of their normal time in bed on the night prior to the second visit.
89623317|NCT02484846|Experimental|80% TIB|Participants were to spend 80% of their normal time in bed on the night prior to the second visit.
89623318|NCT02484846|Experimental|90% TIB|Participants were to spend 90% of their normal time in bed on the night prior to the second visit.
89623319|NCT02484846|Active Comparator|100% TIB|Participants were to spend 100% of their normal time in bed (i.e., no change) on the night prior to the second visit.
89623320|NCT02484846|Experimental|115% TIB|Participants were to spend 115% of their normal time in bed on the night prior to the second visit.
89623321|NCT02484846|Experimental|130% TIB|Participants were to spend 130% of their normal time in bed on the night prior to the second visit.
89623322|NCT04585139|Other|Phase 1 -- Introduction to Dexcom G6 CGM|A 2 week run-in wear period of blinded CGM followed by 12 weeks of wear of a Commercially available CGM
89623323|NCT04585139|Active Comparator|Phase 2 -- Comparison of an Updated G6 Transmitter to Commercial Dexcom G6 CGM|1 group will wear a Commercially available CGM for 12 weeks while the 2 group will wear an Updated CGM for 12 weeks.
89623324|NCT02488044|Experimental|AEB1102|"AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.~Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy."
89623325|NCT04311268|Experimental|Observational|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
89623326|NCT02484768|Experimental|Group A|Infusion of 1000 mg iron isomaltoside 1000 at baseline. The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min
89623327|NCT02484768|Placebo Comparator|Group B|Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min
89623328|NCT05190874||Device: Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler Interference Screw System
89623329|NCT02488122|Experimental|High Impact Exercise|weight bearing exercises, jumps, plyometric exercises
89623330|NCT02488122|Sham Comparator|Low Impact Exercise|Walking, Strength training, Cycling, Yoga.
89623331|NCT02240134|Experimental|Education Intervention (Tx1)|The education components for this intervention are based on recent observations and recommendations from tribal, local, state and federal agencies. The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
89623332|NCT02240134|Active Comparator|Air Filtration Unit Treatment (Tx2)|"Within each randomly assigned home, a 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove."
89623333|NCT02240134|Sham Comparator|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
88989326|NCT05707715||Slight Forward Head Posture|This descriptive cross-sectional study which was approved by Çankırı Karatekin University Ethics Committee (Approval number:). There is FHP if the imaginary line between the tragus of the ear and the middle of the shoulder is not on the same line when viewed from the side. And the horizontal length between that two vertical lines indicates the severity of FHP. The level of FHP is classified as slight/severe/highly FHP according to that horizontal length. The slight FHP is accepted as between 0-2.5cm, and severe FHP above 2.5cm (27).
89037933|NCT02916719|Experimental|Neo-adjuvant radiotherapy|Group of women having undergone a neo-adjuvant radiotherapy for early breast cancer.
89037934|NCT01264081|Experimental|Lapatinib|Lapatinib will be administered as an oral dose of 500 mg twice daily in the morning and evening one hour before or after meals.
89037935|NCT00538707|Experimental|Young subjects|
89037936|NCT00538707|Experimental|Older subjects|
89037937|NCT00538746|Experimental|1|BIPAP (Bilevel Positive Airway Pressure) targeted on: TV 6-8 ml/kg, total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92% (with spontaneous RR between 20-40%)
89037938|NCT00538746|Experimental|2|PSV (pressure support ventilation) targeted on: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated.
89037939|NCT00538746|Experimental|3|PSV+CPAP (continuous positive airway pressure) targeted on: PSV: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated, CPAP (5-10 cmH2O) at least 2 hours a day. If during the CPAP periods at least 1 of the criteria T tube test failure occurs, the patients will come back immediately to PSV.
89037940|NCT05042778|Experimental|Auriculotherapy|Indwelling fixed semipermanent needles embedded in a skin-colored adhesive tape will be used in active points around the vagus nerve stimulation area.
89623334|NCT03319602|Active Comparator|Oxygenation only with nasal canula|intervention: classical oxygenation with nasal canula (High flow)
89623335|NCT03319602|Experimental|Oxygenation with double trunk masknasal canula|oxygenationwith DTM above nasal canula
89623336|NCT02484612|Experimental|Lean adolescents|15 lean adolescents (BMI Under the national cut-offs for obesity), 12-15 years old, males, will be recruited
89623337|NCT02484612|Experimental|Obese adolescents|15 obese adolescents (BMI above the national cut-offs for obesity), 12-15 years old, males, will be recruited
89623338|NCT03316326|Experimental|SIROX|Tegafur-gimeracil-oteracil potassium, irinotecan, oxaliplatin combination
89623339|NCT01751230|Experimental|WIC E-Moms|If picked for this group, you will receive a personalized diet and exercise plan to help you lose the weight you gained during your pregnancy. All information will be given to you using a SmartPhone, such as an iPhone. You can use your own phone or one can be loaned to you for the study. You will also be loaned a scale so you can weigh yourself at home. You will also get advice and services from your WIC clinic.
89623340|NCT01751230|No Intervention|WIC Moms|You will get advice and services for nutrition and weight management after pregnancy from your WIC clinic.
89623341|NCT03321942|Active Comparator|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.
89623342|NCT03321942|Placebo Comparator|Control group|Treatment of chronic renal failure patients with conventional methods.
89623343|NCT05164432|Experimental|High risk of preterm birth|Women at high risk of preterm birth
89623344|NCT05164432|Active Comparator|Women with low risk pregnancies|Women with uncomplicated pregnancies anticipated to deliver at term
89623345|NCT02487732|Active Comparator|Ticagrelor|180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
89623346|NCT02487732|Active Comparator|Prasugrel|60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor
89623347|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Naive)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
89623348|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Naive)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
89623349|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Failure)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
89623350|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Failure)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
89037941|NCT05042778|No Intervention|No intervention|No auriculotherapy will be applied.
89037942|NCT02711969|Experimental|Apatinib mesylate|
89037943|NCT00538941|Active Comparator|1|daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.
89037944|NCT00538941|Placebo Comparator|2|Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.
89037945|NCT01263925|Experimental|Alprostadil|Alprostadil (Prostaglandin E1) intravenous and matching Placebo to Pentoxifylline oral
89037946|NCT01263925|Active Comparator|Pentoxifylline|Pentoxifylline oral and matching Placebo to Alprostadil (Prostaglandin E1) intravenous
89533328|NCT04941274|Experimental|2/Dose Expansion: Group 2b|Abemaciclib (at optimal dose determined in dose escalation portion of the study) for up to 10 previously untreated participants.
89533329|NCT04932512|Experimental|ION224|Multiple doses of ION224 will be administered by SC injection once every 4 weeks for up to 49 weeks.
89533330|NCT04932512|Placebo Comparator|Placebo|Multiple doses of matching placebo will be administered by SC injection once every 4 weeks for up to 49 weeks.
89533331|NCT04931563|Placebo Comparator|placebo|Placebo will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
89533332|NCT04931563|Active Comparator|anifrolumab|Anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
89533333|NCT04928846|Experimental|Telisotuzumab Vedotin|Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
89533334|NCT04928846|Active Comparator|Docetaxel|Participants will receive docetaxel every 3 weeks until meeting study drug discontinuation criteria.
89533335|NCT04923997|Experimental|Health Coaching|All participants will be in the health coaching group. Participants on study will receive a health coach for 6 months.
89533336|NCT04923178||1 / Urothelial cancer|Participants with urothelial cancer.
89533337|NCT04923178||2 / Rare Bladder or Urinary Tract Histology|Participants with small cell carcinoma, adenocarcinoma, urachal squamous cell carcinoma, or pure sarcomatoid carcinoma. These pure histologies can occur in the bladder and/or urinary tract.
89533338|NCT04923178||3 / Urothelial Carcinoma Variants|Participants diagnosed with a urothelial variant histologies at any stage.
89533339|NCT04923178||4 / Rare GU Tumors|Participants with renal medullary carcinoma, testicular Sertoli or Leydig cell tumors, penile cancer, refractory germ cell tumors.
89533340|NCT04917042|Experimental|tazemetostat|
89533341|NCT04915183|Other|1|randomization to either placebo or atorvastin
89533342|NCT04915183|No Intervention|2|observational
89533343|NCT04910503|Active Comparator|Usual strategy|
89533344|NCT04910503|Experimental|Innovative strategy|
89533345|NCT04909229|Experimental|PEAR-003b PDT Intervention|Participants will receive the PEAR-003b digital therapeutic, a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
89533346|NCT04909229|Placebo Comparator|Control Arm|Participants will receive a Fitbit, and materials on sleep hygiene and healthy sleep tips. Using the Hugo platform, patient-generated engagement data, healthcare utilization, and patient activity/clinical outcomes for patients with insomnia will also be collected.
89533347|NCT04892264|Experimental|Arm A (belantamab mafodotin, lenalidomide, daratumumab)|"INDUCTION: Patients receive belantamab mafodotin IV over 30 minutes on day 1 of odd number cycles, lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on days 1, 8, 15, and 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 13, patients receive belantamab mafodotin IV over 30 minutes on day 1 of odd number cycles (starting cycle 13), lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
89533348|NCT04892264|Experimental|Arm B (belantamab mafodotin, lenalidomide, daratumumab, Dxevo)|"INDUCTION: Patients receive belantamab mafodotin IV over 30 minutes on day 1 of cycles 2, 4, 6, 8, 10, and 12, lenalidomide PO QD on days 1-21, daratumumab IV over 90 minutes on days 1, 8, 15, and 22 of cycles 1 and 3, and days 1 and 15 on cycles 5, 7, 9, and 11. Patients also receive dexamethasone PO on days 1, 8, 15 and 22. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 13, patients receive belantamab mafodotin IV over 30 minutes on day 1 of even numbered cycles, lenalidomide PO QD on days 1-21, and daratumumab IV over 90 minutes on day 1 of odd numbered cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
89533349|NCT04890093|Experimental|1/Dose Escalation|Dose escalation of PEN-866 along with fixed doses of vincristine and temozolomide
89533350|NCT04890093|Experimental|2/MTD/RP2D|PEN-866 at the MTD or RP2D from phase 1 plus vincristine and temozolomide
89533351|NCT04888923||Healthy Controls|General public population, including females and males, who are over the age of 18, with a mixture of races and ethnicities representative of North Carolina.
89533352|NCT04885231|Experimental|Opioid-Limiting Perioperative Pain Management Education and Counseling|"Patients will be instructed to take oxycodone only as a last resort if the pain becomes unbearable. The goal should be to take as little oxycodone as possible."
89533353|NCT04885231|Active Comparator|Traditional Perioperative Pain Management Education and Counseling|"Patients will be instructed to take opioids as needed for severe pain to manage and stay ahead of the postoperative pain"
89533354|NCT04884815|Experimental|Stage 1: UX701 Dose Level 1|Participants receive a single, peripheral intravenous (IV) infusion of UX701 at dose level 1.
89533355|NCT04884815|Experimental|Stage 1: UX701 Dose Level 2|Participants receive a single, peripheral IV infusion of UX701 at dose level 2.
89533356|NCT04884815|Experimental|Stage 1: UX701 Dose Level 3|Participants receive a single, peripheral IV infusion of UX701 at dose level 3.
89533357|NCT04884815|Experimental|Stage 2: UX701 or Placebo|Participants randomized 2:1 to receive UX701 or Placebo. Participants randomized to UX701 receive a single, peripheral IV infusion of UX701 at a dose selected in Stage 1. Participants randomized to placebo will receive a single, peripheral IV infusion of normal saline (placebo).
89533358|NCT04884815|Experimental|Stage 3: Placebo or UX701|Participants randomized in Stage 2 to UX701 will receive a single, peripheral IV infusion of normal saline (placebo). Participants randomized in Stage 2 to placebo will be eligible for a single, peripheral IV infusion of UX701 at the selected dose.
89533359|NCT04877288|Experimental|Arm 1: Conversion from a CNI- to belatacept-based regimen after a period of overlap|Conversion followed by tapering and discontinuation of the calcineurin inhibitor (CNI)
89533360|NCT04877288|Active Comparator|Arm 2: Continue calcineurin inhibitor-based regimen|
89623351|NCT03321864|Experimental|Study arm|All patients recruited to the study (this arm) will have an additional transrectal ultrasound whilst already under GA for TP biopsy.
89623352|NCT05463588|Experimental|Collection of pre-test data from the experimental and control groups|Asking vas, ODI, sf-36 quality of life scale questions
88989327|NCT05707715||Severe Forward Head Posture|This descriptive cross-sectional study which was approved by Çankırı Karatekin University Ethics Committee (Approval number:). There is FHP if the imaginary line between the tragus of the ear and the middle of the shoulder is not on the same line when viewed from the side. And the horizontal length between that two vertical lines indicates the severity of FHP. The level of FHP is classified as slight/severe/highly FHP according to that horizontal length. The slight FHP is accepted as between 0-2.5cm, and severe FHP above 2.5cm (27).
88989328|NCT05707390|Experimental|Mild hepatic impairment|
88989329|NCT05707390|Experimental|Moderate hepatic impairment|
88989330|NCT05707390|Experimental|Severe hepatic impairment|
88989331|NCT05707390|Experimental|Healthy participants|
88989332|NCT05704582|Experimental|Avatar Intervention|The Avatar Intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars.
88989333|NCT05704582|Active Comparator|Addiction supportive intervention|The Addiction supportive intervention will take place over 8 consecutive weeks, with one session per week. Additional sessions (up to a maximum of 4 sessions) will be offered if needed. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use.
88989334|NCT05703659|Experimental|HMO consuming bacteria|Infants will given a daily HMO consuming probiotic (B. infantis) for four weeks
88989335|NCT05703659|Experimental|Non-HMO consuming bacteria|Infants will be given a daily non-HMO consuming probiotic (L. reuteri) for four weeks
88989336|NCT05701748|Experimental|EEG SEF values in response to stimuli|EEG SEF values that correspond to the three stimuli being applied
88989337|NCT05697458||Kidney transplant recipients|"In kidney transplant recipients the investigators will perform pretransplant computerized tomography for assessment of iliac arteries calcifications.~From their blood, the bone remodeling biomarkers will be determined in the perioperative period.~The one year patient and graft survival will be determined for included patients."
88989338|NCT05692947|Experimental|Hot/Dry|Core body temperature, skin temperature, heart rate, and heat perceptions will be collected from elite athletes while running or cycling for 45 minutes in the heat at low humidity (38 degrees Celsius with 10-20% relative humidity).
89623353|NCT05463588|Experimental|Calculation of the pre-test fall risk index|Calculation of patients' fall risk indices
88989339|NCT05692947|Experimental|Hot/Humid|Core body temperature, skin temperature, heart rate, and heat perceptions will be collected from elite athletes while running or cycling for 45 minutes in the heat at high humidity (28 degrees Celsius with 80-100% relative humidity).
88989340|NCT05692011||blood purification(AN69ST)|
88989341|NCT05692011||blood purification(PS)|
88989342|NCT05689359|Experimental|Addition of Hydroxychloroquine to paclitaxel|Hydroxychloroquine will be added to chemotherapy in patients with early stage (1-3) breast cancer and gynecological cancers.
88989343|NCT05683106|Experimental|Intervention Group|The participants will receive a custom silicone digital orthosis (CSDO) to realign the toes according to their needs. They will be instructed to use the CSDO throughout the day, remove it to sleep and reposition it on the foot the next day. Furthermore they will be assisted by a stomatherapy specialist, dermatology or clinical podiatry nurse and will receive foot care for thinning the calluses, referral (if necessary) to the Specialized Rehabilitation Center - CER, health equipment linked to SUS, for the purchase of insoles and/ or molded footwear (when indicated) and guidance on the use of therapeutic footwear.
88989344|NCT05683106|No Intervention|Control Group|The participants will be assisted by the stomatherapy specialist, dermatology or clinical podiatry nurse and will receive foot care for thinning the calluses, referral (if necessary) to the Specialized Rehabilitation Center - CER, health equipment linked to SUS, for the purchase of insoles and/ or molded footwear (when indicated) and guidance on the use of therapeutic footwear.
88989345|NCT05679596|Experimental|Exogenous ketone monoester (KET)|KET will be provided at a dose of 360 mg kg-1 body mass per serving at 2 servings per day between each main meal (ΔG®; TΔS Ltd, UK, Oxford, UK).
88989346|NCT05679596|Active Comparator|Energy matched control (CON)|CON will be provided at a dose energy matched to the KET supplement and consist of both carbohydrate (i.e., fructose) and fat (i.e., corn and canola oil 50:50 ratio). 1/3 of the supplemental energy will come from carbohydrate while 2/3 will come from fat. We have excluded protein from the CON supplement since it is well established to influence our primary outcome measure (MPS rates). A non-caloric sweetener will also be added to the CON supplement.
88989347|NCT05678270|Experimental|ICP-192|
88989348|NCT05677217||nab-paclitaxel plus gemcitabine-cisplatin|gemcitabine, 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 100 mg/m2, on days 1 and 8 of 21-day cycles
88989349|NCT05673551|Experimental|Intervention Group|Participants will be using the VR-PAT during burn dressings.
88989350|NCT05673551|No Intervention|Control Group|Participants will not be using the VR-PAT during burn dressings (other distraction methods available in the home allowed).
88989351|NCT05673070|Experimental|Ritual Epre|This group will receive 2 Ritual Epre multivitamin-mineral supplement pills daily.
88989352|NCT05673070|Active Comparator|Control MVI|For the prenatal arm, this group will receive a control multivitamin-mineral supplement pill and a 200 mg docosahexaenoic acid (DHA) pill that are commercially available.
89057356|NCT04540601|Active Comparator|Cancer patients, randomized A|Patients in high-dose antiresorptives with bone metastases
89623354|NCT05463588|Experimental|giving back health education to the experimental and control groups|Back health training was given to both groups, and the experimental group was given training on using virtual glasses.
89623355|NCT05463588|Experimental|collection of post-test data for the experimental and control group|Asking vas, ODI, sf-36 quality of life scale questions
89623356|NCT05463588|Experimental|Calculation of the post-test fall risk index|Calculation of patients' fall risk indices
89037947|NCT04323631|Experimental|The intervention group|The intervention group will receive oral hydroxychloroquine. In the first day 400 mg twice daily, followed by 200mg twice daily on days 2-10 (continued after discharge if discharged before day 10).
89037948|NCT04323631|Other|The control group|The control group will not receive hydroxychloroquine.
89037949|NCT00546234|Active Comparator|1|
89037950|NCT00546234|Active Comparator|2|
89037951|NCT03455348|No Intervention|cathete to less than 4 four centimeters to the wrist joint|
89037952|NCT03455348|Active Comparator|catheter to more than four centimeters to the wrist joint|
89623357|NCT03316248|Experimental|visual feedback|participants in the experimental group were applied usual prosthetic rehabilitation with visual feedback methods. 9 sessions for three days were applied.
89623358|NCT03316248|Active Comparator|Usual prosthetic rehabilitation|participants in the control group were applied usual prosthetic rehabilitation. 9 sessions for three days were applied.
89623359|NCT02487888|Experimental|Pain|Patients presenting to a clinic for pain, that will be either blinded to genetic testing results or unblinded to genetic testing results
89623360|NCT02487888|Experimental|Mental Health|Patients presenting to a clinic for mental health disorders, that will be either blinded to genetic testing results or unblinded to genetic testing results
89037953|NCT00539019||A, observed|measure REE via indirect calorimetry at various time points post burn
89037954|NCT00539097|Experimental|A, treated|treated with Juven po supplement x 3 weeks postop
89037955|NCT00539097|No Intervention|B, control|Usual nutrition therapy received postop
89037956|NCT02664506|Experimental|Word repetition after a tiem delay|People with Aphasia and Short-Term Memory impairment will receive a behavioral treatment: Word repetition after a time delay. This is the intervention: repetition of words after a 5 or 10 second delay.
89037957|NCT05042037|Active Comparator|Double-blind, placebo-controlled interventional study|Active treatment group will receive a 3-gram sachet of probiotics containing multi-strain of lactobacillus and Bifidobacterium 30 Colony Forming Unit x 109 to be taken twice daily for 12 weeks.
89623361|NCT02487888|Experimental|Cardiovascular|Patients presenting to a clinic for cardiovascular complications, that will be either blinded to genetic testing results or unblinded to genetic testing results
89623362|NCT02487888|Experimental|Arthritis|Patients presenting to a clinic for osteoarthritis or rheumatoid arthritis, that will be either blinded to genetic testing results or unblinded to genetic testing results
89623363|NCT02487888|Experimental|Type 2 Diabetes Mellitus|Patients presenting to a clinic for T2DM, that will be either blinded to genetic testing results or unblinded to genetic testing results
89623364|NCT02490774|Experimental|Arm 1: BAY1007626, low relase|Intrauterine device with a low in vitro release rate
89623365|NCT02490774|Experimental|Arm 2: BAY1007626, low to medium release|Intrauterine device with a low to medium in vitro release rate
89037958|NCT05042037|Placebo Comparator|Placebo|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 12 weeks.
89037959|NCT02664038|Experimental|CRT+IDC|Cognitive Remediation Therapy for 13 weeks plus Individual Drug Counseling
89037960|NCT02664038|Active Comparator|Computer Game Play+IDC|Computer arcade games for 13 weeks plus Individual Drug Counseling
89037961|NCT02623439|Experimental|cyclophosphamide post BMT|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
89037962|NCT02599922|Experimental|Group 1: 2.0 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 2.0 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
89037963|NCT02599922|Experimental|Group 2: 4.0 x 10^10 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
89037964|NCT02599922|Experimental|Group 3: 1.2 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
89037965|NCT02599922|Experimental|Group 4: 3.6 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
89037966|NCT02599922|Experimental|Group 4a: 3.6 x 10^11 vg/mL of AGTC-401|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
89037967|NCT02599922|Experimental|Group 5: 1.1 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
89037968|NCT02599922|Experimental|Group 5a: 1.1 x 10^12 vg/mL of AGTC-401|Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
89623366|NCT02490774|Experimental|Arm 3: BAY1007626, medium release|Intrauterine device with a medium in vitro release rate
89623367|NCT02490774|Experimental|Arm 4: BAY 1007626, high release|Intrauterine device with a high in vitro release rate
89623368|NCT02490774|Active Comparator|Arm 5: Levonorgestrel, Jaydess|Intrauterine device releasing levonorgestrel (Jaydess)
89623369|NCT02490774|Active Comparator|Arm 6: Levonorgestrel, Mirena|Intrauterine device releasing levonorgestrel (Mirena)
89623370|NCT02490852|Experimental|Investigational Infant formula|Healthy term infants fed exclusively the investigational Infant Formula
89623371|NCT02490852|Active Comparator|Commercially available Infant formula|Healthy term infants fed exclusively a commercially available Infant Formula
89623372|NCT02490852|Active Comparator|Human milk|Healthy term infants fed exclusively human milk
89623373|NCT03316014||Adverse drug reaction|Children from 0 to 17 years inclusive with ADR notifications recorded in the French pharmaco-vigilance database by the Regional Pharmacovigilance Center of Champagne-Ardenne between 1 January 1985 and 31 December 2014
89037969|NCT02599922|Experimental|Group 6: 3.2 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
89037970|NCT02599922|Experimental|Group 7: MTD of AGTC-401|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGB3 study drug determined by Groups 1-6.
89037971|NCT00539175|Active Comparator|2|active treatment with infrared light
89037972|NCT00539175|Placebo Comparator|1|sham (placebo) treatment without infrared light
89057357|NCT04540601|No Intervention|Cancer patients, randomized B|Drug Holiday as standard operation procedure
89623374|NCT02487654|Active Comparator|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
89623375|NCT02487654|Experimental|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
89623376|NCT02484144||patients receive usual information|Patients receive usual information before Scheduled Coronarography
89623377|NCT02484144||patients receive modern information|Patients receive usual information and a information by video before Scheduled Coronarography
89623378|NCT02490540|Experimental|Anesthesiologist quided analgesia|Sufentanil anesthesiologist analgesia is based on anesthesiologist decision.
89623379|NCT02490540|Experimental|ANI guided analgesia|Sufentanil ANI analgesia based on ANI analgesia monitor figures.
89623380|NCT02490540|Experimental|SPI guided analgesia|Sufentanil SPI analgesia is based on the SPI analgesia monitor figures.
89623381|NCT02490462|Experimental|Education + Conventional PhysicalTherapy|Parents of children with cerebral palsy receive instructions for active inclusion of children in everyday activities. The education program for parents will take place once a week for twelve weeks. Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
88989353|NCT05671991|Experimental|Empagliflozin or Placebo in Acute|Acute phase: Participants will receive 25 mg empagliflozin once on Day 0 or Day 7. Participants receive empaglifozin or placebo on Day 0. On Day 7, they will be crossed over to the alternate treatment.
88989354|NCT05671991|Active Comparator|Empagliflozin in Chronic|Chronic phase: On day 8, all participants will receive 10 mg empagliflozin 10 mg x 8 weeks
88989355|NCT05663788|Experimental|E-learning module gastroenterologists|Gastroenterologists participating in the e-learning module
88989356|NCT05663788|No Intervention|Control group|Gastroenterologists not participating in the e-learning module
88989357|NCT05663346|Experimental|Cannabis & Cancer digital educational intervention|This intervention includes different asynchronous pedagogical modalities that allow, among other things, to reactivate the participants' previous knowledge and promote their autonomy in their learning process. These modalities focus on various problems that oncology nurses may encounter about the use of cannabis in oncology (eg, how to tackle the subject, what are the correct times to approach the topic). To this end, various pedagogical modalities that encourage the active participation of nurses are integrated into the training (eg, interactive videos, and quizzes). Scientific articles and links to external resources (official public websites) are also included so that nurses can consult the content at their own pace. Different aspects related to the use of cannabis are addressed in the training (eg, beneficial effects, and potential side effects).
88989358|NCT05663346|Active Comparator|Standard information regarding cannabis use in oncology|The comparator is composed of an email with basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
88989359|NCT05662605|Experimental|W-PPMA|Participants randomized to this arm will have access to the W-PPMA mobile app throughout the 16-week study. Participants are asked to use the app for at least 5 minutes a day during the treatment phase (first 8 weeks) and then as often as they like during the follow-up phase (last 8 weeks) of the study.
88989360|NCT05662605|No Intervention|Waitlist|Participants assigned to this group will not have access to the W-PPMA mobile app during the treatment phase (first 8 weeks) of the study. They will have access during the follow-up phase (last 8 weeks) of the study and will be instructed to use the app for at least 5 minutes a day.
88989361|NCT05660083|Experimental|iNOS inhibitor and nab-paclitaxel in combination with alpelisib.|iNOS inhibitor and nab-paclitaxel in combination with alpelisib in patients with HER2 negative, metastatic or locally advanced MpBC.
88989362|NCT05659147|Experimental|Imaging markers of exocrine and endocrine insufficiency|"We will prospectively enroll 85 participants; 40 with known or suspected EPI and 45 controls (no known organic gastrointestinal pathology and no history of pancreatic disease) in this aim.~Participants will be undergoing clinically-indicated endoscopy and will have endoscopic pancreatic function tests (ePFTs) collected for research during the clinically-indicated endoscopy examination. A research blood draw and a research stool collection will also be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin within 2 weeks of their clinical endoscopy but no sooner than 2 hours before or after endoscopy."
88989363|NCT05659147|Experimental|Imaging markers of diabetes and prediction of progression to diabetes|"We will prospectively enroll 30 participants; 10 with a single episode of acute pancreatitis, 10 with acute recurrent pancreatitis, and 10 with pancreatitis-related diabetes in this aim.~Participants will undergo a research MRI examination. Participants will also undergo a research blood draw for laboratory analysis and to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes."
89623382|NCT02490462|Active Comparator|Conventional Physical Therapy|Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
88989364|NCT05659147|Experimental|Imaging stratification of stages of pancreatitis|"We will prospectively enroll 60 participants; 15 healthy controls, 15 participants with a single episode of acute pancreatitis, 15 participants with acute recurrent pancreatitis, and 15 participants with chronic pancreatitis.~A research blood draw and a research stool collection will be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin."
89623383|NCT02484300|Experimental|Melatonin 4hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
89623384|NCT02484300|Experimental|Melatonin 2hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
89623385|NCT02484300|Experimental|Melatonin|To determine effects of 10mg daily melatonin on chemoreflex control, oxidation status, loop gain and apnea hypopnea index in obstructive sleep apnea
89623386|NCT02484300|Placebo Comparator|Placebo|Placebo outcomes versus melatonin
89623387|NCT02484066|Experimental|VBN-EBUS-GS group|Fluoroscopy are not used in this group. EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
89623388|NCT02484066|Active Comparator|VBN-EBUS-GS-X-ray group|EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained with fluoroscopic guidance.
89623389|NCT03319056|Active Comparator|Real purification|Air purifier turned on
89037973|NCT02582879||Patient with CLL/SLL|Patients with CLL/SLL in a real-world setting initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens.
89623390|NCT03319056|Sham Comparator|Sham purification|Air purifier turned off
89623391|NCT02727660|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
89623392|NCT02727660|Experimental|BFF MDI (PT009) 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
89623393|NCT02727660|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
89623394|NCT03321474|Experimental|modified gull wing preparation|Gullwing preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation
89623395|NCT03321474|Active Comparator|conventional preparation|"In conventional preparation of veneer it circumvents the contact areas and extends palatally in the incisal third of the tooth only. The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines placed facially to the proximal contacts~Gull wing (dog leg) preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. This preparation design helps to hide the restoration margin when viewed from an angle, especially in discoloration.~The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
89623396|NCT02490384|Active Comparator|Physical exam indicated cerclage|Cerclage
89623397|NCT02490384|No Intervention|Expectant management|No cerclage
89623398|NCT02490072|Experimental|Dexmedetomidine group|
89623399|NCT02490072|Placebo Comparator|normal saline|
89623400|NCT02490228|Other|surgical group|transurethral resection of urethral caruncle
89623401|NCT02483910|Experimental|DI-LL via telehealth|Subjects with autism spectrum disorder (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to receive Direct Instruction-Language for Learning (DI-LL) for 40-48 sessions (roughly twice a week for 24 weeks). Subjects in this arm will be allowed to continue ongoing treatment during the randomized phase of the study
89623402|NCT02483910|Active Comparator|Standard of care delivered via telehealth|"Subjects with (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to continue treatment as usual (TAU) for 24 weeks.~NOTE: after the randomized trial, subjects who do not show a positive response at Week 24, will be offered Direct Instruction-Language for Learning (DI-LL) for 24 weeks."
89623403|NCT03318822||Q-Collar|Subjects wearing the Q-Collar
89623404|NCT02483754||original MOCA|The Chinese retired military cadres were surveyed with the revised MOCA scale.
89623405|NCT02483754||revised MOCA|The random part of participants were surveyed with the revised MOCA scale.
89623406|NCT02490150|Experimental|Day 5|Administration of corifollitropin alfa on Day 5 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
89623407|NCT02490150|Active Comparator|Day 7|Administration of corifollitropin alfa on Day 7 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
89623408|NCT02487576|Other|Carbohydrate-rich_Fat-rich (HC_HF)|Isocaloric carbohydrate-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric fat-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
89623409|NCT02487576|Other|Fat-rich_Carbohydrate-rich (HF_HC)|Isocaloric fat-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric carbohydrate-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
89623410|NCT02483598|Experimental|Buspirone|Buspirone alone
89623411|NCT02483598|Active Comparator|Buspirone plus grapefruit juice|Buspirone plus grapefruit juice
89623412|NCT02483832|Active Comparator|Gain-frame|This group will receive messages about the benefits of colorectal cancer screening.
89037974|NCT02277353||All enrolled patients|This study enrolls patients undergoing elective spine surgery in prone position and all enrolled subjects may receive fluid loading with hemodynamic monitoring by Flotrac/Vigileo and NICOM, but the investigator does not assign specific interventions to the subjects of the study because this is a prospective observational study.
89037975|NCT00539292|Experimental|1|Silastic Spring-Loaded Silo
89037976|NCT00539292|Active Comparator|2|Primary Closure of Abdomen
89037977|NCT00539331|Placebo Comparator|1|Paclitaxel/Carboplatin
89037978|NCT00539331|Experimental|2|Paclitaxel/Carboplatin + AZD2171
89623413|NCT02483832|Active Comparator|Loss-frame|This group will receive messages about the disadvantages of not getting colorectal cancer screening.
89623414|NCT03321318|Experimental|A group|AK-R215, test drug
89623415|NCT03321318|Active Comparator|B group|reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU
89623416|NCT01784861|Experimental|Phase I Dose Level 0: X-82 + Everolimus|"X-82 100 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
89623417|NCT01784861|Experimental|Phase I Dose Level 1: X-82 + Everolimus|"X-82 150 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
89623418|NCT01784861|Experimental|Phase I Dose Level 2: X-82 + Everolimus|"X-82 200 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
89623419|NCT01784861|Experimental|Phase II: X-82 + Everolimus|"X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~28 days =1 cycle"
89623420|NCT01784861|Experimental|Phase I Dose Level 3: X-82 + Everolimus|"X-82 300 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
89623421|NCT01784861|Experimental|Phase I Dose Level 4: X-82 + Everolimus|"Everolimus 10mg by mouth once daily for each cycle MUST BE TAKEN FIRST~X-82 400 mg by mouth once daily 2 HOURS AFTER everolimus dose~28 days =1 cycle"
89623422|NCT03318744|Experimental|aspirin 100mg|Participants will be given aspirin 100mg once per day.
89623423|NCT03318744|Placebo Comparator|placebo|Participants will be given placebo oral tablets once per day.
89037979|NCT00546468|Experimental|Laparoscopy assisted distal gastrectomy|Laparoscopy assisted distal gastrectomy with D2 lymph node dissection.Surgery will be done in similar operative extent with control open distal gastrectomy. Omentectomy will be omitted.
89623424|NCT02489994|Experimental|all subjects|Treatment with the ePrime radiofrequency microneedling device in the upper thighs and buttocks
89623425|NCT02487342|Experimental|milk|semi-skimmed milk (< 2% fat, Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
89623426|NCT02487342|Active Comparator|orange fruit-juice|orange fruit-juice (Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
89623427|NCT02489916|Experimental|CM4307|CM4307 300mg bid，until disease progression,death, unacceptable toxic eff ects, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest
89623428|NCT01751308|Experimental|Phase 1: Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression (DP) or discontinuation due to adverse event (AE) or death (from any cause).
89037980|NCT00546468|Active Comparator|Open Distal Gastrectomy|Conventional standard D2 open distal gastrectomy without omentectomy.
89037981|NCT02236013|Experimental|ASP2215 Dose Escalation (Part 1)|Successive dose escalation cohorts will determine the maximum tolerated dose (MTD)
89037982|NCT02236013|Experimental|ASP2215 Dose Expansion (Part 2)|Once the MTD has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort
89037983|NCT02236013|Experimental|Alternative Anthracycline and Schedule (Part 3)|In Part 3, two cohorts will be enrolled to evaluate an alternative anthracycline and ASP2215 schedule
89037984|NCT02236013|Experimental|Continuous ASP2215 Exposure during Consolidation (Part 4)|During Consolidation, ASP2215 will be given daily on day 1 up to day 56.
89037985|NCT03456999|Active Comparator|MAU868|BKV-specific, pan-serotype neutralizing antibody
89037986|NCT03456999|Placebo Comparator|Placebo|Matching placebo
89037987|NCT00539409|No Intervention|1|Diabetic patients will complete quality of life questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions.
89037988|NCT00539409|Active Comparator|Pulsatile Intravenous Insulin Therapy|
89037989|NCT02178410|Active Comparator|Vitamin D + fish oil|
89037990|NCT02178410|Active Comparator|Vitamin D + fish oil placebo|
89037991|NCT02178410|Active Comparator|Vitamin D placebo + fish oil|
89623429|NCT01751308|Experimental|Phase 1: Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
89623430|NCT01751308|Experimental|Phase 1: Cabazitaxel 30 mg/m^2|Cabazitaxel 30 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
89623431|NCT01751308|Experimental|Phase 1: Cabazitaxel 35 mg/m^2|Cabazitaxel 35 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
89623432|NCT01751308|Experimental|Phase 2: Cabazitaxel 30 mg/m^2|Cabazitaxel at the maximum tolerated dose (MTD) as determined in phase 1 (30 mg/m^2) IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
89623433|NCT02483364|Experimental|Experimental|HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)
89623434|NCT02487186|Active Comparator|Test group: DB+DOX|Test group: DB (full mouth debridment) +DOX (doxicicline) - 45 minutes of full-mouth debridement + subgingival application of PLGA microspheres loading doxycycline 10%.
89037992|NCT02178410|Placebo Comparator|Vitamin D placebo + fish oil placebo|
89037993|NCT00539448|Experimental|1|combination of insulin Glargine & insulin Glulisine as basal bolus regimen
89037994|NCT02100254|Experimental|Arm I (personal narrative)|Participants view videos with information about CRC and screening delivered by personal narrative.
89037995|NCT02100254|Active Comparator|Arm II (fact-based message)|Participants view videos with information about CRC and screening delivered by informative fact-based message.
89037996|NCT04323358|Active Comparator|IOL Master® 700|Biometry will be performed three times consecutively.
89037997|NCT04323358|Active Comparator|Pentacam®|Keratometry will be performed three times consecutively.
89037998|NCT04323358|Active Comparator|Casia II®|Keratometry will be performed three times consecutively.
89037999|NCT04323358|Active Comparator|Spectralis Anterion®|Biometry will be performed three times consecutively.
89038000|NCT05539846|Experimental|test group|
89038001|NCT05539846|No Intervention|control group|
89038002|NCT01808456|Experimental|High Dose Flu Vaccine|influenza trivalent inactive vaccine high dose. IM (intramuscular) injection one time administration
89038003|NCT01808456|Active Comparator|Flu Vaccine|influenza trivalent inactive vaccine IM injection one time administration
89038004|NCT01781741|Experimental|Treatment (TEMLA and SBRT)|Patients undergo TEMLA to remove the mediastinal lymph nodes followed by a single fraction of SBRT to the primary tumor (unless VATS procedure done) and mediastinal lymph node beds (if positive on TEMLA), with or without minimally invasive surgery.
89038005|NCT01715714|Active Comparator|Statin Recapture Therapy|Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin* on admission. (*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)
89038006|NCT01715714|Placebo Comparator|Placebo|Placebo given orally 12 hrs and 2 hrs before CABG
89057358|NCT01682109|Experimental|new paediatric valacyclovir formulation|Newly developed formulation
89623435|NCT02487186|Active Comparator|Control group: DB alone|"Control group: DB alone (Full-mouth debridment)~Intervention: 45 minutes of full-mouth debridement + subgingival application of void PLGA microspheres."
89623436|NCT03315624|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration sessions with the dialyzer FX CORAL 600 (TD 16-1), the dialyzer FX CorDiax 600 or the dialyzer FX 600. In each week the patient is assigned to one type of dialyzer.
89623437|NCT01751386|Experimental|Baclofen|Baclofen 10 mg t.i.d.
88989365|NCT05659147|Experimental|Imaging reproducibility|"We will prospectively enroll up to 20 participants enrolled in Aims 1 or 3 (up to 5 controls and 15 patients with pancreatic disease) to undergo repeat research MRI imaging between 24 hours and 14 days after their first research MRI.~Participants will undergo a research MRI examination with administration of intravenous secretin, identical to the research MRI performed under Aims 1 or 3. MRI images will be quantitatively analyzed and agreement between the two MRI examinations (1st and repeat MRI) will be assessed."
88989366|NCT05659147|No Intervention|Automated or semi-automated image analysis|We will use images prospectively collected under Aims 1-3, as well as existing images that had been obtained for clinical care of children with pancreatitis at CCHMC to develop and optimize image processing pipelines for MRI images. Performance of these pipelines will be benchmarked against manual segmentation performed by multiple observers.
89623438|NCT01751386|Placebo Comparator|Placebo|Placebo t.i.d.
89623439|NCT02486874|Experimental|Treatment group|PoreSkin, a human acellular dermal matrix, were used for scar contracture treatment
88989367|NCT05659134|Active Comparator|Alfredson group (A)|"Participants allocated to the Alfredson exercise program were instructed to exercise twice a day on both legs for 12 months. They performed concentric calf rises (CR) on both legs up and eccentric CR on one leg down.~The protocol contained 15 repetitions and 3 sets on each leg with extended and flexed knee. One session contained 45 reps in the flexed position and 45 reps in the extended position, the total daily number of reps was 180. At the start, the exercises were performed with body weight. Participants could progress by adding the 5, 10 and 15 kg, if they met the criteria. The criteria for adding weight was at least one week of training at the same weight and no disabling pain during or after the exercise during the week."
88989368|NCT05659134|Active Comparator|Silbernagel group (B)|"Participants allocated to the Silbernagel exercise program were instructed to exercise every day with exception of the first week (every other day) for 12 months. The protocol contained 4 phases, which were based on a variety of CR exercises.~The protocol contained concentric and eccentric CR on both legs, CR on one leg, CR in sitting, CR on the step, CR without step, quick rebound CR, CR with added weight and hops on the forefoot.~The daily number of reps for 1st phase was 135, for the 2nd phase was 240, for the 3rd phase was 255 and for the 4th phase was 150. It's performed with body weight, added weight and plyometric loading progressively through all phases (maximal added weight is 15 kilos). To progress to the next phase participant needs to reach pain intensity during and after exercise under 5 from the 10 on the visual analogue scale, morning stiffness should not increase as well as pain during the week."
88989369|NCT05654532|Experimental|AC699 Dose Escalation|Participants will receive an assigned dose of AC699 monotherapy during dose escalation. One cycle is defined as 28 days.
88989370|NCT05654272||Normal|Normal volunteers >=18 years older
88989371|NCT05654272||Cardiovascular Disease Patient|>=18years older with known prior cardiovascular disease
88989372|NCT05653050|Experimental|Fully closed-loop system with age-approved ultra-rapid insulin|"The fully closed-loop system (CamAPS HX) will consist of:~Mylife YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland).~Freestyle Libre 3 real-time CGM sensor (Abbott, Diabetes Care, CA, USA)~Android smartphone hosting CamAPS HX App with the Cambridge model predictive control algorithm.~Cloud upload system to review CGM/insulin data.~Participants will use ultra-rapid insulin aspart in the closed-loop system."
88989373|NCT05653050|Active Comparator|Standard insulin pump therapy with CGM|"Participants will use their own insulin pump and usual insulin throughout this study period.~The CGM will be the Freestyle Libre 3 real-time CGM sensor (Abbott, Diabetes Care, CA, USA)."
88989374|NCT05650307||Healthy controls|
88989375|NCT05650307||Bariatric Surgery patients|
88989376|NCT05650307||Cardiac rehabilitation patients|
88989377|NCT05645224|Experimental|VR-PAT|Participant wears the Pico Neo 3 Pro Eye headset and actively plays the VR-PAT game.
88989378|NCT05645224|No Intervention|Control|Participant wears the Pico Neo 3 Pro Eye headset to protect eyes, but it is not turned on.
88989379|NCT05643560||Hemophilia A patients|Hemophilia patients who had initiated damoctocog alfa pegol treatment.
88989380|NCT05642143||T2D F-/N-|Subjects with T2D and no previous history of any fractures or diabetic neuropathy (n=160)
88989381|NCT05642143||T2D F+|Subjects with T2D with a previous history of a fracture(s) (any fracture, major osteoporotic fracture (MOF) and peripheral) (n=100)
88989382|NCT05642143||T2D N+|Subjects with T2D matched by age and sex with severe peripheral (vibration perception threshold (VPT) > 50) or a history of autonomic neuropathy (n=40)
88989383|NCT05625984|Experimental|Fascigel injection application|Device is administered injected interfascially in the concerned place (low back) in multiple places laterally.
88989384|NCT05624996|Active Comparator|Arm I (image guided RT, chemotherapy, immunotherapy)|Patients undergo conventional IGRT and receive standard of care chemotherapy consisting of paclitaxel IV and carboplatin IV or pemetrexed IV and carboplatin IV or etoposide IV and cisplatin IV or pemetrexed IV and cisplatin IV and then receive durvalumab IV on study. Patients also undergo CT and/or PET/CT during follow up.
88989385|NCT05624996|Experimental|Arm II (SBRT, image guided RT, chemotherapy, immunotherapy)|Patients undergo SBRT and conventional IGRT and receive standard of care chemotherapy consisting of paclitaxel IV and carboplatin IV or pemetrexed IV and carboplatin IV or etoposide IV and cisplatin IV or pemetrexed IV and cisplatin IV and then receive durvalumab IV on study. Patients also undergo CT and/or PET/CT during follow up.
88989386|NCT05621928||cases with positive RT PCR result for Covid 19|Individuals aged 18 years or older, with a suspected clinical picture of COVID-19 virologically confirmed, that is, with positive RT-PCR for SARS-CoV-2 in a respiratory secretion sample collected in the first 7 days of the onset of symptoms , who did not have a positive RT-PCR result for SARS-CoV-2 in the 90 days preceding enrollment in the study.
89057359|NCT01682109|Active Comparator|reference valacyclovir formulation|Formulation derived from FDA label information
89623440|NCT02489760|Experimental|Adalimumab switch to Etanercept|At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.
89623441|NCT02489760|Experimental|Etanercept switch to Adalimumab|At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.
89623442|NCT01752400|Experimental|AUY922|Via intravenous infusion on Days 1, 8 and 15 of each 21 day cycle (once per week). Infusion lasts approximately 60 minutes
89623443|NCT03321240||The SEEG group|Group with the SEEG analysis
89623444|NCT03321240||The direct surgery group|Group with a direct surgery
89623445|NCT01752712|Experimental|CBSST + oxytocin|Cognitive Behavioral Social Skills Training with adjunct oxytocin nasal spray treatment. Participants will receive 80 IU/day of oxytocin administered intranasally in two doses (40 IU morning and evening).
89623446|NCT01752712|Placebo Comparator|CBSST + placebo|Cognitive Behavioral Social Skills Training with placebo nasal spray. The placebo nasal spray bottles will be matched in appearance to the oxytocin nasal spray bottles and similarly administered intranasally in two doses (morning and evening).
89623447|NCT02489370|Experimental|Telemonitoring (intervention)|"an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.~Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made."
89623448|NCT02489370|No Intervention|Usual care (control)|Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
89623449|NCT05127928|Experimental|Supplementation|Vitamin C and Vitamin E before exercise
89623450|NCT05127928|Placebo Comparator|Placebo|Placebo before exercise
89623451|NCT01754350|Experimental|ketogenic diet and transient fasting|Calorie-restricted, ketogenic diet and transient fasting during reirradiation
89623452|NCT01754350|Active Comparator|standard nutrition|nutrition according to recommendations of the German society for nutrition during reirradiation
89623453|NCT02483130||NAC or Placebo|Participants will receive 2400mg capsules of N-Acetylcysteine or placebo
89623454|NCT03318354|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
89623455|NCT03318354|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
89623456|NCT02727192|Active Comparator|PAP-therapy (CPAP or ASV)|Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).
89623457|NCT02727192|No Intervention|Control group|No sleep apnea treatment
89623458|NCT02252068|Other|I-CBT feasibility pilot|Open trial of I-CBT
89623459|NCT02252068|Experimental|I-CBT randomized trial|I-CBT in randomized trial.
89623460|NCT02252068|Active Comparator|IDC randomized trial|Comparison condition (Individualized Drug Counseling) in randomized trial.
89623461|NCT05093140|Experimental|camrelizumab+R-CHOP|Induction therapy: camrelizumab in combination with rituximab Immunochemotherapy: rituximab, cyclophosphamide, hydroxyldaunorubicin, vincristine, prednisone Maintenance therapy: camrelizumab in patients achieved CR after immunotherapy
89623462|NCT05076214|Experimental|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer.~The group training session will begin with a 3-5 minutes check-in round followed by a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied"
89623463|NCT05076214|Active Comparator|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together.
89623464|NCT05021848|Experimental|Experimental group|The experimental group (N=14) received a 90-minute partnered multicomponent exercises intervention once weekly for 12 weeks
89623465|NCT05021848|No Intervention|control group|The control group (N=14) carried out the usual activities without intervention. (After 12-wk, multicomponent exercises intervention will be given)
89623466|NCT00705666||PegIntron as monotherapy or in combination with Ribavirin.|Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in combination with ribavirin.
89623467|NCT04955236|Experimental|Partial scalp block|Bilateral block of the greater lesser and third occipital nerves using bupivacaine 0.25% with epinephrine 1:200,000
89623468|NCT04955236|Active Comparator|Fentanyl group|Fentanyl infusion will be administered till time of dural closure
88989387|NCT05621928||Control|Individuals residing in the vicinity of the case, aged 18 years or older, without a suspected clinical picture of COVID-19 and with RT-PCR negative for SARS-CoV-2 in a respiratory secretion sample collected at the time of inclusion, followed by confirmation of the absence of signs and symptoms suggestive of COVID-19 within the next 7 days.
88989388|NCT05621928||immunogenicity analyzes|a convenience sample composed of all cases exposed or not to vaccination and 200 controls, 100 vaccinated and 100 unvaccinated, for analysis of humoral response.
88989389|NCT05621928||assessment of cellular immunity|a sample of 100 vaccinated cases and 100 unvaccinated cases followed prospectively, and 100 vaccinated controls 100 unvaccinated controls assessed spot-on at enrollment.
89623469|NCT02489292|Experimental|HepaStem|Target total dose 50x10E6 cells/kg
88989390|NCT05621928||analysis of potential genetic risk factors for the occurrence of severe forms of COVID-19 (SRAG)|a total of 50 cases
88989391|NCT05621603|Experimental|Training|Participants receive the intervention, which is a training program.
89623470|NCT04943770||WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|"Patients will be randomised 4:4 to a specific stimulating rates order (A, B, C, D) for approx. 3-6 weeks per rate (12-24 weeks in total). Each period is followed by a wash-out phase.~At each frequency systematic assessment of the sweet-spot(s) will be performed. Various pulse width and amplitude values may be used to optimize therapy (up to 1KHz). These programmes will be saved in the subject's remote control based on the pre-generated rate randomization sequence."
89623471|NCT05463510||Pediatric melanocytic nevus|50 patients and 301 pediatric nevi were evaluated
88989392|NCT05621603|No Intervention|Control|Participants do NOT receive the intervention, which is a training program. This is a waitlist control comparison model.
88989393|NCT05617391||Pediatric Childhood Cancer Survivors|The comparison of two ECGs in terms of predictive risk.
88989394|NCT05615545||Cryoablation|Cryoablation of selected tumor lesions
88989395|NCT05614856||Treatment Group|Patients affected by AIOD classified as TASC B, C or D involving aortic bifurcation and or the first 5mm of one of both common iliacs treated with the unibody endograft AFX (Endologix, Irvine, Calif)
88989396|NCT05613153|Experimental|Peppermint Oil|Peppermint oil will be provided free of charge to participants under the trademark Pepogest produced by the maker Nature's Way® (dosage 0.2 mL, 181 mg peppermint oil).
88989397|NCT05611788|Experimental|Structure Learning Training|The intervention group will receive structure learning training that tap on their ability to extract patterns from prior stimuli presentations to make predictions. Participants will be presented with visual sequences of symbols determined by frequency statistics and upon mastery, more complex context-based statistics. No feedback will be provided and participants are trained in an adaptive manner
88989398|NCT05611788|No Intervention|Passive Control|The passive control group will not receive any intervention but will receive the same pre-post cognitive-behavioural and neuroimaging intervention assessments.
88989399|NCT05608694|Other|High Risk- Positive Germline Mutation (n=40):|Men who harbor known germline mutations that have been associated with an increased risk of prostate cancer and aggressive disease (e.g. BRCA2, ATM, PALB2, etc.) with or without a known family history of prostate cancer.
88989400|NCT05608694|Other|High Risk- High GRS (n=40):|Men who harbor significantly increased disease risk based upon genetic risk score (GRS) value >1.5 with or without a known family history of prostate cancer.
88989401|NCT05608694|Other|High Risk- Family History (n=45):|Men with a family history of prostate cancer in at least one sibling, father, uncle, or grandfather but no known increased genetic risk of prostate cancer (has no pathogenic or likely pathogenic mutation along with a low genetic risk score (GRS<1.5).
88989402|NCT05608694|Other|Low Risk (n=125):|No known germline mutation, low genetic risk score (GRS <1.5), and no known family history of prostate cancer.
88989403|NCT05606835|Active Comparator|Pronation Group|Participants will be assessed using the foot posture index-6 (FPI-6), and those who exhibit pronation of the subtalar joint will be included in the study. Participants to be included in the study will be divided into two groups according to their values for pronation increase in the subtalar joint. Participants with a value between 6 and 9 according to FPI-6 will be included in pronation group.
88989404|NCT05606835|Active Comparator|Hyper pronation group|Participants with a value between 10 and 12 according to FPI-6 will be included in hyper pronation group.
88989405|NCT05605301|Experimental|Sequential ascending dose cohort|Cohort 1 will receive single 40 mg dose once. Cohort 2 will receive single 60 mg dose once. Cohort 3 will receive (2) 60 mg dose on one occasion.
88989406|NCT05598827|Experimental|Watch the Tik Tok|Unlimited Tik Tok viewing was encouraged from 24 hours before chemotherapy until the seventh day after chemotherapy.
88989407|NCT05598827|No Intervention|Tik Tok is not allowed|Viewing of Tik Tok was prohibited from 24 hours before chemotherapy until the seventh day after chemotherapy.
88989408|NCT05598229|Experimental|Watch the Tik Tok|Encouraged to watch the Tik Tok.
88989409|NCT05598229|No Intervention|Tik Tok is not allowed|Tik Tok is not allowed.
88989410|NCT05595239|Experimental|standard treatment+CVVH|
88989411|NCT05595239|Experimental|standard treatment+TPE+CVVH|
88989412|NCT05595239|Experimental|standard treatment+HP+CVVH|
88989413|NCT05594576|Experimental|ENDOCUFF VISION® Endoscopic Cap coupled with GI GENIUS™ Artificial Intelligence (AI)|
88989414|NCT05594576|Active Comparator|GI GENIUS™ Artificial Intelligence (AI) alone|
88989415|NCT05594576|Active Comparator|ENDOCUFF VISION® endoscopic cap alone|
88989416|NCT05593718||FaceMask Ventilation (FMV)|During the period from January 1, 2015, to December 31, 2016, all panendoscopies performed with FMV, whether urgent or scheduled and regardless of indication, were included. Panendoscopies performed with any other oxygenation method were excluded.
88989417|NCT05593718||HFNO|During the period from January 1, 2018, to December 31, 2019, all panendoscopies performed with HFNO, urgent or scheduled and regardless of indication, were included. Panendoscopies performed with any other oxygenation method were excluded.
88989418|NCT05593042|Active Comparator|Heterologous group receiving CoronaVac®|General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of CoronaVac®
88989419|NCT05593042|Experimental|Heterologous group receiving Omicron vaccine|General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of Omicron vaccine
88989420|NCT05593042|Experimental|Heterologous group receiving a trivalent vaccine|General population that received two doses of CoronaVac® as a primary schedule of vaccination and two booster doses as part of the national vaccination schedule with mRNA or viral vector-based vaccines; and who receive a booster dose of trivalent vaccine
88989421|NCT05593042|Experimental|Homologous group receiving Omicron vaccine|Participants of the CoronaVac03CL study who have received the primary regimen and two booster doses with CoronaVac® vaccine; and who receive a booster dose of Omicron vaccine
88989422|NCT05593042|Experimental|Homologous group receiving a trivalent vaccine|Participants of the CoronaVac03CL study who have received the primary regimen and two booster doses with CoronaVac® vaccine and who receive a booster dose of trivalent vaccine
88989423|NCT05591001|Active Comparator|Ketamine-dexmedetomidine group|Dexmedetomidine( 0.4 -0.6 μg/.kg /.h r)) ketamine,( 1-2m/.kg/.hr) infusion and giving bolus of fentanyl,( 1-2μg/.kg/ ) with keeping mean arterial blood pressure and heart rates changes within 25% of the baseline.
89623472|NCT04086862|Active Comparator|The 1 MHz group|The 1 MHz group will receive therapeutic ultrasound at the 1 MHz setting.
88989424|NCT05591001|Active Comparator|propofol group|propofol (100 ug/kg/min) -giving a bolus of fentanyl, (1-2μg/.kg/ ) with keeping mean arterial blood pressure and heart rate changes within 25% of the baseline.
89038007|NCT01540253|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive PI3K inhibitor BKM120 PO QD and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89038008|NCT01497392|Experimental|Treatment (dovitinib lactate, gemcitabine, and capecitabine)|Patients receive dovitinib lactate PO on days 1-5, 8-12, and 15-19, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and capecitabine PO twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89038009|NCT01310192|Experimental|1|Investigational Imaging Device
89057360|NCT02215148||Brain injured patients with hyponatremia|Patients with acute brain injury who develop hyponatremia and are administered tolvaptan via the nasogastric tube, deemed necessary by the primary medical team.
89057361|NCT01682265|Experimental|Stretta procedure|"Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
89533361|NCT04875975|Experimental|Rozanolixizumab|Participants will be randomized to receive a predefined dose of rozanolixizumab.
89533362|NCT04875975|Placebo Comparator|Placebo|Participants will be randomized to receive a dose of placebo.
89533363|NCT04870515|Experimental|Group I (diet, physical activity)|Patients attend 10 in-person or virtual sessions with a registered dietician over 6 months to receive diet instructions. Patients also attend 2 one-on-one sessions with an exercise psychologist to receive instruction to complete aerobic physical activity and strength/resistance training. Patients may also complete up to 21 additional supervised exercise sessions.
89533364|NCT04870515|Active Comparator|Group II (standard lifestyle recommendations)|Patients receive standard lifestyle recommendations and attend an individual session with a dietitian over 20-30 minutes including US dietary guidelines, activity goal of 30 minutes of physical activity 5 days/week; and discussion of the health benefits of weight loss along with general behavior change suggestions for weight loss.
89533365|NCT04857034|Experimental|Active Treatment: Deucravacitinib Dose 1|
89533366|NCT04857034|Experimental|Active Treatment: Deucravacitinib Dose 2|
89533367|NCT04857034|Placebo Comparator|Placebo|
89533368|NCT04852692||Part A: Retrospective Phase|Retrospective collection of data for eligible participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) who initiated salvage treatments from initiation point (administration starting point of the salvage treatment) of the identified last-line of conventional salvage therapy for cGVHD treatment as their second-forth line therapy and will be collected for up to 24 weeks from the initiation point.
89533369|NCT04852692||Part B: Prospective Phase|Prospectively enroll participants with steroid dependent/refractory cGVHD that are decided to be treated with ibrutinib in second-fourth line therapy for the treatment of cGVHD. Participants will continue to receive corticosteroids as a standard of care.
89533370|NCT04850118|Active Comparator|Group 1: Dose|Male participants 12-50 years of age treated by subretinal injection with the of AGTC-501
89533371|NCT04850118|Active Comparator|Group 2: Dose|Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501
89533372|NCT04850118|Other|Group 3: Control|Male participants 12-50 years of age in the untreated control group. Participants in the control group will be followed for a minimum of 24 months. After all participants have reached Month 12, participants in the control group will be given the option to receive the study drug in the fellow eye, if eligible.
89533373|NCT04839978|Experimental|Preventive Intervention|Students in schools assigned to the preventive intervention study condition will take part in the Connect school-based prevention program and the community-level Communities Mobilizing for Change and Action (CMCA) intervention.
89533374|NCT04839978|No Intervention|Delayed Intervention Control Group|Students in schools assigned to the control group will not receive the Connect and CMCA interventions. Schools in the control group will receive usual school and community prevention and be offered the trial's programs after this three-year study ends.
89533375|NCT04837937|Experimental|Condition 1|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise. All participants will complete this exercise; it will serve as the constant.
89533376|NCT04837937|Experimental|Condition 2|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Patient [Advanced]' ' conflict negotiation/dispute resolution exercise
89533377|NCT04837937|Experimental|Condition 3|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise
89533378|NCT04837937|Experimental|Condition 4|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Patient [Advanced]' conflict negotiation/dispute resolution exercise
89533379|NCT04837937|Experimental|Condition 5|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise
89533380|NCT04837937|Experimental|Condition 6|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Patient [Advanced]' conflict negotiation/dispute resolution exercise
89533381|NCT04837937|Experimental|Condition 7|(1) 'Caregiver vs. Patient [Beginner]' negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise
89533382|NCT04837937|Experimental|Condition 8|(1) 'Caregiver vs. Patient [Beginner]' conflict negotiation/dispute resolution exercise; (2) 'Caregiver vs. Caregiver' conflict negotiation/dispute resolution exercise; (3) 'Caregiver vs. Physician' conflict negotiation/dispute resolution exercise; (4) 'Caregiver vs. Patient [Advanced]' conflict negotiation/dispute resolution exercise
89533383|NCT04837040|Experimental|Paltusotine|
89533384|NCT04837040|Placebo Comparator|Placebo|
89533385|NCT04828486|Experimental|Treatment (futibatinib, pembrolizumab)|Patients receive futibatinib PO QD on days 1-21 for cycles 1-9, and days 1-42 for subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-9 and every 42 days for subsequent cycles for up to 2 years in the absence of disease progression or unacceptable toxicity.
89623473|NCT04086862|Experimental|The 3 MHz group|The 3 MHz group will receive therapeutic ultrasound at the 3 MHz setting.
89623474|NCT02489136|Other|Spirit Pass|It is a transfusion of psychic energies. Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
89623475|NCT02489136|Placebo Comparator|laying of hands by workes|Laying of hand by workers and volunteers, not belonging to Spiritism.Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
89623476|NCT02489136|No Intervention|No intervention|No intervention during, in adults before and after ten minutes for 3 days.
89623477|NCT04044274|Experimental|IOPstim|
89623478|NCT04021030|Experimental|Cognitive Behavioral Therapy (CBT)|
89623479|NCT03315234||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
89623480|NCT03315234||0 < SYNTAX score < 23|Low SYNTAX group
89623481|NCT03315234||SYNTAX score ≥ 23|Intermediate-High SYNTAX group
89623482|NCT03957304|Experimental|Dexmedetomidine 1 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 1 mcg/kg (max 100 mcg or 1 mL).
89623483|NCT03957304|Active Comparator|Dexmedetomidine 2 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 2 mcg/kg (max 100 mcg or 1 mL).
89623484|NCT03957304|Active Comparator|Dexmedetomidine 3 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 3 mcg/kg (max 100 mcg or 1 mL).
89623485|NCT03957304|Active Comparator|Dexmedetomidine 4 mcg/kg|Intranasal dexmedetomidine 100 mcg/mL (Precedex, Pfizer) 4 mcg/kg (max 100 mcg or 1 mL).
89623486|NCT02483286|Experimental|ICG|Integrated Care Group
89623487|NCT02483286|Experimental|MTG|Muscle Training Group
89623488|NCT02483286|Experimental|XBG|X-box Group
89623489|NCT03318276|Experimental|SID142|Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
89623490|NCT03318276|Active Comparator|Rinexin® Tab|Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks
89623491|NCT02483208|Experimental|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
89623492|NCT02483208|Other|Advate|Advate infusion to analyze pharmacokinetics.
89623493|NCT03321162||double scan protocol|In C1(double scan technique) , after CT scan for patient wearing scan appliance , two optical scan for the model with and without scan appliance.
89623494|NCT03321162||triple scan protocol|In C2 (triple scan technique) , after CT scan for patient wearing scan appliance , CT scan for scan appliance alone .
89623495|NCT03321084|Experimental|MatPilates|In the beginning was nominated Contrology, but today is known as Pilates. Created by Joseph Humbertus Pilates. This technique is based on respiration, balance, flexibility, proprioception and muscular strength. One of the main work is on the power house (core), biomechanical axis of the body, composed of muscles: rectus abdominis, paravertebral, multifidus, diaphragm, and those of the perineal center.
89623496|NCT03321084|Other|Control|It continues in your daily life with phone monitoring.
88989425|NCT05588323|Experimental|Cohort 1: ≥ 12 to < 18 Years|Participants will receive 0.05 milligrams (mg) to 0.2 mg naldemedine based on their body weight once daily for 7 days.
88989426|NCT05588323|Experimental|Cohort 2: ≥ 6 to < 12 Years|Participants will receive 0.05 mg to 0.2 mg naldemedine based on their body weight once daily for 7 days.
89623497|NCT02486562||People diagnosed with Multiple Sclerosis|
89623498|NCT02488902|Placebo Comparator|Placebo|Placebo was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
89623499|NCT02488902|Experimental|Tafenoquine 25mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
89623500|NCT02488902|Experimental|Tafenoquine 50mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
89623501|NCT02488902|Experimental|Tafenoquine 100 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
89623502|NCT02488902|Experimental|Tafenoquine 200 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
89623503|NCT02488902|Experimental|Mefloquine 250 mg|Mefloquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
89623504|NCT05404776|Experimental|Without tension (tension free)|The study group will undergo induction of labor by placement of a transcervical Foley balloon. The balloon tubing will be left free of tension and will hang freely.
89623505|NCT05404776|Active Comparator|Tension|The control group will undergo induction of labor by placement of a transcervical Foley balloon. The balloon tubing will be pulled to create tension and will then be taped to the patient's inner thigh.
89623506|NCT02253160|Experimental|Spectra Optia CMNC first, then COBE Spectra MNC|Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
89623507|NCT02253160|Experimental|COBE Spectra MNC first, then Spectra Optia CMNC|COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
89623508|NCT05459766|Experimental|AO+MI|Video-clips observation representing motor contents, followed by motor imagery (12 minutes a day per 3 days).
89623509|NCT05459766|Active Comparator|CTRL|Usual care, consisting of preoperative education.
89623510|NCT02254252|Active Comparator|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
89623511|NCT02254252|Active Comparator|Nicorandil|nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
89623512|NCT03315156||Patients|patients with AOM
89623513|NCT02483052|Experimental|RejuvenAir|RejuvenAir if the treatment areas are designated as Segmental, males will be dosed for 11 seconds and females for 10 seconds. If dosing is in the Lobar area males will be dosed for 12 seconds and females for 11 seconds.
89623514|NCT03318198|Active Comparator|Intervention Arm|Attendings on the interventional arm attended daily work rounds with the resident teams in addition to established work rounds on the previously admitted patients on the care team.
89623515|NCT03318198|Placebo Comparator|Control Arm|Attendings crossed over to the control arm in which they did not attend work rounds with the team and only say new admissions with the resident team. This was usual care.
89623516|NCT02255032|Experimental|4 mg CLS-TA|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
89623517|NCT02255032|Experimental|0.8 mg CLS-TA|Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA
89623518|NCT03315078|Experimental|Gene-Modified CD34+ HSCs|Participants will receive palifermin on Days -6, -5, and -4 and then busulfan on Days -3 and -2. On Day 0, participants will undergo the gene transfer treatment with infusion of the gene-modified CD34+ HSCs. They will receive palifermin on Days 1, 2, and 3.
89623519|NCT03320772|Experimental|TMVP1|The TMVP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of TMVP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
89623520|NCT03320772|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
89623521|NCT02255110|Experimental|TH-302 and doxorubicin|
88989427|NCT05588323|Experimental|Cohort 3: ≥ 2 to < 6 Years|"Participants will be enrolled in this cohort after the safety and PK data has been evaluated for cohorts 1 and 2.~Participants will receive 0.05 mg to 0.2 mg naldemedine based on their body weight once daily for 7 days."
88989428|NCT05588245|Active Comparator|Comparison Group (Standard of Care)|Participants will receive the standard of care.
88989429|NCT05588245|Experimental|Intervention Group|Participants will receive a community-based patient navigator with 3 prenatal contacts and 5 postpartum contacts; during each contact, the community-based patient navigator will offer health assessment and education, along with group education and social support.
88989430|NCT05586230|Experimental|Group 1 (≥ 31 kg)|"≥40 kg (Adult Formulation)~31-<40 kg (Dispersible Pediatric Formulation)"
88989431|NCT05586230|Experimental|Group 2 (20-<31 kg)|20-<31 kg (Dispersible pediatric Formulation)
88989432|NCT05586230|Experimental|Group 3 (12-<20 kg)|12-<20 kg (Dispersible pediatric Formulation)
88989433|NCT05586230|Experimental|Group 4 (4-<12 kg)|"8-<12 kg (Dispersible pediatric Formulation)~6-<8 kg (Dispersible pediatric Formulation)~4-<6 kg (Dispersible pediatric Formulation)"
88989434|NCT05584683|Experimental|Pediatric patients with a bacterial infection|
88989435|NCT05584059|Experimental|FACT Group|4-6 weeks of 45-60 minute individual-based Focused Acceptance and Commitment Therapy (FACT) counselling sessions delivered via video-conferencing format or face-to-face
88989436|NCT05582785|Experimental|Hyperfine|For patients that have standard of care head imaging, we will do a secondary analysis to compare their standard of care MRI, CT and/or US exams with Hyperfine MRI exams.
88989437|NCT05582161|Experimental|DAOIB|
88989438|NCT05575323|Experimental|Intervention|Patients will receive high dose, single fraction stereotactic body radiotherapy (SBRT) using differential dosing: 18 or 21 Gy on the metastasis. Within 24 hours after SBRT, patients will have surgical stabilization with or without decompression.
88989439|NCT05575323|Active Comparator|Control|Patients will undergo the standard of care, which is surgical stabilization with or without decompression, followed by conventional radiotherapy (cRT) or SBRT as soon as the wound is healed sufficiently.
88989440|NCT05573113|Active Comparator|AXR Arm 1|Abdomen Radiograph
88989441|NCT05573113|Active Comparator|AXR + BUS Arm 2|Abdomen Radiograph + Bowel Ultrasound
88989442|NCT05570136|Experimental|Treatment|Participants in the treatment group will receive the 12-week STEP by a trained interventionist. In the first four weeks, the interventionist will focus on building participants' selfefficacy and health literacy and help participants learn the STEP exercise and principles. In the following four weeks, the interventionist will help the older adults to be more independent in prescribing exercise activities for themselves. In the last four weeks, participants will be fulling knowledgeable and independent on functional exercising; the interventionist will allocate community resources for long-term maintenance. After program completion, trained raters will administer at post-tests. There will also be a 3-month and 6-month follow-up evaluation after program completion.
88989443|NCT05570136|Sham Comparator|Control|Participants in the control group will receive weekly health newsletters and will not get any suggestions or encouragement to do exercise from the research team. A staff member will call the control group participants weekly to document any new exercise programs from usual community services. At this stage, participants will not be excluded from the study if they join an exercise program, but we will document what kind of exercise they are conducting. Trained raters will administer at post-tests and two follow-ups.
88989444|NCT05568394|Experimental|Intervention group|Manual therapy and therapeutic exercise
88989445|NCT05568394|Experimental|Control group|Routine physical therapy
88989446|NCT05568095|Experimental|Domvanalimab + Zimberelimab + FOLFOX/CAPOX (PI Choice)|Participants in this arm will receive Domvanalimab and zimberelimab doses once every 4 weeks (Q4W) in addition to chemotherapy with FOLFOX (oxaliplatin, leucovorin, fluorouracil) once every 2 weeks (Q2W) or Domvanalimab and zimberelimab once every 3 weeks (Q3W) in addition to chemotherapy with CAPOX (capecitabine and oxaliplatin) Q3W.
88989447|NCT05568095|Active Comparator|Nivolumab + FOLFOX/CAPOX (PI Choice)|Participants in this arm will receive Nivolumab Q2W and FOLFOX Q2W or Nivolumab Q3W + CAPOX Q3W.
89623522|NCT03320694|Experimental|metformin|Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery
89623523|NCT03320694|Active Comparator|Insulin|Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery
89623524|NCT03318042|Experimental|Child-teenagers-walnuts-pomegranate|Intake of walnuts or pomegranate juice for 3 days
89623525|NCT02482740|Experimental|tamoxifen|tamoxifen 20 mg given everyday for 12 months
89623526|NCT02482740|Active Comparator|letrozole|letrozole 2.5 mg given everyday for 12 months
89623527|NCT03317886|Active Comparator|mesenteric approach|mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.
89623528|NCT03317886|Active Comparator|conventional approach|Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.
89623529|NCT03315000|Experimental|Vilanterol|Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
89623530|NCT03315000|Experimental|Fluticasone|Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
89623531|NCT03315000|Placebo Comparator|Placebo|Lactose powder inhaled through Ellipta® inhaler
89623532|NCT04892602||Rheumatiod arthritis patients|
89623533|NCT04892602||Psoaritic arthritis|
89623534|NCT04892602||Control group|
89623535|NCT02482818|Placebo Comparator|Control-Placebo|"Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day.~Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42."
89623536|NCT02482818|Experimental|Pregabalin|"Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day.~Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days.~Forty two days after initial drug administration the Doctor will meet with subjects to follow up."
89623537|NCT02989870|Experimental|SBRT, Sorafenib and Bavituximab|This will be a 3+3 design with 3 dose cohorts. Following the dose escalation phase, an additional 6 patients will be enrolled as part of the dose expansion cohort.
89623538|NCT02488746||EFTR-GERDX|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
89623539|NCT02480088|Experimental|ramosetron|patients receiving ramosetron for prophylaxis of postoperative nausea and vomiting
89038010|NCT05106855|Other|Implants GM Acqua surface, with LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM Acqua, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm.~LLLT protocol:~With a infrared diode laser, wavelength of 808 nm, continuous mode, a dose of 2J per spot, for 20 seconds per spot, the following irradiation protocol shall be applied: immediately after surgery and on days 3 and 7 after surgery, 4 spots (2 in the vestibular and 2 in lingual/palatal of the alveolus/implant)."
89038011|NCT05106855|Other|Implants GM Acqua surface, without LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM Acqua, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm."
89623540|NCT02480088|Active Comparator|palonosetron|patients receiving palonosetron for prophylaxis of postoperative nausea and vomiting
89623541|NCT01807624|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
89623542|NCT02482506|Other|SG-WLP|Self-guided weight loss program
89623543|NCT02482506|Active Comparator|MF-WLP|Moving Forward Weight Loss Program
89623544|NCT03317808|Active Comparator|Heavy slow resistance exercise|
89623545|NCT03317808|Placebo Comparator|Traditional supervised exercise|
89623546|NCT02480244|Experimental|Behavioral intervention|Behavioral intervention consisting of 12 educational sessions promoting healthy diet and increased physical activity
89623547|NCT02480244|Active Comparator|Control|Control arm receives no health-related behavioral intervention
89623548|NCT01808326|Experimental|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
89623549|NCT05714358|Experimental|INTERVENTION GROUP|Face to face education programme and mobile app were used.
89623550|NCT05714358|No Intervention|CONTROL GROUPS|Only face to face education was used.
89623551|NCT03317730|Experimental|RT + Xtampza ER|This study will enroll patients scheduled to receive radiation therapy (RT), but RT details are not specified by this protocol. Patients taking long acting opioid analgesics prior to enrollment will be converted to an equivalent dose of Xtampza ER at the time of enrollment. For the remaining patients not previously prescribed opioid analgesics, Xtampza ER will be initiated when 2 or more daily doses of short acting opioids are required, resulting in a total daily dose of at least 30mg morphine sulfate equivalent. During RT, pain will be assessed on a weekly basis using the PI-NRS and the dose of Xtampza ER will be adjusted at the discretion of the treating physician, with recommendation to maintain an equivalent of 100% daily opioid requirement. Assessment for tapering of Xtampza ER will begin 1 month following the completion of RT at the time of first follow-up.The study period will end 3 months following the final fraction of RT.
89623552|NCT02486484|Experimental|intravitreal ziv-aflibercept|intravitreal ziv-aflibercept
89038012|NCT05106855|Other|Implants GM NeoPoros surface, with LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM NeoPoros, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm.~LLLT protocol:~With a infrared diode laser, wavelength of 808 nm, continuous mode, a dose of 2J per spot, for 20 seconds per spot, the following irradiation protocol shall be applied: immediately after surgery and on days 3 and 7 after surgery, 4 spots (2 in the vestibular and 2 in lingual/palatal of the alveolus/implant)."
89038013|NCT05106855|Other|Implants NeoPoros surface, without LLLT.|"Surgical protocol Periotomes will be used for atraumatic extraction and/or a stainless steel tooth extractor.~The implant, GM NeoPoros, will be placed in a flapless manner through the alveolus, manually or mechanically, and a minimum length of 2 mm longer than the root length. The implant placement site will be prepared following the manufacturer's protocol.~The minimum torque that to be employed to attain primary stability of the implant will have to be ≥ 30 Ncm measured with a manual torque wrench. (Neodent®).~After the implant has been placed, a healing abutment GM (Neodent®) will be placed, with a maximum torque of 10 N.cm."
89623553|NCT01808560|Experimental|LipiFlow Pre-treatment|Subjects randomized to the LipiFlow Pre-Treatment group receive a 12-minute LipiFlow System treatment for MGD in both eyes one month prior to cataract surgery.
89623554|NCT01808560|No Intervention|Untreated Control|Subjects randomized to the untreated control group receive no MGD treatment prior to cataract surgery.
89623555|NCT01808560|Experimental|LipiFlow Post-treatment|Subjects in the untreated control group receive a 12-minute crossover treatment with the LipiFlow System in both eyes three months after cataract surgery.
89623556|NCT03317652|Experimental|Sodium nitroprusside and CO2 reactivity|"The subject rests in the supine position throughout the study that lasts for approximately three hours.~Interventions are:~Hyperventilation~6% CO2 breathing~Infusion of sodium nitroprusside"
89623557|NCT02479854|Experimental|A Test|test drug (Asmakast)1 chewable tablet contains 5 mg Montelukast
89038014|NCT00539565|Active Comparator|A|oral corticosteroids
89038015|NCT00539565|Placebo Comparator|B|as for active regimen
89038016|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive GSK1827771 with the starting dose of 0.3 milligram (mg)
89038017|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
89038018|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
89038019|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
89038020|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
89038021|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
89038022|NCT00539799|Active Comparator|1|Long-term low-dose prednisolone (5 - 7.5 mg/day)
89038023|NCT00539799|Placebo Comparator|2|
89038024|NCT00945152|Experimental|Drug Vancogel,Treatment,Kill MRSA,Heal|Treatment of open wounds with Vancogel(R) 1.25-1.50% to eliminate MRSA. End point is: a negative culture report after 1-3 topical applications. The infected wounds with MRSA will be treated with the Vancomycin 1.25 to 1.50% complex gel formulation and will have conventional management in order to heal the wound. Vancogel is anticipated to accelerate wound healing by eliminating MRSA. A randomized, double blind study protocol approved by FDA.
89038025|NCT00945152|Placebo Comparator|Placebo|Half of the patients in the study will be given a placebo consisting of all ingredients in Vancogel except the active principal Vancomycin in order to compare their clinical efficacy in rate of wound healingafter 1-3 applications
89623558|NCT02479854|Active Comparator|B Reference|reference drug (Singulair) 1 chewable tablet contains 5 mg Montelukast
89623559|NCT02486172|Other|Peer supporter|Peer support program
89623560|NCT01809106|Active Comparator|Morphine|
89038026|NCT00546507|Placebo Comparator|A|placebo
89038027|NCT00546507|Active Comparator|B|celecoxib 200 mg qd p.o.
89623561|NCT01809106|Experimental|Oxycodone|
89623562|NCT01809106|Experimental|Buprenorphine|
89623563|NCT01809106|Experimental|Fentanyl|
89623564|NCT02479932|Active Comparator|Extraperitoneal cesarean|
89623565|NCT02479932|Active Comparator|Transperitoneal cesarean|
89038028|NCT00546507|Experimental|C|TDS-943 40 mg bid topically
89038029|NCT00553241||1|"Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Beijing 100029, P.R.China~Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour."
89038030|NCT00546546|No Intervention|control = conventional treatment|conventional treatment: use of immunosuppressants only if steroid dependency or chronic active disease
89038031|NCT00546546|Experimental|Immunossuppresive treatment|Switch to different immunosuppresive treatment in case of relapse.
89623566|NCT03828136|Experimental|ACDF with Novum Vitrium® Cervical Interbody Device|A resorbable cervical interbody cage.
89623567|NCT03828136|Active Comparator|ACDF with Allograft|Structural allograft made from structural corticocancellous allograft bone.
89623568|NCT03314610||Patients enrolled|Patient with parkinsonian syndromes and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes. A first record of gait speed will be at strong desire to void. A second record will be after voiding or catheterization Gait records consist on : 3x 10 meter walk test, 1x double task 10 meter walk test, 1x Timed up and Go test and 1x GMT
89623569|NCT03804580|Experimental|osimertinib|All patients recieve osimertinib
89623570|NCT02482584|Active Comparator|CPAP treatment|Continuous Positive Airway Pressure (CPAP) treatment during three month.
89623571|NCT02482584|Other|Control group|Control group
89623572|NCT03317574|Experimental|MEDITOXIN|
89623573|NCT03317574|Active Comparator|BOTOX|
89623574|NCT01765972|Other|Test 1/Spectacles/Test 2/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
89623575|NCT01765972|Other|Test 2/Test 3/ Spectacles/Test 1|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.
89623576|NCT01765972|Other|Test 3/Test 1/ Test 2/ Spectacles|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.
89623577|NCT01765972|Other|Spectacles/Test 2/Test 1/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
89623578|NCT02486250||Main Study Recruits|Participants are recruited to come into a clinic and take supervised cognitive tests both online and paper/pencil as well as take unsupervised online cognitive tests at home. Participants will also be given a spit kit in clinic to determine ApOE Status.
89623579|NCT02486250||MRI & PET Substudy|A subset of 34 participants from the Main Study Recruits will be invited to have an MRI and PET scan. The purpose of the sub-study is to obtain feasibility data for collecting longitudinal neuroimaging studies for participants in this sample.
89623580|NCT02486250||ReVeRe 1|A subset of 250 participants from the Main Study Recruits and all MRI & PET Substudy participants will be invited to participate in ReVeRe 1. The purpose of ReVeRe is to validate an additional unsupervised online cognitive measure, administered via an iPad application.
89623581|NCT02486250||ReVeRe 2|A subset of approximately 80 participants from the Main Study Recruits and MRI & PET Substudy participants will be invited to participate in ReVeRe 2. The purpose of ReVeRe 2 is to determine if performance on ReVeRe test battery is sensitive to amyloid positivity in cognitively intact older adults and also sensitive to longitudinal cognitive decline in this patient population.
89623582|NCT01810666|Experimental|Recombinant Factor VIII|
89623583|NCT02482272|Active Comparator|Lamivudine plus Adefovir or Adefovir|Lamivudine+Adefovir or Adefovir for 48 weeks
89623584|NCT02482272|Experimental|Entecavir plus Adefovir|Entecavir+Adefovir for 48 weeks
89623585|NCT01766440|Experimental|Calcitriol 3 mcg/g ointment|Topical application every 12 hours for 14 consecutive days
89623586|NCT03317340||Patient Undergoing Urodynamics|
89623587|NCT01811212|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89623588|NCT03314532|No Intervention|Surgery group|We will completely resection of the visible tumor and made the resection margin negative. We will use regular/irregular resection of the liver tumor tissue, hemihepatectomy or extended hepatectomy.
89623589|NCT03314532|Experimental|TILA-TACE group|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
89623590|NCT02482194|Experimental|Autologous mesenchymal stem cells|use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation
89623591|NCT01767064|Experimental|Posted commitment letter|The poster-sized (18x24 inches) commitment letter, written at the 8th grade reading-level and displayed in English and Spanish, emphasize clinician commitment to guidelines for appropriate antibiotic prescribing and explain why antibiotics are not appropriate in many cases. These letters, featuring clinician photographs and signatures, are displayed in clinician exam rooms for a 16-week period.
89623592|NCT01767064|No Intervention|Control|Usual care with no posted letters.
88989448|NCT05564481|Experimental|Immediate intervention|Participants randomized to the immediate intervention group will participate in 3 video-conferencing sessions with a Certified Diabetes Care and Education Specialist (CDCES) interventionist and connect with a peer parent consultant immediately post randomization (expected intervention duration: 3 months).
88989449|NCT05564481|Active Comparator|Wait-list/delayed intervention|Participants randomized to the delayed intervention group will receive no intervention for 6 months post-randomization; after the 6-month follow-up period, the delayed intervention group also will participate in 3 video conferencing sessions with a CDCES interventionist and connect with a peer parent consultant (expected intervention duration: 3 months).
88989450|NCT05564364|Experimental|Healthy Controls 1|Healthy individuals participating in the study will be divided into two groups.
88989451|NCT05564364|Experimental|Healthy Controls 2|Healthy individuals participating in the study will be divided into two groups.
88989452|NCT05563493|Experimental|Treatment group, Chair-Based Exercise Training|Treatment group will receive chair-based exercise training. Chair-based exercise training consisting of 20 different exercises will be applied in 2-3 sets with an average of 8-15 repetitions. Rest between sets will average 45-60 seconds.
88989453|NCT05563493|Other|Control group, Breathing exercise|Control group will receive breathing exercises.
88989454|NCT05561244|No Intervention|CONTROL GROUP|Control group (n = 16 nursing homes, 64 patients): Patients will be monitored as usual using the Venous International Normalised Ratio strategy. Practices will not be changed (i.e. prospective observation of real-life practices; according to recommendations, at least 1 Venous International Normalised Ratio per month will usually be performed) and patients will not receive any supplementary intervention specific to the trial. A reminder of good International Normalised Ratio practices will be provided to nurses and prescribers.
89038032|NCT00659711|Active Comparator|Januvia 100mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
89038033|NCT00659711|Placebo Comparator|placebo|will be placed on a placebo for 12 weeks.
89038034|NCT00580346|Experimental|2|
89623593|NCT03317184|Experimental|Periumbilical incisions|
89623594|NCT03317184|Experimental|Pfannenstiel incision|
89623595|NCT04350814|Experimental|Self-Compassion Intervention Arm|Participants randomized to this condition will receive access to the audio Mindful Self-Compassion self-help intervention. The intervention is 7 weeks in duration (with a pacing of one lesson per week) and participants are asked to complete study measures once each week of the intervention.
89623596|NCT04350814|Active Comparator|Self-Reflection|Participants randomized to this active control condition will be asked to complete study measures at the same assessment intervals as those in the experimental arm. In addition to completing the measures, participants in the Self-Reflection Active Control condition will be asked to reflect on their self-reported symptoms and changes they may have experienced between assessment intervals.
89623597|NCT01811680|Experimental|supervised treadmill training|Supervised treadmill training on variable sensing treadmill.
89623598|NCT02479776|Active Comparator|Stem cell injection|Stem cells are injected and patients crossed over to placebo at 6 months
89623599|NCT02479776|Placebo Comparator|saline injection|saline is injected and patients crossed over to active arm at 6 months
89623600|NCT02479620|Active Comparator|Dexamethasone Delivery|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution."
89623601|NCT02479620|No Intervention|Control|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control."
89623602|NCT02482038|Experimental|geko device|
89623603|NCT03552562|Other|30 patients with no signs of diabetic retinopathy|
89623604|NCT03552562|Other|30 patients with mild diabetic retinopathy|
89623605|NCT03552562|Other|30 patients with moderate to severe diabetic retinopathy|
89623606|NCT03552562|Other|30 healthy age-and sex- matched control subjects|
89623607|NCT02481960|Experimental|Treatment arm|Intraparenchymal administration of CM-BC2 irinotecan drug-eluting bead in recurrent high grade glioma.
89623608|NCT01767688|Experimental|Moderate Hepatic Impairment Group|
89623609|NCT01767688|Experimental|Healthy Matched Control Group|
89623610|NCT03317028|Experimental|high dose of CS02|Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.
89623611|NCT03317028|Experimental|middle dose of CS02|Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.
89623612|NCT03317028|Experimental|low dose of CS02|Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.
89623613|NCT03317028|Placebo Comparator|placebo control|Subjects will receive placebo combined with a stable dose of metformin monotherapy.
89623614|NCT04492176|Experimental|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with CO2 fractional laser therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%，ACUPULSE,Lumenis) ,once a month for a total of 3 times .CO2 fractional laser stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection.
89623615|NCT04492176|No Intervention|before treatment|the patient did not receive laser treatment
89623616|NCT05713968||patients with EAT-10 higher than 3 or frailty questionnaire higher than 2|patients may have high risk of aspiration
89623617|NCT05713968||patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients may have low risk of aspiration
89623618|NCT03314376|Experimental|Prehabilitation program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
89623619|NCT03314376|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 6-week intervention.
89623620|NCT01768000|Experimental|Family Cognitive Adaptation Training|Participants in this group will receive the Family CAT manual and DVD
89623621|NCT01768000|No Intervention|Control group|Participants in this arm will support their family members as usual, and will not receive the Family CAT manual and DVD provided to those in the experimental arm of the study.
89038035|NCT00546663|Experimental|Open-label|
89038036|NCT00300599|Active Comparator|A|Continue positive airway pressure
89038037|NCT00300599|Placebo Comparator|B|Placebo
89623622|NCT04492878|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|
89623623|NCT02725866||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
89623624|NCT05713812|Active Comparator|Active Comparator|"IFC + Hot pack for 20 minutes~MDT (prone positioning) for 10 minutes.~Lumbar SNAGs + lumbar rotation mobilization.~Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.~Sham Kinesiotape will be applied"
89038038|NCT02581007|Experimental|Reduced-Intensity Mismatched Transplant|Fludarabine, Melphalan & Post-transplant cyclophosphamide
89623625|NCT05713812|Experimental|Experimental Group|"IFC + Hot pack for 20 minutes~MDT (Prone positioning) for 10 minutes.~Lumbar SNAGs + lumbar rotation mobilization.~Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.~Kinesiotape will be applied"
89688437|NCT01723631|Other|primary progressive multiple sclerosis- group 4|Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis
89688438|NCT01723631|Other|control 1|healthy volunteers
89623626|NCT05454072|Experimental|Sinonasal Microbiota Transfer|The transfer site for patients will be prepared by endoscopically removing any visible crusting, mucin, and purulent discharge from the sinuses and via manual high-volume (>60 ml), high-pressure saline wash on day 0. The donor mucus sample will be homogenized using sterile, disposable rotor-stator homogenizer tips for 30 seconds and 5 ml of donor mucus will be instilled into the affected sinus cavity(ies) using a masked syringe under endoscopic visualization, with the recipient's head in a dependent position. Patients will remain in this position for 15 minutes to facilitate transfer.
89623627|NCT05454072|Sham Comparator|Sham Sinonasal Microbiota Transfer|Sterile saline will replace the SNMT donor mucus in the masked syringe and will be delivered in an identical manner to the SNMT intervention.
89623628|NCT04492644||elderly inpatients|Elderly inpatients aged 65 years or older who were able to communicate and were clearly conscious. Elderly individuals who were diagnosed with gastrointestinal (GI) dysfunction, dysphagia, edentulism without rehabilitation with dentures, brain disease, stroke or cancer were excluded due to the possibility of dysphagia, cachexia or masticatory muscle palsy.
89623629|NCT03316794|Experimental|SC-005|SC-005 intravenous (IV) (various doses and dose regimens)
89623630|NCT02481726|Experimental|68Ga|In patients in suspicion of lung cancer or lung tuberculosis; in patients with differential diagnosis difficulties; without treatment or surgery. They underwent a standard routine 18F-FDG PET/CT first, and were injected 10~20MBq 68Ga-Alfatide II in the next day, followed by whole body PET/CT acquisitions.
89623631|NCT02481882|Other|Healthy Volunteers|Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.
89623632|NCT02481882|Other|MS Patients|Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).
89623633|NCT02481804|Experimental|Dietary intervention|There is one arm. Patients will first have an observation period, whre hey will get standard treatment during four weeks. Thereafter they will have the dietary intervention during 14 weeks.
89623634|NCT03314298|Experimental|testosterone anastrozole implant|testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet
89623635|NCT02479542|Active Comparator|Standard Gauze Dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the Standard Gauze Dressing Arm, a saline moistened sterile gauze will be packed into the wound with dry gauze and either tape or other means will be used to secure the dressing. The dressing will be changed daily and measured and photodocumented every 72 hours with the Wound Zoom system.
89623636|NCT02479542|Experimental|WiCare NPWT dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the WiCare NPWT Dressing Arm, a saline moistened sterile gauze will be packed into the wound and then the WiCare dressing and wound pump will be placed on the wound. The dressing will be changed, measured and photodocumented every 72 hours with the Wound Zoom system.
89623637|NCT02479308|Active Comparator|Moxifloxacin|Oral tablet
89623638|NCT02479308|Experimental|ALKS 5461|Sublingual tablet
88989455|NCT05561244|Experimental|INTERVENTIONAL GROUP|Intervention group (n = 16 nursing homes, 64 patients): Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
88989456|NCT05559099|Experimental|Tecovirimat|Tecovirimat capsules administered orally to participants for 14 days plus SOC.
88989457|NCT05559099|Placebo Comparator|Placebo|Matching placebo capsules administered orally to participants for 14 days plus SOC.
88989458|NCT05556343|Experimental|Cohort 1|Participants will receive MYK-224 either as a monotherapy or in combination with standard-of-care consisting of a beta-blocker. Participants who complete Cohort 1 will be eligible for an optional open label extension period
88989459|NCT05556343|Experimental|Cohort 2|Participants will receive MYK-224 in combination with standard-of-care consisting of either a calcium channel blocker or disopyramide (which is given in combination with either a beta-blocker or calcium channel blocker). Participants who complete Cohort 2 will be eligible for an optional open label extension period
88989460|NCT05556096|Experimental|ALXN1720|Participants will receive a weight-based initial (loading) dose of ALXN1720 on Day 1, followed by weight-based maintenance treatment with ALXN1720 on Day 8 and once every week (Q1W) thereafter for a total of 26 weeks. Following this randomized controlled treatment (RCT) period, all participants will receive ALXN1720 in an open-label extension (OLE) period of 105 weeks.
88989461|NCT05556096|Placebo Comparator|Placebo|Participants will receive placebo during the 26-week RCT period, after which they will enter the OLE period of the study and receive ALXN1720.
88989462|NCT05552092|Experimental|Experimental|The patients with ASA class 1-2 (20-65 years old) who are undergoing elective surgery with supine or lithotomy position, without position change, scheduled to last more than 90 min.
88989463|NCT05552066|Other|front phase|The current circuit remains unchanged (medical or nursing validation to confirm chemotherapy administration). Patient satisfaction is collected at each visit to the day hospital unit for chemotherapy.
89623639|NCT02479308|Placebo Comparator|Placebo|
89623640|NCT02485782||Hemodialysis patients|"midweek dialysis session~patients on maintenance hemodialysis at least 3 months~stable dry weight~single-pool Kt/V >1.4~no clinical cardiovascular disease during the 6 months preceding entry"
88989464|NCT05552066|Other|Post Phase|A short circuit is set up. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation). Patient satisfaction is also collected at each visit to the day hospital unit for chemotherapy.
88989465|NCT05550324||Affected Subjects|The subjects must have the diagnosis of cardiovascular disease
88989466|NCT05550324||Syndromes associated with Cardiovascular Disease|The subject must have a syndrome associated with cardiovascular disease
88989467|NCT05550324||Family Members|The subject must be related to an individual in cohort 1 or 2
88989468|NCT05550324||Controls|The subject is considered a control and does not fall into any of the other cohorts
89038039|NCT00546741|Experimental|1|
89038040|NCT00546741|Active Comparator|2|
89038041|NCT00546741|Active Comparator|3|
89623641|NCT02479386||Cohort Geographic Atrophy|Cohort of participants with GA secondary to AMD will be evaluated for changes in GA over time.
89623642|NCT02481492|Experimental|No flip technique|One group of boys will undergo a circumcision with no flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will detach spontaneously without intervention, and the participants are asked to have a visit soon after ring detached. The last scheduled follow-up visit is at 90 days.
89623643|NCT02481492|Experimental|Flip technique|One group of boys will undergo a circumcision with flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 90 days.
89623644|NCT05461560|Sham Comparator|Control: Sucrose solution|Participants will consume 50g of sucrose dissolved in 500 ml of tap water
89623645|NCT05461560|Experimental|Experimental: Seaweed extract in sucrose solution|Participants will consume 50g of sucrose and 1g of seaweed extract dissolved in 500 ml of tap water
89623646|NCT03314220|Experimental|standard care plus preoperative preparation|experimental group received standard care plus preoperative preparation, which included a tour, a cartoon video depicting a boy's surgical journey and familiarization with medical equipment.
89623647|NCT03314220|No Intervention|standard care|
89623648|NCT02481570|Experimental|Anesthesia optimization|Information from the pharmacokinetic simulation during an anesthetic regimen of a propofol based Total Intravenous Anesthetic (TIVA)
89623649|NCT02479464|No Intervention|Part 1|This is the treatment as usual arm to monitor the current standard clinical practice
89623650|NCT02479464|Other|Part 2|This group will be provided with genotyping results after baseline visit to guide clinical medication management
89623651|NCT05713578|Experimental|apantamide+docetaxel+ADT|The dosage is adjusted according to the adverse reaction (according to the instructions).Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally;ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator;The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles. It is up to the researcher to decide whether to use prednisone or prednisolone.
89623652|NCT05713578|Active Comparator|apantamide+ADT treatment|Patients were treated with apantamide and ADT after enrollment. The patient received each drug treatment according to the instructions. The dosage is adjusted according to the adverse reaction (according to the instructions)Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally;ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT used in each research center are determined by the investigator.
89623653|NCT02485548|Experimental|Raltitrexed plus cisplatin|Raltitrexed plus cisplatin and IMRT
89623654|NCT02485548|Active Comparator|5-fluorouracil plus cisplatin|5-fluorouracil plus cisplatin and IMRT
89623655|NCT02478840|Experimental|Lamazym|1 mg Lamazym/kg Body weight
89623656|NCT02479152|Active Comparator|LUCAS 2 AD|LUCAS 2 AD will be used for CPR
89623657|NCT02479152|Other|LUCAS2|LUCAS2 will be used for CPR
89623658|NCT02478918|Experimental|Receiving reminder phone call|Will receive phone call to remind colonoscopy date and bowel prep
89623659|NCT02478918|No Intervention|Not receiving reminder phone call|Will not receive phone call to remind colonoscopy date and bowel prep
89623660|NCT02478996|Experimental|Internet-based exercise program|The intervention group is supervised by a sports scientist eight to twelve weeks before and after surgery. Patients receive an individually designed intensive exercise program based on the functional and Fitness measurements at first diagnosis.
89623661|NCT02478996|No Intervention|Basis therapy|Participants of the Treatment as usual (TAU) group receive written information material enlightening the importance of regular physical activities and general releases on preparation for esophagectomy.
89623662|NCT02479074|Active Comparator|Montelukast (high FeNO)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
89623663|NCT02479074|Active Comparator|Prednisolone, Montelukast (high FeNO)|Prednisolone 5 mg and montelukast 10 mg. Patients to take Prednisolone 5 mg, 4 tablets per day for 14 days patients to take Montelukast 10 mg film-coated tablet per day for another 14 days Prednisolone is a Class A medicine Montelukast is a Class B medicine
89623664|NCT02479074|Active Comparator|Montelukast|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
89623665|NCT02478762|Active Comparator|Normal glycemic control|GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
89623666|NCT02478762|Experimental|Low glycemic control|GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.
89623667|NCT02478684|Active Comparator|30 seconds of DCC|30 Seconds of placental blood transfusion
89623668|NCT02478684|Active Comparator|60 seconds DCC|60 Seconds of placental blood transfusion
89623669|NCT05715060|Active Comparator|stainless steel wire closure|conventional closure of median sternotomy by stainless steel wire
89623670|NCT05715060|Active Comparator|PDS sternal closure|closure of median sternotomy by PDS
89623671|NCT02481180|Experimental|T0001|
89623672|NCT02481180|Active Comparator|Enbrel|
89623673|NCT02480946|Experimental|Single Ascending Dose and Food Effect|Part A will be a single-dose, sequential-group, double-blind, placebo-controlled study of MBS2320.
89623674|NCT02480946|Experimental|Multiple Ascending Dose|Part B will be a multiple-dose, sequential-group, double-blind, placebo-controlled study to investigate 3 planned dose levels.
89623675|NCT02480946|Experimental|Relative Bioavailability|Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.
89623676|NCT02480946|Experimental|Drug-Drug Interaction with Methotrexate|Part D will be a multiple dose study incorporating an open-label, fixed-sequence drug-drug interaction between MBS2320 and methotrexate and biomarker evaluation.
89623677|NCT02480868|Experimental|ARTEBONE|Bone Void Filler
89623678|NCT02478528|Experimental|Experimental|
89623679|NCT03316716|No Intervention|Control Group|Women randomised to the control group will receive the hospital's current standard of care which is the peri-operative administration of room-temperature (25°C) IV fluids (Hartman's solution) started before the insertion of regional anaesthesia and continued until the transfer of the woman to the postnatal ward.
89623680|NCT03316716|Experimental|active warming group|Women randomised in the intervention group will recieve warm IV fluids. The IV fluids (Hartman's solution) will be warmed to 39°C with the use of Hotline™ device.
89623681|NCT02478606|No Intervention|Control Group|Without intervention
89623682|NCT02478606|Experimental|Static Group|Will receive passive static stretching in hamstring muscle
89623683|NCT02478606|Experimental|PNF Group|Will receive passive proprioceptive neuromuscular facilitation stretching in hamstring muscle
89623684|NCT01769170|Placebo Comparator|Placebo|Matching placebo administered orally twice weekly
89623685|NCT01769170|Active Comparator|Brincidofovir|100 mg brincidofovir administered orally twice weekly
89623686|NCT05714904|Experimental|Dose escalation|"2 cohorts of 3 patients each. All the patients enrolled in the study will receive a single subretinal injection in one eye.~Cohort 1: Subretinal administration of a single low dose ZVS101e at Day 0. Cohort 2: Subretinal administration of a single high dose ZVS101e at Day 0."
89623687|NCT04350970|Active Comparator|Control|The cardiopulmonary exercise test was performed with patient breathing room air.
89623688|NCT04350970|Active Comparator|NIV|The cardiopulmonary exercise test was performed with non-invasive ventilation during the test.
89623689|NCT04350970|Active Comparator|HFNT|The cardiopulmonary exercise test was performed with a High flow nasal therapy during the test.
89623690|NCT02480634|Active Comparator|High dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle , a total of six cycle，Radiotherapy dose: 30Gy/10f
89623691|NCT02480634|Experimental|Low dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle, a total of six cycle，Radiotherapy dose: 15Gy/5f
89623692|NCT01815502|Experimental|Dobutamine + Sildenafil|Sildenafil will be given an one time dose 30 to 90 minutes prior to cardiac catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
88989469|NCT05546424||control|"Non-specific cognitive exercises included general advice from MS neuropsychologist specialists on how to manage cognitive difficulties and general cognitives exercises to improve cognitive performance elaborated at our MS Unit, using exercises like sudokus, crosswords and labyrinths.~This control group will require the completion of at least 30 minutes of cognitive exercises daily from Monday to Friday for 5 months. As a complement, patients will be instructed to read newspapers or magazines at least 15 minutes daily."
89038042|NCT00546858||Survey|Patients with interstitial cystitis
89038043|NCT00546936|Experimental|ranibizumab intravitreal injection|0.5 mg intravitreal injection of ranibizumab
89038044|NCT00546936|Active Comparator|Photodynamic Therapy|Photodynamic therapy with Visudyne
89623693|NCT01815502|Placebo Comparator|Dobutamine + placebo|Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to cardiac catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
89623694|NCT01769248|Active Comparator|Fine needle aspiration|fine needle aspiration
89623695|NCT01769248|Active Comparator|Fine needle biopsy|Fine needle biopsy
89623696|NCT03399292||Group 1|10 male and female healthy subjects receive Cationorm MD sine eye drops once
89623697|NCT03399292||Group 2|10 male and female volunteers with dry eye disease receive Cationorm MD sine eye drops once
89623698|NCT03399292||Group 3|10 male and female volunteers with Maibomian gland disease receive Cationorm MD sine eye drops once
89623699|NCT03399292||Group 4|10 male and female volunteers with receive Cationorm MD sine eye drops once
89623700|NCT02726022||Chronic Hepatitis C Participants|Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.
89623701|NCT05714748|Experimental|Treatment Cohort|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval.
89623702|NCT02258152|Placebo Comparator|Placebo|
89623703|NCT02258152|Experimental|SYN120|
89623704|NCT02725788|Experimental|New PIV Dressing|Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
89623705|NCT02725788|Other|Standard PIV Dressing|Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape
89623706|NCT02485626||Anthracycline treated BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated with anthracyclines respectively 5-7 years ago and 10-12 years ago.
89623707|NCT02485626||Anthracycline naive BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated without anthracyclines respectively 5-7 years ago and 10-12 years ago.
89688439|NCT01723631|Other|Control 2|Patients with central or peripheral neurological non-inflammatory, non-autoimmune.
89688440|NCT01723631|Other|Control 3|Patients having an autoimmune pathology
89688441|NCT01723787||Infantile Spasms|Participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
89623708|NCT01817374|Other|2D US grayscale plus quantitative VCEUS|"Patients with breast cancer receiving neoadjuvant chemotherapy will undergo a 2D grayscale imaging followed by quantitative VCEUS imaging:~prior to initiation of treatment (baseline);~at 14 (± 4 days) after initiation of neoadjuvant chemotherapy (early treatment);~at 28 days (± 4 days) after initiation of neoadjuvant chemotherapy (inter-regimen);~at completion of therapy prior to definitive surgery (usually 2-3 months after initiation of treatment). Each patient will undergo a total of four VCEUS examinations."
89623709|NCT04492332|Sham Comparator|normal controls with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
89623710|NCT04492332|Sham Comparator|normal controls without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
89623711|NCT04492332|Active Comparator|BTSS patients with VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were found.
89623712|NCT04492332|Active Comparator|BTSS patients without VVC|BTSS was confirmed by two of magnetic resonance venography (MRV), computed tomography venography (CTV) or digital subtraction angiography (DSA). The index of TSS (ITSS) score was a useful tool for the assessment of BTSS severity. The degree of stenosis was graded from 0 to 4 based on the following scale: 0 = normal; 1 = stenosis up to 1/3; 2 = stenosis between 1/3 and 2/3; 3 = stenosis >2/3; and 4 = hypoplasia. ITSS was calculated as degree of right TSS × degree of left TSS. Vertebral venous collaterals (VVC) were not found.
89623713|NCT02485470|Experimental|MPACT|A 7-week (7 weeks x 3 sessions per week), on site, functional resistance training (FRT) as well as a walking program concurrent with CCRT will be followed by a 7-week post-CCRT home program. The protocol follows American College of Sports Medicine (ACSM) prescription guidelines for cancer patients.
89623714|NCT02485470|No Intervention|Usual Care|
89623715|NCT02478294||the surgical intervention group|Thoracoscopic LAA Excision plus AF Ablation. Patients receiving thoracoscopic left atrial appendage excision plus atrial fibrillation alation
89623716|NCT02478294||oral anticoagulant treatment group|Warfarin or Novel Oral Anticoagulants. Patients receiving warfarin treatment (INR 2.0-3.0) or novel oral anticoagulants
89623717|NCT02485392|Active Comparator|Single-Site robot-assisted cholecystectomy|Single-Site robot-assisted cholecystectomy
89623718|NCT02485392|Active Comparator|Single-incision laparoscopic cholecystectomy|Single-incision laparoscopic cholecystectomy
89623719|NCT01770652|Experimental|Normal renal function|Healthy volunteers, defined as having an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
89623720|NCT01770652|Experimental|Mild Renal Impairment|Mild impairment, defined as having an eGFR 60-89 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
89623721|NCT01770652|Experimental|Moderate Renal Impairment|Mild impairment, defined as having an eGFR 30-59 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
89623722|NCT01770652|Experimental|Severe Renal Impairment|Severe impairment, defined as having an eGFR 15-19 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
89623723|NCT02485314||Participation|Parents will complete the PEM-CY (Participation and Environment Measure for Children and Youth).
89623724|NCT01820416|Experimental|Low-Level Laser Therapy|Low-level laser applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
89623725|NCT01820416|Placebo Comparator|Disabled Laser|Low-level laser device with laser diodes disabled. Also applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
89623726|NCT01820416|No Intervention|Control|Visit laboratory using same schedule as experiment and placebo. No Low-level laser or any treatment applied. Used to assess normal test-retest variability.
89623727|NCT03316482|Experimental|Leuplin DPS 11.25mg s.c. every 12 weeks|Open
89623728|NCT02480790||Patients with malignant disease|Patients with ovarian, tubar or primary peritoneal cancer
89623729|NCT02480790||Patients with benign disease|Patients with suspected ovarian cancer where the final pathologic diagnosis is benign
89623730|NCT03143218|Active Comparator|SMC with SP+AQ|Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
89623731|NCT03143218|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.
89623732|NCT03143218|Active Comparator|RTS,S/AS01 PLUS SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
89623733|NCT02480478||intrahepatic cholestasis of pregnancy|5 ml whole blood sample is going to collect from intrahepatic cholestasis of pregnancy group for the assessment of serum autotaxin levels
89623734|NCT02480478||healthy control group|5 ml of whole blood is going to taken from healthy control group
89623735|NCT02480556|Experimental|Group A|manual seperation of the placenta
89623736|NCT02480556|Active Comparator|Group B|Conservative separation of placenta
89038045|NCT02438891|Experimental|CBT course|8-week internet-based cognitive behavioral therapy and sound therapy course
89038046|NCT00546975|Experimental|1|Resource Support® Novartis
89623737|NCT01771666|Experimental|ISB and ICG|"The dose of Isosulfan blue (ISB) dye and Indocyanine green (ICG) solution will be started.~(IC-GREEN) SPY Elite Imaging willbe used to capture the images of axillary cavity."
89623738|NCT05713188|Experimental|Treatment|All volunteers will receive the same treatment
89623739|NCT02485236|Active Comparator|Low flow oxygen via nasal cannula|In the low flow oxygen via nasal cannula, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
89623740|NCT02485236|Active Comparator|Humidified Nasal High Flow Therapy|Adjustment of humidified high flow air therapy: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
89623741|NCT01821352|Active Comparator|Erchonia Obesity Laser|The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
89623742|NCT01821352|Placebo Comparator|Placebo Laser|Laser device emitting sham green light that has no therapeutic effect.
89623743|NCT02485002|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
89623744|NCT02485002|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
89623745|NCT01772758|Experimental|Protocol 1: AOC|measurements at baseline and 2 hours following the antioxidant cocktail that is comprised of over the counter vitamins (vitamin C 1000mg, vitamin E 600 IU, and alpha lipoic acid 600 mg) that will be given in two doses, 30 minutes apart.
89623746|NCT01772758|Experimental|Protocol 2: BH4 (5mg)|measurements at baseline and 3 hours following the single dose of 5mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
89623747|NCT01772758|Experimental|Protocol 2: BH4 (20mg)|measurements at baseline and 3 hours following the single dose of 20mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
89623748|NCT01772758|No Intervention|Healthy Controls|baseline measurements were done with no intervention
89623749|NCT05712954|No Intervention|control group|The study will start with the women in the control group. The women in the control group, who were selected in accordance with the sample selection criteria and agreed to be a participant, will be given data collection tools for the pre-test on the day of the procedure and no intervention will be made other than the counseling given at the hospital. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics.
89623750|NCT05712954|Experimental|music group|The women in the 1st group will be pre-tested with data collection tools before the HSG, then after they are taken to the table, headphones will be put on and music will be played. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics. After the women in this group are completed, the 2nd group will be started.
89623751|NCT05712954|Experimental|video group|2. The women in the group will be pre-tested with data collection tools before the HSG, and after they are taken to the table, a video with natural landscape pictures prepared by the researcher will be opened on the iPad. VAS and State-Trait Anxiety Inventory will be applied after the procedure. After 24 hours, the women will be reached and questioned whether they use analgesics.
89623752|NCT01775410|Experimental|Wolverine System|Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries
89623753|NCT02485080|Experimental|Simeprevir + sofosbuvir daily, 24 weeks|Eligible and consenting patients will be treated with sofosbuvir (SOF) 400 mg daily and simeprevir (SMV) 150 mg daily for 24 weeks. Both drugs will be administered orally, per manufacturers' instructions.
89623754|NCT02480322||Sleeve group|Patients undergoing gastric sleeve resection.
89623755|NCT02480322||Proximal RYGB group|Patients undergoing proximal gastric bypass surgery.
89623756|NCT02480322||Distal RYGB group|Patients undergoing distal gastric bypass surgery.
89623757|NCT02480322||BMI-matched control group|
89623758|NCT02480322||Normal-weight control group|
89623759|NCT02480400|Experimental|Supported Escitalopram|Escitalopram, with assessment visits at baseline, and weeks 2, 4, 6 and 8
89623760|NCT02480400|Active Comparator|Escitalopram|Escitalopram, with assessment visits at baseline, week 4 and week 8, and a safety visit at week 2
89623761|NCT01823614||Naïve patients, >500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is more than 500 cells per mm3
89623762|NCT01823614||Naïve patients, 350-500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is between 350 and 500 cells per mm3
89623763|NCT01823614||Naïve patients, <350|The group contains patients who have not any ARV therapy experience and the level of CD4 count is less than 350 cells per mm3
89623764|NCT01823614||ARVT <6 months|The group contains patients who have ARVT experience and obtain ART treatment less than 6 months
89623765|NCT01823614||ARVT from 6 months to 3 years|The group contains patients who have ARVT experience and obtain ART treatment from 6 months to 3 years
89623766|NCT01823614||ARVT >3 years|The group contains patients who have ARVT experience and obtain ART treatment more than 3 years
89688442|NCT01723787||biological parents|Biological parents of participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
89688443|NCT02909764|No Intervention|Control Group|Children will receive regularly salted cereal to consume 4 times per week over a 2-month period.
89623767|NCT01824082|Experimental|Ropivacaine 0.5%|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: normal saline.
89623768|NCT01824082|Placebo Comparator|Normal saline (salt water) infusion|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of normal saline placebo fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: ropivacaine 0.5%.
89623769|NCT02725710|Active Comparator|Group 1: Placebo|Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
89623770|NCT02725710|Active Comparator|Group 2: Gabapentin|Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
89623771|NCT02256358|Active Comparator|Midazolam|Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.
89623772|NCT02256358|Experimental|Ketamine|Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.
89623773|NCT05521542|Experimental|SirPlux™ Duo Dual-API Coated PTCA Balloon Catheter|Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and undergo a planned percutaneous coronary intervention with SirPlux™.
89623774|NCT04999098|Active Comparator|treatment group 1: Echinaforce Forte (EFF) Tablets (chewed)|"1st arm (EFF group): Slowly sucking 1 Echinaforce Forte tablet (1 tablet: 1'200mg EF) until dissolution Dose 1. Another 2 X 1 EF Forte tablets (total of 2 tablets: 2'400 mg EF) is taken one-by-one Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Forte tablets."
89623775|NCT04999098|Active Comparator|treatment gorup 2: Echinaforce Chewable (EFC) Tablets (chewed)|"2nd arm (EFC group): Slowly sucking 1 x 3 Echinaforce Chewable tablets (total 3 tablets: 1'200mg EF) until dissolution Dose 1. Another dose of 2 x 2 & 1 x 3 EF Chewable tablets (total 7 tablets: 2'800mg EF) are slowly sucked Dose 2 after swab sampling, which is repeated after complete dissolution of the second dose of EF Chewable tablets."
89688444|NCT02909764|Experimental|Low Sodium Group|Intervention: Children will receive low sodium cereal to consume 4 times per week over a 2-month period.
88989470|NCT05546424||Intervention EMRESERVA|"Specific cognitive rehabilitation program EM-Reserva will be provided by two specialized MS~Neuropsychologists in groups of 6 participants who will meet approximately an hour weekly, for 5 months.EM reserva cognitive program includes the following activities:~Cognitive leisure tasks~Physical exercises (workout exercises)~Activities that promote social relationships (social exercises)"
88989471|NCT05537337|No Intervention|Arm 1 (Control Arm)|Participants will experience an unmodified version of NUSMart that is designed to replicate the traditional shopping experience of any online grocery shopping platform with details such as item description, brand, price, image, nutritional information etc.
88989472|NCT05537337|Experimental|Arm 2 (Multicomponent Intervention Arm)|Participants will experience a modified version of NUSMart with the multicomponent intervention enabled. This intervention consists of a subset of the combined interventions tested in Aim 1 namely, 1. Food labels (with the summary of healthiness of shopping baskets & targets), 2. Ordering and 3. Within Group Healthier Substitution.
88989473|NCT05530720||Online survey with 3.000 participants using mobile website technology|
88989474|NCT05526196|Other|Placebo|A cigarette containing placebo cannabis and placebo tobacco
88989475|NCT05526196|Other|Tobacco|A cigarette with placebo cannabis and active tobacco
88989476|NCT05526196|Other|Cannabis|A cigarette with active cannabis and placebo tobacco
88989477|NCT05526196|Other|Tobacco and cannabis|A cigarette with active cannabis and active tobacco
88989478|NCT05525689|Experimental|Technology Enabled Service|Access to the Intellicare suite of digital mental health self-management tools and coaching
88989479|NCT05525689|Active Comparator|eTreatment as Usual|Current care plus access to a website that will provide content specific to perinatal depression
88989480|NCT05522660|Experimental|standard systemic treatment with stereotactic radiosurgery (SRS)|Arm A
88989481|NCT05522660|Active Comparator|standard systemic treatment without stereotactic radiosurgery|Arm B
88989482|NCT05522361|Experimental|Open-label crossover|Participants crossover to 36 months of open-label risdiplam mono therapy following a comparable period of nusinersen treatment.
88989483|NCT05515315|Experimental|Tislelizumab combined with chemothapy|
88989484|NCT05513950|Experimental|Test Treatment|A single intravenous (IV) dose of CHF10067
88989485|NCT05513950|Placebo Comparator|Reference treatment|A single dose of placebo (commercial source of 0.9% sodium chloride aqueous solution)
88989486|NCT05511597|Experimental|SBT+CP|Split-belt training + complex task practice
88989487|NCT05511597|Active Comparator|SBT+PL|Split-belt training + static exercise
89038047|NCT00546975|Active Comparator|2|Resource Protein®, Novartis
89038048|NCT00546975|Placebo Comparator|3|
89038049|NCT05006313|Experimental|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be utilized to view initial debridement area. Using a sterile marking pen, the surgeon will mark the areas of tissue on skin, subcutaneous tissue, muscle, bone, or other that he or she wishes to debride further due to poor perfusion. A reference point on uninjured tissue of the same extremity at least 10 cm from the wound will be identified and measured for perfusion (set to reference of 100% perfusion). The area to be further debrided will be measured for percent perfusion relative to this reference point.
89038050|NCT01263496|Experimental|Alogliptin 6.25 mg QD|
89038051|NCT01263496|Experimental|Alogliptin 12.5 mg QD|
89038052|NCT01263496|Experimental|Alogliptin 25 mg QD|
89038053|NCT01263496|Experimental|Alogliptin 50 mg QD|
89038054|NCT01263496|Active Comparator|Voglibose 0.2-mg TID|
89038055|NCT00547014|Experimental|Cohort 1 1mg|
89038056|NCT00547014|Experimental|Cohort 2|
89038057|NCT00547014|Experimental|Cohort 3|
89038058|NCT00547014|Experimental|Cohort 4|
89038059|NCT00547014|Experimental|Cohort 5|
89038060|NCT04681937|Experimental|Hyaluronic Acid + Physical Therapy|4 ml hyaluronic acid (subacromial)
89038061|NCT04681937|Experimental|Platelet-Rich-Plasma (PRP) + Physical Therapy|4 ml platelet-rich-plasma (subacromial)
89038062|NCT04681937|Experimental|Steroid + Physical Therapy|methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) (subacromial)
89038063|NCT04681937|Experimental|Placebo (serum saline) + Physical Therapy|4 ml serum saline (subacromial)
89038064|NCT02131649|Experimental|18F-FCH PET/MRI Scan|Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging. Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences. Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
89038065|NCT00547092|Active Comparator|1|tadalafil given the first 12 weeks and after a 4 week washout sildenafil is given for 12 weeks.
89038066|NCT00547092|Active Comparator|2|sildenafil given the first 12 weeks and after a 4 week washout tadalafil is given for 12 weeks.
89038067|NCT01964495|Active Comparator|Common clinical practice|Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
89038068|NCT01964495|Experimental|CRP-guided treatment|Treatment according to CRP levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
89038069|NCT01964495|Experimental|PCT guided treatment|Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
89038070|NCT00547170|Experimental|1|Half of enrolled women will be randomly assigned to group 1.
89038071|NCT00547170|Active Comparator|2|Half of enrolled women will be randomly assigned to group 2
89038072|NCT00900809|Experimental|Neukoplast™ (NK-92)|Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose.
89038073|NCT01263223|Experimental|LY2216684, placebo, LY or placebo|"Period 1: 18 milligrams (mg) LY2216684 administered orally once daily on Days 1-4~Period 2: placebo administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
89623776|NCT04999098|Active Comparator|treatment group 3: Echinaforce Tincture (EFT, gargling)|"3rd arm (EFT group): Gargling of 2 x 19 drops of Echinaforce tincture (1'200 mg EF) is diluted in 2 x35 mL water Dose 1. Another dose of 3 x 30 drops of Echinaforce tincture (2'800 mg EF) diluted in 3 x35 mL water for 15 sec each Dose 2, gargled for 15 sec and swallowed after swab sampling, which is repeated after gargling of the second dose of EF Tincture."
89623777|NCT01824160|Other|Repair of RV-PA Conduit Disruption|Covered stenting of RV-PA conduit injury
89038074|NCT01263223|Experimental|Placebo, LY2216684, placebo or LY|"Period 1: placebo administered orally once daily on Days 1-4~Period 2: 18 mg LY2216684 administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
89038075|NCT00547209|Active Comparator|1|ventilation with air and oxygen
89038076|NCT00547209|Experimental|2|ventilation with nitrous oxide and oxygen
89038077|NCT00547287|Active Comparator|1|Currently prescribed dosage of sildenafil is continued until wash-out period.
89038078|NCT00547287|Active Comparator|2|20 mg tadalafil given after one week sildenafil wash-out period.
89038079|NCT02908958|Experimental|PEG-somatropin|Low dose group, PEG Somatropin 0.14mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
89623778|NCT02478216|No Intervention|C group|Remote ischemic preconditioning will not be applied
89038080|NCT02908958|Experimental|PEG-Somatropin|High dose group, PEG Somatropin 0.2mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
89038081|NCT01263106|Experimental|Theophylline, LY2216684 + Theophylline|Period 1: single 200-milligram (mg) theophylline oral dose on Day 1; Washout period of at least 7 days; Period 2: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3
89038082|NCT01263106|Experimental|LY2216684 + Theophylline, Theophylline|Period 1: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3; Washout period of at least 7 days; Period 2: single 200-mg theophylline oral dose on Day 1
89038083|NCT00547326|Experimental|1|Treatement with osteopatic cranial techniques
89038084|NCT00547326|Placebo Comparator|2|Treatment with placebo
89038085|NCT01263028|Experimental|Ergocalciferol supplementation|
89038086|NCT02908919|Active Comparator|Fortrans pulv. sol|Polyethylene glycol solution. Used 4 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
89038087|NCT02908919|Active Comparator|Picoprep pulv. sol.|Natrium picosulfate/ magnesium citrate solution. Used 2 l before colonoscopy. bowel preparation interval: QD/BID or one day.
89038088|NCT02908919|Active Comparator|Moviprep pulv. sol.|Polyethylene glycol + ascorbic acid solution. Used 2 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
89623779|NCT02478216|Experimental|R group|Remote ischemic preconditioning will be applied.
89623780|NCT04977726|Experimental|STRIVE - Simulation Training for Resilience in Various Environments|
89623781|NCT04977726|Sham Comparator|Control|
89623782|NCT01775800|Experimental|Treatment modification|Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.
89623783|NCT01775800|No Intervention|Usual care|Patients will receive the usual hemodialysis care with no modifications
89623784|NCT02478060|Experimental|Cohort 1|Birch-SPIRE or placebo, 2 weeks apart
89623785|NCT02478060|Experimental|Cohort 2|Birch-SPIRE or placebo, 2 weeks apart
89623786|NCT02478060|Experimental|Cohort 3|Birch-SPIRE or placebo, 2 weeks apart
89623787|NCT02478060|Experimental|Cohort 4|Birch-SPIRE or placebo, 2 weeks apart
89623788|NCT02478060|Experimental|Cohort 5|Birch-SPIRE or placebo, 2 weeks apart
89623789|NCT02724462|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
89623790|NCT02724462|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
89623791|NCT01825408|Active Comparator|Doxycycline, 3 weeks|Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 3 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
89623792|NCT01825408|Active Comparator|Doxycycline, 6 weeks|Subjects with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 6 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
89623793|NCT01825408|Active Comparator|Azithromycin, 3 weeks|Subjects with Chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 3 weeks duration.
89623794|NCT01825408|Active Comparator|Azithromycin, 6 weeks|Subjects with chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 6 weeks duration.
89623795|NCT03108612|Experimental|Study group|Intervention: Análisis de carga de trabajo (ACT)
89623796|NCT01776268|Experimental|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
89623797|NCT01776268|No Intervention|No oral priming|No oral priming
89623798|NCT02477904|Experimental|ASD/KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will receive the ketogenic diet (KD) intervention.
89623799|NCT02477904|Active Comparator|ASD/non-KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
89623800|NCT02477904|Active Comparator|non-ASD/non-KD|Typically developing children (2-21 years of age) diagnosed as not having autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
89623801|NCT04945824|Experimental|Novel Intracanalicular Insertion Device|
89623802|NCT02476656||GPNC|CenteringPregnancy group prenatal care
89623803|NCT02476656||IPNC|Individual prenatal care
89623804|NCT01777126|Active Comparator|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
89623805|NCT01777126|Experimental|Oral Nutrition Protocol (ONP) group|Oral intake was increased progressively with oral fluids and easily digestible food, independent of bowel movements. The corresponding energy content from the meals and oral fluids were calculated. Fortimel Jucy®, 200 ml containing 300 kcal, was used as the formulary energy sip. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician. If the patient tolerated the ONP well, the oral intake was considered equal in terms of calories as the corresponding oral meal in the ONP. From the sixth day, the patient was allowed to eat at will. Only if oral intake remained insufficient after 5 days, which was left to the opinion of the treating physician, PN could be initiated in this group.
89623806|NCT04937634|Experimental|Melphalan|
89623807|NCT01826812||Dry Eye|"The patients with Sjogren Syndrome related or non-Sjogren Syndrome related dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
89623808|NCT01826812||Controls|"The patients without dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
89623809|NCT02725476|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 12 infusions
89623810|NCT04931628|Active Comparator|salvianolic acid group|salvianolic acid group 100mg+0.9%NaCl 250ml, injection, 14 days
89623811|NCT04931628|Placebo Comparator|0.9% NaCl|0.9%NaCl 250ml, injection, 14 days
89623812|NCT02262130|Experimental|Omalizumab|Omalizumab 300 mg W0, W4 and W8
89623813|NCT01777438||control group|a control group of AR patients who visited the ear nose and throat (ENT) department of the University Hospitals Leuven in the same time period
89623814|NCT01777438||patients having SCIT|patients who started immunotherapy at the Department of Allergology of the University Hospitals Leuven between November 2007 and February 2010.
89623815|NCT02578342||Healthy volunteers|healthy volunteer between age of 20 to 55 will undergo MRI examination.
89623816|NCT02578342||ADHD subjects without medication|Medication-naive subjects with ADHD (20-55 years) will undergo MRI examination.
89623817|NCT02578342||ADHD subjects with medication|Subjects with ADHD (20-55 years), under medication will undergo MRI examination.
89623818|NCT02476188|Experimental|Patients|Samples of blood at H0, H+6, H+24 and H+72
89623819|NCT02476188|Experimental|Patients control|Samples of blood at H0
89623820|NCT02476188|Active Comparator|Control (healthy person)|Samples of blood at H0
89623821|NCT04887870|Experimental|Phase 2/3: Open label extension of parent study|The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.
89623822|NCT02476344|Experimental|research arm|40 subjects will undergo the experiment protocol, total 3 days, each consisting different training exercises.
89623823|NCT05665452|Active Comparator|Group (1)|patients will receive stretch and strength exercises
89038089|NCT04323319|Experimental|ESWT Group|Patients in the ESWT group will be treated with ESWT once a week for 4 weeks. Each patient was treated with epine calcaneus and its surroundings. The treatment dose of 10 Hz, 2.5 bar, 2000 shock wave with BTL L-6000 SWT device will be applied by the same therapist. Patient completed plantar fascia and gastrocnemius streching exercises right after treatment. The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
89623824|NCT05665452|Experimental|Group (2)|patients will receive stretch, strength, patellar mobilization, retinacula release and deep friction message
89688445|NCT01724879|Experimental|Dasatinib and chemotherapy|Dasatinib, QD p.o. administration, day 1 to EOS
89038090|NCT04323319|Experimental|Graston Technique® Group|The application was carried out by Graston Technique® (GT®) certified, a therapist with orthopedic rehabilitation and soft tissue treatments for over 12 years. GT® instruments were used to diagnose and treat the damaged soft tissue of gastrocnemius and plantar fascia. The application protocol and the instruments used according to the regions were determined with reference to the GT® manual. GT® treatment can be given to the same region twice a week. A minimum of 2 days break was given between the applications. Gastrocnemius and plantar fascia application completed in 5 minutes in one leg. GT2, GT4 and GT6 instruments used for application.The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
89533386|NCT04823858||Examination Group|There will only be one arm of subjects in this study. The arm will include subjects who plan to undergo a single-level TLIF/PLIF stabilized with pedicle screws and meet all of the eligibility criteria.
89533387|NCT04815746|Experimental|Psychosocial Symptom Management Intervention (PSMI) Experimental Condition Arm|Participants in this group will receive the Cognitive Behavioral Therapy (CBT)-based skills over a 10-week period.
89533388|NCT04815746|Active Comparator|Usual Clinical Care Control Arm|Participants in this group will receive standard education.
89533389|NCT04813263||Participants Treated With Venetoclax|Participants who are administrated venetoclax for treatment of AML under routine clinical practice.
89533390|NCT04803721||Patient with a myelodysplastic syndrome|Patient over 18 years of age with a myelodysplastic syndrome (WHO 2016 classification) of low risk (LR= International Prognostic Scoring System (IPSS)-R<4.5) or high risk (HR=Revised International Prognostic Scoring System>4.5)
89533391|NCT04803721||Control patient|Healthy blood donor (regardless of age) Or Patient >60 years old, see at the geriatrics platform of the hospital la Grave (CHU of Toulouse), having expressed his non opposition to participate in the study
89533392|NCT04803058|Experimental|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
89533393|NCT04803006|Experimental|Arm 1|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
89533394|NCT04803006|Experimental|Arm 2|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
89533395|NCT04803006|Experimental|Arm 3|TCD601administered with non-myeloablative conditioning and standard of care immunosuppression
89533396|NCT04773678|Experimental|CBP-201 Dose 1|CBP-201 Dose 1 subcutaneous (SC) injection.
89533397|NCT04773678|Experimental|CBP-201 Dose 2|CBP-201 Dose 2 subcutaneous (SC) injection.
89533398|NCT04773678|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
89533399|NCT04764331|Other|Intervention|Caps will be provided for each subjects will use the cap once daily for10-minute treatment regimen
89533400|NCT04759586|Active Comparator|Arm A (DA-EPOCH-R)|See Detailed Description
89533401|NCT04759586|Experimental|Arm B (DA-EPOCH-R, nivolumab)|Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and LP for CSF collection during screening. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
89533402|NCT04759586|Active Comparator|Arm C (R-CHOP)|Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
89533403|NCT04759586|Experimental|Arm D (R-CHOP, nivolumab)|Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
89533404|NCT04759586|Active Comparator|Arm E (R-CHOP, radiation therapy)|Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
89038091|NCT04323319|Experimental|Control Group|Stretching group was accepted as the control group. the patient monitored once a week at the hospital and continue home stretching program at home. These patients will be given information about plantar fasciitis as well as other groups. Plantar fascia and gastrosoleus self-stretching exercises will be required to be performed twice a day for thirty seconds and three repetitions for 4 weeks. The patients will be followed with an exercise follow-up form.
89038092|NCT01262989|Active Comparator|tamsulosin Reference|Reference drug administration followed by Test drug administration
89623825|NCT01827358|Experimental|Group 1|Subjects receive a 5-day course of mupirocin calcium ointment 2 % 20 mg intranasally applied every 8 hours and a topical skin application (umbilical and perianal area) of mupirocin calcium cream 2% 20 mg applied every 8 hours for a total of 15 doses
89038093|NCT01262989|Active Comparator|tamsulosin Test|Test drug administration followed by Reference drug administration
89623826|NCT01827358|No Intervention|Group 2|No treatment
89623827|NCT01828216|Active Comparator|Conventional polysomnography|Conventional PSG will be performed as in-patient at Prince of Wales Hospital for every subject in this group, recording electroencephalogram, electro-oculogram, submental electromyogram, bilateral anterior tibial electromyogram, electrocardiogram, chest & abdominal wall movement by inductance plethysmography, airflow measured by a nasal pressure transducer & supplemented by oronasal airflow thermistor, & finger pulse oximetry.
89623828|NCT01828216|Active Comparator|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events.
89623829|NCT01780324|No Intervention|No lidocaine|This group will have urinary catheterization without lidocaine (per standard procedure)
89623830|NCT01780324|Experimental|Lidocaine|The Intervention is the application of intraurethral lidocaine 5 minutes prior to urethral catheterization.
89623831|NCT02989792|Other|Unique study arm|
89623832|NCT02476266|No Intervention|Control|Participants randomized to this group will come in for testing at pre-intervention, post-intervention, three month wash out and six month wash out. Participants will be asked to continue their activities of daily living. To account for any physical activity changes over the length of the study the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire will be administered to all individuals. A control group is necessary to compare to show normal disease progression over the length of the study as well as to demonstrate that improvements in outcome measures are due to the interventions and not practice effects.
89623833|NCT02476266|Active Comparator|Strength Training|Individuals randomized to this program will complete three sets of eight to ten repetitions at 70% of their predicted 1-RM for each of the exercises mentioned above. The speed of the movements in this program will be two to three seconds each for the concentric and eccentric components. When participants are able to complete ten repetitions in their third set for two consecutive days, weight will be increased for the following session by 5% of the current weight that they are at in accordance with Canadian Society for Exercise Physiology (CSEP) and American College of Sports Medicine (ACSM) guidelines. Participants will complete a total of 24 sessions over the course of 12 weeks, two times per week for an hour each session.
89623834|NCT02476266|Experimental|Power Training|Participants randomized to this program will complete three sets of 12 to 15 repetitions completed at 40% of predicted 1-RM for each exercises. The concentric part of the movement will be completed as fast as possible, whereas the eccentric component will be accomplished in two to three seconds. The load in this group is lower as it has been shown that by performing power training at lighter loads, the muscles are able to be activated, throughout the entire concentric component, while maintaining a consistent level of force. The progression will be determined through the same means as the conventional strength training group. Participants will complete a total of 24 sessions over 12 weeks, twice per week for an hour each session
89623835|NCT01780870|No Intervention|Control Group|Obese, otherwise healthy people who are not receiving any nutritional,surgical or behavioral therapy
89623836|NCT01780870|Active Comparator|Weight loss group|Full Meal replacement Protocol
89623837|NCT02477982||control group|BMI ≤ 25 kgm-2
89623838|NCT02477982||obese group|BMI ≥ 30 kgm-2
89623839|NCT02472600|Active Comparator|colistin + neomycin followed by FMT|"CAPSULE APPROACH:~Treatment days 1-5~Colistin sulphate 2 million IU per os 4x/day (for 5 days)~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days) Treatment day 6: no treatment~Treatment days 7 and 8:~-15 capsules of capsulized Fecal microbiota transplantation (FMT) per os per day~NASOGASTRIC TUBE APPROACH:~Treatment days 1-5~Colistin sulphate 2 million IU per os 4x/day (for 5 days)~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days)~Treatment day 6 and 7:~- Omeprazole 20 mg per os 1 dose on the evening of day 6 and on the morning of day 7~Treatment day 7:~- Infusion of 80 ml of a standardized stool suspension through a nasogastric tube - Fecal microbiota transplantation (FMT)"
89623840|NCT02472600|No Intervention|No intervention|Control arm without any intervention
89623841|NCT01781806|Active Comparator|Cohort H (PrEP)|"Participants in the H cohort will be provided with a CPP, including daily oral emtricitabine/tenofovir-based PrEP.~High Risk Cohort Criteria (one or more of the following has to be met):~No condom use during anal intercourse with ≥3 male sex partners who are HIV-positive or of unknown HIV status during the last three months.~STD diagnosis during the last 12 months.~Previous PEP use during the last 12 months (* see exclusion criteria)~Has at least one HIV infected sexual partner for ≥4 weeks."
89038094|NCT00547443|Active Comparator|Arm I|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose external beam radiotherapy (HDRT) as in phase I. Patients also receive consolidation therapy comprising paclitaxel and carboplatin as in phase I.
89038095|NCT00547443|Experimental|Arm II|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and HDRT as in phase I. Patients also receive consolidation therapy comprising paclitaxel, carboplatin, and sorafenib tosylate at the MTD as in phase I, as well as maintenance therapy comprising sorafenib tosylate at the MTD as in phase I.
89038096|NCT02908997|Experimental|5 week baseline|5 week baseline data collection followed by 6 week MindMate intervention
89038097|NCT02908997|Experimental|6 week baseline|6 week baseline data collection followed by 6 week MindMate intervention
89038098|NCT02908997|Experimental|7 week baseline|7 week baseline data collection followed by 6 week MindMate intervention
89623842|NCT01781806|Active Comparator|Cohort LM (PEP)|Participants who do not meet criteria for High Risk (Cohort H) will be assigned to the LM (low moderate) cohort and will receive a customized prevention package based on baseline assessments (in the same manner as the Cohort H Participants). In addition, they will receive education on the availability and use of post-exposure prophylaxis.
89623843|NCT05315076|Experimental|Thoracic Manipulation Posterior anterior and conventional therapy|Thoracic Manipulation Posterior anterior and conventional therapy
89623844|NCT05315076|Experimental|Muscle Energy Technique (PIR) and conventional treatment|Muscle Energy Technique (PIR) and conventional treatment
89623845|NCT04844892|Experimental|PROTECT Diaphragm Pacing Therapy|
89623846|NCT02477592|Experimental|Individualized substrate modification|Circumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.
89623847|NCT02477592|Active Comparator|Stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
89623848|NCT02477514|Experimental|Experimental Arm|Day 1: participants will receive midazolam (2 mg); Day 3: participants will receive rosuvastatin (10 mg); Days 5-13: participants will receive tedizolid phosphate (200 mg); Day 14: participants will receive tedizolid phosphate (200 mg) plus midazolam (2 mg); Day 15: participants will receive tedizolid phosphate (200 mg); Day 16: participants will receive tedizolid phosphate (200 mg) plus rosuvastatin (10 mg); Day 17: participants will receive tedizolid phosphate (200 mg)
89623849|NCT01784848|Experimental|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
89623850|NCT01784848|Active Comparator|Clinical treatment|Optimized clinical treatment including medical management of hypertension.
89623851|NCT01753648|Experimental|hypertensive retinopathy|30 patients with hypertensive retinopathy stage 2 or 3
89623852|NCT01753648|Experimental|healthy controls|30 healthy age- and sex-matched controls
89623853|NCT02472288|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)~BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)~20 minutes duration, middle frequency (30 Hz) of electrical stimulation~conventional treatments permitted"
89623854|NCT02472288|Sham Comparator|Sham group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)~BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)~20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)~conventional treatments permitted"
89623855|NCT02472054|Experimental|hemophagocytic lymphohistiocytosis (HLH)|"Alemtuzumab (CAMPATH®)~Initial Treatment (D1 to D3) D1: 0.5 mg / kg / day Alemtuzumab combined with 2 mg /kg/d of IV Methylprednisolone (MP) or PO Prednisolone, and IVC or PO cyclosporine (CSA) (target rate from 150 to 200 ng / ml in the absence of renal failure) D2 and D3: 1 mg / kg / day Alemtuzumab combined with 2 mg / kg / d of IV MP or PO Prednisolone and IVC or PO CSA (target rate 150-200 ng / ml)~The maximum dose of Alemtuzumab is limited to 30 mg per day (1 vial).~Maintenance treatment (D4 to D14)~MP/Prednisolone progressive tapering starting at D4 (2 mg / kg / day) to reach the dose 0.5 mg / kg / day at D14~CSA IVC or PO at a target rate of 150-200 ng / ml"
89623856|NCT01782898|Active Comparator|Esmolol|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
89623857|NCT01782898|Placebo Comparator|.9 normal saline|.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
89623858|NCT02472132|Experimental|Intervention|Prospective implantation of POC US for CVC tip placement.
89623859|NCT02472132|No Intervention|Control|Retrospective data collection for CVC placement in the medical and surgical ICUs, before the initiation of the study and without the use of POCUS for CVC tip placement.
89623860|NCT02475876|Other|clindamycin|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
89038099|NCT00547482|Sham Comparator|Control|They will all be implanted but not activated for the Initial Study Period (24 weeks), followed by all subjects assigned to treatment (Control Group with device activation) in the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA.
89623861|NCT02475876|Other|trimethoprim-sulfamethoxazole|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
89623862|NCT01744834||18-year-old males|18-year-old males, representative random sample of the Dresden/Berlin (Germany) area, categorized as high and as low-risk drinkers respectively
89623863|NCT02472210|Placebo Comparator|Placebo|Saline IM Injection
89623864|NCT02472210|Active Comparator|Onabotulinum Toxin A|IM Injection
89623865|NCT01831960|Experimental|Cortexolone 17α-Propionate|Topical cream, 1.0% concentration, applied every twelve hours
89623866|NCT04825236|Experimental|Decision Aid Users|Patients with CF who are given access to the MyVoice:CF decision aid
89623867|NCT04825236|Experimental|CF Healthcare Providers|Members of the adult CF care team who interact with patients who have used the decision aid
89623868|NCT04802148|No Intervention|control (natural healing)|Extraction socket is naturally healed
89623869|NCT04802148|Experimental|Test 1 (membrane guided regeneration)|Extraction socket is filled with graft (FDBA) and covered with collagen membrane
89623870|NCT04802148|Active Comparator|Test 2 (collagen plug)|Extraction socket is filled with a collagen plug
89623871|NCT01783054|Experimental|chemotherapy, surgery, genetic expression|"All patients enrolled on study will start study treatment on a chemotherapy treatment regimen of Gemcitabine and abraxane. Treatment will be given on days 1, 8 and 15 of each cycle for 2 cycles over the course of 12 weeks.~Patients will move on to surgery, 4-8 weeks after chemotherapy treatment. Patients must be recovered from any adverse effects of the chemotherapy before proceeding with surgery.~As part of this study, tissue samples will be collect from each patient at the time of surgery for gene expression testing"
89623872|NCT02475642|Active Comparator|PVI-ADT|discontinue antiarrhythmic drugs at 3 months post PVI
89623873|NCT02475642|Active Comparator|PVI+ADT|discontinue antiarrhythmic drugs at 12 months post PVI
89623874|NCT05405088|Other|Open-label cohort, with short follow-up|This is a collection of data from postoperative questionnaires and simple, non-invasive clinical observations. The oral surgery acts in question are performed in daily practice without any change in patient management. The intraoperative data collected come from routine care. Postoperative data (pain and analgesic intake) are collected by self-questionnaires and no visit on purpose is required.
89623875|NCT04784520|Experimental|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
88989488|NCT05506774||Cohort A: Participants With cHL.|Participants who diagnosed with cHL between January 1, 2018 and March 31, 2021, and have demographic and clinical data available in hospital information system (HIS)/electronic medical records (EMRs) or laboratory information management will be observed retrospectively from the date of diagnosis with cHL until death, loss to follow-up, or end of the study, whichever occurs first.
89623876|NCT02725008|Active Comparator|Control|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and a second dose of 0.6 milligrams per kilogram up to 16 milligrams to take 24 hours after ED visit
89623877|NCT02725008|Experimental|Investigational|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and placebo to be taken 24 hours after ED visit
89623878|NCT02475486|Other|high fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is > 5
89623879|NCT02475486|Other|low fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is < or equal to 5
89623880|NCT02471976|No Intervention|Group A|the centres applies their usual practices
89623881|NCT02471976|Other|Group B|strategy promoting early consideration and collegiate vulnerability of patients
89623882|NCT01832506|Experimental|MSC2156119J|
89623883|NCT02477748|Active Comparator|MDX|Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
89623884|NCT02477748|Placebo Comparator|Placebo|Inert tablets
89623885|NCT02477436|Experimental|Avanafil 50mg group|Avanafil 50mg tablet + Placebo 100mg tablet
89623886|NCT02477436|Experimental|Avanafil 100mg group|Avanafil 100mg tablet + Placebo 100mg tablet
89623887|NCT02477436|Experimental|Avanafil 200mg group|Avanafil 100mg 2 tablets
89623888|NCT02477436|Placebo Comparator|Placebo group|Placebo 100mg 2tablets
89623889|NCT01783522|Experimental|Arm I (preventative nutritional supplementation)|Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
89623890|NCT01783522|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
89623891|NCT04734366|Experimental|"Uterine closure with Baseball suture technique"|"Participants will undergo Baseball suture closure of the hysterotomy site at the time of cesarean section."
89623892|NCT04734366|Active Comparator|Single Layer Continuous Locked|Participants will undergo Single Layer Continuous Locked suture closure of the hysterotomy site at the time of cesarean section.
89623893|NCT02471820|Experimental|Lenalidomide, adriamycin & dexamethasone|Lenalidomide 25 mg administered orally for the first 21 days of each 28-day-cycle, plus Adriamycin i.v. on days 1,2,3 & 4 of every cycle, plus Dexamethasone 40 mg orally on days 1, 8, 15 & 22 of every cycle for 4 cycles
89623894|NCT01833130|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
89623895|NCT01833130|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
89623896|NCT02475408|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug).
89623897|NCT02471664|Experimental|Single|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
89623898|NCT01783912|Experimental|Cognitive/Motivational Intervention Group|"This arm of the project will address the following questions:~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?"
89623899|NCT01783912|Active Comparator|Attention Control Group|"This arm of the project will address the following question:~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate that those who are in the experimental treatment group?~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Cognitive/Motivational Intervention Group?"
89688446|NCT04348435|Experimental|Allogeneic HB-adMSCs 200MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 200 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
89688447|NCT04348435|Experimental|Allogeneic HB-adMSCs 100MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 100 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
88989489|NCT05506774||Cohort B: Participants With NHL.|Participants who diagnosed with NHL between January 1, 2018 and March 31, 2021, and have demographic and clinical data available in HIS/EMRs or laboratory information management will be observed retrospectively from the date of diagnosis with NHL until death, loss to follow-up, or end of the study, whichever occurs first.
88989490|NCT05505799|Active Comparator|Preintervention|Normal clinician intubation process
89057362|NCT01682265|Sham Comparator|Sham procedure|"Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
89623900|NCT01783912|No Intervention|Motivated Smokers Comparison Group|"This arm of the project will address the following question:~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~Participants will not receive any intervention but will be consented and enrolled into this group and assessed for utilization of the tobacco quit line services."
89623901|NCT02475330|Experimental|Dietary Supplement: Flaxseed|
89623902|NCT02475174|Experimental|Without upper limb elevation|Manual lymphatic drainage will be held with the voluntary supine without upper limb elevation.
89623903|NCT02475174|Experimental|Upper limb elevation to 30º|Manual lymphatic drainage will be held with the voluntary supine with the upper limb elevation to 30º.
89623904|NCT01783990||Active|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), and urine microalbumin:creatinine ratio were collected at study entry, annually, and exit to Follow-Up Study II. Variable-diversity-joining (VDJ) and a stored blood sample were collected at study entry and study exit. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, magnetic resonance imaging (MRI) / magnetic resonance angiography (MRA), cardiac echocardiogram, or neuropsychology testing were collected once during the study when the child was 10 years old.
89623905|NCT01783990||Passive|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), variable-diversity-joining (VDJ), urine microalbumin:creatinine ratio and a stored blood sample were collected at study entry and exit to Follow-Up Study II. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, MRI/MRA, cardiac echocardiogram, or neuropsychology testing were collected as part of clinical care.
89623906|NCT01733056|Placebo Comparator|Healthy Volunteer|Healthy volunteers without skin disease that received administration of Fluzone
89623907|NCT01733056|Experimental|Azathioprine|Patients with skin diseases taking azathioprine that received administration of Fluzone
89623908|NCT01733056|Experimental|TNF alpha blocker|Patients with skin diseases taking azathioprine that received administration of Fluzone
89623909|NCT04672824|Experimental|ChAdOx1 RVF group 1|Participants will receive ChAdOx1 RVF 5 x 10^9 vp, delivered intramuscularly
88989491|NCT05505799|Experimental|Postintervention|Clinician intubation process after implementation and clinician education with a procedural checklist
88989492|NCT05501756|Experimental|Alemtuzumab|"Patients will be given 10 mg/m2 alemtuzumab divided over days -14, -13, and -12. The first dose should be limited to no more than 3 mg per the manufacturer's recommendation. If the calculated daily dose is greater than 3 mg, the first dose (day -14) should be limited to 3 mg and the remainder of the dosing should be divided over days -13 and -12.~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
88989493|NCT05500430|Experimental|surface pretreatment sandblasting|"Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).~The surface treatment for aged composite will be applied according to manufacturer instructions.~Repairing with bioactive injectable composite, Beautiful Flow Plus X F00(Shofu, Japan) The material will be applied according to manufacturer instructions. After shade selection incremental insertion in layers not exceeding 2 mm and light curing for 10 sec using 3M Eliper curing unite (Elipar Deepcure-S, 3M)."
88989494|NCT05500430|Active Comparator|Repairing with conventional nanohybrid composite|The nanohybrid resin composite will be applied to the the cavity using the conventional incremental technique according to manufacturer instructions.
88989495|NCT05495425|Experimental|NPC-12Y gel|NPC-12Y gel is containing 0.2% Sirolimus
88989496|NCT05495425|Placebo Comparator|NPC-12Y placebo gel|Placebo gel matched NPC-12Y gel
88989497|NCT05494970||Patients with ORL cancer for which radiotherapy treatment is required.|
88989498|NCT05494788|Experimental|CardiolRx|pharmaceutically produced Cannabidiol
88989499|NCT05490602||Running subcutaneous sutures technique|Abdominoplasty patients will be recruited. 50 patients will undergo the running subcutaneous sutures technique closures.
88989500|NCT05490602||Classical closures|Abdominoplasty patients will be recruited. 50 patients will undergo classical closures.
88989501|NCT05486832|Experimental|Cardiovalve TR replacement Group|Cardiovalve TR valve replacement System
88989502|NCT05474079|Experimental|Statin users exercise intervention|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% heart rate reserve (HRR) three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
88989503|NCT05474079|No Intervention|Statin users conventional care control|Participants randomized to the conventional primary care control group will not receive any supervision or guidance throughout the 12-week intervention beyond the initial standard healthcare advice provided by their general practitioner (GP).
88989504|NCT05474079|Experimental|Non-statin users exercise intervention|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
89623910|NCT04672824|Active Comparator|Control group|Placebo (Normal Saline), 0.5ml delivered intramuscularly
89623911|NCT04672824|Experimental|ChAdOx1 RVF group 2|Participants will receive ChAdOx1 RVF 2.5 x 10^10 vp, delivered intramuscularly
89623912|NCT04672824|Experimental|ChAdOx1 RVF group 3|Participants will receive ChAdOx1 RVF 5 x 10^10 vp, delivered intramuscularly
88989505|NCT05474079|No Intervention|Non-statin users conventional care control|Participants randomized to the conventional primary care control group will not receive any supervision or guidance throughout the 12-week intervention beyond the initial standard healthcare advice provided by their GP.
88989506|NCT05473507||Participant with Basal Cell Carcinoma/BCC|Participants have been diagnosed with at least 1 Basal Cell Carcinoma/BCC based on clinical, dermoscopy, RCM (reflectance confocal microscopy) and OCT (optical coherence tomography)
88989507|NCT05469854|Experimental|Linaprazan glurate|Oral administration as a single dose of 300 mg, 600 mg, 200 mg, and a final dose level of maximum 400 mg.
88989508|NCT05469854|Placebo Comparator|Placebo|Oral administration as a singel dose
88989509|NCT05467527|Experimental|PACT Group|A combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks
88989510|NCT05467527|Placebo Comparator|Control Group|A combination of 6 online modules and 4 group-based video conferencing sessions of daily parenting challenges in caring for a child with SHCN plus positive parenting advice via a mobile app across 12 weeks
88989511|NCT05466799|Active Comparator|FOLFIRINOX Chemotherapy|Subjects in Arm A will receive up to 12 cycles of Standard Of Care FOLFIRINOX chemotherapy
88989512|NCT05466799|Experimental|OncoSil™ in addition to FOLFIRINOX Chemotherapy|Subjects in Arm B will be implanted with the OncoSil™ device in addition to up to 12 cycles of Standard Of Care FOLFIRINOX chemotherapy
88989513|NCT05465460|Active Comparator|Banana blossom|Participants received banana blossom 225 mg tablet orally four time per day for 14 days.
88989514|NCT05465460|Placebo Comparator|Placebo|Participants received placebo tablet orally four time per day for 14 days.
88989515|NCT05459961|Active Comparator|active|oral spermidine supplement
88989516|NCT05459961|No Intervention|placebo|matching placebo
88989517|NCT05458024|Active Comparator|Ergocalciferol (Vitamin D2)|300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules. These will be given in a single dose prior to discharge from the Emergency Department.
88989518|NCT05458024|Placebo Comparator|Ergocalciferol placebo|Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU Ergocalciferol capsules administered in the active treatment arm.
88989519|NCT05457699|Experimental|SABR consolidation|
88989520|NCT05457699|Active Comparator|Control - no SABR consolidation|
88989521|NCT05441085|Active Comparator|Nulliparous|Patients of ASA physical status 2-3 with a singleton pregnancy; gestational age > 37 weeks; regular uterine contractions occurring at least every 5 min; cervical dilation 2-5 cm; and pain > 5
88989522|NCT05441085|Active Comparator|Multiparous|Patients of ASA physical status 2-3 with a singleton pregnancy; gestational age > 37 weeks; regular uterine contractions occurring at least every 5 min; cervical dilation 2-5 cm; and pain > 5
88989523|NCT05439512|Experimental|orbital floor fracture|orbital floor fracture
88989524|NCT05438849||Women Veterans receiving primary care in VISN-7 of the VA Healthcare Administration (VHA)|This project will include English-speaking, community-dwelling women Veterans 20 years or older with a diagnosis of UI (all types) and access to the internet via a mobile device or computer. Women Veterans who are currently pregnant or less than 12 weeks postpartum will be excluded. PURSUIT utilizes a mobile health application, called MyHealtheBladder, to connect patients with nonsurgical treatment options.
88989525|NCT05438849||Health care providers in community-based outpatient clinics in VISN-7 of the the VHA|Community-Based Outpatient Clinics (CBOCs) from VA Integrated Service Network (VISN) 7 will be targeted, spanning the states of Alabama, Georgia, and South Carolina. VISN 7 CBOCs, serving at least 50 women Veterans with primary care services, will be recruited.
89623913|NCT01833988|Experimental|Bi-hormonal Bionic Pancreas|Bi-hormonal Bionic Pancreas
89623914|NCT01833988|Active Comparator|Usual Care|Usual Care
88989526|NCT05435651|Experimental|Multitask game-based digital therapy|Multitask game-based digital therapy group will be asked to practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week. Compliance will be monitored electronically.
89623915|NCT02471742||NAC-PC|patients treated with neoadjuvant chemotherapy and NAC-sparing mastectomy
89623916|NCT02471742||NAC|patients treated NAC-sparing mastectomy and adjuvant therapy
89623917|NCT02471742||PC|patients treated with neoadjuvant chemotherapy and conventional mastectomy
88989527|NCT05435651|Active Comparator|Schulte Grid digital game|Schulte Grid digital game group will be asked to practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week. Compliance will be monitored electronically.
88989528|NCT05431270|Experimental|Part A Monotherapy Dose Escalation|A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. The starting dose of PT199 to be evaluated in the dose escalation study is 10 mg/kg weekly (QW). Additional provisional dose levels include: 20 mg/kg QW, and 30 mg/kg QW.
88989529|NCT05431270|Experimental|Part B Combination Therapy Dose Escalation|A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. The starting dose of PT199 to be evaluated in the dose escalation study is 10 mg/kg weekly (QW). The dose level of PD-1 inhibitor, Tislelizumab in all provisional dose levels will be 200 mg once every 3 weeks (Q3W).
89057363|NCT01682343|Placebo Comparator|Placebo|Breakfast consisting of milk-based porridge with a normal calcium content.
89057364|NCT01682343|Experimental|High-Calcium|As control, but with a high-calcium content.
89623918|NCT02477046|Experimental|tOPV + IPV|tOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive tOPV plus IPV boost
89623919|NCT02477046|Experimental|bOPV + IPV|bOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive bOPV plus 1 IPV boost
89623920|NCT02477046|Experimental|bOPV + 2 IPV|bOPV (6, 10, and 14 weeks) + IPV (14 and 18 weeks) Randomized to receive bOPV plus 2 IPV boost
89623921|NCT02475096|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of internet-delivered CBT (Cognitive Behavior Therapy). Parents will also receive 10 weekly specific modules for parents. Main components in the modules directed at children and parents are exposure for symptoms, feared stimuli and situations. The parents modules contain information on how they can support their children in the treatment and is based on social learning theory. Therapist support is provided through written messages within the secure platform. Therapists are trained CBT-psychologists.
89623922|NCT02475018|Experimental|Milk fortified with plant sterol esters|250mL of Shuhua Milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
89623923|NCT02475018|Placebo Comparator|Plain milk|250mL of placebo milk(plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
89623924|NCT02475018|No Intervention|No dairy product consumption|Participants have not consumed any dairy product during the 60-days of study period.
89623925|NCT05363436|No Intervention|Control|Normal Standard Practices of Prescribing
89623926|NCT05363436|Experimental|Intervention|Providers prescribed a base of 15 narcotic pills
89623927|NCT04575870||Treatment Group 1: 90 min waiting period|Participants undergo their planned tracheobronchoscopy + 90 minute waiting period prior to modified functional endoscopic swallowing exam
89623928|NCT04575870||Treatment Group 2: 66 min waiting period|Participants undergo their planned tracheobronchoscopy + 66 minute waiting period prior to modified functional endoscopic swallowing exam
89623929|NCT04575870||Treatment Group 3: 46 min waiting period|Participants undergo their planned tracheobronchoscopy + 46 minute waiting period prior to modified functional endoscopic swallowing exam
89623930|NCT04575870||Treatment Group 4: 28 min waiting period|Participants undergo their planned tracheobronchoscopy + 28 minute waiting period prior to modified functional endoscopic swallowing exam
89623931|NCT04575870||Treatment Group 5: 13 min waiting period|Participants undergo their planned tracheobronchoscopy + 13 minute waiting period prior to modified functional endoscopic swallowing exam
89623932|NCT02474940|Experimental|Intervention #1|NF-HYP
89623933|NCT02474940|Experimental|Intervention #2|MM-HYP
88989530|NCT05431270|Experimental|Part C Combination Therapy Dose Expansion|"Approximately 8 additional patients will be treated in a dose expansion cohort at the MTD/DRDE.~A minimum of 14 evaluable patients should be treated at DRDE before it can be declared as Recommend Phase II dose (RP2D). These can include the evaluable patients who were treated at DRDE in the dose escalation cohort(s). The RP2D may be declared based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation and dose expansion cohort, and upon the consensus of the Investigator(s), medical monitor, and Sponsor."
89623934|NCT02474940|Experimental|Intervention #3|HYP-ONLY
89623935|NCT01784614|Experimental|0.1 milligrams (mg) LY2624803|Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods
89623936|NCT01784614|Experimental|1.0 mg LY2624803|Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
89623937|NCT01784614|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
89623938|NCT01784614|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
89623939|NCT01784614|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods
89623940|NCT05314686||Technical validity of data transmitted remotely.|The first twenty participants will participate in the step of the study aimed at assessing the technical validity of data transmitted remotely from devices connected to the telerehabilitation system.
89623941|NCT05314686||Clinical feasibility.|The last twenty participants will perform their pulmonary rehabilitation program at home using the telerehabilitation system over an eight-week period.
89623942|NCT01733212|Experimental|Ginger|2 gm powder of ginger filled in a capsule
89623943|NCT01733212|Placebo Comparator|Placebo|2 gm of placebo pill (A capsule)
89623944|NCT02474706|Experimental|cefoxitin|Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
89623945|NCT02474706|Active Comparator|imipenem|Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
89623946|NCT01784770||Azithromycin IV|Subjects who are treated with Azithromycin IV for Legionnaires' disease
89623947|NCT02471274|Experimental|Group 1|healthy control subjects with normal hepatic function
89623948|NCT02471274|Experimental|Group 2|subjects with mild hepatic impairment
89623949|NCT02471274|Experimental|Group 3|subjects with moderate hepatic impairment
89623950|NCT02471274|Experimental|Group 4|subjects with severe hepatic impairment
89623951|NCT01784926|Other|IOL repositioning|Operation method: Intraocular lens repositioning by scleral suturing
89623952|NCT01784926|Other|IOL exchange|Operation method: Intraocular lens exchange with retropupillary iris-claw lens
89623953|NCT02471196|Experimental|ORM-12741 low dose|ORM-12741 low dose twice a day for 12 weeks.
89623954|NCT02471196|Experimental|ORM-12741 high dose|ORM-12741 high dose twice a day for 12 weeks.
89623955|NCT02471196|Placebo Comparator|Placebo|Placebo twice a day for 12 weeks.
89623956|NCT02471508|Experimental|Tank top with biofeedback system|"The design of biofeedback tank-top will incorporate sensors to record and monitor the posture of the wearer in real time basis. Alerts will be emitted to the wearer once poor posture is detected. The tank-top will be designed to fit the wearer's body and allow the sensor to be placed securely at the targeted position along the spine to minimize the noise from other factors than the wearers' posture and yet comfortable for long-term wearing."
89623957|NCT01835626|Experimental|Vismodegib and Radiation Therapy|150mg Vismodegib will be taken once a day, daily. Radiation therapy will be started after the patient has completed taking vismodegib for 12 weeks. The patient will take daily vismodegib through the completion of radiation therapy. The patient will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
89623958|NCT04491786|Experimental|GAPA|Participants will treated with preoperative 600 mg of gabapentin plus nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
89623959|NCT04491786|No Intervention|Non-GAPA|Participants will treated with nefopam which will continuously transfused during intraoperative and postoperative 24 hours, and morphine-PCA during postoperative 24 hours
89623960|NCT04749784|Experimental|High dose IP|Two tablets IP daily for 12 weeks
89623961|NCT04749784|Experimental|Low dose IP|One tablet IP + one tablet placebo daily for 12 weeks
89623962|NCT04749784|Placebo Comparator|Placebo|Two tablets placebo daily for 12 weeks
89623963|NCT01786252|Experimental|Drug: human chorionic gonadotropin (hCG)|"Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (Global-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis."
89623964|NCT01786252|Placebo Comparator|"IVF media (Global-trademark)"|Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
89623965|NCT02470026|Experimental|Yohimbine-Placebo|single low dose treatment with yohimbine on test day 1, placebo on test day 2
89623966|NCT02470026|Experimental|Placebo-Yohimbin|placebo on test day 1, single low dose treatment with yohimbine on test day 2
89623967|NCT04749316|Experimental|AcuTENS|Patients treated with TENS over Acupuncture points for faecal incontinence
89623968|NCT04749316|Sham Comparator|Sham|Sham treatment arm with no electrical stimulations over acupuncture points
89623969|NCT03208296|Experimental|Cohort A|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
89623970|NCT03208296|Experimental|Cohort B 1.5|Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
89623971|NCT03208296|Experimental|Cohort B 1.0|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
88989531|NCT05430815|Experimental|Enhanced Postpartum Care System|Women with a documented diagnosis of chronic diabetes, chronic hypertension, gestational diabetes, hypertensive disorder of pregnancy (gestational hypertension or preeclampsia), or pre-pregnancy obesity who are randomized to receive enhanced postpartum care.
88989532|NCT05430815|No Intervention|Standard of Care|Women with a documented diagnosis of chronic diabetes, chronic hypertension, gestational diabetes, or hypertensive disorder of pregnancy (gestational hypertension or preeclampsia), or pre-pregnancy obesity who are randomized to receive standard postpartum care.
88989533|NCT05430555|Experimental|MAGE-A1 - directed TCR transduced autologous T-cells|Single-dose, intravenous infusion
88989534|NCT05420428|Placebo Comparator|endotracheal intubation|under general anesthesia, patients received tracheal intubation.
88989535|NCT05420428|Experimental|supraglottic airway device|under general anesthesia, patients received supraglottic airway device
89623972|NCT02989480||Sarcoidosis|Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.
89623973|NCT02989480||Arrhythmogenic RV cardiomyopathy|Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.
89623974|NCT01786876|Experimental|Radiolabeled SPD557|
89623975|NCT05230290|Experimental|KD6001 Injection|Participants will be administered KD6001 at an applicable dose as monotherapy
89623976|NCT01786954|Experimental|Icare then Goldmann then Tonopen|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Goldmann then Tonopen.
89623977|NCT01786954|Experimental|Icare then Tonopen then Goldmann|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Tonopen then Goldmann.
89623978|NCT01837654|Experimental|Plantarflexion - 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
89623979|NCT01837654|Experimental|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
89623980|NCT02474862|Experimental|Prenatal Walking Program|The Prenatal Walking Program (PWP) is a gentle walking intervention tailored for pregnant women. The PWP intervention consists of 3 components: 1) biweekly session with a study interventionist; 2) the use of activity monitors to increase motivation and self-monitoring; 3) incentives to promote intervention adherence.
89623981|NCT02474862|Active Comparator|Postpartum Prep Program|In the Postpartum Prep Program control condition (PPP) participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn wellbeing.
89623982|NCT02261428|Experimental|Catheter Tiemann|We tested the ability of Tiemman catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
89623983|NCT02261428|Active Comparator|Suction catheter|We tested the ability of suction catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
89623984|NCT01838980|Experimental|Colonoscopy|
89623985|NCT01839058||Non Cardiac Chest Pain Patients|Patients with Chest Pain where Coronary Artery Disease has been formally ruled out are to undergo esophageal manometry testing.
89623986|NCT01839058||Healthy Controls|Healthy volunteers without esophageal symptoms are to undergo esophageal manometry testing.
89623987|NCT01839604|Experimental|AZD9150|There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B).
89623988|NCT02261818|Other|Meetings with peer mentors|Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.
89623989|NCT01789138|Experimental|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention: see 'Interventions' for more details.
89623990|NCT01789138|No Intervention|Adherence counseling, standard of care|Standard of care: Antiretroviral therapy adherence is discussed with patient (study participant) according to usual practice in the medical institution no special protocol followed.
89623991|NCT01841632|Experimental|MultiStem|"Dose escalation~Cohort 1~Drug: MultiStem, Dose 1 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 2~Drug: MultiStem, Dose 2 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 3~Drug: MultiStem, Dose 3 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 4~Drug: MultiStem, Dose 4 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)"
89623992|NCT01807949|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
89623993|NCT01807949|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
88989536|NCT05416216|No Intervention|Control|In the stepped wedge design, ECE centers start the trial at the same point in time and act as controls with no intervention until they are randomized to crossover from control to intervention conditions.
88989537|NCT05416216|Experimental|WELL intervention|'WELL intervention' is when implementation of the one-year, three-strategy WELL intervention begins (see description).
88989538|NCT05414760|Active Comparator|Womed Leaf group|Womed Leaf is inserted immediately after completion of the endometrial ablation.
88989539|NCT05414760|No Intervention|No adhesion prevention group|Standard of care: no IUA prevention, no placebo after ablation
88989540|NCT05408845|Active Comparator|Arm I (docetaxel, trastuzumab)|Patients receive docetaxel IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive trastuzumab IV over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88989541|NCT05408845|Experimental|Arm II (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88989542|NCT05400408|Experimental|Colorectal Cancer|Subjects who were diagnosed as Colorectal Cancer patients by colonoscopy.
88989543|NCT05400408|Experimental|Pancreatic Cancer|Subjects who were diagnosed as Pancreatic Cancer patients by Endoscopic Retrograde Cholangio Pancreatography.
89623994|NCT01807949|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
89623995|NCT02989558|Active Comparator|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
88989544|NCT05400408|Other|Healthy volunteers|Subjects who were found with no Colorectal or Pancreatic malignancies, by either colonoscopy or by Endoscopic Retrograde Cholangio Pancreatography.
88989545|NCT05400252|Experimental|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
88989546|NCT05400252|Active Comparator|Health and Wellness|Health & Wellness is an educational wellness intervention
88989547|NCT05400148||low volume|This cohort will include the patients to whom an analgesic PENG block was administered with a bupivacaine solution volume of up to 20 ml in a dose of 2.5mg/kg-1. This cohort is anticipated to have 56 participants.
89623996|NCT02989558|Active Comparator|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
89623997|NCT01806779|Experimental|Chantix|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
88989548|NCT05400148||high volume|This cohort will include the patients to whom an analgesic PENG block was administered with a bupivacaine solution volume more than 20 ml in a dose of 2.5mg/kg-1. This cohort is anticipated to have 56 participants.
88989549|NCT05395325|Experimental|KT and steroid injection group|the patients will receive steroid injection for only one time before intervention, and receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
88989550|NCT05395325|Sham Comparator|KT group|the patients will receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
88989551|NCT05391906|Experimental|Intravoxel Incoherent Motion(IVIM) MRI|Intravoxel incoherent motion (IVIM) is based on diffusion-weighted imaging (DWI)
88989552|NCT05389267|Experimental|T4090|
88989553|NCT05389267|Placebo Comparator|Placebo|"named Vehicle in the study protocol."
88989554|NCT05387746|Other|Caring Science, Mindful Practice and Reiki Training|
88989555|NCT05375955|Experimental|Atopic Dermatitis PF-07038124 0.01% ointment|Atopic Dermatitis
88989556|NCT05375955|Placebo Comparator|Atopic Dermatitis Vehicle ointment|Atopic Dermatitis
89623998|NCT01806779|Experimental|Chantix + Zyban|For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
89623999|NCT01789840|Experimental|Prostate artery embolization (PAE)|Prostate artery embolization using Embosphere Microspheres
89624000|NCT01789840|Active Comparator|Transurethral resection of the prostate (TURP)|Transurethral Resection of the Prostate (TURP)
89624001|NCT01878526|Experimental|Omeprazole plus alginic acid and placebo of domperidone|
89624002|NCT01878526|Experimental|Omeprazole plus domperidone and placebo of alginic acid|
89624003|NCT01878604||Homozygous Familial Hypercholesterolemia|Gene Analysis for Homozygous Familial Hypercholesterolemia cases
89624004|NCT01792024|Experimental|Treatment (LITT)|Patients undergo Magnetic Resonance imaging (MR) guided laser thermal therapy with Visualase Thermal Therapy device.
89624005|NCT02266576|Active Comparator|Standard Diabetes Prevention Program (DPP)|Participants receive Standard DPP over the course of 20 weeks.
89624006|NCT02266576|Experimental|Enhanced DPP|Participants receive Standard DPP plus Enhanced DPP over the course of 20 weeks.
89624007|NCT02266810|Experimental|PROPEL Mini Sinus Implant|Propel Mini placed in frontal sinus opening following ESS
89624008|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 1|Sinus Surgery only: cohort 1: ESS with standard post-operative care.
89624009|NCT02266810|Experimental|PROPEL Nova Sinus Implant|Propel Nova placed in frontal sinus opening following ESS
89624010|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 2|Sinus Surgery only: cohort 2: ESS with standard post-operative care.
89624011|NCT01879540|Experimental|aTIV|Adult subjects ≥65 years of age received one dose of a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere
89624012|NCT01842646|Experimental|PF-04449913 Treatment|Treatment will be administered on an outpatient basis. All patients will be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles. Patients who demonstrate no evidence of progressive disease (i.e. stable disease or better) may continue on treatment until disease progression or loss of response, limiting toxicity, or death.
89624013|NCT04350736|Experimental|TD-0903 for SAD (Part A)|6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
89624014|NCT04350736|Experimental|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
89624015|NCT04350736|Experimental|TD-0903 for MAD (Part B)|8 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903
89624016|NCT04350736|Experimental|Placebo for MAD (Part B)|2 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
89624017|NCT01607957|Experimental|TAS-102|
89624018|NCT01607957|Placebo Comparator|Placebo|
89624019|NCT01845220|Active Comparator|Broccoli Sprout Extract|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
89624020|NCT01845220|Placebo Comparator|Placebo|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
89624021|NCT01795534|Experimental|Beetroot shot then placebo shot|"Intervention: Participants will first consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK)"
89624022|NCT01795534|Placebo Comparator|Placebo shot then beetroot shot|"Intervention: Participants will first consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK)."
89624023|NCT01806623|Experimental|Fluconazole|
89624024|NCT01806545|Active Comparator|SRM003|One time implant (2 SRM003 pieces) on surgery day. Post-surgery, up to 26 weeks follow-up for assessment of efficacy/safety.
89624025|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
89624026|NCT01806389||Buprenorphine|Buprenorphine maintained women at delivery of their infant
88989557|NCT05375955|Experimental|Atopic Dermatitis PF-07038124 0.03% ointment|Atopic Dermatitis
89624027|NCT01846702|Placebo Comparator|Placebo|Single dose of placebo matching LY3084077 administered subcutaneously (SC).
89624028|NCT01846702|Experimental|LY3084077|Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC.
89624029|NCT01847014|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
89624030|NCT01847560||Dabigatran|
89624031|NCT01847560||Warfarin or other New Oral Anticoagulant (NOAC)|
89624032|NCT01847638|Active Comparator|Prolensa (bromfenac 0.07%)|Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
89624033|NCT01847638|Active Comparator|Ilevro (nepafenac 0.3%)|Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
89624034|NCT05328778|Experimental|Normal Weight group|n=16, 18.5kg/m² ≤ BMI ≤ 24.9kg/m²
89624035|NCT05328778|Experimental|Obese group|n=16, 25≤BMI≤39.9kg/m²
89624036|NCT05328778|Experimental|Morbidly Obese group|n=16, BMI≥40kg/m²
89624037|NCT01796236|Active Comparator|Minimally invasive surgery and BA400|This arm involves no soft tissue reduction around the BA400 implant.
89624038|NCT01796236|Active Comparator|Traditional surgery and BA300|This arm involves traditional soft tissue reduction around the BA300 implant
89624039|NCT02474550||CISL 14-03|"Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL).~Aged 19 or more~Treated with R-CHOP therapy"
89624040|NCT02470962||Patients with muscular dystrophy|Boys aged 8 to 18 years with muscular dystrophy of the Duchenne / Becker type
88989558|NCT05375955|Experimental|Plaque Psoriasis PF-07038124 0.01% ointment|Plaque Psoriasis
89624041|NCT02470962||Children without heart disease|Children without heart disease, aged 8-18 years, as CMR comparison group
89624042|NCT02474628|Placebo Comparator|Placebo|0.3 g∙kg-1body mass of calcium carbonate
89624043|NCT02474628|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
89624044|NCT03109002||Cohort: Pharmacologically Treated Depression (PTD) Cases|This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
89624045|NCT03108768|Experimental|Successor of Phonak Virto V|The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.
88989559|NCT05375955|Experimental|Plaque Psoriasis PF-07038124 0.03% ointment|Plaque Psoriasis
88989560|NCT05375955|Experimental|Plaque Psoriasis PF-07038124 0.06% ointment|Plaque Psoriasis
88989561|NCT05375955|Placebo Comparator|Plaque Psoriasis Vehicle ointment|Plaque Psoriasis
88989562|NCT05372679|Experimental|Renal denervation|Denervating the sympathetic nerves surrounding the renal vasculature using unfocused ultrasound
88989563|NCT05371613|Experimental|Cohort A: Participants with nMPS II|
88989564|NCT05371613|Experimental|Cohort B: Participants with nnMPS II|
88989565|NCT05371613|Experimental|Open-label Treatment Phase|Participants who meet pre-specified criteria may receive DNL310 or idursulfase
88989566|NCT05370404|Active Comparator|Prescription Group for acetaminophen, NSAIDs, and magnesium|"Participants will receive prescriptions from the surgical team for non-opioid pain medications to take at home after discharge from surgery.~The non-opioid pain medications will be acetaminophen 1000 milligram (mg) four times a day (qid) for 3 days then as needed (prn) pain, ibuprofen 600 mg qid for 3 days then prn, and magnesium oxide 400 mg daily prn pain."
88989567|NCT05370404|Active Comparator|Over the Counter Group|"Participants will receive a recommendation from the surgical team to take over-the-counter non-opioid pain medications at home after discharge from surgery.~The non-opioid pain medications will be acetaminophen 1000 mg qid for 3 days then prn pain, ibuprofen 600 mg qid for 3 days then prn, and magnesium oxide 400 mg daily prn pain."
88989568|NCT05370209|Experimental|Otinova® Ear Spray|Otinova® Ear Spray 1-2 sprays, twice daily for 7 days
88989569|NCT05367947|Experimental|In-phase bilateral RRMS Participants A-E|The study follows a concurrent multiple baseline design across subjects, which involves five people with RRMS as five different case studies.
88989570|NCT05367934|Experimental|The Effect of Therapeutic Touch on Nursing Students on Perceived Stress and Stress Coping Behaviors|The nurses in the intervention group were given therapeutic touch for 15 minutes once a week for two weeks.
88989571|NCT05367934|Other|The Effect of Therapeutic Touch on Stress and Stress Coping Behaviors|No treatment was applied to the patients in the control group other than their routine care.
88989572|NCT05367232|Experimental|ICP-033 Dose Escalation|Drug: ICP-033 tablet Administered orally，once a day，every 28 days is a cycle.
88989573|NCT05362357|Experimental|Prevention Group|Web-app with five weekly substance modules. Each module is approximately 15 minutes long.
88989574|NCT05362357|Active Comparator|Comparison Group|Web-app with single abbreviated module combining all five substances. Module is approximately 20 minutes long.
88989575|NCT05362357|No Intervention|Control Group|No access to web-app.
88989576|NCT05360706||CSL220|AAV5 containing a codon-optimized human factor IX gene
88989577|NCT05360615|Experimental|Empagliflozin|
88989578|NCT05360615|Placebo Comparator|Placebo|
88989579|NCT05358379|Experimental|Phase 1 Dose Escalation|Phase 1 = CYC140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.
88989580|NCT05358379|Experimental|Phase 2|Phase 2 = Recommended CYC140 phase 2 dose and schedule administered orally in 28-day cycles.
88989581|NCT05355545|Experimental|Virtually supervised exercise|In the first half of the study (weeks 0 to 12), participants will receive a virtually supervised exercise program. In the second half of the study (weeks 13 to 24), participant will continue to receive the virtually supervised exercise program.
88989582|NCT05355545|Active Comparator|Health education|In the first half of the study (weeks 0 to 12), participants will receive a health education program. In the second half of the study (weeks 13 to 24), participant will receive a the virtually supervised exercise program.
89057365|NCT04542746|Experimental|Minimally invasive surgical technique|The intra-bony defects of subjects allocated in test group were treated with a combination of minimally invasive surgical technique (MIST) and enamel matrix derivative( EMD).
89624046|NCT03108768|Active Comparator|Phonak Virto V|Phonak Virto V will be fitted to the participants individual hearing loss.
89624047|NCT03099564|Experimental|pembrolizumab + Y90 radioembolization|Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)
89624048|NCT02469948|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
89624049|NCT02469948|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
89624050|NCT02469792|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into anterior cruciated ligament.
89624051|NCT02869932|Other|Atypical and classic cystic fibrosis|Lung CT scan without injection
89624052|NCT04362228|Experimental|Whole-body exercise|
89038100|NCT00547482|Active Comparator|Treatment|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation). They will be followed for the Initial Study Period (24 weeks), followed by the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA."
89038101|NCT02909075||PET/CT scans and MRI|Eligible patients will be enrolled onto the study, and will undergo 3 limited field of view (FOV) FDG-PET/CT scans and MRI of the chest: at baseline (within 4 weeks prior to transplantation), and approximately 3 months (+/-2 weeks) and 6 months (+/-2 weeks) after transplant. PET/CT and MR imaging can be completed on the same day. We will also offer the exams on other days if this is easier for the patient. The PET/CT and MR should be performed within 2 weeks of each other.
89038102|NCT03456258|Experimental|Lactoferrin|To measure hemoglobin difference and serum ferritin
89038103|NCT03456258|Experimental|Ferrous sulphate|To measure hemoglobin difference and serum ferritin
89038104|NCT02909114|Experimental|Experimental group|SBRT for oligometastatases from colorectal cancer objectives
89038105|NCT02277210|Placebo Comparator|Non-flushing group|Aspiration alone for all follicular larger than 10mm on both sides. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
89038106|NCT02277210|Active Comparator|Flushing group|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
89210982|NCT04765449|No Intervention|ARM B: Covid-19 Patients Not Receiving CTLs|Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure, temperature, and oxygen level (pulse oximetry) at home and report this information, as well as their progress in getting over the COVID-19 infection, to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.
89210983|NCT00926094||1|
89210984|NCT00926094||2|
89210985|NCT00827138|Experimental|DCC-2036|This is a single arm study
89624053|NCT05328544|Experimental|ACL Reconstruction with the use of autogenous spongiform bone grafts|Stabilization of the tibial insertion with a bioabsorbable screw (Arthrex) with simultaneous application to the tibial canal of autogenous cancellous bone grafts taken during the drilling of this canal.
89624054|NCT05328544|Active Comparator|ACL Reconstruction without the use of autogenous spongiform bone grafts|Stabilization of the tibial attachment with a bioabsorbable screw (Arthrex) without simultaneous application of autogenous cancellous bone grafts to the tibial canal.
89624055|NCT05328310|Active Comparator|Telmisartan|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, telmisartan is given as the primary antihypertensive agent.
89624056|NCT05328310|Experimental|Nebivolol|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, nebivolol is given as the primary antihypertensive agent.
89624057|NCT01848184||PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning
89624058|NCT01797328|Active Comparator|cold provocation|cold arm
89624059|NCT01797328|Active Comparator|to avoid feeling cold|warm arm
89624060|NCT01849822|Experimental|Neural Prosthetic System|The Neural Prosthetic System consists of two Neuroport Arrays, which are described in detail in the intervention description. Both Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subjects will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought. They will then use the end effector to perform various reach and grasp tasks.
89624061|NCT05328232|Experimental|Olive oil|
89624062|NCT05328232|No Intervention|Routine care|
89038107|NCT04682171|Experimental|Low level Laser Therapy|Low Level Laser Therapy and Conventional Exercise therapy
89038108|NCT04682171|Active Comparator|Conventional ExerciseTherapy|Conventional ExerciseTherapy
89038109|NCT02277288|No Intervention|Emptied bladder arm|No instillation of fluid into bladder.
89038110|NCT02277288|Experimental|Filled bladder arm|Instilled bladder with fluid.
89038111|NCT02908724||ERT receiving patients|Patients that were receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 47).
89038112|NCT02908724||non-ERT receiving patients|Patients that were not receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 19).
89038113|NCT00547560|Other|GSI+Placebo|
89038114|NCT02908607|Experimental|experimental|3 groups of patients will be participated: women with cancer, women with premalignant lesions and women with a normal cervix. All patients will undergo the same examination
89038115|NCT00547599|Active Comparator|1|20 mg tadalafil tablet
89038116|NCT02908451|Experimental|AbGn-107|AbGn-107 will be administered every 14-days or 28-days via intravenous infusion. Patients with a complete response (CR), partial response (PR), or stable disease (SD), or with evidence of clinical benefit may be treated every continuously every 14-days or 28-days..
89038117|NCT02908763|Experimental|Pegylated interferon group|Low replicative chronic HBV infection patients with HBsAg <1000 IU/ mL and HBV DNA<2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
89038118|NCT02908763|No Intervention|Observing Group|Only observing and following up in this group.
89038119|NCT00547716|Experimental|1.|Omega-3 Fatty Acids 4 grams/day
89210986|NCT00907998|Experimental|APL180 (first dose level)|
89210987|NCT00907998|Experimental|APL180 (second dose level)|
89210988|NCT00907998|Placebo Comparator|Placebo|
89624063|NCT01797484|Active Comparator|Ranolazine|Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
89624064|NCT01797484|No Intervention|No additional medication|No additional medication - control group
89624065|NCT01798186|Experimental|Cannabis 5% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 5% THC and in a room with no ventilation.
89624066|NCT01798186|Experimental|Cannabis 11% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC and in a room with no ventilation.
89624067|NCT01798186|Experimental|Cannabis 11% THC, Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC in a room with active ventilation.
89624068|NCT01851772|Experimental|Treatment|"Subjects enrolled will undergo brachytherapy treatment in combination with EBRT. The maximum length of treatment will be 56 days. The treating physician will determine the appropriate course of treatment based on the physician's current practice or experience using Iridium-192 or Cesium HDR after-loaders to administer cervical brachytherapy treatments.~Subjects enrolled will be treated with approximately 80-90 Gy total treatment dose over 4-6 fractions. Examples of commonly used dose regimens in the US are listed in section 7.6.7. This study will include data collection from the initiation of EBRT through administration of the final Xoft Axxent treatment fraction, and at one (1) month and three (3) months."
89624069|NCT01852084|Experimental|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
89624070|NCT01852084|Experimental|enVista control lens|Spherical control lens
89624071|NCT01798264|Experimental|10 mcg./day|ITCA 650 (exenatide in DUROS)
89624072|NCT01798264|Experimental|20 mcg/day|ITCA 650 (exenatide in DUROS)
89624073|NCT01798264|Experimental|40 mcg/day|ITCA 650 (exenatide in DUROS)
89624074|NCT01798264|Experimental|80 mcg/day|ITCA 650 (exenatide in DUROS)
88989583|NCT05355441||Multidisciplinar pain treatment patients|Major trauma patients with moderate, severe or incapacitating pain will be referred to consultation specialized in chronic pain and psychology. Patients will be evaluated, in terms of quality of life, before and after the treatment.
88989584|NCT05352711|Experimental|active assisted exercise with Oculus Quest virtual reality (VR) group|This group includes 30 patients suffered from pain and loss of shoulder flexion ROM, The patients will treated with active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand controller ) for 30 min. 2 times per week for 4 weeks The ROM will be assessed by mobile goniometer application and Smart phone version of visual analogue scale (VAS) to assess pain and The Quality-of-Life Scale for Children to assess the psychometric properties after the 1st session, day 14 and day 28.
88989585|NCT05352711|Active Comparator|active assisted range of motion exercise group|This group includes 30 patients suffering from pain and loss of shoulder flexion ROM. Patients will recieve active-assisted ROM physical therapy 2 sessions per week for 4 weeks.
88989586|NCT05348876|Experimental|Darolutamide (BAY1841788)|Participants with high-risk nmCRPC will receive darolutamide.
88989587|NCT05345171|Experimental|DTX301, Then Placebo|Participants receive single peripheral intravenous (IV) infusion of DTX301 in solution. At week 64, participants receive single peripheral IV infusion of placebo.
88989588|NCT05345171|Experimental|Placebo, Then DTX301|Participants receive single peripheral IV infusion of placebo. At week 64, participants receive single peripheral IV infusion of DTX301 in solution.
88989589|NCT05344690||cases|diabetic patients suffering from clinically confirmed diabetic retinopathy
88989590|NCT05344690||controls|matched (based on gender and duration of diabetes) diabetic patients free from diabetic retinopathy will be recruited.
88989591|NCT05339841|No Intervention|Control group|Subjects monitored following usual-care.
88989592|NCT05339841|Experimental|Intervention group|Subjects in the intervention group, in addition to usual-care, will download a mHealth App that contains educational information promoting healthy lifestyle behaviours. The participant will be also able to self-monitor his/her clinical status regarding hypertension, diabetes or hypercholesterolemia.
88989593|NCT05339256|Experimental|Telehealth buprenorphine induction and maintenance|Sublingual (SL) Buprenorphine and a medical management protocol adapted to the unique needs of home-based telehealth for MOUD using SL buprenorphine
88989594|NCT05339256|Active Comparator|Standard in-person SL buprenorphine induction and maintenance|In-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
88989595|NCT05338541|Experimental|Tucidinostat and etoposide|
88989596|NCT05336227|Experimental|Immediate Start - Virtual Reality Exergaming|12 weeks of virtual reality active video gaming using immersive commercially available equipment, with adapted games for people to play in the seated position. Maintain normal eating/nutritional behaviors.
88989597|NCT05336227|No Intervention|Wait-list Control|Maintain habitual physical activity levels for 12 weeks, before receiving the same intervention. Maintain normal eating/nutritional behaviors.
88989598|NCT05327647|Experimental|Bicalutamide|Induction intravesical Bacille Calmette-Guérin treatment with 150 mg daily oral bicalutamide for 90 days
88989599|NCT05327647|Active Comparator|Control Arm|Induction intravesical Bacille Calmette-Guérin treatment
88989600|NCT05321017|Experimental|MEP Wrist Extensor Up-Conditioning|
88989601|NCT05318482|Experimental|Motivational group|The patients of this group will be equipped with an electronic wristwatch and will be monitored every day by the physiotherapist (PT) through an application on their mobiles. The PT will follow these patients with a daily motivational session (15 minutes, modality 1 patient: 1 PT) and with an educational program about the definition, importance and benefits of physical activity.
88989602|NCT05318482|Sham Comparator|Control|The patients of this group will have an electronic wristwatch and will be advised by the PT only with generic recommendations of daily exercise during the hospitalization, besides the usual activities of the rehabilitation program.
89624075|NCT01798966|Experimental|SENSIMED Triggerfish|Sensimed Triggerfish device will be worn by each subject for 24h
89688448|NCT04348435|Experimental|Allogeneic HB-adMSCs 50MM|Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 50 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.
89624076|NCT05326984|No Intervention|Control group|This subjets will receive conventional chemotherapy alone. The Remission induction chemotherapy includes a steroid pre-phase of 7 days of prednisone 60mgm2SCD. The proper remission induction phase consist in prednisone 60mgm2 daily from day 0 to 28; Vincristine 1.5mgm2 on days 0, 7, 14 and 21; Doxorubicin 25mgm2 on days 0, 7, 21; L-asparaginase 10, 000 Um2 on days 2, 4, 6, 8, 10 and 12. Etoposide 300mgm2 and cytarabine 300mgm2 on days 22, 25 and 29. Intrathecal chemotherapy is administered on days 0, 7, 14 and 21.
89624077|NCT05326984|Experimental|Interventional group|"This group will receive conventional chemotherapy plus metformin 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.~The Remission induction chemotherapy includes a steroid pre-phase of 7 days of prednisone 60mgm2SCD. The proper remission induction phase consist in prednisone 60mgm2 daily from day 0 to 28; Vincristine 1.5mgm2 on days 0, 7, 14 and 21; Doxorubicin 25mgm2 on days 0, 7, 21; L-asparaginase 10, 000 Um2 on days 2, 4, 6, 8, 10 and 12. Etoposide 300mgm2 and cytarabine 300mgm2 on days 22, 25 and 29. Intrathecal chemotherapy is administered on days 0, 7, 14 and 21."
89624078|NCT01799278|Experimental|All Patients|MLN8237 at 50 mg twice daily for 7 days repeated every 21 days. Therapy will continue until disease progression, unacceptable toxicity as a result of MLN8237, or withdrawal of patient consent.
89688449|NCT04348435|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14.
88989603|NCT05314569|Placebo Comparator|Control group(C)|anesthesia will be maintained using Isoflurane 1.2MAC keeping the bispectral index( BIS) between 40-60%.
88989604|NCT05314569|Active Comparator|Ketamine-dexmedetomidine group( KD)|After induction of anesthesia , dexmedetomidine will be given(1 ug /kg ) over 10 min, then ketamine(2 m/kg) . maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing Dexmedetomidine( 0.5 μg/.kg /.h r)) ketamine,( 1 m/kg/hr),
88989605|NCT05314569|Active Comparator|. Fentanyl- midazolam group (FM)|After induction of anesthesia fentanyl( 3 μg/kg), midazolam( 100 ug /kg over 2 to 3 minutes) maintenance throughout the procedure, with the bispectral index between 40 and 60%. by infusing midazolam (1 ug /kg /min)-fentanyl( 2 μg/kg/h ).
88989606|NCT05313165|Experimental|Treated with LimFlow|Treatment with the LimFlow Stent Graft System
88989607|NCT05306301|Experimental|Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia|"In the run-in phase, patients will receive a dosage of 15 mg of ICLUSIG (ponatinib). If there are no toxicities observed, 30 mg of ponatinib will be administered in the remaining patients. MRD of patients will be evaluated on weeks 4, 10, 16, and 22. If a donor is available, MRD-positive patients will proceed to an allogeneic transplant after cycle 3. If there is no donor available, they'll continue treatment with 5 additional consolidation/reinduction blocks, followed by 24 28-day cycles of maintenance.~Induction/consolidation cycles are administered at 28 (cycles 1-2) and 21(cycles 2-8) day intervals."
88989608|NCT05302492|Experimental|Sleep apnea group with CPAP|"Intervention group: CPAP for 3 months in elderly diagnosis with sleep apnea and AHI > 15/h.~Control group: sleep apnea and patient refuse treatment or poor compliance."
88989609|NCT05302492|Experimental|sleep disturbance without sleep apnea nor PLMS|Intervention group: light box on elderly with sleep disturbance with PSQI > 5 and no OSA and no PLMS control group: elderly with sleep disturbance with PSQI > 5 and no OSA and no PLMS refuse light box or poor compliance
88989610|NCT05302167|Experimental|Feasibility/ acceptability|
88989611|NCT05298605|Experimental|Faith in Action!|"A train-the-trainer approach will be used to educate lay health navigators to present the culturally adapted Faith in Action! curriculum and to provide breast cancer screening navigation to Korean American women within faith-based settings"
88989612|NCT05298605|Active Comparator|Control|A presentation of lifestyle recommendations (e.g., physical activity, nutrition) will be provided to control groups.
88989613|NCT05297591|Experimental|breast cancer patients|Women and men diagnosed with breast cancer waiting for surgery
88989614|NCT05297201|Experimental|CPL500036 low dose|Patients will receive 20 mg of CPL500036 administered once daily for 28-days treatment period.
88989615|NCT05297201|Experimental|CPL500036 high dose|Patients will receive 40 mg of CPL500036 administered once daily for 28-days treatment period.
88989616|NCT05297201|Placebo Comparator|Placebo|Patients will receive placebo administered once daily for 28-days treatment period.
88989617|NCT05295108|Experimental|Caring Connections intervention|The Caring Connections intervention will consist of non-demanding, messages of care and concern delivered to individuals with SCI/D who had moderate to high social isolation and/or loneliness scores on the baseline survey. The caring messages will be in the form of structured, yet personalized mailed letters from one consistent peer with SCI/D, providing long-term and steady contact. Intervention participants will receive a letter every month over a 6-month period. Following a standardized set of principles, letters will contain cheerful expressions of care and micro-moments of positivity. The PI/Co-Is will provide a brief training and work with volunteer peers with SCI/D to write the letters.
88989618|NCT05295108|Active Comparator|Attention control|We will mail informational materials to individuals with SCI/D in our control group at the same timepoints over 6 months as our intervention letter mailings. The informational materials will discuss life domains that are important to a good quality of life. Topics include community living, physical/healthy living, safety and security, social/spirituality, advocacy/engagement, and employment/volunteering. We will draw information for each topic from the Knowledge Translation Center SCI Factsheets (MSKTC 2021) and the LifeCourse Nexus library (2021).
88989619|NCT05288374|Experimental|Celecoxib|Celecoxib 100 mg orally will be administered in the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
88989620|NCT05288374|Placebo Comparator|Placebo|A placebo pill provided by a hospital pharmacy will be administered in the day of surgery at 6 in the morning and 6 in the afternoon for 3 days.
88989621|NCT05280990|Experimental|Future Liver Remnant Function (FLRF)|Preoperative FLRF risk assessment via 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS)
88989622|NCT05280990|Active Comparator|Future Liver Remnant Volume (FLRV)|Preoperative FLRV assessment by CT/MRI volumetry
88989623|NCT05280535|Experimental|Study Protocol|All participants will receive all laboratory protocol components in a within-person randomized order across two sequential laboratory sessions.
88989624|NCT05278156|Experimental|CPL500036 low dose|Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period.
89624079|NCT01853332||Cross-Sectional|New participant: The purpose of the study is to learn about physical health in midlife and how it has been influenced by experiences and relationships. The study specifically targets health differences and the development of heart disease and diabetes.
89624080|NCT01853332||Longitudinal|Former participants (or the partner of a former participant) of the Adolescent and Family Development Project, Young Adult Development Project, Across Generations Project, and/or Paths Over Time Project may already know that this research shows how people grow, individually and as part of a familial and social network, throughout the course of life. This study focuses on learning about former participants' physical health in midlife and how it has been influenced by their experiences and relationships.
88989625|NCT05278156|Experimental|CPL500036 high dose|Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period.
88989626|NCT05278156|Placebo Comparator|Placebo|Patients are to receive placebo administered once dail for 28-days treatment period.
88989627|NCT05277233||Early-onset preeclampsia|Defined as preeclampsia that develops before 34 weeks of gestation
88989628|NCT05277233||Late-onset preeclampsia|Defined as preeclampsia that develops after 34 weeks of gestation
88989629|NCT05277233||Control|Healthy pregnancies, matched to early and late-onset cases
88989630|NCT05274828|Experimental|H7-Coil Deep TMS Treatment|H7-Coil Deep TMS Treatment
88989631|NCT05271357|Experimental|Bilateral|Theta burst stimulation (TBS)
88989632|NCT05271357|Active Comparator|Unilateral|Theta burst stimulation (TBS)
88989633|NCT05268393|Experimental|BREATHE-T1D|BREATHE-T1D is a 6-week group mindfulness program adapted specifically for teens with type 1 diabetes.
88989634|NCT05268393|Placebo Comparator|BREATHE-T1D Health Education|The health education placebo comparator is a 6-week group diabetes-specific education program designed to be informational but not supportive.
88989635|NCT05266521|Experimental|zLock Facet Locking Implant System|Device: zLOCK Facet Stabilization System zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
88989636|NCT05259553|Experimental|Patients with multiple myeloma|Adult patient, over 18 years old, with newly diagnosed multiple myeloma, indication of chemotherapy.
88989637|NCT05255380|Experimental|Mindful Activity group|Participants complete mindfulness and compassion-based practices via the study app.
88989638|NCT05255380|Sham Comparator|Mindful Awareness group|Participants monitor and report their thoughts and feelings via the study app.
88989639|NCT05243888|No Intervention|control|The control arm corresponds to women receive a conventional invitation letter sent by post to the home address of eligible women recommending them to make an appointment to a doctor or a midwife for the collection of a cervical specimen.
88989640|NCT05243888|Experimental|vaginal self-sampling|eligible women receive at their home address a vaginal self-sampling kit in addition to the conventional invitation letter
88989641|NCT05243888|Experimental|urinary self-sampling|eligible women receive at their home address a urine collection kit in addition to the conventional invitation letter
88989642|NCT05238688|Experimental|Thoracic Epidural Analgesia (TEA) group|Patients in this group will receive Thoracic Epidural analgesia.
88989643|NCT05238688|Experimental|Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group|Patients in this group will receive Thoracic Epidural analgesia in addition to high thoracic ultrasound-guided erector spinae plane block (ESPB).
88989644|NCT05236010|Active Comparator|Active rTMS with Attention Process Training|Subjects in this arm will receive active rTMS and then complete the assigned Attention Process Training battery immediately following active rTMS.
88989645|NCT05236010|Sham Comparator|Sham rTMS with Attention Process Training|Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training immediately following sham rTMS.
89624081|NCT01800838|Experimental|Treatment (silicon phthalocyanine 4 and PDT)|Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
88989646|NCT05236010|Active Comparator|Active HD-tDCS with Attention Process Training|Subjects in this arm will receive active HD-tDCS and complete the assigned Attention Process Training battery during active HD-tDCS.
88989647|NCT05236010|Sham Comparator|Sham HD-tDCS with Attention Process Training|Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training during sham HD-tDCS.
88989648|NCT05234684|Experimental|Orelabrutinib+ R-CHOP|Participants will receive 150 mg of oral orelabrutinib once daily with R-CHOP on day 1 of each cycle (21 days).
88989649|NCT05234684|Placebo Comparator|Placebo+ R-CHOP|Participants will receive 150 mg placebo once daily with R-CHOP on day 1 of each cycle (21 days).
88989650|NCT05230095||Parkinson's disease patients|30 parkinsonian patients scheduled for deep brain stimulation implantation surgery will be recruited
88989651|NCT05230095||Controls|15 healthy volunteers matched in age and sex will be recruited
88989652|NCT05228834|Experimental|Active Drug|Voxelotor 1500mg or equivalent daily as a tablet or powder for oral suspension
88989653|NCT05228834|Placebo Comparator|Placebo|Matching Placebo
88989654|NCT05228106||Patients eligible for [68Ga]-PSMA-617-PET|All cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with a [68Ga]-PSMA-617 dose calculated depending on the characteristics of the PET tomograph and patient weight (maximum 370 MBq). 60-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician. Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed.
88989655|NCT05227287||ADH 1/2 DMS|Participants with ADH1 or ADH2. No investigational product will be administered to participants in this study. Participants will only receive standard of care (SoC) treatment as directed by the participants' treating physicians.
88989656|NCT05225649|Experimental|Behavior Change Intervention|Participants will receive health coaching, patient-directed behavior change support by mobile health, and usual clinical care.
88989657|NCT05225649|No Intervention|Control|Participants will receive usual clinical care.
89624082|NCT01854034|Experimental|AUY922 Treatment Arm|AUY922 administered once weekly via intravenous, 70 mg/m2
89624083|NCT05313880||Digital tool Survey|Sequential patients from the 4 heart failure clinics at our institution will be offered to take part in the study.
89624084|NCT01802554|Experimental|Pleasant Events Program (PEP)|The Pleasant Events Program (PEP) is a Behavioral Activation (BA) treatment for depression. Participants receive 4 weekly sessions of face-to-face therapy (60 minutes each) to increase caregiver participation in pleasurable activities. Two additional phone sessions focus on continued behavioral activation for caregivers as well as problem-solving barriers to activation.
89624085|NCT01802554|Active Comparator|Information-Support (IS)|Participants in the Information-Support (IS) control condition were provided with a resource manual consisting of topics commonly covered in support groups or information packets provided by community agencies. Topics included problem-solving and communication skills, cognitive reframing and behavioral management, self-care help, caregiver fact sheets on a range of social and mental health issues, placement information, financial and legal issues, and lists of local organizations and community resources available. Each IS session allowed caregivers to select issue(s) from the resource manual to discuss. The therapist covered the material based on the caregivers' needs. When requested by the caregiver, supportive psychotherapy was also provided.
89624086|NCT01781975|Experimental|Imatinib Mesylate|400 mg imatinib given once daily basis.
89624087|NCT01781975|Placebo Comparator|Placebo|Placebo given once daily basis.
89624088|NCT01855360|Experimental|TUDCA and Doxycycline|INTERVENTION: Patients meeting study criteria were prescribed TUDCA taken orally, 250 mg three times daily. and doxycycline taken orally, 100 mg twice daily.
89624089|NCT01802710|Experimental|Psychological support|Ten weekly sessions, which the first 8 were in group and the last 2 were individuals. It consists on a) an informational session; b) Beck's cognitive-behavioural therapy; and c) progressive-muscle relaxation according to Jacobson
89624090|NCT01802710|Active Comparator|No psychological support|Patients of this group only received the conventional medical treatment, not receiving any psychological support
89624091|NCT04351126|Other|Control group|patients at high risk for OHSS who are receiving conventional treatment either as a prophylaxis (in the form of bromocriptine) or as a management in case of developing OHSS (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy)
89624092|NCT04351126|Experimental|treatment group|patient who has developed OHSS while on conventional lines of management (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy) patients in this group, fludrocortisone was added to conventional lines of management.
89624093|NCT04351126|Experimental|prevention group|patients at high risk for OHSS who are receiving fludrocortisone as a prophylaxis
89624094|NCT01804673|Experimental|Fentanyl-ITS|
89624095|NCT01856218|Experimental|UX003|"During the initial 14-week treatment period of the study, participants receive 2 mg/kg UX003 every other week (QOW) for 12 weeks. At Week 14, participants continue on UX003 therapy and begin a forced dose titration period for an additional 24 weeks at the dose sequence of 1, 4, and 2 mg/kg UX003 QOW as follows: 1 mg/kg UX003 for 8 weeks beginning on Week 14; then 4 mg/kg UX003 for 8 weeks beginning on Week 22; then 2 mg/kg UX003 for 8 weeks beginning on Week 30. Following the 24 week forced dose titration period, participants who continue on treatment (continuation period) received 2 mg/kg UX003 QOW beginning at Week 38 for up to an additional 36 weeks.~After the first phase of the study, participants who elect to continue drug treatment are transitioned to the long-term extension phase, where they are treated with UX003 at 4 mg/kg beginning at Week 74, for up to an additional 168 weeks."
88989658|NCT05213832|Experimental|Inhalatory group|Patience with severe SAH (WFNS > 3) are enrolled in the study. In these patients we administered a inhalatory dose of Isofluorane
88989659|NCT05213338|Experimental|wear-documentation|Theramon
88989660|NCT05213338|No Intervention|controls|No microchip
88989661|NCT05211960|Experimental|Treatment|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness. Participants will receive a premium account for 1 year; the current study will evaluate outcomes over 3 months. The intervention will be delivered concurrently with treatment as usual which includes standard psychosocial care as participants are referred to their respective programs.
88989662|NCT05208671|Experimental|NOURISH Food Box|12-week food assistance with low Dietary Inflammatory Index (DII) foods
88989663|NCT05208671|No Intervention|Wait-list Control|Wait-list control group eligible to receive NOURISH box after study period
88989664|NCT05197673|Experimental|Intervention group|This arm will receive TPB intervention to build positive attitudes towards COVID-19 related preventive behaviour (e.g., good compliance with infection control measures, encouraging uptake of testing and vaccination), subjective norms (tackling strategies for perceived social pressure from others or normative beliefs), and improve perceived behavioural control towards risks of outbreaks in workplace.
88989665|NCT05197673|No Intervention|Control group|Control group will receive only general health information.
88989666|NCT05194514|Other|SherpaPak™ Cardiac Transport System|When a matching donor heart from a non-local donor offer (from Northern California, Arizona, Nevada or farther geographies) becomes available the recipient will be assigned a subject identification number and randomized 1:1 to receive a heart transported using either standard of care cold storage or the SherpaPak™ Cardiac Transport System.
88989667|NCT05194514|Other|Cold Storage|When a matching donor heart from a non-local donor offer (from Northern California, Arizona, Nevada or farther geographies) becomes available the recipient will be assigned a subject identification number and randomized 1:1 to receive a heart transported using either standard of care cold storage or the SherpaPak™ Cardiac Transport System.
88989668|NCT05192655||HNSCC-patients treated with primary radio(chemo)therapy (R(C)T)|Patients, older than 18 years, with diagnosed HNSCC, attending the Department of Radiooncology and Radiotherapy at Charité for a treatment with curative intension (R(C)T) . All patients received as pretherapeutic diagnostic method a 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging.
88989669|NCT05192655||HNSCC-patients treated with primary surgery|Patients, older than 18 years, with diagnosed HNSCC, attending the Department of Oral and Maxillofacial Surgery or ENT Department at Charité for a treatment with curative intension ( primary surgery +/- combined with adjuvant (R(C)T)). All patients received as pretherapeutic diagnostic method a 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging.
88989670|NCT05192031|Experimental|Smoking cessation support|
88989671|NCT05192031|No Intervention|Usual care|
88989672|NCT05190835|Other|Hallux surgery|These are patients operated on for hallux without change of strategy compared to current care
88989673|NCT05190835|Other|Metatarsal paddle surgery|These are patients operated on for metatarsal paddle without change of strategy compared to current care
88989674|NCT05190835|Other|Hallux and metatarsal pallet surgery|These are patients operated on for hallux and metatarsal paddle without change of strategy compared to current care
88989675|NCT05189483|Experimental|Albumin-bound paclitaxel plus camrelizumab therapy arm|Enrolled patients will receive the following treatment: 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) and 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks.
88989676|NCT05188820|Active Comparator|Corticosteroid group|Patients will receive intra-articular z-joint injection of cortisone
88989677|NCT05188820|Experimental|PRP group|Patients will receive intra-articular z-joint injection of PRP
88989678|NCT05187117|Experimental|Open Label Pilot|"The Open Label Pilot (Phase 4) will include testing the CAPABLE Family intervention with 6 individuals with MCI or early-stage dementia. At least 5 of the 6 older adults will be required to have a family member involved. Assuming all have a family member involved (though one may not), 12 participants will be enrolled in the open label pilot.~Open label pilot participants will be asked to provide feedback halfway through the intervention and at the end via phone conversations with the research study team, allowing the study team to make changes accordingly."
88989679|NCT05187117|Experimental|Randomized Control Pilot - Intervention Arm|After the open label pilot, 17 older adults (and if available, care partners) will be randomized to the CAPABLE Family intervention. They will be assessed at baseline, after the 4 month intervention, and after the waitlist control arm.
88989680|NCT05187117|Active Comparator|Randomized Control Pilot - Waitlist Control Arm|The waitlist control group, 17 older adults and if available, care partners, will receive the intervention after they have served as controls to the immediate treatment group, ensuring all participants have access to the intervention.
88989681|NCT05181189|Experimental|DAOIB+Omega-3|
88989682|NCT05181189|Placebo Comparator|DAOIB+Placebo|
88989683|NCT05180617|Experimental|Individual music therapy (IMT)|"After baseline measures, each Participant will receive 6 x 1 weekly hour of music therapy. During music therapy the participants will be interacting both musically and verbally with the therapist.~Participants will be provided with both acoustic and electronic instruments to be able to improvise with the therapist. In addition, IMT participants will be provided with the opportunity to compose and write songs, take part in preferred music lyric analysis, sing and discuss/talk with the therapist.~During session 2 and 5 EEG hyperscanning of therapist and patient will be applied.~All 5 IMT participants will do the same pre-post intervention test battery."
88989684|NCT05180617|Experimental|Group music therapy (GMT)|"During 6 x 1 weekly hour of GMT, 5 participants will be invited to take part in a range of group music making activities.~Participants will be provided with both acoustic and electronic instruments to be able to improvise within the group setting. In addition, GMT participants will be provided with the opportunity to compose and write songs as a group, take part in preferred music lyric analysis, sing and take part in group discussions.~All 5 GMT participants will do the same pre-post intervention test battery."
88989685|NCT05180617|No Intervention|Control Group|"CG will receive standard treatment, which includes key work sessions, other group work programmes and clinical support (e.g. prescribing).~All 5 CG participants will do the same pre-post intervention test battery."
88989686|NCT05180240|Experimental|CardiolRx|"Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo"
88989687|NCT05180240|Placebo Comparator|Placebo|"Week 1 (p.m. dose of Day 1 to a.m. dose of Day 7): 2.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 2 (p.m. dose of Day 7 to a.m. dose of Day 14): 5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 3 (p.m. dose of Day 14 to a.m. dose of Day 21): 7.5 mg/kg of body weight b.i.d. CardiolRxTM or placebo~Week 4 to end of treatment period (p.m. dose of Day 21 to a.m. dose of last day of treatment period at week 12): 10 mg/kg of body weight b.i.d. CardiolRxTM or placebo"
88989688|NCT05173519|Active Comparator|Omnibond topical skin adhesive|
88989689|NCT05173519|Active Comparator|Dermabond topical skin adhesive|
88989690|NCT05170997|Active Comparator|Iodine Control|Participants taking an iodine-containing multivitamin or supplement and randomly allocated not to receive milk supply.
89624096|NCT01774097|Experimental|ALD-301|Participants will receive ALD-301 via intramuscular injection
89624097|NCT01774097|Placebo Comparator|Placebo (vehicle)|Participants will receive placebo (vehicle)via intramuscular injection
89624098|NCT01856530|Experimental|Oxytocin|Liquid intranasal oxytocin, 24 IU, administered once
89624099|NCT01856530|Placebo Comparator|Placebo|Matched placebo nasal spray
89624100|NCT05302336|Active Comparator|Liposomal doxorubicin + Cyclophosphamide|Liposomal doxorubicin + cyclophosphamide A 35mg(per r square meter of body surface)+C 600mg(per r square meter of body surface) every 3 weeks for 4 cycles
89624101|NCT05302336|Active Comparator|Docetaxel + Cyclophosphamide|Docetaxel + Cyclophosphamide T 75mg(per r square meter of body surface)+C 600mg(per r square meter of body surface) every 3 weeks for 4 cycles
88989691|NCT05170997|Active Comparator|No Iodine Control|Participants not taking an iodine-containing multivitamin or supplement and randomly allocated not to receive milk supply.
89038120|NCT00547716|Placebo Comparator|2.|Placebo comparator along with interferon.
89624102|NCT01804036|Active Comparator|Zolpidem (Ambien) Treatment|A three week treatment of Zolpidem
89624103|NCT01804036|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
89624104|NCT01856764|Experimental|0.5% Roflumilast Cream|Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
89624105|NCT01856764|Placebo Comparator|Vehicle Cream|Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
89624106|NCT01857232|Other|Control|OND + DEX + FOS followed by oral DEX
89624107|NCT01857232|Placebo Comparator|Placebo|OND + APD403 followed by oral PLACEBO
89624108|NCT01857232|Experimental|Low dose APD403|OND + APD403 followed by oral APD403 low dose
89624109|NCT01857232|Experimental|Mid dose APD403|OND + APD403 followed by oral APD403 mid dose
89624110|NCT01857232|Experimental|High dose APD403|OND + APD403 followed by oral APD403 high dose
89624111|NCT01804114|Active Comparator|Local anesthetic continuous infusion|Pain management following hernia repair
89624112|NCT01804114|Placebo Comparator|Placebo continuous infusion|Placebo pain management following hernia repair
89624113|NCT05275036||Cancer Arm|Participants with new diagnosis of lymphoid malignancies, from whom blood samples will be collected.
89624114|NCT05275036||Benign Arm|Participants with new diagnosis of benign lymphoid diseases, from whom blood samples will be collected.
89624115|NCT01766128|Active Comparator|Zonisamide|The patients in this arm are treated with zonisamide 50mg/d
89624116|NCT01766128|Placebo Comparator|Placebo|The patients in this arm are treated with placebo
89624117|NCT02859558|Experimental|Arm 1: Fiebig I/II|Participants enrolled during Fiebig stages I or II (non-reactive HIV-1 antibody).
88989692|NCT05170997|Experimental|Iodine Intervention|Participants taking an iodine-containing multivitamin or supplement and randomly allocated to receive milk supply.
88989693|NCT05170997|Experimental|No Iodine Intervention|Participants not taking an iodine-containing multivitamin or supplement and randomly allocated to receive milk supply.
88989694|NCT05154799|Experimental|Dyspraxic children|Children with Developmental coordination disorder
88989695|NCT05154799|Experimental|Control children|Healthy children
88989696|NCT05154799|Experimental|Dyspraxic adults|Adults with with Developmental coordination disorder
88989697|NCT05154799|Experimental|Control adults|Control adults
88989698|NCT05154643||patients with liver fibrosis|
88989699|NCT05154643||healthy controls|
88989700|NCT05152446|Experimental|Infusion management scheme|To implement infusion management scheme, then observe the continuous changes.
88989701|NCT05150067|Experimental|Experimental group|The participants in the experimental group received a blended learning programme with face-to-face training and an online module on handover practice.
88989702|NCT05150067|Active Comparator|waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed.
88989703|NCT05146427|Experimental|Active Slow-wave enhancement|Participants will wear the Philips SmartSleep Deep Sleep Headband which will play auditory tones to selectively enhance slow-wave activity.
88989704|NCT05146427|Sham Comparator|Sham Slow-wave enhancement|Participants will wear the Philips SmartSleep Deep Sleep Headband which will not be programmed to enhance slow-wave activity
88989705|NCT05138419|Active Comparator|Case Management Model (CMM)|CMM includes 3 visits of pharmacist initiated discussion of workbook content (including AP [action plan] and CKD web-based sites) and AP reinforcement. Pre-testing is done on Visit 1 (V1) and Post testing and program evaluation on V3. Subjects are asked to read 1 chapter a week, write down questions and take tests at the end of chapters. On V1 pharmacist introduces the Workbook System highlighting chapters 1-4 and assist with AP goal selection. On V2, the pharmacist answers questions, provides chapter 4-8 highlights and reviews AP goal progress and food label exercise. On V3, pharmacist answers questions, expands on workbook content and reviews AP goals progress and program evaluation including modality and transplant questions from pre/posttests, identification and ranking of peer cluster leader teaching style and effectiveness, identification of AP goals selected and ranking of helpfulness is completed. Pharmacists track time spent at each visit to compare cost and outcomes.
88989706|NCT05138419|Active Comparator|Self Study (SS)|SS includes 2 visits. Subjects receive the workbook, paper copies of AP and food label exercise. Pre-testing will be done on V1 and Post testing on V2, eight weeks later. Subjects will be asked to read 1 chapter a week for the next 8 weeks. The pharmacist will provide a brief introduction of the workbook (5-10 minutes) and the AP. Only subject initiated questions will be answered. On V2, the pharmacist will answer subject initiated questions and ask about progress in the AP goal attainment and the program evaluation will be completed, as described in arm 1.Pharmacists track time spent at each visit to compare cost and outcomes.
88989707|NCT05138419|Sham Comparator|Control (Ctrl)|Ctrl includes 2 visits. Subjects receive a list of web-based CKD sites, a food label exercise and a copy of the AP with no additional intervention, other than answering subject initiated questions, on V1. Pre-testing will be done on V1 and Post testing on V2 and program evaluation will be done eight weeks later. On V2, the pharmacist will ask about AP goals and answer subject initiated questions. Pharmacists track time spent at each visit to compare cost and outcomes.
88989708|NCT05136560|No Intervention|Placebo|normal saline
89624118|NCT02859558|Experimental|Arm 2: Fiebig III/IV|Participants enrolled during Fiebig stages III or IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2).
89624119|NCT02859558|Experimental|Arm 3: Fiebig V|Participants enrolled during Fiebig stage V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band).
89624120|NCT02830542|Experimental|SER-262|SER-262 [Single dose: 10(4), 10(5), 10(6), 10(7) or 10(8) SCFUs; Multiple dose 10(6), 10(7), or 10(8) SCFUs]
89624121|NCT02830542|Placebo Comparator|Placebo|Placebo
89624122|NCT02267356|Experimental|Low dose 12-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
89624123|NCT02267356|Experimental|Low dose 24-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
88989709|NCT05136560|Experimental|low dose dexamethasone|0.1 mg/kg dexamethasone iv once per day, for 1 or 2 days
88989710|NCT05136560|Experimental|high dose dexamethasone|0.2 mg/kg dexamethasone iv once per day, for 1 or 2 days
88989711|NCT05125016|Experimental|Module 1- Monotherapy|REGN4336
89624124|NCT02267356|Experimental|High dose 12-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
89624125|NCT02267356|Experimental|High dose 24-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
89624126|NCT02267356|Placebo Comparator|Placebo|4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
89624127|NCT05229250||Healthy subjects|Subjects without FLIA
89624128|NCT05229250||Patient subjects|Subjects with FLIA
89038121|NCT02908802|Active Comparator|Probiotic|Probiotic capsules: two capsules twice a day
89038122|NCT02908802|Placebo Comparator|Placebo|Probiotic capsules without the active ingredient: two capsules twice a day
89038123|NCT00547794||CRT-D + AVJ Ablation|
89038124|NCT00547794||Single-Chamber ICD + Pharmacological Therapy|
89038125|NCT02908646|Experimental|microcoil|patients who plan for microcoil localization
89038126|NCT02908646|Placebo Comparator|hookwire|patients who plan for hookwire localization
89038127|NCT00547833||Experimental|Children with language-learning disabilities reading at approximately a 6th grade level
89038128|NCT00547833||Age-Matched|Typical language learners each of whom is pair match to an experimental participant by age and gender.
89038129|NCT00547833||Language-Matched|Typical language learners, each of whom is pair-matched to an experimental participant by reading comprehension skills and gender.
89038130|NCT02908568|Experimental|Spring device|Brisk dilatation of fhe mouth.
89038131|NCT02908568|Sham Comparator|Mandible stimulator|Stimulation of fhe mouth.
89038132|NCT02908412|Experimental|Digital nerve block in left hand|Patients in this group will receive DNB in left hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
89038133|NCT02908412|Experimental|Digital nerve block in right hand|Patients in this group will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
89624129|NCT01860586|Experimental|Bevacizumab|Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
89624130|NCT05166382|Experimental|Group 1: SomaSignal Informed Medical Management (CVDT2D test, informed)|Blood draw for cardiovascular CVDT2D test at baseline and 6 months (+/- 30 days). SomaSignal Test results will be sent to the providers and then shared with study participants. Participants' medical record will be reviewed, and they may be contacted within 30 days after baseline and 6-month visits to review changes in treatment strategy (nothing, add/remove medication, etc.) made at visit.
88989712|NCT05125016|Experimental|Module 2-Combo Therapy|REGN4336 + Cemiplimab
88989713|NCT05125016|Experimental|Module 3-Combo Therapy|REGN4336 + REGN5678
88989714|NCT05117554|Experimental|SAD-AB521 Dose 1|"Participants will receive Dose 1 of AB521 orally with water under fasting conditions."
89038134|NCT04686474|Experimental|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment will be used twice daily for 12 weeks
89038135|NCT04686630||Single group|Only observational study
89038136|NCT02908256|Experimental|PVI group|Monitoring of the PVI during the surgical intervention
89038137|NCT02908256|Active Comparator|Delta PP group|Monitoring of the deltaPP during the surgical intervention
89038138|NCT00547872|Experimental|1|Best medical/behavioral treatment according to guidelines suggestions plus CAD screening by ECG tolerance testing followed by revascularization in case of coronary stenosis.
89038139|NCT00547872|No Intervention|2|Best medical/behavioral treatment according to guidelines suggestions
89038140|NCT02908295|Experimental|A|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
89038141|NCT02908295|Placebo Comparator|B|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
88989715|NCT05117554|Experimental|SAD-AB521 Dose 2|"Participants will receive Dose 2 of AB521 orally with water under fasting conditions."
88989716|NCT05117554|Experimental|SAD-AB521 Dose 3|"Participants will receive Dose 3 of AB521 orally with water under fasting conditions."
88989717|NCT05117554|Experimental|SAD-AB521 Dose 4|"Participants will receive Dose 4 of AB521 orally with water under fasting conditions."
88989718|NCT05117554|Placebo Comparator|SAD-Placebo|Participants will receive matching placebo orally with water under fasting conditions.
89038142|NCT03809442|Experimental|Ropivacaine with Ketamine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that possesses both central and peripheral analgesic effects. Preincisional infiltration of ketamine prolongs the time to first analgesic requirement and also decreases the total amount of analgesics used postoperatively.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group)."
89038143|NCT03809442|Experimental|Ropivacaine with Tramadol|"Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak mu receptor agonist) and nonopioid receptors (inhibits reuptake of nor-adrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway.~It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.~In one study it was found that the addition of tramadol or midazolam to caudal epidural ropivacaine prolongs the duration of analgesia without causing significant side effects.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group)."
88989719|NCT05117554|Experimental|MAD-AB521 Dose 1|"Participants will receive Dose 1 of AB521 orally with water under fasting conditions."
89210989|NCT02549378|Experimental|patients with a hypercapnia test|confocal microscopy patients with a hypercapnia test
89624131|NCT05166382|Placebo Comparator|Group 2: Standard of Care (CVDT2D test, uninformed)|Similar to group 1 but SomaSignal CV test results will not be provided to participants until after the intervention period.
89624132|NCT02273206|Active Comparator|Prevention Care Management for Cancer Screening|The Care Manager will focus on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening.
89688450|NCT01723865||Conventional|Patients with heart failure having an ICD-CRT implanted, followed by conventional visits.
89688451|NCT01723865||Remote Monitoring|Patients with heart failure having an ICD-CRT implanted, followed by remote monitoring.
89624133|NCT02273206|Experimental|Prevention Care Management for Depression and Cancer Screening|"The Care Manager will provide depression care management and motivational support (supportive counseling) and act as a critical link between primary care, mental health care provider, and the patients, helping to develop and implement a treatment plan.~In addition, the Care Manager will work with participants on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening."
89624134|NCT00705432|Placebo Comparator|1. Placebo + PEG + RBV|PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
89038144|NCT03809442|Experimental|Ropivacaine with Midazolam|"The analgesic effect of extradurally administered midazolam is through γ-amino butyric acid (GABA)/benzodiazepine system of spinal cord.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group)."
89038145|NCT03809442|Experimental|Ropivacaine with Dexamethasone|"The glucocorticoid dexamethasone appears to be effective in a small number of preclinical and clinical studies and found that dexamethasone prolongs analgesia from interscalene blocks using ropivacaine or bupivacaine, with the effect being stronger with ropivacaine.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group)."
89038146|NCT03809442|Experimental|Ropivacaine with Dexmedetomidine|"Dexmedetomidine is a new highly selective alpha2 (a2) agonist with known sedative, antihypertensive, anxiolytic, and analgesic properties.~In one study, it was found that wound infiltration with combined ropivacaine and dexmedetomidine found to be significantly superior for postoperative analgesia compared with either combined ropivacaine and tramadol or ropivacaine alone for lumbar discectomies.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kgdexmedetomidine (8mL per incision) (Dexmedetomidine group)."
89038147|NCT03809442|Placebo Comparator|Ropivacaine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg."
89624135|NCT00705432|Experimental|2. Boceprevir + PEG + RBV - 24 Weeks (RGT)|"PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.~At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.~At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up."
89038148|NCT02908217|Experimental|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
89038149|NCT02908217|Placebo Comparator|Placebo|6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks
89038150|NCT00547950|Experimental|1|drug
89038151|NCT02908373||Case group|Nursing homes benefiting first the implementation of the coaching model (methodological help for professionals on the patient safety culture): just after the first measure (overview of the situation)
89038152|NCT02908373||Control group|Nursing homes benefiting the implementation of the coaching model (methodological help for professionals on the patient safety culture): after the second measure (impact of the device on case group)
89038153|NCT02908139||Patients before kidney transplantation|The study included who had been admitted to the TransplantClinic before kidney transplantation
89038154|NCT00534768|Active Comparator|1|debridement on 1st, 3-5th and 7th postoperative days
89624136|NCT00705432|Experimental|3. Boceprevir + PEG + RBV - 44 Weeks|PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
89038155|NCT00534768|Active Comparator|2|
89038156|NCT00547989|Active Comparator|1|control
89038157|NCT00547989|Experimental|2|PVB with ropivacaine and postoperative pump 5ml/h
89624137|NCT04491708|Experimental|Apparatus Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
89624138|NCT04491708|Experimental|Mat Pilates|The same Pilates exercises were performed during the Mat Pilates and Reformer apparatus sessions. For each exercise, one set of 10 repetitions was performed. Between each exercise, participants were allowed to rest for 2 minutes in a lying position. For each exercise in the Reformer apparatus, the number of springs used was defined during the familiarization sessions as the highest number of springs the participant could perform the 10 repetitions of the exercise with proper technique and following the 5 Pilates principles correctly. The exercises performed were (Stott 2003; Stott 2001): 1) Cat stretch; 2) Hip rolls; 3) Ab prep; 4) Breast stroke preps; 5) Hundred; 6) Breast stroke; 7) Half roll back; 8) Single leg stretch; 9) Slow double leg stretch; 10) Double leg stretch; 11) Double leg circle; 12) Scissors; 13) Roll over; 14) Teaser; 15) Spine stretch forward.
89038158|NCT00547989|Experimental|Experimental 1|PVB with ropivacaine, 10 patients included but not analysed
89624139|NCT00704964||All participants|Each site will be evaluated by a site questionnaire and assigned as either a high or low participant management site. Participants are not randomized to a group. However, treatment completion rates will be evaluated based on the high vs low participant management sites.
89624140|NCT02483442||No CT Pulmonary Angiography|Low Clinical Pretest Probability with D-dimer < 1000 ug/L and Moderate Clinical Pretest Probability with D-dimer < 500ug/L
89624141|NCT02483442||CT Pulmonary Angiography Required|Low Clinical Pretest Probability with D-dimer > or = 1000ug/L and Moderate Clinical Pretest Probability with D-dimer > or = 500 ug/L and High Clinical Pretest Probability
88989720|NCT05117554|Experimental|MAD-AB521 Dose 2|"Participants will receive Dose 2 of AB521 orally with water under fasting conditions."
88989721|NCT05117554|Placebo Comparator|MAD-Placebo|Participants will receive matching placebo orally with water under fasting conditions.
88989722|NCT05117554|Experimental|DDI-AB521 Dose + Midazolam|Participants will receive highest safe dose level of AB521 from MAD and midazolam orally with water under fasting conditions
88989723|NCT05116319||Chinese people with no known history of diabetes|
88989724|NCT05113160|No Intervention|Treatment efficacy: Delayed Control Group|Treatment cycle 1 only.
88989725|NCT05113160|Experimental|Experimental: Group Size x Aphasia Severity|Outcomes will be measured for individuals who participate in large group (6-8 group members) compared to dyads (2 group members), and whether this relationship differs as a function of aphasia severity (severe vs. mild-moderate aphasia).
88989726|NCT05113160|Experimental|Experimental: Group composition|Outcomes will be measured for individuals who participate in homogeneous compared to heterogeneous groups (6-8 people with aphasia), based on aphasia severity (severe vs. mild-moderate aphasia).
88989727|NCT05107349|Other|1|
88989728|NCT05100654|No Intervention|No post-operative oral antibiotics|Patients will only receive 24hr of IV peri-operative antibiotics
88989729|NCT05100654|Active Comparator|6 days of oral antibiotics|Patients will receive 24hr of IV peri-operative antibiotics and then 6 days of oral antibiotics
88989730|NCT05098067|Experimental|Intervention group|Participants will receive IV fluid bolus of 1000cc of lactated ringers, metoclopromide 10mg IV and will have 5g of 0.075% capsaicin cream applied to their abdomen. Participants will indicate the severity of their symptoms immediately prior to administration of metoclopromide, at time 0 and every 30 minutes for a total of 120 minutes after administration of the first medications (or discharge) using a 10 cm visual analogue scale (VAS)11,12. The scale will be provided in English or Spanish as appropriate. If at the 90-minute time mark the patient does not report improvement of their symptoms, odansetron 8mg IV will be administered.
88989731|NCT05098067|Placebo Comparator|Placebo group|Participants will receive IV fluid bolus of 1000cc of lactated ringers, metoclopromide 10mg IV and will have 5g of placebo cream applied to their abdomen. Participants will indicate the severity of their symptoms immediately prior to administration of metoclopromide, at time 0 and every 30 minutes for a total of 120 minutes after administration of the first medications (or discharge) using a 10 cm visual analogue scale (VAS). The scale will be provided in English or Spanish as appropriate. If at the 90-minute time mark the patient does not report improvement of their symptoms, odansetron 8mg IV will be administered.
88989732|NCT05092373|Experimental|Cohort 1 (TTF, cabozantinib)|Patients receive TTF continuously for at least 18 hours per day on days 1-21 of each cycle. Patients also receive cabozantinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88989733|NCT05092373|Experimental|Cohort 2 (TFF, atezolizumab, nab-paclitaxel)|Patients receive TTF continuously for at least 18 hours per day on days 1-28 of each cycle. Patients also receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each cycle and atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89624142|NCT02474238|Experimental|The sequential technique|By using the double frequency YAG laser to make the initial bore and the Nd:YAG laser to complete the perforation on iris.
88989734|NCT05081128|Active Comparator|Open Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to active (open shunt group)(setting 4)(110 mm H2O) at time of shunt implantation
88989735|NCT05081128|Sham Comparator|Closed Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to placebo (closed shunt group)(setting 8)(>400 mm H2O) at time of shunt implantation followed by setting to active (setting 4) (110 mm H2O) three months after the procedure.
88989736|NCT05071326|Experimental|HealthyLifetime Group|This project is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making.
88989737|NCT05070923|Experimental|HealthyLifetime Group|"HL is an 8-week, personalized health coaching program that includes a comprehensive assessment made through a survey and a virtual' home visit (via video), a goal-directed strengthening action plan developed by the participant with the guidance of the nurse, a tailored daily planning guide to enhance action steps and goal attainment, and six weekly 30 minute nurse coaching sessions with participants the Healthie application technology via their personal home computer, Tablet or Smartphone device. If a participant does not use a personal device or the device cannot support the Healthie platform, the HL program will provide a Tablet to them for their use during the program. All video sessions ( ie, home visit, strengthening plan, and weekly coaching sessions will use a two-way video but only the audio portions of the sessions will be recorded. The HL program, tailored to each participant's need for strong and resilient function, encompasses the following key elements:"
89624143|NCT02474238|Active Comparator|The pure Nd:YAG laser technique|By using the pure Nd:YAG to make a complete perforation on iris.
89624144|NCT02474394|Active Comparator|Mcgrath|The endotracheal intubation will be provided using Mcgrath series 5 video laryngoscope
89624145|NCT02474394|Active Comparator|Macintosh|The endotracheal incubation will be provided using macintosh laryngoscope
89624146|NCT01861054|Experimental|Treated patients - Total|Patients eligible will be treated with Reparixin as add-in monotherapy
89624147|NCT00704808||Patients|Patients with newly diagnosed and operated glioblastoma multiforme.
89624148|NCT04241718|Other|Single-arm|No comparator, placebo, or randomization
89624149|NCT05323032|Experimental|Normal subjects|Normal subjects at banha university that are seeking regular ophthalmic check-up.
89624150|NCT01861756|Experimental|Diabetes Medication Choice Decision Aid|
89624151|NCT01861756|No Intervention|Standard care|
89624152|NCT05301582||Group|A total of 70 consecutive adult patients, aged 18-65 years scheduled for elective laparoscopic surgery under general anesthesia will be included in the study.
88989738|NCT05070923|No Intervention|Usual Care Group|Participants randomized to the usual care group will be given information about when to expect reminders on the Healthie platform to complete future surveys at the end of week 8, and after three months that will be available on the Healthie Platform for them to fill out and save on the platform. They will also be reminded how to contact the study coordinator if they should have questions. Participants in this group will have the view to other functions on the platform turned off. They will only be able to view documents as the reminders appear for them to complete.
88989739|NCT05069740|Experimental|Salsalate|3000 mg/day salsalate (1500 mg twice daily) for 5 days
88989740|NCT05069740|Placebo Comparator|Placebo|1 capsule contain microcrystalline cellulose filler (twice daily) for 5 days
88989741|NCT05067569|Experimental|Digital brief behavioural therapy for insomnia|Participants randomised to the digital brief behavioural therapy for insomnia (SleepFix app) will be provided an unique access code to download the app. The intervention uses sleep retraining therapy to reduce excess time spent in bed and retrain sleep by matching time in bed (minimum of five and a half hours) to total sleep time. All participants in the intervention arm will also be provided a sleep-tracking wearable device (Fitbit) which will synchronised bed times (going to bed and rising) and are synchronised with the SleepFix app. Participants wil complete a daily sleep diary, rate sleep quality and mood. The intervention is provided for 6 weeks.
88989742|NCT05067569|Active Comparator|Sleep Health Education wait-list control|"Participants randomised to the control group will gain access to the first Sleep Health Education module immediately following completion of baseline questionnaires. There are three modules provided bi-weekly with information about sleep health and broad details about managing sleep disturbances. Participants will receive a link to this information as each module is made available.~Upon completion of the study (week 26), the control group will receive free access to the SleepFix mobile application."
88989743|NCT05066308|Experimental|Cannabidiol (CBD)|The recommended starting dosage is 2.5mg/kg taken twice daily. The titration schedule recommended in the EPIDIOLEX label will be followed, with 2.5 mg/kg twice daily in week 1, 5 mg/kg twice daily in week 2, 7.5 mg/kg twice daily in week 3, and 10 mg/kg twice daily in week 4 with the second PET scan conducted after one week at the maximum labeled dose. Any participant not tolerating a given dose can either go back down to the next lowest dose or delay uptitration at any week in the protocol. Participants will be instructed to take Epidiolex with a meal rather than in a fasted state. Participants will be treated for 4 weeks in total.
88989744|NCT05066308|Placebo Comparator|Placebo|The placebo will be taken at identical doses to the active drug condition.
88989745|NCT05062928|Experimental|Virtual coaching group|In this group, the virtual coach will train and assess.
88989746|NCT05062928|No Intervention|Human instructor group|In this group, a human instructor will train, but the virtual coach will assess.
88989747|NCT05059626|Other|Simvastatin|30 days of Simvastatin (10mg/day)
88989748|NCT05059626|Other|bazedoxifene + conjugated estrogen|30 days of bazedoxifene + conjugated estrogen (0.45mg/20mg/day)
88989749|NCT05058690|Experimental|Individuals who had a CCTA as part of their clinical care|Approximately 90 individuals who had a CCTA as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable;
88989750|NCT05058690|Experimental|Individuals who had a chest CT as part of their clinical care|Approximately 90 individuals who had a chest CT as part of their clinical care (45 identified as having an abnormal FatHealth algorithm calculation and 45 with a normal FatHealth algorithm calculation) will undergo OGTT which is evaluable.
88989751|NCT05053152|Placebo Comparator|Arm I (placebo, SABR)|Patients receive placebo PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity.
89624153|NCT02474316|Experimental|PegINF plus nucleos(i)de analgoue|Peginterferon alfa-2a 180μg /wk plus nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
88989752|NCT05053152|Experimental|Arm II (relugolix, SABR)|Patients receive relugolix PO QD on days 1-180 and undergo SABR for 1-3 weeks in the absence of disease progression or unacceptable toxicity.
88989753|NCT05051540|Experimental|Inelastic Compression System Group|Participants in this group will receive the inelastic compression wrap for daily use on their legs for 6 consecutive weeks.
88989754|NCT05050955||LungCare Surveillance (500 Cases)|Observational evaluation of diagnostic performance characteristics of AlloSure Lung to detect a spectrum of rejection and allograft infection.
88989755|NCT05050162|Experimental|ARM I (high-dose cisplatin, radiation therapy)|NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
88989756|NCT05050162|Experimental|Arm II (low-dose cisplatin, radiation therapy)|NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity.
88989757|NCT05050162|Experimental|Arm III (high-dose cisplatin, radiation therapy)|p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
88989758|NCT05050162|Experimental|Arm IV (low-dose cisplatin, radiation therapy)|p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity.
89624154|NCT02474316|Active Comparator|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
89624155|NCT01862536|Placebo Comparator|Placebo|Placebo tablet
89624156|NCT01862536|Experimental|Tadalafil|Daily use of tadalafil (study drug) at 40 mg orally.
89038159|NCT00534846|Placebo Comparator|A placebo|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
89038160|NCT00534846|Active Comparator|B toremifene|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
89038161|NCT00548067|Active Comparator|1|
89038162|NCT00548067|Active Comparator|2|
89038163|NCT00548067|Active Comparator|3|
89038164|NCT00548067|Experimental|4|
89038165|NCT02907827|Experimental|stage IV melanoma CR>3years|Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
89038166|NCT02907827|Experimental|Stage III Melanoma|AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
89038167|NCT00534885|Experimental|1: Healive® Lot 1|
89038168|NCT00534885|Experimental|2: Healive® Lot 2|
89038169|NCT00534885|Experimental|3: Healive® Lot 3|
89038170|NCT00534885|Active Comparator|4: control vaccine (Havrix)|
89038171|NCT02907671|Active Comparator|Group A|carpal tunnel corticoanesthetic injection between the flexor tendons
89038172|NCT02907671|Active Comparator|Group B|carpal tunnel corticoanesthetic injection next to the median nerve with hydrodissection
89038173|NCT00548106|Experimental|1|Infants will be fed the new hydrolyzate formula.
89038174|NCT00548106|Placebo Comparator|2|Nan HA infant formula
89038175|NCT02907749|Active Comparator|Carvedilol|Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
89038176|NCT02907749|Experimental|Spironolactone and carvedilol|"Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose~Spironolactone is added after carvedilol being tolerated, which starts with 20mg/d and increases to 40mg/d as a maintainence dose"
89624157|NCT03108378||MultiHance Single Dose|Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
89624158|NCT03108378||MultiHance Multiple Dose|Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
89624159|NCT03108378||ProHance Single Dose|Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
89624160|NCT03108378||ProHance Multiple Dose|Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
89624161|NCT03108378||Control Subgroup|Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
89038177|NCT00534924|Placebo Comparator|1|No intervention after IR injury
89038178|NCT00534924|Experimental|2|Postconditioning
89038179|NCT00534924|Experimental|3|Vit. C
89038180|NCT00548223|Experimental|Dengzhan Shengmai capsule|Dengzhan Shengmai capsule 0.18g by mouth twice a day for 1year
89624162|NCT01862614|Experimental|Buffered Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc buffered 4% articaine.
89624163|NCT01862614|Active Comparator|Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc 4% articaine (unbuffered).
89038181|NCT00548223|Placebo Comparator|Placebo|Placebo 0.18g by mouth twice a day for 1year
89038182|NCT02907593|Experimental|0.025 mg/kg Budesonide|0.025 mg/kg Budesonide in Calfactant
89038183|NCT02907593|Experimental|0.050 mg/kg Budesonide|0.050 mg/kg Budesonide in Calfactant
89038184|NCT02907593|Experimental|0.10 mg/kg Budesonide|0.10 mg/kg Budesonide in Calfactant
89038185|NCT02907593|Experimental|0.15 mg/kg Budesonide|0.15 mg/kg Budesonide in Calfactant
89038186|NCT02907710|Experimental|concurrent chemoradiotherapy + endostar|"Drug: Endostar~Endostar 7.5mg / m2,3 cycles of intravenous infusion for ten days, and 2 cycles of maintenance therapy after radiotherapy~Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
89038187|NCT02907710|Active Comparator|concurrent chemoradiotherapy|"Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
89038188|NCT03781362|Experimental|CPI-100 Monotherapy|"Dose Escalation Groups:~CPI-100 will be administered via intravenous infusion once every 2 weeks (Q2W) for up to 5 dose levels and once every 3 weeks (Q3W Arm A) for up to 4 dose levels in a 3 + 3 dose escalation study~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
89038189|NCT03781362|Experimental|CPI-100 Combination with Capecitabine|CPI-100 will be administered via intravenous infusion once every 3 weeks in combination with oral capecitabine for up to 4 dose levels in a dose escalation study (Q3W Arm B)
89038190|NCT02907515|Experimental|cm-loc attachment|cm-loc attachment is a new attachment for dental implants and connect to the denture with resin matrix as housing
89038191|NCT02907515|Active Comparator|ball attachment|ball attachment is the most common attachment for dental implants and connect to the denture by nylon cap and metal housing
89038192|NCT03767907|Experimental|Online Cognitive Behavioural Therapy|Computer-based training for cognitive behavioural therapy (CBT4CBT) consists of seven modules, and includes a series of interactive videos presenting characters portrayed by professional actors struggling with real-life situations. These characters first experience a common risky situation or problem and then demonstrate the application of a targeted skill. The program further comprises games and interactive exercises to teach and model effective use of skills and strategies.
89038193|NCT03767907|Active Comparator|Treatment as Usual|Treatment as usual consists of weekly group and/or individual psychotherapy as determined by the clinical team. Psychotherapy will include structured relapse prevention, include cognitive and behavioural techniques, motivational enhancement, mindfulness, and specialized topics (e.g., vocational training, rainbow services) as appropriate.
89038194|NCT04682249|Experimental|Systemic Chemotheray, Apatinib plus Sintilimab|
89038195|NCT00548379|Active Comparator|1|Vitamin D
89038196|NCT00548379|Placebo Comparator|2|
89038197|NCT04682054|Experimental|surgically-removed eye tissue|
89624164|NCT00558688|Experimental|1|Light Therapy
89624165|NCT00558688|Experimental|2|Light Therapy
89624166|NCT02470650|Experimental|elvitegravir/cobicistat/emtricitabine/tenofovir|EVG / COBI / FTC / TDF (Stribild®) 150 elvitegravir, 150 cobicistat, 200 emtricitabine, 245 tenofovir disoproxil. 1 recovered tablet once a day (on a day)
89038198|NCT04972617||observational group|"In patients with intravenous furosemide administration, an additional 15 ml of blood is taken for the analysis of specific parameters as part of the blood sampling necessary for the treatment of the patient.~The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period.~In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined."
89038199|NCT04682210|Experimental|Arm A|sintilimab 200mg + bevacizumab 7.5mg/kg IV Q3W
89038200|NCT04682210|No Intervention|Arm B|Active surveillance
89038201|NCT00548457||A|
89038202|NCT04682015|Experimental|Intervention|The intervention group will be enrolled into WeChat platform. Participants will receive health education materials, monitor blood pressure at home and sent the blood pressure record to the platform and consult doctors online via platform.
89038203|NCT04682015|No Intervention|Control|Control group will receive usual care and follow up in hospitals and community health centers.
89038204|NCT03664089|Experimental|Intervention|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.
89624167|NCT02470650|Active Comparator|darunavir+ritonavir+lamivudine|Darunavir 800 mg (Prezista®) 1 recovered tablet once a day Ritonavir 100 mg(Norvir® ) 1recovered tablet once a day lamivudine300 mg (Epivir®) 1 recovered tablet once a day
89624168|NCT02470650|Active Comparator|abacavir/lamivudine+rilpivirine|Abacavir 600 mg +lamivudine 300mg (Kivexa®) 1tablet once a day rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
89624169|NCT01866592|Other|Single-Arm, open-label extension trial|Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneous injection 80mg initial dose followed by 40mg maintenance dose every other week for up to 52 weeks.
89038205|NCT03664089|Placebo Comparator|Control|All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
89624170|NCT01375608|Other|decitabine|active treatment
89624171|NCT02474004|Experimental|medial meniscus repair|patients receiving medial meniscus repair
89624172|NCT02474004|Active Comparator|medial partial meniscectomy|patients having medial partial meniscectomy
89624173|NCT02473848|Experimental|Ingenol mebutate 500 ucg|active arm
89624174|NCT02473770||Disaster responders|Conducting emergency disaster relief.
89624175|NCT01868776|Experimental|buffered lidocaine|4% lidocaine with 1:100,000 epinephrine/0.18 mEq/mL sodium bicarbonate.
89038206|NCT00548496|Experimental|Placebo-Controlled based on the two Intervention Groups below|Placebo-Controlled based on the two Intervention Groups below.
89038207|NCT02907476|Experimental|Iyengar Yoga|Twelve-week Iyengar Yoga protocol with two 90-minute classes per week and three 30-minute homework assignments. Classes consist of approximately 60-minutes of yoga postures, 10-minutes of rest and transition, and 20-minutes of Coherent Breathing at 5 breaths per minute. Homework consist of 15-minutes of yoga postures and 15-minutes of Coherent Breathing. Coherent Breathing is CD guided. Yoga classes are taught by certified Iyengar Yoga instructors.
89624176|NCT01868776|Active Comparator|nonbuffered lidocaine|4% lidocaine with 1:100,000 epinephrine
89624177|NCT02469558|Active Comparator|probiotic|Winclove 851 and 110 consist of 6g of a probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g and 10g of a prebiotic mixture of galacto-oligosaccharides P11 (GOS), Fructo-oligosaccharides P6 (FOS), Konjac glucomannan P13 (E425), Maltodextrin, Calcium carbonate (E170), Natural Elderflower flavouring, Gum Arabic (E414), Zinc citrate 3-hydrate, Vitamin D3 (Cholecalciferol) and Vitamin B2 (Riboflavin) (E101) daily for 6 months
89624178|NCT02469558|Placebo Comparator|placebo|a similar looking and tasting placebo without bacteria
89624179|NCT05748340|Other|Control group|21normal infant aged 3-6 months
89624180|NCT05748340|Other|Group a|21 patient of unilateral cleft lip had mishra technique repair
89624181|NCT05748340|Other|Group b|21 patient of unilateral cleft lip had modified Millard technique repair
89624182|NCT00704418|Experimental|Bromfenac|Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily
89624183|NCT00704418|Placebo Comparator|Placebo|Placebo, dosed 1 drop daily
89624184|NCT01869634|Active Comparator|HIV positive naive to ART|HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
89624185|NCT01869634|No Intervention|normal control volunteers|HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.
89624186|NCT02047578|Experimental|Busulfan|Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
89038208|NCT02907476|Active Comparator|Walking|Twelve-week walking intervention will consist of two 60-minute group-walking sessions per week and three 15-minute homework walking sessions at 2.5 miles per hour on flat surface. Walking classes are conducted by research staff.
89038209|NCT04971876|Experimental|Group 1 - Lips Enhancement|Participants treated with HLR-1 for lip enhancement, with optional Touch-Up (TU) 4 weeks afterwards
89038210|NCT04971876|Experimental|Group 2 - Nasolabial Fold Correction|Participants treated with HLR-2 for nasolabial folds (NLFs) correction, with optional Touch-Up (TU) 4 weeks afterwards
89624187|NCT05232552|Experimental|anlotinib|3 cycles of anlotinib (12mg, d1-14)was given concurrently with docetaxel plus cisplatin chemotherapy as induction , then 2 additional cycles of anlotinib concurrent with definitive chemoradiation (IMRT with conccurent cisplatin)
89624188|NCT05748262||Primary infections during March-May 2022|Hospitalized COVID-19 patients infected with BA·2 during 1 March to 23 May 2022 from Huashan Hospital, Renji Hospital, and Shanghai Jing' an Central Hospital.
89624189|NCT05748262||Primary infections during December 2022-January 2023|Primary infections with BA.5-sublineages during 1 December 2022 to 14 January 2023, matched 1:1 by age and sex with reinfections during the same period.
89624190|NCT02470572|Active Comparator|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
89624191|NCT02470572|Placebo Comparator|Conventional light microscope|conventional light microscope
89624192|NCT02266108|Experimental|ESTIMA intervention|This group is randomized to receive the ESTIMA intervention and will be followed for 12 months for follow-up.
89624193|NCT02266108|Other|Wait-list control|This group will receive standard of care (education as well as referrals to testing and treatment). After 12 months of follow-up, this group will receive the ESTIMA intervention.
89624194|NCT01201590|Experimental|High Flavanol Cocoa|609mg cocoa flavanols per 24g serving
89624195|NCT01201590|Placebo Comparator|Low flavanol cocoa|13mg cocoa flavanols per 24g serving
89624196|NCT00916656|Experimental|Prospective Arm|
89624197|NCT00916656|Other|Historical Control|
89624198|NCT01871506|Experimental|Standard Care (SC)|"Participants randomized to standard care (SC) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice."
89624199|NCT01871506|Experimental|Intensive Counseling (IC)|"Participants randomized to intensive counseling (IC) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:~Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).~Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant."
89624200|NCT05127642||Postpartum hemorrhage patients|
89624201|NCT05127642||Controls (non postpartum hemorrhage patients)|
89624202|NCT05351892|Experimental|Treatment A-B|Participants will receive a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
89624203|NCT05351892|Experimental|Treatment B-A|Participants will receive a single dose of elinzanetant supplied in strength level 2 and 9 subsequent multiple doses from Days 4 to 12 of Period 1; followed by a single dose of elinzanetant supplied in strength level 1 and 9 subsequent multiple doses from Days 4 to 12 of Period 2.
89624204|NCT00555646|Experimental|1|Each subject's study plaque areas will be assigned by the investigator to two PH-10 treatment plaque areas and one control plaque area.
89624205|NCT01873846|Experimental|Silicone Hydrogel Contact Lens|Contact lenses to be worn in each eye on a daily wear basis for 2 weeks. Participants will be provided with Bausch + Lomb Biotrue® multi-purpose solution and contact lens cases for daily rinsing, cleaning, disinfecting, and storing their lenses.
89624206|NCT00711282|Experimental|A|
89624207|NCT00711282|Experimental|B|
89624208|NCT01874392|Experimental|T1DM|Adults aged 21-65 years with type 1 diabetes mellitus for at least one year who are using an insulin infusion pump with rapid-acting insulin for at least six months
89624209|NCT04064346|Experimental|Lixivaptan|Lixivaptan capsules, 100-200 mg twice a day (BID)
89624210|NCT04064346|Placebo Comparator|Placebo|Matching placebo capsules BID
89624211|NCT05747872|Experimental|İntervention Grup|Buerger Allen exercises programme will be applied to the type 2 diabetes mellitus patients with foot ulcer. Patients in the intervention group performed daily Buerger Allen exercises for 12 weeks. Patients in the study intervention group were taught Buerger Allen exercises and were asked to exercise twice daily for 12 weeks. Individuals will be given an exercise diary, including the pictures of the exercises, to better manage this process. Reminder phone calls were made once a week to support the exercise program and increase motivation.
89624212|NCT05747872|No Intervention|Control Grup|The control group received standard wound care but no exercises.
89624213|NCT00576654|Experimental|Dose escalation (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days -1 to 14 (days 3-14 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89624214|NCT00576654|Experimental|Expansion portion (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days 1-15 (days 2-15 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89624215|NCT00576654|Experimental|Intermittent dose escalation (irinotecan, ABT-888)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 3 and 10 and veliparib PO BID on days 1 to 4 and 8-11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89624216|NCT05747716|Experimental|SBRT, Fruquintinib, Cadonilimab|
89624217|NCT03314142|Experimental|Glucose as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89624218|NCT03314142|Experimental|White bread as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89038211|NCT04971876|Experimental|Group 3 - Treatment of Midface Volume Deficit|Participants treated with HLR-3 for treatment of midface volume deficit, with optional Touch-Up (TU) 4 weeks afterwards
89624219|NCT03314142|Experimental|Bread enriched with coarse wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89038212|NCT02907554|Placebo Comparator|control group|control group receives a placebo
89038213|NCT02907554|Experimental|intervention group|the intervention group receives 2.5 mg/kg of cyclosporine
89038214|NCT03657303||Healthy volunteers|
89038215|NCT03657303||Osteoarthritis patients|
89038216|NCT02907632|Experimental|Metoclopramide|Blind and randomized allocation to the experimental treatment: Metoclopramide
89038217|NCT02907632|Placebo Comparator|Placebo|Blind and randomized allocation to placebo
89038218|NCT02907437|Active Comparator|Minocycline treatment|Intervention: Drug: Minocycline (200 mg/day)
89038219|NCT02907437|Placebo Comparator|Placebo treatment|Placebo Intervention: Drug: Placebo (200 mg/day)
89038220|NCT02907047|Active Comparator|Tourniquet|These subjects will have their tourniquet inflated during key portions of the total knee arthroplasty procedure
89688452|NCT03404141|Experimental|Experimental group|"The intervention administered to the experimental group will be a cognitive-behavior therapy applied by two specifically trained psychologists.~Due to COVID-19 pandemic, this group will be implemented online using a videocall online platform (from April 2019 to the end of mobility restrictions)."
89038221|NCT02907047|Other|No tourniquet|These subjects will not have their tourniquet inflated during key portions of the total knee arthroplasty procedure
89038222|NCT01262872|Experimental|10PP-HD 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.
89038223|NCT01262872|Active Comparator|Prevnar13 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of Prevnar 13™ at Day 0. Prevnar 13™ was administered intramuscularly in the non-dominant deltoid.
89038224|NCT01262872|Experimental|10PP-LD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its low-dose (LD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, LD formulation, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
89038225|NCT01262872|Experimental|10PP-HD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
89038226|NCT01262872|Active Comparator|Synflorix 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Synflorix™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the Synflorix™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
89038227|NCT01262872|Active Comparator|Prevnar13 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Prevnar 13™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of Prevnar 13™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Prevnar 13™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
89038228|NCT01262872|Experimental|10PP-HD 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received the GSK 2189242A (or 10PP) vaccine, in its high-dose (HD) formulation, and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the 10PP vaccine, HD formulation co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of the same formulation co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age.. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
89624220|NCT03314142|Experimental|Bread enriched with fine wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89624221|NCT03314142|Experimental|Bread enriched with fine wheat and carob|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
89038229|NCT01262872|Active Comparator|Synflorix 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received Synflorix™ and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the Synflorix™ co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of Synflorix™ co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
89038230|NCT03622320||Vitiligo patients|Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
89038231|NCT03622320||controls|Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
89038232|NCT02907125|Experimental|TSM arm|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
89038233|NCT02907125|Experimental|SM arm|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
89038234|NCT02907125|Active Comparator|Comparison arm Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
89038235|NCT02907320|Experimental|CYCLO 3 ® FORT and placebo MPFF|MPFF = Micronized Purified Flavonoid Fraction
89038236|NCT02907320|Active Comparator|MPFF and placebo CYCLO 3 ® FORT|MPFF = Micronized Purified Flavonoid Fraction
89038237|NCT02907320|Placebo Comparator|placebo|MPFF = Micronized Purified Flavonoid Fraction
89624222|NCT05747482|Other|Omentectomy|Omentectomy during cancer gastric surgery
89624223|NCT05747482|Other|Omental preservation|Preserval omentation during cancer gastric surgery
89624224|NCT00704340|Experimental|1|"DuraSeal Dural Sealant System - FDA Approved Device:~The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel."
89624225|NCT00704340|Active Comparator|2|"Standard of Care (control):~Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator."
89624226|NCT03314064|Experimental|HIV positive subjects continuing DTG|HIV positive subjects who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762 and those subjects who end participation in study 200304 in which they received either DTG or LPV/RTV will be included in this study.
89038238|NCT02907164|Active Comparator|Group 1: Control|People receive emails encouraging them to sign up for the challenge. The email does not mention the number of people who have signed up.
89038239|NCT02907164|Experimental|Group 2: Norm|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up.
89038240|NCT02907164|Experimental|Group 3: Norm and health motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay fit in a fun way.
89038241|NCT02907164|Experimental|Group 4: Norm and reward motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay active and earn rewards.
89038242|NCT04323085|Active Comparator|Speech-in-Noise Treatment Program|A behavioural speech therapy program involving 12, one-hour treatment sessions over a 4-week period
89624227|NCT00552058|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg for subcutaneous (sc) injection
89624228|NCT00552058|Placebo Comparator|Placebo|Placebo, saline solution for sc injection
89624229|NCT02473692||Online MigraineTreatment Optimization|After providing informed consent, participants will complete a series of questionnaires related to their headaches and medication beliefs. After completion, they will have full access to an informational website including access to text-based supplemental materials pertaining to headache and headache treatment, and a series of videos designed specifically for this trial. Participants will be asked to watch seven videos of approximately four-minute length each and to complete a post-assessment question following the completion of each of the first 6 videos. The total time required to complete all study activities will be approximately one hour.
89624230|NCT02473302|Placebo Comparator|ham|160g per day during 4 days
89624231|NCT02473302|Experimental|ham + pomegranate extract|160g per day during 4 days
89624232|NCT02473302|Experimental|ham + tocopherol|160g per day during 4 days
89624233|NCT02473302|Placebo Comparator|rare sirloin steak|110g per day during 4 days
89624234|NCT02473302|Experimental|marinated rare sirloin steak|110g per day during 4 days
89624235|NCT02473302|Experimental|marinated cooked sirloin steak|110g per day during 4 days
89624236|NCT02473458|Placebo Comparator|Control|patients with acute ischemic stroke who received standard care plus placebo filled capsules,
89624237|NCT02473458|Experimental|450 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 450 mg of whole extract of licorice.
89624238|NCT02473458|Experimental|900 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 900 mg of whole extract of licorice.
88989759|NCT05050084|Experimental|Arm I (RT)|Patients undergo RT using a recognized regimen (2-3 days a week or 5 days a week for 2-11 weeks) in the absence of disease progression or unacceptable toxicity.
88989760|NCT05050084|Experimental|Arm II (RT, ADT)|Patients undergo RT as Arm I. Patients also receive ADT consisting of leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix at the discretion of the treating physician, for 6 months in the absence of disease progression or unacceptable toxicity. Patients may also receive bicalutamide or flutamide for 0, 30 or 180 days.
88989761|NCT05050084|Experimental|Arm III (RT, ADT)|Patients receive treatment as in Arm II.
88989762|NCT05050084|Experimental|Arm IV (RT, ADT, darolutamide)|Patients receive RT and ADT as in Arm II. Patients also receive darolutamide PO BID on days 1-90. Treatment repeats every 90 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
88989763|NCT05048342|Experimental|Arm 1|LOU064 open-label treatment taken orally for 52 weeks.
88989764|NCT05044312|Other|Sleep Disturbances|Difficulty Sleeping
88989765|NCT05036109|Other|Aspirin, Vitamin D|by mouth every day for up to 90 days
88989766|NCT05031637|Experimental|treatment by night-time BP|titrate drug treatment in the evening against night home blood pressure monitoring (HBPM) SBP (aiming SBP of <120 mmHg; intervention group)
88989767|NCT05031637|Other|treatment by daytime BP|Usual care - titrate drug treatment in the morning against HBPM SBP (aiming SBP of <135 mmHg; control group)
88989768|NCT05030948|Experimental|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. They will take place at community partner sites during times when all participants can attend. In case of adverse weather, indoor locations are available through community partners. Walks will reflect participant goals and abilities, initially lasting 10 minutes, with 5-minute stretching warm-up and 5-minute cool down exercises, for a total of 20 minutes. Walk duration will increase by 5 minutes/week to at least 30 minutes with program content delivery time decreasing to accommodate increased walk times within the 1-hour session. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
88989769|NCT05030948|No Intervention|Attention Control|"If assigned to this group, participants will take part in 1-hour group (5-6 participants) sessions delivered twice a week for 3 months. The sessions will be with a trained Community Health Worker or qualified staff that will involve reviewing education topics in Spanish related to adult health. They will take place at community partner sites or remotely during times when all participants can attend. In case of adverse weather, indoor locations, or remote options will be available. Upon completing the 3 months of education sessions, for the next 3 months, they will receive educational booster sessions delivered every other week via phone calls/text messaging."
88989770|NCT05030571|Experimental|Intervention|Intervention group will receive DPMAS extracorporeal treatment one session per day for 3 consecutive days plus standard therapy. We plan to use blood flow rate of 100-120 ml/hour with filtration fraction for plasma separation of 25-30%. DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China) We do not use any anticoagulant.
88989771|NCT05030571|Active Comparator|Standard care|Standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017
88989772|NCT05026281|Experimental|Group 1|at H0 and H0+30min = blood sample taken
88989773|NCT05024253|Experimental|patient is receiving Tranexemic acid (TXA )|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare TXA injection at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).~Maintenance dose: Throughout surgery, continuous infusion at a dose of 5mg/kg/hour will be given until wound closure."
88989774|NCT05024253|Placebo Comparator|standard treatment (saline)|"Loading dose: Prior to surgical incision, and according to allocated arm, pharmacist will prepare 50 ml of 0.9% saline or TXA at a dose of 10mg/kg diluted in 50ml normal saline (maximum concentration 100mg/ml).~Maintenance dose: Throughout surgery, continuous infusion of saline will be given until wound closure."
88989775|NCT05020626||Controls|
88989776|NCT05020626||Mild cognitive impairment|
88989777|NCT05020626||AD dementia|
88989778|NCT05017298|Experimental|Study Group|Each subject receives three separate doses of 200 million allogeneic adipose-derived mesenchymal stem cells via intravenously infusion on days 0, 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.
88989779|NCT05017298|Placebo Comparator|Control Group|The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care.
88989780|NCT05010902||Multiple sclerosis|Patients with clinically isolated syndrome, relapsing-remitting or progressive multiple sclerosis
88989781|NCT05006404|Experimental|Autus Valve Arm|Pulmonary Valve Replacement Surgery with the Autus Valve
88989782|NCT04997889|Experimental|artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
88989783|NCT04997889|Active Comparator|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
88989784|NCT04991649|Experimental|ACT Group|One two-weekly 2-hour of positive parenting program plus a four-weekly 2-hour group ACT program and routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
88989785|NCT04991649|Other|Treatment-as-usual (TAU) Group|Routine pediatric asthma out-patient services, including medical follow-up, asthma education by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare by psychiatrist/medical social worker for parental training in ADHD care.
88989786|NCT04991077||patients group|patients with malignant hypertension
88989787|NCT04991077||Control group|patients with severe hypertension (Grade 2 or 3 hypertension)
88989788|NCT04975880|Other|Hemodialysis Treatments|All subjects will receive hemodialysis treatments using the SC+ machine for all phases of the trial including in-clinic training, transition, and in the home setting.
88989789|NCT04955821||VAP group|Children with respiratory tract infection by mechanical ventilation
88989790|NCT04955210||Severe infection|Children with severe infection in PICU
88989791|NCT04954287|Experimental|Group 1, 1 x 10^6 PFU CVXGA1 in Ages 18-55|Group 1 (Young adults aged 18 to 55 years - CVXGA1- Low Dose, no prior COVID vaccine or infection)
88989792|NCT04954287|Experimental|Group 2, 1 x 10^7 PFU CVXGA1 in Ages 18-55|Group 2 (Young adults aged 18 to 55 years - CVXGA1- High Dose, no prior COVID vaccine, no prior COVID vaccine or infection allowed if occurring at least 5 months prior to enrollment)
88989793|NCT04954287|Experimental|Group 3, 1 x 10^7 PFU CVXGA1 in Ages 18-55|Group 3 (Young adults aged 18-55 years - CVXGA1 - High Dose, prior receipt of two or more doses of COVID mRNA vaccine (Pfizer Comirnaty® or Moderna Spikevax™) at least 5 months prior to study enrollment. Prior COVID infection allowed if occurring at least 5 months prior to study enrollment).
88989794|NCT04954287|Experimental|Group 4, 1 x 10^7 PFU CVXGA1 in Ages 12-17|Group 4 (Adolescents aged 12-17 years - CVXGA1 - High Dose, prior receipt of two or more doses of COVID mRNA vaccine (Pfizer Comirnaty® or Moderna Spikevax™) at least 5 months prior to study enrollment. Prior COVID infection allowed if occuring at least 5 months prior to study enrollment.
88989795|NCT04952714||Dynamic Cohort|"Initially, participants who meet the inclusion criteria will be recruited to assemble a cohort of patients with sepsis and those who develop sepsis-induced acute kidney injury will be observed.~Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device (Baxter), at a dose of 25 mL / Kg of PrismaSate dialysis solution (Baxter) and the removal filter oXiris® cytokines (Baxter) vs. the standard filter, for patients who require it, in the presence of a confirmed diagnosis of acute renal failure.~Hemodynamic and ventilatory parameters will be monitored every 24 hours, and inflammatory parameters every 48 hours. A follow-up will be done at 28 days to establish mortality."
88989796|NCT04950322|Experimental|Treatment group A|
88989797|NCT04950322|Placebo Comparator|Treatment group B|
88989798|NCT04941729|Experimental|Study Arm (dual mobility)|OR3O™ Dual Mobility in subjects who undergo Primary THA.
88989799|NCT04941729|Active Comparator|Controlled Arm (conventional)|A conventional, single-bearing design Total Hip System in subjects who undergo Primary THA.
88989800|NCT04940130|Experimental|Arm 1 (PfSPZ Vaccine)|134 children ages 6 - 10 will receive three doses of PfSPZ Vaccine (9.0x10^5 PfSPZ) via DVI at 1, 8, and 29 days
88989801|NCT04940130|Placebo Comparator|Arm 2 (normal saline)|134 children ages 6 - 10 will receive normal saline via DVI at 1, 8, and 29 days
88989802|NCT04939298|Experimental|Patients under mechanical ventilation|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation
88989803|NCT04929028|Experimental|High-risk stratum (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88989804|NCT04929028|Experimental|Low-risk stratum (mitomycin|Patients receive mitomycin IV on day 1 and either fluorouracil IV on day 1 or capecitabine PO BID on Monday-Friday until the completion of radiation therapy at the discretion of the treating physician. Patients also undergo IMRT QD for 20-23 treatment sessions over 6 weeks.
88989805|NCT04927013|Experimental|Message-based Outreach Intervention (MBI) for Survivors|Cancer survivors randomized to receive a targeted letter with a unique website log in, access to the expanded website, free genetic counseling, and short message service (SMS) reminders.
88989806|NCT04927013|Active Comparator|Standard Outreach for Survivors|Cancer survivors randomized to receive the standard outreach consisting of a standard letter with website access, access to a condensed version of the study website, and free genetic counseling.
88989807|NCT04927013|Experimental|Message-based Outreach Intervention for Close Relatives|Close relatives of cancer survivors who were randomized to receive the message-based outreach. Close relatives will have access to the expanded version of the study website and free genetic counseling.
88989808|NCT04927013|Active Comparator|Standard Outreach for Close Relatives|Close relatives of cancer survivors who were randomized to receive the standard outreach. Close relatives will have access to a condensed version of the study website and free genetic counseling.
88989809|NCT04926207|Experimental|Physical Activity Breaks Intervention|Participants will sit continuously for 3 hours and interrupt their sitting by walking on a treadmill at a moderate intensity for 3 min.
89624239|NCT02473380|Experimental|Intraoperative fluorescence spectroscopy|The experimental device will be assessed during an open surgical approach for surgical removal of the tumors
89624240|NCT05747326|Experimental|Study group|The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
89624241|NCT03108300|Experimental|propranolol hydrochloride with Doxorubicin|The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily
89624242|NCT02473224|Experimental|Cohort 1|9 secretor-positive subjects will receive 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1; and 2 secretor-positive subjects will receive the placebo, n=11
89624243|NCT02473224|Experimental|Cohort 2|9 secretor-positive subjects will receive either 1.2 x 10^2GEC, or 1.2 x10^6 GEC oral dose on Day 1, depending on the percentage of subjects with illness from Cohort 1; 2 secretor-positive subjects will receive the placebo, n=11
89624244|NCT02473224|Experimental|Cohort 3|9 secretor-positive subjects will receive either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, 1.2 x 10^6 GEC, or 1.2 x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2; 2 secretor-positive subjects will receive the placebo, n=11
89624245|NCT02473224|Experimental|Cohort 4|8 secretor-negative and 3 secretor-positive subjects will receive 1.2 x 10^7 GEC oral dose on Day 1, n=11
89624246|NCT03313908|Experimental|breast surgery|during the breast surgery, detection of the tumor lesion with indocyanine green fluorescence and with radioactive seed localization, in each subject
89624247|NCT02274688|No Intervention|Enhanced Usual Care - Nurse Notification of Patient Concerns|Randomized and will be blindly assessed.
89624248|NCT02274688|Experimental|Patient-centered care transition|"Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.~Randomized and will be blindly assessed."
88989810|NCT04926207|Active Comparator|Talking Breaks Control|Participants will sit continuously for 3 hours. They will interrupt solitary sitting activities (while remaining seated) by talking to a researcher for 3 min on pre-selected topics of general interest.
88989811|NCT04924244|Active Comparator|No Music|No music will be played during the subject's standard of care lumbar spinal interventional procedure (including: epidural steroid injections, facet injections, medial branch blocks).
88989812|NCT04924244|Experimental|Music Therapy|Music of the subject's preferred genre will be played during the subject's standard of care lumbar spinal interventional procedure (including: epidural steroid injections, facet injections, medial branch blocks).
88989813|NCT04922710|Experimental|Home-based aerobic exercise|Un-supervised exercise will be held 3 times a week for 60 minutes in the participant's home
88989814|NCT04906668|Active Comparator|Cryoballoon pulmonary-vein isolation|
88989815|NCT04906668|Active Comparator|Ablation of atrioventricular-node and pacemaker implantation|
88989816|NCT04906577|Experimental|VIZOLF|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to the body odour emitted by the child during the first 5 days of life
88989817|NCT04906577|Experimental|VIZ|visual stimulus (photograph of the child) and olfactory stimulus ad libitum, with a minimum of 6 stimulations per day, to a neutral odour during the first 5 days of life
88989818|NCT04905017|Experimental|Treatment with the Trisol System|
88989819|NCT04902443|Experimental|1/Dose De-Escalation|Treatment with pomalidomide at de-escalating doses if necessary and nivolumab at a fixed dose
88989820|NCT04902443|Experimental|2/Dose Expansion|Nivolumab + pomalidomide (at optimal dose determined in dose escalation portion of the study) for up to 30 participants
88989821|NCT04888988|Experimental|Arm 1 Exercise Intervention- EXCAP|"Participants receive a 6-week home-based individually tailored progressive intervention, Exercise for Cancer Patients (EXCAP©®), consisting of walking and resistance band exercises. Participants receive an EXCAP kit, which includes an activity tracker, EXCAP manual, and resistance bands, meet with a certified exercise instructor for ~1 hour, and receive individualized walking and resistance band prescriptions. To enhance adherence to EXCAP intervention, the exercise instructor will conduct 2 additional Booster Meetings, each lasting 15-30 minutes, with participants during weeks 2 or 3 and weeks 4 or 5.~Participants will complete REDCap questionnaires and touch tests at baseline and post-intervention. Participants will also wear activity trackers and complete daily diary during the entire study period.~Participants may optionally complete magnetic resonance imaging (MRI) scans on the study."
88989822|NCT04888988|Active Comparator|Arm 2 Control condition (standard care)|"Participants receive their standard care. Participants will complete REDCap questionnaires and touch tests and wear activity trackers at baseline and post-intervention. Participants will also complete daily diary during the entire study period.~Participants may optionally complete magnetic resonance imaging (MRI) scans on the study.~Participants will be provided with the EXCAP©® program (i.e., EXCAP©® kit and all materials, one EXCAP©® teaching session with exercise instructor, and two Booster Meetings) after all study requirements have been completed at no cost to them."
88989823|NCT04885465|Experimental|Intervention group|Study participants will receive a web-based support program
88989824|NCT04885465|No Intervention|Control group waiting list|Study participants in the control group waiting list will receive standard support from health care and municipalities. After study termination they will receive access to the same web-based program as the experimental group
88989825|NCT04882202|Experimental|Acetaminophen group|patients receiving acetaminophen
88989826|NCT04882202|Placebo Comparator|Placebo group|patients receiving equal amount of normal saline
88989827|NCT04881630|Active Comparator|Standard Care (SC)|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
88989828|NCT04881630|Experimental|Contingency Management (CM)|CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.
88989829|NCT04871321||Gem/Cis/nab-P|Gemcitabine + Cisplatin + Nab-Paciltaxel
88989830|NCT04865146||TRIGEN™ INTERTAN™|Confirmed femoral fracture subjects who are scheduled for repair using INTERTAN 10S Nail
89624249|NCT02470338|Active Comparator|MBP plus ankle arthroscopy (Group A)|Group A will receive a diagnostic ankle arthroscopy followed by the Modified Brostrӧm Procedure (MBP). In the ankle arthroscopy, multiple pictures are taken inside of the joint to note possible pathologic processes (for example - osteochondral lesions of the talus). Ankle arthroscopy involves one incision in the middle of the ankle anteriomedial (middle) incision and one incision on the outside of the ankle. Each incision (a small cut in the skin) is roughly 5mm in length (which is about 0.2 inches). After the incision is made, the participant will receive a diagnostic ankle arthroscopy.If the surgeon detects an abnormality inside the joint, he will operate on the abnormality with the arthroscope according to the generally accepted principles for treating the abnormality.
89624250|NCT02470338|Sham Comparator|MBP alone (Group B)|Group B will receive sham skin incisions on the ankle a Modified Brostrӧm Procedure (MBP) alone (that is, there will be no diagnostic ankle arthroscopy) followed by the Modified Brostrӧm Procedure (MBP). If a participant is assigned to Group B, the participant will receive two small superficial skin incisions at the sites where the investigators would normally insert instruments for the ankle arthroscopy. As with Group A, there will be one anteriomedial (middle) incision on the middle of the ankle and one anteriolateral (side) incision to on the outside of the ankle. Each incision will be roughly 5mm in length and 5 mm in depth, but will not violate subcutaneous tissue. The width of these incisions will be the width of the blade, at 1mm. However, unlike Group A, the participants in Group B will not have any instruments inserted into their ankle and will not have any operation to repair or remove damaged tissue.
89624251|NCT03313830|Experimental|Whey Protein Hydrolysate (WPH)|The intervention consists of Whey Protein Hydrolysate (WPH) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
89624252|NCT03313830|Experimental|Intact Whey Protein (WHEY)|The intervention consists of Intact Whey Protein (WHEY) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
89624253|NCT03313752|Placebo Comparator|A - placebo|Green, plain, diamond shaped, film coated tablet (orally), not containing active ingredient; once daily, for 4 weeks
89624254|NCT03313752|Experimental|B - experimental drug|Dapagliflozin tablet available at dose of 10 mg, once daily, for 4 weeks
89624255|NCT02473068|Active Comparator|Group 1|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 31°C.
89624256|NCT02473068|Experimental|Group 2|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 27°C.
89624257|NCT03313674|Experimental|Seasonal Affective Disorder|The primary objective is to use neuroimaging paradigms to identify perturbations in neural circuits of SAD patients when they are clinically depressed in the winter, after bright light therapy treatment, and when they are healthy in the summer
89624258|NCT03313674|No Intervention|Major Depressive Disorder|SAD patients will be compared to unipolar depressed patient cohort, who will be imaged in the winter and the summer.
89624259|NCT03313674|No Intervention|Healthy Controls|SAD patients will be compared to healthy controls, who will be imaged in the winter and the summer.
89624260|NCT05747092|Active Comparator|Control group: free gingival graft for gingival recession|
89624261|NCT05747092|Experimental|Test group: connective tissue graft for gingival recession|
89624262|NCT02470104|Experimental|Enteral Donor Breastmilk|"Donor milk will be pasteurized prior to use.~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
89624263|NCT02470104|No Intervention|Control|• Children randomized to the control arm will receive standard enteral or parenteral nutrition per standard clinical practice, supervised by a registered dietician.
88989831|NCT04861623|Active Comparator|Orange Juice then Placebo juice (Fanta)|Participants will be provided orange juice for 84 days in this arm. After 28 days wash-out period, participants will receive Fanta for 84 days.
88989832|NCT04861623|Active Comparator|Placebo (Fanta) then Orange juice|Participants will be provided Fanta for 84 days in this arm. After 28 days wash-out period, participants will receive Orange juice for 84 days.
88989833|NCT04850456||trial group|Human Gamma Globulin
88989834|NCT04850456||control group|conventional treatment
88989835|NCT04850066|Experimental|Equine-assisted intervention|Brief program (3 sessions)
88989836|NCT04850066|No Intervention|Control|Standard care with treatments as usual
89624264|NCT03313596|Active Comparator|LT-only|patients received orthotopic LT and subsequent immunosuppression therapy
89624265|NCT03313596|Experimental|LT+ADV-TK|ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy
89624266|NCT05746936||Obese patients underwent laparoscopic gastric bypass|
89624267|NCT05746936||obese patients underwent robotic gastric bypass|
88989837|NCT04847505|Experimental|Neuroendocrine cancer patients|"All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq/kg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician.~Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed."
88989838|NCT04844970|Experimental|Anamorelin|Patients randomized to anamorelin HCL will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
88989839|NCT04844970|Placebo Comparator|Placebo|Patients randomized to placebo will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
88989840|NCT04842071|Experimental|18F-NaF eligible patients|Eligibility for 18F-NaF PET scans is the same than for bone scintigraphy routinely prescribed in the clinic.
88989841|NCT04835337|Experimental|Air purifier|Participants in this group receive an intervention of real air purifiers placed in the indoor environment.
88989842|NCT04835337|Sham Comparator|Control|Participants in this group receive an intervention of sham air purifiers, we just remove the filter in the purifiers, and the other treatments are the same as the real purification group.
89624268|NCT02470182||At-Home|Overnight sleep at home (30 subjects)
89624269|NCT02470182||Sleep Lab|Overnight sleep at the OHSU sleep lab during routine polysomnography (30 subjects)
89624270|NCT02470182||Sleep Lab + At-Home|Overnight sleep at the OHSU sleep lab during routine polysomnography, followed by overnight sleep at home (30 subjects)
89624271|NCT03313518|Active Comparator|Anodal tDCS|Transcranial Direct Current Stimulation using anodal electrode, 15 patients received real anodal tDCS 2mA for 20 minutes for 10 consecutive days.
89624272|NCT03313518|Sham Comparator|sham group|Fifteen patients received sham anodal tDCS 2mA for 20 minutes for 10 consecutive days.
89624273|NCT04491630|Active Comparator|Self-Hypnosis (SH)|
89624274|NCT04491630|Active Comparator|Mindfulness meditation (MM)|
89624275|NCT04491630|Active Comparator|Christian prayer (CP)|
89624276|NCT04491630|No Intervention|Control condition (CN)|Participants in the CN condition will not be instructed to use any particular coping strategy to cope with the painful stimulation provided by the Cold Pressor Arm Wrap. Participants in the CN condition will listen to a 20-minute natural history audio recording. The option for this recording is supported by: (a) previous research showing that individuals who were asked to listen to it found it to be a neutral, yet relaxing, passage; (b) the use of this passage as an effective control condition in previous studies.
89624277|NCT02989012|Experimental|Drugs for experimental group|GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
89624278|NCT02989012|Sham Comparator|Drugs for control group|Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
89624279|NCT03313440|Experimental|high fibre|A 10 day increase in daily wheat fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
89624280|NCT03313440|Experimental|low fibre|A 10 day control intervention with no additional wheat fibre. Products are provided in boxes that must be consumed each day during the intervention.
89624281|NCT02276638||18-28 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
89624282|NCT02276638||29-80 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
89624283|NCT02276638||29-80 years old pathological|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
89624284|NCT03313362|Experimental|Subjects admitted to Epilepsy Monitoring Units in the VAMC|Subjects being monitored by standard of care, video EEG, in the Epilepsy Monitoring Units in the VAMC will all be placed on a Seizure Monitoring and Alerting System (SPEAC System).
89624285|NCT03108534|Experimental|CHF1535 NEXThaler|CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
89624286|NCT03108534|Active Comparator|CHF1535 pMDI|CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
89624287|NCT03108534|Placebo Comparator|Placebo|Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler
88815682|NCT02440854||Patients with non-small cell lung cancer (NSCLC) treated with afatinib|Patients with advanced/metastatic non-small cell lung cancer (NSCLC) in Greece treated with afatinib. Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib. Patients were observed in the context of the study until the end of study participation, defined as a maximum of 48 months after afatinib treatment initiation or until disease progression, death, withdrawal of consent, unacceptable toxicity, study completion or physician's decision whichever occurred earlier.
88815683|NCT01084148|Experimental|V0034CR01B|cream
89624288|NCT02472834|Experimental|Amino acid supplementation NephrAmine®|250 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 8 weeks plus 4 weeks of follow-up.
89624289|NCT02472834|No Intervention|Standard-of-care|Standard-of-care does not include amino acid supplementation, but this control arm will be evaluated for the same outcomes as the experimental arm for 8 weeks plus 4 weeks of follow-up
89624290|NCT03832894|Active Comparator|Group receiving oestradiol tablets in addition to progesterone|"Group A :Will receive 400mg progesterone in the form of vaginal or rectal suppositories in addition to estradiol valerate oral tablets in a dose of 4mg/day(2x2), for luteal phase support. Starting from the day of ovum pickup and for 14 days after embryo transfer.~Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer."
89624291|NCT03832894|Placebo Comparator|Group not receiving oestradiol tablets.|Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer
89624292|NCT02472990|Other|Duchenne muscular dystrophy children|"No drug and no placebo were used in this study. For 2h30 (time)~Measurement of leg strength using a dynamometer~Measurement of Motor Function~Walk test 6 minutes~Walk test 10 meters~Walk analysis: 3D recording of walking~Muscle MRI"
89624293|NCT02472990|Other|Healthy children|"No drug and no placebo were used in this study. For 2h30 (time)~Measurement of leg strength using a dynamometer~Measurement of Motor Function~Walk test 6 minutes~Walk test 10 meters~Walk analysis: 3D recording of walking~Muscle MRI"
89038243|NCT04323085|Active Comparator|Speech-to-Noise Feedback Device Program|A speech treatment program involving the use of a speech-to-noise feedback device during 12, one-hour treatment sessions over a 4-week period
89038244|NCT04323085|No Intervention|Delayed Treatment|Assessments but no intervention for a period of 13 weeks.
89624294|NCT02989324|Experimental|Vaginal Misoprosto|Vaginal Misoprosto for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Section
89624295|NCT02989324|Active Comparator|Misoprostol Plus Foley Catheter|Misoprostol Plus Foley Catheter for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Sections
89624296|NCT02472678|Other|Standard care|The control group will receive standard care.
89038245|NCT05519488|Experimental|Intervention group|Patients who have scheduled appointments for cancer restaging. Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
89038246|NCT05519488|Active Comparator|Control group|Patients who have scheduled appointments for cancer restaging. Participants will listen to music of their own choice that they believe to be stress reducing
89038247|NCT02907281||Multiple sclerosis patients|Multiple sclerosis patients
89038248|NCT02907281||Healthy volunteers|Healthy volunteers
89038249|NCT04323241|No Intervention|control group|In group 1, plasenta is removed manually. Manual removal of the placenta will be performed by placing surgeon's dominant hand in the uterine cavity and removing the placenta by detaching it from the uterine wall as soon as possible after the delivery of the infant. The emptiness of the uterine cavity is verified manually.
89038250|NCT04323241|Experimental|Study Group|In group 2, plasenta is removed by controlled cord traction. Spontaneous removal will be performed by external uterine massage and traction on the umbilical cord are performed to assist spontaneous delivery of the placenta.
89038251|NCT02899637|Experimental|Spinal Cord Injury (Active Group)|Active high-frequency Transcranial Magnetic Stimulation
89038252|NCT02899637|Sham Comparator|Spinal Cord Injury (Control group)|Sham high-frequency Transcranial Magnetic Stimulation
89038253|NCT02899676|Experimental|Healthy subjects aged 18 to 24|Subjects without neurological or psychiatric history
89038254|NCT02899676|Experimental|Healthy subjects aged 8 to 11|Subjects without neurological or psychiatric history
89624297|NCT02472678|Experimental|Experimental group|In addition to standard care, the experimental group will be given access to the web-based tailored information and support system (with a username/password)
89038255|NCT02899676|Experimental|Healthy subjects aged 12 to 14|Subjects without neurological or psychiatric history
89624298|NCT00550732|Experimental|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
89624299|NCT03311100||Lung cancer|
89624300|NCT03311100||Central Nervous System Cancers|
89624301|NCT03311100||Head and Neck and upper aero-digestive tract cancers|
89624302|NCT03311100||Skin cancers|
89624303|NCT03311100||Sarcomas|
89624304|NCT03311100||Urothelial cancer|
89624305|NCT03311100||Hepatocarcinoma|
89624306|NCT03311022|Experimental|Treatment 1|One tablet of test product (Nefopam Hydrochloride 30mg Tablets) containing 30mg nefopam hydrochloride.
89038256|NCT02899559|Experimental|Control|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The control group will read only summary information about the David Pottruck Health and Fitness Center.
89038257|NCT02899559|Experimental|Nudge Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The nudge message encourages participants to make a plan for when they will exercise at the gym during the next week.
89038258|NCT02899559|Experimental|Boost Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. Those in the Boost condition will also have summary information about the Pottruck gym but will also be given information about why an implantation intention is an effective way to attain long term goals. They will also be given a prompt to form an implementation intention.
89038259|NCT01262677|Experimental|pregabalin CR 330 mg|
89038260|NCT01262677|Experimental|pregabalin CR 165 mg|
89038261|NCT01262677|Placebo Comparator|Placebo|
89038262|NCT02899364|Experimental|Sodium thiosulfate|25 gram sodium thiosulfate is given intravenously in two doses of 12.5 gram (50mL) dissolved in 250 ml sodium chloride 0.9%. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15 mL/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he will receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
89624307|NCT03311022|Active Comparator|Treatment 2|One tablet of reference product (Acupan® 30mg Tablets) containing 30mg nefopam hydrochloride.
89624308|NCT03310866|Active Comparator|fiberoptic, airway|Classical fiberoptic intubation assisted by side fenestrated airway and head tilt- chin lift- jaw thrust by 2 anesthetist
89624309|NCT03310866|Experimental|fiberoptic, Machintosh|oral Fiberoptic bronchoscopic intubation assisted by Macintosh Laryngoscope, by 2 anesthetist
89624310|NCT02469480|Experimental|FERRIC CARBOXYMALTOSE|max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
89624311|NCT02469480|Active Comparator|ferro sanol(R) duodenal 100 mg|200 mg ferro sanol per day over 12 weeks
89624312|NCT03313284|Experimental|Study Group|
89624313|NCT02469402|Active Comparator|Standard infant formula|Standard infant formula
89624314|NCT02469402|Experimental|Protein reduced formula|Protein reduced alpha-lactalbumin formula
89624315|NCT02469402|No Intervention|Breast-feeding|Exclusive breast-feeding
89624316|NCT02274844|Experimental|Peer Coaching|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
89624317|NCT02274844|No Intervention|Usual Care|At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care. There will be no peer storytelling on these DVDs.
89624318|NCT05736094|Other|Dual-frequency ultrasound|Dual-frequency ultrasound for detection of prostate cancer
89624319|NCT03656016||study group|patients with congenital and acquired disorders that can alter the CSF dynamics will undergo phase-contrast magnetic resonance imaging
89624320|NCT03656016||control group|age matched healthy individuals will undergo phase-contrast magnetic resonance imaging
89624321|NCT03304938|Active Comparator|Lavender oil|
89624322|NCT03304938|Placebo Comparator|vehicle (Almond oil)|
89624323|NCT03310554|Experimental|26cm suspended overlength biliary stents group|
89624324|NCT03310554|Experimental|30cm suspended overlength biliary stents group|
89624325|NCT03310554|Other|ordinary plastic biliary stents group|
89624326|NCT03310476|Experimental|Baked, consumed chilled potatoes|
89038263|NCT02899364|Placebo Comparator|Sodium chloride 0.9%|50 ml Sodium chloride 0.9%, added to 250ml sodium chloride 0.9% is administered twice. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15ml/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
89038264|NCT00548613|Experimental|A|Patients with documented acute myocardial infarction (heart attack) occurring within 4-24 hours after onset of symptoms
89038265|NCT00548613|Experimental|B|Candidates for coronary artery bypass grafting that suffered a myocardial infarction (heart attack) within the past 12 months
89038266|NCT04206865|Experimental|ARNI therapy|Patient's randomized to this arm will receive sacubitril-valsartan per study protocol and titrated per titration guidelines.
89038267|NCT04206865|Active Comparator|Standard Oral Vasodilator|Patient's randomized to this arm will receive the oral vasodilator that the clinician chooses including angiotensin receptor blocker (ARB), isosorbide dinitrate, hydralazine, and angiotensin-converting enzyme inhibitor (ACEi).
89038268|NCT02899247|Experimental|No Surface Sealant|Resin composite only
89038269|NCT02899247|Active Comparator|With surface Sealant|Resin composite with surface sealant application
89038270|NCT02899403|Experimental|healthy subjects|
89038271|NCT01262638|Experimental|ETC-1002 120 mg (Group 1)|Subjects with hypercholesterolemia and normal triglycerides
89038272|NCT01262638|Experimental|ETC-1002 80 mg (Group 2)|Subjects with hypercholesterolemia and normal triglycerides
89038273|NCT01262638|Experimental|ETC-1002 40 mg (Group 3)|Subjects with hypercholesterolemia and normal triglycerides
89038274|NCT01262638|Experimental|Placebo (Group 4)|Subjects with hypercholesterolemia and normal triglycerides
89624327|NCT03310476|Experimental|Boiled, consumed hot potatoes|
89624328|NCT03310398||Anxiety|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
89624329|NCT03310398||Depression|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
89624330|NCT00550420|Experimental|Arm 1|Rosiglitazone XR
89624331|NCT03312972|Experimental|HDR Brachytherapy|HDR Brachytherapy implant, Up to 30 Gray (Gy) to target lesion in one to two fractions.
89624332|NCT03312894|Experimental|Cohort 1 (Ketamine Responders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
89624333|NCT03312894|Placebo Comparator|Cohort 1 (Ketamine Responders): Placebo|TAK-653 placebo-matching tablets, orally, once daily up to Day 56
88815684|NCT01084148|Placebo Comparator|V0034 CR 01B vehicle|cream
88815685|NCT01085006|Experimental|Tranexamic acid|
88815686|NCT01085006|Placebo Comparator|normal saline infusion|
89038275|NCT01262638|Experimental|ETC-1002 120 mg (Group 5)|Subjects with hypercholesterolemia and elevated triglycerides
89038276|NCT01262638|Experimental|ETC-1002 80 mg (Group 6)|Subjects with hypercholesterolemia and elevated triglycerides
89038277|NCT01262638|Experimental|ETC-1002 40 mg (Group 7)|Subjects with hypercholesterolemia and elevated triglycerides
89038278|NCT01262638|Experimental|Placebo (Group 8)|Subjects with hypercholesterolemia and elevated triglycerides
89624334|NCT03312894|Experimental|Cohort 2 (Ketamine Nonresponders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
89624335|NCT03312894|Placebo Comparator|Cohort 2 (Ketamine Nonresponders): Placebo|TAK-653 Placebo-matching tablets, orally, once daily up to Day 56
89624336|NCT00559936|Experimental|Topical Avastin 1.0%|Each patient will receive topical Avastin in one eye.
89624337|NCT03304860|Experimental|CRC screening Survey|Residents with parents eligible for CRC screening will be asked to provide their e-mail address, solely for the use of distributing the follow up survey so it can be linked to 2 brief (3-5 min) surveys
89624338|NCT03304782||Preterm birth|Data collected using Fitbit activity tracker from women with delivery prior to 37 weeks gestation
89624339|NCT03304782||Full-term birth|Data collected using Fitbit activity tracker from women with delivery after 37 weeks gestation
89688453|NCT03404141|Active Comparator|Control group|The intervention administered to the control group will consist on a regular parent craft classes offered by the community midwife Due to COVID-19 pandemic, this group will be implemented online using a videocall online platform (from April 2019 to the end of mobility restrictions).
89688454|NCT04377893|Experimental|Treatment arm|Participants will receive eye-gaze AT intervention
89624340|NCT04768738|Experimental|Above Threshold Group|In the above threshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
89624341|NCT04768738|Experimental|Subthreshold Group|In the subthreshold group, biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
89624342|NCT04768738|Sham Comparator|Control Group|In the control group, bicycle exercise was performed under the same load with the current-free headset produced for sham applications for 5 minutes. Participants were shown that the device was working, but no current was given.
89624343|NCT03312816|Placebo Comparator|Placebo|0 mg/d added POP
89624344|NCT03312816|Active Comparator|low dosage|low added POP
89624345|NCT03312816|Active Comparator|Medium dose|medium added POP
89624346|NCT03312816|Active Comparator|Hige dose|high added POP
89624347|NCT03310320|Placebo Comparator|Placebo|Placebo for AZD0284 oral solution
89624348|NCT03310320|Experimental|AZD0284|AZD0284 oral solution 2.5 mg/mL
89624349|NCT03304548||All subjects with PAH|A total of 8 to 10 US-English speaking PAH subjects will be recruited. They will take part in a 30-minute telephone concept elicitation interview. All interviews will be audio-recorded and transcribed verbatim.
89624350|NCT05353192|Experimental|Recombinant human growth hormone|Recombinant human growth hormone Injection (15IU/5mg/3ml/bottle)；0.05 mg/kg/d by subcutaneous injection for 52 weeks
89624351|NCT03310242|Experimental|Sunlight Exposure|Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
89624352|NCT03310242|Experimental|Vitamin D Supplementation|Supplementation of vitamin D3 500 IU/day for 8 weeks
89624353|NCT03310242|Placebo Comparator|Placebo|Intake of placebo for 8 weeks
89624354|NCT03310164||COPD|Smokers with clinically stable chronic obstructive pulmonary disease (COPD)
89624355|NCT03310164||healthy control|Age-matched subjects without chronic obstructive pulmonary disease (COPD)
89624356|NCT05341492|Experimental|Treatment|Patients will receive 2*10e6/kgCAR-T cells.
89624357|NCT03312660|Experimental|Prebiotic group.|Group of 22 families consuming a fermented dairy product with prebiotic components, once a day for 4 months.
89624358|NCT03312660|Placebo Comparator|Placebo group|Group of 22 families consuming a dairy product with similar characteristics regarding color, flavor and nutritional composition, not containing the prebiotic components, once a day for 4 months.
89624359|NCT03312582|Experimental|Manual debridement and 1% metformin gel|
89624360|NCT03312582|Placebo Comparator|Manual debridement and placebo|
89038279|NCT02899520|Active Comparator|Group A|Reference method
89038280|NCT02899520|Experimental|Group B|CMP ® method (Knowledge and Control of Perineum)
89038281|NCT00535119|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib PO twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
89038282|NCT00535197|Experimental|CD34+ stem/progenitor cell therapy|Patients presenting within 7 days of onset with severe anterior circulation ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score≥8). CD34+ cells were collected from the bone marrow of the subjects before being delivered by catheter angiography into the ipsilesional middle cerebral artery.
89038283|NCT04684407|Active Comparator|calcium hydroxide|calcium hydroxide powder is mixed with normal saline and placed as intra-canal medication
89624361|NCT03304470|Experimental|ATx201 2% CREAM|
89624362|NCT03304470|Placebo Comparator|ATx201 Cream Vehicle|
89624363|NCT04350580|Experimental|Intervention - IGIV|Participants in the intervention group will receive a 2g/Kg infusion of human immunoglobulin which should be started before the 96th hours after the start of mechanical ventilation in 4 injections of 0.5 g/Kg over 4 consecutive days.
89624364|NCT04350580|Placebo Comparator|Placebo|Participants of the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.
89624365|NCT03312504|Experimental|Neuromuscular Training Warm-up|Schools randomized to the intervention arm receive a workshop outlining a neuromuscular training program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consist of high-intensity aerobic, strengthening, agility, plyometric, and balance components. The workshop is designed to last two hours, and includes a video outlining the warm-up components, practice time, and group discussions for action planning to address potential barriers to the program.
89624366|NCT03312504|Placebo Comparator|Control Standard-of-practice Warm-up|Schools randomized to the control arm receive a workshop outlining a standard-of-practice program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consists of aerobic exercises and static stretching. The workshop is designed to last one hour, and includes an explanation and demonstration of the exercises, but no video or practice time.
89624367|NCT02469324|Active Comparator|Cognitive-Behavioral Therapy|see intervention explanation
89624368|NCT02469324|Experimental|Compassionate Mind Training|
89624369|NCT03310086|Experimental|Traditional fixed appliance|"Fixed orthodontic appliances will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
89624370|NCT03310086|Experimental|Fixed appliance and corticision|"Fixed orthodontic appliances with corticison will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
89038284|NCT04684407|Experimental|Triple antibiotic paste|"Triple antibiotic paste (TAP)- combination of metronidazole,ciprofloxacin and minocycline mixed in a ratio of 1:1:1 .~TAP paste is combined with propylene glycol and placed as intra canal medication."
89038285|NCT04942080|Experimental|CALRSUIVI cohort|
89624371|NCT03310008|Experimental|Dose level 1 (escalation|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
89624372|NCT03310008|Experimental|Dose level 2 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
89624373|NCT03310008|Experimental|Dose level 3 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
89038286|NCT00548769|Experimental|Sequence ADBC|Subjects will be administered formulation A, formulation D, formulation B and formulation C across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
89038287|NCT00548769|Experimental|Sequence BACD|Subjects will be administered formulation B, formulation A, formulation C and formulation D across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
89038288|NCT00548769|Experimental|Sequence CBDA|Subjects will be administered formulation C, formulation B, formulation D and formulation A across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
89038289|NCT00548769|Experimental|Sequence DCAB|Subjects will be administered formulation D, formulation C, formulation A and formulation B across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
89038290|NCT01262560|Active Comparator|Supportive Care|Standard supportive care
89038291|NCT01262560|Experimental|Liquid Manuka Honey|Manuka honey in liquid form
89038292|NCT01262560|Experimental|Lozenge Manuka Honey|Manuka honey in lozenge form
89038293|NCT03429894|Experimental|Treatment|All patients will undergo imaging (angiography and IVUS) follow-up with approximately one-half of the patients returning for follow up at 9 months and approximately one-half returning for follow up at 12 months.
89038294|NCT04686669|Experimental|Subjects receiving treatment sequence ABC|Subjects will receive treatment sequence ABC on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
89038295|NCT04686669|Experimental|Subjects receiving treatment sequence BCA|Subjects will receive treatment sequence BCA on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
89038296|NCT04686669|Experimental|Subjects receiving treatment sequence CAB|Subjects will receive treatment sequence CAB on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
89038297|NCT04686669|Experimental|Subjects receiving treatment sequence ACB|Subjects will receive treatment sequence ACB on Days 1, 3 and 5 respectively; A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state.
89038298|NCT04686669|Experimental|Subjects receiving treatment sequence BAC|Subjects will receive treatment sequence BAC on Days 1, 3 and 5 respectively; B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state, C= 3x50 milligrams FOR-6219 tablet given in fasted state.
89624374|NCT03310008|Experimental|Recommended dose level (expansion)|The dose expansion arm will use the maximum tolerated dose.
89624375|NCT03304392|Experimental|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
89624376|NCT03304392|Active Comparator|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
89038299|NCT04686669|Experimental|Subjects receiving treatment sequence CBA|Subjects will receive treatment sequence CBA on Days 1, 3 and 5 respectively; C= 3x50 milligrams FOR-6219 tablet given in fasted state, B= 3x50 milligrams FOR-6219 tablet given in fed state, A= 3x50 milligrams FOR-6219 soft gelatine capsule given in fasted state.
89038300|NCT04207450|Placebo Comparator|Placebo Group|Placebo Gel + Placebo Solution (Distilled Water)
89038301|NCT04207450|Experimental|Placebo Gel + Glutaraldehyde (GPG)|Placebo Gel + 5% Glutaraldehyde Aqueous Solution
89038302|NCT04207450|Experimental|Phosphoric Acid + Glutaraldehyde (GAG)|37% Phosphoric Acid + Glutaraldehyde Aqueous Solution (GAG)
89038303|NCT04686396|Experimental|Interpositional Group|Demineralized bone matrix
89038304|NCT04686396|No Intervention|Control|Without demineralized bone matrix
89038305|NCT04322773|Experimental|Roactemra iv|Single dose treatment with 400 mg tocilizumab intravensously
89038306|NCT04322773|Experimental|Roactemra sc|Single dose treatment with 2 x 162 mg tocilizumab subcutaneously
89624377|NCT03309930|Experimental|Comprehension Acquired Brain Injury|All participants will be exposed to 3 conditions: (a) written text, (b) auditory output (synthetic speech), and combined conditions for study 1. For study 2 participants will be repeatedly exposed to synthetic speech output to determine the influence on comprehension. Participants are not required to participate in both studies.
89624378|NCT03312426|Experimental|BMS-986205 under fasted conditions then with high-fat meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a high-fat meal (Day 15).
89624379|NCT03312426|Experimental|BMS-986205 with high-fat meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a high-fat meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
89624380|NCT03312426|Experimental|BMS-986205 under fasted conditions then with light meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a light meal (Day 15).
89624381|NCT03312426|Experimental|BMS-986205 with light meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a light meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
89624382|NCT03309774|Experimental|Complex Regional Pain Syndrome (CRPS)|"Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions."
89038307|NCT04322773|Experimental|Kevzara sc|Single dose treatment with 1 x 200 mg sarilumab subcutaneously
89038308|NCT04322773|Active Comparator|Standard care|Management as usual
89038309|NCT04322812|Active Comparator|Active PBMT|Active PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
89038310|NCT04322812|Placebo Comparator|Placebo PBMT|Placebo PBMT applied three times a week (interval of 48 hours approximately), for three consecutive weeks, totalling nine treatment sessions.
89038311|NCT02888782|Experimental|Pharmacist Consultation|Meet with pharmacist for consultation in addition to regular physician follow up
89038312|NCT02888782|No Intervention|Control|Receive regular physician follow up
89038313|NCT04686591|Experimental|AZD9977|"In Period 1, one 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capsules) and one 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL).~In Period 2, one 100 mg dose of [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)."
89038314|NCT04043494|Other|SR I/II: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~maintenance therapy"
89038315|NCT04043494|Experimental|SR I/II: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment Phase (protocol M)~maintenance therapy"
89038316|NCT04043494|Other|SR: R1 into protocol Ia-Pred|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
89038317|NCT04043494|Experimental|SR: R1 into protocol Ia-Dexa|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
89038318|NCT04043494|Other|"HR: R1 into Pred and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
89038319|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into non-HR extra-compartment phase"|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib)~non-HR extra-compartment phase (protocol M)~reintensification phase (protocol II)~maintenance therapy"
89038320|NCT04043494|Experimental|"HR: R1 into Pred and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone~standard induction phase (protocol Ia-prednisone)~consolidation phase (protocol Ib*)~HR extra-compartment phase (intensified protocol M)~reintensification phase (protocol II)~maintenance therapy"
89038321|NCT04043494|Experimental|"HR: R1 into Dexa and R2 into HR extra-compartment phase"|"cytoreductive prephase with prednisone~experimental induction phase (protocol Ia-dexamethasone)~consolidation phase (protocol Ib*)~HR extra-compartment phase (intensified protocol M)~reintensification phase (protocol II)~maintenance therapy"
89038322|NCT04686357|Experimental|Intervention group (mET)|Microbiome-driven embryo transfer of a single vitrified blastocyst in an HRT cycle according to the EMMA/ALICE test results.
89038323|NCT04686357|Active Comparator|Control group (FET)|Frozen embryo transfer of a single vitrified blastocyst in an HRT cycle according to the clinical standard practice.
89038324|NCT02899481|Experimental|Study group|The study group will be constituted by pregnant women in whom the operative delivery will be preceded by a transabdominal and transperineal ultrasound to evaluate fetal head position and fetal head station, by means of determination of the 'angle of progression'.
89038325|NCT02899481|No Intervention|Control group|The control group will be constituted by pregnant women in whom the operative delivery will be carried out based solely on clinical criteria, namely transvaginal digital examination.
89038326|NCT02899286|Experimental|PEG-BCT-100|PEG-BCT-100 (PEGylated recombinant human arginase)
89624383|NCT03304158|Experimental|FCHV visit-diabetes|
89624384|NCT03304158|No Intervention|FCHV no visit-diabetes|
89624385|NCT03312192|Active Comparator|Plate and Cage|ACDF with interbody cage and anterior plating.
89624386|NCT03312192|Active Comparator|Stand Alone Cage|ACDF with stand alone interbody cage without anterior plating
89624387|NCT03312036|Experimental|CPFA Patients|Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.
89038327|NCT00535275|Experimental|A|
89038328|NCT00535275|Active Comparator|B|Docetaxel monotherapy
89624388|NCT02468622||MO patients|Patients with migraine without aura. We will take blood samples during spontaneous migraine attacks
89624389|NCT02468622||MA patients|Patients with migraine with aura. We will take blood samples during spontaneous migraine attacks
89624390|NCT03309618|Experimental|Treatment group|20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.
89624391|NCT03309618|Placebo Comparator|Control group|16 participants received placebo per orally once daily for 30 days.
89624392|NCT03303924|Experimental|ETX2514 and sulbactam|Healthy male and female subjects, non-smoking, will receive multiple doses of ETX2514 1.0 g and sulbactam 1 g via intravenous (IV) infusion every 6 hours with each dose of medication infused over 3 hours.
89624393|NCT03309540|Experimental|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
89624394|NCT03309540|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
89624395|NCT03309462|Experimental|Re-biopsy tissue sample|The gene testing of re-biopsy tissue sample diagnosed with NSCLC will be performed with NGS using Illumina Miseq squencer and Cobas.
89624396|NCT03309462|Experimental|Peripheral blood sample|The peripheral blood sample will be extracted with DNA and performed with NGS using Illumina Miseq squencer and ddPCR.
89038329|NCT04322344|Experimental|oral escin group|Standard therapy+Escin tablet 40mg*3, os for 12 days
89038330|NCT04322344|Sham Comparator|control group|standard therapy
89038331|NCT04322344|Experimental|parenteral escin group|standard treatment + sodium Escinate 20mg iv/day for 12 days
89038332|NCT04322422|Experimental|ICS/LABA plus Montelukast|
89038333|NCT04322422|Active Comparator|ICS/LABA only|
89038334|NCT02899169|Experimental|Oral Realgar-Indigo naturalis formula(RIF) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: RIF（60mg/kg/d) and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: RIF and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
89038335|NCT02899169|Active Comparator|Intravenous Arsenic Trioxide(ATO) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: ATO and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: ATO and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
89038336|NCT04322188||group 1|Patients in Cohort A were treated with siltuximab after the use of continuous positive airways pressure (CPAP) or non-invasive ventilation (NIV). Patients in Cohort B were treated after intubation
89038337|NCT04322188||Group 2|The control cohort will include all the patients with pneumonia/ARDS in need of non-invasive ventilation (CPAP or NIV) or intubation and not receiving experimental treatments in the ReCOVID-19-2020
89038338|NCT02899130|Experimental|Polyherbal|Combination of 3 whole herbs in a capsule
89038339|NCT02899130|Placebo Comparator|Matching placebo|Similar looking inert capsules
89038340|NCT00548964|Experimental|Ketamine + Lithium|All participants receive the study drug, IV ketamine, open-label
89624397|NCT03311880|Experimental|Intervention|There is no control group for this study. Therefore all participants receive the intervention.
89624398|NCT03311802||1|
89624399|NCT03303768||Pregnant women|Pregnant woman with suspected coarctation of isolated aorta or woman followed in the last 12 for suspected coarctation of the aorta isolated during pregnancy
89624400|NCT03311568|Experimental|surgery in general anaesthesia|10 patients. ultrasound for microcirculatory assessment applied.
89624401|NCT03311568|Experimental|open chest cardiac surgery|10 patients. ultrasound for microcirculatory assessment applied.
89624402|NCT03311568|Experimental|critical septic shock at ICU|20 patients. ultrasound for microcirculatory assessment applied.
89038341|NCT00548964|Active Comparator|Ketamine + Placebo|All participants receive the study drug, IV ketamine, open-label
89038342|NCT04322227|Experimental|Healthy|
89038343|NCT04322227|Experimental|PD|
89038344|NCT02889601||Fronto-temporal lobar degeneration|DAPHNE score building and internal validation through Fronto-temporal lobar degeneration patients.
89038345|NCT02889601||Control|External validation of DAPHNE score among patients with Alzheimer's disease, progressive supranuclear palsy and bipolar disorder with cognitive disorders.
89038346|NCT02898896|Other|HIV-infected patients|HIV-infected patients >= 45 years with 2 or more CV risk factors currently on ART and HIV-RNA < 50 copies >= 12 months (one blip allowed) As part of this research, three additional tubes of blood (EDTA) will be taken from patients (21 mL) during blood tests performed as part of a scheduled consultation for the management of their pathology
89624403|NCT03311568|Experimental|healthy volunteers|10 subjects. ultrasound for microcirculatory assessment applied.
89624404|NCT03311490|Experimental|Intervention|Participants allocated to the intervention group will use Spraino® as a measure to prevent lateral ankle sprains.
89624405|NCT03311490|No Intervention|Control|"Participants allocated to the control group will be a do-as-usual comparator. This implies, that the participants can treat and prevent lateral ankle sprains in any way they wish, except using Spraino®."
89624406|NCT00557830|Active Comparator|Group A: Escalated Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
89688455|NCT01722929|Experimental|Skin sensor on surgery side|Skin sensor will be placed on the side that had surgery. This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
89038347|NCT02899091|Experimental|CB-AC-02|Subjects with Alzheimer's disease Intervention: CB-AC-02
89038348|NCT02899091|Placebo Comparator|Placebo|Subjects with Alzheimer's disease Intervention: Placebo
89038349|NCT04323007|Other|Nephrotic syndrome patients|This study is to evaluate Thyroid Hormone profile in patients with Nephrotic syndrome to identify clinical predictor of Thyroid dysfunction in patients with Nephrotic syndrome
89038350|NCT04684290|Active Comparator|Alcohol Septal Ablation|
89038351|NCT04684290|Active Comparator|Surgical Septal Myectomy|
89624407|NCT00557830|Active Comparator|Group B: Standard Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
89038352|NCT02898857||down-staging of a KRAS|Six with demonstrated down-staging of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
89038353|NCT02898857||no down-staging of a KRAS|Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
89038354|NCT02898857||non-staging and triple negative adenocarcinoma|Six with or without non-staging and triple negative adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
89038355|NCT00549081|Experimental|1|IVF patients who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
89038356|NCT00549081|No Intervention|2|IVF patient who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
89038357|NCT02898779|Experimental|Cohort 1 ( Primaquine Low Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 1 (Low Dose Level)- single dose of 15 mg of S-Primaquine and 15 mg of R-Primaquine compared to 30 mg RS-Primaquine over 24 hours. Participants will cross-over after a one week wash-out period."
89038358|NCT02898779|Experimental|Cohort 2 (Primaquine High Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 2 (High Dose Level)-single dose of 22.5 mg of S-Primaquine and 22.5 mg of R-Primaquine compared to 45 mg RS-Primaquine over 24 hours. Participants will cross-over among the treatment arms following a one week wash-out period between each."
89038359|NCT00535431|Experimental|A|AER 001
89038360|NCT00535431|Placebo Comparator|P|sterile saline
89038361|NCT02898701|Active Comparator|No Overpractice (NoOVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the NoOVP group will cease practicing.
89624408|NCT05207202|Active Comparator|EIT-PEEP strategy|Patients will receive PEEP titrated by EIT with a stepwise decrease PEEP trial
89624409|NCT05207202|Active Comparator|ARDSNet-PEEP strategy|PEEP will be set according to the low FiO2-PEEP table to keep the oxygenation goals: SpO2 between 88% and 95%, and PaO2 between 55mmHg and 80mmHg.
89038362|NCT02898701|Experimental|Overpractice (OVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the OVP group will continue to practice as part of the overpractice phase until they have completed 100% overpractice.
89038363|NCT02898701|Active Comparator|Standard of Care (SoC)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) until they have performed 144 practice trials over the course of one day. At that time, members of the SoC group will cease practicing.
89038364|NCT00549120|Experimental|Propranolol alone|Propranolol 80 mg (5 doses at 6 hourly intervals)
89038365|NCT00549120|Experimental|Propranolol + salbutamol|Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals)
89038366|NCT00549120|Experimental|Salbutamol alone|Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals)
89038367|NCT00549120|Placebo Comparator|Placebo|Placebo (5 doses at 6 hourly)
89038368|NCT00549120|Experimental|Propranolol + ipratropium + salbutamol|Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
89624410|NCT02468466|Experimental|Multi-level suicide prevention programs|The study team, including staff members from the intervention municipalities, provided each municipality with a standardized form of the work plan used in our study. The intervention municipality autonomously conducted the intervention program during the implementation period.
89624411|NCT02468466|Active Comparator|Community intervention as usual|Suicide prevention program as usual
89624412|NCT03304236||Myelopathy hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
89624413|NCT05080686|Experimental|ThoraxBelt (Inpatients)|Received ThoraxBelt after the surgery in addition to oral analgesics. Standard care for pain management will be the same as the Standard Care Arm (Inpatients).
89038369|NCT00549120|Experimental|Placebo + ipratropium + salbutamol|Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
89038370|NCT04680884|Experimental|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
89038371|NCT04680884|Experimental|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
89624414|NCT05080686|No Intervention|Standard Care (Inpatients)|Standard Care with IV PCA and on-request oral painkiller.
89624415|NCT05080686|Experimental|ThoraxBelt (Outpatients)|Received ThoraxBelt at the emergency room in addition to oral analgesics. Standard care for pain management will be the same as the Standard Care Arm (Outpatients).
88815687|NCT01085318|Active Comparator|Arm 1 MS Patients|Rebif 44 tiw
89624416|NCT05080686|No Intervention|Standard Care (Outpatients)|Standard Care and on-request oral painkiller.
89624417|NCT03303690|Experimental|Ankle Spacer (AS)|This arm will surgically receive the to be implanted ankle spacer in their ankle.
89038372|NCT04680884|Experimental|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
89038373|NCT04680884|Other|Best standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
89624418|NCT03309228||Qualitative Research|Semi-structured interviews with patients, relatives and general practitioners.
89624419|NCT00557440|Experimental|Ind/M - FP/Salm - Pbo|"In Treatment Period 1 (Days 1 & 2) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
89038374|NCT03318588||Case|Patients undergoing vitrectomy for primary retinal detachment
89038375|NCT03318588||Control|Patients undergoing vitrectomy for idiopathic macular hole
89038376|NCT02898428||New mothers|New mothers with type 1 diabetes
89038377|NCT02898428||Control group|Non-pregnant, non-breastfeeding women with type 1 diabetes matched for age and BMI
89038378|NCT00549159|Experimental|Cavaterm|
89038379|NCT00549159|Active Comparator|TCRE|Transcervical resection of the endometrium
89038380|NCT00549237|Active Comparator|Nutrition|Pre-operative Glucose load and post-operative immediate enteral nutrition
89038381|NCT00549237|No Intervention|Control|No pre-operative glucose load. No early post-operative nutrition
89624420|NCT00557440|Experimental|FP/Salm - Pbo - Ind/M|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
89624421|NCT00557440|Experimental|Pbo - Ind/M - FP/Salm|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
89624422|NCT03303534|Experimental|PCR|pre-operative protein calorie restricted (PCR) group. participants randomized to this arm will consume scandishake diet (strawberry, caramel, banana cream, vanilla) mixed with almond milk for three days inpatient prior to planned elective carotid endarterectomy. Water is ad libitum for this cohort. Nutritionists will prepare shakes so participants will achieve 30% calorie restriction and severe protein restriction during the three days on the diet.
89624423|NCT03303534|No Intervention|control regular diet|participants in this cohort are randomized to the control group and will have no dietary restriction three days in patient prior to planned elective carotid endarterectomy
89624424|NCT03308994||Oral first line disease modifying treatments|
89624425|NCT03308994||Injectable first line disease modifying treatments|
89624426|NCT03311178|Experimental|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
89624427|NCT02469012|Experimental|IFN-free antiviral treatment|Combination #1 or Combination #2 or Combination #3 or Combination #4 or Combination #5
89624428|NCT02468856|Active Comparator|Armodafinil|Armodafinil 250 mg tablets, one time administration per study session in the morning of day 2
89038382|NCT02898545|Other|SEEQ monitor|Subjects will be monitored via use of the SEEQ monitor
88815688|NCT01085318|No Intervention|Arm 2 Healthy Control|
89038383|NCT02898545|No Intervention|Standard of care|Subjects will not wear the SEEQ monitor or may have a pre-existing implanted device capable of detecting atrial fibrillation
89038384|NCT00535470|Experimental|1|Open label 0.04% Mechlorethamine gel
89038385|NCT02898467||diabetics|Type 2 diabetic patients exhibiting fasting glycemia value over 7 mmol/L or glycated hemoglobin value over 6.5% or type 2 diabetic patients under oral anti-diabetic treatment or type 2 diabetic patient under insulin treatment and in which diabetes has been diagnosed after the age of 45 y
89038386|NCT02898467||non-diabetics|patients without diagnosed diabetes exhibiting fasting glycemia value under 7 mmol/L
89038387|NCT03284112|Placebo Comparator|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Plate program.
89038388|NCT03284112|Experimental|Intervention|School population with the Old SCHOOL Hip-Hop program.
89624429|NCT02468856|Placebo Comparator|Placebo|one time administration per study session in the morning of day 2
89624430|NCT03303456|Experimental|Clinical high risk (CHR)|Subjects at clinical high risk (CHR) for psychosis and/or bipolar disorder, aged 13-30 years. CHR participants will have no history of psychosis and will demonstrate attenuated psychotic symptoms consistent with the Structured Interview for Prodromal Syndromes (SIPS), or genetic risk (first-degree relative with psychosis) in conjunction with a substantial drop in functioning over the past year. Assigned Mobile health application - Ginger.io
89624431|NCT03303456|Experimental|First Episode Psychosis (FEP)|First Episode Psychosis (FEP) subjects aged 13-30 meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder. FEP participants will be ascertained three years or less from illness onset and have diagnoses of affective (i.e. bipolar) and non-affective psychosis (i.e. schizophrenia) according to DSM-IV criteria. Assigned Mobile health application - Ginger.io
89624432|NCT03303456|Experimental|Healthy Controls (HC)|Healthy individuals with no current/past axis I disorders according to DSM-IV criteria and no first-degree relative with a psychotic disorder. Assigned Mobile health application - Ginger.io
89624433|NCT03308838||Cases|Cases consisted of Costa Rican adults who were diagnosed as survivors of a first acute myocardial infarction.
89624434|NCT03308838||Controls|Controls consisted of healthy individuals randomly identified from the underlying source population in Costa Rica and matched to each case by age, sex, and area of residence.
89624435|NCT05202106|No Intervention|Control|Families in the control group will not receive any interventions and will simply complete baseline and endline surveys.
89624436|NCT05202106|Experimental|Home visits|Families in the home visiting arm will receive visits by trained child development agents every two weeks between enrollment and 2 years of age.
89624437|NCT05202106|Experimental|Afini|Families in the Afini arm will be introduced to the Afini app on Messenger and encouraged to use this platform throughout the study.
89624438|NCT03303378|Experimental|Melatonin group|Patients will receive a total intravenous melatonin dose of 11.61 mg (aproximately 166 μg/kg).
89624439|NCT03303378|Placebo Comparator|Control group|Patients will receive the same dose of placebo.
89624440|NCT04491474|Active Comparator|Group 1|bilateral great occipital nerve blockade and bilateral isotonic injection into the supraorbital region.
89624441|NCT04491474|Active Comparator|Group 2|bilateral supraorbital nerve blockade and bilateral isotonic injection into the great occipital nerve region
89624442|NCT04491474|Active Comparator|Group 3|bilateral great occipital nerve blockade and bilateral supraorbital nerve blockade
89624443|NCT04491474|Sham Comparator|Group 4|saline injection to bilateral great occipital nerve and supraorbital nerve region
89624444|NCT00556894|Experimental|CF101 0.1 mg|CF101 0.1 mg was given orally q12h
89624445|NCT00556894|Experimental|CF101 1 mg|CF101 1 mg was given orally q12h
89624446|NCT00556894|Placebo Comparator|Placebo|Matched placebo was given orally q12h
89624447|NCT03308682|Experimental|177Lu-DOTA-EB-TATE dosimetry calculation|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
89624448|NCT03303222||patients on dialysis|patients with kidney disease treated by dialysis
89624449|NCT03303222||patients with chronic kidney disease|patients with chronic kidney disease not treated by dialysis
89624450|NCT05182372|Experimental|Enhanced dCBT-I|This group will complete d-CBTI and be assigned a coach that will help with completion of the treatment and will be available to call personally to discuss questions and issues.
89624451|NCT05182372|No Intervention|Control dCBT-I|Participants in this group will complete dCBT-I individually without assistance from a healthcare provider
89624452|NCT03308604|Experimental|Patients with locally advanced cervical cancer|
89624453|NCT05168956||Sexual offender|Patients followed up in the sexual offender's department of University Hospital of Saint Etienne will be included.
89624454|NCT00553306|Experimental|Arm I|Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2 hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89624455|NCT05110612|Experimental|Extended Episodic Future Thinking|Participants will receive Episodic Future Thinking practice for 8 sessions.
89624456|NCT05110612|Experimental|Brief Episodic Future Thinking|Participants will receive Episodic Future Thinking practice for 2 sessions.
89624457|NCT05110612|Sham Comparator|Control|Participants will receive sham Episodic Recent Thinking intervention.
89624458|NCT02722044|Experimental|All Study Participants|All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
89624459|NCT05728008||subject treated with ustekinumab (anti-IL12-23)|subjects treated with ustekinumab (anti-IL12-23) and have a follow-up at 24 +/- 4 weeks from the start of the third line therapy
89624460|NCT05728008||subject treated withtofacitinib (pan JAK inhibitor)|subjects treated with tofacitinib (pan JAK inhibitor) and have a follow-up at 24 +/- 4 weeks from the start of the third line therapy.
89624461|NCT03302988|Experimental|Everted closure|Wound eversion will be achieved through buried vertical mattress suture or cuticular suture based on surgeon's preference, either buried vertical mattress suture or cuticular sutures
89624462|NCT03302988|Active Comparator|Planar closure|The planar side of the same wond will be closed with traditional buried simple closure and running cuticular sutures
89624463|NCT04490382|Experimental|Patients undergoing Neuromodulation|Patients, who have had a lower limb amputation and undergoing neuromodulation as part of standard of care.
89624464|NCT02988700|Active Comparator|Spinal group|"Intrathecal hyperbaric bupivacaine 0.25mg/kg will be give by lumber puncture that will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.~be given by ."
89688456|NCT01722929|Active Comparator|Skin sensor on non-surgery side|Skin sensor will be placed on the contralateral side from surgery site.This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
89624465|NCT02988700|Active Comparator|Caudal group|"caudal plain bupivacaine 2.5mg/kg 0.25% will be given caudally in The sacral hiatus between the sacral conru that will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
89624466|NCT03308370|Experimental|Platelet rich plasma|intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
89038389|NCT02898584|Other|BP Track|The study participants will be asked to monitor their blood pressure twice daily at home for twelve weeks, and sync the data to the mobile intervention so that a clinical pharmacist can review and incorporate the data into ongoing hypertension management.
89038390|NCT03455309|Active Comparator|NDV-3A|0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
89038391|NCT03455309|Placebo Comparator|Placebo|0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
89038392|NCT00549315|Experimental|1|
89038393|NCT02898350|Active Comparator|Pulsed Dye Laser treatment|Pulsed Dye Laser treatment after suture removal (3 sessions)
89038394|NCT02898350|Active Comparator|CO2 laser treatment|CO2 laser (3 treatment sessions) after suture removal
89038395|NCT02898350|Active Comparator|Combined PDL and CO2 Laser treatment|Combined PDL and CO2 Laser resurfacing (3 treatment sessions) after suture removal
89038396|NCT02898350|Active Comparator|Split PDL and CO2 Laser treatment|Half of the scar was not treated and served as a control, while the other half was treated with CO2 ablative fractional resurfacing immediately after surgery, in addition to the three combined PDL and CO2 treatment sessions after suture removal
89038397|NCT02898389||Group 1: With cardiovascular risk factors|Patients fall within this group when they have at least one of the cardiovascular risk factors listed in the eligibility criteria section.
89624467|NCT03308292|No Intervention|Control Group|
89624468|NCT03308292|Experimental|Intervention Group|"A moderate-intensity aerobic physical exercise programme was carried out during the months of March to May 2017 (12 weeks), with a frequency of three sessions per week (36 sessions in total) with a duration of 45 minutes per session. The intensity was controlled through the Borg 1982 modified scale of perceived exertion (RPE). It is a scale from 0 to 10, considering 0 as nothing at all and 10 as very very strong, setting the moderate intensity as value"
89624469|NCT03302832|Active Comparator|Standard Care Physical Therapy|The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
89624470|NCT03302832|Experimental|Physical Therapy and in-Home Equipment|The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
89624471|NCT03308214||septic shock|Patients with septic shock treat with Imipenem
89624472|NCT03308214||non-septic shock|Patients with infection but not septic shock treat with Imipenem
89624473|NCT03308136|Experimental|subcutaneous anesthesia group (group A)|
89624474|NCT03308136|Active Comparator|muscle anesthesia group (group B)|
89624475|NCT02466906|Experimental|rhGM-CSF group|rhGM-CSF was injected subcutaneously perioperation.
89624476|NCT02466906|Placebo Comparator|placebo group|Placebo was injected subcutaneously perioperation.
89624477|NCT02467140|Active Comparator|Self-fixating mesh|During surgery, the Parietex ProGrib mesh will be used.
89624478|NCT02467140|Active Comparator|Tack fixation|During surgery, the mesh will be fixated with tacks.
89624479|NCT02467062|Active Comparator|4Dflow MRI parallel imaging|4D flow MRI with conventional parallel imaging
89038398|NCT02898389||Group 1: Without cardiovascular risk factors|Patients fall into this group when they do not have any of the cardiovascular risk factors listed in the eligibility criteria section.
89038399|NCT02898038|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PARIS for a period of 9 days.
89038400|NCT02897999|Experimental|SAD Cohort 1|Single dose of 0.05 mL QBKPN or Placebo
89038401|NCT02897999|Experimental|SAD Cohort 2|Single dose of 0.10 mL QBKPN or Placebo
89038402|NCT02897999|Experimental|SAD Cohort 3|Single dose of 0.20 mL QBKPN or Placebo
89038403|NCT02897999|Experimental|SAD Cohort 4|Single dose of 0.40 mL QBKPN or Placebo
89038404|NCT02897999|Experimental|SAD Cohort 5|Single dose of 0.80 mL QBKPN or Placebo
89038405|NCT02897999|Experimental|SAD Cohort 6|Single dose of 1.2 mL QBKPN or Placebo
89038406|NCT02897999|Experimental|MAD Cohort 1|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
89038407|NCT02897999|Experimental|MAD Cohort 2|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
89624480|NCT02467062|Other|4D flow ktARC parallel imaging|4D flow MRI kt ARC spatiotemporal parallel imaging
89624481|NCT02466984|Experimental|metoclopramide subcutaneous|every two days, first from 10 to 20 and then from 20 to 30 mg/d
89624482|NCT02466984|Active Comparator|metoclopramide intravenous|first from 10 to 20 and then from 20 to 30 mg/d
89624483|NCT00556426|Experimental|Filter|All subjects enrolled to the study are in this arm. All subjects receive a filter.
89688457|NCT02982031|Sham Comparator|shamrock|shamrock: both left and right sided scan,both intertransverse and transverse process window
89688458|NCT02982031|Active Comparator|paramedian transverse scan|paramedian transverse scan (PMTS): both left and right, both intertransverse and transverse process window
89688459|NCT03404063|Experimental|Active Group|Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.
89624484|NCT05727852||Experimental: patients with chronic respiratory diseases|"Included patients, aged ≥ 18 years, with chronic respiratory diseases: COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis and other interstitial lung diseases.~Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of electrocardiogram (ECG), phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.~Interventions:~Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor CardioQvark; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N."
89624485|NCT05727852||Active Comparator: Control|"Included subjects, aged ≥ 18 years.~Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.~Interventions:~Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor CardioQvark; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N."
89624486|NCT03302754|Other|Alemtuzumab|"Patients less than 15kg will be given 0.6mg/kg alemtuzumab divided over days -14, -13, and -12 (0.2mg/kg/dose).~Patients greater than 15kg will be given a 3mg test dose on day -14 in order to limit the first dose to no more than 3 mg per the manufacturer's recommendation. This will be followed by 0.23mg/kg/dose on days -13 and -12 (to equal a total dose of approximately 0.5-0.6mg/kg).~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
89624487|NCT00555568|Experimental|Peer-led Groups|Arm 1 is a 3-month recovery-focused mental health education and support group led by peer facilitators
89624488|NCT00555568|Experimental|Clinician-led Groups|Arm 2 is a 3-month recovery-focused mental health education and support group led by a mental health clinician
89624489|NCT00555568|No Intervention|Treatment as Usual|Arm 3 is treatment as usual (no intervention)
89624490|NCT03302676|Active Comparator|Intervention|"Patients use tasteless and sugar free chewing gum up to 5 times a day for 1 month.~Daily registrations in a patient dairy."
89624491|NCT03302676|No Intervention|Control|Patients continue with daily routine to relieve oral discomfort. No chewing gum allowed.
89624492|NCT02988778|Experimental|Budesonid 50mcg (Noex)|"Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
89624493|NCT02988778|Active Comparator|Budesonid 50mcg (Busonid)|"Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
89624494|NCT04490460|Placebo Comparator|First 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. Double blind 50% Placebo capsules identical to those containing WB-0031 and 50% WB-0031
89624495|NCT04490460|Active Comparator|Second 12 Weeks|1 capsule administered twice daily with morning and evening meal for 12 weeks. All participants receiving WB-0031.
89624496|NCT03302598|Other|patients with enterocutaneous fistula|
89624497|NCT04883112|No Intervention|No Intervention: ankle dorsiflexion|ankle dorsiflexion pre measurement with bipedestation position, will be performed
89624498|NCT04883112|Experimental|Experimental: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
89624499|NCT04883112|Placebo Comparator|Placebo: ankle dorsiflexion|ankle dorsiflexion post measurement with bipedestation position, will be performed
89624500|NCT03307902|Experimental|Imiquimod + ID HBVv|topical imiquimod + intradermal hepatitis B vaccination
89624501|NCT03307902|Active Comparator|Aqueous + ID HBVv|topical aqueous + intradermal hepatitis B vaccination
89624502|NCT03307902|Active Comparator|Imiquimod + IM HBVv|topical imiquimod + intramuscular hepatitis B vaccination
89624503|NCT04951570||Hematoma Expansion (HE) group|
89038408|NCT02897999|Experimental|MAD Cohort 3|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
89624504|NCT04951570||non-HE group|
89624505|NCT04490772||Patients with Covid-19|COVID-19 patients presented with gastrointestinal manifestations
89624506|NCT05117346|Experimental|To Establish the Safety and Efficacy of CARDIX-101 in Chronic Bradycardia Patients|"Treatment Regimen: A total of 20±4 chronic bradycardia subjects with a heart rate (H.R.) average of less than 60 bpm will be enrolled in the study (6±3/cohort). A clinical study period of 14±2-days is planned for each enrollment of patients.~Route of Administration: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment."
89038409|NCT02897999|Experimental|MAD Cohort 4|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
89038410|NCT01262365|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
89038411|NCT01262365|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
89038412|NCT01262365|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
89038413|NCT03244176|Other|Open-label|Avelumab - Single-arm open label study
89038414|NCT00535665|Experimental|1: 10 ug, 14 days|
89038415|NCT00535665|Experimental|2: 5 ug, 28 days|
89038416|NCT00535665|Experimental|3: 10 ug, 28 days|
89038417|NCT00535665|Experimental|4: 15 ug, 28days|
89038418|NCT03971110|Experimental|Zoladex and Casodex|Subjects who are diagnosed with advanced prostate cancer at clinical stage of T3 and T4 (N0 or N1, M0 or M1 with five or fewer extra-pelvic lesions) are the target population of this study. The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
89624507|NCT05116410|Experimental|HS-20094 (Single dose)|Escalating doses of HS-20094 administered subcutaneously (SC) once in healthy participants.
89624508|NCT05116410|Experimental|HS-20094 (Multiple doses)|Escalating doses of HS-20094 administered SC once weekly for four weeks in healthy participants.
89624509|NCT05116410|Placebo Comparator|Placebo (Single dose)|Placebo administered SC once in healthy participants.
89624510|NCT05116410|Placebo Comparator|Placebo (Multiple doses)|Placebo administered SC once weekly for four weeks in healthy participants.
89624511|NCT05727618|Experimental|pituitrin group|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
89624512|NCT05727618|Placebo Comparator|normal saline group|Intravenous infusion of normal saline at the same dose and speed
89624513|NCT03302364||risperidone patients|patients that are in accordance with DSM-IV-TR schizophrenia diagnostic criteria, based on concise International Neuropsychological Interview(MINI)
89624514|NCT00702702|Experimental|A 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
89624515|NCT00702702|Experimental|B 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
89624516|NCT00702702|Placebo Comparator|C Placebo|Placebo, 2 capsules daily for 3 months
89624517|NCT03307668|Experimental|CaReS-1S|
89624518|NCT03307668|Active Comparator|Microfracture|
89624519|NCT02467920|Experimental|glargine + exenatide|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
89624520|NCT02467920|Active Comparator|aspart 30|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).
89624521|NCT02467218|Experimental|Immediate Hyperbaric Oxygen Treatment|If a participant is randomized to the group receiving the intervention, the participant will be receiving a baseline assessment functional magnetic resonance imaging (fMRI) and subsequently receiving hyperbaric oxygen treatment for 90 minutes, once daily, five times a week for 8 consecutive weeks (40 treatments with 100% oxygen at 2.0 ATA). A follow-up fMRI will be performed after the last day of treatment.
89624522|NCT02467218|Experimental|Delayed Hyperbaric Oxygen Treatment|If the participant is assigned to the cross group, the participant will also receive a baseline assessment functional magnetic resonance imaging (fMRI). However, it will be followed-up in a controlled manner for 3 months. After 3 months, the participant will be receiving hyperbaric oxygen treatment identical to Group A and a follow-up fMRI will be performed after the last treatment.
89624523|NCT03307590|Active Comparator|D group|Dexmedetomidine with bupivacaine group Caudal dexmedetomidine 1.5 microgram/kg with bupivavaine (0.25%) 1.25 ml/kg were administered
89624524|NCT03307590|Active Comparator|B group|Bupivacaine only group Caudal bupivavaine (0.25%) 1.25 ml/kg without dexmedetomidine was administered
89624525|NCT03302208|Active Comparator|pregabalin group|
89624526|NCT03302208|Placebo Comparator|placebo group|
89624527|NCT03307512|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
89624528|NCT03307512|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection
89624529|NCT02466828|Experimental|Single patient group receiving Feraheme®|Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent
89624530|NCT02467998||NPWT treated wounds|NPWT from any FDA cleared NPWT device including
89624531|NCT03307434|Experimental|experimental group|experimental group is composed of athletes will be followed the Athletics Injury Prevention Program
89624532|NCT03307434|Active Comparator|control group|control group is composed of athletes will be continued their regular training
89624533|NCT02721966|Experimental|AIN457 150mg|Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
89624534|NCT02721966|Experimental|AIN457 300mg|Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
89624535|NCT02721966|Placebo Comparator|AIN457 Placebo|Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.
89624536|NCT00553462|Experimental|paclitaxel + carboplatin + radiation + erlotinib|"Patients receive paclitaxel IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses. Patient with rapid disease progression outside of the chest after induction therapy are removed from study.~Patients with intrathoracic disease progression within the potential radiation field may continue protocol therapy at the discretion of the Study Chair. Patients with no disease progression outside the planned radiation field (either regional or distant) proceed to concurrent erlotinib hydrochloride and radiotherapy.~Beginning on day 43 (week 7), patients receive oral erlotinib hydrochloride once daily. Patients also undergo concurrent radiotherapy 5 days a week for up to 7 weeks (33 fractions) in the absence of rapid disease progression outside of the chest or unacceptable toxicity.~After completion of study therapy, patients are followed every 3 months for 1 year, and then every 6 months for up to 2 years"
89624537|NCT03307278|Experimental|Steroid resistance in HDM allergic patients|
89624538|NCT03307278|Experimental|Steroid resistance in non HDM allergic subjects|
88989843|NCT04835129|Experimental|Safety Run-in|Six subjects will be enrolled. Isatuximab (10 mg/kg) intravenous (IV) on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) by mouth (PO) days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
88989844|NCT04835129|Experimental|Expansion|"Forty-seven subjects with relapsed and/or refractory multiple myeloma will be enrolled.~Isatuximab (10 mg/kg) IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles. Pomalidomide (4 mg) PO days 1-21 of each cycle. Elotuzumab (10 mg/kg) on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles. Dexamethasone 40 mg (20 mg if >75 years) PO or IV on days 1, 8,15 and 22 of each cycle."
89688460|NCT03404063|Placebo Comparator|Control Group|Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.
89688461|NCT04347109||Biventricular Pacing|Patients implanted with a device enabling cardiac resynchronization therapy.
89688462|NCT04347109||Right Ventricular Pacing|Patients implanted with a right ventricular pacing device.
89688463|NCT02793856|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 1 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
89624539|NCT02989090|Experimental|Group A (Intervention Group)|Receive Detailed ICD Information-electronic: Receive ICD Patient Notification Summary via MyChart Patient Portal Account - Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
89624540|NCT02989090|Active Comparator|Group B (Intervention Group)|Receive Detailed ICD Information-paper: Receive ICD Patient Notification Summary via paper Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
89624541|NCT02989090|No Intervention|Group C (Control Group)|Receives Standard of Care-No Report Complete baseline, 3 month and 6 months survey
89624542|NCT05727150|Experimental|Patient operated by Supraclavicular Artery flap for Reconstruction|Supraclavicular artery flap will be used for reconstruction
89624543|NCT02988388||Lung biopsy/lobectomy|Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases.
89624544|NCT03307122|Active Comparator|Routine Infant Formula 1|Routine infant formula with probiotic
89624545|NCT03307122|Active Comparator|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
89624546|NCT03306966||Colon cancer patients|Patients with colon cancer (ascending colon) eligible for laparoscopic or open segmental colectomy.
89624547|NCT03301974|Experimental|conjunctival autograft with fibrin glue|Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision
89624548|NCT03301974|Experimental|sutured conjunctival autograft|Sutured conjunctival autograft done for patients of group 2 after pterygium excision
89624549|NCT03301974|Experimental|sutureless and glue-free conjunctival autograft|Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision
89624550|NCT03306888|Experimental|Physical Activity Coaching Intervention|The intervention will entail one face-to-face coaching session (approximately 1 hour) to be held approximately 1 week following the baseline assessment, and three remote video sessions (via secure Webex connection via computer or smart phone, or phone call if internet/smart phone is not available to participant) lasting approximately 20 minutes.
89624551|NCT03306810|Active Comparator|AG service|"In the Active Comparator Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner."
89624552|NCT03306810|No Intervention|Without AG service|"In the No intervention Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital."
89624553|NCT02468388|Experimental|maltitol|
89624554|NCT02468388|Active Comparator|xylitol|
89624555|NCT02468388|Placebo Comparator|gum base|
89624556|NCT02468388|No Intervention|no gum|
89624557|NCT03306732|Active Comparator|Thiamine group|
89624558|NCT03306732|Placebo Comparator|Placebo group|
89038419|NCT02897921||Carriers of recessive gene mutations of myopathies|"Patients with several different kinds of recessively inherited myopathy genes, such as for example Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, Limb Girdle limb girdle muscle dystrophy (LGMD) type 2A and 2L etc.~Investigated by blood sampling, Biodex 4 Isokinetic Dynamometer, MRI analysis, ECG, Holter monitoring, and echocardiography."
89624559|NCT03306654|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
89624560|NCT03306654|Placebo Comparator|Active control|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
89038420|NCT02897921||Healthy controls|Healthy controls, investigated by blood sampling, Biodex 4 Isokinetic Dynamometer and MRI analysis.
89624561|NCT03306654|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
89624562|NCT03306498||hepatic encephalopathy patients|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d for 3 days
89624563|NCT03306498||hepatic encephalopathy patients-amino|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
89624564|NCT02468310|Experimental|Intervention districts|Access to protocols for management of obstetric and neonatal emergencies via text messaging on request in Intervention districts. Maternal and Neonatal emergency protocols
89624565|NCT02468310|No Intervention|Control districts|No access to protocols for management of obstetric and neonatal emergencies via text messaging in control district
89038421|NCT00549432|Experimental|1|
89038422|NCT02897882|Experimental|Lung transplant|Pain evaluation
89038423|NCT03932812|Experimental|Options Counselor Health Educator Intervention Group|These individuals will receive the Options Counselor Health Educator Intervention
89038424|NCT03932812|No Intervention|Control|These individuals will receive the typical standard of care treatment from clinics
89038425|NCT04322266|Experimental|Sequence 1 (Reference-Test)|Period1: HCP1306+HGP0904+HGP0608, Period 2: HCP1701
89038426|NCT04322266|Experimental|Sequence 2 (Test-Reference)|Period1: HCP1701, Period 2: HCP1306+HGP0904+HGP0608
89038427|NCT02897726|Experimental|NVP-1402|NVP-1402 was administered once a day for 24 hours
89038428|NCT02897726|Active Comparator|NVP-1402R|Active comparator was administered twice a day for 24 hours
89038429|NCT03208959|Experimental|Dose level 1|HTI-1090 tablets will be orally administered on an empty stomach,twice daily, BID i.e., dosing will be 12 hours apart and at approximately the same times each day
89038430|NCT03208959|Experimental|Dose level 2|100% Increment from dose level 1
89038431|NCT03208959|Experimental|Dose level 3|100% Increment from dose level 2
89038432|NCT03208959|Experimental|Dose level 4|100% Increment from dose level 3
89038433|NCT03208959|Experimental|Dose level 5|50% Increment from dose level 4
89624566|NCT02809014|Placebo Comparator|Placebo|Dentifrice without fluoride and tara gum.
89624567|NCT02809014|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF) without tara gum. Positive control
89624568|NCT02809014|Placebo Comparator|Dentifrice with tara gum|Dentifrice without fluoride but with hydrocolloid tara gum.
89624569|NCT02809014|Experimental|Dentifrice F-Complex + NaF|Dentifrice experimental with fluoride (1100 ppm) being half of fluoride incorporated in tara gum and other half freeform of NaF
89624570|NCT02809014|Experimental|Dentifrice F-Complex|Dentifrice experimental with fluoride (1100 ppm) all incorporated in tara gum.
89624571|NCT02466594|Other|Hilotherm Clinic®|Intervention: Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
89624572|NCT05726760||Study group - Parturients having spinal anaesthesia|ASA 1 and 2 full term (37-42 weeks), parturients with singleton pregnancy, normal placental position, scheduled for category 4 LSCS under 'single-shot' spinal anaesthesia will be recruited. The investigators intend to recruit 60 parturients. The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. A patient information leaflet will be provided for the parturients.
89624573|NCT05726760||Control group - Parturients not having spinal anaesthesia|6 parturients will be recruited as a control group. ASA 1 and 2 full term (37-42 weeks), parturients with singleton pregnancy, normal placental position, scheduled for category 4 LSCS under 'single-shot' spinal anaesthesia will be recruited.
89624574|NCT03301818|Experimental|Patients undergoing USI repair|
89624575|NCT02468544|Experimental|Single Arm Intervention Study|All participants will receive individualized text messages based on a schedule determined during the development and refinement of the mHealth text messaging intervention (i.e., once or twice a week). All participants will receive text messages for: 1) medication reminders, 2) appointment reminders, and 3) text messages addressing barriers (educational information to improve HIV knowledge) or promoting facilitators (e.g., routinizing taking of HIV antiretroviral medication) of care engagement. Each participant will complete baseline assessments, and will select their preferences for personalized messages on the day of baseline assessments. Text messages will be deployed for the duration of the 30-day trial. Participants will be followed-up at the completion of the 30-day intervention. Each participant will be asked to complete a follow-up survey, including questions on the acceptability of the mHealth intervention.
89624576|NCT04491162|Active Comparator|Conventional gait therapy|Conventional gait therapy.
89624577|NCT04491162|Experimental|BWST training|Conventional gait therapy + Body weight support treadmill training
89624578|NCT04491318||Experimental group|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
89624579|NCT05726526|Experimental|Intervention Group|Participants randomized to the intervention group will be provided with a wireless BP cuff, weight scale, transcutaneous O2 sat monitor, wearable motion tracker and mobile tablet with the VIEWER application. Patients will be trained to use the VIEWER platform either virtually or in person. Patients will be guided through a daily self-assessment routine via the app (BP, weight, O2 saturation, step count upload) and weekly ESAS-r survey. Participants will use the VIEWER platform for 12 months in addition to receiving usual care. Additionally, participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months, and the System Usability Scale (SUS) at 12 months.
89624580|NCT05726526|No Intervention|Control Group|Participants randomized to the control group will continue to receive usual care either virtually via telephone or video call or in person depending on COVID-19 restrictions in place. Participants will complete the UK Kidney PREM score (adapted to CKD) and the Health related QOL using KDQOL-SF via REDCap or paper form at baseline, 3, 6, 9 and 12 months.
89624581|NCT00553150|Experimental|Everolimus (RAD001), Radiation (RT), Temozolomide (TMZ)|"Patients receive oral everolimus and oral temozolomide and 3D-conformal radiotherapy or IMRT as in phase I. Patients will undergo a 4-6 week rest period in course 2 and then proceed to adjuvant therapy.~Adjuvant therapy with everolimus and temozolomide (courses 3-8): Patients receive oral everolimus and oral temozolomide as in phase I.~Adjuvant therapy with everolimus alone (courses 9 and all subsequent courses): Patients receive oral everolimus as in phase I.~All patients undergo fludeoxyglucose (FDG)- or fluorothymidine-labeled PET/CT scans at baseline and periodically during treatment."
89624582|NCT03301584|Active Comparator|Enhanced collaboration|"Enhanced OT and PT collaboration to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
89624583|NCT03301584|Active Comparator|Usual Care Treatment|Standard rehabilitation
89624584|NCT03306186|Experimental|HemoSpec|Diagnosis of sepsis using HemoSpec device
89624585|NCT03301428|Experimental|Retrain pain educational website|Participants will be invited to consult an educational website developped for patients with chronic pain
89624586|NCT03301428|Experimental|Booklet|Participants will be invited to read an educational booklet for patients with chronic pain
89624587|NCT03301428|No Intervention|Control|Participants in this group will receive the 2 educational tools at the end of the study
89624588|NCT03029728||Participants with Hereditary Angioedema|Participants diagnosed with Hereditary Angioedema disease aged between 2 months and 60 years
89624589|NCT03026218|Experimental|Group and Glucose Mama|Enrolled subjects with have GlucoseMama application and group care.
89038434|NCT04322110|Experimental|VLCK diet group|Subjects undergoing treatment with weight loss program PronoKal Method
89038435|NCT04322110|Active Comparator|Control group|Subjects undergoing treatment with low calorie diet
89038436|NCT02897804|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
89038437|NCT02897804|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
89038438|NCT02897804|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks.
89038439|NCT02897804|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus the perceived benefits and self-efficacy modules for a period up to 3 weeks.
89038440|NCT02897804|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
89038441|NCT02897804|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
89038442|NCT02897804|Experimental|Injunctive norms and perceived benefits|Participants will have access to the knowledge module plus the injunctive norms and perceived benefits modules for a period up to 3 weeks.
89038443|NCT02897804|Experimental|Injunctive norms, perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89038444|NCT02897804|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
89038445|NCT02897804|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
89038446|NCT02897804|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
89038447|NCT02897804|Experimental|Descriptive norms,perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
89038448|NCT02897804|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
89038449|NCT02897804|Experimental|Descriptive norms, injunctive norms,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
89038450|NCT02897804|Experimental|Descriptive and injunctive norms, benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
89038451|NCT02897804|Experimental|Descriptive and injunctive norms, benefits,efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89038452|NCT02897804|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
89624590|NCT03026218|Placebo Comparator|Group and No Glucose Mama|Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application.
89624591|NCT03026218|Experimental|Traditional and glucoseMama|Enrolled subjects will have traditional care and glucoseMama
89624592|NCT03026218|No Intervention|Traditional and no GlucoseMama|enrolled subjects will not have access to group care or GlucoseMama.
89624593|NCT03306030|Active Comparator|Split group|Split-dose of 4l PEG was used before and on the day of colonoscopy
89624594|NCT03306030|Experimental|Three times group|Three times-dose of 4l PEG was used before and on the day of colonoscop of 4l PEG was used before and on the day of colonoscopy
89624595|NCT03193996|Other|SLIL Injury|Surgical interventions for all subjects will be determined based on combined findings of both 4DCT and standard arthroscopy.
89038453|NCT02897804|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
89038454|NCT02897804|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
89038455|NCT02897804|Experimental|Expectancies, perceived benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89038456|NCT02897804|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
89038457|NCT02897804|Experimental|Expectancies, injunctive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
89038458|NCT02897804|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
89038459|NCT02897804|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89038460|NCT02897804|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
89624596|NCT02495610|Other|Gait analysis and MRI|"Gait analysis: Intervention: Treadmill with pressure sensors (FDM-THM-M-System (Force distribution method-treadmill); 'Zebris' medical GmbH), study-specific, but routine procedures.~MRI: Intervention: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
89624597|NCT05726448|Experimental|Telehealth solution|Telehealth solution offered
89624598|NCT05726448|No Intervention|Usual care|Control
89624599|NCT04754152|Experimental|TBS Group|On the basis of drug treatment, a course of TBS treatment is performed every three months and 4 courses of treatment a year.
89624600|NCT04754152|Placebo Comparator|Drug Group|Stable doses of cholinesterase inhibitors for the treatment and primary care guidance.Once every 3 months follow-up.
89624601|NCT03141346|Active Comparator|Control|A control health education program to promote general health and safety
89624602|NCT03141346|Experimental|Sugar Reduction Program Only|A health education program that focuses on sugar reduction
89624603|NCT03141346|Experimental|Sugar Reduction Program & Water Delivery|A health education program that focuses on sugar reduction and provides home bottled water delivery
89624604|NCT04630834|Active Comparator|Intervention group|Intervention Group: ibuprofen 10 mg/kg (maximum 600mg) plus acetaminophen 15mg/kg (maximum 650mg)
89624605|NCT04630834|Placebo Comparator|Placebo Group|Placebo Group: Ibuprofen 10mg/kg (maximum 600 mg) plus placebo 15mg/kg (maximum 650mg)
89624606|NCT03301350|Experimental|Neoadjuvant Chemotherapy|"Regimen A (cycles 1-4):~Paclitaxel 80 mg/m2; administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Carboplatin AUC=2 (dose calculation by determining creatine clearance with Cockroft Gault using adjusted body weight); administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks)~Regimen B (cycles 5-8):~Doxorubicin 60 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Cyclophosphamide 600 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Pegfilgrastim (for use on Doxorubicin/Cyclophosphamide cycles only), filgrastim, or biosimilar support on day 2 - 3 of cycles 5, 6, 7, 8 (every 2 weeks)~There is a one week break between the end of cycle 4 and the beginning of cycle 5.~Regimen C:~Surgical intervention for management of breast cancer diagnosis; procedure and timing as determined by surgical team."
89624607|NCT04737304|Experimental|Dose Regimen Low Dose|Low Dose Strength
89624608|NCT04737304|Experimental|Dose Regimen High Dose|High Dose Strength
89624609|NCT04737304|Placebo Comparator|Placebo|Placebo
89624610|NCT02466750|Experimental|Primary vaccine|Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
89038461|NCT02897804|Experimental|Expectancies, descriptive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
89038462|NCT02897804|Experimental|Expectancies, descriptive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
89624611|NCT02466750|Experimental|Booster series|Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 < 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of < 1:40 for a maximum of 4 booster doses in a year. If the titer remains < 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is < 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is < 1:40, the subject will be considered to have completed the study as a nonresponder.
89624612|NCT03301194||RAMP-HT patients|HT patients who have enrolled into the RAMP-HT between 1 October 2011 and 31 March 2012 and fulfilled the inclusion criteria and without any exclusion criteria
89624613|NCT03301194||Usual care patients|HT patients receiving usual care in GOPCs who have never enrolled into RAMP-HT on or before 31 March 2017 and fulfilled the inclusion criteria and without any exclusion criteria
89624614|NCT04735432|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
89624615|NCT04735432|Experimental|efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
89624616|NCT02722278|Experimental|Oral Testosterone Undecanoate|Approximately 135 subjects will receive oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).
89624617|NCT02722278|Active Comparator|Axiron Testosterone Topical Solution|Subjects randomly assigned to the Axiron treatment group will begin treatment at a dose of 60 mg every morning.
89624618|NCT03024034|Active Comparator|Cohort A|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)
89624619|NCT03024034|Active Comparator|Cohort B|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)
89624620|NCT03024034|Active Comparator|Cohort C|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)
89038463|NCT02897804|Experimental|Expectancies,descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89038464|NCT02897804|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and injunctive norms modules for a period up to 3 weeks.
89038465|NCT02897804|Experimental|Expectancies, descr& injun norms, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
89038466|NCT02897804|Experimental|Expectancies, desc & injun norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
89038467|NCT02897804|Experimental|Expectancies,desc & injun norms,benefits,efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89038468|NCT02889250|Experimental|Open Label DBS|6 months of DBS
89038469|NCT02889016||PANS group|500 children, 1-18 years old at onset with a strict diagnosis of PANS/PANDAS will be recruited
89038470|NCT02889016||Health Controls|100 healthy children age- and gender- matched to the PANS group will be recruited
89038471|NCT02889094||HIV-HBV co-infected individuals|No interventions will be administered. Individuals will be undergoing routine care.
89038472|NCT02897687|Experimental|Facebook Group|Social skills training within an online group.
89624621|NCT03024034|Active Comparator|Cohort D|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)
89624622|NCT03024034|Active Comparator|Cohort E|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)
89624623|NCT03024034|Active Comparator|Cohort F|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)
89210990|NCT03907683|Experimental|Random Messaging|Participants receive 0-5 messages/day from the Random AIM app. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages are selected randomly from three content domains: Move More (40%), Sit Less (40%), and Inspirational Quotes Unrelated to Movement (20%). Half of the messages are accompanied by images. Message selection and timing are determined randomly each night for the following day.
89210991|NCT00929604|No Intervention|Standard of care|Standard of care arm: utilizes the current standard of care per Zambian national guidelines to determine treatment failure and eligibility for second-line ART. HIV-1 viral load measurement is performed if the criteria for either immunologic (i.e., CD4+ lymphocyte count-based) or clinical treatment failure are fulfilled. If both immunologic and clinical treatment failure criteria are fulfilled, the ART regimen is changed to second-line without VL testing.
89210992|NCT00929604|Experimental|Routine HIV-1 viral load testing|Routine viral load testing arm: Routine HIV viral load testing at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30 and 36 months thereafter.
89210993|NCT02549534||Women with Breast Cancer (WBC)|"Defined as women who:~Are 18 to 85 years old at the time of enrollment;~Have histologically-confirmed, first-time, non-metastatic breast cancer (Stage I-IIIB);~Have no history of neurotoxic chemotherapy or radiation treatment at the time of enrollment;~Will be receiving weekly paclitaxel (Taxol® or generic paclitaxel), 80-100mg/m2, or bi-weekly (i.e., dose-dense) Taxol, 175 mg/m2, as a part of their treatment regimen OR~Will be receiving an anthracycline and cyclophosphamide (AC) therapy followed by weekly or bi-weekly (i.e., dose-dense; 175 mg/m2) paclitaxel (Taxol® or generic paclitaxel, 80-100mg/m2);~Are willing to participate in up to four study sessions."
89210994|NCT02549534||Healthy Female Controls (HCs)|"Defined as women who:~Are 18 to 85 years old at the time of study enrollment;~Can read, write, and understand English,~Are willing to participate in three planned study sessions."
89210995|NCT04173195|Experimental|Intervention arm|The CT intervention will be administered by the nurse in charge of the chemotherapy 5 min after the initiation. the CT content will be partially script.
89210996|NCT04173195|No Intervention|No intervention arm|Patients assigned to this arm will received current care.
89210997|NCT00929682|Experimental|Levobupivacaine 0.568mg.mL|
89210998|NCT00929682|Other|Levobupivacaine 1.136mg.mL|
89533405|NCT04759586|Experimental|Arm F (R-CHOP, nivolumab, radiation therapy)|Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
89533406|NCT04752774|Experimental|Dose escalation|One single administration of study medication (IPN10200, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.
89533407|NCT04752774|Experimental|Dose ranging|"Two fixed doses of IPN10200 will be administrated as a single injection into several muscle groups of the upper limb.~Participants will be randomised in the ratio of 3:3:2 (total IPN10200 dose 1: 30 participants; total IPN10200 dose 2: 30 participants; Dysport: 20 participants)"
89533408|NCT04752774|Experimental|Total dose|"One single injection of study medication will be administered locally into several muscle groups of the upper limb.~Participants will be randomized in the ratio of 2:1 (Total IPN10200 dose: 30 participants; placebo: 15 participants, resulting in a total of 45 participants in Stage 3).~Or~Participants will be randomized in the ratio of 3:1 (IPN10200 lower dose: 30 participants; placebo: 10 participants, then IPN10200 higher dose: 30 participants; placebo: 10 participants, resulting in a total of 80 participants in Stage 3)."
89533409|NCT04751760||People with sensitization or allergy|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
89533410|NCT04743999|Experimental|Quality of life evaluation|This prospective arm will consist of evaluating quality of life outcomes in women in women with advanced endometrial cancer undergoing adjuvant concurrent chemotherapy with carbo/Taxol and radiation therapy. Assessments will occur following surgery (baseline), 3, 6, 12, and 24 months.
89533411|NCT04743661|Experimental|Recurrent Medulloblastoma|This arm aims to estimate event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 131I-omburtamab in patients with recurrent medulloblastoma. Patients with recurrent medulloblastoma will undergo surgery if feasible prior to study entry, followed by Induction Chemotherapy with irinotecan, temozolomide, and bevacizumab on study as per the Children's Oncology Group (COG) trial ACNS0821. Following 2 or 4 courses of chemotherapy and if radiographic disease status is stable or improved, patients will receive 2 therapeutic doses of 50 mCi cRIT 131I-omburtamab during Radioimmunotherapy. Following Radioimmunotherapy, patients may resume to Maintenance Chemotherapy with irinotecan, temozolomide, and bevacizumab for up to 12 total courses of chemotherapy or until disease progression, whichever occurs sooner.
89533412|NCT04743661|Experimental|Recurrent Ependymoma|This is a feasibility cohort. The primary objective is to assess feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma and to assess dosimetry. Patients must have progressed after initial surgery, radiation therapy, or other therapies. Patients will undergo surgery (if feasible) prior to study entry with the goal of achieving stable or better disease. Tumor tissue (archived or new) will be tested for B7H3 prior to enrollment. If positive, patients will enroll on Stratum 2 and receive one dosimetry dose (2 mCi) of cRIT 131I-omburtamab with nuclear medicine scintigraphy using SPECT during the Dosimetry Course (14 days in length). Following the Dosimetry Course and within 2 weeks of the dosimetry dose, patients may continue to Radioimmunotherapy to receive 2 therapeutic doses (50 mCi) of cRIT 131I-omburtamab.
89533413|NCT04724330|Experimental|Healthy for Two/Healthy for You (H42/H4U)|Those assigned to the intervention group will receive the H42/H4U health coaching intervention during pregnancy and 12 weeks postpartum.
89533414|NCT04724330|No Intervention|Usual Care Comparison Group: Maintain Health in Pregnancy (mHIP)|Those assigned to the Usual Care comparison group, mHIP, will receive typical, evidence- and guideline-based experience in the prenatal care clinics.
89533415|NCT04717414|Experimental|Experimental Arm: Luspatercept (ACE-536)|Luspatercept will be given to participants via subcutaneous injection (administered on Day 1 of each 21-day treatment cycle)
89624624|NCT03024034|Active Comparator|Cohort G|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)
89624625|NCT03305952|Experimental|Compassion|CBCT was facilitated in an eight weekly, 2-h sessions format through didactics, class discussion, and guided meditation practice. Topics covered in order were: Week 1: Developing attention stability and mental clarity. Week 2. Open awareness of sensations, feelings, and emotions. Week 3: Self-Compassion. Week 4: Practice in impartiality and cultivation of social connection. Week 5: Practice in appreciation, gratitude, social interconnection, and interdependence. Session 6: Practice in affection (endearment) for developing undifferentiated affection for others. Week 7: Development of the aspirational wish that all beings be happy and free from suffering and its causes. Week 8: Active compassion
89038473|NCT02897687|Active Comparator|Book Club Group|An in-person Book Club discussing material related to Autism Spectrum Disorder.
89038474|NCT01262287|Experimental|dutasteride|dutasteride (1 mg oral daily dose) for 8-week treatment period
89624626|NCT03305952|Active Comparator|Treatment as usual|Treatment as usual (TAU) consisted of usual periodical visits to psycho oncologist based on hospital's regular calendar. Hospital's standard treatment was applied to participants. The standard treatment consists of counselling interventions, cognitive-behavioural interventions, family interventions, third generation interventions.
89624627|NCT03305718|Experimental|Meal sequence: 3C1A2B4D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3C1A2B4D."
89038475|NCT01262287|Placebo Comparator|Placebo|placebo daily for 8-week treatment period
89038476|NCT02897609||A simple questionary filled|
89038477|NCT01262092|Active Comparator|Gabapentin|Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.
89038478|NCT01262092|Placebo Comparator|Placebo|Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening
89038479|NCT04322071||Lower risk of long term complications|Young people with diabetes who have HbA1c <58mmols/mol, and family members.
89038480|NCT04322071||Higher risk of long term complications|Young people with diabetes who have HbA1c ≥75mmols/mol and <100mmols/mol, and family members.
89038481|NCT03455946|Experimental|Interventional|DASH Cloud with Alexa
89624628|NCT03305718|Experimental|Meal sequence: 2A3D4C1B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2A3D4C1B."
89038482|NCT00553670||1|Patients with elective coronary intervention for LAD-diagonal bifurcation lesion with provisional side branch intervention strategy with successful intravascular ultrasound and fractional flow reserve measurement
89038483|NCT03165279||Patient with AAA|Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.
89038484|NCT04680962|Experimental|MabionCD20 / MabionCD20|Patients receive one or two treatment courses of MabionCD20, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
89038485|NCT04680962|Active Comparator|EU-Rituximab / EU-Rituximab|Patients receive one or two treatment courses of MabThera®, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26.
89038486|NCT04680962|Active Comparator|US-Rituximab / MabionCD20|Patients receive a single treatment course of Rituxan®, consisting of two 1000 mg i.v. infusions at Day 1 and Day 15. After 24 weeks of follow-up, all patients eligible for re-treatment, are switched to receive a single treatment course of MabionCD20, consisting of two 1000 mg i.v. infusions at Week 24 and Week 26.
89038487|NCT01261975|Experimental|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial microincision
89038488|NCT01261975|Active Comparator|Coaxial Small Incision Cataract Surgery|2.75 mm standard incision
89038489|NCT02897531|Active Comparator|ES anastomosis|Stapled end-to-side anastomosis
89038490|NCT02897531|Active Comparator|SS anastomosis|Stapled side-to-side anastomosis
89038491|NCT00549471|Experimental|BG|cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment. BG children will be given Botulinum Toxin A, as clinically required, in addition to an equivalent program of intensive therapy
89038492|NCT00549471|No Intervention|Control Group|control group: Twenty cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment.CG children will undergo a program of intensive therapy.
89038493|NCT01261780|Sham Comparator|Sham device|Sham therapy device to area of painful chemotherapy induced peripheral neuropathy (CIPN) for 45 minutes daily x 10 days
89038494|NCT01261780|Active Comparator|MC-5A treatment|MC-5A therapy to the area of painful CIPN for 45 minutes daily for a total of 10 days.
89038495|NCT02897843|Sham Comparator|sham tDCS|Sham tDCS sessions will last 20 minutes, but a real stimulus of 2 milliamps (mA) will be applied only during the first minute
89038496|NCT02897843|Experimental|tDCS|20 minute tDCS sessions
89038497|NCT03088410|Experimental|Nevirapine|150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis
89038498|NCT03088410|Active Comparator|Zidovudine|150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis
89038499|NCT03088410|No Intervention|HIV- unexposed Uninfected (HUU) Infants|150 HIV- unexposed Uninfected (HUU) Infants
89038500|NCT02897765|Experimental|Drug: NEO-PV-01 + Nivolumab + Adjuvant|Nivolumab at a dose of 240 mg administered by intravenous (IV) infusion over 30 minutes every two weeks. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with nivolumab.
89038501|NCT02897570|Active Comparator|Glucose|EEG_pre + Oral glucose tolerance test (50-g OGTT) + EEG_post
89038502|NCT02897570|Experimental|Milk + Cereals|EEG_pre + B1: milk (125ml) and cereals (30g) + EEG_post
89038503|NCT02897570|Experimental|Milk + Apple + Snack|EEG_pre + B2: milk (220ml), apple (200g) and cream chocolate filled sponge cake (30g) + EEG_post
89038504|NCT02897570|Experimental|Milk + Apple + Bread w/ cream|EEG_pre + B3: milk (125ml), apple (150g), and bread (50g) with hazelnut chocolate cream (15g) + EEG_post
89624629|NCT03305718|Experimental|Meal sequence: 2D4B3A1C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2D4B3A1C."
89038505|NCT04686162|Experimental|Group using the smartphone application bae|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months.
89038506|NCT02897180|Placebo Comparator|Placebo|Subjects will receive a total of 14 capsules with Placebo
89038507|NCT02897180|Experimental|Nyaditum resae(R)|Subjects will receive a total of 14 capsules with Nyaditum resae(R)
89038508|NCT02897102|Active Comparator|Control group|The individuals in the control group chose to participate in different group activities: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants). The activities were offered once per week in 2 hours classes for 35 weeks and were held between April and November of 2013.
89038509|NCT02897102|Experimental|Training group|was offered in one weekly class for 2 hours for 35 weeks between April and November of 2013. The first 50 minutes were spent performing exercises with the abacus, with increasing difficulty. One or two of the following activities followed the abacus training: playing games, neurobic and group dynamics.
89038510|NCT01261624|Experimental|Givinostat 1.0 mg/kg daily|
89038511|NCT01261624|Experimental|Givinostat 1.5 mg/kg daily|
89624630|NCT03305718|Experimental|Meal sequence: 3B2C1D4A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3B2C1D4A."
89038512|NCT02887911||Asthmatic, not taking inhaled steroids|Men/Women, ages 18-75 who are not currently taking corticosteroids.. No intervention; this is a prospective observational study.
89038513|NCT02887911||Asthmatic, taking inhaled steroids|Men/Women, ages 18-75 who are already taking corticosteroids prescribed by their physician. No intervention; this is a prospective observational study.
89624631|NCT03305718|Experimental|Meal sequence: 4C2B1A3D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4C2B1A3D."
89624632|NCT03305718|Experimental|Meal sequence:1B4D3C2A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1B4D3C2A."
89038514|NCT02887911||Healthy, non-asthmatic without allergies|Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
89038515|NCT02887911||Healthy, atopic non-asthmatic|Men/Women, ages 18-75 with allergies but without a current diagnosis of asthma. No intervention; this is a prospective observational study.
89038516|NCT02888938||Patients suspected of SpA|
89038517|NCT04322032|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
89038518|NCT04322032|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
89038519|NCT04320082||Elderly cohort|Patients >70 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
89038520|NCT04320082||Young cohort|Patients between 18 and 30 undergoing elective orthopaedic or trauma surgery under general anaesthesia.
89038521|NCT02897258||Without anticoagulant/antiplatelet|
89624633|NCT03305718|Experimental|Meal sequence:4A1C2D3B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4A1C2D3B."
89624634|NCT03305718|Experimental|Meal sequence:1D3A4B2C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1D3A4B2C."
89038522|NCT02897258||Treated with antiplatelet only|
89038523|NCT02897258||Treated with anticoagulant only|
89038524|NCT02897258||With antiplatelet/anticoagulant|
89624635|NCT03305718|Experimental|Meal sequence: 4D3B2C1A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4D3B2C1A."
89624636|NCT03305718|Experimental|Meal sequence: 3A4C1B2D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3A4C1B2D."
89624637|NCT03305718|Experimental|Meal sequence: 1C2A3D4B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1C2A3D4B."
89038525|NCT03711331|Experimental|FilmArray® Pneumonia panel plus strategy|patients benefiting from the new strategy based on the system Unyvero ®
89038526|NCT03711331|Sham Comparator|Standard care|patients benefiting from usual standard care
89038527|NCT02887053|Experimental|All subjects|All subjects will have an MRI examination
89038528|NCT04321798|Experimental|Physical Activity|Promoting Engagement in Physical Activity
89038529|NCT05532982||Parkinson's disease patients|
89038530|NCT05532982||Parkinson's disease patients' care-givers|
89038531|NCT05532982||Clinicians|
89038532|NCT05532982||Community stakeholders|
89038533|NCT02897336|Experimental|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
89038534|NCT02897336|Active Comparator|interlaminar|interlaminar epidural corticosteroid injection
89038535|NCT04321642|Experimental|Entonox|Inhalation Entonox in active phase of labor ( cervical dilatation more than 5 cm ) Inhaled Entonox before true uterine contraction in 30 sec , inhaled in 4-5 times for 1 contraction
89038536|NCT04321642|Active Comparator|Not receive Entonox|Not receive any gas when archive in active phase of labor( cervical dilatation more than 5 cm )
89038537|NCT02897219|Experimental|Part 1 ASP1941|ASP1941 will be administered for 24 weeks under double blind conditions.
89038538|NCT02897219|Placebo Comparator|Part 1 Placebo|Placebo will be administered for 24 weeks under double blind conditions.
89038539|NCT02897219|Experimental|Part 2 ASP1941|ASP1941 will be administered for 28 weeks under open label conditions.
89038540|NCT04321603|Other|People living with HIV|Subjects will act as own control between Visit one and Visit two, then will complete six weeks of walking, 30 minutes per walk, three times weekly between Visit Two and Visit Three.
89038541|NCT02882685|Active Comparator|RYGB|Roux-en-Y gastric bypass
89038542|NCT02882685|Active Comparator|SAGB|Single anastomosis gastric bypass
89038543|NCT04321720|Experimental|3-g footbath|Footbath with 3g mustard flour per liter of water
89038544|NCT04321720|Experimental|6-g footbath|Footbath with 6g mustard flour per liter of water
89038545|NCT04321720|Experimental|12-g footbath|Footbath with 12g mustard flour per liter of water
89038546|NCT04321720|Placebo Comparator|Warm water footbath|Footbath with warm water only
89038547|NCT04321837|Active Comparator|Coral calcium complex and ibandronate|
89624638|NCT03305718|Experimental|Meal sequence: 2B1D4A3C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2B1D4A3C."
89624639|NCT03300960|Experimental|Provera|
89624640|NCT03300960|Active Comparator|Orgalutrán Ganirelix (GnRH antagonist)|
89624641|NCT04583254|Experimental|Arm 1 EBRT+High-dose (HDR) Brachytherapy Experimental|
89624642|NCT04583254|Active Comparator|Arm 2 EBRT+High-dose (HDR) Brachytherapy Standard of Care|
89624643|NCT02964442|Experimental|Capsinoids|8 gel capsules equivalent to 12mg
89624644|NCT02964442|Experimental|Cooling Vest|Using Cooling vest (at approxiamately14 degrees Celsius) to cool the body.
89624645|NCT04768582|Experimental|Efient group|ACS patients who received oral Prasugrel after coronary angiography been done
89624646|NCT03300882||CMV+ First Lung Transplant Recipients|Participants enrolled in one of four North American sites in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who are cytomegalovirus positive by serology (e.g., CMV Recipient positive).
89624647|NCT02485444|Active Comparator|Oxytocin|
88989845|NCT04825743|Experimental|zalunfiban Dose 1 (0.110 mg/kg)|Subjects will receive a single subcutaneous injection containing zalunfiban Dose 1 (0.110 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
88989846|NCT04825743|Experimental|zalunfiban Dose 2 (0.130 mg/kg)|Subjects will receive a single subcutaneous injection containing zalunfiban Dose 2 (0.130 mg/kg) in the ambulance after diagnosis of STEMI and before hospital arrival
88989847|NCT04825743|Placebo Comparator|Placebo|Subjects will receive a single subcutaneous injection containing Placebo in the ambulance after diagnosis of STEMI and before hospital arrival
88989848|NCT04808843||Dienogest|Patients with endometriosis who have been prescribed with Dienogest.
88989849|NCT04808453|Experimental|CPI-300|Dose Escalation Group: CPI-300 will be administered via intravenous infusion once every 2 weeks for up to 6 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design
88989850|NCT04807764|Experimental|Real transspinal stimulation delivered during standing followed by locomotor training|Transspinal tonic stimulation of the thoracolumbar region will be delivered at a frequency of 30 Hz during standing with as needed body weight support (BWS) in a standing frame or in the Lokomat to ensure safety.
88989851|NCT04807764|Experimental|Real transspinal stimulation delivered while lying supine followed by locomotor training|Transspinal tonic stimulation will be delivered at a frequency of 30 Hz while lying supine.
89624648|NCT02485444|No Intervention|Observation|
89624649|NCT03300726||MCI due to AD or mild AD dementia|The clinical diagnoses of amnestic MCI due to AD or mild AD dementia will be made according to standard clinical criteria as described by the National Institute of Aging -Alzheimer's Association Working Group and supported by CSF biomarker data for tau, p-tau181, and Aβ42. This includes evaluation for other systemic or neurological disorders which could account for the cognitive impairment, and inclusion of results from ancillary structural imaging (CT or structural MRI), neuro-psychometric testing, and FDG-PET imaging (when available) into the diagnostic scheme. All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
89624650|NCT03300726||Normal controls|Normal cognition will be defined as cognitive performance on detailed neuropsychometric testing that falls within 1 SD of age-, gender-, and education-matched norms in all cognitive domains, and no subjective report of cognitive decline from an individual's baseline (i.e. CDR 0). All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
89624651|NCT04490538||Critically ill patients|Critically ill patients hospitalised at the intensive care unit indicated to echocardiographic examination.
89624652|NCT04490304|Other|posterior soft tissue repair durability|
88989852|NCT04807764|Sham Comparator|Sham transspinal stimulation delivered during standing followed by locomotor training|One sham group will be receiving transspinal stimulation during standing at an intensity where sensation is absent.
88989853|NCT04797897|Experimental|CORI UKA|Subjects in need for unicondylar knee arthroplasty (UKA) as decided by their doctor and treated with CORI.
88989854|NCT04797897|Active Comparator|Conventional UKA|Subjects in need for unicondylar knee arthroplasty (UKA) as decided by their doctor and treated with conventional approach with conventional manual instrumentation.
88989855|NCT04794595||sepsis group with CBP|The child with sepsis should be treated with CBP， but could not receive this treatment for various reasons
88989856|NCT04794595||sepsis group without CBP|The child with sepsis should be treated with CBP and received this treatment
88989857|NCT04793841||General population|sexually experienced adults (aged 18 or above) of the randomly selected household
88989858|NCT04793841||men who have sex with men|men who have sex with men aged 18 or above and normally living in Hong Kong
89038548|NCT04321837|Active Comparator|Ibandronate and vitamin D|
89038549|NCT04321837|Active Comparator|Coral calcium complex|
89038550|NCT02897414||Overall group of all ER/LA opioid excluding hydrocodone|
89038551|NCT02897414||Each type of opioid that has an ER/LA opioid formulation|
89038552|NCT02897414||Overall group that includes all prescription opioids except|
89038553|NCT02897414||Comparator Group taking benzodiazepines|
89038554|NCT02897414||Comparator Group taking IR hydrocodone|
89624653|NCT03305484||Symptomatic Contact Lens Wearers|Contact lens wearers who present to the eye care practitioner's office with a symptomatic red eye
89624654|NCT02468076|Experimental|Radiofrequency ablation (StarMed)|Radiofrequency ablation catheter
89624655|NCT04428346|Active Comparator|Contigency Management (Intervention)|
89057366|NCT04542746|Active Comparator|Conventional open flap debridement with papilla preservation|The intra-bony defects of control group were treated using a combination of conventional open flap debridement with papilla preservation (COFD+PP) and EMD.
89624656|NCT04428346|No Intervention|Standard of Care (Control)|
89624657|NCT04490694|Experimental|TACE Combined with Lenvatinib|
89624658|NCT02988310||Individuals with below knee limb loss|Individuals with below knee limb loss will be participants of the group.
89624659|NCT02988310||Individuals with above knee limb loss|Individuals with above knee limb loss will be participants of the group.
89624660|NCT02988310||Healthy individuals|Healthy individuals will be participants of the group.
89624661|NCT02988076|No Intervention|Control|The Control group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Treatment/Experimental group. A clinician treating a Control Group subject will NOT receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
89624662|NCT02988076|Active Comparator|Treatment|Intervention - Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report - Treatment group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Control group. A clinician treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
89624663|NCT02359474|Experimental|Trabectedin with regional hyperthermia|"Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.~Additional treatment with regional hyperthermia (RHT): RHT treatment of the tumor area and the surrounding tissue (41-44°C for 60 min treatment time) is applied at the end of Trabectedin infusion (+/- 4 hrs)."
89624664|NCT02359474|Active Comparator|Trabectedin|Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.
89624665|NCT02467686|Active Comparator|Cimicifuga racemosa|"The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.~Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
89624666|NCT02467686|Placebo Comparator|Control|"Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
89624667|NCT02987608|No Intervention|Control Phase (No Power Up)|60 young people will receive CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires will be administered three months later.
89624668|NCT02987608|Experimental|Intervention Phase (Power Up)|60 young people use Power Up alongside CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires and a Power Up feedback form will be administered three months later.
89624669|NCT05707962|Experimental|intervention group|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
89038555|NCT02858934|Experimental|preoperative tomotherapy|This study is an open study investigating the effect on quality of life of a very short preoperative radiotherapy for early breast cancer, including approximately 24 women. Radiotherapy will be performed in 1 week and before the surgery in stead of following surgery.Preoperative radiotherapy has the advantage that the tumor is visible on imaging. This can result in smaller boost volumes. The surgery will follow shortly after termination of the radiotherapy, resulting in a very short treatment period.
89038556|NCT02897453||The Spinal Tethering System group|Patients with adolescent idiopathic scoliosis that have been implanted with the Spinal Tethering System in an anterior vertebral body tethering construct.
89038557|NCT02896829||Imatinib treatment ending|Interruption of the treatment by Imatinib
89038558|NCT02854566||periprosthetic fractures of the femur|periprosthetic fractures of the femur treated by osteosynthesis
89038559|NCT00549666|Experimental|Lurasidone 40 mg|
89038560|NCT00549666|Placebo Comparator|Placebo|
89038561|NCT00549666|Active Comparator|Ortho Tri-Cyclen|
89057367|NCT01648257|Experimental|GSK1265744 Na Salt Tablets|Subjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water.
88989859|NCT04788693|Experimental|Motor imagery and gait training group|"Gait training twice a week for six weeks. Each rehabilitation session is composed of an initial 5 minutes of warm-up exercises (general mobility, coordination, strength, flexibility, balance, and breathing), followed by 45 minutes of gait training with motor imagery exercises and a final 10 minutes of muscle stretching.~In the central 45 minutes of the session, exercises will be developed to improve objective characteristics of the gait-related to spatiotemporal and kinematic parameters. Objective and subjective feedback will be used for each exercise. In an interspersed way, motor imagery exercises will be carried out where participants must rehearse or simulate mentally each gait exercise that will be developed in the session."
89533416|NCT04717414|Placebo Comparator|Control Arm: Placebo|Placebo starting dose with volume equivalent to experimental arm subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
89533417|NCT04707534|Experimental|Dexamethasone 20 mg|Dexamethasone 20 mg daily for 5 days, followed by dexamethasone 10 mg daily for 5 days
89533418|NCT04707534|Active Comparator|Dexamethasone 6 mg|Dexamethasone 6 mg daily for 10 days
89533419|NCT04703075|Experimental|Rifapentine 600 mg and Isoniazid 300 mg|Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.
89533420|NCT04703075|Active Comparator|Rifapentine 900 mg and Isoniazid 900 mg|Participants will receive Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.
89533421|NCT04701983|Experimental|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
89533422|NCT04701983|Experimental|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
89533423|NCT04701983|Placebo Comparator|Placebo|SC administration of matching placebo Q2W for up to 52 weeks
89533424|NCT04670172||Chronic rhinosinusitis patients|Adult chronic rhinosinusitis patients capable of using a mobile application.
89533425|NCT04666610|Experimental|Brivaracetam 200 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
89533426|NCT04666610|Experimental|Placebo to 200 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period."
89533427|NCT04666610|Experimental|Brivaracetam 100 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
89533428|NCT04666610|Experimental|Placebo to 100 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period."
89533429|NCT04666610|Experimental|Optimal dose of BRV (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment Period (AT):~Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period."
89533430|NCT04666610|Experimental|Placebo to BRV optimal dose (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period."
89533431|NCT04666610|Experimental|Brivaracetam received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period."
89533432|NCT04666610|Experimental|Placebo received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks."
89533433|NCT04651777|Experimental|Participants with poorly controlled moderate to severe asthma|Participants with poorly controlled moderate to severe asthma will be evaluated during and after a six week trial of triple therapy (ICS/LABA/LAMA) for changes in 129Xe MRI ventilation percent defect, pulmonary function measurements.
89533434|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
89533435|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
89533436|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 3|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
89533437|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 4|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
89533438|NCT04643457|Experimental|Part A: Intravenous UCB9741 arm 5|Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.
89533439|NCT04643457|Experimental|Part A: Subcutaneous UCB9741 arm 1|Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.
89533440|NCT04643457|Experimental|Part A: Subcutaneous UCB9741 arm 2|Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.
89533441|NCT04643457|Placebo Comparator|Part A: Intravenous Placebo arm|Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.
89533442|NCT04643457|Placebo Comparator|Part A: Subcutaneous Placebo arm|Subjects randomized to this arm will receive subcutaneous Placebo to maintain the blinding.
89533443|NCT04643457|Experimental|Part B: Intravenous UCB9741 arm|Subjects randomized to this arm will receive pre-specified intravenous doses of UCB9741.
89624670|NCT05707962|No Intervention|non intervention group|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
89624671|NCT02218840||Behavioral|Evaluation of cigar smoking topography
89624672|NCT03305328|Experimental|Active|Participants within the Active condition receive 30 minutes of alpha-frequency Transcranial Alternating Current Stimulation (tACS) stimulation for four consecutive days. Participants are stimulated at their baseline peak alpha frequency, or the frequency at which they exhibit maximal power within the 8 to 12 Hz range. Stimulation was administered over occipitoparietal sites, where tACS current models showed maximal effect over the dorsal extrastriate.
89624673|NCT03305328|Sham Comparator|Sham Control|Participants within the Sham condition receive 30 minutes of sham Transcranial Alternating Current Stimulation for four consecutive days, during which no current was passed. To control for awareness of the Sham stimulation, all Sham control participants receive a brief, 10 second pulse of random noise stimulation at the beginning and end of the 30 minutes.
89624674|NCT04350346|Active Comparator|The patient group who taken Motilitone|
89624675|NCT04350346|Active Comparator|The patient group who taken Gasmotin|
89624676|NCT00703092|Experimental|Fiber-Stat|2 tablespoons daily
89624677|NCT03305172|No Intervention|Control|Subjects in the Control treatment are not given any financial incentive to achieve the goal.
89624678|NCT03305172|Experimental|Gain Treatment|Financial Incentive: Each subject in the Gain treatment will earn a certain amount of money for each day the goal is achieved. The money earned will be added to a virtual account that the subject has, and will be paid to the subject at the end of the intervention period.
89624679|NCT03305172|Experimental|Loss Treatment|Financial Incentive: Each subject in the Loss treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. For each day that the subject does not achieve the goal, a small portion of that money will be deducted from the virtual account. The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
89624680|NCT03305172|Experimental|Gain Streak Treatment|Financial Incentive: Each subject in the Gain Streak treatment get an increasing amount of money added to his/her virtual account for every continuous day that they achieve the goal. The maximum cumulative amount per week is same as in the other treatment conditions. The payment is reset at the beginning of each week, or if the subject misses the goal on any day. The money in the virtual account will be paid to the subject at the end of the intervention period.
88989860|NCT04788693|Active Comparator|Gait training group without motor imagery|"Gait training twice a week for six weeks. Each rehabilitation session is composed of an initial 5 minutes of warm-up exercises (general mobility, coordination, strength, flexibility, balance, and breathing), followed by 45 minutes of gait training with motor imagery exercises and a final 10 minutes of muscle stretching.~In the central 45 minutes of the session, exercises will be developed to improve objective characteristics of the gait-related to spatiotemporal and kinematic parameters. Objective and subjective feedback will be used for each exercise. In the periods that the experimental group performs the motor imagery exercises, the control group will take breaks."
88989861|NCT04787471|Active Comparator|30 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes
88989862|NCT04787471|Active Comparator|10 minute photoactivation|photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes
88989863|NCT04779138|Experimental|Increasing Uptake of COVID-19 Vaccination|"This is a pre-experimental one group pretest-posttest design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our ACTIVATE triad leaders and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention."
88989864|NCT04770402|Experimental|Acupuncture|
88989865|NCT04770402|Active Comparator|Standard of Care|
88989866|NCT04768634|No Intervention|Observation|Patients will be observed for arrhythmias and treated if they occur.
88989867|NCT04768634|Experimental|Testing|Patients will undergo provocative electrophysiology testing, and antiarrhythmic medication considered if arrhythmias can be induced.
88989868|NCT04762979|Experimental|Alpelisib + Aromatase Inhibitor or Fulvestrant|Subjects will be treated with Alpelisib in combination with either an Aromatase Inhibitor or Fulvestrant per Standard of Care
88989869|NCT04743778|Experimental|Virtual Diabetes Self-Management Education and Support|Participants will receive one hour of DSME/S delivered by a Certified Diabetes Care and Education Specialist (CDCES) per week for 10 weeks delivered via the Zoom for Health at U-M service may be used for Protected Health Information (PHI, regulated by HIPAA). To ensure treatment fidelity, three DSME/S sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
88999219|NCT03004404|Experimental|BA Part: T2/R/T1|"Participants were orally administered 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~Followed by 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
89533444|NCT04643457|Placebo Comparator|Part B: Intravenous Placebo arm|Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.
89533445|NCT04643405|Experimental|APG1387 in combination with Gemcitabine and Nab-Paclitaxel|
89533446|NCT04630392|Experimental|Intervention Group|There are two intervention groups: treadmill walking only, whole-body vibration plus treadmill walking.
89533447|NCT04616014|Experimental|ORMD-0801 QD|16 mg QD, daily, in the morning (two capsules of ORMD--801, 8 mg each
89533448|NCT04606966|Experimental|Therapeutic Horseback Riding|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills as outlined in the study's THR manual, . Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table before class, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for one minute while watching a 1-minute timer. Participants will then don their riding helmets and enter the riding arena. Each week after conclusion of the THR intervention, participants will again sit with their group at an art table for 5 minutes followed by doing another saliva sample.
89533449|NCT04606966|Active Comparator|Barn Activity|This Arm is a 10 week one hour small group (2-4 participants) led by a THR instructor and co-led by a mental health or Occupational therapy provider. Participants will have one assigned volunteer and will have no physical contact with horses at the riding center, just view horses from a distance. There will be a life-sized stuffed toy horse for hands-on learning related to the weekly topic per the BA study manual. Group times will be between 1:00-5:00 PM to collect salivary cortisol. Weekly, participants will follow a consistent routine of wearing both their electro dermal activity and heart rate monitoring devices, sit at a group art table before class, after this, study personnel will instruct participants to place the 10cm long foam swab rod under their tongue for one minute while watching a 1-minute timer. Each week after conclusion of the BA intervention, participants will again sit with their group at an art table for 5 minutes followed by doing another saliva sample.
89533450|NCT04606966|No Intervention|Waitlist|Those assigned to the waitlist group will not have any horse-related intervention during a 10-week waiting period. Following this waiting period and the completion of post assessments, participants in this condition will begin a Hybrid group (see Hybrid Arm)
89533451|NCT04606966|Experimental|Hybrid|Participants completing the Wait list Arm and post assessments, will begin a Hybrid group between 1:00-5:00 PM. The group consists of a 5- week 1 -hour BA small group (2-4 participants) led by a THR instructor and co-led by a mental health counselor or OT. Participants will have one assigned volunteer and have no physical contact with horses at the riding center, just view horses at a distance. There will be a life-sized stuffed horse for hands-on learning weekly topics per BA study manual. Group. Then, participants will complete 5-weeks of Therapeutic Horseback Riding small group (2-4 participants) led by a THR instructor. The group will include a 45-minute mounted activity to learn horsemanship skills followed by a 15-minute unmounted horse grooming and tacking activity per THR manual. Participants will have an assigned horse and volunteer(s).
89533452|NCT04603443|Experimental|BCAA 20g/daily|Branched Chain Amino Acids, 10g BID x 12 weeks
89533453|NCT04603443|Experimental|BCAA 40g/daily|Branched Chain Amino Acids, 20g BID x 12 weeks
89533454|NCT04603443|Experimental|BCAA 60g/daily|Branched Chain Amino Acids, 30g BID x 12 weeks
89533455|NCT04603443|Placebo Comparator|Placebo 20g/daily|Protein without BCAA, 10g BID x 12 weeks
89533456|NCT04602767|Experimental|Vasopressin|Low dose vasopressin as first line vasopressor in cardiac surgery.
89533457|NCT04602767|Experimental|Phenylephrine|Low dose phenylephrine as first line vasopressor in cardiac surgery
89533458|NCT04598893||Teplizumab|Participants who received teplizumab in the PROTECT study
89533459|NCT04598893||Placebo|Participants who received placebo in the PROTECT study
89533460|NCT04586023|Experimental|Fenebrutinib|Participants will receive oral fenebrutinib with teriflunomide-matching placebo.
89533461|NCT04586023|Active Comparator|Teriflunomide|Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.
89533462|NCT04580446|Experimental|Hypofractionated radiotherapy with concurrent chemotherapy (weekly cisplatin 40 mg/m2)|"Level 0: 46.5 Gy in 15 fractions, 5 fractions/week~Level -1: 52 Gy in 20 fractions, 5 fractions/week"
89533463|NCT04577651|Experimental|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with a 16-contact Directional Lead
89533464|NCT04576117|Active Comparator|Efficacy Phase Arm II (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
89533465|NCT04576117|Experimental|Feasibility & Efficacy Phase Arm I (selumetinib, vinblastine)|Patients receive vinblastine sulfate IV over 1 minute or IV infusion on days 1, 8, 15, and 22 and selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days. Patients receive selumetinib and vinblastine for a total duration of 17 cycles followed by 10 additional cycles of selumetinib alone in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial. Patients also undergo blood sample collection during screening and on study.
89533466|NCT04569591|Experimental|1|patients aged 8 or older with Cushing's Disease who are surgical candidates for resection of ACTH producing pituitary adenoma within 12 weeks of PET imaging
89533467|NCT04563507|Active Comparator|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
89533468|NCT04563507|Active Comparator|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
89533469|NCT04563039|Experimental|Ureteroscopic Laser Lithotripsy with Acoustic Enhancer|Ureteroscopic Laser Lithotripsy with Acoustic Enhancer
89533470|NCT04563039|Active Comparator|Standard Ureteroscopic Laser Lithotripsy|Standard Ureteroscopic Laser Lithotripsy
89533471|NCT04562467|Experimental|Icosapent Ethyl + Standard of Care|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] 2 x 1g capsules BID (4g total) as per REDUCE-IT
89038562|NCT04680806|Experimental|Er,Cr:YSGG laser 2780 nm|Group A was treated by an Er,Cr:YSGG laser 2780 nm cylindrical tip (tip 600 μm, 45 millijoule /pulse, average power 2.25 W, frequency 50 Hz, pulse duration 60 µs, energy density 43 J/cm2, water 50%, and air 40%). The procedure was performed completely without anesthesia with the laser tip at angulation ~30° and distance of ~1 mm from the gingival tissue. The laser tip was advancing in scanning movement from in the cervical-apical direction in all pigmented areas. The following settings was used to achieve hemostasis in case of the bleeding was present (tip 600 μm, 30 millijoule /pulse, average power 1.5 W, frequency 50 Hz, pulse duration 700 µs, energy density 28.7 J/cm2, water 10%, and air 20%).
89038563|NCT04680806|Experimental|Diode laser 940 nm|Group B was treated with diode 940 nm Laser. The procedure was performed with a pencil-sized handpiece containing a 400 µm lasing fiber (400 μm initiated tip, average power 0.8 watts, Pulsed mode, Duty cycle 20%, Pulse duration 10 μs, energy density 636.9 J/cm2 per second, no water or air). Infiltration anesthesia was injected for B group . The laser tip was placed in angle ~30° with the gingival surface. Short light paint brush strokes were used in the cervical-apical direction in all pigmented areas.
89038564|NCT04680767|Experimental|[¹⁴C]-LY3502970|A single dose of LY3502970 and [¹⁴C]-LY3502970 administered orally.
89038565|NCT00551538|Active Comparator|1|Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
89038566|NCT00551538|Active Comparator|2|Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.
89038567|NCT04680494|Experimental|Rest|Participants rest quietly for 30 minutes, sitting on a chair. They may read magazines not involving motion-related elements
89038568|NCT04680494|Experimental|Moderate intensity exercise|Participants cycle on a cycle ergometer during 30 minutes at 65% of their maximal cardiac frequency
89038569|NCT04680494|Experimental|High intensity exercise|Participants cycle on a cycle ergometer during 15 minutes at 75% of their maximal cardiac frequency. This session also includes 3 minutes of warm-up and three minutes of cool down at 50% of their maximal cardiac frequency
89038570|NCT00551577|Active Comparator|A1|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
89624681|NCT03305172|Experimental|Loss Streak Treatment|Financial Incentive: Each subject in the Loss Streak treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. An increasing amount of money will be deducted for each consecutive day the subject does not achieve the goal. The payment is reset at the beginning of each week, or when the subject achieves the goal (i.e., deductions are reset when the streak is broken). The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
89624682|NCT05697822|Experimental|Mobile Phone and Cloud-based Electronic Contact and Recording System|In this arm pregnant women will be given a smart mobile-phone with an application installed which will have their detailed health-related information. They will be able to use this application to input their daily symptoms. This will also contain results of examinations or investigations that they have undergone in a clinic. All this information will be stored in a cloud and the healthcare worker at the local health post will also be able to access this information in their mobile phone and keep track of the pregnant women under their care. In the event of a concerning symptom, the health worker will be flagged. The health coordinators in the rural municipality will also be able to keep track of the pregnant women in their area through a cloud-based database.
89038571|NCT00551577|Experimental|A2|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
89624683|NCT05697822|No Intervention|Usual Standard of Care Arm|Pregnant women will visit the health posts or hospitals for antenatal checks routinely as advised. Their records will be kept in paper-based forms and registers. They will not be tracked regularly by their healthcare provider by electronic means. Their daily symptoms will not be recorded anywhere. They will still be able to contact their healthcare providers or visit the health centers if necessary. They will not have a personal electronic health record. No one will keep active track of the pregnant women through electronic means.
89624684|NCT01968538||Prostate Cancer Patients|Prostate cancer patients who underwent radiation therapy
89624685|NCT01968538||Healthy control|age-matched male who has no known prostate cancer
89624686|NCT03300414||Collection of blood specimen|Collection of blood specimen from patients will be performed during the course of routine medical care at UC Davis with no prospective follow up period. The duration anticipated to enroll all 10 study subjects will be 1 year. The estimated date for the investigator to complete analysis and publication is 2 years.
89624687|NCT03300414||Liver Biopsy slides|Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
89624688|NCT04058470|Experimental|TR follow by R-CHOP|"TR follow by R-CHOP:~TR: Toripalimab,Rituximab, R-CHOP: Rituximab, Cyclophosphamide,Doxorubicin,Vincristine,Prednisone"
89038572|NCT04931901|Experimental|Stimpod NMX450X|
89038573|NCT04931901|Active Comparator|Datex-Ohmeda E-NMT|
89038574|NCT04207645||African|patients originating from Nigeria and Sudan (11 centres)
89038575|NCT04207645||Latin American|patients originating from Mexico (5 centres)
89038576|NCT04207645||South Asian|patients originating from India and Pakistan (10 centres)
89038577|NCT04207645||European|patients originating from Spain (11 centres).
89038578|NCT05512585|Active Comparator|awake prone positioning with room air|Participants will stay in the prone position
89038579|NCT05512585|Experimental|awake prone positioning with high-flow nasal cannula|Participants will stay in the prone position and breathe with high-flow nasal cannula
89533483|NCT04497974|Active Comparator|Regular dietary sweetness exposure - Control|Regular dietary sweetness exposure (RSE) - The RSE group consumes a diet with 25 - 30 % energy from sweet tasting foods, for 6 months.
89038580|NCT05512585|Experimental|awake prone positioning with continuous positive airway pressure|Participants will stay in the prone position and breathe with continuous positive airway pressure via face mask
89533484|NCT04497974|Experimental|Low dietary sweetness exposure - Experimental|Low dietary sweetness exposure (LSE) - The LSE group consumes a diet with 10 - 15 % energy from sweet tasting foods, for 6 months.
89533485|NCT04497974|Experimental|High dietary sweetness exposure - Experimental|High dietary sweetness exposure (HSE) - The HSE group consumes a diet with 40 - 45 % energy from sweet tasting foods, for 6 months.
89533486|NCT04494490|No Intervention|Usual Care Condition|"During the usual care condition the therapists will be instructed to act as usual, that is, to read the guidelines on low back pain if they have read previous published guidelines and not read these guidelines if they have not read any other guidelines."
89533487|NCT04494490|Active Comparator|CPG+PIPT Condition|An active Clinical Practice Guidelines (CPG) implementation strategy will be utilized with an education component in Psychologically Informed Physical Therapy (PIPT) with peer opinion leaders and a monthly audit/feedback on CPG adherence rates and patient outcomes
89624689|NCT05696808|Experimental|Indian hepatoprotective diet (IHPD)|The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
89624690|NCT05696808|Active Comparator|Western Diet|The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
89624691|NCT02467530|Experimental|AGE diet|Dietary intervention consistent of consuming low amounts of (AGEs).
89624692|NCT02467530|No Intervention|Original diet|Patients will continue their original diet.
89624693|NCT02467296|Active Comparator|A: 1.5 gr of Sodium|Meal Plans with 1.5 gr of Sodium
89624694|NCT02467296|Active Comparator|B: 3 gr of Sodium|Meal Plans with 3 gr of Sodium
89624695|NCT03300102||Patients with suspected or confirmed renal cell carcinoma|Patients with suspected or confirmed renal cell carcinoma who have consented will either donate tissue, or complete a structured questionnaire or a semi-structured interview. Not all patients will have all three interventions, each patient must have at least one.
89624696|NCT02720484|Experimental|Treatment (Nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity.
89038581|NCT05512585|No Intervention|supine position with room air|Participants will stay in the supine position
89533472|NCT04562467|No Intervention|Standard of Care|Standard of care therapy (including statin therapy as per inclusion criteria)
89038582|NCT05512585|Active Comparator|supine position with high-flow nasal cannula|Participants will stay in the supine position and breathe with high-flow nasal cannula
89038583|NCT05512585|Active Comparator|supine position with continuous positive airway pressure|Participants will stay in the supine position and breathe with continuous positive airway pressure via face mask
89038584|NCT02896790||Stage 1|Patients without therapeutic education
89038585|NCT02896790||Stage 2|Patients with therapeutic education
89533473|NCT04536220||pancreatic mass diagnosed benign|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.
89533474|NCT04536220||pancreatic mass diagnosed malignant|Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.
89533475|NCT04522791|Experimental|RFB+VSOP (MCI)|"For home-based RFB+VSOP: The investigators will instruct subjects to do 10-minutes of app- guided paced breathing at RF daily; for select days, there will be VSOP training immediately following RFB.~A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions."
89533476|NCT04522791|Active Comparator|IR+VSOP (MCI)|The control IR strategy will be used, set-up of which will be the same as the RFB + VSOP intervention group with IR replacing RFB. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
89533477|NCT04522791|Placebo Comparator|IR only (MCI)|Participants randomized to this condition will receive weekly in-person check-in visits, and perform daily 10-minute IR, so that the number of treatment contacts (though not duration) will be equivalent. A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions.
89533478|NCT04522791|Other|RFB+VSOP (HC)|"this is a new healthy control intervention arm used for testing adherence related items.~For home-based RFB+VSOP: The investigators will instruct subjects to do 10-minutes of app- guided paced breathing at RF daily; for select days, there will be VSOP training immediately following RFB.~A total of 8 weeks intervention. The investigators will extend the intervention for additional two weeks for make-up sessions."
89533479|NCT04501406|Active Comparator|Pioglitazone|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving pioglitazone 15mg/day.
89533480|NCT04501406|Placebo Comparator|Placebo|Two arm, randomized, double-blind, placebo-controlled, 72 week treatment study receiving placebo.
89533481|NCT04500158|Experimental|Local anesthesia|Participants will receive local anesthesia in addition to the standard care general anesthesia
89533482|NCT04500158|No Intervention|Standard care|Participants will receive standard care general anesthesia
89624697|NCT05438550|Active Comparator|14-day bismuth-containing quadruple therapy (BQT)|14-day bismuth-containing quadruple therapy (BQT) Nexium (Esomeprazole, Astrazeneca Pharmaceutical Co., LTD.) 20mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
89624698|NCT05438550|Experimental|14-day Tegoprazan high-dose dual therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid
89624699|NCT03299868|Experimental|Routine PICC group|PICC is initially routine insertion at the time of admission of hospice-palliative care unit
89624700|NCT03299868|Active Comparator|General IV group|PICC is inserted if 3 or more times of IV insertion trial per day is required for IV access
89624701|NCT05403684|No Intervention|Usual-volume breastfeeding (UV Group)|Infants will receive cup-feeding (to standardize the volume at each feeding) per standard of care guidelines (SOC: 140-180 mL/kg/day) with volumes adjusted for weight and infant age.
89624702|NCT05403684|Experimental|High-volume breastfeeding (HV Group)|Along with SOC volume provided via cup-feeding, the mother will continue to express and feed the baby hind-milk reaching 240 mL/kg/day with volumes adjusted for weight and infant age (200-240 ml/kg/day).
89624703|NCT02466282|Active Comparator|Angiography-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
89624704|NCT02466282|Experimental|OCT-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
89624705|NCT03299790|Active Comparator|training group 1: HIIT|high-intensity interval exercise training group (T2DM patients)
89624706|NCT03299790|Active Comparator|training group 2: MIT|moderate-intensity exercise training group (T2DM patients)
89624707|NCT03299790|No Intervention|Detraining period|Follow-up: detraining of group 1 and 2 (T2DM patients)
89624708|NCT03299790|No Intervention|Healthy controls|
89624709|NCT03299712|Other|ArteFill|This post-approval study will evaluate the continuing safety of ArteFill® as an injectable implant for correction of nasolabial folds over the course of five years post implantation, with a focus on determining the incidence of granuloma formation. Incidence of adverse events and subject satisfaction with respect to the subject's personal expectations will be assessed.
89624710|NCT05388396||PIMS-TS patients|Pediatric patients with PIMS-TS admitted to the PICU in selected time period
89624711|NCT05382858|Experimental|PSA-STN|Participants randomized in this arm will receive bilateral PSA stimulation in the first two months in the randomized phase and then will be crossovered to the bilateral STN stimulation for another two months.
89624712|NCT05382858|Experimental|STN-PSA|Participants randomized in this arm will receive bilateral STN stimulation in the first two months in the randomized phase and then will be crossovered to the bilateral PSA stimulation for another two months.
89624713|NCT03299556||WHT|The WHT group includes only patients newly enrolled in the Geisinger MPP program who consent to participate in the study. WHT subjects will be recruited over 1 year, with 1 year of follow-up.
89624714|NCT03299556||Historic Control|Patients who were enrolled in the MPP in the preceding year. These patients received the MPP educational program but received no WHT as part of their treatment.
89624715|NCT03299556||Concurrent Control|Patients being treated for chronic pain in the Geisinger Medical Pain Management (MPM) program over the same time period as the WHT group. These subjects do not receive the MPP educational program nor use WHT as part of their treatment
89624716|NCT05352204||micronecrosis(+) group|
89624717|NCT05352204||micronecrosis(-) group|
89624718|NCT02466438|Experimental|Piperacillin-tazobactam|"Piperacillin-tazobactam administration (fixed combination, ratio piperacillin:tazobactam = 8:1).~Recruitment stratified by age group and pediatric populations to ensure good representation of those subgroups. Maximum dose: 16g/day. Treatment duration: up to 14 days depending to the treating physician.~Patients with Normal Renal function:~Pediatric and surgery units: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Pediatric intensive care unit (PICU): 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Haematology-oncology unit: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Patients with Acute Kidney injury:~Pediatric and surgery units: 2 months-6 years (10)~PICU: 2 months-6 years (10)~Haematology-oncology unit: 2 months-6 years (10)"
89624719|NCT05587062|Experimental|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) 2 mg (0.05 mL) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study
89624720|NCT05587062|Active Comparator|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) 2 mg (0.05 mL) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study
89624721|NCT05322876|Experimental|Healthy Hearts Family Program|Participants will be enrolled in the standard Healthy Hearts Family Program 6-month family-based cardiovascular disease prevention program.
89624722|NCT03299400|Experimental|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
89624723|NCT02464566|Experimental|L Group|"Weekly individual session in obesity clinic (15 to 20 min.) for the first 4 weeks then one individual session in obesity clinic (10 to 20 min.) every two weeks (week 5 to week 12).~Total sessions in 12 weeks: 8 (including the final data collection visit). The components of the program:~1) Low carbohydrate (aim to achieve spontaneous reduction in calorie intake) 2) increased physical activity; 3) behavioural strategies to facilitate adherence to diet and activity prescriptions."
89624724|NCT02464566|Active Comparator|C Group|One session regarding diet restriction and physical activity with printed health education papers.
89624725|NCT05516004|Experimental|PXL 330|Participants will receive riboflavin 0.25% solution (Peschke TE), one drop every minute for 25 minutes to the eye, followed by UVA light 9mW/cm2 continuous mode for 10 minutes
89624726|NCT05257512|Experimental|Phase I/II Study of SY-3505|SY-3505 will be given orally in ascending doses (escalation cohort), until the DLT or RP2D is reached. Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose. In phase II, SY-3505 will be given at RP2D in advanced ALK-positive NSCLC patients.
89624727|NCT04489680|Experimental|Surgical Trainees undergoing Cleft Palate Training|26 UK specialty trainees performed a vomerine mucosal flap and intra-velar veloplasty in a one-hour workshop. Pre- and post-simulation questionnaires assessing cleft knowledge and surgical confidence were compared for statistical significance.
89624728|NCT02463006|Experimental|porous bone graft group|Intervention: Flap surgery procedure with porous bone grafting (Periooglass)
89624729|NCT02463006|Active Comparator|Non-porous bone gaft group|Intervention: Flap surgery procedure with non-porous bone grafting (Novabone morsels)
89624730|NCT02463084|Experimental|Low Diet|Diet intervention consisting of foods with low saturated fats, low glycemic index and low salt
89624731|NCT02463084|Experimental|High Diet|Diet intervention consisting of foods with high saturated fats, high glycemic index and high salt
89624732|NCT04756908|Experimental|Opira AIOL|
89624733|NCT04756908|Active Comparator|Monofocal AIOL|
89624734|NCT04756908|Active Comparator|Multifocal AIOL|
89624735|NCT02466204|Active Comparator|corifollitropin alfa (long action FSH)|corifollitropin alfa 150 mcg subcutaneous injection. Seven days after, combines with recombinant FSH 300 IU daily subcutaneous injection
89624736|NCT02466204|Active Comparator|Follitropin Beta (recombinant FSH)|300 IU of recombinant FSH, daily subcutaneous injection
89624737|NCT02462694|Active Comparator|Treatment as Usual|Treatment as usual (TAU): Standard psychological, psychopharmacology and case management services
89624738|NCT02462694|Experimental|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT): weekly individual sessions, skills training group and telephone coaching as needed
89038586|NCT04207528|Experimental|Peer Helping Condition|Participants in the peer helping condition will be asked to write about their experiences in their first-year at UCLA (freshman or first-year after post-transfer), with an emphasis on using the experience to benefit someone who is about to be a first-year student.
89038587|NCT04207528|Active Comparator|Facts-only Control|Participants in the facts-only writing condition will be asked to write facts about their experiences in their first-year at UCLA (freshman or first-year post-transfer). Unlike the previous conditions, they will not be instructed to write for the benefit of another individual.
89624739|NCT02715804|Experimental|PAG: PEGPH20 + nab-Paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (μg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m^2) nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
89624740|NCT02715804|Placebo Comparator|AG: Placebo + nab-Paclitaxel + Gemcitabine|Participants will receive placebo matching to PEGPH20 as an IV infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 mg/m^2 nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
89624741|NCT04749264||Mindfulness Meditation Retreat|6 to 7-days mindfulness meditation retreat
89624742|NCT04749264||No intervention, Matched control|Adults participants will be recruited from social media and local community of meditation practitioners, and will be matched to the retreat group by gender, age and level of experience in meditation.
89624743|NCT02466360||chronic lower back pain|
89624744|NCT04745130|Experimental|Intervention arm 1|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
89624745|NCT04745130|Experimental|Intervention arm 2|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
89624746|NCT02462616||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
89624747|NCT04490226|Experimental|fasting, active|36 hours fasting, PAL 1.6
89057368|NCT01648257|Experimental|GSK1265744 Free Acid Nanomilled Capsules|Subjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
89624748|NCT04490226|Experimental|ketogenic diet, active|24 hours of ketogenic diet (liquid meals), PAL 1.6
89624749|NCT04490226|Experimental|exogeneous ketone bodies, active|24 hours of ketone body supplements (Beta-Hydroxybutyrate as Ca-Mg-salt) additional to a normal diet (liquid meals), PAL 1.6
89624750|NCT04490226|Experimental|fasting, inactive|36 hours fasting, PAL 1.3
89624751|NCT02464800||Higher cutting rate group|Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy
89624752|NCT02464800||Conventional cutting rate group|Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy
89624753|NCT02462304|Experimental|Combination Anti-VEGF and EPM laser|Subjects will receive both anti-VEGF injections and EPM laser.
89624754|NCT02462304|Active Comparator|Anti-VEGF monotherapy|Subjects will receive anti-VEGF injections monotherapy.
89624755|NCT04489602||Intervention|Each patient complete ObsQoR-10F questionnaire 3 times (before delivery, on Day 1, on Day 2)
89624756|NCT05140200|Experimental|Cohort 1: Participants receiving GSK3511294 at Dose level 1|
89624757|NCT05140200|Experimental|Cohort 2: Participants receiving GSK3511294 at Dose level 2|
89624758|NCT05133102||Control|Patients who have undergone an endoscopy within the last three years and have never been diagnosed with Barrett's esophagus.
89624759|NCT05133102||Barrett's Esophagus|Patients who have undergone an endoscopy within the last three years and have histologically confirmed Barrett's esophagus. BE segment must be M>1cm, and has not be treated with endoscopic eradication therapy (focal mucosal resection without subsequent eradication therapy is allowed).
89624760|NCT02466048|Experimental|SurgiFill™ on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
89624761|NCT02466048|Active Comparator|Autograft on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
89624762|NCT02465970|Experimental|TDCS session|Intervention : Stimulation is applied during a 60 min session with STARSTIM
89624763|NCT02465970|Placebo Comparator|TDCS Placebo|Intervention : Stimulation is not applied during a 60 min session with STARSTIM
89624764|NCT04662372||Patients|Patients
89624765|NCT02465892|No Intervention|Standard Care|Subjects in this group will continue receiving standard care from their provider team.
89624766|NCT02465892|Experimental|Pillars4Life|Subjects in this group will complete the Pillars4Life online coping skills curriculum.
89624767|NCT02465814|Experimental|Arm 1 - BAY1002670 + BAY1002670|Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
89624768|NCT02465814|Experimental|Arm 2 - Placebo + BAY1002670|Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
89624769|NCT02465814|Experimental|Arm 3 - BAY1002670 + BAY1002670|Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)
89624770|NCT02465814|Experimental|Arm 4 - Placebo+BAY1002670|Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)
89624771|NCT02465814|Active Comparator|Arm 5 - Ulipristal + Ulipristal|Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
89624772|NCT02465814|Active Comparator|Arm 6- Placebo + Ulipristal|Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
89624773|NCT02465814|Active Comparator|Arm 7- Ulipristal + Placebo|Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)
89624774|NCT04645212||1|Subjects with wet AMD who received any dose of ADVM-022 in a prior clinical study.
89624775|NCT05093244|Experimental|SeQuent Please ReX|Drug coated balloon (DCB) catheter.
89624776|NCT05093244|Active Comparator|Plain old balloon angioplasty (POBA)|
89624777|NCT04617132||Online Mindfulness Group|Families with PPDA receiving evidence-based MBCT/MBSR intervention
89624778|NCT04489446|Experimental|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
89624779|NCT04489446|Placebo Comparator|Control|Patients allocated to this arm will receive a placebo that will be similar in form to sildenafil pills in the interventional arm. These doses will be scheduled every 8 hours and wil be administered orally por up to seven consecutive days.
89624780|NCT03198234|Experimental|Cohort 1|Participants will receive 1 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
89624781|NCT03198234|Experimental|Cohort 2|Participants will receive 3 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
89624782|NCT03198234|Experimental|Cohort 3|Participants will receive 9 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
89624783|NCT02717832|Experimental|Insulin Sensitivity|
89624784|NCT02717754|Experimental|Oseltamivir 100 mg|Participants will receive 100 mg oseltamivir intravenous BID for 5 days.
89624785|NCT02717754|Experimental|Oseltamivir 200 mg|Participants will receive 200 mg oseltamivir intravenous BID for 5 days.
89624786|NCT02717754|Placebo Comparator|Placebo|Participants will receive oseltamivir matched placebo intravenous BID for 5 days.
89624787|NCT04550676|Experimental|High intensity interval training|
89624788|NCT04550676|Active Comparator|Continuous moderate intensity exercise|
89624789|NCT03197142||Out-of-hospital cardiac arrest|All the patients who suffered an out-of-hospital cardiac arrest in the Lombardia Region
89624790|NCT03136848|Experimental|Normothermic perfusion|Kidneys retrieved from deceased donors will undergo the study intervention consisting of 4-10 hours of Normothermic ex-vivo perfusion using a blood-based solution, prior to implantation in the transplant recipient
89624791|NCT05040750||moderate to severe COVID 19 patients|moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed
89624792|NCT04705350|Experimental|Zampilimab Cohorts|Participants will be randomized to receive predefined single doses of zampilimab.
89624793|NCT04705350|Placebo Comparator|Placebo|Participants randomized to this arm will receive matching Placebo to maintain the blinding.
89624794|NCT04467606|Experimental|Experimental|The experimental group will receive a discharge planning which use the strategy of motivational interviewing.
89624795|NCT04467606|No Intervention|Control|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
89624796|NCT02717130|Experimental|Aripiprazole (Abilify Maintena)|Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
89624797|NCT04956198||Patients with newly diagnosed as well as relapsed/refractory sarcomas.|The investigators intend to enroll newly diagnosed or refractory/relapsed pediatric patients with all types of sarcomas where tumor tissue would be available for ex vivo drug screening and genomic profiling. This observational study will assess how ex vivo drug testing and mutation profiling may predict clinical outcomes (response, survival, or relapse). The treating physician will decide which of the standard treatment options is appropriate independent of the DST results. The results of DST will not be available to the treating physician at the time of decision on the treatment regimen. DST will include all drugs from the standard treatment regimens available for all types of sarcomas
89624798|NCT02256696|Experimental|Arm 1|PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
89038588|NCT04319848|Experimental|TE-EK treatment group|The TE-EK surgery will be performed by the Principle Investigator with a standard DSAEK technique. The PI has performed over 300, EK surgeries and we have previously shown that the corneal endothelial loss rates from the PI are 16% at 1 year with a primary graft failure rates of <1.5%. A patient's participation in the study or not will not change the treatment strategy in any manner.
89624799|NCT02256696|Experimental|Arm 2|PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
89624800|NCT02256696|Active Comparator|Arm 3|Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
89624801|NCT02464488||Main cohort (only cohort of the study)|Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban because atrial fibrillation. All patients will have plasma drug concentrations measured and will be followed afterwards similarly
89624802|NCT02331498|Other|A Pazopanib|Open label study with one group
89624803|NCT02192502|Experimental|HES 130/0.4 (Voluven)|6% HES 130/0.4 during surgery
89624804|NCT02192502|Active Comparator|human albumin 5%|human albumin 5% during surgery
89624805|NCT01781429|Experimental|BVD-523|
89624806|NCT01773473|Experimental|Insulin Lispro Mix25|Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
89624807|NCT01773473|Experimental|Insulin Lispro Mix50|Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.
89624808|NCT01772693|Experimental|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR guided Focused Ultrasound
89624809|NCT01772693|Sham Comparator|Sham ExAblate Transcranial MRgFUS|Sham treatment with ExAblate MR guided Focused Ultrasound
89624810|NCT01779869|Experimental|Single group assignment - imaging|All patients will undergo PET-MR myocardial perfusion imaging during rapid intravenous administration of 0.4 mg regadenoson.
89624811|NCT01772537|No Intervention|Open repair of thoracoabdominal aneurysms|These will be patients undergoing an open repair of thoracoabdominal aneurysms with or without cardiopulmonary bypass. The will be observational only.
89624812|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms isoflurane|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive isoflurane as their primary anesthetic.
89624813|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms propofol|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive propofol as their primary anesthetic.
89624814|NCT04572581|Experimental|Exclusively Human Milk Diet|This group will receive human milk only. If the mother is not producing enough breast milk, this group will receive donor milk supplementation.
89624815|NCT04572581|No Intervention|Formula-based Diet|If the mother is not producing enough breast milk, this group will receive formula supplementation (the standard of care).
89624816|NCT01772147|Experimental|Umeclidinium bromide|Long-acting muscarinic antagonist (LAMA)
89624817|NCT01772147|Active Comparator|Fluticasone propionate/Salmeterol|Inhaled corticosteroid (ICS)/Long-acting beta agonist (LABA)
89624818|NCT01771913|Sham Comparator|centrifuged fat graft|female patients who underwent breast reconstruction and present with volume insufficiency will undergo centrifuged fat graft for contour and volume refinements.
89624819|NCT01771913|Active Comparator|ADSCs enriched centrifuged fat graft|female patients who underwent breast reconstruction and present volume insufficiency will undergo ADSCs enriched fat grafting for volume and irregularity contour improvement
89624820|NCT01606787|Experimental|mannitol arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
89624821|NCT01606787|Placebo Comparator|placebo arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
89624822|NCT01778855|Active Comparator|Normothermia|IV t-PA and normothermia
89624823|NCT01778855|Active Comparator|Hypothermia|IV t-PA and hypothermia
89624824|NCT04570319|Experimental|Probiotic Bths-08|a capsule containing the probiotic blend (nutritional complement)
89624825|NCT04570319|Placebo Comparator|Placebo|a capsule containing placebo comparator
89624826|NCT01777997|Experimental|FTC/RPV/TDF|
89038589|NCT02897024|Active Comparator|Usual weekly|Usual weekly physical therapy is 1 hours of therapy one day per week for 40 weeks.
89038590|NCT02897024|Experimental|High intensity periodic|High intensity periodic physical therapy is 2 hours of therapy 5 days a week for 2 weeks, followed by an 18 week break, followed by another bout of high intensity therapy for 2 hours of therapy every weekday for two 10-consecutive-weekdays, followed by another 18 week break from therapy.
89624827|NCT01770509|Active Comparator|Standard of care|Standard of care: Dressings +Compression garments
89624828|NCT01770509|Experimental|Application of NMBM|Daily application of NMBM
89624829|NCT01770353|Experimental|Pilot Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle
89624830|NCT01770353|Experimental|Expansion Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis
89624831|NCT01777763|Experimental|Posaconazole 200 mg|Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
89624832|NCT01777763|Experimental|Posaconazole 300 mg|Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days
89624833|NCT01769339|Experimental|Miconazole plus Hydrocortisone|
89624834|NCT01769105|Active Comparator|Standard Lid Hygiene Regime|Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
89624835|NCT01769105|Active Comparator|Lipiflow|Patients receive a singe Lipiflow-treatment
89624836|NCT01777139|Experimental|Retigabine IR|All subjects will initially receive a starting dose of retigabine IR at 900 mg/day and after the first week of the OLE study, the dose of retigabine IR may be increased or decreased in increments or decrements of decrements of 150 mg/day on weekly basis based on efficacy and tolerability. The overall daily dose of retigabine IR must be maintained between a minimum dose of 600 mg/day and a maximum dose of 1200 mg/day.
89624837|NCT01768637|Experimental|Chronic Kidney Disease|Patients with pre-dialysis stages 4-5 Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
89624838|NCT01768637|Active Comparator|Normal controls|Patients without Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
89624839|NCT01768559|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to Week 26 on top of insulin glargine with or without metformin.
89624840|NCT01768559|Active Comparator|Insulin Glulisine QD|Insulin glulisine QD from randomization up to Week 26 on top of Insulin glargine with or without metformin.
89624841|NCT01768559|Active Comparator|Insulin Glulisine TID|Insulin glulisine thrice daily (TID) from randomization up to Week 26 on top of Insulin glargine with or without metformin.
89624842|NCT00983619|Experimental|Part A-MEDI-551 0.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624843|NCT00983619|Experimental|Part A-MEDI-551 1 mg/kg|Participants will receive IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624844|NCT00983619|Experimental|Part A-MEDI-551 2 mg/kg|Participants will receive IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624845|NCT00983619|Experimental|Part A-MEDI-551 4 mg/kg|Participants will receive IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624846|NCT00983619|Experimental|Part A-MEDI-551 8 mg/kg|Participants will receive IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624847|NCT00983619|Experimental|Part A-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624848|NCT00983619|Experimental|Part B-MEDI-551 6 mg/kg|Participants will receive IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624849|NCT00983619|Experimental|Part B-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624850|NCT00983619|Experimental|Part B-MEDI-551 24 mg/kg|Participants will receive IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
89624851|NCT00983619|Experimental|Part C-MEDI-551 8 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
89624852|NCT00983619|Experimental|Part C-MEDI-551 12 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
89624853|NCT00983619|Experimental|Part D-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches CR or withdraws consent.
89624854|NCT01767857|Experimental|Xilonix|MABp1 administered IV every two weeks, plus best supportive care
89624855|NCT01767857|Placebo Comparator|Placebo|Placebo administered IV every two weeks, plus best supportive care
89624856|NCT04394091||PET CT and ultrasensitive PET CT|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT and ultrasensitive PET CT protocol 12 weeks after the end of IMRT .
89624857|NCT04553835|Experimental|schizophrenia- RAS|Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS).
89624858|NCT04553835|Active Comparator|schizophrenia- no RAS|Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.
89624859|NCT04553835|Experimental|at risk- RAS|At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS.
89624860|NCT04553835|Active Comparator|at risk- no RAS|At-risk individuals in the control group will receive upper-limb training without the aid of RAS.
89038591|NCT04207489||endoscopic submucosal injection of indocyanine green|
89038592|NCT04320160|No Intervention|Positive control group|Include the thirty patients before any treatment
89624861|NCT05608785|Experimental|HER2 protein positive 3+ or FISH amplification or HER protein 2+ but FISH amplification|"Initial treatment (4-6 cycles): IBI315 injection, oxaliplatin, capecitabine~IBI315: 1200 mg per cycle d1 dosing, intravenous drip, 3 weeks as one treatment cycle.~Oxaliplatin: 130 mg/m2, d1 per cycle, intravenous drip, 3 weeks as a treatment cycle.~Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks cycle.~Patients with CR/PR/SD enter maintenance therapy: IBI315 monotherapy maintenance~- IBI315: 1200 mg IV drip per cycle d1 for 3 weeks."
89624862|NCT05608785|Experimental|Positive for Claudin 18.2 protein|"Initial treatment (4-6 cycles): PD-L1 monoclonal antibody, TST001 injection, oxaliplatin, capecitabine~TST001: 3mg, 4.5mg and 6mg dose levels for hill climbing trial, dose per cycle d1, IV drip, 3 weeks for one treatment cycle. 3-6 patients were enrolled in each dose level (3 patients were enrolled if no DLT was present, if present extended to 6 patients)~TQB2450 injection: 1200 mg per cycle d1 dosing, IV drip, 3 weeks as a treatment cycle.~Oxaliplatin: 130 mg/m2 per cycle d1 dosing, intravenous drip, 3 weeks as a treatment cycle.~Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks cycle.~Patients with CR/PR/SD enter maintenance therapy: TQB2450 injection + TST001~TST001: maintenance at the dose level used (3mg/4.5mg/6mg), dosed d1 per cycle, IV drip, 3 weeks as a treatment cycle.~TQB2450 injection: 1200mg, dosed d1 per cycle, intravenous drip, 3 weeks as a treatment cycle."
89624863|NCT05608785|Experimental|Her2 protein, Claudin18.2 protein were negative|"Initial treatment (4-6 cycles): TQB2450 injection, Anrotinib, Oxaliplatin, Capecitabine~TQB2450 injection: 1200mg per cycle d1 dosing, intravenous drip, 3 weeks as a treatment cycle.~Anrotinib: 1 capsule (10 mg) once daily, dosed every cycle d1-d14, stopping for 2 consecutive weeks, 3 weeks as a treatment cycle~Oxaliplatin: 130 mg/m2, d1 per cycle, intravenous drip, 3-week treatment cycle.~Capecitabine: 1000 mg/m2 orally twice daily (1 dose in the morning and 1 dose in the evening), d1-d14 per cycle, 2 weeks off 1 week, 3 weeks as a treatment cycle.~Patients with CR/PR/SD enter maintenance therapy: PD-L1 inhibitor, anlotinib~PD-L1 monoclonal antibody (TQB2450): 1200 mg d1 per cycle, intravenous drip, 3 weeks as a treatment cycle.~Anlotinib: 1 capsule (10mg) once daily, d1-d14 per cycle, stopping for 2 weeks, 3 weeks as a treatment cycle."
89624864|NCT04394013|Experimental|Mindfulness Arm|The content of the approximately 20 minutes video is recorded in advance of the intervention by a certified teacher with teaching experience. The 20 minutes session consists of a series of body stretching exercises (around 17 different gentle and simple stretches from head to toe) with the incorporation of breathing technique (i.e. when to breathe in and breathe out). The whole body stretching exercise is performed with a sitting position, ideally on an exercise mat. As mentioned above, the participants are required to conduct the stretching exercise by following the guidance video for at least 5 days weekly for at least 2 weeks duration. The video will be uploaded onto a webpage which requires participants to log in and view the video. The webpage and video will be accessible through computers and mobile phones.
89624865|NCT04394013|Active Comparator|Non-mindfulness Arm|In this study, for control group, the participants are instructed with a similar video content as the intervention group, minus the incorporation of breathing technique, as breathing technique is hypothesised to be a key component of mindfulness.
89624866|NCT04552509|Other|Observation|Observational study of patient efficacy and side effects
89624867|NCT05608551|Experimental|AA TF-CBT|Participants receive a 10-week animal-assisted trauma-focused group therapy.
89624868|NCT05608551|Active Comparator|TF-CBT|Participants receive a 10-week standard trauma-focused group therapy.
89624869|NCT04556097|Experimental|Early Training|Nurse care managers will be randomized to either early or delayed adapted Care Ecosystem training. The Early Training arm will be the first group to receive training and the first to have the opportunity to use the training in a clinical setting. We anticipate that each nurse care manager will manage 10 PWLD and we anticipate a 50% response rate/data availability, yielding 75 patients per arm.
89624870|NCT04556097|Active Comparator|Delayed Training|The Delayed Training arm will be the second group of nurse care managers to receive training.
89624871|NCT03828760|Experimental|Music Listening|Patients will receive music of choice to listen to using a music-playing device in the waiting room prior to IUD insertion, as well as during the procedure.
89624872|NCT03828760|No Intervention|Standard Care|Patients will receive standard care (excluding the use of music) from providers at the clinic to minimize pain and anxiety during the procedure.
89624873|NCT01775501|Experimental|Experimental Treatment Arm|FOLFOX (Leucovorin, Fluorouracil and Oxaliplatin) + Sorafenib Sorafenib: orally, twice daily FOLFOX: injected via portacath once every two weeks
89624874|NCT03786640||Single Arm|Patients implanted with an SJM Tendril STS 2088 or Isoflex 1944/1948 lead, together with an Assurity MRI or Endurity MRI pacemaker, and who will undergo a 3T MRI scan are eligible to participate in this study.
89624875|NCT04124835|Experimental|Intervention Group|In the intervention group, the use of the Swiss Ball will be performed through active exercises of pelvic anteversion and retroversion, lateralization and circumduction according to the obstetric evaluation.
89624876|NCT04124835|Other|Control Group|The control group will receive the usual routine care of the service.
89624877|NCT04550247||Nivolumab treatment|Administered according to the market authorization in France
89624878|NCT03721042|Experimental|exhaled air|exhaled air analysis of patients
89624879|NCT04553445|Experimental|Chronotype|Determination whether monthly migraine load is affected by exercise in sync with chronotype
89038593|NCT04320160|Active Comparator|PRP group|Include fifteen patients that will recieve PRP sessions .Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
89038594|NCT04320160|Active Comparator|Fractional CO2 group|Include fifteen patients that will recieve FR: CO2 laser sessions.Patients will receive six treatment sessions with one month interval for 6 months and will be followed up after 6 months.
89038595|NCT03678493|Experimental|AML Patients undergoing Intensive Chemothera|
89038596|NCT03678493|Placebo Comparator|AML Patients undergoing Intensive Chemotherapy Control|
89038597|NCT03678493|Experimental|AML Patients undergoing Allo-HCT Patients|
89038598|NCT03678493|Placebo Comparator|AML Patients undergoing Allo-HCT Patients Control|
89038599|NCT02896946|Experimental|diffusion-weighted nuclear magnetic resonance imaging|detection of liver metastasis on diffusion-weighted nuclear magnetic resonance imaging in patients with potentially resectable pancreatic adenocarcinoma
89038600|NCT04321447|Experimental|Clinical practice guideline (CPG) group|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme
89038601|NCT04321447|No Intervention|Usual care group|Usual care
89038602|NCT03627130|Active Comparator|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
89624880|NCT04553445|Experimental|Green exercise|Determination whether monthly migraine load is affected by exercise in a natural environment
89624881|NCT04347525|Experimental|Intervention|This group will receive CaCBT based guided self-help using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
89624882|NCT04347525|No Intervention|Control|This group will receive treatment as usual
89624883|NCT01880320|Experimental|CD0271 0.3% /CD1579 2.5% Gel|active arm
89624884|NCT01880320|Active Comparator|CD0271 0.1% / CD1579 2.5%|Comparator arm
89624885|NCT01880320|Placebo Comparator|Topical Gel Vehicle|Placebo arm
89624886|NCT04346667|Active Comparator|Arm 1|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
89624887|NCT04346667|Experimental|Arm 2|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
89624888|NCT04346667|Active Comparator|Arm 3|Chloroquine 500 mg BID for 5 days plus standard of care
89624889|NCT04346667|Placebo Comparator|Arm 4|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
89624890|NCT04129983|Experimental|Prednisone acetate + somatosensory stimulation|Prednisone acetate 1 mg/kg body weight * 7 days and somatosensory stimulation 30 days were given to sudden deafness patients.
89624891|NCT04129983|Experimental|Prednisone acetate + hyperbaric oxygen|Prednisone acetate 1mg / kg body weight * 7 days and hyperbaric oxygen 15 days were given to sudden deafness patients.
89624892|NCT05608239|Experimental|Sculptra® Aesthetic|
89624893|NCT03426358|Experimental|Patients undergoing HSCT|LSM assessed by Elastographic Techniques
89624894|NCT05608161||Patients with unilateral sudden deafness with complete recovery of peripheral hearing|The patients who recovered from sudden deafness underwent speech recognition rate tests under different masking conditions and different signal-to-noise ratio conditions within 2 weeks after complete recovery of peripheral hearing and were followed up 3 times at 1, 6, and 12 months after recovery. The test content is the same as the first time.
89624895|NCT05608161||Healthy control group|Age-, gender-, and educational-matched healthy controls were enrolled as healthy control group to test speech recognition rates under different masking conditions and different signal-to-noise ratio conditions.
89038603|NCT03627130|Placebo Comparator|Potassium Chloride|Potassium Chloride
89038604|NCT02896868|Experimental|LY3041658|LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).
89624896|NCT02983929||BMI <30 kg.m-2|Patients with a BMI inferior to the obesity limit defined by the World Health Organization.
89624897|NCT02983929||BMI >30 kg.m-2|Patients with a BMI superior to the obesity limit defined by the World Health Organization.
89624898|NCT04129749||Real-Time Analysis Interactive Lab|walk spontaneously or at prescribed speeds of cerebral palsy patient to a standstill in a virtual and secure virtual reality environment.
89624899|NCT02268994|Experimental|KRX-0502 (ferric citrate)|1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron
89624900|NCT02268994|Placebo Comparator|Placebo|Matching Placebo
89624901|NCT04129593|Experimental|Self Awakening|Participant will intend to wake up at a specific time before going to bed.
89624902|NCT04129593|Experimental|Snooze|Participant will set multiple alarms before bed to wake at a specific time.
89624903|NCT04768894|Active Comparator|14-28 days|In group 1,the time interval between initial and re-TUR was 14-28 days,
89624904|NCT04768894|Active Comparator|29-42 days|In group 2, the time interval between initial and re-TUR was 29-42 days
89624905|NCT04768894|Active Comparator|43-56 days|In group 3, the time interval between initial and re-TUR was 43-56 days
89038605|NCT02896868|Placebo Comparator|Placebo|Placebo administered IV once every two weeks over 6 weeks (four doses).
89038606|NCT04321096|Placebo Comparator|Placebo|2 pills 3 times daily for 5 days
89038607|NCT04321096|Experimental|Camostat Mesilate|2x100 mg pills 3 times daily for 5 days
89038608|NCT00549861|No Intervention|A1|CMR study for the assessment of irreversible tissue damage
89038609|NCT04321018|Experimental|Meal with medium chain triglycerdies first|Arm 1: participants randomized to receive the mixed meal with medium chain triglycerides first.
89038610|NCT04321018|Active Comparator|Meal with medium chain triglycerdies second|Arm 2: participants randomized to receive the mixed meal without medium chain triglycerides first.te
89038611|NCT02896985||Participants with Crohn's disease|Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.
89624906|NCT01775189|Placebo Comparator|Treatment A|
89624907|NCT01775189|Experimental|Treatment B|
89624908|NCT01775189|Placebo Comparator|Treatment C|
89624909|NCT01775189|Active Comparator|Treatment D|
89624910|NCT03832582|Experimental|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
89624911|NCT04768816|Placebo Comparator|Placebo Comparator|Placebo 0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
89624912|NCT04768816|Experimental|Experimental|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells#1*10^7/kg). The infusion speed is 1ml/min.
89624913|NCT02988154||Arm A: Simulation training cohort|Recruits to Arm A undergo simulation training (computer simulation of the procedure, followed by simulation on a dead animal model), after which they will attempt to perform an EVD procedure on their own, on a 3D-printed skull model that we designed.
89624914|NCT02988154||Arm B: ''See one, do one'' cohort|Recruits to Arm B will witness an EVD placement as performed by an experienced surgeon, after which they will attempt to perform an EVD procedure on their own, using the aforementioned 3D-printed skull model. This mimics the ''see one, do one'' paradigm prevalent in surgical training.
89038612|NCT04320784|Experimental|Time restricted eating (TRE)|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
89038613|NCT04320784|Active Comparator|Control (CTRL)|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
89038614|NCT03556696|Experimental|ANI-loop|arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
89038615|NCT03556696|Active Comparator|std_practice|arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.
89038616|NCT04320706|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
89038617|NCT04320706|Placebo Comparator|Oral Placebo|Placebo orally (identical ingredients, except the active agent)
89038618|NCT03523819|Experimental|CS1002|Participants will receive CS1002 intravenously at specified dose on specified days.
89038619|NCT03523819|Experimental|CS1003|Participants will receive CS1003 intravenously at fixed dose on specified days.
89624915|NCT04129203|Experimental|Trial arm|Mechanical thrombectomy using Versi Retriever
89624916|NCT04128813|Active Comparator|Vertical whole body vibration platform.|Use of a rotational whole body vibration platform.
89624917|NCT04128813|Active Comparator|Rotational whole body vibration platform|Use of a rotational whole body vibration platform.
89624918|NCT04128813|No Intervention|Control group|No intervention.
89624919|NCT01881412|Experimental|Inhaled corticosteroid (fluticasone)|Child receives: 1) standardized asthma discharge instructions, and the intervention which is 2) inhaled corticosteroid prescription with accompanying instructions.
89624920|NCT01881412|Placebo Comparator|Routine Asthma Care|Child receives: 1) Standard Asthma Discharge Instructions. No intervention in this arm (placebo controlled)
89624921|NCT03378609|Other|Vocal Fatigue Index (VFI)|Standardized Questionnaire assessing vocal fatigue
89624922|NCT03832816|Placebo Comparator|Placebo|Distilled Water
89624923|NCT03832816|Experimental|Vaporized THC alone|5mg pure THC
89038620|NCT04207567|Experimental|Intervention Arm|Participants in this arm will be instructed to perform one set each of push-ups, angled-rows and bodyweight squats every weekday without supervision for a total of 24 weeks. They will receive the equipment necessary to perform the exercises as well as guidance on proper performance. They will also receive training in the Tiny Habits® Method at baseline and digital coaching for the duration of the study.
89038621|NCT04207567|No Intervention|Waitlist Control Arm|"Participants in the control arm will be instructed to refrain from resistance training for the initial 12 weeks of the study.~Note that, after the 12-week follow-up assessment (at which the primary outcome of composite reps will be assessed), this group will begin the RT program. They will receive the same equipment, training, and coaching as the intervention group, and they will continue the RT program for 12 weeks, followed by a 24-week assessment."
89038622|NCT02896673|Experimental|ventilatory conditions and measures with scanner and EIT|"The patient is installed on the scanner bed, EIT electrodes are connected to the acquisition device of the EIT signal.~Esophageal pressure signals, pressure and flow in the airways will be acquired continuously"
89038623|NCT02888704|Experimental|intervention: Biological: ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
89038624|NCT03512158|Experimental|High NCPAP|Administration of high NCPAP (> 8 cmH2O) following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
89038625|NCT03512158|Active Comparator|NIPPV|Administration of NIPPV following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
89624924|NCT03832816|Experimental|Vaporized low CBD alone|50mg pure CBD
89038626|NCT02896439|Experimental|Neurophysiological monitoring|
89038627|NCT02896322|Experimental|Cyberknife|APBI with cyberknife after breast conserving surgery in breast cancer
89038628|NCT02896166|Experimental|microwave ablation|The procedure is performed similar to a needle biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to needle placement for CT-guided biopsy. Appropriate positioning of the microwave ablation antenna is confirmed by CT imaging.
89038629|NCT00553709|Experimental|Nicotine patch|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
89038630|NCT00553709|Placebo Comparator|Placebo patch|Placebo patch 10 cm2
89038631|NCT00551733|Experimental|Arm I|Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89038632|NCT00551733|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89624925|NCT03832816|Experimental|Vaporized medium CBD alone|100mg pure CBD
89624926|NCT03832816|Experimental|Vaporized high CBD alone|200mg pure CBD
89624927|NCT03832816|Experimental|Vaporized low CBD with THC|50mg pure CBD paired with 5mg THC
89624928|NCT03832816|Experimental|Vaporized medium CBD with THC|100mg pure CBD paired with 5mg THC
89624929|NCT03832816|Experimental|Vaporized high CBD with THC|200mg pure CBD paired with 5mg THC
89624930|NCT04129047|Experimental|Omnichroma (one shade universal) composite by Tokuyama|class V cavities will be made under isolation. Omnichroma (one shade universal) composite by Tokuyama will be placed according to guidelines.
89624931|NCT04129047|Active Comparator|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA)|class V cavities will be made under isolation. A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA) will be placed according to guidelines.
89624932|NCT02987764|Experimental|Cord Milking|The research team member will untwist the cord, and hold it in a vertical position. The cord will then be milked twice towards the abdominal insertion of the cord. The cord will be cut 1 inch above the abdominal wall. After milking for exact measurement of the cord will be obtained.
89624933|NCT02987764|No Intervention|Observational|Observational infants will receive usual care with immediate cord clamping by the delivering obstetrician. The time of cord clamping will be recorded for both groups using a timer.
89624934|NCT04231084|Active Comparator|Inhaled Nitric Oxide|Vasodilator testing will be performed with inhaled nitric oxide
89624935|NCT04231084|Experimental|Inhaled Epoprostenol|Vasodilator testing will be performed with inhaled epoprostenol
89624936|NCT04551105|Active Comparator|First session: manual review first and then review with CADx|"Reader Group X interpret the Dataset A cases in different random order without any assistance of AI first, and then interpret the Dataset B cases in different random order with TaiHao AI system."
89624937|NCT04551105|Active Comparator|First session: review with CADx first and then manual review|"Reader Group Y interpret the Dataset A cases in different random order with TaiHao AI system first, and then interpret the Dataset B cases in different random order without any assistance of AI."
89624938|NCT04551105|Active Comparator|Second session: manual review first and then review with CADx|"At least 4 weeks after first session for memory washing out. Reader Group X interpret the Dataset A cases in different random order with TaiHao AI system first, and then interpret the Dataset B cases in different random order without any assistance of AI."
89624939|NCT04551105|Active Comparator|Second session: review with CADx first and then manual review|"At least 4 weeks after first session for memory washing out. Rader Group Y interpret the Dataset A cases in different random order without any assistance of AI first, and then interpret the Dataset B cases in different random order with TaiHao AI system."
89624940|NCT04128345||SBN arm|We will evaluate the feasibility of using an integrated navigation system incorporating pre-operative MRI and intraoperative ultrasound images
89624941|NCT01883440|Placebo Comparator|Saline+glucose|A nasal spray with isotone saline + 5% glucose in a bag-on-valve nasal spray device. The spray will be administered with one puff in each nostril 5 times day one and thereafter trice daily for a total treatment time of one week
89624942|NCT01883440|Active Comparator|Glucose oxidase + glucose|A nasal spray (bag-on-valve device) with 200U/ml glucose oxidase + 5% glucose in isotone saline. One puff in each nostril 5 times daily day one and 3 times daily thereafter. A total treatment time of one week.
89624943|NCT04124211|Experimental|FMT Arm|10 Participants will be enrolled in this arm to receive FMT treatment
89624944|NCT04124289||Pain post surgery|Patients who have completed surgery will be assessed with three types of pain scales. A new pain scale, a functional pain scale (FPS), will be compared to two pain scales that are routinely used: the FACES pain scale and the numeric rating scale (NRS).
89624945|NCT03305146|Experimental|single arm|"For inoperable patients with indeterminate cystic lesions of the pancreas,a EUS FNA will be performed and molecular biology analysis of pancreatic intra-cyst fluid collected by EUS FNA will be performed.~For operable patients, after the pancreatic surgery, molecular biology analysis of extemporaneous pancreatic tissue specimen biopsy will be conducted."
89624946|NCT04127799|Experimental|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
89624947|NCT04127799|Active Comparator|Subjects with AF conventional treatment|Subjects with AF via conventional clinic visit according to the latest relevant guidelines
89624948|NCT04127877|Experimental|CHRONIC HEMODIALYSIS PATIENTS, NICAS-ASSISTED MONITORING|Chronic hemodialysis patients, NICAS-assisted monitored
89624949|NCT04127877|No Intervention|Control hemodialysis patients|Chronic hemodialysis patients, conventional clinical care and monitoring.
89624950|NCT04768660|Other|normal|people will not use chewing gums after whipple operation
89624951|NCT04128033|Experimental|puncture of the RP6 point|The acupuncturist midwife, who does not perform the delivery herself, punctures the RP6 point at the time of the expulsive efforts.
89624952|NCT04128033|Placebo Comparator|puncture of the placebo point|The acupuncturist midwife, who does not perform the delivery herself, punctures the placebo point at the time of the expulsive efforts.
89624953|NCT01883986|Experimental|Intervention|This is a 3 month nurse-led telephone based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer.
89624954|NCT01883986|No Intervention|Usual Care|Subjects randomized to usual care will receive medical oncology, radiation oncology, pulmonary, CT surgery as indicated by the type of cancer. At the completion of 3 months of usual care, subjects are invited to join the intervention arm.
89624955|NCT04128111||Acute Exacerbation|Exacerbations of asthma are episodes characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e. they represent a change from the patient's usual status that is sufficient to require a change in treatment.
89624956|NCT04128111||Non-acute exacerbation|Non-acute exacerbation of asthma includes chronic remission and clinical delays.Clinical remission stage refers to an absence of wheezing, chest tightness, cough and other symptoms for more than 1 year.Chronic duration refers to that symptoms, such as wheezing, chest tightness, cough and so on, attack at different frequency and different degrees every week.
89624957|NCT04128111||Healthy Volunteer|Health is not only the absence of disease or infirmity, but also a state of physical, mental, and social perfection.
89624958|NCT01884064|Experimental|inhibitory rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
89624959|NCT01884064|Placebo Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
89038633|NCT02896283|Experimental|low-level laser therapy|Low-level laser (Diode, 66o nanometer, power:200 milli Watt (mW), Continuous wave, time of irradiation:32 seconds)is irradiated in donor site
89038634|NCT02896283|Placebo Comparator|Turned-off laser|The same protocol is applied in te donor site, unless the laser is remained off.
89038635|NCT02896205|Experimental|Mycophenolate mofetil|Subjects will be started on Mycophenolate Mofetil 500mg twice a day and increased by 500mg every 2 weeks, if tolerated, to a target dose of 2gram per day.
89624960|NCT04123899|Experimental|IGAD→GSTD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
89624961|NCT04123899|Experimental|GSTD→IGAD|"IGAD: Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) GSTD: Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
89624962|NCT04124055|Experimental|Therapeutic drug monitoring (TDM)|Therapeutic drug monitoring (TDM) based on Saliva and Dried blood spot samples
89624963|NCT01884844|Experimental|Vitamin D3|Vitamin D3, Cholecalciferol, 5000IU po qday for 12 weeks
89624964|NCT01884844|Placebo Comparator|Placebo|methylcellulose po qday for 12weeks
89624965|NCT04123431||ACE Acetabular Cup System with XLPE Liner|
89624966|NCT04123431||ACE Acetabular Cup System with Ceramic Liner|
89624967|NCT04123431||ACE Acetabular Cup System with Dual Mobility Insert|
89624968|NCT04123587|Experimental|Sulfonylurea-dependent|Sulfonylurea is replaced by alternative oral hypoglycemic agent.
89624969|NCT01890226|No Intervention|Control|
89624970|NCT01890226|Experimental|Experimental: Intervention|Participants randomized to the intervention arm will receive the mobile personal health record.
89624971|NCT04127721|Experimental|Prevention (itacitinib, busulfan, fludarabine, ASCT)|"CONDITIONING CHEMOTHERAPY: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.~ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.~GVHD PROPHYLAXIS: Patients receive itacitinib PO QD on days -21 to 80. Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day 90. Patients also receive tacrolimus IV then PO BID for 3 months when able, and methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched unrelated donor)."
89624972|NCT04123743|Experimental|Experimental Group|The experimental group will be given topical cream containing Trigonella foenum-graceum extract, Wardah brand facial wash, and Parasol sunscreen SPF 33.
89624973|NCT04123743|Placebo Comparator|Control Group|The control / placebo group will be given placebo topical cream, Wardah brand facial wash, and Parasol sunscreen SPF 33
89624974|NCT04123119|Experimental|Rotarix Arm|
89624975|NCT04393077|No Intervention|Control|Participants will complete the pre-tests of the introductory features form, SUD, STAI-I, and burnout scales sent via Survey Monkey. The participants (n=40) will be given 15 minutes of free time and asked to be in a position where the individuals were comfortable, in the quietest and most tranquil environment possible. At the end of this period, post-test SUD, STAI-I, and burnout scales will be sent to the participants and they will be asked to fill in the scores.
89038636|NCT02896205|Placebo Comparator|Placebo|Subjects in this arm will be given matching placebo, made of lactulose, starting at two tablets per day and increased by one tablet every 2 weeks to a target of 4 tablets per day.
89038637|NCT04922424|Experimental|atorvastatin|We are testing that the lipid sensitive statin, atorvastatin treatment will reduce low density lipoprotein cholesterone, sympathetic nerve activity, increase endothelium-dependent vasodilation and improve autonomic function in trans men, while having little impact on cis women.
89038638|NCT04922424|Placebo Comparator|Placebo|We are testing that the placebo will have little effect on low density lipoprotein cholesterone, sympathetic nerve activity, endothelium-dependent vasodilation, autonomic function in trans men or cis women.
89624976|NCT04393077|Experimental|Intervention|Firstly, people in the entire group fill out the introductory features form on the online questionnaire form. The time of the meeting will be determined by collaborating with the participants in the experimental group. During the interview, they will be asked to be in a position that was comfortable for the individuals, in the quietest and calm environment possible. At the beginning of the meeting, they will be asked to fill in the pre-test SUD, STAI-I, and burnout scales sent via SurveyMonkey. Then, the EFT session (20 minutes) will be conducted once mutually with the researcher, who is an expert in their field. At the end of the session, they will be filled the post-test SUD, STAI-I and burnout scales
89624977|NCT04127487||Periodontitis group|35 Generalized chronic periodontitis subjects without coronary heart diseases
89624978|NCT04127487||periodontitis with CAD group|35 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease
89624979|NCT02996799|No Intervention|Deferred Cord Clamping|Neonate is held at the level of placenta (level of introitus (vaginal delivery ) and mother's thigh or operating table (C/S) and cord clamping is deferred for 60 seconds.
89624980|NCT02996799|Experimental|Umbilical cord milking|Manually stripping 20cm of cord segment toward the umbilicus over a period of 2-3 seconds three times before cord clamping.
89624981|NCT04127643||S-ICD patients|patients who have received the EMBLEM S-ICD system
89624982|NCT02996721|No Intervention|Standard of Care|Patients randomized to the standard of care arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey at baseline and at study conclusion. No other contact is planned with the standard of care patients. Follow-up will be done by the querying of electronic records, which includes any 25[OH] Vit D testing, use of vitamin D supplementation, and outcomes.
89624983|NCT02996721|Experimental|Treatment|Patients randomized to the treatment arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey. If at baseline a patient has a 25[OH] Vit D >40 ng/mL then follow-up testing will occur 1 year from baseline and the patient will continue current treatment strategy (no supplementation or current supplementation dosage). If baseline 25[OH] Vit D levels are <40 ng/mL then the patient will initiate or increase dose and return in 3 months (±15 days) to determine 25[OH] Vit D level. At 3 months, if 25[OH] Vit D >40 ng/mL then current dose should be kept and the patient will return in 1 year for follow-up testing. However, if 25[OH] Vit D <40 ng/mL then patients should double current dose and test again in 3 months. This should occur until 25[OH] Vit D reaches a level >40 ng/mL and once achieved, the patient will return in 1 year for follow-up 25[OH] Vit D testing.
89038639|NCT00550056|Experimental|1|NET
89038640|NCT00550056|Experimental|2|TC
89038641|NCT00550056|No Intervention|3|Monitoring Group
89038642|NCT02896634||group with inflammation|Selection of samples from biobank with groups with inflammation
89038643|NCT02896634||group with denutrition|Selection of samples from biobank with groups with denutrition
89624984|NCT02666326|No Intervention|Conventional diagnostic strategy|"Standard Diagnostics for suspected myocardial infarction, including standard biochemical analysis: min. two measurements of high sensitive troponin T with an interval of minimum 3 hours.~A normal value of high sensitive cardiac troponin-T in both blood samples rules out AMI and the patients can be discharged immediately if no other conditions are suspected."
89624985|NCT02666326|Experimental|Accelerated diagnostic strategy|'Accelerated, combined biomarker rule-out strategy for MI'. Copeptin measurement in a prehospital blood sample combined with high sensitive cardiac troponin T measurement in the first blood sample upon hospital admission, A normal value of both copeptin and cardiac troponin rules out AMI and the patients can be discharged immediately if no other conditions are suspected.
89624986|NCT04122963|Active Comparator|High power group|The experimental group will receive AF ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds).
89624987|NCT04122963|Active Comparator|Standard group|The control group will receive AF ablation according to the standard CLOSE-protocol (35 Watt and stability criteria of 3 mm for 8 seconds)
89624988|NCT04122885||CRS and HIPEC|Cyroreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
89624989|NCT04122885||PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy (if CRS and HIPEC not possible)
89624990|NCT04122651|Experimental|Experimental Arm|Patients will be receiving a toric intraocular lens with either a 2.00 or 4.00 diopter (D) correction, depending on the degree of pre-operative astigmatism, and the astigmatic refractive error will be refined with the use of adjunctive limbal relaxing incisions LRIs and/or off axis rotation of the toric IOL (based on a standardized protocol) so the full amount of corneal astigmatism can be targeted for correction for each patient.
89624991|NCT04122651|Active Comparator|Control Arm|The patient will receive a toric intraocular lens individually tailored to and ordered for each patients' precise degree of corneal astigmatism.
89624992|NCT03022851|Experimental|Occlutech AFR Device|Patients who will get the AFR Device implantation
89624993|NCT04122417||Control Group|"The mothers and infants in the experimental and control groups were assigned to the groups by randomization method. Therapeutic touch didn't apllied to control group.~Babies in the control group who took care practices in accordance with normal hospital procedures."
89624994|NCT04122417||Yakson Group|"The touch method was taught to the mothers in the Yakson group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.~In yakson method, mother's fingers are closed, and she should touch in a way that does not apply excessive pressure. The method is applied for a total of 15 minutes in three cycles. First 5 minutes is resting the hand, 5 minutes is gentle caressing, and another 5 minutes of resting the hand."
89624995|NCT04122417||Gentle Human Touch Group|"The touch method was taught to the mothers in the Gentle Human Touch group by the researcher in the first three days after the birth with the training brochure, video and applications on the model that are prepared in accordance with expert opinion.~Mother slowly places one hand on the baby's hand and the other over pelvic cavity, covering the waist and hips of the baby.~The touch is preserved for 15 minutes. In order to ensure equal touch for the duration of gentle human touch, the mother sits on a stool and her elbows have to be at the same level with baby's bed"
89624996|NCT04122573||Acute chest pain|The population in this study are characterized by acute chest pain as the first symptom for consultation within 24 hours.
89624997|NCT04122807|Active Comparator|Mapping|Standard treatment involving ablation of the slow pathway with cryotherapy
89624998|NCT04122807|Experimental|Ablation|Mapping and ablation of the retrograde fast pathway with cryotherapy
89624999|NCT04126941||Teriparatide|Patients with hypoparathyroidism treated by teriparatide
89625000|NCT02586844||Neuroendocrine tumors (NETs)|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
89038644|NCT02896634||group with none|Selection of samples from biobank with groups with none
89038645|NCT02896634||group with both|Selection of samples from biobank with groups with both.
89038646|NCT00551811|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive single doses of placebo in period 1, SB-656933-AAA with a dose of 50 milligrams in period 2 and 150 milligrams in period 3.
89038647|NCT00551811|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, placebo in period 2 and SB-656933-AAA 150 milligrams in period 3.
89038648|NCT00551811|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, 150 milligrams in period 2 and placebo in period 3.
89038649|NCT00553748|Experimental|I|
89038650|NCT00551850|Experimental|1|
89038651|NCT02896049||Hyperthermia|treatment with the Celsius42 Hyperthermia System
89038652|NCT00550095|Experimental|1|valsartan
89038653|NCT02895893|Experimental|Smartphone app condition|"Men who are at risk for HIV and already prescribed and taking Truvada will be asked to use an application on their smart phones called PrEP Smart."
89038654|NCT00550212|Experimental|1|240 mg
89038655|NCT02895932|Experimental|Case|Patients with diagnosed Parkinson's disease
89038656|NCT02895932|Experimental|Control|Healthy adults
89038657|NCT00551967|Active Comparator|E1 polyethylene|All patients received an E1 polyethylene liner which is the material being monitored in this study.
89038658|NCT02896010|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
89038659|NCT02896010|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
89038660|NCT00552006|Experimental|NET|
89038661|NCT00552006|Active Comparator|AC|
89038662|NCT00552006|No Intervention|WL|Waiting list
89038663|NCT02895854|Active Comparator|LDR-brachytherapy with I125 seeds|Low-dose rate-brachytherapy with I125 permanent seeds in prostate cancer.
89625001|NCT02586844||panNETs|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
89625002|NCT04122027|Active Comparator|Control|Patients undergoing liver transplantation without regional cerebral oxygenation monitoring using a cerebral oximeter.
89625003|NCT04122027|Active Comparator|Intervention|Patients undergoing liver transplantation with regional cerebral oxygenation monitoring using a cerebral oximeter.
89625004|NCT04122105|Experimental|intervention|sildenafil administration perioperative to renal transplant
89625005|NCT04122105|Active Comparator|control|renal transplant recipients
89625006|NCT02385214|Experimental|Arm A Wide Local Excision = 1cm Margin|"ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
89625007|NCT02385214|Active Comparator|Arm B Wide Local Excision = 2cm Margin|"ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
89625008|NCT03202641|Experimental|PEEP_titration|"There is no randomization in this interventional, crossover, physiological study. All participants will receive the same procedures in the same order. The investigators will compare two PEEPs (PEEPARDSnet vs. PEEPLRM).~Interventions:~PEEP ARDSnet: we will select the PEEP based on low PEEP/high FiO2 table (ARDSnet).~PEEP LRM: we will perform a lung recruitment maneuver (LRM) and select PEEP based on transpulmonary pressure."
89625009|NCT04121793||Parkinson's Disease|Parkinson's Disease patients
89625010|NCT04127019|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
89625011|NCT04127019|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
89625012|NCT04127019|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle).
89625013|NCT02244034||760 patients who underwent open cardiac and/or thoracic aortic surgery using CPB|
89625014|NCT02076646|Experimental|Ph I: L19IL2 + DTIC|"Cohorts of 3-6 patients will receive escalating doses of L19-IL2 until MTD is reached.~L19-IL2 will be administered on days 1, 8 & 15 of each 21-day-cycle. Dacarbazine will be given at a fixed dose on day 1 of each 21-day cycle, 30 minutes after the end of the L19-IL2 infusion."
89625015|NCT02076646|Experimental|Ph II - ARM 1: L19IL2 at RD + DTIC|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 1 will receive L19IL2 at the RD + DTIC at a fixed dose.
89625016|NCT02076646|Active Comparator|Ph II - ARM 2: DTIC monotherapy|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 2 will receive DTIC at a fixed dose as monotherapy.
89625017|NCT04127097|Experimental|cartoon group|
89625018|NCT04127097|No Intervention|control group|
89625019|NCT04121481|Placebo Comparator|Placebo|Approximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)
89625020|NCT04121481|Active Comparator|Treatment Group|Approximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced
89625021|NCT04121715|Active Comparator|standard medication|"standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
89625022|NCT04121715|Experimental|standard medication+fastigial nucleus stimulation|"fastigial nucleus stimulation:Use fastigial nucleus stimulation therapy device (Shanghai Renhe Medical Equipment Co., Ltd. CVFT series), each stimulation for 30 min, once a day, each patient treatment for about 20 days.~standard medication:Refer to the Guidelines for Rational Use of Coronary Heart Diseases"
89625023|NCT01894906|Placebo Comparator|Control|Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
89625024|NCT01894906|Experimental|Soluble Ferric Pyrophosphate|Group/ cohort designation: Cellulose dialysis membrane (CT-190)/ Polyamide membrane. Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
89625025|NCT04121247|Experimental|Experimental: Parents in Chad will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
89625026|NCT04121247|Experimental|Experimental: Parents in Turkey will be trained|The education was given individually by the researcher (first researcher / author), before examining the child's doctor. The interactive education was completed in 30-40 min, using questions-answers. The education was conducted by the researcher using the education book.
89625027|NCT04121091|Experimental|Pramipexole|
89625028|NCT04127253|Experimental|transcranial direct current plus Brain training tools|20 minutes of transcranial direct current stimulation along with the application of motor imagery and action observation
89625029|NCT04127253|Placebo Comparator|Placebo transcranial direct current plus Brain training tools|A placebo intervention of direct transcranial stimulation being active during 15 seconds and then it will be turned off the rest of the time until 20 minutes. This group will also carry out the training of action observation and motor imagery.
89625030|NCT04127253|Sham Comparator|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
89625031|NCT03029338|Experimental|CD19 CAR T cells|CD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
89625032|NCT03283605|Experimental|Durvalumab + tremelimumab and SBRT|All subjects will receive durvalumab (1500 mg IV q4week) and tremelimumab (75mg q4week) for 4 doses, followed by durvalumab alone (1500 mg IV q4week) until disease progression, unacceptable toxicity or patient withdrawal. SBRT will be administered between cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
89625033|NCT01895062|Experimental|active cNEP @ -45cmw|cNEP @ -45 cmw is applied to the anterior surface of the neck with a soft collar attached to a vacuum source.
89625034|NCT01895062|No Intervention|no intervention|Routine care is administered without the application of cNEP.
89625035|NCT04121013|Active Comparator|Mothership|Acute stroke patients with suspected large vessel occlusion will be directly transferred to the nearest transportation to the endovascular center
89625036|NCT04121013|No Intervention|drip'n'ship|Acute stroke patients with suspected large vessel occlusion will be transferred to the closest local stroke centre or telemedicine hub as done with the current stroke protocol
89625037|NCT04126707|Experimental|[14C] HQP1351|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (30mg, 100µCi) of [14C] HQP1351 to healthy Chinese male subjects.
89625038|NCT01896544|Active Comparator|Cholecalciferol Dose II|Oral suspension cholecalciferol 400,000 IU
89625039|NCT01896544|Placebo Comparator|Placebo|Oral suspension of placebo cholecalciferol
89625040|NCT01896544|Active Comparator|Cholecalciferol Dose I|Oral suspension cholecalciferol 200,000 IU
89625041|NCT04120623|Experimental|Dapagliflozin combined with CSII|Dapagliflozin 10MG combined with Aspart infused by CSII as glucose lowering therapy.
89625042|NCT04120623|Active Comparator|CSII alone|Aspart infused by CSII alone as glucose lowering therapy.
89038664|NCT02895854|Active Comparator|Hypofractionated RT 5 x 7,25 Gy|Hypofractionated stereotactic radiotherapy 5 x 7,25 Gy delivered every second day in prostate cancer.
89038665|NCT00550251|Active Comparator|Acupressure Bands|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
89038666|NCT00550251|Placebo Comparator|Placebo|Elasticated wrist bands without active bead.
89038667|NCT01261390|Placebo Comparator|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide ~30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breath Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
89038668|NCT01261390|Sham Comparator|Sham PAP (Sham)|"In addition to receiving CMT, participants in this treatment arm will receive a sham-CPAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active PAP arms.~The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up~1-month follow up~3-month follow up~6-month follow up~9-month follow up (will not occur if on a 6-month follow-up protocol)~It is estimated that each in-person follow-up adherence visit with the PAP specialist would last ~30 minutes."
89057369|NCT01648257|Experimental|GSK1265744 Free Acid Micronized Capsules|Subjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
89057370|NCT04540250||Study group of Rheumatoid arthritis patients|RA patients receiving MTX as monotherapy were included in the study. Patients suffering from systemic disease known to cause oral manifestations; salivary gland diseases and malignancies were excluded.
89057371|NCT01648335|Active Comparator|immobilization of the shoulder in internal rotation|
89625043|NCT01767467|Experimental|Vaccine Group|Subjects will receive the candidate HZ vaccine (GSK 1437173A).
89625044|NCT01767467|Placebo Comparator|Placebo Group|Subjects will receive the placebo vaccine.
89625045|NCT02988232|Experimental|Treatment(SGHH)|Admission to Sogyeonghwalhyeol-tang granule
89625046|NCT02988232|Placebo Comparator|Placebo|admission to placebo
89625047|NCT04126629||Normotensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the normotensive group. Every attempt will be made to stratify both groups equally between second and third trimesters.
89625048|NCT04126629||Hypertensive Group|Subject will be allocated to the experimental group based on the clinical characteristics of their blood pressure. This will be the hypertensive group.Every attempt will be made to stratify both groups equally between second and third trimesters.
89625049|NCT04758897|Experimental|Single Arm|"5.0*10^7 on D1~1.0*10^8 on D1~2.0*10^8 on D1~2.0*10^8 on D1 and D2~2.0*10^8 on Days 1 to 3~2.0*10^8 on Days 1 to 4~2.0*10^8 on Days 1 to 5"
89057372|NCT01648335|Experimental|Immobilization of the shoulder in external rotation|
89057373|NCT02215460|Experimental|Full-mouth scaling (FMS)|
89625050|NCT01931878|Placebo Comparator|Placebo , saline|The subject may be randomly assigned to receive Placebo, saline
89625051|NCT01931878|Active Comparator|IncobotulinumtoxinA Treatment|The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)
89625052|NCT01932112|Other|adenosine arm|single arm study
89625053|NCT02987452|Experimental|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
89625054|NCT02987452|Active Comparator|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
89625055|NCT02987452|Active Comparator|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
89625056|NCT04120389|Experimental|BCL group|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)
89625057|NCT04120389|Active Comparator|control group|
89038669|NCT01261390|Active Comparator|Active PAP with RT Support (Active-Beh)|"In addition to receiving CMT, participants will receive active-PAP. The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up (FU)~1-month FU~3-month FU~6-month FU~9-month FU (12-month follow-up protocol only)~All visits will take place with a PAP specialist. All follow-up visits will be anchored to the initial PAP set-up visit. At these visits, using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. Each follow-up visit with the PAP specialist will last 30 minutes."
89038670|NCT01261390|Active Comparator|Active PAP with Behavioral Modification (Active+Beh)|"In addition to receiving CMT and active-PAP, participants will have behavioral intervention sessions to promote PAP adherence. The treatment visit schedule is outlined below:~Visits with Behavioral Interventionist (in addition to active-PAP treatment visits):~PAP Initial Set-Up (in-person, 1-hr)~1-week follow-up (FU) (in-person, 1-hr)~1-month FU~2-month FU~3-month FU~5-month FU~8-month FU (12-month follow-up protocol only)~All follow-up visits will be anchored to the initial PAP set-up visit. PAP treatment visits will occur as outlined in the active-PAP arm.~All behavioral intervention visits will be 30-min phone calls, unless otherwise noted. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training."
89038671|NCT02895815|Experimental|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 microliter (mcL) given by subretinal delivery system.
89038672|NCT02895815|Experimental|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system.
89038673|NCT02895815|No Intervention|Control Group|Participants will undergo observations without surgery.
89038674|NCT00552045||subject|individuals with epilepsy
89038675|NCT02895503|Experimental|Arm I (yoga)|Patients undergo traditional medical treatment, participate in yoga comprising basic postures and breathing exercises 3-4 times per week, and attend yoga class once weekly over 30-60 minutes for 12 weeks.
89038676|NCT02895503|Active Comparator|Arm II (emotional support group therapy)|Patients undergo traditional medical treatment and participate in emotional support group therapy with a chaplain to work on mind-body therapies comprising guided imagery and spirituality once weekly for 12 weeks.
89038677|NCT03455764|Experimental|MCS110+ Trametinib + Dabrafenib|"For Phase 1 MCS110 will be administered intravenously every 3 weeks.~Dabrafenib is given orally every 12 hours.~Trametinib is given orally daily"
89625058|NCT04120077|Placebo Comparator|DSME + placebo supplement (group 1)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects be instructed to consume two capsules (canola oil soft-gels) per day in the morning and two capsules per day in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
89625059|NCT04120077|Experimental|DSME + DVS supplement (group 2)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (canola oil placebo) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
89038678|NCT03455764|Experimental|MCS110 + Trametinib + Dabrafenib Phase 2|"MCS110 will be administered intravenously every 3 weeks.~The Dosage will be determine by the DLT of Phase 1~Dabrafenib is given orally every 12 hours.~Trametinib is given orally daily"
89038679|NCT04902495|Experimental|Pulp Dressing MTA Angelus|pulp therapy
89625060|NCT04120077|Experimental|DSME + DVS supplement + omega-3 supplement (group 3)|Subjects will receive 10-session DSME delivered in a group setting by their optometrist. Subjects will be instructed to consume two capsules per day (EyePromise DVS nutritional supplement) in the morning and two capsules per day (EyePromise EZTears) in the evening along with food and six to eight ounces of water, and continue their normal dietary, exercise and medication regimens. Baseline and 3,6,9, 12-month assessments of color perception, 10-degree visual field, flicker electroretinogram (ffERG), glycosylated hemoglobin, diabetic retinopathy severity and optical coherence tomography/optical coherence tomography angiography (OCT/OCTA) parameters will be assessed. Serum vitamin D, glycohemoglobin and high-sensitivity C-reactive protein (hsCRP) and macular pigment density will be assessed at baseline, 6 and 12 months.
89625061|NCT01897402|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
89625062|NCT01897402|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
89625063|NCT04126239||Participant suffering from obesity|Patient, male or female, over 18 and under 70 years old Patient group with a Body Mass Index (BMI) greater than or equal to 30 kg / m2
89625064|NCT04126239||healthy volunteer|
89625065|NCT04122339|Experimental|MAX-10181|tablet
89625066|NCT02280226|Experimental|Deliberate Apnea Group|Subjects undergo maximum apnea.
89625067|NCT01897792|Experimental|Vitamins C and E|Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
89038680|NCT04902495|Experimental|Pulp Dressing MTA Pro Root|pulp therapy
89038681|NCT04902495|Experimental|Pulp Dressing Biodentine|pulp therapy
89038682|NCT02895542||Oral Anti-Cancer Agent|No intervention
89038683|NCT00552162|Active Comparator|1|NOTES Transvaginal cholecystectomy The gallbladder will be dissected free and will be removed through an incision in the vagina.
89625068|NCT01897792|Placebo Comparator|0.9% saline and sugar pill|100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
89625069|NCT02982915|Experimental|Pilot Phase- Cohort A|Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
89625070|NCT02982915|Experimental|Pilot Phase Cohort B & C|Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
89625071|NCT02982915|Experimental|Double-Blind,Randomized,Placebo Phase|2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose.
88989870|NCT04741750|No Intervention|Usual Care within Community Clinics|Complete blood count, comprehensive metabolic panel, international normalized ratio, HCV RNA, hepatitis B virus (HBV) serologies, point of care HIV test, and point of care liver fibrosis measurement. HCV genotype if required by patient's insurance for prior authorization. Care for opioid use disorder and skin infection is offered. Completion of the initial visit workup is sufficient to initiate a prior authorization request for DAAs from payers and an appointment for MAT follow-up in a community clinic if indicated. Patient coordination; authorization with insurance companies; scheduling appointments, follow-up, and ancillary support services will be conducted by a Patient Navigator. Patients are seen every 2-4 weeks for monitoring and adherence support. HCV treatment regimens are at the discretion of the treating provider in accordance with AASLD/IDSA guidelines and insurance requirements. Twelve weeks after HCV therapy completion, SVR12 HCV RNA and SVR12 CMP tests will be obtained.
88989871|NCT04741750|Experimental|Simplified Care within a Mobile Medical Unit|Simplified Care treatment is the same as for Usual Care with the exception that it is taking place within a mobile medical clinic that is scheduled to deliver treatment in alignment with regular syringe exchange services.
88989872|NCT04736355|Experimental|DAOIB|oral, for 24 weeks
88989873|NCT04736355|Placebo Comparator|Placebo|oral, for 24 weeks
88989874|NCT04736134|Experimental|Active Treatment (BMS 986326) IV|Intravenous (IV)
88989875|NCT04736134|Experimental|Active Treatment (BMS 986326) SC|Subcutaneous (SC)
88989876|NCT04736134|Placebo Comparator|Placebo IV|
88989877|NCT04736134|Placebo Comparator|Placebo SC|
88989878|NCT04736134|Placebo Comparator|Multiple Ascending Dose Placebo SC|Placebo
88989879|NCT04736134|Experimental|Multiple Ascending Dose SC|BMS 986326 SC
88989880|NCT04731974|Placebo Comparator|Placebo|Liquid Placebo
88989881|NCT04731974|Active Comparator|Melatonin|Liquid Melatonin
88989882|NCT04731181|Experimental|mobile application (little lovely dentist).|intervention mobile application simulating the dental procedure that will be done to the child
88989883|NCT04731181|No Intervention|Tell-Show-Do technique.|control behavior technique where ''tell'' is to tell the child about the procedure in non-threatening words, ''show'' is to demonstrate the procedure to the child, and ''do'' is the execution of the procedure
88989884|NCT04726332|Experimental|XL102 Single-Agent Dose-Escalation Cohorts|"Subjects will be separated into three separate groups of cohorts. Formulation A consists of: Fasted, with approximately 9 cohorts (A-FC) starting at 20 mg (qd and/or bid) of XL102, Food-Effect Dose-Escalation at 40 mg qd of XL102, with approximately 3 cohorts (A-FE) and Non-Fasted, with approximately 6 cohorts (A-NF).~Formulation B consists of additional cohorts: Fasted (A-FCFB) starting at 40 mg (qd and/or bid) of XL102 and Non-Fasted (A-NFCFB).~The dose of the remaining A-FE cohorts will be determined by the Cohort Review Committee (CRC) as well as that of the A-NF, and A-NFCFB cohorts."
88989885|NCT04726332|Experimental|XL102 Single-Agent Expansion Cohorts|The Maximum Tolerated Dose (MTD) or recommended dose from the dose-escalation stage may be further explored in subjects with triple-negative breast cancer (TNBC) (Cohort D), epithelial ovarian cancer (EOC) (Cohort E), hormone receptor-positive breast cancer (HR+ BC) (Cohort F), and metastatic castration-resistant prostate cancer (mCRPC) (Cohort G).
88989886|NCT04726332|Experimental|XL102 + Fulvestrant Dose-Escalation Cohorts|Subjects with HR+ BC (Cohort B) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
88989887|NCT04726332|Experimental|XL102 + Abiraterone/Prednisone Dose-Escalation Cohorts|Subjects with mCRPC (Cohort C) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
88989888|NCT04726332|Experimental|XL102 + Fulvestrant Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with HR+ BC (Cohort H).
88989889|NCT04726332|Experimental|XL102 + Abiraterone/Prednisone Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with mCRPC (Cohort I).
88989890|NCT04722848|Experimental|Ponatinib+Blinatumomab|patients will receive induction with ponatinib followed by at least 2 cycles of blinatumomab
88989891|NCT04722848|Active Comparator|Chemotherapy+Imatinib|patients will receive a combination of imatinib and chemotherapy.
88989892|NCT04713280|Active Comparator|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary posterior dento-alveolar intrusion
88989893|NCT04713280|Experimental|Bi-maxillary posterior dento-alveolar intrusion|Mini-screw supported bi-maxillary posterior dento-alveolar intrusion
88989894|NCT04709705|Experimental|Cryopreserved platelets|Cryopreserved platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
88989895|NCT04709705|Active Comparator|Liquid stored platelets|Liquid stored platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal
88989896|NCT04709432||ECMO group|children supported by ECMO in the past 10 years
89038684|NCT00552162|Active Comparator|2|NOTES Transvaginal Appendectomy. The appendix will be dissected free and will be removed through an incision in the vagina.
89038685|NCT02895659|Active Comparator|Ringer lactate|Fluid resuscitation will be performed with lactated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
89038686|NCT02895659|Active Comparator|Ringer acetate|Fluid resuscitation will be performed with acetated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
89210999|NCT03659721|Experimental|FACAM|Intervention participants are assigned a support person (health nurse or a family therapist) who will offer support to the family until the child starts school at age 6. Intensity is up to 37 hours the first year followed by up to 10 hours of support each of the following years. The support person will offer individualized support to the family depending on the needs of the family. The support person will attend midwife consultations and help the pregnant woman to attend consultations with e.g. GP, midwife, or social worker. All intervention participants will also receive either an individual or group-based (COS-P)attachment based intervention during pregnancy and the first months of the child's life.
89211000|NCT03659721|Active Comparator|Care as Usual|Families in the control group receive the usual care that is offered to families in the target group. This includes consultations with e.g. a midwife, social worker, medical doctor, and health visitor. If needed, CAU families can receive e.g. extra home visits or family therapy.
89625072|NCT01933984|Experimental|Individualized dosing|"Ventilator support~Determining personal target airway resistance~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)"
89625073|NCT01933984|Active Comparator|Fixed dosing|"Ventilator support~Determining personal target airway resistance~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met"
89625074|NCT04126083|Experimental|Lofexidine|Patients will receive lofexidine 0.54 mg 4 times daily and the baseline opioid dose will be reduced by 10% daily.
89625075|NCT02282722|Active Comparator|Usual informed consent|Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.
89625076|NCT02282722|Experimental|Investigational informed consent|Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.
89625077|NCT04393545|Active Comparator|HV night splint (SP) group|
89625078|NCT04393545|Active Comparator|exercise (EX) group|
89625079|NCT04393545|Active Comparator|high-voltage galvanic stimulation (EL) group|
89625080|NCT04393155||COVID-19+|Hospitalized patients with acute respiratory failure (new oxygen requirement) due to COVID-19
89625081|NCT01935622|Experimental|Doxycycline 100 mg|Doxycycline 100 mg twice daily for 14 days
89625082|NCT01935622|Experimental|Doxycycline 20 mg|Doxycycline 20 mg twice daily for 14 days
89625083|NCT01935622|Placebo Comparator|Placebo|Placebo
89625084|NCT03010917|Experimental|Fish Oil with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
89625085|NCT03010917|Placebo Comparator|Placebo with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
89625086|NCT03008187|Experimental|SEL24/MEN1703|"SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.~Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients.~Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1."
89625087|NCT01936324|Experimental|Phase 1|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers
89625088|NCT01936324|Experimental|Phase 2a|Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
89625089|NCT04274673|Other|low (less 10ng/dl)|Patients who have low cotinine levels (less 10ng/dl)
89625090|NCT04274673|Other|medium (10-500ng/dl)|Patients who have medium cotinine levels (less 10-500ng/dl)
89625091|NCT04274673|Other|high (more 500ng/dl)|Patients who have high cotinine levels (less 10-500ng/dl)
89625092|NCT02979561|Experimental|group of dabigatran|
89625093|NCT02979561|Active Comparator|group of warfarin|
89625094|NCT01766921|Experimental|aH5N1c - High dose|
89625095|NCT01766921|Experimental|aH5N1c - Low dose|
89625096|NCT01937026|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
89625097|NCT01937026|Experimental|Baricitinib + Probenecid|Oral doses of 1000 mg probenecid once daily on Days 3 through 7, with a single oral dose of 4 mg baricitinib co-administered on Day 5
89625098|NCT04759053|Active Comparator|FNB|
89625099|NCT04759053|Active Comparator|Core biopsy|
89625100|NCT03833050||Heart Transplant Recipients|"Heart Transplant Recipients meeting the criteria for enrollment and consented will be followed post transplant for 1 year after enrollment into the study.~Blood samples will be obtained at their 1, 3, 6, 12 months and any for cause heart biopsy's obtained. There will be no active intervention for recipients that are enrolled. Results from the samples will not be obtained in real time."
89625101|NCT04393467|Experimental|real tSMS|tSMS will be delivered by a magnet applied to M1, bilaterally (120 min daily, for 6 months). Magnet will be kept in position by a plastic helmet.
89625102|NCT04393467|Sham Comparator|sham tSMS|A non-magnetic steel cylinder, with same size, weight and appearance of the magnet, will be used for sham stimulation.
89625103|NCT01774799|Experimental|Advance care planning intervention|At baseline, health care proxies in the intervention arm will be shown a 12-minute Advance Care planning video that describes 3 levels of treatment in advanced dementia: comfort basic and intensive. After viewing the video, the proxies will be asked their preferred level of care for the resident and this choice will be communicated to the residents primary care team in a written form.
89625104|NCT01774799|Active Comparator|Usual care|Residents in control nursing homes with receive the usual advance care planning that occurs in their nursing home.
89625105|NCT03825783|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single infusion in subjects with severe LAD-I
89625106|NCT03824223|Other|new/old HCT component order|"new/old hypoxic challenge test (HCT) component order~Where the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen and the old test uses pulse oximetry to titrate supplementary oxygen."
89625107|NCT03824223|Other|old/new HCT component order|"old/new hypoxic challenge test (HCT) component order~Where the old test uses pulse oximetry to titrate supplementary oxygen and the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen."
89625108|NCT03828903|Experimental|pleural effusion patients|medical thoracoscopy will e performed to patients with pleural effusion and pleural biopsy by forceps ad cryoprobe will be obtained
89625109|NCT01937260|Experimental|Brodalumab 140mg SC|open label, all subjects receive brodulamab
89625110|NCT01937260|Experimental|Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC|MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)
89625111|NCT04125381||Exposed to high Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with high Arsenic concentration in drinking water, were enrolled
88989897|NCT04703647||Patients with CRPS type 1: prospective group|"Ambulatory patients of the Clinique romande de réadaptation (CRR) which have a CRPS type 1 of a limb.~Five measurement times (first visit (T0) and then after 3 (T1), 6 (T2), 12 (T3) and 24 (T4) months). At every time point, following data will be collected: physical examination, monitoring of the health and professional status with the physician, and self-administrated questionnaires. Blood sampling will be performed at T0, T1,T2 and T3.~Eight different self-administrated questionnaires will be used, in their French or Portuguese version. Each participants will answer seven questionnaires each time, depending if he/she suffers of arm or leg injury.~We will assess, in blood samples, the expression levels of specific molecules (miRNAs and a selection of cytokines) in patients diagnosed with acute CRPS. In a second time, miRNAs and cytokines profiles will be compared between acute and chronic (CRPS still diagnosed 6 months after the first diagnosis) CRPS patients."
88989898|NCT04703647||control group for blood analysis|"For the blood analysis, we will recruit 30 healthy controls who did not report any kind of pain. They will be recruited via posters that will be posted on the billboards of the Hôpital de Sion (employees and visitors) and on the visitor's billboards of the CRR. If this is not enough, we will expand the recruitment perimeter with other locations. The healthy control will be adjusted for age, sex and BMI with the CRPS groups. They will be informed about the study and procedure. The procedure for the blood samples will be the same as for patients.The screening for miRNAs of interest will be performed using a decision tree-based ensemble method (Random Forest). For this step, miRNAs profile of 30 control patients will be compared to the same number of CRPS patients.~The control group will have just one blood analysis."
88989899|NCT04700527|Active Comparator|Short Chain Fatty Acid (SCFA)|4-6 grams of powder mixed with food and taken everyday starting 1 week prior-1 week post Radiation Therapy.
88989900|NCT04700527|Placebo Comparator|Placebo (Tapioca)|5 grams taken everyday starting 1 week prior-1 week post Radiation Therapy.
88989901|NCT04699864|Experimental|Diabetic Retinopathy (DR)|Screening of DR with artificial intelligence (NeoRetina algorithm) and diagnostic evaluation with a standard of care ophthalmological examination.
88989902|NCT04697940|Experimental|Refractory or Relapsed Non-Hodgkin's Lymphoma|"A conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, autologous decitabine-primed Tandem CAR19/20 engineered T cells.~Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control."
88989903|NCT04696601|Experimental|Olfactory test|The result of the olfactory test will be compared to the result of the RT-PCR test.
88989904|NCT04694183|Experimental|Conversion therapy|Camrelizumab combined with chemotherapy selected per metastasis site.
89057374|NCT02215460|Experimental|FMS chlorhexidine rinse|
89057375|NCT02215460|Experimental|FMS azithromycin tablets|
89625112|NCT04125381||Exposed to low Arsenic concentration|All the inhabitants, residing in one of the municipalities of Viterbo Province with low Arsenic concentration in drinking water, were enrolled
89625113|NCT04125615|Experimental|Protected Non-Clinical Time|Protected non-clinical time
89625114|NCT04125615|No Intervention|Control Period|No protected non-clinical time
89625115|NCT01902004|Active Comparator|Escitalopram and Memantine|Participants will take a combination of Escitalopram and Memantine for 12 months
89625116|NCT01902004|Active Comparator|Escitalopram and placebo|Participants will take a combination of Escitalopram and placebo for 12 months
89625117|NCT04125303|Experimental|Intervention Group|Based on NANDA diagnosis recommendations, entertainment-sector workers were asked to record their perceptions and the meaning of their substance-use problem in a diary. The intervention was subsequently designed based on brief motivational psychoeducational therapy (BMPT).
89625118|NCT03829995|No Intervention|Control group|Participants in the control group received the normal care following the Danish standard procedure.
89625119|NCT03829995|Active Comparator|Intervention group|Participants in the intervention group received the normal care following the Danish stadard procedure. Additionally the participants was also offered the possibility to contact a hospital pharmacy department by phone or mail for drug counseling.
89625120|NCT01938040|Active Comparator|Ibuprofen|800mg administered IV in 100cc of normal saline over 5 minutes
89625121|NCT01938040|Placebo Comparator|Sugar water|100mL of normal saline to be administered over 5 minutes
89625122|NCT04125849|Active Comparator|Thoraco-laparoscopic esophagectomy|Treated by thoraco-laparoscopic esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
89625123|NCT04125849|Active Comparator|Mediastinoscopy-assisted transhiatal esophagectomy|Treated by mediastinoscopy-assisted transhiatal esophagectomy in the centers with enough experience in esophageal resection and the volume ≧80 cases each year.
89625124|NCT01765751|Active Comparator|Manual Cervical Distraction High Force|Manual Cervical Distraction forces will be limited to greater than 50N in the high force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
89625125|NCT01765751|Active Comparator|Manual Cervical Distraction Medium Force|Manual Cervical Distraction forces will be limited to between 20N-50N in the medium force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
89625126|NCT01765751|Sham Comparator|Manual Cervical Distraction Low Force|Manual Cervical Distraction forces will be limited to less than 20N in the low force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
89625127|NCT03829839|Active Comparator|Oxytocin or PLC|Single dose of intranasal oxytocin (24 international units) or PLC.
89625128|NCT03829839|Active Comparator|Lorazepam or PLC|Single dose of lorazepam (1mg) or PLC
89625129|NCT01938664|Experimental|Candesartan w Cognitive Behavior Therapy|Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
89625130|NCT01938664|Placebo Comparator|Placebo w Cognitive Behavior Therapy|Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
89625131|NCT03829917|Experimental|Paromomycin and Miltefosine|Paromomycin-Aquaphilic cream applied topically once daily for 28 days plus oral miltefosine pills 2.5 mg/day [50 mg tid] for 28 days.
89625132|NCT03829917|Active Comparator|Miltefosine|Miltefosine pills alone [2.5 mg/day [50 mg tid] for 28 days. This group will also receive Aquaphilic-vehicle cream for 28 days
89625133|NCT03829917|Active Comparator|Paromomycin|Paromomycin-Aquaphilic cream applied topically once daily for 28 days.
89625134|NCT03829449|Experimental|rVA576 Coversin|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.
89625135|NCT01736657|Experimental|Red cell exchange in sickle cell|Open arm; Red cell blood exchange for patients with sickle cell disease
89625136|NCT04124679|Experimental|TAES group|In TEAS group, an experienced acupuncturist performed 30 minutes of TEAS treatment at the HT7 (Shenmen) and Neiguan (PC6) acupoints on bilateral side, which were identiﬁed in accordance with the TCM anatomic localizations on the first night before surgery by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no.: SDZ-II; Suzhou Medical Appliances Co. Ltd, Suzhou, China). And after surgery, ST36 (Zusanli) and LI4 (Hegu) acupoints were added for the effect of relieving postoperative complications. 30 minutes of TEAS treatment was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints on the first three nights after surgery
89625137|NCT04124679|No Intervention|Control group|Patients in the control group were attached the gel electrodes at the sham acupoints
89625138|NCT02284126|Experimental|Topical Vancomycin|Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis
89625139|NCT02284126|No Intervention|Standard of Care|Control group, receive standard of care only
89625140|NCT01736579|Experimental|IGIV, 10% at 0.2 g/kg body weight|IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
89625141|NCT01736579|Experimental|IGIV, 10% at 0.4 g/kg body weight|IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months
89625142|NCT02974335||Primary Care Providers (PCPs)|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
89625143|NCT02974335||Medical Assistants (MAs) + Registered Nurses (RNs)|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
89625144|NCT02974335||Patients|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
89625145|NCT01939288|Experimental|Group 1|Half of recruited subjects (n=5)
89625146|NCT01939288|Experimental|Group 2|Other half of recruited subjects (n=5)
89625147|NCT01940146|Placebo Comparator|SPARC Placebo|
89625148|NCT01940146|Experimental|SPARC1310 I|
89625149|NCT01940146|Experimental|SPARC1310 II|
89625150|NCT01940146|Experimental|SPARC1310 III|
89625151|NCT01765673||Vibrotactile Stimulation in Dysphagia|A Vibrotactile stimulation device will be evaluated in patients with chronic moderate to severe dysphagia for more than 6 months post onset due to stroke or following radiation treatment for head and neck cancer to assess which frequency, mode, pressure characteristics are most helpful in increasing the rate of swallowing, increasing the urge to swallow, assisting with the initiation of swallowing and not affecting discomfort.
89625152|NCT04124913|Experimental|Dydrogesterone|
89625153|NCT04124913|Active Comparator|Vaginal progesterone|
89625154|NCT03828279||hereditary angioedema type I|Patients were diagnosed as C1 inhibitor HAE type I when functional and antigenic C1 inhibitor were ≤ 50% of normal
89625155|NCT03828279||hereditary angioedema type II|Patients were diagnosed as type II when functional C1 inhibitor was ≤50% and antigenic was >50% of normal
89625156|NCT02987920|Active Comparator|Placebo - Concentrate|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Placebo - Concentrate by mouth.~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain"
89625157|NCT02987920|Experimental|Dextromethorphan|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Dextromethorphan 60mg tablet~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain, and dextromethorphan 60mg by mouth twice daily"
89625158|NCT03902301|Active Comparator|Dietary group|A diet based on general recommendations for people with insulin resistance for 20 weeks.
89625159|NCT03902301|Experimental|Lactobacillus rhamnosus group|Lactobacillus rhamnosus for 20 weeks, (2x 6×10 9 CFU/per capsulex); A diet based on general recommendations for people with insulin resistance.
89625160|NCT01764659||All enrolled patients|Contrast-enhanced 4D computed tomography
89625161|NCT03828123|Experimental|Autologous Multipotent MSC|Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
89625162|NCT02974257|Experimental|Thiamine|Intervention: Thiamine 500mg IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
89625163|NCT02974257|Placebo Comparator|Placebo|Intervention: Placebo (100mL normal saline) IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
89625164|NCT01736189||Participants treated with adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 104 weeks
89625165|NCT01903564||normal|pregnant women with uncomplicated pregnancies
89625166|NCT01903564||high-risk|pregnant women with pregnancies complicated by fetal arrhythmia or the risk of fetal arrhythmia
89625167|NCT02970981|Experimental|Nivolumab and Ipilimumab|"Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)~Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks."
89625168|NCT02987842|Experimental|Experimental group|Patients in the experimental group will receive feedback using the TruScan Neurofeedback system in order to increase the power of EEG in the range of their individual upper alpha (as determined by the peak alpha frequency)
89625169|NCT02987842|Sham Comparator|Sham group|Patients in the sham group will receive feedback using the TruScan Neurofeedback system for electrical static activity of a disconnected electrode.
89625170|NCT04169711|Experimental|ARO-HIF2|
89625171|NCT03829137|Experimental|Verum laser acupuncture|Verum laser acupuncture：Low level laser therapy stimulates 7 acupuncture points on both sides of the body .
89625172|NCT03829137|Sham Comparator|Sham laser acupuncture|sham laser acupuncture (no laser output)
89625173|NCT03829293|Experimental|High-flow nasal cannula oxygenation group|Participants in the experimental group will receive high-flow nasal oxygen therapy (HFNO) during gastrointestinal endoscopy under sedation (with a flow at 70L/min and oxygen inspired fraction (FiO2) 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
89625174|NCT03829293|No Intervention|Standard Oxygenation|Participants in the current standard of care will receive standard oxygenation by nasal prongs (with a flow at 6L/min) or naropharyngeal catheter (with a flow at 5L/min) or standard face mask (with a flow at 6L/min)
89625175|NCT03828435|Experimental|healthy control|This group does not undergo any treatment . Intervention : rTMS
89625176|NCT03828435|Experimental|stroke patient|"this group undergoes rehabilitative therapy. It is a 24-week program and stroke patients practice the physical exercise for 1 hour each time. The intensity is three times a week.~Intervention : rTMS"
89625177|NCT02983773|Experimental|High THC dose|1 marijuana cigarette (7.2% THC)
89625178|NCT02983773|Experimental|Low THC dose|1 marijuana cigarette (3.0% THC)
89625179|NCT02983773|Placebo Comparator|Placebo|Placebo marijuana cigarette
89625180|NCT03828591|Other|Group A (intensive support)|Patients that receive standard and intensive psychological support during hospitalization
89625181|NCT03828591|Other|Group B (standard support)|Patients that receive only standard psychological support during hospitalization
89057376|NCT02215460|Placebo Comparator|FMS placebo rinse|
89057377|NCT02215460|Experimental|Quadrant scaling (QS)|
89057378|NCT02215460|Experimental|QS chlorhexidine rinse|
89057379|NCT02215460|Experimental|QS azithromycin tablets|
89057380|NCT02215460|Placebo Comparator|QS placebo tablets|
89057381|NCT02215460|Placebo Comparator|FMS placebo tablets|
89057382|NCT02215460|Placebo Comparator|QS placebo rinse|
89057383|NCT01682382||choroidal neovascular (CNV) AMD subjects|Subjects diagnosed with CNV (AREDS Grade 4b)
89057384|NCT01682382||dry AMD subjects|Subjects diagnosed with dry AMD (AREDS Grade 3)
89057385|NCT01682382||age-matched controls|Subjects without AMD (AREDS Grade 1)
89057386|NCT02215499|Active Comparator|Xyrem®|Oral suspension
89057387|NCT02215499|Experimental|JZP-386|Oral suspension
89057388|NCT02215499|Placebo Comparator|Placebo|Oral suspension
89057389|NCT01648608|Experimental|Exemestane|Exemestane for neoadjuvant chemotherapy
89057390|NCT02215538|Experimental|OROS methylphenidate|This was a 4-week double-blind arm. Medication was initiated at 18 mg/day and increased every 2 or 3 days by 9 mg based on treatment response and side effects. Maximum dose - 90 mg/day. Patients were seen weekly. Generally a stable dose was seen in 2 weeks and maintained the last 2 weeks of the arm. Side effects were assessed at each visit.
89057391|NCT02215538|Placebo Comparator|placebo|This arm was identical to the active medication arm except that placebo replaced the active medication.
89057392|NCT01682421|Experimental|Weak steroid|Initial treatment with dexamethasone 6x per day for two weeks, followed by Fluorometholone 4x per day for 2 months, 3x per day for 2 months, 2x per day for 2 months, and finally 1x per day continually during 2 years.
89057393|NCT01682421|Experimental|Potent steroid|Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month - giving a total of 4,5 months of steroid treatment.
89038687|NCT02895464|Experimental|Exercise group|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
89038688|NCT02895464|Other|Control group|The participants will receive ordinary preoperative information, but will also be encouraged to follow the recommendation of 150 minutes/week of moderate physical activity.
89625182|NCT01941472|Experimental|Septic shock|Adult patients (at least 18 years of age) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of invasive hemodynamic monitoring. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
89625183|NCT04274205|Active Comparator|Influence on brief supportive psychotherapy|Intervention group
89625184|NCT04274205|Active Comparator|Influence of brief supportive psychotherapy|Control group
89625185|NCT03828669||Usual Care|Prior to the roll-out of the Recovery Toolkit program, all post-surgical patients receiving current standard of care are given pain care surveys at hospital discharge. Survey questions ask about pain, and satisfaction with pain care. The investigators will conduct chart review for pain and opioid use.
89625186|NCT03828669||Recovery Toolkit|After launch of the Recovery Toolkit program on Jan 25, all post-surgical patients will be offered a Recovery Toolkit by a unit nurse. A pain survey will be administered at hospital discharge to assess about pain in the hospital, satisfaction with pain care, whether they received a Toolkit, use of the Toolkit, and likelihood to recommend the Toolkit. The investigators will conduct chart review for pain and opioid use.
89625187|NCT01941628|Experimental|Rocuronium|In this group rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
89625188|NCT01941628|Active Comparator|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
89625189|NCT02987218|Active Comparator|PROPOFOL|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP(Intracranial pressure) Better cognitive Function preservation
89625190|NCT02987218|Active Comparator|DESFLURANE|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
89625191|NCT03822429||women < 35 years old|
89625192|NCT03822429||women between 36 and 38 years old|
89625193|NCT03822429||women between 39 and 40 years|
89625194|NCT03822429||women > 41 years old|
89625195|NCT01735175|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
89625196|NCT01735175|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
89625197|NCT03822273|Experimental|Traditional acupuncture (TA)|The subject will receive real acupuncture treatment once per day for 3 days after enrollment.
89625198|NCT03822273|Active Comparator|Laser acupuncture (LA)|The subject will receive laser acupuncture treatment once per day for 3 days after enrollment.
89625199|NCT03822273|Placebo Comparator|Sham laser acupuncture (SLA)|The subject will receive sham laser acupuncture treatment once per day for 3 days after enrollment.
89625200|NCT01942720|Other|Capsule endoscopy|
89625201|NCT03827577|Experimental|LAT arm|"Lung resection (if primary in place) + local ablative therapy of all metastatic sites + standard medical treatment.~patients may be enrolled either before any systemic therapy or after 3 months of treatment without progression according to local coordinator decision"
89625202|NCT03827577|Active Comparator|Control Arm|"Standard medical treatment~Local ablative therapy on the brain will be administered in any case to patients harboring cerebral oligometastases"
89625203|NCT01762943|Experimental|Women with Postpartum Depression (PPD)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
89625204|NCT01762943|Experimental|Women without any psychiatric history (Control)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
89625205|NCT01943110|Experimental|Saline injection with ID adapters|"Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:~Upper deltoid with the side-load ID adapter~Upper deltoid with the AD ID adapter~Suprascapular (behind the shoulder) with the side-load ID adapter~Suprascapular with the AD ID adapter~Forearm with the side-load ID adapter~Forearm with the AD ID adapter"
89625206|NCT03827733||AD patients|Participants who are diagnosed with AD.
89625207|NCT03827733||Partners of the AD patients|Partners of AD patients who live together with the AD patients.
89038689|NCT03391882|Experimental|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
89038690|NCT03391882|Active Comparator|subcutaneous apomorphine|subcutaneous apomorphine , Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
89038691|NCT02895620|Other|NMIBC patients Xpert bladder test|Xpert bladder test of urine of patients with NMIBC treated with BCG therapy
89038692|NCT00550485|Other|1|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype A)
89038693|NCT00550485|Other|2|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype B)
89038694|NCT01261000|Experimental|Pegvisomant|
89038695|NCT02895776||General Sedation|Case patients: Endovascular Acute Stroke Therapy scheduled to be performed under local sedation and finally performed under General anesthesia
89038696|NCT02895776||local sedation|Control patients: Endovascular Acute Stroke Therapy scheduled to be performed, and actually performed under conscious Sedation
89038697|NCT00550524|Experimental|A|Knee osteoarthritis
89038698|NCT02895737|Other|balloon-expandable TAVI without cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection
89038699|NCT02895737|Other|balloon-expandable TAVI with cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection
89038700|NCT02895737|Other|self-expandable TAVI without cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection
89038701|NCT02895737|Other|self-expandable TAVI with cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection
89038702|NCT00550563|Experimental|Oral Cholecalciferol|Patients receive oral cholecalciferol 2000 IU once daily for 1 year
89625208|NCT03827733||Elderly participants with normal cognition|Community dwelling elderly with normal cognition and with AD.
89625209|NCT03331354|Active Comparator|Self-help resources|a self-help vocational manual
89038703|NCT02895698|Active Comparator|Treatment group|Dry cupping + active dorsiflexion exercise + stretching exercise
89038704|NCT02895698|Other|Control group|stretching exercise + active dorsiflexion without cupping
89038705|NCT02895191|Experimental|Cohort 1|Cohort 1- Ulinastatin 4.8 million units per day
89038706|NCT02895191|Experimental|Cohort 2|Cohort 2- Ulinastatin 2.4 million units per day
89038707|NCT02895191|Experimental|Cohort 3|Cohort 3- Ulinastatin 1.2 million units per day
89038708|NCT02895191|Placebo Comparator|control group|Placebo
89038709|NCT02895269|Experimental|Collaborative shared care|Conventional primary health care providers (PHCP) are trained to collaborate with and support traditional and faith healers (complementary alternative providers, CAPs) in the care of patients with psychosis. The PHCP are purposively trained to deliver evidence-based treatment for psychosis and to conduct scheduled and on-request visits to the facilities of the CAPs to collaborate in the treatment of patients with psychosis through joint decision making and clinical management. The overall care of the patients remains the responsibility of the healers. The role of the PHCP is to support the healers deliver safe and acceptable care to patients, including the promotion of and respect for human rights and avoidance of harmful practices in the care of patients.
89038710|NCT02895269|Active Comparator|Usual care|Complementary alternative providers deliver intervention for patients with psychosis without active or formal collaboration with conventional primary health care providers. The primary health care providers in this arm nevertheless receive training on evidence-based treatment of psychosis.
89038711|NCT04765020|Experimental|Intervention group|12 weeks moderate to high-intensity exercise program
89625210|NCT03331354|Experimental|Compass|a distant learning vocational program
89625211|NCT02925819||SEVERE MITRAL VALVE DISEASE|All patients with symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement, and not eligible for surgery according to the heart-team.
89625212|NCT01943344|Experimental|Treatment|Subjects that receive VIVASURE CLOSURE DEVICE™
89625213|NCT04392063|Other|Cerebral palsy|Not included
89625214|NCT01903798|Active Comparator|Prednisolone (Lille <0.45)|At Day 8, after randomization, this participants will continue prednisolone 40 mg/day (current standard of care) for 21 days.
89625215|NCT01903798|Experimental|Prednisolone, rilonacept (Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive rilonacept (Arcalyst®) once a week for 21 days. After randomization at Day 8, study participants will be given 320 mg subcutaneously (two injections of 2.0 ml, 160 mg each). On Day 15 and Day 22, study participants will be given 160 mg subcutaneously (one injection of 160 mg).
89625216|NCT01903798|Active Comparator|Prednisolone (Lille >0.45)|Prednisolone (40 mg/day) for the first 7 days, after randomization at Day 8, they will stop all therapy.
89625217|NCT01903798|Experimental|Prednisolone, mycophenolate(Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive mycophenolate mofetil (CellCept®) for a total of 21 days. After randomization at Day 8, they will receive CellCept® at a dose of 1000 mg per day for the first four days followed by 2000 mg per day (two 500 mg tablets bid) for the remaining 17 days.
89625218|NCT03821961|Experimental|Metabolic surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
89625219|NCT01909180|Experimental|Cardiac|Revolution CT Cardiac Imaging Scan
89625220|NCT01909180|Experimental|Body/Extremity|Revolution CT Body and/or Extremity Imaging Scan
89625221|NCT01909180|Experimental|Neuro|Revolution CT Brain and Spinal Cord Imaging Scan
89625222|NCT04273815|Experimental|TQ-A3334 tablets|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle.
89625223|NCT04273815|Experimental|TQ-A3334 tablets + anlotinib capsules|TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89625224|NCT01945138|No Intervention|Control|Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.
89625225|NCT01945138|Experimental|Closed Loop Insulin|Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
89625226|NCT03810339|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
89038712|NCT04765020|No Intervention|Control group|exercise recommendations
89038713|NCT00550641|Active Comparator|1|
89038714|NCT00550641|Experimental|2|
89038715|NCT04680650|Experimental|Group DS|Anesthesia was maintained with sevoflurane and target-controlled infusion of remifentanil in the group DS
89038716|NCT04680650|Active Comparator|Group DP|Anesthesia was maintained with propofol and target-controlled infusion of remifentanil in the group DP
89038717|NCT04680572|Active Comparator|Bipolar hemiarthroplasty group|
89625227|NCT01734785|Active Comparator|Linagliptin|5 mg once daily
89211001|NCT04015674|Experimental|Exercise group|Patients will remain in supine position for 5 minutes to measure their vascular caliber of the AVF by echography. After, will be instructed to perform 30 minutes on stationary bicycle (Model Monark). The AVF vascular caliber will be measured during aerobic exercise. Because it is a cross-over trial, participants will perform the other arm after 7 days.
89211002|NCT04015674|Active Comparator|Control group|The patients will perform 30 minutes of rest in a chair and the measurements will be performed in the same moments established by the exercise group. Because it is a cross-over trial, participants will perform the other arm after 7 days.
89211003|NCT00929760|Active Comparator|nephrologists|Combined management PCP: nephrologists (at least 4 nephrology visits/year)
89211004|NCT00929760|Active Comparator|Primary Care Physicians|Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG
89211005|NCT00817466|Experimental|Racemic adrenaline, fixed intervals|Active drug with fixed intervals of inhalation, adjusted at least every 24h.
89211006|NCT00817466|Experimental|Racemic adrenalin, on demand|Racemic adrenaline, inhalations on demand (max every 2 hrs)
89211007|NCT00817466|Active Comparator|Saline, fixed intervals|Saline inhalation fixed intervals, adjusted at least every 24 hrs
89211008|NCT00817466|Active Comparator|saline on demand|Saline inhalations on demand, max every 2 hrs, adjusted every 12 hrs
89211009|NCT00926250|Experimental|PS-IPC supplementation|
89211010|NCT00926250|Placebo Comparator|Placebo supplementation|
89625228|NCT01734785|Experimental|Empaglifozin + Linagliptin low dose|1 tablet once daily
89625229|NCT01734785|Experimental|Empagliflozin + Linagliptin high dose|1 tablet once daily
89625230|NCT03821805|Experimental|Foot reflexology massage group|The duration of intervention was 30 min (15 min massage duration for each leg)
89625231|NCT03821805|No Intervention|Control group|Rest for 30 min
89625232|NCT03008031|Experimental|arm A (40%)|Patients randomized in arm A will receive a second CESM exam with 40% of the initial dose of the contrast agent.
89625233|NCT03008031|Experimental|arm B (60%)|Patients randomized in arm A will receive a second CESM exam with 60% of the initial dose of the contrast agent.
89625234|NCT03008031|Experimental|arm C (80%)|Patients randomized in arm A will receive a second CESM exam with 80% of the initial dose of the contrast agent.
89625235|NCT03821415|Experimental|1 - RP101 0.05%|RP101 0.05% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
89625236|NCT03821415|Experimental|2 - RP101 0.1% / Placebo|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye in the morning (q.d.) followed by one drop of placebo each eye in the evening for 90 consecutive days
89625237|NCT03821415|Experimental|3 - RP101 0.1%|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
89625238|NCT03821415|Placebo Comparator|4 - Placebo|RP101 matching placebo, ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
89625239|NCT03821181|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
89625240|NCT03821181|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
89625241|NCT03821025|Active Comparator|Multiple Plastic Stents|Patients will receive two 8.5Fr Platic biliary stents placed side by side across the biliary stricture.
89625242|NCT03821025|Active Comparator|Self-expandable Metal Stents|Patients will receive a fully covered Self-expandable Metal Stents (10mm) across the biliary stricture
89211011|NCT03627351||Healthy Women and Men|Group of healthy women and men
89625243|NCT01734395||Galantamine|Patients will receive galantamine 8 mg/day for the first 4 weeks and the dose of galantamine will be increased up to 24 mg (if tolerable).
89211012|NCT04582370|Experimental|Theater program|"The design of the 10-week theater program is based on the principles of acting as written and practiced by Constantin Stanislavski in his revolutionary text on acting: An Actor Prepares [Stanislavsky C, 1989]. The exercises target concentration, voice, physical skills, emotion memory, observation, and dramatic analysis and include 3 components: 1. Preparation for the Actor (which involves relaxation , collaboration, movement, posture, and vocality; 2. Learning the Components of the Repeatable Acting Process (which involves physicality, attention, and concentration); and 3. Synthesizing Components into Characterization (which involves creativity and emotional expression).~Each of these components will be addressed during each of 20 sessions through the use of group warm ups, group ensemble exercises, and group recitations. Participants will perform physical, mental, and emotional exercises similar to those given to beginning acting students in traditional theater schools."
89211013|NCT04582370|No Intervention|Wait-list control|During the study period, the control group will not receive any type of intervention. However, they will be offered the same theater program experience after the primary data collection period ends.
89211014|NCT00908154|Other|Cohort 1|
89211015|NCT00908154|Other|Cohort 4|
89211016|NCT00908154|Other|Cohort 3|
89625244|NCT03820869|Active Comparator|Control|Children with ASD
89211017|NCT00908154|Other|Cohort 2|
89211018|NCT00830648|Experimental|1|
89211019|NCT00929916||AM dosing of MoviPrep®|Take prep morning of exam
89625245|NCT03820869|Experimental|Intervention|Children with ASD
89625246|NCT03820713|Experimental|Investigational arm|Treatment group receives a concentrate of coagulation factors. The device concentrates coagulation factors from donor plasma; the concentrate is applied to the surgical site intended to reduce the incidence, extent and severity of postoperative adhesions.
89625247|NCT03820713|Placebo Comparator|Control arm|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
89211020|NCT00929916||PM/AM dosing of MoviPrep®|half of the volume of prep(1L) solution the evening prior, and half (1L) the morning of, colonoscopy.
89211021|NCT04708899|Active Comparator|Cases|cases will receive the proposed program(the arabic version of differential processing training program)
89211022|NCT04708899|Active Comparator|control|controls will receive the computer based auditory training program (CBAT)
89211023|NCT00926484||Tooth Mousse|
89625248|NCT01945294|Experimental|Arm 1: 16-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).
89625249|NCT01945294|Experimental|Arm 2: 28-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).
89625250|NCT01945294|Experimental|Arm 3: 48-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).
89625251|NCT01947946|Experimental|Benra 30 mg q.4 Weeks|Fixed 30 mg dose of benralizumab (every 4 weeks)
89625252|NCT01947946|Experimental|Benra 30 mg - Placebo q.8 Weeks|Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
89625253|NCT01947946|Placebo Comparator|Placebo|A (Dummy) injection
89625254|NCT03820635||Calcified|those with evidence of vascular calcification
89625255|NCT03820635||Non-calcified|those with no evidence of vascular calcification
89625256|NCT03820401|Experimental|Solacea_postHDF_1/1anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625257|NCT03820401|Experimental|Solacea_postHDF_1/2anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89211024|NCT00926484||fluoride varnish|
89625258|NCT03820401|Experimental|FX800_postHDF_1/1anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625259|NCT03820401|Experimental|FX800_postHDF_1/2anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89211025|NCT00926484||Tooth Mousse + fluoride varnish|
89211026|NCT00930072|Experimental|Block|
89211027|NCT00930072|No Intervention|Standard Care|
89211028|NCT00626522|Experimental|1|
89211029|NCT00626522|Experimental|2|
89211030|NCT00626522|Experimental|3|
89211031|NCT00626522|Placebo Comparator|4|
88989905|NCT04693715|Experimental|RNS60 0.5 mL/kg/h|RNS60 0.5 mL/kg/h infusion for 48h (up to a maximum of 60 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
89211032|NCT00626522|Placebo Comparator|5|
89211033|NCT00626522|Placebo Comparator|6|
89211034|NCT00926562|Experimental|Iopromide|Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation
89211035|NCT00926562|Active Comparator|Iodixanol|Drug: Visipaque 320 mgl/ml, injection of intra-artery
89211036|NCT04366791|Experimental|Supportive care (low-dose radiation therapy)|Patients undergo 1 fraction of low-dose radiation therapy.
89211037|NCT00926640|Experimental|1|Belinostat dose escalation
89211038|NCT00926640|Experimental|2|Belinostat UGT1A1 wild type/*28 variant
89211039|NCT00926640|Experimental|3|Belinostat UGT1A1*60 or 2/3/4 variant
89211040|NCT04656171|Experimental|Minor patients with Fanconi anemia|MRI of hands and forearm, neuropsychological and neuromotor tests
89211041|NCT04656171|Active Comparator|Minor controls|MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation
89211042|NCT00830726||1|Healthy volunteers
89211043|NCT00830726||2|Patients with symptomatic heart failure and EF < 40%
89211044|NCT00830726||3|Patients with symptomatic aortic valve stenosis
89211045|NCT00830726||4|Patients with Acute Coronary syndromes prior to surgical intervention
89211046|NCT00830726||5|Patients with refractory stable angina requiring surgical intervention.
89211047|NCT00830726||6|Patients with pulmonary hypertension and preserved systolic left ventricular function.
89211048|NCT00931398|Experimental|Methylphenidate HCl (Concerta)|
89211049|NCT00931398|Placebo Comparator|Placebo|
89625260|NCT03820401|Experimental|Solacea_HD_1/1anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: standard anticoagulation dose~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625261|NCT03820401|Experimental|Solacea_HD_1/2anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625262|NCT03820401|Experimental|FX800_HD_1/1anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625263|NCT03820401|Experimental|FX800_HD_1/2anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625264|NCT03820401|Experimental|FX800_HD_1/2anticoagulation_albuprime|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625265|NCT03820401|Experimental|Evodial_HD_no anticoagulation|"intervention:~choice of dialyzer: Evodial 1.3 (Baxter, USA)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625266|NCT03820401|Experimental|Evodial_HD_no anticoagulation_albuprime|"intervention:~choice of dialyzer: Evodial 1.3 (Baxter, USA)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625267|NCT03820401|Experimental|Solacea_preHDF_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: pre dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625268|NCT03820401|Experimental|Solacea_postHDF_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625269|NCT03820401|Experimental|Solacea_HD_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625270|NCT03820401|Experimental|Solacea_preHDF_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: pre dilution hemodiafiltration~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625271|NCT03820401|Experimental|Solacea_postHDF_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625272|NCT03820401|Experimental|Solacea_HD_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
89625273|NCT03820245|Experimental|Bixin|Consumption of 0.05 mg bixin/kg b.w. through capsules (once a day) by 7 days in the morning.
89625274|NCT03820245|Experimental|Norbixin|Consumption of 0.05 mg norbixin/kg b.w. through capsules (once a day) by 7 days in the morning.
89625275|NCT03820245|Active Comparator|Lycopene|Consumption of 0.05 mg lycopene/kg b.w. through capsules (once a day) by 7 days in the morning.
89625276|NCT03820245|Placebo Comparator|Placebo|Consumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
89625277|NCT01597505|Experimental|Surotomycin|250 mg Surotomycin over- encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg; and Placebo over encapsulated tablet administered orally, twice daily for 10 days
89625278|NCT01597505|Active Comparator|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
89038718|NCT04680572|Active Comparator|Dual mobility cups total hip replacement group|
89038719|NCT00552435|Experimental|1|Micropulse 810nm diode laser
89038720|NCT00552435|Active Comparator|2|Argon laser photocoagulation
89038721|NCT02895308|Experimental|Online|The Online psychoeducation is presented on on a webpage.
89038722|NCT02895308|Active Comparator|Face-to-face|The face-to-face psychoeducation is provided by psychologist and psychology master students.
89038723|NCT00550797|Experimental|No.1 ASM8 (oligonucleotide)|TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation
89038724|NCT00550797|Placebo Comparator|Phosphate Buffer solution|Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation
89038725|NCT02895113|Experimental|Aspirin|Patients will be treated with aspirin 100 mg/day for one year
89038726|NCT02895113|Placebo Comparator|Placebo|Patients will be treated with placebo for one year
89038727|NCT00552552|Experimental|1|
89038728|NCT00552552|Other|2|waiting control group
89211050|NCT00827216|Placebo Comparator|Physiologic saline|
89211051|NCT00827216|Active Comparator|Erythromycine|
89211052|NCT00827294|Experimental|Self-delivered mirror therapy|All participants were directed to self-deliver mirror therapy for 20 minutes per day.
89211053|NCT03760692|Active Comparator|Group i-gel|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
89211054|NCT03760692|Experimental|Group Ambu Auragain|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
89211055|NCT05097729|Experimental|Stimulation Modality 1|Repetitive TMS will be applied at 100% resting motor threshold intensity to a region of interest located in the parietal cortex, that will be determined based on its connectivity with the hippocampus.
89211056|NCT05097729|Sham Comparator|Stimulation Modality 2|Parameters will be identical to the modality 1, except that the coil will be flipped over.
89211057|NCT05097729|Active Comparator|Stimulation Modality 3|The stimulation will be delivered over the motor cortex contralateral to the predominant painful region, i.e., right motor cortex stimulation if left knee pain. The stimulation intensity will be set at 80% of the resting motor threshold.
89211058|NCT00822848|Experimental|Sorafenib, Epirubicin, Ifosfamide|
89211059|NCT00931554|Active Comparator|Early drain removal|Drain removal in postoperative day 3
89211060|NCT00931554|Active Comparator|Standard drain removal|Drain removal on postoperative day 5
89211061|NCT00926718|Experimental|Dose 1a|
89211062|NCT00926718|Experimental|Dose 2a|
89211063|NCT00926718|Experimental|Dose 3a|
89211064|NCT00926718|Experimental|Dose 1b|
89625279|NCT03821571|Experimental|Patient with primary aldosteronism|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
89625280|NCT03821571|Active Comparator|Patient with essential hypertension|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
89625281|NCT03821103|Experimental|Standard training arm|The standard training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period.
89625282|NCT03821103|Experimental|Behavioral economic enhanced arm|The behavioral economic enhanced training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period in addition to an opt-out invitation, loss-framed incentivization, and weekly tailored text message-based reminders
89625283|NCT05735860|Experimental|Virtual Reality Exposure Therapy (VRET)|
89625284|NCT05735860|Active Comparator|Progressive Muscle Relaxation (PMR)|
89625285|NCT03826485|Experimental|A group|Period 1: PRIC Period 2: Pranlukast hydrate
89211065|NCT00926718|Experimental|Dose 2b|
89625286|NCT03826485|Experimental|B group|Period 1: Pranlukast hydrate Period 2: PRIC
89625287|NCT03029572|Active Comparator|Standard diet|Standard healthy diet after RYGB surgery
89625288|NCT03029572|Experimental|Micro-nutriments' supplementation|Healthy diet and probiotics, minerals, aminoacids, omega-3 acids vitamin and mineral supplementation after RYGB surgery
89625289|NCT03126747||BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain or dysmenorrhea
89625290|NCT01911910|No Intervention|Standard care|Usual care that would be provided by the NHS Health Check or equivalent.
89211066|NCT00926718|Experimental|Dose 3b|
89211067|NCT00823004|Active Comparator|1|A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation
89211068|NCT00823004|Active Comparator|2|MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol
89211069|NCT00930150|Experimental|Posit Science Intervention|Participants will receive targeted cognitive training and participate in a bridging group.
89211070|NCT00930150|Active Comparator|Control|Participants will play commercially available computer games and participate in weekly groups to discuss health and wellness.
89211071|NCT00827450|Placebo Comparator|Ctl|control isocaloric diet; no coffee
89211072|NCT00827450|Placebo Comparator|HF|Hypercaloric. high fructose diet; no coffee
89211073|NCT00827450|Experimental|C1|Hypercaloric, high fructose diet; caffeine-free, torrefied coffee
89211074|NCT00827450|Experimental|C2|Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee
89211075|NCT00827450|Experimental|C3|Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee
89211076|NCT00827528|Experimental|SIS graft|this group will use a biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
89211077|NCT00827528|Active Comparator|2|this group will use a traditional repair on correction of anterior vaginal wall prolapse.
89211078|NCT04015284|Experimental|SSNB + PCB|Single shot US-guided suprascapular nerve block (SSNB) with 5 mL ropivacaine 0.5%, then single shot US-guided posterior cord block (PCB) with 10 ml ropivacaine 0.5%.
89211079|NCT04015284|Active Comparator|ISBPB|Single shot US-guided interscalene brachial plexus block (ISBPB) with 15 mL ropivacaine 0.5%.
89211080|NCT02548442||Autism Spectrum Disorder|Subjects identified as having Autism Spectrum Disorder using behavioral based methods.
89211081|NCT02548442||Developmental Delay|Subjects identified as having a developmental delay that is not Autism Spectrum Disorder using behavioral methods.
89625291|NCT01911910|Experimental|Electronic coaching plus standard care|Tailored coaching for participants randomised to use the HAPPY e-coaching tool. Access to lifestyle and heart health scores and personalised advice to improve suboptimal behaviour.
89625292|NCT03820791|Experimental|Poster|A poster with pictorial information about dysphagia-specific food procedures placed in patients' rooms for one month
89625293|NCT03820791|No Intervention|No poster|No poster is placed in patients' room.
89625294|NCT03823989|Experimental|Promitil 1.25 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.25 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
89625295|NCT03823989|Experimental|Promitil 1.5 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.5 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
89625296|NCT03823989|Experimental|Promitil 1.8 mg/kg|two treatment cycles, intravenous infusion of Promitil at a dosage of 1.8 mg/kg delivered at 21 days interval (confirmatory cohort) and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
89625297|NCT03826719|Experimental|NBP607QIV|1 dose of 0.5mL by Intramuscular injection
89625298|NCT03826719|Active Comparator|Agrippal|1 dose of 0.5mL by Intramuscular injection
89625299|NCT03823677|No Intervention|control group 15|"Protein expression and emotional test~15 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
89625300|NCT03823677|No Intervention|control group 30|"30 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
89625301|NCT03823677|No Intervention|control group 60|"60 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
89625302|NCT03823677|Experimental|hypoxia 5000ft group 15|Intervention: 15 minutes hypoxia
89625303|NCT03823677|Experimental|hypoxia 5000ft group 30|Intervention: 30 minutes hypoxia
89625304|NCT03823677|Experimental|hypoxia 5000ft group 60|Intervention: 60 minutes hypoxia
89625305|NCT03823677|Experimental|hypoxia 8000ft group 15|Intervention: 15 minutes hypoxia
89625306|NCT03823677|Experimental|hypoxia 8000ft group 30|Intervention: 30 minutes hypoxia
89625307|NCT03823677|Experimental|hypoxia 8000ft group 60|Intervention: 60 minutes hypoxia
89625308|NCT03823677|Experimental|hypoxia 10000ft group 15|Intervention: 15 minutes hypoxia
89625309|NCT03823677|Experimental|hypoxia 10000ft group 30|Intervention: 30 minutes hypoxia
89625310|NCT03823677|Experimental|hypoxia 10000ft group 60|Intervention: 60 minutes hypoxia
89625311|NCT03823677|Experimental|hypoxia 15000ft group 15|Intervention: 15 minutes hypoxia
89625312|NCT03823677|Experimental|hypoxia 15000ft group 30|Intervention: 30 minutes hypoxia
89625313|NCT03823677|Experimental|hypoxia 15000ft group 60|Intervention: 60 minutes hypoxia
89625314|NCT01951066|Experimental|Group 1 (dexamethasone implant/anti-VEGF)|Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.
89625315|NCT01951066|Experimental|Group 2 (anti-VEGF/dexamethasone implant)|Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.
89625316|NCT05735626|Experimental|Piperine 150μM + tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA (NeuroConn, Germany) with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of piperine (150μM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or piperine + tDCS randomly in the first or second day depending on the randomization."
89625317|NCT05735626|Experimental|Piperine 1mM+ tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of piperine (1 mM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or piperine + tDCS randomly in the first or second day depending on the randomization."
89625318|NCT05735626|Experimental|Capsaicin 10μM + tDCS 2mA|"tDCS will be applied for 20 minutes at 2.0 mA with the anode electrode positioned over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5 cm lateral / 1 cm anterior to the vertex) and the cathode over the opposite supraorbital region. During central stimulation, 5 ml of capsaicin (10 μM) will be administered orally every 5 min. After each administration, the patient will be asked to perform dry swallows every minute. In order to avoid alterations in the safety and efficacy of swallowing during the procedure, the bolus will be rheologically adapted according to the patient's requirements.~Crossover study, each arm includes a placebo + sham stimulation in one of the two days of treatment. Patients will initiate either placebo + sham stimulation or capsaicin + tDCS randomly in the first or second day depending on the randomization."
89625319|NCT03826329||Study Cohort|The observational study included all patients who had been admitted for their first ACDF surgery during the 16-year span, began on January 1st, 1998 till the end of 2013, recorded in the NHIRD. The admission for cervical disc herniation and spondylosis were identified using the ICD9-CM diagnostic codes of 722.0, 722.4 and 722.71, while the surgery of ACDF was confirmed with the procedure codes of 80.51, 81.00 and 81.02 during the same hospitalization.
89625320|NCT03826017|Experimental|Catechin high contain greentea extract|Catechin high contain greentea extract for 260 mg/day 12 weeks.
89625321|NCT03826017|Placebo Comparator|Placebo|Placebo for 12 weeks.
89625322|NCT01913314|Experimental|[^14C]-LY2835219|Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) [^14C] labeled drug
89038729|NCT02895386|Active Comparator|Treatment Group A|ROX Coupler implantation and continuing antihypertensive medications.
89038730|NCT02895386|Sham Comparator|Control Group B|Sham procedure and continuing current antihypertensive medications.
89038731|NCT00550875|Experimental|1|
89038732|NCT00550875|Experimental|2|10* concentration of arm 1
89038733|NCT00550875|Placebo Comparator|3|
89038734|NCT02894996|Other|Pediatric patient for general anesthesia|Pediatric patients for general anesthesia elected for scheduled surgery Patients weight between 8 and 30 kilograms
89625323|NCT04768192||Pediatric patients with acquired brain injury|Subjects with a acquired brain injury occurred in the last 10 months prior the beginning of the treatment
89625324|NCT03826251||systematic nasogastric tube|NGT was left systematically after surgery and removed after the first flattus
89038735|NCT00552630|Experimental|1|This group will receive d-penicillamine for 6 weeks
89038736|NCT00552630|Placebo Comparator|2|This group will receive placebo for 6 weeks
89038737|NCT02894957|Experimental|Gradual smoking cessation|"Gradual cessation Patients randomized to the gradual cessation group will receive varenicline (0,5 mg once daily for 3 days, 0,5 mg twice daily for 4 days, and 1,0 mg bid thereafter) as an aid for smoking reduction. This pre-treatment phase will last 6 weeks at the end of which all participants must stop smoking altogether. After quitting, they will continue to receive varenicline 1,0 mg bid for a further 12 weeks.~Smoking reduction: Participants will be recommended to reduce their smoking by 25% in the first two weeks, 50% in weeks 3-4, and 75% in weeks 5-6; however, this will be given only as an indication and every subject will be allowed to chose his/her own goal and rate of progress."
89038738|NCT02894957|Active Comparator|Abrupt smoking cessation|Patients in this group will be asked to smoke as usual for 6 weeks after enrolment then stop altogether. However, those feeling ready will be allowed to quit as of week 4. Thereafter, they will receive the standard 12-week varenicline treatment, starting with a 1 week titration period as described above.
89038739|NCT00550914||Control arm|The conventional therapy arm will undergo debridement with either a powered microdebrider or cold instrumentation excision as per the preference of the individual surgeon. Debridement will be deemed complete after removal of gross papilloma to the extent that the individual surgeon feels can be safely accomplished. Standard microsurgical principles of the larynx will guide debridement in that no opposing mucosal surfaces of the true vocal folds, laryngeal ventricle or inter-arytenoid space will be simultaneously debrided
89038740|NCT00550914||Experimental Arm|Patients enrolled into the conventional therapy plus PDL treatment arm will undergo debridement of the supraglottis and subglottis via conventional techniques as per the individual surgeons preferences followed by therapy to anterior commissure, true vocal folds, laryngeal ventricle and inter-arytenoid space with the pulsed dye laser. Standard laser settings will be a 450 microsecond pulse width, 5 J per pulse maximum of 1Hz, 1 mm spot fiber, 1-2 mm spot size and fluences of 38-255 J/cm2.
89038741|NCT02894879|Experimental|Modify group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 4 modify techniques and receive cardiac rehabilitation phase 1 in postoperative period.
89038742|NCT02894879|Sham Comparator|Conventional group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 3 conventional techniques and receive cardiac rehabilitation phase 1 in postoperative period.
89038743|NCT02895074|Experimental|femtosecond laser-assisted cataract surgery group|
89038744|NCT02895074|Experimental|conventional phacoemulsification surgery group|
89038745|NCT02894918|Experimental|Combination group|Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week
89625325|NCT03826251||Non systematic nasogastric tube|Nasogastric tube was removed immediately after surgery and was replaced in case of vomiting
89625326|NCT01951768|Experimental|Garamycin Sponge (Gentamicin-Collagen Sponge)|Garamycin Sponge (Gentamicin-Collagen sponge) applied daily plus systemic antibiotic and standard ulcer care
89625327|NCT01951768|Active Comparator|Systemic Antibiotic|Systemic antibiotic therapy and standard ulcer care
89625328|NCT04758585|Active Comparator|Study Group|
89625329|NCT04758585|No Intervention|Control Group|
89625330|NCT02987140|Experimental|PD+FoG|PD patients with FoG
89625331|NCT02987140|Active Comparator|PD-FoG|PD patients without FoG
89625332|NCT02987140|Active Comparator|Control|age-matched non-disabled adults
89625333|NCT04273659|Experimental|Pulses and Cereal 1|Pulses and cereal 1 containing study product is served. Dietary intervention.
89625334|NCT04273659|Experimental|Pulses and Cereal 2|Pulses and cereal 2 containing study product is served. Dietary intervention.
89625335|NCT05735470|Experimental|Antibacterial bone traction needle|The bone traction needle with an antibacterial coating.
89625336|NCT05735470|No Intervention|bone traction needle|The bone traction needle without an antibacterial coating.
89625337|NCT03825861|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
89038746|NCT02894918|No Intervention|Mono NA group|Maintain NAs mono-therapy oral-daily for 48 weeks.
89038747|NCT00551109|Placebo Comparator|P|Placebo
89038748|NCT00551109|Experimental|A1|SA4503
89038749|NCT00551109|Experimental|A2|SA4503
89038750|NCT02894723|Active Comparator|l-arginine|Patients will receive L-arginine 30 ml twice a day for 8 weeks.
89038751|NCT02894723|Placebo Comparator|syrup|Patients will receive placebo, 30 ml twice a day for 8 weeks.
89038752|NCT00551187|Experimental|1|V504 + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
89038753|NCT00551187|Placebo Comparator|2|Placebo + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
89038754|NCT02894528|Experimental|Ridge Preservation (Test Group)|
89038755|NCT02894528|Active Comparator|Ridge Preservation (Control Group)|
89038756|NCT00551226||1|Patients with tuberculosis
89038757|NCT00551226||2|Healthy controls
89625338|NCT01760447|Experimental|Sitagliptin/Metformin|Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
89625339|NCT01760447|Placebo Comparator|Metformin|Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
89038758|NCT00551265|Experimental|Arm I|Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity.
89625340|NCT01760447|Experimental|Sitagliptin/Metformin XR|Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
89038759|NCT00551265|Active Comparator|Arm II|Patients undergo DTH skin testing and receive oregovomab as in arm I.
89038760|NCT02894489|Experimental|corneal lenses|patients that wear corneal lenses ( Hiclear Rigid Gas Permeable Lenses)
89038761|NCT02894489|Experimental|large diameter lenses|patients that wear scleral lenses (Paragon Normaleyes)
89038762|NCT02894606||Thymoglobulin Induction|Patient receiving thymoglobulin as an induction therapy for renal transplant
89038763|NCT02894606||Basiliximab Induction|Patient receiving basiliximab as an induction therapy for renal transplant
89038764|NCT02894567|Experimental|spiderSTN|It is an Intraoperative test during a deep brain stimulation surgery. The spiderSTN lead is implanted in a selected track in the brain, and is tested for stimulation and recording.
89038765|NCT00551343|Other|PWS|
89038766|NCT00551343|Other|Controls|
89038767|NCT02894411||No ocular motility disorders|Patients without ocular motility disorders, with normal orbital and brain MRI.
89038768|NCT02894411||superior oblique muscle palsy|Clinical features compatible with unilateral paralysis of the SO muscle Atrophy of the SO muscle on the orbital MRI without other orbital or cerebral anomaly
89038769|NCT00551382|Experimental|A|
89038770|NCT00551382|Placebo Comparator|B|
89038771|NCT02894684|Experimental|AZLI then Standard Care|Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
89625341|NCT01760447|Placebo Comparator|Metformin XR|Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
89625342|NCT01952470|Experimental|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa.
89625343|NCT01952470|Active Comparator|Isotonic Saline|Once daily, 5ml inhaled 0.9% normal saline.
89688464|NCT02793856|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
89038772|NCT02894684|Active Comparator|Standard Care then AZLI|Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI
89038773|NCT02894645|Other|Standard Risk (SR)|
89038774|NCT02894645|Other|Intermediate Risk (IR)|
89038775|NCT02894645|Other|High risk (HR)|
89038776|NCT02894372|Experimental|Subjects with oral spray 1|Research subjects, who got oral spray 1. Spray was used 3 times a day 3 sprays a time for seven days. Spray 1 was Faringomoss or simple oily oral spray (unknown because of double blind method).
89038777|NCT02894372|Experimental|Subjects with oral spray 2|Research subjects, who got oral spray 2. Spray was used 3 times a day 3 sprays a time for seven days. Spray 2 was Faringomoss or simple oily oral spray (unknown because of double blind method).
89038778|NCT00552747|Active Comparator|1|fenofibrate 160 mg capsules (QD) Taken once daily with the largest meal of the day
89038779|NCT00552747|Placebo Comparator|2|placebo (capsules identical to those of fenofibrate) taken once daily (QD)with the largest meal of the day
89038780|NCT00551499|No Intervention|CRT for patients with CSA|Patients suffering from HF with central Sleep Apnea (CSA) programmed to DDD/45 (CRT) for 12 weeks. Intervention is CRT.
89038781|NCT00551499|Active Comparator|CRT + AOP for patients with CSA|Patients suffering from HF with central Sleep Apnea programmed to DDD/+15 bpm nocturnal rate (CRT + AOP) for 12 weeks. Intervention is the AOP in addition to CRT.
89038782|NCT02277327|Experimental|Intervention|"Subjects randomized to the intervention group will participate in a bundled intervention that includes action planning and care transitions (for those hospitalized during the study period)"
89038783|NCT02277327|Placebo Comparator|Routine Care|"Subjects randomized to the routine care group will continue to receive their usual care from the Pediatric Medical Home Program at UCLA"
89038784|NCT03455907||Patients|patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
89038785|NCT05427968||Supine group|Spinal anaesthesia was administered in sitting position and then supine position was maintained.
89038786|NCT05427968||Left tilt group|Spinal anesthesia was administered in sitting position was then maintained on supine position until full anesthetic effect (motor and sensory loss) and then table was tilted 15 degrees to the left.
89038787|NCT05427851|Experimental|Group I: Platelet rich Fibrin (PRF) and Biodentine|
89038788|NCT05427851|Experimental|Group II: Diode Laser and Biodentine|
89038789|NCT05427851|Experimental|Group III: Diode laser + PRF + Biodentine|
89038790|NCT04584333|Experimental|INTERVENTION|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established.
89038791|NCT04584333|No Intervention|NO INTERVENTION|Group 2 (non-intervention group): you will receive the usual information regarding the characteristics of your injuries and the role of tobacco and alcohol in their evolution and the importance of abandoning these habits.
89057866|NCT04530227|Experimental|Camrelizumab combined with chemotherapy|"Participants receive camrelizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 18 cycles PLUS Investigator's choice of chemotherapy.~Interventions:~Biological: Camrelizumab"
89057867|NCT01687569|Placebo Comparator|Control Cracker|Base cracker snack
89038792|NCT03455790|Experimental|Wheelchair Basketball|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
89038793|NCT03455790|Experimental|20 Meters Sprint Test|It will be done to evaluate the speed of sportsmen's wheelchair use. The sportsman will be prompted to take the chair as fast as possible after the wheelchair has been positioned so that the front bar is on the field edge. The 2 meter slow-down distance will also be counted in seconds and the completion time of the 20 meter track will be measured.
89038794|NCT03455790|Other|Slalom test|It will be done to measure the ability of sportsmen to use wheelchairs. Five cones will be placed starting 1.5 meters from the starting line of the Sahara, with a distance of 1.5 meters between them. Sportsmen will be required to complete the course by making a slalom between these topics and making a slalom in the same way by turning back and passing through the starting line. Track completion times will be recorded in seconds.
89057868|NCT01687569|Experimental|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
89057869|NCT01687569|Experimental|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
89625344|NCT03820011|Experimental|PEM-Plus Group|For Aim 1, 6 parents of young children were recruited to perform tasks related to navigating the PEM+ interface. Data on completion rate and time, as well as user satisfaction, were analyzed to guide PEM+ improvements. For Aim 2, we recruited 26 participants to enroll in a feasibility trial of PEM+. Caregivers who completed the YC-PEM e-PRO to evaluate their child's participation clicked on a weblink to begin PEM+, whereby they built on their YC-PEM responses for the purpose of creating a participation-focused care plan to share with their child's rehabilitation team. Caregivers were instructed to complete the PEM+ over a two-week (14 day) period because it mimics what would be provided in routine care.
89625345|NCT01915108|No Intervention|group R0|remifentanil Ce of 0 ng/ml
89625346|NCT01915108|Active Comparator|group R0.5|remifentanil Ce of 0.5 ng/ml
89625347|NCT01915108|Active Comparator|group R1.0|remifentanil Ce of 1.0 ng/ml
89625348|NCT01915108|Active Comparator|group R1.5|remifentanil Ce of 1.5 ng/ml
89625349|NCT03825471|Experimental|electrotherapy|Patients undergoing CES and general anesthesia in colon cancer surgery
89625350|NCT03825471|Placebo Comparator|Opioid Anesthetics|Patients undergoing general anesthesia in colon cancer surgery
89625351|NCT05735392|Other|Trastuzumab emtansine as per SmPC for liquid biopsy and tissue collection|"Patients will receive trastuzumab emtansine (T-DM1) at 3.6 mg/kg intravenously every 21 days, as perSummary of Product Characteristics (SmPC).~Peripheral blood samples will be taken by venipuncture prior to initiation of study therapy (T0), and at designated time-points after the first (T1) the second (T2), the third(T3)and after the sixth(T6), the ninth(T9), until the 12thcycle of T-DM1(see Fig.1) on-treatment and finally at progression."
89625352|NCT03825705|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89625353|NCT03096639|Active Comparator|Diaphragm Pacing Therapy DPTS|Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
89625354|NCT03096639|No Intervention|Control Group|Standard of care treatment of weaning failure, no intervention is involved in this control group.
89625355|NCT01917136|Experimental|11c-acetate and 18F-FDG, and cardiac MRI|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed.
89625356|NCT01450059||Spontaneous delivery|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via spontaneous delivery.
89625357|NCT01450059||Cesarean section|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via cesarean section.
89625358|NCT03825549|No Intervention|Control|No intervention
89625359|NCT03825549|Experimental|Individual Audit|Clinicians will receive individual audit feedback informing them of their performance.
89625360|NCT03825549|Experimental|Peer Comparison|Clinicians will receive peer comparison feedback informing them of how their performance compares to their peers.
89625361|NCT03825549|Experimental|Individual Audit and Peer Comparison|Clinicians will receive individual audit feedback informing them of their performance and peer comparison feedback informing them of how their performance compares to their peers.
89625362|NCT01450215|Experimental|Revlimid|
89625363|NCT01450215|No Intervention|Revlimid and dexamethasone|
89625364|NCT01450293|Experimental|Group A|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
89625365|NCT01450293|Experimental|Group B|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
89625366|NCT01450293|No Intervention|Group C|5 to 12 months old infants; no vaccination
89625367|NCT01450293|Experimental|Group D|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
89625368|NCT01450293|Experimental|Group E|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
89625369|NCT01450293|No Intervention|Group F|10 week old babies; no vaccination
89625370|NCT01953874|Experimental|MV ASV+OMT|Minute Ventilation-targeted adaptive servo-ventilation therapy plus optimized medical treatment
89625371|NCT01953874|Active Comparator|OMT only|Optimized Medical Treatment for heart failure in accordance with applicable guidelines (ACCF/AHA Guideline for the Management of Heart Failure and HFSA Heart Failure Guidelines.
89625372|NCT01450371||Interferential|The individuals are treated acutely with interferential electrical stimulation (IES) during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
89038795|NCT03455790|Other|Zone Shot Test|Zone Shot test will be applied to evaluate the shooting skills of the athletes. In the starting position the athlete will be asked to shoot the pot from the athlete with the warning given while on the foul shooting line and then to take their own rebounds. They will have to shoot again from the point where they have taken the rebound and rebound and go back to the foul line. The test will continue for 2 minutes in this manner. At the end of the 2-minute training period, the athletes will score the correct shot 2, the missed shot 1 point and the total score will be recorded.
89038796|NCT03455790|Other|Aerobic Capacity|To measure aerobic capacity values, it shall be measured with Cosmed K5® device and Cosmos-Saturn branded treadmill using TS which is used in routine workout with customized ramp protocol. Before starting the test, the athlete's TS walking belt at a speed of 1 mph (1.7 km / h) at 0% incline for 3 min. and it will be checked whether or not the gas measuring equipment is disturbing the participant. If the athlete is unable to continue, the time at which the test will end will be determined. Time min. . The air that the individual exposes during the test will be collected using a breath by breath method.
89625373|NCT01450371||Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
89625374|NCT04391829|Experimental|SARS-CoV-2 positive men|Men who are tested positive for SARS-CoV-2 by PCR testing on nasopharyngeal swab.
89625375|NCT01954264|Other|Overall Study Group|Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy.
89625376|NCT03825159|Experimental|ES group|Using spinal orthosis with an integrated system of electric surface stimulation and heat sensing.
89625377|NCT03825159|Active Comparator|brace group|Using spinal orthosis BRACE
89625378|NCT01450527||Patient fulfilling the criteria of ARDS|
89625379|NCT01917214||Non-Interventional Study|
89625380|NCT03825237||With sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
89625381|NCT03825237||Without sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
89625382|NCT01450605||Patients ≥ 13 years of age with HIV-1|Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA
89625383|NCT01955434|Experimental|Treatment (SMAC mimetic LCL161 and cyclophosphamide)|Patients receive SMAC mimetic LCL161 PO QD on days 1, 8, 15, and 22. Patients lacking a minor response by end of course 2 or partial response by end of course 4 may also receive cyclophosphamide PO QD on days 1, 8, 15, and 22 at the discretion of the treating physician. Patients taking cyclophosphamide with less than a 25% interval reduction in paraprotein receive SMAC mimetic LCL161 on days 2, 9, 16, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89625384|NCT04758429||Development or Training Cohort|will provide the data to be used for algorithm development and training.
89625385|NCT04758429||Test or Validation Cohort|will provide data to be used for algorithm validation.
89625386|NCT01450839|Experimental|E2020 5 mg tablet and tape|
89625387|NCT01450839|Placebo Comparator|2|
89625388|NCT01917682||Study Cohort|Subjects treated with CorPath-assisted Percutaneous Coronary Intervention (PCI)
89625389|NCT01450917||Group A|Brachial plexus injured patients with phrenic nerve dysfunction
89625390|NCT01450917||Group B|Brachial plexus injured patients without phrenic nerve dysfunction
89625391|NCT01450917||Group C|Non brachial plexus injured patients
89625392|NCT01732913|Experimental|Rituximab + idelalisib|Participants will receive rituximab + idelalisib.
89625393|NCT01732913|Placebo Comparator|Rituximab + Placebo|Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
89625394|NCT03824925|Placebo Comparator|Placebo oral zinc capsules|Group A: It was the control group. Participants were advised to start taking placebo capsule of Zinc in a look alike preparation on their first day of chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended
89625395|NCT03824925|Experimental|Zinc Sulfate 220 MG|Group B: Cap zinc 220 mg (equivalent to 50 mg of elemental zinc) on 1st day of their chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended.
89625396|NCT03825081|Experimental|Intervention|"Interventions will be the drugs:~pilocarpine - 0.5%~brimonidine - 0.2%~One drop of each of the study drugs will be placed in the non-dominant eye and patient will be evaluated for adverse events. At hour 1 and 3 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured and patient will be evaluated for adverse events. At hour 6 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured; patient will be evaluated for adverse events; and quality of life/satisfaction survey (NEI RQL-42) will be given to patient."
89625397|NCT01918072||Stepped wedge participants|"Designated Women's Health Providers with one or more episodes of care for women patients during each period of the intervention.~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
89057870|NCT01199263|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
89057871|NCT01199263|Experimental|Arm II (paclitaxel and wild-type reovirus)|Patients receive paclitaxel as in arm I and wild-type reovirus IV over 1 hour on days 1-5.
89625398|NCT01918072||Electronic consultation survey participants|"Designated Women's Health Providers who completed surveys about use of electronic consultations.~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
89625399|NCT01918072||Quality assessment participants|Primary care providers delivering women's health care for one or more of the following conditions: abnormal uterine bleeding; menopausal symptoms; urinary incontinence.
89625400|NCT04273971|Experimental|Plyometric exercise|
89038797|NCT03455790|Other|Anaerobic Capacity|Using the Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement, TS basketball athletes will be subjected to a Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions.
89038798|NCT03455790|Other|Isokinetic shoulder muscle strength|Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer.
89038799|NCT05427617||Control group|Control group includes patients without ctDNA abnormality and patients without druggable ctDNA abnormality.
89038800|NCT05427617||Case group|Case group includes patients with druggable ctDNA abnormality.
89038801|NCT04581018|Active Comparator|Health supplements + standard care|28 days of health supplements (Synbiotic) daily plus standard care
89038802|NCT04581018|No Intervention|Standard care|No intervention
89625401|NCT04758663|Experimental|Declarative memory|Napping v. wake effect on declarative memory in habitual and non-habitual nappers.
89625402|NCT04758663|Experimental|Overnight Physiology|Napping v. wake effect on overnight physiology in habitual and non-habitual nappers.
89625403|NCT01920802|Experimental|olanzapine|5mg BID olanzapine for up to 4 weeks
89625404|NCT01920802|Experimental|iloperidone|6mg BID iloperidone up to 4 weeks
89625405|NCT01920802|Placebo Comparator|placebo|BID placebo up to 4 weeks
89625406|NCT01451151|Experimental|Treated|
89625407|NCT01732835|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
89625408|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes, endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological results obtained by EBUS-TBNA."
89625409|NCT05734924|Active Comparator|study group|The patient in this group will received low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT for 30 minutes /session, treatment will be conducted for 3times/week for five weeks combined with cervical stabilization exercise protocol
89625410|NCT05734924|Sham Comparator|control group|The patient in this group will sham magnetic therapy in addition to, cervical stabilization exercise protocol; treatment will conduct for 3 times/ week for five weeks.
88815689|NCT01085786|Active Comparator|14-day sequential treatment|One in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the PPI, clarithromycin and metronidazole for 7 days.
89038803|NCT05427500|Other|Single SGB|This arm will receive a single 5 mL dose of 0.5% preservative-free bupivacaine.
89038804|NCT05427500|Other|Repeated SGB|This arm will receive two 5 mL doses of 0.5% preservative-free bupivacaine.
89038805|NCT03455751|No Intervention|Control|The control arm will receive no intervention and will follow standard of care for post-operative pain management.
89625411|NCT03824613||Endometrial cancer patients|
89038806|NCT03455751|Experimental|PGx-guided|The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.
89038807|NCT03455712|Experimental|Intervention|Subjects to receive the Gestational Weight Gain Card at enrollment in addition to standard prenatal care.
89038808|NCT03455712|No Intervention|Standard-of-Care|No intervention to be delivered. Subjects to receive standard prenatal care.
89038809|NCT05427305|Experimental|TAB008|Eligible patients received TAB008 15 mg/kg every three weeks for 6 cycles, then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death.
89038810|NCT05427305|Active Comparator|Bevacizumab|Eligible patients received bevacizumab-EU 15 mg/kg every three weeks for 6 cycles, then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death.
89038811|NCT05427188|Experimental|MIST-paradigm|HV assigned in the MIST paradigm will receive psychosocial stress
89038812|NCT05427188|Sham Comparator|Sham-paradigm|HV assigned in the MIST paradigm will receive no psychosocial stress
89038813|NCT01099449|Experimental|Arm I|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy comprising leucovorin calcium, fluorouracil, and oxaliplatin).
89038814|NCT01099449|Placebo Comparator|Arm II|Patients receive placebo IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy).
89625412|NCT03824613||Control group|Patients without cancer
89625413|NCT01451307||Gastrointestinal malformations|Children who underwent standardized neonatal pediatric surgery due to gastrointestinal malformations
89038815|NCT01099449|Experimental|Arm III|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and placebo IV over 30 minutes immediately after oxaliplatin administration (part of FOLFOX chemotherapy).
89038816|NCT05427071|Experimental|Study arm|Magnetic seed guided lumpectomy and targeted axillary dissection
89038817|NCT04680104||Cohort A|Infusion of Na-Lev plus 5-FU (unique administration by one 48h-infusional pump)
89625414|NCT01451307||No gastrointestinal malformations|Control group of healthy children matched concerning gestational age, weight class and gender
89625415|NCT01957384|Experimental|Treatment 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 1 are randomised to secondly test either:~Coloplast Test product 2 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 2"
89625416|NCT01957384|Experimental|Treatment 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 2 are randomised to secondly test either:~Coloplast Test product 1 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 1"
89625417|NCT01957384|Experimental|Treatment 3,First Standard care (see below)|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active) are randomised to secondly test either:~Coloplast Test product 1 and thereafter Coloplast Test product 2~Coloplast Test product 2 and thereafter Coloplast Test product 1"
89625418|NCT01451619|Experimental|Laropiprant|
89625419|NCT01451619|Placebo Comparator|Placebo|
89625420|NCT03054519|Active Comparator|Metformin|Metformin daily
89625421|NCT03054519|Placebo Comparator|Placebo|Placebo daily for six months.
89625422|NCT01921894|Experimental|Cholecalciferol 4000 IU|Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
89625423|NCT01921894|Experimental|Cholecalciferol 2000 IU|Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
89625424|NCT01921894|Active Comparator|Cholecalciferol 200 IU|Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
89625425|NCT03047577|No Intervention|Standard care arm|Treatment as usual and discussion according to the treating clinicians in the hospital
89625426|NCT03047577|Other|Intervention arm|Patients receive a brief intervention, including a short discussion, opportunity for an appointment with a social worker and written information about effects of alcohol on health and contact information for seeking additional support
89625427|NCT01452009|Experimental|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|
89038818|NCT04680104||Cohort B|Infusion of Ca-Lev followed by infusion of 5-FU (two separated administrations by using one plastic bag followed by one 48h-infusional pump)
89038819|NCT04471740|Experimental|Normal-pressure hydrocephalus only|Patients suffering from normal-pressure hydrocephalus with NO sleep apnea
89038820|NCT04471740|Active Comparator|Normal-pressure hydrocephalus with sleep apnea|Patients suffering from normal-pressure hydrocephalus with sleep apnea
89038821|NCT04680143|Experimental|Systemic erythropoietin injections|The study included 10 patients diagnosed as post papilledemic optic atrophy
89038822|NCT04467762||Meningoencephalitis (ME-PED)|"pediatric patients between 0 and 17 years of age~admission to hospital with suspected meningoencephalitis~confirmed meningoencephalitis within 24 hours after admission"
89038823|NCT04467762||Sepsis-associated encephalopathy (SAE-PED)|"pediatric patients between 0 and 17 years of age~admission to hospital with suspected sepsis~confirmed sepsis within 24 hours after admission or time of diagnosis"
89038824|NCT04467762||Control group (CON-PED)|"pediatric patients between 0 and 17 years of age~exclusion of neurocognitive impairment~admission to hospital for minor surgery (e.g. herniotomy, adenoidectomy, fractures treated by osteosynthesis) or for hemangioma treated by propranolol"
89625428|NCT01452009|Active Comparator|TRAVATAN®|TRAVATAN® administered one drop once daily
89038825|NCT00552825||1|all were in a single group
89625429|NCT03824379|Experimental|Magnesium arm|30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
89625430|NCT03824379|Active Comparator|Control|30 patients will receive the standard therapy (anti-diabetic)
89625431|NCT01957930|Experimental|Intensified insulin treatment|Basal (Monotard) insulin; ones a day Bolus (Actrapid) insulin; thrice a day
89625432|NCT01957930|Active Comparator|Standard treatment|Mixed Insulin (2-3 times a day)
89625433|NCT01957930|No Intervention|Healthy controls|These people were solely controls for the iontophoresis method used in the study. With no intervention or follow-up-
89625434|NCT01759511|Experimental|Simtuzumab|Participants will receive simtuzumab.
89625435|NCT03824457|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours). The period of the treatment with the study drug lasts 3 days.
89625436|NCT03824457|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
89625437|NCT01958320|Experimental|Early treatment|"Infants randomized to the early treatment group will receive pharmacologic treatment of the PDA to produce PDA closure. Within 24-36 hr following the last treatment dose an echocardiogram will be obtained to document the degree of ductus closure or patency.~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
89038826|NCT05426798|Experimental|TQB2618 injection|TQB2618 injection combined with demethylation drugs, 28 days as a treatment cycle until the disease progresses or the investigator judges that it is not suitable for subject to continue to take medicine.
89038827|NCT01234402|Experimental|Ramucirumab DP + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
89038828|NCT01234402|Experimental|Icrucumab + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
89057872|NCT01687647|Other|Screening|Paired-design: low-dose CT scan, sputum sample and blood test will be performed on all subjects.
89625438|NCT01958320|Active Comparator|Conservative Treatment|"Infants randomized to the Conservative Treatment approach will receive no pharmacologic treatment of the PDA but will be followed to determine if they meet criteria for later PDA rescue treatment (Infants will be eligible for rescue treatment of their persistent PDA if they meet the rescue treatment criteria.)~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
89625439|NCT04414007|Experimental|Internet+ home-based cardiac rehabilitation group|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
89625440|NCT04414007|Active Comparator|conventional care group|The UC-assigned patients will maintain standard of care.The conventional rehabilitation group received routine medical care and traditional home-based cardiac rehabilitation based on the rehabilitation manual and exercise diary, followed up by telephone and outpatient.
89625441|NCT01452087|Other|Exercise Session|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
89625442|NCT01452321|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
89625443|NCT01452321|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of active rTMS delivered to the left dorsolateral prefrontal cortex.
89625444|NCT01732757|Active Comparator|Lastacaft®|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
89625445|NCT01732757|Active Comparator|Pataday™|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
89625446|NCT01732757|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
89625447|NCT03824301|Active Comparator|Volume-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with volume-controlled ventilation
89625448|NCT03824301|Active Comparator|Pressure-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with pressure-controlled ventilation
89625449|NCT03824301|No Intervention|No ventilation|During cardiopulmonary bypass period the patients were disconnected from ventilator
89057873|NCT02217995|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in ten 2.5 hour group sessions with 15 participants per group.
89625450|NCT01452399|Experimental|Shave Margins|
89625451|NCT01452399|Active Comparator|No shave margins|
89625452|NCT03824067|Active Comparator|Standard of Care Early Infant Diagnosis|Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID
89625453|NCT03824067|Experimental|Point of Care Early Infant Diagnosis|The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
89625454|NCT01758731|Experimental|Olaparib with C225 and Radiation Therapy|Patients will begin taking Olaparib at the assigned dose three days prior to their first Cetuximab infusion. Patients will receive an initial dose of Cetuximab, 400 mg/m², intravenously over 120 minutes on Day 1. The initial dose of C225 will precede the start of radiation by 5-7 days. All patients will receive RT to a total dose of 69.3 Gy in 33 fractions over 6½ weeks. Weekly C225 will be administered at 250 mg/m2 in combination with daily RT. Patients will be assigned to receive Olaparib (25, 50, 100 or 200 mg bid) in combination with RT and C225. Olaparib will be taken twice daily, beginning three days prior to first scheduled C225 infusion. A further dose level of 300mg or 400mg may be considered should the 200mg Olaparib dose be well tolerated in this C225/RT combination schedule.
89625455|NCT01452477|Active Comparator|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
88989906|NCT04693715|Experimental|RNS60 1 mL/kg/h|RNS60 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
88989907|NCT04693715|Placebo Comparator|Placebo 1 mL/kg/h|Placebo (normal saline) 1 mL/kg/h infusion for 48h (up to a maximum of 120 mL/kg) starting within 30 min of randomization (but prior to arterial access closure)
88989908|NCT04686435||Non-surgical treatment|Shoulder patients referred for non-surgical treatment after being diagnosed at the medical examination.
88989909|NCT04686435||Surgical treatment|Shoulder patients referred for surgical treatment after being diagnosed at the medical examination.
88989910|NCT04662034|Experimental|Device plus Standard of Care|Device plus Standard of Care
88989911|NCT04662034|Other|Standard of Care|Standard of care drug treatment
88989912|NCT04655365|Experimental|Resistant Prostate Cancer and Negative, Equivocal or Oligometastatic Disease on Conventional Imaging|Enrolled subjects will receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL Injection followed by a single PET/CT scan acquired at 1-2 hours post-dosing. After initial 18F-DCFPyL PET/CT, the patients with positive 18F-DCFPyL PET/CT imaging will be treated with enzalutamide (160 mg po id) for M0CRPC disease within less than two weeks. 18F-DCFPyL PET/CT scan will then be repeated 90 days after the start of enzalutamide treatment.
88989913|NCT04644822|Experimental|[18F]PSMA-1007 Injection|A single dose of 3 - 4 MBq/kg Body Weight (up to a maximum of 400 MBq) of [18F]PSMA-1007 Injection will be administered followed by PET/CT imaging. (Patients on ADT treatment will receive the second dose approximately 6 months after the first dose)
88989914|NCT04636411|Experimental|Intervention group|This group group will receive oral magnesium supplementation (250 mg of elemental magnesium daily for three months) plus the standard care for diabetic patients
88989915|NCT04636411|Active Comparator|Control group|This group will receive the standard care for diabetic patients
88989916|NCT04635059|Experimental|Pacritinib|Pacritinib is an oral drug.
88989917|NCT04629469|Experimental|Hyperfine|For patients that have standard of care head imaging, we will do a secondary analysis to compare their standard of care MRI, CT and/or US exams with Hyperfine MRI exams.
88989918|NCT04627090||LCH Patients|Adult patients with LCH, diagnosed starting from January 2001
89038829|NCT01234402|Active Comparator|Capecitabine*|"Crossover Study:~* At the discretion of the investigator, participants will be eligible to receive either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given.~Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant."
89038830|NCT05464017|No Intervention|Standard mHealth screening tool|This is a tested standard phone screening tool which determines the need for in-person follow-up after a patient has been discharge. Consenting trauma patients will be contacted via mobile phone at 0.5, 1, 3, and 6 months post-discharge by a research assistant to complete the screening which will guide whether or not the patient should seek follow-up care based on the number of flagged responses to ≥1 question on the 7-item screening survey.
89038831|NCT05464017|Experimental|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|This arm will receive an improvement to the mHealth triage tool using a machine learning approach. Patients will be called using the optimized tool at outcome timepoints (3 months, 6months and 12months). At each call, research assistants will complete the GOSE survey and the mHealth triage tool, entering call outcomes and patient responses directly into the mHealth system. If follow-up care is indicated, the research assistant will share that information with the patient and offer to schedule an appointment.
89038832|NCT05426720||patients with pulmonary tuberculosis|male patients aged 25-60 with active pulmonary tuberculosis
89625456|NCT01452477|Placebo Comparator|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
89625457|NCT04168775|Other|Home PIFR monitoring|Measurement of PIFR using the InCheck Dial® device and quantification of respiratory symptoms and COPD exacerbations using standardized questionnaires in the patient's home setting and during research visits in the clinic setting
89625458|NCT01452555|Active Comparator|In Person Counseling|Participants will receive an in person HIV and HIV testing counseling session
89625459|NCT01452555|Experimental|Video Presentation|Participants will watch an HIV and HIV testing video
89625460|NCT01452633|Placebo Comparator|Preincision Placebo|This group of patients will receive saline injection at study port site before incision
89625461|NCT01452633|Active Comparator|Preincision Marcaine|This group will receive marcaine injection at the study port site prior to incision
89625462|NCT01452633|Placebo Comparator|Postincision Placebo|This group of patients will receive preincisional marcaine and then saline injection at study port site prior to closure
89625463|NCT01452633|Active Comparator|Postincision marcaine|This group will receive preincisional marcaine and then marcaine injection at study port site prior to closure
89625464|NCT01606319|Experimental|acetaminophen|acetaminophen given as needed for pain or fever
89625465|NCT01606319|Experimental|ibuprofen|ibuprofen given as needed for pain or fever
89625466|NCT01452711|Experimental|TAK-438 20 mg QD|
89625467|NCT01452711|Active Comparator|Lansoprazole 30 mg QD|
89625468|NCT02630121|Placebo Comparator|Placebo/Fluticasone Propionate|Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
89625469|NCT02630121|Active Comparator|Oxymetazoline Hydrochloride /Fluticasone Propionate|Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
89625470|NCT01757405|Experimental|≤ 3 doses of 90 µg/kg rFVIIa BI|
89625471|NCT01757405|Experimental|One dose of 270 µg/kg rFVIIa BI|
89625472|NCT02956785|Active Comparator|Extension of propess+/-second propess|Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
89625473|NCT02956785|Active Comparator|Prostin|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
89625474|NCT02956785|Active Comparator|Dilapan-S|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
89625475|NCT01452867|Active Comparator|Bag-Mask-Ventilation|Bag-Valve Mask-Ventilation in 50 patients in general anesthesia
89625476|NCT01452867|Active Comparator|Laryngeal Mask Ventilation|Laryngeal Mask Ventilation in 50 patients in general anesthesia
89625477|NCT01452867|Active Comparator|Laryngeal Tube Ventilation|Laryngeal Tube Ventilation in 50 patients in general anesthesia
89038833|NCT01260922|Experimental|Investigational Test Product|Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets
89038834|NCT01260922|Active Comparator|Reference Listed Drug|Aricept® 10 mg Orally Disintegrating Tablets
89038835|NCT05426642|Experimental|Intervention group|Receive the e-health video and brochure as the intervention
89625478|NCT04273503|Experimental|Intervention|All participants will receive education on maintaining a healthy diet and improving physical activity.
89625479|NCT02947581|Experimental|Interventions|Albendazole and praziquantel. Albendazole: 15 mg/k/d up to 800 mg/d (days 1 to 20), followed by 15 mg/k/d up to 1200 mg/d (day 21 to 30) and prazicuantel (50 mg/k/d days 1 to 15).
89625480|NCT02947581|Active Comparator|Comparison regime|Albendazole and praziquantel placebo. Albendazole: 15 mg/k/d (days 1 to 30) and prazicuantel placebo in similar doses 50 mg/k/d (days 1 to 15).
89625481|NCT01453257|Experimental|Chemotherapy treatment|Tailored chemotherapy by Therapeutic Targets
89625482|NCT01453491|Experimental|50mg SRT2104|Single oral administration of 50mg SRT2104 study drug will be supplied as 25 mg and 250 mg capsules and will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
89038836|NCT05426642|Other|Control group|Receive brochure as the intervention
89038837|NCT01233817|Experimental|Spinal muscular atrophy|Children and adolescents with diagnosis of SMA type II or III. The intervention group (the only arm/group in this pilot study) receives a home-based, supervised, 12-week progressive strength-training program.
89038838|NCT04206748|Experimental|iGlucose Smart Meter|
89038839|NCT04206748|Placebo Comparator|Rx glucose meter|
89038840|NCT05426603|Experimental|Pulmonary vein isolation + Waveform Periodicity Group|Pulmonary vein isolation + Substrate ablation
89038841|NCT05426603|Other|Pulmonary vein isolation group|Pulmonary vein isolation (Conventional treatment)
89038842|NCT01233232|Placebo Comparator|1|Placebo dose
89038843|NCT01233232|Experimental|2|Treatment arm AZD5069 50mg
89038844|NCT01233232|Experimental|3|Treatment arm AZD5069 80mg
89038845|NCT01233076|Other|Nelfilcon A / Narafilcon B|Nelfilcon A worn first, with narafilcon B worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
89038846|NCT01233076|Other|Narafilcon B / Nelfilcon A|Narafilcon B worn first, with nelfilcon A worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
89038847|NCT05463276||Patients with breast cancer|
89038848|NCT05426135||Lung cancer group|Participants with lung cancer/pulmonary nodules
89038849|NCT05426135||Stomach cancer group|Participants with Stomach cancer/Stomach lesion
89038850|NCT05426135||Colorectal cancer group|Participants with Colorectal cancer/Colorectal lesion
89038851|NCT04389879|Experimental|CAD/CAM|CAD/CAM custom-cut Nickel Titanium (NiTi) FR
89038852|NCT04389879|Active Comparator|Conventional multistranded|Conventional multistranded Stainless Steel (SS) FR
89625483|NCT01453491|Experimental|500mg SRT2104|Single oral administration of 500mg SRT2104 will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
89625484|NCT03823599|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
89625485|NCT03823599|Active Comparator|control group|Alcohol brief intervention
89625486|NCT01453647|Experimental|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
89625487|NCT01453647|No Intervention|control|Participants in the control group will be instructed to maintain their FM treatment regimens as reported at baseline.
89625488|NCT01453803|Experimental|Intravenous Injection and Intanasal infusion of AD-SVF|AD-SVF
89625489|NCT01453881|Experimental|Spacer|Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
89625490|NCT01453881|Active Comparator|Comparator|Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
89625491|NCT05608473|Experimental|Exercise Group|A 10-minute video consisted of 14 exercises was uploaded to the computers of the participants in the exercise group. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
89625492|NCT05608473|No Intervention|Control Group|The control group was given one session of training on postural correction.
89625493|NCT04391751|Experimental|Single incision|Carpal tunnel release and basal joint arthroplasty through a single radial approach
89625494|NCT04391751|Active Comparator|Double incision|Double approach: carpal tunnel release through palmar approach and basal joint arthroplasty through radial approach
89625495|NCT02983851|Experimental|Noninvasive mechanical ventilation|Patients in this group will receive Noninvasive mechanical ventilation as the initial mechanical ventilation (MV) strategy, irrespective of whether Invasive mechanical ventilation is used later during the following treatment.
89625496|NCT02983851|Active Comparator|Invasive mechanical ventilation|Patients in this group will receive Invasive mechanical ventilation as the initial MV strategy, irrespective of whether Noninvasive mechanical ventilation is used later during the following treatment.
89625497|NCT02884401|Other|osteoporotic women with a missing tooth|Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant
89038853|NCT05426018|Experimental|SY-009 -1|0.5mg tid
89038854|NCT05426018|Experimental|SY-009-2|1.0mg tid
88815690|NCT01085786|Experimental|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
89038855|NCT05426018|Experimental|SY-009-3|1.5mg tid
89038856|NCT05426018|Placebo Comparator|Placebo|tid
89038857|NCT01212094|Experimental|Rituximab|Patients received 25mg of rituximab into the CSF and 200mg of rituximab intravenously at Month 0, followed by additional 200mg of rituximab intravenously at Month 0.5 and another 25mg of rituximab into CSF at months 1.5 and 12.
89038858|NCT01212094|Placebo Comparator|Placebo|Patients received normal saline into the CSF and intravenously at Month 0, followed by additional normal saline intravenously at Month 0.5 and another dose of normal saline into CSF at months 1.5 and 12.
89038859|NCT01212094|No Intervention|Baseline|Patients in their first year baseline prior to study drug phase
89038860|NCT05425706|Experimental|experiment group|Number of participant is 16. In addition to the conventional therapy, SNAGs technique was applied.
89038861|NCT05425706|No Intervention|control group|Number of participant is 16. Only the conventional therapy was applied.
89625498|NCT04391361|Experimental|trial group|
89625499|NCT04391361|Placebo Comparator|control group|
89625500|NCT05603325||Patient participants|Current inpatients within the acute mental health ward in which the study is taking place.
89625501|NCT05603325||Staff participants|Staff working within the acute mental health ward in which the study is taking place including nursing, mental, occupational therapy, estate and management team members
89625502|NCT01454037||Prostate cryoablation|Subjects receiving cryotherapy for prostate cancer
89625503|NCT01454037||Radical prostatectomy|Subjects receiving radical prostatectomy
89625504|NCT01454037||Radiation|Subjects receiving radiation for prostate cancer
89625505|NCT04272957|Experimental|HMPL-306|HMPL-306 administered continuously as a single agent orally every day in a 28-day cycle.
89625506|NCT04273191|Experimental|Brexanolone|Participants will receive a single dose of commercial brexanolone as part of standard of care.
89625507|NCT04391985|Active Comparator|Cirrhotic Participants|The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
89625508|NCT04391985|Active Comparator|Non-cirrhotic Participants|The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.
89625509|NCT01454115|Experimental|Panel 1: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
89625510|NCT01454115|Experimental|Panel 2: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
89625511|NCT01454115|Experimental|Panel 3: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
89625512|NCT01454115|Experimental|Panel 4: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
89625513|NCT01454115|Experimental|Panel 5: BMS-708163 or Placebo|"Healthy male subjects (age: 18 to 45 years).~In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation.~In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1"
89625514|NCT01454115|Experimental|Panel 6: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
89625515|NCT01454115|Experimental|Panel 7: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
89625516|NCT01454115|Experimental|Panel 8: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
89625517|NCT01454115|Experimental|Panel 9: BMS-708163 or Placebo|Healthy, elderly male subjects (age: 60 years and greater)
89625518|NCT01454115|Experimental|Panel 10: BMS-708163 or Placebo|Healthy, elderly female subjects (age: 60 years and greater)
89625519|NCT01454115|Experimental|Panel 11: BMS-708163 or Placebo|Healthy male subjects (age: between 46 to 59 years)
89625520|NCT01454115|Experimental|Panel 12: BMS-708163 or Placebo|Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)
89625521|NCT01454115|Experimental|Panel 13: BMS-708163 or Placebo|Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)
89625522|NCT01454115|Experimental|Panel 15: BMS-708163 or Placebo|Healthy young male subjects
89625523|NCT01455597|Experimental|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream 3 times a week for up to 40 weeks.
89625524|NCT01454271|Experimental|Total Hip Arthroplasty CERAFIT® grafted|
89625525|NCT01453101|Other|Fludarabine, Melphalan, Bortezomib|
89625526|NCT01454349|Experimental|PRX302|
89038862|NCT05425628|Experimental|Treatment with NeoChord Transcatheter Mitral Repair System|Implanting ePTFE sutures as artificial neochordae using NeoChord Transcatheter Mitral Repair System
89625527|NCT01454349|Placebo Comparator|Inactive substance|
89625528|NCT02935257|Experimental|CD19CAT-41BBZ CAR T-cells|Treatment with the ATIMP: CD19CAT-41BBZ CAR T-cells
89625529|NCT01454427||healthy volunteers|
89625530|NCT01454661|Active Comparator|placebo mother - LGG infant|Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.
89625531|NCT01454661|Placebo Comparator|placebo mother - placebo infant|Placebo is administered to both the lactating mother and her infant.
89625532|NCT01454661|Active Comparator|LGG mother - placebo infant|The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.
89625533|NCT01454661|Active Comparator|LGG+Bb-12 mother - Placebo infant|A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.
89625534|NCT01454661|Active Comparator|Pacebo mother - LGG+Bb-12 infant|Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12
89625535|NCT02085447|Experimental|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
88815691|NCT01035788|Experimental|Mindfulness-Based CBCT|Mindfulness Based Cognitive Behavioral Conjoint Therapy for PTSD
89057874|NCT02217995|No Intervention|Waitlist|Wait list as per usual.
89625536|NCT04847193|Experimental|Placebo|Participants receive a study drink supplemented with a placebo over a time period of 5 days.
89625537|NCT04847193|Experimental|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol over a time period of 5 days.
89625538|NCT04847193|Experimental|Iso-alpha acids|Participants receive a study drink supplemented with Iso-alpha acids over a time period of 5 days.
89625539|NCT04847193|Experimental|Xanthohumol/Iso-alpha acids|Participants receive a study drink supplemented with a combination of Xanthohumol and Iso-alpha acids over a time period of 5 days.
89625540|NCT03473847|Experimental|Repeatability and Reproducibility - Normal eyes|"This arm will include 20 eyes of 20 patients with no previous ocular surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
89038863|NCT05457426||robotic right hemicolectomy with CME|The robot was set to come and dock from the right shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook/scissors for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R2), and Cadiere's fenestrated forceps in the right lower quadrant port (R3) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transverse mesocolon with the grasp in R3, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R2. All procedures were performed keeping the principle of complete mesocolic excision.
89038864|NCT05457426||laparoscopic right hemicolectomy with CME|In the aparoscopic group, five trocars were used: a periumbilical incision and left upper quadrant for 12-mm trocars, both lower quadrants for 5-mm trocars, and the right quadrant for one more 5-mm trocar. A 30 degrees laparoscope was inserted through the periumbilical trocar site. After insertion of the trocars, the patient was placed in the Trendelenburg position with a 15 degrees rightward tilt. An ultrasonic device was used for dissection. All procedures were performed keeping the principle of complete mesocolic excision.
89038865|NCT05425589|Other|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
89625541|NCT03473847|Experimental|Repeatability and Reproducibility - Post-op eyes|"This arm will include 20 eyes of 20 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
89625542|NCT03473847|Experimental|Comparison between devices - Normal eyes|"This arm will include 101 eyes of 101 patients with no previous ocular surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
89038866|NCT05425394|Experimental|delayed first bath time|Delay first bath to 8 hours after birth
89038867|NCT05425394|No Intervention|regular bath|Birth temperature 36.5°C, regular bath
89625543|NCT03473847|Experimental|Comparison between devices - Post-op eyes|"This arm will include 101 eyes of 101 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
89038868|NCT05425316||Patients with Cirrhosis|This group will be composed of 200 patients with cirrhosis. Patients will be enrolled regardless of compensated vs. decompensated status, prior history of HE, Model for End Stage Liver Disease (MELD), and cirrhosis etiology.
89038869|NCT05425316||Patients without Cirrhosis|This group will be composed of 50 patients without cirrhosis to act as controls. They will have been found on Fibroscan to not have significant fibrosis.
89625544|NCT04273035|Active Comparator|Midazolam Group|"Midazolam(Buccolam 5mg/ml)~0.5mg/kg oral, max 12mg~one time~given 30 min prior to going to holding"
89038870|NCT05422755||Arm 1|Experimental: Test Drug Recombinant Human Erythropoietin Alfa
89038871|NCT05419401|Experimental|Capivasertib|film-coated tablet, 200 mg
89038872|NCT05419401|Experimental|[14C]AZD5363 (Capivasertib)|Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) and Oral Solution, 400 mg (NMT 4.8 MBq)
89038873|NCT04436393||Advanced Breast Cancer|Patients with diagnosis of advanced breast cancer
89625545|NCT04273035|Active Comparator|IPAD group|"No premedication~IPAD when arriving at the holding~any games, movies, clips, puzzles"
89625546|NCT02836899|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
89625547|NCT02836899|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
89625548|NCT01454817|Other|Patients with ICDs|
89625549|NCT01454817|Other|Caregivers of Patients with ICDs|
89625550|NCT01454895|Experimental|Interactive Web-based Info (IWI) & HPDs|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
88815692|NCT01035788|Active Comparator|CBCT Communication Skills|CBCT for PTSD - Communication Skills
89038874|NCT04330560|Experimental|Ex group|Receive CR telerehabilitation (exercise telemonitoring link to the healthcare platform + teleconsultation)
89038875|NCT04330560|Active Comparator|Com group|Receive CR telerehabilitation (exercise self-monitoring + teleconsultation)
89038876|NCT04330560|Placebo Comparator|C group|Standard care - traditional center-based CR
89038877|NCT05409885||General anesthesia group|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
89038878|NCT05409885||Spinal anesthesia group|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
89038879|NCT01232569|Experimental|Tocilizumab 162 mg sc|Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
89038880|NCT01232569|Placebo Comparator|Placebo sc|Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
89038881|NCT00552864|Active Comparator|R|
89038882|NCT00552864|Active Comparator|L|
89038883|NCT04419584|Experimental|Modified Qing-Ying Decoction|Herbal granules, twice per day for 12 weeks
89038884|NCT04419584|Placebo Comparator|Identical looking placebo|Placebo granules, twice per day for 12 weeks
89038885|NCT04416542|No Intervention|Control|Subjects in this group will be implanted with the Inspire UAS system and will undergo a standard in-lab PSG titration study at approximately 3 months post-activation and a 2-night HST at approximately 6 months post-activation
89038886|NCT04416542|Active Comparator|Home Monitoring|Subjects who have undergone implant of the Inspire UAS System and are randomized to this group will undergo a 2-night HST at 3 months post-activation. Depending on the results of the 2-night HST, the subject will either (a) undergo a PSG titration at 5 months post-activation and a 2-night HST at 6 months post-activation OR (b) undergo only a 2-night HST at approximately 6 months post-activation
89038887|NCT01211665|Experimental|Pulsed IVMP|Intravenous methylprednisolone (IVMP) 1 g/day administered the first 3 days of each weekly cycle, and repeated for 3 additional cycles (totaling 4 cycles). If necessary, 2 additional weekly cycles of 1 g IVMP daily for 3 days can be administered at the discretion of the investigator.
89038888|NCT01211665|Experimental|IVMP with oral prednisolone taper|Intravenous methylprednisolone (IVMP) 1g/day for 6 days followed by an oral taper of prednisolone over 2 months (suggested dosages starting at 80 mg and tapering to 5 mg). If necessary, additional cycles of 1 g IVMP daily for 3 to 5 days can be administered at any time.
89038889|NCT04401176|Active Comparator|Heparin & Alkalinized Lidocaine Bladder Instillation|Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
89038890|NCT04401176|Active Comparator|Intradetrusor Onabotulinumtoxin A Injection|100 units onabotulinumtoxinA reconstituted in 10mL of injectable saline, injected in 20 sites with 0.5mL per injection along the posterior wall of the bladder above the trigone.
89038891|NCT04393922|Experimental|Aim 1|"To accomplish this aim, we will conduct one experiment in two sessions separated by 2- 3 days using a crossover design. Participants will be assigned into one of three groups: spastic SCI, non-spastic SCI, and controls. We expect that people enrolled in Aim 1 will complete 2 visits within 1 week.~Visit 1 Measurements:~MVCs~MEP Recruitment Curves~iMEPs~StartReact~Visit 2 Measurements:~Participant Reported Spasticity~MAS~PSAD~KINARM~MRI of brain and spinal cord"
89038892|NCT04393922|Experimental|Aim 2|"To accomplish this aim, we will use a randomized crossover design study with spastic SCI participants receiving a single intervention combining non-invasive acoustic stimuli (Startle) or sham-Startle with motor training to enhance cortico- and reticulo-spinal contribution, separated by ~2 weeks.~Visit 1 and Visit 2~Single intervention of:~Startle + exercise training OR sham-Startle + exercise training~Pre and post measurements:~MVCs~MEP recruitment curves~iMEPs~StartReact~Participant reported spasticity~MAS~PSAD~KINARM~Neuromechanical hand and/or leg testing~GRASSP~TRI-HFT~10-meter walk test~Pendulum Test"
89038893|NCT04389905|Experimental|Motivational Interviewing Oral Health Education Group|The intervention group focused on the mothers from before birth until their child reached the age of 3 years. They received repeated questionnaires and repeated oral health education using the Motivational Interviewing (MI) technique.
89038894|NCT04389905|No Intervention|Local Control Group|The local control group included other mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
89038895|NCT04389905|No Intervention|Similar Socio-economics Control Group|This control group is from a Public Dental Clinic with similar socioeconomics (among the families in the catchment area of the clinic) as in the intervention group. This control group included mothers and their children, who were (randomized according to) born during the same time as the children in the intervention group. They received only a questionnaire before their children were born. Caries data from 3- and 6-year examination is used.
89625551|NCT01454895|Experimental|Interactive Web-based Information (IWI)|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
89625552|NCT01454895|Experimental|Static Web information (SWI) & HPDs|Subjects will receive static Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
89038896|NCT01232491|Active Comparator|Control|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects did not receive dietary consultation except for basic dietary advice at baseline. Insulin doses were individually adjusted.
89038897|NCT01232491|Experimental|Dietician|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects received dietary consultation according to local standard during 3 face-to-face meetings and 3 phone contacts. Insulin doses were individually adjusted.
89038898|NCT04321057||Group questionnaire|Patient's height and weight are asked by questionnaire in this group. It includes patients at the cardiological department of Saarland University.
89038899|NCT04321057||Group male doctor|Patient's height and weight are asked by a male doctor in this group. It includes patients at the cardiological department of Saarland University.
89038900|NCT04321057||Group female doctor|Patient's height and weight are asked by a female doctor in this group. It includes patients at the cardiological department of Saarland University.
89057875|NCT01687725||Renal denervation|Renal denervation using Symplicity Catheter system
89625553|NCT01454895|Active Comparator|Static Web information only|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing.
89625554|NCT01454895|Experimental|Hearing protection Devices only|Subjects will receive a mailed sample of various types of hearing protection devices.
89625555|NCT01454895|Other|Interactive Web-based information only|used for cases enrolling after achievement of study enrollment goal
89625556|NCT02902029|Experimental|Arm A|"After a 3 months run-in period with vemurafenib and cobimetinib [960 mg vemurafenib twice daily (BID), 28/0; 60 mg cobimetinib daily (QD), 21/7], all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7).~After progression of disease patients in Arm A will subsequently receive atezolizumab treatment (1200 mg/ q3w)."
89625557|NCT02902029|Experimental|Arm B|"After a 3 months run-in period with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7), all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with atezolizumab. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on day 1 of each 21 day-cycle.~After progression of disease patients in Arm B will cross back to vemurafenib and cobimetinib treatment (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7)."
89625558|NCT02933697|Active Comparator|Apixaban|2.5 mg apixaban twice daily for 1 to 60 months
89625559|NCT02933697|Active Comparator|Vitamin-K antagonists (Phenprocoumon)|Phenprocoumon by INR (Target: 2.0-3.0) treatment for 1 to 60 months
89625560|NCT04848285|Active Comparator|Standard care group|Standard of care (SC) mobility protocol performed by the Stroke Unit nursing and physiotherapy staff. The SC consists of one or two sessions per days of out-of-bed sitting and standing, adapted to patient´s tolerability, and one session of physiotherapy per day. Mobilization will be schedule to start from 24 hours from symptoms onset according to the local Stroke Unit protocol.
89625561|NCT04848285|Experimental|Intensive mobilization group|The Intensive mobilization intervention will include the standard care plus at least two additional sessions each day of at least 20 minutes each session focused on task specific sitting, standing and walking activities. The intervention will be schedule to start at 24 hours from symptoms onset and will last 14 days or until the patient is discharged.
89625562|NCT01455129|Active Comparator|tiotropium group|18 mcg tiotropium, once daily, inhaled by HandiHaler
89625563|NCT01455129|Placebo Comparator|placebo group|matching placebo, once daily, inhaled by HandiHaler
89625564|NCT02790411|Experimental|healthy volunteers|Imaging devices New Non Invasive Devices
89625565|NCT01455207|Other|alcoholic patients|
89625566|NCT01455207|Other|korsakoff patients|
89625567|NCT01455207|Other|healthy controls|
89625568|NCT02865447||PRESERVE total hip arthroplasty implant|Subjects to be prospectively implanted with the PROFEMUR PRESERVE total hip arthroplasty implant
89625569|NCT01455441|Active Comparator|Training and liraglutide|Treatment with both training and liraglutide for 16 weeks
89625570|NCT01455441|Placebo Comparator|Training and placebo|Treatment wiht both training and placebo for 16 weeks
89625571|NCT01455675|Experimental|IgY, gargling solution|Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
89625572|NCT01455675|Placebo Comparator|Placebo, gargling solution|70 ml gargling solution without antibodies, once daily
89625573|NCT02858583|Experimental|Intervention (CC+SI)|"Infants randomized into the CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression. The SI will be delivered over a period of 45 seconds. This will be followed by PEEP of 5-8 cm water to perform an assessment of the newborn's heart rate. If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 45sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI."
89625574|NCT02858583|Active Comparator|Control (3:1 C:V)|"Infants randomized into the 3:1 C:V group will receive CC at a rate of 90/min and 30 ventilations/min in a 3:1 C:V ratio as recommended by the current resuscitation guidelines."
89625575|NCT01455753||Employees|A total of 1,801 employees of a health benefits administrator that held a free workplace influenza vaccination clinic.
89625576|NCT03823053|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 30 minutes. The content of the physiotherapy program; posture, interscapular muscle strengthening, stretching and lateral flexion exercises are formed.
89625577|NCT03823053|Experimental|Training Group|"In addition to home based traditional scoliosis exercise, the training group will also receive core stabilization exercise training for 8 weeks, 5 days a week, for 30 minutes. Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and latissimus dorsi."
89625578|NCT01455831|Experimental|Extended peri-operative thromboprophylaxis|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
89625579|NCT01455831|Active Comparator|Standard thromboprophylaxis|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
89625580|NCT04840641|No Intervention|Baseline|The investigators measure the baseline of flucloxacillin and cocktaildrugs.
89625581|NCT04840641|Experimental|Flucloxacillin treatment|The investigators measure the concentration of flucloxacillin after 9 and 27 days and the concentration of cocktaildrugs after 10 and 28 days.
89625582|NCT01455909|Experimental|ITCA 650 60 mcg/day|
89625583|NCT01455909|Active Comparator|sitagliptin|sitagliptin 100 mg/day
88989919|NCT04605809|Experimental|combined motor and cognitive training|The combined motor and cognitive training group will undertake physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training.
88989920|NCT04605809|Active Comparator|motor training alone|The motor training alone group will train the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group.
88989921|NCT04605809|Active Comparator|cognitive training alone|The cognitive training alone group will train the same set of cognitive training while sitting as the combined motor and cognitive training group.
88989922|NCT04605809|No Intervention|no intervention control group.|No intervention control group will maintain habit and daily activity.
88989923|NCT04605536|Other|Intervention|Give explanations about conventional capsule endoscopy and watch animation videos
88989924|NCT04605536|Other|Control|Give explanations about conventional capsule endoscopy
89211082|NCT02548442||Typically Developing Children|Subjects identified as not having a developmental delay or autism spectrum disorder using behavioral methods as well as not having another serious medical or psychological condition.
89625584|NCT04844619|Experimental|KDR2-2 group|The patients with NVG will receive 4.0 mg/ml or 16.0mg/ml KDR2-2 suspension eyedrop and the anti-neovascular effect of KDR2-2 would be evaluated during the follow-up visits.
89625585|NCT01757171|Experimental|Arm A (taxane naïve)|No prior Taxane treatment. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
89625586|NCT01757171|Experimental|Arm B (prior taxane therapy)|Subject previously treated with taxane. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
89625587|NCT04847349|Experimental|Live microbial (Probiotic) consortium OL-1, standard dose|Combination of a standard dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
89625588|NCT04847349|Experimental|Live microbial (Probiotic) consortium OL-1, high dose|Combination of a high dose of live microbials (probiotics) taken as a capsule once per day with breakfast for 21 days. Capsules should not be consumed with hot drinks or alcohol.
89625589|NCT04847349|Placebo Comparator|Placebo for live microbial (probiotic) consortium|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics, taken once per day with breakfast for 21 days.
89625590|NCT01456065|Other|Vaccine weekly administration|
89625591|NCT01456065|Other|Vaccine biweekly administration|
89625592|NCT04842123|Other|Atrial fibrillation (AF)|Patients with a known history of AF who are in AF at the time of study screening.
89625593|NCT04842123|Other|Normal Sinus Rhythm (SR)|Patients with no known diagnosis of AF or other arrhythmia
89625594|NCT02555787||Patients converted from tacrolimus BD to Advagraf|Oral
89625595|NCT01756235||Participants with Rheumatoid Arthritis|Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.
89625596|NCT04847583|Experimental|Telacebec (Q203) with COVID-19 standard of care (SoC)|
89625597|NCT04847583|Active Comparator|COVID-19 Standard of care (SoC)|
89625598|NCT01730729|Experimental|Treatment (cabergoline)|Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89625599|NCT04847817||Index cases|Patients infected by SARS-Cov2 Polymerase Chain Reaction (PCR) and hospitalized in a referral center for COVID-19 .
89625600|NCT04847817||Households cases|Household contacts of SARS-Cov2 hospitalized COVID-19 patients.
89625601|NCT03822819|Experimental|probiotic cocktail capsules uptake|Participants take two capsules of probiotic cocktail everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
89625602|NCT03822819|Placebo Comparator|placebo capsules uptake|Participants take two capsules of placebo everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
89625603|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2|SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.
89625604|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1|SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.
89625605|NCT02931513||PBC patients|Patients with primary biliary cholangitis
89625606|NCT01756079|Experimental|PegIFN-2b + RBV+ boceprevir|Participants will receive PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) for 4 weeks and then will receive 44 additional weeks of treatment with PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) + boceprevir (capsules, orally, 800 mg three times per day).
89625607|NCT04272645|Experimental|Arm A - Abemaciclib 200 mg|Abemaciclib twice daily. 1 cycle of treatment is 21 days in length.
89625608|NCT04272645|Experimental|Arm B - Abemaciclib 150 mg + atezolizumab|Atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily.
89625609|NCT04272645|Experimental|Experimental: Arm C - Patients with CDK12 loss|"Group 1 - Atezolizumab: Patients with CDK12 loss will receive atezolizumab monotherapy on the first day of each 21-day cycle~Group 2 - Abemaciclib 150 mg + atezolizumab: Patients with CDK12 loss will receive atezolizumab on the first day of each 21-day cycle in combination with abemaciclib twice daily."
89625610|NCT01456533||hospitalized patients|hospitalized patients with hyponatremia
88989925|NCT04602325||Inherited Hyperammonemias|"A clinical diagnosis of 1 of 7 diagnosed urea cycle disorders:~N-acetylglutamate Synthetase Deficiency (NAGS)~Carbamyl Phosphate Synthetase Deficiency (CPSD)~Ornithine Transcarbamylase Deficiency (OTCD)~Argininosuccinate Synthetase Deficiency (ASD)~Argininosuccinate Lyase Deficiency (ALD)~Arginase Deficiency (AD)~Hyperammonemia-Hyperornithinemia-Homocitrullinuria (HHH)~A clinical diagnosis of 1 of 2 organic acidemias:~Propionic Acidemia (PA)~Methylmalonic Acidemia (MMA)"
88989926|NCT04602325||Acute Metabolic Disorder + Neurological Sequelae|"Acute metabolic disorder without hyperammonemia but with neurological sequelae:~Maple Syrup Urine Disease (MSUD)~Glutaric Acidemia (GA1)"
89038901|NCT04321057||Group male nurse|Patient's height and weight are asked by a male nurse in this group. It includes patients at the cardiological department of Saarland University.
89038902|NCT04321057||Group female nurse|Patient's height and weight are asked by a female nurse in this group. It includes patients at the cardiological department of Saarland University.
89038903|NCT04321057||Group family doctor|Patient's height and weight are asked by questionnaire in this group. This is the control group,including patients at a family doctor.
89038904|NCT05388591|Experimental|Musicotherapy|
89038905|NCT05388591|No Intervention|Standard care|
89038906|NCT04355234|Experimental|all patients|
89038907|NCT04355234|Experimental|patients who presented a SARS-CoV-2 infection confirmed by PCR|
89038908|NCT04335305|Experimental|Tocilizumab plus Pembrolizumab (MK-3475)|"Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose) as an intravenous infusion over 60 minutes; single dose Pembrolizumab (MK3475) 200 mg as an intravenous infusion over 30 minutes; single dose.~Patients who are showing no clinical improvement in respiratory function after 12 hours could receive an additional dose of tocilizumab at the same dose level of the first administration. Patients who are showing SpO2 ≤ 94% on room air could receive an additional administration of pembrolizumab (MK-3475) at the same recommended dose after 3 weeks from treatment initiation and/or an additional dose of tocilizumab after 4 weeks from treatment initiation at physician's discretion."
89038909|NCT04335305|No Intervention|Continued Standard of Care|Standard care per local written policies or guidelines comprises, as necessary and at physician's discretion, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, glucocorticoid, tocilizumab, virally targeted agents, chloroquine or hydroxychloroquine.
89038910|NCT04253951|Experimental|LUS-monitored management (LUS-m)|In the first 3 months, participants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 evaluations (T1, T2 and T3), plus baseline (T0). At any time point, they will undergo at least one LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities.
89038911|NCT04253951|Sham Comparator|Standard care management (SC-m)|Sham protocol with LUS performed at the same timepoints. LUS results in the SC-m group will be available only at the time of data analyses for comparison by investigators. They will not be used for clinical decisions.
89038912|NCT04248530|Experimental|Renal denervation therapy group|The subject treated by renal denervation by using DENEX system.
89038913|NCT04255212|Experimental|Soft tissue treatment|Participants will be treated with 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms.
89625611|NCT03822585|Other|Close Relatives Of β-thalassemia|Laboratory diagnostic tests as (CBC, Iron Study, Serum Ferritin, HPLC, Genetic study) will be done to Brothers, Sisters & Cousins of β-thalassemia Children With Microcytic Hypochromic Anemia Attending Assiut University Child Hospital
89625612|NCT04390815|Experimental|Intervention|"Before starting the therapeutic procedure, all wounds will be fully washed with normal saline.~Group A patients will receive 10 units (0.1 mL) of regular insulin (manufactured by novo nordisk) in solution with 1 cc of normal saline 0.9% for each 10 cm of wound. The solution will be sprayed on the wound surface with an insulin syringe needle, once daily.~The patients in this arm will receive conventional therapy."
89057876|NCT02218034|Experimental|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
89057877|NCT02218034|Experimental|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
89625613|NCT04390815|Placebo Comparator|Control|Before starting the therapeutic procedure, all wounds will be fully washed with normal saline Group B patients will receive conventional topical application without insulin
89625614|NCT01456611|Experimental|Diclofenac Sodium Gel|Diclofenac sodium Topical Gel 1%
89625615|NCT01456611|Active Comparator|Voltaren (R) Gel|Voltaren (R) Gel 1%
89625616|NCT01456611|Placebo Comparator|Placebo|Placebo Topical Gel
89625617|NCT01456689|Experimental|LGH447|Eligible patients will be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
89625618|NCT01456689|Experimental|LGH447 and midazolam|Eligible patients will receive midazolam on two separate days, the first dose will be administered prior to the start of LGH447 and the second will be co-administered with LGH447. After that, the patients will continue to be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
89625619|NCT05827185|Experimental|Ergonomic modifications group (EMG)|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
89625620|NCT05827185|Experimental|Physiotherapy group (PTG)|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. If any participant reported any new red flag signs or showed no signs for manipulation, such as no pain or musculoskeletal dysfunction, then the procedure was not performed.
89688465|NCT02793856|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 4 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
89688466|NCT03403985|Experimental|calcium hydroxide direct pulp capping|calcium hydroxide (Ca(OH)2 direct pulp capping will be performed in this group
89625621|NCT05827185|Experimental|Ergonomic modifications combined with physiotherapy group (EPG)|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. If any participant reported any new red flag signs or showed no signs for manipulation, such as no pain or musculoskeletal dysfunction, then the procedure was not performed."
89625622|NCT05827185|Sham Comparator|Control group (CNG)|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
89625623|NCT05827172|Experimental|AF ablation|The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
89625624|NCT05827172|Other|Medical therapy (rate or rhythm control)|The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. Among patients who were treated for rate control, the recommended criteria varied according to the age of the patient. The aim of the treatment was a ventricular rate of 60 to 80 beats. per minute at rest
89625625|NCT05827094|Experimental|Mobile Intervnetion|Participants randomized to the intervention arm will receive verbal and written instructions as well as one-on-one demonstration of the app features. Participants will have an option of either receiving the study mobile device or will be able to use their own device with an installed app. Following the training, participants will be asked to use the app at least once a week.
89625626|NCT05827094|Active Comparator|Usual Care|Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
89625627|NCT05827029|Experimental|Preoperative carbohydrate drink|
89625628|NCT05827029|Placebo Comparator|Water|
89625629|NCT05826977|Experimental|CASI-Plus|The CASI-Plus arm involves use of a tablet-based computerized self-interview tool. This mHealth tool supports the initial assisted partner services (APS) encounter (providing information on how APS works, eliciting names of all sexual or injection partners, screening for risk of intimate partner violence [IPV], and planning for partner notification), and facilitates case management through partner testing (via repeat follow-up surveys to assess for barriers to notification, interest in provider assistance, IPV, and completion of notification).
89625630|NCT05826977|No Intervention|Standard of care|"Standard APS services involve:~1) Nurses, social workers or doctors introduce APS services to clients during routine health care visits and complete partner elicitation and intimate partner violence (IPV) screening via in-person counseling.~3) HWs discuss options for partner notification. 4) If index clients opts for a HW to notify the partner, the HW makes multiple contact attempts to contact partners by phone. When index clients return for their regular healthcare services, HW follow up with index clients to check if exposed partners have completed the testing process.~5) If partners have an unknown HIV status, they are encouraged to complete HIV testing.~6) Partners who test negative for HIV are referred to HIV prevention services, while those with confirmed HIV diagnoses are linked to HIV care and treatment."
89625631|NCT05826925|Experimental|Decision aid|Participants will use the decision aid in the postpartum period
89625632|NCT05826925|No Intervention|Usual care|Participants will receive standard postpartum care
89625633|NCT05826821||Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
89625634|NCT05826821||Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
89625635|NCT05826795||Control|During the intraoperative period, both before and after CPB, the Control group received fluid, inotropic, and/or vasoactive drugs at the discretion of the attending anesthesiologists to achieve the following goals: MAP 65-90 mmHg; CVP 8-12 mmHg; urine output ≥ 0.5 mL·kg-1·h-1; SpO2 > 95%; and hematocrit 26-30%. Arterial blood gas (ABG) and electrolytes were monitored and corrected hourly.
89625636|NCT05826795||EV1000|The patients were managed to achieve similar goals: MAP 65-90 mmHg; urine output ≥ 0.5 mL·kg-1·h-1; SpO2 > 95%; and hematocrit 26-30%, using information from the FloTrac/EV1000. The EGDT group received: fluid to maintain a SVV < 13%; inotropic drugs to achieve a SVI of 33-65 mL·beat-1·m-2 and CI of 2.2-4.0 L·min-1·m-2; and/or vasoactive drugs to achieve a SVRI of 1600-2500 dynes·s·cm-5·m-2. ABG and electrolytes were monitored and corrected in the same manner.
89625637|NCT05826769|Experimental|Energy- Protein Enriched Nutritional Formula|Liquid, ready-to-use Energy-Protein nutrition formula with energy density of 1 kCal/mL (EP formula)
89625638|NCT05826769|No Intervention|Standard Nutritional Formula|Polymeric formula stage-1 and stage-2 for infants aged 0-6 months and 6-12 months accordingly, providing 0.67 kCal/mL (S-1/S-2 formula)
89625639|NCT05826730|Active Comparator|Exercise|Eccentric muscle training for neck muscles
89625640|NCT05826730|No Intervention|Control|Home exercise program for neck muscles
89625641|NCT05826717|Experimental|Food product 1.|[x] gr apple containing 20 gr fructose as measured with an enzymatic method. Administered one time.
89625642|NCT05826717|Experimental|Food product 2.|[x] gr mashed apple containing 20 gr fructose as measured with an enzymatic method. Administered one time.
89625643|NCT05826717|Experimental|Food product 3.|[x] ml apple juice containing 20 gr fructose as measured with an enzymatic method. Administered one time.
89057878|NCT02218034|Active Comparator|TAZORAC® Gel 0.1%|TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
89057879|NCT02218034|Active Comparator|TAZORAC® Cream 0.1%|TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
89625644|NCT05826717|Experimental|Food product 4.|20 gr of fructose powder dissolved in 300 ml of water. Administered one time.
89625645|NCT05826704|Experimental|PS23|2 capsule daily
89625646|NCT05826704|Placebo Comparator|Placebo|2 capsule daily
89625647|NCT05826691||Patients required prostate surgery for LUTS|Patients with LUTS attributable to bladder outlet obstruction because BPH
89625648|NCT05826652|Active Comparator|subcostal transversus abdominis plane block|At the end of the operation, a right-sided subcostal transversus abdominis plane block will be applied to the patients by ultrasound aided. While applying the subcostal transabdominal plan block, %2,5 Marcaine 20 ml will be given between the transverse and rectus abdominis muscle immediately next to the linea semilunaris. Patient-controlled analgesia devices with Tramadol will be prepared for postoperative analgesia. Rest and coughing pains, nausea and total PCA consumption will be recorded10 minutes, 30 minutes, 1, 3, 6, 24 hours postoperatively. Verbal Numerical Rating Scala (0 = no pain; 10 = the most severe pain you can imagine) for pain and Categorical Scoring Method (0 = none; 1 = less; 2 = too; 3 = too much) for nausea will be used. Complications such as infection, bleeding, and subcutaneous emphysema will be recorded.
89625649|NCT05826652|Active Comparator|Multiple injection subcostal transversus abdominis plane block|At the end of the operation, a right-sided subcostal transversus abdominis plane block will be applied to the patients by ultrasound aided. patients received %2,5 Marcaine 5 ml between the transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volumes lateral to this point near the subcostal margin. Patient-controlled analgesia devices with Tramadol will be prepared for postoperative analgesia. Rest and coughing pains, nausea and total PCA consumption will be recorded10 minutes, 30 minutes, 1, 3, 6, 24 hours postoperatively. Verbal Numerical Rating Scala (0 = no pain; 10 = the most severe pain you can imagine) for pain and Categorical Scoring Method (0 = none; 1 = less; 2 = too; 3 = too much) for nausea will be used. Complications such as infection, bleeding, and subcutaneous emphysema will be recorded.
89038914|NCT04255212|Placebo Comparator|Mechaninsms explanation|Participants will be instructed with a 10 minute lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
89625650|NCT05826626|Experimental|Experimental Group|The group will undergo 10 sessions (2 weeks) of a treatment combining prismatic adaptation (PA) and serious games (SG) for cognitive training, using the Mindlenses Professional device. In each session, firtsly we will perform the PA procedure, followed by approximately 30 minutes of SG. SG will be focused on attention, executive functions and language.
89625651|NCT05826626|Active Comparator|Control Group -1|The group will undergo 10 sessions (2 weeks) of a treatment using the serious games (SG) for cognitive training provided by the Mindlenses Professional device. SG will be focused on attention, executive functions and language.
89038915|NCT04255212|Other|Control group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
89038916|NCT04255212|Experimental|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
89038917|NCT04207268|Experimental|Gardening and Nutrition Advice|Participate in gardening activities, food demonstrations and nutrition advice
89038918|NCT04207268|Placebo Comparator|Nutrition Advice alone|Participate in only nutrition advice
89038919|NCT05353803|Experimental|People older than 60 years with heart failure and living at home.|People older than 60 years with heart failure and living at home.
89038920|NCT00554021||1|Department of Traumatology and Critical Care Medicine, National Defense Medical College
89038921|NCT00552903|Experimental|1|Active intervention - personal health coaching provided
89625652|NCT05826626|Active Comparator|Control Group -2|The group will perform 2 weeks of the standard cognitive training offered by IRCCS San Camillo Hospital.
89625653|NCT05826613||adults with COPD and asthma|Male or female aged >18 years with clinical diagnosis of either COPD or asthma.
89625654|NCT05826548|Experimental|Telerehabilitation group|The TR group will perform 4 weeks of cogntiive training using the FINAGE tablet. The rehabilitation tasks will train the patients on the detected FA deficits, but also on the cognitive domains underlying such abilities. FINAGE TR program will have a modular structure, with 8 different packages including AF and: language, attention, memory, numbers, logical reasoning, executive functions, theory of mind and testamentary capacities. Every package will involve exercises of increasing difficulty. Reaction times, number of stimuli presented and other parameters will be customizable, in order to be adaptable to different patients' cognitive conditions and/or to their achievements from one session to the other.
89625655|NCT05826548|Active Comparator|Conventional treatment group|The CT group will perform 4 weeks of the standard cognitive training offered by IRCCS San Camillo Hospital.
89625656|NCT05826522||asthmatics and asthmatics previously|
89625657|NCT05826522||COPD (chronic obstructive pulmonary disease) patients|
89625658|NCT05826522||cystic fibrosis patients|
89625659|NCT05826522||patients with immunodeficiency with bronchial obstruction|
89625660|NCT05826522||lung transplant recipients with obstructive chronic lung allograft rejection (O-CLAD)|
89038922|NCT00552903|No Intervention|2|Control arm - no intervention, data on health outcomes collected at baseline (entry to the study) and during the 12 month follow-up
89038923|NCT04176029||Children admitted with confirmed severe malaria|
89038924|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 3 hours.|This is a dose optimization study, different dosages will be tested, the lowest dosage that will be tested is 2,5 mg/kg/h for 3 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
89057880|NCT01687764|Experimental|CBGT+ABMT(active)|
89057881|NCT01687764|Experimental|CBGT+ABMT(placebo)|
89057882|NCT01687764|Experimental|PCI+ABMT(active)|
89057883|NCT01687764|Placebo Comparator|PCI+ABMT(placebo)|
89625661|NCT05826483|Experimental|Almonertinib|Almonertinib, 110 mg, po, QD; 28 days every cycle
89625662|NCT05826444||microvascular cardiac allograft vasculopathy|Heart transplant recipients with microvascular cardiac allograft vasculopathy defined by histopathology and invasive index of microvascular resistance.
89625663|NCT05826444||control|Heart transplant recipients without microvascular cardiac allograft vasculopathy defined by histopathology and invasive index of microvascular resistance.
89625664|NCT05826405||Cashew Nut allergic|
89625665|NCT05826340|Experimental|Tailored loading|Participants will be provided with a 5-stage return to sport tool, which gradually increases sports intensity and knee loading. In addition, they are to perform a progressive exercise program at home to increase lower extremity strength and prepare them for the demands of sport. Participants will begin at a starting point in the five stages based on their current symptoms and self reported sports related disability, and given guidance on how to progress / regress their loading within the five stage framework
89625666|NCT05826340|Experimental|Pain within acitvity limits|Participants will be advised to participate in sport/exercise to the extent that pain allows. They will not be restriced full from sport but will be instructed how to use a pain moritoring tool to help monitor pain and balance the amount of activities in which they can participate.
89625667|NCT05826340|No Intervention|Rest until pain subsides|Participants will be provided advice on rest for a minimum of four weeks or until pain subsides
89625668|NCT05826262|Experimental|patients with penetrating anterior abdominal wall injuries|
89625669|NCT05826249|Experimental|SIM0417/Ritonavir|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
89625670|NCT05826236||Patients with knee osteoarthritis|Periarticular knee compression using a sphygmomanometer.
89625671|NCT05826236||Healthy subjects|Periarticular knee compression using a sphygmomanometer.
89625672|NCT05826210||Sarcopenic obesity group|Patients who underwent LSG with FM/FFM>0.80 calculated from the cross-sectional CT image of L3 vertebra.
89625673|NCT05826210||Non-sarcopenic obesity group|Patients who underwent LSG with FM/FFM<0.80 calculated from the cross-sectional CT image of L3 vertebra.
89625674|NCT05826158|Other|Children with Neuroblastoma|
89038925|NCT04152980|Experimental|Pentoxifylline therapy 2,5 mg/kg/h for 6 hours|The second lowest dosage that will be tested is 2,5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
89038926|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 6 hours.|The third lowest dosage, is the start dosage and the dosage that is already used in other clinical studies: 5 mg/kg/h for 6 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
89038927|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 12 hours.|The fourth dosage that is tested is 5 mg/kg/h for 12 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease..
89038928|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 18 hours.|The fifth dosage that is tested is 5 mg/kg/h for 18 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
89038929|NCT04152980|Experimental|Pentoxifylline therapy 5 mg/kg/h for 24 hours.|The sixth dosage that is tested is 5 mg/kg/h for 24 hours every 24 hours for 3 to 6 days. The decision to prolong therapy after 3 days of therapy is made by the treating physician, depending on the clinical state of the patient and the severity of disease.
89038930|NCT01232452|Experimental|Pemetrexed + Cisplatin + Cixutumumab|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
89057884|NCT04529759|Active Comparator|Control Infant Formula|Feed ad libitum
89625675|NCT05826145|Active Comparator|Vocal Expression|Supportive care through vocal expression sessions where participants can talk for approximately 20-30 minutes about the person who died.
89625676|NCT05826145|Experimental|Cognitive Behavioral|Cognitive-behavioral techniques with sessions consisting of approximately 20-30 minutes.
89625677|NCT05826106||R anastomosis|
89625678|NCT05826093||Patients planned for cholecystectomy|Patients planned for elective laparoscopic cholecystectomy received a peroperative ultrasound-guided transversus abdominis plane (TAP) block at the beginning of the procedure.
89625679|NCT05826080||operative group|Procedure/Surgery:Adrenal Vein Sampling;Adrenalectomy
89625680|NCT05825976|Experimental|Intervention group 1|Supplementation with 2 gel-capsules (each containing 720 mg eicosapentaenoic acid (EPA) and 480 mg docosahexaenoic acid (DHA))
89625681|NCT05825976|Experimental|Intervention group 2|Supplementation with 2 gel-capsules (each containing 320 mg eicosapentaenoic acid (EPA) and 200 mg docosahexaenoic acid (DHA))
89625682|NCT05825976|Active Comparator|Control|Supplementation with 2 gel-capsules (each containing 1000 mg extra virgin olive oil)
89625683|NCT05825872|No Intervention|control group|patients will undergo a thoracoscopic surgery under general anesthesia with double-lumen bronchial intubation without any special treatment.
89625684|NCT05825872|Active Comparator|experimental group|patients will receive US-guided iSLN block bilaterally with 2 ml of ( 0.5 ml of 2%lidocaine and 1,5 ml of 0.5% bupivacaine) on either side immediate after the operation concomitant with GA in order to undergo thoracoscopic surgery
89625685|NCT05825820|Experimental|Enhanced Outreach Intervention plus Care as Usual|Participants will receive the Enhanced Outreach Intervention (EOI) plus care as usual for 12 weeks after ED discharge.
89625686|NCT05825703||PPMV|GROUP OF PATIENT POPULATION WHO HAD PROLONGED POST-OPERATIVE MECHANICAL VENTILATION
89625687|NCT05825703||NON PPMV|GROUP OF PATIENT POPULATION WHO DID NOT HAVE PROLONGED POST-OPERATIVE MECHANICAL VENTILATION
89625688|NCT05825690||LGI1- Patients|Patients affected by autoimmune encephalitis with antibodies against LGI1
89625689|NCT05825677|Active Comparator|Active tDCS|Active brain stimulation Direct current stimulation of DLPFC for 30min with an intensity of 1mA
89625690|NCT05825677|Sham Comparator|Sham tDCS|Sham brain stimulation Direct current stimulation of DLPFC for 30sec with an intensity of 1mA
89038931|NCT01232452|Active Comparator|Pemetrexed + Cisplatin|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
89625691|NCT05825664|Experimental|Underwater endoscopic mucosal resection|Intervention: Non-pedunculated polyps will be removed by underwater endoscopic mucosal resection. The UEMR procedure included the following: (1) complete deflation of the colorectal lumen; (2) total immersion of the lesion in normal saline using a mechanical water pump; (3) snaring the lesion and the surrounding mucosa; and (4) resection using electrocautery.
89625692|NCT05825664|Active Comparator|Conventional endoscopic mucosal resection|Intervention: Non-pedunculated polyps will be removed by conventional endoscopic mucosal resection. The CEMR procedure included the following: (1) needle injection of normal saline into the submucosa; (2) entrapment of the mucosal protrusion with a snare; and (3) resection applying the same electrocautery setting as was used for UEMR.
89625693|NCT05825638||Continuous training session|
89625694|NCT05825638||Interval Training session|
89625695|NCT05825612||Heterozygous Familial Hypercholesterolemia|Children and adolescents with Heterozygous Familial Hypercholesterolemia.
89625696|NCT05825612||Homozygous Familial Hypercholesterolemia|Children and adolescents with Homozygous Familial Hypercholesterolemia.
89625697|NCT05825612||Unaffected (non-FH) individuals|Children and adolescents not carrying the investigated FH mutations
89625698|NCT05825599|Experimental|Eyedrops treatment arm|
89625699|NCT05825586|Experimental|Eyedrops treatment arm|
89625700|NCT05825547|Experimental|Cryotherapy|
89038932|NCT01211197|Experimental|A|3 treatments will be investigated in randomized order
89038933|NCT01211197|Experimental|B|3 treatments will be investigated in randomized order
89038934|NCT01211197|Experimental|C|3 treatments will be investigated in randomized order
89038935|NCT04679519|Active Comparator|Control|Control group that was not given a supplement.
89038936|NCT04679519|Experimental|BCAA|Supplement group that was given Branched Chain Amino Acids (BCAA).
89038937|NCT04679519|Experimental|Leucine|Supplement group that was given Leucine.
89038938|NCT04679519|Experimental|HMB|Supplement group that was given β-Hydroxy β-methylbutyric acid (HMB)
89038939|NCT05345067|Experimental|Experimental: Laughter yoga session parts-1|Deep breathing exercises (5 minutes)
89038940|NCT05345067|Experimental|Experimental: Laughter yoga session parts-2|Warm-up exercises (10 minutes)
89038941|NCT05345067|Experimental|Experimental: Laughter yoga session parts-3|Childish games (10 minutes)
89625701|NCT05825456||endoprosthetic reconstruction|This is the group of patients with metastatic pathologic fractures treated with endoprosthesis. For example, proximal femur prosthesis for femoral neck fractures.
89625702|NCT05825456||intramedullary nail|This is the group of patients with metastatic pathologic fractures treated with intramedullary nail, and additional bone cement if needed. For example, proximal femur nail for trochanteric fractures, or long femoral nail for femoral shaft fractures.
89625703|NCT05825456||open reduction internal fixation with plate and screws|This is the group of patients with metastatic pathologic fractures treated with open reduction internal fixation; with plates and screws. For example, reconstruction plates for pelvic fractures or 3.5 locking compression plates for humeral or femur shaft fractures.
89625704|NCT05825378|Experimental|group dexamethasone|Dexamethasone 8mg+0.375% ropivacaine
89625705|NCT05825378|Sham Comparator|group control|0.375% ropivacaine
89625706|NCT05825313|Experimental|Podcast Group|Podcast was applied to the experimental group.
89625707|NCT05825313|No Intervention|Control Group|No intervention was applied to the control group.No intervention was applied to the control group.
89625708|NCT05825287|Active Comparator|Trained by teaching back method|The course method will determine which group to assign the first patient to meet the criteria for inclusion in the study by the researcher. Subsequent patients will be distributed to groups in turn. It is planned to include 40 participants in the study, as losses may occur among the participants. The study will begin on the day that cancer-treated participants receive chemotherapy for the first time. Considering that the participants would be more comfortable and the training would be healthy, the training was planned 30 minutes before the application. The training was planned by the researcher in the chemotherapy case manager's room as face-to-face meetings with each participant separately. Each training will be accompanied by a chemotherapy case manager. Training time is between 20-30 minutes as planned.
89688467|NCT03403985|Experimental|MTA direct pulp capping|Mineral Trioxide Aggregate (MTA) direct pulp capping will be performed in this group
89038942|NCT05345067|Experimental|Experimental: Laughter yoga session parts-4|Laughter exercises (15 minutes)
89038943|NCT04679792||operated|Patients Under 18 years of age who are operated for Chiari Malformation on the basis of routine neurosurgical assessment.
89038944|NCT04679792||non operated|Patients Under 18 years of age who are not operated for Chiari Malformation on the basis of routine neurosurgical assessment.
89038945|NCT04679363|Experimental|Active release technique group|Active release technique group (ART group) will receive Oscillatory mobilization with active release technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
89038946|NCT04679363|Experimental|Post isometric relaxation group|Post isometric relaxation group (PIR group) will receive Oscillatory mobilization with post isometric relaxation technique. Treatment will be provided for 2 session/week for 3 weeks with 40 minutes/session. Patient will be assessed at baseline and after 3rd week of intervention.
89038947|NCT00553137|Active Comparator|1|single dose fluconazole (750 mg) and placebos 150 mg tablets once daily for 14 days
89057885|NCT04529759|Experimental|Experimental Infant Formula|Feed ad libitum
89688468|NCT04364425|Experimental|low dose steroid|patient received ultrasound-guided 40mg triamcinolone + 4cc xylocaine + 12cc NS
89625709|NCT05825287|Experimental|Management training|The course method will determine which group to assign the first patient to meet the criteria for inclusion in the study by the researcher. Subsequent patients will be distributed to groups in turn. It is planned to include 40 participants in the study, as losses may occur among the participants. The study will begin on the day that cancer-treated participants receive chemotherapy for the first time. Considering that the participants would be more comfortable and the training would be healthy, the training was planned 30 minutes before the application. The training was planned by the researcher in the chemotherapy case manager's room as face-to-face meetings with each participant separately. Each training will be accompanied by a chemotherapy case manager. Training time is between 20-30 minutes as planned.
89625710|NCT05825274|Experimental|Refractory Epilepsy Group|50 patients with at least they have 3 crisis per week They Receive Cathodal tDCS We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31
89625711|NCT05825274|Placebo Comparator|Placebo Patients|50 patients with at least they have 3 crisis per week that receive SHAM They Not Receive Cathodal tDCS. We do EEG before and after intervention with 19 channels and the patient complete questionnarie: QUALITY OF LIFE IN EPILEPSY - QOLIE-31
89625712|NCT05825248|Experimental|Reflex integration + fine and gross motor treatment|For 20 minutes per week for 8 weeks, this group will recieve 10 minutes of fine and gross motor treatment and 10 minutes of reflex integration exercises from the Move Play Thrive program.
89625713|NCT05825248|Active Comparator|Fine and gross motor treatment only|For 20 minutes per week for 8 weeks, this group will recieve 20 minutes of standard occupational therapy treatment consisting of fine and gross motor intervention.
89625714|NCT05825196||HBV-associated HCC group|The patient was finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete.
88815693|NCT02412852|Placebo Comparator|Placebo|One placebo tablet administered twice daily for 12 weeks.
89038948|NCT00553137|Active Comparator|2|150 mg fluconazole once daily for 14 days and placebos (5 placebos tablets) 750 mg once
89038949|NCT04679246|Experimental|General Intervention|The strategies will be implemented in the three intervention elementary schools. The schools were conveniently chosen for the size of the student population. In addition to having a sufficient population, it was important that the authorities of each school site agreed to participate.
89038950|NCT04679246|Experimental|Subsample intervention|A group will be randomly selected from each school grade from the intervention schools, and within each chosen group 12 children will be randomly selected per group (48 children in total per school).
89038951|NCT04679246|No Intervention|Control|Three primary schools were selected from a close locality (Villa Corona, Jalisco). This was chosen because it is similar in relation to the social, economic, and geographical context to the locality of intervention. The schools were selected for the similarity in the size of the student population of the intervention schools.
89038952|NCT04090775|Other|Single arm. Subjects receiving treatment.|Cryosurgical freezing and intratumoral combination immunotherapy as determined by the proportion of patients achieving serum PSA decline from baseline of at least 50%.
89038953|NCT00553176||Patients with Crohn's disease|The Registry is an observational research program featuring clinical, economic, and humanistic measures characterizing the treatment of Crohn's disease
89038954|NCT04166136|Active Comparator|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
89038955|NCT04166136|Active Comparator|Transition from the Rearfoot to the Forefoot and Midfoot|"Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. The participants will receive verbal command Try to touch first with the middle region of the foot on the treadmill. In the last four sessions, feedback will be gradually removed. At the end of each session, participants will be asked a question about the naturalness of running the new foot touch pattern on the ground. A scale from 0 to 10 will be used, where 0 means very difficult to perform and 10 indicates easy pattern. The perception of pain will also be evaluated with the numerical scale of pain of 11 points (0 to 10), where 0 means no pain and 10 the greatest pain possible."
89038956|NCT04166136|Active Comparator|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
89038957|NCT04089839||CP-CML participants initiating dasatinib|
89038958|NCT04045145|Experimental|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
89038959|NCT01232296|Experimental|TKI258|capsule
89038960|NCT01232296|Experimental|Sorafenib|tablet
89038961|NCT04041011|Experimental|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|
89038962|NCT04041011|Experimental|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|
89038963|NCT04041011|Experimental|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|
89038964|NCT02888236|Experimental|LEO 32731 tablet|LEO 32731 30 mg two times daily for 16 weeks
89625715|NCT05825196||negative control group|HBV positive but not HCC
89625716|NCT05825196||Healthy control group|Healthy crowd
89625717|NCT05825157|Active Comparator|VLNT|Standard of care vascularized lymph node transfer
89625718|NCT05825157|Experimental|VLNT with Biobridge|Standard of care vascularized lymph node transfer plus BioBridge placement
89625719|NCT05825144|Experimental|Robotic group|This group receives conventional rehabilitation plus robotic exoskeleton-assisted gait rehabilitation.
89211083|NCT00930306|Experimental|1|12 AZD2066 Capsule, 2 mg & 8 mg 2 Caffeine Tablet, 2 x 50 mg 2 Tolbutamide Tablet, half of 500 mg 2 Omeprazole Tablet, 20 mg 2 Midazolam Tablet, 7.5 mg 2 Metoprolol Tablet, 100 mg 2 Bupropion Tablet, 150 mg
89625720|NCT05825144|Active Comparator|Control group|This group receives conventional rehabilitation alone.
89625721|NCT05825053|Experimental|Booster group|Participants assigned to the booster group will receive a three single training sessions 3 months apart targeting gait adaptability using the C-mill. Assessments will take place after giving informed consent which is indicated as the start of the study (baseline), 6 months and 12 months post-baseline.
89625722|NCT05825053|Experimental|Home-based exercise group|Participants assigned to the home-based exercise group will receive a program for training at home aiming at a minimum training time of 60 minutes per week. Assessments will take place after giving informed consent which is indicated as the start of the study (baseline), 6 months and 12 months post-baseline
89625723|NCT05825053|No Intervention|Control group|Participants assigned to the control group will not follow any additional intervention other than the standard care they already receive for the year following the completion of the 5-week gait adaptability training using the C-Mill from the ATTAINS study. Assessments will take place after giving informed consent which is indicated as the start of the study(baseline), 6 months and 12 months post-baseline.
89625724|NCT05824949|Experimental|Osseodensification (test) group|installation of 40 implants using the osseodensification protocol + measurement of implant stability (ISQ)
89625725|NCT05824949|Active Comparator|Conventional (control) group|installation of 40 implants using the conventional drilling protocol + measurement of implant stability (ISQ)
89625726|NCT05824793|No Intervention|Control Group|Participants had their impacted mandibular third molar (IMTM) extracted according to the standard procedure.
89625727|NCT05824793|Experimental|Experimental Group|20ml of venous blood was collected from each participant in this group into two glass tubes (10ml, A-PRF by Choukroun) and centrifuge to create A-PRF+ using Dou Quattro Choukroun PRF machine with a speed of 1300 rpm in 8 minutes, centrifugal force at the bottom of the tube was RCFmax 208g (RCFmin=113g, RCFav=164g, RCFclot=145g). After the standard extraction procedure, place two A-PRF+ clots in the IMTM socket before suturing.
89625728|NCT05823844|Experimental|Suvorexant administration|"Subjects will receive 20 mg Suvorexant beginning the first in-hospital night (day 0) and continuing for their hospital stay. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant. For blinding purposes, each arm will receive two tablets (two 10 mg tablets or one 10 mg tablet and a placebo). Suvorexant will be administered beginning on the night after surgery and through the hospitalization period (it is estimated that stays will be 1-3 days; subjects will be followed for a maximum of 5 days)."
89625729|NCT05823844|Placebo Comparator|Placebo administration|Subjects will receive a placebo (two tablets) and treatment as usual. The placebo will be administered beginning on the night after surgery and through the hospitalization period (it is estimated that stays will be 1-3 days; subjects will be followed for a maximum of 5 days).
89625730|NCT05823831||Healthcare workers group|Children of healthcare worker mothers were grouped as the Healthcare workers group. Doctors, nurses, and paramedics are considered as healthcare workers.
89625731|NCT05823831||Non-healthcare worker group|Children of mothers from other occupations were grouped as Non-healthcare workers group
89625732|NCT05823662|Experimental|DJ stent group|A 5 Fr double J stent will be inserted and then removed after three weeks.
89625733|NCT05823662|Experimental|Silodosin group|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
89211084|NCT00830882|Experimental|1:levosalbutamol|2 puffs four times a day for 2 weeks
89625734|NCT05823363|Experimental|Exparel and Bupivacaine Group|The participants in this group will receive 10 ml of xxparel and 10 ml of bupivacaine in the vaginal cuff
89625735|NCT05823363|Active Comparator|Bupivacaine Only Group|This group will receive 20ml of bupivicaine in the vaginal cuff
89211085|NCT00830882|Active Comparator|2: racemic salbutamol|2 puffs four times a day for 2 weeks
89211086|NCT00830882|Placebo Comparator|3: Placebo|2 puffs four times a day for 2 weeks
89211087|NCT04044092|Active Comparator|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization, Cervical Spine strengthening exercises
89211088|NCT04044092|Experimental|ELDOA stretching exercise|ELDOA stretching exercise protocol along with Conservative physical therapy
89211089|NCT00823160|Active Comparator|1: Sternotomy|Patients who are randomized to a sternotomy after the finding of blood in the pericardial sac.
89211090|NCT00823160|Active Comparator|2: Subxyphoid window|Patients who receive a subxyphoid window after the finding of blood in the pericardial sac.
89211091|NCT03584724|Experimental|Norflo Oro|The study subject will take the entire content of one packet of Norflo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.
89625736|NCT05821816|Experimental|Experimental Group|Standard rehabilitative treatment for stroke + tDCS
89625737|NCT05821816|Active Comparator|Control Group|Only standard rehabilitative treatment for stroke
89625738|NCT05821608|No Intervention|Control|Participants will not receive a message before a nurse tries to contact them via a phone call.
89625739|NCT05821608|Experimental|Heads Up Message 1|"Participants will receive a message before a nurse tries to contact them via a phone call with the following text:~Hi @{account_firstname}, this is @{input_MEGname} at @{account_product_group}. Just a heads up, I'm calling in the next hour about your health care. Text help or stop. Msg&DataRatesMayApply"
89625740|NCT05821608|Experimental|Heads Up Message 2|"Participants will receive a message before a nurse tries to contact them via a phone call with the following text:~Hi @{account_firstname}, this is @{input_MEGname} at @{account_product_group}. Just a heads up, I'm calling in the next hour about your health care. Text HELP for Help and Text STOP to Stop. (Note: replying STOP will stop all further texts from @{account_product_group}). Msg&DataRatesMayApply"
89625741|NCT05821543|Experimental|Reduxin Forte|Arm 1 (n=120) received metformin+sibutramine p. o., 1 tablet (850 mg + 10 mg) once per day. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days.
89688469|NCT04364425|Active Comparator|high dose steroid|patient received ultrasound-guided 10mg triamcinolone + 4cc xylocaine + 15cc NS
89211092|NCT03584724|Placebo Comparator|Placebo for Norflo Oro|The study subject will take the entire content of one packet of Placebo (each box contains 30 packets) with meal twice per day for one year. The study subject will be evaluated in a total of three visits.
89211093|NCT00823238|Active Comparator|systemic|
89211094|NCT00823238|Active Comparator|inhaled|
89625742|NCT05821543|Active Comparator|Reduxin|Arm 2 (n=120) received sibutramine+ microcrystalline cellulose (MCC) p. o., 1 capsule (10 mg + 158.5 mg) once per day in the morning. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days.
89625743|NCT05821101|Experimental|Mini-Monovision Arm|Bilateral implantation of Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision.
89625744|NCT05820971|Experimental|C-short plus usual practice|After accepting to review an article, peer reviewers will receive the automated, journal specific standard email with general information as per each journal's usual practice (e.g. where to access the manuscript, date when the peer review report is due). In addition, peer-reviewers who received a manuscript which was randomised to C-short will receive an additional email including a short version of the CONSORT checklist together with a short explanation of those items.
89625745|NCT05820971|No Intervention|Usual practice|After accepting to review an article, peer reviewers will receive the automated, journal specific standard email with general information as per each journal's usual practice.
89625746|NCT05820724|Experimental|PSMA PET+mpMRI|PSMA PET+mpMRI guided prostate biopsy
89625747|NCT05820724|Active Comparator|mpMRI only|mpMRI only guided prostate biopsy
89625748|NCT05811949||RRMS patients with de novo DMF treatment|RRMS patients with de novo treatment who start DMF.
89625749|NCT05811949||RRMS patients switching to DMF.|RRMS patients who switch from first-line DMT treatment (interferon, glatiramer acetate, teriflunomide) to treatment with DMF.
89625750|NCT05806684||Prematures with jaundice and ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
89211095|NCT00931788|Experimental|Intensive pharmacist case management|
89211096|NCT00931788|Active Comparator|Usual care|
89625751|NCT05806684||Prematures with ROP without jaundice.|Infants who, despite presenting ROP, did not develop jaundice.
89625752|NCT05805670|Experimental|Children with surgical indication scoliosis follow the Yoga and Mindfulness protocol before surgery|Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to.
89625753|NCT05800639||Children with emergence delirium|"Pediatric patients who develop emergence delirium in the post-anesthetic care unit (PACU).~Emergence delirium will be assessed using the Pediatric Assessment of Emergence Delirium (PAED) scale every 10 min until PACU discharge."
89625754|NCT05800639||Children without emergence delirium|"Pediatric patients who do not develop emergence delirium in the post-anesthetic care unit (PACU).~Emergence delirium will be assessed using the Pediatric Assessment of Emergence Delirium (PAED) scale every 10 min until PACU discharge."
89625755|NCT05797454|Experimental|Untreated patients-combined localization|In untreated non-palpable breast cancer patients, positioning focus use wire and marker clip at 1day before operation
89625756|NCT05797454|Active Comparator|Untreated patients-single localization|In untreated non-palpable breast cancer patients, positioning focus use wire at 1day before operation
89625757|NCT05788757||Enrolled Subjects|Patients recruited from the population undergoing knee arthroplasty as part of standard of care. Patients who meet all the inclusion criteria and none of the exclusion criteria should be presented with an opportunity to undergo the informed consent process.
89625758|NCT05788120||Patients with refractory cardiogenic shock assisted with ECMO VA|
89211097|NCT00926874||1|patients who presented an ischaemic stroke(full stroke or TIA)
89211098|NCT00926874||2|patients who present an acute coronary syndrome (ACS).
89625759|NCT05783635|Experimental|Enhanced Usual Care then Usual Surgical Care|Randomized two times (2 possible randomization groups each time). Responder to Enhanced Usual Care
89625760|NCT05783635|Experimental|Enhanced Usual Care then Post-operative Health Coaching|Randomized two times (2 possible randomization groups each time). Responder to Enhanced Usual Care
89625761|NCT05783635|Experimental|Enhanced Usual Care then On-Track|Randomized two times (2 possible randomization groups each time). Non-responder to Enhanced Usual Care
89625762|NCT05783635|Experimental|Enhanced Usual Care then Combine (Postoperative Health Coaching + On-track)|Randomized two times (2 possible randomization groups each time). Non-responder to Enhanced Usual Care
89625763|NCT05783635|Other|Enhanced Usual Care alone|Only completed first randomization. Study withdrawal prior to re-randomization
89625764|NCT05783635|Experimental|Preoperative Virtual Health Coaching then Usual Surgical Care|Randomized two times (2 possible randomization groups each time). Responder to Preoperative Virtual Health Coaching
89625765|NCT05783635|Experimental|Preoperative Virtual Health Coaching then Postoperative Virtual Health Coaching|Randomized two times (2 possible randomization groups each time). Responder to Preoperative Virtual Health Coaching
89625766|NCT05783635|Experimental|Preoperative Virtual Health Coaching then On-Track|Randomized two times (2 possible randomization groups each time). Non-responder to Preoperative Virtual Health Coaching
89211099|NCT00827684|Active Comparator|Response or stable disease|will receive Temsirolimus
89211100|NCT00827684|Experimental|Progression|Will receive a combination of Temsirolimus and Irinotecan
89211101|NCT00930384||Psoriasis group|All adult patients fulfilling inclusion criteria will be considered as cases in which psoriasis is detected and diagnosed by our principal investigator based on the clinical criteria accepted by American Academy of Dermatology. They will have an abdominal ultrasound performed by a radiologist to assess for the presence of nonalcoholic fatty liver disease. They will be referred to the research clinic to have a blood drawn.
89211102|NCT00930384||Control group|For every case an age, sex and body mass index (BMI range - kg/m2) matched control will be selected from the same dermatologic/radiologic clinic. The controls will be invited to voluntarily participate and informed consent will be obtained for performing ultrasonography and analytical tests to ensure the absence of manifest hepatic disease.
88815694|NCT02412852|Active Comparator|40 mg TV1001sr|One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
89211103|NCT00823316|Experimental|1|at a dose of 1x1,000,000 hMSC/kg
89625767|NCT05783635|Experimental|Preoperative Virtual Health Coaching then Combine (Postoperative Virtual Health Coaching + On-track)|Randomized two times (2 possible randomization groups each time). Non-responder to Preoperative Virtual Health Coaching
89625768|NCT05783635|Other|Preoperative Virtual Health Coaching only|Only completed first randomization. Study withdrawal prior to re-randomization.
89625769|NCT05769075|Experimental|Escalation stage|Escalation stage: Multiple doses of TY-2136b for oral administration to find the maximum tolerated dose
89625770|NCT05769075|Experimental|Expansion stage|Expansion stage: 4 distinct expansion cohorts
89625771|NCT05758428|Experimental|Cohort 1|Subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID).
89625772|NCT05758428|Experimental|Cohort 2|Subjects will receive two single doses of 1.5 mg and 6 mg ensifentrine, separated by at least a 7-day washout period using crossover design.
89625773|NCT05753618|Active Comparator|Receive G-CSF|Receive G-CSF injections (either filgrastim or pegfilgrastim) after each cycle of paclitaxel chemotherapy.
89625774|NCT05753618|Experimental|Omission of G-CSF|Omission of G-CSF injections after each cycle of paclitaxel chemotherapy.
89625775|NCT05752461|Experimental|Treatment group A: SHR-2004 injection|
89625776|NCT05752461|Experimental|Treatment group B: SHR-2004 injection|
89625777|NCT05752461|Experimental|Treatment group C: SHR-2004 injection|
89625778|NCT05752461|Active Comparator|Treatment group D: Enoxaparin sodium injection|
89625779|NCT05750277|Experimental|Early Time-Restricted Eating|This group will self-select their eating window as long as it is between 8am-6pm, and will aim to fast within this window as many occasions as possible between Monday-Friday for 4 weeks.
89625780|NCT05750277|No Intervention|Control|This group will maintain their habitual lifestyle for 4 weeks.
89625781|NCT05724550|Active Comparator|Neostigmine|The use of neostigmine 0.02mg/kg for reversal of neuromuscular blocking agent.
89625782|NCT05724550|Experimental|Sugammadex|The use of sugammadex 2mg/kg for reversal of neuromuscular blocking agent.
89625783|NCT05708274|Experimental|CPH + hand training|A single dose of Cyproheptadine (CPH) (8 mg) will be administered. Supplied as 2 over-encapsulated pills of 4 mg each.
89625784|NCT05708274|Experimental|CD-LD + hand training|A single dose of IR Carbidopa-levodopa (CD-LD) (50/200 mg) will be administered. Supplied as 2 over-encapsulated pills (25 mg carbidopa / 100 mg levodopa each).
89625785|NCT05708274|Experimental|ATX + hand training|A single dose of Atomoxetine (ATX) (40 mg) will be administered. Supplied as 1 over-encapsulated pill of 40 mg plus 1 placebo capsule.
89625786|NCT05708274|Placebo Comparator|Placebo + hand training|A single dose of Placebo will be administered. Supplied as 2 gelatin capsules, identical in number, size, shape and color, filled with microcrystalline cellulose.
89625787|NCT05696106||Patients initiating a biologic or immunosuppressive drug|"Patients initiating a biologic or immunosuppressive drug including small molecules for a first IMID (either IBD, inflammatory rheumatic diseases, or cutaneous psoriasis)~Conventional immunosuppressive drug including immunomodulators (thiopurines) and csDMARDs (methotrexate)~Anti-TNF (infliximab, adalimumab, golimumab, certolizumab, etanercept)~Biologics targeting the IL-12/IL-23 pathways (ustekinumab, risankizumab, guselkumab)~Biologics targeting the IL-6 pathways (tocilizumab, sarilumab)~Biologics targeting the IL-17 pathways (secukinumab, ixékizumab, brodalumab)~Biologics targeting cell adhesion, anti-integrins (vedolizumab)~JAK inhibitors (tofacitinib, baricitinib, upadacitinib)"
89625788|NCT05659329||Non-medicated Simplex HV|Retrospective observation of patients who have received a Triathlon Total Knee Replacement implanted with nonmedicated Simplex HV Bone Cement.
89625789|NCT05659329||Gentamycin Simplex HV|Retrospective observation of patients who have received a Triathlon Total Knee Replacement implanted with Gentamycin Simplex HV Bone Cement.
89625790|NCT05653232|Experimental|Prophylaxis (P2W)|Prophylaxis is one dose of sofosbuvir/velpatasvir (SOF/VEL) pre-HCV D+/R- kidney transplant (KT), continued for 2 weeks.
89625791|NCT05653232|Experimental|Transmit and Treat (T&T)|T&T is study-supplied SOF/VEL for 12 weeks starting on post-HCV D+/R- kidney transplant day participant's insurance approves standard of care DAAs, or post-KT day 14, whichever comes first.
89211104|NCT00823316|Experimental|2|at a dose of 5x1,000,000 hMSC/kg
89625792|NCT05653102||Prospective Subjects|Enrolled in the study pre-surgery. Subjects who agree to participate in the study that have not had surgery prior to being enrolled in the study.
89625793|NCT05653102||Retrospective to Prospective|Subjects enrolled in the study post- surgery then continue to participate in the study prospectively. Subjects who agree to participate in the study that have undergone surgery prior to enrollment in the study. Data for these subjects will collected from the subject's medical record for the time period prior to enrollment in the study containing data pertaining to the index surgery (retrospective data) and from the patient after they are enrolled in the study during the post-operative time period (prospectively).
89625794|NCT05653102||Retrospective Only Subjects|Subjects enrolled in the study post-study surgery with no intent to continue as prospective subjects. Patient's clinical record includes a signed HIPAA waiver allowing for the use of clinical record data for the purpose of clinical research outside of the operating institution.
89625795|NCT05646498|Active Comparator|implant retained removable overdentures|"Procedure: Long implant and partial overdentures insertion of long implants anterior to the maxillary sinus to retain partial overdentures~Device: Partial overdentures Distal extension metallic partial dentures retained by attachments to the implants"
89625796|NCT05646498|Active Comparator|implant supported fixed screw retained prosthesis|"Procedure: Sinus lift and long implant performing sinus lift surgical procedure with simultaneous placement of limplants to support screw-retained prosthesis~Device: Metal ceramic prosthesis on long implants porcelain fused to metal fixed screw-retained prosthesis supported by implants"
89625797|NCT05636033||Alcohol use disorder patients|
89625798|NCT05636033||Healthy controls|
89625799|NCT05612750|Experimental|Empowered Relief|A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.
89625800|NCT05612750|Experimental|Online 8-session Cognitive Behavioral Therapy|A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.
89625801|NCT05600543|Experimental|Arm 1: Lumbar belt Lombastab® (Thuasne, Levallois Perret, France)|Low back pain patients wear Lumbar belt Lombastab® during 4 weeks according to the instructions given by the investigator of the study.
89625802|NCT05580419|Experimental|4PCP Course (for practitioners only)|All enrolled practitioners will be assigned to take the 4PCP course as the intervention. Patients will not be assigned to the course and will only be completing surveys before and after their practitioner completes 4PCP.
89625803|NCT05565833|Experimental|SHUTi OASIS|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) for Older Adult Sufferers of Insomnia and Sleeplessness (OASIS) online intervention optimized for older adults. CBTi will be delivered online and metered out over time with each new core becoming available one week after the completion of the previous core. The intervention period is 9 weeks. They will spend 1-2 hours during the intervention period completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions on how to improve their sleep.
89625804|NCT05565833|Placebo Comparator|Patient Education Website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
89625805|NCT05525403|Experimental|Low Fatigue Exercise|Participants will complete a single leg knee extension exercise with weight until they report a fatigue level = 3/10 on the Borg Rating of Perceived Exertion. Participants will complete three sets.
89625806|NCT05525403|Experimental|High Fatigue Exercise|Participants will complete a single leg knee extension exercise with weight until they report a fatigue level = 8/10 on the Borg Rating of Perceived Exertion. Participants will complete three sets.
89625807|NCT05525403|Active Comparator|Quiet Rest|Participants will rest quietly for two minutes, three sets.
89625808|NCT05496036|Experimental|Pembrolizumab|Study participants will undergo a tumor tissue collection biopsy prior to treatment, followed by one dose of pembrolizumab 400mg, then undergo a curative intent resection of all remaining disease 3 weeks after the initial dose of pembrolizumab. Post-operatively, subjects will receive up to 1 year of pembrolizumab 400mg every 6 weeks.
89625809|NCT05493176|Experimental|Dry immersion|5 days of dry-immersion
89625810|NCT05488496|Experimental|Intervention arm|"The intervention arm will undergo the following steps:~Groups of 5-15 persons living in the same area. Two trained facilitators support the group dynamics fostering empowerment.~Each participant undergoes a one-to one personalized interview with the facilitator(s) to build the relationship and know participants' expectations and characteristics.~9 sessions of group-based activities to promote peer support and accessibility and engagement with nature-based activities available in their area according to participant's preferences. A collaborative mapping of nature-based community assets will guide the group to the activities they want to approach and test."
89625811|NCT05488496|Active Comparator|Control arm|The control arm will receive individually usual care (e.g. the existing social prescription as available) and a list of community resources based in nature in the area. Usual care is the appropriate comparison rather than a placebo for complex interventions.
89625812|NCT05393999|Experimental|BMS-986414 and BMS-986413|"Broadly neutralising antibody:BMS-986414 This long-acting antibody will be prescribed to all participants and given as one subcutaneous injection of 200 mg.~Broadly neutralising antibody: BMS-986413 This long-acting antibody will be prescribed to all participants and given as one subcutaneous injection of 200 mg"
89625813|NCT05364918|Experimental|Jeksung|
89038965|NCT02888236|Placebo Comparator|LEO 32731 Placebo tablet|LEO 32731 placebo two times daily for 16 weeks
89038966|NCT04136379||Clinic monitoring|Patients who attend a warfarin clinic for management of their INR
89625814|NCT05364918|No Intervention|Control|
89625815|NCT05363215|Experimental|S-217622: Group A|Participants with mild renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
89625816|NCT05363215|Experimental|S-217622: Group B|Participants with moderate renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
89625817|NCT05363215|Experimental|S-217622: Group C|Participants with severe renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
89625818|NCT05363215|Experimental|S-217622: Group D|Participants with normal renal function will receive a single dose of S-217622 on Day 1, in a fasted state.
89625819|NCT05359380||SG1 - Trifocal Group|Patients implanted bilaterally with trifocal diffractive IOLs
89625820|NCT05359380||SG2 - Bifocal Group|Patients implanted bilaterally with bifocal hybrid (diffractive - refractive) IOLs
89625821|NCT05359380||SG3 - Monofocal Group|Patients implanted bilaterally with monofocal IOLs
89625822|NCT05336747|Experimental|Voice Lessons|Voice Lessons
89038967|NCT04136379||Home monitoring|Patients who undertake home monitoring of their INR using a CoaguChek POC device
89038968|NCT04320862||Duke Health region and beyond|Individuals in the Duke Health region as well as individuals beyond the Duke Health region who have flu-like symptoms, a viral test order for COVID-19, confirmed COVID-19, or concern for exposure to COVID-19.
89038969|NCT04035551||patients receiving home parenteral nutrition|Includes patients receiving home parenteral nutrition for any indication.
89038970|NCT01231984|Experimental|4 mm vs. 8 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 8mm x 31G Pen Needle for 12 weeks (Period 1), then switched to the alternate pen needle (PN) for another 12 weeks (Period 2). Order of PN use was randomly determined.
89038971|NCT01231984|Experimental|4 mm vs. 12.7 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 12.7mm x 29G Pen Needle (PN) for 12 weeks (Period 1), then switched to the alternate PN for another 12 weeks (Period 2). Order of PN use was randomly determined.
89038972|NCT04684095|No Intervention|routine follow-up group|only according to the routine follow-up frequency to the center visit.
89038973|NCT04684095|Experimental|ePRO group|ePRO group : self-evaluation in ePRO mode was accepted, and the patients were visited in the center according to the routine follow-up frequency.
89038974|NCT01210807|Experimental|Multifocal Intraocular Lens|ZMB00 multifocal intraocular lens
89038975|NCT01210807|Active Comparator|Monofocal Intraocular Lens|ZCB00 monofocal intraocular lens
89038976|NCT00552942|Experimental|1|surgery plus omentectomy
89038977|NCT00552942|No Intervention|2|standard gastric bypass
89038978|NCT03969095|Experimental|Immediate|Participants in the immediate intervention arm will begin a 4-week intervention tongue pressure resistance training protocol within 10 days of their baseline Videofluoroscopic Swallowing Evaluation assessment, with 2 face-to-face 1-hour visits per week under direct supervision of a speech-language pathologist. These treatment sessions will be supplemented by daily home practice of the intervention.
89038979|NCT03969095|Active Comparator|Delayed|Participants in the delayed intervention arm will begin their involvement with a 4-week waiting period after the baseline Videofluoroscopic Swallowing Evaluation. Treatment will commence after the second Videofluoroscopic Swallowing Evaluation and will follow the same schedule for the tongue pressure resistance training, supplemented by daily home practice.
89038980|NCT00554138|Placebo Comparator|1|
89625823|NCT05320068|Experimental|Intervention group|A group of patients will be treated with a blinded capsule that contains 125mg of vancomycin every 6 hours for 10 days.
89625824|NCT05320068|Placebo Comparator|Placebo group|A group of patients will be treated with a blinded capsule that contains a placebo every 6 hours for 10 days.
89625825|NCT05296551|Experimental|Dual Task One|Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is simple.
89625826|NCT05296551|Experimental|Dual Task Two|Participants perform a cognitive-motor dual-task where the motor task is the same for all groups and the simultaneously performed cognitive task is complex.
89625827|NCT05296551|Active Comparator|Control|Participants perform only a motor-task that is the same for all groups (no simultaneous cognitive task).
89625828|NCT05291377||high disbility group|Group scored more than half of the score of the neck disability index
89625829|NCT05291377||low disability group|Group scored less than half of the score of the neck disability index
89625830|NCT05286359|Experimental|NxTekTM Malaria Plus Rapid Diagnostic Test (RDT) Devices|
89625831|NCT05284565|Other|Results of reading|All patients who were prick tested and accepted to participate in the study, were prospectively included in the study in only one arm. All of their tests were read by the device and the manual procedure.
89625832|NCT05225168|Active Comparator|laparoscopic burch colposuspension group|this group will only have laparoscopic burch colposuspension
89625833|NCT05225168|Active Comparator|Minisling Suburethral Sling group|this group will only have Minisling Suburethral Sling
89625834|NCT01456377|Active Comparator|corticosteroids, analgesics oral pill|Oral Corticosteroids and oral analgesics
89038981|NCT00554138|Experimental|2|
89038982|NCT03923387|Experimental|MynxGrip|MynxGrip, a vascular closure device indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
89038983|NCT03923387|Active Comparator|Manual compression|Manual compression hemostasis
89038984|NCT01231555|Experimental|GSK2248761 100 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
89625835|NCT01456377|Placebo Comparator|placebo|oral placebo and oral analgesics
89625836|NCT05214950|Experimental|ORI monitoring|SpO2, ECG, NIBP, and oxygen reserve index monitoring
89625837|NCT05214950|No Intervention|Standard monitoring|SpO2, ECG, NIBP monitoring
89625838|NCT05204160|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89625839|NCT05169151||Observational (physical activity tracking)|Patients utilize smartphone application to monitor physical activity and mobility up to 180 days during treatment or post-treatment.
89625840|NCT05161637|Experimental|TLC590 490mg|TLC590 490mg (20mL)
89625841|NCT05161637|Experimental|TLC590 588mg|TLC590 588mg (24mL)
89038985|NCT01231555|Experimental|GSK2248761 200 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
89038986|NCT01231555|Active Comparator|Efavirenz 600 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
89625842|NCT05161637|Active Comparator|Bupivacaine 75mg|Bupivacaine HCl 75mg (30mL)
89625843|NCT05161637|Active Comparator|Ropivacaine|Ropivacaine HCl 150mg (30mL) (Part 1)
89625844|NCT05161637|Placebo Comparator|Normal saline|Normal Saline 0.9% (20mL or 24mL)
89038987|NCT05288907||Pruritus ani patients|Adult patients with pruritus ani (rectal itch) treated with lidocaine ointment
89038988|NCT01210690||Patients, 1 - 11 months old, prescribed Keppra® oral solution|Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol.
89038989|NCT04683861|Experimental|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
89038990|NCT01210651|Experimental|Hatha Yoga Practice Group|Participants in this group practiced 90-minute sessions of hatha yoga exercises twice weekly for a total of 8 weeks.
89625845|NCT05148559|Experimental|Enhanced Reminder|
89625846|NCT05148559|Other|Standard of Care|
89625847|NCT05147116|Experimental|Hypoxia - 15% O2|Participants will sleep in a tent for 10 nights.
89625848|NCT05147116|Sham Comparator|Sham - room air 21% 02|Participants will sleep in a tent for 10 nights.
89625849|NCT05138666|Experimental|biological sample|respiratory and blood sample
89625850|NCT05103722|Experimental|Supportive Care|Patients with metastatic renal cell carcinoma (RCC) who are receiving immune-checkpoint inhibitor therapy
89625851|NCT05102773||Ancillary-correlative (questionnaire, sample collection, CT)|Patients complete a FFQ at baseline, undergo collection of stool samples at baseline, within 2 days of starting corticosteroid treatment (if applicable), when asked for a control sample, and at 12 weeks, and undergo collection of blood samples and CT at baseline and 12 weeks.
89625852|NCT04981782||healthy subjects|"No intervention~Infants will be measured at different time points. At the age of 3,4,6 and 9 months."
89038991|NCT01210651|Active Comparator|Attention Control Education Group|Participants in this group attended 90-minute educational seminars on yoga history twice weekly for a total of 8 weeks.
89038992|NCT03911336|Experimental|Group A - test|Group A (Test) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
89625853|NCT04981782||torticollis group|"No intervention~Infants will be measured at their visit to a Chiropractor. Before and after treatment."
89625854|NCT04967885|Experimental|Immediate Intervention|Participants in the Immediate Intervention condition will create their Implementation Intention (II) messages before the two-week EMA + EMI-II period begins. During the EMA + EMI-II period, participants will complete five daily EMAs, and they will also complete weekly assessments reporting their past week cigarette smoking as a distal outcome and rating intervention acceptability. Following the EMA + EMI-II period, participants will enter a two-week follow-up period. During this time, participants will not receive any messages, but will report past week smoking on a weekly basis.
89625855|NCT04967885|Active Comparator|Waitlist|Participants randomized to the Waitlist control condition will begin with a two-week no intervention condition during which they will report past week smoking on a weekly basis but will not receive any other intervention components. At the end of the two-week waitlist control period, participants will begin the two-week EMA plus EMI-II period. During the EMA plus EMI-II active study period, participants will complete five daily EMAs and weekly assessments to report their past week cigarette smoking and rate intervention acceptability. No follow-up is planned for the wait list control condition.
89625856|NCT04967599|No Intervention|Control (CONTROL)|Participants do not receive PHEN or GENE.
89625857|NCT04967599|Experimental|Phenotype Feedback (PHEN)|Participants receive the PHEN intervention.
89625858|NCT04967599|Experimental|Phenotype and Genotype Feedback (PHEN+GENE)|Participants receive the PHEN and GENE interventions.
89625859|NCT04947410|Active Comparator|OSAS Patients treated with CPAP|"Patients with OSAS will have 1 in 2 chance of being randomized into CPAP group"
89625860|NCT04947410|Sham Comparator|OSAS Patients treated with nasal dilators|"Patients with OSAS will have 1 in 2 chance of being randomized into nasal dilators group"
89625861|NCT04947410|No Intervention|Non OSAS Patients|Non OSAS Patients will be the parallel control group
89625862|NCT04932148|Experimental|Incremental HD|Participants randomised to incremental HD will commence HD twice weekly and continue until an indication for an increase to three sessions/week (trigger point) is reached.
89625863|NCT04932148|Other|Conventional HD|Participants randomised to conventional HD will commence HD thrice weekly from the first HD session.
89625864|NCT04903353|Active Comparator|Treatment with Risperidone|Patients prescribed Risperidone
89625865|NCT04903353|Active Comparator|Treatment with Aripiprazole|Patients prescribed Aripiprazole
89038993|NCT03911336|Active Comparator|Group B - Control 1|Group B (Control 1) - Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3- day period, starting the regime at 2 PM on the day of the extraction.
89038994|NCT03911336|Active Comparator|Group C - Control 2|Group C (Control 2) - Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
89038995|NCT04683822|Experimental|Exercise group|Patients who receive telerehabilitaton
89038996|NCT04683822|No Intervention|Control|Patients with routine care
89038997|NCT04684056||Riva-control group|Routine concentration of Rivaroxaban (Peak)
89038998|NCT04684056||Riva-High group|High concentration of Rivaroxaban (Peak)
89625866|NCT04902508|Experimental|Explicit Master Plus No Additional Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives no additional treatment."
89625867|NCT04902508|Experimental|Explicit Master Plus Explicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 additional sessions of explicit treatment."
89625868|NCT04902508|Experimental|Explicit Master Plus Implicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 sessions of implicit treatment."
89625869|NCT04902508|Experimental|Explicit Non-Master Plus Explicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 additional sessions of explicit treatment."
89625870|NCT04902508|Experimental|Explicit Non-Master Plus Implicit Treatment|"Receives 32 sessions of explicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 sessions of implicit treatment."
89625871|NCT04902508|Experimental|Implicit Master Plus No Additional Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives no additional treatment."
89625872|NCT04902508|Experimental|Implicit Master Plus Implicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 additional sessions of implicit treatment."
89625873|NCT04902508|Experimental|Implicit Master Plus Explicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Mastery and receives 32 sessions of explicit treatment."
89625874|NCT04902508|Experimental|Implicit Non-Master Plus Implicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 additional sessions of implicit treatment."
89625875|NCT04902508|Experimental|Implicit Non-Master Plus Explicit Treatment|"Receives 32 sessions of implicit treatment then assessed. When assessed, demonstrates Non-Mastery and receives 32 sessions of explicit treatment."
89625876|NCT04889417|Experimental|Intervention|Computerized brain game training and online interactive physical exercise training
89625877|NCT04889417|Active Comparator|Control|Control computer games and online interactive stretching exercises.
89625878|NCT04850807|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting
89038999|NCT04684056||Riva-Low group|low concentration of Rivaroxaban (Peak)
89625879|NCT04850807|Experimental|Music & Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences at early signs of agitation
89625880|NCT04848883|Experimental|Advanced AMS program|Three randomily assigned primary care centres in which an infectious diseases expert will be continuously in touch with primary care practitioners.
89625881|NCT04848883|Active Comparator|Standard AMS program|Three primary care centres in which a typical AMS will be promoted.
89625882|NCT04831047|Experimental|Upneeq Group|Participants in this group will receive a one-time dosing of oxymetazoline hydrochloride 0.1% (1 drop applied to ocular surface of each eye of patients in the treatment group)
89625883|NCT04831047|Sham Comparator|Control Group|Participants in this group will receive a one-time dosing of balanced saline solution (1 drop applied to ocular surface of each eye of patients in the control group)
89625884|NCT04775680|Experimental|ADG106 combined with PD-1 antibody Dose Escalation Level 1|
89625885|NCT04775680|Experimental|ADG106 combined with anti PD-1 antibody Dose Escalation Level 2|
89625886|NCT04775680|Experimental|ADG106 combined with anti PD-1 antibody Expansion Phase|
89625887|NCT04743154|Other|In-hospital complete revascularization group.|Patients will undergo to a complete revascularization of non-culprit lesions at least 24 hours after STEMI and before hospital discharge.
89625888|NCT04743154|Other|After-discharge complete revascularization group.|Patients will undergo to a complete revascularization of non-culprit lesions after hospital discharge within 4-6 weeks after STEMI.
89625889|NCT04736576|Other|Group 1|Palbociclib plus endocrine therapy
89625890|NCT04736576|Other|Group 2|Endocrine monotherapy
89625891|NCT04733950|Experimental|Patients with cochlear implant|Patients with cochlear implant for 6 months and more
89625892|NCT04733950|Active Comparator|Healthy volunteers (normal hearing)|Healthy volunteers with a normal tonal audiometry for age
89625893|NCT04725565|Experimental|Genetics ADviSER Decision Aid Plus Standard Genetic Counselling|Participants in the intervention arm will use the Genetics ADviSER to learn about genomic sequencing and to select which results they would like to receive from genomics sequencing results. After using the Genetics ADviSER decision aid they will speak with genetic counselor to discuss their choices and to finalized their selection.
89625894|NCT04725565|Active Comparator|Standard Genetic Counselling Only|Participants will speak with a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
89625895|NCT04719936|Experimental|inferior capsulotomy group|inferior capsulotomy will be conducted during posterior approach.
89625896|NCT04719936|Active Comparator|superior capsulotomy group|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
89039000|NCT04684056||Dabi-control group|Routine concentration of Dabigatran(Peak)
89039001|NCT04684056||Dabi-High group|High concentration of Dabigatran(Peak)
89039002|NCT04684056||Dabi-low group|low concentration of Dabigatran(Peak)
89039003|NCT04684056||Edo-control group|Routine concentration of Edoxaban(Peak)
89039004|NCT04684056||Edo-high group|High concentration of Edoxaban(Peak)
89039005|NCT04684056||Edo-low group|low concentration of Edoxaban(Peak)
89039006|NCT04684134||experimental group|patients with colorectal polyps
89039007|NCT04684134||control group|patients without intestinal diseases
89039008|NCT03850535|Experimental|Dose-Escalation Phase|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to European LeukemiaNet [ELN] 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
89625897|NCT04715087|Other|Atopic dermatitis patients|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be re-applied (via patchtest) to AD patient. After reading the patch test results, skin biopsies will be performed
89625898|NCT04715087|Other|Healthy controls|Bacteriological skin swab samples from AD patients will be performed at screening visit. Each sample will be cultured and isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. After reading the patch test results, skin biopsies will be performed.
89625899|NCT04704973|Experimental|Transdiagnostic short-term psychotherapy|
89625900|NCT04700514|No Intervention|Control group|"Children diagnosed with retinoblastoma and received exam under anesthesia (EUA) before the age of 30 months, and is not yet 4 years old~Children who are undergoing exams and treatment such as EUA, chemoport insertion, or intra-arterial chemotherapy under general anesthesia~Sevoflurane is used only for anesthesia"
89625901|NCT04700514|Experimental|Dexmedetomidine group|"Children who are diagnosed with retinoblastoma and are scheduled for the first EUA before their age of 30 months.~No history of anesthesia"
89625902|NCT04669145|Experimental|Continuous Regional Anesthesia Lower Limb Surgery|Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks A catheter will be placed for the given block for 48 hours. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
89688470|NCT01723943|Active Comparator|Arm I (educational booklet)|"Participants receive the What's Happening to the Woman I Love? booklet, which focuses on ways to understand and deal with marital communication and relationship issues arising from breast cancer diagnosis."
89625903|NCT04669145|Experimental|Single Shot Regional Anesthesia Lower Limb Surgery|"Various types of regional anesthesia blocks will be performed based on the patient's injuries including fascia iliaca plane blocks, femoral nerve blocks, adductor canal blocks, popliteal approach sciatic nerve blocks, and saphenous nerve blocks. These blocks will be given via a single dose or single shot. Those patients undergoing lower limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia."
89625904|NCT04669145|Experimental|Continuous Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
89625905|NCT04669145|Experimental|Single Shot Regional Anesthesia Upper Limb Surgery|Various types of regional anesthesia blocks involving the brachial plexus will be performed based on the patient's injuries. A catheter will be placed for the given block for 48 hours. Those patients undergoing upper limb orthopaedic surgery will be randomized into single shot or continuous (catheter) regional anesthesia.
89625906|NCT04667364|No Intervention|Group MED|A group of participants that receives treatment as usual that consists of medicinal treatment, prescribed by a specialist doctor (Carsten Kock-Jensen, MD) from the CRPS clinic and will be monitored using patients' medicinal records.
89625907|NCT04667364|Experimental|Group TENS|A group of participants that receives transcutaneous electrical nerve stimulation (TENS) which is an inexpensive, noninvasive and safe treatment for pain.
89625908|NCT04652050||lung transplants|Lung transplants on Tolsura for infection
89625909|NCT04651634|Experimental|20 mg|MIT-001 20 mg
89039009|NCT03850535|Experimental|Post-Consolidation Phase|Participants who are idasanutlin treatment-naive, had received induction and chemotherapy consolidation for AML outside of the study, and were in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin.
89039010|NCT03850535|Experimental|Expansion Phase: Favorable/Intermediate-Risk AML|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to ELN 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
89039011|NCT03850535|Experimental|Expansion Phase: High-Risk AML|Participants with newly diagnosed, previously untreated, high-risk AML (defined as adverse risk according to ELN 2017 criteria, and secondary AML) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
89039012|NCT05285436|Experimental|CloudCath detection|Active monitoring of dialysate effluent by the CloudCath System.
89039013|NCT05263089|Experimental|Intervention|Injectable Universal flowable resin composite
89039014|NCT05263089|Active Comparator|Control|Conventional resin composite
89039015|NCT04114929|Experimental|Threshold-Based|Patients will be prescribed exercise based on ventilatory thresholds from a maximal cardiopulmonary exercise test
89039016|NCT04114929|Active Comparator|Standard Care|Patients will be prescribed exercise based on standard guidelines
89039017|NCT03792932|Active Comparator|Laparoscopic distal pancreatectomy|
89039018|NCT03792932|Active Comparator|Open distal pancreatectomy|
89625910|NCT04651634|Experimental|40 mg|MIT-001 40 mg
89625911|NCT04651634|Experimental|60 mg|MIT-001 60 mg
89625912|NCT04651634|Placebo Comparator|Placebo|Matching placebo
89039019|NCT05255367|Experimental|Intake of (poly)phenol rich foods|Daily consumption of 100 ml of a commercial juice of berries and pomegranate, 20 g dark chocolate and 1 green tea, to test if the supplementation of the diet with (poly)phenol rich foods, during 2 months, reduce the cardiometabolic risk in post-post-menopausal women.
89039020|NCT03753620|Experimental|Music listening|The participants listens to their favorite emotional musical extracts. While listening, their Hemodynamic activity (with fMRI), their cerebral electric activity (with EEG) and their peripheral physiological parameters are recorded simultaneously
89039021|NCT04095156||Prospective cohort|Patients with biopsy-proven idiopathic MN, who are candidate to receive a B-cell depleting treatment as per center clinical practice.
89039022|NCT04095156||Retrospective cohort|Patients with biopsy-proven idiopathic MN, who already received a B-cell depleting treatment as per center clinical practice.
89039023|NCT04095156||Healthy volunteers cohort|Subjects > 18 years not known to suffer of any significant illness, not assuming any medication or drug on a regular basis.
89039024|NCT03750266||Congenital Diaphragmatic Hernia referred for fetal MRA|
89039025|NCT04679129|Experimental|Single Ascending Dose-ASC42|ASC42 tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
89039026|NCT04679129|Experimental|Multiple Ascending Dose-ASC42|ASC42 tablet, Dose 1，Dose 2，Dose 3，q.d.×14 days
89039027|NCT04679129|Placebo Comparator|Single Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，Dose 4，and Dose 5, single dose administration
89625913|NCT04650074|Active Comparator|LIDOCAINE 20 mg|4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).
89625914|NCT04650074|Experimental|LIDOCAINE 20 mg + KETAMINE 20 mg|4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).
89625915|NCT04650074|Experimental|LIDOCAINE 20 mg + KETAMINE 40 mg|4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).
89625916|NCT04631445|Experimental|Ketogenic (KD) + Triplet|Ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
89625917|NCT04631445|No Intervention|Non-ketogenic + Triplet|Non-ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.
89625918|NCT04620304|Experimental|Cohort A|receive 4 weekly fixed doses of UB-421 SC at 250 mg
89625919|NCT04620304|Experimental|Cohort B|receive 4 weekly fixed doses of UB-421 SC at 500 mg
89625920|NCT04620304|Experimental|Cohort C|receive 4 weekly fixed doses of UB-421 SC at 700 mg
89625921|NCT04606173|Experimental|Standard Practice plus TEACH|Primary care teamlets will receive standard organizational education and support regarding suicide prevention and also engage in Team Education for Adopting Changes in Healthcare (TEACH) huddles.
89625922|NCT04606173|No Intervention|Standard Practice|Standard Practice condition will involve the current evidence-based support included in web-based provider-trainings and electronic medical record reminders/templates that are standard within an organization
89625923|NCT04601571|Active Comparator|Feeding Tube Placement using CORTRAK stylet|Subjects will already have a feeding tube placed and are undergoing X-rays for placement confirmation.
89625924|NCT04601571|No Intervention|Feeding Tube Placement using X-Ray|Routine X-ray is used to confirm feeding tube placement
89625925|NCT04589598|Experimental|FNS|those who are treated with femoral neck system (FNS)
89625926|NCT04589598|Active Comparator|MCS|those who are treated with multiple cannulated screw (MCS)
89625927|NCT04578886|Placebo Comparator|Placebo|Placebo, lactulose monohydrate, encapsulated, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
89625928|NCT04578886|Experimental|Guanfacine|Guanfacine immediate-release, 2mg dose, over-encapsulated tablet, once nightly at 2100, for up to 14 day study duration or otherwise indicated by study protocol.
89625929|NCT04571060|Experimental|Zavegepant|Participants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar Unidose System (UDS) liquid spray device.
89625930|NCT04571060|Placebo Comparator|Placebo|Participants administered a single intranasal dose of zavegepant matching placebo on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar UDS liquid spray device.
89625931|NCT04567251||Noona® mobile healthcare application|All patients will be instructed to report pre-defined, non-life-threatening cognitive symptoms as often as relevant through the Noona® application for 17 weeks.
89625932|NCT04548713|Experimental|4% EDTA CVC Lock|Patients in this group will be given 4% EDTA as their CVC locking solution.
89625933|NCT04548713|Active Comparator|Standard of Care Saline CVC Lock|Patients in this group will be given standard of care saline as their CVC locking solution.
89625934|NCT04545515|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
89625935|NCT04512066|Experimental|150 mg Once Daily (QD) RO6889450|Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
89625936|NCT04512066|Experimental|45 mg QD RO6889450|Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
89625937|NCT04512066|Placebo Comparator|Placebo|Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks or additional 44 weeks (optional 36-Week Safety Extension Phase).
89625938|NCT04512066|Active Comparator|4 mg QD Risperidone|Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks or 48 weeks.
89625939|NCT04506892|Experimental|Adept Meditators|Subjects will undergo scanning during awake, sleep deprived, and meditative states of consciousness.
89625940|NCT04448847|Placebo Comparator|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
89625941|NCT04448847|Experimental|Bif195 arm|Active trial product with minimum 100 billion CFU daily dose
89625942|NCT04426318|Experimental|Healthy Minds Program Foundations Training|"Healthy Minds Program (HMP) Description:~The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Richard Davidson, PhD. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has >100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose."
89625943|NCT04426318|No Intervention|Wait-list control|Participants assigned to the wait-list control will not receive treatment for the intervention and follow-up period. They will be provided access to the HMP Foundations training after completing follow-up testing.
89625944|NCT04421092|Experimental|Steroid-Lidocaine Mixture|Will receive numbing injection, which is a mixture of steroid and lidocaine
89625945|NCT04421092|Placebo Comparator|Placebo|Will receive saline injection as a placebo
89625946|NCT04406727|Experimental|UB-421|"2-arm Comparison Phase: UB-421(25 mg/kg, every 2 weeks) in combination with ARV~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
89625947|NCT04406727|Active Comparator|Placebo|"2-arm Comparison Phase: Placebo in combination with ARV~Single-arm Maintenance Phase: UB-421 plus optimized background regimen (OBR)."
89625948|NCT04401891|No Intervention|Routine Pre-Operative Education in MD office prior to surgery|
89625949|NCT04401891|Experimental|Formal Pre-operative education/therapy prior to surgery|
89625950|NCT04397614|Experimental|No Elevated Risk for COVID-19 Detected|Continue daily mHealth assessments
89625951|NCT04397614|Experimental|Elevated Risk for COVID-19 Detected|Daily mHealth assessments and telemedicine/nurse triage. If non-emergent intervention, enhanced symptom monitoring will occur.
89625952|NCT04385732|Experimental|Standard of Care plus Melanoma Surveillance Photography|Clinical surveillance standard of care with addition of 2D or 3D Melanoma Surveillance Photography and digital dermoscopy.
89625953|NCT04385732|No Intervention|Standard of Care|Clinical surveillance standard of care without Melanoma Surveillance Photography.
88815695|NCT02412852|Placebo Comparator|Placebo (2)|Two placebo tablets administered twice daily for 12 weeks.
89625954|NCT04364945|Placebo Comparator|Control group|General anesthesia is maintained using sevoflurane only. Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
89625955|NCT04364945|Experimental|Dexmedetomidine-remifentanil(DEX-R) group|General anesthesia is maintained using sevoflurane, dexmedetomidine (1 mcg/kg/hr) and remifentanil (0.1-0.2 mcg/kg/min). Sevoflurane concentration is adjusted to maintain bispectral index value between 40 and 60.
89625956|NCT04356963|Experimental|All patients|All patients were intended to engage in three different 20-30 min sessions run by research coordinators and spaced a minimum of 4 hours apart to allow for washout of effects, including 1) a commercially available, immersive VR environment, theBlu (WEVR, Inc, Venice, California, USA) delivered via Oculus Rift (Oculus VR, Irvine, California, USA) headset (VR Blu), 2) a non-immersive two-dimensional mimic delivered via a tablet computer (Tablet Blu), and 3) a VR control session delivered via a content-less Oculus Rift headset (VR Blank). The three sessions were run by research coordinators and spaced a minimum of 4 hours apart. The intervention order was counterbalanced using a randomized sequence generator.
89625957|NCT04326179||Age 0 to 4 at day of visit|This study is based on chart reviews of data collected as part of clinical care. Data collected as part of this study will not directly inform the care of participating patients and families.
89625958|NCT04319731|Experimental|Treatment|"Treatment groups:~1. Acute care and ICU - 10mL intravenous amniotic fluid every 24 hours for 5 days (6mL)"
89625959|NCT04263948|Experimental|Picado Arm|All the patients undergo multidimensional tele monitoring for 7 weeks using an upgraded version of the Picado internet platform
89625960|NCT04235608|Experimental|inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane, as vaporized via the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
89625961|NCT04235608|Active Comparator|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs
89625962|NCT04233554|Experimental|Intervention Arm - Implementing Patient Priorities Care|Practice staff and providers will be trained on how to identify patient health priorities. Staff and clinicians will implement Patient Priorities Care, document priorities in EHRs, and align patient priorities with health care decisions.
89625963|NCT04233554|No Intervention|Control Arm|Control arm practices will receive no intervention and patients will receive usual care.
89625964|NCT04231097|Experimental|Virtual MBCT|Two cohorts of MBCT participants with approximately 10 participants per cohort.
89625965|NCT04180020|Active Comparator|TAU|Treatment as Usual (TAU).
89625966|NCT04180020|Experimental|ID/LAB|Infectious Disease management of OUD with Long-Acting injectable buprenorphine (ID/LAB).
89625967|NCT04161027|Experimental|Pregabalin|
89625968|NCT04161027|Placebo Comparator|Placebo|
89625969|NCT04144842|Experimental|ATOR-1017|ATOR-1017 administered by intravenous infusions every 3 weeks until confirmed progressive disease, clear clinical deterioration, unacceptable toxicity or withdrawal of consent
89625970|NCT04043104|Experimental|1 x 10^11 vg/gland (single gland)|
89039028|NCT04679129|Placebo Comparator|Multiple Ascending Dose-Placebo|Placebo tablet，Dose 1，Dose 2，Dose 3，q.d.×14 days
89039029|NCT05236452|Experimental|Integrating of the traditional TB care with modern care through screening, and referral linkage|Integrating traditional care with modern care is a collaboration of two systems through referral linkage. A referral linkage model will be used to detect TB cases in both traditional and modern care services. Health care providers, traditional care providers will participate in the integration process.
89039030|NCT05236452|Active Comparator|Patients proceed with the usual care/ control group|The control group will be followed the existing passive case-findings system (self-referral patients to nearby health facilities that use the same national guidelines to treat TB). The usual care will be carried out using nationally standardized guidelines. The findings obtained from the control groups will be compared with the intervention groups. Finally, changes among the two groups will be assessed and concluded.
89039031|NCT04678934||Bicuspid aortic valve subgroup|For analysis in Bicuspid aortic valve population.
89039032|NCT04679090|Experimental|Participant|Participants will answer a series of questionnaires, wear a physical activity tracker (pedometer) and do functional tests (six minute walk test, chair stand test, balance, back scratch, sit and reach, leg strength and hand strength) pre and post.
89039033|NCT05228535|No Intervention|Control|Continue current NICU feeding protocol, introducing human milk fortifier at 8 days
89039034|NCT05228535|Experimental|Intervention|Introducing human milk fortifier at 1 day
89625971|NCT04043104|Experimental|3 x 10^10 vg/gland (both glands)|
89625972|NCT04043104|Experimental|3 x 10^11 vg/gland (single gland)|
89625973|NCT04043104|Experimental|1 x 10^11 vg/gland (both glands)|
89625974|NCT04043104|Experimental|1 x 10^12 vg/gland (single gland)|
89625975|NCT04043104|Experimental|3 x 10^11 vg/gland (both glands)|
89039035|NCT03689660|Experimental|Virtual Reality Training|Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
89625976|NCT04043104|Experimental|3 x 10^12 vg/gland (single gland)|
89625977|NCT04043104|Experimental|1 x 10^12 vg/gland (both glands)|
89625978|NCT04031170|Experimental|Intervention|Parents assigned to the intervention arm will receive the Incredible Years® School Age Basic & Advanced Parent Training Program. It consists of twelve (12) 2-hour classes led by Dean Coffey, a senior psychologist and certified peer coach in the Incredible Years Parent Training Series.
89625979|NCT04031170|Other|Control|Parents assigned to the control arm will be emailed and mailed written parent education materials from the American Academy of Pediatrics called the Bright Futures handouts. The control group is offered the Incredible Years® School Age Basic & Advanced Parent Training Program after a 3-month wait list period.
88815696|NCT02412852|Active Comparator|80 mg TV1001sr|Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
89039036|NCT03689660|Experimental|Biofeedback Training|Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
89039037|NCT03689660|Other|Conventional Rehabilitation|Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.
89039038|NCT05209893|Experimental|Telerehabilitation (TR)|The TR group will be followed up through the application within the 8-week home exercise program.
89039039|NCT05209893|Active Comparator|Paper Based Rehabilitation (PBR)|The PBR group will be followed up through the paper instruction within the 8-week home exercise program.
89039040|NCT04000503|Experimental|Community Health Worker Self-Collection|Door-to-door recruitment of women for self-collected HPV testing
89039041|NCT04000503|Experimental|Community Health Meeting Self-Collection|Community health meeting recruitment of women for self-collected HPV testing
89625980|NCT04019964|Experimental|Nivolumab in biochemically recurrent prostate cancer|"Participants with previous prostatectomy or radiation therapy who subsequently developed detectable prostate specific antigen (PSA) levels (biochemically recurrent prostate cancer)."
89625981|NCT04007432|Experimental|Older patients with hip fracture|Older patients admitted for hip fracture surgery
89625982|NCT03996291|Experimental|SAR442168|"SAR442168 : Experimental - Part A: Double-blind period of continued treatment with the respective SAR442168 dose administered in the DRI15928 study until selection of Phase 3 dose.~Part B: Open-label period of a single-group treatment with SAR442168 selected Phase 3 dose of 60 mg. All participants will be switched to this 60 mg dose."
89625983|NCT03949881|Experimental|FEMJA transplatation|"FEMJA epithelium is obtained by culturing oral mucosal epithelial cells without any need of support substrates, or carriers, and the transparent fabricated sheets show strong, rapid adhesion on corneal stroma in vivo, without any need for suturing.~The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation."
89625984|NCT03941483|Experimental|ASP1128|Participants received ASP1128 solution administered by 15 minutes intravenous infusion with in 24 hours after the end of surgery and thereafter once daily for 2 days.
89625985|NCT03941483|Placebo Comparator|Matching placebo|Participants received placebo matched to ASP1128 solution administered by 15 minutes intravenous infusion with in 24 hours after the end of surgery and thereafter once daily for 2 days.
89625986|NCT03941483|No Intervention|Observational cohort|Participant with postoperative negative NephroCheck® (NC) (AKIRisk score was ≤ 0.3 nanogram per milliliter (ng/mL)^2/1000 at all assessments between 2 to 22 hours after time point 0 (T0) were followed up for 90 days in observational cohort. Participants did not receive any intervention.
89625987|NCT03927521|Experimental|Focal HIFU guided by PET-MRI/68Ga-PSMA imaging|Patient with local/focal prostate cancer recurrence after radiotherapy and no distant metastasis (negative PET-Choline imaging confirmed by PET-MRI/68Ga-PSMA) will be treated by Focal-HIFU
89625988|NCT03889756|Experimental|Ketamine|Ketamine is an FDA-approved anesthetic agent that is commonly used to induce surgical anesthesia due to its low incidence of significant respiratory depression and hypotension. It as a N-methyl-D-aspartate (NMDA) receptor antagonist and glutamatergic modulator, and has been demonstrated in multiple controlled clinical trials to have rapidly acting antidepressant and anti-suicidal effects in adults.
89625989|NCT03889756|Placebo Comparator|Midazolam|Midazolam, the active control in this study, is a medication that is approved by the Food and Drug Administration as a sedative for both children and adults.It is a benzodiazepine with a short half-life that was chosen so as to blind the psychotomimetic effects of Ketamine.
89625990|NCT03887559|Experimental|Intervention group|Group-based stabilization and skill-training combined with individual treatment.
89625991|NCT03887559|Active Comparator|controls|Individual treatment as usual only.
89625992|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 40%|
89625993|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 80%|
89625994|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 40%|
89625995|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 80%|
89625996|NCT03775200|Experimental|Low dose|Low dose Psilocybin
89625997|NCT03775200|Experimental|Medium dose|Medium dose Psilocybin
89625998|NCT03775200|Experimental|High dose|High dose Psilocybin
89625999|NCT03774121|Experimental|CRYO|Subjected to Cryoneurolysis treatment and Neuromuscular training (GLA:D).
89626000|NCT03774121|Sham Comparator|SHAM|Subjected to similar procedures as CRYO, but without freezing temperatures. Subjected to Neuromuscular training (GLA:D).
89626001|NCT03761498||Normal Growth|Require less than or equal to 110 kcal/kg/day to maintain growth curve
88815697|NCT02170220|Experimental|Vortioxetine 5 mg: Normal Hepatic Function Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
89039042|NCT03653117|Experimental|TPLA|TPLA procedure
89039043|NCT03653000|Experimental|Patients undergoing this new block|Descriptive study about the effectiveness and the feasability of this new approach of te ultrasound guided brachial plexus blockade
89039044|NCT03963687|Active Comparator|Control Group|Participants will receive the Standard Nursing Education Intervention first
89039045|NCT03963687|Experimental|Intervention Group|Participants will receive the New Nursing Education Intervention first
89039046|NCT03639389|Active Comparator|Analgesics, multimodal|Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics
89039047|NCT03639389|Experimental|Bupivacaine|Spinal anesthetic with bupivacain + fentanyl/sufentanil
89039048|NCT05174091||With Non- Spesific Low Back Pain|FMS, Spinal mobility, Core Endurance, Physical Capacity.
89039049|NCT05174091||Without Non- Spesific Low Back Pain|FMS, Spinal mobility, Core Endurance, Physical Capacity.
89039050|NCT03603665|Experimental|Arm A|Single intravenous (IV) infusion of 0.033 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
89039051|NCT03603665|Experimental|Arm B|Single IV infusion of 0.165 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
89039052|NCT03603665|Experimental|Arm C|Single IV infusion of 0.330 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
89039053|NCT03943641||Population-based|Population-based cohort of participants registered with a SAIL-contributing practice.
89039054|NCT03579173||Nutrition and Infant PFT|To examine the relationship between nutritional status (weight-for-age (WFA) and weight-for-length (WFL)) at 6 months of age and lung function at 1-2 years of age in infants with CF.
89039055|NCT03579173||Nutrition and Lung Clearance Index|To examine the relationship between nutritional status (WFA and WFL) in infants with CF at 12 months of age and the lung clearance index (LCI) at 3-5 years of age.
89039056|NCT03579173||Passive Tidal Breathing and Infant PFT|To delineate the relationship between passive tidal breathing lung function testing in infants with CF at 4-8 weeks of age and subsequent lung function at 6-12 months of age.
89039057|NCT05172531|Experimental|test group|Participants in the test group received Cisatracurium Besilate 0.12mg/kg/hr Continuous infusion During intubation
89039058|NCT05172531|Sham Comparator|control group|Participants in the control group received saline 0.12ml/kg/hr Continuous infusion During intubation
89039059|NCT03570983|Experimental|BEAM Regimen- Experimental Arm|"Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.~BCNU (Carmustine) Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.~Etoposide (VP-16, Vepesid) Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.~Cytarabine (Ara-C) Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3."
89039060|NCT03570983|Active Comparator|Melphalan Regimen- Control Arm|"Melphalan Dosage: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.~Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to melphalan (day -3) and stops on day -1."
89039061|NCT05170815||ERISMA® LP/LP EVO|120 subjects with ERISMA® LP/LP EVO implant
89039062|NCT05170815||ERISMA® Deformity|120 subjects with ERISMA® Deformity implant
89039063|NCT05170815||ERISMA® MIS|120 subjects with ERISMA® MIS implant
89626002|NCT03761498||Slow Growth|Require more than 110 kcal/kg/day to maintain growth curve
89626003|NCT03737864|Active Comparator|Motivational Interview|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
89626004|NCT03737864|Experimental|Patient navigation and MI|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification plus patient navigation for 30 days, or until the patient is successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
89626005|NCT03689855|Experimental|Ramucirumab + Atezolizumab|"Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg.~Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg."
89626006|NCT03636568|Experimental|Fluid restricted|Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh <=100 kg and 1200 cc/24 hours for patients who weigh > 100kg)
89626007|NCT03636568|No Intervention|Non Fluid Restricted|No fluid restriction
89626008|NCT03635996|Experimental|Etripamil NS 70 mg|The dose of etripamil to be evaluated in NODE-302 is 70 mg.
89626009|NCT03613181|Experimental|ANG1005|ANG1005 Investigational Drug
89626010|NCT03613181|Active Comparator|Physician's Best Choice|One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.
89626011|NCT03598439|Experimental|Recombinant (RIV4) Influenza Vaccine|A single dose of licensed recombinant influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
89626012|NCT03598439|Experimental|Cell-culture (ccIIV4) Influenza Vaccine|A single dose of licensed cell-culture influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20
89626013|NCT03598439|Active Comparator|Standard (IIV4) Influenza Vaccine|A single dose of licensed standard influenza vaccine will be given in each of two influenza seasons - one in 2018-19 and a second in 2019-20.
89626014|NCT03595878|Active Comparator|Randomized Arm - Control Group|Patients randomized to this group will receive standard WBRT.
89626015|NCT03595878|Experimental|Randomized Arm - Intervention Group|Patients randomized to this group will receive parotid sparing WBRT.
89626016|NCT03595878|No Intervention|Observational Arm|Patients enrolled in this arm will be treated per their treating physician's choice.
89626017|NCT03558945|Experimental|Personalized neoantigen vaccine|Patients will receive radical resection surgery and at least one circle of post-operative chemotherapy. After chemotherapy, personalized neoantigen vaccines will be administered subcutaneously.
89626018|NCT03552120|Experimental|Mindfulness|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
89626019|NCT03552120|Active Comparator|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
89039064|NCT05170815||Idys® TLIF PEEK|50 subjects with Idys® TLIF PEEK implant
89039065|NCT05170815||Idys® TLIF TiVAC|50 subjects with Idys® TLIF TiVAC implant
89039066|NCT05170815||Idys® TLIF 3DTi|50 subjects with Idys® TLIF 3DTi implant
89039067|NCT05170815||Idys® ALIF PEEK|50 subjects with Idys® ALIF PEEK implant
89039068|NCT05170815||Idys® ALIF TiVAC|50 subjects with Idys® ALIF TiVAC implant
89039069|NCT05170815||Idys® ALIF 3DTi|50 subjects with Idys® ALIF 3DTi implant
89039070|NCT05170815||Idys® ALIF ZP 3DTi|50 subjects with Idys® ALIF ZP 3DTi implant
89039071|NCT05170815||Idys® LLIF 3DTi|50 subjects with Idys® LLIF 3DTi implant
89626020|NCT03490045|Experimental|Intervention Condition|Postpartum women and their infants will be randomly assigned to the treatment condition and receive a diaper incentive for their participation.
89626021|NCT03490045|Active Comparator|Comparison Condition|Postpartum women and their infants will be randomly assigned to the control condition and will receive a conditional cash transfer of equivalent value of the diapers provided to the intervention group.
89626022|NCT03484078|Experimental|Vibration Platform|The vibration group will stand on a platform that emits a mild vibration 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
89626023|NCT03484078|Placebo Comparator|Placebo Platform|The placebo group will stand on a placebo platform 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
89626024|NCT03468478|Experimental|sirolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
89626025|NCT03468478|Experimental|everolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
89626026|NCT03468478|Active Comparator|mycophenolate +tacrolimus|Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).
89626027|NCT03451708|Experimental|Optimization of OKS|Crossover study examining various OKS protocols on improving symptoms of hemispatial neglect
89626028|NCT03451708|Experimental|Safety and efficacy study|Randomized study assessing the safety and efficacy of OKS in treating hemispatial neglect
89626029|NCT03451708|Experimental|Effect of repetitive stimulation|Benefits of daily, repetitive OKS in treating hemispatial neglect
89626030|NCT03451708|Experimental|OKS and gait|Effect of OKS on gait and balance
88989927|NCT04602325||Fatty Acid Oxidation Disorders|"Acute metabolic disorder without hyperammonemia and without neurological sequelae:~Medium Chain-Acyl CoA Dehydrogenase Deficiency~Very Long Chain-Acyl CoA Dehydrogenase Deficiency~Trifunctional Protein Deficiency~Long Chain Hydroxyacyl-CoA Dehydrogenase Deficiency~Carnitine Palmitoyltransferase I or II Deficiency~Carnitine/Acylcarnitine Translocase Deficiency~Primary Carnitine Transport Deficiency"
88989928|NCT04602325||Hypoxic-Ischemic Encephalopathy|Patients with hypoxic-ischemic encephalopathy
88989929|NCT04590326|Experimental|Module 1|REGN5668 and cemiplimab
88989930|NCT04590326|Experimental|Module 2|REGN5668 and REGN4018
88989931|NCT04588870|Experimental|Preoperative Cochlear Implant|The intervention will be the use of a surgical simulation system preoperatively by the surgeon to develop the surgical plan to optimize electrode array placement with respect to scalar location and modiolar distance.
88989932|NCT04582487|Other|Biological evaluation|A combined approach of Drug Sensitivity and Resistance Profiling (DSRP) and molecular-cytogenetic findings is used in order to prioritize compounds for tailored therapies.
88989933|NCT04581824|Experimental|Participants receiving dostarlimab plus chemotherapy|Participants will receive dostarlimab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
88989934|NCT04581824|Active Comparator|Participants receiving pembrolizumab plus chemotherapy|Participants will receive pembrolizumab on Day 1 of every 21 Day cycle followed by pemetrexed, and then followed by cisplatin or carboplatin (Cycles 1 to 4 only) as per investigator decision.
88989935|NCT04579523|Experimental|Arm A (²¹¹At-OKT10-B10, fludarabine, TBI, HCT)|Patients with HLA-matched related or unrelated donors receive ²¹¹At-OKT10-B10 IV on day -7 (day -10 to -5) and fludarabine IV over 30 minutes on days -4 to -2. Patients then undergo TBI and allogeneic HCT on day 0.
88989936|NCT04579523|Experimental|Arm B (²¹¹At-OKT10-B10, chemotherapy, TBI, HCT)|Patients with HLA-matched haploidentical donors receive ²¹¹At-OKT10-B10 IV on day -8 (day -14 to -7), fludarabine IV over 30 minutes on days -6 to -2, and cyclophosphamide IV over 1 hour on day -6 and -5. Patients then undergo TBI on day -1 and allogeneic HCT on day 0.
88989937|NCT04577638|Experimental|Nivolumab and accelerated IMRT|
88989938|NCT04570852|Experimental|Intensive monitoring of patients|State of the art biochemical assessment of patients with acute pancreatitis including multi-OMICS focusing on transcriptomics and proteomics.
89626031|NCT03449212||SOD1 ALS|
88989939|NCT04560621|Experimental|MAPS+|
88989940|NCT04560621|No Intervention|Standard of Care|
88989941|NCT04543838|Experimental|EEG & SSEP monitoring|Intervention will include standard of care pain management during the postoperative period. Participants in this arm will receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP). EEG will be used to manage blood pressure.
88989942|NCT04543838|Active Comparator|Standard of Care|Control will include standard of care pain management during the postoperative period. Participants in this arm will not receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP).
89626032|NCT03449212||Sporadic ALS|
89626033|NCT03449212||Asymptomatic SOD1 gene carriers|
89626034|NCT03409367|Experimental|Daily Emollient|Parents assigned to the intervention arm will receive a lipid-rich emollient and educational materials promoting once daily full-body emollient use until their infant is 24 months old. Parents will select one of five emollients to be mailed to the dyad's home at enrollment and approximately every six months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2) Vaseline, (3) Cetaphil cream, (4) CeraVe cream, and (5) Vanicream.
89626035|NCT03409367|No Intervention|Natural Skin|Parents assigned to the control arm will receive educational materials promoting general infant skin care guidelines only and will be asked to refrain from emollient use unless dry skin develops (current standard of care guidelines).
89626036|NCT03381729|Experimental|Dose A|Intrathecal administration 6.0 X 10^13 vg of onasemnogene abeparvovec-xioi
88989943|NCT04543773|Experimental|rTMS|Subjects will receive rTMS to the area of the DLPFC most anticorrelated with the ACC.
88989944|NCT04543227||Retrospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries between August 2015 - August 2019.
88989945|NCT04543227||Retrospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure between August 2015 - August 2019.
89626037|NCT03381729|Experimental|Dose B|Intrathecal administration 1.2 X 10^14 vg of onasemnogene abeparvovec-xioi
89626038|NCT03381729|Experimental|Dose C|Intrathecal administration 2.4 X 10^14 vg of onasemnogene abeparvovec-xioi
89626039|NCT03318692|Experimental|MySpine System|pedicle screw implantation (spondylodesis) using the MySpine System. post surgery CT.
89626040|NCT03318692|Active Comparator|free-hand|Freehand (fluoroscopically controlled) implantation of pedicle screw (spondylodesis). Post surgery CT
89626041|NCT03240237|Experimental|CCM therapy|Optimizer SMART
89626042|NCT03234114|Experimental|1-month TAT|Randomized experimental group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg q.d. and aspirin 100 mg q.d.) for 1 month (30 days) then quit aspirin till 12 months after PCI
89626043|NCT03234114|Experimental|6-month TAT|Randomized control group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg q.d. and aspirin 100 mg q.d.) for 6 months (180 days）then quit aspirin till 12 months after PCI
89626044|NCT03234114|Experimental|12-month DAT-1|Randomized experimental group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with clopidogrel 75 mg q.d. for 12 months after PCI
89626045|NCT03234114|Experimental|12-month DAT-2|Randomized control group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with ticagrelor 90 mg b.i.d for 12 months after PCI
89626046|NCT03229031|Experimental|ES135|
89626047|NCT03229031|Placebo Comparator|Placebo|
89626048|NCT03176836|Experimental|MRI Imaging|"Participants will be imaged with the standard MRI technique (STIR-MRI) and also new MRI techniques called diffusion weighted or DW MRI and Positron Emission Tomography (PET)-MRI. PET-MRI will be indicated if the results from the routine MRI and DW MRI are contradictory or if laboratory results do not correspond to the standard MRI and DW MRI results."
89626049|NCT03168464|Experimental|Immunotherapy + Radiation|Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
89626050|NCT03164447|Experimental|Multi-Drug Resistant|
89626051|NCT03136094|Placebo Comparator|SBIRT+Usual Care|The control arm of the trial will receive the usual care prescribed in the Screening, Brief Intervention and Referral to Treatment (SBIRT) model.
89626052|NCT03136094|Experimental|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants will receive caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
89626053|NCT03054792|Experimental|FAZA - BOLD- DW- MRS|"18F-FAZA (F18-Fluoroazomycin Arabinoside) is a radioactive agent developed as a non-invasive probe for the assessment of cellular hypoxia. 18F-FAZA Injection is indicated in a single dose of (5.2 MBq/kg [0.14 mCi/kg]) Route/method of administration: intravenous injection.~Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI, MR Spectroscopy [MRS]"
89626054|NCT03047694|Experimental|Tablet group|Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
89626055|NCT03047694|Active Comparator|Control group|Patients will continue their usual care (1 or more sessions of weekly speech therapy)
89626056|NCT02875262|Experimental|Treatment|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day. duration 3 days
89626057|NCT02875262|Placebo Comparator|placebo|NaCl 0.9% in similar dosis to treatment arm
89626058|NCT02823444||Peripheral Vascular Disease|Gender distribution will be approximately equal. The age range is 18-95, with increased prevalence in the elderly population.
89626059|NCT02823444||Control|In the initial sequence optimization stage, healthy volunteers will also be recruited.
89626060|NCT02818920|Experimental|Pembrolizumab prior to and after surgery|
89626061|NCT02811510|Active Comparator|THC|10 mg Dronabinol will be administered orally.
89626062|NCT02811510|Placebo Comparator|Placebo|Placebo pill (no active cannabinoids).
88815698|NCT02170220|Experimental|Vortioxetine 5 mg: Severe Hepatic Impairment Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
88815699|NCT01036490|No Intervention|Control|Control group
88815700|NCT01036490|Experimental|Exercise|Exercise Group
89039072|NCT03540758|Experimental|Non-diabetic (Diazoxide)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to non-diabetic participants.
89039073|NCT03540758|Placebo Comparator|Non-diabetic (Placebo)|Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to non-diabetic participants.
89039074|NCT03540758|Experimental|T2D (Diazoxide)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants.
89039075|NCT03540758|Placebo Comparator|T2D (Placebo)|Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.
89626063|NCT02786264||Propofol-dominant Sedation|Patients receiving propofol infusion for TAVR as the primary drug for sedation.
89626064|NCT02786264||Dexmedetomidine-dominant Sedation|Patients receiving dexmedetomidine infusion for TAVR as the primary drug for sedation.
89626065|NCT02778971||Qualifying participants|All consented participants referred by a dementia expert physician to receive an amyloid PET scan with [18F]Flutametamol and meeting eligibility criteria will have visual and semi-quantitative software aided scan interpretation, complete care partner questionnaires and providers will document diagnosis, diagnostic confidence, and management plan before and after the scan.
89626066|NCT02756533|Experimental|Telemonitoring|Telemonitoring of daily parameters recorded by NIV, transmitted to a remote monitoring platform. When an alert is received the patient is contacted by phone by a nurse to evaluate the worsening of symptoms. Information are transferred to a referent physician for further medical care if needed.
89626067|NCT02756533|Placebo Comparator|control|"Telemonitoring of daily parameters by NIV, transmitted to a remote monitoring platform with no generation of alerts.~Phone calls to patient during the follow-up like false alerts for the blind procedure."
88989946|NCT04543227||Prospective Burn Injuries|Pediatric patients treated at a large academic pediatric medical center for burn injuries after July 2020.
88989947|NCT04543227||Prospective Knee Arthroscopy|Pediatric patients treated at a large academic pediatric medical center for a knee arthroscopy procedure after July 2020.
88989948|NCT04535661||non CRE|Children with a negative culture for CRE during their stay in PICU are defined as non CRE.
88989949|NCT04535661||CRE colonization|Children who have a positive culture for CRE during their stay in PICU but lack of clinical symptoms are defined as CRE colonization.
88989950|NCT04535661||CRE infection|Children who have a positive culture for CRE during their stay in PICU combined with clinical symptoms are defined as CRE infection.
88989951|NCT04522219|Experimental|Case group|Diagnosis of adnexal torsion confirmed by the surgical intervention: woman allocated to case group
88989952|NCT04522219|Experimental|Control group|Diagnosis of adnexal torsion not confirmed by the surgical intervention: woman allocated to control group
88989953|NCT04519970|Active Comparator|Highest Tier of Case Management (Piggyback) and Biktarvy|The most intensive tier of case management. Includes three appointment reminders; check ins twice per week; travel compensation; housing support; food insecurity support; follow ups for missed appointments and off pill counts; connections with substance use programs; meetings with the benefits department for health insurance needs; childcare support to make appointments; mental healthcare referrals; open pool appointments as back-up options in case of rescheduling needs; late doctor's appointments and prescription pick up for those working during the day; meetings with the health educators to discuss HIV and ART; and re-motivation of HIV treatment every 3 months.
89626068|NCT02726061|Experimental|Internet Based psychological support|The internet-based psychological support intervention (PATH) is an internet based Problem Solving Therapy, stress management training and conflict management training program.
89626069|NCT02444546|Experimental|Treatment (sargramostim, wild-type reovirus)|Patients receive sargramostim SC daily on days 1 and 2 and wild-type reovirus IV over 60 minutes on days 3-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89626070|NCT01993498|Other|breast cancer treatment + blood sampling|Standard treatment of breast cancer with intervention : samples collection
89626071|NCT01965912|Experimental|Kuvan®|
89626072|NCT01948505|Active Comparator|Intervention group|IV acetaminophen: 1000mg IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
89626073|NCT01948505|Placebo Comparator|Placebo Group|IV Normal Saline: 100ml IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
89626074|NCT01934296|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
89626075|NCT01916005|Experimental|endocarditis|
89039076|NCT03540758|Experimental|T2D (Diazoxide + Nicotinic Acid)|Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants after lowering free fatty acids with a nicotinic acid (Niacin) infusion.
89039077|NCT03540758|Experimental|T2D (Nicotinic Acid + placebo for diazoxide)|Pancreatic clamp study will be done after lowering free fatty acids with a nicotinic acid (Niacin) infusion in type 2 diabetic participants, and after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.
89039078|NCT05154045|Experimental|Experimental Formula|One 330 ml serving of study product
89039079|NCT05154045|Active Comparator|Test Meal|40 g Instant oatmeal
89039080|NCT05135481|Active Comparator|CONTROL GROUP|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function.
89039081|NCT05135481|Experimental|STUDY GROUP|"Management in group 2 will include increased lactation care both during hospital stay and post discharge.~Increased lactation care will consist of:~individual consultations on how to properly attach the baby to the breast (at least 3 meetings during hospitalization with personnel trained in lactation counselling), regular (at least once a week) contact with a breastfeeding consultant as part of a closed group on social media or by phone, if necessary (expressed by the mother or based on a referral by a member of the lactation team) an outpatient appointment at the breastfeeding clinic."
89626076|NCT01454401|Other|Weekly LeucoPatch treatment|Weekly treatment of diabetic foot ulcers with LeucoPatch
89626077|NCT01344018|Active Comparator|Surgery alone|En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.
89626078|NCT01344018|Experimental|Preoperative radiotherapy followed by en-bloc surgery|3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions
89626079|NCT01160926|Experimental|AZD6244 + capecitabine + radiotherapy|10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy
89626080|NCT01160926|Experimental|Cediranib + capecitabine + radiotherapy|10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy
89626081|NCT01126957|Experimental|Ketamine|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation.
89626082|NCT01126957|Placebo Comparator|Placebo|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.
89626083|NCT00651885|Placebo Comparator|2 arm|
89626084|NCT00651885|Experimental|1 arm|treprostinil dienthalomine
89626085|NCT00430612||All Registry Participants|Non-voluntary registry of consecutive patients diagnosed as having a MI at each study site.
89626086|NCT00247377|Active Comparator|Laparoscopic Gastric Bypass|Subject undergoes Laparoscopic Gastric Bypass
89626087|NCT00247377|Active Comparator|LAP-BAND|Subject undergoes LAP-BAND procedure
89626088|NCT01456767|Active Comparator|Lactobacillus plantarum WCFS1|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum WCFS1).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
89626089|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104448|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104448).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
89626090|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104450|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104450).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
89039082|NCT04678778|Experimental|Combined, simultaneous physical and cognitive activity|The combined physical and cognitive activity VR arm will participate in our customized spatial navigation program that increases difficulty and length per trial over time. As described in the Game Design section, each session will consist of 5 trials. The first trial will be a long-delay free recall condition from the previous day's path. The next 4 trials will consist of learning, cued recall, and free recall. This VR-based spatial navigation program has been tested in our feasibility trial for safety and tolerability in older adults.
89039083|NCT03187379|Experimental|Exparel, Liposomal Bupivacaine|Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing
89039084|NCT03187379|Active Comparator|Control|Subjects in this arm will receive 0.25% bupivacaine alone
89039085|NCT03182231|Experimental|RYGB patients|Patients who will receive a RYGB surgery
89626091|NCT01456767|Placebo Comparator|Placebo|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of a placebo).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
89626092|NCT01890369|Experimental|Early leucine refeed|15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
89626093|NCT01890369|Experimental|Early EAA refeed|15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
89626094|NCT01890369|Experimental|Mid latency EAA refeed|15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
89626095|NCT01890369|Experimental|Late latency EAA refeed|15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
89626096|NCT01890447||Questionnaire design group|A focus group (group of experts) such as physicians, nurses, or other professionals invited by the investigator.
89626097|NCT01890447||Adaptive questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the adaptive choice based conjoint (ACBC) technique.
89626098|NCT01890447||Standard questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the standard discrete choice experiment (DCE) technique.
89626099|NCT01456845||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
89626100|NCT01890525||PROMISE study patients|
89626101|NCT01456923|Active Comparator|Control (chemotherapy and surgery)|Patients treated with chemotherapy + surgery
89626102|NCT01456923|Active Comparator|Study|Patients treated only with chemotherapy
89626103|NCT01890603|Experimental|Care Coordination Arm|
89039086|NCT05124288||Acute Myeloid Leukemia relapsed patients|Adult patients (< 18 years old), with Acute Myeloid Leukemia, who relapse after allogeneic transplantation from either family or unrelated donors, regardless of the cellular source of the transplant (bone marrow, mobilized peripheral stem cells or cord blood).
89039087|NCT03077360|Experimental|Weight loss only|
89039088|NCT03077360|Experimental|Exercise Only|
89039089|NCT03077360|No Intervention|Delayed Intervention Control|
89039090|NCT03722511|Active Comparator|NET with carcinoid syndrome|Participants with NET and carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
89039091|NCT03722511|Active Comparator|NET w/o cardinoid syndrome|Participants with NET w/o carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
89039092|NCT02964884|Active Comparator|NF1: Lovastatin + reading tutoring|"Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.~And one week of intensive, one-on-one reading tutoring intervention"
89039093|NCT02964884|Placebo Comparator|NF1: Placebo + reading tutoring|Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
89039094|NCT02964884|Placebo Comparator|RD: Reading tutoring|Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
89039095|NCT02964884|Sham Comparator|RD: Other Academic (sham) tutoring|"Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading.~These participants will have the opportunity to receive reading tutoring upon finishing study participation."
89626104|NCT01890603|Active Comparator|Quality Measure Improvement|
89626105|NCT04845321|Experimental|VNRX-9945|Oral dosing
89626106|NCT04845321|Placebo Comparator|Placebo|Oral dosing
89626107|NCT01457001|Experimental|25-OH-D vitamin|
89626108|NCT01457001|No Intervention|control|
89626109|NCT02846883|Active Comparator|Intravenous infusion of 1 million allogenic MSC's/Kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
89626110|NCT02846883|Active Comparator|Intravenous infusion of 3 million allogeneic MSCs/kg|In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
89626111|NCT02846883|Placebo Comparator|Intravenous infusion of Plasmalyte A (placebo)|In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.
89626112|NCT01457235|Active Comparator|Active Group|This group receives cognitive remediation in groups (each group consisting of 6-8 subjects)
89626113|NCT01457235|No Intervention|Waiting List|Patients randomized to the waiting list group continues standard treatment and will be offered a course of cognitive remediation upon completion of participation provided that they still meet the inclusion criteria.
89626114|NCT01457313||BTKA|patients undergoing bilateral staged total knee arthroplasty
89626115|NCT01457391|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
89626116|NCT01457391|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
89626117|NCT01457391|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical intensive outpatient (IOP) treatment that the patient would receive ordinarily at the identified addiction treatment program. Each TAU service operates using the American Society of Addiction Medicine criteria for Level II Intensive Outpatient services: 9-12 hours per week; group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
89626118|NCT02816775|Active Comparator|Group Laryngoscope|Group Laryngoscope; intubation will be made by Macintosh laryngoscope
89626119|NCT02816775|Active Comparator|Group Videolaryngoscope|Group Videolaryngoscope; intubation will be made by McGRATH Videolaryngoscope
89626120|NCT01457469|Active Comparator|Arm I (usual care plus) (closed to accrual as of 3/6/2012)|"Patients receive a personalized letter from their physician with advice to quit smoking and a copy of the National Cancer Institute's Cleaning the Air smoking cessation booklet."
89626121|NCT01457469|Experimental|Arm II (enhanced quitline)|Patients receive a personalized letter and a smoking cessation booklet. Patients also receive an 8-week supply of nicotine replacement patches and undergo a counseling session over 30-45 minutes with a trained nurse or midlevel provider that focuses on the benefits of quitting smoking for cancer patients and addresses cancer-specific concerns about smoking cessation. Patients also undergo a quitline-based smoking cessation intervention comprising 5 individual 25- to 30-minute telephone counseling sessions and unlimited inbound phone-based access to Quit Coaches over 8-11 weeks, mailed written materials, and an interactive online program.
89626122|NCT01457547|Experimental|DTPa 1 Group|
89626123|NCT01457547|Active Comparator|DTPa 2 Group|
89626124|NCT01457625||liver fat contents|
89626125|NCT01457859|Active Comparator|Conventional sutures|
89626126|NCT01457859|Experimental|Antiseptic sutures|
89626127|NCT01890993||Liraglutide|
89626128|NCT01890993||DPP-4|
89626129|NCT02979483|Other|Integrative Supportive Care|All planed procedures established during the first consultation with the investigator is successfully completed within the 14-day (+/-2 days)
89626130|NCT01457937|Active Comparator|PEG IFN/Ribavirin|Standard of care for HCV-positive CAH
89626131|NCT01457937|Experimental|PEG IFN/Ribavirin/Boceprevir|Combination to be tested for possible higher efficacy
89626132|NCT05023629|Other|Patients with a significant coronary artery lesion|Balloon inflation for 90s
89626133|NCT05026671|Active Comparator|Group DL|The control group consists of intubating the trachea with an endotracheal tube alone (without stylet).
89626134|NCT05026671|Experimental|Group DLS|The Experimental group consists of intubating the trachea with an endotracheal tube + stylet.
89626135|NCT05026671|Experimental|Group VL|The Experimental consists of intubating the trachea with an endotracheal tube + Video-laryngoscope
89626136|NCT05026671|Experimental|Group VLS|The Experimental consists of intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
89626137|NCT05028699|Experimental|Snack|32 g of a common bean baked snack per day for 28 days.
89039096|NCT04683705||patients without shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the asymptomatic shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
89626138|NCT05028699|No Intervention|Control|
89211105|NCT00927030|Experimental|Pharmacokinetic|We hope to target 12 of the 30 children to be enrolled for this study to participate in a pharmacokinetic arm of the study. These 12 children would be receiving overnight sleep studies prior to receiving the first dose of melatonin and again at about every 3 week intervals each time the dose increases until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. During the sleep studies an intravenous catheter will be placed in the child's arm to sample small amounts of blood throughout the day (about 3 teaspoons of blood)to allow us to look at how melatonin is produced in children with autism who have sleep problems.
89211106|NCT00927030|Placebo Comparator|flavored inert liquid|Of the 30 targeted participants, 18 will be randomized at the first three week dosing period {1mg of melatonin}. The randomization will be single blind to the parent in a 5:1 ratio (15 children will receive melatonin, and 3 children will receive a flavored placebo at the first 3-week period only). After the initial 3-week dose cycle of 1 mg, all children randomized to placebo will begin 3 mg of melatonin and will continue in dose increase (6mg, 9 mg)until they meet the criteria of falling asleep within 30 minutes of bedtime 5/7 nights per week. No child will take more than 9 mg.
89211107|NCT00827762||Phenylketonuria|Individuals with mild phenylketonuria/hyperphenylalanemia who are beginning treatment with Kuvan.
89211108|NCT00931866|Experimental|Diclofenac Sodium Patch|
89211109|NCT00931866|Placebo Comparator|Topical Placebo Patch|
89626139|NCT04346355|Experimental|Experimental Arm|Tocilizumab within 8 hours from entering the study + standard of care; 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
89626140|NCT04346355|Other|Control Arm|Standard of care; In the event of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
89626141|NCT04272255|Active Comparator|DPI-386 nasal gel|"DPI-386 Nasal Gel is formulated to contain 0.2 mg scopolamine HBr per 0.1 g dose, with each dose therefore described as 0.2 mg / 0.1 g"
89626142|NCT04272255|Placebo Comparator|placebo nasal gel|Placebo nasal gel product is the same but does not contain scopolamine HBr
89626143|NCT04272255|Experimental|Transderm Scop®|TDS patch delivers 1.5 mg of scopolamine over a 72-hour period. TDS arm will apply two TDS patches over the six treatment days.
89626144|NCT04271787||strongly dissatisfied|
89626145|NCT04271787||dissatisfied|
89626146|NCT04271787||neutral|
89626147|NCT04271787||satisfied|
89626148|NCT04271787||strongly satisfied|
89626149|NCT04271787||don't know|
89626150|NCT01458015|Active Comparator|oxycodone|
89626151|NCT01458015|Active Comparator|tapentadol|
89626152|NCT02843763|Other|Renal transplant with 1rst cancer|"Renal transplant patients with first cancer (all cancer excepting skin cancer including in group 2).~Intervention : blood sample"
89626153|NCT02843763|Other|Renal transplant patients without cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status.~Intervention : blood sample"
89626154|NCT02843763|No Intervention|Patient with cancer|Patient with cancer from oncology departement matched for cancer type and stade and CMV/EBV status.
89626155|NCT02843763|Other|Renal transplant with first skin cancer|Renal transplant patients with first epidermoid skin cancer. Intervention : blood sample
89626156|NCT02843763|Other|RT with several skin cancer|Renal transplant patients with several epidermoid skin cancer. Intervention : blood sample
89626157|NCT02843763|Other|Rt patients without cancer apparied to RT skin cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status with renal transplant patients with skin cancer.~Intervention : blood sample"
89626158|NCT01891071|Experimental|Lung volume recruitment|Lung volume recruitment twice daily for 9 months
89626159|NCT01891071|No Intervention|Standard care|Standard care
89626160|NCT01891149||Malawian women|Malawian women who present for care at the Fistula Care Centre
89626161|NCT01891227|Experimental|Capecitabine and Bendamustine|"Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).~Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).~Eligible patients will receive capecitabine in combination with bendamustine for a maximum of eight cycles and afterwards capecitabine mono will be continued until disease progression or unacceptable toxic effects. Safety assessments will be conducted in 3-weekly intervals; efficacy assessments will be conducted every 9 weeks."
89211110|NCT00831116||LipiScan|Subjects who have at least one native coronary artery imaged with the LipiScan CIS.
89211111|NCT04885452||Patients treated with casirivimab/imdevimab according to the ATU protocol|
89626162|NCT04273113|Experimental|Heart Rate Variance (HRV) biofeedback training|Patients to participate in 15 biofeedback sessions, 3 times a week (5 weeks in total).
89626163|NCT04391439||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
89626164|NCT01458483|Experimental|Baroreceptor Stimulation|
89626165|NCT01891383||History of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
89626166|NCT01891383||No history of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
89626167|NCT02884245|Experimental|Arm E2: With estrogens pretreatment|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
89626168|NCT02884245|No Intervention|Arm S: without estrogens pretreatment|No estrogen pretreatment will be delivered
89211112|NCT04885452||Patients treated with bamlanivimab/etesevimab according to the ATU protocol|
89211113|NCT04885452||Patients treated with Xevudy according to the authorisation for early access (AAP) protocol|
89211114|NCT04885452||Patients treated with Paxlovid according to the authorisation for early access (AAP) protocol|
89626169|NCT01891461|Experimental|Floseal|"Floseal will be administered during the procedure and prior to release of the tourniquet (if used PRN during the cementing procedure (±10 minutes)) and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissue by the use of a delivery syringe. Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.~Preparation of Floseal requires mixing 5,000 US units of package thrombin (bovine-derived) made up to 5 milliliters of saline solution, to the Gelatin Matrix solution. In this study, 2-4 vials (15-20 mls total) will be used."
89626170|NCT01891461|No Intervention|standard of care|For patients randomized to the control arm, the surgery will proceed in an otherwise identical fashion (with release of the tourniquet if used PRN during cementing procedure (±10 minutes)) and hemostasis followed by drain insertion and wound closure.
89626171|NCT01891539||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of drug-eluting microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of drug eluting microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
89626172|NCT01458717|Experimental|Neoadjuvant|Neoadjuvant - operation - maintenance chemotherapy
89626173|NCT01458717|Active Comparator|Upfront surgery|Operation - adjuvant chemoradiation - maintenance chemotherapy
89626174|NCT01891617|Experimental|Exercise-high-fat diet|Two bouts of exercise followed by a high-fat meal
89626175|NCT01891617|Experimental|Exercise-high-carbohydrate diet|Two bouts of exercise followed by a high-carbohydrate meal
89626176|NCT01891617|Experimental|Sedentary-high-fat diet|Sedentary trial with two high-fat meals
89626177|NCT01891617|Experimental|Sedentary-high-carbohydrate diet|Sedentary trial with two high-carbohydrate meals
89626178|NCT04272567|Sham Comparator|Control group|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
89626179|NCT04272567|Experimental|0.025 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.025 μg/kg/min).
89626180|NCT04272567|Experimental|0.05 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.05 μg/kg/min).
89626181|NCT04272567|Experimental|0.075 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.075 μg/kg/min).
89626182|NCT04272567|Experimental|0.1 μg/kg/min group|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.1 μg/kg/min).
89626183|NCT01458873|Experimental|sodium bicarbonate 4.2%|"sodium bicarbonate 4.2% 50 ml"
89626184|NCT01458873|Experimental|sodium bicarbonate 2.1%|"sodium bicarbonate 2.1% 1 50 ml"
89626185|NCT01458873|Placebo Comparator|normal saline|"50 ml normal saline"
89211115|NCT00823394||Windsor Village United Methodist Church|Questionnaire + Body Measurements + Self-help Materials
89211116|NCT00831194|Experimental|Diet plan and PDA|
89211117|NCT04366544|Other|Time Point 1: Baseline/Pre-preparatory Samyama|"Survey link for participant~Survey link for spouse/ control~Stool collection from home~Blood sample at home provided by at home phlebotomy services or at Isha Center group meditation by study personnel."
89211118|NCT04366544|Other|Time point 2: Post-Preparatory/Pre-Samyama|"Online Surveys~Participant~Spouse~Stool collection from IIIS/home~Blood sample collection: on site at IIIS/home EEG and fMRI"
89211119|NCT04366544|Other|Timepoint 3: Immediate Post-Samyama|"Online survey to be completed~Survey link for participant~Survey link for spouse~Blood sample collection: on site at IIIS o Participant only - Not spouse/significant other. EEG and fMRI"
89211120|NCT04366544|Other|Timepoint 4: 3 months Post Samyama|"Blood draw at home by at home phlebotomist~Post program online survey follow up to be completed~Survey link for participant~Survey link for spouse: https~Stool collection from home"
89211121|NCT00930462|No Intervention|Conventional colonoscopy|No cap fitted on the colonoscopes for this group.
89626186|NCT01891773|Experimental|School-based therapy|Daily dose of medication to be provided in the school setting.
89626187|NCT01891773|No Intervention|Usual Care|Daily medication to be taken at home.
89626188|NCT01459029|Active Comparator|D-serine|D-serine up to 6000 mg/day subject to tolerability
89626189|NCT01459029|Placebo Comparator|Control|Treatment with inert capsules (placebo)
89626190|NCT01891851|Experimental|TMC435350 / Ritonavir|TMC435350 2 capsules of 100-mg twice daily / Ritonavir one 100-mg capsule twice daily
89626191|NCT02831283|Experimental|Cognitive impairment|Alzheimer's disease, Preclinical Alzheimer's disease or Impairment due to suspected non-Alzheimer's disease pathophysiology
89626192|NCT02831283|Active Comparator|No cognitive impairment|Normal aging
89626193|NCT01459185|Experimental|S-1|Single arm of the patients who received complete resection of pathological stage IB, II, or IIIA Non-small cell lung cancer
89626194|NCT02826681|Active Comparator|Injectafer|750 mg undiluted slow IVpush (100 mg/minute) of Injectafer® (Ferric Carboxymaltose - FCM)
89626195|NCT02826681|Placebo Comparator|Normal Saline|Placebo (15 ml of Normal Saline [NS]) IV push at 2 ml/minute on Day 0 and 7.
89626196|NCT01891929|Experimental|RECOS|The RECOS program (COgnitive REmediation for Schizophrenia) was designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 6 main cognitive functions (selective attention; verbal memory; visuo-spatiale attention and memory, working memory, reasoning, and speed of execution) which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS is determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participates in the module corresponding to his/her most altered cognitive area.
89039097|NCT04683705||patients with shoulder pain|This was a cross-sectional study investigating suprascapular nerves in the painful shoulders of participants. All the participants were required to ambulate independently, have normal cognitive function and complete the given questionnaires. The group included at least 60 participants.
89039098|NCT02837042|Experimental|Pembrolizumab 200 mg|Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
89626197|NCT01891929|Active Comparator|TAU (Treatment as Usual)|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
89626198|NCT04390269||Infected group|The infected group will be classified according to the severity whether mild ,moderate or severe
89626199|NCT04390269||susceptible (non infected|This group either exposed and not infected .
89626200|NCT04390269||control group|normal control subject
89626201|NCT01459263||GSV insufficiency|Patients with insufficiency of the greater saphenous vein (GSV) will be included.
89626202|NCT04390035|No Intervention|Control|Participants in the control arm will follow the standard-of-care treatment exercises for the 6 months following ACL reconstruction surgery.
89626203|NCT04390035|Experimental|Test (BFRT)|Participants in the test arm will follow the identical physical therapy exercises as the control arm but will perform the exercises with BFRT during the first 16 weeks post-surgery. After reaching the 16-week mark, participants will complete the identical standard-of-care rehabilitation between weeks 16-24.
89626204|NCT05022693|Experimental|BIO89-100 30 mg, Open Lable, Single Dose|
89626205|NCT05029089|Experimental|Experimental: Entire Papilla Preservation Modified Technique (EPPMT)|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated (subperiosteal tunnel). Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. Microsurgical suturing technique with 7-0 materials was performed. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
89626206|NCT05029089|Active Comparator|Entire Papilla Preservation Modified Technique + EMD|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. 24%EDTA was applied on the exposed root surface for 2 minutes, than rinsed and EMD was applied. Vertical incision was closed with simple single sutures(7-0),whereas due to modification of the original technique additional sling suture was applied.
89626207|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft|Procedure:The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
89626208|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft+sCTG|Procedure: After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. sCTG taken form palate was sutured to the inner part of mucosa flap. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
89626209|NCT01459419|Experimental|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up to 9 subjects will be treated at each dosage level
89626210|NCT01459419|Placebo Comparator|Sodium chloride|Up to 9 subjects will receive placebo. Subjects will receive the drug in a similar manner as as the treatment group
89626211|NCT01892241|Experimental|180µg of peginterferon alfa-2a|Cases in group A receive 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
89626212|NCT01892241|Active Comparator|Entecavir|cases in group B received an continual entecavir therapy(0.5 mg orally once daily)
89626213|NCT01892241|No Intervention|Control group|Those in group C didn't accept any antiviral regiment .
89626214|NCT04391127|Experimental|Hospitalized patients with COVID-19 QTc < 500 mseg|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc < 500 ms could be randomized to hydroxychloroquine, ivermectin or placebo.
89211122|NCT00930462|Experimental|Cap-assisted colonoscopy|
89211123|NCT00827840|Experimental|1. Paliperidone ER|New antipsychotics
89211124|NCT00827840|Active Comparator|2 Risperidone|
89626215|NCT04391127|Experimental|Hospitalized patients with COVID-19 infection with QTc >500ms|Patients with confirmed COVID-19 infection by RT-qPCR SARS-CoV-2 or suspected by chest computed tomography with criteria of hospitalization because emergency medical criteria, with no need of critical care assistance. The risk of hydroxychloroquine complications will be assessed by QT corrected by Bazett formula. If QTc > 500 ms could be randomized to ivermectin or placebo.
89626216|NCT04390893|Experimental|ultrasound positioning group|
89626217|NCT04390893|Active Comparator|leak test positioning group|
89626218|NCT01459731||Age 18-29|
89211125|NCT05280288|No Intervention|The control group (Standard care)|No intervention. This arm will continue standard clinical practice consisting of clinical assessment regarding side effects and management under follow-up having usual care alone conducted by physicians and therefore not able to use the app Bone@BC in any versions (access denied).
89211126|NCT05280288|Experimental|The intervention group|Intervention: This arm will be assigned to the intervention which will be that the participants will be invited to become active users of the app Bone@BC version 4.0 combined with usual care alone.
89626219|NCT01459731||Age 30-39|
89626220|NCT01459731||Age 40-49|
89626221|NCT01459731||Age 50-59|
89626222|NCT01459731||Age 60-69|
89626223|NCT01459731||Age 70+|
89626224|NCT01892475|Experimental|Cash Only (CO)|As part of the Incentive-based physical activity program, drivers assigned to the Cash Only (CO) arm will earn incentives in the form of cash for meeting specified monthly step goals from Months 1 to 4.
89626225|NCT01892475|Experimental|Mental-Accounting (MA) based|As part of the Incentive-based physical activity program, drivers assigned to the Mental-Accounting (MA) based arm will receive incentives in the form of taxi rental credits for meeting specified monthly step goals from Months 1 to 4.
89626226|NCT01892553|Experimental|motor/premotor cortex stimulation|Active and sham tDCS applied over the motor/premotor cortex
89626227|NCT01892553|Experimental|insular cortex stimulation|Active and sham tDCS applied over the insular cortex
89626228|NCT01459809|Experimental|ARM 1: glimepiride alone|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if Fasting Plasma Glucose (FPG) at baseline < 180 mg/dL (10 mmol/L) taken once in the morning before breakfast. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg, and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
89626229|NCT01459809|Experimental|ARM 2: metformin alone|24-week treatment period: After randomization, starting dose will be of 500 mg of metformin twice a day during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 2000 mg, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
89626230|NCT01459809|Experimental|ARM3: Glimepiride/metformin free combination|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if FPG at baseline < 180 mg/dL (10 mmol/L) taken once in the morning and 500 mg of metformin twice a day taken during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg of glimepiride and 2000 mg of metformin, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain values ≤.
89626231|NCT01459887|Experimental|combination group|
89626232|NCT01459887|Experimental|sequential group|
89626233|NCT01892631|Other|Standard care|Practices in the standard care arm will proceed with their seasonal influenza campaign as planned.
89626234|NCT01892631|Experimental|Text messaging intervention|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
89626235|NCT01890057|Experimental|Young adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
89039099|NCT04683744||Healthcare system leadership, providers, and staff|Leadership, providers, and staff at the study team's affiliated health systems.
89211127|NCT02549300|No Intervention|Control Group|15 patients will be included in control group. Control group will just receive advices about life style modifications, such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.
89211128|NCT02549300|Experimental|Study Group|15 patients will be included in study group. Study group will be treated with connective tissue massage in addition to life style modifications (such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.). Connective tissue massage will be applied 5 times a week, totally 20 sessions in a month. Each session lasts approximately 20-30 minutes. Connective tissue massage will be applied on basic part, lower thoracic, scapular, inter scapular and neck regions.
89211129|NCT00930618|Experimental|IMN|Isosorbide mononitrate
89626236|NCT01890057|Experimental|Elderly adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
89626237|NCT01890135|Active Comparator|endothelin receptor antogonist|10 mg of zibotentan
89626238|NCT01890135|Placebo Comparator|placebo|matched placebo
89626239|NCT02876211|Experimental|paricalcitol plus epoetin beta|Paricalcitol 2 capsules /three times per week & epoetin
89626240|NCT02876211|Placebo Comparator|placebo plus epoetin beta|Placebo 2 capsules/three times per week & epoetin
89039100|NCT04683744||Patients receiving primary care at the study team's affiliated health systems|Patients who had a least one primary care visit during the past 24 months at the study team's affiliated health care systems.
89039101|NCT02710643|No Intervention|MRD - BEFORE RT|Patients who had negative baseline Bcl-2 in PB and BM will not undergo further treatment after radiotherapy; they will not repeat Bcl-2 during subsequent follow-up visits.
89039102|NCT02710643|No Intervention|MRD + BEFORE RT AND MRD - AFTER RT|Patients who had positive baseline Bcl-2 in PB and / or BM and become negative after local radiotherapy will not undergo further treatment.
89626241|NCT05587023|Experimental|Test group|the test group was injected with 0.5% ropivacaine 6ml.
89626242|NCT05587023|Placebo Comparator|Control group|The control group was injected with 6ml normal saline
89626243|NCT01890213|Experimental|Vaccine|AVX701 Vaccine:4 x 10EE8 IU intramuscularly every 3 weeks for 4 total immunizations
89626244|NCT02681601|Active Comparator|Diet + Nutrawell Powder with Fish Oil|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) including Nutrawell powder with fish oil.
89626245|NCT02681601|Active Comparator|Dietary Intervention Only|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) not including servings of Nutrawell powder with fish oil.
89626246|NCT01892787|Experimental|Formoterol (Atimos Modulite)|Atimos Modulite 1 puff (12 micrograms) twice a day
89626247|NCT01892787|Active Comparator|Salmeterol (Serevent Accuhaler)|Serevent Accuhaler 1 puff (50 micrograms) of twice a day
89626248|NCT01892943||Patients with LHON|
89626249|NCT01893723|Experimental|ANI guided remifentanil arm|remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.
89626250|NCT01893723|Other|ANI blind arm|remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.
89626251|NCT01453959|Other|Diet cycles|The patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days). After 4 weeks without any intervention, the patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days.
89626252|NCT01453959|Other|Fludrocortisone|The patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days. After 4 weeks without any intervention, the patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days).
89626253|NCT02669901|Other|Patients with opioid substance abuse disorders|All participants will receive Naloxone autoinjector as a preventative tool for accidental opioid overdose
89626254|NCT01755767|Experimental|Tivantinib 240 mg BID Cohort|The tivantinib dosage of 240 mg tablets administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 480 mg.
89626255|NCT01755767|Experimental|Tivantinib 120 mg BID Cohort|Tivantinib 120 mg is administered by oral tablet BID, once in the morning and once in the evening, with food, for a total daily dose of 240 mg (amended dosing group; primary analysis group).
89626256|NCT01755767|Placebo Comparator|Placebo Matching 240 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
89626257|NCT01755767|Placebo Comparator|Placebo Matching 120 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
89626258|NCT05023707|Experimental|CAR-T infusion|FLT3 positive relapsed or refractory acute myeloid leukemia
89626259|NCT01893021||Postpartum Malawian women|
89626260|NCT01893099|Experimental|Sorafenib- Cohort 1|Sorafenib 400 mg BID will be started 14 days after the administration of SIRT with SIR-Sphere®.
89626261|NCT01893099|Experimental|Sorafenib- Cohort 2|Sorafenib 400 mg BID will be started 11 days after the administration of SIRT with SIR-Sphere®.
89626262|NCT01893099|Experimental|Sorafenib- Cohort 3|Sorafenib 400 mg BID will be started 3 days after the administration of radioembolization with SIR-Sphere®.
89626263|NCT01893099|Experimental|Sorafenib- Cohort 4|Sorafenib 400 mg BID will be started 7 days prior to the administration of radioembolization with SIR-Spheres® and be given continuously, without drug holidays.
89626264|NCT05586633|Active Comparator|deep paravertebral- periforaminal ozone injection|
89626265|NCT05586633|Active Comparator|transforaminal steroid injeciton|
89626266|NCT02327403|Experimental|Proteinuric Kidney Transplant Recipients|Belatacept conversion
89626267|NCT02372877|Experimental|Amicus Red Cell Exchange in SCD patients|Open arm. Patients with sickle cell disease (SCD) treated using one Amicus Red Cell Exchange procedure.
89626268|NCT01893177|Experimental|Elderly subjects aged over 60 years|
89626269|NCT01893177|Experimental|Adults from 18 to 60 years old inclusive|
89626270|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 1|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
89626271|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 2|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
89626272|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose X|Double-Blind, Once-Daily, 2-Day Treatment
89626273|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose Y|Double-Blind, Once-Daily, 2-Day Treatment
89626274|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose XX|Double-Blind, Once-Daily, 2-Day Treatment
89626275|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose YY|Double-Blind, Once-Daily, 2-Day Treatment
89626276|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 1|Double-Blind, Once-Daily, 2-Day Treatment
89626277|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 2|Double-Blind, Once-Daily, 2-Day Treatment
89626278|NCT02655393|Experimental|Mitopure 250 mg single dose|single dose of Mitopure soft gel capsules at 250 mg dose, n=8 subjects (6 Active, 2 Placebo)
89626279|NCT02655393|Experimental|Mitopure 500 mg single dose|single dose of Mitopure soft gel capsules at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
89626280|NCT02655393|Experimental|Mitopure 1000 mg single dose|single dose of Mitopure soft gel capsules at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
89626281|NCT02655393|Experimental|Mitopure 2000 mg single dose|single dose of Mitopure soft gel capsules at 2000 mg dose, n=8 subjects (6 Active, 2 Placebo)
89626282|NCT02655393|Experimental|Mitopure 500 mg single dose-Food Effect|single dose of Mitopure admixed in yoghurt at 500 mg dose, n=8 subjects (6 Active, 2 Placebo)
89626283|NCT02655393|Experimental|Mitopure 1000 mg single dose-Food Effect|single dose of Mitopure admixed in yoghurt at 1000 mg dose, n=8 subjects (6 Active, 2 Placebo)
89626284|NCT02655393|Experimental|Mitopure 250 mg multiple dose|Repeated 28 day dosing of Mitopure soft gel capsules at 250 mg dose, n=12 subjects (9 Active, 3 Placebo)
89211130|NCT00930618|Placebo Comparator|Placebo|Administration of placebo of IMN
89211131|NCT00936780|Experimental|Infinnium-Core™ Paclitaxel eluting Coronary Stent|
89211132|NCT00823550|Experimental|A|entecavir 0.5 mg QD
89211133|NCT00823550|Active Comparator|B|lamivudine 100 mg QD
89626285|NCT02655393|Experimental|Mitopure 500 mg multiple 28 day dose|Repeated 28 day dosing of Mitopure soft gel capsules at 500 mg dose, n=12 subjects (9 Active, 3 Placebo)
89626286|NCT02655393|Experimental|Mitopure 1000 mg multiple 28 day dose|Repeated 28 day dosing of Mitopure soft gel capsules at 1000 mg dose, n=12 subjects (9 Active, 3 Placebo)
89626287|NCT02360943||PEAGE|Patients older than 75 years receiving an anticoagulant treatment for a symptomatic and confirmed PE
89626288|NCT01922986|Experimental|Active rTMS with conventional therapy|20 minutes of active rTMS followed by conventional stroke therapy
89626289|NCT01922986|Sham Comparator|sham rTMS with conventional therapy|20 minutes of sham rTMS stimulation followed by conventional stroke therapy
89626290|NCT05740150|Experimental|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|
89626291|NCT05740150|Active Comparator|Heparin lock (heparin 100 IU/mL)|
89626292|NCT02359383|Active Comparator|Chest Physiotherapy group|Conventional medical treatment plus Chest Physiotherapy
89626293|NCT02359383|No Intervention|Control grup|Conventional medical treatment
89626294|NCT05734612|Experimental|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
89626295|NCT05734612|Placebo Comparator|Placebo|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
89626296|NCT01893255||Cohort|
89626297|NCT02349867|Experimental|Treatment (chemotherapy, chemoradiation)|Participants receive gemcitabine IV infusion over 30 minutes (200 mg/m2 weekly) x 6, concurrent administration of oral sorafenib and oral vorinostat (both per dose-escalation schema), and concurrent RT( 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy) administered at 1.8-Gy fractions to a total dose of 50.4 Gy over 5 ½ weeks (28 daily fractions).
89626298|NCT01924390|Active Comparator|mineralized FDBA alone|Socket grafting with mineralized freeze-dried bone allograft alone
89626299|NCT01924390|Experimental|Combination of mineralized and deminieralized FDBA|Socket grafting with a combination of mineralized and demineralized freeze-dried bone allograft alone
89626300|NCT01730339|Active Comparator|Group 1|
89211134|NCT00937014|Active Comparator|Standard infant formula|
89211135|NCT00937014|Experimental|Test formula|
89626301|NCT01730339|Active Comparator|Group 2|
89626302|NCT01925404|Experimental|Frequent User Arm|Park users will be able to earn rewards or prizes by coming more frequently to the park
89626303|NCT01925404|Experimental|Free Physical Activity Classes/programs|We will offer at least 100 free physical activity classes at the park
89626304|NCT01925404|Experimental|Combined arm|We will offer free classes and the frequent user program at the park
89626305|NCT01925404|No Intervention|Control|Business as usual, no special physical activity programs offered
89626306|NCT05734534|Experimental|BFR-ST and BFR-HIT|Participants will be allocated to a BFR intervention including resistance training and high-intensity intervals performed on a bicycle ergometer, both performed with BFR.
89211136|NCT00828152|Experimental|1|Internet-delivered CBT. Contact with therapist thru an e-mail system. 12 weeks.
89626307|NCT05734534|Active Comparator|HL-ST and HIT|Participants will be allocated to heavy load resistance training and high-intensity intervals performed on a bicycle ergometer, both performed without BFR
89626308|NCT05734534|Experimental|BFR-P|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will be allocated to application of BFR twice daily throughout their hospitalization. Participants are resting in a supine position throughout the application of BFR.
89626309|NCT05734534|Experimental|BFR-NMES|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will be allocated to application of BFR with neuromuscular electrical stimulation (BFR-NMES) twice daily throughout their hospitalization. Participants are resting in a supine position throughout the application of BFR-NMES.
89626310|NCT05734534|Active Comparator|Control group|Participants with COPD experiencing an acute exacerbation of their COPD requiring hospitalization will allocated to usual care, consisting of daily physiotherapy sessions.
89626311|NCT02629419|Experimental|CAMB (Encochleated Amphotericin B)|Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
89626312|NCT05740072|Experimental|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
89626313|NCT05740072|Active Comparator|No drying before wrapping|Immediately after birth, the infant will be wrapped in a plastic bag without drying
89211137|NCT00828152|Placebo Comparator|2|On line discussion group.
89211138|NCT00932100|Experimental|REG1-a|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
89211139|NCT00932100|Experimental|REG1-b|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
89211140|NCT00932100|Experimental|REG1-c|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
89211141|NCT00932100|Experimental|REG1-d|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
89211142|NCT00932100|Active Comparator|Heparin|Heparin per standard of care at the local institution
89211143|NCT00828230|Experimental|1|2mg rectal budesonide per day for 8 weeks
89211144|NCT00828230|Placebo Comparator|2|One application of placebo foam once daily for 8 weeks
89626314|NCT02334735|Experimental|DC Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptide-pulsed DCs:~DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) and KLH will be administered intracutaneous as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
89626315|NCT02334735|Active Comparator|Montanide Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptides and Montanide® ISA-51 VG:~Vaccine consisting of NY-ESO-1 peptide, Melan-A/MART-1 peptide, and KLH with an oil phase containing Montanide ISA-51 VG adjuvant will be administered subcutaneously as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
89626316|NCT02329600|No Intervention|control subjects|10 systemically healthy control subjects taking no medication.
89626317|NCT02329600|Active Comparator|OLP and corticosteroid|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.
89626318|NCT02329600|Experimental|OLP and corticosteroid and green tea|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.
89626319|NCT02620761|Placebo Comparator|Control|Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
89626320|NCT02620761|Experimental|Fenoldopam|Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.
89626321|NCT01754753|Active Comparator|Telephone friendship groups|"Participants allocated to telephone friendship groups will take part in 12 weekly group telephone discussions. The participant will be called, by a trained Age UK Sheffield volunteer, in their own home. The group discussions will take place for about an hour each week and involve between 6-8 participants. Participants will be introduced to weekly group calls by the volunteer who will call each participant individually for around 20 minutes each week for up to six weeks before the group is established.~The group may have a particular focus or talk about different topics each week. The individual participants are joined together through a teleconferencing system (provided by Community Network)."
89626322|NCT01754753|No Intervention|Usual health and social care|Participants allocated to the control arm will not receive any research intervention. However, they will participate in the research by completing questionnaires about their health and wellbeing.
89626323|NCT04758273|Experimental|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
89626324|NCT04758273|Experimental|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
89626325|NCT04758273|Placebo Comparator|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
89626326|NCT04758273|Experimental|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
89626327|NCT04758273|Experimental|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
89211145|NCT02548988|Experimental|Healthy|Healthy women are submitted to selective neuromuscular electrical stimulation on VMO.
89626328|NCT04758273|Placebo Comparator|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
89626329|NCT04758273|Experimental|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
89626330|NCT04758273|Experimental|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
89626331|NCT04758273|Placebo Comparator|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
89626332|NCT02613273|Experimental|Experimental: Arm 1 (Aerobic Exercise)|Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
89626333|NCT02613273|Experimental|Experimental: Arm 2 (Resist. Exercise)|Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
89626334|NCT02613273|No Intervention|No Intervention: Arm 3 (Control)|Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
89626335|NCT01729871|Experimental|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
89626336|NCT01729871|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
89626337|NCT02611323|Experimental|Dose-Escalation Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and venetoclax when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
89626338|NCT02611323|Experimental|Dose-Escalation Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at escalating doses to identify the RP2D of venetoclax when combined with fixed doses of polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
89626339|NCT02611323|Experimental|Expansion Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at the RP2D identified during the dose-escalation phase, in addition to obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
89211146|NCT02548988|Experimental|Patellofemoral pain syndrome|Women with patellofemoral pain syndrome are submitted to selective neuromuscular electrical stimulation on VMO.
89626340|NCT02611323|Experimental|Expansion Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at the RP2D identified during the dose-escalation phase, in addition to polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
89626341|NCT02608359||Abiraterone Acetate (Zytiga) Post-marketing Surveillance (PMS)|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
89626342|NCT01729559|Experimental|5000 Units unfractionated Heparin Q 8 hr|Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
89626343|NCT01729559|Active Comparator|30mg enoxaparin Q12 hr|Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
89626344|NCT01893333|Experimental|Nerve sparing radical hysterectomy group|"sparing hypogastric nerve~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
88989954|NCT04519970|Active Comparator|Middle Tier of Case Management (Got Your Back) and Biktarvy|The middle tier (Got Your Back) will work closely with the CORE case managers to augment their work in housing support, transportation assistance, mental healthcare referrals, childcare assistance, substance use program referrals, food insecurity support and health insurance needs. The retention specialist will additionally provide this middle tier 2 reminders for appointments; check ins once per week; follow ups for missed appointments or off pill counts; support with scheduling appointments for limited availability; meetings with the health educators for information on HIV or ART; and re-motivation for treatment at the 6 and 9 month marks of participation.
89626345|NCT01893333|Active Comparator|Radical hysterectomy group|Conventional radical hysterectomy
89626346|NCT01926496|Experimental|Ingenol Mebutate|Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8
89626347|NCT01926496|Active Comparator|Imiquimod|Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8
89626348|NCT05739916|Experimental|Sequence A(Before→ After)|
89626349|NCT05739916|Experimental|Sequence B(After→ Before)|
89626350|NCT01728779|Experimental|Nelfinavir w/Stereotactic Body Radiation Therapy (SBRT)|Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
88989955|NCT04519970|Active Comparator|Lowest Tier of Case Management (Backbone) and Biktarvy|The top tier (Backbone) will need the least amount of support and also have a CORE Center case manager for a majority of the support in housing, food, insurance, transportation, childcare, substance use, and mental healthcare. The retention specialist will still provide an appointment reminder; check ins every other week; text checkups after missed appointments or off pill counts; support with scheduling for appointments or prescription pick up for limited availability; and re-motivation of treatment for HIV at the 9 month mark of study participation.
88989956|NCT04514406||APERTO OTW DCB|Dialysis patients treated with APERTO OTW following (re)stenosis of central veins
88989957|NCT04513717|Active Comparator|Arm I (de-intensification study)|Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity.
88989958|NCT04513717|Experimental|Arm II (de-intensification study)|Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity.
88989959|NCT04513717|Active Comparator|Arm III (intensification study)|Patients undergo RT over 2-11 weeks and receive ADT as in Arm I.
88989960|NCT04513717|Experimental|Arm IV (intensification study)|Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide PO QD. Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity.
88989961|NCT04494698|Active Comparator|DuoTherm VibraCool Back Device|A low back pain relief device incorporating multiple speeds and patterns of vibration and optional heat, cold, or pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice daily for 20 minutes.
88989962|NCT04494698|Active Comparator|Multimodal TENS Unit|LG SMART TENS stimulator is a portable electrotherapy device featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
88989963|NCT04491175|Active Comparator|DuoTherm|A low back pain relief device incorporating 8 harmonic patterns of mechanical stimulation (vibration) capable of neuromodulatory nociceptor block and vasodilation, and optional heat, cold, and pressure delivered through a sculpted metal plate attached with a belt and controlled by buttons on the belt. Patients will be instructed to use the device twice a day for 20 minutes.
88989964|NCT04491175|Active Comparator|Multimodal TENS|An 8-channel TENS unit (LG Smart). Patients will be instructed to use the TENS twice a day for 20 minutes.
88989965|NCT04475731|Experimental|Experimental arm|"MRD+ Ph+ ALL adult patients will receive Ponatinib x 4 weeks x 3 courses; +/-Concomitant chemotherapy (according to hematologic status).~Patients will receive the study drug until disease relapse or progression."
89626351|NCT01927120|Experimental|GVHD Regimen|Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).
89626352|NCT05586867||Hemodialysis patient|
89626353|NCT01728623|Experimental|E7080|
89626354|NCT05586399|Experimental|Exercise intervention|Participants performing a rehabilitation program for 5 times a week in a total of 4 weeks in one of two rehabilitation centers in Trondheim, Norway. The aim is to perform a total of 20 maximal strength training interventions supervised by one or more health professionals. Maximal strength training will be performed with 4 repetitions and 4 series at 90-95% of one repetition maximum.
89626355|NCT02585349||First-ever and recurrent ischemic and hemorrhagic stroke|First-ever and recurrent ischemic and hemorrhagic stroke patients are enrolled in the study. Recurrent strokes are only included if the patient is fully recovered from the previous event, which occurred at least 3 years ago, without obvious residual symptoms.
89039103|NCT02710643|Experimental|MRD + BEFORE RT AND MRD + AFTER RT|"Patients who had positive baseline Bcl-2 in PB and / or BM and remain positive after local radiotherapy get Ofatumumab (8 weekly infusion of 1000 mg total dose).~Patients Bcl-2 negativized either after radiotherapy or after Ofatumumab, who became Bcl-2 positive during the follow-up monitoring will be treated/retreated with Ofatumumab 8 weekly infusions at the conventional dose of 1000 mg; Bcl-2 monitoring will be continued subsequently according to the program.In case of persistent positive PCR after Ofatumumab the treatment will not be repeated."
89039104|NCT05093205|Experimental|Part A|To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of atorvastatin (20 mg tablet) and midazolam (5 mg syrup).
89039105|NCT05093205|Experimental|Part B|To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of an Oral Contraceptive (Levonorgestrel 0.15 mg and Ethinyl Estradiol 0.03 mg tablet).
89039106|NCT00552981|Active Comparator|1|
89039107|NCT00552981|Sham Comparator|2|
89039108|NCT02623751|Experimental|KHK2375 PO and Exemestane PO|KHK2375 and Exemestane
89039109|NCT02469155|Experimental|20 mg ITI-007|20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
89039110|NCT02469155|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
89039111|NCT02469155|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
89039112|NCT02469155|Active Comparator|Risperidone|Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
89039113|NCT02465606|Experimental|Group 1: Lebrikizumab Dose Level 1 Monotherapy|During the 2-week run-in period, participants will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 12-week treatment period, lebrikizumab monotherapy will be administered by subcutaneous (SC) injection, but participants assigned to this group will not receive topical corticosteroids. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
89039114|NCT02465606|Active Comparator|Group 2: Topical Corticosteroid Creams Only|During the 2-week run-in period and during the 12-week treatment period, participants assigned to this group will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
89039115|NCT05080530|No Intervention|1. Normal Vit D (> 30ng/mL)|Follow-up after 3 months with standard treatment
89039116|NCT05080530|Experimental|2. Insufficient Vit D (20-30ng/mL)|single oral dose capsule 200,000 IU of Cholecalciferol
89039117|NCT05080530|No Intervention|3. Insufficient Vit D (20-30ng/mL)|Follow-up after 3 months with standard treatment
89039118|NCT05080530|Experimental|4. Deficient Vit D|single oral dose capsule 200,000 IU of Cholecalciferol
89626356|NCT01754129||Participants with Parkinson's disease|Participants with advanced levodopa-responsive Parkinson's disease and severe motor fluctuations and hyper-/dyskinesia who were prescribed and treated in accordance with the local levodopa/carbidopa intestinal gel product label
89626357|NCT02573337|Experimental|Intradermal injection|Emervel Classic Lidocaine and/or Emervel Deep Lidocaine
89626358|NCT02781363|Other|Candidates patients chest X-ray with pneumonia|thoracic sonography CXR Clinical control 48h
89626359|NCT02781363|Other|Candidates patients chest X-ray without pneumonia|thoracic sonography CXR Clinical control 48h
89626360|NCT04757727||EDB|Adult women (> 18 years old) with hereditary dystrophic epidermolysis bullosa (dominant or recessive) followed at the Nice University Hospital or at the St Louis Hospital of the APHP
89039119|NCT00554177|Experimental|1|Medicane (mifepristone)
89039120|NCT00554177|Placebo Comparator|2|Placebo
89039121|NCT03487692|Experimental|2018 Training Cohort|10 health centers will be randomized to the 2018 Training Cohort. Teams from these health centers will be trained and will implement a 6 month diabetes group visit and text messaging intervention (Diabetes MESSAGES Program).
89039122|NCT03487692|Other|2020 Training Cohort|10 health centers will be randomized to the 2020 Training Cohort. Prior to beginning training, these health centers will collect data on randomly selected patients receiving usual care to serve as the control group. After this first parallel group trial period, teams from these health centers will be trained and will implement the 6 month diabetes group visit and text messaging intervention during a second single group trial period (Diabetes MESSAGES Program (second trial)).
89039123|NCT02456675|Experimental|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
89626361|NCT01728077|Experimental|Brivaracetam|At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.
89626362|NCT04757181|Experimental|IBD patients|IBD patients will be used as their own control. Participants will start the study in a baseline phase (4 weeks) and intervention phase (8 weeks)
89626363|NCT02307279|Experimental|Gelesis100|Gelesis100 twice daily
89626364|NCT02307279|Placebo Comparator|Placebo|Matching placebo twice daily
89626365|NCT01606007|Active Comparator|Arm 1: Saxagliptin+Metformin XR+Placebo|
89626366|NCT01606007|Active Comparator|Arm 2: Dapagliflozin+Metformin XR+Placebo|
89626367|NCT01606007|Experimental|Arm 3: Saxagliptin+Dapagliflozin+Metformin XR|
89626368|NCT02301819|Active Comparator|Invasive|Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)
89626369|NCT02301819|Active Comparator|Conservative|Early conservative therapy according to standard practice
89626370|NCT02300883||no treatment|no treatment
89626371|NCT01928290|Experimental|Arm A: FOLFIRINOX (HER2-negative)|"Irinotecan 180 mg/m2 IV on Days 1 & 15.~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.~Leucovorin 400 mg/m2 IV on Days 1 & 15.~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
89626372|NCT01928290|Experimental|Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)|"Trastuzumab 8 mg/kg on Cycle 1 Day 1 then 4 mg/kg on Day 15 and Day 1 of all future cycles.~Irinotecan 180 mg/m2 IV on Days 1 & 15.~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.~Leucovorin 400 mg/m2 IV on Days 1 & 15.~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
89626373|NCT04272177|Experimental|SDM group|Shared decision making using PDAs. PDAs is used as a tool explain the advantages and disadvantages of the traditional reversal drugs and sugammadex. And by following SDM principles, the patients are guided to consider their individual values and preferences and helped to make a choice that best meet their needs.
89626374|NCT04272177|No Intervention|Control group|Current approach to explain details of anesthesia using a single introductory sheet made by the two hospitals or provided by the pharmaceutical companies is used.
89626375|NCT01893489|Active Comparator|Atherosclerosis|coronary artery disease patients with carotid plaques confirmed by a ultrasound study
89626376|NCT01893489|Sham Comparator|control|no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
89626377|NCT01894113|Active Comparator|transbronchial forceps lung biopsy|transbronchial lung biopsy forceps
89626378|NCT01894113|Active Comparator|transbronchail cryo lung biopsy|transbronchial lungbiopsy with cryoprobe
89626379|NCT02772939|Experimental|Renal Denervation|Renal denervation for therapy resistant arterial hypertension
89626380|NCT02282319|Experimental|A chloro|spinal chloroprocaine 40 mg
89626381|NCT02282319|Experimental|B chloro+ spin dexdor|Spinal chloroprocaine 40 mg spinal dexmedetomidine 0.5 mcg
89626382|NCT02282319|Experimental|C chloro + IV dexdor|Spinal chloroprocaine 40 mg IV dexmedetomidine 0.5 mcg/kg
89626383|NCT02281695|Active Comparator|Arm A|"Patients that are mechanically ventilated for less than 24 hours until the weaning process can be started.~At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen."
88989966|NCT04474483|Placebo Comparator|Control|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
89039124|NCT02456675|Experimental|INCB040093 and itacitinib (INCB039110) Combination Therapy|Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets. The dose of itacitinib will be orally given once daily (QD). Doses should be taken in the morning on an empty stomach if possible.
89039125|NCT02456480|Experimental|CLS001 topical gel, 2.5%|
89626384|NCT02281695|Active Comparator|Arm B|Patients that are mechanically ventilated for more than 24 hours until the weaning process can be started. At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen.
89626385|NCT02278965|Experimental|Main Arm|Open Label- Metformin and Omega-3 fatty acids for 12 months post baseline data collection.
89626386|NCT02514837||Temperature measured by RTM device|Both the internal temperature and skin temperature will be measured non-invasively through the skin.
89626387|NCT02757339||Women with History of Childhood Abuse|The study will enroll up to 140 female patients with either DID or PTSD ages 18-89
89626388|NCT02757339||Healthy Control Group|We will recruit up to 60 control subjects matched for demographics (age, race, gender).
89626389|NCT01928446|Experimental|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
89626390|NCT01928446|Placebo Comparator|Placebo|Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study
89626391|NCT02983149|Other|Double lumen tube|One lung ventilation will be achieved using a double lumen tube
89039126|NCT02456480|Experimental|CLS001 topical gel 1%|
89039127|NCT02456480|Placebo Comparator|Vehicle gel|
89039128|NCT03425565|Experimental|Pembrolizumab|
89039129|NCT04678700|Experimental|Experimental groupe|"Intervention; 10 sessions telematics. Before starting and at the end of the respiratory physiotherapy program, the patient complete an online form which includes a quality of life questionnaire, an effort dyspnea questionnaire and an anxiety questionnaire.~The intervention of the following study follow the recommendations of chest physiotherapy in the management of the patient post covid-19 (1)(17).~Pre-session; respiratory frequency, dyspnea, oxigenation level are taken. Breathing techniques;~Abdominal-diaphragmatic breathing(1)(16). (10 times).~Costal expansion exercises with flexion and abduction of the upper limbs. (10 times)(1).~Self-passive stretching of the ribcage and neck muscles, accessory to inspiration(25)(26).~Jacobson's progressive relaxation(27). Post-session, respiratory frequency and the Borg's dyspnea index/ oxigenation level."
89039130|NCT04678700|Other|control groupe|The control group will complete the same questionnaires before and after the intervention, which will give us an idea of whether our intervention has had any improvement. In order for all patients to be able to receive the therapy if they want to. The control group will be on the waiting list to perform the sessions.
89626392|NCT02983149|Other|Fuji blocker|One lung ventilation will be achieved using the Fuji blocker
89626393|NCT02983149|Other|EZ blocker|One lung ventilation will be achieved using the EZ blocker
89626394|NCT02983383|Active Comparator|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
89626395|NCT02983383|Active Comparator|Group without TAP (Group P)|Patients in Group P will have adjuvant added to spinal anesthesia.
89626396|NCT02987296|Active Comparator|Immunonutrition with arginine|Patients will receive the nutritional supplement for 5 days prior to surgery and for 5 days after. The drink will contain arginine.
89626397|NCT02987296|Placebo Comparator|Immunonutrition without arginine|This group of patients will also receive a nutritional drink but containing no arginine for 5 days before surgery and for 5 days after surgery.
89626398|NCT02748369|No Intervention|Control Group|No somatostatin and glucagon infusions
89626399|NCT02748369|Active Comparator|Intervention Group|Somatostatin and glucagon infusions
89626400|NCT01928524|Experimental|DOS2W Dose level 1A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
89626401|NCT01928524|Experimental|DOS2W Dose level 2A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
89626402|NCT01928524|Experimental|DOS2W Dose level 3A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
89626403|NCT01928524|Experimental|DOS2W Dose level 4A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
89626404|NCT01928524|Experimental|DOS3W Dose level 1B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
89626405|NCT01928524|Experimental|DOS3W Dose level 2B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
89626406|NCT01928524|Experimental|DOS3W Dose level 3B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
89626407|NCT05739760|Experimental|"Families assigned the Cuddle and Calm booklet"|A poem about emotional expression in times of upset
89626408|NCT05739760|Experimental|"Families assigned the Health and Safety booklet"|A poem about health and safety with tips on topics such as first aid and injury prevention
89626409|NCT01894191|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
89626410|NCT01894191|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy.
89626411|NCT01894191|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
89626412|NCT01928680|Experimental|Cisplatin/Capecitabine|"Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.~This is a single arm phase II clinical trial."
89626413|NCT02488785|No Intervention|Control|Patients in this group will attend regular clinical and education appointments as offered by the clinic for their diabetes care.
89626414|NCT02488785|Experimental|Intervention|Patients in this group will be part of a Virtual Diabetes Self-Care and Education Program. They will receive a phone to communicate with a diabetes educator for 6 months. They will connect with the diabetes educator for weekly video conferences of up to 30 minutes for twelve consecutive weeks, followed by 7 phone calls. Additionally, they will receive a weekly text message about diabetes for 6 months.
89039131|NCT05073627|No Intervention|Baseline|The investigators measure the baseline of dicloxacillin and the probe drug dabigatran etexilate.
89039132|NCT05073627|Experimental|Dicloxacillin treatment|The investigators measure the concentration of dicloxacillin after 9 and 27 days and the concentration of dabigatran after 10 and 28 days of continuously taking dicloxacillin.
89039133|NCT05050695||Subjects with unilateral chronic low back pain|Subjects with low back pain for more than 3 months on one side of the spine
89039134|NCT05050695||Healthy subjects|Subjects without a history of low back pain
89039135|NCT04678739|Experimental|Group A: Remdesivir + Tocilizumab treatment group|"Drug: Remdesivir Injectable solution Tocilizumab Injectable solution A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (>40kg) daily following randomization.~Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart."
89039136|NCT04678739|No Intervention|Group B: Control group|Treatment as given without Remdesivir and Tocilizumab.
89039137|NCT00554333|Experimental|1|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
89626415|NCT01929460|Other|Drug (Standard group)|"Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.~Ciprofloxacin 500mg by mouth twice a day for three days."
89626416|NCT01929460|Placebo Comparator|Intervention group|"Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration~Oral Placebo, one cap twice a day for three days."
89626417|NCT02249169||IBS-C|Patients with a clinical diagnosis of constipation-predominant irritable bowel syndrome
89626418|NCT02249169||IBS-D|Patients with a clinical diagnosis of diarrhea-predominant irritable bowel syndrome
89626419|NCT02249169||Healthy subjects|Subjects without a clinical diagnosis of IBS-C or IBS-D
89626420|NCT02249169||Healthy Controls|Subject without a clinical diagnosis of IBS-C or IBS-D and who is either a first-degree relative of an IBS participant or is not genetically related but resides with the IBS participant
89626421|NCT03029416|Experimental|Single Fraction of SBRT|Stereotactic Body Radiation Therapy delivered in a single session on one day
89626422|NCT03029416|Experimental|Fractionated SBRT|Stereotactic Body Radiation Therapy delivered in three to five fractions with one fraction delivered every other day
89626423|NCT01753193|Experimental|Anifrolumab|Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
89626424|NCT02477163|Experimental|single group|Patients of chronic renal failure
89626425|NCT02470377|Experimental|Target 1: Occipital Cortex|After determination of the motor threshold, the TMS coil will be positioned over the midline occipital cortex using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
89626426|NCT02470377|Experimental|Target 2: Cerebellar Vermis|After determination of the motor threshold, the TMS coil will be positioned over the midline cerebellar vermis using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
89626427|NCT02470377|Active Comparator|Target 3: Cerebellar Hemisphere|After determination of the motor threshold, the TMS coil will be positioned over the lateral cerebellar hemisphere using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
89626428|NCT02283814|Experimental|Group A BIA 2-093 + Topamax|"Group A~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days~Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days"
89626429|NCT02283814|Experimental|Group B BIA 2-093 + Topamax|"Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;~Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;~Treatment: 200 mg once daily dose of TPM administered for four consecutive days;~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days"
89626430|NCT02737293|Experimental|Control Diet|Menu based on the average American diet.
89626431|NCT02737293|Experimental|Med Diet|Menu based on the typical Mediterranean diet (Med Diet) pattern.
89626432|NCT02737293|Experimental|Med Diet + Whole Egg|Menu based on the typical Mediterranean diet (Med Diet) pattern with the addition of 1 whole egg per 1000 kilocalories.
89626433|NCT02231697||XLMTM patients - deceased|Non-interventional, retrospective medical chart review
89626434|NCT02231697||XLMTM patients - living|Non-interventional, retrospective medical chart review
89626435|NCT02466009|Experimental|Regorafenib|"120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)~Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (< 30% fat) breakfast."
89211147|NCT04469556|Active Comparator|Modified Folfirinox|"Modified FOLFIRINOX (Folinic acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin) administered intravenously.~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
89626436|NCT05739604||Survivors|Patients hospitalized in the Department of Anaesthesiology and Intensive Care with sepsis or septic shock, undergoing continuous renal replacement therapy due to acute kidney injury, in whom the outcome of treatment was survival.
89626437|NCT05739604||Nonsurvivors|Patients hospitalized in the Department of Anaesthesiology and Intensive Care with sepsis or septic shock, undergoing continuous renal replacement therapy due to acute kidney injury, in whom the outcome of treatment was fatal.
89626438|NCT02462421|Active Comparator|Wild type genotype|Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
89626439|NCT02462421|Experimental|Nonsense mutation in SLC5A4|Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
89626440|NCT02462421|Experimental|Nonsense mutation in SLC5A9|Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
89626441|NCT02462421|Experimental|Missense variant in SLC2A9|Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.
89626442|NCT02727387|Experimental|TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL|2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for<14 years old ,800 mg/die for>14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for<14 years old, 50 mg/m2 for>14 years old)
89626443|NCT01727297|Other|REVEAL Implantable Cardiac Monitor|
89626444|NCT05583357|Experimental|Cohort 1|
89626445|NCT05583357|Experimental|Cohort 2|
89626446|NCT05583357|Active Comparator|Cohort 3|
89626447|NCT05583357|Active Comparator|Cohort 4|
89626448|NCT05726968|Active Comparator|● Group P1 (N 15)|Patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
89626449|NCT05726968|Active Comparator|● Group P2 (N 15)|Patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).
89626450|NCT05726968|Active Comparator|● Group P3 (N 15)|patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)
89626451|NCT04757025|Experimental|Electrical Impedance Tomography|patient monitored by Electrical Impedance Tomography
89626452|NCT04757025|Active Comparator|Peripheral arterial Saturation|patient monitored by Peripheral arterial Saturation alone
89626453|NCT02453919||RECOVIH|"Complete cardiac examination including echocardiography, ischemia tests, and ambulatory blood pressure monitoring.~Collection of clinical information and biochemical laboratory results."
89626454|NCT02987062||Acenocoumarol|Patients with AF treated with acenocoumarol.
89626455|NCT02987062||Warfarin|Patients with AF treated with warfarin.
89626456|NCT02987062||Apixaban|Patients with AF treated with apixaban.
89626457|NCT02987062||Dabigatran|Patients with AF treated with dabigatran.
89626458|NCT02987062||Rivaroxaban|Patients with AF treated with rivaroxaban.
89626459|NCT05583045|Experimental|Olive Leaf Tea (OLT)|Daily intake, for 12 weeks, of olive leaf tea + lifestyle behavior change program.
89626460|NCT05583045|Placebo Comparator|Placebo tea (CON)|Daily intake, for 12 weeks, of placebo tea + lifestyle behavior change program
89039138|NCT00554333|Active Comparator|2|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
89039139|NCT03418701|Active Comparator|Patient Centered Culturally Sensitive WLM|This program is designed to enable physicians to: (a) talk with their patients about their weight, weight loss goals, goal barriers, strategies for overcoming these barriers, and deliver this talk in patient-centered, culturally sensitive ways, (b) assist their patients with engaging in self-identified strategies for achieving and sustaining their self selected goals for weight loss and overall health, (c) be knowledgeable about health-smart behaviors, (d) use behaviors and display attitudes in physician-patient interactions with patients that are provider cultural sensitivity indicators in published literature, and (e) say and display behaviors and attitudes that patients identified as important when discussing obesity and losing weight.
89039140|NCT03418701|Active Comparator|Standard Behavioral WLM|This program is designed to enable physicians to: (a) implement motivational interviewing approaches when talking with their patients about their weight loss goals and behavioral strategies to achieve these goals, (b) become knowledgeable about empirically supported behavioral change principles that have been used to help patients maintain weight loss in previous interventions, (c) communicate how to use these empirically supported behavioral change principles to have patients initiate or maintain their self-selected health-smart goals related to weight loss and/or weight loss maintenance, and (d) use motivational interviewing approaches to communicate empathy and understanding with patients who are struggling to maintain their weight loss and/or accomplish a behavioral goal.
89626461|NCT02445651|Other|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of D5W, frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
89626462|NCT02445651|No Intervention|Control Cohort|Standard of Care Treatment
89626463|NCT02986828|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
89626464|NCT02986828|Active Comparator|Normal saline|Normal saline for ultrasound-guided hydrodissection
89626465|NCT02204709|Experimental|Diploid Trout entrees|Subjects will consume a 200 gram portion of 2N trout (diploid; two sets of chromosomes) twice weekly in a prepared meal.
89626466|NCT02204709|Experimental|Triploid Trout entrees|Subjects will consume a 200 gram portion of 3N trout (triploid; three sets of chromosomes) twice weekly in a prepared meal.
89626467|NCT02204709|Experimental|Tilapia entrees|Subjects will consume a 200 gram portion of tilapia twice weekly in a prepared meal.
89626468|NCT01893957|Experimental|Healthy|Healthy women undergoing high voltage electrical stimulation
89626469|NCT01893957|Experimental|Axillary lymphadenectomy|Axillary lymphadenectomy volunteers undergoing to high voltage electrical stimulation
89626470|NCT02284516|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
89626471|NCT02284516|Placebo Comparator|Placebo|Placebo to match active treatment, BID for 84 days
89626472|NCT05581485|No Intervention|Intubated general anesthesia LMS|The patients received a LMS with intubated general anesthesia.
89626473|NCT05581485|Experimental|Non-intubated LMS with spontaneous breathing|The patients received a non-intubated LMS optiflow(HFNO) device and maintained spontaneous breathing.
89626474|NCT05581485|Experimental|Non-intubated LMS with dexmedetomidine|The patient received a non-intubated LMS optiflow (HFNO) device and was administered dexmedetomidine.
88815701|NCT01036802|Active Comparator|Warfarin|Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
88815702|NCT01036802|Placebo Comparator|Placebo|matching active products
89626475|NCT05738980|Experimental|anti-Tim3-blocked RAK cells|ubjects were randomly assigned to receive anti-TIM-3 blocked RAK cells or untreated RAK cells.
89626476|NCT05738980|Experimental|Unblocked RAK cells|ubjects were randomly assigned to receive anti-TIM-3 blocked RAK cells or untreated RAK cells.
89626477|NCT02721537|Active Comparator|Arm A: Healthy Collegiate Athletes|Healthy collegiate athletes will take active Nicotinamide Riboside
89626478|NCT02721537|Placebo Comparator|Arm B: Healthy Collegiate Athletes|Healthy collegiate athletes will take a matching placebo
89626479|NCT04748614||Before SARS-Cov2|Before SARS-Cov2
89626480|NCT04748614||After SARS-Cov2|After SARS-Cov2
89626481|NCT02185209|Experimental|Placebo|Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
89626482|NCT02185209|Active Comparator|amoxicillin + metronidazole|Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
89626483|NCT02185209|Active Comparator|phenoxymetylpencillin + metronidazol|Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days
89626484|NCT02718105||Receiver patients in donor oocyte -ART|Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor
89626485|NCT01894035||Group 1|
89039141|NCT03368196|Experimental|DS-8201a|DS-8201a administered by intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W)
89626486|NCT05457400|Active Comparator|ENSO 16|The participants receive 30g ENSO 16 dissolved in 200 mL water and blood will be collected at defined time points (0 - 15 - 30 - 45 - 60 - 90 - 120 - 180 minutes; ±3 min at each time point).
89626487|NCT05457400|Active Comparator|Glucose Powder|The participants receive Glucose in the same dosage and blood is also taken at the same time points.
89626488|NCT01727141|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)
89626489|NCT01727141|Active Comparator|QAB149|27.5 ug b.i.d.
89626490|NCT01727141|Active Comparator|NVA237|12.5 ug b.i.d.
89626491|NCT01727141|Placebo Comparator|Placebo|b.i.d
89626492|NCT05738668||Anti-NMDAR encephalitis|Patients with well-characterized anti-NMDAR encephalitis.
89626493|NCT02716311|Other|Afatinib|Afatinib 40 mg/d until progression
89626494|NCT02716311|Experimental|Afatinib + cetuximab|Afatinib 40 mg/d until progression + cetuximab 500 mg/m² every 2 weeks during 6 months (beginning at D15 at 250 mg/m²)
89626495|NCT05439694|Experimental|Gelatin Sponges soaked with TXA|21 patients will have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) each sponge will be soaked with one ampoule and applied between the anterior rectus sheath and the rectus abdominis muscle, one sponge on each muscle.
89626496|NCT05439694|Experimental|Gelatin Sponges|2 Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2)
89626497|NCT05439694|No Intervention|NO SPONGE|21 patients will have no sponge inserted 10 ml of saline
89626498|NCT02170155||Patients with CSM|
89626499|NCT02170155||Patients with spinal injury (SCI)|
89626500|NCT02170155||Healthy controls|
89626501|NCT05738590||inflammatory muscle disease|
89626502|NCT05738590||degenerative muscle disease|
89626503|NCT03029182|Experimental|Walking+simulated-altitude|8-week exercise training program that involves 3 supervised, treadmill walking sessions each week with 16% oxygen, which will be administered through an exercise mask.
89626504|NCT03029182|Active Comparator|Walking (control)|8-week exercise training program that involves 3 supervised, treadmill walking session each week.
89626505|NCT05738512|Active Comparator|Medial Flap Coblation Turbinoplasty|
89626506|NCT05738512|Active Comparator|Submucous Resection|
88815703|NCT01037192|Experimental|Vanco once daily|Subject receives vancomycin 30 mg/kg dose
88815704|NCT01037192|Active Comparator|Vanco twice daily|Subject receives vancomycin 15 mg/kg twice daily
88815705|NCT03014258|Active Comparator|Control Cohort 1|Immunologic malaria-naïve subjects will undergo CHMI #2 with 5 NF54 P. falciparum-infected mosquitoes at months 8-9. n=6.
88815706|NCT03014258|Active Comparator|Control Cohort 2|Immunologic malaria-naïve subjects will undergo a CHMI #3 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #2. n=6.
88815707|NCT03014258|Active Comparator|Control Cohort 3|Immunologic malaria-naïve subjects will undergo a CHMI #4 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #3. n=6.
88815708|NCT03014258|Active Comparator|Control Cohort 4|Immunologic malaria-naïve subjects will undergo a CHMI #5 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #4. n=6.
88815709|NCT03014258|Experimental|Repeat CHMI|Subjects will initially be challenged with 5 uninfected mosquitoes (mock), followed by 5 challenges (CHMI # 1-5) with 5 NF54 P. falciparum-infected mosquitoes 2, 8, 14-20, and 20-32, and 32-36 months later. n=10.
88815710|NCT01088672|Other|Acute Ischemic Stroke|Single arm post market surveillance study for CE marked mechanical thrombectomy device, Trevo retriever for treatment of eligible patients experiencing acute ischemic stroke Mechanical thrombectomy intervention for all subjects in Acute Ischemic Stroke
89626507|NCT04350034|Experimental|Xbox training group|The study group received Xbox training plus routine physical therapy protocol treatment. The dose of Xbox training was 50 min, three times a week for 12 weeks, using the Xbox gaming system (Xbox 360 Kinect console; Microsoft Inc., Redmond, Washington, USA).
89626508|NCT04350034|Placebo Comparator|Control group|patients participated in a routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
88815711|NCT02386098|Experimental|Arm 1: BMS-955176 + ATV + RTV + DTG|BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally
88815712|NCT02386098|Other|Arm 2: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
88815713|NCT02386098|Experimental|Arm 3: BMS-955176 + ATV + DTG|BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
88815714|NCT02386098|Experimental|Arm 4: BMS-955176 + ATV + DTG|BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
88815715|NCT02386098|Other|Arm 5: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
89039142|NCT02436824|Experimental|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days.
89039143|NCT02436824|Placebo Comparator|Placebo patch|Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.
89039144|NCT02433158|Experimental|Cohort 1|Includes one adult stratum (>18 years old) and one pediatric stratum (12-17 years old). Subjects aged 12 and over who weigh >40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg.
89039145|NCT02433158|Experimental|Cohort 2|Includes one pediatric stratum (6-11 years old). Subjects 6 to 11 years of age or subjects who weigh 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
89039146|NCT05029479|Experimental|Yamakin TMR-Aquabond0|Novel Moisture Resistant, M-TEG-P Phosphate Monomer Based Universal Adhesive (YAMAKIN TMR-Aquabond0)
89039147|NCT05029479|Active Comparator|3m ESPE Single Bond Universal Adhesive|Conventional Universal Adhesive
89039148|NCT02428088|Experimental|Dasotraline 2 mg|Dasotraline 2 mg
89039149|NCT02428088|Experimental|Dasotraline 4 mg|Dasotraline 4 mg
89039150|NCT02428088|Placebo Comparator|Placebo|Placebo
89039151|NCT03261609||Extremely preterm (EPT)|"All adults born at gestational age (GA) <29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97.~Inclusion criteria: (a) Birth at GA<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function).~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study."
89039152|NCT03261609||Term or controls|"Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant.~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion."
89039153|NCT02422979|Experimental|PART 1 - Cohort 1|3-6 patients
89039154|NCT02422979|Experimental|PART 1 - Cohort 2|3-6 patients
89039155|NCT02422979|Experimental|PART 1 - Cohort 3|3-6 patients
89039156|NCT02422979|Experimental|PART 2 - Cohort 1|Number of patients depend on Part 1
89039157|NCT02422979|Experimental|PART 2 - Cohort 2|Number of patients depend on Part 1
89039158|NCT02422979|Experimental|PART 3|Up to 30 patients
89039159|NCT03230565|Active Comparator|Continuous Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
89039160|NCT03230565|Active Comparator|Intermittent Bolus Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
89039161|NCT02416076|Active Comparator|Group A - LT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at the default Energy Level [EL2].
89039162|NCT02416076|Active Comparator|Group B - RT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at the default Energy Level [EL2] .
89039163|NCT02416076|Active Comparator|Group C - LT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
89039164|NCT02416076|Active Comparator|Group D - RT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at a higher Energy Level [EL4] .
89039165|NCT02416076|Active Comparator|Group E - LT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers' and 7-3.0 'Ulthera System, standard transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
89039166|NCT02416076|Active Comparator|Group F - RT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers'and 7-3.0 standard transducer on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFTof the face at a higher Energy Level [EL4].
89039167|NCT02389985|Experimental|CRLX101 and weekly paclitaxel|CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.
89039168|NCT02377895|Experimental|Nasapaque Nasal Solution|250 ul in each nostril at Day 1 and Day 8
89039169|NCT02377895|Active Comparator|Placebo Saline Nasal Solution|250 ul in each nostril at Day 1 and Day 8
89039170|NCT05018832|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
89039171|NCT03455075|Experimental|Lower DMAU + LNG|DMAU 100 mg + LNG 30 mcg administered orally in capsules.
89039172|NCT03455075|Experimental|Middle DMAU + LNG|DMAU 200 mg + LNG 30 mcg administered orally in capsules.
89039173|NCT03455075|Experimental|Middle DMAU + Placebo|DMAU 200 mg + placebo administered orally in capsules.
89039174|NCT03455075|Experimental|Higher DMAU + Placebo|DMAU 400 mg + placebo administered orally in capsules.
89626509|NCT02290444|Experimental|Cognitively Relapsing Patients|For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days.
89039175|NCT03455075|Placebo Comparator|Placebo|Placebo administered orally capsules.
89039176|NCT04684017|Experimental|Anlotinib plus etoposide and carboplatin|Etoposide and carboplatin plus anlotinib for 4 cycles and anlotinib as maintenance therapy
89039177|NCT00554450|Experimental|Arm 1|50 mg single dose
89039178|NCT00554450|Experimental|Arm 2|20 mg up to 7 days
89039179|NCT05000151||Patients|Hypermobile Ehlers-Danlos patients (n=21)
89039180|NCT05000151||Healthy subjects|Healthy subjects recruited from the clinic's staff (n=21) Age, Gender and BMI matched with hEDS patients
89039181|NCT00554528|Other|A|patient receiving cervical disc prosthesis with a mobile insert named Mobi-C and product by LDR médical
89039182|NCT00554528|Other|B|patient receiving intersomatic cage
89039183|NCT04683198|Experimental|Experimental: camrelizumab +apatinib+ Carboplatin + Etoposide|Induced stage：camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1 ; maintenance stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally, once daily in 21-day cycle .
89039184|NCT00554567|Experimental|Intervention Arm|Fully Decentralized HIV Testing and Care Services
89039185|NCT02346422|Experimental|MYDICAR|Single intracoronary infusion of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 2.5 x 10^13 DRP. Administered in MYDICAR Phase 1 and MYDICAR Phase 2.
89039186|NCT02346422|Placebo Comparator|Placebo|Single intracoronary infusion of placebo (Sodium Chloride Injection, USP) (Placebo Phase 2 only).
89039187|NCT03048552|No Intervention|Standard of Care|This arm is comprised of caregiver-youth dyads randomized to work with the youth's probation officer as usual to link youth to substance use services.
89039188|NCT03048552|Experimental|Family CONNECT|This arm is comprised of caregiver-youth dyads randomized to work with linkage specialists to link youth to substance use services.
89039189|NCT02342249|Placebo Comparator|VX-787 Placebo BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of matching placebo of VX-787 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
89039190|NCT02342249|Active Comparator|VX-787 300 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 300 milligram (mg) tablet along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
89039191|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 600 mg (2*300 mg tablets) along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
89039192|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir 75 mg BID|Subjects will receive 10 doses of VX-787 600 mg tablets (2*300 mg tablets) along with 75 mg Oseltamivir capsule twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
89039193|NCT04683276|Active Comparator|small flap medium-sized macular hole (SFMM)|small flap (1-2 disc-diameter) was performed in medium sized macular hole (250-400 um)
89039194|NCT04683276|Active Comparator|large flap medium-sized macular hole (LFMM)|large flap (3-4 disc-diameter) was performed in medium sized macular hole (250-400 um)
89039195|NCT04683276|Active Comparator|small flap large-sized macular hole (SFLM)|small flap (1-2 disc-diameter) was performed in Large sized macular hole (>400 um)
89039196|NCT04683276|Active Comparator|large flap Large-sized macular hole (LFLM)|large flap (3-4 disc-diameter) was performed in large sized macular hole (>400 um)
89039197|NCT02933970|No Intervention|Control|Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist
89039198|NCT02933970|Other|Intervention|Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)
89039199|NCT02339129|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
89039200|NCT02339129|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
89039201|NCT04678622||Classic Orthrosis|Group of patients who they will wear the usual splint indicated by the servicio physicians
89039202|NCT04678622||3D Orthrosis|Group of patients who they will wear the personalized splint designed by the company OPTIMUS 3D.
89039203|NCT04971798|Experimental|Cell-free Stem cell-derived Extract Formulation (CCM)|Intraarticular administration of CCM
89039204|NCT04678388|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
89039205|NCT04678388|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
89039206|NCT04678388|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
89039207|NCT04678388|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
89039208|NCT04678388|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
89039209|NCT04678388|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
89039210|NCT02884206|Experimental|LCZ696|Patients will receive LCZ696 at 100 mg twice daily during a single-blind treatment run-in period to ensure patients tolerate this medication before they are randomized. Down-titration is not allowed during this period. Patients who are able to tolerate LCZ696 100 mg twice daily are eligible to enter the randomized treatment period. Patients randomized to receive LCZ696 will be given LCZ696 at 200 mg twice daily. Patients will receive randomized study drug for three years.
89039211|NCT02884206|Active Comparator|Valsartan|Patients will receive valsartan at 40mg and/or 80mg twice daily during a single-blind treatment run-in period. Following the run-in period, patients randomized to receive valsartan will be given valsartan at 160 mg twice daily for three years.
89039212|NCT04678973|Experimental|Intervention|Participants in the intervention group will receive a 4 week program delivered via text message. Week 1 will include psychoeducation delivered via brief readings and video. Weeks 2-4 will include daily guided mindfulness practice focusing on self-compassion and weight and body image concerns.
89039213|NCT04678973|No Intervention|Wait-list control|Participants in the control group will receive no study content during the 4 week intervention period. They will receive access to intervention content (text messages, audio files) after completing end-of-treatment surveys 4 weeks after randomization.
89039214|NCT04961541|Experimental|Group A - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
89626510|NCT02290444|No Intervention|Stable Multiple Sclerosis Patients|Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state.
89626511|NCT01726517|Experimental|LDV/SOF 8 Weeks (TN)|Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
89626512|NCT01726517|Experimental|LDV/SOF+RBV 8 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
89626513|NCT01726517|Experimental|LDV/SOF 12 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
89626514|NCT01726517|Experimental|LDV/SOF 12 Weeks (TE)|Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor [PI]+pegylated interferon [PEG]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
89626515|NCT01726517|Experimental|LDV/SOF+RBV 12 Weeks (TE)|Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.
89626516|NCT05738356|Active Comparator|Three-step adhesive|The orthodontic appliances were bonded to the patients teeth using conventional 3 step adhesive (3M™ Transbond™ XT, 3M Unitek, United States)
89626517|NCT05738356|Experimental|Self-etch primer adhesive|The orthodontic appliances were bonded to the patients teeth using self-etch primer (3M™ Transbond™ Plus, 3M Unitek, United States).
89039215|NCT04961541|Experimental|Group B -ICC Vaccine Formulation|2 doses of Formulation 2. 1 dose each on Days 0 and Day 56.
89039216|NCT04961541|Experimental|Group C - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
89039217|NCT04961541|Experimental|Group D - ICC Vaccine Formulation|2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
89039218|NCT04961541|Experimental|Group E - ICC Vaccine Formulation|2 doses of Formulation 4. 1 dose each on Days 0 and Day 56.
89039219|NCT04961541|Experimental|Group F- ICC Vaccine Formulation|2 doses of Formulation 5. 1 dose each on Days 0 and Day 56.
89039220|NCT04961541|Experimental|Group G- ICC Vaccine Formulation|2 doses of Formulation 6. 1 dose each on Days 0 and Day 56.
89039221|NCT04961541|Experimental|Group H- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
89039222|NCT04961541|Experimental|Group I- ICC Vaccine Formulation|2 doses of Formulation 8. 1 dose each on Days 0 and Day 56.
89039223|NCT04961541|Experimental|Group J -ICC Vaccine Formulation|2 doses of Formulation 9. 1 dose each on Days 0 and Day 56.
89039224|NCT04961541|Experimental|Group K - ICC Vaccine Formulation|2 doses of Formulation 10. 1 dose each on Days 0 and Day 56.
89039225|NCT04961541|Experimental|Group L - ICC Vaccine Formulation|2 doses of Formulation 11. 1 dose each on Days 0 and Day 56.
89039226|NCT04961541|Experimental|Group M -ICC Vaccine Formulation|2 doses of Formulation 12. 1 dose each on Days 0 and Day 56.
89039227|NCT04961541|Experimental|Group N- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
89039228|NCT04961541|Experimental|Group O - qNIV with Matrix-M1 adjuvant|2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70.
89626518|NCT05738356|Experimental|One-step adhesive system|The orthodontic appliances were bonded to the patients teeth using one-step adhesive system (GC Ortho Connect™, GC Orthodontics, Germany)
89626519|NCT01752023|Experimental|Cisplatin + Gemcitabine with SUBATM-itraconazole|SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.
89626520|NCT01752023|Active Comparator|Cisplatin + Gemcitabine|Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.
89039229|NCT04961541|Experimental|Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant|2 doses of Formulation 14. 1 dose each on Days 0 and Day 56.
89039230|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 100 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
89039231|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 200 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
89039232|NCT02326454|Placebo Comparator|Saline/Light dose 100 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
89039233|NCT02326454|Placebo Comparator|Saline/Light dose 200 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
89039234|NCT02324309|Experimental|BIOD-531 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
89039235|NCT02324309|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
89039236|NCT02324309|Active Comparator|Humulin R U-500 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
89039237|NCT02324309|Experimental|BIOD-531 post-meal|Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.
89039238|NCT02307851|Experimental|Group A|Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
89039239|NCT02307851|Experimental|Group B|Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
89626521|NCT02986906|Experimental|5% dextrose|The perineural injection with 5% dextrose is a new and potential treatment for peripheral entrapment neuropathy
89626522|NCT02986906|Active Comparator|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|The Ultrasound-guided injection with 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
89211148|NCT04469556|Active Comparator|Gemcitabine/nab-Paclitaxel|"Gemcitabine/nab-Paclitaxel administered intravenously.~Given that both regimens are standard of care, study treatment will be administered as per standard of care at each institution including a maintenance therapy approach which is encouraged in both arms. Dose modifications, anti-emetics, supportive medications, and use of growth factors should follow institutional guidelines."
89211149|NCT00540423|Experimental|SB-497115-GR group|Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.
89211150|NCT00540423|Placebo Comparator|placebo group|Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.
89211151|NCT00932178|Experimental|Calmer Life|Skills-based intervention to reduce anxiety and worry in adults age 50+.
89626523|NCT01726049|Active Comparator|Sildenafil|Sildenafil orally 3 times 20mg for 2 weeks , followed by 3 times 60 mg for 10 weeks
89626524|NCT01726049|Placebo Comparator|Placebo|placebo orally 3 times 20mg tablets, followed by 3 times 60 mg for 10 weeks
89626525|NCT05654350||Patients with neglect anosognosia|Subacute or chronic right hemispheric stroke patients with left hemispatial neglect and neglect anosognosia.
89626526|NCT05654350||Patients without neglect anosognosia|Subacute or chronic right hemispheric stroke patients with left hemispatial neglect but no neglect anosognosia.
89626527|NCT02162667|Experimental|CT-P6|
89626528|NCT02162667|Active Comparator|Trastuzumab|
89626529|NCT01605617|Active Comparator|PTNS + fesoterodine fumarate first, then PTNS + placebo|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
89626530|NCT01605617|Placebo Comparator|PTNS + placebo first, then PTNS + fesoterodine fumarate|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate
89626531|NCT05651854|Experimental|Bhramari pranayama breathing|Bhrāmarī Prāṇāyāma breathing involves inhalation through both nostrils and producing humming sound of a bee while exhaling (Nivethitha et al., 2016).
89626532|NCT05651854|Experimental|Sheetali pranayama breathing|Sheetali pranayama involve inhalation through extension of the tongue outside the mouth and roll the sides of the tongue up so that it would form a tube. At the end of inhalation, the tongue is drawn in, mouth is closed and exhale through the nose (Thanalakshmi et al., 2014).
89626533|NCT05403190|Experimental|Study arm|Patients with prostate cancer
89626534|NCT05402020||Tio/Olo cohort|COPD patients included in the NHI database between 2014 and 2019 and who received Tiotropium/olodaterol (Tio/Olo).
89626535|NCT05402020||ICS/LABA cohort|COPD patients included in the NHI database between 2014 and 2019 and who received inhaled corticosteroids/ Long-acting ß2-agonists (ICS/LABA).
89626536|NCT02284828|Experimental|Group 1 BIA 2-093|A single dose of oral ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg.
88989967|NCT04474483|Experimental|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
89211152|NCT04014504||study group|The results of the hearing screening test of the beats of the patients who have undergone pethidine in the active phase of labor will be examined. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at.
89626537|NCT01751867|Experimental|3-Day Dose schedule|Decitabine will be administered at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3 hour period, repeated every 8 hours for 3 consecutive days. Cycles will be repeated every 6 weeks.
89626538|NCT01751867|Experimental|5-Day Dose schedule|Decitabine will be administered at a dose of 20 mg/m2 as a intravenous infusion within 1 hour, once daily for 5 consecutive days. Cycles will be repeated every 4 weeks.
89626539|NCT05637658|No Intervention|control group|No application will be made to the participants in the control group.
89626540|NCT05637658|Experimental|Exercise group|Participants will perform aerobic exercise 3 times a week at an intensity of 60-80% of age-adjusted maximal heart reserve on the treadmill and bicycle ergometer for 4 weeks.
89626541|NCT02418195|Active Comparator|MDD with recent Suicide Attempt|All subjects with Major Depressive Disorder with a recent Suicide Attempt (in the past 2 weeks) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40 milliliters (mL) over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
89626542|NCT02418195|Active Comparator|MDD with Suicidal Ideation no attempt|All subjects with Major Depressive Disorder with recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
89626543|NCT02418195|Active Comparator|MDD without Suicidal Ideation no attempt|All subjects with Major Depressive Disorder without recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.
89626544|NCT02418195|No Intervention|Healthy Controls|Healthy Control subjects without a psychiatric diagnosis will have a one-time blood draw to examine miRNAs.
89626545|NCT05633914|Experimental|Tucidinostat and nab-paclitaxel|
89626546|NCT04756947||Pelvic injury|Paediatric patients (age ≤ 18 years) with a single pelvic bone fracture or pelvic ring injury, excluding pathological fractures.
89626547|NCT04756947||Pelvic and acetabular injury|Paediatric patients (age ≤ 18 years) with a combined pelvic and acetabular injury or an isolated acetabular fracture, excluding pathological fractures.
89211153|NCT04014504||control group|In the active phase of labor, hearing screening test results of beats of pediatric patients will be evaluated. the results will be reported as passed - remained; the false positivity rate according to the retest of the remaining group is to be looked at. control group.
89211154|NCT03710850|Experimental|Responders|Responders in terms of fecal butyrate production after acute inulin test.
89626548|NCT05383612|Experimental|Group I:3% diquafosol|70 people, 70 eyes.
89626549|NCT05383612|Other|Group II:3% diquafosol and warm compresses and lid massage|70 people, 70 eyes.
89626550|NCT05382364|Experimental|Tucatinib Treatment|Chinese participants with HER2+ advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma, or colorectal cancer receive tucatinib 300 mg by mouth twice daily during 21-day cycles. Treatment continues until there is evidence of unacceptable toxicity or documented progression.
89626551|NCT02712801|Experimental|Intervention group|Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
89626552|NCT02712801|Active Comparator|Control group|Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.
89626553|NCT05381896|Active Comparator|Control Group|Patients in this group will receive conventional scoliosis exercise program for 1 hour, 6 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
89626554|NCT05381896|Experimental|Training Group|In addition to the conventional scoliosis exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 6 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
89626555|NCT02712723|Active Comparator|Placebo + Letrozole|Placebo randomized to 3 capsules/day 3 weeks on/1week off or 2 capsules/day continuous dosing + Letrozole 2.5 mg PO daily
89626556|NCT02712723|Experimental|Ribociclib 600 mg + Letrozole|Ribociclib 600 mg PO daily 21 days on/7 days off + Letrozole 2.5 mg PO daily
89626557|NCT02712723|Experimental|Ribociclib 400 mg + Letrozole|Ribociclib 400 mg continuous daily dosing + Letrozole 2.5 mg PO daily
89626558|NCT02152683|Experimental|long protocol|Renova
89626559|NCT02152683|Experimental|short protocol|Renova
89626560|NCT05736250||TEST group|smoker patients
89626561|NCT01751165|Experimental|HZ/su-0,2 Group|Subjects will receive HZ/su vaccine on a 0,2-month schedule.
89626562|NCT01751165|Experimental|HZ/su-0,6 Group|Subjects will receive HZ/su vaccine on a 0,6-month schedule.
89626563|NCT01751165|Experimental|HZ/su-0,12 Group|Subjects will receive HZ/su vaccine on a 0,12-month schedule.
89626564|NCT02145351|Active Comparator|Pacing off first, then pacing on|No-pacing on for the first for 4 weeks, followed by 4 week washout period, and then cross-over to pacing on for an additional 4 weeks.
89626565|NCT02145351|Experimental|Pacing on first, then pacing off|Pacing on for the first for 4 weeks, followed by 4 week washout period, and then cross-over to pacing off for an additional 4 weeks
89626566|NCT01751087|Other|Osmotic dilators + placebo (vit c) + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
89626567|NCT01751087|Active Comparator|Osmotic dilators + placebo (vit c) + misoprostol|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
89626568|NCT01751087|Active Comparator|Osmotic dilators + mifepristone + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
89626569|NCT04566419|Active Comparator|Control group|Oxygen delivered by Venturi Mask
89626570|NCT04566419|Experimental|HFNC - high flow nasal cannulae|Oxygen delivered by high flow nasal cannula (HFNC) 60 l/min
89626571|NCT02706093|Other|High Intensity Interval Training #1|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
89626572|NCT02706093|Other|Moderate intensity continuous training|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
89211155|NCT03710850|Experimental|Non-responders|Non-responders in terms of fecal butyrate production after acute inulin test.
89211156|NCT00932256|Experimental|STAHIST for seasonal allergic rhinitis|STAHIST for seasonal allergic rhinitis: each white, scored tablet contains pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, and atropine sulfate .24mg
88989968|NCT04473066||Adenotonsillectomy (AT)|Children diagnosed with moderate-to-severe OSA (OAHI ≥3/h) and tonsillar hypertrophy (tonsil grade ≥2) at the age of 5-12 years old and underwent AT since 2012.
89211157|NCT00932334|Experimental|TALK Plus|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
89626573|NCT02706093|Other|High Intensity Interval Training #2|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
89626574|NCT02706093|Other|High Intensity Interval Training #3|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
89626575|NCT02393157|Experimental|Central Nervous System (CNS) Negative|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
89211158|NCT00932334|Experimental|TALK Standard|Participants receive and educational video and booklet about living kidney donation
89626576|NCT02393157|Experimental|CNS Positive|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
89626577|NCT01750697|Experimental|Rituximab|
89626578|NCT02127723|Experimental|Macrolane|All subjects will receive hyaluronic acid injection (Macrolane VRF30)
89626579|NCT01750229|Sham Comparator|Sham|Frequency Setting - Sham
89626580|NCT01750229|Experimental|1200 Hz|Frequency Setting - 1200 Hz
89626581|NCT01750229|Experimental|3030 Hz|Frequency Setting - 3030 Hz
89626582|NCT01750229|Experimental|5882 Hz|Frequency Setting - 5882 Hz
89626583|NCT05586711|Active Comparator|Vaginal estradiol 10 μg|
89626584|NCT05586711|Active Comparator|Vaginal DHEA 6,5 mg|
89626585|NCT02124057||Healthy female control|Age-matched healthy control women
89626586|NCT02124057||Healthy male control|Age-matched healthy control men
89626587|NCT02124057||Other Motor Neuron Disease Patients|Male participants with other motor neuron disease
89626588|NCT02124057||SBMA Patients|Men with genetically confirmed SBMA
89626589|NCT02124057||SMBA|SBMA carrier women
89626590|NCT03029260|Experimental|Neural mobilization - tension|It is anticipated that 30 participants will be in this group. They will receive tension type neural mobilization of the peroneal nerve in the dominant limb. This will consist of positioning the lower limb with inversion and plantar flexion of the ankle, extension of the knee and maximum flexion of the hip without pain. A physiotherapists will move the hip from this maximum position of flexion in direction to extension (for example if the participants reaches 80º of flexion the mobilization will be between 40º and 80º of flexion). Each participant will receive four series of 10 mobilizations with 1 minute rest between series.
89626591|NCT03029260|Active Comparator|Neural mobilization - sliding|It is anticipated that 30 participants will be in this group. They will receive sliding neural mobilization of the peroneal nerve in the dominant limb. Each participant will receive four series of 10 mobilizations with 1 minute rest between series of the following combination of movement: from ankle dorsiflexion, knee extension and hip extension to ankle plantarflexion, knee and hip flexion.
89626592|NCT01724489|Active Comparator|Growth Hormone|Growth Hormone is Genotropin, provided by Pfizer Inc. It is self administered daily for 18 months using a 5 mg injection pen device. Dose will be titrated based on IGF-1 levels.
89626593|NCT01724489|Placebo Comparator|Placebo|Placebo will be provided by Pfizer Inc. It will appear identical to active growth hormone and will be administered in the same manner.
89626594|NCT01996293||Lamotrigine for Bipolar|antepartum and peripartum women taking lamotrigine for Bipolar Disorder
89626595|NCT02986750|Experimental|Experimental: Patients with dry eye syndrome 1|40 Patients with dry eye syndrome
89626596|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 2|40 Patients with dry eye syndrome
89626597|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 3|40 Patients with dry eye syndrome
89626598|NCT05304364|Experimental|DLP-160 alpha-10|One time single Naltrexone Implant for a duration of 123 days
89626599|NCT01992393|Experimental|TIME|This arm will receive the TIME intervention.
89626600|NCT01992393|No Intervention|Treatment as Usual (TAU)|This arm will receive treatment as usual.
89626601|NCT01724177|Experimental|Lenalidomide|Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity
89626602|NCT02117817|Experimental|Treatment (BKM120 in Combination with Weekly Nabpaclitaxel)|
88989969|NCT04473066||Refused AT|Children diagnosed with moderate-to-severe OSA and tonsillar hypertrophy but refused AT in the same period.
88989970|NCT04473066||Normal control|Children reported to have no habitual snoring (less than 3 nights per week) and confirmed to have no OSA (OAHI <1/h) by overnight sleep study in the same period.
89626603|NCT05257798|Experimental|PF-06823859|Participants will receive 900 mg of PF-06823859 via intravaneous (IV).
89626604|NCT05257798|Placebo Comparator|Placebo|Participants will receive placebo via IV.
88989971|NCT04469686|Experimental|Twice Daily - Active|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure suppository applicator
88989972|NCT04469686|Experimental|Once Daily - Active|Once daily 90 mg hydrocortisone acetate and once daily placebo suppository administered with Sephure suppository applicator
88989973|NCT04469686|Placebo Comparator|Placebo|Twice daily placebo suppository administered with Sephure suppository applicator
88989974|NCT04468451|Experimental|ROC-48 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 48 hours for a total of 12-week intervention.
89039240|NCT02307851|Experimental|Group C|Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
89626605|NCT02109471||corneal opacities|
89626606|NCT05693740|Active Comparator|group 1|Patients in this group will undergo pulsed light accelerated crosslinking (pl-ACXL)
89626607|NCT05693740|Active Comparator|group 2|Patients in this group will undergo continuous-light accelerated crosslinking (cl-ACXL)
89626608|NCT05529784||Severe, uncontrolled CRSwNP patients in therapy with Dupilumab|
89626609|NCT04415866|Experimental|Effects of PASAT on Sensory Testing|After baseline evaluation of light and pain sensitivity FM subjects and controls will undergo the PASAT task. This task consists of responding to a rapid presentation of numbers by ear phones. Subjects are asked to add each 2 consecutive numbers and provide a response each time the sum is equal to 13. This test will last several minutes and delivered at increasing speed.
89626610|NCT04349488|Active Comparator|Treatment|Anode placed over the affected primary motor cortex, cathode over contralateral supra orbital area. 2 mA, 20min stimulation, 5 days a week for 4 weeks
89626611|NCT04349488|Placebo Comparator|Placebo|Anode montage but current is ramped up over 15 secondes, then ramped down. 2 mA, 20min stimulation, 5 days a week for 4 weeks
89626612|NCT02076867|Experimental|Intensive Short Term Dynamic Psychotherapy (ISTDP)|
89626613|NCT02076867|Active Comparator|Medical Care As Usual (MCAU)|
89626614|NCT04406740||All Participants|Adult patients >18 years of age, who are scheduled to undergo any elective procedure under general anesthesia in the MHealth East Bank operating rooms in which the administration of a nondepolarizing neuromuscular blocking drug (rocuronium or cisatracurium) is anticipated.
89626615|NCT01894659|No Intervention|Control|Neonates randomized to this arm will receive the standard of practice at Loma Linda University NICU.
89626616|NCT01894659|Experimental|24% oral sucrose with pacifier|Neonates randomized to this arm will receive 24% sucrose before every painful procedure on days of life 3-7 in the NICU.
89626617|NCT01894659|Experimental|30% oral glucose with pacifier|Neonates randomized to this arm will receive 30% oral glucose before every painful procedure on days of life 3-7.
89626618|NCT04404712|Experimental|[11C]MK-3168 PET Scan|
89626619|NCT04349800|Experimental|Single Ascending Dose - 5 mg|
89626620|NCT04349800|Experimental|Single Ascending Dose - 10 mg|
89626621|NCT04349800|Experimental|Single Ascending Dose - 20 mg|
89626622|NCT04349800|Experimental|Single Ascending Dose - 40 mg|
89626623|NCT04349800|Experimental|Single Ascending Dose - 80 mg|
89626624|NCT04349800|Experimental|Single Ascending Dose - 160 mg|
89626625|NCT04349800|Experimental|Single Ascending Dose - 300 mg|
89626626|NCT04349800|Experimental|Single Ascending Dose - 600 mg|
89626627|NCT04349800|Experimental|Formulation Screen|
89626628|NCT04349800|Experimental|Food Effect|
89626629|NCT01962753|Experimental|18FAV45|
89211159|NCT00932334|Other|Usual Care|Participants receive their usual medical care
89626630|NCT01960881||Prostate Cancer Patients|Prostate Cancer Patients
89626631|NCT01530009|Active Comparator|Amoxicillin|A liquid preparation of amoxicillin will be administered during the study through a nasoduodenal catheter after random patient assignment.
89626632|NCT01530009|Placebo Comparator|Placebo|A liquid placebo will be administered via a nasoduodenal catheter to patients based on random assignment.
89626633|NCT04919590|Experimental|This is Quitting|"Participants will be enrolled to receive messages from This is Quitting.~Users receive one age-appropriate message per day tailored to their enrollment date or quit date, which can be set and reset via text message. Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for a week preceding it and 8 weeks afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting, and cutting down to quit. Keywords COPE, STRESS, SLIP, and MORE provide on-demand support."
89626634|NCT04919590|Other|Assessment only control|After an initial enrollment message, participants will be contacted monthly to assess e-cigarette use. At the end of the study data collection period, they will receive information on how to sign up for This is Quitting if they are interested in the program.
89626635|NCT04919590|Other|Waitlist control|After an initial enrollment message, participants will receive no contact from study staff except for 1-month and 7-month follow-up assessments. At the end of the study data collection period, they will receive information on how to sign up for This is Quitting if they are interested in the program.
89626636|NCT01895595|Experimental|Guided Imagery|The guided imagery program curriculum, added to the lifestyle education curriculum, consists of 12 weekly, 45-minute modules, delivered one-on-one immediately following the lifestyle education class each week. Guided imagery was based on 2 major underlying theoretical principles: 1) relaxation/stress reduction imagery; and 2) imagery designed to improve eating and physical activity behaviors.
89626637|NCT01895595|Active Comparator|"Digital storytelling (Control)"|The digital storytelling program curriculum, to control for contact time with research staff, consists of 12 weekly 45-minute modules delivered one-on-one immediately following the lifestyle education class each week.
89626638|NCT01894737|Placebo Comparator|immobilisation and placebo|Seven days of one-legged knee immobilisation with placebo supplementation
89626639|NCT01894737|Experimental|immobilisation and creatine|Seven days of one-legged knee immobilisation with creatine supplementation
89626640|NCT04915144|Active Comparator|Standard PRRT|For standard PRRT 177Lu-DOTATOC therapy, the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.
89626641|NCT04915144|Experimental|Personalized PRRT|For 177Lu-DOTATOC therapy, for the first cycle the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.Subsequent cycles will be adjusted based on dosimetry calculations.
89626642|NCT04871464|Experimental|Probiotics|Bifidobacterium triple viable capsules（BIFICO），containing Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis(each ≥ 1.0×10^7 CFU/capsule)，Day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
89211160|NCT00937092|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
89626643|NCT04871464|Placebo Comparator|Placebo|Placebo，day 1-14, 2 capsules twice daily; Day 15-24 weeks, 4 capsules twice daily, taken orally half an hour after meals.
89626644|NCT04871464|No Intervention|Healthy control|Healthy subjects without constipation matched for age and sex to PD subjects
89626645|NCT01724021|Experimental|Arm A|Participants in Arm A received one cycle of rituximab 375 mg/m^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
89626646|NCT01724021|Experimental|Arm B|Participants in Arm B received four cycles of rituximab 375 mg/m^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
89626647|NCT05197504||intervention|atezolizumab + bevacizumab
89039241|NCT02307851|Active Comparator|Group D|Comparator TIV, intramuscular injection (0.5mL)
89626648|NCT02293096|Experimental|Metoprolol succinate, CYP2D6 Genotyping, CYP2D6 Phenotyping|"The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol. The following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.~metoprolol succinate~Genotyping: CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete.~CYP2D6 Phenotyping: Phenotype can be discordant from what is predicted by genotype. CYP2D6 henotyping using dextromethorphan will be used. Investigators will be blind to the patient blood pressure outcome for this intervention."
89626649|NCT04866082||ESICM and ESAIC members|questionnaire - Members of European Society of Intensive Care and European Society of Anaesthesiology and Intensive Care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
89626650|NCT01723397|Active Comparator|Nasaleze spray|"Nasaleze spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
89626651|NCT01723397|Placebo Comparator|Placebo spray|"Placebo spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
89626652|NCT01723163|Experimental|Intervention|Abstinence Reinforcement Therapy (ART)
89626653|NCT01723163|Other|Control|Telephone Counseling
89626654|NCT02293798|Experimental|SERI|Subjects receiving SERI for mastopexy
89626655|NCT01722071|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
89626656|NCT01722071|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
89626657|NCT04155580|Experimental|Part 1|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
89626658|NCT04155580|Experimental|Part 2|ASTX660 once daily (Days 1-7 and 15-21 per 28-day cycle) as a single agent or in combination with ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
89626659|NCT04155580|Experimental|Part 3|ASTX660 at the recommended dose for expansion identified in Part 2 + ASTX727 FDC once daily (Days 1-5 per 28-day cycle)
89626660|NCT01721759|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, intravenously over 60 minutes every 2 weeks (on Day 1 of each cycle) until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. Every 2-week treatment period was considered to be a cycle.
89626661|NCT02297308||SoloPath Sheath|The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access
89626662|NCT01721369||Transient Loss of Consciousness (T-LOC)|Transient Loss of Consciousness (T-LOC). Treatment according to normal clinical practice.
89626663|NCT02298322|Experimental|CoolSculpting Treatment|The intervention is the CoolSculpting System.
89626664|NCT04776850|Experimental|Treatment (PTIS, HCT)|See Detailed Description.
89626665|NCT04132648|Experimental|Curcumin|Patients will receive curcumin (Longvida) 2000 mg one time prior to exercise trials
89626666|NCT04132648|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
89626667|NCT02331940|Active Comparator|Handihaler|Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
89039242|NCT02826213||Kidney : perfusion device lifeport|Each donor (n=140) will provide one kidney for pulsatile perfusion.
89039243|NCT02826213||Kidney : perfusion device waves|Each donor (n=140) will provide one kidney for continuous perfusion.
89626668|NCT02331940|Active Comparator|Respimat|Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
89626669|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm A|Combination of nivolumab and relatlimab.
89626670|NCT04095208|Experimental|Experimental: Randomized phase II trial - Arm B|Treatment by nivolumab alone.
89626671|NCT02291302|Active Comparator|Environmental Intervention|Active Classroom air purifiers and school integrated pest management environmental intervention
89626672|NCT02291302|Placebo Comparator|Sham and Control (control)|Sham air purifiers and no school integrated pest management environmental intervention
89626673|NCT02291302|Placebo Comparator|Active Air Purifier and Control|Active air purifiers and no school integrated pest management environmental intervention
89626674|NCT02291302|Sham Comparator|Sham and Inegrated Pest|Sham air purifiers and active school integrated pest management
89626675|NCT02292082|Active Comparator|Peri-Articular Injections only|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Surgeon will perform the periarticular injections:~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine~Intravenous sedation with midazolam and propofol."
89039244|NCT02306291|Experimental|Arm A (Phase I)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
89039245|NCT02306291|Experimental|Arm B (Phase II Arm A)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
89626676|NCT02292082|Experimental|Peri-Articular Injections and Adductor Canal Block|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Adductor canal block technique:~Supine position, after IV sedation~Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches~Femoral artery will be identified in the adductor canal deep to the Sartorius muscle~15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone~Local anesthetic will be delivered periarterial between 12 and 6 o'clock~Intravenous sedation with midazolam and propofol.~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 20 ml 0.25% bupivacaine"
89626677|NCT05072704|Active Comparator|Control group|Sufentanil IV injection
89626678|NCT05072704|Experimental|OFA group|Dexmedetomidine IV infusion
89626679|NCT03951454|Experimental|Conexiones|5 telephone sessions of Conexiones, with each session delivered 2 weeks apart across a total period of 8 weeks
89626680|NCT03951454|Other|Taking Time|1 telephone session consisting of a scripted protocol guiding participants through the NCI's Taking Time Booklet.
89626681|NCT03924934||Possible CA-HRE|Patients with suspected CA-HRE, discharged home after a previous hospitalization or outpatient visit during which CA-HRE was isolated from a clinical culture (approximately 210 patients)
89626682|NCT03924934||HA-HRE|Hospitalized patients with healthcare-associated HRE, who are not discharged home (HA-HRE) (210 selected control patients)
89039246|NCT02306291|Experimental|Arm C (Phase II Arm B)|GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older
89039247|NCT02302079|Experimental|ASP8232 + sham intravitreal (IVT) injections|ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals
89039248|NCT02302079|Experimental|ASP8232 + ranibizumab intravitreal (IVT) injections|ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
89039249|NCT02302079|Active Comparator|Placebo + ranibizumab intravitreal (IVT) injections|Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
89039250|NCT01210495|Experimental|A|Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration
89039251|NCT01210495|Placebo Comparator|B|Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study
89039252|NCT02289716|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase.
89626683|NCT03924934||HA-HRE discharged home|Patients eventually discharged home, either directly or through another facility, after a hospitalization during which HA-HRE was isolated from a clinical culture (100)
89626684|NCT03924934||Community contacts|Contacts of patients with HRE (approximately 1,500)
89626685|NCT04349956||Patients from a randomized placebo-controlled study of UBX0101|Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.
89626686|NCT04648774|Active Comparator|Active serratus anterior plane (SAP) block with Ropivacaine 0.2%|
89626687|NCT04648774|Placebo Comparator|Placebo serratus anterior plane (SAP) block with normal saline|
89626688|NCT02980588|Other|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
89626689|NCT03208504|Experimental|Treatment|All subjects in treatment arm will be implanted with the Single Branch Nexus™ Aortic Arch Stent graft System.
89626690|NCT04349878|Placebo Comparator|Control|scaling and root planing alone
89626691|NCT04349878|Active Comparator|phytotherapeutic|scaling and root planing plus phytotherapeutic agent
89626692|NCT02299258|Active Comparator|Tailored stents MTN-WE-20/100-A|The distal portion of the GOO tailored stents was semi-spherical, with a length of 20 mm, and a diameter of 28 mm. The middle segment had a diameter of 20 mm. The overall length of the stents was 100 mm. Both the middle part and the bottom of the proximal cup segment, and a part of the proximal funnel segment, were covered by a polyethylene membrane.
89626693|NCT02299258|Experimental|Standard stents MTN-CG-s-20/100|Standard uncovered stents were used in the control group. The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
89626694|NCT04607122|Experimental|Landiolol group|Landiolol infusion (2µg/kg/min) administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
89039253|NCT02289716|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase.
89039254|NCT02289716|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase.
89626695|NCT04607122|Placebo Comparator|Placebo group|Saline solution infusion administrated after the surgery, on arrival at the ICU, until restoration of an effective oral beta-blocker treatment.
89626696|NCT03057964|Experimental|PDL (Pulsed Dye Laser) and Fractional Photothermolysis|
89626697|NCT03057964|No Intervention|Control|
89626698|NCT01721057|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
89039255|NCT04922697|Experimental|Prevention (educational videos, questionnaires)|Participants watch 2 educational videos during week 3 regarding air pollution, health effects, and personal preventive health behaviors to reduce air pollution exposure. Participants will use wearable air pollution sensors. Participants will complete questionnaires at weeks 1 and 5.
89039256|NCT02289092|Experimental|Family Check-Up Intervention|Prior to the feedback session, trained clinicians will observe family interactions by reviewing the video-taped observations and questionnaires filled out by parents. Therapists then use this data to inform the intervention process and provide feedback to parents based on norms for this age period. Feedback sessions will include a discussion of goal attainment and plans to achieve goals, with specific attention to the parent's role in supporting positive behavior. Options for obtaining goals are based on the literature about empirically supported interventions for this age group and include (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
89039257|NCT02289092|No Intervention|Control|Control families will receive services as usual that are being provided to the families within their school
89039258|NCT04918095||Moderate-Severe COPD|COPD patients diagnosed GOLD 2- 3, C- D for moderate-severe, poorly controlled
89039259|NCT02267642|Experimental|AbGn-168H|Seven (7) intravenous doses of AbGn-168H on D1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), Day D29 (Week 4), D43 (Week 6), Day 57 (Week 8) and Day 71 (Week 10)
89039260|NCT04917822|Experimental|Emotion regulation arm|The emotion regulation arm aims at improving emotional regulation skills among parents and children.
89039261|NCT04917822|Active Comparator|Information provision arm|The information provision arm aims at providing information about Hong Kong, such as education, community resources, medical care, employment, housing, and job-seeking among parents and children.
89039262|NCT02267525|Experimental|Velusetrag 5mg|Velusetrag 5mg capsules QD (once daily) x 12 weeks
89039263|NCT02267525|Experimental|Velusetrag 15mg|Velusetrag 15mg capsules QD x 12 weeks
89039264|NCT02267525|Experimental|Velusetrag 30mg|Velusetrag 30mg capsules QD x 12 weeks
89039265|NCT02267525|Placebo Comparator|Placebo|Placebo capsules QD x 12 weeks
89039266|NCT04678076|Experimental|ketoprofen 25mg/5ml oral gel stick pack|Single dose of ketoprofen 25mg/5ml oral gel stick pack will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
89039267|NCT04678076|Active Comparator|OKi 80 mg granules for oral solution (bipartite sachet)|Single dose of half sachet containing 40 mg of ketoprofen lysine salt (corresponding to 25 mg as ketoprofen) will be administered to healthy volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
89626699|NCT01721057|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
89626700|NCT01721057|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
89626701|NCT04570384|Active Comparator|IV L-Citrulline (Turnobi) Arm|Patients randomized to citrulline will receive an initial intravenous bolus of 20 mg/kg (to a maximum of 1500 mg) L-citrulline over 10 minutes. The study solution will be prepared as a 5% isotonic solution (50 mg/mL) in 5% dextrose water. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9 mg/kg (max 700 mg) per hour will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
89626702|NCT04570384|Placebo Comparator|Placebo Arm|Patients randomized to placebo arm will receive an infusion of 5% dextrose water matched for volume and color to the citrulline infusion. The placebo infusion will consist of an initial iv bolus (up to 30 mL) over 10 minutes followed by a continuous infusion of 5% dextrose water (about 15 mL/hr). The initial bolus and subsequent infusion will be administered through a dedicated intravenous line or port of a multi-lumen catheter.
89626703|NCT02928172|Other|Depth of Anesthesia|Subjects will have the qCON-qNOX and BIS monitor
89626704|NCT02299570|Active Comparator|Group A|Two enemas of RBX2660 (microbiota suspension) administered 7 days apart
89626705|NCT02299570|Placebo Comparator|Group B|Two enemas of placebo administered 7 days apart
89626706|NCT02299570|Active Comparator|Group C|1 enema of RBX2660 (microbiota suspension) and 1 enema of placebo administered 7 days apart
89626707|NCT02301364|Experimental|Buparlisib (BKM120)|This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
89626708|NCT04507828|Experimental|Combined DIBH-Expiration Planning Technique|Patients will undergo a 4D scan as well as a DIBH scan and an expiration breath hold scan. In order to develop a combined DIBH-Expiration treatment plan, the DIBH scan, the expiration phase of the 4D scan or the expiration breath hold scan will be used. If the radiation plan meets the coverage goals and normal tissue constraints, the patient will receive treatment using the new DIBH Planning Technique. If coverage and normal tissue constraints are not met per protocol, the patient will be treated per standard of care and not on protocol. Patients treated on protocol will undergo radiation treatment with SBRT for a total of 3 fractions and will receive each fraction no more frequently then every other day. Patients will then be evaluated at 1 month after SBRT completion and every 3 months for 2 years
89626709|NCT02637778|Experimental|Cardioprotective diet|The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
89039268|NCT00554645|Experimental|1|Multi-disciplinary group intervention
89039269|NCT00554645|Active Comparator|2|traditional information
89039270|NCT02257619|Experimental|Itacitinib plus docetaxel|
89039271|NCT04683471|Experimental|Neuromodulation|Neuromodulation
89039272|NCT04683471|Sham Comparator|Sham|Sham
89626710|NCT02637778|Experimental|Cardioprotective diet + 3 g EPA+DHA/d|"The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).~Participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)."
89626711|NCT03664726|Experimental|Episodic Future Thinking (EFT) & Neutral Narrative|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months). Participants will also be asked to think about a neutral narrative that describes a situation in which changes to their income are neutral or minimal
89626712|NCT03664726|Active Comparator|Episodic Recent Thinking (ERT) & Neutral Narrative|Participants will complete an episodic recent thinking task to generate episodic cues where they will list and describe events for different time periods. The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event. ERT participants will list positive recent events they enjoyed and list events that happened recently (e.g. 1 - 7 days ago). Participants will also be asked to think about a neutral narrative that describes a situation in which changes to their income are neutral or minimal (e.g. department job transfer).
89626713|NCT03664726|Experimental|Episodic Future Thinking (EFT) & Scarcity Narrative|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months). Participants will also be asked to think about a narrative to induce a scarcity mindset by describing a situation in which changes to their income are negative (e.g. loss of job).
89626714|NCT03664726|Experimental|Episodic Recent Thinking (ERT) & Scarcity Narrative|Participants will complete an episodic recent thinking task to generate episodic cues where they will list and describe events for different time periods. The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event. ERT participants will list positive recent events they enjoyed and list events that happened recently (e.g. 1 - 7 days ago). Participants will also be asked to think about a narrative to induce a scarcity mindset by describing a situation in which changes to their income are negative (e.g. loss of job).
89626715|NCT03648112|Active Comparator|Intervention 1|"Intervention 1: Crude oat flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes."
89626716|NCT03648112|Active Comparator|Intervention 2|"Roasted oat flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~These oat flakes were roasted at 150°C for 20 minutes.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes."
89626717|NCT03648112|Active Comparator|Intervention 3|"Crude barley flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes"
89626718|NCT03648112|Active Comparator|Intervention 4|"Roasted barley flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes."
89626719|NCT03648112|Placebo Comparator|control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
89626720|NCT03613402||Cohort 1|Patients at risk of VTE who are prescribed betrixaban to prevent VTE
89626721|NCT03613402||Cohort 2|Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis
89626722|NCT02563522|Active Comparator|Active|Engensis (VM202) + standard of care
89626723|NCT02563522|Placebo Comparator|Control|Placebo (VM202 Vehicle) + standard of care
89626724|NCT03578146|Experimental|Module 2 (210 mg)|210 mg andexanet IV bolus administered over 7 minutes (~30 mg/min)
89626725|NCT03578146|Experimental|Module 2 (420 mg)|420 mg andexanet IV bolus administered over 14 minutes (~30 mg/min)
89626726|NCT03578146|Experimental|Module 2 (600 mg)|600 mg andexanet IV bolus administered over 20 minutes (~30 mg/min)
89626727|NCT03578146|Experimental|Module 2 (720 mg bolus + 240 mg infusion)|720 mg IV bolus administered over 24 minutes [~30 mg/min] followed by 240 mg continuous IV infusion [4 mg/min over 60 min)
88989975|NCT04468451|Active Comparator|ROC-24 group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. Parents/caregivers and the occupational therapist will be responsible for ride-on car with a standing posture training. The dosage will be 24 hours for a total of 12-week intervention.
89039273|NCT02235272|Experimental|XG-102|
89039274|NCT02235272|Placebo Comparator|Placebo|
89039275|NCT04891302|Experimental|Clevudine|Clevudine 150 mg once a day for 10 days
89039276|NCT04891302|Placebo Comparator|Placebo|Matching Placebo once a day for 10 days
89039277|NCT02229929|Placebo Comparator|Part A: Placebo|Intravenous matched placebo
89039278|NCT02229929|Experimental|Part A: CR845 0.5 mcg/kg|Intravenous CR845, 0.5 mcg/kg
89039279|NCT02229929|Experimental|Part A: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
89626728|NCT03578146|Experimental|Module 2 (800 mg bolus + 960 mg infusion)|800 mg IV bolus administered over 26.7 minutes [~30 mg/min] followed by 960 mg continuous IV infusion [8 mg/min over 120 min]
89039280|NCT02229929|Experimental|Part A: CR845 2.5 mcg/kg|Intravenous CR845, 2.5 mcg/kg
89039281|NCT02229929|Placebo Comparator|Part B: Placebo|Intravenous matched placebo
89039282|NCT02229929|Experimental|Part B: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
89626729|NCT03578146|Experimental|Module 2 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.
89626730|NCT02464332|Experimental|BLZ-100|"All participants in the study will receive the investigational drug product BLZ-100.~In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.~In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose)."
89626731|NCT01946919||cinepazide|Inpatient using the cinepazide in department of neurology
89626732|NCT02986438|Active Comparator|Active rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 5 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 5Hz, to 100% of the motor threshold.
89626733|NCT02986438|Sham Comparator|Sham rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 5 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks.
89626734|NCT01895673||PET-MRI|Twenty patients with RFA/MWA for CRLM or RFA/MWA of recurrent liver lesions after prior local treatment of CRLM and are eligible to undergo MRI-scanning are included when they have adequate renal function. Patients that do not meet inclusion criteria for undergoing an MRI scan are excluded.
89626735|NCT02716896|Active Comparator|Surgery (radical cystectomy)|In brief, radical cystectomy is the removal of the entire bladder, nearby lymph nodes (lymphadenectomy), part of the urethra, and nearby organs that may contain cancer cells. In men the prostate, the seminal vesicles, and part of the vas deferens are also removed. In women the cervix, the uterus, the ovaries, the fallopian tubes, and part of the vagina are also removed. Participants in this group may also undergo neoadjuvant chemotherapy prior to the surgery. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, Glomerular Filtration rate (GFR), participant's preference, and availability of chemotherapeutic regimen.
89626736|NCT02716896|Active Comparator|Radiation and Chemoradiation|Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
89626737|NCT02986360|Active Comparator|Vidscrip educational video|Patients receive Vidscrip education video discussing breast density in the context of their normal mammogram result
89626738|NCT02986360|No Intervention|Standard of care|Receive normal mammogram result and standard letter about breast density without any additional educational tools to contextualize breast density
89626739|NCT02465346|Experimental|MSU-based stroke management|The Mobile Stroke Unit (MSU) and the conventional emergency medical Service (EMS) will meet at the emergency site. The patient's medical history, the physical examination will directly be performed by a physician. Laboratory tests will be analyzed by a point of care laboratory. CT will be performed. After performance of the acute stroke diagnostic work-up the patients and, if indicated thrombolysis, the patient will be transported according to the diagnostic results: Stroke due to large vessel occlusion or to intracranial hemorrhage-> Neurovascular centre; Stroke without large vessel occlusion or without hemorrhage-> primary hospital with regional stroke unit.
89039283|NCT02224235|Experimental|Group 1- COBRA 1 week DAPT|COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
89039284|NCT02224235|Active Comparator|Group 2 - DES 6 month DAPT|Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
89039285|NCT02224235|Experimental|Group 3 - COBRA Aspirin|COBRA PzF coronary stent followed by aspirin alone
89039286|NCT02529852|Experimental|Lenalidomide + Obinutuzumab + CHOP|"Phase I: Participants take Lenalidomide by mouth on Days 1 - 14 of each cycle. Participants receive Obinutuzumab by vein over 3 - 4 hours on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6. Participants receive Cyclophosphamide by vein over about 1 hour on Day 1 of all cycles. Participants receive Doxorubicin and Vincristine by vein over about 15 minutes each on Day 1 of all cycles.~Phase II: Participants treated at the recommended phase II dosing (RP2D) of Lenalidomide determined in the Phase Ib portion for 6 cycles of therapy. Dose of Obinutuzumab, Cyclophosphamide, Doxorubicin and Vincristine remain the same as in Phase I.~Each study cycle is 21 days."
89039287|NCT02223182|Experimental|Viaskin Milk 150 mcg|
89039288|NCT02223182|Experimental|Viaskin Milk 300 mcg|
89039289|NCT02223182|Experimental|Viaskin Milk 500 mcg|
89039290|NCT02223182|Placebo Comparator|Viaskin Placebo|
89039291|NCT02222948|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 at Weeks 0, 2, 4 and 8
89626740|NCT02465346|Active Comparator|Control stroke management|After performing patient's medical history, physical examination (reassessment of the extended Face Arm Speech Time score) and glucose testing by the (stroke trained) emergency personnel, the patient will be transported according to current best clinical practice and relevant guidelines to the next stroke unit or neurovascular centre. The hospital stroke team will be prenotified by the EMS. According to the patients needs the patient might be further transferred.
89626741|NCT03510988|Experimental|Women with newly diagnosed breast cancer|Women with newly diagnosed breast cancer recruited for hybrid dedicated breast PET/MRI for extent of disease staging prior to management in lieu of breast MRI alone. IV FDG and Gadolinium was injected once prior to the study as per protocol and weight. In each second consecutively recruited patient FDG dosage was decreased by 20% up to 40% of weight-based dosage to ascertain feasibility of imaging at lower FDG dosages. IV Gadolinium was injected once with weight dependent dosages as per clinical standard of care.
89626742|NCT02462226|Active Comparator|Arm Precaution|"Patients assigned to Education #1 will receive arm precaution self-care strategies. The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb. Exercises to promote limb mobility will also provided. Only the patients in the control group will be given access to Arm Precautions section.~Patients will be given access to the website to learn about the arm precaution program."
89626743|NCT02462226|Experimental|The-Optimal-Lymph-Flow|"The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.~Patients will be given the access to the website to learn about the The-optimal-Lymph-Flow program"
89626744|NCT01934985||Group 1|Patients scheduled to have clinically indicated stress MPI with low pre-test likelihood (0-15%) of coronary disease based on criteria of Diamond and Forrester. And those who have already had a clinical indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.
89626745|NCT01934985||Group II|Patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic selective coronary angiography (SCA) and will be performed electively, at least 4 to 7 days later. Viability will be assessed in these patients only in the presence of WM abnormalities, and with serial analysis of WM, as described above. Patients will be followed for death or infarction or other events more than 3 months after study, for up to 3 years following participation in the protocol.
89039292|NCT02222948|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 at Weeks 0, 2, 4 and 8
89626746|NCT01934985||Group III|"Patients found at SCA to have lesions of borderline clinical significance, preferably in the absence of other associated lesions."
89626747|NCT01934985||Group IV|Patients who were diagnosed with advanced heart failure including patients who had or will have cardiac resynchonization therapy (CRT) or a heart transplant.
89626748|NCT02465502|Experimental|Regorafenib (BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
89626749|NCT01516593|Experimental|intensive short term immuno-chemotherapy|Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.
89626750|NCT02042391|Experimental|Low-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
89626751|NCT02042391|Experimental|High risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
88989976|NCT04468451|Active Comparator|Control group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay. The participant's clinical occupational therapist will be responsible for the regular therapy. The dosage will be their regular dosage for a total of 12-week intervention.
88989977|NCT04462302|Experimental|Internet-based program + Pain Education|If you are in this group, in additional to your usual care, you will be provided access to the 8-session Internet-based pain program plus pain education. You will need to complete your sessions within 10 weeks of being provided your log-in code. You will be allowed to revisit sessions that you have completed during this 10 weeks. After completion of the study, you will still be provided access to the 8-session Internet-based pain program.
88989978|NCT04462302|No Intervention|Pain Education Only|If you are in this group, in addition to your usual care, you will be provided pain education at your initial clinic visit. After you have completed the 6-month follow up assessment, you will be provided a secure log-in code and invited to complete the 8 sessions of this Internet-based pain program on your own.
88989979|NCT04458922|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on ay 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans and undergo biopsy and collection of blood samples on study.
88989980|NCT04457089|Experimental|Simvastatin|
88989981|NCT04452916|Active Comparator|Fasting|Starts immediately with 5 days of Buchinger fasting
88989982|NCT04452916|Placebo Comparator|Waiting list control|Starts with 5 days of Buchinger fasting after a waiting period of 12 weeks
89626752|NCT02042391|Experimental|Very high-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.
89626753|NCT02465424||questionnaire order|the order of presentation of the 4 quality of life questionnaires to the patients will be randomised to reduce the impact of boredom and habituation on responses
89626754|NCT02465580|Active Comparator|hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
89039293|NCT02222948|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 at Weeks 0, 2, 4 and 8
89039294|NCT02222948|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 at Weeks 0, 2, 4 and 8
89039295|NCT02222948|Placebo Comparator|Placebo|Placebo (for Vatelizumab) at Weeks 0, 2, 4 and 8
89039296|NCT02221232|Experimental|ZuraPrep Config 1|Isopropyl alcohol (IPA) 70% Standard scrub time.
89039297|NCT02221232|Experimental|ZuraPrep Config 2|Isopropyl alcohol (IPA) 70% Half scrub time.
89039298|NCT02221232|Placebo Comparator|ZuraPrep Vehicle|ZuraPrep without IPA
89039299|NCT02221232|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
89039300|NCT02206100|Experimental|Cohort 1|100 mg PER977 (10 subjects); the dose may be repeated two (2) times after an approximate one (1) hour interval for a maximum total of three (3) doses
89039301|NCT02206100|Experimental|Cohort 2|200 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour for a maximum total of two (2) doses
89039302|NCT02206100|Experimental|Cohort 3|300 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour after the initial dose for a maximum of total of two (2) doses
89039303|NCT02206100|Experimental|Cohort 4|4 x 25 mg PER977 (10 subjects); study drug will be administered every 30 minutes for a total of 4 doses (cumulative dose of 100 mg PER977)
89039304|NCT02409303|Experimental|Screen-Refer-Treat Intervention|PCPs and EI Providers receive training workshops on validated, evidence-based practices (i.e., Online M-CHAT-R/F, STAT, and RIT) and then receive TA (i.e., Screen-Refer-Treat Intervention). At the county level, providers are randomized to the order/timing at which they will receive this system intervention
89039305|NCT02409303|No Intervention|Control|No intervention received.
89039306|NCT00554723|Experimental|A|NeuroAid
89039307|NCT00554723|Placebo Comparator|B|NeuroAid matched Placebo
89039308|NCT01231516|Experimental|GSK1349572 + Raltegravir Placebo|Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
89039309|NCT01231516|Active Comparator|Raltegravir + GSK1349572 Placebo|Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
89039310|NCT04668911||Controls tested PCR (-) for COVID-19|
89039311|NCT04668911||Tested PCR (+) for COVID-19, Mild - not admitted to the hospital|
89039312|NCT04668911||Tested PCR (+) for COVID-19, Severe - admitted to ICU (Intensive Care Unit)|
89039313|NCT04669106||Healthy group|90 research subjects coming from mothers who had healthy children
89039314|NCT04669106||Stunting group|90 research subjects came from mothers who had stunted children or other nutritional disorders
89039315|NCT04668755|Active Comparator|Charcot Restraint Orthotic Walker 3d printed sole|the group fit with Charcot Restraint Orthotic Walker 3d printed sole for 12 week. the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
89039316|NCT04668755|Active Comparator|Generic Charcot Restraint orthotic walker|the group fit with Generic Charcot Restraint Orthotic Walker for 12 week.the protocol of gait analysis testing starts with a reacclimation period during which the subject walked usual freely walking across the path for a duration of four minutes and then the testing session data collection done by four acceptable force platform strikes for the feet fitted with the CROW.
89039317|NCT01231321|Experimental|adalimumab|Adalimumab / pre-filled syringe 40 mg/0.8 ml
89039318|NCT04668482|Experimental|SCS off|SCS is switched off
89039319|NCT04668482|Experimental|SCS on|SCS is switched on
89039320|NCT04668560|Experimental|Intervention|Course intervention, six weeks wellbeing course
89039321|NCT04668560|No Intervention|Control|Follow-up as usual
89039322|NCT01627548|Active Comparator|Waitlisted Intervention|Couple will be consented, assessed and randomized to a waitlist of 4 months. The couple will be reassessed at 8 weeks and prior to initiating intervention.
89039323|NCT01627548|Active Comparator|Immediate Intervention|Eligible couples who are randomized to immediate intervention will begin sessions with a trained interventionist within weeks of consent and initial assessments
89039324|NCT04668404||COVID-19 positive patient with ARDS|All patients with COVID-19 diagnosed with RT-PCR.
89039325|NCT01210222|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89039326|NCT04668287|Other|Increasing Self-Esteem|All participants will be included in working groups.
89039327|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Long Agonist Protocol|
89039328|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Multi-dose Antagonist Protocol|
89039329|NCT01351467||Parkinson's disease patients|People diagnosed with Parkinson's disease by a physician
89039330|NCT05423470|Experimental|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
89626755|NCT02465580|Placebo Comparator|hrIL-2 placebo|1 million U doses of placebo s.c. injection
89626756|NCT02461836|Experimental|Chemo|adjuvant chemotherapy using Gemcitabine for 6 rounds
89626757|NCT02461836|Experimental|Chemo+SBRT|SBRT is delivered prior to adjuvant chemotherapy with Gemcitabine for 6 rounds
89626758|NCT01924221||CRT|Patients with implanted cardiac resynchronization therapy defibrillator
89626759|NCT01986946|Experimental|Intravenous opioids|This is the standard of care method for post-operative analgesia following lumbar spine fusion surgery. Participants randomly assigned to this arm will receive Intravenous Patient-Controlled Analgesia (IVPCA) with dilaudid (or other opioid) for post-operative pain control.
89626760|NCT01986946|Experimental|Epidural Catheter|The intervention to be tested in this study against standard intravenous opioids is infusion of local anesthetic and dilaudid via epidural catheter for post-operative pain control in patients undergoing lumbar spine fusion surgery.
89626761|NCT02034747|Experimental|Corticosteroid with the 50% reduced dose|oral
89626762|NCT02034747|Active Comparator|Corticosteroid with the maintained dose|oral
89626763|NCT01987414|Experimental|Group A|Forearm rotation orthosis (6 weeks); Forearm rotation orthosis plus occupational therapy task-oriented approach (6 weeks)
89626764|NCT01987414|Active Comparator|Group B|no treatment (6 weeks); occupational therapy task-oriented approach (6 weeks)
89626765|NCT02464254|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
89626766|NCT02464254|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
89626767|NCT01909713|Experimental|Facial Cleanser and Moisturizer SPF 30|All subjects used Cetaphil® DermaControl™ Oil Control Foam Wash and Cetaphil® DermaControl™ Oil Control Moisturizer SPF 30 at least once daily for 22 days.
89626768|NCT03437200|Experimental|Arm A: Chemoradiation + Nivolumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT.~Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year."
89626769|NCT03437200|Experimental|Arm B: Chemoradiation + Nivolumab + Ipilimumab|Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year
89626770|NCT05566587|Other|Western to Mediteranean to Western Diet|Weeks 2 and 3 = WD Weeks 4 and 5 = MD Weeks 6 and 7 = WD
89626771|NCT05566587|Other|Mediteranean to Western to Mediteranean Diet|Weeks 2 and 3 = MD Weeks 4 and 5 = WD Weeks 6 and 7 = MD
89626772|NCT01903473|Experimental|Donor Treg infusion arm|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 60-90 days after.
89626773|NCT01903473|Active Comparator|Control|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.
89626774|NCT01894425||Study population|"The study population consists of couples under care for infertility in the participating centers. Gamete donations are not included. Please see inclusion and exclusion criteria.~Intervention: HPV screening for women Intervention: HPV screening for men"
89626775|NCT01900977|Active Comparator|Arm A Universal Testing w/Immediate ART|
89626776|NCT01900977|Active Comparator|Arm B ART according to National Guidelines|
89626777|NCT01900977|Other|Standard of Care|"Includes:~Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community."
89626778|NCT02715726|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
89626779|NCT02715726|Experimental|Alirocumab 75 mg Q2W/up to 150 mg Q2W|Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was >=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter [mmol/L]) at Week 8.
89626780|NCT01893567|Experimental|Clobex spray|
89626781|NCT04249596|Experimental|Open Treatment|All subjects will be treated for 8 weeks of treatment with Tianeptine (Tianeurax 12.5 mg) 3 times a day (9am, 1pm, 5pm).
89626782|NCT01476501|Experimental|2,000 IU/day vitamin D|2,000 IU/day vitamin D for 6 months (n=60).
89626783|NCT01476501|Experimental|40,000 IU/month vitamin D|40,000 IU/month for 6 months (n=60).
89626784|NCT04248816|Experimental|Usual Care|Standard of care
89626785|NCT04248816|Experimental|Opt-out|Facilitated outreach and opt-out framing
89626786|NCT04248816|Experimental|Opt-out + Incentive|Facilitated outreach and opt-out framing plus a financial incentive
89626787|NCT03426124||Retrospective|Individuals with intermediate-high or high risk pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.
89626788|NCT03426124||Prospective|Individuals who are experiencing intermediate-high or high risk pulmonary embolism where the treating investigator has selected the EKOS device and thrombolytic drug. The duration of ultrasound and volume of thrombolytic drug are selected per physician discretion.
89626789|NCT02464020|Experimental|primary sclerosing cholangitis|Two week course of oral vancomycin 500mg twice a day.
89626790|NCT02464020|No Intervention|Control group|A control group of participants without Primary Sclerosing Cholangitis. Control group will consist of both healthy subjects and subjects with Inflammatory Bowel Disease.
89626791|NCT04756089|Experimental|Breast stimulation|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
89626792|NCT04756089|Active Comparator|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
89626793|NCT02465112|Experimental|metabolic radiotherapy|In111-Pentetréotide at 12, 18 and 24 weeks after surgery,
89626794|NCT02465112|Active Comparator|No metabolic radiotherapy - simple monitoring|No metabolic radiotherapy - simple monitoring without theraoy
89211161|NCT00937092|Active Comparator|low-dose dopamine + low-dose furosemide|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
89211162|NCT04124601|Other|Neoadjuvant Chemoradiotherapy|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days)
89211163|NCT04124601|Experimental|Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab|Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days) with sequential Ipilimumab (1 mg/kg IV on day 7) and Nivolumab (3 mg/kg IV on day 14, 28 and 42)
89626795|NCT01888887|Experimental|Cetaphil Daily Facial Cleanser|All subjects receive Cetaphil Daily Facial Cleanser
89626796|NCT03397888|Experimental|Cohort 1|Mild Impairment, Child-Pugh Category A
89626797|NCT03397888|Experimental|Cohort 2|Moderate Impairment, Child-Pugh Category B
89626798|NCT03397888|Experimental|Cohort 3|Essentially Healthy man or woman without liver disease matched to Cohorts 1 & 2 for age, sex and weight.
89626799|NCT01886859|Experimental|Treatment (ibrutinib and lenalidomide)|Patients receive a run-up cycle of ibrutinib PO daily on days 1-28. Patients then receive ibrutinib PO and lenalidomide PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients who have achieved CR/CRi, nodular PR, partial remission with persistent lymphocytosis, partial remission, or who have stable disease discontinue lenalidomide and continue ibrutinib.
89626800|NCT00877344|Experimental|1|Immediate insertion of either a LNG-IUC or a Copper T380 IUD after 12-24 week abortion
89626801|NCT00877344|Experimental|2|Interval insertion (two to four weeks post abortion) of either a LNG-IUC or a Copper T380 IUD after 12-24 abortion
89626802|NCT01885377|Experimental|Specific exercise group|A progressive program of strength-endurance exercises for the rotator cuff and scapula stabilizing muscles combined with mobilization of the joint capsule when needed
89626803|NCT01885377|Active Comparator|Control exercise group|General movements for the neck and shoulder and self-stretching. No progression some addition of exercises during the three month period.
89626804|NCT01989130|Experimental|Real-time results with Cepheid Xpert CT/NG Test|Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
89626805|NCT01989130|Active Comparator|Batched results with Roche AMPLICOR CT/NG test|Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
89626806|NCT03299010||DM patient|Patients with a documented clinical diagnosis of DM and were receiving care in the Hospital Authority (HA) primary care General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) on or before 1 July 2006 identified from the HA clinical management system (CMS) database.
89626807|NCT01894971|Experimental|twice coagulated side of fallopian tube|twice coagulated side of fallopian tube once coagulated sied of fallopian tube
89626808|NCT01989910|Active Comparator|Raltegravir|Raltegravir 400mg oral twice daily
89626809|NCT01989910|Active Comparator|Efavirenz|Efavirenz 600mg oral at bedtime
89626810|NCT02464722|Experimental|Dexmedetomidine|"Before induction of Anesthesia, 1 mcg/kg iv loading dose of dexmedetomidine over 10 minutes.~Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~After Mask ventilation with 6 vol% desflurane in 100% oxygen for 3 minutes, tracheal intubation was done~Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~At the end of surgery, discontinuation of desflurane and dexmedetomidine, sending recovery room."
89626811|NCT02464722|Active Comparator|Remifentanil|"Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~Mask ventilation with 6 vol% desflurane in 100% oxygen for 2 minutes.~After 1 mcg/kg iv loading dose of remifentanil over a period of 1 minutes. tracheal intubation was done.~Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~At the end of surgery, discontinuation of desflurane and remifentanil, sending recovery room."
89626812|NCT02314156|Experimental|Arm I (transdermal telapristone acetate)|Patients receive telapristone acetate transdermally and placebo PO QD for 4 weeks.
89626813|NCT02314156|Active Comparator|Arm II (oral telapristone acetate)|Patients receive placebo transdermally and telapristone acetate PO QD for 4 weeks.
89626814|NCT01991548|Other|Diabetic participants with study devices|
89626815|NCT02461680|Experimental|Tangential resection|the tendon's injury is treated with a tangential resection
89626816|NCT02461680|Active Comparator|Suture|The tendon's injury is sutured
89626817|NCT02461914|Experimental|Warfaring and PEX168(200µg)|Warfarin: 5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
89626818|NCT01991860|Experimental|APD421|APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.
89626819|NCT01991860|Placebo Comparator|Placebo|Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia
89211164|NCT00930696|Experimental|Extensive Abdominal Lavage|women with full thickness excision of deep endometriosis involving the bowel
89211165|NCT00930696|Active Comparator|Standard Rinsing|women with full thickness excision of deep endometriosis involving the bowel
89211166|NCT00937170|Experimental|Gender Specific LPS flex|Participants in this arm will receive the Zimmer LPS flex Gender Specific Implant design
89211167|NCT00937170|Active Comparator|LPS flex|Participants in this arm will receive the Zimmer High Flex LPS implant
89211168|NCT00937170|Active Comparator|Triathlon|Participants in this arm will receive the Stryker Triathlon Implant design
89211169|NCT00932412|Experimental|CLARA|Clofarabine / Intermediate-Dose Cytarabine (CLARA) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
89211170|NCT00932412|Active Comparator|HDAC|High-Dose Cytarabine (HDAC) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
89626820|NCT01874223||IPF-diagnosed patients|A group of up to 40 patients with a diagnosis of mild to severe IPF per American Thoracic Society (ATS) guidelines, either with no cough at baseline to severe cough at baseline, will be followed for at least a one-time assessment and every six months for up to 18 months to establish validity, responsiveness, and reliability of cough, dyspnea, and QOL instruments in patients with IPF.
89626821|NCT01986790|Experimental|Plain Language|This intervention group will receive a plain-language table describing the features and costs of health insurance plans, with definitions of health insurance terms incorporated into the table.
89626822|NCT01986790|Experimental|Plain Language + Visuals|This intervention group will receive the plain-language table plus visuals that focus on specific features of the plans. Participants will be able to view the information about each health insurance feature one feature at a time, in the order they prefer.
89626823|NCT01986790|Experimental|Plain Language + Narratives|This intervention group will receive the plain language table plus narratives about how others might use and rate the insurance plans.
89626824|NCT02463552|Placebo Comparator|Placebo|
89626825|NCT02463552|Experimental|Naproxen|
89626826|NCT01992016|Experimental|Arm I (localized prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment. Patients may then undergo robotic or open radical prostatectomy.
89626827|NCT01992016|Experimental|Arm II (metastatic prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment.
89626828|NCT01871571|Experimental|Treatment (bevacizumab, mFOLFOX7)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV continuously over 46-48 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after treatment, patients undergo surgery.
89626829|NCT01992172|Active Comparator|Photocil for Atopic Dermatitis|Active Drug - Photocil for Atopic Dermatitis
89626830|NCT01992172|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
89626831|NCT03296982||Blood Sample|Blood will be sampled by direct venipuncture on 8 occasions.
89626832|NCT03296904|Experimental|CLs++|Baseline assessment, intervention, final assessment
89626833|NCT02463630|Experimental|Compression distraction reduction|All the participants in this group will be performed Posterior Compression Distraction Reduction Technique for reduction of basilar invagination and atlantoaxial dislocation
89626834|NCT00493701|Other|Lifestyle|Measurement of body weight in a fown with light undercloting (30 minutes) and height.
89626835|NCT00493701|Other|DEXA Scanner|Low-dose X0rays to determine the amount of fat, bone and muscle in your body.
89626836|NCT01895829|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|"On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. The study MRI performed in the same way that a standard MRI is performed.~On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed."
89626837|NCT03296748|Active Comparator|TOT only group|60 patients with stress incontinence and asymptomatic grade 2 cystocele.
89626838|NCT03296748|Active Comparator|concomitant repair group|63 patients with stress incontinence and asymptomatic grade 2 cystocele.
89626839|NCT03298776|Active Comparator|standard white light endoscopy|Patients will undergo the standard of care which is standard white light endoscopy
89626840|NCT03298776|Experimental|Endoscopy and I-Scan|Patients will undergo standard of care endoscopy plus the I-Scan
89039331|NCT05423470|Sham Comparator|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
89626841|NCT03298698|Experimental|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
89626842|NCT03298698|Active Comparator|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
89626843|NCT02463942|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
89626844|NCT02463942|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
89039332|NCT04668053|Active Comparator|Traditional training protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills
89039333|NCT04668053|Experimental|Hip flexor resistance protocol|Mobility and core strengthening, The step, The Lunge, Body weight squat, Body weight split squat , Bilateral hip raise, Push-up ,Cricket related skills and hip flexors resistance protocol
89039334|NCT01209949|Other|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|
89039335|NCT04667936||moderate to severe COVID-19 ARDS|patients with an oxygenation index <200 under intubation anesthesia and mechanical ventilation.
89039336|NCT04667975|Experimental|Part 1(Dose escalation)|"Part 1: 3 or 6 subjects are enrolled, per each dose group in a traditional 3+3 design.~Begin with the starting dose determined by the non-clinical study and increase the dose according to the dose levels. If DLT does not occur in the 3 subjects when they have completed the 1st cycle at each dose level, increase the dose to the next level. Dose escalation proceeds until the maximum tolerated dose (MTD) is reached.~Dose-limiting toxicity (DLT) is evaluated following the completion of dosing for the 1st cycle of all subjects enrolled in each dose group in order to determine whether to proceed to the next level. Following completion of the DLT evaluation of the planned dose level in this study, the SRC reviews the outcome of the evaluation and determines whether to set additional dosing or proceed to PART 2 (Dose expansion)."
89626845|NCT02463942|Other|Healthy controls|"Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.~Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia."
89626846|NCT03385408|Experimental|HILT group|High-intensity laser therapy application through HIRO 3.0 device
89626847|NCT03385408|Sham Comparator|Placebo group|Sham high-intensity laser therapy application through HIRO 3.0 device
89626848|NCT01853163|Other|GBCA|Patients who have received GBCAs in the past
89626849|NCT03298620|Experimental|Intervention|Electric toothbrush
89626850|NCT03298620|Active Comparator|Control|New standard manual toothbrush
89626851|NCT03360136|Other|Multi-professional CBT-rehabilitation|24 weeks CBT-based multi-professional rehabilitation.
89626852|NCT03298542|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
89626853|NCT03298542|Placebo Comparator|Group 2: Placebo|Participants will receive a SC matching placebo to golimumab.
89626854|NCT03350698|Experimental|active drug|Human Papilloma virus ,Gardasil, 9 valent vaccine
89626855|NCT03296670|Experimental|alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
89626856|NCT03296670|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
89039337|NCT04667975|Experimental|Part 2(Dose expansion)|"Part 2: The primary objective of Part 2 is to evaluate the efficacy of CKD-702 by identifying the ORR after administering the RP2D of CKD-702 determined in Part 1. Along with this, to determine the CKD-702 effective patient group, the patient groups were classified into several cohorts based on non-clinical study results.~Therefore, in Part 2, the RP2D determined in Part 1 is administered until the occurrence of an adverse event causing PD occurrence, death or treatment discontinuation, and tumor response is evaluated based on RECIST version 1.1."
89039338|NCT04831593||Group Elective|In our clinic, pediatric patients who will undergo elective surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in elective pediatric patients before general anesthesia.
89039339|NCT04831593||Group Emergency|In our clinic, pediatric patients who will undergo emergency surgery, are performed gastric ultrasound before the operation. We aimed to see how often we met with empty and full stomach and to determine relationship between fasting time and qualitative assessment of gastric content in emergency pediatric patients before general anesthesia.
89039340|NCT04825509||Successful weaning group|Patients will be in this group according to primary outcome, if they will succeed spontaneous breathing trial for 120 minutes and will be extubated successfully without need for invasive or non-invasive ventilation for 48 hours
89039341|NCT04825509||Weaning failure group|"Patients will be in this group according to primary outcome, if they will fail spontaneous breathing trial or extubation within 48 hours~Weaning failure will be considered if:~Patients will need MV during spontaneous breathing trial within 120 minutes, or~patients will need invasive or non-invasive ventilation within 48 hours"
89626857|NCT02463864|Experimental|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercise sessions
89626858|NCT02463864|Sham Comparator|Sham exercise|Twice daily, individual, stretching and relaxation exercise sessions
89626859|NCT03296514|No Intervention|Wait List Control|Will receive voucher for MBSR after study is concluded
89626860|NCT03296514|Other|Intervention|These people will receive the MBSR
89626861|NCT03296436|Experimental|Treatment Group|Group that will be receiving the investigational product
89039342|NCT04667897|Experimental|601 1.25mg|
89039343|NCT04667897|Experimental|Ranibizuman 0.5 mg|
89039344|NCT04683081||Foley catheter group|pregnant women who were applied Foley catheter for cervical ripening
89039345|NCT04683081||Cook balloon catheter group|pregnant women who were applied Cook balloon catheter for cervical ripening
89626862|NCT03298464|Experimental|NGM313|
89626863|NCT03298464|Active Comparator|Pioglitazone|
89626864|NCT03287596|Experimental|HEALTHY VOLUNTEERS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium"
89626865|NCT03287596|Experimental|SPA + NON-SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
89626866|NCT03287596|Experimental|SPA + SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
89626867|NCT03287596|Experimental|MECHANIC TENDINOPATHY|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
89626868|NCT01852071|Experimental|Gene Therapy|Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells
89626869|NCT03219736|Active Comparator|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. To summarize, all moderate and severe acute asthma exacerbations receive albuterol and atrovent continuous aerosols, oral or intravenous steroids and intravenous magnesium sulfate. At the discretion of the treating physician, the patient may also receive subcutaneous terbutaline or epinephrine
89626870|NCT03219736|Active Comparator|NiPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine (EnVe Ventilator). Optimal settings for each participant should be achieved within 20 minutes of initiation of NiPPV. Pediatric asthma scores will continue to be recorded at least every hour or with every physician suggested NIPPV ventilator setting change for an 8 hour period. Furthermore, the NIPPV machine in conjunction with NM3 volumetric end tidal CO2 monitoring will record ventilatory data in this NIPPV/BiPAP group and will be compared to other study groups. The subjects will remain in the study for minimum of 4 hrs NIPPV therapy and total of 8 hours.
89626871|NCT04084548|Experimental|Lidocaine and placebo|Lidocaine and placebo
89626872|NCT04084548|Experimental|Ketamine and placebo|Ketamine and placebo
89626873|NCT04084548|Experimental|Lidocaine and ketamine|Lidocaine and ketamine
89626874|NCT04084548|Placebo Comparator|Placebo and placebo|Placebo and placebo
89626875|NCT02059642|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product Route, frequency: Administered orally once daily
89626876|NCT02059642|Experimental|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) Dose, route, and frequency: 1400 mg administered orally once daily
89626877|NCT03296358|No Intervention|Control group|Chlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication
89626878|NCT03296358|Experimental|Experiment 1|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
89626879|NCT03296358|Experimental|Experiment 2|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication
89626880|NCT04756323|Experimental|medium dosage on day 0, 14(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
89626881|NCT04756323|Experimental|high dosage on day 0, 14(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,14
89626882|NCT04756323|Placebo Comparator|placebo on day 0, 14(18~59years)|Two doses of placebo on the schedule of day 0,14
89626883|NCT04756323|Experimental|medium dosage on day 0, 28(18~59 years)|Two doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
89626884|NCT04756323|Experimental|high dosage on day 0, 28(18~59 years)|Two doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28
89626885|NCT04756323|Placebo Comparator|placebo on day 0, 28(18~59years)|Two doses of placebo on the schedule of day 0,28
89039346|NCT04683081||Modified double-balloon Foley catheter group|pregnant women who were applied modified double-balloon Foley catheter for cervical ripening
89039347|NCT01209832|Experimental|Drug Interaction arm|
89039348|NCT04667819|Experimental|sodium hyaluronate|Sodium hyaluronate has become a novel and effective eye drop for the treatment of the dry eye. However, we design a special method of usage of sodium hyaluronate in dry eye patients.
89626886|NCT04756323|Experimental|medium dosage on day 0, 28, 56(18~59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
89626887|NCT04756323|Experimental|high dosage on day 0, 28, 56(18~59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
89039349|NCT04683159|No Intervention|Control|No intervention, only routine pre-operative drops
89039350|NCT04683159|Experimental|Brimonidine 0.15%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.15% in the operating eye
89039351|NCT04683159|Experimental|Brimonidine 0.025%|Routine pre-operative drops + 1 drop of brimonidine tartrate 0.025% in the operating eye
89626888|NCT04756323|Placebo Comparator|placebo on day 0, 28, 56(18~59 years)|Three doses of placebo on the schedule of day 0,28,56
89626889|NCT04756323|Experimental|medium dosage on day 0, 28, 56(>59 years)|Three doses of medium dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
89039352|NCT01230892|Active Comparator|Nebivolol|
89039353|NCT01230892|Active Comparator|Atenolol|
89039354|NCT04667624|Active Comparator|Reference|TWYNSTA Tablet 80/5mg(Telmisartan/Amlodipine)
89039355|NCT04667624|Experimental|Test|LodienT Tablet 80/2.5mg(Telmisartan/S-amlodipine)
89039356|NCT04667351|Active Comparator|5-fu 2400|
89039357|NCT04667351|Experimental|5-fu 1200|
89626890|NCT04756323|Experimental|high dosage on day 0, 28, 56(>59 years)|Three doses of high dosage inactivated SARS-CoV-2 vaccine on the schedule of day 0,28,56
89626891|NCT04756323|Placebo Comparator|placebo on day 0, 28, 56(>59 years)|Three doses of placebo on the schedule of day 0,28,56
89626892|NCT03298386|Experimental|"Intervention Group STOPP/START"|Training of General Practitioners with the tool STOPP/START Systematic medication review by GP with STOPP/START
89626893|NCT03298386|No Intervention|Control group|Patient's usual care by the general practitioner (who will not be trained in the STOPP/START tool)
89626894|NCT04756713|Active Comparator|Chemotherapy|Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
89039358|NCT01230814|Experimental|Arm 1|Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.
89039359|NCT01230814|Placebo Comparator|Arm 2|Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.
89039360|NCT01230307|Active Comparator|Vitamin D|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
89039361|NCT01230307|Placebo Comparator|Placebo|A placebo loading dose will be given followed by two placebo tablets daily for 6 months.
89039362|NCT04810377|Experimental|EUS-guided gastroenterostomy in malignant gastric outlet obstruction|The patients with malignant gastric outlet obstruction will be confirmed as follows: Histopathological report of cancer, thoracoabdominal tomography and impaired tolerance to oral feeding (tolerance to liquids only or null).
89039363|NCT00556595|Experimental|1|primary electrophysiological approach
89039364|NCT00556595|Active Comparator|2|primary anatomical approach
89039365|NCT01209598|Experimental|Palbociclib 200mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
89039366|NCT01209598|Experimental|Palbociclib 125mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
89039367|NCT04809090|Active Comparator|SMT Group|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews
89211171|NCT05046639|Experimental|Treatment group 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
89211172|NCT05046639|Placebo Comparator|Sham preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
89626895|NCT04756713|Experimental|Uterine evacuation|Patients randomized to undergo a second curettage will undergo manual or electronic vacuum aspiration under ultrasound guidance. Following discharge after the second curettage patients will return to weekly hCG monitoring. If hCG levels are decreasing, patients will remain on weekly hCG follow-up until the first normal hCG (<5 IU/L) is achieved. Then they will have monthly hCG monitoring for 12 months. If patients do not attain remission and develop persistent GTN as established by FIGO 2000, the tumor will be re-staged and appropriate chemotherapy will be initiated.
89211173|NCT04014036|Experimental|1|30 subjects receive ESWT (LM-IASO, Litemed Co., Taiwan) for 6 courses in 3 weeks (0.05mJ/mm2, 3000 pulses). Thereafter, the two groups are cross over.
89211174|NCT04014036|Sham Comparator|2|30 subjects receive Sham therapy for 3 weeks (the machine turning on but the energy is zero). Thereafter, the two groups are cross over.
89211175|NCT05007951|Experimental|Test group (GBP510) - Cohort 1|Immunogenicity Cohort
89626896|NCT04489056||Study group|This group will consist of 50 pregnant women, who experienced pPROM between 22+5 and 28+0 gestational weeks, either presenting at the primary study site, or being referred from other hospitals, and delivered at preterm by cesarean section.
89626897|NCT04489056||Control group|This group will consist of 50 pregnant women, who are scheduled for elective cesarean section at the outpatient department of the primary study site, between a 32+0 and 37+0 gestational weeks, and delivered at term by cesarean section.
89626898|NCT00469755|Active Comparator|1|Differin® Gel, 0.1% for 12 weeks
89626899|NCT00469755|Active Comparator|2|Tazorac® Cream, 0.1% for 12 weeks
89626900|NCT00469755|Active Comparator|3|Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
89626901|NCT03296202||HIV patients|4500 patients infected with HIV-1
89626902|NCT02463396|Experimental|Mindfulness Based Cognitive Therapy (MBCT) for ADHD|Adapted MBCT for ADHD
89626903|NCT02463396|No Intervention|Treatment as usual (TAU)|Usually medication & psycho-education
89626904|NCT00458133|Experimental|1|We randomly assigned 72 individuals to an aerobic exercise training only group.
89626905|NCT00458133|Experimental|2|We randomly assigned 73 individuals to an resistance exercise training only group.
89626906|NCT00458133|Experimental|3|We randomly assigned 76 individuals to a combination of aerobic plus resistance training group.
89626907|NCT00458133|Placebo Comparator|4|We randomly assigned 41 individuals to a stretching and relaxation group.
89626908|NCT03296046||PPBL patients|
89626909|NCT00453531|Experimental|Healthy Volunteers|
89626910|NCT03295968|No Intervention|Water and Rest|
89626911|NCT03295968|Experimental|Water and High Intensity Exercise|
89626912|NCT03295968|Experimental|Ibuprofen and Rest|
89211176|NCT05007951|Active Comparator|Control group (ChAdOx1-S) - Cohort 1|Immunogenicity Cohort
89211177|NCT05007951|Experimental|Test group (GBP510) - Cohort 2|Safety Cohort
89626913|NCT03295968|Experimental|Ibuprofen and High Intensity Exercise|
89211178|NCT05007951|Active Comparator|Control group (ChAdOx1-S) - Cohort 2|Safety Cohort
89211179|NCT05007951|Experimental|Test group (GBP510) - Cohort 3|Booster Subcohort
89626914|NCT03298308|Experimental|Brainwave|Brainwave analysis after cranial electric stimulation
89626915|NCT01812291|Experimental|Stepped Care Approach for Depression|"Step 1: Diabetes-Specific CBT (5 group sessions)~Step 2: Depression-Specific CBT (6 single sessions)~Step 3: Referral to Psychotherapist and/or Psychiatrist"
89626916|NCT01812291|Active Comparator|Treatment-as-usual|Standard Diabetes Education
89626917|NCT03298230|Experimental|REmotely SuPervised Exercise Training|12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.
89626918|NCT03298230|Active Comparator|Supervised Exercise Training|As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.
89626919|NCT02461524|Other|Endovasculair repair|Endurant Evo AAA Stent graft system
89626920|NCT02087163|Experimental|Movement Enhancement Technique|Movement Enhancement Technique Clear Aligner
89626921|NCT03298152|Active Comparator|Emax CAD Endocrowns|Using lithium disilicate e.max restorations is documented in literature as a successful restoration. Two different ceramic crowns systems were investigated clinically for three-years and howed that patient was satisfied with the final restoration
89626922|NCT03298152|Experimental|Cerasmart Endocrowns|A new material CERASMART (Force Absorbing Flexible nano ceramic CAD/CAM block) with high density of ultrafine glass particles with 71 wt% filled nano-composite. It combines high strength and unique aesthetics. full homogeneous and even distribution nano ceramic network lead to unique physical properties for cerasmart . Uniform scuttle (very short inter-particle distance) of silanated and bonded particles is key to delivering CERASMART's™ with exceptional strength, retention, acceptable level of marginal adaptation
89626923|NCT01892592|No Intervention|Usual Care|No Interventions
89211180|NCT05007951|Active Comparator|Control group (ChAdOx1-S) - Cohort 3|Booster Subcohort
89211181|NCT04014816||Group I|Patients who had GI dysfunction (Group I) for one or more occasions.
89211182|NCT04014816||Group II|Patients who had normal GI function (Group II) for one or more occasions.
89211183|NCT00932490|Experimental|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and an advanced practice nurse will suggest individualized strategies to overcome barriers to adherence
89211184|NCT00932490|No Intervention|Control|
89211185|NCT00932724|Experimental|CY-503|
89211186|NCT00932724|Placebo Comparator|Placebo|
89626924|NCT01892592|No Intervention|Medication enhancement|Pharmacist will optimize current Kaiser medication protocol for treatment of hypertension.
89626925|NCT01892592|Experimental|Diet and Lifestyle Arm|Patients will receive up to 16 wellness coaching sessions focusing on DASH doest and lifestyle changes - Behavioral Intervention
89626926|NCT02318979|Experimental|Running|Participants will run on an instrumented treadmill at one speed using three different prostheses.
89626927|NCT02318979|Experimental|Sprinting|Participants will run on an instrumented treadmill at a range of speeds from a jogging speed up to top speed.
89626928|NCT03298074|Experimental|Apatinib plus Etoposide|Apatinib,500mg,PO.QD, continuous administration Etoposide,100mg, PO.QD，D1-D10, Q3W
89626929|NCT03298074|Active Comparator|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
89626930|NCT03295890|Sham Comparator|Sham Needling|Intervention = Sham Needling
89626931|NCT03295890|Active Comparator|Active Needling|Intervention = Active Needling
89626932|NCT01895907||Special Olympic athletes|
89626933|NCT03297996||SIT|Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT)
89626934|NCT03297996||NYU|New York University (NYU) Human Microbiome and Colorectal Tumor study
89626935|NCT01992874|Experimental|Pimasertib Capsule/Pimasertib Tablet|
89626936|NCT01992874|Experimental|Pimasertib Tablet/Pimasertib Capsule|
89626937|NCT04489836|Experimental|Meal A + Glutalytic®|350 mg Glutalytic® capsule, taken by mouth, once, with Meal A
89626938|NCT04489836|Experimental|Meal A + DE111®|350 mg DE111® capsule, taken by mouth, once, with Meal A
89626939|NCT04755621|Experimental|Core stability Group|
89626940|NCT04755621|Active Comparator|Control Group|
89626941|NCT01804179|Active Comparator|Standard Intervention (SI)|"At Baseline Visit, Participants in the standard intervention (SI) condition will get: I-FOBT kit and Screen for Life brochure, a mailed reminder card at two weeks post-intervention to remind them about FOBT testing and follow up assessments at 12 months."
89626942|NCT01804179|Experimental|CARES Intervention|Colorectal Cancer Awareness, Research, Education and Screening (CARES). At Baseline Visit, Participants in the CARES intervention will receive: I-FOBT kit, a newly developed DVD and booklet, and a mailed reminder card at two weeks post-intervention to remind them about FOBT testing, and follow-up assessments at 12 months.
89626943|NCT04755543|Experimental|I-A|LP002 dose escalation (3+3 design): 6-12 patients with malignant digestive system neoplasms (mainly include gastric/ gastroesophageal junction/ esophageal carcinoma) failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment will receive LP002 600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W), for up to 2 year.
89626944|NCT04755543|Experimental|I-B|If the safety profile in Arm A is acceptable, 9-12 patients with malignant gastric/ gastroesophageal junction carcinoma who are PD-L1 positive and failed (experienced progressed disease or unable to tolerate) at least two lines of previously standard treatments will receive LP002 600mg or 900 mg IV on Day 1, Q2W, for up to 2 year.
89626945|NCT04755543|Experimental|I-C|If the safety profile in Arm A is acceptable, 15-20 patients with metastatic gastric carcinoma who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W,for up to 2 year.
89626946|NCT04755543|Experimental|I-D|Perioperative treatment: If the safety profile in Arm A is acceptable, 15-20 patients with gastric or gastroesophageal junction carcinoma of cT2-4a, any N, M0 who are PD-L1 positive and systemic treatment-naive will receive LP002 900 mg IV on Day 1, Q2W, and Cisplatin 50mg/m2 IV on Day 1, Q2W, and Fluorouracil 2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W, for 3 cycles, 4-6 weeks before operation of the tumor and receive additional 6 cycles of the same therapy 4 weeks after the operation.
89626947|NCT04755543|Experimental|I-E|Dose escalation (3+3 design) of OH2 (an oncolytic virus) + LP002 900mg：If the safety profile in Arm A is acceptable, 15-30 patients with advanced solid tumors (mainly include digestive system neoplasms) who failed (experienced progressed disease or unable to tolerate) at least one line of previously standard treatment or lack of standard treatments will receive LP002 900mg IV on Day 1, Q2W, and OH2 10^6 or 10^7 or 10^8 CCID50/mL by intra-tumoral injection, Q2W, for up to 2 year.
89626948|NCT01993108|Experimental|Healthy Controls|Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
89626949|NCT01993108|Experimental|Adult Attention-Deficit/Hyperactivity Disorder|ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
89626950|NCT00437151|Active Comparator|1|More frequent than normal office visits
89626951|NCT00437151|Active Comparator|2|Electronic reminders (voice, e-mail, text messages)
89626952|NCT00437151|Active Comparator|3|Parental involvement / intervention reminders
89626953|NCT00437151|Active Comparator|4|No intervention or reminders
89626954|NCT02307526|Experimental|Spinal Cord Injury|After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
89626955|NCT02307838|Other|Phase 2 CFTY720D2201 (NCT02307838) participants|CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
89626956|NCT01371201|Experimental|Sunitinib|sunitinib 37.5 mg per day
89626957|NCT01371201|Placebo Comparator|Placebo|Placebo 37.5 mg per day
89626958|NCT00436527|Other|1|
89626959|NCT02307916|Experimental|FGF-2|FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
89626960|NCT02307916|Placebo Comparator|Placebo|Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
89626961|NCT00433563|Experimental|Once daily radiotherapy|Once daily radiotherapy
89626962|NCT00433563|Active Comparator|Twice daily radiotherapy|Twice daily radiotherapy
89626963|NCT01994746|Experimental|Nasal Glucagon|At one visit, a glucagon dose of 3 mg was administered in a nostril with a prefilled delivery device that delivers a single dose upon activation.
89626964|NCT01994746|Active Comparator|Intramuscular Glucagon|At a separate visit, 1 mg of glucagon was administered into the deltoid muscle of the non-dominant arm (intramuscular [IM]).
88989983|NCT04442646|Experimental|ASG= Asthma School Group, with educational intervention|"experimental asthma school group (ASG) will attend control visits as Control Group every three months. In addiction, ASG will attend 3 further meetings consisting in multidisciplinary lessons (pneumologist, nurse, biologist and respiratory therapist) once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day"
88989984|NCT04442646|No Intervention|CG= Control Group, With no educational intervention|Control group will attend control visits every three months.
89520640|NCT03342417|Experimental|Neoadjuvant Breast Cancer|"Newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. These patients have not received prior therapy for their breast cancer and intend to undergo surgery after completion of investigational neoadjuvant therapy.~Each patient will be treated with two 6-week treatment cycles of Nivolumab 240 mg administered by intravenous (IV) infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given every two weeks (q2w) whereas Ipilimumab is given every 6 weeks (q6w), both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1 and 43. On these days, Ipilimumab is to be given immediately after Nivolumab."
89520641|NCT03342417|Experimental|Platinum-resistant ovarian cancer|Platinum-resistant/refractory ovarian cancer (PRROC) patients. Each patient will be treated with four 6-week treatment cycles of Nivolumab 240 mg administered by IV infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab.
89520642|NCT03342417|Experimental|Advanced gastric cancer patients|"Advanced gastric cancer patients who are recurrent/refractory to a prior therapy not involving herceptin.~Each patient will be treated with four 6-week treatment cycles of Nivolumab and Ipilimumab . Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab."
89520643|NCT03437915|Experimental|Treatment Arm|28.5 Gy delivered in 5 daily fractions then 4-12 weeks post NIBB, surgery via partial mastectomy
89520644|NCT03234309|Experimental|Diagnostic (ferumoxytol, MRI)|Patients undergo MRI with GBCA per standard of care over 45-60 minutes and then receive ferumoxytol IV followed by MRI over 10 minutes on day 1. Patients may optionally undergo MRI over 30 minutes without any contrast agent on day 2. Each study visit consisting of 2 days may repeat no more frequently than 4 weeks for up to 5 study visits at different stages of the disease as determined by the investigator.
89520645|NCT03433157|Experimental|Hall technique|SSCs placed on primary teeth using Hall technique
89520646|NCT03433157|Active Comparator|Traditional technique|SSCs placed on primary teeth using Traditional technique
89520647|NCT03830931||Primary knee arthroplasty patients|Fasting Plasma Glucose test will be obtained the morning after surgery and the frequency of hyperglycemia in non diabetic and diabetic patients will be evaluated
89520648|NCT03437759|Experimental|Experimental group|Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling.
89520649|NCT03437759|No Intervention|Control group|Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling.
89520650|NCT03192189||Patients with acute kidney injury|Requiring treatment with dialysis
89520651|NCT03433079||Acute Kidney Injury|Patients > 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.
89520652|NCT02657031|Active Comparator|Control Arm|This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
89520653|NCT02657031|Experimental|Study Arm|This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.
89520654|NCT04944953|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®) 100 Unit
89520655|NCT04944953|Experimental|Botulinum toxin type A(HG-102)|Botulinum toxin type A(HG-102) 100 Unit
88990001|NCT04440540|Experimental|lifestyle modification program group|
88990002|NCT04440540|Experimental|usual care group (control)|
88990003|NCT04438304|Experimental|Intervention|64Cu-SARTATE will be administered at a fixed administration dose of 200 MBq (5.4 mCi) given as a single bolus intravenous injection.
88990004|NCT04434170||Heart failure|outpatients with heart failure with reduced ejection fraction in treatment with sacubitril/valsartan according to guidelines
88990005|NCT04432129|Experimental|IBBIS II|Integrated Mental Health Care and Vocational Rehabilitation
88990006|NCT04432129|Active Comparator|Service As Usual|Standard vocational rehabilitation and treatment
88990007|NCT04423367|Experimental|bortezomib/dexamethasone|Enrolled patients will receive the combination therapy of bortezomib and dexamethasone.
88990008|NCT04419831||Healthy volunteers|community volunteers
88990009|NCT04419831||Binge Heavy drinkers|Individuals who report regular binge alcohol intake and hazardous drinking levels
88990010|NCT04419831||Cannabis Use Disorder|Individuals with cannabis use disorder
88990011|NCT04419831||Alcohol Use Disorder|Individuals with alcohol use disorder
88990012|NCT04419831||Individuals with Moderate to Severe Pain|Individuals with chronic pain
88990013|NCT04419831||Opioid Use Disorder in medication assisted treatment|Individuals with opioid use disorder
89520656|NCT03437603|Experimental|Eltrombopag group|Starting dose is 25mg daily for the first 3 days, then increasing to 50mg for another week. Maintenance dosage is 50mg or 75 mg per day dependent on patients' status and doctors' opinion.Planned duration of treatment with eltrombopag is 8 weeks.When patients achieve persistent complete response for 2 weeks,they may stop medicine.
89520657|NCT03059433||AVID Intervention|175 students will be randomized via lottery by the participating high school to be part of the AVID program. These students will receive 4 surveys (8th, 9th, 10th, and 11th grade).
89626965|NCT05333601|Experimental|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
89626966|NCT01722916|Experimental|Dose of Hyaluronidase|
89626967|NCT01795677|Experimental|RUXOLOTINIB|Ruxolotinib : patient with donor HSCT 4 months later patients without donor: ruxolotinib alone
89626968|NCT01347177|Experimental|Zirconia-based adhesive bridges|Patients in this group will be treated with the employment of zirconia-based adhesive bridges to replace the missing tooth/teeth.
89626969|NCT01347177|Experimental|Metal-based adhesive bridges|Patients in this group will be treated with the employment of metal-based adhesive bridges.
89626970|NCT04489290|Experimental|D005 Vaginal Mousse|
89626971|NCT04489290|Placebo Comparator|Placebo|
89626972|NCT01999192|Experimental|Dose Level 1 Tregalizumab|25mg Tregalizumab s.c. weekly
89626973|NCT01999192|Experimental|Dose Level 2 Tregalizumab|100mg Tregalizumab s.c. weekly
89626974|NCT01999192|Experimental|Dose Level 3 Tregalizumab|200mg Tregalizumab s.c. weekly
89626975|NCT01999192|Placebo Comparator|Placebo|Placebo s.c. weekly
89626976|NCT00291525|Experimental|AVR Low Risk without warfarin|AVR Low Risk without warfarin
89626977|NCT00291525|Active Comparator|AVR low risk with standard warfarin|AVR low risk with standard warfarin
89626978|NCT00291525|Experimental|AVR High risk with lower warfarin|AVR High risk with lower warfarin
89626979|NCT00291525|Active Comparator|AVR High Risk with standard warfarin|AVR High Risk with standard warfarin
89626980|NCT00291525|Experimental|MVR with lower warfarin|MVR with lower warfarin
89626981|NCT00291525|Active Comparator|MVR with standard warfarin|MVR with standard warfarin
89626982|NCT04030650||healthy volunteers|
89626983|NCT04030650||patients|patients with lower limb amputations
89626984|NCT01337349|Placebo Comparator|Sugar Pill|Placebo control Group with sugar pill three times daily for 6 months
89626985|NCT01337349|Experimental|Pentoxifylline|Pentoxifylline 400mg tablets to be taken three times daily for 6 months
89211187|NCT00931008|Experimental|SID530|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
89626986|NCT03297918|Active Comparator|Intervention group|Patients will be asked to participate in a structured singing and respiratory training for 12 weeks.
89626987|NCT03297918|No Intervention|Control group|no intervention
89626988|NCT01895985|Experimental|Latanoprostene Bunod|Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.
89626989|NCT01999348||Patients with POAG or OHT|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
89626990|NCT02463474|Experimental|mHealth Intervention|Each week for 10 weeks, participants will receive two text messages on their cell phone. The first text message will contain a link to a culturally tailored, informational video clip about living with breast cancer. The second text message that provides a supportive message about the video content.
89626991|NCT03297840||Treatment|Patients with Borderline Personality Disorder receiving DBT treatment. Measurement takes place at the beginning of the treatment and a second time after 12-weeks treatment.
89626992|NCT03297840||Waitlist|Patients with Borderline Personality Disorder on the waitlist for inpatient DBT treatment. Measurement takes place twice at baseline and after 12-weeks waiting.
89626993|NCT03297762|Experimental|Gamification|Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
89626994|NCT03297762|Active Comparator|Standard care|Use of continuous glucose monitor (Dexcom G5) per usual care.
89626995|NCT00280761||1|Single Arm Trial
89626996|NCT02716584|Experimental|Physical exercise|Participants participate in brisk walking exercises.
89626997|NCT02716584|Active Comparator|Stretching exercise|Participants participate in non-aerobic, non-Yoga stretching exercises
89626998|NCT02061748||dabigatran|
89626999|NCT02061748||warfarin|
89627000|NCT03295656|Experimental|IV Contrast-Enhanced US|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
89627001|NCT02463318|Experimental|Multiple slerosis|Melatonin,,one millimolar,one micromolar,one nanomolar, 12 hr treatment.
89627002|NCT02463318|Experimental|Healthy subjects|Melatonin,one millimolar,one micromolar,one nanomolar, 12 hr treatment. hydrogen peroxide, 250 micromollar,2 hr treatment
89627003|NCT01436968|Experimental|ProstAtak®|Aglatimagene besadenovec (CAN-2409) + valacyclovir + radiation therapy +/- ADT
89627004|NCT01436968|Placebo Comparator|Control|Placebo + valacyclovir + radiation therapy +/- ADT
89627005|NCT02461212|Experimental|Liver MRI|Liver MRI imaging will be performed on subjects undergoing a liver biopsy
89627006|NCT02461212|Experimental|Liver MRI repositioned|Liver MRI imaging will be performed on subjects undergoing a liver biopsy and then they will be repositioned and will repeat the MRI
89627007|NCT02463162|No Intervention|Control|"This group will receive usual care which is to receive no intervention."
89627008|NCT02463162|Experimental|Intervention|This group will receive the intervention which is two Conversations Matter videos about Advance Care Planning and Goals of Care Designations respectively
89627009|NCT04441866|Active Comparator|Automated algorithms|Automated 3D techniques in measuring fetal biometry and reconstructing standard anatomical planes
89627010|NCT04441866|Placebo Comparator|Standard technique|Standard 2D assessment
89627011|NCT02462772|Experimental|Cabotegravir|Women randomised to the cabotegravir arm will receive daily oral cabotegravir (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of cabotegravir LA (800 mg, administered as two 400 mg injections) every 12 weeks
89039368|NCT04809090|Experimental|SMT+CA|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews and subjects will use an APP together a CA (Conversational Agent) an Artificial Intelligence.
89039369|NCT04809090|Experimental|Only CA|This group will receive only an APP together a CA (Conversational Agent) an Artificial Intelligence.
89039370|NCT04809090|No Intervention|Waiting-List|This group will not receive any intervention
89627012|NCT02462772|Placebo Comparator|Placebo|Women randomised to the placebo arm will receive daily oral tablets (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of Intralipid® 20% every 12 weeks
89627013|NCT02062294||Cohort|
89627014|NCT04441632|Other|Positive feedback|Participants in the study will provide consistent positive feedback to the colleagues they work with in the medical ICU (MICU) over a 4 week duration.
89627015|NCT03295578|Experimental|Personalized feedback group|In between the two measurement periods, the personalized feedback group will receive an explanation and personalized feedback on their self-measured data (interstitial glucose, cognition, wellbeing and food intake).
89627016|NCT03295578|Placebo Comparator|General feedback group|The generic feedback group will receive a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
89627017|NCT03295422|Active Comparator|RF ablation PVI alone|RF catheter ablation of pulmonary veins alone
89627018|NCT03295422|Experimental|RF ablation PVI plus LPAW|RF catheter ablation PVI plus left atrial posterior wall
89627019|NCT03297528|Experimental|study group|Participants receive chemotherapy and donor lymphocyte infusions based on the state GvHD, even the participants have a negative result of minimal residual disease (MRD). If the participants have no GvHD,they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD.
89627020|NCT03297528|No Intervention|control group|Participants don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD,in dispite of whether or not GvHD.
89627021|NCT02062606||AIS|Surgical implantation of the K2M MESA Rail™ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS).
89627022|NCT02063230|Experimental|Selumetinib HV|Healthy volunteers (HV)
89627023|NCT02063230|Experimental|Selumetinib mild impairment|Mild (Child Pugh A) hepatic impaired patients
89627024|NCT02063230|Experimental|Selumetinib moderate impairment|Moderate (Child Pugh B) hepatic impaired patients
89627025|NCT02063230|Experimental|Selumetinib severe impairment|Severe (Child Pugh C) hepatic impairment patients
89627026|NCT02000908|Experimental|Realief Therapy|Each patient will be given 15-18 treatments depending on response of 30-minute duration of photobiomodulation with the Realief Therapy system, scheduled every three times weekly for 5-6 weeks. The treatments will include laser exposure of any or all of 27 differentiated areas of the legs, feet, cervical spine region and lumbar spine region, for durations of 3 to 30 minutes, based on the symptom presentation at the time. Power densities will vary from 5 to 12 watts, based on the symptom presentations through the course of therapy.
89627027|NCT02000908|Sham Comparator|Sham Treatment|"The placebo group will receive sham treatment, during which a heat probe will be guided over both lower extremities over a period of 30 minutes, consistent with the treatment arm. The laser device will be activated during the treatment so that the visual and auditory environment prior to therapy will be the same for both treatment and sham control.~After 8 weeks of sham treatment the subjects in this arm will be offered the photobiomodulation combined with physiotherapy."
89627028|NCT02716194|Experimental|Cohort 1 - Low dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
89627029|NCT02716194|Experimental|Cohort 2 - Medium dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
89627030|NCT02716194|Experimental|Cohort 3 - High dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
89627031|NCT02002702|Experimental|Serelaxin 10 mcg/kg/Day|Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
89627032|NCT02002702|Experimental|Serelaxin 30 mcg/kg/Day|Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
89627033|NCT02002702|Placebo Comparator|Placebo|Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.
89627034|NCT02002936|Experimental|SyB C-1101|
89627035|NCT02461056|Active Comparator|Ibuprofen|Ibuprofen: Patients receive ibuprofen 50 mg, 100 mg, 200 mg, 400mg or 800 mg intravenously once at post-anesthesia care unit.
89039371|NCT00556634|Active Comparator|B|
89039372|NCT00556634|Experimental|A|
89039373|NCT01209520|Experimental|Adjuvant Chemotherapy + Vidaza|
89039374|NCT01209325|Experimental|Vaccination|Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
89039375|NCT04667273|Experimental|Exercise Training (ET) + Neuromuscular Electrical Stimulation (NMES) group|volunteer patients with Subacromial Impingement Syndrome
89039376|NCT04667273|Other|Exercise Training (ET) group|volunteer patients with Subacromial Impingement Syndrome
89039377|NCT04798677|Experimental|Influenza vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Influenza vaccine followed by 30 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
89039378|NCT04798677|Placebo Comparator|Influenza vaccine + placebo|Influenza vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
89039379|NCT04798677|Experimental|Covid-19 vaccine + intervention with beta-glucan complex and Saccharomyces cerevisiae consortium|Covid-19 vaccine followed by 35 days of supplementation with a beta-glucan complex and Saccharomyces consortium rich in selenium and zinc
89211188|NCT00931008|Active Comparator|Taxotere|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
89211189|NCT00932802||Group 1|
89211190|NCT05360199|No Intervention|control group|no recall PROMs group ; without knowledge of previous PROMs scores
89211191|NCT05360199|Active Comparator|intervention group|recall PROMs group ; with knowledge of previous PROMs scores
89627036|NCT02461056|Active Comparator|hydromorphone|Hydromorphone: Patients receive hydromorphone 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, or 2 mg intravenously once at post-anesthesia care unit.
89627037|NCT02461056|Active Comparator|ibuprofen+hydromorphone|Ibuprofen+Hydromorphone: Patients receive ibuprofen 25 mg + hydromorphone 0.125 mg, ibuprofen 50 mg + hydromorphone 0.25 mg, ibuprofen 100 mg + hydromorphone 0.5 mg, ibuprofen 200 mg + hydromorphone 0.75 mg, or ibuprofen 400 mg + hydromorphone 1 mg intravenously once at post-anesthesia care unit.
89627038|NCT02003404||Control Abdominal Skin|Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.
89627039|NCT02003404||Peristomal Abdominal Skin|Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.
89627040|NCT05229978||Patients with AD or mild cognitive impairment due to AD|All three 'arms' take part in a focus group or interview. The conversation topics will be the same (with the aim to gauge interpretations / needs / thoughts / feelings with regard data usage for research and the role health data engagement interfaces (Dynamic Consent) may play in this.
89627041|NCT05229978||Informal carers of patients with AD or mild cognitive impairment due to AD|All three 'arms' take part in a focus group or interview. The conversation topics will be the same (with the aim to gauge interpretations / needs / thoughts / feelings with regard data usage for research and the role health data engagement interfaces (Dynamic Consent) may play in this.
89627042|NCT05229978||Dementia experts/specialists|Given their expertise on dementia from a professional point of view, a focus group is conducted with dementia specialists in order to elicit their views and ideas on health data engagement interface like Dynamic Consent.
89627043|NCT01173172|Experimental|BNCT, recurrent head and neck cancer|Single arm treated by BNCT only
89627044|NCT00003270|Experimental|Arm 1|Patients eligible to undergo total body irradiation (TBI) first receive cyclophosphamide IV over 2 hours on days -5 and -4, then undergo TBI twice a day on days -3 to -1. Patients also receive antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1. Cord blood is infused on day 0
89627045|NCT02005354|Active Comparator|Trans-cutaneous Electrical Nerve Stimulation (TENS)|"The Intervention-TENS group will have 2 electrodes applied proximal to the painful area along neuro-anatomical distribution (electrode-one placed 5cm superior and 2cm medial to the posterior superior iliac spine and electrode-two placed 5cm medial to the posterior superior iliac spine) in the same way as the control-TENS group.~The concealed electrical parameter in this group will be within the therapeutic window, that is, well above the sensory detection threshold but below the pain threshold giving a strong but comfortable sensation. From previous studies, this is likely to be 50-110Hz.~The device will be activated prior to entry into the treatment room and 2 minutes before administration of local anaesthetic and for 2 minutes after removal of the biopsy needle. This will cover the expected duration of pain as assessed in the pilot study.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
89627046|NCT02005354|Placebo Comparator|Trans-cutaneous Electric Nerve Stimulation (TENS)|"Patients in the CT group will have 2 gel-electrodes applied proximal to the sampling area (usually the right posterior superior iliac crest).~The Control-TENS device will be identical in appearance to the Intervention-TENS device with a functioning display panel. The concealed electrical parameter in this group will be titrated to and set at the sensory detection.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
89627047|NCT03290898|Active Comparator|Training group|"Supervised High intensity interval training (HIIT) 3 times a week for 6 months.~Training session:~10 minutes warm up (Low-moderate intensity) 30 minutes intervention (16 minutes HIIT) 10 minutes cool down(Low-moderate intensity)"
89627048|NCT03290898|No Intervention|Control group|Control group, usual lifestyle. Aside from training intervention, all other visits are the same as intervention group (training).
89627049|NCT02066740|Experimental|EverFlex™ stent with Entrust™ delivery system|
89211192|NCT00937482|Experimental|Treatment (cediranib maleate and WBRT)|Patients receive oral cediranib maleate on day 1. Patients undergo whole-brain radiotherapy 5 days a week for 3 weeks beginning on day 3. Treatment continues treatment in the absence of disease progression or unacceptable toxicity.
89211193|NCT00937716||Diagnosis of Schizophrenia|Patients with a diagnosis of schizophrenia that have been off antipsychotic medicine and would like to resume treatment will be enrolled in the study.
89211194|NCT00937716||Healthy Volunteers|Healthy Volunteers without a psychiatric diagnosis, central nervous system condition, serious head injury, or current drug use will be matched on an individual basis to schizophrenic participants and used as a control population.
89211195|NCT00932958||All comers >18 yrs old|This study is observational, studying patients who are already scheduled to undergo CCTA. Minors and those unable to consent to the study are excluded.
89211196|NCT00933036|Experimental|Treatment arm|Crosstrees Pod System for PVA.
89211197|NCT04004559||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|Cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the training cohort.
89211198|NCT04004559||Sun Yat-sen University Cancer Center|Cohort of Sun Yat-sen University Cancer Center is validation cohort 1.
89211199|NCT04004559||Tungwah Hospital of Sun Yat-Sen University|Cohort of Tungwah Hospital of Sun Yat-Sen University is validation cohort 2.
89211200|NCT00566982|Experimental|Ospemifene 60 mg/day|Ospemifene will be taken orally, once daily, in the morning, with food for 52 weeks.
89211201|NCT00566982|Placebo Comparator|Placebo|Placebo will be taken once daily, in the morning, with food for 52 weeks.
89211202|NCT00624338|Experimental|Atacicept 75 mg|
89211203|NCT00624338|Experimental|Atacicept 150 mg|
89211204|NCT00624338|Placebo Comparator|Placebo|
89211205|NCT00933114||Functional Imaging|Functional imaging with MRI and PET
89627050|NCT03290820|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radiotherapy and concurrent chemotherapy.
89627051|NCT03290820|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radiotherapy and concurrent chemotherapy plus daily aspirin.
89627052|NCT01135342|Experimental|Diet & Exercise plus Sleep Intervention|Diet and exercise instruction to promote weight loss plus cognitive behavioral therapy for insomnia.
89627053|NCT01135342|Sham Comparator|Diet & Exercise plus Passion and Balance|Diet and exercise instruction to promote weight loss plus sessions that are of general interest, but unrelated to diet, exercise, or sleep.
89627054|NCT03295188|Experimental|Intervention Group|Two 0.5 mg plasmalogen capsules per day
89627055|NCT03295188|Placebo Comparator|Placebo Group|Two placebo capsules containing no plasmalogen per day
89627056|NCT03295110|Experimental|Functionalities of the Lili Smart Solution activated|Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
89627057|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
89627058|NCT02066896|Sham Comparator|Sham Comparator: Sham Lasertherapy|Sham lasertherapy in parotid, submandibular and sublingual glands for six weeks.
89627059|NCT02066896|Active Comparator|Active Comparator: Lasertherapy|Low level lasertherapy in parotid, submandibular and sublingual glands for six weeks.
89627060|NCT03773484|Experimental|Clinical Decision Support|"Clinical decision support nudges within the electronic health record to discourage unnecessary opioid prescribing through the application of behavioral insights-empirically-tested social and psychological interventions that affect choice. Participating clinicians will receive any of three nudges when eligibility criteria are met within a patient's chart."
89627061|NCT02334358||YVOIRE Classic s|Treatment with YVOIRE Classic s
89039380|NCT04798677|Placebo Comparator|Covid-19 vaccine + placebo|Covid-19 vaccine followed by 30 days of supplementation with a placebo, similar en aspect, flavor and odour to the intervention product
89039381|NCT04667429|Experimental|Food effect|HEC83518 40mg will be administered fasted, or with high-fat meal for once.
89039382|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 20mg|HEC83518 20mg will be administered before sleep for 15 days .
89039383|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 40mg|HEC83518 40mg will be administered before sleep for 15 days .
89039384|NCT04667429|Experimental|Multiple Ascending Doses-HEC83518 80mg|HEC83518 80mg will be administered before sleep for 15 days .
89211206|NCT00933192||Group 1: young healthy patients|
89627062|NCT03290742||Patients without documented infection.|Patients without infection during 30 day follow-up after radical cystectomy.
89627063|NCT03290742||Patients with documented infection.|Patients with documented any kind of infection (urinary tract infection, blood infection/septic shock, surgical site infection) during 30 day follow-up after radical cystectomy.
89627064|NCT02005510|Experimental|In-home HPV Screening|"Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
89627065|NCT02005510|Placebo Comparator|Usual Care|"Usual care. Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
89627066|NCT03295032|Experimental|group-based ACT|Stroke survivors were randomised into group-based ACT intervention consisting of 2hr sessions for four consecutive weeks.
89627067|NCT03295032|No Intervention|Waiting list control|Waiting list control - received treatment as usual.
89627068|NCT03108222||Healthy Subjects|Healthy subjects, free of CKD
89627069|NCT03108222||Moderate CKD Subjects|Subjects with moderate-stage CKD
89627070|NCT03108144|No Intervention|Control - Group A|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group A will not receive computer alerts but will still have access to the alcohol consumption data as part of the baseline assessment (Screening). Healthcare providers will have access to all the same resources available as the intervention clinic (Treatment as usual).
89627071|NCT03108144|Experimental|Intervention - Group B|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group B will receive computer alerts (Screening). The alert will provide a 5 minute script (Brief Intervention) for the health care providers to relay to patients and the ability to print or email a self-help resource to the patient each time the patient visits (Referral to Treatment).
89627072|NCT03283410|Experimental|Single Study Arm|All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose.
89627073|NCT04318704|Other|Single Arm Active|Ifenprodil
89627074|NCT03283176||Sofo-Dacla with Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir with Ribavirin
89627075|NCT03283176||Sofo-Dacla without Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir without Ribavirin
89627076|NCT03290430|Experimental|Group Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 1-2 hours. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
89627077|NCT03290430|Experimental|Individual Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 30-45 minutes. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
89627078|NCT03290430|Experimental|Telephone Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 phone calls over 4 week, each lasting between 30-45 minutes. During these phone calls, participants will learn about how to quit smoking by changing habits. Sessions may be audio taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
89627079|NCT03290430|Experimental|Video Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 video calls over 4 week, each lasting between 30-45 minutes. During these video calls, participants will learn about how to quit smoking by changing habits. Sessions may be recorded.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
89627080|NCT03290352||Head and neck cancer patients|Patients with oral cavity, tongue, gingival, pharyngeal, laryngeal, or salivary gland cancer and cervical lymph node metastasis who received free flap reconstruction would be enrolled in this study. However, we excluded the patients with distant metastasis identified in their medical records, and those undergoing reconstruction other than anterolateral thigh, fibular bone and radial forearm flaps.
89627081|NCT03294798|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 600-900μg,once per two weeks.
89627082|NCT03294798|Active Comparator|Pegasys|Pegasys 180 mcg, once per week
89627083|NCT03294720|Experimental|Bio ACL Reconstruction|Normal ACL reconstruction with either patellar or hamstring autograft will be done and prior to fixation the graft will be wrapped in a amion collagen wrap. Bone marrow aspirate will be obtained from distal femur at the time of the arthroscopy and stem cells isolated using the Arthrex Angel System. These stem cells with be under direct visualization impregnated into the ACL autograft amion wrap complex.
89039385|NCT04667429|Placebo Comparator|Multiple Ascending Doses-placebo|Placebo will be administered before sleep for 15 days .
89039386|NCT04667546|Other|Patient having urinary tract infection|Patients with a confirmed urinary tract infection in accordance with the GPIP (french Pediatric Infectious Disease Group) definition and inclusion criteria.
89039387|NCT04784754|Placebo Comparator|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
89039388|NCT04784754|Experimental|Melatonin 3 mg|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
89039389|NCT04784754|Experimental|Melatonin 30 mg|Melatonin capsules will be prepared using hypromellose capsules containing 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
89039390|NCT04666883||Splenic flexure cancer patients|Splenic flexure cancer patients
89039391|NCT04666805||Drug Group|Endocrine therapy drugs include selective estrogen receptor modulators (Tamoxifen, Toremifene) and aromatase inhibitors (Anastrozole, Letrozole, Exemestane), which have been widely used in the adjuvant treatment of hormone receptor positive breast cancer.
89039392|NCT04666376|Other|Vitrified ovarian tissue|Ovarian tissue will be vitrified and warmed by Ova kit type M protocol.
89039393|NCT04666337|Active Comparator|Group B (bupivacaine group)|patients received 20 ml bupivacaine 0.5% plus normal saline (2ml)
89039394|NCT04666337|Active Comparator|Group F (fentanyl group)|patients received 20 ml bupivacaine 0.5% plus fentanyl (100µg-2 ml)
89039395|NCT04666337|Active Comparator|Group T (tramadol group)|patients received 20 ml bupivacaine 0.5% plus tramadol (100mg-2 ml)
89039396|NCT00556790|Other|1|Standard Care
89039397|NCT00556790|Other|2|Fast Track Care
89039398|NCT04738461|Experimental|Telerehabilitation|Telerehabilitation program will be applied 5 days a week for 3 weeks to patients in the telerehabilitation group. A physiatrist will meet with patients via videoconferencing over the internet and guide the program.
89039399|NCT04738461|Active Comparator|Standard Physiotherapy|Patients in the standard physiotherapy group will receive one-to-one physiotherapy sessions in the hospital 5 days a week for 3 weeks. In these sessions, active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
89039400|NCT04738461|Active Comparator|Home exercise group|The home exercise program was explained to the patients in the control group by the physiotherapist and the relevant brochures were delivered to the patients. Home exercise program will consist of telerehabilitation group exercises. However, patients will be not under any supervision and exercise themselves at home.
89039401|NCT00556868|Experimental|A|Breakfast on the first day of intervention, fasting (no breakfast) on the second day of intervention
89039402|NCT00556868|Experimental|B|Fasting (no breakfast) on the first day of intervention, breakfast on the second day of intervention
89039403|NCT00556907|Other|1|Patients will receive IORT
89211207|NCT00933192||Group 2: old healthy patients|
89211208|NCT03977454|Experimental|Group 1 patients will receive nerve block per standard of care|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA), per standard of care of anesthesia block service.~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA; and~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA Preoperatively, Group 1 patients will receive nerve block per standard of care as stated above. Intraoperatively, Group 1 will NOT receive PAI."
89211209|NCT03977454|Active Comparator|Group 2 will NOT receive any nerve blocks.|Intraoperatively, the surgeon will perform PAI with exactly the same medication as group 1, ie, 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA, per standard of care of Surgeon.
89627084|NCT04488744|Experimental|nicotine infusion 0.2mg|"nicotine infusion~0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) The day order will be randomized over 5 days."
89627085|NCT04488744|Experimental|nicotine infusion 2.0mg|0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries),
89627086|NCT04488744|Experimental|nicotine infusion 1.0mg|1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries)
89627087|NCT04488744|Experimental|nicotine infuison 1.0mg|1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
89627088|NCT04488744|Placebo Comparator|Saline|saline delivered over 2minutes ,2.5minutes,10 minutes
89627089|NCT02005666|Experimental|Test-Cadila healthcare limited|Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
89627090|NCT02005666|Active Comparator|Reference|Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
89627091|NCT02005666|Placebo Comparator|Placebo|Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
89627092|NCT03283020|Active Comparator|RemifentanilMNTX|Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
89627093|NCT03283020|Active Comparator|PlaceboMNTX|Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
89627094|NCT03294642|Experimental|Trial 1|Water Intervention: In one of the 3 cycling trials, participants will receive only water and no carbohydrate supplementation during the 2 hour cycling challenge.
89627095|NCT03294642|Experimental|Trial 2|Carbohydrate Gel Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of commercially available gels (15g every 15 minutes) during the 2 hour cycling challenge.
89627096|NCT03294642|Experimental|Trial 3|Potatoes Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of pureed russet potato (15g every 15 minutes) during the 2 hour cycling challenge.
89627097|NCT00494182|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|Participants receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1, and sorafenib PO BID on days 2-19. Treatment repeats every 21 days for up to 6 courses. Starting with course 7, participants receive sorafenib PO daily in the absence of disease progression or unacceptable toxicity.
89627098|NCT03294564|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
89627099|NCT03294564|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
89627100|NCT03290274|Experimental|Deep brain stimulation (fornix)|Deep brain stimulation at fornix area
89627101|NCT03290274|Experimental|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation at Basal nucleus of Meynert
89627102|NCT02006056|Experimental|Secondary prophylaxis|Patients already experiencing mild nausea/vomiting within 24 hours before radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
89627103|NCT02006056|Experimental|Primary prophylaxis|Patients experiencing no nausea and vomiting 24 hours before commencement of radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
89627104|NCT03290196|Other|EXPAREL 1.3 % in 20 ML Injection|"EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% [13.3 mg/mL]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:~size of surgical site~volume required to cover the area~individual patient factors that may impact the safety of an amide local anesthetic~maximum doe of 266 mg (20 mL)"
89627105|NCT03282942|Experimental|Exercise training protocols|Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST). Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
89627106|NCT03282942|No Intervention|Control Group|The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
89211210|NCT00828386|Experimental|Induction chemotherapy + concurrent chemoradiotherapy|"Induction chemotherapy (Docetaxel + Cisplatin + 5-FU):~Docetaxel 75 mg/m² administered on D1 of each course, every 3 weeks, via one-hour IV infusion~Cisplatin 75 mg/m² administered on D1 via one-hour infusion followed by~5-Fluorouracil (as a continuous infusion): 750 mg/m²/d administered as a continuous infusion from D1 to D5.~The cycles will be repeated every 3 weeks up to a total of 3 courses. Followed by concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks)."
89211211|NCT00828386|Active Comparator|Concurrent radiochemotherapy alone|Concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).
89627107|NCT02006836|Other|Diabetic|Diabetic patients use metformin or only on diet control(met or diet).18 of the patients were on metformin treatment and 2 patients were on diet control due to the early stage of this disease. On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of diabetic patients enrolled for the case control period.
89627108|NCT02006836|Other|Healthy|On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of volunteers enrolled for the case control period.
89627109|NCT02006836|Other|Diabetic 2 - without pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 4th to 6th day with a constant dose of insulin and did not consumed Majia pomelos after meals, and this intervention was defined as blank.
89627110|NCT02006836|Other|Diabetic 2 - with pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 7th to 9th day with a constant dose of insulin and consumed 100g Majia pomelos after meals (breakfast, lunch and dinner).
89627111|NCT03290118|Experimental|Traffic Light|"Participants in this group will be provided with a survey that shows the food and beverage packages with traffic light front of pack labels only.~Intervention is the Nutrition Rating System - Traffic Light"
89627112|NCT03290118|Experimental|Star System|"Participants in this group will be provided with a survey that shows the food and beverage packages with health star rating front of pack labels only.~Intervention is the Nutrition Rating System - Health Star Rating"
89627113|NCT03290118|Experimental|Warning Label|"Participants in this group will be provided with a survey that shows the food and beverage packages with warning front of pack labels only.~Intervention is the Nutrition Rating System - Warning Labels"
89627114|NCT03290118|No Intervention|Control|Participants in this group will be provided with a survey that shows the food and beverage packages without any front of pack labels.
89627115|NCT04378530|Experimental|Personalized Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be asked to select a cue to use to remember to meditate.
89627116|NCT04378530|Active Comparator|Study control|Participants in the control group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive non-anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day.
89627117|NCT04378530|Experimental|Fixed Cue|Participants in the intervention group will be recommended to participate in at least 10 minutes per day of meditation via a smartphone application for 8 weeks. Participants will receive anchoring specific push notifications and will respond to one, multiple-choice EMA (ecological momentary assessment) question 1x per day. Participants will be given a specific cue (i.e. leaving the bathroom in the morning) to use to remember to meditate.
89627118|NCT02068846|Active Comparator|Ciprofloxacin|Active treatment twice daily for 28 days
89627119|NCT02068846|Placebo Comparator|Placebo|Placebo treatment twice daily for 28 days
89627120|NCT03282864|Active Comparator|Bedroom air filtered by an air filtration device|The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
89627121|NCT03282864|Placebo Comparator|Bedroom air filtered by a placebo air filtration device|The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks.
89627122|NCT03282786|Active Comparator|CD patient with CO2 insufflation|The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
89627123|NCT03282786|No Intervention|CD patient with air insufflation|The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
89627124|NCT03282786|Active Comparator|UC patient with CO2 insufflation|The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
89211212|NCT00831350|Experimental|ranibizumab|
89211213|NCT00933348|Active Comparator|OPAL A plus standard wound care|
89627125|NCT03282786|No Intervention|UC patient with air insufflation|The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
89627126|NCT03289884||Control Group (CE1)|"All patients must have cystic lesions which must exceed 30mm in diameter.~All patients must be aged 16 or over and able to provide informed consent.~Patients will have an MRI scan (not involving ionising radiation)~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent."
89211214|NCT00933348|Placebo Comparator|Placebo plus standard wound care|
89211215|NCT00823628|Active Comparator|iopromide|
89211216|NCT00823628|Experimental|iodixanol|
89211217|NCT00937872|Experimental|SRT2104|Single arm with crossover from single dose of oral suspension formulation to single dose intravenous formulation.
89211218|NCT00938028||Microbiome, Metabolome, Stool, Toddler|healthy infant stool samples
89627127|NCT03289884||CE group (CE2-4)|"All patients must have hepatic CE, as confirmed by positive blood tests, with lesions identified on the standard of care MRI/CT scan, one or more of which must exceed 20 mm in diameter.~All patients must be aged 16 or over and able to provide informed consent.~All patients will have an MRI scan (not involving ionising radiation)~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent.~Patients from the CE group undergoing surgery or aspiration will have fluid samples sent for analysis as part of standard clinical care. These cyst fluid samples will then be transported to the MRI scanner for Ex vivo scanning."
89627128|NCT03289806||Cases|Glaucoma surgery
89627129|NCT03289806||Controls|Strabismus surgery
89627130|NCT03294486|Experimental|Combination of TG6002 and flucytosine (5-FC, Ancotil®)|All patients within a given cohort will be treated with the same dose schedule of TG6002, administred as 3 weekly IV infusions at days 1, 8 and 15. following the 1st and 2nd infusions of TG6002, patients will be given oral 5-FC for 3 days starting on day 5 and 12 . following the 3rd infusion, patients will be given oral 5-FC for 21 days starting on day 19.
89627131|NCT05235048|Placebo Comparator|Standard of care control|Tooth extraction and spontaneous healing
89627132|NCT05235048|Experimental|Socket seal with CT graft|Tooth extraction and socket sealing with autologous connective tissue graft
89627133|NCT05235048|Experimental|Socket seal with CT graft and bone replacement graft|Tooth extraction and socket sealing with autologous connective tissue graft and positioning of bone replacement graft in coronal portion of the socket
89627134|NCT05235048|Experimental|Tooth extraction and socket sealing and BRG with membrane|Tooth extraction and socket sealing with autologous connective tissue graft and positioning of bone replacement graft in coronal portion of the socket and positioning of collagen membrane
89627135|NCT03294252|Experimental|Oxaliplatin|The experimental drugs used in this protocol are Oxaliplatin, 5-Fluorouracil and L-Folinic acid. All are used as part of their marketing authorization, with the exception of Oxaliplatin as regards its mode of administration specific to the PIPAC procedure (injection and nebulisation in intraperitoneal).
89627136|NCT03282708|Experimental|Microbiome|"Caretakers of captive great apes. One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
89627137|NCT03282708|No Intervention|Anthropology|Caretakers of captive great apes. Two four-hour participant-observations of each caretaker's activities with captive great apes
89627138|NCT03294174||Opioid naive|Patients who have not been exposed to opioids, but will receive ropivacaine injection
89627139|NCT03294174||Opioid exposure|Patients who have been exposed to(> 6months), but not currently taking opioids, but will receive ropicacaine injection
89627140|NCT03294174||opioid tolerance|Patients who have been actively taking opioids with a tolerant dose based on FDA guideline, but will receive ropivacaine injection
89627141|NCT03289494|Active Comparator|Diet A|Balanced diet high in Slowly Digestible Starch
89627142|NCT03289494|Placebo Comparator|Diet B|Balanced diet low in Slowly Digestible Starch
89627143|NCT03282630|Experimental|active acupuncture|"Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
89627144|NCT03282630|Sham Comparator|sham acupuncture|Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
89627145|NCT03289416|Other|Platelet Rich Plasma (PRP)|Blood will be drawn from the patient using the Pure PRP II system into a syringe with anticoagulant (sodium citrate). 1 mL of blood will be separated and sent to a lab for analysis. Remaining blood will be separated into a single concentrating device and centrifuged to separate red blood cells from plasma and platelets. The plasma and platelets will be separated off with a syringe and re-centrifuged to separate the platelets from the plasma. 1 mL will be separated and sent to a lab for analysis leaving 6 mL for injection. Both the 1 mL of blood and the 1 mL of PRP will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F. Physician will then inject the PRP into the affected knee joint.
89627146|NCT03289416|Other|Bone Marrow Concentrate (BMC)|Bone marrow will be harvested from the posterior iliac crest using the PureBMC system. 50 mL of bone marrow will be drawn into one syringe containing 10 mL of sodium citrate. Marrow will be filtered and centrifuged for separation of the bone marrow concentrate. Plasma and cell concentrate will be separated off with two syringes and re-centrifuged to separate the cell concentrate from the plasma. After plasma is drawn off, BMC will be drawn into a syringe for injection into affected knee. BMC production procedure results in 7 mL of product and 1 mL will be separated and sent to a lab for analysis. Both 1 mL of BMA and 1 mL of BMC will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F.
89627147|NCT03294096|Experimental|experimental group|
89627148|NCT03294096|Active Comparator|control group|
89627149|NCT03282552|Active Comparator|Study Group 1|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
89627150|NCT03282552|Active Comparator|Study Group 2|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min."
89039404|NCT04721457|Placebo Comparator|Distilled Water|Vigorously rinse with 15 ml of the distilled water for 30 s (Water for Injections BP; Pharmaceutical Solutions Industry, Jeddah, SA)
89627151|NCT03282552|No Intervention|Control group|"In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.~In this group all patients will receive the usual standard of care, with no other interventions included"
89627152|NCT03294018||Bradycardia during sugammadex administration|Recording any heart rate changes during planned administration of sugammadex.
89627153|NCT03289338|Experimental|Zoledronic acid|Bisphosphonate Zoledronic acid
89627154|NCT03289338|Active Comparator|Methylprednisolone|Glucocorticoid Methylprednisolone
89627155|NCT03289338|Placebo Comparator|Placebos|Placebo normal saline
89627156|NCT02069704|Experimental|Bevacizumab biosimilar (BEVZ92)|Bevacizumab 25 mg/mL (strength: 100 mg/4 mL).
89627157|NCT02069704|Active Comparator|Avastin® (bevacizumab, ref. product)|Bevacizumab 25mg/ml (strength: 100mg/4ml)
89627158|NCT02314546|Placebo Comparator|Saline placebo|saline placebo
89627159|NCT02314546|Active Comparator|Nasal Midazolam only|Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam
89627160|NCT02314546|Active Comparator|Midazolam and Xylocaine|Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam
89627161|NCT02314936|Experimental|Litesse powder containing 12 g polydextrose|12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
89627162|NCT02314936|Experimental|Litesse powder containing 8 g polydextrose|8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
89627163|NCT02314936|Experimental|Litesse powder containing 4 g polydextrose|4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
89627164|NCT02314936|Placebo Comparator|Placebo|Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
89627165|NCT03289260|Experimental|Interventional Arm|Imiquimod 5% cream therapy Fulguration
89627166|NCT03289260|Placebo Comparator|Placebo Arm|Placebo cream therapy Fulguration
89627167|NCT03289182||MabThera|Participants with NHL will be administered 1400 milligrams (mg) and those with with CLL will be administered 1600 mg MabThera subcutaneously at the discretion of the physician in accordance with local clinical practice and local labeling, and will be observed for 6 years.
89627168|NCT03289104|Active Comparator|Steel Wires|In this arm, patients will have their sternum closed with steel wires.
89627169|NCT03289104|Experimental|ZipFix Sternal Closure System (Plastic Cables)|In this arm, patients will have their sternum closed with the ZipFix system.
89627170|NCT03289026|Experimental|aripiprazole group|Patients receive aripiprazole treatment
89627171|NCT03293940|Experimental|Cryoablation Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the cryoablation procedure.~Participants will have the option to crossover to tPNB 90 days post the initial intervention."
89627172|NCT03293940|Active Comparator|Control Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the nerve block procedure.~Participants will have the option to crossover to cryoablation treatment 90 days post the initial intervention."
89039405|NCT04721457|Active Comparator|Povidone Iodine (PVP-I)|Vigorously rinse with 15 ml of the 1% povidone-iodine (PVP-I) (Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA) for 30 s
89627173|NCT02460510|Experimental|Mannitol|Treatment with mannitol intravenous (IV) bolus over 20 to 30 minutes. The dose is 0.25 g/kg IV as a 20% solution repeated every 4th hourly.(8) Mannitol infusion to be stopped if s osmolarity >320mm
89039406|NCT04721457|Active Comparator|Hydrogen Peroxide (H2O2)|Vigorously rinse with 15 ml of the 1.5% hydrogen peroxide (H2O2) (Peroxyl; Colgate-Palmolive, Guildford, UK) for 30 s
89627174|NCT02460510|Active Comparator|3% hypertonic saline|Treatment with 3% hypertonic saline as continuous infusion. Continuous 3% NaCl infusion to be started at a rate of 25ml /hr and titrated q4hrs per sliding scale to achieve a target serum sodium level of <160 mmol/L.
89627175|NCT02460744|Experimental|Single arm treatment with radiation|Patients with breast cancer will be given adjuvant hypofractionated radiotherapy
89627176|NCT04137042|Active Comparator|Saline|intraoperative fluid therapy by using 0.9% saline
88990014|NCT04419402|Experimental|Lu-PSMA + Enzalutamide|"Lu-PSMA - 7.5 GBq (± 10%): doses 1 and 2 (Days 15 and 57). Doses 3 and 4 (Days 113 and 169) will be given following result of PSMA PET/CT scans at Day 92.~Enzalumatide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity."
88990015|NCT04419402|Active Comparator|Enzalutamide|Enzalutamide - 160 mg (four 40 mg capsules): daily until participant is no longer clinically benefiting, or experiences unacceptable toxicity.
89627177|NCT04137042|Experimental|Balanced crystalloid|intraoperative fluid therapy by using balanced crystalloid
89627178|NCT02334436|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
89627179|NCT02334436|Placebo Comparator|Placebo|0.9% sterile, unpreserved saline
89627180|NCT02459808||GBS Patients|Patients with Guillain-Barré syndrome
89627181|NCT03293862|Active Comparator|Suture group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture only, without mesh, aiming a suture length to wound length ratio higher than four. Randomization occurs after fascial closure.
89627182|NCT03293862|Experimental|Prophylactic mesh group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture aiming a suture length to wound length ratio higher than four AND further polypropilene onlay mesh. Randomization occurs after fascial closure.
89627183|NCT01958788|Experimental|Cognitive-Behavioural Treatment|12 sessions of cognitive-behavioral treatment targeting negative beliefs about uncertainty
88990016|NCT04404556|Experimental|Diabetes Journey|Diabetes Journey is a web-based intervention to address key adherence barriers. Participants randomized to this arm will first receive the mandatory Introduction and Problem-Solving Module. Based on their elevations on the Barriers to Diabetes Adherence measure, participants will receive up to 7 modules in total. Participants will navigate through the web-based theme park map and complete modules independently and then will have accompanying Zoom telehealth sessions with a therapist.
89211219|NCT00938184|Experimental|Treatment sequence A/B/C|Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
89211220|NCT00938184|Experimental|Treatment sequence A/C/B|Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
89211221|NCT00938184|Experimental|Treatment sequence B/A/C|Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
89627184|NCT03288870|Experimental|BCD-100 monotherapy|Patients will receive solution of BCD-100 in a dose 3 mg/kg every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity
89627185|NCT03288870|Active Comparator|Docetaxel monotherapy|Patients will receive solution of docetaxel in a dose 75 mg per square meter every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity, maximum 6 cycles
89627186|NCT03288792|Experimental|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
89627187|NCT02070640|Experimental|NIRF-C|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence (NIRF-C) and standard of care intraoperative cholangiography. 2.5 mg of indocyanine green is injected 30-60 minutes prior to surgery. Visualization of the biliary tree during surgery is achieved with a near-infrared light source and camera.
89627188|NCT03282474|Experimental|Sofosbuvir|Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.
89627189|NCT02460354|Experimental|Metformin|Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally
89627190|NCT02071108|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
89627191|NCT03293706|Active Comparator|CHO Control 1 Glucose|25 g glucose
89627192|NCT03293706|Active Comparator|CHO Control 2 Glucose|25 g glucose
89627193|NCT03293706|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
89627194|NCT03293706|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
89627195|NCT03293706|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
89627196|NCT03293706|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
89627197|NCT03293628|Experimental|Conization With Vaginal Packing|Experimental Arm. Haemostasis at the end of the procedure using vaginal packing and Monsel's solution.
89627198|NCT03293628|Active Comparator|Conization Without Vaginal Packing|Haemostasis at the end of the procedure using only Monsel's solution.
89627199|NCT02008942|Experimental|PL2200 Aspirin Capsules|PL2200 Aspirin Capsules
89627200|NCT02008942|Active Comparator|Enteric-coated aspirin caplets|Enteric-coated aspirin caplets
89627201|NCT03288636|Experimental|Experimental|"PKGroup:~Ravidasvir + Danoprevir/ Ritonavir"
89627202|NCT03288636|Placebo Comparator|Placebo|"Placebo Group:~Placebo"
89627203|NCT02071420|Experimental|Experimental Group|This group will receive the seated active workstation intervention, the ergonomic intervention and the email intervention for 16 weeks.
89627204|NCT02071420|Active Comparator|Active Control|This group will receive the ergonomic intervention and email intervention only for 16 weeks. This group will not receive a seated active workstation.
89211222|NCT00938184|Experimental|Treatment sequence B/C/A|Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
89211223|NCT00938184|Experimental|Treatment sequence C/A/B|Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
89627205|NCT03293550||patients over 65 years undergoing elective surgery|patients over 65 years undergoing elective cardiac surgery or elective hip or knee surgery
89627206|NCT01959178|Experimental|LD127025 MF|Mid add daily disposable soft contact lens worn on a daily wear basis for 1 week.
89627207|NCT01959178|Active Comparator|Air Optix Aqua MF|Medium add daily disposable soft contact lens worn on a daily wear basis for one week.
89627208|NCT03107832|Active Comparator|general anesthesia|In general anesthesia group (Group G), and induction was managed using 1.5 mg/kg fentanyl and 2 mg/kg propofol; 0.5 mg/kg rocuronium and sevoflurane in a 50% oxygen /air mixture was used. Blood gas analysis monitoring was performed in the 30th minute before and after pneumoperitoneum
89627209|NCT03107832|Experimental|thoracic epidural anesthesia|In epidural anesthesia group(Group E), a catheter was installed and received 20 mg lidocaine hydrochloride, 15 mg bupivacaine, and 25 mg fentanyl citrate adjusted to 10 cc with normal saline to be injected by the epidural catheter. Bi-spectral index -controlled sedation was provided
89627210|NCT03293472|Experimental|Ropivacaine|"Experimental: 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm.~supplementary bolus doses of ropivacaine as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period"
89627211|NCT03293472|Active Comparator|Bupivacaine|"0.5% v Bupivacaine mg (isobaric) loading dose of 0.5% bupivacaine, 3.0 ml for the patients < 160 cm tall, 3.3 ml for 161-170 cm tall, 3.6 ml for 171-180 cm tall, and 4.0 ml > 180 cm.~and supplementary bupivacaine bolus dose as required, followed by 0,12% bupivacaine 1 ml/h for the postoperative period"
89627212|NCT03288558|Experimental|Intervention Group|Subjects randomized to the intervention group will receive a comprehensive perioperative mechanical ventilation strategy that includes a bundle of protective settings (use of PEEP, recruitment maneuvers and continuation of mechanical ventilation during CPB).
89627213|NCT03288558|No Intervention|Control Group|Subjects randomized to the control group will receive mechanical ventilation according to the current usual care.
89627214|NCT02071810|Experimental|BIA 9-1067 5 mg|BIA 9-1067 (OPC, Opicapone) 5 mg
89627215|NCT02071810|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (OPC, Opicapone) 10 mg
89627216|NCT02071810|Experimental|BIA 9-1067 20 mg|BIA 9-1067 (OPC, Opicapone) 20 mg
89627217|NCT02071810|Experimental|BIA 9-1067 30 mg|BIA 9-1067 (OPC, Opicapone) 30 mg
89627218|NCT02071810|Experimental|Placebo|Placebo, PLC
89627219|NCT02715258|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will self-administer bexagliflozin tablets once daily for 24 weeks.
89627220|NCT02715258|Placebo Comparator|Placebo tablets|Each subject will self-administer placebo (inactive tablet) once daily for 24 weeks.
89627221|NCT01959490|Experimental|Cohort 1P (HER2 positive)|Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
89627222|NCT01959490|Experimental|Cohort 1T (HER2 positive)|Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
89627223|NCT01959490|Experimental|Cohort II (HER2 negative)|Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.
89627224|NCT03282318|Experimental|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
89627225|NCT03282318|Placebo Comparator|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
89627226|NCT02714868|Experimental|Project TEAM Intervention|Project TEAM is a manualized intervention co- facilitated by a disability advocate and a licensed professional. The intervention includes eight group sessions and two experiential learning field trips. In addition, young adults with disabilities serve as peer mentors on field trips and contact youth weekly to support attainment of goals. Project TEAM outcomes are to: increase youths' knowledge of environmental factors and modification strategies; reduce the impact of environmental barriers on participation; increase self-efficacy and self-determination; and increase participation in a personal activity goal in the area of education, employment, or community life.
89627227|NCT02714868|Active Comparator|Matched comparison|Youth with disabilities who are matched controls will receive their typical educational or therapeutic services. Youth will receive a stipend to participate in a preferred activity in the community; youth will document what they did and with whom they participated. Attempts to control for the impact of resources on participation and goal achievement.
89627228|NCT03288402|Experimental|ongoing fasted|ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min
89039407|NCT04721457|Active Comparator|Cetylpyridinium Chloride (CPC)|Vigorously rinse with 15 ml of the 0.075% cetylpyridinium chloride (CPC) (Colgate Total; Colgate-Palmolive, Guildford, UK) for 30 s
89039408|NCT04721457|Active Comparator|Sodium Hypochlorite|Vigorously rinse with 15 ml of the 80 ppm sodium hypochlorite (NaOCl) (Clinisept Dental Mouthwash; Clinical Health Technologies, Hinckley, Leicestershire, UK) for 30 s
89039409|NCT04721457|Placebo Comparator|No rinse group|There is no mouth rinse in this group. Patients will collect the saliva at all 4-time points without gargling with the mouth rinse.
89039410|NCT04666415|Experimental|Osteopathic treatment + as-usual treatment|"Osteopathic treatment: a protocol of 5 sessions of osteopathic treatment that have a 25 minutes duration and are spaced of around one week between two sessions.~As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers."
89039411|NCT04666415|No Intervention|As-usual treatment|As-usual treatment: The outpatient and inpatient treatment of the patients will be done in compliance with the Health Authorities' recommendations (HAS 2010). Multi-disciplinary care is proposed, possibly involving nurses, psychologists, psychiatrists, general practitioners, gynecologists, rheumatologists, dieticians, occupational therapists, body approach specialists and social workers.
89039412|NCT00557024|Experimental|1|radiotherapy after RFA
89039413|NCT00557024|Active Comparator|2|RFA alone
89039414|NCT04666493|Experimental|Facing Your Fears - Open label|All participants in the study will receive 12 weekly sessions of Facing Your Fears intervention, each lasting approximately 1 to 1.5 hour. Each session involves a component with all the parents and children (30-45 minutes) and a separate time with all the parents only (30-45 minutes). Additionally, there will be two check-in calls (30 minutes each) with the families after weeks 7 and 9 of the program.
89039415|NCT04711785|Active Comparator|Intervention|Multicomponent exercise program twice a week (2 hours per week) during six months
89627229|NCT03288402|Experimental|intake of caffeine containing beverages|10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min
89627230|NCT03288402|Experimental|intake of 5 item English breakfast|10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min
89627231|NCT03288246|No Intervention|Standard-of-care|Participants in the standard-of-care arm will receive a standard laboratory-based viral load test at baseline, 3, and 6 months.
89039416|NCT04711785|No Intervention|Control Goup|Usual routine.
89039417|NCT04666220||Renal cell carcinoma (RCC)|"For all series, clinical and epidemiological features will be recorded, all available histological slides will be reviewed and, on the primary tumor slides, histological characteristics will be re-assessed.~Whenever multiple samples of tumors would be present, those having the tumor-surrounding tissue interface will be selected and stained with CD34 antibody.~VETC will be evaluated independently by, at least, two pathologists, blinded to clinical data. VETC will be recorded as positive or negative, being VETC defined as CD34 unequivocal immunoreactivity of a continuous lining of endothelial cells around tumor clusters. VETC will be considered alternative to the common capillary pattern, consisting in small circular or linear blood vessels."
89627232|NCT03288246|Experimental|Point-of-care|Participants in the point-of-care arm will receive a point-of-care viral load test at baseline, 3, and 6 months.
89627233|NCT03288168||0-18 y/o Patients with Medulloblastoma|Patients treated with comprehensive treatments including surgery, chemo-therapy with / without (less than 3 y/o) radiation, during the period of Jan 2008 and Dec 2012, whose tumor samples will be tested by NanoString and Histochemistry methods, are enrolled in this cohort group.
89627234|NCT02011516|Placebo Comparator|Sugar pill, psychosocial intervention|twice weekly appointments with a certified clinician
89627235|NCT02011516|Active Comparator|Baclofen, psychosocial intervention|20 mg. q.i.d. twice weekly appointments with a certified clinician
89627236|NCT03287934|Experimental|digital light processing stent|according to the allocation, the experimental group will receive a digital light processing stent for immediate implant drilling and placement after atraumatic extraction of the target tooth.
89627237|NCT03287934|Active Comparator|selective laser sintering|according to the allocation, the intervention for the control group will be a selective laser sintering stent after atraumatic extraction of the target tooth for immediately implant placement. the selective laser sintering stent will be adapted and drilling will be done through the stent.
89627238|NCT04349410|Experimental|Treatment 1|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Azithromycin 500 mg IV on day 1, followed by 250 mg IV on days 2-5 (to prevent bacterial superinfection ).
89627239|NCT04349410|Experimental|Treatment 2|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated and Doxycycline 100mg IV q 12 hrs with each dose given over 1 to 4-hours (to prevent bacterial superinfection ).
89627240|NCT04349410|Experimental|Treatment 3|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
89627241|NCT04349410|Experimental|Treatment 4|Hydroxychloroquine 200 mg po q 8 hrs (600 mg qD) for a total of 10-days OR Hydroxychloroquine 155 mg IV every 8-hours (600 mg qD) for 10-days if patient is intubated Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days.
89627242|NCT04349410|Experimental|Treatment 5|Primaquine 200 mg po on day # 1. Clindamycin 150-450 mg po q6 hours x 10 days OR 4800 mg IV daily - beginning with 150 mg initial rapid infusion, followed by continuous infusion q 24-hours for 7-days. This treatment arm is not available for intubated patients due to the absence of an IV form of Primaquine.
89627243|NCT04349410|Experimental|Treatment 6|Remdesivir 200 mg IV on day 1, followed by 100 mg IV qD for a total of 10-days.
89627244|NCT04349410|Experimental|Treatment 7|"Tocilizumab 8mg/kg IV (not to exceed 800 mg) over 60-minutes. If clinical improvement is not noted, three additional doses may be administered at q 8-hour intervals from the initial infusion for a total of 4-doses maximum.~ANY PATIENT DEMONSTRATING CYTOKINE RELEASE SYNDROME WILL HAVE THIS TREATMENT ARM AUTOMATICALLY ADDED."
89039418|NCT04666220||Adrenal carcinoma|see (RCC)
89039419|NCT04666142|Active Comparator|Individual Characteristics of the Individuals in the Experimental and Control Groups|The personal characteristics of the individuals included in the study were examined.
89039420|NCT04666142|Active Comparator|Disease Characteristics of the Individuals in Experimental and Control Groups|The intensive care experience of the individuals included in the study, their status of receiving respiratory support, and the reason for staying in the intensive care unit were explained.
89039421|NCT04666142|Active Comparator|Distribution of Findings Regarding Sleep Activity of the Individuals in Both Groups|The personal characteristics of the individuals in the experimental and control groups regarding sleep were examined.
89039422|NCT04666142|Active Comparator|Comparison of the Individuals in the experimental and control groups after 24 hours of sleep|The effect of light after 24 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
89039423|NCT04666142|Active Comparator|Comparison of physiological parameters of individuals in both groups after 24 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 24 hours after their admission to the ICU.
89039424|NCT04666142|Active Comparator|Comparison of the Sleep Times of the Individuals in Both Groups 48 Hours After Intensive Care|The effect of light after 48 hours in the experimental and control groups of individuals hospitalized in the intensive care unit was examined.
89039425|NCT04666142|Active Comparator|Comparison of physiological parameters of individuals in both groups after 48 hours|Comparison of the physiological parameters of the individuals in the experimental and control groups 48 hours after their admission to the ICU.
89039426|NCT04666142|Active Comparator|Distribution of Total Sleep Times of the Individuals in the Experimental and Control Groups|The sleep times of the individuals in both groups were compared
89039427|NCT04650126|Experimental|ATM001|Escalating dose levels of ATM001 administered as single dose in healthy subjects
89039428|NCT04650126|Placebo Comparator|ATM001 Placebo|Escalating dose levels of ATM001 Placebo administered as single dose in healthy subjects
89039429|NCT04665908|Other|PT-led triage|Patients are assessed by PT
89039430|NCT04665908|Other|Standard care|The patiens are assessed by a orthopedic surgeon
89627245|NCT04349410|Experimental|Treatment 8|Methylprednisolone 125 mg IV every 6-hours for 3 days; then 125 mg IV every 12-hours for 2 days; then 125 mg IV daily for 2 days; then 60 mg IV daily for 2 days [with each infusion given over 30-minutes]; then Solumedrol dose pack to taper off steroids.
89627246|NCT04349410|Experimental|Treatment 9|Interferon alpha-2b 5 million units per nebulizer BID.
89627247|NCT04349410|Experimental|Treatment 10|Losartan 25 mg po qD. IRB held due to questions about benefit.
89627248|NCT04349410|Experimental|Treatment 11|Convalescent Plasma 2-units ABO-compatible with antibody titer of 1:320 dilution. Each unit intravenously infused over 4-hours.
89627249|NCT03287856|Experimental|Treatment|Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis
89627250|NCT01961362||Pulmonary fibrosis patients|Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
89627251|NCT03287700||Focus group participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK) OR Adults who have been referred to a UK auditory implant programme for assessment for cochlear implantation but who have not yet been implanted
89627252|NCT03287700||Online patient survey participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK)
89627253|NCT03287700||Online clinician survey participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
89627254|NCT03287700||Trial design workshop participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
89627255|NCT03287700||Manufacturer's forum participants|Representatives of manufacturers of cochlear implants who provide devices on the NHS
89627256|NCT03287700||Care pathway working group participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
89627257|NCT03287466|Experimental|SpO2 88-92%|The intervention is targeted oxygen therapy (TO2T) to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88-92%.
89627258|NCT03287466|Active Comparator|Current best practice|The control group will have no specific SpO2 targets. Clinicians will be able to target SpO2 according to parameters they feel are suitable for the patient, according to standard UK practice.
89627259|NCT03287388|Experimental|No Rocuronium|Phase 1: no neuromuscular blockade
89627260|NCT03287388|Experimental|Rocuronium (moderate NMB)|Phase 2: moderate neuromuscular blockade (TOF 1-3)
89627261|NCT03287388|Experimental|Rocuronium (deep NMB)|Phase 3: deep neuromuscular blockade (PTC 0-1)
89627262|NCT03293316|Sham Comparator|Sham Transcranial Random Noise Stimulation|The sham tRNS condition involves 30 seconds of 1.5 mA tRNS, with a ramping period of 30 seconds at the onset and offset. This procedure ensures that, in both the Active and Sham conditions, participants experience the sensations associated with the onset of transcranial electrical stimulation (e.g., tingling sensation)
89627263|NCT03293316|Experimental|1mA Transcranial Random Noise Stimulation|The 1mA tRNS condition consists of 1 mA peak-to-peak (-.5 mA to .5 mA) high frequency noise (100-500 Hz), with amplitude values that are normally distributed and have a mean of zero. The stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
89627264|NCT03293316|Experimental|2mA Transcranial Random Noise Stimulation|The only factor that varies for the 2mA tRNS condition is that the high frequency noise has a peak-to-peak of -1 mA to 1mA as opposed to -.5 mA to .5 mA. Again, the stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
89627265|NCT03293160||Treatment group|The set of patients in the sample who are offered enrollment in care management services.
89627266|NCT03293160||Control group|The set of patients in the sample who are not initially offered enrollment in care management services (will be offered enrollment after six months).
89627267|NCT03293004|Experimental|Hydrolyzed collagen|First, we aim to determine the optimal amount of hydrolyzed collagen with a constant dose of vitamin C in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of hydrolyzed collagen (control (0 g), 5 10, 20 and 30 g hydrolyzed collagen) with a constant dose of vitamin C (50 mg). Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
89039431|NCT04644744|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of end-ischemic Hypothermic machine perfusion (HOPE) for a minimum of 2 hours (until hepatectomy)
89039432|NCT04644744|Experimental|Normothermic machine perfusion (NMP)|Application of end-ischemic normothermic machine perfusion (NMP) for a minimum of 4 hours (up to 24 hours)
89039433|NCT04644744|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
89039434|NCT04665986|Experimental|NHP|Navelbine, Herceptin, Pertuzumab
89039435|NCT04665986|Active Comparator|THP|Docetaxel, Herceptin, Pertuzumab
89039436|NCT04638309|Experimental|Cohort 1|Dose level 1
89039437|NCT04638309|Experimental|Cohort 2|Dose level 2
89039438|NCT04638309|Experimental|Cohort 3|Dose level 3
89627268|NCT03293004|Experimental|Vitamin C|Second, we aim to determine the optimal amount of vitamin C with the determined optimal dose of hydrolyzed collagen in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of vitamin C (0 (control), 50, 250 and 500 mg) with an optimized dose of hydrolyzed collagen as determined from the first arm. Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
89627269|NCT03293004|Experimental|Optimized Collagen and Vitamin C supplement|The findings from the first 2 arms of the study will be used to inform a training-based study aimed to determine whether exercise together with this optimal dose of hydrolyzed collagen and vitamin C is sufficient to improve rate of force development (RFD) and performance. A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
89627270|NCT03293004|Placebo Comparator|Gummy Placebo|A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement or placebo will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
89627271|NCT03292848|Experimental|10 to <13 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 1.5 mg the second dose of 3 mg.
89627272|NCT03292848|Experimental|6 to <10 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 0.75 mg and the second dose of 1.5 mg.
89627273|NCT03292770|No Intervention|Control Group|Embryo transfer will be performed as per clinic's routine protocol, where cervical mucus is gently removed with a cotton swab. No manipulation of the cervical canal is executed.
89627274|NCT03292770|Experimental|Flushing Group|"A catheter will be used to perform a flushing of the cervical canal with culture media. The Flushing Catheter has a flared proximal end that is designed to affix to a standard Luer slip syringe and a pre-curved distal closed end, with a biseled opening on the side, 2mm from the tip, in which liquid flushes towards the outside of the cervical canal.~Device: Cook Flushing Catheter J-IUIC-352200 (3.5fr 20cm flushing catheter with positioner closed end) (CEE approval)."
89627275|NCT03292536|Experimental|Merestinib, all patients|
89627276|NCT03292380||Caffeine intake recall|All subjects completed 24-hour urine collection, and subsequently completed the 24-hour Caffeine Intake Recall (CIR-24) developed by the research group and the Caffeinated Beverage Frequency Questionnaire (CBQ) developed by the Fred Hutchison Cancer Centre. The order of completing the CIR-24 and the CBQ was alternated each day of data collection.
89627277|NCT03282162|Experimental|Oxytocin then placebo|Subjects will first receive oxytocin (24 IU).They then will receive placebo (24 IU) 2 weeks later.
89627278|NCT03282162|Experimental|Placebo then oxytocin|Subjects will first receive placebo (24 IU).They then will receive oxytocin (24 IU) 2 weeks later.
89627279|NCT03287076|Experimental|Active|Patients will receive exenatide injections
89627280|NCT03287076|No Intervention|Standard Care|Standard care for stroke as per hospital protocol
89627281|NCT03286998||placenta previa|pregnant women with singleton living healthy fetus diagnosed as having placenta previa by grey scale ultrasound (placental tissue covers the internal cervical os or within 2 cm from it)
89627282|NCT03282084||Unproven GERD|Subjects with no prior testing, normal prior EGD or prior LA Grade A esophagitis
89627283|NCT03282084||Proven GERD|LA Grade B-D esophagitis, long-segment Barrett's, prior positive pH study
89627284|NCT03286920||Oral natural diet|As for patients in oral natural diet group, the the participants shall receive oral natural diet.
89627285|NCT03286920||Oral nutrition supplement group|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
89627286|NCT03286920||Tube feeding nutrition supplement group|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.
89627287|NCT02460276|Experimental|Lenalidomide, ibrutinib and rituximab.|
89627288|NCT02460432|Experimental|Paclitaxel-eluting metal Stent|Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)
89627289|NCT02460432|Active Comparator|Covered Metal Stent|ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)
89627290|NCT03282006|Experimental|Pivmecillinam|Patients treated with pivmecillinam
89627291|NCT03291912|Experimental|Chuna Manual Therapy (CMT)|"Chuna manual therapy (CMT), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~CMT and UC group will receive the same UC regimen."
89627292|NCT03291912|Active Comparator|Usual Care (UC)|"Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~CMT and UC group will receive the same UC regimen."
89039439|NCT04666103|Experimental|Thyroid lobectomy with intraoperative thermal ablation|"Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection. After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
89039440|NCT04666103|No Intervention|Thyroid lobectomy|Thyroid lobectomy was performed with a standard technique of fine capsular en bloc dissection and resection, from inferior pole to superior pole. Superior parathyroid glands were identified and preserved in situ, inferior parathyroid glands were protected in situ or autotransplanted in the sternocleidomastoid muscle according to three certain types based on their blood supply and location. All the patients underwent lobectomy received ipsilateral therapic central compartment neck dissection.
89627293|NCT03281928|Experimental|Low Sodium plus Potassium Citrate|
89627294|NCT03281928|Placebo Comparator|Low Sodium plus placebo|
89627295|NCT03281928|Experimental|High Sodium plus Potassium Citrate|
89627296|NCT03281928|Placebo Comparator|High Sodium plus placebo|
89627297|NCT02460120|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
89211224|NCT00938184|Experimental|Treatment sequence C/B/A|Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
89627298|NCT02459652|Experimental|Neoadjuvant S-1/RT|This is a single arm prospective study. All eligible subjects will receive neoadjuvant S-1 and concurrent radiation followed by surgical resection. Subjects may receive adjuvant chemotherapy after surgical resection at the clinical discretion of the medical oncologists.
89627299|NCT03281772||Provider|Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
89627300|NCT03281772||Patients|In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
89627301|NCT03286764|Placebo Comparator|Placebo|Distilled water spray as a placebo during Colonoscopy
89627302|NCT03286764|Experimental|Peppermint Oil|Peppermint Oil spray during Colonoscopy
89627303|NCT03291678|Experimental|new laparoscopic orchiopexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum with closure of internal ring
89627304|NCT03291678|Active Comparator|classic laparoscopic orchoipexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum
89627305|NCT03291600|Experimental|Virtual Psychiatric Care Group|Participants randomized to the intervention group will have the option to receive video-based psychiatrist care in addition to care as usual. Participants will be assigned to begin immediately after randomization.
89627306|NCT03291600|No Intervention|Control Group|Women allocated to the control condition will receive care as usual (in-person psychiatric care) from the study site to which they were referred.
89627307|NCT03291366|Experimental|MSC|infusion of aUCMSC and conventional therapy
89627308|NCT03291366|Active Comparator|conventional|conventional therapy
89627309|NCT03281694|Other|Nicotine - AVL-3288 Interaction Study|Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
89627310|NCT03281616|Active Comparator|Diet and Physical Activity Recording|
89627311|NCT03281616|Active Comparator|Diet and No Physical Activity Recording|
89627312|NCT03281460|Experimental|with in-bag morcellation|with More-cell-Safe AMI bag morcellation
89627313|NCT03281460|Active Comparator|without any morcellation bag|without any morcellation bag
89627314|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
89627315|NCT03281226|Active Comparator|RIPE (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (combined fixed dose tablet according to the weight) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months.
89627316|NCT03281226|Experimental|RIPE+NAC (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (combined fixed dose tablet according to the weight) plus N-acetylcysteine (NAC) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months. The NAC is administered by means of effervescent tablet 1200 mg (two sachets of 600 mg) to be diluted in 200ml of water and administered in a 12-hour interval.
89627317|NCT03291054|Experimental|Epacadostat and pembrolizumab|Subjects will receive epacadostat and pembrolizumab
89627318|NCT03290976|No Intervention|Control Group|The control group will consist of patients who choose not to undergo CIM treatments for their CIPN-related symptoms. Participants in this arm of the study will receive standard conventional supportive care, as provided by their oncology health care professionals (HCPs), and closely monitored for any changes in the severity of their CIPN-related symptoms.
89627319|NCT03290976|Active Comparator|Intervention Group A: Single Modality (acupuncture)|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture x2/week, for 6 weeks.
88990017|NCT04404556|Active Comparator|Enhanced Standard of Care|Participants randomized to Enhanced Standard of Care will receive general education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) from each site across 12-weeks. Content to address adherence barriers were modified and or newly developed for the Enhanced Standard of Care group via the T1DToolkit website.
89211225|NCT00931320||3000 patients|Who have at least made 1 visit to the outpatient clinic within previous 6 months .
89211226|NCT00938262|Experimental|Fimasartan, Ketoconazole, Rifampicin|
89211227|NCT00933426|Experimental|Lenalidomide and Paclitaxel|"Phase I: Up to 5 differing doses of Lenalidomide tested plus fixed dose of Paclitaxel.~Phase II: Lenalidomide at highest tolerated dose from Phase I plus Paclitaxel."
89211228|NCT04014582|Experimental|Communal Coping Intervention|This group will participate in diabetes education + a communal coping based intervention.
89627320|NCT03290976|Active Comparator|"Intervention Group B: Multi-modality (acupuncture plus)"|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture with additional CIM treatment modalities, x2/week, for 6 weeks.
89627321|NCT03286374|Other|Occupational rehabilitation|The participants will receive the current occupational rehabilitation program at Muritunet.
89627322|NCT03286296|Experimental|LZM009|
89627323|NCT04539522|Experimental|Three-dimensionally corrective exercise for scoliosis|Experimental group will perform three-dimensionally corrective exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home.For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
89627324|NCT04539522|Active Comparator|Conventional exercise|Control subjects will perform conventional exercise for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home. For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
89627325|NCT03281148|Experimental|Computer guided implant insertion group|According to the allocation, the experimental group will receive implants immediately placed in extraction sockets using CAD/CAM surgical guides.
89627326|NCT03281148|Active Comparator|Free hand implant insertion group|According to the allocation, the control group will receive implants immediately placed in extraction sockets using traditional free hand technique.
89627327|NCT04443504|Experimental|Intervention Group|
89627328|NCT04443504|No Intervention|Waitlist Group|The waitlist group will receive the intervention 3 months after the intervention group.
89627329|NCT03286140|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)
89627330|NCT03286140|Experimental|Early arm|Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard compression therapy
89627331|NCT03286062|Experimental|VM110|Escalating dose of agent VM110 given to patients to visualize occult cancer with laproscopic infra red detect
89627332|NCT01776723|Experimental|I: Dose Escalation - Ruxolitinib|"Phase I: Dose Escalation. In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day [BID] dosing) according to the rolling six Phase I design."
89627333|NCT01776723|Experimental|II: Maximum Tolerated Dose - Ruxolitinib|Phase II: Treatment at Maximum Tolerated Dose (MTD).
89627334|NCT01775007|Experimental|Normal Healthy Subjects|Brillouin Ocular Analyser
89627335|NCT03280914||CPAP group|Automatic Continuous Positive Airway Pressure treatment and usual care
89211229|NCT04014582|Active Comparator|Control|This group will participate in diabetes education and an individual intervention.
89627336|NCT03280914||Usual care group|Usual care without Continuous Positive Airway Pressure treatment
89627337|NCT04350294||Serious Mental Illness *RECRUITMENT IN THIS GROUP IS CLOSED|"Mothers with a serious mental illness*~*received hospitalisation, treatment or intervention from a secondary care (mental health) service in the last 5 years."
89627338|NCT04350294||Healthy Controls|Mothers with no history of mental illness, who have given birth since February 2021
89627339|NCT00228579||Bariatric Surgery|Subjects will be recruited from patients undergoing bariatric surgery at Emory Bariatrics. The cost of surgical procedures will not be provided by the research study.
89627340|NCT03285906|Experimental|Treatment group|Apatinib：500 mg，po，qd
89627341|NCT01895205|Experimental|Iron isomaltoside 1000|A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.
89627342|NCT01895205|Active Comparator|Red blood cell transfusion|"Allogenic RBC transfusion is dosed to trigger Hb:~Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC~Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC"
89627343|NCT03285828|Other|First group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
89627344|NCT03285828|Other|Second group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
89627345|NCT01895283|Experimental|Moderate-intensity training|Regular supervised moderate-intensity training on a bike ergometer, three times per week, for 30 minutes a total of 10 weeks.
89627346|NCT04264962|Experimental|Yang Yin Fu Zheng Jie Du therapy|
89627347|NCT04264962|Placebo Comparator|Routine medical care|
89627348|NCT01748175||Longitudinal follow up|Patients will undergo a characterization phase, which includes a baseline evaluation (1 visit), and a steroid responsiveness evaluation (2 visits). The longitudinal phase will include 3 office visits (annually) over 36 months with bi-annual phone calls. During the study patients will answer questionnaires, perform lung function testing and provide blood, urine, sputum and exhaled breath condensate samples.
89627349|NCT04261764|Experimental|TCM-FMD|"Fasting-Mimicking Diet Combined With a Dispelling Dampness Meal Replacement Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
89627350|NCT04261764|Placebo Comparator|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
89627351|NCT03280758|Experimental|Muscle strengthening group|Participants will be required to perform muscle strengthening exercises 3 hours per week. Close kinetic chain exercises will be performed progressively according to the ACSM guidelines over the 4-month intervention period. The exercise intervention will be conducted by an experienced sports trainer.
89627352|NCT03280758|No Intervention|Control group|No exercise training.
89627353|NCT04755387|Other|Ticagrelor 90mg|Standard strategy group receive ticagrelor 90mg twice daily
89627354|NCT04755387|Experimental|Ticagrelor 60/45mg|De-escalation strategy group receive ticagrelor 60 mg twice daily or 45mg twice daily if patients with body weight <60kg, or age >75 years old.
89627355|NCT04046328|Experimental|"Low Dose ECC Regimen"|ECC at the 1.7 g daily dose, administered BID (twice daily) as 2 capsules of ECC, plus 3 capsules of placebo, at least 30 minutes before breakfast and 2 capsules of ECC, plus 3 capsules of placebo at least 30 minutes before evening meal.
89627356|NCT04046328|Experimental|"High Dose ECC Regimen"|ECC at the 4.25 g daily dose, administered BID (twice daily) as 5 capsules of ECC at least 30 minutes before breakfast and 5 capsules of ECC at least 30 minutes before evening meal.
89627357|NCT01726959||Methotrexate|Methotrexate for rheumatic diseases, 2.5 - 25 mg weekly
89627358|NCT03285672|Experimental|Arm 1|FP-101
89627359|NCT03285672|Placebo Comparator|Arm 2|Placebo Comparator
89627360|NCT03285516|Experimental|START|The Safety Aid Reduction Treatment (START) protocol will consist of eight group sessions, delivered once weekly, lasting approximately one hour in duration. START will be delivered in-person by the PI and group co-leader.
89627361|NCT03280680|Experimental|Female+male group sessions|
89627362|NCT03280680|Experimental|Female group sessions|
88990018|NCT04404309||Population 1|Any patient admitted to a psychiatric ward with a clinical diagnosis of (unipolar) major depression
88990019|NCT04404309||Population 2|Any patient with a clinical diagnosis of a moderate or severe unipolar depressive disorder with suicidal tendencies that persist for at least 48 hours after admission
88990020|NCT04404309||Population 3|Patients with moderate or severe unipolar depressive episodes validated by research interviews and suicidal tendencies that persist for at least 48 hours after admission who will be followed up for 6 months
88990021|NCT04402632|Active Comparator|Surgery Cohort: Control Arm|Control
88990022|NCT04402632|Experimental|Surgery Cohort: Treatment Arm|Treatment
88990023|NCT04402632|Active Comparator|Observational Cohort: Control Arm|Control
88990024|NCT04402632|Experimental|Observational Cohort: Treatment Arm|Treatment
88990025|NCT04391049|Experimental|Treatment (OBP-301, carboplatin, paclitaxel, radiation)|Patients receive OBP-301 by intratumoral injection on days -3, 12, and 26. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.
88990026|NCT04387552|Experimental|Prenatal SS/Postnatal BF|Prenatal Safe Sleep/Postnatal Breastfeeding Mobile Health Messages
89627363|NCT03280680|Other|No group sessions|
89627364|NCT03285360|Experimental|sylc bioactive glass|"Sylc is a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment.~Steps:~Isolation: D.M. will make proper isolation for the teeth using cotton rolls.~Hand piece: NSK Prophymate Neo will be used to deliver the powder particles on the sensitive areas. Air stream adjusted at 40-46 psi.~Application: The hand piece will be held at constant distance (3-4mm) away from the tooth surface, with 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth in a circular movement.~Suction: High volume suction will be used on lingual side of the teeth to suck any particles, and avoid patient from swallowing it."
89627365|NCT03285360|Active Comparator|fluoride varnish (Bifluorid 10)|"fluoride varnish Bifluorid 10(by VOCO) will be used. It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.~The single dose form will be used, to make sure the amount of fluoride varnish used is standardized.~Steps:~Preparation: The tooth will be properly cleaned, and the surface will be air-dried.~Dispensing: The foil will be pierced using a micro- tim, the opening will be enlarged, the brush will be wet in a circular movement.~Application: Thin coat will be applied on the tooth surface. The varnish will be left from 10-20 seconds then air dried.~Concerning the storage of the Bifluoride 10, it will be stored in refrigerator at the operative clinic to avoid exposure to high temperature or sunlight."
89627366|NCT00160173|Experimental|EstroGel® Gel 0.9 grams 0.03%|0.9 g of EstroGel® 0.03% applied to one arm and 1.25 g of placebo gel applied on the other arm once daily for 12 weeks.
89627367|NCT00160173|Experimental|EstroGel® Gel 1.25 grams 0.03%|1.25 g of EstroGel® 0.03% applied to one arm and 0.9 g of placebo gel applied on the other arm once daily for 12 weeks.
89627368|NCT00160173|Placebo Comparator|Placebo Gel|0.9 g of placebo gel applied to one arm and 1.25 g of placebo gel applied on the other arm once daily for 12 weeks.
89627369|NCT03285282|Active Comparator|Intervention|Thoracolumber interfascial plane block
89627370|NCT03285282|No Intervention|Control|
88990027|NCT04387552|Experimental|Prenatal BF/Postnatal SS|Prenatal Breastfeeding/Postnatal Safe Sleep Mobile Health Messages
88990028|NCT04387552|Experimental|Prenatal SS/Postnatal SS|Prenatal Safe Sleep/Postnatal Safe Sleep Mobile Health Messages
88990029|NCT04387552|Experimental|Prenatal BF/Postnatal BF|Prenatal Breastfeeding/Postnatal Breastfeeding Mobile Health Messages
88990030|NCT04383314|Experimental|Exercise Program Group|Participants will be prescribed an individualized 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (ACSM) Guidelines.
88990031|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + enzalutamide|Participants will receive oral etrumadenant in combination with intravenous (IV) zimberelimab and standard oral enzalutamide
88990032|NCT04381832|Active Comparator|Stage 2: enzalutamide|Participants will receive standard oral enzalutamide
89627371|NCT03285204||ALS patients|
89627372|NCT03285204||Friedreich Ataxia patients|
89627373|NCT03285204||Healthy control|
89627374|NCT04046172|Experimental|test group|intensive periodontal treatment (IPT)
89627375|NCT04046172|Sham Comparator|control group|Control periodontal treatment (CPT)
89627376|NCT00136695|Experimental|anastrozole|anastrozole
89627377|NCT00136695|Placebo Comparator|placebo|placebo
89627378|NCT03996720||severe sepsis|patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay
89627379|NCT03996720||sepsis|patients recover from sepsis without developing into organ dysfunction
89211230|NCT04013958|Active Comparator|IV Ketamine|IV Ketamine group will receive IV Ketamine with IV morphine and IM saline.
89627380|NCT01896453|Active Comparator|tDCS real + TENS real|"Real transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
89627381|NCT01896453|Experimental|tDCS real + TENS sham|"Real transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
89627382|NCT01896453|Experimental|tDCS sham + TENS real|"Sham transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
89627383|NCT01896453|Sham Comparator|Sham tDCS + Sham TENS|"Sham transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
89627384|NCT02459730|Experimental|ART with GIC containing 1.25% CHX|The cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
89627385|NCT02459730|Active Comparator|ART with GIC|The cavities were filled with the press finger technique using KetacMolar Easymix® (control group).
89627386|NCT04756167|Active Comparator|Conventional Group|The treatment of 21 individuals in the conventional group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes) and exercise(passive and active range of motion) approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week.
89627387|NCT04756167|Active Comparator|Myofascial Release Group|Treatment of 21 individuals in the Myofascial Release group will be done by the researcher. Among the conservative treatment methods, hot pack(15 minutes) around the glenohumeral joint, conventional TENS(15 minutes) for painful points, ultrasound(1.5 watt / cm² power, 5 minutes),exercise(passive and active range of motion) and myofascial release to subscapularis and serratus anterior muscles approaches will be applied. Individuals will be asked to come to the center where the research will be conducted for a total of fifteen sessions for three weeks, five times a week. Myofascial release will be done in the first five sessions of treatment programs.
89627388|NCT03280602|Active Comparator|Tension band wiring (TBW)|TBW following the AO principles with 2 x 1.6 mm K-wires and wire wire cerclage.
89627389|NCT03280602|Active Comparator|Plate fixation|Plate fixation with Syntes VA-LCP olecranon plates 2.7/3.5
89627390|NCT03280524|Placebo Comparator|Control Group|Control Group will receive self-care guidelines with feet
89627391|NCT03280524|Experimental|Treatment Group|Treatment will receive self-care guidelines with feet and 12 sessions of foot reflexology
89627392|NCT04756011||Group A (insulin pump)|30 patients who are on insulin pump.
89627393|NCT04756011||Group B (MDI)|30 patients who are on multiple daily injection.
89627394|NCT01896063|Experimental|Electroacupuncture preconditioning|
89627395|NCT03280446|Experimental|30 pre-menopause and post-menopause women|Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
89627396|NCT03285048|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Training is comprised of 8 weeks of active cognitive training using Brain HQ auditory and visual training tasks. Training is twice per week for up to 2 hours. Also included is a Bridging Group at each training session. The Bridging group provides information about cognitive training and compensatory strategies to generalize the benefits of training to daily life.
89627397|NCT03284970||Rebif (interferon beta 1a)|This study will retrospectively collect the data from the subjects who had been treated with Rebif subcutaneously (SC) at a dose of 44 micro-grams three times a week.
89627398|NCT03284970||Tecfidera (dimethyl fumarate)|This study will retrospectively collect the data from the subjects who had been treated with Tecfidera.
89627399|NCT04802343|Experimental|BAY1817080 dose escalation|Healthy male subjects will receive BAY1817080 dose 1 and dose 2 as a single oral dose and BAY1817080 dose 3 as a single oral dose on Day 1 and twice daily (BID) from Day 7 to Day 16 followed by a last dose in the morning of Day 17.
89627400|NCT04802343|Placebo Comparator|Placebo|Healthy male subjects will received corresponding placebo.
89627401|NCT02459496|Active Comparator|low-carb diet, followed by conventional DGE diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory low-carb ketogenic diet (VLCKD, below 40 g carbs per day), followed by an isocaloric or moderate hypocaloric low-carb diet (below 40 kcal% carbs per day)
89627402|NCT02459496|Active Comparator|very-low calory diet, followed by conventional diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory diet (VLCD; MODIFAST substitute, approx. 1200 kcal/day), followed by a conventional isocaloric or moderate hypocaloric diet under DGE guidelines
89627403|NCT02459574|Active Comparator|Group 3-Conventional AF Ablation|This will involve an ablation procedure carried out in the usual manner. The patient will have three sheaths placed in the leg veins. Catheters will be passed up to the patient's heart from these veins. Two crossing are required into the left atrium. The ablation will involve freeze technology using the Advance Cryoballoon. It will include measuring the electrical signals and may also involve radiofrequency or 'burning' technology in addition.
89211231|NCT04013958|Experimental|IM Ketamine|IM Ketamine group will receive IM Ketamine with IV morphine.
89211232|NCT00933504|Experimental|Dermacyd Silver Floral (Lactic Acid)|Lactic Acid sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
89211233|NCT00933660|Active Comparator|Control-1|ERC-training by instructor
89211234|NCT00933660|No Intervention|Control-2|No intervention
89211235|NCT00933660|Experimental|Experimental-1|Web-based training only
89211236|NCT00933660|Experimental|Experimental-2|Web-based training with a personal training manikin
89211237|NCT00938574|Experimental|Drug Atu027|
89211238|NCT00938730|Experimental|1. YM150, Dose W, twice daily|
89211239|NCT00938730|Experimental|2. YM150, Dose X, once daily|
89211240|NCT00938730|Experimental|3. YM150, Dose X, twice daily|
89211241|NCT00938730|Experimental|4. YM150, Dose Y once daily|
89211242|NCT00938730|Experimental|5. YM150, Dose Y twice daily|
89211243|NCT00938730|Experimental|6. YM150, Dose Z, once daily|
89211244|NCT00938730|Active Comparator|7. Warfarin|
89211245|NCT00933816|Experimental|Sorafenib with Low-dose FP|
89520658|NCT03059433||Non AVID|175 students will be randomized via lottery by the participating high school to be part of our control group. This group of students will be similar to the AVID group, except they will not be in the AVID program. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
89520659|NCT03059433||High Performing|175 students who are identified as high performing (middle school grade point average >3.5) by the participating high school. They will also complete 4 surveys (8th, 9th, 10th, and 11th grade).
89520660|NCT03437525|Experimental|Peer Support Intervention|The experimental group will receive the peer support intervention for 12 months.
89520661|NCT03437525|No Intervention|Control|Usual care
89520662|NCT03797469|Active Comparator|Nicotinamide and Pyruvate (N&P)|This group will receive two separate sets of tablets containing 3 x 1000 mg of Vitamin B3 (nicotinamide) and 2 x 1500 mg of Pyruvate.
89520663|NCT03797469|Placebo Comparator|Placebo|This group will receive an equal number of tablets as the N&P group.
89520664|NCT03432923|Experimental|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
89520665|NCT03432923|Placebo Comparator|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
89520666|NCT03294993|Experimental|Ultrasound assess group|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
89520667|NCT04534829|Experimental|Ultrasound-Guided SIJ RFA|"Utilizing short axis views, the S1, S2 and S3 foramen and tubercles would be localized and marked by a surgical skin marker. Then, the ultrasound transducer will be moved laterally to achieve a long axis view between the S1 and S2 tubercle. Local skin and subcutaneous tissue freezing would be performed with Lidocaine 1% utilizing a 30-gauge needle. An 18-gauge radiofrequency (RF) cannula will be directed utilizing an in-plane approach toward the S2 and S3 lateral branches between the S2 and S3 tubercles. A small amount of 1% lidocaine will be injected in order to provide comfort.~The RF generator will be set to continuous monopolar RF ablation and the needle will be heated to 80 degrees Celsius for 90 seconds. The needle will then be repositioned proximally to obtain a slightly larger burn in a similar fashion previously described. A similar approach will be utilized for the S1 lateral branch RF ablation between the S1 and S2 tubercles."
89520668|NCT04534829|Active Comparator|Fluoroscopic-Guided SIJ RFA|An anterior-posterior approach is used to identify the S1-S3 foramen. A 3-inch spinal needle would be used for marking. Local tissue freezing would be accomplished with Lidocaine 1% and a 30-G needle. An 18-G RF cannula will be positioned over the 12 o'clock position of the S1 foramen and a second cannula placed in the 2 o'clock or 10 o'clock position for the right and left respectively (4-5 mm distance between the cannula). A small amount of 1% lidocaine will be injected for comfort. A lateral projection is taken to ensure the needles are not placed into the foramen. The RF generator will be set to continuous bipolar RF ablation and heated to 80 degrees Celsius for 90 seconds. Then another 18-G RF cannula will be positioned at the 4 o'clock or 8 o'clock position (4-5 mm distance between the cannula) to achieve the second RF ablation. The third RF ablation will be performed with the RF cannula at the 6 o'clock position. An identical fashion is utilized at the S2 and S3 foramen.
89520669|NCT02809989||Ovaleap®|Single group prospective treatment cohort
89520670|NCT03432845||Sugammadex reversal group|Surgical patients will have their muscle relaxant reversed with sugammadex
89520671|NCT03432845||Glycopyrrolate / Neostigmine reversal group|Surgical patients will have their muscle relaxant reversed with glycopyrrolate and neostigmine
89520672|NCT04435899|Experimental|EFFECTS OF A CHAIR-YOGA EXERCISES ON STRESS HORMONE LEVELS.|assess the changes mediated by exercise on activities of daily life and falls (autonomy), physical fitness, salivary cortisol and alpha amylase in older adults living in social care givers centers. Methods: 35 women (83.81 ± 6.6 years old) were divided into two groups: chair-yoga exercises (CY, n=20) and control group (CG, n=15). All subjects were evaluated before and after 14-weeks of intervention. CY was involved in classes two times per week, while the GC did not participate in any exercise.
89520673|NCT04435899|Experimental|Physical fralty and health outcomes of fitness, sex hormones.|The study aimed to investigate the association of frailty with diverse geriatric health characteristics and how the latter might contribute to the former. Cross-sectional data of 140 women aged over 75 years were analyzed. Fried's definition of physical frailty, psychological, sex hormones, disability and physical fitness outcomes were examined. Prevalence of frailty was 40%. Frail women had lower scores in cognitive and physical fitness, and high scores for depression and comorbidities. Significant correlations emerged between frailty and disability, fear of falling, aerobic resistance and cognition showed that only aerobic resistance and cognition. A trend towards lower systolic blood pressure in the frail group may reflect being less physically active and/or having more systemic comorbidity. Using simple functional fitness and cognitive measures rather than using less reliable self-report assessments can better identify those with physical frailty.
89627404|NCT02459574|Active Comparator|Group 2-Anti-arrhythmic therapy|Anti-arrhythmic drugs: On the treatment start date the patient will have a new tablet prescribed or a change in the dosage of the medication. The patient will be reviewed at 8wks (visit 1) later to see if the medication is working. If the tablets are working, the patients medication will be left unchanged. If not, an alternative tablet or a higher dose will be used.
89627405|NCT02459574|Experimental|Group 1-AVATAR-AF Ablation Protocol|AF ablation with pulmonary vein isolation. The patient will have two sheaths in their leg veins instead of the usual three sheaths. Catheters will be passed up to the heart from these leg veins. The single crossing into the left atrium will be by the usual method. Veins will be ablated using freeze technology known as the Advance Cryoballoon. After the ablation is completed the patient will have scans on their heart and checks of the leg veins. If all the checks are satisfactory at six hours after the procedure the patient will be allowed to go home on the same day. The patient will be reviewed in clinic in 8 weeks (visit 1) after the procedure and if it has been successful, will be reviewed again a month later (visit 2) and if all is well, the patient will be discharged from clinic.
89627406|NCT03284814|Active Comparator|Standard product group|This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
89627407|NCT03284814|Active Comparator|Comparative product group|This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
89627408|NCT03284814|Experimental|Investigational product group|This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
89627409|NCT00047853|Experimental|Healthy Volunteer|Healthy volunteer will undergo Functional magnetic resonance imaging (fMRI) and/or magneto-encephalography (MEG) and will be scanned during runs of either shock or no shock.
89627410|NCT00047853|Experimental|Patient|Participant with a current diagnosis of generalized anxiety disorder (GAD), panic disorder, social anxiety disorder (SAD), specific phobia, posttraumatic stress disorder (PTSD), or major depression will undergo Functional magnetic resonance imaging (fMRI) and will be scanned during runs of either shock or no shock.
89627411|NCT02459340|Experimental|patient group|Inpatient setting (cPTSD, DDNOS, DIS): Trauma-adapted psychotherapy (individual and group setting), body-related, cognitive stabilization groups, pharmacotherapy, and other non-verbal treatment modalities (e.g. music, art, and occupational therapy)
89627412|NCT02459340|No Intervention|healthy control group|passive control group
89627413|NCT03284736|Experimental|Periapical surgery with membrane|"After retrofilling of teeth with MTA , defect was covered with collagen resorbable membrane.~healiguide collagen type 1 resorbable membrane covering the defect by extending 2-3 mm in every direction."
89627414|NCT03284736|Active Comparator|Periapical surgery without membrane.|After retrofilling of teeth with MTA, flap was closed without application of collagen resorbable membrane.
89627415|NCT03280368||A healthy volunteers|Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.
89627416|NCT03280368||A patients|Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.
89627417|NCT03280368||B|"Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.~Inclusion before initiation of anticoagulation."
89627418|NCT03280368||C|Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.
89627419|NCT00028119||Cohort 1|HIV-uninfected non-sex worker women
88990033|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + docetaxel|Participants will receive oral etrumadenant in combination with IV zimberelimab and standard IV docetaxel
88990034|NCT04381832|Active Comparator|Stage 2: docetaxel|Participants will receive standard dose of IV docetaxel
88990035|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab|Oral etrumadenant in combination IV zimberelimab
88990036|NCT04381832|Experimental|Stage 2: Etrumadenant + zimberelimab + quemliclustat|Participants will receive oral etrumadenant in combination with IV zimberelimab and IV quemliclustat
88990037|NCT04381832|Experimental|Stage 2: Etrumadenant + quemliclustat|Participants will receive oral etrumadenant in combination with IV quemliclustat
88990038|NCT04381832|Experimental|Stage 1: Etrumadenant + zimberelimab PK Sub-Study|Participants will receive oral etrumadenant in combination with IV zimberelimab
88990039|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + SG|Participants will receive oral etrumadenant in combination with IV SG.
88990040|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + Zimberelimab + SG|Participants will receive oral etrumadenant in combination with IV zimberelimab and SG.
88990041|NCT04361214|Experimental|Leflunomide|"Leflunomide 300 mg once daily administered for three days followed by 30 mg once daily administered for two days or until fevers abate (maximum ten days of treatment allowed).~If patients report symptoms attributed to the medication, the dose will be administered at 50 mg once daily for the loading dose followed by 20 mg once daily."
88990042|NCT04360265|Other|Cohort 1|Participants who have completed a prior clinical trial involving the administration of ABO-102 and are able to comply with onsite scheduled visits and assessments. Select participants may receive adjuvant IS therapy.
88990043|NCT04360265|Other|Cohort 2|Participants who have completed a prior clinical trial involving the administration of ABO-102 and who cannot participate in Cohort 1. Participants will partake in a reduced number of assessments, performed either onsite or at home via a combination of telehealth and home healthcare visits.
88990044|NCT04333537|Experimental|Sentinel Lymph Node (SLN) Biopsy|Patients receive an imaging agent via injection and undergo planar imaging and SPECT/CT over 1-2 hours. Patients then undergo SLN biopsy.
88990045|NCT04333537|Active Comparator|Elective Neck Dissection (END)|Patients undergo standard END.
88990046|NCT04333147|Experimental|Otilimab 90 mg|Participants who received Otilimab 90mg in a qualifying study and continued on Otilimab 90mg in study 209564 or participants who received either tofacitinib 5mg (study 201790 or 201791) or sarilumab 200mg (study 202018) in a qualifying study and were exposed for the first time to Otilimab 90mg in study 209564. Otilimab 90mg was administered through subcutaneous (SC) injection once weekly.
89627420|NCT00028119||Cohort 2|HIV-discordant heterosexual couples attending STD clinics
89627421|NCT03280290|Experimental|receivers|"Eligible for allo-HSCs from peripheral blood stem cells from a compatible donor HLA family (Appendix 1, the pre-transplant assessment must be enabled)~In a complete remission rate of leucocytes with ≥ 2G / L~Affiliated to social security person or beneficiary of such a scheme."
89627422|NCT03280290|Experimental|Donors|"Member of the siblings and HLA-matched A, B, Cw, DR, DQ~Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled)~Having a rate of circulating lymphocytes ≥ 1 G / L~Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population~The statutes CMV and EBV are known (positive or negative).~Affiliated to social security person or beneficiary"
89627423|NCT04168398|Experimental|Plavix 75mg and juspirin 81 mg therapy|Clopidogrel 75 mg (Plavix 75mg) plus Aspirin (juspirin) 81 mg.
89039441|NCT04633473|Experimental|SIBTime|50 primary parents will be assessed at enrollment, then provided the SIBTime technology and exposed to the learning routines for 4 weeks, and then re-assessed at 4 weeks (after treatment completion).
89039442|NCT04665830|Active Comparator|Group 1|Evolocumab group, patients who are receiving this therapy for 12 months.
89039443|NCT04665830|Placebo Comparator|Group 2|The Statin group includes patients who are maintained on statin therapy.
89039444|NCT04631133||Participants with low-back pain and degenerative lesions of grade II, III, IV (Pfirrmann MRI class)|Participants with low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification)
89039445|NCT04665791|Experimental|Challenge|Challenge participants will be inoculated intranasally with reconstituted, previously lyophilised Neisseria lactamica (LyoNlac). The initial dose will be 10^5 colony forming units and will be escalated to a maximum of 10^7 colony forming units to find the dose which successfully colonises at least 70% of volunteers.
89039446|NCT04665674||Pulmonary Langerhans cell histiocytosis (PLCH)|All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older) referred to the French national reference centre for Histiocytoses
89039447|NCT04683237|Other|MA alone|enrolled patients will receive megestrol acetate 160mg po qd
89039448|NCT04683237|Experimental|MA+liraglutide|enrolled patients will receive megestrol acetate 160mg po qd plus liraglutide (1.8mg/d or the max tolerable dosage)
89039449|NCT04665518|Experimental|Acupressure group|The following applications will be made 10 minutes before the patients in the acupressure group. Hands are washed before applying acupressure. Before acupressure is applied, the patient is allowed to sit in a comfortable position on the sofa in the single blood collection room. Before starting the acupressure application, the arm is rubbed from fingertips to the elbow to relax, and press the acupressure points (Large Intestine Meridian 4th Point [LI 4], Large Intestine Meridian 11th Point [LI 11], and Heart Meridian 7th Point [HT 7]). application is carried out. 2 minutes to each acupressure point. pressure (3 to 5 kg of pressure) is applied. Only one acupressure session is given to each patient, and each acupressure session lasts 10 minutes. Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
89039450|NCT04665518|No Intervention|Control group|Venipuncture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 * 38 mm (21G x 1½, green).
89039451|NCT04568694|Experimental|Delayed Lung Transplantation|Patients that received lung(s) delayed for transplantation
89039452|NCT04568694|Active Comparator|Conventional Lung Transplantation|Reference Therapy
89039453|NCT04665323||People living with FOP|
89039454|NCT04665323||Parent or legal guardian primary caregivers|
89039455|NCT04665323||Parent or legal guardian|
89039456|NCT04665323||Siblings|
89039457|NCT04549701|Experimental|CAVAL US group|Patients assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to the treating medical team, in addition to standard care. Diuretic titration: There will not be a specific treatment protocol, but clinicians will be encouraged to tailor treatment, particularly with the use of diuretics, according to the number of B-lines and dilation in the IVC. The therapeutic objective will be discharge patients normal CAVAL US, with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory alterations that contraindicate discharge.
89039458|NCT04549701|Active Comparator|Standard of care group|Patients assigned to this group will receive standard care, and diuretic titration will be based on standard practice (physical examination, symptoms, and laboratory results). The therapeutic objective will be discharge patients with relief of congestive signs and symptoms of HF, without electrocardiographic or laboratory abnormalities that contraindicate discharge.
89039459|NCT04665362|Experimental|M1-c6v1 combined with SHR-1210 and Apatinib|Single-arm
89039460|NCT04683120|Experimental|Single Arm Study|This is a single arm study, which will involve all patients qualifying for Breast Conservation Therapy as a part of their breast cancer management excluding patients undergoing neoadjuvant therapy for inoperable disease.
89039461|NCT04665401|Active Comparator|Standard MERIT|24 sessions of Metacognition Reflection and Insight Therapy
89039462|NCT04665401|Experimental|Tailored MERIT|24 sessions of personalized Metacognition Reflection and Insight Therapy (sessions personalized using real-world interactions)
89039463|NCT04503291|Experimental|supra-papillary metal stent group|The distal ends of metal stents are located above the major papilla in the common bile duct.
89627424|NCT04168398|Experimental|Eliquis 2.5mg and juspirin 81 mg therapy):|Apixiban 2.5 twice daily (Eliquis 2.5mg) plus Aspirin (juspirin) 81 mg.
89627425|NCT00011193||Non-Exercise Control Group|We randomly assigned 102 women in the non-exercise control group and were asked to maintain their level of activity for the 6-month study period.
89627426|NCT00011193||4-kcal/kg Energy Expenditure per week|We randomly assigned 155 women to the 4-kcal/kg per week group for 6 months.
89627427|NCT00011193||8-kcal/kg Energy Expenditure per week|We randomly assigned 104 women to the 8-kcal/kg per week group for 6 months.
89627428|NCT00011193||12-kcal/kg Energy Expenditure per week|We randomly assigned 103 women to the 12-kcal/kg per week group for 6 months.
89627429|NCT03280212|Experimental|Tranexamic Acid Arm|"Tranexamic Acid 500 milligrams (MG)~Participants of the Tranexamic Acid (TXA) arm will receive the study drug, TXA. Participants of average body weight (60-100kg) will receive TXA according to a 500mg three times daily (TID) dose regimen. Weight deviations from this range will see dose adjustments as follows: participants <60kg will receive 500mg two times daily (BID), and participants >100kg will receive 1000mg BID."
89627430|NCT03280212|No Intervention|Control Arm|"No intervention~Participants in the control arm will not receive any additional intervention, medication, or placebo, and will serve as a comparative arm for the experimental arm."
89627431|NCT01264185||Asia--Thailand; S. America--Brazil|
89627432|NCT01264185||Africa--Zambia|
89627433|NCT03536520|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89627434|NCT03536520|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89627435|NCT04784169|Experimental|free middle turbinate flap group|A free middle turbinate flap is used to repair the leakage
89627436|NCT04784169|Active Comparator|vascularized nasoseptal flap|A vascularized nasoseptal flap is used to repair the leakage
89627437|NCT03280134|No Intervention|predictive nSLN-|No further axillary lymph node dissection (ALND)
89627438|NCT03280134|Active Comparator|predictive nSLN+|axillary lymph node dissection (ALND)
89627439|NCT03521466|Experimental|Intervention|Smoking Cessation counseling by trained medical students with or without Nicotine Replacement Therapy
89627440|NCT03521466|No Intervention|Control|The control group will receive counseling and/or NRT at the discretion of the treating physician.
89627441|NCT04784325|Experimental|Women recruited from a general population subject to I/E criteria|All study participants will administer three blood collection modalities (2 TAP II, 1 ADx card, and phlebotomist-performed venipuncture).
89627442|NCT05228184|Experimental|Treatment|Tirosint®-SOL (levothyroxine sodium) oral solution (IBSA Pharma Inc.) at the following strengths: 25, 37.5, 44, 50, 62.5, 75, 88, 100 mcg.
89627443|NCT05228184|Active Comparator|Control|Crushed levothyroxine sodium tablets
89627444|NCT04784403||Students and workers at the University of Barcelona|"The study population will be randomly selected from the different groups of the University:~Students from the different centers and type of studies (undergraduate / graduate).~Administrative and service personnel.~Teaching and Research Staff."
89627445|NCT03284580|Experimental|Ergonomic intervention group|Ergonomic intervention program at home for caregivers
89627446|NCT03284580|Experimental|Postural + kinesiotherapy intervention group|A postural + kinesiotherapy intervention program at home for caregivers
89039464|NCT04503291|Active Comparator|trans-papillary metal stent group|The distal ends of metal stents are located below the major papilla in the duodenum.
89627447|NCT03284580|Other|Control or conservative group|A conservative intervention by general information for caregivers
89627448|NCT04783623||Non-recurrence group|
89627449|NCT04783623||Recurrence group|
89627450|NCT01679457|Experimental|ACT-Focused ERP|One Session.
89627451|NCT01679457|Active Comparator|TAU-ERP|One Session.
89627452|NCT03284346|Experimental|Arm I (CARE)|Patients undergo supervised exercise sessions comprised of CARE over 50 minutes 3 days weekly for 16 weeks. Patients receive a Polar heart rate monitor to monitor heart rate during the CARE sessions.
89627453|NCT03284346|Active Comparator|Arm II (standard stretching)|Patients undergo a standard stretching program 3 days weekly for 16 weeks. After 16 weeks, patients may undergo supervised exercise sessions comprised of CARE as in Arm I.
89627454|NCT01673217|Experimental|Treatment (chemotherapy and vaccine therapy)|Patients receive decitabine IV over 3 hours on day 1, pegylated liposomal doxorubicin hydrochloride IV on day 8, and NY-ESO-1 peptide vaccine emulsified in incomplete Freund's adjuvant and sargramostim subcutaneously on day 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89627455|NCT01668849|Experimental|1 - Grape extract|Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy.
89627456|NCT01668849|Active Comparator|2 - Lortab, Fentanyl patch, mouthwash|Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels.
89627457|NCT03438630||Study cohort|All patients with a first registration (baseline) in the BOA Register between 2008 and 2016 (approximately n=75 000). These patients have sought treatment for knee and/or hip pain in primary health care in Sweden and been referred to the standardized core treatment of education and supervised exercises after confirmed clinical and/or radiographic OA diagnose.
89627458|NCT03438630||Control cohort|Covering the general Swedish population, who never have been included in the BOA register, will be recruited from the Swedish population register at Statistics Sweden and matched (1:3) to each patient in the study cohort by the same year of birth, gender and residence (as for the study cohort at baseline) (approximately n=225 000).
89039465|NCT04498182|Experimental|AR15512 Ophthalmic Solution (0.0014%)|Low Dose
89627459|NCT01668225||G-CSF FIV nat|Patient following a natural In Vitro Fecondation cycle
89627460|NCT03284190||ASDH Copenhagen, Denmark|
89627461|NCT03284190||ASDH Odense, Denmark|
89627462|NCT03284190||ASDH Århus, Denmark|
89627463|NCT03284190||ASDH Ålborg, Denmark|
89039466|NCT04498182|Experimental|AR15512 Ophthalmic Solution (0.003%)|High Dose
89039467|NCT04498182|Placebo Comparator|Vehicle|AR15512 Ophthalmic Solution Vehicle
89627464|NCT03284190||ASDH Lund, Sweden|
89627465|NCT03284190||ASDH Linköping, Sweden|
89627466|NCT03284190||ASDH Gothenburg, Sweden|
89627467|NCT03284190||ASDH Stockholm, Sweden|
89627468|NCT03284190||ASDH Uppsala, Sweden|
89627469|NCT03284190||ASDH Umeå, Sweden|
89627470|NCT03279198|Placebo Comparator|Usual Care (UC)|The usual care group received usual care that varies dependent upon the practice setting.
89627471|NCT03279198|Active Comparator|TIWeb|TIWeb (Tailored Web Intervention) program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
89627472|NCT03279198|Active Comparator|Cancer Screening Call (CSC)|CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
89627473|NCT03279198|Active Comparator|TIWeb+CSC|TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
89627474|NCT03278964|Active Comparator|Antro-ethmoidal technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by antro-ethmoidal technique.
89627475|NCT03278964|Experimental|Lateral wall technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by lateral wall technique.
89627476|NCT03107910|Other|Experimental Stigma Counseling|Single session, stigma focused, anticipated HIV stigma counseling will be provided. Intervention will include a focus on barriers to testing.
89627477|NCT03107910|Other|Control Health Information|Single session, online health information seeking and evaluation. HIV/STI testing appointments are provided online. Stigma and Structural Interventions
89627478|NCT03277716|Experimental|TACE+MWA|Transcatheter arterial chemoembolization combined with microwave ablation: 2-3 times of TACE treatment, then followed by ablation treatment using MWA system.
89627479|NCT01252719|Experimental|Single-Dose IV Oritavancin Diphosphate|
89627480|NCT01252719|Active Comparator|IV Vancomycin|
89627481|NCT03283956||Patient records|Medical records of all patients who underwent DC bead TACE.
89627482|NCT01233531|Other|A--Monthly cash transfers|Monthly cash transfer payments
89627483|NCT01233531|Other|B--No cash transfers|No cash transfers.
89627484|NCT03272490|Active Comparator|Medartis|Surgery using the Medartis Implant
89627485|NCT03272490|Active Comparator|Synthes|Surgery using the Synthes implant
89627486|NCT02342314|Experimental|LY3143753 (Part A)|Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1
89627487|NCT02342314|Experimental|LY3185643 (Part B)|Single SC injection of ascending doses of LY3185643 on Day 1
89627488|NCT02342314|Placebo Comparator|Placebo (Part A)|Single SC injection of normal saline on Day 1
89627489|NCT02342314|Active Comparator|rGlucagon (Part B)|Single SC injection on Day 1
89627490|NCT02342314|Placebo Comparator|Placebo (Part B)|Single SC injection of normal saline on Day 1
89627491|NCT01230411|Placebo Comparator|placebo|IV saline administration as placebo
89627492|NCT01230411|Experimental|Ibuprofen|IV ibuprofen
89627493|NCT03283800|Experimental|Copper impregnated compression stocking|Copper compression stocking containing 2-3% copper ions to be worn on one leg, daily for 8 weeks.
89627494|NCT03283800|Placebo Comparator|Normal compression stocking|Similar compression stocking without copper to be worn on the other leg, daily for 8 weeks
89627495|NCT02459184|Experimental|Early intervention|Participants will meet with the Income Security Health Promoter immediately.
89627496|NCT02459184|Active Comparator|Late intervention|Participants will meet with the Income Security Health Promoter at 6 months.
89627497|NCT01962688|Experimental|Handheld ultrasound - inpatient|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
89627498|NCT01962688|Sham Comparator|Sham ultrasound - inpatient|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
89627499|NCT01962688|Experimental|Handheld ultrasound - ambulatory|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
89627500|NCT01962688|Sham Comparator|Sham ultrasound - ambulatory|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.
89627501|NCT04389723|Other|Placebo→ Qualia Mind|Subjects are first administered the placebo then crossover to the investigational product
89627502|NCT04389723|Other|Qualia Mind→ Placebo|Subjects are first administered the investigational product then crossover to the placebo
89627503|NCT00149487|Experimental|Experimental: Tailored Problem Solving Intervention|Participants will be randomized to follow a tailored problem solving intervention for the child.
89627504|NCT00149487|Active Comparator|Control: Family Education Intervention|Participants will be randomized to follow a family education intervention.
89627505|NCT03276000|Active Comparator|Group A|50 patients receive 200 mg oral misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy
89627506|NCT03276000|Active Comparator|group B|50 patients receive 200 mg misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy moistened with saline solution will be inserted in posterior fornix of vagina.
89627507|NCT03283644||Patients with a BMI over 40|Participants were aged between 27-65 years, BMI >40 , Co-Morbidities associated with obesity including sleep apnoea, hypertension, depression, hypercholesterolaemia and type 2 diabetes, Undergoing Gastric Band surgery
89627508|NCT03283644||Lean, healthy individuals|Participants were aged between 27-65 years, BMI<28 , Systemically healthy, taking no prescribed medication
89627509|NCT04058769|Other|Software first|Patients that are pre-operatively assessed first software-guided and then traditional
89627510|NCT04058769|Other|Traditional|Patients that are first pre-operatively assessed in the traditional way and then with aid of the software
89627511|NCT02459886|Experimental|Cohort 1|Single intravenous (IV) low dose infusion with staggered participant dosing
89627512|NCT02459886|Experimental|Cohort 2|Single IV ascending dose infusion with staggered participant dosing
89627513|NCT02459886|Experimental|Cohort 3|Single IV ascending dose infusion with staggered participant dosing
89627514|NCT02459886|Experimental|Cohort 4|Single IV ascending dose infusion with staggered participant dosing
89627515|NCT02459886|Experimental|Cohort 5|Single IV ascending dose infusion with staggered participant dosing
89627516|NCT02459886|Experimental|Cohort 6|Single IV ascending dose infusion with staggered participant dosing
89627517|NCT02459886|Experimental|Cohort 7|Single IV ascending dose infusion with staggered participant dosing
89627518|NCT02309944|Active Comparator|Standard Wound Closure|Standard surgical closure of the fascia and skin.
89627519|NCT02309944|Experimental|Negative Pressure Wound Therapy|Standard surgical closure as used by the standard of care group plus placement of the Prevena™ Incision Management System over the closed incision.
89627520|NCT03271398||Adult victims of sexual assault|
89627521|NCT03271398||Children who have been exposed to domestic abuse|
89627522|NCT03271398||Women with perinatal emotional complications|
89627523|NCT03271398||Teens with behavior problems and histories of abuse|
89627524|NCT03271398||Veterans with military-related trauma|
89627525|NCT03271398||Survivors of intimate partner violence|
89627526|NCT02311972|Active Comparator|Control - Standard of Care|Infants in the standard of care group will receive no study interventions other than study recorded axillary temperatures on admission, and at 1, 4, 8 and 24 hours. Infants will receive standard delivery room stabilization and NICU stabilization. Infants in the control group will receive a feeding tube as standard of care, and the standard issue feeding tube used in the Intensive Care Nursery does not have the capability to record or display esophageal temperatures. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age for each infant in both groups on a data sheet at the bedside. These data will be entered into a RedCap data base created for the study.
89627527|NCT02311972|Active Comparator|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|The nurse will insert an InnerSense temperature sensor/feeding tube per normal standards as soon after birth as possible, during delivery room stabilization. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age. The InnerSense tube will be attached to the infant's bedside monitor to continuously display esophageal temperatures. The tube will stay in place until the infant is 24 hours of age. Central body temperature will be displayed continuously for care-providers in the delivery room, through transport from the birthing center to the NICU and through stabilization. Infants will have a thermistor placed on the abdominal skin with standard skin tape once admitted in the NICU. This thermistor will be attached to a Squirrel SQ2010 (Grant Instruments) temperature monitor/data logger to collect abdominal temperatures every minute for the first 24 hours of life. All temperatures entered into the study database.
89627528|NCT03271008|Active Comparator|Macintosh laryngoscopy|In this group intubation attempt is carried out with a standard Macintosh (size 3 or 4) direct laryngoscopy blade.
89627529|NCT03271008|Active Comparator|KingVision videolaryngoscope|In this group intubation attempt is carried out with KingVision videolaryngoscope with a channeled, disposable single-use blade.
89627530|NCT03271008|Active Comparator|VividTrac videolaryngoscope|In this group intubation attempt is carried out with VividTrac Adult model using a smartphone or laptop running the VividVision proprietary software.
89627531|NCT03274596|Active Comparator|Treatment A|Group A: received 12.5 IU of vitamin E orally every 12 hours, from 72 h of birth to 28 days old.
89627532|NCT03274596|Placebo Comparator|Treatment B|Group B: received 12.5 IU of placebo orally every 12 hours, from 72 hours of birth to 28 days old.
89627533|NCT01963078|Placebo Comparator|PTSD placebo Day 1, Oxytocin Day 2|Participants PTSD will self-administer matching placebo (containing all ingredients except OT) at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
89627534|NCT01963078|Experimental|PTSD Oxytocin Day 1, Placebo Day 2|Participants with PTSD will self-administer 24 IUs of OT nasal spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
89627535|NCT01963078|Placebo Comparator|Resilient Placebo Day 1, Oxytocin Day 2|Resilient controls will self-administer matching placebo spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
89627536|NCT01963078|Experimental|Resilient Oxytocin Day 1, Placebo Day 2|Resilient controls will self-administer 24 IUs of OT nasal spray at 10:30 a.m.on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
89627537|NCT03269760|No Intervention|Control|Current practice of postoperative care without sleep medicine measures
89627538|NCT03269760|Experimental|Interventional Sleep Medicine|Use of a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem to improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.
89627539|NCT03269916|Experimental|IBD patients|IBD patients, 17-40 years old, female
89627540|NCT03269916|Other|healthy control|17-40 years old , female, without any gynecological disease
89627541|NCT01963234|Experimental|Seva|Up to 100 patients in each of 3 intervention clinics will receive access to the Seva mobile health system for drug use disorders.
89627542|NCT02457858|Experimental|BMX-010 treated islets|Islet isolation using BMX-010
89627543|NCT02457624||Experienced endoscopists|All the experienced endoscopists will receive education and feedback on the diagnosis for premalignant lesion of chronic atrophic gastritis and intestinal metaplasia
89627544|NCT02346916|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test at the time of the study visit. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion. This method should allow an individual's subjective sensitivity to the TRPV1-mediated noxious stimulus of myocardial ischemia to be compared with his/her sensitivity to the TRPV1-mediated noxious stimulus of cutaneous capsaicin in extra-cardiac tissues."
89627545|NCT01964092|Experimental|Individual Placement and Support|Individual Placement and Support (IPS) is a well-defined intervention aiming to help people with disabilities participate in the competitive labor market by working in jobs they prefer with the professional help that they need. IPS actively facilitates job acquisition and provides ongoing support once the client is employed.
89627546|NCT01964092|Active Comparator|Ordinary employment schemes|The control group will receive treatment as usual in terms of the ordinary employment schemes offered to this group, primarily Work with assistance and/or Traineeship in a sheltered business.
89627547|NCT03274362|Experimental|Headspace Application Treatment Group|Participants in the treatment group will be given a free 3-month access code to Headspace. The app contains a series of sessions that guide the user through mindfulness training.
89627548|NCT03274362|No Intervention|Standard Care Control Group|Participants in the control group will be provided a list of resources that provides guidance on mindfulness and general health.
89627549|NCT04349176|Experimental|Group A 100U|
89627550|NCT04349176|Experimental|Group A 155U|
89627551|NCT04349176|Experimental|Group B 100U|
89627552|NCT04349176|Experimental|Group B 155|
89627553|NCT03274128|Active Comparator|Study Group|The treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
89627554|NCT03274128|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
89627555|NCT04329546||Cases|Cases are patients with COVID-19.
89627556|NCT04329546||Contacts|Contacts are household contacts of an index (case) patient.
89627557|NCT01966354|Experimental|Long axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Long axis, in-plane needle:~Jugular vein is ultrasonographically visualized in a longitudinal fashion (long axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
89627558|NCT01966354|Experimental|Short axis, out-of-plane needle|"Ultrasound-guided Internal jugular venous approach~Short axis, out-of-plane needle:~Jugular vein is ultrasonographically visualized in a transverse fashion (short axis) and the needle is inserted perpendicular to the longitudinal axis of the transducer (out-of-plane)."
89627559|NCT01966354|Experimental|Oblique axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Oblique axis, in-plane needle:~Jugular vein is ultrasonographically visualized in an oblique axis (intermediate view between long and short axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
89627560|NCT02459028|Experimental|T3P Intervention group|"Intervention group: Participants are instructed to practice 4 out of 10 different Positive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
89627561|NCT02459028|Active Comparator|Control group|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
89627562|NCT02017210||Lean/normal weight|Individuals with body mass index (BMI)<25 kg/m^2 in the baseline study
89627563|NCT02017210||Overweight/Obese Insulin-Sensitive|Individuals with BMI>25kg/m^2 who were deemed insulin-sensitive by the hyperinsulinemic -euglycemic clamp (with M/I value above median for men and women separately)
89627564|NCT02017210||Overweight/Obese Insulin-Resistant|Individuals with BMI>25kg/m^2 who were deemed insulin-resistant by the hyperinsulinemic -euglycemic clamp (with M/I value under median for men and women separately)
89627565|NCT02458482|Active Comparator|Standard Nebulizer Mask Group|"Patients randomized to this Control or standard therapy group are to receive current institutional standard therapy for moderate asthma exacerbation which includes 10 mg Albuterol combined with 1.5mg Ipratropium nebulized therapy over one hour."
89627566|NCT02458482|Experimental|AccuPAP Group|"Patients randomized to this group must also have moderate asthma exacerbation and will use an investigational device called AccuPAP to receive three allotments of Albuterol and Ipratropium in nebulized form."
89627567|NCT03264690||Microbial composition measured from IBD and non-IBD groups|Participants with inflammatory bowel disease (IBD) and non-IBD will be measured for microbial composition.
89627568|NCT03264612|Active Comparator|Swimming group|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
89627569|NCT03264612|No Intervention|Non swimming group|no intervention
89627570|NCT03264924||Phase A, Study One|Semi-structured interviews to investigate staff and patients' experiences of participating and facilitating cardiac and pulmonary rehabilitation.
89627571|NCT03264924||Phase A, Study Two|Focus group with rehabilitation stakeholders to discuss perceived feasibility and acceptability of the intervention design.
89627572|NCT03264924||Phase A, Study Three|Pilot of the intervention, using a group of exercise physiologists external to the community rehabilitation services.
89627573|NCT03264924||Phase B|Community rehabilitation service staff will participate in the intervention. Patients will then participate in the rehabilitaiton programme. Physical activity levels of patients will be recorded throughout the rehabilitation programme and for six months post-discharge. Qualitative and quantitative follow-up sessions will patients will take place at discharge (8 weeks after start of rehabilitation), and three and six months post-discharge.
89627574|NCT03273192|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab auto-injector devices produced by CinnaGen Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
89627575|NCT03273192|Active Comparator|AbbVie adalimumab|Humira® (adalimumab auto-injector devices produced by AbbVie Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
89627576|NCT03264846||Group 1|PCOS participants with periodontitis
89627577|NCT03264846||Group 2|PCOS participants with periodontally healthy
89627578|NCT03264846||Group 3|systemically healthy participants with periodontitis
89627579|NCT03264846||Group 4|systemically and periodontally healthy participants
89627580|NCT02348632|Other|75 mg - 300 mg of JZP-110|Once Daily Dosing
89627581|NCT03269604|Active Comparator|Prophylactic antibiotic five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
89627582|NCT03269604|Active Comparator|Prophylactic antibiotic three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
89627583|NCT03269604|Experimental|Only a single dose of Prophylactic antibiotic|Only a single dose of Prophylactic antibiotic on the day of the procedure
89627584|NCT02458872|Experimental|Intervention Arm|Safety huddle alarm intervention.
89627585|NCT02458872|No Intervention|Control Arm|Usual care.
89627586|NCT03264768|Other|control|standard care in case collateral ventilation is observed (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post allocation.
89627587|NCT03264768|Experimental|Endobronchial valves|Endobronchial valves in case collateral ventilation is absent (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post intervention.
89627588|NCT02349178|Experimental|Bridging Arm|Days 1-5 Receive 20 mg/m2 IV Clofarabine (CLOLAR) over 2 hours followed by 100 mg/m2 IV Etoposide (VP-16, Etopophos) over 2 hours followed by 300 mg/m2 IV Cyclophosphamide (Cytoxan, CTX) as a 30-60 minute infusion
89627589|NCT03273114|Experimental|Cognitive Functional Therapy (CFT)|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
89627590|NCT03273114|Active Comparator|Core Training Exercise and Manual Therapy (CORE-MT)|The active comparator will be the combination of Core Training Exercise and Manual Therapy (CORE-MT).
89627591|NCT03970356|Experimental|intervention|The antibiotic stewardship intervention will encourage to prescribe according to the latest relevant UTI guidelines which promote more restrictive use of antibiotics in case of non-specific symptoms.
89627592|NCT03970356|No Intervention|control|Usual care
89627593|NCT01966900|Active Comparator|Group A|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 6; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
89627594|NCT01966900|Active Comparator|Group B|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 12; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
89627595|NCT03269370|Experimental|1: Anchors Away|Family will receive access to the basic Anchors Away mobile app to test over 6 weeks.
89627596|NCT03269370|Experimental|2: Parent Enhanced Anchors Away|Family will receive access to the Parent Enhanced Anchors Away mobile app to test over 6 weeks.
89627597|NCT03269370|Active Comparator|3: Self-Help E-Book|"Group 3 will receive the Self Help e-Book as a comparative condition (families provided a kindle version copy of Helping Your Anxious Child: A Step-by-Step Guide ; Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)."
89627598|NCT03269370|No Intervention|4: Waitlist Control|Group 4 will not receive any intervention, but will be randomized into an active study arm at 6 weeks.
89627599|NCT04023084|Experimental|Atopic Dermatitis Group|Receive crisaborole intervention
89627600|NCT02349646||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
89627601|NCT05075460|Experimental|Tucidinostat, Azacitidine combined with CHOP|Tucidinostat, Azacitidine combined with CHOP
89627602|NCT05075460|Active Comparator|CHOP|CHOP
89627603|NCT02457234|Experimental|Cultural Immersion Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons within a cultural immersion context as part of the camp program.
89627604|NCT02457234|Active Comparator|University Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons in addition to camp activities that did not include cultural immersion.
89627605|NCT02457234|No Intervention|Recreational Children's Sports Day Camp|Participants in this group participated in existing camp activities that were exclusively physical activity.
89627606|NCT01966978|Active Comparator|Control: Metformin, Insulin Detemir, Insulin Aspart|Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
89627607|NCT01966978|Active Comparator|Metformin, insulin determir, Liraglutide|"Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)"
89627608|NCT03264378|Experimental|PEI-GTO-ThAI|Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
89627609|NCT03264378|Active Comparator|PEI-Standard|Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
89039468|NCT04494555|Experimental|Adaptable Prosthetic Socket|Using measurements of limb-socket displacements from sensors embedded within the socket wall, adaptable sockets make small adjustments to socket size so as to maintain consistent displacements while prosthesis users are active. They do not require the user to stop activity or to touch or modify the prosthesis, and they do not distract users from their objectives.
89627610|NCT03264300|Active Comparator|Development of advanced MRI methods|Subjects with brain tumor. Subjects may be scanned using a single time-point to permit development and optimization of advanced MRI methods. Subjects may be scanned up to two times, with both visits occurring within one month, to permit analysis of test-retest reliability/repeatability.
89627611|NCT03264300|Active Comparator|Validation of rCBV accuracy|64 subjects with primary glioma and 96 subjects with recurrent glioma. Subjects will be scanned using a single time-point to validate rCBV accuracy.
89627612|NCT02350660|Experimental|Cow's milk for alpha-gal allergics|daily consumption of cow's milk
89627613|NCT02350660|Experimental|Peanut powder|peanut oral immunotherapy
89627614|NCT03269292||warm autoimmune hemolytic anemia|corticosteroid either oral form or intravenous followed by oral
89627615|NCT03269214|No Intervention|control group|Patients underwent debridement of necrotic bone and the involved area closed primary
89627616|NCT03269214|Experimental|treatment group|Patients received topical Phenytoin 5%+ Tetracycline after debridement before final closure.
89627617|NCT05075148||Aneurysmal bone cyst|Patient aging from 0 to 30 years with diagnosis of aneurysmal bone cyst treated by percutaneous alcolisation or endovascular embolization.
89039469|NCT04665167|Active Comparator|Body image exposure|Guided non-judgmental exposure, 40 minutes total
89627618|NCT05075304|Experimental|A low dose of BDB-001|6 patients administered low dose of BDB-001 injection
89627619|NCT05075304|Experimental|A intermediate dose of BDB-001|6 patients administered intermediate dose of BDB-001 injection
89627620|NCT05075304|Experimental|A high dose of BDB-001|3-6 patients administered high dose of BDB-001 injection
89627621|NCT02457390|Experimental|CE-LUS|"Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases.~After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes.~The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form."
89627622|NCT02457468||Stenosis patients treated with coflex|Patients with a primary diagnosis of lumbar spinal stenosis treated with coflex after decompression
89627623|NCT05074836|Experimental|Formula Milk|"Formula milk designed for young children aged over 3 years;~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
89627624|NCT05074836|Active Comparator|Regular milk|"Regular milk (pure milk);~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
89627625|NCT05074836|Other|Control foods|"Grain foods: e.g., bread;~Dosage: 20-40 g/time;~Frequence: 2 times /day;~Duration: 12 months"
89627626|NCT03264144|Experimental|Intervention|Students in the schools assigned to the intervention group will receive the intervention after the baseline survey. The intervention will be a social norms campaign involving posters, table tents, flyers and an online banner.
89627627|NCT03264144|No Intervention|Control|Students in the schools assigned to the control group will not receive anything during the randomised controlled trial. They will receive the intervention materials after the trial.
89627628|NCT05074602|Experimental|SHR8008|
89627629|NCT05074602|Active Comparator|Fluconazole|
89627630|NCT03264222|Other|Exposition to safety screening|One armed study with exposition to a new safety device (model QPS100) using radiofrequency technology
89627631|NCT02457312|Active Comparator|Letrozole group|Letrozole 10 mg daily for 7 days before suction evacuation
89627632|NCT02457312|Placebo Comparator|Placebo group|Placebo tablets (look identical to letrozole tablets) daily for 7 days before suction evacuation
89627633|NCT03268902|Experimental|Nicotinamide and Antimicrobials|Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
89627634|NCT03268902|Experimental|Antimicrobials only|Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
89627635|NCT03268902|Experimental|Nicotinamide only|Nicotinamide Placebo Placebo
89627636|NCT03268902|Placebo Comparator|No active treatment|Placebo Placebo Placebo
89627637|NCT03268980||Patients group|All patients (over 18y) admitted to the Hospices Civils de Lyon the day of the study, whatever the reason, able to fullfill the questionnaire by themselves.
89627638|NCT03268980||Hospital staff group|Anyone, whatever age and trade, paid directly by the Hospices Civils de Lyon on the day of the survey, regardless of the duration of the employment contract, and present on one of the sites of the Hospices Civils de Lyon the day of the investigation.
89627639|NCT03268980||Students group|Everyone who is regularly enrolled in one of the schools or institutes of the Hospices Civils de Lyon or in one of the two faculties of medicine of the Université Lyon I, in any initial training and present on one of the sites of the faculties the day of the investigation
89627640|NCT02458794|Active Comparator|LMA SupremeTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
89627641|NCT02458794|Active Comparator|Ambu-Aura GainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
89627642|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination - 8 weeks apart|Astra-Zeneca vaccine 0.5 mL/dose
89627643|NCT05074368|Active Comparator|mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
89627644|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
89627645|NCT05074368|Active Comparator|The mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose
89627646|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
89627647|NCT02456922|Other|Group A|Subjects wearing Harmony 1 Sensor for up to 10 days.
89627648|NCT03263754|Experimental|Intervention|
89627649|NCT03263754|Active Comparator|Control|
89627650|NCT02458716|Experimental|Surgery followed by hormone therapy (ADT)|Patients undergo Robotic Assisted Radical Prostatectomy (RARP) or conventional open retropubic radical prostectomy (RRP). Immediately following surgery, patients receive the standard systemic androgen deprivation therapy.
89627651|NCT03263988||PIEZO-Group|All patients in this study receive IBP by PICCO and piezocapacitative-interlayer-technology measurement.
89627652|NCT03263910|Experimental|NPO-11|
89627653|NCT03263910|Placebo Comparator|Placebo|
89627654|NCT05037396||Brolucizumab|Participants received brolucizumab injection during the index period
89627655|NCT02713542|Experimental|Autologous Conditioned Plasma (ACP)|3 Intra-articular (IA) injections at 1 week intervals
89627656|NCT02713542|Placebo Comparator|Normal Saline (NS)|3 NS Intra-articular (IA) injections at 1 week intervals
89627657|NCT02457078|Experimental|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
89627658|NCT02457078|Placebo Comparator|Control Supplement|Control Supplement: Capsule containing soybean oil and α-tocopheryl (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
89627659|NCT03268512|Experimental|L-PRF|One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.
89627660|NCT03268512|Experimental|A-PRF|One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.
89627661|NCT03268512|No Intervention|Control|The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.
89627662|NCT02458326|Experimental|Aerobic Training|The experimental group will follow the protocol: performing heating for 5 minutes at low speed on a treadmill; after heating, the speed is increased gradually until the patient reaches the proper heart rate for aerobic training obtained during cardiopulmonary exercise testing, maintaining the same for 20 minutes to perform the aerobic workout; completed, the velocity will be decreased to regain speed heating maintained for 5 minutes and finishing training. It is envisaged that in practice using the FC to ensure proper aerobic exercise for 20-60 minutes at a frequency of 3-5 times per week are effective in increasing the functional capacity of individuals with low fitness
89627663|NCT02458326|Other|Control Training|In the control group, these women will be guided to perform 10 minutes of heating on the treadmill with a low speed that does not cause patient effort (monitored by the Borg scale and FC close to the basement).
89627664|NCT03268278|Active Comparator|buprenorphine and local anesthetic|buprenorphine added to local anesthetic
89627665|NCT03268278|Placebo Comparator|sterile saline and local anesthetic|sterile saline (placebo) added to local anesthetic
89627666|NCT03268434|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
89627667|NCT03268434|Active Comparator|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks
89627668|NCT05045586|Experimental|Modified Coronally Advanced Tunnel With Connective Tissue Graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
89627669|NCT05045586|Active Comparator|MCAT With Cross-linked Hyaluronic Acid in Addition to CTG|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with cross-linked hyaluronic acid. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
89627670|NCT03268044||Weekend admission|Adults admitted to hospital at the weekend (Saturday or Sunday) and who underwent surgery
89627671|NCT03268044||Weekday admission|Adults admitted to hospital on a weekday (Tuesday to Thursday) and who underwent surgery
89627672|NCT03268122|Active Comparator|Standard Contact Isolation|Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
89627673|NCT03268122|Active Comparator|Targeted Contact Isolation|Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
89627674|NCT03267732|Active Comparator|1|Pegilodecakin (5 μg/kg) dosed on Day 1, and Days 4-9 SQ
89627675|NCT03267732|Active Comparator|2|Pegilodecakin (10 μg/kg) dosed on Day 1, and Days 4-9 SQ
89627676|NCT03263676|Experimental|Icon reusable underwear|
89627677|NCT03263676|Placebo Comparator|Disposable pad|
89039470|NCT04665167|Active Comparator|Self-compassion|8 Short self-compassion meditations, 40 minutes total
89627678|NCT04736862|Experimental|Continuous monitoring group|
89627679|NCT04736862|Active Comparator|Intermittent monitoring group|
89627680|NCT03263286|Experimental|HandSOME|The intervention is given to this group.
89627681|NCT03267966|Experimental|Group A|Leeds Pathology Protocol (LEEPP)
89627682|NCT03267966|No Intervention|Group B|"Conventional method of pathological evaluation"
89627683|NCT03263520|Experimental|Group 1: nandrolone and corticosteroid|the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
89627684|NCT03263520|Active Comparator|Group 2: corticosteroid|Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
89627685|NCT02456844|Experimental|Group 1|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
89627686|NCT02456844|Experimental|Group 2|Methotrexate,Leucovorin and BMS-986142
89627687|NCT03263208|Experimental|CD19 CAR-T|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
89627688|NCT03259542|Experimental|Arm 1|Mifepristone 300 MG alone or Mifepristone 300 MG with Itraconazole 100 MG will be administered.
89627689|NCT03267654|Experimental|gefitinib combined with chemotherapy|gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
89627690|NCT03267654|Experimental|gefitinib combined with apatinib|gefitinib 250mg Qd combined with apatinib 250mg per 21 days
89627691|NCT03267654|Active Comparator|gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
89627692|NCT03267342|Experimental|All participants|low-income people with mental illness will be given one-on-one financial counseling, a weekly peer support group, supported access to mainstream banking services and access to a matched savings account for a 12-14 month period.
89627693|NCT03267420|Experimental|Group 1|A group of 30 randomly assigned study participants that will undergo the BpTRU First, Unattended Omron Second exposure.
89627694|NCT03267420|Active Comparator|Group 2|A group of 30 randomly assigned study participants that will undergo the Unattended Omron First, BpTRU Second exposure.
89627695|NCT03267420|Active Comparator|Group 3|A group of 30 randomly assigned study participants that will undergo the Partially Attended Omron First, Unattended Omron Second exposure.
89627696|NCT03262818|Experimental|Transvaginal Ultrasound + Ultrasound/Photoacoustic imaging|"Transvaginal ultrasound (US) prior to surgery~Immediately after the transvaginal US, US/PAI imaging will be performed~Once the surgeon has removed the ovary(ies) they will be imaged ex vivo. The in vivo and ex vivo US/PAI images will be compared with the final pathologic diagnosis"
89627697|NCT03263052||Tacrolimus XR|
89627698|NCT03262896||Patients with brain death|Ten patients with definite etiology, who were diagnosed with brain death because of Apnea test positive and / or cranial reflexes were not available and were male and female patients aged 18-72 years
89627699|NCT03259386||Transradial or Transhumeral amputees|High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.
88990047|NCT04333147|Experimental|Otilimab 150 mg|Participants who received Otilimab 150mg in a qualifying study and continued on Otilimab 150mg in study 209564 or participants who received either tofacitinib 5mg (study 201790 or 201791) or sarilumab 200mg (study 202018) in a qualifying study and were exposed for the first time to Otilimab 150mg in study 209564. Otilimab 150mg was administered through subcutaneous (SC) injection once weekly.
88990048|NCT04328779|Experimental|multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks.
88990049|NCT04328779|Active Comparator|multi-task treadmill walking|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill.
88990050|NCT04328779|Active Comparator|traditional rehabilitation|Traditional rehabilitation group will train strength, balance, and gait.
88990051|NCT04328727|Experimental|eltrombopag|Participants will receive eltrombopag in combination with r-ATG and CsA.
88990052|NCT04328337|Experimental|Non-diabetic, normal weight individuals receiving Intralipid|Non-diabetic, normal weight individuals receiving Intralipid. Participants will receive an infusion of Intralipid 20% for 12 hours through an IV (prior to and during scan #2)
88990053|NCT04328337|Placebo Comparator|Non-diabetic, normal weight individuals receiving saline|Non-diabetic, normal weight individuals receiving saline. Participants will receive an infusion of normal saline (1:1 randomization) at 30 ml/hr for 12 hours through an IV (prior to and during scan #2
89627700|NCT03259230||Malignancy-Associated Hemophagocytic Lymphohistiocytosis|
89627701|NCT03259230||Absence of HLH in patients diagnosed with malignancy|
89627702|NCT03262428||Patients|Patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
89627703|NCT03262428||Caregivers|Caregivers of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
89627704|NCT03262428||Health care professionals|Health care professionals involved in the care of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
89627705|NCT03259152|Experimental|Pre-Denosumab GctB|Specimens obtained during biopsy
89627706|NCT03259152|Experimental|Post-Denosumab GctB|Specimen after administration of Denosumab
89627707|NCT03262506|Experimental|Cognitive Training|
89627708|NCT02456142|Experimental|caudal bupivacaine|1ml/kg of 0.125% caudal bupivacaine given over 2 minutes will be given at the end of surgery
89627709|NCT02456142|Active Comparator|intravenous morphine|0.05mg/kg intravenous morphine given over 5 minutes
89627710|NCT03262740|Experimental|BMS-986195 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
89627711|NCT03258918|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
89627712|NCT05234814|Active Comparator|Control group|The control group was given the Traditional Chinese Medicine auricular acupuncture point buried seeds therapy.
89627713|NCT05234814|Experimental|Observation group|The observation group was given the auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.
89627714|NCT03266718|Other|Physical Activity Intervention|Couples will receive four 60-minute intervention sessions via videoconference with Duke staff. Study staff will provide couples with instructions for use of the iPad computer and videoconference software which will be used to deliver the intervention sessions.The first 3 sessions will be conducted weekly, with a booster session occurring approximately one month later.
89627715|NCT03266718|Other|Waitlist control|Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
89627716|NCT03266562|Other|FES vs FDG|All patients will undergo two PEM studies, one with F-18 FDG and the second with F-18 FES. Co-registration of the PEM images from F-18 FDG and F-18 FES will be used to assess the heterogeneity of uptake of the F-18 FES relative to that of F-18 FDG. Heterogeneity of ER expression in the tumor will be determined by immunohistochemistry on the pathologic tissue
89627717|NCT03258840|Placebo Comparator|EPA placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 2 times/day, for 8 weeks
89627718|NCT03258840|Active Comparator|EPA supplement|EPA supplement softgel (containing 2 g EPA per day), 2 times/day, for 8 weeks.
89627719|NCT03266796||Patients & Physical therapists|First consultations of peoples with musculoskeletal disorders and their physical therapists will be audiotaped. Audiotapes will be used to analyse the communication between the patients and their physicaltherapists to explore how much physical therapists involve their patients in the goal setting process, to see if there is a shared decision making existing.
89627720|NCT03266406|Experimental|Effect of hyaluronidase on IOP|
89627721|NCT03258684|Active Comparator|vitamin C、hydrocortisone、thiamine|Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
89627722|NCT03258684|Placebo Comparator|normal saline|Normal saline 500ml every day for 4 days，then 200ml every day for 3 days.
89627723|NCT02456766||F0|Liver Steatosis Grade: <5%
89627724|NCT02456766||F1|Liver Steatosis Grade: 5-33%
89627725|NCT02456766||F2|Liver Steatosis Grade: 34-66%
89039471|NCT04665011||Clinically stable adults, including heart failure patients visiting an outpatient clinic|Observational to compare simultaneous pulse tracings from PPG and non-invasive blood pressure monitors in capturing the pulse responses to a Valsalva maneuver.
89039472|NCT04665284|Experimental|Empagliflozin|
89039473|NCT04665284|Active Comparator|Usual Care Group|
89039474|NCT04432974|Experimental|ACTIVA|ACTIVA closed-loop anesthesia control system
89039475|NCT04424394|Experimental|DualStim Therapy with Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of umbilical cord-derived Wharton's Jelly formulation.
89039476|NCT04424394|Active Comparator|DualStim Therapy without Wharton's Jelly Injection|DualStim therapy with intracavernosal injection of normal saline.
89039477|NCT04664660||Patients with previous histologic diagnosis of endometriosis|
89039478|NCT04664660||Patient without endometriosis|
89627726|NCT02456766||F3|Liver Steatosis Grade: > 66%
89627727|NCT03262272|Experimental|Hemodialysis|patients treated by conventionnal hemodialysis
89627728|NCT03262272|Experimental|Hemodiafiltration post dilution|patients treated by HDF post-dilution
89627729|NCT03258528|Active Comparator|right lateral position group|Neonates kept in the right lateral position for 6 hours with head tilted 30 degree upward with rolled towel supports the infant back at 90 degree angle on the bed.
89627730|NCT03258528|Active Comparator|supine position group|"Neonates kept in supine position for 6 hours with head tilted 30 degrees upward.~Infants were fed while in their positions via feeding tube."
89627731|NCT03262350|Experimental|Yoga Group|Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
89039479|NCT04664699|Other|Plethysmographic Variability Index group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the PVI group
89039480|NCT04664699|Other|Standard monitoring group|32 patients who presented to emergency department HUSM diagnosed with severe traumatic brain injury who were randomly assigned to the standard monitoring group
89039481|NCT04664504|Active Comparator|Group CRT|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
89039482|NCT04664504|Experimental|Group SCRT|Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
89039483|NCT04664504|Experimental|Group es-SCRT|Local dose increase of Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)
89039484|NCT04415073|Active Comparator|Axatilimab (SNDX-6352)|Axatilimab on Days 1 and 15, IV + SOC
89039485|NCT04415073|Placebo Comparator|Placebo|Matching placebo on Days 1 and 15, IV + SOC
89039486|NCT00557102|Other|cetuximab, FOLFIRI|
89039487|NCT04682808|Experimental|Dose Escalation and Expansion|FCN-338 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL , until the maximum tolerated dose or recommended dose is reached. Followed by up to 43 patients enrolled in the expansion cohort at the recommended dose.
89627732|NCT03262350|No Intervention|Control Group|Participants will be required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, health habits, body image, sleep habits and loneliness and have their height and weight measured. The overall time commitment for Control Group participants is 3 hours of assessments total.
89627733|NCT03266250||spinal anesthesia Hypotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
89627734|NCT03266250||spinal anesthesia Normotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
89627735|NCT03258372|Experimental|Cohort 1|Mifepristone 300 MG, 1 tablet
89627736|NCT03258372|Experimental|Cohort 2|Mifepristone 1500 MG, 5 tablets
89627737|NCT03258450|Experimental|Psycho-behavioural intervention arm (PBI)|Participants will receive 4 sessions(PBI) that lasts approximately 60 mins.
89627738|NCT03258450|No Intervention|Waitlist Control Arm (WLC)|The WLC group receives standard usual care before being offered the same PBI protocol and assessment thereafter.
89627739|NCT03266328||group 1|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is up to 40 years old
89627740|NCT03266328||group 2|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is more than 40 years old
89627741|NCT02456454|Experimental|Risperidone|Risperidone, PO 0.25-2 mg/day
89627742|NCT02456454|Experimental|Valproic|Valproic Acid PO to achieve plasma levels of 85-100
89627743|NCT02456454|Placebo Comparator|Placebo|Liquid placebo PO matched for color and taste.
89627744|NCT02456688|Experimental|Patients with im paired hepatic function|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
89627745|NCT02456688|Experimental|Healthy Volunteers|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
89627746|NCT03258294|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
89627747|NCT03258294|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
89627748|NCT03261648||hospitalized patient|100 patients will completed the 'State-Trait-Anxiety Inventory (Forme Y) questionnaire Patients will evaluated here pain answering to a pain level scale
89627749|NCT03261648||partner of the hospitalized patient|100 partners will completed the State-Trait-Anxiety Inventory (Forme Y) questionnaire
89627750|NCT03258216||peptic ulcer|patients who had upper GI symptoms and diagnosed as peptic ulcer by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
89627751|NCT03258216||healthy|patients who had no past history or systemic disease, diagnosed as UGI negative finding by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
89627752|NCT03265704||AGA Neonates|AGA Control Group Appropriate for gestational age newborns of healthy mothers
89627753|NCT03265704||SGA Neonates|SGA - Control Group Small for gestational age newborns of healthy mothers
89627754|NCT03265704||AGA-PIH Neonates|AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
89627755|NCT03265704||SGA-PIH Neonates|SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
89627756|NCT03265782|Experimental|ibuprofen group|treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done
89627757|NCT03265782|Experimental|paracetamol group|treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done
89627758|NCT03261726|Experimental|MedEl Test Electrode Placer|MedEl Test Electrode Placed at VIIIth nerve tumor resection
89627759|NCT03798054|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning on top of metformin for 24 weeks.
89627760|NCT03798054|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
89627761|NCT03798054|Active Comparator|Lyxumia (lixisenatide)|Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
89627762|NCT03261882||Foreign-born Mexican-Americans|
89627763|NCT03261882||US-born Mexican-Americans|
89627764|NCT03261882||non-Hispanic Whites|
89627765|NCT03265470|Experimental|Dexmedetomidine|Patients received intravenous infusion of dexmedetomidine
89627766|NCT03265470|Active Comparator|Fentanyl|Patients received intravenous infusion of fentanyl
89627767|NCT02456376|Experimental|Children with Cerebral palsy|"Sensory integration testing~SR stimulation and Sensory integration testing"
89627768|NCT02456376|Active Comparator|Children with Typical Development|"Sensory integration testing~SR stimulation and Sensory integration testing"
89627769|NCT02350816|Active Comparator|HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W|"Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).~HGT-SAN-093 = NCT02060526"
89627770|NCT02350816|Active Comparator|HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
89627771|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W|Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
89627772|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
89039488|NCT04664543|Active Comparator|3 days of low residue diet|Currently participants in the colorectal cancer screening program follow a 3 days low residue diet before colonoscopy. This is the active comparator arm of this study.
89039489|NCT04664543|Experimental|Free diet|Participants assigned to this arm are NOT instructed to follow any kind of restriction in the diet before colonoscopy.
89039490|NCT04682613|Experimental|"Prevention Program young In Favor of Myself, active teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers will also participate by delivering planned activities to do with their pupils in addition to each week's topic, parallel to the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
89039491|NCT04682613|Active Comparator|"Prevention Program young In Favor of Myself, passive teachers"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The teachers won't participate in the program, they will only be present in the classroom during the externally-delivered program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
89039492|NCT04664816|Experimental|n-3PUFAs group|These patients will receive omega-3 plus (1200 mg) orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
89039493|NCT04664816|Placebo Comparator|Control group|These patients will receive placebo orally, twice a day for at least 12 months. The treatment will start after TURBT, as soon as the histopathology will be obtained. The treatment will be discontinued if recurrence develops, unacceptable or serious adverse events occur or according to the patients' request.
89039494|NCT04664348|Experimental|Experimental: Posteroanterior lumbar mobilization (extension of the lumbar spine)|
89627773|NCT02456298|Active Comparator|Standard FA+FCT|Parents are coached via weekly telehealth visits to use Functional Analysis (FA) to assess problem behavior and Functional Communication Training (FCT) to treat the problem behavior identified.
89627774|NCT02456298|Experimental|Pragmatic FA+FCT|Parents are coached via weekly telehealth visits to use a brief, streamlined version of Functional Analysis (FA) to assess problem behavior and to follow that assessment with Functional Communication Training (FCT) to treat the problem behavior identified. The version of FCT used in the Pragmatic arm involves significantly less data scoring and graphing than the version used in the Standard arm.
89627775|NCT02019940|Experimental|Riluzole|Riluzole 50 mg orally twice per day
89627776|NCT03258060|Active Comparator|Mechanical Dyssynchrony|Those with cardiac MRI evidence of mechanical dyssynchrony
89627777|NCT03258060|Active Comparator|No Mechanical Dyssynchrony|Those without mechanical dyssynchrony on cardiac MRI
89627778|NCT03261258||Patients|Patients hospitalised in the ICU of Dijon CHU Burgundy
89627779|NCT03261258||Proches|Relatives/close friends of patients hospitalised in the ICU of Dijon CHU Burgundy
89627780|NCT01967836|Other|Glad Press 'n Seal|Cohort Subjects will use Glad Press 'n Seal product as a moisture barrier to an IV line
89627781|NCT01229943|Experimental|Arm I (octreotide acetate and everolimus)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28 and octreotide acetate 20 mg IM on day 1.
89627782|NCT01229943|Experimental|Arm II (octreotide acetate, everolimus, and bevacizumab)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28, octreotide acetate 20 mg IM on day 1 and bevacizumab 10 mg/kg IV on days 1 and 15.
89627783|NCT02457936|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|This group will receive 8 weeks of Mindfulness Based Cognitive Therapy
89627784|NCT02457936|Active Comparator|Waiting list|This group will be tested twice 8-10 weeks apart and then receive 8 weeks of Mindfulness Based Cognitive Therapy
89627785|NCT03257982|Experimental|BCI-FES hand therapy|BCI-FES hand therapy sessions (set up and use of system)
89627786|NCT02020018|Experimental|Prospective group|Negative pressure wound therapy (Prevena Incision Management System) applied immediately postoperatively.
89627787|NCT02020018|Active Comparator|Retrospective arm|Conventional sterile dry wound dressing applied immediately postoperatively.
89627788|NCT03265626|Experimental|Comprehensive (Intervention 1)|A total of 586 study particpnats will be invloved on this comprehensive (main) experiment group.This arm will receive a comprehensive intervention package that include advocacy to local governors, community mobilization, awareness creation, training of community representatives and engagement partners. community mobilization through engaging husband as change agent to avert domestic violence in collaboration with community Health Extension Workers. The intervention will target married or cohabited women, partner, and community representatives (religious leaders, and elders). The intervention will be focused on physical, psychological and sexual violence, decision making, negotiation, communication on household matters, gender equality and equity norms, and their relationship with women's health. In addition, massive public information dissemination will be done in the intervention community.
89627789|NCT03265626|Active Comparator|Intervention 2|A total of 586 study particpnats will be invloved on this active comprator group. The intervention package such as advocacy to local governors, community mobilization, awareness creation and training of community representatives will be carried out for 12 months period.The main diffrence from the arm-1,here is no husband involvment in the interevntion targets. This intervention will be targeted married and cohabited women and community representatives (religious leaders, health care provider, police, politicians and associations). This group of participant will be selected from one urban and one rural Kebele in Banja District. Same tool and approach will be used to track the intervention progress.
89627790|NCT03265626|Other|Control/Comparator|"A total of 586 study partipants will be assigned to the control group that will receive the existing standard services from both urban and rural kebeles of the Guagussa Shikudad district. As comparator purpose, baseline and endline evaluation data will be taken.~-No intervention package but standard service will be maintained"
89039495|NCT04664348|Experimental|Experimental: Posteroanterior lumbar mobilization (lumbar spine in neutral positioning)|
89039496|NCT04664114|Experimental|Experimental group|Both the evaluation of the fetus and the ultrasound for visual purposes took 15-20 minutes in total. These pregnant women were asked to bring their mobile phones with them during delivery. When the birth of the pregnant woman started, she was hospitalized by the third researcher. The follow-up and deliveries during the labor were carried out by the 3rd and 4th researchers. With an application installed on the pregnant woman's phone, these two-dimensional images were transformed into three-dimensional images and the pregnant women were watched consecutively with the VR Box 3D virtual reality glasses. In cases where the program was not compatible with the phone of the pregnant woman, the researcher was watched by the midwife. The total image viewing time was recorded.
89039497|NCT04664114|No Intervention|Control Group|Only one pregnant woman was included in the study at the same time in order to avoid any interruption in the follow-up of the pregnant women. VAS was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale and the Perinatal Anxiety Screening Scale were applied.
89039498|NCT04682418|Experimental|xvision Spine|
89039499|NCT04664036||NAFLD + type 1 diabetes|type 1 diabetes patient with NAFLD on screening
89039500|NCT04664036||noNAFLD + type 1 diabetes|type 1 diabetes patient without NAFLD on screening
89039501|NCT04664231||Children with JIA|Children with JIA coming to clinic
89039502|NCT04664231||Healthy Children|Healthy Children in the school
89039503|NCT01209286|Experimental|Blinatumomab 15 μg|Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
89627791|NCT02020252||Touchscreen Participants|New lung, gastric and pancreatic cancer patients presenting to the University of Chicago outpatient oncology clinics, a large research institution located on Chicago's Southside, were identified for study accrual, using the electronic scheduling system.
89627792|NCT03265548|No Intervention|Standard|Usual Direct view laryngoscopy
89627793|NCT03265548|Experimental|Intervention|Video laryngoscopy
89627794|NCT03265392|Other|Part 1 - Bread + Water|Participants in this arm will randomly consume bread and 250 mL of water on 1 out of 3 visits of Part 1.
89627795|NCT03265392|Other|Part 1 - Bread + Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice on 1 out of 3 visits of Part 1.
89039504|NCT01209286|Experimental|Blinatumomab 5/15 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
89039505|NCT01209286|Experimental|Blinatumomab 5/15/30 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
89039506|NCT05423080|Experimental|Bolus group|Participants in this group are administered remimazolam via the bolus injection method during anesthesia induction.
89627796|NCT03265392|Other|Part 1 - Bread + Tea|Participants in this arm will randomly consume bread and 250 mL of tea on 1 out of 3 visits of Part 1.
89039507|NCT05423080|Active Comparator|Infusion group|Participants in this group are administered remimazolam via the continuous infusion method during anesthesia induction.
89627797|NCT03265392|Other|Part 2 - Bread + water|Participants in this arm will randomly consume bread and 250 mL of water supplemented with 20 peas on 1 out of 3 visits of Part 2.
89627798|NCT03265392|Other|Part 2 - Bread+ Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice supplemented with 20 peas on 1 out of 3 visits of Part 2.
89627799|NCT03265392|Other|Part 2 - Bread+ tea|Participants in this arm will randomly consume bread and 250 mL of tea supplemented with 20 peas on 1 out of 3 visits of Part 2.
89627800|NCT02020408|Experimental|[11C]raclopride, [11C]DASB, amphetamine|One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.
89627801|NCT03263832||Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
89627802|NCT03263832||Not Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who not have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
89627803|NCT03553524|Experimental|Morning first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 1 of the study will perform HIIT at 08:30 during visit 2, and after a 1-week washout period will perform HIIT at 19:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
89627804|NCT03553524|Experimental|Afternoon first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 2 of the study will perform HIIT at 19:30 during visit 2, and after a 1-week washout period will perform HIIT at 08:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
89627805|NCT02352298|Experimental|Dario Blood Glucose Monitoring System|Blood obtained via fingerstick and blood glucose level is tested on the Dario Blood Glucose Monitoring System
89627806|NCT02352298|Active Comparator|YSI STAT|Blood obtained via fingerstick and blood glucose level is tested on the YSI STAT for comparison to the results obtained with the Dario Blood Glucose Monitoring System
89039508|NCT04663763|Experimental|Neoadjuvant short-course radiotherapy+immunotherapy+chemotherapy|"A total of 40 patients receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 4 cycles of CAPOX chemotherapy.~Interventions:~Shor-course radiotherapy: 25Gy/5Fx;~Induction immunotherapy: Sintilimab 200mg ivgtt d1 q3w x 4 cycles;~Concurrent Chemotherapy: Oxaliplatin: 130mg/m2 d1 q3w + Capecitabine: 1000mg/m2 d1-14 q3w x 4 cycles;"
89039509|NCT04663880|Experimental|Asthmatic subjects allergic to house dust mite|24 subjects were randomized in a doubleblinded manner into six subgroups. All were exposed first to placebo then in cross over to three different Der p1 concentrations, respectively 15, 25, and 46 ng/m3.
89039510|NCT04663880|Active Comparator|Asthmatic subjects not allergic to house dust mite|13 subjects were exposed first to placebo then to Der p1 concentration of 25 ng/m3.
89039511|NCT04663919|Active Comparator|Anorexia Nervosa|Patients diagnosed with Anorexia Nervosa, having a BMI of <18, being followed up and treated in the Psychiatry Eating Disorders Polyclinic and endocrinology outpatient clinics, and who have approximately 10% weight gain during the treatment process
89039512|NCT04663919|Active Comparator|Morbidly Obese|Patients with a BMI> 40 diagnosed with Morbid Obesity and who lost approximately 10% of their weight by performing obesity surgery (gastric bypass or sleeve gastrectomy)
89627807|NCT04782843||Cohort|"he retrospective cohort studied includes all the patients included in a previous study carried out in our center, the objective of which was to study the diagnostic performance of the HEP score in surgical intensive care.~The cohort studied is made up of all patients admitted for surgical resuscitation between October 2011 and October 2013 and validating the following criteria:~Inclusion criteria: any adult patient (age ≥ 18 years), admitted to surgical intensive care, treated with heparin (UFH or LMWH), and suspected of TIH by a clinician in the department according to the criteria of the SFAR 2002.~Non-inclusion criteria: minor patients, pregnant women and adults incapable."
89627808|NCT01219257||SpA patients|The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.
89039513|NCT04663919|No Intervention|Healthy Volunteer|Volunteers with normal BMI and without any additional chronic disease
89039514|NCT04353102|Experimental|YH002|All subject will receive YH002 intravenously as single agent every three weeks (Q3W) for up to 2 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first. Subjects who remain on treatment in the absence of disease progression for more than 2 years may continue to receive study drug through a single patient IND.
89039515|NCT04351737|Experimental|Pterygium patients|patients with bilateral pterytium
89039516|NCT04347915|Experimental|Clevudine|Clevudine 120mg (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
89627809|NCT01197027|Experimental|Enhanced counseling|5 intensive counseling sessions following acute HIV infection
89627810|NCT01197027|Active Comparator|Standard counseling|Standard HIV counseling following acute HIV infection
89627811|NCT01895439|Experimental|MSCs injection|Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients
89627812|NCT04782765|Experimental|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
89627813|NCT01615887|Experimental|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
89627814|NCT01615887|Placebo Comparator|Sugar pill|Placebo will be administered in the same fashion as the treatment arm
89627815|NCT04389801|Experimental|Desferal|An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours
89627816|NCT04389801|Placebo Comparator|control group|Will receive glucose 5% over 4 hrs infusion
89627817|NCT04782141|Experimental|Positioning the trunk and upper limb to improve the coordination the hand.|The study investigated the effects of the trunk and upper limb positioning on improving wrist and hand coordination.
89627818|NCT01189851|Other|IORT|Treated with Intraoperative Radiation Therapy
89627819|NCT01606995||Group 1|
89627820|NCT04782453|Experimental|ToQuit|Participants from the ToQuit intervention arm will receive the messages on their mobile phones for 8 weeks. The messages will be sent for 3-4 days a week.
89627821|NCT04782453|Other|Control|Participants from the control group will be sent the details of other functional tobacco helplines in India.
89627822|NCT03548220|Placebo Comparator|Placebo|Participants received a matching placebo to AG-348 tablets, for a period of 12 weeks as an optimized dose. This was followed by matching placebo further, for a period of 12 weeks as a fixed-dose.
89627823|NCT03548220|Experimental|AG-348, 5 mg|Participants received AG-348 tablets, 5 milligrams (mg) twice daily (BID), administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 5 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
89627824|NCT03548220|Experimental|AG-348, 20 mg|Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 20 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
89627825|NCT03548220|Experimental|AG-348, 50 mg|Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 50 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.
89627826|NCT04050969|Active Comparator|Atrial Fibrillation (AF) Catheter Ablation-Group A|Participants will undergo catheter ablation using either radiofrequency or cryo-ablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extra-pulmonary sites at the physician's discretion.
89627827|NCT04050969|Experimental|Bariatric surgery prior to AF Catheter Ablation-Group B|"Participants will undergo either a Roux-en-Y gastric bypass or a laparoscopic sleeve gastrectomy. The choice of the procedure will be based on numerous factors including current practice, the surgeon's and participant's choice, BMI, and the presence of certain comorbidities and their severity such as GERD, kidney stones, and past surgical history. Participants will undergo standard preoperative evaluation including dietary consultation and psychological evaluation during the eligibility process.~After bariatric surgery, in addition to routine post-surgical management, patients will follow up with cardiologist prior to AF catheter ablation."
89627828|NCT01589211|Active Comparator|Brief advice|A brief advice to stop smoking of about 10 min accompanied with self-help material
89627829|NCT01589211|Experimental|Compact cessation course|Cessation intervention of 2 x 120 min in a group setting
89627830|NCT01589211|Active Comparator|Standard cessation course|Cessation course in a group setting over 6 dates
89039517|NCT04347915|Placebo Comparator|Placebo|Matching Placebo (4 capsules) once a day will be administered orally and can be taken regardless of food intake for 14 days (up to 21 days)
89627831|NCT03257670|Active Comparator|CO2RE Laser|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
89627832|NCT03257670|Active Comparator|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
89627833|NCT04781985|Experimental|suprapubic cystolithotomy|Extraction of the vesical stone via open exploration of the bladder.
89627834|NCT03265002|Placebo Comparator|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
89627835|NCT03265002|Experimental|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
89627836|NCT03265002|Active Comparator|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
89627837|NCT03265002|Active Comparator|Inulin and Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
89627838|NCT04754997|No Intervention|Control group|This group will not take any exercise intervention.
89627839|NCT04754997|Active Comparator|Traditional exercise training group|This group will get traditional therapy that is include range of motion exercises and resistance exercise training.
89627840|NCT04754997|Experimental|Specific exercise training group|This group will get a specific programme that combinated with closed kinetic chain exercises and core exercises training
89627841|NCT03257592|Experimental|Patients with Schizophrenia Disorder|Patients with Schizophrenia Disorder will be imaged with [11C] DPA-713
89627842|NCT03257592|Experimental|Patients with Bipolar Disorder|Patients with Bipolar Disorder will be imaged with [11C] DPA-713
89627843|NCT03257592|Experimental|Control|Normal volunteers will be imaged with [11C] DPA-713
89627844|NCT01145235||Females previously treated with Macrolane in their breasts.|
89627845|NCT03265236||Group1|Patients with early rheamatoid arthritis
89627846|NCT03265236||Group 2|patients with late rheamatoid arthritis
89627847|NCT03265236||Group 3|Healthy control
89627848|NCT02458248|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
89627849|NCT02458248|No Intervention|Usual care|For all participants, standard care will be provided at the nephrology clinic at GUH or by local general practitioners, and includes treatment of hypertension, underlying comorbidities and optimizing the metabolic profile. Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
89039518|NCT03455361||Stark Implant with low primary stability|Patient who had received bone level V-Blast implants with low primary stability.
89039519|NCT03455361||Stark Implant with primary stability|Patient who had received bone level V-Blast implants and achieved primary stability.
89039520|NCT04663685|Experimental|Single Arm|This is the only arm in the study. All participants will be allocated to this arm, where they will receive an 8-week remotely-delivered exercise and nutrition program.
89039521|NCT04663451||Toxic Nodule|Hyperthyroid patients with underlying toxic nodule
89039522|NCT04663451||Toxic multinodular goiter|Hyperthyroid patients with underlying toxic multinodular goiter
89039523|NCT04185051|Experimental|Cohort 1: JNJ-67953964 or Placebo|Participants will receive JNJ-67953964 or matching placebo oral capsules once daily (QD) over 4 weeks (28 days).
89039524|NCT04185051|Experimental|Cohort 2: JNJ-67953964 or Placebo|Participants in this cohort will receive JNJ-67953964 only or will be randomly assigned to receive JNJ-67953964 or matching placebo.
89039525|NCT04663412|Experimental|Patients FIGO IB stage|Vulvar Cancer IB stage
89039526|NCT04663490||simple acute diverticulitis|Ninety-one percent (n=295) were categorized as simple acute diverticulitis
89039527|NCT04663490||complicated acute diverticulitis|9% (n=30) presented were categorized as complicated acute diverticulitis
89627850|NCT02457780|Experimental|Relaxation Response Resiliency Program|The Relaxation Response Resiliency Program (3RP) is an 8-session (90min/session) group based intervention which includes a variety of skills and techniques designed to address chronic stress. Techniques used include psychoeducation on healthy lifestyle behaviors, goal-setting, CBT skills, relaxation training and self-monitoring.
89627851|NCT02457780|Active Comparator|Health Enhancement Program|The Health Enhancement Program (HEP) is an 8-session (90min/session) group based intervention which includes psychoeducation and self-monitoring of health behaviors (e.g., sleep hygiene, nutrition, exercise, substance use etc).
89627852|NCT02456610|Experimental|Infusion of CMV/EBV specific CTLs|Repetitive CTLs infusion to treat CMV/EBV activation and infection
89627853|NCT04778241|Experimental|Micro-Osteoperforation group|All the participants bonded by the care provider with 0.022 inch MBT prescription appliance (Ortho TechanologyTM,USA). Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
89627854|NCT04778241|No Intervention|Control group|All the participants in this group bonded by the principal investigator with 0.022-inch slot MBT prescription appliance (Ortho TechanologyTM,USA). No micro-osteoperforation was used in this group.
89039528|NCT04662983|Experimental|Experimental group|The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions.
89627855|NCT03537066|Other|CPAP treatment|All included OSA patients are going to be treated by CPAP
89627856|NCT04754919|Active Comparator|Transition intervention group|Intervention group -will be working with the specialist diabetes transition nurse. The nurse will follow a specific protocol involving visits, clinic support, community support and appointment rearranging. She will also maintain communication with the Hospital based adult and paediatric diabetes teams and the participants General Practitioner and relevant community health care professionals.
89627857|NCT04754919|Placebo Comparator|Post Transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
89627858|NCT04754841|Experimental|SURVIVAL AND FUNCTIONALITY INVITRO IN CRYOPRESERVED PLATELETS|Platelet concentrates will be administered 3 alternatives of cryopreservative solution: 5% dimethylsulfoxide (solution 1), 5% dimethylsulfoxide plus 160 mg of 5% dextrose (solution 2) and 5% dimethylsulfoxide plus 2% albumine (solution 3 ). They will then be frozen at -80 ° C and their survival and functionality will be subsequently evaluated in vitro.
89627859|NCT03757806|Experimental|Experimental group|The experimental group will receive the LiFE4D in addition to usual care (e.g., pharmacologic treatment).
89627860|NCT03757806|No Intervention|Control group|The control group will receive usual care only.
89627861|NCT04001595||Participants with FKRP gene mutation|
89627862|NCT03257826|Experimental|surgery|Percutaneous Kirschner wire
89627863|NCT03261492|Experimental|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program and presently includes 12 lessons that can be delivered once or twice a week. The SAGE garden-based curriculum includes active games and discussion as well as activities that include watering the ECEC garden.
89627864|NCT03261492|Active Comparator|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest. The curriculum will include concepts and lessons for educating young children on fire, pedestrian, water, household, neighborhood and playground safety. The curriculum includes handouts, coloring sheets, comic books, games, and songs that can be implemented with minimal training and preparation.
89627865|NCT04781829|No Intervention|Control|Critically ill patients with pneumonia will be treated with an antibiotic strategy at the discretion of the treating clinician
89627866|NCT04781829|Experimental|Interventional|Critically ill patients with pneumonia will be treated with an antibiotic strategy based on results from the BioFire Pneumonia Panel
89039529|NCT04663139|Experimental|normal weight healthy adult volunteers receiving Xla1|one capsule Xla1 given once daily
89039530|NCT04663139|Experimental|overweight and class 1 obese adult patients receiving Xla1|one capsule Xla1 given once daily
89039531|NCT04663139|Placebo Comparator|overweight and class 1 obese adult patients receiving placebo|one capsule placebo given once daily
89039532|NCT04095780|Experimental|Advanced oral hygiene care programme|Patients with stroke will receive the advanced oral hygiene care programme (AOHCP) comprising powered tooth brushing and mouth rinsing with chlorhexidine (with a supply of standardized power tooth brushes, mouth rinse, tooth paste and oral hygiene instruction).
89039533|NCT04095780|Experimental|Oral hygiene instruction|Patients with stroke will only receive the oral hygiene instruction.
89039534|NCT04662788|Experimental|Administration of NK cells/Combined Monoclonal Antibodies|
89039535|NCT04088994|Experimental|pathological model|The children assigned to the experimental group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a model with a similar manipulation strategy but improved with respect to the child's current abilities.
89039536|NCT04088994|Active Comparator|Healthy model|The children assigned to the control group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
89039537|NCT04662749||concave group|the group whose level of sinus floor is lower than both of the adjacent teeth
89627867|NCT03261180|Experimental|Group I (Nestle Impact AR)|Patients receive Nestle Impact AR for 5 days before and after surgery in addition to regular diet.
89627868|NCT03261180|Active Comparator|Group II (regular diet)|Patients receive regular diet.
89627869|NCT04778319|Active Comparator|tubal occlusion|occlusion of tubes
89627870|NCT04778319|Sham Comparator|non occlusion of tube|non occlusion of tubes
89627871|NCT03261414|Experimental|With preoperative hypnosis|standard care plus hypnosis followed by administration of propofol for anesthesia induction
89627872|NCT03261414|Active Comparator|Without preoperative hypnosis|standard care without preoperative hypnosis followed by administration of propofol for anesthesia induction
89627873|NCT01110681|Experimental|Solesta|"Open label. Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) The study treatment consisted of 4 submucosal injections, 1 mL Solesta each, in the proximal part of the high pressure zone in the anal canal.~Re-treatment is allowed one month after initial treatment if the subject is still incontinent."
89627874|NCT03257514|Active Comparator|alpha lipoic acid|51 women will receive alpha lipoic acid drug (thiotacid film coated tablets 600 mg) for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography (by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
89627875|NCT03257514|Placebo Comparator|placebo|51 women will receive a placebo drug for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography(by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
89627876|NCT02456064|Experimental|Lifestyle counseling|"In this group we will make an intensive program based on: workshops, educational talks, group medical practices and expert patient among others conduct auditions."
89627877|NCT02456064|No Intervention|Normal group|In this group will be controlled as usual in the consultations.
89627878|NCT01102569||Pancreatic cancer and Ashkenazi decent|Patients with pancreatic cancer will be asked to join the study if they identify themselves as being of Ashkenazi descent, as well as patients at a high-risk of pancreas cancer based on family history, and will be followed from the time of diagnosis.
89627879|NCT03257748|Experimental|LED group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
89627880|NCT03257748|Experimental|Laser group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
89627881|NCT04778007||Globus pharyngeus patients|The first group consists of 80 globus pharyngeus patients who have at least a year of globus sensation complaints. The participants will given the Turkish Version of the Laryngopharyngeal Measure of Perceived Sensation Questionnaire (T-LUMP), consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale. After the two weeks, 80 participants will given the T-LUMP and Visual analog scale for sampling.
89627882|NCT04778007||Healty subjects|The second group consists of 80 healty participants will given the T-LUMP consist of 8 questions, Glasgow Edinburg Throat Scale, and Visual analog scale
89627883|NCT04781751|No Intervention|dexamethasone|dexamethasone with local anesthetics injected for carpal tunnel relief
89627884|NCT04781751|Active Comparator|Insulin group|insulin with local anesthetics and dexamehtasone injected for carpal tunnel relief
89627885|NCT04781205|Experimental|Intervention|Members of clinics randomized into intervention arm will be consented on a blood test for DNA evaluation (up to WGS), a single feces sample for microbiome analysis and tentative agreement to ware monitors of various vital signs of body function
89627886|NCT04781205|No Intervention|Usual care|No intervention at all
89627887|NCT05387928|Experimental|Dose Escalation|KL340399 weekly on Days 1, 8 and 15 on repeated 21-day cycles in escalating doses.
89627888|NCT04777695||CICU Inpatients|This is a prospective observational study of all children admitted to the pediatric CICU during a one month period of time for patients aged 0 to less than or equal to 22 years of age, as per the World Health Organization definition of a pediatric patient.
89627889|NCT04488276||Pregnant women|Non smoking pregnant and post-partum women
89627890|NCT04488276||Smoking fathers|Expectant or new fathers who smoke
89627891|NCT03257280|Experimental|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
89627892|NCT03257280|No Intervention|control group|In our center, the classical postoperative management consisted in one week period of non oral intake and total parenteral nutrition. At the 7 day, an oral contrast image is performed to prove the correct function of the anastomosis, in witch case, a three days progressive oral diet is begin.
89627893|NCT04781439|No Intervention|non-switching|control group
89627894|NCT04781439|Experimental|IV-to-PO conversion within 48-72 hours|early switching
89627895|NCT04781439|Experimental|IV-to-PO conversion after 72 hours|late switching
89627896|NCT03252678|Experimental|A Book and Videos about ACP|Subjects in experimental group get a book of 45 pages and three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish reading and watching the materials, they fill out the questionnaire.
89627897|NCT03252678|Active Comparator|A Book and Videos about Pain Control|Subjects in the group get a book and two videos about pain control for cancer patients. After they finish reading and watching the materials, they fill out the questionnaire.
89627898|NCT04777773|Other|control group|classical physical therapy+ classical physical therapy
89627899|NCT04777773|Other|study group|classical physical therapy+ dual-task training
89627900|NCT03261024|Active Comparator|Friction mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. Hook between upper laterals and canines will be fixed on the main archwire.~Nickel Titanium coil spring ( friction mechanics of retraction)will be used for maxillary en-masse retraction by extending the spring from the hook to the molar bands.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
89627901|NCT03261024|Active Comparator|Frictionless mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. T-loops retraction arch ( frictionless mechanics of retraction)will be used for maxillary en-masse retraction. The wire will be cinched distal to the molar bands.~Re-activation of the retraction loops will be done in the follow up visits to maintain a constant force through the study"
89627902|NCT04777383|Experimental|Vascular effects of iontophoresed vasoactive substances|"Iontophoretically administered vasoactive substances in five concentrations (1%,0.1%,0.01%,0.001%, 0.0001%) dissolved in sterile water. Each concentration of the drug is separately administered using a electrical charge of 12 millicoulomb (mC) (600 seconds x 0.02 milliampere) for 3 repeated pulses (total electrical charge 36 mC). Each iontophoresis pulse is separated by a 30 minute wash-out period.~Vasoactive substances:~Miochol-E (Acetylcholine),10 mg/ml, Bausch & Lomb~Methacholine chloride, 100 mg/ml, APL~Norepinephrine, 1 mg/ml, Pfizer~Phenylephrine, 10 mg/ml, Unimedic~Atropine, 10 mg/ml, Bausch & Lomb~Neostigmine, 2.5 mg/ml, Unimedic Pharma~Sterile water, 100 ml, Braun"
89627903|NCT03260946||Palliative/Supportive care|Individuals with cancer receiving palliative or supportive care
89627904|NCT03257124|Experimental|AZD9291 in BM or LM cohort in T790M positive|"Brain metastasis cohort (BM cohort)~Leptomeningeal metastasis cohort (LM cohort)"
89627905|NCT02089113|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
89627906|NCT02089113|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
89627907|NCT03252990||Optimization subjects|Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
89627908|NCT03252990||Patients from the VieCuri hospital|15 NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital will be included. These patients will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+ and an additional optical coherence tomography (OCT) examination (during the PCI procedure) at the Viecuri hospital. OCT will be performed as a reference standard to validate 18F-choline PET-MRI for detection of vulnerable plaques in the coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI and OCT will be performed as additional measurements.
89627909|NCT03257046|Experimental|1 mg ITI-214|Administered once daily for 7 days
89627910|NCT03257046|Experimental|3 mg ITI-214|Administered once daily for 7 days
89627911|NCT03257046|Experimental|10 mg ITI-214|Administered once daily for 7 days
89627912|NCT03257046|Experimental|30 mg ITI-214|Administered once daily for 7 days
89627913|NCT03257046|Experimental|90 mg ITI-214|Administered once daily for 7 days
89627914|NCT03257046|Placebo Comparator|Placebo|Administered once daily for 7 days
89627915|NCT03252444|Experimental|Biofeedback group|After 1 minute of rest, participants will perform 6 trials of bilateral, active, weighted arm elevation in the scapular plane and a therapist classifies the scapular motion into specific patterns of scapular dyskinesis. After the evaluation of scapular dyskinesis, the kinematics and surface EMG (sEMG) data will be collected during 5 trials of the same arm movements and 3 selected exercises.
89627916|NCT03252444|Active Comparator|Conscious control group|Conscious correction of scapular orientation will be taught to the subjects in the manner described in previous studies. The starting position is determined in each individual by actively positioning the scapula between maximal upward and downward rotation, external and internal rotation, and posterior and anterior tilt. Scapular assistance test (SAT) is also conducted by passively assisting patients' scapula into appropriate position to correct scapula dyskinesis
89627917|NCT03252288|No Intervention|No intervention|No intervention
89627918|NCT03252288|Experimental|Reminders only|Reminders are sent 1 week and 1 day before each scheduled vaccination date
89627919|NCT03252288|Experimental|Reminders + Conditional financial transfer|Reminders are sent 1 week and 1 day before each scheduled vaccination date; and conditional financial transfers are made for each on-time vaccination visit
89627920|NCT03260634||Voriconazole|"Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals <40 kg the maintenance dose is 100 mg twice daily in oral form.~The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment."
89627921|NCT03256890|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
89627922|NCT03256890|Active Comparator|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
89627923|NCT04777227|Active Comparator|Debridement|A debridement (procedure involving cleaning and removing all hyperkeratotic tissue) was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr
89627924|NCT04777227|Sham Comparator|Debridement with needle insertion|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
89627925|NCT04777227|Placebo Comparator|Debridement with physiological water injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 0.9% sterile sodium chloride water. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
89627926|NCT04777227|Experimental|Debridement with lidocaine injection|A debridement was followed by the insertion of a 27-gauge needle on a 3 mL syringe that was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side. The podiatrist pressed completely on the syringe to inject 1 mL of 2% lidocaine solution. The syringe was removed and the IPK was bandaged with a sterile gauze and medical tape.
89627927|NCT03260556|Active Comparator|Pirfenidone|Pirfenidone titrated to three 267 mg tablets three times a day
89627928|NCT03260556|Placebo Comparator|Placebos|Placebo titrated to three tablets three times a day
89627929|NCT04780737||Prophylactic cholecystectomy|Patient who undergo resection of primary ileal neuroendocrine tumor and contemporarly cholecystectomy
89627930|NCT04780737||On-demand cholecystectomy|Patient resected for primary ileal neuroendocrine tumor, treated with cholecystectomy in a different operation and only if needed, for the development of biliary stone disease
89627931|NCT04776915||Study Group|Infertile patients due to polycystic ovarian syndrome
89627932|NCT04776915||Control Group|Infertile patients due to unexplained infertility
89627933|NCT02712996|Active Comparator|Vyvanse|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
89627934|NCT02712996|Placebo Comparator|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
89627935|NCT03252366|Active Comparator|GELFOAM (ABSORBABLE GELATIN)|"Sterile Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic.~it act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids its effect appears to be more physical than the result of altering the blood clotting mechanism. When placed in soft tissues, GELFOAM is usually absorbed completely within four to six weeks, without inducing excessive scar tissue"
89627936|NCT03252366|Active Comparator|XENOGRAFT (TUTOGEN)|xenografts as a sinus bone replacement graft ,The osteoconductive properties of xenografts in human sinus grafting have been well documented. They are due to both their chemical composition and their macro and micro morphology.The efficacy of xenografts as a sinus bone replacement graft may be due to combination of factors. Foremost would be the osteoconductive capacity of xenografts. In addition, they supply minerals that are necessary for bone formation, their density provides stability to the graft and the implants placed in them, and this density persists long term due to the fact that these grafts do not completely resorb.
89627937|NCT04780347|Experimental|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel combined with capecitabine
89627938|NCT04780347|Active Comparator|Capecitabine|Capecitabine
89627939|NCT02455596|Experimental|Experimental|Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week.
89627940|NCT01013415|Experimental|ARM 1|Arm I (N=5) received antiretroviral therapy (ART) plus low dose IL-2 (1.2 million units/m2) subcutaneously daily for 56 days
89627941|NCT01013415|Experimental|ARM 2|Arm 2 (N=5) received ART plus a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
89627942|NCT01013415|Experimental|ARM 3|Arm 3 (n=5) received ART plus IL-2 (1.2 million units/m2) and a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
89627943|NCT03256500|Experimental|tDCS administered|Subjects will receive stimulation via tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
89627944|NCT03256500|Sham Comparator|Sham tDCS administered|Subjects will receive sham tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
89627945|NCT04776603||Group 1|group 1 includes patients who axial length(AL)<26mm
89627946|NCT04776603||Group 2|group 2 includes patients who axial length（AL）≥26mm
89627947|NCT03256110|Experimental|Intervention|Patients and providers in this arm receive the culturally-tailored Improving Communication about Serious Illness (ICSI) Intervention. The ICSI involves providing the provider and the patient with an individualized, one-page summary of patient-specific preferences for advance care planning communication that prompts the patient and the provider to have a conversation about advance care planning at the next clinical visit.
89627948|NCT03256110|No Intervention|Control|Patients and providers in this arm receive usual care.
89627949|NCT04780191|Experimental|Active MyoRegulator® treatment|Five consecutive days of 20 minutes active stimulation with MyoRegulator® device
89627950|NCT04780191|Sham Comparator|Sham MyoRegulator® treatment|Five consecutive days of 20 minutes sham stimulation with MyoRegulator® device
89627951|NCT03252132|Active Comparator|12-week resistance training|
89627952|NCT03252132|No Intervention|No training|
89627953|NCT03252210|Experimental|Stereoscopic Versus Methylene Blue|"In the same participant,we perform both Stereoscopic and Methylene Blue localization。Then，compare the distance between the methylene blue's anchor point and the location of lesion,stereoscopic Localization's anchor point and the location of lesion,methylene blue's anchor point and stereoscopic Localization's anchor point.~Post Hoc Multiple Comparisons"
89627954|NCT02455440|Active Comparator|Esmolol|500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol until 30 minutes after extubation.
89627955|NCT02455440|Placebo Comparator|control|Control group did not receive esmolol or other b-blocker in the perioperative period.
89627956|NCT03937167|No Intervention|Control|Standard treatment at Hospital Infanta Leonor with Endocrinology and Psyquiatry
89627957|NCT03937167|Experimental|Completers|Randomized to treatment AND complete treatment 14 sessions are needed
89039538|NCT04662749||angle group|the group whose level of sinus floor is lower than one of the adjacent teeth and higher than the other one of the adjacent teeth
89211246|NCT00538785|Experimental|Motavizumab|Motavizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
89211247|NCT00538785|Active Comparator|Pailvizumab|Palivizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
89211248|NCT02058459|Active Comparator|Targeted Lung Denervation|active targeted lung denervation
89211249|NCT02058459|Sham Comparator|Sham-Control|non-active targeted lung denervation
89211250|NCT00990015|Experimental|PF-04308515|
89211251|NCT00990015|Placebo Comparator|Placebo|
89627958|NCT03937167|No Intervention|Drop-out|Randomized to treatment BUT do not assist or do not complete treatment Less than 14 sessions
89627959|NCT03260166|Experimental|nicotinamide|Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
89627960|NCT02089191|Other|DACP/MyDay|Nelfilcon A contact lenses worn in Period 1, with stenfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
89627961|NCT02089191|Other|MyDay/DACP|Stenfilcon A contact lenses worn in Period 1, with nelfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
89627962|NCT03260010|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
89627963|NCT03260088||patients with pleural effusion|In patients with pleural effusion that remains undiagnosed with common diagnostic algorithm, immunoglobulin G4 will be done in pleural fluid
89627964|NCT04779723|Active Comparator|LRYGB Procedure|LRYGB technique was performed by placing 4 to 6 trocars, a 150 cm ante-colic Roux-limb gastric pouch (30 to 50 ml) was created with linear stapled or circular stapled gastro-jejunostomy, a 50-cm long biliopancreatic limb was chosen. A passive drainage was kept near to the gastro-jejunostomy.
89627965|NCT04779723|Active Comparator|LSG Procedure|35 Fr bougie was used for the calibration of a gastric tube. 3 to 6 cm of longitudinal incision of the stomach was done at pylorus to the angle of His. Using of absorbable suture, the staple line was sewn.
89627966|NCT05387850||Elderly patients over the age of 65|Elderly patients over the age of 65 undergoing elective non-cardiac surgery
89627967|NCT01896219|Active Comparator|Gesture performed under control tomodensitometric (CT)|Conventional
89627968|NCT01896219|Experimental|Gesture performed under Navigation-assisted procedure (NAV)|Use of the IMACTIS-CT® Navigation System
89627969|NCT04776135|Experimental|MT-1186 orally|Subjects receive the edaravone oral suspension orally.
89627970|NCT04776135|Experimental|MT-1186 via a nasogastric tube|Subjects receive the edaravone oral suspension via a nasogastric tube
89627971|NCT03256188|Experimental|Active classroom|Twenty elementary school teachers implemented 10, 3-minute moderate-to-vigorous physical activity breaks (50-75% of heart rate maximum), 5 days per week in their classrooms over a 16-week period.
88990054|NCT04326257|Experimental|Nivolumab+Relatlimab|"Nivolumab will be dosed 480mg IV q 4 weeks and Relatlimab 160mg IV q 4 weeks~One cycle is defined as 4 weeks of treatment and both drugs are given on the same day.~Patients will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
89211252|NCT04237545|Experimental|T3 short implant|The short implants are available in lengths of 5mm and 6mm and in diameters of 5mm and 6mm. For study both configurations, T3 short without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 short with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
89627972|NCT04775823|Experimental|Hybrid composite nano-ceramic|
89627973|NCT03474276|Active Comparator|Control group|"Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months).~200 grams / day for children between 6 and 11 months. 300 grams / day for children aged from 12 to 24 months old."
89627974|NCT03474276|Active Comparator|Azythromycin|Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months) associated to Azythromycin, 20mg/kgs/days during the three first days of the study.
89627975|NCT03474276|Active Comparator|Prebiotic|Fortified Blended Flour mixed with Inuline and fructo-oligosaccharides (Synergy1) 2g/day, given to the child through the whole intervention (in association with a single dose of Albendazole at inclusion for children older than 12 months)
89627976|NCT04779801|Experimental|ABFT|Adolescents and one or both parents will complete 16 weeks of Attachment-Based Family Therapy treatment.
89627977|NCT03259776||Visitors|Qualitative interviews and questionnaire survey
89627978|NCT04779255|Experimental|Tumescent anesthesia|Patient who will receive tumescent anesthesia as analgesic treatment
89627979|NCT04779255|Active Comparator|Painkillers and cold water|Patient who will receive painkillers 1 hour before photodynamic therapy and cold water during session as analgesic treatment
89627980|NCT03252054||Patients aged 70 or over|Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition
89627981|NCT03256422|Experimental|4 days / 7|Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks
89627982|NCT03256422|Active Comparator|7 days / 7|Patients included in this arm will continue their ARV therapy 7 days per weeks during 48 weeks and after W48, they will take their ARV treatment 4 days per week until W98
89627983|NCT04775901|Other|CT-guided lung biopsy|Participants in this arm received conventional CT-guided percutaneous transthoracic lung biopsy.
89627984|NCT04775901|Experimental|Template-guided lung biopsy|Three-dimensionally printed navigational template was designed based on the CT scan images acquired before the biopsy. Under the guidance of navigational template, percutaneous transthoracic lung biopsy was conducted.
89039539|NCT04662749||flat group|the group whose level of sinus floor is similar to both of the adjacent teeth
89627985|NCT01968382|Experimental|IMM 124-E 2400 mg/day|Imm-124-E (2400 mg/day) will be provided in two divided doses daily in the form of powder to be mixed with water. Subjects will get 1 active drug powder and 1 placebo powder with each dosing for a total of 4 sachets daily.
89627986|NCT01968382|Experimental|IMM 124-E 4800 mg/day|Imm-124-E (4800 mg/day) will be provided in two divided doses daily in the form of 2400 mg in the form of a powder to be mixed with water. The total number daily will be 4 sachets.
89627987|NCT01968382|Placebo Comparator|Placebo (High protein milk powder)|Subjects will receive 2 sachets of placebo powder to be mixed with water in the morning and 2 sachets of placebo powder (to be mixed with water) in the evening for a total of 4 sachets of placebo daily.
89627988|NCT00951249|Experimental|A|HIV-infected and uninfected black MSM
89627989|NCT04779567|Experimental|Acetaminophen|Acetaminophen 1 gr in 100 ml saline 0,9% iv 4 times a day
89627990|NCT04779567|Placebo Comparator|Placebo|100 ml saline 0.9% iv 4 times a day
89627991|NCT03259854|Active Comparator|oxygen mask control group|patients will receive oxygen by mask will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
89627992|NCT03259854|Experimental|non invasive ventilation study group|patients will receive non invasive ventilation after successful weaning from invasive ventilation and will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
89627993|NCT03291210|Experimental|Normoxemia|Patients randomized to the normoxemia group receives inspired oxygen fraction of 0.3 from initiation of induction of anesthesia to the end of the procedure.
89627994|NCT03291210|Active Comparator|Hyperoxemia|Patients randomized to the hyperoxemia group receives inspired oxygen fraction of 0.8 from initiation of induction of anesthesia to the end of the procedure.
89627995|NCT03255876|Experimental|Enriched pomegranate juice|Participants will consume 200 ml of pure pomegranate juice enriched with grape seed and apple peel extracts concomitantly with 109 g of white bread
89627996|NCT03255876|Placebo Comparator|Placebo beverage|Participants will consume 200 ml of placebo drink concomitantly with 109 g of white bread
89627997|NCT03251898||study group|pregnant women who are diagnosed as PROM or chorioamnionitis and whose gestational age is ≥ 24 weeks
89627998|NCT03251898||control group|pregnant women without PROM and chorioamnionitis
89627999|NCT02352844|Experimental|Arm 1 (everolimus)|Everolimus is an oral drug which will be administered on an outpatient basis at a dose of 10 mg daily on a 28-day cycle.
89628000|NCT03255642|Active Comparator|Melatonin 2mg|4 weeks of 2mg of prolonged release Melatonin
89628001|NCT03255642|Placebo Comparator|ClonazePAM 0.5 MG|4 weeks of 0.5mg of rivotril
89628002|NCT03562377|Experimental|Tralokinumab|"Week 0 to 16:> Tralokinumab will be given as subcutaneous injections. >~> Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14."
89628003|NCT03562377|Placebo Comparator|Placebo|"Placebo (dummy treatment) will be given as subcutaneous injections. >~> Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14."
89628004|NCT03255720||20 patients with Alzheimer disease|"The study will be performed at the Radiodiagnosis department of assiut university hospital.~Selection of 20 patients clinically and laboratory diagnosed as Alzheimer disease and another 20 people matched healthy controls who have no complaints of cognitive problems."
89628005|NCT03255720||20 people matched healthy controls|health control people who have no complaints of cognitive problems.
89628006|NCT02352922|Experimental|Liposomal Bupivacaine|extended-release bupivacaine (EXPAREL)
89628007|NCT02352922|Active Comparator|Bupivacaine HCl|short-acting bupivacaine
89628008|NCT02456220|Experimental|Herbst Group|Patients treated with Herbst appliance.
89628009|NCT02456220|No Intervention|Comparison Group|Patients that received only teeth movement (alignment and leveling before Herbst insertion), without any orthopedic intervention.
89628010|NCT03255330|Experimental|Arm G1800|administration of gabapentin with a gradual increasing dose of up to 1800 mg / day
89628011|NCT03255330|Active Comparator|G0|Standardized medical treatment of central neuropathic pain: metamizole, tramadol
89628012|NCT01969162||All Participants|Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
89628013|NCT02089659|Experimental|Part 1: Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.
89628014|NCT02089659|Experimental|Part 1: Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.
89039540|NCT04065516|Experimental|Argon Plasma Coagulation of the gastroesophageal junction|Participants with abnormal acid exposure after peroral endoscopic myotomy for achalasia, will be treated by ablation of the gastroesophageal junction with hybrid argon plasma coagulation
89039541|NCT04037007|Active Comparator|Fistulotomy - High experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in high experienced endoscopists.
89039542|NCT04037007|Active Comparator|Fistulotomy - Low experienced|Fistulotomy precut with a needle knife, ERBE Endocut I, Effect 2; as the primary cannulation technique in low experienced endoscopists.
89628015|NCT02089659|Experimental|Part 2: Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.
89628016|NCT03259464|Experimental|BI 685509|Chinese & Japanese subjects
89628017|NCT03259464|Placebo Comparator|Placebo|Chinese & Japanese subjects
89211253|NCT04237545|Active Comparator|T3 standard length|The T3 external hex implants available for this study will consist of lengths of 10mm, 11.5mm, 13mm, 15mm, 18mm and diameters of 4mm, 5mm, and 6mm. They have integrated platform switching (medialized implant/abutment junction). For study both configurations, T3 without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
89211254|NCT05360121|Experimental|Muscle energy technique+ Thermotherapy +Back Strengthening exercise|
89211255|NCT05360121|Active Comparator|General stretching+ Thermotherapy +Back Strengthening exercise|
89211256|NCT01563939|Active Comparator|Continuous infusion|Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.
89211257|NCT01563939|Active Comparator|Demand Bolus|Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.
89211258|NCT04004715|Experimental|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
89211259|NCT04004715|Active Comparator|Whey Protein|commercially available whey protein isolate
89211260|NCT04004715|Active Comparator|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
89211261|NCT05360043|Experimental|LPNY side|1064-nm LPNY (Gentle YAG, Candela ®, USA)
89211262|NCT05360043|Experimental|NAFL side|1565-nm NAFL(ResurFX mode, M22, Lumenis ®, Yokneam, Israel)
89628018|NCT03246282|Experimental|Treatment Group|"Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by light emitting diode(s). A small adapter attaches directly to a standard 20-guage catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the proximal end of the catheter. Polychromatic light is emitted to illuminate the catheter near the site of catheter entrance. Concurrently, normal saline flows through the optic adapter, into and through the 20-gauge catheter.~Device: UVL1000 Treatment Station Drug: Normal Saline 0.9% Infusion Solution Bag Device: Peripheral Catheterization"
89628019|NCT04754685|Active Comparator|Mild knee osteoarthritis|30 patients had mild knee osteoarthritis
89628020|NCT04754685|Active Comparator|Moderate knee osteoarthritis|30 patients had moderate knee osteoarthritis
89628021|NCT04754685|Active Comparator|Severe knee osteoarthritis|30 patients had severe knee osteoarthritis
89628022|NCT02353780|Active Comparator|Different TNF inhibitor|The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.
89628023|NCT02353780|Active Comparator|Abatacept|The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.
89628024|NCT02353780|Active Comparator|Tocilizumab|The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.
89628025|NCT03246438|Experimental|Control|Colonoscopy only outreach and follow-up
89628026|NCT03246438|Experimental|Sequential Choice|Colonoscopy outreach + mailed FIT follow-up
89628027|NCT03246438|Experimental|Active Choice|Colonoscopy + mailed FIT outreach and follow-up
89628028|NCT04775589|Experimental|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps.
89211263|NCT00990171||PD-BCM|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
89211264|NCT04004637|Experimental|CD7 CAR-T cells Infusion|
89211265|NCT03287271|Experimental|Defactinib (VS-6063) +Carboplatin/Paclitaxel|
89211266|NCT00538629||schizophrenic|patients with schizophrenia
89211267|NCT00538629||bipolar disorder|patients with bipolar disorder
89211268|NCT03163095|Active Comparator|Open Abdomen Management with ANPPT dressing|The abdominal fascia will not be closed, but a temporally abdomenal closure (TAC) dressing (such as AbThera dressing) will be placed to protect the viscera with active Negative Pressure Peritoneal drain. Formal abdominal closure or dressing change at 24-72 hours from placement should be performed.
89211269|NCT03163095|Sham Comparator|Closed Abdomen Management|Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain). Any decision to perform a re-laparotomy will be at the discretion of the treating surgical team.
89211270|NCT04232163|Experimental|Immediate Treatment Group|Participants will receive the intervention right away
89211271|NCT04232163|No Intervention|Delayed Treatment Group|Participants will receive usual care (no intervention), however, they will receive the intervention after a 3 week delay
89211272|NCT00990405|Experimental|Lansoprazole+Clarithromycin+Amoxycillin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
89211273|NCT00990639|Experimental|candesartan+UDCA group|oral candesartan(8 mg/day) in addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months
89628029|NCT03251742|Active Comparator|Fontan patient population|
89628030|NCT03251742|Sham Comparator|Healthy volunteers|
89628031|NCT04775277||cases|pregnant female with idiopathic pulmonary fibrosis
89628032|NCT04775277||control group|pregnant female with bronchial asthma
89628033|NCT02022826|Experimental|SmartPill Monitoring System|patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test
89628034|NCT04775511|Experimental|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
89628035|NCT04775511|Experimental|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
89039543|NCT04037007|Active Comparator|Conventional (guidewire) cannulation- High experience|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in high experienced endoscopists.
89039544|NCT04037007|Active Comparator|Conventional (guidewire) cannulation - Low experienced.|Conventional cannulation with an sphincterotome and 0.035 inch hydrophilic tip guidewire as the primary cannulation technique in low experienced endoscopists.
89039545|NCT04010253|Experimental|SIMEOX|
89039546|NCT04010253|Active Comparator|Autogenic Drainage|
89039547|NCT04662866|Active Comparator|Metformin|Metformin 500 mg x 1, morning, for 2 weeks, then Metformin 500 mg x 2, morning and evening for 10 weeks.
89039548|NCT04662866|Active Comparator|Empagliflozin|Empagliflozin 10 mg x 1, morning, for 2 weeks, then Empagliflozin 10 mg morning + Placebo evening for 10 weeks.
89628036|NCT04775511|Other|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
89628037|NCT03246360|Active Comparator|Intermittent administration of cloxacillin|
89628038|NCT03246360|Experimental|continuous administration of cloxacillin|
89628039|NCT01969240|Active Comparator|Chest Pain Choice Decision Aid|Patients randomized to the decision aid arm.
89628040|NCT01969240|No Intervention|Usual Care|Patients randomized to the usual care arm (no decision aid used)
89628041|NCT02455752|Active Comparator|Reroperitoneal Group|LE-TME
89628042|NCT02354092|Sham Comparator|Sham Group|"This non-intervention group will receive the sham paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~Sham Paracervical Block done with capped spinal needle~osmotic dilators placed in the usual fashion~postprocedural assessment"
89628043|NCT02354092|Experimental|Paracervical Block Group|"This intervention group will receive the paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~18 ml 1% buffered lidocaine Paracervical Block~osmotic dilators placed in the usual fashion~postprocedural assessment"
89628044|NCT00907101|Experimental|Study Treatment|"Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)~Other Names:~Epiduo® Gel Apply once daily"
89628045|NCT03251976|Experimental|Intervention|video decision aid
89628046|NCT03251976|Active Comparator|Usual care|
89628047|NCT03251664||Anemic|Hemoglobin <11 g/l
89628048|NCT03251664||Non-anemic|Hemoglobin 11 g/l (and above)
89628049|NCT02455830||Cell-treated|Infants with encephalopathy who receive autologous umbilical cord blood cell therapy along with therapeutic hypothermia.
89628050|NCT02455830||Cooled only|Infants with encephalopathy who receive therapeutic hypothermia only.
89628051|NCT03251586|Experimental|20-29|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
89628052|NCT03251586|Experimental|30-39|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
89628053|NCT03251586|Experimental|40-49|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
89628054|NCT03251586|Experimental|50-59|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
89628055|NCT03251586|Experimental|60-69|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
89628056|NCT03251586|Experimental|70-79|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
89628057|NCT03251586|Experimental|80-89|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
89628058|NCT03251586|Experimental|90-99|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
89628059|NCT04488120|Experimental|Occlutech septal occluder ( Figulla Flex II)|Occlutech septal occluder (Figulla Flex II)
89628060|NCT04488120|Active Comparator|Amplatzer Septal Occluder (ASO)|St. Jude AGA septal occluder (Amplatzer ASO)
89628061|NCT03251274|Experimental|machine bathing group|structured machine bathing for 20-min duration at evening.
89628062|NCT03251274|Active Comparator|traditional bathing group|traditional bathing at evening.
89628063|NCT04488042|Experimental|Stapler-less|after the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
89628064|NCT04488042|Active Comparator|Conventional Stapler|no reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
89628065|NCT00701064|Experimental|Bright Light Exposure|Bright Light (30 min/day)
89628066|NCT00701064|Placebo Comparator|Negative Ion Generator|Negative Ion Generator (30 min/day)
89628067|NCT03245970|Active Comparator|Treatment Arm|"Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
89628068|NCT03245970|No Intervention|Non Treatment|Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
89628069|NCT03255486|Experimental|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
89628070|NCT02454348|Active Comparator|Norepinephrine and vasopressin|Norepinephrine (0.05 to 0.5 mcg/kg/min) and vasopressin (0.04 units/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
89039549|NCT04662866|Active Comparator|Linagliptin|Linagliptin 5 mg x 1, morning, for 2 weeks, then Linagliptin 5 mg morning + Placebo evening for 10 weeks.
89039550|NCT04662866|Active Comparator|Pioglitazone|Pioglitazone 30 mg x 1, morning, for 2 weeks, then Pioglitazone 30 mg morning + Placebo evening for 10 weeks.
89039551|NCT04662476|Active Comparator|Vitamin D supplement|331 children will each received 60,000IU of vitamin D once a month for 3 months.
89039552|NCT04662476|Active Comparator|Intervention|The intervention arm will receive vitamin D3.
89039553|NCT04008927|Other|All patients|All participants recruited during the RDS survey.
89039554|NCT04008927|Other|HCV infected patients|HCV-RNA assay (GeneXpert, Cepheid) will be performed to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL)
89039555|NCT04008927|Other|Patients with hepatitis C|Patients diagnosed with chronic hepatitis C will be prescribed with DAA treatment on research site. After one month they will be referred to conventional health structure for treatment follow-up.
89039556|NCT04662437||Covid-19 Patient Group|10 ml of venous blood was taken from the forearm venous vein from people in the Covid-19 Patient Group, and the level of parathyroid hormone, calcium, phosphorus, alkaline phosphatase was measured from this blood.
89039557|NCT04662437||Healthy Control Group|10 ml of venous blood will be taken from the forearm venous vein from the healthy control group and the parathyroid hormone, calcium, phosphorus, alkaline phosphatase level will be measured from this blood.
89039558|NCT03986424|Experimental|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg once daily
89628071|NCT02454348|Active Comparator|Norepinephrine|Norepinephrine (0.05 to 0.5 mcg/kg/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
89628072|NCT02455908|Experimental|Proleukin®|"Subcutaneous administration of low doses of IL2 (Proleukin) following the therapeutical scheme indicated for crioglobulinemic nephropathy:~cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5 consecutive days, starting from 3 weeks after the first cycle.~cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first cycle.~Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first cycle."
89628073|NCT06112795||Observational|Participants attend an interview or participate in a focus group on study.
89628074|NCT06112782|Other|Keravive by Hydrafacial Treatment|Subjects will receive 3 in-office scalp Keravive by Hydrafacial treatments every 4 weeks in combination with daily application of Keravive Peptide Spray.
89039559|NCT03986424|Active Comparator|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg twice daily
89039560|NCT04662593|Experimental|Intervention Group|"The intervention group participates in a 17-week whole health program including:~Weekly, small group online meetings with a health coach;~Supportive social media including a private Facebook group and selective text messaging;~Exposure to community tree planting and stewardship (through live streaming or in-person if COVID-19 public health guidance at the time, permits."
89039561|NCT04662593|No Intervention|Control Group|The control group participates only in questionnaire data collection at baseline, 4 months, and 6 months as well as daily weighing. Control group participants will be offered 3 web-based seminars (webinars) highlighting the effective lifestyle approaches demonstrated in the study and intervention group health education materials. The webinars and materials will be provided after the 6-month data collection which concludes the study.
89039562|NCT03974451|Experimental|IOL implantation experimental|Implantation of the PhysIOL FineVision POD F® IOL
89628075|NCT06112691||main group|diabetes mellitus
89628076|NCT06112691||control group|without diagnosis of diabetes mellitus without retinal diseases
89628077|NCT06112665|Experimental|Tofactinib|Patients receive Tofacitinib and Naproxene
89628078|NCT06112665|Active Comparator|Placebo Arm|Patients receive placebo pills and Naproxene
89628079|NCT06112639|Experimental|DANCEREX Treatment|Multidimensional dance-based program with motivational support integrated into applied game. The treatment will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
89628080|NCT06112639|Active Comparator|Multidimensional dance-based program|Multidimensional dance-based program without motivational support. The treatment will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
89039563|NCT03974451|Active Comparator|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL.
89039564|NCT04661969||1|Foreign Substance disseminated to both lower extremities and buttocks
89039565|NCT04661969||2|Foreign Substance isolated to buttocks with moderate to severe skin changes
89628081|NCT06112639|Placebo Comparator|Educational Program|Educational/informative videos on managing of clinical conditions.The program will last 12 weeks with a frequency of two sessions a week, each lasting about 45 min.
89628082|NCT06112600|No Intervention|Control Group|No attention-diverting method was applied to the children in this group and routine vaccination was administered.
89628083|NCT06112600|Experimental|Virtual Reality group|The VR group received a VR application using the Oculus Quest 2 while being vaccinated.
89039566|NCT04661969||3|Foreign substance isolated to lower legs with mild skin changes and superficial ulcerations
89039567|NCT04661969||4|Foreign substance isolated to lower legs with moderate to severe skin changes and/or ulceration
89039568|NCT03943368|Experimental|Experimental: Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
89039569|NCT03943368|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
89039570|NCT03899181|Active Comparator|1 Hz 2400 TNT Treatment|Intervention: TNT treatment intervention with 2400 total stimulations with the magnetic coil..
89628084|NCT06112600|Experimental|Kaleidoscope group|In the Kaleidoscope group, children were given a kaleidoscope toy while being vaccinated.
89628085|NCT06112587|Experimental|Migraine and tension-type headache patients|Patients diagnosed by a neurologist following the 3rd edition of the International Classification of Headaches Disorders (ICHD-III)
89628086|NCT06112574|Active Comparator|Single-task|Visuomotor training
89628087|NCT06112574|Experimental|Dual-task|Visuomotor + cognitive components training
89039571|NCT03899181|Active Comparator|1 Hz 3600 TNT Treatment|Intervention: TNT treatment intervention with 3600 total stimulations with the magnetic coil.
89039572|NCT03899181|Sham Comparator|Sham TNT Treatment|This arm will have the sham treatment session. First we will assess the motor threshold intensity described above. Next, a sham coil is placed on each of 4 regions (2 lumbar & 2 sacral), and 600 stimulations will be given at each site in 2 trains, with a 5 minutes rest period between each site and 3 minutes between trains.
89039573|NCT00557141||1|Age > 18 years, Asthma with irregular or regular use of short acting beta-agonists and / or: Asthma treatment with inhaled steroids, Ability to understand the questionnaire
89628088|NCT06112548|Experimental|TKA with pain management by multimodal periarticular injection.|Patients going TKA and getting an injection of a mixture of 20ml of low body weight bupivacaine 5mg/ml plus 1ml of ketorolac 30mg/ml plus 0.5ml adrenaline 1mg/ml injected in medial and lateral retinaculum, medial and lateral collateral ligaments, quadriceps and patellar tendon, joint capsule, subcutaneous fat before closure.
89628089|NCT06112548|Experimental|TKA with pain management by IV/oral analgesics.|Patients going TKA and getting a standard pain control regime of IV opioids when needed, IV ketorolac, and IV/oral paracetamol.
89628090|NCT06112509|Other|Radiosurgery|
89628091|NCT06112483||Children and adolescents with special education needs|Children and adolescents with special education needs, including (a) specific learning difficulties; (b) intellectual disability; (c) autism; (d) attention deficit hyperactivity disorder; (e) physical disabilities.
89039574|NCT03883230||Patients with chronic wound|All patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later.
89039575|NCT00557180||BASALT|Participants in the ACRN BASALT study
89039576|NCT00557180||TALC|Participants in the ACRN TALC study
89039577|NCT03818724||CoolLoop® cryoablation system|Cryoablation for treatment of atrial fibrillation using the CoolLoop® cryoablation system
89211274|NCT00990639|Placebo Comparator|UDCA group|ursodeoxycholic acid(UDCA,600 mg/day)only for 6 months
89628092|NCT06112470||Interview|Monocentric qualitative study with a descriptive socio-demographic section, a descriptive qualitative section on the experience and perception of allergy, then on the obstacles to allergological assessment, and finally a descriptive quantitative section to evaluate knowledge of antibiotic therapy.
89628093|NCT06112405|Other|App-based CCAAP|Patients in this group will be provided App-based CCAAP to remind them take medicine regularly and direct them what to do when asthma get worse.
89628094|NCT06112405|Other|written CCAAP|Patients in this group will be provided written asthma action plan and direct them what to do when asthma get worse.
89628095|NCT06112366|Experimental|The study group used tissue adhesive for wound closure after extraction of impacted wisdom teeth|In this study of 30 patients, 21 females and 9 males, 60 fully impacted lower wisdom teeth were extracted bilaterally and in the same position. One of the bilaretal teeth of the patients was randomly selected and tissue adhesive (Periacryl 90) was applied for wound closure as an experimental group.
89628096|NCT06112366|Placebo Comparator|Control group used silk sutures after extraction of impacted wisdom teeth|Bilateral impacted wisdom teeth of the patients were randomly selected. After the tooth in the experimental group was extracted, the other impacted wisdom tooth was selected as the control group and silk sutures were used for wound closure.
89039578|NCT00557219|Placebo Comparator|Placebo|Control group receiving placebo
89628097|NCT06112340|Active Comparator|Low Dose|Active Arm Low Dose Linsitinib
89628098|NCT06112340|Active Comparator|High Dose|Active Arm High Dose Linsitinib
89628099|NCT06112288|Experimental|Compressive myofascial release (cmr)|Participants in the CMR group were instructed to lie prone on the treatment table with their feet off the end of the table. The clinician began the treatment by bending the knee to 90° and shaking the muscle belly of the triceps surae group for 30 seconds. Next, the knee was fully extended, and CMR was performed on the medial and lateral sides of the Achilles tendon for 1 minute, followed by the musculotendinous junction for 2 minutes. Treatment consisted of broad strokes applied with the clinician's knuckles to release superficial restrictions, followed by more specific strokes applied with the clinician's thumb to any located restrictions. Strokes were applied at a contact point of 45° to the tissue, with pressure directed from distal to proximal. At the end of the intervention, the clinician shook the belly of the triceps surae complex for 30 seconds. The same examiner (T.S.) applied all CMR treatments.
89628100|NCT06112288|Experimental|ankle mobilization|The joint mobilization group received two sets of ankle joint mobilizations. Each set consisted of two-minutes of Grade III anterior-to-posterior talocrural joint mobilizations with a one-minute rest between sets with the patient in a long-sitting position. This mobilization was operationally defined as large-amplitude, one-second rhythmic oscillations from the mid- to end ROM with translation taken to tissue resistance
89628101|NCT06112223|Experimental|Gabapentin|Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
89628102|NCT06112223|Experimental|Tramadol|Patients will receive oral tramadol 100 mg 1 hour before the surgery.
89628103|NCT06112210|Experimental|HBOT group|
89628104|NCT06112210|Placebo Comparator|CON group|
89628105|NCT06112145|Experimental|group I|Flexor tendon zon II rupture patients
89628106|NCT06112145|Experimental|group II|Flexor tendon other zon rupture patients
89039579|NCT00557219|Experimental|Ketanserin|patients receiving ketanserin infusion
89039580|NCT00557219|Experimental|Fenoldopam|patients receiving fenoldopam infusion
89039581|NCT03798405|Experimental|Proactive|"Proactive Analgesic Inpatient Narcotic-Sparing:~Pain management in patients in the proactive physician-behavior group will be based on the IBD Pain orderset in our EMR. This orderset is already in use and standard-of-care at Cedars. The orderset uses pain medications, which have evidence for use in IBD. The orderset is simply a guide to clinicians and does not force any doctor or patient to be in a protocol."
89628107|NCT06112119||cohort|patients >16y with sepsis associated with disturbance in conscious level, the first braun CT scan will be routinely performed on admission, the second further brain CT Scan will be obtained whenever prolonged disturbance of consciousness will be detected.
89628108|NCT06112067|Experimental|DBS intervention group|This is a single arm, prospective, open label clinical study, participants who fit inclusion standards, don't fit exclusion standards and fit surgical implantation standard will start DBS system stimulation and adjust parameters after 7-14 days of implantation. Then after stimulation for 8-24 weeks, they will be evaluated for treatment efficacies. This study is extendable, with agreements from participants, long term efficacy and safety follow-up study will be performed after 24 weeks ± 7 days, specific plan depends on different mental disorders.
88990055|NCT04326257|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be dosed at 3mg/kg IV q 2 weeks and Ipilimumab 1mg/kg IV q 6 weeks.~Patients will receive four doses of Ipilimumab and the last dosage of Nivolumab 3mg/kg IV q 2 weeks will be given at the time of the 4th dose of Ipilimumab, followed 2 weeks later by Nivolumab 480 mg IV q 4 weeks. A cycle of therapy will be defined as 4 weeks of treatment. The patient will receive the prescribed therapy continuously for up to 24 cycles until progression of disease or adverse event(s) requiring treatment discontinuation."
88990056|NCT04313244|Experimental|9vHPV+TDV|Participants will receive 0.5 mL 9vHPV intramuscularly (IM) with 0.5 mL TDV subcutaneously (SC) once on Day 1 (Month 0) followed by 0.5 mL TDV SC once on Day 90 (Month 3) and 0.5 mL 9vHPV IM once on Day 180 (Month 6).
88990057|NCT04313244|Experimental|9vHPV|Participants will receive 0.5 mL 9vHPV vaccine IM once on Day 1 (Month 0) followed by 0.5 mL 9vHPV vaccine IM once on Day 180 (Month 6).
88990058|NCT04310410|Experimental|Combined Focused Ultrasound and Radiotherapy|Combination of focused ultrasound and external beam radiotherapy
88990059|NCT04307914|Active Comparator|External Beam Radiotherapy|In the control arm, patients will undergo standard radiotherapy for painful bone metastases.The radiation schedule is at the discretion of the treating radiation oncologist.
88990060|NCT04307914|Experimental|MR-HIFU|In the intervention arm, patients will be offered MR-HIFU treatment instead of standard radiotherapy. Treatment will be given following the international guidelines for MR-HIFU.
88990061|NCT04307914|Experimental|Combination EBRT + MR-HIFU|In the combination arm, patients will undergo standard radiotherapy followed by MR-HIFU in a short timeframe.
88990062|NCT04307381|Experimental|Donidalorsen|Participants will be administered donidalorsen SC for up to 53 weeks. Participants will also be administered donidalorsen in the extended treatment period for an additional 156 weeks, up to week 209.
88990063|NCT04305184|Experimental|Single Ascending Dose (SAD): 0.03 mcg|Participants received single dose of 0.03 microgram (mcg) ASP0598 Otic Solution into the affected ear on day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 [End of Study (EOS)].
88990064|NCT04305184|Experimental|SAD: 0.15 mcg|Participants received single dose of 0.15 mcg ASP0598 Otic Solution into the affected ear on Day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 (EOS).
88990065|NCT04305184|Experimental|SAD: 0.75 mcg|Participants received single dose of 0.75 mcg ASP0598 Otic Solution into the affected ear on day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 (EOS).
88990066|NCT04305184|Experimental|SAD: 2.25 mcg|Participants received single dose of 2.25 mcg ASP0598 Otic Solution into the affected ear on day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 (EOS).
89211275|NCT04211727||Cohort 1|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
89211276|NCT04211727||Cohort 2|Patients receiving standard of care systemic anti-cancer therapy for solid organ malignancy and has received at least one cycle aged 18 years and over.
89628109|NCT06112041|Experimental|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
88990067|NCT04305184|Placebo Comparator|SAD: Placebo|Participants received single dose of placebo matched to ASP0598 Otic Solution into the affected ear on day 1 and returned to the investigative site for assessments on days 2, 3, 8, 15, 29, and 57 (EOS).
88990068|NCT04305184|Experimental|Multiple Ascending Dose (MAD): 0.75 mcg|Participants received multiple doses of 0.75 mcg ASP0598 Otic Solution into the affected ear on days 1, 15 and 29 and returned to the investigative site for assessments on days 8, 15, 22, 29, 36, 57, and 85 (EOS).
88990069|NCT04305184|Experimental|MAD: 2.25 mcg|Participants received multiple doses of 2.25 mcg ASP0598 Otic Solution into the affected ear on days 1, 15 and 29 and returned to the investigative site for assessments on days 8, 15, 22, 29, 36, 57, and 85 (EOS).
88990070|NCT04305184|Placebo Comparator|MAD: Placebo|Participants received multiple doses of placebo matched to ASP0598 Otic Solution into the affected ear on days 1, 15 and 29 and returned to the investigative site for assessments on days 8, 15, 22, 29, 36, 57, and 85 (EOS).
88990071|NCT04304040|Experimental|Single Arm|
88990072|NCT04301765|Experimental|testosterone 1.62% gel|Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
88990073|NCT04301765|Placebo Comparator|placebo gel|The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
88990074|NCT04289467|Experimental|Fenfluramine treatment|Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.
88990075|NCT04287959|Active Comparator|A: wean to 30%|wean to 30% oxygen on high flow and then turn off high flow support and place onto standard low flow oxygen.
88990076|NCT04287959|Active Comparator|B: wean to 21%|wean to 21% oxygen on high flow and then turn off high flow support and place directly into air.
89211277|NCT03742947|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
89211278|NCT03742947|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL)
89211279|NCT04003935||Control|Continuing habitual diet and lifestyle.
89628110|NCT06112028|Experimental|Experimental group|In addition to oral aspirin enteric coated tablets (0.1g qd), Clopidogrel bisulfate tablets (75mg qd), rosuvastatin calcium tablets (10mg qd) or atorvastatin calcium tablets (20mg qd), Tongxinluo capsule (Shijiazhuang Yilin Pharmaceutical Co., LTD.) was added to 0.78g TID for continuous treatment for 12 months.
89628111|NCT06112028|Sham Comparator|control group|Take aspirin enteric coated tablets (0.1g qd), Clopidogrel bisulfate tablets (75mg qd), Rosuvastatin calcium tablets (10mg qd) or atorvastatin calcium tablets (20mg qd) orally.
89628112|NCT06112002|Experimental|Health Services Research (educational session and materials)|Participants attend an educational session with CHEs and receive educational materials on study.
89039582|NCT03798405|No Intervention|Reactive (Control Group)|Pain management in patients in the reactive group (control group) will follow traditional prescribing habits. As different providers vary in the way they treat pain, analgesic medication prescribing in the control group will be inherently variable in nature. The control group does not constitute a lack of treatment or placebo; rather, pain management in the control group will not be proactive as in the intervention group.
89039583|NCT03796338||Critically ill patients|age > 18 years
89628113|NCT06111989||Stroke patients|Patients who suffered ischemic or hemorrhagic stroke.
89628114|NCT06111976|Experimental|rTMS with simultaneous reactivation of traumatic memory in resistant PTSD|rTMS with simultaneous reactivation of traumatic memory in resistant PTSD during 12 sessions (3 to 4 weeks)
89628115|NCT06111976|Placebo Comparator|sham rTMS and simultaneous reactivation of traumatic memory in resistant PTSD|sham rTMS and simultaneous reactivation of traumatic memory in resistant PTSD during 12 sessions (3 to 4 weeks)
89628116|NCT06111950|Other|RNU4ATAC patient|Patient with bi-allelic mutation of the RNU4ATAC gene
89628117|NCT06111950|Other|RNU4ATAC fetus|Fetus with bi-allelic mutation of the RNU4ATAC gene
89628118|NCT06111950|Other|RNU4ATAC parent|Parent of patient or fetus with bi-allelic mutation of the RNU4ATAC gene and who present themselve mono-allelic mutation of the RNU4ATAC gene
89628119|NCT06111950|Other|RTTN patient|Patient with bi-allelic mutation of the RTTN gene
89628120|NCT06111950|Other|RTTN fetus|Fetus with bi-allelic mutation of the RTTN gene
89628121|NCT06111924|Experimental|Task oriented circuit training based telerehabilitation (TOCT-TR) group|This group will recieve Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call in 18 sessions.
89628122|NCT06111924|Experimental|Clinic based Task oriented circuit training (TOCT-CR) group|This group will recieve In person treatment at clinical setting that will be Task oriented circuit training based telerehabilitation in 18 sessions.
89628123|NCT06111911|Experimental|Urine Specimen|
89628124|NCT06111911|Experimental|Cervical Swab Specimen|
89628125|NCT06111885|Active Comparator|Indapamide + Hydrochlorothiazide + Chlorthalidone|1 capsule containing 2.5 mg indapamide per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 50 mg hydrochlorothiazide per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 25 mg chlorthalidone per day for 28 days.
89628126|NCT06111885|Active Comparator|Hydrochlorothiazide + Chlorthalidone + Indapamide|1 capsule containing 50 mg hydrochlorothiazide per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 25 mg chlorthalidone per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 2.5 mg indapamide per day for 28 days.
89628127|NCT06111885|Active Comparator|Chlorthalidone + Indapamide + Hydrochlorothiazide|1 capsule containing 25 mg chlorthalidone per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 2.5 mg indapamide per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 50 mg hydrochlorothiazide per day for 28 days.
89628128|NCT06111885|Active Comparator|Hydrochlorothiazide + Indapamide + Chlorthalidone|1 capsule containing 50 mg hydrochlorothiazide per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 2.5 mg indapamide per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 25 mg chlorthalidone per day for 28 days.
89628129|NCT06111885|Active Comparator|Indapamide + Chlorthalidone + Hydrochlorothiazide|1 capsule containing 2.5 mg indapamide per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 25 mg chlorthalidone per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 50 mg hydrochlorothiazide per day for 28 days.
89628130|NCT06111885|Active Comparator|Chlorthalidone + Hydrochlorothiazide + Indapamide|1 capsule containing 25 mg chlorthalidone per day for 28 days, followed by a 28 days wash out phase, followed by a second treatment phase with 1 capsule containing 50 mg hydrochlorothiazide per day for 28 days, followed by a 28 days wash out phase, followed by a third treatment phase with 1 capsule containing 2.5 mg indapamide per day for 28 days.
89039584|NCT00539916|Experimental|Jus d'orange|
89628131|NCT06111859|Experimental|Liver Biopsy Cohort|
89628132|NCT06111833||Case (MODY)|"Age at diagnosis of diabetes ≤ 25 years old; and~BMI ≤ 25kg/m2; and~At least one parent suffers from type 2 diabetes"
89628133|NCT06111833||Family|Direct blood relatives/brothers and sisters of the Case group, who have contacted the research team through the subjects and are willing to participate in this study after giving full informed consent.
89628134|NCT06111833||Control|"Age at diagnosis of diabetes ≤ 40 years old, and without typical MODY characteristics~At least one parent suffers from type 2 diabetes"
89039585|NCT00539916|Placebo Comparator|Boisson contrôle|
89039586|NCT04661618|Active Comparator|GT|12 weeks of progressive training in the first phase and 12 weeks of maintenance training in the second phase.
89039587|NCT04661618|Other|Control|"No intervention for the first phase and will be active comparator in the second phase.~No intervention for the first 12 weeks (first phase) and 12 weeks of progressive training in the second phase."
89039588|NCT00539955|Other|1|Standard 40 hour state-mandated batterer intervention
89628135|NCT06111820|Experimental|iACT service users|All participants enrolled in the programme will participate in the iACT service referring to the aforementioned details.
89628136|NCT06111768|Experimental|SGLT2i administration|A 10 mg oral dose of dapagliflozin will be administered daily for three days.
89628137|NCT06111768|No Intervention|Usual Care|Subjects continue with usual care.
89628138|NCT06111716|Active Comparator|Information-Based Childbirth Education Group|"Information-Based Birth Preparation Education Content; Physical and mental preparation for birth, the birth process, non-pharmacological methods that reduce birth pain and facilitate birth, postpartum period characteristics, physiological and psychological effects on the mother after birth.It includes topics such as changes, adaptation to the maternal role, newborn care. Education is information-based, not based on a philosophy or model."
89628139|NCT06111716|Experimental|Mindfulness-Based Childbirth Education Group|Mindfulness-Based Childbirth Education includes topics related to birth as well as mindfulness, mindfulness attitudes and practices, mindfulness in daily life, mindfulness during pregnancy and postpartum period, mindfulness breastfeeding and meditation practices. The training duration is 8 weeks (2 hours each week).
89628140|NCT06111690|Experimental|Preoperative Exercises|Intervention is blood flow restriction training (BFRT)
89628141|NCT06111638|Experimental|Arm of BBM-H803|The dose of BBM-H803 will be calculated according to participant's weight
89628142|NCT06111625|Experimental|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion. Patients underwent myeloablative conditioning therapy consisting of fludarabine-and-busulfan-based regimen. Peripheral stem cells from HLA-matched sibling donors (MSD), matched unrelated donors (MUD), or haploidentical donors (HID) were reinfused two days after conditioning. Follow-up examinations were scheduled at +1, +2, +3, +4, +6, +9, +12, +18, and +24 months post-transplant.
89628143|NCT06111599|Experimental|Group A|Proximal arterial obliteration
89628144|NCT06111599|Experimental|Group B|Distal arterial obliteration
89628145|NCT06111599|Experimental|Group C|Complex arterial obliteration
89628146|NCT06111560||Patients with tumor progression or recurrence|Patients enrolled in our retrospective study with tumor progression or recurrence
89628147|NCT06111560||Patients without tumor progression or recurrence|Patients enrolled in our retrospective study without tumor progression or recurrence
88990077|NCT04285879|Experimental|BFR Exercise Group|"In addition to the standard ACL protocol, patients in this study will utilize the Owen Recovery Science exercise protocol for BFR [18]. The following guidelines will be followed concerning exercise progression, occlusion pressure and difficulties with volume achievement.~A total of 20 youth and adolescent patients undergoing a surgical procedure for ACL reconstruction at Connecticut Children's Elite Sports Medicine and completing physical therapy at Connecticut Children's Sports Physical Therapy will be recruited for this study."
88990078|NCT04285879|No Intervention|Non-BFR exercise group|As part of this pilot study, the investigators will additionally collect prospective controls. This population will be patients not participating in physical therapy at Connecticut Children's but underwent ACL reconstruction by Elite Sports Medicine
88990079|NCT04276259|Experimental|Buprenorphine Injection + Oral Placebo Pill|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~6 hours) and an oral placebo tablet.
88990080|NCT04276259|Experimental|Naltrexone Oral Tablet + Intramuscular Saline Injection|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: ~1 hour; duration: ~24 hours) and a saline IM injection.
89628148|NCT06111534|Experimental|MHC group|Each MHC group participant (n=30) was brought to the procedure room by its mother. The mother sat in a comfortable chair with back support. She held her baby close to her chest, with the baby's head in a crossed position so that it could see its mother. The same nurse collected the blood sample. The mother communicated with the baby verbally and made eye contact with it to calm it down during the procedure. She was holding the baby both during and after the procedure.
89628149|NCT06111534|Experimental|PHC group|Each PHC group participant (n=30) was brought to the procedure room by its father. The father sat in a comfortable chair with back support. He held his baby close to his chest, with the baby's head in a crossed position so that it could see its father. The same nurse collected the blood sample. The father communicated with the baby verbally and made eye contact with it to calm it down during the procedure. He was holding the baby both during and after the procedure.
89628150|NCT06111534|No Intervention|Control group|The control group participants (n=32) underwent the procedure according to the routine clinical practice. Either parent brought the baby into the procedure room and laid it on the procedure table in the supine position. The nurse collected the blood sample. The parent was present in the room and communicated with the baby only verbally during the procedure. The parent picked up the baby after the procedure.
89039589|NCT00539955|Other|2|Brief alcohol intervention combined with standard batterer intervention
89039590|NCT04661696|Experimental|single-arm|Paclitaxel (albumin-bound) 130 mg/m2, i.v., d1, 8; Carboplatin AUC 5, i.v. d1; repeat every 21days, 6 cycles.
89039591|NCT03766191|Active Comparator|Food Ads and fMRI|Exposure to food ads during an fMRI scan
89039592|NCT03766191|Sham Comparator|Non-Food Ads and fMRI|Exposure to non-food ads during an fMRI scan
89628151|NCT06111521|Experimental|LY3537982 + Digoxin & Rosuvastatin (Part 1)|Single oral doses of digoxin and rosuvastatin with or without multiple doses of LY3537982 administered orally
89628152|NCT06111521|Experimental|LY3537982 + Midazolam (Part 2)|Single doses of midazolam administered either orally or intravenously (IV) with or without multiple doses of LY3537982 administered orally
89628153|NCT06111482|Experimental|IPL only|Group A will be treated with an intense pulsed light (IPL) device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar IPL device that is cleared for use by the FDA.
89039593|NCT03766191|Active Comparator|Food Ads and TV show|Exposure to food ads embedded in an age-appropriate TV program
89039594|NCT03766191|Sham Comparator|Non-Food Ads and TV show|Exposure to non-food ads embedded in an age-appropriate TV program
89039595|NCT06087536|Experimental|OMN6 treatment|OMN6 on top of Meropenem and Colistin
89039596|NCT06087536|Placebo Comparator|Placebo|Placebo on top of Meropenem and Colistin
89628154|NCT06111482|Experimental|RF Microneedling Only|Group B will be treated with a radiofrequency (RF) microneedling device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF microneedling device that is cleared for use by the FDA.
89628155|NCT06111482|Experimental|RF Only|Group C will be treated with an RF device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF device that is cleared for use by the FDA.
89628156|NCT06111482|Experimental|Combination|Group D will receive combination treatments and will be treated with 2 or more of the study devices.
89628157|NCT06111456||Population 1Q|Parents or co-parents of a newborn child.
89628158|NCT06111456||Population 2|Parents or co-parents whose youngest child is 1 week to 3 years old.
89628159|NCT06111456||Population 3|Parents or co-parents whose child had a suspicious newborn screening result that was confirmed at the diagnosis phase (except hearing).
89628160|NCT06111456||Population 4|Parents or co-parents whose child was diagnosed later based on clinical signs for diseases not included in the list of diseases screening in French newborn screening, but included in the list of diseases screened in newborn screening in other countries.
89628161|NCT06111417||Standard arm|Analysis carried out using the gold standard with BRCA1/2 results provided on average in 2 months + ultrafast BRCA1/2 test (nanopore test) with no communication of results to the patient at 1-2 weeks.
89628162|NCT06111417||Experimental arm|Analysis carried out using the gold standard with BRCA1/2 results provided in an average of 2 months + ultra-rapid BRCA1/2 test (nanopore test) with results communicated to the patient in 1-2 weeks. This communication will be accompanied by the necessary explanations to enable the patient to understand that this is a preliminary result and that only the gold standard will constitute a definitive result.
89628163|NCT06111404|Active Comparator|Group A (central group)|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
89628164|NCT06111404|Active Comparator|Group B (lateral group)|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
89628165|NCT06111391|Active Comparator|maxillary titanium zirconium full arch fixed prosthesis|maxillary titanium zirconium full arch fixed prosthesis and mandibular distal extension partial denture.
89628166|NCT06111391|Active Comparator|maxillary peek composite full arch fixed prosthesis|maxillary peek composite full arch fixed prosthesis and mandibular distal extension partial denture.
89628167|NCT06111378||Group 1:|control group (n:7)
89628168|NCT06111378||Group 2:|fish oil group (n:7)
89628169|NCT06111378||Group 3:|linseed oil group (n:7)
89628170|NCT06111378||Group 4:|walnut oil group (n:7)
89628171|NCT06111378||Group 5:|sham group (non-lactating rats) (n:4)
89628172|NCT06111365||IVF|Women undergoing fresh IVF treatment using their own eggs or donor eggs
89628173|NCT06111352|Experimental|Group A|"Patients will be treated with Atropine plus pralidoxime~Pralidoxime: Dosage:1gram; Dosage form: Intravenous infusion; Frequency: 8 hourly~Atropine:"
89628174|NCT06111352|Other|Group B|Patients will be treated with only atropine
89039597|NCT06087471|Sham Comparator|Control snack|42 participants will be randomly assigned to the control snack. Snacks should be consumed twice per day, once as a mid-morning snack and again as a mid-afternoon snack.
89039598|NCT06087471|Experimental|Experimental snack|42 participants (50%) will be randomly assigned to snack on the intervention snack. Snacks should be consumed twice per day, once as a mid-morning snack and again as a mid-afternoon snack.
89039599|NCT06087289|Experimental|Part 1: Dose escalation to determine Recommended Phase II Dose (RPIID)|"Part 1 of the study will include escalating doses of KAND567 administered in combination with carboplatin (according to standard of care) to approximately 10 subjects in total (may range from 6 to 24 subjects depending on DLTs). Carboplatin will be given on Day 1 of the 21-day cycle at a dose of AUC 5 according to standard of care. KAND567 will be orally administered during the first 2 weeks (Days 2 to 14) of each 21-day carboplatin cycle for up to 6 treatment cycles (or until unacceptable toxicity or disease progression).~KAND567 dose escalation will apply for the first week (Days 2 to 7) of the treatment cycle. During the second week of the treatment cycle (Days 8 to 14), KAND567 will be administered at a fixed dose of 250 mg BID to all subjects. Doses of KAND567 will be escalated according to an adaptive, intra-individual dose escalation design."
89211280|NCT04003935||Active 1|Ingestion of a macro- and micro-nutrient rich shake, otherwise continuing habitual diet and lifestyle.
89211281|NCT04003935||Active 2|Ingestion of an encapsulated vitamin and phytonutrient supplement, otherwise continuing habitual diet and lifestyle.
89628175|NCT06111326|Experimental|BC3402+Durvalumab|Subjects will receive BC3402 and Durvalumab in a treatment cycle.
89628176|NCT06111300|Experimental|group d|Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery.
89628177|NCT06111300|Placebo Comparator|group c|Patients in this group will receive volume- matched normal saline infusion (NaCL 0.9%) as a placebo.
89039600|NCT06087289|Experimental|Part 2: Expansion cohort to evaluate RPIID|"An expansion cohort will be enrolled in Part 2 of the study to further evaluate the RPIID (approximately 20 subjects; may range from 6 to 24 subjects, depending on Part 1). If the number of subjects with confirmed CX3CR1 expression in tumor cells is below 50%, an additional 15 subjects may be included in Part 2 of the study.~Carboplatin will be given on Day 1 of the 21-day cycle at a dose of AUC 5 according to standard of care. For KAND567, the RPIID will be orally administered to the cohort during the first week of each carboplatin cycle (Days 2 to 7). During the second week of the treatment cycle (Days 8 to 14), KAND567 will be administered at 250 mg BID. Up to 6 treatment cycles will be given (or until unacceptable toxicity or disease progression)."
89039601|NCT06087263|Experimental|Regorafenib|
89039602|NCT06087250||Fluid responsive|"A 15% increase in cardiac output following a fluid challenge ( 6ml/kg crystalloid solution infusion in 30 min).~Carotid corrected flow time measured before and after fluid challenge by ultrasound."
89039603|NCT06087250||Fluid non-responsive|"Failure of 15% increase in cardiac output following a fluid challenge ( 6ml/kg crystalloid solution infusion in 30 min).~Carotid corrected flow time measured before and after fluid challenge by ultrasound."
89039604|NCT06087211|Active Comparator|Duloxetine and magnesium sulphate|this group will receive Duloxetine orally and magnesium sulphate intravenous infusion 1 hour before surgery.
89039605|NCT06087211|Active Comparator|Duloxetine|this group will receive Duloxetine orally and 200ml normal saline infusion
89628178|NCT06111274|Experimental|ABSK021 with chemotherapy|There are 2 cohorts in both part A and Part B. In cohort 1, the participant will receive the treatment of ABSK021 in combination with chemotherapy (the Gemcitabine and nab-Pacilitaxel) , 3 weeks as one cycle, about 8 cycles in total.
89628179|NCT06111274|Experimental|ABSK021 in combination with chemotherapy plus the Toripalimab|There are 2 cohorts in both part A and Part B. In cohort 2, the participant will receive the treatment of ABSK021 in combination with chemotherapy (the Gemcitabine and nab-Pacilitaxel), with Toripalimab, 3 weeks as one cycle, about 8 cycles in total.
89039606|NCT06087211|Placebo Comparator|control|this will receive placebo capsule and an IV infusion of 200ml normal saline
89628180|NCT06111261|Experimental|Albumin-massive transfusion protocol|At the initiation of MTP, 200ml of 20% albumin will be infused followed by transfusion of packed RBC:FFP:Platelet concentrate with ratio of 1:1:1.
89628181|NCT06111261|Active Comparator|Conventional-massive transfusion protocol|At the initiation of MTP, Balanced crystalloid will be infused followed by transfusion of packed RBC:FFP:Platelet concentrate with ratio of 1:1:1. Albumin will be transfused according to the serum albumin level.
89628182|NCT06111209|Active Comparator|Testosterone|Testosterone Cypionate 25-mg weekly by intramuscular injection
89628183|NCT06111209|Placebo Comparator|Placebo|Placebo intramuscular injections weekly
89628184|NCT06111183|Experimental|AUP1602-C|AUP1602-C is administered topically during the treatment period.
89628185|NCT06111183|Placebo Comparator|Placebo|Placebo is administered topically during the treatment period.
89628186|NCT06111170|Active Comparator|Compression dressing|Compression dressing was applied to one of the eyelids which was chosen by randomization postoperatively
89628187|NCT06111170|No Intervention|no dressing|No dressing was applied on the other eyelid (control group)
89628188|NCT06111118|Experimental|Immediate ThermaCare HeatWraps|Immediately after the completion of standardized exercise ThermaCare HeatWraps will be applied on each leg centered over the quadriceps and lying longitudinally over the muscle for 8 hours. The application of a new ThermaCare HeatWraps will be repeated in the same manner, for 8 hours each, at 24 and 48 hours after exercise (i.e., 3 applications in total).
89628189|NCT06111118|Experimental|Delayed ThermaCare HeatWraps|On Day 2, 24 hours after the completion of standardized exercise, Group 2 subjects will apply ThermaCare HeatWraps in the same manner as described above for 8 hours. Subsequent heat wraps will be applied for 8 hours each at 48 and 72 hours after exercise (i.e., 3 applications in total).
89628190|NCT06111118|No Intervention|No treatment|Standardized exercise alone
89628191|NCT06111066||vitamin D deficiency|The umbilical cord blood 25(OH)D levels: <30nmol/L
89628192|NCT06111066||vitamin D insufficiency|The umbilical cord blood 25(OH)D levels: 30~50nmol/L
89628193|NCT06111066||vitamin D sufficiency|The umbilical cord blood 25(OH)D levels: >50~250nmol/L
89039607|NCT06087172||Hypertensive Individuals|Patients diagnosed with arterial hypertension
89039608|NCT06087159|Experimental|mWEL Intervention|Teachers or parents of children in participating schools who are randomly assigned to receive the mWEL intervention.
89039609|NCT06087159|No Intervention|Control|Teachers or parents of children in participating schools who are randomly assigned to the control arm.
89628194|NCT06111053|Experimental|ENDS and CI|Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking as well as 6 weeks' worth of provisions of ENDS and will receive 4 weeks of monetary incentives for complete abstinence from smoking (after a controlled ramp down of smoking).
89628195|NCT06111053|Experimental|No ENDS and CI|Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking and will receive 4 weeks of monetary incentives for complete abstinence from smoking (after a controlled ramp down of smoking).
89628196|NCT06111053|Experimental|ENDS and NI|Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking as well as 6 weeks' worth of provisions of ENDS and will receive monetary incentives for providing breath samples only (non-contingent on smoking status).
89628197|NCT06111053|Experimental|No ENDS and NI|Participants in this arm will receive information about the comparative risk of electronic nicotine devices (ENDs) relative to smoking and will receive monetary incentives for providing breath samples only (non-contingent on smoking status).
89628198|NCT06111027|Experimental|Intervention|Will use the device, single group
89628199|NCT06111001|Active Comparator|Active Study Group|Participants actively using the AirEmail v1 Digital Tool features.
89628200|NCT06111001|Placebo Comparator|Contemporary Observational Group|Participants whose email use data is collected via the AirEmail v1 Digital Tool
89628201|NCT06110988|Experimental|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assisted PCI
89628202|NCT06110949||At home hospitalization cohort|Participants admitted with acute medical diseases to at home hospitalization units will be included in a prospective registry in order to investigate the 90 days incidence of thromboembolic disease. A group of such patients will be controlled with triaxial accelerometer in order to collect raw data regarding patient mobility during admission.
89628203|NCT06110949||Conventional hospitalization cohort|Participants admitted with acute medical diseases to a conventional hospitalization unit will be included in a prospective registry in order to investigate the 90 days incidence of thromboembolic disease. A group of such patients will be controlled with triaxial accelerometer in order to collect raw data regarding patient mobility during admission.
89628204|NCT06110923|Experimental|A1 (Test group)|CKD-846 A, Single dose
89628205|NCT06110923|Experimental|R (Reference group)|D091, Multi dose
89628206|NCT06110923|Experimental|A2 (Test group)|CKD-846 A, Single dose
89628207|NCT06110923|Experimental|B2 (Test group)|CKD-846 B, Single dose
89628208|NCT06110923|Experimental|A3 or B3 (Test group)|CKD-846 A or B, Single dose
89628209|NCT06110910||prospective cohort|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
89628210|NCT06110910||retrospective cohort|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
89628211|NCT06110910||ambispective cohort|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
89628212|NCT06110884|Experimental|Music therapy group|
89628213|NCT06110884|Active Comparator|Control group|
89628214|NCT06110871|Experimental|Working Group 1(inhaled lavender)|In study group 1, 3 drops of lavender oil will be dropped on aromastone and participants will be asked to inhale deeply 10 times. Then, participants will be allowed to inhale lavender oil for a total of 30 minutes in the waiting room where aromastone is located and in the ria application room.
89628215|NCT06110871|Experimental|Working Group 2: Focusing|"After the internet connection is established with the smartphone, you can click on www.youtube.com and watch the Relaxation Project 1 (SBS VR) video for the image and ask to focus."
89628216|NCT06110871|Experimental|Working Group 3 music|You will be able to listen to Turkish classical music for a total of 30 minutes in the RIA application waiting room and RIA application room.
89628217|NCT06110871|No Intervention|Control Group|The care and practices will be the same as in routine IUD application.
89628218|NCT06110819|Experimental|Workgroup|.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health.
89628219|NCT06110819|Other|Control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
89628220|NCT06110806|Experimental|Mindfulness-based interoceptive exposure (MBIE)|Outpatient therapy for individuals with ARFID using mindfulness and exposures in a family-based therapy approach.
89628221|NCT06110767|Experimental|Routine diet + Non-immersive virtual reality-based physical activity application|Non-immersive virtual reality will be applied 30 minutes a day, 3 days a week for 4 weeks.
89628222|NCT06110767|Experimental|Diet Program for healthy eating + Non-immersive virtual reality-based physical activity app|In addition to the 4-week diet program,Non-immersive virtual reality will be applied 30 minutes a day, 3 days a week for 4 weeks.
89628223|NCT06110767|Experimental|Diet program for healthy eating|4-week diet program will be applied.
89628224|NCT06110741||Sampling and survey group|This group will complete questionnaires and participate in sample collection.
89628225|NCT06110741||Survey group|This group will only complete questionnaires
89628226|NCT06110702|Experimental|8-week EMDR Intervention|"Phase 1: The therapist and client develop a secure working relationship. The client's history is discussed and a treatment plan is developed.~Phase 2: The therapist explains the EMDR therapy process. Phase 3: The target event is identified. Baseline measures are set using the Subjective Units of Disturbance (SUD) and the Validity of Cognition (VOC) scale.~Phase 4: Desensitization, sounds, or taps are begun while focusing on the traumatic event until the client's SUD reduces to zero.~Phase 5: The client associates and strengthens a positive belief with the target event until it feels true.~Phase 6: The client is asked to hold in mind the target event and the positive belief while scanning the body.~Phase 7: Reprocessing is complete when the client feels neutral about it (SUD=0, VOC=7), and the body is clear of disturbance.~Phase 8: The client and therapist discuss processed memories to ensure that distress is low and that the positive cognition is strong."
89628227|NCT06110702|No Intervention|Control condition - No intervention|The control group will follow routine daily activities
89628228|NCT06110676|Experimental|LZM012 Q4W|Patients receive 320mg of LZM012 treatment once every 4 weeks
89628229|NCT06110676|Experimental|LZM012 Q4W-Q8W|Patients receive 320mg of LZM012 treatment once every 4 weeks till 12th week, then once evey 8 weeks
89628230|NCT06110676|Active Comparator|Active control|Patients receive 300mg of secukinumab treatment once every 4 weeks
89628231|NCT06110663|Experimental|HS-10241+Almonertinib|Experimental group (Experimental): HS-10241 combined with Almonertinib NSCLC with MET amplification after failure of EGFR-TKI treatment randomized to HS-10241 combined with Almonertinib
89628232|NCT06110663|Active Comparator|Pemetrexed + Cisplatin /Carboplatin|Control group (Active Comparator): Pemetrexed combined with Platinum NSCLC with MET amplification after failure of EGFR-TKI treatment randomized to standard chemotherapy treatment of platinum-based chemotherapy
89039610|NCT06087094|Experimental|Cohor 1: HRS-7450 dose 1 or Placebo;|
89628233|NCT06110377|Active Comparator|MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)|After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
89628234|NCT06110377|Experimental|MMP (INJECTIONS WITH TATTOO MACHINE)|After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
89628235|NCT06109870|Experimental|PRECEDE-PROCEED|To identify predisposing, enabling, and reinforcing factors that could influence women's decision to participate in self-sample HPV testing and diagnostic follow-up.
89628236|NCT06109129|Experimental|Intervention Group|First group will participate in the Mollii Suit application for 60 minutes 3 days a week. Mollii Suit consists of a pair of trousers and a jacket. It is a neuromodulation garment consisting of a non-invasive removable control unit that sends electrical signals to the user through electrodes inside. The child will wear the Molli Suit when he/she comes to each session, and the child will be asked to sit or lie down throughout the application in order to avoid any interference with the effectiveness of the suit.
89628237|NCT06109129|No Intervention|Control Group|The control group will continue the routine pediatric physiotherapy program 3 days a week. This program, which includes exercises appropriate to the child's motor function level, includes stair climbing, walking exercises, balance, strengthening and flexibility exercises.
89628238|NCT06107829|Experimental|Valbenazine|This an open-label study in which all participants will have their valbenazine dose titrated from 40 mg to 80 mg per day, which will remain the valbenazine dose through end of study, unless interrupted by adverse events. Participants taking valbenazine who are concurrently taking strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, duloxetine) will continue their valbenazine dose at 40 mg per day through end of study. Participants taking valbenazine who are concurrently taking strong CYP3A4 inhibitors (ketoconazole, fluconazole, cimetidine, verapamil) will continue their valbenazine dose at 40 mg per day through end of study.
89628239|NCT06107270|Experimental|Group A|(n=15) will be treated by Post Isometric Relaxation, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks).
89628240|NCT06107270|Experimental|Group B|(n=15) will be treated by DNF training, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks)
89628241|NCT06107270|Experimental|Group C|(n=15) will be treated by Post Isometric Relaxation combined DNF training, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks)
89628242|NCT06105710||Asthma|Participants with a history of asthma
89628243|NCT06105710||Healthy Controls|Participants without a history of asthma
89628244|NCT06105645|Experimental|Arm with fast-ripples information|Patients for whom 4-6 usual clinical macro-electrodes will be replaced by hybrid micro-macro electrodes and for whom fast-ripples will be assessed
89628245|NCT06105645|Active Comparator|Arm without fast-ripples information|Patients who will undergo an SEEG with the usual electrodes and for whom fast-ripples will not be assessed.
89628246|NCT06104579||Patients operated on rectal cancer, included in the Catalan Cancer Registry|Patients operated on rectal cancer, included in two compulsory audits of the Catalan Cancer registry, and who suffered an organ-space surgical infection.
89628247|NCT06104579||Patients operated on rectal surgery, included in the Catalan Infection Surveillance Program|Patients included in the voluntary Catalan Infection Surveillance Program, and followed for 30 days postoperatively, and who suffered an organ-space surgical infection.
89628248|NCT06100289|Experimental|Induction Period: Participants ≥30 kg, Vedolizumab (High Dose) IV|Participants weighing ≥30 kg will receive vedolizumab (High Dose) IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.
89628249|NCT06100289|Experimental|Induction Period: Participants >15 to <30 kg, Vedolizumab (Medium Dose) IV|Participants weighing >15 to <30 kg will receive vedolizumab (Medium Dose), IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.
89628250|NCT06100289|Experimental|Induction Period: Participants ≥10 to ≤15 kg, Vedolizumab (Low Dose) IV|Participants weighing ≥10 to ≤15 kg will receive vedolizumab (Low Dose), IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.
89628251|NCT06100289|Experimental|Maintenance Period: Participants ≥30 kg, Vedolizumab 108 mg SC Q2W|Participants with clinical response at Week 14 weighing ≥30 kg will receive vedolizumab 108 mg, SC injection, Q2W from Week 14 to Week 32 in the Maintenance Period.
89628252|NCT06100289|Experimental|Maintenance Period: Participants ≥10 to <30 kg, Vedolizumab 108 mg SC Q4W|Participants with clinical response at Week 14 weighing ≥10 to <30 kg will receive vedolizumab 108 mg, SC injection, Q4W from Week 14 to Week 30 in the Maintenance Period.
89628253|NCT06098846|Placebo Comparator|Placebo patch|Placebo transdermal patch daily
89628254|NCT06098846|Active Comparator|Dose Frequency 1|Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
89628255|NCT06098846|Active Comparator|Dose Frequency 2|Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
89628256|NCT06098846|Active Comparator|Dose Frequency 3|Active transdermal patch daily (actives could be alternated with placebo in a given sequence)
89628257|NCT06081972|Placebo Comparator|Placebo|Participants who will be randomized in the placebo group will receive maltodextrin (500mg/day).
89628258|NCT06081972|Experimental|Chicory RG-I|Participants who will be randomized in the placebo group will receive Chicory RG-I (500mg/day).
89628259|NCT06081972|Experimental|Carrot RG-I|Participants who will be randomized in the placebo group will receive Carrot RG-I (500mg/day).
89039611|NCT06087094|Experimental|Cohor 1: HRS-7450 dose 2 or Placebo;|
89628260|NCT06078345|Experimental|BAT positive|Maximal activated supraclavicular BAT SUVmean >1,5 g/ml-
89628261|NCT06078345|Experimental|BAT negative|Maximal activated supraclavicular BAT SUVmean <1,5 g/ml
89628262|NCT06069154|Active Comparator|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
89628263|NCT06069154|Sham Comparator|Sham Procedure|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
89628264|NCT06066450||OSFITTM drug-eluting stents.|"Treatment Group: Group of patients who received treatment with OSFITTM drug-eluting stents.~Subgroup with OCT (OCT Subgroup): Subgroup of patients who underwent Optical Coherence Tomography (OCT) to verify stent placement accuracy."
89628265|NCT06064617|Experimental|Center Distance Multifocal Contact Lens|All participants will wear a Biofinity center distance multifocal contact lens with a +2.50 add and measurements will be obtained.
89211282|NCT00990717|Experimental|NK-92 cells|Preparation of irradiated NK-92 cells suspended in a saline and plasma solution. NK-92 working cell bank was established from a master cell bank supplied by Conkwest Inc. (San Diego CA).
89628266|NCT06064617|Experimental|Center Near Multifocal Contact Lens|All participants will wear a Biofinity center near multifocal contact lens with a +2.50 add and measurements will be obtained.
89628267|NCT06062667|Experimental|experimental group|Fathers will accompany their husbands during the birth process
89628268|NCT06062667|No Intervention|Control group|routine maintenance
89628269|NCT06051500|Experimental|Nostril focus followed by belly focus|Participants will be randomly assigned to concentrate on the nostrils first, then the belly second following a period of rest.
89628270|NCT06051500|Experimental|Belly focus followed by nostril focus|Participants will be randomly assigned to concentrate on the belly first, then the nostrils second following a period of rest.
89628271|NCT06031194||Observational|Participants undergo blood sample collection and have their medical records reviewed on study.
89628272|NCT06029530|Active Comparator|0.01% Atropine|0.01% atropine eye drops
89628273|NCT06029530|Active Comparator|0.03% Atropine|0.03% atropine eye drops
89628274|NCT06029530|Active Comparator|0.05% atropine|0.05% atropine eye drops
89628275|NCT06024759||Retrospective Cohort|Individuals in this group were previously seen by physicians at the Inherited Arrhythmia Clinic at University Hospital, London Health Sciences Centre, yet are no longer being actively followed here anymore. These patients will have their data retrospectively obtained annually, ten years into the past, to collect data on key variables providing insight on LVNC progression over time.
89628276|NCT06024759||Prospective Cohort|Patients being actively followed up by physicians at the Inherited Arrhythmia Clinic will be approached either in person or via e-mail for consent and enrollment into this study. These patients will have their medical charts accessed annually to collect data on key variables providing insight on LVNC progression over time.
89628277|NCT06024707||Asthma patients|All asthma patients will be observed and receive their regular treatment
89628278|NCT06023212|Experimental|tranexamic acid group|injection of 2 bottles of tranexamic acid (1g/bottle) before making incision; tranexamic acid soaked gauze applied to the wound before closing the wound; Intravenous injection of tranexamic acid 3 times (every 8 hours）within 24 hours after operation；
89628279|NCT06023212|Placebo Comparator|SPSS group|injection of 2 bottles of stroke-physiological saline solution（SPSS）before making incision; SPSS soaked gauze applied to the wound before closing the wound; Intravenous injection of SPSS 3 times (every 8 hours）within 24 hours after operation；
89628280|NCT06018766|Experimental|LAM-001|
89628281|NCT06018766|Placebo Comparator|Placebo|
89628282|NCT06012721|Experimental|Part 1 Treatment A|30 mg ORIC-114 (3 x 10 mg tablets) administered at Hour 0 on Day 1 under fasting conditions.
89628283|NCT06012721|Experimental|Part 1 Treatment B|30 mg ORIC 114 (3 x 10 mg tablets) administered at Hour 0 on Day 1, 30 minutes after the start of a meal.
89628284|NCT06012721|Experimental|Part 2 Treatment A|xx mg ORIC-114 (n x 10 mg tablets) administered at Hour 0 on Day 1 under fasting conditions.
89628285|NCT06012721|Experimental|Part 2 Treatment B|xx mg ORIC 114 (n x 10 mg tablets) administered at Hour 0 on Day 1, 30 minutes after the start of a meal.
89628286|NCT06010251|Experimental|SCI with pain|Participants will undergo 2-4 weeks of combined intervention including transcranial direct current stimulation (tDCS) and bodily illusions (10 sessions total).
89628287|NCT05995886|Experimental|Wiidookaage'win Facebook Group|The Wiidookaage'win Facebook Group is an online, asynchronous group intervention that will run for 3-months with approximately 30 days of content developed. It is private and hidden, meaning only those in the study will be able to see or find the group. It will be moderated by two women from the study team (one AIAN and one biracial). A back-up moderator will also have access to the group. Participants will be able to comment, react, view, and post in the intervention group, and are encouraged to interact with one another.
89628288|NCT05995886|No Intervention|Online Resources Landing Page|The Online Resources Landing Page was developed by the study team using https://carrd.co. It includes links to local programs in family services, substance use recovery, legal advocacy, etc. which already exist and may help support their recovery.
89628289|NCT05994651|Experimental|Tidal Model improvement model|In order to provide individualized care to the individuals in the experimental group, initiatives will be implemented by starting individual interviews and in line with the goals of the individuals and the research objectives.
89628290|NCT05994651|No Intervention|Tidal Model Control Group|Individuals in the control group will continue their lives.
89628291|NCT05993728|Experimental|Clinician-led Body Project|Participants randomized to this condition will take part in virtual Body Project groups led by clinicians.
89628292|NCT05993728|Experimental|Peer-led Body Project|Participants randomized to this condition will take part in virtual Body Project groups led by peers.
89628293|NCT05993728|Active Comparator|Educational control|Participants randomized to the educational control group will receive educational videos on body image and eating disorders
89039612|NCT06087094|Experimental|Cohor 1: HRS-7450 dose 3 or Placebo;|
89039613|NCT06087094|Experimental|Cohor 1: HRS-7450 dose 4 or Placebo;|
89211283|NCT04004013|Active Comparator|Lifenol|50 participants who meet the eligibility criteria will be randomised under active arm and will receive Lifenol product during 12 months
88990081|NCT04276259|Experimental|Oral Placebo Pill + Intramuscular Saline Injection|Inert pill and saline injection that have no inherent power to produce an effect. In the inert pill condition, participants will receive one IM arm injection of saline (1ML) and an oral placebo tablet.
88990082|NCT04276155|Experimental|Device|Acute Coranary Syndrome and de novo Atrial Fibrilation patients treated by DAPT only, in association with an implantable cardiac monitoring device and a follow-up by telecardiology. The anticoagulant treatment will only be administered to patients presenting a recurrence of Atrial Fibrilation
88990083|NCT04276155|No Intervention|Control|Acute Coranary Syndrome and de novo Atrial Fibrilation patients with standard management: DAPT in association with an anticoagulant treatment.
88990084|NCT04265079|Experimental|Added weight to hand|
89628294|NCT05993039|Active Comparator|Inhalational Anesthesia|"Adults:~The control group will receive general inhalational anesthesia (sevoflurane, isoflurane). The will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with isoflurane 1.5-2% or sevoflurane 1-2%.~Children (12 or younger) induced with a combination of volatile anesthetic gases, including sevoflurane (up to 8%) and nitrous oxide gas (up to 70%). Those who are older than 12 will have an intravenous line placed in the preoperative area and as such will be induced with remifentanil and propofol as above. For maintenance, children in the control arm will receive 0.6 - 1.5% sevoflurane."
89628295|NCT05993039|Active Comparator|Total Intravenous Anesthesia (TIVA)|"Adults:~The comparator arm will receive total intravenous anesthesia (propofol and remifentanil). They will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, and lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with propofol 100-200mcg/kg/min, remifentanil 0.05-2µg/kg/min.~Children (12 or younger) induced with a combination of volatile anesthetic gases, including sevoflurane (up to 8%) and nitrous oxide gas (up to 70%). Those who are older than 12 will have an intravenous line placed in the preoperative area and as such will be induced with remifentanil and propofol as above. For maintenance, they will receive 100-200mcg/min propofol and 0.05-2µg/kg/min remifentanil."
89628296|NCT05988372|Experimental|Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine|enrolled, eligible patients receive Surufatinib, Serplulimab, Gemcitabine and Albumin-paclitaxel
89628297|NCT05988372|Experimental|Albumin-paclitaxel + Gemcitabine|enrolled, eligible patients receive Gemcitabine and Albumin-paclitaxel
89628298|NCT05972564|Active Comparator|Empagliflozin Arm|Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes. To ensure blinding, empagliflozin will be over-encapsulated in identical gelatin capsules as placebo.
88990085|NCT04239092|Experimental|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
88990086|NCT04239092|Experimental|9-ING-41 plus Irinotecan|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days (cycle duration is 21 days).
88990087|NCT04239092|Experimental|9-ING-41 plus Irinotecan plus Temozolomide|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Irinotecan will be administered at a dose of 50 mg/m2/day over 90 minutes IV on days 1-5 every 21 days. Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 ((cycle duration is 21 days).
89628299|NCT05972564|Placebo Comparator|Placebo Arm|Placebo consists of gelatin capsules.
89628300|NCT05970068|Experimental|Group 1: Surgery + best medical treatment|The intervention group would receive the novel treatment of implantation of hydrophobic tubes for edema fluid drainage and the best medical treatment available.
89628301|NCT05970068|Active Comparator|Group 2: best medical treatment|This control group would receive only the best medical treatment available.
89628302|NCT05968508|Experimental|BAT1806 prefilled subcutaneous injection|
88990088|NCT04239092|Experimental|9-ING-41 plus Cyclophosphamide plus Topotecan|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5. Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5. 9-ING-41 intravenous infusion twice weekly (cycle duration is 21 days).
88990089|NCT04238949|No Intervention|Standard Diabetes Care Group|Patients receive standard diabetes care.
88990090|NCT04238949|Experimental|Community Health Worker Group|Patients are assigned a community health worker for the first year in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
88990091|NCT04231266|Active Comparator|ManNAc|Oral ManNAc will be administered at a dose of 4 grams three times daily (total of 12 grams daily).
88990092|NCT04231266|Placebo Comparator|Placebo|Oral Placebo will be administered three times daily.
89628303|NCT05968508|Active Comparator|RoActemra® (from EU)|
89628304|NCT05951231|Active Comparator|Liver transplanted patient|Patients who are transplanted with an ECD liver after pretreatment with a liver perfusion machine
89628305|NCT05951231|No Intervention|Non-liver transplanted patient|Patients who are not offered a liver transplantation during the inclusion period
89628306|NCT05946265|Experimental|Intervention group|Intervention Group - RAR + FBM (n=22): The researcher responsible for FBM will remove the randomization envelope and apply Laser Therapy XP at the points indicated in Figure 2. All dosimetric parameters, details of sessions, and the number of FBM applications are described in Table 2.
89628307|NCT05946265|Placebo Comparator|Control Group|Control Group - RAR + FBM simulation (n=22): Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention. The study flowchart presents the details of the project
88990093|NCT04229797|Active Comparator|Comparator|Extraction of the unerupted third molars before distalization of mandibular first molar using Mandibular buccal shelf mini-screws.
88990094|NCT04229797|Experimental|Intervention|Leaving the unerupted third molars and distalizing using Mandibular buccal shelf mini-screws.
89628308|NCT05932342|Experimental|Integrated program of cognitive remediation, physical exercise and socially- stimulating activity|"Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport.~The integrated, 12-week, group-based program consists of CR 1h/day, 2 days/week, 30min of physical exercises 1day/week and 1h of socially stimulating activities 1day/week"
89628309|NCT05924204|Experimental|G1 TREATMENT GROUP|In the Treatment group the FMB with 4 J of energy by point
89628310|NCT05924204|Sham Comparator|G2 SHAM GROUP|In the Sham group, the the device will be turned off
89628311|NCT05923892|Experimental|3 dose groups of OPS-2071|OPS-2071 tablets, 50 mg OPS-2071 tablets, 100 mg OPS-2071 tablets, 200 mg Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
89628312|NCT05923892|Placebo Comparator|placebo group|Placebo tablets Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
89628313|NCT05920343|Experimental|Rivaroxaban|Participants receiving study drug (Rivaroxaban)
89628314|NCT05920343|Placebo Comparator|Control|Participants receiving matched placebo
89628315|NCT05898659|Active Comparator|ABFnoS then ABFS|Cochlear Implant with ABFnoS first during 6 weeks then with ABFS during 6 weeks
89628316|NCT05898659|Active Comparator|ABFS then ABFnoS|Cochlear Implant with ABFS first during 6 weeks then with ABFnoS during 6 weeks
89628317|NCT05895604|Experimental|Treatment-NFP|NFP is a prenatal and infancy home visiting program for vulnerable first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, guiding the mothers-to-be on different aspects of the parental role and offer practical and emotional support. The nurses continue visiting regularly until the child is two years old (up to 64 visits in total).
89628318|NCT05895604|No Intervention|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
89628319|NCT05893186|Experimental|STN DBS|Patients with implanted STN DBS leads will be allocated to this group for DBS stimulation of the STN, within FDA-approved limits and labeling, for symptoms of PD.
89628320|NCT05893186|Experimental|GP DBS|Patients with implanted GP DBS leads will be allocated to this group for DBS stimulation of the GP, within FDA-approved limits and labeling, for symptoms of PD.
89628321|NCT05884541|Experimental|Intervention|Children and parents receiving Early Math Texts (TipsbyText)
89628322|NCT05884541|No Intervention|Control|Children and parents not receiving Early Math Texts (TipsbyText)
88990095|NCT04229316|Experimental|zLock Facet Locking Implant System|
88990096|NCT04229030|Active Comparator|RZL-012|"A single-treatment injection, multiple subcutaneous injections of RZL-012 administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL RZL-012 (5mg).~Lipomas in the size of:~2-3.9 cm will be dozed with 0.4mL RZL-012 (20mg). 4-5.9 cm will be dozed with 0.8mL RZL-012 (80mg). 6-7.9 cm will be dozed with 1 mL RZL-012 (100mg). 8-10 cm will be dozed with 1.2 mL RZL-012 (120mg)."
88990097|NCT04229030|Placebo Comparator|Vehicle of RZL-012|"A single-treatment injection, multiple subcutaneous injections of vehicle administered into 4-8 lipomas in each subject, preferably 6. Dosing will be done according to lipomas size, as will be determined by Ultrasound. Each injection contains 0.1mL vehicle.~Lipomas in the size of:~2-3.9 cm will be dozed with 0.4mL vehicle. 4-5.9 cm will be dozed with 0.8mL vehicle. 6-7.9 cm will be dozed with 1 mL vehicle. 8-10 cm will be dozed with 1.2 mL vehicle."
88990098|NCT04218071|Experimental|9-ING-41|9-ING-41 is administered by intravenous infusion twice weekly at a dose of 9.3 mg/kg. Cycle duration is 28 days.
88990099|NCT04218071|Experimental|9-ING-41 plus Ruxolitinib|9-ING-41 9.3 mg/kg will be administered by intravenous infusion twice weekly for cycle durations of 28 days with Ruxolitinib at doses specified in the protocol as appropriate for patient's platelet count.
88990100|NCT04215809|Experimental|APG2575 200mg|APG2575 200mg ramp up
88990101|NCT04215809|Experimental|APG2575 400mg|APG2575 400mg ramp up
88990102|NCT04215809|Experimental|APG 2575 600mg|APG2575 600mg ramp up
88990103|NCT04215809|Experimental|APG2575 800mg|APG2575 800mg ramp up
88990104|NCT04215809|Experimental|APG2575 1000 mg|APG2575 1000 mg ramp up
88990105|NCT04215809|Experimental|APG2575 1200mg|APG2575 1200mg ramp up
88990106|NCT04211350|Experimental|NightBalance Sleep Position Therapy|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
88990107|NCT04211350|Experimental|Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
88990108|NCT04204538||Urban|Young adults living in urban communities of Rwanda
88990109|NCT04204538||Rural|Young adults living in rural communities of Rwanda
88990110|NCT04200300||Nurses working with patients with mental disorders|Nurses in Germany currently working with patients with mental disorders
88990111|NCT04200209|Experimental|Hospital|Twelve wards of the hospital will be evaluated at the same time.
88990112|NCT04199689|Experimental|9vHPV vaccine|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
88990113|NCT04199689|Placebo Comparator|Placebo|Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6
88990114|NCT04197063|Experimental|Current SSB restaurant portions purchase refill|Offered a menu with current SSB restaurant portion sizes with the option to purchase refills
88990115|NCT04197063|Experimental|Current SSB restaurant portions free refill|Offered a menu with current SSB restaurant portion sizes plus free beverage refills
89628323|NCT05884333|Experimental|Cord Blood Transplant|Adult patients with high-risk hematologic malignancies and a suitable double-unit CB graft will undergo work-up to assess protocol eligibility. CB graft selection will be based on established MSKCC guidelines. Patients will receive standard conditioning with Cy 50 mg/kg, Flu 150 mg/m2, Thio 10 mg/kg, and TBI 400 cGy according to the eligibility criteria. GVHD prophylaxis will consist of CSA and MMF starting day -3. The double-unit CB graft will be infused on day 0 per standard practice. Optimized CBT practices, will be implemented in this protocol.
89628324|NCT05879757||MM Participants With SID|Participants with MM diagnosed with SID will be treated with HyQvia as part of routine clinical care and will be followed prospectively from the date of starting HyQvia treatment through 12 months of follow-up.
89628325|NCT05879640|No Intervention|Before- standard care|
89628326|NCT05879640|Other|After- intervention|Patients studied in this arm receive the new educational intervention delivered in conjunction with standard care
89628327|NCT05878483|Experimental|Autonomous blood drawing|"Hospital Sites (outpatients visiting blood drawing department):~In study Phase A1, B1, B2, C1, a subject visiting the outpatient blood drawing department will receive one automated blood draw with the Venipuncture Device. This blood draw is additional to the manual blood draw.~In study Phase C2 the automated blood draw replaces the manual blood draw. In Phase C2, the subject might therefore receive two automated blood draws, in case a redraw is required.~Vitestro Site (volunteers):~In study Phase A, C1 volunteers visit Vitestro Site. Participants receive one to two automated blood draws."
89628328|NCT05873569|Experimental|Mothers and Babies Virtual Group Intervention|Women randomized to the Mothers and Babies Virtual Group (MBVG) arm will receive the 10 session MBVG intervention. Sessions are delivered weekly or bi-weekly via Zoom, making 20 weeks the longest possible MB-VG cohort. Sessions were designed to last 60 minutes, with an additional 15 minutes for sessions including a Resource Advocate or pediatrician. Prior to the first session, a member of the research team will test Zoom connections with each participant. All MB-VG groups will be delivered in Spanish by a trained MB-VG facilitator, with a study team member available to provide tech support as needed. MB-VG sessions will be delivered in chronological order.
89628329|NCT05873569|No Intervention|Usual Family Support Services|Women randomized to the usual family support services arm will receive family support services from the early childhood center in which they are enrolled but no MB-VG intervention.
89628330|NCT05867498|Experimental|Concurrent exercise|"Strength component (circuit-based exercise) 7 exercises:~General (2 sets of 15-18 Rep, OMNI-Resistance Exercise Scale 4-5, x 10 s) 180 s~Block (3 sets of 12-15 Rep, OMNI-Resistance Exercise Scale 5-6, x 10 s) 70 s~Concentrated (3 sets of 10-12 Rep, OMNI-Resistance Exercise Scale 7-8, x 15 s) 110 s~Aerobic component~Low-to-moderate-intensity continuous training: 16 min to 18 min (< VT 1)~Interval training: in a block (> VT 2)~5 bouts of 30 s loads. Work:rest ratio: 1:1~4 bouts of 45 s loads. Work:rest ratio: 1:1~5 bouts of 50 s loads. Work:rest ratio: 2:1~4 bouts of 60 s loads. Work:rest ratio: 2:1~3 bouts of 70 s loads. Work:rest ratio: 2:1~4 bouts of 80 s loads. Work:rest ratio: 2:1"
89628331|NCT05867498|Active Comparator|Aerobic exercise|"Low-to-moderate-intensity continuous training: 36 min (< VT 1)~Interval training: in two blocks (> VT 2) 5 bouts of 35 s loads. Work:rest ratio: 1:1 4 bouts of 45 s loads. Work:rest ratio: 1:1 4 bouts of 60 s loads. Work:rest ratio: 2:1 3 bouts of 75 s loads. Work:rest ratio: 2:1 4 bouts of 80 s loads. Work:rest ratio: 2:1"
89628332|NCT05866250||critically ill patients|All newly admitted ICU patients
89628333|NCT05861050|Experimental|Treatment (venetoclax, glofitamab, lenalidomide)|Patients receive venetoclax PO, obinutuzumab IV, glofitamab IV, and lenalidomide IV on study. Patients undergo bone marrow biopsy, blood sample collection, and CT scan and/or PET scan throughout the study. Patients may undergo tumor biopsy throughout the study.
89628334|NCT05849857|Experimental|Subcutaneous mosunetuzumab|"The duration of each treatment cycle is 21 days.~Cycle 1 Day 1:~5 mg Mosunetuzumab SC~Cycle 1 Day 8:~45 mg Mosunetuzumab SC~Cycle 1 Day 15:~45 mg Mosunetuzumab SC~Cycle 2-8 Day 1:~45 mg Mosunetuzumab SC~Patients in complete remission after 8 cycles enter follow-up. Patients with stable disease or partial remission can receive up to a total of 17 cycles:~Cycle 9-17 Day 1:~45 mg Mosunetuzumab SC"
89628335|NCT05848895|Experimental|Osteopathic Manipulative Treatment|Patients will be treated once a week with OMT x 8 weeks
88990116|NCT04197063|Experimental|</= 16 oz. SSB portions with the option to purchase refills|Offered a menu with </= 16 oz. SSB portion sizes with the option to purchase refills
88990117|NCT04197063|Experimental|</= 16 oz. SSB portions plus free refills|Offered a menu with </= 16 oz. SSB portion sizes plus free refills
88990118|NCT04193735||CIPO (case)|MRI scan of gastrointestinal content and activity
88990119|NCT04193735||Chronic constipation (control)|MRI scan of gastrointestinal content and activity
88990120|NCT04193722|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy consists of 30-40 treatment sessions (1 session per day during 5 days per week). During the hyperbaric oxygen (HBO) sessions the pressure will be raised to 2.4 atmospheres absolute in a hyperbaric chamber and patients breath in 100% oxygen during 4 times 20 minutes.
88990121|NCT04193722|No Intervention|Usual care|Usual care may consist of physiotherapy, analgetics, edema therapy
88990122|NCT04186598|Experimental|Experimental: CPAP|Participants will be treated with CPAP. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
88990123|NCT04186598|Placebo Comparator|Control: High flow oxygen|Participants will be treated with an altered CPAP mask that will deliver high flow oxygen. All patients will be treated with nifedipine unless there is a contraindication like hypotension and bradycardia.
88990124|NCT04180904|Active Comparator|Diet 1|Diet 1 will focus on the dietary pattern and monitor types of foods, supplementary nutrition, and provide nutritional support with a dietitian.
88990125|NCT04180904|Active Comparator|Diet 2|Diet 2 will focus on the dietary pattern and monitor the amount of food, complimentary nutrition, and nutritional support with a dietitian.
88990126|NCT04180904|No Intervention|Diet 3|Diet 3 will focus on healthy dietary patterns and provide nutritional support with a dietitian.
88990127|NCT04172246|Experimental|Zanubrutinib|
88990128|NCT04171492||Open Label|Nodify XL2 results will be reported to the investigator and available to the subject.
88990129|NCT04171492||Blinded|Nodify XL2 results will not be available to the investigative site or subject.
89211284|NCT04004013|Placebo Comparator|Placebo|50 participants who meet the eligibility criteria will be randomised under Placebo arm and will receive placebo product during 12 months
89211285|NCT05359497|Other|Additional sequences and extra MRI|"PSC patients, suspected for having a dominant stenosis, that undergo additional LMS sequences next to standard care MRI prior to ERCP and an additional MRI/MRCP with additional LMS sequences 8 weeks after ERCP.~MRI images will be analysed by the post-processing tool called MRCP+ and Liver Multiscan, which are performed after the MRI is performed."
89211286|NCT05279079||Group 1|Drug-associated AP: patients aged 18 or more years undergoing drug treatment that has a defined risk of AP prior to and at the onset of AP
89211287|NCT05279079||Group 2|Other cause AP: patients aged 18 or more years not undergoing drug treatment that has a defined risk of AP prior to and at the onset of AP
89211288|NCT05279079||Group 3|Chronic pancreatitis: patients aged 18 or more years with symptomatic chronic pancreatitis confirmed by CT or MRI
89211289|NCT05279079||Group 4|Pancreas cancer: patients aged 18 or more years with biopsy proven pancreas cancer
89628336|NCT05848895|Active Comparator|Standard of Care Repositioning|Patients will only receive repositioning only x 8 weeks and all parents will receive standardized materials to counsel/instruct on the repositioning
89628337|NCT05834439|Experimental|Experimental group|Experimental group
89628338|NCT05834439|Other|Control group|Control group
89628339|NCT05827536|Other|AB where A=standard of care and B=PKU GOLIKE|Patients will receive 3 daily self-administrations of their usual standard of care for 2 consecutive days in the first period followed by 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the second period.
89628340|NCT05827536|Other|BA where B=PKU GOLIKE and A=standard of care|Patients will receive 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the first period followed by 3 daily self-administrations of their usual standard of care for 2 consecutive days in the second period.
89628341|NCT05824572|Active Comparator|Audio|Researchers will audio record both in-person and telehealth visits of participants in the intervention group.
89628342|NCT05824572|Placebo Comparator|Usual care|Participants will receive Usual Care
89628343|NCT05818397|Experimental|Self-Compassion Intervention|
89628344|NCT05815147|Experimental|Study Group|Participants will be asked to take study product.
89628345|NCT05794542|Experimental|Intervention|Use of Cue X intervention
89628346|NCT05779072|Other|Dual Focus for 3 years|Group of subjects who completed dual focus soft contact lens wear treatment for 3 years
89628347|NCT05779072|Other|Dual Focus for 6 years|Group of subjects who completed dual focus soft contact lens wear treatment for 6 years
89628348|NCT05739565|Experimental|Acti-Pair program|"Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals"
89628349|NCT05739565|No Intervention|Usual care|The control group will be made up of patients followed up for prostate cancer and benefiting from usual care which consists of giving advice and recommendations for physical activity in consultation, aiming to make patients more active in their daily lives (=usual practice, physical activity to be carried out independently, at home).
89628350|NCT05734066|Experimental|Phase 1 Part 1: Dose Selection|"Pediatric participants ≥ 2 to < 18 years of age with previously treated solid tumors of any histology at 5 dose levels to determine the RP2D, followed by a safety expansion cohort.~Participants aged ≥ 6 to < 18 years will be enrolled at the starting dose of 3.2 mg/m^2 lurbinectedin. After the drug is deemed safe based safety and PK data from the older participants, participants aged ≥ 2 to < 6 years are enrolled at the same starting dose. After this, the study opens to all participants (aged ≥ 2 to < 18 years) for all dose levels.~Upon completion of the cohort at all dose levels, participants may be eligible to enroll in a safety expansion cohort."
89628351|NCT05734066|Experimental|Phase 1 Part 2: RP2D|Participants aged ≥ 2 to ≤ 30 years with recurrent/refractory Ewing sarcoma at the RP2D to assess safety and efficacy signals.
89211290|NCT05279079||Group 5|Diabetes mellitus: patients aged 18 or more years with type 1 or type 2 diabetes mellitus in receipt of insulin or oral hypoglycaemics
89211291|NCT05279079||Group 6|Healthy volunteers
89211292|NCT00990795|Experimental|Cyclosporine|Cyclosporine Group: Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
89628352|NCT05734066|Experimental|Phase 2|If a signal of efficacy is observed in Phase 1 Part 2, additional participants aged ≥ 2 to ≤ 30 years with recurrent/refractory Ewing sarcoma will be enrolled. Phase 2 will further assess the safety and efficacy of lurbinectedin monotherapy.
89628353|NCT05733416|Experimental|Intensive Cancer Screening|Usual care plus PDG PET/CT
89211293|NCT00990795|Placebo Comparator|Placebo|Placebo: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
89211294|NCT00622700|Placebo Comparator|Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg|"Core treatment period: Placebo matched to teriflunomide tablet once daily orally.~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally."
89628354|NCT05733416|Other|Usual Care|Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)
89628355|NCT05725655|Experimental|Hot water immersion|Patients allocated to hot water immersion will enter a bath and submerge down to the neck in warm water (40 degrees celsius) for 15 min.
89628356|NCT05725655|No Intervention|Control|Patients allocated to control group will sit down for a 15 min rest.
89628357|NCT05724173|Other|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
89628358|NCT05722457|Other|Investigation of the Effects of External Focused Ex. on Functionality in Individuals|Sub-branches of the study are planned as Investigation of the Effects of External Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain. Sub-branches of the study are planned as Investigation of the Effects of External Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain.
89628359|NCT05722457|Other|Investigation of the Effects of İnternal Focused Ex. on Functionality in Individuals|Sub-branches of the study are planned as Investigation of the Effects of internal Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain. Sub-branches of the study are planned as Investigation of the Effects of İnternal Focused Dynamic Balance Training on Functionality in Individuals with Chronic Low Back Pain.
89628360|NCT05721898||Fracture Cases|Fragility Fracture Cases: Post-menopausal females between 50-80 years who have experienced a fragility fracture of the arms (including wrist fractures) or legs (including hip, pelvis, or ankle fractures) after the age of 50 years. Fractures of the spine, digits, toes or face will not be considered. A fragility fracture is operationally define based on self-report of an arm or leg fracture caused by falls from a height <6 inches. A fragility fracture will not count if it is associated with 1) running, bicycling or other similar fast-moving activity such as sports subjects, 2) being struck by a falling or otherwise quickly moving heavy object, or 3) a motor vehicle accident. Insufficiency/stress fractures will not be included. Body mass index between 18.5 and 35 kg/m2.
89628361|NCT05721898||Non-Fracture Controls|Controls: Post-menopausal females between 50-80 years who have not experienced a fracture at any site after the age of 40 years (does not include fractures of the digits, toes or face). Does not self-report losing more than 1.5 inches in stature (height) in the previous 15 years. Body mass index between 18.5 and 35 kg/m2.
89628362|NCT05687916|Experimental|TAK-861 Dose 1|TAK-861 dose 1, orally for 8 weeks.
89628363|NCT05687916|Experimental|TAK-861 Dose 2|TAK-861 dose 2, orally for 8 weeks.
89628364|NCT05687916|Placebo Comparator|Placebo|TAK-861 matching placebo tablets, orally for 8 weeks.
89628365|NCT05687162|Active Comparator|(Study 1) 3-week Loneliness Program|The second and third sessions are completed in the second and third week, respectively, after beginning the study.
89628366|NCT05687162|Experimental|(Study 1) Single-session loneliness program|
89628367|NCT05687162|Active Comparator|(Study 1) Single-session active control program|
89628368|NCT05687162|Experimental|(Study 2) Popular online content-based single-session intervention for distress|
89039614|NCT06087094|Experimental|Cohor 1: HRS-7450 dose 5 or Placebo;|
89039615|NCT06087068|Experimental|test group|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
89039616|NCT06087055|Experimental|Period 1|GST-HG171/ritonavir orally
89039617|NCT06087055|Experimental|Period 2|Itraconazole+GST-HG171/ritonavir orally
89039618|NCT06087042||Group I|patients suffering from oral squamous cell carcinoma
89039619|NCT06087042||Group II|patients diagnosed with potentially malignant lesions such as leukoplakia, and dysplastic erosive or atrophic oral lichen planus
89039620|NCT06087042||Group III|individuals with no oral mucosal lesions
89039621|NCT06087016||Bladder cancer group|Bladder cancer group represents patients attending or hospitalized in Urology department, Reims University Hospital and in whom, tumor is visualized during cystoscopy and confirmed by the histological examination of entire resected lesion after Trans Urethral Resection of Bladder Tumor (TURBT).
89039622|NCT06087016||Control group|Control group includes patients consulting for cystoscopy examination in Urology department, Reims University Hospital without any tumor visualization during cystoscopy examination.
89039623|NCT06087003||Basilliximab induction group|Basiliximab was administered intravenously 4 hours before kidney graft reperfusion and at day 4 after kidney transplantation. For pediatric patients weighing > 30kg, the dose of Basiliximab was 20mg, otherwise was 10mg.
89039624|NCT06087003||rATG induction group|Rabbit antithymoglobulin (rATG) was administered intravenously during kidney transplantation (pre-reperfusion) and 1-2 days after transplantation. The dose was about 0.5-1 mg/kg per day.
89039625|NCT06086990|Experimental|Telemonitoring Platform|"Patients assigned to the active intervention group will have access to a smartphone application named Contigo. This application is designed to identify signs and symptoms of oncology drug toxicity while providing educational content. It equips patients with the necessary tools to manage typical clinical situations associated with the diagnosis and treatment of their disease."
89039626|NCT06086990|No Intervention|Traditional Follow-Up|Individuals designated to the traditional follow-up group will undergo standard care, including in-person check-ups as determined by their attending physician.
89039627|NCT06086925|Experimental|BRB treatment|Day 1 of BRB will be determined based upon the anticipated surgery day. Subjects will be instructed to consume a total dose of 5 Gm/day (orally) by taking one BRB five times a day: one upon waking in the morning, one in the morning, one at noon, one in the evening, and one at bedtime. BRB should not be given during meals and drinking. The subject should avoid eating for about 30 minutes before and after taking a BRB.
89628369|NCT05687162|Active Comparator|(Study 2) Researcher-created single-session intervention for distress|
89628370|NCT05687162|Active Comparator|(Study 2) Online help-seeking as usual|
89628371|NCT05687162|Experimental|(Study 3) Popular online content-based single-session intervention for loneliness|
89628372|NCT05687162|Active Comparator|(Study 3) Researcher-created single-session intervention for loneliness|
89211295|NCT00622700|Experimental|Teriflunomide 7 mg/7 mg|"Core treatment period: Teriflunomide 7 mg tablet once daily orally.~Extension treatment period: Teriflunomide 7 mg tablet once daily orally."
89628373|NCT05687162|Active Comparator|(Study 3) Single-session active control program|
89628374|NCT05667779|Experimental|QRL-101|Single-ascending doses of QRL-101 will be administered orally to healthy participants
89628375|NCT05667779|Placebo Comparator|Placebo|Single-ascending doses of comparator placebo will be administered orally to healthy participants
89628376|NCT05663463|Experimental|booster group|Participants who have undergone a solid organ transplant will receive two doses of an inactivated high dose influenza vaccine
89628377|NCT05663463|Active Comparator|Control group|Participants who have undergone a solid organ transplant will receive one dose of inactivated high dose influenza vaccine followed by a placebo injection
89039630|NCT06086847|Experimental|Warm up Exercise + stretching Exercise + progressive resistance exercises|"Group A (Experimental Group):~Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~3. Progressive Resistance exercises:~Leg press :( dual leg press): Leg press target the~Quadriceps or quads .but they also work your Hamstrings.~Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~Rectus femoris~Vastus lateralis~Vastus medialis~Vastus intermedius~4. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):"
89039631|NCT06086847|Active Comparator|warm up exercise + Stretching exercises|"Warm up exercise (for 5 min)~Stretching exercises (upper and lower extremity"
89628378|NCT05661773|Experimental|combined use of vacuum assisted suction and heat exchanger warming|The novel idea that this study proposes, is the combined use of vacuum assisted suction and heat exchanger warming. It is well known that heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
89628379|NCT05661773|No Intervention|expectant medical management|expectant medical management will continue to the contralateral hand
89628380|NCT05660629|Experimental|Mulligan Mobilization|"Rehabilitation Program (Active wrist ROM exercises):~Forearm pronation and supination~Wrist flexion and extension~Wrist flexion and extension (in the form of a fist)~MCP Joint Flexion and Extension~Thumb IC joint Flexion and Extension~Abduction and Adduction of Fingers~These exercises will be performed by the physiotherapist in the form of 5 seconds of movement / 15 seconds of rest, 10 repetitions a day, 5 days a week for 6 weeks.~Mulligan Mobilization:~Carpal Medio-lateral Glide (open kinetics, wrist flexion and extension movement)~Carpal Rotation (open kinetics, wrist flexion and extension)~Scaphoid Antero-posterior Glide (open kinetics)~Metacarpal Antero-posterior Glide (When Clenching)~Medio-lateral Glide to PIP-DIP joints (open kinetics, fingers flexed)"
89628381|NCT05660629|Sham Comparator|Sham Mobilization|Participants will receive sham mobilization in addition to the ROM exercises given in the Mulligan group. Sham mobilization will be done in the same position as Mulligan but without any glide force.
89628382|NCT05660629|No Intervention|Control|Participants will receive therapeutic patient training consisting of home exercise recommendations, basic disease information, physical activity advice, and joint protection methods.
89628383|NCT05658523|Active Comparator|Bivalent Moderna (mRNA-1273.214)|"Participants who have received three doses of COVID-19 vaccine, with the last dose at least 6 months prior to the study, will receive a booster dose of bivalent mRNA Moderna COVID-19 vaccine (mRNA-1273.214)~The mRNA-1273.214 encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in RNA-lipid nanoparticles composed of 4 lipids and 1-monomethoxypolyethyleneglycol-2, 3-dimyristylglycerol with polyethylene glycol. 25μg of each mRNA sequence that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 [BA.1])."
89628384|NCT05658523|Active Comparator|Novavax|"Participants who have received three doses of COVID-19 vaccine, with the last dose at least 6 months prior to the study, will receive a booster dose of Novavax COVID-19 protein subunit vaccine.~Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms)."
89628385|NCT05658523|No Intervention|Control group- no vaccine|Participants who have received three doses of COVID-19 vaccine, with the last dose at least 6 months prior to the study, will be recruited but will not receive any COVID-19 vaccine.
89628386|NCT05655091|Active Comparator|intervention group|Subjects randomized into the intervention group will receive FLU or CZO respectively as continuous infusion as soon as targeted S. aureus treatment is initiated (+24h). The choice of antibiotic is determined by the treating physician in accordance to the recommendations of the infectious diseases (ID) specialists. The loading dose and dose adjustments of FLU and CZO will be determined by the use of a pharmacokinetic modelling application. The maximum daily dose will not exceed the daily licensed dose according to the Summary of Product Characteristics (SmPC).
89628387|NCT05655091|Active Comparator|control group|Subjects randomized to the control group will receive standard of care intermittent bolus infusion FLU or CZO dosed according to the recommendations of the ID specialist and treating physician. Drug concentration will be analysed directly, but the results will not be communicated to the study team or a physician involved in the treatment of the patient. No TDM-guided dose adjustment will be performed in the control group.
89628388|NCT05643729|Experimental|Group 1: Zofin|Group 1 Treatment Arm (10 subjects): Zofin + Standard of care (SOC) Ten subjects will receive 1 mL of Zofin on Day 0, Day 4, and Day 8, containing 1-5 x 10^11 particles/ml. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside. In addition to Zofin all subjects in this trial will receive SOC throughout the study period.
89628389|NCT05643729|Placebo Comparator|Group 2: Placebo|Group 2 Control Arm (10 subjects): Placebo + SOC Ten subjects will receive placebo on Day 0, Day 4, and Day 8, containing 101 mL of sterile saline at subject's bedside. In addition to placebo all subjects in this trial will receive SOC throughout the study period.
89628390|NCT05631197|Experimental|Trial group|
89628391|NCT05631197|Active Comparator|Control group|
89628392|NCT05628285|Experimental|Sentio 1 sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
89628393|NCT05628051||Hypotension after anesthetic induction group|Patients with hypotension after anesthetic induction
89628394|NCT05628051||Non-hypotension after anesthetic induction group|Patients without hypotension after anesthetic induction
89039632|NCT06086808|Experimental|Group A|Resistance Training Group
89039633|NCT06086808|Active Comparator|Group B|General Fitness and Toning Group
89039634|NCT06086782|Experimental|autogenic inhibition|isometric of muscles and stretching of the same side
89039635|NCT06086782|Experimental|reciprocal inhibition|isometric of muscles and stretching of the opposite side
89211296|NCT00622700|Experimental|Teriflunomide 14 mg/14 mg|"Core treatment period: Teriflunomide 14 mg tablet once daily orally.~Extension treatment period: Teriflunomide 14 mg tablet once daily orally."
89039636|NCT06086743|Experimental|Experimental Group|"10 min of warm up exercises will be performed.~Arm swings~Jogging on the spot~Walks on treadmill The following exercises will be performed along with EMS after warm up exercises.~Bicep curls~Triceps dips~Squats~Quadriceps chair~The following cool down exercises will be performed after resistance exercises along with EMS.~Light jogging and walking~Upper body stretches~Knee to chest pose Galvanic current would be administer, with intensity of 100 A."
89039637|NCT06086743|Active Comparator|Control Group|"10 min of warm up exercises will be performed.~Arm swings~Jogging on the spot~Walks on treadmill The following exercises will be performed after warmups.~Bicep curls~Triceps dips~Squats~Quadriceps chair~The following cool down exercises will be performed after resistance exercises.~Light jogging and walking~Upper body stretches~Knee to chest pose"
89211297|NCT00538473|Experimental|FluAS25 (GSK576389A) Group|Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).
89211298|NCT00538473|Active Comparator|Fluarix Group|Subjects received 1 dose of Fluarix™.
89628395|NCT05609331|Experimental|Stage I-(Simulated Online Adaptive Planning)|Participants will receive treatment with the conventional CT-based radiation therapy and receive additional MRI scans.
89628396|NCT05609331|Experimental|Stage II (Stereotactic MRI-guided adaptive radiotherapy-SMART)|Participants will receive treatment with the investigational MRI-guided radiation therapy.
89628397|NCT05587192|Experimental|18F-PSMA-1007 PET/CT based on USTC diagnostic model|Patinets will complete the 18F-PSMA-1007 PET/CT based USTC diagnostic model firstly. If clinically significant prostate cancer is considered by 18F-PSMA-1007 PET/CT. Patinets will receive radical prostatectomy directly or undergo prostate biopsy according to patients own decisions, patients with negative results in prostate biopsy will be asked to complete rebiopsy after 3 months.
89628398|NCT05581589|Experimental|Treatment (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 3 hours on days 1 and 8 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks after last dose, patients undergo radical cystectomy and pelvic lymph node dissection.
89628399|NCT05580874|Experimental|Massage group|"Babies in the massage group will be given a five-minute massage once a day, one hour after the morning feeding (between 9.30-11.30 am). Before, during and after the massage procedure, the video will be recorded to observe the stress behavior of the babies. Vital signs will be recorded a minute before the starting of the massage, at fifth minutes during the procedure and a minute after the end of the massage, and a video will be recorded during these processes. A saliva cortisol sample will be taken the massage five minutes before and 30 minutes after the massage. The scores given to the Newborn Stress Scale will be evaluated by watching the videos recorded after the procedure by experts in the field."
89628400|NCT05580874|Other|Control group|"Babies in the swaddling group will form the control group. The swaddling process will be done one hour after the babies are feding (between 9.30-11.30 am). Before, during and after the swaddling procedure, the video will be recorded to observe the stress behavior of the babies. A minute before swaddling, video recording will start. Babies will be swaddling for five minutes and video recording will be continue. After this process, a minute video recording will be made while the baby is not swaddling. Vital signs will be recorded one minute before starting the swaddling at fifth minutes during the procedure, and a minute after the swaddling.~A saliva cortisol sample will be taken five minutes before and 30 minutes after the swaddling. The scores given to the Newborn Stress Scale will be evaluated by watching the videos recorded after the procedure by experts in the field."
89628401|NCT05571046|Active Comparator|Glucocorticoid injection|Intramuscular glucocorticoid (5 mg betamethasone dipropionate and 2 mg betamethasone sodium phosphate)
89628402|NCT05571046|Placebo Comparator|Placebo injection|Intramuscular saline (%0.9 isotonic sodium chloride)
89628403|NCT05567627|Experimental|Initial dose cohort|1.2x10^14 vg/kg of GC301 administered via intravenous infusion
89628404|NCT05546411|Experimental|mFOLFIRINOX + NIS793|"Participants will be randomly assigned to receive:~FOLFIRINOX + NIS793 on day 1 of each 14 day cycle up to 8 cycles/16 weeks~Cycles 9+: Based on study team determination, some participants may be offered chemoradiation following completion of chemotherapy and/or surgery following either completion of chemotherapy or chemoradiation"
89628405|NCT05546411|Active Comparator|mFOLFIRINOX|"Participants will be randomly assigned to receive:~FOLFIRINOX on day 1 of each 14 day cycle up to 8 cycles/16 weeks~Cycles 9+: Based on study team determination, some participants may be offered chemoradiation following completion of chemotherapy and/or surgery following either completion of chemotherapy or chemoradiation"
89628406|NCT05495737||Phase 1: Nurse Participants|n=8-10 nurses
89628407|NCT05495737||Phase 1: Patient Participants|n=8-10 patients
89628408|NCT05495737||Phase 2: Nurse Participants|n=8-10 nurses
89628409|NCT05495737||Phase 2: Patient Participants Meaning-Centered Psychotherapy/MCP-PC Intervention Arm|n=30
89628410|NCT05495737||Phase 2: Patient Participants Treatment As Usual/TAU Intervention Arm|n=30
89628411|NCT05478954|Experimental|Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ)|Children aged 3-59 months will receive SPAQ during the study period.
89628412|NCT05474859|Experimental|Cohort 1|XT-0528 250 mg administered once daily
89628413|NCT05474859|Experimental|Cohort 2|XT-0528 500 mg administered once daily
89628414|NCT05474859|Experimental|Cohort 3|XT-0528 1000 mg administered once daily
89628415|NCT05474859|Experimental|Cohort 4|XT-0528 1500 mg administered once daily
89628416|NCT05474859|Experimental|Cohort 5|XT-0528 2500 mg administered once daily
89628417|NCT05460273|Experimental|Dato-DXd Arm|This single-arm study consists of multiple cohorts, divided by indication.
89628418|NCT05456113|Placebo Comparator|Placebo|Vehicle control, does not contain cannabidiol
89628419|NCT05456113|Experimental|Cannabidiol|Active ingredient experimental arm, contains full spectrum connabidiol
89628420|NCT05449665|Experimental|Control - High Fibre - Low Fibre (CTRL - HF - LF)|"Phase 1 - CTRL: Control diet with moderate fibre consumption for 13days.~Phase 2 - HF: ad libitum consumption of HF meals for 13days.~Phase 3 - LF: ad libitum consumption of LF meals for 13days."
89628421|NCT05431556|Experimental|Virtual mind-body group exercise classes (VMB)|Will be provided with the schedule and links to the web-based mind-body exercises offered by MSK in real-time via the Zoom video conferencing platform. Each session is led by a licensed clinician (e.g., licensed dance therapist, certified yoga instructor, nurse specialist/physical trainer) with specific expertise in the oncology setting.
89039638|NCT06086678|Experimental|Conventional physical therapy group|Strengthening exercises, stretching exercises for the weak and tightened muscles respectively, facilitation of equilibrium and protective reactions and breathing exercises in form of Deep breathing, Diaphragmatic breathing and Pursed lip breathing exercises
89628422|NCT05431556|Active Comparator|Enhanced usual care (EUC)|Pre-recorded self-care videos.
89628423|NCT05416515|Experimental|Carpal Tunnel Syndrome|Adult men and women who have a clinical diagnosis for Carpal Tunnel Syndrome (CTS) will receive Fisetin for 2 day periods for 2 months
89628424|NCT05414955|Experimental|Treated|Patients implanted with neuromodulation
89628425|NCT05403528|No Intervention|3D-3D|All items presented in 3D form
89628426|NCT05403528|Experimental|3D-2D|Initial items in 3D, retention and generalization in 2D
89628427|NCT05403528|Experimental|2D-3D|Initial items in 2D, retention and generalization in 3D
89628428|NCT05403528|Experimental|2D-2D|All items in 2D
89628429|NCT05399446|Experimental|Diabetes Body Project|
89628430|NCT05399446|Active Comparator|Educational Group|
89628431|NCT05379400|Experimental|Portable Air Cleaner (PAC) group|"This study will utilize a portable air cleaner as an intervention for the potential reduction of air pollution-associated inflammation. This commercially available device has no significant risks. The researchers plan to use a commercially available PAC with a true HEPA filter for the true arm."
89628432|NCT05379400|Sham Comparator|Sham Portable Air Cleaner (PAC) group|For the sham arm, the same model will be used with HEPA filter removed, and has identical appearance and sound. The researchers will use a PAC designed to filter air in rooms up to approximately 350 ft2, with minimal noise on the lowest setting.
89628433|NCT05373043|Experimental|Exercise Rehabilitation|Participants will be assigned to the Exercise+Placebo or Exercise+Mito-Q rehabilitation interventions using block randomization (block size 10).
89628434|NCT05373043|Placebo Comparator|Exercise Rehabilitation with Placebo|Participants will be assigned to Exercise+Placebo rehabilitation using block randomization (block size 10)
89628435|NCT05371327||Public Deliberants|Minors and adults recruited from vulnerable populations through a community outreach process.
89628436|NCT05359549||Two adjacent dental implants|25 patients with two missing adjacent teeth in the maxillary aesthetic region which was treated 10 years ago with dental implant placement and an implant-supported restorations.
89628437|NCT05350098|Experimental|A dietary intervention of plant-protein based diets|
89628438|NCT05350098|Active Comparator|A dietary intervention of control diets|
89628439|NCT05341986|Other|Link-Out|Clinicians will be trained on the web-based portal of the CDS tool and shown where the Link to the tool will be available in the EHR.
89628440|NCT05341986|Other|BPA + Link-out|Clinicians will be trained on how a BPA is triggered when a patient is diagnosed with AF. The alert will pop up within the EHR with the Link-out to the web portal.
89628441|NCT05341986|Other|BPA + FHIR|Instead of a link to the web-based portal, the BPA will contain a link to the FHIR-integrated CDS tool portal. FHIR will automatically pull EHR data about the patient into the CDS tool portal. Data include demographic information, comorbidities in the active problem list, past medical and surgical history, and social history. Clinicians will also receive training before the implementation of this step.
89628442|NCT05340998||Crossover Group|Patients with Transradial access failure for percutaneous coronary procedures necessitating vascular crossover
89628443|NCT05340998||Non Crossover Group|Patients with successful transradial access for percutaneous coronary procedures
89039639|NCT06086678|Experimental|Hydrotherapy and conventional physical therapy group|Strengthening exercises, stretching exercises for the weak and tightened muscles respectively, facilitation of equilibrium and protective reactions and breathing exercises in form of Deep breathing, Diaphragmatic breathing and Pursed lip breathing exercises in addition to hydrotherapy
89211299|NCT04004091|Experimental|24-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 24 days of pregnancy. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
89628444|NCT05323721|No Intervention|Control - No SMC|This arm will not receive any SPAQ
89628445|NCT05323721|Active Comparator|Intervention SMC - SPAQ|This arm will receive SPAQ as seasonal malaria chemoprevention
89628446|NCT05323721|Active Comparator|Intervention SMC - SP|This arm will receive SP as seasonal malaria chemoprevention
89628447|NCT05306873|Experimental|MMF|Participants will receive 500 mg mycophenolate mofetil (MMF) bid for 7 days, followed by 500mg and 1,000mg MMF in divided doses for 7 days. They will then continue at a stable dose of 1,000mg MMF bid. Visits to evaluate AEs, vital signs, hematology and chemistry, study medication compliance, medication use, disease status, participant reported outcomes, and to obtain biomarker samples will occur every 4 weeks after randomization
89628448|NCT05306873|Placebo Comparator|Placebo for MMF|Participants will receive 500 mg corresponding mycophenolate mofetil (MMF) placebo bid for 7 days, followed by 500mg and 1,000mg corresponding MMF placebo in divided doses for 7 days. They will then continue at a stable dose of 1,000mg corresponding MMF placebo bid. Visits to evaluate AEs, vital signs, hematology and chemistry, study medication compliance, medication use, disease status, participant reported outcomes, and to obtain biomarker samples will occur every 4 weeks after randomization
89628449|NCT05306873|Experimental|MMF+ Placebo for Voclosporin|Participants randomized in this arm will receive up to 24 weeks of mycophenolate mofetil (MMF) plus placebo for voclosporin, also during the first 2 weeks of treatment, a single intramuscular injection of 80 mg methylprednisolone acetate may be administered if needed to achieve amelioration of symptoms without meeting the definition of treatment failure in Stage 3 and without a requirement to stop Stage 3 study-provided medication
89628450|NCT05306873|Experimental|MMF+ Voclosporin|Participants randomized in this arm will receive up to 24 weeks of mycophenolate mofetil (MMF) plus voclosporin, also during the first 2 weeks of treatment, a single intramuscular injection of 80 mg methylprednisolone acetate may be administered if needed to achieve amelioration of symptoms without meeting the definition of treatment failure in Stage 3 and without a requirement to stop Stage 3 study-provided medication
89628451|NCT05306587||Multiple Myeloma|40 patients with Multiple Myeloma in Department of Hematology at Odense University Hospital, Denmark
89628452|NCT05303987|Experimental|Propofol sedation|2.5 mg/kg loading dose, then continue at an infusion of 250 mcg/kg/minute.
89039640|NCT06086678|Experimental|Aerobic exercise and conventional physical therapy group|Strengthening exercises, stretching exercises for the weak and tightened muscles respectively, facilitation of equilibrium and protective reactions and breathing exercises in form of Deep breathing, Diaphragmatic breathing and Pursed lip breathing exercises in addition to aerobic exercise
89039641|NCT06086665||Observation cohort (Cohort A)|All patients who did not receive any kind of maintenance therapy for primary epithelial ovarian cancer from Dec 2019 to Dec 2022
89039642|NCT06086665||Cohort B|All patients who received or who are receiving niraparib maintenance therapy for primary epithelial ovarian cancer in 1st line setting
89039643|NCT06086665||Cohort C|All patients who received or who are receiving niraparib maintenance therapy for recurrent epithelial ovarian cancer in 2nd or 3rd line setting
89039644|NCT06086665||Cohort D|All patients who received or who are receiving salvage niraparib therapy for recurrent epithelial ovarian cancer in 4th line or more line setting
89039645|NCT06086639|Experimental|Research group; mothers receiving online occupational therapy group training|"Participants in this group received online occupational therapy group training for 1 hour per week for 4 weeks.~Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs"
89039646|NCT06086639|No Intervention|Control group; Participants in this group did not receive any occupational therapy intervention duri|Participants in this group did not receive any occupational therapy intervention during the 4-week period.
89039647|NCT06086613|Experimental|AGA2115|"In Part A, up to 6 single ascending dose cohorts.~In Part B, up to 3 multiple ascending dose cohorts.~In Part C, up to 2 multiple dose cohorts."
89039648|NCT06086613|Placebo Comparator|Placebo|Participants will receive matching placebo.
89039649|NCT06086600|Experimental|Instrument Assisted Soft Tissue Mobilization|"Graston tool on gastrocnemius and soleus muscle. Conventional treatment will include~Hot pack for 10-15 min (calf muscles)~Stretching exercises of gastro-soleus (10reps x 2Sets).~Post session : Cold pack for 5 minutes (calf muscles)"
89039650|NCT06086600|Active Comparator|Dynamic oscillatory stretch technique|"Dynamic oscillatory stretch technique on gastrocnemius and soleus muscle10reps x2 second hold oscillation x 3 sets.~Conventional treatment will include~Hot pack for 10-15 min (calf muscles)~Stretching exercises of gastro-soleus (10reps x 2 Sets).~Post session : Cold pack for 5 minutes (calf Muscles"
89628453|NCT05303987|Experimental|Dexmedetomidine sedation|1 mcg/kg loading dose, then continue at an infusion of 1 mcg/kg/hour
89628454|NCT05302596|Experimental|Semaglutide|Semaglutide, added to standard of care, starting dose of 0.25mg titrated up to 1mg dose. for a total of 16 weeks.
89628455|NCT05302596|No Intervention|standard of care only|Standard of Care (SOC) weight loss intervention alone (personalized lifestyle and exercise)
89628456|NCT05299502|Experimental|Nutritional Intervention|Intervention promoting healthy eating by a Registered Dietitian.
89628457|NCT05299502|No Intervention|Standard Care|Women will have their usual medical pregnancy follow-ups by their MDs without access to nutritional care.
89628458|NCT05290792|Other|Intra-individual changes of physiological and activity parameters|"Participants will be administered FluMist (live attenuated influenza vaccine) to induce a low grade VRTI (Day 0). Participants will be monitored in the 7 days prior and 7 days after vaccination via symptom questionnaires, blood draws, stair tests and vital sign monitoring from wearable sensors.~Each participant will serve as their own control, relying on the baseline measurements obtained over the 7-day period prior to inoculation."
89628459|NCT05279846|Experimental|MOB015B|Applied at bedtime daily for 8 weeks and then reduced to once weekly for 40 weeks
89628460|NCT05279846|Placebo Comparator|Control Arm|Applied at bedtime daily for 8 weeks and then reduced to once weekly for 40 weeks
89628461|NCT05268887|Experimental|Parkinson's Active Arm|Exposure to active sensory stimulation (40Hz) for 30-60 minutes.
89628462|NCT05268887|Sham Comparator|Parkinson's Control Arm|Exposure to control stimulation (sham) for 30-60 minutes.
89628463|NCT05263284|Experimental|Treatment (8-chloroadenosine, venetoclax)|Patients receive 8-Cl-Ado IV over 4 hours daily on days 1-5 and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89628464|NCT05255003|Experimental|Modified dose LMWH without platelet transfusion support|"Patients will be given modified dose LMWH as below based on the first platelet count of the day (daily in admitted patients or at least 2 times a week in outpatients), without empiric platelet transfusion:~I. Platelet count 25-50,000/µL: 50% dose LMWH~II. Platelet count < 25,000/µL: hold anticoagulation"
89628465|NCT05255003|Active Comparator|Higher dose LMWH with platelet transfusion support|"Patients assigned to higher dose LMWH (see below) will be given transfusion for 14 days when the first platelet count of the day falls below 50,000/uL (daily inpatient or at least 2 times a week in outpatients). Post-transfusion counts will not be routinely obtained unless clinically indicated~I. Platelet count 25-50,000/µL: platelet transfusion + 100% dose LMWH~II. Platelet count < 25,000/µL: platelet transfusion + 50% dose LMWH~After Day 14, patients will be transitioned to modified dose LMWH as the other arm without platelet transfusion.~LMWH can include enoxaparin, dalteparin, or tinzaparin, with 100% as:~Enoxaparin - 1mg/kg subcutaneously twice daily~Dalteparin - 200 IU/kg subcutaneously daily for 1 month then 150 U/kg daily~Tinzaparin - 175 units/kg subcutaneously daily"
89628466|NCT05246280|Experimental|Candidates for initiation of anti-TNFα bDMARD therapy|All subjects will be candidates for initiation of, or change to, a new anti-TNFα bDMARD for RA treatment.
89628467|NCT05235620||Pharmacy staff|Pharmacy staff working at pharmacies which have chosen to implement PatientToc software for this implementation science project and evaluation. Pharmacy staff will be observed and participate in interviews pertaining to their experiences using PatientToc.
89628468|NCT05235620||Pharmacy patients|Patients engaged in completing medication adherence-related questionnaires in the PatientToc software at their pharmacies. Patient-level medication, health history, and self-reported adherence information will be collected from patients meeting eligibility criteria. Patients will also be observed and interviewed about their experiences using PatientToc.
89628469|NCT05228899|Experimental|Group 1: Zofin|Group 1 (15 subjects) Fifteen subjects will receive 1 mL of Zofin diluted with 100ml of sterile saline on day 0, day 4 and day 8, containing 2-5 x 10^11 particles/ml intravenously.
89628470|NCT05228899|Placebo Comparator|Group 2: Placebo|Group 2 (15 subjects) Fifteen subjects will receive 1mL of placebo diluted with 100ml of sterile saline on day 0, day 4 and day 8, containing sterile saline intravenously.
89628471|NCT05224375|Experimental|Treatment|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.
89628472|NCT05220501|Active Comparator|Micro-US Only|Subjects will undergo biopsy using micro-ultrasound only.
89628473|NCT05220501|Active Comparator|mpMRI + Micro-US|Subjects will undergo fusion biopsy using mpMRI and micro-ultrasound
89628474|NCT05220501|Active Comparator|mpMRI Only|Subjects will undergo biopsy using mpMRI fused with regular ultrasound
89628475|NCT05217966|Experimental|Preoperative radiotherapy for early breast cancer|Radiation: Single Pre-Operative Radiation Therapy
89039651|NCT06086574||Patients diagnosed with stage 3 NSCLC|"Patients will receive standard of care curative-intent radiotherapy treatment as decided by their primary oncologist. This includes radical radiotherapy, sequential chemoradiotherapy and concurrent chemoradiotherapy +/- consolidation immunotherapy.~No changes in treatment. Patients will have data collected at baseline, during radiotherapy and for one year following radiotherapy. This longitudinal collection will include blood for circulating-tumour DNA analysis, electronic PROMS and radiomic analysis of standard of care imaging."
89039652|NCT06086548||cases|patients with molecular diagnosis of facioscapulohumeral dystrophy
89039653|NCT06086548||controls|healthy volunteers
89039654|NCT06086509|No Intervention|control group|Questionnaires and scales were filled out by the researcher five minutes before the CT scan. Routine CT scans were performed on the control group without listening to music by wearing a Bluetooth headset. The scales were repeated five minutes after the CT scan.
89039655|NCT06086509|Experimental|music group|"Questionnaires and scales were filled out by the researcher five minutes before the CT scan. Just before the CT scan began, the children in the music group were started to listen to Lullaby K 350 music by inserting a Bluetooth headset into their ears. If the process took longer, the music was played again. Additionally, the Bluetooth headset was properly disinfected before each use to prevent the spread of infectious diseases among patients."
89039656|NCT06086483|Active Comparator|iPACK block+ABC block|Patients received a preoperative ultrasound-guided iPACK block with 20 mL of 0.25% ropivacaine and an Adductor Canal block with 20mL 0.25% ropivacaine.
89039657|NCT06086483|Active Comparator|Sham blocks|Patients received a preoperative ultrasound-guided iPACK block with 20 mL of 0.9% normal saline and an Adductor Canal block with 20mL 0.9% normal saline.
89039658|NCT06086366||COVID-DNP|Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
89039659|NCT06086366||Healthy Control|Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
89039660|NCT06086353||Patients with ATTR-CM in India|
89039661|NCT06086327|Experimental|68Ga-Pentixafor, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
89628476|NCT05217589|Experimental|Funny/Amusing Video Clips|Participants will watch 5-7-min video clips that are meant to be funny/amusing
89628477|NCT05217589|Experimental|Horror/Scary Video Clips|Participants will watch 5-7-min video clips that are meant to be scary
89628478|NCT05217589|Experimental|Thrilling/Suspenseful Video Clips|Participants will watch 5-7-min video clips that are meant to be thrilling/suspenseful
89628479|NCT05200013|Experimental|Cohort 1|Dose 0.3mg/kg
89628480|NCT05200013|Experimental|Cohort 2|Dose 1mg/kg
89628481|NCT05200013|Experimental|Cohort 3|Dose: 3 mg/kg
89628482|NCT05200013|Experimental|Cohort 4|Dose: 10 mg/kg
89628483|NCT05200013|Experimental|Cohort 5|Dose: 20 mg/kg
89628484|NCT05200013|Experimental|Cohort 6|Dose: 40 mg/kg
89628485|NCT05196984|Experimental|Down Syndrome Experimental|Experimental arm within Down Syndrome participant group: exposure to active 40Hz stimulation for 30-60 minutes.
89628486|NCT05196984|Sham Comparator|Down Syndrome Sham|Sham arm within the Down Syndrome participant group: exposure to control stimulation for 30-60 minutes.
89628487|NCT05196984|Experimental|Cognitively Normal Experimental|Experimental arm within the cognitively normal control participant group: exposure to active 40Hz stimulation for 30-60 minutes.
89628488|NCT05196984|Sham Comparator|Cognitively Normal Sham|Sham arm within the cognitively normal control participant group: exposure to control stimulation for 30-60 minutes.
89628489|NCT05196776|Experimental|Portable, Handheld Device|Patients will receive a point-of-care ultrasound using a handheld, portable ultrasound device.
89628490|NCT05196776|Active Comparator|Traditional, Cart-based Ultrasound|Patients will receive a point-of-care ultrasound using a traditional, cart-based ultrasound machine.
89628491|NCT05189353|Experimental|Gastric sleeve operated|12 subjects with normal glucose tolerance (NGT) operated with SG minimum 12 month earlier
89628492|NCT05189353|Placebo Comparator|Matched control group|12 weight-matched unoperated subjects with NGT
89628493|NCT05170984|Experimental|CACIPLIQ20®|Treatment of the target wound with CACIPLIQ20® in addition to optimal local care
89039662|NCT06086314|Experimental|reactive exercise training|They will attend the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. After this program, they will receive reactive exercise training.
89211300|NCT04004091|Experimental|26-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 26 days of pregnancy. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
89628494|NCT05170828|Other|Regmin A (RIC)|Pre-transplant conditioning treatment with Fludarabine, Cyclophosphamide, and Total Body Irradiation (TBI)
89628495|NCT05170828|Other|Regimen B (FIC)|Pre-transplant conditioning treatment with Busulfan and Cyclophosphamide OR Fludarabine
89628496|NCT05170828|Other|Regimen C (FIC)|Pre-transplant conditioning treatment with Cyclophosphamide and Total Body Irradiation (TBI)
89039663|NCT06086314|Experimental|reactive exercise training with co-contraction|They will attend the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. After this program, they will receive reactive exercise training aimed at creating co-contraction.
89039664|NCT06086314|Active Comparator|functional reaching training|They will attend the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. After this program, they will receive functional reaching training.
89628497|NCT05142800||Target Therapy Drug-Stand Care|"Screening procedures confirm participation in the research study.~Participants limb volume is measured prior to treatment start date.~Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card.~Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication"
89628498|NCT05142800||Target Therapy-Early or Metastatic Breast Cancer|"Screening procedures confirm participation in the research study.~Participants limb volume is measured prior to treatment start date.~Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card.~Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication"
89628499|NCT05130788|Experimental|Intervention Group A|Participants will be assigned to a 6-week intervention period.
89628500|NCT05130788|Experimental|Intervention Group B|Participants will be assigned to a 12-week intervention period.
89628501|NCT05130788|Active Comparator|Control Group|
89628502|NCT05130476|Experimental|NIRAF+ICGA|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
89628503|NCT05130099|Experimental|Interdisciplinary complex intervention|
89628504|NCT05130099|No Intervention|Usual care|Six months after the intervention period (T3), the participants randomized to usual care will be offered a modified version of the intervention in line with their personally expressed needs.
89628505|NCT05121649||Before|Injured patients included in the study from health trusts where video streaming not yet has been implemented in the EMCC
89628506|NCT05121649||After|Injured patients included in the study from health trusts where video streaming has been implemented in the EMCC
89628507|NCT05090904|Experimental|Brensocatib 10 mg|Participants will be administered brensocatib at a dose of 10 mg once per day for 28 days. The participants will be stratified based on cystic fibrosis transmembrane conductance regulators (CFTRs) modulator treatment.
89628508|NCT05090904|Experimental|Brensocatib 25 mg|Participants will be administered brensocatib at a dose of 25 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
89628509|NCT05090904|Experimental|Brensocatib 40 mg|Participants will be administered brensocatib at a dose of 40 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
89628510|NCT05090904|Experimental|Brensocatib 65 mg|Following review of safety and pharmacokinetic data by the safety review committee, an additional cohort of participants may be administered brensocatib at a dose of 65 mg once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
89628511|NCT05090904|Placebo Comparator|Placebo|Participants will be administered a placebo matching brensocatib once per day for 28 days. The participants will be stratified based on CFTRs modulator treatment.
89628512|NCT05089682|Experimental|Deep Brain Stimulation (DBS) system|Subjects with existing DBS systems implanted for neurological disease (e.g., Parkinson's, pain, epilepsy) will have targeted stimulation patterns during specific stages of sleep using their existing DBS device.
89039665|NCT06086288|Experimental|Single Arm|
89039666|NCT06086262||Athletic group|twenty basketball and tennis players
89039667|NCT06086262||Non athletic group|were recruited from undergraduate students
89628513|NCT05084417||Cohort 1: Alopecia Areata|Cohort 1 is limited to patients clinically diagnosed with Alopecia Areata. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional AA-specific measures throughout the length of the study.
89628514|NCT05084417||Cohort 2: Atopic Dermatitis|Cohort 2 is comprised of patients that have been clinically diagnosed with Atopic Dermatitis. Patients in this cohort will receive the universal PROs and ClinROs, but will also receive additional AD-specific measures throughout the length of the study.
89628515|NCT05084417||Cohort 3: Hidradenitis Suppurativa|Cohort 3 is limited to patients clinically diagnosed with Hidradenitis Suppurativa. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional HS-specific measures throughout the length of the study.
89628516|NCT05084417||Cohort 4: Psoriasis|Cohort 4 is limited to patients clinically diagnosed with Psoriasis. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional PsO-specific measures throughout the length of the study.
89628517|NCT05084417||Cohort 5: Vitiligo|Cohort 5 is limited to patients clinically diagnosed with Vitiligo. Patients in this cohort will receive the universal ClinROs and PROs (i.e. not disease specific) as well as additional VL-specific measures throughout the length of the study.
89628518|NCT05062473|Other|Hypertension telemedicine curriculum|All participants participate in the 12-week telemedicine curriculum. All participants will be asked to record their steps via pedometer and their blood pressure measurements via automatic blood pressure arm cuff.
89628519|NCT05055128|Experimental|X842 25 mg BID|Patients will receive 2 tablets (X842 25mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 25 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
89628520|NCT05055128|Experimental|X842 50 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
89628521|NCT05055128|Experimental|X842 75 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 25 mg) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg + X842 25 mg) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
89628522|NCT05055128|Experimental|X842 100 mg BID|Patients will receive 2 tablets (X842 50 mg×2) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
89211301|NCT04004091|Experimental|28-Day Spermine Group|Subjects are given prenatal spermine (20 mg per body weight) during 28 days of pregnancy. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
89211302|NCT04004091|No Intervention|24-Day Non Spermine Group|Subjects are not given any intervention. On day 24 pregnancy is terminated and intestinal tissue sample is taken to be examined.
89628523|NCT05055128|Active Comparator|Lansoprazole|Patients will receive 2 tablets (X842 dummy×2) and 1 capsule (Lansoprazole 30 mg) in the morning, and 2 tablets (X842 dummy×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
89628524|NCT05054504|Other|Intervention|The primary intervention is a multi-phase, mixed methods, implementation research study that will investigate the feasibility and acceptability of the limited introduction of ultrasound via the Butterfly iQ device into routine ANC service delivery at health center level in Blantyre, Malawi. The study will occur in three phases: 1) Training, 2) Iterative Service Delivery, and 3) Final Evaluation.
89628525|NCT05053100||Observational (record review, blood collection)|Patients' electronic health record are reviewed for 12 months and/or undergo collection of blood at pretreatment and on days 7, 28, 90, and 180.
89628526|NCT05038020|Experimental|AKST4290|Subjects will receive AKST4290, 400mg twice daily, for 24 weeks
89628527|NCT05038020|Placebo Comparator|Placebo|Subjects will receive matching Placebo, twice daily, for 24 weeks
89628528|NCT05009758|Active Comparator|T2-high asthma with nasal polyps|"FeNO > 25 ppB~Had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months~Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)~Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
89628529|NCT05009758|Active Comparator|T2-high asthma without nasal polyps|"FeNO > 25 ppB~Had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months~Absence of NP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)~Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
89628530|NCT05009758|Active Comparator|CRSwNP in absence of asthma|"Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines26~Evidence of Type 2 inflammation: blood eosinophils >= 250 cells/µl measured in the blood OR total IgE >100 kU/L26 at the screening visit~Absence of asthma and N-ERD~Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a washout period of 5 half-lives or at least 3 months have passed"
89628531|NCT05004987|Active Comparator|Escitalopram (ESC)|
89628532|NCT05004987|Placebo Comparator|Placebo (PBO)|
89628533|NCT04981275||Women with PCOS|Women previously diagnosed with PCOS not using hormonal therapy and without other significant health or endocrine issues
89628534|NCT04981275||Healthy controls|Women self-identifying as generally healthy, not using hormonal therapy, and without any significant health or endocrine issues
89628535|NCT04974736|Experimental|iEHR + Navigator|
89628536|NCT04974736|No Intervention|Usual Care Control|Usual care delivery in pediatric primary care offices.
89628537|NCT04968834||GENOMIC PROFILING AND SPECIMEN BANKING REGISTRATION ARM|The research study procedures include screening for eligibility, reviewing and signing this consent form, collecting patient information and clinical data, obtaining previously collected bone marrow and blood samples, and completing a brief optional Household Survey. Bone marrow and blood samples may also be collected in the future as part of your routine clinical procedures
89628538|NCT04965935|Experimental|Dapagliflozin Tablets|Patients will be randomized to therapy with dapagliflozin 10mg PO daily for 12 weeks.
89628539|NCT04965935|Placebo Comparator|Placebo Matching Dapagliflozin Tablets|Patients will be randomized to therapy with placebo matching dapagliflozin tablets PO daily for 12 weeks.
89628540|NCT04957394|Experimental|Experimental (Family Partner)|The treatment group will receive six hours follow-up and support weekly. The service will be provided by a dedicated Family Partner.
89628541|NCT04957394|No Intervention|Control group|"The control group will receive default support from the child welfare services. The service will be business as usual, provided by the local staff at the child welfare services."
89628542|NCT04940286|Experimental|Treatment (durvalumab, oleclumab, nab-paclitaxel, gemcitabine)|Patients receive durvalumab IV over 1 hour on day 1, oleclumab IV over 1 hour, nab-paclitaxel IV, and gemcitabine IV over 1 hour over 30-40 minutes on days 1 and 15. Treatment repeats every 28 days for 2-6 cycles. Within 4-8 weeks after completion of last cycle of treatment, patients undergo surgical resection. After surgical resection, patient may receive adjuvant therapy with durvalumab and oleclumab, durvalumab, oleclumab, gemcitabine, and nab-paclitaxel, other chemotherapy, or observation only at the discretion of the treating physician.
89628543|NCT04887857|Experimental|CC-486 in combination with Venetoclax|
89628544|NCT04878965|Other|Smartwatch|Individuals receiving the smartwatch
89628545|NCT04855578|No Intervention|Usual Medical Care|During the control period, patients admitted to the study sites who qualify for the trial will receive a pharmacy medication reconciliation as part of usual medical care. Study participants will be informed that the goal of the trial is to evaluate medication use and medication changes after discharge, but they will not be informed that gabapentinoids are specifically being targeted. Medical staff will not receive specific information about the trial, or particular instructions with regards to deprescription during the control period.
88990130|NCT04168008|Experimental|Adherence|Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for ART adherence and engagement in HIV care.
88990131|NCT04168008|Active Comparator|Parenting|Women randomized to the parenting control arm will also attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. The educational sessions will be focused on parenting and baby care.
89211303|NCT04004091|No Intervention|26-Day Non Spermine Group|Subjects are not given any intervention. On day 26 pregnancy is terminated and intestinal tissue sample is taken to be examined.
89628546|NCT04855578|Experimental|In-Hopsital Patient Educational Brochure and Physician Education about Gabapentinoid Prescription|During the intervention period, patients admitted to the study sites who qualify for the trial will receive an in-hospital educational brochure. Additionally, the medical team will attend an educational session about gabapentinoid prescription.
89628547|NCT04851028|Experimental|One2One|1) Weekly individual (one2one) Music Therapy intervention lasting 5 months (n=20 sessions)
89628548|NCT04851028|Experimental|Small-group|2) Weekly small group (max 8 people per group) Music Therapy intervention lasting 5 months (n=20 sessions)
89628549|NCT04851028|No Intervention|Control|Standard weekly music social listening in large group available in all care-homes. Lasting 5 months (n=20 sessions)
89628550|NCT04841096|Experimental|Group A1: Glimepiride (1mg) / Vildagliptin (50mg) / Metformin (500mg).|Tablets, orally, once a day. Initial dose for the first 45 days of intervention.
89628551|NCT04841096|Experimental|Group B1: Glimepiride (1mg) / Vildagliptin (50mg) / Metformin (500mg)|Tablets, orally, once a day. Initial dose for the first 45 days of intervention.
89628552|NCT04841096|Experimental|Group A2: Glimepiride (2mg) / Vildagliptin (50mg) / Metformin (1000mg)|Tablets, orally, once a day. Dose escalation if the patients meets established criteria.
89628553|NCT04841096|Experimental|Group B2: Glimepiride (4mg) / Vildagliptin (50mg) / Metformin (1000mg)|Tablets, orally, once a day. Dose escalation if the patients meets established criteria.
89628554|NCT04836000|Placebo Comparator|Placebo Group|In addition to the conservative treatment of the control group, low-level laser therapy (turned off) will be applied for 6 weeks. In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions.
89628555|NCT04836000|Experimental|Experimental Group|In addition to the conservative treatment of the control group, low-level laser therapy will be applied for 6 weeks.
89628556|NCT04836000|Active Comparator|Control Group|For 6 weeks, all three groups will receive five sessions per week of a protocolised treatment based on therapeutic exercises, analgesic electrotherapy and cryotherapy.
88990132|NCT04167605||Breast cancer metastatic to bone|No direct intervention(s) will be administer to the patients. We will use the sample (slides) recovered from the surgery on primary tumor (breast cancer responsible for metastatic disease).
89628557|NCT04831788||Adults|Adults older than 50 years of age, residing in the city of Novi Sad, Serbia and providing oropharyngeal and nasopharyngeal swab specimen upon signing informed consent
89628558|NCT04824612|Sham Comparator|Sham Group|"intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide (Triancil®, Apsen Farmacêutica S.A.) - two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.~Sham PBM in the preoperative and postoperative periods of keloid removal surgery: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month."
88990133|NCT04167605||Bone metastasis|No direct intervention(s) will be administer to the patients. Waste material will be analysed for the expression of specific proteins
88990134|NCT04165733||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
89211304|NCT04004091|No Intervention|28-Day Non Spermine Group|Subjects are not given any intervention. On day 28 pregnancy is terminated and intestinal tissue sample is taken to be examined.
88990135|NCT04165720||Psychiatrists in Germany|Psychiatrists in Germany currently working with patients with mental disorders
89211305|NCT00831506|Experimental|A|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
89211306|NCT00831506|Experimental|B|digoxin once daily (0.125 mg QD) plus Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
89211307|NCT02548130||Patients before MELD score|Recipients before the MELD score
89211308|NCT02548130||Patients after the MELD score|Recipients after the MELD score
89211309|NCT00990951|Experimental|Senna alexandrina and associations|Association of Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
89211310|NCT00828620||PET-CT|Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab
89211311|NCT02842359|Experimental|Rovelito|Fixed-dose combination of irbesartan/atorvastatin will be given orally daily for 28 days
89211312|NCT02842359|Active Comparator|Irbesartan|Irbesartan will be given orally daily for 28 days
89211313|NCT02842359|Active Comparator|Atorvastatin|Atorvastatin will be given orally daily for 28 days
89211314|NCT00823784|Experimental|1THD group|Series of 135 patients with 3rd degree Hemorrhoids treated by THD device under spinal anaesthesia
89211315|NCT00823784|Active Comparator|2 stapler group|135 patients with 3rd degree hemorrhoids will be treated by staple hemorrhoidopexy
89211316|NCT01564017|Experimental|Allergovac depot. Group 1|Increasing dosages till the maintenance dose of 0.0625 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
89211317|NCT01564017|Experimental|Allergovac depot. Group 2|Increasing dosages till the maintenance dose of 0.125 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
89211318|NCT01564017|Experimental|Allergovac depot. Group 3|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
89211319|NCT01564017|Experimental|Allergovac depot. Group 4|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
89211320|NCT01564017|Experimental|Allergovac depot. Group 5|Increasing dosages till the maintenance dose of 0.75 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
89628559|NCT04824612|Experimental|Experimental Group|"Transcutaneous PBM will be performed on the keloid in the preoperative period and on the remaining scar in the postoperative period using blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J). Frequency: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month.~Intralesional administration of corticoid (IAC): intralesional injection of 20 mg/ml triamcinolone hexacetonide: two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies."
89628560|NCT04804514|Experimental|KH001|The study consists of sequential dosing cohorts, 8 subjects per cohort will be administered KH001 or placebo.
89628561|NCT04804514|Placebo Comparator|Placebo|The study consists of sequential dosing cohorts, 8 subjects per cohort will be administered KH001 or placebo.
89628562|NCT04803201|Experimental|Arm A (duvelisib, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive duvelisib PO BID on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89628563|NCT04803201|Experimental|Arm B (CC-486, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive CC-486 PO QD on days -6 to 0 of cycle -1 and days 8-21 of cycles 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89628564|NCT04803201|Active Comparator|Arm C (CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89628565|NCT04798664|No Intervention|Basic Usual Care|Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.
89628566|NCT04798664|Active Comparator|Enhanced Usual Care|Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
89628567|NCT04798664|Active Comparator|Enhanced Usual Care plus Financial Incentives|Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
89628568|NCT04798664|Active Comparator|Enhanced Usual Care plus Financial Incentives plus Mobile Health Application|"Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the future is now between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner."
89628569|NCT04796610|Experimental|Intervention patients|Unsuppressed HIV patients at the intervention clinic will receive guidance from their health care provider on the selection of a treatment partner. The patient will receive education on HIV treatment and how treatment partners can support patients in treatment adherence.
89628570|NCT04796610|No Intervention|Control patients|Patients at the control clinic will receive standard of care at the clinic during the intervention assessment period.
89628571|NCT04796610|Experimental|Intervention treatment partners|Unsuppressed HIV patients at the intervention clinic will receive guidance from their health care provider on the selection of a treatment partner. The treatment partner will receive education on HIV treatment and how treatment partners can support patients in treatment adherence.
89211321|NCT01564017|Placebo Comparator|Allergovac depot placebo. Group 6|The same scheme of treatment as the active groups
89211322|NCT00828698||Acute Myocardial Infarction patients|
89211323|NCT04044014|Active Comparator|Arm A|Left arm: Gellan sheet; Right arm: Mepitel One.
89211324|NCT04044014|Active Comparator|Arm B|Left arm: Mepitel One; Right arm: Gellan sheet.
89211325|NCT04044014|Active Comparator|Arm C|Left arm: Gellan fluid gel; Right arm: Mepitel One.
89211326|NCT04044014|Active Comparator|Arm D|Left arm: Mepitel One; Right arm: Gellan fluid gel.
89211327|NCT00991107|Experimental|HE3286|HE3286 20 mg (10 mg BID)
88990136|NCT04161885|Experimental|Part 1: Venetoclax + Azacitidine (AZA) + Best Supportive Care|Participants will be administered various doses and dose regiments of venetoclax and AZA. Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days)
88990137|NCT04161885|Experimental|Part 2: Arm A - Venetoclax + Azacitidine (AZA) + BSC|Participants will be administered with venetoclax and AZA at a dose level determined in Part 1 in addition to best supportive care (when required). Venetoclax will be administered once daily (QD) (Days 1-28) for up to 24 cycles, AZA QD on Days 1-5 of each 28-day cycle for up to 6 cycles and best supportive care (BSC) for 24 cycles (each cycle = 28 days).
88990138|NCT04161885|Experimental|Part 2: Arm B - Best Supportive Care (BSC)|Participants will receive treatment as prescribed by their physician according to the BSC for up to 24 cycles (1 cycle = 28 days)
89211328|NCT00828776|Experimental|1|Heparin Cristália
89628572|NCT04796610|No Intervention|Control treatment partners|Treatment partners will not receive any intervention; treatment partners' patients at the control clinic will receive standard of care at the clinic during the intervention assessment period.
89628573|NCT04788680|Experimental|Experimental: Beverage 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
89628574|NCT04788680|Experimental|Experimental: Beverage 2|Participants receive a beverage with a defined amount of non-nutritive sweetener.
89628575|NCT04788680|Experimental|Experimental: Beverage 3|Participants receive a beverage with a defined amount of monosaccharide.
89628576|NCT04788680|Experimental|Experimental: Beverage 4|Participants receive a beverage with a defined amount of disaccharide.
89628577|NCT04782258|Experimental|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.
89628578|NCT04782258|Experimental|Tolvaptan Tablets|Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets. Treatment duration is 18 months.
89628579|NCT04779307|Experimental|Induction Period: Participants ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of ≥30 kg are included in this arm.
89628580|NCT04779307|Experimental|Induction Period: Participants >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of >15 to <30 kg are included in this arm.
89628581|NCT04779307|Experimental|Induction Period: Participants 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with UC having Baseline weight of 10 to 15 kg are included in this arm.
89628582|NCT04779307|Experimental|Maintenance Period: Participants ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
89628583|NCT04779307|Experimental|Maintenance Period: Participants ≥30 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
89628584|NCT04779307|Experimental|Maintenance Period: Participants >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
89628585|NCT04779307|Experimental|Maintenance Period: Participants >15 to <30 kg, Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
89628586|NCT04779307|Experimental|Maintenance Period: Participants 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
89628587|NCT04779307|Experimental|Maintenance Period: Participants 10 to 15 kg, Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
89628588|NCT04767191|Active Comparator|artemether lumefantrine|The drug is approved and in use by the Kenya Ministry of Health as the 1st line treatment for malaria. The study is to assess the continued efficacy of the drug.
89628589|NCT04767191|Active Comparator|dihydroartemisinin piperaquine|The drug is approved and in use by the Kenya Ministry of Health as the 2nd line treatment for malaria. The study is to assess the continued efficacy of the drug.
89628590|NCT04765657|Experimental|inclisiran sodium 300 mg|Subcutaneous injection
89628591|NCT04765657|Placebo Comparator|Placebo|Subcutaneous injection
89628592|NCT04754412|Active Comparator|Arm I (control writing)|Patients write about facts regarding their cancer diagnosis and treatment for 3 weekly 30-minute sessions.
89628593|NCT04754412|Experimental|Arm II (self-regulation writing)|Patients write about stress and coping, emotional disclosure, and benefit finding for 3 weekly 30-minute sessions.
89628594|NCT04754412|Experimental|Arm III (self-cultivation writing)|Patients write about positive thoughts and feelings regarding their breast cancer experience for 3 weekly 30-minute sessions.
89628595|NCT04747522||Kidney Transplanted patients|Kidney transplanted patients transplanted at least 6 months prior to SARS-CoV-2 vaccination. Vaccination according to national plan with messenger Ribonucleic acid (mRNA) vaccine
89628596|NCT04747522||Healthy controls|Healthy hospital staff receiving SARS-CoV-2 mRNA vaccine as being front line Healthcare workers.
89628597|NCT04729504|Other|Adapted Project BRAVE Group|Participants in this group will receive a single session intervention of a culturally and linguistically adapted Project BRAVE.
89628598|NCT04722666|Experimental|MIJ821 (mg/kg) - very low dose|MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
89628599|NCT04722666|Experimental|MIJ821 (mg/kg) - low dose|MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
89628600|NCT04722666|Experimental|MIJ821(mg/kg) - high dose|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
89628601|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
89628602|NCT04722666|Placebo Comparator|Placebo|40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
89628603|NCT04722666|Experimental|MIJ821 (mg/kg) - high dose/Placebo|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
89628604|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose/Placebo|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
89628605|NCT04715555||Atrial Fibrillation|Participants with a diagnosis of atrial fibrillation (AF) who exhibited AF in previous AF screening (as part of the SAFER Programme).
89628606|NCT04715555||Non-Atrial Fibrillation|Participants without a diagnosis of atrial fibrillation (AF) who have previously undergone AF screening (as part of the SAFER Programme).
89628607|NCT04711109|Experimental|Arm A (denosumab)|Patients receive denosumab SC q6m for up to 5 years in the absence of disease progression or unacceptable toxicity.
89628608|NCT04711109|Placebo Comparator|Arm B (placebo)|Patients receive placebo SC q6m for up to 5 years in the absence of disease progression.
89628609|NCT04705896|Active Comparator|20-25% Albumin fluid|100 mL 20-25% Albumin fluid at the initiation of continuous renal replacement therapy (CRRT), prolonged intermittent renal replacement therapy (PIRRT), or intermittent hemodialysis (IHD) and another 100 mL 20-25% Albumin fluid and halfway through RRT sessions in ICU.
89628610|NCT04705896|Placebo Comparator|Normal Saline|100 mL at the initiation of CRRT, SLED or IHD and another 100 mL 0.9% Normal Saline halfway through RRT sessions in ICU.
89628611|NCT04702997|Experimental|Bardoxolone methyl|"Patients randomized to receive bardoxolone methyl capsules orally once daily for 12 weeks at a starting dose of 5 mg and titrated up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g)~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
89628612|NCT04702997|Placebo Comparator|Placebo|"Patients who received placebo, once-daily, orally, remained on placebo throughout the study duration of 12 weeks and followed the same titration to maintain the blind,~Patients will be scheduled to be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Patients will not receive any drug during a 5-week off-treatment period between Weeks 12 and 17. Patients will be assessed on Day 3 off-treatment (OT), Day 7 OT, Day 14 OT, Day 21 OT, Day 28 OT, and Day 35 OT. The OT day corresponds to days after last dose.~Patients will be assessed at and end-of-study (EOS) visit on Week 17."
89628613|NCT04684979|Experimental|HLA-compatible Related Donor|This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies. Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
89628614|NCT04684979|Experimental|Unrelated Donor|This is a phase 2 study to evaluate NMA PBSCT incorporating peri-transplant rituximab and utilizing PBSC to augment graft cell dose in patients with selected B lymphoid malignancies. Salvage chemotherapy will be required as part of transplant eligibility, both to achieve debulking of disease to allow sufficient time for the development of a post-transplant GVL effect, and to contribute to recipient immune suppression and thus facilitate donor engraftment.
89628615|NCT04668300|Experimental|Treatment (oleclumab, durvalumab)|Patients receive oleclumab IV over 1 hour every 2 weeks for 5 doses, then every 4 weeks thereafter. Patients also receive durvalumab IV over 1 hour every 4 weeks. Cycle repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89628616|NCT04666038|Experimental|Arm A (LOXO-305)|Orally
89628617|NCT04666038|Active Comparator|Arm B (Idelalisib plus rituximab [IdelaR] or bendamustine plus rituximab [BR])|Investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR).
89628618|NCT04662827|Experimental|Palmithylethanolamid|Probands receive PEA 3xday for 28 days, 8 weeks wash out will follow, then they receive placebo for 28 days
89628619|NCT04662827|Placebo Comparator|placebo|Probands receive placebo 3xday for 28 days, 8 weeks washout will follow, then they receive PEA for 28 days
89628620|NCT04662125|Active Comparator|group A|Group A (conservative treatment): oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
89628621|NCT04662125|Active Comparator|group B|Group B (oral prednisolone): patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days.
89628622|NCT04662125|Active Comparator|group C|Group C (oral pregabalin): patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
89628623|NCT04654689|Experimental|Intervention group|30 patients will be given the combination of resveratrol and curcumin liposomed with G04CB02, in a single daily dose for 4 months.
89628624|NCT04654689|Placebo Comparator|Control group|30 patients, who will receive a placebo with the same dosage pattern and for the same period of time. The placebo will consist of water with sucrose replacing the liposomal polyphenols, and a soft capsule of microcrystalline methylcellulose instead of G04CB02. Both the packaging and the capsule format will be identical to those of the treatment administered in the intervention group
89628625|NCT04604275|Experimental|Sucrase intervention followed by placebo|Participants in this arm will receive sucrase for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of placebo.
89628626|NCT04604275|Experimental|Placebo followed by sucrase intervention|Participants in this arm will receive placebo for 4 weeks followed by wash out of 1 week with no drug administered then 4 weeks of sucrase.
89628627|NCT04594876|Other|Flouroscopic guidance Cervical Epidural injection|Group (P) flouroscopic guidance cervical epidural injection
89628628|NCT04594876|Other|Flouroscopic guidance cervical facet injection|Group (F) Flouroscopic guidance cervical facet injection
89628629|NCT04579848|Active Comparator|Methotrexate|"Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.~Additional Folic acid 1mg prescribed daily."
89628630|NCT04579848|Placebo Comparator|Placebo|"3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.~Additional Folic acid 1mg prescribed daily."
89628631|NCT04556201|Experimental|Thulium Fiber Laser lithotripsy|Subjects who have a medical indication for ureteroscopy, percutaneous nephrolithotomy (PCNL) or mini PCNL
89628632|NCT04555317|No Intervention|Standard of Care|No intervention. Standard of care cancer pathway followed.
89628633|NCT04555317|Active Comparator|Musculoskeletal Health Package|3 month prehabilitation exercise program during radiotherapy and assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
89628634|NCT04548154|Experimental|Proximal Resistance Training|Participants will receive 6 one-on-one supervised intervention visits and 8 telerehabilitation visits over 10 weeks. For the first 4 weeks intervention frequency will start with 1x/ week in clinic and 1x/ week via telerehabilitation, and the participant will be asked to perform exercises 2x/ week independently. For the final 6 weeks there will be 1x week supervised visits (weeks 6 and 8 in person, and weeks 5,7, 9, and 10 via telerehabilitation) and the participant will be asked to perform exercises 3x/ week independently.
89628635|NCT04523350|Experimental|Instylla HES|
89628636|NCT04523350|Active Comparator|Control|TAE or cTACE
89628637|NCT04516538|Experimental|Young people|Men or Women under 35 years old
89628638|NCT04516538|Experimental|Old people|Men or Women between 60 and 80 years old
89628639|NCT04516538|Experimental|Very old people|Men or Women over 80 years old
89628640|NCT04462159|Experimental|Risk Reduction Program|All participants will receive education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component.
89628641|NCT04449991|Experimental|Intervention arm: Repeat kidney biopsy at M12|Patients will undergo repeat kidney biopsy at month 12 from baseline.
89628642|NCT04449991|No Intervention|Control arm: No repeat kidney biopsy|Patients will not undergo repeat kidney biopsy at month 12 from baseline.
89628643|NCT04445662|Active Comparator|Control (n=90)|"Varenicline~Tobacco coaching~Saliva cotinine monitoring with fixed payments ($10) regardless of results"
89628644|NCT04445662|Experimental|Financial incentives (n=90)|"Varenicline~Tobacco coaching~Saliva cotinine monitoring with escalating payments ($25-70) for levels <30 ng/ml"
89628645|NCT04440670|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after birth. Cell dose for all patients was targeted at 5×107 cells per kilogram.
89628646|NCT04440670|Placebo Comparator|control group|Those in control group will receive an infusion of a placebo solution which is normal saline with the same volume.
89628647|NCT04435834|Experimental|Propofol|"Subject will receive propofol anesthesia during their MRI. Dosage form: injectable solution. Dosage: 100-300 mcg/kg/min, or as per clinical standard of care appropriate for specific subjects.~Frequency and duration: continuous infusion while undergoing MRI."
89628648|NCT04435834|Experimental|Sevoflurane|"Subject will receive sevoflurane anesthesia during their MRI. Dosage form: volatile liquid for inhalation Dosing: 0-1 month full term neonate (3.3% in oxygen), 1-6 months old (3% in oxygen), 6 months to <3 years old (2.8% in oxygen), or as per clinical standard of care appropriate for specific subjects.~Frequency and duration: continuous infusion while undergoing MRI."
89628649|NCT04429958||GDM|125 mothers with a history of GDM in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
89628650|NCT04429958||abnormal GCT group|125 mothers with an abnormal glucose challange test (GCT of 130mg/dl or more) in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
89628651|NCT04429958||normal group|125 mothers with both a normal GCT and OGT in pregnancy at the time of the BEDIP study and their offspring born during the BEDIP study
89628652|NCT04428190|Active Comparator|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have been shown to stimulate the production of short chain fatty acids, especially propionate. Propionate has been shown to be important in attenuating hypertrophy, fibrosis, vascular dysfunction and hypertension (Bartolomaeus H et al 2019Mar12) and extremely important for the gut kidney axis (Li L et al 2017Dec11)."
89628653|NCT04428190|Placebo Comparator|Placebo|"10 g sachet, self-administered for 3 months.~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
89628654|NCT04423874|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while listening to vocalisations. Physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
89628655|NCT04383444||SARS-CoV-2 exposure|NIH staff exposed to SARS-CoV-2 or current or previous SARS-CoV-2 infection, but currently asymptomatic
89628656|NCT04369612|Active Comparator|Standard of care|Standard follow-up after kidney transplantation during the first 7-8 post-transplant weeks
89628657|NCT04369612|Experimental|Home-based monitoring|Every second visit will be performed without patients actually visiting the hospital. They take a capillary blood sample themselves, send it to the lab and get a telecom follow-up by treating physician the same day.
89628658|NCT04354012|Experimental|Treatment|methylene blue, gentian violet, and ovine forestomach wound dressings to HS lesions
89628659|NCT04352400|Active Comparator|Nafamostat|Nafamostat mesylate on top of best standard of care.
89628660|NCT04352400|Placebo Comparator|Placebo|Placebo on top of best standard of care.
89628661|NCT04351698|Active Comparator|Investigation|Montelukast
89628662|NCT04351698|Placebo Comparator|Match Placebo|Matched Placebo
89628663|NCT04349059|Active Comparator|Plant-based arm|The plant-based arm consists of 3 visits to the clinical research center, following a plant-based diet and using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
88990139|NCT04149691|Experimental|CPL304110|CPL304110 will be administered once daily to adults with advanced solid malignancies in 28-day cycles.
88990140|NCT04134260|Active Comparator|Arm I (hormone therapy, radiation therapy)|Patients receive standard of care hormone therapy per physician discretion for 24 months. Patients also undergo standard of care pelvis and prostate bed radiation therapy 5 days per week over 5-6 or 7-8 weeks beginning within 90 days of randomization in the absence of disease progression or unacceptable toxicity.
88990141|NCT04134260|Experimental|Arm II (hormone therapy, radiation therapy, apalutamide)|Patients undergo standard of care hormone therapy and radiation therapy as in Arm I. Patients also receive apalutamide PO QD on days 1-90. Cycles repeat every 90 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
88990142|NCT04128696|Experimental|Participants receiving feladilimab and pembrolizumab|Participants were administered feladilimab (humanized anti-ICOS immunoglobulin G4 [IgG4] monoclonal antibody [mAb]) and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an intravenous (IV) infusion once every three weeks.
88990143|NCT04128696|Active Comparator|Participants receiving placebo and pembrolizumab|Participants were administered placebo and pembrolizumab (humanized anti-PD-1 IgG4 mAb) as an IV infusion once every three weeks.
88990144|NCT04118010|Active Comparator|Vitamin D3 and Inulin|Vitamin D3 50,000 IU/week and 12 g/day chicory-derived prebiotic inulin for 12 weeks
88990145|NCT04118010|Active Comparator|Vitamin D3 and placebo Inulin|Vitamin D3 50,000 IU/week and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
89211329|NCT00828776|Active Comparator|2|Heparin - Roche
89628664|NCT04349059|Active Comparator|Animal-based arm|The animal-based arm consists of 3 visits to the clinical research center, following an animal- based diet and using the Rigiscan™ device to measure the frequency, rigidity, and duration of nocturnal erections.
89628665|NCT04339699|Active Comparator|NobleStitch™EL|Participants treated with the NobleStitch™EL device
89628666|NCT04339699|Active Comparator|Amplatzer PFO Occluder|Participants treated with the Amplatzer PFO Occluder device
89628667|NCT04326192|Experimental|All subjects|All subjects will have two PET/CT scans on days 3 and 5 after SCS electrode implantation: (1) Baseline and (2) SCS-activated. Other than SCS activation, both studies will be conducted under identical conditions. For the first scan, subjects will be randomly assigned to either a baseline (no SCS during PET/CT) or with SCS during PET/CT prior to the day of their first scan. The second scan will complete the sequence with either a baseline or SCS-activated scan, as randomized.
89628668|NCT04306952|Experimental|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat.
89628669|NCT04306952|Experimental|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat.
89628670|NCT04306952|Experimental|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks, with optional office hoursin between the bi-weekly group sessions and one all day meditation retreat."
89628671|NCT04303013|Active Comparator|Standard of Care|
89628672|NCT04303013|Experimental|Meditation|
89628673|NCT04300556|Experimental|Dose Escalation Part: Farletuzumab ecteribulin|Participants with selected tumor type will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once every 3 weeks in a 21 days cycle.
89628674|NCT04300556|Experimental|Dose Confirmation Part: Farletuzumab ecteribulin|Participants with EC and OC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once every 3 weeks in a 21 days cycle.
89628675|NCT04300556|Experimental|Dose Optimization Part A, Cohort 1: Farletuzumab ecteribulin + Oral Corticosteroids|Participants with EC and OC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once on Day 1 and oral corticosteroids on Days 8, 9 and 10 of every 21-day cycle.
89628676|NCT04300556|Experimental|Dose Optimization Part A, Cohort 2: Farletuzumab ecteribulin|Participants with EC and OC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once on Days 1, 8 and 15 of every 21-day cycle.
89628677|NCT04300556|Experimental|Dose Optimization Part A, Cohort 3: Farletuzumab ecteribulin|Participants with EC and OC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, once on Days 1 and 8 of every 21-day cycle.
89628678|NCT04300556|Experimental|Dose Optimization Part B, Cohort 1: Farletuzumab ecteribulin|Participants with EC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, at a dosing regimen identified during Part A.
89628679|NCT04300556|Experimental|Dose Optimization Part B, Cohort 2: Farletuzumab ecteribulin|Participants with EC will receive farletuzumab ecteribulin (MORAb-202) as an intravenous infusion, at a dosing regimen identified during Part A.
89628680|NCT04298190|Experimental|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
89628681|NCT04298190|Active Comparator|Enhanced Usual Care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
89628682|NCT04295564|Experimental|eCPAP|Participants will remain on CPAP for 2 additional weeks once CPAP stability criteria is met.
89628683|NCT04295564|No Intervention|dCPAP|Participants will discontinue CPAP as per usual care once CPAP stability criteria is met.
89628684|NCT04291105|Experimental|Melanoma intratumoral|Melanoma, IT VV1 + IV cemiplimab Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
89628685|NCT04291105|Experimental|Head and Neck SCC intratumoral|HNSCC, IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
89039668|NCT06086236|Experimental|PNS Index<-2 and SNS Index>2|Participants with Parasympathetic Nervous System (PNS) and Sympathetic Nervous System (SNS) Indexes values ''PNS<-2, SNS>2'' according to the results of heart rate variability measurements were included in this group. Then bilateral transcutaneous auricular vagus nerve stimulation was performed.
89039669|NCT06086236|Experimental|PNS Index<-2 and SNS Index<2|Participants with Parasympathetic Nervous System (PNS) and Sympathetic Nervous System (SNS) Indexes values ''PNS<-2, SNS<2'' according to the results of heart rate variability measurements were included in this group. Then bilateral transcutaneous auricular vagus nerve stimulation was performed.
89039670|NCT06086236|Experimental|PNS Index>-2 and SNS Index>2|Participants with Parasympathetic Nervous System (PNS) and Sympathetic Nervous System (SNS) Indexes values ''PNS>-2, SNS>2'' according to the results of heart rate variability measurements were included in this group. Then bilateral transcutaneous auricular vagus nerve stimulation was performed.
89039671|NCT06086236|Experimental|PNS Index>-2 and SNS Index<2|Participants with Parasympathetic Nervous System (PNS) and Sympathetic Nervous System (SNS) Indexes values ''PNS>-2, SNS<2'' according to the results of heart rate variability measurements were included in this group. Then bilateral transcutaneous auricular vagus nerve stimulation was performed.
89628686|NCT04291105|Experimental|Colo-rectal Carcinoma intratumoral|IT VV1 + IV cemiplimab, Patients will receive both treatments on Day 1 and every 3 weeks thereafter until lack of clinical benefit or limiting toxicity. VV1 or cemiplimab can continue after the first dose in combination or as a single agent treatment in subsequent doses.
89628687|NCT04271774||Infants with ASD-affected sibling|Infants, enrolled at 0-6 months of age, who have a sibling diagnosed with ASD.
89628688|NCT04264780||Younger than 50 years of age|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently less than 50 years of age
89628689|NCT04264780||50 years of age or older|Patients who have undergone epilepsy surgery ten years ago or longer, and are currently 50 years of age or more
89628690|NCT04255147|Experimental|Mesenchymal Stromal Cell Therapy|Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee.
89628691|NCT04250194|Experimental|Navigation Bronchoscopy (NB) with F-Nav|
89628692|NCT04250194|Experimental|CT-guided Biopsy|
89628693|NCT04233346|Experimental|Ponatinib|CP-CML:Chronic Phase Chronic Myeloid Leukemia; AP-CML:Accelerated Phase Chronic Myeloid Leukemia; BP-CML:Blast Phase Chronic Myeloid Leukemia; Ph+ ALL:Ph+ Acute Lymphoblastic Leukemia;
89628694|NCT04228731|Experimental|Outpatient|Patients in the outpatient group (same day discharge following TKA) are discharged the same day following surgery. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
89628695|NCT04228731|Active Comparator|Inpatient|Patients in the inpatient group (following day discharge following TKA) stay in the hospital overnight and then are discharged home the next day. All patients are required to meet the discharge criteria to be sent home (i.e., capable of using crutches, relatively free of pain, free of nausea and vomiting, free of excess bleeding, alert and oriented, given take-home medications, and in the company of a caregiver).
89628696|NCT04210128||Breast cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of breast neoadjuvant chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
89628697|NCT04210128||Pancreatic cancer patients|A blinded continuous glucose monitor (specifically a Freestyle Libre Pro) will be worn for a 14 day period by patients during the first and third cycles of pancreatic chemotherapy. At the end of that period (after completion of the one round of chemotherapy) readings will be downloaded from the sensor and the sensor will be removed. Readings will be evaluated by the treating endocrinologist as well as the study team and appropriate clinical interventions.
89628698|NCT04207931|Active Comparator|Topical steroid plus oral antibiotic group|Participants in this group receive topical steroid (class I-II applied once daily) plus oral antibiotic group (doxycyline 100 mg twice daily for 6 months), and then topical minoxidil (5% solution or foam) after 8 months of treatment.
89628699|NCT04207931|Active Comparator|Topical steroid plus intralesional steroid injection group|Participants in this group receive topical steroid (class I-II applied once daily) plus intralesional steroid group (7.5mg/cc of kenaolog, max dose of 3 cc), and then topical minoxidil (5% solution or foam) after 8 months of treatment
89057394|NCT04540172|Experimental|Music Therapy|music therapy was applied in the practice room. Environmental noise was reduced as much as possible; the room was dimly lit. The students were asked to close their eyes after sitting comfortably in a chair and focus on the music by asking them to imagine a different memory and place that would relax them instead of the thoughts that occupied their minds. The music was played through a portable computer for 15 minutes under the supervision of the researchers using an mp3 player program on the computer.
89211330|NCT00622466|Experimental|Sorfenib + Paclitaxel|Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
89628700|NCT04207723|Experimental|TENS Therapy|Tens therapy + placebo drug therapy
89628701|NCT04207723|Sham Comparator|Control|Standard treatment (paroxetine 20 mg) + sham therapy
89628702|NCT04207723|Experimental|Combination therapy|Tens therapy + standard treatment (paroxetine 20 mg)
89628703|NCT04207177|Active Comparator|Mycophenolate mofetil|In the subgroup of living donor recipients included before transplantation this group will be treated with mycophenolate mofetil (750 mg BID) for one week
89628704|NCT04207177|Active Comparator|Tacrolimus|In the subgroup of living donor recipients included before transplantation this group will be treated with tacrolimus (BID, dose by weight) for one week
89211331|NCT02617251||neonatology patients|neonatology patients
89211332|NCT02617251||paediatric patients|paediatric patients
89211333|NCT02550158|Experimental|Educated Group|"Training of patients by the educational program EDU-MICI"
89628705|NCT04186429||traumatic brain injury|Children with traumatic brain injury
89628706|NCT04186429||orthopedic injury|Children with orthopedic injury
89628707|NCT04177628|Experimental|Arm A: Shared decision making|Patients will be informed by a doctor randomized to practice shared decision making and use the in-consultation PtDA during the consultation on adjuvant radiotherapy.
89628708|NCT04177628|No Intervention|Arm B: Usual practice|Patients will be informed by a doctor randomized to inform about adjuvant radiotherapy according to usual practice.
89628709|NCT04173494|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match danazol
89628710|NCT04173494|Active Comparator|Danazol|Participants will receive danazol plus placebo to match momelotinib
89628711|NCT04167631|Other|Multiparametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) using multi-parametric MRI.
89628712|NCT04152512||Whole Cohort|Whole cohort administration of questionnaire at 7 times
89628713|NCT04150640|Experimental|Cohort 1: HER2 Negative|Participants in Cohort 1 (HER2-negative) will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), 5-FU (2400 mg/m^2 over 46 hrs), and oxaliplatin (60 mg/m^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
89628714|NCT04150640|Experimental|Cohort 2: HER2 Positive|Participants in Cohort 2 (HER2-positive) will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), trastuzumab (6 mg/kg C1D1, then 4 mg/kg on each subsequent treatment days), 5-FU (2400 mg/m^2 over 46 hrs), and oxaliplatin (60 mg/m^2). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle.
89628715|NCT04150640|Experimental|Cohort 3: HER2 Negative|Participants in Cohort 3 (HER2-negative) will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), 5-FU (2400 mg/m^2 over 46 hrs), oxaliplatin (60 mg/m^2), and nivolumab. (240 mg). Each cycle is 28 days. Participants will receive treatments on day 1 and 15 of each cycle
89628716|NCT04150640|Experimental|Cohort 4: HER2 Positive|Participants in Cohort 4 (HER2-positive) will be treated with nal-IRI (50 mg/m^2 - intravenously over 90 min), trastuzumab (6 mg/kg C1D1, then 4 mg/kg on each subsequent treatment days), 5-FU (2400 mg/m^2 over 46 hrs), oxaliplatin (60 mg/m^2), and pembrolizumab (400 mg). Each cycle is 42 days. Participants will receive chemotherapy and trastuzumab treatments on day 1, 15, and 29 of each cycle. Pembrolizumab will be given on day 1 of each cycle.
89628717|NCT04147780||Primary vulvar cancer, tumor ≥ 4cm|"Patients with primary squamous cell vulvar cancer, unifocal tumor ≥ 4cm:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
89628718|NCT04147780||Primary vulvar cancer, multifocal tumor|"Patients with primary squamous cell vulvar cancer, multifocal tumor:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
89628719|NCT04147780||Local recurrence after vulvar cancer, no earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier without treatment of the groins or solely sentinel node biopsy:~Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy"
89628720|NCT04147780||Local recurrence after vulvar cancer, earlier treatment|"Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier treatment of the groins by lymphadenectomy and / or (chemo-)radiation:~Sentinel node biopsy if detectable, otherwise no groin treatment"
89628721|NCT04140331||complicated post-operative evolution|Patients with a postoperative intensive care unity length of stay ≥ 5 days after elective cardiac surgery. They will have an accelerometer.
89628722|NCT04140331||simple post-operative evolution|Patients with a postoperative intensive care unity length of stay < 5 days after elective cardiac surgery. They will have an accelerometer.
89628723|NCT04119544|Active Comparator|Conventional Rehabilitation|at least 4 sessions/week for 6 weeks, from 1 hour of conventional upper limb rehabilitation by an occupational therapist.
89628724|NCT04119544|Experimental|Intensive Visual Simulation|at least 4 sessions/week for 6 weeks, of 1 hour of upper limb rehabilitation including 45 minutes of conventional rehabilitation (occupational therapy) and 15 minutes of work with a medical device allowing intensive visual digital simulation.
89628725|NCT04098484|Active Comparator|Normal-weight|Subjects with a BMI of 18-25 kg/m2
89628726|NCT04098484|Experimental|Obese|Subjects with a BMI of > 30 kg/m2
89628727|NCT04087278|Active Comparator|Metabotype A|Taking treatment
89628728|NCT04087278|Active Comparator|Metabotype B|Taking treatment
88990146|NCT04118010|Active Comparator|Placebo vitamin D3 and Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day chicory-derived prebiotic inulin for 12 weeks
89628729|NCT04087278|Active Comparator|Metabotype 0|Taking treatment
89628730|NCT04087278|Placebo Comparator|Placebo|Taking matching placebo
88990147|NCT04118010|Placebo Comparator|Placebo vitamin D3 and placebo Inulin|Matching to Vitamin D3 placebo capsules, and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks
88990148|NCT04117945|Experimental|Arm A (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
88990149|NCT04117945|Experimental|Arm B (cetuximab, panitumumab, irinotecan)|Patients receive cetuximab or panitumumab IV over 30-90 minutes on days 1 and 15. Patients may also receive irinotecan IV on days 1 and 15 as determined by the study doctor. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
88990150|NCT04114136|Experimental|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Metformin|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)~Metformin - 500 mg by mouth twice daily"
88990151|NCT04114136|Experimental|Anti-PD-1 mAb (nivolumab or pembrozilumab) plus Rosiglitazone|"nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)~Rosiglitazone - 4 mg by mouth once daily"
89039672|NCT06086223|Experimental|those patients who will go for ORIF plus arthroscopy|"we will start with a standard ankle arthroscopy. A leg holder and ankle joint distractor will be used. We will start with the anteromedial portal and introduce the 4-mm scope into the ankle joint. Next, under direct visualization, and taking care to preserve any branches of the superficial peroneal nerve, we will perform the anterolateral portal.~We will carry out a standard diagnostic ankle arthroscopy to evaluate the ankle cartilage, wash intra-articular haematoma, identify, and remove any intra-articular fracture fragments and loose bodies, perform dynamic ligamentous stress examinations while directly visualizing the syndesmosis, the deltoid ligament, and the lateral collateral ligament.~Following fracture fixation, arthroscopy will be also used as a second look to evaluate the quality of both articular and syndesmotic reduction, perform any needed arthroscopic intervention for deltoid ligament injury or management of chondral lesions (OCLs)"
89039673|NCT06086223|Experimental|patients who will go for ORIF without arthroscopy|"Posterior malleolus fractures will be addressed when it is present whatever its size.~The fibula fractures will be fixated using either a posterolateral or direct lateral incision. Lag screws will be used when the fracture pattern allows, and all fractures will be also treated with a neutralization or antiglide plate depending on the pattern and approach.~If a medial malleolus fracture is present, this will be addressed through a direct medial incision. These fractures will be either fixed with cannulated screws or tension band cerclage wiring or a plate and screw construct depending on the fracture pattern.~Once all bony injuries will be stabilized, a Cotton test will be performed under live fluoroscopy to determine syndesmosis stability. If positive, the syndesmosis will be stabilized using fully threaded screws."
89039674|NCT06086210|Active Comparator|Low-level laser therapy group|Low-level laser therapy was applied to the patients with the elbow at 45° flexion, creating a total of 5 areas by drawing 2 cm intervals 4 cm below the elbow and 6 cm above the elbow. The patients in the group used the elbow rest splint throughout the night during the treatment.
89039675|NCT06086210|Sham Comparator|Sham group|Sham group was applied with a laser probe by the elbow in 45° flexion, creating a total of 5 areas by drawing 2 cm intervals 4 cm below the elbow and 6 cm above the elbow. The patients in the group used the elbow rest splint throughout the night during the treatment.
89039676|NCT06086158|Experimental|Nordic Reverse Protocol|"The intervention group performed the reverse Nordic exercise or quadriceps drop protocol for four weeks in their training sessions. Participants assigned to the intervention group warm up for approximately 15/20 minutes, consisting of five minutes of continuous running at low speed (approximately 10 km/h), followed by 3 minutes of stretching the lower extremities and three separate progressive sprints.~between them with two minutes of rest to finish, then they will carry out the corresponding series and repetitions of the protocol and continue with their usual training."
89039677|NCT06086158|No Intervention|Usual Training Sessions|The control group did not have any intervention, the participants randomly assigned to this group continued with their usual training sessions.
89039678|NCT06086119||Patients who will be subjected to total laryngectomy and placement of voice prosthesis|Prospective, multicenter observational study involving patients who will be subjected to total laryngectomy and placement of voice prosthesis.Evaluate the patient's quality of life and voice perception underwent surgery for the placement of a voice prosthesis, through the administration of validated quality of life questionnaires: EORTC QLQ - H&N35; EORTC QLQ -C30, V-RQOL, VHI, SECEL3,4
89628731|NCT04083001|Experimental|OTR4132MD|"one medical device (10mL) of one of the 5 available concentrations (20 μg/mL, 50 μg/mL, 100 μg/mL, 150 μg/mL, 200 μg/mL) will be administrated as a one shot-dose to the patient.~The respective total dose of OTR4132 received by a patient will be one of the following: 0,20 mg, 0,50 mg, 1 mg, 1,5 mg and 2 mg."
89628732|NCT04068012|Experimental|Intervention|Ventilator management using the proposed protocol in both acute and weaning phases
89628733|NCT04056741|Experimental|Surfactant administered via supraglottic administration device|Patients in this group will have Calfactant at 3ml/kg administered via the supraglottic administration device.
89628734|NCT04038502|Active Comparator|Treatment Arm 1 - Carboplatin to Olaparib|Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles.
89628735|NCT04038502|Active Comparator|Treatment Arm 2 - Olaparib to Carboplatin|Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.
89628736|NCT04008147|Active Comparator|High Iron Group|15 women taking 100 mg iron twice daily for 4 days (800 mg).
89628737|NCT04008147|Active Comparator|Low Iron Group|15 women taking 30 mg iron once daily for 14 days (420 mg).
89628738|NCT03982316|Experimental|Telehealth Behavioral Migraine Management|Participants will receive weekly online education sessions in the following categories: Relaxation, Early Warning Signs, Triggers, Medication Adherence, Reducing Migraine Impact, Stress Management, Biofeedback, and Relapse Prevention. Participants will receive four monthly 50-minute telehealth sessions with a doctoral psychology student in a clinical health psychology program covering these topics, and three check-ins to enhance adherence to behavior change strategies. Participants will complete a daily headache diary throughout the course of treatment.
89628739|NCT03975387|Experimental|ASTX295|
89628740|NCT03973697|Experimental|Single dose of PMT|
89628741|NCT03973697|Experimental|Two doses of PMT|Administered within 24 hours
89628742|NCT03951142|Experimental|Study A: Recurrent glioblastoma (denoted 'AR')|"Patients with recurrent glioblastoma (N=54) with be randomized (ratio 1:1:1) to doses of 25mg, 50mg or 100mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 2 weeks (14 consecutive days) defined as a treatment cycle. Based on randomization, a minimum of three cycles and a maximum of 12 cycles will be administered for a total of 6 weeks (42 days) to 24 weeks (168 days), respectively. Patients randomized to 100mg of losartan will all receive treatment for the maximum duration.~A stepped-wedge randomized design (ratio 1:1:1 for all doses over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving chemotherapy (temozolomide or lomustine tablets)."
89628743|NCT03951142|Experimental|Study A: Newly diagnosed glioblastoma (denoted 'AN')|"Patients with newly diagnosed glioblastoma (N=54) with be randomized (ratio 1:1:1) to doses of 25mg, 50mg or 100mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 2 weeks (14 consecutive days) defined as a treatment cycle. Based on randomization, a minimum of three cycles and a maximum of 17 cycles will be administered for a total of 6 weeks (42 days) to 34 weeks (238 days), respectively. Patients randomized to 100mg of losartan will all receive treatment for the maximum duration.~A stepped-wedge randomized design (ratio 1:1:1 for all doses over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving adjuvant chemotherapy (Temozolomide tablets)."
89628744|NCT03951142|Experimental|Study B: Brain metastases (denoted 'BM')|"Patients with brain cancer from non-small cell lung cancer (N=45) with all receive a dose of 50mg daily of losartan while on treatment. Losartan (tablet) will be administered every day, with 3 months (90 consecutive days) defined as a treatment cycle. A minimum of one cycle and a maximum of three cycles will be administered for a total of 3 months (90 days) to 9 months (270 days), respectively.~A stepped-wedge randomized design (ratio 1:1:1 over the three first cycles) is proposed to compare participants on- and off- study IMP and assess any dose-response relationship losartan. This study arm will also investigate any additional long-term beneficial effects of losartan while receiving chemotherapy alone (carboplatin in combination with vinorelbin or pemetrexed or equivalent analogs) or in combination with pembrolizumab (2mg/kg/3rd week)."
89628745|NCT03920215|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, 0.12 mg/mL
89628746|NCT03920215|Active Comparator|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.60 mg/mL
88990152|NCT04114136|Active Comparator|Anti-PD-1 mAb (nivolumab or pembrozilumab)|nivolumab (480mg IV q 4 weeks) or pembrozilumab (200mg IV q 3 weeks) - dependent upon approved indication. (If both agents are approved for the disease indication, selection is at the discretion of the investigator)
88990153|NCT04113603|Experimental|A_Single bolus|Single bolus computed tomography urography (CTU)
88990154|NCT04113603|Experimental|B_Split bolus|Split bolus computed tomography urography (CTU)
89628747|NCT03920215|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
89628748|NCT03920215|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
89628749|NCT03917498|Experimental|Single Pre-Operative Radiation Therapy with Delayed Surgery|Single Pre-Operative Radiation Therapy with Delayed Surgery
89628750|NCT03878134|Experimental|Patients undergoing conventional and Photon Counting CT scan on the investigational scanner|18 and older patients who undergo the conventional CT scan and the photon counting CT (PCCT) scan. Patient's images on the conventional scanner provide internal control to compare to the PCCT images.
89628751|NCT03874429|Experimental|T2259|1 drop in each eye 2 to 4 times daily
89628752|NCT03874429|Active Comparator|Vismed Multi|1 drop in each eye 2 to 4 times daily
89628753|NCT03871153|Other|Treatment|Neoadjuvant chemotherapy(Durvalumab, Paclitaxel, Carboplatin), radiation and immunotherapy (durvalumab) followed by surgical resection followed by adjuvant immunotherapy (durvalumab)
89628754|NCT03870360|Experimental|HOLA: A Culturally-Tailored Health Promotion Intervention|16 week, multicomponent, health promotion intervention
89628755|NCT03870360|Active Comparator|Healthy lifestyles education program|Educational material on mental health, physical activity, and information on community resources
89628756|NCT03845517|Placebo Comparator|Placebo|Placebo
89628757|NCT03845517|Experimental|PF-06700841 15 mg|PF-06700841 15 mg
89628758|NCT03845517|Experimental|PF-06700841 30 mg|PF-06700841 30 mg
89628759|NCT03845517|Experimental|PF-06700841 45 mg|PF-06700841 45 mg
89628760|NCT03799302|No Intervention|Standard Consultation|Sites in this arm will receive the standard consultation from the TFCO or MDFT purveyors
89628761|NCT03799302|Experimental|SIC Coaching Consultation|In addition to the standard consultation from the TFCO or MDFT purveyors, sites in this arm will also receive feedback on how they are doing in terms of completing expected activities in their efforts to implement the designated EBP.
89628762|NCT03786094|Active Comparator|Eribulin|
89628763|NCT03786094|Experimental|Balixafortide + Eribulin|
89628764|NCT03776747|Experimental|Group One: Prone MRI Scans|Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
89057886|NCT01687803|Experimental|Physical Activity|Physical activity intervention will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
89628765|NCT03776747|Active Comparator|Group Two: Supine MRI scans|Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
89628766|NCT03742089||Treatment|Bone Anchored Hearing Surgery using a BHX implant manufactured by Oticon Medical
89628767|NCT03734354|Experimental|1 mg dosing group|Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets
89628768|NCT03734354|Experimental|2 mg dosing group|Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets
89628769|NCT03734354|Experimental|4 mg dosing group|Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets
89628770|NCT03734302|Experimental|Multiple dose oral administration|1mg Once Daily (QD) , oral administration,14 consecutive days
89628771|NCT03734211|Experimental|Evolocumab|Evolocumab (Repatha®) will be administered subcutaneously once monthly in the abdomen, thigh, or upper arm for the duration of the treatment period (one year). The 420 mg evolocumab/placebo will be administered by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
89628772|NCT03734211|Placebo Comparator|Placebo|The placebo is presented in an identical prefilled autoinjector. It is supplied as a sterile, single-use, preservative-free solution for subcutaneous injection in a disposable, spring-based prefilled autoinjector. The prefilled autoinjector contains a 1.0 mL deliverable volume of 1.1% (w/v) sodium carboxymethylcellulose, 250 mM proline, 10 mM acetate, and 0.01% (w/v) polysorbate 80, pH 5.0.
89628773|NCT03733730|Experimental|Cohort 1|ACRYSOF IQ RESTOR Multifocal Toric IOL (+3.0 D or +2.5 D) implanted in at least one eye during cataract surgery, with implantation occurring from November 2018 through July 2020.
89628774|NCT03733730|Experimental|Cohort 2|ACRYSOF IQ RESTOR +3.0 D Multifocal Toric IOL or ACRYSOF IQ RESTOR +2.5 D Multifocal IOL implanted in at least one eye during cataract surgery, with implantation occurring after July 2020.
89628775|NCT03732781|Experimental|Radspherin|
89628776|NCT03724695|No Intervention|Control|Usual Care
89628777|NCT03724695|Experimental|AHCAH Nudge|"The investigators have developed methods for sending nudges to clinicians via secure text messages to primary teams to alert them that their patient was identified as high-risk for 6-month mortality and that an AHCAH liaison would visit their patient to discuss the AHCAH program and to facilitate enrollment if the patient was amenable. The investigators propose that these secure text messages would be sent to the teams of patients randomized to the intervention by the AHCAH liaison within 72 hours of eligibility identification (to allow for the liaison not being available over the weekend). The investigator team will track all aspects of messaging and timing. Clinicians can choose to opt out a patient from the liaison visit and AHCAH enrollment within a two-hour timeframe."
89628778|NCT03723161||Treatment|Bone Anchored Hearing surgery using a BHX implant manufactured by Oticon Medical
89628779|NCT03713632|Active Comparator|Secukinumab 1|Secukinumab 300mg every 2 weeks
89628780|NCT03713632|Active Comparator|Secukinumab 2|Secukinumab 300mg every 4 weeks
89628781|NCT03713632|Placebo Comparator|Placebo 1|Placebo group to secukinumab 300mg every 2 weeks
89628782|NCT03713632|Placebo Comparator|Placebo 2|Placebo group to secukinumab 300mg every 4 weeks
89628783|NCT03682900|Experimental|Intervention: Click City Tobacco Prevention Program|Participation consisted of a baseline assessment one-week prior to starting the program, and a follow-up assessment one-week following completion of the program. The expectation was that students complete two lessons a week of the computer-based program over a four-week period.
89628784|NCT03682900|Experimental|Control: Usual Tobacco Prevention Curriculum|Students in control schools completed the baseline and follow-up assessments during the same week as students in their yoked intervention school. The expectation was that students would participate in the standard tobacco curriculum over this period.
89628785|NCT03673826|Experimental|Arm A|Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
89628786|NCT03673826|Experimental|Arm B|KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
89628787|NCT03657394|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 20-30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC.
89628788|NCT03657394|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after birth (within 60 seconds)
89628789|NCT03637595|Active Comparator|Positive Control Group|Acupuncture
89628790|NCT03637595|Sham Comparator|Negative Control Group|Sham Intervention
89628791|NCT03637595|Experimental|Energy Medicine (EM) Intervention|Energy Medicine by an energy medicine practitioner
89628792|NCT03573921|Experimental|Gastrografin Arm|Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
89628793|NCT03573921|Experimental|Control Arm|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.
89628794|NCT03517436|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
89628795|NCT03476330|Experimental|Quercetin|All patients will be treated with oral quercetin.
89628796|NCT03458455||A|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions
89628797|NCT03458455||B|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions
89628798|NCT03458455||C|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + nivolumab or pembrolizumab
89057887|NCT01687803|Other|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
89628799|NCT03458455||D|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions + ipilimumab, nivolumab or pembrolizumab
89628800|NCT03458455||E|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + epidermal growth factor receptor (EGFR) inhibitors
89628801|NCT03448601|No Intervention|Non-tailored control group|Participates will read the standard Alzheimer's disease and Precision Medicine brochure with standard text-based content NOT specifically tailored for AI/ANs.
89628802|NCT03448601|Experimental|Culturally tailored video intervention group|Participants will view a short 5-minute culturally-tailored video.
89628803|NCT03448601|Experimental|Culturally tailored brochure intervention group|Participants will read a culturally-tailored educational brochure on Alzheimer's disease and Precision Medicine.
89628804|NCT03430973|Experimental|Experiment 1|The purpose of Experiment 1 is to develop a standardized measure of aggressive driving for driver simulation experiments. After giving their consent, participants (N=200) will complete several personal variables (i.e., gender, age, driving experience, driving frequency, trait anger, self-reported aggressive and prosocial driving). Next, participants will watch several short videos of aggressive driving (e.g., speeding, tailgating, driving on shoulder), and road rage (e.g., hitting another vehicle or pedestrian). Participants will indicate whether the driver's behavior was aggressive (yes, no), and will rate how aggressive it was on an 11-point scale (0=not at all aggressive to 10=extremely aggressive). A debriefing will follow.
89628805|NCT03430973|Experimental|Experiment 2|Experiment 2 tests whether participants actually drive more aggressively after a playing a violent or nonviolent racing video game. After giving their consent, participants (N=60, n=30 each group) will complete the same personal variables as in Experiment 1, and will report the video games they play. Next, participants will be randomly assigned to play one of two types of video games for 20 minutes: (1) violent racing video game, (2) nonviolent racing game, or (3) a neutral game. After participants complete the driving scenario, participants will complete measures of state and hostile appraisals. A debriefing will follow.
89628806|NCT03430973|Experimental|Experiment 3|"Experiment 3 tests the effects of racial bumper stickers on black and white participants. After giving their consent, participants (N=120; n=60 black, n=60 white) will complete the personal variables (see Experiment 1), the race IAT, and report their political party. Some cars in the driving scenario will contain bumper stickers. Experiment 3 contains four conditions: (1) white participants / All Lives Matter stickers, (2) black participants / All Lives Matter stickers, (3) white participants / Black Lives Matter stickers, (4) black participants / Black Lives Matter stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward the #BLM and #ALM movements. A debriefing will follow."
89628807|NCT03430973|Experimental|Experiment 4|"Experiment 4 tests the effects of political bumper stickers on aggressive driving in Republicans versus Democrats. After giving their consent, participants (N=120; n=60 Republicans, n=60 Democrats) will complete the personal variables (see Experiment 1). Some cars in the driving scenario will contain bumper stickers. Experiment 4 has four conditions: (1) Republicans / Donald Trump for President 2016 stickers, (2) Republicans / Hillary Clinton for President 2016 stickers, (3) Democrats / Donald Trump for President 2016 stickers, (4) Democrats / Hillary Clinton for President 2016 stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward Trump and Clinton. A debriefing will follow."
89628808|NCT03430973|Experimental|Experiment 5|Experiment 5 tests whether alcohol-related cues can increase aggressive driving. After giving their consent, participants (N=40) will complete the personal variables (see Experiment 1). Next, participants will be randomly assigned to one of two conditions: (1) 12-pack of beer on passenger seat, or (2) 12-pack of sparkling water on passenger seat. Participants will be told that the object on the seat is part of a different experiment that the other experimenter forgot to clean up, which they should ignore it. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
89628809|NCT03430973|Experimental|Experiment 6|Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
89628810|NCT03430973|Experimental|Experiment 7|"Experiment 7 tests whether roadside vegetation can reduce aggression in frustrated drivers. After giving their consent, participants (N=90, n=30 per group) will complete the personality variables (see Experiment 1). Next, they will complete the Enjoyment of Nature Scale (Cheng & Moore, 2012), which contains 7 items (e.g., I like to see wild flowers in nature and Being in the natural environment makes me feel peaceful; 1=strongly disagree to 5= strongly disagree; Cronbach =.87). Next, participants will be randomly assigned to one of three driving scenarios: (1) roadside vegetation, (2) trash, or (3) control (no roadside vegetation / no trash). After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed."
89628811|NCT03414034|Experimental|Arm A: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone. This arm was discontinued.
89628812|NCT03414034|Experimental|Arm B: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 14-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
89628813|NCT03414034|Experimental|Arm C: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 12 mg/m^2 for 14 days (Day 1 through Day 14) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
89628814|NCT03375619||Participants who received CAR-T cells.|Participants who received CAR-T cells at Froedtert Hospital & the Medical College of Wisconsin in clinical trials (e.g., NCT05976555, NCT05094206, NCT05990465, NCT03019055 or NCT04186520).
89628815|NCT03344666|Experimental|First Treatment|Participants will be randomized to first treatment to compare Brief Intervention + Health Coach (Step 1 Treatment BI+HC) to Brief Intervention + Text Messages (Step 1 Treatment BI+TM). Participants in the BI+HC will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks. Participants in the BI+TM will receive a BI in the ED, followed by daily TMs for 4 weeks.
89628816|NCT03344666|Experimental|Second Treatment for Responders and Non-Responders|"Beginning in week 5, all participants will be classified as Responders or Non-Responders (based on weekly assessments) and re-randomized.~Step 2 Treatment Responders: Responders will be randomized to either stay the course or be stepped down. Specifically, participants in the BI+HC will either continue to receive the HC or stepped down to receive a control brochure; participants in the BI+TM will either continue to receive the TM or stepped down to receive a control brochure.~Step 2 Treatment Non-Responders: Non-Responders will be randomized to either stay the course or be stepped up. Specifically, participants in the BI+HC will either continue to receive the HC or stepped up to receive a HC+; participants in the BI+TM will either continue to receive the TM or stepped up to receive HC."
89628817|NCT03340129|Active Comparator|Nivolumab + ipilimumab|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
89628818|NCT03340129|Active Comparator|Nivolumab + ipilimumab,concurrent SRS|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.~Stereotactic radiotherapy 16 to 22 Gy in 1 fraction or 24 to 30 Gy, hypofractionated for larger lesions. Stereotactic radiotherapy to commence within 7 days of of the baseline / planning MRI brain. Hypofractionated stereotactic radiotherapy should be completed within 14 day of the first fraction.~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
89628819|NCT03333408|Active Comparator|Group A (Antibiotic)|Group A will receive postoperative oral antibiotics for 10 - 14 days (Clindamycin or Augmentin) upon discharge.
89628820|NCT03333408|No Intervention|Group B (no Antibiotic)|Group B will not be given postoperative oral antibiotics upon discharge.
89628821|NCT03317860|Sham Comparator|Sham tDCS plus RTP|Single session of bilateral sham parietal cortex tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
89628822|NCT03317860|Active Comparator|Active tDCS plus RTP|Single session of bilateral active parietal cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
89628823|NCT03308409|Active Comparator|Protocol 1|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
89628824|NCT03308409|Experimental|Protocol 2|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six initial sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz for six weeks, followed by monthly maintenance sessions (every 4 weeks) for five months. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
89628825|NCT03308409|Experimental|Protocol 3|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six monthly sessions in which 3000 pulses will be applied at 0.20 mj/mm2, at a frequency of 4Hz, with 2000 pulses distributed to the body of the penis and 1000 pulses applied to the base
89628826|NCT03282396|Experimental|Treatment (ibrutinib)|Participants receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for 5 years in the absence of disease progression or unacceptable toxicity.
89628827|NCT03240861|Experimental|Treatment (Genetically engineered PBMC and PBSC)|"G-CSF AND PLERIXAFOR MOBILIZED LEUKAPHERESIS: Between 6 months and 3 weeks before infusion of cells, patients undergo G-CSF and plerixafor mobilization of CD34+ peripheral blood stem cells. Patients receive G-CSF SC on mobilization days 1-8 and plerixafor SC on mobilization days 4-7. Patients also undergo an unmobilized leukapheresis on day -5 before infusion of cells.~CHEMOTHERAPY CONDITIONING REGIMEN: Patients receive busulfan IV on days -4 to -2 and fludarabine IV over 30 minutes on days -3 to -2.~Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0, and after approximately 24 hours, patients receive RV-NYESO TCR PBMC IV on day 1. Beginning on day 2, patients receive aldesleukin SC BID for up to 7 days. Patients undergo blood collection for safety and immune monitoring on days 0, 1, 3, 5, 7, 14, 30, 60, 90, and 120. Patients receive 18F-FHBG IV, and after 1 hour, undergo PET/CT on days 25 and 120."
88990155|NCT04112693|Experimental|Esophageal biopsies during POEM|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020.~The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse."
88990156|NCT04111315|Active Comparator|metamizole + educational intervention|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
89628828|NCT03170349|Experimental|Edwards PASCAL Transcatheter Mitral Valve Repair System|
89057888|NCT01687842||Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
89628829|NCT03164993|Placebo Comparator|Arm Chemotherapy + Placebo|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + placebo
89628830|NCT03164993|Active Comparator|Arm Chemotherapy + Atezolizumab|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + Atezolizumab
89628831|NCT03110822|Experimental|Rux Len and Steroid|Ruxolitinib Oral Tablet [Jakafi] at 5mg, 10mg or 15mg BID, Lenalidomide Oral at 5mg or 10mg QD and Methylprednisolone Oral at 40mg QOD. (Dose varies during dose escalation portion of the study)
89628832|NCT03110822|Experimental|Rux and Steroid until progression, then add Len|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 15mg BID, and Methylprednisolone at 40mg QOD until disease progression. Lenalidomide at 10mg QD will be added to the treatment (Ruxolitinib, Methylprednisolone) once disease progression was confirmed.
89628833|NCT03110822|Experimental|Expanded Eligibility Criteria|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 15mg BID, Lenalidomide at 10mg QD, and Methylprednisolone at 40mg QOD until disease progression.
89628834|NCT03110822|Experimental|High-dose Ruxolitinib|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 20mg BID and Methylprednisolone at 40mg QOD until disease progression.
89628835|NCT03077542|Experimental|recipient|recipient
89628836|NCT03051256|Experimental|REL-1017 25 mg|REL-1017 75 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 25 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
89628837|NCT03051256|Experimental|REL-1017 50 mg|REL-1017 100 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 50 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
89628838|NCT03051256|Placebo Comparator|Placebo|100 mL Ocean Spray® Diet Cranberry Juice will be administered as a single oral dose daily for 7 days.
89628839|NCT03037021||SCD Adult Patients|Focus group or individual interview and survey
89628840|NCT03037021||SCD Adolescent Patients|Focus group or individual interview and survey
89628841|NCT03037021||SCD Healthcare Providers|Focus group or individual interview and survey
89628842|NCT03037021||Parents of SCD Adolescents|Focus group or individual interview and survey
89628843|NCT02998229|Experimental|Artisse™ Intrasaccular Device|
89628844|NCT02931721||MRI Positive|Men with sperm found in MD-TESE
89628845|NCT02931721||MRI Negative|Men with no sperm found in MD-TESE
89628846|NCT02931721||Control group|No intervention, fertile
89628847|NCT02925221||ADPKD patients on tolvaptan|ADPKD patients who are newly prescribed with JINARC™ (tolvaptan) or already treated with JINARC™ (tolvaptan) will be eligible.
89628848|NCT02915120|Active Comparator|Real Pulsed Radiofrequency|Before needle insertion, the patient's inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches will be identified under ultrasound guidance. RF needles and probes will be advanced to each of the target nerves under ultrasound guidance. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of < 0.5 mA to identify the nerve position, the current intensity (mA) will be reduced at < 0,2 mA. During the sensorial stimulation, the patients will be asked if they feel tingling, pain, or discomfort inside the knee. The RF probe will be maintained in place until one of those feelings is elicited. In order to avoid inactivating motor nerves, the nerve will be tested for the absence of fasciculation in the the lower extremity on stimulation of 0,5 mA at 2 Hz.
89628849|NCT02915120|Sham Comparator|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
89628850|NCT02836236|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
89628851|NCT02836236|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
89628852|NCT02836236|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
89628853|NCT02823821|Active Comparator|137mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
89628854|NCT02823821|Active Comparator|140mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
89628855|NCT02728531|Experimental|Bendamustine, Rituximab, Cytarabine|"Bendamustine on Days 1 and 2 of Cycles 1, 3, and 5.~In Cycle 1, rituximab on Day 1 or 2 at the investigator's discretion. Given on Day 1 of Cycles 2 through 6.~On Days 1 and 2 of Cycles 2, 4, and 6, cytarabine will be administered every 12 hours for a total of 4 doses.~Growth factor will be administered subcutaneously within 72 hours of completion of each even-numbered cycles of chemotherapy.~Leukapheresis will begin when the total WBC ≥ 5000/ μL and continue daily until collection of ≥ 2x106 CD34+ cells/kg (with a maximum of 5 courses of apheresis).~Standard of care peripheral blood autologous stem cell harvest will proceed per institutional guidelines and begin during Cycle 6 following rituximab and cytarabine therapy, when the total WBC ≥ 5000/ μL. Collection will continue on a daily basis until collection of ≥ 2x106 CD34+ cells/kg."
89628856|NCT02710331|Experimental|Active THC and Placebo Ethanol|
89628857|NCT02710331|Experimental|Active THC and Active Ethanol|
89628858|NCT02710331|Experimental|Placebo THC and Active Ethanol|
89628859|NCT02710331|Placebo Comparator|Placebo THC and Placebo Ethanol|
89628860|NCT02677974||On-X Aortic Heart Valve replacement|Patients with On-X Aortic Valve maintained on low dose warfarin anticoagulation with an INR target of 1.5 to 2.0, with or without home monitoring.
89628861|NCT02670525|Experimental|Relapsed/Refractory Leukemia|"Cohort 1: Relapsed/Refractory Leukemia~Acute lymphoblastic leukemia (ALL), first or greater relapse~Acute myeloid leukemia (AML), first or greater relapse~Leukemia refractory to induction chemotherapy~Other recurrent leukemia~Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy~After the screening procedures confirms patient eligibility:~Leukemia Profiling will be performed~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
89628862|NCT02670525|Experimental|New Diagnosis|"Cohort 2: New Diagnosis~Acute myeloid leukemia (AML), new diagnosis (excluding acute promyelocytic leukemia (APL))~New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (<40 chromosomes) ALL~Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage~Secondary leukemia~Myelodysplastic syndrome (MDS) not eligible for stem cell transplant~After the screening procedures confirms eligibility:~Leukemia Profiling will be performed~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
89628863|NCT02476435|Active Comparator|Experimental = Active rTMS|Daily rTMS with Active coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
89628864|NCT02476435|Placebo Comparator|Sham Comparator = Sham rTMS|Daily rTMS with Sham coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
89628865|NCT02461927|Experimental|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular naltrexone once a month (a total of 2 injections).
89628866|NCT02461927|Experimental|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
89628867|NCT02461927|Placebo Comparator|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous placebo treatment (psychoactive placebo midazolam) once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
89628868|NCT02403323|Experimental|Part 1: Etrolizumab Open-Label Extension|Participants will receive open-label treatment with etrolizumab once every 4 weeks until commercial availability in their country or sponsor's decision to terminate the study, whichever is earlier (up to approximately 10 years after the first patient is enrolled).
89628869|NCT02403323|No Intervention|Part 2: Safety Monitoring|Participants who have stopped etrolizumab treatment (either by exiting Part 1 of this study or by entering directly from Study GA29144 [NCT02394028]) will be monitored for 92 weeks for progressive multifocal leukoencephalopathy (PML) and other safety events.
89628870|NCT02394795|Experimental|Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks.
89628871|NCT02394795|Active Comparator|Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks.
89628872|NCT02344498||Urban|HBV patients in Addis Abeba. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
89628873|NCT02344498||Rural|HBV patients in Harar. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
89628874|NCT02294357|Experimental|Carfilzomib + Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration.
89628875|NCT02294357|Experimental|Carfilzomib + Prednisone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Prednisone (IV or PO) will be given prior to each carfilzomib administration.
89628876|NCT02294357|Experimental|Carfilzomib + Methylprednisolone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Methylprednisolone(IV or PO) will be given prior to each carfilzomib administration.
89628877|NCT02294357|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Lenalidomide will be given at the same dose and schedule as patient was receiving previously.
89628878|NCT02294357|Experimental|Carfilzomib+Pomalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Pomalidomide will be given PO at 4mg daily on days 1-21 of a 28-day cycle
89628879|NCT02255422|Experimental|omaveloxolone Capsules 2.5 mg and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
89628880|NCT02255422|Experimental|omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
89628881|NCT02255422|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
89628882|NCT02255422|Experimental|omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
89628883|NCT02255422|Experimental|omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
89628884|NCT02255422|Experimental|omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
89628885|NCT02255422|Experimental|omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
89628886|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 0.5%|Omaveloxolone Lotion at a fixed dose of 0.5% administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 16 weeks)
89628887|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 3%|Omaveloxolone Lotion at a fixed dose of 3% administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 19 weeks)
89628888|NCT02142959|Placebo Comparator|Vehicle Lotion|Vehicle Lotion administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 16 weeks)
89628889|NCT02128113|Placebo Comparator|Vehicle Ophthalmic Solution|A single drop of Vehicle Ophthalmic solution was instilled into the study eye twice daily (approximately 12 hours apart) for a maximum of 28 days, beginning 3 to 7 days prior to cataract surgery and continuing on the day of surgery and for 3 weeks after surgery
89628890|NCT02128113|Experimental|Omaveloxolone Opthalmic Suspension 0.5%|A single drop of Omaveloxolone Ophthalmic suspension 0.5% was instilled into the study eye twice daily (approximately 12 hours apart) for a maximum of 28 days, beginning 3 to 7 days prior to cataract surgery and continuing on the day of surgery and for 3 weeks after surgery
89628891|NCT02128113|Experimental|Omaveloxolone Opthalmic Suspension 1%|A single drop of Omaveloxolone Ophthalmic suspension 1.0% was instilled into the study eye twice daily (approximately 12 hours apart) for a maximum of 28 days, beginning 3 to 7 days prior to cataract surgery and continuing on the day of surgery and for 3 weeks after surgery
89057889|NCT01687959|Active Comparator|activity of peritoneal fibrinolysis|measurements of peritoneal fibrinolysis using tissue-type plasminogen activator and its specific activity, urokinase-type plasminogen activator, and plasminogen activator inhibitor type 1
89057890|NCT01687959|Active Comparator|surgical outcomes|surgical outcomes of laparoscopic cholecystectomy
89628892|NCT02065375|Experimental|Omaveloxolone Ophthalmic Suspension 1.0%|Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 1.0% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
89628893|NCT02065375|Experimental|Omaveloxolone Ophthalmic Suspension 0.5%|Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 0.5% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
89628894|NCT02065375|Placebo Comparator|Placebo|Patients will receive a single drop of vehicle for Omaveloxolone Ophthalmic suspension was instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery
89628895|NCT02061306||Infants with a first-degree relative with celiac disease|Infants who have a first-degree relative diagnosed with celiac disease.
89628896|NCT02036970|Experimental|Part 1 Dose-Ranging Bardoxolone methyl 2.5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 2.5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
89628897|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
89628898|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 10 mg/Part 2: Open-Label|Participants received bardoxolone methyl 10 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
89628899|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 20 mg/Part 2: Open-Label|Participants received bardoxolone methyl 20 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
89628900|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 2.5 mg/Part 2: Bardoxolone methyl 2.5 mg|Participants received bardoxolone methyl 2.5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
89628901|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 5 mg/Part 2: Bardoxolone methyl 5 mg|Participants received bardoxolone methyl 5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
89628902|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants received bardoxolone methyl 10 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
89628903|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 20 mg/Part 2: Bardoxolone methyl 20 mg|Participants received bardoxolone methyl 20 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
89628904|NCT02036970|Experimental|Part 1: Dose Titration: Bardoxolone methyl 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 started with bardoxolone methyl 5 mg once-daily from Day 1 and escalated to bardoxolone methyl 10 mg once-daily starting at Week 4 thru Week 16. Participants who continued to Part 2 continued to receive the same bardoxolone methyl dose once-daily in Part 2 (Week 16 and onwards)
89628905|NCT02036970|Placebo Comparator|Part 1: Dose Titration: Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 received Placebo once-daily from Day 1 thru Week 16. Participants who continued to Part 2 initially received bardoxolone methyl 5 mg once-daily from Week 16 thru Week 20 and bardoxolone methyl 10 mg from week 20 onwards
89628906|NCT02013154|Experimental|DKN-01 150 mg plus paclitaxel|DKN-01 150 mg administered on Days 1 and 15 and paclitaxel 80 mg per meter squared of body surface area (mg/m2) administered on Days 1, 8, 15, and 22
89628907|NCT02013154|Experimental|DKN-01 300 mg plus paclitaxel|DKN-01 300 mg administered on Days 1 and 15 and paclitaxel 80 mg per meter squared of body surface area (mg/m2) administered on Days 1, 8, 15, and 22
89628908|NCT02013154|Experimental|DKN-01 150 mg plus pembrolizumab|DKN-01 150 mg administered on Days 1 and 15 and pembrolizumab 200 mg administered on Day 1
89628909|NCT02013154|Experimental|DKN-01 300 mg plus pembrolizumab|DKN-01 300 mg administered on Days 1 and 15 and pembrolizumab 200 mg administered on Day 1
89628910|NCT02013154|Experimental|DKN-01 300 mg monotherapy|DKN-01 300 mg administered on Days 1 and 15
89628911|NCT01909492||Group 1|Group 1 will consist of 10 subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
89628912|NCT01909492||Group 2|Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
89628913|NCT01909492||Group 3|Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
89628914|NCT01827787|Experimental|Cohort 1: HR+/HER2-|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
89628915|NCT01827787|Experimental|Cohort 2: TNBC|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
89057891|NCT02216240|Active Comparator|Accident and emergency|Patients randomised to A&E were treated as per standard care and given no information other than that pertaining to the study.
88990157|NCT04111315|Active Comparator|metamizole + standard care|"(A) Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Standard care will be prescribed by the GP."
89628916|NCT01823848|Active Comparator|Sodium phosphate enema|Administration of sodium phosphate (fleets) enema for functional constipation in children ages 4-12 years Age 4-5: 33ml per rectum Age 5-12: 66ml per rectum
89628917|NCT01823848|Active Comparator|Normal saline enema|Administration of normal saline enema for functional constipation in children ages 4-12 years Admininstered as 10ml/kg with maximum of 700ml
89628918|NCT01823848|Experimental|Mineral oil enema|Administration of mineral oil enema for functional constipation in children ages 4-12 years Administered as 66ml per rectum
89628919|NCT01743950|Active Comparator|Bevacizumab-naïve with recurrent IDH wildtype high grade glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
89628920|NCT01743950|Active Comparator|Bevacizumab-exposed with refractory recurrent IDH wildtype high grade glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
89628921|NCT01743950|Active Comparator|Bevacizumab-naïve with recurrent IDH mutant glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
89628922|NCT01743950|Active Comparator|Bevacizumab-exposed with recurrent IDH mutant glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
89628923|NCT01717261|Experimental|Single Pre-Operative Radiation Therapy|
89628924|NCT01593202|Experimental|Dialectical behavior therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
89628925|NCT01593202|Active Comparator|Enhanced usual care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
89628926|NCT01522768|Experimental|Afatinib and Paclitaxel|This is a multi-institution, open-label, non-randomized, Phase II evaluation of oral afatinib daily and intravenous paclitaxel (weekly, 3 weeks on, 1 week off) in patients with trastuzumab refractory HER2-positive metastatic or recurrent esophagogastric adenocarcinoma. An initial biopsy prior to the start of therapy is required for the correlative studies evaluating the biologic effects of afatinib. It will be obtained for all patients whose tumors are feasible to biopsy. At the site investigator's discretion, a second biopsy will also be obtained. At the discretion of the MSK Principal Investigator, select participants who show response on this study and then progress may be asked to have an optional third biopsy.
89628927|NCT01484327||Carvedilol, LVEF, Heart Failure|Patients with Heart Failure on carvedilol therapy measured for their LVEF value
89628928|NCT01484210|Experimental|Elpenhaler Active - Diskus Placebo|Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.
89628929|NCT01361477||patient|"Prolonged ICU stay~Unplanned ICU admission~Complication/adversel during ICU admission~Result of intraoperative complications and admission to ICU 5 Result of early postoperative (within 7 days) and ICU admission"
89628930|NCT00836823|Experimental|Alpha blocker|Alfuzosin 10mg
89628931|NCT00230100|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
88990158|NCT04111315|Active Comparator|ibuprofen + educational intervention|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Educational short intervention: patients receive two leaflets with information non-specific LBP and exercises to alleviate LBP. Further, patients receive a 10-minute standardized telephone intervention during the first 4 treatment days."
89039679|NCT06086106||group B systemic opioids for pain relive|systemic opioids belong to a class of analgesics, they act by attaching to opioid receptors in the brain and spinal cord. For relief of pain, they are frequently utilized in a variety of surgical procedures and can be given intravenously, and in intramuscular injections. Although opioids are considered highly effective in pain control, they can lead to several adverse effects, such as nausea, vertigo, and respiratory depression, some of which can be dangerous.
89628932|NCT00230100|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
89039680|NCT06086041||severely to profoundly deaf patients with cochlear implantation indication|"Severely to profoundly deaf patients consulting in Grenoble University Hospital with cochlear implantation indication.~Patients are followed according to current care during 1 year after cochlear implantation."
88990159|NCT04111315|Active Comparator|ibuprofen + standard care|"(A) Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42). The treatment duration will depend on the duration of pain. Patients are considered to be recovered when their pain is below 2 (NRS 0-10) on 2 consecutive days after they stopped the pain medication (end of treatment).~(B) Standard care will be prescribed by the GP."
88990160|NCT04110522|Experimental|Intervention with Direct Access to Rheumatologist|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions on how to directly schedule a rheumatologic evaluation
88990161|NCT04110522|Experimental|Intervention with Standard of Care Referral|Psoriasis patients with no prior diagnosis of PsA randomized to receive intervention PsA questionnaire, including instructions to talk with their doctor about a referral to a rheumatologist
88990162|NCT04110522|No Intervention|Control|Psoriasis patients with no prior diagnosis of PsA randomized to not receive an intervention PsA questionnaire
88990163|NCT04104243|Experimental|Power-Up|Participants randomized to this arm will undergo 16 classes tailored for men, that discuss food choices, physical activity, and managing stress over 6 months, which are called the core, and 6 classes over the following 6 months, which is called the maintenance phase.
89039681|NCT06086002|Active Comparator|Overlapping ablation with single antenna|
89039682|NCT06086002|Experimental|Simultaneous ablation with two antennas|
89039683|NCT06085989|Experimental|Infant directed singing|The intervention group will receive standard breastfeeding support from health care staff combined with maternal infant-directed singing during breastfeeding. The starting point of the singing will be individually assessed and tailored to the dyads and will start approximately a few minutes before breastfeeding starts. An educational video about how to apply infant-directed singing will be shown to all mothers in the intervention group.
89039684|NCT06085989|Active Comparator|Standard care|Mothers allocated to the control group will be offered standard breastfeeding support from health care staff, and data on secondary outcome measures will be collected during one breastfeeding session.
89039685|NCT06085976|Experimental|Treatment arm (octreotide)|This patient will receive the treatment: Octreotide charge 100 mcgr + continuous infusion during the surgery 25 mcgr/h
89039686|NCT06085976|Experimental|Placebo arm (saline solution)|This patient will receive physiologic saline solution at the same infusion
89211334|NCT02550158|Other|Control group|"During the first 6 months : no training of patients by the educational program EDU-MICI. Then, a crossover allowed uneducated patients to benefit from the educational program the next 6 months."
89211335|NCT04043858|Experimental|Midodrine daily|Midodrine hydrochloride 2.5 mg tab once per day
89039687|NCT06085950|Experimental|Transcranial Ultrasonic Stimulation with Personalized Acoustic Lens|Low-intensity transcranial focused ultrasound stimulation of deep brain target, using a personalized acoustic lens to correct the aberrations induced by the skull
89039688|NCT06085937|Experimental|Ketamine|All patients will receive the experimental drug.
89039689|NCT06085898|Experimental|Stryphnodendron Adstringens (Barbatimão)|Intimate Soap
89628933|NCT03251430||Control group|38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
89628934|NCT03251430||Distal Gastrectomy (DG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
89628935|NCT03251430||Total Gastrectomy (TG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
88990164|NCT04104243|No Intervention|Standard NDPP (National Diabetes Prevention Program)|Participants randomized to this arm will undergo 16 mixed gender classes that discuss food choices, physical activity, and managing stress over 6 months which are called the core and 6 classes over the following 6 months which is called the maintenance phase.
88990165|NCT04095572|Active Comparator|intervention group A|50 ml of a sterile sodium HA (800 mg)- CS (1g) solution (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Via Martiri di Cefalonia 2, 26900 Lodi, Italy) weekly for four weeks, then every second week in the second month and four weeks later
88990166|NCT04095572|Placebo Comparator|control group B|50 ml sterile purified water weekly for four weeks, then every second week in the second month and four weeks later
88990167|NCT04079712|Experimental|Treatment (cabozantinib s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib s-malate PO QD on days 1-21 of cycles 1-4 and days 1-28 of subsequent cycles, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 90 minutes on day 1 of cycles 1-4 only. Treatment repeats every 21 for 4 cycles then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity.
88990168|NCT04075617|Experimental|intervention group|electronic habit reminder will fabricated to treat thumb/finger sucking habit containing two parts: acrylic part specially fabricated for the child finger/thumb connected to the reminder in the shape of wrist watch.
89628936|NCT00897507||Ancillary-Correlative (genotype assessment)|Tumor tissue samples undergo genotype assessment on the Pyrosequencing platform. Contingency tables and X^2 test performs a univariate analysis of the risk of relapse and genotype, and multivariable analyses using logistic regression. Cox proportional hazards evaluate the risk of relapse given genotype and other confounders. Genotype patterning, classification and regression trees, and multifactor dimensionality reduction evaluates for patterns of single nucleotide polymorphisms associated with toxicity and relapse risk.
89628937|NCT03254862|Experimental|Group A: CSS & AsynS|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS"
89628938|NCT03254862|Experimental|Group B: CSS & AsynR|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR"
89628939|NCT00891891||Spina Bifida|140 children with spina bifida (ages 8-15)
89628940|NCT03245502||Transfused|Patients who have blood transfusion during cardiac surgery
89628941|NCT03245502||Not-Transfused|Patients who don't have blood transfusion during cardiac surgery
89628942|NCT00888771||1|
89628943|NCT00888771||2|
89628944|NCT00888771||3|
89628945|NCT00888771||4|
89628946|NCT04487730|Experimental|"Engage & Connect Psychotherapy"|"Engage & Connect, a modified adapted version of Engage. Its principal intervention is social reward exposure - facilitating engagement in rewarding and meaningful social activities with significant others. In Engage-S therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding social activities of their choice."
89628947|NCT04487730|Active Comparator|Symptom Review and Psychoeducation (SRP)|In this intervention, the therapist will review the participant's symptoms and provide literature-based clinical explanations and clarifications about the symptoms, the course, and the causes of depression. In SRP, the therapist reviews the depressed individual's symptoms, and level of information on depression, identifies misconceptions, and guides selection of educational material which could benefit the patient.
89628948|NCT03845361|Experimental|C. hand|Radial artery cannulation
89628949|NCT03845361|No Intervention|N.C. hand|No cannulation of the radial artery
89628950|NCT04775121|Experimental|Experimental|Oral administration of 20 g Deuterium Glucose on a 3-hour period followed by sequential blood sampling to sort monocytes on a 30-days period of time
89628951|NCT03251040|Other|Fibrin sealant|Single arm pilot study
89628952|NCT04754763|Experimental|Propolis|Propolis was applied by disposable micro brush on particular sensitive teeth and left undisturbed for 60 seconds to let it dry. Followup was done at 7th, 15th and 30th day
89628953|NCT04754763|Active Comparator|Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE)|Application of Seventh generation Dentine Bonding Agent (Scotchbond™ Universal Adhesive, 3M ESPE) on sensitive surfaces was applied single coated for 20 seconds, gently applied air for 5 seconds and cured for 10 seconds (as per manufacturer's instructions). Followup was done at 7th, 15th and 30th day
89628954|NCT03254550|No Intervention|Control phase|This is the provision of PrEP without the use of the PrEP Promotion Package. PrEP promotion in the control phase consists of each clinic displaying posters that advertise PrEP, pamphlets, and palm cards that patients can take home from the clinic.
89628955|NCT03254550|Experimental|Intervention phase|This is the provision of PrEP as in the control phase plus the addition of five PrEP promotion components, which constitute the PrEP Promotion Package (PPP). These five additions are: 1) a PrEP promotion video to be played in the waiting room, 2) T-shirts advertising PrEP to be worn by healthcare workers, iii) a flipchart to support healthcare workers' PrEP counseling, iv) an informational booklet for clients to take home, and v) self-risk assessment forms to be displayed in the waiting room.
89628956|NCT04774653||MIH Group in short stature from 6-8 years old|Molar Incisor Hypomineralization in stunted children aged from 6-8 years
89628957|NCT04774653||HSPM Group in short stature from 5-8 years old|Hypomineralization of Second Primary Molars in stunted children aged from 5-8 years
89628958|NCT04774653||Both MIH &HSPM Group in stunted (from 5-8) years old|When both primary molars and permanent teeth( First permanent molars & permanent incisors) are hypo-mineralized in children with short stature with age range from 5-8 years old
89628959|NCT02455206|Active Comparator|Usual Care|outpatient pulmonary Rehabilitation program
89628960|NCT02455206|Experimental|Counseling|outpatient pulmonary Rehabilitation program plus physical activity counseling
89039690|NCT06085820|Experimental|Experimental (birth ball)|"Group B~Meeting~The researcher will introduce himself/herself, provide information about the research and obtain verbal and written consent.~Privacy will be ensured~After the routine maintenance of the hospital is carried out in the latent phase, the researcher will first introduce the birthing ball to the pregnant women and the movements to be performed will be demonstrated by the researcher.~Starting from the active phase, movements will be performed for 20 minutes every hour. During the contraction, there will be a break until the contraction ends, and the pregnant woman will be given the opportunity to rest in a comfortable position. The same movements will be applied again. The partograph will be recorded. VAS and VCS will be applied.~When the perineum is crowned, the pregnant woman will be taken to the table.~SEMSNB will be applied within 1-4 hours after birth."
89057892|NCT02216240|Experimental|Paramedic|Treatment at the scene by a paramedic. Valsalva manoeuvre with subsequent administration of 6mg and 12mg of adenosine unless the supraventricular tachycardia terminated. Patients were taken to accident and emergency if the tachycardia did not terminate, restarted, or the patient had continuing symptoms, a persistently abnormal ECG (other than T wave inversion) or was heamodynamically unstable. Prior to discharge from the ambulance patients received an information pack and a referral letter for their GP to refer them to an arrhythmia clinic.
89057893|NCT01688115|Experimental|Procedure|
89057894|NCT01688115|Active Comparator|Standard Care|
89628961|NCT02454894|Experimental|Group 1|no anesthesia; postoperative management
89628962|NCT02454894|No Intervention|Group 2|no anesthesia; lying without the pillow and fasting water and food for four hours after lumbar puncture
89628963|NCT02454894|Experimental|Group 3|surface anesthesia with lidocaine; postoperative management
89628964|NCT02454894|Experimental|Group 4|surface anesthesia with lidocaine; lying without the pillow and fasting water and food for four hours after lumbar puncture
89628965|NCT02455128|Experimental|Experimental Group|This group will receive the therapeutic listening.
89628966|NCT02455128|No Intervention|Control Group|This group will receive usual care offered by the hospital where the study will be conducted.
89628967|NCT03250962|Experimental|SHR-1210-plus-Decitabine|Decitabine 10 mg/day, days 1-5; SHR-1210 200 mg, day 8, every 3 weeks.
89628968|NCT03250962|Experimental|SHR-1210|SHR-1210 200 mg, day 1, every 3 weeks.
89628969|NCT04778943||oblique lateral interbody fusion (OLIF)|Patients with lumbar spinal stenosis undergoing oblique lateral interbody fusion (OLIF)
89628970|NCT04778943||minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)|Patients with lumbar spinal stenosis undergoing minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
89628971|NCT04774341||CDSS (MedicBK) Analysis|
89628972|NCT04774341||Core Laboratory Analysis|
89628973|NCT03250806||newly identified aortic stenosis|Patients identified on auscultation or target echocardiography with aortic stenosis. Consecutive patients per centre with no limit to numbers.
89628974|NCT04774263||General population|general population
89628975|NCT04774263||emergency caregivers|emergency caregivers
89628976|NCT04774029|Experimental|BVN Block|Patients will receive temporary basivertebral nerve block using lidocaine during the vertebral augmentation procedure for osteoporotic compression fracture.
89628977|NCT03245346|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
89628978|NCT03245346|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
89628979|NCT03245034|Experimental|fourth-year Obstetrics and Gynecology residents|The intervention will be three sessions of auricular acupuncture therapy; there will be no control intervention.
89628980|NCT03244956|Experimental|patients with RAS mutation|
89628981|NCT03244956|Experimental|patients with BRAFV600E mutation|
89628982|NCT03244878|Experimental|Intervention - Thrive program|Participants will receive access to the Thrive program for 8 weeks
89628983|NCT03244878|No Intervention|Wait-list Control|Participants will have no access to the Thrive program for 8 weeks upon enrollment. They will receive a link to the NIMH website to read about information on depression.
89628984|NCT02454270|Experimental|Dose Escalation: Participants With Certain B-Cell Malignancies|During accelerated dose titration in Group 1, participant will receive duvortuxizumab starting at 0.5 nanogram per kilogram (ng/kg) for biweekly dosing. Dose will be increased by half logarithmic steps in subsequent Dose Level (DL). After safety stopping criteria are met, Dose Escalation (DE) in Group 1 will transition to 3+3 design, and will continue until the Maximum tolerated Dose (MTD) is defined. DE in Groups 2 and 3 will follow 3+3 design, begin after initial dose level in Group 1 is deemed safe and recommended phase 2 doses (RP2D) for Part 1 of study can be decided. Duvortuxizumab at a starting dose of 50 ng/kg weekly will also be investigated in Group 1 and will follow 3+3 study design continue until the MTD or Maximum administered dose (MAD) is reached. Disease-specific dose escalation in Group 2 and 3 will not be initiated until dose in Group 1 is determined safe.
89628985|NCT02454270|Experimental|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Participants with Diffuse-Large B-Cell Lymphoma (DLBCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
89628986|NCT02454270|Experimental|Dose Expansion: Follicular Cell Lymphoma Participants|Participants with Follicular Cell Lymphoma (FL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
89628987|NCT02454270|Experimental|Dose Expansion: Mantle Cell Lymphoma Participants|Participants with Mantle Cell Lymphoma (MCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
89628988|NCT02454270|Experimental|Dose Expansion: Chronic Lymphocytic Leukemia Participants|Participants with Chronic Lymphocytic Leukemia (CLL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
89628989|NCT02454270|Experimental|Dose Expansion: Acute Lymphoblastic Leukemia Participants|Participants with Acute Lymphoblastic Leukemia (ALL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
89628990|NCT03244488||HIV-Positive|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
89039691|NCT06085820|Experimental|Experimental (birth dance)|"Group C~Meeting~The researcher will introduce himself/herself, provide information about the research and obtain verbal and written consent.~Privacy will be ensured~The environment will be made suitable~The pregnant woman will be asked to wear slippers that make her feel comfortable.~Pregnant will be given training on how to perform the birth dance during the latent phase. VCS and VAS will be applied.~Birth dance practice will be started on the pregnant woman starting from the active phase.~Starting from the active phase, the partograph will be recorded.~Birth dance cervical dilation will be performed for 20 minutes every hour, in the range of 5-8 cm.~At the end of the active phase, VCS and VAS will be applied again. The researcher will be with the pregnant woman throughout the application and labor.~When perineum is crowned, the pregnant woman will be taken to the delivery table.~SEMSNB will be applied within 1-4 hours after birth."
89039692|NCT06085820|No Intervention|control group|"Midwifery Interventions Made to the Control Group~The pregnant woman will be greeted politely.~The researcher will introduce himself/herself, provide information about the research and obtain verbal and written consent.~Privacy will be ensured~An introductory information form will be filled out.~Routine monitoring and care will be provided by the medical staff working in the delivery room.~At the end of each phase (latent, active), GKS and SCS will be applied once.~EFM (Electronic Fetal Monitoring) will be applied in each phase.~Child Heart Sound (CHS) will be listened to every half hour and recorded on the partograph.~Cervical changes will be evaluated with bimanual examination and recorded on the partograph.~When the perineum is crowned, the pregnant woman will be taken to the table.~NDAMDÖ will be applied to women taken to the postpartum room within a period of 1-4 hours."
89039693|NCT06085794|Active Comparator|Percutaneous nephrolithotomy|the standard-PCNL group (will be performed by urologists with more than 2 years of experience of PCNL), Fluoroscopic-guided percutaneous renal access will be done for patients in the prone position.
89211336|NCT05359419|Experimental|Ameluz|AMELUZ® (aminolevulinic acid hydrochloride) gel, 10% with its approved light source (BF-RhodoLED® lamp, 635 nm ± 9 nm, Biofrontera, Inc., Wakefield, MA, US)
89628991|NCT03244488||HIV-Negative|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
89628992|NCT03244332|Experimental|Decompensated cirrhosis|Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.
89628993|NCT03244332|Experimental|Compensated cirrhosis|Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)
89628994|NCT02454738|Experimental|Chest CT scan|Two follow-up ultralow dose chest CT scans will be taken 3 months and 1 year after the initial ultralow dose chest CT scan in close contact at high risk for developing multidrug- or extensively drug-resistant tuberculosis.
89628995|NCT03244254||Test Group|Children up to 17 years of age at recruitment undergoing endoscopy in order to diagnose or rule out Celiac disease, whose Marsh score at endoscopy is 2 or higher.
89628996|NCT03244254||Control Group|Children up to 17 years of age undergoing endoscopy as part of abdominal pain workup, whose Celiac serology is negative, and the Marsh score found at endoscopy is 0.
89628997|NCT03244410||immune thrombocytopenic purpura|immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
89628998|NCT02455986|Experimental|Intervention|"The intervention group includes 150 participants aged 12-14 across three schools. Each participant has been given a Fitbit Zip pedometer to wear for a six month period and enrolled on the StepSmart challenge. Participants within the intervention group will take part in two competitions during this period.~School and team based competition. 27/05/15 - 22/06/15 (8 weeks)~Individually focused competition. 22/06/15 - 26/10/15 (18 weeks)~Prizes of low monetary value will be given to participants based on competition performance"
89628999|NCT02455986|No Intervention|Control|The control group for the study involves approximately 90 participants aged 12 - 14. across two schools. Participants within the control group will complete the same measures as the intervention group including wearing an actigraph GT3X accelerometer for a seven day period and completing all questionnaires at the same time points as the intervention group.
89629000|NCT03243942|Experimental|Definity for pressure measurements|2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).
89629001|NCT03254784|Experimental|Tablet-Capsule Crossover 1|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
89629002|NCT03254784|Experimental|Tablet-Capsule Crossover 2|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
89629003|NCT03254784|Experimental|Tablet-Capsule Crossover 3|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
89629004|NCT03254784|Experimental|Tablet-Capsule Crossover 4|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
89629005|NCT03254784|Experimental|Tablet-Capsule Crossover 5|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
89629006|NCT03254784|Experimental|Tablet-Capsule Crossover 6|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
89629007|NCT03245190|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
89629008|NCT01969708|Active Comparator|aflibercept|2.0 mg aflibercept every 4 weeks
89629009|NCT01969708|Active Comparator|bevacizumab|1.25 mg bevacizumab every 4 weeks
89629010|NCT03243864||Ceftazidime and Avibactam|Ceftazidime-avibactam pharmacokinetic monitoring
89629011|NCT03250494|Active Comparator|group (I) (GI) (n=25)|
89629012|NCT03250494|Active Comparator|group (II) (GII) (n=25)|
89629013|NCT03250494|Placebo Comparator|group (III) (GIII) (control group) (n=25)|
89629014|NCT02354482||Diverse, high-risk patient populations|
89629015|NCT03250572||control group|
89629016|NCT03250572||NAFLD patients without hepatic fibrosis|
89629017|NCT03250572||NAFLD patients with hepatic fibrosis|
88990169|NCT04075617|Active Comparator|control group|palatal crib will be cemented after impression taking and fabrication
88990170|NCT04075240|Active Comparator|THA-control arm|Total Hip Arthroplasty: 5 days of rivaroxaban, followed by 30 days of aspirin
88990171|NCT04075240|Experimental|THA-study arm|Total Hip Arthroplasty: 35 days of aspirin
88990172|NCT04075240|Active Comparator|TKA-control arm|Total Knee Arthroplasty: 5 days of rivaroxaban, followed by 9 days of aspirin
88990173|NCT04075240|Experimental|TKA-study arm|Total Knee Arthroplasty: 14 days of aspirin
88990174|NCT04071756|Experimental|Topical Tazarotene 0.1% Gel Plus BPS|"Pharmacy teaching call~DFCI approved teaching sheets will be provided~20% urea applied to the palms and soles in the morning + tazarotene 0.1% gel, applied to the palms and soles nightly"
88990175|NCT04071756|Placebo Comparator|Placebo Gel Plus BPS|"A substance that has no therapeutic effect, used as a control in testing new drugs~Pharmacy teaching call~DFCI approved teaching sheets will be provided~20% urea applied to the palms and soles in the morning with placebo gel applied in the evening."
88990176|NCT04067609|Experimental|patients receiving dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
88990177|NCT04067609|Placebo Comparator|placebo|100mL of normal saline (placebo) immediately upon the subjects' arrival to the Post Anesthesia Care Unit (PACU) after leaving the operating room from their scheduled c-section
88990178|NCT04064359|Experimental|OBT076 Dose Escalation and Expansion|OBT076 administered intravenously (IV) every 3 weeks in escalating dose cohorts during Part A and OBT076 administered at or below the MTD in the Part B expansion cohort. In Part C sequential administration of OBT076 administered at the recommended phase 2 dose (RP2D) followed by Balstilmab. Part D will evaluate the safety, tolerability, preliminary efficacy of OBT-076 in combination with Balstilmab.
88990179|NCT04059822|Experimental|Slow and deep breathing|Daily practice of slow and deep breathing for 10 minutes per day. Breathing frequency will be 6 breaths per minute, with participants accessing a video aid to help guide their breathing. Breathing exercises will be conducted from enrolment until birth (maximum ~20 weeks if enrolment at 20 weeks gestation until ~40 weeks gestation birth)
88990180|NCT04057716|Experimental|Sleep restriction followed by extension|Children will spend 8 hours in bed for one week, engage in one week of wash-out, and then spend 11 hours in bed for one week.
88990181|NCT04057716|Experimental|Sleep extension followed by restriction|Children will spend 11 hours in bed for one week, engage in one week of wash-out, and then spend 8 hours in bed for one week.
89629018|NCT03254628|Experimental|Full - Train/oxy&miso/ B&M/Mentor/Phone|Helping Mothers Survive- Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of Clinical Mentor in each facility to support deliberate practice, phone-based support from district trainer for Clinical Mentor.
89629019|NCT03254628|Experimental|Partial - Train/oxy & miso/ B&M/Mentor|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of clinical mentor in each facility to support deliberate practice.
89629020|NCT03254628|Active Comparator|Comparison - Train/oxy & miso/ B&M|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask,.
89629021|NCT03254706|Active Comparator|Peak etch-and-rinse (P1)|Application Mode - According to the manufacturer's instructions.
89629022|NCT03254706|Experimental|Peak applied for double time(P2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
89629023|NCT03254706|Active Comparator|Single Link etch-and-rinse (SL1)|Application Mode - According to the manufacturer's instructions.
89629024|NCT03254706|Experimental|Single Link double time (SL2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
89629025|NCT01970176|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
89629026|NCT01970176|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
89629027|NCT03254160|Experimental|DNS-3379 (0.5mg)|
89629028|NCT03254160|Experimental|DNS-3379 (2.5mg)|
89629029|NCT03254160|Placebo Comparator|Placebo|
89629030|NCT02023918|Experimental|Pegvisomant arm|Pegvisomant 20 mg subcutaneously Qday x 28 days will be administered by the study subject.
89629031|NCT03250728|Other|CDG with stroke-like history|
89629032|NCT03250728|Other|CDG without stroke-like history|
89629033|NCT03243708|No Intervention|Usual Care|Control: Standard order set without risk calculator (usual care)
89629034|NCT03243708|Active Comparator|Risk calculator|Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
89629035|NCT02454036|Experimental|BBI Intervention|Biobehavioral Intervention
89629036|NCT02024386|Experimental|Riociguat 0.5 mg|Riociguat 0.5 mg tablets, one-time oral dose of 0.5 mg
89629037|NCT02024386|Experimental|Riociguat 1.0 mg|Riociguat 0.5 mg tablets, one-time oral dose of 1.0 mg
89629038|NCT02024386|No Intervention|Control arm|No drug
89629039|NCT03243474||65 - 69 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
89629040|NCT03243474||70 - 74 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
89629041|NCT03243474||75- 79 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
89629042|NCT03243474||80 - 84 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
89629043|NCT03243474||85 - 89 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
89039694|NCT06085794|Active Comparator|Endoscopic combined intrarenal surgery|the ECIRS group (will be performed by urologists with more than 2 years of experience of PCNL and RIRS), patients will be oriented in the GMSV position.flexible ureteroscope will be inserted through the access sheath to observe the stone distributions. Under the guidance of fluoroscopy and endoscopic vision, a 18-20 Fr percutaneous tract will be established using sequential fascial dilators and a matching sheath for stone manipulation simultaneously. We use a 12-F nephroscope (Karl Storz).
89039695|NCT06085768|Experimental|VRE intervention group|"The intervention group will receive 2 VR exposure interventions, once a week, and each intervention will experience 2 complete flight processes for about 90 minutes each time. A complete flight process includes: (1) waiting for the airport bus at the station, (2) check-in, security check, waiting, and boarding at the airport, (3) taxiing, taking off, cruising, landing, and leaving the aircraft during flight. Among them, the flight process requires the participant to sit on the flight seat, which takes about 24 minutes each time.~A scale assessment and skin electrode and heart rate data collection will be conducted before and after each intervention. The participants' skin electrode and heart rate data will also be collected during the intervention. They will be followed up in the 2nd week after the intervention. Follow-up content includes scale evaluation and safety evaluation."
89039696|NCT06085768|No Intervention|wait-list control group|The control group will receive scale assessments in weeks 1, 2, and 4, and after the waiting period, receive the same VR exposure intervention once a week for 2 weeks as the intervention group.
89039697|NCT06085716|Experimental|Psychoeducational Intervention|Participants will be randomly assigned to 1 of 3 study groups. The study treatment participants get will be chosen by chance, like rolling the dice. Both participants and the study staff will know which treatment you were assigned:
89039698|NCT06085716|Experimental|Open Label Placebo|Participants will be randomly assigned to 1 of 3 study groups. The study treatment participants get will be chosen by chance, like rolling the dice. Both participants and the study staff will know which treatment you were assigned:
89629044|NCT03243474||≥90 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
89629045|NCT03250650|Active Comparator|Group 1: TTNS|Intervention for Group 1: transcutaneous tibial nerve electric stimulation (TTNS), using a Device Dualpex 961(Quark medical), with 2 silicone electrode in the tibial nerve path, being one on the lower border of the medial malleolus and another one, 10cm above. Once a week for 12 weeks. The parameters used on device were, 200 microseconds for pulse time and 10Hz for Frequency, during 30 minutes.
89629046|NCT03250650|Experimental|Group 2: ES + TTNS|Intervention for Group 2: transvaginal electric stimulation plus transcutaneous tibial nerve electric stimulation (ES + TTNS), using a Device Dualpex 961(Quark medical), with transvaginal electrode, located inside the vagina. Once a week for 12 weeks. The parameters used on device were 1milisecond for pulse time and 10Hz for Frequency, during 20 minutes. After transvaginal stimulation, the tibial stimulation will be applied like described on Group 1.
89629047|NCT03250260|No Intervention|Standard Care|Patient receives standard pre-operative preparation which involves a discussion in to the likely aesthetic outcome with their surgeon or specialist nurse
89629048|NCT03250260|Experimental|2-dimensional Portfolio|Patient views photographs of women matched for BMI, age, and breast volume who are 1-5 years post BCT pre-operatively.
89629049|NCT03250260|Experimental|3-dimensional simulation|Patient pre-operatively views a simulation of their own breast of their likely outcome after BCT.
89629050|NCT03250338|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
89629051|NCT03250338|Placebo Comparator|Placebo|Placebo following salvage chemotherapy
89629052|NCT01971580|Other|Ambrisentan first, Placebo second|These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
89629053|NCT01971580|Other|Placebo first, Ambrisentan second|These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
89629054|NCT00354562|Active Comparator|A|Docetaxel + ABT-751
89629055|NCT00354562|Placebo Comparator|B|Docetaxel + placebo
89629056|NCT00838383|Experimental|sitaxsentan (1.0 mg/kg)|
89629057|NCT00838383|Experimental|sitaxsentan (2.0 mg/kg)|
89629058|NCT00838383|Placebo Comparator|Placebo|
89629059|NCT01972204|Experimental|Intensive adherence instruction|Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
89629060|NCT01972204|Sham Comparator|Control|The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
89629061|NCT02355886|Experimental|Arm I (gabapentin)|Patients receive gabapentin PO TID for 48 hours after surgery.
89629062|NCT02355886|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO TID for 48 hours after surgery.
89629063|NCT03254082|Experimental|F-1000 (fontanelle flour)|Fontenel sorghum flour
89629064|NCT03254082|Experimental|Sumac|Sumac sorghum flour
89629065|NCT03254082|Experimental|Wheat|Wheat flour
89629066|NCT03254082|Experimental|MMR|MMR cultivar of sorghum flour -- from MMR Genetics, a company that produces sorghum seed.
89629067|NCT03254082|Active Comparator|Sucrose|Table sugar
89629068|NCT04779099|Experimental|4-session intervention|
89629069|NCT04779099|Active Comparator|Treatment as usual|
89629070|NCT03243162|Experimental|CBPT-ACLR|CBPT-ACLR program consisting of weekly phone calls.
89629071|NCT03243162|Active Comparator|Education|Education program consisting of weekly phone calls.
89629072|NCT02356198|Active Comparator|TAP block (EXPAREL)|After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.
89629073|NCT02356198|Active Comparator|Intrathecal opioid (IT)|single injection intrathecal hydromorphone analgesia given preoperatively
89629074|NCT03254004|Experimental|single arm: pembrolizumab|pembrolizumab 200 mg every 3 weeks
89629075|NCT04778865|Experimental|Vitamin D-correction|Subjects will receive one capsule with 50.000 IU cholecalciferol weekly for 3 months.
89629076|NCT04778865|Active Comparator|Vitamin D-RDA|Subjects will receive one capsule with 4.200 IU cholecalciferol weekly for 3 months.
89629077|NCT03242850|No Intervention|Regular care group|This group will receive regular care including standard guidance on shared reading. Participants in this arm will not view the video at the time of enrollment nor will they receive the text messages throughout the 6 months of the randomized controlled trial.
89629078|NCT03242850|Experimental|Intervention group|
89039699|NCT06085716|Experimental|Psychoeducational Intervention+Placebo|Participants will be randomly assigned to 1 of 3 study groups. The study treatment participants get will be chosen by chance, like rolling the dice. Both participants and the study staff will know which treatment you were assigned:
89629079|NCT02025634|Experimental|Intravenous acetaminophen|Infusion of Intravenous acetaminophen (Ofirmev)
89629080|NCT02025634|Placebo Comparator|Placebo (0.9% Normal Saline Infusion)|Infusion of 100 ml of 0.9 NS Normal Saline
89629081|NCT03249948|No Intervention|Standard defibrillation|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
89629082|NCT03249948|Other|Vector change defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
89629083|NCT03249948|Other|Double-sequential defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
89629084|NCT04773951|Experimental|Dose escalation and extension group|"JS004 dose escalation: 1mg/kg, IV Q3W; 3mg/kg, IV Q3W; 10mg/kg, IV Q3W;~JS004 dose extension: 3mg/kg, IV Q3W; 200mg, IV Q3W;~JS004+Toripalimab Injection dose escalation: JS004 100mg+Toripalimab Injection 240mg, IV Q3W; JS004 200mg+Toripalimab Injection 240mg, IV Q3W;~JS004+Toripalimab Injection dose extension: JS004 100mg+Toripalimab Injection 240mg, IV Q3W or JS004 200mg+Toripalimab Injection 240mg, IV Q3W，to be determined."
89629085|NCT03253536||entire cohort|none (observational study)
89629086|NCT04773717|Experimental|Ascorbic acid|"Patients received a high dose of intravenous ascorbic acid in four equal parts daily for 96 hours.~Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours."
89629087|NCT04773717|Placebo Comparator|Placebo|Patients received placebo solution matching ascorbic acid solution as four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.
89629088|NCT04444167|Experimental|AK104 and Lenvatinib|AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD
89629089|NCT03243006|Placebo Comparator|group Placebo|Patients in this group (Placebo Oral Tablet) received two placebo tablets
89629090|NCT03243006|Active Comparator|group Paracetamol|Patients in this group received two 500 mg paracetamol tablets
89629091|NCT03243006|Active Comparator|group Tramadol/Paracetamol combination|Patients in this group (Tramadol/Paracetamol combination ) received 2 tablets of Tramadol/Paracetamol combination (37.5mg/325mg)
89629092|NCT03249402|Experimental|Oral Contraceptive Tablet + JNJ-42847922|All participants will receive one oral contraceptive (OC) tablet containing ethinyl estradiol (EE) 0.03 milligram (mg) and levonorgestrel (LN) 0.15 mg once daily on Days 1 to 21 for both cycle 1 and cycle 2. In addition, in cycle 2, participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21. Participants will not be given OC tablet on Days 22 to 28 during cycle 1 and cycle 2 (tablet-free period).
89629093|NCT04401111||Survivors of Intensive care unit patients|Survivors of severe COVID-19 pneumonia after intensive care unit
89629094|NCT03249480|Experimental|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
89629095|NCT04342143||Stroke|Patients who have a diagnosis of stroke by a stroke consultant from UK National Health Service Trust within 3 months to 5 years of study start date.
89629096|NCT03242460|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
89629097|NCT01972516|Experimental|Tivozanib|Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
89629098|NCT01972516|No Intervention|Standard Care|Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.
89039700|NCT06085703|Experimental|Henagliflozin Group|Henagliflozin will be initiated and maintained at 5mg/ day every morning until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Empagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
89057895|NCT04529486|Experimental|Group 1: Kinesio taping|Kinesio taping was applied to the study group to improve posture and improve function in the shoulder area. Measurements were carried out for the study group before and after application (with tape on). The tape was then removed and the measurements were repeated after 1 week.
89629099|NCT04773561|Experimental|multifetal pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
89629100|NCT04773561|Active Comparator|singleton pregnancy in the 3rd trimester|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed in the 3rd trimester, 30-36 weeks of gestational age.
89057896|NCT04529486|No Intervention|Group 2: Control|No application was made to the control group.
88990182|NCT04055012|Experimental|High Dose Metformin|High Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 2 tabs per day (1,000mg) for the first week then increase to 3 tabs per day (1,500mg) for the remaining 6 months.
88990183|NCT04055012|Experimental|Low Dose Metformin|Low Dose Metformin Group (n=100). Subjects will receive metformin and will be instructed to take 1 tab per day (1 metformin tab (500mg) for 6 months.
88990184|NCT04055012|Placebo Comparator|Placebo|Placebo Group (n=100). Subjects will receive placebo and will be instructed to take either 2 tabs per day for the first week then increase to 3 tabs per day for the remaining 6 months OR take 1 placebo tab for 6 months.
88990185|NCT04055012|Other|Wait-List Control|"Control Group (n=100). Subjects will be told that they are in the wait-list control group. They will have a 3 month waiting period before they will be randomized again to a treatment group. They will be randomized to one of the previous groups."
88990186|NCT04050709|Experimental|PD-L1 t-haNK Dose Level 1|PD-L1 t-haNK will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 1 is 3 to 6.
88990187|NCT04050709|Experimental|PD-L1 t-hanK Dose Level 2|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 2 is 3 to 6.
88990188|NCT04050709|Experimental|PD-L1 t-haNK Dose Level Recommended phase 2 dose (RP2D)|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into RP2D is 4.
89629101|NCT04773561|Active Comparator|age-stratified healthy non-pregnant women|Corneal tomography, optical coherence tomography and optical coherence tomography angiography were performed.
89629102|NCT03253380|Experimental|early rehabilitation program on mechanical ventilated COPD pat|compare the effect of early rehabilitation program on mechanical ventilated COPD patient in RICU to those using current standard care as regarding (morbidity and thirty day mortality ,diaphragm function and weaning outcomes, disease exacerbation , Duration spent on machin , Length of ICU stay.
89629103|NCT05605743|Experimental|Exercised group|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
89629104|NCT05605743|No Intervention|control group|this will be a thirty-patient wait-list group that will no receive any shape of training
89629105|NCT03242694||persistent atrial fibrillation|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
89629106|NCT03242616|Experimental|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)~Pemetrexed (500 mg/m2, day 1)~Actinamide 1mg IM: 1 week before 1st dose, q 9 weeks (1wk before 1st cycle, 4th,7th,10th…. cycle after then.)~Folic acid 1mg daily: 1 week before 1st dose until 3 weeks after last dose~Dexa 4mg po bid on D0-2"
89629107|NCT03242616|Active Comparator|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
89629108|NCT04773327|Experimental|PEG-rhG-CSF prevention|Mecapegfilgrastim subcutaneous injection, 6mg, 24-48h after the end of antitumor drug administration in each chemotherapy cycle,
89629109|NCT04773327|No Intervention|non-prevention|Only close monitoring after chemotherapy
89629110|NCT01748825|Experimental|ARM 1 AZD1775 200 mg Once Daily|
89629111|NCT01748825|Experimental|ARM 2 AZD1775 225 mg Once Daily|
89629112|NCT01748825|Experimental|ARM 3 AZD1775 225 mg Twice Daily|
89629113|NCT01748825|Experimental|ARM 4 AZD1775 225 mg Twice Daily (week 1-only dosing)|
89629114|NCT01748825|Experimental|ARM 5 AZD1775 250 mg Once Daily|
89629115|NCT01748825|Experimental|ARM 6 AZD1775 300 mg Once Daily|
89629116|NCT01748825|Experimental|ARM 7 AZD1775 300 mg Twice Daily|
88990189|NCT04050709|Experimental|PD-L1 t-haNk Dose -1a (if needed)|PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level -1a is 3 to six, if needed.
88990190|NCT04047355|Experimental|Group A: Propranolol first|"Participants randomly assigned to this group will receive Propranolol first. After the washout period, they will receive Placebo.~Propranolol will be given in liquid or pill form."
88990191|NCT04047355|Placebo Comparator|Group B: Placebo first|"Participants randomly assigned to this group will receive Placebo first. After the washout period, they will receive Propranolol.~Placebo will look identical to the study drug Propranolol."
88990192|NCT04037254|Experimental|Phase I (niraparib, GnRH, IMRT)|Patients receive niraparib PO QD and receive standard of care GnRH agonist androgen suppression therapy. Treatment with niraparib continues for 12 months, and GnRH agonist therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib and GnRH agonist, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks, depending on type of radiation therapy given, in the absence of disease progression or unacceptable toxicity.
88990193|NCT04037254|Active Comparator|Phase II, Arm I (GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
89057897|NCT01688154|Active Comparator|Product 1|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)
89057898|NCT01688154|Placebo Comparator|Control product|2 empty capsules
89629117|NCT01748825|Experimental|ARM 8 AZD1775 400 mg Once Daily|
89629118|NCT01748825|Experimental|ARM 9 Expansion Cohort 1: AZD1775 225 mg Twice Daily|
89629119|NCT01748825|Experimental|ARM 10 Expansion Cohort 2: AZD1775 300 mg Once Daily|
89629120|NCT03242538|Experimental|Pelvic Exercise Intervention|Patients will perform two pelvic exercises prior to each external beam radiation treatment.
89629121|NCT03249636||ALL patients|New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
89629122|NCT03253224|Placebo Comparator|Saline|Patient who received normal saline during the operation
89629123|NCT03253224|Experimental|Magnesium|Patient who received magnesium sulfate during the operation
89039701|NCT06085703|Experimental|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/ day every morning until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Gliclazide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
89039702|NCT06085677||Normal/mild gastritis|Patients enrolled with normal stomach epithelium or mild gastritis
89039703|NCT06085677||Chronic atrophic gastritis|Patients enrolled with chronic atrophic gastritis
89039704|NCT06085677||Intestinal metaplasia|Patients enrolled with intestinal metaplasia
89039705|NCT06085625|Experimental|Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy|"Participants will first complete a survey about the severity of your symptoms. This will be done at your pre-surgery (pre-operative) visit and should take about 5-10 minutes to complete.~Study Groups~At your pre-surgery visit, you will be assigned to either be sent home on the same day as surgery or to stay in the hospital overnight (or longer) for observation. This will be determined based on which group your surgeon has been assigned to. Participants will be told which group you are in."
89039706|NCT06085586|Experimental|1) Early Full Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
89039707|NCT06085586|Active Comparator|2) Normal Full Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
89039708|NCT06085469|Experimental|Intervention Group|Used Temporal Adaptation Approach
89039709|NCT06085469|No Intervention|Control Group|Follow up via telephone calls
89629124|NCT02028208|Experimental|Ammoniated mercury|Subjects will be patch tested with 4 experimental doses of ammoniated mercury, 0.013 mg/cm², 0.040 mg/cm², 0.12 mg/cm², and 0.36 mg/cm², a negative control and corresponding reference allergens, 1.0% ammoniated mercury in petrolatum and 0.5% elemental mercury in petrolatum. Patch tests will be worn for 48 hours.
89629125|NCT02028208|Experimental|Aluminum chloride and aluminum lactate|Subjects will be patch tested with 4 experimental doses of aluminum chloride, 0.040 mg/cm², 0.12 mg/cm², 0.36 mg/cm² and 0.72 mg/cm², 4 experimental doses of aluminum lactate 0.047 mg/cm², 0.14 mg/cm², 0.42 mg/cm² and 0.84 mg/cm², a negative control and corresponding reference allergens, 2.0% aluminum chloride in petrolatum and 12.0% aluminum lactate in petrolatum. Patch tests will be worn for 48 hours.
89629126|NCT02028208|Experimental|Sodium tetrachloropalladaate (Palladium)|Subjects will be patch tested with 5 experimental doses of sodium tetrachloropalladate 0.011 mg/cm², 0.033 mg/cm², 0.10 mg/cm², 0.30 mg/cm² and 0.60 mg/cm², a negative control and corresponding reference allergens, 3.0% sodium tetrachloropalladate in petrolatum and 1.0% palladium chloride 1.0% in petrolatum. Patch tests will be worn for 48 hours.
89629127|NCT03249324|Experimental|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will discuss potential costs of unhealthy behaviors and the benefits of healthier lifestyle choices, and how they apply not only to adults, but also to developing children. Theoretically, discussing these perspectives will make the mothers more likely to make healthier lifestyle choices in the future.
89629128|NCT03249324|Active Comparator|Usual Care (UC)|UC includes regular clinic visits, routine blood and urine screening tests, and anticipatory guidance from a primary care provider in accordance with the VA/DoD Guideline for the Management of Pregnancy. After delivery, participants receive routine well-child care in accordance with established guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians.
89629129|NCT03253458|Experimental|Optical imaging|All consenting patients will undergo Confocal Laser Endomicroscopy or Optical Coherence Tomography imaging prior to biopsy or surgery.
89629130|NCT02356900|Experimental|Hyperoxic, Hyperbaric|Hyperoxic hyperbaric interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis at 1.4 ATA of oxygen in a hyperbaric chamber.
89629131|NCT02356900|Sham Comparator|Normoxic, Normobaric|Normoxic, normobaric, interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis.
89629132|NCT00789399|Active Comparator|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
89629133|NCT00789399|Placebo Comparator|Placebo|
89629134|NCT01720667|Experimental|Intravenous levetiracetam|Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
89629135|NCT01720667|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance
89629136|NCT03253146||sepsis|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.~The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.~ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.~In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs."
89629137|NCT03253146||septic shock|Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation.
89629138|NCT02455674||Age under 6 years|"All children 1 to 6 years~Used formula for weight calculation:~Children 1-5 years: Weight (kg) = (2 × age in years) + 8"
89039710|NCT06085456||EOC group|Patients diagnosed with epithelial ovarian cancer
89039711|NCT06085456||Control group|Patients diagnosed with benign gynecological diseases, including ovarian cysts, uterine fibroids and uterine prolapse.
89039712|NCT06085443|Experimental|Auricular spray|Subjects using the medical device under investigation: 2 sprays in each ear, every 3 days at home.
89039713|NCT06085443|No Intervention|Control|Subjects not using any spray (can use ear drops in case of discomfort or pain)
89039714|NCT06085430|Experimental|Right eyes: Treatment|
89039715|NCT06085430|No Intervention|Left eyes: Control|
89629139|NCT02455674||Age over 6 years|"All children 6 to 12 years~Used formula for weight calculation:~Children 6-12 years: Weight (kg) = (3 × age in years) + 7"
89629140|NCT03253770|Experimental|Digital Cognitive Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid in the hand of the leader during crises management.
89629141|NCT03253770|Experimental|No digital aid|No cognitive aid in the hand of the leader during crises management. Intervention : no cognitive aid in the hand of the leader during crises management.
89629142|NCT03253770|Experimental|Paper Cognitive Aid|"The paper cognitive aid is the document officially recommended to be used in case of crises by the French Society of Anaesthesia and Intensive Care.~Intervention : paper cognitive aid in the hand of the leader during crises management."
89629143|NCT04773093|Active Comparator|Continous Intravenous Lidocaine Infusion|Patient will recieve Continous Intravenous Lidocaine Infusion
89629144|NCT04773093|Placebo Comparator|Placebo|Patient will recieve placebo (NaCl 0.9% infusion)
89629145|NCT01720043|Experimental|All participants|All participants enrolled
89629146|NCT00700752|Active Comparator|senofilcon A/balafilcon A|senofilcon A silicone hydrogel contact lens worn during first 4-week period, balafilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
89629147|NCT00700752|Active Comparator|balafilcon A/senofilcon A|balafilcon A silicone hydrogel contact lens worn worn during first 4-week period, senofilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
89629148|NCT02455362|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
89629149|NCT02455362|Experimental|Morphine sulfate (0, 0, 8 mg)|Placebo during treatment week one and two and morphine 8 mg per day week three.
89629150|NCT02455362|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo during treatment week one and morphine 8 mg per day week two and three.
89629151|NCT02455362|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.
89629152|NCT02455362|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg per day during all three treatment weeks.
89629153|NCT02455362|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg per day week one and two and morphine 16 mg per day week three.
89629154|NCT02455362|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg per day week one and morphine 16 mg per day week two and three.
89629155|NCT02455362|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.
89629156|NCT02455362|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg per day during all three treatment weeks.
89629157|NCT02455362|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.
89039716|NCT06085417|Sham Comparator|Group B (bupivacaine) (n= 30)|"For Group B (control group), 100 mg bupivacaine hydrochloride+ isotonic saline (5ml) was administered in a total volume of 25 ml. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
89057899|NCT02216279|Experimental|Pulmonary Hypertension Patients|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
89057900|NCT02216279|Active Comparator|Control Non-Smoking Participants|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
89057901|NCT01688193||HCP 1004|
89057902|NCT01688193||Vimovo 500/20mg|
89629158|NCT02455362|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.
89629159|NCT02455362|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.
89629160|NCT03246789|Experimental|Engage-M|Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
89629161|NCT03246789|Active Comparator|Wellness in Mind and Body (W-MH)|Participants will meet with a therapist for group therapy once a week for eight weeks. Each weekly session will last approximately 50 minutes. During these weekly sessions, the therapist will educate participants about health and mental health.
89629162|NCT01747811|Experimental|wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
89629163|NCT01747811|Placebo Comparator|wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
89629164|NCT03242304||Control group|A control group composed of subjects without physical or psychiatric disease.
89629165|NCT03242304||Acute Ischemic Stroke group|An AIS group composed of subjects within the first 24 hours of the neurovascular event.
89629166|NCT03242226|Experimental|two spectacles|
89629167|NCT03242226|Active Comparator|single vision spectacles|
89629168|NCT03249246||Infection only|The patients have only infection
89629169|NCT03249246||Infection + SIRS|Patients have infection plus systemic inflammatory response syndrome (SIRS)
89629170|NCT03249246||Severe sepsis|Septic patients with newly developed organ dysfunctions
89629171|NCT03249246||Septic shock|Sepsis plus sepsis related hypotension
89629172|NCT03253068|Experimental|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
89039717|NCT06085417|Experimental|Group Group B+D (bupivacaine + dexamethasone group) (n= 30)|For Group B+D (bupivacaine + dexamethasone group), 100 mg bupivacaine hydrochloride + 4 mg dexamethasone phosphate+ isotonic saline (4 ml) was administered in a total volume of 25 ml. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded. During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy.
89057903|NCT04529681|Experimental|Intervention Group|Intervention group will be equipped with Stroke Riskometer Apps and informational leaflets. In the beginning of the study, investigators will guide the participants to download and install the Stroke Riskometer Apps and how to use the application to measure, monitor and self-manage the stroke risk. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
89211337|NCT05359419|Active Comparator|Levulan|LEVULAN® KERASTICK® (aminolevulinic acid HCl) topical solution, 20% with its approved light source (BLU-U® Blue light photodynamic Therapy Illuminator Model 4170, 417 nm ± 5 nm, DUSA Pharmaceuticals, Wilmington MA, US)
89629173|NCT01747655||Duodopa|Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)
89629174|NCT01747655||Standard of Care|Participants that return to oral or transdermal anti-parkinson's disease medications
89629175|NCT03252912|Experimental|Biological samples|The CSF samples will be taken at the occasion of the first lumbar puncture performed for clinical purposes (suspected LM). If necessary for the routine diagnosis, a second and a third lumbar puncture will be performed according to the gold standard Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar puncture and transferred at ambient temperature to the Biological Resource Center of the ICM (Jean-Pierre Bleuse, Biobank number BB-0033-00059) to be processed within 1 hour Blood samples will be centrifuged at 3,000 g for 10 minutes at ambient temperature and will be aliquoted in 4 plasma and 4 serum aliquots and then stored at -80°C. Aliquots must be anonymized.
89629176|NCT03253614||Exposed group|250 children aged 6-15 years exposed to gentamicin in the neonatal period
89629177|NCT03253614||Control group|25 healthy children aged 6-15 years NOT exposed to gentamicin in the neonatal period
89629178|NCT03248934|Experimental|Patient Self-Administered Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will first complete a patient self-administered diagnostic exam.
89629179|NCT03248934|Active Comparator|Clinician-Performed Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will next complete a clinician-performed diagnostic exam.
89629180|NCT05605041|No Intervention|Did Not Use Headspace|Those that did not use headspace during the time the study is conducted
89629181|NCT05605041|Experimental|Did Use Headspace|Those that were randomized into the group and used Headspace at least once during the study period
89629182|NCT02454816|Experimental|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
89629183|NCT02454816|Active Comparator|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
89629184|NCT03104049|Active Comparator|the PD NMT Group|the NMT Group were treated with NMT
89629185|NCT03104049|No Intervention|The PD Group without NMT|The patients received only their usual pharmacological PD therapy
89629186|NCT03241992|Experimental|MyChart Intervention|Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires. At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months. At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart. If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services. Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
89629187|NCT03241992|No Intervention|Usual Care|Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled. Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution. For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment. Subjects will receive generic, non-IBD related messages through MyChart.
89629188|NCT03239262|Experimental|Group GP|Thirty-five patients (35%) from our population underwent concomitant mapping and radiofrequency ablation of ganglionated plexi (Group GP).
89629189|NCT03239262|Experimental|Group LA|Sixty five patients (65%) in whom no intervention related to ganglionated plexi was performed (Group LA).
89629190|NCT01718483|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
89629191|NCT01718483|Placebo Comparator|Placebo|
89629192|NCT03241758||Group #1|Patients with prostate cancer who will undergo radical prostatectomy
89629193|NCT03241446|Experimental|50 ug Tilmanocept|Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
89629194|NCT03241446|Experimental|200 ug Tilmanocept|Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
89211338|NCT00823862|Experimental|Active (SD-101)|SD-101 in cohorts of escalating doses
89211339|NCT00991263||Group 1|Tissue blocks from CALGB-9344 and CALGB-9741 are utilized to purify RNA to be tested in the PAM50 assay (a 50-gene quantitative PCR assay, that provides an intrinsic breast cancer subtype diagnosis) and generate risk of relapse (ROR) scores. For more information, see Details section.
89211340|NCT02548598||AIMS-Full Characterization|Participants in this group undergo characterization at the UCSF Airway Clinical Research Center 6 weeks following their scheduled sinus surgery.
89211341|NCT02548598||AIMS-OR|Participants in this group complete limited questionnaires and provide biological samples that are collected during their scheduled sinus surgery. No further characterization in done in this group.
89211342|NCT02548598||AIMS-M|Participants returning to UCSF Sinus Center clinic following sinus surgery who have nasal secretions that are removed by a study clinician will provide samples at these clinic visits.
89211343|NCT00828932|Experimental|Lorcaserin 10mg|
89211344|NCT00537771|Experimental|1|Anastrozole (ARIMIDEX)
89211345|NCT00537771|Active Comparator|2|Tamoxifen
89211346|NCT00831740|Experimental|Speech Therapy|
89211347|NCT00831740|Active Comparator|ACT NoW Visitor|
89211348|NCT00831818||1|Mothers of healthy infants who breastfeed on demand
89211349|NCT00831818||2|Mothers of healthy infants who do not breastfeed
89211350|NCT00831896|Experimental|1|TAK-701
89211351|NCT00823940|Placebo Comparator|Cohort A1|Dose escalation: 5 - 100mg and placebo in 4 planned doses
89211352|NCT00823940|Placebo Comparator|Cohort A2|Dose escalation: 100-600mg and placebo in 4 planned doses
89211353|NCT00823940|Other|Cohort B1|Glucagon challenge test
89211354|NCT00823940|Active Comparator|Cohort B3|Glucagon challenge test + selected dose of GSK1362885
89211355|NCT04043546|Experimental|Exercise intervention|
89629195|NCT03241446|Experimental|400 ug Tilmanocept|Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
89629196|NCT00736749||Observational (long-term follow-up)|Within 3 months of enrollment of ALTE05N1, patients receive a mailed packet introducing the LTFC. Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone number.
89629197|NCT04487418|Experimental|Surgery group with electro cautery|Surgery will be performed with electro cautery.
89629198|NCT04487418|Experimental|High level diode laser surgery|High power diode laser surgery will be performed.
89629199|NCT02454582|Other|Group 1|15min without CPAP, then 15min with CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
89629200|NCT02454582|Other|Group 2|15min with CPAP, then 15min without CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
89629201|NCT01717859|Other|Tocilizumab|All subjects will receive tocilizumab.
89629202|NCT03239184|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89629203|NCT03239184|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89629204|NCT03239184|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89629205|NCT03239184|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89629206|NCT03249168|Experimental|case group|Duloxetine 60mg orally 12 hours before surgery
89629207|NCT03249168|Active Comparator|Control group|Placebo (glucose powder in a tablet) orally 12 hours before surgery
89629208|NCT03248856|Other|Group 1|Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
89629209|NCT03248856|Other|Group 2|Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
89629210|NCT03248856|Other|Group 3|Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
89629211|NCT03248856|Other|Group 4|Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
89629212|NCT03241524|Experimental|Exercise program for pelvic muscle floor|Training program for pelvic muscles and application of 3 questionnaires for sexual function evaluation and the use of PERFECT and Perina methods to evaluate perineal musculature.
89629213|NCT03241602|Active Comparator|group of Pulmonary recruitment & Intraperitoneal libocai|
89629214|NCT03241602|Active Comparator|Group of Intraperitoneal lidocaine|
89211356|NCT00831974|Experimental|2|masitinib (AB1010) 6 mg/kg/day
89211357|NCT00831974|Experimental|1|masitinib (AB1010) 3 mg/kg/day
89211358|NCT00829322|Experimental|Treatment group|
89211359|NCT00829322|Placebo Comparator|Control group|
89211360|NCT00623480|Experimental|Recombinant Factor VIII prophylaxis treatment|Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
89211361|NCT00623480|Experimental|Recombinant Factor VIII on-demand treatment|Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.
89629215|NCT03241602|Active Comparator|Group of pulmonary recruitment|
89629216|NCT03241602|No Intervention|group receive passive exsufflation through port|
88990194|NCT04037254|Experimental|Phase II, Arm II (niraparib, GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months, and niraparib PO QD for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
88990195|NCT04034732|Experimental|Mindfulness-based Relapses Prevention (MBRP)|The MBRP program will be delivered by an instructor with training in MBSR/MBCT who has more than two years of teaching experience in MBSR/MBCT. The MBRP programme will consist of 2.5 hour weekly sessions for 8 weeks. The mindfulness curriculum will include training in mindfulness through (1) a body scan, (2) sitting meditation and (3) mindful stretching exercises.
88990196|NCT04034732|Active Comparator|Usual Care Control Group (UCCG)|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
88990197|NCT04033237|Experimental|Very low nicotine content cigarettes|
88990198|NCT04033237|No Intervention|Usual Brand|
88990199|NCT04033224||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill patients undergoing EBPTs for support/replacement renal function or immunomodulation will be prospectively observed.
88990200|NCT04024787|Experimental|Immediate intervention|
89629217|NCT03241680|No Intervention|Control Group with conventional citology|Patients who do not have high grade cervical intraepithelial neoplasia and will have anal cytology performed by conventional method
89629218|NCT03241680|No Intervention|Control Group with liquid based citology|Patients who do not have cervical intraepithelial neoplasia of high grade and will have anal cytology performed by liquid based method
89629219|NCT03241680|No Intervention|CIN 2-3/Conventional Citology|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by conventional method
89629220|NCT03241680|Active Comparator|CIN 2-3/Liquid Based|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by liquid based method
89629221|NCT01973608|Experimental|MSB0010445 Low Dose Cohort 0.3 mg/kg|
89629222|NCT01973608|Experimental|MSB0010445 Intermediate Dose Cohort 1.0 mg/kg|
89629223|NCT01973608|Experimental|MSB0010445 High Dose Cohort 1.8 mg/kg|
89629224|NCT01973608|Experimental|MSB0010445 High Dose Cohort 2.4 mg/kg|
89629225|NCT02234232|Experimental|Aerobic exercise|"Cycling-participants will exercise for 15 minutes at the initial session followed by a weekly increase of 2 min and 3 seconds over 12 weeks. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
89629226|NCT02234232|Experimental|Resistance|"Resistance training of lower limbs using ankle weights. Participants will complete 10-15 repetitions of 4 lower limb exercises: knee extension, straight leg raise, hip abduction, and hip flexion. Exercises will progress from 1 set of each exercise up to 3 sets of each exercise and with weight. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
89629227|NCT02234232|Experimental|Combined aerobic and resistance|Participants will complete both the aerobic (cycling) and resistance (ankle weights) exercise prescriptions.
89629228|NCT02234232|Active Comparator|Flexibility|"A non-progressive flexibility regimen using a stretch band. Participants will perform 2 sets of the following exercises: seated pelvic tilt, seated calf stretch, supine hamstring stretch, and supine gluteal stretch. Participants will exercise 3 times per week and an intensity of very light (9 on the Borg scale). All exercises will be performed during hemodialysis."
89629229|NCT03248778|Experimental|disclosure-support counseling|
89629230|NCT03248778|No Intervention|Treatment as Usual|
89629231|NCT02357290|Experimental|Open-label Treatment with NAC|"12-week, open-label treatment with NAC. Subjects will be treated with the following dose:~Subjects ages 5-12:~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM~Subjects ages 13-17:~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence."
89629232|NCT00715143|Other|All subjects will be receive the Novation Ceramic on Ceramic Articulating Hip System|All subjects will receive the Novation Ceramic on Ceramic Articulating Hip System.
89629233|NCT03238872|Experimental|Prompt Mental Health Care|Clients in the experimental group receive short-term cognitive behavioural therapy in the form of a psycho-educational group course, guided self-help, or individual face-to-face therapy.
89629234|NCT03238872|Active Comparator|Treatment as usual|Clients in the comparison group are offered treatment as usual from their general practitioner.
89629235|NCT02453880|Experimental|Web-based Cognitive Behavioral Therapy|"Participants will be directed to a web-based CBT self-help program with weekly modules."
88990201|NCT04024787|No Intervention|Waitlist|
88990202|NCT04009967|Experimental|Prostate Cancer|Participants will receive 3 cycles of pembrolizumab regardless of PD-L1 status. After completion of the second cycle of pembrolizumab treatment, and just before the third injection of pembrolizumab an 18FDG-PET/CT scan will be performed to assess a potential metabolic response. Then between 2 to 4 weeks after the third treatment, subjects will undergo radical prostatectomy. Subjects will be followed every 3 months during the first year post-surgery and according to physician decision during the following years.
89629236|NCT04296045|Active Comparator|Glucose|Glucose
89629237|NCT04296045|Experimental|MCE|
89629238|NCT04296045|Experimental|MCE + Glucose|
89629239|NCT00693459|Other|Circular anal dilator|Circular anal dilator group-An anoscope has been developed that outlines the precise path for hemorrhoid excision. This instrument allows a modified Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation.
89629240|NCT02454192|Other|CHAMPS Intervention|Tailored asthma education and counseling for children with moderate to severe asthma who have confirmed allergies to environmental triggers present in their homes provided through a combination of clinic and home visits
89629241|NCT02454192|No Intervention|Usual Care|Usual asthma care and management
89629242|NCT00687765|Experimental|1|
89629243|NCT03248544|Experimental|vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
89629244|NCT03248544|Other|control|Control patients will not be received any intervention
89629245|NCT03238950|Other|Porcine Group|Training conducted on Porcine model
89629246|NCT03238950|Other|Synthetic|Training conducted on synthetic model
89629247|NCT03239028||Danish National Birth Cohort|
89629248|NCT04486794|Experimental|Treatment at baseline|
89629249|NCT04486794|Active Comparator|Treatment at Month 1|
89629250|NCT03241290||Use of C-ARM ARCO FP-Rk521S|C-ARM ARCO FP-Rk521S is mobile X-ray device that combines a X-Ray sensor and a sensor management software used during surgeries for real-time imaging.
89629251|NCT03241212|No Intervention|Control|"At baseline enrollment: participants will be asked to fill out a demographic survey, the MWIKAD survey and the SMOD-A survey. HbA1c, frequency of Blood Glucose (BG) checks and percent of glucose values above, within and below the target range will be extracted from chart review.~Surveys (with the exception of demographics) and chart extraction will be repeated at 3 months and 6 months post enrollment."
89629252|NCT03241212|Experimental|Texting|"Participants will be asked to complete the same surveys on the same timeline as above. The texting group will be asked to provide their cell phone number to the texting software.~From baseline appointment to 26 weeks post enrollment, participants will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen."
89629253|NCT03238716|Experimental|Electric DN, NM Re-ed, Exercise|
89629254|NCT03238716|Active Comparator|NM Re-ed and Exercise|
89629255|NCT03238404|Experimental|NAC group|Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.
89629256|NCT03238404|Active Comparator|Surgery alone group|Patients will not receive NAC before the gastrectomy and ERAS.
89629257|NCT03240744|Experimental|vaccine (3.0EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
89629258|NCT03248466|Placebo Comparator|Traditional treatment|Traditional treatment such as insulin,antidiabetes,dressing
89629259|NCT03248466|Experimental|PRG combined with BMMSCs transplantation|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs
89629260|NCT03248466|No Intervention|PRG treatment|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG
89629261|NCT03248700|Experimental|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
89629262|NCT03238482|Active Comparator|Seretide Diskus|salmeterol-fluticasone 2 inhalations as a single dose
89629263|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, E|salmeterol-fluticasone 2 inhalations as a single dose
89629264|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, F|salmeterol-fluticasone 2 inhalations as a single dose
89629265|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, G|salmeterol-fluticasone 2 inhalations as a single dose
89629266|NCT02454660|Experimental|SMS (Text messaging)|This group will receive text messages during their entire enrollment period in the study.
89629267|NCT02454660|No Intervention|No SMS (No text messages)|This group will not receive text messages during their entire enrollment period in the study.
89629268|NCT02454504|Active Comparator|sugammadex|this arm will receive sugammadex at the end of the surgery
89629269|NCT02454504|Active Comparator|neostigmine|this arm will receive neostigmine at the end of the surgery
89629270|NCT03240822|Experimental|Penile Allotransplant and Immunosuppression Treatment|Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
89629271|NCT03240432|Active Comparator|Continuous Glucose Monitor group|CGM group participants will be asked to use a Dexcom CGM sensor on a daily basis, inserting a new sensor as needed. Participants will be instructed to use the sensor according to FDA labeling. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading. Participants will have clinic visits at 10 days, 4 weeks, 8 weeks, 16 weeks, and 26 weeks.
89629272|NCT03240432|No Intervention|Blood Glucose Meter group|BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
89629273|NCT04486482|Other|KB109 + Self Supportive Care (SSC)|
89629274|NCT04486482|Other|Self Supportive Care (SSC) Alone|
89629275|NCT02453958|Experimental|mTBI-diagnosed group|Subjects diagnosed with mTBI were assessed with a multi-modal assessment system.
89629276|NCT02453958|Experimental|non mTBI-diagnosed group|Non-concussed subjects were assessed with a multi-modal assessment system.
89629277|NCT04486092|Experimental|Valproic Acid|
89629278|NCT03238638|Experimental|Acquired Resistance Cohort and Suboptimal Benefit Cohort|"Patients will be divided into two cohorts. Investigators anticipate 15 patients per cohort.~Cohort 1: Acquired Resistance Cohort~Treat upon emergence of acquire resistance~Prior benefit from an9-PD-1/PD-L1 therapy defined as a. preior response, and/or b. greater than or equal to 5 months of stable disease~Progressive disease on recent scans~Intercurrent therapy is allowed~Cohort 2: Suboptimal Benefit Cohort~Treat subop. mal response/benefit, BEFORE emergence of acquired resistance~Prolonged stable disease greater than or equal to 5 months OR Subop9mal response (greater than 10% and less than 50%)~Ongoing stable disease on recent scans~Both cohorts will receive pembrolizumab and epacadostat."
89629279|NCT00668655||1|Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea
89629280|NCT03240354|Experimental|Saline|Use of saline to inflate cuff of endotracheal tube
89629281|NCT03240354|Active Comparator|Control|Use of air to inflate cuff of endotracheal tube
89629282|NCT03240276|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte
89629283|NCT03240276|Active Comparator|IMSI Procedure|The IMSI procedure is the injection of normal ultramorphological spermatozoa that have been selected using an inverted microscope with magnification of 6300x (MSOME)
89629284|NCT02454426|Experimental|Open-Label Treatment|Patients will be initiated on vortioxetine 5 mg/day for 4 days, then increased to 10 mg/day. After the week 2 visit, patients will then be increased to 20 mg/day for the remainder of the study
89629285|NCT03238092|Active Comparator|Estradiol group|In the late luteal phase, the participant will receive estradiol 2mg and will take orally a total of 4mg per day (2mg in the morning and 2 mg in the night) until the next menstrual bleeding. After that, the patient will descontinue the medication and proceed to the regular in vitro fertilization protocol.
89629286|NCT03238092|No Intervention|Control group|No pre-treatment will be administrated. The regular in vitro fertilization protocol will be performed.
89629287|NCT03238092|Experimental|Testosterone group|Testosterone 25mg (10mg/g) transdermal during the late luteal phase, until the next menstrual bleeding.
89629288|NCT01896765|Experimental|Intensive prevention program|"Standard care with respect to medical and interventional therapy plus intensive prevention program with study nurse-coordinated education sessions, regular telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
89629289|NCT01896765|Other|Usual care|Standard care with respect to medical and interventional therapy.
89629290|NCT05588115||Concussion|Patients presenting to the ED who are diagnosed with concussion according to the ICD-10 criteria and absent of comorbidities.
89629291|NCT05588115||MSK|Patients presenting to the ED who are diagnosed with a muscle or skeletal injury (MSK; soft tissue damage or inflammation, fractured bone, etc.) and absent of comorbidities.
89629292|NCT03247998|Experimental|General Anesthesia|"Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). General Anesthesia Protocol: (Melinda J. Davis, Cynthia R. Campos-Herrera, & David P. Archer, 2012; Powers et al., 2015; Talke et al., 2014). Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
89629293|NCT03247998|Experimental|Conscious Sedation with Remifentanil|"Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
89629294|NCT00632307||1|COPD
89629295|NCT00632307||2|lung cancer
89629296|NCT00632307||3|airway infection
89629297|NCT00632307||4|interstitial lung disease
89629298|NCT00632307||5|sleep apnea
89629299|NCT00632307||6|pulmonary disorders with pleural infusions
89629300|NCT00632307||7|sarcoidosis
89629301|NCT00632307||8|healthy persons
89629302|NCT03248076||Fentanyl citrate|Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
89629303|NCT03240120|Experimental|Dabigatran etexilate & Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed dabigatran 150mg twice daily from Day 6 onward till 6 months after underlying disease remission.
89629304|NCT03240042|Experimental|Nasoendo group|Participants received nasotracheal intubation under general anesthesia for the anterior cervical spine surgery.
89629305|NCT03240042|Other|Oroendo group|Participants received orotracheal intubation under general anesthesia for the anterior cervical spine surgery.
89629306|NCT03240198||COPD|
89629307|NCT03240198||Controls|
89629308|NCT04771845||EEG-grid-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using electroencephalogram grid guided navigation
89629309|NCT04771845||MRI-guided-TMS|Patients with Alzheimer disease and mild cognitive impairment receiving TMS using MRI guided navigation
89629310|NCT04771845||NACC controls|National Alzheimer's Coordinating Center matched controls
89629311|NCT03237936|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
89629312|NCT03247920|Active Comparator|Oral group|"After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured."
89629313|NCT03247920|Active Comparator|Intravenous group|Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.
89629314|NCT04771533|Experimental|Passive stabilization of the trunk and the upper extremity|The intervention (passive stabilization of the trunk and the upper arm) was tested in post-stroke patients (study group) and in patients with back pain, but without neurological deficits (control group)
89629315|NCT03238014|Experimental|High-intensity noninvasive ventilation|High-intensity noninvasive positive pressure ventilation aims at maximally improving PaCO2.
89629316|NCT03238014|Active Comparator|Low-intensity noninvasive ventilation|Low-intensity noninvasive positive pressure ventilation is a classic setting of noninvasive ventilation.
89629317|NCT04771143|Experimental|AFQ056|Experimental study drug
89629318|NCT04771143|Placebo Comparator|Placebo|Matching placebo
89629319|NCT04487184|Active Comparator|Facilitation|From origin to insertion
89629320|NCT04487184|Experimental|Relaxation|From insertion to origin
89629321|NCT04487184|Placebo Comparator|Cross|Cross the muscle fiber
89629322|NCT04487184|Sham Comparator|Control|No tape
89629323|NCT03239964|Active Comparator|excision only group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section. Primary closure of wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. The wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.~Routine postoperative medications are given to all patients. They are advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) are used in any of the patients. All patients are reviewed once per month for 6 months."
89629324|NCT03239964|Active Comparator|excision and injection group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section and primary closure of the wound in layers. A running subcuticular prolene 2/0 stitch is used to suture skin.In 73 patients (group B), wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. The wound is painted with betadine and sealed until postoperative day 14 to remove the subcuticular stitch.~Routine postoperative medications are given, avoidance of direct sun exposure for one month,No postoperative applications as compression, steroid injections, etc. All patients are reviewed once per month for 6 months."
89629325|NCT02453646|Experimental|NexSite HD Patients|NexSite HD patient catheter device placement
89629326|NCT03239886|Experimental|Discontinuation|All subjects will discontinue imatinib
89629327|NCT03102723|Experimental|Cangrelor|Cangrelor (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
89629328|NCT03102723|Placebo Comparator|Placebo|Matching normal saline placebo (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
89629329|NCT03237312|Other|The control group|Four punctures in each ovary were done regardless of the level of antimullerian hormone
89629330|NCT03237312|Other|The study group|The number of ovarian drills was adjusted according to antimullerian hormone level
89629331|NCT03097575|Experimental|ICG Intervention|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
89629332|NCT05450835|Experimental|Arm A|In OGT group,After the enterotomy was made, the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube. Then, the anaesthesiologist continued to pull back the nasogastric tube for 10 cm to ensure that the stapler would not clamp the nasogastric tube. After that, the surgeon began to fire the stapler to perform side-to-side esophagojejunostomy.
89629333|NCT05450835|Active Comparator|Arm B|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al. After firing the stapler, two openings were converted into a single entry hole to create an end-to-side oesophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
89629334|NCT03239652|Experimental|Taiwan ACE Beads microspheres|The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.
89629335|NCT03241914|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
89629336|NCT03241914|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
89629337|NCT00057681|Experimental|1|Participants will receive treatment with lithium for 8 to 16 weeks
89629338|NCT00057681|Experimental|2|Participants will receive treatment with valproate for 8 to 16 weeks
89629339|NCT00057681|Experimental|3|Participants will receive treatment with risperidone for 8 to 16 weeks
89629340|NCT03235362|Experimental|1|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
89629341|NCT03235362|Experimental|2|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
89629342|NCT03235362|Experimental|3|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3."
89629343|NCT03235362|Experimental|4|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3.~There will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period."
89629344|NCT03235362|Experimental|5|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
89629345|NCT03235362|Experimental|6|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
89629346|NCT03234894|Other|SiteSeal Endovascular|"After intervention (deployment and removal of the Site Seal endovascular adjunctive compression device), the physician determines whether or not there was laceration of the femoral nerve or laceration of the femoral artery per protocol. A series of possible minor and/or major complications are noted per protocol.~There is a secondary metric as to patient reported pain on a 1-10scale."
89629347|NCT03234816|Experimental|- 0.05 mcg /Kg/min group|will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
89629348|NCT03234816|Experimental|- 0.1 mcg /Kg/min group|will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
89629349|NCT03234816|Experimental|- 0.15 mcg /Kg/min group|will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
89629350|NCT03247608|Experimental|Ambio Health Remote Monitoring|Ambio Health is an end-to-end remote patient monitoring system which includes a weight scale, blood pressure meter and blood glucose meter with wireless transmission of biometric readings through a home gateway to a web-based care management application that provides population health remote patient monitoring and engagement with automated delivery of the CarePlans.
89629351|NCT03247842|Active Comparator|suprascapular nerve RF|Eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups (Figure1); forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (PRF) followed by injection through the radiofrequency needle of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1)
89629352|NCT03247842|Active Comparator|suprascapular nerve block|and forty patients received fluoroscopically guided supra-scapular nerve injection of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.
89629353|NCT03247452|Active Comparator|One-day low fiber diet|"Patients assigned to the active comparator will receive oral and written instructions about the same structured low fiber diet designed by an Endocrinologist but they will follow this diet only the day before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
89629354|NCT03247452|Experimental|Three-day low fiber diet|"Patients assigned to the experimental group will receive oral and written instructions about a structured low fiber diet designed by an Endocrinologist. They must follow this diet three days before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
89629355|NCT03237468|Experimental|Exercise arm|This arm will perform twice weekly neck strengthening exercises.
89629356|NCT03247140|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
89629357|NCT03247140|Experimental|Group II(Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
89629358|NCT03237546|Active Comparator|Serratus blocks|The serratus plane is interstitial tissue, below the serratus muscle. The injection of bupivacaine numbs the anterior branch of the thoracodorsal nerve. This technique allows for the medication to diffuse along the area of the serratus plane to provide numbing of that area. Upon completion of the block, the patient will be evaluated for extubation and emerged from general anesthesia if appropriate.
89629359|NCT03237546|Active Comparator|PCA-alone (no block)|All subjects will receive fentanyl intravenous patient controlled anesthesia pumps as part of standard care. The amount of fentanyl self-administered by the patient or given by a clinician during 24 hours following surgery will be compared amongst the two groups.
89629360|NCT03234426|Experimental|Experimental Group|manual perturbations were given in forward, Backward,right and left sideways, 10 perturbations were given,6 days in week,in fallowing positions- sitting,kneeling, standing positions
89629361|NCT03234426|Placebo Comparator|Control group|Conventional Physiotherapy were given 6 days in a week, for 30 mins for 4 weeks, includes stretching, strengthening of contralateral limbs
89629362|NCT03237078|Experimental|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
89629363|NCT03247296||Group A|Patients taking Sofosbuvir and Daclatasvir
89629364|NCT03247296||Group B|Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
89629365|NCT03247218|Experimental|Single group of patients|"In this study 40 patients with SCD will be included. Twenty patients aged 18 years or older (cohort 1) and twenty patients 10 - 17 years old (cohort 2).~All the patients will receive Memantine Teva® film-coated tablets (Memantine hydrochloride) produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.~The study drug will be taken once a day per os, during one year."
89629366|NCT03234348|Experimental|Magmaris|Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
89629367|NCT03234348|Placebo Comparator|Orsiro|Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
89629368|NCT03237624|Experimental|Functional chewing gum|Subjects given as intervention functional chewing gum device to supplement oral hygiene practices. Functional gum contains chitosan which is a food additive or generally recognized as safe food product. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
89629369|NCT03237624|Placebo Comparator|Control chewing gum|Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
89629370|NCT03234660|Experimental|Dexmedetomidine|dexmedetomidine infusion
89629371|NCT03234660|Placebo Comparator|control|placebo infusion
89629372|NCT04485780|Placebo Comparator|Botulinum toxin injection during surgery|Patients in this group underwent Botulinum toxin injection during surgery
89629373|NCT04485780|Experimental|Botulinum toxin injection one week before surgery|Patients in this group underwent Botulinum toxin injection at the outpatient clinic one week before surgery
89629374|NCT00059475|Experimental|Adj-2 MART-1: 27-35|melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).
89629375|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 27-35|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)
89211362|NCT02513667|Experimental|ALK-inhibitor naive patients|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
89629376|NCT00059475|Experimental|Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).
89629377|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)
89629378|NCT00059475|Experimental|Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4|melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).
89629379|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)
89629380|NCT00059475|Experimental|Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).
89629381|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)
89629382|NCT03234504||Normal healthy volunteers|
89629383|NCT02453802|Active Comparator|Topic TXA group|"Primary total knee replacement with intravenous 0.9% normal saline (20 ml) administration before deflation of the tourniquet and intraarticular application of Tranexamic Acid 5%,5ml/amp 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
89629384|NCT02453802|Active Comparator|IV TXA group|"Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously before deflection of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
89629385|NCT02453802|Placebo Comparator|Control group|"Primary total knee replacement with 0.9% normal saline administration intravenously before deflation of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
89629386|NCT00060333|Experimental|Treatment (adjuvant radiation therapy)|Within 8 weeks after surgical resection, patients undergo radiation therapy twice weekly over approximately 2.5 weeks for a total of 5 fractions in the absence of disease progression or unacceptable toxicity.
89629387|NCT03234270|Experimental|F35 pilots|
89629388|NCT03234270|Active Comparator|F15 pilots|
89629389|NCT03234192|Active Comparator|Therapeutic ultra sound|
89629390|NCT03234192|Active Comparator|Astym Treatment Technique|
89629391|NCT03234192|Active Comparator|Graston Treatment Technique|
89629392|NCT04770987||hyperlaxity|30 individuals with systemic hyperlaxity as defined by a score of 5 or greater on the Beighton Hypermobility Scale
89629393|NCT04770987||control|30 healthy, age and gender matched individuals without hyperlaxity
89629394|NCT04486872|Experimental|anti-CD19 and anti-CD20 dual specific CAR-T Cells|
89629395|NCT04770597|Experimental|Intervention|CO2 values on sensor visible to staff
89211363|NCT02513667|Experimental|Patients recieved prior ALK inhibitor|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
89629396|NCT04770597|Sham Comparator|Sham control|CO2 values on sensor not visible to staff
89629397|NCT03237000|Experimental|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
89629398|NCT02028676|Experimental|Clinically Driven Monitoring (CDM)|
89629399|NCT02028676|Active Comparator|Laboratory plus Clinical Monitoring (LCM)|
89629400|NCT02028676|Active Comparator|Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
89629401|NCT02028676|Experimental|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
89629402|NCT02028676|Experimental|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
89629403|NCT02028676|Experimental|Once-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed once-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed once-daily according to weight-bands following WHO
89629404|NCT02028676|Active Comparator|Twice-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO
89629405|NCT02028676|Active Comparator|Continued cotrimoxazole prophylaxis|Once-daily doses 5-<15 kg: 200 mg of trimethoprim + 40 mg sulfamethoxazole 15-<30 kg: 400 mg trimethoprim + 80 mg sulfamethoxazole >=30 kg: 800 mg trimethoprim + 160 mg sulfamethoxazole
89629406|NCT02028676|Experimental|Stopped cotrimoxazole prophylaxis|Children had been taking once-daily cotrimoxazole prophylaxis since at least ART initiation. Children randomised to this experimental arm stopped taking cotrimoxazole prophylaxis.
89629407|NCT03233958||Workshop participants|Participants of systemic / family constellation workshops
89629408|NCT03247062|Other|Cohort study (Before-after desgin)|"Quality improvement - sleep bundle Intervention consists in a sleep bundle, an aggregate of several propositions to improve the sleep of patients.: implementation of a sleep bundle.~The entire ICU population will be observed before and after intervention."
89629409|NCT03236844|Experimental|Gantenerumab G4|Participants will receive single dose of gantenerumab HCLF manufactured by G4 process on Day 1.
89629410|NCT03236844|Experimental|Gantenerumab G3|Participants will receive single dose of gantenerumab HCLF manufactured by G3 process on Day 1.
89629411|NCT03233880|Active Comparator|Azithromycin group|Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) will be given to pregnant women at 16/20 weeks of pregnancy
89629412|NCT03233880|Placebo Comparator|placebo group|- Matching placebo orally, single dose
89039718|NCT06085417|Active Comparator|Group B+M (bupivacaine + magnesium group) (n= 30)|"For Group B+M (bupivacaine + magnesium group), 100 mg bupivacaine hydrochloride (20ml 0.5% marcaine aspen, turkey) + 150 mg magnesium sulfate (1ml 15% magnesium sulfate, onfarma, turkey) + isotonic saline (4 ml) was administered in a total volume of 25 ml. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
89039719|NCT06085404|Other|Interventional|
89629413|NCT03236766|Other|No intervention|
89629414|NCT04485936|Experimental|Epitomee Device|the participants receive the device which is non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of early satiation and prolonged satiety
89629415|NCT00061893|Experimental|Combination chemotherapy|Metastatic Ewing Sarcoma - 14-cycle study building on conventional tx (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, ifosfamide, etoposide) and adding two antiangiogenic agents: the vinca alkaloid vinblastine and the cyclooxygenase-2 inhibitor celecoxib. Refer to the Interventions section for dosages, method of delivery and frequency of administration.
89629416|NCT02452788|Other|Intervention|Pharmaceutical care with educational intervention provided by a pharmacist to ambulatory hemodialysis patients
89629417|NCT02452788|No Intervention|Usual Care|Usual Care
89629418|NCT03236922|Active Comparator|Pubococcygeus Sling|This is one anti-incontinence technique commonly used at the time of fistula surgery.
89629419|NCT03236922|Active Comparator|Rectus Fascia Sling|This is another anti-incontinence technique used at the time of fistula surgery, however, less commonly than the pubococcygeus.
89629420|NCT03233568||Indirect Calorimetry group (IC group)|Group who performed indirect calorimetry. REE measured by indirect calorimetry.
89629421|NCT03233568||NO Indirect Calorimetry group (NO-IC group)|Group who did not perform indirect calorimetry. Resting Energy Expenditure calculated by Harris-Benedict formula
89629422|NCT05383833|Experimental|Creatine Monohydrate Arm|This study a single arm intervention. All participants will receive 20 grams of creatine monohydrate daily for the whole intervention (8 weeks).
89629423|NCT02663076||VKA - Vitamin K antagonist group|VKAs used in correspondence with the national guidelines for therapy of NVAF in the respective country.
89629424|NCT02663076||Rivaroxaban group|Rivaroxaban used in correspondence with the national guidelines for therapy of NVAF in the respective country.
89039720|NCT06084520||Test group - patients with chronic pain treated with opioids|Patients with long-term, non-cancer-related pain (>3 months) at least 3 days a week, age 18-75 years, who have been treated with opioids for at least 1 month and who can speak, read and write in Swedish, recruited within Uppsala County Primary, Secondary and Tertiary Care.
89039721|NCT06084520||Control group - patients with chronic pain not-treated with opioids|Patients with long-term, non-cancer-related pain (>3 months) at least 3 days a week, age 18-75 years, who are not treated with opioids (at inclusion and during the last 3 months) and who can speak, read and write in Swedish, recruited within Uppsala County Primary, Secondary and Tertiary Care.
89039722|NCT06084468||Cystic Fibrosis|"Adult CF patients (>/=18 years) at Department of Infectious Diseases, Copenhagen University Hospital, will be invited to participate in this study. Potential participants are invited by their regular CF physician to participate during routine visits at the CF outpatient clinic.~Inclusion criteria:~Diagnosis of CF and age >/=18 years.~Exclusion criteria:~Lung transplanted patients~Inability to cooperate~Inability to understand and sign informed consent"
89039723|NCT06084468||Control group|The control group will consist of a random sample of age- and sex-matched participants from the general population examined in the 5th Copenhagen City Heart Study, 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).
89629425|NCT02663076||noAC group|noAC used in correspondence with the national guidelines for therapy of NVAF in the respective country.
89629426|NCT02957019|Experimental|L19-IL2 + RTX|"Phase I (Dose definition):~Cohorts of 3-6 patients will receive Rituximab on day 1 and 8 of the first 3-weeks cycle (C1D1 and C1D8, respectively) and on day 1 of the second 3-weeks cycle (C2D1). During two uninterrupted 3-weeks cycles, L19-IL2 will be administered on C1D1, C1D8, C1D15 and C2D1, C2D8, C2D15.~Phase II (Activity Evaluation):~During Phase II, 14 patients will receive Rituximab on C1D1 and C1D8 and on C2D1. Two uninterrupted 3-weeks cycles of L19-IL2 at the RD determined during Phase I will be administered on C1D1, C1D8 and C1D15 and C2D1, C2D8 and C2D15."
89629427|NCT02028754|Experimental|Sodium Carboxymethylcellulose and Conventional Therapy|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
89629428|NCT02028754|Active Comparator|Conventional Therapy|Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
89629429|NCT01897389|Experimental|Sequence 1: abiraterone acetate|Treatment sequence 1 is defined as: AEBD
89629430|NCT01897389|Experimental|Sequence 2: abiraterone acetate|Treatment sequence 2 is defined as: BACE
89629431|NCT01897389|Experimental|Sequence 3: abiraterone acetate|Treatment sequence 3 is defined as: CBDA
89629432|NCT01897389|Experimental|Sequence 4: abiraterone acetate|Treatment sequence 4 is defined as: EDAC
89629433|NCT01897389|Experimental|Sequence 5: abiraterone acetate|Treatment sequence 5 is defined as: DECA
89629434|NCT01897389|Experimental|Sequence 6: abiraterone acetate|Treatment sequence 6 is defined as: EADB
89629435|NCT01897389|Experimental|Sequence 7: abiraterone acetate|Treatment sequence 7 is defined as: ABEC
89629436|NCT01897389|Experimental|Sequence 8: abiraterone acetate|Treatment sequence 8 is defined as: BCAD
89629437|NCT02453490|Experimental|Raltitrexed-based chemotherapy|Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
89629438|NCT02453490|Active Comparator|5-fluorouracil-based chemotherapy|5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan
89629439|NCT01974700|Active Comparator|Levetiracetam|
89629440|NCT01974700|No Intervention|No anti-epileptic treatment|
89629441|NCT04753281|Other|Lifestyle counselling|Participants will receive an assessment appointment and up to 8 follow up sessions with a Health Psychologist to help them set goals and monitor changes of their own self management behaviour.
89629442|NCT04753281|No Intervention|Treatment as usual|Treatment as usual
89629443|NCT03236610|Experimental|tenofovir|
89629444|NCT03236610|Active Comparator|tenofovir plus entecavir|
89629445|NCT02030080|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm.
89629446|NCT02030080|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm.
89629447|NCT02030080|Experimental|Feedback 50th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
89629448|NCT02030080|Experimental|Feedback 75th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
89629449|NCT03233490|Experimental|CPR training and web corse intervention|The students performed a web course (Help Brain Heart) prior training
88990203|NCT04002843|Experimental|- Virgin patients with Botulinum Toxin, first injection|"Experimental: - Virgin patients with Botulinum Toxin, first injection~A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.~Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)~Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of the elbow flexor muscle chosen (biceps brachialis, anterior brachialis), located ultrasonographically.~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
89629450|NCT03233490|Experimental|CPR training intervention|CPR training without web course
89629451|NCT02453412|No Intervention|Control|Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician.
89629452|NCT02453412|Experimental|Simulation|Standard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation).
89629453|NCT05287893|Experimental|IBSM challenge and pyronaridine PK/PD population profile|"Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes.~Day 8 participants will be dosed with pyronaridine when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL.~Different doses of pyronaridine will be administered across and within cohorts in order to effectively characterise the PK/PD relationship.~The highest dose of pyronaridine administered will be no more than 720 mg; the lowest dose administered will be no less than 180 mg.~Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and pyronaridine concentration.~Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 47±2, or earlier."
89629454|NCT02357758|Active Comparator|Antibiotic Prophylaxis|Patients with RUTI receiving Septra (Trimethoprim dose 2mg/kg) or nitrofurantoin (dose 2 mg/kg) as determined by clinician.
89629455|NCT02357758|No Intervention|Healthy Population|Healthy population
89629456|NCT02357758|No Intervention|Clinical Observation|Patients experiencing RUTI that do not require antibiotic prophylaxis as determined by clinician.
89629457|NCT05606445||1|Healthy young (18-30 years old) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
89629458|NCT05606445||2|Healthy middle aged (40-55y) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
89629459|NCT05606445||3|Healthy old (>65y) (n = 40). This group will be used to assess the development of paratonia in healthy conditions.
89629460|NCT05606445||4|People with mild cognitive impairment (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
89629461|NCT05606445||5|People with mild dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
89629462|NCT05606445||6|People with moderate dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
89629463|NCT05606445||7|People with severe dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
89629464|NCT02357836|Other|Itraconazole|600 mg twice daily for 10-14 days
89629465|NCT03246594|Experimental|Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.~Placement of oesophageal probe for temperature measurement"
89629466|NCT03246594|Experimental|No Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.~Intervention: Power limitation of RF generator"
89629467|NCT01897467|Placebo Comparator|Control|"The control is a wait-list control, and will have the option to participate in the intervention at the end of the initial 12-week study period. The control group will be asked to not change any of their dietary or exercise habits over the course of the 12 weeks."
89629468|NCT01897467|Experimental|Wii Fit|"Participants in the intervention group will be assigned a Wii console and a Wii Fit balance board. The intervention group will be asked to play for 30 minutes a day, 3 times per week, using only the participant profile pre-programmed for them. They will complete yoga poses and strength training exercises for the first 10 minutes and balance coordination games for the remaining 20 minutes. They will be asked to complete each exercise at least twice, preferably by cycling through all exercises. Participants will be asked to do all of the exercises in one 30-minute session, rather than breaking them up throughout the day.~All participants will be asked to keep a record of which games they play and for how long. The Wii Fit software also keeps a digital record of which exercises were completed and how long they were performed. At the end of the intervention the investigator will use the information stored in the Wii, as well as activity logs, to assess compliance."
89629469|NCT03107676|Active Comparator|trunk endurance with hands above head|participants had to practice trunk extensors endurance training with having hands above head.
89629470|NCT03107676|Active Comparator|trunk endurance with hands behind head|participants had to practice trunk extensors endurance training with having hands behind head.
89629471|NCT03107676|Active Comparator|trunk endurance with hands parallel|participants had to practice trunk extensors endurance training with having hands parallel to the trunk.
89629472|NCT03107676|No Intervention|trunk endurance with no intervention|participants will be tested for trunk extensors endurance with having hands on chest but no intervention.
89629473|NCT04752969||Hypothyroidia|20 subjects diagnosed with hypothyroidism
89629474|NCT04752969||Hyperthyroidia|20 subjects diagnosed with hyperthyroidism
89629475|NCT04752969||Healthy|20 age-matched healthy control subjects
89629476|NCT03233334|Experimental|Purpose Project Group|Group receiving Purpose Project intervention.
89629477|NCT02359006|Active Comparator|minocycline|200mg minocycline
89629478|NCT02359006|Placebo Comparator|Placebo|Sugar pill
89629479|NCT03236454|Active Comparator|anodal tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of 2 mA anodal stimulation
89629480|NCT03236454|Sham Comparator|sham tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of sham stimulation; Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end;
89629481|NCT04486014|Experimental|Erector spinae plane block (ESP)|Patients would receive erector spinae plane block
89629482|NCT04486014|Experimental|Serratus anterior plane block (SAP)|Patients would receive serratus anterior plane block
89629483|NCT04485702|Active Comparator|MELT-100|3mg midazolam and 25mg ketamine sublingual tablet
89629484|NCT04485702|Active Comparator|IV midazolam|2mg Intravenous midazolam
89629485|NCT04485702|Active Comparator|IV ketamine|6mg Intravenous ketamine
89629486|NCT00068367|Experimental|Arm I (OSI-774)|"Drug: erlotinib hydrochloride~Other Names:~OSI-774 150 mg per day, daily until disease progression"
89039724|NCT06084416|Experimental|Dose Level 1|Subjects will receive sovilnesib once daily at Dose Level 1 in 28-day cycles.
89039725|NCT06084416|Experimental|Dose Level 2|Subjects will receive sovilnesib once daily at Dose Level 2 in 28-day cycles.
89039726|NCT06084416|Experimental|Dose Level 3|Subjects will receive sovilnesib once daily at Dose Level 3 in 28-day cycles.
89039727|NCT06084416|Experimental|Dose Level 4|Subjects will receive sovilnesib once daily at Dose Level 4 in 28-day cycles.
89039728|NCT06084000|Experimental|Drug-coated balloon dominant strategy|"Patients will receive DCB (Bingo©, Yinyi Ltd., China) only if pre-dilation of the lesion was successful, or otherwise receive bailout stenting.~If bailout stenting is indicated, patients will receive any type of commercially available 2nd Gen DES at physician's preference."
89039729|NCT06084000|Active Comparator|Drug-eluting stent only strategy|-For conventional stenting, patients will receive any type of commercially available 2nd Gen DES at physician's preference.
89039730|NCT06083831||Sequential feeding group|After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) by continuous feeding, continuous feeding was changed into intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
89629487|NCT03236532|Experimental|Glutamine and exercise|Glutamine dipeptide (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
89629488|NCT03236532|Placebo Comparator|Maltodextrin and exercise|Maltodextrin (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
89629489|NCT01975090|Experimental|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter
89629490|NCT03229434|Experimental|Widely pristine area|Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in a widely pristine area with moderate intensity (Rating of perceived exertion: ~ 11-15).
89629491|NCT03229434|Active Comparator|Anthropogenically influenced area|"Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in an anthropogenically influenced area with moderate intensity (Rating of perceived exertion: ~ 11-15).~All characteristics of the hiking (duration, time, difference in altitude, ...) are planned to be comparable to the experimental condition except the area."
89629492|NCT03229590||Surgical dislocation|Reduction of slipped epiphysis via surgical dislocation technique
89629493|NCT02880891|Experimental|splinted|splinted crown
89629494|NCT02880891|No Intervention|non-splinted|single crown
89629495|NCT03233412|Other|Control|Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
89629496|NCT03233412|Experimental|Imiquimod|Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
89629497|NCT01976416|Experimental|Hydroxyurea|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
89629498|NCT01976416|Placebo Comparator|Placebo|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
89629499|NCT05255133|Experimental|GEP-NET and lung-NET patients|Liquid biopsies and scans
89629500|NCT02453178|Experimental|Steady state moderate intensity cycling|Moderate intensity exercise training will be a 12-week supervised cycling program, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes passive cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, we will add 6 minutes of moderate intensity cycling per session, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
89629501|NCT02453178|Active Comparator|Intermittent cycling|The intermittent cycling group will come to the exercise lab for the same duration and frequency each week and complete primarily passive cycling such that a motor in the stationary bicycle moves the pedals for them. To maintain interest in this intervention, we will include short bouts of moderate intensity activity. The short bouts of moderate intensity cycling will be designed to be ineffective for substantially increasing cardiorespiratory fitness over the course of the intervention.
89629502|NCT02032420|Experimental|STAR|Introductory training by video depicting 4 sequential maneuvers for reacquisition of needle image in ultrasound: see, tilt, align, rotate.
89629503|NCT02032420|Active Comparator|ART|Introductory training with a video depicting 3 probe position aspects for reacquisition of needle image by ultrasound: alignment, rotation, tilt.
89629504|NCT02453100|Experimental|Exercise|"Women will be included in group mobility and pelvic floor exercise classes for one and a half hours twice weekly for 12 weeks and encouraged to carry out independent exercises each day when there is no group session.~A research paramedics will meet with the woman each month for six months from the initial training session to encourage her continued participation and adherence to the individual exercise program. At this meeting the research paramedic will also provide and reinforce simple education about how to manage urinary incontinence."
89629505|NCT02453100|Placebo Comparator|Education|On recruitment and each month for six months a research paramedic will meet with each woman to provide and reinforce simple education about how to manage urinary incontinence.
89629506|NCT03233178||SGLT2|Patients initiating SGLT2 inhibitors
89629507|NCT03233178||Liraglutide|Patients initiation liraglutide
89629508|NCT03233178||Sitagliptin|Patients initiating sitagliptin
89629509|NCT03233178||Control Group|Patients who did not initiate any new anti-hyperglycemic treatment
89629510|NCT03229044||BMI 18-21|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2
89629511|NCT03229044||BMI 33-39|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2
89629512|NCT03229044||BMI 25-30|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2
89039731|NCT06083831||Continuous feeding group|Patients received continous feeding with a constant velocity by an enteral feeding pump over one day.
89039732|NCT06083467|Other|Diagnostic Assessments|Subjects may receive an Amyloid PET scan, a brain MRI and neurological exam with diagnostic assessments.
89039735|NCT06083233|Experimental|"Study group Responders"|Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anesthesia. Before surgery patients undergo lumbar puncture or external lumbar drainage placement to confirmed the diagnosis and responsivity to VP shunt placement.
89039736|NCT06083233|Experimental|"Study group Non-responders"|Patients with diagnosed hydrocephalus. VP shunt non-responsivity confirmed.
89039737|NCT06083038||Metastatic breast cancer starting alpelisib|
89039738|NCT06081452||Public|General public to be approached to answer this survey via GPs, charities and exhibitions such as Great Exhibition Road Festival.
89039739|NCT06081088|Experimental|Group 1|"Study group: Graded Motor Imagery Training + Conventional Physiotherapy~In this group, each participant will be received a treatment protocol consisting of Graded Motor Imagery training, conventional physiotherapy, and home exercises.~Graded Motor Imagery (GMI)~Conventional Physiotherapy Program~Home Exercise Program"
89039740|NCT06081088|Active Comparator|Group 2|"Control group: Conventional Physiotherapy~In this group, each participant will be received a treatment protocol consisting of conventional physiotherapy, and home exercises.~Conventional Physiotherapy Program~Home Exercise Program"
89039741|NCT06080347|Active Comparator|Arm_1|Anti-inflammatory Diet
89039742|NCT06080347|Experimental|Arm_2|Healthy Diet
89039743|NCT06080126|Other|Control|
89039744|NCT06080126|Other|Intervention|
89039745|NCT06079801|Experimental|Real tDCS|Patients will undergo real tDCS applied to both DLPC. Two daily sessions of 20 minutes each were administered (40 minutes a day in total), with a 5-minutes break in between, 5 days a week (Monday to Friday) and with 20 tDCS sessions in total for participant
89039746|NCT06079801|Placebo Comparator|Sham tDCS|Patients will undergo sham tDCS applied to both DLPC. Two daily sessions of 20 minutes each were administered (40 minutes a day in total), with a 5-minutes break in between, 5 days a week (Monday to Friday) and with 20 tDCS sessions in total for participant
89039747|NCT06079801|Active Comparator|anti-CGRP|Patients will undergo anti-CGRP treatment
89039748|NCT06079541|Experimental|JMKX003142 SAD experimental group|Participants will be randomized into 7 cohorts to receive single oral dose of JMKX003142 on Day 1. The doses in each cohort will be escalated based on the safety and pharmacokinetics (PK) / Pharmacodynamics (PD) data of the previous cohort.
89629513|NCT03236376|Experimental|sensorimotor therapy|sensorimotor therapy will consist of 30minutes of sensory discrimination training and 30 minutes of sensorimotor training per session. The sensory discrimination training is based on on the SENSe training of Carey et all. The sensorimotor training is the same individually tailored motor therapy as described below, but with integration of sensory discrimination training aspects.
89039749|NCT06079541|Experimental|JMKX003142 MAD experimental group|Participants will be randomized into 3 cohorts to receive orally once -daily of JMKX003142 for 7 consecutive days. The second cohort will be escalated based on the safety and pharmacokinetics (PK)/ Pharmacodynamics (PD) data of the previous cohort.
89039750|NCT06079541|Experimental|JMKX003142 FE experimental group|Participants will receive 2 Sequence regimens, with a washout period between treatments.
89211364|NCT00829400|Experimental|Posit Science|Brain Fitness, Insight, and Aristotle Cognitive Software Training Suites Targeting 100 hours of training
89039751|NCT06079541|Experimental|Placebo in Cohorts 1 to 7|Participants in Cohorts 1 to 7 will receive single oral dose of matching placebo on Day 1.
89039752|NCT06079541|Experimental|Placebo in 3 Cohorts|Participants in 3 Cohorts will receive orally once -daily of matching placebo for 7 consecutive days.
89039753|NCT06078969|Experimental|Oral prednisone|Oral prednisone, 0.5mg/kg/day, first 5 days/month, 6months
89039754|NCT06078969|No Intervention|Regular observation|Regular observation and follow up without medication
89039755|NCT06078306|Experimental|CAR-T therapy|Therapeutic outcomes in adults with Ph- B-ALL have substantially improved in the last decade, with complete remission (CR) and long-term overall survival (OS) rates of around 90% and 40%-50%, respectively. The presence of measurable residual disease (MRD) is the strongest predictor of relapse in B-ALL. In this study, high risk Ph- B-ALL patients receive the induction chemotherapy with Azacitidine+Venetoclax. After induction chemotherapy with Azacitidine+Venetoclax (VA regime), each subject receives CD19CD22 CAR-T cells by intravenous infusion. The patients with MRD negative will undergo HSCT.
89039756|NCT06077981|Active Comparator|Hydroxyethylamide Group|15 will be from the hydroxyethylamide Group, where the submucosal endoscopic dissection will be performed with submucosal injection of hydroxyethylamide.
89039757|NCT06077981|Active Comparator|Hyaluronic acid group (TS-905 Blue Eye)|15 will be from the Hyaluronic acid group (TS-905 Blue Eye), where the submucosal endoscopic dissection with submucosal injection of hyaluronic acid (TS-905 Blue Eye) will be performed.
89039758|NCT06077955|Active Comparator|Group A (control) - with stapled anastomosis|A variant of the surgery with the stapled formation of a gastrojejunostomy.
89629514|NCT03236376|Active Comparator|motor therapy|The motor therapy consists of 30 minutes of cognitive and attention-based table top games and 30 minutes of motor training per session. The cognitive-attention-based therapy consists of table top games such as chess, rush hour, or other smart games. Individually tailored motor therapy consists of a unilateral motor exercise program for the upper limb, while seated at a table, under supervision of a therapist to match the therapy and intensity provided in the other sensorimotor therapy group. This 30 minutes of motor arm training is based on a set of standardized exercises which comprise task-related practice for gross movements and dexterity including different grips and selective finger movements, and training in daily life activities, however without any attention to sensory discrimination training.
89629515|NCT03233100|Experimental|FMT group|
89039759|NCT06077955|Experimental|Group B (study) - with hand-sewn anastomosis|A variant with a hand-sewn formation of a gastrojejunostomy.
89039760|NCT06076668|Experimental|Group D (n=30)|patients will receive intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
89629516|NCT03236298|Active Comparator|PIEB speed of infusion 250 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 250 ml/hr by the CADD-Solis Ambulatory Infusion System.
89629517|NCT03236298|Active Comparator|PIEB speed of infusion 125 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 125 ml/hr by the CADD-Solis Ambulatory Infusion System.
89039761|NCT06076668|Experimental|Group M (n=30)|patients will receive oral melatonin tablet 3 mg at 9:00 p.m.
89039762|NCT06076668|Placebo Comparator|Control group|patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
89629518|NCT01976572|Placebo Comparator|Candesartan alone|Single dose of 16 mg candesartan was administered orally on Day 1.
89039763|NCT06074211|Experimental|Safe Sleep Education|The intervention group will receive safe sleep education via the Safety in Seconds mobile app.
89039764|NCT06074211|Active Comparator|Car seat safety|The attention matched control group will receive car seat safety education via the Safety in Seconds mobile app.
89039765|NCT06073041|Experimental|Adopter|Clinics that decide to adopt the EIMG Program
89039766|NCT06073041|No Intervention|Non Adopter|Clinics that decide not to adopt the EIMG Program
89039767|NCT06072521|Active Comparator|Lactoferrin bovine once a day|15 patients will be subjected to take 100mg of lactoferrin bovine in the form of sachets twice per day for 15 days.
89039768|NCT06072521|Active Comparator|Lactoferrin bovine twice a day|15 patients will be subjected to take 100mg of lactoferrin bovine in the form of sachets once per day for 15 days.
89039769|NCT06072521|No Intervention|Control group|15 patients will be subjected to take only the standard treatment regimen that is applied at the National hepatology and tropical medicine research institute in Egypt.
89629519|NCT01976572|Active Comparator|T0hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-0 of 3 dosing time-points means the single dose of candesartan was administered at the same time relative to the first daily dose of colestilan.
89629520|NCT01976572|Active Comparator|T-1hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-1 of 3 dosing time-points means the single dose of candesartan was administered at 1 hour before relative to the first daily dose of colestilan.
89629521|NCT01976572|Active Comparator|T+3hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T+3 of 3 dosing time-points means the single dose of candesartan was administered at 3 hour after relative to the first daily dose of colestilan.
89629522|NCT03236142|Active Comparator|Standard Duodenal Switch (DS)|
89629523|NCT03236142|Experimental|Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS)|
89629524|NCT03232866|Experimental|Experimental group|(n = 20) will practice Pilates exercises
89629525|NCT03232866|No Intervention|Control group|(n = 20) will not carry out the intervention
89211365|NCT00829400|Active Comparator|Nintendo Brain Age|Brain Age 2 Nintendo DS Portable Device for home or office use, targeting 100 hours of training
89211366|NCT00829478|Placebo Comparator|1|Usual Care
89057395|NCT04540172|Experimental|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercises were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association. Warning messages were hung on the door of the room, environmental noise was reduced as much as possible, and the room was provided with dim lighting. The students were asked to close their eyes and breathe deeply after sitting comfortably in a chair. After taking two deep breaths, they were told to dangle their arms and relax as much as possible. The hands, shoulders, neck, chest, abdomen, hips, legs, feet, toes, and facial muscles were made to relax while they breathed and relaxed while exhaling. They were asked to store the experience into their memories thoroughly so that they could recall this feeling for comfort during the day."
89211367|NCT00829478|Experimental|2|Intervention
89039770|NCT06064812|Experimental|Part A: Dose Escalation of FWD1802 as a Monotherapy|"Part A study will be conducted in subjects diagnosed with ER+/HER2- unresectable locally advanced or metastatic breast cancer.~A maximum of 27 subjects will be enrolled. They will be sequentially allocated to 5 planned dose cohorts: 25 mg, 75 mg, 150 mg, 300 mg and 450 mg.~Subjects enrolled will be orally administered a single dose of FWD1802 Tablet on C0D1, followed by a 3-day observation period. Starting on C1D1, FWD1802 Tablet will be orally administered continuously QD for 28 consecutive days of each cycle. The DLT observation period is set as 32 days(C0D1-C1D28). The second cycle and subsequent cycles will last for 28 days per cycle. The patients will continue to receive the study treatment until PD, death, unacceptable toxicity, withdrawal of informed consent, or other reasons to discontinue study treatment occurs, whichever comes first."
89039771|NCT06064812|Experimental|Part B- Dose Escalation of FWD1802 in combination with palbocilib|"The dose expansion study will be conducted in approximately 12 eligible subjects diagnosed with ER+/HER2- unresectable locally advanced or metastatic breast cancer, to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of FWD1802 in combination with palbocilib.~The starting dose level for Part B study will be determined by SMC based on safety data (including the AE rate of non-DLT) , PK, PD and preliminary efficacy in Part A. Every treatment cycle consists of 28 days.~In brief, based on the available data obtained from Part A, 1 to 2 dose levels may be selected as the recommended dose levels (RDs) to evaluate FWD1802 in combination with palbocilib in these patients."
89039772|NCT06064812|Experimental|Part C - Dose Expansion Study|"Part C (Dose Expansion of FWD1802 as a Monotherapy) can be conducted in parallel with Part A provided that the following two conditions are met:~The starting dose of Part C study should be lower than the dose of monotherapy RP2D or the dose that has been explored and confirmed as safe for monotherapy.~The SMC will review all available PK, PD, safety, tolerability and efficacy data for Part A study and decide whether the study may proceed to Part C portions.~The dose expansion study will be conducted in approximately 60 eligible subjects diagnosed with ER+/HER2-/ESR1 mutation unresectable locally advanced or metastatic BC, to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of FWD1802 Tablet at the recommended 1~2 dose level(s) for expansion."
89039773|NCT06060028|Experimental|General Practitioner (GP) care plus interoceptive non-invasive tactile stimulation treatment|Participants will receive General Practitioner (GP) care and interoceptive non-invasive tactile stimulation (affective touch) for 30 min two times a week for 12 weeks.
89039774|NCT06060028|Sham Comparator|GP care plus sham treatment|Participants will receive General Practitioner (GP) care and a sham stimulation for 30 min two times a week for 12 weeks.
89039775|NCT06055751||Transcatheter aortic valve replacement (TAVR) with Boston Scientific Loop Recorder|This is a group of patients who have undergone TAVI procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473).
89039776|NCT06053983|Experimental|rosuvastatin 20 mg|
89039777|NCT06053983|Experimental|atorvastatin 40 mg|
89039778|NCT06053840|Experimental|Treatment|
89039779|NCT06051968|Experimental|Intervention group|Participants get hearing rehabilitation according to common practice and the online hearing support.
89039780|NCT06051968|Active Comparator|Control group|Participants get hearing rehabilitation according to common practice.
89629526|NCT02360488|Experimental|Telerehabilitation Therapy|The Telerehabilitation arm of this study will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During half of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
89629527|NCT02360488|Active Comparator|In-Clinic Therapy|The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
89629528|NCT03233022|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
89629529|NCT03233022|Active Comparator|Negatively-focused tracks|"Participants use two pre-selected Happify tracks that focus on remediating negatives (e.g. conquering negative thoughts and managing stress). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period."
89629530|NCT03233022|Active Comparator|Positively-focused tracks|Participants use two pre-selected Happify tracks that focus on improving positives (e.g. building well-being, using one's strengths). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
89629531|NCT03233022|Placebo Comparator|Placebo condition|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
89629532|NCT03233022|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
89629533|NCT03232944||CRT non-responders with MPP enabled|Patients enrolled and implanted with a CRT Quad system, who are identified as CRT non-responder, for which MPP is enabled.
89057396|NCT04540172|No Intervention|Control|No additional method was applied in the control group.
89629534|NCT01976650||OZURDEX®|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
89629535|NCT02361736|Sham Comparator|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
89629536|NCT02361736|Experimental|Hydroxyethyl Starch|6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery
89629537|NCT01978600|Experimental|SIMBRINZA™|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, 1 drop 3 times a day (8AM, 3PM, 10PM) in each eye for 4 weeks
89629538|NCT01978600|Active Comparator|Timolol Maleate 0.5%|Timolol Maleate 0.5%, 1 drop twice a day (8AM, 8PM) in each eye for 4 weeks
89629539|NCT03236220|Experimental|N-acetyl-L-cysteine group|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.
89629540|NCT03107598|Experimental|colloid preload|Group CoP: group with colloid preload The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES) administered by gravity at a wide-open rate over a period of 15-30min before induction of spinal anesthesia.
89629541|NCT03107598|Placebo Comparator|crystalloid coload|Group CrC: group with crystalloid coload The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.
89629542|NCT03107442|Experimental|Exercise|12-weeks aerobic exercise intervention
89629543|NCT03107442|No Intervention|Control|Usual care, with recommendations for a healthy lifestyle.
89629544|NCT03236064|Experimental|Nerve injury to palm and fingers|Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
89629545|NCT03232788|Experimental|Test group|Bone regeneration with autogenous bone + scaffold.
89629546|NCT03232788|Active Comparator|Control group|Bone regeneration with autogenous bone + collagen membrane.
89629547|NCT03232632|Experimental|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
89629548|NCT03228810||Men >18 years old with metastatic prostate cancer|
89629549|NCT03235908||Patients with an acute psychosis|Acute psychosis in schizophrenia spectrum disorder, affective disorder and bipolar disorder; Observation only
89629550|NCT03228654|Experimental|Unipolar electrocautery|vaginal hysterectomy using Unipolar electrocautery
89629551|NCT03228654|Active Comparator|Purohit's technique|Vaginal hysterectomy using Purohit's technique
89629552|NCT03228888|Experimental|Artificial Sounds|"Participants were provided headphones and a portable MP3 device which played a metronome tick at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
89629553|NCT03228888|Experimental|Ecological Sounds|"Participants were provided headphones and a portable MP3 device which played an ecological rhythmic sound obtained by actual footsteps of human at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
89629554|NCT01747499|Experimental|Cohort 1|"Conditioning treatment~Transplant on Day 0~15 mg/m^2 azacitidine Days 7-11~15 mg/m^2 azacitidine Days 35-39~15 mg/m^2 azacitidine Days 63-67~15 mg/m^2 azacitidine Days 91-95"
89629555|NCT01747499|Experimental|Cohort 2|"Conditioning treatment~Transplant on Day 0~30 mg/m^2 azacitidine Days 7-11~30 mg/m^2 azacitidine Days 35-39~30 mg/m^2 azacitidine Days 63-67~30 mg/m^2 azacitidine Days 91-95"
89629556|NCT01747499|Experimental|Cohort 3|"Conditioning treatment~Transplant on Day 0~37.5 mg/m^2 azacitidine Days 7-11~37.5 mg/m^2 azacitidine Days 35-39~37.5 mg/m^2 azacitidine Days 63-67~37.5 mg/m^2 azacitidine Days 91-95"
89629557|NCT01747499|Experimental|Cohort 4|"Conditioning treatment~Transplant on Day 0~45 mg/m^2 azacitidine Days 7-11~45 mg/m^2 azacitidine Days 35-39~45 mg/m^2 azacitidine Days 63-67~45 mg/m^2 azacitidine Days 91-95"
89629558|NCT01747499|Experimental|Phase II Cohort|"Conditioning treatment~Transplant on Day 0~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 7-11~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 35-39~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 63-67~Dose determined in Phase I - 45 mg/m^2 attitudinize Days 91-95"
89629559|NCT03107130||SUI Surgery Patients in 2015|All women 18 years of age or older, who underwent surgery for SUI between January 2015 and December 2015
89629560|NCT00071721|Experimental|1|
89629561|NCT00071721|Placebo Comparator|2|
89629562|NCT03107208|Experimental|Early glargine (Lantus)|A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
89629563|NCT03107208|Other|Control group|A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
89629564|NCT01717391|Experimental|Fluorothymidine F 18 PET/CT|Fluorothymidine F 18 (FLT) PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.
89629565|NCT03107364||Colorectal surgery|Patient who underwent elective colorectal surgery
89629566|NCT03107364||Hip fracture|Patient who underwent urgent surgical procedure for hip fracture
89629567|NCT05606055|Experimental|SDT|-75 patients of immediate treatment, will be those patients without immuno-virological data that accept to start the treatment the same day of the first consultation with the hospital specialist (arm 1 or SDT).
89629568|NCT05606055|Active Comparator|Conventional|- 75 patients of conventional treatment, will be those who in their first consultation with the hospital specialist already have previous immuno-virological data or reject the start of immediate treatment (arm 2 or conventional).
89039781|NCT06049160|Active Comparator|Pre-operative and post-operative rectal misoprostol|64 participants who will receive combined pre-operative and post-operative rectal misoprostol (400μg rectal misoprostol during urinary catheter insertion just after spinal anesthesia plus 200μg after abdominal closure).
89039782|NCT06049160|Active Comparator|Post-operative rectal misoprostol|64 participants who will receive rectal misoprostol post-operative only (600μg of rectal misoprostol after closure of the Cesarean Wound)).
89629569|NCT01896609|Experimental|Arm 1 (Standard therpy)|"Arm 1 : subject randomized to this arm will be receiving the standard care therapy for 48 weeks:~Reiferon Retard® 160 µg /week subcutaneous injection.~Ribavirin in a dose of 13 mg/kg/day orally"
89629570|NCT01896609|Experimental|Arm 2 ( Xerovirinc)|"Arm 2 : Subjects randomized to this arm will be receiving the following medications for 48 weeks;~Reiferon Retard® 160 µg /week subcutaneous injection~Ribavirin in a dose of 13 mg/kg/day orally~Xerovirinc® 500mg twice daily orally."
89629571|NCT01896609|Experimental|Arm 3 ( Bon one )|"Arm 3: Subjects randomized to this arm will be receiving the following medications for 48 weeks:~Bon-One ® 0.5 µg daily orally~Reiferon Retard® 160 µg /week subcutaneous injection~Ribavirin in a dose of 13 mg/kg/day orally~Xerovirinc® 500mg twice daily orally."
89629572|NCT03232554|Experimental|Buxue Yimu Pills|Buxue Yimu Pill 12g pill by mouth, twice daily
89039783|NCT06047834|Placebo Comparator|Control|All participants will receive non pharmacologic interventions per the local standard of care (i.e. non-pharmacologic measures and morphine when indicated).
89039784|NCT06047834|Experimental|Low Dose Lofexidine|Drug: Lofexidine (LX2) All participants will receive standard of care and be administered 32 µg/kg/day. The daily dose will be divided into 8 equal doses administered every 3 hours. Lofexidine will be tapered to discontinuation.
89629573|NCT03232554|Experimental|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
89629574|NCT03232554|Active Comparator|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
89629575|NCT05605977|No Intervention|Control group|regular early intervention
89629576|NCT05605977|Experimental|Traditional visual-motor training program|traditional visual-motor training program plus regular early intervention
89629577|NCT05605977|Experimental|Computerized visual-motor training program|computerized visual-motor training program plus regular early intervention
89629578|NCT03232398|Active Comparator|Apixaban|Apixaban Oral Tablet [Eliquis]
89629579|NCT03232398|Active Comparator|Warfarin|Warfarin - Vitamin K antagonist
89039785|NCT06047834|Experimental|Mid Dose Lofexidine|Drug: Lofexidine (LX2) All participants will receive standard of care and be administered 52 µg/kg/day. The daily dose will be divided into 8 equal doses administered every 3 hours. Lofexidine will be tapered to discontinuation.
89039786|NCT06047834|Experimental|High Dose Lofexidine|Drug: Lofexidine (LX2) All participants will receive standard of care and be administered 80 µg/kg/day. The daily dose will be divided into 8 equal doses administered every 3 hours. Lofexidine will be tapered to discontinuation.
89039787|NCT06046937|Experimental|Monolaurin Ointment|treatment arm
89629580|NCT04753125|Active Comparator|compliance treatment|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance for 3, 6. 9 and 12 months
89629581|NCT04753125|Active Comparator|compliance for blood test|controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance, follow-up via a game in a smartphone app through an interactive game with stimuli to pass the phase as the treatment was completed and blood tests were performed in 3,6,9 and 12 months.
89629582|NCT04753125|Placebo Comparator|demographic socio-economic and sexuality questionnaire|Questionnaire applied to all patients with positive VDRL
89039788|NCT06046937|Active Comparator|Mupirocin Ointment|control drug
89039789|NCT06046443|Experimental|LB54640 Low dose|Participants will be randomized to receive LB54640 low dose, middle dose, or high dose, or placebo by oral administration in a 1:1:1:1 ratio.
89039790|NCT06046443|Experimental|LB54640 Middle dose|Participants will be randomized to receive LB54640 low dose, middle dose, or high dose, or placebo by oral administration in a 1:1:1:1 ratio.
89039791|NCT06046443|Experimental|LB54640 High dose|Participants will be randomized to receive LB54640 low dose, middle dose, or high dose, or placebo by oral administration in a 1:1:1:1 ratio.
89039792|NCT06046443|Placebo Comparator|Placebo|Participants will be randomized to receive LB54640 low dose, middle dose, or high dose, or placebo by oral administration in a 1:1:1:1 ratio.
89039793|NCT06042088|Experimental|Double Gloves:Regular Size|Procedure A: Double gloves, participants will wear both gloves in their surgical glove size.
89629583|NCT03235830|Active Comparator|Enhanced Standard of Care (ESoC)|Subjects received a condensed version of the American Academy of Pediatrics Bright Futures content at their scheduled well-child visits though 6 months of age. The enhanced standard of care (ESoC) materials were added, by members of the research team, to registration packets and were given to caregivers by clinic staff, who were all trained to give the ESoC. For any patients who did not receive ESoC materials at their visit, an age-appropriate ESoC was mailed to the caregiver.
89629584|NCT03235830|Experimental|Enhanced Standard of Care (ESoC) + Text|Subjects assigned to the text messaging intervention group received four educational messages per week until their child was 6 months of age in addition to the ESoC documents. The text messages directly reflected Bright Futures and ESoC content, addressing infant development, safety, care, and the most common causes of nonurgent visits in the first year. Bright Futures content was adapted both for language and length to accommodate character limits and the patient population.
89629585|NCT02362048|Experimental|Experimental: Arm 1|ACP-196 alone
89629586|NCT02362048|Experimental|Experimental: Arm 2|ACP-196 in combination with pembrolizumab
89629587|NCT03232476|Other|Loaded upper extremity|This is a one-arm study. In postmenopausal women prescribed teriparatide for osteoporosis treatment, enrolled subjects will perform voluntary loading exercises on one upper extremity. A data logger device will assist in recording exercises and determining goal force during the exercises. Each subject's non-loaded upper extremity will serve as a control.
88990204|NCT04002843|Experimental|- Injected group: Patients already injected|"- Injected group: Patients already injected~A clinical evaluation of spasticity with the Modified Ashworth Scale by the referent practitioner.~Pain management: according to the patient's wishes, local anaesthetic can be provided on the target area (EMLA patch type)~Single fiber electrophysiological evaluation by the principal investigator: comfortable installation of the patient in decubitus, with the upper limb in the optimal relaxation position, supported by the examiner to achieve minimal tone. Arrangement of the needle electrode at the level of in one elbow flexor muscle (biceps brachialis, anterior brachialis), located ultrasonographically.~Repeated measurements at D0, week 4 to 6 and week 12 for the stroke patients. Only one measure for controls subjects"
89629588|NCT00158223|Placebo Comparator|placebo|Participants will receive encapsulated placebo made to match active drug
89629589|NCT00158223|Experimental|pimozide|Participants will receive pimozide flexible dosing
88990205|NCT04002843|Other|Control|healthy patient matched in age and sex to included patients
89629590|NCT03228576||TREVISE|
89629591|NCT00158379|Experimental|Paclitaxel|
89629592|NCT03235674|Experimental|High-intensity stair climbing exercise|3 x 60 seconds of stair climbing, at a vigorous pace as described by rating of perceived exertion, separated by 60 seconds of rest. Subjects will complete supervised sessions 3 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
89629593|NCT03235674|No Intervention|standard cardiac rehabilitation exercise|Subjects will complete the traditional cardiac rehabilitation program, combination of aerobic and resistance exercise 2 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
89629594|NCT03228498|Experimental|Choline alphoscerate|"Drug: Choline alphoscerate 1200 mg per day and Nimodipine 90 mg per day~concomitant administration"
89629595|NCT03228498|Placebo Comparator|Placebo|"Placebo and Drug: Nimodipine 90 mg per day only~concomitant administration"
89629596|NCT02362672|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
89629597|NCT02362672|Placebo Comparator|Placebo|Placebo to match NKTR-181 twice daily (BID) tablets
89629598|NCT03232320|Experimental|MEDITOXIN|
89629599|NCT03232320|Placebo Comparator|Placebo|
89629600|NCT03232086|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
89629601|NCT03232086|Active Comparator|Concentrated PM2.5|Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
88990206|NCT03995862||Patients in care, at high risk of HIV infection|Patients in care, at high risk of HIV infection, according to the criteria defined by the French Ministry Of Health for the use of FTC / TDF in PreP (men who have sex with men, transgender, heterosexual women migrants or not, sex workers (sexual intercourse in exchange for money, drugs, housing, food), intravenous drug users) HIV-negative, exposed by their sexual practices to a high risk of HIV infection.
88990207|NCT03982342|Active Comparator|Catheter-closure of PDA|Infants randomized to this group will undergo a catheter procedure to close hemodynamically-significant patent ductus arteriosus (HSPDA).
89629602|NCT00158925|Experimental|EASYTRAK EPI Lead|Subjects in this arm will be implanted or attempted with the EASYTRAK EPI lead.
89629603|NCT03235596|Experimental|treated arm|Patients received cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2 mA during 15 minutes. They have 10 sessions in 5 consecutive days, 2 sessions per day.
89629604|NCT03232008|Experimental|Experiment A- experimental|3g Canderel in 250ml water
89629605|NCT03232008|No Intervention|Experiment A- control|3g of maltodextrin in 250 ml of water
89211368|NCT00991419|Experimental|A|[18F]4694
89211369|NCT00829556|Experimental|1|
89211370|NCT00829556|No Intervention|2|Standard Surgical skin preparation
89211371|NCT03823911|Active Comparator|HIV Mono-Infected|Patients infected with HIV only, and not currently or previously infected with hepatitis C.
89211372|NCT03823911|Experimental|Hepatitis C Mono-Infected|Patients infected with Hepatitis C and have no evidence of active HIV or hepatitis B infection
89629606|NCT03232008|Experimental|Experiment B- experimental|3g Canderel + 35g Lyle's Golden Syrup in 250 ml water
89629607|NCT03232008|No Intervention|Experiment B- control|3g Lyle's Golden Syrup + 35g of maltodextrin in 250 ml of water
89629608|NCT02364076|Experimental|Pembrolizumab and Epacadostat|Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
89629609|NCT03235440|Experimental|Kids N Fitness|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
89211373|NCT03823911|Experimental|HIV and Hepatitis C Co-Infected|Patients co-infected with HIV and hepatitis C, and have no evidence of active hepatitis B infection.
89211374|NCT00829634|Other|l-methamphetamine|
89211375|NCT05277753|Experimental|CART/CTL/DCvac cells to treat T-ALL|
89211376|NCT00991497|Active Comparator|24 hours compression bandaging|
89211377|NCT00991497|Active Comparator|5 days compression bandaging|
89039794|NCT06042088|Experimental|Double Gloves: Regular Size and Half-Size Bigger|Procedure B: Double gloves, Participants will wear their own glove size and half-size bigger glove on top
89039795|NCT06042088|Experimental|Double Gloves: Half-Size Bigger and Regular Size|Procedure C: Double gloves, participants will wear a half-size big glove and their own glove size on top.
89629610|NCT03231930|Experimental|Intervention group|Rapid point of care testing will be done using the OraQuick HCV Ab test and the Xpert HCV RNA viral load test. All participants will undergo rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid, followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at the clinic and referred to appropriate practitioners for HCV treatment. As these tests are not yet licensed for diagnostic use in Australia, confirmatory testing using standard laboratory tests will be performed for all participants.
89629611|NCT02364700|Experimental|interventional group|This is a single group, interventional pilot study. All participants will receive 6-week hand training on the HOH device.
89629612|NCT02453022|Experimental|Danirixin HBr + Danirixin FB + Omeprazole|Subjects will receive danirixin FB 50 milligram (mg) immediate release (IR) tablet, single dose, in the fed state (treatment A), danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment B), danirixin HBr 50 mg IR tablet, single dose, in the fasted state (treatment C), or danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment D) as per randomization in period 1 to 4. In treatment Period 5, subjects will receive danirixin HBr 50 mg IR table, single dose, in the fed state with concomitant, steady state OMP (40 mg once daily for 5 days) (treatment E). Subject will receive treatment with washout period of 5 days in one of the four sequence DCABE, ADBCE, BACDE, CBDAE.
89629613|NCT03231696||Patients receiving Regional Anesthesia|All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.
89629614|NCT02364778||Provisional stenting strategy|Patients with stable coronary artery disease with angiographic main vessel lesion not involving side branch (SB) in whom provisional stenting strategy is planned.
89629615|NCT03231852||Study Population|Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials.
89629616|NCT02365714|Other|Treatment-Radiation|CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
89629617|NCT03235752|Experimental|TJ301 300mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
89629618|NCT03235752|Experimental|TJ301 600mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
89629619|NCT03235752|Placebo Comparator|Placebo|Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
89629620|NCT00163293|Placebo Comparator|Placebo|
89629621|NCT00163293|Active Comparator|Ciclesonide 100 µg|Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
89629622|NCT00163293|Active Comparator|Ciclesonide 200 µg|Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
89629623|NCT03231618|Experimental|Normal weight group|20 normal-weight males taking 3 types of assigned diets in random orders
89629624|NCT03231618|Experimental|Overweight/ obesity group|20 overweight/ obesity males taking 3 types of assigned diets in random orders
89629625|NCT03228342|Experimental|Ultrasound shared|Patient will be assessed with ultrasound (GUS-7 score)
89629626|NCT03228342|Experimental|Ultrasound not shared|Patient will be assessed with ultrasound (GUS-7 score)
89629627|NCT02033200|Experimental|Active|Stendra 200 mg
89629628|NCT02033200|Placebo Comparator|Placebo|placebo
89629629|NCT00076245|Experimental|1 Light therapy|
89629630|NCT00076245|Experimental|2 Cognitive behavioral therapy|
89629631|NCT00076245|Experimental|3 Light therapy plus cognitive behavioral therapy|
89039796|NCT06042088|No Intervention|One Glove|Procedure D: Participants will wear only one glove.
89629632|NCT00076245|No Intervention|4 Control|
89629633|NCT03231384|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
89629634|NCT03231384|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
89629635|NCT02365870|Active Comparator|rotigotine|rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
89629636|NCT02365870|Placebo Comparator|placebo|placebo transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
89629637|NCT03228108|Experimental|Targeted antimicrobial prophylaxis|"Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:~trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or~fosfomycin 3 g orally 2 hours before prostate biopsy, or~pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy."
89039797|NCT06041620|Experimental|VGB-Ex01|Each subject will accept one dose of VGB-Ex01.
89057397|NCT01682499|Experimental|Calcium and Magnesium Infusion|
89057398|NCT04540055||Paravertebral (Group P)|Patients underwent MRM under the combination of general anesthesia and paravertebral block.
89057399|NCT04540055||General Anesthesia (Group G)|Patients underwent MRM under general anesthesia.
89057400|NCT02215655|Active Comparator|Motivational interviewing|Motivational interviewing counselling will be administered to the subjects
89039798|NCT06038851|Experimental|Para-Sartorial Compartment (PACS) Block + Femoral Triangle Block (FTB) + IPACK block|"In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment).~For all patients, an infiltration between popliteal artery and capsule of the knee block (IPACK) will be performed concomitantly, in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000."
89039799|NCT06038851|Active Comparator|Femoral Triangle Block (FTB) + IPACK block|"This block is currently the most used in practice and is considered a standard of care. It consists of a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle~For all patients, an infiltration between popliteal artery and capsule of the knee block (IPACK) will be performed concomitantly, in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000."
89039800|NCT06036108|Experimental|Fasting-state administration group|Brexpiprazole QW formulation in a fasting-state administration
89629638|NCT03228108|Active Comparator|Routine empirical prophylaxis|Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.
89629639|NCT01981564|Experimental|Asthma Express Intervention|Clinic visit for asthma education + nurse home visits
89629640|NCT01981564|Active Comparator|Standard Asthma Education Control group|Standard asthma education during nurse home visits
89629641|NCT03235128||Group1|Steroid sensitive nephrotic syndrome(10 cases).
89629642|NCT03235128||Group2|Steroid resistant nephrotic syndrome(10 cases).
89629643|NCT03235128||Group3|immunosuppressive resistant nephrotic syndrome(10 cases).
89629644|NCT03235128||Group4|Refractory nephrotic syndrome(10 cases).
89629645|NCT03235128||Group5|Normal children as a healthy control group(5 cases).
89629646|NCT00078897|Active Comparator|Selenium|Participants receive oral selenium 200 mcg once daily.
89629647|NCT00078897|Placebo Comparator|Placebo|Participants receive oral placebo once daily.
89629648|NCT01746017|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 4 study periods in Part A
89629649|NCT01746017|Experimental|LY2922470 (Part A)|Single ascending dose of LY2922470 [starting at 1 milligram (mg)] administered orally to healthy participants in up to 3 of 4 study periods in Part A
89629650|NCT01746017|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
89629651|NCT01746017|Experimental|LY2922470 (Part B)|Single ascending dose of LY2922470 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
89039801|NCT06036108|Experimental|Fed-state administration group|Brexpiprazole QW formulation in a fed-state administration
89039802|NCT06035211|Active Comparator|Virtual 3D model group|exchange time with the virtual 3D model of the kidney to be operated on as information support
89039803|NCT06035211|Active Comparator|3D Printed Model Group|eexchange time with the printed three-dimensional model of the kidney to be operated on as information support
89039804|NCT06035211|No Intervention|Control group|discussion time with the patient information sheet of the French Association of Urology (AFU) as information support
89039805|NCT06027034|Experimental|Online program for psoriasis (GAIA-PSO-01) + TAU|Participants allocated to the intervention group will receive access to an online program for psoriasis (GAIA-PSO-01) in addition to treatment as usual (TAU).
89629652|NCT05234502|Experimental|Group-1 (Ketogenic diet)|Group-1 will be given an adequate and balanced healthy diet program during the standard neoadjuvant treatment (12 weeks) with an anthracycline. And simultaneously with standard neoadjuvant therapy containing taxane (12 weeks), KD will be planned for Group-1
89629653|NCT05234502|Other|Group-2 (Adequate and balanced healthy diet)|Group-2 will be given an adequate and balanced healthy diet program during the standard neoadjuvant treatment (12 weeks) with anthracycline and taxane (12 weeks).
89629654|NCT03228030|Experimental|Thiamine mononitrate 500mg po daily|3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm
89629655|NCT03228030|Placebo Comparator|Placebo|3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine
89629656|NCT02091531|Experimental|MLN0128|Patients will be treated with the established phase II dose of MLN0128 (4mg po daily continuously; 1 cycle=4 weeks) to assess mechanisms of sensitivity and resistance in men with CRPC who have received either enzalutamide and/or abiraterone.
89629657|NCT02367430|Experimental|Critical Time Intervention for Hoarding Disorder|Patients with Hoarding Disorder received CTI Model
89629658|NCT03227952|Active Comparator|Active treatment|Vibrotactile sensory stimulation
89629659|NCT03227952|Sham Comparator|Sham|Identical device. No vibration
89039806|NCT06027034|No Intervention|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
89057401|NCT02215655|No Intervention|No intervention: control group|No motivational interviewing counselling will be administered to the subjects
89211378|NCT00832052|Experimental|Cohort 1|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
89629660|NCT03227796|Experimental|Cohort 1 Healthy Volunteers Active|LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers
89629661|NCT03227796|Experimental|Cohort 2 Healthy Volunteers Active|LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers
89629662|NCT03227796|Experimental|Cohort 3 Healthy Volunteers Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers
89629663|NCT03227796|Experimental|Cohort 4 Osteoarthritis Patients Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients
89629664|NCT03227796|Experimental|Cohort 5 Osteoarthritis Patients Active|LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients
89629665|NCT03227796|Experimental|Cohort 6 Osteoarthritis Patients Active|LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients
88990208|NCT03982342|Active Comparator|Conservative management of PDA|"Infants randomized to this group will be treated to reduce the symptoms of a hemodynamically-significant patent ductus arteriosus (HSPDA), in the hopes that over time the HSPDA will become reduced in size (to the point of no longer meeting criteria for being hemodynamically significant) or close naturally. Infants in this group with declining health status attributable to a PDA which meet qualifying criteria may receive catheter closure (intervention) if deemed medically necessary."
88990209|NCT03974854|Experimental|Arm A: XELOXIRI-3|capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days
88990210|NCT03974854|Active Comparator|Arm B: Gemcitabine|1000 mg / m2 on D1, D8 and D15, every 28 days
89629666|NCT03227796|Experimental|Cohort 7 Osteoarthritis Patients Active|LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients
89629667|NCT03227796|Experimental|Cohort 8 Healthy Volunteers Active|LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Healthy Volunteers
89629668|NCT03227796|Placebo Comparator|Cohort 1 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
89629669|NCT03227796|Placebo Comparator|Cohort 2 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
89629670|NCT03227796|Placebo Comparator|Cohort 3 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
89629671|NCT03227796|Placebo Comparator|Cohort 4 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
89629672|NCT03227796|Placebo Comparator|Cohort 5 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
89629673|NCT03227796|Placebo Comparator|Cohort 6 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
88990211|NCT03974152|Experimental|Own brand cigarette first, then ENDS with protonated nicotine, then ENDS with unprotonated nicotine|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
88990212|NCT03974152|Experimental|ENDS with unprotonated nicotine first, then ENDS with protonated nicotine, then Own brand cigarette|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
88990213|NCT03974152|Experimental|ENDS with protonated nicotine first, then Own brand cigarette, then ENDS with unprotonated nicotine|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
88990214|NCT03974152|Experimental|ENDS with protonated nicotine first, then ENDS with unprotonated nicotine, then Own brand cigarette|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
88990215|NCT03974152|Experimental|Own brand cigarette first, then ENDS with unprotonated nicotine, then ENDS with protonated nicotine|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
88990216|NCT03974152|Experimental|ENDS with unprotonated nicotine first, then Own brand cigarette, then ENDS with protonated nicotine|In each of the 3 sessions, participants will be instructed to take one puff of the tobacco product (cigarette or Subox Mini C ENDS with 18 mg nicotine) every 30 seconds for 5 minutes followed by a 2nd blood draw (if staffing allows). Next, participants will be given 90 minutes to use ad lib, i.e., as much as desired.
88990217|NCT03971487|Active Comparator|Ocrelizumab|Two doses of 300 mg of ocrelizumab will be administered as an intravenous infusion two weeks apart.
88990218|NCT03971487|Placebo Comparator|Placebo|Two placebo intravenous infusions will be administered two weeks apart.
88990219|NCT03963752|Experimental|Ziyinxiehuo Granules and Megestrol Acetate|Experimental：Group Ziyinxiehuo Granules and Megestrol Acetate Tablet Intervention :Subjects in Group Ziyinxiehuo Granules and megestrol acetate tablet will be treated with Ziyinxiehuo Granules and megestrol acetate tablet for 6 months.1 pack of Ziyinxiehuo granules Herbs includes shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g. Ziyinxiehuo Granules is administered after dissolved,1pack every time, 2 times per day after a meal; and the dosage of megestrol acetate is 6-8mg/d, which is taken in 3 times after a meal.
88990220|NCT03963752|Active Comparator|Gonadotrophin|Active Comparator: Group Gonadotrophin Intervention: Subjects in Group Gonadotrophin will be treated with gonadotrophin releasing hormone agonist for 6months. In our study Leuprorelin Acetate 3.75mg Injection will be applied, the dosage of which is 80μg/kg every time by subcutaneous injection, every 4 weeks for once.
88990221|NCT03963245|Experimental|Intervention group|MA&R - an eight months rehabilitation intervention in addition to standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
88990222|NCT03963245|Active Comparator|Control group|Standard care and treatment in Community Mental Health Centres in Copenhagen, and psychiatric rehabilitation services in Copenhagen, Odense and Svendborg, Denmark
88990223|NCT03960008|Other|Stereotactic Body Radiation Therapy (SBRT)|Radiation Therapy
88990224|NCT03960008|Other|Trans-Arterial Chemoembolization (TACE)|Procedure/Surgery - Chemoembolization Drug: Doxorubin
88990225|NCT03948048||septic shock|The critically ill children with septic shock (ss group)
89629674|NCT03227796|Placebo Comparator|Cohort 7 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
89629675|NCT03227796|Placebo Comparator|Cohort 8 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
89629676|NCT03227718||athletic background|ex-gymnasts
89629677|NCT03227718||control|age-matched non-gymnastics background
89039807|NCT06026826|Active Comparator|real stimulation|Participants will receive active tACS twice daily for one week. The anode was placed over AF3 with return electrodes placed at the contralateral mastoid process. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes per session, twice daily over 7 consecutive days, and the stimulus frequency was set as 8 Hz.
89039808|NCT06026826|Sham Comparator|sham stimulation|Participants will receive sham tACS twice daily for one week. Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
89039809|NCT06017180|Experimental|Myofascial Release Group|54 healthy people playing volleyball will be included in our study and randomly divided into groups. In group I (myofascial release group), myofascial release will be applied to the shoulder and elbow region.
89039810|NCT06017180|Sham Comparator|Control Group|54 healthy people playing volleyball will be included in our study and randomly divided into groups. The sham method will be applied to the shoulder and elbow region of group II (control group).
89039811|NCT06014047|Experimental|No-Touch vein|No-touch vein group has two No-touch saphenous vein grafts, anastomose to the right coronary or left coronary system. All patients also acquired LITA-LAD anastomosis to complete the revascularization.
89039812|NCT06014047|Active Comparator|Radial artery|Radial artery group has one radial artery graft and one conventional saphenous vein graft, anastomose to the right coronary or left coronary system basing on surgeons' decision. All patients also acquired LITA-LAD anastomosis to complete the revascularization.
89039813|NCT06009523|Experimental|Active tDCS|Participants received an active tdcs: transcranial direct current with an intensity of 2 mA for 30 minutes
89039814|NCT06007677|Experimental|Dose Regimen 1: STAR-0215|Participants will receive STAR-0215 every 3 months.
89039815|NCT06007677|Experimental|Dose Regimen 2: STAR-0215|Participants will receive STAR-0215 every 6 months.
89039816|NCT05988151||New surgical approach (Fibonacci ratio)|Agroup of 60 patients who underwent VaGinoplasti+ labioplasty ( wedge resection) with fibonacci ratio surgical ratio.
89629678|NCT01717313|Experimental|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week for 24 weeks (Phase A) followed by omarigliptin 25 mg administered orally once a week plus placebo to metformin daily (Phase B). Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
89629679|NCT01717313|Placebo Comparator|Placebo to Omarigliptin|Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phase B). Open-label metformin was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
89629680|NCT03231540|Experimental|intervention group|whey protein supplement enriched enteral nutrition, with protein intake of 1.5g/kg/day; in addition to standardized exercise training
89629681|NCT03231540|No Intervention|control group|standard enteral nutrition, with protein intake of 1g/kg/day; in addition to standardized exercise training
89629682|NCT00080535|Experimental|LMB-2 for cutaneous Tcell lymphoma|30 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with cutaneous T-cell lymphoma, a group of lymphoproliferative disorders characterized by malignant CD4+ T-lymphocytes which localize tot he skin on initial presentation.
89629683|NCT01897545|Active Comparator|PV isolation|
89629684|NCT01897545|Active Comparator|PV isolation+renal denervation|
89629685|NCT03222804|Active Comparator|Exclusively breastfed|Exclusive breastfeeding will be defined at screening as infants who have not consumed any infant formula after 7 days postnatal and have been exclusively breastfed without formula between day 7 of life through the end on the Lead-in period. ). Infants will consume B. infantis for twenty-one consecutive days.
89629686|NCT03222804|Active Comparator|Exclusively formula fed|Exclusive formula feeding is defined at screening as infants who consume only infant formula between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
89629687|NCT03222804|Active Comparator|Mixed fed|Mixed feeding is defined at screening as infants who consume a combination of infant formula and breast milk between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
89629688|NCT05061381|Experimental|A Lust for Life Schools Programme Group|A Lust for Life programme will be delivered to primary school pupils by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
89629689|NCT05061381|No Intervention|Waiting list control group|Participants will be placed on a sixteen-week waiting list for the programme.
89039817|NCT05988151||Classical surgical approach (control group)|A group of 30 patients who underwent Vaginoplasty + Labioplasty( wedge resection) with classical surgical approach.
89039818|NCT05986266|Active Comparator|Group A|patients will receive carbetocin, The optimal carbetocin dose(IV or IM) is 100 mcg. The carbetocin group will receive 100 mcg IV carbetocin (Pabal; Ferring Pharmaceuticals) in 10 mL saline solution. The anesthesiologists will administrate carbetocin slowly over 5 minutes (at a rate of 2 mL/min) to maintain hemodynamic stability.
89039819|NCT05986266|Experimental|Group B|patients will receive adrenalin, infiltration of the serosa and/or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine HCL 0.25% and 0.5 mg of adrenaline.The anesthesiologist will be informed prior to the injection of the solution to ensure proper monitoring. The solution will be prepared just before the procedure. Before each infiltration, aspiration will be performed to avoid intravascular injection
89039820|NCT05982041||idiopathic inflammatory myopathy|
89039821|NCT05980728||Connective Tissue Disease Patients With Pulmonary Hypertension|Connective Tissue Disease Patients With Pulmonary Hypertension
89039822|NCT05980728||Connective Tissue Disease Patients Without Pulmonary Hypertension|Connective Tissue Disease Patients Without Pulmonary Hypertension
88990226|NCT03948048||refractory septic shock with ECMO|The critically ill children with refractory septic shock with ECMO treatment
88990227|NCT03948048||refractory septic shock without ECMO|The critically ill children prediction model th refractory septic shock without ECMO treatment
89629690|NCT01745393|Experimental|Clinic Quality Improvement + Behavioral Counseling|This multilevel intervention includes advice and a referral from a pediatrician, behavioral counseling by study staff, and community systems navigation, all designed to reduce pediatric secondhand smoke exposure. Over the course of 12 weeks participants receive a home visit designed to orient them to the program and trained health counselors provide multiple individualized phone counseling sessions designed to build coping skills, urge management skills, and self-efficacy. Counseling also includes assistance with goal setting and navigation of local resources.
89629691|NCT01745393|Active Comparator|Clinic Quality Improvement + Attention Control|The attention control intervention parallels the format of the experimental group but focuses on family nutrition information. The intervention includes a home visit to orient the participant to the program and multiple phone counseling sessions conducted by a trained health counselor.
88990228|NCT03933722||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
88990229|NCT03929952|Experimental|Chronic low back pain|
89629692|NCT03230994||Different Treatment Groups|Women would receive different pharmacotherapy from the standard approach，such as levonorgestrel-releasing intrauterine system(LNG-IUS)，Gonadotrophin releasing hormone agonist(GnRH-a),surgery,etc.
89629693|NCT00081861|Experimental|Avastin + Rituximab|Avastin 10 mg/kg given intravenously every 2 weeks for 4 doses, and Rituximab 375 mg/m^2 intravenously weekly for 8 doses.
89629694|NCT03120234|Experimental|Dexmedetomidine and ketamine|The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.
89629695|NCT03120234|Experimental|fentanyl and placebo|pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group
89211379|NCT00832052|Experimental|Cohort 2|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
89629696|NCT03119922||SCD french new born|New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
89629697|NCT03222726|Active Comparator|exercise group|6000 steps/day or 40,000 steps/week
88990230|NCT03927989|Experimental|Treatment Arm|Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients
88990231|NCT03927989|Active Comparator|Standard Care|Advice to quit and brief discussion of tobacco use
88990232|NCT03924037|Active Comparator|Zero Suicide|Participants randomly assigned to the Zero Suicide arm will also participate in a weekly support group until the final follow-up time point when they will be crossed-over into the intergenerational knowledge sharing group.
88990233|NCT03924037|Experimental|Zero Suicide plus KICKS|Participants randomly assigned to the Zero Suicide plus KICKS arm will participate in a weekly intergenerational knowledge sharing group.
88990234|NCT03922542|Active Comparator|Accelerated|Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
88990235|NCT03922542|Active Comparator|Standard|Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes
89211380|NCT00832052|Experimental|Cohort 3a|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
88990236|NCT03918369|Experimental|Laparoscopic Intracorporeal anastomosis|Laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis.
88990237|NCT03918369|Active Comparator|Laparoscopic extracorporeal anastomosis|Laparoscopic right hemicolectomy with extracorporeal anastomosis.
88990238|NCT03906578|Active Comparator|Probiotic|Two sachets Vivomixx® containing 8 strains of life bacteria (9 x 10^11 CFU) in the evening for 8 weeks
89211381|NCT00832052|Experimental|Cohort 3b|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
89211382|NCT00832052|Experimental|Cohort 4|
89211383|NCT00991575||Diabetes, type 1|
89211384|NCT00824174||Questionnaire|1 questionnaire, about 15-20 minutes.
89211385|NCT04003467|Experimental|EBP05 1.5mg|subjects will be randomly assigned to receive 3 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
89211386|NCT04003467|Experimental|Placebo for EBP05 0.5mg (1, 2, 3 or 5)|subjects will be randomly assigned to receive 3 or 5 tablets of matching EBP05 placebo orally each day for 6 months
89629698|NCT03222726|Other|less-exercise group|less than 6000 steps/day or 40,000 steps/week
89629699|NCT03230760|Experimental|treatment|
89629700|NCT03230682||major depressive disorder|
89629701|NCT02451618||Epidermal Electronic System|EES, wireless tattoo electrode
89629702|NCT02451618||Hydrogel electrode|EKG electrode, looking at hairline placement of electrodes.
89629703|NCT03120546|Experimental|Group A|rigid video stylet intubation - video laryngoscope intubation
89629704|NCT03120546|Experimental|Group B|video laryngoscope intubation - rigid video stylet intubation
89629705|NCT02367820|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
89629706|NCT03227874|Experimental|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
88990239|NCT03906578|Placebo Comparator|Placebo|Two sachets placebo in the evening for 8 weeks
89211387|NCT04003467|Experimental|EBP05 2.5mg|subjects will be randomly assigned to receive 5 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
89629707|NCT03227874|Experimental|Muffin|two muffins, each with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
89629708|NCT03222258||Early palliative care for adult|Being referred to palliative care team before totally terminating their chemotherapy among adult participants.
89629709|NCT03222258||Routine hospice care for adult|Being referred to palliative care team when their last chemotherapy is ended among adult participants.
89629710|NCT03222258||Unused palliative care for adult|haven't been under the palliative care among adult participants
89629711|NCT03222258||Palliative care for pediatrics|receiving the palliative care among pediatric participants
89211388|NCT04003467|Experimental|EBP05 0.5mg|subjects will be randomly assigned to receive 1 tablet of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
89629712|NCT03222258||Unused palliative care for pediatrics|haven't received the palliative care among pediatric participants
89629713|NCT02036320|Experimental|etafilcon A with additive printed limbal ring|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
89629714|NCT02036320|Active Comparator|etafilcon A|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
89629715|NCT03232710|Experimental|pilot study group|
89629716|NCT03232710|Experimental|group 1 (under fasting condition)|
89629717|NCT03232710|Experimental|group 2 (under fasting condition)|
89629718|NCT03232710|Experimental|group 3 (under fed condition)|
89629719|NCT03232710|Experimental|group 4 (under fed condition)|
89629720|NCT03227640|Active Comparator|stripping|standardized laparoscopic stripping technique
89629721|NCT03227640|Experimental|CO2 laser vaporization|drainage of the cyst content and vaporization of the internal wall with CO2 laser
89629722|NCT02451540|Active Comparator|Roflumilast|Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
89629723|NCT02451540|Placebo Comparator|Placebo|Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.
89629724|NCT03227484|Active Comparator|Empagliflozin|25mg Empagliflozin once daily over 8 weeks
89629725|NCT03227484|Placebo Comparator|Placebo|Matching placebo tablet once daily over 8 weeks
89629726|NCT01744691|Experimental|ibrutinib|All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.
89629727|NCT01982968|No Intervention|Control|Subjects to receive standard anti-reflux treatment per clinical discretion
89629728|NCT01982968|Active Comparator|Surgery|Subjects will receive laparoscopic fundoplication surgery
89629729|NCT04485390||First responder group|Cardiac arrest victims in remote areas resuscitated by the first responders before the arrival of the EMS.
89629730|NCT04485390||EMS groups|Cardiac arrest victims in remote areas resuscitated by the EMS.
89629731|NCT03230448||positive alcoholism|positive acute alcoholism had questionnaire about suicidal intentionality
89629732|NCT03230448||negative alcoholism|negative acute alcoholism had questionnaire about suicidal intentionality
89629733|NCT02038894|Active Comparator|Intubated with Sevoflurane (IS)|Anesthetic technique during (EGD)
89629734|NCT02038894|Active Comparator|Intubated with Propofol (IP)|Anesthetic technique during (EGD)
89629735|NCT02038894|Active Comparator|Native Airway - no intubation|Anesthetic technique during (EGD)
89629736|NCT01716533|Other|Recurrence group|Male or female subjects aged 18 years or older at the time of enrollment, who experienced recurrence of Clostridium difficile infection (CDI) after clinical response to antibiotic treatment to treat the initial CDI episode.
89629737|NCT01716533|Other|Sustained response group|Male or female subjects aged 18 years or older at the time of enrollment, who did not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
89629738|NCT01716533|Other|Failure to antibiotic Group|Male or female subjects aged 18 years or older at the time of enrollment, withdrawn due to failure of antibiotic treatment to treat the initial CDI episode.
89629739|NCT01716533|Other|Unclassified Group|Male or female subjects aged 18 years or older at the time of enrollment, who couldn't be classified as sustained response, recurrence, or failure to antibiotic due to missing data.
89211389|NCT04003467|Experimental|EBP05 1.0mg|subjects will be randomly assigned to receive 2 tablets of EBP05 containing 0.5mg hPTH(1-34) orally each day for 6 months
89211390|NCT00832208|Active Comparator|Ambisome control:|Ambisome, Total dose 21.0 mg given as 7 x 3mg on days 1,2,3,4,5, and 14 and 21
89211391|NCT00832208|Experimental|Ambisome test|Single dose Ambisome in sequence(7.5 / 10.0/ 12.5 / 15.0mg)
89211392|NCT05361057|Experimental|venetoclax pluse azacitidine arm|azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21
89629740|NCT01375374|Experimental|Lacosamide|commercial 50 mg (pinkish) and 100 mg (yellow) tablets
89629741|NCT04348786|Experimental|Doxycyclien|Measure eradication rate of Helicobacter pylori infection with Doxycycline and bismuth subsalicylate
89629742|NCT04348786|Active Comparator|Levofloxacine|Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole
89629743|NCT03230370|Experimental|enhanced upper-extremity program, EUEP|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity.~The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly, one group can be used as the control group of the other one."
89629744|NCT03230370|Experimental|enhanced lower-extremity program,ELLP)|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.~The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly,one group can be used as the control group of the other one."
89629745|NCT02369068|Experimental|Onabotulinumtoxin A|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 200u of onabotulinumtoxin A and saline injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~An injection of 30 cc of ropivicaine (5cc/6 sites) will be used, followed by a mixture of 200 u of Onabotulinumtoxin A and 6 cc of saline (1cc/injection site)."
89629746|NCT02369068|Active Comparator|Kenalog|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 40mg/cc of Kenalog (triamcinolone) and ropivicaine 0.5% (29cc) injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~A mixture of 40mg/1 cc of triamcinolone (40 mg) and 29cc of ropivicaine 0.5% (5cc/6 sites) will be used, followed by 6 cc of saline (1cc/injection site)."
89629747|NCT03222024||Severe ischaemic stroke|patients with severe stroke on admission
89629748|NCT03222024||Malignant ischaemic stroke|patients without severe stroke on admission but developing it in hospital
89629749|NCT03222024||Mild to moderate ischaemic stroke|patients without severe stroke from onset to discharge
89629750|NCT03230214||DNA positive patients|patients who have bacterial DNA in their samples
89629751|NCT03230214||DNA negative patients|patients who do not have bacterial DNA in their samples
89629752|NCT03222180|Experimental|Website|Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
89629753|NCT03222180|No Intervention|Usual Care|Participants' children with T1D will receive care for T1D at their respective institutions equivalent to that received by comparable patients who do not enroll in the trial. At all sites, Usual Care is designed to be consistent with the current American Diabetes Association Standards of Care for T1D in this clinical population.
89629754|NCT02370004|Experimental|Resistive Flexibility and Strength Training|Each subject will undergo Resistive Flexibility and Strength Training (RFST) with a trained practitioner.
89629755|NCT03221790|Experimental|Low and High FODMAP Diets in IBS|"This study will be comprised of the following four time periods: baseline, run-in, low FODMAP diet, and high FODMAP diet. Participants will undergo baseline assessment with questionnaires on demographics, IBS symptoms (IBS symptom severity scoring questionnaire), diet, and psychological parameters. Baseline mucosal colonic biopsies will be obtained, and metabolome analysis from urine samples. These will be repeated 3 other times during each of the above time periods. Low FODMAP Diet followed by a High FODMAP Diet"
89629756|NCT03221868|Experimental|Physical exercise intervention|Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
89629757|NCT03221868|Active Comparator|Control|Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
89629758|NCT01983826|Experimental|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
89629759|NCT01983826|Placebo Comparator|Placebo capsule|Microcrystalline cellulose (daily) for 8 weeks
89629760|NCT03229980|Active Comparator|Group L|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg The content of cardioplegic solution will be (K+, 10mmol/L) lidocaine 50 mg/L, magnesium sulphate 1 gm/L,dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery. Cardioplegic infusion duration will be infused over 300s.
89629761|NCT03229980|Active Comparator|Group S|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg The content of cardioplegic solution will be (K+, 30mmol/L) lidocaine 150 mg/L, magnesium sulphate 3 gm/L, dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery.
89629762|NCT02452632|Experimental|ASP1941 group|once daily over a 24 week treatment
89629763|NCT02452632|Placebo Comparator|Placebo group|once daily over a 24 week treatment
89629764|NCT02371252|No Intervention|Original alendronate (Fosamax)|The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
89629765|NCT02371252|Active Comparator|Generic alendronate (Bonmax)|The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
89629766|NCT02452710|Experimental|Open-Label Placebo|- Placebo Tablets-Twice a day for 3-4 weeks
89629767|NCT02452710|No Intervention|NT-Control|- No Placebo Tablets
89629768|NCT03221946|Active Comparator|Diclofenac sodium oral|Group A which included 30 patients of either gender. Dosage drug: Diclofenac sodium Dosage form: Oral medication Frequency: twice daily Dose: 50mg Duration: 2 days
89629769|NCT03221946|Experimental|diclofenac sodium patch|Group B which included 30 patients who were prescribed Drug: Diclofenac sodium Dose: 100mg Drug form: transdermal patch to equate the oral dosage of 50mg Duration: for 2 days Frequency: Once daily
89629770|NCT03221946|Other|Diclofenac sodium injection|Group C which included 30 patients of either gender Drug: diclofenac sodium intra muscular injections Dose: 75mg which was the nearest available dosage to 100 mg availability in India Frequency: once daily Duration: for 2 days
89629771|NCT03229746|Experimental|hydroxychloroquine group|hydroxychloroquine tablets 200mg ,two times/day for at least 6 month
89629772|NCT03229746|Active Comparator|vincristine group|vincristine ampoule , 1mg/ week, I.v drep over 2 hours for 4 weeks
89629773|NCT03229746|Active Comparator|azathioprine group|azathioprine tablet 50mg, dose 100-150 mg daily for 6 month
89629774|NCT02040298|Active Comparator|3 months Clemastine, 2 months Placebo|4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequency of placebo for last 2 months
89629775|NCT02040298|Active Comparator|3 months Placebo , 2 months Clemastine|Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.
89629776|NCT03229668|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
89629777|NCT03229668|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
89039823|NCT05980728||healthy|healthy people
89629778|NCT03229668|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
89629779|NCT03230058|Experimental|group 1|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
89629780|NCT03230058|Placebo Comparator|group 2|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
89629781|NCT01985542|Active Comparator|subcutaneous immunotherapy|Starts with birch pollen subcutaneous immunotherapy
89629782|NCT01985542|No Intervention|no immunotherapy|not starting with birch pollen subcutaneous immunotherapy
89629783|NCT03229902|Experimental|mantra meditation|Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.
89629784|NCT02371876|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the ONYX PLUS Investigational Blood Glucose Monitoring System.
89629785|NCT02372344|Experimental|Fasting|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered at the end of a 10-hour fast.
89629786|NCT02372344|Experimental|Before meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered before consumption of a low calorie, low-fat breakfast (within 30 minutes before starting food intake).
89629787|NCT02372344|Experimental|After meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
89039824|NCT05978687|Experimental|Topical lidocaine gel|All patients will receive topical 2% lidocaine gel (Ophtesic lidocaine gel) prior to surgery
89039825|NCT05978687|Active Comparator|Subconjunctival xylocaine injection|All patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle
89039826|NCT05971082||Recall study|Recruited individuals aged 20-60 at index imaging date invited for follow-up with liver elastography and fat prosentage measurement
89039827|NCT05967598|Active Comparator|taVNS100 in advanced PD patients|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz to advanced PD patients. Participants will complete an 8 minute block design fMRI block.
89629788|NCT03229824|Experimental|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
89039828|NCT05967598|Active Comparator|taVNS25 in advanced PD patients|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz to advanced PD patients. Participants will complete an 8 minute block design fMRI block.
89039829|NCT05967598|Placebo Comparator|xVNS in advanced PD patients|The electrode will be placed in the left cyma conchae however no electrical current will be applied to advanced PD patients. Participants will complete an 8 minute block design fMRI block.
89039830|NCT05967598|Active Comparator|taVNS100 in early PD patients|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz to early PD patients. Participants will complete an 8 minute block design fMRI block.
89629789|NCT03229824|No Intervention|Standard care|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.
89629790|NCT00081939|Experimental|Study Treatment|Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects > 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.
89629791|NCT03221556|Active Comparator|Engagement-Focused Care Coordination|The brief intervention in Engagement-Focused Care Coordination is the Engagement Interview. In this model, providers meet one to two times with mothers who screen positive for depression, and use techniques of shared decision-making to help mothers process the results of the screen; explore treatment options; and connect with formal mental health services. Engagement-Focused Care Coordination emphasizes referral to formal mental health services.
89629792|NCT03221556|Active Comparator|Problem Solving Education (PSE)|The brief Problem Solving Education (PSE) is a six-session cognitive-behavioral program. PSE offers immediate intervention in the PCMH, followed by referral to further treatment if symptoms persist.
89629793|NCT02373124|Experimental|open-label|52 minute infusion of NMDA antagonist
89629794|NCT03221478|Active Comparator|Kinesio Taping placebo and exercises|kinesio placebo and exercises
89039831|NCT05967598|Active Comparator|taVNS25 in early PD patients|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz to early PD patients. Participants will complete an 8 minute block design fMRI block.
89629795|NCT03221478|Experimental|Kinesio Taping and exercises|kinesio with tension and exercises
89629796|NCT03221478|Experimental|Kinesio Taping with tension|Kinesio Taping with tension
89039832|NCT05967598|Placebo Comparator|xVNS in early PD patients|The electrode will be placed in the left cyma conchae however no electrical current will be applied to early PD patients. Participants will complete an 8 minute block design fMRI block.
89039833|NCT05961332|Experimental|Fundus autofluorescence (FAF) imaging|
89629797|NCT03221634|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.
89629798|NCT03221088|Experimental|Jintrolong® low dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
89629799|NCT03221088|Experimental|Jintrolong® high dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
89629800|NCT03221088|No Intervention|Negative control group|Untreated Control Group
89629801|NCT05003037|Experimental|Wild-type Genotype|
89039834|NCT05961059|Experimental|A1 - Low dose vaccine (Netherlands)|10 Dutch participants who receive three 2.5 μg doses of the vaccine without adjuvant at a 28-day interval in Cohort A.
89629802|NCT05003037|Experimental|EGFR mutation|
89039835|NCT05961059|Experimental|A2 - Low dose vaccine + adjuvant (Netherlands)|10 Dutch participants who receive three 2.5 μg dose of the vaccine with 0.1 μg of adjuvant at a 28-day interval in Cohort A.
89629803|NCT04485000|Experimental|Immediate Treatment|The experimental (immediate workshop) group will receive the online workshop at baseline (T1) in addition to receiving standard postnatal care.
89039836|NCT05961059|Experimental|B1/C1 - High dose vaccine (Netherlands & Zambia)|10 Dutch participants who receive three 10 μg vaccine doses without adjuvant at a 28-day interval in Cohort B and 15 Zambian participants who receive three 10 μg vaccine doses without adjuvant at a 28-day interval in Cohort C.
89039837|NCT05961059|Experimental|B2/C2 - High dose vaccine + adjuvant (Netherlands & Zambia)|10 Dutch participants that receive three 10 μg vaccine doses with 0.1 μg of adjuvant at a 28-day interval in Cohort B and 15 Zambian participants that receive three 10 μg vaccine doses with 0.1 μg of adjuvant at a 28-day interval in Cohort C.
89039838|NCT05961059|Placebo Comparator|A3/B3/C3 - Placebo (Netherlands & Zambia)|5 Dutch participants who receive three placebo vaccinations at a 28-day interval in Cohort A, another 5 Dutch participants who receive three placebo vaccinations at a 28-day interval in Cohort B and 5 Zambian participants who receive three placebo vaccinations at a 28-day interval in Cohort C.
89039839|NCT05960994|Experimental|Sequence 1|Sequence 1 will consist of a 3-month control period, followed by a 3-month transition period, and finally, a 19-month intervention period. The total duration of sequence 1 will be 25 months.
89039840|NCT05960994|Experimental|Sequence 2|Sequence 2 will consist of a 7-month control period, followed by a 3-month transition period, and finally, a 15-month intervention period. The total duration of sequence 2 will be 25 months.
89039841|NCT05960994|Experimental|Sequence 3|Sequence 3 will consist of a 11-month control period, followed by a 3-month transition period, and finally, a 9-month intervention period. The total duration of sequence 3 will be 25 months.
89039842|NCT05960994|Experimental|Sequence 4|Sequence 4 will consist of a 15-month control period, followed by a 3-month transition period, and finally, a 7-month intervention period. The total duration of sequence 4 will be 25 months.
89039843|NCT05960994|Experimental|Sequence 5|Sequence 5 will consist of a 19-month control period, followed by a 3-month transition period, and finally, a 3-month intervention period. The total duration of sequence 5 will be 25 months.
89039844|NCT05948813|Experimental|TY-9591 Tablets|TY-9591 (160mg orally, once daily), in accordance with the randomization schedule.
89629804|NCT04485000|Other|Waitlist Cpntrol|The waitlist control group will receive standard postnatal care for 12 weeks and will participate in the online 1-day CBT-based workshop at T2 (12 weeks post baseline).
89629805|NCT02374060|Active Comparator|Periocular triamcinolone 40mg|"Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
89629806|NCT02374060|Active Comparator|Intravitreal triamcinolone 4mg|"(preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
89039845|NCT05948813|Active Comparator|Osimertinib|Osimertinib (80mg orally, once daily), in accordance with the randomization schedule.
89039846|NCT05945303|Experimental|Responder group|About 20 Adult patients Planned for elective CABG surgery
89039847|NCT05945303|Experimental|Not Responder group|About 20 Adult patients Planned for elective CABG surgery
89039848|NCT05944965|Experimental|Atomoxetine-plus-Oxybutynin (AtoOxy)|80mg atomoxetine and 5mg of oxybutynin administered to participant, 30 min prior to bed.
89039849|NCT05944965|Active Comparator|Atomoxetine|80mg atomoxetine and placebo administered to participant, 30 min prior to bed.
89039850|NCT05944965|Placebo Comparator|Placebo|Placebo plus placebo administered to participant, 30mins prior to bed
89039851|NCT05935085|Experimental|ANB032 SC Dose 1|This arm will receive treatment SC
89039852|NCT05935085|Experimental|ANB032 SC Dose 2|This arm will receive treatment SC
89039853|NCT05935085|Experimental|ANB032 SC Dose 3|This arm will receive treatment SC
89039854|NCT05935085|Placebo Comparator|Placebo|This arm will receive Placebo SC
89039855|NCT05921149|Active Comparator|Carboplatin and paclitaxel with standard diet|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6-10 cycles in the absence of disease progression or unacceptable toxicity. A standard diet is consumed throughout each cycle of therapy.
89211393|NCT05361057|Active Comparator|venetoclax pluse DA arm|daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
89629807|NCT02374060|Active Comparator|Dexamethasoneintravitreal implant|"Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0~Second injection permitted at Week 12 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
89629808|NCT03221166|Experimental|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
89629809|NCT03221166|Active Comparator|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
89629810|NCT03221010|Experimental|Motivational Interviewing|Intervention Group: in this group, composed of 6 randomized Basic Health Units, the professionals who coordinate the smoking groups will receive the training for the use of the Motivational Interviewing as an additional resource to the work of motivation and cognitive-behavioral approach usually performed in the groups, however , With an approach based on Motivational Interviewing.
89629811|NCT03221010|Active Comparator|Traditional cognitive-behavioral approach|Control Group: in this group composed of the remaining 6 Randomized Basic Health Units, professionals will use only the traditional cognitive-behavioral approach advocated by the Brazilian Ministry of Health's smoking program.
89629812|NCT03207828|Experimental|Behavioral activation group|This group will receive usual care for fibromyalgia with comorbid major depression plus in-group behavioral activation.
89629813|NCT03207828|Other|Usual care|"This group of participants will only receive usual care for fibromyalgia with comorbid depression.~Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) of the Red Salud Christus, the most important private medical care network in Chile. In this clinic treatment of fibromyalgia includes administering pregabalin and pain killers (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed."
88990240|NCT03901469|Experimental|Part 1 and Part 2|ZEN003694 will be administered PO QD with Talazoparib PO QD in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
88990241|NCT03901469|Experimental|Expansion Cohort A - Combination Treatment in post-TROP2-ADC patients|ZEN003694 will be administered PO QD with Talazoparib PO QD at the RP2D in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
88990242|NCT03901469|Experimental|Expansion Cohort B - ZEN003694 Monotherapy|ZEN003694 will be administered PO QD as monotherapy at the RP2D in 28-day cycles with the option to cross-over to combination treatment of ZEN003694 PO QD with Talazoparib PO QD at the time of disease progression (but no sooner than after 6 weeks of monotherapy). Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in the US and EU.
88990243|NCT03901469|Experimental|Expansion Cohort C - Combination Treatment in TROP2-ADC-naïve patients|ZEN003694 will be administered PO QD with Talazoparib PO QD at the RP2D in 28-day cycles. Patients have histologically confirmed Triple Negative Breast Cancer and have no documented germline mutations of BRCA1 or BRCA2. Includes sites in China only.
88990244|NCT03899077|Active Comparator|Arm A|The standard hormonal treatment in combination with salvage radiotherapy is ADT by a LHRH agonist or antagonist for 24 weeks. LHRH agonists and antagonists include leuprolide, goserelin, triptorelin, and degarelix.
88990245|NCT03899077|Experimental|Arm B|Patients will receive 6 cycles (each cycle is 30 days) of the study drug (4x 60mg tablets daily in a single intake).
88990246|NCT03892096||Metastatic Lung Cancer, Colorectal Cancer or Breast Cancer|A total of 750 subjects with lung cancer, CRC and breast cancer will be consecutively enrolled. It is expected that 250 subjects will be lung cancer patients, 250 mCRC patients and 250 breast cancer patients.
88990247|NCT03885466|Experimental|Nordic walking|Nordic walking exercise intervention, 3 times per week over 12 weeks
88990248|NCT03885466|No Intervention|Control|Waiting list controls will be offered same Nordic walking intervention after 3 month follow-up measurements
88990249|NCT03880656|Experimental|Autologous BM-MNCs High Dose|Administration of autologous bone marrow mononuclear cells at High dose (700,000 cells/cc of tissue)
88990250|NCT03880656|No Intervention|Observational Control|Standard of care provided for subjects that have undergone a fasciotomy following a diagnosis of compartment syndrome. No autologous bone marrow mononuclear cells will be administered.
88990251|NCT03880656|Experimental|Autologous BM-MNCs Low Dose|Administration of autologous bone marrow mononuclear cells at a Low dose (350,000 cells/cc of tissue)
88990252|NCT03875625|Experimental|Morbid obesity- Bariatric surgery group|Morbid obese subjects who will consent to bariatric surgery
88990253|NCT03875625|Experimental|Morbid obesity-Dietitian led life style intervention group|Morbid obese subjects who will not consent to bariatric surgery but instead opt for dietitian led life style intervention
88990254|NCT03875625|Experimental|Mild obesity-Dietitian led life style intervention group|Mild- Moderate subjects assigned through a randomized controlled trial to the dietitian led life style intervention
88990255|NCT03875625|Experimental|Mild obesity-Conventional care group (control)|Mild- Moderate subjects assigned through a randomized controlled trial to conventional care
88990256|NCT03865940|Experimental|Lidocaine then Lidocaine + Guanfacine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine (Day 1).~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine."
88990257|NCT03865940|Experimental|Lidocaine + Guanfacine then Lidocaine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine (Day 1).~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine."
88990258|NCT03864068|Placebo Comparator|Placebo Treatment bid|Women with PCOS (N = 30) will receive the daily placebo (maltodextrin and inulin) in an identical fashion as the active study group and will be monitored the same.
88990259|NCT03864068|Experimental|Active Treatment with Inositol 1gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 1000 mg of myo-inositol and 25 mg of d-chiro-inositol) over the initial 3 mos RCT period.
89629814|NCT01985932|Other|Functional MRI|Subjects in this arm receive functional MRI during radiation therapy treatment planning.
89629815|NCT03220932|Experimental|Cytoreductive surgery combined with HIPEC|All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression
89629816|NCT03220932|Active Comparator|Aurelia arm|Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression
89629817|NCT02042872|Experimental|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
89629818|NCT02042872|No Intervention|No Intervention|Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.
89629819|NCT03207906|Active Comparator|Lower concentration VBP-926|VBP-926 solution applied to affected area BID
89629820|NCT03207906|Active Comparator|Higher concentration VBP-926|VBP-926 solution applied to affected area BID
89629821|NCT03207906|Placebo Comparator|Vehicle|Vehicle solution applied to affected area BID
89629822|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 1 - Every 28 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days."
89629823|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 2 -Every 21 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
89629824|NCT02374138|Active Comparator|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
89629825|NCT02374138|Experimental|Intervention|Parental stress management in addition to IMPACT DC intervention of guideline-based clinical care, education, and short-term care coordination.
89629826|NCT03227328|Active Comparator|Treatment Arm A|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
89629827|NCT03227328|Experimental|Treatment Arm B|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
89629828|NCT04821921||Patients with diabetes mellitus|Approximately 750 patients with diabetes mellitus from 3 GP practices specialized on diabetes treatment
89629829|NCT00082329|Experimental|G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers|Participants received subcutaneous injection of G-CSF (10 mcg/kg/day) for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
89629830|NCT03220620||GDT Group|receives goal-directed therapy
89629831|NCT03220620||Not GDT Group|receives no individualized goal-directed therapy
89629832|NCT02451462|Experimental|Zoledronic acid arm|Zoledronic acid
89629833|NCT02451462|No Intervention|placebo arm|placebo
89629834|NCT02451384|Experimental|routine surgery|In this arm the patients will be performed routine surgery to remove the tumors. And then we compare their circulating tumor cell countings in the pre and post-operation.
89629835|NCT02451384|Experimental|no-touch surgery|In this arm the patients will be performed no-touch surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
89629836|NCT02451384|Experimental|laparoscopy surgery|In this arm the patients will be performed laparoscopy surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
89629837|NCT03220386|Other|Emergency Department patients|All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.
89629838|NCT03207204|Active Comparator|G1 - 35% Hydrogen peroxide bleaching|In-office bleaching performed with 35% hydrogen peroxide (4 sessions, 1 session/week);
89629839|NCT03207204|Active Comparator|G2 - 30% Carbamide peroxide bleaching|In-office bleaching performed with 30% carbamide peroxide (4 sessions, 1 session/week);
89629840|NCT03207204|Experimental|G3 - Violet LED bleaching 1|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 1 session/week);
89629841|NCT03207204|Experimental|G4 - Violet LED bleaching 2|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 2 sessions/week);
89629842|NCT03207204|Experimental|G5 - Photochemical protocol 1|In-office bleaching performed Violet LED associated to 35% hydrogen peroxide (4 sessions, 1 session / week);
89629843|NCT03207204|Experimental|G6 - Photochemical protocol 2|In-office bleaching performed Violet LED associated to 30% carbamide peroxide (4 sessions, 1 session / week)
89629844|NCT03207204|Experimental|G7 - Hybrid technique 1|hybrid technique HP (Violet LED + application of 35% hydrogen peroxide + violet LED) (4 sessions, 1 session/week)
89629845|NCT03207204|Experimental|G8 - Hybrid technique 2|Hybrid technique CP HP (Violet LED + application of 30% carbamide peroxide + violet LED) (4 sessions, 1 session/week).
89629846|NCT02092311|Experimental|Combined Microscopic Varicocelectomy|Patients in this arm were operated with Combined Mini-incision Microscopic approach
89629847|NCT02092311|Active Comparator|Inguinal and Subinguinal Varicocelectomy|Patients in this arm have the same including criteria as Experimental arm but they were operated with conventional and currently popular approach of Microscopic Inguinal and Sub inguinal varicocelectomy suggested by Goldstien and associates
89629848|NCT03207360|Experimental|Pain Coping Skills|
89629849|NCT03207516|Active Comparator|Sourdough --> Brewer's Yeast|"Sourdough --> Brewer's Yeast~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
89629850|NCT03207516|Active Comparator|Brewer's Yeast --> Sourdough|"Brewer's Yeast --> Sourdough~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
89629851|NCT03207126|Other|Women needing endometrial biopsy|All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
89629852|NCT02092857|Active Comparator|34 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid
89629853|NCT02092857|Active Comparator|25 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid
89629854|NCT02092857|Placebo Comparator|Infant formula without arachidonic acid|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
89629855|NCT03220308|Other|Care-as-usual (CAU) only|Care-as-usual for children (8-16 years old) with ADHD
89629856|NCT03220308|Experimental|Mindfulness for child and parent + CAU|MYmind mindfulness training in addition to care-as-usual for children aged 8-16 years with ADHD
89629857|NCT03207048|Experimental|Active rTMS|10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 15 mins each time, 5 times per week for up to 6 weeks (interrupt for 1-2 weeks after 10 times).
89629858|NCT03207048|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation
89629859|NCT02451306|Experimental|Quetiapine|"18 patients of the risk-group will receive quetiapine (Seroquel Prolong (c)) for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~Dosages: 50mg (day 1-3), 100mg (day 4-6) and 150mg (from day 7 onwards). Administration: Quetiapine will be given once daily before bedtime, not together with a meal and swallowed as a whole."
89629860|NCT02451306|Placebo Comparator|Placebo|"18 patients of the risk-group will receive placebo for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~The placebo does not contain any psychoactive substance."
89629861|NCT02451306|No Intervention|Control-group|18 depressive patients without a heightened risk for BPD will not receive any medication apart from their standard antidepressant therapy (control-group).
89629862|NCT00167661|Experimental|Campath 1-H|Campath 1-H
88990260|NCT03864068|Experimental|Active Treatment with Inositol 2 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 2000 mg of myo-inositol and 50 mg of d-chiro-inositol) over the initial 3 mos RCT period.
88990261|NCT03864068|Experimental|Active Treatment with Inositol 3 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 3000 mg of myo-inositol and 75 mg of d-chiro-inositol) over the initial 3 mos RCT period.
88990262|NCT03863145|Experimental|1|Part 1 (Dose Escalation): 100 mg daily.
88990263|NCT03859687|Experimental|Intervention group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) plus a liquid oral vitamin A supplementation
88990264|NCT03859687|Experimental|Control group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) only, 'No vitamin A supplementation'
88990265|NCT03859388||Chronic ABMR|Single arm; patients with chronic ABMR diagnosed by Banff 2017 criteria and recommended for monthly treatment with tocilizumab will undergo monthly testing for donor-derived cell-free DNA (Allosure) and then have a follow-up biopsy after six monthly infusions of tocilizumab
88990266|NCT03848065|Experimental|V114-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of V114 on Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age). Infant participants will receive a single 0.5 mL SC injection of concomitant study vaccine [Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV) at the same time as V114-SC.
88990267|NCT03848065|Experimental|V114-IM|Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age). Infant participants will receive a single 0.5 mL SC injection of concomitant study vaccine (DTaP-IPV) at the same time as V114-IM.
89211394|NCT00832286|Experimental|Cipro|At Week 12, subjects will receive a 3-day course of oral Ciprofloxacin 500 mg every 12h.
89629863|NCT03206892|Experimental|LESS surgery|Laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using laparoendoscopic single-site surgery (single incision through the umbilicus using modified Hasson technique).
89629864|NCT03206892|Active Comparator|conventional multi-port laparoscopy|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using conventional multi-port laparoscopy (three port system using a closed technique on the umbilicus, left and right lower quadrant areas).
89629865|NCT03220542|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin
89629866|NCT03220542|Experimental|Broccoli|Broccoli Sprouts Extract + Esomeprazole + Amoxicillin + Clarithromycin
89629867|NCT03220542|Active Comparator|Triple Therapy|Esomeprazole + Amoxicillin + Clarithromycin
89629868|NCT03206580|Experimental|Concentric training|Concentric training
89629869|NCT03206580|Experimental|Concentric-eccentric training|Concentric-eccentric training
89629870|NCT03220152|Experimental|emtricitabine / tenofovir 200/300 mg|emtricitabine / tenofovir 200/300 mg Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
89629871|NCT03227094|Other|Standard OGTT|OGTT standard test at hospital (75g glucose beverage; 2-h test with plasma glucose collection)
89629872|NCT03227094|Experimental|Home-based OGTT (Beverage)|Home-based OGTT with CGM device, without glucose collection (75g glucose beverage; 2-h test: glycemia measured by CGM)
89629873|NCT03227094|Experimental|Home-based OGTT (Candy)|Home-based OGTT with CGM device, without glucose collection (75g of glucose (Jelly Beans); 2-h test: glycemia measured by CGM)
89629874|NCT03220464|Experimental|Close contacts of active pulmonary tuberculosis patients|One arm study of conducting ULDCT, chest x-ray, and IGRA
89629875|NCT02395978|Experimental|Part I: 1 PDC-1421 Capsule|1 PDC-1421 Capsule TID, p.o. after meal for 28 days
88990268|NCT03848065|Active Comparator|PCV13-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of pneumococcal 13-valent conjugate vaccine (PCV13) at Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age). Infant participants will receive a single 0.5 mL SC injection of concomitant study vaccine (DTaP-IPV) at the same time as PCV13-SC.
89629876|NCT02395978|Experimental|Part I: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 28 days
88990269|NCT03838042|Experimental|Nivolumab and Entinostat|Combination Study of Nivolumab and Entinostat
88990270|NCT03834220|Experimental|Cohort 1: Debio 1347 (Biliary Tract Cancer)|Participants with biliary tract cancer were included in this cohort to receive Debio 1347 80 milligrams (mg) tablets, orally, once daily (QD), from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 20 weeks).
88990271|NCT03834220|Experimental|Cohort 2: Debio 1347 (Urothelial Cancer)|Participants with urothelial cancer were included in this cohort to receive Debio 1347 80 mg tablets, orally, QD, from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 5.86 weeks).
89629877|NCT02395978|Experimental|Part II: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 42 days
88990272|NCT03834220|Experimental|Cohort 3: Debio 1347 (All Other Solid Tumor Histologies)|Participants with all other solid tumor histologies were included in this cohort to receive Debio 1347 80 mg tablets, orally, QD, from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 8.14 weeks).
89629878|NCT02395978|Experimental|Part II: 1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days
89629879|NCT02395978|Placebo Comparator|Part II: 2 placebo|2 placebo TID, p.o. after meal for 42 days
89629880|NCT03206658|Placebo Comparator|placebo oral capsules|Placebo capsules equal to those in the study drug, will be administered every 24 hours for the first 5 days after entry into the critical care unit
89629881|NCT03206658|Experimental|spironolactone|capsules of spironolactone 25 mg equal to placebo, will be given every 24 hours for the first 5 days after entry to the critical care unit
89629882|NCT00170157|Experimental|Arm I|Patients receive either leuprolide acetate intramuscularly (IM) or goserelin subcutaneously (SC) on days 0, 28, and 56. Patients also receive oral flutamide three times daily or oral bicalutamide once daily. Treatment with antiandrogen (AA) therapy continues for 3 months (3-4 months for patients who initiated AA therapy <= 21 days prior to enrollment) in the absence of disease progression or unacceptable toxicity. Patients receive ipilimumab IV over 90 minutes on day 7 (within 7-28 days post-initiation of AA therapy for patients who initiated AA therapy <= 21 days prior to enrollment) of AA therapy.
89629883|NCT00170157|Active Comparator|Arm II|Patients receive AA therapy as in arm I. Patients may crossover to arm II in the case of disease progression.
89629884|NCT03220074|Other|treatment|oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)
89629885|NCT03206346|Experimental|Ingavirin|Broad spectrum antiviral drug
88990273|NCT03831243|Active Comparator|Single fraction of 8 Gy|The current standard treatment will be prescribed, i.e. a 3D-conformal radiotherapy of a single fraction dose of 8.0 Gy to the metastasis with a planning target volume (PTV) margin for set-up and positioning uncertainties of 1 cm. This can be performed at any linear accelerator.
89057904|NCT04529681|Other|Control Group|Control group will be given the informational leaflets consist of stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors. Participants will be followed up until six weeks with four points of data collection; baseline, second week, fourth week and sixth week.
89629886|NCT03206346|Placebo Comparator|Placebo oral capsule|Placebo capsule identical in appearance to Ingavirin capsule
89629887|NCT02043574|Other|Stretching (Control)|Six months of stretching
89629888|NCT02043574|Experimental|Treadmill Exercise|Six months of treadmill training
89629889|NCT03206502|Experimental|Embrace+Alert App|Participants are allowed to enter the trial (to use Embrace+Alert app) whether or not they have epilepsy. People without epilepsy may use Alert in this trial even though they are not expected to have seizures, as long as they are willing to mark false positives. Since many people with epilepsy live active lives and appear perfectly healthy outwardly, it is important that their active lifestyle data not trigger false alarms. Allowing healthy participants without epilepsy to contribute active lifestyle data helps us make the detection algorithm even stronger and better.
89629890|NCT03226860|Experimental|Gait Myoelectric Stimulator|The Gait Myoelectric Stimulator device stimulates the dorsiflexor and plantarflexor muscles at the correct time for typical walking.
89629891|NCT03226860|Active Comparator|Ready, Set, Go! 5210 program|Nationwide Initiative which recommends eating 5 servings a day of fruits and vegetables, 2 hours a day or less of screen time, 1 hour/day or more of physical activity, and 0 sugary drinks/day. This program supports the current focus in pediatric physical therapy on life-long fitness in youth with disabilities.
89629892|NCT00170625|Experimental|Hycamtin|
89629893|NCT02043652|Experimental|Chloroquine and primaquine|Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.
89629894|NCT02452164|Active Comparator|Teaching group|Parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals at the first study visit.
89629895|NCT02452164|Other|Control group|Families receive the cellphone otoscope as if they had bought it themselves from the internet. After the first study week, parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals.
89629896|NCT02986204|Other|removal of ENG implant group|20 women who have an ENG implant that is difficult to feel on exam and would like to have it removed.
89629897|NCT02986204|Other|continuation of ENG implant|20 women who have are continuing to use their ENG implant.
89629898|NCT03218982|Experimental|Active Intervention|Six weekly intervention sessions (2 hours, each) that include enhanced psycho-education and discussion of AD and cultural impacts on beliefs about dementia and caregiving, management of problem behaviors, facilitation of support seeking, and mindful Tai Chi.
88990274|NCT03831243|Experimental|Single fraction of 20 Gy|Within the framework of stereotactic body radiotherapy, a single fraction dose of 20.0 Gy will be delivered to the metastasis using a PTV margin of 3-5 mm based on high-precision image-guided radiotherapy (IGRT). Therefore, only linear accelerators with the European Organization for Radiotherapy & Oncology advisory committee on radiation oncology practice (ESTRO-ACROP) specifications for SBRT can be accepted. A risk-adapted approach will be applied, aiming for the highest possible dose no less than 16 Gy, while respecting the tolerances of critical organs at risk (e.g. spinal cord, cauda equina, brainstem etc.).
88990275|NCT03830788|Active Comparator|Brachytherapy|radiation by brachytherapy: brachytherapy by Iodine 125 delivering 144 Gy to the prostate
88990276|NCT03830788|Experimental|stereotactic body radiotherapy (SBRT)|radiation by SBRT: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate. The prostate can be tracked/localized/treated thanks to the Cyberknife or a conventional linac equipped with an ExacTrac or a Calypso4D system.
88990277|NCT03822793|Placebo Comparator|Placebo|Patient will be included in this group by randomization and they will receive an intravenous perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 9 minutes, starting at the time of surgical incision.
88990278|NCT03822793|Experimental|Group 1: perfusion of 300 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
88990279|NCT03822793|Experimental|Group 2: perfusion of 500 mg Exacyl|Patient will be included in the group 2 by randomization and they will receive an intravenous perfusion of 500 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision..
88990280|NCT03822793|Experimental|Group 3: perfusion of 1000 mg Exacyl|Patient will be included in the group 3 by randomization and they will receive an intravenous perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
88990281|NCT03822793|Experimental|Group 4: perfusion of 3000 mg Exacyl|Patient will be included in the group 4 by randomization and they will receive an intravenous perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
88990282|NCT03819595|Experimental|Supervised arm|Supervised exercise. The intervention will be a free 12-week, small-group (~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
88990283|NCT03819595|Active Comparator|Control arm|"Supervised exercise.The intervention will be a Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.~After 3 months, it become supervised arm"
88990284|NCT03816358|Experimental|Arm I (anetumab ravtansine, nivolumab)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
88990285|NCT03816358|Experimental|Arm II (anetumab ravtansine, nivolumab, ipilimumab)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive ipilimumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of cycles 2-4. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
89211395|NCT00991653||Breast cancer|Diagnosed with breast cancer 1/1/2003 - 31/12/2007.
89629899|NCT03218982|No Intervention|Control|Participants will receive educational materials/pamphlets on dementia and occasional phone-calls by research assistants to maintain contact, as is the standard of care in most caregiver intervention studies.
89629900|NCT01898169|Experimental|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|
89629901|NCT03227016|Experimental|Combination Topo/Veli|Topotecan and Veliparib in increasing doses
89629902|NCT02043808||Dabigatran|
89629903|NCT02043808||Warfarin|
89629904|NCT04748991|Experimental|Intravenous Vernakalant|Patients randomized to Vernakalant will receive a bolus of 3mg/kg over 10 minutes and an observation period of 15 minutes, if the patient is still in AF, they will receive an additional 2.0mg/kg bolus of Vernakalant.
89629905|NCT04748991|Active Comparator|Intravenous Amiodarone|Patients randomized to an amiodarone arm will receive 150mg IV bolus and an amiodarone infusion of 1mg/hr x 6 hours followed by 0.5mg/hr x 12 hours.
89629906|NCT03230136|Experimental|Multimodal cardioprotection therapeutic strategy|
89629907|NCT03230136|Active Comparator|Traditional anesthetic and therapeutic|standard anesthetic procedure No intervention (Control).
89629908|NCT03120156|Active Comparator|No insoles|Control group of people with poor postural control that won't use insoles
89629909|NCT03120156|Active Comparator|Normal insoles|Control group of people with poor postural control that will get normal standard insoles.
89629910|NCT03120156|Active Comparator|Sensomotoric insoles|Control group of people with poor postural control that will get normal standard insoles.
89629911|NCT03218046|Experimental|EMDR group|This is the treatment arm that will receive EMDR therapy
89629912|NCT03119844|Experimental|Exercise and placebo phototherapy|Placebo phototherapy and Cycle ergometer exercise rehabilitation protocol
89629913|NCT03119844|Experimental|Exercise and active phototherapy|Active phototherapy and Cycle ergometer exercise rehabilitation protocol
89629914|NCT03206268||healthy eyes|
89629915|NCT03206268||uveitis eyes|
89629916|NCT03217656||Mother-child birth cohort|
89629917|NCT03206034|Experimental|Treatment|The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.
89629918|NCT03206034|Placebo Comparator|Control|The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.
89629919|NCT03120000|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
89629920|NCT03206112||Focal Dystonia|Subjects diagnosed with Focal Dystonia
89629921|NCT03206112||Healthy Volunteers|Healthy Volunteers
88990286|NCT03816358|Experimental|Arm III (anetumab ravtansine, nivolumab, gemcitabine)|Patients receive anetumab ravtansine IV over 1 hour on day 1 and nivolumab IV over 30 minutes on day 8 of cycle 1 and on day 1 of subsequent cycles. Patients also receive gemcitabine hydrochloride over 30-40 minutes on days 1 and 8. Treatment repeats every 21 or 28 days (cycle 1) for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a biopsy and collection of blood on study.
89629922|NCT03217344|Experimental|1-week|patients undergoing 1-week immobilization period
88990287|NCT03809728|Other|IBD patients|All patients with an established Crohn's disease or ulcerative colitis
89629923|NCT03217344|Experimental|3-week|patients undergoing 3-week immobilization period
89629924|NCT00176865|Active Comparator|Arm 1 - Matched sibling donor|Stem Cell Transplant: human leukocyte antigen (HLA) genotypic matched sibling donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
89629925|NCT00176865|Active Comparator|Arm 2 - Matched unrelated donor|Stem Cell Transplant: HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
89629926|NCT00176865|Active Comparator|Arm 3 - Mismatched double cord donors|Stem Cell Transplant: two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord) and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
89629927|NCT02451072|Experimental|Placebo, LSD, Ketanserin/LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject
89629928|NCT03205878|Active Comparator|Control group|Patients will receive standard care, being CPAP treatment
89629929|NCT03205878|Experimental|Intervention group|Patients will receive CPAP and telecoaching
89629930|NCT03205800|Active Comparator|Mini-screw placement|One mini-screw (8 mm length) will be placed at the buccal plate of the extraction socket one week after the atraumatic extraction of maxillary first or second premolars in one side.
89629931|NCT03205800|No Intervention|No treatment|The other extraction socket site will be untreated.
89629932|NCT03226782|Active Comparator|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
89629933|NCT03226782|Active Comparator|Long Intervention protocol|"Consisting of 29 exercises to be performed at home. The guideline is to perform each exercise 6 to 8 times in a gentle manner keeping your attention on movement.~This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect."
89629934|NCT03226626|Active Comparator|IVAD|IV antibiotic delivery (IVAD) alone as surgical site infection prevention. The intervention is IV antibiotics alone.
89629935|NCT03226626|Experimental|TAAD + IVAD|Both subcutaneous tumescent anesthesia & antibiotic delivery (TAAD) and IVADThe The intervention is subcutanious and IV antibiotics
89629936|NCT02451228||Single-group|Observational opportunistic pharmacokinetic study of 300 pregnant women receiving Indomethacin therapy as standard of care for risk of preterm birth. Receive serial blood collection from IV.
89629937|NCT02450994|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
89629938|NCT02450994|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
89629939|NCT00177255|Experimental|Docetaxel + Capecitabine|"Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.~Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days. Cycle 2 will begin on day 22."
89629940|NCT03205722||Melanoma patients with 1st-line Nivo treatment|Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
89629941|NCT02401048|Experimental|Phase 1b/ 2: Follicular lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
88990288|NCT03807414||Critically ill patients|In centres that obtained IRB approval for this prospective study, all critically ill adult patients (>18yrs) undergoing treatment with oXiris will be prospectively observed.
89211396|NCT00829946|Experimental|2|
89211397|NCT04016792|Placebo Comparator|Placebo|Placebo qd
89211398|NCT04016792|Experimental|SPN-812|200 mg SPN-812
89629942|NCT02401048|Experimental|Phase 1b/ 2: Diffuse large B-cell lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
89629943|NCT03215550||Carotid Endarterectomy|Patients who are scheduled to undergo carotid endarterectomy for symptomatic carotid artery stenosis (≥50% by NASCET criteria for men, ≥70% for women) who are above 40 years of age.
89629944|NCT00178191|Experimental|200 units Botox|200 units Botulinum-A toxin
89629945|NCT00178191|Experimental|300 units Botox|300 units Botulinum-A toxin
89629946|NCT00178191|Placebo Comparator|Placebo|Placebo
89629947|NCT03215784|Placebo Comparator|Eutrophy Control|Gelatin capsules a day, from 28ª week to 36ª week gestation.
89629948|NCT03215784|Experimental|Eutrophy+ Probiotic|Capsules gastro resistant containing 2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
88990289|NCT03801876|Experimental|Group I (PBT, Chemotherapy, Esophagectomy)|Patients undergo PBT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive chemotherapy (Choice of 3 regimens: 1. Carboplatin/Paclitaxel, 2. FOLFOX/CAPOX or 3. Docetaxel/5-FU [with capecitabine as an acceptable substitute for 5-FU]) per institutional standards while undergoing PBT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
89629949|NCT03215784|Experimental|Obesity + Fish oil|DHA (100 mg) + EPA (137 mg) a day, from 13ª week gestation to 36ª week gestation
89629950|NCT03215784|Experimental|Obesity + Probiotic|2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
89629951|NCT02046382|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
89629952|NCT02046382|Placebo Comparator|Normal Saline|Subjects will receive a 100mL dose of saline every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
89629953|NCT03205176|Experimental|AZD5153 Monotherapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine maximum tolerated dose (MTD). AZD5153 will be taken once per day (QD) or two times per day (BID) for 21 days as an oral capsule. Once the MTD is finalized, patients may be enrolled into an expansion cohort at the MTD.
89629954|NCT03205176|Experimental|AZD5153 + Olaparib Combination Therapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
89629955|NCT02046772|Experimental|Bupivacaine + Morphine Chloride|People in this arm will receive treatment with morphine chloride in addition to a low dose solution of the local intradural anaesthetic bupivacaine.
89629956|NCT02046772|Active Comparator|Bupivacaine standard dose|People in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine
89629957|NCT03205254|Active Comparator|Group A|Participants randomized to group A follow the 4-day Mediterranean diet and then the 4-day fast food diet with a 4-day washout period in between.
89629958|NCT03205254|Active Comparator|Group B|Participants randomized to group B follow the 4-day fast food diet and then the 4-day Mediterranean diet with a 4-day washout period in between.
89629959|NCT00178503|Placebo Comparator|MPH Trial-Placebo|24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase
89629960|NCT00178503|Active Comparator|MPH Trial: Low Dose|24 Participants with ASD-ADHD underwent 1 week at a low dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
89629961|NCT00178503|Active Comparator|MPH Trial: Med Dose|24 Participants with ASD-ADHD underwent 1 week at a medium dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
88990290|NCT03801876|Active Comparator|Group II (IMRT, Chemotherapy, Esophagectomy)|Patients undergo IMRT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive chemotherapy (Choice of 3 regimens: 1. Carboplatin/Paclitaxel, 2. FOLFOX/CAPOX or 3. Docetaxel/5-FU [with capecitabine as an acceptable substitute for 5-FU]) per institutional standards while undergoing IMRT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
89211399|NCT04044170|Experimental|Poziotinib|"Cohort 1 : Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC"
89629962|NCT00178503|Active Comparator|MPH Trial: High Dose|24 Participants with ASD-ADHD underwent 1 week at a high dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
89629963|NCT02376010|Active Comparator|rivaroxaban|rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
89629964|NCT02376010|Active Comparator|warfarin|warfarin orally once a day, titrated to INR of 2-3
89629965|NCT03205332|Experimental|Concreteness Training|Participants receive 1 session of training in concrete processing during the pre-intervention visit. They are then asked to engage in 30 minutes of concreteness practice daily, for 7 days.
89629966|NCT03205332|No Intervention|Control|Assessment only.
89629967|NCT03205410|Experimental|Patients with RIPC|intervention: remote ischemic preconditioning - three cycles of 5-min ischemia, achieved by inflation of blood-pressure cuff to 200 mmHg, followed by 5-min reperfusion while the cuff was deflated were applied to the upper left arm.
89629968|NCT03205410|Sham Comparator|Patients without RIPC|intervention: no - remote ischemic preconditioning - in controls, the cuff was placed around the arm but not inflated.
89629969|NCT03227250||GPI DBS|patients who had freezing of gait and underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi)
89629970|NCT02452086|Active Comparator|Low Level Laser Therapy|"In laser therapy group, group who received interventions was the patients received laser with 2 Joule/centimeters2, 90 milliwatt~, 3 days/week, for 4 weeks (12 sessions)"
89629971|NCT02452086|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the LLLT group, but the laser light was off and Guiding light was laser was on
89629972|NCT00085293|Experimental|Treatment|Starting dose 6 mg/m^2 Decitabine intravenous (IV) over 1 hour on days 1-5 and 8-12 of weeks 1 and 2 (course 1). Week 3, Iodine I 131 (131I) scanning using thyrotropin alfa injections. Participants whose scan do not demonstrate iodine uptake continue suppressive thyroid hormone therapy but no further study therapy; these participants who do show uptake undergo thyroid hormone withdrawal on weeks 4-8 and second course of decitabine (as in course 1) on weeks 7 and 8, with 131I therapy on week 9.
89629973|NCT03215628|Active Comparator|Group A - TCEUS with HLM|General neonatal cardiac surgery with HLM (art. switch, aortopulmonary shunts)
89629974|NCT03215628|Experimental|Group B - TCEUS with HLM|Surgery of the aortic arc
89629975|NCT03215628|Active Comparator|Group C - TCEUS without HLM|Neonatal cardiac surgery without HLM
89629976|NCT03215394|Experimental|Enhanced Social ABCs|Receive 4-week attention training program, followed by 12-week Social ABCs intervention. The stimuli include four gaze-contingent training tasks that will be presented on a laptop screen using custom MATLAB scripts. Each task will be presented until the infant becomes inattentive, at which point they will go to the next task or take a break. Training stimuli will be presented until toddlers become fidgety or distressed.
89629977|NCT03215394|Sham Comparator|Standard Social ABCs|Receive 4-week sham attention program, followed by 12-week Social ABCs intervention. Sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training intervention. Infants are exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (infant appropriate television clips and animations). Sham attention stimuli will be presented until toddlers become fidgety or distressed.
89629978|NCT03215394|Other|Treatment As Usual|A convenience sample of age-equivalent toddlers who meet clinical eligibility criteria but are otherwise unable or unwilling to participate in the interventions, will be used as a Treatment as Usual comparison group. The same assessments will be administered at parallel time points through an existing research study. Receive no attention training program and no Social ABCs.
89629979|NCT03215160|Experimental|Mobilization Exercise Group|Mobilization exercises in addition to classical exercises performed in the early post-op period
89629980|NCT03215160|Active Comparator|Classical Exercise Group|only classical exercises performed in the early post-op period
89629981|NCT03226314||stool sampled community patients|community patients entering emergency ward or intensive care unit in Reunion Island university hospital and having the stools sampled for bacterial analysis.
89629982|NCT03205098||Runners|To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
89629983|NCT02402062|Experimental|TH-302 + Sunitinib|TH-302 + Sunitinib. Single arm Study.
89629984|NCT03205020||women with preterm labor|
89629985|NCT03205020||women delivered at full term|
89629986|NCT02379442|Experimental|1|Target dose of 2 times 106 MSC/kg for up to 12 doses
89629987|NCT02450760|Other|Control|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. If subjects miss blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. Subjects will also receive weekly emails with their blood pressure data for the week.
89629988|NCT02450760|Other|Social Incentive|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. Subjects in this arm will also identify a social supporter who may help subjects adhere to daily blood pressure readings. If the subject misses blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. The identified social supporter will also receive these alerts, with the expectation that the social supporter will remind the subject to take their blood pressure. Both the subject and the social supporter will also receive weekly emails with their blood pressure data for the week.
89629989|NCT02048878||Insomnia group|"Assessment of physiologic hyper-arousal across the two following domains:~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
89629990|NCT02048878||Matched Control Group|"Assessment of physiologic hyper-arousal across the two following domains:~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
89629991|NCT02450838|Experimental|Adjuvanted V180 vaccine|Participants will receive one intramuscular (IM) injection of adjuvanted (with Alhydrogel™) V180 at study entry.
89629992|NCT02450838|Experimental|Nonadjuvanted V180 vaccine|Participants will receive one IM injection of nonadjuvanted V180 at study entry.
89629993|NCT02450838|Placebo Comparator|Placebo|Participants will receive one IM injection of placebo at study entry.
89629994|NCT02402296|Active Comparator|Group II (test group)|Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
89629995|NCT02402296|Placebo Comparator|Group I (control group)|Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
89629996|NCT03214302|No Intervention|control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.healthy Pregnant women with HBsAg(-), HBeAg(-)
89629997|NCT03214302|Experimental|experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation and drug withdrawal after delivery immediately, and drug withdrawal in the 6 weeks after delivery.
89629998|NCT00085839|Experimental|Erlotinib|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
89629999|NCT00085839|Active Comparator|Standard Chemotherapy|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
89630000|NCT03204864|Active Comparator|Conventional CS lead placement|Patients will be implanted with a CRT device with or without defibrillator (P/D) as per standard clinical practice, without CS lead pacing specific optimization.
89630001|NCT03204864|Experimental|RLD Group|Patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
89630002|NCT02402452|Experimental|Normal Renal Function|Participants will receive a single dose of voxilaprevir on Day 1.
89630003|NCT02402452|Experimental|Severe Renal Impairment|Participants will receive a single dose of voxilaprevir on Day 1.
89630004|NCT03204708|Active Comparator|iv analgesia|patients were given intravenously 100 mg of tramadol (contramal) 30 minutes before extubation after modified radical mastectomy.
89211400|NCT00832364|Experimental|1|U0279 and Injectable Biologic
89211401|NCT00832364|Placebo Comparator|2|Placebo and Injectable Biologic
89211402|NCT00832442||Beta blocker|
89630005|NCT03204708|Active Comparator|catheter group|patients were placed a catheter under clavipectoral fascia and 30 ml of local anesthetic solution were given via catheter for postoperative analgesia
89630006|NCT03204630|Active Comparator|Bifido|Infant formula containing Bifidobacterium breve CECT7263
89630007|NCT03204630|Active Comparator|Lfer|Infant formula containing Lactobacillus fermentum CECT5716
89630008|NCT03204630|Placebo Comparator|Control|Standard infant formula
89630009|NCT02049502|Experimental|fecal microbiota transplant|fecal microbiota transplant
89630010|NCT02260869|Active Comparator|Cooled radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 17 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A cooled radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, cooled genicular nerve radiofrequency ablation is carried out at 60 Celsius for 150 seconds.
89630011|NCT02260869|Active Comparator|Monopolar radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 16 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A conventional radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, genicular nerve radiofrequency ablation will be carried out at 80 Celsius for 90 seconds.
89211403|NCT00832442||Placebo|
89211404|NCT00824330|Other|Control Phase; Exercise Phase|"Participants act as their own control.~Control Phase:~Participants will not change their activity during the 3 month control phase (defined as no strength training and less than 30 minutes brisk walking/moderate exercise per week, no vigorous exercise) Baseline measures will be obtained.~Exercise Phase:~This phase will consist of a Titration phase followed by an Intervention Phase. During the Titration phase, under the guidance of a trainer, subjects will increase their number of steps by 20% per week until they have reached 10,000 steps or 3 months have passed. During the Intervention Phase subjects will continue to walk 10,000 steps (or the number of steps they reached in the Titration phase)."
89211405|NCT00830414|Experimental|1|
89211406|NCT00830414|Active Comparator|2|DEPO-PROVERA®
89630012|NCT03204474|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each]), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion)
89630013|NCT03204474|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each])
89630014|NCT03204318|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
89211407|NCT00830492|Active Comparator|2|In group A (n=100), the patients were stimulated conventional. They desensitized with buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg and ovarian stimulation would commence with 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
89211408|NCT00830492|Experimental|clomiphen/gonadotropin/GnRH antagonist|Patients in group B ( n=100 ) were stimulated clomiphene citrate ( ) 100 mg from cycle day three through seven and continuous gonadotropin stimulation with of r_FSH 75 IU daily from cycle day 5. Ultrasound in two group was performed on 8 cycle day. In group B 0.25 mg GnRH antagonist (Ganirelix , Organon ,Netherland ) daily was started with dominant follicle ≥14mm and in this day 75 IU human menopoasl gonadotropin (HMG) (Menogon, ferring, pharmacenticals , Germany ) increased to the initial gonadotropin . LH assessment on the day of starting antagonist was performed and if LH was >15 IU/L , cycle was cancelled. Human chorionic gonadotropin 10000 IU ((pregnyl, Organon, Oss, the Netherlands ) was given when 1 to 3 follicles reached 18 mm
89630015|NCT03204318|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
89630016|NCT03204318|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
89630017|NCT02402764|Experimental|Selinexor Treatment|"Screening period (which may last up to 28 days), followed by Selinexor treatment for qualified participants.~During the treatment period, participants will undergo physical examination every 2 weeks until Cycle 6 Day 1 (C6D1), and then every 4 weeks and assessment of tumor response every 8 weeks.~Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo a final visit (end of treatment visit)."
89630018|NCT03204006|Active Comparator|Dexmedetomidine group|35 patients will receive dexmedetomidine 0.5 µg/kg was administered intravenously using a syringe pump over 10 min sterile saline pre-induction of anesthesia.
89630019|NCT03204006|Placebo Comparator|Control group|35 patients will receive sterile saline 0.5 µg/kg was administered intravenously using a syringe pump over 10 min pre-induction of anesthesia.
89039856|NCT05921149|Experimental|Carboplatin and paclitaxel with fasting mimicking diet (FMD)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6-10 cycles in the absence of disease progression or unacceptable toxicity. A fasting mimicking diet (FMD) is consumed beginning 3 days prior to chemotherapy and on the day of chemotherapy (days -2, -1, 0 and 1 of each cycle).
89039857|NCT05910502|No Intervention|Treatment As Usual Group|This group will receive treatment as usual.
89039858|NCT05910502|Experimental|Coaching Group|Coaching Group will receive Project AFECT intervention, in addition to treatment as usual.
89039859|NCT05908253|Sham Comparator|sham neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
89039860|NCT05908253|Active Comparator|nonadaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
89039861|NCT05908253|Active Comparator|adaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
89039862|NCT05903547|Active Comparator|Dermabond Prineo Group|At time of cesarean delivery, patients in the Dermabond Prineo group will undergo skin closure with the Dermabond Prineo skin adhesive system.
89039863|NCT05903547|Placebo Comparator|Suture Group|At time of cesarean delivery, patients in the Suture group will undergo skin closure with standard subcuticular suture.
89039864|NCT05895006|Experimental|With PTSD for study|80 patients with PTSD in randomized, double-blind, controlled design
89039865|NCT05895006|Active Comparator|Health controls for study|80 healthy subjects in randomized, double-blind, controlled design
89630020|NCT02380612|Experimental|All Participants (within patient control)|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
89630021|NCT03204162|No Intervention|Teams with no CPR Coach|This will be a standardized Resuscitation team with no CPR Coach
89630022|NCT03204162|Experimental|Teams with CPR Coach|This will be a standardized Resuscitation team where one member will be the CPR Coach and provide CPR Coaching to the team.
89630023|NCT03226080|Placebo Comparator|Placebo|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given 10cc normal saline. Once skin closure has been initiated, 2mL normal saline will be administered.
89630024|NCT03226080|Active Comparator|Neuromuscular Blockade|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given IV rocuronium 0.6mg/kg in a volume of 10cc. Once skin closure has been initiated, sugammadex 200mg in 2ml will be administered.
89630025|NCT03226002|Active Comparator|Airtraq NT right nostril|nasotracheal intubation with Airtraq NT through the right nostril
89630026|NCT03226002|Active Comparator|Airtraq NT left nostril|nasotracheal intubation with Airtraq NT through the left nostril
89630027|NCT02403622|Experimental|Intervention: Fecal Microbiota Preparation|"Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.~Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor"
89630028|NCT03225924|Experimental|Experimental|Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
89630029|NCT02381392|Experimental|AV400|The nurse will use the Accuvein AV400 to assist with intravenous access. If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter without using the device. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400.
89039866|NCT05894655|Placebo Comparator|San Ysidro Health Center - Main Clinic|At the main clinic all 3 strategies will be available: walk-up testing, vending machine, and Community Health Worker (CHW) providing education.
89039867|NCT05894655|Experimental|San Ysidro Health Center - Logan Heights|A vending machine and Community Health Worker (CHW) providing education will be available at Logan Heights
89039868|NCT05894655|Experimental|San Ysidro Health Center - Lincoln Park|A vending machine and Community Health Worker (CHW) providing education will be available at Lincoln Park
89039869|NCT05894655|Experimental|San Ysidro Health Center - Chula Vista|A vending machine and Community Health Worker (CHW) providing education will be available at Chula Vista
89039870|NCT05867030|Experimental|Parsaclisib+rituximab|parsaclisib（2.5 mg QD，D1~D14/ per28 days）+rituximab ( 375mg/m2, IV, C1D1\D8\D15\D22, C2D1\C3D1\C4D1\C5D1).
89211409|NCT00830570||1|Historical control group. Patients in this group are drawn from the same plan populations as the intervention group, but they are identified during the 1-year period prior to the start of patient enrollment in the intervention group. The historical control group is closely matched with the intervention group on demographic characteristics, practice patterns, and benefit plan features that may affect resource utilization.
89211410|NCT00830570||2|Concurrent control group. Patients in this group are drawn from different set of plan populations, but they initiate warfarin treatment during the same time period as patients in the intervention group. Outcomes data for the concurrent control group will be used to evaluate whether any differences between the intervention group and the historical control group can be attributed to changes in clinical practice over time. Baseline data for the concurrent control group will help validate the incidence assumptions used in the calculation of statistical power. This use of baseline population norms is an effective means of limiting bias in quasi-experimental studies.
89211411|NCT00830570||3|Active study group. For plans participating in the active arm of the study, enrollment is offered to every patient who initiates warfarin therapy during the enrollment period (beginning in July 2007) and who meets the eligibility criteria. Patients are identified for the active study group if they have a warfarin pharmacy claim and no prior warfarin claims during the preceding 180 days. Only patients who remain eligible for the pharmacy benefit throughout the study period are included in the final sample.
89630030|NCT02381392|No Intervention|Standard|The nurse will use the standard technique for intravenous access (not using the Accuvein AV400). If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter with the help of the Accuvein AV400. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400 if they crossed over to the AV400 after two failures.
89630031|NCT03226236|Experimental|study treatment|boost radiotherapy (XRT) plus intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate (Autologous DC vaccine) plus High-Dose IL-2
89630032|NCT02986126|Active Comparator|Resources for Services|Resources for Services (RS) is an evidence-based depression QI toolkit developed for primary care, but adapted for health- and community-based programs. Protocols support training licensed providers in clinical assessment, medication management, and CBT; all staff in team management; and non-clinical staff in addressing patient safety, screening, behavioral management skills (behavioral activation, problem solving) to enable education, coordination, and referral. RS is offered as an initial 1-day / 8-hour training with follow-up through 12 webinars, 3 each on team management, medication management, psychotherapy, and case management. Programs will be invited to have a staff lead per training component, with no limit on number of staff at trainings. Training experts include a psychiatrist, psychologist/CBT trainer, case manager, support staff, and patient / community advocate liaison. All enrolled study participants will be nested within programs participating in RS.
89630033|NCT02986126|Active Comparator|Resiliency Class +|"Resiliency Classes (RC) are a manualized, 7-session, CBT, psychoeducation class, lead by community health workers, that teaches skills to enhance mood. The RC manual covers: Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation Each RC will be 90-120 minutes in duration; once a week in community settings with up to 10 participants. RC will be supplemented with automated mobile text reminders about basic concepts and follow-up for care. Half of enrolled participants will be randomized to the Resiliency Class +. As of July 12, 2018, we will be offering bus tokens and $5 for completion of a satisfaction survey."
89630034|NCT03119532|Experimental|Receive feedback email|Anesthesia care providers who receive monthly feedback emails on the participants specific quality measures
89630035|NCT03119532|No Intervention|Did not receive feedback email|Anesthesia care providers who did NOT receive monthly feedback emails on the participants specific quality measures
89630036|NCT00180297|Experimental|Mid septal site location|RV lead is placed at mid septum.
89630037|NCT00180297|Active Comparator|Apical site location|RV lead is placed in apical position
89630038|NCT02312986|Experimental|Fecal microbiota transplantation|Subjects will receive 150mL of fecal microbiota product via enema.
89630039|NCT02404168|Active Comparator|lamotrigine brand tablet1|lamotrigine tablet Lamictal
89630040|NCT02404168|Experimental|lamotrigine generic tablet1|lamotrigine tablet Teva
89630041|NCT02404168|Active Comparator|lamotrigine brand tablet2|lamotrigine tablet Lamictal
89630042|NCT02404168|Experimental|lamotrigine generic tablet2|lamotrigine tablet Teva
89630043|NCT04733937|Active Comparator|a2 Group|The infant group consuming a2 Platinum® stage 1 infant formula
89630044|NCT04733937|Active Comparator|Control Group|The infant group consuming conventional, A1 and A2 β-casein containing stage 1 infant formula
89630045|NCT04733937|No Intervention|breast feeding|
89630046|NCT02051452|Experimental|Methylphenidate|Methylphenidate
89630047|NCT02051452|Placebo Comparator|placebo|Saline
89630048|NCT00180687|Sham Comparator|Control|No intraperitoneal therapeutics (No nebulised Bupivacaine)
89630049|NCT00180687|Placebo Comparator|IP Aerosolized Normal Saline|Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
89630050|NCT00180687|Experimental|Nebulised Bupivacaine intraperitoneally|Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
89630051|NCT00180687|Active Comparator|Injected Bupivacaine intraperitoneally|Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
89630052|NCT02313454|Experimental|Intranasal Application|Intranasal Tear Neurostimulator device, intranasal application for approximately 3 minutes on Day 0 when the participant experienced an Ocular Discomfort Score (ODS) ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
89630053|NCT02313454|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device, extranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
89630054|NCT00181623|Experimental|recombinant human prolactin treatment|Open label twice daily recombinant human prolactin
89630055|NCT02404792|Active Comparator|HIV-uninfected|HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
89630056|NCT02404792|Experimental|HIV-infected|HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
89630057|NCT02383420|Experimental|Predicate & Invest-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
89630058|NCT02383420|Experimental|Predicate & Invest-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
89630059|NCT02383420|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
89630060|NCT04708132|Active Comparator|screw retained restorations|
89630061|NCT04708132|Other|implant-retained ball overdentures|
89630062|NCT00087633|Experimental|1|
89630063|NCT00087633|No Intervention|2|
89630064|NCT02384044|Active Comparator|Crest® Sensi-Stop™ Strips|Professionally Applied
89630065|NCT02384044|Active Comparator|Colgate® Sensitivity Relief Pen|Professionally Applied
89630066|NCT02384200|Experimental|Antibiotic|"1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily starting 1 week prior to planned kidney stone surgery (PCNL).~In addition, each patient receives a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin."
89630067|NCT02384200|Active Comparator|No preoperative oral antibiotics|Each patient does receive a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin.
89630068|NCT02314000|Active Comparator|SCS starting with supra-perception|Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception followed by sub-perception SCS
89630069|NCT02314000|Experimental|SCS starting with sub-perception amplitude|Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception followed by supra-perception SCS
89039871|NCT05867030|Experimental|Parsaclisib+rituximab + lenalidomide|parsaclisib（2.5 mg QD，D1~D14/ per28 days）+rituximab( 375mg/m2, IV, C1D1\D8\D15\D22, C2D1\C3D1\C4D1\C5D1)+lenalidomide( 20mg PO, D1-D21/Cycle, no more than 12cycles).
89630070|NCT02051686|Active Comparator|Tranexamic Acid|Group I will receive 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
89630071|NCT02051686|Placebo Comparator|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
89630072|NCT02407132|Active Comparator|Standard DSME|Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
89039872|NCT05862051|Experimental|Local ablative therapies (LAT) arm|"A maximum of three Local ablative therapy (LAT) modalities can be administered for each participant, with a maximum of 2 modalities per organ, provided all LAT can be delivered within 12 weeks and participant can safely resume systemic treatment within 16 weeks from randomisation.~After completing LAT, participant is to resume a further two to three months of first-line systemic treatment to a total of 6 months (including the initial 3-4 months of treatment). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion. The treating clinician may choose to discontinue systemic treatment following LAT for patients who have experienced prior intolerable toxicity."
89039873|NCT05862051|Placebo Comparator|Control arm|The first-line systemic treatment will be standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
89039874|NCT05829785||overweight group|Subjects with a body mass index (BMI) ≥ 25
89039875|NCT05829785||normal weight group|Subjects with BMI < 25
89039876|NCT05825170|Experimental|FASY L|Subjects will be consecutively included to receive FASY L in lips at level of their scar
89039877|NCT05806424||pelvic muscle awareness|
89039878|NCT05806424||not pelvic muscle awareness|
89039879|NCT05801510|Experimental|Treatment|The treatment group will receive seven sessions of CMT over a 14 week period.
89039880|NCT05801510|No Intervention|Control|The control group will be advised to continue with their usual care.
89039881|NCT05801198|Experimental|Artemisia Afra|artemisia afra 10g/ day for 14 days
89039882|NCT05801198|Experimental|Artemisia Annua|artemisia annua 10g/ day for 14 days
89039883|NCT05801198|No Intervention|No treatment|
89039884|NCT05795621|Placebo Comparator|Placebo|Participants with TED will be randomized to receive 4 intravenous infusions of Placebo with an interval of 3 weeks for phase II and 8 intravenous infusions of Placebo with an interval of 3 weeks for phase III.
89039885|NCT05795621|Active Comparator|IBI311|Participants with TED will be randomized to receive 4/8 intravenous infusions of IBI311 with an interval of 3 weeks for phase II/III.
89039886|NCT05783908|No Intervention|Without Non-magnetic screen|Radiotherapy treatment with Linac MRI without non-magnetic shielding
89039887|NCT05783908|Experimental|With non-magnetic screen|Radiotherapy treatment with Linac MRI with non-magnetic screen
88990291|NCT03799523|Experimental|Subjects undergoing breast radiotherapy|At the time of CT simulation study participants will receive temporary skin markings to be covered in clear medical grade tape. Light-based surface imaging will be used to determine alignment between the patient and the radiation machine. Radiation treatment will proceed as standard of care.
88990292|NCT03777657|Experimental|Tislelizumab (BGB-A317) + chemotherapy|Tislelizumab and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-Fluorouracil regimens are used as the backbone chemotherapy.
88990293|NCT03777657|Placebo Comparator|Placebo + chemotherapy|Placebo and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-FU regimens are used as the backbone chemotherapy.
88990294|NCT03775265|Active Comparator|Arm I (RT, chemotherapy)|Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
88990295|NCT03775265|Experimental|Arm II (RT, chemotherapy, atezolizumab)|Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
89630073|NCT02407132|Experimental|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
89630074|NCT02052544||Study patients|Patients receiving unfractionated heparin (UFH)
89630075|NCT02387008|Active Comparator|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
89630076|NCT02387008|Active Comparator|GUIDOR® membrane alone|horizontal bone augmentation with synthetic GUIDOR® membrane
89630077|NCT02387008|Active Comparator|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
89630078|NCT02387476|Experimental|FRESCA mask first night|"FRESCA mask first night (experimental device) | CPAP second night (active comparator)"
89630079|NCT02387476|Experimental|CPAP Mask first night|"CPAP Mask first night (active comparator)| FRESCA mask second night (experimental device)"
89630080|NCT00182793|Experimental|Arm I|Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®). One day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation. No more than 7 weeks later, patients proceed to course 2. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
89630081|NCT00182793|Experimental|Arm II|Patients undergo stem cell collection. Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
89630082|NCT01954875||Subjects with ALS|subjects diagnosed with amyotrophic lateral sclerosis
89630083|NCT01954875||subjects with non-ALS neurodegenerative disease|subjects diagnosed with non-ALS neurodegenerative disease
89630084|NCT01954875||healthy controls|healthy subjects as controls
89630085|NCT00183339|Placebo Comparator|Placebo|Placebo, liquid solution flexible dose 0.5 to 5ml every morning (AM)
89630086|NCT00183339|Experimental|fluoxetine|Fluoxetine, 20mg/5ml solution, flexible dose 0.5 to 5ml every AM
89630087|NCT01743989|Experimental|Nilotinib 24-month treatment|Participants were treated with nilotinib 300mg BID for 24 months and, thereafter, entered the 36-month TFR phase
89630088|NCT01743989|Experimental|Nilotinib 36-month treatment|Participants were treated with nilotinib 300mg BID for 36 months and, thereafter, entered the 24-month TFR phase
89630089|NCT01743989|Experimental|Not randomized|Participants were treated with nolotinib 300mg BID for 24 months, but did not achieve a sustained molecular response after 24 months of treatment.
89630090|NCT00183729|Experimental|Memantine (1)|Memantine for 12 weeks
89630091|NCT00183729|Placebo Comparator|Placebo (2)|Placebo for 12 weeks
89630092|NCT00185679|Experimental|Haploidentical Allogeneic Transplant Using CliniMACS System|The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
88990296|NCT03773393|Experimental|CK0801|All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one intravenous dose of CK0801 (Treg cells) on study Day 0.
88990297|NCT03764852|Experimental|outpatient laparoscopic|Patients will have laparoscopic outpatients. The procedure is identical to that performed in hospital. What changes is that the patient will return home at night if her condition allows it.
88990298|NCT03757858|Experimental|HT+ACT|
88990299|NCT03757858|Experimental|HT+ACT+PD-1|
88990300|NCT03757858|Experimental|HT+ACT+CT|
88990301|NCT03757858|Active Comparator|HT+CT|
88990302|NCT03748485|Experimental|wait and watch group|clinical local advanced colorectal cancer (cTxN1/2M0) following pre-operational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) without adjuvant chemotherapy
88990303|NCT03748485|Active Comparator|adjuvant chemotherapy group|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) with adjuvant chemotherapy
88990304|NCT03745053|Experimental|XLIMUS DES|Xlimus DES Implantation during coronary angioplasty
88990305|NCT03745053|Active Comparator|Synergy DES|Synergy DES Implantation during coronary angioplasty
88990306|NCT03734809|Experimental|pembrolizumab|"Total 51 weeks for 17 doses of pembrolizumab:~Neoadjuvant pembrolizumab-chemotherapy: 6 weeks (2 doses of pembrolizumab)~Concurrent pembrolizumab-chemoradiation: 9 weeks (3 doses of pembrolizumab~Maintenance pembrolizumab: 36 weeks (12 doses of pembrolizumab)"
89211412|NCT00837278||1 IVF|Pregnancies conceived with the use of assisted reproductive technologies. This is defined as a pregnancy conceived with all gametes being handled outside of the body.
89630093|NCT00186069|Active Comparator|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by 2 grams per hour
89630094|NCT00186069|Placebo Comparator|Normal Saline|Normal Saline 4 gram bolus, followed by 2 grams per hour
89630095|NCT01898247|No Intervention|Traditionally-trained Procedures|Patients who undergo thoracentesis procedures by traditionally-trained residents who have not undergone simulation-based mastery learning.
89630096|NCT01898247|Experimental|Simulator-trained Procedures|Patients who undergo thoracentesis procedures by residents who have undergone simulation-based mastery learning.
89630097|NCT01898325|Other|Naïve GD patients|"Naïve GD patients~Intervention: device - Fibroscan"
89630098|NCT01898325|Other|GD treated with ERT|GD treated with ERT Intervention: device - Fibroscan
89630099|NCT01898325|Other|Healthy control|Healthy control Intervention: device - Fibroscan
89630100|NCT01898325|Other|NonAlcoholic Steatohepatitis Patients|Patients with NonAlcoholic Steatohepatitis( NASH) Intervention: device - Fibroscan
89211413|NCT00837278||2 Control|Spontaneously conceived pregnancies.
89630101|NCT01605461|Experimental|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
89630102|NCT01742897|Experimental|TTS-fentanyl|Transdermal therapeutic system (TTS) fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
89630103|NCT01715831|Experimental|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.
89630104|NCT01741259|Experimental|Meperidine PCEA|Epidural Meperidine (5mg/ml) bolus of 20 mg, lockout of 30 min, hourly limit of 50 mg.
89630105|NCT01741259|Experimental|Meperidine PCEA with basal|Epidural meperidine (5mg/ml) basal rate of 10 mg/hr, bolus 20 mg, lockout 30 min, hourly limit 40 mg
89630106|NCT01715129|Experimental|11.25mg|11.25mg, SC on Day 1 and Day 92
89630107|NCT02407756|Experimental|Cohort 1|Cohort 1 will receive dupilumab dosing regimen 1
89630108|NCT02407756|Experimental|Cohort 2|Cohort 2 will receive dupilumab dosing regimen 2
88990307|NCT03734107|Experimental|PREP-DC Intervention|50 participants will be randomized to the Plan, Reflect, and Engage with Providers for Diabetes Care (PREP-DC) intervention. Participants will complete 3 intervention sessions with study interventionists and will receive text messages and other study resources during the active intervention period (3 months).
88990308|NCT03734107|No Intervention|Standard Care Comparison|50 participants will be randomized to standard care and will participate in regular diabetes clinic visits and receive standard materials on the transition to adult diabetes care, as they would have done without participation in this study.
88990309|NCT03729596|Experimental|Cohort 1|0.5 mg/kg IV every 3 weeks
88990310|NCT03729596|Experimental|Cohort 2|1.0 mg/kg IV every 3 weeks
88990311|NCT03729596|Experimental|Cohort 3|2.0 mg/kg IV every 3 weeks
88990312|NCT03729596|Experimental|Cohort 4|3.0 mg/kg IV every 3 weeks
88990313|NCT03729596|Experimental|Cohort 5|4.0 mg/kg IV every 3 weeks
89211414|NCT00837356|Experimental|Advate®/turoctocog alfa|
89630109|NCT02387554|Experimental|HGP0904+HGP0608+HGP1405|amlodipine + losartan + chlorthalidone
89630110|NCT02387554|Active Comparator|HGP0904|amlodipine
89630111|NCT02387554|Active Comparator|HGP0608|losartan
89630112|NCT02387554|Active Comparator|HGP1405|chlorthalidone
89630113|NCT02408692|Active Comparator|Normal BMI ECx1|5 normal weight women (BMI<25 kg/m2) taking 1.5mg LNG
89630114|NCT02408692|Active Comparator|Obese BMI ECx1|5 obese women (BMI >30 kg/m2) taking 1.5mg LNG
89630115|NCT02408692|Active Comparator|Obese BMI ECx2|5 obese women (BMI >30 kg/m2) taking 3mg LNG
89630116|NCT02387710|Active Comparator|Tiagabine|Tiagabine PO 12 mg before sleep
89630117|NCT02387710|Placebo Comparator|Placebo|Placebo PO before sleep
89630118|NCT02409784|Experimental|Ketogenic diet|"Pre/Post TEP study with a 4 days ketogenic diet (KD).~Interventions 1: Pre-KD = Participants did a TEP before starting the 4-day diet~Intervention 2: Post-KD = Participants did a TEP after completing the 4-day diet"
89630119|NCT02388568|Active Comparator|Lorcaserin plus Lifestyle Modification|
89630120|NCT02388568|Placebo Comparator|Placebo plus Lifestyle Modification|
89630121|NCT02388646|Active Comparator|Exercise Only|Home exercise program.
89630122|NCT02388646|Active Comparator|Brace Only|Reaction Web brace.
89630123|NCT02388646|Active Comparator|Bracing + Exercises|Reaction Web brace and home exercises.
89630124|NCT01740791|Experimental|Velpatasvir 5 mg (GT 1a)|Participants with genotype (GT) 1a HCV infection will receive velpatasvir 5 mg or placebo once daily for 3 days under fasted conditions.
89630125|NCT01740791|Experimental|Velpatasvir 25 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
89630126|NCT01740791|Experimental|Velpatasvir 50 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
89630127|NCT01740791|Experimental|Velpatasvir 100 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 100 mg or placebo once daily for 3 days under fasted conditions.
89630128|NCT01740791|Experimental|Velpatasvir 150 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
88990314|NCT03729596|Experimental|mCRPC expansion|3.0 mg/kg IV every 3 weeks
88990315|NCT03729596|Experimental|NSCLC expansion|3.0 mg/kg IV every 3 weeks
88990316|NCT03729596|Experimental|TNBC expansion|3.0 mg/kg IV every 3 weeks
88990317|NCT03729596|Experimental|Melanoma expansion|3.0 mg/kg IV every 3 weeks
88990318|NCT03729596|Experimental|SCCHN expansion|3.0 mg/kg IV every 3 weeks
88990319|NCT03727997||AKI patients stage 3|
88990320|NCT03704610|Experimental|INFLIXIMAB|Infliximab 5 mg/kg D1-D15, then infliximab every 4 weeks W6-W10-W14
88990321|NCT03704610|Other|Placebo|placebo injection D1-D15 then infliximab 5 mg/kg W6-W8-W12-W16-W20
88990322|NCT03698487|No Intervention|Retrospective Chart Review|"Specifically, it consists of:~A retrospective study (NB: ethics for this part of the overall study has been sought separately and already approved, file number 1023666).~A before/after intervention~A multiple case study (a sub-study of the before/after intervention)"
88990323|NCT03698487|Active Comparator|Intervention|"A before/after intervention~A multiple case study (a sub-study of the before/after intervention)"
88990324|NCT03682991|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
89630129|NCT01740791|Experimental|Velpatasvir 150 mg (GT 1b)|Participants with GT 1b HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
89211415|NCT00832754|Experimental|RDT+ACT group|RDT+ACT group (ACT offered to RDT positive cases only)
89211416|NCT00832754|Active Comparator|Clinical judgement+ACT group|Clinical judgement+ACT group (ACT offered to all suspected cases of malaria by clinical judgement)
89630130|NCT01740791|Experimental|Velpatasvir 150 mg (GT 2)|Participants with GT 2 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
89630131|NCT01740791|Experimental|Velpatasvir 25 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
89630132|NCT01740791|Experimental|Velpatasvir 50 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
89630133|NCT01740791|Experimental|Velpatasvir 150 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
89630134|NCT01740791|Experimental|Velpatasvir 150 mg (GT 4)|Participants with GT 4 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
89630135|NCT01740791|Experimental|Velpatasvir up to 400 mg (GT 2)|Participants with GT 2 HCV infection will receive velpatasvir up to 400 mg or placebo once daily for 3 days under fasted conditions.
89630136|NCT01740323|Placebo Comparator|Placebo|Placebo
89630137|NCT01740323|Experimental|Curcumin|500 mg BID
89630138|NCT00090051|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
89630139|NCT00090051|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
89630140|NCT01740089|Experimental|Algeron 1.5 μg/kg|Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
89630141|NCT01740089|Experimental|Algeron 2.0 μg/kg|Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
89630142|NCT01740089|Active Comparator|PegIntron|PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
89630143|NCT01739933|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 5 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr."
89630144|NCT01739933|Active Comparator|Propofol|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 10 mg/mL propofol. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the propofol group, dose will range from 5-50 mcg/kg/min."
89630145|NCT00094497|Active Comparator|EDP-M|etopodide, doxorubicin, cisplatin and mitotane
89630146|NCT00094497|Active Comparator|Sz-M|streptozotocin and mitotane
89630147|NCT01738919|Active Comparator|Non-subluxated - splinting|Conservative treatment with splinting for 6 weeks.
88990325|NCT03682991|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
88990326|NCT03682770|Experimental|dupilumab + AR101|Participant randomization of a ratio of 2 active dupilumab arms
88990327|NCT03682770|Experimental|placebo matching dupilumab + AR101|Participant randomization of a ratio of 1 placebo arm
88990328|NCT03675672|Active Comparator|Group 1|Misoprostol Oral tablet, 200mcg, QID
88990329|NCT03675672|Placebo Comparator|Group 2|Placebo Oral Tablet, 1 tab, QID
88990330|NCT03671720|Experimental|personalized vaccine|
89039888|NCT05776602||Pediatric patients with suspected or confirmed brain tumor|New method och standard MRI in clinical care
89211417|NCT00824486|Active Comparator|TIPP|Injury prevention education using TIPP materials
89211418|NCT00824486|Experimental|Safe Home Model|Injury prevention education using safe home model
88990331|NCT03661905|Experimental|Cognitive Therapy|A modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments. Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
88990332|NCT03661905|Active Comparator|Behavioural Therapy|Method of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response. Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
88990333|NCT03651271|Experimental|"Hot tumors for Advanced Metastatic Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
88990334|NCT03651271|Experimental|"Cold tumors for Advanced Metastatic Cancer"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
88990335|NCT03651271|Experimental|"Hot tumors for Advanced Prostate Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
88990336|NCT03651271|Experimental|"Cold tumors for Advanced Prostate Cancer Cohort A"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
88990337|NCT03651271|Experimental|"Cold tumors for Advanced Prostate Cancer Cohort B"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
88990338|NCT03648710|No Intervention|Enhanced Usual Care|Enhanced usual care will be standardized across sites with transition/transfer of care checklists that will be used at all sites. Enhanced usual care will minimally include (1) patient seen by the pediatric provider with the parent outside the examination room, (2) a social work consult to screen and address sociodemographic risk factors, (3) information on health insurance adequacy provided to patient, (4) adult hematologist identified, (5) adult primary care provider identified, (6) medical release signed, and (7) medical record viewable or sent to adult provider.
89039889|NCT05756673|Other|Brush Only|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes under virtual supervision in the morning. At home, participants will brush a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary.
89630148|NCT01738919|Active Comparator|Non-subluxated - operation|Operative treatment with extension block technique
89630149|NCT00094887|Experimental|Inhaled Nitric Oxide|Participants receive Inhaled nitric oxide (INO)
89630150|NCT00094887|Placebo Comparator|Placebo|Participants receive Nitrogen gas
89630151|NCT01712399|Experimental|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years.
89630152|NCT04552301|Experimental|Cognitive Processing Therapy and Targeted Asthma Education|Intervention group - Cognitive Processing Therapy and Targeted Asthma Education
89630153|NCT04552301|Active Comparator|Psychotherapy and General Asthma Education|Control group - Psychotherapy and General Asthma Education
89211419|NCT00832832|Experimental|Eyelid closure|Eyelids will be closed after administration of eye drop
89211420|NCT00832832|Active Comparator|No eyelid closure|Eyelids will not be closed after eye drop instillation
89630154|NCT00097695|Experimental|Icatibant- Randomized|Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.
89630155|NCT00097695|Placebo Comparator|Placebo-Randomized|Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.
89630156|NCT00097695|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
89630157|NCT00097695|Experimental|Untreated Patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )
89630158|NCT02096679|Experimental|[14C]-AZD9291 20mg (oral solution)|Volunteers will receive 20 mg [14C]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
89630159|NCT01950897||subjects dx'd clinically w/ muscular dystrophy|subjects with muscular dystrophy from whom muscle samples are obtained for clinical diagnosis or for any other medical purpose
89630160|NCT01950897||normal controls|subjects who do not have muscular dystrophy and from whom muscle samples are obtained for any medical purpose
89630161|NCT00195039|Experimental|All patients|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
89630162|NCT02054338|Experimental|vinflunine plus gemcitabine|vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
89630163|NCT02054338|Active Comparator|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
89630164|NCT00198081|Experimental|Surgical Candidate|COX-2 Inhibitor 6-8 weeks prior to surgery
89630165|NCT00198081|Experimental|Medical Candidate|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
89630166|NCT02054572|Experimental|[¹⁴C]Etelcalcetide|Participants received a single dose of 10 mg radiolabelled etelcalcetide administered by intravenous (IV) bolus injection at the end of hemodialysis on day 1.
89630167|NCT00100659|Active Comparator|Pegylated interferon/ribavirin|"Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.~Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets."
89630168|NCT00100659|Placebo Comparator|Pegylated interferon/placebo|Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).
89630169|NCT02055430|Active Comparator|percutaneous nephrostomy|percutaneous nephrostomy insertion (6-8 Fr in size) for initial urinary drainage followed by definitive stone management.
89630170|NCT02055430|Active Comparator|Bilateral double J ureteric stents|double J ureteric stent insertion (4.8-6 Fr JJ in size) for initial urinary drainage followed by definitive stone management.
89630171|NCT02388880|Experimental|ITPR|Use of the ITPR for 240 minutes.
89630172|NCT00101361|Active Comparator|1|oxandrolone
89630173|NCT00101361|Placebo Comparator|2|placebo
89630174|NCT01726179|Experimental|Resin infiltration|"This study is a split mouth design. One tooth with a proximal caries lesion is randomized into this arm and another tooth to the arm Control. Teeth in this arm are treated by the resin infiltration technique using Icon (DMG, Germany) according to manufactures´ instructions. In addition patients and their guardians are instructed to floss once a day and to brush with fluoridated toothpaste twice a day.~Digital bitewing radiographs will be taken at baseline and repeated after 12 months. Additionally caries risk will be evaluated."
89630175|NCT01726179|Other|Control|"This study is a split mouth design. One tooth with a proximal caries lesion is randomized into this arm and another tooth to the arm Resin infiltration. Teeth randomized into this arm do not recieve any special treatment except general oral nonivasiv treatment (flossing and brushing). Patients and their guardians are instructed to floss once a day and to brush with fluoridated toothpaste twice a day.~Digital bitewing radiographs will be taken at baseline and repeated after 12 months. Additionally caries risk will be evaluated."
89630176|NCT02410018|Experimental|Cohort 1 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 week post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
89630177|NCT02410018|Experimental|Cohort 2 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 month post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
88990339|NCT03648710|Experimental|Peer Community Health Worker|The CHW program will primarily be modeled after the highly successful IMPaCT Program developed by the Penn Center for Community Health Workers and CHOP's Youth CHW Program for Pediatric to Adult Transitions developed by our research team, which were both developed with high levels of patient input. SCD specific content and expertise from the CHW Program through the Sickle Cell Disease Association of American Philadelphia Delaware Valley Chapter and other published models will be included. Components will include: 1) development of patient-centered goals and individualized action plan around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; and 3) tailored peer support using telephone calls and/or visits
88990340|NCT03648710|Experimental|Mobile Health|All participants enrolled in the mHealth arm will download an enhanced version of iManage, which was developed by Co-Investigator Lori Crosby at and adolescents and young adult patients with SCD. Components include: 1) development of patient-centered goals around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; 3) virtual peer support where users can encourage others to complete goals, forms teams, and interact with other youth with SCD; and 4) daily symptom tracking and visual tracking of goal completion. Investigators will add with daily tailored texting.
88990341|NCT03647852|Experimental|Methylprednisolone group|In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
88990342|NCT03647852|Active Comparator|IVIG group|In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
88990343|NCT03636490|Experimental|Psychological Stress|All participants will undergo stress-inducing tasks (psychological stress intervention) using cognitive research tools.
88990344|NCT03610061|Experimental|Radiotherapy plus Durvalumab|"A minimum of 3 patients will initially be enrolled in each cohort of this arm. Patients will be allocated to a radiotherapy dose and site cohort from the schedule at registration. There will be no intra-patient dose or site escalations.~Cohorts will escalate in number of anatomical sites of radiotherapy and dose of radiotherapy given subject to safety. Durvalumab will be administered at a fixed dose every 4 weeks IV."
89630178|NCT03225846|Experimental|WVE-120102 (2 mg) or placebo|
89630179|NCT03225846|Experimental|WVE-120102 (4 mg) or placebo|
89630180|NCT03225846|Experimental|WVE-120102 (8 mg) or placebo|
89211421|NCT00837668||sarcoidosis|sarcoidosis patients undergoing clinical bronchoscopy
89211422|NCT00824642|Experimental|Group 1|Applied Acu-TENS prior to exercise
89211423|NCT00824642|Experimental|Group 2|Applied Acu-TENS prior to and during exercise
89211424|NCT00824642|Placebo Comparator|Group 3|Applied placebo TENS prior to exercise
89211425|NCT00837746||1|Women taking risedronate for 5 years
89630181|NCT03225846|Experimental|WVE-120102 (16 mg) or placebo|
89630182|NCT03225846|Experimental|WVE-120102 (32 mg ) or placebo|
89630183|NCT02410798|Experimental|TransLoc electrode|Electrode placement
89630184|NCT03225690|Placebo Comparator|serum physiologic|2 ml serum physiologic will apply via epidural catheter before surgical incision.
89630185|NCT03225690|Active Comparator|Preemptive Morphine|1 mg morphine will apply via epidural catheter before surgical incision.
89630186|NCT03225690|Active Comparator|Morphine|1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
89630187|NCT02389738|Experimental|BBB disruption with regadenoson|"This is an exploratory (pilot) study to assess whether Regadenoson can disrupt the BBB, change the barrier permeability, to enhance the temozolomide delivery to brain.~Five evaluable patients will be studied in this trial. The sample size justification is not based on statistical rationale but clinical affordability. If the investigators detect ≥ 50% increase in temozolomide brain interstitium concentrations after Regadenoson, then the investigators will consider future studies evaluating additional patients."
88990348|NCT03588299|Experimental|BAY2599023 / (DTX201)|Adult patients with severe hemophilia A, who have been previously treated with FVIII products
89630188|NCT03213132|Experimental|SHUTi for older adults|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
89630189|NCT03213132|Active Comparator|SHUTi for older adults with stepped care|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. This is the same intervention as the first arm but with the addition of personalized emails or phone calls to participants by study personnel at specific time points as a result of not completing assigned tasks.
89630190|NCT03213132|Placebo Comparator|Patient Education website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
89630191|NCT03225612|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
89630192|NCT00200343|Experimental|Ursodeoxycholic acid 150mg / day|
89630193|NCT00200343|Experimental|Ursodeoxycholic acid 600mg / day|
89630194|NCT00200343|Experimental|Ursodeoxycholic acid 900mg / day|
89630195|NCT03204084||the LTP group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving Low-temperature Plasma Surgery System(LTP group),
89630196|NCT03204084||the control group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving the conventional method using surgical micro knife and ophthalmic hemostasis(control group)
89630197|NCT03203928|Experimental|Occupational Therapy for Women with ADHD|7-week tailored intervention for women with ADHD who have difficulty carrying out student, worker, spousal, and parenting roles due to poor time management, organization of their physical environments, management of internal and external stressors, and regulation of internal and external stimulation. Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
89630198|NCT03203928|No Intervention|Control|No treatment provided.
89630199|NCT00201123|Placebo Comparator|Standard Treatment|Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy
88990349|NCT03572465||NAFLD, NASH patients|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
88990350|NCT03572465||Non-obese volunteers|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
88990351|NCT03569891|Experimental|AMT-061|"Single infusion of AMT-061~Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After study drug administration (post study drug), subjects will be monitored for tolerance to the study drug and detection of potential immediate AEs at the clinical trial site for a few hours after dosing."
88990352|NCT03569891|Active Comparator|FIX replacement (Lead-in Period)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
88990353|NCT03561220|Active Comparator|IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
88990354|NCT03561220|Active Comparator|Proton Therapy Standard of Care|As this trial is pragmatic, all treatment will be standard of care.
89630200|NCT00201123|Experimental|Aerosol Interferon-gamma|Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
88990355|NCT03561220|Experimental|Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions. This is Arm 1 of the embedded randomized trial.
88990356|NCT03561220|Experimental|Hypofractionated Proton therapy|60.0 Gy (RBE) in 20 fractions This is Arm 2 of the embedded randomized trial.
88990357|NCT03559543|Experimental|Ocoxin-Viusid®|
88990358|NCT03554278||Anemia|Stool samples from infants with anemia. Severe anemia defined as hematocrit less than 25%. Anemia defined as hematocrit greater than or equal to 25% and less than 30%.
88990359|NCT03554278||No Anemia|Stool samples from infants without anemia. No anemia defined as hematocrit equal to or greater than 30%.
88990360|NCT03549494|Experimental|Ocoxin-Viusid®|
88990361|NCT03549273|Experimental|Treatment|Glizigen® spray + Ocoxin-Visuid® oral solution
88990362|NCT03520686|Experimental|Cohort A (Experimental)|
88990363|NCT03520686|Experimental|Cohort B (Experimental)|
88990364|NCT03520686|Experimental|Cohort C (Experimental)|
88990365|NCT03520686|Active Comparator|Cohort A (Control)|
89630201|NCT00201123|Experimental|Subcutaneous Interferon-Gamma|Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
89630202|NCT01712009|Experimental|Prophylactic naproxen|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
89630203|NCT01712009|Experimental|Prophylactic loratadine|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
89630204|NCT01712009|Other|No prophylactic treatment|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
89630205|NCT03225768|Experimental|Guided Training|
89630206|NCT03212352|Placebo Comparator|Misoprostol|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
89630207|NCT03212352|Experimental|Misoprostol and Mifepristone|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).
89630208|NCT01175655|Experimental|MSC|
89630209|NCT04633395|Experimental|Music before bedtime|Participants will be listening to music before bedtime for a duration of up to 1 hour each night, in a total treatment period of 4 weeks. Participants will also receive the sleep hygiene guidelines, and be told to follow these.
89630210|NCT04633395|Active Comparator|Sleep hygiene|Participants will be given sleep hygiene guidelines, and be asked to follow these during the total treatment period of 4 weeks.
89630211|NCT00201825|Experimental|Docetaxel and Capecitabine|
89630212|NCT02390050|Active Comparator|Bexagliflozin tablets, 5 mg|Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
89630213|NCT02390050|Active Comparator|Bexagliflozin tablets, 10 mg|Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
89630214|NCT02390050|Active Comparator|Bexagliflozin tablets, 20 mg|Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
89630215|NCT02390050|Placebo Comparator|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, once daily by mouth before breakfast
89630216|NCT03203538|Experimental|Light intensity, 1000 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 1000 lux (4000 Kelvin) administered through standard room lighting.
89630217|NCT03203538|Active Comparator|Light intensity, 100 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 100 lux (4000 Kelvin) administered through standard room lighting.
89630218|NCT03203538|Experimental|Colour temperature, 7000 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 7000 K (200 lux) administered through standard room lighting.
89630219|NCT03203538|Active Comparator|Colour temperature, 2500 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 2500 K (200 lux) administered through standard room lighting.
89630220|NCT03203538|Experimental|Blue light, 455 nm|Participants work one night shift with blue LED-light (peak wavelength 455 nm) administered through standard room lighting.
89630221|NCT03203538|Active Comparator|Red light, 615 nm|Participants work one night shift with red LED-light (peak wavelength 615 nm) administered through standard room lighting.
89211426|NCT00832910||Rheumatoid Arthritis group1|This group had patients with rheumatoid arthritis
89630222|NCT04563377|Experimental|ChAdOx1.HTI and MVA.HTI vaccination|"1x dose of ChAdOx1.HTI at 5 x 10^10 vp~1x dose of MVA.HTI at 2 x 10^8 pfu"
89630223|NCT01898481||Health Care Triads|This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider.
89630224|NCT03203772|Experimental|Limb neuropathic conditions|Includes phantom limb pain, complex regional pain syndrome
89630225|NCT01711853|Experimental|Dabigatran Etexilate|patient to receive a capsule containing 75 mg of dabigatran etexilate
88990366|NCT03520686|Active Comparator|Cohort B (Control)|
88990367|NCT03520686|Active Comparator|Cohort C (Control)|
88990368|NCT03475108|Experimental|Community Health Worker Group|Patients are assigned a community health worker for one year, in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
88990369|NCT03475108|Other|Standard Diabetes Care Group|Patients receive standard diabetes care for one year. They receive a community health worker for the second year (as part of a crossover trial).
88990370|NCT03473548|Experimental|Unmonitored Polysomnography|All eligible subjects will be asked to conduct an unattended, overnight sleep study performed in their home prior to in-laboratory polysomnography, using a standard Type III portable monitor. The type III portable sleep monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
89211427|NCT00832910||2|
89211428|NCT04043702||on topiramate|"topiramate, conviban® group vs no treatment ( control group)."
89630226|NCT03212196|Active Comparator|Pancreaticogastrostomy|Pancreaticogastrostomy with external drain
89630227|NCT03212196|Active Comparator|Pancreaticojejunostomy|Pancreaticojejunostomy with transanastomotic drain
89630228|NCT01708187|Experimental|Clarix™1k graft|Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
88990371|NCT03473548|Active Comparator|In-laboratory Polysomnography|All eligible subjects will have in-laboratory polysomnography as is routinely performed in the diagnostic work up for suspected sleep disordered breathing.
89211429|NCT04043702||on empagliflozine|"empagliflozine, jardiance® vs no treatment ( control group)."
89211430|NCT04043702||on topiramate plus empagliflozine|all patients' vs no treatment ( control group).
89211431|NCT04043702||no treatment|all patients' vs no treatment ( control group).
89211432|NCT00832988||Pacemaker patients|Patients who are implanted with a SJM Zephyr™ DR device for a standard pacing indication will be eligible
89630229|NCT01708187|No Intervention|Control arm without Clarix™1k graft|Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
89630230|NCT00202449|Experimental|1|Prazosin
89630231|NCT00202449|Active Comparator|2|Paroxetine
89630232|NCT00202449|Placebo Comparator|3|Placebo
89630233|NCT03203304|Experimental|Nivolumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation."
89630234|NCT03203304|Experimental|Nivolumab and ipilimumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks."
89630235|NCT03225456|Experimental|Oxytocin|Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
89630236|NCT03225456|Placebo Comparator|Placebo|Participants will received match placebo, again in two doses in a single session
89630237|NCT03119376|No Intervention|USUAL PEER REVIEWER|Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.
89630238|NCT03119376|Experimental|COBPeer|Junior peer reviewers will be invited to participate in an online training course on peer review (COBPeer).
89630239|NCT03119376|No Intervention|GOLD STANDARD|Pairs of systematic reviewers will independently extract data from eligible reports. Reviewers involved in the data extraction will have expertise in the conduct of systematic reviews and will assess the completeness of reporting from the systematic reviewer perspective. They will not have access to the tool to avoid being influenced by the tool. The systematic reviewers will also systematically compare the primary outcome(s) reported in the manuscript and the primary outcome(s) reported in the registry and will document any discrepancies.
89630240|NCT00203229|Placebo Comparator|Placebo|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
89630241|NCT00203229|Active Comparator|Lamotrigine|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
89630242|NCT03225300|Experimental|Simultaneous integrated boost|In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.
89630243|NCT03225066|Experimental|Poly-L-Lactic Acid - Sculptra|Each area will be treated with a dose contained in a vial of Sculptra®. For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area. It will be 3 session with interval of 1 month in total.
89630244|NCT03224988||Normal Adults|
89630245|NCT03224988||MCI Adults|
89630246|NCT00203931|Active Comparator|Cetuximab|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes.
89630247|NCT00203931|Experimental|Cetuximab and Pemetrexed|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Starting on day 15 and then subsequently on day 1 of each 21 day cycle, Pemetrexed 500 mg/m2.
89630248|NCT02412982|No Intervention|Serum anti-Xa >= 0.1 IU/mL|Patients with serum anti-Xa level >= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
89630249|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 40 mg q12h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.
89630250|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 30 mg q8h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours
88990372|NCT03472092|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.
88990373|NCT03472092|Placebo Comparator|Placebo|The placebo pill will be administered once a day at home, to be taken by mouth.
88990374|NCT03472092|Active Comparator|Amitriptyline|Amitriptyline will be administered once a day at home, to be taken by mouth. Dosage will be weight-based.
88990375|NCT03472092|Active Comparator|Biofeedback-Assisted Relaxation Training (BART)|Biofeedback-Assisted Relaxation Training (BART) is a mind and body based intervention that focuses specifically on mind and body techniques such as deep breathing, muscle relaxation, and guided imagery skills to manage pain.
88990376|NCT03472092|Active Comparator|Cognitive Retraining (CR)|Cognitive Retraining (CR) is a mind and body based intervention that focuses on the use of tests of evidence and other cognitive strategies such as positive coping statements and pleasant activities and mindfulness to manage pain.
88990377|NCT03455868||Sleeve gastrectomy diabetes|70 Men and women with or without type 2 diabetes and obesity undergoing sleeve gastrectomy
88990378|NCT03455868||Control without obesity or diabetes|30 Men and women who are overweight (without obesity) and without diabetes
88990379|NCT03449251|Experimental|Substudy 1A - Apelin|In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range
88990380|NCT03449251|Experimental|Substudy 1B - Apelin/Normal Saline|In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline
88990381|NCT03449251|Experimental|Substudy 2A - Relaxin/Normal Saline|In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin
88990382|NCT03449251|Experimental|Substudy 2B - Relaxin|In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)
89039890|NCT05756673|Experimental|Brush/Rinse (LISTERINE ZERO Alcohol Mouthwash COOL MINT)|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes and then rinse for 30 seconds with LISTERINE ZERO Alcohol Mouthwash COOL MINT under virtual supervision in the morning. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary.
89211433|NCT02550080|Experimental|The prospective genetic screening arm|Prospective HLA-B*1301 screen before administrated treatment included dapsone
89057402|NCT01202773|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 24 weeks. Participants receive a 240-mg loading dose when initiating treatment.~During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Week 16, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
89211434|NCT02550080|Active Comparator|The control arm|No HLA-B*1301 screen before administrated treatment included dapsone
89630251|NCT02412982|No Intervention|Serum anti-Xa < 0.1 IU/mL|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
89630252|NCT03203616|Experimental|Kadcyla (T-DM1)|trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
89630253|NCT02450370|Active Comparator|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
89630254|NCT02450370|Experimental|Low FODMAP diet group|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
89211435|NCT00833066|Placebo Comparator|Placebo|
89211436|NCT00833066|Experimental|gpASIT 25|
89630255|NCT03203226|Experimental|EXPERIMENTAL GROUP|This protocol has an unique period or phase of 30 week. Experimental group will be composed by 30 volunteer who were previously randomly assigned to this group. This group will receive a intervention based on 30 1-hour session of Feldenkrais Method (1 hour per week).
89630256|NCT03203226|No Intervention|CONTROL GROUP|This protocol has an unique period or phase of 30 week. Control group will be composed by 30 volunteer who were previously randomly assigned to this group. They will not receive any intervention.
89630257|NCT02390908|Experimental|Site 1 Immediate PLUS intervention|Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
89630258|NCT02390908|Active Comparator|Wait-list PLUS condition|Received the PLUS intervention at 12 months post baseline
89630259|NCT02390908|Experimental|Site 2 Immediate PLUS intervention|Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
89630260|NCT02390908|Experimental|Site 3 Immediate PLUS intervention|Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
89630261|NCT02450214|Sham Comparator|Control group (C)|50 mL syringe with saline, plus 1 flask of 100 mL saline (Saline)
89630262|NCT02450214|Experimental|Ketamine group (K)|50 mL syringe with ketamine (50mg / 50ml), plus 1 flask of 100 mL saline (Ketamine)
89630263|NCT02450214|Experimental|Magnesium + ketamine group (MGK)|50mL syringe with ketamine (50mg / 50ml), plus a flask of 100ml of saline with 5 g of magnesium sulfate (Ketamine + magnesium)
89630264|NCT02450682|Active Comparator|Apixaban|30 participants prescribed Apixaban 3-14 days before and 28 days after CIED procedure.
89630265|NCT02450682|Other|Warfarin|30 participants will take stable dose of warfarin and go through the procedure without drug interrupt. The dose is adjusted by INR level. Length of treatment is 42 days, 14 days before and 28 days after the procedure.
89630266|NCT01740401|Experimental|Cyclophosphamide, Ipilimumab|"Treatment:~Cyclophosphamide 300 mg/m2 po - Day 1 of Weeks 1, 4, 7, and 10, for a total of 4 doses; (premedication prior to each dose of Cyclophosphamide 8mg Zofran po, then prn)~Ipilimumab 10 mg/kg iv - Day 3 of Weeks 1, 4, 7, and 10 for a total of 4 doses Maintenance treatment will be given on Weeks 24, 36, and 48 Ipilimumab 10 mg/kg iv"
89630267|NCT02413684|Other|Asthma Patients|Patient engagement toolkit
89630268|NCT03202836|Experimental|vaginal progesterone|Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours
89630269|NCT03202836|Other|no medication|only tocolysis plus corticosteroid for 48 hours
89630270|NCT03203070|Active Comparator|Metamizol iv|The patients will receive only intravenous analgesia with Metamizole 2g/8 hours for control of postoperative pain.
89630271|NCT03203070|Experimental|TAP block|The patients will receive intravenous analgesia with Metamizol iv 2g/8h and intraoperative laparoscopic-guided TAP block for control of postoperative pain.
89630272|NCT03209856|Experimental|Vitamin D supplement|This group will receive weekly oral 50000 international units of vitamin D supplement for 8 weeks before the start of ICSI cycle. In addition, the routine care will be given.
89211437|NCT00833066|Experimental|gpASIT 100|
89211438|NCT00833066|Experimental|gpASIT 400|
89211439|NCT02547506||Parkinson Disease (Boxing)|Individuals with Parkinson Disease who participate in boxing on a regular basis
89630273|NCT03209856|No Intervention|Routine care|This group will receive the routine care.
89630274|NCT02413918|Experimental|Open Label iloperidone|open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
89630275|NCT03209622|Experimental|A intervention|"intervention = Nicotine replacement therapy (NRT): initiated in cardiology intensive care unit, Some hours after acute coronary syndrome.~Drug: One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks. The patient leave with an appointment to the external consultation for follow-up."
89211440|NCT02547506||Parkinson Disease (Group Exercise)|Individuals with Parkinson Disease who participate in group exercise other than boxing on a regular basis
89211441|NCT02547506||Healthy Controls|Individuals without disability who participate in group exercise other than boxing on a regular basis
89211442|NCT03850808||decline in left ventricular function|This group will be patients in whom a decline in left ventricular systolic function was found.
89211443|NCT03850808||preserved left ventricular function|This group will consist of patients in whom left ventricular systolic function is preserved.
89211444|NCT02547272||Nasal and rectal samples|ICU patients with nasal and rectal bacterial samples for the presence of S Aureus
89211445|NCT02550236||LIFE Child Health|The LIFE Child HEALTH cohort is a sample of over 5.000 children and adolescents. A basic program that will be carried out annually at each study centre visit. This program includes clinical history (perinatal and past medical history, medications, allergies, immunizations, developmental history and family history) clinical examination, collection of blood, hair, stool and urine samples, anthropometry and different age-dependent questionnaires. Questionnaires are completed by the parents and starting at the age of ten years also by the child itself.
89630276|NCT03209622|Active Comparator|B: control|Intervention: Nicotine replacement therapy (NRT) initiated after hospital discharge, some days after acute coronary syndrome. The patient leave with an appointment to the external consultation for follow-up without pach of nicotine.One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks.
89630277|NCT00099021|Experimental|Prevention (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.
89630278|NCT00354874|Experimental|GW642444 50mcg|
89630279|NCT00354874|Experimental|GW642444 100mcg|
89630280|NCT00354874|Experimental|GW642444 200mcg|
89211446|NCT02550236||LIFE Child Obesity|The LIFE Child OBESITY cohort is a sample of 500 obese children and adolescents that will be assessed and compared to a lean control group (N=500) with equally detailed phenotyping including metabolic and cardiovascular evaluation. The LIFE Child OBESITY cohort (including the control group) performs the basic program of the LIFE Child HEALTH cohort plus additional parameters such as electrical bioimpedance, assessment of basal metabolic rate, oral glucose tolerance test, liver elastography and spirometry.
89211447|NCT02550236||LIFE Child Health: Pregnancy/Birth|The LIFE child Pregnancy/Birth cohort is a sample of over 1,200 pregnant women and their offspring. Prenatal examinations are conducted during the 24th to 26th and 34th to 36th week of gestation. During the first year of life, data is collected from children at 3, 6 and 12 month of age.
89630281|NCT00354874|Active Comparator|salmeterol 50mcg|
89630282|NCT00354874|Placebo Comparator|placebo|
89630283|NCT03202914|Active Comparator|Usual protein and phosphorus diet|protein: 1.3 g/kg/day, phosphorus: 16-20 mg/kg/day
89630284|NCT03202914|Active Comparator|Low protein and phosphorus diet|protein: 0.58 g/kg/day with ≥0.35 g of protein high in amino acids, phosphorus: 5-10 mg/kg/day
89630285|NCT03202914|Experimental|Very low protein and phosphorus|protein: 0.28 g/kg/day, phosphorus: 4-9 mg/kg/day; keto-acid and amino acid supplement (0.28 g/kg/day)
89630286|NCT05508646|Experimental|Intervention arm|Twelve participants will be randomized for the intervention. The music therapy intervention takes place once a week for 6 weeks via telemedicine, with the first session reserved for music therapy intake/assessment. There are 5 additional visits, once per week. The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
89630287|NCT05508646|Other|Control arm|Twelve participants will be randomized to receive a personalized music CD that they keep and can listen to as they wish.
89211448|NCT00838058|Experimental|Part1; controlled release formulation 4; 250 mg|one 250 mg controlled release tablet, once in the morning, in fasted state
89211449|NCT00838058|Experimental|Part1; controlled release formulation 4; 500 mg|2x250 mg, once in the morning, in fasted state
89211450|NCT00838058|Experimental|Part 1; controlled release formula 4; 1000 mg|4x250 mg tabs, once in the morning, in fasted state
89211451|NCT00838058|Experimental|Part 1; controlled release formulation 4; 500 mg FED|2x250 mg, once in the morning , in fed state
89630288|NCT01711619|Experimental|SQS plus OMM|subcutaneous nerve stimulation plus optimized medical management
89630289|NCT01711619|Active Comparator|OMM|optimized medical management
89630290|NCT03209466|Experimental|Standard management and Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
89630291|NCT03209466|Placebo Comparator|Standard management and physiological saline sterile solution|Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
89630292|NCT02415244||Age 0 - 18|TEE visualization of the spinal cords in patients age between 0 - 18
89630293|NCT02415244||Age 18 plus|TEE visualization of the spinal cords in patients age 18 or greater
89630294|NCT05508412|Experimental|Intervention with HRV monitor|
89630295|NCT05508412|Experimental|Intervention without HRV monitor|
89630296|NCT04485078||Axial spondyloarthritis patients|QST with clinical scales
89630297|NCT04485078||Healthy controls|QST
89630298|NCT01710527|Other|Metformin 500mg|Cross over, two treatment, two period, two sequence, cross over, single dose
89630299|NCT01710527|Other|Glucophage 500mg|Cross over, two treatment, two period, two sequence, sigle dose
89630300|NCT05507242|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
89630301|NCT05507242|Placebo Comparator|Placebo|Placebo subcutaneous injection
89630302|NCT03209544|Experimental|Intervention group|The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
89630303|NCT03209544|No Intervention|Control group|Waitlist control group. They receive access to Think Life after 12 weeks.
89630304|NCT03202992|Experimental|Dose 1 -Single Ascending Dose (SAD)|SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
89630305|NCT03202992|Experimental|Dose 2 -Single Ascending Dose (SAD)|SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
89630306|NCT03202992|Experimental|Dose 3 -Single Ascending Dose(SAD)|SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
89039891|NCT05756673|Experimental|Interdental Brush/Brush|"Participants will use their interdental brush according to their personalized mouth map, rinse with water then brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes under virtual supervision in the morning. At home, participants will brush a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. Throughout the study, only tooth brushing will be performed a second time in the evening (no interdental brush use). First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary."
89211452|NCT00838058|Experimental|Part 2; IR formulation 500mg|4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1
89211453|NCT00838058|Experimental|Part 2; IR formulation, 500 mg FED|4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.
89211454|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FASTED|2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.
89211455|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FED|2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1
89630307|NCT03202992|Experimental|Dose 4 -Single Ascending Dose(SAD)|SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
89630308|NCT03202992|Experimental|Dose 5 -Single Ascending Dose(SAD)|SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
89630309|NCT03202992|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
89630310|NCT03202992|Experimental|Dose 2 -Multiple Ascending Dose(MAD)|MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
89630311|NCT03202992|Experimental|Dose 3 -Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
89039892|NCT05756673|Experimental|Interdental Brush/Brush/Rinse (LISTERINE COOL MINT Antiseptic Mouthwash)|"Participants will use their interdental brush according to their personalized mouth map, rinse with water, brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes and then rinse for 30 seconds with LISTERINE COOL MINT Antiseptic Mouthwash under virtual supervision in the morning. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. Throughout the study, only tooth brushing will be performed a second time in the evening (no interdental brush use). First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary."
89039893|NCT05756673|Experimental|Interdental Brush/Brush/Rinse (LISTERINE ZERO Alcohol Mouthwash COOL MINT)|"Participants will use their interdental brush according to their personalized mouth map, rinse with water, brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protections Toothpaste for 2 timed minutes and then rinse for 30 seconds with LISTERINEZERO Alcohol Mouthwash COOL MINT under virtual supervision in the morning. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for the first 3 months of the study (up to visit 3). After visit 3, for the next three months until the end of the study, weekday virtual visits will drop to three times a week. Throughout the study, only tooth brushing will be performed a second time in the evening (no interdental brush use). First product use will occur at the site under supervision. Participants will be required to record their daily product use times on a participant diary."
89039894|NCT05745935|Experimental|Group A|About 50 Patients Will receive 20 units of local oxytocin infiltration before skin closure . 10 units of oxytocin will be infiltrated at the upper skin edge and 10 units of oxytocin will be infilterated at the lower skin edges at equal intervals of 2 cm in between infiltration points.
89630312|NCT03202992|Experimental|Multiple Ascending Dose (MAD) Cohort Expansion|MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
89630313|NCT03202992|Experimental|Dose 4-Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
89630314|NCT03209700|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm
89630315|NCT01706939|Experimental|Reduced Dose Radiation|Patients randomized to receive a reduced (5600 cGy) dose radiotherapy with weekly Carboplatin
89630316|NCT01706939|Active Comparator|Standard Dose Radiation|Patients randomized to receive a standard (7000 cGy) dose radiotherapy with carboplatin
89630317|NCT03209778|Active Comparator|Control group|Control participants without psychiatric nor neurological history
89039895|NCT05745935|Experimental|Group B|About 50 Patients Will receive the 10 units of local oxytocin infiltration before skin closure . 5 units will be infiltrated at the upper skin edge and 5 units will be infiltrated at the lower skin edge at equal intervals of approximately 2 cm in between infiltration points.
89630318|NCT03209778|Experimental|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
89630319|NCT03209076|Experimental|Robotic|Robotic low anterior resection
89630320|NCT03209076|Active Comparator|Laparoscopic|Laparoscopic low anterior resection
89630321|NCT05719246|Experimental|IBS Patients Doing Yoga|"All patients will fall under the arm of IBS Patients Doing Yoga and will follow the yoga videos that are assigned to them during the study. The participants are their own controls and their symptom changes will be recorded pre- and post-video watching and participation."
89630322|NCT00355810|Experimental|placebo followed by probiotic|placebo, then washout period, then Lactobacillus plantarum MF1298
89630323|NCT00355810|Experimental|probiotic followed by placebo|Lactobacillus plantarum MF1298, then washout period, then placebo
89630324|NCT03209310||The children with Cerebral Palsy|Cerebral palsy (CP) can be defined as a group of disorders of movement and posture, causing activity limitation that are attributed to nonprogressive deficits that take place in the immature brain. The motor disorders of CP are often accompanied by deficits in sensation, cognition, communication, perception, behavioral and respiratory system.
89630325|NCT03209310||Control Group|Children with typical development were included in this study
89630326|NCT05719168|Experimental|Patients with medical refractory GERD|"Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.~Participants undergo a hydrogen and emthane breath test on a seperate day."
89630327|NCT05719168|Active Comparator|Healthy controls without gastrointestinal symptoms|Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.
89630328|NCT04907500|Experimental|Multifocal IOL|Implantation of a multifocal intraocular lens
89630329|NCT03209232|Experimental|Accelerated induction|Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
89039896|NCT05740813|Experimental|ABBV-CLS-7262 Dose 1|
89039897|NCT05740813|Experimental|ABBV-CLS-7262 Dose 2|
89039898|NCT05740813|Placebo Comparator|Matching Placebo|
89039899|NCT05720000|Experimental|PDO thread with active red LED photobiomodulation (PBM)|Participants will receive the PDO thread and the intervention with PBM using red light (Newskin, MMO) 150 mW, 2J per point, 4J/cm2, 10 points, twice a week.
89039900|NCT05720000|Sham Comparator|PDO thread with sham photobiomodulation (PBM)|Participants will receive the PDO thread and the simulated intervention with PBM using Newskin, MMO.
89039901|NCT05718089|Experimental|Continuous aerobic exercise|The participants will complete a 10-min warm up, followed by 40 min of continuous aerobic exercise at an individualized intensity at 64-76% of the maximal heart rate HRmax on a bicycle ergometer/walking.
89630330|NCT03209232|Active Comparator|Per protocol|Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.
89630331|NCT05719090|Active Comparator|Autoregulated blood flow restriction|Autoregulated BFR expands as the muscle progresses into the stretch-shortening cycle.
89630332|NCT05719090|Active Comparator|Non-autoregulated blood flow restriction|Non-autoregulated BFR does not expand as the muscle progresses into the stretch-shortening cycle.
89630333|NCT05719090|Active Comparator|No blood flow restriction|This group serves as the control group for this study
89630334|NCT04485312|Active Comparator|caries preventive protocol|preventive protocol for special needs ( tooth brushing , topical fluoride and mouth wash)
89630335|NCT04485312|Other|chlorhexidine varnish added to the caries preventive protocol|chlorhexidine varnish preventive caries protocol for special needs
89630336|NCT03202680|Active Comparator|USDA Style Diet|Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
89630337|NCT03202680|Experimental|Lean Beef Diet|Healthy, low saturated fat, high in lean beef diet.
89630338|NCT01709903|Experimental|QVA149|QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg
89630339|NCT01709903|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device
89630340|NCT03202446|Experimental|Arm 1: LIT and Placebo|Patients receive laser-assisted immunotherapy along with Placebo cyclophosphamide tablets. Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
89630341|NCT03202446|Experimental|Arm 2: LIT and low-dose Cyclophosphamide|Patients will receive laser-assisted immunotherapy and low-dose cyclophosphamide (300 mg, administered orally once per week between treatment weeks 0-11 in each treatment cycle). Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
89630342|NCT03202446|Active Comparator|Arm 3: Control Arm|Patients will receive the standard of care.
89630343|NCT03202524|Active Comparator|Albumin|Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.
89630344|NCT03202524|Experimental|Fresh Frozen Plasma|Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed
89630345|NCT03202290|Other|Gambling disorder|patients suffering from gambling disorder
89630346|NCT03202290|Other|Controls|healthy controls
89630347|NCT02452242|Experimental|ABX464|
89211456|NCT02550392|Experimental|Group psychoeducation|The intervention group will receive a group psychoeducational intervention (designed in Phase 1: Qualitative study) and usual care.
89630348|NCT02452242|Placebo Comparator|Placebo|
89630349|NCT05462080||Movement Disorders Patients|
89630350|NCT03208920|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)
89630351|NCT03208920|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months
89630352|NCT03208764|Experimental|Nitric Oxide treatment|
89630353|NCT03208608||Normal hearing older adults|Older adults with normal hearing or age-related hearing loss
89630354|NCT03208998|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
89630355|NCT03208998|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
89630356|NCT03224832|Experimental|group 1|group 1 will be Pancreatoduodenectomy With Mesopancreas. Artery-first Approach
89630357|NCT03224832|Experimental|group2|group2 will be Pancreatoduodenectomy With Mesopancreas Dissection. Standard Approach
89630358|NCT00355498||1|Controls
89630359|NCT00355498||2|Mild Cognitive Impairment
89630360|NCT00355498||3|Alzheimer's disease
89211457|NCT02550392|No Intervention|Control group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
89630361|NCT00355498||4|FTD
89630362|NCT03202368|Experimental|Tocilizumab: GCA Flare or Persistent Disease Activity|Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.
89630363|NCT03202212|Experimental|Mixed on-line hemodiafiltration|Mixed on-line hemodiafiltration (mOL-HDF using FX 1000 CorDiax, Fresenius Medical Care, Bad Homburg, Germany), three sessions per week, four hours per session
89630364|NCT03202212|Active Comparator|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
89211458|NCT02547350|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy
89211459|NCT02547350|Experimental|single intravesical instillation|intravesical instillation within 24 hours postoperatively
89630365|NCT03202056|Experimental|Dry needling|Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
89630366|NCT03202056|Sham Comparator|Sham Dry needling|Sham Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
89630367|NCT03202056|No Intervention|Control|Control group. No intervention.
89630368|NCT03208842||women with previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
89630369|NCT03208842||women without previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
89630370|NCT03201822|Experimental|100 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
89630371|NCT03201822|Experimental|200 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
89039902|NCT05718089|Experimental|High intensity interval training|The training consists of 10 minutes of warm up followed by 25 minutes of high intensity interval training (5 bouts of 4 min at >85% HRmax interspaced by 4 minutes of low intensity training) and finally a 4 min cool-down.
89039903|NCT05718089|Experimental|Resistance training|The participants will complete moderate intensity whole-body resistance training. This will consist of 4 sets with 4 exercises (leg press, chest press, back row, leg extension in appropriate machines) with a brief warm-up prior to each exercise. Each set will be interspersed by 2-min breaks. Each set (including breaks) will thus equate to 2.5 min. Intensity will be set a 12-repetition max (RM, i.e., can repeated no more than 12 times) or 10 repetitions with 1-2 repetitions in reserve (i.e., 10 repetitions where failure would occur within 1-2 more repetitions).
89039904|NCT05693077|Experimental|Group A (phase 1) (N=10)|5 doses of 10E4 NTCD spores on day 0-4.
89039905|NCT05693077|Experimental|Group B (phase 1) (N=10)|5 doses of 10E7 NTCD spores on day 0-4.
89039906|NCT05693077|Placebo Comparator|Group C (phase 1) (N=4)|5 doses of placebo on day 0-4.
89039907|NCT05693077|Experimental|Group D (phase 2) (N=10)|"Based upon the colonisation results of phase 1, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all three groups in phase 2:~Option 1: 3 doses of 10E4 NTCD spores on day 0-2.~Option 2: 3 doses of 10E7 NTCD spores on day 0-2.~Option 3: 1 day of vancomycin on day -7, followed by 5 doses of 10E4 NTCD spores on day 0-4."
89039908|NCT05693077|Experimental|Group E (phase 2) (N=10)|"Based upon the colonisation results of phase 1, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all three groups in phase 2:~Option 1: 1 dose of 10E4 NTCD spores on day 0, and 2 doses of placebo on day 1-2.~Option 2: 1 dose of 10E7 NTCD spores on day 0, and 2 doses of placebo on day 1-2.~Option 3: 1 day vancomycin on day -7 followed by 5 doses of 10E7 NTCD spores on day 0-4."
89057403|NCT01202773|Experimental|90 mg LY2127399|"Given Q2W for 24 weeks. Participants receive a 180-mg loading dose when initiating treatment.~At Week 16, both responders and NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
89630372|NCT03201822|Experimental|400 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
89630373|NCT03201822|Experimental|1000 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
89630374|NCT03224286||Incubator + <1500 g|Infants currently in an incubator with a weight of less than 1500 grams will be monitored while lying on a pressure sensitive mat.
89630375|NCT03224286||Incubator + 1500 - 2500 g|Infants currently in an incubator with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
89630376|NCT03224286||Overhead warmer + <1500 g|Infants currently in an overhead warmer with a weight less than 1500 grams will be monitored while lying on a pressure sensitive mat.
89630377|NCT03224286||Overhead warmer + 1500 - 2500 g|Infants currently in an overhead warmer with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
89630378|NCT03224286||Overhead warmer + >2500 g|Infants currently in an overhead warmer with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
89630379|NCT03224286||Crib + 1500 - 2500 g|Infants currently in a crib with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
89630380|NCT03224286||Crib + >2500 g|Infants currently in a crib with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
89630381|NCT00355888|Experimental|Open label study of MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
89630382|NCT05424640|No Intervention|Baseline|Collection of baseline data 1 week before intervention
89630383|NCT05424640|Experimental|Dietary fiber 1|"15 g/day oat fiber 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
89630384|NCT05424640|No Intervention|Wash-out 1|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
89630385|NCT05424640|Experimental|Dietary fiber 2|"15 g/day dietary fiber mix I 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
89630386|NCT05424640|No Intervention|Wash-out 2|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
89630387|NCT05424640|Experimental|Dietary fiber 3|"15 g/day dietary fiber 3 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
89630388|NCT05424640|No Intervention|Wash-out 3|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
88990383|NCT03449251|Experimental|Substudy 3A - Relaxin with Apelin/Saline|In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)
88990384|NCT03449251|Experimental|Substudy 3B - Apelin with Relaxin/Saline|In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)
88990385|NCT03449251|Experimental|Substudy 4 - Apelin and Relaxin|In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin
88990386|NCT03449251|Experimental|Substudy 5 - Relaxin/Saline|In sub-study 5 Healthy participants will be allocated to 1 of 4 Relaxin dosing groups and will receive dorsal hand vein infusion of 3 incremental doses of Normal Saline/ D5W and Relaxin
88990387|NCT03447405|Experimental|Dino Egg Safety and useability|Test the usability of the device (safety for the NICU was confirmed), not the effectiveness of the parents' voice delivery for the infant. Parent and nursing questionnaires about the importance of the device availability and its usability will be collected from parents and RN staff that choose to provide the feedback.
88990388|NCT03447405|No Intervention|Standard of Care|
88990389|NCT03424421|Experimental|subscapular sling|semitendinosus subscapular sling procedure
89211460|NCT02547350|Experimental|multiple intravesical instillation|intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
89630389|NCT05424640|Experimental|Dietary fiber 4|"15 g/day rye fiber 3 weeks intervention~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
89630390|NCT05424640|No Intervention|Wash-out 4|"2 weeks~At the end of period following analyses are collected:~1 week food diary blood sample microbiome sample gut health questionnaire"
89630391|NCT03208686|Other|Intervention Group|A single-arm intervention comprised of discussion groups, text messages, and a cloud-based cellular glucometer.
89630392|NCT03224442|Experimental|PRF with immediate implants|Immediate implants placed and covered with two prf layers
89630393|NCT03224442|Active Comparator|palatal pedicle graft|immediate implant placement followed by soft tissue augmentation by oalatal pedicle graft
89630394|NCT05718388|Other|Control group (A)|They received a physiotherapy program
89630395|NCT05718388|Experimental|study Group (B)|They received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second
89630396|NCT03201744|Experimental|Moderate Neuromuscular Block|Train of four count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
89630397|NCT03201744|Experimental|Deep Neuromuscular Block|Post tetanic count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
89630398|NCT05718310|Active Comparator|Nitroglycerin|Nitroglycerin diluted in 250 ml of sodium chloride 0.9% will be administered once via an infusion pump intravenously, at a dose of 0.5 μg/kg/min in 20 minutes.
89630399|NCT05718310|Placebo Comparator|Saline|250 ml of sodium chloride 0.9% will be administered intravenously in 20 minutes via an infusion pump.
89630400|NCT03201978|Experimental|GSK2894512 cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
88990390|NCT03424343||cancer survivor, parents, sibling|study samples adolescent and young adult survivors of pediatric cancer, their parents, and one sibling; they are assessed using self-report questionnaires, so no intervention takes place
88990391|NCT03418480|Experimental|RNA Vaccine A|"Arm 1A: 15 (6+9) patients with previously treated HPV16+ head and neck squamous cell carcinoma receiving increasing doses of HPV vaccine.~- COMPLETE no longer recruiting"
88990392|NCT03418480|Experimental|RAN Vaccine B|"Arm 1B: 29 (15+14) patients with HPV16+ advanced disease receiving increasing doses of HPV vaccine.~OPEN to recruitment"
88990393|NCT03410121|Other|Standard 1 : Thoracic location|The intervention is characterized by the randomization into thoracic arm which means that patients will have an implantable Venous Access Device implanted into thoracic location
88990394|NCT03410121|Other|Standard 2 : Humeral location|The intervention is characterized by the randomization into humeral arm which means that patients will have an implantable Venous Access Device implanted into humeral location
88990395|NCT03409198|Active Comparator|Arm A|Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
88990396|NCT03409198|Experimental|Arm B|Chemo + ipilimumab + nivolumab
88990397|NCT03393858|Experimental|Immunotherapy plus Hyperthermia|
88990398|NCT03391921|Active Comparator|ARM B: 3 doses (0, 2 and 6 months)|ARM B: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 3 doses at 0,2 and 6 months intramuscularly
88990399|NCT03391921|Experimental|ARM A: 2 doses (0 and 6 months )|ARM A: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 2 doses at 0 and 6 months intramuscularly. A third facultative dose will be given if antibodies measured at month 7 are insufficent.
88990400|NCT03378336||Observational Group|This is an observational study with only one group/cohort with no intervention
88990401|NCT03375203|Placebo Comparator|Placebo|Participants will receive matching placebo to JNJ-42847922 as oral capsules at normal study bedtime on Nights 1 through 14.
88990402|NCT03375203|Experimental|JNJ-42847922 5 milligram (mg)|Participant will receive JNJ-42847922 5 mg dose as oral capsules at normal study bedtime on Nights 1 through 14.
88990403|NCT03375203|Experimental|JNJ-42847922 10 mg plus Placebo|Participant will receive JNJ-42847922 10 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
88990404|NCT03375203|Experimental|JNJ-42847922 20 mg plus Placebo|Participant will receive JNJ-42847922 20 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
89630401|NCT03201978|Placebo Comparator|Vehicle cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
89630402|NCT03224208|Experimental|Single arm|"Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28. Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle until disease progression.~Treatments will be continued until the development of progressive disease (as per Investigator assessment), unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor."
88990405|NCT03375203|Experimental|Zolpidem plus Placebo|Participants will receive Zolpidem 5 mg plus one placebo capsule or 10 mg dose as oral capsule at normal study bedtime on Nights 1 through 14.
89630403|NCT05718232|Experimental|SBRT+TACE+Lenvatinib|Patients in SBRT+TACE+Lenvatinib group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib. SBRT will begin within 3 weeks after the first TACE.
89630404|NCT05718232|Active Comparator|Lenvatinib|Patients in Lenvatinib group will take oral lenvatinib alone.
89630405|NCT02450448||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
89630406|NCT02450448||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
89630407|NCT02450448||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
89630408|NCT02450448||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
89630409|NCT00355966|Active Comparator|A|In group A, immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
89630410|NCT00355966|Active Comparator|B|In Group B immediate induction of labour will be done by application of vaginal PGE2 gel 0.5 gm at an interval of 6 hours , a maximum of 2 doses.
89630411|NCT03208218|Experimental|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
89630412|NCT03208218|Active Comparator|Revlimid cap.|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
89630413|NCT05372380|Experimental|Sequence F/AE/F+AE|A total of 32 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(F, AE, F+AE) assigned to on sequence group in Period 1, Period 2, and Period 3.
89630414|NCT03201276||Drug group|patients taking glucosamine
88990406|NCT03367702|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy (IMRT) once daily 5 fractions per week for 28 fractions over less than 32 business days.
88990407|NCT03367702|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo Stereotactic Body Radiation Therapy (SBRT) at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.
88990408|NCT03365882|Experimental|Arm I (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88990409|NCT03365882|Experimental|Arm II (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may optionally crossover to Arm I.
88990410|NCT03360630|Experimental|Anti-PD-1 plus DC-CIK|
88990411|NCT03360630|Active Comparator|Anti-PD-1 alone|
88990412|NCT03345069||Infants born very preterm|This is a single group prospective longitudinal, multisite cohort study of very preterm infants born at or below 32 weeks gestational age at birth
88990413|NCT03339115|Experimental|Cardiovalve Transfemoral Mitral Valve|Mitral replacement valve delivered through a transfemoral access and transseptal approach
88990414|NCT03301012|Active Comparator|Recovery Support as Usual Control|Participants in the control and experimental condition will have access to post treatment recovery support services as usual.
88990415|NCT03301012|Experimental|Smartphone Addiction Recovery Coach (SARC) - Assisted Relapse Prevention|Participants in the experimental condition will receive a smartphone, a calling/texting/data plan, and the SARC-YA mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle.
88990416|NCT03253705||Controls|Healthy Controls
88990417|NCT03253705||Research Subjects|Research Subjects already enrolled on other NIH protocols
89211461|NCT00833144||1|Congestive Heart Failure
89039909|NCT05693077|Placebo Comparator|Group F (phase 2) (N=3 or 6)|"Based upon the colonisation results of phase 1, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all of the groups:~Option 1 (N=6): 3 doses of placebo on day 0-2.~Option 2 (N=6): 3 doses of placebo on day 0-2.~Option 3 (N=3): 1 day vancomycin on day -7, followed by 5 doses of placebo on day 0-4."
89039910|NCT05693077|Experimental|Group G (phase 3) (N=10)|"Escalation to the third phase will only be done if option 3 is selected in phase 2. Based upon the colonisation results of phase 2, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all of the groups in phase 3:~Option 1: 1 day vancomycin on day -7, followed by 3 doses of 10E4 NTCD spores on day 0-2.~Option 2: 1 day vancomycin on day -7, followed by 3 doses of 10E7 NTCD spores on day 0-2.~Option 3: 5 days of vancomycin on day -11 until day -7, followed by 5 doses of 10E4 NTCD spores on day 0-4."
89039911|NCT05693077|Experimental|Group H (phase 3) (N=10)|"Escalation to the third phase will only be done if option 3 is selected in phase 2. Based upon the colonisation results of phase 2, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all of the groups in phase 3:~Option 1: 1 day of vancomycin on day -7, followed by 1 dose of 10E4 NTCD spores on day 0, and 2 doses of placebo on day 1-2.~Option 2: 1 day of vancomycin on day -7, followed by 1 dose of 10E7 NTCD spores on day 0 and 2 doses of placebo on day 1-2.~Option 3: 5 days of vancomycin on day -11 until day -7, followed by 5 doses of 10E7 NTCD spores on day 0-4."
89039912|NCT05693077|Placebo Comparator|Group I (phase 3) (N=3)|"Escalation to the third phase will only be done if option 3 is selected in phase 2. Based upon the colonisation results of phase 2, there are three dosing options for this group, one of the three options will be chosen, the chosen option number will be congruent for all of the groups in phase 3:~Option 1: 1 day of vancomycin on day -7, followed by 3 doses of placebo on day 0-2.~Option 2: 1 day of vancomycin on day -7, followed by 3 doses of placebo on day 0-2.~Option 3: 5 days of vancomycin on day -11 until day -7, followed by 5 doses of placebo on day 0-4."
89039913|NCT05692271|Experimental|Propranolol|Medication treatment regimen will consist of 12 weeks of 40 mg immediate-release propranolol BID
89039914|NCT05692271|Placebo Comparator|Placebo|Matching placebo will be administered BID for 12 weeks
89039915|NCT05683925|No Intervention|baseline|Participants will receive no stimulation, the electrode will be placed in the ear in a random position and turned off. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
89039916|NCT05683925|Active Comparator|taVNS100|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
89039917|NCT05683925|Active Comparator|taVNS25|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
89039918|NCT05683925|Sham Comparator|sVNS|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
89039919|NCT05679726|Experimental|Intervention group (reflexology group)|The group in which reflexology massage (foot massage) was applied once a week for 20 minutes (10 minutes on each foot) for a total of 4 weeks, and the pain scale and fatigue and stress level were measured once a week at the beginning of the study and at the end of the study 4 weeks later.
89039920|NCT05679726|No Intervention|Control group|Pain scale once a week for 4 weeks without any application, and fatigue and stress level at the beginning of the study and at the end of the study after 4 weeks were measured in the group.
89039921|NCT05651360||Abdominal Pain|Participants under evaluation for an acute abdominal condition who are referred to CT of the abdomen and pelvis.
89211462|NCT00833144||2|Patients without congestive heart failure
88990418|NCT03223766||Participants|Participants will be those enrolled to receive proton therapy on other protocols at SJCRH on or after November 18, 2015.
88990419|NCT03208283|Active Comparator|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
89039922|NCT05648045||Overweight|BMI Cut-Off Points (kg/m²) by International Obesity Task Force; IOTF Overweight (including obesity) ≥25.00
89039923|NCT05648045||Obese|"BMI Cut-Off Points (kg/m²) by International Obesity Task Force; IOTF~Obese ≥30.00"
89039924|NCT05648045||Normal-weight|"BMI Cut-Off Points (kg/m²) by International Obesity Task Force; IOTF~Healthy Weight - 18.5-24.99"
89039925|NCT05647889|Experimental|Jet lidocaine group|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
89039926|NCT05647889|Experimental|Ice group|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
89039927|NCT05647889|Active Comparator|Control group|Standard PVC procedure will be applied
89630415|NCT05718076||group 1|Eyes are categorized by fundus META-PM as grade 0
89630416|NCT05718076||group 2|Eyes are categorized by fundus META-PM as grade 1
89630417|NCT05718076||group 3|Eyes are categorized by fundus META-PM as grade 2
89039928|NCT05645341||Eligible participants for smartphone-based ocular surface tumors diagnosis|
89630418|NCT03224364|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC
89630419|NCT03224364|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
89630420|NCT05370118|Experimental|Telerehabilitation physical activity behavioral (TPAB) intervention|Individuals in the TPAB intervention will participate in a weekly session for 12 weeks with their primary caregiver and the research interventionist (RH). Established behavior-change techniques will be used in the TPAB intervention, based largely on the combination of the Social Cognitive Theory, Control Theory, and Operant Conditioning,43 including behavioral techniques, and patient-centered communication (e.g., motivational interviewing).44 The behavior-change techniques are designed to target and improve daily steps. Individuals in the CTL group will receive usual care and no intervention over the 12 weeks.
89630421|NCT05370118|No Intervention|Control Group|Individuals in the CTL group will receive usual care and no intervention over the 12 weeks.
89630422|NCT03201510||Observational|Observational study
89630423|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
89630424|NCT03201588|Experimental|Formulaid|Formulaid 2:1 Arachidonic acid/Docosahexaenoic acid (AA/DHA). Enteral supplement of AA (0,1-1ml) (100mg(kg/day) and DHA (50mg/kg/day) from birth to 40 weeks postmenstrual age in addition to conventional parenteral fatty acid treatment with Clinoleic
89630425|NCT03201588|No Intervention|Clinoleic|"Sterile fat emulsion [containing a mixture of refined olive oil (approximately 80%) and refined soya oil (approximately 20%)] 200 g, egg lecithin (purified egg phospholipids) 12 g, glycerol 22.5 g, sodium oleate 0.3 g and Water for Injections to 1,000 mL (final pH between 6.0-8.0).~One of the active ingredients, soya oil, contains ascorbyl palmitate as an antioxidant (free radical scavenger), in the concentration of 0.15 mg/g of oil."
89630426|NCT02979106|Experimental|oral fructose load|test meal calculated to provide 25% of basal energy requirement containing 13C-labeled fructose (0.35 g/kg), protein (0.21 g/kg) and lipid (0.22 g/kg).
89630427|NCT03201432|Other|Bare metal stent (BES) group|Percutaneous vertebral artery stenting using bare metal stents (Boston Scientific：Express SD) in patients randomized to BES group
89630428|NCT03201432|Experimental|Drug eluting stent (DES) group|Percutaneous vertebral artery stenting using drug eluting stents (Liaoning Biomedical Materials R&D Center Co., Ltd. ：YINYI) in patients randomized to DES group
89630429|NCT03201354|Active Comparator|Filtration surgery with Express|Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)
89630430|NCT03201354|Active Comparator|Non penetrating surgery|- Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)
89630431|NCT03119298||High-fear-of-physical-activity group|Group members with high fear of physical activity
89630432|NCT03119298||Low-fear-of-physical-activity group|Group members with low fear of physical activity
89630433|NCT03119298||Control group|Healthy subjects matched for age and sex
89630434|NCT02451774|Experimental|Pentoxifylline Plus Chemotherapy|"Pentoxifylline: 10-20 milligrams per kilogram, doses daily by oral, for 30 days.~Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine"
89630435|NCT02451774|Placebo Comparator|Placebo Plus Chemotherapy|Placebo: double blind period, one doses daily for 30 days. Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine
89630436|NCT03119220|Other|Low informational support|After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only.
89630437|NCT03119220|Other|high informational support|The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.
89630438|NCT03201120|Experimental|Outdoor Sun Exposure Behavior|"A convenience sample of white, English-speaking adults ages 18 to 49 will be recruited via online advertisements in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 120 adults to test outdoor UV exposure messages. The investigators will quota sample to ensure representation across age and gender groups.~The inclusion criteria are that adults must be white, must be between 18-49 years old and must speak English."
88990420|NCT03208283|Active Comparator|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
88990421|NCT03190811|Experimental|Anti-PD-1 plus DC-CIK|
88990422|NCT03190811|Active Comparator|Anti-PD-1 alone|
88990423|NCT03187535|Experimental|Transcutaneous Electrical Acupoint Stimulation|"Subjects in the Transcutaneous Electrical Acupoint Stimulation (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV."
88990424|NCT03187535|Sham Comparator|No Transcutaneous Electrical Acupoint Stimulation|"Subjects in the No Transcutaneous Electrical Acupoint Stimulation group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered."
88990425|NCT03181789|Experimental|Group 1 (Treatment): p24CE1/2 pDNA + p55^gag pDNA + IL-12 pDNA|Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
88990426|NCT03181789|Placebo Comparator|Group 1 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
89211463|NCT00824798||haemophiliacs A and B|haemophiliacs A and B mild, moderate or severe from 4 to 80 years old, with or without inhibitors.
89211464|NCT00833222||Full Term Infants|Infants born between 37 4/7 weeks and 42 3/7 weeks gestation.
89211465|NCT00833222||Preterm Infants|Infants born between 32 4/7 weeks and 35 3/7 weeks gestation.
89211466|NCT00838214|Experimental|budesonide|3mg capsules 3x/day for 6 months
89211467|NCT00838214|Active Comparator|prednisone|5mg tablet, 40mg starting dose titrated to 10mg over 3 months
89211468|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 1)|Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
89211469|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 2)|Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
89630439|NCT03201120|Experimental|Indoor Tanning Behavior|"A convenience sample of white, English-speaking females ages 18 to 25 will be recruited via online advertisements and flyers in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 60 adults to test indoor tanning messages.~The inclusion criteria are that adults must be white, female, must be between 18-25 years old, must have used an indoor tanning bed at least once in the past 12 months, and must speak English."
89630440|NCT02448342|Experimental|ReDS Guided Treatment|After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
89630441|NCT02448342|Active Comparator|Standard of Care- Control arm|After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
89630442|NCT00355576|Experimental|Minocycline + Creatine|Minocycline 100 mg BID and Creatine 10 g BID
89630443|NCT00355576|Experimental|Celecoxib + Creatine|Celecoxib 400 mg BID and Creatine 10 g BID
89630444|NCT03195582|Experimental|Test group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the test group, Corsodyl gel 1% Chlorohexidine will be applied on the implant and the healing abutment. Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
89630445|NCT03195582|No Intervention|CONTROL group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the control group, Corsodyl gel 1% Chlorohexidine will not be applied on the implant and the healing abutment). Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
89630446|NCT05334940||Atopic disorders|Patients with at least 2 atopic disorders who are eligible for systemic therapy with biologics
89630447|NCT02448264|Experimental|BCX7353|BCX7353 capsules administered orally
89630448|NCT02448264|Placebo Comparator|Placebo|Placebo to Match BCX7353 capsules, administered orally
89630449|NCT02448186|Experimental|ESTEEM|cognitive behavioral treatment adapted to improve depression, anxiety, and co-occurring health risks (i.e., alcohol use, sexual compulsivity, condomless sex) among young adult gay and bisexual men by reducing minority stress processes that underlie sexual orientation-related mental health disparities
89630450|NCT02448186|No Intervention|Waitlist|3-month waitlist control
89630451|NCT03201042||1a:Lyme patients- Erythema Migrans(EM)rash present|Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
89630452|NCT03201042||1b:Lyme patients no typical EM|Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
89630453|NCT03201042||Cohort 2: healthy controls|Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
89630454|NCT05278468||case group|Adult Egyptian participants attending the diagnostic center at faculty of Dentistry, Cairo University who had positive real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
89630455|NCT05278468||control group|Adult Egyptian participants attending the diagnostic center at faculty of Dentistry, Cairo University with negative positive real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
89630456|NCT02979028|Experimental|TEAS group|Electric stimulation was given through electrode attached to acupoints SP6 and ST36 .TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
89630457|NCT02979028|Sham Comparator|Sham group|Non-acupoint is located 2cm inward to the specific acupoints.TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
89630458|NCT02979028|Placebo Comparator|Control group|Control patients will receive the same treatment without electrical stimulation.
89630459|NCT03223818|Experimental|Fast-track Arm|Patients recruited will undergo ERAS perioperative program.
89630460|NCT03223818|No Intervention|Conventional Group|Patients recruited to conventional group will undergo conventional perioperative program
89630461|NCT04730518|Experimental|Yoga-based Group Therapy|"The yoga-based group therapy (YBGT) involves a four-week intervention with weekly group therapy sessions in addition to TAU. The fifty-minute session takes place with a group size of max. 10 participants and was held once a week by a psychologist who is experienced in yoga-based therapy.~A yoga session starts with breathing exercises (pranayama), followed by various exercises in standing, sitting and lying down (asanas), which are accompanied by mindful instructions from the psychologist. Every yoga session ends with a final relaxation (shavasana), which can take the form of a body scan, for example."
89630462|NCT04730518|Active Comparator|Treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
89630463|NCT02449980|Active Comparator|Primary Surgery Group|Patients randomized to the primary surgical intervention group will undergo VATS (video-assisted thoracoscopic surgery), apical blebectomy and mechanical pleurodesis during the initial hospital admission by the admitting staff surgeon. The general principles of the surgical technique consist of a 3-port thoracoscopic approach, stapled blebectomy, apical mechanical pleurodesis, and placement of chest tube . Variations of this technique will be at the discretion of the surgeon.
89630464|NCT02449980|Active Comparator|Initial Non-operative management|Those randomized to the control group will be admitted and their chest tube or percutaneous drainage catheter managed according to standard protocol. This consists of a minimum of 48 hours of Pleur-Evac suction and daily chest radiographs. The drainage tube is then placed to water seal when resolution of the pneumothorax is documented by x-ray, as well as absence of an air leak. If there are no clinical or radiographic changes after a water seal period, the chest tube is then removed. A post-removal chest radiograph is obtained and the patient is discharged if clinical and radiographic criteria are met.
89630465|NCT04484844|Experimental|Shield Force Plus Varnish|Shield force plus (SFP), Self-reinforcing (SR) monomer technology supplied in the form of one component self-etching light-cured dental adhesive, which is characterized by an SR monomer component that penetrates the tooth substrate. Multi-point interactions with apatite calcium and three-dimensional cross-linking occur reactions.it forms a thin even, hard coating on the tooth surface that gives the tooth substrate a superior binding power.
89630466|NCT04484844|Active Comparator|Sodium Fluoride varnish|Topical application of varnish fluoride (sodium fluoride NaF) effect on exposed dentine as a desensitizing agent, the varnish fluoride process is caused by the reaction between NaF and calcium ions resulting in calcium fluoride crystals being deposited on the openings of the dentinal tubules that decrease pain.
89630467|NCT03119454||Patients receiving diprospan|Patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.
89630468|NCT03119454||Control subjects|Patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.
89630469|NCT04673656|Placebo Comparator|Test Group 1|Group 1 will receive 84 days of placebo BID
89630470|NCT04673656|Active Comparator|Test Group 2|Group 2 will receive 84 days of 0.5 g of BKR-017 BID
89630471|NCT04673656|Active Comparator|Test Group 3|Group 3 will receive 84 days of 1.0 g of BKR-017 BID
89039930|NCT05631756|Experimental|Patient Population|All patients included in the study, meaning patients in the ICU presenting an interstitial syndrom no matter the aetiology
89039931|NCT05622279|Experimental|percutaneous tenotomy + PRP|There will be a single arm receiving the treatment being evaluated
89039932|NCT05606237|Experimental|Low Level Red Light Treatment Arm|On top of wearing single vision spectacles, subjects in the intervention group will receive low-level red light treatment twice a day from Monday to Friday, with each treatment lasting for 3 minutes at a minimal interval of 4 hours.
89039933|NCT05606237|No Intervention|Control Treatment Arm|Subjects in the control group will wear single vision spectacles.
89039934|NCT05597345|Experimental|Experimental: Treatment|Selinexor 40mg weekly for up to 12 cycles. Each cycle will be 28 days in length.
89630472|NCT04673656|Active Comparator|Test Group 4|Group 4 will receive 84 days of 1.5 g of BKR-017 BID
89039935|NCT05576974|Active Comparator|Part 1 - Cohort A|In Part 1 the single dose of 1 mg/kg of pegsitacianine given 6-100 hours prior to surgery will be used to image primary tumors in patients with HNSCC to evaluated to verify the diagnostic performance of pegsitacianine fluorescence imaging for detecting primary tumors and metastatic lymph nodes.
89211470|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 3)|Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
89630473|NCT04485156|Active Comparator|Arm 1 (Conventional treatment group)|"Will be treated as recommended by Korean Guidelines For Tuberculosis as well as WHO guidelines (e.g. isoniazid, rifampicin, ethambutol, and pyrazinamide for 2 months followed by isoniazid, rifampicin, (and ethambutol)) Duration of the treatment~- 6 months in total"
89630474|NCT04485156|Experimental|Arm 2 (High-dose rifampicin group)|"High-dose rifampicin, isoniazid, and pyrazinamide~Rifampicin: 30mg/kg~Isoniazid: 300mg/day~Pyrazinamide: 1000mg/day (<50kg), 1500mg/day (50-70kg), 2000mg /day (>70kg), till culture conversion Duration of the treatment~Till 12 weeks after culture conversion on liquid media"
89630475|NCT04666012|Experimental|Group 1: low dose|Subject will receive single dose of AdCLD-CoV19(2.5x10^10VP) as intramuscular injection.
89630476|NCT04666012|Experimental|Group 2: middle dose|Subject will receive single dose of AdCLD-CoV19(5.0x10^10VP) as intramuscular injection.
89630477|NCT04666012|Experimental|Group 3: high dose|Subject will receive single dose of AdCLD-CoV19(1.0x10^11VP) as intramuscular injection.
89630478|NCT04666012|Experimental|Group 4: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
89630479|NCT04666012|Experimental|Group 5: selected dose|Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
89630480|NCT02448030|Experimental|Functional electric stimulation|Other: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively.
89630481|NCT02448030|Placebo Comparator|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test.
89630482|NCT04637620|Experimental|NMDAE|An NMDA enhancer
89630483|NCT04637620|Active Comparator|SSRI|Sertraline (selective serotonin reuptake inhibitor)
89630484|NCT04637620|Placebo Comparator|Placebo|Placebo
89630485|NCT02448108|Experimental|i-IPSRT|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer.
89630486|NCT02448108|Experimental|i-IPSRT + CH|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer. Additionally, i-IPSRT support will be delivered by Clinical Helpers, who will reach out to participants in this arm via 5-10 minute weekly phone calls.
89630487|NCT02448108|Other|CC (Controlled Condition)|Participants randomized to this arm will receive brief written psychoeducational material that includes information about social rhythm regularity. This information will be either mailed or e-mailed to them.
89630488|NCT03200652|Experimental|metabolic availability of lysine in wheat|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a baked wheat bread with or without lentils, which will all be provided by the investigators."
89630489|NCT03200730|Experimental|Family Dignity Intervention group|"A standard framework of 12 FDI questions is given to patient-family dyads in the intervention group during baseline to provides them with the opportunity to think about their responses. During the intervention interview scheduled 2-3 days later, the FDI therapist follows that dyad's cues, help them to organize their thoughts, facilitate disclosure of cherished memories, and encourage the expression of appreciation. The interview is be recorded, quickly transcribed verbatim then edited into a coherent narrative. A second review session is arranged to review and finalize the edited transcript with the dyads. Once the legacy documents are ready, a final family sharing session is arranged for the dyads to share and read this document to each other and their loved ones."
89630490|NCT03200730|No Intervention|Control group|Patient-family dyads in the control group have at least four interviews with a designated member of the research team via psychosocial home visits. Completing the assessments and taking part in the interviews provides them with the opportunity to share their feelings and emotions along their illness trajectory. The extent to which they feel sharing is therapeutic is explored in the interview.
89630491|NCT04614766|Experimental|Combination Therapy|Combined treatment with Lutathera® and Azedra® Administered amounts of each drug are based on imaging and radiation dose constraints to the kidneys and the bone marrow. The drug administration is individualized to each participant.
89630492|NCT04614766|Active Comparator|Lutathera® only|Single agent Lutathera® administered per standard of care: 200 millicuries of drug every 8 weeks for a total of 4 doses.
89630493|NCT00355186|No Intervention|Control|
89630494|NCT00355186|Experimental|Early|
89630495|NCT00355186|Experimental|Late|
89630496|NCT03200886||Sinovial H-L Group|The patients treated have received one cycle of two injections (at baseline and 15 days apart) of 1 ml of Sinovial H-L® (3.2% - 16mg + 16mg, Ibsa).
89630497|NCT03200886||Control Group|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
89630498|NCT05717764|Experimental|Experimental group|Patients will receive mitoxantrone hydrochloride liposome injection combined with capecitabine therapy
89630499|NCT05717764|Active Comparator|Control group|Patients will receive capecitabine monotherapy.
89630500|NCT03223584||Pharmacists-Leuven|Individual interviews with approximately 5 pharmacists
89630501|NCT03223584||Pharmacists-Bruges|Individual interviews with approximately 5 pharmacists
89630502|NCT03223584||Pharmacists-Mortsel|A focus group with pharmacists and general practitioners
89630503|NCT03223584||General Practitioners-Leuven|Individual interviews with approximately 5 general practitioners
89630504|NCT03223584||General Practitioners-Bruges|Individual interviews with approximately 5 general practitioners
89630505|NCT03223584||General Practitioners-Mortsel|A focus group with pharmacists and general practitioners
88990427|NCT03181789|Experimental|Group 2 (Treatment): p55^gag pDNA + IL-12 pDNA|Participants will receive the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Months 1, 3, and 6.
88990428|NCT03181789|Placebo Comparator|Group 2 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
88990429|NCT03180268|Other|Arm I (Clinical Observation)|Patients undergo observation after gross total resection.
88990430|NCT03180268|Experimental|Arm II (Radiation Therapy)|Patients undergo radiation therapy 5 days a week over 6.5-7 weeks for a total of 33 fractions after gross total resection.
88990431|NCT03158454|Other|Capsula Closure|
88990432|NCT03158454|Other|Non-Capsula Closure|
88990433|NCT03140423|Active Comparator|Arm 1: Routine Care (Mupirocin/CHG)|ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
88990434|NCT03140423|Active Comparator|Arm 2: Iodophor/CHG Decolonization|ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
88990435|NCT03106779|Experimental|Asciminib|Patients were randomized to asciminib 40mg BID
88990436|NCT03106779|Active Comparator|Bosutinib|Patients were randomized to bosutinib 500mg QD
88990437|NCT03093116|Experimental|Repotrectinib (TPX-0005)|"Phase 1~Oral repotrectinib (TPX-0005):~Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.~Phase 2~Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts~EXP-1: ROS1 TKI-naïve ROS1+ NSCLC~EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC~EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)~EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)~EXP-5: TRK TKI-naïve NTRK+ solid tumors~EXP-6: TRK TKI-pretreated NTRK+ solid tumors"
88990438|NCT03091413||case group|diaphragm ultrasounds during weaning and Pimax measures
88990439|NCT03084523|Experimental|1|80 patients with intracranial atherosclerosis
88990440|NCT03059121||HIV-infected ART-naïve|HIV-infected subjects ≥ 16 years who are ART-naïve starting their first antiretroviral regimen
88990441|NCT03043053|Experimental|oxytocin|oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
88990442|NCT03043053|Placebo Comparator|placebo|placebo nasal spray (4 times per day for 8 weeks)
88990443|NCT03038672|Active Comparator|Group I (nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.
88990444|NCT03038672|Experimental|Group II (varlilumab, nivolumab)|Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.
88990445|NCT03035552|Experimental|Treatment prior to surgery|Infants randomized to receive the pacifier activated music player and mother's voice treatment prior to surgery for 5 sessions, and mother's voice playing freely post surgery.
88990446|NCT03035552|Experimental|Treatment post surgery|Infants randomized to receive the mother's voice playing freely prior to surgery,and pacifier activated music player and mother's voice treatment post surgery for 5 sessions.
88990447|NCT03033771|Experimental|Treatment|Patients presenting with chronic type B aortic dissection will have the MFM implanted.
88990448|NCT03031912|Active Comparator|Group 1: 50 HIV-infected adults CD4 ≥ 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
88990449|NCT03031912|Active Comparator|Group 2: 50 HIV-infected adults CD4 > 350 and < 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
88990450|NCT03031912|Active Comparator|Group 3: 50 HIV-infected adults CD4 ≥ 200 and ≤ 350 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of theV920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
88990451|NCT03031912|Active Comparator|Group 4: HIV infected adolescents CD4 ≥ 200 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
88990452|NCT03031912|Active Comparator|Group 5: HIV infected adults and adolescents CD4 ≥ 200 cells/mm^3 with 2 doses|Participants will be randomly assigned to receive two dosse of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
88990453|NCT03024554|Experimental|treatment|aortic aneurysm involving iliac arteries treatment with the Bifurcated Multilayer Flow Modulator (BMFM)
88990454|NCT03018132|Other|Mental Health Screening Education and Referral|Investigators will prospectively assign all 200 women to this screening, education and referral intervention, without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. The health-related intervention, in this case, is an educational program and related process-of-care changes.
88990455|NCT03014167|Experimental|Community-wide deworming|Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
88990456|NCT03014167|Active Comparator|Targeted deworming|Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.
88990457|NCT03007758|Active Comparator|robotic ventral hernia repair (VHR)|Robotic VHR
88990458|NCT03007758|Active Comparator|open ventral hernia repair (VHR)|Open VHR
88990459|NCT02987465||Chronic Kidney Disease patients|Up to 12 patients with anaemia associated with CKD.
88990460|NCT02987465||Healthy Volunteers|Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.
88990461|NCT02985918|Experimental|High-intensity NPPV|Patients will receive high-intensity NPPV.
89630506|NCT05717608|Active Comparator|high fructose in caucasian dutch type 2 diabetes subjects|high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.
89630507|NCT05717608|Placebo Comparator|low fructose in caucasian dutch type 2 diabetes subjects|low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.
89630508|NCT05717608|Active Comparator|high fructose in surinamese asian type 2 diabetes|high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of SAS ethnicity.
89630509|NCT05717608|Placebo Comparator|low fructose in surinamese asian type 2 diabetes|low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of SAS ethnicity.
89630510|NCT03118830|Active Comparator|Long GnRH agonist|daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low E2 < 50 and LH < 5IU/l with either HMG or rFSH in a starting dose of 150-300 IU/day
89630511|NCT03118830|Active Comparator|GnRH antagonist|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l. Daily sc rFSH injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done
89630512|NCT03223506|Experimental|Paracetamol arm|Administration of 10 mg/ml of paracetamol
89630513|NCT03223740|Experimental|Arm 1 pre-operative chemoradiation|Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
89630514|NCT03223740|Active Comparator|Arm 2 post operative chemoradiation|Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
89630515|NCT03223896|Active Comparator|Group A|max 8 mg/per day naloxone nasal spray
89630516|NCT03223896|Active Comparator|Group B|max 16 mg/per day naloxone nasal spray
89630517|NCT03195504|Experimental|HFNC (High Flow Nasal Cannulae)|High Flow Nasal Cannulae providing humidified, high-flow oxygen during induction of anesthesia
89630518|NCT03195504|Active Comparator|CON (control)|Standard flow oxygen during induction of anesthesia
89630519|NCT03118908|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
89630520|NCT03118908|Placebo Comparator|Placebo|Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
89630521|NCT03200418|Experimental|Test of new adhesives|"On the peristomal area four different patches are applied to the skin. There is a bag welded on each patch. The bag contains real output.~The difference between the four patches is that they consist of different adhesives.~One patch is made of a standard hydrocolloid adhesive~The primary endpoint is maesured after 8 hours and 24 hours And the three other patches consist of the newly developed adhesives. P-4 P-15 P-16"
89630522|NCT02447796|Active Comparator|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)
89630523|NCT02447796|Active Comparator|Dexmedetomidine (DEX)|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)
89630524|NCT05225116|Experimental|Sintilimab+Lenvatinib+Radiotherapy|
89630525|NCT02447640|Experimental|Part 1|A receptor occupancy dose curve will be obtained by using an adaptive design in this arm.
89630526|NCT02447640|Experimental|Part 2|In this arm, the time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1.
89630527|NCT04503772|Experimental|Experimental arm (all patients)|"Patients will receive preoperative hypofractionated stereotactic radiosurgery (SRS).~According to the association of french-speaking neuro-oncologists (ANOCEF) recommendations, total dose and fractionation will be 33 Gy in 3 fractions at the isocenter, 23.1 Gy in envelope (70% isodose), i.e. 30 Gy in growth tumor volume (GTV) envelope.) Surgery will take place within 3 days of the preoperative SRS."
89630528|NCT03195348|Experimental|HBF Bed Rest|7 days control period followed by a washout period, then 7 days of HBF.
89630529|NCT03200496|Experimental|TALION®|
89630530|NCT03200496|Experimental|DA-5206(Fasting)|
89630531|NCT03200496|Experimental|DA-5206(Fed)|
89630532|NCT04492618|Experimental|Necrobiosis Lipoidica|Adults with cutaneous Necrobiosis Lipoidica (NL) up to 10% of the body surface area (BSA) treated with Ruxolitinib cream
89630533|NCT03195036|No Intervention|Control|The control group of women/children dyads who consent and are patients at the control clinics will not have any exposure to ECD programming.
89630534|NCT03195036|Experimental|Intervention Arm|The intervention group of women/children dyads who consent and are patients at the intervention clinics will receive regular home-based ECD services focused on positive parenting and early stimulation.
89630535|NCT04485234||All patients|All lesions undergo assessment with coronary pressure sensor and either Doppler velocity or coronary thermodilution
89630536|NCT03195114||Multimodality Imaging and Biomarkers|Post-TAVR patients who received commercial Medtronic Evolut-R or Evolut PRO bioprosthesis implant and found to have at least mild PVL on 1-month post-TAVR echocardiogram will undergo multimodality imaging and biomarkers evaluation at 1-month and 7-months post-TAVR.
89630537|NCT03200028|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 30 treatment sessions, up to 5 sessions per week, 30 minutes per session.
89630538|NCT05711836||patients|
89630539|NCT05711836||controls|
89630540|NCT02449824||magnetic resonance imaging|Participants will undergo MRI at baseline, after 1 cycle, 3 cycles and at completion of neoadjuvant chemotherapy.
89630541|NCT03223116|Experimental|Radiofrequency|Radiofrequency delivery to the gastroesophageal junction
89630542|NCT03200184|Experimental|Treatment|Subjects will receive sofosbuvir and daclatasvir
89630543|NCT04438564|Other|cancer of breast, colorectal, ovarian and endometrial|Patient who diagnostic of Breast cancer, Colorectal cancer, cancer of Ovary, and cancer of Endometrial are can recruit.
89630544|NCT03222960|Experimental|Propolis-containing toothpaste|Assessment of caries risk for participants using Propolis-containing toothpaste before the treatment , after 3 months and 6 months follow up.
89039936|NCT05576974|Active Comparator|Part 2 - Cohort B|In Part 2, pegsitacianine the single dose of 1 mg/kg of given 6-100 hours prior to surgery will be used to in patients with unknown primary cancer of the head and neck. These patients typically undergo exam under anesthesia with a laryngoscopy as well as panendoscopy for identifying the source of the metastatic cancer found in the cervical nodes. The diagnostic performance of pegsitacianine fluorescence imaging for detecting primary tumors and metastatic lymph nodes in these patients will be evaluated. All the available data to date will be used to decide the additional tumor type(s), number of patients per tumor type, and number of Group(s) to be enrolled.
89039937|NCT05576129|Active Comparator|TGP-tACS|Patients perform a motor skill acquisition task with the affected hand during TGP-stimulation over the sensorimotor cortex on the lesioned side.
89039938|NCT05576129|Sham Comparator|Sham-tACS|Patients perform a motor skill acquisition task with the affected hand during sham-stimulation over the sensorimotor cortex on the lesioned side.
89039939|NCT05551455|Other|Normal Carbohydrate Availability|"Participants will complete a supervised morning cycling session daily (each morning for five days) to achieve a 15 kcal/kg FFM/day exercise energy expenditure, with samples collected pre-, during- and post-exercise. Participants will then be provided (daily) with all subsequent dietary intake for the intervention period.~In the Normal Carbohydrate Availability trial arm, participants will be provided with 60 kcal/kg FFM/day of energy intake, to elicit a net energy availability of 45 kcal/kg FFM, with ~60% of this energy intake from carbohydrates.~The intervention will last for four days, spanning five testing mornings (i.e. trial begins following fasted baseline assessments on morning 1, finishing with final sample collection on morning 5)."
89039940|NCT05551455|Experimental|Low Carbohydrate Availability|"Participants will complete a supervised morning cycling session daily (each morning for five days) to achieve a 15 kcal/kg FFM/day exercise energy expenditure, with samples collected pre-, during- and post-exercise. Participants will then be provided (daily) with all subsequent dietary intake for the intervention period.~In the Low Carbohydrate Availability trial arm, participants will be provided with 60 kcal/kg FFM/day of energy intake, to elicit an energy availability of 45 kcal/kg FFM, with ~1.5 g/kg provided from carbohydrate and ~70-80% of energy intake in the form of fat.~The intervention will last for four days, spanning five testing mornings (i.e. trial begins following fasted baseline assessments on morning 1, finishing with final sample collection on morning 5)."
89630545|NCT03222960|Experimental|Fluoride-containing toothpaste|Assessment of caries risk for participants using Fluoride-containing toothpaste before the treatment , after 3 months and 6 months follow up.
89630546|NCT03831802|Experimental|experimental group|The experimental group will make use of the Alert app that sends alarms to patients mobile devices, and if desired to the mobile devices of their caregivers. This group will also use the Mate app which is used as a seizure diary
89630547|NCT03831802|Active Comparator|Control group|The control group will only use the Mate app and not the Alert app. This group will thus not receive any notification, from the device, and will be unaware, of the devices performance
89630548|NCT02447484|Experimental|Mujer Segura Siempre|Twice-daily safer-sex and safer-drug-use text messages, 5 days per week, for 24 months. Text message content based on 8 different constructs of behavior-maintenance theory and tailored to specific preferences and motivators provided by participant.
89630549|NCT02447484|Active Comparator|General Health Message Texts|Twice-daily text messages, 5 days per week, for 24 months. Text message content centered on general health promotion, including getting regular medical checkups and maintaining good dietary and exercise habits.
89630550|NCT05704504|Experimental|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with ecological momentary assessment (EMA)and personalized telephone support.
89630551|NCT05704504|Active Comparator|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention.
89630552|NCT05704504|No Intervention|No intervention control group (CON)|Participants in the CON group will not be given any intervention during the study period but will be advised to remain their typical lifestyle throughout the trial period.
89630553|NCT02447562|Active Comparator|G_AH|Usual care group
89630554|NCT02447562|Other|G_SP|Phone-based care
89630555|NCT02447562|Experimental|G_NOMHAD|Intervention group with a health platform NOMHADchronic
89630556|NCT00355654|Experimental|Group 1|Participants will receive PEDIACEL with Prevenar at Visit 1 and ENGERIX-B Kinder at Visit 2
89630557|NCT00355654|Active Comparator|Group 2|Participants will receive Infanrix hexa with Prevenar at Visit 1
89630558|NCT03199716|Experimental|Parent Mentors and Intervention Group|Parent mentors are parents from our UC Davis Pediatrics Endocrinology clinic who have met our parent mentor inclusion criteria; the intervention group are families in our clinic who have met our mentee family inclusion criteria
89630559|NCT03199716|No Intervention|Control Group with no Parent Mentors|The control group is made up of families at our UC Davis Pediatrics Endocrinology clinic who have met the mentee family inclusion criteria but are not matched with a parent mentor
89630560|NCT03195192|Other|Single arm|This is a biomarker study analyzing tissue for baseline biomarkers and collecting tissue at progression for further analysis of biomarkers changes after treatment with CDK 4/6 inhibitors and endocrine therapy
89630561|NCT03118440|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
89630562|NCT03118440|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
89630563|NCT05681260|Experimental|Standard risk Arm A|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who achieve at least a PR at the end of Induction (EOI). Induction I followed by consolidation, Capizzi escalating methotrexate (interim maintenance) , delayed intensification and maintenance therapy. Triple intrathecal injections.
89630564|NCT05681260|Experimental|Standard risk Arm B|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who achieve at least a PR at the end of Induction (EOI). Induction I followed by consolidation, high dose methotrexate (interim maintenance) , delayed intensification and maintenance therapy. Triple intrathecal injections.
89630565|NCT05681260|Experimental|High Risk T-LBL|Any pediatric patients with newly diagnosed T-LBL Stage II to IV who fail to achieve at least a PR at the end of Induction (EOI). Induction I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), deIayed intensification, and maintenance therapy. Triple intrathecal injections.
89630566|NCT03193086||Alemtuzumab treated MS patients|Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).
89630567|NCT03118206|Active Comparator|Lumbar spinal manipulation|Lumbar spinal manipulation will be performed up to 8 times within 1 month (no more than 2 times per week) by Dr. WangTso-Liang, who is a well-trained and experienced manual therapy doctor. If the symptoms subside before the end of 1 month' treatment, the manipulation is discontinued.
89630568|NCT03118206|Active Comparator|Physical therapy|Physical therapy will include treatment with therapeutic exercise and modalities (lumbar traction, heattherapy, electric stimulation, and therapeutic exercise) for 2 month with frequency 3 times per week.
89630569|NCT03118206|Active Comparator|Surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
89630570|NCT03199950|Experimental|Prophylactic Haloperidol arm|Patients will receive oral haloperidol 2dd1mg (08.00am & 10.00pm)
89630571|NCT03199950|Placebo Comparator|No treatment|Patients will receive oral placebo 2dd (08.00am & 10.00pm)
89630572|NCT03118284||Foley catheter group|Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.
89630573|NCT03118284||Healthy control group|Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus
89630574|NCT05156632|Experimental|Medium-dose group|4800 participants including 3400 participants aged 18-59 years ,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of medium-dose COVID-19 Vaccine 5-8 months after their second dose.
89630575|NCT05156632|Experimental|High-dose group|4800 participants including 3400 participants aged 18-59 years,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of high-dose COVID-19 Vaccine 5-8 months after their second dose.
88990462|NCT02985918|Active Comparator|Low-intensity NPPV|Patients will receive low-intensity NPPV.
88990463|NCT02946996|Experimental|OPC|Subjects will take one OPC capsule at the same time each morning and evening, approximately 12 hours apart during weeks 1-12.
88990464|NCT02931188||Anacetrapib|Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
88990465|NCT02931188||Placebo|Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
88990466|NCT02903160|Experimental|Intensive, Non-Cross Reactive Therapy|Prostate Cancer Rapidly cycling, Intensive, Non-Cross Reactive Therapy (PRINT) Rapidly cycling, consecutive treatment modules: 1. Abiraterone acetate; 2. Cabazitaxel + Carboplatin; 3. Enzalutamide + Radium-223
88990467|NCT02879695|Experimental|Treatment (blinatumomab, nivolumab, ipilimumab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes on day 11 and then every 2 weeks for up to year. Some patients also receive ipilimumab IV over 90 minutes on day 11 and then every 6 weeks for up to 1 year. Patients also undergo bone marrow aspiration and biopsy and blood sample collection throughout the study.
88990468|NCT02856906|Experimental|Occlusal adjustment group|Patients in this group will receive treatment of occlusal adjustment based on the clinical and lab examination results.
88990469|NCT02784691|Experimental|Patients|
88990470|NCT02768792|Other|open-label, multicenter, single-arm|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2-years of maintenance therapy (i.e., beginning on day 1 of maintenance). Patients who are ineligible for pembrolizumab administration by day 21 will be removed from the study.
88990471|NCT02750540|Active Comparator|Product A dose|Product A will contain tenofovir (TFV) 220 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
88990472|NCT02750540|Active Comparator|Product B dose|Product B will contain tenofovir (TFV) *660 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
89039941|NCT05535361|Experimental|Eclipse XL1 Coil Treatment Group|All subjects will be assigned to the XL1 Coil treatment group.
89039942|NCT05530863|Active Comparator|Sleep Hygiene|This arm will receive behavioral education, such as sleep hygiene and other advice. Additional details cannot be provided since that will compromise the participant blinding
89630576|NCT05156632|Placebo Comparator|Placebo group|4800 participants including 3400 participants aged 18-59 years,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of placebo 5-8 months after their second dose.
89630577|NCT03118362|Experimental|Plasmalyte®|Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
89630578|NCT03118362|Experimental|Ringer Lactate®|Ringer Lactate® is a balanced solution containing a low chloride concentration (i.e. 111mmol/L), it also contains lactate (29 mmol/L) as buffer solutions.
89630579|NCT05132374|Experimental|Treatment Group|Those receiving standard practice early childhood mental health consultation but enhanced with the I-T CHILD as a framework for consultation
89630580|NCT05132374|No Intervention|Waitlist-control group|Those who receive no intervention until the end of the evaluation period)
89630581|NCT03195738|Experimental|Intervention arm|"The Cognitive Orientation to Occupational Performance (CO-OP) Approach will be delivered over 10 30-60 minute sessions over a seven week period as follows: 2 sessions/week for 3 weeks, then 1 session per week for 4 weeks. In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which will be the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
89630582|NCT03199404||Treated Subjects|Subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ICA) through the distal middle cerebral artery (MCA) and in which the TRAP technique is used for at least the first two thrombectomy passes per occluded vessel and that meet the other inclusion-exclusion criteria.
89630583|NCT02447016|Experimental|eviplera (complera)|Tab eviplera QD
89630584|NCT02447016|Active Comparator|atripla|Tab Atripla QD
89630585|NCT02447094||Exposed|AIS patients evaluated through RTP and who receive i.v. tPA
89630586|NCT02447094||Un-exposed|AIS patients evaluated through RTP and who do not receive i.v. tPA
89630587|NCT02446860|Experimental|Nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit
89630588|NCT05676346||LUTS|Patients with lower urinary tract symptoms with CACV > 3 and/or IPSS > 7.
89630589|NCT02449746|Active Comparator|Intravenous Immunoglobulin (IVIG)|"Intravenous Immunoglobulin IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
89630590|NCT02449746|Active Comparator|Plasma Pheresis / Plasma Exchange (PLEX)|Plasma Exchange (PLEX) is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and its use was first reported in myasthenia gravis in 1976, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects . PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice
89630591|NCT03199560|Active Comparator|Tilmanocept|Tc 99m tilmanocept
89630592|NCT03199560|Active Comparator|Sulfur Colloid|Tc 99m filtered sulfur colloid
89630593|NCT02446782|Experimental|Cefazolin|A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.
88990473|NCT02750540|Active Comparator|Product C dose|Product C will contain tenofovir (TFV) *660 mg in 125 mL hypo-osmolar solution at half the osmolarity of iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
89630594|NCT02446782|Placebo Comparator|saline|100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.
89630595|NCT06076512||Adult chronic pain patients|Adult chronic pain patients who received pain management and/or addiction therapy
89630596|NCT06076486|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID)
89630597|NCT06076486|Placebo Comparator|Elagolix placebo|Participants received elagolix placebo twice a day (BID)
88990474|NCT02750540|Placebo Comparator|Take-home normal saline (NS) enema|The normal saline (NS) solution will be provided following administration of Product A which is iso-osmolar. The volume of NS enema (120 mL) was selected to approximately match that of Product A (125 mL)
89211471|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 4)|Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
88990475|NCT02750540|Placebo Comparator|Take-home half normal saline (½ NS) enema|The ½ normal saline (½ NS) solution will be provided following administration of Product C which is hypo-osmolar. The volume of the ½ NS enema (120 mL) was selected to approximately match that of Product C (125 mL)
88990476|NCT02716246|Experimental|Cohort 1 Low Dose|Dose of 0.5 X 10^13 vg/kg
88990477|NCT02716246|Experimental|Cohort 2 Mid Dose|Dose of 1 X 10^13 vg/kg
89211472|NCT00838292|Active Comparator|ART: food|ART + food supplementation + nutrition counseling
89211473|NCT00838292|Active Comparator|ART: no food|ART + nutrition counseling
89630598|NCT06076460|Experimental|Early Total Enteral Feeding|Mom's milk or donor milk at 80 ml/kg/day after randomization within the first 2 hours
89630599|NCT06076460|Active Comparator|Conventional Enteral Feeding|Mom's milk or donor milk at 20 ml/kg/day and rest of the requirement as Total parenteral nutrition after randomization within the first 2 hours.
89630600|NCT06076434|Experimental|Effect of 10 second Pressure Times on Bruising and Pain|"The patients were randomized according to age and gender and included in the groups.~Patients were injected with heparin subcutaneously in the upper arm by the clinic nurse in accordance with the procedure of the clinic. The area was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected with a 27 gauge needle at a 90° angle to the tissue. The heparin was injected in approximately 10 seconds without aspirating the syringe. After injection, the area was pressurized with dry cotton wool for the specified time. After the injection, pressure was applied to the area with dry cotton for specified periods. Pain level was determined at the time of injection. Using an acetate pen, a circle of approximately 5 cm was marked around the needle insertion site and the bruising level was measured and recorded 48 hours later using a transparent film."
89630601|NCT06076434|Experimental|Effect of 35 second Pressure Times on Bruising and Pain|"The patients were randomized according to age and gender and included in the groups.~Patients were injected with heparin subcutaneously in the upper arm by the clinic nurse in accordance with the procedure of the clinic. The area was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected with a 27 gauge needle at a 90° angle to the tissue. The heparin was injected in approximately 10 seconds without aspirating the syringe. After injection, the area was pressurized with dry cotton wool for the specified time. After the injection, pressure was applied to the area with dry cotton for specified periods. Pain level was determined at the time of injection. Using an acetate pen, a circle of approximately 5 cm was marked around the needle insertion site and the bruising level was measured and recorded 48 hours later using a transparent film."
89630602|NCT06076434|Experimental|Effect of 60 second Pressure Times on Bruising and Pain|"The patients were randomized according to age and gender and included in the groups.~Patients were injected with heparin subcutaneously in the upper arm by the clinic nurse in accordance with the procedure of the clinic. The area was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected with a 27 gauge needle at a 90° angle to the tissue. The heparin was injected in approximately 10 seconds without aspirating the syringe. After injection, the area was pressurized with dry cotton wool for the specified time. After the injection, pressure was applied to the area with dry cotton for specified periods. Pain level was determined at the time of injection. Using an acetate pen, a circle of approximately 5 cm was marked around the needle insertion site and the bruising level was measured and recorded 48 hours later using a transparent film."
89630603|NCT06076382|Experimental|the endoscopic ultrasound guided colorectal ESD surgery group|The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. Then undergo the colorectal ESD surgery.
89630604|NCT06076382|Active Comparator|the traditional colorectal ESD surgery group|the traditional colorectal ESD surgery
89630605|NCT06076369||The tubular adenoma group|The anatomical site was determined, and the size and morphology of the polyps were observed. The classification of the microvascular ECV of the polyps and its adjacent normal mucosal microvascular ECV (white light+NBI) was observed, and methylene blue staining was used to approach and magnify the glandular duct opening to observe the IIIL type (pit pattern). Magnified to the maximum magnification of EC endoscopy to the clearest cell level (approximately 520 times), and observed the morphology of the opening of the IIIL type glandular duct and the opening of the colonic innominate groove, including the morphology of cell cytoplasm and nucleus, proportion of opening length to field of view (more than 1 field of view is calculated as 1.0), and ratio of maximum to minimum opening diameter; Distribution characteristics of glandular duct openings.
89630606|NCT06076369||the colonic innominate groove group|The methylene blue staining area of the normal mucosa adjacent to the polyp was observed to identify the colonic innominate groove.Magnified to the maximum magnification of EC endoscopy to the clearest cell level (approximately 520 times), and observed the morphology of the opening of the IIIL type glandular duct and the opening of the colonic innominate groove, including the morphology of cell cytoplasm and nucleus, proportion of opening length to field of view (more than 1 field of view is calculated as 1.0), and ratio of maximum to minimum opening diameter; Distribution characteristics of glandular duct openings.
89630607|NCT06076343|Experimental|Dialectical behavior therapy/Family Connections|Outpatients with a diagnosis of BPD will be assigned to DBT skills-training intervention (6-10 participants per group). Each DBT skills-training group will receive 24 sessions. Family members of people with BPD will be assigned to psychoeducational intervention. Each FC group (10-12 participants) will receive 12 sessions. Each session for BPD patients and for caregivers lasts 1.5 hours and it is conducted by a leader and a co-leader (two trained psychotherapists).
89630608|NCT06076330|Experimental|20% albumin infusion with plasmalyte|"Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance~S. albumin > 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr~S. albumin < 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr"
88990478|NCT02716246|Experimental|Cohort 3 High Dose|Dose of 3 X 10^13 vg/kg
88990479|NCT02698579||Lenti-D Drug Product|Participants who have received Lenti-D Drug Product in a parent clinical study (bluebird bio-sponsored clinical trial) and who meet the eligibility criteria for the study LTF-304 will be followed in this observation study for 13 years (for a total of 15 years of follow-up after drug product infusion in the parent study).
88990480|NCT02690558|Experimental|pembrolizumab, gemcitabine and cisplatin|There is one arm in this study. Subjects will receive Pembrolizumab 200mg IV on day 1 in combination with cisplatin 35mg/m2 and gemcitabine 1000mg/m2 on day 1 and day 8 every 3 weeks for 4 cycles over 12 weeks.
88990481|NCT02686515|Active Comparator|Single-task balance training group|Participants in the single-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks. They will start walking on a treadmill with a self-selected comfortable speed for 5 minutes of warm-up and then receive an individually-progressed program of balance training aimed at improving standing balance and walking abilities.
89211474|NCT00838292|Active Comparator|pre-ART: food|no ART (cotrimoxazole provided) + food supplementation + nutrition counseling
89630609|NCT06076330|Active Comparator|5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose|"5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose~In case of failure to attain a sustained MAP >65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC~Group A: Plasmalyte bolus of 15-20 ml/kg over 15-30 mins~Group B: 5ml/kg of 5% albumin over 15-30 mins"
89630610|NCT06076278|Active Comparator|Group A (Resistant Training)|Patients in this group will recieve Clinic based resistant training . A total of 12 sessions will be conducted over a period of 4 week 3 days a week.
89630611|NCT06076278|Experimental|Group B (Home Based resistant training)|Patients will recieve home based resistant training. A total of 12 sessions will be conducted over a period of 4 week ,3 days a week .
89630612|NCT06076265||Single arm group|
89630613|NCT06076252|Experimental|Modified Blumgart Anastomosis of LPD|The effect of modified Blumgart technique in the treatment of periampulltrary carcinoma on postoperative pancreatic fistula
89630614|NCT06076252|Other|Conventional Blumgart Anastomosis of LPD|The effect of Conventional Blumgart Anastomosis in the treatment of periampulltrary carcinoma on postoperative pancreatic fistula
89630615|NCT06076239|Experimental|ESWT Group|The participants in the ESWT Group (n=16) were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment.1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (<0.28 mJ/mm2).
89630616|NCT06076239|Active Comparator|Control Group|Control group (n=16) received only conventional treatment for five days per week for 3 consecutive weeks. Conventional treatment includes Ultrasound therapy(Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes around the glenohumeral joint of the cases in both groups participating in the study; at an intensity that the patient can tolerate, covering the painful area TENS applied (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
89630617|NCT06076226||Donors aged 40 years or older|
89630618|NCT06076226||Donors aged < 40|
89630619|NCT06076187||Group 1: Patients over 65 years of age who had undergone Roux-en-Y bariatric surgery|Group 1: Patients over 65 years of age who had undergone Roux-en-Y bariatric surgery
89630620|NCT06076187||Group 2: Patients over 65 years of age who had undergone sleeve gastrectomy surgery|Group 2: Patients over 65 years of age who had undergone sleeve gastrectomy surgery
89630621|NCT06076187||Group 3: Patients over 65 years of age without previous bariatric surgery|Group 3: Patients over 65 years of age without previous bariatric surgery
89630622|NCT06076148|Experimental|Individual then multiplayer games|Participants of this group will conduct the sessions in the following order : Focus group about individual virtual reality games then Focus group about multiplayer virtual reality games.
88990482|NCT02686515|Experimental|Dual-task balance training group|Participants in the dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks. They will perform a cognitive task or motor task concurrently with the balance/gait task. The framework of progressive balance exercises in the dual-task training group will be progressed from simple to more complex tasks as outlined for the single-task training group. In addition, a variety of added tasks will be progressively integrated into the dual-task balance training program.
88990483|NCT02678624|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
88990484|NCT02678624|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
88990485|NCT02594202||1|Adults (= 18 years of age) with biopsy-proven or suspected prostate cancer
88990486|NCT02583828|Active Comparator|Cyclophosphamide alone|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in this arm will receive cyclophosphamide 50 mg daily.
88990487|NCT02583828|Experimental|Cyclophosphamide plus letrozole for resistant patients|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in the this will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
88990488|NCT02583828|Experimental|Cyclophosphamide plus letrozole for treat-naive patients|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
88990489|NCT02583828|Active Comparator|letrozole alone|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive letrozole 2.5 mg daily.
88990490|NCT02545127|Experimental|Merotocin (a selective oxytocin-receptor agonist)|
88990491|NCT02545127|Placebo Comparator|Placebo|
88990492|NCT02455193|Experimental|Exercise intervention|10 weeks of a moderate exercise intervention
88990493|NCT02455193|Active Comparator|Diet intervention|10 weeks of a diet intervention
88990494|NCT02432092||Affected|participants with cardiomyopathy
88990495|NCT02432092||Family Members of affected|Family members of participants with cardiomyopathy (can be affected or unaffected)
89211475|NCT00838292|Active Comparator|pre-ART: no food|no ART (cotrimoxazole provided) + nutrition counseling
89211476|NCT00838370|Experimental|DPYD*2A|Patients are screened for a DPD-deficiency. Patients with a DPYD*2A mutation are eligible for intervention with capecitabine/5-FU .
89630623|NCT06076148|Experimental|Multiplayer then individual games|Participants of this group will conduct the sessions in the following order : Focus group about multiplayer virtual reality games then Focus group about individual virtual reality games.
89630624|NCT06076122|Experimental|Food supplement based on Salicornia extracts|Participants will receive food supplement based on halophyte plant (Salicornia) extracts, 1 g (two 0.5 gram capsules) orally once a day for a treatment period of 3 months (substudy A), 11 months (substudy B), 1 year (substudy C) or 7-30 days (substudy D).
89211477|NCT00838448|Experimental|Cannabis users|Cannabis users
89630625|NCT06076122|Placebo Comparator|Placebo|Participants will receive two capsules once a day of placebo physically equal to the nutritional supplement for a treatment period of 3 months (substudy A), 11 months (substudy B), 1 year (substudy C) or 7-30 days (substudy D).
89630626|NCT06076109|Active Comparator|PRONE POSITION|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
89630627|NCT06076109|Placebo Comparator|STANDARD TREATMENT|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
89630628|NCT06076057||8:00 Measurement team|At 08:00 , monitoring respiratory rate, pulse rate, oxygen saturation, body position, thoracic and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration, partial pressure of transcutaneous oxygen, and partial pressure of transcutaneous carbon dioxide.
89630629|NCT06076057||10:30 Measurement team|At 10:30 , monitoring respiratory rate, pulse rate, oxygen saturation, body position, thoracic and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration, partial pressure of transcutaneous oxygen, and partial pressure of transcutaneous carbon dioxide.
89630630|NCT06076057||16:30 Measurement team|At 16:30 , monitoring respiratory rate, pulse rate, oxygen saturation, body position, thoracic and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration, partial pressure of transcutaneous oxygen, and partial pressure of transcutaneous carbon dioxide.
89630631|NCT06076057||high altitude environment|In high altitude environments, monitoringRespiratory rate, pulse rate, oxygen saturation, body position, chest and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration
89630632|NCT06076057||limited space|In limited space environments, monitoringRespiratory rate, pulse rate, oxygen saturation, body position, chest and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration
89630633|NCT06076057||electrified operation|In electrified operation , monitoringRespiratory rate, pulse rate, oxygen saturation, body position, chest and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration
89630634|NCT06076057||work site|In work site , monitoringRespiratory rate, pulse rate, oxygen saturation, body position, chest and abdominal respiratory movements, electromyography (EMG), electroencephalogram (EEG), partial pressure of end-expiratory CO2 concentration
89630635|NCT06076031|No Intervention|Routine care|Analgesic use
89630636|NCT06076031|Experimental|lntervention|streaming media (video and audio) use
89630637|NCT06075992|Experimental|Premature babies in this group will be massaged.|On the first day of the study and at the end of the 4th week, the Infant Motor Performance Test (TIMP) will be used to evaluate the infant's motor performance consisting of postural control and selective extremity movements. Anthropometric measurements of all babies included in the study immediately afterwards; The baby's body weight, height and head circumference will be checked on the first day of the study and at the end of the 4th week. The stress level of babies will be evaluated by looking at cortisol and ACTH (Adrenocorticotropic hormone) hormones. Massage therapy will be given according to the Field medium pressure massage therapy protocol. In addition to the medical treatment, the application group will be massaged by an experienced physiotherapist according to the Field baby massage therapy protocol, at least 1 hour after the babies are fed, 3 days a week, 2 times a day and for 4 weeks.The massage will be applied for 15 minutes.
89630638|NCT06075992|No Intervention|An experimental application will not be made to premature babies in this group.|No application will be made other than medical treatment. On the first day of the study and at the end of the 4th week, the Infant Motor Performance Test (TIMP) will be used to evaluate the infant's motor performance consisting of postural control and selective extremity movements. Anthropometric measurements of all babies included in the study immediately afterwards; The baby's body weight, height and head circumference will be checked on the first day of the study and at the end of the 4th week. The stress level of babies will be evaluated by looking at cortisol and ACTH (Adrenocorticotropic hormone) hormones.
89630639|NCT06075940|Experimental|MAGNITUDE BRS|
89630640|NCT06075927|Experimental|VSTs infusion|"Phase I (dose escalation) : An open, single-arm, dose-escalation clinical study to explore the safety, tolerability, and cytodynamic characteristics of CMV and EBV-specific T cells (VSTs), with initial efficacy observations. Subjects enrolled with refractory CMV and/or EBV infection after allogeneic hematopoietic stem cell transplantation were subjected to a 3+3 dose-climb test. Exploring the safety, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of intravenous infusion of multi-virus VSTs.~(2) Phase II (dose expansion) : According to the clinically recommended or safe and effective dose determined by the phase I climb test, the extended study of 1-2 dose groups with 20 cases per dose was performed after joint review by the investigators and project collaborators."
88990496|NCT02432079||Heterotaxy and congenital heart defects|Patients and family members with heterotaxy and related congenital heart defects
88990497|NCT02420847|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|Patients receive ixazomib citrate PO, gemcitabine hydrochloride IV over 90 minutes, and doxorubicin hydrochloride IV over 15-30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89630641|NCT06075914|Experimental|Ketogenic Diet Arm|The goal of the KD is to have participants achieve consistent blood BHB ≥0.5 mM; preferably in the range of >1 to 3 mM. We will measure ketones daily via finger stick to provide individual feedback and provide a quantitative measure of compliance. The KD will consist of approximately 50 g carbohydrate and 1.5 g/kg reference weight protein. These may be adjusted based on daily BHB readings. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods. A wide range of foods will be incorporated including non-starchy vegetables, fruits (berries, olives, tomatoes, lemons/limes), meats (beef, chicken, pork, fish, lamb), nuts and seeds, oils (olive, canola, coconut), cheese, butter, cream, eggs, and fatty fish (salmon, sardines). Nutritional ketosis is associated with natriuresis that will lead to sodium and fluid loss if the extra sodium excreted is not compensated, thus slightly higher sodium and potassium intakes will be required.
89630642|NCT06075914|Placebo Comparator|Mediterranean Diet + Placebo|The MD+PL arm will be modeled after a Mediterranean style eating pattern. It will contain the same amount of protein as the KD, but with slight variations in protein sources, including limiting red meat to 1x/wk. The diet will provide unprocessed, higher-fiber foods with emphasis on vegetables, fruits, nuts and seeds, legumes, tubers, whole grains, and fish and seafood. Poultry, eggs, cheese, and yogurt will be included in moderate amounts. Use of olive oil and other monounsaturated fat sources (e.g., avocados and olives) will be encouraged while keeping added sugars to a minimum and avoiding highly processed foods (refined grains, fruit juice, processed meats). Saturated fat will be <10% of energy. We will include adequate omega-3 fats (e.g., salmon). No alcohol will be included in both diets, but we will track consumption. This group will also consume two daily doses of placebo.
89630643|NCT06075914|Active Comparator|Mediterranean Diet + Ketone Ester|The MD+KE arm will consume the exact same diet as the MD+PL group with the exception they will consume two daily doses of KE instead of the placebo.
89630644|NCT06075719||Stroke Survivor|Survivor of acute ischemic stroke or intracerebral hemorrhage in the last 6 weeks
89630645|NCT06075719||Caregiver|Primary caregiver of stroke survivor
89630646|NCT06075693||Longitudinal|We will ask eligible volunteers to provide a CSF sample by a lumbar puncture procedure, a urine sample, undergo a cognitive assessment, and to undergo an MRI scan once per year for two years.
89630647|NCT06075693||Single|We will ask eligible volunteers to provide a CSF sample by a lumbar puncture procedure, a urine sample, undergo a cognitive assessment, and to undergo an MRI scan once.
89630648|NCT06075680|No Intervention|Healthy|Periodontally healthy patients received no intervention.
89630649|NCT06075680|Active Comparator|Gingivitis|Gingivitis group received Non-Surgical Periodontal Treatment. They received Scaling and Root Planning procedure with ultrasonic scalers and hand curettes. The entire non-surgical periodontal treatment of gingivitis groups was completed in a total of 2 sessions in a week.
89630650|NCT06075680|Active Comparator|Stage III Grade C Periodontitis|Stage III Grade C group received Non-Surgical Periodontal Treatment. They received Scaling and Root Planning procedure with ultrasonic scalers and hand curettes. The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
89630651|NCT06075641|Active Comparator|Surgical Stripping|
89630652|NCT06075641|Experimental|Erbium, chromium:yttrium-scandium-gallium-garnet (Er,Cr:YSGG) Laser Techniques|
89630653|NCT06075628||Amplatzer Amulet|This is the group of subjects who are implanted with Amplatzer Amulet device.
89630654|NCT06075628||Watchman / Watchman FLX|This is the group of subjects who are implanted with Watchman / Watchman FLX device.
89039943|NCT05530863|Experimental|ART and Sleep Hygiene|This arm will receive behavioral education, such as sleep hygiene and other training. Additional details cannot be provided since that will compromise the participant blinding
89039944|NCT05526469|Active Comparator|Group serratus anterior plane (SAP)|patients will receive ultrasound guided single shot serratus anterior plane block with 0.5 ml/kg bupivacaine 0.25%
89039945|NCT05526469|Active Comparator|Group erector spinae plane (ESP)|patients will receive ultrasound guided single shot erector spinae plane block with 0.5 ml/kg bupivacaine 0.25%
89039946|NCT05521568||Index test : Abbott ID NOW STREP A 2|
89039947|NCT05521568||Reference standard test : Composite of culture and PCR-based tests based on a throat swab|
89039948|NCT05521568||Comparator test : Rapid antigen detection test (usual care)|
89039949|NCT05520034|Experimental|Intervention group|The participants will be provided a basic health education regarding the understanding of stroke and the risk factors, lifestyle changes related to modifiable factors, (self)-monitoring of daily blood pressure (BP), and compliance with medication and hospital/clinic visits.At 12 month RA nurses will collect data and samples for lab test from patient's house if patient cannot come in NINSH for any reason.We will provide all the patients lab test cost and transportation fees if they will visit any healthcare center for any lab test related to our study.
89039950|NCT05520034|No Intervention|Control Group|The participants will receive a one-time telephone call by research nurses every month to keep in contact (telephone call does not include health education).At 12 month RA nurses will collect data and samples for lab test from patient's house if patient cannot come in NINSH for any reason. We will provide all the patients lab test cost and transportation fees if they will visit any healthcare center for any lab test related to our study.
89039951|NCT05517083|Experimental|Ultrathin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure for EGFR mutation (including T790M positivity) evaluation.
89039952|NCT05514340|Active Comparator|Normal Saline + Standard of care|Patients will receive the best available standard of care. Normal saline will be administered as an intravenous bolus over one minute every 3 hours on day 1, day 3, and day 6 post randomizations.
89039953|NCT05514340|Experimental|Sovateltide + Standard of care|Patients will receive the best available standard of care. Dose of sovateltide (0.3 µg/kg) will be administered as an intravenous bolus over one minute every 3 hours on day 1, day 3, and day 6 post randomizations.
89039954|NCT05490511|Active Comparator|CYP3A5 expressers without chronic kidney disease|
89039955|NCT05490511|Active Comparator|CYP3A5 non-expressers without chronic kidney disease|
89039956|NCT05490511|Active Comparator|CYP3A5 expressers with chronic kidney disease|
89039957|NCT05490511|Active Comparator|CYP3A5 non-expressers with chronic kidney disease|
89630655|NCT06075602||Treatment|The project ́s main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of patients with complex coronary lesions treated with current PCI techniques/ devices, but also CABG strategies in different clinical settings.
89630656|NCT06075563|Experimental|Treatment|Total lymphoid irradiation (TLI)
89630657|NCT06075550|Experimental|TotalFill BC Sealer|single cone technique with TotalFill BC Sealer
89630658|NCT06075550|Experimental|TotalFill BC Sealer HiFlow|warm vertical compaction technique with TotalFill BC Sealer HiFlow
89630659|NCT06075524||Observational (Blood and stool sample collection)|Patients undergo blood sample collection throughout the study. Patients also undergo optional stool sample collection and have their medical records reviewed on study. In addition, patients provide previously-collected tissue sample, if available.
89630660|NCT06075485||Patient|Infants (from 5 months) and children up to 17 years of age follow up for drug resistant epilepsy
89630661|NCT06075472|Experimental|Treatment Group|IMT: Inspiratory Muscle Training. Five days per week, 30 minutes per day.
89630662|NCT06075472|Active Comparator|Control Group|Balance exercises: It has been specially designed for the patient.
89630663|NCT06075446||Treatment|Those with an exposure.
89630664|NCT06075446||Control|Those without an exposure.
89630665|NCT06075381|Experimental|Conventional management plus Pulmonary Expansion Device (PED)|The conventional management used in the intensive care unit as a lung expansion strategy in patients with tracheostomy plus Pulmonary Expansion Device (PED).
89630666|NCT06075381|Active Comparator|Conventional management alone|Conventional management employed in the intensive care unit as a lung expansion strategy in tracheostomized patients, without utilizing the Pulmonary Expansion Device (PED).
89630667|NCT06075342||elite athlete|training year > 10 years and weekly training time > 20 hours
89630668|NCT06075342||casual player|training year < 10 years and weekly training time < 20 hours
89630669|NCT06075342||healthy control|healthy participants with irregular exercise habits
89630670|NCT06075303|Experimental|Easier Targets|"All participants will participate in a modified Cycles approach where speech targets are worked on for a short period of time and switched within a cycle. During the Easier Targets arm, children will work on target sounds that are easier based on their pre-treatment scores of 8, 9, 10, or 11 on the Glaspey Dynamic Assessment of Phonology. Children will complete 8 sessions in this arm that are each 50-minutes long and occur two times per week with each target addressed for 2 sessions."
89630671|NCT06075303|Experimental|Harder Targets|"All participants will participate in a modified Cycles approach where speech targets are worked on for a short period of time and switched within a cycle. During the Harder Targets arm, children will work on target sounds that are harder based on their pre-treatment scores of 15, 14, 13, or 12 on the Glaspey Dynamic Assessment of Phonology. Children will complete 8 sessions in this arm that are each 50-minutes long and occur two times per week with each target addressed for 2 sessions."
89630672|NCT06075238|Experimental|blinatumomab|Participants will take intravenous blinatumomab after allo-HSCT. The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
89630673|NCT06075225|Experimental|Ruxolitinib|Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
89630674|NCT06075225|No Intervention|Control|Patients assigned to the control group are treated based on symptom-triggered aGvHD therapy.
89630675|NCT06075212||Blin-PTCY|Post-transplant cyclophosphamide is used as graft versus host disease (GvHD) prophylaxis. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation.
89630676|NCT06075212||Blin-ATG|Antithymocyte globulin is used as graft versus host disease (GvHD) prophylaxis. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation.
89630677|NCT06075212||Control|Patients don't take blinatumomab treatment after transplantation.
89630678|NCT06075134|Experimental|EMG-guided Botox injection|Botox injection in patients with gummy smile will be done under electromyography guidance to target the most hyperactive and effective muscle that is the chief factor causing the condition.
89630679|NCT06075134|Active Comparator|Conventional Botox injection in Yonsei point|Conventional injection of Botox is located in Yonsei point, which is the center of a triangle formed by the convergence of Levator labii superioris alaeque nasi (LLSAN), levator labii superioris (LLS), zygomaticus minor (ZMn), muscles, and is located 1 cm lateral to the ala of the nose horizontally and 3 cm above the lip line vertically.
89630680|NCT06075121|Experimental|Abdominal massage group|Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening for 15 minutes.
89630681|NCT06075121|No Intervention|Control group|Routine treatment and care practices in the hospital will continue for 5 days without any additional intervention and the same data will be evaluated at the same time.
89039958|NCT05488067|Experimental|Atorvastatin+ALGS-Xanthoma|"Drug: atorvastatin Dosage form: tablet Route of administration: oral Duration: 6 months （After 6 months of medication, according to the actual situation of the patient, choose to maintain the original dosage, gradually reduce the dosage or stop the medication）~Administration method:~Initial dose: ① < 1 year old: 1.25mg/d, qd; ② 1-5 years old: 2.5mg/d, qd; ③ 6-9 years old: 5mg/d, qd; ④ ≥ 10 years old: 10mg/d, qd. The maximum dose is 40mg/d and not more than 1mg/kg/d. During the follow-up, the medication was adjusted according to the laboratory results until non-HDL-C≤4.2mmol/L（162 mg/dL）, xanthoma disappear, or the patient had moderate or more serious adverse reactions."
89630682|NCT06075108|Other|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
89630683|NCT06075082|Experimental|Sleep positional therapy by using the LEFT smartwatch app|
89630684|NCT06075069|Experimental|Feeding appliance immediately after birth|
89630685|NCT06075069|Experimental|Feeding appliance after 1-3 months|
89630686|NCT06075069|Experimental|Feeding appliance after 4 -12 months|
89630687|NCT06075056||Chronic spinal cord injuries|Defined as spinal cord injuries secondary to a single traumatic event to the Cervical or thoracic spine, more than 6 months ago.
89630688|NCT06074991|Experimental|experimental group|Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy. Posttest-1 data were collected immediately after the end of the music therapy. 30 minutes after the posttest-1 data, the posttest-2 data were collected. The patients in the control group, on the other hand, did not undergo any procedure other than medical intervention. Posttest-1 data were collected 30 minutes after the pretest and posttest-2 data 30 minutes after the posttest-1.
89630689|NCT06074991|No Intervention|control group|The control group did not receive any therapy, and there was no interaction between the experimental group and the control group during the training period.
89630690|NCT06074965|Experimental|Arm 1|These subjects will be using infusion set A for the first 3 months and infusion set B for the following 3 months
89630691|NCT06074965|Experimental|Arm 2|These subjects will be using infusion set B for the first 3 months and infusion set A for the following 3 months
89630692|NCT06074952|Other|Group A- Control group|Control group will use distilled water as a control medium
89630693|NCT06074952|Other|Group B- Study group|In this group, 4 sub-groups will be made in which acrylic teeth of Welbite brand will be immersed in tea, coke, turmeric, and honey solutions.
89630694|NCT06074952|Other|Group C- Study group|In this group, 4 sub-groups will be made in which acrylic teeth of the Huge Kaili brand will be immersed in tea, coke, turmeric, and honey solutions.
88990498|NCT02397720|Experimental|Arm I (azacitidine, nivolumab)|Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88990499|NCT02397720|Experimental|Arm II (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
88990500|NCT02289209|Experimental|Reirradiation + MK-3475|Reirradiation 1.2 Gy BID for 5 days a week for 5 weeks with MK-3475 (Keytruda, pembrolizumab) 200mg intravenous every 3 weeks until 3 months post completion of reirradiation.
88990501|NCT02274155|Experimental|Group 1|Anti-OX40 antibody administration 3 weeks prior to surgical resection
89630695|NCT06074913|Other|Healthy group|After the healthy volunteers met the requirements through screening (i.e., demographic data recording,medical history taking, physical examination report review and recording on the day of enrollment), IRT was performed on the extremities, with 1 image automatically taken every 10 s for 1 min, and 6 images for each site.
89630696|NCT06074913|Other|Diabetic group|After screening to meet the inclusion criteria for this study, IRT was performed on the extremities, with 1 image automatically taken every 10s for 1 min, and 6 images for each site.
89630697|NCT06074913|Other|Diabetic peripheral neuropathy group|After screening to meet the inclusion criteria for this study, IRT was performed on the extremities, with 1 image automatically taken every 10s for 1 min, and 6 images for each site.
89630698|NCT06074913|Experimental|EA group|Subjects in this group received electroacupuncture along with the basic treatment at a frequency of 2 treatments per week for 6 weeks for a total of 12 interventions.
89630699|NCT06074913|Other|Waiting list group|The subjects in this group will receive only basal treatment with no additional therapies during the study period.
89630700|NCT06074887|Experimental|İntervention group|
89630701|NCT06074887|No Intervention|Control group|
89630702|NCT06074848|Experimental|Pain/fatigue tDCS real|"tDCS will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during motor training. The anode will be positioned in the area referring to the left motor cortex (C3). The cathode will be positioned in the contralateral supraorbital region.~Motor Training: the participant will be positioned on the mat where the initial 5 minutes will be warmed up with the target heart rate maintained at 50-60% of the maximum heart rate. The treadmill speed must be adjusted to keep the HR within the pre-established target range. At 5 minutes, Borg scale values, treadmill speed and HR should be recorded. The central 20 minutes will be considered the main part. For this, the target HR must be maintained between 64-76% of the maximum HR. Every 5 minutes (minutes 10, 15, 20 and 25) the values of the Borg scale, treadmill speed and HR must be recorded. In the final 5 minutes, the target HR must be kept below 60% of the maximum HR. Totaling 30 minutes of training on the treadmill."
88990502|NCT02274155|Experimental|Group 2|Anti-OX40 antibody administration 2 weeks prior to surgical resection
88990503|NCT02274155|Experimental|Group 3|Anti-OX40 antibody administration 1 week prior to surgical resection
88990504|NCT02263859|Experimental|Treatment|The Treatment Group will be implanted with the aura6000 System and have therapy turned ON at the Month 1 follow-up visit.
89211478|NCT00838448|Experimental|Cannabis no-users|Cannabis no-users
89211479|NCT00510718|Experimental|1|MDV3100
89211480|NCT00537381|Active Comparator|Docetaxel + Prednisone + Placebo|Matching placebo as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 milligram per square meter (mg/m^2) as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
89211481|NCT00537381|Experimental|Docetaxel + Prednisone + Intetumumab|Intetumumab 10 mg per kilogram (mg/kg) as intravenous infusion every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
89211482|NCT00833300|Active Comparator|1|Haloperidol
89211483|NCT00833300|Active Comparator|2|Olanzapine
89211484|NCT00833378|Active Comparator|Period 2|Treatment B
89630703|NCT06074848|Sham Comparator|Pain/fatigue tDCS sham|"tDCS will be applied for 30 seconds (2 mA; 0.057 mA/cm²) during motor training. The anode will be positioned in the area referring to the left motor cortex (C3). The cathode will be positioned in the contralateral supraorbital region.~Motor Training: the participant will be positioned on the mat where the initial 5 minutes will be warmed up with the target heart rate maintained at 50-60% of the maximum heart rate. The treadmill speed must be adjusted to keep the HR within the pre-established target range. At 5 minutes, Borg scale values, treadmill speed and HR should be recorded. The central 20 minutes will be considered the main part. For this, the target HR must be maintained between 64-76% of the maximum HR. Every 5 minutes (minutes 10, 15, 20 and 25) the values of the Borg scale, treadmill speed and HR must be recorded. In the final 5 minutes, the target HR must be kept below 60% of the maximum HR. Totaling 30 minutes of training on the treadmill."
89630704|NCT06074848|Experimental|Cognitive deficit and depressed mood tDCS real|"tDCS will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during cognitive training. For volunteers with symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3) and cognitive training will be performed. The cathode will be positioned in the contralateral supraorbital region.~Cognitive Training: For cognitive training, performed during tDCS, a n-Back task will be performed online in the PsyToolkit (https://www.psytoolkit.org/). A previous study demonstrated the benefit of tDCS when combined with this cognitive training on working memory learning curves."
89630705|NCT06074848|Sham Comparator|Cognitive deficit and depressed mood tDCS sham|"tDCS will be applied for 30 seconds (2 mA; 0.057 mA/cm²) during cognitive training. For volunteers with symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3) and cognitive training will be performed. The cathode will be positioned in the contralateral supraorbital region.~Cognitive Training: For cognitive training, performed during tDCS, a n-Back task will be performed online in the PsyToolkit (https://www.psytoolkit.org/). A previous study demonstrated the benefit of tDCS when combined with this cognitive training on working memory learning curves."
89630706|NCT06074822||Constitution of biocollection|Collection of remains of neuromuscular biopsy samples (nerve and muscles)
89630707|NCT06074809|Experimental|Traditional Chinese medicine treatment group|Chinese medicine will be administered to patients in this group.
89630708|NCT06074809|Placebo Comparator|Placebo group|Placebo will be administered to patients in this group.
89630709|NCT06074783|Experimental|MSC Intervention Group|"Participants will be enrolled into one of four subgroups listed below Firm connective tissue injury (Cartilage, bone, disc, and meniscus) Firm connective tissue degeneration (Cartilage, bone, disc, and meniscus) Soft connective tissue injury (Ligament, tendons, and muscles) Soft connective tissue degeneration (Ligament, tendons, and muscles)~Treatment: Eligible patients will receive 50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under ultrasound guidance along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury is not feasible. Additional dose can be administered. Minimum interval between two local doses is 2 months and systemic doses is 3 months."
89630710|NCT06074757|Other|cohort 1|Test (25mg) vs RLD (500mg) to assess the safety and tolerability of the test dose
89630711|NCT06074757|Experimental|cohort 2|Test 100 mg
89630712|NCT06074757|Experimental|cohort 3|Test 250 mg
89630713|NCT06074757|Experimental|cohort 4|Test 500mg
89630714|NCT06074718|Experimental|pricking therapy and wheat grain moxibustion combined with chemotherapy|pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points combined with chemotherapy
89211485|NCT00833378|Active Comparator|Period 1|Treatment A
89211486|NCT00833378|Active Comparator|Period 3|Treatment C
89211487|NCT05359341|Active Comparator|Sitagliptin 50 mg twice daily|sitagliptin 50 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
89211488|NCT05359341|Active Comparator|Empagliflozin 12.5 twice daily|Empagliflozin 12.5 mg is added for 12 weeks to T2DM not controlled with diet, exercise and metformin with or without other oral antidiabetic drugs.
89211489|NCT05359341|Active Comparator|Sitagliptin 50 mg + empagliflozin 12.5 mg|empagliflozin 12.5 mg is added to the patients with HbA1c 7-10 % of sitagliptin 50 mg group for another 12 weeks.
89211490|NCT05359341|Active Comparator|Empagliflozin 12.5 + sitagliptin 50mg|sitagliptin 50 mg is added to the patients with HbA1c 7-10 % of empagliflozin 12.5 mg group for another 12 weeks.
89211491|NCT05398731||patients received ACEI|patient who use ACEI ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
89211492|NCT05398731||patients received ARBs|patient who use ARBs ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
89211493|NCT05398731||other antihypertensive drugs|patient who use other antihypertensive drugs(for example ca channel blockers and Beta blockers) ( Duration, type of response, and the time period between the begining of and the emergence of symptoms of COVID-19)
89211494|NCT05398731||non hypertensive group|Non hypertensive persons with matched age and sex
89211495|NCT00833456||1|Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion
89211496|NCT00833456||2|Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion
89211497|NCT05384301|Experimental|Urban Afforestation Group|Participants will perform an afforestation activity with a duration of 90 minutes.
89630715|NCT06074718|Active Comparator|chemotherapy|Conventional chemotherapy regimen
88990505|NCT02263859|Other|Control|The Control Group will be implanted with the aura6000 System and receive treatment as-usual, (i.e. any non-PAP, non-surgical OSA treatment including oral appliances and positional devices being used prior to enrollment in the study) until 14 days (washout period) prior to the Month 4 visit. At the Month 4 + 1 day follow-up visit, subjects in the Control Group will have therapy turned ON for the duration of the study.
88990506|NCT02199054|Placebo Comparator|Run-in Intervention|Control wheat pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of control wheat pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
88990507|NCT02199054|Active Comparator|Wheat-Safflower Oil Arm|Wheat-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of wheat-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
88990508|NCT02199054|Active Comparator|Soy-Safflower Oil Arm|Soy-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of soy-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
89630716|NCT06074705|Experimental|Part 1, Dose Escalation Cohort 1: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
89630717|NCT06074705|Experimental|Part 1, Dose Escalation Cohort 2: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
89630718|NCT06074705|Experimental|Part 1, Dose Escalation Cohort 3: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
88990509|NCT02178657|Experimental|Bone marrow transplantation low dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 2x10^6 per kilogram)
88990510|NCT02178657|Experimental|Bone marrow transplantation high dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 5x10^6 per kilogram)
88990511|NCT02178657|No Intervention|Control|
89630719|NCT06074705|Experimental|Part 1, Dose Escalation Cohort 4: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
89630720|NCT06074705|Experimental|Part 1, Dose Escalation Cohort 5: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
89630721|NCT06074705|Experimental|Part 1, Dose Escalation Cohort 6: DS-1471a|Participants with locally advanced or metastatic tumors will receive intravenous DS-1471a.
89630722|NCT06074705|Experimental|Part 2, Dose Expansion (Tumor-specific Cohort 1): DS-1471a|Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
89630723|NCT06074705|Experimental|Part 2, Dose Expansion (Tumor-specific Cohort 2): DS-1471a|Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
89630724|NCT06074705|Experimental|Part 2, Dose Expansion (Tumor-specific Cohort 3): DS-1471a|Participants will receive intravenous DS-1471a at the maximum tolerated dose and/or recommended dose for expansion as established in Part 1 Dose Escalation.
89630725|NCT06074679|Experimental|Single-incision laparoscopic cholecystectomy|SILC was defined as laparoscopic surgery done through a single trans-umbilical incision
89630726|NCT06074679|Active Comparator|Conventional laparoscopic cholecystectomy|CLC was defined as three or four port surgery carried out with either French or American position.
89630727|NCT06074601||Pregnant People|Enrolling any pregnant person over the age of 18 with a singleton pregnancy with their pregnancy having been effectively dated by first trimester ultrasound or last menstrual period
89630728|NCT06074575|Experimental|Negative emotional condition|The participant will watch a short video-clip with negative emotional content.
89630729|NCT06074575|Experimental|Positive emotional condition.|The participant will watch a short video-clip with positive emotional content.
89630730|NCT06074575|Experimental|Neutral condition.|The participant will watch a short video-clip with neutral emotional content.
89630731|NCT06074575|Experimental|Control condition.|The participant will not watch a video-clip, but will wait without specific instructions about what to think about.
89630732|NCT06074523|Experimental|Attention and Working Memory Tests|All participants will complete a series of behavioral tasks, including cued visual search with positive (target color), negative (distractor color) and neutral (baseline) cues, learned visual search with a repeated salient distractor color, a visual working memory capacity task, and a daily life inattentive traits questionnaire (self-report). Single Arm.
89630733|NCT06074497|Experimental|KGX101- Cohort 1|Dosage level: Dose level 1 Dose form: White-like lyophilized powder Route of administration: Intravenous
89630734|NCT06074497|Experimental|KGX101- Cohort 2|Dosage level: Dose level 2. Dose form: White-like lyophilized powder Route of administration: Intravenous
89630735|NCT06074497|Experimental|KGX101- Cohort 3|Dosage level: Dose level 3 Dose form: White-like lyophilized powder Route of administration: Intravenous
89630736|NCT06074497|Experimental|KGX101- Cohort 4|Dosage level: Dose level 4 Dose form: White-like lyophilized powder Route of administration: Intravenous
89630737|NCT06074497|Experimental|KGX101- Cohort 5|Dosage level: Dose level 5 Dose form: White-like lyophilized powder Route of administration: Intravenous
89630738|NCT06074497|Experimental|KGX101- Cohort 6|Dosage level: Dose level 6 Dose form: White-like lyophilized powder Route of administration: Intravenous
89630739|NCT06074497|Experimental|KGX101- Cohort 7|Dosage level: Dose level 7 Dose form: White-like lyophilized powder Route of administration: Intravenous
89039959|NCT05465434|Active Comparator|Group 2|25 patients will receive 50mg Zinc Sulphate plus the standard direct acting anti-viral therapy for 3 months.
89039960|NCT05465434|No Intervention|Group 1|25 patients will receive their standard direct acting anti-viral therapy for 3 months
89630740|NCT06074497|Experimental|KGX101- Cohort 8|Dosage level: Dose level 8 Dose form: White-like lyophilized powder Route of administration: Intravenous
89630741|NCT06074484|Experimental|RC48-ADC +AK104|Participants received 4 preoperative cycles of RC48-ADC（2.0 mg/kg，Q2W） plus AK104（6.0 mg/kg，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，Q3W）and 6 cycles of postoperative RC48-ADC（2 mg/kg，Q3W）
89630742|NCT06074445||People with Cancer|No intervention
89630743|NCT06074445||Partners of People with Cancer|No intervention
89630744|NCT06074432||Emergency Colorectal Cancer Resection|Patients that underwent emergent resection because of histopathologically confirmed colorectal carcinoma
89630745|NCT06074419|Experimental|Experimental group|Virtual reality glasses will be applied 3 days a week for 6 weeks. A sleep quality scale and a mental well-being scale will be applied before and after the procedure.
89630746|NCT06074419|No Intervention|Control group|There will be no virtual reality application. Sleep quality and mental well-being scale will be applied every 6 weeks.
89630747|NCT06074016|Experimental|Zolmitriptan intranasal.|
89630748|NCT06074016|Experimental|Zolmitriptan oral.|
89630749|NCT06073886|Experimental|Active continuous theta-burst stimulation (cTBS) plus exposure|10 days of active, continuous theta-burst stimulation (cTBS) will be delivered to a personalized region of the ventromedial prefrontal cortex (vmPFC) based on baseline brain circuit mapping for each individual participant.
89630750|NCT06073886|Sham Comparator|Inactive/Sham continuous theta-burst stimulation (cTBS) plus exposure|10 days of inactive, or sham, continuous theta-burst stimulation (cTBS) will be delivered to a personalized region of the ventromedial prefrontal cortex (vmPFC) based on baseline brain circuit mapping for each individual participant.
89630751|NCT06073886|Active Comparator|Active Comparator continuous theta-burst stimulation (cTBS) plus exposure|10 days of active, continuous theta-burst stimulation (cTBS) will be delivered to a personalized region of the ventromedial prefrontal cortex (vmPFC) based on baseline brain circuit mapping for each individual participant.
89630752|NCT06073522||Typically developing children|Children aged 5 to 15 years old with no clinically documented disorders.
89630753|NCT06073522||Children with Unilateral Cerebral Palsy|Children aged 5 to 15 years old with a diagnosis of Unilateral Cerebral Palsy
89630754|NCT06073275|Experimental|Beetroot juice intake|Beetroot juice was administered 3 h before the start of the rowing ergometer test since the peak of nitrite in the blood occurs 2-3 h after nitrate ingestion. Beetroot juice was provided in a 140 mL maroon plastic bottle with no label. Participants were provided with a randomized bottle containing 140 mL (~12.8 mmol, ~808 mg of nitrate) of BRJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, UK).
89630755|NCT06073275|Placebo Comparator|Placebo intake|Placebo was administered 3 h before the start of the rowing ergometer test. Placebo was provided in a 140 mL maroon plastic bottle with no label. Participants were provided with a randomized bottle containing 140 mL. The placebo drink was made by dissolving in 1 liter of water 2g of powdered SUPER BEETROOT (~ 0.01 mmol, 0.620 mg of nitrate, diet, food, Poland), 100% natural beetroot juice and organic label, and adding lemon juice to imitate the flavor and texture of the beetroot juice drink
89630756|NCT06073262||Non-specific low back pain individual with chronic consipation|
89630757|NCT06073262||Individual without low back pain with chronic consipation|
89630758|NCT06073249|Experimental|Auricular vagus stimulation:|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear (auricle). Somatosensory innervation is provided by the auricular branch. The name of this device is vagustim device, which consists of a TENS device placed in the outer ear; headphones that can be selected to the size of the individual's ear and a TENS device in which stimulation current is given superficially. In our study, we will perform the application non-invasively by stimulating the branch of the vagus nerve in the auricle. The application time will take 20 minutes.
89630759|NCT06073249|Active Comparator|Tibial Nerve Stimulation|The nervus tibialis approaches the surface when it approaches the medial malleolus. In this study, transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus at the point where the nervus tibialis contacts the surface and approximately bilaterally.
89630760|NCT06072261|Experimental|Kinesio Tape Group|"Before the standard rehabilitation program, kinesio taping was applied to both upper extremities in the form of a Y tape from the medial epicondyle to the wrist flexors, with 15-20% tension, to the patients hospitalized in the orthopedic service after lower extremity surgery. The tape should remain on the patient's arm throughout the hospital stay"
89039961|NCT05465148||ASD|Individuals with Autism Spectrum Disorder indicated by medical records, self diagnosis, or reported by a legally authorized representative. Individuals may be of any age, however, minors (under the age of 18 years) will be required to provide the assent form or a parental permission form, in addition to the Informed Consent Form signed by the parents/guardians prior to any study related activities.
89039962|NCT05461326|Active Comparator|Quad tendon|ACL graft harvested from the quadriceps tendon
89039963|NCT05461326|Active Comparator|BTB tendon|ACL graft harvested from the patellar tendon
89039964|NCT05453227|Active Comparator|Zinc Group|25 cases will be undergo treatment with active ingredient
89039965|NCT05453227|Placebo Comparator|Plcebo Group|25 cases will be undergo treatment with placebo
89039966|NCT05451836|Experimental|Group 1|Group 1 (Two emergency departments) will receive patient education leaflets for 6 months and will receive physician feedback for the next 6 months on top of the patient education.
89039967|NCT05451836|Experimental|Group 2|Group 1 (Two emergency departments) will receive physician feedback for 6 months and will receive patient education leaflets for the next 6 months on top of the physician feedback.
89039968|NCT05433688||UBS|unidirectional barbed suture (Symmcora® mid term, UBS)
89039969|NCT05433688||CS|conventional suture (Novosyn®, CS)
89630761|NCT06072261|No Intervention|Control Group|For the control group data, patients who underwent lower extremity surgery at the same institution for similar periods, but were included in the standard rehabilitation program, but did not apply kinesio tape, will be included. Standard rehabilitation practice includes in-bed transfer training, gait training, practice of daily living activities, and therapeutic exercise practices
89630762|NCT06071455|Experimental|Platelet-rich Fibrin|A 20 ml blood sample will be drawn from the median cubital vein into a PRF tube. Centrifugation will be done at 700 rpm for 3 minutes and the liquid of PRF will be suctioned out using a separate syringe. PRF will be injected distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
89630763|NCT06071455|Experimental|Vitamin D3|Subjects will receive vitamin Dꝫ injection distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
89039970|NCT05425251||BRAINI2-ELDERLY DIAGNOSTIC & PROGNOSTIC|2370 patients suffering mild Traumatic brain injury
89039971|NCT05425251||BRAINI2-ELDERLY REFERENCE|480 non-tbi elderly reference patients
89630764|NCT06071429|Experimental|MAGNITUDE BRS|Participants who receive the MAGNITUDE BRS device will be included in this arm
89630765|NCT06071429|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receive a PTA device will be included in this arm
89630766|NCT06071156|Active Comparator|CMR-guided therapy management,|The scheme of Anakinra treatment was three months at full dosage, the next three months of therapy at full dosage every other day, and the last three months at halved dosage every other day until the end of treatment. Cardiac magnetic resonance [no pericardial edema and/or late gadolinium enchantment (LGE)] guided each anakinra dose reduction. If the tests were positive for ongoing pericardial inflammation [pericardial edema present or LGE present], the reduction was postponed, and one more month of therapy was administered before the reduction.
89630767|NCT06071156|Active Comparator|CRP-guided therapy management,|The scheme of Anakinra treatment was three months at full dosage, the next three months of therapy at full dosage every other day, and the last three months at halved dosage every other day until the end of treatment. Laboratory tests [C-reactive protein (CRP) <0.6 mg/dL] guided each anakinra dose reduction. If the tests were positive for ongoing systemic inflammation (CRP > 0.6 mg/dL), the reduction was postponed, and one more month of therapy was administered before the reduction.
89039972|NCT05423210|Experimental|Treatment|
89039973|NCT05419362|Experimental|GEN-001 with avelumab|42 patients in total with metastatic GC/Gastroesophageal Junction Adenocarcinoma who have progressed after 2 prior systemic treatments and confirmed PD-L1 positive expression will be enrolled in this study.
89039974|NCT05414812|Experimental|Multi-component oncofertility care intervention|After the intervention implementation, all breast cancer patients presenting to oncology clinical visits that meet eligibility criteria will receive the multi-component oncofertility care intervention.
89039975|NCT05414812|No Intervention|Usual Care|Prior to the intervention implementation, all breast cancer patients presenting to oncology clinical visits that meet eligibility criteria will receive usual care.
89039976|NCT05408780|Experimental|Part A - Food Effect Assessment|Subjects will be randomized before administration of the first dose of active or matching placebo IMP in a 1:1:1:1 ratio to 1 of 4 treatment sequences (ABCD, BACD, ABDC, BADC) so that all subjects receive Regimens A, B, C and D across the 4 periods.
89039977|NCT05408780|Experimental|Part B - Titration Tolerability|"Subjects will be dosed BID in the morning and afternoon (approximately 5 h apart) on Days 1 to 27. Both doses of active or matching placebo IMP will be administered in the fed state either 30 min after completion of a standard-fat and calorie content breakfast or 30 min after a standardized-fat and calorie content lunch.~Participants will be randomised to either study drug or the matching placebo."
89039978|NCT05365919|Experimental|Intervention|The intervention group will be offered to participate in the Family Talk Intervention
89039979|NCT05365919|No Intervention|Standard support|The control group will receive standard support
89039980|NCT05359731|Active Comparator|Perineural Bupivacaine|Bupivacaine without Dexamethasone in axillary brachial plexus blockade
89039981|NCT05359731|Experimental|Perineural Bupivacaine plus Dexamethasone|Bupivacaine with Dexamethasone in axillary brachial plexus blockade
89039982|NCT05355337|Active Comparator|Pramipexole|Pramipexole prolonged-release tablet, 0.26 mg base to 3.15 mg base / day for 9 weeks (individually varying dose titrating during these weeks).
89039983|NCT05355337|Placebo Comparator|Placebo|Tablets in appearance identical to the active comparator tablets, but without the the active substance (pramipexole).
89039984|NCT05355337|No Intervention|Healthy controls|40 healthy controls who will carry out blood sampling, lumbar puncture and fMRI according to the same protocol as the depressed patients.
89039985|NCT05348083||ESPB|A prospective cohort of 25 patients ASA 2 (according to American Society of Anesthesiologists physical status classification) with normal singleton pregnancy, scheduled for elective caesarean section under spinal anesthesia without intrathecal morphine, who underwent bilateral echo-guided ESPB at T9 level at the end of surgery.
89039986|NCT05348083||p-QLB|A historical cohort of 25 patients ASA 2 (according to American Society of Anesthesiologists physical status classification) with normal singleton pregnancy, scheduled for elective caesarean section under spinal anesthesia without intrathecal morphine, who underwent bilateral echo-guided p-QLB at the end of surgery.
89211498|NCT00825032|Active Comparator|1: comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
89630768|NCT06070168|Experimental|Telephone Counseling|"Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the depression form will be filled in, a pre-test will be done and the communication will be completed will get their numbers.~The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum). It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups."
89630769|NCT06070168|No Intervention|control group|
89630770|NCT06070051|Experimental|Cohort 1a: Low Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost|Participants assigned to Cohort 1a will receive a low dose prime vaccination of AdC7 vector on Day 1. They will receive a low dose boost vaccination of vector AdC6 on Day 91.
89630771|NCT06070051|Experimental|Cohort 1b: Low Dose VRON-0200-AdC6 Prime, No Boost|Participants assigned to Cohort 1b will receive a low dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.
89630772|NCT06070051|Experimental|Cohort 2a: High Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost|Participants assigned to Cohort 2a will receive a high dose prime vaccination of AdC7 vector on Day 1. They will receive a high dose boost vaccination of AdC6 vector on Day 91.
89630773|NCT06070051|Experimental|Cohort 2b: High Dose VRON-0200-AdC6 Prime, No Boost|Participants assigned to Cohort 2b will receive a high dose prime vaccination of AdC6 vector on Day 1. They will not receive a booster vaccination.
89630774|NCT06069349|Placebo Comparator|usual treatment|
89630775|NCT06069349|Experimental|Early mobilization|early mobilization in the ICU
89630776|NCT06068517|Experimental|Closed incision negative pressure wound therapy|At the completion of the surgical procedure, the skin will be closed with staples at a distance of two centimeters from each other. After skin closure, ciNPWT will be applied, using a commercially available device. The device will be left in place for 7 days.
89630777|NCT06068517|Active Comparator|Standard dressing|At the completion of the surgical procedure, the skin will be closed with staples at a distance of two centimeters from each other. After skin closure, conventional dry dressings will be applied. Conventional dressings will be changed according to clinical practice in the participating study centers.
89630778|NCT06068309|Experimental|CareAide Interventional Group|Participants allocated to the Interventional group (IG) uses the CareAide® app on their smartphones in addition to prescribed usual therapeutic care.
89630779|NCT06068309|No Intervention|Control Group|Participants allocated to the Control group (CG) receives prescibed usual therapeutic care
89630780|NCT06067204|Experimental|Automatic ventilation|After the advanced airway is placed, an automatic pneumatic ventilator will be connected and provides ventilation in every 6 seconds.
89630781|NCT06067204|Active Comparator|Manual ventilation|After the advanced airway is placed, a bag valve mask resuscitator will be connected and provides ventilation in every 6 seconds by the emergency medical technician.
89630782|NCT06065293||Mothers involved in a local non-profit|
89630783|NCT06062914||oral nutritional supplement group|Only oral nutritional supplement was used as enteral nutrition, including but not limited to Ensure®, Nutrison® and etc.
89630784|NCT06062914||no-oral nutritional supplement group|no enteral nutrition was received
89630785|NCT06054191|Experimental|Cohort 1: BRAF V600 mutation|Dabrafenib + Trametinib
89630786|NCT06054191|Experimental|Cohort 2: MET ex14 skip mutation|Capmatinib
89630787|NCT06052904|Experimental|Intervention group|Home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, an online video conferencing platform, by a qualified music therapist.
89630788|NCT06052904|Active Comparator|Control group|Eight weekly online educational modules on medical information and advice about caring for a child who has been newly diagnosed with cancer via email for 2 months.
89630789|NCT06048471|Experimental|HiTop|
89630790|NCT06048471|Sham Comparator|Sham stimulation|
89630791|NCT06041919|Experimental|1 (Active)|Inhaled RESP301 6ml via nebulisation three times daily
89630792|NCT06041919|Active Comparator|2 (Control)|HRZE taken orally once daily
89630793|NCT06041919|Experimental|3 (Active)|Inhaled RESP301 6 ml via nebulisation once daily
89630794|NCT06041919|Experimental|4 (Active)|Inhaled RESP301 6 ml via nebulisation twice daily
89630795|NCT06041919|Experimental|5 (Active)|Inhaled RESP301 6 ml via nebulisation three times daily plus HRZE taken orally once dialy
89039987|NCT05341817|Experimental|Letrozole|Day 1: Oral letrozole 10mg under direct observation therapy (DOT) in the clinic Day 2: Oral letrozole 10mg to self-administer at home Day 3: Oral letrozole 10mg to self-administer at home or at the hospital. Vaginal misoprostol 800mcg given in the ward, followed by vaginal misoprostol 400mcg, approximately 4 hours later, if subject showed no signs of abortion
89630796|NCT06028672|Experimental|Toripalimab Plus Actinomycin-D|Toripalimab 200mg intravenously(IV) every 2 weeks (Q2W) Actinomycin-D 1.25mg/m2，2mg max dos, intravenously(IV) every 2 weeks (Q2W)
89630797|NCT06028672|Active Comparator|Actinomycin-D Alone|Actinomycin-D 1.25mg/m2，2mg max dos, intravenously(IV) every 2 weeks (Q2W)
89630798|NCT06028451||Survivors|Critically ill patients with invasive aspergillus infection who survived
89630799|NCT06028451||Nonsurvivors|Critically ill patients with invasive aspergillus infection who not survived
89630800|NCT06028321|Experimental|Part 1 Group1 (AB)|"Part 1 Group1 Subjects were randomised to two treatment regimens (A and B) and received treatment sequence AB in a 2-period cross over.~Regimen A = 15 mg ACM-001.1 and matching placebo. Regimen B = 30 mg pindolol."
89630801|NCT06028321|Experimental|Part 1 Group 1 (BA)|"Subjects were randomised to two treatment regimens (A and B) and received treatment sequence BA in a 2-period cross over.~Regimen B = 30 mg pindolol. Regimen A = 15 mg ACM-001.1 and matching placebo."
89630802|NCT06028321|Experimental|Part 1 Group 2 (C)|"Subjects were non-randomised; received regimen C in parallel with Group 1 in a single period.~Regimen C = 15 mg pindolol."
89630803|NCT06028321|Experimental|Part 2 Group D|Subjects received one of the four regimens over a four day treatment period. Regimen D = 20 mg pindolol BID (bis in die) for four days.
89630804|NCT06028321|Experimental|Part 2 Group E|Subjects received one of the four regimens over a four day treatment period. Regimen E = 5 mg ACM-001.1 and placebo BID for four days.
89630805|NCT06028321|Experimental|Part 2 Group F|Subjects received one of the four regimens over a four day treatment period. Regimen F = 10 mg ACM-001.1 and placebo BID for four days.
89039988|NCT05341817|Active Comparator|Control|Day 1: Oral mifepristone 200mg (control) under direct observation therapy (DOT) in clinic Day 2: NIL medication to be self-administered at home Day 3: NIL medication to be self-administered at home. Vaginal misoprostol 800mcg given in the ward, followed by vaginal misoprostol 400mcg, approximately 4 hours later, if subject showed no signs of abortion
89039989|NCT05341232|Experimental|Problem-Solving Training|Participants will learn to program LEGO robots and will be encouraged to actively solve problems.
89039990|NCT05341232|Active Comparator|Step-By-Step Training|Participants will learn to program LEGO robots and will be instructed step by step.
89039991|NCT05341232|Placebo Comparator|Board Games|Participants will play boards games under a schedule matching the Experimental and Active Comparator arms.
89630806|NCT06028321|Experimental|Part 2 Group G|Subjects received one of the four regimens over a four day treatment period. Regimen G = 15 mg ACM-001.1 and placebo BID for four days.
89630807|NCT06024733|Experimental|Target Controlled Infusion|Patient's age and weight will be entered into the Target Controlled Infusion unit, enabling target propofol concentrations to be set and the infusion to be started. Target induction concentrations will be 4-6 mcg/ ml. and anesthesia will be maintained with Target Controlled Infusion propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60
89039992|NCT05336435|No Intervention|Control Arm - Current sex-uniform manufacturer provided 99th percentile URL of troponin|Standard use of the current sex-uniform manufacturer provided 99th percentile URL of troponin is utilized at Danish hospitals as a diagnostic cutoff for acute MI for both men and women
89039993|NCT05336435|Active Comparator|Intervention Arm - New population and sex-specific 99th percentile URLs of troponin|Implementation of the new population and sex-specific 99th percentile URLs of troponin for the specific assay utilized at the enrolled centers.
89630808|NCT06024733|Experimental|Target Controlled Infusion and maintenance by sevoflurane|Patients will be induced with intravenous propofol 1.5 mg/kg and fentanyl 1- 2 μg/kg. Tracheal intubation after adequate neuromuscular blockade with rocuronium 0.6 mg/kg will be performed. Anesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 & 1.0.
89630809|NCT06024733|Experimental|Target Controlled Infusion and lidocaine|patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure and 1mg/kg/h for 24 h postoperative.
89630810|NCT06023316|Experimental|mGain system|mGain system: passive, noninvasive, Bluetooth-enabled, wire-free, surface electromyography measurement device that provides input to a mobile app for an interactive gaming platform
89630811|NCT06020105|Experimental|Intervention Group|The intervention will be a combination of consultations and face-to-face follow-ups, with teleconsultations, based on other observational and experimental studies. The intervention program includes monitoring for one year of patients enrolled in the bariatric surgery consultation, with criteria for surgeries.
89630812|NCT06020105|No Intervention|Control Group|The control group will only carry out the assessments and will be offered the same intervention as the intervention group at the end of the intervention.
89630813|NCT06013059|Active Comparator|level (I) arthroscopy (Lysis and lavage)|
89630814|NCT06013059|Active Comparator|level (II) arthroscopy (operative arthroscopy)|
89630815|NCT06013059|Active Comparator|level (III) arthroscopy (operative arthroscopy + disc repositioning and fixation)|
89630816|NCT06006442||DHMC Ambulatory EEG Patients|Dartmouth Hitchcock Medical Center (DHMC) patients aged 21 years or older who already have planned ambulatory EEG study ordered and admit to vaping.
89630817|NCT06004804|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
89630818|NCT06004804|Experimental|Mindfulness Meditation|Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.
89630819|NCT06004804|Active Comparator|Cognitive Behavioral Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
89039994|NCT05334173|Active Comparator|RYGB TYPE 1 - LONGER ALIMENTARY LIMB (LAL-GB)|150 cm alimentary limb and 70 cm biliopancreatic limb
89039995|NCT05334173|Active Comparator|RYGB TYPE 2 - LONGER BILIOPANCREATIC LIMB (LBPL-GB)|70 cm alimentary limb and 150 cm biliopancreatic limb
89039996|NCT05301543|Experimental|Behavioral approach 1|This includes sleep hygiene and other elements to serve as an experimental arm; subjects will receive a clinically proven therapeutic intervention.
89039997|NCT05301543|Active Comparator|Behavioral approach 2|This includes sleep hygiene and other elements to serve as an active comparator; subjects will receive a clinically proven therapeutic intervention.
89039998|NCT05290090|Experimental|Rituximab, lenalidomide, zanubrutinib and RCHOP|"Rituximab, lenalidomide, zanubrutinib for 2 cycles: rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~RCHOP for 4 cycles: rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
89039999|NCT05279534|Experimental|Probiotic|Active test product contains four lactic acid bacteria strains with Qualified Presumption of Safety (QPS) status by European Food Safety Authority (EFSA): Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, with maltodextrin (E1400, qs) as excipient, formulated in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0. Active test product is a food supplement and not an investigational medicinal product
89630820|NCT06000709|Experimental|Ultrasound-guided Genicular Nerve Phenol Neurolysis|One time injection of 1.5 mL of phenol 6% at 3 target locations: superomedial, superolateral and inferomedial genicular nerves
89630821|NCT06000709|Active Comparator|Ultrasound-guided Intraarticular Steroid Injection|Intraarticular knee injection of 40 mg of methylprednisolone acetate in a volume of 5 mL of saline
89630822|NCT05984966|Experimental|Supported Employment|Supported employment program (Peer Connect2Test) for people who inject drugs to provide SARS-CoV-2 rapid tests to others in their networks
89630823|NCT05983393|Sham Comparator|Control group|No block was performed
89630824|NCT05983393|Active Comparator|Erector spinae plane block|Erector spinae plane block was performed, morphine was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
89630825|NCT05980468|Experimental|Intervention group|Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session. Forms will be applied at the first meeting and for five weeks.
89040000|NCT05279534|Placebo Comparator|Control|The control study product is identical in packaging and formulation except that none of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485 and Pediococcus acidilactici CECT7483 (probiotic bacteria) are present. The Control product contains maltodextrin (E1400, qs) only, in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
89040001|NCT05278741|Experimental|Surgery for unilateral breast reconstruction|"Patients treated in oncological surgery at the Center Georges-François Leclerc (CGFL) in Dijon for unilateral breast reconstruction after therapeutic total mastectomy.~Before the surgery, 2 questionnaires will be completed by patients : BREAST-Q and DASH. Also, the isokinetic test and EMG will be performed.~After the surgery, 2 questionnaires will be completed at one month, 3 months and 6 months. The Two tests will be performed at 3 moths and 6 months after the surgery."
89040002|NCT05278260|Placebo Comparator|Control|
89040003|NCT05278260|Experimental|Active|
89040004|NCT05275725|Experimental|Sildenafil|
89040005|NCT05259319|Experimental|Atezolizumab + Tiragolumab + SBRT|"Atezolizumab + Tiragolumab (every 21 days during 24 months or until progression) + SBRT (treatment will be delivered on 5 days).~The combination of SBRT and Immunotherapies will be performed using to different schemes. For the 6 first inclusions the combination will use a sequential scheme. If the safety criteria are respected the following patients will be able to be treated by concomitant scheme."
89040006|NCT05254886|No Intervention|Routine practice|Patients who benefit from the classic management of CD (i.e. clinical + biological ± radiological ± endoscopic follow-up ± therapeutic education program).
89040007|NCT05254886|Experimental|Routine practice + nurse-led program|Patients who receive, in addition to routine practice, a single nursing consultation dedicated to the identification and management of comorbidities and EIMs in CD at the inclusion visit.
89040008|NCT05247853||Group 1|HPV-vaccinated women living with HIV
89040009|NCT05247853||Group 2|HPV-unvaccinated women living with HIV
89040010|NCT05247853||Group 3|HIV[-] women who are HPV-vaccinated
89040011|NCT05243966||Myriad™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
89040012|NCT05243680|Experimental|Participants diagnosed with asthma receiving GSK3511294 (Depemokimab)|
89040013|NCT05242848|Experimental|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is >13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
89630826|NCT05980468|No Intervention|Control group|No application has been made. Forms will be applied at the first meeting and for five weeks.
89630827|NCT05973500|Experimental|Mediterranean Diet|Mediterranean Diet for 42 Days
89630828|NCT05969535|Experimental|intervention group|This group will consist of 35 primiparous pregnant women. The training program, prepared in line with travelbe's human-human relations model, will continue for a total of 4 weeks, 2 days a week.
89630829|NCT05969535|No Intervention|control group|This group will consist of 35 primiparous pregnant women. No training program will be given to this group and routine pregnant follow-up will continue.
89630830|NCT05965960|Active Comparator|Active Low Intensity Transcranial Focused Ultrasound|NeuroFUS device stimulation with 4 channel transducer Stimulation target = M1/GPi Stimulation parameters = Theta burst protocol and 30 Watts
89040014|NCT05242848|No Intervention|Standard|Participants randomised to standard treatment will receive regular OAT clinic follow-up without added supplementation.
89040015|NCT05231915|Other|HOXB13 c.853delT mutation|Mutation is detected using Next Generation Sequencing (NGS) technique
89211499|NCT00825032|Experimental|2: UEET + PR|Experimental program consisting in additional 15 daily sessions of unsupported UEET over and above the same PR program used for control patients.
89630831|NCT05965960|Sham Comparator|Sham Low Intensity Transcranial Focused Ultrasound|NeuroFUS device stimulation with 4 channel transducer Stimulation target = M1/GPi Stimulation parameters = Theta burst protocol and 0 Watts
89630832|NCT05961696|Experimental|Mosunetuzumab|Participants will be assigned to a dose level of mosunetuzumab based on when the participants join this study. Up to 2 dose levels of mosunetuzumab will be tested. The first group of participants will receive the lowest dose level. A second group will receive a higher dose than the group before it, if no intolerable side effects were seen.
89630833|NCT05961098|Experimental|RBD1016/placebo 100 mg Q4W group|Participants in the 100 mg Q4W dose group will receive corresponding doses of RBD1016 injection or placebo by subcutaneous injection on D1, D29, D57, and D85.
89630834|NCT05961098|Experimental|RBD1016/placebo 200 mg Q4W group|Participants in the 200 mg Q4W dose group will receive corresponding doses of RBD1016 injection or placebo by subcutaneous injection on D1, D29, D57, and D85.
89040016|NCT05229770|Experimental|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
89040017|NCT05229770|No Intervention|Standard|Participants randomised to standard treatment will receive regular OAT clinic follow-up without added supplementation.
89040018|NCT05215223|Experimental|whole body vibration|the patient will be received whole body vibration for three times/ week in addition to aerobic exercise for 3 times per week, 45 minutes per session for eight weeks
89040019|NCT05215223|Active Comparator|Aerboic exercise|Moderate intensity aerobic exercise in form of walking on treadmill for 3 times per week, 45 minutes per session for eight weeks
89040020|NCT05214430|Experimental|3 months exclusive enteral nutrition after surgery|3 months exclusive enteral nutrition after surgery
89040021|NCT05214430|Experimental|less than 1 months exclusive enteral nutrition after surgery|less than 1 months exclusive enteral nutrition after surgery
89630835|NCT05961098|Experimental|RBD1016/placebo 200 mg Q12W group|Participants in the 200 mg Q12W dose group will receive corresponding doses of RBD1016 injection or placebo by subcutaneous injection on D1, and D85.
89630836|NCT05961098|Experimental|RBD1016+PegIFN-α 200 mg Q4W group|Participants in the 200 mg Q4W dose group will receive corresponding doses of RBD1016 injection by subcutaneous injection on D1, D29, D57, and D85, and also receive 180 µg PegIFN-α subcutaneously every week for 48 weeks
89630837|NCT05957055|Active Comparator|Methylphenidate first, lisdexamfetamine second|Initial treatment after PT training - methylphenidate (prolonged-release tablet) once-daily with dose optimization for 5-7 weeks and 6 months total therapy then change to lisdexamfetamine once-daily with dose optimization for 5-7 weeks and 6 months total therapy.
89630838|NCT05957055|Active Comparator|Lisdexamfetamine first, methylphenidate second|Initial treatment after PT training - lisdexamfetamine once-daily with dose optimization for 5-7 weeks and 6 months total therapy then change to methylphenidate (prolonged-release tablet) once-daily with dose optimization for 5-7 weeks and 6 months total therapy.
89630839|NCT05951465|Experimental|eskatemine 0.3mg/kg + propofol|eskatemine dose will be 0.3 mg/kg. Propofol dose for the first patient will be 2.5mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
89630840|NCT05951465|Experimental|eskatemine 0.6mg/kg + propofol|eskatemine dose will be 0.6 mg/kg. Propofol dose for the first patient will be 2.0mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
89630841|NCT05949645|Experimental|Apreo Implant Group|This group will undergo up to 2 procedures and will receive up to 3 implants in each lung.
89630842|NCT05948085|Experimental|Zavegepant 10 mg Intranasal (IN)|All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
89630843|NCT05941689|Experimental|AI-assisted group|Subjects in this group undergo AI-assisted colonoscopy. The AI-assisted system not only has the function of automatic polyp detection, but also has the function of colonoscopy quality control.
89630844|NCT05941689|No Intervention|control group|Subjects in this group undergo routine colonoscopy.
89630845|NCT05941065|Experimental|Balancing gel cream|"Product will be used twice daily in the morning and in the evening for 6 weeks. 1-2 pumps (dime size) of product will be applied on the face.~In addition to the study product, a Cetaphil cleanser will be used as well. Cleanser will be applied twice daily in the morning and in the evening for 6 weeks. Cleanser will be used on wet face and gently pat dry."
89040022|NCT05204290|Experimental|Stereotactic Body Radiotherapy and Pembrolizumab Treatment|MRI scans of your spine (before treatment, 2 months after treatment, and 6 months after treatment) and immunotherapy with Pembrolizumab
89040023|NCT05202626||Sun Yat-Sen University Cancer Center|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Sun Yat-Sen University Cancer Center. The physicians in Sun Yat-Sen University Cancer Center consider it necessary to perform an endoscopic image-guided biopsy.
89040024|NCT05202626||Guangdong Provincial People's Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Guangdong Provincial People's Hospital. The physicians in Guangdong Provincial People's Hospital consider it necessary to perform an endoscopic image-guided biopsy.
89040025|NCT05202626||Nanfang Hospital, Southern Medical University|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Nanfang Hospital. The physicians in Nanfang Hospital consider it necessary to perform an endoscopic image-guided biopsy.
89040026|NCT05202626||Fujian Provincial Cancer Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Fujian Provincial Cancer Hospital. The physicians in Fujian Provincial Cancer Hospital consider it necessary to perform an endoscopic image-guided biopsy.
89040027|NCT05202626||Hainan Provincial People's Hospital|The participant who is found to have a nasopharyngeal lesion through the nasopharyngeal endoscopy in Hainan Provincial People's Hospital. The physicians in Hainan Provincial People's Hospital consider it necessary to perform an endoscopic image-guided biopsy.
89040028|NCT05197426|Experimental|Oral Azacitidine|
89040029|NCT05197426|Placebo Comparator|Placebo|
89630846|NCT05940649|Experimental|Continuous norepinephrine administration|
89630847|NCT05940649|No Intervention|Bolus norepinephrine administration|
89630848|NCT05938803|No Intervention|Control arm|Participants randomized to the control arm of the study will receive a modestly enhanced standard of care. Specifically, they will receive HIV transition information in the form of a paper brochure and/or a video link, and a package of supplies (i.e., a pillbox, a folder to store medical documents). Participants will undergo depression and substance use screening and will be referred as needed.
89630849|NCT05938803|Experimental|Intervention arm|Participants randomized to the intervention arm of the study will receive a modestly enhanced standard of care. Specifically, they will receive HIV transition information in the form of a paper brochure and/or a video link, and a package of supplies (i.e., a pillbox, a folder to store medical documents). Participants will undergo depression and substance use screening and will be referred as needed. Participants allocated to this group will also receive the PASEO intervention.
89630850|NCT05932329|Active Comparator|Sweet Taste|The intervention will be provided to participants in written form, in an opaque sealed envelope.
89630851|NCT05932329|Active Comparator|Taste|The intervention will be provided to participants in written form, in an opaque sealed envelope.
89040030|NCT05193227|Experimental|Treatment (ST-01)|Administration of ST-01 as single-dose into the cutaneous, subcutaneous and fascia region of the surgical site and/or as nerve block.
89040031|NCT05193227|Active Comparator|Control (Standard of Care)|Administration of Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®) as single-dose into the cutaneous, subcutaneous and fascia region of the surgical site and/or as nerve block.
89040032|NCT05188404||Cannabis Users|Older adults (60 and up) who report pain, sleep problems, and/or negative mood (anxiety and/or depression) and who desire to use cannabis for these issues (n=300)
89040033|NCT05188404||Cannabis Non-users|Older adults (60 and up) who report pain, sleep problems, and/or negative mood (anxiety and/or depression) and do NOT desire to use cannabis for these issues (n=50)
89040034|NCT05158764|Experimental|URGO BD001|Treatment with URGO DB001 during 12-week treament period (5 medical visits are planned: D0, W2, W4, W8, W12)
89040035|NCT05158764|Active Comparator|Kit Biflex|Treatment with Kit Biflex during 12-week treament period (5 medical visits are planned: D0, W2, W4, W8, W12
89040036|NCT05124184||PAD Cohort|Patient was treated for peripheral arterial disease or peripheral arterial aneurysm requiring bypass treated with GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft
89040037|NCT05124184||AAA Cohort|Patient underwent simultaneous or staged aortic aneurysm repair (open surgical AAA or TAAA) involving a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft
89040038|NCT05124184||Dialysis Access Cohort|Patient required the creation of a vascular access graft for hemodialysis secondary to a diagnosis of End-Stage Renal Disease using a GORE-TEX® Vascular Graft, GORE® INTERING® Vascular Graft, GORE-TEX® Stretch Vascular Graft or GORE® PROPATEN® Vascular Graft
89630852|NCT05932329|Active Comparator|No Taste|The intervention will be provided to participants in written form, in an opaque sealed envelope.
89630853|NCT05924750|Experimental|Study treatment|Participants receive BL-M11D1 as intravenous infusion for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89630854|NCT05923528|Experimental|Group A: IPL group|participants will receive IPL treatment with 12 homogeneously spaced pulses of light to both eyes at day 0, day 14, and day 28
89040042|NCT05097599|Other|Lorbrena® (lorlatinib)|
89040043|NCT05097599|Other|Braftovi® (encorafenib) + Mektovi® (binimetinib)|
89040044|NCT05097599|Other|Talzenna® (talazoparib)|
89040045|NCT05097599|Other|Enhertu® (fam-trastuzumab deruxtecan-nxki)|
89630855|NCT05923528|Experimental|Group B: HEM group|participants were applied an air-activated disposable eye mask on both closed eyes (Ocuface Medical Co., Ltd., Guangzhou, China) simultaneously for 15 minutes according to the manufacturer's instructions every day for 42 days
89630856|NCT05923528|Experimental|Group C: VTPS group|VTPS group, Patients will receive a single 12-minute treatment using the LipiFlow® (TearScience Inc., Morrisville, NC) on both eyes at day 0
89630857|NCT05923528|Experimental|Group D: EyePeace® group|Participants were followed immediately by 10 gentle squeezes of the eyelid massage device (EMD) on both eyes, and 10 gentle eyelid massaging movements using the index and middle fingers every day for 42 days.
89630858|NCT05921305|Experimental|MTX and corticosteroid|Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone). MTX (5mg/m^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR.
89630859|NCT05921305|Active Comparator|Corticosteroid|Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
89630860|NCT05918575|Experimental|Intervention Group (NIV with HFNC)|Patients randomized to the intervention group will receive NIV alternating with HFNC for 24 hours after extubation
89630861|NCT05918575|Active Comparator|Control Group (HFNC alone)|Patients randomized to the intervention group will receive HFNC only for 24 hours after extubation
89040046|NCT05097599|Other|Padcev® (enfortumab-vedotin)|
89040047|NCT05097599|Other|Trodelvy® (sacituzumab govitecan-hziy)|
89040048|NCT05097599|Other|Keytruda® (pembrolizumab)|
89040049|NCT05097599|Other|Inlyta® (axitinib)|
89040050|NCT05097144|Experimental|Lens A, then Lens B|Participants wore Lens A for one month and then wore Lens B for one month.
89040051|NCT05097144|Experimental|Lens B, then Lens A|Participants wore Lens B for one month and then wore Lens A for one month.
89040052|NCT05068947|Experimental|Study drug: GV101|400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the treatment group, cohort 5 to 7.
89040053|NCT05068947|Placebo Comparator|Placebo|Matched placebo control 400 mg (10 mL liquid), 800 mg (20 mL liquid), 1600 mg (40mL liquid) of GVS101 will be administered once, orally to subjects in the control group, cohort 5 to 7.
89630862|NCT05918510||Group 1|High miR value
89630863|NCT05918510||Group 2|Control group
89630864|NCT05911061|Experimental|Experimental group 1|high dose
89630865|NCT05911061|Experimental|Experimental group 2|low dose
89630866|NCT05911061|Active Comparator|Control group|Control group
89630867|NCT05911061|Placebo Comparator|Placebo control group|Placebo control group
89630868|NCT05911048|Experimental|Experimental group|Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
89630869|NCT05911048|Active Comparator|Control group|Recombinant COVID-19 Vaccine (Sf9 Cell)(WSK-V101)
89040054|NCT05060289||Modeling group|The data of modeling group is used to construct a predictive model of DILI endpoint events.
89040055|NCT05060289||Validation group|Validation group is used to validate the predictive model externally.
89040056|NCT05058196|Other|Whole breast radiotherapy after surgery|WBRT will be delivered at 50 Grays (2 Grays x 25 fractions), 5 days/week for 5 weeks after breast surgery
89040057|NCT05058196|Other|Intra Operative Radiotherapy|IORT will be delivered at a single dose of 20 grays to the tumor bed during breast surgery
89040058|NCT05058196|No Intervention|no radiotherapy|No radiotherapy will be administrated to the patients during or after breast surgery
89630870|NCT05892887|Experimental|Erector 10|Received 10ml of preoperative bilateral ultrasound guided ESPB by bupivacaine 0.25% on each side
89630871|NCT05892887|Experimental|Erector 15|Received 15ml of preoperative bilateral ultrasound guided ESPB by bupivacaine 0.25% on each side
89040059|NCT05058157|Active Comparator|Ketone Precursor Formula 1|Formula 1 (in each cycle, up to 4 formula will be tested) Ketone precursors formula (powder to reconstitute in drinking water, or in a ready-to-drink format).
89040060|NCT05058157|Active Comparator|Ketone Precursor Formula 2|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format).
89040061|NCT05058157|Active Comparator|Ketone Precursor Formula 3|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format)
89040062|NCT05058157|Active Comparator|Ketone Precursor Formula 4|Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format), or placebo
89040063|NCT05048719|Experimental|3 milligrams (mg) LY3502970|Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
89040064|NCT05048719|Experimental|12 mg LY3502970|Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
89040065|NCT05048719|Experimental|24 mg LY3502970|Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
89630872|NCT05892887|Experimental|Erector 20|Received 20ml of preoperative bilateral ultrasound guided ESPB by bupivacaine 0.25% on each side
89630873|NCT05861674|Experimental|HH-003 (20mg/kg)+TAF|Subjects will receive HH-003 20 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.
89630874|NCT05861674|Experimental|HH-003 (10mg/kg)+TAF|Subjects will receive HH-003 10 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.
89630875|NCT05861674|Other|TAF|Subjects will receive TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period.
89630876|NCT05845281|Active Comparator|Group ESP, Erector Spina Plane Block (n= 30)|After the surgical procedure was completed in patients who underwent general anesthesia, the necessary sterility was provided for the ESPB procedure while the patient was in the lateral position. 1mg/kg 0.5% bupivacaine + 1mg/kg 2% lidocaine was drawn into the same syringe and the volume was completed to 20 ml with normal saline. A linear 10-18 MHz USG probe was placed at the thoracic 7 level (Esaote MyLab 30, Geneva, Italy) in the paramedian plane between two transverse processes. The prepared local anesthetic drug was administered under the guidance of USG.
89630877|NCT05845281|Experimental|Group PCA, Patient Controlled Analgesia (n= 30)|For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
89630878|NCT05842915||First Contact Practitioner (FCP)|"A continuous routine-data cohort study involving FCP primary care services aiming to recruit a minimum of 25patients per service from 10 FCP services, with complete data from at least 25 patients at baseline and 3-month follow up per service for each 12-month period. Data collection will involve:~Patient survey (to collect outcomes and experiences)~Organisational characteristics (collected via a survey to service leads and via publicly available national sources)~Electronic health record (EHR) data (collected via a standardised FCP template and search within EHR systems)"
89630879|NCT05842915||MSK Community Services|"A continuous routine-data cohort study involving MSK Community Services, aiming to recruit a minimum of 250 patients per service from a minimum of 10 MSK services, with complete data from at least 250 patients at baseline and 3-month follow up per service for each 12-month period. Data collection will involve:~Patient survey (to collect outcomes and experiences)~Organisational characteristics (collected via a survey to service leads and via publicly available national sources)"
89630880|NCT05842538|Experimental|MAKO TKA|
89630881|NCT05842538|Active Comparator|Conventional|
89630882|NCT05834348||Advanced/metastatic non-small cell lung cancer patients|
89040066|NCT05048719|Experimental|36 mg LY3502970 - 1|Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
89040067|NCT05048719|Experimental|36 mg LY3502970 - 2|Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
89040068|NCT05048719|Experimental|45 mg LY3502970 - 1|Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
89040069|NCT05048719|Experimental|45 mg LY3502970 - 2|Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
89040070|NCT05048719|Active Comparator|1.5 mg Dulaglutide|Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
89040071|NCT05048719|Placebo Comparator|Placebo|Participants received matching placebo.
89630883|NCT05832814|Experimental|Integrated training|Rhythm-guided walking exercise coordinated with singing training as training activity in pulmonary rehabilitation: 12 weeks, three times a week for 1 hour, leading to a total of 36 sessions
89630884|NCT05832814|Experimental|Rhythm-guided exercise training|Rhythm-guided walking exercise as training activity in pulmonary rehabilitation: 12 weeks, three times a week for 1/2 hour, leading to a total of 36 sessions
89040072|NCT05048498|Active Comparator|Azacitidine|"Treatment phase 1: the patients will receive regular treatment with azacitidine for 4 days.~Treatment phase 2: the patients will receive regular treatment with azacitidine for 3 days."
89040073|NCT05048498|Experimental|NEX-18a|"Treatment phase 1: the azacitidine dose for day 5 will be replaced by a single dose NEX-18a~Treatment phase 2: the azacitidine dose for day 4 and 5 will be replaced by a single dose NEX-18a"
89040074|NCT05030207|Experimental|Real-Time Gated 4DCT and Conventional 4DCT|During the simulation (radiotherapy planning) session, the participant will undergo both the experimental 'Real-Time Gated 4DCT' and standard 'Conventional 4DCT'.
89630885|NCT05832814|No Intervention|Usual care|The usual care is the comparator in the trial, consisting of standard medical treatment and educational sessions including physical training, smoking cessation and vaccination. And after the trial, the patients in this group will also be offered standard pulmonary rehabilitation according to the national guideline.
89630886|NCT05818943|Experimental|Radiprodil|Liquid suspension of Radiprodil, administered twice a day (bid) either orally or via gastric or nasogastric tube, slowly up-titrated to the highest tolerated dose.
89630887|NCT05808959|Experimental|Education group|Structured training on sexual health will be given to patients in this group. After the discharge training given at the clinic in the postoperative period, the participants will be given structured training on sexual health. It is anticipated that the training will take approximately 30 minutes. Immediately after the training, feedback will be received from the patient through a question-answer activity, and areas that are not understood will be repeated. It is thought that the training will take approximately 45-60 minutes in total.
89630888|NCT05808959|No Intervention|Control group|The clinic's routine discharge training will be applied to the participants in the control group.
89630889|NCT05794568|Active Comparator|OITcontrol group|
89630890|NCT05794568|No Intervention|paperPRO group|
89630891|NCT05789940|Experimental|Arm A: Hysteroscopy|Patients randomized to the hysteroscopy arm will receive misoprostol antibiotic prophylaxis to dilate the cervix before surgery, and anti-adhesion barrier gels will be used, according to routine procedures at each center. In case of intrauterine retention complicated by endometritis, antibiotic treatment for 48 hours (penicillin, metronidazole, fluoroquinolones or a combination of these antibiotics) will be administered according to the standard practice of each center. Evacuated retention product will be sent for pathological examination. Rh-negative women will receive prophylaxis to prevent Rh alloimmunization.
89630892|NCT05789940|Experimental|Arm B: Aspiration|Patients randomized to the aspiration arm will receive misoprostol antibiotic prophylaxis to dilate the cervix before surgery and anti-adhesion barrier gels will be used, according to routine procedures at each center. In case of intrauterine retention complicated by endometritis, antibiotic treatment for 48 hours (penicillin, metronidazole, fluoroquinolones or a combination of these antibiotics) will be administered according to the standard practice of each center. Evacuated retention product will be sent for pathological examination. Rh-negative women will receive prophylaxis to prevent Rh alloimmunization.
89630893|NCT05788588|Experimental|HR19006|
89630894|NCT05788588|Active Comparator|All-in-one parenteral nutrition|
89630895|NCT05777278|Experimental|Savolitinib Plus Docetaxel|Single Arm
89040075|NCT05028114|Experimental|Part 1 (Formulation Optimisation)|Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided 30 minutes after study drug administration. There will be 4 different formulations of the study drug and participants will be randomised to one of 4 sequences. There will be a washout of 2 days between each administration.
89040076|NCT05028114|Experimental|Part 2 (Placebo Assessment)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.~Participants are randomised to 1 of 2 sequences (tricaprilin formulation - matching placebo; matching placebo - tricaprilin formulation) with a 2-day washout between periods."
89630896|NCT05774327|Experimental|Foam Roller+Foot Core Exercises Group|Participants in the foam roller+exercise group underwent foam roller application, which is a self-myofascial release method, 2 days a week for 6 weeks in addition to exercises. Medium-hard foam rollers were used in the applications. Foam roller application was performed on thoracolumbar fascia, iliotibial band, hamstring, gastro-soleus, peroneals and plantar fascia for 60 seconds on each region. A metronome was used to determine the rhythm during foam roller application. The rhythm of the metronome was set to 60 beats per minute (60 rpm). When determining the amount of load on the tissue, the participants were told to give the maximum amount of load possible.
89630897|NCT05774327|Experimental|Foot Core Exercises Group|The foot core exercises in the treatment program for young adults with pes planus were taught to the participants one by one. It was checked that each exercise in the program was performed correctly by the participants. An exercise brochure was prepared and given to all participants so that the participants could learn the exercises better and perform them correctly. The exercise program follow-up of the participants and gradual progression of the difficulty levels were performed by the responsible researcher. The exercises were performed two days a week for six weeks under the supervision of the researcher. On the other days, the exercise program follow-up was checked daily via an online platform.
89040077|NCT05028114|Experimental|Part 3 (Titration Tolerability)|"Study drug administered orally after an overnight fast (minimum 8 hours). A standard breakfast will be provided either 30 minutes before or after study drug administration, depending on the results of the food effect assessment.~Participants will be randomised to either study drug or the matching placebo."
89211500|NCT03791398|Experimental|ONC201 Level 1 (Starting Dose Level)|625mg ONC201 Cycle 1 Day -7 dose then once week
89211501|NCT03791398|Experimental|ONC201 Level 2|500 mg ONC201 Cycle 1 Day -7 dose then once week
89211502|NCT03791398|Experimental|ONC201 Level 3|375 mg ONC201 Cycle 1 Day -7 dose then once week
89630898|NCT05772299|Experimental|Er:Yag laser treatment|"The experimental (test) group will receive the following treatment:~The submucosal debridement will be performed with an Er:Yag laser (AdvErL EVO, Morita Corporation, Japan). The P-400 tip is placed into the peri-implant mucositis pockets mesially, lingually, distally and buccally while rinsing water. Careful attempts are to cover the full circumference of the implant."
89630899|NCT05772299|Active Comparator|Ultrasonic device treatment|"The active comparator (control) group will receive the following treatment:~The submucosal debridement will be performed by a piezoelectric ultrasonic device with a PEEK coated tip (EMS, Switzerland). The tip is placed into the peri-implant mucositis pockets mesially, lingually, distally and buccally while rinsing water. Careful attempts are to cover the full circumference of the implant."
89630900|NCT05768425||Dementia with Lewy Bodies (DLB)|Mild cognitive impairment (MCI) to moderate dementia with probable DLB No other severe neurological or psychiatric diseases. No alcohol or drug abuse.
89040078|NCT05017779|Experimental|Intervention (Unstuck & On Target: High School)|School staff will receive training on the Unstuck and On Target: High School (UOT:HS) curriculum, and deliver lessons to students during the school day. Interventionists will have the option to participate in ongoing check-ins with study staff. Parents are provided home extensions for each lesson and have the option to participate in trainings delivered by study staff to support generalization of skills to the home environment.
89040079|NCT05017779|Other|Usual Care|Participants in schools assigned to the TAU condition will continue to receive the standard school-based Individualized Education Plan (IEP) accommodations and school supports that would typically be provided.
89630901|NCT05768425||Alzheimers disease (AD)|MCI to moderate dementia with probable AD. No other severe neurological or psychiatric diseases. No alcohol or drug abuse.
89630902|NCT05768425||Healthy Controls (HC)|Young healthy controls under the age of 40.
89630903|NCT05767294||Neonatal|
89040080|NCT05009862|Placebo Comparator|Control|Participants will receive 81mg daily of aspirin + placebo for 30 days.
89040081|NCT05009862|Experimental|Intervention|Participants will receive 81mg of aspirin + rivaroxaban 2.5mg twice daily for 30 days.
89630904|NCT05767294||1-3 months old|
89630905|NCT05767294||3-6 months old|
89630906|NCT05767294||6 months-1 year old|
89630907|NCT05767294||1-2 years old|
89630908|NCT05767294||2-5 years old|
89630909|NCT05763303|Experimental|intervention group|"received interventional program which will consist of :~-The educational part: the health education intervention will be in the form of brief counselling five sessions (about half an hour for each session at 1-week intervals) which are introduced after data collection and blood analysis by simplified manner, in the study's clinic.~Training part: We will invite every participant to join this part of the program which will be performed in the fitness center of the faculty of physical education, Assiut University. The entire duration of the 8-week exercise training program is closely supervised by 2 qualified personnel. The exercise session includes running or walking on treadmill, and cycling on bicycle ergometer, about 30 minutes, 3 times per week,"
89630910|NCT05763303|Other|control group|traditional care: the participants will received traditional care in health facility but nothing by researcher
89630911|NCT05761925|Experimental|Intervention|Caregivers will participate in 6 30-minute skills sessions. A clinical psychologist will deliver all of the sessions. The main intervention goal is to provide dyads with resiliency skills to reduce emotional distress and prevent chronic distress.
89630912|NCT05761431|Experimental|5 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008（octreotide long-acting injection) or placebo at dose of 5 mg (8 active : 2 placebo).
89630913|NCT05761431|Experimental|10 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 10 mg (8 active : 2 placebo).
89630914|NCT05761431|Experimental|20 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 20 mg (8 active : 2 placebo).
89630915|NCT05761431|Experimental|30 mg cohort|Subjects will be randomly assigned 4:1 to single dose of either SYHX2008 or placebo at dose of 30 mg (8 active : 2 placebo).
89630916|NCT05761431|Experimental|Octreotide long-acting release ( Sandostatin LAR®) 20 mg cohort|Subjects will be treated with single dose of octreotide long-acting release ( Sandostatin LAR®) at dose of 20 mg.
89630917|NCT05761431|Experimental|Sandostatin® 0.1mg cohort|Subjects will be treated with single dose of Sandostatin® at dose of 0.1mg.
89630918|NCT05759663|Experimental|MIRRAD|A 3 cm vertical incision is made above the umbilicus. The umbilicus is de-attached from the Linea alba so that Linea alba 5-7 cm above and 3-5cm below the umbilicus is exposed. The abdominal rectus muscle diastasis is then plicated with double layer barbed suture. The first suture line is over and over continuous suture and the second suture line continuous suture line. The umbilicus is then re-attached with a single stich .
89630919|NCT05759663|Active Comparator|Plication of the entire diastasis arm|A low transverse incision is made and the subcutaneous tissue along the Linea alba dissected. If there is any hernia present in the Linea alba, it is invaginated in a plicated suture line. The entire DRAM along the Linea alba is plicated with continuous sutures. Excessive skin and subcutaneous tissue along the incision is excised and the wound closed. The subcutaneous tissue is closed with interrupted 4-0 PDS stitches.
89630920|NCT05755178|Experimental|Musical group intervention|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
89630921|NCT05748236|Active Comparator|Lamotrigine|Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day)
89630922|NCT05748236|Active Comparator|Carbamazepine|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day)
89057404|NCT01202773|Placebo Comparator|Placebo|"Given Q2W for 24 weeks. Participants receive 2 injections of placebo when initiating treatment.~At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.~At Week 16, NR will receive a 180-mg loading dose of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
89057405|NCT01648686|Active Comparator|Women treated by bisphosphonate|Postmenopausal osteoporotic women treated by alendronate 70 mg weekly per os
89040082|NCT04994886|Experimental|Targeted Epidural Spinal Stimulation|"Participants will undergo a surgery for Targeted Epidural Spinal Stimulation (TESS). The neurostimulation system will be used to manage blood pressure instability.~Patients will then proceed to one month of an intensive device configuration protocol to configure the TESS settings of their investigational device to regain hemodynamic stability. After the intensive device configuration phase, daily supervised at-home hemodynamic TESS will be tested for 5 sessions per week for two weeks. Thereafter, and up to 10 months post-implant, patients will have a minimum of 5 TESS supported at-home sessions per week and one laboratory visit per month during a long-term at-home hemodynamic TESS phase. Finally, patients will have to undergo additional testing during a configuration of additional TESS programs phase. During this phase TESS configurations for hemodynamic stability, respiratory function, trunk stability and spasticity will be tested."
89040083|NCT04972227|Experimental|CY6463|CY6463 once-daily (QD) for 14 days
89040084|NCT04972227|Placebo Comparator|Placebo|placebo QD for 14 days
89040085|NCT04962997||Transgender women|Major person identifying as a transgender women consulting at Cayenne Hospital (French Guiana) or Bichat Hospital (Paris) between 06/2021 and 10/2022
89040086|NCT04954001|Experimental|Single Arm|
89040087|NCT04949802|Experimental|Laser|Treated with ViaLase Laser
89630923|NCT05739669|Other|Sequential EEG Recordings with a wet electrode device a dry electrode device in multiple settings|"one recording per patient (epilepsy), performed by specialized staff in a clinic, with a CE-certified wet electrode EEG device (Micromed Brain Quick)~one recording per patient (epilepsy), performed by specialized staff in a clinic, with the investigational device Atlas with dry electrodes~multiple daily recordings from patients with epilepsy, gathered by lay people for 14 days, at home, with the investigational device Atlas with dry electrodes"
89630924|NCT05739058|Experimental|Low Exposure to Violet-Blue Light|ID 1-7 are assigned to the low dosage group
89630925|NCT05739058|Experimental|Medium Exposure to Violet-Blue Light|ID 8-15 are assigned to the medium dosage group
89630926|NCT05739058|Experimental|High Exposure to Violet-Blue Light|ID 16-22 are assigned to the high dosage group
89630927|NCT05729061|No Intervention|Participant with normal assistive device|Normal assistive device refers to the habitual assistive device that may be prescribed by a provider of care or no assistive device if the individual does not normally use.
89630928|NCT05729061|Other|Participant with intervention|Intervention refers to investigational assistive devices or commercially available assistive devices that individuals may use during this study.
89630929|NCT05724004|Experimental|Radiotherapy + alectinib|All patients receive consolidation radiation therapy to all active tumour lesions after induction treatment with alectinib.
89630930|NCT05707975||Adolescents hospitalized in the service|Adolescents between 12 and 16 years old Intervention: filling of three scales (CAS, C-SSRS, HAD)
89630931|NCT05706298|No Intervention|Habitual lifestyle|Participants in the control group will be asked to maintain their habitual lifestyle.
89630932|NCT05706298|Experimental|Active breaks|Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min (16 bouts per day, equalling 48 min of walking) from 9am-5pm every day throughout the 4 week period. To improve adherence should participants miss a bout of walking they will be asked to do 6 min during the next bout.
89630933|NCT05699499|Experimental|KeryFlex|Patients 18 years and older presenting with retronychia and/or lichens planus of the toenails and/or fingernails to the Weill Cornell Medicine, Department of Dermatology, specialized nail clinic.
89630934|NCT05682547|Experimental|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 8 weeks.
89630935|NCT05682547|Active Comparator|HA group|Participants in HA group will be administered one drop of 0.1% Sodium hyaluronate artificial tears (preservative free) six times per day for 8 weeks
89630936|NCT05675865|Experimental|VT Cryoablation|all enrolled patients will have a ablation procedure using the Adagio VT Cryoablation System for MVT
89040088|NCT04938583|Experimental|oregovomab, bevacizumab, paclitaxel and carboplatin|Combination of anti-angiogenesis and Chemo-immunotherapy
89040089|NCT04925856|Experimental|Experimental|"4 différents cohorts:~Paclitaxel cohort (N=30)~Epirubicine - cyclophosphamide cohort (N=30)~Eribuline cohort (N=30)~Palbociclib (N=20) ou Abemaciclib (N=20) ou Ribociclib cohort (N=21)~Study diagram :~Inclusion and screening visite~Visit 1: J1C1~Visit 2 : J8C1 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C1 to Palbociclib ou Abemaciclib ou Ribociclib cohort~Visit 3 :J21C1~Visit 4 : J8C3 to Paclitaxel cohort / Epirubicine - cyclophosphamide cohort / Eribuline cohort and J15C3 to Palbociclib ou Abemaciclib ou Ribociclib cohort~During these visits, we collect, before the start of treatment administration ;~Vital signs,~Concomitant treatments,~Blood sample:~1 heparinized tube (4 mL) for collection of plasma and storage~1 heparinized tube (4 mL) for immunophenotyping,~4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
89040090|NCT04924907||Dysbiosis microbiota|microbiota with proinflammatory pattern or dysbiosis
89040091|NCT04924907||Normal microbiota|microbiota with antiinflammatory pattern or normal
89040092|NCT04913142||control|patients not suffering from COVID-19 hospitalized in intensive care unit
89040093|NCT04913142||patients COVID-19|patients suffering from COVID-19 hospitalized in intensive care unit
89040094|NCT04888416|Experimental|Acute care|Acute care practitioners who will receive the I-STROM intervention
89040095|NCT04888416|Experimental|Inpatient|Inpatient practitioners who will receive the I-STROM intervention
89211503|NCT03791398|Experimental|Nivolumab|240mg IV flat dose q 2 weeks
89630937|NCT05675657|Placebo Comparator|Control group|Patients will be operated under general anesthesia.
89630938|NCT05675657|Active Comparator|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block type III bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
89630939|NCT05675657|Active Comparator|Erector Spinae Plane Block Group|Patients will receive ultrasound-guided erector spinae plane block bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
89630940|NCT05672836|Experimental|Enavogliflozin Group|0.3 mg 1 tablet once daily
89630941|NCT05672836|Active Comparator|Standard-of-Care Group|Guideline-directed medical therapy.
89040096|NCT04888416|Experimental|Outpatient|Outpatient practitioners who will receive the I-STROM intervention
89040097|NCT04878575||ASD group|120 ASD patients (aged 5-18 years)
89040098|NCT04878575||ADHD group|120 ADHD patients (aged 5-18 years)
89040099|NCT04878575||TDC group|120 age-, and sex-matched typically developing controls (TDC) will be recruited from the same geographic areas of the ASD/ADHD groups via referral by teachers or the invitation of participants without any psychiatric disorders
89040100|NCT04876989|Active Comparator|US-SGB|5 ml of 1% mepivacaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
89040101|NCT04876989|Active Comparator|US-TPVB|10 ml of 1% mepivacaine is injected for thoracic paravertebral block using the Ultrasound(US)-guided sagittal approach at the second thoracic paravertebral space.
89040102|NCT04873674||ASD group|240 ASD patients (aged 4-25 years)
89040103|NCT04873674||Unaffected siblings of ASD|60-100 unaffected siblings of ASD probands
89040104|NCT04873674||TD group|120 age-, and sex matched TDC from the same geographic areas of the ASD group via referral by teachers, or advertisement at college or community.
89040105|NCT04871672|Experimental|pilates and home exercises (PAH) group|these subjects will receive pilates and home exercises.
89040106|NCT04871672|Active Comparator|control home exercises group (COH)|these subjects will receive only home exercises.
89040107|NCT04797442|Experimental|Experimental|
89040108|NCT04797442|Placebo Comparator|Placebo comparator|
89040109|NCT04768153||Patients|
89040110|NCT04763564|Experimental|Liraglutide then Placebo|Participants will be randomly assigned to 6-week Liraglutide treatment. Then after a 5-day washout, treatment will continue with 6 weeks of placebo.
89040111|NCT04763564|Experimental|Placebo then Liraglutide|Participants will be randomly assigned to 6-week placebo treatment. Then after a 5-day washout, treatment will continue with 6 weeks of Liraglutide.
89040112|NCT04743505|Experimental|Phase I Dose Level 1: APL-101 + Standard of Care Osimertinib|"After 8-16 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose twice daily on Days 1 through 28 of each 28-day cycle~Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
89040113|NCT04743505|Experimental|Phase I Dose Level 2: APL-101 + Standard of Care Osimertinib|"After 8-16 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose twice daily on Days 1 through 28 of each 28-day cycle~Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
89057406|NCT01648686|Sham Comparator|Women didn't treat by bisphosphonate|Postmenopausal osteoporotic women untreated by bisphosphonates
89057407|NCT02215694|Experimental|probiotic group|consumed 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
89211504|NCT00838838||Group 1|
89040114|NCT04743505|Experimental|Phase II: APL-101 + Standard of Care Osimertinib|"After 8-16 weeks of osimertinib, patients will be imaged as per standard of care. If imaging does not show disease progression, patients will continue on to study treatment with the combination of osimertinib and APL-101.~APL-101 is an oral drug which will be administered on an outpatient basis at the assigned dose (this dose will be determined in Phase I of the study) twice daily on Days 1 through 28 of each 28-day cycle~Osimertinib is an oral drug which will be administered on an outpatient basis at a dose of 80 mg once daily on Days 1 through 28 of each 28-day cycle."
89040115|NCT04742504||BENRA Treated Patients|Patients with severe eosinophilic asthma who will be treated with benralizumab (Fasenra®, Astra Zeneca) will be able to participate in a volunteer manner in the study after sing informed consent.
89040116|NCT04742504||Non BENRA TREATED PATIENTSP|patients with controlled severe asthma requiring high-dose inhaled corticosteroids plus long-acting beta agonists (with or without oral corticosteroids) but without request of benralizumab (Fasenra®, Astra Zeneca) treatment will be recruited
89040117|NCT04730154|Experimental|Pain Neuroscience Education (PNE) + Motivational Interviewing (MI)|Breast cancer survivors assigned to the experimental intervention will participate in 1 online PNE session followed by 3 PNE + MI sessions spread over 4 weeks. Each session will last for approximately 45 minutes and all sessions will be held in one-on-one format, allowing to individually tailor content to the patient's maladaptive beliefs and perceived injustice. After the first live session, breast cancer survivors will receive a perceived injustice-targeted PNE information leaflet that they need to read carefully at home.
89630942|NCT05672017|Active Comparator|Dietary Instructions: Increase sweet food consumption|Participants are asked to increase their consumption of sweet foods throughout their diet. Participants will be provided with clear instructions, where sweet foods will be highlighted and additional means of increasing sweet food consumption will be offered.
89040118|NCT04730154|Active Comparator|Biomedically-focused Education|Breast cancer survivors assigned to the experimental intervention will participate in 1 online biomedically-focused education session followed by 3 biomedically-focused education sessions spread over 4 weeks. Each session will last for approximately 45 minutes and all sessions will be held in one-on-one format in order to balance nonspecific treatment effects between treatment arms, the duration, format and number of sessions as well as the didactical approach will be identical in both treatment groups. After the first live session, breast cancer survivors will receive an information leaflet from 'Kom op tegen Kanker' regarding 'Pain in and after treatment' that they need to read carefully at home.
89630943|NCT05672017|Active Comparator|Dietary Instructions: Decrease sweet food consumption|Participants are asked to decrease their consumption of sweet foods throughout their diet. Participants will be provided with clear instructions, where sweet foods will be highlighted and means of decreasing sweet food consumption will be offered.
89630944|NCT05672017|Placebo Comparator|Dietary Instructions: Usual Diet|Participants are asked to retain their consumption of sweet foods throughout their diet.
89630945|NCT05656807|Active Comparator|Go NAPSACC|Centers randomized to Go NAPSACC will receive the traditional Go NAPSACC program. This will include the center director leading the Go NAPSACC effort with support from a Go NAPSACC Implementation advisor. The advisor will orient each center to Go NAPSACC and its online tools and check in monthly with directors as they work through 2 cycles of Go NAPSACC over 6 months. Centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals.
89630946|NCT05656807|Experimental|Go NAPSACC Enhanced|Centers randomized to Go NAPSACC Enhanced will receive the traditional Go NAPSACC program as described in the Active Comparator arm. Additionally, child care providers will simultaneously receive a weight management program, Go NAPSACC Cares over 6 months. The health educator will orient providers with the website and its tools and resources. Providers will take a self-assessment and choose a goal of weight maintenance or weight loss. They will go through 18 lessons with accompanying resources. Within the website they will self-monitor their weight, physical activity, and red foods (diet quality). Providers will receive daily tips, weekly reminders via text message or email, and tailored weekly feedback based on their weight management goals and progress.
89630947|NCT05636319|Experimental|Test group 1: ABO1020|Intramuscularly inject 15 μg of ABO1020 into lateral deltoid region of the upper arm of subjects on D0 and D28, respectively.
89630948|NCT05636319|Placebo Comparator|Test group 2: Placebo|Intramuscularly inject 0 μg of placebo into lateral deltoid region of the upper arm of subjects on D0 and D28, respectively.
89630949|NCT05619809|Experimental|Thermogenic Dietary Supplement|Arm in which the thermogenic dietary supplement is consumed.
89630950|NCT05619809|Placebo Comparator|Placebo Dietary Supplement|Arm in which the placebo supplement is consumed.
89630951|NCT05619809|No Intervention|Control|Control arm with no intervention.
89630952|NCT05614843|Experimental|PBM group|Energy density 7.5 J / cm2
89630953|NCT05614843|Placebo Comparator|Control group|The placebo control group will carry out the same protocol used in irradiated patients (including the use of protective goggles) using the same laser device to imitate a real irradiation; however, the device will be turned off and recording of the emission sounds will be used to give the patient the hearing sensation of the PBM therapy.
89630954|NCT05608499|Experimental|Duobrii|Duobrii is the study treatment drug. Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii.
89630955|NCT05608499|Placebo Comparator|Placebo|Placebo
89630956|NCT05578807|Experimental|Total tubeless percutaneous nephrolithotomy without reverse insertion of a ureteral catheter|In total tubeless percutaneous nephrolithotomy surgery, there is no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no need to change the position, and no need to re-sterilize and lay towels.
89630957|NCT05578807|No Intervention|Conventional total tubeless percutaneous nephrolithotomy|In total tubeless percutaneous nephrolithotomy surgery, there is reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, need to change the position, and need to re-sterilize and lay towels.
89630958|NCT05576662|Experimental|Nirmatrelvir plus ritonavir|Participants receive nirmatrelvir plus ritonavir (Paxlovid) for 15 days, and attend follow-up visits through week 15.
89630959|NCT05576662|Placebo Comparator|Placebo plus ritonavir|Participants receive placebo to match nirmatrelvir plus ritonavir for 15 days, and attend follow-up visits through week 15.
89630960|NCT05564650|Experimental|Treatment (navitoclax, decitabine, venetoclax)|
89040119|NCT04719832|Experimental|Participants receiving GSK3511294 (Depemokimab)|
89040120|NCT04719832|Placebo Comparator|Participants receiving placebo|
89040121|NCT04718870|Experimental|Atopic Dermatitis Participants|Pediatric participants with moderate-to-severe atopic dermatitis (AD) and with baseline body weight more than or equal to (>=) 15 kilograms (kg) and less than (<) 30 kg received a subcutaneous (SC) loading dose of dupilumab 600 milligrams (mg) (2 injections of dupilumab 300 mg) on Day 1 (Week 0) followed by dupilumab 300 mg SC injection every 4 weeks (Q4W), from Week 4 to Week 12. Pediatric participants with body weight >=30 kg and <60 kg received SC loading dose of dupilumab 400 mg (2 injections of dupilumab 200 mg) on Day 1 (Week 0), followed by dupilumab 200 mg SC injection every 2 weeks (Q2W), from Week 2 to Week 14.
89040122|NCT04718870|No Intervention|Healthy Volunteers|Healthy volunteers with age, gender, location of targeted skin lesion area and study site matched to selected AD participants, received no treatment, but were monitored in a similar way as AD participants.
89040123|NCT04718103|Experimental|Participants receiving GSK3511294 (Depemokimab)|
89040124|NCT04718103|Placebo Comparator|Participants receiving Placebo|
89040125|NCT04708860|Experimental|Prolonged Nightly Fasting Plus Exercise|"Participants will be grouped into two cohorts determined by whether they receive palbociclib or alpelisib as part of their breast cancer treatment and then receive a 12 week prolonged nightly fasting plus exercise program consisting of:~Prolonged overnight fasting: Not consume any calorie-containing food/drinks after 8pm, waiting a minimum of 13 hours after their last meal of the day before eating the next day, target goal of fasting at least 6 days a week, daily record of first and last meals~Exercise Program: Coach provided at-home, personalized exercise regimen with target goal of 120 minutes of moderate-intensity aerobic activity each week as well as two 30-45-minute virtual strength training classes per week, receive fitbit for exercise and heart rate monitoring, weekly telephone-based support sessions with coach."
89040126|NCT04705220|Experimental|Nutritional Supplementation with Test Product|Subjects will receive 1 tablet of MERIVA® in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months. This treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
89040127|NCT04705220|Placebo Comparator|Control Group without Nutritional Supplementation|Subjects will receive 1 tablet of placebo in two administrations per day (one in the morning, one in the evening during meals) for a period of 6 months.
89040128|NCT04696887|Experimental|Tele Tai Chi|8-week Tele Tai Chi intervention
89040129|NCT04691557|Experimental|Intervention Group|The intervention group receives the YoungAsthma developing for the smartphone or tablet additionally usual nursing care.
89040130|NCT04691557|Active Comparator|Control Group|The control group receives the usual nursing care.
89040131|NCT04691232|Experimental|Regulatory T cells|Intravenous infusion of a single dose of 0.5x10e6, 1x10e6, 2x10e6, 5x10e6 or 10x10e6 Treg/kg body weight
89040132|NCT04683315|Experimental|Subtype diagnosis and classification: Basal|Patients will be classified by (molecular) subtype (using the PurIST classifier) into two groups: basal and classical pancreatic cancer. Upon diagnosis, patients categorized as basal will receive two months of the Gemcitabine/Nab-paclitaxel Treatment Regimen.
89040133|NCT04683315|Experimental|Subtype diagnosis and classification: Classical|Patients will be classified by (molecular) subtype (using the PurIST classifier) into two groups: basal and classical pancreatic cancer. Patients in the classical group will receive two months of the mFOLFIRINOX Treatment Regimen.
89040134|NCT04683315|Experimental|Basal Group: Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
89040135|NCT04683315|Experimental|Classical Group: Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
89040136|NCT04683315|Experimental|Basal Group: Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
89040137|NCT04683315|Experimental|Classical Group: Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
89057408|NCT02215694|Placebo Comparator|placebo group|consumed 2g of powder daily without probiotics
89630961|NCT05564169|Experimental|Masitinib (4.5) & SOC|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Dose up-titration is subjected to a safety control. Masitinib will be administered as an add-on to cholinesterase inhibitor and/or memantine standard of care (SOC).
89630962|NCT05564169|Placebo Comparator|Placebo & SOC|Participants receive a matched dose placebo, given orally twice daily. Placebo will be administered as an add-on to cholinesterase inhibitor and/or memantine standard of care (SOC).
89630963|NCT05561816|Experimental|Dioxidin|Patients will apply Dioxidin® 3 times a day (in the morning, afternoon and evening) by spraying (4 pressings of the spray nozzle on each affected area corresponding to 1% of the body area) on the affected skin areas from a distance of about 10 cm, so that the entire affected surface is covered with the solution. After application, you should wait until the preparation is completely dry. The therapy duration will be 10 days.
89630964|NCT05561816|Active Comparator|Miramistin|Patients will apply Miramistin® to the affected areas of the skin by wiping with sterile gauze swabs liberally moistened with the preparation three times a day (in the morning, lunchtime, and evening). The therapy duration will be 10 days.
89630965|NCT05558462|Experimental|RT-sequence|Group 1 (12 volunteers, RT sequence) will take 4 tablets of XC8, 10 mg, in Period 1 and 1 tablet of XC8, 40 mg, in Period 2
89630966|NCT05558462|Experimental|TR-sequence|Group 2 (12 volunteers, sequence TR) will take 1 tablet of XC8, 40 mg, in Period 1 and 4 tablets of XC8, 10 mg, in Period 2.
88990512|NCT02057185||Study population|"Patients diagnosed with Chronic Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndromes (low risk), Chronic Thrombocytopenia or Hodgkin Disease in complete remission, who have signed written informed consent according to ICH/EU/GCP and Italian laws, aged between 15 and 74 years old.~The study excludes non Italian speaking patients or unable to fully understand the study's forms."
89630967|NCT05557721||MP-TLT in topical anesthesia|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage. Thereafter, MP-TLT will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations. In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning.
89630968|NCT05546788|Active Comparator|hydroxylated polymethyl flavones group|SRP then hydroxylated polymethyl flavones addition
89630969|NCT05546788|Active Comparator|Chlorohexidine group|SRP then Chlorohexidine gel application
89630970|NCT05546788|Placebo Comparator|placebo group|SRP then placebo gel application
89630971|NCT05544916|Experimental|XC221|Patients will take 1 tablet of XC221, tablets, 100 mg twice daily, in the morning (between 7:00 and 11:00 a.m.) and in the evening (between 7:00 and 11:00 p.m.), for 5 days.
89630972|NCT05544916|Placebo Comparator|Placebo|Patients will take 1 placebo pill orally twice a day, in the morning (between 7:00 and 11:00 a.m.) and in the evening (between 7:00 and 11:00 p.m.), for 5 days.
89630973|NCT05534802|Sham Comparator|Conventional treatment group|Cardiac surgery patients undergoing cardiopulmonary bypass are not treated with ulinastatin
89630974|NCT05534802|Experimental|Ulinastatin|Cardiac surgery patients undergoing cardiopulmonary bypass are treated with ulinastatin
89630975|NCT05534256|Experimental|Intervention Group|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth.
89630976|NCT05534256|No Intervention|Control Group|The control group will receive usual medical care and American Heart Association's Healthy Living booklet
88990516|NCT01824875|Experimental|Arm A (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
88990517|NCT01824875|Experimental|Arm B (temozolomide and capecitabine)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
88990518|NCT01814397||Women starting AI therapy|There is only a single cohort. Postmenopausal women with ER positive breast cancer who are starting treatment with anastrozole 1 mg daily, letrozole 2.5 mg daily, or exemestane 25 mg daily. Choice of therapy is at the discretion of the treating physician.
88990519|NCT01754025||Cancer patients with T790M|Have a diagnosis of cancer of any type. Have an EGFR T790M mutation identified on either genotyping of their cancer at diagnosis OR on quantitative plasma genotyping with evidence of high level (>40% allelic fraction) EGFR T790M. OR another EGFR mutation previously reported as germline detected on tumor genotyping of their cancer.
88990520|NCT01754025||Relatives of Carriers|Have a relative known to carry a germline EGFR mutation (either T790M or other novel germline EGFR mutation)
88990521|NCT01754025||Individuals known to be carriers|Have a known germline EGFR mutation (either T790M or other novel germline EGFR mutation)
88990522|NCT01701986|Experimental|Treatment (gemcitabine, clofarabine, busulfan, BMT or PBSCT)|"PREPARATIVE REGIMEN: Patients receive gemcitabine hydrochloride IV over 40-180 minutes on days -6 and -4, clofarabine IV over 1 hour on days -6 to -3, and busulfan IV over 3 hours on days -6 to -3. Patients with matched unrelated donors also receive antithymocyte globulin IV on days -3 to -1 and patients with CD20-positive disease also receive rituximab IV on days -14, -7, 1, and 8.~TRANSPLANT: Patients undergo allogeneic BMT or PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO beginning on day -2 for up to 6 months and mycophenolate mofetil IV over 2 hours or PO TID beginning day 0."
88990523|NCT01696734|Experimental|Treatment (domperidone)|Patients receive domperidone PO TID or QID. Treatment continues in the absence of disease progression or unacceptable toxicity.
89040138|NCT04683315|Experimental|Basal Group: Restaging: Local Disease Progression|Further treatment will be based on treatment response. If the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
89630977|NCT05510089|Experimental|EAP regimen|The combination regimen of etoposide, cytarabine and PEG-rhG-CSF.
89630978|NCT05504408||Systemic Mastocytosis with associated t(8;21) AML|SM and AML were diagnosed according to the 5th edition WHO classification criteria.
89630979|NCT05504408||The t(8;21) AML without Systemic Mastocytosis|The t(8;21) AML patients do not have associated Systemic Mastocytosis according to the 5th edition WHO classification criteria and no AML1-ETO clone was detected in mast cells.
89630980|NCT05504408||OSM (Oligo-mastocytic SM) with associated t(8;21) AML|The t(8;21) AML patients do not have associated Systemic Mastocytosis according to the 5th edition WHO classification criteria, but AML1-ETO clones were detected in mast cells.
89630981|NCT05497492|Active Comparator|P group|single administration of propofol
89630982|NCT05497492|Experimental|P + S group|administration of propofol and sufentanil in combination
89630983|NCT05497492|Experimental|P + K group|administration of propofol and esketamine in combination
89630984|NCT05497492|Experimental|P + L group|administration of propofol and lidocaine in combination
89630985|NCT05453500|Experimental|Treatment (DA-EPOCH+/-R, tafasitamab)|Patients receive etoposide, doxorubicin, and vincristine IV continuously over 96 hours on days 1-4 of each cycle, cyclophosphamide IV over 1 hour on day 5 of each cycle, prednisone PO BID on days 1-5 of each cycle, and tafasitamab IV weekly on days 1, 8, and 15 of each cycle. CD20 positive patients also receive rituximab IV per guidelines on days 1 or 5 of each cycle. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89630986|NCT05427838||Intervention (training)|"Subjects undergo online CT Head interpretation training:~Summary:~The trial participants will be required to complete a baseline assessment where users will review a set of scans and provide a diagnosis before submitting the case. Users will then be given access to an online training module. Once the training is completed, the users will complete a second assessment.~They will then be asked to evaluate a minimum of 30 CT scans each during their clinical shifts over a 3-month period. They will be asked to record their scan interpretation, the time the scans was performed, and the time they reviewed the scan. They will also be asked to retrospectively document the findings of the standard clinical radiology report, and the time it was issued.~At the end of the 3 month period they will repeat the online assessment to assess their performance, and again after a further three months to assess their retention of any improvement in reporting performance."
89630987|NCT05427838||Control (no Training)|"Subjects do not undergo online CT Head interpretation training:~Summary:~To provide a control for comparison as to the relative benefits of the online training phase and the clinical interpretation phase in terms of improving reporting performance, 30 participants (6 clinicians from each site) will be randomised to undertake the clinical interpretation phase prior to the training module."
89630988|NCT05426954|Active Comparator|BFR deflate|BFR cuff will be deflated at the end of each of the 4 BFR exercises, BFR cuff is inflated prior to start next BFR exercise.
89630989|NCT05426954|Active Comparator|BFR do not deflate|BFR cuff will not be deflated at the end of each of the 4 BFR exercises. Cuff remains inflated start exercise 1 thru completion exercise 4.
89630990|NCT05416086|Other|iCLAS Cryoablation arm|all subjects will receive a cryoablation procedure with the iCLAS System and be followed up for 12-month
89630991|NCT05414136|Experimental|A1/3mg/kg|Dose: 3mg/kg
89630992|NCT05414136|Experimental|A2/6mg/kg|Dose: 6mg/kg
89630993|NCT05414136|Experimental|A3/10mg/kg|Dose: 10mg/kg
89630994|NCT05414136|Experimental|A4/15mg/kg|Dose: 15mg/kg
89630995|NCT05414136|Experimental|A5/20mg/kg|Dose: 20mg/kg
89630996|NCT05410496|Experimental|TAF switching therapy cohort|A prospective single-arm cohort to evaluate the safety, drug adherence, and efficacy of TAF switching therapy in kidney or liver or transplant patients with chronic HBV infection.
89630997|NCT05410210|Experimental|Pharmaceutical care|The intervention group will receive the pharmaceutical care from a pharmacist and the existing standard care available in the Parkinson's disease and movement disorders clinic.
89630998|NCT05410210|No Intervention|Usual care|The usual care includes the current existing care provided to patients in the Parkinson's disease and movement disorders clinic except the pharmaceutical care provided by pharmacists.
89630999|NCT05408754|Experimental|Pulsed Field Ablation (PFA) group|PsAF patients treated by PFA
89631000|NCT05408754|Experimental|Pulsed Field CryoAblation (PFCA) group|PsAF patients treated by PFCA
89631001|NCT05391126|Experimental|Genocare Guided|
89631002|NCT05391126|No Intervention|Usual Care|
89631003|NCT05388643|Experimental|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
89631004|NCT05388643|Active Comparator|Standard of Care GDM Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
89631005|NCT05384938|Other|Benralizumab|Single arm, Phase-IV
89040139|NCT04683315|Experimental|Classical Group: Restaging: Local Disease Progression|Further treatment will be based on treatment response. If the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
89040140|NCT04677790|Active Comparator|"Very short arm (12 months)"|Very short arm (12 months): 3 months between every step. Step by step gradual introduction of egg containing food products during 12 months, unless next step can not be taken.
89040141|NCT04677790|Active Comparator|"Short arm (20 months)"|Short arm (20 months): 5 months between every step. Step by step gradual introduction of egg containing food products during 20 months, unless next step can not be taken.
89631006|NCT05371132|Experimental|Basic science (zirconium Zr 89-Df-crefmirlimab, PET, SBRT)|Patients receive zirconium Zr 89-Df-crefmirlimab IV over 5-10 minutes and then under PET imaging 24 hours after infusion before and after SBRT. Patients undergo SBRT every 2-5 days for a total of 5 fractions. For lymphoma patients only, IMRT on consecutive days may be used.
89631007|NCT05370937|Active Comparator|ELEVATOR|After knotting the posterior root of the medial meniscus with a fiber rope, a tunnel will be opened for the rope to pass through the medial of the proximal crest of the tibia. Then, arthroscopically, the rope will be taken through the joint and passed through the tunnel, and the knot will be fixed to the tibia by using the endobutton elevator system
89631008|NCT05370937|Active Comparator|FREE KNOT|The first stage of fixation is the same, and fixation to the tibia will be done with an endobutton by tying a free knot without using an elevator system.
89631009|NCT05357508|Experimental|Intervention group|Participants in the Intervention group receive a brochure with their personalized risk score for colorectal cancer and screening recommendations (FIT or colonoscopy) corresponding to their risk level.
89631010|NCT05357508|Active Comparator|Usual care group|Participants in the Usual care group receive the standard brochure designed by the Vaud screening program. This brochure recommends screening to all individuals beginning at age 50 and presents both FIT and colonoscopy as equal options.
89631011|NCT05346029|No Intervention|Standard of care|Patients will be followed-up according to standard clinical practices
89631012|NCT05346029|Experimental|Lifestyle intervention|Patients will undergo a 12 week lifestyle intervention (physical therapy and nutritional assessment)
89631013|NCT05345990|Experimental|Hepatitis B immunoglobulins|"20 patients treated in two cohorts for 12 weeks with hepatitis B Immunoglobulins (HBIG, Hepatect®CP/ Zutectra®).~Cohort A:~10 HBsAg positive, HBeAg-negative patients being treated with anti-HBV nucleotide or nucleoside analogous (NAs) for at least 12 months before screening. HBV-DNA should be below the lower limit of detection at screening. HBsAg should be positive and below 100 IU/ml.~Cohort B:~10 HBsAg positive, HBeAg-negative patients untreated with NAs for at least 12 months before screening. Patients with HBV-DNA levels below 2000 IU/ml and ALT < 1.5 times upper the limit of normal. HBsAg should be positive and below 100 IU/ml.~Trial duration: A recruiting period of approximately 6 months is planned. The total time per patient to complete all study visits is approximately 40 weeks including:~an 28 day screening period~an 12 week treatment period~an 24 week follow-up period"
88990524|NCT01665144|Experimental|Siponimod (BAF312)|Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on the treatment epoch for 3 months. During the Core Part of the study, participants participated in a maximum of 3 epochs. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312.
88990525|NCT01665144|Placebo Comparator|Placebo|Matching placebo to BAF312 was administered orally during the Core Part of the trial. Following the Core Part, eligible participants enter the Extension Part during which all receive open-label BAF312.
88990526|NCT01651065|Experimental|Microclinic Social Network Program|Subjects will be receiving a 10/9-month Microclinic Diabetes Education Program (Team Up 4 Health) and 6 months of follow up. In the intervention these subjects will engage in the Microclinic Program support groups. The intervention program consists of 25 event sessions. Sessions are offered weekly the first month, and biweekly thereafter.
88990527|NCT01651065|Active Comparator|Active Controls|Individuals will receive screening by clinical staff. Control group subjects are offered standard of care from local health department, but will not participate in program activities, other than offered option to join open-community health events.
89631014|NCT05342012|Experimental|Experimental: Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 140ml a day for 2 weeks, and finally visit the investigators once more following another 140ml drink.
89631015|NCT05342012|Experimental|Experimental: Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 140ml a day for 2 weeks, and finally visit the investigators once more following another 140ml drink.
89631016|NCT05324306|Experimental|Application of Tourniquets on Lower Extremities|Participants will have their baseline blood pressure measured in their upper extremities followed by application of CAT tourniquets to both lower extremities. Blood pressure will be measured again in the upper extremities once the CAT tourniquets are deployed. This will be repeated 3 times.
89631017|NCT05321719|Experimental|Experimental: BeReady2Smile Video, App, & Coach|This arm will test the feasibility of the BeReady2Smile Video and App to promote dental health of young children with a parent education program.
89631018|NCT05321719|Experimental|Assess the Contributions of BRS2 Components|Outcomes of video, app, and coach
89631019|NCT05318690|Experimental|PlayGait (Exoskeleton)|Experimental lower-limb device.
89631020|NCT05318690|Active Comparator|Baseline|Baseline condition without using any prescribed lower-limb orthoses.
89631021|NCT05308264|Experimental|Experimental|Dose Level 1: 250mg PO qd Dose Level 2: 500mg PO qd Dose Level 3: 750 mg PO qd and 1000 mg PO qd
89631022|NCT05302011|Experimental|Neoadjuvant Pembrolizumab Plus Chemotherapy|Neoadjuvant Pembrolizumab Plus Chemotherapy
89631023|NCT05296746|Experimental|Responder (ROR-low)|Ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years
89631024|NCT05296746|Other|Non-responder (ROR-medium/high)|"Adjuvant chemotherapy. 3 regimens are permitted.~Regimen 1:~- Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2) and Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles, followed by Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks.~Regimen 2:~- Docetaxel 75-100 mg/m2 IV day 1 and Cyclophosphamide 600-830 mg/m2 day 1 every 21 days for 4-6 cycles.~Regimen 3:~- Paclitaxel 80 mg/m2 every week for 12 weeks or Docetaxel 75-100 mg/m2 every 3 weeks for 12 weeks followed by Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2) and Cyclophosphamide 600-830 mg/m2 day 1 every 14/21 days for 4 cycles.~Then, patients will receive ribociclib (400 mg/day; 3 weeks ON and 1 week OFF) in the adjuvant setting for 33 cycles. Letrozole or other aromatase inhibitor treatment duration must be of at least 5 years"
89631025|NCT05291260|Experimental|Cast immobilization|Cast immobilization to immobilize the thumb for 4 weeks. After 2 weeks the thumb will be re-examined to determine if surgery is required. It is expected that at re-evaluation at 2 weeks after starting the cast treatment about 1 in 10 patients will still need surgery.
89631026|NCT05291260|Active Comparator|Surgery|The intervention is compared to surgery, which is standard treatment for complete ulnar collateral ligament ruptures.
89631027|NCT05289570|Experimental|Voxelotor Arm|500 mg of Voxelotor two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day), if subject tolerates the initial dose as determined by study doctor.
89631028|NCT05287399|Experimental|ASC61 200 mg 1|ASC61 200 mg orally once
89631029|NCT05287399|Experimental|ASC61 200 mg 2|ASC61 200 mg orally twice daily
89631030|NCT05287399|Experimental|ASC61 300 mg|ASC61 300 mg orally twice daily
89631031|NCT05287399|Experimental|ASC61 400 mg|ASC61 400 mg orally twice daily
89631032|NCT05287399|Experimental|ASC61 600 mg|ASC61 600 mg orally twice daily
89631033|NCT05279872|Experimental|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
89631034|NCT05265338|Experimental|Group A|In the fasting state, KC1036 po only once (60mg QD) and after 7 days，in the high fat diet state，KC1036 po only once (60mg QD).
89631035|NCT05265338|Experimental|Group B|In the high fat diet state, KC1036 po only once (60mg QD) and after 7 days, in the fasting state, KC1036 po only once (60mg QD).
89631036|NCT05253820|Experimental|distal radial approach group|subjects randomized to experimental group were underwent coronary diagnosis and intervention via distal radial approach
88990528|NCT01602666|Experimental|Treatment (combination chemotherapy, radiation therapy)|See Detailed Description
89040142|NCT04645732|Experimental|Personalized exercise therapy and self-management program in addition to usual care|"Participants randomized to the personalized exercise therapy and self-management support program will participate in a 12-week program tailored to people with multimorbidity at one of the intervention sites. The program will consist of 24 exercise therapy and self-management sessions distributed across the program (twice weekly, each lasting around 1.5 hour).~Furthermore, this group will receive the treatment described under usual care below."
89040143|NCT04645732|Active Comparator|Usual care alone|Usual care is the care that the participants would receive had they not participated in the study, i.e. treatments or services that are routinely provided in the settings from which the participants are recruited. Participants will continue their current treatment, if needed, and be allowed to receive other treatments if their general practitioner or specialist finds it relevant for their particular comorbidities.
89040144|NCT04645667||Adult patients of allogeneic hematopoietic HCT|Patients who receive their first allogeneic HCT transplant and who receive tacrolimus for aGVHD prophylaxis per standard of care.
89631037|NCT05253820|Active Comparator|conventional radial access group|subjects randomized to active comparator group were underwent coronary diagnosis and intervention via conventional radial approach
89631038|NCT05245552|Experimental|Safety group|PhaseⅠ,30 subjects will receive two doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.
89631039|NCT05245552|Experimental|Experimental Group of quadrivalent influenza vaccine(0.25ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.25ml) on the immunization schedule of day 0,28.
89631040|NCT05245552|Experimental|Experimental Group of quadrivalent influenza vaccine(0.5ml)|1100 subjects phase III will receive two doses of quadrivalent influenza vaccine(0.5ml) on the immunization schedule of day 0,28.
89631041|NCT05245552|Active Comparator|Control Group of trivalent influenza vaccine(BV)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BV) on the immunization schedule of day 0,28.
89631042|NCT05245552|Active Comparator|Control Group of trivalent influenza vaccine(BY)|550 subjects phase III will receive two doses of trivalent influenza vaccine(BY) on the immunization schedule of day 0,28.
89631043|NCT05237583|Experimental|Prehabilitation|Multimodal prehabilitation program
89631044|NCT05236335|Experimental|Ketone ester|
89631045|NCT05236335|Placebo Comparator|Placebo|
89631046|NCT05211284|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (72 weeks)
89631047|NCT05211284|Placebo Comparator|Placebo Arm|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (72 weeks).
89631048|NCT05206227|Experimental|Aerobic Exercise|Blood and skeletal muscle microdialysate collected during dynamic knee-extension exercise
89631049|NCT05206227|Experimental|Heating|Blood and skeletal muscle microdialysate collected during local and/or whole body heating
89631050|NCT05206227|Experimental|Resistance and Aerobic Exercise|Blood and urine collected during recovery from two modalities of exercise
89631051|NCT05206227|Experimental|Aerobic Exercise and Muscle Perfusion|Muscle perfusion measured during aerobic exercise
89631052|NCT05199350||Population including people with NGT, IFG and IGT and diabetes.|"Normal Glucose Tolerance (NGT) is defined as a plasma glucose concentration i.e < 140 mg/dl.~IFG is defined by an elevated fasting plasma glucose (FPG) concentration i.e ≥ 100 and < 126 mg/dl.~IGT is defined by an elevated post-prandial plasma glucose concentration i.e ≥140 and < 200 mg/dl.~Presence of confirmed diabetes (HbA1c level > 6.4 %) without complications i.e no neuropathy, no retinopathy, no nephropathy etc.~Presence of confirmed diabetes (HbA1c level > 6.4 %) with at least one of the above complications."
89631053|NCT05172336||Assisted reproductive technology (Biopsied ICSI)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
89631054|NCT05172336||Assisted reproductive technology (Non-Biopsied ICSI)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
89631055|NCT05172336||Spontaneous conception (SC)|the study materials that will be used will include fetal ultrasound (fetal echocardiography) at 29 weeks ± 1week gestation.
89631056|NCT05159570|Experimental|Ketone ester|
89631057|NCT05159570|Placebo Comparator|Placebo|
89631058|NCT05156762|Experimental|Bariatric surgery group|Participants randomized to the bariatric surgery arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass to achieve a BMI ≤ 40 kg/m2.
89631059|NCT05156762|Experimental|Medical weight loss group|Participants randomized to the medical weight loss study arm will attempt to lose weight through diet, exercise, and potentially pharmacotherapy an effort to lower their BMI to ≤ 40 kg/m2.
89631060|NCT05156762|Other|"Usual Standard of Care"|"Patients randomized to the usual standard of care study arm will be counseled on the importance of losing weight to optimize their BMI and will be provided with referral information (name and clinic number) to either the bariatric surgery or medical weight loss clinics."
89040145|NCT04644029|Experimental|ISL QM|ISL (islatravir) once monthly AND placebo to FTC/TDF (emtricitabine/tenofovir disoproxil) once daily during Part 1.
89631061|NCT05154981|Experimental|Partners in School with Education Communication Skills (ECS) Training|Parents and teachers in the experimental condition will receive Partners in School with communication training.
89631062|NCT05154981|Active Comparator|Partners in School without Education Communication Skills (ECS) Training|Parents and teachers in the control condition will receive Partners in School without communication training.
89631063|NCT05123807|Other|Cytoreductive surgery|
89631064|NCT05118672|Experimental|Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)|Group 1: paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg FDC (experimental drug).
89631065|NCT05118672|Placebo Comparator|Placebo group|Group 2: Placebo
89631066|NCT05100212|Active Comparator|Adult-RBC transfusions|Adult-red blood cell concentrate transfusions
89631067|NCT05100212|Experimental|CB-RBC transfusions|Cord blood-red blood cell concentrate transfusions
89631068|NCT05088603|Experimental|Clear Mask|Subjects randomized to this group will have a neurologist who wears a clear mask during their procedure and during their interaction with the subject.
89631069|NCT05088603|No Intervention|Standard Mask|Subjects randomized to this group will have a neurologist who wears a standard mask during their procedure and during their interaction with the subject.
89040146|NCT04644029|Active Comparator|FTC/TDF QD|FTC/TDF (TRUVADA™ or generic product emtricitabine/tenofovir disoproxil) administered once daily in Parts 1, 2, and 3. Placebo to ISL (islatravir) also administered once monthly during Part 1.
89040147|NCT04640077|Other|Part A Validation of Remote Scale Assessments|"Alternating at-home and on-site cognitive and functional scale assessments~Group 1: Cognitive/functional scale assessment at the study site (on-site), followed by an at-home assessment (VTC; video teleconference), or Group 2: Cognitive/functional scale assessment at home (VTC), followed by assessment on-site"
89040148|NCT04640077|Other|Part B Donanemab|Donanemab administered intravenously (IV)
89631070|NCT05084066|Experimental|Experimental group|20 patients with PAD and claudication
89040149|NCT04626297|Experimental|Lebrikizumab|Participants received a loading dose of 500 milligram (mg) lebrikizumab injection administered subcutaneously (SC) at baseline and week 2, and 250 mg once every two weeks (Q2W) from week 4 to 14.
89631071|NCT05084066|Sham Comparator|Control group (sham)|20 patients with PAD and claudication
89631072|NCT05082584|Experimental|Vadadustat|Cohort 1: participants with ≥12 years to <17 years; Cohort 2: participants with ≥6 years to <12 years; Cohort 3(a): participants with ≥2 years to <6 years; and Cohort 3(b): participants with ≥4 months to <2 years
89631073|NCT05053633||Combined spinal epidural anesthesia|The assessments are conducted in conscious patients under the procedure of Combined spinal epidural anesthesia.
89631074|NCT05045482|Experimental|Saroglitazar Magnesium 1 mg|"The study drug will be administered from Day 1 to Day 28 once daily in the morning before breakfast without food.~Study drug -Saroglitazar Magnesium tablets; Dosage form- Tablets (immediate release); Dose- 1 mg/day; Frequency- One tablet per day (in the morning before breakfast without food); Duration of treatment- 28 consecutive days"
89631075|NCT05045482|Experimental|Saroglitazar Magnesium 2 mg|"The study drug will be administered from Day 1 to Day 28 once daily in the morning before breakfast without food.~Study drug -Saroglitazar Magnesium tablets: Dosage form- Tablets (immediate release); Dose- 2 mg/day; Frequency- One tablet per day (in the morning before breakfast without food); Duration- 28 consecutive days"
89631076|NCT05039411|Experimental|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|Two million cells per milliliter (2M/mL) with a total of 60 million PF2020-CELL (UC-MSCs) will be injected locally around the fistula tract, with a separation of 1 cm between injections. All patients to receive allogeneic PF2020-CELL (UC-MSCs) via intralesional injection for 5 consecutive visits, with a 4-week interval between the injections. If the patient is completely healed during any course of stem cell injections, subsequent stem cell treatments can be discontinued. However, patients will still be required to undergo regular follow-up examinations, including physical examinations and other medical tests, until the study is completed.
89631077|NCT05030558|Experimental|Interventional group|The web-supported interactive nursing program intervention will last 4 weeks. In the first week of the training, the identity and causes of the disease, which is one of the sub-dimensions of the perception of illness, will be emphasized, and the themes of misperception determined in this field through qualitative study will be emphasized. In the second week, they will be asked to look at training sessions that discuss perceptions of the illness's timeline and consequences. In the last two weeks of the training, they will be asked to attend the trainings for the control of Fibromyalgia symptoms. During the study, short mobile phone messages containing reminders and motivations will be sent regularly twice a week (8 times). Data collection forms will be applied to the intervention group 3 times before starting the web-based interactive nurse program, at the end of the program (in the 1st month) and then at the end of the 2nd month.
89631078|NCT05030558|Active Comparator|Control Group|"The Fibromyalgia patient booklet of the Turkish Physical Medicine and Rehabilitation Association will be available in pdf format on the website of the participants assigned to the control group. Participants in this group will be able to access other trainings after the end of the study, if they wish.~Data collection forms will be applied to the control group 3 times in total, before the start of the study, in the 1st month and the 2nd month of the study."
89040150|NCT04626297|Placebo Comparator|Placebo|Participants received placebo SC injection Q2W from baseline to week 14.
89040151|NCT04621526|Active Comparator|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
89040152|NCT04621526|Active Comparator|dexmedetomidine- propofol|patients will receive combination from 1 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
89040153|NCT04592809|Active Comparator|Ketamine|0.5 mg/kg intravenous ketamine will be administered 4 times in a 2 week period. Ketamine will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
89040154|NCT04592809|Active Comparator|Midazolam|0.02 mg/kg midazolam will be administered 4 times in a 2 week period. Midazolam will be dissolved in 0.9% sodium chloride in a total volume of 100ml and administered with a syringe infusion pump at a constant rate.
89040155|NCT04584255|Experimental|Arm A Triple Negative Breast Cancer (TNBC)|"Participants will be randomized 1:1 to treatment with the combination (Arm A)~Niraparib-Daily beginning with week 1, day 1~Dostarlimab-Once every three weeks beginning with week 1, day 1"
89040156|NCT04584255|Experimental|Arm B TNBC|"Participants will be randomized 1:1 to treatment with the combination (Arm B)~3-week lead-in of niraparib monotherapy followed by treatment with the combination~Niraparib Daily beginning with week 1, day 1~Dostarlimab Once every three weeks beginning with week 4, day 1"
89040157|NCT04584255|Experimental|Arm C ER+/HER2-|"exploratory cohort of estrogen receptor (ER) positive HER2-negative participants will be enrolled to Arm C.~Niraparib Daily beginning with week 1, day 1~Dostarlimab Once every three weeks beginning with week 1, day 1"
88990529|NCT01527149|Experimental|Treatment (monoclonal antibody and combination chemotherapy)|"COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or PO on days 3-6 and 13-16.~COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5.~All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Eligible patients then undergo standard HDC-ASCT."
88990530|NCT01514552|Placebo Comparator|Placebo gummy|Each 6 gram placebo gummy contains 79% corn syrup (Karo, ACH Food Companies, Memphis, TN), 20% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL), 1% artificial strawberry flavors (Kool-Aid Kraft Foods, East Hanover, NJ).
88990531|NCT01514552|Active Comparator|Strawberry gummy|Each 6 gram strawberry gummy contains 45% freeze-dried fruit (California Strawberry Commission), 44% corn syrup (Karo, ACH Food Companies, Memphis, TN), 11% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL). With this formulation, daily fruit consumption is equivalent to 1 cup of whole strawberries. All ingredients (wheat starch, freeze-dried fruit, and high fructose corn syrup) will be purchased from a single lot. When a single lot is not available then the multiple manufacturing lots will be mixed into a single lot to be used for production of fruit gummies.
88990532|NCT01494753|Active Comparator|Prostaglandin|One drop.
88990533|NCT01494753|Experimental|T2345|One drop
88990534|NCT01471834|Experimental|Device and Medical Management|Participants will be implanted with the BAROSTIM NEO System and will continue to receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
88990535|NCT01397864||Hereditary Angioedema|
88990536|NCT01365169|Experimental|Arm I (colorectal cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
88990537|NCT01365169|Experimental|Arm II (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
88990538|NCT01365169|Experimental|Arm III (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.
89057409|NCT01648725|Experimental|Hypnosis|standard care plus hypnosis followed by closed-loop administration of propofol for anesthesia induction
89057410|NCT01648725|Active Comparator|Control|standard care without hypnosis followed by closed-loop administration of propofol for anesthesia induction
89631079|NCT05015088||Gastrocnemius Stretching Group|The study will enroll 20 healthy subjects between the ages of 18 to 65 years old. Individuals will be recruited from multiple locations. Exclusion criteria include: any boney or tendinous foot/ankle operative procedure, diagnosis of neuromuscular disorder, any previous ankle fracture or degenerative changes that would limit dorsiflexion range of motion. Participants must have no obvious gait asymmetries demonstrated through observation. In addition, participants who are pregnant will be excluded from participation in the study.
89631080|NCT05008484|Experimental|NMES Plus Vitamin D|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach and 2000IU oral vitamin D supplementation daily for 9 months.
89631081|NCT05008484|Experimental|Passive movement plus vitamin D|Subjects will undergo 9 months of simple passive movement exercise at home and 2000IU oral vitamin D supplementation daily for 9 months.
89631082|NCT04980495|Experimental|efgartigimod IV - I|Patients receiving efgartigimod IV treatment (Continuous regimen: efgartigimod 10 mg/kg q2w)
89631083|NCT04980495|Experimental|efgartigimod IV - II|Patients receiving efgartigimod IV treatment (Cyclic regimen: efgartigimod 10 mg/kg q7d for a total of 4 infusions per TP for 2 TPs with a fixed 4-week IP between each TP)
89631084|NCT04978090|Experimental|Enteroatmospheric fistula (EAF) management solution|Participants will receive a custom fitted device designed to isolate EAF effluent independent of negative pressure wound therapy (NPWT) utilizing 3D printing technology to design a participant-matched device that more easily and effectively separates the participant's fistula and any emanated intestinal contents surrounding the wound.
89631085|NCT04972383|Experimental|Platelet Rich Plasma group|single injection platelet rich plasma
89631086|NCT04972383|Experimental|Hyaluronic Acid group|single injection of hyaluronic acid
89631087|NCT04953754|Experimental|Melatonin Group|This group will get melatonin 5mg nightly
89631088|NCT04953754|Active Comparator|Control Group|This group will not get any treatment (melatonin)
88990539|NCT01365169|Experimental|Arm IV (cancer survivors that are current/former smokers)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
88990540|NCT01365169|Experimental|PCS (pancreatic surgery patients)|Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.
88990541|NCT01365169|Experimental|TAPS (Technological Approach to Performance Status)|Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.
88990542|NCT01032603|Active Comparator|Bilateral lateral rectus recession|Bilateral lateral rectus recession surgery
88990543|NCT01032603|Active Comparator|Unilateral lateral rectus recession|Unilateral lateral rectus recession w/ medial rectus resection surgery
88990544|NCT00962910|Experimental|Pathway|A care pathway will be implemented in this experimental group.
88990545|NCT00962910|No Intervention|Usual Care|Usual Care will be provided.
88990546|NCT00946881|Experimental|WST11 (TOOKAD® Soluble)|WST11-mediated-VTP The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers using 753 nm laser light at escalating fixed energy doses
88990547|NCT00616967|Active Comparator|Arm I|Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
88990548|NCT00616967|Experimental|Arm II|Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
88990549|NCT00502463|Experimental|Single Arm|3 cycles of induction chemotherapy consisting of docetaxel, cisplatin, and 5-FU followed by radiotherapy plus cetuximab
88990550|NCT00390793|Experimental|Treatment (chemotherapy, dasatinib)|See detailed description in outline.
88990551|NCT00338377|Experimental|Group A: Chemotherapy + IL-2 plus T-cells|"Cyclophosphamide 60 mg/kg/d by vein (IV) over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.~Group A has been closed to new patient entry as of January 14, 2016."
88990552|NCT00338377|Experimental|Group B: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
88990553|NCT00338377|Experimental|Group C: Prior Treatment with BRAF Inhibitor|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
88990554|NCT00338377|Experimental|Group D: Leptomeningeal Disease|"T-cells: 5.0x109 TIL administered on Day 1 and 10x109 TIL on Day 15.~IL-2: 1.2 MIU of IL- 2 on Days 2, 4, 9, 11, 16 and 18 as tolerated. After this period, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks, patients switched to IL-2."
89631089|NCT04945239|Experimental|Amplification of Positivity Training (6 Sessions)|
89631090|NCT04945239|Active Comparator|Stress Management Training (6 Sessions)|
89631091|NCT04913285|Experimental|Dose Escalation Monotherapy (Part A1)|Dose escalation of KIN-2787
89040158|NCT04567407|Experimental|Bilateral erector spinae blocks|All enrolled patients will have bilateral erector spinae blocks (with catheters for postoperative local anesthetic infusion) placed by the by a member of the clinical regional anesthesia team (under the supervision of a member of the research team) in a sterile fashion after the cardiac surgical procedure is completed. Postoperative continuous infusion of local anesthetic (ropivacaine) via the nerve block catheter is initiated and managed by the Acute Pain Service (per standardized, clinical weight-based protocols).
89040159|NCT04566978|Experimental|Cohort 1|Up to 3 participants will be enrolled to receive a single dose of 89Zr-DFO-REGN3767 (total 2mg antibody mass). Participant to undergo 3 PET/CT scans and concurrent blood draws for PK
89040160|NCT04566978|Experimental|Cohort 2|Up to 3 participants will be enrolled to receive a total 5mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
89040161|NCT04566978|Experimental|Cohort 3|Up to 3 participants will be enrolled to receive a total 10mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
89040162|NCT04566978|Experimental|Cohort 4|Up to 3 participants will be enrolled to receive a total 20mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
89040163|NCT04533165|Experimental|Virtual exercise program|This arm will receive the virtual exercise program.
89040164|NCT04532177|Experimental|Active|
89040165|NCT04529408||COVID-19 Follow up clinic|Patients attending routine post-COVID-19 follow up clinic
89040166|NCT04529408||Pulmonary Disease clinic|Patients attending routine outpatient appointment for pulmonary disease
89040167|NCT04500964||failed transcather aortic valve (Stenotic)|
89040168|NCT04500964||failed transcather aortic valve (Regurgitation)|
89040169|NCT04500964||failed transcather aortic valve (Regurgitation and stenotic))|
89040170|NCT04465097|Experimental|Tucidinostat and Exemestane|Patients receive exemestane from week 1 to week 26 and Tucidinostat BIW from week 3 to week 26. Courses continue in the absence of disease progression or unacceptable toxicity. If the patient is premenopausal, leuprorelin or goserelin will be prescribed.
89040171|NCT04462588||Medical Treatment Group|Medical treatment group of uncomplicated acute appendisitis
89040172|NCT04462588||Surgery|Operated group of uncomplicated acute appendisitis
89040173|NCT04440150|Other|Complicated Acute Appendicitis|The patients were assigned to the complicated acute appendicitis group (Group C) based on the preoperative imaging findings (periappendiceal abscess formation or significant periappendiceal fat tissue contamination in ultrasonography and computed tomography), intraoperative exploration findings (presence of gangrenous appendicitis, perforation or abscess formation), and pathological examination findings (acute phlegmonous appendicitis, acute gangrenous appendicitis or acute perforated appendicitis).
89631092|NCT04913285|Experimental|Dose Escalation Combination therapy (Part A2)|Dose escalation of KIN-2787 and binimetinib
89631093|NCT04913285|Experimental|Dose Expansion Monotherapy (Part B1)|Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787
89631094|NCT04913285|Experimental|Dose Escalation Combination therapy (Part B2)|Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 and binimetinib
89631095|NCT04893681|Experimental|Fluoridated bottle water|5-gallon bottles containing water from the New Bern Water Resources Division's Black Creek aquifer which contains naturally-occurring fluoride in a concentration of approximately 0.8 mg/L F
89631096|NCT04893681|Placebo Comparator|Non-fluoridated bottled water|5-gallon bottles containing water from the North Lenoir Water Corporation's Black Creek aquifer which contains a negligible concentration of fluoride.
89631097|NCT04866771|Experimental|Transcranial Direct Current Stimulation (tDCS)|Facilitatory transcranial direct current stimulation (tDCS)
89631098|NCT04866771|Sham Comparator|Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group|Sham tDCS followed by a switch to anodal tDCS.
89631099|NCT04818853||COVID Patients with Aspergillosis and Other fungal Infections|All patients have been diagnosed with COVID-19. The purpose of this study is to look at this group of patients in the potential to develop Aspergillosis and other fungal infections.
89631100|NCT04795869|Experimental|Treatment (brentuximab vedotin, pembrolizumab)|Patients receive brentuximab vedotin IV over 30 minutes on day 1, and pembrolizumab IV over 30 minutes on day 3 of cycle 1, day 1 of subsequent cycles. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. After 6 cycles of treatment, patients may discontinue treatment if they experience disease progression, are eligible for stem cell transplant, or if they elect to not undergo SCT.
89631101|NCT04772131|Experimental|Desara® One|Single Incision Sling
89631102|NCT04772131|Active Comparator|Desara® Blue|Transobturator Sling
89631103|NCT04737122|Experimental|LM-061 single agent escalation|The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. The subject in single agent dose levels will be administered multiple oral doses of LM-061 once daily.
89040174|NCT04440150|Other|Uncomplicated Acute Appendicitis|The patients were assigned to the uncomplicated acute appendicitis group (Group UC) based on the increased diameter and wall thickness of the appendix and detection of minimal contamination in the surrounding fat tissue in the imaging tests; the presence of edema and the absence of gangrene, perforation or abscess in the the exploratory surgery of appendix, and confirmation of the diagnosis of acute appendicitis by the pathological examination findings
89040175|NCT04437823|Experimental|Group 1 : Treatment|Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10^5 UCMSCs per Kg body weight delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).
89040176|NCT04437823|No Intervention|Group 2: standard care|Five (5) subjects will be treated under Standard of Care (SOC) .
89040177|NCT04433065|Experimental|Primary Cohort|Device: Intrepid TTVR System
89040178|NCT04429243||GORE® VIABAHN® Stent Graft|Participants will be examined 1, 3, 6, 12 and 24 months following the GORE® VIABAHN® Stent Graft installation.
89057411|NCT04539782|Experimental|Physiotherapy intervention|Pelvic floor muscle training given by a physiotherapist in four sessions and follow up phone calls twice in 14 weeks
89040179|NCT04418011|Active Comparator|Active 10 Hz rTMS|Active treatment will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered at 10 Hz according to conventional FDA-approved parameters (4 s on and 26 s off; 3000 pulses per session; total duration 37.5 mins) .
89040180|NCT04418011|Active Comparator|Active iTBS|Active iTBS will be targeted to an intensity that is 120% of the resting motor threshold. Stimulation will be delivered in triplet 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 9 seconds.
89040181|NCT04418011|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters as either 10 Hz rTMS or iTBS.~For both active and sham stimulation, TMS coil positioning for each individual will be optimized by combining participant fMRI data, meta-analytic functional analysis, electric field modelling, and real-time neuronavigation."
89040182|NCT04409119|Experimental|HIS/LBB pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS, to correct the LBBB or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead. If that is not possible either, a left ventricular (LV) lead is implanted.
89040183|NCT04409119|Active Comparator|LV pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold), implantation of a HIS-pacing lead is attempted instead. If that is not possible or the threshold for correcting the LBBB is > 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead.
89040184|NCT04404140|Experimental|Ipatasertib + Atezolizumab + Docetaxel|"Part A (Safety Run-In): 12 Participants will be administered Ipatasertib orally once a day [QD] from Day 1 to Day 14 in combination with Atezolizumab administered by intravenous (IV infusion) every 3 weeks (Q3W) on Day 1 of each cycle (a cycle being 21 days) and Docetaxel administered by IV infusion (Q3W) on Day 1 of each cycle. Docetaxel will be administered for a maximum of 10 cycles (approximately 7 months), after which Atezolizumab and Ipatasertib will be administered as a doublet until disease progression. During Part A, a staggered recruitment will be applied to the first and potentially first 6 participants to enrol a participant only once the former one has safely overcome the safety time window (Cycle 1).~Part B (Expansion): 38 Participants will be administered Ipatasertib, Atezolizumab and Docetaxel as described above, though without a staggered enrolment or safety assessment window."
89040185|NCT04349358|Other|FDG and FCH PET/CT|
89040186|NCT04346654|Experimental|Eltrombopag + Dexamethasone|Patients will be treated with eltrombopag in combination with a standard high-dose dexamethasone (1 cycle: 40 mg QD from day 1-4) to induce sustained response off treatment.
89040187|NCT04346654|Active Comparator|Dexamethasone|Patients will be treated with a standard high-dose dexamethasone (1-3 cycles: 40 mg QD day 1-4 every 14-28 days) to induce sustained response off treatment
89040188|NCT04319094|Experimental|PEERS|Peer mentors who have experience of depression are trained and supervised to deliver depression care. Peers will meet with depressed older adults for 8 weekly meeting lasting approximately 45 minutes. Peer mentors will provide social support defined as emotional, informational and appraisal support that includes coping strategies. Peers will be supervised by a mental health professional.
89040189|NCT04319094|Active Comparator|Social interaction|A study staff member will provide eight weekly social interaction visits and phone calls to the depressed older adult.
89040190|NCT04291508|Active Comparator|IV Acetaminophen-Active|Patients randomized to the Acetaminophen arm will receive Acetaminophen at the dose of 1 gram (or 15 mg/kg if actual body weight < 50kg) in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses).
89040191|NCT04291508|Active Comparator|IV Vitamin C-Active|Patients randomized to the Vitamin C arm will receive Vitamin C at the dose of 50 mg/kg in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses). Note: This arm is now closed.
89631104|NCT04737122|Experimental|LM-061 combination escalation|The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. The subjects in combination dose levels will be administered multiple oral doses once daily of LM-061 and Toripalimab fixed dose injections every 3 weeks
89631105|NCT04732325|Experimental|Burst / kHz / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
89631106|NCT04732325|Experimental|Burst / Sham / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
89631107|NCT04732325|Experimental|kHz / Sham / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
89631108|NCT04732325|Experimental|kHz / Burst / Sham / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
89631109|NCT04732325|Experimental|Sham / Burst / kHz / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
89631110|NCT04732325|Experimental|Sham / kHz / Burst / Tonic|Participants will be randomized to one of six treatment arms. Participants will receive burst, kHz, tonic, and sham spinal cord stimulation (SCS). Each treatment will be applied for a duration of seven days. Participants will be blinded during programming.
89631111|NCT04732091||Subproject 1 - acute STEMI|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure until complete a total of 50 minutes.
88990555|NCT00338377|Experimental|Group E: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
88990556|NCT00040222||1|Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study.
88990557|NCT06182904||1|Management of pilon fractures with fibula fixation
88990558|NCT06182904||2|Management of pilon fracture without fibula fixation
88990559|NCT06182891|Experimental|Dulaglutide|Dulaglutide was injected subcutaneously at standard dose and frequency for consecutive 12 months.
88990560|NCT06182891|Active Comparator|other hypoglycemic agents not including GLP-1 receptor agonists|Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.
88990561|NCT06182878|Experimental|Tender loving care intervention|Weekly prenatal counseling messages sent via an online platform.
88990562|NCT06182865|Experimental|Ga-68 Dolacga Injection|Ga-68 Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
88990563|NCT06182852||glucagon-like peptide-1receptor agonists|Once a week, hypodermic injection.
88990564|NCT06182826|Experimental|Group A|Patients in this group will receive Core Stability Protocol with Routine Exercise Protocol. A total of 3 sessions per week for 6 weeks will be given.
88990565|NCT06182826|Active Comparator|Group B|Patients will receive Routine Exercise Protocol. A total of 3 sessions per week for 6 weeks will be given.
88990566|NCT06182813|Experimental|Group A- Experimental Group|"Group (A)/ Experimental group involves participants listening to the beta auditory beats for a duration of 25 min total.~Out of these 25 minutes, the first 20 min will be spent while listening to the beta beats stimulus and the remaining 5 minutes will be used to carry out 3 trials of 30 seconds each with a rest period of 1 minute between each trial. The average values are taken for each participant out of the three trials. The number of successful catches are noted down for this test."
88990567|NCT06182813|Active Comparator|Group B- Control Group|"Group (B)/ Control group involves participants listening to the white noise for a duration of 25 min total.~Out of these 25 minutes, the first 20 min will be spent while listening to the white noise stimulus and the remaining 5 minutes will be used to carry out 3 trials of 30 seconds each with a rest period of 1 minute between each trial. The average values are taken for each participant out of the three trials. The number of successful catches are noted down for this test."
88990568|NCT06182800|Experimental|Adebrelimab Combined with Bevacizumab and Docetaxel|"Adebrelimab: 1200 mg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Docetaxel: 60-75 mg/m2 Docetaxel is given on days 1 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
88990569|NCT06182761|Experimental|sunvozertinib in combination with Anlotinib|
88990570|NCT06182748|Experimental|Training on eccentric ergocycle (experimental group)|In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.
88990571|NCT06182748|Active Comparator|Training on concentric ergocycle (control group)|In concentric cycling, quadriceps contract to push pedals.
88990572|NCT06182735|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|"Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.~Potential CGC729 doses:~Dose level 1: 5.0×106 CAR- NKT cells/m2; Dose level 2: 1.5×107 CAR- NKT cells/m2; Dose level 3: 4.5×107 CAR- NKT cells/m2."
88990573|NCT06182709|Experimental|online modeled exposure + mental retrieval cue group exposure|online modeled exposure training followed by group exposure training, including mental retrieval cue with five standardized exposure steps
89631112|NCT04732091||Subproject 2 - acute STEMI initially treated with fibrinolytic|Participants with acute STEMI initially treated with fibrinolytic therapy within 12 hours will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI; High MI will continue after PCI procedure until complete a total of 50 minutes.
89631113|NCT04732091||Subproject 3 - NSTEMI|Participants with NSTEMI or with high-risk unstable angina will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
89631114|NCT04732091||Subproject 4 - No reflow|Participants with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2 MI) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
89631115|NCT04732091||Subproject 6 - Pre-hospital care (ambulance)|Participants with acute STEMI routing from the ambulance to the emergency department will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with 4-20 usec and custom designed high mechanical index (MI) impulses (1.1 to 1.3 MI) designed for the 1.8 MHz S5-1 transducer while waiting for percutaneous coronary intervention. A control group (PCI only) undergoing low MI (<0.2) imaging only with limited (no more than 3) diagnostic high MI impulses to assess regional wall motion and microvascular perfusion before and after PCI. High MI will continue after PCI procedure until complete a total of 50 minutes.
89631116|NCT04731207|Other|Healthy pregnant women|All participants will be investigated by Optovue® in follicular phase, ovulatory phase, luteal phase of menstrual cycle. The investigation will be done between 12 PM and 1 PM at each phase. Urine pregnancy testing was done at first and last visits. LH ovulation test was performed by the participants own. if the ovulation was detected by urine strip test, the participant have to underwent the Optovue® within 48 hours.
89631117|NCT04727398|Other|Cataract patients who was scheduled for phacoemulsification|Wide-field optical coherence tomography was performed before the surgery, and then was done at 1, 3, 6 and 12 months following the phacoemulsification.
89631118|NCT04720417|Experimental|Treatment (defactinib, VS-6766)|Patients receive defactinib PO BID and VS-6766 PO BIW (Monday and Thursday or Tuesday and Friday) for 3 weeks in every cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89631119|NCT04719949|Experimental|Behavioral Activation (BA) Therapy|Participants complete four sessions of BA, 60-90 minutes per session.
89631120|NCT04719949|Active Comparator|Problem Solving Therapy (PST)|Participants complete four sessions of PST, 60-90 minutes per session.
89631121|NCT04677504|Experimental|Arm A: Atezo+Bev+CisGem, followed by Atezo+Bev|Participants will receive atezolizumab intravenously on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. Participants will receive bevacizumab intravenously on Day 1 of each 21-day cycle. Participants will receive cisplatin intravenously followed by gemcitabine on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
89631122|NCT04677504|Active Comparator|Arm B: Atezo+PBO+CisGem, followed by Atezo+PBO|Participants will receive atezolizumab intravenously on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status. Participants will receive placebo matching bevacizumab intravenously on Day 1 of each 21-day cycle. Participants will receive cisplatin intravenously followed by gemcitabine on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
89631123|NCT04650178||Observational (questionnaire, quality of life)|Patients complete an online questionnaire over 15 minutes about their experiences regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.
89631124|NCT04635631|Experimental|talazoparib|1 mg QD
89631125|NCT04620538||Controls|Healthy Controls with or without risk factors for Chronic Liver Disease (i.e. patients referred due to concerns re: liver disease but found to have no evidence of chronic liver disease following assessment)
89631126|NCT04620538||Fibrosis|Patients with evidence of Liver Fibrosis on the basis of current diagnostic techniques / expert opinion.
89631127|NCT04620538||Compensated Cirrhosis|Patients with evidence of Compensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
89631128|NCT04620538||Decompensated Cirrhosis|Patients with evidence of Decompensated Cirrhosis on the basis of current diagnostic techniques / expert opinion.
88990574|NCT06182709|Active Comparator|live modeled exposure + mental retrieval cue group exposure|live modeled exposure training followed by group exposure training, including mental retrieval cue with five standardized exposure steps
88990575|NCT06182709|Active Comparator|online modeled exposure + standardized group exposure|online modeled exposure training followed by group exposure training with five standardized exposure steps
88990576|NCT06182709|Active Comparator|live modeled exposure + standardized group exposure|live modeled exposure training followed by group exposure training with five standardized exposure steps
89040192|NCT04291508|Placebo Comparator|Acetaminophen-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
89040193|NCT04291508|Placebo Comparator|Vitamin C-Placebo|Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses). Note: This arm is now closed.
89631129|NCT04620538||Hepatocellular Carcinoma|Patients with evidence of Hepatocellular Carcinoma on the basis of current diagnostic techniques / expert opinion.
89631130|NCT04566172|Experimental|Prehabilitation program|Patient undergoing thoracic or upper abdominal surgery as part of their regular medical care will be approached. Participants will receive a prehabilitation program that includes an inspiratory muscle training that they will do leading up to the day of their surgery.
89631131|NCT04543396|Experimental|Physical Thearpy + Resistance Training|Subjects will receive standard of care treatments from their physical therapist. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
89631132|NCT04543396|No Intervention|Physical Thearpy|Subjects will receive standard of care treatments from their physical therapist. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
89631133|NCT04543396|Experimental|Chiropractic Care + Resistance Training|Subjects will receive standard of care treatments from their chiropractor. In addition, an investigative team member will customize a program of core-strengthening resistance exercises that will be prescribed to all intervention group subjects. Subjects will be expected to complete the protocol twice (2x) per week for an 8 week period. The protocol was approved by the Mayo Clinic IRB. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
89631134|NCT04543396|No Intervention|Chiropractic Care|Subjects will receive standard of care treatments from their chiropractor. Evaluations will be completed at baseline, week 4, and week 8 for all subject groups. Evaluations will consist of a strength assessment, standard clinical questionnaires about back health, a Sorenson's Back Endurance Test, and ultrasound images of back musculature. Longitudinal follow-ups will be completed quarterly for one year after the initial evaluation. These follow-ups will be performed remotely via phone and/or email and incorporate clinical questionnaires.
89631135|NCT04534309|Other|Self-Directed Weight Loss with year-long weight tracking|Written Weight Loss Material.
89631136|NCT04534309|Other|App-Directed Weight Loss with year-long weight tracking|Smart phone Weight Loss App.
89631137|NCT04534309|Other|Coach-Directed Weight Loss with year-long weight tracking|Behavioral Lifestyle Weight Loss Intervention with Smart phone Weight Loss App.
89631138|NCT04524832|Experimental|Semaglutide D 50 mg|Participants will receive once daily semaglutide D formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
89631139|NCT04524832|Experimental|Semaglutide C 50 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
89631140|NCT04524832|Experimental|2 x Semaglutide C 25 mg|Participants will receive once daily semaglutide C formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 2 x 25 mg (week 13-16)
89631141|NCT04524832|Experimental|Semaglutide E 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 16 weeks: A) Semaglutide C formulation: 2.4 mg (week 1-2), 5.6 mg (week 3-4) and 11.2 mg (week 5-8). B) Semaglutide E formulation: 25 mg (week 9-12) and 50 mg (week 13-16)
89631142|NCT04524832|Experimental|Semaglutide F 50 mg|Participants will receive once daily semaglutide F formulation tablets in a dose escalating manner for 16 weeks: 2.4 mg (week 1-2), 5.6 mg (week 3-4), 11.2 mg (week 5-8), 25 mg (week 9-12) and 50 mg (week 13-16)
89631143|NCT04502745|Experimental|Treatment Group|During clinically indicated surgery for subdural hematoma, the patient will undergo a single burr hole evacuation with the MICAS device with endoscopic assistance.
89631144|NCT04487327|Experimental|Dry Needling within the Myofascial Trigger Point|Randomized to receive DN at the site of the MTrP
88990577|NCT06182696|Experimental|OriCAR-017 ( GPCRC5D-directed chimeric antigen receptor modified T cells )|"Phase I (Dose-Escalation) The subjects enrolled will be sequentially assigned to the corresponding dose level to determin the RP2D. The dose-escalation part of the study will adopt the the standard 3+3 design, wherein 3 dose levels are planned to be evaluated.~Phase I (Dose-Expansion) After determining the RP2D, one of the dose levels will be selected for further evaluation during the dose-expansion part. Up to 10 to 15 additional subjects who are diagnosed with relapsed/refractory MM will be enrolled to further explore the anti-tumor activity of Ori-CAR-017.~Phase II The Phase II part of the study will be initiated at the RP2D of OriCAR-017 which will be selected based on the clinical data obtained during the Phase I part of the study."
88990578|NCT06182683|Active Comparator|Angiography-guided PCI group|This group of patients are intended to undergo PCI with conventional angiography-guidance. Procedural optimization determined by angiographic assessment.
88990579|NCT06182683|Experimental|Concurrent OCT/FFR-guided PCI group|This group of patients are intended to undergo PCI with concurrent OCT/FFR-guidance. Procedural optimization determined by OCT and FFR assessment.
88990580|NCT06182670|Experimental|Subcrestal implant and gingival former abutment (GFA)|The subjects receive a subcrestal implant and a prosthodontic device (GFA) immediately during the surgery. The GFA will not be removed upon prosthetic load. It will be an integral part of the prosthetic finalization.
89631145|NCT04487327|Active Comparator|Dry Needling away from Myofascial Trigger Point Site|Randomized to receive DN 2 cm away from the site of the MTrP but within the same muscle
89631146|NCT04483102|Experimental|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. NMP of the donated declined liver utilizing the OrganOx® metra device. NMP involves (warm) machine perfusion with oxygenated blood at normal body temperature. During NMP, the device also allows for ongoing assessment of donor liver function and further viability assessment to help determine suitability of the organ for transplant.
89631147|NCT04483102|Active Comparator|Standard cold preservation of liver|This group will receive liver transplant using the standard method of preservation. There will be 3 comparison groups: one local comparison group and two comparison groups from the national UNOS data.
89631148|NCT04477772|Experimental|1mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects
89631149|NCT04477772|Experimental|3mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 9 subjects
89631150|NCT04477772|Experimental|10mg/kg JS004, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects
89631151|NCT04477772|Experimental|200mg, Q3W until to 2 years|Dose expansion, enrolled 9 subjects and indication expansion if RP2D is 200mg
89631152|NCT04477772|Experimental|240mg JS004+100mg JS001, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 6-9 subjects and indication expansion if RP2D is confirmed this arm
89631153|NCT04477772|Experimental|240mg JS004+200mg JS001, Q3W until to 2 years|Dose escalation, enrolled 3-6 subjects; Dose expansion, enrolled 6-9 subjects and indication expansion if RP2D is confirmed this arm
89631154|NCT04471597|Placebo Comparator|Control group|patients will receive 5ml of normal saline 0.9% topically 15 min before the expected end of surgery.
89631155|NCT04471597|Active Comparator|bupivacaine group|patients will receive 5ml of bupivacaine 0.5% topically 15 min before the expected end of surgery.
89631156|NCT04469920|Experimental|Group 1- mild hepatic impairment without evidence of PHT|Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points
89631157|NCT04469920|Experimental|Group 2- mild hepatic impairment with evidence of PHT|Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points
89631158|NCT04469920|Experimental|Group 3-moderate hepatic impairment|Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points
89631159|NCT04469920|Experimental|Group 4- severe hepatic impairment|Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)
89631160|NCT04469920|Experimental|Group 5-cholestatic liver disease|Subjects with cholestatic liver disease
89631161|NCT04469920|Experimental|Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH|Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH
89631162|NCT04469920|Experimental|Group 7- normal hepatic function|Subjects with normal hepatic function
89631163|NCT04456413|Experimental|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients
89631164|NCT04456413|Active Comparator|Best Supportive Care|Patients will receive best supportive care. Patients randomized to best supportive care may receive plasma should they require hospitalization for progression of COVID-19 disease.
89040194|NCT04256759|Experimental|Dupilumab|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
89631165|NCT04454411|Experimental|Buprenorphine|Participants assigned to treatment with extended-release buprenorphine
89631166|NCT04454411|Active Comparator|Naltrexone|Participants assigned to treatment with extended-release naltrexone
89631167|NCT04446507|Experimental|Group 1|Subjects in severe renal impairment group will be enrolled and dosed consecutively (i.e. first 8 subjects of group 1 will receive 2 mg dose, followed by another 8 subjects who will receive 4 mg dose).
89631168|NCT04446507|Experimental|Group 2|Subjects (Normal renal function eGFR ≥90) will be matched according to age (± 10 years), sex, and weight (± 10 kg) with participants in Group 1 (Severe renal impairment not on HD) on a one to one basis based on demographic characteristic. Here, 8 participants will be administered single dose of 2 mg Saroglitazar Magnesium and 8 participants will be administered single dose of 4 mg Saroglitazar Magnesium.
89631169|NCT04387500|Experimental|Sintilimab injection combined with Inlyta|"Sintilimab injection 10ml: 100mg, 200mg intravenously, once every three weeks. Course of treatment: discontinue medication when the disease progresses clinically or radiologically.~Inlyta 5mg orally, twice a day. Course of treatment: continue treatment as long as a clinical benefit is observed, or until an unacceptable toxicity is present that cannot be controlled by combination or dose adjustment.~In the whole research process, if the disease progresses, the attending doctor has the right to carefully choose other anti-tumor methods, including radiotherapy, chemotherapy and other targeted drugs."
89631170|NCT04384263|Experimental|Tai Chi group|"During the 12-week online Tai Chi intervention, participants in the Tai Chi group will attend live online Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 45 minutes/session for 12 weeks. The participants will also practice Tai Chi offline between sessions using instructional videos that will be shared with them at the end of each live online Tai Chi session.~Participants in the Tai Chi group will be instructed: 1) to maintain their regular level of physical activity outside of the live online Tai Chi exercise sessions and offline Tai Chi exercise, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
89631171|NCT04384263|No Intervention|control|"Participants in the control group will perform only their regular habitual daily activities throughout the 12 weeks of intervention period.~Participants in the control group will be instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed."
89631172|NCT04369846|Experimental|Test drug group|The arm applies the test drug of GM-XANTHO
89040195|NCT04255823|Experimental|Multi-faceted intervention|"A patient education material on PPI deprescribing will be send to patients with long-term treatment with PPI (>300DDD/patient/year).~Their general practitioner (GP) will receive a dear doctor letter with an algorithm related to PPI deprescribing."
89631173|NCT04369846|Placebo Comparator|Placebo group|The arm applies the placebo
89631174|NCT04269395|Active Comparator|MAL Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit of the active cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
89631175|NCT04269395|Placebo Comparator|Vehicle Cream Arm|Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit in the vehicle cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
89631176|NCT04258566|Experimental|Suspected hepatic malignancy|Malignancy determination of new onset hepatic lesion
89631177|NCT04250402||Arm 1|"Endoscopic submucosal dissection. Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.~Other Name: ESD"
89631178|NCT04250402||Arm 2|"Distal subtotal gastrectomy with D2 lymphadenectomy. After exclusion of T4b, bulky lymph nodes, or distant metastasis case, distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally."
89631179|NCT04250402||Arm 3|Total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. The type of reconstruction will be with jejunal interposition reconstruction.
89631180|NCT04250402||Arm 4|Proximal gastrectomy with D2 lymphadenectomy. The type of reconstruction will be jejunal interposition with double anastomosis method.
89631181|NCT04232917|Experimental|2LPAPI® arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
89631182|NCT04232917|Placebo Comparator|Placebo arm|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
89631183|NCT04207775||NSCLC|Patients with confirmed EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed from first line EGFR-TKI therapy who will receive different treatment
89040196|NCT04255823|Experimental|"Dear doctor letter of the GP"|"Only the GP will receive the dear doctor letter with the algorithm.~Their patients will not receive any patient education material."
89631184|NCT04157608|Active Comparator|Habitual Prosthesis|Participant's existing baseline prescribed prosthesis
89631185|NCT04157608|Experimental|e-MIP|Experimental ankle-foot prosthesis
89631186|NCT04153019|Other|Cancer cachexia|Psycho-educational session: 3 weekly face-to-face consultations between a dyads (patients-caregivers) and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
89040197|NCT04255823|No Intervention|Control|Neither the patients nor their GP will receive information.
89040198|NCT04242498|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
89040199|NCT04242498|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
89040200|NCT04242498|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
89040201|NCT04242498|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
89040202|NCT04240158|Experimental|IW-6463|IW-6463 tablets administered orally
89040203|NCT04240158|Placebo Comparator|Placebo|Matching placebo tablets administered orally
89040204|NCT04169191|Experimental|Sildenafil|
89040205|NCT04160325|Experimental|3 months exclusive enteral nutrition plus azathioprine|patients underwent surgery in this arm will given 3 months exclusive enteral nutrition,and free diet after 3 months. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
89040206|NCT04160325|Active Comparator|normal diet plus azathioprine|patients underwent surgery in this arm will given free diet all through. All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
89040207|NCT04154189|Experimental|Randomization Phase: Lenvatinib + Ifosfamide + Etoposide|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
89040208|NCT04154189|Active Comparator|Randomization Phase: Ifosfamide + Etoposide|Participants with relapsed or refractory osteosarcoma will receive ifosfamide with etoposide. Participants with relapsed or refractory osteosarcoma may receive optional lenvatinib plus or minus chemotherapy (Ifosfamide and Etoposide) if disease progression is observed in study.
89040209|NCT04115527|Active Comparator|Standard lymphadenectomy|Standard lymphadenectomy includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes harvested during the pancreaticoduodenectomy with CHILD's digestive reconstruction
89040210|NCT04115527|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, para-aortic lymph nodes (No16) is included, in particular No 16b1 lymph nodes (Lymph nodes along the psterior side of the pancreas between the aorta and inferior vena cava).
89057412|NCT04539782|No Intervention|No intervention|Standard care
89057413|NCT01180660|Active Comparator|Lidocaine|Lidocaine infusion
89631187|NCT04143594|Experimental|Lenacapavir, F/TAF, and TAF|"Induction: Participants will receive oral lenacapavir 600 mg, 600 mg, and 300 mg at Days 1, 2, and 8, respectively. Participants will also begin oral daily emtricitabine/tenofovir alafenamide (F/TAF) 200/25mg from Day 1 onwards for a total of 28 weeks. On Day 15 participants will receive subcutaneous (SC) lenacapavir 927 mg.~Maintenance: Participants will receive SC lenacapavir 927 mg at Week 28 and every 26 weeks. Participants will discontinue oral daily F/TAF 200/25 mg at Week 28 and begin taking oral daily TAF 25 mg.~May require oral weekly bridging if an SC injection of GS-6207 cannot be administered for any reason within the protocol visit window.~Participants willing to continue the study beyond Week 80 will continue to receive SC lenacapavir 927 mg every 6 months (26 weeks) and oral daily TAF 25 mg from Week 80 onwards."
89631188|NCT04143594|Experimental|Lenacapavir, F/TAF, and BIC|"Induction: Participants will receive oral lenacapavir 600 mg, 600 mg, and 300 mg at Days 1, 2, and 8, respectively. Participants will also begin oral daily F/TAF 200/25 mg from Day 1 onward for a total of 28 weeks. On Day 15 participants will receive SC lenacapavir 927 mg.~Maintenance: Participants will receive SC lenacapavir 927 mg at Week 28 and every 26 weeks. Participants will discontinue oral daily F/TAF 200/25 mg at Week 28 and begin oral daily bictegravir (BIC) 75 mg.~May require oral weekly bridging if an SC injection of GS-6207 cannot be administered for any reason within the protocol visit window.~Participants willing to continue the study beyond Week 80 will continue to receive SC lenacapavir 927 mg every 6 months (26 weeks) and oral daily bictegravir (BIC) 75 mg from Week 80 onwards."
89631189|NCT04143594|Experimental|Lenacapavir and F/TAF|"Participants will receive oral lenacapavir 600 mg at Day 1 and Day 2. On Day 3, participants will begin oral daily lenacapavir 50 mg. Participants will begin oral daily F/TAF 200/25 mg from Day 1 onwards.~Participants willing to continue the study beyond Week 80 will continue to receive oral daily lenacapavir 50 mg and oral daily F/TAF 200/25 mg from Week 80 onwards."
89631190|NCT04143594|Active Comparator|B/F/TAF|Participants will receive oral daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg at Day 1 and throughout their participation in the study.
89631191|NCT04132323|Active Comparator|hypertonic glucose|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~to inject the 75% glucose, with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
89631192|NCT04132323|Active Comparator|0.05% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~to inject the 0.05% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
89631193|NCT04132323|Active Comparator|0.1% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~to inject the 0.1% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
89631194|NCT04132323|Active Comparator|0.15% sodium tetradecyl sulfate|"to take photo of problem area in the patient's standing position in the room with artificial lighting using the iPhone 6s and above, Samsung Galaxy S7 and above from a distance of 20 cm.~to measure the maximum diameter of telangiectasia using the Dermatoscope scale.~to inject the 0.15% sodium tetradecyl sulfate with a 2 ml luer-lock syringe through 30 G needle in telangiectasia until the vessel disappears."
89631195|NCT04102228|Experimental|Multi-modality aphasia therapy plus 1Hz rTMS|Participants receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of 1Hz rTMS delivered at 100% of resting motor threshold over the right pars triangularis.
89631196|NCT04102228|Sham Comparator|Multi-modality aphasia therapy plus sham rTMS|Participants receive 10 days of 3.5hrs of multi-modality aphasia therapy (M-MAT) preceded by 20 minutes of sham rTMS is achieved using a sham TMS coil which attenuates the magnetic output of the stimulator by 80%.
88990581|NCT06182670|Active Comparator|Crestal implant and traditional abutment|The subjects receive a crestal implant and healing abutment. The healing abutment will be replaced by a definitive abutment to the prosthetic load.
88990582|NCT06182631|Experimental|Vapocoolant|Will have nurse spray vapocoolant on the skin before IV insertion, will then videotape patient and ask them and parent to fill out FACES form.
88990583|NCT06182631|Experimental|Buzzy Bee|Will have nurse put Buzzy Bee on arm before, and leave it on during IV insertion. Will then videotape patient and ask them and parent to fill out FACES form.
88990584|NCT06182631|Placebo Comparator|Placebo|Will have nurse place a rubber band around arm before IV insertion. Will then videotape patient and ask them and parent to fill out FACES form.
88990585|NCT06182618||low-carbohydrate diet|20-30% carbohydrates, 40-45%fat, and 30-40%protein
88990586|NCT06182618||balanced diet|50-65% carbohydrate, 20-30% fat and 10-20% protein
88990587|NCT06182618||pharmacotherapy|semaglutide (1mg per week) or/and metformin (o.5g three times a day)
88990588|NCT06182605|Experimental|Multi-functional instruments|Patients undergoing cataract with lens subluxation surgery with Multifunctional cataract-assisted retractor
88990589|NCT06182605|Active Comparator|Traditional instruments|Patients undergoing cataract with lens subluxation surgery with traditional capsule retractor
88990590|NCT06182553|Experimental|Group (1) : ERCC Group|- The researcher will implement the ERCC technique for 10 minutes as follows: the researcher will use both hands bilaterally to gradually squeeze the rib cage (on the anterolateral region of the chest at the level of the last six ribs) in conjunction with chest-wall vibration during the expiratory phase of the ventilatory cycle. From the end of inspiration to the end of expiration, an attempt will be made to compress the rib cage over the region of the lungs that is most affected and the force will be applied every 2 breaths only during the expiration, synchronizing the maneuver rate with the breathing frequency of the subject. At the end of each expiratory phase, rib-cage compression is interrupted to permit free manual hyperinflation-induced inspiration. The ERCC technique will be implemented twice per day.
89631197|NCT04082988|Other|Nivolumab|"Nivolumab treatment according to label: 3 mg/kg nivolumab IV Q2W, 240mg Q2W or 480mg Q4W as an IV infusion until disease progression or unacceptable toxicity.~FDG PET-CT will be performed at baseline and between 7 and 14 days after treatment initiation"
89631198|NCT04068376|Active Comparator|Control group (C-GR)|Control group of an aerobic-balance-stretching exercise program led by a coach for 24 weeks (C-GR).
89040211|NCT04108481|Experimental|Y90-RE in combination with immunotherapy (durvalumab)|"The treatment phase starts of with the immunotherapy drug (durvalumab) - priming doses every 2 weeks prior to patient getting mapped and ready for treatment with Y90-RadioEmbolization.~Post-Y90-RE, treatment is approximately 2 months in combination with fixed doses (750 mg) of durvalumab. The number and timing of doses of durvalumab each patient will receive will depend on the dose level the patient is assigned to (range 2-5 doses of immunotherapy).~A single patient will be treated per dose level until the first dose limiting toxicity (DLT) is recorded. Once the first DLT is recorded, two additional patients are treated at the same dose level and the trial reverts to a standard 3+3 design. Up to 6 patients will be treated at each dose level. The maximum tolerated dose (MTD) will be defined as the highest dose level for which at most 1 out of 6 patients experience a DLT."
89040212|NCT04095026||Patients|Patients age >18 years and <= 65 years enrolled in 11-N-0051 Epilepsy Surgery
89040213|NCT04083859|Experimental|mPATH-Lung|Participants randomized to the mPATH arm will complete a self-survey and a brief video decision aid, and then invites them to estimate their personal risks and benefits of screening by completing 8 survey items needed to calculate their predicted risk of developing lung cancer based on the validated Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Model 2012.
89057414|NCT01180660|Placebo Comparator|Placebo|Placebo Normal Saline Infusion
89631199|NCT04068376|Experimental|T1-GR training sessions by health professional|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health professional with a nursing background previously certified to coach SSE trainings by the Institute of Square-Stepping Exercise in Mie, Japan (Chief Tomohiro Okura and Overseas Director Professor Ryosuke Shigematsu).
89631200|NCT04068376|Experimental|T2-GR older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
89631201|NCT04068051|Experimental|AXS-07|
89631202|NCT04065971|Experimental|2LHERP® arm|Group N°1: 2LHERP® treatment (6 months of treatment)
89631203|NCT04065971|Placebo Comparator|Placebo arm|Group N°1: Placebo treatment (6 months of treatment)
89631204|NCT04046549|Experimental|Belatacept+VIB4920|Participants will be admitted to the transplant center for the administration of VIB4920 and belatacept (with Thymoglobulin and corticosteroids) and will be discharged on Day 3/4 at the discretion of the investigator. Participants will return to the study center to receive study drugs (VIB4920 and /or belatacept) weekly for 2 visits, then every 2 weeks for 5 visits, and then monthly for 9 visits for safety monitoring.
89631205|NCT04034511|Experimental|Medically-tailored meal delivery and medical nutrition therapy|Participants assigned to this arm will receive home-delivered, medically-tailored meals for 3 months combined with monthly individual Medical Nutrition Therapy sessions for 6 months. Participants will also receive participants' usual case management services from participants' Medicaid insurance program.
89631206|NCT04034511|No Intervention|Usual care|Participants assigned to this arm of the study will receive usual care and case management services from participants' Medicaid insurance program.
89631207|NCT03975231|Experimental|Treatment (dabrafenib, trametinib, IMRT)|See Detailed Description
89631208|NCT03964753|Experimental|Neo-adjuvant chemotherapy group|"cisplatin and nab-paclitaxel: Nab-paclitaxel, 125mg/m(2), d1,d8, Cisplatin, 75mg/m(2), d1, 3 week, 2 cycles.~Surgery:~4-6weeks after Neo-adjuvant chemotherapy"
89631209|NCT03964753|Active Comparator|Surgery alone|Surgery alone
89631210|NCT03933384|Active Comparator|Tenofovir alafenamide group|Study subjects will receive tenofovir alafenamide 25 mg/tab once daily for 3 years (144 weeks).
89631211|NCT03933384|Active Comparator|Entecavir group|Study subjects will receive entecavir 0.5 mg/tab once daily for 3 years (144 weeks).
89631212|NCT03915431|Experimental|NCS-01|human bone marrow derived cells
89631213|NCT03915431|Sham Comparator|sham|sham procedure
89631214|NCT03879018|Experimental|Reinforcement Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For reinforcement training, participants will not see their hand or a cursor, but instead participants will receive target-specific binary feedback after each reach (i.e. based on running average of last 10 reaches to that target). Binary feedback indicates only whether the reach was successful or unsuccessful and provides no specific information about the location of the hand.
89631215|NCT03879018|Experimental|Standard Practice Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For standard practice, participants will be able to see a cursor that represents the position of the hand at all times and try to make straight reaches to the targets. This type of feedback provided specific information about the location of the hand.
89631216|NCT03877640|Active Comparator|Active EMSELLA treatment|6 treatments on the BTL EMSELLA using a device protocol that is active HIFEM technology
89631217|NCT03877640|Sham Comparator|Sham EMSELLA treatment|6 treatments on the BTL EMSELLA with a sham device protocol that provides some sensation without active HIFEM technology
89520674|NCT04435899|Experimental|physical fitness and frailty syndrome institutionalized older|"This study analyzed the relationship between old physical frailty syndrome (PF) and PhFi indicators and assessed how the latter might predict the former. Participants were 119 elderly women (81.96 ±7.89 years) recruited from four social and healthcare centers. PhFi was assessed through muscle strength tests of upper and lower limbs, endurance, agility-dynamic balance, flexibility and body composition.~The following PF indicators were assessed: weight loss, exhaustion, weakness, slowness and low physical activity level."
89520675|NCT04435899|Experimental|THE RELATIONSHIP BETWEEN FUNCTIONAL DISABILITY OUTCOMES|The associations between functional disability activities of life activities and frailty have already been explored. The contribution of each component of physical frailty and their contribution to understanding the early physical decline of older individuals are poorly explored. The relationships between PF and functional disability and to identify the independent components of frailty that most influence on disability in older women. A cross-sectional study of 119 (81,96±7,89) older women aged 75 and over. Functional disability was assessed through Agility-dynamic and Static balance tests, Activities of daily life and Falls risk screen outcomes.
89520676|NCT03437369|Experimental|Ivabradine|Drug: Ivabradine Oral tablets 2.5 mg Dose: 10-15 mg/day Duration: 30 days
89520677|NCT03437369|Other|Standard of Care|The study drug will be compared with standard of Care treatment
88990591|NCT06182553|Experimental|Group (2) : PEEP-ZEEP Group|"The researcher in the presence of the attending physician will apply the PEEP-ZEEP maneuver in the following manner: During the inspiration phase of the ventilatory cycle, it is proposed to increase PEEP to 15 cmH2O, while maintaining a PIP of 40 cmH2O. Following the completion of five ventilatory cycles, PEEP will be abruptly decreased to 0 cmH2O during the expiration phase, referred to as ZEEP. Subsequently, during the subsequent inspiration phase, PEEP will be restored to the previously established levels. The maneuver will be repeated for a duration of 10 minutes, with a gap of two ventilatory cycles between every repetition.The PEEP-ZEEP maneuver will be implemented twice per day. At the end of the PEEP-ZEEP maneuver, the patient will receive tracheal suction as mentioned before.~The patients will be monitored continuously, and the maneuver will be interrupted if the patients become hemodynamically unstable or develop psychomotor agitation."
89057415|NCT04539860||Healthy Controls|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
89520678|NCT02616081||Clean Intermittent Catheterization|Participants performing intermittent catheterization of their bladder, having not had augmentation cystoplasty or creation of a catheterizable channel
89520679|NCT02616081||Indwelling Catheter|Participants utilizing an Foley catheter or a suprapubic tube (cystostomy)
89520680|NCT02616081||Surgery|Undergoing any of the following surgeries: augmentation cystoplasty with or without a catheterizable channel, creation of catheterizable channel alone, urinary diversion (conduit or continent catheterizable pouch)
89520681|NCT02616081||Voiding|Participants with volitional control, voiding into diapers or a condom catheter via crede, valsalva, or spontaneous leakage
89520682|NCT02384577||Single group prospective treatment|
89520683|NCT02521649|Experimental|10µg, Stage I-III|10µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
89520684|NCT02521649|Experimental|100µg, Stage I-III|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
89520685|NCT02521649|Experimental|250µg, Stage I-III|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
89520686|NCT02521649|Experimental|100µg, Stage IV|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
89520687|NCT02521649|Experimental|250µg, Stage IV|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
89520688|NCT02215941|Experimental|TV-45070 7%|twice daily topical application to 7% body surface area for 7.5 days (15 applications)
89520689|NCT02215941|Experimental|TV-45070 21%|twice daily topical application to 21% body surface area for 7.5 days (15 applications)
89520690|NCT02215941|Experimental|TV-45070 53%|twice daily topical application to 53% body surface area for 7.5 days (15 applications)
89520691|NCT02215941|Placebo Comparator|Placebo|
89520692|NCT03437291||Abnormal placental invasion|patients had placenta previa with histopathologically confirmed abnormal invasion with all three grades i.e. accreta, increta and percreta,
89520693|NCT03437291||Normal placenta|patients had placenta previa with no abnormal invasion
89520694|NCT03437213|Experimental|Total intravenous anesthesia group|propofol, and fentanyl-based regimen.
89520695|NCT03437213|Active Comparator|Total intravenous plus block group|ultrasound guided paravertebral block before induction then propofol and fentanyl maintenance.
89520696|NCT02030457|Experimental|Treatment A|Treatment A: beclomethasone dipropionate BAI, 160 mcg - a single administration of 4 inhalations (40 mcg/inhalation)
89520697|NCT02030457|Experimental|Treatment B|Treatment B: beclomethasone dipropionate BAI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
89520698|NCT02030457|Experimental|Treatment C|Treatment C: beclomethasone dipropionate MDI, 320 mcg - a single administration of 4 inhalations (80 mcg/inhalation)
89520699|NCT03991247|Experimental|Internet Behavioral therapy program + spa therapy|Patient following a program of computerized behavioral therapy for insomnia management during a 3 weeks spa treatment.
89520700|NCT03991247|Active Comparator|Internet Behavioral therapy program at home|Patient following a program of computerized behavioral therapy for insomnia management during 3 weeks at home.
89520701|NCT01847859|Experimental|Ultrasound performed by nurses|Focused examination of the pleural and pericardial cavity. Cardiologists perform reference ultrasound examinations.
89520702|NCT03437135||Witness patients|Healthy Volunteers
89520703|NCT03437135||Type 1 diabetic patients|patients with type 1 diabetes
89520704|NCT03437135||Type 2 diabetic patients|patients with type 2 diabetes
89631218|NCT03835117|Experimental|Wide-spectrum nutritional supplement|The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion.
89631219|NCT03835117|Placebo Comparator|Placebo control|Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing.
89631220|NCT03821714|Experimental|Glucocorticoid combination therapy Group|Hydrocortisone 200mg continuous intravenous infusion(24h) combined with vitamin C1.5g intravenous infusion every 6 hours and vitamin B1 200mg intravenous infusion every 12 hours.
89631221|NCT03821714|Active Comparator|Glucocorticoid Group|Hydrocortisone 200mg continuous intravenous infusion(24h)
89631222|NCT03783715||Ketoprofen|Participants will take ketoprofen for six months. They will have evaluations at baseline and month 6.
89631223|NCT03725436|Experimental|Treatment (paclitaxel, ALRN-6924)|Patients receive paclitaxel IV over 1 hour and MDM2/MDMX inhibitor ALRN-6924 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89631224|NCT03703050|Experimental|Cohort 1|Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
89631225|NCT03703050|Experimental|Cohort 2|Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy. In this case, nivolumab would be considered as consolidative immunotherapy instead as HSCT.
89631226|NCT03691350|Active Comparator|Group I (usual cigarette brand)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Participants continue to smoke their usual brand of cigarettes. Participants undergo a second bronchoscopy on day 71.
89040214|NCT04083859|Placebo Comparator|Usual care (CONTROL)|Participants randomized to the control arm will see an animated video about exercise for lung health based on recommendations from the European Lung Foundation. They will not be offered the opportunity to estimate their predicted benefits and harms of screening or to request a lung cancer screening visit.
89040215|NCT04073303|Active Comparator|Botulinum Toxin Type A (BOTOX®)|Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments
89040216|NCT04073303|Placebo Comparator|Placebo|Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter
89040217|NCT04068441||Regular treatment|no intervention
89040218|NCT04068441||Treatment interruption|no intervention
89040219|NCT04056078||Team Handball Players Playing with Shoulder Pain|Team Elite Handball players playing with shoulder pain i their dominated shoulder for more than 3 months.
89040220|NCT04056078||Team Handball Players playing without shoulder pain|Team Elite Handball players who never have experience shoulder pain i their dominated shoulder.
89040221|NCT04056078||Team Handball Players playing with previous shoulder pain|Team Handball players who have had shoulder pain i their dominated shoulder, but currently have been playing without shoulder pain in the previous 6 months.
89040222|NCT04048161|Experimental|Tacrolimus(Group A)|Tacrolimus: 0.5mg and 1mg; Capsule; 0.05-0.10mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
89040223|NCT04048161|Active Comparator|Mycophenolate Mofetil(Group B)|Mycophenolate Mofetil: 250mg; Dispersible tablets; 20~30mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;
89040224|NCT04032964|Experimental|Arm L19TNF + DOXO|"Patients will be treated with:~doxorubicin 75 mg/m2 i.v. on day 1 of each 21-day cycle;~L19TNF 13 µg/kg i.v. on day 1, 3 and 5 of each 21-day cycle"
89040225|NCT03976193|Placebo Comparator|BfitBwell program|BfitBwell is a 3-month supervised exercise program for cancer survivors delivered at the Anschutz Health and Wellness Center. This program has demonstrated effectiveness for improving physical fitness, fatigue, and depression among participants
89631227|NCT03691350|Experimental|Group II (SREC with nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. After the baseline bronchoscopy, participants learn to use the SREC with nicotine for 2 weeks and switch completely to the SREC with nicotine starting day 15 for 8 weeks. Participants undergo a second bronchoscopy on day 71.
89631228|NCT03691350|Experimental|Group III (SREC without nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC without nicotine for 2 weeks and switch completely to the SREC without nicotine starting day 15 for 8 weeks. Participants will be offered varenicline to aid cessation. Participants undergo a second bronchoscopy on day 71.
89631229|NCT03691350|Experimental|Group IV (Nicotine Replacement Therapy [NRT])|Participants undergo bronchoscopy over 30-60 minutes at baseline. One week before the day 15 quit date, participants stop smoking using NRT comprising either patch, gum, or lozenge for 8 weeks. Participants undergo a second bronchoscopy on day 71.
89631230|NCT03657342|Experimental|L-CsA treatment plus SoC|Liposomal Cyclosporine A 5 mg twice daily for 48 weeks + Standard of Care Therapy
89631231|NCT03657342|Active Comparator|Control treatment|In this arm only the standard of care is administered. Standard of care is a maintenance regimen of immunosuppressive agents.
89631232|NCT03656926|Experimental|L-CsA treatment plus SoC|Liposomal Cyclosporine A (L-CsA) 10 mg twice daily for 48 weeks, plus Standard of Care Therapy
89631233|NCT03656926|Active Comparator|Standard of Care|This is a maintenance regimen of immunosuppressive agents
89057416|NCT04539860||Patients|Blood pressure measurements by standard assessment methods and Transdermal Optical Imaging
89057417|NCT01648842||Pregnant women|
89057418|NCT01202227|Experimental|Pregabalin|Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period
89211505|NCT00838994|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
89631234|NCT03639623|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
89631235|NCT03617458|Active Comparator|Metformin + mHealth Intervention|"Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg po three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total)."
89631236|NCT03617458|Placebo Comparator|Placebo + Usual Care|Patient will receive non active medicine and routine medical care.
89631237|NCT03617458|Active Comparator|Metformin + Usual Care|"Patient will receive active ingredient medicine with routine medical care.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total)."
89631238|NCT03617458|Placebo Comparator|Placebo + mHealth Intervention|Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
89631239|NCT03617263|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium once daily in the morning before breakfast
89631240|NCT03617263|Placebo Comparator|Placebo|Placebo tablet once daily in the morning before breakfast
89631241|NCT03607890|Experimental|Cohort 1: Nivolumab and Relatlimab|480mg/160mg (co-administered)
89631242|NCT03607890|Experimental|Cohort 2: Nivolumab and Relatlimab|480mg/960mg or 480mg/160mg (sequential administration)
89631243|NCT03607890|Experimental|Cohort 3: Nivolumab and Relatlimab|480mg/480mg (sequential administration)
89631244|NCT03580499|Experimental|Supportive Care (vitamin B6)|Participants receive vitamin B6 PO daily for 12 weeks.
89631245|NCT03564600||ABC Group|Veterans with back pain for at least the past 6 months.
89631246|NCT03564600||UC Group|Veterans with back pain for at least the past 6 months.
89631247|NCT03471845|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
89631248|NCT03466476|Experimental|Wearable Technology Group|Patients in this arm will be provided with their own Consensus TracPatch wearable device postoperatively and instructed on its use for six weeks.
89631249|NCT03466476|No Intervention|Current Standard of Care Group|Patients in this arm will not be provided with any wearable device. Participants will be evaluated as part of the study for a total of six weeks.
89631250|NCT03466177||Ab+ AD patients|"amyloid positive Alzheimer's Disease patients~- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)"
89631251|NCT03466177||Ab+ Mild Cognitive Impairment (MCI) patients|"amyloid positive Mild Cognitive Impairment patients~- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)"
89631252|NCT03466177||Ab+ cognitively intact volunteers|"amyloid positive cognitively intact volunteers~- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)"
89631253|NCT03466177||Ab- cognitively intact volunteers|"amyloid negative cognitively intact volunteers~- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)"
89631254|NCT03466177||Glaucoma patients|- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)
89631255|NCT03466177||Age-related macular degeneration patients|- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), Dynamic Vessel Analyzer (DVA)
89631256|NCT03466177||Diabetic retinopathy patients|- Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging), DVA
89631257|NCT03466151|Experimental|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
89631258|NCT03466151|Active Comparator|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
89631259|NCT03425422|Experimental|Therapy|VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy
89631260|NCT03425422|No Intervention|Control|Stable guideline-directed medical therapy
89631261|NCT03403205|Experimental|ALXN1840|"ALXN1840 was administered orally for 48 weeks at doses ranging from 15 milligrams (mg) every other day (QOD) up to a titrated dose of 60 mg daily.~Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period."
89631262|NCT03403205|Active Comparator|Standard of Care (SoC) Medication|SoC medication was administered for 48 weeks. Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.
89631263|NCT03375112|Experimental|Fascia Iliaca Compartment Block|A Fascia Iliaca Compartment Block will be administered in the block room.
89631264|NCT03375112|Placebo Comparator|Control|The patients will be brought back to the block room, prepped, and a blunt needle will be touched to the skin. A band aid will be applied over the site.
89631265|NCT03206710||smokers who received Vitamin C|
89631266|NCT03206710||smokers who received placebo|
89040226|NCT03976193|Active Comparator|BfitBwell + 6, bi-weekly PA Behavior Change counseling session|Participants randomized to BfitBwell + PA behavior change counseling sessions will receive six, 1-1.5 hour sessions lead by a Certified Exercise Physiologist, trained on the study protocol. Sessions will be held once per week, every other week at the Anschutz Health and Wellness center. Participants will attend the sessions in groups, as schedules allow. Behavior change discussion topics will target self-efficacy for exercise, barriers to exercise, goal setting, behavior modification strategies, time management, cognitive reframing, and relapse prevention. Participants in this study arm will receive a group education workbook in congruence to discussion session topics to promote notetaking, and self-reflective journaling.
89040227|NCT03949673|Other|Knee or Hip Joint Arthroplasty|Patients with OA of the knee or hip who are participating in an ongoing fasinumab phase 3 parent study
89040228|NCT03922529|Active Comparator|Usual Care|Care after an acute heart event will be at the discretion of the participants' clinical providers.
89040229|NCT03922529|Experimental|MACRO-I|A coaching intervention that supplements usual care.
89631267|NCT03206710||control group non-smokers|
89040230|NCT03919955|Experimental|Atomoxetine and Oxybutynin|Participants will take Atomoxetine and Oxybutynin nightly for one month. Half doses will be given on the first three nights.
89631268|NCT03187951|Experimental|Arm A: Standard of Care (SOC)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants encouraged to remain active during chemotherapy and/or radiation. Participants receive a booklet that contains a stretching guide with full-body stretches and safety."
89631269|NCT03187951|Experimental|Arm B: Multi-Modal Exercise and Nutrition Program (MMENP)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants complete moderate-intensity aerobic exercise 5 days each week. Participants complete strength training exercises 2 times per week.~Participants contacted by phone by member of study staff 1 time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing."
89631270|NCT03162432|Experimental|Vitamin D3 Treatment|Subjects receiving Remicade will be treated with oral Vitamin D3
89631271|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), low|Biological/Vaccine: ≥3.0logCCID50/ml but <3.5 logCCID50/ml Attenuated Mumps vaccine (KMB-17)[ ≥3.0logCCID50/ml but <3.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
89631272|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), high|Biological/Vaccine: ≥4.5logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
89631273|NCT03133923|Active Comparator|Measles and Mumps Combined Vaccine，Live|manufacturer：Shanghai Institute of Biological Products Co., Ltd. (SIBP ) Measles and Mumps Combined Vaccine，Live in 360 infants in 360 infants (8-24 months old) on 0 day
89631274|NCT03122106|Experimental|Personalized neoantigen DNA vaccine|"Vaccines will be weeks 1, 5, 9, 13, 17, and 21. Vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. All study injections will be given intramuscularly using TDS-IM system. At each vaccination time point, patients will receive 2 injections of the neoantigen DNA vaccine, 1 injection into each deltoid or lateralis.~Minimum observation of 30 minutes. Vital signs will be taken at 30-45 minutes post-immunization. The injection sites will be inspected for evidence of local reaction. Follow up on subject well-being will be performed by telephone on the 1st or 2nd day following each injection. -Post-vaccination follow-up visits are at Week 25 ± 7 days and Week 77 ± 14 days. Additional follow-up visits or telephone contact will be scheduled at Week 129 and annually thereafter if the patient is alive and available for follow-up.~At intervals throughout the study (both before and after vaccination) subjects will have blood drawn for immunologic assays."
89631275|NCT03120871||All subjects|Female sex, obese, aged 9-17 years, Tanner stages 1-5.
89631276|NCT03118531|Experimental|Coronary Stent|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (34/38 mm)
89631277|NCT03076203|Experimental|Treatment (niraparib, radium Ra 223 dichloride)|Patients receive niraparib orally daily and radium Ra 223 dichloride IV over 1 minute every 4 weeks. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89631278|NCT03075423|Experimental|Ipilimumab plus nivolumab|Ipilimumab 1mg/kg plus nivolumab 3mg/kg, both, will be administered i.v. every 3 weeks for 4 times as an induction therapy followed by a maintenance therapy with a fixed dose of 240 mg nivolumab every two weeks or 480 mg every four weeks until progression.
89631279|NCT03075423|Active Comparator|Standard of Care therapy|Standard of Care therapy is administered according to the physician´s decision.
89040231|NCT03919955|Placebo Comparator|Placebo|Participants will take Placebos nightly for one month. Half doses will be given on the first three nights.
89040232|NCT03909919|Experimental|Heart Failure|Heart Failure patients Subjects diagnosed with heart faikure, who will receive the best treatment of clinical practice, will be recruited. They must be more than 70 years old.
89631280|NCT03033914|Experimental|< 60 years of age with advanced stage (HL) untreated|The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of A(B)VD and 8 doses of nivolumab. In dose level 1, patients will receive nivolumab in combination with AVD during cycle 6 only followed by 6 additional doses of nivolumab. In subsequent dose levels, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3. A PET scan will be performed after 2 cycles of ABVD and those with a PET-negative response (defined by Deauville 1, 2 or 3) will proceed with 4 additional cycles of ABVD or AVD (per treating physician preference).
89631281|NCT03033914|Experimental|60 years of age and older with HL (any stage) untreated|The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of AVD and 12 doses of nivolumab. In this cohort, patients will receive nivolumab in combination with AVD during cycles 5 and 6 only, followed by 8 additional doses of nivolumab. In subsequent cohorts, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3. Prophylactic growth factor support is mandatory for all patients on Cohort B and should be used per the treating physician's discretion for all other patients.
89631282|NCT03007095|Experimental|preterm children|
89631283|NCT03007095|Active Comparator|term children|
89631284|NCT03001986|Experimental|vaccine (3.0 EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
89631285|NCT02957032|Experimental|F16IL2 + cytarabine|Patients will be enrolled sequentially in cohorts and treated at different dose levels of F16IL2 and a fixed dose of cytarabine.
89631286|NCT02920892|Experimental|Double-Blind AFQ056 with language intervention|"After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive AFQ056 suspension by mouth twice per day in an 8 month double-blind treatment period.~During the double-blind treatment period, subjects in the AFQ056 treatment group began with a dose of 25 mg AFQ056 twice per day and titrated to their maximum tolerated dose over the course of 7 weeks. After 7 weeks the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on a stable dose of AFQ056 (ranging from 12.5 mg BID to 100 mg BID), for the next 6 months.~Safety and efficacy assessments were performed throughout."
89040233|NCT03909919|Active Comparator|Healthy Subjects|Healthy Subjects/ Match control Healthy subjects of the same age as people with heart failure.
89631287|NCT02920892|Placebo Comparator|Double-Blind Placebo with language intervention|"After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive a placebo suspension by mouth twice per day in an 8 month double-blind treatment period.~During the double-blind treatment period, dose titration to maximum tolerated dose of matching placebo occurred over 7 weeks. After 7 weeks, the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on placebo for the next 6 months.~Safety and efficacy assessments were performed throughout."
89631288|NCT02920892|Experimental|Open-Label AFQ056 with language intervention|"After 8 months of treatment in the placebo-controlled phase, all subjects had assessments completed and were given the opportunity to enter the open-label extension (OLE) in which all subjects received AFQ056. The OLE began with 2 months of flexible dose titration to each subject's maximum tolerated dose followed by a period of stable treatment. Subjects also continued the language intervention through the extension phase.~The duration of the stable treatment depended on when the subject was enrolled into the study. Those enrolled prior to June 15-30, 2019 received a 6-month period of stable treatment. Those enrolled after June 15, 2019 had their period of stable treatment shortened on a sliding scale, such that their treatment including weaning, if necessary, ended before August 31, 2021 (study drug expiration)."
89631289|NCT02897375|Experimental|Arm A (palbociclib, cisplatin)|Patients receive cisplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89040234|NCT03905512|Experimental|SEL-212|Intravenous (IV) infusion of SEL-212 every 28 days for up to 6 infusions
89040235|NCT03905512|Active Comparator|KRYSTEXXA|IV infusion of KRYSTEXXA® according to the manufacturer's prescribing information every 14 days for up to 12 infusions
89040236|NCT03891875|Experimental|Elamipretide|40 mg subcutaneous injection of elamipretide using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
89040237|NCT03891875|Placebo Comparator|Placebo|subcutaneous injection of placebo using the elamipretide delivery system for 48 weeks followed by a 4 week follow-up period.
89040238|NCT03856827|Experimental|IW-6463|IW-6463 tablets administered orally as single ascending doses, multiple ascending daily doses, and single doses with or without food
89040239|NCT03856827|Placebo Comparator|Placebo|Matching placebo tablets administered orally
89040240|NCT03834064|Experimental|Intervention|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the intervention arm. Caregivers working in that home will receive the oral health promotion strategy/intervention over the course of a year.
89040241|NCT03834064|No Intervention|Control|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the control arm. Caregivers in that home will not receive the oral health promotion strategy/intervention over the course of a year but will be offered a compressed intervention after a year.
89040242|NCT03830164|Experimental|Treatment (atorvastatin, vitamin E, pentoxifylline)|Patients receive atorvastatin PO QD for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Beginning week 7, patients receive atorvastatin PO QD, vitamin E PO QD, and pentoxifylline PO TID for up to 12 months in the absence of disease progression or unacceptable toxicity.
89040243|NCT03795311|Experimental|Administration of chemotherapy molecules|"The treatment period is divided into 15-day periods.~Schema of the administration to the treatments which will proceed in the same way with each cycle:~Bevacizumab (5 mg/kg; during 30 min) + Oxaliplatine (85 mg/m2, during 2 hours) + Acide folinique (400 mg/m2) or Levofolinate de calcium (200 mg/m2) AND Irinotecan (during 2 hours) + 5-fluorouracile (2400 mg/m2 ; 46 hours) + Irinotecan (1 hour)"
89631290|NCT02897375|Experimental|Arm B (palbociclib, carboplatin)|Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89631291|NCT02875184||Psoriatic arthritis patients treated with apremilast|Psoriatic arthritis patients who are treated with apremilast according to daily practice
89631292|NCT02841618|Experimental|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (10g grapeseed oil) 1 per day for 2 weeks Phase 1: N=39 adults single arm Phase 2: N=42 adults
89631293|NCT02841618|Placebo Comparator|High Oleic Acid Healthy Cookies|High Oleic Acid Healthy Cookies (10g safflower oil) 1 per day for 2 weeks Matched for Phase 2: N=42 adults
89040244|NCT03776136|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
89040245|NCT03769181|Experimental|Cohort A1: cHL: Isatuximab + Cemiplimab|Classic Hodgkin's lymphoma (cHL), anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitor naïve participants received isatuximab 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion once a week (QW) in Cycle 1 and then every 2 weeks (Q2W) from Cycle 2 to Cycle 6 (each cycle of 28 days), and then every 3 weeks (Q3W) from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 milligrams (mg) Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30, with optional radiotherapy until, unacceptable adverse events (AEs) or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of complete response [CR], whichever was longer) of delivery of investigational medicinal product(s) without documented progressive disease (PD), or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
89040246|NCT03769181|Experimental|Cohort A2: cHL: Isatuximab + Cemiplimab|cHL, anti-PD-1/PD-L1 inhibitor progressor participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30, with optional radiotherapy until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
89040247|NCT03769181|Experimental|Cohort B: DLBCL: Isatuximab + Cemiplimab|Diffuse large B-cell lymphoma (DLBCL), anti PD-1/PD-L1 naïve participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30 until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
89040248|NCT03769181|Experimental|Cohort C: PTCL: Isatuximab + Cemiplimab|Peripheral T-cell lymphoma (PTCL), anti PD-1/PD-L1 naïve participants received isatuximab 10 mg/kg, IV infusion, QW in Cycle 1 and then Q2W from Cycle 2 to Cycle 6 (each cycle of 28 days) and Q3W from Cycle 7 to Cycle 30 (each cycle of 21 days) along with cemiplimab 250 mg Q2W, IV infusion from Cycle 1 to 6 and then 350 mg Q3W from Cycle 7 to Cycle 30 until, unacceptable AEs or participant's decision to stop the treatment, or at least 96 weeks (at least 48 weeks from initial signal of CR, whichever was longer) of delivery of investigational medicinal product(s) without documented PD, or study cut-off date, whichever occurs first (maximum duration: up to 103 weeks).
89040249|NCT03766672||Intervention Arm|Identify the genetic profile of type 2 endometrial carcinomas in Martinique from tumor sample for extraction of tumor DNA .
89040250|NCT03676478|No Intervention|start enteral support @ POD1|The standard of care (SoC) in our department consists of enteral nutritional support of maximum 1000 kilocalories (kCal) through a peroperatively placed jejunostomy feeding tube started at POD 1. Oral caloric intake is resumed at POD 4.
89040251|NCT03676478|Active Comparator|delayed start enteral support @ POD5|As study intervention (INT), a period of caloric restriction is set by starting the enteral nutritional support later, at POD 5. Oral caloric intake is resumed at POD 4, similarly as in the control group. This intervention results in a relative caloric defect of more than 4.000 kCal in the immediate postoperative course.
89040252|NCT03657628|Experimental|Physical activity|"The exercise intervention will consist of a supervised, moderate-intensity aerobic exercise program.~Will receive social/behavioral support~Will receive research staff contact time to encourage them to increase their physical activity level~The participants will be given the option of a third supervised session each week"
89040253|NCT03638297|Experimental|PD-1 antibody + cox inhibitor|BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks
89040254|NCT03623490|Experimental|accented follow-up|Initial consultation with a trio oncologist / pharmacist / nurse; weekly telephone follow-up with a nurse between each treatment and follow-up visit with the oncologist at each renewal of treatment.
89040255|NCT03623490|No Intervention|standard follow-up|Initial consultation with the oncologist and follow-up visit with the oncologist
89631294|NCT02781792|Experimental|Arm 1: Temozolomide morning|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00).~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
89631295|NCT02781792|Experimental|Arm 2: Temozolomide evening|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00).~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
89631296|NCT02753283|Experimental|Denosumab, then Zoledronic Acid|Semi-annual dose: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of Denosumab.
88990592|NCT06182553|Experimental|Group (3) : ERCC + PEEP-ZEEP Group|The ERCC technique will be applied as mentioned above, followed by PEEP-ZEEP maneuvers according to the standard steps mentioned before. Also, the patients will be monitored continuously, and the maneuver will be interrupted if the patients become hemodynamically unstable or develop psychomotor agitation.
88990593|NCT06182553|No Intervention|Group (4) : control Group|"The researcher will observe the conventional nursing care provided by CCNs in the study settings which may affect oxygenation, ventilation, and airway clearance for 30 minutes twice daily for five consecutive days. These conventional nursing practices may include enteral feeding, changing patients' positions, routine suctioning, and other traditional physiotherapies such as chest percussion and vibration.~Part II of tool one will be used to assess physiological parameters, and tool two will be used to assess oxygenation, ventilation parameters, and airway clearance indicators for patients in the control group twice per day from the 1st day to the 5th day of the study pre and post-conventional nursing care."
88990594|NCT06182540|Experimental|Ileostomy cohort|
88990595|NCT06182540|Experimental|Non-Ileostomy cohort|
88990596|NCT06182527|Experimental|CGM Group|Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded. In addition perception of hypoglycemia and counter action will be assessed.
88990597|NCT06182488|Experimental|ERAS Group|According to the ERAS guidelines, the ERAS group received ERAS protocol.
88990598|NCT06182488|Other|Conventional group|Conventional perioperative interventions
88990599|NCT06182475|Experimental|EPPCom Provider Training|A highly engaging and interactive 60-minute, in-person communication skills training program will be developed as part of this project. Participating transplant providers will complete a brief online survey before (pre) and after (post) participating in the training.
88990600|NCT06182462|Experimental|Virtual Reality Distraction|Use of virtual reality (VR) during dental procedure.
88990601|NCT06182462|Active Comparator|Standard Treatment|Dental Clinic's standard treatment during dental procedure.
88990602|NCT06182449|Experimental|Virtual Reality Distraction|Use of virtual reality (VR) during maternal milk expression.
88990603|NCT06182449|Active Comparator|Standard Treatment|Mothers will express their maternal milk in a private room in the NICU with their baby or a photo of the baby.
88990604|NCT06182436|Experimental|Virtual Reality Distraction|The child will play with the VR device for five minutes prior to the subcutaneous injection.
88990605|NCT06182436|Active Comparator|Standard Treatment|Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention
88990606|NCT06182397|Active Comparator|MagicTouch PTA sirolimus DCB|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
88990607|NCT06182397|Placebo Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
88990608|NCT06182371|Experimental|Disengagement of the breathing circuit|When the patient's position is changed from the supine position to the lateral decubitus position, the anesthesiologist disengages the breathing circuit.
88990609|NCT06182371|No Intervention|Connect the breathing circuit|When the patient's position is changed from the supine position to the lateral decubitus position, the anesthesiologist maintains the normal connection of the breathing line.
88990610|NCT06182358|Experimental|Active Treatment|XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days
88990611|NCT06182358|Placebo Comparator|Control|Vehicle of XDEMVY ophthalmic solution, administered topically twice a day for approximately 43 days
88990612|NCT06182293|Other|Systemic sclerosis|
88990613|NCT06182293|Other|Controls|
88990614|NCT06182280|No Intervention|Condition A: Standard of Care (SOC)|SOC will include linkage to the CDC's HIV Prevention Services Locator, a US directory of HIV testing and PrEP services. A Digital Library of HIV prevention, sexual health, and anti-stigma materials (written and video media) will be provided. This content is curated from CDC, Gate Trans Men & HIV Project, UCSF Center for Excellence in Trans Health, and National LGBTQIA+ Health Education Center, among other sources.
88990615|NCT06182280|Experimental|Condition B: Online one-on-one peer navigation (SOC + PrEP4T)|PrEP4T is an individualized TMSM-specific intervention consisting of online one-on-one sessions between a peer and a participant. PrEP4T has 9 hours of content: 6 1.5-hour sessions conducted weekly for 6 weeks. Participants will also receive access to the SOC materials.
88990616|NCT06182280|Experimental|Condition C: Online peer-delivered small group-based behavioral intervention (SOC + LS4TM)|LS4TM is a theory-based peer-delivered small group-based behavioral intervention. The LS4TM manualized intervention is comprised of 9 hours of content: 6 2-hour small-group sessions with up to 12 participants per group delivered weekly for 6 weeks. Participants will also receive access to the SOC materials.
88990617|NCT06182280|Experimental|Condition D: Peer-delivered and group-based intervention (SOC + PrEP4T + LS4TM)|Both PrEP4T and LS4TM will be delivered to participants. Group D will receive 21 hours of content: 6 2-hour LS4TM sessions and 6 1.5-hour PrEP4T sessions. Group D participants may not receive both interventions simultaneously within 6 weeks.
88990618|NCT06182254|Experimental|Experimental group: OPTIMISTIC follow-up|follow-up by nurses specialized in collecting the patient's point of view concerning his or her state of health, in addition to the usual conventional follow-up according to routine care directive interviews carried out preoperatively and at Days 1, 3, 14 and 28 postoperatively (modified QoR-15f score, PROMS...)
88990619|NCT06182254|Active Comparator|Control group: Usual conventional follow-up|usual conventional follow-up according to routine care (modified QoR-15f score will be administered to all patients at visit 0 and Day 35).
89040256|NCT03621696|Experimental|Arm 1: POAmCRT|"Patients with extracapsular extension (ECE) or positive margin but not clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant modified chemoradiation therapy (POAmCRT) which is 42 Gy radiation therapy in 21 doses and 1 dose of cisplatin.~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
89040257|NCT03621696|Experimental|Arm 2: POAmRT|"Patients with no extracapsular extension (ECE) and no positive margins and not clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant modified radiation therapy (POAmRT) which is 42 Gy radiation therapy in 21 doses~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
89211506|NCT00838994|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Deltoideus [in the middle of the line insertion of Binao LI 14 and acromion], Forearm [1 inch laterally of the middle point between Shaohai HE3 and Shenmen HE7], Upper arm [1 inch laterally of Tianfu LU 3] and Lower leg [0.5 inch dorsally of Xuanzhong GB39]. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
89631297|NCT02753283|Placebo Comparator|Placebo Group, then Zoledronic Acid|Semi-annual: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of placebo.
89631298|NCT02720679||Study Participants|Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
89631299|NCT02605369|Experimental|Intervention arm: An integrated package|Pregnant women in the intervention clusters will receive an integrated package consisting of peer support for facility based births by pregnancy buddies, mama kits and mobile phone messages. These components will all aim at mitigating the three delays and increasing the proportion of facility based births.
89631300|NCT02605369|No Intervention|Control arm: Standard of care|Pregnant women in the control clusters will continue to receive the standard of care for pregnant women according to Ugandan Ministry of Health guidelines
89631301|NCT02596685|Experimental|Arm A (electronic-cigarette)|"Patients receive nicotine-free and flavor-free electronic cigarettes and instructed to use them BID over a 2 hour period for 4 weeks.~Patients undergo a second bronchoscopy during week 5."
89631302|NCT02596685|Experimental|Arm B (control)|"Patients receive no intervention.~Patients undergo a second bronchoscopy during week 5."
89631303|NCT02596685|Experimental|Arm I (bronchoscopy of the left lung)|Patients undergo bronchoscopy of the left lung over 30-60 minutes.
89631304|NCT02596685|Experimental|Arm II (bronchoscopy of the right lung)|Patients undergo bronchoscopy of the right lung over 30-60 minutes.
89631305|NCT02509052|Experimental|Arm 1: 20 mg leflunomide|Patients receive 20 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89631306|NCT02509052|Experimental|Arm 2: 40 mg leflunomide|Patients receive 40 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89631307|NCT02509052|Experimental|Arm 3: 60 mg leflunomide|Patients receive 60 mg leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89631308|NCT02365597|Experimental|Erdafitinib (8 milligram)|Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants enrolled in DDI substudy will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression. Participants who completed the DDI substudy and continue to benefit from erdafitinib treatment, will continue to receive erdafitinib in long-term extension (LTE) phase.
89631309|NCT02361320|Experimental|Computed Tomography Scans (CT)|Participants to receive 2 computed tomography (CT) scans that are part of their regular cancer care. One (1) scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist. Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit.
89631310|NCT02231632|Experimental|Live attenuated Poliomyelitis vaccine (human diploid cell)|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
89631311|NCT02231632|Experimental|Poliomyelitis（Live）Vaccine(Monkey Kidney Cell),Oral|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
89631312|NCT02223923|Experimental|Dose Escalation|AZD6738 PO 20 to 380mg BD increasing
89631313|NCT02223923|Experimental|AZD6738 - Expansion Phase|AZD6738 starting dose and regimen to be determined in dose escalation phase
89631314|NCT02223923|Experimental|AZD6738 + Radiotherapy (Head and Neck)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
89631315|NCT02223923|Experimental|AZD6738 + Radiotherapy (Abdomen / Pelvis)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
89631316|NCT02220894|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
89631317|NCT02220894|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
89631318|NCT02124733|Active Comparator|Group 1: 30 minutes|The first 4 patients enrolled will be considered Group 1, and will receive 30 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated in terms of erythema immediately post-PDT (Day 1) and on Day 4 . If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 2
89631319|NCT02124733|Active Comparator|Group 2: 45 minutes|Patients in this group will receive 45 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema response immediately post-PDT and at Day 4. If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 3.
89631320|NCT02124733|Active Comparator|Group 3: 60 minutes|Patients in this group will receive 60 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema responses immediately post-PDT and at Day 4. If the post-PDT reaction on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of patients, then the protocol will terminate after 15 patients (total for all groups) have been treated.
89631321|NCT02068092|Experimental|Hydroxytyrosol|Hydroxytyrosol 25 mg orally once daily for 1 year.
89631322|NCT02063165|Experimental|Linoleic Acid|
89631323|NCT02050347|Experimental|Subgroup A1|Patients with residual or relapsed B-cell ALL and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
89631324|NCT02050347|Experimental|Subgroup B1|Patients with other B-cell malignancies and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
89631325|NCT02050347|Experimental|Subgroup A2|Patients with residual or relapsed B-cell ALL and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
89631326|NCT02050347|Experimental|Subgroup B2|Patients with other B cell malignancies and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
88990620|NCT06182241|Experimental|Participant intervention|The intervention group will likely consist of one to two sessions, conducted in-person, coupled with text- or phone-based client navigation.The intervention group will complete three major assessments: baseline (T1), at the conclusion of the intervention (T2), and a six-month follow-up (T3). Until the follow-up assessment, the interventionist will send participants up to 6 SMS messages (one-way) per month. The content of these messages will be developed collaboratively between the participant and the interventionist during the second session; messages could include reminders about follow-ups and/or prompts to use new skills and resources for navigating specific barriers.
88990621|NCT06182241|No Intervention|Treatment as usual|The treatment as usual (TAU) group will receive treatment as usual, including being notified of their abnormal Pap results via SMS and instructed to set up a follow-up appointment, as is typical in routine care. The TAU group will complete the T1 assessment and will complete T2 assessment two-months post-baseline.
88990622|NCT06182202|No Intervention|Individuals Without Amputation|No Intervention Tested in identical tasks for comparison to Individuals with Amputation
88990623|NCT06182202|Experimental|Individuals With Amputation|Tasks with a passive prosthesis Tasks with a powered active prosthesis
88990624|NCT06182189||Patients with a benign prostatic hyperplasia condition|Patients with a benign prostatic hyperplasia condition
88990625|NCT06182163|Experimental|Sedentary time intervention|
88990626|NCT06182163|No Intervention|Education Control|
88990627|NCT06182137|Experimental|rTMS and CBT|During 5 weeks of therapy, the subjects will undergo 12 CBT sessions combined with 15 rTMS procedures lasting about 30-60 minutes.
88990628|NCT06182137|Sham Comparator|Sham and CBT|During 5 weeks of therapy, the subjects will undergo 12 CBT sessions combined with 15 rTMS procedures (coil replaced with sham) lasting about 30-60 minutes.
88990629|NCT06182111||No morphine|Participants who have undergone surgery before anesthesia protocol was changed. These participants have not received morphine during surgery.
88990630|NCT06182111||Morphine|Participants who have undergone surgery after anesthesia protocol was changed. These participants have received morphine during surgery.
88990631|NCT06182098|Experimental|Bolus|Will receive a normal saline bolus
88990632|NCT06182098|Placebo Comparator|Control|Will receive 1/2 maintenance normal saline
88990633|NCT06182072|Experimental|Dose Escalation|"ProAgio Dose Levels (DL) 1,2,3,4~ProAgio combined with gemcitabine and nab paclitaxel is administered to study participants by intravenous injections on days 1, 8, 15, 22 every 4-week Cycle.~Other Names:~ACT50, G-nP: Gemcitabine and nab-Paclitaxel"
89631327|NCT02023463|Experimental|Treatment (enzalutamide, radiation therapy, hormone therapy)|Patients receive enzalutamide PO QD for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate SC or leuprolide acetate IM or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH therapy, patients undergo either IMRT or VMAT daily five days a week for 8 weeks.
89040258|NCT03621696|Experimental|Arm 3: POACRT|"Patients with clinical or pathologic T4 or clinical N3 disease~Standard of care surgery (surgical resection of the primary tumor via a transoral approach and surgical management of cervical lymph nodes~Treated with post-operative adjuvant chemoradiation therapy (POACRT) which is 60 Gy radiation therapy in 30 doses and 3 doses of cisplatin (if there is pathologic evidence of ECE or positive margins)~The first dose of cisplatin will given on one of the days during the initial 5 days of radiation therapy, the 2nd dose on the day of radiation dose 16, and the 3rd dose on the day of radiation dose 26.~It is recommended that radiation therapy begin within 28-49 days (no later than 56 days) after surgical resection~Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) is to be used for this study"
89040259|NCT03592641|Experimental|Treatment (savolitinib)|Patients receive savolitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89040260|NCT03538119|Experimental|High Intensity Interval Training Program|Three sessions of exercises will be performed weekly with duration of 30 min to 45 min, divided into warm up, aerobic exercise (4x4 high-intensity intervals at 85%-95%) and recovery.
89631328|NCT01959672|Experimental|Treatment (chemotherapy, oregovomab, SBRT, surgery)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV, leucovorin calcium IV over 30 minutes, and fluorouracil IV over 24 hours on days 1 and 8. Treatment repeats every 3 weeks for 7 courses.~IMMUNOTHERAPY: Patients with CA125 level >= 10 receive oregovomab IV over 15-30 minutes on day 15. Treatment repeats every 3 weeks for 3 courses (weeks 1, 4, 7) and post- radiation therapy for 1 course (week 14). Patients may receive an additional 3 courses concurrently with chemotherapy upon recovery from surgery based on CA125 level. Patients also receive nelfinavir mesylate PO BID for 5 weeks beginning on day 15 of week 9.~STEREOTACTIC RADIATION THERAPY: Beginning in week 11, patients undergo SBRT in 5 fractions over 5 consecutive days. Upon completion of radiation therapy, patients resume nelfinavir mesylate for 14 days (week 12-13). Patients without metastasis and with resectable disease undergo surgery in week 17-18."
89631329|NCT01958593|Placebo Comparator|Placebo with therapy|Participants will receive placebo with therapy during each of two experimental sessions.
89631330|NCT01958593|Experimental|MDMA-assisted therapy|Participants will receive MDMA (initial dose of 125 mg followed by a supplemental dose of 62.5 mg) with therapy during each of two experimental sessions.
89631331|NCT01949857|Experimental|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-15 years \6.50 lgCCID50/ml in adults aged 16 up to 65 years old
89631332|NCT01949857|Experimental|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
89631333|NCT01949857|Experimental|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
89631334|NCT01949857|Experimental|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
89631335|NCT01760005|Experimental|Gantenerumab|This arm completed and is closed.
89631336|NCT01760005|Experimental|Solanezumab|This arm completed and is closed.
89631337|NCT01760005|Placebo Comparator|Matching placebo (Gantenerumab)|This arm completed and is closed.
89631338|NCT01760005|Placebo Comparator|Matching Placebo (Solanezumab)|This arm completed and is closed.
89631339|NCT01760005|No Intervention|Cognitive Run-in|
89631340|NCT01760005|Active Comparator|Gantenerumab Open Label Extension|Subcutaneously every 4 weeks at escalating doses
89631341|NCT01760005|Experimental|E2814 plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
89631342|NCT01760005|Experimental|Matching placebo (E2814) plus lecanemab|"Symptomatic Population (Cohort 1)~At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period.~At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period.~Asymptomatic Population (Cohort 2)~At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period.~At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period."
89631343|NCT01712906|Experimental|3.50±0.25logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 adults aged 16-59 years old on day 0.
89631344|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
89631345|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
89631346|NCT01712906|Placebo Comparator|0 logCCID50/ml in adults|0 logCCID50/ml in 18 adults aged 16-59 years old on day 0.
89631347|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 5-15 years old on day 0.
89631348|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
89631349|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
89631350|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (5-15 years old)|0 logCCID50/ml in 18 children aged 5-15 years old on day 0.
89631351|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 2-4 years old on day 0.
88990634|NCT06182072|Experimental|Standard Arm|"Participants will receive ProAgio at the RP2D combined with gemcitabine and nab paclitaxel is administered to study participants by intravenous injections on days 1, 8, 15, 22 every 4-week Cycle.~Other Names:~ACT50, G-nP: Gemcitabine and nab-Paclitaxel"
88990635|NCT06182046|Experimental|Intervention group: Balance exercise with BOSU Ball added to complete decongestive treatment|Complete decongestive treatment program consists of manual lymph drainage, multi-layer bandaging, skin/nail care and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks. Patients in the intervention group will also receive balance exercises with a BOSU ball. These exercises will be performed in 2 sets, 5 days a week for 3 weeks. Each set will last 15 minutes. It will take 15 sessions in total. These exercises include 10 balance exercise movements performed on a bosu ball.
88990636|NCT06182046|Active Comparator|Active Control group: Complete decongestive treatment|Patients in this group will receive only a complete decongestive treatment program consisting manual lymph drainage, multilayer bandaging, skin/nail care, and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.
89631352|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
89631353|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
89631354|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (2-4 years old)|0 logCCID50/ml in 18 children aged 2-4 years old on day 0.
89631355|NCT01712906|Active Comparator|Attenuated Mumps vaccine in children (2-4 years old)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 children aged 2-4 years old on day 0.
89631356|NCT01712906|Experimental|3.50±0.25logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 infants aged 8-23 months old on day 0.
89631357|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
89631358|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
89631359|NCT01712906|Placebo Comparator|0 logCCID50/ml in infants|0 logCCID50/ml in 18 infants aged 8-23 months old on day 0.
89631360|NCT01712906|Active Comparator|Attenuated Mumps vaccine in infants|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 infants aged 8-23 months old on day 0.
89631361|NCT01712308|Experimental|Treatment Monotherapy (sotatercept)|Patients receive sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.
89631362|NCT01712308|Experimental|Treatment combination (Ruxolitinib + sotatercept)|patients that are already on therapy with ruxolitinib (for at least for 6 months, and on stable dose for last 2 months) will continue ruxolitinib in addition to sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.
89631363|NCT01655836|Experimental|Treatment (HDR brachytherapy, SBRT)|Patients undergo HDR brachytherapy on day 0 followed by SBRT on days 15-30
89631364|NCT01556256|Experimental|Arm I (TMV)|See detailed description.
89631365|NCT01556256|Experimental|Arm II (TMV+P)|See detailed description.
89631366|NCT01133951|Experimental|OAC triple therapy|
89631367|NCT01133951|Placebo Comparator|Placebo|
89631368|NCT00607945|Placebo Comparator|0 g CLA|Avandia (Rosiglitazone) 4-8mg/day OR other diabetes medication currently prescribed to participant, 0 g CLA, 8 g Placebo oil (based on typical American diet)
89631369|NCT00607945|Experimental|3.2 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 3.2 g CLA, 4.8 g placebo oil (based on typical American diet)
89631370|NCT00607945|Experimental|6.4 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 6.4 g CLA, 1.6 g placebo oil (based on typical American diet)
89631371|NCT00574509|Experimental|131I-Anti-B1|BEAM + 131Iodine-Anti-B1 radioimmunotherapy and autologous HSCT
88990637|NCT06182033|Experimental|Peer-mediated pivotal response intervention|"Facilitators hold four 15-minute training sessions with the peer group to engage the target child. The facilitator explicitly identifies the buddy and asks the children to use four strategies to play with the child during center time: (a) offer your buddy some play options; (b) show and talk about how to play with your buddy; (c) compliment your buddy; and (d) show your buddy how to take turns. At each training session the facilitator will describe one strategy, provide examples, and practice the strategy through role play. After trainings, the facilitator provides ongoing support during center time to implement the strategies over 12 weeks during months 3-6 of the 9 months of study participation."
88990638|NCT06182033|No Intervention|Control|Business as usual
88990639|NCT06182020|Experimental|Integrated care|Participants in this group will receive both the peripheral functional magnetic stimulation to both the upper and lower limbs and nutritional supplement for consecutive 8 weeks.
88990640|NCT06182020|Active Comparator|Usual care|Participants in this group will receive an educational DVD and one session of oral instructions on general care and exercise suggestions for sarcopenia.
88990641|NCT06182007||No Pneumothorax|Patients with no pneumothorax reported from the first chest imaging after hospital admission.
88990642|NCT06182007||Pneumothorax|Patients with a pneumothorax reported from the first chest imaging after hospital admission.
88990643|NCT06181981||incidental Leukoaraiosis (LA)|Eligible patients in the incidental LA group will be pre-identified by the radiologist at the time of the 3T MRI or CT scan, and recruited by the neurologist at their first routine neurology consultation in the days following the MRI.
88990644|NCT06181981||LA and ischemic stroke|Eligible patients in the LA + ischemic stroke group will be recruited by the neurologist during hospitalization for ischemic stroke
89631372|NCT00571818|Active Comparator|Euglycemic pancreas transplant recipients|Participants receiving a pancreas transplant who have blood glucose level is within the normal range
89631373|NCT00571818|Active Comparator|Hyperglycemic pancreas transplant recipients|Participants receiving a pancreas transplant who have high blood glucose (blood sugar)
89631374|NCT00571818|Active Comparator|Euglycemic Kidney Transplant Recipients|Participants receiving a kidney transplant who have blood glucose level is within the normal range
89631375|NCT00571818|Active Comparator|Euglycemic Healthy Control Participants|Participants who do not receive either a pancreas or kidney transplant who have blood glucose level is within the normal range
89631376|NCT00071760|Experimental|Arm A - 4weeks - less than 2 years old (FPV/RTV bid)|"Cohort 2A - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)~Cohort 1A - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)"
89631377|NCT00071760|Experimental|Arm B- 4weeks - less than 2 years old (FPV bid)|"Cohort 2B - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)~Cohort 1B - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)"
89631378|NCT04745260|Experimental|Intranasal Midazolam and Intranasal Fentanyl|Study participants assigned to the combination (experimental) group will receive a weight-based dose of intranasal Fentanyl (50mcg/mL concentration at 2mcg/kg up to 100mcg) followed by intranasal Midazolam (5mg/mL concentration at 0.2mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
89631379|NCT04745260|Active Comparator|Intranasal Midazolam|Study participants assigned to the control (active comparator) group will receive only intranasal Midazolam (5mg/mL concentration at 0.3mg/kg up to 10mg) using a mucosal atomizer device (1mL syringe with an attached atomizer).
89631380|NCT03195426|Experimental|distal nerves blocks group|"This study aims at assessing the effectiveness of combined supra scapular nerve block, infraclavicular block and supraclavicular nerve block as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery.~These blocks are performed for decades in routine care. The originality of this study is to analyze the combination of these different blocks for post-operative pain relief in arthroscopic shoulder surgery. This combination can be considered as an alternative to interscalene block well known to be associated with diaphragmatic paralysis.~Local anesthetics used in this study are used for many years in routine care: Ropivacaine 0.375%. A single injection will be performed under ultrasounds. No continuous injection will be performed."
89631381|NCT05123872|Experimental|prefrontal tDCS at home|trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
89631382|NCT03199482|Active Comparator|Drug dexamethasone|preoperative single dose of dexamethasone 0.5 mg oral tablet given to patients before starting of root canal treatment by 30 minutes.
89631383|NCT03199482|Placebo Comparator|Placebo|Placebo will be administrated to patients before stating of root canal treatment
89631384|NCT05650372|Experimental|High intensity resistive exercise group|Participants of this group will be applied manual lymphatic drainage and compression bandaging and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition.
89631385|NCT05650372|Active Comparator|Low intensity resistive exercise group|Participants in this group will be applied manual lymphatic drainage and compression bandaging and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition.
89631386|NCT02446704|Experimental|Olaparib and Temozolomide|"- Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. Once the MTD is determined, the study will move to the phase II portion.~Olaparib- Oral, on determined days per cycle~Temozolomide- Oral, on determined days per cycle"
89631387|NCT06243016|Active Comparator|High-Intensity Interval Training (HIIT) Breaks|Sitting interrupted every 30 min by 6-min HIIT bouts.
89631388|NCT06243016|Sham Comparator|Light-Intensity Interval Training (HIIT) Breaks|Sitting interrupted every 30 min by 6-min LIIT bouts.
89631389|NCT06242990|Experimental|Y-PATH Intervention Group|Participants will receive the Y-PATH NI intervention programme which is an adapted form of physical education classes.
89631390|NCT06242990|No Intervention|Control Group|Participants will continue to receive their usual physical education classes.
89631391|NCT06242977|Experimental|Intervention arm - EMLA cream|This arm will receive EMLA cream 30 minutes prior to their procedure, applied to the scrotum. The patient is blinded to which cream they have received and this cream is removed prior to entering the procedural suite.
89631392|NCT06242977|Placebo Comparator|Control arm - Control cream|This arm will receive lotion cream 30 minutes prior to their procedure, applied to the scrotum. The patient is blinded to which cream they have received and this cream is removed prior to entering the procedural suite.
89631393|NCT06242964|Experimental|PRISM-SN Intervention|Skill-based psychosocial program
89631394|NCT06242964|No Intervention|Usual Care|Standard psychosocial care
88990645|NCT06181981||LA and intracerebral hemorrhage|Eligible patients in the LA + intracerebral hemorrhage group will be recruited by the neurologist during hospitalization
88990646|NCT06181955|Experimental|Experimental|The participants in this group received Extracorporeal Shock Wave Therapy (ESWT) in addition to conventional physical therapy.
88990647|NCT06181955|Active Comparator|Control group|The participants in this group received conventional physical therapy only.
88990648|NCT06181942||single-port urological surgeries with the SP single-port robot|who have received or plan to receive radical prostatectomy (RP), partial nephrectomy (PN), radical nephrectomy (RN), radical resection of the renal pelvic carcinoma (one position), pyeloplasty and other single-port urological surgeries with the SP single-port robot.
88990649|NCT06181916|Experimental|Amp mHealth App|Amp, video-based, virtual support system on an mHealth platform with resources and tools to help YBMSM living with HIV become and stay virally suppressed.
88990650|NCT06181916|No Intervention|Standard of Care|Standard of care (SOS) linkage to care services typically provided by linkage specialists, health navigators, or case workers.
88990651|NCT06181903|Experimental|Emotional freedom technique group|Emotional freedom technique will be applied to risky pregnant women in the emotional freedom technique group.
88990652|NCT06181903|No Intervention|Control group|Pregnant women in the control group will not receive any intervention other than routine hospital care.
89040261|NCT03538119|Experimental|Moderate Intensity Continuous Training Program|Three sessions of exercises will be performed weekly with duration of 45 min to 60 min, divided into warm up, aerobic exercise (continuous intensity at 70-75%HRpeak) and recovery.
89631395|NCT06242938|Experimental|Early intensive antihypertensive treatment group|"Treatment starts within 1 hour after randomization~SBP target:130-140 mmHg within 1 hour after treatment~Under the guidance of medication, the researchers can independently select oral + intravenous antihypertensive medications"
89040262|NCT03538119|No Intervention|Control Group|Usual care. The patients will receive nutritional counseling as well as physical activity.
89040263|NCT03468985|Active Comparator|Arm A (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89040264|NCT03468985|Experimental|Arm B (nivolumab, cabozantinib)|Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89040265|NCT03468985|Experimental|Arm C (nivolumab, cabozantinib, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89631396|NCT06242938|No Intervention|Standard antihypertensive treatment group|"Empirical antihypertensive treatment~SBP target: 140-180 mmHg after randomization"
89631397|NCT06242912|Experimental|Therapy|Regular disease assessment (eg radiographic imaging) and QOL questionnaires
89631398|NCT06242899|Experimental|8-minutes short exercise group|Participants performed an intervention for 3 sessions/week, over 3 weeks and a cycle ergometer was used. The workout regimen consisted of a structured warm-up lasting 2 minutes. The main exercise phase comprised an 8-minute cycling session performed at 75% of HRmax. Finally, a cool down phase lasting 2 minutes.
89631399|NCT06242899|Experimental|10-minutes short exercise group|Participants performed an intervention for 3 sessions/week, over 3 weeks and a cycle ergometer was used. The workout regimen consisted of a structured warm-up lasting 2 minutes. The main exercise phase comprised an 10-minute cycling session performed at 75% of HRmax. Finally, a cool down phase lasting 2 minutes.
89631400|NCT06242899|Experimental|15-minutes short exercise group|Participants performed an intervention for 3 sessions/week, over 3 weeks and a cycle ergometer was used. The workout regimen consisted of a structured warm-up lasting 2 minutes. The main exercise phase comprised an 15-minute cycling session performed at 75% of HRmax. Finally, a cool down phase lasting 2 minutes.
89631401|NCT06242886|Experimental|Oxytocin massage|The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
89631402|NCT06242886|Experimental|Breast massage|The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
89631403|NCT06242886|No Intervention|Control|No intervention
89631404|NCT06242873|Experimental|Transcutaneous Spinal Cord Stimulation and Gait Training|Transcutaneous Spinal Cord Stimulation (TSCS), TSCS will be applied using an oval electrode placed midline on the skin on the back and two rectangular electrodes placed on the skin over the lower abdomen. There will be a small electrical current through those electrodes for 30 minutes.
89631405|NCT06242873|Sham Comparator|Transcutaneous Spinal Cord Stimulation within a single session|Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
89631406|NCT06242860|Active Comparator|Single ELM Treatment|"To undergo the ELM procedure, the subject will sit comfortably in an exam chair.~The Headset and Eye Pads will be adjusted to fit comfortably over gently closed eyelids. The subject will rest their head back. The ELM will be turned on, and will be active for 15 minutes wherein patients will feel a warming sensation to their eyes and a gentle vibration. The ELM is then removed."
89631407|NCT06242860|Active Comparator|Daily ELM Treatment|"To undergo the ELM procedure, the subject will sit comfortably in an exam chair.~The Headset and Eye Pads will be adjusted to fit comfortably over gently closed eyelids. The subject will rest their head back. The ELM will be turned on, and will be active for 15 minutes wherein patients will feel a warming sensation to their eyes and a gentle vibration. The ELM is then removed. Subject will take personalized ELM home and use it as directed on a daily basis"
89631408|NCT06242834|Experimental|Treatment (pembrolizumab, tazemetostat)|Starting on day 14 after standard of care ASCT or CAR-T cell treatment patients receive pembrolizumab IV on day 1 of each cycle. Starting cycle 2, patients receive tazemetostat PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography during screening, CT scan, PET scan, and blood sample collection throughout the study.
89040266|NCT03468985|Experimental|Arm T (Targeted cohort; nivolumab, cabozantinib)|Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89040267|NCT03447912|Experimental|Intervention Condition|Fourteen communities will be assigned to the intervention.
89040268|NCT03447912|No Intervention|Control Condition|The 14 communities assigned as controls will participate in the population-level survey and will be provided with a site-specific summary of findings but will not participate in any aspects of the intervention. To examine potential contamination in the control communities, a follow-up interview will be conducted with public health center leaders to assess any local coalition or grassroots actions regarding tobacco control that may have naturally occurred or be influenced by coalition activity in other communities.
89040269|NCT03434418|Experimental|osimertinib|
89040270|NCT03417336|Experimental|brachytherapy + External radiotherapy|Prostate booster, HDR brachytherapy with 15Gy in 1 fraction + external radiotherapy 25Gy in 5 fractions
89631409|NCT06242821|Placebo Comparator|Observation|Patients who select to be part of the trial, but not partake in either yoga or physical therapy (PT), choosing to be part of an observation group.
89631410|NCT06242821|Active Comparator|Physical Therapy|Patients who select or are randomized into the Physical Therapy group will partake in PT as per non-surgical AIS standard of care.
89631411|NCT06242821|Active Comparator|Yoga|Patients who select or are randomized into the yoga group will partake in an online 20 min yoga class 2 days per week for 6 months, consisting of a set protocol.
89631412|NCT06242795|Experimental|Single arm treatment group with 7% HS|All study participants will receive 7% HS by nebulizer twice a day for two weeks as part of airway clearance.
89631413|NCT06242782|Active Comparator|Positive Control|VRA using Ti-Reinforced d-PTFE membrane
89631414|NCT06242782|Experimental|Test 1|VRA using Ti-Reinforced e-PTFE membrane
89631415|NCT06242782|Experimental|Test 2|VRA using 3D printed Titanium mesh
89631416|NCT06242782|Experimental|Test 3|VRA using Reinforced PTFE mesh
89631417|NCT06242769|Active Comparator|Group I|Stannous Fluoride Toothpaste (SnF) Colgate Adult Extra Clean soft-bristle toothbrush brushing 2 X day for 2 min
89631418|NCT06242769|Placebo Comparator|Group II|Fluoride Toothpaste (CDC) Colgate Adult Extra Clean soft-bristle toothbrush brushing 2 X day for 2 min
89631419|NCT06242743|Experimental|Test group|
89631420|NCT06242743|Active Comparator|Control group|
89631421|NCT06242730||People living with HIV participating in the Swiss HIV Cohort Study on doxycycline STI PEP|The target population for this study are MSM or TGW at high risk for a bacterial STI (≥1 occasional partners within the preceding 6 months) taking teh doxycycline STI PEP
89631422|NCT06242704|Experimental|Working Memory Training|The intervention is a computer-based training aimed at improving working memory in order to decrease delay discounting. Active training sessions include: Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Digits - Visual, Sequenced Reverse Recall of Digits - Visual, Sequenced Recall of Words - Auditory, Sequenced Recall of Words - Visual, Sequenced Reverse Recall of Words - Auditory, Sequenced Reverse Recall of Words - Visual. Participants will complete at least 10 sessions with each session taking approximately 30 minutes to complete.
89631423|NCT06242704|Active Comparator|Working Memory|The comparison control condition is a multi-session control computer training condition that is designed to not engage working memory during computer-based engagement sessions: Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Digits - Visual, Sequenced Reverse Recall of Digits - Visual, Sequenced Recall of Words - Auditory, Sequenced Recall of Words - Visual, Sequenced Reverse Recall of Words - Auditory, Sequenced Reverse Recall of Words - Visual. Participants will complete at least 10 sessions with each session taking approximately 30 minutes to complete.
89631424|NCT06242678|Experimental|SCS trial lead|placement of spinal cord stimulator trial leads
89631425|NCT06242652|Experimental|608 Dose A|608 Dose A subcutaneous (SC) injection.
89631426|NCT06242652|Experimental|608 Dose B|608 Dose B subcutaneous (SC) injection.
89631427|NCT06242652|Experimental|608 Dose C|608 Dose C subcutaneous (SC) injection.
89631428|NCT06242652|Active Comparator|Positive control group|Adalimumab subcutaneous (SC) injection.
89631429|NCT06242652|Placebo Comparator|Placebo|Placebo subcutaneous (SC) injection.
89631430|NCT06242639||metal-ceramic FPD|
89631431|NCT06242626||Low T3|
89631432|NCT06242626||Low T3T4|
88990653|NCT06181890||control group|"Infertile women who will be included in the control group will be interviewed twice in total. Pretest data will be obtained by applying the Personal Information Form, Infertility Impact Scale, Infertility Self-Efficacy Scale - Short Form and Coping with Infertility Stress Scale in the first interview. Four weeks after obtaining the pre-test data, post-test data will be obtained by applying the Infertility Impact Scale, Infertility Self-Efficacy Scale - Short Form and Coping with Infertility Stress Scale."
88990654|NCT06181890||intervention group|"Before starting motivational interviews with infertile women in the intervention group, pre-test data will be obtained by applying the Personal Information Form, Infertility Impact Scale, Infertility Self-Efficacy Scale - Short Form and Coping with Infertility Stress Scale. A total of 4 sessions of motivational interviews will be held for infertile women, 1 session per week for four weeks. At the end of four weeks, post-test data will be obtained by applying the Infertility Impact Scale, Infertility Self-Efficacy Scale - Short Form and Coping with Infertility Stress Scale."
88990655|NCT06181877||Hemiplegic Patients|Patients with hemiplegia after stroke
89631433|NCT06242613||Robotic Surgery|Patients underwent gastric surgery through the use of a robotic system.
89631434|NCT06242613||Laparoscopic Surgery|Patients underwent gastric surgery with laparoscopic procedures.
89631435|NCT06242548|Other|physical activity at altitude while maintaining usual diet|"organisation of physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic); '.~collection of capillary blood samples (blood sugar, ketone levels), non-invasive biometric data (weight, oxygen saturation by transcutaneous sensor), and questionnaires (BORG scale, food consumption before/during/after exercise)."
89631436|NCT06242509||Metastatic castration resistant prostate cancer (CRPC) receiving next generation hormonal therapy|
89631437|NCT06242496||Patients with brain abscesses after transplantation|
89631438|NCT06242483|No Intervention|Usual care group|Patients randomized to usual care will receive standard care, in which hypertension treatment will be provided according to local practices and will not have access to the Elfie solution. Additionally, they will be requested not to access/use other mobile phone apps or participate in any kind of digital health intervention related to hypertension treatment during the trial.
89631439|NCT06242483|Experimental|Digital health intervention group (Elfie solution)|Patients randomized to digital health intervention group will receive standard care plus the Elfie solution. Participants randomized to the Elfie solution will be instructed to download the Elfie app and will receive training on how to register in the app and on how to use all the app features. Participants will be then instructed to use the app according to the monitoring plan created by the app for the following 6 months. Participants in the digital health intervention group will be provided with a Bluetooth-enabled automated upper-arm BP monitor at the randomization visit to be able to measure their blood pressure as part of their monitoring plan.
89631440|NCT06242392||effective group|The tumor size of each diameter of the tumor before and after treatment was measured on magnetic resonance imaging or CT. According to Recist 1.1 criteria, patients who were evaluated as complete remission, partial remission and stable disease were included in the effective group. Patients assessed as having progressive disease were included in the treatment-refractory group.
89631441|NCT06242392||ineffective group|The tumor size of each diameter of the tumor before and after treatment was measured on magnetic resonance imaging or CT. According to Recist 1.1 criteria. Patients assessed as having progressive disease were included in the ineffective group.
89631442|NCT06242340|Experimental|Group 1|Preterm (between 32 0/7 and 36 6/7 weeks)
89631443|NCT06242340|Experimental|Group 2|Preterm (between 32 0/7 and 36 6/7 weeks)
89631444|NCT06242340|Experimental|Group 3|Early term (between 37 0/7 and 38 6/7 weeks)
89631445|NCT06242340|Experimental|Group 4|Early term (between 37 0/7 and 38 6/7 weeks)
89631446|NCT06242314|Experimental|L-PRF|L-PRF was laid directly on the palatal wound immediately after free gingival graft harvesting and stabilized with silk suture.
89631447|NCT06242314|Experimental|A-PRF|A-PRF was laid directly on the palatal wound immediately after free gingival graft harvesting and stabilized with silk suture.
89631448|NCT06242314|Placebo Comparator|Palatal stent|Palatal stent was prepared by taking impression of the palate before surgery. After FGG harvesting, periodontal paste (COE-PAK periodontal dressing, GC, Illinois, USA) was applied on the wound surface of the palatal stent and the palate was closed.
89631449|NCT06242301|Other|The COPE-D intervention|
89631450|NCT06242236|Active Comparator|Intervention group: respiratory effort guide sedative dosage adjustment.|Following the enrollment of participants (acute respiratory failure requiring mechanical ventilation which sedation needed), the investigators proceeded to randomize participants into two groups: this intervention group, which employed the optimal respiratory effort parameters to guide the adjustment of sedative levels.
89631451|NCT06242236|No Intervention|Control group: usual care guide sedative dosage adjustment.|Following the enrollment of participants (acute respiratory failure requiring mechanical ventilation which sedation needed), the investigators proceeded to randomize participants into two groups: this control group, which employed usual care to guide the adjustment of sedative levels.
89631452|NCT06242223|Active Comparator|Multimodal HIIT|multimodal HIIT protocol followed by sprinting
89631453|NCT06242223|Experimental|conventional HIIT|Conventional protocol with 4-5 repetitions of 40 seconds maximum running
89631454|NCT06242210|Experimental|Pursed Lip Breathing Technique|Patient will be asked to attain fowler's position by placing a pillow in front of his trunk to support a comfortable breathing pattern. Then, patient will be instructed to inhale through nose deeply until no more air can be inhaled and which will be followed by a slow expiration through pursed or rounded lip, like at the time of whistling.Patient will also be demonstrated visually for the proper breathing pattern even for once to multiple times till complete understanding before performing itself. The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed.
89631455|NCT06242210|Experimental|Stacked Breathing|Patient will be asked to attain recumbent position by lying supine at a reclining angle to support a comfortable breathing pattern. Then, patient will be instructed to inhale slowly and deeply once through nose and hold it, then inhale again slowly and deeply through nose and trap the air in again over the first one, then inhale again until no more air can be inhaled and which will be held for a bit then followed by a slow and quiet expiration. Patient will also be demonstrated visually for the proper breathing pattern even for once to multiple times till complete understanding before performing itself
89631456|NCT06242197|Experimental|written advice|written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.
89631457|NCT06242197|Active Comparator|standard verbal advice|verbal advice about cancer risk and screening methods was given to CRC patients to pass on to their first degree relatives
89631458|NCT06242158||Case with massive rotator cuff tear|Case with massive rotator cuff tear defined as more than 2 complete tendon tear that is repairable
89631459|NCT06242145|Active Comparator|clopidogrel arm|The clopidogrel arm will receive (300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day)
88990656|NCT06181864|Experimental|Experimental group|Twenty children from the experimental group will undergo the treatment using Robot Nao.
88990657|NCT06181864|Other|Control group|Twenty children belonging to the control group will be subjected to the same training but in a traditional way.
88990658|NCT06181851||Infertile men|Patients diagnosed with idiopathic non-obstructive azoospermia
88990659|NCT06181851||Fertile men|fertile subjects (pregnancy within 12 months of the start of the research by the couple, according to WHO 2010 criteria)
88990660|NCT06181851||Old fertile men|Subjects known to have been fertile subjects (pregnancy within 12 months of the start of the research by the couple, according to WHO 2010 criteria)
88990661|NCT06181799||Experimental group|The group is planned to include 30 people with myocardial perfusion defect on the stress computed tomography myocardial perfusion Imaging (by using contrast enhanced multi-slice spiral computed tomography (CE-MSCT) using adenosine triphosphate (ATP)).
88990662|NCT06181799||Control group|The group is planned to include 30 people without myocardial perfusion defect on the stress computed tomography myocardial perfusion imaging (by using contrast enhanced multi-slice spiral computed tomography (CE-MSCT) using adenosine triphosphate (ATP)).
88990663|NCT06181786|Experimental|Phase 1a, Single Ascending Doses (SAD) Cohorts: IMB-101 or Placebo|Healthy participants will receive either planned dose levels of IMB-101 or placebo through a single intravenous administration.
88990664|NCT06181786|Experimental|Phase 1b, Multiple Ascending Dose (MAD) Cohorts: IMB-101 or Placebo|Participants with RA will either receive multiple doses of IMB-101 or placebo through multiple intravenous administration once every 2 weeks for up to 10 weeks.
88990665|NCT06181721|Experimental|Group A with Type 1 Diabetes|Participants with Type 1 Diabetes
88990666|NCT06181721|Experimental|Group B with Type 2 Diabetes|Participants with Type 2 Diabetes
89631460|NCT06242145|Active Comparator|cilostazol arm|The cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day)
89631461|NCT06242132|Active Comparator|clopidogrel arm|The clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day)
89631462|NCT06242132|Active Comparator|cilostazol arm|The cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day)
89631463|NCT06242106|Experimental|Aerobic exercises + self-stretching|• After the baseline assessment, the patient in the experimental group received self-stretching with aerobic exercises. Self-stretching that includes butterfly stretch, wall stretching and cat and cow pose for 5 sec each and 10 repetitions, with aerobic exercises that includes 30 minutes (2 sets each is of 15 minutes) of treadmill, Static cycling for 15 minutes and walking for straight 20 minutes. For 7 weeks
89631464|NCT06242106|Active Comparator|Control Group (Self stretching)|After the baseline assessment, the patient in the control group received self-stretching without aerobic exercises. Self-stretching that includes butterfly stretch, wall stretching and cat and cow pose for 5 sec each and 10 repetitions for 7 weeks
89631465|NCT06242093|Experimental|GROUP A WBVT and Conservative treatment|"WBVT and Conservative treatment~Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform.~Time: 3-4 Times/WEEK for 8 weeks"
89631466|NCT06242093|Active Comparator|GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.|"Pelvic floor muscle training (PFMT) and conservative treatment.~Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~Time: 3-4 Times/WEEK for 8 weeks"
89631467|NCT06242067|Experimental|Irinotecan,Trifluridine-tipiracil in combination with Bevacizumab|
89631468|NCT06242054|Experimental|Patients with cervical spine myelopathy|
89631469|NCT06242054|Other|Healthy people|
89631470|NCT06242041|Experimental|Treatment group|Routine treatment, and on the non-dialysis day, sodium zirconate silicate is given four times a week, starting from 5g/ day each time, and the blood potassium before dialysis is maintained at 4.0-5.0mmol/L, which can be adjusted by 10g/ week each time, and the highest dose can be increased to 80g/ week.
89631471|NCT06242041|Placebo Comparator|Control group|Routine treatment.
89631472|NCT06242015|Experimental|Carbohydrate-first meal|
89631473|NCT06242015|Experimental|Carbohydrate-last meal|
89631474|NCT06242002|Experimental|Experimental group|"For patients participating to the clinical trial, the sensor will be positioned at the end of the procedure, under the surgical dressing, at ankle level.~This dressing is a definitive dressing which is only removed during the post-operative consultation on day 8, during which the sensor will be removed.~During this 7 days, data from the sensor will be collected every 4 hours."
89631475|NCT06241989|Experimental|Intervention|The intervention group will receive health education supported by motivational interviewing.
88990667|NCT06181708||Primary care practitioners|A one off questionnaire to be sent to primary care practitioners via qualtrics to determine the current practice in primary care for venous leg ulcer management and availability of services to onward referral.
88990668|NCT06181708||Vascular Scientists|A Delphi Consensus questionnaire will be performed via Qualtrics to determine the current practice for diagnosis and management of suspected venous leg ulcers in vascular scientist departments across the UK
88990669|NCT06181695|Experimental|Sufentanil IN + Morphine IV|Intranasal Sufentanil + IV morphine:
88990670|NCT06181695|Placebo Comparator|Placebo IN + Morphine IV|Placebo of Sufentanil administered intranasally (IN) . One single administration +IV morphine similar to the experimental arm:
88990671|NCT06181682|Active Comparator|dexmedetomidine group|patients will receive intranasal dexmedetomidine (1 microgram/kg) -Intranasal dexmedetomidine will be prepared from the 100 mcg/ml parenteral preparation in a 1-ml syringe, and 0.9% saline will be added to make a final volume of 1 ml- (0.5 ml will be administrated in each nostril) before starting the anesthesia with monitoring of sedation level and oxygen saturation.
88990672|NCT06181682|Active Comparator|midazolam group|patients will receive intranasal midazolam (0.2 mg/kg) up to 5 mg - Intranasal midazolam will be prepared from a 5 mg/ml parenteral preparation, and 0.9% saline will be added to make a final volume of one ml in a 1-ml syringe- (0.5 ml will be administrated in each nostril) before starting the anesthesia with monitoring of sedation level and oxygen saturation.
88990673|NCT06181669||Standard of Care|There are no interventions in this study. Standard of care activities will be captured in the eCRF and samples will be collected and tested. Results will not be returned to the sites or participants.
88990674|NCT06181643|Experimental|Group 1: Survivorship Sleep Program with Individual Delivery + No Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). No booster sessions.
88990675|NCT06181643|Experimental|Group 2: Survivorship Sleep Program with Group Delivery + No Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). No booster sessions.
88990676|NCT06181643|Experimental|Group 3: Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session), followed by 3 monthly booster sessions.
88990677|NCT06181643|Experimental|Group 4: Survivorship Sleep Program with Group Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session), followed by 3 monthly booster sessions.
88990678|NCT06181630|Experimental|Lactating women receiving treatment with Ozanimod and their infants|
88990679|NCT06181617||Participants diagnosed with non-obstructive hypertrophic cardiomyopathy|
88990680|NCT06181617||Participants diagnosed with obstructive hypertrophic cardiomyopathy|
88990681|NCT06181617||Control group|
88990682|NCT06181578|Experimental|GP Ablation Group|Participants in this group will undergo a combined intervention, including standard ablation (pulmonary vein isolation and linear ablation) and additional ablation targeting the autonomic ganglionated plexus (GP).
88990683|NCT06181578|No Intervention|Standard Ablation Group|Participants in this group will undergo standard ablation treatment, which includes pulmonary vein isolation (PVI) and linear ablation.
89631476|NCT06241989|No Intervention|Control|
89631477|NCT06241976|Other|White Caucasian group|Participants from white Caucasian origin
89631478|NCT06241976|Other|South Asian group|Participants from South Asian origin
89631479|NCT06241976|Other|Black African-Caribbean|Participants from Black African-Caribbean origin
89631480|NCT06241937|Experimental|DGSOM Class of 2027|
89631481|NCT06241924|Experimental|Epilepsy|
89631482|NCT06241924|Experimental|parkinson disease|
89631483|NCT06241911|Active Comparator|Transcutaneous auricular vagus nerve stimulation|The tVNS protocol consisted of a 500-µs pulse width and 25-Hz frequency, with a 30-second on/off cycle. The stimulation was applied for a total of 2 hours per day, divided into four 30-minute periods. At least one of these periods occurred within 2 hours before bedtime.The stimulation point was only limited to the left auricular concha.
89631484|NCT06241911|Sham Comparator|sham Transcutaneous auricular vagus nerve stimulation|The same stimulation parameters were used for stVNS, but the stimulation point was the left earlobe.
89631485|NCT06241898|Experimental|dose escalation|BB-1709 will be administered as an intravenous infusion by Q3W or Q2W as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
89631486|NCT06241898|Experimental|dose expansion|BB-1709 will be administered as an intravenous infusion by Q3W or Q2W as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
89631487|NCT06241885|Experimental|Intervention group I|The women in this group will be covered with a gynaecological drape on the gynaecological table by the same researcher before vaginal examination, covering the abdomen and kneecap. This cover will be prepared as disposable, terikoton fabric and 80x200 cm in size.
89631488|NCT06241885|Experimental|Intervention group II|Women in Intervention Group II will wear gynaecological shorts specially developed by the researchers before vaginal examination. These shorts will be made of disposable fabric and will be sewn by the researchers in four different sizes (S-M-L-XL) according to the weight of the women. The middle part of the shorts to be developed will be closed with a snap button, and the opening will be provided when the snap button is opened during vaginal examination. In addition, these shorts will be approximately knee-cap length for women.
89631489|NCT06241885|No Intervention|Control|The women in the control group will not be subjected to any additional hospital procedure during vaginal examination.
89631490|NCT06241755|Experimental|Medium-risk non-muscle invasive bladder cancer (NMIBC)|Induction phase: Once weekly instillation for six consecutive times; Maintenance phase: Once every two weeks (Q2W) for three consecutive times and then once every four weeks (Q4W) for a total of 19 times.
89631491|NCT06241755|Experimental|High-risk non-muscle invasive bladder cancer (NMIBC)|Induction phase: Once weekly instillation for six consecutive times; Maintenance phase: Once every two weeks (Q2W) for three consecutive times and then once every four weeks (Q4W) for a total of 19 times.
89631492|NCT06241716|Active Comparator|Ultrasound-assisted localization, US-AS|
89631493|NCT06241716|Experimental|Real-time ultrasound guidance, US-RTG|
89631494|NCT06241703|Experimental|ICCAUT Group|Patients undergoing laparoscopic/robotic rectal cancer TME surgery will undergo bladder training. The bladder training include intermittent catheter clamping and active urination to facilitate complete bladder emptying each time the catheter is released, which we called ICCAUT strategy. The training will commence at 9:00 am on the first postoperative day, and the catheter will be removed at 9:00 am on the second postoperative day after the bladder is empty.
89631495|NCT06241703|Other|Free Drainage Group|Patients undergoing laparoscopic/robotic rectal cancer TME surgery will have their urinary catheter kept open postoperatively, and the catheter will be removed at 9:00 am on the second postoperative day.
89631496|NCT06241690|Experimental|the cold applications in post-suture pain reduces the child's pain|The population of the study consists of children aged 12-17 who were treated in the pediatric emergency departments of the designated hospitals between December 2021 and July 2022 and met the working criteria. The sample consists of 300 children who applied to the pediatric emergency service between December 2021 and July 2022 and met the research criteria. Socio-Demographic presentation form and Visual Analog Scale were used as data collection tools. Statistical analysis of the data was made in SPSS 22 package program.
89631497|NCT06241651|Experimental|CSP group|In this group, CSP lead is attempted to be placed, including LBBP and HBP.
89631498|NCT06241651|Active Comparator|BiVP group|In this group, traditional RA lead , RV lead and LV lead are attempted to be placed.
89631499|NCT06241638|Active Comparator|Dapagliflozin group|Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months
89631500|NCT06241638|Experimental|Vitamin B12 and Dapagliflozin group|Vitamin B12 and Dapagliflozin group received orally Vit. B12 supplements methylcobalamin 500 µg once daily with their usual anti-diabetic therapy Dapagliflozin 10 mg/daily for twelve months.
89631501|NCT06241625|Experimental|VR-Visual Function Test|Assessment of virtual reality based vision function in Patients with AMD
89040271|NCT03417336|Active Comparator|External radiotherapy|Exclusive external radiotherapy. 25Gy in 5 fractions + a 40Gy prostate boost in stereotaxic conditions.
89631502|NCT06241612|Active Comparator|Standard group|Upper-neck irradiation at the uninvolved neck
89631503|NCT06241612|Experimental|Experimental group|The low-risk clinical target volume would be reduced to two vertebral levels below the vertebral level of the metastatic level II-V nodes.
89631504|NCT06241599|Experimental|AK104|AK104: 6mg/kg intravenous infusion for more than 60 minutes
89040272|NCT03386539|Experimental|Everolimus/Low-Dose Tacrolimus|"Everolimus approximately 0.6 mg/m2/dose taken by mouth every 12 hours for 30 months. Everolimus dose will be adjusted to achieve a trough concentration of 3-8 ng/ml.~Tacrolimus 0.0125 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 3-5 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 2.5-4.5 ng/mL.)"
89631505|NCT06241599|Placebo Comparator|Placebo|placebo: 6mg/kg intravenous infusion for more than 60 minutes
89631506|NCT06241586||the early period group|Patients admitted before January 2021 received the hybrid strategy of traditional and novel surgical strategies.
89631507|NCT06241586||the late period group|Patients admitted during and after January 2021 received the complete novel PMMI surgical strategy.
89631508|NCT06241547|Experimental|stimulation group|accept general drug prevention, wear the equipment, and receive electrical stimulation.
89631509|NCT06241547|Placebo Comparator|control group|accept general drug prevention and wear the equipment but receive no electrical stimulation
89631510|NCT06241521||Myasthenia gravis patients|
89040273|NCT03386539|Active Comparator|Tacrolimus/Mycophenolate Mofetil|"Tacrolimus 0.05 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 7-10 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 5-8 ng/mL.)~Mycophenolate mofetil 600 mg/m2/dose by mouth every 12 hours for 30 months."
89040274|NCT03366103|Experimental|Treatment (navitoclax, vistusertib)|Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89040275|NCT03314337|No Intervention|Distal Pancreatectomy without pancreatic stent|
89040276|NCT03314337|Experimental|Distal Pancreatectomy with pancreatic stent|pancreatic stent will be placed in the main pancreatic duct during the operation
89631511|NCT06241508|Experimental|Low-intensity priming intermittent theta burst stimulation|"Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability.~In the present study, real stimulation will be delivered in an intensity of 55% (low-intensity) or 70% (conventional intensity) individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% (ineffective) individual resting motor threshold.~Low-intensity priming intermittent theta burst stimulation will use a session of 55% RMT cTBS followed by a session of 70% RMT iTBS. Both sessions will be applied to the ipsilesional primary motor cortex."
89631512|NCT06241508|Experimental|Conventional intensity priming intermittent theta burst stimulation|"Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability.~In the present study, real stimulation will be delivered in an intensity of 55% (low-intensity) or 70% (conventional intensity) individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% (ineffective) individual resting motor threshold.~Conventional intensity priming intermittent theta burst stimulation will use a session of 70% RMT cTBS followed by a session of 70% RMT iTBS. Both sessions will be applied to the ipsilesional primary motor cortex."
89631513|NCT06241508|Active Comparator|Standard, nonpriming intermittent theta burst stimulation|"Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability.~In the present study, real stimulation will be delivered in an intensity of 55% (low-intensity) or 70% (conventional intensity) individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% (ineffective) individual resting motor threshold.~Nonpriming priming intermittent theta burst stimulation will use a session of 20% RMT cTBS followed by a session of 70% RMT iTBS. Both sessions will be applied to the ipsilesional primary motor cortex."
89631514|NCT06241495|Experimental|Aromatherapy|
89631515|NCT06241495|Placebo Comparator|Control Group|
89631516|NCT06241469|Experimental|Experimental Arm|Sintilimab combined with nab-paclitaxel and tegio
89631517|NCT06241443|Experimental|hybrid simulation|These students participated in a natural birth approach scenario with a hybrid simulation (n=28).
89631518|NCT06241443|Active Comparator|video-modeling group|The students in this group participated in a video modeling education (n=28).
89631519|NCT06241430|Experimental|CardioMems|Participants randomized to this arm will receive hemodynamic-guided GDMT titration with CardioMems.
89631520|NCT06241430|No Intervention|Usual Care|Participants randomized to this arm will receive usual care involving GDMT.
89631521|NCT06241417||renal recovery|Renal recovery was defined as not satisfied by AKI criteria which was defined by KDIGO.
89631522|NCT06241417||non renal recovery|Non renal recovery was defined by presenting at least KDIGO Stage 1 criteria or death.
89631523|NCT06241404|Experimental|therapeutic exercise group|patients who have been treated for shoulder tendinopathy by exercise therapy
89631524|NCT06241404|Active Comparator|trigger points group|patients who have been treated for shoulder tendinopathy by trigger point therapy
89631525|NCT06241378||patient with stress urinary incontinence|"A hundred twenty-three female with SUI at least once/ week~Patients were recruited from Kasr Al Aieny women's health outpatient clinic, Giza, Egypt.~Females with an age range 18-65years.~Being able to read and write~Being able to use Internet and phone services.~All of patients with no history of other neurological manifestation.~Primiparous and multiparous women."
89631526|NCT06241365||surgery group|Patients were divided into surgery group and conservative group based on whether they underwent surgery.
89631527|NCT06241365||conservative group|Patients were divided into surgery group and conservative group based on whether they underwent surgery.
89040277|NCT03307109||Patients having prosthetic joint infection|The primary aim is to measure the evolution of quality of life in patients having prosthetic joint infection during their medical care and possibly psychologic assistance in the Infectious and Tropical Diseases Department of Croix-Rousse Hospital.
89040278|NCT03304821|Experimental|GM-CSF|Participants receiving 500µg of granulocyte-macrophage colony stimulating factor (GM-CSF), administered subcutaneously. Prior to randomization to a study arm, eligible participants will be trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.
89040279|NCT03304821|Placebo Comparator|Placebo|Participants receiving 500µg of a placebo, administered subcutaneously. Prior to randomization to a study arm, eligible participants will be trained to perform subcutaneous injections and instructed to walk at least three times a day until they develop claudication or symptomatic limitation for 4 weeks.
89040280|NCT03267121|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
89040281|NCT03253679|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89631528|NCT06241300|Experimental|Chicago Parent Program|Half of the dyads will be randomized to participant in the Chicago Parent Program (CPP), an evidence-based parenting preventive intervention for urban poor parents with children between the ages of 2-8 with behavior problems. The Chicago Parent Program consists of 12 groups sessions (11 weekly, 1 booster session). The groups are co-facilitated by two certified group leaders. Parents learn positive parenting and effective child behavior management skills, strategies to support the child's attention, literacy, and social skills, and stress management and problem solving techniques. Skill building is accomplished through watching videos of real-life parents and children during parent-child interactions, group discussion, role-playing, and weekly homework assignments.
89631529|NCT06241300|No Intervention|Control Condition|Half of the dyads will be randomized to the no intervention arm.
89631530|NCT06241287|Experimental|Intervention group|The intervention group will receive the Better Living with Non-memory led Dementia programme, an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups.
89631531|NCT06241287|Other|Control group|The waiting list control group will receive signposting to the publicly available Rare Dementia Support website (https://www.raredementiasupport.org/) and any kind of support the participants may already being receiving (e.g. psychological support, online information, support groups, etc). This a wait list study where the control group will be given access to the intervention ́s educational modules and material after the individuals' last point of data collection.
89631532|NCT06241274|Experimental|Moxibustion|Subjects received symptomatic supportive treatment combined with moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
89631533|NCT06241248||Ocean Test|The OCEAN Dx tests for the diagnosis of sepsis will be performed on 9 milliliters of blood collected at the patient's bedside.The sample will be collected at the same time as the blood cultures are taken. The blood tubes will then be transported to OCEAN Dx laboratories.
89631534|NCT06241235|Experimental|Part 1: Dose Escalation|Part 1 is a dose escalation study of ZG005 combined with paclitaxel and platinum-based ± bevacizumab to evaluate the tolerability and safety of the combination regimen
89631535|NCT06241235|Experimental|Part 2: Dose Expansion|Part 2 is a dose expansion study to further evaluate the initial efficacy and safety of the combination regimen
89631536|NCT06241222|No Intervention|control group|pregnancies in control group need no intervention.
89631537|NCT06241222|Experimental|probiotics group|pregnancies in probiotics group need probiotics management
89631538|NCT06241209|No Intervention|Group 1 (online news)|"Group 1 with an odd number year of birth will be asked to view 15 minutes of online news three days per week for 2 months. LIVE: Canadian News | Weather & Traffic - Latest Sports | Breaking News (globalnews.ca)"
89631539|NCT06241209|Active Comparator|Group 2 (PowerPoint program)|Group 2 with an even number year of birth will be asked to view the 15-minute PowerPoint program three days per week for 2 months.
89631540|NCT06241196|Active Comparator|Group I|Ten sites will be treated by immediate implant and VST with Alloderm + allogenic bone membrane and xenograft.
89631541|NCT06241196|Experimental|Group II|Ten sites will be treated by immediate implant and VST with connective tissue graft + allogenic bone membrane and xenograft.
89631542|NCT06241183|Active Comparator|Intravenous Famotidine|Patients in this group will receive 20 mg of intravenous famotidine.
89631543|NCT06241183|Active Comparator|Oral Maalox|Patients in the group will receive 30 ml of oral Maalox/ Mylanta.
89631544|NCT06241170|Experimental|mesentery-guided resection margin group|The research team positions the proximal margin of the anastomosis in a way that the mesentery reaches the point of being palpable and where the fat appears entirely normal under direct visual observation, in contrast to the mesentery near the proximal and distal ends of the anastomosis.
89631545|NCT06241170|No Intervention|traditional resection margin group|The proximal margin is defined as being 2 cm from the point where visible mucosal lesions are present. Macroscopic lesions are defined as visible pathologies such as intestinal narrowing, thickening of the intestinal wall, or mucosal ulcers. In both groups, the distal margin is located at the hepatic flexure of the ascending colon, where both the mesentery and the intestinal wall are macroscopically normal.
89040282|NCT03208010|Experimental|Diabetes Prevention Intervention|The intervention is 12 weeks of education on diet and physical activity, followed by 15 biweekly support groups for problem solving. Then, 3 booster sessions are scheduled, each one at 6-month intervals. Further, motivational interviewing is infused into all group sessions.
89040283|NCT03208010|Active Comparator|Enhanced Usual Care|"The comparator is an enhanced usual care control group that receives health care from personal physicians plus has access to: a) data collection sessions; b) individualized exit interviews with program staff after each data collection session to receive immediate feedback on lab results and trends in personal health indicators (e.g., BMI, A1C) and to ask questions; c) referral to a local physician or clinic, if needed; and d) Spanish-language materials on diabetes prevention."
89040284|NCT03187340|Active Comparator|Sleep education and relaxation 1|Behavioral education intervention about sleep and relaxation
89211507|NCT00838994|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
89211508|NCT05360979|Experimental|Neoadjuvant and adjuvant therapy|After signing the informed consent, eligible subjects who meet the inclusion criteria will receive neoadjuvant therapy comprising envafolimab combined with platinum-containing chemotherapy and recombinant human endostatin, as well as postoperative envafolimab single-agent adjuvant therapy.
89211509|NCT02547194||No touch vein grafts|The grafts were harvested with there surrounding tissues.
89211510|NCT02547194||Conventional vein grafts.|The grafts were stripped from surrounding tissue.
89211511|NCT00991731|Active Comparator|Faith-based|Faith-based interventions incorporate tenets of the faith-based organization (e.g., religious beliefs, scriptural references) and involve the faith-based organization in the planning of the intervention from beginning to end
89211512|NCT00991731|Active Comparator|Non-faith-based|A curriculum designed for delivery without biblical references. In the traditional teachings of how to increase physical activity.
89211513|NCT00991731|No Intervention|Control|"This group will receive a printed pamphlet Energize Yourself! Stay Physically Active, published by the National Heart Lung and Blood Institute, that encourages participation in at least 30 minutes of daily physical activity all at once or in bouts lasting 10 minutes at a time."
89211514|NCT00833534|Experimental|Group I (consolidation phase)|Patients receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
89211515|NCT00833534|Experimental|Group II (consolidation phase)|Patients receive lenalidomide as in group I. Patients also receive rituximab IV once on the day before the start of lenalidomide and then once between days 25-30, 50-55, and 75-80 for a total of 4 doses in the absence of disease progression or unacceptable toxicity.
89211516|NCT00833612|No Intervention|Control arm of study|
89211517|NCT05283369|Experimental|Videogame therapy|Participants will receive conventional physical therapy, plus 300 minutes of videogame in-home therapy a week, for 8 weeks.
89211518|NCT05283369|Active Comparator|Conventional therapy|Participants will receive conventional physical therapy, plus conventional occupational therapy, as prescribed by the doctor for 8 weeks.
89211519|NCT00625820|Experimental|6R BH4|Subjects will receive 6R-BH4 400mg bid for 6 weeks, sequentially followed by 6R-BH4 plus Vitamin C 500mg bid for another 6 weeks. Patients will have scheduled visits at Weeks 0,3,6,9 and 12, with an exit-visit at week 16. Albuminuria will be assessed in 24-hour urine collections as well as early morning spot urine samples for albumin:creatinine ratio. Blood and urine will be tested for routine clinical laboratory tests, blood nitric oxide (NO), and also archived for later assays for special biomarkers. The primary outcome will be level of albuminuria as measured in a 24-hour urine collection at 6 and 12 weeks of therapy. Secondary outcomes will include urine albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), and blood pressure .
89211520|NCT00145327|Experimental|Zoledronic Acid 6|Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
89631546|NCT06241157|Experimental|Pediatric Quiz Game|"Behavior Guidance Technique (BGT) group (Pedo-Quiz group) Whereas, with the novel BGT so called The Pediatric-Quiz Game (PQ), dentists start interacting with children in the waiting room before entering the operating room. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child. Each child will be asked to fill out the Facial Shape Scale and the Venham Picture Test before the procedure. After the session, the Frankl Behavior Scale and the Patient Evaluation Form will be filled out by the dentist. Their families (parents/guardians) will be asked to fill out the Child Fear Assessment Scale-Dental Subscale (CFSS-DSc) before the session. 35 children will be included in the study.Main goal in this sesion is to evaluate in which dental practice step can be progressed in an anxious child by using this new behavior managament technique."
89631547|NCT06241157|No Intervention|Control|"This group is the control group. Tell-show-do technique, which is a frequently used behavioral management techniques will be used.~In this group, each child will be asked to fill out the Facial Shape Scale and the Venham Picture Test before the procedure. After the session, the Frankl Behavior Scale and the Patient Evaluation Form will be filled out by the dentist. Their families (parents/guardians) will be asked to fill out the Child Fear Assessment Scale-Dental Subscale (CFSS-DSc) before the session. 35 children will be included in the study. Main goal in this sesion is to evaluate in which dental practice step can be progressed in an anxious child by using classical behavior managament technique."
89631548|NCT06241144|Experimental|Intervention|
89631549|NCT06241144|No Intervention|Control|
89631550|NCT06241131|Experimental|desflurane with remifentanil anesthesia|Subjects were randomly assigned to the experimental group。In this group, desflurane was inhaled at a starting concentration of 1 MAC (Minimal Alveolar Concentration), and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
89631551|NCT06241131|Active Comparator|sevoflurane with remifentanil anesthesia|Subjects were randomly assigned to the active comparator group。In this group, sevoflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
89631552|NCT06241105|Experimental|Lenvatinib+Toripalimab|"Administer 8 mg of Lenvatinib orally, once a day, for continuous usage;~Administer 240mg of Toripalimab via intravenous infusion, first time seven days post-lenvatinib intake, and subsequently every three weeks thereafter."
89631553|NCT06241092||TCGA|
89631554|NCT06241092||SYSMH|
89631555|NCT06241079||ypT0N0|
89631556|NCT06241079||ypT0N+|
89631557|NCT06241079||ypT+N0|
89631558|NCT06241079||ypT+N+|
89040285|NCT03187340|Experimental|Sleep education and relaxation 2|Behavioral education intervention about sleep and relaxation
89040286|NCT03181477|Other|radiotherapy + chimiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
89040287|NCT03155906|Experimental|Integrated treatment|Patients randomised to receive integrated treatment will be counselled on treatment by physician working at MAR outpatient clinic where patient receive OST care, and will receive medication and follow-up at the same MAR outpatient clinic. Treatment medication will be given in line with national guidelines with a close and integrated follow-up.
89040288|NCT03155906|Active Comparator|Standard treatment|Those randomised to receive standard treatment will be offered referral for standard HCV treatment at a medical ward hospital clinic. Treatment medication will be given in line with national guidelines.
89040289|NCT03099148|Experimental|LY3337641 (R-fasted)|A single, PO dose of reference formulation (R) given orally with water after an overnight fast in one of four periods.
89040290|NCT03099148|Experimental|LY3337641 (T1-fasted)|A single, PO dose of LY3337641(20mg) test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.
89040291|NCT03099148|Experimental|LY3337641 (T1-fed)|A single, PO dose of LY3337641 (20mg) test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.
89040292|NCT03099148|Experimental|LY3337641 (T2-fasted)|A single, PO dose of LY3337641 (20 mg) test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.
89040293|NCT03099109|Experimental|LY3321367 Dose Escalation|LY3321367 given intravenously (IV).
89040294|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Escalation|LY3321367 and LY3300054 given IV.
89040295|NCT03099109|Experimental|LY3321367 Dose Expansion|LY3321367 given IV.
89040296|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Expansion|LY3321367 and LY3300054 given IV.
89040297|NCT03099109|Experimental|Japanese Arm D LY3321367|LY3321367 given IV.
89040298|NCT03099109|Experimental|Japanese Arm E LY3300054|LY3300054 given IV.
89040299|NCT03099109|Experimental|Japanese Arm F LY3321367 + LY3300054|LY3321367 and LY3300054 given IV.
89211521|NCT00145327|Placebo Comparator|Zoledronic Acid 3 Placebo 3|Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
88990684|NCT06181565||Patients who will have isolated aortocoronary bypass grafting surgery|"Patients who will have isolated aortocoronary bypass grafting surgery will be included.~The Medistim machine will be use before and after pericardial closure. Datas will be collected and analysis."
88990685|NCT06181552||Participants with CVD|"Meeting any of the following:~Established coronary heart disease, including previously diagnosed myocardial infarction, previous treatment with coronary intervention or coronary artery bypass grafting, coronary artery stenosis ≥50%, or chest pain with objective evidence of myocardial ischemia (indicated by stress electrocardiogram or stress imaging)~Stroke"
88990686|NCT06181552||Participants with high CVD risk|"Participants without CVD, but meeting at least two of the following:~Men aged ≥ 60 years old, or women aged ≥ 65 years old;~Diabetes;~Total cholesterol>5.2 mmol/L, or LDL-C>3.4 mmol/L, or HDL-C<1.0 mmol/L;~Currently smoking, defined as daily smoking lasting for 1 year or more."
89211522|NCT00145327|Experimental|Placebo 3 Zoledronic Acid 3|Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.
89631559|NCT06241066||Surgery alone group|Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection without any prior treatment are included in this group. These patients had not been diagnosed with any other cancer. Finally, 96 patients were included.
88990687|NCT06181526|Experimental|Intrathecal administration combined with intravenous administration of Aleeto(0.5μg/kg) or placebo|"Four patients will be randomly assigned to the treatment group and the placebo group. 3 patients will receive intrathecal administration combined with intravenous administration of 0.5 μg/kg Aleeto and sodium chloride, while another patient will receive the same dose of placebo.~Day 1-12: Intrathecal administration of Aleeto will be conducted on Days 1, 4, 8, and 11, and intravenous administration of Aleeto on Days 2, 3, 5, 6, 9, 10, 12, and 13.~Day 31-36: Intrathecal administration of Aleeto will be conducted on Days 31 and 34, and intravenous administration of Aleeto on Days 32, 33, 35, and 36.~D61-66: Intrathecal administration of Aleeto will be conducted on Days 61 and 64, and intravenous administration of Aleeto on Days 62, 63, 65, and 66."
89631560|NCT06241066||Neoadjuvant chemotherapy group|Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 89 patients were included.
89631561|NCT06241066||Neoadjuvant chemotherapy combined with immunotherapy group|Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy combined with immunotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 81 patients were included.
89631562|NCT06241066||Neoadjuvant chemotherapy combined with radiotherapy group|Patients who were diagnosed with esophageal squamous cell carcinoma and underwent esophageal squamous cell carcinoma resection, and underwent routine chemotherapy combined with radiotherapy before surgery were included in this group. These patients were not diagnosed with any other cancers Finally, 93 patients were included.
89631563|NCT06241053|Experimental|Multimodal therapy with McConnell taping|"Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~MacConnell taping will be applied during exercise and then nearly for 18 hours according to patient's comfort."
89631564|NCT06241053|Experimental|Multimodal therapy without McConnell taping|Multimodal therapy includes core exercises, hip exercises and vastus medialis training.
89631565|NCT06241040|Experimental|Aerobic Exercise Group with Core Muscle strengthening Group|Participants assigned to this group will undergo a combination of aerobic exercise and core muscle strengthening interventions. The aerobic exercise component will be similar to the first group, while additional exercises targeting the core muscles (abdomen, back, and pelvis) will be included.
89631566|NCT06241040|Active Comparator|Aerobic Exercise without Core Muscle Strengthening Group|Participants assigned to this group will engage in aerobic exercise interventions
89631567|NCT06241027|Experimental|Nerve flossing technique|Nerve flossing technique will be repeated 3 times a week for 15 minutes per session include 2 sets of 10 repetitions for 4 weeks
89631568|NCT06241027|Experimental|Myofascial release|Myofascial release technique will be given to the patients 3 times a week for 10 minutes with a total 4 weeks of treatment plan.
89631569|NCT06241001|Experimental|Eccentric streching|Group A will receive eccentric stretching for ankle sprain
89631570|NCT06241001|Active Comparator|IASTM|Group B will only receive IASTM.
89631571|NCT06240988|Experimental|Modified Constraint Induced Movement Therapy|Group that will be provided with Modified Constraint Induced Movement Therapy. A protocol of 10 minutes of MCIMT therapy will be given including constraints.
89631572|NCT06240988|Experimental|Motor Imagery Technique|Group that will be provided with Motor Imagery Technique by grasping an object and placing it into a container, or in imagining to perform the same action.
89631573|NCT06240975|Other|Theragun Technique|Theragun is a handheld percussive therapy device that can be used for massage and muscle relaxation. Use the Theragun for a designated duration per session, such as 5-10 minutes for 6 weeks
89631574|NCT06240975|Other|Dry Needling Technique|Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues, and muscle without the use of an anesthetic. Hold each stretch for an adequate duration (typically 15-30 seconds) to allow for muscle relaxation
89631575|NCT06240962|Other|Strength Training|They will receive the strength training only will follow a protocol (6 weeks, 3 sessions/week) that feature training modifications to help control injury-related symptoms.
89631576|NCT06240962|Other|Mindfulness Exercise|They will receive the mindfulness-exercise group will receive an 6-week mindfulness intervention in addition to the strength training protocol.
89631577|NCT06240949|Experimental|Positional release technique|Positional release technique will be applied on iliopsoas muscle.
89631578|NCT06240949|Experimental|Manual pressure technique|Manual pressure technique will be applied on iliopsoas muscle.
89631579|NCT06240936|Active Comparator|Active cycle of breathing technique|ACBTs will be applied on the patients. It consist of the following three phases, breathing control,tboracic expension and forced expiration technique.
89211523|NCT05408793|Experimental|Transcranial Pulse Stimulation (TPS group)|Subjects in the TPS group will be given 6 verum TPS sessions (Pulse: 800 / session) across two weeks time, with 3 sessions per week.
89631580|NCT06240936|Experimental|Active Cycle of breathing with Acapela|ACBTs will be applied on the patients. It consist of the following three phases, breathing control,tboracic expension and forced expiration technique. The Acapella device is a handheld device used to help loosen mucus in the lungs. Sit up straight and hold the device in the upright position. Take a deep breath in and seal lips around the mouthpiece. Exhaleforcefully through the mouthpiece, using your stomach muscles to push the air out. Repeat this process several times, taking breaks. After using Acapella cough to clear any mucus that has been loosened. Clean the device after each use.
89631581|NCT06240923|Experimental|Group 1: Single coil spring|A single open coil spring was inserted between the maxillary second premolar and the maxillary first molar with a distalizing force 300 gm.
89631582|NCT06240923|Experimental|Group 2: Double coil spring|Two open coil springs were inserted. The first coil spring was inserted between the maxillary second premolar and the maxillary first molar with a distalization force 300gm, and the second coil spring was inserted between the maxillary first and maxillary second molar with a distalization force 200 gm.
89631583|NCT06240910|Experimental|Neurodynamics|Neuro dynamics involving Stretching and gliding of the Sciatic nerve (performing each exercise for 30 s at a slow and comfortable pace of 1 repetition per ~3-4 s. The participants rested for 60 s between each exercise. The total duration of the interventions was approximately 10 min.).The whole treatment session on a single day will be of 40-60 minutes of duration (involving both aerobic exercise + neurodynamics) 3. times a week for 6 weeks according to the American diabetes association, accumulating a minimum of 150 minutes/week.
89631584|NCT06240910|Experimental|Aerobic training|Aerobic exercise will involve warm-up by stretching and flexibility exercises for 5 minutes, Treadmill walking for 6 minutes, and Stationary bicycle for 6 minutes
89631585|NCT06240897|Experimental|Digital games|Each CURATE.DTx session will be 12 minutes long. The game will be played by each participant via a study-provided tablet. During first session prior to commencing data collection, a trained trial team member will explain in detail how to play the game-based multitasking intervention. The session will require 12 minutes of gameplay for a minimum of three days and up to five days for a total duration of hospitalisation. Participants will also be encouraged to play an optional digital game that is designed to help with their emotional and cognitive health.
89631586|NCT06240884|Experimental|Infraspinatus-teres minor interfascial block|Patients will receive Infraspinatus-teres Minor Interfascial Block with 20 ml of 0.375% ropivacaine prior to induction of general anesthesia.
89631587|NCT06240884|Active Comparator|interscalene block|The patient underwent an ultrasound-guided brachial plexus nerve block in the interosseous sulcus using 20 ml of 0.375% ropivacaine.
89631588|NCT06240871||Pulmonary artery pressure measurements|The investigators will compare noninvasive right sided pressure measurements with invasive right heart catheterization performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
89631589|NCT06240845|Experimental|High Level Laser Therapy|This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
89631590|NCT06240845|Experimental|Low Level Laser Therapy|This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
89040300|NCT03095352|Experimental|Arm A: Pembrolizumab + Carboplatin|Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients then receive pembrolizumab alone on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
89040301|NCT03095352|Experimental|Arm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only|Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Carboplatin may be continued or added back into the treatment regimen at the investigator's discretion. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89040302|NCT03088813|Experimental|Part 1: Experimental Arm, dose level 1|Irinotecan liposome injection
89631591|NCT06240832|Experimental|Aerobic and strength training in children with CLD|AEROBIC AND STRENGTHENING EXERCISE USING TREADMILL AND WEIGHT TO IMPROVE FUNCTIONAL OUTCOMES IN CHILDREN WITH CHRONIC LIVER DISEASE
89631592|NCT06240819|Other|Sleeper Stretch|Sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR for three sets with three repetitions.
89631593|NCT06240819|Other|Cross Body Stretch|cross-body stretch will be done in sitting position. Three sets of the each stretch position would be held for 30 seconds with a 1 minute break between sets.
89631594|NCT06240806|Active Comparator|Manuka honey interventional arm|Manuka honey used as mouth rinse in treatment of xerostomia
89631595|NCT06240806|Placebo Comparator|Saline mouthwash control group|Saline used as mouth rinse for xerostomia
89040303|NCT03088813|Experimental|Part 1: Experimental Arm, dose level 2|Irinotecan liposome injection
89040304|NCT03088813|Experimental|Part 2: Experimental Arm|Irinotecan liposome injection
89040305|NCT03088813|Active Comparator|Part 2: Control Arm|Topotecan
89040306|NCT03061474|Experimental|Nicotinamide|1500mg twice daily: 2, 750mg tablets taken orally twice daily
89040307|NCT03061474|Placebo Comparator|Placebo|1500mg twice daily: 2, 750mg tablets taken orally twice daily
89040308|NCT03040726|Experimental|Group I (netupitant, palonosetron hydrochloride)|Patients receive netupitant orally (PO) and palonosetron hydrochloride PO on days 1, 6, and 11 in the absence of disease progression or unacceptable toxicity.
89040309|NCT03040726|Placebo Comparator|Group II (placebo)|Patients receive placebo PO on days 1, 6, and 11.
89040310|NCT02936453|Experimental|All patients|"Patients will participate during 8-12 months, during which there will be :~Pre-implant evaluations (6-8 weeks)~Device implantation and stimulation optimization (6-8 weeks)~Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system.~An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system."
89040311|NCT02899728|Experimental|Arm I (chemotherapy, cediranib maleate, olaparib)|"Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.~NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion."
89040312|NCT02899728|Experimental|Arm II (chemotherapy, cediranib maleate, olaparib)|"Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28."
89040313|NCT02899065|Experimental|Intervention|The intervention arm will receive pharmacist-led education and stewardship intervention and a procalcitonin test to aid in the decision of how to treat the patient. This intervention will include direct delivery of education from the pharmacist to the treating clinician about interpreting the Roche Cobas Liat Flu/RSV and procalcitonin test results, recommendations for antiviral-treatment for high-risk patients and information about infection control precautions for patients being hospitalized with a positive RSV or influenza test.
89040314|NCT02899065|No Intervention|Standard of care|The second arm will be usual care (i.e. Roche Cobas Liat Flu/RSV test only). Results will be delivered via standard of care.
89040315|NCT02894177|Experimental|tcPCO2 measurement arm|Patients will be monitored by tcPCO2 during spontaneous breathing trials
89040316|NCT02893930|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89040317|NCT02840890|Experimental|experimental|Patients will have a visceral osteopathic technique perform with continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
89040318|NCT02840890|Placebo Comparator|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
89040319|NCT02796781|Experimental|lung stem cells|Patients will receive 0.5-5x10^6 (0.5-5 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
89040320|NCT02785562|Other|Assessment of PDL1 expression|Other : assess clinical and pathological characteristics of PDL1 expression in Non Small Cell Lung Cancer patients.
89631596|NCT06240793|Other|Unilateral transforaminal epidural block|The necessary oblique and cranio-caudal angles will be provided in fluoroscopy for the patients' designated procedure area. Skin and subcutaneous tissue anesthesia will be applied to the injection site with 3 ml of 2% prilocaine. The neural foramen will be entered using a blunt-tipped sympathetic block needle and a guiding needle. After needle localization is confirmed with antero-posterior and lateral fluoroscopic images, 1-2 ml of contrast material will be injected following negative aspiration. After confirming the contrast material spread in the anterior epidural area and periradicular area, 8 mg dexamethasone will be injected. If the application will be performed bilaterally, the specified techniques will be applied in half the same way on the contralateral side. Patients will be observed for one hour after the procedure for possible complications.
89631597|NCT06240793|Active Comparator|bilateral transforaminal epidural block|The necessary oblique and cranio-caudal angles will be provided in fluoroscopy for the patients' designated procedure area. Skin and subcutaneous tissue anesthesia will be applied to the injection site with 3 ml of 2% prilocaine. The neural foramen will be entered using a blunt-tipped sympathetic block needle and a guiding needle. After needle localization is confirmed with antero-posterior and lateral fluoroscopic images, 1-2 ml of contrast material will be injected following negative aspiration. After confirming the contrast material spread in the anterior epidural area and periradicular area, 8 mg dexamethasone will be injected. If the application will be performed bilaterally, the specified techniques will be applied in half the same way on the contralateral side. Patients will be observed for one hour after the procedure for possible complications.
89631598|NCT06240780|Active Comparator|ACL Arthroscopic Active Participants|After the surgery, the patient will be placed in the study provided semiconductor element interwoven Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
89631599|NCT06240780|Placebo Comparator|ACL Arthroscopic Placebo Participants|After the surgery, the patient will be placed in the study provided plain fabric Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
89631600|NCT06240780|No Intervention|ACL Arthroscopic Stand of Care Participants|After the surgery, the patient will be placed in thigh high compression hose, bilaterally, worn 23 hours per day for 31 days.
89631601|NCT06240780|Active Comparator|ACL + MCL Arthroscopic Active Participants|After the surgery, the patient will be placed in the study provided semiconductor element interwoven Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
89631602|NCT06240780|Placebo Comparator|ACL + MCL Arthroscopic Placebo Participants|After the surgery, the patient will be placed in the study provided plain fabric Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock, on the operative leg, and a thigh high compression hose on the non operative leg, worn 23 hours per day. At day 31 patient will wear the leg sleeve at night and be placed in the Incrediwear Knee Sleeve.
89631603|NCT06240780|No Intervention|ACL + MCL Arthroscopic Stand of Care Participants|After the surgery, the patient will be placed in thigh high compression hose, bilaterally, worn 23 hours per day for 31 days.
89631604|NCT06240767|Experimental|Clinical study of human granulocyte in the treatment of advanced recurrent tumor|"Experimental: Anticancer mouse characteristic human granulocyte treatment of advanced recurrent tumors.~A single infusion of human granulocytes with anti-cancer mouse characteristics was performed for 5 consecutive transfusions at a interval of 2±1 day, and the safety and efficacy were clinically observed."
89631605|NCT06240754|Experimental|Enasidenib|"Participants will receive enasidenib 100 mg daily for 18 cycles (each cycle is 28 days).~Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator."
89631606|NCT06240715|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 20-30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for early cord clamping (ECC).
89631607|NCT06240715|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after birth (within 60 seconds)
89631608|NCT06240689|Experimental|Interventional arm|The experimental group started treatment within 1 month after the end of chemoradiotherapy, and Sintilimab was given intravenously on the first day of each cycle, and a cycle of 21 days, and a total of 18 cycles were expected to be administered, or until disease progression.
89631609|NCT06240689|Placebo Comparator|Control arm|The control group started treatment within 1 month after the end of chemoradiotherapy, and placebo was given intravenously on the first day of each cycle, and a cycle of 21 days, and a total of 18 cycles were expected to be administered, or until disease progression.
89631610|NCT06240676|Experimental|experimental group|After the 3rd month postpartum, mothers who are given classical breastfeeding training by the researcher will then be given a breastfeeding training based on mindfulness therapy methods. After the classical breastfeeding training, a pre-test will be applied and then mindfulness-based training will be started. The effectiveness of the training will also be determined within the group with the post-test to be applied after the training. A sleep diary will be applied to the newborn. After breastfeeding, how many hours of sleep and body temperature will be noted.
89631611|NCT06240676|No Intervention|control group|From mothers whose information was collected during pregnancy, only breast milk will be taken for 1 week without any intervention in the 3rd month after birth.
89631612|NCT06240663|Experimental|Fasted|Half the participants completed this exercise intervention in the fasted state.
89631613|NCT06240663|Experimental|Fed|Half the participants completed this exercise intervention in the fed state.
89631614|NCT06240650|Experimental|modified Health- Dx™ (mHDx) study capsule|
89631615|NCT06240650|Other|modified Health- Dx™ (mHDx) control capsule|
89631616|NCT06240624||Patients with Parkinson's disease and Levodopa-induced dyskinesia|"Inclusion criteria:~Aged 18 or more~Clinically established or probable PD according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease~Peak-of-dose levodopa-induced dyskinesia~Stable antiparkinsonian medicine for 4 weeks~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of other neurologic or psychiatric disease~Pacemaker or other implanted metallic or electronic devices which contraindicate MRI or TMS of the brain~Claustrophobia"
89631617|NCT06240624||Patients with Parkinson's disease without Levodopa-induced dyskinesia|"Inclusion criteria:~Aged 18 or more~Clinically established or probable PD according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease~No levodopa-induced dyskinesia~Stable antiparkinsonian medicine for 4 weeks~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of other neurologic or psychiatric disease~Pacemaker or other implanted metallic or electronic devices which contraindicate MRI or TMS of the brain~Claustrophobia"
89040321|NCT02783664||Questionnaires to Evaluate Patient Stress Levels|
89040322|NCT02780804|Experimental|Treatment (entinostat)|Patients receive entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
89040323|NCT02710968|Experimental|11540KE and Balt Goldbal 2 balloon|"Patients meeting inclusion criteria will receive fetoscopic tracheal occlusion using the fetoscopy sheath 11540 KE and the Balt Goldbal2 detachable balloon.~Participants with an O/E LHR <25% (severe group) will have FETO completed at 27 weeks + 0 days to 29 weeks + 6 days gestation. Balloon removal is 4-5 weeks after that.~Participants with an O/E LHR 25 to <30% (less severe group) will have FETO completed at 30 weeks + 0 days to 31 weeks + 6 days gestation. Balloon removal is 3 - 4 weeks after that."
89040324|NCT02688959|Experimental|Tai Chi|Participants in this arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize experiential learning with 2 weeks of introductory sessions on gait, posture, and tai chi principles followed by instruction in the 24-form Yang style sequence. Students will be given a video to aid learning outside of class, and maintenance of practice post-intervention.
89631618|NCT06240624||Healthy controls|"Inclusion criteria:~Aged 18 or more~Age- and sex-matched the PD groups~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of other neurologic or psychiatric disease~Pacemaker or other implanted metallic or electronic devices which contraindicate MRI or TMS of the brain~Claustrophobia"
89631619|NCT06240611||Group A (Control)|A healthy matched volunteers' group (n = 23) between 18 and 23 years of age was included in this study. For students of both genders, the body mass index was not less than 18.5 and not more than 29.5, and there was no recent or previous musculoskeletal injury or pain.
89631620|NCT06240611||Group B (Experimental)|Participants with CNSNP (n = 22) were between 18 and 23 years of age. Patients with CNSNP For students of both genders, the duration of the non-specific neck pain was more than 3 months (for the symptomatic group with no neurological manifestations and with referral from orthopedic surgeons by diagnosis of non-specific neck pain), and for matched students, they did not have any history of neck pain. The student's age ranges from 18 to 23 years. Neck pain intensity on the numerical Pain Rating Scale was between 3 and 8, and neck pain-related disability on the Neck Disability Index was between 5 and 14 points (10-28%) for mild disability and 15-24 points (30-48%) for moderate disability. The body mass index for students was not less than 18.5 and not more than 29.5.
89631621|NCT06240585||patients with ICU-acquired bacteremia|
89631622|NCT06240585||patients without ICU-acquired bacteremia|
89631623|NCT06240572||Adults who attended the emergency department|
89631624|NCT06240520|No Intervention|control|
89040325|NCT02688959|Active Comparator|Exercise|Participants in the exercise arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize cardio-aerobic fitness training. Students will be given a video to aid practice outside of class, and maintenance of practice post-intervention.
89040326|NCT02688959|No Intervention|Control|Participants in the control arm will not attend a class and not be given a video.
89040327|NCT02629393|Experimental|ORGN001 (formerly ALXN1101)|
89040328|NCT02604459|Active Comparator|Usual general anesthesia care|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
89040329|NCT02604459|Experimental|Optimized general anesthesia care|The subjects will have general anesthesia with propofol, fentanyl, sevoflurane. In addition the subjects will be monitored with a depth of anesthesia monitor (BIS) and a cerebral oximeter (Foresight). These additional monitors will be used to direct care. BP management: Systolic BP will be maintained within 20% of baseline systolic BP variables.
89040330|NCT02604459|Active Comparator|Mini Mental State Exam|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
89040331|NCT02604459|Other|Tested and Excluded|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
89631625|NCT06240520|Experimental|panobinostat|
89631626|NCT06240520|Experimental|lenalidomide|
89631627|NCT06240520|Experimental|pyrimethamine|
89631628|NCT06240520|Experimental|panobinostat + lenalidomide|
89631629|NCT06240520|Experimental|panobinostat + pyrimethamine|
89631630|NCT06240520|Experimental|lenalidomide + pyrimethamine|
89631631|NCT06240507|Active Comparator|pulsed radiofrequency group|posterior tibial nerve pulsed radiofrequency for painful calcaneal spur and plantar fasciitis
89631632|NCT06240507|Active Comparator|radiofrequency thermocoagulation group|intralesional radiofrequency thermocoagulation for painful calcaneal spur and plantar fasciitis
89631633|NCT06240481|Active Comparator|Group I|Meridol ToothPaste Brush 2 x day / 2 mins Meridol Mouthwash (AmCl+Zn +NaF) Swish 15 mL / 30 secs after brushing
89631634|NCT06240481|Placebo Comparator|Group II|regular fluoride ToothPaste, Brush 2 x day 2 mins
89631635|NCT06240468||AIS patient|"AIS inclusion criteria~(1) Inclusion criteria~Meet the diagnostic criteria for AIS or TIA;~Age 18-80 years old;~within 7 days of the onset of stroke;~Sign informed consent, provide relevant medical history and biological specimens;~Have lived in the local city for the last three years.~(2) Exclusion criteria~Patients with recurrent stroke within the past year when first enrolled;~mRS > 2 points before stroke onset;~malignant tumor;~Liver and kidney dysfunction (alanine aminotransferase or aspartate aminotransferase >2 times the upper limit of normal, creatinine > 1.5 times the upper limit of normal);~History of drug abuse and chemical poisoning (e.g. pesticide poisoning);~In the acute stage of stroke (within 7 days from the onset of stroke) stool specimens could not be collected."
89040332|NCT02548351|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the remainder of the study
89040333|NCT02548351|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the remainder of the study
89040334|NCT02548351|Placebo Comparator|Placebo|One tablet daily for the remainder of the study
89040335|NCT02543268|Experimental|Group 1|Ad26.ZEBOV -Batch #1, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
89631636|NCT06240468||Cognitive/emotional subcohort|"(I) Inclusion criteria:~It has been included in the AIS queue, meeting the inclusion criteria of the main AIS queue;~NIHSS≤15; (II) Exclusion criteria:~(1) Patients with aphasia and unable to cooperate in completing the cognitive/emotional assessment during the study; (2) previous severe mental disorder and dementia (AD8 scale score ≥2); (3) A history of severe anxiety and depression; (4) Previous history of seizures."
89040336|NCT02543268|Experimental|Group 2|Ad26.ZEBOV -Batch #2, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
89040337|NCT02543268|Experimental|Group 3|Ad26.ZEBOV -Batch #3, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
89040338|NCT02543268|Experimental|Group 4|Placebo (0.9% saline)- single dose IM injection on Day 1 and Day 57
89631637|NCT06240468||healthy person|health
89631638|NCT06240442|Experimental|Fasted Exercise|Exercise followed by breakfast
89631639|NCT06240442|Experimental|Fed Exercise|Breakfast followed by exercise
89631640|NCT06240429|Experimental|Collagen Supplementation|Participants will receive a daily dose of 10 g each of collagen peptides
89631641|NCT06240429|No Intervention|Placebo|Participants will receive a daily dose of 10 g each of placebo
89631642|NCT06240416|Experimental|Control group|High speed drilling (800 rpm) with irrigation
89040339|NCT02500797|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.
89040340|NCT02500797|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.
89040341|NCT02309190||transpulmonary pressures|Esophageal balloon to measure transpulmonary pressures. PEEP adjustment as per transpulmonary pressures.
89040342|NCT02225119||Affected|Participants with macular disease
89040343|NCT02225119||Unaffected|Healthy volunteers
89040344|NCT02136147||Children with ADHD medication|Identified responders and non-responders in children/adolescents starting medication for treatment of ADHD in public child and adolescent psychiatric services in Stockholm, on Gotland, and in Västerbotten.
89040345|NCT02136147||Lisdexamphetamine medication|Identified responders and non-responders in children/adolescents starting medication with lisdexamphetamine in public child and adolescent psychiatric services in Stockholm and on Gotland.
89040346|NCT02136147||Atomoxetine medication|Identified responders and non-responders in children/adolescents starting medication with atomoxetine in public child and adolescent psychiatric services in Stockholm and on Gotland.
89040347|NCT02136147||Methylphenidate medication|Identified responders and non-responders in children/adolescents starting medication with methylphenidate in public child and adolescent psychiatric services in Stockholm and on Gotland.
89040348|NCT02136147||Guanfacine medication|Identified responders and non-responders in children/adolescents starting medication with guanfacine in public child and adolescent psychiatric services in Stockholm and on Gotland.
89040349|NCT02090101|Experimental|ANAKINRA|LV5FU2 + bevacizumab + anakinra
89040350|NCT02047461|Experimental|ORGN001 (formerly ALXN1101)|daily IV infusions
89040351|NCT02017704|Active Comparator|IMRT and Capecitabine|"Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
89631643|NCT06240416|Experimental|Test group|Low speed drilling (50 rpm) without irrigation
89631644|NCT06240403|Placebo Comparator|Placebo|Two capsules of placebo taken orally per day for three months
89040352|NCT02017704|Experimental|Endo-HDR|"Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
89040353|NCT02014415||Liver Biopsy|Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
89040354|NCT02014415||Known Severe Liver Disease|Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
89040355|NCT02014415||Post Liver Transplant|Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
89040356|NCT02005471|Active Comparator|Bendamustine + Rituximab|Participants will receive bendamustine 70 milligrams per meter square (mg/m^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
89040357|NCT02005471|Experimental|Venetoclax + Rituximab|Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
89040358|NCT02005471|Experimental|Bendamustine + Rituximab Crossover Substudy|Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.
89211524|NCT05408793|Sham Comparator|Sham TPS Group|Subjects in the Sham TPS group will be given 6 sham TPS sessions across two weeks time, with 3 sessions per week.
89211525|NCT00833768|Active Comparator|Sevelamer carbonate|
89211526|NCT00833768|Placebo Comparator|Placebo|
89631645|NCT06240403|Experimental|Digoxin|Two capsules containing 62.5mcg digoxin taken orally per day for three months
89631646|NCT06240390|Experimental|Epte Bipolar System 2.0 - Ultrasound-guided percutaneous neuromodulation (NMP)|Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. Ultrasound-guided percutaneous neuromodulation (NMP)
89631647|NCT06240390|Experimental|pharmacological treatment by Opioids|"Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.~Tramadol (Ultram®) Hydromorphone (Dilaudid®) Methadone (Dolophine®, Methadose®) Morphine (Apokyn®, Avinza®, Kadian®, MS-Contin®, among others) Oxycodone (OxyContin®, OxyIR®, Roxicodone®) Hydrocodone Oxymorphone (Opana®) Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others) Tapentadol (Nucynta®)"
89631648|NCT06240377|Active Comparator|Epte Bipolar System 2.0 - Ultrasound-guided percutaneous neuromodulation (NMP)|EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. Ultrasound-guided percutaneous neuromodulation (NMP)
89631649|NCT06240377|Active Comparator|Epte Bipolar System 2.0 - Transcranial direct current stimulation (tDCS)|EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. Transcranial direct current stimulation (tDCS)
89631650|NCT06240364|Experimental|Saffron extract (Crocus sativus)|Daily intake of one tablet for 84 days.
89631651|NCT06240364|Placebo Comparator|Placebo|Daily intake of one tablet for 84 days. This tablet is organoleptically indistinguishable from the experimental tablet.
89631652|NCT06240325|Experimental|Sleep Promotion Program|Participants will receive the Sleep Promotion Program (SPP), consisting of 2 individual sessions with a clinician via telehealth (or in-person if desired), about 2 weeks apart, and web-based intervention components.
89040359|NCT02005471|Experimental|Venetoclax + Rituximab Re-Treatment|Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.
89040360|NCT01977651|Experimental|Enzalutamide 160 mg|Participants received 160 mg of enzalutamide orally once a day, for 4 months. At the end of the 4-month treatment period, participants who were assessed as deriving benefit from enzalutamide treatment continued in the extension period. The total study drug treatment duration for the extended period depended on individual clinical benefit. If a participant experienced a Grade 3 or higher toxicity that was attributed to enzalutamide and could not be ameliorated by the use of adequate medical intervention, treatment with enzalutamide was allowed to be interrupted for 1 week or until the toxicity grade improved to Grade 2 or lower severity. Subsequently, enzalutamide was restarted at the original dose 160 mg per day or a reduced dose 120 or 80 mg per day in consultation with the medical monitor.
89040361|NCT01949311|Experimental|Dupilumab|Participants will receive repeat doses of dupilumab
89040362|NCT01933932|Experimental|Selumetinib + Docetaxel|Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
89040363|NCT01933932|Experimental|Placebo + Docetaxel|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
89040364|NCT01711658|Placebo Comparator|IMRT + cisplatin + placebo|Intensity Modulated Radiation Therapy (IMRT) with cisplatin and placebo
89040365|NCT01711658|Active Comparator|IMRT + cisplatin + lapatinib|IMRT with cisplatin and lapatinib
89040366|NCT01698008|Experimental|Mobile application Diabetes Doctor|The intervention group will send in blood glucoses once a month using the mobile phone app, Diabetes Doctor. All subjects will be evaluated at initial, 3 month, and 6 month visits. They will receive HbA1c on each visit. After 3 months, a Diabetes Quality of Life (QOL) survey will be completed. A Usability and Satisfaction of Diabetes Doctor (USDD) survey will also be obtained. At the 3 month visit, they will also be given the chance to discontinue the mobile app and switch to standard of care. At 6 months, all mobile app users will complete the USDD and satisfaction and QOL survey. If they are not using the mobile app, then they will complete the QOL survey.
89040367|NCT01698008|No Intervention|Standard of Care|The standard of care arm will not use the mobile application Diabetes Doctor to communicate with their physician about their blood sugars. They will attend clinic visits and have evaluations initially, and at 3 and 6 months. They will also receive a HbAIc at each visit. They will do the same QOL survey at 3 months. At 6 months, they will be given the QOL survey.
89040368|NCT01656447||Patients with Scleroderma|Patients who have been diagnosed at any point in their life with Scleroderma will compose the cohort.
89040369|NCT01622868|Experimental|Arm A (WBRT or SRS)|Patients undergo WBRT 5 days a week for 3 weeks for a total of 15 treatments, or SRS for 1 treatment.
89631653|NCT06240325|Active Comparator|Sleep Psychoeducation|Participants will receive Sleep Psychoeducation (SPE), a 20-minute discussion with a clinician via telehealth (or in person).
89631654|NCT06240286|Experimental|Healthy Subjects|Healthy subjects will attend the the Active Wellness Office at the Dan Abraham Healthy Living Center (DAHLC) at Mayo Clinic in Rochester, Minnesota, for four consecutive days. On day one, individuals will use a sitting workstation (control); based on randomization, three active workstations (standing, stepping, or walking stations) will be randomly assigned on the following days (2-4).
89631655|NCT06240273|Experimental|Metabolic Syndrome patients|Cornsilk (Stigma maydis) is used for preventing symptoms of metabolic syndrome patients Dietary Intervention: Cornsilk Extract Dosage: 2g/day
89040370|NCT01622868|Experimental|Arm B (lapatinib ditosylate, WBRT or SRS)|Patients undergo WBRT or SRS as in Arm A. Patients also receive lapatinib ditosylate PO QD for 6 weeks.
89040371|NCT01518556|Experimental|Idarubicin|Idarubicin dose intensification for remission induction in acute myeloid leukemia
89631656|NCT06240260|Experimental|TENS unit|Patients who choose to use a TENS unit for their IUD insertion procedure
89631657|NCT06240260|Active Comparator|Standard care|Patients who decline to use a TENS unit for their IUD insertion procedure
89631658|NCT06240247||Gingival healthy|People who do not have clinical attachment loss in their gums, pocket or bone loss, and whose bleeding percentage in their gums is 10% or less
89631659|NCT06240247||Gingivitis|People who do not have clinical attachment loss in their gums, pocket or bone loss, and whose bleeding percentage in their gums is 10% or more
89631660|NCT06239987|Experimental|Care-oriented group|Care-oriented practical training intervention is a 2-hour care-oriented applied group training program for intensive care nurses in groups of 13-15 people.
89631661|NCT06239792|Experimental|Sleep Promotion Program|Participants will receive the Sleep Promotion Program (SPP), consisting of 2 individual sessions with a clinician via telehealth (or in-person if desired), about 2 weeks apart, and web-based intervention components.
89631662|NCT06239571|Experimental|Dyadic Resiliency Intervention|All participants will receive the intervention, a brief dyadic resiliency intervention
89631663|NCT06238011|Active Comparator|Dexmedetomidine|Patient in this arm will receive dexmedetomidine loading 60ml/hour before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass
89631664|NCT06238011|Placebo Comparator|Normal Saline|Patient in this arm will receive normal saline loading 60ml/hour before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary artery bypass
89631665|NCT06237972|Experimental|FES group|This group will conduct the experimental protocol using neuromuscular electrical stimulation during the training.
89631666|NCT06237972|Active Comparator|No-FES group|This group will conduct the experimental protocol without using neuromuscular electrical stimulation during the training.
89631667|NCT06237881|Experimental|Arm 1: Phase 1- Safety Lead-in (Cohort 1)|Approximately 6 patients with melanoma, NSCLC or HNSCC will be enrolled in the Safety Lead-in phase of the study with a KSQ-001EX dose.
89631668|NCT06237881|Experimental|Arm 2: Phase 1- Safety Lead-in (Cohort 2)|Patients in Cohort 2 will receive IL-2 dosing (600,000 international units [IU]/kg administered every 8 to 12 hours for up to 6 doses, as tolerated).
89631669|NCT06237881|Experimental|Arm 3: Phase 2- Expansion Phase|It is expected that approximately 20 participants will be enrolled in each of the 3 indication specific cohorts.
89631670|NCT06237842||Healthy participants|Participants from 3 to 18 years old, from both genders and with no sleep disorders
89040372|NCT01516190|Active Comparator|Exercise Group|Supervised exercise sessions and independent exercise
89040373|NCT01516190|Active Comparator|Mind-Body Group|Surgical preparation program
89040374|NCT01513408|Experimental|CD8/Foxp3|patient suffering from non-metastatic breast cancer
89040375|NCT01421095|Experimental|Basal Testing|
89040376|NCT01315782||Multi-organ failure|Alveolar dead space on mechanically ventilated patients with severe sepsis or septic shock.
89040377|NCT00566345|Experimental|Influenza vaccine|Vero-cell derived influenza vaccine
89040378|NCT00566345|Placebo Comparator|Placebo|Phosphate buffered saline (packaged in syringes identical to those used for the investigational vaccine)
89040379|NCT00463814|Experimental|AZD6244|
89631671|NCT06237842||Participants with sleep disorders|Participantes with one sleep disorder or complaint.
89631672|NCT06237803||Subjects with MGUS, SMM, MM, PCL|"Subjects with Monoclonal Gammopathy of Undetermined Significance (MGUS), smouldering Multiple Myeloma (SMM), Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)~Timepoints and samples to be collected are the following:~bone marrow aspirate, bone marrow biopsy, EMD biopsy, peripheral blood and serum at baseline;~bone marrow aspirate, bone marrow biopsy, peripheral blood and serum pre-maintenance in TE patients or after 1 year of therapy in Non-Transplant-Eligible (NTE) patients;~bone marrow aspirate, bone marrow biopsy, peripheral blood and serum during maintenance therapy and only if performed as SOC;~bone marrow aspirate, bone marrow biopsy, EMD biopsy peripheral blood and serum at 1st and later PD."
89040380|NCT00317720|Experimental|Trastuzumab + RAD001|Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. Starting RAD001 dose 10 mg by mouth daily.
89040381|NCT00540033|Experimental|2|Study arm was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks; the control arm was fed with breast milk or mixed feeding without probiotics.
89040382|NCT04661345||Septic group|The septic group is composed of patients with prosthetic joint infection mediated by coagulase-negative Staphylococci (CoNS)
89040383|NCT04661345||Aseptic group|The aseptic group is composed of patients with implant failure unrelated to infection.
89211527|NCT01009606|Active Comparator|Arm 1 : Control : usual strategy|
89040384|NCT03759405|Experimental|Chronic heart failure treatment group|One case of CHF caused by coronary heart disease, one case of CHF caused by dilated heart disease and one case of CHF caused by Keshan disease were selected and treated with autologous iPS differentiated cardiomyocyte intravenous transplantation.
89040385|NCT04661111|Experimental|Hymovis ONE Arm|Hymovis® ONE (32 mg/4 ml) intra-articular mono injection. Patients will be followed during 12 months including 6 visits.
89040386|NCT04660916||isotretinoin|The patients aged 18-45 that were planned to begin treatment with isotretinoin for acne
89040387|NCT04660916||control|Healthy volunteers aged 18-45 without any diseases/drugs affecting the nail
89040388|NCT00540111|Other|1|"Study of intervention, prospective,uncontrolled Group Number: 1~Group Type:Other - the subjects of group were compared the initial moment (M0 - moment without soluble fiber supplementation)with the others two moments: M1 (one month after soluble fiber supplementation) and M2 (four months after soluble fiber supplementation).~Group Description - HIV-positive individuals with hypertriglyceridemia (serum levels ≥ 200 to ≤ 500 mg/dL),who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study.~Intervention:Received 20g/day of soluble fiber® (partially hydrolyzed guar gum) for 4 months at pre-established times."
89040389|NCT00540150|Active Comparator|1|Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
89040390|NCT00540150|Active Comparator|2|Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
89040391|NCT05102253|Experimental|TEAS+DCEAS group|Subjects assigned to TEAS+DCEAS group will receive TEAS+DCEAS in addition to routine care.
89040392|NCT05102253|Other|Wait-list control: Routine care group|Subjects assigned to this group will continue their current routine care as usual.
89040393|NCT04660604|Experimental|Graston Technique® Group|Participants were asked to warm up at a speed that they felt comfortable for 5 minutes at a gentle tempo with an ergometer. Time was followed by a stopwatch. Participants who completed warm-up were taken to GT® application. Application was implemented by a GT® certified therapist with 13 years of experience in orthopedic rehabilitation. Intervention dosage was determined as 2 times a week, 12 sessions over 6 weeks. GMed muscle was scanned between crista iliaca and trochanter major, and a fascial release was applied. Each session lasted 5 minutes. At the end of sessions, iliotibial band stretching exercises (30 seconds, 3 repetitions) was given to the treated side. Application protocol has been determined with reference to GT® manual
89040394|NCT04660604|No Intervention|Control Group|Control group is followed up for 6 weeks without intervention.
89040395|NCT04660253|Experimental|LTP Plus Dads|Participants in this group will receive 10 sessions of LTP plus dads
89040396|NCT04660292|Experimental|Study Group|The study group was treated with Maitland mobilization and manipulation techniques including postero-anterior Maitland mobilization for C1-C2, Maitland lateral PA glide for C3-C6 and Maitland thrust manipulation for cervico-thoracic junction. Frequency of mobilization was 2 days a week for 4 weeks. While intensity of mobilization was grade 3 and 4 based on the Maitland concept.13 Time of oscillations was 2 or 3 oscillations in a second for 1 to 2 minutes.
89211528|NCT01009606|Experimental|Arm 2: Comparator : modified strategy|
89211529|NCT05590611|Placebo Comparator|Brown Bread|
89631673|NCT06237322||Healthy|"Blood Pressure, Heart Rate and Respiration Rate Measurements:~Observations will be made using a medically approved blood pressure monitor, Heart Rate Monitor, Respiration Rate Monitor.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~Measurement:~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
89631674|NCT06237322||Cardio vascular diseases|"Blood Pressure, Heart Rate and Respiration Rate Measurements:~Observations will be made using a medically approved blood pressure monitor, Heart Rate Monitor, Respiration Rate Monitor.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~Measurement:~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
89631675|NCT06237322||Pre-Diabetes|"Blood Glucose Measurement:~Participants will use a medically approved glucometer to measure their blood glucose levels.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~PPG Data Collection with Mobile App:~Before each blood glucose measurement, participants will use the RE.DOCTOR Vitals mobile app to collect raw PPG signals.~Then without closing the app, they use medical device and enter blood glucose data from the glucometer into the app after each measurement.~Data collection will be initiated by participants clicking the collect data button on the mobile app.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
89631676|NCT06237322||Diabetes I|"Blood Glucose Measurement:~Participants will use a medically approved glucometer to measure their blood glucose levels.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~PPG Data Collection with Mobile App:~Before each blood glucose measurement, participants will use the RE.DOCTOR Vitals mobile app to collect raw PPG signals.~Then without closing the app, they use medical device and enter blood glucose data from the glucometer into the app after each measurement.~Data collection will be initiated by participants clicking the collect data button on the mobile app.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
89631677|NCT06237322||Diabetes II|"Blood Glucose Measurement:~Participants will use a medically approved glucometer to measure their blood glucose levels.~Measurements will be taken at three specific times:~In the morning after 6-8 hours of sleep. 2 hours after the first meal of the day. Before bedtime.~PPG Data Collection with Mobile App:~Before each blood glucose measurement, participants will use the RE.DOCTOR Vitals mobile app to collect raw PPG signals.~Then without closing the app, they use medical device and enter blood glucose data from the glucometer into the app after each measurement.~Data collection will be initiated by participants clicking the collect data button on the mobile app.~Observations:~Participants will be guided on the correct use of the glucometer and instructed to note down readings accurately."
89631678|NCT06237244||coronary artery disease|patients with coronary angiography of at least one vessel with more than 50% stenosis
89631679|NCT06237244||no coronary artery disease|patient with no stenosis in coronary angiography
89631680|NCT06236841|Experimental|XH-S004|Participants will receive XH-S004 as per assigned treatment regimen on scheduled days. Starting dose in single asceding dose: 5 mg.
89631681|NCT06236841|Placebo Comparator|XH-S004 placebo tablet|Participants will receive matching placebo as per assigned treatment regimen on scheduled days.
89631682|NCT06236685|Experimental|General anesthesia|Patients undergoing general anesthesia with mechanical ventilation will be monitored by electrical impedance tomography in addition to standard monitoring. Moreover, esophageal pressure catheter will be used in cases where indicated by clinician or in case of an indication of nasogastric tube, as esophageal pressure can be measured by a combined catheter.
89631683|NCT06236685|Experimental|Intensive Care Unit|Patients ventilated in the ICU for various reasons will receive standard care, including advanced monitoring of mechanical ventilation.
89211530|NCT05590611|Active Comparator|Wholemeal Sourdough Bread|
89211531|NCT01009684||DNG/EV|Users of the oral contraceptive containing Dienogest and Estradiol valerate
89211532|NCT01009684||Other OCs|Users of oral contraceptives (OCs) containing other progestins and estrogens
89211533|NCT00839150||1|Diabetic patients without diabetic retinopathy : No intervention
89040397|NCT04660292|Active Comparator|Control Group|While placebo treatment with conventional physiotherapy (active exercises-10 repetitions in all direction in pain free range, isometrics 5-10 seconds brief but maximum contraction each held for 5-16 seconds for flexors, extensors, side flexors and rotators)14 without gliding, oscillations and thrust were recommended for the control group.The placebo group was treated with baseline treatment including TENS 10 minutes and moist hot packs in sitting position for 15 minutes on cervical region in with head resting on table with a pillow.
89040398|NCT00540189|Other|Initial appendectomy|children with complicated appendicitis will undergo initial appendectomy
89040399|NCT00540189|Other|Interval appendectomy|children with complicated appendicitis will undergo initial antibiotic treatment followed by an interval appendectomy
89040400|NCT04660409|Other|Child Pugh A|
89040401|NCT04660409|Other|Child Pugh B|
89631684|NCT06235788|No Intervention|Control Group Intelligent Continuous Expertise Monitoring System (ICEMS) only verbal feedback group|"43 participants. Individuals receive standard information. They perform 6 5-min practice scenario resections with a 5-min break between each one. The 7th attempt is the 13-min realistic scenario.~Participants receive no feedback during the first repetition. They will then receive feedback on 4 metrics, one metric a time: instrument tip separation, low bipolar force, high aspirator force, high bipolar force. Once an attempt is completed without receiving feedback, the next repetition will assess the next metric in the list above. During the 5-min break after an attempt is completed without receiving feedback, participants can watch an optional expert-level demonstration video corresponding to the next metric. Participants receive no feedback during the 6th repetition. They will have no feedback in their 7th repetition, the realistic scenario."
89631685|NCT06235788|Experimental|Experimental Group ICEMS verbal feedback with pause group|"43 participants. Individuals receive standard information. They perform 6 5-min practice scenario resections with a 5-min break between each one. The 7th attempt is the 13-min realistic scenario.~Participants receive no feedback during the first repetition. They will then receive feedback on 4 metrics, one metric a time: instrument tip separation, low bipolar force, high aspirator force, high bipolar force. Once an attempt is completed without receiving feedback, the next repetition will assess the next metric in the list above. During the 5-min break after an attempt is completed without receiving feedback, participants can watch an optional expert-level demonstration video corresponding to the next metric. Participants receive no feedback during the 6th repetition. They will have no feedback in their 7th repetition, the realistic scenario."
89631686|NCT06235788|Experimental|Experimental Group ICEMS verbal feedback with pause and expert-level video demonstration|"43 participants. Individuals receive standard information. They perform 6 5-min practice scenario resections with a 5-min break between each one. The 7th attempt is the 13-min realistic scenario.~Participants receive no feedback during the first repetition. They will then receive feedback on 4 metrics, one metric a time: instrument tip separation, low bipolar force, high aspirator force, high bipolar force. Once an attempt is completed without receiving feedback, the next repetition will assess the next metric in the list above. During the 5-min break after an attempt is completed without receiving feedback, participants can watch an optional expert-level demonstration video corresponding to the next metric. Participants receive no feedback during the 6th repetition. They will have no feedback in their 7th repetition, the realistic scenario."
89631687|NCT06234787||ICU Patients|Patients admitted to the Intensive Care Unit (ICU) at HLA Moncloa Hospital
89631688|NCT06232603|Active Comparator|Education at baseline|video and ambulatory visit summary (AVS) education will be provided at baseline visit
89631689|NCT06232603|Other|Education at the first follow up|video and AVS education will be provided at the first follow up visit
89631690|NCT06232200|No Intervention|CONTROL GROUP|REGULAR TREATMENT
89631691|NCT06232200|Experimental|ACUPUNCTUR GROUP|"Acupuncture application will be performed by bilateral needling of The Sanyinjiao (SP6), Yin Ling Quan (SP9), Zu San Li, Leg Three Mile (ST36) , Tai Chong (LIV3), Hegu (LI4), Taixi (KID3) , Zhongliao (BL33) and Guan Yuan (CV4) acupuncture points using sterile, disposable metal acupuncture needles. The needles will remain in place for approximately 20 minutes during the treatment, a total of 8 sessions are planned, 2 per week."
89040402|NCT04660409|Other|Child Pugh C|
89040403|NCT04660409|Other|HCC|
89040404|NCT04660409|Other|Healthy|
89040405|NCT01208233|Experimental|1 mg PF-03049423|
89040406|NCT01208233|Experimental|3 mg of PF-03049423|
89040407|NCT01208233|Experimental|6 mg of PF-03049423|
89040408|NCT01208233|Placebo Comparator|Placebo|
89040409|NCT04660565|Experimental|Glucocorticoid monotherapy Group|Patients treated with single glucocorticoid
89040410|NCT04660565|Experimental|Combination therapy Group|Patients treated with Belimumab and glucocorticoid
89040411|NCT04660136|Experimental|CEUS|
89040412|NCT01208038|Experimental|Testosterone|Testosterone transdermal patch 300micrograms, twice weekly for 12 weeks
89040413|NCT00540267||Schizophrenia|Chronic schizophrenia with aged 18-80 years
89040414|NCT04659980|Active Comparator|hilotherapy|
89040415|NCT04659980|Active Comparator|frozen gloves|
89040416|NCT04659785|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
89040417|NCT03609021||Observational (bilateral screening mammogram)|Participants provide bilateral screening mammogram taken prior to all cancer treatment and within 8 weeks prior to registration to A011502 and an annual bilateral mammogram as near as possible to 1 year post-registration to A011502 and as near as possible to 2 years post-registration to A011502. Participants also undergo collection of blood sample and menstrual cycle data within 2 weeks after registration and at 1 and 2 years after registration to A011502.
89040418|NCT04659395|Other|Emergency nurses|Emergency nurses who are trained in an one-day course
89040419|NCT01207687|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
89040420|NCT04659434|Experimental|treatment group|Sintilimab 200mg ivdrip Q3W; Rituximab 375mg/m2 ivdrip; Gemcitabine 1000mg ivdrip; Oxaliplatin 100mg/m2 ivdrip
89211534|NCT00839150||2|Sex and age-matched control subjects : No intervention
89211535|NCT05358405|Other|Müller maneuver|Open Label with intervention Müller maneuver
89211536|NCT00825110||No treatment|confirmed diagnosis of colorectal carcinoma
89211537|NCT00510484|Experimental|A|
89211538|NCT00510484|Placebo Comparator|B|
89211539|NCT00839228|Experimental|Perhexiline|perhexiline 100mg o bd for 3 months
89211540|NCT00839228|Placebo Comparator|Placebo|Placebo one tablet bd for 3 months
89211541|NCT00839384|Experimental|Implant Advisa IPG|Advisa IPG implant
89211542|NCT00839462|Experimental|Arm 1|
89211543|NCT00839462|Active Comparator|Arm 2|
89211544|NCT01009996||Coronary bifurcation lesions|
89211545|NCT05590143|Experimental|Intervention|Dapagliflozin 10 mg
89211546|NCT05590143|Placebo Comparator|Placebo|Matching Placebo
89631692|NCT06231355|Experimental|Lipo-bupivacaine|Paravertebral block is performed with liposomal bupivacaine.
89631693|NCT06231355|Active Comparator|Bupivacaine|Paravertebral block is performed with bupivacaine.
89631694|NCT06230354|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
88990688|NCT06181526|Experimental|Intrathecal administration combined with intravenous administration of Aleeto (1μg/kg) or placebo|"Seven patients will be randomly assigned to the treatment group and the placebo group. 6 patients will receive intrathecal administration combined with intravenous administration of 1μg/kg Aleeto and sodium chloride, while another patient will receive the same dose of placebo.~Day1-12: Intrathecal injection of Aleeto would be given on Day 1, 4, 8, and 11, and intravenous injection of Aleeto on Day 2, 3, 5, 6, 9, 10, 12, and 13.~Day31-36: Intrathecal injection of Aleeto would be given on Day 31 and 34, and intravenous injection of Aleeto on Day 32, 33, 35, and 36.~D61-66: Intrathecal injection of Aleeto would be given on Day 61 and 64, and intravenous injection of Aleeto on Day 62, 63, 65, and 66."
89211547|NCT00622388|Experimental|Ofatumumab|8 weekly intra-venous (I.V.) infusions, 1 x 300mg and 7 x 1000mg
89631695|NCT06230354|Placebo Comparator|Placebo|Placebo subcutaneous injection
89631696|NCT06227286|Experimental|EECP Arm|Participants would be assigned for treating with EECP initiated with 0.030 MPa, 30-45 minutes per day, 5 days per week, 7 weeks in total.
89631697|NCT06227286|Sham Comparator|Sham-EECP Arm|Participants would be assigned for treating with Sham-EECP initiated with 70 mmHg, 30-45 minutes per day, 5 days per week, 7 weeks in total.
89631698|NCT06226155|Experimental|TENDAI4PrEP|TENDAI4PrEP problem-solving intervention will likely entail 4-5 sessions, inclusive of the dyadic session with a partner, with an optional postpartum booster session. The intervention will involve PrEP education and psychoeducation, Nzira Itsva (a culturally adapted Life Steps intervention), and problem-solving therapy.
89631699|NCT06226155|Active Comparator|Enhanced Treatment as Usual (ETAU)|Participants randomized to ETAU will receive care as usual, which is monthly visits to the ANC, plus a pamphlet of information that describes PrEP efficacy, safety during pregnancy/postpartum, and PrEP availability at the ANC. Antenatal treatment as usual will also be enhanced at the clinic level through the provider-level training, which will be offered to all clinic staff in a nonrandomized design. ETAU participants will also be referred for psychological services at the hospital.
89211548|NCT01156389|Active Comparator|Arm A Ritonavir plus Pyramax|7 days of ritonavir followed by 3 days of ritonavir plus Pyramax followed by 7 days of ritonavir followed by a 33 day follow-up period (40 days since last Pyramax dosing) and a study completion evaluation.
89211549|NCT01156389|Active Comparator|Arm B Pyramax|3 day treatment course of Pyramax, followed by a follow up period of 40 days since last Pyramax dosing and a study completion evaluation.
89211550|NCT04043624|Experimental|Lidocaine group|First group (lidocaine group) will include those who receive a intraoperative lidocaine infusion.Induction bolus dose of 1.5 mg/kg body weight ( 30 minutes before incision)followed by a continous lidocaine infusion of 2mg/kg/h，until 1 hours after skin closure.
89211551|NCT04043624|Placebo Comparator|Saline group|The second group（saline group） will include those who receive a intraoperative placebo.The same dosage of saline was given according to the same method of administration in the lidocaine group.
89211552|NCT01105767|No Intervention|Group 1 Standard|Trainees received a preventive medicine briefing augmented with SSTI and MRSA SSTI prevention information and personal hygiene instructions. Trainees seeking medical care for an SSTI received standardized SSTI care (e.g., antimicrobial therapy, wound management, patient education) at the Troop Medical Clinic. High-touch common surfaces within the battalion areas were cleaned with standard Environmental Protection Agency-registered disinfectants.
89211553|NCT01105767|Active Comparator|Group 2 Enhanced Standard|Trainees received the components of the Standard group as well as supplemental training, education and hygiene. They were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit. Supplemental SSTI education for trainees and drill sergeants was also provided (e.g., pocket cards, posters). Drill sergeants received briefings on SSTI and skin inspection/minor wound care.
89211554|NCT01105767|Active Comparator|Group 3 Chlorhexidine|Trainees received the components of the Standard and Enhanced Standard groups and were offered chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) to use with a wash cloth after using their personal soap for the additional once-weekly shower. Trainees were provided with verbal and written/graphic instructions for use.
89211555|NCT05589987|Experimental|Power mobility|The study will take place in the child's natural environment for 12 weeks.
89211556|NCT05589987|No Intervention|Non-power mobility|Children will perform their typical daily routine without any modification. After the study they will be invited to participate in the experimental group if positive benefits are obtained.
89211557|NCT00834158|Active Comparator|TACE|perform TACE only
89211558|NCT00834158|Experimental|TACE+PVE|perform TACE and PVE sequentially
89211559|NCT05589909||Infection Group|Both suspected and confirmed sepsis occurred ≤72 hours after delivery were counted as cases of EONS.
89211560|NCT05589909||None Infection Group|No evidence clinical or laboratory of infection
89211561|NCT03693430|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
89211562|NCT03693430|Placebo Comparator|Placebo|Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
89631700|NCT06222515||Women with storage lower urinary tract symptom|The women with lower urinary tract symptoms, including urinary urgency (UU), stress urinary incontinence(SUI), urgency urinary incontinence (UUI), nocturia (N) and frequency (F).
89631701|NCT06222398||Exoskeleton Users|This study includes patients who are current exoskeleton users. Exoskeleton users will engage in normal activities of daily living (ADLs) that they currently perform at wheelchair level while using the exoskeleton. Researchers will observe the ADLs the exoskeleton users are and are not able to complete while using their exoskeleton.
89631702|NCT06221800||Treatment with PD1/L1 monotherapy|
89631703|NCT06221800||Treatment with PD1/L1 + chemotherapy|
89631704|NCT06221800||Treatment with Tyrosine Kinase Inhibitor|
89631705|NCT06221488||Health workers|Health workers with baseline negative interferon gamma release assays
89631706|NCT06219018|Active Comparator|Medical grade honey formulation (MGH) (L-Mesitran®) for CIN II group 1|Group 1, pt 0-20: daily application of 5 grams (with applicator) for 1 month. Followed by weekly applications (5 grams withapplicator) for 5 months.
89631707|NCT06219018|Active Comparator|Medical grade honey formulation (MGH) (L-Mesitran®) for CIN II group 2|Group 2, pt 20-40: daily application of 5 grams (with applicator) for 3 months. Then weekly applications (5 grams with applicator) for3 months.
89631708|NCT06219018|Active Comparator|Medical grade honey formulation (MGH) (L-Mesitran®) for CIN II group 3|Group 3, pt 40-60: daily application of 5 grams (with applicator) for 6 months
89631709|NCT06218563|Experimental|vibration-induced illusion of movement|"The protocol consists of 4 or 2 different conditions (repeated 2 times) of vibration-induced illusion of movement in healthy and stroke participants respectively, resulting in 8 or 4 vibration blocks with 3 vibrations per block:~Healthy participants, 2 times each (24 vibrations):~Right arm, eyes opened (no-illusion condition; RO)~Right arm, eyes closed (illusion condition; RC)~Left arm, eyes opened (no-illusion condition; LO)~Left arm, eyes closed (illusion condition; LC)~Stroke participants, 2 times each (12 vibrations):~Deficient side, eyes opened (no-illusion condition; DO)~Deficient side, eyes closed (illusion condition; DC)"
89631710|NCT06218212|Active Comparator|Arm 1 patients with AKI and acute on top of CKD who will be treated by electrolytes binders.|they will start calcium carbonate (phosphorus binder) with dosage 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
89631711|NCT06218212|Experimental|Arm 2 patients with AKI and acute on top of CKD who will be treated by Renastart formula.|"Renastart formula will be used with breast milk, standard infant formula or with diet.~Preparation: Adding one level scoop of Renastart to 30 ml water.~Renastart formula will be started to represent ¼ recommended daily allowance of daily caloric intake and the dose will be adjusted according to serum electrolyte levels."
89631712|NCT06213103||o Patient cohort|Patient with moleculary proven mitochondrial disorder
89631713|NCT06213103||o Control cohort|People without moleculary proven mitochondrial disorder
89631714|NCT06194864|Experimental|Part 1|ecopipam 89.6 mg on Days 1 and 9 with repeat doses of itraconazole Days 6-16.
89631715|NCT06194864|Experimental|Part 2|ecopipam 179.2 mg on Days 1 and 13 with repeat doses of rifampicin days 6-20.
88990689|NCT06181526|Experimental|intrathecal injection and intravenous injection of Aleeto (2μg/kg) or placebo|"Seven patients will be randomly assigned to the treatment group and the placebo group. 6 patients will receive intrathecal administration combined with intravenous administration of 2μg/kg Aleeto and sodium chloride, while another patient will receive the same dose of placebo.~Day1-12: Intrathecal injection of Aleeto would be given on Day 1, 4, 8, and 11, and intravenous injection of Aleeto on Day 2, 3, 5, 6, 9, 10, 12, and 13.~Day31-36: Intrathecal injection of Aleeto would be given on Day 31 and 34, and intravenous injection of Aleeto on Day 32, 33, 35, and 36.~D61-66: Intrathecal injection of Aleeto would be given on Day 61 and 64, and intravenous injection of Aleeto on Day 62, 63, 65, and 66."
88990690|NCT06181526|Experimental|intravenous injection of Aleeto (2μg/kg)|"Six patients will receive intravenous administration of 2 μg/kg Aleeto and sodium chloride.~Day1-12: Patients would be given intravenous injection of Aleeto(2μg/kg) +100ml sodium chloride for 12 days (Day 1 to 6, 8 to 13) once a day.~Day31-36: Patients would be given intravenous injection of Aleeto(2μg/kg) +100ml sodium chloride for 6 days (Day 31 to 36) once a day.~D61-66: Patients would be given intravenous injection of Aleeto(2μg/kg) +100ml sodium chloride for 6 days (Day 61 to 66) once a day."
88990691|NCT06181513|Experimental|Probiotics|Participants received 1 capsule daily of probiotics, administered orally for 16 weeks.
88990692|NCT06181513|Placebo Comparator|Placebo|Participants received 1 capsule daily of placebo, administered orally for 16 weeks.
88990693|NCT06181500|Experimental|Home-based multicomponent exercise intervention program|
88990694|NCT06181461|Experimental|Experimental Group A|Group A received Gong's mobilization, involving 15 mins of electrical stimulation with heat therapy. In a side-lying stance, maintaining 90-degree shoulder abduction, the therapist applied anterior to posterior pressure on the humerus for 10-15 seconds, followed by a 5-second relaxation. Actions included pressing the shoulder joint, extending the articular capsule, and performing shoulder medial rotation. To enhance ROM, oscillation at Maitland's grades 3 and 4 was followed by 7 seconds of prolonged stretching at the grade 4 technique. Routine physical therapy included a 30-45 min session with 15-min TENS. Patients followed daily care instructions, using the affected shoulder in daily activities, and performed pendulum and active shoulder exercises twice a day.
88990695|NCT06181461|Experimental|Experimental Group B|Group B will receive Kaltenborn mobilization in the study. Routine therapy includes 15 mins of electrical stimulation with heat. Kaltenborn mobilization involves KM Grade III posterior translation for sustained stretching. With the patient supine and a wedge under the damaged scapula, the therapist abducts the humerus, flexes the elbow, and rotates the forearm for end-range glenohumeral joint positioning. Posterior translation is applied in 30-sec sets, repeated 15 times over 10 mins, with 10-sec rests. Routine physical therapy includes 30-45 min sessions with 15-min TENS. Patients follow daily care instructions, use the affected shoulder in daily activities, and perform pendulum and active shoulder exercises twice a day.
89631716|NCT06194331|Experimental|iCHART/cASAP|"An intervention previously studied in the ETUDES Center along with a computerized version of our As Safe As Possible intervention.~Safety Planning App for suicidal youth which enables a primary care provider to streamline the gold standard of care for those with current suicidality symptoms through an app;~Mental Health Screener questionnaire that gathers additional mental health symptoms, treatment preferences, and family's readiness for treatment engagement to help a primary care provider make a personalized, tailored treatment plan a suicidal youth is more likely to adhere to;~Text Messages which aims to provide texts for 2-3 weeks to motivate you to engage with the safety plan and recommended treatment following the patient visit.~cASAP is a computerized version of the As Safe As Possible intervention that offers self-led modules with psychoeducation about safety planning, cognitive-behavioral skills to cope with distress, and facilitate collaboration with parents."
89631717|NCT06194331|Active Comparator|Treatment as usual|When patients disclose suicidal ideation on the PHQ-9, a treatment as usual approach will be given to the patient and their parent by the pediatrician which includes a paper safety plan will be completed and given to the patient and a referral placed for the patient to begin behavioral health services.
89631718|NCT06190652||Arm A|Chemotherapy combined with immunotherapy group
89631719|NCT06190652||Arm B|Chemotherapy combined with immunotherapy + radiotherapy group
89631720|NCT06183229|Experimental|Cycloferon|Intake of Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
89631721|NCT06183229|Placebo Comparator|Placebo|Intake of Placebo, 4 tablets per day, on days 1, 2, 4, 6 and 8.
89631722|NCT06179628|Active Comparator|Low Concentration and Volume|0.15% bupivacaine 10 ml boluses for continuous adductor canal block
89631723|NCT06179628|Placebo Comparator|Standard Concentration and Volume|0.25% bupivacaine 20 ml boluses for continuous adductor canal block
89631724|NCT06179511|Experimental|Module 1: Dose Escalation|Ascending dose level cohorts of AZD9829 in AML and MDS participants.
89631725|NCT06177652|Active Comparator|Paravertebral Block|Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
89631726|NCT06177652|Active Comparator|Serratus Plane Block|Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
89631727|NCT06175286|Experimental|POWERBreath|Subjects will train with the POWERBreath twice per day, for 30 continous breaths
89631728|NCT06175286|No Intervention|Control|Subjects will carry on with their normal daily life
89631729|NCT06175273|Active Comparator|Control|Standard of Care who have either weight gain, weight maintenance, or weight loss <10%.
89631730|NCT06175273|Experimental|Oral Nutrition Supplements|Those receiving ONS will be prescribed a standard ONS (1.0 kcal per mL) that will meet a minimum of 50% of estimated energy needs to promote weight gain but allow for continued regular dietary intakes. The ONS will be prescribed as 8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs.
89631731|NCT06175273|Experimental|Enteral Nutrition|Those randomized to EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs to allow for continued regular dietary intakes during the day.
89631732|NCT06175273|Experimental|Appetite Stimulants|Those receiving age-appropriate appetite stimulants will be provided either cyproheptadine or dronabinol. Subjects will be given cyproheptadine if they fall between the ages of 2-12 years of age and dronabinol if they are >12 years of age or older.
89631733|NCT06174701|Experimental|Intervention|"Participants in the intervention arm will receive PST. Meetings via videoconferencing or phone will occur at a frequency of 1 time every week for an estimated 2-3 sessions before surgery and 6-7 sessions after surgery for a total of 9 sessions.~PST: Essential components of the PST that the patient will be taught include: (1) define the nature of the problem, (2) generate wide range of possible solutions, (3) systematically evaluate the potential solutions and select the most optimal ones to implement, (4) monitor and evaluate the actual solution outcome after implementation."
89631734|NCT06174701|No Intervention|Enhanced Usual Care|"Participants in the control arm will receive enhanced usual care. They will receive additional mental health education in the form of educational handouts mailed or emailed to them."
89631735|NCT06163534||Metastatic or unresectable recurrent HNSCC|Up to 500 participants (including primary tumor location of pharynx, larynx, oral cavity and oropharynx) with metastatic or unresectable recurrent HNSCC who are intended for first line immunotherapy or combination therapy. No intervention.
89631736|NCT06160986|Experimental|Horizons Group|Participants will receive the Horizons Group intervention for up to 8 weeks.
89631737|NCT06150937|Experimental|AEGIDA intervention arm|Four session behavioral intervention to promote consistent HIV testing, frequent HIV testing and intention to uptake PEP/PrEP.
88990696|NCT06181448||Hospitalized patients with acute exacerbations of chronic liver disease|"Patient data will be collected through a mobile application, providing real-time prognostic scores for patients.~Standary therapy for chronic liver disease with ALI and/or AD"
88990697|NCT06181422|Active Comparator|Group1: Metformin|Group1: (Metformin, n=30) who will receive metformin 500 mg three times daily.
88990698|NCT06181422|Active Comparator|Group 2 :Lactoferrin|Group 2 :(Lactoferrin, n=30) who will receive lactoferrin 100 mg three times daily
88990699|NCT06181396|Experimental|Immediate oxytocin|This arm will receive oxytocin when entering 2nd stage (full dilation)
88990700|NCT06181396|Other|Delayed oxytocin|This arm will receive oxytocin one hour after entering 2nd stage (full dilation)
88990701|NCT06181344|Experimental|implementation condition|Under implementation condition, a fear of cancer recurrence screening program will be implemented in routine oncological clinics using 5 implementation strategies including training, audit and feedback, facilitation and adaptable workflow.
89040421|NCT01207453|Other|Milnacipran then placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive milnacipran for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to a placebo for 6 weeks.
89040422|NCT01207453|Other|Placebo then milnacipran|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive placebo for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to milnacipran for 6 weeks."
89631738|NCT06150937|Active Comparator|AEGIDA control arm|Four session didactic intervention to promote self-screening for common health problems, including HIV self-testing.
89040423|NCT00540345|Active Comparator|A, RVR LD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV A, RVR LD RBV B, RVR SD RBV
89040424|NCT00540345|Active Comparator|B, RVR SD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV
89040425|NCT00540345|Active Comparator|C, non-RVR 24w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D) (C, non-RVR 24w) (D, non-RVR 48w)
89040426|NCT00540345|Active Comparator|D, non-RVR 48w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D)(C, non-RVR 24w) (D, non-RVR 48w)
89040427|NCT04659356||Patients admitted in Intensive Care Units|All patients admitted in our ICU since august were enrolled in our study, after they have been informed and given their consent for their participation in this observational study.
89040428|NCT01207414|Experimental|iloperidone gradual switch|"Participants taking risperidone, olanzapine or aripiprazole gradually decreased the dose they were taking: 50% of original dose on Day 1, 25% of original dose after the first week and the total discontinuation of the drug after the second week.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
89040429|NCT01207414|Experimental|iloperidone immediate switch|"Participants taking risperidone, olanzapine or aripiprazole discontinued the drug immediately.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
89040430|NCT00540384|Experimental|NESP - Schedule 1 Part A|Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
89040431|NCT00540384|Experimental|NESP - Schedule 2 Part A|NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
89631739|NCT06148792|Experimental|TQRevised|Patients are treated with schizontocidal treatment plus a single weight-based oral dose of TQ (target dose 7.5mg/kg)
89631740|NCT06148792|Active Comparator|TQStandard|Patients are treated with schizontocidal treatment plus single fixed oral dose of 300mg TQ (TQStandard)
89631741|NCT06148792|Experimental|PQ7|Patients are treated with schizontocidal treatment plus oral high dose PQ (total dose 7 mg/kg) over 7 days (PQ7)
89631742|NCT06147505|Experimental|Experimental|Subjects With Primary Glioblastoma
89631743|NCT06145854||Cisgender Females|
89631744|NCT06139692|Experimental|the dexmedetomidine group|In the experimental group, dexmedetomidine is used for intraoperative sedation. Dexmedetomidine is prepared as an 8μg/ml intravenous infusion. It begins with an initial loading dose of 1μg/kg, administered over a period exceeding 10 minutes.If dexmedetomidine fails to achieve a satisfactory level of sedation during surgery, physicians may opt for rescue sedation with propofol or consider transferring the patient to general anesthesia. Propofol (20ml 0.2g) starts with a loading dose of 0.3mg/(kg*h) and a maintenance dose of 0.3-4mg/(kg*h). The infusion rate can be adjusted based on the sedation effect to achieve the appropriate level of sedation during EVT.
89631745|NCT06139692|Active Comparator|the midazolam group|In the control group, midazolam is used for intraoperative sedation. Midazolam is prepared as a 1mg/ml intravenous infusion. It starts with an initial intravenous push of 0.05mg/kg, followed by a maintenance dose of 0.04-0.2mg/kg administered intravenously via an infusion pump. If midazolam fails to achieve a satisfactory level of sedation during surgery, physicians may opt for rescue sedation with propofol or consider transferring the patient to general anesthesia. Propofol (20ml 0.2g) starts with a loading dose of 0.3mg/(kg*h) and a maintenance dose of 0.3-4mg/(kg*h). The infusion rate can be adjusted based on the sedation effect to achieve the appropriate level of sedation during EVT.
89631746|NCT06137560|Active Comparator|Assigned Intervention 1|Single vision spectacle lens
89040432|NCT00540384|Placebo Comparator|Placebo - Schedule 1 Part A|Placebo Q3W for 12 weeks
89040433|NCT00540384|Experimental|NESP - Schedule 1 Part B|Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb < 13.0g/dL and/or RBC transfusion in previous 2 weeks.
89040434|NCT00540384|Placebo Comparator|Placebo - Schedule 2 Part A|Placebo Q4W for 12 weeks
89631747|NCT06137560|Experimental|Assigned Intervention 2|Single vision spectacle lens + S.T.O.P.® Kit 1
89631748|NCT06137560|Experimental|Assigned Intervention 3|Single vision spectacle lens + S.T.O.P.® Kit 2
89631749|NCT06137560|Active Comparator|Assigned Intervention 4|Static optical signal: single vision spectacle lens + S.T.O.P.® spectacle film
89631750|NCT06137560|Experimental|Assigned Intervention 5|Dynamic optical signal: single vision spectacle lens + S.T.O.P.® Kit 1 or 2
89631751|NCT06137118|Experimental|Part A: AZD0486 Dose Escalation|Ascending dose level cohorts of AZD0486 in B-ALL participants aged 16-80 years.
89631752|NCT06137118|Experimental|Part B: Dose Optimization|Up to 2 cohorts will evaluated prior declared safe-doses and schedules in order to determine the recommended phase 2 dose (RP2D). Participants will receive AZD0486 IV infusions and randomized in a 1:1 ratio.
89631753|NCT06137118|Experimental|Part C: Dose Expansion|Part C will consist of 1 cohort of participants aged 12-80 years, treated with the optimal dose selected in Part B and receive IV AZD0486 monotherapy.
89631754|NCT06126328|Active Comparator|Materna Prep Device|Materna Prep Device
89631755|NCT06126328|No Intervention|Standard of Care (SOC)|Standard of Care Control
89631756|NCT06125483|Experimental|38 patients with hematological malignancies who received TBI/Flu/Bu/Mel combined with secondary UCBT|Treatment stage : ( 1 ) conditioning : -7d, total body irradiation (TBI), 4Gy, 2 times ; -7d, semustine ( MECCNU ) 250mg / m2 ; -6d ~ -3d ; fludarabine ( Flu ) 30mg / m2 / d, ivgtt ; -6d ~ -5d, busulfan ( Bu ) 2.4mg / kg / d, 3 times a day, ivgtt ; -4d ~ -3d, melphalan ( Mel ) 40mg / m2 / d, ivgtt. ( 2 ) Transplantation : On day 0, unrelated umbilical cord blood ( TNC ≥ 2.3 × 107 / kg or CD34 + ≥ 1 × 105 / kg ) was transplanted, and the donor-recipient HLA matching degree was ≥ 6 / 10.
89631757|NCT06124404|Experimental|Small dose|
89631758|NCT06124404|Experimental|Medium dose|
89631759|NCT06124404|Experimental|Large dose|
89040435|NCT00540384|Experimental|NESP - Schedule 2 Part B|Open-label NESP at the dose of study drug administered at the end of Part A
89040436|NCT01207219|Experimental|Yoga therapy|Hatha yoga including breathing control (10 minutes), body posture(40-45minutes), and relaxation (5 minutes).
89040437|NCT01207219|Experimental|Aerobic exercise|Aerobic exercise includes walking on the treadmill for 15-20 minutes and stationary cycling for 25-30 minutes.
89040438|NCT01207219|No Intervention|Waitlist group|Patients in waiting list will be treated as usual and acted as control group.
89040439|NCT04659551|Experimental|Arm 1|Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed by Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses plus exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) started concomitantly to anthracycline based chemotherapy, to be continued until surgery.
89040440|NCT04659668|Experimental|MMG-23-04-2019|MMG-23-04-2019 is composed by sodium hyaluronate at concentration of 2% (20 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent, in aqueous solution at physiological pH. The filler of 1ml is administered once or twice depending on the individual necessity.
89040441|NCT01206517|Experimental|Cohort 1|Participants 10 or 11 years of age
89040442|NCT01206517|Experimental|Cohort 2|Participants 10 or 11 years of age
89040443|NCT01206517|Experimental|Cohort 3a-d|"Cohort 3a: Participants 10 or 11 years of age~Cohort 3b: Participants 12 or 13 years of age~Cohort 3c: Participants 14 or 15 years of age~Cohort 3d: Participants 16 or 17 years of age"
89040444|NCT00540462|No Intervention|1|Medical Group
89040445|NCT00540462|Active Comparator|2|Surgical Group with gastric bypass
89040446|NCT00540462|Active Comparator|3|Sugical Group with Sleeve gastrectomy
89040447|NCT01206439|Experimental|Nebivolol 5 or 10 mg, oral, daily|Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
89040448|NCT04318912||COPD patients|Adults age 40 or older with a diagnosis of chronic obstructive pulmonary disease (COPD) having been prescribed any COPD treatment (initial or subsequent) outside of a clinical trial.
89040449|NCT01206322|Experimental|Insulin vs. placebo|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
89040450|NCT01206322|Other|Healthy vs. Diabetic|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
89040451|NCT04659200||Covid Disease Patient Group|Researchers evaluated serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies in patients hospitalized for COVID-19 infection. The researchers evaluated the results of white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in Covid-9 patients.
89631760|NCT06117982|Experimental|Patients with POI receiving G-CSF injections|"Patients will receive 0.5 ml SC injections of G-CSF (Neupogen, Amgen, USA) at 300 micrograms/day for 4 consecutive days. The first injection will be administered in our office with a 60-minute observation period. Subsequent injections can be self-administered at home for three days, with a return to our clinic for monitoring the following day. This 4-day Neupogen regimen will be repeated in one month.~Patients may undergo two rounds of G-CSF treatment one month apart. If no improvement is observed in gonadotropin, anti-Mullerian levels, and antral follicle count, a third treatment may be offered a month later. Follow-up includes blood assessment of AMH and FSH, as well as ultrasound measurement of basal antral follicle count for three months after the last G-CSF infusion."
89631761|NCT06115330|Experimental|Ear Acupuncture with Standard Medical Therapy|The intervention group was give a press needle acupuncture with standard medical therapy for gynecological cancer pain
89631762|NCT06115330|No Intervention|Standard Medical Therapy|The control group was given standard medical therapy for gynecological cancer pain
89631763|NCT06115278||nurses|Our inclusion criteria for the nurses are the following: (1) 18 years old or older; (2) currently employed as a licensed nurse; and (3) current employment duties include routinely assessing the musculoskeletal pain of cognitively intact, adult outpatients. Our exclusion criteria for the nurses are the following: (1) currently managing a painful musculoskeletal condition; and (2) has ever felt musculoskeletal pain on most days for 3 months or longer.
89631764|NCT06115278||patients|"Our inclusion criteria for the patients are the following: (1) 18 years old or older; (2) currently being treated by a health care provider for a painful musculoskeletal condition; (3) has felt a usual musculoskeletal pain intensity rating of 2 or higher on a 0 to 10 scale over the last 24 hours; (4) has felt extreme pain that completely disappeared; (5) has felt musculoskeletal pain on most days of the last 3 months; (6) chronic musculoskeletal pain has increased and decreased during the last 3 months; and (6) has felt musculoskeletal pain in more than one location on most days of the last 3 months. Our exclusion criterion for the patients is ever employed as a licensed health care provider."
89631765|NCT06109818|Experimental|ICP-488 low dose|
89631766|NCT06109818|Experimental|ICP-488 high dose|
89631767|NCT06109818|Placebo Comparator|Placebo|
89631768|NCT06109194|Experimental|Intervention|Pre-assessment of active and passive range of motion in the paretic ankle, and five strides of gait assessment on a pressure-sensitive mat. Intervention will be moderate grade III anterior-to-posterior directed ankle mobilization for 2 minutes while supine, ankle muscle stretch for 75 seconds in standing, ankle muscle training for 3 minutes while seated. Post-assessment is repeated in the same sequence and content as pre-assessment.
89631769|NCT06098677|Experimental|Carotenoids group|Participants in the intervention group receive oral supplementation of 10 mg L, 10 mg MZ and 2mg Z in a formula base oil suspension as one soft gel capsule in the morning per day. Each capsule contains 22 mg of carotenoids (10+10+2mg), thus each participant in the intervention group will receive a total of 22 mg of carotenoids per day.
89631770|NCT06098677|Placebo Comparator|Placebo group|Participants in the control group receive one soft gel capsule of placebo oil per day.
89631771|NCT06094972|Experimental|TAU + A-CRA|"TAU: Interventions and treatments usually offered and delivered in institutional care. See below for examples.~12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Examples of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to meet youth individual goals and needs."
89631772|NCT06094972|Active Comparator|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
89631773|NCT06091566|Experimental|Electrical stimulation|Electrical stimulation to the dorsal genital nerve.
89631774|NCT06088095|Experimental|intervention group|
89631775|NCT06088095|No Intervention|control group|
89631776|NCT06081166|Active Comparator|obicetrapib + atorvastatin|Obicetrapib 10 mg tablets daily from Days 1-17 plus atorvastatin calcium 80 mg tablets on Day -4 and Day 12
89040452|NCT04659200||Covid-Free Control Group|Researchers evaluated the results of serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies, white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in the non-patient control group.
89040453|NCT01206166|Experimental|Enteral Nutrition + Parenteral Nutrition|Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
89040454|NCT01206166|No Intervention|Enteral Nutrition Only|Enteral nutrition only - no intervention
89040455|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 50mg/hour|Oseltamivir1 150mg PO q12h for 5 doses + Zanamivir IV continuous infusion at 50mg/hour for 72 hours
89040456|NCT00540501|Experimental|Zanamivir IV 50mg/hour|Zanamivir IV continuous infusion 50mg/hour for 16 hours (total dose of 800mg)
89040457|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 600mg|Oseltamivir 150mg PO q12h for 5 doses + Zanamivir 600mg IV q12h
89040458|NCT00540501|Active Comparator|Oseltamivir 150mg|Oseltamivir 150mg PO q12h for 3 days
89040459|NCT04659239|Experimental|Investigational Vaccine|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) according to the immunization schedule of D0, D14.
89040460|NCT04659239|Placebo Comparator|Placebo|Participants will receive 2 doses of the placebo according to the immunization schedule of D0, D14.
89040461|NCT03511248|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
89040462|NCT03511248|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
89040463|NCT00540618|Active Comparator|1|MEDI-507
89040464|NCT00540618|Placebo Comparator|2|
89040465|NCT00540618|Active Comparator|3|MEDI-507
89040466|NCT00540618|Active Comparator|4|MEDI-507
89040467|NCT04658459||Results at short term follow up|Functional and Radiological results at short-term follow up (one year at least)
89040468|NCT04658459||Results at middle term follow up|Functional and Radiological results at the last follow up of the patient (2 years at least)
89040469|NCT00557453||A|Antibiotic treatment
89040470|NCT00557453||B|Non antibiotic treatment
89040471|NCT01207102|Experimental|Abraxane, Carboplatin|Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
89040472|NCT04658732|Experimental|Alprazolam (A group)|patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer.
89040473|NCT04658732|Experimental|Gabapentin (G group)|patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer.
89040474|NCT04658732|Experimental|Dexmedetomidine (D group)|Dexmedetomidine 0.25 µg/kg loading dose will be infused intravenously over 10 minutes through syringe pump before surgery in the control group (Prepared using Precedex vial 200mcg/2ml manufactured by Hospira Inc, Highway 301,Rocky Mount,NC 278001 USA)
89040475|NCT00540696|Experimental|darbepoetin alfa|
89040476|NCT04658615|Other|group with rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
89631777|NCT06081166|Active Comparator|obicetrapib + rosuvastatin|Obicetrapib 10 mg tablets daily from Days 1-17 plus rosuvastatin calcium 40 mg tablets on Day -4 and Day 12
89631778|NCT06077188|Experimental|intervention group|
89631779|NCT06077188|No Intervention|Control group|
89631780|NCT06076304|Active Comparator|antibiotic|amoxicillin/clavulanate
89631781|NCT06076304|Placebo Comparator|placebo antibiotic|placebo antibiotic
89631782|NCT06076304|Active Comparator|antibiotic plus intranasal corticosteroid|amoxicillin/clavulanate plus budesonide
89631783|NCT06076304|Other|placebo antibiotic plus intranasal corticosteroid|placebo antibiotic plus budesonide
89631784|NCT06066502|Experimental|Precision ventilation|Ventilator support will be calibrated to maintain the range of lung stress typical of relaxed breathing in healthy adults. The ventilator management protocol takes into account pleural pressure, tidal volume and driving pressure, fraction of inspired oxygen (FiO2) and oxygen saturation (SpO2), and positive end-expiratory pressure (PEEP) titration.
89631785|NCT06066502|Active Comparator|Guided usual care|Ventilator support will be managed by the clinical team per usual care with select protocol-based guard rails to avoid practice extremes beyond the current body of evidence. PEEP titration will be performed by the clinical team within the limits set in. The allowable combinations of PEEP and FiO2 in the control arm reflect pre-intervention usual care observed at baseline in the recent large federally-funded multicenter ARDS trials.
89631786|NCT06063538|Experimental|CardiaMend Pericardial and Epicardial Reconstruction Matrix used in combination with amiodarone|Patients randomized to this study arm includes the CardiaMend which will be used according to the instructions for use. It will be patted dry to facilitate implantation. Pieces will be cut to cover the right and left atria. The remaining piece will be contoured to close the anterior pericardial space. Four ampules of amiodarone (150mg/3ml; 12cc total volume) will be drawn into a syringe. 2cc will be dripped over the right atrium and a small CardiaMend patch placed to cover this area. Another 2cc will be used over the left atrium and covered with the CardiaMend. The anterior pericardial space will be closed without putting pressure on the underlying structures using the CardiaMend attached to the native pericardium utilizing running 4-0 monofilament suture.
88990702|NCT06181344|No Intervention|Control condition|In the control condition, the clinical outpatient operation is performed as usual. The FCR screening tool and referral forms will be provided to the study sites and nursing staff are encouraged to adopt fear of cancer recurrence screening. Patients referred to JCICC will be managed following the predefined clinical pathway triage system. A briefing session about the purpose of the implementation program and the introduction of the FCR screening tool will be given to the staff at each study unit before the start of the first 4-months control condition. The briefing session will be recorded for the purpose of fidelity assessment.
88990703|NCT06181331|Experimental|First stage intervention: eConquerFear|Participants in the eConquerFear intervention group will receive six online modules with each containing educational text, illustrative graphics, interactive exercises, and brief videos. Every module will teach a specific topic, such as self-examination and medical surveillance, values-based goal setting, attention training, detached mindfulness, worry management and treatment summary and relapse prevention.
88990704|NCT06181331|Active Comparator|First stage intervention: eHealthMaintenance|Participants in the eHealthMaintenance group will receive six videos, which were designed to provide comprehensive lifestyle guidance (e.g., relaxation techniques, diet and physical activity advices) to help with survivors' maintenance of health in long-term.
88990705|NCT06181331|Experimental|Second stage intervention: ConquerFear-HK|ConquerFear-HK is a culturally adapted, manualized intervention consisting of 6 individual face-to-face sessions over 10 weeks.
88990706|NCT06181331|Active Comparator|Second stage intervention: eConquerFear+eHealthMaintenance|The augmented eConquerFear + eHealthMaintenance intervention is a combined unsupervised, self-guided web-based intervention that consists of 10 weekly online modules covering the content of eConquerFear and eHealthMaintenance interventions.
88990707|NCT06181318||Study group|Participants will be recruited after they have been diagnosed and their treatment has been planned by a multidisciplinary tumor board. Patients indicated to undergo major liver resection (> 3 segments based on Brisbane classification [23]) will be eligible for participation.
88990708|NCT06181292|Experimental|PHH-1V81|One dose of 40ug of PHH-1V81, administered intramuscularly
88990709|NCT06181292|Active Comparator|Comirnaty Omicron XBB1.5|One dose of 30ug of Comirnaty Omicron XBB1.5, administered intramuscularly
88990710|NCT06181188|Experimental|Ketamine and Midazolam|Patients will receive 1mg of midazolam and a bolus of 0.25 - 0.5mg/kg of ketamine to initiate sedation. Additional 10-20mg of ketamine will be given every 3-5 minutes to achieve adequate sedation. If additional anxiolysis is needed, additional doses of midazolam will be given every 3-5 minutes in 1mg increments. .
88990711|NCT06181188|Active Comparator|Midazolam and Fentanyl|Patient will receive midazolam and fentanyl in 1mg and 25mcg increments respectively until adequate procedural sedation is achieved. Additional increments will be given every 3-5 minutes as needed to achieve adequate sedation.
88990712|NCT06181175|Active Comparator|ARM 1: PEAPROSTIL 600 mg + Tamsulosin 0.4 mg|"PEAPROSTIL 600 is a food supplement based on Palmitoylethanolamide and Serenoa Repens, respectively for each sachet there are 600 mg of PEA and 320 mg of Serenoa oil. The net content of a sachet is 2.45 g and can be orodispersible without the need for the use of water. The drug does not contain gluten or lactose.~• Tamsulosin 0.4 mg is a drug belonging to the category of alpha-blocker drugs used as first choice drugs (according to European Urology association guidelines) for the treatment of LUTS/BPH. The recommended dose is 0.4 mg per day (1 administration), to be taken preferably at the same time during the day, indifferently with or without meals."
88990713|NCT06181175|Active Comparator|ARM 2: PEAPROSTIL 600 mg|PEAPROSTIL 600 is a food supplement based on Palmitoylethanolamide and Serenoa Repens, respectively for each sachet there are 600 mg of PEA and 320 mg of Serenoa oil. The net content of a sachet is 2.45 g and can be orodispersible without the need for the use of water. The drug does not contain gluten or lactose.
88990714|NCT06181175|Active Comparator|ARM 3: Tamsulosin 0.4 mg|Tamsulosin 0.4 mg is a drug belonging to the category of alpha-blocker drugs used as first choice drugs (according to European Urology association guidelines) for the treatment of benign prostatic hyperplasia. The recommended dose is 0.4 mg per day (1 administration), to be taken preferably at the same time during the day, indifferently with or without meals.
88990715|NCT06181084|Experimental|Group 1: Tablet versus Capsule|"Treatment A: LY3410738 capsule on Day 1 as a single oral dose in the morning following a fast of at least 10 hours prior to and 4 hours after dosing.~Treatment B: LY3410738 tablet on Day 4 as a single oral dose in the morning 10 hours prior to and 4 hours after dosing."
88990716|NCT06181084|Experimental|Group 2: Food Effect Comparison Group|"Treatment B: LY3410738 table on Day 1 as a single oral dose in the morning following a fast of at least 10 hours prior to and 4 hours after dosing.~Treatment C: LY3410738 table on Day 4 as a single oral dose in the morning 30 minutes after starting a standard low-fat meal."
89040477|NCT04658615|Other|group without rheumatoid arthritis|Non-surgical periodontal therapy (NSPT)
89631787|NCT06063538|No Intervention|University of Chicago's standard of care in patients undergoing isolated CABG or valve surgery|The standard of care for this study at The University of Chicago is to ligate the left atrial appendage (LAA) during the proposed cardiac surgery (intra-operative) to reduce the occurrence of post operative atrial fibrillation (A-FIB) in combination with amiodarone injections (if applicable).
89631788|NCT06059495|Experimental|Dostarlimab-based treatment|After inclusion patients will receive dostarlimab at 500 mg q3w (± 2-3 days) for 4 cycles (C1-C4). Then, an adaptive treatment strategy will be determined based on clinical assessment of the patient.
89631789|NCT06053268|Experimental|Single-arm, within-subject pilot: EmbracePlus smartwatch|Prior to engaging in the intervention participants will complete baseline assessments of stress and coping. Participants will then engage in a daily mindfulness practice via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control. During the first and fourth week of the intervention, participants will complete EMAs assessing mood, current activity, and intervention engagement. Participants will also wear a wrist-worn device to assess biomarkers of stress. At the completion of the intervention participants will complete follow-up assessments related to intervention and data collection procedures feasibility and acceptability as well as coping behaviors and stress.
89631790|NCT06050785||Vancomycin group|
89631791|NCT06050785||Gentamycin group|
89631792|NCT06044740|Experimental|Sevoflurane+Pain|Single-arm study. All subjects receive sevoflurane and painful electric nerve stimulation, as described in the interventions.
89631793|NCT06042751|Experimental|Exercise Therapy|Six online consultations focusing on exercise therapy, each lasting 50 minutes every two weeks, resulting in 300 min in 3 months.
89631794|NCT06042751|Experimental|Psychotherapy|Six online consultations focusing on psychotherapy, each lasting 50 minutes every two weeks, resulting in 300 min in 3 months.
89631795|NCT06042751|Experimental|Combined exercise and psychotherapy|Both interventions (exercise and psychotherapy) are combined. Six biweekly online session with 50% exercise therapy (a 25 min) and 50% psychotherapy (a 25 min) will take place, resulting in 300 min overall therapy in 3 months. The content of the procedure is simultaneous to the interventions described in the exercise therapy arm and the psychotherapy arm, respectively.
89631796|NCT06042413|Experimental|Group A/C (intervention)|"Participants randomized to this intervention group will receive the following interventions:~Personalized CPC Prehabilitation~Cognitive Training~Meditation~Daily Exercise~Enhanced Social Support~Additionally, they will undergo standard of care routine intraoperative SSEP and EEG monitoring during the scheduled surgery."
89631797|NCT06042413|Active Comparator|Group B/C (SOC control)|Participants randomized to the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC. Participants will receive standard of care routine intraoperative SSEP and EEG monitoring during the scheduled surgery.
89040478|NCT03470064||RV Dysfunction|All pediatric patients who present to pediatric cardiothoracic unit, Assiut University Hospital and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their surgical procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis
89040479|NCT04658420|Experimental|Ketamine|One group will receive IV ketamine 0.5mg/kg infused over forty minutes
89040480|NCT04658420|Experimental|Ketamine + Music|One group will receive IV ketamine 0.5mg/kg infused over forty minutes with one hour of pre-planned music
89040481|NCT04658420|Experimental|Music|One hour of pre-planned music without ketamine
89040482|NCT04658420|No Intervention|Treatment as usual|No music nor ketamine given
89040483|NCT00540735|Experimental|1|PDT
89040484|NCT00540735|No Intervention|2|
89040485|NCT00557531|Experimental|BL-1040|
89040486|NCT04658264|Experimental|Treatment Arm|The Treatment group shall receive 2 Kg of the composite flour every week, sufficient for 21 chapattis, and shall eat chapattis made from this flour instead of their usual wheat flour chapattis. The participants shall continue to receive the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study.
89631798|NCT06042413|Experimental|Group A/D (intervention + SOC)|"Participants randomized to this intervention group will receive the following interventions for study Part I:~Personalized CPC Prehabilitation~Cognitive Training~Meditation~Daily Exercise~Enhanced Social Support~If eligible to continue to Study Part 2, participants who received the Part I intervention will receive standard of care monitoring that includes: Routine intraoperative SSEP and EEG monitoring."
89631799|NCT06042413|Experimental|Group B/D (SOC + proactive bundle interventions)|"Participants randomized to the control group in study Part I will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.~If eligible to continue to Study Part 2, participants who received standard of care pre-operatively, will receive Proactive Bundle Interventions during surgery that includes: Participants randomized to the proactive bundled intervention group (Group D) will receive a routine intraoperative SSEP and EEG monitoring as well as optimization of intraoperative physiology by maintaining normal blood pressure, oxygen levels, opioid sparing analgesia, avoiding deep anesthesia and benzodiazepines."
89631800|NCT06038968|Experimental|Methotrexate group|methotrexate group will receive 40 mg of MTX in 500 ml of irrigation fluid during vitrectomy and 250 ug intra-silicone oil injection at the end of vitrectomy
89631801|NCT06038968|Placebo Comparator|Control group|control group will not receive MTX in irrigation fluid during vitrectomy nor intra-silicone at the end of vitrectomy
89631802|NCT06023498|Experimental|Manual Therapy and Exercise (MTE)|"Participants will be asked to attend 10 sessions of manual therapy that will be administered by a chiropractic physician and will consist of movements designed to enhance flexibility and muscle health. Session will last ~ 20 minutes.~The home exercise program (HEP) will consist of a light aerobic program (either walking with the lumbar spine in slight flexion while supported by a wheeled walker, going up and down a flight of stairs, using a treadmill, or using an exercise bicycle), neural mobilization self-stretches, individualized muscular stretches and core strengthening exercises. Participants will be encouraged to do the HEP 1-2 times per day, starting with 5 minutes and working up to 30 minutes.~During the subsequent 6 months, there will be no additional treatment administered. Participants will be asked to continue their HEP."
89040487|NCT04658264|No Intervention|Control Group|This group shall receive only the usual treatment suggested by their physician along with any changes that the physician deems necessary during the 3 month period of this study. They will continue to eat their usual diet as before their enrollment. They shall however receive usual counseling on lifestyle modifications including diet
89040488|NCT04657913|Experimental|cold water spray group|application of cold water in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
89631803|NCT06023498|Experimental|MTE Plus MTE Boosters|"Participants will be asked to attend 10 sessions of manual therapy that will be administered by a chiropractic physician and will consist of movements designed to enhance flexibility and muscle health. Session will last ~ 20 minutes.~The home exercise program (HEP) will consist of a light aerobic program (either walking with the lumbar spine in slight flexion while supported by a wheeled walker, going up and down a flight of stairs, using a treadmill, or using an exercise bicycle), neural mobilization self-stretches, individualized muscular stretches and core strengthening exercises. Participants will be encouraged to do the HEP 1-2 times per day, starting with 5 minutes and working up to 30 minutes.~During the subsequent 6 months, participants will be asked to return for monthly MTE booster sessions, and they will be asked to continue their HEP."
89631804|NCT06023498|Experimental|MTE and Intramuscular Electroacupuncture (IMEA) Plus MTE and IM Boosters|"Participants will be asked to attend 10 sessions of manual therapy that will be administered by a chiropractic physician and will consist of movements designed to enhance flexibility and muscle health. Session will last ~ 20 minutes.~Participants also will be asked to attend weekly intramuscular electroacupuncture (IMEA) sessions administered by a licensed acupuncturist. 30-gauge acupuncture needles will be placed in the muscles of the lower back and buttocks and gentle pulsing electrical stimulation will be delivered for 20 minutes.~The home exercise program (HEP) will be identical to that in the MTE and the MTE + Boosters groups.~During the subsequent 6 months, participants will be asked to return for monthly MTE and IMEA boosters. Participants also will be asked to continue their HEP."
89631805|NCT06018753||Patients with cancer|No intervention or sample collection is required on the study.
89631806|NCT06018376||Observational Study Group|"Age greater than or equal to 18 years and less than or equal to 70 years.~Diagnosis of lung cancer stages IB to IV.~Having received systemic oncological treatment for at least 3 months~ECOG ≤ 2"
89631807|NCT06015724|Experimental|Pancreatic Ductal Adenocarcinoma|
89631808|NCT06015724|Experimental|Refractory Non-Small Cell Lung Cancer|
89631809|NCT06014853|Experimental|Group 1|Period 1: Zytiga® 1000mg / Period 2 : SOL-804-F 302.5mg / Period 3 : SOL-804-F 242.0mg / Period 4 : SOL-804-F 181.5mg
89631810|NCT06014853|Experimental|Group 2|Period 1 : SOL-804-F 181.5mg / Period 2 : Zytiga® 1000mg / Period 3 : SOL-804-F 302.5mg / Period 4 : SOL-804-F 242.0mg
89631811|NCT06014853|Experimental|Group 3|Period 1 : SOL-804-F 242.0mg / Period 2 : SOL-804-F 181.5mg / Period 3 Zytiga® 1000mg / Period 4 : SOL-804-F 302.5mg
89631812|NCT06014853|Experimental|Group 4|Period 1 : SOL-804-F 302.5mg / Period 2 : SOL-804-F 242.0mg / Period 3 : SOL-804-F 181.5mg / Period 4 : Zytiga® 1000mg
89631813|NCT06013865|Other|Empagliflozin|Open Label, Empagliflozin 12.5 mg QD
89631814|NCT06013501|Experimental|Puppet Show Group|puppet show before and during subcutaneous injection
89631815|NCT06013501|No Intervention|Control group|standart care
89631816|NCT06012669|Experimental|Low Dose|0.34 g Recombinant Human Lactoferrin
89631817|NCT06012669|Experimental|High Dose|3.4 g Recombinant Human Lactoferrin
89631818|NCT06012669|Active Comparator|Active Control|3.4 g Bovine Lactoferrin
89631819|NCT06003608||Healthy control (HC)|25 neurotypical controls, age-matched to the Parkinson's disease group
89040489|NCT04657913|Experimental|cold saline spray group|application of cold 0.9% SF (saline) in the form of a spray to mouth of patients will be applied 2 times per hour, starting 2 hours after the end of the operation.
89040490|NCT04657913|No Intervention|control group|no intervention
89040491|NCT04657874|Active Comparator|Bromelain and Escin|
89040492|NCT04657874|Placebo Comparator|Placebo|
89040493|NCT03324438|Active Comparator|Home Telehealth T1D (CoYoT1-HR)|Home Telehealth T1D (C2oYoT1-HR), standard of care delivered via Telehealth for high-risk youth
89631820|NCT06003608||Parkinson's disease (PD)|75 Parkinson's disease patients
89631821|NCT05999097|Experimental|Short Chain Fructooligosaccharides Group|This group will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours for 10 days, diluted in 250 ml
89631822|NCT05999097|Placebo Comparator|Placebo Group|This group will receive Corn Starch as a Placebo control 12 gr. every 24 hours for 10 days, diluted in 250 ml
89631823|NCT05995652||ESWL sucess and failed gps|post ESWL 50 pt large gp will be devided into sucess gp and failed gp
89631824|NCT05986084|Experimental|CAB-LA PrEP|Following a negative HIV test, long-acting Cabotegravir Injection (CAB-LA) 600mg will be administered as a 3mL intramuscular (IM) injection in the gluteal muscle at enrollment, 1 month, and then every 2 months, for a maximum of 13 injections over 24 months of follow up.
89631825|NCT05985057||Patients with carbapenem resistant Klebsiella spp. infection|
89040494|NCT03324438|Experimental|Personalized Adherence Feedback|C2oYoT1-HR+Personalized Adherence Intervention
89040495|NCT03324438|Experimental|Personalized Behavioral Health|C2oYoT1-HR+Personalized Behavioral Health
89631826|NCT05985057||Patients with carbapenem sensitive Klebsiella spp. infection|
89631827|NCT05978180|Experimental|Medical Device : HO-1|"Single injection Hyaluronic acid associated with tranexamic acid 4.8 ml will be injected in one time Intra-articular single injection~Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
89631828|NCT05978180|Experimental|Medical Device : HS-3|"Three injections Hyaluronic acid associated with tranexamic acid 2.2 ml will be injected in three times (one injection per week) Intra-articular single injection~Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
89631829|NCT05978180|Active Comparator|Medical Device : SINOVIAL® ONE|"Hyaluronic acid 2.5 ml will be injected in one time Intra-articular single injection~Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
89631830|NCT05974787||Cancer patients|All adult patients with solid or hematological malignancies and receiving systemic therapy or having received systemic therapy within the last 3 months admitted to the emergency department of the Erasmus Medical Center for the oncology, hematology, lung- and neuro-oncology medical unit are eligible for inclusion.
89631831|NCT05974605|Experimental|Combined mindfulness meditation and cognitive training|"Participants train at home for 20 hours over 8 weeks, splitting the time between mindfulness meditation and cognitive training. Participants train for 30 minutes per day, for 5 days a weeks on a provided tablet computer. The participants are to keep a paper log of dates and durations.~The mindfulness meditation portion of the training is a commercially available mobile app. Participants listen to guided meditations and follow the instructions. The program includes common mindfulness meditation exercises such as body scan or breath awareness.~The cognitive training portion of the intervention uses a highly demanding attentional control training program BirdWatch game (BWGU). BWGU is a gamified n-back paradigm where participants randomly switch the focus of attention to update or maintain an adaptively growing set of bird stimuli in their working memory and are sometimes required to inhibit their response."
89631832|NCT05971979||Critically ill patients with presumed or confirmed lower respiratory tract infection|Non-interventional. Admitted to intensive care unit. Presumed or confirmed lower respiratory tract infection. Receiving either piperacillin/tazobactam or meropenem. Participants will have samples collected during an antimicrobial dose cycle.
89631833|NCT05971108|Experimental|Patients with liver cirrhosis eligible for HCC Surveillance|Real-world HCC surveillance cohort will be exposed to Elecsys® GAAD in parallel with standard of care tests.
89631834|NCT05955053|Experimental|Midwifery care applied in line with Midwife-Pregnant cooperation|The group that received care in line with the midwifery care model checklist
89631835|NCT05955053|No Intervention|Control group|The group with routine hospital protocol
89631836|NCT05947188|Experimental|Sample for Circulating Tumoral Cells|Sampling of Circulating Tumoral Cells will be done
89631837|NCT05946551|Experimental|HRA Treatment Arm|Participants randomized to Treatment Arm will receive dual histamine receptor antagonists: famotidine and cetirizine daily.
89631838|NCT05946551|Placebo Comparator|Placebo Arm|The compounding study pharmacy will provide placebo capsules to the patients randomized to Placebo. These capsules are manufactured to match each treatment drug for oral administration.
89631839|NCT05941650|Experimental|Short Chain Fructooligosaccharides Group|This group will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours for 10 days, diluted in 250 ml
89631840|NCT05941650|Placebo Comparator|Group|This group will receive Corn Starch as a Placebo control 12 gr. every 24 hours for 10 days, diluted in 250 ml
89631841|NCT05935007||Interventions|"Device: Aveir DR Leadless Pacemaker System~This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study."
89631842|NCT05933941|Experimental|Group 1|This group will perform cervical mobility exercises and exercises with virtual reality glasses. 2 sessions will be held per week with a total of 8 sessions
89631843|NCT05933941|Active Comparator|Group 2|This group will only perform cervical mobility exercises at two sessions per week with a total of 8 sessions.
89631844|NCT05933941|No Intervention|Control group|This group will not receive any treatment or perform any type of exercise during the duration of this study.
89040496|NCT03324438|Experimental|C2oYoT1-HR + Adherence + Behavioral|C2oYoT1-HR + both Personalized Adherence Feedback + Personalized Behavioral Health (C2oYoT1-HR + Adherence + Behavioral)
89040497|NCT00540813|Experimental|Drug Eluting Balloon|
89631845|NCT05931289|Active Comparator|Enhanced Crisis Response Planning|Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.
89631846|NCT05931289|Active Comparator|Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)|This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
89631847|NCT05931016||Patients with known lung disease and LTOT (long term oxygen therapy)|Patients with i.e. interstitial lung, emphysema, pulmonary hypertension or COPD with the need for LTOT
89631848|NCT05926817|No Intervention|Control group|Postoperative standard analgesia was administered to patients in the control group.
89631849|NCT05926817|Placebo Comparator|Placebo-VR group|Patients in the Placebo-VR group watched a 10-minute relaxation-based 2D film through VR headsets along with receiving conventional analgesia.
89040498|NCT04658030|Experimental|VR 360 video surgery preparation|Preparing pediatric patients for surgery with a newly developed VR 360 degree video. Maximum 30 minutes, one time.
89040499|NCT04658030|Active Comparator|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
89040500|NCT00540852|Other|Diagnostic Tool|Diffuse Optical Spectroscopy Imaging
89040501|NCT04658225|Active Comparator|Solution 1|0.12% chlorhexidine
89040502|NCT04658225|Placebo Comparator|Solution 2|Saline solution
89040503|NCT04657952|Active Comparator|Standard medical Treatment (paracetamol)|Patients will receive paracetamol 1 gm every 6 hours daily intravenously for a day.
89040504|NCT04657952|Experimental|Sphenopalatine block|Patients will receive sphenopalatine block
89631850|NCT05926817|Experimental|QTC-VR group|Patients in the QTC-VR group engaged in 10-minute interactive pain relief 3D VR programs while wearing VR headsets along with receiving conventional analgesia.
89631851|NCT05922683|Experimental|Vivomixx|Participant in the treatment arm will receive a daily dose of the probiotic Vivomixx for 8 weeks.
89631852|NCT05922683|Placebo Comparator|Placebo|Participant in the control arm will receive a daily dose of a placebo (microcrystalline maltose) for 8 weeks.
89631853|NCT05921994||secukinumab|Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
89631854|NCT05921435|Experimental|Sequence A|"Period 1: D958~Period 2: CKD-341~Period 3: D958~Period 4: CKD-341"
89631855|NCT05921435|Experimental|Sequence B|"Period 1: CKD-341~Period 2: D958~Period 3: CKD-341~Period 4: D958"
89631856|NCT05918523||CKD patients previously treated with REACT|Participants Exposed to Renal Autologous Cell Therapy from studies RMCL-002, REGEN-003, REGEN-004 (REGEN-008S1).
89631857|NCT05918224|Experimental|Experimental group|S. salivarius K12 group: The S. salivarius K12 lozenges (NOW Foods, USA) contained not less than 1×109 CFU viable cells of S. salivarius K12 as the active ingredient. The S. salivarius K12 lozenges were dissolved in the mouth and then swallowed through the first day of RT to the end of treatment (1 lozenge 3 times a day).
89631858|NCT05918224|Placebo Comparator|Placebo group|Placebo group: Placebo lozenges contained sugar and starch used as excipients in the active formulation. The placebo lozenge were dissolved in the mouth and then swallowed through the first day of RT to the end of treatment (1 lozenge 3 times a day).
89040505|NCT03256227|Experimental|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
89040506|NCT03256227|Active Comparator|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
89040507|NCT04657718|Other|All subjects|The KODEX-EPD system will be used in combination with leads to image during all procedures.
89040508|NCT00541086|Experimental|A - anastrozole|Up-front adjuvant anastrozole for 5 years
89040509|NCT00541086|Experimental|B - exemestane|Up-front adjuvant exemestane for 5 years
89040510|NCT00541086|Experimental|C - letrozole|Up-front adjuvant letrozole for 5 years
89040511|NCT00541086|Active Comparator|D - tamoxifen followed by anastrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by anastrozole for 3 years
89040512|NCT00541086|Active Comparator|E - tamoxifen followed by exemestane|Switch adjuvant treatment with tamoxifen for 2 years followed by exemestane for 3 years
89040513|NCT00541086|Active Comparator|F - tamoxifen followed by letrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by letrozolefor 3 years
89040514|NCT04657484|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 2 weeks, 10 mg/day for 2 weeks
89631859|NCT05909085|Active Comparator|Handheld traditional ultrasound|Traditional US will be used to compare number of needle manipulations to the handheld US.
89631860|NCT05909085|Other|Handheld Automated ultrasound|Automated device provides automatic information pertaining to distance to epidural space distance and interspace location.
89631861|NCT05908084|Experimental|HAV treatment arm|HAV will be implanted as an arterio-venous (AV) access into the forearm or upper arm
89631862|NCT05908084|Active Comparator|AVF treatment arm|AVF creation procedure (1-stage AVF or 2-stage AVF) as an arterio-venous (AV) access into the forearm or upper arm
89631863|NCT05906810|Experimental|Peri-implantitis|Subjects diagnosed with peri-implantitis according to the most recent international guidelines and without cardiovascular diseases.
89631864|NCT05906810|Active Comparator|Peri-implant mucositis|Subjects diagnosed with peri-implant mucositis according to the most recent international guidelines and without cardiovascular diseases.
89631865|NCT05906810|No Intervention|Healthy|Subjects without periodontitis and with good gingival health.
89040515|NCT04657484|Active Comparator|Low dose prednisolone|A dose of 10 mg/day of prednisolone will be administered for 6 weeks
89040516|NCT00541125|Other|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire
89040517|NCT00541164|Experimental|1|300 mg CoQ10 chewable wafer twice a day
89040518|NCT00541164|Placebo Comparator|2|Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
89040519|NCT04657757|Experimental|Intraoral apparatus|intraoral apparatus in which two platelets of each of the 8 materials (Esteticor Lumina PF; Esteticor Lumina PF - after Lactic acid storage; Pagalinor 2; Esteticor Economic; Pekkton ivory - untreated; Pekkton ivory - rough; Oralloy; Machined Titan Zirconia (TiZr) alloy) are to be examined. Examination is a crystal violet OD595 staining (10 minutes). The color absorbed by the bacteria is then dissolved with a 30% acetic acid and measured spectrophotometrically at 595 nm. The plaque formed on the material surface is removed immediately after removal from the oral cavity and analyzed by determination of Colony Forming Unit (CFU) number.
89040520|NCT03243279||Surgical|No interventions. Patients undergoing cardiothoracic surgery will be assessed for baroreflex sensitivity and the outcomes of interest.
89040521|NCT04657601||Treatment Group|Patients undergo polypectomy facilitated by the study device.
89040522|NCT03231072|Experimental|Electrical Impedance Tomography record|Electrical Impedance Tomography monitoring of the pleural effusion evacuation.
89631866|NCT05889052||Active cohort control|Children (aged 6-9 months) in the control arm will receive the standard of care: 5 doses of SP at EPI visits (at 10 weeks, 14 weeks, 6 months, 9 months and 15 months).
89631867|NCT05889052||Active cohort intervention|Children (aged 6-9 months) in the intervention arm with receive PMC: 8 doses of SP at EPI visits (at the same contacts as group 1 plus at 12 months, 18 months and 24 months)
89631868|NCT05887401|Experimental|Condition 1|Core + Green Foods Monitoring + Nutrition Goals + Supportive Text Messages + All Lessons
89631869|NCT05887401|Experimental|Condition 2|Core + Green Foods Monitoring + Nutrition Goals + Supportive Text Messages + Weekly Lessons
89631870|NCT05887401|Experimental|Condition 3|Core + Green Foods Monitoring + Nutrition Goals + No Supportive Text Messages + All Lessons
89040523|NCT04656977|Active Comparator|VR+TAU|Participants will participate first to a VR-based intervention and then to the TAU condition. The TAU condition is a homogenous standard program proposed by the Centre d'études et de recherché en intervention familiale (CERIF) at Université du Québec en Outaouais (UQO) based on group counseling offered to women and men who experienced a perinatal loss.
89040524|NCT04656977|Active Comparator|TAU+VR|Participants will be invited first to participate to the TAU condition and then to the VR-based intervention.
89040525|NCT03221322||Control|20 kg/m2 ≤ BMI ≤ 25 kg/m2, healthy, with no eating disorder, 150 subjects, 20 - 40 years old
89040526|NCT03221322||Superlean|15 kg/m2 ≤ BMI ≤ 18 kg/m2, healthy, with no eating disorder, 150 subjects, 25 - 35 years old in particular
89040527|NCT00541281|Active Comparator|A|weekly docetaxel and prednisone
89040528|NCT00541281|Active Comparator|B|weekly docetaxel (35mg/m&) plus prednisone 10mg a day associated with estramustine form day 1to 5 and 8 to 12
89040529|NCT04656860|Experimental|Juice Plus+|Participants will consume 6 capsules daily consisting of a combination of Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend and Juice Plus+ Berry Blend. Participants will consume supplements for 24-months.
89040530|NCT04656860|Placebo Comparator|Placebo|Participants will consume 6 capsules daily consisting of microcrystalline cellulose, rice starch, vegetarian capsule (cellulose), and magnesium stearate. Participants in this condition will receive 1-year of supplements after the study is completed.
89040531|NCT04657172|Experimental|Pilocarpine 1% Solution|1% pilocarpine ophthalmic solution administered with the Optejet dispenser
89040532|NCT04657172|Experimental|Pilocarpine 2% Solution|2% pilocarpine ophthalmic solution administered with the Optejet dispenser
89040533|NCT04657172|Placebo Comparator|Placebo Solution|Placebo ophthalmic solution administered with the Optejet dispenser
89040534|NCT03199794||OBIZUR participants|Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
89040535|NCT04656821|Active Comparator|Control Group|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.
89040536|NCT04656821|Experimental|Erector Spinae Block (ESB) group|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
89040537|NCT04656821|Experimental|Thoracic Paravertebral Block group|Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography
89040538|NCT04656509|Experimental|4-s sprint inertial load training|Participants trained three times a week for eight weeks following the training program consisting of 30 bouts of 4s all-out cycling on an inertial-load ergometer with progressively decreasing recovery time (30 to 24 to 15s).
89057419|NCT04539821|Other|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials. First, the patient is mailed or emailed (based on their preference) an informational packet prior to intake appointment. Second, using the collaborative medication management model established in VHA,3 the intake appointment is led by the CPS using a standardized intake evaluation. The CPS and physician design a plan presented to the patient. If BUP switch is offered and accepted, the physician completes additional brief evaluations, including a history, medication review, treatment planning, and discussion of other VCPM components, using two-way audio-video visits (with telephone as a back-up).
89057420|NCT01682694|Experimental|Glucosamine and Chondroitin|Glucosamine and Chondroitin
89631871|NCT05887401|Experimental|Condition 4|Core + Green Foods Monitoring + Nutrition Goals + No Supportive Text Messages + Weekly Lessons
89631872|NCT05887401|Experimental|Condition 5|Core + Green Foods Monitoring + No Nutrition Goals + Supportive Text Messages + All Lessons
89631873|NCT05887401|Experimental|Condition 6|Core + Green Foods Monitoring + No Nutrition Goals + Supportive Text Messages + Weekly Lessons
89631874|NCT05887401|Experimental|Condition 7|Core + Green Foods Monitoring + No Nutrition Goals + No Supportive Text Messages + All Lessons
89631875|NCT05887401|Experimental|Condition 8|Core + Green Foods Monitoring + No Nutrition Goals + No Supportive Text Messages + Weekly Lessons
89631876|NCT05887401|Experimental|Condition 9|Core + Red Foods Monitoring + Nutrition Goals + Supportive Text Messages + All Lessons
89631877|NCT05887401|Experimental|Condition 10|Core + Red Foods Monitoring + Nutrition Goals + Supportive Text Messages + Weekly Lessons
89631878|NCT05887401|Experimental|Condition 11|Core + Red Foods Monitoring + Nutrition Goals + No Supportive Text Messages + All Lessons
89631879|NCT05887401|Experimental|Condition 12|Core + Red Foods Monitoring + Nutrition Goals + No Supportive Text Messages + Weekly Lessons
89631880|NCT05887401|Experimental|Condition 13|Core + Red Foods Monitoring + No Nutrition Goals + Supportive Text Messages + All Lessons
89631881|NCT05887401|Experimental|Condition 14|Core + Red Foods Monitoring + No Nutrition Goals + Supportive Text Messages + Weekly Lessons
89631882|NCT05887401|Experimental|Condition 15|Core + Red Foods Monitoring + No Nutrition Goals + No Supportive Text Messages + All Lessons
89631883|NCT05887401|Experimental|Condition 16|Core + Red Foods Monitoring + No Nutrition Goals + No Supportive Text Messages + Weekly Lessons
89631884|NCT05885737|Experimental|12-weeks double-blind period - Difelikefalin|
89631885|NCT05885737|Placebo Comparator|12-weeks double-blind period - Placebo|
89631886|NCT05885737|Experimental|14-weeks optional open-label period following the double-blind period - Difelikefalin|
89631887|NCT05882344|Active Comparator|Deep Brain Stimulation|Patients who are implanted and receive intermittent stimulation daily for the first 12 months
89057421|NCT01682694|Placebo Comparator|Placebo|Inactive ingredients
89057422|NCT04539587||adjuvant hormonal therapy for breast cancer|Women more than 18 years old, with hormone receptor-positive early BC, with completed surgery as well as chemotherapy and/or radiotherapy, if indicated, and had begun their hormonal therapy for less than 6 months.
89631888|NCT05882344|Sham Comparator|Non-Deep Brain stimulation|Patients who are implanted but do not receive intermittent stimulation daily for 12 months, but receive it after this period for the duration of the study
89631889|NCT05879835|Experimental|KiteLock 4% Sterile Catheter Lock Solution|4% Tetrasodium EDTA lock solution (KiteLock 4% Sterile Catheter Lock Solution; SterileCare Inc., Canada) will be administered 4-24 hours daily while the patient is cycled off their PN, as per site standard operating procedures.
89631890|NCT05879835|Active Comparator|Heparin Lock Solution|Heparin lock solution will be administered daily per investigator judgement, given its significant clinical risk in the youngest/smallest/vulnerable subjects.
89631891|NCT05875740||septic patients|patients with sepsis defined based on Sepsis 3.0 criteria within 24 hours after admission
89631892|NCT05875740||non-septic patients|patients without sepsis defined based on Sepsis 3.0 criteria within 24 hours after admission
89631893|NCT05875740||healthy control group|healthy adults
89631894|NCT05875571|Active Comparator|Ketorolac|The group of patients will receive IV Ketorolac before placement of IUD under sedation.
89631895|NCT05875571|Placebo Comparator|Placebo|The group of patients will receive placebo before placement of IUD under sedation.
89631896|NCT05874453|Experimental|Intervention Group|Eye care protocol to be appliedevaluation.
89631897|NCT05874453|No Intervention|Control Group|Routine intensive care Eye care protocol to be applied
89631898|NCT05868291||Group 1|"During the period going from November 2022 to March 2023, data from all the patients (approx. 500) hospitalized in the 4 closed wards will be collected (duration of stay, medication use...).~The group 1 will be exposed to the standard lighting system in Bispebjerg Hospital."
89631899|NCT05868291||Group 2|"During the period going from November 2023 to March 2024, data from all the patients (approx. 500) hospitalized in the 4 closed wards will be collected (duration of stay, medication use...).~The group 2 will be exposed to the new lighting system that will have been optimized (higher intensity and blue content in the morning and progressively dimmed light after 14:00)."
89631900|NCT05857475|Experimental|CPAP therapy|CPAP therapy will be used in this arm for 2 month.
89631901|NCT05857475|Other|Control|CPAP therapy will not be used in this arm for 2 month. (subject were assign to normal waiting list in order to borrowing hospital PAP machine.)
89631902|NCT05856357||Active cohort control|Children (aged 10 weeks to 6 months) in the control arm will receive the standard of care: 0 doses of SP.
89631903|NCT05856357||Active cohort intervention|Children (aged 10 weeks to 6 months) in the intervention arm with receive PMC: five doses of SP at EPI visits (10 weeks, 14 weeks, 9 months, 15 months, 18 months)
89631904|NCT05846581||ESRD patients that require hemodialysis access through the GORE® ACUSEAL Vascular Graft.|"Patient population - patients with CKD in ESRD that require hemodialysis access through the GORE® ACUSEAL Vascular Graft.~Registry subject population - those patients with CKD in ESRD that require hemodialysis access through the GORE® ACUSEAL Vascular Graft meeting the inclusion and exclusion criteria will be eligible for screening for participation in this registry.~The registry has been designed with broad eligibility criteria to capture real-world GORE® ACUSEAL Vascular Graft use, for which the device is intended to be implanted. Only patients who meet all of the inclusion criteria and none of the exclusion criteria will be implanted.~No vulnerable populations are included in this registry."
89631905|NCT05844826|Experimental|Single Arm|Participant swallows and retrieves capsule in stool. Intestinal fluid samples collected by SIMBA capsules from the MS and HC participants, along with a fecal and blood samples, will be used for gut microbiome, viral and metabolomic analysis.
89631906|NCT05840510|Experimental|Dose Escalation and Clinical Efficacy|Dose escalation of adagrasib and nab-Sirolimus to determine maximum tolerated dose in combination and evaluate the clinical efficacy of adagrasib in combination with nab-sirolimus in patients with solid tumors (Phase 1) and NSCLC (Phase 2) harboring a KRAS G12C mutation
89631907|NCT05806216||2a - Model Development|Enrollment for the purposes of training the EarliPoint system data models in children ages 31-84 months suspected of autism spectrum disorder or related developmental delays or those who are typically developing.
89631908|NCT05806216||2b - Model Testing|Enrollment for the purposes of testing/validating the EarliPoint system data models in children ages 31-84 months suspected of autism spectrum disorder or related developmental delays or those who are typically developing.
89631909|NCT05798793|No Intervention|Surgery followed by postoperative RT|The participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
89631910|NCT05798793|Experimental|Neoadjuvant TP chemotherapy|The participants will receive 2 courses of TP chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
89631911|NCT05798793|Experimental|Neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy|The participants will receive 3 doses of PD-1 blockade and 2 courses of TP chemotherapy. Then the participants will take a radical surgery followed by radiotherapy or chemoradiotherapy if necessary.
89631912|NCT05796752|Experimental|Memantine and Behavioral Therapy|All subjects will receive 8-weeks of memantine treatment (10mg po qday for the first two weeks, then 20 mg po qday for the remaining six weeks). After the 8-weeks of memantine treatment, the dose will be discontinued. Then, after a 4-week washout period, all subjects will receive 8-weeks of ComB therapy. Therapy will be once a week for 30 minutes. After the 8-weeks of ComB treatment, the therapy will be discontinued.
89631913|NCT05796557|Active Comparator|Higher platelet transfusion strategy|Participants randomized to this arm will be transfused if the platelet count is < 90 x 10e9 cells/L.
89631914|NCT05796557|Experimental|Lower platelet transfusion strategy|Participants randomized to this arm will be transfused if the platelet count is < 50 x 10e9 cells/L.
89631915|NCT05790278||Adults with Early Stage Cancer|
89631916|NCT05790278||Adults with Traumatic Brain Injury|
89631917|NCT05790278||Health Control Adults|
89631918|NCT05789797||The control group|Ademethionine, lyophilisate for solution for intravenous and intramuscular injection, by intravenous drop infusion in the dose of 800 mg/day, on everyday basis for 14 days
89631919|NCT05789797||The test group|Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
89631920|NCT05789615||200 haplo-HSCT recipients who are CMV seropositive|"The study consists 200 cases CMV-R+ adult (>18 years) recipients of haplo-HCT. All patients will receive letermovir prophylaxis. Consider a simple interim analysis of the experimental group could be arranged after 150 patients are enrolled if necessary.~Supportive care is provided by institutional standards of care (e.g., acyclovir for herpes simplex virus and varicella zoster virus prevention).~Letermovir prophylaxis is started on day 0 or no longer than 28 days after transplantation. During the study period, letermovir 480 mg PO/IV once daily (or 240 mg per day in patients taking cyclosporine) was administered from day 0 to day +100 post-HCT.~CMV monitoring and preemptive therapy were performed according to local protocol. Plasma CMV viral load (VL) is monitored by quantitative CMV PCR, starting on day +7 and continued weekly until week 6, then every 2-4 weeks for months until week 24."
89631921|NCT05785832|Experimental|Intervention group|Participants who skip or successfully complete the run-in will be randomly assigned 2:1 to the Intervention group using t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM for 13 weeks.
89631922|NCT05785832|Active Comparator|Control group|Continuation of pre-study basal-bolus insulin delivery method, plus use of study CGM (Dexcom G6).
89631923|NCT05780463|Experimental|MP0420 plus SOC|"MP0420 600 mg solution (4 vials of 15 mg/mL); administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
89631924|NCT05780463|Placebo Comparator|Placebo plus SOC|"Placebo administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
89040539|NCT00541359|Experimental|Arm I|"PART I (completed as of 09/06/06; all patients enrolled in study after 09/06/06 are enrolled in part II): Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8 followed 6 hours later by bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~PART II: Patients receive bortezomib IV on days 1, 4, 8, and 11 followed 6 hours later by escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~In both parts of the study, patients who achieve a response may receive additional courses of treatment."
89040540|NCT04656743|Experimental|intra-articular injection group|will receive ultrasound guided intraarticular injection consisting of 20 mL of 0.25% bupivacaine before surgical procedure. The surgical procedure will be started 30 min after intraarticular injection.
89631925|NCT05780424|Experimental|BRII-196/BRII-198 plus SOC|"BRII-196 1000 mg solution; administered as IV infusion~BRII-198 1000 mg solution; administered as IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
89631926|NCT05780424|Placebo Comparator|Placebo plus SOC|"Placebo administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
89040541|NCT04656743|Experimental|genicular nerve block group|will receive ultrasound guided genicular nerve block at three nerves, i.e., superomedial, superolateral, and inferomedial genicular nerves consisting of 15 ml bupivacaine 0.25% before surgical procedure. The surgical procedure will be started 30 min after genicular nerve block.
89040542|NCT03111927|No Intervention|Reference Arm: Breastfed|Epidemiological reference group of breastfed infants.
89040543|NCT03111927|Experimental|Investigational|Infant Formula: enriched level of myelin-relevant nutrients
89040544|NCT03111927|Active Comparator|Control|Infant formula: standard level of myelin-relevant nutrients
89040545|NCT04656782||Expert panelists|Expert panelists will be recruited from EORTC Imaging Group, EORTC GI Group, ESOI and ESGAR and will actively participate in the imaging survey rounds.
89040546|NCT04656782||Facilitators|The two central facilitators will moderate and guide the survey rounds. Blinded results will be forwarded to the expert panelists by the facilitators. Further Survey rounds will be adapted by the facilitators according to the previous answers given by the panelists.
89631927|NCT05775718|Experimental|1-<2 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
89631928|NCT05775718|Experimental|2-<3 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
89040547|NCT00541398|Experimental|A|
89040548|NCT00541398|No Intervention|B|
89040549|NCT04656626|Experimental|COVID19 Frontline Health Care Providers recieving mindfulness intervention|This arm will receive mindfulness audios (randomized and double blinded)
89040550|NCT04656626|Placebo Comparator|COVID19 Frontline Health Care Providers receiving progressive muscle relaxation|This arm will receive progressive muscle relaxation audios (randomized and double blinded)
89040551|NCT03456921|Experimental|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
89040552|NCT04658069||One Cohort receiving routine hemodialysis therapy without any specific interventions|all HD patients enrolled in this study
89040553|NCT04656704|Experimental|Hyaluronidase 200mg monthly|Hyaluronidase 200mg monthly (Weeks 0, 4, 8, 12, 16, 20); for six doses; a 6-month treatment course with follow-up 1 month after
89040554|NCT03096249|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
89040555|NCT03096249|Placebo Comparator|Placebo|Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray
89040556|NCT04656548||HydroPICC|Cohort who received the HydroPICC
89040557|NCT04656548||Standard of Care|Cohort who received something different than HydroPICC
89040558|NCT04656665|Experimental|75mg|Take 75mg of aspirin daily in tihis group
89040559|NCT04656665|Active Comparator|100mg|Take 100mg of aspirin daily in this group
89040560|NCT04656665|No Intervention|blank|Not taking aspirin in this group
89040561|NCT03014622|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
89040562|NCT03014622|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
89040563|NCT04656314||Healthy participants aged 18 to 40|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
89040564|NCT04656314||Healthy participants aged 60 and above|3 identical functional MRI scans. Blood samples to quantify level of physiological stress are taken before and after each scan.
89040565|NCT04656119||patients without irAEs or patients with good efficacy|
89040566|NCT04656119||patients with irAEs or patients with poor efficacy|
89040567|NCT04656197||Patients with dry eye disease|
89040568|NCT04656197||Healthy controls|
89040569|NCT04655846|Active Comparator|Control group|Usual manage during prenatal control program
89040570|NCT04655846|Experimental|Intervention group|Educational intervention towards the maintenance of exclusive breastfeeding in the first six months in first pregnant adolescents enrolled in the prenatal control program
89040571|NCT04655534|Experimental|IMW Group|Patients who performed inspiratory muscle warm-up (IMW) before inspiratory muscle training (IMT)
89040572|NCT04655534|Experimental|Standart IMT Group|Patients who performed standard inspiratory muscle training (IMT) without inspiratory muscle warm-up (IMW) protocol
89040573|NCT04655807|Experimental|Group 1- Standard of Care (SOC) Biological Therapy: Adalimumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo subcutaneous (SC) injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to adalimumab or its biosimilar as SOC therapy.
89040574|NCT04655807|Experimental|Group 2: SOC Biological Therapy: Ustekinumab|Participants will receive JNJ-64304500 Dose 1 or matching placebo SC injection as induction dose (Week 0) followed by JNJ-64304500 Dose 2 or matching placebo SC injection from Week 2 through Week 10 as maintenance dose in addition to ustekinumab as SOC therapy.
89040575|NCT04655417|Experimental|INTERVENTION GROUP|SINGLE ARM OF PATIENTS WHO WILL RECEIVE SAME TREATMENT
89040576|NCT00541515|Experimental|closed loop system|Device: continuous glucose sensors and insulin pump
89040577|NCT02937831||All Study Participants|
89040578|NCT04655339|Experimental|Group-1|Bilateral abdominal Lap-TAP block injection near incision site with 0.25% Bupivacaine HCl (30cc) with 30ml being injected bilaterally. Remaining residual is injected into port incision sites.
89631929|NCT05775718|Experimental|≥ 3 years post stem cell transplant|At Visit 1 participants will be given information about the nature of HZ and its recognition and given a questionnaire for completion should they develop HZ during the study. They will also be asked to contact the study team if they develop HZ so that further evaluation of potential HZ is completed and the details of the event recorded. A swab of an active lesion or crust from a dried lesion will be obtained for VZV PCR. A participant who develops HZ will be asked to complete the questionnaire weekly for 4 weeks and then at 8 and 12 weeks. In addition, the subject will be asked about pain medications taken during the episode. Information on HZ incidence will be supplemented from the clinic medical records and the electronic medical records. Subjects will be followed for 1 year after enrollment for the occurrence of HZ and of post-herpetic neuralgia (PHN).
89631930|NCT05769842|Experimental|propofol group|Children aged 3 to 8 years who had had their tonsil adenoidectomy were collected. Propofol 3mg/kg, remifentanil 3-5ug /kg and atropine 0.01mg/kg were used for intravenous induction intubation. Sevoflurane was used for intraoperative anesthesia, propartamol 30mg/kg and hydromorphone 5-10ug /kg were used for postoperative analgesia.When sevoflurane was shut down at the end of the operation, oxygen flow was increased to more than 7L/min, and extubation was prepared for spontaneous respiration recovery, propofol was given a small amount of 1~2mg/kg multiple times without inhibition of spontaneous respiration.
89631931|NCT05769842|Sham Comparator|control group|Anesthesia induction is the same as before.At the end of the operation, sevoflurane was shut down and oxygen flow was increased to more than 7L/min. No other treatment was performed during extubation.
89631932|NCT05761223|Experimental|Phase Ia dose-escalation part of FB849 Monotherapy|Participations will receive FB849 orally once a day.
89631933|NCT05761223|Experimental|Phase Ib dose-expansion of FB849 monotherapy|Participations will receive FB849 orally once a day.
89631934|NCT05761223|Experimental|Phase IIa dose-escalation part of FB849 in Combination with Pembrolizumab|Participations will receive FB849 orally once a day in combination with pembrolizumab.
89631935|NCT05761223|Experimental|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)|Participations will receive FB849 orally once a day in combination with pembrolizumab.
89631936|NCT05761223|Experimental|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)|Participations will receive FB849 orally once a day in combination with pembrolizumab.
89631937|NCT05761223|Experimental|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)|Participations will receive FB849 orally once a day in combination with pembrolizumab.
89631938|NCT05755711||Female subjects referred for percutaneous coronary intervention|Female subjects referred for percutaneous coronary intervention (PCI) with coronary IVL and stenting per standard of care.
89631939|NCT05746520|Experimental|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.~Participants undergoing standard of care (SOC) with complicated (gangrenous or perforated) appendicitis will receive 24 hours of SOC post-operative antibiotics."
89631940|NCT05746520|Other|Restricted Duration of SOC Antibiotic Use|Use of Standard of Care Antibiotics, type as determined by the clinician, will be restricted to none or 24 hours of post-operatively.
89631941|NCT05746520|Active Comparator|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will receive 24 hours of post-operative antibiotics.~Participants undergoing standard of care (SOC) with complicated (gangrenous or perforated) appendicitis will receive 4 days of SOC post-operative antibiotics."
89631942|NCT05746520|Other|Liberal Duration of SOC Antibiotic Use|Use of Standard of Care Antibiotics, type as determined by the clinician, will be permitted for 24 hours or 4 days of post-operatively.
89631943|NCT05742893|Experimental|diagnostic|all patients have the study test
89631944|NCT05733975|Other|Use of Decision Making Tool|Single Arm design, study team will deliver the tool to be used by the parent(s) to help guide them in discussion with their infant's clinicians.
89040579|NCT04655339|Experimental|Group-2|Bilateral abdominal Lap-TAP liposomal Bupivacaine (Exparel®) injection with 133mg (20ml) Exparel® plus bupivacaine 0.25% (30ml), plus 10ml of normal saline for a total volume of 60ml, injecting 30ml each side.
89040580|NCT04655339|No Intervention|Group-3|
89040581|NCT04655105|Experimental|Truanatomy rotary file|use of tru anatomy rotary files root canal instrumentation followed by post operative pain evaluation
89040582|NCT04655105|Experimental|hyflex EDM rotary file|use of hyflex EDM rotary files root canal instrumentation followed by post operative pain evaluation
89040583|NCT04655105|Experimental|edge endo reciprocating rotary file|use of edge endo reciprocating rotary files root canal instrumentation followed by post operative pain evaluation
89631945|NCT05733624|Experimental|SCAI-001 0.01%|Cyclosporine 0.01%
89040584|NCT04655105|Active Comparator|protaper gold rotary file|use of protaper gold rotary files root canal instrumentation followed by post operative pain evaluation
89040585|NCT04655183|Experimental|Part 1A (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight < 77 kilograms (kg) or baseline platelet count < 150, 000 per cubic millimeter will be included in this Part. Dose escalation of M4344 administered along with niraparib.
89040586|NCT04655183|Experimental|Part 1B (Dose escalation): Niraparib plus M4344 once daily|Participants with baseline body weight > =77 kilograms (kg) and baseline platelet count >=150, 000 per cubic millimeter will be included in this Part. M4344 will be administered at a dose and schedule that was determined as the recommended dose for expansion (RDE) in Part 1A. Dose of niraparib will be escalated to the next higher dose level.
89057423|NCT01682733|Experimental|Botulinum toxin at injection site|All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.
89631946|NCT05733624|Experimental|SCAI-001 0.02%|Cyclosporine 0.02%
89631947|NCT05733624|Active Comparator|Restasis|Cyclosporine 0.05%
89631948|NCT05728658|Experimental|ICP-248|ICP-248 was divided into 6 dose groups, and each dose group was given progressively
89631949|NCT05718245|Experimental|HEPA first and sham|This group of participants will be assigned an intervention of HEPA filters with the capacity to reduce PM2.5 levels at their residence for 6 months. After 6-month wash-out period, will be assigned to sham filters for 6 months.
89211563|NCT00625742|Experimental|Multimodal Treatment Strategy|Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.
89211564|NCT00834314|Experimental|Vacuum-pack|see Interventions
89211565|NCT00834314|Active Comparator|Abdominal dressing|see Interventions
89211566|NCT05589441|Experimental|Nebulized inhalation of salbutamol group|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
89211567|NCT05589441|Experimental|Insulin complex glucose group|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
89631950|NCT05718245|Sham Comparator|Sham first and HEPA|This group of participants will be assigned an intervention of sham filters without the capacity to reduce PM2.5 levels at their residence for 6 months. After 6-month wash-out period, will be assigned to HEPA filters for 6 months.
89631951|NCT05705622|Experimental|Experimental intervention group|"Sociodemographic information, comorbidity, habits and disease information of the patients included in the experimental group were obtained through the Patient Diagnosis Form and recorded in the form. The patients were evaluated for oral mucositis by diagnosing the mouth. It was recorded in the World Health Organization Mucositis Evaluation Form, Oral Mucositis Risk Assessment Scale in Hematology Patients, Oral Mucous Membrane Evaluation and Follow-up Form. After the diagnosis of oral mucositis was made, a pre-test was performed using the Oral Mucositis Knowledge Level Evaluation Form to measure the oral mucositis knowledge level of the patients. Later, the patients included in the experimental group were given training on the evaluation, prevention, care and treatment of oral mucositis, and a training booklet was given for the benefit of the patients."
89631952|NCT05705622|No Intervention|No intervention control group|The first follow-up of the patients included in the control group was made in the patient's room on the day of their admission to the bone marrow transplant unit. Sociodemographic information, comorbidity, habits and disease information of the patients were obtained through the Patient Diagnosis Form and recorded in the form. The patients were evaluated for oral mucositis by diagnosing the mouth. It was recorded in the World Health Organization Mucositis Evaluation Form, Oral Mucositis Risk Assessment Scale in Hematology Patients, Oral Mucous Membrane Evaluation and Follow-up Form. The patients in the control group were not given training on oral mucositis and the training booklet prepared by the researcher was not given.
89631953|NCT05701345|Experimental|medical device used group|Wearable visual device(HMD)-VR-based software medical device(OMNIFIT DTx-MDD)
89631954|NCT05701345|Placebo Comparator|medical device unused group|Patients receiving only standard treatment
89631955|NCT05698329|Experimental|AIV007 low dose|Periocular injection, low dose
89631956|NCT05698329|Experimental|AIV007 intermediate dose 1|Periocular injection, intermediate dose 1
89631957|NCT05698329|Experimental|AIV007 intermediate dose 2|Periocular injection, intermediate dose 2
89631958|NCT05698329|Experimental|AIV007 intermediate dose 3|Periocular injection, intermediate dose 3
89631959|NCT05698329|Experimental|AIV007 High dose|Periocular injection, high dose
89631960|NCT05690776||Patients who received the Quattro X BroadBand|No specific interventions will be administered.
89631961|NCT05688982|Other|A--general information|Patients in Arm A will receive paper handouts with general oral health and aSDoH resources
89631962|NCT05688982|Other|B--geographic information|Patients in Arm B will receive paper handouts with geographically-proximate oral health and aSDoH resources.
89631963|NCT05688982|Other|C--geographic information and navigational assistance|Patients in Arm C will receive geographically-proximate oral health and aSDoH resources plus active navigational assistance.
89631964|NCT05675371||1a - Typically developing (ages 16-30 months)|Typically developing toddlers ages 16 - 30 months (chronological age).
89631965|NCT05675371||1a - ASD/DD (ages 16-30 months)|Toddlers ages 16-30 months with autism spectrum disorder and/or related developmental delay who are undergoing applied behavioral analysis (ABA) or related therapies.
89631966|NCT05675371||1b - Typically developing (ages 31-84 months)|Typically developing children ages 31-84 months (chronological age).
89631967|NCT05675371||1b - ASD/DD (ages 31-84 months)|Children ages 31-84 months with autism spectrum disorder and/or related developmental delay who are undergoing applied behavioral analysis (ABA) or related therapies.
89631968|NCT05669430|Experimental|Part A - Dose Escalation|Part A involves a 3 + 3 dose escalation scheme to evaluate safety and dose limiting toxicities and to establish the maximum tolerated dose and/or the recommended Phase 2 dose of GV20-0251.
89631969|NCT05669430|Experimental|Part B - Multiple Expansion Cohorts|Part B consists of multiple expansion cohorts in which eligible participants will be treated at the recommended Phase 2 dose of GV20-0251 to further characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of GV20-0251 as well as to evaluate anti-tumor activity in participants with selected malignancies.
89631970|NCT05661331||Ascites|N = A target of 88 treated patients and thereof, a maximum of ~10 subjects with a pre-TIPS LVP frequency ≥ 2 LVP per month
89211568|NCT00825188|Active Comparator|eplerenone|
89211569|NCT00825188|Active Comparator|amlodipine|Amlodipine 5-10mg daily times 8 weeks
89211570|NCT00834392|No Intervention|Control|
89211571|NCT00834392|Experimental|Exercise|
89211572|NCT00834470|Experimental|Atropine|Atropine 0.01mg/kg IV
89211573|NCT00834470|Placebo Comparator|Normal saline|Same volume of atropine
89211574|NCT03997864|Active Comparator|Treatment - prazosin|Participants randomized to this group will receive the medication prazosin.
89211575|NCT03997864|Placebo Comparator|Control - placebo|Participants randomized to this group will receive placebo .
89211576|NCT05407467|No Intervention|Control Group|There is no additional intervention other than subject's standard diabetes treatment
89211577|NCT05407467|Experimental|Interventional Group|This group will received additional supplementation of curcumin and virgin coconut oil aside from their standard treatment
89211578|NCT04043468|Experimental|Improved A&F intervention|Two feedback sessions and four structured focus groups
89211579|NCT04043468|Active Comparator|Standard A&F intervention|Two feedback sessions
89211580|NCT01010152|Experimental|Codeine Sulfate|30 mg tablet
89211581|NCT01010152|Active Comparator|Tylenol #3|30 mg tablet
89211582|NCT00834548||1|WB-MRA standard protocol
89211583|NCT00834548||2|WB-MRA hybrid protocol
89211584|NCT05589129|Experimental|Whey Protein Supplement|Whey protein will come in powder form and will consist of 20g of protein, and 25.3g of product. We will use Optimum Nutrition Double Chocolate Whey Protein Isolate.
89211585|NCT05589129|Placebo Comparator|Carbohydrate Control|Carbohydrate control will come in powder form and will consist of 20g of carbohydrate and 21.6g of product. We will use Nesquick Chocolate Powder mix.
89211586|NCT00839774|Experimental|1|Whole yellow pea flour
89211587|NCT00839774|Experimental|2|Fractionated yellow pea flour
89211588|NCT00839774|Experimental|3|White wheat flour
89211589|NCT02549846|Active Comparator|Acute Group|Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission
89631971|NCT05661331||Variceal bleeding|N = At least 88 treated patients and thereof, a maximum of ~10 subjects enrolled with Child-Pugh class C
89631972|NCT05661331||Other Primary Indication|Portal vein obstruction or thrombosis, pre-operative TIPS, hepatorenal Syndrome Type 1, hepatorenal Syndrome Type 2, other) N = Approximately 20 treated patients
89631973|NCT05660070|Experimental|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
89631974|NCT05645029|Experimental|glass ionomer-chlorhexidine|
89631975|NCT05645029|Experimental|glass ionomer -titanium dioxide powder.|
89631976|NCT05645029|Active Comparator|glass ionomer|
89631977|NCT05636852|Experimental|Altropane (123I) Injection|
89631978|NCT05633706||Healthy|Not belonging to the other cohorts as described below.
89631979|NCT05633706||Irritable Bowel Syndrome|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
89211590|NCT02549846|Other|Stable Group|Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.
89211591|NCT01888653|Placebo Comparator|Comparison-Training-Program|Placebo-training program: attention control training (ACT), is identical to the ABM protocol except that during the presentation of the trials where a threat word is presented, the probe will appear with equal frequency in the position of the threat and neutral word. Thus, neither threat nor neutral words provide information regarding the position of the target probe, and there is no contingency between the position of either threat or neutral words, and the position of the probes
89631980|NCT05633706||Crohns Disease|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
89631981|NCT05633706||Ulcerative Colitis|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
89631982|NCT05633706||Celiac Disease|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
89631983|NCT05633706||Functional Dyspepsia|As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
89631984|NCT05630482|Experimental|Healthy Family Foundations Intervention|Participants randomized to the HFF intervention condition will participate in 10 weekly 2 hour classes (5 prenatal and 5 postnatal) in groups of 5-10 couples. Due to COVID, all classes will take place via Zoom. The classes will be led by male/female facilitator teams. The facilitators will be hired, trained and supervised by Penn State. Postnatal classes will occur 2-8 months after birth and will also be weekly and last 2 hours each.
89631985|NCT05630482|Active Comparator|Control Condition|Participants randomized to the control condition will receive standard of care and opportunities for education at their site, including information about infant growth and development, infant care (including brief, standard information regarding breastfeeding/introduction to solid food), and quality childcare selection.
89631986|NCT05612594|Experimental|Bexagliflozin|Bexagliflozin once daily for 6 months
89631987|NCT05612594|Placebo Comparator|Placebo|Placebo once daily for 6 months
89631988|NCT05605054|Experimental|Coach-guided|In person or phone call with an assigned Health Coach for about 1 hour per week for 12 weeks to complete the Health Literacy course, and with an assigned Service Navigator for 30 minutes per week for 12 weeks to address health and social service needs.
89631989|NCT05605054|Active Comparator|Self study|Self-guided printed or online version of the Health Literacy course (approximately 1 hour per week for 12 weeks) and comprehensive Service Navigation report with recommended referrals to services, providers, and contact information for service providers so that the participant can access these resources independently (i.e., without Navigator assistance).
89211592|NCT01888653|Active Comparator|Attention Biased Modification|Attention-bias-modification treatment (ABM) is designed to implicitly modify patients' biased threat attendance via computerized training protocols. During each session, 240 trials (80 neutral-neutral pairs, 160 threat-neutral pairs) will be presented. On trials where participants see one neutral word and one threat word, the probe will always follow the neutral word location. Thus, although there is no specific instruction to direct attention away from threat words, on 66% of all trials (and 100% of the threat-neutral trials) the position of the neutral word will indicate the position of the target probe.
89211593|NCT00840008|Experimental|Educational intervention|see protocol
89211594|NCT00840008|No Intervention|Standard care|distribution of guidelines and a published algorithm
89211595|NCT05407155|Experimental|Experimental arm|Patients received bevacizumab plus nab-paclitaxel and platinum as second-line therapy.
89211596|NCT05358093||45|
89211597|NCT00840242|Experimental|Nicotine gum|Nicotine gum
89211598|NCT00840242|Placebo Comparator|Placebo gum|Placebo gum
89211599|NCT00840242|Active Comparator|Nicotine inhaler|Nicotine inhaler
89211600|NCT00840242|Placebo Comparator|Placebo inhaler|Placebo inhaler
89211601|NCT00621296|Experimental|MP-424|
89211602|NCT00840320|Experimental|1|Repeat doses of active at escalating doses
89211603|NCT00840320|Placebo Comparator|2|Repeat doses of placebo
89211604|NCT00840398|Experimental|1|
89211605|NCT00840398|Active Comparator|2|
89211606|NCT00537303|Experimental|Advanced|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
89631990|NCT05601453||redo-TAVI patients|Patients with severe aortic stenosis (sAS) treated with TAVI developing SVD and thus an indication for redo-TAVI procedure
89631991|NCT05591742|Placebo Comparator|placebo|As it is blinded, no one knows which arm participants enter. After 3 months the other arm is entered.
89631992|NCT05591742|Active Comparator|Femidur|As it is blinded, no one knows which arm participants enter. After 3 months the other arm is entered.
89631993|NCT05585619||Chronic pain patients|New chronic pain consults seen by a trainee and attending pain physician
89631994|NCT05583526|Experimental|Ritlecitinib 50 mg|Ritlecitinib 50 mg QD (ritilecitinib 50 mg QD arm; approximately 400 participants)
89631995|NCT05583526|Placebo Comparator|Placebo|Placebo (placebo arm; approximately 200 participants)
89631996|NCT05577507|Active Comparator|Test group|"Group 1:~(cholestyramine 12 gram), 40 patients will take a dose of cholestyramine 4-gram sachet in 150-200 ml water or juice three times daily within meals as an add-on therapy with standard therapy calcium-based phosphate binder (Calcimate).~Dosage: one sachet on 150 ml water three times daily duration : 8 weeks"
89631997|NCT05577507|Placebo Comparator|Control group|Group 2: Control group, 40 patients will take only the standard therapy calcium-based phosphate binder (Calcimate).
89631998|NCT05574946|Experimental|All-inside technique|Both of the femoral and tibial tunnel will be drilled in a retrograde manner using flip-cutter and femoral and tibial sockets will be created. Graft will be passed from the portal. Adjustable suspensory cortical fixation both on tibial and femoral side will be used.
89631999|NCT05574946|Active Comparator|Complete tibial tunnel technique|Femoral tunnel will be drilled in an inside-outside manner using standard technique. Then the tibial tunnel will be drilled completely. Graft will be passed from the tibial tunnel. Adjustable suspensory cortical fixation both on the tibial and femoral side will be used.
89040587|NCT04655183|Experimental|Part 2 (Dose expansion): PARPi resistant, Niraparib plus M4344|Participants with Poly(ADP-ribose) polymerase inhibitor (PARPi) resistant, germline breast cancer 1/2 mutated (gBRCA1/2m) human epidermal growth factor receptor 2 (HER2) negative advanced Breast Cancer (aBC) will receive the combination of niraparib and M4344 at the RDE which was determined in Part 1.
89040588|NCT04655183|Experimental|Part 3 (Dose expansion): PARPi-naive, Niraparib|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive niraparib as a single agent.
89040589|NCT04655183|Experimental|Part 3 (Dose expansion): PARPi-naive, Niraparib plus M4344|Participants with PARPi-naive germline BRCA1/2 wild type (gBRCAwt) homologous recombination repair gene mutated (HRRm) advanced breast cancer (aBC) will be randomized to receive the combination of niraparib and M4344 at the RDE as determined in Part 1 of this study.
89040590|NCT00541710|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
89040591|NCT00541710|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
89040592|NCT04654871|Experimental|Experimental Group|
89040593|NCT04654871|Experimental|Active Comparator Group|
89040594|NCT04654793|Experimental|Intervention group|Robot assisted inclined bed treatment and FES
89040595|NCT04654793|Active Comparator|Control group|conventional inclined bed treatment
89040596|NCT04654520|Experimental|Drug therapy combined with radiotherapy for primary tumor omitted CTV|"IMRT (omitted CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.~IMRT (omitted CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
89040597|NCT04654520|No Intervention|Drug therapy combined with radiotherapy for primary tumor with CTV|"IMRT (with CTV) concurrent with systemic chemotherapy on paticipants of kown negative gene mutation .After it, the paticipants may choose immunotherapy.~IMRT ((with CTV) concurrent with targeted drug on paticipants of kown sensitive gene mutation."
89040598|NCT00541788|Experimental|1|Administration of Common Sage
89040599|NCT04654598|Other|BPA level|BPA (bisphenol A) in urine, blood and follicle fluid samples
89040600|NCT02731716|Experimental|New Payment Model|Providers in the first arm will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level.
89040601|NCT02731716|Experimental|Social Comparisons|Providers will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care.
89632000|NCT05568927||Post-pulmonary embolism patients|"Consecutive patients who, during the study period, underwent the SEARCH algorithm to a diagnostic endpoint at one of the UCAPE network of outpatient pulmonary embolism clinics (UC San Diego, UC Irvine, UC Los Angeles-Harbor, UC Los Angeles, UC Riverside, UC Davis, UC San Francisco or UC San Francisco-Fresno) three months or more after the occurrence of acute pulmonary embolism or any risk type.~The SEARCH algorithm is the standard of care throughout the UCAPE network, so the experimental portion of this study is limited to the reporting of the (de-identified) results to the evaluation group and the analyses described in Aims 1 and 2. However, there may be patients who are lost to follow up or have other reasons for which the SEARCH algorithm is not followed. Those patients will not be included in the study. The numbers of such patients will be recorded at each center."
89632001|NCT05557110|Experimental|reduced-intensity chemotherapy followed by berintuzumab|"Induction therapy was performed with reduced intensity chemotherapy (including 1 dose of Idarubicin 8 mg/m2, 1 dose of Vindesine 3 mg/m2, and 7 days of Dexamethasone 9 mg/m2/d) followed by 2 weeks of Blinatumomab (9 ug/d d8-14, 28 ug/d d15-21) immediately. Bone marrow evaluation was performed on day 22±2, and consolidation therapy was performed after achieving bone marrow remission (CR/CRh/CRi). If CR/CRh/CRi was not achieved in the first course of induction therapy, Blinatumomab (28ug/d×14d) should be continued and bone marrow evaluation should be evaluated again.~The regimen of consolidation therapy is recommended as multidrug combination chemotherapy (including high-dose Methotrexate or Cytarabine combined with Asparaginase) or alternating with Blinatumomab (28 ug/d×28d). If Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) is not performed, consolidation therapy needs at least 4 courses before 2 years maintenance therapy."
89632002|NCT05555290|Experimental|Treatment A (PT027) [experimental], then Treatment B (PT007) [active comparator] Part 1 & 2|At Visit 2, participants will receive repeated oral inhalations of PT027 to treat acute airway obstruction induced by a repeated airway challenge, followed by a washout period of 10-14 days. At Visit 3, participants will receive repeated oral inhalations of PT007 to treat acute airway obstruction induced by a repeated airway challenge.
89632003|NCT05555290|Experimental|Treatment B (PT007) [active comparator], then Treatment A (PT027) [experimental] Part 1 & 2|At Visit 2, participants will receive repeated oral inhalations of PT007 to treat acute airway obstruction induced by a repeated airway challenge, followed by a washout period of 10 to 14 days. At Visit 3, participants will receive repeated oral inhalations of PT027 to treat acute airway obstruction induced by a repeated airway challenge.
89632004|NCT05547321|Experimental|Monotherapy (OMTX705)|OMTX705 is administered as single agent.
89632005|NCT05547321|Experimental|Combination (OMTX705 + pembrolizumab)|OMTX705 is administered in combination with pembrolizumab.
89632006|NCT05535855|Experimental|UCD19 CAR T Infusion|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T cells. Infusion is subject to a seven (7) day delay following chemotherapy completion if needed for resolution of clinical toxicities or to allow for product release.
89632007|NCT05532735|Experimental|2 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 2 mg daily during five days.
89632008|NCT05532735|Experimental|4 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 4 mg daily during five days.
89632009|NCT05532735|Experimental|1 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 1 mg daily during five days.
89632010|NCT05532735|Experimental|6 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 6 mg daily during five days.
89632011|NCT05532735|Experimental|8 mg ANXV|ANXV (human recombinant Annexin A5), infusion, 8 mg daily during five days.
89632012|NCT05526300|Active Comparator|The standard care group|
89632013|NCT05526300|Experimental|Intelligent intervention group|
89632014|NCT05500534|Experimental|RevoLix HTL+|Laser lithotripsy using the RevoLix HTL+ with active stone recognition
89632015|NCT05500534|Other|Historic control group|Laser lithotripsy without active stone recognition
89632016|NCT05497778|Experimental|Dose Escalation Phase followed by a Dose Expansion Phase|In the Dose Escalation Phase of the study, we will identify the RPD2 of IM156. Subsequently, we will evaluate IM156 at the RP2D (established in the Dose Expansion Phase) and gemcitabine + nab-paclitaxel in the Dose Expansion Phase.
89632017|NCT05496829|Experimental|Adherence Intervention|Multicomponent Adherence Intervention
89632018|NCT05496829|Other|Usual Care|Usual Care from treating providers
89632019|NCT05486234|Experimental|Group A: Treatment Group|
89632020|NCT05486234|Sham Comparator|Group B: Control Group|
89632021|NCT05481593|Experimental|Scheduled Coaching Calls & Gamified Rewards|
89632022|NCT05481593|Experimental|No Scheduled Coaching Call & Gamified Rewards|
89632023|NCT05481593|Experimental|Scheduled Coaching Calls & Independent rewards (No Gamification)|
89632024|NCT05481593|Experimental|No Scheduled Coaching Calls & Independent Rewards (No Gamification)|
89632025|NCT05480462|Experimental|Clodivac|
89632026|NCT05480462|Active Comparator|Td-Impfstoff Merieux|
89632027|NCT05479422||Treatment of stricture of the anterior urethra with optilume DCB|Standard of care treatment of stricture of the anterior urethra using the Optilume Drug Coated Balloon.
89632028|NCT05478018|Experimental|Exercise|"The patients will be randomized to 12-week supervised exercise training intervention or no exercise training. The exercise training program includes three supervised sessions per week over a 12-week period.~The program consists of high intensity endurance training on ergometer bicycles. The intensity will progress throughout the 12 weeks of training. The training consists of 10 minutes of warm up at 40-60% maximum heart rate (HRmax), followed by 25 minutes of high intensity interval training (4 bouts of 4 min at >85% HRmax interspaced by 3 minutes of low intensity training at 40-60% Hrmax) and finally a 3-10 min cool-down of 50% Hrmax"
89632029|NCT05478018|No Intervention|Non-Exercise|Control group, therefore no supervised exercise regime. Subjects are asked to not increase habitual exercise routines.
89632030|NCT05470621|Experimental|Playground Curriculum Arm|Staff (after-school staff, recess aides, and physical education teachers) receive training to implement a playground curriculum in an after-school program; children receive a training to use the curriculum during recess
89632031|NCT05470621|No Intervention|Program As Usual|Staff and students receive no training and participate in after-school programs and recess as usual
89632032|NCT05460832|Placebo Comparator|Placebo|
89632033|NCT05460832|Experimental|MBS2320 5 mg|
89632034|NCT05460832|Experimental|MBS2320 20 mg|
89632035|NCT05460832|Experimental|MBS2320 40 mg|
89632036|NCT05450380|Experimental|Experimental: LIFT001|"LIFT001 is composed by sodium hyaluronate at concentration of 2,5% (25 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent, in aqueous solution at physiological pH. The filler of 1ml is administered once or twice depending on the individual necessity.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
89632037|NCT05423262|Experimental|Part 1 : TRK-950|"Solid Tumor~TRK-950 will be administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle. Two dose levels will be explored during this Arm."
89632038|NCT05423262|Experimental|Part 2 Cohort 1: TRK-950+Nivolumab|"Nivolumab-eligible solid tumor~Nivolumab will be administered intravenously on days 1 and 15 of a 28-day cycle. TRK-950 will be administered as an intravenously infusion on days 1, 8, 15 and 22. After the administration of Nivolumab on days 1 and 15, TRK-950 will be administered as an intravenously infusion."
89632039|NCT05423262|Experimental|Part 2 Cohort 2: TRK-950+Nivolumab|"Nivolumab-eligible solid tumor~Nivolumab will be administered intravenously on days 1 and 15 of a 28-day cycle. TRK-950 will be administered as an intravenously infusion on days 1 and 15. After the administration of Nivolumab on days 1 and 15, TRK-950 will be administered as an intravenously infusion."
89040602|NCT02731716|Experimental|A1c Member/Provider Incentive|Providers will no longer be paid based upon FFS, but on the new payment model, which includes a PMPM payment for attributed members, a quality incentive payment based upon attainment of quality metrics, and a possible bonus payment for savings in total cost of care. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care. There is also a shared incentive between the member and the provider. The member incentive will be a payment made to diabetic patients with an A1C of greater than or equal to 9% who experience a reduction of at least 0.5%. Each participating member and PCP can receive up to $75 per quarter for A1C reduction.
89040603|NCT04654481|Active Comparator|Standard Care Plus Monitoring|All subjects will be monitored via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
89040604|NCT04654481|Experimental|Standard Care Plus Monitoring and HCFWO|In addition to home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments, subject will receive an Afflovest device for home use.
89040605|NCT04654637|Experimental|Arm A|fix model of cycle exercise(online supervise) and routine nutrition consult
89040606|NCT04654637|Experimental|Arm B|fix model of cycle exercise(online supervise) and online nutrition consult
89040607|NCT04654637|Experimental|Arm C|individualize cycle exercise(online supervise) and routine nutrition consult
89040608|NCT04654637|Experimental|Arm D|individualize cycle exercise(online supervise) and online nutrition consult
89040609|NCT00541905|Experimental|NT 201 (50-300 Units)|"NT 201 (Xeomin®, also know as IncobotulinumtoxinA or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
89040610|NCT04654403|Experimental|Camrelizumab|Camrelizumab (200 mg every 2 weeks),Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years)
89040611|NCT04654403|Active Comparator|Camrelizumab plus chemotherapy|Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
89040612|NCT00541983|Active Comparator|1|
89632040|NCT05399004||Observational (survey)|Patients complete surveys over 15-20 minutes at baseline and at 3, 6, and 12 months.
89632041|NCT05397067|Experimental|Peer specialist and Vouchers|Intervention arm
89040613|NCT00541983|Placebo Comparator|2|
89632042|NCT05397067|No Intervention|Standard of care|
89632043|NCT05395624|Experimental|Healthy Volunteer participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
89632044|NCT05395624|Experimental|Amyotrophic Lateral Sclerosis participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
89632045|NCT05395624|Experimental|Alzheimer's Disease participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
89632046|NCT05395624|Experimental|Multiple Sclerosis participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
89632047|NCT05395624|Experimental|Parkinson's Disease participants|Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
89632048|NCT05386576|Experimental|Venetoclax in Combination With Chemotherapy|All patients will complete Induction I and II of the treatment regimens, consisting of several chemotherapy agents including Peg-ASP.
89040614|NCT01205776|Active Comparator|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
89040615|NCT01205776|Active Comparator|Coronary Artery Bypass Graft|Those patients receiving CABG
89040616|NCT04654715||Localized prostate cancer treatment induced rectourethral fistula|Every patient over 18 years old operated for closure of a rectourethral fistula with gracilis flap interposition after localized prostatic cancer treatment (Radiotherapy, surgery, cryotherapy and HIFU).
89040617|NCT04654442||Cases|30 cases will be recruited : Patient diagnosed by RT-PCR for a COVID19 at Grenoble University Hospital
89040618|NCT04654442||Controls|30 controls will be recruited : Patient suspected for a COVID-19 but negative by RT-PCR for a COVID19 at Grenoble University Hospital
89040619|NCT00542061|Experimental|A|Device: monitoring services
89040620|NCT00542061|No Intervention|B|Control group: no monitoring procedures
89040621|NCT01205581|Active Comparator|Leukemia-HD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
89632049|NCT05385926|Experimental|RT group|
89632050|NCT05380544|Sham Comparator|Sham shockwave therapy|Sham shockwave therapy in standard ulcer care.
89632051|NCT05380544|Active Comparator|Low dose shockwave therapy|100 shocks per cm2 plus standard ulcer care
88990717|NCT06181084|Experimental|Group 3: Potential of Hydrogen (pH) Effect Fasted Group|"Treatment B: LY3410738 table on Day 1 as a single oral dose in the morning following a fast of at least 10 hours prior to and 4 hours after dosing.~Treatment D: Esomeprazole single oral dose once daily (QD) in the morning on Days 4 through 8 in fasted state followed by a standard low-fat meal. On Day 9, Esomeprazole a single oral dose followed by LY3410738 tablet as a single oral dose in the morning, following a fast of at least 10 hours prior to and 4 hours after esomeprazole and LY3410738 coadministration."
88990718|NCT06181084|Experimental|Group 4: pH Effect Fed Group|"Treatment C: LY3410738 table on Day 1 as a single oral dose in the morning 30 minutes after starting a standard low-fat meal.~Treatment E: Esomeprazole as a single oral dose QD in the morning on Days 4 through 8, in fasted state followed by a standard low-fat meal. On Day 9, Esomeprazole as a single oral dose followed by a LY3410738 tablet in the morning in fed state standard low-fat meal."
88990719|NCT06181071|Other|Distal Fatigue of The Lower Extremity|Distal muscle fatigue of the lower extremity involves the plantar and dorsiflexor muscles of the ankle.
88990720|NCT06181071|Other|Proximal Fatigue of The Lower Extremity|Proximal muscle fatigue of the lower extremity involves hip flexor and extansor muscles.
88990721|NCT06181045|Experimental|Cohort 1 (Treatment A): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule formulation.
88990722|NCT06181045|Placebo Comparator|Cohort 2 (Treatment B): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule formulation.
88990723|NCT06181045|Experimental|Cohort 3 (Treatment C): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
88990724|NCT06181045|Experimental|Cohort 4 (Treatment D): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
88990725|NCT06181045|Experimental|Cohort 5 (Treatment E): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
88990726|NCT06181045|Experimental|Cohort 6 (Treatment F): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
88990727|NCT06181045|Experimental|Cohort 7 (Treatment G): LY3410738|Single oral dose of LY3410738 or placebo administered as over-encapsulated capsule or tablet formulation.
88990728|NCT06181019|Active Comparator|Be treated with mirabegron.|Patients were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.
88990729|NCT06181019|Experimental|Be treated with acupuncture combined with mirabegron.|Patients were treated with acupuncture combined with mirabegron.
88990730|NCT06181006|Experimental|Cohort 1 (Treatment A): Pirtobrutinib|A single oral dose of pirtobrutinib will be administered.
88990731|NCT06181006|Experimental|Cohort 2 (Treatment B): Pirtobrutinib|A single oral dose of pirtobrutinib will be administered.
88990732|NCT06181006|Experimental|Cohort 3 (Treatment C): Pirtobrutinib|A single oral dose of pirtobrutinib will be administered.
88990733|NCT06180993||At birth cohort|Subjects born from September 25, 2023 to March 31 in each of the 3 RSV seasons under study 2023/2024, 2024/2025, 2025/2026
88990734|NCT06180993||Risk Cohort|Subjects with risk factors born between 1 October 2021 and 31 March 2023
88990735|NCT06180993||Catch-up cohort|Subjects born between 1 April and 24 September 2023
88990736|NCT06180980|Experimental|Pirtobrutinib (Fasting condition)|A single oral dose of pirtobrutinib will be administered under fasted conditions.
88990737|NCT06180980|Experimental|Pirtobrutinib (High-fat breakfast)|"A single oral dose of pirtobrutinib will be administered under fed conditions.~There will be a washout period of 7 days between fasted and fed conditions."
88990738|NCT06180967|Experimental|Midazolam (Intravenous [IV] Bolus)|A single IV bolus dose of midazolam will be administered in the morning following a 10-hour fast prior to dosing and a 4-hour fast postdose on Day 1 and Day 15.
89632052|NCT05380544|Active Comparator|High dose shockwave therapy|500 shocks per cm2 plus standard ulcer care
89632053|NCT05376462|Experimental|Quantra System with the QStat Cartridge|Decisions regarding transfusion of blood products will be made based on information derived from the Quantra System with the QStat Cartridge.
89632054|NCT05376462|Active Comparator|Standard Laboratory Coagulation Testing|Decisions regarding transfusion of blood products will be made based on the site's standard of care which is information derived from standard laboratory coagulation tests.
89632055|NCT05370469|Experimental|Cohort A|Subjects who, at enrollment, have been on a TKI for less than 4 weeks will be monitored with the Sensus smartphone application, Fitbit Sense, RX Cap, and paper surveys. Visits will be at: Screening, Baseline, 1 Week, 2 Weeks, 4 Weeks, 8 Weeks, 16 weeks, and 24 weeks.
89632056|NCT05370469|Experimental|Cohort B|Subjects who, at enrollment, have been on a TKI for 4 weeks or more will be monitored with the Sensus smartphone application, Fitbit Sense, RX Cap, and paper surveys. Visits will be at: Screening, Baseline, Week 1, and then every 8 weeks for 24 weeks.
89632057|NCT05368246|Experimental|Interventional arm|Electrical stimulation to the dorsal genital nerve.
89632058|NCT05359835|Experimental|Chelation with open-label Ca-DTPA and Zn-DTPA|Six chelation treatments utilizing Ca-DTPA on day 1 and Zn-DTPA on day 2. Paired, 2-chelation day treatments will take place at intervals of one week or more.
89632059|NCT05351112||Patients who received the Anatomical Shoulder 2.0 Fracture|Anatomical Shoulder 2.0 Fracture
89632060|NCT05347485|Experimental|Ciltacabtagene Autoleucel (Cilta-cel)|Eligible participants will receive bridging therapy (that is, anti-plasma cell directed treatment) based on participant's clinical status and timing of availability of cilta-cel (JNJ-68284528) along with lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square [mg/m^2] intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants will receive a single IV infusion of cilta-cel (JNJ-68284528) at a total targeted dose of 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg).
89632061|NCT05342077|Experimental|Virtual Reality-Reward Training (VR-RT)|7 sessions of positive VR immersion and positive memory specificity training exercises designed to savor rewarding features of immersion followed by memory specificity training exercises to savor rewarding features of autobiographical memory.
89632062|NCT05342077|Active Comparator|Virtual Reality-Memory Training (VR-MT)|7 sessions of neutral VR immersion and neutral memory specificity training exercises, designed to train memory of objective non-emotional stimuli followed by memory exercises to neutral autobiographical memories.
89632063|NCT05327816|Experimental|Arm 1a: Respiratory Syncytial Virus (RSV) preFusion (preF) Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in cohort (C) 1 (Group [G] 1) and C 2 through intramuscular injection on Day 1.
89632064|NCT05327816|Experimental|Arm 1b: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 1-4) and C 2 through intramuscular injection on Day 1.
89632065|NCT05327816|Experimental|Arm 1c: Placebo|Participants will receive single dose of placebo in C 1 (G 1-4) and C 2 through intramuscular injection on Day 1.
89632066|NCT05327816|Experimental|Arm 2: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
89632067|NCT05327816|Experimental|Arm 3: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
89632068|NCT05327816|Experimental|Arm 4: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
89632069|NCT05327816|Experimental|Arm 5: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
89632070|NCT05327816|Experimental|Arm 6: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 2) and C 2 through intramuscular injection on Day 1.
89632071|NCT05327816|Experimental|Arm 7: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 3) and C 2 through intramuscular injection on Day 1.
89632072|NCT05327816|Experimental|Arm 8: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 3) and C 2 through intramuscular injection on Day 1.
89632073|NCT05327816|Experimental|Arm 9: RSV preF Based Vaccine|Participants will receive single dose of mixture of RSV preF-based vaccine in C 1 (G 4) and C 2 through intramuscular injection on Day 1.
89632074|NCT05327816|Experimental|Arm 10: RSV preF Based Vaccine|Participants will receive a single dose of selected formulation (based on C 1 and 2 results) in C 3 through intramuscular injection on Day 1.
89040622|NCT01205581|Active Comparator|Leukemia-SD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
89040623|NCT01205581|Active Comparator|Solid Tumor-HD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
89040624|NCT01205581|Active Comparator|Solid Tumor-SD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
89040625|NCT01205581|Active Comparator|HIV-HD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
89040626|NCT01205581|Active Comparator|HIV-SD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
89040627|NCT00557648|Experimental|1|CBT for children only
89040628|NCT00557648|Experimental|2|CBT for children with parental involvement
89040629|NCT00557648|No Intervention|3|No intervention control group: families free to seek treatment on their own
89040630|NCT00542100|Experimental|1|
89040631|NCT00542100|Experimental|2|
89632075|NCT05327816|Experimental|Arm 11a: RSV preF Based Vaccine and Placebo|Participants in C 3 will receive a single dose of first vaccination with selected formulation (as per data C1 and 2) plus placebo on Day 1 and re-vaccination with selected formulation whenever revaccination would be needed through intramuscular injection.
89632076|NCT05327816|Experimental|Arm 11b: RSV preF Based Vaccine and Placebo|Participants in C 3 will receive a single dose of first vaccination with selected formulation (as per data from C 1 and 2) plus placebo on Day 1 and re-vaccination with placebo whenever revaccination would be needed through intramuscular injection.
89632077|NCT05327816|Experimental|Arm 12: RSV preF Based Vaccine and Placebo|Participants in C 3 will receive first vaccination with placebo on Day 1 and re-vaccination with selected formulation (as per data from C 1 and 2) whenever revaccination would be needed through intramuscular injection.
89632078|NCT05327816|Experimental|Arm 13: RSV preF Based Vaccine|Participants in C 3 will receive the mixture of RSV preF-based vaccine plus placebo on Day 1 through intramuscular injection.
89632079|NCT05327816|Experimental|Arm 14: RSV preF Based Vaccine|Participants in C 4 will receive first vaccination with selected formulation (as per data from C 1 and 2) on Day 1 and re-vaccination with selected formulation whenever revaccination would be needed through intramuscular injection.
89632080|NCT05327816|Experimental|Arm 15: RSV preF Based Vaccine and Placebo|Participants in C 4 will receive first vaccination with selected formulation (as per data from C 1 and 2) on Day 1 and re-vaccination with placebo whenever revaccination would be needed through intramuscular injection.
89632081|NCT05327816|Experimental|Arm 16: RSV preF Based Vaccine and Placebo|Participants in C 4 will receive first vaccination with placebo on Day 1 and re-vaccination with selected formulation (as per data from C 1 and 2) whenever revaccination would be needed through intramuscular injection.
89040632|NCT01205269|Experimental|First 50 mcg, then 200 mcg, then placebo|period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo
89040633|NCT01205269|Experimental|First 50 mcg, then placebo, then 200 mcg|period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg
89040634|NCT01205269|Experimental|First 200 mcg, then placebo, then 50 mcg|period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg
89040635|NCT01205269|Experimental|First 200 mcg, then 50 mcg, then placebo|period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo
89040636|NCT01205269|Experimental|First placebo, then 200 mcg, then 50 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg
89632082|NCT05321251|Experimental|Topical insulin|Topical insulin (Humulin R) will be compounded under sterile conditions at a local pharmacy at a concentration of 25 IU / ml in sterile balanced saline solution (0.9%). Topical insulin will be administered four times per day to the affected eye. A bottle of topical insulin can be used for 14 days. Any remaining topical insulin will be discarded as waste after 14 days.
89632083|NCT05321251|Active Comparator|Tarsorrhaphy|Patients in this group will receive a temporary, central tarsorrhaphy and will not use additional eye drops.
89632084|NCT05297617|Experimental|Aromatase inhibitor|Patient will receive standard endocrine therapy (single agent aromatase inhibitors) for a maximum of 2 years.
89632085|NCT05294952|Experimental|preeclampsiapregnant women|"Inclusion criteria~A total of 41 women in third trimester pregnancy complicated with PE showing:~Blood pressure ≥140/90 mmHg and~Proteinuria ≥300 mg/24 hours with or without~Edema in pregnant woman after week 20 of gestation (American Congress of Obstetricians and Gynecologists (ACOG2013) (17)~B-Exclusion criteria~Patients with autoimmune, acute inflammatory, and chronic diseases, are excluded from the study."
89211607|NCT00537303|Active Comparator|Basic|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
89632086|NCT05294952|No Intervention|normal pregnant women|This will include age matched 41 normal pregnant women in their third trimester of pregnancy with normal blood pressure, absence of proteinuria, and without any other systemic or endocrine disorder.
89632087|NCT05292950|Experimental|ARO-MUC5AC|ARO-MUC5AC Inhalation
89632088|NCT05292950|Placebo Comparator|Placebo|(0.9% NaCl)
89632089|NCT05291754|Other|Cranioplasty PEEK|
89632090|NCT05288816|Experimental|Cohort 1: ALXN1210 400 mg (Single)|A single dose of ALXN1210 was administered intravenously.
89632091|NCT05288816|Experimental|Cohort 2: ALXN1210 800 mg (Single)|A single dose of ALXN1210 was administered intravenously.
89632092|NCT05288816|Experimental|Cohort 3: ALXN1210 800 mg (Multiple)|ALXN1210 (800 mg) was administered intravenously every 4 weeks for a total of 5 doses.
89632093|NCT05288595|Experimental|Pediatric patients with malignant or non-malignant hematologic condition|The infusion of the final TCRαβ/CD19 depleted product will be given through the recipient's central venous catheter and will be administered fresh, without cryopreservation whenever possible. If the product must be cryopreserved and then thawed, this will be done according to institutional standards.
89632094|NCT05279651|Active Comparator|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
89632095|NCT05279651|Placebo Comparator|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
89632096|NCT05274243|Experimental|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
89632097|NCT05274243|Placebo Comparator|Placebo|Matching placebo (provided as three capsules) three times per day for 4 weeks
89632098|NCT05265845|Experimental|Intervention|Interactive text messages that include goal setting, tailored feedback, and skills training.
89632099|NCT05265845|Active Comparator|Control|Text4Baby
89632100|NCT05265247|Experimental|Test Product/Reference Product|Participants will be randomly assigned to receive Esomeprazole 20 mg delayed-release one capsule once daily as oral administration on day 1 of period 1 and will receive Esomeprazole 20 mg delayed-release one capsule (Nexium 24HR) once daily as oral administration on day 1 of period 2. Participants are instructed to consume the entire amount of ambient temperature water (240 milliliter [mL]) along their investigational product. There will be washout period of 7 days between two treatment periods.
89632101|NCT05265247|Experimental|Reference Product/Test Products|Participants will be randomly assigned to receive Esomeprazole 20 mg delayed-release one capsule (Nexium 24HR) once daily as oral administration on day 1 of period 1 and will receive Esomeprazole 20 mg delayed-release one capsule once daily as oral administration on day 1 of period 2. Participants are instructed to consume the entire amount of ambient temperature water (240 milliliter [mL]) along their investigational product. There will be washout period of 7 days between two treatment periods.
89632102|NCT05250466|Experimental|Radiofrequency group|AI Temperature-controlled Radiofrequency Technology
89632103|NCT05250466|Active Comparator|Electrical stimulation group|Electrical Stimulation
89632104|NCT05231421||Low-income smokers|Interested participants will first complete a screening survey asking about their demographic information and checking whether are eligible for this study. If eligible, participants will read a consent statement. Only those who give consent would be allowed to proceed. If participants agree to be in this study, they will continue to participate in the study and schedule a time for focus group discussion.
89632105|NCT05228821|Experimental|Active Drug|Generic Name: Voxelotor Dosage Form: tablet Dosage: 1500mg Frequency: QD Duration: 24 weeks
89632106|NCT05225857|Experimental|AGA2118|"In SAD part, various single doses of AGA2118 will be administered to the participants via either SC injection or IV infusion. The starting dose was 0.3 mg/kg, with sequential escalation up to 15 mg/kg.~In MAD part, various multiple doses of AGA2118 will be administered every four weeks (Q4W) to the participants via SC injection for 12 weeks. The starting dose was 1 mg/kg, with sequential escalation up to 12 mg/kg."
89211608|NCT00840554|Active Comparator|Physical Therapy|
89211609|NCT00840554|Experimental|Home Exercise|
89211610|NCT02548286|Active Comparator|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
89211611|NCT02548286|Experimental|CKD-330|CKD-330 8/5mg, PO, 1day or 22day
89211612|NCT00834704|Other|1|Dose determination
89632107|NCT05225857|Placebo Comparator|Placebo|"In SAD part, a single dose of placebo comparator will be used for each cohort of either SC or IV administration.~In MAD part, multiple doses of placebo comparator will be used for each cohort of SC administration."
89632108|NCT05214118|No Intervention|Brochure|
89632109|NCT05214118|Experimental|Technology-based program|
89632110|NCT05209386|Experimental|Patient Participants|"This single-group study will recruit patients through the PI's clinical practice who are undergoing invasive neurophysiological monitoring (sEEG) with clinically necessary placement of electrodes in the supratemporal plane.~All participants will complete the same behavioral response paradigms."
89632111|NCT05204992|Experimental|Hydrodissection|ultrasound guided hydrodissection
89632112|NCT05202860|Experimental|HPV vaccine|Commercially available nonavalent HPV vaccine (Gardasil(R) 9) given intramuscularly at baseline, month 2 and month 6
89632113|NCT05202860|Placebo Comparator|Isotonic Saltwater Vaccine|0.9% NaCl given intramuscularly at baseline, month 2 and month 6
89632114|NCT05195008|Experimental|Part A [Single Ascending Dose (SAD)]: BIIB113 Cohort 1|Participants aged 18 to 64 years will receive Dose 1 of BIIB113, orally, once daily (QD), on Day 1 of Part A of the study.
89632115|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 2|Participants aged 18 to 64 years will receive Dose 2 of BIIB113, orally, QD, on Day 1 of Part A of the study
89632116|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 3|Participants aged 18 to 64 years will receive Dose 3 of BIIB113, orally, QD, on Day 1 of Part A of the study.
89632117|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 4|Participants aged 18 to 64 years will receive Dose 4 of BIIB113, orally, QD, on Day 1 of Part A of the study.
89632118|NCT05195008|Experimental|Part A (SAD): BIIB113 Cohort 5|Participants aged 18 to 64 years will receive Dose 5 of BIIB113, orally, QD, on Day 1 of Part A of the study
89632119|NCT05195008|Placebo Comparator|Part A (SAD): BIIB113-Matching Placebo (Cohorts 1-5)|Participants aged 18 to 64 years will receive BIIB113-matching placebo, orally, QD, on Day 1 of Part A of the study.
89632120|NCT05195008|Experimental|Part B [Multiple Ascending Dose (MAD)]: BIIB113 Cohort 6|Participants aged 18 to 64 years will receive Dose 3 of BIIB113, orally, QD, up to Day 14 of Part B of the study.
89632121|NCT05195008|Experimental|Part B (MAD): BIIB113 Cohort 7|Participants aged 18 to 64 years will receive Dose 4 of BIIB113, orally, QD, on Days 1 to 14 of Part B of the study.
89632122|NCT05195008|Experimental|Part B (MAD): BIIB113 Cohort 8|Participants aged 18 to 64 years will receive Dose 6 of BIIB113, orally, QD, on Days 1 to 14 of Part B of the study.
89632123|NCT05195008|Placebo Comparator|Part B (MAD): BIIB113 Cohort 9|Participants aged 65 to 75 years will receive BIIB113, orally, QD, on Days 1 to 14 of Part B of the study. The calculated dose level will be adaptive by design based on review of the safety, tolerability, and PK data from Cohorts 1 to 7.
89632124|NCT05195008|Placebo Comparator|Part B (MAD): BIIB113-Matching Placebo (Cohorts 6 to 9)|Participants aged 18 to 75 will receive BIIB113-matching placebo, orally, QD, on Days 1 to 14 of Part B of the study.
89632125|NCT05195008|Experimental|Part C (OGA-PET SAD): BIIB113|Participants aged 20 to 64 will receive single dose of BIIB113, orally, QD, on Day 1 of Part C of the study, followed by a radiotracer specific to OGA ([11^C]BIO-1819578), on Days 1 to 4 of Part C of the study.
89632126|NCT05195008|Experimental|Part C (OGA-PET MAD): BIIB113|Participants aged 20 to 64 years will receive multiple doses of BIIB113, orally, QD, on Days 1 to 14 of Part C of the study, followed by a radiotracer specific to OGA ([11^C]BIO-1819578) on Day 1 and either of Day 15, Day 16 or Day 17 of Part C of the study.
89632127|NCT05144620|Experimental|Preoperative Imaging|
89632128|NCT05139121|Experimental|MR-100A-01|MR-100A-01 is a transdermal delivery system designed to deliver daily hormone exposure of Norelgestromin and Ethinyl Estradiol
89632129|NCT05107908|Experimental|Active Implicit Priming|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect. This will be completed on a weekly basis for 12 weeks, for approximately 10 minutes each time.
89632130|NCT05107908|Placebo Comparator|Control Implicit Priming|Participants will complete control implicit priming, which matches the active intervention, but with neutral stimuli as primes. This will be completed on a weekly basis for 12 weeks, for approximately 10 minutes each time.
89632131|NCT05107908|Active Comparator|Food Exposure Task|Participants will complete a Food Exposure Task, in which they will be asked to smell, feel, lick, and imagine eating food items, but without actually eating them. This will be completed on a weekly basis for 12 weeks, for approximately 10-30 minutes each time.
89632132|NCT05100316|Other|Participants with solid tumors and hematological malignancies|Participants with solid tumors and hematological malignancies will be included. No study treatment will be administered in this study.
89632133|NCT05081999|Other|Continuation of Beta-Blockers|For patients already on β-blocker therapy, the treatment will be continued and titrated at the discretion of the patient's most responsible physician(s).
89632134|NCT05081999|Other|De-Adoption of Beta-Blockers|For patients on β-blocker therapy, medication will be tapered over 3-7 days to minimize the potential for withdrawal-related symptoms. A standardized angina treatment algorithm, which is independent of β-blocker use, will minimize any worsening of angina symptoms during drug withdrawal by utilizing other guideline recommended anti-anginal agents, such as calcium-channel blockers, long acting nitrates, or ivabradine. An anticipated 5% of patients allocated to this arm will not be able to tolerate discontinuation, however, patients will continue participation as per intention-to-treat principle. Background lifestyle measures and medical therapies will be recommended according to current Canadian guideline recommendations and individual patient profiles. Structured algorithms to achieve blood pressure goals that exclude the use of a β-blocker based on the Canadian Hypertension Education Program Guidelines will be provided.
89057424|NCT01682772|Experimental|Olaparib 400mg|Oral Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle
89632135|NCT05074355|Experimental|Azacitidine and Venetoclax|"A treatment cycle is 28 days long.~Azacitidine will be given by injection under the skin, once a day, for the first 6 days of every cycle.~Venetoclax will be given orally, once a day, as follows at the discretion of their study doctors:~Cycle 1:~Day 1 - 100 mg~Day 2 - 200 mg~Days 3 to 28 - 400 mg~Cycle 2:~Participants with a response to the study drugs will continue taking 400 mg from Days 1 to 21, with no study drug from Days 22 to 28 during Cycle 2.~Participants who have not yet responded to the study drugs will continue taking 400 mg from Days 1 to 28 during Cycle 2.~Cycle 3 and subsequent cycles:~Participants with a response to the study drugs will continue to take 400 mg from Days 1 to 21, with no study drug from Days 22 to 28.~Participants whose disease has not worsened will continue taking 400 mg from Days 1 to 28.~Participants have not responded to the study drugs will be withdrawn from the study."
89632136|NCT05067712|Active Comparator|Open Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposed with the Open Technique followed by the Orthodontic Treatment phase
89632137|NCT05067712|Active Comparator|Closed Surgical Exposure Technique|After randomization, the PDC allocated to this arm is surgically exposure with the Closed technique followed by the Orthodontic Treatment phase.
89632138|NCT05055206|Experimental|Lymphatic drainage mapping in patients with oropharynx cancer|"Participants will be given 4 to 6 injections of the radiotracer 99m-Technetium Sulfur Colloid by a needle into one of the veins of the radiotracer around the tumour.~Participants will then have at least 1 or possibly 2 SPECT-CT scans (a special x-ray scan of the body from many angles that are turned into 3-dimensional pictures on a screen)."
89632139|NCT05033743|Experimental|Treatment Group|Secnidazole treatment
89632140|NCT05027269|Experimental|Part A Single Dose: AOC 1001 Dose Level 1|AOC 1001 will be administered once.
89632141|NCT05027269|Placebo Comparator|Part A Single Dose: Placebo|Saline will be administered once.
89632142|NCT05027269|Experimental|Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2 & 3|AOC 1001 will be administered three times.
89632143|NCT05027269|Placebo Comparator|Part B Multiple Ascending Dose: Placebo|Saline will be administered three times.
89632144|NCT04993027|Experimental|Vancomycin Group:|patients will have single dose of 1g vancomycin powder placed on their incision during surgery in addition to: pre- and post-operative intravenous antibiotic administration, sterile surgical helmet systems, saline pulse lavage irrigation, and antimicrobial drapes.
89632145|NCT04993027|No Intervention|Control Group|pre- and post-operative intravenous antibiotic administration, sterile surgical helmet systems, saline pulse lavage irrigation, and antimicrobial drapes.
89632146|NCT04984278|Experimental|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Study dependent: Each spray delivers 100 microliters (μL) of nabiximols. A pre-determined number of sprays, but no less than 4 sprays, of nabiximols will be self-administered by participants as an oromucosal spray, under supervision of trial staff during 2 study visits to the trial site after they temporarily discontinued treatment with prescribed nabiximols (Sativex) as part of their regular medication.
89632147|NCT04984278|Placebo Comparator|Placebo|Placebo to match nabiximols is presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray delivers 100 μL containing no active ingredients.
89632148|NCT04972318|Active Comparator|ARDSNet strategy|"Patients will receive a mechanical ventilation strategy based on fixed values of positive end-expiratory pressure according to inspired fraction of oxygen.~Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before.~This arm is similar to the ARMA (Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome) trial."
89632149|NCT04972318|Experimental|STAMINA strategy|"Patients will receive a mechanical ventilation strategy based on positive end-expiratory pressure tailored to achieve the optimal respiratory system compliance and to have driving pressure limited to 14 cmH2O.~Plateau pressure will be limited at 30 cmH2O. This strategy will be mantained and monitored for 3 days, unless the patient dies or is extubated before."
89632150|NCT04966520|Experimental|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or sham|"Patients will participate in the prospective longitudinal research protocol over a period of 1.5 months.~Treatment will include 8 visits of either accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or iTBS sham stimulation. Patients will be informed that iTBS sham stimulations will be part of the protocol (but will be blind to when treatment/sham will be administered)."
88990739|NCT06180967|Experimental|Midazolam Oral|A single oral dose of midazolam will be administered in the morning following a 10-hour fast prior to dosing and a 4-hour fast postdose on Day 3 and Day 17.
88990740|NCT06180967|Experimental|Pirtobrutinib|Multiple oral doses of Pirtobrutinib once a day (QD) will be administered on Days 5 through Day 17.
88990741|NCT06180954|Experimental|Part 1: [14C]-LOXO-305|A single dose of [14C]-LOXO-305 oral solution will be administered
88990742|NCT06180954|Experimental|Part 2: LOXO-305|A single dose of LOXO-305 oral tablets will be administered
88990743|NCT06180954|Experimental|Part 2: [14C]-LOXO-305|A single dose of [14C]-LOXO-305 intravenously (IV) solution will be administered
89040637|NCT01205269|Experimental|First placebo, then 50 mcg, then 200 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg
89040638|NCT04654286|Active Comparator|Control group (Nerve transfer procedure)|Patient will receive nerve transfer procedure without augmentation
89040639|NCT04654286|Experimental|Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)|Following nerve transfer procedure, the end-to-end anastomosis will be wrapped with HAM-AdMSC composite as augmentation
89211613|NCT05360433|Active Comparator|10 tablet prescription group|These participants receive 10 tablets of oxycodone 5 mg at discharge for postoperative pain.
89211614|NCT05360433|Active Comparator|20 tablet prescription group|These participants receive 20 tablets of oxycodone 5 mg at discharge for postoperative pain.
89211615|NCT00834782||IOP|Measuring IOP
89632151|NCT04962126|Experimental|Treatment naive advanced follicular lymphoma|All consenting participants will be receive an intravenous infusion of Obinutuzumab (1000mg) + Atezolizumab (1200mg) q3/52 x 6 cycles (plus 1000mg Obinutuzumab on day 8 and 15 of cycle 1). Responding participants (PR or SD) who do not achieve a CR at the end of cycle 2 will receive involved site radiotherapy (4Gy, 2 fractions) between cycle 3 and 4. At the end of cycle 6 and completion of the induction phase, responding participants (CR/PR/SD) will receive maintenance phase Obinutuzumab (1000mg IV) q8/52 for up to 12 cycles.
89632152|NCT04949360|Active Comparator|Standard CBTi (CBTi-S):|This is a positive control group/active comparator, in which standard CBTi (the golden standard behavioral treatment for insomnia) will be made available. This treatment consists of an eight-week treatment composed by weekly and structured appointments with a board-certified sleep psychologist. The professionals performing the CBTi sessions will not be part of the research team. Due to the restriction imposed by the COVID-19 pandemic, the appointments will be made remotely (video calls with psychologists), which have already been proven to be equivalent to the in-person CBTi.
89632153|NCT04949360|Placebo Comparator|Minimal intervention - Sleep hygiene (MI-SH):|This group corresponds to a negative control group/placebo comparator, subjected to minimal intervention. It is based on the delivery of informative material regarding normal sleep pattern and sleep hygiene (through regular mail and e-mail). This procedure is more adequate as a control than the commonly used no-treatment or waiting list controls, due to the behavioral nature of insomnia.
89632154|NCT04949360|Experimental|Online CBTI (CBTI-O)|This group will receive access to an eight-month CBTi-based treatment through the SleepUp app. The platform will be updated into a non-commercial version, and all features other than the CBTi track, the sleep log and the clinical tests will be removed. This way, the participants of this group will receive interventions equivalent to the standard in-person CBTi, but provided through a digital platform. The treatment last eight weeks.
89632155|NCT04949360|Experimental|Online CBTi + additional features (CBTi-O+)|This group will have access to the complete premium version of SleepUp platform. It includes those presented in the CBTi-O group and other therapeutic and complementary features (including meditation audios and videos, mindfulness therapy, relaxation soundtracks, sleep hygiene tips, virtual assistant, and telehealth.
89632156|NCT04936139|Experimental|Art Therapy|Patients assigned to the intervention group will participate in 12 weekly group therapy workshop sessions.
89632157|NCT04936139|No Intervention|Control group|"Patients assigned to the control group will receive the usual follow-up care of each center provided for the cancer patient and will not perform art therapy workshops.~They will be offered the opportunity to participate in the workshops once they have completed their participation in the study, putting them on a waiting list."
89632158|NCT04933968|Placebo Comparator|Placebo|Placebo, visually identical to ALVR106
89632159|NCT04933968|Active Comparator|ALVR106|ALVR106, visually identical to placebo
89632160|NCT04925193|Experimental|Arm 1 SPd|"Selinexor 60 mg PO days 1, 8, 15~Pomalidomide 4 mg PO on days 1-21~Dexamethasone 40 mg PO or IV on days 1, 8, 15, 22~28 day treatment cycles"
89211616|NCT00989391|Experimental|Cohort 1|Subjects will be assigned to receive either PF-03654764 or placebo.
89632161|NCT04925193|Experimental|Arm 2 SDd|"Selinexor 80 mg PO days 1, 8, 15~Daratumumab 1,800mg/30,000 units subcutaneous injection on days 1, 8, 15, 22 of cycles 1 and 2, days 1, 15 of cycles 3-6, day 1 of cycles >6~Dexamethasone 40 mg PO or IV days 1, 8, 15, 22~28 day treatment cycle"
89632162|NCT04925193|Experimental|Arm 3 SKd|"Selinexor 80 mg PO days 1, 8, 15~Carfilzomib IV infusion 20 mg/m2 cycle 1, day 1, 56 mg/m2 cycle 1 day 8, 15. Cycle 2+ days 1, 8, 15.~Dexamethasone 40 mg IV or PO days 1, 8, 15, 22~28 day treatment cycle"
89632163|NCT04910282||Eye Disease Patients|Patients with eye diseases age 65 and above will be included. Patients from the Ivey Eye Institute, St. Joseph's Health Care London, ON will be recruited in-person, based on inclusion and exclusion criteria.
89632164|NCT04910048|Active Comparator|Standard of Care|The first arm consists of UAMS standard of care (SOC), including providing a brochure with information (contact information, brief educational information) for the patient to consult with a nutritionist to help with self-directed weight loss.
89632165|NCT04910048|Experimental|Intervention (POPOP)|The second arm is a specified 2-month POPOP focused on weight loss administered by the external partner, 20Lighter. The program includes customized meal plans; vitamin, mineral and nutritional supplementation; and daily engagement via a smartphone app with a 20Lighter health care provider. Video conferencing appointments will occur approximately every 3 weeks. The program does not require any exercise or physical engagement but does necessitate that patients have a smartphone or tablet with Bluetooth capability, cell signal or WIFI connection. During the first 40 days the customized meal plans are adhered to, then from days 41-60 patients will transition back to a normal dietary lifestyle via a customized plan based on considerations including, food preferences, physical engagement and height. Patients who achieve a BMI below 40.0 before the end of the 60 day program may be seen sooner than 90d for follow-up appointment in the UAMS clinic.
89211617|NCT00989391|Experimental|Cohort 2|Subjects will be assigned to receive either PF-03654764 or placebo.
89211618|NCT00989391|Experimental|Cohort 3|Subjects will be assigned to receive either PF-03654764 or placebo.
89211619|NCT00834860|Active Comparator|CHC, HCC|100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
89211620|NCT00834860|Active Comparator|CHC, LC|100 naïve CHC patients without malignancy
89211621|NCT00834938||1|Patients with DM2 undergoing RYGB with remission of DM2
89211622|NCT00834938||2|Patients with DM2 undergoing RYGB without remission of DM2
89211623|NCT00835016|Experimental|Early psychosocial stimulation (LTP)|The 10 session of Early psychosocial stimulation (LTP)will be delivered to depressed mothers in the intervention group
89632166|NCT04906408|Experimental|Prevena|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
89632167|NCT04906408|Experimental|Prineo|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
89632168|NCT04906408|Active Comparator|Standard Dressing|Patients will then be randomized to group A (Prevena™) or group B (Prineo™) or group C (Standard wound dressing) using a random number generator made in Microsoft Excel. They will be made aware of which group they are in after the consent and randomization process, in order for proper post-operative teaching during the pre-operative clinic visit. The principal investigator, co-investigators and operating room staff will be aware of which post-operative intervention is being used on the day of surgery.
89632169|NCT04886518|Active Comparator|Higher dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
89632170|NCT04886518|Active Comparator|Lower dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning"
89632171|NCT04886518|Placebo Comparator|Placebo|"Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
89632172|NCT04876950|Experimental|Virtual Care with Remote Automated Monitoring|Patients randomized to the PVC-RAM-2 intervention will take biophysical measurements with the RAM technology, complete a daily recovery survey, complete video visits with a virtual care clinical team, and take would photos during the 30 days after randomization. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician.
89632173|NCT04876950|No Intervention|Standard Care|Standard post-surgical care.
89632174|NCT04872400|No Intervention|Control|Subjects randomized to the Control Arm will receive standard of care open fracture wound care (no powder) by the clinical team.
89632175|NCT04872400|Experimental|Vancomycin|Subjects randomized to the Intervention arm will receive standard of care plus 1 gram of vancomycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
89632176|NCT04872400|Experimental|Tobramycin|Subjects randomized to the Intervention arm will receive standard of care plus 1.2 grams of tobramycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
89632177|NCT04871477||Observational (audio recording)|Patients audio record the recommendations and instructions given to them by the doctor record as part of their clinic visit at the Supportive Care Center.
89632178|NCT04860791||Multiple Sclerosis patients|
89632179|NCT04858880|Experimental|Continued salvage radiotherapy + lymph node irradiation (non responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present) + the addition of lymph node irradiation (46 Gy/23 fractions) given in sequence. Total number of fractions: 35 + 8 = 43 with 15 of the lymph node irradiation fractions delivered concomitant with the prostate bed/local recurrence irradiation. These patients are classified as non responders according to weekly PSA measurements during the first 4 weeks of radiotherapy.
89632180|NCT04858880|Active Comparator|Continued salvage radiotherapy (non responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present). These patients are classified as non responders according to weekly PSA measurements during the first 4 weeks of radiotherapy.
89632181|NCT04858880|No Intervention|Continued salvage radiotherapy (responders)|Continued salvage radiotherapy as initially planned (to 70.0 Gy/73.5 Gy in 35 fractions to the prostate bed/local recurrence if present). These patients are classified as responders according to weekly PSA measurements during the first 4 weeks of radiotherapy, and are not followed according to the study protocol, follow up according to clinical practice.
89632182|NCT04857138|Experimental|Part 1: Dose Escalation (RO7300490 Monotherapy)|Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
89632183|NCT04857138|Experimental|Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)|Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
89632184|NCT04857138|Experimental|Part 3: Dose Expansion (Disease-specific Expansion(s))|Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
89632185|NCT04855981|Experimental|whole body vibration|the subjects will receive whole-body vibration three times per week for twelve weeks +supplementations
89632186|NCT04855981|Experimental|aerobic exercise|the subjects will receive aerobic exercise three times per week for twelve weeks+supplementations
89632187|NCT04855981|Active Comparator|supplementations|the subjects will receive supplementations three times per week for twelve weeks
89632188|NCT04844749|Experimental|Either VERU-111 32mg or 26mg dose will be supplied as capsules 1 orally once a day|32mg of VERU-111 26mg of VERU-11
89632189|NCT04844749|Active Comparator|Active control alternative androgen receptor targeting agent|The alternative androgen receptor targeting agent will be administered according to the dosing instructions in the current product prescribing information.
89632190|NCT04838977|Experimental|RESET|Children will view 8 educational modules online and participate in 8 sessions with a therapist via telehealth.
89632191|NCT04838977|No Intervention|Control|Children will receive usual post-trauma care.
89632192|NCT04832399||Natalizumab|Natalizumab 300 mg is administered by intravenous infusion once every 4 weeks.
89632193|NCT04816149|Active Comparator|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
89211624|NCT00835016|Active Comparator|Waiting group|Waiting group will receive standard follow-up by their own LHWs. This group intervention will be documented at baseline, 3 months (end of the trial) and at 6 months. Similar training of Learning through Play will be provided to the mothers in this group at the end of the study.
89632194|NCT04816149|Experimental|Treatment for Relationships and Safety Together (TR&ST)|TR&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
89632195|NCT04811729|Experimental|Experimental Group|Intervention based on the Motivational Interview, previously receiving a training program
89632196|NCT04811729|Active Comparator|Control Group|Usual care based on a health counci
89632197|NCT04806919|No Intervention|Control group: Amelgen ® 400 mg BID|Continue daily dose progesteron
89632198|NCT04806919|Experimental|Intervention group: Amelgen ® 400 mg TID|Increase daily progesteron dose
89632199|NCT04788953|Experimental|Solriamfetol (Sunosi)|"Participants will start at 75 mg and take that dose for 3 consecutive days. Participants will take their first 75mg dose on an early morning work day and take the next two 75 mg doses upon awakening regardless of their work schedule.~They will then move to 150mg on the next early morning work day and for all subsequent early morning shift work days. The drug/placebo will be taken orally within 30 minutes after awakening, before the start of each early morning shift. Prior to the end of study of visit (Visit 5), drug will be taken at home within 30 minutes of awakening."
89632200|NCT04788953|Placebo Comparator|Control|Participants randomized into the Control arm will receive a placebo
89632201|NCT04730258|Experimental|1A: Monotherapy escalation and expansion|Dose escalation and expansion arm with CFI-400945
89632202|NCT04730258|Experimental|2A: Combination escalation and expansion|Dose escalation and expansion arm with CFI-400945 and azacitidine
89632203|NCT04717388|Experimental|impact of tinnitus on executive cognitive functioning|
89632204|NCT04717388|Experimental|impact of tinnitus on reorganization of functional/ structural brain connectivity maps|
89632205|NCT04715191|Experimental|CARE T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 plus IL21 (CARE T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
89632206|NCT04709601|Experimental|Group 1 - Patients with negative and positive urine culture|
89632207|NCT04699786|Active Comparator|Arm A|Participants randomized to Arm A will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document. Arm A is a neuroimaging arm.
89632208|NCT04699786|Active Comparator|Arm B|Participants randomized to Arm B will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document. Arm B is a neuroimaging arm.
89632209|NCT04699786|Active Comparator|Arm C|Participants randomized to Arm C will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document. Arm C is a plasma amyloid arm.
88990744|NCT06180941|Active Comparator|magnesium sulfate as adjuvant to bupivacaine.|Group M: 2mg/kg Magnesium sulfate will be added to 0.5 mL.kg-1 of 0.25% bupivacaine (max 2 mg/kg) with a total volume of 0.5 ml/kg, (according to the spread of local anesthetic surrounding the brachial plexus)
89632210|NCT04699786|Active Comparator|Arm D|Participants randomized to Arm D will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document. Arm D is a plasma amyloid arm.
89632211|NCT04698499|Active Comparator|Pen and Paper|Participants will complete swallowing exercises using printed materials and diary for tracking.
89632212|NCT04698499|Experimental|Mobile health system|Participants will complete swallowing exercises using a mobile health system with surface electromyography (sEMG) biofeedback.
89632213|NCT04696861|Experimental|IDEAS for Hope Intervention|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
89632214|NCT04696861|Active Comparator|Enhanced Standard of Care with Safety Planning|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
89632215|NCT04684524|Experimental|Dupilumab|Dupilumab administered every 2 or 4 weeks based on weights
89040640|NCT02888431||Arterial blood sample|0.5 mL blood sample from arterial line which is clinically indicated
89211625|NCT01564173||VT Ablation|Patients undergoing epicardial mapping and ablation procedure for a ventricular tachycardia
89632216|NCT04684524|Placebo Comparator|Matching placebo|Placebo administered every 2 or 4 weeks based on weights
89632217|NCT04659343||Cohort 1|Patients treated for metastatic renal cell carcinoma in Denmark over a 6-year period.
89632218|NCT04657679|Active Comparator|African American/Black|Subject who self identify as African American or Black with metastatic HR+/HER2- advanced breast cancer (estimate 3 participants who are CYP3A5 poor metabolizers and approximately 15 participants who are CYP3A5 intermediate or normal metabolizers)
89632219|NCT04657679|Active Comparator|Non-Hispanic White|Subjects who self-identify as non-Hispanic White with metastatic HR+/HER2- advanced breast cancer (estimate 3 participants who are CYP3A5 poor metabolizers and approximately 15 participants who are CYP3A5 intermediate or normal metabolizers)
89632220|NCT04656535|Experimental|AB122 + AB154 Safety Cohort (Cohort A)|Eligible patients will be sequentially enrolled to receive intravenous AB154 combined with AB122 (N=6). AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat).
89632221|NCT04656535|Experimental|AB154 Surgical Cohort (Cohort B1)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B1 (N=10): AB154 single agent (10 mg/kg) + placebo~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
89632222|NCT04656535|Experimental|AB122 Surgical Cohort (Cohort B2)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B2 (N=10): AB122 single agent (240 mg) + placebo~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
89632223|NCT04656535|Experimental|AB154 + AB122 Surgical Cohort (Cohort B3)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B3 (N=10): AB154 (10 mg/kg) +AB122 (240 mg)~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
89632224|NCT04656535|Experimental|Placebo Surgical Cohort (Cohort B4)|"Candidates for surgical resection will be enrolled and initiate study treatment approximately two weeks prior to the resection. The pre-surgical dose (neoadjuvant treatment) will be double-blinded.~B4 (N=10): Two placebo infusions~Following surgery, all patients will initiate treatment with the combination of AB154 and AB122. AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat)."
89632225|NCT04636190|Other|Triathlon All-Polyethylene Tibia Knee|All subjects enrolled will have received the Triathlon All-Polyethylene Tibia Knee device.
89632226|NCT04632498|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
89632227|NCT04632498|No Intervention|Wait-list Control (WL)|Patient Control receiving no treatment
89632228|NCT04632498|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
89632229|NCT04598646|Experimental|Cario-Oncology Rehabilitation (CORE)|"CORE consists of exercise therapy, CVD risk factor management, and behavioural support for 3 months.~Exercise therapy: Staff will prescribe and deliver a standardized, yet individually tailored (based on CPET results), aerobic exercise programs consisting of two days of supervised, facility- and home-based high-intensity interval training (HIIT) and one day of supervised home-based moderate-intensity continuous training (MICT) per week. Exercise HRs and durations will be monitored using an accurate commercially available wrist-worn HR monitor and PA tracker.~CVD risk factor management: CVD risk factors will be assessed and treated according to Canadian guidelines.~Behavioural support: All participants will receive a planned sequence of educational and instructional material via email and ongoing PAYA-CS tailored education and peer support during the follow-up period using a peer support online system."
89040641|NCT02888431||peripheral venous blood sample|0.5 mL blood sample drawn simultaneously with arterial sample from clinically indicated peripheral line
89040642|NCT00542139|Experimental|1|
89040643|NCT00542139|Active Comparator|2|
89040644|NCT04653974|Active Comparator|Needle-free injection group|In needle-free injection techniques, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using the Comfort-In system.
89040645|NCT04653974|Active Comparator|Dental injection group|In the conventional dental-injection method, 2% lidocaine with 1/80.000 epinephrine (Lidocaine, Colombia) was injected using a 27G, 40-mm, disposable syringe with a needle.
89040646|NCT00542217|Placebo Comparator|Cohort 1|Single dose of 0.5 mg/kg Imprime PGG administered over 1 hr
89040647|NCT00542217|Placebo Comparator|Cohort 2|Single dose of 1.0 mg/kg Imprime PGG administered over 1 hr
89040648|NCT00542217|Placebo Comparator|Cohort 3|Single dose of 2.0 mg/kg Imprime PGG administered over 1 hr
89040649|NCT00542217|Placebo Comparator|Cohort 4|Single dose of 4.0 mg/kg Imprime PGG administered over 2 hr
89040650|NCT00542217|Placebo Comparator|Cohort 5|Single dose of 6.0 mg/kg Imprime PGG administered over 3 hr
89040651|NCT04654247|Sham Comparator|Control group|Endoscopists in control group were informed standard quality indicators requirements and the corresponding references during informed consent.
89040652|NCT04654247|Experimental|Feedback group|Endoscopists in feedback group were informed standard quality indicators requirements and the corresponding references during informed consent. In addition to the quality requirements, endoscopists randomized to feedback group received customized quality reports feedback from Endo.Adm weekly.
89040653|NCT02493114||Patients with lung cancer|No study intervention
89040654|NCT02493114||Healthy controls|No study intervention
89040655|NCT04654091|Experimental|Cryoteraphy with liquid nitrogen|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
89040656|NCT04654091|Experimental|Nitric-zinc complex|Patients older than 18 years with a diagnosis of plantar wart, who have agreed to participate in the study.
89040657|NCT04654169|Experimental|The IAI and SSNB group|Ultrasound-guided IAI and SSNB are planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
89040658|NCT04654169|Active Comparator|The only-IAI group|Ultrasound-guided IAI is planned to apply by at least three-year experienced physiatrists. Patients are planned to initiate a six-week rehabilitation program supervised by the same physiotherapist one day after the intervention.
89632230|NCT04598646|Experimental|Support|The Support group will receive the behavioural support only. The timing and nature of all education, information provided to Support participants will be identical to what is provided to CORE participants. All Support participants will receive the same wrist-worn HR monitor and PA tracker as the CORE participants and will be given the challenge of meeting and maintaining the updated PA guidelines for cancer survivors (i.e., 90 to 150 minutes of moderate to vigorous intensity PA per week).
89632231|NCT04596995|Experimental|Rozanolixizumab Treatment Arm|All study participants will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
89632232|NCT04574765||Healthcare Worker|Individuals who work within a food production, healthcare, research or clinical organization of participating institutions.
89632233|NCT04574037||follow up of stroke patients with a upper limb deficit|Usual follow up of stroke patients with a upper limb deficit
89632234|NCT04572841|Experimental|SAR441344|SAR441344 single intravenous (IV) loading dose on Day 1 followed by a single subcutaneous (SC) dose administered once every 2 weeks from Week 2 to Week 10 (5 administrations)
89632235|NCT04572841|Placebo Comparator|Placebo|Matching placebo
89632236|NCT04570956|Experimental|Oral Tamoxifen 10 mg/day|Oral Tamoxifen 10 mg/day
89632237|NCT04570956|Experimental|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day|"Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day~+oral placebo"
89632238|NCT04570956|Experimental|Control|Oral and gel placebo
89632239|NCT04559529|Experimental|Levetiracetam (LEV), then Placebo|Participants will first receive two 250mg LEV capsules on the same day. After one week, they will receive two placebo capsules on the same day.
89632240|NCT04559529|Experimental|Placebo, then Levetiracetam (LEV)|Participants will first receive two placebo capsules on the same day. After one week, they will receive two 250mg LEV capsules on the same day.
89632241|NCT04558138|Experimental|Discharge day of surgery|Patient discharges day of surgery and given surveys to complete at home on post operative day (POD) #1 and #7.
89632242|NCT04558138|No Intervention|Discharge post operative day 1|Patient Discharges POD #1 and completes survey prior to discharge. Patient given surveys to complete POD #7 at home.
89632243|NCT04544449|Experimental|Fenebrutinib|Participants will receive oral fenebrutinib and intravenous (IV) ocrelizumab-matching placebo.
89632244|NCT04544449|Active Comparator|Ocrelizumab|Participants will receive intravenous (IV) ocrelizumab and oral fenebrutinib-matching placebo.
89632245|NCT04534777||Consciousness disorder patients|"The overall outcome of this project will allow to draw better single-patient predictions of state, prognosis, and rehabilitation strategies and furthermore, a better understanding the pathophysiological mechanisms behind DoC that could result in groundbreaking new personalized therapeutic approaches.~Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years."
89632246|NCT04516746|Experimental|AZD1222|Approximately 20,000 participants randomized to the AZD1222 arm
89632247|NCT04516746|Placebo Comparator|Placebo|Approximately 10,000 participants randomized to the saline placebo arm
89632248|NCT04516070|Experimental|Treatment (SRS)|Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.
89632249|NCT04515667|Experimental|Mindfulness|
89632250|NCT04515667|Placebo Comparator|Control|
89632251|NCT04506775|Experimental|Wrist one|Wrist one will have both the ViTrack wrist cuff on one wrist
89057425|NCT01682772|Experimental|Olaparib 300mg|Oral Olaparib at a dose of 300mg twice daily, continuously on a 28 day cycle
89057426|NCT01682850|Active Comparator|Intervention|The Intervention Arm will receive 10 sessions of Mindfulness Based Pulmonary Rehabilitation prior to lung surgery
89057427|NCT01682850|Placebo Comparator|Usual Care|The Usual Care Arm will receive the normal care that a patient with severe COPD having a lung surgery would receive.
89057428|NCT04539197||IgG4-RD group|300 IgG4-RD were enrolled and followed up for more than 6 months. Peripheral blood of all patients were collected at baseline, disease remission and relpase for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline, each follow up were collected.
89057429|NCT04539197||other autoimmune disease group|200 patients( RA, SLE, pSS, BD, et al) were enrolled in this study. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
89057430|NCT04539197||IgG4-RD mimicker group|60 IgG4-RD mimickers (pancreatic cancer, cholangiocarcinoma, vasculitis, lymphoproliferative diseases, inflammatory bowel disease, kimura disease) were collected. Peripheral blood of all patients were collected at baseline for plasmablast/plasma cells detection. All clinical data and laboratory parameters at baseline were collected.
89057431|NCT04539197||healthy control group|100 healthy controls were collected. Peripheral blood of healthy controls were collected at baseline for plasmablast/plasma cells detection. Demographic features of healthy controls were collected.
89057432|NCT01649037|Experimental|nor adrenaline and terlipressin|
89057433|NCT01649037|Active Comparator|step up terlipressin|
89057434|NCT04539119|Experimental|Entecavir and Tenofovir|
89057435|NCT04539119|Active Comparator|Entecavir|
89057436|NCT02279511|Experimental|24 hours infusion of ATP|
89057437|NCT02279511|Experimental|6 hours infusion of ATP|
89057438|NCT02279511|Placebo Comparator|24 hours infusion of placebo|
89057439|NCT02279511|Placebo Comparator|6 hours infusion of placebo|
89057440|NCT04538885|No Intervention|control group|No intervention
89057441|NCT04538885|Experimental|experimental group|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2)
89057442|NCT01682889|Placebo Comparator|Placebo|NaCl 0.9% intravenously for 24 hours after induction of anaesthesia
89057443|NCT01682889|Active Comparator|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours after induction of anaesthesia
89057444|NCT04538963|Experimental|Banded Tooth|This tooth will have an orthodontic band and glass ionomer cement placed as an intervention for interproximal incipient caries.
89211626|NCT00825422|Experimental|A|first bolus of 20 ml of ropivacaine(5mg/ml) and continuous infiltration (8ml/h)of ropivacaine (2mg/ml)
89211627|NCT00825422|Placebo Comparator|B|first bolus of 20 ml of physiological saline solution(9%) and continuous infiltration (8ml/h)of physiological saline solution(9%)
89211628|NCT04003545|Active Comparator|Active group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
89211629|NCT04003545|Placebo Comparator|Placebo group|Thirty eight patients will be recruited from UNINOVE outpatient units and randomly allocated in the two groups.
89632252|NCT04506775|Active Comparator|Wrist Two|Wrist two and the radial artery catheter in the opposite wrist.
89632253|NCT04502407|Experimental|De-intensified Cisplatin-based Chemoradiation|This is a non-randomized study, with all patients undergoing de-intensified post-operative cisplatin-based chemoradiation. Dosage level and duration of administration will be determined by whether the patient is high risk or not as assessed by the treating investigator.
89632254|NCT04475939|Experimental|Participants receiving niraparib plus pembrolizumab|Eligible participants will receive niraparib along with pembrolizumab.
89632255|NCT04475939|Placebo Comparator|Participants receiving placebo plus pembrolizumab|Eligible participants will receive matching placebo along with pembrolizumab.
89632256|NCT04471532|Experimental|Behavior change intervention|A 3-month behavior change intervention i.e. one initial, face-to-face, physical activity counselling and two telephone-assisted counselling.
89632257|NCT04471532|No Intervention|Control|No attention
89211630|NCT00835250|Active Comparator|Laparoscopy|Laparoscopic cholecystectomy
89211631|NCT00835250|Experimental|Transumbilical|Transumbilical endoscopic cholecystectomy
89211632|NCT00835250|Experimental|Transvaginal|Transvaginal endoscopic cholecystectomy
89211633|NCT05358015|Experimental|scaphoid nonunion|pedicled and free ABG for treatment of scaphoid nonunion
89211634|NCT04043780|Experimental|Decompression prototype splint|The patients of this group will wear the decompression prototype splint.
89211635|NCT04043780|Active Comparator|standard splint|The patients of this group will wear a standard splint.
89211636|NCT00505414|Placebo Comparator|Matching Placebo|Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
89211637|NCT00505414|Active Comparator|Morphine Controlled Release|Oral Morphine 45 mg to 90 mg twice daily.
89211638|NCT00505414|Experimental|Tapentadol Extended Release|Oral Tapentadol 100 mg to 250 mg twice daily.
89211639|NCT00840788|Experimental|Skin adhesive|perineal skin repair with octyl-2-cyanoacrylate skin adhesive
89211640|NCT00840788|Active Comparator|subcuticular suture|continuous subcuticular suture of perineal skin using rapidly absorbable polyglactin 910
89211641|NCT05549739||Control Group|Individuals without cardiac and pulmonary disease
89211642|NCT05549739||Study Group|Individuals with coronary artery disease
89211643|NCT02549924|Experimental|Resveratrol|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
89211644|NCT02549924|Placebo Comparator|Placebo|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
89211645|NCT01813227|Experimental|Carfilzomib|Carfilzomib 20 mg/m2 on day 1, 2 then 56 mg/m2 days 8, 9 and 15, 16 over 30 minutes every 28 days. Dexamethasone 4 mg (8 mg if > 45 mg/m2) orally each day of carfilzomib therapy. If less than a partial remission (PR) after 4 cycles, add rituximab 375 mg/m2 on day 16 of each cycle. Patients who meet the criteria for progression prior to 4 cycles of therapy will have rituximab added to their treatment. For patients receiving rituximab, the carfilzomib dose will be decreased to 27 mg/m2. Patients will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
89211646|NCT00825578|Active Comparator|1|Upper-lobe predominant emphysema
89211647|NCT00825578|Active Comparator|2|Non-upper lobe predominant emphysema
89211648|NCT01012882|Experimental|sublingual application of allergen extract|
89211649|NCT01012882|Placebo Comparator|sublingual application of placebo|
89211650|NCT00841022|Experimental|1|Information of children with comic leaflet
89211651|NCT00841022|No Intervention|2|
89211652|NCT00989469|Experimental|Sorafenib and irinotecan|
89211653|NCT04709458|Experimental|TBX-2400 treatment|Single intravenous infusion of TBX-2400
89211654|NCT02546882|Experimental|stromal vascular fraction|The adipose tissue in abdomen or thigh will be harvested and digested at 37 °C for 60 min with 0.2% collagenase I/Ⅲ. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is stromal vascular fraction (SVF).
89211655|NCT02546882|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
89211656|NCT00989547|Active Comparator|A|
89632258|NCT04470726|Experimental|AIV001 Treatment Dose 1|Intradermal/intratumoral, Dose 1
89632259|NCT04470726|Experimental|AIV001 Treatment Dose 2|Intradermal/intratumoral, Dose 2
89632260|NCT04470726|Experimental|AIV001 Treatment Dose 3|Intradermal/intratumoral, Dose 3
89632261|NCT04470726|Experimental|AIV001 Treatment Dose 4|Intradermal/intratumoral, Dose 4
89211657|NCT00989547|No Intervention|B|
89632262|NCT04457622|Experimental|Main study group|All participants signed up for experiment 1, 2, 3 or 4 complete the same protocol (1 study arm) with an intent for intra-subject correlational analyses
89632263|NCT04451291|Experimental|Decidual Stromal Cells (DSC)|Participants will receive one dose of DSC at 1x10^6/kg. A second dose may be given sometime between Day 5 and Day 8 if the participant's condition improves.
89632264|NCT04450329|Experimental|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
89632265|NCT04450329|Active Comparator|Eylea (Aflibercept)|"Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.~At Week 32, subjects in Eylea group will re-randomized into SB15 or Eylea group. After re-randomization, subjects transited to SB15 group will receive SB15 2 mg (0.05 mL) once every 8 weeks until Week 48 and subjects remaining in Eylea group will continue to receive Eylea 2 mg (0.05 mL) once every 8 weeks until Week 48."
89632266|NCT04427761||pancreatic cancer health-illness transition|In this prospective longitudinal correlational study, a convenience sample of patients with pancreatic cancer receiving chemotherapy will be asked to report on their health-illness transition experiences and their level of distress.
89632267|NCT04423718|Active Comparator|Aflibercept 2q8|In the double-masked study part (Years 1 and 2), Aflibercept 2 mg administered every 8 weeks after a loading phase. (Active Comparator) In Year 3, high dose aflibercept administered according to individual patient response. (Experimental)
89632268|NCT04423718|Experimental|Aflibercept HDq12|Aflibercept high dose (HD) administered every 12 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.
89632269|NCT04423718|Experimental|Aflibercept HDq16|Aflibercept high dose administered every 16 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.
89632270|NCT04370691||JETi Peripheral Thrombectomy System|Subjects who were treated with JETi Peripheral Thrombectomy System will be included.
89632271|NCT04362930||Neurological and psychiatric impact of COVID-19|Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection
89211658|NCT01010308|Experimental|Intervention Group:|"The patients in this study are infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement~Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years as a control group"
89211659|NCT01010308|No Intervention|Historical control group|Ten infants (1-12 months of age) treated with propranolol will be identified from a Dermatology Database. Patients will be considered as controls if they were treated with propranolol before 1 year of age and had digital photography documentation of their hemangioma.
89211660|NCT01010308|No Intervention|Angiogenesis marker control group|The angiogenesis marker control group will consist of 6 -10 patients seen in the Dermatology clinic for conditions other than IH and not receiving corticosteroids or beta blockers.
89211661|NCT04002687|Experimental|ATV-PG 1000-400 mg + AQ 612 mg|T1 (n=16) - Atovaquone (ATV),Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) 612 mg on days 1,2, 3.
89211662|NCT04002687|Active Comparator|ATV-PG 1000-400 mg + AQ unmatched placebo|T 2 (n=12) - Atovaquone (ATV)-Proguanil (PG) 1000-400 mg + Amodiaquine (AQ) unmatched placebo on days 1,2, 3.
89211663|NCT04002687|Active Comparator|ATV-PG unmatched placebo + AQ 612 mg|T 3 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + Amodiaquine (AQ) 612 mg on days 1,2, 3.
89632272|NCT04362930||Impact of Covid-19 in patients with neurological pathology|patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection
89632273|NCT04355611||Patients with MS or NMO|Cohort study evaluating the epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
89632274|NCT04345718|Experimental|Interventional|Single subcutaneous injection of a 28-day formulation of extended-release buprenorphine within 72 hours of anticipated hospital discharge.
89632275|NCT04345718|Active Comparator|Treatment as Usual|Community standard of care that includes initiation of either methadone, sublingual (SL) buprenorphine, or naltrexone prior to hospital discharge.
89632276|NCT04331041|Experimental|MR-guided SBRT + Defactinib|"Participants in this study will receive 5 fractions of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) and seventeen 21-day cycles of defactinib (beginning on Day 2 of radiation).~Participants who are candidates for surgical resection will undergo standard of care surgery at 2 weeks post-end of SBRT (+/- 1 weeks) or 12 weeks post-end of SBRT (+/- 1 week). These participants will discontinue defactinib the day prior to the operation and will resume taking it for the remainder of the 17 cycles 4 to 6 weeks after surgery. Participants who are not candidates for surgical resection will continue to receive defactinib uninterrupted. All participants should receive 17 cycles of defactinib unless they experience disease progression or intolerable toxicity."
89632277|NCT04331041|Active Comparator|MR-guided SBRT|-Participants in this study will receive 5 fractions of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT)
89632278|NCT04305587|Experimental|Active Obesity|Part B
89632279|NCT04305587|Placebo Comparator|Placebo Obesity|Part B
89211664|NCT04002687|Placebo Comparator|ATV-PG unmatched placebo + AQ unmatched placebo|T 4 (n=12) - Atovaquone (ATV)-Proguanil (PG) unmatched placebo + AQ unmatched placebo on days 1,2, 3.
89632280|NCT04305587|Experimental|Active T2DM|Parts A and C
89632281|NCT04305587|Placebo Comparator|Placebo T2DM|Parts A and C
89632282|NCT04279964|Experimental|Boot Camp Translation|Intervention practices will undergo the Boot Camp Translation process.
89632283|NCT04279964|Active Comparator|Control|Control practice will behave as usual.
89632284|NCT04252625|Active Comparator|Arm 1: Q-Urol|"Patients will be randomized in a 1:1 ratio to receive Q-Urol, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
89632285|NCT04252625|Placebo Comparator|Arm 2: Placebo|"Patients will be randomized in a 1:1 ratio to receive Placebo, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
89211665|NCT02548052|Experimental|GSK2981278, Vehicle, Betamethasone valerate|All subjects will receive all six treatments (GSK2981278 ointment 0.03%, 0.1%, 0.8%, 4%, vehicle to match GSK2981278 ointment and betamethasone valerate 0.1% cream); with random assignment of the treatments to 6 test fields on identified stable plaque(s) on the upper extremities, thighs and/or trunk. Subjects will be treated once-daily (except Days 7 and 14) over 19 days (a total of 16 applications) under semi-occlusive conditions (covered by an adhesive non-woven fabric).
89211666|NCT04590417|Other|20 HIV-negative TGW|A single-arm prospective PK study of HIV-negative TGW taking FHT and daily PrEP.
89211667|NCT00825656|Experimental|1|Sinol-M
89211668|NCT00825656|Active Comparator|2|Sinol
89211669|NCT01010386|Placebo Comparator|atmospheric (20%) oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
89632286|NCT04231851|Experimental|CPX-351 and Glasdegib|"In Induction, subjects receive 44mg/m2/100mg/m2 IV on days 1, 3 and 5 and Glasdegib 100mg PO daily on days 6 to 28.~If re-induction is needed: Subjects receive 44mg/m2/100mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.~In consolidation: Subjects receive 29mg/m2/65mg/m2 IV on days 1 and 3 and Glasdegib 100mg PO daily on days 4 to 28.~If maintenance is required, Subjects receive Glasdegib 100mg PO daily for up to one year"
89632287|NCT04224948|Experimental|PET-MR arm|Every eligible patient will be scanned by PET-MR at baseline and following 1 cycle of chemotherapy. PET-CT at baseline will also be obtained as it is the current standard of care and will be used to determine trial eligibility (no evidence metastasis at baseline).
89632288|NCT04209387||Control|No PTSD, TBI, and Depression
89632289|NCT04209387||PTSD|Veterans with PTSD
89632290|NCT04197934|Experimental|Dose escalation (WSD0922-FU)|Patients receive WSD0922-FU PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans, MRI, and collection of blood samples throughout the trial.
89632291|NCT04197934|Experimental|Dose expansion Cohort I (WSD0922-FU)|Patients with GBM/AA receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans, MRI, and collection of blood samples throughout the trial.
89632292|NCT04197934|Experimental|Dose expansion Cohort II (WSD0922-FU, surgery)|Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans, MRI, and collection of blood samples throughout the trial.
89632293|NCT04197934|Experimental|Dose expansion Cohort III (WSD0922-FU)|Patients with NSCLC receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans, MRI, and collection of blood and CSF samples throughout the trial.
89632294|NCT04176523||Methylmalonic_acidemia|Patients with confirmed diagnosis of methylmalonic acidemia, and treated with carglumic acid, at any dose form, any dosage,
89632295|NCT04176523||Propionic_Acidemia|Patients with confirmed diagnosis of propionic acidemia, and treated with carglumic acid, at any dose
89632296|NCT04141475|Active Comparator|Alpha-Lipoic Acid group|
89632297|NCT04141475|Placebo Comparator|placebo group|
89632298|NCT04137900|Experimental|TAB004 0.3 mg/kg repeat dose every 21 days up to 2 years|
89632299|NCT04137900|Experimental|TAB004 1 mg/kg repeat dose every 21days up to 2 years|
89632300|NCT04137900|Experimental|TAB004 3 mg/kg repeat dose every 21 days up to 2 years|
89632301|NCT04137900|Experimental|TAB004 10 mg/kg repeat dose every 21 days up to 2 years|
89632302|NCT04137900|Experimental|TAB004 200mg repeat dose every 21 days up to 2 years|
88815716|NCT01089062|Other|Treatment A, then Treatment B, then Treatment C|"The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
89057445|NCT04538963|No Intervention|Non-banded Tooth|This tooth will be monitored per standard of care; encourage good dental hygiene at home.
89057446|NCT04538807||Lumbar disc herniation|Patients are complaining of lower extremity radiating pain due to lumbar disc herniation.
89057447|NCT01682967||Experimental group|Patients suffering from PDPH would form this group
89057448|NCT01682967||Control group - Epidural|Patients who received an epidural during labour but did not have symptoms of PDPH would form this reference group
89057449|NCT01682967||Control Group without Epidural analgesia|Patients in labour who did not receive an EDA would form this cohort of controls
89057450|NCT04542902|Experimental|Allergic asthma patients|Allergic asthma patients and sensitization to house dust mites (D. pteronyssinus) allergen.
89057451|NCT04542902|Experimental|Severe eosinophilic asthma patients|
89057452|NCT04542902|Active Comparator|Healthy subjects as a control group|Healthy subjects without allergic and other chronic respiratory diseases (control group).
89057453|NCT02279628|Experimental|Continuous wound infiltration alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 1 ml sodium chloride 0.9% (without morphine). Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
89057454|NCT02279628|Active Comparator|Intrathecal moprhine alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of sodium chloride 0.9% 8 ml/H via a preperitoneal catheter.
89632303|NCT04137900|Experimental|TAB004 20mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89632304|NCT04137900|Experimental|TAB004 70mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89632305|NCT04137900|Experimental|TAB004 200mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89632306|NCT04137900|Experimental|TAB004 500mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
89632307|NCT04137224|Experimental|Sequence A (IgPro20/IgPro10)|Participants received IgPro20 of a total dose of 0.5 grams per kilogram (g/kg) over 2 sessions per week as a subcutaneous (SC) injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2 to 5 sessions on consecutive days every 4 weeks as an intravenous (IV) infusion for up to 16 weeks in Treatment Period 2.
89632308|NCT04137224|Experimental|Sequence B (IgPro10/IgPro20)|Participants received IgPro10 of a total dose of 2 g/kg over 2 to 5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.
89632309|NCT04125927|Experimental|Open-label arm|
89632310|NCT04116151|Experimental|Intervention group|Local administration of the Alantel (R) cream on the affected skin
89632311|NCT04116151|Placebo Comparator|Control group|Local administration of the Placebo cream on the affected skin
89632312|NCT04105166|Experimental|RP-L301|RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
89632313|NCT04092777|Experimental|Strong Minds Program|This is a 10-session, culturally-adapted intervention, that includes cognitive behavioral therapy techniques combined with mindfulness exercises, led by a Community Health Worker.
89040659|NCT00542256|Active Comparator|1|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each of the 10 weekday training sessions, participants will receive 40 minutes of active tDCS over the primary motor cortex.
89057455|NCT02279628|Experimental|Intrathecal morphine&wound infiltration|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
89632314|NCT04092777|Other|Enhanced Usual Care|Enhanced usual care includes check in calls by a Care Manager 4 times over the course of 6 months and educational materials about depression and anxiety.
89632315|NCT04078152|Experimental|Treatment|Durvalumab Monotherapy
89632316|NCT04078152|No Intervention|Off Treatment|Follow up Only
89632317|NCT04071236|Active Comparator|Arm A (radium-223 dichloride)|Patients receive radium-223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89632318|NCT04071236|Active Comparator|Arm B (radium-223 dichloride, nedisertib)|Patients receive radium-223 dichloride as in Arm A and peposertib PO or BID on days 3-26. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89632319|NCT04071236|Experimental|Arm C (radium-223 dichloride, nedisertib, avelumab)|Patients receive radium-223 dichloride IV as in Arm A and peposertib PO QD or BID as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 15 of cycles 2-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89632320|NCT04057807|Experimental|Patients receiving endotoxin|The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously
89632321|NCT04054648|Active Comparator|Bedtime Antihypertensive Medications|The LTC facility's pharmacist will switch all once daily antihypertensive medications, one at a time as tolerated, to bedtime. Blood pressure lowering medications taken more than once per day are left alone.
89632322|NCT04054648|No Intervention|Morning Antihypertensive Medications|No change to blood pressure medication timing is made. By default, most patients are using once daily antihypertensive medications in the morning at baseline.
89632323|NCT04040296|No Intervention|Usual Care|Kidney Action Team Recommendations will not be delivered to the primary care teams of randomized patients.
89632324|NCT04040296|Experimental|Kidney Action Team Recommendations|Recommendations made by the Kidney Action Team will be delivered to the patient's primary care team within 30 minutes of AKI development.
89632325|NCT04022850|Active Comparator|Non-reflective decision assistance strategy|The decision support tools integrated in the electronic health record (EHR) for the non-reflective decision assistance strategy will be applied to all FPs from the 13 Integrated Healthcare Organizations (IHOs) of Osakidetza- Basque Health Service
89632326|NCT04022850|Experimental|Reflective and non-reflective decision information strategy in addition to the previous arm|At least 58 FPs from two IHOs (Barakaldo-Sestao and Ezkerraldea-Enkarterri-Cruces) will be randomly assigned to this experimental arm (decision assistance strategy + decision information strategy)
89632327|NCT04022850|Experimental|A reflective decision structure strategy in addition to the previous arm|At least other 58 FPs from two IHOs (Barakaldo-Sestao and Ezkerraldea-Enkarterri-Cruces) will be randomly assigned to this experimental arm (decision assistance strategy + decision information strategy + decision structure strategy)
89632328|NCT04009109|Experimental|Lenalidomide|12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.
89632329|NCT04009109|Experimental|Lenalidomide, Ixazomib, Daratumumab, and Dexamethasone|12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 year maintenance therapy.
89632330|NCT04008836|Experimental|Untrained Subjects WITH Diabetes use the T-PLUS BGMS|Untrained subjects WITH Diabetes test capillary fingerstick and palm blood (and study staff test subject fingerstick blood) using the T-PLUS BGMS. All blood glucose results are compared to reference method results. Also, study staff test subject's venous blood and the blood glucose results are compared to the reference method results.
89632331|NCT03980769|Experimental|Treatment (chemotherapy, transplant)|Patients receive thiotepa IV BID over 2 hours on day -7, treosulfan IV over 120 minutes on days -6 to -4, fludarabine phosphate IV over 60 minutes on days -6 to -2, and rabbit anti-thymocyte globulin IV over 4-6 hours on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0.
89632332|NCT03927157|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
89632333|NCT03927157|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
88990745|NCT06180941|Active Comparator|clonidine as adjuvant to bupivacaine.|Group C: 0.75 μg.kg-1 of clonidine will be added to 0.5 mL.kg-1 of 0.25% bupivacaine (max 2 mg/kg) with a total volume of 0.5 ml/kg, (according to the spread of local anesthetic surrounding the brachial plexus)
88990746|NCT06180915|Experimental|Experimental Group|Participants will be informed that they must answer the surveys and forms completely and appropriately, as well as attend all training sessions and fulfill their session duties. At the end of the 3-week training program (interim measurement) and 4 weeks later (post-test), the Rathus Assertiveness Inventory, Internalized Misogyny Scale and Flirting Violence Attitude Scale will be converted into an online survey via Google Forms®, the link will be sent to the participants and they will be asked to fill it out.
89632334|NCT03883165|Experimental|high-intensity neck strengthening group|
89632335|NCT03883165|Other|Control group|
89632336|NCT03872128|Active Comparator|patients receiving 300mg PREG|Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
89632337|NCT03872128|Active Comparator|patients receiving 500mg PREG|Patients randomly assigned to receive 500mg of pregnenolone (PREG) daily.
89632338|NCT03872128|Placebo Comparator|placebo|Patients randomly assigned to receive a placebo daily.
89632339|NCT03867201|Experimental|Erenumab|Administered by pre-filled syringe
89632340|NCT03867201|Placebo Comparator|Placebo|Administered by pre-filled syringe
89632341|NCT03851237|Experimental|Cohort 1a: Treatment Whipple/Surgical Procedure/Surgery following neoadjuvant therapy|"Early-staged localized pancreatic cancer~Standard of care diagnostic biopsy~64Cu-DOTA-ECL1i-PET/CT imaging - immediately after the dynamic study~Receive treatment with upfront surgery such as whipple procedure or surgery following neoadjuvant therapy."
89632342|NCT03851237|Experimental|Cohort 1b: Standard of Care Treatment Chemotherapy|"Borderline resectable, locally advanced/metastatic or recurrent pancreatic cancer~Standard of care diagnostic biopsy (if available tissue to be used for CCR2 expression)~64Cu-DOTA-ECL1i-PET/CT imaging pretherapy~Treatment with any standard of care (SOC) chemotherapy~Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with positive scan at baseline/early therapy at the time of standard of care follow-up imaging appointment --Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with negative scan at baseline/early therapy at time recurrence is diagnosed by any standard imaging modality"
89632343|NCT03851237|Experimental|Cohort 2: CCR2-Targeted Therapy|"Locally advanced or borderline resectable pancreatic cancer~Biopsy per therapeutic protocol (if available tissue to be used for CCR2 expression)~64Cu-DOTA-ECL1i-PET/CT imaging pretherapy~2 cycles of CCR2-targeted therapy~Biopsy per therapeutic protocol (tissue to be used for CCR2 expression) --Additional 64Cu-DOTA-ECL1i-PET/CT imaging after 2 cycles of therapy"
89632344|NCT03842033|Other|PEAKmAAP|"The Pulmonary Education and Asthma Knowledge mobile asthma action plan (PEAKmAAP) group will use a mobile app that will help manage asthma. Participants will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. mAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification."
89632345|NCT03842033|Other|PEAKmAAP-Data Sharing (DS)|PEAKmAAP with Data Sharing (PEAKmAAP-DS) group will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. PEAKmAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification. The primary care provided (PCP) will receive monthly reports to help them know how the participant's asthma symptoms are over time.
89632346|NCT03842033|Other|Nutrition Map (NutriMap) Usual Care|Participants in this arm will use a smartphone application that sends daily non-asthma-related reminder for attention control. Participants will be asked to log their daily fruits and vegetables eaten. Participants will answer survey questions about their asthma and symptoms management.
89632347|NCT03834168|Other|Study Individuals|Healthy self-identified African-American and white male participants will be screened. Study consent will be obtained, medical history and physical examination administered, and study eligibility determined based on the inclusion and exclusion criteria. Eligible subjects will meet a bio-nutritionist who will explain the 5 days of standardized diet at the screening visit and will review instructions for complying with the diet. If the subject agrees to adhere to the study diet, they will then be enrolled in the study (stratified by race).
89632348|NCT03824158|Active Comparator|Facilitated advance care planning (in-person or telephonic)|Patients randomized to this arm will participate in in-person or telephonic facilitated advance care planning (ACP) discussions using the Respecting Choices model.
89632349|NCT03824158|Active Comparator|Web-based advance care planning|Patients randomized to this arm will participate in web-based ACP via the PREPARE website.
89040660|NCT00542256|Sham Comparator|2|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each training day tDCS will be applied for 40 minutes with the current active for only 30 seconds over the primary motor cortex.
89040661|NCT04653935|Experimental|Full app with all app components|Users receive app that contains all intervention components including: Symptom and Lifestyle information, Energy management, Goal Setting, Managing Difficult Times, Assertiveness and Communication Skills.
89040662|NCT04653935|Active Comparator|Control minimal app with information component only|Users receive app that contains only Symptom and Lifestyle information, and cannot see other intervention components.
89040663|NCT00542295|Experimental|A|
89040664|NCT00542295|Placebo Comparator|B|
89040665|NCT03454841||Prasugrel|Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.
89040666|NCT03454841||Ticagrelor|Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.
89040667|NCT03454802|Active Comparator|Normal subjects|Normal subjects 'Passive Leg Raising'
89040668|NCT03454802|Active Comparator|ICU patients|ICU patients 'Passive Leg Raising'
89040669|NCT03454802|Active Comparator|Cardiac Outpatients|Cardiac Outpatients 'Passive Leg Raising'
89040670|NCT03454763|Experimental|Arm A, Intensive|Arm A, Intensive every 5 weeks
89040671|NCT03454763|Experimental|Arm B, Non Intensive|Arm B, Non Intensive every 8-10 weeks
89040672|NCT04653506|Experimental|Paracetamol group|Women who were treated with a double-blind mechanism in an envelope containing paracetamol pills (1000 mg)
89040673|NCT04653506|Experimental|Ibuprofen group|Women who were treated with a double-blind mechanism in an envelope containing Ibuprofen pills (400 mg)
89040674|NCT04653701||Patients with hepatocellular carcinoma treated with TAMDEM® 100 micron and SEQURE® microcatheter|Patients included in this study and with chemoembolization indications will be superselective embolized using TAMDEM® 100 micron preloaded particles (Doxorubicin) and SEQURE® microcatheter combination (SYNERGIC EFFECT). Objective tumoral response and 30 days-complications (Safety) are primary outcomes.
89040675|NCT04653857||High-level athlete who had a recent COVID 19 infection, symptomatic or not|High-level athlete who had a recent COVID 19 infection, symptomatic or not
89040676|NCT04653623|Experimental|Tranexamic acid before high tibial osteotomy|"Interventions~Procedure/Surgery: High tibial osteotomy~Drugs: Tranexamic acid"
89040677|NCT04653623|Active Comparator|High tibial osteotomy only|"Interventions~- Procedure/Surgery: High tibial osteotomy"
89040678|NCT00542529|Placebo Comparator|Cohort 1|Placebo or 2.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
89040679|NCT00542529|Placebo Comparator|Cohort 2|Placebo or 4.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
89040680|NCT02015832||Percutaneous Coronary Intervention|All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)
89040681|NCT00542568|Experimental|1|Cohort 1 (Low Dose group) 18-25 IU/kg/day
89040682|NCT00542568|Experimental|2|Cohort 2 (Intermediate Dose group): 35-45 IU/kg/day
89040683|NCT00542568|Experimental|3|Cohort 3 (High Dose group): 55-65 IU/kg/day
89040684|NCT04653779|Experimental|Group A|Patients receive Evogliptin 5mg/Metformin 1000mg once a day
89040685|NCT04685031|Experimental|nitroglycerin|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
89040686|NCT04685031|Experimental|clobetasol|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
89040687|NCT04685031|No Intervention|routine|routine nursing care
89040688|NCT01972932|Placebo Comparator|Placebo|Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
89040689|NCT01972932|Active Comparator|Bio K+®|Bio K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
89040690|NCT04653311|Experimental|Endomina procedure + lifestyle intervention|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. This group will also receive the medical standard treatment defined as lifestyle intervention.
89040691|NCT04653311|No Intervention|Lifestyle intervention|The group will receive the medical standard treatment defined as lifestyle therapy combining diet (mediterranean diet) with increased physical activity
89040692|NCT04653155|Experimental|Treatment arm|Participants in the treatment group will show significant improvement on insomnia symptoms after intervention compared to those in the waitlist control group.
89040693|NCT04653155|No Intervention|Waitlist control|Participants in the waitlist control group will show little improvement on insomnia symptoms after the treatment period of the treatment group.
89040694|NCT01854684|Experimental|Treatment (surgery and intraoperative PDT)|Patients receive temoporfin IV over no less than 6 minutes and then undergo standard surgical resection with intraoperative PDT.
89040695|NCT04653077|Experimental|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
89040696|NCT01827579|Experimental|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
89040697|NCT01827579|No Intervention|Control (normal HSCT)|Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.
89057456|NCT04538924|Other|MINOCA (group I) - conventional MI treatment|Traditional MI treatment with optimal doses of statin, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), beta-blockers (BB) and dual antiplatelet therapy (DAPT).
89040698|NCT04653233|Experimental|Intervention|After the theoretical lesson, the students in the experimental group were taken to the laboratory room where the 3D Systems Touch Haptic Simulator is located. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option. Since the preparation of the material in the full teaching method in the simulator takes a long time, these steps were removed to show similarity with the control group. The skill practice option for an average of 5-10 minutes where all steps of the Checklist for Teaching Urinary Catheterization Skill can be applied was used. Urinary catheterization with 3D Systems Touch Haptic Simulator was explained by 1 researcher who was responsible for the Fundamentals of Nursing course.
89040699|NCT04653233|No Intervention|Control|"After the theoretical lesson, the control group was taken to Fundamentals of Nursing Skill Laboratory. 1 researcher, who is responsible for the Fundamentals of Nursing, was explained on the Simple Urinary Catheterization Model by applying the steps of Checklist for Teaching Urinary Catheterization Skills. The students were allowed to ask questions and the questions asked were answered. Then all the students in the control group were taken to an empty class. The two researchers prepared the necessary materials for the urinary catheterization skill practice in the same way in separate rooms. The doors were closed to keep the environment calm during the application. One student was taken to each laboratory rooms in order not to be affected by each other. While the student was practicing, both researchers filled in the Checklist for Teaching Urinary Catheterization Skills. Satisfaction Questionnaire was given to the student who completed the application and asked to fill it."
89040700|NCT00542802|Experimental|LEV|Levetiracetam
89632350|NCT03813654|No Intervention|Control (Group A)|During the intervention block of the Field Trial, at the end of the first night shift, the participant will be told about their randomization group. In the control group (Group A), participants will not be given any instructions about the timing or duration of their sleep, but will be instructed to follow their usual night shift sleep routine.
89632351|NCT03813654|Experimental|8-h Afternoon-Evening Sleep (Group B)|In the 8-h afternoon-evening sleep intervention group (Group B), participants will be instructed to go to bed between 13:00 and 14:00 (depending on their individual commute time) and to remain in bed attempting to sleep for 8 hours (until 21:00-22:00) before the next two night shifts.
89632352|NCT03813654|Experimental|8-h Free Sleep (Group C)|In the 8-h free sleep group (Group C), participants will be instructed to remain in bed for 8 continuous hours before the next two night shifts, but will not be given any instruction regarding which 8 hours they should sleep.
89632353|NCT03800693|Active Comparator|2-hour infusion group|Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89632354|NCT03800693|Experimental|6-hour infusion group|Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89632355|NCT03798145|Experimental|Surgical Retinotomy|Surgical retinotomy will be constructed in the area of the scotoma.
89632356|NCT03784248||asymptomatic carrier|
89632357|NCT03784248||uninfected subjects|
89632358|NCT03760744|Experimental|CDT with Negative Pressure|CDT with LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
89040701|NCT00542802|Active Comparator|CAR|Carbamazepina
89040702|NCT04652648|Active Comparator|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID for 10 days
89040703|NCT04652648|No Intervention|Control|No Intervention
89632359|NCT03760744|Active Comparator|CDT alone|CDT alone without LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
89632360|NCT03740698|No Intervention|SAP, open-loop|Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system)
89632361|NCT03740698|Experimental|BiAP, fixed bolus calculator|Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator
89632362|NCT03740698|Experimental|BiAP, ABC4D|Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D)
89632363|NCT03736863|Experimental|CohortA：Apatinib+SHR-1210（Camrelizumab）|Apatinib+SHR-1210（Camrelizumab）for ESCC who progressed or were intolerant to first-line systemic chemotherapy
89632364|NCT03736863|Experimental|CohortB：Apatinib+SHR-1210（Camrelizumab）|Apatinib+SHR-1210（Camrelizumab）for ESCC who have failed prior immune checkpoint inhibitor therapies
89632365|NCT03736863|Experimental|CohortC：Apatinib+SHR-1316（Adebrelimab）|Apatinib+SHR-1316（Adebrelimab）for ESCC who have failed prior immune checkpoint inhibitor therapies
89632366|NCT03672695|Experimental|Initial Schedule - S64315 low dose and venetoclax high dose administered in combination|
89632367|NCT03672695|Experimental|Initial Schedule - S64315 medium dose and venetoclax low dose administered in combination|
89632368|NCT03672695|Experimental|Initial Schedule - S64315 medium dose and venetoclax medium dose administered in combination|
89632369|NCT03672695|Experimental|Initial Schedule - S64315 medium dose and venetoclax high dose administered in combination|
89632370|NCT03672695|Experimental|Initial Schedule - S64315 high dose and venetoclax medium dose administered in combination|
89040704|NCT00542841|Experimental|1|
89057457|NCT04538924|Other|MINOCA (group II)|Treatment with a low-dose statin and ACEI/ARB. In case of vasospasm, calcium channel blockers.
89057458|NCT04538612|Experimental|measure capillary refill time|
89057459|NCT04542629|Experimental|RITUXIMAB|rituximab INTRAVENOUS 750MG/m2 every 2 weeks for 2 doses
89057460|NCT04542629|Active Comparator|KETOGENIC DIET|"The common element of these different approaches is variable reduction in the amount of carbohydrate with appropriate increase in fat.~Diets that produce a state of ketosis are referred to as ''ketogenic"
89632371|NCT03672695|Experimental|Alternative Schedule - Venetoclax medium dose administered with no S64315|
89632372|NCT03672695|Experimental|Alternative Schedule - S64315 medium dose and venetoclax medium dose administered in combination|
89632373|NCT03672695|Experimental|Alternative Schedule - S64315 high dose and venetoclax low dose administered in combination|
89632374|NCT03671928|Other|bowel ischemia|
89632375|NCT03671928|Other|non-digestive abdominal pain|
89632376|NCT03650114|Experimental|Ofatumumab|Subcutaneous injection
89211670|NCT01010386|Active Comparator|physiologic (5%) oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
89632377|NCT03611335||Site 1 H+H|Lincoln Medical and Mental Health Center
89632378|NCT03611335||Site 2 H+H|Bellevue Hospital
89632379|NCT03611335||Site 3 H+H|Metropolitan Hospital
89632380|NCT03611335||Site 4 H+H|Elmhurst Hospital Center
89632381|NCT03611335||Site 5 H+H|Coney Island Hospital
89632382|NCT03611335||Site 6 H+H|Woodhull Medical and Mental Health Center
89632383|NCT03575611|Experimental|Treatment (SBRT)|Patients undergo SBRT over 1 day to 3 weeks based on the judgment of the treating radiation oncologist.
89632384|NCT03541642|Experimental|Enhanced Intervention|Women who are eligible and randomized to the Enhanced Intervention will receive targeted PrEP counseling; targeted written/visual materials, follow up supportive text messages, and distribution of PrEP at the syringe exchange
89632385|NCT03541642|Active Comparator|Basic Intervention|"Women who are eligible and randomized to the Basic Intervention will receive usual care with general messaging from medical personnel, reminder text messages, and distribution of PrEP at the syringe exchange"
89632386|NCT03538665||Cases|Women undergoing clinically-indicated hysterectomy for endometrial cancer or precursors
89632387|NCT03538665||Controls|Women undergoing clinically-indicated hysterectomy for benign conditions
89632388|NCT03534284|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia sessions: a 30-minute treatment session once weekly for six weeks.
89632389|NCT03534284|Active Comparator|Medication- Trazodone|Trazodone (50-100 mg):
89632390|NCT03534284|Placebo Comparator|Medication- Placebo|Placebo (for trazodone)
89632391|NCT03533543||New-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization.
89632392|NCT03533543||Non new-onset atrial fibrillation|Patients with MI who are free from a medical history of AF will be recognized as Non-NOAF if they persist with sinus rhythm (based on CEM) during hospitalization.
89211671|NCT00989625|Active Comparator|10mg Sumatriptan/60mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
89632393|NCT03509012|Experimental|HNSCC Arm 1|Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
89632394|NCT03509012|Experimental|NSCLC Arm 1|Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
89632395|NCT03509012|Experimental|NSCLC Arm 2|Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
89632396|NCT03509012|Experimental|NSCLC Arm 3|Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
89632397|NCT03509012|Experimental|SCLC Arm 1|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
89632398|NCT03509012|Experimental|SCLC Arm 2|Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
89632399|NCT03509012|Experimental|SCLC Arm 3|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
89211672|NCT00989625|Active Comparator|30mg Sumatriptan/180mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
89211673|NCT00989625|Active Comparator|85mg Sumatriptan/500mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
89632400|NCT03509012|Experimental|SCLC Arm 4|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
89632401|NCT03496402|Experimental|High risk Cohorts|Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
89632402|NCT03496402|Experimental|Low risk Cohort|Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
89632403|NCT03444298|Placebo Comparator|Placebo first, then Gamma Tocopherol|Participants that are randomized to placebo treatment will take a short treatment course of Neutral Oil followed by chamber exposure with wood smoke particulate. After a 4-week washout period, participants will cross over to the gamma Tocopherol (active) treatment group.
89632404|NCT03444298|Active Comparator|GammaTocopherol first, then Placebo|Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.
89632405|NCT03428828|Experimental|Amygdala Neurofeedback|attempt to up regulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Five sessions will be performed within a 2 month period.
89632406|NCT03428828|Active Comparator|Parietal Neurofeedback|attempt to upregulate the left horizontal segment of the intraparietal sulcus, a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback. Five sessions will be performed within a 2 month period.
89632407|NCT03420118|Experimental|Tumor tissue and blood samples collection|
89632408|NCT03411356|Active Comparator|Daily Caloric Restriction (DCR)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
89632409|NCT03411356|Experimental|Intermittent Fasting (IMF)|Participants in this group will focus on modified intermittent fasting as their dietary weight loss strategy.
89632410|NCT03391479|Experimental|Avelumab and Best Supportive Care|"Avelumab will be given intravenously (by vein) at a dose of 10 mg/kg, once every 2 weeks~Best supportive care will be provided as required."
89632411|NCT03376659|Experimental|Phase I - Safety|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly~Bevacizumab - q2weeks (colorectal cancer patients only)"
89632412|NCT03376659|Experimental|Phase II - Colorectal Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly~Bevacizumab - q2weeks"
89632413|NCT03376659|Experimental|Phase II - Pancreatic Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly"
89632414|NCT03375463|Experimental|5 mg Tirzepatide SC (Solution)-Part A|Participants received 5 milligrams (mg) of tirzepatide subcutaneous (SC) solution formulation.
89632415|NCT03375463|Experimental|5 mg Tirzepatide SC (Lyophilized)-Part A|Participants received 5 mg of tirzepatide SC lyophilized formulation.
89632416|NCT03375463|Experimental|0.5 mg LY3298176 IV-Part B|Participants received Intravenous (IV) infusion of a single 0.5 mg dose of tirzepatide formulation.
89040705|NCT00542958|Experimental|NK012|"This is a Phase I dose-escalation study of the intravenous administration of NK012 in patients with refractory solid tumors. Patients will receive NK012 as an intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (3 weeks) per cycle. Two patient populations will be evaluated separately: patients with UGT1A1*28 genotype homozygous wild type (wt/wt) and heterozygous (wt/*28) variants as one group, and patients with UGT1A1*28 homozygous variant (*28/*28) as another group. Dose-escalation in each patient population will proceed according to the predefined dose level.~For UGT1A1*28 (wt/wt and wt/*28) patients, at least 3 evaluable patients will be treated at each dose level.~UGT1A1 homozygous (*28/*28) patients will be treated at 50% of the current dose level.~Patients will receive up to 6 cycles of NK012, unless they experience unacceptable toxicity or disease progression, requiring withdrawal from the study."
89040706|NCT04652492|Experimental|Tislelizumab in combination with cTACE|Tislelizumab in combination with on-demanded cTACE
89040707|NCT01185210|Placebo Comparator|Placebo|Subjects will receive placebo (mix of sugar and salt).
89040708|NCT01185210|Experimental|Alanine - 12.5|Subjects will receive 12.5 grams of alanine
89040709|NCT01185210|Experimental|Alanine - 25|Subjects will receive 25 grams of alanine.
89632417|NCT03375463|Experimental|5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C|Participants received tirzepatide subcutaneous solution at 5 mg on Days 1 (week 1) and 8 (Week 2), 7.5 mg on Day 15 (Week 3) and 10 mg on Day 22 (Week 4).
89632418|NCT03375463|Placebo Comparator|Placebo SC-Part C|Participants received SC injection of placebo.
89632419|NCT03375463|Experimental|0.5 mg LY3298176 Bolus IV-Part D|Participants received IV bolus of 0.5 mg tirzepatide lyophilized formulation.
89632420|NCT03366337|Experimental|Bardoxolone Methyl - ADPKD|Participants with autosomal polycystic kidney disease (ADPKD) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
89632421|NCT03366337|Experimental|Bardoxolone Methyl - IgAN|Participants with IgA nephropathy (IgAN) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
89632422|NCT03366337|Experimental|Bardoxolone Methyl - T1D|Participants with Type 1 diabetes (T1D) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
89632423|NCT03366337|Experimental|Bardoxolone Methyl - FSGS|Participants with focal segmental glomerulosclerosis (FSGS) will receive bardoxolone methyl capsules at a starting dose of 5 mg and titrate up to a maximal dose of 20 mg (participants with UACR less than or equal to 300 mg/g) or 30 mg (participants with UACR greater than 300 mg/g) daily.
89632424|NCT03358875|Experimental|BGB-A317|100 mg per vial, 200mg intravenous (IV), Q3W
89632425|NCT03358875|Experimental|Docetaxel|75 mg/m2 IV Q3W
89040710|NCT04652336|Active Comparator|LSG|This group will receive standard laparoscopic sleeve gastrectomy
89040711|NCT04652336|Experimental|LSG with LTC|This group will receive LSG along with the novel LTC procedure
89040712|NCT04652297|Experimental|HS-10356 single dose|Single oral dose of HS-10356 ascending dose
89040713|NCT04652297|Placebo Comparator|placebo single dose|Single oral dose of placebo ascending doses
89040714|NCT04652297|Experimental|HS-10356 multiple doses|Multiple oral doses of HS-10356 ascending doses
89040715|NCT04652297|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo ascending doses
89040716|NCT04652024|No Intervention|CONTROL GROUP|Girls in the control group received pelvic floor muscle exercise (kegel exercise) daily in the outpatient clinic 12 weeks.
89040717|NCT04652024|Experimental|STUDY GROUP|Girls in the study group received the same physical therapy program given to the control group in addition to anorectal biofeedback for six sessions per week. in addition to kegel exercise
89040718|NCT04651907|Experimental|acupuncture group|The needle set for the sham acupuncture group and the real acupuncture group will use the CASOON Acupuncture Needle (Wuxi Jiajian Medical Instrument Company, limited), which needle size is 0.3mm×30mm. The needle placed for the real acupuncture group will be the same needle size as 0.3mm×30mm. The depth of needling varied based on the patient's body sizes. After insertion, the needles were manually manipulated to obtain the De Qi sensation, which was defined as the acupuncturist feeling a tugging or grasping sensation from the needle manipulation and the patient feeling soreness, fullness, heaviness, or local distension at local needling sites.
89057461|NCT04542629|Active Comparator|TRACE ELEMENTS|. Essential trace elements that include zinc, copper, magnesium, and selenium
89632426|NCT03324373|Experimental|Lenvatinib and Everolimus prior to cytoreductive nephrectomy|Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.
89632427|NCT03237780|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and CT with contrast throughout the trial. Patients may undergo biopsy during screening and on study.
89632428|NCT03237780|Experimental|Arm II (atezolizumab, eribulin mesylate)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle and eribulin mesylate IV over 2-3 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and CT with contrast throughout the trial. Patients may undergo biopsy during screening and on study.
89632429|NCT03209401|Experimental|Niraparib and Carboplatin|"Niraparib will be administered orally, once daily for 21 days of each 21-day cycle in escalating doses depending on cohort patient is assigned to.~Carboplatin will be administered via an injection on Day 2 of a given 21-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
89632430|NCT03197350|Active Comparator|HFpEF|"We intend to recruit consecutive patients admitted for HFPEF in our institution during the next years. Eligible patients include those with age ≥50 years, LVEF ≥50%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥350 pg/mL) within the 60 days before inclusion.~Intervention: cMR"
89632431|NCT03197350|Active Comparator|Controls|"We plan to recruit 10 per decade of age. These subjects will allow us to evaluate the effects of age on the parameters of our study. They will have no risk factors, a normal ECG at rest and normal heart ultrasound and no abnormalities on a stress test.~Intervention: cMR"
89632432|NCT03197350|Active Comparator|HFrEF|"We intend to recruit consecutive patients admitted for HFrEF in our institution during the next years. Eligible patients include those with age ≥50 years, LVEF ≤40%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥350 pg/mL) within the 60 days before inclusion.~Intervention: cMR"
89632433|NCT03190278|Experimental|Dose Escalation|"UCART123v1.2 tested at several dose levels with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D)~Dose Expansion: UCART123v1.2 administered at the RP2D determined from the dose escalation phase"
89632434|NCT03181516|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
89632435|NCT03181516|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
89632436|NCT03144674|Experimental|Cohort 1- Closed to Further enrollment|Participants who have received prior ibrutinib.
89632437|NCT03144674|Experimental|Cohort 2|Participants who have not received a prior BTK inhibitor.
89632438|NCT03066843|Experimental|Zero incubation with ALA (5-aminolevulinic acid)|Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
89632439|NCT03066843|Experimental|One hour incubation with ALA (5-aminolevulinic acid)|Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
89632440|NCT03057002||Cardiomyopathy|Patients with Cardiomyopathy will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
89040719|NCT04651907|Placebo Comparator|sham-controlled group|The sham acupuncture group will be performed by superficial needling with less than 4mm depth. The needling location is about 0.5 cm away from the acupoints. Both the real acupuncture group and the sham acupuncture group received the same treatment protocol.
89040720|NCT04651907|No Intervention|waitlist-controlled group|As an waitlist control group, no acupuncture will be performed.
89040721|NCT00543114|Experimental|Lenalidomide, fludarabine and rituximab|Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle
89040722|NCT03454724|Experimental|MeRes100 BRS|MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
89040723|NCT03454724|Active Comparator|Xience EES|Xience EES is a Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
89040724|NCT00543153||Patients diagnosed with cancer|
89040725|NCT04652258|Other|Treatment arm|"The patients will be administered Tocilizmab (Actemra) at the following dosage :~First dose: 8mg/kg, max. 800mg iv. during 60min~If necessary second dose: 8mg/kg, max. 800mg iv. during 60min after 20-36 hours from first dose"
89040726|NCT01014546|Experimental|Treatment (arsenic trioxide with or without ascorbic acid)|Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.
89040727|NCT04652141|Active Comparator|AsthmaTuner field tests|Trail treatment with AsthmaTuner up to 3 months. Objective asthma criteria: Positive reversibility test, FEV1 >12% and 200 ml or positive periodic variability PEF/FEV1 >20%. Treatment recommendation is prescribed individually by treating physician.
89040728|NCT04652141|No Intervention|Traditional trial treatment|Treatment recommendation is prescribed individually to patient by treating physician. The treatment plan is transferred to patient on printed paper and/or oral communication.
89040729|NCT04651517|Experimental|Study arm|Subjects undergoing procedures with the XACT ACE Robotic system.
89040730|NCT00557843|Active Comparator|bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
89040731|NCT00557843|Placebo Comparator|Placebo|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
89057462|NCT04542629|Active Comparator|CORTICOSTEROID|corticosteroid pulse therapy 30 mg /kg /day for 5 days monthly for 6 month
89632441|NCT03057002||Control|Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
89632442|NCT02887859|Experimental|HAV Treatment|Human Acellular Vessel (HAV)
89632443|NCT02836574|Experimental|Immediate Treatment|Renal Autologous Cell Therapy (REACT) immediate treatment - Patients who are randomized to receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
89632444|NCT02836574|Active Comparator|Delayed Treatment|Renal Autologous Cell Therapy (REACT) delayed treatment - Patients who are randomized to receive standard of care treatment for the first 12 months after REACT product is made available before receiving 2 injections of REACT.
89632445|NCT02791542||Asthma|Participants with a history of asthma
89632446|NCT02791542||Healthy controls|Participants without a history of asthma
89632447|NCT02791542||Asthma Bronchoscopy sub-group|Participants with a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
89632448|NCT02791542||Healthy Bronchoscopy sub-group|Participants without a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
89632449|NCT02789345|Experimental|Arm A: Ramucirumab + Osimertinib|Dose Finding: Participants received Ramucirumab 10 milligrams/kilogram (mg/kg) given intravenously (IV) on day 1 every 2 weeks and osimertinib 80 milligrams (mg) given orally daily during each 14-day cycle.
89632450|NCT02789345|Experimental|Arm B: Necitumumab + Osimertinib|Dose Finding: Participants received Necitumumab 800 mg given IV on days 1 and 8 every 3 weeks and osimertinib 80 mg given orally daily during each 21 day cycle.
89632451|NCT02789345|Experimental|Cohort A: Ramucirumab + Osimertinib|Dose Expansion: Participants received Ramucirumab 10 mg/kg given IV on day 1 every 2 weeks and osimertinib 80 mg given orally daily during each 14-day cycle.
89632452|NCT02766153||patients|
89632453|NCT02766153||healthy volunteers|intrafamily marrow donors
89632454|NCT02755896|Other|Arm 1 - 600 cGY x 5 fractions|Patients will receive 600 cGY x 5 fractions of radiation therapy over 5 consecutive days.
89632455|NCT02755896|Other|Arm 2 - 800 cGY x 3 fractions|Patients will receive 800 cGY x 3 fractions of radiation therapy every other day for 3 days.
89632456|NCT02747927|Placebo Comparator|Placebo|Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0).
89632457|NCT02747927|Experimental|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received TDV, SC injection, based on the randomization on Day 1 (Month 0).
89632458|NCT02722525|Experimental|Diagnostic (cardiac MRI, skeletal muscle PMRS)|Patients undergo a treadmill stress CMR focused on cardiac muscle comprised of resting MRI over 10-15 minutes followed by treadmill exercise until peak stress. Patients then undergo MRI and gadopentetate dimeglumine perfusion imaging immediately after exercise and after a 6-8 minute recovery period. Within 24 hours of treadmill CMR exam, patients also undergo skeletal muscle PMRS while at rest, during, and in the recovery phase of resistive lower extremity exercise which patients complete over 30 seconds. Both procedures are performed before initiation of ADT treatment (baseline) and 4-7 months after initiation of ADT treatment.
89632459|NCT02714881|Other|Tumor necrosis factor inhibitor|Subjects who are about to start on a tumor necrosis factor inhibitor (TNFi) as part of usual care will be recruited. They will have measurements including routine lipids, advanced lipoproteins, and coronary flow reserve (CFR) before and after their TNFi.
89632460|NCT02650414|Experimental|CART22 cells|"Subjects <50kg will receive 0.2-1 x 10^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10^6 CART22 cells/kg~Day 2, 30% fraction: 0.6-3x10^6 CART22 cells/kg~Day 3, 60% fraction: 1.2-6x10^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10^7~Day 2, 30% fraction: 0.3-1.5x10^8~Day 3, 60% fraction: 0.6-3x10^8"
89040732|NCT04651478|Experimental|Action Observation+Motor Imagery through BCI|"Action Observation+Motor Imagery through a Brain-Computer Interface training paradigm in Virtual Reality using the NeuRow platform during 10 sessions of 20 minutes, divided in 4 series of 5 minutes."
89040733|NCT04651478|Placebo Comparator|Action Observation through non-related with movement illustrations|Control Action Observation protocol of non-related with movement illustrations during 10 sessions of 20 minutes, divided in 4 series of 5 minutes.
89040734|NCT00419328|Experimental|Experimental Arm A|Patients were scheduled to receive a 1 hour intravenous (iv) infusion of NGR-hTNF every 3weeks.- The dose of administered NGR-hTNF was: 0.2, 0.4, 0.8, 1.6 μg/m2 (step 1); 3.2, 6.4, 12.8 μg/m2 (step 2); 19.2, 28.8, 43.2 64.8 μg/m2 (step 3); 86.2, 114.6, 152.4 μg/m2 (step 4)
89040735|NCT04651751|No Intervention|Control|No Intervention: Control Participants exercised on their own without receiving any instructions.
89040736|NCT04651751|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
89040737|NCT00543270|Experimental|Endovascular Repair - EVAR (Powerlink System)|EVAR (Powerlink System)
89040738|NCT00543270|Active Comparator|Open Surgical Control|Open Surgical Control
89040739|NCT04651556|Active Comparator|Parenteral Analgesia|receive ordinary analgesics via intravenous route as paracetamol (7.5- 10 mg/kg) and ketorolac (0.5 mg/kg).
89040740|NCT04651556|Active Comparator|Intraperitoneal instillation|receive (Magnesium sulphate 40 mg/kg and bupivacaine 4mg/kg) in 30 ml of isotonic 0.9%N.S intra peritoneal at the end of surgery.
89040741|NCT02587767|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
89632461|NCT02647437|Experimental|Levetiracetam, Then Placebo|2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).
89632462|NCT02647437|Experimental|Placebo, Then Levetiracetam|2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).
89040742|NCT02587767|Active Comparator|HD-PDT|Half-dose photodynamic therapy (HD-PDT) is administered to the patients. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689nm, and a treatment duration of 83 seconds.
89040743|NCT04651322|Experimental|Training group|
89040744|NCT04651322|Other|Control group|
89632463|NCT02644941|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
89632464|NCT02644941|Active Comparator|ePTFE|The comparator (one of two commercially available 6mm ePTFE grafts) will be surgically implanted in the forearm or upper arm on Study Day 0.
89632465|NCT02628067|Experimental|Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years of treatment).
89632466|NCT02628067|Experimental|Pembrolizumab 400 mg|Participants with any advanced solid tumor that has failed at least one line of therapy and is Tumor- Mutational Burden-High (TMB-H), excluding participants with mismatch repair deficient (dMMR/MSI-H) tumors. The dosing regimen for this cohort will be 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to approximately 2 years of treatment).
89632467|NCT02612831|Other|Early bariatric surgery|patient receive their procedure early (within 3 months)
89632468|NCT02612831|Other|Delayed bariatric surgery|Patient receive their procedure later (in 12 - 15 months), following a year of optimal medical treatment
89632469|NCT02557295||Remsima™|Patients who have received only Remsima or switched from non-biologic treatment to Remsima were included in this analysis group.
89632470|NCT02557295||Switch to Remsima|Patients who switched from Remicade to Remsima were included in this analysis group.
89632471|NCT02557295||Remicade|Patients who have received only Remicade or switched from non-biologic treatment to Remicade were included in this analysis group.
89632472|NCT02557295||Switch to Remicade|Patients who switched from Remsima to Remicade were included in this analysis group.
89632473|NCT02557295||Other Anti-TNF|"Following patients were included in other anti-TNF group.~Patients who have received only anti-TNF other than Remsima or Remicade~Patients who switched from non-biologic treatment to anti-TNF other than Remsima or Remicade~Patients who switched from biologic treatment other than anti-TNF before study enrolment to anti-TNF other than Remsima or Remicade"
89632474|NCT02556567|Other|Intervention|Participants will wear the Fitbit® Charge Heart Rate (HR) wristband for eight weeks.
89632475|NCT02529462|Experimental|NEUROPHARMAGEN-Guided Treatment|In the study patient group, the psychiatrist will have the results of the NEUROPHARMAGEN genetic test as supporting information to help him/her select the best treatment for the patient.
89632476|NCT02529462|Active Comparator|Treatment As Usual|"In the control patient group, treatment as usual will be selected and prescribed in accordance with routine clinical practice ."
89632477|NCT02467881|Active Comparator|Physical Activity Increase (GLB-MOD)|Participants randomized to this arm will follow the traditional GLB program with an activity goal of 150 minutes per week of moderately intense physical activity similar to a brisk walk. Progression of the activity goal each week is slow and safe with increases of no more than 30 minutes per week. Participants are requested to try and achieve 20-30 minutes per day of moderate activity but, to allow for flexibility, that amount can be split into 10 minute increments. Self-reported monitoring for this group includes keeping track of weight, daily food intake as well the number of minutes each day spent being active as part of their planned activity goal. This is all recorded in the self-monitoring keeping track book.
89632478|NCT02467881|Active Comparator|Sedentary Time Decrease (GLB-SED)|"The GLB curriculum will be adapted to direct participants to decrease the time they spend sitting in a day rather than to increase moderate+ physical activity as is the case in the current GLB program. In order for the participant to become aware of how much time they spend sitting and where most of their sitting time occurs, they will fill out a 7 Day Sedentary Diary that consists of daily entry of time spent sitting over the course of one week. Participants will be asked to eliminate a 45 minute sitting bout in a day with non-sitting activity. They will initially be asked to eliminate 45 minutes of sitting for two days in that week. This will increase one day a week until 7 days in a week are met."
89632479|NCT02467881|Other|6-month delayed (DELAYED)|Those assigned to the DELAYED group at baseline will wait for 6 months to begin intervention. During the delayed time period, these participants will receive periodic health information newsletters. At the end of 6 months, the DELAYED participants will be randomly assigned to GLB-MOD or GLB-SED intervention, and will begin their intervention program at that time.
89632480|NCT02450708|Experimental|For patients with 1 HLA-compatible donor for URD HCT|For patients with 1 URD: donor KIR genotyping will be performed on the donor. Because donor selection will not depend on KIR/HLA genotyping, completion of donor KIR genotyping is not required prior to transplant.
89632481|NCT02450708|Experimental|For patients with >1 HLA-compatible donor for URD HCT|For patients with 1 or more donor candidates, KIR genotyping may be performed for up to 5 donors. For patients with HLA-B alleles harboring the Bw4 epitope, KIR3DL1 allele typing will be performed at MSKCC.
89632482|NCT02425046|Experimental|health coaching and community screening|Family Health Coaching and community benefits screening
89632483|NCT02425046|Other|community screening|community benefits screening only
89632484|NCT02318849|Experimental|First initiation site|University randomized to receive intervention after 1 baseline assessment. Duration of intervention was 3 semesters. This was University of Hawaii at Manoa (UHM).
89632485|NCT02318849|Experimental|Second initiation site|University randomized to receive intervention after 3 baseline assessments. Duration of intervention was 2 semesters. This was University of Hawaii at Hilo (UHH).
89632486|NCT02318849|Experimental|Third initiation site|University randomized to receive intervention after 5 baseline assessments. Duration of intervention was 2 semesters. This was Hawaii Pacific University (HPU).
89632487|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 2.5 and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg administered orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
89632488|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) Capsules, 10 mg administered orally once daily for 12 weeks
89632489|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 20 mg|Omaveloxolone (RTA 408) Capsules, 20 mg administered orally once daily for 12 weeks
89632490|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 40 mg|Omaveloxolone (RTA 408) Capsules, 40 mg administered orally once daily for 12 weeks
89632491|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 80 mg|Omaveloxolone (RTA 408) Capsules, 80 mg administered orally once daily for 12 weeks
89040745|NCT04651049||Propranolol treatment group|
89040746|NCT02497443|Experimental|study group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs [AEDs]) and receiving autologous mesenchymal stem cells
89040747|NCT02497443|No Intervention|control group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)
89040748|NCT04651205|No Intervention|Untreated|This control group will be untreated for 8 weeks as to be a controlled group. Then all participants in the control group will be randomised again to either Mg-B1 or B1-Mg groups for another 8 weeks (delayed-start intervention).
89040749|NCT04651205|Experimental|Mg-B1 early start|Participants in the Mg-B1 are the 'early start' group where they will receive 400 mg of Mg per day for 4 weeks then add on 100 mg of B1 per day for another 4 weeks, a total duration of 8 weeks (MgB1).
89040750|NCT04651205|Experimental|B1-Mg early start|Participants in the B1-Mg are the 'early start' group where they will receive 100 mg of B1 per day for 4 weeks then add on 400 mg of Mg per day for another 4 weeks, a total duration of 8 weeks (B1Mg).
89040751|NCT03456648|Experimental|Part A : postdialysis low dose|Interdialytic kinetics of low dose (2.5 mg apixaban) post-dialysis
89040752|NCT03456648|Experimental|Part A: ipostdialysis high dose|Interdialytic kinetics of high dose (5 mg apixaban) post-dialysis
89632492|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 160 mg|Omaveloxolone (RTA 408) Capsules, 160 mg administered orally once daily for 12 weeks
89632493|NCT02255435|Experimental|Part 1 Omaveloxolone Capsules 300 mg|Omaveloxolone (RTA 408) Capsules, 300 mg administered orally once daily for 12 weeks
89632494|NCT02255435|Placebo Comparator|Part 1 Placebo Capsules|Placebo capsules administered orally once daily for 12 weeks
89632495|NCT02255435|Placebo Comparator|Part 2 Placebo Capsules|Placebo capsules administered orally once daily for 48 weeks
89632496|NCT02255435|Experimental|Part 2 Omaveloxolone Capsules 150 mg|Omaveloxolone (RTA 408) Capsules, 150 mg administered orally once daily for 48 weeks
89632497|NCT02229123|Experimental|Intravenous levetiracetam|1 loading dose of 30, 40 or 50 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10 or 12.5 mg/kg.
89632498|NCT02216864|Experimental|Multiple Subcision|Subjects will receive multiple subcision treatments to their randomized side of the face 5 times total spaced 4 weeks apart.
89632499|NCT02216864|No Intervention|Control|Subjects will receive no intervention control on the other side of the face.
89632500|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Follicular Lymphoma subjects
89632501|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive Follicular Lymphoma subjects
89632502|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects
89040753|NCT03456648|Experimental|Part B : predialysis low dose|Intra- and interrdialytic kinetics of low (2.5 mg) apixaban pre-dialysis
89040754|NCT03456648|Experimental|Part B : predialysis high dose|Intra- and interrdialytic kinetics of high (5 mg) apixaban pre-dialysis
89632503|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects
89632504|NCT02180711|Experimental|Part 3: acalabrutinib Regimen 1|acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects
89632505|NCT02159755|Experimental|Treatment (ibrutinib, palbociclib)|Patients receive ibrutinib PO QD on days 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89632506|NCT02125149|No Intervention|Control|Standard of care
89632507|NCT02125149|Experimental|Intervention|Exercise intervention from 12 week gestation until delivery
89632508|NCT02061423|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months.
89632509|NCT01881048|No Intervention|Arm I|Patients undergo observation.
89040755|NCT04651283|Experimental|Adaptive seating equipment group|Study group who received the same selected program for hand function on adaptive swiss ball seating
89040756|NCT04651283|Active Comparator|Traditional seat group|Control group who received a specially selected physical therapy program for hand function on a standard chair seating.
89632510|NCT01881048|Experimental|Arm II (fish oil)|Patients receive omega-3 fatty acid by mouth everyday until the morning of surgery.
89632511|NCT01881048|Experimental|Arm III (celecoxib)|Patients receive celecoxib by mouth twice a day until the morning of surgery.
89632512|NCT01822652|Experimental|iC9-GD2 T Cells - fresh - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
89632513|NCT01822652|Experimental|iC9-GD2 T Cells - frozen - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
89632514|NCT01822652|Experimental|iC9-GD2 T cells,Cytoxan,Fludara,Keytruda|Fresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
89040757|NCT02428491|Experimental|DTaP-IPV-HB-PRP~T Vaccine|All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age).
89632515|NCT01792583||Prospective Cohort|Prospective is defined per protocol: prospective data of pregnancy exposure are data acquired prior to the knowledge of the pregnancy outcome or prior to the detection of a congenital malformation at prenatal examination (e.g. fetal ultrasound, serum markers).
89040758|NCT00557921|Experimental|1|
89040759|NCT00557921|Active Comparator|2|
89040760|NCT03456609|Experimental|shenqifuzheng|
89040761|NCT03456609|Placebo Comparator|0.9%sodium chloride|
89040762|NCT02346162|Experimental|Intervention|Weight management intervention
89040763|NCT02346162|Other|Usual Care Control|Usual Care for planning healthy pregnancy
89057463|NCT01683006|Active Comparator|Neuromuscular blocker group|"Continuous application of neuromuscular blockers during therapeutic hypothermia.~Bolus application of placebo in case of shivering."
89632516|NCT01792583||Retrospective Cohort|Retrospective is defined per protocol: retrospective data of pregnancy exposure are data acquired after the outcome of the pregnancy is known or after the detection of a congenital malformation on prenatal examination.
89040764|NCT02324283|Active Comparator|Desflurane|Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
89040765|NCT02324283|Active Comparator|Propofol|Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
89040766|NCT00543426|Experimental|1|Fuzheng Huayu Tablets
89040767|NCT00543426|Sham Comparator|2|sham Fuzheng Huayu Tablets
89632517|NCT01777802||Prostate Cancer|Patients with prostate cancer will be treated with SBRT, IMRT or brachytherapy
89632518|NCT01777802||Breast Cancer|Patients with breast cancer will be treated with SBRT, IMRT or brachytherapy
89632519|NCT01777802||Lung Cancer|Patients with lung cancer will be treated with SBRT, IMRT or brachytherapy
89632520|NCT01777802||Melanoma Cancer|Patients with melanoma cancer will be treated with SBRT, IMRT or brachytherapy
89632521|NCT01721798|Active Comparator|Copper T-380a Intrauterine Device (C-IUD)|Copper T-380A Intrauterine Device with approximately 380 mm2 exposed copper. Devices used were those included as part of the South African public sector health formulary.
89632522|NCT01721798|Active Comparator|Levonorgestrel IUD (LNG-IUD)|Levonorgestrel IUD containing 52 mg levonorgestrel registered for contraceptive use in South Africa at the time of the trial.
89632523|NCT01688063||Part A: 3 Arms|Subjects will be recruited and enrolled to fill one of three Arms. The first Arm will include 25 subjects who are scheduled to receive resurfacing or tightening procedures AS STANDARD OF CARE (CO2 resurfacing or tightening procedure (1 treatment), radiofrequency (2 tx), Fraxel ( 2 tx), or PDL. These subjects will have baseline elasticity measurements recorded on their face and right forearm before their procedures, and follow up measurements will be repeated 3 months following their last treatment. The second Arm will include 25 subjects who are not scheduled to receive any cosmetic procedures but who agree to return for repeated measurements 3 months following the first. Baseline elasticity measurements will be recorded from subjects' face and right forearm and subjects will return in 3 months for follow-up measurements. The third Arm will include the remaining 50 subjects; these subjects will have the elasticity measurements performed only once on their face and forearm.
89632524|NCT01688063||Part B|The study population in the second cohort will consist of 250 subjects who have a surgical scar >2 cm in length. Subjects enrolled will have three elasticity measurements performed in one study visit. Elasticity will be measured directly in the center of the scar, 3cm perpendicular to the center of the scar, and 3cm in line from one end of the scar (Appendix 2).
89632525|NCT01492036||Gene Transfer Therapy|Study participants receiving gene therapy product at MD Anderson Cancer Center
89632526|NCT01291953|Experimental|Screening|Opportunist Screening asymptomatic patients. Taking the arterial pulse. Will invite patient to realize an ECG, if pulse is irregular
89632527|NCT01291953|Active Comparator|Control|Case finding of patient whith symptoms of atrial fibrilation. Taking the arterial pulse. ECG if pulse is irregular
89040768|NCT00557999|Other|Experimental group|Application of a weaning mechanical ventilation protocol
89040769|NCT00557999|No Intervention|Control group|
89040770|NCT00558077|Experimental|A|Metformin plus clomiphene citrate
89040771|NCT00558077|Active Comparator|B|Laparoscopic ovarian drilling
89632528|NCT01241864|Experimental|Allogenic islet cells (human, U. Chicago)|
89632529|NCT01038778|Experimental|Treatment (entinostat, aldesleukin)|"Patients receive entinostat PO every 2 weeks beginning on day -14 and high-dose aldesleukin IV every 8 hours on days 1-5 and 15-19. Cycles repeat every 84 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients with evidence of tumor shrinkage may receive up to 3 cycles of high-dose aldesleukin therapy. Patients with stable disease by RECIST version 1.0 criteria, but without evidence of tumor shrinkage after two cycles will receive only entinostat until disease progression is documented."
89632530|NCT01014286||Advanced Adenocarcinoma|Stage IV adenocarcinoma who have undergone biopsy with remnant tissue.
89040772|NCT00558116|Experimental|1|Treatment with Dynasplint device
89040773|NCT00558116|No Intervention|2|Control group; does not receive conservative or surgical treatment.
89040774|NCT04650971|Experimental|"Vaccine UniFluVec 6.7 log EID50/dose"|"Cohort 1 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 6.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
89040775|NCT04650971|Experimental|"Vaccine UniFluVec 7.7 log EID50/dose"|"Cohort 2 - 30 subjects were randomized in a 2:1 ratio to be treated either with Vaccine UniFluVec 7.7 log EID50/dose (20 subjects) or with placebo (10 subject, see placebo arm)."
89040776|NCT04650971|Placebo Comparator|Placebo|Placebo comparator arm consists of 20 subjects (10 subject in each Сohort).
89040777|NCT00543504|Experimental|Bevacizumab + Sunitinib|Arm 1: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sunitinib 12.5 mg orally daily for 4 weeks, then 2 weeks off.
89040778|NCT00543504|Experimental|Bevacizumab + Sorafenib|Arm 2: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sorafenib 200 mg by mouth daily for 28 Days
89040779|NCT00543504|Experimental|Bevacizumab + Erlotinib + Cetuximab|Arm 3: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Erlotinib 50 mg By Mouth Daily for 28 Days + Cetuximab loading dose 100 mg/m² IV and maintenance 75 mg/m² on Days 1, 8, 15, 22.
89040780|NCT00543504|Experimental|Bevacizumab + Trastuzumab + Lapatinib|Arm 4: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Trastuzumab loading dose 2 mg/kg IV then maintenance dose 1 mg/kg IV on Day 1 + Lapatinib 250 mg By Mouth Daily for 21 Days.
89040781|NCT04651127|Experimental|Toripalimab + Chidamide Arm|
89040782|NCT04650776|Experimental|High heat strain|participants exercised at 75% of their heart rate maximum (HR max) and wore light athletic clothing (t-shirt and shorts)
89040783|NCT04650776|Experimental|Low heat strain|participants exercised at 50% HR max, wearing protective firefighter clothing (jacket and trousers)
89632531|NCT00980954|Experimental|Arm I: Cisplatin/Radiation Therapy|Patients undergo standard EBRT or IMRT to the pelvis once daily 5 days a week for 5-6 weeks. Patients also receive concurrent cisplatin IV over 1 hour once weekly for 6 weeks.
89632532|NCT00980954|Experimental|Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel|Patients receive chemoradiotherapy as in arm I. Beginning 4-6 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89632533|NCT00748995||Neurocognition Deployment Health Study (NDHS) participants|Surviving NDHS participants who returned from their initial deployment to Iraq or Afghanistan.
89632534|NCT00716066|Experimental|Treatment (immunosuppressive therapy followed by transplant)|Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.
89632535|NCT00704288|Experimental|Group A cabozantinib 175 mg|cabozantinib, 175 mg, taken orally once per day (qd).
89632536|NCT00704288|Experimental|Group B cabozantinib 125 mg|cabozantinib, 125 mg, taken orally once per day (qd).
89632537|NCT00704288|Experimental|Group C 125 mg|cabozantinib, 125 mg, taken orally once per day (qd).
89632538|NCT00085930|Experimental|EBV specific CTLs w/out lymphodepletion|Escalating doses of 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) and 14g2a.zeta transduced autologous peripheral blood T-cells administered to patients with Neuroblastoma.
89632539|NCT00031512|Placebo Comparator|Placebo|Placebo.
89632540|NCT00031512|Experimental|Pleconaril (VP63843)|The first dosing cohort received 5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation. Subsequent dosing cohorts are receiving 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
89632541|NCT03199248||the participant accepted needle assisted capsulotomy for DMC|
89632542|NCT03199248||the participant accepted aspiration for DMC only|
89632543|NCT04745338|Placebo Comparator|low caloric diet|low caloric diet (1200cal/day)
89632544|NCT04745338|Active Comparator|cryolipolysis|cryolipolysis 3 sessions one session every 6 weeks by 3max cool shaping device
89632545|NCT01605227|Experimental|cabozantinib|Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
89632546|NCT01605227|Active Comparator|prednisone|Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
89632547|NCT02446548|Experimental|aliskiren - placebo - losartan|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
89632548|NCT02446548|Experimental|losartan - placebo - aliskiren|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
89632549|NCT04291768|Experimental|Intervention group|Shortened antibiotic treatment of 5 days
89632550|NCT04291768|Active Comparator|Control group|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician
89632551|NCT02446470|Experimental|Sinus Tarsi approach|The Sinus Tarsi approach is the surgical approach for the incision.
89632552|NCT02446470|Active Comparator|Extensile Lateral approach|The Extensile Lateral approach is the surgical approach for the incision.
89632553|NCT03199326|Experimental|Collaborative Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the collaborative practice, the caseworkers will conduct a standard CPS investigation. Additionally, caseworkers will seek parental permission to contact an identified primary health care provider at two points in the CPS investigation for information sharing related to health needs, social risks, and recommended interventions.
89632554|NCT03199326|No Intervention|Comparison Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the comparison practice, the caseworkers will conduct a standard CPS investigation.
89632555|NCT03199170|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.2 mg, 0.9%NSS each side
89632556|NCT03199170|Experimental|Intrathecal morphine with bilateral Quadratus Lumborum Block|Intrathecal morphine 0.2 mg, 0.25%Bupivacaine 25 ml each side
89632557|NCT03199170|Experimental|Bilateral Quadratus Lumborum Block|No intrathecal morphine, 0.25%Bupivacaine 25 ml each side
89632558|NCT04229056|Experimental|Specific computer-based cognitive rehabilitation|350 patients (200 with stroke, 100 with Parkinson's disease and 50 with heart attack) will be allocated to specific computer-based cognitive rehabilitation. This group will train with 10 exercises from the cognitive rehabilitation software 'Scientific Brain training PRO'. These 10 exercises are designed to train various executive functions.
89632559|NCT04229056|Active Comparator|General computer-based cognitive stimulation|350 patients (200 with stroke, 100 with Parkinson's disease and 50 with heart attack) will be allocated to general computer-based cognitive stimulation. This group will train with 10 generally mentally stimulating games on a website specifically designed for this trial. These 10 games are chosen because they are believed to have a low load on executive functions but stimulate over-all concentration and visuoperceptual abilities.
89040784|NCT00543660|Experimental|Intervention arm DSEK|Intervention: DSEK
89632560|NCT03118128|Active Comparator|metformin|Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
89632561|NCT03118128|No Intervention|No metformin|
89632562|NCT03199092|Experimental|RRT+sat|RRT in combination with specific auditory training (sat) administered for a total of 20 hours over 10 weeks (60 minutes biweekly sessions).
89632563|NCT03199092|Experimental|Abilmente|Abilmente method administered for a total of 10 hours over 5 weeks (60 minutes biweekly sessions).
89632564|NCT03198936|Experimental|Cognizin® SynapsaTM|Dose - 2 capsules twice a day with meals
89632565|NCT03198936|Placebo Comparator|Placebo|Matching placebo capsules with microcrystalline cellulose with added colours Dose - 2 capsules twice a day with meals
89632566|NCT03199014|Experimental|prolonged deployment strategy group|"in deploying the Drug-eluting Stents with a prolonged time group,the inflation time was more than 30 seconds when the Drug-eluting Stents deploying,unless the patients was unstable."
89211674|NCT02548208|Active Comparator|Verum focused extracorporeal shockwave therapy|Verum focused extracorporeal shockwave therapy is applied at 7 equidistant points, perpendicular to the belly of the biceps brachii muscle on a thought line between the radial tuberosity and the coracoid process (Dermagold120, Tissue Regeneration Technologies, Woodstock, Georgia, U.S.). Shock waves are generated by electrohydraulic mechanisms.
89211675|NCT02548208|Sham Comparator|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy. The study personal is blinded to the applicators. All handling, adjustments and noises are thus same in this group.
89211676|NCT02548208|No Intervention|Control|Control procedure stipulates participants to lay down on the same therapy table for 5 minutes receiving no intervention.
89211677|NCT01010464|Experimental|Adhesion Reduction Plan|Lysis of adhesions and application of Seprafilm
89211678|NCT01010464|No Intervention|Standard Management|Standard management and no application of Seprafilm
89211679|NCT00841256|Experimental|Immunotherapy|Grass pollen allergens in a water/glycerol solution
89211680|NCT00841256|Placebo Comparator|Placebo|Water/glycerol solution with phosphate buffered saline
89211681|NCT05360355||patients undergone total face reconstruction and intraoperative indocyanine green angiography|This clinical study enrolled 10 patients treated with total face reconstruction and intraoperative indocyanine green angiography from Jun 2018 to Jun 2021.
89211682|NCT01010542|Active Comparator|ILV-095|
89211683|NCT01010542|Placebo Comparator|placebo|
89211684|NCT00989703|Experimental|1|GLPG0259 25/50/75 mg/day for 14 days
89211685|NCT00989703|Placebo Comparator|2|placebo for 14 days
89211686|NCT01012960|Placebo Comparator|Placebo|Placebo= normal saline
89211687|NCT01012960|Active Comparator|methylnaltexone|peripheral opioid antagonist
89211688|NCT04572009|Experimental|Augmented physician|Medical decision assisted by the bio-mathematical model to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
89632567|NCT03199014|Active Comparator|rapid deployment strategy group|"in deploying the Drug-eluting Stents with a conventional time group, a conventional method was used to deploying drug-eluting stents,the actual inflation time was within 10s determined by interventional cardiologist."
89632568|NCT05642650|Experimental|Novel wearable device strategy group|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps.
89632569|NCT05642650|No Intervention|Control group|Patients receive a standard of care for heart failure without a wearable device.
89632570|NCT03198780|Experimental|Breathing Awareness|"In the clinic, once patients are proficient with the proposed tool, they will (1) independently don the pulse oximeter, (2) use the prototype to perform the mindful breathing intervention. The whole session will last no longer than 60 minutes with 30 minutes for the consent and demonstrations, two minutes to don the study devices, 15 minutes to practice mindful breathing, and two minutes to doff the study devices. The mindful breathing portion will be divided into three sessions. Each session will last three minutes and display a different presentation of Heart Rate Coherence biofeedback.~At home, after completing the in-clinic study, five patients will take the mindful breathing tool home for a week to practice pursed-lip breathing at least five times. They will don the study devices, perform the intervention, and doff study devices."
89632571|NCT03198624|Active Comparator|HTL0018318 Low dose, Part A.|Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).
89632572|NCT03198624|Active Comparator|HTL0018318 High dose, Part A|1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).
89632573|NCT03198624|Active Comparator|HTL0018318 Low dose, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
89211689|NCT04572009|Placebo Comparator|Control|Unassisted medical decision to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.
89211690|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
89632574|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
89211691|NCT01683825|Other|F-18 florbetapir PET-Healthy Controls|Individuals without documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
89211692|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Reproducibility Subjects|Some of the individuals with documented cardiac amyloidosis from arm 1 will undergo a second F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) within 30 days to measure reproducibility
89632575|NCT03198624|Active Comparator|HTL0018318 High dose, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
89211693|NCT02547116|No Intervention|Standard anti-staphylococcal antibiotic|
89211694|NCT02547116|Experimental|Standard anti-staphylococcal antibiotic + Rifampin|Individuals with known, persistent small-colony variant MRSA, who are treated with standard anti-staphylococcal antibiotics, will be treated with their standard therapy in addition to Rifampin.
89211695|NCT05377047|Experimental|Experimental SABR arm|Standard first line systemic therapy + SABR.
89211696|NCT05377047|No Intervention|Control systemic therapy arm|Standard first line systemic therapy.
89211697|NCT00841490||1|Intellectually & Developmentally Disabled Adults
89632576|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
89632577|NCT03194724||High Vitamin A exposure|There was no intervention
89632578|NCT03194724||Low vitamin A exposure|No intervention
89632579|NCT03194802|Experimental|Sleeping Without Pills Program|Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering
89632580|NCT03194802|Active Comparator|Self-Monitoring|Daily Self-monitoring of sleep and sleep medication using sleep diary
89632581|NCT03198858|Other|Ablation with Carto® 3 System|Ablation with Carto® 3 System
89632582|NCT03198858|Other|Ablation CartoUnivu™|Ablation CartoUnivu™
89632583|NCT01709513|Other|Atorvastatin (statin rechallenge arm)|Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
89632584|NCT01709513|Active Comparator|Ezetimibe|Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
89632585|NCT01709513|Experimental|Alirocumab 75 mg/ up to 150 mg|Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.
89632586|NCT05637190|Experimental|Expressive Arts Therapy group|The Expressive Arts Therapy group will receive the Expressive Arts intervention via face-to-face workshops for 2 consecutive weeks (2 hours per session). there are a total of 3 batches (around 15 participants per batch) for the intervention.
89632587|NCT05637190|No Intervention|Waitlist control group|The Waitlist control group will not receive any intervention during the study, but they will receive self-help art therapy materials after the whole study procedure.
89632588|NCT02449590|Active Comparator|Onion powder|Initial test meal contained 20g freeze dried onion powder in hot meals (1 potato soup and 1 meatball-meal daily). Subsequent daily meals contained 20g onion powder in the same meal formats.
89632589|NCT02449590|Placebo Comparator|Placebo|Hot meals (1 potato soup and 1 meatball-meal daily)containing 8.5 g sucrose and 2 g soy protein instead of onion powder
89632590|NCT04152148|Experimental|500mg BAT4306F|3 weeks of a cycle
89632591|NCT04152148|Experimental|750mg BAT4306F|3 weeks of a cycle
89632592|NCT04152148|Experimental|900mg BAT4306F|3 weeks of a cycle
89632593|NCT04152148|Experimental|1000mg BAT4306F|3 weeks of a cycle
89632594|NCT02446158|Experimental|Chlorhexidine gluconate|PD (peritoneal dialysis) paitents with daily chlorhexidine exit site care
89632595|NCT02446158|No Intervention|Control group|PD (peritoneal dialysis) patients with usual (Normal saline) exit site care
89632596|NCT02446002|Experimental|Lofexidine + Naltrexone|
89632597|NCT04125316||Asthma|Asthma patients
89632598|NCT02445924||Control group 1|ten non smoker volunteers
89632599|NCT02445924||Control group 2|ten smoker volunteers
89632600|NCT02445924||NSCLC patients|twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
89632601|NCT02446080|Experimental|Probiotic Group|Milk drink with probiotic culture (150 mL/daily) for 60 days.
89632602|NCT02446080|Active Comparator|Control Group|Milk drink (150 mL/daily) for 60 days.
89632603|NCT05627830|Experimental|Ultrasound Guided Prolotherapy forTreatment of Internal Derangement of TMJD.|"Injection procedure in TMJ Space guided by ultrasound probe the injection materials will be composition of ( !0% Dextrose ) + (Saline ) + (2% Lidocaine, plain anesthesia ).~The intervention procedure will done after TMJ MRI assessment for patients who have anterior disc displacement with reduction (DDWR)"
89040785|NCT04650737|Active Comparator|Group A (single shot,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine ;ultrasound guided ESPB
89040786|NCT04650737|Active Comparator|Group B (continous infusion,n=20)|Patients in this group will receive 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs;ESPB
89632604|NCT05627830|Active Comparator|Non-Guided Ultrasound ( Blind) Prolotherapy for Treatment of Internal Derangement of TMJD.|"Injection procedure in TMJ Space by anatomical land mark (blindly), and we also call it ( conventional prolotherapy ) the injection materials will be composition of ( !0% Dextrose ) + (Saline ) + (2% Lidocaine, plain anesthesia ).~The intervention procedure will done after TMJ MRI assessment for patients who have anterior disc displacement with reduction (DDWR)"
89632605|NCT04118764|Experimental|Focused ultrasound treatment|Neuronavigation-guided focused ultrasound treatment in Alzheimer's disease patients using a single-element transducer in conjunction with Definity Microbubbles (10 μl/kg).
89632606|NCT01605071|Active Comparator|Early Postmenopausal|Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy
89632607|NCT01605071|Active Comparator|Late Postmenopausal|Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy
89632608|NCT02710422|Experimental|Arm 1 - Amniotic Membrane Placement|Participants who receive the human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
89632609|NCT02710422|Other|Arm 2 - No Amniotic Membrane Placement|Participants who do not receive human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
89632610|NCT04345198|Experimental|Intervension|Adrenal artery ablation is performed in PA patients with resistant hypertension.
89632611|NCT03198390||Subjects with chronic skin conditions|Subjects with chronic skin conditions including but not limited to atopic dermatitis, contact dermatitis, hidradenitis suppurativa, and psoriasis
89632612|NCT03198390||Healthy subjects|
89632613|NCT03192618|Experimental|treatment group|
89632614|NCT03192618|No Intervention|control group|
89632615|NCT01706159|Experimental|rFXIII|
89632616|NCT01706159|Active Comparator|Placebo|
89040787|NCT04650503||Patients with eosinophilic asthma at baseline|Patients showing ≥3% sputum eosinophils at baseline
89040788|NCT04650503||Patients with non eosinophilic asthma at baseline|Patients showing <3% sputum eosinophils at baseline
89040789|NCT04650620|Experimental|Plenhyage® thin|Plenhyage® thin for the treatment of mild wrinkles;
89040790|NCT04650620|Experimental|Plenhyage® medium|Plenhyage® medium for the treatment of moderate wrinkles;
89040791|NCT04650620|Experimental|Plenhyage® strong|Plenhyage® strong for improving the skin tones and irregularities (atrophies) of the skin surface in neck, abdomen, thighs and buttocks
89057464|NCT01683006|Placebo Comparator|Placebo group|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of neuromuscular blockers in case of shivering."
89632617|NCT03198312|Experimental|CathiportTM|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
89632618|NCT03198312|Active Comparator|Implant Port|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
89632619|NCT04113226|Active Comparator|classical rituximab-based chemotherapy|Rituximab-based physician's choice chemotherapy
89632620|NCT04113226|Experimental|rituximab plus lenalidomide|Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression.
89632621|NCT04552145|Active Comparator|surgery|Decompression surgery
89632622|NCT04552145|Active Comparator|physiotherapy|Physical therapy program
89632623|NCT02444208|Experimental|Cocaine Inhibitory Control Training|This group will receive active inhibitory control training.
89632624|NCT02444208|Placebo Comparator|Neutral Inhibitory Control Training|This group will receive neutral inhibitory control training.
89632625|NCT05044000|Experimental|Heavy blanket|Patients will start with heavy blanket during 15 days
89632626|NCT05044000|Placebo Comparator|Non-heavy blanket|Patients will start with non-heavy blanket during 15 days
89632627|NCT04551989||Participants with EGPA who have received NUCALA treatment|Data will be collected of participants who have already received NUCALA for 96 weeks in routine clinical practice.
89632628|NCT02444364|Experimental|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
89632629|NCT05039476|Active Comparator|Retinol face cream|Retinol face cream on one half of the participant's face
89632630|NCT05039476|Placebo Comparator|Placebo face cream|Placebo face cream on one half of the participant's face
89632631|NCT02445846||Pregnant women|Pregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia
89632632|NCT05031598|Experimental|Long-term fasting|The participants will undergo 6-12 fasting days according to the Buchinger Wilhelmi fasting program
89632633|NCT01706003||Telemedicine Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated via telemedicine for migraine headaches
89632634|NCT01706003||In-Office Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated in the clinician's office for migraine headaches
89632635|NCT02445690||Clinical remission without inflammation|Patients with Crohn's disease in clinical remission and no inflammation in the colonoscopy
89632636|NCT02445690||Clinical remission with inflammation|Patients with Crohn's disease in clinical remission and active inflammation in the colonoscopy
89632637|NCT02445612||Experimental: MA09-hRPE|Sub-retinal transplantation of MA09-hRPE cells
89632638|NCT00356356|Experimental|All subjects|257 subjects
89632639|NCT03194412|Experimental|Diet /nutritional|Special diet for elderly. It should be rich in the appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients.
89632640|NCT03194412|Experimental|Physical activity|Regular physical activity in everyday life of the elderly - exercises to improve coordination and balance, stretching exercises, strength exercises.
89632641|NCT03194412|Experimental|Comprehensive therapy|Special diet for elderly (appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients) and regular physical activity in everyday life of the elderly (exercises to improve coordination and balance, stretching exercises, strength exercises)
89632642|NCT03194412|Experimental|Caregivers of elderly|Education about frailty: prevention and treatment (nutrition, physical activity, dietary supplement diet).
89632643|NCT03194412|No Intervention|Control group|Without intervention
89632644|NCT04032730|No Intervention|Control|Participants assigned to the control arm will undergo treatment and care for MDR/XDR-TB as per the South African Department of Health guidelines.
89632645|NCT04032730|Experimental|Intervention|Participants assigned to the intervention arm will undergo extensive counselling, participants will be provided with an electronic pillbox that monitors their adherence to one of their TB and one of their ART medication. Based on the recordings provided by the wisepill device we will determine if a participant is adherent to their medication and intervene with counselling, phone calls, home visits and relevant referrals.
89211698|NCT00841490||2|Control Group of Adults without Intellectual & Developmental Disabilities
89632646|NCT03194178||Pierre Robin sequence patients|Patients presenting a Pierre Robin sequence, and who have been cared in their early childhood by either the Necker or Trousseau hospitals teams, and who are between 12 and 18 years old at the beginning of the study.
89632647|NCT03194100||Diabetes Mellitus|
89632648|NCT03194100||Prediabetes|
89632649|NCT03194100||Normal glucose tolerance|
89632650|NCT02444052|Experimental|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
89632651|NCT02444052|Experimental|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
89632652|NCT02443974|Experimental|Knee brace group|Patients received knee brace with hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
89632653|NCT02443974|Experimental|Knee sleeve group|Patients received knee sleeve without hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
89057465|NCT04542668|Other|Cycling as first intervention|Cycling -> Running -> Inotropy -> Resting
89632654|NCT02443974|No Intervention|Control group|Keep medication usual
89632655|NCT01705691|Active Comparator|Arm 1: Paclitaxel then AC|Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
89632656|NCT01705691|Experimental|Arm 2: Eribulin then AC|Eribulin 1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle for 4 cycles, followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
89632657|NCT04016974|Experimental|Oral semaglutide|
89632658|NCT04016974|Placebo Comparator|Placebo|
89632659|NCT02449668|Sham Comparator|Acupuncture on sham points (SA)|The control group received treatment with acupuncture needles on sham points (SA).
89632660|NCT02449668|Experimental|True acupuncture (TA)|The intervention group received treatment with true acupuncture techniques (TA) on a selection of points described as effective in the literature.
89632661|NCT02450058|Active Comparator|FEC|5-Fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, intravenously on day 1, every 21 days
89632662|NCT02450058|Active Comparator|EP|Epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, 3-hour infusion on day 1, every 21 days
89632663|NCT03197532||Group 1|Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment.
89632664|NCT03197532||Group 2|Healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy.
89632665|NCT03197532||Group 3|Reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility
89632666|NCT02445300|Active Comparator|AQUACEL® Ag Surgical dressing|AQUACEL® Ag Surgical dressing is used to cover the surgical wound in the OR. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer.
89632667|NCT02445300|Active Comparator|Sofra-Tulla® dressing|The Sofra-Tulle® dressing was used in the OR and routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine.
89632668|NCT04971070||Hypoglycemic disturbance group|
89632669|NCT04971070||Hypoglycemia was not a disorder of consciousness group|
89632670|NCT02445378|Experimental|Group I (aromatherapy and essential oils week 1)|Patients select between 3 scented essential oils: peppermint, lavender, or chamomile which is diffused in the hospital room from approximately 9 PM in the evening until morning during week 1 and placebo intervention using rose water during week 2.
89632671|NCT02445378|Experimental|Group II (aromatherapy and essential oils week 3)|Patients undergo placebo intervention using rose water during week 1 and aromatherapy and essential oils as in Group I during week 2.
89632672|NCT02445144||SCA Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
89632673|NCT02445144||Control Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
89632674|NCT02445066|Other|Open label|Vitamin D3 - 4,000 IU/day for 4 months
89632675|NCT02443584|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
89632676|NCT02443584|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
89632677|NCT03197610|Experimental|SCTG+EMD|TEST GROUP: Langer and Langer technique was used to prepare the recipient side. The vestibule surfaces of adjacent interdental papillae were de-epithelialized. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges. EMD (Emdogain®, Straumann, Basel, Switzerland) was used in the test group in addition to SCTG. Prior to EMD application, the root surface was applied with 24% EDTA (PrefGel, Straumann, Basel, Switzerland) for 2 minutes. The area was washed with saline and then EMD was applied.
89632678|NCT03197610|Experimental|ONLY SCTG|CONTROL GROUP: Langer and Langer technique was used to prepare the recipient side. The anesthetic solution was applied to the donor site in the palatinal region on the same side as the operation site. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges.
89632679|NCT02443428||Eribulin Mesilate|Participants will be treated in accordance with normal clinical practice. The recommend dose of eribulin is 1.23 mg/m2 administered intravenously on days 1 and 8 of every 21-day cycle. Treatment with eribulin is continued until disease progression, onset of unacceptable drug toxicities, or participant/physician's request to discontinue.
89632680|NCT03197298||Clopidogrel Period|ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen
89632681|NCT03197298||Ticagrelor Period|ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen
89632682|NCT05723224|Experimental|Endoscopic ultrasound-guided gallbladder treatment|Endoscoipc gallbladder drainage under EUS guide using lumen apposing metal stents (LAMS) followed when needed by endoscopic lithotripsy.
89632683|NCT03197220|Experimental|fish|
89632684|NCT03197220|Experimental|walnut|
89632685|NCT03197220|Experimental|fish-walnut|
89632686|NCT02443506|Experimental|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
89632687|NCT02443506|Placebo Comparator|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
89632688|NCT03197688||Notapplicable|Not applicable as non-interventional study
89632689|NCT03903484|Experimental|Deprescribing intervention|Included patient participants will meet with their clinical pharmacist to complete a survey about medication use and quality of life. Then working with the pharmacist, patients will prioritize medications that are no longer needed for discontinuing. A deprescribing plan will be created and the pharmacist will work with the patient to complete this plan. The patient will also be provided resources from the study toolbox to support the patients as they work through deprescribing the targeted drugs. Once the deprescribing plan is completed there will be a patient survey that will capture satisfaction with the deprescribing experience and patient quality of life.
89632690|NCT02443272|Active Comparator|Control Arm|Receive standard incision and drainage
89632691|NCT02443272|Experimental|Intervention Arm|Receive minimal invasive loop drainage using the Vesi-loop device
89632692|NCT05723146|Experimental|Spatial cognition assessment|A single session of spatial cognition assessment (baseline) will be proposed to participants. This assessment will be based on paper-and-pencil tasks and immersive virtual reality tasks (with an HTC Vive Pro Head-Mounted-Display). The assessment will last around 1 hour.
89211699|NCT00144781|Active Comparator|1|0.58 mg Aldurazyme/kg of body weight (100 U/kg) administered every week (labeled dose). Final Visit is Week 27 for patients randomized to every week regimen.
89632693|NCT00357448|Experimental|Arm I|Patients receive intraperitoneal denileukin diftitox over at least 15 minutes on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89632694|NCT03192384||Before intervention|Data from clusters before educational programme intervention implemented.
89632695|NCT03192384||After intervention|Data from clusters after educational programme intervention implemented
89632696|NCT05715658|Experimental|Evaluating the pharmacokinetics of dabigatran etexilate in elderly healthy subjects|Adult healthy subjects and elderly healthy subjects only took one 110mg dabigatran etexilate capsule orally, and elderly patients with atrial fibrillation took dabigatran etexilate according to routine medical care.
89632697|NCT02443194|Active Comparator|Group # 1- ACTIVE|"Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age, KPS, the degree of tumor resection) two research groups:~Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg Cymbalta duloxetine -morning for a week and then a dose exceeding 60 mg for 3 months."
89632698|NCT02443194|Placebo Comparator|Group # 2-PLACEBO|Group # 2 will include 50 patients treated immediately after diagnosis with placebo for 3 months
89632699|NCT03772288|Experimental|Dose Escalation: TAK-659 + NKTR-214|TAK-659 tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 in a 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participant. The dose escalation phase will determine the MTD or RP2D of TAK-659. Dose escalation of TAK-659 will be based on available safety and tolerability data.
89632700|NCT03772288|Experimental|Safety Expansion: TAK-659 + NKTR-214|TAK-659, tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 of 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participants. TAK-659 and NKTR-214 MTD/RP2D will be determined from the dose escalation phase.
89632701|NCT03196908|Experimental|Energy Drink Brand 1|Two 16-oz bottles of Energy Drink Brand 1
89632702|NCT03196908|Experimental|Energy Drink Brand 2|Two 16-oz bottles of Energy Drink Brand 2
89632703|NCT03196908|Placebo Comparator|Placebo|Two 16-oz bottles that each contain 390 ml of carbonated water, 20 ml of reconstituted lime juice, and 70 ml of cherry flavoring
89632704|NCT03193944|Active Comparator|Intervention group|Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks
89632705|NCT03193944|Placebo Comparator|control group|Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.
89632706|NCT03766906|Experimental|Talk STEM Familia App|This arm will test the feasibility of the Talk STEM Familia app to improve English language acquisition and family engagement and promote long-term educational and health outcomes among first- and second-generation Latino families.
89632707|NCT03193164|Experimental|group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
89632708|NCT03193164|Sham Comparator|group 2|Decubitus Position with the limbs raised to 20º without NMES and after NMES.
89632709|NCT03196830|Experimental|Treatment group|the group of patients who received CAR-T treatment
89632710|NCT04745182|Experimental|MASTERY|For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and will contain space to write a specific physical activity goal and to track physical activity (e.g., through step counter data) over the subsequent week. At the in-person visit #2, interventionists will explain PP exercise 1 and MI session 1 to the participants. Calls will last ~30 minutes. Participants will then independently complete PP exercises and MI-based goals and review them at phone sessions over 12 weeks. PP and MI components will be delivered stepwise within sessions (rather than intertwined) based on our experience, participant feedback, and pilot work.
89632711|NCT00357604|Active Comparator|A1|
89632712|NCT00357604|Experimental|A2|
89632713|NCT02442960|Active Comparator|Cohort 1|Herbal treatment (SA100) 500 mg/day (250 mg twice per day)
89632714|NCT02442960|Active Comparator|Cohort 2|Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)
89632715|NCT02443038|Active Comparator|Home Exercise|Participants will practice 10 minutes of yoga in addition to 5 minutes of relaxation exercises at home each day when not in class.
89632716|NCT02443038|Placebo Comparator|Relaxation Exercise|Participants will practice 5 minutes of relaxation exercises at home each day when not in class.
89632717|NCT02959294|Experimental|Microcannula Harvest Adipose|Acquisition Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via close syringe microcannula harvest from subdermal fat deposits
89632718|NCT02959294|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
89632719|NCT02959294|Experimental|Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline deployment via IV
89057466|NCT04542668|Other|Running as first intervention|Running -> Cycling -> Inotropy -> Resting
89057467|NCT01683045|Experimental|The Estech COBRA® Surgical System|
89057468|NCT01683162|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
89057469|NCT01683162|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin
89057470|NCT01683162|Experimental|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
89057471|NCT02215733||Patients prescribed antihypertensives|
89057472|NCT01683201|Experimental|Functional exercise class|Functional exercise class 45 mins twice weekly from week 12 to week 18
89057473|NCT01683201|Placebo Comparator|Usual Care Group|Usual Care
89057474|NCT02215772|Experimental|BI 44370 BS|200 mg containing 2.43 megabecquerel (MBq) 14C-radioactivity
89057475|NCT01202188|Experimental|indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
89632720|NCT02444598|Experimental|Negative-pressure wound therapy|Vaccum Assisted Closure device. Patients will receive negative-pressure wound therapy according to manufacturer treatment guidelines.
89632721|NCT02444598|Active Comparator|Standard|Patients will be treated with conventional wound dressings according to local treatment protocols.
89632722|NCT05715424|Experimental|Cluster A|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster A. The intervention was administered at month 6 and monitored for two years.
89632723|NCT05715424|Experimental|Cluster B|The study population (school-based) was divided into four clusters. Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster B. The intervention was administered at month 12 and monitored for one and a half years.
89632724|NCT05715424|Experimental|Cluster C|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention. and one cluster was randomly selected as Cluster C. The intervention was administered at month 18 and monitored for a continuous period of one year.
89632725|NCT05715424|Experimental|Cluster D|The study population (school-based) was divided into four clusters.Each cluster will receive the same intervention.and one cluster was randomly selected as Cluster D. The intervention was implemented at month 18 and an evaluation of the effect of the intervention was performed.
89632726|NCT03196752|Experimental|Only arm|Patient's cricoid membrane is identified using both laryngeal handshake method and simple palpation
89632727|NCT03193788|Experimental|pemetrexed maintenance|"Drug: Pemetrexed Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.~Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment~Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment~Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment"
89632728|NCT03193788|No Intervention|observation|observation group will be observed with best supportive care until progressive disease
89632729|NCT02444520|Experimental|Integrated GP Care|"GP training in utilising cognitive behavioural skills during 10-minute consultations;~GP Supervision;~Audio-visual and written materials/guidelines for GP's;~Copies of self-help materials for patients;• Integrated case management discussion prior to secondary care referral. GPs will be encouraged to consult with a colleague before making a referral;~Booklets for patients once consent gained."
89632730|NCT02444520|No Intervention|Waiting List Control Group|Patients in the waiting list control group will continue to receive treatment as usual (TAU), and will be crossed over to receive 'Integrated GP Care' at 6 months post randomization.
89632731|NCT02443116|Placebo Comparator|Cohort 1 - Placebo|Cohort 1 - Placebo
89632732|NCT02443116|Experimental|Cohort 1 - NGM282 3mg|Cohort 1 - NGM282 3mg
89632733|NCT02443116|Experimental|Cohort 1 - NGM282 6mg|Cohort 1 - NGM282 6mg
89632734|NCT02443116|Experimental|Cohort 2 - NGM282 0.3mg|Cohort 2 - NGM282 0.3mg
89632735|NCT02443116|Placebo Comparator|Cohort 2 - NGM282 1mg|Cohort 2 - NGM282 1mg
89632736|NCT02443116|Experimental|Cohort 2 - NGM282 3mg|Cohort 2 - NGM282 3mg
89632737|NCT02443116|Experimental|Cohort 3 - NGM282 1mg|Cohort 3 - NGM282 1mg
89632738|NCT02443116|Placebo Comparator|Cohort 4 - Placebo|Cohort 4 - Placebo
89632739|NCT02443116|Experimental|Cohort 4 - NGM282 1mg|Cohort 4 - NGM282 1mg
89211700|NCT00144781|Active Comparator|2|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every week. Final Visit is Week 27 for patients randomized to every week regimen.
89632740|NCT05715190|No Intervention|Control|Visiting the medical psoriasis outpatient clinic. Receiving a medical consultation, phototherapy and methotrexate treatment.
89632741|NCT05715190|Other|Education|Usual care as described for the CG will also be provided to the IG (visit to the outpatient clinic as prescribed by the physician). Psoriasis plaque measurement, psoriasis care and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a multidisciplinary nurse-led educational program
89632742|NCT02442882||Boxers|Individuals who participate in a boxing tournament will be tested on balance, neuropsychological, and visual functions before and after the tournament.
89211701|NCT00144781|Active Comparator|3|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
89632743|NCT03196596||Computer simulation|Patients in whom a computer simulation model will be obtained based on pre procedural CT
89632744|NCT03196596||Prospective compare group|Patients in whom no computer simulation model will be obtained
89211702|NCT00144781|Active Comparator|4|1.8 mg Aldurazyme/kg of body weight (300 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
89211703|NCT00835562|Experimental|Osteosynthesis|
89632745|NCT00358072|Experimental|1|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
89632746|NCT02442726|Active Comparator|Thermal Injury|A first degree heat injury is induced by a contact thermode (12.5 cm2; 47C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
89632747|NCT02442726|Sham Comparator|Sham Injury|"A sham injury is induced by a contact thermode (12.5 cm2; 38C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC) is used to assess"
89632748|NCT02442648|Experimental|Group A (5-8 patients) - Carfilzomib|Two cycles of carfilzomib desensitization given.
89632749|NCT02442648|Experimental|Group B (5-8 patients) - Carfilzomib/plasmapheresis|Two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
89632750|NCT02442648|Experimental|Group C (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
89632751|NCT02442648|Experimental|Group D (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to three cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
89632752|NCT00356746||1|elective CABG only patients
89632753|NCT00356746||2|elective ICD replacement surgical patients requiring general anesthesia
89632754|NCT00356824||1|HIV-infected children in Uganda
89632755|NCT02442570|Active Comparator|DC-TAB 7.5 mg|three intravenous injections of 7.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
89632756|NCT02442570|Active Comparator|DC-TAB 12.5 mg|three intravenous injections of 12.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
89632757|NCT02442570|Active Comparator|DC-TAB 17.5 mg|three intravenous injections of 17.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
89632758|NCT02442570|Placebo Comparator|placebo|three intravenous injections of placebo, 2 months apart
89632759|NCT05722756||group A|treated with Vojta therapy
89632760|NCT05722756||group B|treated with Vojta therapy combined with craniosacral therapy
89632761|NCT01705145|Experimental|Ivacaftor|"Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than [<] 14 kilograms [kg]) or 75 mg (for participants weighing greater than or equal to [>=] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study..~Part B: Ivacaftor 50 mg (for participants weighing <14 kg) or 75 mg (for participants weighing >=14 kg) q12h for 24 weeks during Part B of the study."
89632762|NCT03716934|Experimental|Cryoablation|Cryoablation for bidirectional block of all pulmonary veins
89632763|NCT03716934|Active Comparator|Antiarrythmics|The drug will be chosen based on the preference of the researcher based on clinical practice guidelines.
89632764|NCT05722600|Experimental|Hardaliye Group|Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
89632765|NCT05722600|Placebo Comparator|Placebo Group|Placebo Group consumed 250 ml/day of placebo drink for 28 days.
89632766|NCT03196674|Active Comparator|manipulated feedback|
89632767|NCT03196674|Active Comparator|non-manipulated feedback|
89040792|NCT04650386|No Intervention|Treatment As Usual (TAU)|Participants assigned to the TAU condition will be scheduled for buprenorphine medication management appointments and will receive OBOT at the FQHC and adjunctive psychosocial treatment as typically provided at the FQHC. The team will continue to meet with the patient during subsequent MAT visits on a decreasing frequency, with some slight site-specific variation. The schedule of MAT visits generally includes 3 clinic visits during the week of induction, 1-2 visits per week until the patient is stabilized, and monthly thereafter. Behavioral health clinicians provide support to the patient, discuss UDS results, assist with strategic problem-solving around recovery and adjustment to sobriety, and monitor the patient's engagement in MAT.
89040793|NCT04650386|Experimental|Adaptive Intervention|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
89632768|NCT03632200|Experimental|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions."
89632769|NCT03632200|No Intervention|Control group|The patients will be followed according to the current recommendations of the French Society Clinical Nutrition and Metabolism (SFNEP).
89632770|NCT04483830|Placebo Comparator|group A|patient with the early stages of COVID-19 to received an oral dose of placebo twice a day for 21 days
89040794|NCT00665769|Placebo Comparator|Hypercapnia|Hypercapnic ventilation. The goal will be to maintain transcutaneous CO2 55 mm Hg (50-60 mm Hg) during the first week of life, or until extubation. A written, laminated hypercapnic ventilator algorithm will be placed at the bedside.
89632771|NCT04483830|Active Comparator|group B|patient in the early stages of COVID-19 to received an oral dose of 500LRU of sulodexide twice a day for 21 days.
89040795|NCT00665769|Active Comparator|Normocapnia|Normocapnic ventilation. The goal will be to maintain transcutaenous CO2 40 mm Hg (35-45 mm Hg) during the first week of life, or until extubation. A written, laminated normocapnic ventilator algorithm will be placed at the bedside.
89211704|NCT00835562|Experimental|Non-surgical|
89211705|NCT00835562|Experimental|Hemiarthroplasty|
89632772|NCT05712382|Active Comparator|Coping with emotions, Parent handbook, Problem-solving risky situations, and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632773|NCT05712382|Active Comparator|Coping with negative emotions, Parent handbook , and Problem-solving for risky situations|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
89632774|NCT05712382|Active Comparator|Coping with negative emotions, Parent handbook , and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632775|NCT05712382|Active Comparator|Coping with negative emotions and Parent handbook|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. The participants' parent(s) will also receive a handbook that encourages communication with their child about alcohol use.
89632776|NCT05712382|Active Comparator|Coping with negative emotions, Problem-solving for risky situations , and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632777|NCT05712382|Active Comparator|Coping with negative emotions and Problem-solving for risky situations|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
89632778|NCT05712382|Active Comparator|Coping with negative emotions and Recovering from slips|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632779|NCT05712382|Active Comparator|Coping with negative emotions|Participants will learn to use techniques based in mindfulness as a means for coping with negative emotions.
89632780|NCT05712382|Active Comparator|Parent handbook , Problem-solving for risky situations , and Recovering from slips|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632781|NCT05712382|Active Comparator|Parent handbook and Problem-solving for risky situations|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632782|NCT05712382|Active Comparator|Parent handbook and Recovering from slips|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632783|NCT05712382|Active Comparator|Parent handbook|The participants' parent(s) will receive a handbook that encourages communication with their child about alcohol use.
89632784|NCT05712382|Active Comparator|Problem-solving for risky situations and Recovering from slips|Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers. To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632785|NCT05712382|Active Comparator|Problem-solving for risky situations|Participants will be prompted to identify both barriers to reducing their alcohol use and protective strategies for navigating those barriers.
89632786|NCT05712382|Active Comparator|Recovering from slips|To improve their confidence to resume moderate drinking after having a heavy drinking episode, participants will be presented with narratives from other students who successfully resumed moderate drinking after a heavy drinking episode. Students will also be prompted to identify alcohol free activities that they enjoy and can engage in after experiencing a heavy drinking episode.
89632787|NCT05712382|No Intervention|Assessment only control condition|Participants in this condition will complete assessments but will not receive any additional intervention content.
89632788|NCT04484064|No Intervention|Standard care|"Patients in the standard care arm will use an electronic adherence monitor (MEMS®) without any feedback (electronic data will be blinded to patients, clinicians and investigators until the analysis)"
89632789|NCT04484064|Experimental|Adherence program|"Patients in the adherence program will use the MEMS® and the pharmacist will provide an electronic feedback on medication adherence since the last visit. The identified determinants of medication adherence will be discussed with the patient."
89632790|NCT02442492|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
89632791|NCT02442492|Placebo Comparator|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
89632792|NCT05712304|No Intervention|conventional examination|For patients in the CE group, the colonoscope was withdrawn directly from the splenic flexure to the rectum, and polyps that were found were removed
89632793|NCT05712304|Experimental|second examination|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
89632794|NCT02442258|Experimental|Group 1 - Mild Renal Impairment|Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
89632795|NCT02442258|Experimental|Group 2 - Moderate Renal Impairment|Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
89632796|NCT02442258|Experimental|Group 3 - Severe Renal Impairment|Subjects with severe renal impairment. eGFR (by MDRD equation) range 15 - 29 mL/min/1.73 m2 as determined at Screening.
89632797|NCT02442258|Experimental|Group 4 - End Stage Renal Disease, Not Yet on Dialysis|Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range < 15 mL/min/1.73 m2 as determined at Screening.
89632798|NCT02442258|Experimental|Group 5 - Normal Renal Function|Subjects with normal renal function. eGFR (by MDRD equation) range ≥ 90 mL/min/1.73 m2 as determined at Screening.
89632799|NCT02442258|Experimental|Group 6 - End Stage Renal Disease, Requiring Dialysis.|Subjects with end stage renal disease, requiring dialysis. eGFR (by MDRD equation) < 15 mL/min/1.73 m2 as determined at Screening.
89632800|NCT02442024|Experimental|Modified diet|This group will follow a modified diet over a period of two months.
89632801|NCT02442024|Active Comparator|Standard diet|This group will follow a standardized diet over a period of two months.
89632802|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
89632803|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks
89632804|NCT02449122|Experimental|Nano drug|Lung cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
89632805|NCT02449122|Active Comparator|Drug MicroSpheres|Lung cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
89632806|NCT02449122|No Intervention|Control|Liver cancer patients never received any interventional therapy.
89632807|NCT05165550|Experimental|Cohort 1|Elsulfavirine 20 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
89632808|NCT05165550|Experimental|Cohort 2|Elsulfavirine 40 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
89632809|NCT05165550|Experimental|Cohort 3|Elsulfavirine 80 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
89632810|NCT04166669|Experimental|Cohort 1|Drugs: APX001, itraconazole
89632811|NCT04166669|Experimental|Cohort 2|Drugs: APX001, rifampin
89632812|NCT03193710||Total intravenous anesthesia group|The anesthesia of patients in the total intravenous anesthesia group will be maintained with propofol and remifentanil.
89632813|NCT03193710||Inhalational anesthesia group|The anesthesia of patients in the inhalational anesthesia group will be maintained with sevoflurane and remifentanil.
89632814|NCT03193632||Study group|critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for more than one day US Muscle layer thickness (MLT) estimation will be used to estimate LBM and REE estimation by indirect calorimetry will be performed
89632815|NCT01704599|Experimental|Humira then Humira plus 3 B vitamins|"Humira then Humira plus 3 B vitamins~The only arm: After 16 weeks on adalimumab, modulators of homocysteine (oral vitamin B12, oral vitamin B6 or pyridoxine, and oral folic acid) will be added to adalimumab therapy for an additional 12 weeks. At end of this therapy can stop or continue. Telephone call day 70 after formal end of in person study the investigators will assess general health of each subject."
89632816|NCT03196362|Active Comparator|PIO/MET|one fixed dose pioglitazone/metformin (15mg/500mg) tablet will be orally administrated twice daily
89632817|NCT03196362|Placebo Comparator|placebo|one tablet of placebo will be given twice daily
89040796|NCT04650308|Active Comparator|Healthy group|healthy men and women aged 20-60 years old.
89040797|NCT04650308|Active Comparator|Non-healthy group|pregnant women, nursing mothers, impaired kidney and liver function, chronic disease, or other metabolic disorders.
89040798|NCT00543933|Experimental|iNO administered|iNO administered at 40 ppm via a non-rebreather mask
89040799|NCT04650347|Experimental|internal urethrotomy using Holmium laser representing group|In group 1, a three hundred micron laser fiber was used to conduct the laser energy. holmium laser pulse energy of approximately 1 joule was used that was generated from a Holmium laser Quanta device and total power of 15 watts. the laser fiber was aimed directly to the midline at 12 o'clock position to start the procedure and cut the fibrous tissue till access to a wide lumen.
89632818|NCT03193320|Active Comparator|Liberal group protocol|Fluid loading with 500 ml at induction. Baseline fluid infusion - 8 ml/kg/h. Fluid challenge - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
89632819|NCT03193320|Active Comparator|Restrictive group protocol|No fluid loading at induction. Baseline fluid infusion - 4 ml/kg/h. Fluid challenges - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
89632820|NCT03193320|Experimental|PVI-guided group protocol|No fluid loading at induction. Baseline fluid infusion - 2 ml/kg/h. PVI will be monitored continuously since anesthesia induction. Fluid challenges - if PVI rises >=13 (or MAP falls < 65 mmHg), a fluid challenge will be administered.
89632821|NCT02449278|Experimental|ISRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals) .~Consolidation involved-site radiotherapy (ISRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
89040800|NCT04650347|Active Comparator|internal urethrotomy with Sachs cold knife|In group B, Sache cold knife internal urethrotomy was used with the same technique as Holmium laser internal urethrotomy at the same site to mechanically cut instead of the laser fiber.
89040801|NCT02909010|Active Comparator|BIS™ Brain Monitoring System|BIS monitoring to adjust sedation in order to maintain values between 50-60
89040802|NCT02909010|Placebo Comparator|RASS Monitorization|sedation was adjusted with the exclusive useof Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2.
89040803|NCT04649762||Control|Group 1 includes patients with anxiety consulting a doctor not practicing hypnosis
89040804|NCT04649762||TAC|Group 2 includes patients with anxiety consulting a doctor practicing hypnosis
89040805|NCT04650113|Experimental|group A|placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude ) 9.The pellet will be remove, and the pulp chamber filled with MTA. 10.The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement
89040806|NCT04650113|Active Comparator|group B|"Pre-operative radiograph showing all roots and their apices.~Local anesthesia will be administered and a rubber dam will take place ,that ensure good isolation of the treated teeth.~Removal of caries~Pulp chambers will access using a no.330 bur in a high-speed hand piece with water coolant.~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece~Pulp amputation will perform using a spoon excavator.~Hemorrhage control will obtain within 5 minutes using sterile cotton pellets placed with light pressure over the pulpal stumps (if hemorrhage control will not be achieve, tooth will be exclude )~The pellet will be remove, and the pulp chamber will be filled with MTA.~The tooth will prepare and restore with a stainless steel crown cemented with glass ionomer cement.~The periapical radiographic will be taken at this baseline visit ."
89040807|NCT04649996||Pandemic period|patients admitted in hospital for acute appendicitis
89040808|NCT04649996||control period|patients admitted in hospital for acute appendicitis
89040809|NCT02908971||Soy based formula|"soy group will include children from the children who had milk allergy, and consumed a soy-based substitute formula for longer than three months and agreed to participate in this study."
89040810|NCT02908971||Healthy control|The control group will included children (at a rate of 2:1) who will be assigned randomly from the healthy population at the initial cohort, and who will agree to participate.
89040811|NCT04649723|Experimental|Rifampicin 600 mg + SHR1459 Tablets 200 mg|
89040812|NCT04649723|Active Comparator|SHR1459 tablets 200 mg|
89040813|NCT02908893|Experimental|Salient|"Messages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app.~Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy."
89040814|NCT02908893|Active Comparator|NonSalient|"Messages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated.~Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy"
89040815|NCT02908893|No Intervention|Control|Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded.
89040816|NCT04649684|Experimental|Conventional robot-assisted gait training group|they got conventional robot-assisted gait training, guidance force given equally to both limbs
89040817|NCT04649684|Experimental|Lower CIMT robot-assisted gait training group|they got robot-assisted gait training based on CIMT concept
89632822|NCT02449278|Active Comparator|IFRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
89632823|NCT03511794||hep B vaccine|1. Patient must have received at least one dose of the hepatitis B vaccine
89632824|NCT02441868|Experimental|Intervention|all participants will receive the training
89632825|NCT02441790|Experimental|Early Active Range of Motion|Early Active Range of Motion (EAROM) 3-9 days following hand fracture
89632826|NCT02441790|Active Comparator|Standard Immoblization|Standard immobilization with plaster splint for 21-27 following hand fracture
89632827|NCT02449200|Experimental|Multimodal physiotherapy group|4 week multimodal physiotherapy treatment programme provided by an experienced musculoskeletal physiotherapist
89632828|NCT02449200|No Intervention|Advice to stay active group|Advice to stay active and continue use of prescribed medication as appropriate, via weekly phone calls from a physiotherapist over a 4 week period.
89632829|NCT03196128|Active Comparator|Digital|
89632830|NCT03196128|Active Comparator|Non Digital|
89632831|NCT04484298|Experimental|reference group|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
89632832|NCT04484298|Experimental|TRINITRINE|0.6 mg of nitroglycerin was given to the patient sublingual and we measure the cardiac output by BIOPAC system(0.6 mg of Nitroglycerin was administered sublingually and CO was evaluated.
89632833|NCT02441712|Experimental|Motor PENS|Motor PENS will be a strong tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors for strength training (50Hz impulses for 200ms every 1500 ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program.
89632834|NCT02441712|Sham Comparator|Subsensory PENS|Subsensory PENS will be a sub sensory stimulus also administered by a tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors (50Hz impulses for 200ms every 1500ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program
89632835|NCT03196050|Experimental|Telemonitoring using a handheld device|Patients will be euqipped with either an app or a handheld device with a pre-installed app to communicate with the coordinating center.
89632836|NCT02441556|Active Comparator|standard medical therapy|Patients receive standard medical therapy alone.
89632837|NCT02441556|Experimental|endovascular + standard medical therapy|Patients receive endovascular treatment plus standard medical therapy.
89632838|NCT03162978|Experimental|HIIT + POE|High-intensity interval training (HIIT) plus positive outcome expectations (POE) from participating in the exercise program.
89632839|NCT03162978|Experimental|HIIT only|High-intensity interval training (HIIT) only.
89632840|NCT03157362|Active Comparator|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
89632841|NCT03157362|Active Comparator|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
89632842|NCT03157362|Active Comparator|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
89632843|NCT03157362|Active Comparator|Time 4|Participant will complete the remaining intervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
89632844|NCT03599518|Experimental|DS-1205c with Gefitinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 800 mg, 1000 mg, 1200 mg) in combination with daily 250 mg oral dose of gefitinib
89632845|NCT03099486|Experimental|Regorafenib + 5FU/LV Treatment Arm|
89632846|NCT04483986|Active Comparator|Study group|This arm is going to include the patients who are performed rectus reapproximation.
89632847|NCT04483986|No Intervention|Control group|This arm is going to include the patients who are not performed rectus reapproximation.
89632848|NCT03192072||Subjects with Acute Respiratory Illness|Patients with acute respiratory illness identified in the Emergency Department
89632849|NCT02448966||Traditional open esophagectomy|Treated by traditional three-incision esophagectomy in the centers with enough experience in esophagectomy via right thoracotomy and the volume ≧50 cases each year.
89632850|NCT02448966||Minimally invasive eophagectomy|treated by minimally invasive thorascopic/laparoscopic esophagectomy in the centers with enough experience in VATS esophagectomy and the volume≧50 cases each year.
89632851|NCT02441478|Experimental|Patients|
89632852|NCT02441478|Active Comparator|Controls|
89632853|NCT02441400||EndoStim LES Stimulation System implant.|Registry subjects whom have been implanted commercially with the EndoStim LES Stimulation System device.
89632854|NCT03192930||Saturation|Individuals exposed to prolonged hyperbaric exposure
89632855|NCT03192930||Control|Individuals not exposed to prolonged hyperbaric exposure
89632856|NCT05710198|Experimental|citicoline eye drops 2%|Citicoline eye drops 2%. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication.
89632857|NCT05710198|Placebo Comparator|Placebo eye drops|Placebo eye drops. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication
89632858|NCT02448888|Experimental|Adapted exercise|The experimental group is going to follow a home-exercise program designed specifically to compensate the overloads and strength necessities of the workplace, the patient enter the description of the workplace in a mobile application and the APP shows the specific exercise that the patient needs to practice and general exercise recommendations.
89632859|NCT02448888|Experimental|General exercise recommendations|The control group is going to receive general exercise recommendations (ACSM recommendations) with the same kind of APP to control the amount of exercise that each patient performs during the week.
89040818|NCT02909088|Experimental|Ecopipam 50mg|50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
89040819|NCT02909088|Experimental|Ecopipam 100mg|If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
89040820|NCT04649528|Experimental|Supervised HIIT|Exercise intervention, 20 supervised by healthcare professional
89040821|NCT04649528|Experimental|APP HIIT|Exercise intervention, 20 self-monitored assisted by a mobilephone application
89040822|NCT04649645|Active Comparator|Standard Arm (Arm A)|Participant continues smoking their own cigarette brand.
89040823|NCT04649645|Active Comparator|Intervention Arm (Arm B)|Participant switches to using C-F NDS.
89040824|NCT04649645|Active Comparator|Control Arm (Arm C)|Participant continues to not smoking or using of any nicotine/tobacco products.
89040825|NCT00544128|Active Comparator|Epzicom Arm|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
89040826|NCT00544128|Active Comparator|Truvada Arm|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg
89632860|NCT02448732|Experimental|ACM-1 team|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
89632861|NCT05722054||Incidence of tropical infectious diseases|All study participants will be followed up for 12 months through active and passive detection visits. Active detection takes place every month for all pathogens except for P. falciparum which is detected every two weeks.
89632862|NCT05722054||Healthy and equilibrate diet|One-fourth of the study participants will be randomly assigned to receive an equilibrate diet for 21 days comprising breakfast, lunch and educational recommendations for an equilibrate diet
89632863|NCT05722054||In vitro|30 to 50 participants selected from the study population. The in vitro study procedures are performed at the screening visit and every two months+/- 1, and when an active case of tropical infection occurs
89632864|NCT05722054||Adaptive in vitro|100 to 150 selected participants. The adaptive in vitro study procedures are performed at the screening visit and every two months+/- 1 and when an active case of tropical infection occurs.
89632865|NCT05722054||Ex vivo|All study participants. The ex vivo are performed at the screening visit and every two months+/- 1 and when an active case of tropical infection occurs.
89632866|NCT01787682|Experimental|Boost High Protein|Boost high protein with added spirulina
89632867|NCT01687920|Experimental|BAY94-8862 (1.25mg)|single dose BAY94-8862 IR tablet 1.25mg
89632868|NCT01687920|Experimental|BAY94-8862 (2.5mg)|single dose BAY94-8862 IR tablet 2.5mg
89632869|NCT01687920|Experimental|BAY94-8862 (5mg)|single dose BAY94-8862 IR tablet 5mg
89632870|NCT01687920|Experimental|BAY94-8862 (7.5mg)|single dose BAY94-8862 IR tablet 7.5mg
89632871|NCT01687920|Experimental|BAY94-8862 (10mg)|single dose BAY94-8862 IR tablet 10mg
89632872|NCT01336530|Experimental|Tepilta®|
89632873|NCT01336530|Active Comparator|Oxetacaine|
89632874|NCT01336530|Active Comparator|Antacids|
89632875|NCT01336530|Placebo Comparator|Placebo|
89632876|NCT02441244|Experimental|Probiotic Group|Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
89632877|NCT02441244|Placebo Comparator|Placebo Group|Placebo comparator group
89632878|NCT02441166|Other|Mastocytosis diagnosis|For each enrolled subject, 5 mL sample of peripheral blood and 1 mL sample of BM aspirate will be collected the same day to do diagnosis mastocytosis tests (quantification of the kit mutations by qPCR, plasma tryptase level, immunophenotyping of BM mastocytes by flow cytometry, BM tryptase level, degree of dilution of the BM aspirate...) using the WHO criteria as the reference standard.
89632879|NCT00777348|Experimental|1|DSCG + Reproterol
89632880|NCT00777348|Active Comparator|2|DSCG
89632881|NCT00777348|Active Comparator|3|Reproterol
89040827|NCT04649606||Experimental|Eligible subjects will undergo repeated observations to evaluate the Meibomian gland appearance
89040828|NCT00544206|Experimental|#1|Diabetes specific enteral feeding product
89040829|NCT00544206|Active Comparator|#2|Standard enteral feeding product
89040830|NCT02908854|Experimental|School Lunch Participants|School lunch participants will be given vegetables with and without additional spices and herbs to determine if intake will increase with the addition of spices and herbs.
89040831|NCT01240915|Experimental|Cohort 1|The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 & 2).
89040832|NCT01240915|Experimental|Cohort 2|This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.
89632882|NCT00777348|Placebo Comparator|4|Placebo
89632883|NCT04484454|Experimental|Omega 3 Oil Supplementation|Following all necessary screening, patients will be provided with the ProdromeNeuro Omega-3 oil supplement and instructed to consume the equivalent of 1 cc of the oil supplement per day for the first month, followed by 2 cc of the supplement/day for the second month, and finally ending with 4 cc/day of the supplement for the third month. Neurocognitive assessment and serology testing will take place at baseline, end of month 1, end of month 2, end of month 3, and one month post intervention-termination.
89632884|NCT03836560|Active Comparator|Usual group|"Usual group with nicotine patch only:~Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches."
89211706|NCT05359107|Experimental|"The Free From Pain Exercise Book"|"Participants who consent and are randomised into Group 1 (experimental group) will be provided with the Free From Pain Exercise Book. Participants in Group 1 will be asked to independently engage in the exercises included in the book throughout the entire 6 month study period. They will be advised to either do all 3 sets of exercises 3 times a week or to do the neck and low back exercises twice a week and the Otago exercises 3 times a week. The exercises should take around an hour to complete each day.~Furthermore, it will be recommended that participants in this group read one information chapter and one metaphor each week for 12 weeks, to ensure that they absorb the information fully and do not overbear themselves with information."
89632885|NCT03836560|Active Comparator|Intervention group|"Nicotine patch and nicotine gum:~Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required."
89211707|NCT05359107|Active Comparator|"The Back Book"|"Participants who consent and are randomised into Group 2 (control group) will be provided with The Back Book. Participants in Group 2 will be asked to ensure that they read the book in its entirety during the 12-week intervention period and refer to relevant sections during the follow-up period for advice if required."
89211708|NCT03971695|Experimental|BI 706321|
89632886|NCT02448498|Experimental|Strength Training Only|Participants in the strength-training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in strength training 3 days per week for approximately 60 minutes each exercise session.
89632887|NCT02448498|Experimental|Aerobic Training Only|Participants in the aerobic training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in aerobic training over 3 -5 days per week to achieve the targeted dose of 12 kcal/kg per week at a training intensity between 50-80% VO2 max.
89632888|NCT02448498|Experimental|Combination (Strength and Aerobic) Training|Participants in the combination (strength and aerobic training) group will take part in a 9-month exercise intervention at a local exercise facility. They will engage aerobic training that will expend 10 kcal/kg/week in combination with strength-training, 3 days per week.
89632889|NCT02440152|Experimental|Deep brain stimulation|
89632890|NCT04483596||M|will receive 5 mg melatonin orally at 9 p.m. the night before surgery and another 5 mg melatonin with 15 ml of plain water 30 min before operation and 5 mg melatonin at 9 p.m. in the day of operation and for the first three postoperative days
89632891|NCT04483596||C|received a placebo in the form of one tablet of 500 mg paracetamol that packaged the same way as melatonin at the same times
89632892|NCT05721586|Experimental|CURODONTTM REPAIR: + Fluoride varnish (DURAFLOR)|
89211709|NCT03971695|Placebo Comparator|Placebo|
89211710|NCT02549690|Active Comparator|Testosterone gel|Testosterone gel 10mg, used transdermally, once a day. Treatment duration: 6-8 weeks
89632893|NCT05721586|Active Comparator|Fluoride Varnish (DURAFLOR) only|
89632894|NCT03190512|Active Comparator|Test Group|"Psychological measurements were taken from periodontal disease patients before treatment and after 6 weeks.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and the Psychological questionnaires were filled."
89632895|NCT03190512|Placebo Comparator|Control Group|"Psychological measurements were taken from periodontal disease patients at the baseline and after 6 weeks without the periodontal treatment.~Intervention: The Psychological questionnaires were filled."
89632896|NCT02441010|No Intervention|Group 1|Participants without suboptimal health status are randomly grouped into the group without monitor (Group 1) and the monitor group (Group 2 or Group 3). Thus, no monitoring or intervention technologies are used in Group 1.
89632897|NCT02441010|Sham Comparator|Group 2|Group 2 are participants without metabolic abnormality in the monitor group. Group 2 use the monitoring device with three months.
89632898|NCT02441010|Sham Comparator|Group 3|Group 3 are participants with metabolic abnormality in the monitor group. Group 3 use the monitoring device and the health information push technology with three months.
89632899|NCT02441010|Active Comparator|Group 4|All of participants with suboptimal health status use the monitoring device with three months, and are randomly grouped into the non-intervention group (Group 4 or Group 5) and the intervention group using the meridian therapy instrument (Group 6 or Group 7). Group 4 are participants without metabolic abnormality in the non-intervention group. No intervention technologies are used in Group 4.
89632900|NCT02441010|Active Comparator|Group 5|Group 5 are participants with metabolic abnormality in the non-intervention group. Group 5 use the health information push technology with three months.
89632901|NCT02441010|Experimental|Group 6|Group 6 are participants without metabolic abnormality in the intervention group. Group 6 use the meridian therapy instrument with two weeks. If the suboptimal health status is not improved, then the meridian therapy instrument will continue to be used with an interval of one week.
89632902|NCT02441010|Experimental|Group 7|Group 7 are participants with metabolic abnormality in the intervention group. Group 7 use the health information push technology with three months and the meridian therapy instrument with two weeks. Similar with Group 6, if the suboptimal health status is not improved after the treatment of the meridian therapy instrument, then the instrument will continue to be used with an interval of one week.
89632903|NCT02440932|Experimental|Phenylketonuria-type diet|"Breakfast: one pouch of amino acid supplement (174 mls supplemented drink PKU cooler 20, Vitaflo®; 20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich [low protein bread (Juvela, UK), no protein vegan cheese (Viotros, UK)], low protein crackers (Vitaflo, UK), and low protein cookies (Juvela, UK).~Dinner: ad libitum buffet meal"
89211711|NCT02549690|Active Comparator|DHEA|DHEA 25mg tablet, orally, three times per day. Treatment duration: 6-8 weeks
89211712|NCT05357937|Active Comparator|Obese group|Received standard physiotherapy program
89211713|NCT05357937|Active Comparator|Non-Obese group|Received standard physiotherapy program
89211714|NCT02549768|Active Comparator|Dexmedetomidine|Use of dexmedetomidine during surgery (1 mcg/kg in 10 minutes, then infusion at 0.7 mcg/kg/h)
88990747|NCT06180915|No Intervention|Control Group|The control group will not be subjected to any training. The Control Group will fill out the Introductory Information Form, Rathus Assertiveness Inventory, Internalized Misogyny Scale, Flirting Violence Scale and Cyber Flirting Violence Scale simultaneously with the experimental group at the beginning of the study.
88990748|NCT06180876|Experimental|remimazolam|remimazolam continuous infusion is used for general anesthesia; dosage:0.7-1.5mg/kg/h; duration: from start of anesthesia induction to end of surgery
88990749|NCT06180876|Active Comparator|propofol|propofol continuous infusion is used for general anesthesia; dosage:4-8mg/kg/h; duration: from start of anesthesia induction to end of surgery
88990750|NCT06180863|Experimental|Oral azacitidine (CC-486)|"Patients on study will receive 300 mg CC-486 for 14 out of 28 days per cycle with dose modification according to the Onureg United States Prescribing Information (USPI). Up to 3 cycles of CC-486 will be allowed, and a minimum of 1 cycle is to be given prior to transplant. Multiple cycles will be allowed only if donor-specific or logistical issues prevent transplantation after the first cycle. CC-486 will be dispensed on day 1 of each treatment cycle and only 1 cycle equivalent is to be dispensed at the beginning of each cycle.~Post-transplant maintenance with CC-486 can be started 60 days (range 60-120 days) after hematopoietic progenitor cell infusion which should allow time for count and graft recovery after post-transplant cyclophosphamide (PTCY). The CC-486 maximum preferred pre-emptive dose post-ASCT is 200 mg daily, which will be administered for 14 of 28 days per cycle (max 12 cycles)."
88990751|NCT06180837|No Intervention|Control Group|Provided with general health information on diet and physical activity.
88990752|NCT06180837|Experimental|Intervention Group|Sleep extension-based intervention focused on increasing time in bed by 2 hours per night.
88990753|NCT06178549|Experimental|Intervention arm (single arm)|Intervention arm to complete HPV self-sampling
88990754|NCT06177015|Active Comparator|Continuous treatment group|Darolutamide: 600mg, bid+ADT: Leuprorelin (3.6mg qm or 10.8mg q3m) or goserelin 80mg qm until mCRPC
88990755|NCT06177015|Experimental|Intermittent treatment group|Only ADT as background treatment without Darolutamide. PSA check every three months, when the patient's PSA > 1ng/ml (or PSA > 1ng/ml and PSA has risen by more than 20% comparing baseline), restart the darolutamide, until mCRPC.
88990756|NCT06176963|Experimental|SB11 PFS|Subjects received a single dose of SB11 PFS containing 0.5 mg ranibizumab in 0.05 mL solution.
89211715|NCT02549768|Placebo Comparator|Placebo|"Use of crystalloid solution (sodium chloride 0.9%), injection pump programmed with drug Dexmedetomidine with 1 mcg/kg in 10 minutes, infusion 0.7 mcg/kg/h."
89211716|NCT04551651|Active Comparator|ApplTree reminder app intervention|A reminding app developed with features that, based on previous research, will increase use and ease of use for individuals with ABI when setting smartphone reminders.
89211717|NCT04551651|Active Comparator|Google Calendar reminder app intervention|A widely available calendar app that can be used to set reminders.
89632904|NCT02440932|Other|Normal diet|Breakfast: 174 ml of milk (20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich, crackers, and cookies (regular foods) Dinner: ad libitum buffet meal
89632905|NCT02978482|Experimental|durvalumab|durvalumab alone
89632906|NCT02978482|Experimental|durvalumab+tremelimumab|durvalumab plus tremelimumab
89632907|NCT03191994|Experimental|MDD exercise group|This group will receive eight weeks of moderate exercise in addition to their usual treatment
89632908|NCT03191994|No Intervention|MDD control group|This group will receive usual care with no exercise
89632909|NCT03191994|Experimental|Healthy Exercise|This group will perform an eight week moderate intensity exercise intervention
89632910|NCT03191994|No Intervention|Healthy control|This group will not perform exercise
89632911|NCT04344808|Experimental|Navigation group|Dental implants will be placed using a dynamic computer assisted surgery system
89632912|NCT04344808|Active Comparator|Freehand group|Dental implants will be place without any guidance. Only virtually planning the ideal position on a 3D image (Cone beam computed tomography)
89632913|NCT02448576|Experimental|PCI group|Receiving prophylactic cranial irradiation after response to first line chemotherapy.
89632914|NCT02448576|No Intervention|observation group|Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.
89632915|NCT05721508|Experimental|Individual practice at home|Participants will undergo a training program combining physical and cognitive activities in individual practice at home.
89632916|NCT05721508|Experimental|Group practice in a traditional group environment (gymnasium)|Participants will undergo a training program combining physical and cognitive activities in group practice in a traditional group environment (gymnasium).
89632917|NCT05721508|Experimental|Group practice in an enriched environment fostering social relations|Participants will undergo a training program combining physical and cognitive activities in group practice in an enriched environment fostering social relations.
89632918|NCT02978560||control|The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once.
89632919|NCT02978560||Wound Group|The source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care.
89632920|NCT02978950|Experimental|Surveillance arm|Bilateral duplex ultrasound surveillance
89632921|NCT02978950|Active Comparator|No surveillance arm|no duplex ultrasound surveillance
88990757|NCT06176885|Experimental|Camrelizumab Group|Combined with Camrelizumab after irinotecan leucovorin and fluorouracil (FOLFIRI) chemotherapy and bevacizumab targeted induction therapy
89040833|NCT01240915|Experimental|Cohort 3|These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo.
89040834|NCT00558155|Experimental|SEN|standard enteral nutrition
89040835|NCT00558155|Experimental|IMEN|immunostimulating enteral nutrition
89040836|NCT00558155|Experimental|SPN|standard parenteral nutrition
89040837|NCT00558155|Experimental|IMPN|immunostimulating parenteral nutrition
89040838|NCT05476432|Experimental|HAIC 1d|Oxaliplatin, leucovorin, and bolus fluorouracil were conducted equally in the both groups, while infusional fluorouracil 2400 mg/m² was given over 23 hours in the HAIC 1d group
89040839|NCT05476432|Active Comparator|HAIC 2d|Oxaliplatin, leucovorin, and bolus fluorouracil were conducted equally in the both groups, while infusional fluorouracil 2400 mg/m² was given over 46 hours in the HAIC 2d group
89040840|NCT02908815|Experimental|4 weeks active treatment|4 weeks of rTMS active treatment applied using an active rTMS coil.
89040841|NCT02908815|Experimental|2 weeks active treatment|2 weeks of rTMS active treatment applied using an active rTMS coil.
89040842|NCT02908815|Sham Comparator|4 weeks sham treatment|4 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
89040843|NCT02908815|Sham Comparator|2 weeks sham treatment|2 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
89632922|NCT05721352|Experimental|Single Arm Study|"All participants will receive access to the phone application with a virtual reality headset and heart rate variability Bluetooth ear sensor.~Participants will be instructed to download a free phone app Elite Heart Rate Variability, login using study provided de-identified research email address, pair the Bluetooth ear sensor and record a five-minute resting heart rate variability reading at baseline and each time point of the study prior to beginning intervention.~Participants will be asked to use the intervention phone application for 7-10 minute sessions twice daily 5 days a week for 8 weeks.~For the first 8 weeks, participants will receive brief, daily texts encouraging participation in the smart phone application.~During weeks 9 through 12, will receive relaxation reminders daily via text to determine if use is sustained past the intervention phase"
89632923|NCT03240640|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
89632924|NCT03240640|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
89632925|NCT03229564|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
89632926|NCT00357682|Experimental|Arm A|20mg Esomeprazole
89632927|NCT00357682|Experimental|Arm B|80mg Esomeprazole
89632928|NCT00357682|Experimental|Arm C|20mg Esomeprazole + 300mg Aspirin
89632929|NCT00357682|Experimental|Arm D|80mg Esomeprazole + 300mg Aspirin
89632930|NCT05721040||Covid-19 Group|"Motor nerve study was performed in the median and posterior tibial nerve to assess the motor function of the upper and lower limbs.~Sensory nerve study was done for the median and sural nerves to estimate the peripheral neurological function of both upper and lower limbs.~F wave study was performed for the upper limb in the median nerve."
89632931|NCT05721040||Control Group|"Motor nerve study was performed in the median and posterior tibial nerve to assess the motor function of the upper and lower limbs.~Sensory nerve study was done for the median and sural nerves to estimate the peripheral neurological function of both upper and lower limbs.~F wave study was performed for the upper limb in the median nerve."
89632932|NCT00105027|Active Comparator|CRVO Observation|
89632933|NCT00105027|Active Comparator|CRVO 1 mg dose triamcinolone acetonide|
89632934|NCT00105027|Active Comparator|CRVO 4 mg dose triamcinolone acetonide|
89632935|NCT00105027|Active Comparator|BRVO standard care|
89632936|NCT00105027|Active Comparator|BRVO 1 mg dose triamcinolone acetonide|
89040844|NCT01239745||1|
89040845|NCT01239472|No Intervention|tacrolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone.
89040846|NCT01239472|Active Comparator|everolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone, and converted for everolimus, mycophenolate sodium, and prednisone 90 days after renal transplantation.
89057476|NCT01202188|Active Comparator|glycopyrronium (NVA237)|NVA237 50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
89211718|NCT00841646|Other|1|
89632937|NCT00105027|Active Comparator|BRVO 4 mg dose triamcinolone acetonide|
89632938|NCT03145012|Experimental|Treatment Group|"This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.~Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally."
89632939|NCT00106119|Active Comparator|Liothyronine and Levothyroxine|Hypothyroid patients treatment with Levothyroxine and Liothyronine in 2 crossover, randomized phases
89632940|NCT03832660|Active Comparator|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
89632941|NCT03832660|Active Comparator|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
89040847|NCT04649450|Experimental|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days (post-operative day 1, 2 and 3) at the neurosurgical ward they will receive music twice a day for 30 minutes. All participants will further receive standard of clinical care.
89040848|NCT04649450|No Intervention|Standard of clinical care|Standard of clinical care.
89040849|NCT00544284|Experimental|Treatment (temozolomide, bortezomib)|GROUP A: Patients receive oral temozolomide once a day on days 1-5 and bortezomib IV on days 2, 5, 9, and 12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. GROUP B: Patients receive temozolomide and bortezomib as in group A. Cohorts of patients in both groups receive escalating doses of both study drugs until the maximum tolerated doses are determined. All patients undergo blood sample collection periodically for pharmacokinetic studies. Samples are analyzed for bortezomib concentration (groups A and B) and trough levels of anticonvulsants (group A only).
89040850|NCT02888275|Experimental|DEX|dexmedetomidine 1mcg/kg for 10min. loading and continuous infusion during the surgery 0.5mcg/kg/hr.
89040851|NCT02888275|Active Comparator|no_DEX|Normal saline 1mcg/kg for 10min. and continuous infusion during the surgery 0.5mcg/kg/hr.
89040852|NCT03456531|Active Comparator|group 1|20 patients will receive pulsed radiofrequency for 6 minutes to suprascapular nerve
89040853|NCT03456531|Placebo Comparator|group 2|"20 patients will receive their medical treatment in the form of NSAIDs ibubrofen,Aspirin"
89040854|NCT02909049|Active Comparator|CONTROL|Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy
89040855|NCT02909049|Experimental|EXPERIMENTAL|Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.
89040856|NCT04649216|Experimental|Mass Balance|Subjects will receive a single oral dose of [14C]PCO371 Oral Solution.
89040857|NCT04649216|Experimental|Absolute Bioavailability and Mass Balance|Subjects will receive a single oral dose of PCO371 capsules, followed by a single IV infusion of [14C]PCO371 over 10 min, starting 2 h post-oral dose.
89040858|NCT01229449|Experimental|Ibuprofen/acetaminophen (lower dose)|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
89040859|NCT01229449|Experimental|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
89040860|NCT01229449|Active Comparator|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
89040861|NCT01229449|Active Comparator|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
89040862|NCT01229449|Placebo Comparator|Placebo|Two placebo tablets
89040863|NCT04648865|Experimental|LY3537031|LY3537031 administered subcutaneously (SC).
89040864|NCT04648865|Placebo Comparator|Placebo|Placebo administered SC.
89040865|NCT01239316|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89040866|NCT01239160|Experimental|Advanced PCD|The use of an advanced PCD device to reduce and maintain limb volume
89040867|NCT01239160|Active Comparator|Simple PCD|The use of the Simple PCD is to reduce and maintain limb volume
89632942|NCT03832660|No Intervention|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
89632943|NCT00006411|Active Comparator|1|cornea assigned from donor age group <66.0 years
89632944|NCT00006411|Active Comparator|2|cornea assigned from donor age group >= 66.0 years
89040868|NCT01239121|Experimental|HIE-Enhanced Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
89040869|NCT01239121|Active Comparator|Optimal Medication Reconciliation without HIE|Optimal Medication Reconciliation without Health Information Exchange (HIE) for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
89632945|NCT04374747|Experimental|Dietary Intervention|Intensive dietary counseling and fruit and vegetable box delivery.
89632946|NCT04374747|No Intervention|Information|Control condition of information on healthy eating during breastfeeding
89632947|NCT00030147|Experimental|Raloxifene|Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks
89632948|NCT00030147|Experimental|Rimostil|Rimostil (phytoestrogen) 1000 mg twice a day and placebo skin patch for eight weeks
89632949|NCT00030147|Active Comparator|Transdermal estradiol|17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks
89632950|NCT00030147|Placebo Comparator|Placebo|Placebo skin patch and placebo tablets for eight weeks.
89632951|NCT04359459||Mild COVID-19|Patients with mild disease who tested positively for SARS-CoV2 infection, but only experience mild symptoms and do not need hospitalization.
89632952|NCT04359459||Severe COVID-19|Patients with severe disease admitted to hospital, without the need to be admitted to the intensive care.
89632953|NCT04359459||Very Severe COVID-19|Patients with very severe disease admitted to intensive care, who require mechanical ventilation.
89632954|NCT02709486|Experimental|Low dose|Investigational product
89632955|NCT02709486|Experimental|High dose|Investigational product
89632956|NCT02709486|Placebo Comparator|Placebo|Investigational product
89632957|NCT03195816|Experimental|computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program.
89632958|NCT03195816|No Intervention|MCI control group|The control group will receive a usual standard care without engagement in intervention
89040870|NCT01239121|Other|Pilot HIE-Enhanced Outpatient Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans seen as outpatients in Geriatrics Primary care clinic
89040871|NCT01239043|Experimental|Menomune® vaccine group|Participants received Menomune® vaccine in MTA29 (NCT00874549)
89040872|NCT01239043|Experimental|Menactra® vaccine group|Participants received Menactra® vaccine in trial MTA29 (NCT00874549)
89040873|NCT01238848|Experimental|Hypertonic|Nebulized hypertonic saline (sodium chloride 3%) + albuterol
89040874|NCT01238848|Active Comparator|Normal|Normal saline (sodium chloride 0.9%) + albuterol
89040875|NCT02888509||healthy control|Well mathed with patients in age, gender, education
89040876|NCT02888509||major depression disorder|patients with major depression disorder
89632959|NCT02440074|Experimental|MSV autologous transplantation|
89632960|NCT03191838|Experimental|Audiovisual|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
89632961|NCT03191838|No Intervention|Controls|The control group will not be given distraction equipment.
89632962|NCT03191448|Experimental|Ridge preservation in molar sites|"Patient who will need a single molar site extracted as part of their treatment will be screened and consented for this research study.~Ridge preservation will be performed in single molar extraction site. The site will be grafted with freezed dried bone allograft (FDBA) and covered with a collagen wound dressing (Collaplug). This is already part of clinical standard care using FDA approved products in an FDA approved fashion. The study aims at documenting the clinical outcome of such accepted procedure more precisely and compare it existing data using other materials."
89632963|NCT02439996|Experimental|IVIG(1g/kg,once)|The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.
89632964|NCT02439996|Experimental|IVIG(1g/kg,twice)|The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
89632965|NCT02439996|Active Comparator|IVIG(2g/kg.once)|The KD children will be randomly assigned to three groups. The patients in group A will receive IVIG 2g/kg once.
89632966|NCT02439840||Light sedation|Light sedation is defined as RASS of +1 to -2.
89632967|NCT02439840||Deep sedation|Deep sedation is defined as RASS of -3 to -5
89632968|NCT03833596|Active Comparator|Standard course CS with Regular Food|40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
89632969|NCT03833596|Experimental|Standard course CS with EEN|40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
89632970|NCT03833596|Experimental|Short course CS with EEN|40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.
89632971|NCT03191682|Experimental|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression
89632972|NCT03188562|Experimental|EBUS-TBNA, EUS-NA|"PET/CT~Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA)"
89632973|NCT03188562|Experimental|TEMLA|"PET/CT~Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)"
89632974|NCT03188328|Experimental|AvidinOX/177Lu-ST2210|Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them
89632975|NCT02434224|Experimental|music therapy|two to three sessions per week: The therapist will stay with one hand on the infants' chest (or back) in order to continuously assess the infants' breathing pattern. Based on and oriented towards the assessed breathing pattern, the infants' behavioral state, facial and gestural expression, the therapist transforms the infants' rhythms and subtle expressions into infant-directed improvised humming.
89632976|NCT02434224|No Intervention|control|standard care
89040877|NCT02888509||anxiety disorder|patients with anxiety disorder
89632977|NCT02440542||Postoperative Popliteal nerve block|All patients in the cohort are receiving a postoperative popliteal nerve block as part of their surgical plan. Outcomes including length of stay, Visual Analog Scale Scores, narcotic intake, and patient satisfaction will be collected as the intervention.
89040878|NCT02888509||bipolar depression disorder|patients with bilopar depression disorder
89040879|NCT01238575|Experimental|Extended-release guanfacine|
89632978|NCT00358306||a|those with previous history of Acute kidney injury
89632979|NCT03189966|Experimental|Group T|Patients in transversalis fascia plane block group(Group T) will receive ultrasound-guided transversalis fascia plane block using0.3% ropivacaine(0.8 ml/kg) after general anesthesia
89632980|NCT03189966|Experimental|Group Q|Patients in quadratus lumborum block group（Group Q） will receive ultrasound-guided quadratus lumborum block using0.3%ropivacaine(0.8 ml/kg).after general anesthesia.
89632981|NCT03189966|No Intervention|Group C|Patients in the third group as control (Group C)receive no nerve block.Patients will be extubated based on clinical criteria.
89632982|NCT02959372|Experimental|lung ultrasound group|lung ultrasound results
89632983|NCT02959372|Placebo Comparator|control group|The attending physician will not have the result of the lung ultrasound
89040880|NCT01238575|Placebo Comparator|Inactive placebo|
89040881|NCT02888158|Active Comparator|Pelvic Trainer without robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart.~Intervention: Pelvic Trainer"
89040882|NCT02888158|Experimental|Pelvic Trainer with robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart but with robotic assistance.~Intervention: Robotic assistance~Intervention: Pelvic Trainer"
89211719|NCT04464213|Experimental|Single dose experiments|
89040883|NCT06022445||Patients with septic shock after allo-HSCT|patients who underwent allo-HSCT and experienced septic shock
89040884|NCT06022432|Experimental|Reducing Negative Expectations|This group will watch a video of a patient-therapist interaction. The testimonial of the patient is framed to reduce negative expectations about therapeutic treatment.
89040885|NCT06022432|Experimental|Maximizing Positive Expectations|This group will watch a video of a patient-therapist interaction. The testimonial of the patient is framed to maximize positive expectations about therapeutic treatment.
89040886|NCT06022432|Other|Control Group|This group will explicate their current treatment expectations in a writing task.
89040887|NCT06022419|Active Comparator|Lucerne Cast|
89040888|NCT06022419|Active Comparator|Forearm Cast and Finger Splint|
89040889|NCT06022380||Round 1|Participants will be asked to score each outcome domain on a 9 point scale proposed by the GRADE group [http://www.gradeworkinggroup.org], in which 1 to 3 signifies an outcome of 'limited importance', 4 to 6 'important but not critical', and 7 to 9 'critical'. Round 1 will also provide participants with the opportunity to add further outcomes which they think may be important. Any suggested outcomes deemed to represent a new outcome domain by the study group (following discussion within study advisory group and a majority decision) will be added to the list for consideration in round two. Round 1 will last for approximately 2 months.
89040890|NCT06022380||Round 2|All items (in addition to further new outcome domains identified by participants in round 1) will be carried forward for consideration in round 2. Descriptive statistics (graphs) will be used to summarize the scores from round 1 and presented to participants. Participants will see the results of their individual score for each outcome in addition to the median score of each stakeholder group. The rationale for showing participants the scores from other groups is that it may improve consensus between the stakeholder groups. In addition, by carrying all items forward from round 1, it may be possible to identify changes in scoring patterns as a result of viewing other scores. Participants will be asked to score all items once again using the 9-point scale. Round 2 will last for approximately 2 month
89040891|NCT06022367|Experimental|Raise-Turn Sequence|Participant performs cVEMP twice using the head raise activation technique followed by the head turn activation technique.
89040892|NCT06022367|Experimental|Turn-Raise Sequence|Participant performs cVEMP twice using the head turn activation technique followed by the head raise activation technique.
89632984|NCT02439528|Other|Combined pulmonary fibrosis and emphysema syndrome|Genetic analysis on patients with combined pulmonary fibrosis and emphysema syndrome.
89040893|NCT06022354|Experimental|Part 1 : cohort 1: SIM0278 or placebo|
89632985|NCT02439528|Other|Pulmonary fibrosis|Genetic analysis on patients with pulmonary fibrosis.
89040894|NCT06022354|Experimental|Part 1 : cohort 2: SIM0278 or placebo|
89632986|NCT02439528|Other|Emphysema|Genetic analysis on patients with emphysema.
89632987|NCT02439528|Other|Healthy subject|Genetic analysis on healthy subject.
89632988|NCT02831998|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
89632989|NCT02831998|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
89632990|NCT02831998|Placebo Comparator|ZP Vehicle|ZP without IPA
89632991|NCT02434614|Experimental|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
89632992|NCT02434614|Active Comparator|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
89632993|NCT02439606|Active Comparator|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
89632994|NCT02439606|Experimental|Parker-Flex-It Directional Stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It Directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
89040895|NCT06022354|Experimental|Part 1 : cohort 3: SIM0278 or placebo|
89040896|NCT06022354|Experimental|Part 1 : cohort 4: SIM0278 or placebo|
89632995|NCT04345042|No Intervention|First Group|In the first group; the investigators applied the TP such as hot pack, ultrasound, exercise and TENS.
89632996|NCT04345042|Experimental|Second Group|In the second group; the investigators applied the classic massage (Swedish Technique) together with TP.
89632997|NCT02829190|Experimental|Healthy volunteers|Magnetic Resonance Imaging (MRI)
89632998|NCT02829190|Experimental|Patients treated by radiotherapy|Magnetic Resonance Imaging (MRI)
89632999|NCT02829190|Experimental|Patients treated by embolization|Magnetic Resonance Imaging (MRI)
89633000|NCT02829190|Experimental|Patient operated on with free flap|Magnetic Resonance Imaging (MRI)
89040897|NCT06022354|Experimental|Part 1 : cohort 5: SIM0278 or placebo|
89040898|NCT06022354|Experimental|Part 1 : cohort 6: SIM0278 or placebo|
89040899|NCT06022354|Experimental|Part 1 : cohort 7: SIM0278 or placebo|
89040900|NCT06022354|Experimental|Part 2 : cohort 1: SIM0278 or placebo|
89040901|NCT06022354|Experimental|Part 2 : cohort 2: SIM0278 or placebo|
89040902|NCT06022354|Experimental|Part 2 : cohort 3: SIM0278 or placebo|
89040903|NCT06022354|Experimental|Part 2 : cohort 4: SIM0278 or placebo|
89040904|NCT06022341|Other|Leukemic transformation of myeloproliferative neoplasms|"120 patients will be studied for :~Multiomic characterization~In vitro drug screening"
89040905|NCT06022315|Experimental|restricted high carbohydrate low fat diet with exercise training program|exercise training combined with the consumption of caloric restricted high CHO-low FAT diet. The interventions will last for four weeks.
89040906|NCT06022315|Experimental|restricted High fat low carbohydrate diet with exercise training program|exercise training with consumption of caloric restricted low CHO-high FAT diet. The interventions will last for four weeks.
89057477|NCT01202188|Active Comparator|indacaterol (QAB149)|QAB149 150 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
89633001|NCT05720260|Active Comparator|goserelin/ fulvestrant|Control arm
89633002|NCT05720260|Experimental|goserelin/ fulvestrant/ capivasertib|Control arm plus AKT inhibitor
89633003|NCT05720260|Experimental|goserelin/ fulvestrant/ capivasertib/ durvalumab|Control arm plus AKT inhibitor and immunotherapy
89633004|NCT05720260|Experimental|goserelin/ fulvestrant/ durvalumab|Control arm plus immunotherapy
89633005|NCT03191604||Endoscopists familiar with EET|Physicians familiar with conducting endoscopic eradication therapy.
89633006|NCT03188250|Experimental|Chama cha MamaToto|Pregnant women in communities where chama cha mamatoto is taking place will be invited to join and participate in bi-weekly group meetings for a year
89633007|NCT03188250|No Intervention|Referent|Pregnant women attending at least one prenatal visit in communities where chama cha mamatoto was implemented three months later served as the comparison
89633008|NCT03188406||Gastric cancer|Patients with clinical or histological diagnosis of stomach cancer
89633009|NCT03188406||Gastric intestinal metaplasia|Patients classified as OLGIM >0
89633010|NCT03188406||Non-atrophic gastritis|Patients classified as OLGA 0
89633011|NCT02978170|Experimental|Diagnostic (CBCT)|Patients undergo CBCT during standard of care bronchoscopy.
89633012|NCT02440386|No Intervention|Control|The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
89633013|NCT02440386|Experimental|Incentive|The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.
89633014|NCT02959216|Experimental|Aerobic Exercise|Aerobic exercise participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during an initial treadmill test. Participants will be asked to exercise once a day up to 90% of their assigned HRT for a minimum of 20 minutes. Participants will wear a heart rate monitor to track their heart rate during aerobic exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
89633015|NCT02959216|Placebo Comparator|Stretching Exercise|Stretching exercise participants will receive a prescription to complete a standardized physical therapy stretching protocol once a day for approximately 20 minutes. Participants will wear a heart rate monitor to track their heart rate during the stretching exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
89633016|NCT03188016|Experimental|Intensive Interaction with music|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker plus music improvised by a music therapist with the aim of enhancing child - support worker interaction
88990758|NCT06176443|Experimental|One anastomosis gastric bypass with combined fundoplication|"One anastomosis gastric bypass with combined fundoplication FundoRing"
88990759|NCT06176443|Active Comparator|One anastomosis gastric bypass without combined fundoplication|One anastomosis gastric bypass without combined fundoplication
88990760|NCT06176378|Experimental|Traditional Pulpotomy procedures|In the traditional pulpotomy group, the coronal pulp was removed by the traditional method the the capping material applied
88990761|NCT06176378|Experimental|Diode laser Pulpotomy procedures|in the low-level diode laser pulpotomy group, the radicular pulp was biostimulated using low-level diode laser before application of capping material
88990762|NCT06176235|Experimental|Teriflunomide plus Dexamethasone|Oral Teriflunomide was given at a dose of 7 mg once daily for 24 weeks and dexamethasone was given at a dose of 40mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Nonresponsive participants with platelets less than 20 x10^9/L or with active bleeding were allowed to repeat the 4-day course of dexamethasone treatment.
88990763|NCT06176235|Active Comparator|Dexamethasone|Dexamethasone was given at a dose of 40mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than 20 x 10^9/L or with active bleeding were also allowed to repeat the 4-day course of dexamethasone treatment.
88990764|NCT06175780|Experimental|KY-0118|
88990765|NCT06175780|Experimental|Cohort1: KY-0118|
88990766|NCT06175780|Experimental|Cohort2: KY-0118|
88990767|NCT06175455||control|Healthy, age and sex matched controls
88990768|NCT06175455||Long Covid|patients who experienced persistent respiratory symptoms four weeks after contracting COVID-19
88990769|NCT06175078||Patient with suspected breast cancer|Patients with suspected breast cancer will be recruited and scanned for this study. The results of ultrasound data analysis will be compared and correlated to the histopathology reports on routine core biopsy specimens, surgery reports, or radiology reports.
89633017|NCT03188016|Active Comparator|Standard Intensive Interaction|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker
89633018|NCT05720026|Experimental|Treatment group|SYSA1901 combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
89633019|NCT05720026|Active Comparator|Control group|Perjeta® combined with trastuzumab and docetaxel will be administrated intravenously on a 3-weekly schedule for 4 cycles (21 days per cycle).
88990770|NCT06174610||Acute Kidney Injury + CRRT|"Critically ill patients admitted to the intensive care unit (ICU), undergoing continuous renal replacement therapy due to Acute Kidney Injury.~Diagnostic Test: Daily Doppler measurement of Renal Resistive Index"
88990771|NCT06174532|Placebo Comparator|Traditional method|Patients with mandibular tumors will be treated by the traditional method
88990772|NCT06174532|Active Comparator|Virtual surgical planning method|Patients with mandibular tumors will be treated by traditional method with virtual surgical planning
88990773|NCT06174155|Active Comparator|Control group|The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist.
88990774|NCT06174155|Active Comparator|Study group A|The study group A will receive Botulinum toxin-A injection in addition to physical therapy program as control group
89211720|NCT04464213|Experimental|Multi-dose experiments|
89633020|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
89633021|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
89633022|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
89633023|NCT03187938||Pregnant women at 24-28 weeks gestation|Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
89633024|NCT04483674|Experimental|Biktarvy|Patients will receive one pill with 50mg bictegravir/200mg emtricitabine /25mg tenofovir alafenamide orally once a day, for 48 weeks
89633025|NCT05719870|Experimental|Intervention group|Patients hospitalized in the Geriatric Unit aged 60 years or older, that living in the community setting and who will be discharged at home and with expected survival >7 days.
89633026|NCT05719870|No Intervention|Control group|"Patients hospitalized in the Geriatric Unit aged 60 years or older, that living in the community setting and who will be discharged at home and with expected survival >7 days.~The control group will be discharged following standard care procedures, and will receive only appropriate corrections and clarifications in case mistakes in the comprehension of the medical recommendations."
88990775|NCT06174155|Active Comparator|Study group B|The study group B will receive shock wave therapy in addition to physical therapy program as control group.
88990776|NCT06173583||Adult In-patient Cardiac surgery|Adult patients undergoing elective open-heart surgery
88990777|NCT06173518|Experimental|AUTO1|
88990778|NCT06173258|Active Comparator|Water exchange alone|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
89633027|NCT03191214||No Warming|Patients undergoing brief surgical procedures of >15 minutes for whom no warming devices are being employed.
89633028|NCT03191214||Forced Air Warming|Patients undergoing surgical procedures in which forced air warming, is being used
89633029|NCT03190980|Experimental|5% glucose|neonates will receive 2 ml of 5% glucose before heel prick
89633030|NCT03190980|Experimental|30% glucose|neonates will receive 2 ml of 30% glucose before heel prick
89633031|NCT03190980|Placebo Comparator|Placebo|neonates will receive 2 ml of sterile water before heel prick
89633032|NCT05638750|Experimental|Intervention|Participants will participate in the rehabilitation intervention.
89633033|NCT02434458||Fibromyalgia case group|Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
89633034|NCT02434458||Control|Healthy control subjects
89633035|NCT02434458||Rheumatoid arthritis group|Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
89633036|NCT05719792||Those who had lumbar radicular pain|Patients with lumbar radicular pain identified by inclusion and exclusion criteria
89633037|NCT02438982|Active Comparator|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
89633038|NCT02438982|Experimental|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3 , it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
89633039|NCT03187704|Active Comparator|filtration|Air filtration in homes
89633040|NCT03187704|Sham Comparator|no filtration|Sham air filtration
89633041|NCT02425774|Placebo Comparator|Sham stimulation + Placebo|"no stimulation~1 placebo tablet at two different timepoints before surgery"
88990779|NCT06173258|Experimental|Water exchange plus Artificial intelligence (AI)|During colonoscopic insertion, residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion. Commercially available AI system (GI Genius, Medtronic, USA; CAD-EYE, Fujifilm, EU and Taiwan; Endo-AID, Olympus, EU and Taiwan) will be employed. During AI-assisted procedures, the AI will be activated during the withdrawal phase of the procedure, providing a bounding box as output any time a lesion that is suspected to be a polyp is recognized by the AI device.
88990780|NCT06173154|Experimental|ID prevention unit|One healthcare unit will implement the healthcare system for the prevention of iatrogenic dependency (ID) and one healthcare unit will provide standard care without any specific system in place.
88990781|NCT06173154|Sham Comparator|Control unit|One healthcare unit will implement the healthcare system for the prevention of iatrogenic dependency (ID) and one healthcare unit will provide standard care without any specific system in place.
88990782|NCT06172764|Experimental|Group A|vitamin D Deficient group having initial caries
88990783|NCT06172764|Active Comparator|Group B|vitamin D deficient group having initial caries
88990784|NCT06172764|Placebo Comparator|Group C|vitamin D sufficient group having initial caries
88990785|NCT06172400|Active Comparator|Touniquet|Local injection of Mepivacaine (10 mg/ml) approximately 10 ml in the incisional area at least 10 minutes before surgery start. Use of a forearm tourniquet at the pressure of 250 mmHg.
88990786|NCT06172400|Experimental|Adrenaline|Local injection of Mepivacaine (10 mg/ml) and adrenaline (5 mcg/ml) approximately 10 ml in the incisional area at least 10 minutes before surgery start. Forearm tourniquet applied but not inflated.
89633042|NCT02425774|Active Comparator|Vagus stimulation + placebo|"Stimulation at the beginning and the end of the surgery~1 placebo tablet at two different timepoints before surgery"
89633043|NCT02425774|Active Comparator|Prucalopride + sham stimulation|"1 prucalopride tablet at two different timepoints before surgery~no stimulation"
89633044|NCT03190902|Experimental|specific computer training (ST) - POMS|
89633045|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - POMS|
89633046|NCT03190902|Experimental|specific computer training (ST) - ADHD|
89633047|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - ADHD|
89633048|NCT03191136|Experimental|Group1|taking YHD1119 (pregabalin 300mg) in fasted state at Period 1
89633049|NCT03191136|Experimental|Group2|taking YHD1119 (pregabalin 300mg) in fed state at Period 1
89633050|NCT03187626|Experimental|Intra-articular botulinum toxin A and splinting|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
89040907|NCT06022289|Experimental|Monotherapy or combination therapy based on Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
89040908|NCT06022276|Experimental|Monotherapy or combination therapy based on Nimotuzumab|Nitozumab injection 400mg/cycle, every 21 days/cycle, until disease progression, intolerable toxicity or death, or subject decision to withdraw from the study.The molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Nitozumab+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
89040909|NCT06022263|Placebo Comparator|Placebo|1.5 mL of Omnipaque mixed with water for injection
89040910|NCT06022263|Experimental|STA363|1.5 mL of STA363 (lactic acid, 120 mg/mL) mixed with Omnipaque
89040911|NCT06022250|Experimental|JS207|
89040912|NCT06022237|Experimental|Ibandronate|Ibandronate 150 mg once monthly in a supervised manner in front of student investigator and will be observed for 2 hours following ingestion. Patients will also receive Calcium 500mg BD and Vitamin D3 1000 mg OD
89040913|NCT06022237|Active Comparator|Placebo|Group B will receive placebo once monthly along with Calcium 500mg BD and Vitamin D3 1000 mg OD
89633051|NCT03187626|Active Comparator|Intra-articular saline and splinting|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
89633052|NCT03190746||No SNP|Subjects have two copies of the wild type gene
89633053|NCT03190746||SNP present|Subjects have one or two copies of the SNP
89633054|NCT03117894|Active Comparator|GA with RA|Regional Anesthesia and General Anesthesia.
89633055|NCT03117894|Active Comparator|GA without RA|Only General Anesthesia (without a supplemental Regional Anesthesia).
89633056|NCT02438670|No Intervention|Open-Loop Care|The subjects Open-Loop Care for the 24-hour period prior to each study sessions assessed for time in the target range 70-180 mg/dL, and frequency of hypoglycemia and hyperglycemia as assessed by CGM.
89633057|NCT02438670|Experimental|PID algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a proportional-integral-derivative (PID) control algorithm, incorporating a personalized model of glucose-insulin dynamics.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
89633058|NCT02438670|Experimental|MPC algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a model predictive control (MPC) control algorithm with HMS, using the identical model as in the first experimental arm.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
89633059|NCT05719480||Liver Cancer patients|Patients who meet the diagnostic criteria of the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (Version 2019) of the Chinese Medical Association
89633060|NCT05719480||Liver Cirrhosis patients|Patients who meet the diagnostic criteria of the Guidelines for the Diagnosis and Treatment of Liver Cirrhosis (2019) issued by the Hepatology Branch of the Chinese Medical Association
89633061|NCT05719480||Fatty Liver patients|Patients whose liver imaging findings meet the imaging diagnostic criteria for diffuse fatty liver disease or whose liver biopsy histology changes meet the pathological diagnostic criteria for fatty liver disease
89633062|NCT05719480||Hepatitis patients|Patients who meet the diagnostic criteria for hepatitis B (ws 299-2008) and are diagnosed as hepatitis B;
89633063|NCT05719480||healthy people|Healthy people without liver related medical history or other diseases known to affect blood lipid/protein metabolism
89040914|NCT06022198|Experimental|Recovered From COVID-19 Pneumonia|Bronchoalveolar Lavage in Recovered From COVID-19 Pneumonia
89633064|NCT04483752|Other|Patients hospitalised for SARS CoV-2 infection.|
89633065|NCT02438748||Patients|Individuals undergoing Repetitive Transcranial Magnetic Stimulation treatment for major depressive disorder.
89633066|NCT02438748||Controls|Healthy age-, and sex-matched control individuals.
89633067|NCT03187548|Experimental|CPP-ACP|Casein phosphopeptide amorphous calcium phosphate dental paste
89633068|NCT03190044|Experimental|Migraineurs (verum)|One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.
89633069|NCT03190044|Placebo Comparator|Migranineurs (placebo)|One pill per day of placebo: Cellulose
89633070|NCT02433990||Adult Congenital Heart Disease|18 years and older with congenital heart disease
89633071|NCT03190122|Active Comparator|group with pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Pealing Of The Outer Layer Of The Cavernous Sinus
89633072|NCT03190122|Experimental|group without pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision Without Pealing Of The Outer Layer Of The Cavernous Sinus
89633073|NCT03189888|Other|apheresis|leukapheresis in ulcerative colitis
89633074|NCT02042326|Experimental|Sirolimus treatment|"Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml.~The starting dose will be 2 mg per day, and will be adapted every week for one month.~The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment."
89633075|NCT02434068||stone residuals|all patients are going to be submitted to the same intervention: CT, US, KUB
89633076|NCT05718544|Experimental|Combined supplement|Patient-controlled analgesia is established with esketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
89040915|NCT06022133|Experimental|Dietary sodium restriction|DIetary sodium restriction
89040916|NCT06022133|No Intervention|Usual diet|Usual diet
89633077|NCT05718544|Placebo Comparator|Placebo|Patient-controlled analgesia is established with sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lock-out interval of 8 minutes and a background infusion rate at 1 ml/h.
89633078|NCT03190824|Experimental|OBP-301|Eligible patients with unresectable Stage III and IV melanoma will receive up to 13 treatments of OBP 301 at a concentration of 1 × 1012 virus particles (VP)/mL for 24 weeks.
89040917|NCT06022120|Other|An integrated health literacy intervention|Intervention: A group of students at each school will develop and implement their own project activities at meetings two times during the intervention. Activities are implemented in schools for all students.
89040918|NCT06022120|No Intervention|Reference|No intervention activities
89040919|NCT06022094|Experimental|Delta of before/after the intervention|Data will be collected before and after the reduced carb intervention
89633079|NCT05616598|Active Comparator|Pateint group|Men with HCV
89633080|NCT05616598|No Intervention|Control group|Men without HCV
89633081|NCT03190356||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
89633082|NCT03190356||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
89633083|NCT05717296|Experimental|with multimedia support|
89633084|NCT05717296|Sham Comparator|without multimedia support|
89633085|NCT03190434||amniotic fluid|amniotic fluid identification by AL-SENSE product
89633086|NCT03187392|Active Comparator|lidocaine injection|
89040920|NCT06022042|Experimental|On1 Abutment + Nobel PMC implant Set|Subjects who takes implant therapy using On1 Abutment + Nobel PMC implant
89040921|NCT06022042|Experimental|On1 Abutment + Nobel PCC Implant Set|Subjects who takes implant therapy using On1 Abutment + Nobel PCC Implant
89040922|NCT06022042|Experimental|On1 Abutment + Nobel CC Implant Set|Subjects who takes implant therapy using On1 Abutment + Nobel CC Implant
89040923|NCT06022042|Active Comparator|One-Stage Abutment + Nobel PMC Implant Set|Subjects who takes implant therapy using One-Stage Abutment + Nobel PMC Implant
89040924|NCT06022042|Active Comparator|One-Stage Abutment + Nobel PCC Implant Set|Subjects who takes implant therapy using One-Stage Abutment + Nobel PCC Implant
89633087|NCT03187392|Experimental|lidocaine-prilocaine cream|
89040925|NCT06022042|Active Comparator|One-Stage Abutment + Nobel CC Implant Set|Subjects who takes implant therapy using One-Stage Abutment + Nobel CC Implant
89040926|NCT06021951|Experimental|Bempedoic acid|
89040927|NCT06021951|Experimental|Bempedoic acid/ezetimibe fixed combination drug product|
89040928|NCT06021912||ITA GROUP|Patients with asthma or allergic rhinitis who have received allergen immunotherapy (ITA).
89040929|NCT06021912||STANDARD TREATMENT|patients with asthma or allergic rhinitis who have received standard allergen treatment.
89040930|NCT06021899|Active Comparator|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
89040931|NCT06021899|Experimental|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
89040932|NCT06021873|Active Comparator|Laparoscopic SADI-S|Patients with indication to laparoscopic Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
89040933|NCT06021873|Active Comparator|Robotic SADI-S|Patients with indication to robotic Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
89040934|NCT06021847|Active Comparator|Group I patients treated with ozonated water|The patients were used ozonated water as mouth wash for treatment of denture associated oral stomatitis.
89633088|NCT01464268|Active Comparator|Riboflavin drops every minute|Administration of riboflavin every 2 minutes for the duration of UV exposure.
89633089|NCT01464268|Active Comparator|Riboflavin drops every 2 minutes|Administration of riboflavin every 1 minute for the duration of UV exposure.
89633090|NCT02430324||TBI, no cerebral infarction|patients with moderate or severe brain injury that do not develop posttraumatic cerebral infarction
89633091|NCT02430324||TBI, posttraumatic cerebral infarction|patients with moderate or severe brain injury that develops posttraumatic cerebral infarction
89633092|NCT05717218|Experimental|Interventional|All patients included
89633093|NCT02438124|Experimental|Patient|Patient with Parkinson's Disease with walking test and neuropsychological evaluation
89633094|NCT02438124|Experimental|Contrôle|normal control with walking test and neuropsychological evaluation
89633095|NCT01177618||Probands|Severe, early-onset COPD subjects that bring the family into the study
89040935|NCT06021847|Active Comparator|Group II patients treated with chlorhexidine mouthwash|The patients were used chlorhexidine mouth wash for treatment of denture associated oral stomatitis
89040936|NCT06021834|Active Comparator|control group|The control group will be invited to attend the program three times per week and will engage in an endurance training program
89040937|NCT06021834|Experimental|experimental group|the experimental group will be invited to attend the program three times per week and will participate in a combined endurance training and cognitive training program.
89040938|NCT06021821|Experimental|Intervention Group|Participants will listen to the SoundMind app for 20 minutes per day, ideally during a moment of stress.
89633096|NCT01177618||Relatives|Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
89633097|NCT05608798|Other|Examination with the ODI-Tech medical device|"Diffuse reflectance spectroscopy (DRS) operating within the visible wavelength region will be used for the microvascular oxygen saturation and haematocrit measurements.~Computer-assisted microscopy (CAM) will be used for recording frames of skin microcirculation."
89633098|NCT02430246|Experimental|Primary prevention - Urex Plus|Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
89633099|NCT02430246|Placebo Comparator|Primary prevention - Placebo|Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
89211721|NCT00841724|Active Comparator|Busilvex, Fludara, Thymoglobuline|D-6: Fludara D-5: Fludara + Busilvex D-4: Fludara + Busilvex D-3: Fludara + Busilvex D-2: Fludara + Thymoglobuline D-1: Thymoglobuline D0: graft infusion
89211722|NCT00843362|Experimental|1|24-hours vaginal dinoprostone pessary
89633100|NCT02430246|Experimental|Secondary prevention - Urex Plus|Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
89633101|NCT02430246|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
89633102|NCT02430246|Experimental|Eradication - Urex Plus|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
89633103|NCT02430246|Placebo Comparator|Eradication - Placebo|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
89633104|NCT02430246|Other|Lactobacilli transfer - probiotic capsule|Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
89633105|NCT02430246|Other|Lactobacilli transfer - probiotic capsule after 2 months|Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.
89633106|NCT05605600||Patients with Low Anterior Resection Syndrome|Patients with lived-experience of anterior resection surgery, who may or may not have subsequently developed bowel dysfunction symptoms, will be invited to take part in a focus group. They will discuss a new questionnaire and the phrasing of the questions, ensuring clarity and reducing the potential variability in interpretation of each question.
89633107|NCT00214539|Experimental|Treatment|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
89633108|NCT00214539|Active Comparator|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
89633109|NCT00955552|Active Comparator|Cosamin DS®|"glucosamine hydrochloride 500 mg and chondroitin sulfate 400 mg (Cosamin DS®, Nutramax Laboratories).~The medication was supplied as capsules, with the daily dose of 3 capsules."
89633110|NCT00955552|Experimental|Glucosamine/ chondroitin sulphate|Glucosamine hydrochloride 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal The medication was supplied as capsules, with the daily dose of 3 capsules.
89633111|NCT00608764||NHW COPD Participants|Non-Hispanic white participants with COPD
89633112|NCT00608764||NHW Control Group|Non-Hispanic white participants with normal spirometry (do not have COPD)
89633113|NCT00608764||AA COPD Participants|African-American participants with COPD
89633114|NCT00608764||AA Control Group|African-American participants with normal spirometry (do not have COPD)
89211723|NCT00843362|Active Comparator|2|Vaginal dinoprostone gel
89211724|NCT04003233|Experimental|Spring Distraction System|The SDS device will be implanted during a scoliosis correction operation.
89211725|NCT04003233|Experimental|Minimal Invasive Deformity Correction system|The MID-C device will be implanted during a scoliosis correction operation.
89211726|NCT00841802|Experimental|Prednisone|Steroid medication
89211727|NCT00841802|No Intervention|No Intervention|No Intervention
89211728|NCT05300295|Experimental|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
89633115|NCT00216099|Experimental|Investigational Treatment|"Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle~Oral Folic Acid, once per day for 7 days preceding pemetrexed dose, continued daily, and for 21 days after the last dose of pemetrexed.~Vitamin B12, 1000ug intramuscular injection 7 days preceding pemetrexed dose, and every three cycles thereafter on the same day of pemetrexed administration"
89633116|NCT04344652|Experimental|Photoscreening|Photoscreening of patients 0 to 10 years of age
89633117|NCT05716828|Experimental|Balint group|Participants in the Balint group completed Balint training for a period of three months.
89633118|NCT05716828|No Intervention|non-Balint group|
89633119|NCT00039195|Experimental|Induction R-CHOPac Therapy for patients with B-Cell Lymphoma|Patients received 4 cycles if accelerated R-CHOP (cyclophosphamide. doxorubicin, vincristine and prednisone + rituximab) followed by 3 cycles ICE (ifosfamide, carboplatin and etoposide) consolidation therapy.
89633120|NCT05591170|Experimental|Study Group|"Participants received single, high, oral dose of vitamin D3 (120,000 IU), serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) at baseline, 3 days and 7 days after bolus dose were measured.~The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA)."
89633121|NCT05591170|No Intervention|Control Group|"Serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) were measured at baseline, 3 days and 7 days after.~The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA)."
89211729|NCT00989859||Plethysmographic monitoring|Plethysmographic monitoring
89211730|NCT00621140|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
89211731|NCT00621140|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
89211732|NCT00841880|Experimental|1|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril + Felodipine
89633122|NCT00218439|Experimental|1|Active medication for 4 weeks followed by placebo for 4 weeks
89633123|NCT00218439|Experimental|2|Placebo for 4 weeks followed by active for 4 weeks
89633124|NCT04344730|Placebo Comparator|Standard oxygen 1|Standard oxygen and placebo of Dexamethasone
89040939|NCT06021821|Active Comparator|Spotify Group|Participants will listen to a specified Spotify playlist for 20 minutes per day, ideally during a moment of stress.
89040940|NCT06021821|No Intervention|Control Group|This group will have no tasks prescribed.
89633125|NCT04344730|Experimental|Standard oxygen 2|Standard oxygen and Dexamethasone
89633126|NCT04344730|Experimental|CPAP 1|CPAP and placebo of Dexamethasone
89633127|NCT04344730|Experimental|CPAP 2|CPAP and Dexamethasone
89633128|NCT04344730|Experimental|HFNO 1|HFNO and placebo of Dexamethasone
89633129|NCT04344730|Experimental|HFNO 2|HFNO and Dexamethasone
89633130|NCT04344730|Placebo Comparator|mechanically ventilated 1|placebo
89633131|NCT04344730|Experimental|mechanically ventilated 2|Dexamethasone
89633132|NCT05716672||240mg group|Maintenance of the 240mg dose for 12 weeks after the first administration of Lazertinib
89633133|NCT05716672||160mg group|Reduction of the 160mg dose for 12 weeks after the first administration of Lazertinib
89633134|NCT01898559|Experimental|Black & Mild little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking Black & Mild little cigars.~Other: Switch to smoking only little cigars"
89633135|NCT01898559|Experimental|King Edward little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking King Edward little cigars.~Other: Switch to smoking only little cigars"
89633136|NCT02977858||Dissemination|Educational practice for HCPs,Dissemination only - Practices who will participate in education for constipation management guidelines via dissemination of webinar alone.
89633137|NCT02977858||Dissemination + ISE|Educational practice for HCPs,Spaced Education - Practices who will participate in education for constipation management guidelines via dissemination of webinar along with a web-based format referred to as Interactive Spaced Education.
89633138|NCT00108303||Diagnostic|A diagnostic was performed
89633139|NCT05716594|Experimental|Enteral-extended Anti-reflux Stents Group|Patients are going to implant enteral-extended anti-reflux stents
89633140|NCT05716594|Active Comparator|Traditional Stents Group|Patients are going to implant traditional stents
89633141|NCT05723302|Experimental|Maximal Inspiratory Pressure|MIP Maximal Inspiratory Pressure
89040941|NCT06021782||All subjects|Patients scheduled to have their transvaginal ultrasound for medical reasons at the fetal care center and gynecology clinic will be asked to participate in this study. Also, patients undergoing pelvic floor surgery at either the Main OR or outpatient surgery center at UVA will be asked to participate.
89040942|NCT06021769||Women being fitted with pessaries|Women being fitted with pessaries as standard of care will be eligible to participate. They will be asked to complete a recorded verbal interview and written questionnaires the day they have their pessaries fitted and at their follow-up clinic appointments at 4-6 weeks, 3 months, 6 months, and 12 months. Another recorded video interview will be completed at the 12 month appointment.
89040943|NCT06021756|Experimental|Intervention: Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
89040944|NCT06021730|No Intervention|Control|Patients received standard after visit procedure based on the provider
89040945|NCT06021730|Experimental|Standardized After Visit Instructions Only|The standardized after visit instructions (AVI) only group included patients receiving typed standardized AVI which included a text template that providers used to write customized AVI for the patient.
89211733|NCT00841880|Active Comparator|2|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril 10 mg
89040946|NCT06021730|Active Comparator|Standardized After Visit Instructions & Teach Back|The standardized AVI & teach back (TB) group included standardized written AVI with the patient repeating to the provider which changes and future management had been agreed upon during the visit.
89040947|NCT06021717|Experimental|Group A|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1) as postoperative analgesia.
89040948|NCT06021717|Active Comparator|Group B|PCA morphine (Pfizer Inc., US) 1 mg ml-1 as postoperative analgesia.
89633142|NCT05723302|Experimental|Maximal Expiratory Pressure|MEP Maximal Expiratory Pressure
89633143|NCT04344418|Active Comparator|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at the Kenyatta National Hospital (KNH) and Aga Khan University Hospital Nairobi (AKUHN). A diagnosis will be selected based on the same pre-defined checklist and the time the diagnosis is made recorded.
89633144|NCT04344418|Experimental|Nurse-performed focused cardiac ultrasound (FoCUS)|The experimental arm will consist of nurse-performed FoCUS for patients with cardiorespiratory failure. A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
89633145|NCT00358384|Experimental|Subjects receiving treatment A|Eligible subjects will receive 0.1 percent pazopanib ointment.
89633146|NCT00358384|Experimental|Subjects receiving treatment B|Eligible subjects will receive 0.5 percent pazopanib ointment.
89633147|NCT00358384|Experimental|Subjects receiving treatment C|Eligible subjects will receive 1 percent pazopanib ointment.
89633148|NCT00358384|Placebo Comparator|Subjects receiving treatment D|Eligible subjects will receive pazopanib vehicle as negative control.
89633149|NCT00358384|Placebo Comparator|Subjects receiving treatment E|Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control.
89633150|NCT00358384|Placebo Comparator|Subjects receiving treatment F|Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control.
89633151|NCT02959060|Experimental|BMS-986177 and Rifampin|
89633152|NCT00109005|Experimental|Cohort 1 - 25 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks
89633153|NCT00109005|Experimental|Cohort 2 - 5 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks
89633154|NCT05716360||Group 1|Aneuryms treated with Flow-Diverting Stents and had a diameter above 8 mm
89040949|NCT06021691||Gestational diabetes offspring cohort|The Gestational diabetes(GDM) offspring cohort is to learn about language development assessment in 2-year-old children and causal association with their mother who diagnosed GDM
89040950|NCT06021691||Healthy maternal offspring cohort|Healthy maternal offspring cohort is to learn about language development assessment in 2-year-old children and causal association with their health mother
89040951|NCT06021665|Experimental|Fortetropin Group|The Fortetropin group will receive a 20cc size scoop with their product and will be instructed to mix 2 scoops of product with water or a milk of their choice daily.
89040952|NCT06021665|Placebo Comparator|Control Group|The control group will receive a 50cc size scoop with their product and will be instructed to mix 2 scoops of product with water or a milk of their choice daily. The difference in scoop size is to allow for macronutrient matching of the intervention and control products.
89040953|NCT06021652|Experimental|Virtual Reality|Participants electing to participate in the virtual reality based smoking cessation platform
89040954|NCT06021652|No Intervention|Control|Those utilizing standard of care smoking cessation therapies
89633155|NCT05716360||Group 2|Aneuryms treated with Flow-Diverting Stents and had a diameter below 8 mm
89633156|NCT05716360||Group 3|Aneurysms treated with metalic bare stents
89040955|NCT06021587||Levosimendan|Major patients in heart failure with impaired LVEF (< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at different French Hospital, and who have received Levosimendan preoperatively
89040956|NCT06021587||Control - No Levosimendan|Major patients in heart failure with impaired LVEF (< 40%) who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at different French Hospital and who have not received Levosimendan preoperatively
89040957|NCT06021574|Experimental|A single intravenous administration of 1mg VDJ001 or placebo|Drug: VDJ001 Drug: Placebo
89040958|NCT06021574|Experimental|A single intravenous administration of 2mg VDJ001 or placebo|Drug: VDJ001 Drug: Placebo
89040959|NCT06021574|Experimental|A single intravenous administration of 4mg VDJ001 or placebo|Drug: VDJ001 Drug: Placebo
89040960|NCT06021574|Experimental|A single intravenous administration of 8mg VDJ001 or placebo|Drug: VDJ001 Drug: Placebo
89040961|NCT06021535||Calcified Aortic Stenosis|Patients with calcified aortic valve or aortic stenosis will be enrolled Stool, blood samples and aortic valve of operated patients will be retrieved to evaluate the composition of the gut microbiota and its metabolites A follow up is planned for patients with no intervention on the aortic valve to assess the evolution of the aortic stenosis and the change in the gut microbiota.
89040962|NCT06021535||Control|Patients without calcified aortic valve will be enrolled Stool and blood samples will be retrieved to evaluate the composition of the gut microbiota and its metabolites No follow up is scheduled.
89040963|NCT06021522|Experimental|Ecopipam 1.8 mg/kg/day|Ecopipam tablets will be administered orally (PO) once daily in the evening without regard to meals at concentrations 11.2, 22.4, 33.6, 44.8, 67.2 and 89.6 milligrams (mg) containing 12.5, 25, 37.5, 50, 75 and 100 mg ecopipam HCl, respectively in 4-week titration phase to achieve a target dose of 1.8 milligram per kilogram per day (mg/kg/day) ecopipam (2 mg/kg/day ecopipam HCl). Participants will be evaluated for safety at each baseline visit and at all treatment visits up to 24 months and at follow up visits at 7 and 14 days after last dose of ecopipam.
89040964|NCT06021509|Experimental|NovoClasp system|
89040965|NCT06021496|No Intervention|control group|Participants in the control group continued to receive standard cervical cancer screening service of the Ministry of Health. No further intervention was made.
89040966|NCT06021496|Experimental|Face-to-face training group|"In addition to the standard cervical screening service of the Ministry of Health, face-to-face health education through home visits and a reminder by phone call were made once.~brochure given"
89040967|NCT06021496|Experimental|Online training group|In addition to the standard cervical screening service of the Ministry of Health, online health education via video call and a reminder with a phone call once. A digital brochure was given.
89211734|NCT03971851||Low frailty|Frailty risk score less than 5
89211735|NCT03971851||Intermediate Frailty|Frailty risk score 5-15
89633157|NCT05365828||Gestational parents|The study is composed of a sample of LGBTQIA+ and cisgender, heterosexual parents who are receiving antenatal care at the participating hospitals.
89633158|NCT00359008||1|Intermediate AMD
89633159|NCT00359008||2|New untreated CNV subject
89633160|NCT02978014|Experimental|ProSpare Arm|ProSpare (obturator) image guided IMRT (i.e. radiotherapy administered to patients with the ProSpare device inserted in the rectum)
89633161|NCT02978014|No Intervention|Non-ProSpare Arm|Standard of Care (non-obturator) image guided IMRT (i.e. radiotherapy administered to patients without the ProSpare device inserted in the rectum)
89633162|NCT05716126|Experimental|[14]Iruplinalkib(WX-0593) 120 mg(orla solution)|Volunteer will receive a single oral dose of 120 mg [14C]Iruplinalkib (WX-0593) administered by mouth, as a solution.
89633163|NCT04745494|Active Comparator|OT administration|All participants will receive a single dose of 24IU OT (40.32µg, Syntocinon) delivered via a nasal spray.
89633164|NCT04745494|Placebo Comparator|Placebo administration|All participants will receive a single dose of a placebo delivered via a nasal spray.
89633165|NCT05552950|Experimental|experimental group|Individuals using the BioBlock® antiviral nasal spray immediately after waking up in the morning and thereafter once every 4 hours and so for 28 days.
89633166|NCT05552950|Placebo Comparator|control group|Placebo is used by individuals immediately after waking up in the morning and thereafter once every 4 hours and so for 28 days.
89633167|NCT00359866|Experimental|Pelvic IMRT with Tomotherapy|"Helical tomotherapy will be used to plan and deliver the radiation treatment.~Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions.~External beam radiation will be delivered in 160-180 cGy daily fractions to a total dose of 4500-5120 cGY.~Receive treatment once a day for five days a week for approximately 6 weeks.~Treating physician will make determination if patient is to receive intracavitary brachytherapy.~Treating physician will make determination if patient is to receive chemotherapy (allowed but not mandated)."
89040968|NCT06021470|Experimental|Cognitive rehabilitation intervention arm|Five-week group-based and largely interactive format, with groups of four patients. Short presentations are delivered by the clinical neuropsychologist relating to psychoeducation and adjustment to stroke-related deficits in executive function, attention, and memory, respectively, and strategies addressing the activities and participation levels of functioning. Each session lasts approximately 2.5 hours, with a break in the middle. Tailored home activities are included for completion between group sessions to encourage self-efficacy and generalisation of skills and strategies. A member of the research team contacts all participants by telephone twice a week to assess engagement and reported self-efficacy in managing cognitive difficulties. In addition, a weekly text message is sent to all participants. In the proposed pilot RCT, for those receiving the intervention, the text message will contain tips on implementing compensatory strategies.
89040969|NCT06021470|No Intervention|Usual care|"Those in the control group will be allocated to usual care from their multidisciplinary rehabilitation team in both acute and rehabilitation settings. Usual rehabilitation care is likely to vary across hospital settings (acute vs. rehabilitation). Information about type, dose, and amount of rehabilitation therapy will be captured from patients' medical charts in both the intervention and control arm of the study.~A member of the research team (RA) contacts all participants by telephone twice a week to assess engagement and reported self-efficacy in managing cognitive difficulties. In addition, a weekly text message is sent to all participants. For those in the wait-list control condition, the text message will contain a positive affirmation."
89040970|NCT06021405|Experimental|Tape stripping|
89040971|NCT06021366||12-month follow-up cohort|
89040972|NCT06021366||Treatment-naïve 12-month sub-cohort|
89040973|NCT06021366||Treatment-experienced 12-month sub-cohort|
89040974|NCT06021366||Treatment-experienced, persistent 12-month sub-cohort|
89040975|NCT06021366||18-month follow-up cohort|
89040976|NCT06021366||Treatment-naïve 18-month sub-cohort|
89040977|NCT06021366||Treatment-experienced 18-month sub-cohort|
89040978|NCT06021366||Treatment-experienced, persistent 18-month sub-cohort|
89040979|NCT06021327|Active Comparator|Erector spinae plane block|will receive a US-guided ESPB
89040980|NCT06021327|Active Comparator|Retrolaminar block|will receive a US-guided RLB
89633168|NCT05547100|Experimental|5mg OLZAPINE /10mg SAMIDORPHAN|Open label, single dose 5mg OLZ/10 mg SAM
89633169|NCT00109473|Experimental|Growth Hormone plus cortecosteroid|Growth Hormone (nutropin AQ 0.075 mg/kg/day subcutaneously daily)
89633170|NCT00109473|Active Comparator|Cortecosteroids alone|Cortecosteroid therapy as prescribed by the referring gastroenterologist
89633171|NCT04344106|Experimental|Prone positioning|"Participants are all turned to prone position for an optimal minimum duration of 3 hours .~Tolerance, oxygen saturation, heart rate and position are monitoring during all procedure. Arterial blood gases are realized before, 1 to 2 hours after the beginning of the prone position, and 6 to 12 hours after resupination."
89633172|NCT00040443|Experimental|CX516|CX516 - 900 mg
89633173|NCT00040443|Placebo Comparator|Placebo|Placebo
89633174|NCT05136430|Experimental|Self-Regulation strategies + large changes (SR)|This arm will receive the Self-Regulation strategies + large changes (SR) intervention followed by smoking cessation treatment
89633175|NCT05136430|Active Comparator|Healthy Lifestyle Education (LE)|This arm will receive the healthy Lifestyle Education (LE) intervention followed by smoking cessation treatment
89633176|NCT00044655|Active Comparator|Stay on baseline medication prescribed|Participants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
89040981|NCT06021314||Adolescent Idiopathic Scoliosis|
89040982|NCT06021262||control group|healthy individuals without previous acute or chronic exposure to organophosphates
89040983|NCT06021262||chronic exposure group|patients with chronic occupational or environmental exposure to organophosphates
89040984|NCT06021262||acute exposure group|patients with acute exposure to organophosphates in accidental or suicidal settings
89040985|NCT06021249|Sham Comparator|Group of Control (Part I experiment)|Traditional ventilation strategies
89040986|NCT06021249|Experimental|Group of traditional lung-protective ventilation (Part I experiment)|Traditional lung-protective ventilation strategies
89040987|NCT06021249|Experimental|Group of innovative lung-protective ventilation (Part I experiment)|Innovative lung-protective ventilation strategies
89040988|NCT06021249|Experimental|Group of traditional & innovative ventilation (Part I experiment)|Traditional & innovative lung protection ventilation strategies
89040989|NCT06021249|Sham Comparator|Group of Control (Part II experiment)|"lung-protective ventilation；~negative pressure extubation"
89040990|NCT06021249|Experimental|Group of positive pressure extubation (Part II experiment)|"lung-protective ventilation；~positive pressure extubation"
89040991|NCT06021249|Experimental|Group of breathing training (Part II experiment)|"lung-protective ventilation；~negative pressure extubation；~postoperative breathing training"
89040992|NCT06021249|Experimental|Group of positive pressure extubation & breathing training (Part II experiment)|"lung-protective ventilation；~positive pressure extubation；~postoperative breathing training"
89040993|NCT06021223|Experimental|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
89040994|NCT06021223|Experimental|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
89040995|NCT06021223|Placebo Comparator|Placebo|140ml of placebo (caesinate) to be consumed daily for 2 weeks
89040996|NCT06021210|Experimental|mNGS detection before stem cell transplantation|Using letermovir to prevent CMV reactivation for high-risk patients with pre-existing CMV viremia based on the mNGS detection technology before HSCT
89633177|NCT00044655|Active Comparator|Switch per study protocol|Participants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
89633178|NCT05130892|Experimental|Colchicine group|1 tablet (0.5mg) / time, once a day
89040997|NCT06021171|Active Comparator|Regular Girl (Sunfiber + Bifidobacterium lactis)|Regular Girl, a synbiotic supplement containing the Prebiotic Sunfiber + Bifidobacterium Lactis
89040998|NCT06021171|Placebo Comparator|Maltodextrin|Maltodextrin
89040999|NCT06021171|Active Comparator|Sunfiber|SunFiber, a prebiotic fiber supplement
89041000|NCT06021119|Active Comparator|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors with Iftar meal
89041001|NCT06021119|No Intervention|Control group|No Dipeptidyl peptidase-4 inhibitors intake with Iftar meal
89041002|NCT06021080||CVVHD|Continuous Veno-Venous Hemosdialysis
89041003|NCT06021080||CVVH|Continuous Veno-Venous Hemofiltration
89041004|NCT06021067|Experimental|Death mesenchymal stem cell therapy plus standard treatment for radiation pneumonia|Subjects (n=3) received a standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4~6 weeks. . If dose-limiting toxicity (DLT) does not occur within 30 days of the first administration, the dose is escalated by three times.
89041005|NCT06021028|Experimental|Beautifil II Resin composite|Giomer restorative
89633179|NCT05130892|Experimental|Tranilast group|1 capsule (0.1g) / time, 3 times a day;
89633180|NCT05130892|Experimental|Oridonin group|2 tablets (0.5g) / time, 3 times a day
89633181|NCT05130892|No Intervention|Non-intervention group|
89633182|NCT02093793|Experimental|High Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
89633183|NCT02093793|Active Comparator|Commercial Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
89633184|NCT05130346|Experimental|Mindfulness Based Stress Reduction (MBSR)|
89633185|NCT05130346|No Intervention|Standard of Care (SOC)|
89633186|NCT02093949||Studied|Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
89633187|NCT02093949||Control|The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
89633188|NCT00223665|Experimental|Intermittent Androgen Suppression (IAS)|"Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.~Flutamide dosed as 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.~Leuprolide Acetate dosed as 7.5mg intramuscular (IM) injections once per month for a total of 9 months."
89633189|NCT05311540|Experimental|Zinc intervention|9 mg/day Zinc suspension via og tube along with the routinely used standard multivitamin product containing 3 mg daily dose of Zn, started on day 7 until discharge from hospital
89633190|NCT05311540|No Intervention|Control|These infants received only standard commercial multivitamin product containing 3 mg daily dose of Zn
89633191|NCT05122390|Experimental|Contraction Coper|The digital application Contraction Coper is provided from pregnancy week 25. The application contains two different modules. One is an informational module about the method (about 60 minutes), the other is a contraction module to be used in early labour (in total 6 hours).
89041006|NCT06021028|Active Comparator|Neo Spectra resin composite|Nano-hybrid resin composite
89041007|NCT06021015|Experimental|Experimental group|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
89041008|NCT06021015|Active Comparator|Control group|Irinotecan and HepaSphere Microspheres
89041009|NCT06021002|Other|Single nasal challenge R848 allergic rhinitis|
89041010|NCT06021002|Other|Single nasal challenge R848 healthy|
89041011|NCT06021002|Other|Single nasal challenge saline|Single nasal challenge saline allergic rhinitis and healthy
89041012|NCT06021002|Other|Repeat nasal challenge R848 allergic rhinitis|
89041013|NCT06021002|Other|Repeat nasal challenge R848 healthy|
89041014|NCT06021002|Other|Repeat nasal challenge saline|Repeat nasal challenge saline allergic rhinitis and healthy
89041015|NCT06021002|No Intervention|Sample collection only|Sample collection only (no nasal challenge) to optimise laboratory protocols
89041016|NCT06020989|Experimental|A|Lazertinib + chemotherapy combination
89041017|NCT06020989|Active Comparator|B|Lazertinib monotherapy
89041018|NCT06020989|Active Comparator|C|Lazertinib monotherapy
89041019|NCT06020924||UFs with infertile patients|Uterine fibroids combined with infertile women
89041020|NCT06020924||UFs with non-infertile patients|Uterine fibroids combined with non-infertile women
89041021|NCT06020911|Active Comparator|Biodentine|17 primary second molars of 17 children will be capped with Biodentine.
89041022|NCT06020911|Active Comparator|Theracal light cured|17 primary second molars of 17 children will be capped with Theracal light cured
89211736|NCT03971851||High frailty|Frailty risk score 15 and above
89633192|NCT05122390|Active Comparator|Contraction Coper Plus|The digital application Contraction Coper with additionally support from a midwife in two different occasions during pregnancy.
89633193|NCT05122390|No Intervention|Control|Conventional antenatal care.
89633194|NCT00223821|Active Comparator|Drug Therapy Aone|Oxybutynin chloride, extended-release, individually-titrated
89633195|NCT00223821|Experimental|Drug Therapy + Behavioral Training|Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
89633196|NCT00359164|Active Comparator|1|Bevacizumab with verteporfin at Low Fluence Photodynamic Therapy.
89633197|NCT00359164|Active Comparator|2|Bevacizumab with verteporfin at Very Low Photodynamic Therapy.
89633198|NCT00359164|Sham Comparator|3|Bevacizumab with verteporfin with Sham Photodynamic Therapy.
89633199|NCT00359242|Experimental|1|Soothing and Calming instructions given at 2 weeks of life
89633200|NCT00359242|Experimental|2|Repeated food exposure instructions given between 4 and 6 months of life
89633201|NCT00359242|Experimental|3|Receive both interventions: Soothing and Calming and Repeated food exposure
89633202|NCT00359242|No Intervention|4|Group receiving neither of the interventions.
89633203|NCT00224289|Other|1|All participants will be taking Latanoprost; This study compares efficacy within age groups.
89633204|NCT01897623|Other|ultrasound of aorta|
89633205|NCT00045435|Experimental|Treatment (nonmyeloablative donor PBSC transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive CSP PO BID on days -3 to 56 with taper to day 77. Patients also receive MMF PO BID on days 0-27."
89633206|NCT05529238|Other|supervised group during study|monthly physiotherapist appointment for half of the cohort including pelvic floor examination by physiotherapist including digital palpation and perineometry.
89633207|NCT05529238|No Intervention|unsupervised group during study|No intervention. Participants to practice kegel exercises at home.
89633208|NCT01897155|Other|SBP 20-30% under baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index (40-60). Patients received a phenylephrine infusion to maintain systolic blood pressure (SBP) 20% to 30% under baseline. The lower limit of SBP was 75 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
89633209|NCT01897155|Other|SBP 20-30% over baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index(40-60). Patients received a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over baseline. The upper limit of SBP was 165 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
89633210|NCT00047619|Experimental|Pulsatile lavage group|pulsatile lavage therapy
89633211|NCT00047619|Sham Comparator|Sham lavage group|sham pulsatile lavage
89633212|NCT05102188||African American adults with poor sleep|Individuals with self-identified poor sleep quality and/or quantity
89633213|NCT05292820||Transwomen vaginoplasty|Transgender women who underwent vaginoplasty
89633214|NCT00111657|Experimental|pegloticase|"All study participants received intravenous pegloticase at dose of 8 mg, administered every 21 days for a maximum of 5 doses.~There was no control group for this open label study."
89633215|NCT02097303|Other|Single arm|All subjects receive concurrent administration of Radium Ra223 Dichloride and Abiraterone Acetate plus Prednisone
89633216|NCT00703326|Experimental|ramucirumab (IMC-1121B) + docetaxel|
89041023|NCT06020885|Experimental|Experiment group|"This is a prospective, single-arm, phase 1 trial. A total of 18 unresectable LA-ESCC patients are required to be enrolled.~Induction chemo-immunotherapy All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.~Hypo-CCRT Evaluation will be performed three weeks after the induction chemo-immunotherapy, LA-ESCC patients without disease progression will continue the split-course hypo-CCRT treatment.~Split-course hypo-CCRT is administered at the following three dose levels:~Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
89041024|NCT06020872|Experimental|Health literacy group|Participants received the health literacy related to healthy plate.
89041025|NCT06020872|No Intervention|Control group|Participants did not receive the health literacy related to healthy plate.
89041026|NCT06020859|Experimental|NaviEC-2000Pro Gastro Scan|NaviEC-2000Pro Gastro Scan is a new mode of NaviEC-2000Pro
89041027|NCT06020859|Experimental|NaviEC-2000Pro Routine gastric examination|NaviEC-2000Pro Routine gastric examination is a mode of NaviEC-2000Pro
89633217|NCT00703326|Placebo Comparator|placebo + docetaxel|
89633218|NCT02097537|Experimental|Methacholine Chloride|children with bronchial asthma
89633219|NCT02097849|Active Comparator|Non-Pegylated IFN Treated Plus Vaccinations|"Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
89633220|NCT02097849|Experimental|Tecfidera Treated Plus Vaccinations|"Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
89633221|NCT00358540|Experimental|Group B|Group B is a dose escalation phase designed to determine the optimal biological dose of eltrombopag in subjects with sarcoma who received chemotherapy treatment with Adriamycin and Ifosfamide
89633222|NCT00358540|Experimental|Group A|Group A will be used for further exploration of the optimal biological dose (as initially established by completion of Group B), by using 2 different dosing schedules of eltrombopag.
89633223|NCT04752423||PATIENT group|Adult patients shedule for general anesthesia
89633224|NCT04752423||NURSE group|Nurse anesthesist in charge of the corresponding patient
89633225|NCT03187158||Pune Maternal Nutrition Cohort|Study has been planned on the F1 generation of the mothers recruited under the PMNS study at Diabetes Unit, KEM-Pune. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation. This study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
89633226|NCT03187158||New Delhi Birth Cohort|Study has been planned on the F1 generation of the mothers recruited under the New Delhi Birth Cohort in New Delhi, India. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation, the study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
89633227|NCT05101720|Experimental|Ultrasound Guided Axillary Access|Direct visualization of axillary vein with ultrasound will be obtained and used as a guidance for venous puncture.
89041028|NCT06020859|Active Comparator|NaviEC-1000 Routine gastric examination|NaviEC-1000 Routine gastric examination is a mode of NaviEC-1000
89211737|NCT03969745|Experimental|Time restricted feeding (TRF)|Participants restricted their daily energy intake window to between 8 am and 4 pm for two weeks. They were encouraged to not alter the quantity and composition of their diet or alter physical activity patterns.
89211738|NCT03969745|Active Comparator|Caloric deficit|The investigators observed significant weight loss in the TRF group with participants reporting to consume ~400 kilocalories less per day. Therefore the investigators added a caloric deficit group to control for the effects of weight loss on metabolism. Total energy expenditure was measured for one week and was used to prescribe a 400 kilocalories/day energy deficit diet to follow for two weeks.
89211739|NCT00835952|Experimental|ATX-101|
89211740|NCT03971773|Experimental|Patient ongoing hypnosis sessions|
89211741|NCT00843440|Experimental|Bevacizumab|Study using a Gehan design, 7 patients will be included in the first phase and 18 additional patients will enter the second phase.
89633228|NCT05101720|Active Comparator|Fluoroscopic Guided Axillary Access|Standard technique: using the intersection of the lateral borders of the second and third rib as a radiological landmarks.
89633229|NCT00047697|Experimental|Donepezil HCl|Donepezil HCL 5 mg and 10 mg
89633230|NCT00047697|Placebo Comparator|Placebo|Placebo
89633231|NCT02430168|Active Comparator|RIRS|Retrograde intrarenal surgery
89633232|NCT02430168|Active Comparator|PCNL|Percutaneous nephrolithotomy
89633233|NCT02430012|Active Comparator|Intervention group|The intervention group will take the secondary prevention quality improvement strategies into implementation.
89633234|NCT02430012|No Intervention|Control group|The control goup will maintain the routine practice pattern.
89633235|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
89633236|NCT00112125|Experimental|Optimizer System + Optimal medical treatment|Optimizer System implanted and cardiac contractility modulation therapy activated.
89633237|NCT00112125|No Intervention|Optimal medical treatment|Treatment with optimal medical therapy only.
89633238|NCT00359320|Experimental|Mucosa-to-jejunal mucosa technique of pancreaticojejunosto|Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate
89633239|NCT02437812|Experimental|Paclitaxel, carboplatin and metformin|"Drug: Metformin (850 mg) Drug: Carboplatin (AUC 5 or 6) Drug: Paclitaxel (80 mg/m2)~The regimen will be administered as a dose dense schedule."
89211742|NCT00504556|Experimental|1|DU-176b 30mg tablet once daily
89211743|NCT00504556|Experimental|2|DU-176b 60mg once daily
89211744|NCT00504556|Experimental|3|DU-176b 30mg b.i.d.
89211745|NCT00504556|Experimental|4|DU-176b 60mg tablets two times a day
89211746|NCT00504556|Active Comparator|5|warfarin tablets
89211747|NCT05274009|Experimental|Extreme heat event simulation + no cooling (control)|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
89211748|NCT05274009|Experimental|Extreme heat event simulation + recommended cooling|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
89211749|NCT05274009|Experimental|Extreme heat event simulation + hybrid cooling|Adults aged 60-85 years with or without type 2 diabetes and/or hypertension
89211750|NCT00836030||A|
89211751|NCT00206323|Placebo Comparator|placebo/sugar pill|Placebo or sugar pill
89211752|NCT00206323|Active Comparator|Topiramate|Topiramate 25 mg to 200 mg
89211753|NCT03903159|Other|Treatment Group|Positive Peer Journaling (PPJ)
89211754|NCT04043000|Experimental|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
89211755|NCT04043000|Placebo Comparator|Placebo|" The placebo without Super 13 Pro & Prebiotics was given three times a day for four weeks."
89211756|NCT02546804|Experimental|HOT SALT WATER|3% HOT SALT WATER , 25ml used for rinsing for 60 sec, twice daily for 60 days.
89633240|NCT00359398|Experimental|Platelet sequestration|Sequestration of platelet rich plasma before cardiopulmonary bypass
89633241|NCT00359398|No Intervention|Standard care|No platelet rich plasma sequestration undertaken before cardiopulmonary bypass (usual practice)
89633242|NCT02438046|Experimental|Palatal wound bandage by PRF|Intervention: In the test group (n=20 patients) the palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
89633243|NCT02438046|Placebo Comparator|Palatal wound bandage by gelatin sponge|Intervention: The control group patients (n=20) will have their palatal wound medicated by absorbable gelatin sponge.
89633244|NCT02437968|Experimental|Wave 1|South New Jersey school service providers.
89633245|NCT02437968|Experimental|Wave 2|Philadelphia suburbs and surrounding community service providers
89633246|NCT02437968|Experimental|Wave 3|Mississauga, ON (Canada) school district service providers.
89211757|NCT02546804|Experimental|POTASSIUM PERMANGANATE|0.01% POTASSIUM PERMANGANATE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
89211758|NCT02546804|Active Comparator|CHLORHEXIDINE|0.2% CHLORHEXIDINE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
89211759|NCT00205855|Experimental|Precision SCS|Precision SCS. Patients who receive Precision Spinal Cord Stimulator (SCS) Stimulus system
89211760|NCT01013038|Active Comparator|Conventional percutaneous coronary intervention|
89211761|NCT01013038|Experimental|Thrombus aspiration|
89633247|NCT02437734|Other|Coronary angiography|Selected patients will be asked to undergo Coronary angiography with cardiac magnetic resonance imaging before and after Percutaneous Coronary Intervention. Clinical data collection will happen over a 30 month period.
89633248|NCT05083468|Experimental|SR750 tablet|Ascending single and multiple doses of SR750 tablets orally
89633249|NCT05083468|Placebo Comparator|matching placebo|Ascending single and multiple doses of matching placebo orally
89633250|NCT00112593|Experimental|Treatment (allogeneic hematopoietic stem cell transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine IV over 2 hours on days -4, -3, and -2. Patients undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2 to 3 times daily on days -3 to 99 with taper beginning on day 100 and continuing until day 177 in the absence of GVHD. Beginning within 6 hours after transplantation, patients also receive mycophenolate mofetil IV or PO 3 times daily on days 0 to 40 followed by a taper in the absence of GVHD."
89633251|NCT02437422|Experimental|SANGUINATE|Single infusion of SANGUINATE
89633252|NCT05280106|Experimental|Pre-dilution online hemodiafiltration|The study was conducted for a 28-week period in two phases: For the first 12 weeks, all of the patients were subjected to CD with pre-dilution oL-HDF.After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. The second phase will run after finishing the first phase with the same protocol but with post-dilution online HDF.There will be 2 weeks washout period before starting this phase
89041029|NCT06020833|Experimental|Roxadustat combined with retinoic acid group|
89633253|NCT03187314|Experimental|Experimental Group|Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
89633254|NCT00360022|Experimental|Joint Visits|Transition patients will have 2 joint visits performed with the pediatric GI specialist and the adult GI specialist as they transfer care to an adult GI provider.
89633255|NCT00360022|No Intervention|Control|Transition patients in the control group will transfer care to adult GI provider in typical manner.
89633256|NCT00112671|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89688471|NCT01723943|Experimental|Arm II (Helping Her Heal program)|"Participants undergo the Helping Her Heal educational counseling program comprising 5 1-hour sessions 2 weeks apart.~SESSION I: Participants learn stress management skills and discover ways stress affects themselves and their partner.~SESSION II: Participants practice attentive listening and reduce the tendency to try to distract patients from talking about sad or difficult aspects of the cancer experience.~SESSION III: Patients learn to help their spouse talk when she is quiet or withdrawn, to add to their understanding of what she is thinking and feeling, and to add to their ways of supporting her during especially difficult times with the cancer.~SESSION IV: Participants learn strategies for physically reconnecting with spouses.~SESSION V: Participants review skills from prior sessions, identify strategies he or she will continue to use to manage their personal stress, and identify ways to maintain connection and support."
89688472|NCT04355377||Patients|
89688473|NCT04378829||ambulatory follow-up|
89688474|NCT04378829||hospital follow-up|
89041030|NCT06020820|Experimental|Cervical Rehabilitation program (Intervention Group) Group A|Positional release technique on trapezius muscle, Suboccipital muscle release, Stretching of pectoralis muscle
89041031|NCT06020820|Active Comparator|(control group) Group B|neck and shoulder ROMS
89041032|NCT06020794|Active Comparator|Control Group|First group (14 people): 4-weeks home exercise program will be given to control group. The exercise program includes quadriceps isometric exercises (holding for 10 seconds, 20 reps), straight leg raises (20 reps holding for 6 seconds), and semi-squatting exercises (20 reps), hip flexors, hamstring and iliotibial band stretching exercises (20-repetitions), strengthening exercises for hip abductors and adductors (holding for 6 seconds with 20 repetitions). These exercises were said to be performed for 30 minutes, once a day, every day for 4 weeks.
89041033|NCT06020794|Active Comparator|LP-PRP Group|Second group (14 people): LP-PRP injection and 4-week exercise program will be applied by targeting the suprapatellar bursa. The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
89041034|NCT06020768|Experimental|the different bed-head angles in the supine position|The researcher brought the patient to the supine position with the bed-head at 0 degree, and immediately (minute 0) made haemodynamic measurements: central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation. It was taken into account that this could change haemodynamic parameters, and immediately after a 10-minute period of rest, the same haemodynamic measurements were repeated. After this, the bed-head was adjusted to an angle of 20 degree, and the same procedure was repeated, with measurements after 0 and 10 minutes. The same procedure was followed with the bed-head raised to 30 degree and then to 45 degree. In positioning the patients' bed-heads to different angles, a spirit level and a protractor were used.
89041035|NCT06020742|Experimental|MT transfer|
89041036|NCT06020729|Experimental|Occlusion Training|
89041037|NCT06020729|Active Comparator|General exercises without occlusion|
89688475|NCT04378829||intensive care unit follow-up|
89041038|NCT06020716|Experimental|Intervention group 1 (IV 1) Arm A|In the first Intervention group (IV 1), 90 children will be randomly be assigned 1:1 to receive either amoxicillin-clavulanate syrup or placebo (Arm A and B) for 14 days. IV 1 Arm A will receive 14 days amoxicillin-clavulanate syrup..
89041039|NCT06020716|Placebo Comparator|Intervention group 1 (IV 1) Arm B|In the first Intervention group (IV 1), 90 children will be randomly be assigned 1:1 to receive either amoxicillin-clavulanate syrup or placebo (arm A and B) for 14 days. IV 1 Arm B will receive 14 days placebo syrup.
89041040|NCT06020716|Experimental|Intervention group 2 (IV2) Arm C|In the second intervention group (IV 2), 210 children will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup (arm C and D). IV 2 Arm C will receive 14 days amoxicillin-clavulanate syrup and 14 days placebo.
89041041|NCT06020716|Experimental|Intervention group 2 (IV 2) Arm D|In the second intervention group (IV 2), 210 children will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup (arm C and D). IV 2 Arm D will receive 28 days amoxicillin-clavulanate syrup.
89211762|NCT04526704|Experimental|Treatment Continuation Cohort|Previously-treated participants with TGCT continuing their current dose of pexidartinib treatment.
89211763|NCT04526704|Experimental|Treatment-Free/Re-Treatment Cohort|Previously-treated participants with TGCT who discontinue pexidartinib treatment (Treatment-Free Period) and resume pexidartinib treatment at dose at completion of prior study (Re-Treatment Period).
89211764|NCT00842114|Experimental|R+CVP+IFN|8 cycles of Rituximab plus CVP chemotherapy (Bagley's et al) associated with Interferon for 12 weeks
89633257|NCT02437578||Infertile couples|Infertile couples referred to Dansk fertilitetsklinik (Danish Fertility clinic) for IUI, IVF and ICSI treatment
89211765|NCT00842192||A|
89211766|NCT00536991|Experimental|Treatment (calcitriol, ketoconazole, hydrocortisone)|"PHASE I: Patients receive calcitriol PO QD on days 1-3, 8-10, 15-17, and 22-24. Patients also receive ketoconazole PO TID on days 1-24 and therapeutic hydrocortisone PO BID on days -1 to 24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive calcitriol and therapeutic hydrocortisone as in phase I. Patients also receive ketoconazole PO TID on days 4-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89211767|NCT00842270|Experimental|2|4,5 mg/kg/day
89211768|NCT00842270|Experimental|3|6 mg/kg/day
89211769|NCT00842270|Placebo Comparator|4|matching placebo for AB1010 3, 4,5 and 6 mg/kg/day
89633258|NCT02437656|Experimental|Metformin treatment|"J1 : dosimetric scan~J3 : initiation of the Metformin therapy (at a dosage of 1700 mg / day)~J10 : increasing the dose of Metformin (2550 mg / day) + initiation of the radiochemotherapy~J44 : end of the radiochemotherapy~Between J86 and J100 : surgery (discontinuation of the Metformin therapy 48 hours before surgery)"
89633259|NCT05273632|Active Comparator|Oxytocin|Pre- Operative Oxytocin is given intravenously 5-10 minutes slowly before skin incision
89633260|NCT05273632|Active Comparator|Tranexamic acid and Etamsylate|Tranexamic acid and Etamsylate are slowly given intravenously 10 minutes before start of Cesarean Delivery
89633261|NCT05273632|Placebo Comparator|Saline|Normal saline (about 200 ml) is given intravenously 10 minutes before start of Cesarean Section
89633262|NCT02429622|Experimental|Radical 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
89633263|NCT02429622|Experimental|Radical 2.17|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.17Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
89633264|NCT02429622|Experimental|Radical 2.21|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.21Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
89633265|NCT02429622|Experimental|Neoadjuvant 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 4 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity. Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
89633266|NCT02429544|Experimental|Experimental Support Group (ESG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
89211770|NCT00842270|Experimental|1|AB1010 3 mg/kg/day
89211771|NCT00836108|Sham Comparator|1|spontaneous
89211772|NCT00836108|Experimental|2|coordinating arm elevation with inspiration
89211773|NCT00836108|Experimental|3|coordinating arm elevation with expiration
89211774|NCT00504166|Active Comparator|alendronate sodium|alendronate sodium 70 mg tablet once a week for 24 months
89211775|NCT00504166|Placebo Comparator|placebo|placebo to match alendronate sodium
89211776|NCT02547584|Active Comparator|Group 1: with baseline anxiety+catheter ablation|Baseline anxiety will be defined as; Cardiac Anxiety Questionnaire (CAQ) score >2.14 Hospital Anxiety and Depression Questionnaire (HAD) >7 State-Trait Anxiety Inventory (STAI): State-anxiety score >40
89211777|NCT02547584|Active Comparator|Group 2: Without baseline anxiety + catheter ablation|Cardiac Anxiety Questionnaire (CAQ) score <2.14 Hospital Anxiety and Depression Questionnaire (HAD) <7 State-Trait Anxiety Inventory (STAI): State-anxiety score <40
89211778|NCT01013116|Experimental|modified allergen extract of house dust mites|
89211779|NCT01013116|Placebo Comparator|Placebo|
89211780|NCT04002765|Other|New RA patients|"Adults aged 18 to 90 years-old~Diagnosis of rheumatoid arthritis (RA) based on ACR-EULAR 2010 criteria~Onset of disease duration at least 1 year and at most 10 years prior to inclusion"
89211781|NCT02546648|Experimental|Tranexamic Acid vs. matching placebo|Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.
89633267|NCT02429544|Experimental|Standard Support Group (SSG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
89633268|NCT02429544|Other|Standard of Care Group (SOC) - No Residential Program|"Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
89633269|NCT03186924|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
89633270|NCT03186924|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle, including the promotion of recommended physical activity levels and health nutrition.
89633271|NCT02429154|Active Comparator|Normocapnia|The Child will be ventilated in order to achieve an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa). Measurements will be performed after steady state condition. Then the ventilation will be reduced to allow ETCO2 to reach 6.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a normocapnia condition.
89633272|NCT02429154|Other|Mild Hypercapnia|The Child will be ventilated in order to achieve a ETCO2 of 6.5 kPa. Measurements will be performed after steady state condition. Then the ventilation will be increased to allow ETCO2 to reach 5.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a mild hypercapnic condition
89633273|NCT05494996||Questionnaires assessed partners|"≥18 years old;~Participants who are married or in a romantic relationship;~Be able to read and communicate in Chinese."
89633274|NCT05075278|Active Comparator|Attending physician for direct 1:1 supervision|Participants will be assigned to an attending physician for direct 1:1 supervision. The participants will fill out a survey at the end of the day for 16 consecutive days.
89633275|NCT05075278|Experimental|Senior resident for direct 1:1 supervision|Participants will be assigned to an senior resident as a direct supervisor with oversight from an attending physician (in accordance with CMS/ACGME staffing criteria). The participants will fill out a survey at the end of the day for 16 consecutive days.
89633276|NCT02429466|Experimental|Guadecitabine (SGI-110)|
89041042|NCT06019091|Active Comparator|Group 1, low frequency group, 20 Hz.|Compass Health TENS 3000, 3 mode Analog Unit. Normal Mode (N), pulse width of 200 microseconds and an intensity to be determined in the office based upon when the participant feels sensitive to the TENS unit. Frequency (pulse rate) 20 Hz
89041043|NCT06019091|Active Comparator|Group 2, medium frequency, 50 Hz.|Compass Health TENS 3000, 3 mode Analog Unit. Normal Mode (N), pulse width of 200 microseconds and an intensity to be determined in the office based upon when the participant feels sensitive to the TENS unit. Frequency (pulse rate) 50 Hz
89041044|NCT06019091|Active Comparator|Group 3, high frequency, 100 Hz.|Compass Health TENS 3000, 3 mode Analog Unit. Normal Mode (N), a pulse width of 200 microseconds and an intensity to be determined in the office based upon when the participant feels sensitive to the TENS unit. Frequency (pulse rate) 100 Hz
89041045|NCT06018155||Single cohort|Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
89633277|NCT02977390|Other|Passive Leg Raise (PLR)|"The patient is placed in a 45 degree recumbent position. Stroke volume is measured in ml.~Intervention:The patient is placed horizontal and the legs are passively raised to 45 degrees.~Measurement:The effect of the PLR on Stroke Volume is measured. Thereafter the patient is repositioned to the initial position and Stroke Volume is measured again."
89633278|NCT03184896||Hip Fracture|
89633279|NCT02429388|Experimental|High dose spironolactone|This arm of the study will include addition of high dose spironolactone upto 100mg twice daily in adjunct to usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
89633280|NCT02429388|No Intervention|Usual Care|This arm of the study will continue the usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
89633281|NCT02429232|Experimental|Pioglitazone|Pioglitazone 30 mg once daily will be administered orally for total 48 weeks.
89041046|NCT06018012||1 or acute bilirubin encephalopathy|Group (1): included 26 cases with BIND or acute bilirubin encephalopathy (ABE).
89041047|NCT06018012||2 or neonatal hyperbilirubinemia|Group (2): included 30 cases with neonatal hyperbilirubinemia on
89041048|NCT06018012||Control|control group: 20 healthy, age-matched neonates
89041049|NCT06016192|Active Comparator|Continuous aerobic training|Moderate continous endurance training, ergometer
89041050|NCT06016192|Experimental|Interval aerobic training|Moderate intensity interval training, ergometer
89633282|NCT02429232|Active Comparator|Linagliptin|Linagliptin 5 mg once daily will be administered orally for total 48 weeks.
89688476|NCT02911324|Experimental|Nabilone|Will receive nabilone at 1 mg daily (BID) over 4 weeks.
89041051|NCT06015191|Experimental|Remote Cardiac Rehabilitation|Following a 2-week ramp-up period, participants will attend group exercise sessions, remotely delivered in their homes, 3 days per week for 45-minutes over 12-weeks led by a live-interactive health coach. There are 4 exercise session types with different modalities: Session A: 75% aerobic, 25% resistance; Session B: 25% aerobic, 75% resistance; Session C: 50% aerobic, 50% resistance; and Session D: Exercise games (mix of modalities). Each participant will rotate through a 5-week set of exercise sessions (20 sessions) twice over the 10-weeks of group exercise period.
89041052|NCT06015191|Active Comparator|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
89041053|NCT06014814||Pulsed Field Ablation - General Anaesthesia|Patients undergoing pulsed field ablation for atrial fibrillation under general anaesthetic.
89041054|NCT06014814||Pulsed Field Ablation - Mild Conscious Sedation|Patients undergoing pulsed field ablation for atrial fibrillation under mild conscious sedation.
89041055|NCT06014294|Experimental|High-intensity interval training (HIIT)|HIIT program for 16 weeks with a frequency of 2 times per week.
89041056|NCT06014294|Active Comparator|Moderate intensity continuous training (MICT)|Baduanjin exercise as MICT will be applied with the same program duration and frequency as the HIIT group. The entire set of Baduanjin Qigong exercises in the current study includes 8 postures.
89041057|NCT06014294|Placebo Comparator|Non-exercise control|Participants will not receive any exercise training, but attending 32 recreation workshops.
89041058|NCT06014021|Experimental|Experimental group 1|All participants will use an Smartphone application with access to information about pelvic floor and communication with healthcare team, and a strengthening program for PF, while using an intracavitary biofeedback device.
89041059|NCT06014021|Active Comparator|Experimental group 2|All participants will use an Smartphone application with access to information about pelvic floor and communication with healthcare team, and a strengthening program for PF.
89041060|NCT06014021|Active Comparator|Control group|All participants will use an Smartphone application with access to information about pelvic floor and communication with healthcare team.
89041061|NCT06009185|Experimental|HTD < 200 mg zamicastat|Tablets for oral administration under fed conditions. Zamicastat has to be taken in the morning after breakfast. Each patient will continue treatment with the individual highest tolerated dose (HTD) he/she was taking at MPV3 of the study BIA-51058-201 and will take this dose until visit V5.
89041062|NCT06009185|Experimental|HTD 200 mg zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat (two tablets of 100 mg). Zamicastat has to be taken in the morning after breakfast. Each patient will continue treatment with the individual highest tolerated dose (HTD) he/she was taking at MPV3 of the study BIA-51058-201 and will take this dose until visit V5.
89633283|NCT04343950|Experimental|Intervention 1: SMS reminders in colorectal cancer screening|SMS reminders will be sent to individuals who received an invitation letter from Colorectal Cancer Screening Program and haven't participated within 6 weeks.
89041063|NCT06006793|Experimental|Dose-escalation and Dose-expansion|"In dose-escalation phase, SY-5933 tablets will be administrated orally, repeat daily, 28 days as a dosing cycle, in ascending doses.~In dose-expansion phase, RP2D of SY-5933 determined in dose-escalation phase will be administrated orally, repeat daily, 28 days as a dosing cycle."
89041064|NCT06006754||Cardiogenic shock|
89041065|NCT06004739|Other|Antibiotics|Participants will be randomized to start or continue with antibiotics. Antibiotic type and duration targeted to lower urinary tract infection as directed by the Most Responsible Physician (MRP).
89041066|NCT06004739|Other|No Antibiotics|Participants will be randomized to no antibiotics
89041067|NCT06004232|Experimental|PRY-D intervention|Participants in the intervention group will complete 8 prenatal yoga sessions (1x/week) in a virtual group format. The first session will be in person, in which they will meet the instructor, connect with one another through brief introductions, receive their yoga practice materials, practice basic yoga poses, and be given the schedule for the remaining sessions, including virtual access links (e.g., Webex).
89041068|NCT06004232|Active Comparator|Treatment as Usual (TAU)|Participants in the the TAU group will receive routine prenatal care, during which time all patients are given information on the importance of physical activity during pregnancy.
89041069|NCT06003010|No Intervention|Study group|This group will be given standard pre- and post-surgery movement instructions.
89041070|NCT06003010|Experimental|Yoga group|This group will be asked to do a 6 week series of yoga videos at home pre- and post-surgery.
89041071|NCT05994027|Other|ATTACH™ Online Platform Parenting Program|"A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups.~Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls, was deemed unacceptable and even unethical by patients, healthcare professionals, and health system administrators in engagement activities surrounding the preparation of this proposal."
89633284|NCT04343950|Active Comparator|Usual Care 1: Reminder letter in colorectal cancer screening|Reminder letters will be sent to individuals who received an invitation letter from the Colorectal Cancer Screening Program and haven't participated within 6 weeks.
89633285|NCT04343950|Experimental|Intervention 2: SMS reminders to return the screening test|SMS reminders will be sent to individuals who picked the fecal immunochemical test at the pharmacy and haven't returned it within 14 days.
89633286|NCT04343950|Active Comparator|Usual Care 2: No intervention|No reminders will be sent.
89633287|NCT04343950|Experimental|Intervention 3: SMS invitation among prior participants|Invitation by SMS will be sent to women who previously participated in the Breast Cancer Screening Program.
89633288|NCT04343950|Active Comparator|Usual Care 3: Invitation letter|Letter invitations will be sent.
89633289|NCT03189498|Experimental|Group 1: Participants With Normal Renal Function|Adult participants with normal renal function (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter per minute [mL/min]) will receive a single oral dose of 1,000 milligram (mg) JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
89057478|NCT01202188|Active Comparator|tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
89633290|NCT03189498|Experimental|Group 2: Participants With Mild Renal Impairment|Adult participants with mild impaired renal function (eGFR >=60 to less than [<] 90 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
89633291|NCT03189498|Experimental|Group 3: Participants With Moderate Renal Impairment|Adult participants with moderate impaired renal function (eGFR >=30 to <60 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
89633292|NCT03189498|Experimental|Group 4: Participants With Severe Renal Impairment|Adult participants with severe impaired renal function (eGFR >= 15 to <30 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
89633293|NCT03189498|Experimental|Group 5: Participants With ESRD With or Without Hemodialysis|Adult participants with end-stage renal disease (ESRD) (eGFR <15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
89633294|NCT02437266|Experimental|Scapular mobilization|The participants will receive a twenty minutes session of scapular mobilization onto the scapular
89633295|NCT02437266|No Intervention|Control|Rest on the bed for twenty minutes
89633296|NCT03186768|Experimental|Intervention arm|Intervention arm receives a training of trainers on the soap on a rope hall pass intervention.
89633297|NCT03186768|No Intervention|Control arm|Control arm delays the training of trainers on the soap on a rope hall pass intervention until endline hand washing data has been collected.
89633298|NCT03186690|Experimental|Biodentine|This includes teeth that were treated with Biodntine cement
89633299|NCT03186690|Experimental|Mineral Trioxide Aggregate|This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement
89633300|NCT03189654||Treatment group|Non-invasive ventilation after pleurocentesis
89633301|NCT03189654||Control group|Oxygen Administration via nasal tube
89633302|NCT03186846|Active Comparator|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
89633303|NCT03186846|Active Comparator|placebo|No multimodal monitoring will be applied in control group.
89633304|NCT03189732|Experimental|Metformin oral +exercise|Metformin, one dose 2000mg, 2.5h before the start of 60 min physical exercise
89633305|NCT03189732|Active Comparator|Metformin local in AT +exercise|Metformin perfused into microdialysis probe inserted in adipose tissue, 0.3ug/min 1.5h before the exercise and during 60min physical exercise
89633306|NCT03189732|Active Comparator|No metformin + exercise|60min physical exercise without pretreatment of metformin
89633307|NCT05057728|Experimental|Intervention group (SEP+)|SEP+ is designed as a multi-focused (child, teacher, parent) school-based intervention, which can be employed as either a universal (i.e. targeting all children) or an indicated prevention program (i.e. targeting specifically children at risk for behavior problems). The SEP+ intervention comprises three types of intervention: 1) the classroom-based intervention in the form of a curriculum of 43 activities (2-3 activities/week) delivered over 4-months aimed at developing social-emotional skills; 2) a 6-sessions (2-2.5h/session) teacher training focused on increasing the use of positive discipline strategies and developing coaching skills for supporting children's social-emotional learning; and 3) a 6 sessions parent training (1.5.-2h/session) aiming to teach ways to manage parenting stress, to increase parent-child quality time, support children's emotion regulation and problem-solving, as well as increase positive discipline strategies.
89633308|NCT02436954|Placebo Comparator|CO2 insufflation at intra-abdominal pressure 8 mmHg|CO2 insufflation with intra-abdominal pressure 8 mmHg during deep-NMB
89041072|NCT05989945||Hidradenitis suppurativa patients|HS patients will be recruited prospectively from the Outpatient Clinic, Department of Dermato-Allergology, Herlev and Gentofte University Hospital, Denmark and the Outpatient Clinic, Department of Dermato-Allergology, Bispebjerg and Frederiksberg Hospital, Denmark. In order to approximate a random sample as accurate as possible including patients with mild HS, the project group will issue a general invitation to participate in the study through appropriate channels such as the Patientforeningen HS Danmark's newsletter and collaborating private dermatologists.
89041073|NCT05989945||Control group|The control group will consist of a retrospective random sample of around 1.000 patients from the general population examined in the 4th and 5th Copenhagen City Heart Study, 2001-2003 and 2011-2014 (ClinicalTrials.gov identifier NCT02993172, I-Suite no. 03741, National Committee on Health Research Ethics approval HEH-2015-045). Existing data from the Copenhagen City Heart Study will be transferred to the current study and will include personal identification number from the Central Office of Civil Registration, echocardiographic assessments, electrocardiograms as well as health related data (health conditions including symptoms, risk factors for cardiovascular disease, medication, prior clinical and/or paraclinical assessments including blood test results and procedures relevant to psoriasis and potential heart disease).
89057479|NCT01202188|Placebo Comparator|Placebo|Matching placebo capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
89211782|NCT02546648|Experimental|Rosuvastatin vs. matching placebo|Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery
89633309|NCT02436954|Active Comparator|CO2 insufflation at intra-abdominal pressure 12 mmHg|CO2 insufflation with intra-abdominal pressure 12 mmHg during deep-NMB
89633310|NCT02433600|Active Comparator|Cow's milk-based infant formula|
89633311|NCT02433600|Experimental|Cow milk-based infant formula with enriched protein fractions|
89633312|NCT05243056|Experimental|Arm I (Y-AMBIENT)|Patients receive three themed education sessions over 1 hour each, written materials, and videos at month 1. Patients also participate in 3, 20 minutes telephone reinforcement calls to discuss how they are doing and discuss any concerns that they are still managing at months 2, 3, and 4.
89633313|NCT05243056|Active Comparator|Arm II (enhanced usual care)|Patients receive usual care at month 1. Patients also participate in 3, 20 minutes telephone reinforcement calls to discuss their chemotherapy regimen at months 2, 3, and 4.
89688477|NCT02911324|Experimental|Nabilone and EX/RP|Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks.
89688478|NCT04355299|Experimental|Intervention group|a mixed exercise program including aerobic, balance, and resistance exercises that were personally tailored.
89688479|NCT04355299|Other|control group|usual care
89688480|NCT01729403|Experimental|Aleglitazar|
89633314|NCT02437032|Active Comparator|Group 1: recombinant FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of rFSH (Gonal-F®, Merck-Serono, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously
89633315|NCT02437032|Active Comparator|Group 2:urinary FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of urinary FSH (uFSH) (Fostipur®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously.
89633316|NCT02437032|Active Comparator|Group 3: with hMG|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of hMG (HMG-Lepori®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously, and transvaginal oocyte retrieval was performed 36 h later.
89633317|NCT02433444||Patients receiving ERCP|Patients receiving Endoscopic retrograde cholangiopancreatography (ERCP) at Cedars-Sinai Medical Center.
89633318|NCT05232994|Experimental|combination metformin and esomeprazole|Combination 2 g of oral extended release metformin, in divided doses and Esomeprazole 20mg daily until delivery.
89633319|NCT05232994|No Intervention|expectant management|
89633320|NCT02436798||Pediatric patients|"Children <6 months to 18 years of age receiving ondansetron for management of:~Post-operative nausea and vomiting~Chemotherapy-induced nausea and vomiting"
89633321|NCT02436798||Female patients|"Pregnant patients or women of a reproductive age (18-45 years) receiving ondansetron for management of:~Hyperemesis gravidarum~Post-operative nausea and vomiting"
89633322|NCT05231044|Experimental|KX01 Ointment 1%|KX01 Ointment 1% is applied topically once daily for 5 consecutive days on face or scalp
89633323|NCT05231044|Placebo Comparator|Placebo|Vehicle Ointment is applied topically once daily for 5 consecutive days on face or scalp
89633324|NCT03185130|Active Comparator|Standard Treatment Arm|Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
89633325|NCT03185130|Experimental|Study Arm|Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
89633326|NCT02428920|Experimental|Peer Groups|Individuals in Intervention Group Arm will attend biweekly or monthly peer support groups (approximately 10 people per group) for evaluating changes and promoting mutual support. 12-month duration.
89633327|NCT02428920|No Intervention|Control Arm|The control arm, will attend the initial educational group lectures at baseline assessment and will receive no intervention thereafter.
89633328|NCT02428764|Experimental|Intervention group|Patients were assigned to receive neoadjuvant nimotuzumab plus gemcitabine and carboplatin followed by surgery.
89633329|NCT05466214|Experimental|CBC Treatment Group|For this group, school staff who work with families and teachers to address student emotional and behavioral concerns will use the CBC model to do so.
89633330|NCT05466214|No Intervention|Control Group|For this group, school staff who work with families and teachers to address student emotional and behavioral concerns will engage in business as usual.
89633331|NCT05445544||Pregnant women and Follow-up of pregnant women's newborns|The pregnant woman is pregnant until she gives birth. The fecal ,serum,saliva,urine,vaginal secretions,umbilical cord blood,placenta and amniotic fluids who are were caesarean delivered will be collected
89633332|NCT05218018|Other|Intervention|Only one arm of study
89633333|NCT05429476|Experimental|Alteplase with standard therapy|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
89633334|NCT05429476|No Intervention|Standard therapy|Standard therapy
89633335|NCT02977546||Heart Failure|Patients with chronic heart failure NYHA >= 2 based on a reduced left ventricular ejection fraction (LV-EF <= 45%). All patients receive pulmonary artery catheterization and noninvasive pulse contour Analysis.
89633336|NCT04745416||Leukemia and COVID-19|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization and confirmed diagnosis of COVID-19 by RT-PCR test
89633337|NCT04745416||Leukemia|Patients diagnosed with acute lymphoblastic leukemia according to the criteria of the World Health Organization without suspicion of COVID-19
89633338|NCT04999696|Experimental|Laparoscopic radical hysterectomy|
89633339|NCT04999696|Active Comparator|Laparotomic radical hysterectomy|
89633340|NCT04343794|Experimental|Biovitals|Continuous physiological monitoring using Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
89633341|NCT04343794|No Intervention|Control|Usual standard care
89633342|NCT00360256||Control|
89633343|NCT00360256||Case group|
89633344|NCT00358852||Patients with Schizophrenia|
89633345|NCT05008276||Youth with obesity and elevated HbA1c|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
89041074|NCT05989217|Experimental|Occlusal Splint|"Participants allocated will receive therapy with a stabilizing plate made by the simplified technique. This plate is made of an acetate plate, plasticized in a plaster model, and individualized by acrylic resin. This technique allows the professional to make and install the plate in a short time, without the laboratory step, and is also more economical.~After the plate installation and adjustments, the participant will be instructed to use the device every night during sleep. Weekly adjustments will be performed for 4 weeks, and in these sessions information regarding the research parameters will be collected."
89211783|NCT03997942||proprioceptive neuromuscular facilitation|PNF will be applied to randomly selected patients.
89633346|NCT05008276||Healthy normal-weight controls|All participants will under go GFR (Iohexol Inj 300 MG/ML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI
89633347|NCT04971772||"DCB (Legflow .035) group"|"treatment with Drug Coated Balloon angioplasty with the Legflow .035 Paclitaxel Balloon Dilatation catheter."
89633348|NCT04971772||POBA group|treatment with standard POBA (uncoated) angioplasty (type and brand at the physician's discretion)
89633349|NCT04877080|Experimental|Fast Dual CAR-T treatment|CD19+ R/R B-NHL patients be treated with a single dose of Fast Dual CAR-T cells. Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
89633350|NCT05381662|Experimental|Cohort 1|This cohort will determine the safety and efficacy of CD19 CAR-T cells and CD19 positive feeder T cells for CD19+ acute lymphoblastic leukemia without Chemotherapy pretreatment
89633351|NCT05381662|Experimental|Cohort 2|This cohort will determine the safety and efficacy of CD19 CAR-T cells and CD19 positive feeder T cells for CD19+ acute lymphoblastic leukemia with Chemotherapy pretreatment
89633352|NCT02977078|Sham Comparator|Control|Inhaler use monitored by device but no feedback to participants (control); this group is unaware of the second arm receiving feedback on inhaler use.
89633353|NCT02977078|Experimental|Active|Inhaler use monitored with feedback to participants (active); participants randomized to this group sign an additional consent to receive feedback on inhaler use
89633354|NCT04492306|Active Comparator|3M single bond, etch and rinse adhesive|"O.I. will clean the labial surface of tooth with polishing paste and brush Roughening of the surface may be needed by diamond point The tooth will be isolated by rubber dam. Apply etchant for 30 s for enamel and 15 s for dentin. Rinse thoroughly with water for 10 s. blot-drying with paper tissue was carefully performed leaving the dentin surface slightly moist.~Apply 2 to 3 consecutive coats of the adhesive for 15 s. Gently air for 5 s. Light cure for 10 s. Composite build ups (Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA) were performed in increments and individually light-cured for 40 s. Light curing of all resin materials was performed using a LED device (Bluephase 20i, Ivoclare Vivadent, Schaan, Liechtenstein) delivering 1100 mW/cm2."
89633355|NCT04492306|Experimental|DMSO pre-treatment before 3M single bond application|The same steps of the comparator group with additional step, after dentin etching and humidity control, dentin pretreatments were performed consisting of active application of 1% DMSO/H2O solutions on etched-dentin followed by blot drying until paper filters no longer absorbed liquids from the bonding surface by capillarity then apply adhesive.
89633356|NCT04486924|Experimental|Globe Mapping and Ablation System|
89633357|NCT04868500|Experimental|Massachusetts General Hospital (MGH) Participants|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
89633358|NCT04868500|Experimental|Massachusetts General Hospital (MGH) Clinical Site Staff|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
89633359|NCT04842760||No platelet disorders or no HIT|Patients without platelet disorders or without HIT, without anti-PF4/H antibodies, without anti-aggregant treatment.
89633360|NCT04842760||HIT patients with anti-PF4/H antibodies|patients with anti-PF4/H antibodies but for whom HIT was ruled out.
89633361|NCT04842760||platelet dysfunction or HIT|Patients with platelet dysfunction or suffering from HIT
89633362|NCT04454086|Experimental|Supportive care (exercise program, counseling)|Patients undergo aerobic exercise over 10-30 minutes and resistance exercise comprising 1-3 sets of 8-12 repetitions of 10 different exercises over 1 hour for 24 weeks. Patients also receive behavioral activity counseling once a week and nutritional counseling over 30 minutes for 10 sessions after center-based exercise sessions during months 1-2.
89633363|NCT04932694|Experimental|Study group|Core stabilization exercises will be conducted for 8 weeks, 3 sessions per day at home, and exercises will be supervised remotly.
89633364|NCT04932694|No Intervention|Control group|No exercise will be given to the participants in the control group
89633365|NCT04448158||5 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 5 years
89633366|NCT04448158||10 years of virological suppression|- Patients harboring a fully suppressed HIV-1 plasma viral load for at least 10 years
89633367|NCT04442464|Experimental|Study Eye|One eye will be randomly selected to wear the scleral lenses to be worn during study measurements
89633368|NCT04442464|No Intervention|Control Eye|Non-lens wearing eye
89633369|NCT04833010|Active Comparator|No cloth face mask|Cross-over randomization. Participants randomized to this arm will not wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
89633370|NCT04833010|Experimental|Cloth face mask|Cross-over randomization. Participants randomized to this arm will wear a cloth face mask for Test 1 which they do a progressive step-exercise cycling test to exhaustion
89633371|NCT00360802|Active Comparator|CBT|Cognitive Behavioral Treatment
89633372|NCT00360802|Active Comparator|MBSR|Mindfulness Based Stress Reduction
89633373|NCT02976610|No Intervention|1|This is the control group where no intervention takes place. Blood sampling carried out according to routine at the emergency department.
89688481|NCT01729403|Placebo Comparator|Placebo|
89688482|NCT01724645|Experimental|Korean traditional diets|Korean traditional diets (calorie 2,100kcal) for 12weeks
89688483|NCT01724645|Active Comparator|Control group|"Control group : told to eat as usal diet) for 12weeks"
89211784|NCT03997942||Mirror therapy|Mirror therapy will be applied to randomly selected patients.
89041075|NCT05989217|Experimental|Laser Therapy|"All participants will be examined and pain trigger points will be identified, if any. The laser will be applied at predetermined points and at specific trigger points identified during the clinical examination. The application of the laser will be symmetrical, i.e. on both sides of the face, with the same number of points, regardless of whether it is a trigger point or not.~The equipment to be used and the parameters for the applications have the following characteristics: 808 nm wavelength, 100 mW of useful emitter power, 105 J/cm2 of energy density, spot area 0.028 cm2, Energy/point 3 J, 1 application per week for 4 weeks."
89041076|NCT05989217|Experimental|Occlusal Splint + Laser Therapy|The therapies will be associated during the same period as the other groups, ensuring the same application and evaluation protocols.
89633374|NCT02976610|Experimental|2|"During the blood sampling the health care professional will screen all vacuum Lithium Heparin tubes, with the Hemolysis point-of-care test (H-POCT). If the health care professional receives a negative test the bloodsample is sent to the local laboratory.~If H-POCT indicates a positive test, of free hemoglobin in plasma, the bloodsample and H-POCT will be discarded and a new sample will be collected and screened for hemolysis. This can be repeated 3 times."
89633375|NCT04907110|Experimental|Exercise + NR|Participants will be asked to take two pills of NR (250mg/pill) twice daily (a total of 4 pills/day; 1000mg/day), for 40 days. During days 17-38 of the NR intervention, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of NR supplementation.
89633376|NCT04907110|Placebo Comparator|Exercise + Placebo|Participants will be asked to take two pills of placebo, twice daily (a total of 4 pills/day), for 40 days. During days 17-38 of the intervention, participants will perform a 3-weeks supervised exercise training program with four ~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions. To assess the outcomes, participants will undergo three test days before the start of the NR supplementation and repeat these three test days at the end (day 38-40) of the placebo supplementation.
89633377|NCT04807738|Active Comparator|"Neuroproprioceptive facilitation and inhibition"|"ARM 1 - Neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT), with former positive probative evidence on MS and are recommended for MS intervention."
89633378|NCT04807738|Experimental|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"ARM 2. Experimental group, neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) through virtual reality and software inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). We believe that the VR environment might lead to better results due to greater motivation effect, novelty effect, entertainment effect, as well as activating the reward system. We believe the VR might enhance the activation of mirror neurons, it might also activate proprioception. The present physiotherapist is to ensure proper execution of the tasks. The correlation of the two arms of the study should indicate, whether virtual reality and the software used are as effective, or more effective in sustaining the hand motor function and axial stability, than traditionally led therapy."
89633379|NCT02977234|Experimental|Iso-Amyl 2-Cyano Acrylate|Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx
89041077|NCT05989113||Lower limb amputee patients with devices|
89041078|NCT05981924|Experimental|Oxycodone with Perioperative Music Therapy|Using perioperative music therapy plus oxycodone to manage the postoperative pain
89041079|NCT05981924|No Intervention|Oxycodone without Perioperative Music Therapy|Using oxycodone only to manage the postoperative pain
89041080|NCT05978843|Active Comparator|Arm 1 - 10% TFP|Participants will receive $40/month in fruit and vegetable benefits for 6 months ($240 total).
89041081|NCT05978843|Active Comparator|Arm 2 - 20% TFP|Participants will receive $80/month in fruit and vegetable benefits for 6 months ($480 total).
89041082|NCT05978843|Active Comparator|Arm 3 - 30% TFP|Participants will receive $110/month in fruit and vegetable benefits for 6 months ($660).
89041083|NCT05976477|Experimental|Intervention|Patients randomized to intervention arm during the 12 weeks after randomization will receive on their smartphone and/or via e-mail, information materials such as videos, images and recipes for reminders specifically designed to make patients aware on the importance of reducing dietary salt intake and suggestions on how to do it. The educational interventions will be delivered once a week. The main objective of the educational interventions is to spread knowledge about the health risks of excessive salt intake, the actual amount of salt in food, measures to reduce salt intake (e.g. use spices, eat fresh fruits and vegetables, check food labels, gradually reduce the salt in favorite recipes, avoid putting salt and salty sauces on the table, etc.). The interventions, conceived with nutritionists, will be delivered once a week to the participants and to their caregivers and/or the closest family member, involved in the food shopping and the preparation of meals.
89041084|NCT05976477|No Intervention|Control|Patients randomized to Control Group will only receive short tips on controlling blood pressure.
89041085|NCT05975580|Experimental|Group A: Topiramate 50 mg|Topiramate will be started at 25 mg daily and the dose will be increased to 50 mg daily after 15 days. Responders at Month 4 will continue the same treatment until Month 12.
89041086|NCT05975580|Experimental|Group B: Topiramate 100 mg|Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
89041087|NCT05975580|Experimental|Group C: Phentermine 7.5 mg/Topiramate 50 mg|Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
89688484|NCT02914132|Other|Seraph 100 Filter|Renal replacement patient with bacteremia.
89688485|NCT01724099|Experimental|Euiiyin-tang|powder type, 3 times per day before the meal, 12 weeks total
89688486|NCT01724099|Placebo Comparator|Placebo|powder type, 3 times per day before the meal, 12 weeks total
89211785|NCT03997942||Standart therapy|Standard treatment will be applied to randomly selected patients.
89633380|NCT02976454|Experimental|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will include 14 meetings over 6 months to mimic the structure of the proposed Medicare funding for obesity treatment for adults. These meetings will include a single one-hour meeting and 13 twenty-minute meetings that occur in the clinic. During this time, the health coach will assess patient/parent readiness to engage in behavior change, assess barriers and facilitators to behavior change, engage in behavior change and problem solving, and provide feedback and accountability.
89633381|NCT02976454|Active Comparator|Family-based behavioral obesity treatment|The active control group will receive usual care, i.e. PCP provides obesity management using decision support tools in the electronic health record and refers to a tertiary care program at the academic center. This program is the traditional family-based behavioral weight control program which consists of 20 one-hour, group-based sessions over 6 months.
89633382|NCT04394416|Experimental|Imatinib|Imatinib oral 400 mg daily for 14 days.
89633383|NCT04394416|Active Comparator|Placebo|Placebo oral for 14 days
89633384|NCT02976844||Low PEEP group|The positive end-expiratory pressure was less than 10cmH2O
89041088|NCT05975580|Experimental|Group D: Phentermine 7.5 mg|Phentermine will be started at 7.5 mg daily. Responders at Month 4 will continue the same treatment until Month 12.
89633385|NCT02976844||High PEEP group|The positive end-expiratory pressure was higher or equal to 10cmH2O.
89633386|NCT04796506|Active Comparator|Exercise Group|PD participants randomized to progressive resistance training PRT) will have 12 weeks of supervised PRT 3 times per week. After the 1st 12 weeks, responders to PRT (increase in slow wave sleep) will continue PRT for an additional 12 weeks, non-responders to PRT will transition to endurance training (ET).
89633387|NCT04796506|Placebo Comparator|Delayed Exercise Group|PD participants randomized to the delayed exercise control group will not exercise for the 1st 12 weeks of the study. After the 1st 12 weeks, participants in the delayed exercise group will transition to PRT for the 2nd 12 weeks.
89633388|NCT04792528|Experimental|One training period|One training period of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
89633389|NCT04792528|Experimental|Two training periods|Two training periods of 30 minutes of daily adaptive training for 4-5 days a week up for 20- 25 trainings using computerized cognitive training.
89633390|NCT04792528|Active Comparator|Active control|The generalized brain training group (Active control) will play solitaire 30 minutes daily for 25 sessions
89633391|NCT04782232||Patients with failing/absence of the right heart|Patients with acute or chronic, conservatively uncontrollable heart failure of varying pathogenesis, graded as stage III or IV according to NYHA, with an anticipated need for short-term to long-term right ventricular or biventricular support.
89633392|NCT04388332||Retrospective|20 patients that received one or two level ACDF structural allograft with plates with autograft and /or allograft comprised of cancellous and/or corticocancellous bone chips.
89041089|NCT05975580|Experimental|Group E: Phentermine 15 mg|Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
89041090|NCT05975580|Experimental|Group F: Phentermine 7.5 mg/Topiramate 50 mg|Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12. For Group F, topiramate will be dosed at 25 mg daily for the 15 days in Month 5 and 50 mg daily thereafter,
89041091|NCT05975580|Placebo Comparator|Group P: Placebo|Placebo group will receive placebo.
89633393|NCT04388332||Prospective|20 patients who are receiving Tritanium C as standard of care.
89633394|NCT04372186|Placebo Comparator|Placebo|Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.
89633395|NCT04372186|Experimental|Tocilizumab|Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.
89633396|NCT04360174|Experimental|OTX-TIC-Cohort 1|15 µg (formulation1) implant
89633397|NCT04360174|Experimental|OTX-TIC-Cohort 2|26 µg (formulation1) implant
89633398|NCT04360174|Experimental|OTX-TIC-Cohort 3|15 µg (formulation 2) implant
89041092|NCT05969340|Experimental|Experimental group|Patient diagnosed with Posterior canal BPPV
89041093|NCT05969340|Placebo Comparator|Control group|Patient who are scheduled for CT-imaging as part of standard clinical routine and do not have BPPV
89041094|NCT05963347|Experimental|Go-CHOP|Golidocitinib in combination with CHOP
89633399|NCT04360174|Experimental|OTX-TIC-Cohort 4|5 µg (formulation 3) implant
89633400|NCT02976298|Sham Comparator|transcranial magnetic stimulation|sham transcranial magnetic stimulation
89633401|NCT02976298|Experimental|supplementary motor area stimulation|supplementary motor area transcranial magnetic stimulation
89041095|NCT05945121|Experimental|Cardio-oncology program|The cardio-oncology program consists of a multimodal approach, which includes individualized exercise prescription following a detailed CV assessment and medical management of CV risk factors occurring over 8 weeks.
89041096|NCT05943964|Experimental|Virtual exercise and rehabilitation program|Trial of exercise and rehabilitation program delivered via a virtual platform for patients undergoing HCT at Children's Healthcare of Atlanta.
89041097|NCT05943288||CADe +|Olympus Endoscopy Computer-Aided Detection (CADe) system
89041098|NCT05943288||CADe -|Standard of Care Endoscopy (HD Whitelight)
89041099|NCT05928026|Experimental|Immediate Financial Support|This group will receive $500 at the completion of their baseline visit
89041100|NCT05928026|Active Comparator|Delayed Financial Support|This group will receive no financial support at their completion of their baseline visit, but will receive $500 at their 1-month visit.
89041101|NCT05912049|Experimental|9MW3811 Injection|single dose escalation for experimental drug
89633402|NCT02976298|Experimental|cerebellar stimulation|cerebellar transcranial magnetic stimulation
89633403|NCT04358224|Other|open-label|open-label
89633404|NCT04357132|Other|VR-Biofeedback|
89633405|NCT04357132|Other|VR-Distraction|
89633406|NCT04357054|Active Comparator|Normal uterus|Darwish test
89633407|NCT04357054|Active Comparator|Myomatous uterus|Darwish test
89688487|NCT04281667|Experimental|Mechanical Bowel Preparation and Oral Antibiotics|Mechanical Bowel Preparation and Oral Antibiotics
89633408|NCT02976376|Experimental|The Box|"After randomization, patients in the intervention group will receive a box (The Box) with all the devices described above. Instructions about the installation and usage of the devices will be given. Patients will be asked to measure their weight and blood pressure once a day. Furthermore, patients will be asked to record an ECG using the AliveCor once a day. Moreover, they are asked to record an ECG in case of any symptoms of possible cardiac origin, as judged by the patient. All data will be automatically transferred to the Leiden University Medical Center. Lastly, two of the four outpatient clinical visits will be done via a video connection. The content of the interview will be comparable to the content of a regular outpatient clinic visit."
89633409|NCT02976376|No Intervention|Control|Patients who are randomized to the control group will receive regular care.
89633410|NCT02977000|Experimental|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h. investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
89633411|NCT02975986|Other|Controlled metabolic diet|All study patients will be placed on an instructed controlled metabolic diet. Intervention: Uptake of radioactive isotope by the kidney Radiotracer: 123I-BMIPP, 99mTc-MAG3
89633412|NCT00112827|Experimental|Arm I|See Detailed Description
89633413|NCT04317040|Experimental|Efprezimod alfa|Participants receive single dose of 480 mg efprezimod alfa, diluted to 100 ml with normal saline, intravenous (IV) infusion in 60 minutes on Day 1.
89633414|NCT04317040|Placebo Comparator|Placebo|Participants receive single dose of placebo as normal saline solution 100 ml, IV infusion in 60 minutes, on Day 1.
89633415|NCT01897701|Experimental|Group A|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
89633416|NCT01897701|Experimental|Group B|Intermediate dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
89633417|NCT01897701|Experimental|Group C|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & 21
89633418|NCT01897701|Experimental|Group D|Low dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & Day 21
89633419|NCT01897701|Experimental|Group E|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
89633420|NCT01897701|Experimental|Group F|Low dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
89633421|NCT01897701|Experimental|Group G|Placebo; IM; Day 0 & 21
89633422|NCT04752345|Active Comparator|Control group|Pharmacoinvasive strategy, fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early invasive strategy (in case of successful fibrinolysis)
89633423|NCT04752345|Experimental|Experimental group|Reduced-dose fibrinolysis combined with immediate invasive therapy
89041102|NCT05912049|Placebo Comparator|Placebo|matching placebo administration for control
89041103|NCT05885438|Experimental|Intervention|Participants in the intervention group will receive the ACT workshop
89633424|NCT04314076|Active Comparator|Gait Training (GT) with Rhythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes,with RAS
89633425|NCT04314076|Other|Gait training (GT) without Rhythmic Auditory Stimulation (RAS)|Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes without RAS
89633426|NCT04752111|Experimental|Group E (esmolol infusion)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection esmolol 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side .
89633427|NCT04752111|Placebo Comparator|Group T (TAP block)|10 minutes before induction of anesthesia the patients will receive a loading dose of injection 30 ml isotonic saline in the iv line, followed by an IV infusion of saline at a rate of 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side.
89633428|NCT04313140|Experimental|Patient's Glioma grade|magnetic resonance spectroscopy
89633429|NCT04748770||patients with BMI≥30 kg/m2|
89633430|NCT04748770||patients with 25≤BMI≤30 kg/m2|
89633431|NCT02976688|Experimental|Sodium propionate|Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.
89633432|NCT00226239|Experimental|Head and neck cancer patients|Induction chemotherapy consists of 3 cycles of cisplatin 75 mg/m^2, on day 1, docetaxel 75 mg/m^2, on day 1, and cetuximab weekly days 1,8,15, repeated every 21 days (cetuximab dose is 400 mg/m^2 on day 1 and 250 mg/m^2 on subsequent weekly treatments). After 3 cycles of induction, patients receive standard radiation 70 Gy/200 cGy/daily, 5 days/week with concurrent weekly cisplatin 30 mg/m^2 and cetuximab 250 mg/m^2. After completing radiation therapy, patients receive cetuximab weekly as maintenance therapy for 6 months (see section 5 for detailed treatment plan and dose modifications)
89041104|NCT05885438|No Intervention|Waitlist Control|Participants in the waitlist control group will not receive the intervention until all members of the intervention group have received the workshop. Once all members of the intervention group have received the workshop, participants in the waitlist control group will be able to receive the workshop if they so desire.
89041105|NCT05880147|Experimental|App-based consent|Prototype consent app based on REDCap eConsent module
89041106|NCT05880147|Active Comparator|Traditional paper-based consent|Traditional paper-based consent
89211786|NCT00843596|Experimental|vacuum device - suction cup|
89211787|NCT00842426|No Intervention|Usual Care|Usual Care
89211788|NCT00842426|Experimental|Self-Management Program|Online Self-Management.
89633433|NCT04033822|No Intervention|Standard of Care|Patients randomized to the standard of care arm of the trial will not receive accelerated cholecystectomy surgery to correct cholecystitis. No services will be taken away but patients will continue with care as originally provided by the healthcare system.
89688488|NCT04281667|Active Comparator|Mechanical Bowel Preparation Only|Mechanical Bowel Preparation Only
89041107|NCT05857748||Single arm of DED patients|"Age ≥18 years at index date.~Confirmed diagnosis of DED.~Newly started on lifitegrast ophthalmic solution within the recruitment period and not receiving lifitegrast ophthalmic solution within 6 months prior to recruitment.~Received continuous medical care at the healthcare site defined as at least one clinical visit within 6 months."
89041108|NCT05847517|Active Comparator|Metoprolol|Participants will be administered IV Metoprolol tartrate 15 mg (3 ampoules of 5 ml) diluted in 100 ml of saline.
89041109|NCT05847517|Placebo Comparator|Saline|Participants will be administered IV saline (0.9% sodium chloride) (3 ampoules of 5 ml) diluted in 100 ml of saline.
89633434|NCT04033822|Experimental|FAST Intervention|Patients diagnosed with cholecystitis and randomized to the FAST intervention arm of the study will undergo surgery as soon as possible with a goal of surgery within 6 hours of diagnosis.
89633435|NCT04729972|Experimental|NT-501 CNTF Implant|Participants from the NTMT-01/02 Extenstion study or participants from the NTMT-03 study which received an implant Studies with a CNFT implant in one eye will receive an implant in the fellow eye
89041110|NCT05828615|Active Comparator|Group A|Alternate nostril breathing exercise 2 times a day, 10 min duration of exercise each time, for 5 days
89041111|NCT05828615|Active Comparator|Group B|Breathing control exercise 2 times a day, 10 min duration of exercise each time, for 5 days
89041112|NCT05826860|No Intervention|Control group|Survey only, no mindfulness/storytelling intervention
89041113|NCT05826860|Experimental|Intervention group|Mindfulness and storytelling workshop intervention plus survey
89041114|NCT05799976|No Intervention|Usual Care|This is a group will serve as usual care and have no intervention during the study period
89041115|NCT05799976|Experimental|Text Message Group|This group of primary care practices will be randomized to have the text message intervention
89041116|NCT05797623|Experimental|Trappa ethanolamine tablets combined with ciclosporin|
89041117|NCT05797623|Placebo Comparator|Placebo combined with ciclosporin|
89041118|NCT05794620||Children with Autism|
89041119|NCT05794620||Neurotypical siblings|
89633436|NCT00227019|Experimental|bevacizumab+ pemetrexed|pemetrexed (500 mg/m² IV) + bevacizumab (15 mg/kg IV). In addition to Vitamin B12 + Folate + Dexamethasone
89633437|NCT00113217|Experimental|Bevacizumab|10 mg/kg intravenous (IV) Day 1 of 14-day cycle.
89633438|NCT02976064|Experimental|PreHab_Intervention|Experimental group of the prehabilitation trial
89633439|NCT02976064|No Intervention|PreHab_Control|Control group of the prehabilitation trial
89633440|NCT02976064|Experimental|Chronic patients_Intervention|Experimental group of the Rehabilitation in chronic stable patients in primary care trial
89633441|NCT02976064|No Intervention|Chronic patients_Control|Control group of the Rehabilitation in chronic stable patients in primary care trial
89633442|NCT02976064|Experimental|Citizens & mild disease_Intervention|Experimental group of the Rehabilitation in mild chronic patients and citizens at risk trial
89633443|NCT02976064|No Intervention|Citizens & mild disease_Control|Control group of the Rehabilitation in mild chronic patients and citizens at risk trial
89633444|NCT04718116|Active Comparator|tapentadol 50 mg|tapentadol 50mg p.o 3 times daily for two days
89041120|NCT05774288|Experimental|Cera™ patent foramen ovale occluders|Patients with cryptogenic stroke complicated with patent foramen ovale will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
89041121|NCT05774288|Active Comparator|Another patent foramen ovale occluders|Patients with cryptogenic stroke complicated with patent foramen ovale will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
89041122|NCT05747573|Active Comparator|A 100mg GB1211 tablet, fasted|Single dose of 100 mg GB1211 as a tablet (100 mg strength) under fasted conditions (n=4 per period)
89041123|NCT05747573|Active Comparator|B 100 mg GB1211 capsules, fasted|Single dose of 100 mg GB1211 as two capsules (50 mg strength) under fasted conditions (n=4 per period)
89041124|NCT05747573|Active Comparator|C 100 mg GB1211 tablet, fed|Single dose of 100 mg GB1211 as a tablet (100 mg strength) under fed conditions (n=4 per period)
89041125|NCT05736770|Experimental|Respiratory rehabilitation and out of bed mobilization group|The Respiratory rehabilitation and out of bed mobilization group will perform 4 exercises.
89041126|NCT05736770|Active Comparator|Conventional exercise program group|The conventional exercises program will perform conventional exercises
89041127|NCT05735080|Experimental|Part A: Dose Escalation|Multiple doses of INX-315 monotherapy, oral administration
89041128|NCT05735080|Experimental|Part B: Ovarian Dose Expansion|INX-315 monotherapy, oral administration
89041129|NCT05735080|Experimental|Part C: ER+/HER2- BC Dose Expansion|INX-315 in combination with CDK4/6i and endocrine therapy, oral administration
89041130|NCT05726617|Experimental|Experimental: Avatar Intervention|The Avatar Intervention will take place over 8 consecutive weeks, with one session per week. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars.
89633445|NCT04718116|Active Comparator|tapentadol 75 mg|tapentadol 75 mg p.o 3 times daily for two days
89633446|NCT04718116|Active Comparator|tramadol 100 mg|tramadol 100 mg p.o 3 times daily for two days
89633447|NCT00115869|No Intervention|No-intervention control|
89633448|NCT00115869|Experimental|Social influences school-based smoking prevention curriculum|
89633449|NCT04276792|Experimental|Horizontal implementation approach|The Horizontal implementation approach of the O-TLM intervention is accompanied by facilitated collaboration between Criminal Justice and Community Behavioral Health systems. Direct involvement of stakeholders with differing perspectives and buy-in from agency leadership and policymakers are key elements. The Horizontal approach involves first developing a prototype (including how to modify existing practices, overcome implementation barriers, and manage roles and responsibilities) that are tested and refined before being rolled out systematically to other units within an agency.
89633450|NCT04276792|Active Comparator|Vertical implementation approach|The Vertical implementation approach of the O-TLM intervention relies on the traditional criminal justice system's typical use of a hierarchical structure and the use of a top-down implementation approach (i.e., administrative orders) for directing change. Top-down regulatory and policy changes are viewed as vital levers for driving system change.
89633451|NCT00053703|Active Comparator|olanzapine|oral olanzapine 5-20mg per day for up to 52 weeks
89633452|NCT00053703|Active Comparator|risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
89211789|NCT00842426|Experimental|Care Management Program|Care management lifestyle modification program with intensive intervention phase with exercise and nutrition specialist. Followed by a online self-management phase.
89633453|NCT00053703|Active Comparator|molindone|oral molindone from 10-140mg/daily for up to 52 weeks
89633454|NCT02975440|Experimental|Treatment|Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days
89633455|NCT04269772|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
89633456|NCT04269772|Other|Treatment As Usual (TAU)|Treatment As Usual (TAU) consists of unrestricted treatment provided by prison and community providers, as part of routine care in the criminal justice re-entry context. Study staff will provide no additional treatment in this arm.
89633457|NCT00231309|Other|single arm|
89633458|NCT04267120|Experimental|Lenvatinib + Pembrolizumab|"Lenvatinib 20 mg/day will be administered orally on a daily basis and pembrolizumab 200 mg will be infused once every 3 weeks.~Subjects may be treated with pembrolizumab for a maximum of 35 cycles or approximately 2 years, but treatment with lenvatinib can continue beyond 2 years if the subject does not meet other treatment discontinuation criteria."
89211790|NCT01010620||Screening|Screening Assessment battery. Specific to study(or studies) the individual is screening for.
89211791|NCT00842504|Other|Micafungin|3 mg/kg given once
89211792|NCT00842582|Experimental|Single group assignment|Patients will receive Azacitidine at 20, 40, or 75 milligrams per meter squared subcutaneous once daily for 7 days.
89633459|NCT00116337|Experimental|Expiratory Muscle Stimulator|Procedure/Surgery: spinal cord stimulation to restore cough
89633460|NCT04252846||Perampanel|Participants with a diagnosis of epilepsy (POS with or without SG or PGTCS associated with IGE) will initiate treatment with perampanel as first adjunctive treatment as per the clinical judgment of the treating physician as part of routine clinical care. All participants will be observed prospectively for up to 12 months after initiation of perampanel treatment.
89633461|NCT00232479|Experimental|arm 1|single arm study evaluating the efficacy of neoadjuvant taxotere, herceptin and carboplatin given in a dose dense fashion
89633462|NCT04713202|Experimental|Telotristat Ethyl + PRRT|"Telotristat ethyl, 250 mg, PO, three times daily, continuous.~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
89633463|NCT04713202|Placebo Comparator|Placebo + PRRT|"Placebo, PO, three times daily, continuous.~+ Peptide Receptor Radionuclide Therapy(PRRT) every 8 weeks"
89633464|NCT01897311|Experimental|grupo TENS com frequência de 100 Hz|TENS application of high frequency (100 Hz, 100 μs)
89211793|NCT00843908|Active Comparator|TVT|Women in this arm will undergo the Tension Free Vaginal Tape procedure
89211794|NCT00843908|Experimental|Miniarc|Women in this group will undergo the Miniarc suburethral sling procedure
89633465|NCT01897311|Experimental|grupo TENS com frequência de 4 Hz|Application of low-frequency TENS (4 Hz, 100 μs)
89633466|NCT01897311|Placebo Comparator|Placebo with TENS off|TENS application when off
89633467|NCT00233103|Experimental|Sertraline|Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg).
89633468|NCT00233103|Placebo Comparator|Placebo|Placebo for 10 weeks.
89211795|NCT00842660|Experimental|Gemzar,survival|
89211796|NCT00836264||Morphine T & A|"Subjects ages 4-18 years of age who have a Tonsillectomy and Adenoidectomy and receive morphine for pain control and who have also enrolled in the CAG study at CHOP, A Study of the Genetic Causes of Complex Pediatric Disorders (GCPD study), as approved by the CHOP IRB, 2006-7-4886."
89633469|NCT04000750|Experimental|Time Restricted Eating (16:8)|Participants will consume all calories within an 8 hour window each day.
89633470|NCT04000750|Active Comparator|Control|Participants will consume all calories within a ~12 hour window each day (4 separate meals + needed snacks).
89633471|NCT04704076|Experimental|Early, Small-Volume Supplementation (ESVS)|Breastfeeding with up to 59 mL formula daily until 30 days of age, followed by recommendation to breastfeed exclusively through 6 months of age
89633472|NCT04704076|Active Comparator|Exclusive Breastfeeding|Recommendation to breastfeed exclusively for 6 months without any other food or fluid except vitamins, minerals and medications
89633473|NCT00117585|Other|Treatment Phase 1|Stepped intervention consisting of treatment phase 1, 2 and 3. Subjects whose orthostatic hypotension is resolved after treatment phase 1 will not receive new treatments (phase 2 and 3)
89688489|NCT04378985|Experimental|Wearing a wearable device (the smart watch) for 8 weeks|The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.
89211797|NCT00509236|Experimental|Sitagliptin 25 mg|
89211798|NCT00509236|Active Comparator|Glipizide 2.5 mg - 20 mg|
89211799|NCT00836420||liver|patients with acute liver failure
89211800|NCT00842738|Active Comparator|Mindfulness meditation|Women with mild dysplasia offered mindfulness meditation
89211801|NCT00842738|Other|No meditation|Women with mild dysplasia offered health care services as usual
89211802|NCT00842738|Other|Controls|Women with normal cervical cells
89633474|NCT00703014||Mothers Corifollitropin Alfa 150 µg|Participants from the Base Trial P05787 who received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG); multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
89633475|NCT00703014||Mothers recFSH 200 IU|Participants from the Base Trial P05787 who received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG; multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
89633476|NCT04246216|Experimental|Percutaneous Electrical Nerve Stimulation|The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
89633477|NCT04246216|Active Comparator|Surgery|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
89041131|NCT05716386|Experimental|Intervention|The low sodium diet will be provided low salt diet 1.5 gm/day in three main meals for three months.The food will be provided by the nutritionists and delivered directly to their home
89041132|NCT05716386|Placebo Comparator|Control|The control group will continue with their usual diet and record the food recall
89633478|NCT02433522|Experimental|Rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months
89633479|NCT02433522|Placebo Comparator|Placebo|Placebo infusion at the randomization visit and every 6 months for 18 months
89211803|NCT00842816|Experimental|1|10 mg ST101
89041133|NCT05714462|Experimental|postmenopausal with normal/overweight BMI that eats primarily beef as their protein source|
89041134|NCT05714462|Experimental|postmenopausal with normal/overweight BMI that eats vegetables as their protein source|
89633480|NCT03997630|Experimental|Interventional group|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
89633481|NCT03997630|Active Comparator|Control group|Control group: All patients included in this group will receive a low flow oxygenation (flow rate < 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
89041135|NCT05714462|Experimental|postmenopausal with obese BMI that eats primarily beef as their protein source in study meals|
89041136|NCT05714462|Experimental|postmenopausal with obese BMI that eats vegetables as their protein source in study meals|
89041137|NCT05714462|Active Comparator|premenopausal with normal/overweight BMI that eats primarily beef as their protein source|
89041138|NCT05714332||Advanced practice physiotherapy and orthopedic surgeon group|Patients cared by both an advanced practice physiotherapist and an orthopedic surgeon.
89041139|NCT05714332||Orthopedic surgeon only group|Patients cared only by an orthopedic surgeon.
89041140|NCT05708989|Active Comparator|Caudal Block|Patients will receive a caudal block prior to surgery.
89041141|NCT05708989|Experimental|Pudendal Block|Patients will receive a pudendal block prior to surgery.
89041142|NCT05705440|Other|RSVPreF3 Group|Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-011, RSV MAT-010, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study.
89041143|NCT05705440|Other|Control Group|Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-011, RSV MAT-010, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study.
89041144|NCT05694507|Experimental|Experimental group|In the experimental group, participants will go through one assigned chatbot each day for 10 days, with the sequence of the assigned chatbot randomized. One group of participants will receive chatbot notifications for 10 days, another group of participants will not receive chatbot notifications. They can freely access all chatbots after the completion of post-evaluation. After completing the pre-evaluation questionnaire, they will complete 2 more sets of questionnaires, including a post-evaluation 11 days after group allocation, and a follow-up questionnaire 21 days after group allocation. All participants will be able to access the chatbot materials in an online platform after they have completed the research.
89041145|NCT05694507|No Intervention|Waitlist control group|In the waitlist control group, participants are to refrain from using the chatbot until they finished the follow-up questionnaire. One group of participants will receive study notifications for 10 days, another group of participants will not receive study notifications. After completing the pre-evaluation questionnaire, they will complete 2 more sets of questionnaires, including a post-evaluation 11 days after group allocation, and a follow-up questionnaire 21 days after group allocation. All participants will be able to access the chatbot materials in an online platform after they have completed the research.
89211804|NCT00842816|Experimental|2|60 mg ST101
89211805|NCT00842816|Experimental|3|120 mg ST101
89633482|NCT02433912|Experimental|Test - Laterally positioned flap|Incisions were made in mesial and distal aspects of the recession, in order to remove the epithelial attachment. The root surface was then instrumented. The flap design was outlined by two vertical incisions which extended from the horizontal incision which was performed either at the gingival, or 1 - 2mm apically, following the marginal gingival contour. The flap was rotated laterally in order to completely cover the recession defect and extend for approximatelly 1mm coronal to the CEJ. Careful flap suturing was performed in order to position and secure the soft tissues over the root surface by means of sling and simple sutures.
89041146|NCT05682079||children with cerebral palsy|"After recording demographic data, Trunk control measurement scale (TCMS) to evaluate trunk control, Gorge motor function classification system (GMFCS) to measure gross motor functions, Pediatric Disability Assessment Inventory (PDI) to evaluate activities of daily living, balance 'Pediatric Berg Balance Scale' was used to evaluate functional capacities and '2-minute walking test' was used to evaluate functional capacities. In addition, respiratory muscle strength was evaluated with maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measurements."
89041147|NCT05682079||typical kids|"After recording demographic data, Trunk control measurement scale (TCMS) to evaluate trunk control, Gorge motor function classification system (GMFCS) to measure gross motor functions, Pediatric Disability Assessment Inventory (PDI) to evaluate activities of daily living, balance 'Pediatric Berg Balance Scale' was used to evaluate functional capacities and '2-minute walking test' was used to evaluate functional capacities. In addition, respiratory muscle strength was evaluated with maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measurements."
89633483|NCT02433912|Active Comparator|Control - Coronally advanced flap|The CAF was designed performing two vertical releasing incisions at both the mesial and distal aspects of the recession to be treated, in such a way that both the proximal papillae were not included as part of the flap. The vertical incisions were joined by an intrasulcular incision. A combined mucoperiosteal-mucosal flap was elevated. Thorough root planning was performed. A complementary horizontal incision was performed on the apical aspect of the flap, releasing it from the attached periosteum. This allowed the elongation and free coronal positioning of the flap. The flap was coronally positioned and maintained in place by means of individual 5.0 monofilament sutures.
89633484|NCT00361660|Experimental|1|Therapy is provided every other day 3 days per week (Monday, Wednesday, Friday).
89633485|NCT00361660|Active Comparator|2|The same therapy is provided daily Monday through Friday
89633486|NCT02436486|Placebo Comparator|Placebo|
89041148|NCT05682014|Experimental|İntervention Group|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
89633487|NCT02436486|Experimental|Idalopirdine 120 mg|Therapeutic dosages
89633488|NCT02436486|Experimental|Idalopirdine 360 mg|Supra-therapeutic dosages
89633489|NCT02436486|Active Comparator|Moxifloxacin 400 mg|Positive Control
89633490|NCT04342858|Other|Standard of care|Control will receive standard oral hygiene instructions (OHI every three months)
89633491|NCT04342858|Active Comparator|Standard of care + Fluoride varnish|Intervention 1 will receive standard OHI and application of topical fluoride varnish containing 5% NaF (Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK) every three months
89633492|NCT04342858|Experimental|Standard of care + Fluoride varnish with Tricalcium phosphate|Intervention 2 will receive standard OHI and application of topical fluoride varnish containing 5% NaF + TCP (Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA) every three months
89633493|NCT02428998|Experimental|Korean Red Ginseng|Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses
89633494|NCT02428998|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses
89633495|NCT04243096|Experimental|Exercise-based Physical Therapy|12 week in-person exercise-based physical therapy
89633496|NCT02429076|Experimental|Propofol|Subjects in this arm will receive propofol general anesthesia
89633497|NCT02429076|Experimental|Sevoflurane|Subjects in this arm will receive sevoflurane general anesthesia
89633498|NCT04236544|Experimental|PExMS and DECIMS-Wiki|After allocation, the intervention group will receive access via a data-protected study platform (www.erecover.de) to PExMS and DECIMS-Wiki for a two-week period. The former is a multimedia website providing experiential information. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
89633499|NCT04236544|Active Comparator|DECIMS-Wiki|After allocation, the control group will receive access to the DECIMS-Wiki for a two-week period. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
89633500|NCT02433132|Other|Diagnostic test|Diagnostic test will be perform on cell from nasal brushing
89633501|NCT04676854|Experimental|PRIMA Bionic Vision System|
89633502|NCT00255177|Placebo Comparator|Placebo|
89633503|NCT00255177|Active Comparator|150 mg daily|
89633504|NCT00255177|Active Comparator|300mg daily|
89633505|NCT00255177|Active Comparator|300mg twice daily|
89633506|NCT04670224|Experimental|QLB technique|
89633507|NCT04670224|Active Comparator|Intravenous anesthesia without QLB|
89633508|NCT00360958|Experimental|Ultrafiltration|Ultrafiltration treatment
89633509|NCT00360958|Active Comparator|Usual treatment|Usual HF treatment
89633510|NCT04223986|Other|Ultrasound and Troponin T|5 images transferred to cardiologist
89633511|NCT02976142|Experimental|neoadjuvant chemoimmunotherapy|Patients with gastric cancer and verified free cancer cells who receive 1 course of intraperitoneal immunotherapy with interleykin-2 + 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
89633512|NCT02976142|No Intervention|neoadjuvant chemotherapy|Patients with gastric cancer and verified free cancer cells who receive 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
89633513|NCT00361036|Experimental|1|BeadBlock treatment arm
89633514|NCT00361036|Active Comparator|2|Embospheres control arm
89633515|NCT03955432|Experimental|LINQ ICM|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population. The LINQ ICM is approved by the FDA for use in patients where there is a suspicion of occult cardiac arrhythmias and is therefore being utilized in this study in accordance with the FDA labeling.
89633516|NCT00361114|Active Comparator|A|SP in symptomatic children aged 6-59 months
89633517|NCT00361114|Experimental|B|SP to asymptomatic infected children aged 2-10 months
89633518|NCT00361114|Experimental|C|Chlorproguanil/dapsone in symptomatic 6-59 month old children
89633519|NCT04342936|Experimental|Camrelizumab for Injection|Participants receive Camrelizumab 200mg intravenously (IV) on Day 1 of each 2-week cycle
89633520|NCT04342936|Active Comparator|Chemotherapy|Participants receive investigator's choice of chemotherapy (Gemox, IGEV or DHAP) for up to 6 cycles.
89633521|NCT04201288|Experimental|Acceptance-Based Behavior Therapy (ABBT)|The 2-session ABBT will be delivered in person at session 1 and by telephone at session 2.
89633522|NCT04201288|Placebo Comparator|Enhanced-Treatment-as-Usual (ETAU)|In addition to receiving treatment-as-usual at the clinic, ETAU participants will receive a 2-session program of HIV education.
89633523|NCT04200274||Mental Health Nurses in Germany|Nurses in Germany currently working with patients with mental disorders
89041149|NCT05682014|No Intervention|Control Group|Only one session online breastfeeding training will be given and the training brochure for this training will be delivered to the participants via whatsapp.
89041150|NCT05678972|Experimental|Mindfulness group|Participants in the mindfulness group will be expected to complete a self-help online mindfulness-based intervention, delivered over a 4-week period via an e-learning mental health platform. They will be assessed at three different time points: (1) before the intervention (pre-test assessment), (2) right after the 4-week intervention (post-test assessment), and (3) four weeks after the intervention (follow-up assessment).
89041151|NCT05678972|No Intervention|Waitlist control group|The participants in waitlist control group will be offered access to the online mindfulness course after the study has ended.
89041152|NCT05669833|Experimental|GUS|Guselkumab (GUS)
89041153|NCT05669833|Experimental|GUS and Placebo|Guselkumab (GUS) and Matching Placebo
89041154|NCT05669833|Active Comparator|GOL|Golimumab (GOL)
89041155|NCT05661097|Active Comparator|Small hernia ring group with continuous suture|Continuous suture of hernia ring with barbed wire<3cm
89041156|NCT05661097|Active Comparator|Small hernia ring group with discontinuous full-thickness suture|Intermittent full layer suture to close hernia rings<3cm
89041157|NCT05661097|Active Comparator|Large hernia ring group with continuous suture|Continuous suture of hernia ring with barbed wire>3cm
89633524|NCT03931174|Active Comparator|Addiction Technology Transfer Center (ATTC) Training|Half of the opioid treatment centers will receive the ATTC training strategy.
89633525|NCT03931174|Experimental|Enhanced ATTC (E-ATTC) Training Strategy|Half of the opioid treatment centers will receive the E-ATTC training strategy.
89633526|NCT00702624||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
89041158|NCT05661097|Active Comparator|Large hernia ring group with discontinuous full-thickness suture|Intermittent full layer suture to close hernia rings>3cm
89041159|NCT05661097|Experimental|Large hernia ring group with continuous suture and discontinuous full-thickness suture|Continuous suture with barbed thread and discontinuous full-thickness suture to close hernia rings>3cm
89041160|NCT05660577|Experimental|e Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens|
89041161|NCT05657496|Active Comparator|Steroid|A 6mL injection at the initial visit of triamcinolone 40 mg/1 mL (Kenalog) with 5 mL of 1% lidocaine
89041162|NCT05657496|Experimental|Platelet-rich Plasma|An injection at the initial visit of approximately 4-6 mL of PRP
89057480|NCT01649115|No Intervention|Usual Care|The Usual Care arm, will not be receiving the interactive nutrition education. They will be meeting with the Registered Dietitian twice in person after the participants are randomized in each arm, and once on the phone. The first meeting, they will be receiving pamphlets and handouts, which are typically given as part of usual care. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool. The second meeting and the follow-up phone call are both the same for usual care and the Healthy Lifestyles Passport arm.
89211806|NCT00842816|Placebo Comparator|4|Placebo
89211807|NCT00842894||Insulin detemir|
89211808|NCT00842894||Biphasic insulin aspart 30|
89633527|NCT00702624||recFSH 150 IU|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
89633528|NCT03915496|Experimental|PF-04965842 200 mg|
89633529|NCT03915496|Experimental|PF-04965842 100 mg|
89633530|NCT03915496|Placebo Comparator|Placebo|
89633531|NCT00702546||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. But in base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
89633532|NCT00702546||recFSH 150 IU|In this follow-up study, no medication or investigational product was administered. However, in base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
89633533|NCT02976532|Other|EMT Arm|The study is performed with a single arm, as the system is an additional tool for derotation measurement and the surgical procedure itself and its technique is not changed.
89633534|NCT02709330|Experimental|Lunasin regimen|"The Lunasin regimen consists of:~LunaRich X Capsules (12 capsules per day)~Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)~Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)~It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate."
89633535|NCT02709330|Active Comparator|Historical controls|For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
89633536|NCT02976766|Experimental|Gypenosides|
89633537|NCT02976766|Placebo Comparator|Placebo|
89633538|NCT02436174||study group|patients undergoing cesarean under epidural anesthesia
89633539|NCT02709096|Experimental|BPX-01, 1% Topical Gel|BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
89633540|NCT02709096|Placebo Comparator|BPX-01, Vehicle Gel|BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
89633541|NCT04638712|Other|Group 1 without trastuzumab|
89633542|NCT04638712|Other|Group 2 with trastuzumab|
89633543|NCT04177264|Experimental|Osteopathic Manipulative Treatment (OMT)|In 4 randomized study sessions, combinations of two different osteopathic manipulative treatment (OMT) techniques (occipito-atlantal decompression [OA DC] and splenic lymphatic pump technique [SpLPT]) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of OMT techniques or sham interventions will be performed.
89633544|NCT04177264|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|In 4 randomized study sessions, combinations of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), osteopathic splenic lymphatic pump technique (SpLPT) or their respective sham interventions will be performed. The 4 study sessions are at least one month apart and consist of 3 consecutive study days on which the same combination of taVNS, SpLPT, or sham interventions will be performed.
89633545|NCT04177264|No Intervention|Time Control|In 4 study sessions, no intervention will be performed. As with the two experimental arms, the 4 study sessions are at least one month apart and consist of 3 consecutive study days on which no intervention will be performed. This arm serves as a time control group.
89633546|NCT01372410|Active Comparator|Tiotropium|18 mcg, inhaled long acting muscarinic antagonist
89633547|NCT01372410|Experimental|GSK573719|inhaled medication
89633548|NCT01372410|Placebo Comparator|Placebo|inactive/excipients only
89633549|NCT02975830||0-2 years|Children aged from birth to 24 months Three dimensional CT based images
89633550|NCT02975830||2-4 Years|Children aged from 25-48 months Three dimensional CT based images
89633551|NCT02975830||4-6 Years|Children aged from 49-72 Three dimensional CT based images
89633552|NCT02975830||6-8 years|Children aged from 73-96 months Three dimensional CT based images
89633553|NCT03184818||No antibacterial from other provider (Arm 1)|Patients with symptomatic, uncomplicated urinary tract infection presenting without a prescription for an antibacterial from another health care practitioner.
89633554|NCT03184818||Antibacterial from other provider (Arm 2)|Patients with symptomatic, uncomplicated urinary tract infection or asymptomatic bacteriuria presenting with a prescription for an antibacterial from another health care practitioner.
89633555|NCT02428686|Experimental|epoetin beta|
89633556|NCT02432976|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
89633557|NCT02432976|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
89633558|NCT02428452|Experimental|Treatment|Six-month Social ABCs parent-training program received immediately
89633559|NCT02428452|No Intervention|Control|Participants randomized to the Control group do not receive the Social ABCs parent training program for the 6-month control phase. Control participants may access other approved community services as outlined in the study protocol and consent during the Control Phase, which is considered 'treatment as usual'. After the 6-month Control Phase, participants are offered the Social ABCs parent training program.
89633560|NCT02975596|Other|Youth|Youth between the ages beteen ages 13-18 will be offered awareness, education, empowerment and accessibility intervention components.
89633561|NCT02975596|Other|College|Age between 18-23 will be offered awareness, education, empowerment and accessibility intervention components.
89633562|NCT02975596|Other|Adult|parents of adolescents and young adults will be offered awareness, education, and accessibility intervention components.
89633563|NCT02975596|No Intervention|Parent focus group|Parents discussed barriers and reviewed MenB education materials.
89633564|NCT02975596|No Intervention|Provider focus groups|Providers discussed barriers and reviewed MenB education materials.
89633565|NCT02428374|Active Comparator|rosuvastatin plus clopidogrel|rosuvastatin 40 mg and clopidogrel 75 mg
89633566|NCT02428374|Active Comparator|Rosuvastatin plus ticagrelor|Rosuvastatin 40 mg plus ticagrelor 90 mg bid
89633567|NCT02428374|Active Comparator|simvastatin plus clopidogrel|Simvastatin 40 mg plus clopidogrel 75 mg
89633568|NCT02428374|Active Comparator|Simvastatin plus ticagrelor|Simvastatin 40 mg plus ticagrelor 90 mg bid
89633569|NCT03186612|Active Comparator|OT intervention|Conventional occupational therapy (OT) treatment will consist of 20 sessions in total, during which subjects will perform activities for training manipulative and functional dexterity of the upper limb aimed at activities of daily living. These will be distributed in two OT sessions per week, each lasting 30 minutes.
89633570|NCT03186612|Experimental|OT+VR intervention|The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
89633571|NCT03184740|Experimental|Active-tDCS|A constant current (anodic) of 2mA will be applied for 20 minutes over the Primary motor cortex (M1).
89633572|NCT03184740|Sham Comparator|Sham-tDCS|A constant current (sham) of 2mA will be applied on the Primary motor cortex, but the stimulator will be turned off after 30 seconds .
89633573|NCT02436018|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
89633574|NCT02436018|Experimental|Nasopharyngeal airway group|Oxygen(2L/min) supplied directly through WEI NASAL JET without jet ventilator
89633575|NCT02436018|Experimental|WEI NASAL JET group|Oxygen supplied through WEI NASAL JET with a manual jet ventilator
89633576|NCT02435862|Experimental|1.0mg Luminate®|1.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
89633577|NCT02435862|Experimental|2.0mg Luminate®|2.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
89041163|NCT05627063|Experimental|ABSK121-NX|"Dose escalation of oral ABSK121-NX will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. Patients will receive a single dose of ABSK121-NX on Day -7 followed by a 7-day washout, as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD).~The dose escalation will start at 3 mg QD followed by dose escalation of a total of 8 potential dose levels. Once RDE is determined, an RDE-confirmation group of up to 24 more patients may be enrolled at the selected dose levels to further evaluate safety and efficacy (up to 12 per dose level/regimen), if approved by the sponsor. In addition, a preliminary food-effect (FE) may be evaluated in at least 6 patients from the RDE- confirmation part.~After the RDE is confirmed in the dose Escalation part, the dose Expansion phase will be conducted."
89041164|NCT05609929|Experimental|Omeprazole combined with AB-106 group|
89041165|NCT05607459|Experimental|Dry Needling Group|This group will receive dry needling, manual therapy (consisting of a manual compression over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus) and therapeutic exercise interventions
89041166|NCT05607459|Active Comparator|Sham Dry Needling Group|This group will receive manual therapy (consisting of a manual compression over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus), therapeutic exercise interventions and a previously described sham dry needling intervention.
89057481|NCT01649115|Experimental|Healthy Lifestyles Passport|The Healthy Lifestyles Passport arm will be receiving the intervention. They will be meeting with the Registered Dietitian twice in person after the participants are randomized into each arm, and once on the phone. The first meeting, they will be receiving the Healthy Lifestyles Passport, including the interactive nutrition education. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool.
89057482|NCT02215811|Experimental|Mesenchymal stromal cells|
89041167|NCT05607407|Experimental|Surgical Resection, Pharmacodynamic Assays, and Methimazole|Participants with recurrent glioblastoma for whom surgical resection is indicated will have baseline peripheral blood pharmacodynamic assays (PBPD) followed by oral mehimazole at least 5 days pre-operatively or until lower circulating theyroid hormone levels are achieved. PBPD assays will then be repeated. After surgical resection, PBPD will be repeated a day later. When the participant is deemed able to begin methimazole (no sooner than 10 days post-op) PBPD assays will be repeated and the participant will begin methimazole for 4 weeks. At the end of the first 4 week cycle, an MRI will be performed. PBPD assays will be repeated after which secondary chemotherapy will be added at the treating physician's discretion. After 4 weeks, PBPD will be repeated and the participant will undergo another MRI at 8 weeks.
89041168|NCT05600036|Experimental|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
89041169|NCT05600036|Experimental|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
89633578|NCT02435862|Experimental|3.0mg Luminate®|3.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
89633579|NCT02435862|Placebo Comparator|Balanced Salt Solution 0.10cc|Balanced Salt Solution 0.10cc injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
89633580|NCT04343014|Experimental|Tongue Root Retractor|Patients in this arm will receive fibroscopic endotracheal intubation with tongue root retractors.
89633581|NCT04343014|Active Comparator|Conventional Fibroscope|Patients in this arm will receive fibroscopic endotracheal intubation without any other devices.
89041170|NCT05600036|Experimental|ESK-001 Dose Level 3|ESK-001 administered as an oral tablet
89041171|NCT05600036|Experimental|ESK-001 Dose Level 4|ESK-001 administered as an oral tablet
89633582|NCT02435784|Active Comparator|2-COM group|Patients will use the Two-Way Communication Checklist (2-COM) once in a psychiatric consultation.
89633583|NCT02435784|Placebo Comparator|TAU group|Treatment as usual (TAU) group.
89633584|NCT03186222||cases with acne vulgaris|A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
89633585|NCT03186222||control group|control group of 100 age and sex matched healthy volunteers. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
89633586|NCT03184350|Other|Adjuvant pelvic proton radiation|
89633587|NCT02428218|Experimental|BG00012|Participants will receive 120 mg capsule(s) BG00012 taken orally.
89633588|NCT02428218|Experimental|Placebo|Participants will receive matching placebo capsule(s) taken orally.
89041172|NCT05600036|Experimental|ESK-001 Dose Level 5|ESK-001 administered as an oral tablet
89041173|NCT05600036|Placebo Comparator|Placebo|Placebo administered as an oral tablet
89633589|NCT03186300|Other|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
89633590|NCT04606576|Placebo Comparator|Placebo|Fish Oil
89633591|NCT04606576|Experimental|ORMD-0801 QD|8 mg ORMD-0801 administered QD at night
89633592|NCT04606576|Experimental|ORMD-0801 BID|8 mg ORMD-0801 administered at night and in the morning 45 minutes before breakfast.
89633593|NCT03866590||Patients being at risk for Pyruvate Kinase Deficiency|Patients, older than 5 years and younger than 30 years old, being at risk for Pyruvate Kinase Deficiency, due to chronic anaemia or cholelithiasis or cholecystitis of undetermined aetiology
89041174|NCT05594628|Experimental|Neuromuscular Training+Basketball training|After all participiants are evaluated, they will be divided randomly to two groups, which one group will be taking neuromuscular training+usual basketball training
89041175|NCT05594628|No Intervention|Control group(Basketball training)|After all participiants are evaluated, they will be divided randomly to two groups, which one group will be taking just the usual basketball training and not any extra interventions.
89041176|NCT05591755|Experimental|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)|
89041177|NCT05591755|Experimental|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)|
89633594|NCT02428062|No Intervention|Standard-of-Care|The intraoperative hemodynamic management of the patients assigned to this arm will be left to the discretion of the anesthesiologist, without any indication as to the intraoperative hemodynamic strategy to be adopted.
89041178|NCT05591755|Experimental|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)|
89041179|NCT05591755|Experimental|Vehicle ophthalmic solution (n = 56)|
89041180|NCT05587478|Experimental|EDP-323 SAD Cohorts|EDP-323 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, orally, once daily in one single administration
89041181|NCT05587478|Experimental|EDP-323 MAD Cohorts|EDP-323 Dose 1, Dose 2, Dose 3 and Dose 4 orally, once daily for 7 days
89041182|NCT05587478|Placebo Comparator|EDP-323 SAD Placebo Cohorts|Matching placebo, orally, once daily in one single administration
89041183|NCT05587478|Placebo Comparator|EDP-323 MAD Placebo Cohorts|Matching placebo, orally, once daily for 7 days
89057483|NCT01580046|Experimental|Iodixanol|
89633595|NCT02428062|Experimental|Treatment|The anesthesiologist will have as hemodynamic target for patients assigned to this arm the maintenance of mean arterial blood pressure within 10% of the baseline blood pressure value (recorded at the preoperative evaluation). The strategy to reach this hemodynamic target will be left to the clinical judgment of the anaesthesiologist in charge. The possible strategies include a vasoconstrictor agent (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine), intravenous fluids, patient's positioning or reduction of depth of anesthesia.
89057484|NCT01580046|Active Comparator|iopromide|
89633596|NCT02428062|No Intervention|Control|"Subjects assigned to this arm will undergo the same geriatric, neuropsychologic and audiologic evaluations administered to patients of the Standard-of-Care and Treatment arms at the same time points (baseline, 3 months and 1 year). These subjects will not undergo any surgical procedure and will therefore not be evaluated for post-operative complications or delirium occurrence."
89633597|NCT03189264|Active Comparator|Percutaneous nephrolithotomy with Coaxial Dilatation|Percutaneous nephrolithotomy with Coaxial Dilatation for treatment of kidney stones greater than 2 cm.
89633598|NCT03189264|Placebo Comparator|Percutaneous nephrolithotomy with Pneumatic Balloon|Percutaneous nephrolithotomy with Pneumatic Balloon for treatment of kidney stones greater than 2 cm.
89633599|NCT02435550|Experimental|Acute Myeloid Leukemia|Patients with acute myeloid leukemia will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
89633600|NCT02435550|Experimental|Acute Lymphoblastic Leukemia|Patients with acute lymphoblastic leukemia will have blood, bone marrow aspirate , and saliva collected from them as part of routine care.
89633601|NCT02435550|Experimental|Myelodysplastic Syndrome|Patients with myeloplastic syndrome will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
89633602|NCT02435550|Experimental|Myelofibrosis|Patients with myelofibrosis will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
89633603|NCT02435550|Experimental|Multiple Myeloma|Patients with multiple myeloma will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
89633604|NCT04596202|Experimental|Supine Position|It is the supine position. The body parts of the patient stand as if the patient is standing upright. The head, neck and shoulders should be supported with a pillow placed under the head. Arms are aside and body muscles are relaxed. The upper arms should lie on both sides of the body, should slightly be moved away from the body and should be supported by a pillow.
89633605|NCT04596202|Experimental|Prone Position|It is the position where the patient lies face down with his/her head turned to the side. Arms are stretched to both sides of the head. The prone position (prone lying) is a relaxing and resting position.
89633606|NCT04596202|Experimental|Lateral position|Lateral position is the left or right lateral lying position. The lateral position is given to the patient to provide proper anatomical lying and to reduce lateral flexion of the back and the strain of the large back muscles. This position prevents pressure on the bones in the back.
89633607|NCT02432586|Other|Intensive Education|Attendance of 2 intensive education sessions
89633608|NCT02975518|Active Comparator|Intra-venous infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-venously at an activity equal to that injected with the labelled endothelial cells.
89633609|NCT02975518|Active Comparator|Intra-Arterial infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-arterially at an activity equal to that injected with the labelled endothelial cells.
89633610|NCT02975518|Experimental|Intra-venous injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-venously with their distribution tracked using PET CT.
89633611|NCT02975518|Experimental|Intra-Arterial injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-arterially with their distribution tracked using PET CT.
89633612|NCT02435628||Satisfaction Questionnaires|"After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale.~Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap."
89633613|NCT02435394|Experimental|Remote Coach plus Asthma Module|The intervention is for practices to have remote coach support for patients with asthma in addition to doctors using CHADIS-Asthma module. Practices will start sequentially for a time series analysis.
89633614|NCT02435394|Experimental|Asthma Module- No Coach|The intervention is for practices to use CHADIS-Asthma module to improve patient care without a remote coach assisting patient adherence.
89041184|NCT05585229|Experimental|Psilocybin-assisted Psychotherapy|Participants will undergo a single-arm, 8-week therapeutic intervention using natural standardized psilocybin-assisted psychotherapy as a treatment for opioid tapering in chronic pain patients. Specifically, they will undergo one or two standardized natural psilocybin (PEX010) dosing sessions; 25mg at week 3 and 37.5mg at week 7.
89041185|NCT05579730|Experimental|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combination ophthalmic solution, n = 75|
89041186|NCT05579730|Experimental|Ketotifen fumarate ophthalmic solution 0.035% (n = 75)|
89041187|NCT05579730|Experimental|Brimonidine tartrate ophthalmic solution 0.025% (n = 75)|
89041188|NCT05579730|Experimental|Vehicle ophthalmic solution (n = 75)|
89041189|NCT05579262|Experimental|Normal|Subjects will consume 140mL of beetroot juice per day (800mg NO3/day), taken twice a day (70mL) in the afternoon and evening.
89041190|NCT05579262|Experimental|Pre-diabetic|Subjects will consume 140mL of beetroot juice per day (800mg NO3/day), taken twice a day (70mL) in the afternoon and evening.
89041191|NCT05557071|Experimental|Intervention|An online, asynchronous, self-paced, 6-week long, physical activity intervention.
89041192|NCT05557071|No Intervention|Control|A waitlist control; continue with life/activity as usual. Control participants will receive access to the intervention at 6 weeks following all measurements.
89041193|NCT05548361|Experimental|Active Chx|This group will receive active chlorhexidine and placebo probiotics
89041194|NCT05548361|Experimental|Active probiotics|This group will receive placeo chlorhexidine and active probiotics
89041195|NCT05548361|Experimental|Active Chx & probiotics|This group will receive active chlorhexidine and active probiotics
89041196|NCT05542667|Active Comparator|Giomer varnish|PRG coat barrier by SHOFU is varnish based on a new technology named Giomer by incorporating pre-reacted glass ionomer particles, so varnish contains GI particles embedded in a resin matrix, it should be applied once per year since it is the only varnish in the market that is light cured so it is more durable than others.
89041197|NCT05542667|Active Comparator|Fluoroide varnish|Bifluorid 10 by VOCO is a varnish containing 5% sodium fluoride and 5 % calcium fluoride, it should be applied once each 6 months by a professional dentist and it tends to decrease the hypersensitivity of the teeth as well as decrease the risk of caries.
89041198|NCT05533671|Experimental|Operative Group|This group will have surgical procedure called a medial patellofemoral reconstruction where the kneecap is anchored back into its correct position)
89633615|NCT02435394|Active Comparator|CHADIS- no Asthma module|Practices using CHADIS but no Asthma module as a control condition.
89633616|NCT04594798|Experimental|Experimental: Polatuzumab Vedotin and R-CHOP|The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)
89041199|NCT05533671|Active Comparator|Non-operative group|This group will have physical therapy for their knee dislocation by following a specific rehabilitation plan.
89633617|NCT02427906||TIPS group|patients who have transjugular intrahepatic portosystemic shunt
89633618|NCT02427906||Non-TIPS group|patients who have endoscopic variceal ligation
89041200|NCT05532189|Experimental|ACL reconstruction with internal brace augmentation (suture tape)|This group will receive a standard ACL reconstruction using a BTB autograft with suture tape augmentation on the graft to strengthen it during the surgical procedure.
89041201|NCT05532189|Active Comparator|ACL reconstruction without internal brace augmentation|This group will only receive a standard ACL reconstruction using a BTB autograft. No suture tape will be added to the graft during the surgical procedure.
89041202|NCT05532150|Experimental|Operative group|The operative group will undergo an arthroscopic Bankart repair, which is type of surgery used to repair a dislocated shoulder.
89041203|NCT05532150|Active Comparator|Non-operative group|The non-operative group will undergo physical therapy following a specific rehabilitation schedule.
89633619|NCT04592770|Experimental|The experimental intervention (walk):|In this group, the nature walk will take place in a conserved and by far the largest recreational area of Karachi city. The safari park covering an area of 148 acres (0.60 km2), It has a zoo, geared with woodland, mountain viewing, safari tracks, as well as two natural lakes. The experiment will take place in the afternoon on a 5 km marked area. The duration of the stretching exercise sessions will be of 10 minutes followed by 50 minutes' walk session five times per week (total 12 weeks). participants will be asked to walk at moderate pace.
89633620|NCT04592770|Placebo Comparator|The control intervention (sit & relax):|Subjects will undergo 12 weeks of nature therapy that includes exposure to natural landscapes. The duration of the sessions will be 60 minutes five times per week. The subjects will be asked to sit and relax in the evening, in the same recreational area which is used for the experimental group.
89211809|NCT02546726|Experimental|Heat & Aerobic Training (HEAT) Condition|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the HEAT condition will be asked to sit quietly on the bench in the steam-room within their same-sex locker room for no more than 20 minutes. They will start at 11 minutes to get acclimated to the mild heat stress, and gradually work up to 20 minutes. A trained research staff member will be stationed outside the room.
89633621|NCT02432508|Active Comparator|laser acupuncture|One hundreds of hemodialysis patients include and give intervention with laser acupuncture (50mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to shame laser acupuncture treatment (5mW).
89633622|NCT02432508|Sham Comparator|sham laser acupuncture|One hundreds of hemodialysis patients include and give intervention with sham laser acupuncture (5mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to laser acupuncture treatment (50mW).
89633623|NCT04590976||Healthcare Professionals (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
89633624|NCT04590976||Stage 1 (n = 5)|Intervention: Single, Semi-Structure Interview to identify and define the key attributes associated with treatment options that would warrant trade-off evaluation. These will be used to create the first version of the questionnaire
89633625|NCT04590976||Stage 2 (n = 10)|"Intervention: Single, Think Aloud Interview Interview. These will be analysed using an inductive thematic analysis by at least two researchers. Common themes will be extracted by researchers individually and then discussed and agreed."
89633626|NCT04590976||Stage 3 (n = 300)|Intervention: Single, Discrete Choice Experiment Questionnaire at Enrollment Visit
89633627|NCT03184584|Experimental|PBI-4050|
89633628|NCT03184662|Experimental|HIPA group|"Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.~The sessions will be preferably performed in sports gyms but if required can also be performed online with supervised coaches, trained for the study."
89041204|NCT05524532|Experimental|Immulina TM 800 mg/day|Immulina Dietary supplementation (200 mg per capsule) 2-200 mg capsules given by mouth in the morning and 2-200 mg capsules given by mouth in the evening for 8 weeks duration
89041205|NCT05524532|Placebo Comparator|Placebo|inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 8 weeks duration
89041206|NCT05501717|Experimental|ALXN2030 Dose A|ALXN2030 will be administered as a single dose.
89041207|NCT05501717|Experimental|ALXN2030 Dose B|ALXN2030 will be administered as a single dose.
89041208|NCT05501717|Experimental|ALXN2030 Dose C|ALXN2030 will be administered as a single dose.
89041209|NCT05501717|Experimental|ALXN2030 Dose D|ALXN2030 will be administered as a single dose.
89041210|NCT05501717|Experimental|ALXN2030 Dose E|ALXN2030 will be administered as a single dose.
89041211|NCT05501717|Placebo Comparator|Placebo|Placebo will be administered as a single dose.
89041212|NCT05481684|Experimental|Normal Progesterone group|Progesterone level ≥ 10 ng/mL on ET day.
89041213|NCT05481684|Active Comparator|Low Progesterone group|Progesterone level <10 ng/mL on ET day. Grup a Rescue vaginal progesterone, Grup b Rescue subcutan progesterone
89041214|NCT05477420|Experimental|Experimental group|"Participants in the experimental group will be expected use the decision aid developed in this study. They will be assessed at two different time points:~(1) before intervention (T0) and (2) post-intervention (T1)."
89057485|NCT02215850|Experimental|SLC-0111|
89057486|NCT01683318|Experimental|Treatment|Patients will undergo Thermal Pulsation treatment of Meibomian Gland Dysfunction using the TearScience System (Lipiflow).
89633629|NCT03184662|Active Comparator|Control group|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).
89633630|NCT03184506|Sham Comparator|control group|
89633631|NCT03184506|Active Comparator|pre-warming group|
89633632|NCT03184272|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
89633633|NCT02435004|Other|Spinal Modulation Axium™|Spinal Modulation Axium™: an external trial neurostimulator (TNS) is used for the trial period, followed by an implanted neurostimulator (INS) if the TNS is successful. The TNS and INS are a pacemaker-sized devices that send out mild electrical pulses. The stimulator contains a battery and electrical components. Both TNS and INS are constant voltage devices. The TNS is used first and is worn on the outside of the clothing. The INS is implanted under the skin and support:
89633634|NCT02435082||Concussion with TCD|Any patient (adolescent/adult) receiving a Transcranial Doppler (TCD) for a head injury, suspected concussion, or suspected mild traumatic brain injury (sports related or not).
89633635|NCT02432430|Experimental|quality improvement technical support|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and attend 6 virtual QI Learning Sessions and 12 monthly conference calls with a coach and other participant teams. On a monthly basis for 11 months, participants collect, submit and review immunization data of 10-20 of their patients ages 3 months to 18 months. After 12 months, participants attend a virtual QI Debriefing Session.
89633636|NCT02432430|Active Comparator|pay for performance|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and are informed of a tiered incentives structure. Practices receive bonuses for both improvement in individual practice coverage as well as improvement in coverage for all practices allocated to this study arm.
89633637|NCT02432664|Experimental|ODM-108 Part I|Oral capsules dosage 0.2 - 240 mg once daily for one day
89633638|NCT02432664|Placebo Comparator|Placebo Part I|Oral capsules given once daily for one day
89633639|NCT02432664|Experimental|ODM-108 Part II|Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days
89633640|NCT02432664|Placebo Comparator|Placebo Part II|Oral capsules 1 - 4 times per day for 7 days
89633641|NCT02432664|Experimental|ODM-108 Part III|Oral capsules 1-4 times daily for 7 to 10 days
89633642|NCT02432664|Active Comparator|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
89633643|NCT02432352|Experimental|Intervention|Families are randomly allocated to a behavioral intervention arm (called Our Family Our Future) focusing on reducing sexual risk behavior in adolescents and reducing or maintaining symptoms that fall below the clinically significant range for depression. Arms will be allocated using urn randomization.
89633644|NCT02432352|No Intervention|Control|Families are randomly allocated to the control arm (which receives standard usual care, and then offered the intervention after outcome assessments as a wait-list) using urn randomization.
89633645|NCT03189186|Experimental|Pembrolizumab|Advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma will be first treated with cryoablation on a large primary tumor and then given 200 mg pembrolizumab every 3-week for 3 cycles, followed by cytoreductive or partial/radical nephrectomy. After the surgery, patients will resume pembrolizumab for additional 5 cycles or up to a total of 2 years if a partial response is observed at the discretion of the treating medical oncologist or urologist until a complete tumor remission, disease progression, unacceptable toxicity, subject refusal, or subject death due to any cause.
89633646|NCT03820492|Other|Patient with left-main stenosis|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
89633647|NCT02435160|Experimental|Ulcerative Colitis|
89633648|NCT03189030|Experimental|Treatment arm|pLADD treatment cycle is once every 3 weeks; starting dose 1×10^8 colony-forming units (CFU) administered IV over 1 hour, and if tolerated increasing to 1×10^9 CFU
89633649|NCT02432118|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
89633650|NCT02427828|Active Comparator|Treatment Group|Assessment of Visensia Respiration Rate Estimation Service (product) to provide Respiration Rate from PPG signal, providing 3 vital signs (heart rate, oxygen saturation and respiration rate) to facilitate continuous Safety Index (VSI) calculation by Visensia, alongside standard routine intermittent observations (vital signs every 4 - 6 hours).
89633651|NCT02427828|No Intervention|Control Group|Using standard routine intermittent observation (vital signs every 4 - 6 hours) and calculation of NEWS/MEWS scores for early detection of patient deterioration.
89633652|NCT03186144|Experimental|No arm : descriptive study|
89633653|NCT03811600||OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour
89633654|NCT03811600||Non OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index <15 per hour
89633655|NCT02427594|Experimental|Controlled diet first|In this arm participants will first consume a controlled diet plus added table salt (sodium chloride) for one week. They will then consume an identical controlled diet plus sodium bicarbonate for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
89633656|NCT02427594|Experimental|Sodium bicarbonate first|In this arm participants will first consume a controlled diet plus sodium bicarbonate for one week. They will then consume an identical controlled diet plus added table salt (sodium chloride) for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
89633657|NCT02427516||NVAF-VKA cohort|NVAF patients who initiate a VKA treatment
89633658|NCT02427516||VTE-VKA cohort|VTE patients who initiate a VKA treatment
89633659|NCT02427438|Active Comparator|Video Home Program Education|Subjects in this group will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a video with verbal instruction for guidance of proper technique and repetitions.
89633660|NCT02427438|Active Comparator|Handout Home Program Education|Subjects will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a handout with two dimensional pictures and written instructions for guidance of proper technique and repetitions.
89633661|NCT00361894|Experimental|Arm 1|
89633662|NCT00361894|Active Comparator|Arm 2|
89633663|NCT02427282|Active Comparator|MS. Frog|miniscrew-supported frog molar distalizing appliance
89633664|NCT02427282|Experimental|Stand. Frog|Standard Frog appliance
89633665|NCT02434692|Experimental|Single-arm intervention ARGOS-IO system|The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.
89633666|NCT04556578|Experimental|High-flow ECCO2R|Extracorporeal support using high flow circulation
89633667|NCT03185910|Experimental|MBCP education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
89633668|NCT03185910|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
89211810|NCT02546726|Active Comparator|Exercise Only|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the Exercise Only condition will be asked to sit quietly on the bench in the lobby of the fitness facility, initially for 11 minutes and then gradually working up to 20 minutes.
89211811|NCT04043390|Experimental|CRP and Xpert ULTRA MTB/RIF|Scheme 1 will screen all patients for HIV using rapid tests routinely used by the clinics and a rapid CRP. Patients with CRP >10 will be further tested using Xpert ULTRA. Individuals with HIV will undergo an HIV VL using Xpert HIV-1 VL.
89211812|NCT04043390|Experimental|CRP and Molbio Truenat MTB|Scheme 2 will screen individuals for HIV and CRP (as in scheme 1) and patients with CRP >10 will be tested using Molbio Truenat MTB. Individuals with HIV will undergo an HIV VL using Molbio Truenat HIV-VL and individuals with Truenat MTB-positive samples wil be tested with Truenat MTB RIF.
89211813|NCT04043390|No Intervention|standard test Xpert|All patients receiving in scheme 1 and scheme 2 will be tested using the standard tests used in the study context. These are rapid HIV tests, Xpert MTB/RIF and culture.
89211814|NCT00843128|Experimental|1: RAGT|Following randomization, 20 patients will be treated with RAGT, 12 sessions over three weeks
89211815|NCT00843128|Active Comparator|2: Control|The control group will be treated by CWT, 12 sessions in three weeks.
89211816|NCT00508924|Experimental|ARG250|
89633669|NCT03804814|Active Comparator|Motivational Interviewing Training|Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters.
89041215|NCT05477420|No Intervention|Attention control group|"The control group participants will be asked to search information related to Depression and therapies for Depression online. They will be assessed at two different time points:~(1) at baseline (T0) and (2) after searching for information (T1)."
89041216|NCT05473715|Experimental|Customized treatment interval|After the initial study injection at baseline, participants will receive their next study injection at Week 16. Participants in this study arm will also be issued a home monitoring device, which will allow for regular OCT monitoring (at least 5 times a week) at home.
89041217|NCT05473715|Active Comparator|Treat and extend (T&E) 2 week adjustment|Participants will receive treatment in intervals maintained (8 weeks) or adjusted in 2 weeks increments each time (up to a maximum of 16 weeks and minimum of 4 weeks), as long as all extension/shortening criteria are met.
89041218|NCT05470933|Experimental|WJ01075 tablets|Once a week (QW).
89041219|NCT05455008|Experimental|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
89041220|NCT05437172|Experimental|injectable platelet rich fibrin with deminerlized dentin graft|injectable platelet rich fibrin with deminerlized dentin graft for ridge preservation after teeth extraction
89041221|NCT05437172|Active Comparator|deminerlized dentin graft|deminerlized dentin graft for ridge preservation after teeth extraction
89041222|NCT05431686|Experimental|SMA visit intervention arm|SMAs will occur once every 3 months, and consist of 4-6 underserved youth with T1D and their primary diabetes caregiver
89057487|NCT01201915|Experimental|Cohort 1: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
89057488|NCT01201915|Experimental|Cohort 2: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
89211817|NCT00508924|Experimental|ARG300|
89211818|NCT00508924|Experimental|ARG350|
89211819|NCT00508924|Placebo Comparator|Heparin|
89211820|NCT00836576|Experimental|1|
89633670|NCT03804814|No Intervention|Standard Clinical Encounter|Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters.
89633671|NCT03185988|Experimental|GI tumor beyond CRC, ESCC, BTC,GC&GEJA|HER2 positive GI tumor beyond CRC, ESCC, BTC,GC&GEJA
89633672|NCT03185988|Experimental|Esophageal squamous cell carcinoma|HER2 positive Esophageal squamous cell carcinoma
89633673|NCT03185988|Experimental|Biliary tract cancer|HER2 positive Biliary tract cancer
89633674|NCT03185988|Experimental|Colorectal cancer|HER2 positive and RAS/BRAF wild type colorectal cancer
89633675|NCT02431962|Experimental|Screening arm|Annual low dose screening chest CT scan x 3.
89633676|NCT02431962|Experimental|Smoking cessation counseling|Active smokers randomized to this arm will be contacted by a trained smoking cessation counselor and offered cessation support and advice.
89633677|NCT02431962|Active Comparator|Smoking cessation control|Active smokers randomized to this arm will receive general information on available smoking cessation resources.
89633678|NCT03184116|Experimental|Individual intervention|Individual intervention using cognitive-behavioral principles
89633679|NCT03184116|No Intervention|Control|No additional intervention
89211821|NCT00836576|Active Comparator|2|
89211822|NCT00836654|Active Comparator|1 Catumaxomab|Patient received Catumaxomab and paracentesis
89211823|NCT00836654|No Intervention|2:|Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm
89211824|NCT00844064|Experimental|AP 12009|
89633680|NCT04072432|Experimental|Cohort 1|120 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
89633681|NCT04072432|Experimental|Cohort 2|240 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
89633682|NCT04072432|Experimental|Cohort 3|360 mg, single IV infusion in healthy volunteers and volunteers with CKD Stage 3-4
89633683|NCT03189342|Experimental|Single Task Training|Performed balance and gait exercises
89633684|NCT03189342|Experimental|Dual task training|Performed cognitive activity simultaneously with balance and gait exercises
89633685|NCT03189342|Experimental|Exercise-Cognitive Activity Combined Training|Performed cognitive, balance and gait activity training asynchronously at different times during the same day
89633686|NCT00361348|Active Comparator|Palifermin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period
89633687|NCT00361348|Experimental|Palifermin + Heparin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period + unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
89633688|NCT00361348|Active Comparator|Heparin|unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
89633689|NCT02431884||body fluids/tissues & history|collect body fluids/tissues & med history from subjects with polycystic ovary syndrome(PCOS), congenital uterine malformations, endocrine malfunctions, endometriosis, and infertility;
89633690|NCT02431728|Active Comparator|Melatonin|capsule containing 5mg melatonin plus cellulose
89633691|NCT02431728|Placebo Comparator|Matched Placebo|capsule containing cellulose
89633692|NCT03188640|Other|Surgery|Participants will be operated using laparoscopic gastric bypass surgery.
89633693|NCT04343326|Active Comparator|accelerated corneal cross linking+ delivery of systemic oxygen|corneal cross linking is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
89633694|NCT04343326|Active Comparator|accelerated corneal collagen cross-linking|corneal cross linking with the same accelerated protocol without additional oxygen therapy.
89633695|NCT04343326|Active Comparator|conventional corneal collagen cross-linking|Conventional corneal cross linking using 30 mW/CM2 UV-A ablation for 30 minutes
89633696|NCT03183960|Experimental|Mentor|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
89633697|NCT03183960|Active Comparator|Traditional rehabilitation|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
89041223|NCT05415956|Experimental|Walking exercise therapy|"7 week intervention group. 6-12 persons per group. 2 sessions per week, 14 sessions in total.~Surface: the investigators aim to involve as much forest/gravel trails as possible, with up/down hill walking.~Uneven session numbers: warm-up (6 minutes at BORG 10-11), continous walking (starting at 12-20 minutes at BORG 13-14 and progressing to 20-40 minutes at BORG 15-16, adjusted according to the starting level of each participant) and cool-down (approximately 10 minutes at BORG 10-11).~Even session numbers: warm-up (6 minutes at BORG 10-11), intermittent walking (starting at 3-4 intervals of 2 minutes at BORG 14-15 and progressing to 4-5 intervals of 2-3 minutes at BORG 16-17; with all intervals being interspersed by 1 minute rest) and cool-down (approximately 10 minutes at BORG 10-11)."
89041224|NCT05415956|No Intervention|Control/Waitlist|7 week control/waitlist group. Continuation of habitual lifestyle during the 7 week intervention period (yet these participants will receive the exact walking exercise therapy afterwards).
89057489|NCT01201915|Experimental|Cohort 3: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 8 weeks, followed by 4 weeks with no treatment, followed by a second 8-week vismodegib treatment period.
89057490|NCT01649154|Active Comparator|Ligasure Small-JAW|
89057491|NCT01649154|Active Comparator|Harmonic Focus|
89211825|NCT04003077|Experimental|Laser meridian massage|They are treated with laser meridian massage on the back including Bladder meridian and Governor vessel three times a week for 4 weeks.
89211826|NCT04003077|No Intervention|Control|A control group of participants without laser meridian massage treatment are matched by age.
89211827|NCT05221593|No Intervention|control group|will receive chemotherapy regimen with placebo
89633698|NCT04536376|Experimental|Resilience Program|a 4 week program focused on improving resilience
89633699|NCT03183882|Experimental|Normative Peer Comparison|One-time summary report of 14-month individual history of opioid prescribing WITH comparisons to (a) other providers at their site and (2) other providers at 15 ED sites with similar prescribing
89633700|NCT03183882|Active Comparator|Control Feedback|One-time summary report of their individual history of opioid prescribing
89633701|NCT03183726||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101
89633702|NCT00362206|Experimental|1|
89633703|NCT00362206|Experimental|2|
89633704|NCT00362206|Active Comparator|3|
89633705|NCT03185442|Experimental|PRF-fMRI|
89633706|NCT03748186|Experimental|STRO-002 treatment|"Dose Escalation: STRO-002 at increasing dose levels~Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg"
89633707|NCT02974972||Pith Moromo 2 Cohort|
89633708|NCT02314468|Active Comparator|negative pressure wound therapy (NPWT)|negative pressure wound therapy (NPWT)
89633709|NCT02314468|Active Comparator|Glycerol Preserved Allografts (GPA)|Glycerol Preserved Allografts (GPA)
89688490|NCT02914210|Other|Virtual physical therapy|Virtual physical therapy rehabilitation program (VERA) used in the home with care planning and remote support and monitoring by physical therapists
89688491|NCT02914210|Other|Traditional physical therapy|No intervention. Standard home health physical therapy and/or outpatient clinic physical therapy as prescribed.
89633710|NCT01704287|Experimental|Pembrolizumab 2 mg/kg|Participants were initially randomized to receive pembrolizumab 2 mg/kg intravenously (IV) once every 3 weeks (Q3W). With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
89633711|NCT01704287|Experimental|Pembrolizumab 10 mg/kg|Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
89633712|NCT01704287|Active Comparator|Investigator-Choice Chemotherapy (ICC)|Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
89633713|NCT01704287|Experimental|ICC→Pembrolizumab 2 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
89633714|NCT01704287|Experimental|ICC→Pembrolizumab 10 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
89633715|NCT00362752|Placebo Comparator|Placebo|
89633716|NCT00362752|Experimental|Norfloxacin 400 mg bid|
89633717|NCT00118209|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy~Cyclophosphamide 750 mg/m^2 IV on Day 1~Doxorubicin 50 mg/m^2 IV on Day 1~Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1~Prednisone 40 mg/m^2/day PO on Days 1-5~filgrastim or pegfilgrastim as defined in the protocol~Required ancillary medications is administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6."
89633718|NCT00118209|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment:~Cycle 1 Doses:~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy~Doxorubicin 10 mg/m^2/day CIVI on Days 1-4~Etoposide 50 mg/m^2/day CIVI on Days 1-4~Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours)~Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions)~Prednisone 60 mg/m^2 PO BID on Days 1-5~Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not being monitored, during every cycle.~Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle.~Required ancillary medications are administered during all cycles as defined in the protocol.~Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6."
89633719|NCT02276326|Experimental|VSL#3 sachets|VSL#3 is a mix of lactic acid bacteria and bifidobacteria (original De Simone's formulation)
89633720|NCT01897779|Experimental|Single and multiple dose of RPX7009|Single and multiple dose of RPX7009
89633721|NCT01897779|Experimental|Single and multiple dose of RPX2014|Single and multiple dose of RPX2014
89633722|NCT01897779|Placebo Comparator|Normal Saline|Single and multiple dose of normal saline
89633723|NCT01897779|Experimental|Combination RPX7009 and RPX2014|Single and Multiple dose of Combination RPX7009 and RPX2014
89633724|NCT04342156|Experimental|Intervention|"Treatment arm will be given Hydroxychloroquine sulfate. Dose: 800 milligrams (mg) (4 pills of 200mg) in two divided doses on day 1 followed by 400mg (2 pills of 200mg) in two divided doses on day 2, 3,4, 5.~Mode of administration: Oral pills of 200mg of HCQ; Supply: The total supply of all the pills (12 pills of 200mg per subject in the study group) will be given to the recruited subject from day 1."
89633725|NCT04342156|Other|Standard Preventive Measures|No intervention. Standard recommended preventive measures by the ministry of health.
89057492|NCT01649154|Active Comparator|Clamp-and-Tie technique|
89057493|NCT04542122|No Intervention|Choices then judgements|
89057494|NCT04542122|Active Comparator|Judgements then choices|Switch in the order of clinical cases in the survey
89057495|NCT04532879|Experimental|All patients enrolled|"Bowel habits before and after the HygiRelief procedure will be assessed.~Samples will be sent for microbiome evaluation."
89057496|NCT01649193||Chronic Respiratory Disease|Any patient with a chronic respiratory disease referred for pulmonary rehabilitation
89057497|NCT01179919|Experimental|Oseltamivir Dosed Group|Oseltamivir 75 mg by mouth every 12 hours for 9 doses
89057498|NCT01649310|Experimental|WVB Training|
89057499|NCT01201798|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop in study eye, 4 times a day for 14 days, followed by a 14-day tapering period
89057500|NCT01201798|Active Comparator|Pred Forte|Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period
89057501|NCT04539353||chronic pain|Patients with chronic pain, regardless of the cause of the pain.
89057502|NCT02887456|Active Comparator|Vitapex|Endodontic treatment using Vitapex
89057503|NCT02887456|Experimental|MTA paste|Endodontic treatment using MTA paste
89057504|NCT01201759|Experimental|Placebo to Salsalate 2gr BID|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
89057505|NCT01201759|Experimental|Salsalate 2gr BID to placebo|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days.
89057506|NCT04315597|Experimental|Hypericum extract STW 3-VI (Laif® 900, BAY98-7108)|
89057507|NCT04315597|Placebo Comparator|Placebo|
89057508|NCT01683396|Placebo Comparator|Placebo|
89520705|NCT04514055|Experimental|De-epithelialized connective tissue graft wall|"Simplified papilla preservation flap will be applied in the narrow interproximal spaces (≤2 mm), where an oblique incision starting from the gingival margin at the buccal-line angle of the involved tooth reaching the mid-interproximal portion of the papilla under the contact point of the adjacent tooth will be performed using a 15c blade.~A free gingival graft will be obtained from the hard palate and de-epithelized extra-orally.~A Coronally advanced flap will be performed. The de-epithelialized FGG will be sutured coronally using a 6-0 vicryl suture to the anatomical papillae of the two teeth adjacent to the defect and apically to the periosteum left in place apical to the exposed bone.~The flap will be sutured using internal Horizontal mattress suture at the base of the simplified papilla and a vertical mattress suture will be placed in a more coronal position so complete soft tissue closure can be obtained."
89520706|NCT03980405|Experimental|Group 1|Control Diet 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ Low residue diet and 6 more weeks of Oral 5ASA+ Free diet
89520707|NCT03980405|Experimental|Group 2|6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ UC diet and 6 more weeks of Oral 5ASA+ UC diet stage 2
89041225|NCT05410132|Experimental|Internet-based mindfulness-based training group (iMBT)|"Participants in the iMBT group will be expected to complete an Internet-based mindfulness-based training delivered over a 6-week period via an internet e-learning mental health platform. They will be assessed at four different time points:~(1) before intervention (T0), (2) 2,4 weeks since the commencement of group (T1,2), (3) 6 weeks after (i.e., when the intervention ends) (T3), (4) at 3-month follow-up(T4)."
89041226|NCT05410132|No Intervention|Treatment-as-usual control group (TAU)|The TAU group will be advised to seek assistance from their usual healthcare provider when needed. They will be offered access to the Internet-based mindfulness-based course content after the study has ended.
89041227|NCT05407077||females with isolated patellofemoral arthritis|those with anterior knee pain
89041228|NCT05407077||healthy females|those without anterior knee pain
89520708|NCT03432767||Women having a vaginal delivery|A non-invasive hemoglobin monitor will be attached to the patient's finger and kept on for 2 hours after she delivers. Heart rate and blood pressure will be measured every 10 minutes.
89041229|NCT05403450|Experimental|Phases 1 and 2: Tolinapant + Oral Decitabine/Cedazuridine|"Tolinapant, orally, once daily (QD) on Days 1 to 7 and 15 to 21 of each 28-day cycle in combination with oral decitabine/cedazuridine fixed-dose combination (FDC) tablet, QD on days determined by the Lead-in Phase during each 28-day cycle. The starting dose of tolinapant will be escalated stepwise in successive cohorts until the RP2D is determined.~Based on RP2D and results determined from Phase 1 participants would receive tolinapant at the identified RP2D in combination with decitabine/cedazuridine, FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle in Phase 2."
89041230|NCT05403450|Experimental|Phase 1: Oral Decitabine/Cedazuridine|Decitabine/cedazuridine FDC tablet, orally, QD on days determined by the Lead-in Phase during each 28-day cycle.
89041231|NCT05388708||Usual care ECMO Cohort|"The cohort will be comprised of 550 patients, aged 14 days to 20 years, who go on extracorporeal membrane oxygenation (ECMO) support due to pediatric acute respiratory distress syndrome (PARDS) at physician discretion. Patients with qualifying PARDS must have one oxygenation index (OI) ≥ 16 or two OIs 12 ≥ to < 16 (at least 4 hours apart) or two oxygenation saturation indexes (OSIs) ≥ 10 (at least 4 hours apart) or one OI 12 ≥ to < 16 and one OSI > 10 (at least 4 hours apart) Subjects must be on mechanical ventilation for less than 240 hours (10 days) prior to cannulation. These measures must be after endotracheal intubation and before ECMO start. Chest radiograph prior to ECMO must show bilateral lung disease.~Subjects cannulated on ECMO for no more than 96 hours prior to gaining consent."
89057509|NCT01683396|Experimental|gevokizumab|
89520709|NCT03437057|Experimental|Patients treated with acethylsalicylic acid 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
89520710|NCT03579693|Active Comparator|CoQ10|Coenzyme Q10, 2 - 250 mg tablets twice a day (1000 mg total daily dose) for 6 weeks
89520711|NCT03579693|Active Comparator|Nicotinamide riboside|Nicotinamide riboside, 1 - 600 mg tablet twice a day (1200 mg total daily dose) for 6 weeks
89520712|NCT03579693|Placebo Comparator|Placebo|Placebo, inactive sugar pill for 6 weeks
89520713|NCT03432689|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
89520714|NCT03432689|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
89520715|NCT02991807|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg or 2.5mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
89520716|NCT02991807|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
89520717|NCT04470869|Experimental|OLAF group|The interventional group (OLAF) benefit from a psychiatric follow up, from virtual visiting of the patient and video interview with ICU team.
89520718|NCT04470869|Placebo Comparator|Control|The control group contains the relatives of patients hospitalized after the confinement measure but before the OLAF intervention. This group benefit from phone contact with the ICU team at the admission in ICU then two contact per week minimum to one contact per day maximum during the stay, excepting the specific phone calls associated with favorable or unfavorable evolution.
89520719|NCT05106933|Placebo Comparator|Plain water|Group A patient will be given 400cc of plain water, 2 hours prior to gastroscopy
89520720|NCT05106933|Experimental|Carborie|Group B patient will be given 400cc of carborie (carbohydrate drink), 2 hours prior to gastroscopy
89633726|NCT01682837|Experimental|KMgCit, KCit, KCl, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate (KMgCit) powder, Potassium Citrate (KCit) powder, Potassium Chloride (KCl) powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633727|NCT01682837|Experimental|KMgCit, KCit, Placebo, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633728|NCT01682837|Experimental|KMgCit, KCl, KCit, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633729|NCT01682837|Experimental|KMgCit, KCl, Placebo, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633730|NCT01682837|Experimental|KMgCit, Placebo, KCit, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633731|NCT01682837|Experimental|KMgCit, Placebo, KCl, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633732|NCT01682837|Experimental|KCit, KMgCit, KCl, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633733|NCT01682837|Experimental|KCit, KMgCit, Placebo, KCl|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633734|NCT01682837|Experimental|KCit, KCl, KMgCit, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633735|NCT01682837|Experimental|KCit, KCl, Placebo, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633736|NCT01682837|Experimental|KCit, Placebo, KMgCit, KCl|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633737|NCT01682837|Experimental|KCit, Placebo, KCl, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633738|NCT01682837|Experimental|KCl, KMgCit, KCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89041232|NCT05388708||PROSpect protocolized therapies cohort|"The cohort will be comprised of 1000 patients, aged 14 days to 20 years, who are endotracheally intubated for PARDS. Patients with qualifying PARDS must have one oxygenation index (OI) ≥ 16 or two OIs 12 ≥ to < 16 (at least 4 hours apart) or two oxygenation saturation indexes (OSIs) ≥ 10 (at least 4 hours apart) or one OI 12 ≥ to < 16 and one OSI > 10 (at least 4 hours apart). These measures must be after endotracheal intubation. Chest radiograph must show bilateral lung disease. Patient must be enrolled in a clinical trial Prone and Oscillation Pediatric Clinical Trial (PROSpect) NCT01515787 which is distinct from ASCEND.~PROSpect is a response adaptive randomized clinical trial, testing the impact of supine/prone positioning and conventional mechanical ventilation/high-frequency oscillatory ventilation on short and long-term clinical outcomes in children with severe PARDS. PROSpect manages severe PARDS subjects using a rigorous protocol that reserves ECMO for protocol failure."
89041233|NCT05376215|Active Comparator|Fitting method A first, then fitting method B|"Participants will be fit with a set of hearing devices that are programmed to fitting method A first. This fitting method will use specific programming parameters and software to determine the most appropriate fitting algorithm.~Following a home trial with fitting method A, participants will then be fit with a set of hearing devices that are programmed to fitting method B. This fitting method will use a different set of programming parameters and software to determine the most appropriate algorithm."
89041234|NCT05376215|Experimental|Fitting method B first, then fitting method A|"Participants will be fit with a set of hearing aids that are programmed using fitting method B. This fitting method will use a different set of programming parameters and software to determine the most appropriate algorithm.~Following a home trial with fitting method B, participants will then be fit with a set of hearing devices that are programmed to fitting method A. This fitting method will use specific programming parameters and software to determine the most appropriate fitting algorithm."
89041235|NCT05361109|Experimental|Barcitinib|All subjects will initially receive baricitinib 2mg daily for 8 weeks. If no unexpected serious adverse events related to baricitinib have occurred during the first 8 weeks of treatment in the opinion of the investigator, the dose will be increased to 4 mg daily for 16 weeks.
89041236|NCT05359276||Cohort 1|Patients with a confirmed diagnosis of ASMD under early access to olipudase alfa in France
89041237|NCT05355389|Experimental|Cognitive-motor training group|
89633739|NCT01682837|Experimental|KCl, KMgCit, Placebo, KCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633740|NCT01682837|Experimental|KCl, KCit, KMgCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633741|NCT01682837|Experimental|KCl, KCit, Placebo, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633742|NCT01682837|Experimental|KCl, Placebo, KMgCit, KCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633743|NCT01682837|Experimental|KCl, Placebo, KCit, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633744|NCT01682837|Experimental|Placebo, KMgCit, KCit, KCl|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633745|NCT01682837|Experimental|Placebo, KMgCit, KCl, KCit|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633746|NCT01682837|Experimental|Placebo, KCit, KMgCit, KCl|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633747|NCT01682837|Experimental|Placebo, KCit, KCl, KMgCit|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633748|NCT01682837|Experimental|Placebo, KCl, KMgCit, KCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
89633749|NCT01682837|Experimental|Placebo, KCl, KCit, KMgCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
88990787|NCT06171152|Experimental|Study Group 1 (Drug Regimen A)|"During the study, liraglutide will be given in cycles. A cycle is a scheduled period of time for taking study drugs. For this study, each cycle length as well as the dose of liraglutide participants take will be based on the drug regimen (or schedule) they receive. The drug regimen receive each participant receives will be selected using a random assignment process, similar to flipping a coin.~Participants in this study group will receive Drug Regimen A, which means they will take liraglutide at the below doses and times:~Dose Schedule Cycle Length 0.6mg Daily 1 week 1.2mg Daily 1 week 1.8mg Daily 1 week 2.4mg Daily 1 week 3.0mg Daily 8 weeks"
88990788|NCT06171152|Experimental|Study Group 2 (Drug Regimen B)|"During the study, liraglutide will be given in cycles. A cycle is a scheduled period of time for taking study drugs. For this study, each cycle length as well as the dose of liraglutide participants take will be based on the drug regimen (or schedule) they receive. The drug regimen receive each participant receives will be selected using a random assignment process, similar to flipping a coin.~Participants in this study group will receive Drug Regimen B, which means they will take liraglutide at the below doses and times:~Dose Schedule Cycle Length 0.6mg Daily 5 weeks 1.2mg Daily 1 week 1.8mg Daily 1 week 2.4mg Daily 1 week 3.0mg Daily 4 weeks"
88990789|NCT06170060|Experimental|Laparoscopic Sleeve Gastrectomy|
88990790|NCT06169241|Placebo Comparator|Placebo|The placebo group will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
88990791|NCT06169241|Active Comparator|Beetroot extract|Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
88990792|NCT06168981|Experimental|Chewing Gum|Before the surgery, the patient will chew gum for 2 minutes and routine nursing care will be applied. Anxiety level will be evaluated before and after chewing gum.
88990793|NCT06168981|No Intervention|Control Group|Anxiety level will be evaluated before and after routine nursing care.
88990794|NCT06167915|Experimental|Low dose vaccine group|30μg dose of LYB002V14 vaccine IM, on day 0.
88990795|NCT06167915|Experimental|High dose vaccine group|60μg dose of LYB002V14 vaccine IM, on day 0.
88990796|NCT06167915|Placebo Comparator|Placebo group|placebo IM, on day 0.
88990797|NCT06167772|Experimental|Branched-chain Amino Acid (BCAA) group|"branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral & parenteral.~duration: 10 days standard nutrition: oral nutrition supplement (high protein) or parenteral with target energy of 20 kcal/kg BW/day standard neuromuscular electrical stimulation 30 minutes per day"
89041238|NCT05355389|Active Comparator|Cognitive training group|
89041239|NCT05355389|Active Comparator|Motor training group|
89041240|NCT05344300||Lung-healthy group|
89633750|NCT02213068|Experimental|belatacept + MPA|"subjects continue MPA per SOC, receive bimonthly infusions of belatacept while gradually reducing and then discontinuing tacrolimus:~Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 40-60% of the previous dose Day 21 (~ 3 weeks into study): 20-30% of the previous dose Day 30 (about 1 month): discontinue~MPA: administered according to SOC"
89688492|NCT04355455|Active Comparator|Citalopram|Administration of citalopram to assess the esophageal sensitivity in HV
89633751|NCT02213068|Active Comparator|belatacept + Low-Dose Tac|"Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 10% of the previous dose Day 21 (~ 3 weeks into study): 20% of the previous dose Day 30 (~ 1 month into study): 20% of the previous dose Target trough level ≤ 5 mg per ml of tacrolimus thereafter."
89633752|NCT02213068|Other|Tacrolimus + MPA standard treatment regimen|"Standard of Care treatment regimen:~Tacrolimus: administered orally twice daily (BID) The total initial dose of Tacrolimus is given at 0.1 mg/kg in two divided doses to achieve a stable 12-hour trough level of 8 - 12 ng/mL on Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.~MPA: dosed orally per package insert beginning on the day of transplantation. Methylprednisolone as sodium succinate is administered as 500 mg IV, 250 mg IV, 125 mg IV, on Days 0, 1, and 2 without corticosteroid taper.~MPA dose adjustments for gastrointestinal side effects or leukopenia will be made at the discretion of the investigator."
89633753|NCT00702234||Women/Expectant Mothers - Corifollitropin Alfa 150 µg|In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.
89633754|NCT04483284|Experimental|TACE combined with Camrelizumab|Camrelizumab（200mg q3w ivgtt）combined with TACE,the interval between TACE treatment and Carilizumab is not less than 7 days.
89633755|NCT00235833|Experimental|Adalimumab 40 mg eow|
89633756|NCT03188952|Active Comparator|ICDAS|International Caries Detection and Assessment System : Caries assessment system which is used to assess Any carious lesions then they are rated in codes from 0,1,2,3,4,5,6
89633757|NCT03188952|Experimental|ICCMS|International Caries Classification and Management System Any carious lesions detected are rated in score as the follow:Code 0 = ICDAS 0 Code A = ICDAS 1,2 Code B = ICDAS 3,4 Code C= ICDAS 4,6
89633758|NCT02434380|Active Comparator|Low dose vitamin D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
89633759|NCT02434380|Active Comparator|High dose vitamin D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
89633760|NCT01703819|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
89633761|NCT01703819|Placebo Comparator|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
89633762|NCT01898715|Experimental|ATR-101|ATR-101 will be administered as capsules or tablets by mouth once or twice per day to ascending dose cohorts
89633763|NCT03185598||non-MACE|no MACE occurred
89633764|NCT03185598||MACE|MACE occurred
89633765|NCT02425410||Isis-Virus|T1D patients of the Isis-Diab cohort with genetic data (GWAS) and specific environmental data on viral events during childhood
89633766|NCT00255801|Experimental|Doxil and Targretin® (bexarotene)|Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
89633767|NCT02427048|No Intervention|Pre-Intervention|Delayed feedback and peer comparison
89633768|NCT02427048|Experimental|Feedback with Peer Comparison|Individualized adherence feedback with peer comparison
89633769|NCT01898871|Experimental|Ready to Use Suplementary Food (RUSF)|A daily ration of 40 kcal/kg of body weight during 56 days
89041241|NCT05344300||Bronchiectasis group|
89633770|NCT01898871|Active Comparator|Corn Soya Blend (CSB+)|A daily ration of 40 kcal/kg of body weight during 56 days
89633771|NCT02431416|Active Comparator|Gonadotropin releasing hormone (GnRH)|A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
89633772|NCT02431416|Placebo Comparator|Sodium chloride|A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
89633773|NCT02425332|Experimental|Lokomat assessment|
89633774|NCT01898949|Experimental|Cold Exposure|
89633775|NCT02431338|Experimental|Intervention group|Remote ischemic conditioning through intermittent arm ischemia with four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff performed in the ambulance during transport to primary percutaneous coronary intervention.
89211828|NCT05221593|Experimental|study group|"will receive chemotherapy regimen with Lithium Carbonate in controlled release formula (400mg b.i.d).~In order to avoid the potential for bone marrow stimulation at the time chemotherapy was administered, the administration of lithium was started 24 hours after the administration of chemotherapy and continued for 18 days of every 21.the lithium serum level will be measured at specific times to ensure lithium serum level between 0.4-0.8 mmol\L along the treatment course."
89211829|NCT00844142|Other|1|etanercept 25mg twice weekly
89041242|NCT05340426|Experimental|Porcine Kidney (UKidney) transplant|In this phase I single arm study patients with acute renal failure will be transplanted with a porcine xenograft versus a human allograft-after transplantation the best practice standard of care will be followed for monitoring and immunosuppression with the exception of additional monitoring for potential porcine transmitted infections
89041243|NCT05338619|Experimental|Lazertinib|Lazertinib 240mg, oral, QD
89211830|NCT00844142|Active Comparator|2|Sulfasalazine 2000- 3000mg daily
89211831|NCT00837044|Active Comparator|1|Treximet, cognitive testing
89211832|NCT00837044|Placebo Comparator|2|Placebo, Cognitive testing
89633776|NCT02431338|No Intervention|Control group|Standard treatment with primary percutaneous coronary intervention alone.
89633777|NCT00708084|Experimental|A|CL184 combined with rabies vaccination
89633778|NCT00708084|Active Comparator|B|HRIG combined with rabies vaccination
89633779|NCT01682759|Experimental|Omarigliptin|Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
89633780|NCT01682759|Active Comparator|Glimepiride|Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.
89633781|NCT02426970||Lumbar spine pain inpatients|The study population corresponds to inpatient rehabilitative care for lumbar spine pain in the Departments of Physical Medicine and Functional Rehabilitation at the Nîmes and Montpellier University Hospitals.
89633782|NCT00239733|Experimental|1|Participants will be given anti-D in an outpatient setting. Participants will be observed for any adverse effects for 1 hour postinfusion. Some participants may require additional doses of anti-D later in the study, depending on individual response to the drug; participants may receive 1 to 6 doses of anti-D.
89633783|NCT03185754|Experimental|early phase lung cancer|sublobar resection and lobectomy
89633784|NCT02431182|Experimental|Memory training group|"Memory training:The intervention consists of twelve 90-minutes group sessions given once a week by a specialized psychologist.~The groups are formed by around 15 people. Each session has its own objectives, material and activities. The content of the intervention is based on memory training from different perspectives as cognitive and emotional aspects or social and individual skills."
89633785|NCT02431182|No Intervention|Control group|No intervention will be administred until the delayed post-test is finished
89633786|NCT01682681||Topiramate|
89633787|NCT03183804||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201
89633788|NCT03183804||Standard therapy|Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201
89633789|NCT03182712|Experimental|n-3 PUFA Group|Subjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
89633790|NCT03182712|Placebo Comparator|Placebo Group|Subjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
89633791|NCT01682603|Experimental|Botulinum toxin A|BoNT-A (BOTOX 300U)
89041244|NCT05329610|Experimental|Beta-alanine|Slow-release beta-alanine (Natural Alternatives International, Carlsbad, CA, USA). Dose: 4.8 grams per day for 3-months (potential total intake of 432 g beta-alanine). The daily intake will be split into four doses of 2 x 600 mg. Participants will be instructed to consume each dose alongside their main daily meals (e.g., breakfast, lunch, and dinner) and before bed.
89041245|NCT05329610|Placebo Comparator|Placebo|Taste and appearance-matched placebo (tapioca starch) (Natural Alternatives International, Carlsbad, CA, USA). Doses equivalent to the experimental arm.
89041246|NCT05320380|Experimental|Cohort 1 (IMGN632)|Patients receive IMGN632 IV on days 1 and 22. Treatment repeats every 42 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89041247|NCT05320380|Experimental|Cohort 2 (IMGN632, CPX-351, ITT, fludarabine, cytarabine)|"CYCLE 1: Patients receive IMGN632 IV on days 1 and 22 and CPX-351 IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients with CNS1 also receive ITT consisting of methotrexate IT, hydrocortisone or prednisolone IT, and cytarabine IT on day 0 of cycle 1 (NOTE: Patients who received IT cytarabine or ITT at time of diagnostic LP do not need to repeat ITT on day 0 if given within 7 days of starting protocol therapy). Patients with CNS2 receive ITT QW until the CSF is clear for a maximum of 6 ITT treatments in the absence of disease progression or unacceptable toxicity.~CYCLE 2: Patients receive ITT on day 0, IMGN632 IV on days 1 and 22, fludarabine IV over 30 minutes QD on days 1-5, and cytarabine IV over 1-3 hours QD on days 1-5 in the absence of disease progression or unacceptable toxicity."
89041248|NCT05320380|Active Comparator|Cohort 3, Arm A (CPX-351, fludarabine, cytarabine)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 of cycle 1 in the absence of disease progression or unacceptable toxicity. Patients then receive fludarabine IV over 30 minutes QD on days 1-5 of cycle 2 and cytarabine IV over 1-3 hours QD on days 1-5 of cycle 2 in the absence of disease progression or unacceptable toxicity.
89057510|NCT04532840|Active Comparator|Group A: (control group)|This group includes 30 patients will receive routine medical treatment and routine physical therapy as (Exercising, Positioning and splinting, Pressure Therapy and Massage).
89211833|NCT01013272|Active Comparator|Entecavir|Ongoing entecavir 0.5mg daily
89633792|NCT03183024|Placebo Comparator|placebo|placebo for benralizumab sc given during run-in phase
89633793|NCT03183024|Experimental|benralizumab|benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase
89633794|NCT00240981|Experimental|Treatment|
89633795|NCT00240981|Placebo Comparator|Placebo|
89633796|NCT03182790|Experimental|Group A|Instant Messaging IM + regular messages +AWARD advice + warning leaflet + referral card
89633797|NCT03182790|Experimental|Group B|COSH booklet + general brief advices +Placebo Messages
89633798|NCT02431026|Experimental|Cooling present|"Cooling pack activated before start of MRI scan for the condition cooling present."
89633799|NCT02431026|No Intervention|No cooling present|"Cooling pack will not be activated in the condition no cooling present."
89633800|NCT01682213|Experimental|dabrafenib|This is a single institution phase II trial assessing the efficacy of adjuvant dabrafenib (GSK2118436) in patients with surgically resected AJCC stage IIIC melanoma characterized by a BRAFV600E/K mutation.
89633801|NCT04483128|Sham Comparator|Sham IFC therapy: Control group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).~IFC parameters:~Carrier frequency of 4000 Hz~Amplitude modulated frequency of 65 Hz (AMF)~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~NO intensity (0 mA)~Session duration: 25 minutes"
89633802|NCT04483128|Experimental|IFC therapy: Experimental group|"This group will recieve also instructions for core strengthening exercises and a single session of interferential current (IFC).~IFC parameters:~Carrier frequency of 4000 Hz~Amplitude modulated frequency of 65 Hz (AMF)~Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~Intensity will depend on subjet's tolerance but without generating visible muscle twitches.~Session duration: 25 minutes"
89041249|NCT05320380|Experimental|Cohort 3, Arm B (CPX-351, fludarabine, cytarabine, IMGN632)|Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 of cycle 1 and IMGN632 IV on days 1 and 22 of cycle 1 in the absence of disease progression or unacceptable toxicity. Patients then receive fludarabine IV over 30 minutes QD on days 1-5 of cycle 2, cytarabine IV over 1-3 hours QD on days 1-5 of cycle 2, and IMGN632 IV on days 1 and 22 of cycle 2 in the absence of disease progression or unacceptable toxicity.
89041250|NCT05320146||CORT118335-860 Participants|This group will include patients who participated in CORT118335-860 study and received at least one dose of miricorilant.
89041251|NCT05320146||CORT118335-861 Participants|This group will include patients who participated in CORT118335-861 study and received at least one dose of miricorilant.
89041252|NCT05316389||A Retrospective|A = retrospective cohort including all patients treated at the ICO Angers between January 2017 and September 2021
89041253|NCT05316389||B Prospective|B = prospective including all patients treated at the ICO from February 2022 (2 years of recruitment)
89211834|NCT01013272|Active Comparator|Lamivudine|Switch to lamivudine 100mg daily
89633803|NCT03183336|Experimental|Interpositional block graft|ridge split interpositional block graft
89633804|NCT03183336|Active Comparator|Onlay block graft|decortication onlay block graft
89520721|NCT03432611|Experimental|Complete app|198 women with primary dysmenorrhea who receive an app which includes a self-care information feature and a self-acupressure feature.
89041254|NCT05306886|Experimental|Intervention group|ICB Special Insoles
89041255|NCT05306886|Active Comparator|Control group|ICB Insoles
89041256|NCT05291208|Experimental|Treatment group|This group will receive a cognitive training intervention combined with alternating current electrical stimulation (i.e., treatment).
89041257|NCT05291208|Sham Comparator|Control group|This group will receive a traditional cognitive training intervention with sham electrical stimulation.
89057511|NCT04532840|Experimental|Group B: (Study group)|This group includes 30 patients will receive cryotherapy (at least 10 minutes at -14 degree , 2 sessions per week , for 10 weeks ) in addition to routine medical and physical therapy treatment.
89057512|NCT04538846|Experimental|Culinary Art Therapy Group|Patients with eating disorders that will participate in a weekly session of culinary art therapy group.
89211835|NCT02546024||Treatment responder|Participants who receive standard care and achieve HAM-D score reduction of 50% or more, or score below 8 at Week 12.
89520722|NCT03432611|Active Comparator|Control intervention I|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-care information feature, but not the self-acupressure feature.
89520723|NCT03432611|Active Comparator|Control intervention II|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-acupressure feature, but not the self-care information feature.
89520724|NCT01331187|Active Comparator|Usual care|Usual care diagnostics. No routinely ultrasound examination
89520725|NCT01331187|Experimental|Routinely ulasonography|Patients will routinely be examined with ultrasound at admittance in addition to usual care diagnostics
89520726|NCT01081197||Out-day patients' clinic|Alcohol abusers referred to out-day patients' clinic which consent to participate in the study
89520727|NCT01081197||Control|Control group for the cardiac arm of the study will be matched controls from the Nord-Trøndelag Health Study (HUNT)
89520728|NCT00845013||HIV Infection|HIV-infected individuals with the clinical diagnosis of pulmonary hypertension or HIV-infected individuals who have mildly elevated pulmonary arterial pressures
89520729|NCT00829803|Experimental|SNAP Monitor EEG signals|
89520730|NCT00829803|Active Comparator|BIS Monitor EEG signals (VISTA)|
89520731|NCT05118321|Other|Refinement and Feasibility Trial|"It is intra - individual comparison study~Arm 1: participant wore the custom-made upper limb exosuit and hand exoskeleton to perform the series of tasks Arm 0: participant perform the same tasks without the custom-made upper limb exosuit and hand exoskeleton."
89520732|NCT05018013|Active Comparator|Duloxetine group|The eligible subjects will receive duloxetine hydrochloride enteric-coated capsules plus placebo to Ammoxetine.
89520733|NCT05018013|Placebo Comparator|Placebo group|The eligible subjects will receive placebo to Ammoxetine and placebo to Duloxetine.
89520734|NCT05018013|Experimental|Ammoxetine group-cohort 1|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
89520735|NCT05018013|Experimental|Ammoxetine group-cohort 2|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
89520736|NCT05018013|Experimental|Ammoxetine group-cohort 3|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
89520737|NCT05018013|Experimental|Ammoxetine group-cohort 4|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo to Duloxetine.
89520738|NCT05118165|No Intervention|control group|
89520739|NCT05118165|Experimental|intervention group|
89520740|NCT03432221||MDD|Patients who met DSM-5 criteria for MDD attending the outpatient psychiatric service of the Hospital Universitari Parc Taulí. Patients must have a lack of response to SSRI (Maximize dose for adequate time), being the next therapeutic option the introduction of desvenlafaxine.
89520741|NCT03432221||Healthy Controls|Healthy participants matched by age, gender and educational level without history of psychiatric disorders and no familial history of mood disorders will be recruited
89520742|NCT04364529|Experimental|Intervention (pit crew model group)|13 groups being taught the pit crew model
89520743|NCT04364529|No Intervention|control (traditional ALS education)|13 groups being taught along traditional ALS education
89520744|NCT04375397|Experimental|Ibrutinib 420 mg + SOC|420 mg ibrutinib administered once daily as three hard gelatin capsules (140 mg each) with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC)
89520745|NCT04375397|Placebo Comparator|Placebo + SOC|Three hard gelatin placebo capsules administered once daily with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC)
89520746|NCT05112471|Experimental|Guided Biofilm Therapy|Airflow with erythritol powder to remove supra and sub gingival biofilm and plaque, perioflow with erythritol powder at deep pathological pockets (PPD > 4mm) and ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus.
89520747|NCT05112471|Active Comparator|Scaling and Root Planning - Ultrasonic Debridement|Ultrasonic debridement with an ultrasonic scaler for remove supra and sub gingival calculus, manual debridement with curettes at deep pathological pockets (PPD > 4mm) and rubber cup with polishing to remove supra gingival biofilm and plaque.
89520748|NCT05112393||Development Cohort|Half of the data will be randomized into development cohort by using a random number generated in Microsoft Excel. This cohort aim to develop a new estimating Glomerular Filtration Rate (eGFR) equation that produce accurate eGFR specifically in Malaysian multiracial population.
89633805|NCT02430792|Active Comparator|Football|Recreational football 1-hour twice weekly in a local football club on a disease specific team
89633806|NCT02430792|No Intervention|Control|A 15-30-minute guidance session upon group allocation to encourage engagement in the standard rehabilitation offered by the municipality
89633807|NCT02126553|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89520749|NCT05112393||Validation Cohort|Half of the data will be randomized into development cohort by using a random number generated in Microsoft Excel. This cohort aim to validate the newly developed estimating Glomerular Filtration Rate (eGFR) equation.
89041258|NCT05288218|Experimental|Leak-free bronchoscope adapter|"The mechanical ventilation circuit used in patients with respiratory failure is considered a closed-loop circuit between the patient and the ventilator. This allows air to flow from the ventilator to the patient and back to the circuit without escaping to the ambient environment. To perform bronchoscopy, a standard adapter is spliced into the ventilator circuit, which allows the bronchoscope to enter the ventilation circuit granting access to the patient's airways. This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. The intervention is considered the leak-free bronchoscope adapter."
89041259|NCT05288218|Active Comparator|Standard bronchoscope adapter|The mechanical ventilation circuit used in patients with respiratory failure is considered a closed-loop circuit between the patient and the ventilator. This allows air to flow from the ventilator to the patient and back to the circuit without escaping to the ambient environment. To perform bronchoscopy, a standard adapter is spliced into the ventilator circuit, which allows the bronchoscope to enter the ventilation circuit granting access to the patient's airways. This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. This arm utilizes the standard adapter.
89520750|NCT05117697|Experimental|main group|Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.
89520751|NCT05117697|Experimental|control group|In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy.
89520752|NCT03128333|Experimental|RunKeeper app + physiotherapy coaching|Group A will use the RunKeeper app for half a year to self-monitor leisure-time PA. Besides, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is all explained in a brief user's manual. In addition, patients will be educated about the health risks of a sedentary lifestyle, inactivity and (when applicable) other unhealthy lifestyle behaviors (e.g. unhealthy diet, overweight or obesity, sun exposure, alcohol intake). Benefits of a behavior change, becoming physically active and pursuing a healthy lifestyle will be explained by a trained physiotherapist who will also coach the patient during the PA program.
89520753|NCT03128333|Other|usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
89520754|NCT03436589|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
89520755|NCT03436589|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
89520756|NCT02387216|Experimental|Arm A: Experimental Arm|MM-121 in combination with Docetaxel
89520757|NCT02387216|Active Comparator|Arm B: Comparator Arm|Docetaxel alone
89520758|NCT03436511||Subjects with COPD|Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.
89520759|NCT03128489|Experimental|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 6, 10 and 14 weeks of age.
89520760|NCT03431909|Experimental|Kallikrein group|Subjects receive kailikang treatment according to real clinical practice (suggest above 14 days treatment),0.15 peptide nucleic acids(PNA), once a day.
89520761|NCT03431909|Sham Comparator|Control group|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
89520762|NCT03436355|Experimental|Physical activity|60 minutes of daily physical activity (see intervention)
89520763|NCT03436277|Placebo Comparator|Placebo|Sucralose 1,5 g
89520764|NCT03436277|Experimental|L-Carnitine|L- Carnitine 1,5 g
89520765|NCT03941717|Experimental|Mindfulness-Based Condition|Parents and children in the mindfulness intervention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of a mindfulness activity. There is a parent and child version of the mindfulness intervention. Both scripts were developed by Siegel and Bryson (2011), and include a parent and child version of a mindfulness activity targeting worries and anxiety. Adjustments to the child script were informed by the work of Petter and colleagues (2013). Adjustments to the parent script were informed by the work of Garland and colleagues (2015). This activity will last 5-minutes.
89041260|NCT05285865|Active Comparator|Conventional Treatment|Thrice a day ,Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
89041261|NCT05285865|Experimental|Scapular Mobilization|Thrice a day Scapular mobilization (SM) along with Conventional treatment
89041262|NCT05254951|Experimental|Patients enrolled in the protocol|Patients will receive a tidal volume challenge to assess fluid responsiveness and then a volume expansion bolus to classify them into responders and not responders
89633808|NCT02425020|Experimental|Meat protein|Post workout (training days) or breakfast (non training days) 20g of meat protein mixed with 250ml of orange juice and water
89633809|NCT02425020|Experimental|Whey Protein|Post workout (training days) or breakfast (non training days) 20g of whey protein isolate mixed with 250ml of orange juice and water
89633810|NCT02425020|Active Comparator|Carbohydrate|Post workout (training days) or breakfast (non training days) maltodextrin mixed with 250ml orange juice and water
89633811|NCT01703741|Experimental|Testosterone gel (FE 999093)|Subjects received testosterone gel with initial dose as fixed on Day 56 (23 mg, 46 mg or 69 mg) during the 000023 study. The dose could further be down titrated based on serum testosterone levels at Day 90/91 of 000023 study. Testosterone gel was applied daily in morning using an applicator, to the shoulder/upper arm in a contralateral fashion for 6 months.
89633812|NCT02430948|Active Comparator|Standard Support Outreach|Providers receive standard written screening recommendations and do not receive academic detailing (educational outreach)
89633813|NCT02430948|Experimental|Standard materials and academic detailing|Providers receive standard written screening recommendations and receive academic detailing (educational outreach)
89211836|NCT02546024||Treatment non-responder|Participants who receive standard care but have HAM-D score reduction less than 50% at Week 12.
89211837|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 1|formulation 1
89211838|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 2|formulation 2
89211839|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 3|formulation 3
89633814|NCT02430948|Experimental|Color-coded materials and no academic detailing|Providers receive color-coded written screening recommendations and do not receive academic detailing (educational outreach)
89633815|NCT02430948|Experimental|Color-coded materials and academic detailing|Providers receive color-coded written screening recommendations and receive academic detailing (educational outreach)
89041263|NCT05230888||Cohort|The effect of immunotherapy treatment will be assessed using the comprehensive geriatric assessment (CGA) and vulnerable elders survey (VES-13) in 100 non-small cell lung cancer patients, aged ≥70 years old, receiving immune checkpoint inhibitor (ICI) treatment.
89041264|NCT05191355||subjects with familial hypercholesterolemia|blood test
89041265|NCT05191355||healthy subjects|blood test
89633816|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 50U|"Drug dilution and dosage:~Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline.~Prepare in 1 ml syringe to get 50U/ml :0.1 ml drawn from the mother solution and add 0.9 ml of 0,9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 50U are divided equally into 4 salivary glands, 12.5U each gland"
89633817|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 100U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 100U/ml :0.2 ml drawn from the mother solution and add 0.8 ml of 0.9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 100U are divided equally into 4 salivary glands, 25U each gland"
89041266|NCT05177393||Participants with Esophageal Cancer|Participants with esophageal cancer will be administered questionnaires, and medical charts will be accessed to collect study related data.
89041267|NCT05159739||Total Joint Arthroplasty (TJA)|Recruitment of families with an increased incidence of TJI with PJI.
89041268|NCT05154656||patients with early stage of liver fibrosis|
89041269|NCT05154656||subjects with no liver fibrosis|
89041270|NCT05134649|Experimental|BOTOX|BOTOX will be injected into the platysma muscle for up to 3 administrations.
89041271|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
89041272|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
89041273|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
89211840|NCT01010698|Active Comparator|cimetidine (or acyclovir) reference|reference product
89211841|NCT00851162|Experimental|Trinity|Trinity multipotent stem cells
89211842|NCT00851162|Active Comparator|Demineralized bone matrix|Demineralized bone matrix
89211843|NCT03541486|Experimental|Investigational Therapy (ASC)|75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
89211844|NCT03541486|Active Comparator|Standard Therapy (ChemoRT)|600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
89211845|NCT00851240|Experimental|BTT1023|
89211846|NCT00851240|Placebo Comparator|Placebo|
89211847|NCT00620750|Experimental|Extended release injectable naltrexone|
89211848|NCT04884243|Placebo Comparator|CBT-006|
89211849|NCT04884243|Experimental|2.5% CBT-006|
89211850|NCT04884243|Experimental|10% CBT-006|
89211851|NCT00851396||Obese female adolescents|Obese adolescents will be screened for vitamin D deficiency through an existing study. Those found to be vitamin D deficient will be given standard treatment of vitamin D deficiency. In this study, patients who self report that they had taken the treatment for vitamin D will be screened for serum 25 OH D level and will undergo OGTT. The OGTT results as well as insulin resistance indices will be compared to their initial values.
89211852|NCT02547896|Experimental|Pain control using codeine + diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of codeine + 50mg of diclofenac
89211853|NCT02547896|Experimental|Pain control using diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of diclofenac
89041274|NCT05124275|Placebo Comparator|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
89633818|NCT02425176|Active Comparator|Botulinum toxina A (BoNT-A) 200U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum ToxinA Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 200U/ml :0.4 ml is drawn from the mother solution and 0.6ml of 0.9% saline is added. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 200U are divided equally into 4 salivary glands, 50U each gland"
89633819|NCT02430714||Arm 1|A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.
89633820|NCT02425254|Experimental|Preemptive paracetamol|1000mg intravenous paracetamol given ≥15 minutes before surgical incision and intravenous saline 15 minutes before the end of surgery
89633821|NCT02425254|Active Comparator|Postincision paracetamol|Intravenous saline ≥15 minutes before surgical incision and 1000mg intravenous paracetamol given 15 minutes before the end of surgery
89041275|NCT05113953|Experimental|Centanafadine 400 mg|Participants received centanafadine 200 mg SR tablets, orally, twice daily (BID) at a TDD of 400 mg for 8 weeks.
89041276|NCT05113953|Experimental|Centanafadine 200 mg|Participants received centanafadine 100 mg SR tablets, orally, BID at a TDD of 200 mg along with centanafadine matching placebo tablets, orally, BID for 8 weeks.
89633822|NCT02424942|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
89633823|NCT02424942|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
89633824|NCT02426736|Active Comparator|Low dose intravenous dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
89633825|NCT02426736|Active Comparator|High dose intravenous dexamethasone|8 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
89633826|NCT02426736|Active Comparator|Low dose perineurial dexamethasone|4 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
89633827|NCT02426736|Active Comparator|High dose perineurial dexamethasone|8 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
89633828|NCT03182634|Experimental|Cohort A - Extended-dose fulvestrant|Fulvestrant 500mg IM on Cycle 1 Days 1, 8 and 15 and Cycle 2 onwards Days 1 and 15
89633829|NCT03182634|Experimental|Cohort B - Neratinib|Neratinib 240mg PO on a continuous schedule starting on Cycle 1 Day 1 AND in ER positive breast cancer, fulvestrant 500mg IM on Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
89633830|NCT03182634|Experimental|Cohort C - AZD5363 and fulvestrant|AZD5363 400mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment AND fulvestrant 500mg IM Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
89633831|NCT03182634|Experimental|Cohort D - AZD5363|AZD5363 480mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment
89041277|NCT05113953|Placebo Comparator|Placebo|Participants received centanafadine matching placebo tablets, orally, BID for 8 weeks.
89041278|NCT05093972|Experimental|Panel A: Mild HI|Participants with mild HI receive a single oral dose of ulonivirine 400 mg on Day 1.
89041279|NCT05093972|Experimental|Panel B: Moderate HI|Participants with moderate HI receive a single oral dose of ulonivirine 400 mg on Day 1.
89041280|NCT05093972|Active Comparator|Panel C: Healthy Controls|Healthy matched control participants receive a single oral dose of ulonivirine 400 mg on Day 1.
89041281|NCT05072301|Experimental|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
89041282|NCT05072301|Placebo Comparator|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
89041283|NCT05055778|Experimental|SmokfreeTXT|Research version of the publicly available SmokefreeTXT program
89633832|NCT03182634|Experimental|Cohort E - olaparib and AZD6738|AZD6738 160mg to be administered once daily on Days 1-7 of each cycle and olaparib 300mg to be administered twice daily on a continuous schedule starting on Cycle 1 Day 1.
89041284|NCT05054400|Other|F18 Fluciclovine|"radioactive imaging agent help researchers better see how the disease is responding to laser interstitial thermal therapy (LITT)"
89041285|NCT05033054||Group 1|Group 1: take prescribed SGLT2i after baseline visit.
89041286|NCT05017818||Treated and untreated subjects with TK2 deficiency|Two TK2 deficiency groups. (1) Subjects treated with chemical-grade dCMP/dTMP, dC/dT, and/or MT1621 outside of a Modis sponsored study. (2) Subjects not treated with chemical-grade dCMP/dTMP, dC/dT, and/or MT1621 outside of a Modis sponsored study.
89041287|NCT05009927|Experimental|Imatinib interruption|Immediate interruption of imatinib until progressive disease. In case of 1st relapse, imatinib will be reintroduced at 400mg/d and further increased at 800mg/d in case of 2nd relapse after re-introduction.
89041288|NCT05009927|No Intervention|Imatinib maintenancce|Maintenance of imatinib at the last dose routinely taken by the patient in the 10-year period prior to randomization (either 300 or 400 mg once daily). In case of progressive disease imatinib will be increased up to 800mg/day.
89041289|NCT05005442|Experimental|Pembrolizumab/vibostolimab coformulation|Participants will receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years.
89041290|NCT05002322|Experimental|intervention health facilities|Health facilities implement the optimization of the cascade under research team support and continuous supervision.
89633833|NCT03185676|Experimental|Billberry|A bilberry-based probiotic beverage
89633834|NCT03185676|Active Comparator|Control|A control beverage without bilberries or probiotics
89633835|NCT03182556|Placebo Comparator|Stretching|Stretching sessions was held twice a week in the University of Almería facilities, lasting approximately one hour and they included different muscle areas exercises as well as stretching across the board.
89633836|NCT03182556|Experimental|Aquatic Exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
89633837|NCT03182556|Experimental|Electromyography-Biofeedback training|The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
89633838|NCT03182478|Active Comparator|Individual Treatment|Intervention with the Rothbaum Protocol in individual format, with eight weekly sessions each one of 45 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
89633839|NCT03182478|Active Comparator|Group Treatment|Intervention with the Rothbaum Protocol in group format up to 10 patients, with eight weekly sessions each one of 90 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
89633840|NCT03183258|Experimental|Sentinel Skin Flap|
89633841|NCT02426424|Experimental|Investigatory 1|The sleep study will be performed via Watchpat during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge for three months.
89633842|NCT02426424|Experimental|Investigatory 2|The sleep study will be performed via Watchpat at home three months after hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP for three months.
89633843|NCT01681511|Experimental|ICET™ TIC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
89633844|NCT01681511|Active Comparator|BARD® LUBRI-SIL® IC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
89633845|NCT02426190|Active Comparator|Arm 1|Patients in Arm 1 receive standard of care rehabilitation protocol using a recumbent or Nu-step bike during warm-up, followed by individualized therapeutic exercise, and cool-down protocols. The warm-up phase in the study refers to therapeutic exercise. The therapeutic exercise aims to condition and prepare patients for subsequent functional or therapeutic activities. The active comparator (Arm 1) is to ask participants to use modalities, such as a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
89633846|NCT02426190|Experimental|Arm 2|Patients in Arm 2 will use an anti-gravity treadmill (AlterG) during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
89633847|NCT02426190|Experimental|Arm 3|Patients in Arm 3 will use a recumbent or Nu-step bike along with the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
89041291|NCT05002322|No Intervention|Control|Health facilities prior to intensive phase receive standard supervision without research team support
89041292|NCT04994301||Patient with Cystic Fibrosis|Patients (male, female) age 5-11 with confirmed diagnosis of Cystic Fibrosis. These patients will begin clinically prescribed FDA-approved Trikafta therapy.
89041293|NCT04989569|No Intervention|control|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the control group will not be given to the dietitians for adjusting the diet formula according to the patient's body composition.
89041294|NCT04989569|Experimental|nutritional intervention|The investigators will use the random number generator to divide the patients into two groups, the control group (with no nutritional intervention) and the intervention group (with nutritional intervention). The body composition data (of day 1, 3, 8) of the patients in the intervention group will be given to the dietitians for adjusting the diet formula according to the patient's body composition.
89041295|NCT04956224|Experimental|VLA2001|
89041296|NCT04953910|Experimental|Group B: Moderate hepatic impairment|Cancer participants with moderate hepatic impairment [total bilirubin > 1.5x - 3x upper limit of normal (ULN); any aspartate aminotransferase (AST) level]
89041297|NCT04953910|Experimental|Group C: Severe hepatic impairment|Cancer participants with severe hepatic impairment (> 3x ULN; any AST level)
89041298|NCT04953910|Active Comparator|Group A: Normal hepatic function|Cancer participants with normal hepatic function (total bilirubin ≤ ULN; AST ≤ ULN)
89041299|NCT04925570|Experimental|W-SUDs|Woebot (W-SUDs), a Conversational Agent (CA) instantaneously available 24 hours per day, 7 days per week, 'checks in' with users. Using conversational tones, it encourages mood tracking and delivers general psychoeducation as well as tailored empathy, cognitive behavior therapy (CBT)-based behavior change tools, and behavioral pattern insight. Woebot's app-based platform and user-centered design philosophy makes it an optimal modality for Substance Use Disorders (SUD) treatment delivery. It offers immediate, evidence-based tailored support in the patient's peak moment of craving.
89041300|NCT04925570|Other|Digitally-delivered Psychoeducation|"Psychoeducation delivers weekly fact sheets that include information on:~Alcohol-specific topics;~Drug-specific topics;~General addiction topics;~Statistics relating to alcohol and substance use."
89041301|NCT04915157|Other|Group A: High Density stimulation - No Stimulation|Patients in this group will receive high density stimulation (parasthesia free form of stimulation) during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive no stimulation during the final 6 months of the study period.
89041302|NCT04915157|Other|Group B: No Stimulation - High Density Stimulation|Patients in this group will receive no stimulation during the first 6 months of the study period. After 6 months cross-over will take place and patients will receive high density stimulation (parasthesia free form of stimulation) during the final 6 months of the study period.
89041303|NCT04915027|Experimental|Intervention i.e. with Rehabkompassen®|The participants will use the digital graphic Rehabkompassen® at follow-up.
89041304|NCT04915027|Active Comparator|Control exposure i.e. without Rehabkompassen®|"The participants will use Post-Stroke Checklist at follow-up as recommended by Socialstyrelsen."
89041305|NCT04902261|Experimental|Tislelizumab combined with Nab-paclitaxel and Gemcitabine|
89041306|NCT04902261|Active Comparator|Nab-paclitaxel and Gemcitabine|
89041307|NCT04884100|Other|PPG recording|arrhythmia recording using PPG monitor
89633848|NCT02426190|Experimental|Arm 4|Patients in Arm 4 will use both an anti-gravity treadmill (AlterG) and the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
89633849|NCT03117270|Experimental|oral filgotinib tablets|
89633850|NCT03117270|Placebo Comparator|placebo tablets|
89633851|NCT03117504||First trimester|women during first trimester(less than 14 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
89633852|NCT03117504||Third trimester|women during third trimester(more than 28 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
89633853|NCT03182322|Experimental|intranasal insulin|rH-insulin formulation and for a dose of 440 IU insulin to the nasal mucosa. Treatment will be administered daily for the first 7 intervention days, and one day per week thereafter for 6 months.
89633854|NCT03182322|Placebo Comparator|intranasal placebo|Treatment with placebo nasal spray daily for the first 7 intervention days and one day per week thereafter for 6 months.
89633855|NCT03185364|Experimental|Interventional group|Sildenafil Citrate, 20mg, tid for 12 weeks
89633856|NCT03185364|Placebo Comparator|Control group|placebo oral tablet, 12 weeks
89041308|NCT04868357|Experimental|Hypnosis|Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group hypnosis. It includes 1 hypnotic induction, multiple suggestions of relaxation and a feeling of air entering the lungs, and a closing exercise. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness. This arm is structured following the classic format of didactic hypnosis interventions, were patients discover the exercise by doing it, and receive keys to be able to recreate the hypnotic state on their own.
89041309|NCT04868357|Active Comparator|Relaxation|"Delivered twice during the 4-week PRP program (weeks 1,3). It consists of 45-minute sessions of group dynamic relaxation. It includes 1 exercise to liberate tension, 3 exercises to increase proprioception and calmness, and 3 exercises for calming and regulating the breath. The intervention includes a prescription to use these exercises freely throughout the PRP, as a tool for self-managing discomfort and inducing calmness.~Provides additional care that motivates the patients to participate in the control group.~Allows the controlling of number of group interventions accross arms (2).~Allows to control for motivation, as both arms are introduced identically: the benefits and interest of using self-relaxation techniques for complementary care in anxiety and anxiety-related dyspnea are underscored.~It allows the disentanglement of hypnosis and relaxation effects . This was crucial, inasmuch as hypnosis too includes physical relaxation and breathing exercises."
89633857|NCT02424864|Other|4D PET-CT|Other intervention: 4D PET-CT
89633858|NCT02424786|Other|Intervention group|"Medication lists from the patients randomized in the intervention group will be evaluated by the research physician with the help of STOPP/START criteria.~Feedback of this screening will be given to the team responsible for patient treatment."
89633859|NCT02424786|No Intervention|Control|Patients in this arm will receive standard pharmacological treatment
89633860|NCT02424552|Experimental|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
89633861|NCT02424552|Placebo Comparator|Placebo|Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks
89041310|NCT04847635|Experimental|Subthreshold laser group|To evaluate the efficacy of Subthreshold laser in the treatment of reticular pseudodrusen.
89041311|NCT04847635|Sham Comparator|Sham group|The light from the retinal illumination system on the laser device will be used instead of the laser beam in all follow-up evaluations.
89041312|NCT04842786|Experimental|Coconut oil at 5 mg/Kg body weight twice daily|Coconut oil (Parachute Brand) is a marketed product that is routinely used for daily massage after birth for infants in India. An amount of 5 mg/Kg body weight will be applied twice daily by the health care provider from enrollment until discharge, or until day of life 28, whichever occurs first.
89041313|NCT04842786|No Intervention|No intervention|Subjects assigned to this arm will have their skin gently stroked twice daily for the time that would be required to apply an oil. This will simulate the stroking received by the intervention arm subjects. This will occur from enrollment until discharge, or until day of life 28, whichever occurs first.
89041314|NCT04841434|Experimental|Dose escalation|Patients will receive up to 6 cycles of HD-MTX Treatment Dose escalation will be performed using three dose levels of MTX: 3.0 g/m2, 3.5 g/m2, 4.0 g/m2
89041315|NCT04838301|Experimental|Allo group|Allopregnanolone 4mg IV 30-minute infusion once per week for 12 months.
89041316|NCT04838301|Placebo Comparator|Control group|Placebo (normal saline) IV 30-minute infusion once per week for 12 months.
89041317|NCT04817189|Experimental|NEPA (300mg netupitant/0.5mg palonosetron) + Dexamethasone 8 mg|"Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Dexamethasone (8 mg) will be administered on Day 1 of each cycle."
89041318|NCT04817189|Active Comparator|Standard of care + Dexamethasone 8 mg|"Dexamethasone (or equivalent corticosteroids) 8 mg administered by the oral route (or equivalent IV dose) on Day 1, approximately 1 hour before chemotherapy and one of the 5-HT3-RAs recommended by European Society for Medical Oncology (ESMO) and Multinational Association of Supportive Care in Cancer (MASCC) guidelines (standard of care), i.e. either:~Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)"
89057513|NCT04538846|No Intervention|No Culinary Art Therapy Intervention|Patients with eating disorders that are not scheduled to come to the outpatients ward on the day of intervention.
89057514|NCT01683435|Experimental|hylauronin binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
89057515|NCT04532684|Active Comparator|Duloxetine|33 patients received 60 mg/day of duloxetine HCL orally for 12 weeks
89633862|NCT02424708|Placebo Comparator|Placebo|The study medication is packaged in sterile 1 ml pre-filled syringes, containing saline, which will be delivered intranasally.
89633863|NCT02424708|Active Comparator|Reduced Glutathione 100mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 100 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
89633864|NCT02424708|Active Comparator|Reduced Glutathione 200mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 200 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
89633865|NCT03182088|Experimental|0.025 mcg /Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.05 mcg/Kg/min) equivalent to norepinephrine infusion (0.025 mcg/Kg/min).
89633866|NCT03182088|Experimental|0.050 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.1 mcg/Kg/min) equivalent to norepinephrine infusion (0.050 mcg/Kg/min).
89633867|NCT03182088|Experimental|0.075 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.15 mcg/Kg/min) equivalent to norepinephrine infusion (0.075 mcg/Kg/min)
89633868|NCT02426346|Active Comparator|JOIN FOR ME|The JOIN for ME curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are scheduled for 60 minutes and are facilitated by a YMCA coach. Interventions include behavioral weight control and parent-based incentives. Parents attend group at weeks 1, 2 and 16 with their teen.
89633869|NCT02426346|Experimental|TEEN JOIN|Similar to the JOIN FOR ME condition, adolescents in the TEEN JOIN condition attend 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Interventions include behavioral weight control, group-based physical activity, and group-based incentives. Parents attend separate meetings at weeks 1, 2, and 16.
89041319|NCT04811703|Experimental|Combined PIPAC / IV chemotherapy treatment|Patients will undergo 3 cycles of combined chemotherapy, consisting of PIPAC (cisplatin-doxorubicin, escalating doses) and systemic chemotherapy (paclitaxel-carboplatine, standard doses). First patient will be treated at the lowest dose: doxorubicin 2.1 mg/m² and cisplatin 10.5 mg/m². Subsequent patients will be treated at the dose recommended by the CRM algorithm in the absence of dose-limiting toxicity. A total of 11 dose levels with a factor between 1 and 3 are considered. The maximum dose considered will be doxorubicin, 6.3 mg/m² and cisplatin, 31.5 mg/m². The doses of intravenous chemotherapy will be defined in a standard way, according to the habits of the investigating clinicians and in accordance with the doses received previously. Each cycle will last 28 days and will begin at day 1 with PIPAC procedure and will be completed at day 8 with systemic chemotherapy. Combined chemotherapy will be repeated every 4 weeks for up to 3 cycles in the absence of unacceptable toxicity.
89633870|NCT02425878|Experimental|Experimental|Ulipristal Acetate 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
89633871|NCT02425878|Placebo Comparator|Control|Placebo, 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
89041320|NCT04805645||Non-Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit which died before or on day 28 post ICU admission
89041321|NCT04805645||Survivors|Participants who had Critically-ill COVID-19 and admitted to the Intensive Care Unit whom are still alive on day 28 post ICU admission
89041322|NCT04755361|Experimental|Housing Outreach Project - Collaboration (HOP-C) + Treatment as Usual|The treatment condition is HOP-C plus treatment as usual (TAU).
89041323|NCT04755361|No Intervention|Treatment As Usual|TAU for this population reflects the standard array of services accessed by transitional youth populations. Most will have some contact with a youth worker with ranging focus and intensity (none likely to receive case management at HOP-C intensity), and very few will have any routine contact with other professionals or peer support. They may have some sporadic access to skills development programs and primary healthcare providers with mental health and addictions needs addressed primarily through emergency services at times of crisis.
89041324|NCT04743479||New Onset Diabetes|"New Onset Diabetes must meet one of the following criteria:~Documented diabetes diagnosed within the past 3 years.~Definite new-onset diabetes based on recent fasting blood glucose (FBG) values ≥126 mg/dl (7.0 mmol/L) or Hemoglobin A1c (HbA1c) ≥ 6.5%. All glycemic parameters must be measured in an outpatient setting."
89041325|NCT04743479||Familial pancreatic cancer|"Familial pancreatic cancer must meet one of the following criteria:~≥ 2 blood relatives with pancreatic cancer (includes 1st-3rd degree relatives)~One 1st degree relative with PDAC diagnosed before age 60"
89041326|NCT04743479||Inherited syndromes associated with pancreatic cancer|"Family history includes with inherited syndromes associated with pancreatic cancer ( ≥ 2 blood relative, includes 1st-3rd degree relatives).~Inherited syndromes must meet one of the following criteria:~Hereditary pancreatitis~Familial atypical multiple mole and melanoma syndrome~Hereditary nonpolyposis colon cancer~Peutz-Jeghers syndrome~Hereditary breast and ovarian cancer syndromes"
89041327|NCT04743479||Pancreatic Cystic Neoplasm|Pancreatic Cystic Neoplasm, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), which are defined by endoscopic ultrasound or serial imaging.
89041328|NCT04743479||Chronic pancreatitis|Chronic pancreatitis, defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist.
89041329|NCT04735575|Experimental|EMB-06|"In Phase I part: participants enrolled at different time will receive EMB-06 by IV infusion at different ascending dose levels.~In Phase II part: participants will receive EMB-06 by IV infusion at previously defined RP2D."
89041330|NCT04725916|Active Comparator|Study Arm 1|Subjects assigned to Arm 1 will be instructed to shower daily beginning on post-operative Day 2 and maintain this daily schedule until the subject's 3-month standard of care clinic follow-up visit. They will receive specific instructions on caring for the incision site and drains until they are removed.
89633872|NCT02146144|No Intervention|no peeling|where the ILM peeling will not be made
89633873|NCT02146144|Active Comparator|active peeling|where the ILM peeling will be made
89633874|NCT02425722|Experimental|ASP0456 0.0625mg|oral
89633875|NCT02425722|Experimental|ASP0456 0.125mg|oral
89633876|NCT02425722|Experimental|ASP0456 0.25mg|oral
89633877|NCT02425722|Experimental|ASP0456 0.5mg|oral
89633878|NCT02425722|Placebo Comparator|Placebo group|oral
89633879|NCT02070328||Radiation therapy Registry|Cancer patients who have received proton therapy
89633880|NCT03185286|Experimental|3D-printed personalized metal implant|3D-printed personalized metal implant will be used in bone defect surgeries.
89633881|NCT02061514|Experimental|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
89633882|NCT02061514|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
89633883|NCT02425800||Ancillary-Correlative (human prostate tissue model)|Tissue samples are collected from patients with benign prostatic hyperplasia for decellularization and preparation as human extracellular matrix for growing human prostate CSCs. Tissue samples are also collected from patients with prostate cancer for the analysis of TROP2+ cells by flow cytometry. Cytology Specimen Collection Procedure. Laboratory Biomarker Analysis.
89041331|NCT04725916|Active Comparator|Study Arm 2|Subjects assigned to Arm 2 will be instructed not to shower post-operatively until their surgical drains are removed. They will receive specific instructions on bathing and caring for the incision sites and drains.
89041332|NCT04724837|Experimental|Zibotentan Dose A + Dapagliflozin|Participants will receive once daily oral dose A of zibotentan and 10 mg dapagliflozin for 12 weeks.
89633884|NCT02430636|Experimental|IRE Group|irreversible electroporation for Unresectable Stomach Neoplasms
89633885|NCT02430636|No Intervention|Control|The patients without treatment
89041333|NCT04724837|Experimental|Zibotentan Dose B + Dapagliflozin|Participants will receive once daily oral dose B of zibotentan and 10 mg dapagliflozin for 12 weeks.
89041334|NCT04724837|Experimental|Placebo + Dapagliflozin|Participants will receive once daily oral dose of dapagliflozin 10 mg and placebo for 12 weeks.
89633886|NCT03183492|Experimental|HAV Group|Subjects who were vaccinated under UMV with 2 doses of Havrix® Junior at infancy and will receive a single challenge dose of Havrix Adult at Visit 1 (Day 1).
89633887|NCT03183414||cardiac surgery patients|cardiac surgery patients with a significant peroperative aortic valve stenosis (gradient>40mmHg and/or aortic valve area <1cm2). During cardiac surgery measurements of right ventricular dysfunction were taken by echocardiography
89041335|NCT04714047|Experimental|Group 1:|PRT
89041336|NCT04714047|Experimental|Group 2:|PRT + Booster sessions
89041337|NCT04714047|Active Comparator|Group 3:|NEMEX
89041338|NCT04714047|Experimental|Group 4:|NEMEX + Booster sessions
89041339|NCT04694794|Experimental|Interventional|Single arm, interventional. All participants will be administered Educational Brochure to educate them regarding management of side effects experienced during chemotherapy treatment
89041340|NCT04690816||Healthy Volunteers|Healthy Volunteers to have a comparative group,without an underlying autoimmune disease or other significant medical problems
89041341|NCT04690816||Systemic Autoimmune Diseases|Patients with associated systemic autoimmune diseases.
89633888|NCT03182010|Experimental|Cesarean section incision closure using barbed sutures|Cesarean section incision is closed using barbed sutures
89633889|NCT03182010|Active Comparator|Cesarean section incision closure using conventional sutures|Cesarean section incision is closed using conventional sutures
89633890|NCT03181854|Experimental|Intervention group|Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3 months and once in 2 weeks for another 3 months.
89633891|NCT03181854|No Intervention|Control Group|Usual palliative care can be provided if desired.
89633892|NCT02430402|Experimental|Climate therapy|Climate therapy consisting of 3 week stay at rehabilitation facility in Spain
89633893|NCT02430402|No Intervention|Usual care|Usual care provided as needed / agreed between patient and health care providers
89633894|NCT02424318|Experimental|Topiramate|topiramate 25mg twice for 1 week -> topiramate 50mg twice for 7 weeks
89041342|NCT04603001|Experimental|Dose Escalation Arm A (Monotherapy)|Patients not requiring a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
89633895|NCT03179280|Active Comparator|Adolescents with T1D on CSII|3 standard meals with varying composition were consumed and combined with alternative types of D/WB and S/WB All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
89633896|NCT03179280|No Intervention|Healthy adolescents|3 standard meals with varying composition were consumed
89633897|NCT02424396|Experimental|1 : IL2|Interleukin-2 (ILT-101)
89633898|NCT02424396|Placebo Comparator|2 : Placebo|Placebo
89633899|NCT02424240||IGF-I/ IGFBP-3 ratio group|
89633900|NCT02424240||IGF-1 and IGFBP-3|
89633901|NCT02424474|Experimental|Genetic NIPT and regular serum screening|All woman will be tested using the two tests, genetic NIPT (Non Invasive Prenatal Testing) and regular serum screening.
89041343|NCT04603001|Experimental|Dose Escalation Arm B (Monotherapy)|Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection.
89633902|NCT01681433|Experimental|Experimental: Arm A|OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone
89633903|NCT01681433|Active Comparator|Control Arm: Arm B|Continuation of standard therapy with abiraterone acetate and prednisone
89633904|NCT01681277|Experimental|BI 113608 high dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
89633905|NCT01681277|Experimental|BI 113608 low dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
89041344|NCT04603001|Experimental|Dose Escalation Arm C (LY3410738, Venetoclax, and Azacitidine)|Patients with no prior venetoclax therapy and not requiring a strong CYP3A4 inhibitor for active treatment within 7 days of starting LY3410738.
89041345|NCT04603001|Experimental|Cohort 1|Patients with relapsed/refractory (R/R) AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor.
89633906|NCT01681277|Experimental|BI 113608 medium dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
89633907|NCT01681277|Experimental|BI 113608 high dose qd|powder in the bottle for oral solution, oral administration with 240 ml water
89633908|NCT01703117|Experimental|age matched cohort 50-95 years old|20-22 subjects between the ages of 50-95 will receive riluzole
89633909|NCT01703117|Placebo Comparator|24 subjects between 50-95 years old|20-22 subjects between 50-95 will receive placebo
89633910|NCT01702961|Other|BEAM+R: Autologous Stem Cell Transplant|Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
89688493|NCT04355455|Placebo Comparator|Placebo|Administration of placebo to assess the esophageal sensitivity in HV
89041346|NCT04603001|Experimental|Cohort 2|Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor.
89041347|NCT04603001|Experimental|Cohort 3|Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation.
89633911|NCT01593917||Subjects previously implanted with a Trifecta™ valve in the Trifecta™ IDE Study|Subjects enrolled in this clinical study were implanted with the Trifecta™ aortic bioprosthetic valve during 2007, 2008 and 2009 as part of the Trifecta™ IDE Study conducted to obtain FDA approval.
89633912|NCT01593761|Experimental|Single Arm for CG400549|All the patients will be administered with CG400549.
89633913|NCT02706834|Experimental|Cohort 1, Sequence I|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
89041348|NCT04603001|Experimental|Cohort 4|Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations.
89041349|NCT04603001|Experimental|Cohort 5|Patients with newly diagnosed AML, R/R AML, or other advanced hematologic malignancy harboring IDH1 and/or IDH2 mutations with no prior venetoclax therapy. Strong CYP3A4 inhibitor allowed but not required.
89633914|NCT02706834|Experimental|Cohort 1, Sequence II|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
89633915|NCT02706834|Experimental|Cohort 1, Sequence III|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
89041350|NCT04602741|Experimental|A4i Intervention|"App4Independence (A4i)~Experimental: A4i Intervention App4Independence (A4i) The study intervention is the digital health platform A4i. A4i operates on the individual's own phone with or without data.~Specific A4i functionality includes:~Addressing social isolation and cognitive challenges through personalized prompts, scheduling of activities, and connections to a range of resources.~Fostering illness self-management through evidence-informed content.~A peer-peer engagement platform that facilitates strategy/tip sharing between users (anonymous and moderated).~Daily wellness and goal attainment check-ins.~An ambient sound detector with an oscilloscope-type indicator that assists individuals with auditory hallucinations separate hallucinations from real sounds.~Passively collected data on phone use as a proxy for sleep.~A provider dashboard. Both control and experimental condition participants will be receiving standard outpatient care (TAU)."
89041351|NCT04602741|No Intervention|Treatment As Usual|Treatment as usual participants will be recieving outpatient mental health care through the standard supports (most typically, case management and psychiatric support) that are available in a large, Canadian, urban centre.
89633916|NCT02706834|Experimental|Cohort 1, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
89633917|NCT02706834|Experimental|Cohort 2, Sequence I|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
89633918|NCT02706834|Experimental|Cohort 2, Sequence II|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
89041352|NCT04588922|Experimental|Group 1. Dose escalation in patients with relapsed/refractory AML|
89041353|NCT04588922|Experimental|Group 2. Dose escalation in patients with relapsed/refractory CLL/SLL or lymphoma|
89633919|NCT02706834|Experimental|Cohort 2, Sequence III|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
89041354|NCT04588922|Experimental|AML Patients relapsed/refractory to vene and who will be treated with GFH in combo with vene & aza|Group 3. Patients with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens
89041355|NCT04581733|Experimental|Single Arm|Male and female Participants <18 years
89633920|NCT02706834|Experimental|Cohort 2, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. There was a 7-day washout period between each period. Each period lasted 4 days with a 7-day washout period between periods.
89633921|NCT02706834|Experimental|Cohort 3, Sequence I|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
89633922|NCT02706834|Experimental|Cohort 3, Sequence II|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
89633923|NCT02706834|Experimental|Cohort 3, Sequence III|Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
89633924|NCT03117348|Experimental|Gradual goal-dose EN|Patients in Gradual Goal-dose EN group will receive increased calories gradually by enteral nutrition and will reach the 80% of target energy by enteral nutrition at day 8.
89041356|NCT04576715|Experimental|TEaM Intervention Group|Dedicated Provider Education plus Information Technology Support. The IT support includes addition of an eMR concussion screening, followed by an alert to the provider, followed by a structured assessment / evaluation template.
89041357|NCT04576715|Active Comparator|Control Group|Standard medical protocol for the management of mTBI in children. This group will not receive interventional Provider Training on the TEaM concussion evaluation examination and utilization of the eMR template.
89041358|NCT04576364|Active Comparator|12-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 12-hour postpartum Mgso4
89041359|NCT04576364|Active Comparator|24-hour postpartum Mgso4|Patients having preeclampsia with severe features will receive 24-hour postpartum Mgso4
89633925|NCT03117348|Experimental|Immediate goal-dose EN|Patients in immediate Goal-dose EN group will reach the 100% of target energy by enteral nutrition at day 3 after abdominal surgery.
89633926|NCT01702025|Placebo Comparator|Placebo|"Administer a single dose of placebo (yellow corn meal in a capsule, gelatin ) in Normoxic Conditions.~Following a minimum of 7 days a single dose placebo will be administered (yellow corn meal in a gelatin capsule) in Hypoxic conditions."
89041362|NCT04538976|No Intervention|Control|Patients in the control group will receive standard care.
89041363|NCT04538976|Active Comparator|Sildenafil|Patients in the Sildenafil group will receive standard care and targeted Sildenafil-treatment.
89041364|NCT04537351|Experimental|CYP-001|The investigational medicinal product used in this study is known as CYP-001. The active agent in CYP-001 is Cymerus™ MSCs. CYP-001 is supplied as 100 million Cymerus MSCs formulated in 20 mL cryoprotectant medium. On D1 and D3, each participant randomised to receive CYP-001 will receive an IV infusion of 2 million Cymerus MSCs/kg of body weight (up to a maximum of 200 million cells per infusion).
89041365|NCT04537351|No Intervention|Standard of care|Control participants will be randomised to received standard of care treatment.
89041366|NCT04522544|Experimental|SIRT (Arm A)|Y-90 SIRT + Tremelimumab + Durvalumab
89041367|NCT04522544|Experimental|TACE (Arm B)|DEB-TACE + Tremelimumab + Durvalumab
89041368|NCT04521686|Experimental|LY3410738|Phase 1 dose escalation - Multiple doses of LY3410738
89041369|NCT04521686|Experimental|LY3410738 alone or in combination with gemcitabine and cisplatin or in combination with durvalumab|Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of LY3410738 alone or in combination with gemcitabine plus cisplatin or in combination with durvalumab
89041370|NCT04487678|Experimental|Low-dose KE|141 mg/kg bodyweight of ketone esters
89041371|NCT04487678|Experimental|High-dose KE|282 mg/kg bodyweight of ketone esters
89041372|NCT04482036|Placebo Comparator|Dementia Collaborative Care|"Patient and caregivers assigned to the three in-person assessments and no mobile application group will complete the following:~The caregiver will be asked to complete three in-person assessments that involve answering survey questions and an interview.~Some of the questions asked will be related to Behavioral and/or Psychological Symptoms the patient experiences.~The caregiver will be asked to answer questions about the patient, the patient's experience with the research study and the caregiver's own experience with the research study.~If the patient's symptoms or the caregiver's distress answers reach a high enough level, a member of the research study team and clinical team will contact the caregiver to ask more questions and check in on the patient and caregiver's safety.~The research study team will also notify Dr. Bateman (the person responsible for the research)."
89041373|NCT04482036|Active Comparator|Dementia Collaborative Care Plus BrainCare Notes Application|"Patient and caregivers assigned to the three in-person assessments and mobile application group will complete the same tasks that Group 1 (control group) will complete with the addition of the following:~The caregiver will be asked to monitor the patient and complete 5 to 10-minute long surveys (the neuropsychiatric inventory questionnaire) sent to the caregiver through the mobile application or in-person at each follow-up visit.~The caregiver will be asked to monitor and complete these surveys at different times for a period of 6 months."
89041374|NCT04447794|Active Comparator|Step Away App|Participants randomly assigned to this arm will access the Step Away smartphone-based mobile application immediately upon enrollment.
89041375|NCT04447794|Experimental|Step Away Chatbot|Participants randomly assigned to this arm will access the Step Away mobile, text-based, interactive AI chatbot immediately upon enrollment.
89041376|NCT04447794|No Intervention|Step Away App Delay|Participants randomly assigned to this arm will be provided access to the Step Away smartphone-based mobile application three months after enrollment.
89041377|NCT04444518|Experimental|VAX-MOM Intervention|
89633927|NCT01702025|Active Comparator|Aminophylline|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Hypoxic conditions."
89633928|NCT01702025|Active Comparator|Methazolamide|"Administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
89041378|NCT04444518|Active Comparator|Standard of Care|
89041379|NCT04437043|Other|Laparoscopic ventral hernia repair with closure of the defect|In laparoscopic intraperitoneal onlay mesh or IPOM repair, the mesh is inserted intra-abdominally and fixed to the peritoneum / abdominal wall. The general steps include safe entry into the peritoneum, insufflation and placement of the trocars to gain access and visibility (via laparoscope) of the defect. Careful adhesiolysis is performed, which is the removal of scar tissue connecting tissues and organs. The content of the hernia, which may include intestine and fatty tissue, is returned into the abdominal cavity. After closure of the hernia defect, a wide intraperitoneal mesh is fixed over the defect. Desufflation releases the gas from the abdomen. The trocars will be removed and the incisions are closed.
89041380|NCT04437043|Other|Open ventral hernia repair with closure of the defect|An open retromuscular ventral hernia repair involves an incision through the abdominal wall. Adhesiolysis is performed and the content of the hernia is returned into the abdominal cavity. The posterior rectus sheath is separated from the rectus muscle and closed, which closes the abdominal cavity. The mesh is then placed behind the muscle and anterior to the re-approximated posterior rectus sheath. Preperitoneal mesh extension is allowed via transversus abdominis release (TAR). The anterior rectus sheath is closed over the mesh, which closes the hernia.
89041381|NCT04437043|Other|Robotic ventral hernia repair with closure of the defect|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar closure of the hernia defect and similar retromuscular mesh placement as for the open approach. Preperitoneal mesh extension is allowed via TAR. The da Vinci System is a robotic-assisted surgical device that allows the surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of the abdominal cavity. Rather than one long incision with open repair, four to six small incisions are made along the outer part of the abdomen between the rib cage and the hip.
89041382|NCT04431635|Experimental|Arm A: Copanlisib, Nivolumab & Rituximab|Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
89041383|NCT04420962||Microbial Keratitis|Presence of a bacteria or fungal keratitis with ≥ 2mm stromal infiltrate
89041384|NCT04420962||Viral or Inflammatory Keratitis|Non-infectious inflammatory, Viral, Acanthamoeba, or other forms of keratitis
89057516|NCT04532684|Active Comparator|Pregabalin|33 patients received 300 mg/day of pregabalin orally for 12 weeks
89057517|NCT01683474|Experimental|Venus A-Valve|single arm with intervention that percutaneous implantation of the Venus MedTech Aortic Valve Prosthesis
89633929|NCT01702025|Active Comparator|Aminophylline+Methazolamide|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.(Aminophylline+Methazolamide)~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
89633930|NCT03117426|Experimental|SYMFONY IOL|"The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
89633931|NCT03117426|Active Comparator|AT LISA tri 839MP IOL|"This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
89633932|NCT03106896||postherpetic neuralgia (PHN group)|"persist more than 3 months after the resolution of the acute shingles episode and have pain intensity greater than 4 on the visual analog scale (VAS 0, no pain; 10, worst pain imaginable)."
89633933|NCT03106896||acute herpetic pain (AHP group)|have pain (VAS≧4 ) duration of within 7 days after zoster onset at initial interview
89633934|NCT03106896||healthy control (CON group)|healthy population
89633935|NCT01592747|Experimental|Memantine 1|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight-based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for up to 12 weeks.
89633936|NCT01592747|Experimental|Memantine 2|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for up to 12 weeks.
89633937|NCT01592747|Placebo Comparator|Placebo|Dosing will be once daily for up to 12 weeks.
89633938|NCT03106974|Active Comparator|Macintosh Laryngoscope|orotracheal intubation (OTI) with Macintosh Laryngoscope Direct laryngoscopy
89633939|NCT03106974|Active Comparator|Totaltrack VLM|orotracheal intubation (OTI) with Totaltrack VlM Indirect laryngoscopy
89633940|NCT02425488|Experimental|Nursing therapeutics education|People who are educated by the nurse (Behavioral intervention: Nursing therapeutics education) and follow all the program (12 months)
89633941|NCT02425488|No Intervention|Non NET|People who receive basic information without follow the educational program but clinically controlled
89633942|NCT02426112|Active Comparator|Azithomycin|"Azithromycin tablets 250 mg, 30mg/kg/week by mouth, once a week for 12 months.~10-20 kg: 250 mg~20-29 kg: 500 mg~30-39 kg: 750 mg~40-49 kg: 1250 mg"
89633943|NCT02426112|Placebo Comparator|Placebo|"Placebo tablets 250 mg, 30 mg/kg/week by mouth, once a week for 12 months.~10-20 kg: 250 mg~20-29 kg: 500 mg~30-39 kg: 750 mg~40-49 kg: 1250 mg"
89633944|NCT03117192|Experimental|Zinc sulfate|Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
89633945|NCT03117192|Placebo Comparator|Sucrose syrup|Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
89633946|NCT02421198|Experimental|face-to-face|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
89633947|NCT02421198|Experimental|face-to-face + mobile hybrid|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face and via a mobile platform by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
89633948|NCT04768439|Experimental|200 IU/d vitamin D|Patients will receive low-dose vitamin D (200 IU/d)
89041385|NCT04373928|Experimental|Drug guided by Mini-PDX/PDX|Procedure: The tumor tissue is used for drug sensitivity test by Mini-PDX, building PC PDX, and acquiring the genetic information by the second genetic sequence or RNA-sequence. PC patients will accept personalized treatment guided by the experimental results of mini-PDX and sequencing.
89041386|NCT04373928|No Intervention|Drug according to guideline|The drugs (gemcitabine, Nab-paclitaxel, S-1) are used ccording to NCCN pancreatic cancer guideline。
89041387|NCT04350775|Experimental|RE-IADL group|Reablement
89633949|NCT04768439|Experimental|1600 IU/d vitamin D|Patients will receive high-dose vitamin D (1600 IU/d)
89633950|NCT02421042|Experimental|Lenvatinib|Subjects determined to be eligible for the protocol will receive either a 5- or 10-mg single oral dose of lenvatinib on Day 1, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
89633951|NCT02986295||BioMimeTM Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with BioMimeTM Stent
89633952|NCT02986295||Ultimaster® Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with Ultimaster® stent
89633953|NCT02416596|Experimental|Group Undergoing Hysterosopy|This group will include 340 women with unexplained primary infertility undergoing their first trial of IVF/ICSI (intracytoplasmic sperm injection). This group will undergo hysteroscopy in the mid luteal phase of the proceeding cycle.
89633954|NCT02416596|No Intervention|Group With No intervention|This group will include 340 women with unexplained primary infertility they will undergo their first trial of IVF/ICSI (intracytoplasmic sperm injection) without hysteroscopy in the mid Luteal phase of the proceeding cycle.
89633955|NCT04767815|Experimental|Sequence 1|"Period 1: A (Fasting)~Period 2: B (30 minutes after a High-fat meal)~Period 3: C (2 hours after a High-fat meal)"
89633956|NCT04767815|Experimental|Sequence 2|"Period 1: B (30 minutes after a High-fat meal)~Period 2: C (2 hours after a High-fat meal)~Period 3: A (Fasting)"
89633957|NCT04767815|Experimental|Sequence 3|"Period 1: C (2 hours after a High-fat meal)~Period 2: A (Fasting)~Period 3: B (30 minutes after a High-fat meal)"
89041388|NCT04350775|Placebo Comparator|Control group|General community rehabilitation
89041389|NCT04324307|Experimental|PD-L1/CTLA4 BsAb|For 2nd line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W
89041390|NCT04324307|Experimental|PD-L1/CTLA4 BsAb + GP|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Gemcitabine 1000 mg/m2 and Nab-paclitaxel 125 mg/m2 , 28days/cycle
89041391|NCT04324307|Experimental|PD-L1/CTLA4 BsAb + FOLFIRINOX|For 1st line treatment，PD-L1/CTLA4 BsAb 5mg/kg Q2W in combination with Oxaliplatin 68 or 85 mg/m2, Irinotecan 135 or 150 or 180 mg/m2, Calcium Folate 400 mg/m2, Fluorouracil 2400mg/m2, 14 days/cycle
89041392|NCT04268173|Experimental|Immediate Intervention|Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention.
89057518|NCT04538768|Experimental|Mesh Augmentated|
89057519|NCT04538768|Other|Direct Suture|
89633958|NCT04767815|Experimental|Sequence 4|"Period 1: A (Fasting)~Period 2: C (2 hours after a High-fat meal)~Period 3: B (30 minutes after a High-fat meal)"
89633959|NCT04767815|Experimental|Sequence 5|"Period 1: C (2 hours after a High-fat meal)~Period 2: B (30 minutes after a High-fat meal)~Period 3: A (Fasting)"
89633960|NCT04767815|Experimental|Sequence 6|"Period 1: B (30 minutes after a High-fat meal)~Period 2: A (Fasting)~Period 3: C (2 hours after a High-fat meal)"
89633961|NCT03181776|Experimental|left lateral tilting arm|all patients will be put in three angles of left lateral tilt in randomized order (supine position - left lateral tilting in 15 degrees - and left lateral tilting in 30 degrees) and the hemodynamic data will be compared in the three angles.
89633962|NCT03181464|Experimental|experimental - lidocaine 4%|Continuous infusion lidocaine at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx.
89633963|NCT03181464|Placebo Comparator|placebo comparator|Continuous infusion saline at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx
89633964|NCT02416362|No Intervention|Control|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
89633965|NCT02416362|Experimental|GE1|The GE1 (Vibration at 30 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 30 Hz.
89633966|NCT02416362|Experimental|GE2|The GE1 (Vibration at 50 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
89633967|NCT02416440||screening for diabetes prevalence|blood samples
89633968|NCT03179124||Hemiparetic cerebral palsy|Unilateral paresis in which upper extremities are more severely affected than lower extremities.
89633969|NCT03179124||Diparetic cerebral palsy|Lower extremities were more affected than upper extremities
89633970|NCT02424162|Experimental|2.75 group|Patients with 2.75 diopters multifocal intraocular lens
89633971|NCT02424162|Active Comparator|3.25 group|Patients with +3.25 diopters multifocal intraocular lens
89633972|NCT02424006|Experimental|RHCIII-MPC cornea|Patients of this arm will undergo RHCIII-MPC bioengineered cornea transplantation using anterior lamellar keratoplasty technique
89633973|NCT02424006|Active Comparator|Donor cornea|Patients of this arm will undergo human donor cornea transplantation using anterior lamellar keratoplasty technique
89633974|NCT03181698||first group|patients with more than one episodes of mania
89633975|NCT03181698||second group|sex-matched and age- matched healthy controls
89633976|NCT03116724|Experimental|CVC catheterization through Rt. IJV|"The depth of central venous catheter during central venous catheterization through Rt. IJV will be decided by using real-time TEE.~The position of tip of CVC will be guided by TEE to fit the tip at 2 cm away from the junction between right atrium and superior vena cava."
89633977|NCT02416284|Experimental|NFBDG|Multi-faceted, 2 week intervention to increase compliance to the NFBDG.
89633978|NCT03116802|Experimental|Statin Group|A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c <6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
89041393|NCT04268173|Experimental|Delayed Intervention|"Participants enrolled in this arm will receive a 12-week community-based, client-centered, prevention intervention after being put on a wait-list for three months.~Per the protocol amendment approved on 9/3/2021, no additional participants will be recruited into the delayed intervention arm."
89041394|NCT04268173|No Intervention|Nonintervention|Participants enrolled in this arm will receive services as usual from Vivent Health and will not engage in the intervention.
89041395|NCT04251130||Cognitively Normal Older Adults|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
89041396|NCT04251130||Mild Cognitively Impaired Older Adults or Older Adults with Alzheimer's Disease|Subjects will receive an IV bolus injection of approximately 5 mCi ± 20% of [18F]PI-2620. All subjects will undergo a 30-minute brain PET/CT scan performed starting at approximately 45 minutes' post injection of [18F]PI-2620. A low-dose CT scan will be acquired according to standard PET/CT imaging procedures to be used for attenuation correction. All images will be reconstructed using standard reconstruction techniques
89041397|NCT04217395||Reinforced support: X-ailes program users|
89041398|NCT04216628|Other|Early amniotomy group|Amniotomy will be performed as the exclusive primary intervention. Oxytocin infusion will begin as per local standard dose protocol no earlier than 2 hours following amniotomy.
89633979|NCT03116802|Active Comparator|Control Group|"Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.~They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)"
89633980|NCT03116646|Experimental|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
89633981|NCT02423928|Experimental|Cryoimmunotherapy|"Patients with castration resistant prostate cancer and imaging proven metastases will be treated by autologous dendritic cell based cryoimmunotherapy of the prostatic tumor tissue assisted by immunomodulation consisting of low-dose metronomic cyclophosphamide for all patients plus ipilimumab for the latter half of all patients.~Update January 2019: The protocol was changed as approved by the Norwegian Medicines Agency and the Regional Ethical Committee in Western Norway for the 3 last patients of altogether 18 patients. Consequently, the 3 last patients received 200 mg i.v. of pembrolizumab (and no ipilimumab) post-CryoIT."
89633982|NCT02051608|Placebo Comparator|Part 1 (Double Blind treatment): Placebo|Participants received matching placebo by subcutaneous (SC) injection every 4 weeks (Q4W) up to 100 weeks during Part 1 of the study.
89633983|NCT02051608|Experimental|Part 1 (Double Blind treatment): Gantenerumab|Participants received 105 mg Gantenerumab by SC injection Q4W for 24 weeks and if eligible 225 mg SC injection Q4W from weeks 28-100 during Part 1 of the study.
89633984|NCT02051608|Placebo Comparator|Part 2 (Open-Label Extension [OLE] treatment): Placebo switched to Gantenerumab Up to 1200 mg|Participants who had received Placebo in Part 1, received Gantenerumab at doses up to 1200 mg by SC injection Q4W for up to 2 years. Additionally, participants were given the option to continue receiving open-label gantenerumab treatment for 3 years.
89041399|NCT04216628|Other|Late amniotomy group|Oxytocin infusion will begin as per local standard dose protocol. Amniotomy will be performed no earlier than 2 hours following the commence of oxytocin infusion
89041400|NCT04192019|Experimental|Micro-dose glucagon|80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
89041401|NCT04192019|Experimental|Mini-dose glucagon|150 µg mini-dose of subcutaneous Dasiglucagon 5 min before exercise the start of exercise
89041402|NCT04192019|No Intervention|No treatment|No treatment before the start of exercise
89041403|NCT04174170|Experimental|Brexpiprazole + Sertraline|3 pills: Fixed dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
89057520|NCT01683513|No Intervention|humaan chorion gonadotropine|ovulation induction with 5000E hCG
89633985|NCT02051608|Experimental|Part 2 (OLE treatment): Gantenerumab up to 1200 mg|Participants who had received Gantenerumab in Part 1, received treatment at doses up to 1200 mg by SC injection Q4W for up to 2 years. Additionally, participants were given the option to continue receiving open-label gantenerumab treatment for 3 years.
89041404|NCT04174170|Experimental|Sertraline|3 pills: Fixed dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
89041405|NCT04174170|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
89633986|NCT02705586|Experimental|only one arm - open label study|2 hour video based mindfulness-based stress reduction class once a week for 10 weeks.
89633987|NCT02423850||Diabetic foot ulcers|Newly referred patients with diabetic foot ulcers from the multidisciplinary clinic: University Centre for Wound healing, Odense University Hospital, Denmark.
89633988|NCT03106740|Experimental|Minocycline Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
89633989|NCT03106740|Placebo Comparator|Placebo Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
89633990|NCT02415972||All study participants|Patients with Stroke
89633991|NCT03106818|Active Comparator|group A|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
89633992|NCT03106818|Active Comparator|group B|bupivacaine 0.125% infusion in the presternum , for 48 hours
89041406|NCT04172779|Experimental|Erlotinib treatment|
89041407|NCT04165343||Non-Alcoholic Fatty Liver Disease (NAFLD)|"Cohort: Patients with known Non-Alcoholic Fatty Liver Disease (NAFLD)~All patients will undergo the following interventions:~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood test"
89041408|NCT04165343||Healthy Control Subjects|"Cohort: Healthy controls~All healthy subjects will undergo the following interventions:~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood tests"
89633993|NCT03106818|Active Comparator|Group C|will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
89633994|NCT03181620|No Intervention|Continuous Infusion Arm|Patients receive typical continuous infusions (drips) of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on RASS and CPOT.
89041409|NCT04146298|Experimental|TCR Transduced T cell therapy|"Pre-conditioning: Non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine~TCR transduced T cell infusion: mutant KRAS G12V-specific TCR transduced autologous T cells (1e9~1e11). If the participant responds to the first infusion, the second or more infusions will be considered when the disease is progressing.~Anti-PD-1 therapy: anti-PD-1 will be administered if needed."
89041410|NCT04144738||Individuals eligible for CRC Screening|Individuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy.
89041411|NCT04126590|Experimental|KN044 0.03 mg/kg dose group|KN044 0.03 mg/kg dose group,once every 3 weeks，a total of four cycles
89041412|NCT04126590|Experimental|KN044 0.1 mg/kg dose group|KN044 0.1 mg/kg dose group,once every 3 weeks，a total of four cycles
89041413|NCT04126590|Experimental|KN044 0.3mg/kg dose group|KN044 0.3mg/kg dose group,once every 3 weeks，a total of four cycles
89041414|NCT04126590|Experimental|KN044 1 mg/kg dose group|KN044 1 mg/kg dose group,once every 3 weeks，a total of four cycles
89633995|NCT03181620|Experimental|Intermittent Sliding Scale Arm|Patients receive hourly boluses of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on a sliding scale of RASS and CPOT.
89041415|NCT04126590|Experimental|KN044 3 mg/kg dose group|KN044 3 mg/kg dose group,once every 3 weeks，a total of four cycles
89633996|NCT01592045|Experimental|Sequence 1|UTC ch14.18 for two courses and NCI ch14.18 for three courses
89633997|NCT01592045|Experimental|Sequence 2|NCI ch14.18 for two courses and UTC ch14.18 for three courses
89041416|NCT04126590|Experimental|KN044 6mg/kg dose group|KN044 6mg/kg dose group,once every 3 weeks，a total of four cycles
89041417|NCT04126590|Experimental|KN044 10mg/kg dose group|KN044 10mg/kg dose group,once every 3 weeks，a total of four cycles
89041418|NCT04124614|Experimental|Brexpiprazole + Sertraline|3 pills: Dose of up to 3 mg /day may be administered of brexpiprazole, dose up to 150 mg/day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
89041419|NCT04124614|Experimental|Sertraline|3 pills: Dose up to 150 mg/ day may be administered of sertraline, placebo or a combination of these. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
89633998|NCT03181230||Adolescents|Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
89633999|NCT03181230||Parents|One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
89634000|NCT03178968|Experimental|15 minutes' erosion|Orange juice is administered ex vivo and in vivo for 5 minutes and repeated a total of 3 times
89634001|NCT03178968|Experimental|30 minutes' erosion|Orange juice is administered ex vivo and in vivo for 10 minutes and repeated a total of 3 times
89041420|NCT04124614|Other|Placebo|3 pills: Brexpiprazole-matched placebo tablets and Sertraline-matched placebo tablets may be administered. Doses to be taken simultaneously. Assignment to these options may change during the treatment period.
89634002|NCT03178968|Experimental|45 minutes' erosion|Orange juice is administered ex vivo and in vivo for 15 minutes and repeated a total of 3 times
89634003|NCT04767659|Experimental|Women candidate for clinical trial|Twenty adult women with a recent diagnosis of breast cancer, candidate for NAC, besides assessing the response to neoadjuvant chemotherapy using standard imaging evaluation, will undergo optical imaging at six selected time points from prior to commencement of NAC/baseline to the completion of NAC treatment (prior to surgery).
89634004|NCT02415582|Experimental|Aerobic exercise|Aerobic exercise on treadmill at 65-70% of the heart rate reserve during a session.
89634005|NCT02415582|Experimental|Combined exercises|A session combines resistance and aerobic exercises, with aerobic exercise on treadmill at 65-70% of the heart rate reserve, followed by 60 minutes for cardiorespiratory recovery, and resistance exercise.
89634006|NCT02415582|Sham Comparator|Control|Participants do not exercise and remain sitting for 45 minutes
88990798|NCT06167772|Placebo Comparator|Control group|No placebo. Not given intervention product. standard nutrition: oral nutrition supplement (high protein) or parenteral with target energy of 20 kcal/kg BW/day standard neuromuscular electrical stimulation 30 minutes per day
88990799|NCT06166238||Group I|Patients who will be subjected to Millard Technique
88990800|NCT06166238||Group II|patients who will be subjected to Tension Randal
88990801|NCT06165549|Experimental|Light therapy|about 30 individuals with internet gaming disorder will be randomly assigned to the light therapy group
88990802|NCT06165549|Placebo Comparator|Light placebo|about 30 individuals with internet gaming disorder will be randomly assigned to the light placebo group
88990803|NCT06165549|Other|EABM training group|about 30 individuals with internet gaming disorder will be randomly assigned to the EABM training group
88990804|NCT06165484|Experimental|patient with failed ivf cycle|
89634007|NCT01591499|Experimental|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
89634008|NCT01591499|Active Comparator|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
88990807|NCT06163820|Experimental|Intervention|"Patients will receive the following:~Bevacizumab 7.5 mg/kg every 3 weeks for 4 cycles~Nivolumab 1 mg /kg + ipilimumab 3 mg/kg every 3 weeks for 4 cycles (induction phase) followed by nivolumab monotherapy at 480mg every 4 weeks (maintenance phase)~hSRT (24-27Gy/3# or 25-30Gy/5#)"
88990808|NCT06162234||entire cohort|entire cohort made up of high myopia patients（observational study）
88990809|NCT06162117|Experimental|Traumatic meniscus tear|Patients with traumatic meniscus tears will be enrolled in this study
88990810|NCT06162104||Post-poliomyelitis syndrome group|Patients suffering from post-poliomyelitis syndrome
88990811|NCT06162104||Healthy volunteers|Control gruoup with healthy volunteers
88990812|NCT06161454|Experimental|Population 1: Transplant Recipients|Participants who are a CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir.
88990813|NCT06161454|Experimental|Population 2: Waitlisted Patients for Transplant|Participants who are waitlisted CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir marboxil.
88990814|NCT06161454|Experimental|Population 3: Household Members (Non-Transplant)|Non-Transplanted Household Members aged 5 years or older will receive a single dose of Baloxavir marboxil.
88990815|NCT06161454|No Intervention|Population 4: Non-Baloxavir treatment subjects|"CHOP transplant recipients and all other non-transplanted household members who are 2-4 years of age.~Subjects 5 years and up who are Influenza positive but whom do not receive Baloxavir treatment"
88990816|NCT06161402|Experimental|EB-PRT|EB-PRT will implemented during week 1-14. A purposive sample of 12 participants invited for qualitative interview during 21st -22nd week. There are 2 post-test evaluations at 14th week and 26th week. After the second evaluation at week 26, the group will receive usual care with routine follow-up.
88990817|NCT06161402|No Intervention|Usual care|The control group will receive usual care including the medical care offered by the specialist out-patient clinic during 1-26 week. There are 2 post-test evaluations at 14th week and 26th week. From week 27 to week 40, this wait-list control group will receive the same EB-PRT as the intervention group.
88990818|NCT06160908|Sham Comparator|sham irradiation group.|
88990819|NCT06160908|Experimental|Near infrared light group|
88990820|NCT06158984|Experimental|IPL group|IPL group will use 2 sessions of IPL therapy, 15 days apart for the management of drug-induced dry eye in glaucoma patients.
88990821|NCT06158984|No Intervention|Control group|The control group received no treatment
88990822|NCT06157957|Other|Active smokers|We do a CT scan in active smokers and ex-smokers plus an spirometry combined to a tobacco cessation programme in active smokers
88990823|NCT06157801||Interview Study|In the interview study, participants will watch the video, then complete an interview. This will take about 50 minutes.
88990824|NCT06157801||Survey Study|In the survey study, participants will complete a survey about your education and complete a quick test about your knowledge of hereditary cancer. Participants will then watch the video. complete another survey similar to the one before the video. This should take about 30 minutes.
89057521|NCT01683513|Active Comparator|GnRH agonist + 1500E hCG|ovulation induction with GnRH agonist and 1500E hCG one hour after egg retrieval
89057522|NCT01649466|Experimental|Vildagliptin|Patients randomized to the vildagliptin group will receive 50mg vildagliptin once daily add-on to their current glimepiride monotherapy for 24 weeks. No dose titrations are permitted during the study.
89057523|NCT01649466|Active Comparator|Protaphane|Patients randomized to the Protaphane group will receive a individualized dose of Protaphane once daily as bedtime dose. The Protaphane dose will be titrated within the first 4 weeks to reach fasting plasma glucose values below 100 mg/dl.
89057524|NCT01200589|Experimental|Arm A: Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
89634009|NCT03178656|Active Comparator|PVTT WITH SORAFENIB|"AASLD recommend therapy:~sorafenib tablet, 400mg, bid."
89634010|NCT03178656|Experimental|PVTT WITH OPERATION|patients suitable for surgery
89634011|NCT03177096|Experimental|Peds QL questionnaire and diabetes modulate|Routine practice of a continuous measure sensor of the glycemia with insulin pump for children aged 2 to 13 years followed at Mulhouse Hospital for type 1 diabetes : 5 sessions after enrollment visit(V1) (1 session 2 months, 4 months, 6 months, 8 months and 10 months) This study will be proposed to patients treated for type 1 diabetes enrolled in kindergarten, primary school, attending a nursery or a childcare center (patient's participation = 10 months) and will evaluate the child quality of life and the parents and staffs in preschool and school felt too.
89634012|NCT02420886|Active Comparator|Cytokines supplemented In Vitro single culture media|We will add Cytokines (LIF, HB-EGF and GM-CSF) to LIFEGLOBAL culture media and assess the embryogenesis and pregnancy.
89634013|NCT02420886|No Intervention|Traditional Single step culture media|
89634014|NCT02415504|Experimental|Enhanced care transition|The enhanced care transition will offer: (1) an integrated behavioural care plan, (2) an in- person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
89041421|NCT04099797|Experimental|C7R-GD2.CAR T cells|"The dose level for autologous cell C7R-GD2.CART cell immunotherapy administered via intravenous (IV) infusion was determined in the initial phase of the protocol. The IV dosing is 30 million cells/m2 (two equal half-doses of 15 million cells/m2) given at least 5 days and no greater than 10 days apart. Infusion 1 will be given at least 5 days after initial ICV infusion. The second half dose will be given at least 5 days after infusion 1 and will be delayed if CRS or ICANS of Grade 2 or higher is present.~In this subsequent phase of the study, the safe dosing levels for autologous cell C7R-GD2.CART cell immunotherapy administered intracerebroventricularly (ICV) via ommaya reservoir or programmable VP shunt in combination with subsequent IV doses will be determined."
89041422|NCT04089488||Observational (respond to surveys, medical record review)|Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
89041423|NCT04038060|Experimental|WhatsApp Group|Participants will be assigned to participate in a WhatsApp Group
89041424|NCT04038060|Experimental|2-way SMS|Participants will be assigned to receive weekly 2-way SMS initiated by the study team
89041425|NCT04038060|Experimental|2-way SMS and monthly counseling sessions|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and monthly counseling sessions
89041426|NCT04038060|Experimental|2-way SMS and drug level feedback|Participants will be assigned to receive weekly 2-way SMS initiated by the study team and drug level feedback
89041427|NCT04038060|Experimental|WhatsApp Group and monthly counseling sessions|Participants will be assigned to participate in a WhatsApp Group and monthly counseling sessions
89041428|NCT04038060|Experimental|WhatsApp Group and drug level feedback|Participants will be assigned to participate in a WhatsApp Group and drug level feedback
89041429|NCT04009291|Experimental|TransCon PTH 15 mcg|TransCon PTH 15 mcg delivered once daily by subcutaneous injection
89041430|NCT04009291|Experimental|TransCon PTH 18 mcg|TransCon PTH 18 mcg delivered once daily by subcutaneous injection
89634015|NCT02415504|Other|Standard care transition|The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
89634016|NCT01590797|Experimental|Sitagliptin|Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
89634017|NCT01590797|Placebo Comparator|Placebo|Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
89634018|NCT03181074||CHC patients in Mexico|patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
89634019|NCT01590563|Experimental|SCu300A IUB|Insertion of a spherical IUD (intrauterine device) with one year follow-up
89634020|NCT03180762|Experimental|Part 1: Cohort 1 (JNJ-64140284 or Placebo)|Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.
89041431|NCT04009291|Experimental|TransCon PTH 21 mcg|TransCon PTH 21 mcg delivered once daily by subcutaneous injection
89041432|NCT04009291|Placebo Comparator|Placebo|Placebo mimicking 15, 18, or 21 mcg of TransCon PTH delivered once daily by subcutaneous injection
89041433|NCT04009291|Experimental|Open-Label Extension Period|Subjects who complete the four-week blinded period are assigned to open-label treatment with TransCon PTH for up to 262 weeks, with up to an initial 14 weeks of TransCon PTH titration and standard of care optimization, followed by approximately 248 weeks of individualized dosing.
89041434|NCT03990506|Experimental|Epi-on PiXL|Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.
89041435|NCT03990506|Active Comparator|Epi-off PiXL|Photorefractive intrastromal corneal crosslinking with epithelium debridement.
89041436|NCT03954431|Experimental|Dedicated breast computed tomography (BCT)|All subjects will undergo bilateral breast CT (BCT) imaging exam.
89041437|NCT03953131|Experimental|Diagnostic (gallium Ga 68-DOTATATE PET/CT)|Patients receive gallium Ga 68-DOTATATE IV over a few minutes and, after 60 minutes, undergo a PET/CT scan over 5-10 minutes 14 days before starting scheduled radiation therapy and 6 weeks after completion of radiation treatment.
89041438|NCT03948204||Prostate cancer|Men diagnosed with prostate cancer
89041439|NCT03948204||Men without prostate cancer|Men without prostate cancer matched for age and county
89041440|NCT03947424|Experimental|Experimental 1|Long-pulse (LP) Er:YAG laser snoring treatment.
89041441|NCT03947424|Experimental|Experimental 2|Fotona SMOOTH mode Er:YAG laser snoring treatment.
89041442|NCT03947424|Sham Comparator|Control|Sham laser snoring treatment with no energy applied.
89041443|NCT03938571|Experimental|Standard DS|"Standard duodenal switch:~Sleeve gastrectomy over a 35 Fr bougie~Division of the duodenum 2-3 cm distally of the pylorus~Measurement of the small bowel. 100 cm common channel. 150 cm alimentary limb.~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.~Entero-entero-anastomosis linear stapled and handsewn.~Division between the two anastomosis.~Closure of the mesenteric defects."
89057525|NCT01200589|Active Comparator|Arm B: Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
88990825|NCT06157242|Experimental|Open Label, Single Dose Combination of Ceftibuten & Xeruborbactam oral prodrug|"32 participants will be enrolled with varying degrees of renal impairment as well as participants with normal renal function (NRF). 8 participants will be enrolled in each group based on estimated glomerular filtration rate at screening:~Group 1: Mild renal impairment (eGFR 60 to 89 mL/min/1.73m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation)~Group 2: Moderate renal impairment (eGFR 30 to < 60 mL/min/1.73m2 calculated using the CKD-EPI equation)~Group 3: Severe renal impairment (eGFR < 30 mL/min/1.73m2 calculated using the CKD-EPI equation) not receiving HD therapy~Group 4: Healthy participants with NRF matched to patients in Groups 1, 2 and 3 based on age, gender and BMI~All subjects will receive a single dose of ceftibuten & QPX7831 on Day 1.~Participants will remain in the clinic until completion of the post-dose procedures on Day 6. Participants will be contacted by phone between Days 8-10 for follow-up."
88990826|NCT06157138||Patients undergoing open abdominal surgery|Patients older than 18 years undergoing open abdominal surgery. They will be followed by a protocol of pulmonary echography during and after surgery in the postoperative care unit
88990827|NCT06156540|No Intervention|Control group|No intervention was made to the control group. The posttest was administered four weeks after the pretest.As a result, caregivers' care burden and psychological well-being will be measured.
88990828|NCT06156540|Experimental|Virtual Reality Group|A pretest was administered to the experimental group. Then, 360-degree VR videos (nature walks, trips, etc.) were watched three days a week for four weeks. Then, the final test was administered.As a result, caregivers' care burden and psychological well-being will be measured.
88990829|NCT06155227|Experimental|Experimental Group|
88990830|NCT06155227|Active Comparator|Control Group|
88990831|NCT06153875|Experimental|Sensory Threshold, Burst High Frequency|The technique consists of percutaneous peripheral electrical stimulation on the Spinal or Inferior Gluteal and Tibial Nerve through a ultrasound-guided needle.
88990832|NCT06153875|Experimental|Theta-Burst Stimulation|The technique consists of percutaneous peripheral electrical stimulation on the Spinal or Inferior Gluteal and Tibial Nerve through a ultrasound-guided needle.
88990833|NCT06153875|Active Comparator|Transcutaneous Electrical Nerve Stimulation|The technique consists of transcutaneous electrical nerve stimulation on the trapezius or low back and internal calf muscles through surface electrodes.
88990834|NCT06153563||Mitral valve prolapse|Patients with mitral valve prolapse
88990835|NCT06153563||Restrictive ischemic mitral valve|Patients with restrictive ischemic mitral valve
88990836|NCT06153485|Experimental|AutoO2|Automated Titration of Oxygen (Auto-O2) using a closed-loop system in which the oxygen flow to the participant is continuously adjusted on the basis of pulse oximetry signals to maintain a target range of oxygen saturation to meet the patient's immediate needs.
88990837|NCT06153485|Active Comparator|FixedO2|Fixed flow oxygen delivery administered using manual flow meters according to standard clinical procedures.
89041444|NCT03938571|Active Comparator|SADI-DS|"Duodenal switch with Single anastomosis duodeno-ileostomy:~Sleeve gastrectomy over a 35 Fr bougie~Division of the duodenum 2-3 cm distally of the pylorus~Measurement of the small bowel. 250 cm alimentary limb/common channel.~Duodenoileostomy completely handsewn with 250 cm distance to the ileocecal valve.~Closure of the mesenteric defects."
88990838|NCT06152237|Experimental|Cohort 1|Dose Level 1
88990839|NCT06152237|Experimental|Cohort 2|Dose Level 2
88990840|NCT06152146|Active Comparator|SWT group|Participants randomized to the treatment group will receive nine (9) shockwave sessions in total: one (1) shockwave session once per week for four (4) weeks, followed by one (1) shockwave session once per month (30±7 days) for the next five (5) months. 1,440 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura) for a total of 12,960 shocks. Participants will be in this group for up to 6 months.
89041445|NCT03936517|Other|Prednisolone first; hydrocortisone second|Participant will receive 4 months of prednisolone in the first study period and 4 months of hydrocortisone in the second study period.
89041446|NCT03936517|Other|Hydrocortisone first; prednisolone second|Participant will receive 4 months of hydrocortisone in the first study period and 4 months of prednisolone in the second study period.
89634021|NCT03180762|Experimental|Part 1: Cohort 2 (JNJ-64140284 or Placebo)|Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
89634022|NCT03180762|Experimental|Part 1: Cohort 3 (JNJ-64140284 or Placebo)|Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
89634023|NCT03180762|Experimental|Part 1: Cohort 4 (JNJ-64140284 or Placebo)|Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
89634024|NCT03180762|Experimental|Part 1: Cohort 5 (JNJ-64140284 or Placebo)|Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
89634025|NCT03180762|Experimental|Part 1: Cohort 6 (JNJ-64140284 or Placebo)|Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
89634026|NCT03180762|Experimental|Part 2: Cohort 7 (JNJ-64140284)|Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics [PK] of preceding dose levels; no more than 50 percent (%) of the highest dose tested [though as high as possible within this restriction] and considered well tolerated in Part 1) under fed conditions on Day 1.
89634027|NCT03180762|Experimental|Part 3: Cohort 8 (JNJ-64140284 or Placebo)|Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.
89634028|NCT02415660|Experimental|SMT and TDN|Thoracic spinal manipulation and trigger point dry needling using Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
89634029|NCT02415660|Sham Comparator|SMT and Sham TDN|Thoracic spinal manipulation and trigger point dry needling sham. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
89634030|NCT02420730|Experimental|Cohort 1A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
89634031|NCT02420730|Experimental|Cohort 1B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable.
89634032|NCT02420730|Experimental|Cohort 1C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable.
89634033|NCT02420730|Placebo Comparator|Cohort 1: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
89041447|NCT03889795|Experimental|Dose Escalation|C3 (Metformin, Simvastatin and Digoxin) will be dosed each day of a 28 calendar day cycle. The starting dose level will be increased with each cohort. There are 3 cohorts. Upon reaching maximum tolerated dose, an expansion cohort will be opened. Cohort 1 - Metformin 850mg po/day, Simvastatin 5mg po/day, Digoxin 0.0625 mg po/day. Cohort 2 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 20 mg po/day, Digoxin 0.25 mg po/day. Cohort 3 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 40 mg po/day, Digoxin 0.25 mg po/day for two weeks, 0.375 mg po/day for the next two weeks for cycle 1. Subjects will receive 0.50 mg po/day in Cohort 3, Cycle 2 and beyond. Metformin to be taken at Breakfast and Dinner time (as applicable), Simvastatin at Bed time and Digoxin once daily.
89634034|NCT02420730|Experimental|Cohort 2A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
89634035|NCT02420730|Experimental|Cohort 2B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable.
89634036|NCT02420730|Experimental|Cohort 2C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable.
89634037|NCT02420730|Placebo Comparator|Cohort 2: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
89634038|NCT02415192||Patients treated with Levacalm|"In this group, the patients will be enrolled treated with Levacalm tab. as an anti-hypertensive drug.~The number of this group will be double than the control group to get more information about safety and efficacy."
89634039|NCT02415192||Patients treated with Valsartan/amlodipine|In this group, the patients will be enrolled treated with Valsartan/amlodipine combination drug as an anti-hypertensive drug.
89634040|NCT03178734|Other|Indwelling Foley Catheter|These patients will have a traditional foley catheter with attached drainage bag (Indwelling Foley Catheter).
89634041|NCT03178734|Other|Self-Contained Valved Catheter|These patients will have a BARD Flip Flo Catheter Valve attached to the original foley catheter (Self-Contained Valved Catheter).
89634042|NCT02415348|Experimental|Fibroscan|Fibroscan under simultaneous cardiac monitoring
89634043|NCT03180606||Predicted and personalized primary care|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives personalized primary care
89634044|NCT03180606||Predicted but with treatment as usual|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives treatment as usual
89634045|NCT03178812|Active Comparator|Patients with pancreatic cysts|Fine-needle aspiration (FNA) by Endoscopic Ultrasound (EUS) will collect liquid from patients' pancreatic cysts to measure their Interleukin and TNF levels
89634046|NCT03178812|Active Comparator|Healthy volunteers|Laboratory blood test to measure Interleukin and TNF levels
89634047|NCT02415270|Experimental|Reduced Nicotine Cigarettes|Participants will be randomized to receive low nicotine cigarettes to replace their usual high nicotine brand.
89634048|NCT02415270|Experimental|Reduced ROS/RNS|Participants will be randomized to receive Reduced Oxidative/Nitrogen Species (ROS/RNS) cigarettes to replace their usual cigarettes.
89634049|NCT02415270|Placebo Comparator|Control Group|Participants will be assigned to continue smoking their usual brand of cigarettes.
89041448|NCT03839108|Active Comparator|Paraffin wax group|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
89041449|NCT03839108|Experimental|Prolotherapy group|"Drug = prolotherapy (%15 dextrose solution) into hand joints~%15 dextrose solution will be injected into medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period."
89041450|NCT03819075|Experimental|Laser|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units.
89634050|NCT02415114|Active Comparator|Healthy Population|Healthy Population with Omega Q Plus Resveratrol (with 50mg CoQ10)
89634051|NCT02415114|Active Comparator|Population taking Statins|Population taking Statins with Omega Q Plus Resveratrol (with 50mg CoQ10)
89634052|NCT03178422|Experimental|CQSS2 System (nicotine 21 mg)|Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.
89634053|NCT03178422|Active Comparator|NicoDerm® CQ® patch (21 mg)|NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
89634054|NCT02420496|Experimental|Enteral fish oil|Infants will receive enteral fish oil at a dose of 1mg/kg/day divided in two daily doses given enterally.
89041451|NCT03819075|Active Comparator|Control|Standard periimplantitis treatment will be conducted in the control group.
89634055|NCT02420496|Active Comparator|UDCA (ursodeoxycholic acid)|Infants will receive UDCA at a dose of 10mg/kg/dose in two daily doses given enterally
89634056|NCT02420496|Placebo Comparator|Placebo|Infant will receive placebo in two daily doses given enterally
89634057|NCT02414880|Active Comparator|Sugammadex/ Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
89634058|NCT02414880|Active Comparator|Neostigmine / Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
89634059|NCT02414880|Active Comparator|Sugammadex / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
89634060|NCT02414880|Active Comparator|Neostigmine / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
89634061|NCT02423694|Experimental|Electroacupuncture|"Baihui, Yintang, Guanyuan(dual), Zigong(dual), Sanyinjiao(dual), Hegu(dual), Taichong(dual).~Insert needles to the acupoints mentioned above after sterilized.Needle handles of Baihui and Yintang are connected with the electroacupuncture instrument wire. And needle handles of bilateral Zigong are conneted with the electroacupunture instrument wire. And needle handles of bilateral Tianshu are connected with the electroacupunture instrument wire. Density wave, frequency of 10/50Hz and current intensity is 0.5~1.0 mA for 30 minutes. 3 times per week. Each treatment interval of more than 24 hours, continuous treatment for 12 weeks."
89634062|NCT02423694|Active Comparator|escitalopram oxalate tablets|0.5 hour after breakfast oral taking 10mg escitalopram oxalate tablets, continuous treatment for 12 weeks.
89041452|NCT03808025|Experimental|education|The teaching arm would consist of a standardized dialogue the surgeon will complete with the patient in order to familiarize the patient with the risks of over-prescribing opioid medication and set patient expectations regarding the clinic's opioid prescribing pattern protocol, in an effort to minimize the number of opioid pills prescribed or refills required, the amount actually used, and the untoward side effects of opioid use (e.g. respiratory depression, nausea, sedation, restriction from driving, and access to and use by those the medication was not intended).
89041453|NCT03808025|No Intervention|no education|Standard preoperative care without dedicated teaching regarding opioid use and risks
89041454|NCT03802084|Experimental|vactosertib/imatinib combination|
89041455|NCT03790280|Experimental|Standard of Care PLUS HFO|Surgery is tailored by HFOs and standard ECoG interpretation (spikes on intra-operative ECoG or seizure onset on extra-operative ECoG) (arm 1).
89634063|NCT02423538|Experimental|single ascending doses|single ascending doses, oral tablets
89634064|NCT02423538|Placebo Comparator|Placebo|Placebo Comparator, oral tablets
89634065|NCT02420418|Active Comparator|NAC ( baseline )and 12 week|"subjects with tobacco use disorder (TUD) and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo at baseline for a period of 12 weeks The participants with TUD (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be asses laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
89041456|NCT03790280|No Intervention|Standard of Care|Surgery is tailored by standard ECoG alone (arm 2).
89041457|NCT03777462|Active Comparator|Group A of neoadjuvant chemotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And surgical resection is performed after completion of the whole chemotherapy.
89041458|NCT03777462|Experimental|Group B of neoadjuvant chemoradiotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
89041459|NCT03777462|Experimental|Group C of neoadjuvant chemoradiotherapy|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of nab-paclitaxel (125 mg/m2) is initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And S-1 is orally administrated at a dose of 80 mg/m2 for 18 days followed by a 10-day rest during each 4-week cycle, which aslo continues for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
89041460|NCT03745326|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12D mTCR PBL + highdose aldesleukin
89041461|NCT03745326|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12D mTCR PBL + high-dose aldesleukin
89041462|NCT03730181|Experimental|Single Arm Rifapentine and Isoniazid|Single arm, open label and exposure-controlled. Intervention is rifapentine given in a new fixed dose combination once-weekly, in combination with isoniazid for 12 weeks, in HIV-infected and HIV-uninfected children aged 0-12 years in whom LTBI treatment is indicated. The protocol allows for parallel enrolment of children into cohorts 1 and 2, simultaneously, using a predetermined modeled initial dose for each cohort, separately. Similarly, cohorts 3 and 4 will be enrolled in parallel, using modeled doses for each cohort, based on data from cohorts 1 and 2 and historical data from TBTC trials.
89634066|NCT02420418|Placebo Comparator|placebo ( baseline ) and 12 week|"subjects with tobacco use disorders (TUD and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo for a period of 12 weeks.~The participants with TUD and bipolar disorders (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be assessed laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
89634067|NCT03180372|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
89634068|NCT02423616|Experimental|Healthy individuals|Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors.
89634069|NCT02414802|Experimental|Combined thrombectomy device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
89057526|NCT04532762|Experimental|Coldamaris akut|One puff (140µl) into each nostril
89057527|NCT04532762|Placebo Comparator|Placebo|One puff (140µl) into each nostril
89057528|NCT01683552|Other|Aprepitant|Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus
89634070|NCT02414802|Other|Catheter-directed thrombolysis|Participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units urokinase will be pulse-spray injected through the catheter once every 4-6 h. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
89634071|NCT01701401|Experimental|LDV/SOF 12 weeks|LDV/SOF administered for 12 weeks
89634072|NCT01701401|Experimental|LDV/SOF+RBV 12 weeks|LDV/SOF+RBV administered for 12 weeks.
89634073|NCT01701401|Experimental|LDV/SOF 24 weeks|LDV/SOF administered for 24 weeks
89634074|NCT01701401|Experimental|LDV/SOF+RBV 24 weeks|LDV/SOF+RBV administered for 24 weeks.
89634075|NCT04482504||healthy pregnant women|"200 healthy pregnant women in 36.-38. Week of pregnancy. The investigators involve every healthy pregnant woman in 36.-38. week of pregnancy.~Exclusion criteria:~Unwilling to participate~Minors (under 18 years old)~e) Unfamiliar with slovak language f) Multiple pregnancy g) Musculoskeletal and neurological abnormalities"
89634076|NCT04482504||non-pregnant women|"30 non-pregnant healthy control women The investigators involve every healthy non-pregnant woman.~Exclusion criteria:~Unwilling to participate~Minors (under 18 years old)~e) Unfamiliar with slovak language f) Pregnancy g) Musculoskeletal and neurological abnormalities"
89634077|NCT02414568|Experimental|PVAB regimen|Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1
89634078|NCT02420340|Other|HOPES Group|Participants will participate in twice weekly sessions of the HOPES program until curriculum is completed (approximately 1 year) or discharge from Glencliff home
89634079|NCT04410497|Experimental|Porcine xenograft|Conformité Européenne/European Conformity (CE)-marked dressing product used in clinical practise (Standard of care).
89634080|NCT04410497|Active Comparator|Silver foam|Conformité Européenne/European Conformity (CE)- marked dressing product used in clinical practise
89634081|NCT02420106|Active Comparator|OMM alone|Subjects who are not receiving botulinum treatment consenting to Osteopathic Manipulative Medicine intervention
89634082|NCT02420106|Active Comparator|OMM plus Botulinum|Subjects who are receiving botulinum treatment and will have osteopathic manipulative medicine intervention.
89634083|NCT03116880||Image registration|
89634084|NCT01701245|No Intervention|Standard of care|No intervention, standard of care
89634085|NCT01701245|Active Comparator|GammaCore|Three stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
89634086|NCT03117114|Other|Standard Arm|Standard colonoscopy without mounted Endocuff Vision device. Therefore standard polypectomy in case of polyp resection.
89634087|NCT03117114|Active Comparator|Endocuff Vision Arm|Endocuff Vision device mounted to the endoscope prior to the beginning of the procedure. Therefore EVD assisted polypectomy in case of polyp resection.
89634088|NCT02420028|Experimental|OptiVein IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
89634089|NCT02420028|Active Comparator|Vasofix Certo IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
89634090|NCT04348877|Other|Antibody-Rich Plasma|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
89634091|NCT03176628|Experimental|Basis|Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
89634092|NCT03176628|Placebo Comparator|Placebo|Capsules identical in appearance and number to the agent used in Steps 1-4.
89634093|NCT01590017|Experimental|Cistplatin and Radiation Therapy|Cisplatin 40 mg/m2 (max = 70 mg) IV over 30-60 minutes given weekly on days 1, 8, 15, 22, 29 and 36 for a total of 6 weekly cycles. Radiation therapy over 8 weeks: External pelvic radiation therapy (41.4-45.0 Gy/1.8 Gy per fraction/23-25 fractions/five weeks), intracavitary brachytherapy (low dose: 35-43.6 Gy/1-2 implants; high dose: 18-28 Gy/2-4 implants), with parametrial boost to involved parametria (5.40 - 9.00 Gy/1.8 Gy/3-5 fractions/3-5 days).
89634094|NCT03180060||SPECT|SPECT compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
89634095|NCT03180060||Stress Echo|Stress Echo compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
89041463|NCT03679559|Experimental|Arm I (home-based walking program, resistance training)|Participants wear Fitbit, receive home-based DVD containing instructions to warm-up and cool-down, and brisk walk 30 minutes per day 5 days a week in order to achieve the 150 minutes per week of moderate intensity exercise. Participants also receive resistance training by watching the illustration video and completing 6 total blocks of 2-week per block exercise using the Thera-BandR exercise bands.
89634096|NCT03180060||CMR perfusion|CMR perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
89634097|NCT03180060||CT perfusion|CT perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
89634098|NCT03180060||Positron Emission Tomography|PET compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
89634099|NCT02419794||Group with endovascular treatment|Group with additional endovascular treatment
89041464|NCT03679559|Experimental|Arm II (home-based Zumba program, resistance training)|Participants wear Fitbit and receive a XBOX system and the video game to strive for at least 3 50-minute medium or high intensity classes per week over 12 weeks. Participants may also take 20-minute classes or a mixture of 50- and 20-minute classes to meet the target. Participants receive resistance training as in Arm I.
89041465|NCT03679559|Experimental|Arm III (HIIT, resistance training)|Participants wear Fitbit and attend supervised HIIT exercise sessions 3 days per week over 12 weeks. Participants receive resistance training as in Arm I.
89041466|NCT03679559|Active Comparator|Arm IV (supervised moderate intensity walking program)|Participants wear Fitbit and attend supervised moderate intensity walking sessions weekly for 50-60 each over 12 weeks. Participants undergo resistance training as in Arm I.
89041467|NCT03679559|Active Comparator|Arm V (usual physical activity)|Participants wear Fitbit and continue their usual physical activity over 12 weeks.
89041468|NCT03674671|Experimental|Intravenous Ketamine|
89041469|NCT03674671|Active Comparator|Electroconvulsive Therapy|
89634100|NCT02419794||Group without endovascular treatment|Group without additional endovascular treatment
89634101|NCT03179826||Study population|Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring.
89634102|NCT01700621|Experimental|measles-rubella and rotavirus vaccines|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
89634103|NCT01700621|Active Comparator|measles-rubella vaccine|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age
89634104|NCT02419872||Patient Participants|Patients are confirmed to have either Persistent Asthma or COPD
89634105|NCT03178500|Experimental|Traditional|Clomiphene citrate (50mg) will be given for 5 days (days 3-7). Transvaginal ultrasound from 9th-20th every other day if ovulation occur the patient will be excluded. If no ovulation, we will wait for the next menses and increase the dose to (100mg). if no ovulation occurred increase the dose to (150mg) in the next cycle if no ovulation increase the dose to (200mg) TVUS from 9th-20th ovary other day. If no ovulation we will wait for next cycle and increase the dose to (250mg) and so till 6 cycles.
89634106|NCT03178500|Experimental|Stair step protocol|If there is no response (no follicle >10mm), so, (100mg) clomiphene will be initiated immediately for 5 days and ultrasound will be repeated 1 week after the first ultrasound. If there is no response, (150mg) clomiphene will be initiated immediately for another 5 days and TV/US will be performed 1 week after the second TV/US
89634107|NCT02414412|Active Comparator|Ulmus|Ulmus macrocarpa water extract 250mg orally 2 times a day for 4 weeks
89634108|NCT02414412|Placebo Comparator|Placebo|placebo 250mg orally 2 times a day for 4 weeks
89041470|NCT03668119|Experimental|Nivolumab + Ipilimumab Combination|
89041471|NCT03668119|Experimental|Nivolumab Monotherapy|
89041472|NCT03659799|Active Comparator|Aspart - 60-minutes postprandial exercise|
89041473|NCT03659799|Active Comparator|Aspart - 120-minutes postprandial exercise|
89041474|NCT03659799|Active Comparator|FiAsp - 60-minutes postprandial exercise|
89041475|NCT03659799|Active Comparator|FiAsp - 120-minutes postprandial exercise|
89041476|NCT03653364|Experimental|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
89041477|NCT03624244|Experimental|Interruption of aromatase inhibitors|Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.
89041478|NCT03624244|Other|Maintenance of aromatase inhibitors|Maintenance of aromatase inhibitors
89041479|NCT03620019|Experimental|Single Arm: Denosumab+ PD-1 Inhibitor|Subjects in this trial will be given denosumab every 4 weeks, starting on day 1 of study treatment. An additional loading dose of denosumab will be administered on day 8. Subjects who started Pembrolizumab (initiated 21 days after the first dose of denosumab is given) will continue to have it administered intravenously (IV) every 3 weeks. New subjects will receive Nivolumab administered intravenously (IV) every 4 weeks (initiated 21 days after the first dose of denosumab is given). Combination therapy will continue as long as subjects benefit from therapy for up to 1 year.
89041480|NCT03607565||good perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(good perfusion)
89041481|NCT03607565||middle perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(middle perfusion)
89041482|NCT03607565||poor perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(poor perfusion)
89041483|NCT03591770|Experimental|UC patients on tofacitinib monotherapy|Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
89041484|NCT03591770|Active Comparator|UC patients on anti-TNF monotherapy|Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
89041485|NCT03591770|Active Comparator|UC patients on anti-TNF and a thiopurine|Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
89041486|NCT03591770|Active Comparator|UC pts. on aminosalicylates or off immunomodulatory therapy|Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.
89041487|NCT03569813|Experimental|PrEP@Home System|The experimental group will be assigned to the remote care system for one year of follow-up PrEP care to include home test kits and behavioral surveillance, and telemedicine visits as needed.
89041488|NCT03569813|Active Comparator|Standard of Care|The comparator group will receive active linkage to a local PrEP provider for clinic-based PrEP follow-up. Participants in this study arm will be seen quarterly by a health care provider, per standard of care when taking PrEP.
89041489|NCT03559647||Cohort 1|Participants who have demonstrated a lack of Clinical Benefit from Atezolizumab
89041490|NCT03559647||Cohort 2|Participants who demonstrated durability of Clinical Benefit and Tumor Response to Atezolizumab
89041491|NCT03557502|Experimental|Heat Therapy Group|Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.
89041492|NCT03557502|Experimental|Aerobic Exercise Group|Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
89041493|NCT03489057|Experimental|PERC Program|Prostate Cancer Education and Resources for Couples (PERC) program. Participants assigned to experimental condition will receive access to the PERC website.
89211854|NCT04002999|Active Comparator|Ceramic braces, directly placed|Patients in this group will be treated with directly-bonded traditional tooth-colored ceramic brackets
89634109|NCT02414100||Patient derived cancer cell lines|Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.
89634110|NCT03179982|Experimental|Intervention|"Male adolescents (15-17 years) will be randomly allocated to an intervention arm based on permuted blocked randomization. The intervention arm will receive the HIV-IPV intervention called Safe South Africa.~Safe South Africa is a group-based, facilitated behavioral intervention for prevention of HIV risk and IPV perpetration specifically tailored for male adolescents. The behavioral intervention is comprised of 2-hour sessions, held once a week for a total of two weeks."
89634111|NCT03179982|No Intervention|Control|Male adolescents (15-17 years) will be randomly allocated to a control arm based on permuted blocked randomization. The control arm will consist of ordinary usual care. The ordinary usual care condition will consist of a packet of existing available brochures on HIV and other sexually transmitted diseases including testing, prevention, and treatment; IPV prevention and intervention; and places to access prevention, care, and support for these outcomes and related health outcomes.
89041494|NCT03489057|Active Comparator|usual care plus NCI website|Participants in this usual care plus NCI website group will be automatically directed to the NCI prostate cancer website after logging in to the study website homepage.
89041495|NCT03360643|Active Comparator|Point-of-care ultrasound prior to radiology ultrasound|
89041496|NCT03360643|Active Comparator|Radiology-performed ultrasound|
89041497|NCT03321734|Experimental|Extended Caffeine Treatment|Infants in the extended caffeine treatment arm will, beginning the next day after stopping routine caffeine treatment, receive 5 mg/kg/day of caffeine base and increase to 5 mg/kg/twice-a-day (BID) of caffeine base beginning at 36 weeks + 0 days PMA and continuing the BID doses through 42 weeks + 6 days PMA.
89211855|NCT04002999|Experimental|Ceramic braces, indirectly placed|Patients will be treated with the same brackets from treatment group 1 but using the indirect bonding technique
89634112|NCT03116958|Active Comparator|Standard care|"Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit as per usual care.~Patients will be fitted with a mask and given a CPAP and instructed on how to use the device. Each CPAP machine will be provided with a modem sending daily compliance and adherence information to MyOSA web site but no intervention based on these data is planned in this group. All patients will be visited at 1,3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine. Information will be downloaded from their machines (CPAP adherence, applied CPAP pressure, mask leak, and residual respiratory events…)."
89634113|NCT03116958|Experimental|Telemedicine|"Patients diagnosed as OSA and treated with CPAP, followed up in sleep unit, adding a telemedicine integrated system.~Patients will be fitted with a mask , given a CPAP, and instructed on how to use the device. Using patients' baseline and initial follow-up data a software will provide a prediction of CPAP compliance at 6 months, and propose personalized interventions to increase compliance (smartphone app). All patients will be visited at 3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine."
89634114|NCT03178188|Experimental|laser treated DLE lesions|DLE which received the pulsed-dye laser
89041498|NCT03321734|Placebo Comparator|Placebo|Infants in the placebo arm will, beginning the next day after stopping routine caffeine treatment, receive the equivalent (to study drug) volume of placebo daily and increase to the equivalent (to study drug) volume placebo BID through 42 weeks + 6 days PMA.
89041499|NCT03316196|Experimental|COGENT|Participants will be Veterans assigned to the active cognitive training (see below for details).
89041500|NCT03316196|Sham Comparator|Non-Training|Participants will be Veterans assigned to a non-training cognitive program matched for time and memory demands (see below for details).
89041501|NCT03306316|Experimental|Experimental|Experimental Arm
89041502|NCT03306316|Placebo Comparator|Control|Placebo Control Arm
89634115|NCT03178188|Sham Comparator|sham treated DLE lesions|DLE which received the sham
89634116|NCT02423460|Experimental|Threonine requirement|The threonine requirement in healthy male subjects and in patients with Crohn's disease and Ulcerative colitis
89634117|NCT02423382|Other|3-6 months group|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 3-6 months.
89634118|NCT02423382|Other|6-9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 6-9 months.
89634119|NCT02423382|Other|>9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for more than 9 months.
89634120|NCT02423304||test|"50 periodontitis patients~• Patients will be categorized by Periodontal Disease Index (PDI) by P. Ramfjord(1959) blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase( MMP)-13 in all the patients. studies showing that there is co relation of these genes with increase inflammation."
89634121|NCT02423304||control|50 periodontally healthy individuals blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase (MMP)-13 in all the patients
89634122|NCT02414334|Active Comparator|Immediate SABR|Immediate stereotactic ablative radiotherapy (standard arm)
89634123|NCT02414334|Experimental|Delayed SABR|Delayed stereotactic ablative radiotherapy (delayed= treatment six months after randomisation or at disease progression) (experimental arm)
89041503|NCT03261830|Active Comparator|Pre-operative Antibiotics|Patients randomized to preoperative antibiotics will receive 25mg/kg cefazolin IV up to 1g or clindamycin 10mg/kg up to 600mg IV in cases of documented allergy to cefazolin.
89634124|NCT01589237|Experimental|LCQ908|Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.
89634125|NCT01700387|Experimental|OnabotulinumtoxinA + Topiramate|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with topiramate. During the first month of the treatment period, subjects will titrate as follows:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
89634126|NCT01700387|Placebo Comparator|OnabotulinumtoxinA + Placebo|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with placebo. During the first month of the treatment period, subjects will titrate as follows:~Week 1: 1 tab qhs Week 2: 1 tab bid Week 3: 1 tab q am + 2 tabs qhs Week 4: 2 tabs bid"
89634127|NCT01699685|Placebo Comparator|Sequence A|Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI
89634128|NCT01699685|Active Comparator|Sequence B|Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI
89634129|NCT01587989|Active Comparator|A Methotrexate|
89634130|NCT01587989|Experimental|B Methotrexate Placebo|
89634131|NCT01697969|Experimental|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop once daily in both eyes for 14 days
89634132|NCT01586819|Active Comparator|Botulinum Toxin|The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
89041504|NCT03261830|Placebo Comparator|Saline Placebo|Patients randomized to the no-antibiotic group will receive a saline placebo. This placebo will consist of a 10 mL pre-filled syringe of normal saline.
89041505|NCT03237182|Experimental|Individualized treatment for drug resistant tuberculosis|Patients with drug resistance will have whole genome sequencing performed on the respective positive MGIT sample. An individualized TB treatment regimen will be provided to patients based on the whole genome sequencing results
89041506|NCT03237182|Active Comparator|Standard treatment regimen for drug resistant tuberculosis|As per South African Department of Health Standard of Care for the treatment of drug resistant tuberculosis
89211856|NCT04002999|Experimental|3D printed customized ceramic braces|Patients will be treated using indirectly bonded 3D-printed ceramic (tooth-closed) brackets
89211857|NCT01564251|Experimental|Stage 1 Arm 1: GDC-0575 Monotherapy|Participants will receive escalating doses of GDC-0575, administered orally, for 3 consecutive days, starting on Days 1, 8, and 15 of each 21-day cycle.
89634133|NCT01586819|Active Comparator|Chemical Peel Only|"After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water.~Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly."
89634134|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycle 1|Participants were administered intravenous (IV) fosaprepitant at the following weight-adjusted doses: participants 4 months to <12 years old were administered 5 mg/kg (not to exceed 150 mg); participants 1 to <4 months old were administered 2.5 mg/kg; participants 0 to <1 month old were administered 1.25 mg/kg. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
89634135|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 150 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 3 mg/kg (not to exceed 150 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
89634136|NCT01697579|Experimental|Fosaprepitant 1.2 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 60 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 1.2 mg/kg (not to exceed 60 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
89634137|NCT01697579|Experimental|Fosaprepitant 0.4 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 20 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 0.4 mg/kg (not to exceed 20 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
89634138|NCT01697579|Placebo Comparator|Placebo Control-Cycle 1|Participants were administered IV normal saline at volume to match age and weight specific doses of fosaprepitant. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
89634139|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from the 5 mg/kg fosaprepitant arm in Cycle 1 were administered fosaprepitant 5 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5- hydroxytryptamine 3 (5-HT3) antagonist with or without dexamethasone. Participants 1 year or less were required to receive ondansetron in all cycles as the 5-HT3 antagonist.
89634140|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from Cycle 1 fosaprepitant arms (3, 1.2, or 0.4 mg/kg) or Cycle 1 control arm were administered fosaprepitant 3 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5-HT3 antagonist with or without dexamethasone.
89634141|NCT01586195|Experimental|Vemurafenib|Participants with untreated or previously treated locally advanced, unresectable, Stage IIIc or metastatic melanoma who have an activating exon 15 BRAF mutation other than V600E received vemurafenib 960 milligram (mg) orally twice daily (BID) until disease progression.
89634142|NCT01585961||Catheter Ablation|These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.
89634143|NCT01697501|Experimental|Chronic hepatitis B patients|
89634144|NCT01697345|Experimental|Vaginal Testosterone|Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).
89634145|NCT01769092|Experimental|Fish Oil|Each capsule contains 625 mg of fish oil (100 mg EPA & 250 mg DHA). Participants will take 12 capsules per day over 6 months.
89634146|NCT01769092|Placebo Comparator|Safflower Oil|Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
89634147|NCT03528226|Experimental|Exercise Training|
89634148|NCT03528226|Other|Control|
89634149|NCT00362830|Experimental|1|
89634150|NCT01498042||stroke, thrombolysis, over 80, outcome|To study the outcome of stroke patients over 80 years treated with thrombolysis.
89634151|NCT01106794||Patient samples|Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma
89634152|NCT02975050||Side location|u-Cor device will be applied on side location
89211858|NCT01564251|Experimental|Stage 1 Arm 2a: GDC-0575 + Gemcitabine (750 or 1000 mg/m^2)|Participants will receive gemcitabine 750 milligrams per meter square (mg/m^2) or 1000 mg/m^2, intravenously, on Days 1 and 8 followed by escalating doses of GDC-0575 orally, on Days 2 and 9 of each 21-day cycle.
89211859|NCT01564251|Experimental|Stage 1 Arm 2b: GDC-0575 plus Gemcitabine (500 mg/m^2)|Participants will receive gemcitabine 500 mg/m^2, intravenously, once weekly for approximately 2 consecutive weeks of any 3-week period and escalating doses of GDC-0575 orally approximately 24-hours after each gemcitabine dose.
89211860|NCT01564251|Experimental|Stage 2: GDC-0575 plus Gemcitabine|Participants will receive GDC-0575 in combination with gemcitabine intravenously (1000 mg/m^2 and/or 500 mg/m^2), at or below the MTDs for the combination treatments that are determined during Stage 1.
89634153|NCT02975050||Front location|u-Cor device will be applied on front location
89634154|NCT02441062|Other|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
89634155|NCT02442700|Experimental|Treatment sequence A, B|Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
89634156|NCT02442700|Experimental|Treatment sequence B, A|Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks
89041507|NCT03224819|Experimental|Dose Escalation|"The dose-escalation cohorts to estimate the MTD will use 2 schedules of emerfetamab administration: Schedule A (Day 1/Day 5 dosing in 14-day cycles) and Schedule B (once daily dosing for cycle 1 followed by twice weekly dosing in following cycles).~For Schedule A the starting dose for the first cohort will be 0.05 μg emerfetamab administered as short term IV infusions on day 1 and day 5. The doses administered for the following cohorts will be recommended by the Dose Level Review Team (DLRT).~For Schedule B the starting dose will be 72 μg emerfetamab administered as short-term IV infusions daily (QD) during the 14-day cycle 1 after the 72 μg target dose is found to be relatively safe and tolerable by the DLRT for Schedule A."
89041508|NCT03224819|Experimental|Expansion Phase|For each schedule, upon completion of the dose escalation cohorts, additional participants may be enrolled to receive emerfetamab at a dose at or below the MTD estimated in the dose escalation cohorts.
89041509|NCT03215043|Experimental|Group A|Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
89041510|NCT03215043|Experimental|Group B|Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
89041511|NCT03215043|Experimental|Group C|Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
89041512|NCT03215043|Placebo Comparator|Group D|Individuals will receive the placebo with corn starch excipient for 12 weeks
89041513|NCT03064568|Experimental|Misoprostol 100Mcg Tab|Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.
89634157|NCT02442856|Experimental|Intervention|We will measure dCA with both TCD and DCS during acute changes in mean arterial pressure using thigh cuff deflation techniques in vascular risk factor subjects. Measurements will be compared between TCD and DCS in order to validate DCS as a tool to measure dCA in this population.
89634158|NCT02443792|Experimental|Unicirc with tissue adhesive|Unicirc under topical anesthetic w/ cyanoacrylate wound sealing
89041514|NCT03064568|Placebo Comparator|Placebo|Patients will receive identical inert tablets per rectum 30 minutes preoperatively.
89041515|NCT03048786|Active Comparator|Control Arm|Participants will receive automated text messages drawn from the script used by SmokefreeTXT.
89634159|NCT02443792|Active Comparator|Open Surgical|Open surgical circumcision under local anesthetic with suturing
89634160|NCT02445196|Experimental|PTSD Coach|Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
89634161|NCT02445196|Active Comparator|Waitlist Control|"Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them."
89041516|NCT03048786|Experimental|Peer Mentoring Arm|Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor.
89041517|NCT02885142|Experimental|Transanal endoscopic microsurgery group|
89041518|NCT02885142|Active Comparator|endoscopic submucosal dissection group|
89041519|NCT02879201|Active Comparator|Slow efficiency dialysis|SLED is a kind of hemodialysis technique performed using Fresenius 4008B dialysis machine with FDX 120 GW (NIKKISO Japan) dialyzer. SLED sessions were 6-8 hour duration, three times per week (except Sunday), In case of severe volume overload, the session could be increased to meet clinical situation. Blood flow was maintained between 150-200 mL/hr and the dialysate flow of 300 mL/hr. Both the groups use unfractionated heparin as anticoagulant to prevent clotting of the extracorporeal circuit .the target partial thromboplastin time( PTT) was not more than twice the control level.
89041520|NCT02879201|No Intervention|Continuous renal replacement therapy|CRRT is a kind of therapy involved continuos dialysis throughout 24 hours by using Edward Delivery system (Edward Life Science) as continuous venovenous hemodiafiltration (CVVHDF) mode using Aquamax HF 12 dialyzer. Blood flow rate was kept from 100-200 mL/hr and target effluent rates of 20 mL/hr . The substitution fluid was infused at a rate of 1,000 ml/hr with ultrafiltration rate at 100-300 mL/hr.Intervention here is the different mode of dialysis
89041521|NCT02785042|Experimental|Normal healthy volunteers|imaging with Heidelberg Spectralis OCT
89041522|NCT02785029|Experimental|Normal healthy Volunteers|OCT imaging
89041523|NCT02783950|Other|GC (Decipher) Arm|If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
89634162|NCT00619528|Experimental|1|No separate arms: All Enrolled Receive Same Treatment
89634163|NCT02447926|Other|Leaukapheresis of End Stage Liver Disease Patients|Leukapheresis. All subjects will receive the same treatment arm.
89634164|NCT00568672|Active Comparator|1|Olanzapine 5 mg / day
89634165|NCT00568672|Placebo Comparator|2|Placebo
89634166|NCT04744246|Active Comparator|Without Load|5 kilometer walk with no load carried
89634167|NCT04744246|Experimental|With Load|5 kilometer walk with load
89634168|NCT02448862||Elderly patients|Patients aged over 70 who had used fentanyl based IV-PCA for postoperative pain.
89634169|NCT02448862||Young adults|Patients aged 20 to 39 who had used fentanyl based IV-PCA for postoperative pain.
89041524|NCT02783950|No Intervention|Usual-Care-Based (UC) Arm|If enrolled during the UC period, only the CAPRA-S results will be provided.
89211861|NCT00844220|Experimental|CT/MR|CT/MRI-directed clinical management strategy
89634170|NCT01697267|Experimental|Rituximab Maintenance|Rituximab maintenance: 1g at 4, 8, 12, 16 & 20 months with standardised steroid taper
89634171|NCT01697267|Active Comparator|Azathioprine Maintenance|Azathioprine Maintenance: 2mg/kg/day with standardised steroid taper, from month 4 (randomisation) (200 mg maximum daily dose). Azathioprine withdrawn at month 27.
89634172|NCT02449174|Active Comparator|Frozen Microbiota|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
89634173|NCT02449174|Active Comparator|Lyophilized Microbiota|Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
89634174|NCT02449798|Experimental|"AccuCath 2.25 BC Intravascular Catheter"|"Use of AccuCath 2.25 BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins."
89634175|NCT00362908|Active Comparator|Group 1|"Subjects consume study diets in the following order:~Diet 1 (20% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 2 (40% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
89634176|NCT00362908|Active Comparator|Group 2|"Subjects consume study diets in the following order:~Diet 2 (40% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 1 (20% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
89634177|NCT00362986|Experimental|sunscreen|"Patients apply sunscreen generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
89211862|NCT00844220|Active Comparator|Catheterization|Standard clinical management
88990841|NCT06152146|Placebo Comparator|SHAM group|Participants randomized to the sham (control) group will have nine (9) sham therapy sessions in total: one (1) sham session once per week for four (4) weeks, followed by one (1) sham session once per month (30±7 days) for the next five (5) months. The shockwave machine will be set to deliver 1,440 shock treatments, but a barrier will be placed around the shockwave probe to ensure that no shockwaves are delivered. Participants will be in this group for up to 6 months.
88990842|NCT06150573|Experimental|Test Dentifrice|Participants will dose the toothbrush provided with a strip of test dentifrice (5% KNO3, 1% alumina, 5% STP and 1150 parts per million [ppm] fluoride as sodium fluoride) and will brush for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice will be used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants will perform the first application of peroxide tooth bleaching as per the instructions provided and continue the application daily for up to 7 days.
88990843|NCT06150573|Active Comparator|Reference Dentifrice|Participants will dose the toothbrush provided with a strip of reference dentifrice (dentifrice containing 1150 ppm fluoride as sodium fluoride) and will brush for two timed minutes twice daily (morning and evening) for up to 27 weeks (dentifrice will be used for 2 weeks pre peroxide, 1 week during peroxide and 24 weeks post peroxide application). At Week 3, participants will perform the first application of peroxide tooth bleaching as per the instructions provided and continue the application daily for up to 7 days.
88990844|NCT06146816|Experimental|high intensity fIR therapy|Patients will undergo 10 sessions of 30 minutes high intensity fIR therapy at the IBD clinic of the TLVMC by a trained and qualified staff member. Each abdominal quadrant will receive a similar amount of time of exposure to the IR, except for the quadrant of the inflamed intestine (usually the right lower quadrant) which will be exposed longer to the IR. During the treatment, energy levels and skin temperature will be recorded at 10 minutes intervals. Patients responding to therapy (clinical response: ∆HBI≥3 and/or 50% reduction in calprotectin), who did not achieve remission can continue for 10 more treatments.
88990845|NCT06146816|Placebo Comparator|lowest intensity fIR therapy|Patients will undergo 10 sessions of 30 minutes lowest intensity fIR therapy, at the IBD clinic of the TLVMC by a trained and qualified staff member. Each abdominal quadrant will receive a similar amount of time of exposure, except for the quadrant of the inflamed intestine (usually the right lower quadrant) which will be exposed longer. During the treatment, energy levels and skin temperature will be recorded at 10 minutes intervals.
88990846|NCT06145191|Experimental|Tranexamic acid|
88990847|NCT06145191|Experimental|Adrenaline|
88990848|NCT06145191|Placebo Comparator|Placebo|
88990849|NCT06141967|Experimental|WITHINGS Sleep Analyzer|The sleep apnea screening device used is a medical screening device WITHINGS Sleep Analyzer (WSA)
88990850|NCT06140173|Experimental|Contrast group (CG)|
88990851|NCT06140173|Active Comparator|Traditional group (TG)|
88990852|NCT06132334|Experimental|Upper extremity aerobic exercise training|The training group will receive upper extremity aerobic exercise training on an arm ergometer accompanied by a physiotherapist for 6 weeks.
88990853|NCT06132334|Sham Comparator|Control Group|The control group will not be given any training for 6 weeks during the study period.
88990854|NCT06131099|Active Comparator|Group A|In this group patient will be treated with standard treatment protocol. This group will receive therapy session for 1 hour, three sessions in a week and for 6 weeks, total sessions will be 18. Group A will receive soft tissue massage therapy for 5 mins and the task specific training interventions include bicycle training for 10 mins. After that aerobic exercises includes and finally some of progressive resistive exercises will involve in it.
89041525|NCT02773004|Other|EndoPredict (EP)clin testing|Once the patient is registered, the most representative block of the primary tumor from surgery (or 10 paraffin slides) are sent to the central analysis platform for EP clin testing. The EPclin method is based on analysis of tumour genes in combination with the classical prognostic factors of nodal status and tumour size.
89041526|NCT02691078|Experimental|Adult patients with neuroendocrine tumors|
89041527|NCT02549573|Active Comparator|Apokyn treatment before physical therapy|"APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit."
89041528|NCT02549573|Other|Apokyn treatment withheld before physical therapy|"APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation."
89634178|NCT00362986|Placebo Comparator|placebo|"Patients apply placebo generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
89634179|NCT00363376|Experimental|Sugar pill|"olanzapine and placebo (sugar pill)"
89634180|NCT00363376|Experimental|Zonisamide|olanzapine and zonisamide (active drug)
89634181|NCT02451202|Experimental|Deep Neuromuscular Blockade arm|"After initial doses of 0.6 mg Rocuronium, a continuous infusion can be initiated to maintain 0 responses to train-of-four (TOF) stimulation or 1-2 responses to Post-Tetanic Count (PTC) (Deep NMB). The pump rate will vary and depends on the PTC value. The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required PTC value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthetist. Deep NMB should be maintained throughout the operation.~The infusion of Rocuronium will be discontinued and Sugammadex will be given 4 mg/kg at the end of surgery, which is from deep NMB (PTC = 1-2)."
89634182|NCT02451202|Active Comparator|Moderate Neuromuscular Blockade arm|"After evidence of early spontaneous recovery (< 10% of control T1) from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain 1 to 2 responses to train-of-four stimulation (Moderate NMB). The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required TOF value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthesiologist. Moderate paralysis should be maintained throughout an operation.~At the end of surgery, the infusion of Rocuronium will be discontinued and Sugammadex 2 mg/kg via bolus injections]will be administered at least reappearance of T2."
89634183|NCT02451514|Experimental|MenABCWY+OMV Group|Subjects who received 2 doses of MenABCWY+OMV vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received a booster dose of MenABCWY+OMV vaccine in the current study at Day 1.
89634184|NCT02451514|Experimental|MenACWY Group|Subjects who received MenACWY vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received 2 doses of MenABCWY+OMV vaccine, one month apart (Day 1 and Day 31), in the current study.
89634185|NCT02451514|Experimental|Naive Group|Subjects similar in age to subjects in the MenABCWY+OMV and MenACWY groups, who had not previously received any meningococcal vaccine and who received 2 doses of MenABCWY+OMV vaccine, 1 month apart (Day 1 and Day 31), in the current study.
89634186|NCT02452060|Placebo Comparator|treatment/placebo|saline infusion
89041529|NCT02542657|Experimental|Treatment (PiC-D therapy)|"Patients receive pomalidomide PO QD on days 1-21; ixazomib citrate PO on days 1, 8, and 15; clarithromycin PO BID on days 15-21 of course 1 and days 1-21 of courses 2-6; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY:~Patients receive pomalidomide, ixazomib citrate, and dexamethasone as above and receive clarithromycin PO BID or QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89041530|NCT02503423|Experimental|Phase 1 - Part 1 (completed)|Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
89041531|NCT02503423|Experimental|Phase 1 - Part 2 (completed)|Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
89041532|NCT02503423|Experimental|Phase 1 - Part 3 (optional)|The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
89041533|NCT02503423|Experimental|Phase 2 - Cohort 1|Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
89041534|NCT02503423|Experimental|Phase 2 - Cohort 2|Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
89041535|NCT02503423|Experimental|Phase 2 - Cohort 3|Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
89041536|NCT02503423|Experimental|Phase 2 - Cohort 4|Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
89057529|NCT01683552|Other|Aprepitant after anti-itch standard therapy|Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week
89057530|NCT04532723|Experimental|ExoAtlet II|Safety/feasibility of utilizing the ExoAtlet II in a clinical setting with a group of individuals with SCI
89634187|NCT02452060|Experimental|treatment|ketamine (0.4mg/kg)
89634188|NCT01696955|Experimental|Arm I (cetuximab and tivantinib)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89634189|NCT01696955|Experimental|Arm II (cetuximab)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89634190|NCT02452528|Experimental|ARC-520|"Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug."
89634191|NCT02452528|Placebo Comparator|Placebo|"Intravenous administration of normal saline (0.9%) once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of placebo."
89634192|NCT04743700|Experimental|Piezocision on Experimental Side A|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome to accelerate maxillary canine retraction
89634193|NCT04743700|Experimental|Micro-osteoperforations on Experimental side B|Three MOPs with the help of mini-implant screw driver,mesial and distal to canine(in a vertical line) with the help of minisrew implant driver to accelrate maxillary canine retraction
89634194|NCT02702388|Experimental|24 mg Lenvatinib|Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
89634195|NCT02702388|Experimental|18 mg Lenvatinib|Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
89634196|NCT04744168|Experimental|Acupuncture|In the experimental arm, pregnant women at term will benefit one or two acupuncture sessions with five points : 4GI, 6RP, 34VB,36E,3F. The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both.
89634197|NCT04744168|Placebo Comparator|Placebo acupuncture|"In the placebo arm, pregnant women will benefit one or two acupuncture sessions with one point which is located outside the acupuncture meridian.~The first session at 41 amenorrhea weeks and the second at 41 amenorrhea weeks and 3 days if they are not delivered between the both."
89634198|NCT02456896|No Intervention|Healthy control|Twenty five (25) age and sex matched healthy individuals will serve as the control group. Control subjects will be evaluated at baseline only.
89634199|NCT02456896|Experimental|Oxcarbazepine|Twenty five (25) patients of bipolar mania will be prescribed oxcarbazepine for 4 weeks.
89634200|NCT01696877|Active Comparator|Degarelix|Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg at 14 (±3) days prior to surgery. A telephone follow-up interview (or an in-person clinic visit) to evaluate for adverse events will occur 28 (±21) days after prostatectomy. Patients will then be followed by their urologists according to standard institutional practices, but will require prostate-specific antigen evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.
89634201|NCT01696877|Experimental|Cyclophosphamide, GVAX and Degarelix|Cyclophosphamide will be given at a dose of 200 mg/m2 as a single intravenous infusion. 1 day later, prostate GVAX will be administered as five 0.8-mL intradermal injections of PC3 (2.5 × 108 cells) and five 0.5-mL intradermal injections of LNCaP (2.5 × 108 cells), for a total dose of 5 × 108 cells. On day 14, Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg.
89634202|NCT02416102|Active Comparator|Healthy non-smokers|10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
88990855|NCT06131099|Active Comparator|Group B|In this group patient will be treated with Dohsa hou exercises. This group will receive therapy session for 1 hour, three sessions in a week and for 6 weeks, total sessions will be 18. Group B will receive Dohsa hou exercises, session will be included three activity parts: (a) 10 minutes of instruction and preparation, (b) 45 minutes of skill instruction and practice, and (c) 5 minutes in a closing activity.
88990856|NCT06130969|Experimental|Group A|Cervical Retraction exercise without diaphragmatic breathing along with baseline treatment
88990857|NCT06130969|Experimental|Group B|Cervical Retraction exercise with diaphragmatic breathing along with baseline treatment
88990858|NCT06127147|Experimental|Study Group|Patients who will perform inspiratory muscle training (IMT) with %60 of MIP intensity
88990859|NCT06127147|Sham Comparator|Sham Group|Patients who will perform Sham-IMT
88990860|NCT06126523|Active Comparator|ESWT once|A single session of rESWT will be applied on the same day after BTX-A injection.
88990861|NCT06126523|Active Comparator|ESWT twice|A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.
88990862|NCT06126523|Sham Comparator|Sham ESWT|A single session of placebo rESWT will be applied after BTX-A injection.
88990863|NCT06117813|Experimental|Nu.T|Nu.T, 5 times a week for 8 weeks.
88990864|NCT06117813|Other|No-treatment Control|No-treatment was administered during control period.
88990865|NCT06113042|Experimental|Comprehensive support (Group 1)|Comprehensive health support will be performed both in district community hub and school. Interventional services include heath talks, learning packs, hub-based comprehensive lifestyle modification programme, school healthy environment evaluation.
88990866|NCT06113042|Experimental|School-based support (Group 2)|Interventional services will be performed in school only, including heath talks, learning packs, school-based lifestyle modification programme, school healthy environment evaluation.
89211863|NCT00508144|Experimental|Alimta|Alimta 500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks.
88990867|NCT06113042|Experimental|District-based support (Group 3)|Interventional services will be performed in community hub only, including heath talks, learning packs, hub-based lifestyle modification programme.
88990868|NCT06113042|Placebo Comparator|Control (Group 4)|Limited services will be provided including health talks and learning packs.
88990869|NCT06106087|Other|QI Training|Frontline staff in personal care homes will receive quality improvement training from an experienced quality advisor and support staff in making changes aimed to improve the quality of care for residents in the home.
88990870|NCT06104618|Experimental|Treatment (Enfortumab vedotin)|Patients receive enfortumab vedotin IV over 30 minutes on days 1,8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88990871|NCT06104553|Experimental|SHR-A1912 combined with R-Chemo (Phase 1b)|
89211864|NCT00844454|Experimental|QFEA|multi-pronged ethanol ablation
89211865|NCT00844454|Active Comparator|RFA|radiofrequency ablation
89211866|NCT02545712||Neonatal patients|Receiving 2 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
89211867|NCT02545712||Pediatric patients (28 days ≤ 5 years)|Receiving 3 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
89211868|NCT01011010|Other|Single Arm|Single Arm Trial
89634203|NCT02416102|Experimental|Smokers without COPD|10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
89634204|NCT02416102|Experimental|Ex-smokers with COPD|10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
89634205|NCT03178110|Experimental|Physical therapy and dynasplint|Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week.
89634206|NCT03177876|Experimental|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles [Nanostreams] with simultaneous implant placement
89634207|NCT03177876|Active Comparator|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
89634208|NCT02458768|Experimental|IVF-M HP Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
89634209|NCT02458768|Active Comparator|Menopur® Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
89634210|NCT02423226|Active Comparator|CT alone|Treated with systemic chemotherapy alone (FOLFIRI).
89634211|NCT02423226|Experimental|CT+BT|Treated with systemic chemotherapy (FOLFIRI) plus computed tomography guided radioactive seeds implant.
89634212|NCT02418676|Experimental|Gel with HPβCD-I complex|A quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
89634213|NCT02418676|Active Comparator|Gel with insulin|A quantity of 5 grams of gel with insulin was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
89634214|NCT02418676|Placebo Comparator|Control gel|A quantity of 5 grams of gel without active was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
88990872|NCT06104553|Experimental|SHR-A1912 combined with R-Chemo (Phase 2)|
88990873|NCT06099886|Experimental|Lithium aspartate|Lithium aspartate capsules will be titrated in each patient to the maximum tolerated dosage between 30-45mg/day.
89634215|NCT02423148|Experimental|FluoSCOPE device|"All study interventions will occur intraoperatively during the subject's planned surgery. No deviation from standard of care will be performed with the exception of the following specific interventions:-~Intraoperative injection of indocyanine green (ICG) around tumor and imaging with the FluoSCOPE NIR endoscopic imaging system~Treatment will be administered on an inpatient basis"
89634216|NCT02413866|Experimental|Calorie Restriction Only|Participants in this group will be decreasing their caloric intake to approximately 95% of their resting metabolic rate. We will provide one meal for 4 days of the week, and participants will be required to keep an accurate dietary record of all food and drink. Participants assigned to this group will be instructed to keep a fixed sleep schedule based on their own sleep/napping habits.
89634217|NCT02413866|Experimental|Sleep & Calorie Restriction|Participants in this group will decrease their caloric intake to approximately 95% of their resting metabolic rate in addition to reducing their total time in bed by 90 minutes 5 days a week.
89634218|NCT02419690|No Intervention|Usual Care|The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
89634219|NCT02419690|Active Comparator|text message intervention|Subjects in the intervention arm will receive usual care plus text messages that have been developed to promote overall teen sexual health.
89634220|NCT02419638||Randomized Treatment Arm: Rebif|120 patients treated with Rebif (IFN β-1a subcutaneous three times per week)
89634221|NCT02419638||Randomized Treatment Arm: Tecfidera|120 patients treated with Tecfidera (dimethyl fumarate)
89634222|NCT02413944|Experimental|healthy volunteers|ACTH stimulation test
89634223|NCT02460172|Active Comparator|Zip Surgical Skin Closure|Subject will be randomized to receive one knee (right or left) closed with Zip Surgical Skin Closure and the other knee closed with steel staples.
89634224|NCT02460172|Active Comparator|Steel Staples|Subject will be randomized to receive one knee (right or left) closed with steel staples and the other knee closed with Zip Surgical Skin Closure.
89634225|NCT02422836|Experimental|Three Product Anti-Aging Regimen|"Three Product Anti-Aging Treatment Regimen:~Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks"
89634226|NCT02419924|Experimental|Experimental|Pelvic floor support device to treat refractory constipation.
89634227|NCT02419482|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
89634228|NCT02419482|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
89634229|NCT02419482|No Intervention|control|Physical activity recommended
89634230|NCT02461966|Other|Hepatocellular carcinoma (HCC)|Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)
89634231|NCT02461966|Other|20 cirrhotic patients|Estimation of serum aflatoxin level in 20 patients with liver cirrhosis
89634232|NCT02461966|Other|Control group|Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
89634233|NCT03179358|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
89634234|NCT02413710|Active Comparator|Usual Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
89634235|NCT02413710|Experimental|Soy Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the USDA MyPlate program (www.choosemyplate.gov) with the incorporation of two servings of study food providing soy protein per day.
89634236|NCT02419950||No fixation of mesh in TEP|Patient having no mechanical fixation of the mesh in TEP. This will include both no fixation at all och glue fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
89634237|NCT02419950||Fixation of mesh in TEP|Patients having fixation of the mesh using mechanical, non absorbable fixating devices.This will include mechanical fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
89634238|NCT03179592||Low-volume contrast media injection protocol|Patients will receive a low-volume contrast media (Ultravist 370Mg I/Ml Solution for Injection) injection protocol that is tailored to a specific tube voltage. Tube voltages will be automatically selected by the scanner to be used for the CCTA acquisition.
89634239|NCT02413632|Other|First period|"creation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
89634240|NCT02413632|Other|Second period|"validation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
89634241|NCT02421094|Active Comparator|GR-MD-02|Active
89634242|NCT02421094|Placebo Comparator|Placebo|Placebo
89041537|NCT02503423|Experimental|Phase 2 - Cohort 5|Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.
89041538|NCT02503423|Experimental|Phase 2 - Cohort 6|Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
89041539|NCT02497534||Affected with Friedreich's ataxia|Friedreich's ataxia patients aged 8 to 70 (inclusive). Assessments will include collection of genetic mutation reports, cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing with a recombinant bike and/or hand ergometer, pulmonary function testing, and gait analysis. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
89041540|NCT02497534||Healthy controls|Health controls aged 8 to 70 (inclusive). Assessments will include cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing, hand ergometer for exercise testing, pulmonary function testing, gait analysis, and an optional blood draw.
89634243|NCT02419404||Patients having cardiac surgery|Patients having cardiac surgery who have a pulmonary artery catheter will be eligible for inclusion in this study
89634244|NCT03179514|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
89634245|NCT03179514|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
89634246|NCT02462122|Experimental|IDP-118 Lotion|Lotion
89634247|NCT02462122|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
89634248|NCT00707304|Experimental|1|Talactoferrin alfa (talactoferrin or TLF, also known as recombinant human lactoferrin, rhLF or talactoferrinum alfa) is a recombinant version of the glycoprotein expressed in and purified from Aspergillus niger var. awamori. Talactoferrin is structurally and functionally similar to native human lactoferrin. The structural equivalence of talactoferrin to native human lactoferrin has been demonstrated by a comparison of the 3-dimensional structure, molecular weight, biological activity and other physicochemical properties, and is known to differ only in the nature of glycosylation.
89634249|NCT00707304|Placebo Comparator|2|Placebo contains the same phosphate-based buffer used as the diluent for the talactoferrin solution. In addition, the placebo will contain FD&C/EU grade dyes suitable for oral use to mimic the color of the vialed drug product.
89634250|NCT02423122|Experimental|VX-745 dose 1|Active Group 1: VX-745 40 mg twice daily
89634251|NCT02423122|Experimental|VX-745 dose 2|Active Group 2: VX-745 125 mg twice daily
89634252|NCT02464540|Active Comparator|Light-cured resin cement|Laminate veneers luted using light-cured resin cement
89041541|NCT02497534||Carriers of Friedreich's ataxia|An obligate carrier aged 18 to 70 (inclusive) of the abnormal Friedreich's ataxia gene by being a parent of a child with Friedreich's ataxia. No assessments are to be conducted. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
89634253|NCT02464540|Active Comparator|Light-cured flowable composite|Laminate veneers luted using light-cured flowable composite
89634254|NCT02423200|Experimental|VX-745 dose level 1|Active Group 1: VX-745 dose level 1 twice daily
89634255|NCT02423200|Experimental|VX-745 dose level 2|Active Group 1: VX-745 dose level 2 twice daily
89634256|NCT02422992||PD|100 PD patients were patients diagnosed with Parkinson's disease
89634257|NCT02422992||Controls|242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients
89634258|NCT02422758|Experimental|Active Prewarming 3M™ BairHugger™Blanket|Patients will have the whole body covered with the3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket of forced air warming system for 20 minutes, at average power.Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
89634259|NCT02422758|Placebo Comparator|Passive Prewarming|Passive prewarming with a cotton sheet and blanket for 20 minutes. Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
89634260|NCT02423980|Experimental|Glucagon|1 mg G-Pen™ (glucagon injection) first, followed by 0.5 mg
89634261|NCT02422914|Experimental|Nicotine|Smoking cessation program TFC and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (with nicotine) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
89634262|NCT02422914|Placebo Comparator|Nicotine-free|Smoking cessation program TFC-free and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (nicotine-free) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity trackerand ad-hoc items.
89634263|NCT02422914|Active Comparator|No-cig|Smoking cessation program and activity tracker. Three months low intensity counselling at distance program;subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
89634264|NCT02424526|Active Comparator|high-intensity group|Children will engage in home-based treadmill training 5 days/week, twice daily for 10-20 min for 6 weeks
89634265|NCT02424526|Active Comparator|low-intensity group|Children will engage in home-based treadmill training 2 days/week, once daily for 10-20 minutes for 6 weeks
89634266|NCT03176316|Experimental|Naloxone|1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours
89634267|NCT02419170|Experimental|Surgery/Apheresis/Cyclophosphamide/Vaccine|"Standard of care surgery~Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery~Cyclophosphamide 300 mg/m^2 intravenously (Day -4)~Personalized vaccine (Day 1)~Booster dose of personalized vaccine (Day 43)~Booster dose of personalized vaccine (Day 85)"
89634268|NCT00363454|Experimental|Dose Escalation|Phase I: Triciribine Phosphate Monohydrate
89634269|NCT02419326|Experimental|Couples|The patient and their significant other receive psychotherapy treatment for the patient's BED.
89041542|NCT02378181|Experimental|Toolkit (TK)|Patients in the TK condition will receive counseling sessions from participating counselors who have been trained to use the Health Education Toolkit (TK).
89634270|NCT02974426|Experimental|Arm I (PORT-first strategy)|Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.
89634271|NCT02974426|Active Comparator|Arm II (PORT-last strategy)|Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.
89041543|NCT02378181|Active Comparator|Treatment-as-usual (TAU)|Patients in the treatment-as-usual (TAU) condition will receive the same number of counseling sessions as patients in the TK condition from participating counselors who have not been trained to use the Health Education Toolkit. Counselors working with patients in this condition will receive a control training of the same length and intensity on recovery topics that are covered in the Health Education Toolkit, but will not be equipped with the Toolkit.
89041544|NCT02371460|Experimental|DHA-rich algal oil|1200mg DHA per day
89041545|NCT02371460|Placebo Comparator|Placebo|No supplementation in DHA
89041546|NCT02301663|Experimental|Women w/microvascular disease|10 women with microvascular disease
89041547|NCT02301663|Experimental|Normal controls|10 age-matched women with no evidence of microvascular disease
89041548|NCT02301663|Experimental|calibration|10 healthy individuals who will help to synchronize our imaging and stress testing maneuvers.
89634272|NCT02413242||ICU subjects, S. aureus+ at ICU admission|"Adult ICU patients, with a positive colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Positivity of either of the two qualifies the patient to be enrolled as a subject in this group."
89211869|NCT05357391|Experimental|The pressure injury prediction and education model group|The experimental group will be provided a pressure injury prediction of the patient and personalized care information of pressure injury by a smart care platform. The participants (primary caregivers) will fill out the questionnaires online at admission (baseline-T0) and before the patient is discharged(T1). The questionnaires will collect the following data, including demographic information(only T0), knowledge, self-efficacy, anxiety, depression of wound care(T0&T1), and satisfaction of the smart care platform(only T1). The time to fill out the questionnaires will be about 10 minutes.
89211870|NCT05357391|No Intervention|The control group|Routine care
88990874|NCT06099002||Individuals with COPD over the age of 65 with a history of falls|Individuals with COPD who were over the age of 65 and had a history of falling were included in this group.
89634273|NCT02413242||ICU subjects, S. aureus- at ICU admission|"Adult ICU patients, with a negative colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Negativity of both qualifies the patient to be enrolled as a subject in this group."
89634274|NCT02413476|Experimental|Robotic-assisted Gastrectomy(RAG)|Robotic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
89634275|NCT02413476|Active Comparator|Laparoscopic-assisted Gastrectomy(LAG)|Laparoscopic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
89634276|NCT02426476|Experimental|active HRVB training|Heart rate variability biofeedback training
89634277|NCT02426476|Sham Comparator|sham HRVB training|passive relaxation
89634278|NCT02413554|Experimental|Patch applied patients|"The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture.~Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation."
89634279|NCT02413554|No Intervention|Patch non-applied patients|The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches.
89211871|NCT00851708|Active Comparator|NAC|treatment
89211872|NCT00851708|No Intervention|control|
89634280|NCT02422602|Active Comparator|Taking conventional charge|No further information is given to the patient during the first and only contact with the nurse of the coordinator center. A time will be dedicated by the IDE to answer questions of the patient.
89634281|NCT02422602|Experimental|Personalized information intervention|The intervention of personalized information will be made as appropriate to the patient's needs and will include: Personalized telephone information carried by a nurse trained in therapeutic education. A time will be dedicated by the IDE to answer questions of the patient. The delivery of paper documents, a list of recommended websites and phone remote monitoring will be performed by the nurse at J30 and J45 to check understanding of the information provided, the actual reading of the paper documents, or effective consultation of websites. A time will be dedicated by the IDE to answer questions at the remote monitoring of the patient to J30 and J45.
89634282|NCT02465632|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|apply a thin layer of gel to the face
89634283|NCT02465632|Active Comparator|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|apply a thin layer of the gel to the face
89634284|NCT02465632|Placebo Comparator|Placebo topical gel|apply a thin layer of the gel to the face
89634285|NCT02419092||Obstructive Sleep Apnea|Subjects scheduled to undergo bariatric surgery and with Obstructive Sleep Apnea
89634286|NCT02419092||No Obstructive Sleep Apnea, controls|Subjects scheduled to undergo bariatric surgery and without Obstructive Sleep Apnea, control group
89634287|NCT02466412|Active Comparator|CHTP 1.1 M then mCC|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CHTP 1.1 M)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of mCC)."
89634288|NCT02466412|Active Comparator|mCC then CHTP 1.1 M|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of CHTP 1.1 M)."
89634289|NCT02422680||Patients referred to a colonoscopy|A min. of 800 patients referred to colonoscopy at Aalborg University Hospital. The 800 patients are from the out patient clinic. A mix of screening and non-screening patients.
89634290|NCT02466646|Active Comparator|Full-mouth Disinfection IPT|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
89634291|NCT02466646|Experimental|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
89634292|NCT02466646|Experimental|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
88990875|NCT06099002||Individuals with COPD who are over the age of 65 and have no history of falling|Individuals with COPD who were over the age of 65 and did not have a history of falling were included in this group.
88990876|NCT06097819|Experimental|Mobile app-based game group|The mobile app-based game group will receive the Becure mobile game program in addition to occupational therapy interventions and the sensor-based game application. This program will be implemented for 10 minutes a day, 5 days a week, for a duration of 6 weeks.
88990877|NCT06097819|Experimental|Supervised combined sensor-based game group|A supervised combined sensor-based game intervention based on occupational therapy will be applied to this group. For this group, a supervised combined sensor-based game program was designed in addition to 12 sessions of occupational therapy interventions over 6 weeks, with 2 sessions per week and each session averaging 30 minutes
88990878|NCT06097819|Experimental|Individualized occupational therapy group|Individualized occupational therapy group will receive occupational therapy sessions. During these sessions, activities that involve weight transfer, balance, fine motor skills, neuromuscular function, and cognitive skills will be implemented. Treatment will be administered for 2 days a week over a period of 6 weeks. Each session will last an average of 30 minutes. A total of 12 occupational therapy sessions will be conducted
89211873|NCT01011088||Early phase|Psychoses within the first 3 months after baby born
88990879|NCT06093542|Experimental|AZD7503|Participants will subcutaneously receive AZD7503.
89211874|NCT01011088||Delayed phase|Psychoses > 3 months to one year after baby born
89211875|NCT01011166|Experimental|IDX184 50 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo once daily (QD) in combination with Peg-IFN/RBV on Days 14-28 and Peg-IFN/RBV on Days 14-28.
89211876|NCT01011166|Experimental|IDX184 100 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
89211877|NCT01011166|Experimental|IDX184 100 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo twice daily (BID) in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
89211878|NCT01011166|Experimental|IDX184 150 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 150 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
89211879|NCT01011166|Experimental|IDX184 200 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
89211880|NCT01011166|Experimental|IDX184 200 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 200 mg or placebo BID in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
89634293|NCT02703636|Other|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
89634294|NCT02419014|No Intervention|Usual Care|Participants in this group will continue receiving their previously prescribed therapy during the 8 week data collection period.
89634295|NCT02419014|Active Comparator|Active CES Device|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
89634296|NCT02419014|Placebo Comparator|Sham CES Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
89634297|NCT02422056|Placebo Comparator|Placebo|Saline infusion: Group receiving saline as placebo during the surgical procedure
89634298|NCT02422056|Experimental|Intervention|Tranexamic acid infusion: Group that received a Tranexamic acid bolus of 10mg / kg, followed by continuous infusion of 1 mg / kg / hr until the end of the procedure.
89634299|NCT02466958|Active Comparator|levomilnacipran (FETZIMA)|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
89634300|NCT02466958|Placebo Comparator|Placebo|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
89634301|NCT02418936||WS|WS diagositic kit
88990880|NCT06093542|Placebo Comparator|Placebo|Participants will subcutaneously receive placebo.
88990881|NCT06086873|Experimental|NGA Implant|NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)
88990882|NCT06086873|Experimental|BLX implant (BLX) modSLA Surface|BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)
88990883|NCT06086873|Experimental|TLX implant (TLX) modSLA Surface|TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland).
88990884|NCT06086730|Experimental|blow bottle positive expiratory pressure|Water was poured into a 1 L plastic container until it reached a 10 cm height. A 30 cm long tube was put into the water in the bottle, 8 cm deep. The participants were instructed to close their mouths around the tubing in the apparatus for three seconds to produce bubbles, do this for a total of 10 breaths, perform two huffs, then cough. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized
89041549|NCT02229968|Experimental|Amicar (ε-aminocaproic acid)|Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.
89041550|NCT02229968|Placebo Comparator|normal saline|Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.
89041551|NCT02222844|No Intervention|Preoperative CT scan|CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)
89211881|NCT00621842|Experimental|Open-Label Lamotrigine Treatment|
89211882|NCT05356143|Other|Sequence 1|Subjects will take comparator and active drug at different study periods Treatment sequence AAB
89211883|NCT05356143|Other|Sequence 2|Treatment sequence ABA
89211884|NCT05356143|Other|Sequence 3|Treatment sequence BAA
89211885|NCT04849455|Experimental|Active Treatment|This group will receive a continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 120 minutes with 2ml/hr continuous infusion (14mls total every 2 hours per catheter)
89211886|NCT04849455|Placebo Comparator|Placebo|This group will receive a superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
89634302|NCT02418936||LVAS|LVAS diagositic kit
89634303|NCT02422134|Active Comparator|Cytokine plus Hyalurinan embryo transfer arm|To monitor the pregnancy and implantation of the patients in this arm after adding Cytokine to the embryo transfer medium.
89634304|NCT02422134|No Intervention|Hyalurinan embryo transfer group|To transfer the embryos using a Hyaluronan enriched medium only
89634305|NCT02421978||Chemotherapy-treated breast cancer group|Female subjects with Stage I-III breast cancer treated with chemotherapy will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
89634306|NCT02421978||Non-Chemotherapy-treated breast cancer group|Non-chemotherapy treated female subjects with Stage I-III breast cancer will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
89634307|NCT02421978||Control group|Age and race-matched healthy women will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
89634308|NCT02467504|Active Comparator|Experimental|hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
89634309|NCT02467504|Placebo Comparator|Placebo Comparator|hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
89634310|NCT02422212|Active Comparator|healthy weight group|Postop RYGBP patients who underwent surgery at least 2 years previously and have healthy weight (at least 50% loss of excess weight) (HW group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
89041552|NCT02222844|Experimental|Preoperative MRI scan|Standard treatment plus an additional MRI scan before surgery
89041553|NCT02222844|No Intervention|Observational|Observational only
89041554|NCT02201108|Placebo Comparator|Placebo|Matching placebo tablets
89041555|NCT02201108|Experimental|Teriflunomide|Teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent
89041556|NCT02180243|Experimental|Mindfulness meditation/Acupuncture|Eligible participants may be randomized to participate in iRest Yoga Nidra/ auricular acupuncture group classes.
89634311|NCT02422212|Other|Obese group|Clinically severe obese patients (Body Mass Index greater than 40 kg/m2, without co-morbidities and greater than 35 kg/m2 with co-morbidities) (OB group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
89634312|NCT02422212|Active Comparator|weight regain group|Patients who suffered weight regain after RYGBP (at least 10% above the minimum weight after surgery and less than 50% loss of preop excess weight) (WR group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
89041557|NCT02180243|Active Comparator|Gulf War Health Education|Eligible participants may be randomized to participate in Gulf War Health Education group classes.
89041558|NCT02153229|Experimental|patients who undergo RP plus photofrin-based PDT|
89041559|NCT02153229|Experimental|patients who undergo RP alone|
89041560|NCT01998750||Early-onset severe obesity|The study will enroll children and young adults up to 21 years of age with early onset severe obesity (BMI > 99th percentile noted at an age < 6 years of age).
89041561|NCT01975597||Bone marrow aspirates and biopsy|
89041562|NCT01884051||PAH patients|Patients diagnosed with WHO Group 1 PAH
89041563|NCT01884051||Healthy subjects|Subjects who have been evaluated for heart and lung disease and found to be healthy
89634313|NCT02413164|Experimental|Physical intervention group|12 weeks of groupal sessions of individualised multimodal physiotherapy programme of therapeutic exercises with education healthy-style-of-life based, 2 times for week.
89634314|NCT02413164|No Intervention|Control group|This group will receive usual care and will be in wait list status for the duration of study, later the intervention will be offered to this group.
89634315|NCT02413086|Experimental|Early-stage amputation+external herbs chitosan|Individuals with DFU were given early-stage amputation and wound was given herbs chitosan after amputation.
89634316|NCT02413086|Experimental|Early-stage amputation+traditional gauze|Individuals with DFU were given early-stage amputation and wound was given traditional gauze after amputation.
89634317|NCT02413086|Experimental|Amputation+external herbs chitosan|Individuals with DFU were given amputation and wound was given herbs chitosan after amputation.
89634318|NCT02413086|Experimental|Amputation+traditional gauze|Individuals with DFU were given amputation and wound was given traditional gauze after amputation.
89634319|NCT02468830|Experimental|Mirabegron|Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
89634320|NCT03176082|Experimental|Intervention Group|"Intervention group will receive:~A reminder letter indicating need for screening~A FIT kit with completion instructions~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the Mecklenburg County Public Health Department (MCPHD)~A pre-paid return mailer for FIT Kit"
89634321|NCT03176082|Active Comparator|Comparison Group|"Comparison group will receive:~A reminder letter indicating need for screening~Instructions for obtaining a FIT kit~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the MCPHD"
89041564|NCT01864460|Experimental|Diet, Physical Activity and Balance Enhancement Program (DPAE|Subjects in the DPAEP group will undergo a structured weight loss for approximately 6 months, followed by approximately 6 months of weight maintenance, as well as 12 months of aerobic exercise. This intervention stresses a personalized program emphasizing activities that are meaningful to and are tailored to individual participants; provides consistent contact between the participants and research staff; and allows monitoring of activity levels using questionnaires, actigraphy, monitoring of heart rate, direct and telephone contact. Participants dietary and physical activity goals as assessed by the dietician and trainer will be discussed at face-to face meetings to re-establish these goals. These programs will be tailored to meet the realistic goals of the individual participant. The program stresses aerobic exercise, rather than other types of exercise interventions, as aerobic exercise appears to correlate best with improved autonomic function.
89041565|NCT01864460|Active Comparator|Standard Care (SC)|The SC group will be assigned an interventionist assessor. This assessor will meet with the subjects during their orientation meeting and will be provided guidelines and a weight loss and physical activity target to achieve by the end of the program at their orientation meeting. Participants will contacted approximately weekly during the approximate 12 month period.
89041566|NCT01842204|Experimental|active kit|Patient receives an active kit with pulsed electromagnetic field over wound surface area.
89041567|NCT01842204|Placebo Comparator|non-active kit|Patient receives a non-active kit.
89041568|NCT01816100|Experimental|exercise session|"6 months weight resistance session, with before/after evaluations by MEG and DTI. Fifty minute exercise sessions, twice weekly will be done. Each session will rotate between 3 separate exercise protocols: Static weights, free weights and balance. Exercises will be done with each extremity independently. For consistency and convenience, the resistance training will be performed at Fast Forward Gym, Omaha, NE.~The primary outcome exercise data include strength and endurance"
89041569|NCT01789879|Active Comparator|Control group (no current ART)|Levonorgestrel subdermal implant in subjects not yet receiving ART (control group)
89041570|NCT01789879|Active Comparator|NVP-based ART group|Levonorgestrel subdermal implant in subjects receiving nevirapine-based ART
89041571|NCT01789879|Active Comparator|EFV-based ART group|Levonorgestrel subdermal implant in subjects receiving efavirenz-based ART
89041572|NCT01772563|Experimental|Volasertib + itraconazole then volasertib|Administration of volasertib in combination with itraconazole (Cycle 1) and afterwards alone (Cycle 2 and beyond).
89041573|NCT01771900|Experimental|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
89041574|NCT01771900|Experimental|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
89041575|NCT01765439|Experimental|CD resected|Patients with Crohn´s disease with the history of single resection (<60 cm) of distal leum.
89041576|NCT01765439|Experimental|UC unoperated|Patients with ulcerative colitis without history of gut resection.
89041577|NCT01765439|Experimental|UC IPAA|Patients with ulcerative colitis after proctocolectomy and ileal pouch-anal anastomosis(IPAA).
89041578|NCT01765439|Experimental|Healthy volunteers|Subjects without any sign of disease of the digestive tract.
89041579|NCT01622725|Experimental|Resorbable mesh|Long-term resorbable mesh implanted to treat primary and secondary ventral hernia.
89041580|NCT01622725|Active Comparator|Non-resorbable mesh|Non-resorbable synthetic mesh implanted to treat primary and secondary ventral hernia.
89041581|NCT01622127||incisional hernias|
89041582|NCT01598818||Visual acuity|Comparison of best visual acuity and refraction using the First Sight Refractive System with autorefraction in subjects with refractive error.
89634322|NCT03176160||Patients receiving palliative regimen consisting of LITT|Patients with WHO grade IV malignant glioma who are approved for and receive the LITT (Laser Interstitial Thermal Therapy) procedure
89634323|NCT02418858|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Essential tremor patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intraoperative stimulation."
89634324|NCT02418858|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery: Essential tremor patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrode placement at the time of surgery.
89634325|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended Release Capsules, 10 mg. Active drug, administered once
89634326|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended Release Capsules, 15 mg. Active drug, administered once
89634327|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended Release Capsules, 20 mg. Active drug, administered once
89634328|NCT02418702|Experimental|0.2mg/kg ketamine|After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks.
89634329|NCT02418702|Placebo Comparator|placebo|After being assessed, and giving informed consent, participants would receive a placebo. Symptoms will be monitored.
89634330|NCT02412930|Active Comparator|Group Paravertebral Block|With ultrasound guidance at T10 to L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. 5 mL bupivacaine 0.5% was injected in each dermatome level.
89634331|NCT02412930|Placebo Comparator|Group tramadol|Patients in group T were given a loading dose of tramadol of 1 mgkg-1
89634332|NCT02432716|Experimental|Insulin (glulisine), then Placebo|Participants first receive one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril). After a washout period of 2 weeks, they then received one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril).
89041583|NCT01543789|Experimental|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity
89041584|NCT01543789|Active Comparator|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
89041585|NCT01445171|Other|Study Valve|Subjects act as own control
89041586|NCT01316523|Experimental|Lenalidomide + Rituximab|Patients will receive lenalidomide 20 mg daily (oral), on days 1-21 of a 28 day cycle. Rituximab 375 mg/m2 (into the vein) will be administered weekly for 4 doses starting day 15 of cycle 1, to be repeated if patient does not achieve a complete response after cycle 4, on days 1, 8, 15 and 22 of cycle 5.
89041587|NCT01307657|Other|Clopidogrel impact on platelet function|Participants will have a baseline blood sample drawn after a 12 hour fast at 8 am, then be administered a 600 mg dose of clopidogrel. At noon, another blood sample will be drawn to evaluate the extent of maximum platelet inhibition in the fasting state. Participants will then be provided a standardized high-fat meal, then an additional blood sample at 2 pm to evaluate the impact of the high-fat on platelet function assessment.
89634333|NCT02432716|Experimental|Placebo, then Insulin (glulisine)|Participants first receive one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril). After a washout period of 2 weeks, they then received one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril).
89634334|NCT02421900||group 1|Atrial fibrillation patients
89634335|NCT02418624|Experimental|Dose escalation|carboplatin, olaparib
89634336|NCT02418780|Experimental|Tai Chi|6-month Tai Chi training program combined with usual medical care
89041588|NCT01200927|No Intervention|Typically Developing Infants|Typically developing infants (5 months old, SD .5 months at entry) were followed longitudinally as a comparison for postural variables. The primary outcome measure is Center of Pressure (COP) data, from which linear and nonlinear variables were extracted. The Gross Motor Function Measure (GMFM) sitting subsection was our clinical outcome measure.
89041589|NCT01200927|Active Comparator|Home Program|Home program (1x/week for 8 weeks). The primary outcome measure is Center of Pressure (COP) data, from which linear and nonlinear variables were extracted. The Gross Motor Function Measure (GMFM) sitting subsection was our clinical outcome measure.
89041590|NCT01200927|Active Comparator|Perceptual-motor intervention|Perceptual-motor intervention (2x/week for 8 weeks. The primary outcome measure is Center of Pressure (COP) data, from which linear and nonlinear variables were extracted. The Gross Motor Function Measure (GMFM) sitting subsection was our clinical outcome measure.
89041591|NCT01179815||1|Patients with type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
89041592|NCT01109771|Active Comparator|absorbable fixation left side|
89041593|NCT01109771|Active Comparator|absorbable fixation right side|
89041594|NCT01042561|Placebo Comparator|placebo|This group will recieve the current standard of care for infants in the NICU, recieving infant formula that provides less than 400 IU of vitamin D a day.
89041595|NCT01042561|Experimental|Vitamin D|This group will recieve standard of care infant formulas that provide less than 400 IU of vitamin D a day, in addition they will be supplemented with 400 IU of vitamin D3 daily.
89634337|NCT02418780|No Intervention|Usual Care|Waitlist control group receiving usual medical care alone
89634338|NCT02433496||Physician coaching|This group includes 4 intervention primary care clinics that are part of the University of Wisconsin's Department of Family Medicine. These clinics will receive an organizational coaching intervention that includes in-person site visits and phone/email communication. Each participating clinic will designate one primary care physician to act as a clinic lead in working with the coach to coordinate an initial site visit (during project month 13, July 2015), a follow-up site visit (month 15, October, 2015), and communicating with the coach throughout the 6-month follow-up period via phone and email.
89634339|NCT02433496||Control Group|This group includes 4 control primary care clinics that will not receive any intervention. A de-identified dataset will be created to examine differences in outcome variables between intervention and control clinics.
89634340|NCT03177954|Experimental|Patient Oriented Discharge Summary|A one hour patient oriented discharge summary meeting will take place with participants.
89634341|NCT02412774|Experimental|Diet Beverages (DBs)|Diet beverages after the main meal+ Diet
89041596|NCT00848328|Experimental|Lenalidomide and Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15. Lenalidomide 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
89041597|NCT00573339||Normal Controls|
89041598|NCT00573027|Other|Single Arm|"fill out baseline demographic and health/medical history questionnaires, CV risk factors, reasons of diagnosis of ischemia, information of coronary artery, and medication use~undergo clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory (Appendix);~undergo noninvasive Peripheral Artery Tonometry (PAT) testing (Appendix);~undergo clinically indicated Cardiac Magnetic Resonance (CMR) imaging (Appendix) to detect subendocardial ischemia (if indicated and referred by the treating physician). The three tests (heart catheterization with adenosine coronary flow reserve testing, acetylcholine provocative vasomotor testing during heart catheterization, cardiac MRI) are performed for standard care.~have blood and urine testing.~fill out health questionnaires~be followed prospectively 6-week, 6-month, and annually for clinical status"
89041599|NCT01237951|Experimental|GemBuMel|"Gemcitabine 1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.~Busulfan 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan area under curve (AUC) 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.~Melphalan 60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.~Palifermin 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~Palifermin 60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.~Dexamethasone 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.~Stem Cell Transplant: On Day 0, stem cells returned to body by vein over 30-60 minutes."
89041600|NCT02908581|Active Comparator|Placebo|21 Patients Placebo Each tablet by mouth once daily for 12 weeks
89041601|NCT02908581|Experimental|Iron 150 mg and Folic acid 0.5 mg|21 Patients Iron 150 mg and Folic acid 0.5 mg Each tablet by mouth once daily for 12 weeks
89041602|NCT00544362|Experimental|Neoadjuvant chemoradiotherapy|Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5
89041603|NCT02908776|Experimental|Dietary supplement - Probiotics|4 sachets of Ecoviesel (probiotics) per day for at least 2 weeks before undergoing a coronary angiography with possible ad hoc angioplasty; and 2 sachets of probiotic per day after angioplasty, if performed.
89041604|NCT02908776|Placebo Comparator|Placebo|Sachets with inactive substance indistinguishable from Ecoviesel
89041605|NCT04648943|Active Comparator|Patients undergoing Ex-Press mini shunt insertion|Patients in this arm had the Ex-Press mini shunt inserted in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
89634342|NCT02412774|Experimental|Water|Water after the main meal+ Diet
89634343|NCT02435524|Experimental|A&T Intervention Communes|
89634344|NCT02435524|No Intervention|Control Communes|
89688494|NCT00913913|Experimental|bevacizumab,IL-2, IFN, DC vaccine|Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
89688495|NCT03403829|Experimental|maintenance arm|Gemcitabine maintenance treatment
89634345|NCT02421744|Experimental|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
89634346|NCT02421744|Active Comparator|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
89634347|NCT02439814|Experimental|Pregnenolone|
89634348|NCT02439814|Placebo Comparator|Placebo|
89634349|NCT02421822|Experimental|Fitwits Intervention|Fitwits office tool and games
89634350|NCT02421432|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
89634351|NCT02440204|Active Comparator|Remifentanil 1.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
89634352|NCT02440204|Active Comparator|Remifentanil 1.5 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
89634353|NCT02440204|Active Comparator|Remifentanil 2.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
89634354|NCT02410590|Experimental|Rocuronium + Sugammadex|Participants will receive rocuronium administered at a dosage adequate to make intubation possible and provide deep NMB (defined as no response to train-of-four stimulation but at least one response to five post-tetanic count [PTC]) for the duration of surgery, until the end of the procedure. Sugammadex will be administered to participants once at a dosage of 4 mg/kg real body weight (RBW) IV at the end of surgical procedure. Sugammadex will be used as the only reversal drug in all participants who receive rocuronium as a neuromuscular blocker.
89634355|NCT02410590|Active Comparator|Succinylcholine + Cisatracurium + Neostigmine/Atropine|After receiving succinylcholine 1.0 mg/kg RBW for intubation, participants will receive cisatracurium administered at dosage adequate to have a moderate NMB (defined as a target of TOF ratio = 10% with a range: 2-3 twitches to TOF ratio of 20%) for the duration of surgery, until the end of the procedure. Neostigmine/Atropine will be administered to participants once at respective dosage of 0.05 mg/kg RBW and 0.01 mg/kg RBW at least after the reappearance of T2 after surgery completion. The maximum allowed dosage for Neostigmine is 5 mg. Neostigmine will be used as only reversal drug in all participants who received Cisatracurium as neuromuscular blocker.
89634356|NCT02410668|Active Comparator|Flaxseed|30 grams Flaxseed powder combine with dietary and exercise recommendation
89634357|NCT02410668|Placebo Comparator|control|dietary and exercise recommendation
89634358|NCT02517580|Experimental|Vitamin K2 (MK7)|Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks
89041606|NCT04648943|Active Comparator|Patients undergoing trabeculectomy|Patients in this arm had standard trabeculectomy in the operated eye in order to reduce the Intraocular Pressure. The corneal biomechanical properties were measured before and at 1, 6 and 12 months after surgery with the Ocular Response Analyzer
89041607|NCT02908503|Other|1 x 2 inch PVA based film|1 x 2 inch polyvinyl acetate (PVA) based vaginal film
89041608|NCT02908503|Other|2 x 2 inch PVA based film|2 x 2 inch polyvinyl acetate (PVA) based vaginal film
89041609|NCT02908503|Other|1 x 2 cellulose based film|1 x 2 cellulose based vaginal film
89041610|NCT02908503|Other|2 x 2 cellulose based film|2 x 2 cellulose based vaginal film
89041611|NCT04648670|Experimental|Group intervention|"The experimental group consists of 101 participants have been subdivided into two groups of 25/26 that perform the same intervention but on a different day of the week.~The two subgroups have received 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.~."
89041612|NCT04648670|No Intervention|Group Control|The control group consists of 100 participants. The no intervention group did not receive any type of intervention
89041613|NCT01239394|Other|ofatumumab|single-arm, open-label, interventional
89041614|NCT00553293|Active Comparator|A,1|rFSH + rLH arm
89041615|NCT00553293|Placebo Comparator|A,2|rFSH alone
89041616|NCT04648514|Active Comparator|Using of bone osteotomes for closed sinus lifting|Using of summers' osteotome technique by bone osteotomes for closed sinus lifting then evaluation the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement in posterior edentulous maxilla .
89041617|NCT04648514|Active Comparator|Patient satisfaction evaluation after using bone osteotomes|Evaluation of patient satisfaction numerically will be done after using summers' osteotome technique by bone osteotomes for closed sinus lifting in posterior edentulous maxilla
89041618|NCT00544401|Experimental|1|Hypnopuncture Treatment
89041619|NCT00544401|No Intervention|2|Conventional IVF/ICSI treatment only
89041620|NCT02908737|Experimental|Bass and Treble controls|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively.
89041621|NCT04648397|Experimental|Short chewing|Subjects consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a short chewing protocol.
89041622|NCT04648397|Experimental|Long chewing|Subjects will consume two starch-based foods varying in fibre content e.g. brown rice and chick-peas in duplicate following a long chewing protocol.
89041623|NCT00544518|Experimental|2|
89041624|NCT00544518|Active Comparator|1|
89688496|NCT03403829|Sham Comparator|control arm|observe and follow-up
89041625|NCT04648592|Experimental|Intervention|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral salt supplements (9 grams) to achieve an overall daily sodium intake of 200 mmol.
89041626|NCT04648592|Placebo Comparator|Control|Low salt diet, aiming at a daily sodium intake of 50 mmol plus oral placebo supplements to achieve an overall daily sodium intake of 50 mmol.
89041627|NCT02908698|Experimental|Prednisone Treatment|"Prednisone will be administered orally for 15 days at the following doses:~0.75 mg/kg of body weight for 5 days 0.5 mg/kg of body weight for 5 days 0.25 mg/kg of body weight for 5 days"
89041628|NCT02908698|Placebo Comparator|Placebo Control|Placebo will be administered orally for 15 days in a capsule identical to the experimental treatment.
89041629|NCT00544596|Experimental|Treatment (R-(-)-gossypol acetic acid, cisplatin, etoposide)|"Patients receive oral R-(-)-gossypol twice daily on days 1-3, cisplatin IV over 60 minutes on day 1*, and etoposide IV over 30 minutes on days 1*-3. Treatment repeats every 21 days for up to 6 courses during the dose escalation and 4 courses in the expanded extensive stage small cell lung cancer cohort, in the absence of disease progression or unacceptable toxicity.~Blood samples are collected on day 1 of courses 1 and 2 for pharmacokinetic analysis, biomarker assays, and correlative studies.~After completion of study treatment, patients are followed for 30 days.~[Note: *Cisplatin and etoposide will be started on day 2 during course 1; they will be given on day 1 during all subsequent courses.]"
89041630|NCT00558194|Experimental|1|Standard behavioral weight loss treatment with cognitive and affective skills training
89041631|NCT00558194|Active Comparator|2|Standard behavioral weight loss treatment
89041632|NCT00544635|Experimental|A|scars will be treated with light
89041633|NCT00544635|Placebo Comparator|B|no intervention
89041634|NCT00558233|Experimental|Intervention group|
89041635|NCT00558233|Placebo Comparator|Placebo group|
89041636|NCT02908425|Other|Healthy taking statin|healthy subjects currently taking cholesterol lowering statin
89041637|NCT02908191|Experimental|ABI-H0731 or Matching Placebo|ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
89041638|NCT02908191|Experimental|ABI-H0731 or Placebo and ETV or TDF|ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
89041639|NCT02908191|Experimental|ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
89041640|NCT04648007||Control|10 patients with no personal or family problems with gambling as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
89041641|NCT04648007||Moderate Gamblers|10 patients with moderate gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
89041642|NCT04648007||Severe Gamblers|10 patients with severe gambling addiction as assessed by the PG-YBOCS (obsessions-compulsions scale Yale-Brown (Y-BOCS), adapted for pathological gambling) (PG-YBOCS).
89041643|NCT00544752|Experimental|16|indoor temperature of 16 degrees celcius
89041644|NCT00544752|Experimental|20|indoor temperature 20 degrees celcius
89041645|NCT00544752|Experimental|24|indoor temperature of 24 degrees celcius
89041646|NCT00544791|Experimental|A|melatonin 5 mg, daily dose for 6 months
89041647|NCT00544791|Placebo Comparator|B|
89041648|NCT04647812|Experimental|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology
89041649|NCT04647812|Experimental|Conventional rehabilitation|Traditional multidisciplinary rehabilitation
89041650|NCT04647773|Experimental|HSK16149 20mg BID|
89041651|NCT04647773|Experimental|HSK16149 40mg BID|
89041652|NCT04647773|Experimental|HSK16149 60mg BID|
89041653|NCT04647773|Experimental|HSK16149 80mg BID|
89041654|NCT04647773|Active Comparator|Pregabalin 150mg BID|
89041655|NCT04647773|Placebo Comparator|Placebo BID|
89041656|NCT00544947||D, F|"Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.~Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section."
89041657|NCT01237678|Experimental|IMGN901 with carboplatin and etoposide|Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
89041658|NCT01237678|Active Comparator|Carboplatin and Etoposide|Patients will receive Carboplatin and etoposide for up to 6 cycles.
89041659|NCT04647461|Experimental|BRIDIN-T Eye drops 0.15%(Non preservative)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
89041660|NCT04647461|Active Comparator|ALPHAGAN-P Eye drops 0.15%(Preservatives)|Brimonidine Tartrate 1.5mg : 1 drop 3 times a day for 12 weeks to target eyes
89041661|NCT04684992|Experimental|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
89041662|NCT01229371|Active Comparator|Subjects ≥18 to ≤60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group A will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
89041663|NCT01229371|Active Comparator|Subjects >60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group B will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
89057531|NCT01200511|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
89057532|NCT04532567|Experimental|GLPG1205 dose A|Participants will receive a single dose with dose A of GLPG1205 on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
89634359|NCT02412462|Experimental|AB-16B5|Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
89634360|NCT02412384||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
89634361|NCT02412384||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
89041664|NCT01229371|Experimental|Subjects ≥18 to ≤60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group C will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
89041665|NCT01229371|Experimental|Subjects >60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group D will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
89041666|NCT02908230|Placebo Comparator|Active Control|Active Control: exposure to a non-nutrition, physical activity, or mental health curriculum/program
89041667|NCT02908230|Active Comparator|Standard Care|Standard Care: exposure to a nutrition and physical activity curriculum/program
89041668|NCT02908230|Experimental|Enhanced Care|Enhanced Care: exposure to a nutrition, physical activity, and mental health curriculum/program
89041669|NCT02908152|Active Comparator|curcumin|curcumin
89041670|NCT02908152|Placebo Comparator|placebo|
89041671|NCT01237327|Active Comparator|1|
89041672|NCT01237327|Experimental|2|
89041673|NCT04321213||Healthcare professionals in the Region of Västmanland|Healthcare professionals of all professions working in-hospital with patient contact at two hospitals in the Region of Västmanland, Sweden. Data is collected by questionnaires.
89041674|NCT04321213||Healthcare professionals in the Region of Dalarna|Healthcare professionals of all professions working in-hospital with patient contact at three hospitals in the Region of Dalarna, Sweden. Data is collected by questionnaires.
89041675|NCT02907021|Experimental|Heart failure|Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
89041676|NCT01237054|Experimental|Imaging in MGUS, SMM, and MM|Participants will have three imaging studies on separate days: a standard positron emission tomography/computed tomography scan (18-FDG PET/CT), a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT), and magnetic resonance imaging (DCE-MRI).
89041677|NCT02906982|Experimental|Gum health formulation in intra-oral device|The interventional gum health formulation is applied to the participant's mouth by means of an intra-oral device for a single eight-minute application, daily. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
89041678|NCT02906982|Experimental|Gum health formulation on toothbrush|The interventional gum health formulation is applied to the participant's mouth by means of a toothbrush and toothpaste, plus the gum health formulation, for two-minute applications, twice daily, morning and night.
89041679|NCT02906982|No Intervention|Control group (split-mouth design)|The control group did not receive the interventional gum health formulation. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night. In addition, participants instructed to floss only half of their mouth daily, and the non-flossed half serves as the untreated comparative control receiving no intervention.
89041680|NCT04319536||Healthy individuals|
89041681|NCT04647695|Experimental|IFN-beta 1b and remdesivir|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
89041682|NCT04647695|Active Comparator|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
89041683|NCT02908113|Other|preterm infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
89041684|NCT02908113|Other|term infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
89041685|NCT04647305|Experimental|Closed face shield + Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial, as well as one closed face shield. Additionally, each participant will receive an educational intervention (video).
89041686|NCT04647305|Active Comparator|Surgical face mask|Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial. Additionally, each participant will receive an educational intervention (video).
89041687|NCT04647344|Experimental|Nonsquamous NSCLC|
89041688|NCT04647344|Experimental|Squamous NSCLC|
89041689|NCT02906748|Experimental|new site for parathyroid auto-graft|choose the site fairly close to the antecubital vein for parathyroid auto-transplantation
89041690|NCT02906748|Active Comparator|traditional parathyroid autograft|choose not intensely close to antecubital vein for parathyroid auto-transplantation
89041691|NCT04647149|Experimental|Early Time-Restricted Eating|8-hour eating window between 08:00 and 16:00
89041692|NCT04647149|Experimental|Delayed Time-Restricted Eating|8-hour eating window between 12:00 and 20:00
89041693|NCT04647149|Experimental|Control|12-hour eating window between 08:00 and 20:00
89041694|NCT02907957|Active Comparator|Caudal|Participants receiving a caudal neuraxial blockade, as clinically indicated.
89041695|NCT02907957|Sham Comparator|No Caudal|Participants not receiving a caudal neuraxial blockade, as clinically indicated.
89041696|NCT04646954|Experimental|Study group|All eligible participants are included in the study group
89041697|NCT02907879||Ultrasound perfusion imaging|Measuring methods of UPI with phase inversion harmonic imaging
89041698|NCT04647188||Urology group|Includes patients undergoing prostatectomy (n=100)
89634362|NCT02412384||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
89634363|NCT02412384||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
89634364|NCT02517658|Active Comparator|Standard Discharge Teaching|Parents will receive standard discharge teaching from the nurse prior to discharge.
89634365|NCT02517658|Experimental|Video w/ post exam immediately after video|Parents will watch the video and then take the post test immediately after watching the video.
89634366|NCT02517658|Experimental|Video w/ post exam after discharge teaching|Parents will watch the video but wait to take the post exam until after the discharge instructions are given by the nurse prior to discharge.
89634367|NCT02417922|Experimental|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that whole blood spinning is conducted for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (around 4 mls).~ACP is injected at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date."
89634368|NCT02417922|Placebo Comparator|Saline|Saline (4 mls) is injected around the ruptured achilles tendon at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date.
89634369|NCT02522104|Experimental|Normal-renal function|Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men
89634370|NCT02522104|Experimental|Glomerular hyperfiltration|Glomerular renal hyperfiltration: GFR > 130 mL/min/1.73m2 in women and GFR > 140 mL/min/1.73m2 in men.
89634371|NCT02522104|Experimental|Moderate renal failure|Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2
89634372|NCT02412150|Experimental|Dexmedetomidine (Group D)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued.~Then, dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage and duration of hospital staying, postoperative complications are measured until POD#3."
89634373|NCT02412150|Placebo Comparator|Normal Saline (Group N)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued. Then, normal saline has started infusion for 15 min (same rate as Group D). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage duration of hospital staying, postoperative complications are measured until POD#3."
89634374|NCT02523196|Other|(HVPG) and HepQuant-SHUNT (HQ-Shunt)|"Successful Hepatic Venous Pressure Gradiant (HVPG) testing is required prior to administration of the HepQuant-SHUNT test.~Comparison of Disease Severity Index (DSI) from HQ-SHUNT with HVPG in identifying patients with cirrhosis and patients with varices."
89688497|NCT04355221|Active Comparator|Group A|using the standard settings of pulsed radiofrequency technique (PRFT). two cycles, each one for 2 minutes at 45 Volts (V) with a pulse width of 10 milliseconds (ms) and a pulse frequency of 4 Hertz (Hz). The cut-off needle tip temperature is set at 420 Celsius (C).
88990885|NCT06086730|Active Comparator|acapella|"Make sure the frequency adjustment dial has been rotated counterclockwise to the lowest frequency-resistance setting before using the Acapella for the first time. On a chair, adopt a straight stance. maintaining a straight back and relaxing your elbows on a table. Now gradually tilt your head upward to maintain the opening of your upper airways. Inhale more deeply than you frequently do. Make sure your lips are encircling the mouthpiece, then blow into the device with a strong expiration. You should ideally blow out roughly twice as quickly as usual. For around ten breaths. Make careful to expel to clear the secretions from the airways after the final try. You can even conduct 2 to 3 huffs to improve secretion elimination when necessary. It should be noted that while using the device, you must be capable of exhale for a minimum of three to four seconds."
88990886|NCT06075875|Active Comparator|control=mixed animal and vegetable proteins|"mixed animal and vegetable proteins in the standard ratio (2/3:1/3; 60%:40% respectively) present in the nutritional menu over all hospitals in the general organization of teaching hospitals and institutes GOTHI; Egypt= as a control group.(average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm)."
88990887|NCT06075875|Experimental|study= pure vegetable proteins|pure vegetable proteins (a study group). (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).
88990888|NCT06072885||Laparoscopic pediatric surgery|Pediatric patients who are scheduled for laparoscopic surgeries in supine position (e.g. laparoscopic appendectomy, laparoscopic cholecystectomy, laparoscopic nissen fundoplication)
88990889|NCT06072053||BHC group|Patients with CSDH recruited from the neurosurgery departments of 6 medical centers in China who had clinically significant symptoms confirmed by computed tomography or magnetic resonance imaging and ultimately treated with Bulr-hole Craniotomy.
88990890|NCT06072053||YL-1 Needle Puncture group|Patients with CSDH recruited from the neurosurgery departments of 6 medical centers in China who had clinically significant symptoms confirmed by computed tomography or magnetic resonance imaging and ultimately treated with YL-1 needle puncture.
88990891|NCT06071611|Experimental|Oxygen-Ozone (O2-O3)|A small catheter is inserted into the rectum and a total amount of 150cc of O2-O3 mixture at the concentration of 30ug of O3 per cc of O2 over a 5-10 min period is administered.
88990892|NCT06071611|Active Comparator|Oxygen (O2)|A small catheter is inserted into the rectum and a total amount of 150cc of O2 over a 5-10 min period is administered.
88990893|NCT06071611|Placebo Comparator|Placebo (Air)|A small catheter is inserted into the rectum and a total amount of 150cc of air over a 5-10 min period is administered.
88990894|NCT06070298||Abnormal Echocardiography Diagnosis|Participants with abnormal echocardiography diagnosis within three years.
89041699|NCT04647188||Colorectal group|Includes patients undergoing anterior rectal resection (n=100)
89634375|NCT02410434|Experimental|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
89041700|NCT04647188||Thoracic group|Includes patients undergoing lobectomy or segmentectomy (n=100)
89041701|NCT04647188||Gynaecological group|Includes patients undergoing hysterectomy (n=100)
89041702|NCT04647188||HpB group|Includes pancreatic tumour resection patients (n=50)
89041703|NCT04647188||Ear, Nose & Throat group|Includes patients undergoing lateral oropharyngectomy (n=50)
89041704|NCT04646876|Active Comparator|intervention arm ( Group A )|"including 30 patients Group A was given magnesium Sulphate~Administration regimen of Mgso4 was as following:~Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs."
89634376|NCT02418078||Geriatri|patients ageing ≥ 65 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
89634377|NCT02418078||non-geriatri|patients ageing 19-64 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
89634378|NCT02523586||Oxygen administration|Via Simple Mask, Via Non-rebreather, Via OxyMask, Via Anesthesia Mask (head strap and J-R circuit), Via Room Air
89634379|NCT05067114||Observational Cohort|Screening, detection, and referral for atrial fibrillation
89634380|NCT03174990||Aspirin responsive|The participant is shown to be responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
89634381|NCT03174990||Aspirin non-responsive|The participant is shown to be non-responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
89041705|NCT04646876|Placebo Comparator|Placebo arm (Group B )|including 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate
89634382|NCT03174990||Clopidogrel responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
89634383|NCT03174990||Clopidogrel non-responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
89634384|NCT03175926|Experimental|Group 1|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
89634385|NCT03175926|Experimental|Group 2|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
89634386|NCT03175926|Experimental|Group 3|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
89634387|NCT02524054|Experimental|Aerosol furosemide Study 2a|Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min. This will be a single, unblinded administration.
89634388|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm F|Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
89634389|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm S|Inhalation of saline aerosol one one day then furosemide aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
89634390|NCT03175458|Experimental|sinus lift,implant placement,tenting|elevation of the sinus membrane with simultaneous implant placement without the use of any bone graft material(tenting technique)
89634391|NCT03175458|Active Comparator|sinus lift,implant placement,bovine bone|elevation of the sinus membrane with simultaneous implant placement together with deproteinized bovine bone graft substitute for augmentation
89634392|NCT03174834|Other|Bladder Stimulation Technique|Single arm study, where urine collection will be done via bladder stimulation and subsequently catheterization if they meet the eligibility criteria.
89634393|NCT03175770||Patients with benign or malign tumor in the oropharynx|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
89634394|NCT03106662|Experimental|Mesenchymal Stem Cell in Haplo-SCT|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
89041706|NCT04646915||Patients with CuRC undergoing day surgery|Patients with CuRC undergoing laparoscopic colectomy or anterior resection in day surgery center.
89041707|NCT02906904|Experimental|CASE (adult sleepwalking patients)|
89041708|NCT02906904|Experimental|CONTROL (adult healthy volunteers)|
89041709|NCT04646720||Neck pain patients|Patients with neck pain evaluated with new technologies and face-to-face
89041710|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery High Dose|High-Dose Group: 0.4 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
89634395|NCT02417610|Experimental|Polynucleotide - PNHA - Newart|50 patients will be enrolled and treated with three weekly injections of polynucleotide plus hyaluronic acid
89634396|NCT02417610|Active Comparator|Hyaluronic acid - HA - Ialart|50 patients will be enrolled and treated with three weekly injections of hyaluronic acid
89634397|NCT03175614|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and nutrition.
89634398|NCT03175614|Experimental|Intervention group|Add for three months a Smartphone with an app (EVIDENT III) and a Smartband to lose weight and improve physical activity.
89634399|NCT03175692||critical illness in infants and children|Those infants and children who has congenital metabolism disorder or acute disorder.
89634400|NCT02417454|Experimental|Probiotic|Participants will undergo the same study procedures as for the comparator; however, the product given will be the active probiotic supplement (ProbioStick).
88990895|NCT06070298||Normal Echocardiography Diagnosis|Participants with normal echocardiography diagnosis within three years.
88990896|NCT06065943|Active Comparator|Ultrasound guidance|
89634401|NCT02417454|Placebo Comparator|Placebo|Participants will undergo the same study procedures as for the probiotic; however, the product given will be a placebo, identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients in the probiotic supplement
89634402|NCT03175536||HDHP with PDL|Enrollees switched from a high-deductible health plan (HDHP) to a HDHP with a preventive drug list (PDL)
89634403|NCT03175536||HDHP without PDL|Enrollees switched from a traditional plan to a high-deductible health plan (HDHP) without a preventive drug list (PDL). Enrollees who stayed in a HDHP without a PDL will also serve as controls for the study group who switch from HDHPs without PDLs to HDHPs with PDLs.
89041711|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery Low Dose|Low-Dose Group: 0.1 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
89057533|NCT04532567|Placebo Comparator|Placebo dose A|Participants will receive a single dose placebo on Day 1 in Period 1, and 14 days q.d. dosing on Days 1 to 14 in Period 2.
89634404|NCT03175536||traditional plan|Enrollees who remained in a traditional health plan with a deductible < $500
89634405|NCT03175848|Experimental|Chemotherapy,radiotherapy|Lymphatic metastasis patients undergoing 2 cycles of chemotherapy(TP/TC), blood metastasis patients receiving 4 cycles of chemotherapy, then patients with therapeutic evaluation for (CR+PR+SD) will undergo the radiotherapy (external irradiation plus brachytherapy) for primary lesion area , all patients completed total 6 cycles of chemotherapy (TP/TC), and finally will determine the of treatment plans of metastasis areas based on tolerance and discuss results by MDT.
89634406|NCT03116490||group RA|the anesthesia type for patients with hip fracture surgery is regional anesthesia
89634407|NCT03116490||group GA|the anesthesia type for patients with hip fracture surgery is general anesthesia
89634408|NCT02417298|Active Comparator|Ketamine|Ketamine 0.3 mg/kg intravenous push followed by ketamine infusion at 0.1 mg/kg/hr for 3 hours
89057534|NCT04532567|Experimental|GLPG1205 dose B|Participants will receive 14 days q.d. dosing with dose B of GLPG1205 on Days 1 to 14.
89057535|NCT04532567|Placebo Comparator|Placebo dose B|Participants will receive 14 days q.d. dosing placebo on Days 1 to 14.
89634409|NCT02417298|Placebo Comparator|Saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
89634410|NCT02409966|Active Comparator|Quadrant-wise scaling|Patients underwent quadrant scaling under local anesthesia in four weekly sections.
89634411|NCT02409966|Experimental|Full-mouth 24-hour scaling|Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours.
89634412|NCT02409888|Experimental|Intervention|Study participants receive either motivational enhancement therapy (MET) or cognitive behavioral therapy (CBT).
89634413|NCT02409888|Experimental|Assessment|IB Assessment study participants receive semi-annual assessments specific to their alcohol and other drug use and FC Assessment study participants receive quarterly assessments specific to diverse areas of functioning (e.g., alcohol and other drug use, social, occupational, legal, psychological/psychiatric, marital).
89634414|NCT03174600||Stroke patients|Stroke patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months
89634415|NCT03116412|No Intervention|Routine follow up|Follow up according to national guidelines.
89634416|NCT03116412|Experimental|Radiological assessments|Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
89634417|NCT02525536|Experimental|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 milligram/kilogram (mg/kg), 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
89634418|NCT02525536|Experimental|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
89634419|NCT02525536|Experimental|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
89634420|NCT02411994|Experimental|Pyronaridine-artesunate|pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
89634421|NCT02411994|Active Comparator|Artemether-lumefantrine|artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.
88990897|NCT06065943|Other|Palpation and Fluoroscopy|
89057536|NCT04528368|Experimental|Convalescent Plasma + Standard treatment|Participants will receive the standard treatment and convalescent plasma
88990898|NCT06062576|No Intervention|control group 1|The optimal clinical treatment scheme was used to treat the wound of progressive infection period patients for 2 weeks
88990899|NCT06062576|Experimental|powder group 1|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of progressive infection period patients for 2 weeks
88990900|NCT06062576|Experimental|ointment group 1|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of progressive infection period patients for 2 weeks
88990901|NCT06062576|No Intervention|control group 2|The optimal clinical treatment scheme was used to treat the wound of granulation period patients for 2 weeks
89057537|NCT04528368|No Intervention|Standard treatment|Participants will receive the standard treatment
89634422|NCT02411838|No Intervention|Control group|Steroid treatment (10 total days), which is a standard therapy for significant MS relapses.
89057538|NCT01683591||High-risk aspiration group|Among the consecutive stroke patients, categorized to high-risk group in the patient (1) was not on alert mentality (from drowsy to comatose mentality), (2) was not able to sit upright or control his/her head, and (3) failed to pass indirect water swallow test.
89057539|NCT01683591||Low-risk aspiration group|Patents without oropharyngeal neurologic signs
89634423|NCT02411838|Experimental|Calorie restriction|"The intervention in this group will be to undergo a regimen of calorie restriction through fasting every other day (named alternate day fasting).~Specifically this group will undergo alternate day fasting plus the same steroid regimen as the control group (CR GROUP).~During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of IVMP) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point."
89634424|NCT02417220|Active Comparator|Weight Watchers Online 2015|
89634425|NCT02417220|Experimental|Weight Watchers Online 2015 Enhanced|
89634426|NCT02530294|Experimental|glycopyrronium|glycopyrronium Topical Wipes
89634427|NCT02530294|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
89634428|NCT03177720|Active Comparator|Ciprofloxacin|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
89634429|NCT03177720|Active Comparator|Imipenem|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
89634430|NCT02411682|Active Comparator|YesB|On YesB day the patients will consume breakfast , lunch and dinner
89634431|NCT02411682|Experimental|NoB|On NoB Day The patient will consume only lunch and dinner
89634432|NCT02530450||Group 1|Initially blinded to continuous glucose monitoring (CGM) data after 1st use Not blinded to continuous glucose monitoring data after 2nd and 3rd use
89634433|NCT02530450||Group 2|Never blinded to continuous glucose monitoring (CGM) data
89634434|NCT03175380|Experimental|bacillus Calmette-Guérin|All participants will receive a total of two doses of bacillus Calmette-Guérin (BCG), by intradermal injection, approximately 6 months apart. They will be observed for 284 days
89634435|NCT02411214||<12 years|children under 12 years diagnosed with cancer questionnaire survey
89634436|NCT02411214||12-18 years|adolescents diagnosed with cancer questionnaire survey
89634437|NCT02411214||parents|parents of children and adolescents diagnosed with cancer questionnaire survey
89634438|NCT02530528|Experimental|2% CHG 1 min|single administration, 1 min application time
89634439|NCT02530528|Experimental|2% CHG 2 min|single administration, 2 min application time
89634440|NCT02530528|Experimental|2% CHG 3 min|single administration, 3 min application time
89634441|NCT02530528|Active Comparator|Comparator 2% CHG|Single administration, Marketed CHG
89634442|NCT02411136|Experimental|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
89634443|NCT02411136|Placebo Comparator|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
89634444|NCT02411058|Experimental|Uninformed|Condition 1
89634445|NCT02411058|Experimental|Informed about Incentives and Purpose|Condition 2
89634446|NCT02530996|Experimental|Placebo before BH4|Six SSc received oral placebo 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral BH4 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
89634447|NCT02530996|Experimental|BH4 before Placebo|Six SSc received oral BH4 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral placebo 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
89634448|NCT03174756|Experimental|HOCl 0.025%|15 ml of Hypochlorous acid mouthwash at 0.025%
89634449|NCT03174756|Experimental|HOCl 0.05%|15 ml of Hypochlorous acid mouthwash at 0.05%
89634450|NCT03174756|Active Comparator|CHX 0.2%|15 ml of chlorhexidine mouthwash at 0.2%
89634451|NCT03174756|Active Comparator|CHX 0.025%|15 ml of chlorhexidine at mouthwash0.025%
89634452|NCT03174756|Placebo Comparator|Placebo|15 ml of Sterile water
89057540|NCT01683591||Intermediate-risk aspiration group|If any one of following was positive, categorized to intermediate-risk group; (1) dysarthria, (2) motor aphasia, (3) inability to close and open lips or (4) facial weakness, (5) tongue deviation or (6) uvula deviation, (7) loss of gag reflex, and (8) inability to cough voluntarily.
89634453|NCT03174678|Experimental|Dexmedetomidine|Group administered 1µg/kg dexmedetomidine oral
89634454|NCT03174678|Other|Control|Apple juice
89634455|NCT02409498|Active Comparator|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine. 10 ml of Bupivacaine will be injected on either side using the pudendal nerve block tray.
89634456|NCT02409498|Placebo Comparator|no pudendal block|Saline
89634457|NCT02409420|Experimental|PACT|PACT: a brief physiotherapy intervention based on ACT principles optimised to promote self-management. ACT aims to promote the acceptance of pain, the belief that it is not always necessary to change pain to move forward and the understanding that focusing on pain avoidance.
89634458|NCT02409420|No Intervention|Control|Usual care
89634459|NCT02409576|Experimental|Expanded, activated NK Cells(NKEXPSARC)|Intravenous infusion of expanded, activated NK Cells Donor cell will be expanded and activated in the cGMP compliant TECT lab for 10 to 12 days prior to infusion into the patient.
89634460|NCT03174444|Experimental|Small Media|Participants receive bilingual brochures and access to bilingual website about colorectal cancer screening.
89634461|NCT03174444|No Intervention|Control|Participants receive no information about colorectal cancer screening from the study during the intervention period, but may receive usual care from health care provider.
89634462|NCT02409030||Cognitively Healthy controls|"The neuropsychological test assessment must confirm that there is no cognitive impairment.~In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted."
89634463|NCT02409030||Alzheimer Disease|Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).
89634464|NCT02409030||Frontotemporal dementia|Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).
89634465|NCT03177564|Active Comparator|Protective Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
89634466|NCT03177564|Active Comparator|Protective Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
89634467|NCT03177564|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
89634468|NCT02409186|Active Comparator|Nimotuzumab plus chemoradiotherapy|Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
89634469|NCT02409186|Placebo Comparator|placebo plus chemoradiotherapy|placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
89041712|NCT02908035|Placebo Comparator|Placebo Comparator: Saline Delivery|Control Group: Saline/contrast (80% normal saline for injection:20% non-ionic contrast) The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
89041713|NCT04646759|Experimental|Fulvestrant Combined With Pyrotinib|Fulvestrant, 500 mg, was injected intramuscularly on D1, D15, D28, D28, once every 28 days； Pyrotinib, 400mg, orally administered daily.
89634470|NCT02410746|Active Comparator|standard chirocaine infiltration|non-targeted infiltration of 10ml 0.25% Chirocaine into breast pocket
89634471|NCT02410746|Experimental|targeted chirocaine pec block|pectoral muscle block with 10ml 0.25% chirocaine
89041714|NCT04646759|Active Comparator|Capecitabine Combined With Pyrotinib|Capecitabine, 1000mg / m^2, twice daily; Pyrotinib, 400mg, orally administered daily.
89634472|NCT03177174|Active Comparator|Docetaxel|
89041715|NCT02906826|No Intervention|Reported adherence|During a 4 month period the investigators will measure adherence to therapy as reported in a daily diary by participants against actual adherence which will be measured by a digital manometer attached to the participants therapy device which uploads real time data to the cloud.
89041716|NCT02906826|Active Comparator|Adherence with a video game|During the second 4 month period, participants will be given a video game on a tablet which is operated through the digital manometer by their performing their therapy correctly.Actual adherence will be measure again during this time and be compared to the no intervention arm
89041717|NCT04646798|Active Comparator|Hemi Arthroplasty (HA) of the elbow.|Hemi Arthroplasty (HA) of the elbow, where the surgeon replaces the bottom of the humerus bone at the elbow.
89041718|NCT04646798|Active Comparator|Total Elbow Arthroplasty (TEA).|Total Elbow Arthroplasty (TEA), where the surgeon fits a new elbow joint replacing damaged parts of the humerus bone and forearm bone that it joins onto.
89041719|NCT02907801|Experimental|Perception-Action Approach|Perception-Action Approach (P-AA) intervention components include environmental set-up for activity and participation in play, manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions, and caregiver education in modifications to everyday activities consistent with the P-AA. All components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing the environmental supports and therapist's hands to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
89041720|NCT02906514|Experimental|Hydroxyethyl starch 130/0.4|
89634473|NCT03177174|Active Comparator|Cisplatin|
89634474|NCT03177174|Active Comparator|DocetaxelCisplatin|Cisplatin combined with Docetaxel
89634475|NCT03175146|Experimental|Experimental|Stereotactic Body Radiation Therapy
89634476|NCT02409108|Experimental|Exatherm-TBH system|One treatment of Total Body Hyperthermia
89634477|NCT02409264|Experimental|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the determined individualised homeopathic remedy, in the potency decided by the researcher in accordance with the laws that govern homeopathic prescribing. The dose and repetition of the remedy will be determined by the researcher in accordance with the aforementioned laws. A remedy will be prescribed every 2 weeks, after its determination by the researcher. No remedy will be prescribed after week 8.
89634478|NCT03177252|Experimental|Scalp block with lidocaine and bupivacaine|"Scalp block with a mixture of 2% lidocaine and 0.5% bupivacaine~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
89634479|NCT03177252|Placebo Comparator|Scalp block with saline|"Scalp block with saline~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
89634480|NCT03174912|Active Comparator|Group 1|Whole patient group (patients not treated with BCG and patients treated with BCG)
89634481|NCT03174912|No Intervention|Group 2|Patients not treated with BCG
89634482|NCT03174912|Active Comparator|Group 3|Patients treated with BCG
89688498|NCT04355221|Experimental|Group B|using prolonged duration of PRFT. four cycles, each one for 2 minutes at 45V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
89041721|NCT02906514|Placebo Comparator|Sodium Chloride 0.9%|
89041722|NCT04646408||Participants with CKD|Recruitment is from a cohort of HIV positive individuals of African ancestry with Chronic Kidney Disease CKD defined as eGFR <60 mL/min/1.73m2, and/or albumin/creatinine ratio >30 mg/mmol or protein/creatinine ratio >50 mg/mmol Anticipated n=75
89041723|NCT04646408||Participants with diabetes|"Recruitment is from a cohort of HIV positive individuals of African ancestry with diabetes. Diabetes is defined as being on diabetic medications or HbA1c >48 mmol/mol.~Anticipated n=75"
89634483|NCT02408640|Experimental|Intervention group|"Individuals randomized to the intervention group will directly after randomization answer questions about alcohol and drug use (other than alcohol and cannabis), depression, anxiety, a sense of context and whether they during the last 12 months has received professional help to reduce or quit their cannabis use or during the same period have raised this issue with their relatives or friends.~Further, they will fill out a survey about Internet-based services for individuals who wish to reduce or quit their cannabis use. The study participants will then be informed that they, within two days, will gain access to an internet based treatment program designed to help them quit their cannabis use and that they through the program will be able to communicate with a therapist. Within the next two days, they will gain access to the internet-based treatment program, they will have access to it for two months and they will be contacted again after three months to complete the follow-up."
89041724|NCT04646408||Participants with ischaemic heart disease/stroke|Recruitment is from a cohort of HIV positive individuals of African ancestry with previous ischaemic heart disease or stroke Anticipated n=50
89041725|NCT04646408||No CKD/DM/CVD cohort|"Recruitment is from a cohort of HIV positive individuals of African ancestry who do not have CKD, diabetes or prior ischaemic heart disease/stroke.~Anticipated n=200"
89041726|NCT02906475|Other|Intervention: standardized skin care regimen|Intervention: The milk lotion will be applied once daily on the total body including the face by the parents or care givers at home. If bathing is needed, the bathing addendum is used in addition to water.
89041727|NCT02906475|No Intervention|Control|In the control group no predetermined or standardized skin care regimen is prescribed.
89634484|NCT02408640|No Intervention|Control group|"Individuals randomized to the control group will undergo exactly the same procedure as the intervention group. The difference is that the control group will be informed that they in about three months will gain access to an internet based treatment program designed to help them quit their cannabis use (i.e. when the data collection for follow-up is completed).~Otherwise, participants in both groups will have the opportunity to use factual information that is available to everyone on Cannabishjalpen.se."
89634485|NCT02703324|Experimental|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
89634486|NCT02703324|Active Comparator|Insulin Lispro|Insulin lispro delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
89634487|NCT02408718|Active Comparator|Training group|Subjects randomized to this group will receive a 6 week Assistive Device Training program in the use of their assistive device. They will have mobility assessments taken at baseline, after the training program has been completed, and 3 months later. During this time, their falls will be recorded monthly using prospective falls calendars. Members of this group will also receive MRI scans at baseline and after the completion of the training program.
89634488|NCT02408718|No Intervention|Wait-list control|Subjects in this group will participate in the same mobility assessments and completion of the falls calendars, but will receive no intervention during this time. These subjects will have the opportunity to receive the training sessions when all assessment visits have been completed. These subjects will not receive MRI scans.
89634489|NCT02408562|Experimental|sNN0031|sNN0031 Infusion Solution (in aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
89634490|NCT02408562|Placebo Comparator|Placebo|Articifial Cerebro Spinal Fluid (aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
89634491|NCT03171870|Other|Idiopathic Pulmonary Fibrosis|Idiopathic pulmonary fibrosis patients on high resolution computed tomography characterized by presence of reticular opacities often associated with traction bronchiectasis
89634492|NCT03171948|Experimental|Almond group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
89634493|NCT03171948|Experimental|Nut Free group|Nut Free group (NFG), as control group, who continue their diet without any nut consumption.
89634494|NCT02701764|Experimental|Pregabalin|Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.
89634495|NCT02701764|Placebo Comparator|Placebo|Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.
89634496|NCT03171714|Experimental|Derma-Stent|The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.
89634497|NCT03171714|Active Comparator|Usual Care, cotton gauze packing|Standard of care to pack a drained abscess for healing.
89634498|NCT03116256|Other|VLCD only|Very low calorie diet (VLCD) only group- participants in this group will receive complete meal replacement for 6 weeks.
89634499|NCT03116256|Active Comparator|VLCD+RET|VLCD+RET group- participants in this group will receive complete meal replacement for 6 weeks and resistance exercise training 3 times every week for 6 weeks.
89634500|NCT03116256|Active Comparator|VLCD+HIIT|VLCD+HIIT group- participants in this group will receive complete meal replacement for 6 weeks and High intensity interval training 3 times every week for 6 weeks.
89041728|NCT02907723|Experimental|Continuous Sleep Recording|Continuous Sleep Recording in Patients
89041729|NCT02907567|Active Comparator|Active Treatment-Low|6 subjects randomized to 280 mg (Low) CT1812
89041730|NCT02907567|Active Comparator|Active Treatment-High|6 subjects randomized to 560 mg (High) CT1812
89041731|NCT02907567|Placebo Comparator|Placebo|4 subjects randomized to matching placebo of CT1812
89041732|NCT04646018|Experimental|Lumbar Manipulation Group|Group that receives experimental lumbar non-thrust manipulation
89041733|NCT04646018|Sham Comparator|Sham Manipulation Group|Group that receives sham lumbar non-thrust manipulation
89041734|NCT02906436|Experimental|ExVivo lung reconditioning|
89057541|NCT02216981|Experimental|Intensive Cognitive Behavioural Therapy|Intensive CBT (an average of 12-18 hours of CBT offered in an intensive format, delivered on 2-3 days per week over a period of 3 weeks)
89634501|NCT03174210|Experimental|COPD patients with delivery order 1, 2|Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))
89634502|NCT03174210|Experimental|COPD patients with delivery order 2,1|Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))
89634503|NCT03174288|Experimental|Exercise alone|24 weeks of exercise treatment
89634504|NCT03174288|Experimental|spironolactone alone|24 weeks of Spironolactone treatment
89634505|NCT03174288|Experimental|Exercise + Spironolactone|24 weeks of exercise + Spironolactone treatment
89634506|NCT02532010|Active Comparator|Arm A: Pacritinib and Decitabine|Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
89634507|NCT02532010|Active Comparator|Arm B: Pacritinib and Cytarabine|Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
89634508|NCT03176862||CKD|40 patients per group of CKD from stage 2 to stage 5.
89634509|NCT03176862||Kidney transplant recipients|20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
89634510|NCT03176862||Controls|40 healthy controls and 40 hypertensive controls.
89634511|NCT02532556|Experimental|1|Stimulation of muscle in this order: vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius
89634512|NCT02532556|Experimental|2|Stimulation of muscle in this order: rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials
89634513|NCT02532556|Experimental|3|Stimulation of muscle in this order: vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris
89634514|NCT02532556|Experimental|4|Stimulation of muscle in this order: tibialis anterior, peroneus longus, and the medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis
89634515|NCT02532556|Experimental|5|Stimulation of muscle in this order: peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior
89634516|NCT02532556|Experimental|6|Stimulation of muscle in this order: medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus
89634517|NCT02532556|Experimental|7|Stimulation of muscle in this order: lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius,
89634518|NCT02406300|Active Comparator|Subarachnoid anesthesia|"Patients submitted to subarachnoid anesthesia for proximal femur fracture surgical repair.~Up to 12.5 mg of bupivacaine or levobupivacaine will be used"
89634519|NCT02406300|Active Comparator|PNB/GA|Patients are submitted to a femoral, a lateral cutaneous nerve of the thigh and an anterior obturator nerve blocks with ropivacaine and an inhalational general anesthesia with sevoflurane or desflurane
89634520|NCT02533726|Experimental|Treatment - Optimal Turning|All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
89634521|NCT02533726|Active Comparator|Control - Standard Care|All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.
89634522|NCT03176940|Experimental|2-HOBA first dose|Dose escalation studies in humans: 50mg dose
89634523|NCT03176940|Experimental|2-HOBA second dose|Dose escalation studies in humans: 100mg dose
89634524|NCT03176940|Experimental|2-HOBA third dose|Dose escalation studies in humans: 200mg dose
89634525|NCT03176940|Experimental|2-HOBA fourth dose|Dose escalation studies in humans: 330mg dose
89634526|NCT03176940|Experimental|2-HOBA fifth dose|Dose escalation studies in humans: 550mg dose
89634527|NCT03176940|Experimental|2-HOBA sixth dose|Dose escalation studies in humans: 825mg dose
89634528|NCT00363922|Experimental|1|Rehabilitation in institution
89634529|NCT00363922|Active Comparator|2|Rehabilitation at home
89634530|NCT03176706||Lebanese pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in the Lebanon.
89634531|NCT03176706||Thai pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Thailand.
89634532|NCT03176706||South African pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in South Africa.
89634533|NCT03176706||New Zealand pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in New Zealand.
89634534|NCT03176706||Swedish Pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Sweden.
89634535|NCT03176706||Peruvian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Peru.
89634536|NCT03176706||Russian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Russia.
89634537|NCT03174054||Patients with no clear lesion in PET or MRI|If the clinical suspicion of cancer is low, there will be no biopsy, only follow-up. If the decision is to perform a biopsy on the prostate, it will be performed with transrectal sonar guidance and systematic biopsies will be performed (12 samples will be taken from different areas of the prostate)
89634538|NCT03174054||Patients with MRI lesions and overlapping mapping lesions|If MRI and PET are matched, a US FUSION MRI biopsy will be taken between 4-8 samples directly from the lesion as well as other systemic prostate samples according to the surgeon's decision. Will be taken and sent separately to pathology.
89634539|NCT03174054||Patients with a discrepancy between the PET and MRI|A FUSION approach will be biopsy. Four to eight samples for each lesion, as well as other systemic prostate samples will be taken according to the surgeon's decision, and the samples will be marked and sent separately to the pathology.
89634540|NCT02538016|Other|Tolvaptan|
89634541|NCT02406144|Active Comparator|Lenalidomide|Oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years
89634542|NCT02406144|Experimental|MLN9708 plus Lenalidomide|MLN9708 during the two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.
89634543|NCT04341142|Experimental|Serological tests will be applied on patients blood sampling|Serological tests will be applied on patients blood sampling
89634544|NCT02416752||remifentanil group|Group received intra op remifentanil infusion
89634545|NCT02416752||conventional opioid gropup|Group received only conventional opioids and No infusion of remifentanil
89634546|NCT02405910|Experimental|A - Nab-paclitaxel 100mg + Gemcitabine 1250mg|Nab-paclitaxel 100 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 21 day cycle. On days 1 and 8 of each cycle, nab-paclitaxel administration will be followed by the administration of gemcitabine 1250 mg/m2 as a 30 minute infusion (maximum 40 minutes).
89634547|NCT02405910|Experimental|B - Nab-paclitaxel 125mg + Gemcitabine 1000mg|Nab-paclitaxel 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 28 day cycle. Each nab-paclitaxel administration will be followed by the administration of gemcitabine 1000 mg/m2 as a 30 minute infusion (maximum 40 minutes) on days 1, 8 and 15. Treatments will be repeated until progression or intolerance.
89634548|NCT02539108|Experimental|Study Group 1|Participants at 6 months to < 36 months age at enrollment
89634549|NCT02539108|Experimental|Study Group 2|Participants at 3 years to < 9 years age at enrollment
89634550|NCT02406066|Placebo Comparator|Placebo|Subjects will receive capsules containing no active pharmaceutical ingredients.
89634551|NCT02406066|Active Comparator|Low Dose (Cohort 1)|270 mg metyrapone and 12 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
89634552|NCT02406066|Active Comparator|Medium Dose (Cohort 2)|540 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
89634553|NCT02406066|Active Comparator|High Dose (Cohort 3)|720 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
89634554|NCT02408328|Active Comparator|Inpatient Observation|Continued inpatient monitoring of apnea, bradycardia, and/or desaturation until an event free period of time (5 days per the current standard of care at each participating institution) has been established and deemed appropriate for discharge home per the discretion of the responsible provider.
89634555|NCT02408328|Active Comparator|Caffeine and Outpatient Monitoring|Patients will receive a loading dose of caffeine on day 1 with a daily maintenance dose thereafter. Infants will then receive continued inpatient monitoring of apnea/bradycardia/desaturation until an event free period of time has been established and deemed appropriate for discharge home per the discretion of the responsible provider. Infants discharged home on caffeine therapy will receive instructions regarding use of a home monitor. Follow up in the pulmonary clinic will be arranged at 42-43 weeks gestational age. At 43 weeks corrected gestational age, caregivers will be instructed to discontinue caffeine therapy. An outpatient recorded oximetry study will be arranged at least 1 week after discontinuation of caffeine therapy. Home pulse oximetry monitoring will be discontinued if no significant events, as previously defined, are recorded.
89634556|NCT02539342|Experimental|Caphosol Arm|Caphosol Arm: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day from the start of chemotherapy until 7 days after the completion of chemotherapy AND until the ANC is >500 after count recovery OR until the the symptoms or oral mucositis resolve, whichever occurs last. Patients will also complete a study diary to record symptoms of oral mucositis.
89634557|NCT02539342|Active Comparator|Control Arm|Control Arm: Subjects randomized to the Control Arm will use Biotene 4 times per day. They will also complete a study diary to record doses and any symptoms of oral mucositis. This will begin at the start of chemotherapy until for 7 days AND until ANC >500 after nadir or oral mucositis resolves (whichever occurs later)
89634558|NCT02405988|Experimental|Intravenous naloxone|0,4 mg/ml Naloxone B Braun 2,5 ML intravenously
89634559|NCT02539654|Experimental|EXE844|EXE844 Sterile Otic Suspension, 0.3%, single ototopical dose (4 drops) in each ear following tympanostomy tube insertion
89634560|NCT02402010|Experimental|Adjunctive Yoga|Participants may be randomized to receive up to 10 weeks of group yoga class, as an adjunct to medication treatment as usual provided by community clinicians.
88990902|NCT06062576|Experimental|powder group 2|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder was used to treat the wound of granulation period patients for 2 weeks
88990903|NCT06062576|Experimental|ointment group 2|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao ointment was used to treat the wound of granulation period patients for 2 weeks
88990904|NCT06061146|Experimental|Arm A|"Tislelizumab + S1 + Radiotherapy Drug: Tirellizumab IV infusion，200 mg/3w, for 1 year~Drug: S1 PO, 40~60mg，BID（d1-14，d22-35，two cycles）~Radiation: Radiation Concurrent Radiation, 1.8Gy/f, 28f"
88990905|NCT06061146|Active Comparator|Arm B|"S1 + Radiotherapy~Drug: S1 PO, 40~60mg，BID（d1-14，d22-35，two cycles）~Radiation: Radiation Concurrent Radiation, 1.8Gy/f, 28f"
88990906|NCT06059729|Experimental|Experimental group|Al-Lisaan digital application will be given to participants for self assessment and management
88990907|NCT06059729|Other|Controlled group|Home plan will be given
89688499|NCT04355221|Experimental|Group C|using higher voltage PRFT.. two cycles, each one for 2 minutes at 60V with a pulse width of 10ms and a pulse frequency of 4Hz. The cut-off needle tip temperature is set at 420C.
89688500|NCT04364113|Active Comparator|Study A Usual Protein Usual Pressure|Study A Usual Protein and Usual Pressure
88990908|NCT06059456||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
88990909|NCT06059456||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
88990910|NCT06052384|Experimental|Reinforced sleep program|standard pain management + sleep disorders management
88990911|NCT06052384|No Intervention|Standard care|Control group: standard pain management
88990912|NCT06052371||Neonates|Newborn babies who are 28 days old or less with a corrected gestational age of at least 34 weeks and a weight of at least 1700g or more at the time of participation. They will be recruited from hospital neonatal units or wards.
89634561|NCT02402010|Other|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
89634562|NCT04482348|Active Comparator|the mind is a great story teller-positively framed|explanations for more pain than expected
89634563|NCT04482348|Active Comparator|the mind is a great story teller-negatively framed|explanations for more pain than expected
89634564|NCT04482348|Active Comparator|emotionally-framed explanation-stressed or down-positive frame|explanations for more pain than expected
89634565|NCT04482348|Active Comparator|emotionally-framed explanation-stressed or down-negative frame|explanations for more pain than expected
89634566|NCT04482348|Active Comparator|"mixed emotion and cognition (mind and body work together)"|explanations for more pain than expected
89634567|NCT04482348|Active Comparator|"physically based explanations over-excited state"|explanations for more pain than expected
89634568|NCT04482348|Active Comparator|"physically based explanations overstimulated"|explanations for more pain than expected
89634569|NCT02542150|Experimental|acetate arm|IV acetate given during magnetic resonance scan
89634570|NCT02542150|Experimental|alcohol arm|jello shots given before magnetic resonance scan
89634571|NCT03173820|Placebo Comparator|Conventional|no genotype of CYP3A5 investigated to adjust tacrolimus dosage regimen
89634572|NCT03173820|Active Comparator|Genotype guided|Use CYP3A5 genotype to adjust dosage regimen for tacrolimus
89634573|NCT03173742|Experimental|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
89041735|NCT04646135|Experimental|Sequence 1|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.2 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
89041736|NCT04646135|Experimental|Sequence 2|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.2 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.03 mg/kg/hour LZ"
89634574|NCT03173742|Experimental|T1, T3, T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
89634575|NCT03173742|Experimental|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
89634576|NCT03173742|Experimental|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
89634577|NCT03173742|Experimental|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
89634578|NCT03173742|Experimental|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
89634579|NCT02542462|Active Comparator|Rotarix® alone|monovalent rotavirus vaccine (Rotarix®, RV1)
89634580|NCT02542462|Active Comparator|Rotarix®,with other routine vaccines|monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
89634581|NCT02542462|Active Comparator|RotaTeq®, alone|pentavalent rotavirus vaccine (RotaTeq®, RV5)
89634582|NCT02542462|Active Comparator|RotaTeq®,with other routine vaccines|pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
89041737|NCT04646135|Experimental|Sequence 3|"The subjects enrolled in this arm, will undergo the following lorazepam administration scheme:~Day 1: 6 Boluses at 0.3 mg/kg LZ every 4 hours~Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hours~Day 3: Continuous Infusion at 0.025 mg/kg/hour LZ"
89041738|NCT02906553|Experimental|Glyceryl Trinitrate|Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.
89041739|NCT02906553|Placebo Comparator|Placebo|The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.
89041740|NCT06237777|Experimental|Dose-escalation|SKG0106 one-time deliver
89041741|NCT06237764||Genetics in exfoliation glaucoma|Prospective recruited patients suffering from exfoliation glaucoma.
89041742|NCT06237751|Other|sildenafil|Sildenafil vs. blank control group
89634583|NCT03173898|Experimental|primary periodontal ligament anesthesia|PDL anesthesia versus local infiltration
89057542|NCT02216981|Active Comparator|Weekly Cognitive Behavioural Therapy|Weekly CBT (an average of 12-18 hours of CBT delivered in 60-90 minute sessions on a weekly basis)
89057543|NCT02216981|No Intervention|Wait list|Wait list (3 months). Participants randomized to wait list will commence treatment after 3 months, in the treatment condition to which they are re-randomized (either Intensive or Weekly CBT).
89634584|NCT03173898|Active Comparator|local infiltration|PDL anesthesia versus local infiltration
89634585|NCT02401932||Hemophagocytosis|The group includes patients who have the evidence of hemophagocytosis in their bone marrow or other sites.
89634586|NCT02543398|Other|Ridge preservation|"The molar extraction socket is grafted with FDA approved materials, which includes a bone graft material derived from human donors (enCore®, Osteogenics biomedical, Lubbock, TX) and a membrane (like a thin sheet of paper) covering the grafted extraction socket. The membrane used will need to be removed at a later point since it is non-resorbable (it will not dissolve by itself). This membrane is made of dense polytetrafluoroethylene (dPTFE) (Cytoplast™, Osteogenics biomedical, Lubbock, TX). The procedure is called Ridge preservation"
89634587|NCT02543398|Other|No ridge preservation|"The molar extraction socket is left to heal by itself without any grafting material or membrane, i.e. Spontaneous Healing (No ridge preservation is performed)"
89634588|NCT02408172|Experimental|OSA-amlodipine|To observe the effects of amlodipine (5mg) on blood pressure variation after 12 weeks of treatment
89688501|NCT04364113|Experimental|Study A Usual Protein Low Pressure|Study A Usual Protein and Low Pressure
89041743|NCT06237738|Experimental|Stress Ball Intervention|Participants in this group were provided with stress balls to use during their hemodialysis sessions, specifically before the cannulation process. These stress balls, made from medium-firm, high-quality silicone, were utilized by squeezing with the hand opposite the one receiving cannulation. This activity, performed three minutes before the cannulation, aimed to reduce the levels of pain experienced by the participants. The use of stress balls was integrated into the regular hemodialysis routine, and participants consistently engaged in this practice before each cannulation over the course of the study. This intervention provided valuable insights into the effectiveness of simple, non-pharmacological methods for pain management in a clinical setting.
89041744|NCT06237738|No Intervention|Standard Care Control|Participants in the control group did not receive any additional intervention. They continued to receive standard care during their hemodialysis sessions, without the use of any extra tools like stress balls for pain management. This group served as a comparison point to assess the effectiveness of the intervention implemented in the experimental group. By maintaining their routine hemodialysis care, the control group provided essential data for evaluating the impact of the stress ball intervention. The completion of their participation in the study was crucial in establishing a baseline for pain levels during cannulation without any non-pharmacological interventions.
89041745|NCT06237725|Experimental|Nutrition of Continuous|Experimental: Intervention Group to Nutrition of Continuous
89041746|NCT06237725|No Intervention|Control Group Nutrition of Continuous|Control Group to Nutrition of Continuous
89041747|NCT06237725|Experimental|Nutrition of Bolus|Experimental: Intervention Group to Nutrition of Bolus
89634589|NCT02408172|Experimental|OSA-metoprolol|To observe the effects of metoprolol (47.5mg) on blood pressure variation after 12 weeks of treatment
89634590|NCT02401776|Experimental|small dose monster energy drink|This will be a small dose of monster energy drink
89634591|NCT02401776|Experimental|medium dose monster energy drink|This will be a medium dose of monster energy drink
89634592|NCT02401776|Active Comparator|coffee|This will be a coffee group and will drink Starbuck's K-cup Breakfast Blend. This will be mixed according to packing instructions and will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 11 ounce cup of coffee for a person weighing 75 kg).
89634593|NCT02543554||Pre-intervention group|mechanically ventilated patients before implementation of ED lung protective ventilation
89634594|NCT02543554||Intervention group|mechanically ventilated patients after implementation of ED lung protective ventilation
89041748|NCT06237725|No Intervention|Control Group Nutrition of Bolus|Control Group to Nutrition of Bolus
89634595|NCT02547064|Active Comparator|90 degree|The ETT with the 90° angle stylet was bent at a point 8 cm from its distal end.
89634596|NCT02547064|Experimental|70 degree|The ETT was bent by 70° at a point 6 cm from its distal end and the proximal portion of the ETT was formed as the shape of the GL blade until the point of the handle.
89634597|NCT02407860|Experimental|treatment|one single osteopathic treatment in addition to usual breastfeeding counselling
89634598|NCT02407860|Active Comparator|control|usual breastfeeding counselling. Osteopathic evaluation of entire body
89634599|NCT02405832|Experimental|Zinc - active arm|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
89041749|NCT06237699||ICU survivors without an ICU diary|
89041750|NCT06237699||ICU relatives without an ICU diary|
89041751|NCT06237699||ICU survivors with a digital ICU diary|
89041752|NCT06237699||ICU relatives with a digital ICU diary|
89041753|NCT06237686|Experimental|one-armed study|
89634600|NCT02405832|Placebo Comparator|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
89634601|NCT02548312|Experimental|Review 1- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
89634602|NCT02548312|Experimental|Review 1- competing interest statement 2|Variations of financial competing interest statements.
89634603|NCT02548312|Experimental|Review 1- competing interest statement 3|Variations of financial competing interest statements.
89041754|NCT06237673|Experimental|CT|CT-directed clinical management strategy
89041755|NCT06237673|Active Comparator|Invasive coronary angiography (ICA)|Standard clinical management directed by conventional invasive coronary angiography (ICA).
89041756|NCT06237660||Aim 1|"To test the proposed panel of simple bedside tests below, to see how accurately they corelate with lower airway infection or inflammation.~The aim is correlate the results from the bronchoscopy with the panel of test proposed, and evaluate if these simple bedside tests can pick up the same level of infection or inflammation and obtain the same results, as the bronchoscopy, which is a much more invasive test, but the only method available at present to get this information."
89041757|NCT06237660||Aim 2|The aim is to test how acceptable these bedside tests are to parents and children, and if they reflect the child's symptoms, symptoms control and medication use.
89057544|NCT01683708||Symbiotic group|Jaundiced patients who have symbiotic therapy
89057545|NCT01683708||No Symbiotic therapy|Jaundiced patients who not have symbiotic therapy
89057546|NCT02217059||Prehypertension|Using the JNC7 definition
89057547|NCT02217059||Stage I Hypertension|Using the JNC7 definition
89057548|NCT02217059||Stage II Hypertension|Using the JNC7 definition
89057549|NCT01649544|Experimental|EPICOR|"Cardiac ablation system EPICOR (CE n°0344).~ablation device EpicorTM UltraCinchTM LP (Class III device)~Positioning system and calibration EpicorTM LP (LP PASTM; device Class IIa)~Cable connection EpicorTM LP (unsterile)~Ablation Control System EpicorTM LP (Class IIb)"
89634604|NCT02548312|Experimental|Review 1- competing interest statement 4|Variations of financial competing interest statements.
89634605|NCT02548312|Experimental|Review 2- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
89634606|NCT02548312|Experimental|Review 2- competing interest statement 2|Variations of financial competing interest statements.
89634607|NCT02548312|Experimental|Review 2- competing interest statement 3|Variations of financial competing interest statements.
89634608|NCT02548312|Experimental|Review 2- competing interest statement 4|Variations of financial competing interest statements.
89634609|NCT04481100|Experimental|Experimental Group|Itraconazole capsule 100mg twice daily for 6 weeks concurrent with chemoradation.
89634610|NCT02405754||Treatment Group|Patients receiving Age/Sex/Gene Expression Score (ASGES) or Corus CAD test
89634611|NCT02405598|Experimental|Salbutamol|"age 2-6 year: 0.1mg/kg tid x 2 weeks, then gradually increase to 0.2mg/kg tid (daily total maximal12mg)~age 6-12 year: 2mg tid x 2 weeks, then gradually increase to 4mg tid (daily total maximal 24mg)~age 12 year and above: 4mg tidx 2 weeks, then gradually increase to 8mg tid (daily total maximal 32mg)"
89634612|NCT03171402||Low fruit and vegetable consumers|Participants with low F&V consumption, as defined by 24-hr dietary recall
89634613|NCT03171402||High fruit and vegetable consumers|Participants with high F&V consumption, as defined by 24-hr dietary recall
89634614|NCT03173586||NHS|"Least-squares mean (95% CI) concentrations of biomarkers by frequency of sugar sweetened beverage (SSB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of artificially sweetened beverage (ASB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of fruit juice intake among participants free of diabetes and cardiovascular disease in the NHS."
89634615|NCT03173274|Experimental|Contingency Management (CM)|Those in the CM condition will continue to provide CO values twice-daily, and will receive escalating reinforcement values for CO values indicating continuous smoking abstinence (CO < 6 ppm).
89634616|NCT03173274|Active Comparator|Non-Contingent Reinforcement|Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
89634617|NCT03173352||Infant hemangioma(IH)|Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, We designed the study to collect data about both epidemiology related risk ractors of infantile hemangioma in China.
89634618|NCT02401386|Experimental|EB group|Trained and guided by EB certified physicians, patients in EB group received closely supervised, group-format EB program and practiced EB for one hour, twice weekly for 12 weeks in the Guang'anmen Hospital.
89634619|NCT02401386|No Intervention|Control group|The participants in usual therapy-controlled group will stay on their previous treatment through 12 weeks. As compensation, they will be invited to receive LEB training for 12 weeks after the end of the study.
89634620|NCT02407938|Experimental|rice meal|High resolution manometry will be performed. Esophageal function will be tested using liquid swallows, solid swallows and a test meal (200g rice)
89634621|NCT03173508|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
89634622|NCT03173508|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
89634623|NCT03171558|Experimental|Gastric Pull Up|Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.
89634624|NCT03171558|Active Comparator|Free Flap|Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.
89634625|NCT03171324|Experimental|AGA 6 weeks|Iron supplementation will be started at 2mg/kg from 6 weeks of age to 1 year
88990913|NCT06042894|Experimental|BL-B01D1 + SI-B003|Participants receive SI-B003 or BL-B01D1 + SI-B003 therapy in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
88990914|NCT06038760||Trial Cohort|Patients with a solid primary brain tumor due to undergo surgery as standard of care
88990915|NCT06037174||minimally invasive surgery|undergoing thyroidectomy with endoscopy-assisted subclavian approach, robot-assisted transaxillary approach, robot-assisted transoral approach, robot-assisted retroauricular approach, etc.
88990916|NCT06037174||traditional open surgery|undergoing thyroidectomy with tradition open surgery
89634626|NCT03171324|Experimental|AGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
89634627|NCT03171324|Experimental|SGA 6 weeks|Iron supplementation will be started from 6 weeks of age to 1 year
89634628|NCT03171324|Experimental|SGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
89057550|NCT01649544|Active Comparator|Amiodarone|"Cordarone :~400 mg/d during the 2 first months 200 mg/d from 3th to 18th month"
89057551|NCT04528290|Experimental|Group A (reference): Current ozanimod capsule formulation|Single oral dose of ozanimod 0.92 mg
89634629|NCT02401620||single-group studies|Patients with RA diagnosed
89634630|NCT03173430|Experimental|Arm 1|An evaluable subject is any subject who completes two 28-day cycles of blinatumomab or discontinues blinatumomab after completion of less than one cycle due to toxicity.
89634631|NCT03172962|Experimental|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
89634632|NCT03172962|Active Comparator|Usual care (control)|Will receive the usual care at the hospital
89634633|NCT03173040|Experimental|NiuBangZi pill group|Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate
89634634|NCT03173040|Placebo Comparator|Placeo group|Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate
89634635|NCT02401074|Experimental|Segmental bronchoprovocation with Allergen (SBP-Ag)|Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment.
89634636|NCT03173196||Sepsis group|Patients with a septic shock or a severe sepsis (surgical and non-surgical patients), staying on Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
89634637|NCT03173196||Non-septic group|Patients without sepsis (surgical and non-surgical patients), staying at least 24 hours on an Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
89634638|NCT02407782|Experimental|Ivermectin|
89634639|NCT02407782|Experimental|Permethrin|
89634640|NCT02405364|Experimental|Front line therapy|Induction: 4 cycles of 28 days of Carfilzomib/Lenalidomide/Dexamethasone Stem Cell Harvest+Intensification Consolidation 4 cycles of 28 days of Carfilzomib/ Lenalidomide/Dexamethasone Maintenance: Lenalidomide 13 cycles of 28 days
89634641|NCT02405286||Upeer gastrointestinal bleeding|"Adult Egyptian patients.~Patients with acute upper G.I hemorrhage.~Informed consent."
89634642|NCT02405130|Active Comparator|epinephrine|intracoronary epinephrine is two ampoules each of 1:1000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline (to 20 μg/mL epinephrine solution); a 5 ml syringe prepared will then contain 100 μg
89634643|NCT02405130|Other|no intracoronary epinephrine|no epinephrine
89634644|NCT04896450|Experimental|Test group|Test subjects receive GTR and early initiation of OTM.
89634645|NCT04896450|Active Comparator|Control group|Control subjects receive only GTR.
89634646|NCT03169374|Experimental|Virtual Reality Technology|Virtual Reality Therapy
89634647|NCT02405052||Patients|Emergency department patients with unexplained chest pain
89634648|NCT03171090|Active Comparator|sphenopalatine block using local anasthetic|
89634649|NCT03171090|Placebo Comparator|sphenopalatine block using saline|
89634650|NCT02404740||VP shunt functioning|No intervention, just a physiological category--patients with VP shunts that are functioning normally.
89634651|NCT02404740||VP shunt malfunctioning|No intervention, just a physiological category--patients with VP shunts that are malfunctioning.
89634652|NCT02404740||No known intracranial pathology|No intervention, just a physiological category--patients without VP shunts that have no known intracranial pathology.
89634653|NCT02407470|Active Comparator|Rabbit antithymoglobulin （ATG）|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.
89634654|NCT02407470|Experimental|Rabbit ATG & AD-MSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.
89634655|NCT02407470|Experimental|Rabbit ATG & AD-HSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4.
89634656|NCT02549014|Experimental|Panel A: MK-1064 5 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634657|NCT02549014|Experimental|Panel B: MK-1064 10 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634658|NCT02549014|Experimental|Panel A: MK-1064 25 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634659|NCT02549014|Experimental|Panel B: MK-1064 50 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 50 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634660|NCT02549014|Experimental|Panel A: MK-1064 100 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 100 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634661|NCT02549014|Experimental|Panel B: MK-1064 150 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 150 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634662|NCT02549014|Experimental|Panel A: MK-1064 200 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 200 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634663|NCT02549014|Experimental|Panel B: MK-1064 250 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 250 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634664|NCT02549014|Experimental|Panel A: MK-1064 25 mg (Fed)|In Period 5, participants received a single MK-1064 dose of 25 mg administered in the evening following a standard high-fat breakfast.
89634665|NCT02549014|Experimental|Panel B: MK-1064 50 mg (Night)|In Period 5, participants received a single MK-1064 dose of 50 mg administered in the evening after a 4-hour fast.
89634666|NCT02549014|Placebo Comparator|Panels A & B: Placebo|Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
89634667|NCT01696643|Experimental|CB-5945|0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
89634668|NCT01696643|Placebo Comparator|Placebo|Placebo, administered orally, BID for 52 weeks
89634669|NCT02407626|Experimental|Sevoflurane|Volatile anesthesia for elective cardiac surgery
89634670|NCT02407626|Active Comparator|Propofol|Total intravenous anesthesia for elective cardiac surgery
89634671|NCT02407392|Active Comparator|Non targeted quadrantic biopsies|Patients undergo current gold standard Barrett's surveillance with quadrantic Seattle protocol biopsies
89634672|NCT02407392|Experimental|Acetic Acid targeted biopsies|Patients undergo dye spray gastroscopy with Acetic Acid and targeted biopsies for areas of dysplasia.
89688502|NCT04364113|Experimental|Study A Low Protein Usual Pressure|Study A Low Protein and Usual Pressure
89688503|NCT04364113|Experimental|Study A Low Protein Low Pressure|Study A Low Protein and Low Pressure
89634673|NCT02551432|Experimental|Paclitaxel pembrolizumab|"PD-L1 Induction phase : Paclitaxel 175 mg/m2, Day 1 q 3weeks, intravenous,~Post Induction treatment phase: Paclitaxel 175 mg/m2, Day 1 q 3weeks (maximum up to total 6 cycles) + pembrolizumab 200 mg D1 q 3 weeks, intravenous,~Maintenance phase: pembrolizumab 200 mg D1 q 3 weeks, intravenous till PD or unacceptable toxicity"
89634674|NCT02407548|Experimental|combined group|each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.
89634675|NCT02407548|Experimental|CoQ10 group|each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.
89634676|NCT02407548|Other|placebo group|each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.
89041758|NCT06237660||Aim 3|"Small proof-of-concept study. This is for a feasibility trial of using the proposed tests and deciding the treatment of their wheeze, based on the results of the tests. Children with evidence of allergen sensitisation +/- blood eosinophilia (>0.3x109/L) will be prescribed regular inhaled corticosteroids. Children who are non-atopic (non-atopic is defined as blood eosinophil of <0.3x109/L + no evidence of allergen sensitisation) with positive bacterial detection in sputum, will be prescribed four weeks of targeted antibiotics. Children who are non-atopic with no bacteria detected in sputum, will be prescribed only be prescribed short acting bronchodilators as required. All medications will be prescribed, as per the British National Formulary for Children, based on age and weight.~The aims of this preliminary study are to understand whether parents will agree to be part of such an interventional trial. This will help the research team when designing a future larger clinical trial."
89041759|NCT06237647|Experimental|PRP+HA|5mL of PRP+HA
89041760|NCT06237647|No Intervention|PRP injection|4mL of PRP added 1 mL of lidocaine
89041761|NCT06237647|No Intervention|Steroid|1 mL of rinderon added 4 mL of lidocaine
89041762|NCT06237647|Experimental|PROLOTHERAPHY|4 mL of 20% dextrose added1 mL lidocaine
89634677|NCT01695317|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine tablets
89634678|NCT01695317|Placebo Comparator|Sugar pills|Glucose with lemon acid
89634679|NCT04480866|Other|First-void urine collection|Women self-collect three first-void urine samples (random order) at home.
89634680|NCT02551744|Active Comparator|proton pump inhibitor group|Pantoprazole Tab 40mg qd for 6 monthrs.
89634681|NCT02551744|Experimental|histamine-2 receptor antagonist group|famotidine Tab 40 mg qd for 6 months.
89634682|NCT03169218|Experimental|Mirror therapy group|Mirror therapy group: exercises looking at the reflection in the mirror of the hand moving
89634683|NCT03169218|Placebo Comparator|Placebo group|Placebo group: exercises performed with the mirror turned to avoid the reflection of the hand and looking at the hand that did not remain hidden.
89634684|NCT04743544||Voriconazole|All eligible patients will be followed up for voriconazole related adverse drug events and efficacy
89634685|NCT04481802|Experimental|RadiaAce gel|RadiaAce Gel is a clear, non-oily Hydrogel wound dressing for the management of Radiation Dermatitis which provides optimal moist wound environment necessary to the healing process. RadiaAce gel contains Acemannan, a high molecular polysaccharide obtained from the inner gel of Aloe Vera leaves and it is considered the main functional component of Aloe vera (Sahu et al. 2013).
89634686|NCT04481802|Active Comparator|Biafine|one of the standard skin care in radiation oncology, this treatment was chosen as the comparator.
89634687|NCT02551822|Active Comparator|Cycling|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to on-off cycles (on 16 seconds, off 8 seconds). This means the devices are not continuously on. Rather they are on a cycling program."
89634688|NCT02551822|Active Comparator|Continuous|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to be on continuously. This means the devices are continuously on. They are on a continuous program."
89634689|NCT02552368|Experimental|IpsiHand|IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.
89634690|NCT02401152|Placebo Comparator|Placebo group|Sports drink containing maltodextrin
89634691|NCT02401152|Active Comparator|Sports drink 1|Sports drink with a specific source of carbohydrates (CHO).
89634692|NCT02401152|Active Comparator|Sports drink 2|Sports drink with a specific source of CHO.
89634693|NCT02407314|Sham Comparator|Aspirin only|Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
89634694|NCT02407314|Experimental|Aspirin + Ticagrelor|ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
89634695|NCT02555098|Experimental|Sapphire contact lenses|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
89634696|NCT02555098|Active Comparator|senofilcon A|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
89634697|NCT02407080|Experimental|RG7388|"Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388"
89634698|NCT02556112|Active Comparator|Group Lifestyle Balance|Participants receive the Group Lifestyle Balance intervention as per the standard curriculum
89634699|NCT02556112|Active Comparator|Better Body Better Life|Participants receive the Better Body Better Life intervention as per the standard curriculum
89634700|NCT02556112|Active Comparator|Fitness Improvement Program|Participants take the Fitness Improvement Program on-line
89634701|NCT02406924|Experimental|Sausage graft|Bone graft performed with a mixture of particulated autogenous and lyophilized bovine bone, stabilized with collagen membrane and pins.
89041763|NCT06237634|Active Comparator|control group|First group (30 people): A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side..
89041764|NCT06237634|Active Comparator|corticosteroid group|Second group (30 people): In addition to the treatment and recommendations given to the first group, 40 mg (1 ml) triamcinolone acetonide was injected into the wrist under ultrasound guidance.
89634702|NCT02406924|Active Comparator|Bone block graft|Bone graft performed with a block of autogenous bone stabilized by a screw associated with lyophilized bovine bone and collagen membrane.
89634703|NCT04340986||patients with Hepatocellular carcinoma|
89634704|NCT04340986||patients with Cholangiocarcinoma|
89634705|NCT04743622|Experimental|Monoprost (preservative-free latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
89634706|NCT04743622|Active Comparator|Xalatan (preserved latanoprost eye drop)|latanoprost : 1 drop once a day for 12 weeks to target eyes
89634707|NCT02400918|Experimental|Workbook|They will be directed to use the 8-week plan included in The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013), an ACT-based self-help book and to access mindfulness audio files located on the publisher's website (as described in the book).
89634708|NCT02400918|No Intervention|Control|Waitlist control
89634709|NCT02404974|Experimental|Exercise|This is a single arm pilot study. All participants who answer yes to interest in exercise question on the web-based osteoarthritis preference tool will be included in the exercise intervention. After completing baseline measures, they will be put in contact with the Fitness Instructor and follow the protocol described.
89634710|NCT03168984|Experimental|UCB0942|Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)
89634711|NCT03168984|Placebo Comparator|Placebo|Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo
89634712|NCT02701296|Experimental|Posterior capsular injection|Ultrasound guided posterior capsular injection of ropivacaine with epinephrine
89634713|NCT02701296|Active Comparator|Tibial nerve block|Ultrasound selective tibial nerve block of ropivacaine
89634714|NCT02558374|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
89634715|NCT02558374|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
89634716|NCT01582451|Experimental|LY2605541|Administered by subcutaneous (SQ) injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on fasting blood glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications (OAMs) whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
89634717|NCT01582451|Active Comparator|Insulin glargine|Administered by SQ injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on FBG. Insulin glargine will be used alone or in combination with up to 3 pre-study OAMs whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
89634718|NCT02404662|Experimental|Supportive text messages intervention|Patients in the intervention group will receive twice daily supportive text messages to their mobile phone for 6 months following discharge from a 4-week in-patient dual diagnosis treatment programme. The messages will be sent by a computer programme at 10am and 7pm each day and will be set up and monitored by the research worker who will not participate in follow-up assessments. They will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The intervention group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
89634719|NCT02404662|Active Comparator|Control group|Patients in the control group will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
89634720|NCT02560324|Experimental|Ramelteon|"The study will be performed using 8mg of ramelteon, which is currently marketed for the treatment of sleep problems. The proposed study follows the typical dosing regimen for ramelteon (8mg once a day) for 5 days during each quit assessment period.~Ramelteon will be purchased and packaged into blister packs by the Investigational Drug Service (IDS) at the University of Pennsylvania. In accordance with FDA recommendations, subjects will be instructed to take study medication within 30 min prior to going to bed and avoid taking study medication with or immediately after a high fat meal."
89634721|NCT02560324|Placebo Comparator|Placebo|"5-day placebo-controlled medication period.~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at UPenn. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take ramelteon during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by ramelteon during the second medication period."
89634722|NCT02406846||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
89041765|NCT06237634|Experimental|ozone group|Third group (30 people): In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
89041766|NCT06237621||People at risk of PAD|
89057552|NCT04528290|Experimental|Group B (test): Ozanimod granule formulation|Single oral dose of ozanimod 0.92 mg using Sprinkle capsule. Ozanimod Sprinkle Capsule will be opened, and the entire contents sprinkled onto a teaspoon (5 mL) of applesauce.
89057553|NCT04538690|No Intervention|Control Group|Age and sex matched non interventional, healthy control group
89634723|NCT02406846||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
89634724|NCT02406846||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
89634725|NCT02406846||cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
89634726|NCT02406768||HIV negative unexposed|HIV negative controls
89634727|NCT02406768||HIV negative exposed|HIV-negative children born to HIV-infected mothers
89634728|NCT03173118|Other|suspected chronic pancreatitis patients|Patients with suspected chronic pancreatitis will undergo Endoscopic ultrasound elastography to assess whether this detects chronic pancreatitis.
89634729|NCT03173118|Other|Assessment of abdominal pain patients|Patients who are referred for assessment of abdominal pain without risk factors or any other tests suggesting chronic pancreatitis will undergo Endoscopic ultrasound elastography
89634730|NCT02404428|Active Comparator|standard broccoli soup|one portion (300 g each) per week of a soup containing standard broccoli
89634731|NCT02404428|Experimental|beneforte extra broccoli soup|one portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'
89634732|NCT03115554|Active Comparator|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
89634733|NCT03115554|Active Comparator|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
89634734|NCT02561338|Experimental|HMS5552 dose 1|75mgQD oral administration
89634735|NCT02561338|Experimental|HMS5552 dose 2|100mgQD oral administration
89634736|NCT02561338|Experimental|HMS5552 dose 3|50mgBID oral administration
89634737|NCT02561338|Experimental|HMS5552 dose 4|75mgBID oral administration
89634738|NCT02561338|Placebo Comparator|Placebo|Placebo, BID/QD oral administration
89634739|NCT03172806||Study Group|All patients included in the study. First: clinical scores were collected in all patients. Second: all patients underwent a polysomnography in order to compare this results with these of the clinical scores.
89634740|NCT03115398|No Intervention|Activity Monitoring with Routine Care|Subjects randomized to the control arm will wear activity trackers but will have no specific instructions to increase their activity levels.
89634741|NCT03115398|Experimental|Pedometer-based Walking Program|Subjects randomized to the experimental arm will be instructed to meet the customized daily step count goals that are displayed on their fitness trackers. Patients who fail to meet their step count goal for three consecutive days will be contacted by a study coordinator and reminded to try to meet the activity goals. If the patient reports that his or her activity is limited by treatment-related toxicities, the patient's treating physicians will be notified to ensure that supportive care needs are being met.
88990917|NCT06010719|Experimental|Azithromycin|Children enrolled in the trial will be randomized to either the azithromycin, amoxicillin, or placebo arm. Children randomized to the azithromycin arm will receive all standard severe acute malnutrition (SAM) outpatient treatment per Burkinabe national guidelines, except that the standard amoxicillin treatment will be changed to azithromycin. Children will receive a directly observed dose of azithromycin (20 mg/kg, single directly observed dose, oral suspension), followed by a 7-day course of placebo (administered at 80 mg/kg, split into 2 daily doses for 7 days, oral suspension).
88990918|NCT06010719|Active Comparator|Amoxicillin|Children enrolled in the trial will be randomized to either the azithromycin, amoxicillin, or placebo arm. Children randomized to the amoxicillin arm will receive all standard severe acute malnutrition (SAM) outpatient treatment per Burkinabe national guidelines, including a 7-day course of amoxicillin (administered at 80 mg/kg, split into 2 daily doses for 7 days, oral suspension).
89057554|NCT04538690|Experimental|Exercise Group|Individuals who are taken part of shoulder exercises with painful shoulder disorders.
89634742|NCT03115320|Experimental|Pregnyl (Human chorionic gonadotropin)|In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
89634743|NCT03115320|Other|Home ovulation test|The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.
89634744|NCT03172650||study group|non alcoholic fatty liver disease patients
89634745|NCT03172650||Control group|fatty liver patients
89634746|NCT03172572||Indication for surgery|Solid neoplasms
89634747|NCT02404506|Experimental|Arm: Eribulin mesilate|
89634748|NCT03169140|Active Comparator|Group 1|Receive a combination of products (TheraBand Kinesiology Tape and Biofreeze) to use for one week for at home pain management.
89634749|NCT03169140|Active Comparator|Group 2|Receive TheraBand Kinesiology Tape product to use for one week for at home pain management.
89634750|NCT03169140|Active Comparator|Group 3|Receive a topical product, Biofreeze, to use for one week for at home pain management
89634751|NCT03169140|Active Comparator|Group 4|Receive advice sheet outlining at home pain management strategies to use for one week.
89634752|NCT04481646||1|Patients admitted to hospital with COVID-19 symptoms will be approached to undertake a face mask sample and nasopharyngeal swab at two time points 12 hours apart on a single day whilst in hospital. Medical records will be accessed for basic clinical, demographic and microbiological data.
89634753|NCT04481646||2|Healthcare workers who have report COVID-19 symptoms will be asked to undertake a face mask sample and nasophayngeal swab on days 1,3,5,7,10,14 and 21 of the study, for part of which they will be quarantined at home.During this time they will complete a simple symptom diary. Medical records will be accessed for basic clinical, demographic and microbiological data.
89634754|NCT04481646||3|Healthcare workers from different areas of the hospital will be approached as part of a screening programme. They will be asked to undertake a single face mask and swab sample. Basic clinical and environmental data will be collected about each participant so they exposure risk can be stratified.
89634755|NCT03168828|Experimental|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
89634756|NCT03115866|Experimental|FRUVED|Individuals that are at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet with 50% fruit and vegetables.
89634757|NCT03115866|Experimental|FRUVED + LRC|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low refined carbohydrates.
89634758|NCT03115866|Experimental|FRUVED + LF|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low fat.
89634759|NCT03116178|Active Comparator|Group B|"Group B- intervention -Body weight guided Intraoperative fluid administered @ 6-8 ml/kg and blood loss replacement with colloid.~hourly urine output if less than 0.5ml/hr 100-200ml bolus of plasmalyte was administered."
89634760|NCT03116178|Active Comparator|Group G|Group G- intervention - PVI( Masimo co oximeter) guided fluid therapy.
89634761|NCT03115944|Experimental|UltraSpeed Treatment|UltraSpeed ultrasound treatments
89634762|NCT02562898|Experimental|Dose escalation for safety and toxicity|All patients in phase Ib dosing escalation with extended safety and toxicity cohorts will start treatment with daily dosing of ibrutinib concurrently with standard doses of gemcitabine and nab-paclitaxel. Ibrutinib (560 mg/day, 840 mg/day, or 420 and 280 mg/day if de-escalation is necessary) will be started on day 1. Approximately patients 15-30 will be enrolled in escalation and extended safety cohort.
89634763|NCT02562898|Experimental|Immune Response cohort|Subjects who are assigned to the Immune Response Cohort will have a biopsy before starting ibrutinib-only therapy. They will then receive ibrutinib for 7 days and have a second biopsy after completing the ibrutinib-only therapy, before starting the combination of chemotherapy with ibrutinib. Approximately 20 patients will be enrolled in this arm.
89634764|NCT03168594|Experimental|A:Irinotecan combined with cisplatin (IP regimen)|patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
89634765|NCT03168594|Experimental|B:Etoposide combined with cisplatin (EP regimen)|patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
89634766|NCT04482192|Active Comparator|Thoracic paravertebral block group|Continuous thoracic paravertebral block with 1% lidocaine infusion for 3 postoperative days through a paravertebral catheter inserted intraoperatively by the surgeon.
89634767|NCT04482192|Active Comparator|Systemic analgesia group|patients in this group will receive paracetamol and ketorolac by intravenous infusion every 6 hours for 3 postoperative days
89634768|NCT02563834|Experimental|Saline|Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
89634769|NCT02563834|Experimental|Insulin Clamp|Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
89634770|NCT02563990|Experimental|High Pressure|High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
89634771|NCT02563990|Active Comparator|Low Pressure|Low pressure injection of Ropivacaine local anesthetic at less than 15 psi
89634772|NCT02564926|Experimental|Dapagliflozin|Dapagliflozin 10mg + Metformin 1000mg
89634773|NCT02564926|Active Comparator|Glimepiride|Glimepiriide 1-2mg + Metformin 1000mg
89634774|NCT02700984|Experimental|Cataract Surgery + CyPass|CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
89634775|NCT02700984|Active Comparator|Cataract Surgery Only|Cataract Surgery (COMPASS trial) with no CyPass Micro-Stent implantation
89634776|NCT02567968|Placebo Comparator|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
89634777|NCT02567968|Active Comparator|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
89634778|NCT02404584||The study population|"Patients with kidney cancer and will be starting treatment via sunitinib at the study start will be included.~Intervention: Blood drawn for genotyping Intervention: Blood drawn for pharmacokinetic measures"
89634779|NCT02404272||Preterm neonates|All preterm neonates of less than 34 weeks' of gestation admitted to the Neonatology and Neonatal Intensive Care unit of an university hospital located in Lyon, France
89634780|NCT02571634|Other|Open label|Open label, no blinding, everyone receives Lazanda.
89634781|NCT02404194|Experimental|Targeted Cognitive Training|40 hours of computerized cognitive training
89634782|NCT02404194|Placebo Comparator|Computer Games|40 hours of computer games
89634783|NCT02404038|Active Comparator|Arm A: Injectable|This arm will receive Nur-Isterate administered as an intramuscular injection administered bi-monthly (every 8 weeks).
89634784|NCT02404038|Active Comparator|Arm B: Intra-vaginal|This arm will receive the Nuvaring a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days.
89634785|NCT02404038|Active Comparator|Arm C: Oral|This arm will receive Triphasil a daily oral contraceptive of 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
89688504|NCT04364113|Active Comparator|Study B Low Protein Usual Pressure|Study B Low Protein and Usual Pressure
89688505|NCT04364113|Experimental|Study B Low Protein Low Pressure|Study B Low Protein and Low Pressure
89688506|NCT04364113|Experimental|Study B Very Low Protein Usual Pressure|Study B Very Low Protein and Usual Pressure
89634786|NCT03172728|Experimental|Therapeutic intervention- psycho-education pamphlet|"Psycho-education information (appendix 1) will be provided by research assistant in a pamphlet and audio recording, with a written referral to the women's mental health services in case symptoms arise. This psycho-education information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond within a week will be contacted by a research assistant and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
89634787|NCT03172728|No Intervention|Control group|"Control group will receive general psychoeducation about the emotional after effects of childbirth in a pamphlet and audio recording and the phone number for the women's mental health services. This psychoeducation information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond will be contacted by a research assistant within a week and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
89634788|NCT02574598|Experimental|Docetaxel + MK-3475|"Docetaxel 75 mg/m2 every 3 weeks until progression of disease~MK-3475 (administered on day 8) 200mg every 3 until progression of disease"
89634789|NCT02574598|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease
89634790|NCT03116022|Active Comparator|proximal estriol group (PEG )|This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
89634791|NCT03116022|Experimental|distal estriol group (DEG)|This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
89634792|NCT03116022|Placebo Comparator|Control group (CG)|This arm is composed of women using vaginal gel lubricant base water during intercourse
89634793|NCT02400840|Experimental|Heart graft rejection|Assessment of cardiac allograft recipient with rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
89634794|NCT02400840|Active Comparator|No rejection|Assessment of cardiac allograft recipient without any rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
89634795|NCT02574832|Experimental|Spinal Lidocaine Administration|"Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg."
89634796|NCT02400606|Experimental|Intervention|The intervention group were presented with a short case overview introducing four cardiopulmonary VP cases as well as the final diagnosis and had to complete the history, physical findings, and lab results, i.e. constructing VP cases.
89634797|NCT02400606|Active Comparator|Control|The participants were presented with a short case overview introducing four cardiopulmonary VP cases to be solved, i.e. solving VP cases.
89634798|NCT02400684||Deep endometriosis|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with only deep endometriosis without endometriomas.
89634799|NCT02400684||Deep endometriosis and endométriomas|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with deep endometriosis and endometriomas.
89634800|NCT02400528|Other|Patients With Profound and Multiple Disabilities|
89634801|NCT02406534||Normal Pulmonary Function|
89634802|NCT02406534||Reduced Pulmonary Function|
89634803|NCT02406690||Case Group|Patients who failed to achieve adequate endometrial lining during a synthetic embryo transfer. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
89634804|NCT02406690||Control Group|Patients who have achieved an adequate endometrial lining. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
89634805|NCT02406456|Experimental|Neurofeedback|
89634806|NCT02400138|Experimental|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
89634807|NCT02400138|Sham Comparator|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring, which will be also concealed. The control group will also attend the weekly sessions and undergo the same procedures, except for the load adjustments. If the training proves to be effective, the control subjects will be informed and have the choice to receive the training with proper loads.
89634808|NCT02575300|Experimental|Ibrutinib Therapy|Ibrutinib Initial Dose 560 mg by mouth (PO) every day (QD)
89634809|NCT04440696|Experimental|group 1:dose 1.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
89634810|NCT04440696|Experimental|group 2:dose 3g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
89634811|NCT04440696|Experimental|group 3:dose 4.5g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
89634812|NCT04440696|Experimental|group 4:dose 6g|There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）
89634813|NCT02974348|Active Comparator|arm 1: Arthemeter-lumefantrine|Arthemeter-lumefantrine (ART-LUM) is an antimalaria drug manufactured as fixed combination tablets, each containing 20 mg of artemether and 120 mg of lumefantrine. ART-LUM was administrated according to body weight as six consecutive doses: The first dose at diagnosis and the second dose eight hours later, 0- 24-48 hours
89634814|NCT02974348|Active Comparator|arm 2 : Artesunate mefloquine|Artesunate mefloquine (ASMQ) is an antimalaria drug administered as a combination of artesunate, 4 mg/kg/day, with mefloquine, 8 mg/kg/day orally once a day for 3 days or three times, at an interval of 24 hours (0 h - 24 h - 48 h).
89634815|NCT02974348|Active Comparator|arm 3 : Dihydroartemisinin piperaquine|Dihydroartemisinin piperaquine (DHA-PQ ) is an antimalaria drug administered as a combination of dihydroartemisinin, 2.5 mg per kg, with piperaquine phosphate, 20mg per kg daily for 3 days or three times, at an interval of 24 hours
89634816|NCT02974348|Other|Paracetamol|Oral paracetamol is administered at of 50mg/kg body weight per day in three divided doses for fever exceeding 37.5oC.
89211887|NCT02545010|Experimental|LDWART + paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices. Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
89211888|NCT01013506|Experimental|Letrozole +/-goserelin, OSI-906 (Arm I )|Patients receive oral letrozole once daily on days 1-28 plus subcutaneous goserelin (the latter for pre-menopausal women only) on day 1 and oral IGF-1R inhibitor OSI-906 twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89211889|NCT01013506|Experimental|Letrozole +/- goserelin, OSI-906, erlotinib (Arm II)|Patients receive oral letrozole and subcutaneous goserelin (the latter for pre-menopausal women only) and oral IGF-1R inhibitor OSI-906 as in arm I. Patients also receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89634817|NCT02974348|Other|Amoxicillin|amoxicillin is an antibiotic administered at 50mg per kg body weight per day for seven days in the event of concomitant bacterial infection, absent on day 0 but present during the follow up.
89634818|NCT02974348|Other|Quinine|Quinine is an antimalarial recommended by the WHO and NMCP to be used as second line treatment for malaria. In this study, for cases of treatment failure with the artemisinin based combination therapies, quinine sulphate is administered as a second line or rescue drug at a dose of 25mg base per kg body weight per day in three divided doses for five days. The participant is then classified as ETF or LTF and excluded from the study.
89634819|NCT03170622||IBD|Children (age <18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
89634820|NCT02400372|Experimental|research group|Medihoney Dressing
89634821|NCT02400372|No Intervention|control group|Paraffin gauze with saline Dressing
89634822|NCT02400372|No Intervention|3. Comparison group|Polymem dressing
89634823|NCT03170310|Experimental|Apatinib|
89634824|NCT02577640|Experimental|Dose Escalation (DE) Phase|Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
89688507|NCT04364113|Experimental|Study B Very Low Protein Low Pressure|Study B Very Low Protein and Low Pressure
88990919|NCT06010719|Placebo Comparator|Placebo|Children enrolled in the trial will be randomized to either the azithromycin, amoxicillin, or placebo arm. Children randomized to the placebo arm will receive all standard severe acute malnutrition (SAM) outpatient treatment per Burkinabe national guidelines, except that the the standard amoxicillin treatment will be changed to placebo (administered at 80 mg/kg, split into 2 daily doses for 7 days, oral suspension).
88990920|NCT05999539||Faller transtibial prosthetic users|Transtibial prosthetic users who fell at least once in the last year.
88990921|NCT05999539||Non-faller transtibial prosthetic users|Transtibial prosthetic users who have no fall history.
88990922|NCT05997030|Experimental|Neuromodulation|Subjects meeting eligibility criteria will undergo Exablate low intensity focused ultrasound neuromodulation
88990923|NCT05993169|No Intervention|Control|Normal Care
88990924|NCT05993169|Experimental|Nutritional consultation|Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
88990925|NCT05987683|Experimental|Thread-Embedding Acupuncture|Thread-Embedding Acupuncture using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread
88990926|NCT05987683|Sham Comparator|Sham Thread-Embedding Acupuncture|Sham Thread-Embedding Acupuncture using a 29-gauge TEA needle but thread-removed, just needle alone
88990927|NCT05981911||XIENCE Skypoint™ stent|Patients receiving Xience-Skypoint™ stents
88990928|NCT05980923||GROUP 1: Acute illness and abnormal thyroid function|Patients admitted to the hospital with acute illness and found to have thyroid function abnormalities.
89211890|NCT00844688|Other|sorafenib/gemcitabine|
89211891|NCT04541680|Experimental|Nintedanib|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
89634825|NCT02577640|Experimental|Maximum Tolerated Dose (MTD) Phase|After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
89634826|NCT02404116|Experimental|Metacognitive Therapy|12 weeks of Metacognitive Therapy
89634827|NCT02404116|Other|Wait List Control|The Waiting list control will control for time and repeated assessments during an initial 12 week period
89634828|NCT00364000|Active Comparator|I|Calcium acetate 670 mg tablets
89634829|NCT00364000|Experimental|II|label sevelamer (RenagelR) 800 mg tablets
89634830|NCT02400450|Experimental|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix. The food items will contain a standardized amount of functional ingredients.
89634831|NCT02400450|Placebo Comparator|Control Ingredient Group|The control group will receive a comparable set of food items that contain an equivalent amount of calories per portion but without the added functional ingredients.
89634832|NCT00422188|Experimental|Deoxycholic Acid Injection 0.5%|Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
89041767|NCT06237595|Active Comparator|1 Vagus nerve stimulation|The first group will receive cervical transcutaneous vagus nerve stimulation that will be carried out with a TENS device, using a small self-adhesive surface electrodes (1 cm diameter). The electrodes will be positioned on the surface of the neck that corresponds to the position of the left cervical branch of the vagus nerve, over the carotid pulse just medial to the sternocleidomastoid muscle (Molero-Chamizo et al., 2022) using a biphasic, asymmetrical waveform with a pulse duration that is less than 250 microseconds and a frequency of 20 hertz. Intensity is adjusted according to the sensory threshold level of each patient, each session lasts for 30 minutes (Kutlu et al., 2020). All patients will receive 3 sessions per week for a total of 12 sessions, The sessions will be carried on at Department of Rheumatology and Rehabilitation, Cairo University Hospital
89041768|NCT06237595|Active Comparator|2 Medical treatment|This group will receive medical treatment in the form of: Gabapentin 300 mg capsule once at night, and Duloxetine 30 mg cap once daily for 30 days.
89634833|NCT00422188|Experimental|Deoxycholic Acid Injection 1.0%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
89634834|NCT00422188|Experimental|Deoxycholic Acid Injection 2.0%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
89634835|NCT00422188|Experimental|Deoxycholic Acid Injection 4.0%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
89634836|NCT00422188|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
89634837|NCT03172182|Experimental|Virtual reality (VR) group|Immersive education using a 360-degree VR video tour at operation day
89634838|NCT03172182|No Intervention|Control Group|Conventional verbal education of preoperative proceudres
89634839|NCT02581384|Experimental|Cohort 1 Dose Level 1 [Phase I]|Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.
89634840|NCT02581384|Experimental|Cohort 1 Dose Level 2 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
89634841|NCT02581384|Experimental|Cohort 1 Dose Level 3 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
89634842|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
89634843|NCT02581384|Experimental|Cohort 2 Dose Level 3 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
89634844|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase II]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
89634845|NCT03170466|Experimental|Primary Palliative Care|The intervention will be delivered through four primary mechanisms. First, an existing HF nurse will deliver the intervention to patients during regularly scheduled visits. Second, telephone calls will reinforce topics. Third, patients will regularly report symptoms through the MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the patient's cardiologist and primary care physician, as well as facilitating other resources (e.g., home health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks post-intervention delivery. Caregivers will complete surveys during the first in-person visit and then during the follow-up assessments.
89634846|NCT03170466|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality HF care provided to all patients. Control patients may still receive palliative care outside of the study.
89634847|NCT02403960|Active Comparator|probiotic|The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months.
89634848|NCT02403960|Placebo Comparator|placebo|The participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months.
89634849|NCT02403882|Experimental|Order|The investigators arrange the placement of the targeted good to see if the order affects selection.
89634850|NCT02403882|Experimental|Packaging|The investigators adjust the packaging of the targeted good to determine the effects on selection.
89634851|NCT02403882|Experimental|Pricing|In food pantries, few products are priced. The investigators use pricing of products to determine its effect on selection.
89634852|NCT02403882|Experimental|Relative Proportions|The investigators adjust the proportion of the products to determine the effect on the selection of the targeted product.
88990929|NCT05980923||GROUP 2: Acute illness and normal thyroid function|Patients admitted to the hospital with acute illness and found to have normal thyroid function.
88990930|NCT05979311|Experimental|DTG/3TC|Participants will receive FDC of DTG/3TC once daily until Week 96.
88990931|NCT05979311|Active Comparator|BIC/FTC/TAF|Participants will receive BIC/FTC/TAF once daily until Week 96.
88990932|NCT05977829||Breast cancer patients with abnormal uterine bleeding|"Transvaginal ultrasonography~Outpatient Hysteroscopy"
88990933|NCT05977829||Breast cancer patients without abnormal uterine bleeding|"Transvaginal ultrasonography~Outpatient Hysteroscopy"
88990934|NCT05973539|Experimental|High carbohydrate, low fat diet|65% of energy is derived from carbohydrates, 20% from fat, and 15% from protein.
88990935|NCT05973539|Experimental|High fat, low carbohydrate diet|65% of energy is derived from fat, 20% from carbohydrates, and 15% from protein.
89520766|NCT03941717|Sham Comparator|Unfocused attention Condition|Parents and children in the unfocused attention condition will be provided with a tablet and accompanying headphones, and will listen to pre-recorded audio of an unfocused attention activity. There is a parent and child version of this activity. The parent version has been validated in other research with healthy adults as a control for a mindfulness intervention (Garland, Hanley, Farb, & Froeliger, 2015). This script was condensed in time from the original reading. The child version of the activity was developed for the current study, and was adapted from a mind-wandering script used for children aged 7-12 in past research (Spann, 2016). It was also informed by the unfocused attention script used for parents (Garland, Hanley, Farb, & Froeliger, 2015), and work by Cahn and Polich (2009). This activity will last 5-mintues.
89520767|NCT03436121|Experimental|Experimental Arm|Participants will be assigned to receive a single dose of IV ketamine (0.3 mg.kg) + midazolam
89520768|NCT03436121|Active Comparator|Active Placebo Arm|Participants will be assigned to receive a single dose of IV placebo + midazolam
89520769|NCT04899635||Diseased cardiac tissue|Heart muscle or cells (cardiomyocytes) will be obtained from patients undergoing cardiac surgery, namely coronary artery bypass grafting or for severe valvular heart disease.
89520770|NCT04899635||Healthy cardiac tissue|Healthy donor hearts from deceased individuals that are not transplantable due to technical reasons
89520771|NCT03436043|Experimental|Transmural stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks followed by transmural plastic stenting in the residual cavity.
89520772|NCT03436043|No Intervention|No stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks without any further intervention.
89520773|NCT02417246|Active Comparator|Study Sequence A|Start with brand name metoprolol ER, switch to Generic B metoprolol, switch back to brand name metoprolol ER, then switch to Generic A metoprolol
89520774|NCT02417246|Active Comparator|Study Sequence B|Start with brand name metoprolol ER, switch to Generic A metoprolol, switch back to brand name metoprolol ER, then switch to Generic B metoprolol.
89520775|NCT03431753|Experimental|PSA, STHLM3 and mpMRI for PC detection|mpMRI, and if suspect MR-targeted prostate biopsy, in men with increased PC risk as judged from the STHLM3 test and/or an elevated prostate specific antigen test.
89520776|NCT04309487||ShuntCheck|Participants will be administered the ShuntCheck diagnostic test.
89520777|NCT03431675|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
89520778|NCT03431675|Active Comparator|Household prophylaxis arm|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
89520779|NCT03431675|Active Comparator|Community prophylaxis arm|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
89520780|NCT02424734|Experimental|Ceftaroline Fosamil|Ceftaroline Fosamil
89520781|NCT03431597|Experimental|oral nutritional supplementation|Daily novel micronutrient supplement: 800 μg folic acid, 5.2 μg cyanocobalamin (B12), 2.8 mg Riboflavin-5'- phosphate (B2), 4g trimethylglycine (betaine) in drink powder form. The drink will be dissolved in 200ml of water and taken daily for 12 weeks
89520782|NCT03431597|Active Comparator|oral nutritional supplementation, UNIMMAP|The United Nations Multiple Micronutrient Preparation (UNIMMAP) supplement is a capsule containing 15 micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Fe, Zn, Cu, I, Se) at the Recommended Daily Allowance level. UNIMMAP will be provided in capsule form and taken daily with water for 12 weeks.
89520783|NCT03431597|No Intervention|control|no treatment will be given to this group observation only (no placebo)
89520784|NCT03435965||PPROM from 20- less than 28 weeks|pregnant ladies with PROM from 20 - 28 weeks
89520785|NCT03435965||PROM from more than 28 weeks - less than 37 weeks|pregnant ladies with PROM from more than 28- less than37 weeks
89520786|NCT03435965||control group pregnant ladies in labour after 37 weeks|control group pregnant ladies in labour after 37 weeks with rupture of membrane in labour or in cs
89520787|NCT04283981|Active Comparator|Control Group|
89520788|NCT04283981|Experimental|Treatment Group|
89520789|NCT02424578|Experimental|Diclofenac Capsules low dose|Diclofenac Capsules low dose three times daily for up to three days
89520790|NCT02424578|Experimental|Diclofenac Capsules high dose|Diclofenac Capsules high dose three times daily for up to three days
89520791|NCT03435887|Active Comparator|Alere q HIV-1/2 Detect for point of care infant testing|POC testing with Alere q HIV-1/2 Detect at birth and 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
89520792|NCT03435887|Active Comparator|GeneXpert HIV-1 Qual for point of care infant testing|POC testing with GeneXpert HIV-1 Qual at-birth and at 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
89520793|NCT03431519||Group A|The subjects received VP with PEEK and Sr-HA
89520794|NCT03431519||Group B|The subjects received VP with PEEK and PMMA
89634853|NCT02403882|Experimental|Default Option|The investigators provide a targeted product to subjects at one point. Later, investigators offer subjects the possibility to exchange the targeted product for a close substitute.
89634854|NCT05249296|Experimental|Group 1: intervention/control group|"Phase 1: Two weeks of green space intervention~Phase 2: One week wash out period Resume daily activities~Phase 3: Two weeks of 'daily activities' Regular, daily activities are resumed by the participants~Phase 4: One week wash out period Resume daily activities~Between each phase, detailed questionnaires, neurocognitive tests and cardiovascular measurements are taken from the participants."
89634855|NCT05249296|Experimental|Group 2: control/intervention group|"Phase 1: Two weeks of 'daily activities' Regular, daily activities are resumed by the participants~Phase 2: One week wash out period Resume daily activities~Phase 3: Two weeks of green space intervention~Phase 4: One week wash out period Resume daily activities~Between each phase, detailed questionnaires, neurocognitive tests and cardiovascular measurements are taken from the participants."
89634856|NCT03172104||Very preterm group|"Preterm infants <30 weeks' GA at birth admitted to one of the neonatal nurseries at the Royal Women's Hospital in Melbourne, Australia.~Inclusion criteria: Infants admitted to the Royal Women's Hospital, Melbourne, Australia, neonatal nurseries, born <30 weeks' GA. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment and (ii) infants with non-English speaking parents."
89634857|NCT03172104||Term control group|Inclusion criteria: Infants admitted to the Royal Women's Hospital Melbourne, Australia, born >36 completed weeks' GA and weighing >2500 g. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment (ii) infants requiring admission to neonatal intensive or special care nursery and (iii) infants with non-English speaking parents.
89634858|NCT05249218|Active Comparator|Group starting intervention with vegetable protein|Phase A followed by Phases B, C, D, E.
89634859|NCT05249218|Active Comparator|Group starting intervention with animal protein|Phase A followed by Phases D, E, B, C.
89634860|NCT02399904|Experimental|1|
89634861|NCT04481022|Other|group will receive proximal control exercises|
89634862|NCT05248048|Experimental|NKG2D CAR-NK|CAR-T infusion
89634863|NCT02399826|Other|Standard of Care|Surgical debridement of diabetic foot ulcer, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice offloading, reassessment weekly at office visit
89634864|NCT02399826|Experimental|Amniotic Membrane / Amnioband|Application of Amnioband with dressing application, to be changed weekly following surgical debridement. Patient will practice offloading. If the ulcer is not closed completely Amnioband will be applied weekly at weeks 2-11
89634865|NCT02399982|Active Comparator|CBT-GSH|Traditional CBT-GSH with paper and pencil self-monitoring
89634866|NCT02399982|Experimental|CBT-GSH + Noom Monitor|CBT-GSH with smartphone application for self-monitoring
89634867|NCT02403804|Other|All subjects|"All 3 weeks will occur during luteal phase of menstrual cycle with a two-to-three week washout period between weeks.~Week 1: Phosphatidylcholine 3600 mg qam and 2700 mg qpm~Week 2: Betaine anhydrous 588 mg qam and 412 mg qpm~Week 3: Betaine anhydrous 1000 mg BID"
89634868|NCT03169764|Experimental|Nant HNSCC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, nivolumab, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
89634869|NCT02396784||High risk|One parent has a BMI of greater than or equal to 28, or both parents have a BMI of greater than or equal to 24
89634870|NCT02396784||Normal risk|Both parents have a BMI of smaller than 24
89634871|NCT03858712|Other|Passive Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.~Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice~ePRO Home: -- ePRO oral between visits at home.~Passive care team alert -- EHR inBasket notification"
89634872|NCT03858712|Other|Active Care Team Alert|"DFCI patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.~Screening: ePRO Clinic:-- complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice~ePRO Home: -- ePRO oral between visits at home.~Active care team alert -- practice nurse monitoring of ePRO home responses score = 3 indicating a moderate-severe toxicity (grade 3 or higher"
89634873|NCT02396706|Active Comparator|Ivy Leaves Cough Liquid|Ivy Leaves Cough Liquid
89634874|NCT02396706|Placebo Comparator|Placebo|Placebo
89634875|NCT02399592|Experimental|Bevacizumab and Tocotrienol|
89634876|NCT03801304|Experimental|Atezolizumab associated with vinorelbine|"Atezolizumab will be administered with IV infusions. The first one will be a 60-min IV infusion; the subsequent infusions will last 30 minutes when well-tolerated at the dose of 1200 mg on day 1 of each 21-day cycle.~Vinorelbine capsules are taken orally on days 1, 3 and 5 of each week of the 21-day cycle. Vinorelbine will be administered at the dose of 40 mg per day on days 1, 3 and 5 of each week of the 21-day cycle. In case of toxicity, the dose will be decreased to 30 mg."
89634877|NCT04480398||Ayurveda|Guduchi Ghan Vati was given to Covid patients 2 tablets (500 mg each) twice daily were given orally after meal for 28 days. Guduchi ghan vati is a powdered aqueous extract of Tinospora cordifolia in tablet form and prepared in GMP certified Pharmacy of the University, following standard protocol.
89634878|NCT04480398||Control|Standard care for asymptomatic confirmed cases is isolation (to contain virus transmission) and clinical monitoring as per recommended Guidelines.
89634879|NCT04708522|Experimental|Breath Control|Participants in the breath control study arm will be given a breathing exercise that is to be completed in a comfortable upright seated posture. This intervention exercise will be completed daily for a period of 8 weeks.
89634880|NCT04708522|Experimental|Guided Mindfulness|Participants in the guided mindfulness study arm will be lead through a seated mindfulness exercise. This intervention exercise will be completed daily for a period of 8 weeks.
89634881|NCT04708522|Sham Comparator|Control|Participants in the control group will receive a sham intervention. The sham intervention will involve minimal instructed meditation exercise. This intervention exercise will be completed daily for a period of 8 weeks.
89634882|NCT02396628|Experimental|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
89211892|NCT04541680|Placebo Comparator|Placebo|Control group will receive Placebo BID for 12 months in addition to SoC. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient. Standard of care may include pulmonary rehabilitation.
89211893|NCT04815369||Guidance Clinical Pathway|Facilities will be provided a standardized infrastructure and process for collecting and reporting of urine test results including unique lab requisitions that contain the option to order Guidance® UTI, Standard Urine Culture (SUC), and Urine Analysis (UA) along with a protocol for results notification to a central point person within the Nursing Home (NH) facility
89211894|NCT04815369||Traditional Clinical Pathway|Facilities will employ their current standard clinical care practices for suspected UTI, including SUC, UA, and Guidance® UTI testing as per current reporting practices. Providers at these facilities will have the option to order any diagnostic test they deem appropriate.
89211895|NCT00855530|Experimental|1|
89634883|NCT02396628|Active Comparator|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
89211896|NCT03883191|Experimental|Mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
89211897|NCT03883191|Placebo Comparator|Placebo powder|Taking 1 pack of placebo powder three times a day before meals for three months.
89634884|NCT02396550|Experimental|Positive Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into positive
89634885|NCT02396550|Experimental|Neutral Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into neutral
89634886|NCT03559816||Selective use of Episiotomy|Vaginal delivery assisted with selective use of episiotomy and prospective classification of perineal laceration with a sub-classification of second-degree tears. Data of subclassifications are registered with data usually recorded in delivery ward register.
89634887|NCT03559816||Not selective use of Episiotomy|Vaginal delivery assisted without a selective use of episiotomy. Data retrospectively retrieved by delivery ward register that were usually recorded.
89634888|NCT00365014||Blood disease patients|People with blood diseases presenting at Shanghai hospitals
89634889|NCT02696850|Experimental|Budesonide|"The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80."
89634890|NCT02696850|Placebo Comparator|Saline Alone|Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
89634891|NCT02403726||osteoporosis associated vertebral fractures|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures.
89634892|NCT02403648|Experimental|BIOD-961, 1 mg IM|Intramuscular delivery of BIOD-961.
89634893|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg IM|Intramuscular delivery of Lilly glucagon.
89634894|NCT02403648|Active Comparator|Novo Glucagon, 1 mg IM|Intramuscular delivery of Novo glucagon.
89634895|NCT02403648|Experimental|BIOD-961, 1 mg SC|Subcutaneous delivery of BIOD-961,
89634896|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg SC|Subcutaneous delivery of Lilly glucagon.
89634897|NCT02403648|Active Comparator|Novo Glucagon, 1 mg SC|Subcutaneous delivery of Novo glucagon.
89211898|NCT00855608|Experimental|adalimumab arm|intravitreal mode of delivery
89211899|NCT00851864|Experimental|A|Women requiring therapeutic anticoagulation, singleton pregnancy,<30weeks
89211900|NCT00851942|Experimental|Synacthen 250 micrograms|IV injection of 250 micrograms of Synacthen in 1m
89211901|NCT04190186|Active Comparator|Biotronik ICM-guided AF management|ICM obtained data will be actively used to guide and monitor treatment .
89211902|NCT04190186|No Intervention|Conventional AF Management|Treating physicians/nurses will be blinded to the AF episodes data from the monitor, but will be provided information on asystole, or ventricular arrhythmia events (for safety).
89211903|NCT02545790||Persistent hypertrophy|Elevated cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
89634898|NCT02399670||Decrease femoral offset|The FO of operated side was reduced more than 5mm compared with the contralateral side.
89634899|NCT02399670||Restored femoral offset|The FO of operated side was within 5mm restored compared with the contralateral side.
89211904|NCT02545790||Normal geometry|Normal cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
89211905|NCT00503776|Active Comparator|Arm IA|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
89211906|NCT00503776|Active Comparator|Arm IB|Patients undergo SNT and low weight resistance training (LWRT).
89211907|NCT00503776|Experimental|Arm IIA|Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
89211908|NCT00503776|Experimental|Arm IIB|Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
89634900|NCT02399670||Increased FO|The FO of operated side was increased more than 5mm compared with the contralateral side.
89634901|NCT02403570||Multiple Sclerosis|Brain MRI using advanced MR techniques
89634902|NCT03446092|Experimental|Mindfulness group|Group will receive mindfulness intervention
89688508|NCT03403595|Experimental|177Lu-EB-PSMA-617 dosimetry calculation|All patients were intravenous injected with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then monitored at 2, 24, 72, 120 and 168 hours post-injection.
89688509|NCT04354987|Experimental|Group A|R+R+T+T Period 1 : R Period 2 : R Period 3 : T Period 4 : T
89211909|NCT00852020|Experimental|1|oral nutritional supplement containing n-3-fatty acids, amino acids and antioxidants
89211910|NCT00852020|Placebo Comparator|2|oral nutritional supplement (isocaloric, isonitrogenous)
89211911|NCT04002531|Other|Single Visit|"General and neurological examination~Vital signs including height, weight, blood pressure, pulse, temperature~12 lead ECG~2 hour Holter monitor for heart rate variability~Echocardiogram~Renal function will be assessed by the eGFR. The eGFR will be calculated from serum creatinine using CKD-EPI equation.~CBC with differential~Complete metabolic panel~Urinalysis~Urine Albumin/creatinine ratio.~Urine and plasma samples for biomarkers (Gb3, lyso-Gb3) that will be stored in -80 freezer and assayed in our lab.~Brief Pain Inventory questionnaire.~Quality of Life Questionnaires (SF36)"
89211912|NCT02545634|Placebo Comparator|Placebo powder|Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
89520795|NCT03431285|Active Comparator|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration.
89634903|NCT02396472|Placebo Comparator|Order by time and topic|"Volunteers from the American Cancer Society's Cancer Survivors' Network (CSN) will see some of their messages delivered using CSN's default ordering, which shows messages within a conversational thread ordered by time stamp. Conversational threads are nested within a broad topic-based forum, like breast cancer or colorectal cancer survivors.~Note that this is a within-participant trial, so that all participants participate in all arms of the trial. Messages, not people, are randomly assigned to condition."
89634904|NCT02396472|Active Comparator|Order by information relevance|In this condition some messages will be highlighted if they match the type of content the user has previously shown interest in, by previously contributing or reading semantically similar material.
89634905|NCT02396472|Active Comparator|Order by social relationship|In this condition some messages will be highlighted because they come from people the user has previously shown interest in, by previously reading their posts or communicating with them.
89634906|NCT02396472|Active Comparator|Order by help giving|In this condition some messages will be highlighted because they seek help and therefore provide an opportunity for participants to provide social support to others.
89634907|NCT02396472|Active Comparator|Order by self-disclosure|In this condition some messages will be highlighted because in them the writer is self-disclosing, and they provide provide an opportunity for participants to self-disclose in return.
89634908|NCT03400150|Experimental|ProSpace group|Marking + ProSpace implantation + IMRT
89634909|NCT03400150|Sham Comparator|Control group|Marking + IMRT
89634910|NCT02396862||Patients with moderate to severe Hemophilia A / Cohort 1|Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%)
89634911|NCT02399514|Other|RePneum coils|Patients who needed lung volume reduction with RePneum coils
89634912|NCT02403492|No Intervention|Observational (No OSAS)|Comprised of obese children are not found to have obstructive sleep apnea and do not require cPAP
89634913|NCT02403492|Experimental|Experimental - cPAP, Continuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who continue using cPAP during the 2 week RCT
89634914|NCT02403492|Experimental|Experimental - cPAP Discontinuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who discontinue using cPAP during the 2 week RCT
89520796|NCT03431285|Active Comparator|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration
89520797|NCT02416934|Experimental|Treatment 1; Dexamethasone|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
89520798|NCT02416934|Placebo Comparator|Treatment 0; Saline placebo|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
89520799|NCT02819635|Placebo Comparator|SS1: Placebo|During the 8-week induction phase in Substudy 1, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
89520800|NCT02819635|Experimental|SS1: Upadacitinib 7.5 mg|During the 8-week induction phase in Substudy 1, participants received 7.5 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
89520801|NCT02819635|Experimental|SS1: Upadacitinib 15 mg|During the 8-week induction phase in Substudy 1, participants received 15 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
89520802|NCT02819635|Experimental|SS1: Upadacitinib 30 mg|During the 8-week induction phase in Substudy 1, participants received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.
89520803|NCT02819635|Experimental|SS1: Upadacitinib 45 mg|During the 8-week induction phase in Substudy 1, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.
89634915|NCT02440360|Active Comparator|Permanent Supportive Housing|Permanent Supportive Housing (PSH) is subsidized housing with closely linked or on-site supportive services that typically include case management, physical and mental health care, substance use treatment services and vocational support.
89634916|NCT02440360|Placebo Comparator|Usual Care|Usual Care consists of public benefits (e.g., General Assistance and CalFresh), integrated medical and behavioral health services provided by Valley Medical Center and the rest of the County Health & Hospital System including those offered by Valley Homeless Healthcare Program, specialty mental health and substance abuse treatment services and housing programs, and approximately 2,000 year-round beds of emergency shelter and transitional housing.
89634917|NCT02399436|Experimental|School-Based Healthy Snacking Campaign|Students who attend middle and high schools in the experimental county that participate in the healthy snacking campaign intervention.
89634918|NCT02399436|No Intervention|Comparison Schools|Students who attend middle and high schools in the comparison county, which does not receive any intervention components.
89634919|NCT02399436|Experimental|Community Cooking Classes|Adults in the intervention county who enroll in group cooking classes (single-group pretest-posttest)
89634920|NCT02377492|Experimental|Paracervical & Intramyometrial|Vasopressin will be placed paracervically (8mL, 4 units) and intramyometrial (8mL, 4 units)
89634921|NCT02377492|Active Comparator|Intramyometrial|Vasopressin will be placed intramyometrial (16mL, 8 units)
89634922|NCT02396394|Experimental|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
89634923|NCT01763320|Experimental|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
89634924|NCT01763320|Active Comparator|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
89634925|NCT02396238|Experimental|Adipose Derived Regenerative Cells|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs administered in 2 injections per digit on both hands.
89634926|NCT02396238|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution mixed with small amount of study subject's own freshly drawn blood and administered in 2 injections per digit on both hands.
89634927|NCT01614106|Experimental|Intervention|The Retention Clinic will incorporate HIV primary care and mental health services with on-site substance abuse treatment and patient navigation. The central components will include: Primary HIV Care; Mental Health Services; Skill-building; and On-Site substance abuse treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
89634928|NCT01614106|No Intervention|Treatment as Usual (TAU)|The treatment as usual (TAU) group condition will represent standard of care at both of the participating clinics. Standard of care at both clinics includes primary HIV care, the provision of mental health services, and the assignment of a clinic case manager. These case managers meet with patients when they first come to clinic and then meet with them as needed and typically offer substance-using patients a referral to substance abuse treatment in the community as needed. Case managers usually do not follow up to determine the uptake of these referrals.
89634929|NCT02399280|Experimental|Lunch|Lunch as main meal(LM)+ Diet
89634930|NCT02399280|Experimental|Dinner|Dinner as main meal(DM)+ Diet
89634931|NCT01113736|Experimental|Human Peritoneal Membrane: AlloMEM™|For use as a homologous tissue where native peritoneum is absent or traumatized. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.
89634932|NCT03169920|Active Comparator|Test Group|Modified-Minimally Invasive Surgical Technique + PRF
89634933|NCT03169920|Active Comparator|Control Group|Modified-Minimally Invasive Surgical Technique alone.
89634934|NCT02594644|Experimental|10-minute Incubation with Microneedle Roller & Sham|10-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
89634935|NCT02594644|Experimental|20-minute Incubation with Microneedle Roller & Sham|20-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
89634936|NCT03168204|Experimental|Risk of being frail experimental group|
89634937|NCT03168204|No Intervention|Risk of being frail control group|
89634938|NCT03168204|No Intervention|No/low risk of being frail|
89634939|NCT03168204|No Intervention|Risk of being frail care avoiders|
89634940|NCT02596750|Active Comparator|Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
89634941|NCT02596750|Sham Comparator|Sham Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
89634942|NCT02403336|Experimental|Behavioral group intervention|Professionals: 3 training sessions for updating the knowledge and learning skills. Patients: Health education workshop.
89634943|NCT02403336|Active Comparator|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
89634944|NCT02403258|Experimental|Plum-blossom needle group|Patients randomized into this group will receive plum-blossom needle as treatment. DU 20, DU 16, GB 20, EX-HN5, BL 15, BL 18, BL 23 will be selected as acupoints. Each point will be tapped gently one by one by plum blossom needle until the skin get slightly redness. The treatments will be given two sessions per week, consistently for 12weeks (24 sessions in all).
89634945|NCT02403258|Active Comparator|HRT group|Patients randomized into this group will receive habit reversal training (HRT) as treatment. Habit reversal training will consist of the following 4 parts: (1) self-monitoring, (2) competing responses, (3) relaxation training and (4) contingency management. The training will be given weekly in the 12 weeks (totally 12 sessions) by a special rehabilitation therapist, first two sessions 1.5 h, and remaining sessions 1 h for each treatment.
89634946|NCT02601976|Experimental|PegInterferon alfa-2a and Ribavirin|PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight
89634947|NCT03168126||Pro-AQT-Monitoting|Patients with OSCC of the jaws and tumor resection + primary free flap reconstruction
89634948|NCT02396082|Experimental|MIND-S Intervention|Participants (persons with dementia (PWD) and their family caregiver (CG)) in this group will receive up to 18 months of the MIND-S dementia care coordination intervention by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (PWD and CG needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.
89634949|NCT02396082|Other|Augmented Usual Care|Participants (persons with dementia (PWD) and their family caregiver (CG)) and their primary care physicians in this group will receive an initial in-home needs assessment and then a written report indicating any unmet care needs identified and potential recommendations of care for meeting those needs. They will be able to pursue any interventions or treatments they or their treating physicians deem appropriate. They will also receive a standardized Aging and Caregiver Resource Guide developed in the previous MIND trial. The study team will perform another in-home needs assessment at 18 months and the written report along with recommendations for care will be provided to the family and the PWD's primary care physician.
89634950|NCT04742218|Experimental|Fasted-Fed|Single dose of K-877 administered in a fasted condition on Day 1 (Treatment Period 1) and postprandially on Day 4 (Treatment Period 2)
89634951|NCT04742218|Experimental|Fed-Fasted|Single dose of K-877 administered postprandially on Day 1 (Treatment Period 1) and in a fasted condition on Day 4 (Treatment Period 2)
89634952|NCT02603926|Experimental|Allopregnanolone|Subjects will receive an intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period. The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
89634953|NCT02399202|Experimental|osilodrostat ( LCI699)|Each participant will undergo a 28 day screening /baseline period (day-28 to Day -1), followed by a 4 day treatment period ( a single 30 mg dose of LCI699 (Day 1) with 4 days of PK smple collection
89634954|NCT03168048|Experimental|Mobile application|Patients undergoing radiotherapy will receive additional therapy support by an application installed on a mobile device
89634955|NCT02605876|Experimental|Whole Body Vibration|Subjects will receive whole body vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
89634956|NCT02605876|Experimental|Local Muscle Vibration|Subjects will receive local muscle vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
89634957|NCT02605876|No Intervention|Control|Subjects will perform the same procedures as the experimental groups with the exception that no vibratory stimulus will be applied.
89634958|NCT04933422|Experimental|CM93 pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), pre-treatment with CM93 prior to surgical resection of recurrent glioblastoma
89634959|NCT04933422|No Intervention|No pre-treatment arm|Applicable only for part 3 of this trial (surgical window of opportunity), no pre-treatment prior to surgical resection of recurrent glioblastoma
89634960|NCT02606500|Experimental|Elonva 150 mcg|Elonva 150 mcg intramuscular daily obese
89634961|NCT02606500|Active Comparator|Elonva 100 mcg|Elonva 100 mcg intramuscular daily normal weight
89634962|NCT02403024|Experimental|InterWalk|The intervention program will prescribe that patients performing 150 min of interval training per week.
89634963|NCT02403024|Other|Waiting list Control|Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.
89041769|NCT06237595|Active Comparator|3 Combined vagus nerve stimulation and medical treatment|This group will receive cervical t-VNS in the same protocol like the vagus nerve stimulation group, in addition to medical treatment in the form of: Gabapentin 300 mg capsule once at night, and Duloxetine 30 mg cap once daily for 30 days.
89041770|NCT06237582|Experimental|patients|"patients planned for complete cytoreductive surgery~Only one arm in the study: all patients operated for complete cytoreductive surgery and who signed informed consent form"
89041771|NCT06237569||Grup 1 -Ketamine Group|Ketamine Group (GROUP 1) 0.5 mg/kg IV single dose bolus diluted to 5 ml with 0.9% saline
89041772|NCT06237569||Group 2-ketamine + midazolam|Midazolam 0.0125 mg/kg is given followed by a single IV bolus dose of 0.5 mg/kg diluted to 5 ml with 0.9% saline.
89041773|NCT06237569||Group 3-placebo|Group 3-placebo ;A single dose of IV 5 ml physiological saline will be given.
89041774|NCT06237543||Hypotension|Patients with a 30% decrease in SBP from baseline and a decrease in MAP below 65 mmHg in the first 10 minutes after anesthesia induction will be considered to have hypotension.
89041775|NCT06237543||none hypotension|Patients who do not have a 30% decrease from the baseline in SBP and a decrease in MAP below 65 mmHg in the first 10 minutes after anesthesia induction will be considered as not having hypotension.
89041776|NCT06237530|Experimental|Visceral Body Scan (VBS)|The VBS consisted of a mindfulness exercise designed to bring awareness to visceral sensations in the cardiac, respiratory, gastrointestinal, and urinary systems. These physiological systems were chosen because most of the paradigms developed in the literature to assess interoception focus on them (Khalsa et al., and they are widely recognized in the literature as interoceptive senses (Nord & Garfinkel, 2022)
89520804|NCT02819635|Experimental|SS2: Placebo/Upadacitinib 45 mg|During the Substudy 2 Part 1 induction period, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label extended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.
89520805|NCT02819635|Experimental|SS2: Upadacitinib 45 mg/Upadacitinib 45 mg|During the Substudy 2 Part 1 induction period, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label expended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.
89634964|NCT02606734|Other|Treatment Arm|All subjects enrolled in the trial will use the DyeVert System.
89634965|NCT03106506|Experimental|Test-implant with graft|Patients who received a connective tissue graft around implants
89634966|NCT03106506|Active Comparator|Control-Implant without graft|Implant installation surgery with cone morse system without the placement of connective tissue graft.
89634967|NCT04340674|Experimental|Telerehabilitation based on aerobic exercise|Aerobic low-impact exercise guided by audiovisual material. The intensity of exercise is adapted to each participant and is established according to the perceived effort after each session, according to the modified Borg perceived effort scale.
89634968|NCT04340674|No Intervention|Control group|Group that maintain the same medical treatment and not receive additional intervention.
89634969|NCT03106584|Active Comparator|Glucosamine sulphate|"Glucosamine sulphate will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Glucosamine will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Aquamin-plus), after a washout period of not less than 1 month between the intervention arms of the study."
89634970|NCT03106584|Experimental|Aquamin-plus|"Aquamin-plus will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Aquamin-plus will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Glucosamine sulphate), after a washout period of not less than 1 month between the intervention arms of the study."
89634971|NCT03167736|Experimental|Electric dry needling, manipulation|
89634972|NCT03167736|Active Comparator|conventional physical therapy|
89634973|NCT02399358||High-dose Cyclophosphamide|Patients requiring infusion of high-dose cyclophosphamide in the period 2015-2017 will be included. After informed consent, patients will de follow up from the infusion of cyclophosphamide to 30 days after hospital discharge.
89688510|NCT04354987|Experimental|Group B|R+T+R+T Period 1 : R Period 2 : T Period 3 : R Period 4 : T
89688511|NCT04354987|Experimental|Group C|T+R+T+R Period 1 : T Period 2 : R Period 3 : T Period 4 : R
89041777|NCT06237530|Active Comparator|Somatosensory body scan (SBS)|The SBS consisted of a mindfulness exercise designed to bring awareness to tactile (e.g., itching) and musculoskeletal (e.g. g., tension) sensations in different parts of the body, namely, the head and neck, back, arms, and legs. Body scan exercises typically focus on these types of bodily cues (in addition to breathing) (Williams, 2010).
89041778|NCT06237530|Sham Comparator|External control meditation (ECM)|The ECM consisted of a mindfulness exercise designed to bring awareness to external stimuli, including sounds and visual properties of the environment
89688512|NCT04354987|Experimental|Group D|T+T+R+R Period 1 : T Period 2 : T Period 3 : R Period 4 : R
89041779|NCT06237504|Active Comparator|Ambu Auragain|Patients receiving general anesthesia with airway maintained with the 2nd generation SAD, Ambu Auragain.
89041780|NCT06237504|Experimental|SaCoVLM|Patients receiving general anesthesia with airway maintained with the video LMA, SaCoVLM.
89041784|NCT06237478|Experimental|Group L|The HR at 10 minutes after the start of surgery was considered as the baseline HR. Patients were divided into two groups based on their baseline HR: Group L: Baseline HR 40-60 beats/min.
89041785|NCT06237478|Experimental|Group H|The HR at 10 minutes after the start of surgery was considered as the baseline HR. Patients were divided into two groups based on their baseline HR: Group H: Baseline HR 60-100 beats/min.
89041786|NCT06237465|Experimental|Experimental|During their treatment visit, subjects will receive Botulinum Toxin-A in one axillae and normal saline in the other, in a double-blinded fashion.
89041787|NCT06237465|Placebo Comparator|Placebo Comparator|At three months, Group 1 subjects will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
89041788|NCT06237439|Experimental|Move with HaRT|Move with HaRT is a 12-session, weekly, manualized mental health intervention led by trained paraprofessionals. It is delivered in groups of 8-12 individuals and includes breathwork, yoga poses, guided meditations, and discussions aligned with weekly themes. Group discussions include topics such as noticing how we feel in our bodies, recognizing and allowing all emotions, practicing self-acceptance, and developing deeper connections with others with whom we feel safe.
89041789|NCT06237439|Active Comparator|Services as Usual|Services as usual are ongoing activities provided by anti-trafficking agencies that include basic counseling, vocational training, games and entertainment (e.g., movies and social activities).
89041790|NCT06237400|Experimental|Phase 1 Dose Escalation|"Dose escalation will begin with rapid dose escalation for the low-dose groups (50 mg QD 、150 mg QD) and a 3 + 3 dose-escalation protocol for the high-dose groups."
89041791|NCT06237400|Experimental|Phase 2 Dose Expansion|Upon completing the dose escalation part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS G12C mutant advanced solid tumors，Including non-small cell lung cancer, colorectal cancer and Other advanced solid tumors
89041792|NCT06237374|Experimental|Treatment|Community health workers (CHWs) will receive the intervention training videos, job aids and chatbot tool to share with patients via WhatsApp in addition to standard CHW training provided by Lwala Community Health Alliance.
89041793|NCT06237374|Active Comparator|Control|Participants in the control group will receive standard community health worker (CHW) training provided by Lwala Community Health Alliance.
89041794|NCT06237361|Experimental|traditional physical therapy programs|group that received traditional physical therapy programs (TPTP) alone
89041795|NCT06237361|Experimental|Pilates group|received both traditional physical therapy programs and Pilates exercises.
89634974|NCT02395770|Experimental|Subacromial pain group|Rehabilitation Program: The program was developed to target the deficits described in individuals with SPS. It included movement training, manual therapy, strengthening and stretching exercises, and patient education. Each supervised session lasted around 30 minutes, with 75% of the session for movement training. Three treating physiotherapists supervised the program and initially attended a training session to standardize the program.
89634975|NCT02395926|Active Comparator|R|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
89634976|NCT02395926|Experimental|T1|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
89634977|NCT02395926|Experimental|T2|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
89634978|NCT02607124|Experimental|RB+ High Grade Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
89634979|NCT02607124|Experimental|Non-Biopsied Diffuse Instrinsic Pontine Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
89041796|NCT06237348|Experimental|Simeox|Airway clearance device
89041797|NCT06237348|Active Comparator|Control|Usual chest physiotherapy (manual, breathing exercise, PEP/oPEP)
89634980|NCT02402868|Experimental|Intranasal ketamine and saline|Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg
89634981|NCT02402868|Active Comparator|Intravenous ketamine and saline|Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares
89634982|NCT02399046|Experimental|Total Knee System made in China|Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China
89634983|NCT02399046|Active Comparator|Total Knee System made outside of China|Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China
89634984|NCT02609308|Active Comparator|Short leg cast|The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
89634985|NCT02609308|Experimental|Platelet-rich plasma|In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
89634986|NCT02402946|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor but not showed to the patients; in the biofeedback group, patients will be instructed to control, abdomino-thoracic muscle activity
89634987|NCT02402946|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patienst will take a pill of placebo and receive no instructions about controlling muscular activity.
89634988|NCT02398968|Active Comparator|RURTI+IDA+iron therapy|children with iron deficiency anemia on therapeutic iron fumerate therapy (6mg/kg/d) for 3 months, then maintained on iron fumerate supplementation(1mg/kg/d) for 12 months
89041798|NCT06237309|Experimental|Part A1 High Dose|Single ascending dose cohort
89634989|NCT02398968|Active Comparator|B1:RURTI+no anemia+iron maintenance|children with recurrent upper respiratory tract infection and no anemia receiving oral iron fumerate (1mg/kg/d) for 12 months
89634990|NCT02398968|No Intervention|B2:RURTI+no anemia|children with recurrent upper respiratory tract infection and no anemia followed up for 12 months
89634991|NCT02610634||Parkinson's disease|People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21).
89634992|NCT02610634||Older Adults|Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26).
89634993|NCT02402712|Experimental|Herceptin SC + Perjeta IV + docetaxel IV|Single arm
89634994|NCT02398812|Active Comparator|Active comparator|In addition to usual care, participants allocated to intervention group will receive medication assessment and treatment plan based on it
89634995|NCT02398812|No Intervention|Usual care|Usual care (reference group).
89041799|NCT06237309|Experimental|Part A1 Low Dose|Single ascending dose cohort
89041800|NCT06237309|Experimental|Part A1 Optional|Single ascending dose cohort
89041801|NCT06237309|Experimental|Part A2 Sacubitril-valsartan High Dose|Single ascending dose cohort
89041802|NCT06237309|Experimental|Part A2 Sacubitril-valsartan Low Dose|Single ascending dose cohort
89041803|NCT06237309|Experimental|Part A2 Low estimated glomerular filtration rate (eGFR) High Dose|Single ascending dose cohort
89041804|NCT06237309|Experimental|Part A2 Low eGFR Low Dose|Single ascending dose cohort
89041805|NCT06237309|Experimental|Part B High Dose|
89041806|NCT06237309|Experimental|Part B Low Dose|
89041807|NCT06237309|Placebo Comparator|Part B Placebo Only|
89041808|NCT06237257|Experimental|SHR-1316 plus concurrent chemoradiotherapy|
89041809|NCT06237218|Experimental|COTID program|"The intervention takes place entirely in the homes of elderly people with neurocognitive disorders.~It takes an average of 10 hours of intervention per treatment, spread over 5 to 10 weeks.~The COTID program is divided into several phases:~Phase A: Problem definition and analysis~Phase B: Formulation of objectives and treatment plan~Phase C: Implementation of the treatment plan."
89634996|NCT02402634||Mechanical ventilatory lung care|liver transplantation recipients under mechanical ventilatory lung care
89634997|NCT02395458|Experimental|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
89634998|NCT02395458|Active Comparator|Triple therapy|Patient receive Omeprazole plus clarithromycin and amoxicillin during 14 days
89634999|NCT02395380|Experimental|C-reactive protein dosage|
89635000|NCT02402478||Stable coronary artery disease|Patients with chest pain
89635001|NCT02402400|Active Comparator|Oral Ticagrelor|
89635002|NCT02402400|Experimental|Sub Lingual Ticagrelor|
89635003|NCT02402556|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
89635004|NCT02402556|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Although the families in the wait-listed control group will start out as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
89635005|NCT02398578|Experimental|Amphora OAB Device|Specialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
89635006|NCT02398344|Experimental|1- tDCS ACTIVE|1. Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes, intensity 2mA With Simulator anodic electro stimulation from bloodstream on right and left temporal cortex region (T3 area) and cathodic position in contralateral supraorbital region to anode (Fp2), associated Cardiac Frequency Variability (HRV) as measured by spectral analysis by spectral analysis Polar RS800 cx.
89635007|NCT02398344|Experimental|2- tDCS SHAM|Placebo tDCS will be administered using Tct Research 1 CH tdcs Simulator model 101 and will follow the same procedures as active tDCS active, but the tDCS device will only be switched on for 30 seconds.
89635008|NCT02610868|Experimental|MYOBLOC Injection|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.
89635009|NCT02394990|Experimental|Violence Brief Intervention|Participants receive a standard of care brief motivational intervention (BMI) to address alcohol consumption (ABI) based on self reported use and their relationship between consumption and behavior, followed by an additional BMI to address how involvement in violence (VBI) impacts their life, relationship to social norms, and strategies to avoid violence.
89635010|NCT02394990|Active Comparator|Control|Participants receive only ABI
89635011|NCT02395068|Experimental|Single-dose PK|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation. 1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
89211913|NCT02545634|Experimental|Probiotic powder|The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases.
89211914|NCT00852098|Active Comparator|1|dividing short gastric vessels
89211915|NCT00852098|Active Comparator|2|non-dividing short gastric vessels
89211916|NCT05356689|Experimental|traditional physiotherapy|Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
89211917|NCT05356689|Experimental|3- 2dimensional lumbar traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed.
89211918|NCT00852176||On-label treatment|"Patients treated in routine clinical practice following FDA Pre-Market Approval of the Beta-Cath(TM) 3.5F System within the parameters of the approved indications for use for the System (on-label)."
89211919|NCT00855686|Experimental|Memantine|
89211920|NCT00855686|Placebo Comparator|Placebo|
89635012|NCT02395068|Experimental|Weekly fixed dose|Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks.
89635013|NCT02395068|Experimental|Bioweekly fixed dose PK|Nimotuzumab 600mg, administered once every 2 weeks for 8 weeks. Dosing regimens can be adjusted according to the results of preliminary experiments. Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
89635014|NCT02398422|Experimental|Filtered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
89688513|NCT03835091||Patient with mechanical ventilation and sedation|All patient hospitalized in intensive care under sedation and mechanical ventilation without neurologic disorder
89211921|NCT04041908|Experimental|Experimental Product|Drink mix powder
89211922|NCT04001283|Experimental|sodium nitrite 24hours before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 24 hours prior to CABG surgery
89211923|NCT04001283|Experimental|sodium nitrite 30minutes before|10umol/min intravenous sodium nitrite for 30minutes at 1ml/min over a period of 30minutes, 30 minutes prior to CABG surgery
89211924|NCT04001283|Placebo Comparator|0.9% sodium chloride|Intravenous normal (0.9%) sodium chloride infused at 1ml/min
89211925|NCT02546414||Esophageal varices haemorrhage group|HBV hepatic cirrhosis with first esophageal varices haemorrhage were included and stratified using their Child-Pugh score. The platelet count were evaluated, and ultrasound was used to measure the longest diameter of the spleen. The platelet count(PC)/spleen diameter (SD)ratio was calculated and analyzed to determine whether it can predict the variceal haemorrhage. Upper gastrointestinal endoscopy was used as the gold standard.
89211926|NCT02546414||no haemorrhage but esophageal varice presence|HBV hepatic cirrhosis with no esophageal varices haemorrhage were included and upper gastrointestinal endoscopy were validate.They also stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated, The PC/SD ratio was calculated and analyzed to determine whether it can predict the variceal presence.
89211927|NCT02546414||no esophageal varice but cirrhotic|HBV hepatic cirrhosis with no esophageal varices were included and also validated by upper gastrointestinal endoscopy.They stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated,The PC/SD was calculated and analyzed to determine whether it can predict the variceal absence .
89211928|NCT00991965||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
89211929|NCT00844922|Experimental|Org 34517|Org 34517 titrated to 900 mg daily for 2 weeks
89211930|NCT00844922|Placebo Comparator|Placebo|
89211931|NCT05272761||Oronasal Route|Patients will sleep in the sleep lab for CPAP titration wearing a custom oronasal mask with 2 open oral and nasal compartments. The titration was split between the first half of the night and the second half. The titration will be started with the patient remaining for 90 minutes with the pressure he uses at home (supine position and in lateral decubitus), after a period of 90 minutes the patient will be titrated in order to abolish respiratory events in both positions of the body.
89211932|NCT05272761||Oral Route|"Group/Cohort Interventions Oronasal Route~Patients will sleep in the sleep lab for CPAP titration using a custom 2-compartment oronasal mask. In this titration, the nasal compartment will be closed and the patient will be titrated only through the oral route. The titration split between the first half of the night and the second half. The titration will be started with the patient staying for 90 minutes with the pressure used at home (during the supine position and lateral position), after the 90 minute period the patient will be titrated in order to abolish respiratory events in both positions of the body."
89635015|NCT02398422|Experimental|Nonfiltered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (nonfiltered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
89635016|NCT02398422|No Intervention|Assessment-only|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
89635017|NCT02614222|Experimental|Peripheral Nerve Block with CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
89635018|NCT02614222|No Intervention|Peripheral Nerve Block without CAIG|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
89635019|NCT02614924|Other|Flexible fibre-optic scope|Randomly allocated to fibreoptic group
89635020|NCT02614924|Other|Pentax AWS videolaryngoscope|Randomly allocated Pentax AWS videolaryngoscope
89635021|NCT02615158|Experimental|Maternal Physical Activity and Nutrition|A maternal intervention focusing on healthy diet and physical activity patterns for mothers.
89635022|NCT02615158|Experimental|Parenting|A toddler parenting intervention focusing on parenting, limit setting, and development strategies.
89635023|NCT02615158|Experimental|Child Safety|Attention control group. The parents received intervention to promote safety among toddlers.
89635024|NCT02616250|Experimental|Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream|"Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.~Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks."
89635025|NCT02616250|Placebo Comparator|CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream|Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
89635026|NCT05443204|Experimental|Standard Formula (Fortimel)|Fats 35% total caloric volume (VCT) Carbohydrates: 49% del VCT Proteins: 16% del VCT Density: 1.5 kcal/ ml
89635027|NCT05443204|Experimental|Specific formula for diabetes (Nutrision Advanced)|Fats: 46% del VCT (60% monounsaturated fatty acids) Carbohydrates: 31% del VCT Proteins: 21% del VFiber: 2% VCT (80% soluble y 20% insoluble) Density: 1.5kcal/ml
89635028|NCT02698410|Experimental|Lanreotide (Autogel formulation) and Temozolomide|"Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks."
89635029|NCT04340518|Experimental|Post-scleral lens wear|Normal subjects without ocular diseased who have worn scleral lenses for at least 8 hours.
89635030|NCT05731414|Experimental|Individual CBTp + Group Sham CR|"Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness.~Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion."
89635031|NCT05731414|Experimental|Group CR + Individual Befriending (Sham CBTp)|"Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials.~Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth."
89635032|NCT05731414|Experimental|Individual CBTp + Group CR|"Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness.~Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials."
89635033|NCT02395146|Experimental|Monitoring|intraoperative EBSLN monitoring will take place
89635034|NCT02395146|No Intervention|Non-Monitoring|No intraoperative EBSLN monitoring will take place (standard practice)
89635035|NCT02394678|Experimental|Intervention - clot removal|Patients will undergo rheolytic thrombectomy for intraventricular hemorrhage
89635036|NCT02699892||Rheumatoid arthritis participants|Participants who were on rituximab for rheumatoid arthritis and who will continue receiving rituximab treatment (at the discretion of treating physician) according to previous approved indication will be observed for a period of 72 weeks.
89635037|NCT05731336||NR group (Non-retreatment/rechallenge group)|participants who receive immunotherapy or targeted drugs or other chemotherapy beyond treated with oxaliplatin and irinotecan
89635038|NCT05731336||RT group (Retreatment group)|participants retreated oxaliplatin or irinotecan who were treated with oxaliplatin and irinotecan and progressed after 3 months of oxaliplatin or irinotecan discontinuation.
89635039|NCT05731336||RC group (Rechallenge group)|participants rechallenging oxaliplatin or irinotecan who were treated with oxaliplatin and irinotecan and progressed within 3 months of oxaliplatin or irinotecan discontinuation.
89635040|NCT04481178||patients with nevus of Ota|patients with nevus of Ota who had been treated with laser at Siriraj hospital
89635041|NCT04340908|Experimental|Treatment|Dapagliflozin 10 mg tablet
89635042|NCT04340908|Placebo Comparator|Control|matching placebo tablet
89635043|NCT02398110|Experimental|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
89635044|NCT02398110|Active Comparator|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
89635045|NCT04480320|Experimental|Pericapsular nerve group block|
89635046|NCT04480320|Placebo Comparator|Saline placebo group|
89635047|NCT02398266|Experimental|Healthy subjects|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Normal healthy subjects (n=10) will be used for optimization of dose and acoustic settings for performing real-time contrast ultrasound perfusion imaging of the limb.
89635048|NCT02398266|Experimental|Patients with PAD and ABI 0.4-0.6|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Patients with moderate to severe PAD (ABI 0.4 to 0.6) will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm to determine whether symptoms better correlate with perfusion imaging than other measures of PAD severity.
89635049|NCT02398266|Experimental|Patients with PAD Undergoing Revascularization|Intervention: administration of ultrasound contrast agent (drug) to assess change in muscle perfusion produced by revascularization (surgical or percutaneous procedure). Patients with symptomatic PAD will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm before and within 1 month of revascularization to determine whether improvement in symptoms correlate with perfusion imaging data.
89635050|NCT05730790|Experimental|Cognitive-motor dual task training (DTT)|Participants attended 14 sessions (40 minutes each) of dual task cognitive-motor training, 2 times per week for 7 weeks. Each cognitive-motor training session comprised of performing a dual task activity - gameplay using a virtual reality (VR) system while walking on a treadmill, of progressive difficulty pitched to the participant's performance.
89635051|NCT05730790|Active Comparator|Cognitive single task training (CSTT)|Participants attended 14 sessions (32 minutes each) of single task cognitive training, 2 times per week for 7 weeks. Each cognitive training session comprised of game play using a virtual reality (VR) system, of progressive difficulty pitched to the participant's performance
89635052|NCT05730790|Active Comparator|Motor single task training (MSTT)|Participants attended 14 sessions (40 minutes each) of single task motor training over a period of 7 weeks. Each motor training session comprised of walking on a treadmill, of progressive difficulty pitched to the participant's performance
89635053|NCT02394522|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
89635054|NCT02394522|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
89635055|NCT05730634|Experimental|Intervention arm|Atorvastatin 40mg once daily.
89635056|NCT02394366|Experimental|Active|Original Healing Salve (Puremedy, Inc.) including 1x homeopathic dilutions of Calendula, Echinacea, and Sambucus extracts, plus extracts from pine and Balsam fir; acute effects only
89635057|NCT02394366|Placebo Comparator|Control|Original Health Salve olive oil and beeswax base only without homeopathic or herbal extracts; acute effects only
89635058|NCT03167814|Active Comparator|Diet group|Diet group will be on no-fat diet including MCT-oil supplement starting right after surgery according to our pancreas ERAS-protocol.
89635059|NCT03167814|No Intervention|Normal food-group|This study group will follow normal ERAS-protocol after pancreas surgery and start normal diet after surgery. If chyle-leak is diagnosed then it will be treated with the same no-fat diet as the intervention group.
89635060|NCT05705830|Experimental|Pulse Magnetotherapy+medication group|150 patients with anxiety disorder and insomnia who met the inclusion criteria received pulse magnetic therapy and conventional antianxiety drugs
89635061|NCT05705830|Sham Comparator|medication group|150 patients with anxiety disorder and insomnia who met the inclusion criteria received sham magnetic therapy and conventional antianxiety drugs
89635062|NCT05705830|Other|Healthy control|100 healthy controls who met the inclusion criteria received sham magnetic therapy
89635063|NCT05745792||Patients with Hu Abs|Patients harboring Hu Abs and a neurological syndrome
89635064|NCT02398032|Experimental|CPAP nasal|Nasal continuous positive airway pressure, during the night
89635065|NCT02398032|Sham Comparator|sham CPAP nasal|Nasal sham continuous positive airway pressure, during the night
89635066|NCT02397798|Experimental|Intervention|Person-centered high-intense training three times a week under supervision (supervision two times a week) during 5 months
89635067|NCT02397798|Active Comparator|Control|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week during 5 months
89635068|NCT05681494|Active Comparator|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
89635069|NCT05681494|Experimental|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
89635070|NCT05745714|Experimental|Ruxolitinib + venetoclax + dexamethasone + cyclophosphamide + cytarabine|"Each cycle has 28 days~Cycle 1: All patients will receive 14 days of of ruxolitinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 3) and two blocks of four consecutive days of cytarabine (days 5 to 8 and days 12 to 15). A 1-day venetoclax ramp-up is proposed in this study.~Cycle 2 and subsequent cycles:~All patients will receive 14 days of of ruxolitinib (days 1-14), 28 days of venetoclax (days 1-28), one block of five days of dexamethasone (days 1-5), one dose of cyclophosphamide (day 1) and two blocks of four consecutive days of cytarabine (days 3 to 6 and days 10 to 13).~Patients in dose level -1, will receive a lower dose of venetoclax compared to dose level 1.~Patients in dose level 2, will receive a higher dose of venetoclax compared to dose level 1.~All patients receive age adapted intrathecal chemotherapy."
89688514|NCT03834935|Experimental|Pim|20 patients receiving topical Elidel (pimecrolimus 1%) bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
89635071|NCT04840030|No Intervention|Standard health advice (SHA-control)|"The participant will receive verbal information of risk factors and information, reassessment, and written materials regarding approved recommendations on active and healthy aging on topics such as diet, physical activity, cognitive training as well as risk factor control following the state of the art and published guidelines by the Department of Health of the Basque Government/ Basque Country Public Health System (Osakidetza) and the WHO (Guidelines for risk reduction of cognitive decline and Dementia and the Guidance on person-centered assessment and pathways in primary care - ICOPE). Participants in this group will receive the best standard health care from their primary care and specialist health teams according to already established routines as well as usual social services assessments and care as needed."
89635072|NCT04840030|Experimental|Multidomain intervention (MM-Int)|Participants in this group will receive the same verbal and written recommendations as to the ones in the SHA-Control group but then they will perform a 2 year structured program with periodic individual and group visits regarding 1) Risk factor control (vascular factors, polypharmacy); 2) Cognitive training, 3) Physical activity, 4) Dietary changing program and 5) emotional counseling and social engagement.
89635073|NCT02974270|Experimental|Leuprolide acetate|
89635074|NCT02394444|Experimental|Preterm intervention TRT group|"Parents with premature infants received the intervention called Triadic parent-infant's Relationship Therapy (TRT) :~the psychological intervention included home visits twice month during the first four months and then monthly visits in the neonatal ward until the 18 months corrected age resulting in a total of 22 visits during the whole intervention; TRT gave attention to emotional distress and the promotion of parenting skills and attachment security; The three sessions of intervention targeted objectives specific to each child's development; A basic manual was designed to ensure uniformity of the defined themes during each session"
89635075|NCT02394444|No Intervention|Preterm control group|Parents with premature infants without intervention program TRT (Triadic parent-infant's Relationship Therapy) received routine follow-up medical care with monthly visits to a practitioner for the first six months and then very three months
89635076|NCT02394444|No Intervention|Full-term control group|Parents with full-term infants without intervention program TRT
89635077|NCT04770922||Pediatric ALL patients on 6-mercaptopurine|Pediatric ALL patients treated with 6-mercaptopurine who did not experience neutropenia.
89635078|NCT04770922||Pediatric ALL patients on 6-mercaptopurine with neutropenia|Pediatric ALL patients treated with 6-mercaptopurine who experienced neutropenia.
89635079|NCT02394288||Adults without cardiac disease|Extremity orthopedic or trauma surgery
89635080|NCT02394210||Group 1|Patients in relapse/biological progression (under the criteria of the IMW (International Myeloma Workshop) Consensus Panel 1 not receiving treatment until clinical relapse.
89635081|NCT02394210||Group 2|"Patients in relapse/biological progression receiving anti-MM treatment at the time of relapse/biological progression): Patients in this group may receive conventional anti-myeloma treatment as per routine clinical practice at the participating site:~Upon relapse/biological progression, defined as per the criteria of the IMW (International Myeloma Workshop) Consensus Panel Panel1 Or~Upon a significant relapse of paraprotein, defined as:~Duplication of M-component in two consecutive readings taken ≤2 months apart; or~An increase in absolute levels of serum M-protein ≥1 g/dL or M-protein in urine at ≥500 mg/24h, or~Increase in light chain levels ≥20 mg/dL with an abnormal ratio in two consecutive readings taken ≤2 months apart), which suggests the presence of biological progression/relapse criteria, but without including any clinical details of those involved in clinical relapse."
89635082|NCT03167424||BVS restenosis|Patients with a Bioresorbable Vascular Scaffold Restenosis
89635083|NCT04580602||ADR Group|Major Bleeding BARC Bleeding Criteria Type 2,3,5
89635084|NCT04580602||Control Group|No ADR or treatment failure, case-control matched to experimental groups
89635085|NCT04580602||Treatment Failure Group|Major Adverse Cardiovascular Events (MACE)
89635086|NCT02397876|Experimental|partially hydrolyzed whey formula|The group of patients who pass an oral food challenge to partially hydrolyzed whey formula and will be continued on it through out the study
89635087|NCT02397876|No Intervention|No intervention|Patients who do not pass an oral food challenge to partially hydrolyzed whey formula will continue on their prior diet of cows milk avoidance.
89635088|NCT04480788|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
89635089|NCT04053192||High-Gradient Aortic Stenosis (HG-AS)|(Pmean >40mmHg, AVA <1cm^2, Vmax >4m/s)
89635090|NCT04053192||Low-Flow-Low-Gradient Aortic Stenosis (LF-LG)|(Pmean <40mmHg, AVA <1cm^2, Vmax <4m/s, EF <50%)
89635091|NCT04053192||Paradoxe Low-Flow Low Gradient Aortic Stenosis (pLF-LG AS)|Pmean <40mmHg, AVA <1cm^2, Vmax < 4m/s, EF >50%)
89635092|NCT03167580|Experimental|Ventilation with restricted PEEP level|Use of the restricted PEEP level (0 - 5 cm H2O, the lowest possible PEEP level) after intubation and during all mechanical ventilation.
89635093|NCT03167580|Active Comparator|Ventilation with liberal PEEP Level|Use of the liberal PEEP level (8 cm H2O) after intubation and during all mechanical ventilation.
89635094|NCT03167268|Experimental|Lycopene 20mg cpr/die|Lycopene is a compound belonging to carotenoid group, largely contained in tomatoes and their derivatives, which has an extreme antioxidant activity. In Dermatology, prolonged use of β-carotenoids in general and of lycopene in particular in the diet showed to be effective in skin protection from ageing, sunlight and radiotherapy damages because these compounds may accumulate in skin and thus contribute to reduce free radicals and inflammation effects.
89635095|NCT03167268|Placebo Comparator|Placebo|"Containing same excipients than the experimental Lycopene 20 mg but not active principle (Lycopene)"
89635096|NCT03167502|Active Comparator|concentric work|patient suffering from knee osteoarthritis will follow a concentric work. This training is 2 sessions per week for 6 weeks
89635097|NCT03167502|Experimental|eccentric work|patient suffering from knee osteoarthritis will follow an eccentric work. This training is 2 sessions per week for 6 weeks
89635098|NCT02393898||Elderly Participants with Ovarian Cancer|Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.
89635099|NCT02393820|Experimental|pazopanib|Pazopanib per os, 800mg daily until progression
89635100|NCT04741048|Experimental|CI624 Slim 20 Electrode|
89635101|NCT04740970|Experimental|JNJ-64304500|Participants will receive JNJ-64304500 dose 1 subcutaneous (SC) injection at Week 0 and then dose 2 SC injection every 2 weeks from Week 2 through Week 22.
89041810|NCT06237218|No Intervention|Routine care|Patient's needs without a COTID program.
89635102|NCT04740970|Placebo Comparator|Placebo|Participants will receive matching placebo SC injection at Week 0 and then every 2 weeks from Week 2 through Week 22.
89635103|NCT04309084|Experimental|Phase I|Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.
89635104|NCT04340128|Active Comparator|1|Intra-lesional injection of Glucantime once a week
89635105|NCT04340128|Experimental|2|Intra-lesional injection twice a week, 0.1/cm2
89635106|NCT04740502|Other|Concordant preoperative studies|Patients with concordant neck ultrasound and MIBI scan
89635107|NCT04740502|Other|Unclear preoperative studies|Patients with discordant or negative neck ultrasound and MIBI scan
89635108|NCT04145674|Experimental|25 mg d-methadone|The experimental drug is a tablet formulation of d-methadone HCl in dose strength of 25 mg.
89635109|NCT04145674|Placebo Comparator|Placebo|The placebo is an exact match to the active tablets in size, color and marking without the active ingredient d-methadone HCl.
89635110|NCT00366964|No Intervention|Device|
89041811|NCT06237205|Experimental|Niraparib|
89041812|NCT06237192|Experimental|MRD-positive with Target therapy|MRD-positive patients after induction therapy in target therapy group (for B-ALL- blinatumomab, for T-ALL - venetoclax+ChT)
89041813|NCT06237153|Experimental|Triamcinolone acetonide extended release suspension injection|Active drug treatment
89041814|NCT06237153|Placebo Comparator|Saline Placebo Injection|Placebo comparator
89041815|NCT06237140|Experimental|PNF exercise group|proprioceptive neuromuscular facilitation (PNF) techniques will be applied to the cervical region. In the study, flexion-lateral flexion and rotation patterns will be studied together with antagonist patterns. In the antagonist movement involving cervical extension, the hand above the head is displaced diagonally and positioned to resist extension, lateral flexion and rotation. Before the exercise, the patient will be informed about the diagonal direction of the movement and made to feel it, and then the exercises will be performed in 5 sets, each set containing 10 repetitions. Participants will be given sufficient time to rest between sets.
89041816|NCT06237140|Active Comparator|biofeedback exercise group|cervical stabilization exercises will be used to stimulate cervical proprioceptors. Neck stabilization training will be applied with a low load to strengthen the longus capitis and longus colli, the deep muscles of the upper cervical vertebra. The oblique and costal muscles, which are the auxiliary respiratory muscles, will be relaxed and the neck will be flexed. A pressure biofeedback device will be placed on the upper cervical spine (below the occiput) while lying with the air pocket set at 20 mmHg to obtain visual feedback from the dial. The pressure will be gradually increased to 30 mmHg in 2 mmHg increments. While the patient was asked to retract his chin, the contraction duration was determined as 10 seconds. While the contractions are repeated 10 times, a 3-5 second rest period will be given between each contraction.
89041817|NCT06237127|Experimental|Goji berry|For the goji berry arm, participants will consume goji berries.
89041818|NCT06237127|Active Comparator|Fiber|For the fiber arm, participants will consume fiber supplements that closely matches the fiber type and amount found in the portion of goji berries.
89041819|NCT06237088|Active Comparator|eight-week mindfulness programs|The intervention consists of 2.5-hour classes per week over a period of eight weeks.
89041820|NCT06237088|Experimental|online mindfulness program|The intervention includes an eight-week internet-based mindfulness program. The program introduces participants to a new mindfulness topic every week. These topics are heavily inspired by the eight-week mindfulness programs.
89041821|NCT06237088|No Intervention|care as usual|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
89041822|NCT06237075|Experimental|tDCS stimulation|2-milliamp stimulation for 5~15 min
89635111|NCT02698176|Experimental|Birabresib 20 mg CRPC Cohort-Part A|Participants in the CRPC cohort in Part A of the study received birabresib 20 mg orally (PO), twice a day (BID), in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
89635112|NCT02698176|Experimental|Birabresib 20 mg NMC Cohort-Part A|Participants in the NMC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
89635113|NCT02698176|Experimental|Birabresib 20 mg TNBC Cohort-Part A|Participants in the TNBC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
89635114|NCT02698176|Experimental|NMC Cohort-Part B|Participants (up to 30) in Part B will receive birabresib at one dose level below the dose currently being administered in Part A of the study. Once the recommended Phase 2 dose (RP2D) from Part A is established, participants in Part B will receive birabresib at the RP2D. Participants will continue receiving birabresib at an assigned/adjusted dose level for continuous cycles up to 24 months.
89635115|NCT02393976|Other|CONTROL|STANDARD NUTRITION
89635116|NCT02393976|Experimental|IMMUNONUTRITION|INMUNONUTRITION
89635117|NCT02394054|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
89635118|NCT02394054|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
89635119|NCT03167190|Other|Control|Traditional landmark-based lumbar puncture technique by palpation
89635120|NCT03167190|Experimental|Experimental (ultrasound)|Use of point-of-care ultrasound to identify bony landmarks.
89635121|NCT02393742|Experimental|Sodium Nitrite Supplementation|80 mg/day (40 mg 2x/day) slow release sodium nitrite (TheraVasc, Inc) for 3 months
89635122|NCT02393742|Placebo Comparator|Placebo|placebo 2x/day for 3 months
89635123|NCT02393664|Experimental|Nonintubated group|Patients undergoing thoracoscopic surgery using nonintubated technique with propofol and bupivacaine.
89635124|NCT02393664|Active Comparator|Intubated group|Patients undergoing thoracoscopic surgery using intubated general anesthesia with sevoflurane and rocuronium.
89635125|NCT02393352|Experimental|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
89635126|NCT02393352|Active Comparator|Electrical Stimulation Therapy|Diadynamic fixed current phase in active trigger points, with pulses of 10msec, and intervals of equal duration.
89635127|NCT02397642|Active Comparator|Dual trigger|GnRH agonist plus 1000 IU of HCG to trigger final maturation
88990938|NCT05971056|Experimental|Care transition|-At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location.
88990939|NCT05971056|Active Comparator|No care transition|-At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location.
88990940|NCT05969431||fathers of mature infants|Fathers of newborns' above 37 weeks of gestation
88990941|NCT05969431||fathers of moderate and late preterm infants|Fathers of moderate and late preterm infants, i.e. gestational age from 32 0/7 to 36 6/7 weeks of gestation.
88990942|NCT05969431||fathers of very low birth weight preterm infants|Fathers of very low birth weight preterm infants, i.e. gestational age from 22 0/7 to 31 6/7 weeks of gestation and with a birth weight below 1500 g.
89635128|NCT02397642|Active Comparator|Booster HCG dose|GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
88990943|NCT05968612|Experimental|Treatment A (Test-Fed)|Following a 10-hour overnight fasting period, subjects will eat a high-fat, high-calorie breakfast, and 30 minutes later subjects will receive a single dose of 2 Lumacaftor 200 mg Film-Coated Tablets.
88990944|NCT05968612|Active Comparator|Treatment B (Reference-Fed)|Following a 10-hour overnight fasting period, subjects will eat a high-fat, high-calorie breakfast, and 30 minutes later subjects will receive a single dose of 2 Lumacaftor 200 mg/Ivacaftor 125 mg Combination Film-Coated Tablets (Orkambi®)
88990945|NCT05968612|Experimental|Treatment C (Test-Fasted)|Following a 10-hour overnight fasting period, subjects will receive a single dose of 2 Lumacaftor 200 mg Film-Coated Tablets.
88990946|NCT05962905||Pediatric|Subjects meeting inclusion criteria weighing between 4 and 40 kg
88990947|NCT05962905||Infant|Subjects meeting inclusion criteria weighing under 40 kg
88990948|NCT05959330|Experimental|Neural Tension Technique(ulnar, median, radial)|Neural Tension Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
88990949|NCT05959330|Experimental|Neural Slider Technique (ulnar, median, radial)|Neural Slider Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
88990950|NCT05959330|Experimental|Neural Tension Technique and Neural Sliding Technique(ulnar, median, radial)|Neural Tension and Sliding Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
89635129|NCT02393508|Active Comparator|Fresh Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are less than or equal to 7 days of age from the time of donation.
89635130|NCT02393508|Active Comparator|Aged Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are greater than 21 days and up to a maximum of 42 days of age from the time of donation.
89635131|NCT03167658|Experimental|Treatment|Employees at treatment worksites will be given access to workplace wellness programming. Participation by employees will be voluntary, but all employees at treatment sites will be considered as part of the treatment group. Employees will also be invited to complete on-site biometric assessments and questionnaires. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
89635132|NCT03167658|No Intervention|Primary Control|Employees at primary control worksites will be invited to complete on-site biometric assessments and questionnaires, but will not have access to the workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
89635133|NCT03167658|No Intervention|Secondary Control|Employees at secondary control worksites will not participate in in-person screenings or questionnaires, and will not have access to workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
89635134|NCT03733054||Men|Men with lower limb amputation
89635135|NCT03733054||Women|Women with lower limb amputation
89635136|NCT02397486|Experimental|Intervention Group|"Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks."
88990951|NCT05959317|Other|Pilates Exercises|Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
88990952|NCT05959317|Other|Neural dynamic mobilization|Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
88990953|NCT05939830|Experimental|Omit ALND|"Omitting Axillary Lymph Node Dissection (ALND) in SrLNB-proven axillary complete response patients.~Finishing regional lymph node irradiation (RNI) including the axilla after surgery."
89635137|NCT02397486|Active Comparator|Control Group|Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .
89635138|NCT02393586|Experimental|Faropenem/augmentin|Faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
89635139|NCT02393586|Experimental|Rifampicin/faropenem/augmentin|Rifampicin 10mg/kg plus faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
89635140|NCT02393586|Experimental|Rifampicin|Rifampicin 10mg/kg
89635141|NCT03503812|No Intervention|No intervention to DDS exposure - Asthma in Children|
89635142|NCT03503812|Experimental|Intervention 1 - Asthma in Children|
89635143|NCT03503812|Experimental|Intervention 2 - Asthma in Children|
89635144|NCT03503812|No Intervention|No intervention to DDS exposure - Atrial Fibrillation|
89635145|NCT03503812|Experimental|Intervention 1 - Atrial Fibrillation|
89635146|NCT03503812|Experimental|Intervention 2 - Atrial Fibrillation|
89635147|NCT04480632|Experimental|ABO compatible convalescent plasma|A 500 ml dose of convalescent plasma (from a single donor or two 250 ml units from one or two donations) collected by apheresis will be administered. In case of plasma storage, plasma unit will be thawed following parameters of blood bank. Administration will take place slowly and over the course of four hours. When two 250 ml units are administered, second unit must be administered after the first unit in a period not exceeding 12 hours.
89635148|NCT04480632|No Intervention|Usual care|Usual medical care for critically ill patients at ICU
89635149|NCT02393430|Experimental|experimental|The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
89635150|NCT02393430|Placebo Comparator|control|The control group were only optimized their life style.
89635151|NCT03453892||anti CTLA-4|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
89635152|NCT03453892||anti PD-1/PD-L1|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
89635153|NCT02393274||28-day Survival|survive for at least 28 days after placement of extra-corporeal membrane oxygenation life support
89635154|NCT02393274||28-day Nonsurvival|not survive for 28 days after placement of extra-corporeal membrane oxygenation life support
89635155|NCT04340440|Active Comparator|D1 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and limited D1 lymphadenectomy
89635156|NCT04340440|Active Comparator|D2 lymphadenectomy|Operable gastric cancer was treated by radical gastrectomy and extended D2 lymphadenectomy
89635157|NCT00367042|No Intervention|1|
89635158|NCT00367198|Active Comparator|1|30 ml per serving
89635159|NCT00367198|Active Comparator|2|60 ml per serving
89635160|NCT00367198|No Intervention|3|chronic hemodialysis patients
89635161|NCT00367198|No Intervention|4|healthy subjects
89635162|NCT02693418|Experimental|Acidform Gel, Group A|Administration of a single vaginal dose of Acidform gel (5 g)
89635163|NCT02693418|Experimental|Acidform Gel, Group B|Administration of a single vaginal dose of Acidform gel (4 g)
89635164|NCT02693418|Experimental|Acidform Gel, Group C|Administration of a single vaginal dose of Acidform gel (3 g)
89635165|NCT02693418|Placebo Comparator|Placebo Gel, Group D|Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
89635166|NCT02693418|No Intervention|No intervention, Group E|No vaginal product administered
88990954|NCT05938920|Experimental|INS018_055|"Group 1: INS018_055 once daily up to 12 weeks, low dose~Group 2: INS018_055 twice daily up to 12 weeks, low dose~Group 3: INS018_055 once daily up to 12 weeks, high dose"
88990955|NCT05938920|Placebo Comparator|Placebo|Group 4: Placebo once or twice daily up to 12 weeks
88990956|NCT05938530|Experimental|Sirolimus drug-coated balloon|The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the graft vein junction by inflating the balloon for 2 minutes at rated burst pressure (typically 12 to 14ATM).
89635167|NCT05745324|Experimental|Smoker vs Nonsmokers|SRP would be performed for Smokers (ENDS and conventional cigarette) and Nonsmokers and their inflammatory biomarkers would be assessed.
89635168|NCT05745324|Experimental|ENDS users and Nonsmokers|SRP would be performed for ENDS users and Nonsmokers and their inflammatory biomarkers would be assessed.
89635169|NCT05745324|Experimental|Smokers with periodontitis and Nonsmokers|SRP would be performed for Smokers with periodontitis and health nonsmokers and their inflammatory biomarkers would be assessed.
89635170|NCT05745324|Experimental|Smokers with periodontitis and Nonsmokers with periodontitis|SRP would be performed for Smokers and Nonsmokers with periodontitis and their inflammatory biomarkers would be assessed.
89635171|NCT03166956|Experimental|GA (glutamine and vitamin C) group|"Interventions of glutamine and vitamin C enteral supplementations were given to surgical intensive care unit (ICU) patients.~Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan)."
89635172|NCT03166956|Placebo Comparator|Control (C) group|"Placebo:~Subjects in the C group received isocaloric maltodextrin as placebo."
89635173|NCT02397330|Active Comparator|group BIS|scheduled for ultrasound guided interscalene blockade with 30 ml of bupivacaine 0.25%
89635174|NCT02397330|Experimental|group BS|scheduled for selective blockade of the ultrasound guided suprascapular (15 ml bupivacaine 0.25%) and supraclavicular (15 ml bupivacaine 0.25%) nerves blocks
89635175|NCT03081052|Active Comparator|Lung transplant with iNO|
89635176|NCT03081052|Active Comparator|Lung transplant with iEPO|
89635177|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iNO|
89635178|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iEPO|
88990957|NCT05938530|Active Comparator|Stent graft|Stent graft is the current standard of care for treatment of arteriovenous graft malfunction. A stent graft will be deployed at the graft vein junction.
88990958|NCT05938296|Experimental|BS006 injection|Subjects will receive BS006 every two weeks, and up to 4mL BS006 will be given. BS006 will be given intratumorally.
88990959|NCT05936866|Experimental|Pelvic floor stretching|Pelvic floor stretching exercises
88990960|NCT05936866|Active Comparator|Pelvic floor strengthening|Pelvic floor strengthening Exercises
89635179|NCT02693106|Experimental|Ketogenic potential|"Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated followed by a period of 4-hour with multiple blood sampling.~Intervention 1: Control; no supplement Intervention 2: 5 g of leucine Intervention 3: 3.6 g of butyrate Intervention 4: 7.2 g of butyrate Intervention 5: 5 g of octanoate Intervention 6: 10 g of octanoate Intervention 7: 1.95 g of carnitine Intervention 8: 65 g of butter fraction rich in MCT"
89635180|NCT02393196|Active Comparator|Group Preloading (Group P)|Group Preloading (Group P): 500 mL hydroxyethyl starch (6% HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible before spinal anesthesia.
89041824|NCT06237023|Other|pre-pandemic group|Patients who presented to the Orthopedics and Traumatology unit for any trauma-related reason during the one-year period prior to the pandemic
89041825|NCT06237023|Other|post-pandemic group|Patients who presented to the Orthopedics and Traumatology unit for any trauma-related reason within one year from the start of the pandemic
89041826|NCT06236997|Experimental|Treatment (etoposide, carboplatin, radiation, Adebrelimab)|Participants receive etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
89041827|NCT06236984||AKI patients|Patients with an indication for the extracorporeal blood treatment suffering from AKI who received CKRT adult mode treatment
89041828|NCT06236971||MRI scanning|The subjects are receiving MRI scanning first in the supine position, and then in the lateral position. The field of view was determined from the length and girth of each patient's head, at least including the skull base to the level of tracheal bifurcation.
89041829|NCT06236958||Transnasal jejunal tube enteral nutrition group|Naso-jejunal tube was placed to the distal 15cm of Traitz ligament during the operation; short peptide enteral nutrient solution was heated by enteral nutrition pump and infused slowly and continuously 24 hours after the operation; during the period of infusion, the gastrointestinal tolerance of the patients was evaluated dynamically, and attention was paid to the absence of abdominal pain, diarrhea, constipation, vomiting, regurgitation, and misaspiration. According to the results of regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the dosage of enteral nutrients in patients in appropriate amounts; patients with no abdominal distension after exhaustion and fluid intake, that is, the removal of nasojejunal tube, and replaced by oral intake of food.
89635181|NCT02393196|Active Comparator|Group Coloading (Group C)|Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
89635182|NCT03016936||Subgroup for NTproBNP Substudy|Planned subgroup analyses in patients undergoing vascular, orthopaedic, thoracic surgery, and in patients aged 65 years or older with a RCRI <2 and NSQIP- MICA <1%
89635183|NCT02392962|Experimental|Experimental I|This group performed static stretching
89635184|NCT02392962|Active Comparator|Experimental II|This group performed dynamic stretching
89635185|NCT02397018|Experimental|Allogeneic Umbilical Cord Blood Infusion|All subjects in this study will receive an intravenous infusion of ABO/Rh matched umbilical cord blood.
89635186|NCT00422344|Experimental|RAD001 AND SUNITINIB|RAD001 AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA PATIENTS
89635187|NCT02393118|Experimental|BrainPort V200 Device|Single Arm
89635188|NCT02952352|Experimental|Diabetes Intervention|Diabetes Prevention Program
89635189|NCT02952352|Other|Delayed Intervention|Diabetes Prevention Program
89635190|NCT02397252|Experimental|Eve Medical self-collection system©|Device: Self-sampling swab from Eve Medical for collection of vaginal cells.
89635191|NCT02397252|Placebo Comparator|cobas® PCR Female swab self-sampling|Device: Regular polyester swab for collection of vaginal cells.
89635192|NCT02397252|Placebo Comparator|Physician-collected sampling|Routine colposcopy sample collected by a physician.
89635193|NCT02397174|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
89635194|NCT02397174|Active Comparator|hypocaloric diet|The diet programme will be characterized by carbohydrates (50%),total lipids (30%) and proteins (20%). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
89635195|NCT02396940|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic inguinal hernia repair performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
89635196|NCT02396940|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
89635197|NCT00367276|Experimental|Arm 1|
89635198|NCT02546986|Experimental|CC-486 plus Pembrolizumab|In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days.
89635199|NCT02546986|Experimental|Pembrolizumab plus Placebo|In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.
89635200|NCT02196844|Experimental|Yoga Group|Couple-Based Hatha Yoga Program: 5-6 weeks of a yoga program, three sessions per week (up to 15 sessions) during radiation treatment. At fifth session, CD given for practicing yoga at home. 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
89635201|NCT02196844|Experimental|Wait-List Control Group|"10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule, at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.~Participants given the option to take part in the couple-based Hatha Yoga program (off study) after they finish their last questionnaire packet."
89211933|NCT00619112|Experimental|Temozolomide|single arm trial; Patients treated with temozolomide at a dose of 150mg/m2 daily for seven consecutive days of every other week. One 28-day cycle will include treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14
89635202|NCT02196844|Experimental|Caregivers|"Yoga Group - Caregivers: 5-6 weeks of yoga during patient's radiation treatment. At fifth session, caregiver given CD for practicing yoga at home. During each week of patient's radiation, caregiver completes questionnaire about their feelings about yoga sessions. 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation, at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after patient's radiation therapy.~Waitlist-Control Group - Caregivers: 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation. at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after radiation therapy.~Caregivers given option to take part in yoga program after they finish their last questionnaire packet."
89635203|NCT02689206|Experimental|GSK1278863 10 mg|Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
89635204|NCT02689206|Experimental|GSK1278863 15 mg|Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
89635205|NCT02689206|Experimental|GSK1278863 25 mg|Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
89635206|NCT02689206|Experimental|GSK1278863 30 mg|Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
89635207|NCT02689206|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
89635208|NCT01695239|Experimental|Ixekizumab Q2W|Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
89635209|NCT01695239|Experimental|Ixekizumab Q4W|Administered by 80 mg SC injection every 4 weeks (Q4W).
89635210|NCT01695239|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
89635211|NCT01695239|Active Comparator|Adalimumab Q2W|Administered by 40 mg SC injection Q2W.
89635212|NCT01984762|Active Comparator|RYGBP|Roux-en-Y gastric bypass
89635213|NCT01984762|Active Comparator|SG|sleeve gastrectomy
89635214|NCT00975520|Active Comparator|Radiation Therapy|Investigational Treatment
89635215|NCT00975520|Other|Observation|Observation
89635216|NCT04449250|Active Comparator|CTx-1301 Fasted|Subjects will receive CTx-1301 in a fasted state.
89635217|NCT04449250|Active Comparator|CTx-1301 Fed|Subjects will receive CTx-1301 in a fed state (high fat test meal).
89635218|NCT04344028|Experimental|True Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program improves performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
89635219|NCT04344028|Active Comparator|True Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of a cognitive training program that has previously been shown to improve cognition."
89635220|NCT04344028|Placebo Comparator|Control Cognitive Training Placebo|"Participants will receive a positive expectation message (e.g., Previous research has shown that training with this program increases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
89635221|NCT04344028|Sham Comparator|Control Cognitive Training Nocebo|"Participants will receive a negative expectation message (e.g., Previous research has shown that training with this program decreases performance on other tasks.) and will complete approximately 7 hours of control training program that has not previously been shown to improve cognition."
89635222|NCT04317430|Active Comparator|Treatment group|Niclosamide tablets 1 gram once daily
89635223|NCT04317430|Placebo Comparator|Control group|Lactose tablets
89635224|NCT04277884|Experimental|Firibastat|Capsules
89635225|NCT04277884|Placebo Comparator|Placebo|Matching capsules
89211934|NCT00845078||1|Immediate reconstruction followed by radiation therapy
89635226|NCT04129840|Active Comparator|Intervention 1: dual combination|dual combination of half-dose Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB), dosage increases at 4 and 8 weeks if target blood pressure is not reached at the respective time point
89211935|NCT00845078||2|Radiation therapy followed by delayed reconstruction
89211936|NCT00855998||1|With BRCA1 or BRCA2 mutations
89211937|NCT00855998||2|Without BRCA1 or BRCA2 mutations
89211938|NCT00845156|Active Comparator|Anti-Oxidant|Alpha Lipoic Acid
89211939|NCT00845156|Placebo Comparator|Placebo|Placebo
89635227|NCT04129840|Active Comparator|Intervention 2: triple combination|triple combination of quarter-dose of Calcium Channel Blocker (CCB), Thiazide diuretic (TZD) and Angiotensin II Receptor Blocker (ARB) with dosage increases of all drugs at 4 and 8 weeks, if target blood pressure is not reached at the respective time point
89635228|NCT04129840|Placebo Comparator|Standard of care|start normal dose Calcium Channel Blocker (CCB), add Thiazide diuretic (TZD) after 4weeks and increase of TZD dosage after 8 weeks, if target blood pressure is not reached at the respective time point
89635229|NCT04023058|No Intervention|CABG/increasing MR|non-massive IMR with increasing IMR during exercise - CABG only
89635230|NCT04023058|Experimental|CABG+mitral surgery (MS)/increasing MR|non-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
89635231|NCT04023058|No Intervention|CABG/non-increasing MR|non-massive IMR non-increasing IMR during exercise - CABG only
89635232|NCT04023058|Experimental|CABG+MS/non-increasing MR|non-massive IMR non-increasing IMR - CABG+ mitral surgery
89635233|NCT04023058|Other|Control 1|massive IMR at rest without increasing during exercise - CABG+ mitral surgery
89635234|NCT04023058|Other|Control 2|massive IMR at rest with increasing during exercise - CABG+ mitral surgery
89688515|NCT03834935|Placebo Comparator|Pl|20 patients receiving placebo (control group), cold cream bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
89635235|NCT03921814|Experimental|Treatment with IPL device|This study will be conducted in women, aged 18 to 65 years, with skin types I up to and including V, and measured melanin values of ≤ 553 Melanin index in each qualifying treatment area in face (upper lip), axilla, bikini line, and leg. Each of the 2cm x 4cm treatment area bilateral located in axilla, bikini line and leg should count a minimum of 24 hairs. In face (upper lip) on upper lip, a minimum of 10 hairs should be available in each of the 1cm x 2cm selected treatment area bilateral located. The procedure to define the treatment area is described in the Training Manual [5]. Skin type must be determined based on an evaluation by a dermatologist or designee at site according to the Fitzpatrick Skin Type Scale.
89211940|NCT04001985|Active Comparator|Immediate NG tube removal|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
89635236|NCT03680794|Experimental|Patients with ophthalmic surgery|
89635237|NCT03595540|Experimental|Prolon - FMD|Patients undergoing active cancer treatment are assigned monthly cycles of the fasting-mimicking diet Prolon
89635238|NCT03353116|Active Comparator|maxilla first group|the maxillary osteotomy is going to be done and fixed first
89635239|NCT03353116|Experimental|mandible first group|the mandibular osteotomy is going to be done and fixed first
89635240|NCT03185026|Active Comparator|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
89635241|NCT03185026|Experimental|Psychoeducational group|The patients will experiment the last innovating psychological skills in order to acquire the ability to engage in behaviors to manage their disease.
89635242|NCT03084016||Acute asthma exacerbation|Recruited in secondary care when presenting with acute asthma exacerbation.
89635243|NCT03084016||At risk of acute asthma exacerbation|Recruited in outpatient clinics. Acute exacerbation within the previous 12 months.
89635244|NCT01694849|Experimental|GFT505 80mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
89635245|NCT01694849|Experimental|GFT505 120mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
89635246|NCT01694849|Placebo Comparator|Placebo|hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.
89635247|NCT02535286|Experimental|TG-1501 + Ublituximab + Umbralisib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Umbralisib oral daily dose TG-1501 IV infusion at scheduled intervals
89635248|NCT02249572|Experimental|gamma knife radiosurgery|Single fraction gamma knife radiosurgery given at 12 Gy to tumor periphery for vestibular schwannoma
89635249|NCT02249572|No Intervention|Expectation|No active treatment given for vestibular schwannoma
89635250|NCT01834924|Active Comparator|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
89635251|NCT01834924|No Intervention|Control|Standard provider medication counseling
89635252|NCT01126840||Questionnaire + Telephone Interview|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete. The phone interview should take 30-45 minutes to complete.
89635253|NCT00610402||blood sample tear drop sample|blood sample tear drop sample
89635254|NCT00556114||Optical Coherence Tomography|Optical Coherence Tomography
89635255|NCT02643862|Active Comparator|xolair|Pts will be randomized to receive xolair at a 3 active:1 placebo ratio
89635256|NCT02643862|Placebo Comparator|Placebo|This is a placebo that looks similar to Xolair and is given as a subcutaneous shot, just like Xolair
89635257|NCT02646826|Placebo Comparator|Placebo|Subjects are treated with placebo tablets.
89635258|NCT02646826|Experimental|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol.
89635259|NCT02646826|Experimental|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol.
88990961|NCT05935228|Other|The control group|"The control group will consist of patients included in phase 1. These are the patients from the before phase, i.e. before the implementation of the Difficult Intravenous Access Scale."
89635260|NCT02646826|Experimental|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol.
89635261|NCT02648230|Experimental|Pressure wire and Microcatheter|All subjects enrolled will have both an FFR done measured by a pressure wire (PW) and then again by a microcatheter (MC).
89635262|NCT02649322|Experimental|Group A|Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure.
89635263|NCT02649322|Active Comparator|Group B|Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure.
89635264|NCT01694771|Experimental|Olodaterol and Tiotropium|2 puffs olodaterol from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
89635265|NCT01694771|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
89635266|NCT02649556|Experimental|THS 2.2|Ad libitum use of THS 2.2
89635267|NCT02649556|Active Comparator|CC|Ad libitum use of CC
89635268|NCT02651272|Experimental|macitentan|10mg macitentan tablets, taken once daily (QD), by mouth (PO), for the treatment period lasting 16 weeks.
89635269|NCT01582061|Experimental|Pasireotide 600 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 600 μg bid group includes all patients whose mean daily dose < 1500 μg /day.
89688516|NCT01724255||staple removal day 4 dressing removal day 1|early staple removal and early dressing removal
89688517|NCT01724255||staple removal day 4 dressing removal day 4|early staple removal and day 4 dressing removal
89520806|NCT02819635|Experimental|SS3: M14-675 clinical responders|Participants in Study M14-675 (NCT03653026) who achieved clinical response defined by Adapted Mayo Score at Week 8 or Week 16 in that study and did not meet any study discontinuation criteria were eligible to enroll into Substudy 3. Participants were re-randomized and treated with a blinded treatment assignment (15 mg upadacitinib film-coated tablets once daily by mouth [QD], or 30 mg upadacitinib film-coated tablets QD, or placebo for upadacitinib film-coated tablets QD) for up to 52 weeks.
89520807|NCT03435809|Active Comparator|Pozzi for intrauterine insemination|Treatment done with a pozzi tenaculum forceps
89520808|NCT03435809|Active Comparator|No Pozzi for intrauterine insemination|Treatment done without a tenaculum forceps
89520809|NCT04912544|Experimental|Arm 1|Patient talking with microphone first turned on and then off
89520810|NCT04912544|Experimental|Arm 2|Patient talking with microphone first turned off and then on
89520811|NCT03435731|Experimental|Treatment Group|This group will undergo 1 month Dual Therapy.
89520812|NCT03435653|Active Comparator|Control group|Control group OFD with DFDBA
89520813|NCT03435653|Experimental|Test group|Test group OFD with decortication and DFDBA
89520814|NCT04914416|Placebo Comparator|Verum T1|
89520815|NCT04914416|Experimental|Verum T2|
89520816|NCT04914416|Experimental|Verum T3|
89520817|NCT04914416|Experimental|Verum T4|
89520818|NCT04914416|Experimental|Verum T5|
89520819|NCT04914416|Experimental|Verum T6|
89520820|NCT04914416|Experimental|Verum T7|
89520821|NCT04914416|Experimental|Verum T8|
89520822|NCT04914416|Experimental|Verum T9|
89520823|NCT04914416|Experimental|Verum T10|
89520824|NCT04914416|Experimental|Verum T11|
89520825|NCT04914416|Experimental|Verum T12|
89520826|NCT04914416|Experimental|Verum T13|
89520827|NCT04914416|Experimental|Verum T14|
89520828|NCT04914416|Experimental|Verum T15|
89520829|NCT04914416|Experimental|Verum T16|
89520830|NCT04914416|Placebo Comparator|Verum T17|
89520831|NCT03431207||healthy group|"For the healthy group, the visual acuity of both eyes was in the 95% referenced range with no structural abnormalities.~The referenced range could be found in the following publication:~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
89520832|NCT03431207||mildly impaired group|"The mildly impaired group was defined as a VA out of the 95% reference range in at least 1 eye, but the VA of both eyes was in the 99% referenced range with structural abnormalities."
89520833|NCT03431207||severely impaired group|"For the severely impaired group, the VA of both eyes was out of the 99% referenced range or worse than light perception with structural abnormalities."
89520834|NCT03435575|Active Comparator|Intervention group|Children in the intervention group will receive Boosth: Boosth activity tracker, Boosth syncc app and Boosth game app
89520835|NCT03435575|No Intervention|Control group|Standard care
89520836|NCT03874325|Experimental|Safety Run In: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited. Six participants will be enrolled in the safety run in stage. If 1 or fewer of six participants have a DLT, expansion stage will open to enrollment.
89520837|NCT03874325|Experimental|Expansion: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited.
89520838|NCT02424344|Experimental|Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg|8 weeks, double blind treatment period
89520839|NCT02424344|Placebo Comparator|Placebo to Aclidinium/Formoterol|8 weeks, double blind treatment period
89520840|NCT03435419||CL suspects|"Individuals with suggestive signs of cutaneous leishmaniasis presenting themselves at the National Malaria & Leishmaniasis Control Program (NMLCP) Leishmaniasis clinic in Kabul, Afghanistan.~These will be tested by diagnostic tests under evaluation:~i) LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection ii) CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection And their performance compared against a reference combining microscopy and PCR."
89520841|NCT03435341||Patients diagnosed with AML|The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.
89520842|NCT02423798|Other|Open-label, single-sample design|"The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).~As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint."
89520843|NCT03861611|Experimental|Ketorolac + Educational Intervention|Participants may be randomized to receive Ketorolac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
89520844|NCT03861611|Experimental|Ibuprofen + Educational Intervention|Participants may be randomized to receive Ibuprofen for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
89520845|NCT03861611|Experimental|Diclofenac + Educational Intervention|Participants may be randomized to receive diclofenac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
89520846|NCT03841409||Bupivacaine dosage in ESP block|The pharmacokinetics of bupivacaine 0.5% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following an ESP block will be determined by the collection of blood samples at predetermined time points.
89520847|NCT03435263||hospital admission group B|Women presented with premature rupture of membranes will be admitted at hospital.
89520848|NCT03435263||home management group A|home management
89520849|NCT03430817|Experimental|Group C|Citicholine Drug
89520850|NCT03430817|Experimental|Group A|Amantadine Drug
89520851|NCT03430817|Experimental|Group D|Both Citocholine and Amantadine
89041830|NCT06236958||Transvenous parenteral nutrition group|Nutrient solution was evenly titrated starting 24 hours after surgery. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, diabetic patients depending on the blood glucose level to adjust the pancreatic glucose ratio, and then assisted by subcutaneous injection of insulin to control blood glucose, if necessary, pay attention to the total amount of rehydration fluids, electrolytes, vitamins and micronutrient supplementation. Nutritional solution was evenly mixed in the laminar flow clean table and infused through the intravenous route, and oral feeding was started after exhaustion.
89635270|NCT01582061|Experimental|Pasireotide 900 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
89635271|NCT01693523|Experimental|Minocycline|Minocycline 100 mg by mouth two times a day (200 mg/day). Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
89635272|NCT01693523|Placebo Comparator|Placebo|Matching placebo capsules by mouth twice a day. Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
89635273|NCT03924323|Experimental|Escitalopram 10 mg/day|Oral administration with the possibility of dose escalation to 20 mg/day at the investigator's discretion
89635274|NCT03924323|Placebo Comparator|Placebo|Matching oral administration of placebo once daily
89635275|NCT01581593|Experimental|Kedrion IVIG 10%|Kedrion IVIG 10% treatment.
89635276|NCT01581281|Active Comparator|Amitriptyline|Drug to be administered twice daily.
89635277|NCT01581281|Active Comparator|Topiramate|Drug to be administered twice daily.
89635278|NCT01581281|Placebo Comparator|Placebo|To be administered twice daily.
89635279|NCT02692716|Experimental|Oral semaglutide|
89635280|NCT02692716|Placebo Comparator|Placebo|
89635281|NCT05745012|Sham Comparator|group A: control group|
89635282|NCT05745012|Experimental|group B: ARMS procedure|
89635283|NCT01580969|Experimental|Dose Level 0: 100 mg bid|Patients receiving minocycline 100 mg bid, bevacizumab, and radiation therapy.
89635284|NCT01580969|Experimental|Dose Level 1: 200 mg bid|Patients receiving minocycline 200 mg bid, bevacizumab, and radiation therapy.
89635285|NCT01580969|Experimental|Dose Level 2: 400 mg bid|Patients receiving minocycline 400 mg bid, bevacizumab, and radiation therapy.
89635286|NCT02392884|Active Comparator|EON-MEM|Intervention: Cognitive Rehabilitation and compensatory strategies will be taught to subjects to help them remember routes, viral load count, CD4 count, faces of providers and managing their schedules. Over the course of 5 visits, subjects will receive this intervention.
89635287|NCT02392884|Active Comparator|Compensatory Cognitive Training|Cognitive Rehabilitation and physical reminders, such as calendars, smart phones, self-notes and other methods to help subjects remember to attend all medical appointments and take their HIV medication. Subject will be exposed to 5 sessions of this particular training.
89635288|NCT02392884|No Intervention|Psychoeducation|The psychoeducation group, which aims to teach subjects the importance of taking medications and attending all doctor's appointment for HIV treatment. If you subjects are assigned to this group, they will be followed and receive the care generally followed for individuals with this condition.
89635289|NCT01693367|Active Comparator|DLS 5.0 (Dynamic Locking Screws)|ORIF with DLS 5.0 (Dynamic Locking Screws)
89635290|NCT01693367|Active Comparator|SLS (Standard locking screw)|ORIF with SLS (Standard locking screw)
89635291|NCT03165162|Experimental|Study Arm|Food Order: Randomly assigned orders of 7 bowls of granola, each with a different food label.
89635292|NCT02696226|Experimental|SAVR Warfarin Arm|Warfarin arm-(target INR of 2-3)
89635293|NCT02696226|Experimental|TAVR Warfarin and Clopidogrel Arm|Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
89635294|NCT02696226|Experimental|SAVR Aspirin Arm|Aspirin arm (81mg/day)
89635295|NCT02696226|Experimental|TAVR Aspirin and Clopidogrel Arm|Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
89635296|NCT02393040|Experimental|PRP/Saline|"PRP/Saline~Briefly, for PRP preparation, approximately 18 mL of blood from each patient is drawn into a tube containing 3,8 % sodium citrate. The tubes were centrifuged at 450 g for 8 minutes, resulting in three basic layers: an erythrocyte layer at the bottom of the tube, a PRP layer in the middle, and a platelet-poor plasma (PPP) layer at the top of the tube. After removing the platelet-poor plasma (PPP) layer, the PRP is obtained, activated with 10 % calcium chloride.~In the same patient, PRP will be injected to half-head and in the other half-head will be injected with saline solution (placebo).~This study includes 4 visits: 3 visits (with 1-month interval) and 1 visit of follow-up (month 6)."
89635297|NCT02392728|Experimental|Intervention VE|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
89635298|NCT02392728|Active Comparator|Intervention GI|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
89635299|NCT01692275|Active Comparator|Medical Care + Chiropractic Care|Medical care plus chiropractic manipulative therapy
89635300|NCT01692275|Active Comparator|Conventional Medical Care Only|Conventional medical care only
89635301|NCT03167112|Experimental|FOLFIRINOX|Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil
89635302|NCT02692560|Experimental|I-STAND|Participants randomly assigned to the I-STAND intervention group will receive 2 in-person health coaching sessions and 4 biweekly phone-based health coaching sessions. They will receive a wristband that gives a mild vibration after 20 minutes of inactivity and will be encouraged to stand if possible after each inactivity alert. Participants may also choose to receive biweekly email reminders in the weeks between coaching calls. They will also receive a workbook with content around reducing sitting time.
89635303|NCT02692560|Active Comparator|Healthy Living|Participants randomly assigned to the Healthy Living enhanced usual care control group will receive 1 in-person health coaching session and 5 biweekly check-in letters by mail. They will receive a workbook with general healthy living topics that are not expected to impact sitting time. All content is taken from Kaiser Permanente Washington's website and is available to all members. Participants will select topics of interest and review them on their own with no further health coaching.
89520852|NCT02504281||RM|Women 18-43 years of age who are scheduled for IVF or ICSI with a history of recurrent spontaneous abortion (miscarriage occurred earlier than 22 weeks of gestation for equal or greater than 3 times) in our IVF institute.
89520853|NCT02504281||Control|Normal females who are visiting Shanghai JIAI genetics and IVF institute for IVF/ICSI because of only male factor.
89520854|NCT02383940|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
89520855|NCT02383940|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.
89520856|NCT03430739||Babies; Usage time of Helmet between 15-18 hours a day|Babies who worn the helmet for 15-18 hours a day
88990962|NCT05935228|Experimental|The experimental group|"The experimental group will consist of the patients included in phase 3. These are the patients from the after phases i.e after the implementation of the algorithm."
89520857|NCT03430739||Babies; Usage time of Helmet between 19-23 hours a day|Babies who worn the helmet for 19-23 hours a day
89520858|NCT03444415|Experimental|Motivational interviewing in groups|The Intervention is performed at Primary Care Centers by health professionals (General Practitioners, Nurses, Pediatricians and Midwives), during pregnancy and the first 2 years of the child. Researchers will be trained in motivational interviewing and group dynamics. Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children. They intend to encourage the shift towards healthy lifestyles to parents on issues related to diet, physical activity and smoking habit, encourage breastfeeding and increase their knowledge and self-efficacy to promote healthy habits regarding diet, physical activity and sleep habits of their children.
89520859|NCT03444415|Other|Control Group|"Control Group: Usual Care as established in the Programa Integral de Atención a la Mujer (Comprehensive Program of Woman Assistance) and the Programa de Atención al Niño Sano (Well Child Program) in the Servicio Murciano de Salud.~Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits."
89520860|NCT02383862|Experimental|Feedback Group|Patients whose clinician received baseline PROMIS symptom scores at the time of their clinic visit
89041831|NCT06236932|Active Comparator|Mediterranean diet group|At baseline (T0), all patients will be subjected to anthropometric determinations, including body weight and height for BMI calculation, body composition by mean of DXA Scan, blood, serum and urine collection, oral cavity swab and stool sampling. Patients will undergo a session of behavioural dietary counselling by which patients will be educated to adhere to a hypocaloric MD for the first 12w (T1).
89520861|NCT02383862|No Intervention|Control Group|Patients whose clinician did not receive baseline PROMIS symptom scores at the time of their clinic visit
89520862|NCT02521675|Other|Diabrasport then Rest|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
89520863|NCT02521675|Other|Rest then Diabrasport|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
89520864|NCT03442153|Experimental|Solgar No7|Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
89520865|NCT03442153|Placebo Comparator|Placebo for Solgar No7|Placebo 1 Capsule by mouth, every 24 hours for 90 days
89520866|NCT04896307||Physicians at The Ottawa Hospital|Online survey completed by physicians working at The Ottawa Hospital consisting of the 2-item Maslach Burnout Inventory, a Satisfaction Questionnaire and the 12-Item Participatory Management Leadership Score.
89520867|NCT02383472|Experimental|MedX Health Console model 1100|The treatment group will receive LED treatments over 6 weeks, 3 times per week, totaling 18 visits. All treatments will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
89520868|NCT02383472|Placebo Comparator|MedX Health Console model 1100-placebo|Subjects enrolled in the placebo group will be on the same schedule as the treatment group. The placebo group will receive LED placebo over 6 weeks, 3 times per week, totaling 18 visits. All placebo patients will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
89520869|NCT03729947|Active Comparator|Drain placed|Subfascial drain at end of procedure
89520870|NCT03729947|Placebo Comparator|No drain placed|No drain left at the end of study
89520871|NCT05370638|Experimental|rounding on discharging patients first|Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day.
89520872|NCT05370638|No Intervention|usual practice|Usual practice was categorized as: seeing discharging patients first, sickest patients, decompensating patients, new patients (i.e. patients admitted to their team overnight), or based on geography.
89520873|NCT03430583||MZ101|Dosing per treatment regimen
89520874|NCT03442075||Group 1|Group 1 an analgesic suppository was applied
89520875|NCT03442075||Group 2|Group 2 was administered analgesic orally
89520876|NCT03442075||Group 3|Group 3 was given trans rectal gel
89520877|NCT03442075||Group 4|Group was performed peri prostatic infiltration.
89520878|NCT03442075||Group 5|Group was performed by placebo oral
89520879|NCT03435029|Experimental|Cognitive Remediation Program (REHACOP)|The cognitive rehabilitation program (REHACOP) is a 5 month intervention that allows both individual and group intervention. For the purpose of this study, we included intervention in several domains: attention, language, memory, processing speed, and executive functioning for 3 months, 3 times per week, in 60 minute per session.
89520880|NCT03435029|Active Comparator|Occupational Therapy|The control group performed of occupational group activities (memory tasks, reading the newspaper, drawing, singing or doing crafts). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
89688518|NCT01724255||staple removal day 7, dressing removal day 1|late staple removal and early dressing removal
89520881|NCT03430505|Active Comparator|Bilevel|Bilevel 10 minutes after bronchoprovocation with saline solution 4.5%. IPAP 12 and EPAP 8
89041832|NCT06236932|Active Comparator|Mediterranean diet plus melatonin group|After the first 12 w of the study (T2), all patients will continue a hypocaloric MD adding the supplementation with 1mg/die of melatonin before bedtime for other 12w.
89041833|NCT06236919|Experimental|VR cognitive training|The VR cognitive training group will engage in a subset of six games with adaptive difficulty, designed to target specific cognitive functions.
89041834|NCT06236919|Active Comparator|VR nature-exposure relaxation group|The control group will be immersed in VR nature-based content and perform relaxation exercises.
89041835|NCT06236906|Experimental|Intervention|Child and parent in digi-physical family treatment
89041836|NCT06236867|Experimental|Kaleidoscope Group|In order for the patients in the kaleidoscope group to recognize the device and increase their compliance during the procedure, a practice was performed using the device before the AVF cannulation procedure. Kaleidoscope application was performed during cannulation.
89041837|NCT06236867|Experimental|Ice Application Group|Ice application application was made with non-melting ice molds to the area where the index finger and thumb of the hand with fistula are joined (HOKU point).
89041838|NCT06236867|Experimental|Control Group|In the control group, the vital signs of the patients before AVF cannulation will be recorded. Before, during and after AVF cannulation, VAS pain scores will be evaluated after cannulation without any intervention.
89041839|NCT06236854||POD-Absent|The group of older-aged surgical patients who are not diagnosed with delirium as assessed for the following fives days post-surgery.
89520882|NCT03430505|Active Comparator|Albuterol|400micrograms after bronchoprovocation with saline solution 4.5%.
89520883|NCT03434951|Experimental|Intrathecal morphine and bupivacaine|0,2mg intrathecal morphine and 12,5mg bupivacaine administered
89520884|NCT03434951|Active Comparator|Placebo|12,5mg bupivacaine and NaCl 0,9% to match the same volume administered
89520885|NCT04450589|Active Comparator|ALRV5XR|The ALRV5XR (active) group will receive ALRV5XR active treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the placebo products.
89520886|NCT04450589|Placebo Comparator|Placebo|The Placebo group will receive a placebo (vehicle) treatment. Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials (vehicle) as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.
89520887|NCT03430271|Active Comparator|Physical Activity (PA) Intervention|
89520888|NCT03430271|Placebo Comparator|Health Education (HE) Intervention|
89520889|NCT02234323|Experimental|rFVIIIFc|Participants were to receive rFVIIIFc as follows- Prophylaxis regimen (PR): rFVIIIFc 25-80 international units per kilogram (IU/kg), at 3- to 5-day intervals until participant reached greater than or equal to (>=) 50 exposure days (ED: 24-hour period in which >=1 injection/dose of rFVIIIFc was given), or study withdrawal/end of study. Adjustments to dose/dosing interval was done as needed by investigator; Treatment with an optional ER (Episodic regimen) can be initiated before PR at investigators discretion; ITI: rFVIIIFc 200 IU/kg, daily for participants who, after exposure to rFVIIIFc, had positive high titer inhibitor (>=5.00 Bethesda Units per milliliter [BU/mL]) or positive low titer inhibitor (>=0.60 and <5.00 BU/mL) and had poorly controlled bleeding despite increased rFVIIIFc doses, or required bypassing agent to treat bleeding.
89520890|NCT03434873|Active Comparator|Sacral magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over sacral roots
89520891|NCT03434873|Active Comparator|Cortical magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over motor cortex
89520892|NCT03430193|Experimental|FIRM group|FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward. PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.
89520893|NCT03430193|Active Comparator|Conventional group|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
89520894|NCT03430193|No Intervention|No-rehabilitation group|Discharged patients not transferred to rehabilitation unit after surgery for hip fracture.
89520895|NCT03128255||Regular Thyroid Work-up|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics. Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
89520896|NCT03128255||Regular Thyroid Work-up and I-124 PET/US|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
89520897|NCT03128645||Group 1|Standard method group
89520898|NCT03128645||Group 2|Abdominal corset group
89520899|NCT03429959|Experimental|SOCKNLEG|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
89520900|NCT03429959|Active Comparator|SIGVARIS Cotton|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
89635304|NCT02688192|Active Comparator|Arm I (Intervention)|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~Participate in a fitness program which includes:~8 group meetings of 90 minutes weekly~Behavioral internet based intervention engage in private social support messaging within the app and Facebook private groups and mobile app"
89635305|NCT02688192|Active Comparator|Arm II (Waitlist Control [WLC])|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~After waiting 6 months they will begin the fitness program as described in Arm I"
89635306|NCT01579565|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
89635307|NCT01579565|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
89635308|NCT01578785|Experimental|Glatiramer Acetate|Glatiramer acetate (GA) 20 mg/0.5 ml solution in prefilled syringe for subcutaneous injection once daily.
89635309|NCT01578785|Placebo Comparator|Placebo|Placebo solution in prefilled syringe for subcutaneous injection once daily.
89635310|NCT02692482|Experimental|polyurethane foam|Hydrocellular polyurethane foam multilayer dressing shaped for the sacral area
89635311|NCT02692482|Active Comparator|standard care|
89635312|NCT03167034|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
89635313|NCT03167034|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
89635314|NCT02392338|No Intervention|Thoracoscopic ablation group|Patients who will undergo thoracoscopic ablation only
89635315|NCT02392338|Active Comparator|Hybrid procedure|Patients who will undergo hybrid procedure (thoracoscopic ablation and eletrophyologic study with or without additional ablation)
89635316|NCT01578551|Experimental|Arm A|Paclitaxel, Carboplatin, Bevacizumab, and Metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning chemotherapy, if possible, but chemotherapy will not be delayed for metformin loading.
89635317|NCT01578551|Active Comparator|Arm B|Paclitaxel, Carboplatin, and Bevacizumab
89635318|NCT02392182||healthy volunteers|no intervention to be administered in this observational study, although all participants will undergo fiberoptic bronchoscopy.
89635319|NCT03106350||questionnaire|EORTC-QLQ-30 questionnaire
89635320|NCT03106428|Experimental|acute myeloid leukemia|Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available
89041840|NCT06236854||POD-Present|The group of older-aged surgical patients who are diagnosed with delirium as assessed for the following fives days post-surgery.
89041841|NCT06236828||Endovascular Thrombectomy|For patients who onset within 4.5 hours and meet the criteria for intravenous thrombolysis treatment, they could receive intravenous thrombolysis treatment beforehand and bridging to endovascular therapy.
89635321|NCT03106428|Experimental|Multiple Myeloma|Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen.
89635322|NCT03106428|Experimental|Diffuse Large B-cell Lymphoma|Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen.
89635323|NCT02392260|Experimental|Vasculight prototype zero level|
89635324|NCT03166878|Experimental|Treatment (UCART019)|"The UCART019 will be administered by i.v. injection over 20-30 minutes as a using a split dose approach to dosing: Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose"
89635325|NCT01692197|Experimental|E7070 + Idarubicin + Cytarabine|E7070 400 mg/m2 IV over 1 hour on day 1 and day 8 (+/- 2 days on Day 8 only) followed by, Idarubicin 8 mg/m2 IV over 1 hour daily for 3 days (days 9-11) and Cytarabine 1.0 g/m2 IV over 24 hours daily on day 9-12 (age <60 years) or days 9-11 (age > 60 years). Dexamethasone 10 mg IV daily for 3-4 days with cytarabine.
89635326|NCT01692119|Experimental|regular, pharmacy-based intervention|providing medication in weekly dosing aids and regular contacts with the local pharmacy
89635327|NCT01692119|No Intervention|usual care|usual care
89635328|NCT03165552|Experimental|Educational Arm|This group will receive an acute kidney injury educational intervention
89635329|NCT01691885|Experimental|A/B|Placebo followed by Fluticasone Furoate Vilanterol Combination
89635330|NCT01691885|Placebo Comparator|B/A|Fluticasone Furoate Vilanterol Combination followed by Placebo
89635331|NCT03166800|Placebo Comparator|Placebo|20 subjects will receive placebo.
89635332|NCT03166800|Active Comparator|20mg oral MitoQ|MitoQ is a potent antioxidant supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.
89635333|NCT03166800|Active Comparator|40mg oral MitoQ|MitoQ is a potent antioxidant supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.
89635334|NCT03166254|Experimental|Cohort A: Stage IV squamous NSCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
89635335|NCT03166254|Experimental|Cohort B: Extensive stage SCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
89635336|NCT02391870|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
89635337|NCT02651428|Experimental|Neutrolin arm|Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution
89635338|NCT02651428|Active Comparator|Heparin arm|Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution
89635339|NCT03166566|Other|laminar drainage implant surgery|patients included and operated
89635340|NCT01587703|Experimental|Single and Repeat Dose finding cohort|All subjects will follow a 3+3 dose escalation design for GSK525762 and the dose will be escalated based on all available data, including PK data and the safety profile of prior cohorts, as well as the recommended dose from the Neuenschwander- Continuous Reassessment Method (N-CRM) design.
89635341|NCT01587703|Experimental|Expansion Cohort|Up to 150 additional subjects with NMC and other solid tumors may be enrolled in expansion cohorts. The recommended Phase 2 (Part 2) dose (RP2D) of GSK525762 will be determined based on the MTD or biologically active dose (example: clinical response), the safety profile and available pharmacodynamic data generated from all subjects in Parts 1
89635342|NCT01587703|Experimental|Besylate Sub study|Tablet and amorphous tablet in one of the two sequences (ABCD or BACD). Where Treatment A: RP2D/MTD as amorphous free-base tablet + low dose stable isotope in solution, fasted Treatment B: RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment C: half to one-third of RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment D: RP2D/MTD as besylate tablet, fed
89635343|NCT01577381|Experimental|PF-04382923|
89635344|NCT01577381|Placebo Comparator|Placebo|
89635345|NCT02686164|Experimental|Lenvatinib + midazolam|Participants with histologically confirmed unresectable or refractory solid tumors.
89635346|NCT03167970||Pill cam and EGD|Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
89635347|NCT02651584|Experimental|SL BPN/NX tabs + placebo SC injections|"SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.~CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w)."
89635348|NCT02651584|Experimental|CAM2038 SC injections + SL placebo tabs|"CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 or 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).~CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).~SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily"
89635349|NCT01691105|No Intervention|Academic Detailing (AD)|Standard of care for patients who are smokers and admitted to the hospital.
89635350|NCT01691105|Experimental|AD + Integrated Tobacco Order Set|Access to the Integrated Tobacco Order Set (ITOS) Nicotine Replacement Therapy with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
89635351|NCT02685072|Experimental|TNP + Progesterone|Transdermal Nicotine Patch + Progesterone (200 mgs BID)
89635352|NCT02685072|Placebo Comparator|TNP + Placebo|Transdermal Nicotine Patch + Placebo (for Progesterone)
89635353|NCT02652208|Active Comparator|Online decision aid|This group will receive the access to an online decision aid that covers the main treatment options for stable chest discomfort.
89635354|NCT02652208|Active Comparator|Video decision aid|This group will receive the DVD and booklet decision aid describing stable chest discomfort and the main treatment options including medical therapy and stents.
89635355|NCT04339192|Experimental|Surgery group|receiving minimally invasive tricuspid surgery including tricuspid valve replacement or repair plus medical treatment.
89635356|NCT04339192|No Intervention|Medical group|receiving medical treatment only
89635357|NCT02653144|Experimental|dexmedetomidine and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml + 75mcg of dexmedetomidine
89635358|NCT02653144|Experimental|dexamethasone and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with. Ropivacaine 0.5% 20ml + 4mg dexamethasone
88990963|NCT05935202|Experimental|Mitapivat|"subjects who enter the Dose Escalation Period will receive an initial dose of 50 mg mitapivat BID. After 4 weeks dose will be increased from 50 mg BID to 100 mg BID unless dose-limiting side effects have occurred or maximum allowed Hb levels have been reached. Subjects who safely tolerate mitapivat may be eligible to continue in two consecutive 24-week Fixed Dose Periods, allowing patients to remain on their tolerated dose of mitapivat for up to 48 weeks after dose escalation. During the Fixed Dose Periods, the dose may not exceed the maximum dose that was used during Dose Escalation Period.~8 weeks: Dose Escalation Period 24-week: Fixed Dose Period 1 24-week: Fixed Dose Period 2"
88990964|NCT05931159|Experimental|Abdominal Hypopressive Training|The Abdominal hypopressive Exercises along with home plan based on conventional exercises.
88990965|NCT05931159|Active Comparator|Conventional Physical therapy for DrA|Draw-in maneuver in supine, quarduped, prone lying, bent leg fall outs, curl ups, and front and side planks.
88990966|NCT05930834|Experimental|Exercise|All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max
89211941|NCT04001985|Active Comparator|NG tube clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
89211942|NCT00856076||VTE case group 1/2|Women with first time venous thromboembolism in pregnancy. VTE data validated from medical records.
89211943|NCT00856076||VTE control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
89211944|NCT00856076||VTE control group 2|Randomly drawn from group 1 (using the Norwegian Birth Registry), but matched for time of delivery. Without history of venous thromboembolism, and with validated data from medical records.
89211945|NCT00856076||VTE case group 3|Subjects from VTE case group 1/2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
89211946|NCT00856076||VTE control group 3|Subjects from VTE control group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
89211947|NCT00856076||IUFD group 1|Women who have experienced IUFD - data verified from medical records.
89211948|NCT00856076||IUFD group 2|Subjects from IUFD group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
89211949|NCT00856076||IUFD control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
89211950|NCT00856076||IUFD control group 2|Subjects from VTE control group 1/2 with validated data from medical records.
89211951|NCT00856076||IUFD control group 3|Subjects from VTE control group 3 invited to answer a disease specific questionnaire for IUFD.
89211952|NCT00852332|Experimental|Curcumine|With curcumin capsules
89211953|NCT00852332|Active Comparator|Drug taxotere only|Without curcumin
89635359|NCT02653144|Active Comparator|ropivacaine only group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml (acting as control)
89635360|NCT00118365|Placebo Comparator|Arm II (placebo)|Patients receive oral double placebo once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
89635361|NCT00118365|Experimental|Arm I (eflornithine and sulindac)|Patients receive oral eflornithine (DFMO) and oral sulindac once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
89635362|NCT02695524|Active Comparator|Scapula-focused exercises|Side lying external rotation, prone horizontal abduction , Scapular punch, Knee Push, Full can, D1 Diagonal, three times a week, 8 weeks, 3x10 repetitions
89635363|NCT02695524|Experimental|Motor control exercises|Towel slide, Scapular Clock, PNF scapular, Inferior Glide modified, Scapular Orientation Exercise, protraction and retraction of scapula, three times a week, 8 weeks, 3x10 repetitions
89635364|NCT01576367|Experimental|canakinumab|Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)
89635365|NCT02653456|Experimental|RA-308 Excimer Laser and DABRA Catheter|Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
88990967|NCT05930457|Experimental|64Cu-FAPI-XT117 PET/CT|
88990968|NCT05925192||Chronic musculoskeletal pain patients|Chronic musculoskeletal pain patients
88990969|NCT05923996|Experimental|Microbotox injection|21 Egyptian patients with wide facial pores will be treated in a split-face manner. In this side of the face will received single session of microbotox injection contains 20 units of botulinum toxin A.
89211954|NCT00992043|Placebo Comparator|exercise and placebo|
89211955|NCT00992043|Experimental|exercise and creatine|
89211956|NCT00845234|No Intervention|Standard of Care Group|Received the current standard of care as operationally defined by the investigators- Q&A session + Video
89211957|NCT00845234|Experimental|Intervention Group|Intervention group- Patients will receive the brief educational CBT intervention + video and Q&A session
89211958|NCT00852410|Active Comparator|1% lidocaine with 1:100000 adrenaline|high dose adrenaline
89211959|NCT00852410|Active Comparator|1% lidocaine with 1:200,000 adrenaline|low dose
89211960|NCT00992121|Other|Part I and 2 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles
89211961|NCT00992121|Other|Part I and 3 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles
89211962|NCT00852488|Experimental|Catheter|Cohort undergoing catheter placement using the new technique being studied
89211963|NCT04002609||Group A, Active comparator|Patients in this group did not receive any rountine oxygen supplementation during the procedure. Rescue supplemental oxygen through nasal cannual was provided if clinically significant desaturation could be observed during bronchoscopy. This significant desaturation was defined as systemic oxygen saturation ≤90% on pulsoxymetry or a relative change of ≥ 4% lasting for 1 minute. N=31 patients
89211964|NCT04002609||Group B, Active comparator|Supplemental oxygen was provided for the patients through nasal cannula by a flow rate of 2 l/minutes throughout the procedure. N= 31 patients
89211965|NCT04002609||Group C, Active comparator|Supplemental oxygen administration through nasal cannula by a flow rate of 4 l/minutes throughout the procedure. N= 30 patients
89688519|NCT01724255||staple removal day 7, dressing removal day 7|late staple removal and late dressing removal
89688520|NCT01724255||staple removal day 7, dressing removal day 4|late staple removal and day 4 dressing removal
89688521|NCT02796352|Experimental|High dose bolus interleukin-2 (HD IL2)|
89688522|NCT00939367|Experimental|Test|Torrent's Zolpidem TartrateTablets 10 mg
89688523|NCT00939367|Active Comparator|Reference|Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg
89041842|NCT06236828||Standard Medical Therapy|For patients who onset within 4.5 hours and met the criteria for intravenous thrombolysis treatment, recombinant tissue plasminogen activator (rt-PA) or urokinase, and other intravenous thrombolysis therapies should be pre-administrated.
89635366|NCT05744622|Experimental|chemically cured conventional glass ionomer restorative (Ketac Universal Aplicap)|For restoration of M1 group, capsule activation will be performed through loading of the KetacTM Universal AplicapTM GIC capsule into its activator keeping the applicator nozzle closed, using the ball of my hand to depress the activator lever firmly as far as it will go and hold it down for 2 to 4 seconds. Then the capsule will be mixed in a high frequency mixing device for 8 seconds. The mixed capsule will be immediately removed from the mixer and loaded into the AplicapTM Applier then application nozzle will be opened to extrude the mixture directly into the preparation as a single bulk within 1:40 minute. The preliminary contour will be done using a ball burnisher.
89635367|NCT05744622|Experimental|Ketac Universal Aplicap enhanced with light-emitting diode radiant heat|Restoration of M2 group will be performed following the same steps which will be carried out for M1 group but the achieved restorations will be enhanced by light-emitting diode radiant heat for 60 seconds
89041843|NCT06236802|Experimental|ProVee treatment|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
89041844|NCT06236789||Castration-resistant prostate cancer patients treated with ifosfamide/mesna|
89041845|NCT06236750|Experimental|Patients with Non-Ischemic Chronic Wounds|Patients with intractable diabetic foot ulcer or venous leg ulcer that have not decreased in surface area by at least 50% after 4 weeks of conventional therapies.
89041846|NCT06236737|Experimental|Sensorimotor Exercise Group|Sensorimotor exercise group; oculomotor exercise to provide information from the visual system, laser target exercise to provide information from the proprioception system, and postural stability exercise to provide information from the vestibular system. Within the scope of oculomotor exercise, gaze stability exercise and head-body coordination exercise will be given to the participants. Laser target exercise will be given with the laser target fixed on the participant's head and 90 cm away from the target. Postural stability exercise will be given in the form of tandem exercise and standing on one leg.
89041847|NCT06236737|Experimental|Yoga Exercise Group|Yoga group will be given yoga exercises including 14 poses. These exercises are: bridge pose, corpse pose, bharadvaja's twist, downward facing dog, downward facing hero, extended side angle, extended triangle, mountain pose, prosperous pose, reclining big toe, standing half forward bend, thunderbolt pose, upward hand
89041848|NCT06236711|Experimental|tDCS interventional arm|Participants will receive a 30-minute tDCS treatments at 2 mA twice daily over the course of 5 days.
89041849|NCT06236698||Essential hypertension|Adult patients meet the ACC/AHA hypertension guidelines for a diagnosis of essential hypertension but without other obvious features of PA.
89041850|NCT06236698||Primary aldosteronism|Adult patients meet the Endocrine Society Clinical Practice Guidelines for a diagnosis of primary aldosteronism.
89635368|NCT01689857|Experimental|Scarclinic™ Thin|Scarclinic™ Thin
89635369|NCT01689857|Active Comparator|Scarclinic™ Normal|Scarclinic™ Normal
89635370|NCT03165240|Experimental|BI 690517 Dose 1|
89635371|NCT03165240|Experimental|BI 690517 Dose 2|
89635372|NCT03165240|Experimental|BI 690517 Dose 3|
89635373|NCT03165240|Experimental|Eplerenone|
89635374|NCT03165240|Placebo Comparator|Placebo|
89635375|NCT03165084|Experimental|Intervention arm|Participants in the intervention group will receive usual care, and also use a diabetesapp and a homepage and advice personally tailored according to the personal needs to provide support for them to manage e.g. food choices, exercise, medicine, blood sugars and emotional adaptation.
89635376|NCT03165084|Other|Control arm|Participants in the control group will receive usual care and also take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
89635377|NCT03165084|Other|External comparison group|An external comparison group will be recruited from two other primary health care centers in order to analyse possible Hawthorne effects.
89635378|NCT03165318|Active Comparator|Pulsed Electromagnetic Field Therapy|Active Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
89635379|NCT03165318|Sham Comparator|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
89635380|NCT05746416||s-TDAPT group|Ticagrelor 180mg + Aspirin 100mg within 6 months after index PCI
89635381|NCT05746416||l-TDAPT group|Ticagrelor 120mg + Aspirin 100mg within 6 months after index PCI
89635382|NCT01587079|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
89041851|NCT06236672||GLP-1 RA group|adult patients with T2D and CKD who initiated GLP-1 RA therapy
89041852|NCT06236672||basal insulin group|adult patients with T2D and CKD who initiated basal insulin therapy
89041853|NCT06236646|Experimental|Thai dance with twenty-five squares (TDT)|The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.
89041854|NCT06236646|Sham Comparator|Control (CON)|The CON group did not have any intervention but usual care.
89041855|NCT06236620|Active Comparator|Control wheat flakes|Wheat flakes made of whole derived from unprocessed wheat
89041856|NCT06236620|Active Comparator|Flakes from sprouted wheat|Wheat flakes made of whole derived from sprouted wheat
89041857|NCT06236620|Active Comparator|Flakes from hydrothermally processed wheat|Wheat flakes made of whole derived from hydrothermally processed wheat
89635383|NCT01587079|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
89635384|NCT01587079|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
89635385|NCT01587079|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
89635386|NCT01587079|Experimental|PT003 (Dose 5)|PT003 MDI Dose 5
89635387|NCT01587079|Experimental|PT001|PT001 MDI
89635388|NCT01587079|Experimental|PT005|PT005 MDI
89635389|NCT01587079|Active Comparator|Spiriva® Handihaler®|Tiotropium Bromide
89635390|NCT03028909|Experimental|Oseltamivir + low dose MEDI8852|Low Dose of MEDI8852 + Oseltamivir will be studied
89635391|NCT03028909|Experimental|Oseltamivir + high dose MEDI8852|High dose of MEDI8852 + Oseltamivir will be studied.
89688524|NCT01724333||Group 1- in active treatment|Questionnaires only
89041858|NCT06236607|Active Comparator|Multiple daily injections|Participants randomized into this arm will use multiple daily injections of insulin.
89041859|NCT06236607|Experimental|BetaBionics iLet HCL system|Participants randomized into this arm will use the BetaBionics iLet HCL system.
89041860|NCT06236607|Experimental|Insulet OP 5 HCL system|Participants randomized into this arm will use the Insulet OP 5 HCL system.
89041861|NCT06236607|Experimental|Tandem Control IQ HCL system|Participants randomized into this arm will use the Tandem Control IQ HCL system.
89057555|NCT01179334|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
89057556|NCT01179334|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
89057557|NCT01649583|Experimental|Jaw Dynasplint System|
89635392|NCT03028909|Active Comparator|Oseltamivir + Placebo|Oseltamivir in conjunction with placebo will be studied.
89635393|NCT02654860|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
89635394|NCT02654860|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
89635395|NCT02654860|Experimental|120 mg Paracetamol 3% (4mL)|120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
89635396|NCT02654860|Placebo Comparator|Phase II Only: Saline solution 0.9%|Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
89635397|NCT01587001|Active Comparator|Oral N-acetyl-cysteine|oral NAC 900mg three times daily for 8 weeks
89635398|NCT01587001|Placebo Comparator|Matching Placebo|oral placebo three times daily for 8 weeks
89635399|NCT02656420|Placebo Comparator|Placebos|Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
89635400|NCT02656420|Experimental|High Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
89635401|NCT02656420|Experimental|Medium Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
89635402|NCT02656420|Experimental|Low Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
89635403|NCT00367900||NIH-AARP Diet and Health Study sub study: PAGE|Diet and Health Study members who self-reported a Parkinson's disease (PD) diagnosis on a follow-up questionnaire, and randomly selected controls, will participate in the PAGE sub study.
89635404|NCT04739644|Experimental|Experimental: WRISTBOT Group|"The patients in the WRISTBOT Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation by WRISTBOT device"
89635405|NCT04739644|Active Comparator|Control group|The patients in the Control Group underwent to following interventions: 1. General Rehabilitation 2. Specific wrist rehabilitation performed by physiotherapist.
89635406|NCT01568047|Placebo Comparator|Placebo|"PLC, Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
89635407|NCT01568047|Experimental|BIA 9-1067 - 5 mg|"5 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
89057558|NCT01649583|No Intervention|Control Arm|
89057559|NCT02886520|Active Comparator|PVDF transobturator tape|Transobturator tension-free suburethral tape made of polyvinylidene fluoride.
89635408|NCT01568047|Experimental|BIA 9-1067 - 15 mg|"15 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
89635409|NCT01568047|Experimental|BIA 9-1067 - 30 mg|"30 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
89635410|NCT04739488|Experimental|Breathing exercise and inhaler training|This group were given pursed lip breathing exercise and inhaler training.
89635411|NCT04739488|Experimental|inhaler training|This group were given only inhaler training
89635412|NCT01688999|Experimental|Cabozantinib|Administered orally at a dose of 60 mg once daily on each day of a 28-day cycle.
89635413|NCT02658994|Experimental|THPP+|As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
89635414|NCT02658994|Active Comparator|Enhanced Usual Care|Women in the control clusters who were depressed prenatally have been receiving Enhanced Usual Care (EUC). At the time of the screening, women, their Lady Health Workers, and their local primary health care facility were informed of the diagnosis, and women were given an information sheet about depression and how to access care. There are no new EUC protocols put in place post-partum as part of the THPP+.
89635415|NCT01541917|Experimental|Web-based coping skills training|Involves completion of a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support.
89635416|NCT01541917|Active Comparator|Online disease education|Involves viewing 12 educational websites about Juvenile Idiopathic Arthritis over the course of 12 weeks.
89635417|NCT05746338|Experimental|Ring-type wearable device|The ring-type wearable device achieved continuous monitoring of blood oxygen saturation during sleep and established a OSAS screening algorithm based on oxygen saturation, which might become a complement to polysomnography.
89688525|NCT01724333||Group 2 - 2-6 months post-treatment|Questionnaires only
89635418|NCT05746338|Active Comparator|Polysomnography|Overnight polysomnography (PSG) monitor was used as the gold standard to: 1) examine the accuracy of blood oxygen monitoring assessed via a ring-type wearable device in comparison to traditional finger clip pulse oximeter; 2) assess the agreement between the ring-type wearable device and PSG monitor on OSAS screening.
89635419|NCT02660788|Active Comparator|Control Arm|Mail
89635420|NCT02660788|Experimental|Family Physician Reminder Letter Arm|Mail
89635421|NCT03166410|Experimental|Cell Treatment|
89635422|NCT01688921|Experimental|STRATIS Needle-Free|Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
89635423|NCT01688921|Active Comparator|Needle-Syringe|Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
89635424|NCT00118755|Experimental|1|
89635425|NCT00118755|Active Comparator|2|
89635426|NCT03165006||Screened women with breast cancer|
89635427|NCT02661256|Active Comparator|on NCPAP|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS) while NCPAP was administered via a RAM cannula® (intervention). With the NCPAP turned on each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow), a total of 20 swallows were recorded. These swallows were termed on NCPAP swallows. The swallows were assessed in real time for any swallowing dysfunction."
89635428|NCT02661256|Active Comparator|Off NCPAP|"Immediately following the on NCPAP condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed off NCPAP swallows."
89635429|NCT03166488|Experimental|Tricuspid Valvular Repair Patients|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE) within 1 month preoperatively and as close to 6 months postoperatively as reasonably achievable.
89635430|NCT01541371|Experimental|Paliperidone ER|
89635431|NCT00121173|Experimental|Low dose|"3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals.~Genetic (recombinant DNA vaccine)"
89635432|NCT00121173|Experimental|Intermediate dose|3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
89635433|NCT00121173|Experimental|High dose|3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
89635434|NCT02662036|Active Comparator|Group 1: Bupivicaine|-TAP block of 30 cc of 0.25% bupivicaine
89635435|NCT02662036|Experimental|Group 2: Liposomal bupivacaine|-TAP block of 266 mg/30 cc liposomal bupivacaine
89635436|NCT01687673|Experimental|Treatment|Combination temsirolimus plus sorafenib
89635437|NCT00121251|Experimental|Sorafenib + Gemcitabine + Capecitabine|Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.
89635438|NCT04546139||fast group|
88990970|NCT05923996|Experimental|Fractional carbon dioxide laser in second side of the face|21 Egyptian patients with wide facial pores will be treated in a split-face manner. In this side will be treated by Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals.
88990971|NCT05922215|Experimental|Experimental Group|
88990972|NCT05922215|Active Comparator|Control Group|
88990973|NCT05919485|Experimental|Interventional-DLPFC|DLPC/F3-F4 group will consist of 20 PD-MCI patients and 20 aMCI patients; 2mA anodal tDCS over DLPFC The current density will be 0.06mA/cm2 from each electrode with total density of 0.054/cm2 and will be delivered for 20 minutes for the atDCS group for 5 days a week, for 10 days and a total of 10 sessions in 14 days.
88990974|NCT05919485|Experimental|Interventional-LPC|LPC/P3-P4 group will consist of 20 PD-MCI patients and 20 aMCI patients; 2mA anodal tDCS over LPC The current density will be 0.06mA/cm2 from each electrode with total density of 0.054/cm2 and will be delivered for 20 minutes for the atDCS group for 5 days a week, for 10 days and a total of 10 sessions in 14 days.
88990975|NCT05919485|Sham Comparator|Sham|"Sham control group will consist of 40 patients (20 aMCI and 20 PD-MCI patients).~2mA anodal sham tDCS protocol. For the sham protocol, the stimulation will be delivered for one time with a very low current frequency, enough to cause slight tingling, and for 15 seconds long which will also be delivered for 20 minutes, 5 days a week, for 10 days and a total of 10 sessions in 14 days."
89635439|NCT04546139||slow group|
89635440|NCT02664220|Experimental|Povidone-iodine irrigation|
89635441|NCT02664220|Active Comparator|No irrigation|
89635442|NCT02664532|Experimental|Miller group|In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
89635443|NCT02664532|Other|Macintosh group|In Macintosh group, the curved blade was introduced to lift the base of the epiglottis to visualize larynx and then trachea intubated conventionally.After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
89635444|NCT04339348|Experimental|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus vaginal inert placebo cream at the time of IUD insertion
89635445|NCT04339348|Active Comparator|lidocaine prilocaine cream|Lidocaine-prilocaine anesthetic cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo will be given 3 hours before LNG-IUD insertion
89635446|NCT04339348|Placebo Comparator|placebo|inert vaginal placebo cream will be placed on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours before LNG-IUD insertion
89635447|NCT02664922|Experimental|Sedation - Group 1|Sedation - monitored anesthesia with propofol.
89635448|NCT02664922|Experimental|Sedation - Group 2|Sedation - monitored anesthesia with ketamine + propofol
89635449|NCT02664922|Experimental|Sedation - Group 3|Sedation - monitored anesthesia with remifentanil + propofol
89635450|NCT02664922|Experimental|General Anesthesia - Group 1|General anesthesia (GA) with Sevoflurane + O2
89635451|NCT02665468|Other|Arm 1: Supported Adoption Intervention (SAI)|Supported adoption intervention
89635452|NCT02665468|Active Comparator|Arm 2: General wellness information|General wellness information
89635453|NCT02666560|Active Comparator|Auditory cueing at self paced cadence|Participants performed a functional task with auditory cueing set at self paced cadence.
89635454|NCT02666560|Experimental|Cueing at 20% above self paced cadence|Participants performed a functional task with auditory cueing set at 20% above self paced cadence whilst performing a functional task.
89635455|NCT02666950|Experimental|Arm B (cytarabine and WEE1 inhibitor AZD1775|Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
89635456|NCT02666950|Experimental|Arm C (WEE inhibitor AZD1775)|Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
89635457|NCT02668198|Experimental|Endoscopic scar assessment|Using endoscope with high definition white light, high definition white light with near focus, narrow band imagining, and narrow band imaging with near focus.
89635458|NCT02668432|Experimental|Partial Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive <4g IV or < 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
89635459|NCT02668432|Active Comparator|Full Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
89635460|NCT01687595|Experimental|HerpV 240 μg + QS-21 50 μg|Participants will receive a combination of HerpV 240 micrograms (μg) and QS-21 50 μg injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1. At Week 24, participants who completed treatment period 1 will receive a booster dose of combination of HerpV 240 μg and QS-21 50 μg in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
89635461|NCT01687595|Placebo Comparator|Placebo|Participants will receive a placebo injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1 and at Week 24 in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
88990976|NCT05917873|Experimental|LaKe arm|Ingestion of a combined lactate and ketone body ester, 25 ml twice daily for 28 days.
88990977|NCT05917873|Placebo Comparator|Placebo arm|Placebo treatment
88990978|NCT05916820|Experimental|Tanzberger Exercises|It consist of patients who will receive Tanzberger exercises 3 sessions per week for 4 weeks.
88990979|NCT05916820|Experimental|Pelvic floor muscle training|It consists of patients who will receive pelvic floor muscle training 3 sessions per week for 4 weeks.
88990980|NCT05915988|Other|open-label|UNEEG EpiSight solution
88990981|NCT05913895|Experimental|hydrogen water|At the end of cancer treatment (chemotherapy, radiotherapy, or Chemoradiotherapy), a hydrogen water gargle (dissolved for 12 hours or longer) was administered by the investigator or a researcher every Monday through Friday. The changes in six scales described above were tracked in the experimental and control groups on days 1 (T1), 3 (T2), 7 (T3), and 14 (T4) after the end of treatment.
89057560|NCT02886520|Active Comparator|PP transobturator tape|Transobturator tension-free suburethral tape made of polypropylene.
89635462|NCT01687283|Experimental|fluticasone propionate|1 mg BID inhalation via nebulizer
89635463|NCT01687283|Active Comparator|budesonide suspension|2 mg BID inhalation via nebulizer
89635464|NCT02684370|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89635465|NCT02684370|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89635466|NCT02684370|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
89635467|NCT02669914|Experimental|Cohort A: Non-small cell lung cancer w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
89635468|NCT02669914|Experimental|Cohort B: Epithelial origin solid tumors w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
89635469|NCT02669914|Experimental|Cohort C: NSCLC or non-NSCLC w/corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
89635470|NCT01686581||BOTOX®|BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.
89635471|NCT04739410|Experimental|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12mg stat per oral and then 12 mg per oral after 12 hours and 12mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue. and any side effects of the drugs were noted as well.
89635472|NCT04739410|Placebo Comparator|SOC standard of care|These participants were given standard of care without Ivermectin standard of care only symptomatic treatment
89635473|NCT03165864|Experimental|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
89635474|NCT03165864|Placebo Comparator|Placebo|Saline .9%
89688526|NCT01724333||Group 3 - 6 mos-3yrs post-treatment|Questionnaires only
89688527|NCT01724333||Group 4 - Palliative treatment|Questionnaires only
89520901|NCT03434639||1 - Ophthalmology patients|Ophthalmology patients who are receiving an intravenous dose of either fluorescein or indocyanine green (ICG) as part of their routine ophthalmic care (e.g. as part of a fluorescence angiography examination) will be recruited to the first stage of this study. These patients will take part in preliminary studies aimed at determining whether it is possible to detect fluorescein and ICG in the blood using transcutaneous fluorescence measurements.
89520902|NCT03434639||2a - Healthy subjects|Healthy subjects with no known issues of increased gut permeability. These subjects will act as negative controls in all gut permeability studies.
89520903|NCT03434639||2b - Healthy subjects (gastric emptying)|A subset of healthy volunteers will be recruited to take part in experiments to help in understanding the impact of gastric emptying rate as a confounding factor in measurements of gut permeability.
89520904|NCT03434639||3 - Increased permeability|Gastro-intestinal (GI) and non-GI patients who are expected to exhibit increased gut permeability (e.g. patients with celiac disease, inflammatory bowel disease (IBD), liver disease, HIV or another condition in which increased intestinal permeability is common). The more extreme cases in this group will act as positive controls.
89520905|NCT03128177|Experimental|High sodium diet|High sodium diet is 6 g sodium per day for 10 days
89520906|NCT03128177|Experimental|Low sodium diet|Low sodium diet is 1.5 g sodium per day for 10 days
89520907|NCT04449653||Lupus Cases|Individuals who are diagnosed with System Lupus Erythematosus and consent to the study will be placed in this cohort. Upon enrollment they will be given the opportunity to invite a non-SLE-diagnosed friend to enroll in the study as a healthy control. These individuals will answer weekly questions and receive a smartwatch to measure their physical activity.
89520908|NCT03434483||Acute Coronary Syndrome|Patients with an episode of acute coronary syndrome. Clinical evaluation 1 year. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
89520909|NCT03434483||ACS-Angiographic substudy|"Patients included in the Acute Coronary Syndrome group with clinical indication for revascularization.~Clinical evaluation. Assessment of the atherosclerotic plaque in a moderate lession at baseline and 1-year .~Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis"
89520910|NCT03434483||Chronic coronary atherosclerosis|Patients with chronic atherosclerosis. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
89520911|NCT03434405|Experimental|SocialMind|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
89520912|NCT03434327|Experimental|Strength Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
89520913|NCT03434327|Experimental|Power Training|For power training the subjects will perform the concentric phase at high speed, while eccentric portion will last approximately 2 sec. Loads will vary from 30-80% of the subject's maximum depending on the biomechanical nature of the joints involved in the exercise. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
89520914|NCT04449419||very severe COPD|Patients diagnosed with COPD and FEV1 less than 30
89520915|NCT04449419||Severe COPD|Patients diagnosed with COPD and FEV1 less than 50
89520916|NCT04449419||Moderate COPD|Patients diagnosed with COPD and FEV1 less than 80
89520917|NCT04449419||Mild COPD|Patients diagnosed with COPD and FEV1 80 or more.
89520918|NCT04449419||CONTROL|Non-copd control group
89520919|NCT04449419||Exacerbated Patients|Patients 48 hours after hospital admission for COPD exacerbation.
89520920|NCT03429881|Active Comparator|Laparoscopic stripping ovarian endometriomas|
89520921|NCT03429881|Active Comparator|Laser CO2 treatment ovarian endometriomas|
89520922|NCT03434171|Active Comparator|Aerobic excercise|women who practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
89520923|NCT03434171|Active Comparator|Dietary modfications|women who received diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
89520924|NCT03434093|Active Comparator|PPC-DLPFC|In this arm, the TMS paired-pulses will be first delivered over the posterior parietal cortex (PPC) and then over the dorsolateral prefrontal cortex (DLPFC)
89520925|NCT03434093|Active Comparator|DLPFC-PPC|Arm Description: In this arm, the TMS paired-pulses will be first delivered over the over the dorsolateral prefrontal cortex (DLPFC) and then posterior parietal cortex (PPC)
89520926|NCT04247399|Experimental|Simulation-based learning + clinical training|
89520927|NCT04247399|No Intervention|Clinical training|
89520928|NCT03429725|Experimental|Individualism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For individualism condition, participant is tasked to write statements relating to his/her differences from the his/her immediate community, circle pronouns that relate to the self, and read passages related to individualism.
89520929|NCT03429725|Experimental|Collectivism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For collectivism condition, participant is tasked to write statements relating to his/her similarities to the his/her immediate community, circle collective pronouns, and read passages related to collectivism.
89520930|NCT03128567||Stimulation of the subthalamic nucleus|25 patients with Parkinson's disease
89520931|NCT03128567||Best medical treatment|25 patients with Parkinson's disease
89520932|NCT03429647|Other|Sigmoid perfusion|Measured by visible light spectroscopy
89635475|NCT02672176|Sham Comparator|Usual Care-Chronic Disease Management|Usual Care through Chronic Disease Management: The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
89635476|NCT02672176|Active Comparator|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (2, 3). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org).
89635477|NCT04545749|Experimental|Group A (Low dose)|20 subjects will be enrolled to receive low dose of UB-612 vaccine.
89635478|NCT04545749|Experimental|Group B (Medium dose)|20 subjects will be enrolled to receive medium dose of UB-612 vaccine.
89635479|NCT04545749|Experimental|Group C (High dose)|20 subjects will be enrolled to receive high dose of UB-612 vaccine.
89635480|NCT02691936|Experimental|CO2 fractionated vaginal laser|Postmenopausal women will undergo treatment intravaginally with the fractional microablative CO2 laser system MonaLisa Touch vaginal laser protocol x 3 time points at baseline, 6 weeks and 3 months.
89635481|NCT02691936|Active Comparator|Estrogens, Conjugated (USP)|The women in the vaginal estrogen group will be prescribed and asked to administer the conjugated estrogen cream 0.5 g of cream equivalent to 0.625 mg of conjugated estrogen.
89635482|NCT04739332|Experimental|NBO intervention for at-risk mothers|NBO intervention for at- risk mothers. 3 NBO sessions added to the routine follow-up delivered once per week during the first month postpartum. The intervention is delivered by a nurse certified in the NBO system.
89635483|NCT04739332|No Intervention|Treatment as usual|Participants receive 3 routine follow-up by the local health visitor/midwife during the first month
89635484|NCT04339114|Sham Comparator|Control meal|Pancake
89041862|NCT06236581|Experimental|GEM Intervention|A lifestyle coach will deliver the GEM intervention over 4 weeks in person and/or virtually (synchronously) to permit interaction with participants. A pocket-sized manual will be provided with 4 units corresponding to session topics, and diary pages to record glucose responses to food and physical activity (PA). Session 1: Introduce GEM, identify personal motivation, learn about foods that cause glucose to go high (high glycemic load (GL) foods) and those that do not (low GL foods), learn how physical activity affects glucose, and begin monitoring how these choices affect glucose. Session 2: Replacement, substitution, and portion control to reduce consumption of high GL foods. Session 3: Increasing PA and reducing sedentary behavior, esp. after a meal. Session 4: Ways to continue lifestyle changes over a lifetime, handle relapses, and thank loved ones for their support. Text message reminders may be sent to participants between sessions to prompt diary entries and for encouragement.
89635485|NCT04339114|Active Comparator|Control meal + Cinnamon|Pancake seasoned with cinnamon
89635486|NCT04339114|Active Comparator|Control meal + Italian herb mix|Pancake seasoned with Italian herb mix
89635487|NCT04339114|Active Comparator|Control meal + Active-Herbs/Spice mix|Pancake seasoned with pumpkin spice
89635488|NCT04707898|Experimental|Group Single Bond Universal|Single Bond Universal adhesive system with selective-etch approach following the manufacturer's instruction
89635489|NCT04707898|Experimental|Group G-Premio Bond|G-Premio Bond Adhesive System with selective-etch approach following the manufacturer's instruction
89635490|NCT04707820|Experimental|Patient group|- Patient with an acute SARS-CoV-2 infection, confirmed by PCR or typical CT images, requiring hospitalization in a COVID unit at Rouen University Hospital.
89635491|NCT04707820|No Intervention|control group|- Rouen University Hospital staff free of any symptomatology compatible with an SARS-CoV-2 infection (fever, cough, fatigue, loss of taste, loss of smell) since February 1, 2020
89635492|NCT04707742|Experimental|Povidone-iodine 2% (Betadine© bucal 100 mg/ml)|"Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain).~The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (3 mL of povidone-iodine 10% for oral use - Betadine© with 12 mL of distilled water)."
89635493|NCT04707742|Experimental|Hydrogen peroxide 1% (Oximen® 3%)|Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain). The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (5 mL of hydrogen peroxide 3% - Oximen© with 10 mL of distilled water).
89635494|NCT04707742|Experimental|Clorhexidine 0,12% (Clorhexidine Dental PHB©)|"Clorhexidine 0,12% (Clorhexidine Dental PHB©) contains clorhexidine (C22H30N10Cl2).~Rinses were ready to use in their commercial formulas."
89041863|NCT06236581|No Intervention|Waitlist|Participants will be invited to receive the GEM intervention after they posttest, the next time it is offered.
89041864|NCT06236555|Other|Kahramanmaraş Sütçü İmam University|Patients who apply to our clinic for routine periodontal treatment will be included in the study.
89041865|NCT06236542|Experimental|Automated tracheostomy suctioning device|Participants in this group will receive tracheostomy suctioning using an automated robotic suctioning device.
89635495|NCT04707742|Experimental|Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©)|"Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©) contains cetylpyridinium chloride (C21H38ClN).~Rinses were ready to use in their commercial formulas."
89635496|NCT04707742|Placebo Comparator|Control (Distilled Water)|Distilled water.
89635497|NCT02679976|Experimental|Study Lens (etafilcon A) for Multifocal|All Subjects in this study will wear the same contact lenses. However subjects wil be stratified as Hyperopes or Myopes using a 1:1 allocation. The study lens will be worn for a period of approximately 4 hours to allow lenses to settle on the eyes.
89635498|NCT02680054|Active Comparator|Arm 1 (usual treatment)|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
89635499|NCT02680054|Active Comparator|Arm 2|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
89688528|NCT01724333||Group 5 - Referred to dentist/oral team|Questionnaires only
89688529|NCT01724411|Experimental|Resistant Starch 3|Resistant Starch Type 3:dose of 26g/day males and 22g/day female during 11 days of the maintenance period. (C ActiStar 11700, Tapioca Maltodextrin, Cargill, Belgium)
89520933|NCT02414828|Placebo Comparator|Placebo|Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
89520934|NCT02414828|Experimental|AERAS-402 3 x 10^8 vp|AERAS-402: 1.0 mL containing 3 x 10^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
89520935|NCT02414828|Experimental|AERAS-402 3 x 10^9 vp|AERAS-402: 1.0 mL containing 3 x 10^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
89520936|NCT02414828|Experimental|AERAS-402 3 x 10^10 vp|AERAS-402: 1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
89520937|NCT04450433||Baseline table of patients|
89520938|NCT04450433||Differential metabolites of two groups of control patients|
89520939|NCT04450433||Functional verification of differential metabolites|
89520940|NCT02413346|Experimental|Placebo/Sarecycline|Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
89520941|NCT02413346|Experimental|Sarecycline/Sarecycline|Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
89520942|NCT04450121|Active Comparator|GA (n =22)|Patients will be intubated using Air-Q airway
89041866|NCT06236542|Experimental|Mixed-reality tracheostomy tube change system|Participants in this group will receive tracheostomy tube changes using a mixed-reality tracheostomy tube change device.
89041867|NCT06236542|Experimental|NextGen Tracheostomy Toolkit|Participants in this group will receive tracheostomy care using the NextGen Tracheostomy Toolkit. Providers will be trained using virtual reality educational modules. Participants in this group will receive tracheostomy suctioning using an automated robotic suctioning device and tracheostomy tube changes using a mixed-reality tracheostomy tube change device.
89520943|NCT04450121|Active Comparator|GF (n =22)|Patients will be intubated using Fekry airway
89520944|NCT03585257|Experimental|IV albumin|25% IV albutein (albumin) formulation will be infused 1.0g/kg IV over one hour weekly for 5 weeks
89520945|NCT03585257|Placebo Comparator|Placebo|Normal saline will be infused 1.0g/kg IV over one hour weekly for 5 weeks
89520946|NCT03433937|Experimental|Negative pressure wound therapy|
89520947|NCT03433937|Active Comparator|Control|Micropore tape
89520948|NCT03433859|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb
89520949|NCT03433859|Active Comparator|Topical Aluminium Chloride|Topical Aluminium Chloride (cosmetic product) on the lower limb
89520950|NCT03429569|Sham Comparator|accelerated conventional technique|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
89520951|NCT03429569|Sham Comparator|iontophoresis|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
89520952|NCT03429491|Placebo Comparator|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
89520953|NCT03429491|Experimental|Leucine-enriched protein|Juice based supplement containing leucine-enriched protein
89520954|NCT03429491|Experimental|Leucine-enriched protein + LC n-3 PUFA|Juice based supplement containing leucine-enriched protein and LC n-3 PUFA
89520955|NCT03429257||Pregnant Women in Mukono Uganda|Single-group study
89520956|NCT03429179|Experimental|High anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety butorphanol group were >10，and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
89520957|NCT03429179|Placebo Comparator|High anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety 0.9% saline group were >10, and received an infusion of the same volume of 0.9% saline
89520958|NCT03429179|Experimental|Low anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety butorphanol group were ≤10,and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
89520959|NCT03429179|Placebo Comparator|Low anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety 0.9% saline group were ≤10, and received an infusion of the same volume of 0.9% saline
89635500|NCT02680054|Active Comparator|Arm 3|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
89635501|NCT02681458||Drug Users|Case group that consisted of drug users with fungal infections
89520960|NCT03429101|Experimental|Poziotinib|"Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.~Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD."
89520961|NCT04173689|Active Comparator|Inspiratuar muscle training group|This group will be given inspiratory muscle training (IMT) at home for 15 minutes twice a day for 7 days a week with the resh Threshold IMT 'device. In the IMT group, the initial training intensity will be determined by measuring the maximal inspiratory muscle strength (MRP) with the intraoral pressure measuring device, 30% of the measured MRP value will be started at the first evaluation and the new training intensity will be determined by calculating 30% of the measured value by repeating the MRP measurement every week.
89520962|NCT04173689|Active Comparator|Exercise group|This group will perform upper extremity and trunk exercises combined with breathing exercises at home for 7 days, twice a day for 15 minutes. Patients in both groups will perform a single 15-minute session once a week at the hospital under the supervision of a physiotherapist.
89211966|NCT02545946|Active Comparator|Traditional|cutaneous abscess with be opened in the traditional incision and drainage technique with large incision, breaking up of pockets of pus, washing out the pocket and with or without packing gauze placed into residual cavity
89520963|NCT03433625|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
89520964|NCT03433625|No Intervention|Waiting list|6 week wait (with assessments) before being transferred to the experimental condition.
89520965|NCT04449575||Health care workers with hand eczema|Swabs will be taken from eczema lesions on dominating hand (if possible) and nostril
89520966|NCT04449575||controls (health care workers without hand eczema)|swabs will be taken from healthy skin on dominating hand and nostril
89520967|NCT03433547|Experimental|Buckle|Macular buckling, Limbal paracentesis, and intraocular gas injection.
89520968|NCT03433547|Active Comparator|Vitrectomy|Vitrectomy, peeling internal limiting membrane, and gas tamponade.
89520969|NCT04449107|Experimental|Intervention Arm|The intervention arm in addition to the standard counselling will include receiving text messages, voice messages, pictorial messages and video messages regarding vaccination once a week till the child turns 14 weeks
89041868|NCT06236542|No Intervention|Control group|Participants in this group will receive usual tracheostomy care.
89041869|NCT06236529|No Intervention|Control|Participants receive no intervention.
89041870|NCT06236529|Active Comparator|Self-management program (SMP)|Participants engage in a nurse-led evidence-based web-enabled group self-management class for 6 weeks.
89041871|NCT06236529|Experimental|Self-management program (SMP) with Health Behavior Change Counseling (HBCC)|Participants engage in a nurse-led evidence-based web-enabled group self-management class for 6 weeks and receive three telephone-based health behavioral change counseling sessions based on the principles and practices of motivational interviewing.
89520970|NCT04449107|No Intervention|Control Arm|The control group will receive one-time standard verbal counselling at the time of initial visit for on-time EPI vaccines at 10 and 14 weeks of age as recommended by EPI, government of Pakistan.
89520971|NCT04048343|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
89520972|NCT04016753|Experimental|Monotherapy|
89520973|NCT04449887|Experimental|The treatment group|The subjects in this group were treated with Xiangsha Liujunzi granule for 4 weeks
89520974|NCT03428789||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction with additional sensory nerve coaptation.
89520975|NCT03428789||Non-innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction without sensory nerve coaptation.
89520976|NCT04449809|Experimental|Exercise|Exercise program
89520977|NCT03390101|Experimental|BCD-085 Q2W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50."
89041872|NCT06236503|Experimental|Real Stimulation|Time A. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. Time C. Behavioral assessment using the coma recovery scale-R (CRS-R). Rest Period 2 months.
89041873|NCT06236503|Placebo Comparator|Placebo Stimulation|Time A. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time D: Behavioral assessment using the coma Recovery Scale-R (CRS-R).
89041874|NCT06236412|Experimental|Intervention arm 1: pregnant woman alone|"Breastfeeding education:~Breast milk features, contents, advantages, how to improve its quality, and quantity.~Pre-lacteal feeding: meaning, addressing misconceptions, to avoid any foods/fluids up to 6 months and its harmful effects Colostrum feeding: meaning, its contents, advantages and addressing related misconceptions Early initiation of breastfeeding: proper time to initiation of breastfeeding & advantages for mother & child Exclusive breastfeeding: meaning, advantages, how long to exclusively breastfed.~They will also receive iron suphate/folic acid supplementation as recommended practice, at least for 90 days (90+ days)"
89057561|NCT01649622|Experimental|Bendamustine|"Patients receive Bendamustine at dose of 75 mg/m2 by vein over 30 minutes twice daily for four days (Days 1-4). Bendamustine dose based on actual body weight.~Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses."
89520978|NCT03390101|Experimental|BCD-085 Q4W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50."
89520979|NCT03390101|Placebo Comparator|Placebo|"Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50."
89520980|NCT02732639|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
89057562|NCT04538300|Active Comparator|Group Gum|"Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.~Degree of nausea and Abramowitz Emezis score were evaluated as the interventions. If PONV persists second chewing gum was gived. 15 minutes later PONV was evaluated. If PONV was persisted ondansetron 4 mg, then dexamethasone 4 mg , then propofol 10 mg intravenously were given, respectively."
89520981|NCT05063747||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 is defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) diagnosis U07.1 in the nationwide Swedish intensive care registry.
89520982|NCT05063747||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up not including patients in the COVID-19 ICU cohort. COVID-19 is defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
89520983|NCT05063747||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. ICU and hospital admitted COVID-19 patients are not included.
89520984|NCT03232151|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
89520985|NCT05045495||Healthy Volunteer|120 Healthy Volunteers will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
89520986|NCT05045495||CSID Case|50 CSID cases defined by being on Sucraid for at least 12 months will perform the 50-gram sucrose challenge test, Sucrose hydrogen methane breath test, 13C-sucrose breath test and collect buccal swab samples for genetic testing.
89520987|NCT02732561|Sham Comparator|Sham Device|Sham device
89520988|NCT02732561|Active Comparator|Intervention|CES device. cranial electrotherapy stimulation device. Alpha Stim device
89520989|NCT03423563|Experimental|Flexible fiberoptic bronchoscopy|Fiberoptic intubation has been considered for a long time the gold standard technique for intubation when there is anticipated or known difficult airway or as a rescue device in can't intubate but can ventilate scenarios
89520990|NCT03423563|Experimental|Fexible intubation video endoscopy|Video-assisted techniques allow to indirectly visualize the laryngeal structures with fiber optical or camera chip technique and to show the video picture on an external or built-in monitor
89520991|NCT03428555|Experimental|Integrate Care Pathway|"The intervention is an Integrated Care Pathway with 3 key components.~Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People.~Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol.~Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD)."
89520992|NCT03428555|Active Comparator|Treatment As Usual|Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.
89520993|NCT02521337||pregnant women not in active labor|
89520994|NCT02521337||pregnant women in preterm labor|
89520995|NCT02521337||pregnant women in term labor|
89520996|NCT02412878|Experimental|Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone|"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
89520997|NCT02412878|Experimental|Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone|"Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
89520998|NCT03428399||Breast reconstruction patients|Self-reported psychosocial variables and a clinical interview assessing mental health history will be administered prior to participants' scheduled mastectomy and breast reconstruction surgery (which is part of their routine medical care for cancer treatment or prevention). Follow up self-report measures will be collected after the surgery as well.
89041875|NCT06236412|Experimental|Intervention arm 2: Pregnant woman with mother-in-law|"Breastfeeding education:~Breast milk features, contents, advantages, how to improve its quality, and quantity.~Pre-lacteal feeding: meaning, addressing misconceptions, to avoid any foods/fluids up to 6 months and its harmful effects Colostrum feeding: meaning, its contents, advantages and addressing related misconceptions Early initiation of breastfeeding: proper time to initiation of breastfeeding & advantages for mother & child Exclusive breastfeeding: meaning, advantages, how long to exclusively breastfed.~They will also receive iron suphate/folic acid supplementation as recommended practice, at least for 90 days (90+ days)"
89520999|NCT03428243||truSculpt|truSculpt effectiveness after 18 months
89521000|NCT03423485|Experimental|Study arm|Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device
89521001|NCT03423329|Experimental|Group A|"Intervention:Drug: Brufen & Placebo~Brufen syrup 10 ml, once, 1 hour before local anesthesia"
89521002|NCT03423329|Experimental|Group B|"Intervention: Drug: Cital and Placebo~Cital Syrup 10 ml, once 1 hour before Local anesthesia"
89521003|NCT03423329|Placebo Comparator|Group C|"Intervention: Drug: Placebo~Other names:~(Placebo for Brufen) (Placebo for Cital)~Sansovit Iron Multivitamin syrup, an orange-coloured, orange-flavoured"
89521004|NCT02380742|Experimental|lidocaine-prilocaine|4 mL of lidocaine-prilocaine cream
89521005|NCT02380742|Placebo Comparator|Placebo|4 mL of placebo cream
89521006|NCT02944019||Edoxaban|Patients with established Non Valvular Atrial Fibrillation (NVAF) treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
89521007|NCT03423095|Placebo Comparator|Active Jaw Exercise with Relaxation|Participants randomized to this arm will complete active jaw exercises and visualization relaxation exercise (control group).
89521008|NCT03423095|Active Comparator|Active Tongue Exercise|Participants randomized to this arm will complete active tongue exercises only.
89521009|NCT03423095|Experimental|Active Tongue Exercise + Mental Practice|Participants randomized to this arm will complete active tongue exercises and mental practice of tongue exercise via motor imagery.
89521010|NCT03423095|Experimental|Mental Practice Tongue Exercise|Participants randomized to this arm will complete mental practice of tongue exercise via motor imagery only.
89521011|NCT03422939||Less experienced dietitians|There was no intervention, but we conducted separate analyses to identify differences according to the level of experience of the dietician. We used the median number of years of professional experience (median=8) to split the sample and create two subgroups: 1) less experienced dieticians (less than 9 years of experience; n= 225)
89521012|NCT03422939||More experienced dietitians|and 2) more experienced dieticians (9 years of experience or more; n=215).
89211967|NCT02545946|Active Comparator|Minimally Invasive|Cutaneous abscess will be opened with two small incisions just large enough to pass a vessel loop through both to keep them open. Pockets of pus will be broken up and the cavity washed out before placing the loop through both incisions and loosely tieing it over the skin
89211968|NCT03131193|No Intervention|No provider - No cash transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
89521013|NCT02022059|Experimental|Lidocaine|patient nécessitant une SNG pour nutrition entérale bénéficiant d'une pré-médication par vaporisateur de lidocaïne lors de l'insertion (group A = lidcoaine)
89521014|NCT02022059|Placebo Comparator|Placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion (group B)
89521015|NCT03422549|Active Comparator|CPAP|"Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.~Intervention: Device: Drager VN500 Ventilator"
89521016|NCT03422549|Active Comparator|NHFOV|"Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality has not been well studied to date.~Intervention: Device: Drager VN500 Ventilator"
89521017|NCT03428087||patients undergoing prostatic biopsy|Patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total PSA value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods.
89521018|NCT02922725|Active Comparator|Depressed patients receiving study drug|Participants diagnosed with MDD
89521019|NCT02922725|Placebo Comparator|Depressed patients receiving placebo|Participants diagnosed with MDD
89521020|NCT02922725|No Intervention|Healthy Control|
89521021|NCT03422315|Experimental|External control|propofol;injection;2mg/kg;single-dose
89521022|NCT03427853|Experimental|LY06006|LY06006 18mg, 60mg 120mg subcutaneous injection
89521023|NCT03427853|Placebo Comparator|Placebo|Placebo subcutaneous injection
89521024|NCT03422081||growth hormone deficiency|
89521025|NCT03422081||small for gestational age|
89521026|NCT03422081||matched controls|
89521027|NCT03127475|Experimental|real tDCS|Device: Transcranial direct current stimulation In tDCS,the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 min, with a linear fade in /fade out of 10 s in anodal and cathodal conditions resulting in a current density of 0.8A/M2 which is 177 times below the lesion effect of tDCS in the rats study(142.9A/m2)
89521028|NCT03127475|Sham Comparator|sham tDCS|Device: Sham tDCS Sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
89521029|NCT03427775||pre-MP3|before implementation of the multimodal analgesia protocol
89521030|NCT03427775||post-MP3|after implementation of the multimodal analgesia protocol
89521031|NCT03127553|No Intervention|A - control|Free diet with standard bread
89521032|NCT03127553|Active Comparator|B - low-salt diet with normal bread|Low-sodium diet with standard bread
89521033|NCT03127553|Experimental|C - low-salt diet with low-salt bread|Low-sodium diet with low-sodium bread
89635502|NCT02681458||Non-drug Users|Control group that consisted of non drug users with fungal infections
89057563|NCT04538300|Active Comparator|Group Control|In Group Control, Degree of nausea and Abramowitz Emezis score were evaluated as the interventions in recovery room. If patients with moderate and severe nausea were given 4 mg ondansetron intravenously. If PONV continues, we planned to give dexamethasone 4 mg and propofol 10 mg intravenously, respectively.
89057564|NCT02886676|Experimental|Spirulina capsules and scaling & root planing|Patients in test group will be provided with Spirulina capsules 2gm daily, after meals for 1 month
89635503|NCT00368056|Experimental|1|eszopiclone 3 mg
89635504|NCT00368056|Placebo Comparator|2|Placebo tablet
89521034|NCT03127241|Active Comparator|Armon Ayura|Upper limb assistive device with active solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
89521035|NCT03127241|Active Comparator|Jaeco Wrex|Upper limb assistive device with passive solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
89521036|NCT03427697|Experimental|Intervention group|Head-mounted video display which shows video with virtual reality and accommodation relax technique in combination,40 minutes per day
89521037|NCT03427697|No Intervention|Control group|No intervention will be performed in the control group
89521038|NCT03427541||Patients with surgeries|NSCLC patients with surgeries
89057565|NCT02886676|Active Comparator|Placebo capsules and scaling & root planing|Patients in test group will be provided with placebo capsules after meals for 1 month
89521039|NCT03427385|Experimental|Minimum Effective dose|Local anesthetic Ropivacaine 0.5% injection for adductor canal block
89521040|NCT03427229|Experimental|Multiple-infusion FMT|Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
89521041|NCT03427229|Active Comparator|Single-infusion FMT|Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
89521042|NCT04449185|Experimental|HP eradication group|"HP eradication group~Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days"
89521043|NCT03427151|Experimental|IPP-201101|every 4 weeks
89521044|NCT03426839|Active Comparator|Conventional group|In the conventional group (group 1) haemostasis strategy guided by conventional coagulation tests will be carried out.
89521045|NCT03426839|Active Comparator|Point of care group|In the point of care group (group 2) transfusion algorithms guided by point-of-care (POC) tests will be applied. We will use viscoelastic thromboelastometry and impedance aggregometry.
89521046|NCT02837159|Experimental|mHealth application|The assessment of the end points will be made at three moments: at baseline, at 8 weeks (at the end of the program) and at 12 months of follow-up. The intervention will consist in: 1)Feedback daily or weekly of physical exercise and diet through the application (notice) according to the records of diet and exercise and following recommendations of International Organizations 2) Participation in three sessions of seminars (1 hour each every 15 days) on habits of life healthy and cancer and the self-regulation through measurements performed by the application 3) Calls weekly to the patients of way individual to comment possible errors or doubts about the application, of 10 min of duration (8 calls).
89521047|NCT02837159|No Intervention|Usual care|Usual care
89521048|NCT03426527|Placebo Comparator|Levobupivacaine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine General anesthesia
89521049|NCT03426527|Active Comparator|Levobupivacaine-Dexmedetomidine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine-dexmedetomidine General anesthesia
89521050|NCT03426449|Active Comparator|Posterolateral sphincterotomy|Division of internal anal sphincter at 5 o'clock position
89521051|NCT03426449|Active Comparator|Lateral sphincterotomy|Division of internal anal sphincter at 3 o'clock position
89521052|NCT03426371|Experimental|Experimental|All eligible subjects will receive KL-140 in combination with mFOLFOX-6 chemotherapy regimen.
89521053|NCT03426371|Placebo Comparator|Placebo Comparator|All eligible subjects will receive Placebo in combination with mFOLFOX-6 chemotherapy regimen.
89521054|NCT03426215||Ten year follow-up group|No interventions will be administered (Magnetic Resonance Imaging (MRI) will be administered as an outcome measurement).
89521055|NCT02805257|Experimental|Mitomycin-C|0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.
89521056|NCT02805257|Placebo Comparator|Balanced Salt Solution (BSS)|0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.
89521057|NCT02734589|Active Comparator|Fecal microbiota transplantation (FMT) without Diet|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 from the same donor without dietary conditioning.
89521058|NCT02734589|Experimental|FMT with Diet for the donor and for the recipient|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 with dietary pre-conditioning of the donor for 14 days and dietary treatment of the recipient immediately after transplantation and for the following 12 weeks.
89521059|NCT02734589|Active Comparator|Dietary therapy only|The patient will receive detailed instructions regarding the UC diet to be used over 12 weeks without FMT.
89521060|NCT03426059||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
89521061|NCT03127787||CMV infected|CMV infected observational study testing using DxN CMV Assay. Study is observational and results not used to manage patient care.
89521062|NCT03425981|Experimental|WB-EMS-SRT|Training with basic global electrostimulation
89521063|NCT03425981|Experimental|WB-EMS-WT|Training with specific global electrostimulation for runners
89521064|NCT03425981|Placebo Comparator|CG|The participants in the control group will maintain the volume and intensity of the training prior to the intervention study and the subjects of the WB-EMS and WB-EMS-AC groups will substitute one conventional training day for one with global electrostimulation for six weeks; the training of the first group will be non-specific and that of the second specific for runners and the duration of both will be 20 minutes.
89521065|NCT03425903|Active Comparator|Whole Body Cryotherapy sessions|10 Whole Body Cryotherapy sessions administered on alternate days. Patient fills the questionaires and then comes into the cabin wearing only underwear. The door is closed and the session begins, with the release of nitrogen gas to the cabin indoors, which will be in contact with the patient's body surface for 3 minutes. The intervention is performed on alternate days, so 3 sessions per week are administered. Afterwards will be compared when intervening as an control group without sessions, and with 3 visits per week and fills in the questionnaires
89521066|NCT03425903|No Intervention|Control group|Without sessions. Patient attends a control visit weekly, for 3 consecutive weeks and fills in the questionnaires to control the variables while treatment is not applied. Afterwards will be compared when intervening as an intervention group receiving 3 sessions per week and fills in the questionnaires.
89521067|NCT02636387||Desmopressin|0.2mg tablets, dose titrated to effect
89521068|NCT02636387||Placebo|Placebo Comparator
89521069|NCT02333435|Experimental|Purified EPA group|3g per day of purified EPA, capsules, to be taken once a day, for 14 months.
89521070|NCT02333435|Experimental|Placebo group|3 g per day of high-oleic sunflower oil capsules, to be taken once a day, for 14 months.
89521071|NCT03425747|Active Comparator|Calcium Carbonate|Calcium Carbonate
89521072|NCT03425747|Active Comparator|calcium Citrate|Calcium Citrate
89041876|NCT06236412|Active Comparator|Control arm: 'Pregnant woman in routine care'.|Pregnant women in this arm receive routine care, which includes existing community and health facility-based health care. The routine (standard) care at the community level includes those services given by the health extension workers such as hygiene (personal, food and environmental hygiene), and family health services such as antenatal care, postnatal care, immunization, breastfeeding, nutrition. In this trial, the control arm will receive counseling about antenatal care, health facility delivery, postnatal care, dietary intake (additional meal during pregnancy and after delivery), hygiene, and less deep information about breastfeeding practices such as on demand feeding day and night, exclusive breastfeeding, continuing breastfeeding for at least 24 months, to balance and make the frequency and duration with that of the intervention arm. They will also receive iron suphate/folic acid supplementation as recommended practice, at least for 90 days (90+ days)
89521073|NCT03425513||Hepatitis B group|
89521074|NCT03425357|Experimental|Low Load Exercises|An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction.
89521075|NCT04815161|Other|Pilloxa pillbox|Patients receiving the Pilloxa pillbox for drug administration
89521076|NCT04756349|Active Comparator|Clearfil SE|Group containing 10-MDP and HEMA monomers
89521077|NCT04756349|Active Comparator|Optibond All-in-One|Group containing HEMA monomer
89521078|NCT04756349|Active Comparator|Prime & Bond Universal|Control Group containing other monomers
89521079|NCT03425123|Experimental|REP Group|All participants in this single arm study will receive Regenerative Endodontic Procedure (REP). It regenerates the root tip on recently erupted permanent teeth that did not complete root development due to pulp infection and necrosis by allowing cells to migrate from the surrounding periapical tissue and enter the pulp space. Cells contained within the intentional bleeding create at the root tip help in root completion as well as increasing the thickness of the canal walls over up to two years following the procedure.
89521080|NCT03425045|Experimental|Repetitive Transcranial Magnetic Stimulation|Patients in this study arm will undergo the rTMS stimulation as described above.
89041877|NCT06236386|Other|VR Experience|A VR headset will be loaned to patients to be immersed in a VR environment while undergoing their colonoscopy.
89041878|NCT06236373||Cancer Survivors|Cancer Survivors
89041879|NCT06236373||Cancer Survivors Caregiver|Family members or/and caregivers
89041880|NCT06236373||Cancer Survivors Stakeholders|Health professionals, patients associations
89041881|NCT06236360|Experimental|Mediterranean diet intervention|The intervention study will involve scheduled communications (via phone, video call, and/or email) with a trained nutritionist based on protocol-determined parameters and recommendations, organized weekly in the first month, every other week in the second month, and once a month in the third month. Each patient will receive general guidance and information about the MD. Additionally, a personalized nutritional plan based on the MD will be prepared for each patient, considering their initial dietary habits, preferences, food accessibility, and financial constraints. Throughout the 12-week period, patients will be motivated to adhere to the prescribed dietary regimen.
89041882|NCT06236360|No Intervention|Continuing with previous diet|The control group will continue with their usual/current diet, with the exception of supplementation of those in whom low serum vitamin D level (in accordance with current medical recommendations)
89041885|NCT06236334|Experimental|Lifestyle intervention|The intervention will be a twelve week lifestyle intervention (live and online)
89041886|NCT06236321|Experimental|Rectal cancer patients|Patients with locally advanced rectal cancer who require neoadjuvant chemoradiotherapy
89041887|NCT06236308|Experimental|TTAX03 10mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. 10 mg of TTAX03 in a 0.5 mL solution of sterile, preservative-free 0.9% NaCl (saline).
89041888|NCT06236308|Experimental|TTAX03 25mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. 25 mg TTAX03 in a 0.5 mL saline solution; or 0.5 mL of saline alone.
89041889|NCT06236308|Placebo Comparator|Saline Control|0.5 mL of saline alone
89041890|NCT06236282||ArtiSential® Use|Laparoscopic low anterior resection, with use of both straight devices and articulated devices
89041891|NCT06236282||ArtiSential® Non-Use|Laparoscopic low anterior resection, with use of straight devices only
89635505|NCT02683174|Experimental|Single study arm|All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance
89635506|NCT01685801|Experimental|Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
89635507|NCT01685801|Experimental|Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
89041892|NCT06236269|Experimental|Sacituzumab Govitecan|Sacituzumab govitecan will be given on Days 1, 8 of a 21-day cycle at a dose of 10 mg/kg intravenously, continuously until progression of the disease or unacceptable toxicity.
89635508|NCT01685801|Experimental|Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
89635509|NCT01685801|Experimental|Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
89635510|NCT01353222|Experimental|DN24-02|Subjects received infusion of DN24-02, at 2-week intervals, for a total of 3 infusions.
89635511|NCT01353222|Other|Standard of Care|Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population.
89635512|NCT02683954||endometriosis|30 women with laparoscopically diagnosed endometriosis. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
89635513|NCT02683954||control|30 women without any laparoscopically detected pelvic endometriotic pathology. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
89635514|NCT04544735|Experimental|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will will integrate two key components: pelvic health PT interventions (i.e., vaginal dilators, Pelvic Floor Muscle Training) and coping skills training for managing symptoms and improving treatment adherence. The intervention aims to improve women's sexual function after pelvic radiation
89635515|NCT04475315|Experimental|Papillary Muscle Sling Group|Participants in the papillary muscle sling group will receive the sling technique performed in conjunction with their standard of care (SOC) Coronary Artery Bypass Grafting (CABG) surgery.
89635516|NCT04475315|Active Comparator|Controls Group|Participants in the control group will receive their SOC CABG surgery only, without any additional intervention.
89635517|NCT05746104|Experimental|SWIG Arm|This is the only arm for the study and will be experimental. All patients will receive the appropriate dosage of the study drug, which will then be used for visualization of the tumor intraoperatively.
89635518|NCT02684188|No Intervention|Standard hospital discharge services|Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
89635519|NCT02684188|Experimental|Enhanced rural discharge and transition|Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.
89635520|NCT01684943|Experimental|Multiplex pharmacokinetic profiling|Multiplex pharmacokinetic profiling of regular human insulin, insulin aspart, insulin lispro, insulin glulisine, and regular human insulin. All subjects participated in the single study arm and received injections of each type of insulin. Blood samples were drawn at intervals for pharmacokinetic profiling.
89635521|NCT01684943|Experimental|Continuous insulin monitoring|Continuous insulin monitoring (CIM) of insulin lispro. Some subjects participated in the CIM sub-study, which is distinct from the Multiplex Pharmacokinetic Profiling study. This intervention involved administering insulin lispro and monitoring pharmacokinetic profile of the drug using blood samples and an investigational continuous insulin monitoring system.
89635522|NCT03115242|Experimental|Acute ischemic carotid stroke|"Patients hospitalized in the neurovascular intensive care unit for an acute ischemic stroke with a carotid plaque responding to inclusion criteria.~These patients receive a contrast injection Sonovue® will be performed during the neck vessels doppler ultrasound."
89041893|NCT06236256|Experimental|AHCL group|Participants will be connected to the MiniMed 780G AHCL system for the 12 months study period. This group will have two additional visits to allow for patients to be trained on the AHCL system.
89041894|NCT06236256|Placebo Comparator|MDI/CSII group|The patient will continue MDI/CSII treatment as per their routine procedures. At the beginning, middle and end of the stage they will be connected to a standalone sensor from which glucose data will be collected.
89041895|NCT06236243|Active Comparator|G1899 Korean Red Ginseng Extract Powder 120 mg/tablet|480 mg of Korean Red Ginseng Extract powder per day for a total of 12 weeks.
89688530|NCT01724411|No Intervention|Control Non- RS3|Non-Resistant Starch type 3 food items during 11 days of the maintenance period.
88990982|NCT05913895|Placebo Comparator|boiled water|At the end of cancer treatment (chemotherapy, radiotherapy, or Chemoradiotherapy),boiled water gargle was administered by the investigator or a researcher every Monday through Friday. The changes in six scales described above were tracked in the experimental and control groups on days 1 (T1), 3 (T2), 7 (T3), and 14 (T4) after the end of treatment.
88990983|NCT05911906|Experimental|Treatment Group|Five days of Remdesivir infusion delivered by IV.
88990984|NCT05909735|Experimental|Visually significant partial LSCD|Patient with visually significant partial LSCD, as defined by a best corrected visual acuity of 20/100 or less, and partial LSCD on slit lamp exam with at least 25% of the limbus intact or at least 25% of the corneal surface covered with corneal epithelium will be enrolled in the first arm.
89521081|NCT03425045|Sham Comparator|Sham stimulation|Patients in this study arm will undergo the sham stimulation as described above.
89521082|NCT03425045|Active Comparator|Ginkgo Biloba Extract|Patients in this study arm will receive medication therapy as described above, without any rTMS or sham procedure.
89521083|NCT03424967|Experimental|ABM therapy|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
89521084|NCT03424889|Experimental|Xylometazoline|Patients receiving topical xylometazoline nasally during bronchoscopy
89521085|NCT03424889|Placebo Comparator|Saline placebo|Patients receiving topical saline nasally during bronchoscopy
89521086|NCT03424811|Experimental|Intervention Group|Includes core behavior change strategies and behavioral skills training designed to promote healthy eating behaviors.
89521087|NCT03424811|No Intervention|Control Group|Information provided will mimic what families may receive during a routine well-child visit.
89521088|NCT03424733|Active Comparator|Current Plegridy Users|Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
89521089|NCT03424733|Experimental|New Plegridy Users|Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.
89521090|NCT03424655|Experimental|Group TFA|Twisted files were used serially with a single controlled motion according to the manufacturer's instructions.
89521091|NCT03424655|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
89521092|NCT03424655|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
89521093|NCT03424655|Experimental|Group REC|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
89521094|NCT03424577|Experimental|H3B-6527|Healthy male participants will be randomly assigned to 1 of 2 possible treatment sequences: either H3B-6527 capsule with food on Day 1 and H3B-6527 capsule without food on Day 5 (treatment sequence fed/fasted), or H3B-6527 capsule without food on Day 1 and H3B-6527 capsule with food on Day 5 (treatment sequence fasted/fed).
89521095|NCT03424031|Experimental|Verticalization|the patient will be placed in the most vertical position possible.
89521096|NCT03424031|No Intervention|Passive mobilization|Passive mobilization of the lower limb deficit
89521097|NCT03421925|Other|Divided mesh group|In this group, surgeon will use a mesh divided in to two legs in laparoscopic totally extraperitoneal repair
89521098|NCT03421925|Other|Non divided mesh group|In this group, surgeon will use a non divided mesh in laparoscopic totally extraperitoneal repair
89521099|NCT03423875|No Intervention|Control|Patients assigned to the control condition will be treated using the current standard of care, clinical assessments, to identify delirium.
89521100|NCT03423875|Experimental|Intervention|PrEDICTgame score (subject's relative risk of delirium) will be shared with ED physicians in the intervention arm. After viewing the tests results, ED physicians will be asked to reassess delirium risk, and indicate if they would change their management based on the PrEDICT app scores.
89521101|NCT03423797|Active Comparator|NaF without fTCP|25% AgNO3 solution followed by 5% NaF.
89521102|NCT03423797|Experimental|NaF with fTCP|25% AgNO3 solution followed by 5% NaF with fTCP.
89521103|NCT03421847||Major Depression Group|We will measure the vestibular activity of Major depression patients with Rotatory Test and electronystagmography
89521104|NCT03421847||Healthy Control Group|We will measure the vestibular activity of Healthy subjects with Rotatory Test and electronystagmography.
89521105|NCT03423719|Experimental|Verum|This arm receives 2 x 450 mg capsules of Fiit-ns®, a blend of polyphenol-rich fruit and vegetables extracts, daily for 16 weeks.
89521106|NCT03423719|Placebo Comparator|Placebo|This arm receives 2 x 450 mg capsules of Placebo, containing maltodextrin only, daily for 16 weeks.
89521107|NCT03421769|Experimental|EA and AMLK|Corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe ocular burns.
89521108|NCT03421769|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe ocular burns.
89521109|NCT03417323|Experimental|Compressive garment|Groups wear compression garment after WB-EMS induced muscle soreness
89521110|NCT03417323|No Intervention|No compression garment|Groups wear no compression garment after WB-EMS induced muscle soreness
89521111|NCT03421613|Experimental|3VM1001 cream|Patients will be randomized to self treat with 2 g of VM1001 cream times daily for ten days, have a five day wash out period and then 10 days of self treatment with the comparator.
89041896|NCT06236243|Active Comparator|G1899 Korean Red Ginseng Extract Powder 500 mg/tablet|2000 mg of Korean Red Ginseng Extract Powder per day for a total of 12 weeks.
89041897|NCT06236243|Placebo Comparator|Placebo|Inactive Ingredients
89041898|NCT06236230|Experimental|levodopa/carbidopa/entacapone|levodopa/carbidopa/entacapone is a combination drug consisting of levodopa, carbidopa, and entacapone. Each tablet contains a 1:4 ratio of carbidopa to levodopa and 200 mg of entacapone. The optimum daily dosage of levodopa/carbidopa/entacapone must be determined by careful titration in each patient.
89041899|NCT06236217|No Intervention|Control group|Patients received standard of care with no intervention before spinal anesthesia.
89635523|NCT01683383|Active Comparator|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
89635524|NCT01683383|Experimental|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
89635525|NCT03114852||CKD patients|"'blood collection'~Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed."
89635526|NCT03114852||Renal Familiar Disease|'blood collection' They will have blood tested to renal genetic diseases
89635527|NCT05744388|Active Comparator|Stylet shape modification group|"Endotracheal tube diameter size 7.5 mm and disposable rigid blade size 3 for the female patients and ETT diameter size 8.00 mm and disposable rigid blade size 4 for the male patients will be prepared. The under surface of the blade will be lubricated by soluble jelly, taking care not to touch the camera source of light.~The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis. Once the tip of the tube introduced inside the glottis, the stylet will be removed and the tube will be advanced more inside the trachea. The equality of air entry will be assessed by the stethoscope and the tube will by fixed by adhesive tape after inflating the cuff."
89635528|NCT05744388|No Intervention|Standard shape of the stylet group|The second group will be a control group, they will be handled by the standard shape of the stylet and the blade without lubrication.
89635529|NCT05746026|Experimental|STUDY GROUP|• The study subjects who fulfilled the inclusion criteria were interviewed individually in the garden of the clubs in order to collect the necessary data (tool I, II, III, and IV). Then, the researcher interviewed the clients in group composed of 8 older adults to implement the Psycho-educational Program . Each session taken about 30-45 minutes.
89635530|NCT05746026|Active Comparator|Control group|Control group exposed to the usual routine care
89635531|NCT05425108|Active Comparator|CP1 device|
89635532|NCT05425108|No Intervention|Control|
89635533|NCT02694744|Experimental|Group 1 - Dosing Without Food|Patiromer dosing without food
89635534|NCT02694744|Active Comparator|Group 2 - Dosing With Food|Patiromer dosing with food
89635535|NCT04738630|Experimental|Experimental: HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
89635536|NCT03106194|Other|history of injection drug use|"Men and women ≥ 18 years old with a history of injection drug use, enrolled in the opiate substitution program of CAD Limburg.~Case management"
89635537|NCT05339542|Experimental|Platelet rich plasma group|"platelet rich plasma (PRP) will be produced through whole blood centrifuge using a specific methodology in a strict aseptic setting. Then, blood will be collected and mixed with anticoagulant and Citrate-phosphate-dextrose adenine in a 10 volume blood to 1 volume anticoagulant ratio. The blood will be centrifuged for 10 minutes at 1000 rpm. Afterward, the plasma will be transferred to a new glass tube and centrifuged for 15 minutes at 3000 rpm. At the bottom of the tube, platelets will form a pellet. Finally, pure platelet-rich plasma will be obtained at a concentration of up to four times higher than baseline. Prior to the injection, calcium gluconate will be combined with PRP (at a ratio of 0.3 ml ca gluconate/ml PRP).~The injection will be done once."
89635538|NCT05339542|Active Comparator|Methylprednisolone group|"2 ml methylprednisolone acetate 40mg/ml (total 80mg methylprednisolone acetate) together with 1 ml lidocaine 2% (total 3 ml solution) will be directly injected under ultrasound guidance to the plantar fascia.This group serves as active comparative group.~The injection will be done once."
89635539|NCT03162900|Experimental|Glasdegib QT Therapeutic Exposure|Randomized sequence of Glasdegib clinical exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
89635540|NCT03162900|Experimental|Glasdegib QT Supra-therapeutic Exposure|Randomized sequence of glasdegib supra-therapeutic exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
89635541|NCT04338568|Active Comparator|LUS observer 1|The subject will undergo a Lung Ultrasound by observer nr 1
89041900|NCT06236217|Experimental|Carotid Ultrasound group|The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.
89041901|NCT06236217|Experimental|Electrical cardiometry group|Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
89041902|NCT06236204|Experimental|Arthroscopic Scapholunate Ligament Reconstruction|Experimental: patients with dynamic scapholunate instability wrist arthroscopy: bone-tendon reconstruction of the volar and dorsal part of the scapholunate complex
89041903|NCT06236191|Experimental|Intervention|Intervention group is transcranial pulse electrical stimulation
89041904|NCT06236191|Active Comparator|Comparator|comparator is Melatonin
89635542|NCT04338568|Active Comparator|LUS observer 2|The subject will undergo a Lung Ultrasound by observer nr 2
89041905|NCT06236178|Active Comparator|Autologous Blood Injection Mixed With Local Anesthetic|Autologous Blood Injection group were administered 1ml of autologous venous blood mixed with 2ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.
89635543|NCT05297812||Moderate to Advanced Emphysema|Patients with moderate or advanced Emphysema as measured by baseline inspiratory PERC-15 below the study median
89635544|NCT05297812||Minimal Emphysema|Patients with minimal emphysema as measured by baseline inspiratory PERC-15 above the study median
89635545|NCT05291806|Placebo Comparator|Reference|
89635546|NCT05291806|Active Comparator|Whole cereal kernels Dose A|
89635547|NCT05291806|Active Comparator|Whole cereal kernels Dose B|
89635548|NCT05291806|Active Comparator|Cut cereal kernels Dose A|
89635549|NCT05273788|Active Comparator|1Hz Arm|ThorS-MagNT treatment intervention with 2400 total stimulations at 1Hz with the magnetic coil.
89635550|NCT05273788|Active Comparator|10Hz Arm|ThorS-MagNT treatment intervention with 2400 total stimulations at 10Hz with the magnetic coil.
89635551|NCT05273788|Sham Comparator|Sham Arm|Sham intervention with 2400 total sham stimulations with the magnetic coil.
89635552|NCT05227534|Experimental|Participants 40 years of age or older with cancer risk|The study will aim to enroll participants 40 years of age or older with cancer risk. Specific cancer risks will be enriched to increase the number of cancer events that are observed during the study.
89635553|NCT05218252|Other|Hand soft tissue defects|Patients with mild to moderate hand soft tissue defects with exposed bone, tendons or cartilage resulting from trauma, tumor ablation or postburn deformities.
89635554|NCT00368602|Experimental|1|This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
89635555|NCT00368602|Placebo Comparator|2|The group will be given standard of care with placebo medication.
89635556|NCT01683071|Experimental|(Part 1) EXPAREL 67 mg|5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
89635557|NCT01683071|Experimental|(Part 1) EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
89635558|NCT01683071|Experimental|(Part 1) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
89635559|NCT01683071|Placebo Comparator|(Part 1) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
89635560|NCT01683071|Experimental|(Part 2) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
89635561|NCT01683071|Placebo Comparator|(Part 2) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
89635562|NCT04707508|Experimental|Valsartan and metformin|
89635563|NCT04707508|Active Comparator|Metformin only|
89635564|NCT05189080|Experimental|Open Trial|Patients within the Wake Forest Baptist Health system who no-showed for scheduled well child visits at Pediatrics-Downtown Health Plaza, Family Medicine-Piedmont Plaza, Pediatrics-Winston East, Family Medicine-Peace Haven, and Pediatrics-Clemmons.
89635565|NCT05140642|Active Comparator|Sonographer Annotation|Currently, sonographer technicians provide preliminary interpretations prior to validation and overreading by cardiologists. This staggered, stepwise evaluation allows for the introduction of AI decision support with minimal impact on patient care. Physicians are already used to adjusting the preliminary report given the variable training of sonographers and on the lookout for changes, variation, or adjustments that need to be made.
89041906|NCT06236178|Active Comparator|Corticosteroid Injection Mixed With Local Anesthetic|Corticosteroid Injection category were given 1ml of 40 mg methylprednisolone acetate(Prednol-L 40mg,Mustafa Nevzat,Turkey) mixed with 2ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.
89041907|NCT06236178|Active Comparator|Combined Injection Mixed With Local Anesthetic|Combined Injection group received a mixture containing 1ml each of autologous venous blood and 40mg methylprednisolone acetate(Prednol-L 40mg,Mustafa Nevzat,Turkey), along with 1ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.
89635566|NCT05140642|Experimental|Artificial Intelligence Annotation|In preliminary work, a novel AI algorithm developed to assess LVEF was shown to be more precise than human interpretation in 10,030 echocardiograms done at Stanford University (Ouyang et al. Nature, 2020). With randomization, a proportion of the preliminary interpretations will be done by AI technology and the study team will assess how different this preliminary interpretation is from the final interpretation.
89041908|NCT06236152|Active Comparator|Deltacortil|Deltacortil 10mg was given in oral formulation once daily for 4 to 6 weeks
89635567|NCT05099068|Experimental|IMMUNOTHERAPY COHORTS|This cohort include following cancers treated with immunotherapy : metastatic Small cell lung cancer (SLCC); recurrent/Metastatic Head and Neck squamous cell carcinoma (HNSCC); MSI-High, any tumor types and HPV-related cancers,any tumor types
89635568|NCT05099068|Experimental|TARGETED THERAPIES COHORTS|This cohort include following cancers treated with targeted therapies : Metastatic GIST; BRAF-mutated tumors (CRC (BRAF V600E), lung (V600 only) and thyroid (all BRAF mutation with known sensitivity to Dabrafenib) cancer); All solid tumor types with RET fusion / mutation and Chronic Lymphocytic Leukemia (CLL) in the relapsed setting.
89635569|NCT05099068|Experimental|CHEMOTHERAPY COHORTS|This cohort include following cancers treated with chemotherapies : metastatic Small cell lung cancer (SLCC); recurrent/Metastatic Head and Neck squamous cell carcinoma (HNSCC); Metastatic Triple negative breast cancer (TNBC); Glioblastoma; Advanced high grade epithelial ovarian cancer
89635570|NCT01567865|Active Comparator|Reference Lot|Lot of Vaccine produced in existing facility
89635571|NCT01567865|Experimental|New Lot #1|First lot of vaccine produced in new facility
89041909|NCT06236152|Placebo Comparator|Placebo|Iron 150mg was given in oral formulation once daily for 4 to 6 weeks
89057566|NCT04315753||cancer patients (clinical stage I and II) +controls|70 lung cancer patients (clinical stage I and II) diagnosed outside screening and candidates to surgical resection at Humanitas Hospital, and 70 controls with benign nodules. Cancer patients will undergo blood collection before and at 4 months after surgical resection. Blood will be used for CTC analysis, exosome antigens and circulating free DNA (cfDNA) mutational analysis.
89635572|NCT01567865|Experimental|New Lot #2|Second lot of vaccine produced in new facility
89635573|NCT01567865|Experimental|New Lot #3|Third lot of vaccine produced in new facility
89635574|NCT05049226|Experimental|Two doses of SV at interval 60 to less than 90 days|Participants who have received two doses of SV at interval 60 to less than 90 days
89041910|NCT06236139|Experimental|Treatment (STEAP1 CART, enzalutamide)|Patients undergo leukapheresis then receive cyclophosphamide IV and fludarabine IV on days -5, -4 and -3 and STEAP1 CART IV on day 0. Patients may receive enzalutamide PO on day 0 then QD in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline, day 14 and optionally at progression. Patients additionally undergo blood sample collection, NM bone scan and CT scan, or MRI or PET scan throughout study. Additionally, patients may undergo ECHO or MUGA at screening.
89635575|NCT05049226|Experimental|Two doses of SV at interval 90 to less than 120 days|Participants who have received two doses of SV at interval 90 to less than 120 days
89635576|NCT05049226|Experimental|Two doses of SV at interval 120 to 180 days|Participants who have received two doses of SV at interval 120 to 180 days
89635577|NCT05006872|Experimental|DIABE-TEXT|Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
89635578|NCT05006872|No Intervention|Usual care|Participants allocated to the control group will not receive any intervention apart from usual care.
89635579|NCT05005546|Experimental|Experimental: Yoga|
89635580|NCT05005546|Experimental|Experimental: Laughter Yoga|
89635581|NCT05005546|No Intervention|Control|
89635582|NCT01567163|Experimental|ramucirumab (IMC-1121B) and docetaxel|"Cycle 1: docetaxel administered on Day 1 of 3-week cycle~Cycle 2: ramucirumab and docetaxel administered on Day 1 of 3-week cycle~Cycle 3 and beyond: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle~Extension Phase: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle"
89635583|NCT05002114|Placebo Comparator|Placebo Group|Does not get active topical CBD. Instead, gets an identical placebo-containing topical agent.
89635584|NCT05002114|Experimental|Active Group|Does get active topic CBD.
89635585|NCT02986061|Active Comparator|Control Group|Patients with indwelling urinary catheter
89635586|NCT02986061|No Intervention|Study Group|Patients without indwelling urinary catheter
89635587|NCT04597840|Experimental|biosynthetic mesh group|Patient will undergo incisional hernia repair with biosynthetic mesh reinforcement. Based on the discretion of the surgeon, two types of biosynthetic mesh from different brand can be used: the Phasix mesh from BARD or the BioA mesh from GORE. These two biosynthetic meshes are resorbable, which means they are gradually absorbed by the body.
89635588|NCT04597840|Other|standard of repair group|Patient will undergo incisional hernia repair according to the standard of repair, which is simple suture or mesh reinforcement (using synthetic or biological meshes).
89635589|NCT04567810|Experimental|Part A: 2 mg preparation|Participants receive a single 2 mg dose of anti-SARS-CoV-2 IgY.
89635590|NCT04567810|Experimental|Part A: 4 mg preparation|Participants receive a single 4 mg dose of anti-SARS-CoV-2 IgY.
89635591|NCT04567810|Experimental|Part A: 8 mg preparation|Participants receive a single 8 mg dose of anti-SARS-CoV-2 IgY.
89635592|NCT04567810|Placebo Comparator|Part A: placebo preparation|Participants receive placebo matching anti-SARS-CoV-2 IgY.
89635593|NCT04567810|Experimental|Part B: 6 mg total daily dose|Participants receive a 2 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
89635594|NCT04567810|Experimental|Part B: 12 mg total daily dose|Participants receive a 4 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
89635595|NCT04567810|Experimental|Part B: 24 mg total daily dose|Participants receive a 8 mg dose of anti-SARS-CoV-2 IgY three times daily for 14 days.
89635596|NCT04567810|Placebo Comparator|Part B: 0 mg total daily dose|Participants receive placebo matching anti-SARS-CoV-2 IgY three times daily for 14 days.
89635597|NCT04556344|Experimental|Emotional skills|3 individual sessions in which patients are going to learn how to identify, understand, express and regulate emotions
89635598|NCT04556344|Sham Comparator|Short free talk and relaxation|3 individual sessions in which patients are going to follow relaxation instructions after a non-directive talk about their current or past experience of cancer.
89635599|NCT04338802|Placebo Comparator|Placebo group|Empty capsules with the same appearance and ingredients as Nintedanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
89635600|NCT04338802|Experimental|Nintedanib group|Nintedanib cloth sulfonate soft capsule treatment: According to the drug manual recommendation, give Nintedanib cloth sulfonate soft capsule 150mg twice daily with an interval of about 12 hours each time. Continuous medication for 8 weeks.
89635601|NCT04455022||Any infant who will have a blood culture collected.|During the study period educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
89635602|NCT04453150|Experimental|Standard hypocaloric diet|Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits 3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
89635603|NCT04453150|Experimental|Intermittent fasting 16/8 (early fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 12 am. to 8 pm.), maintaining 16 fasting hours (from 8 pm. to 12 am. the following day).
89041911|NCT06236126|Active Comparator|INTRADERMAL|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine either intradermally (Group Intradermal).
89041912|NCT06236126|Active Comparator|SUBCUTANEOUS|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine subcutaneously (Group Subcutaneous).
89041913|NCT06236100|Experimental|Strengthening Families Program + Family Advocate|Families in the treatment group will be connected to clinically trained, trauma-informed FAs that will assess and refer families to community services. The intervention will provide wraparound supports to prevent ACEs and substance use and, critically, enable providers and community-based partners to align their services in a way that addresses the social determinants of health and other community-level factors that impact substance use and the relationship between social connection and ACEs. The FA component of the intervention will run concurrent to the Strengthening Families Program 7-17 sessions, with the FAs interacting weekly with families over the 10- to 14-week intervention period. On a weekly basis, FAs will conduct 1-hour, post-session check-ins with each family. This 1-hour period will consist of a 20-minute phone call with families to discuss their needs, with the remaining 40 minutes used to debrief, make service referrals, and complete documentation.
89521112|NCT03421613|Placebo Comparator|Placebo|Patients will be randomized to self treat with either active product or placebo comparator thrice daily for 10 days followed by a 5 day wash out period then 10 days of experimental treatment thrice daily for 20 days.
89521113|NCT02064803|Active Comparator|Control group: A|Gastro-entero anastomosis only
89521114|NCT02064803|Experimental|Experimental: B|Gastric partitioning Plus Gastro-entero anastomosis
89521115|NCT01791595|Experimental|AZD3965 Cohort 1 (5 mg OD)|
89521116|NCT01791595|Experimental|AZD3965 Cohort 2 (10 mg OD)|
89521117|NCT01791595|Experimental|AZD3965 Cohort 3 (20 mg OD)|
89521118|NCT01791595|Experimental|AZD3965 Cohort 4 (30 mg OD)|
89521119|NCT01791595|Experimental|AZD3965 Cohort 5 (15 mg BD)|
89521120|NCT01791595|Experimental|AZD3965 Cohort 6 (10 mg BD)|
89521121|NCT01791595|Experimental|AZD3965 Expansion Cohort (10 mg BD)|
89521122|NCT05061433|No Intervention|Usual Care|Participants receive standard of care.
89521123|NCT05061433|Experimental|Intervention|"Initial Home Visit: MIH/CP provider team will visit the patient's home at the scheduled time following a specific General Followup Protocol involving 1. Assessment of patient understanding of recent illness and medical therapy including reinforcement of medical adherence, 2. Any other disease-specific concerns, 3. Performance of a home safety evaluation, 4. If patients have concerns relating to their ability to manage their disease process at home, 5. MIH/CP providers and an on-call social worker will provide assistance in the form of on-site, telephone, and electronic referrals or provision of appointments with appropriate services.~Subsequent visits: The MIH/CP team will decide in conjunction with Medical Control and the PMD if further followup is needed, and the most appropriate followup interval., At 30 days from initial hospital discharge, the patient will be discharged from the MIH/CP program in conjunction with the PMD."
89521124|NCT04451941|Experimental|RecoveriX with individual EEG calibration|RecoveriX applied functional electrical stimulation (FES) according to individual brainwave by individual EEG calibration for 4 weeks
89521125|NCT04451941|Sham Comparator|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 4 weeks
89521126|NCT03441997|Experimental|Full mind-body exercises|Participants will be trained to perform a type of mind-body exercise that involves low intensity exercise and body movements similar to Tai Chi. Participants will be asked to exercise 2 times per day for 8 weeks.
89521127|NCT03441997|Active Comparator|Light mobility exercises: Control Group|The Light mobility exercises group will perform a similar exercise as the experimental group. However without a few components. Participants will be asked to exercise two times per day for 8 weeks.
89521128|NCT03441997|No Intervention|Healthy Controls|Healthy females will be asked to make one visit to complete aerobic exercise test, questionnaires, and provide blood samples.
89521129|NCT03441919||Patients with type 1 diabetes, poor glycemic control|"Diagnosis based on clinical criteria~Duration of diabetes ≥10 years~Age ≥20 years, ≤ 60 years~HbA1c >64 mmol/mol"
89521130|NCT03441919||Patients with type 1 diabetes, good glycemic control|"Diagnosis based on clinical criteria~Duration of diabetes ≥10 years~Age ≥20 years, ≤ 60 years~HbA1c <64 mmol/mol"
89521131|NCT03441919||Healthy subjects|"Absence of disease, no use of medication~Matched for age, gender and BMI~HbA1c <42 mmol/mol"
89521132|NCT03441841|Experimental|Lidocaine + prilocaine|Single topical dose of a combination of nanoencapsulated lidocaine (2.5%) and prilocaine (2.5%) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
89521133|NCT03441841|Active Comparator|Lidocaine|Single topical dose of lidocaine nanoencapsulated gel (2.5 %) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
89521134|NCT03441841|Active Comparator|Prilocaine|Single topical dose of prilocaine (2.5 %) nanoencapsulated gel formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
89521135|NCT02692339||Lenalidomide/Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma
89521136|NCT03444103|Active Comparator|Clazakizumab / Clazakizumab|Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
89521137|NCT03444103|Placebo Comparator|Placebo / Clazakizumab|Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
89521138|NCT03444025|Experimental|Group A|Goserelin 3.6 mg depot injection will be administered subcutaneously every month along with standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
89521139|NCT03444025|No Intervention|Group B|Standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
89521140|NCT03443947|Experimental|D group|
89521141|NCT02667067|Other|Anterior cervical discectomy & fusion (ACDF)|
89521142|NCT02667067|Experimental|Simplify Disc|Simplify Disc
89635604|NCT04453150|Experimental|Intermittent fasting 16/8 (late fasting)|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein, but it will be consumed for 8 hours a day (from 8 am. to 4 pm.), maintaining 16 fasting hours (from 4 pm. to 8 am. the following day).
89635605|NCT04453150|Experimental|Alternate-day fasting|In this diet subjects alternate norm caloric diet during 24 h (according to Harris-Benedict equation) and a diet including only 25% of caloric requirements the following 24 h (this day diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein).
89635606|NCT04453150|Experimental|Ketogenic diet|Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 5 % carbohydrates, 65% fat and 30% high biological value protein.
89635607|NCT04439656||Absence Seizures|Participants with absence seizures will have their eye movements compared to the EEG recording.
89635608|NCT04357990|Experimental|Viruxal Oral and Nasal Spray|The Device will be administered to the oral and nasal passages, three times per day.
89635609|NCT04357990|Placebo Comparator|Placebo|The placebo will be administered to the oral and nasal passages, three times per day.
89635610|NCT01567085|Experimental|Eculizumab|"Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion.~Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days.~Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days."
89635611|NCT04344184|Active Comparator|Infusion|L-Ascorbic Acid (Vitamin C), intravenous infusion
89635612|NCT04344184|Placebo Comparator|Placebo|Dextrose 5% Water
89635613|NCT04290754|Experimental|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
89635614|NCT04290754|Active Comparator|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive-behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
89635615|NCT01566773|Experimental|PT001 MDI (Dose 1)|
89635616|NCT01566773|Experimental|PT001 MDI (Dose 2)|
89635617|NCT01566773|Experimental|PT001 MDI (Dose 3)|
89635618|NCT01566773|Experimental|PT001 MDI (Dose 4)|
89635619|NCT01566773|Experimental|PT001 MDI (Dose 5)|
89635620|NCT01566773|Experimental|PT001 MDI (Dose 6)|
89635621|NCT01566773|Placebo Comparator|PT001 Placebo MDI|
89635622|NCT01566773|Active Comparator|Spiriva® Handihaler® (Tiotropium Bromide)|
89635623|NCT04276714|Experimental|Adjustable socket|First week of the study is with adjustable socket
89635624|NCT04276714|Experimental|Classical socket|First week of the study is with classical socket
89635625|NCT04134442|Experimental|Bupivacaine Liposome|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist).~Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
89635626|NCT04134442|Active Comparator|Standard therapy|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist).~Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
89635627|NCT01566149|Active Comparator|MF/F 200/10 mcg MDI BID|Participants receiving MF/F 200/10 mcg MDI twice daily (BID) for 12 weeks
89635628|NCT01566149|Active Comparator|MF/F 400/10 mcg MDI BID|Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks
89635629|NCT04068064|Experimental|EABM training group|about 40 individuals with IGD will be randomly assigned to the EABM training group
89635630|NCT04068064|Placebo Comparator|Control training group|about another 40 individuals with IGD will be randomly assigned to the control training group
89635631|NCT04341922|Experimental|Intervention: Online Cognitive-Behavioral intervention|The three-week intervention is a structured self-guided program without therapist support, administered via a secure web platform and organized in five brief modules. The treatment is provided through an encrypted online platform (login through BankID and double authentication) provided by the eHealth Core facility at Karolinska Institutet
89635632|NCT04341922|No Intervention|Wait-list|The wait-list controlled composes of no intervention for three weeks. Participants randomized to the wait-list group will be crossed over to receive the Online Cognitive-Behavioral intervention after three weeks (post-treatment).
89041914|NCT06236100|Active Comparator|Strengthening Families Program-Only|Families in the control group will participate in the Strengthening Families Program 7-17 (SFP7-17) Group Class Curriculum for families with children ages 7-17. Parents and children participate in SFP7-17, both separately and together, as the curriculum has lessons for parents, teens, and children plus a joint Family Practice class. SFP7-17 meetings are 2 hours in length and are typically held in person (but families can participate remotely, during extenuating circumstances) with participating families completing 11 sessions over a 10- to 14-week period.
89635633|NCT01565993|Active Comparator|Hemoclip|In group HEMOCLIP, one or more clips were placed (based on the criteria of the endoscopist in accordance with the size of the pedicle), and the polyp was subsequently resected using a diathermy loop
89635634|NCT01565993|Active Comparator|Conventional Polipectomy|In group CONVENTIONAL POLYPECTOMY, a conventional polypectomy was performed, which was not aided beforehand by any other hemostatic technique
89635635|NCT01565291|Experimental|Subjects With AD|Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24)
89635636|NCT01565291|Experimental|Healthy Elderly Subjects|Cognitively normal with MMSE of 29 or higher; age 50 years or older
89635637|NCT03417388|Experimental|Intensive Medical Treatment (IMT)|"The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
89635638|NCT03417388|Active Comparator|Usual Care (UC)|"The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
89635639|NCT02691702|Experimental|Multiple Doses - Part A|Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
89635640|NCT02691702|Experimental|Multiple Dose - Part B|Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
89635641|NCT02691702|Experimental|Multiple Doses - Elderly|Multiple ascending doses administered to elderly subjects
89635642|NCT02975128|Experimental|Patients|
89635643|NCT02974894|Experimental|Probiotic|Capsules containing potato starch as a filler and Lactobacillus plantarum
89635644|NCT02974894|Placebo Comparator|Placebo|Capsules containing potato starch
89635645|NCT03374566||Screened patients|Immunodeficiency screening: Heparinized peripheral blood is obtained from patients with severe EBV infections for immunological function assays and genetic analysis, when current screening is performed after parents' information and consent.
89635646|NCT02974816|No Intervention|Standard of Care|Subjects in this arm will visit their physician once every 3 months and will receive usual care.
89635647|NCT02974816|Experimental|Remote Monitoring|Subjects in this arm will visit their physician once every 3 months and will receive usual care. In addition, in between clinic visits, subjects will measure their blood glucose (BG) readings at least once a day and share their BG readings with their CDE using Glooko's mobile application. Once a week, the CDE will review the subject's BG readings on Glooko's population tracker and reach out to the subjects if he/she experienced clinical incident(s). During the conversation, the CDE will either recommend medication or lifestyle modification to address the clinical incident.
89635648|NCT05742204||Lung cancer group|Patients age over 18, with confirmed diagnosis of lung cancer.
89635649|NCT05742204||Control group|Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
89635650|NCT05742048||traumatic patient suspect to have long bone fracture between 18 - 65 years old|
89635651|NCT05740644|Experimental|Blood Loss and Saline Infusion|
89635652|NCT01564277|Experimental|Arm I (1.5mg rasburicase)|Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
89635653|NCT01564277|Experimental|Arm II (3 mg rasburicase)|Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
89635654|NCT05553912|Experimental|QBSafe intervention|
89635655|NCT05553912|No Intervention|usual care|
89635656|NCT02679222|Experimental|Supplementation|Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT [tricaprylin/tricaprin]; coconut oil + MCT [50:50]; Coconut oil + tricaprylin [50:50]) taken twice, once at breakfast and once at mid-day.
89635657|NCT01563185|Experimental|DUEXIS|800 mg ibuprofen/26.6 mg famotidine
89635658|NCT02974660|Active Comparator|Protamine sulfate|After obtaining optimal valve deployment patients will receive protamine sulfate (1 mg for each 100 units of UFH i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after protamine sulfate administration).
89635659|NCT02974660|Placebo Comparator|0.9% NaCl|After obtaining optimal valve deployment patients will receive 0.9% saline (20 ml i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after placebo administration).
89635660|NCT05735496|Experimental|TQB2102 injection|intravenous infuse TQB2102 injection every three weeks, 21 days as a treatment cycle. (1.5mg/kg, 3mg/kg, 4.5mg/kg, 6mg/kg, 7.5mg/kg, 9mg/kg)
89635661|NCT04771169|Experimental|Vestibular Training Group|This Group will receive vestibular Adaptation and Balance exercises
89635662|NCT04771169|Active Comparator|Virtual Reality Group|This Group will receive virtual reality training by using exergaming.
89635663|NCT04410029|Experimental|Intervention|Standard counseling + Healthwise Decision Aid
89635664|NCT04410029|Active Comparator|Control|Standard counseling + a control informational handout.
89635665|NCT03316300|Experimental|NT-501|
89635666|NCT03316300|Sham Comparator|Sham|
89211969|NCT03131193|Experimental|No Provider - Cash Transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
89635667|NCT03305848|Other|Oral nitroglycerin solution|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes
89635668|NCT01563029|Active Comparator|Arm 1|Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
89635669|NCT01563029|Active Comparator|Arm 2|Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
89635670|NCT01563029|Active Comparator|Arm 3|Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
89635671|NCT01563029|Active Comparator|Arm 4|Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
89635672|NCT01563029|Placebo Comparator|Arm 5|Placebo inhalation powder once daily in the evening Placebo powder
89635673|NCT03293368|Experimental|Platelet rich plasma|0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
89635674|NCT03293368|Active Comparator|Croticosteroids|0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
89635675|NCT01562873|Experimental|Ruxolitinib-Cohort A|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
89635676|NCT01562873|Experimental|Ruxolitinib-Cohort B|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
89635677|NCT03273712|Experimental|90Y-DOTA-tyr3-Octreotide|Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.
89635678|NCT04113317|Experimental|Treatment Group|Subcutaneous injection of G-CSF with dose of 5μg/kg/day for 5 days consecutively, in addition to a single dose every 3 days up to 12 times, as well as liver cirrhosis standard regimen
89635679|NCT04113317|No Intervention|Control Group|Liver cirrhosis standard treatment only
89635680|NCT04341844|Experimental|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
89635681|NCT04341844|Placebo Comparator|Control|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
89635682|NCT01562327||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens.
89635683|NCT01561313|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
89635684|NCT01561313|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
89635685|NCT01561079|Experimental|Maternal buprenorphine treatment|Buprenorphine maintenance during pregnancy
89635686|NCT01559675|Active Comparator|Hydrocortisone High Dose|Intervention: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
89635687|NCT01559675|Experimental|Hydrocortisone Low Dose|Intervention: 1/3 Intravenous equivalent dose (IVED) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD) 1, followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
89635688|NCT03028493|Experimental|Adapted SAFE Intervention|Adapted version of the SAFE Health Behavior and Exercise intervention.
89635689|NCT03028493|Active Comparator|Original SAFE Intervention|Original version of the SAFE intervention.
89635690|NCT01374906|Experimental|10 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
88990985|NCT05909735|Experimental|Total/near-total LSCD with recurrent or persistent epithelial defects (PED)|Patient with visually significant total LSCD, as defined by a best corrected visual acuity of 20/100 or less, and total LSCD on slit lamp exam with over 25% of the limbus intact or less than 25% of the corneal surface covered with corneal epithelium; and a history of a persistent epithelial defect that has persisted over 2 weeks despite maximal medical therapy, or a history of recurrent epithelial erosions that occur more frequently than once a month; will be enrolled in the second arm.
88990986|NCT05904314|Experimental|Experimental Group|Investigation of the effectiveness of scenario-based standardized patient simulation training and electronic fetal monitor management of midwifery students
88990987|NCT05904314|No Intervention|Control Group|Behavioral: Examining the effectiveness of electronic fetal monitor management of midwifery students with theory training
88990988|NCT05904288||Arm 1|The study group will receive noninvasive, in-depth clinical assessments similar in frequency to monitoring pertinent to normal clinical practice aimed at people with Parkinson's disease. In addition, within the mobile application provided as a gateway for data collection from the wearable sensors, subjects will also have the ability to access a library of video-recorded exercises, the effect of which on symptom modification, however, is not the subject of this investigation.
88990989|NCT05903625|Experimental|Control Group - Standard White Bread|This arm serves as the control group in the clinical trial, providing a baseline comparison for the intervention arms. Participants in this arm consume standard white bread
89635691|NCT01374906|Experimental|30 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
89635692|NCT02974504|Experimental|evogliptin|evogliptin 5mg qd
88990990|NCT05903625|Experimental|Lysine Group - Lysine-Fortified Bread|This arm investigates the effect of lysine-fortified bread on glycemic response. Participants in this arm consume bread fortified with lysine, an essential amino acid.
89635693|NCT02974504|Active Comparator|linagliptin|linagliptin 5mg qd
89635694|NCT04744948|Placebo Comparator|low caloric diet|low caloric diet 1200cal/day
89635695|NCT04744948|Experimental|treadmill|treadmill aerobic exercise training
89635696|NCT04341688|Experimental|Povidone-Iodine 0.2% (BETADINE®)|0.2% Povidone-Iodine (BETADINE®) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
89635697|NCT04341688|Experimental|Hydrogen peroxide 1% (ActiveOxy)|ActiveOxy (1% Hydrogen peroxide) 10 ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
89635698|NCT04341688|Active Comparator|Neem extract (Azadirachta indicia)|Neem extract (Azadirachta indicia) gargle will be prepared by chemistry laboratory. patients will do 10ml gargle and nasal lavage for 20-30 seconds, thrice daily for 6 days.
89211970|NCT03131193|Experimental|Physician - No Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
89211971|NCT03131193|Experimental|Physician - Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
89211972|NCT03131193|Experimental|Mid-level Provider - No Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
89211973|NCT03131193|Experimental|Mid-level Provider - Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
89211974|NCT04420299|Experimental|Experimental - therapeutic bemiparin dose|Sub-cutaneous dose of bemiparin at therapeutic dose for 10 days
89635699|NCT04341688|Active Comparator|Hypertonic saline (2%NaCl)|10 ml gargle and nasal lavage using Hypertonic saline for 20-30 seconds, thrice daily for 6 days.
89635700|NCT04341688|Placebo Comparator|Positive controls|10 ml gargle and nasal lavage using distilled water for 20-30 seconds, thrice daily for 6 days.
89635701|NCT03065686|Experimental|Identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
89635702|NCT03029806|Active Comparator|Afr-Amer risk allele|African Americans carrying the LSD1 affected allele
89635703|NCT03029806|Placebo Comparator|Cauc risk allele|Caucasians carrying the LSD1 affected allele
89635704|NCT03029806|Placebo Comparator|Afr-Amer non-risk allele|African Americans carrying the LSD1 non-risk allele
89635705|NCT03029806|Placebo Comparator|Cauc non-risk allele|Caucasians carrying the LSD1 non-risk allele
89635706|NCT03028948|Experimental|Arm I (ITW)|Patients access ITW and complete each module over 30-40 minutes. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
89635707|NCT03028948|Active Comparator|Arm II (usual care)|Patients receive usual care and are then offered ITW. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
89211975|NCT04420299|Experimental|Control - prophylactic bemiparin dose|Sub-cutaneous dose of bemiparin at prophilactic dose for 10 days
89211976|NCT00619502|Experimental|DTaP-IPV-Hep B-PRP~T Vaccine Group|Participants received a primary series of 3 vaccinations with DTaP-IPV-Hep B-PRP~T, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-HepB-PRP~T at 15 to 18 months of age in the present study
89211977|NCT00619502|Active Comparator|Pentaxim™ + Engerix B™ Vaccines Group|Participants received a primary series of 3 vaccinations with Pentaxim™ and Engerix B™ vaccines, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-Hep B-PRP~T at 15 to 18 months of age in the present study.
89635708|NCT03013504|Experimental|HD201 in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
89635709|NCT03013504|Active Comparator|Herceptin® in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
89635710|NCT04744792||Patients|All the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
89635711|NCT04744792||Spouses|Spouses of the patients who underwent anterior resection, low anterior resection and abdominoperineal resection between march 2006 and novenmer 2010
89635712|NCT02683746|Experimental|Albiglutide active LAI plus Placebo lyophilized DCC PI|Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
89635713|NCT02683746|Experimental|Albiglutide lyophilized DCC PI plus Placebo LAI|Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
89635714|NCT03883529|Experimental|Women reviewing birth experience|Women who had their antenatal care provided at a high-risk antenatal clinic, will be offered to write about and review their birth experience about 6 weeks post-partum with a known midwife from antenatal care.
89688531|NCT02797054|Experimental|Tailored Intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
89211978|NCT00992199|No Intervention|control arm|adjuvant intravenous system chemotherapy
89635715|NCT02691468|Active Comparator|PVC DLT|"After the induction of general anesthesia, a left sided PVC DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of PVC DLT is calculated from difference in tracheal distance between supine and lateral position."
89635716|NCT02691468|Active Comparator|silicon DLT|"After the induction of general anesthesia, a left sided silicon DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of silicon DLT is calculated from difference in tracheal distance between supine and lateral position."
89635717|NCT02678676||Pioglitazone|Participants who previously received pioglitazone in the PROactive study (NCT00174993).
89635718|NCT02678676||Placebo|Participants who previously received Pioglitazone-matching placebo in the PROactive study (NCT00174993).
89635719|NCT03162276|Experimental|Intervention|Inquiry Based Stress Reduction
89635720|NCT03162276|Placebo Comparator|Control|The placebo group participants will receive a modified form of the intervention at the close of the study
89635721|NCT01558739|Experimental|INC424|Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.
89635722|NCT03162120|Active Comparator|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
89635723|NCT03162120|Active Comparator|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
89635724|NCT03162198||Cirrhosis with HCC|
89635725|NCT03162198||Cirrhosis without HCC|
89635726|NCT03162042||Squamous cell carcinoma|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
89635727|NCT03162042||Control group|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
89635728|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg untrained|Patients receiving Handihaler who have not been trained (real-life use) for over 3 months on its use. Here the investigators want to see that if patients have on-going symptoms but are on Handihaler-Tiotropium 18mcg what is happening PRIOR to proper inhaler technique training - that is their 'real-life' use of the inhaler - to their lung function (large and small airways) and also symptoms or exercise limitation (determined by CAT score) will already be recorded as entry criteria
89635729|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg trained|Patients will be trained in their use of Handihaler-Tiotropium and asked to take 18 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER proper inhaler technique training on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score)
89635730|NCT02683668|Experimental|Respimat-Tiotropium 5 mcg trained|Patients will be switched to trained Respimat Tiotropium 5 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER this efficient device Respimat (trained) compared to PREVIOUS device Handihaler (trained) on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score). The investigators want to see if the properties of the Respimat device with deeper lung deposition (slow velocity and small particles) can improve small airway measures (and indeed large airway measures) that might also be related to an improvement in symptoms.
89635731|NCT02678286|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
89635732|NCT02678286|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
89635733|NCT03115008|Experimental|Video-based terminal feedback|
89635734|NCT03115008|No Intervention|Conventional concurrent feedback|
89635735|NCT03115164||Patients with DIA / DIG treated at the French SFCE pediatric|
89635736|NCT03166020|Experimental|Rehabilitation with Interactive Table|Included patients will be invited to participate in 10 sessions, focused on the movement and manipulation of instrumented objects on interactive table with serious game, during 30 minutes per day, 5 days a week, for 14 days. An occupational therapist will be required only for patient installation in front of the table.
89041915|NCT06236087||Aim 1 & 2 - Dataset|"For Aims 1 and 2, an existing, de-identified dataset will be used for secondary analysis, including records for a maximum of 500 individuals.~Aim 1 will use machine learning to identify sub-groups for whom OPC use is most and least protective of overdose risk. Identifying key intersectional groups across demographic (e.g., race/ethnicity, gender, and age), PSU factors (e.g., drug types and routes of administration), and socio-behavioral (e.g., mental health history, justice history, and homelessness) characteristics will inform targeted service delivery. Aim 2 will use epidemiological methods to estimate the association of OPC use with mental health services salient to PSU populations (e.g., hospitalization for depression, anxiety, and bipolar disorder). Measuring the association of OPC use with treated mental health outcomes for PSU-involved populations will foster an understanding of the impacts of OPCs on critical but unevaluated outcomes."
89041916|NCT06236087||Aim 3 - Harm Reduction Staff|For Aim 3, individuals employed at harm reduction programs in NYC will be enrolled for a one-time qualitative interview. Qualitative interviews will explore organizational (i.e., readiness, culture, and priorities), individual (i.e., attitudes and norms), and intervention (i.e., complexity and advantage) characteristics related to the integration of mental health and harm reduction services. Findings will inform efforts to scale ancillary mental health services high-risk PSU population.
89041917|NCT06236074|Other|Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours|
89041918|NCT06236061|Active Comparator|LCZ 200mg|Oral administration, 1 tablet of LCZ 200 mg daily, 4 capsules of Amlodipine placebo daily.
89635737|NCT03166020|Active Comparator|Self Rehabilitation|Included patients will be instructed to perform 10 self-rehabilitation sessions with 9 exercises (3 stretching, 3 reinforcement, 3 spot-oriented work) during 30 minutes per day, 5 days a week, for 14 days.
89635738|NCT03165786|Experimental|FREE Group|Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
89635739|NCT03165786|No Intervention|Control Group|Real-time continuous glucose monitoring
89635740|NCT03165630|No Intervention|Group 1|Education or Control group.
89635741|NCT03165630|Experimental|Group 2|Transportation incentives
89635742|NCT03165630|Experimental|Group 3|Transportation and rehabilitation services incentives
89635743|NCT03165708||anesthesiologist|The active comparators for this study will be expert anaesthesiologists (operator). The operators will be blinded to all visual and audible CompuFlo® real-time pressure feedbacks.Inter-rater agreement, or concordance, between an expert anaesthesiologist and the CompuFlo® Epidural Computer Controlled System for the epidural space verification will be assessed by blinded tagging of the operator's feeling of the ligamenta and epidural space on the screen of the Compuflo to be eventually compared with the pressure's variations
89635744|NCT03164694|Experimental|Apatinib|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
89635745|NCT03164694|Active Comparator|Control|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).
89635746|NCT02682264|Experimental|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
89635747|NCT02930902|Active Comparator|Arm A (pembrolizumab, paricalcitol)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each course and paricalcitol IV over 15 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
89041919|NCT06236061|Experimental|LCZ 200mg + AML 2.5mg|Oral administration, 1 tablet of LCZ 200 mg daily, 1 capsule of Amlodipine 2.5 mg daily and 3 capsules of Amlodipine placebo daily.
89041920|NCT06236061|Experimental|LCZ 200mg + AML 5mg|Oral administration, 1 tablet of LCZ 200 mg daily, 2 capsules of Amlodipine 2.5 mg daily and 2 capsules of Amlodipine placebo daily.
89041921|NCT06236061|Experimental|LCZ 200mg + AML 10mg|Oral administration, 1 tablet of LCZ 200 mg daily, 4 capsules of Amlodipine 2.5 mg daily.
89041922|NCT06236048||Healthy volunteers|
89041923|NCT06236048||Schizophrenia - remission|
89041924|NCT06236048||Treatment resistant schizophrenia|
89041925|NCT06236022|No Intervention|Control|patients with dilated cardiomyopathy infected with Kaposi sarcoma-associated virus to receive standard DCM therapy
89041926|NCT06236022|Experimental|Sirolimus|patients with dilated cardiomyopathy infected with Kaposi sarcoma-associated virus to receive sirolimus (at a dose of 2 mg once daily) in addition to standard DCM therapy
89041927|NCT06235983|Experimental|LY3537982|LY3537982 administered orally.
89041928|NCT06235957|Other|Group A|Three weeks of cast immobilisation
89041929|NCT06235957|Other|Group B|One week of brace immobilisation
89041930|NCT06235944|Experimental|Caudal block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.
89041931|NCT06235944|Experimental|Sacral erector spinae|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
89635748|NCT02930902|Experimental|Arm B (pembrolizumab, paricalcitol, chemotherapy)|Patients receive pembrolizumab and paricalcitol as in Arm A. Patients also receive gemcitabine hydrochloride IV over 30 minutes and nab-paclitaxel IV over 30-40 minutes on days 1, 8, and 15 of course 1 in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
89635749|NCT02926066|Experimental|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
89635750|NCT02900482||case group|Patients with a history of congenital hip dislocation
89635751|NCT02900482||control group|Patients with no history of congenital hip dislocation
89635752|NCT02900482||parents of case group|Parents of patients with a history of congenital hip dislocation
89041932|NCT06235931|Experimental|Treatment group|Dalcilib +AI (letrozole/anastrozole/exemestane) + pyrrolizinib
89041933|NCT06235918|Experimental|Neoadjuvant therapy of tislelizumab with chemotherapy|Neoadjuvant Tislelizumab plus double platinum based chemotherapy for 2 cycles
89635753|NCT02817802||Magmaris|Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
89635754|NCT02767804|Experimental|X-396 (ensartinib)|Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
89041934|NCT06235866||Follow-up cohort of patients with severe COVID-19|The scores of various scales, pulmonary function and imaging changes of patients with severe COVID-19 were collected at 3 months, 6 months and 12 months after rehabilitation and discharge.
89041935|NCT06235853||Patients after TURBT with NMIBC|Patients who underwent successful TURBT with histopathological proof of non-muscle invasive bladder cancer. Blood and urine specimen have been gathered prior to hospital admission during visit in out-patient clinic.
89057567|NCT04315753||prospective screening cohort of high risk individuals|a prospective screening cohort of high risk individuals enrolled at Humanitas Hospital (1000) will allow to recruit 50 patients with screening detected lung cancer and a large number of negative controls. Analysis of CTC, exosome antigens and cfDNA mutation profile will be performed.
89057568|NCT02886598||Firmagon®|Treatment according to standard clinical practice.
89635755|NCT02767804|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
89635756|NCT02741128|Experimental|CYD Dengue vaccine group|Subjects will receive 3 doses of CYD dengue vaccine at 0, 6, and 12 months
89635757|NCT02741128|Placebo Comparator|Placebo vaccine group|Subjects will receive 3 doses of placebo (NaCl, 0.9%) vaccine at 0, 6, and 12 months
89635758|NCT02721316|Experimental|Supported with intensive nursing follow|Supported with intensive nursing follow post hospitalization the team of hospital output of the unit to 12 weeks after discharge. These interviews will be conducted at the hospital, at home or by phone and their pace will be adjusted according to the patient's condition. The expected duration of close outpatient follow-up is of maximum 3 months.
89635759|NCT02721316|No Intervention|usual care|For control patients, monitoring will be identical to their usual care as part of their pathology.
89635760|NCT02660554|No Intervention|Usual care|In the usual care arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be given at the discretion of the care team. If bacterial cultures are negative for MRSA at 72 hours, the treating physician will be prompted to discontinue MRSA therapy.
89635761|NCT02660554|Experimental|Polymerase Chain Reaction|In subjects randomized to the polymerase chain reaction (PCR) arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be determined by the results of the PCR test. In subjects who are clinically stable, results from the PCR must be available prior to the administration of MRSA therapy. Subjects with a positive MRSA PCR will be administered MRSA therapy. In subjects with a negative MRSA PCR, MRSA therapy will be withheld. In subjects randomized to the automated PCR arm who are clinically unstable, empiric MRSA therapy will be allowed until the PCR is completed. In these cases of unstable subjects, empiric MRSA therapy will be discontinued if the PCR is negative.
89635762|NCT01566721|Experimental|Cohort A: SC Herceptin by Needle/Syringe|Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
89635763|NCT01566721|Experimental|Cohort B: SC Herceptin by SID|Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.
89635764|NCT01541215|Experimental|Lira + Met|
89635765|NCT01541215|Placebo Comparator|Placebo + Met|
89635766|NCT01540981|Active Comparator|SOC - Standard of Care|Standard of care consists of pressure relief, creams, wound cleansing and dressings as needed
89635767|NCT01540981|Active Comparator|MIST Therapy with SOC|Standard of Care including pressure relief, wound cleansing, creams, and dressings as needed plus MIST Therapy daily for 5 days and then every other day for up to 7 more days
89635768|NCT01585987|Experimental|Arm A: Ipilimumab|Ipilimumab 10 mg/kg solution intravenously, 90 minute infusion, once every 3 weeks for 4 doses, then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
89635769|NCT01585987|Other|Arm B: Best Supportive care (BSC)|BSC may include the continuation of the Fluoropyrimidine that was used during the lead-in chemotherapy, but no other systemic anti cancer therapy
89635770|NCT01585831|Experimental|Testosterone gel 1%|Testosterone gel 1% applied to skin once per day for 1 year. Starting dose 1.25mL per day, titrated in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day. Titration based on testosterone levels with target level in mid-range of normal for Tanner stage.
89635771|NCT01585831|Placebo Comparator|Placebo gel|Placebo gel applied to skin once per day for 1 year. Starting dose 1.25mL per day. Dose randomly adjusted in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day.
89688532|NCT02797054|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
89688533|NCT02797054|Other|Usual Care|Intervention: usual care as experienced during appointment with primary care provider. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
89041936|NCT06235840|Experimental|Working memory adaptive cognitive training|In the intervention, the n-back task involving working memory in terms of its content updating was applied. This task is based on the continuous presentation of items (letters in this study) that appear and disappear one by one. During each presentation, the participant must judge whether the currently displayed item matches the item presented 'n' trials earlier. The n-back task used in the current study was computerized and was programmed in PsychoPy software. All participants started their training from the 1-back level. The training was adaptive, meaning that, according to the performance accuracy achieved, participants progressed to higher (or dropped to lower) levels of difficulty. The increasing/decreasing difficulty was based on a rise/fall in the 'n' parameter. Participants were involved in 12 sessions, three in each of the four weeks. Each session lasted approximately 45 minutes.
89041937|NCT06235840|Active Comparator|Multi-domain non-adaptive cognitive training|Non-adaptive multi-domain computerized training included tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. Participants were involved in 12 sessions, three in each of the four weeks. Each session lasted approximately 45 minutes.
89041938|NCT06235840|No Intervention|No contact|The passive control group was the no-contact group. Participants had no contact with the researcher for 4 weeks, corresponding to the duration of the intervention (training) in the experimental group.
89041939|NCT06235827|Experimental|Green tea group|Patients in Group A will have to consume two cup (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes.
89041940|NCT06235827|Experimental|Control Group|Patients in Group B will not consume green tea for 6 months during study period.
89057569|NCT01683747|Experimental|Tranexamic acid|Study group receives enteral tranexamic acid in normal saline in addition to usual care.
89057570|NCT01683747|Placebo Comparator|Control group|Control group receives vehicle (normal saline) without study drug and usual care.
88990991|NCT05903625|Experimental|Phosphorus Group - Phosphorus-Fortified Bread|This arm explores the impact of phosphorus-fortified bread on glycemic response. Participants in this arm consume bread fortified with phosphorus, an essential mineral.
89635772|NCT04409899||Urological surgical patients during COVID-19 pandemic|During the COVID-19 pandemic, the urological patients in the need of a surgical intervention have been screened on the basis of the underline conditions, the priority of surgery, and risk-benefit assessment. A pre-surgical work-out was performed in the selected patients, with some of them being detected of COVID-19 at RT-PCR or suspected for it according to the risk-assessment survey. Enhanced blood tests and X-rays of the thorax were performed as baseline assessments. In case of development of post-surgical unspecific symptoms, clinical and laboratory work-out were performed before to expedite a new RT-PCR, which would have required preventive isolation of a patient in a COVID-19 ward. We evaluated the impact of COVID-19 in this selected cohort and the complications eventually associated with the viral infection.
89635773|NCT03028207||COPD|Subjects with FEV1/FVC score less than 0.70 post-bronchodilator test will be allocated to COPD group and the prevalence of COPD will be evaluated. Subjects in this group will be categorized in 4 groups namely GOLD I - IV depending on the disease severity.
89635774|NCT03028207||Non-COPD|Subjects with FEV1/FVC score greater than or equal to 0.70 post-bronchodilator test will be allocated to non-COPD group.
89635775|NCT03028051||chronic pain patients|Finnish speaking, adult chronic pain patients, aged 18 - 75 years, referred to pain clinic
89635776|NCT01565941|Active Comparator|Tight Glycemic Control 1 (TGC-1)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm.
89635777|NCT01565941|Active Comparator|Tight Glycemic Control 2 (TGC-2)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm.
89635778|NCT03027895|Experimental|Lumen-apposing metal stent(LAMS)|Lumen-apposing metal stent(LAMS) will be deployed by endoscopist under the guidance of EUS
89635779|NCT03027895|Active Comparator|Double pigtail plastic stent(DPPS)|Double pigtail plastic stent(DPPS) will be deployed by endoscopist under the guidance of EUS
89635780|NCT01558271|Experimental|LY2189265|Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
89635781|NCT01558271|Placebo Comparator|Placebo/LY2189265|Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
89635782|NCT01558271|Active Comparator|Liraglutide|Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.
89635783|NCT01565707|Placebo Comparator|Placebo Children|Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
89635784|NCT01565707|Experimental|Solifenacin Succinate Suspension Children|Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
89635785|NCT01565707|Placebo Comparator|Placebo Adolescents|Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
89635786|NCT01565707|Placebo Comparator|Solifenacin Succinate Suspension Adolescents|Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
89635787|NCT01557569|Active Comparator|Atomoxetine|Group receiving atomoxetine
89635788|NCT01557569|Placebo Comparator|Placebo|Group will receive placebo instead of atomoxetine
89635789|NCT04756271|Experimental|Health-care workers|Healthy health-care workers at Zagazig University Hospital who opt by their free well to administer 2 doses of SARS-Cov-2 inactivated vaccine at 0 and 21 days. Blood samples will be withdrawn from them to investigate the immune response to the given vaccine
89635790|NCT01538719|Placebo Comparator|Placebo|2:1 randomization
89635791|NCT01538719|Active Comparator|Rilonacept|2:1 randomization
89635792|NCT01537783|Experimental|Intervention group|In this arm, patients are treated with chlorhexidine scrubs once a day for 5 days and mupirocin nasal ointment inserted to both nostrils twice a day for 5 days. Both treatments are begun 7 days after enrollment, or when the abscess has healed fully if it has not healed by day 7.
89635793|NCT01537783|No Intervention|Standard of Care|In this arm, patients receive routine care of their abscess, which may or may not include either topical or oral antibiotics, at the discretion of the treating clinician.
89635794|NCT01556165|Experimental|rasagiline|
89635795|NCT01556165|Placebo Comparator|placebo|
89635796|NCT01537549|Experimental|Juvenon|
89635797|NCT01555931|Experimental|Immediate|Placement within 48 hours of delivery
89635798|NCT01555931|Active Comparator|Control|Placement 4-8 weeks after delivery
89635799|NCT01583179|No Intervention|Control group|will get only local anesthetic and epinephrine in block. no additive in block
89635800|NCT01583179|Experimental|buprenorphine|will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block
89635801|NCT01582945|Experimental|Ketamine IV|Patients will receive open label augmentation with IV Ketamine at 0.5mg/kg, twice a week for 3 weeks
89688534|NCT00920075||1 Alendronate for 12 months, post study|Participants earlier were treated with alendronate for 12 months either in an open label study (without control) or double blind study with placebo control. These studies were completed. In this post study evaluation, available participants will be scheduled for one clinic visit to assess their current status of the bone density and no treatment is involved.
89688535|NCT04364035|Experimental|CCMM+GS-9620|ChAdOx1.HTI 2 doses, MVA.HTI 2 doses, GS-9620 10 doses.
89688536|NCT04364035|Placebo Comparator|PLACEBO|ChAdOx1.HTI placebo 2 doses, MVA.HTI placebo 2 doses, GS-9620, placebo 10 doses.
89057571|NCT01683903||Non coronary patients (NC)|Patient with myocardial infarction with non-coronary (NC) etiology
89057572|NCT01683903||Coronary patients (C)|Patients with myocardial infarction due to coronary disease
89635802|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle (1 cycle = 21 days) as a loading dose of 840 milligrams (mg), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg per kilogram (mg/kg), followed by 6 mg/kg on Day 2 of each subsequent cycle. Vinorelbine IV infusion (will be administered after trastuzumab) on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg per meter-squared (mg/m^2) followed by 30-35 mg/m^2 on Day 2 and Day 9 of each subsequent cycle. Pertuzumab and trastuzumab will be administered sequentially in separate infusion bags, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
89635803|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg/kg, followed by 6 mg/kg on Day 1 of each subsequent cycle. Vinorelbine IV infusion on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Day 1 and Day 8 of each subsequent cycle. If administration of all 3 drugs is well tolerated in Cycle 1, then on Day 1 of each subsequent cycle, pertuzumab 420 mg and trastuzumab 6 mg/kg will be administered in a single infusion bag, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
89635804|NCT01582789|Active Comparator|enfilcon A/senofilcon A|Subjects were randomized to wear enfilcon A then Senofilcon A for two weeks.
89635805|NCT01582789|Active Comparator|senofilcon A/enfilcon A|Subjects were randomized to wear senofilcon A then enfilcon A for two weeks
89635806|NCT01537393|Other|0-7d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 0 to 7 days prior to transplant.
89635807|NCT01537393|Other|8-14d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 8 to 14 days prior to transplant.
89635808|NCT01555151|Experimental|Mometasone furoate 80 μg|Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.
89635809|NCT01555151|Experimental|Mometasone furoate 200 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.
89635810|NCT01555151|Experimental|Mometasone furoate 320 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.
89635811|NCT01555151|Experimental|Mometasone furoate 800 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.
89635812|NCT01537081|Experimental|Mucinex 2400 mg/day|The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600 mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
89635813|NCT01537081|Active Comparator|Immediate-release Guaifenesin 800 mg/Day|The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
89635814|NCT01537081|Placebo Comparator|Placebo|Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
89635815|NCT01564459|Experimental|MK-6096 10 mg→MK-6096 10 mg|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive MK-6096 10 mg once daily for 2 weeks during double-blind treatment period.
89635816|NCT01564459|Placebo Comparator|MK-6096→Placebo|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive placebo once daily for 2 weeks during double-blind treatment period.
89635817|NCT01555073|Active Comparator|Pregabalin/celecoxib group|pregabalin/celecoxib twice a day for 13 days.
89635818|NCT01555073|Active Comparator|Pregabalin/placebo group|pregabalin/placebo twice a day for 13 days.
89635819|NCT01555073|Active Comparator|Celecoxib/placebo group|celecoxib/placebo twice a day for 13 days.
89635820|NCT01555073|Placebo Comparator|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
89635821|NCT01582243|Experimental|Vildagliptin plus metformin (SPC)|Eligible participants received oral vildagliptin 50 mg plus metformin 500 mg (SPC) twice daily from week 1 to week 24.
89635822|NCT01536535|Experimental|Mild UC|"Mild = Initiated on mesalazine, or on oral CS with Pediatric Ulcerative Colitis Activity Index (PUCAI) < 45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-Tumour Necrosis Factor alpha (TNFα) therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-MP at 1-1.5 mg/kg/day Colectomy"
89635823|NCT01536535|Experimental|Moderate to Severe UC|"Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-TNFα therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-Mercaptopurine (MP) at 1-1.5 mg/kg/day Colectomy"
89635824|NCT01554527|Experimental|CPAP treatment|Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care. For analysis purposes those children who were non-adherent (CPAP use <4 hours per night) vs. adherent (CPAP use at least 4 hours per night) will be analyzed separately.
89635825|NCT01554527|Other|No CPAP treatment|Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.
89635826|NCT04767763||Patients with Acute Kidney Injury|Patients with acute kidney injury and indications for initiation of continuous renal replacement therapy (CRRT) were included to this study irrespective of their gender, race and age.
89635827|NCT01563913|Experimental|Arm 1|Docosahexaenoic Acid (DHA)
89635828|NCT01563913|Placebo Comparator|Arm 2|Placebo
89635829|NCT01553747|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.
89635830|NCT01553747|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.
89635831|NCT01553747|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.
89635832|NCT01536379|Experimental|Belimumab 10 mg|Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.
89635833|NCT01536379|Placebo Comparator|Placebo|Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care
89635834|NCT04409977||Patient group|Patients suffering from cluster headache will be included in this group. When analysing the data, the investigators will distinguish those in the in-bout period from those in the out-bout period. People in this group may participate twice: once in the in-bout and once in the out-bout period.
89635835|NCT04409977||Control group|Participants not suffering from cluster headache will be included in this group.
89635836|NCT01536145|Experimental|Single agent CP-751,871|dose escalation design
89635837|NCT01536067|Experimental|Treatment (monoclonal antibody therapy)|"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
89041941|NCT06235775|Experimental|GV1001 1.12 mg|"In GV1001-PSP-CL2-011 study, subjects who were in the trial group (Study Group 1(GV1001 0.56 mg/day), Study Group 2(GV1001 1.12 mg/day) is alternately administered High-dose test drug(GV1001 1.12 mg/day) and placebo once a week from Ex-Visit 1(Visit 16, Week 26) to Ex-Visit 5(Visit 20, Week 30) and High-dose test drugs(GV1001 1.12 mg/day) are administered from Ex-Visit 6 (Visit 21, Week 32) to Ex-Visit 26(Visit 41, Week 72) every two weeks.~In the GV1001-PSP-CL2-011 study, subjects who were in the placebo group are administered placebo at Ex-Visit 1 (Visit16, Week26), the first visit of the extension study, and Ex-Visit 2 (Visit17, Week27) to Ex-Visit 5 (Visit 20, Week 30), High-dose test drugs(GV1001 1.12 mg/day) are administered once a week and High-dose test drugs (GV1001 1.12 mg/day) are administered from Ex-Visit 6 (Visit 21, Week 32) to Ex-Visit 26(Visit 41, Week 72) every two weeks."
89041942|NCT06235762|No Intervention|Conventional Medical Evaluation|Participants in the control group will only undergo conventional medical evaluation.
89041943|NCT06235762|Active Comparator|Conventional Medical Evaluation Plus Nutritional Assessment|Participants in the intervention group will undergo the same medical care, concomitantly with nutritional assessment.
89041944|NCT06235749|Experimental|calcium gluconate|Administration of Calcium Gluconate 10% IV following umbilical cord clamping.
89041945|NCT06235749|Placebo Comparator|normal saline 0.9%|Administration of normal saline 0.9% IV following umbilical cord clamping.
89041946|NCT06235736||MRI-confirmed ACL tear group|This group will have had a complete ACL tear confirmed by MRI scan
89041947|NCT06235736||Normative group|This group will provide normative data for the study. They will have no previous history of significant knee injury and no current symptomatic lower limb injuries.
89041948|NCT06235710||Group 1: Nursing home residents without dementia|"Mentally competent nursing home resident ≥ 65 years;~No diagnosis of dementia (major neurocognitive disorder according to DSM-5 criteria);~The nursing home resident provides informed consent to participate in the study.~In this study, nursing home residents all undergo a physical examination of the musculoskeletal system.~In addition:~- In group 1: nursing home residents provide an answer on 3 non-incriminating questions (assessment general health, severity of joint complaints and pain in general)."
89057573|NCT04538027|Active Comparator|6 weeks|Microdiscectomy was done at 6 weeks of starting symptoms
89057574|NCT04538027|Active Comparator|3 months|Microdiscectomy was done at 3 months of starting symptoms
89057575|NCT04538027|Active Comparator|6 months|Microdiscectomy was done at 6 months of starting symptoms
89041949|NCT06235710||Group 2: Nursing home residents with dementia|"Nursing home resident with dementia (major neurocognitive disorder according to DSM-5 criteria) ≥ 65 years;~The legal representative of the nursing home resident provides informed consent to participate in the study.~In this study, nursing home residents all undergo a physical examination of the musculoskeletal system.~In addition:~In group 2: if possible, provide an answer on 1 non-incriminating question (severity of joint complaints). If the nursing home resident cannot answer this question (reliably), we use the Pain Assessment Checklist for Seniors with Severe Dementia (PACSLAC-D)."
89041950|NCT06235697|Active Comparator|EBRT + Brachy Boost|
89635838|NCT04410211|Active Comparator|Group S (inhalational Sevoflurane sedation)|"The inhalational anaesthetic agent and oxygen will be delivered via an anaesthetic circuit with a vaporizer (Sevotec 3, Ohmeda, Streeton UK) with a nasal mask.~Patients who are allocated for Sevoflurane will be given initial oxygen flow of 8L/min and then Sevoflurane was introduced at a concentration of 0.2% and was increased stepwise by 02% for every 30s up to a maximum of 1.0 minimum alveolar concentration (MAC; 2.05% end tidal). Patient's deepest sedation was recorded and adjusted to achieve optimal Observer's Assessment of Alertness/ Sedation Scale (OAAS) score of 3.~Inadequate or over sedation was treated by reducing or increasing the Sevoflurane concentration dial by 0.2 - 0.6% until the desired effect is reached.~Full vital signs monitoring are done for every participant"
89635839|NCT04410211|Active Comparator|Group M (Intravenous Midazolam sedation)|"Patients who are allocated for Midazolam will be given the similar nasal mask delivering 8L/min oxygen. However, Sevoflurane will not be introduced to these patients.~Midazolam is titrated slowly to achieve OAAS score of 3 but no more than 2.5mg is to be given within 2 minutes period to patients selected to be in Midazolam group.~Inadequate sedation is treated by giving slow titration of the medication based on the unblinded observer's judgement. Over sedation is treated by withholding the midazolam and continuing oxygen supplementation until the patient returned to the desired sedation level. No other sedative agents are allowed to be given to the patient or else patient will be excluded from this study."
89635840|NCT01582009|Experimental|Arm I: Oral Panobinostat and Oral Everolimus|Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89635841|NCT01553591|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.
89635842|NCT01553591|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.
89635843|NCT01553591|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.
89635844|NCT01581931|Experimental|Linagliptin/metformin|fixed dose combination tablet (FDC)
89635845|NCT01581931|Experimental|Linagliptin and metformin|single tablets
89635846|NCT01581619|Experimental|Partial Breast Irradiation|Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks
89635847|NCT01581307|Experimental|2nd Line Chemotherapy With Radiotherapy|"Administration of 2nd line chemotherapy will consist of a modified FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) will take place at least 2 weeks after the completion of first-line chemotherapy. Generally, second-line chemotherapy is given every two weeks for 6-10 cycles.~The goal of treatment with TheraSpheres is to allow a large dose of radiation to be delivered directly to the tumor(s) with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue."
89635848|NCT01580995|Experimental|Valacyclovir|Valacyclovir 500 mg po bid
89635849|NCT01580995|Placebo Comparator|Placebo|Matching placebo twice daily
89635850|NCT01535599|Experimental|AL-60371|AL-60371, 0.3% Otic Suspension, 4 drops to the affected ear(s) twice daily for 7 days
89635851|NCT01535599|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops to the affected ear(s) twice daily for 7 days
89635852|NCT01553279|Experimental|V419 and MCC-TT|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-TT (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of a measles, mumps, and rubella (MMR) vaccine (at 12 months of age).
89635853|NCT01553279|Experimental|V419 and MCC-CRM|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-CRM (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of an MMR vaccine (at 12 months of age).
89635854|NCT01562743|Experimental|SPM 962|Rotigotine transdermal patch
89635855|NCT03028571|Placebo Comparator|Intact Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of saline at 48 ml/hr IV
89635856|NCT03028571|Experimental|Blocked Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of trimethaphan (4mg/min) IV.
89635857|NCT01535443|Experimental|Bromfenac|Drug: Bromfenac ophthalmic solution 1 drop 4 times per day
89635858|NCT03028259||lab results|monitoring of
89041951|NCT06235697|Experimental|SBRT|
89041952|NCT06235684||Single Arm study|Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion
89041953|NCT06235671|Experimental|Chiropractic intervention|Upper cervical chiropractic care
89041954|NCT06235658|No Intervention|Control|Participants in the control group will not receive any intervention but will be provided with printed or electronic versions of the American Heart Association's 'Life's Essential 8' at baseline, which includes information on how to improve and maintain cardiovascular health.
89041955|NCT06235658|Experimental|Online Yoga Intervention|Participants in the intervention group will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks.
89041956|NCT06235632|Experimental|Policy and Training Intervention|This intervention includes the combination of a 2-hour policy meeting held by the Oregon Liquor and Cannabis Commission to teach the current laws around selling recreational marijuana as well as access to the TrainToTend program which contains 5 modules: The Laws, ID Checking, Health Effects, Customer Service, and Rules of the Trade
89057576|NCT01178671|Experimental|Sertraline and Mirtazapine|Flexible dose of both medications for up to 24 weeks
89635859|NCT04108403|Experimental|Pain Inducing Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
89635860|NCT04108403|Active Comparator|Pain Inducing Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
89635861|NCT04108403|Active Comparator|Pain Free Massage and Positive Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a positive expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
89635862|NCT04108403|Active Comparator|Pain Free Massage and Negative Expectation Instructions|A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a pain free massage (pain = 0/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
89041957|NCT06235632|Active Comparator|Usual and Customary Policy and Training (UC-PT) (Control) Condition|This is basic Responsible Marijuana Vendor training currently provided by the Oregon Liquor and Cannabis Commission and includes reading a booklet on selling recreational marijuana responsibly and passing and exam
89041958|NCT06235619||Non aneurysm patients|CT anatomical characteristics of the aortic arch in subjects without aneurysms requiring treatment.
89041959|NCT06235619||Aneurysm patients|CT anatomical characteristics of the aortic arch in subjects withaneurysms requiring treatment.
89041960|NCT06235580||Patients|
89635863|NCT01535287|Active Comparator|Dexmedetomidine|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
89635864|NCT01535287|Placebo Comparator|Placebo|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
89635865|NCT02985775|Experimental|Donor-derived CMVpp65-specific T cells|Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.
89635866|NCT01551173|Experimental|Fluvastatin sodium Extended Release Tablet|Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks
89635867|NCT01551173|Active Comparator|Fluvastatin sodium Immediate Release Capsule|Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks
89635868|NCT01549613|Active Comparator|standard treatment with daptomycin|Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol
89635869|NCT01549613|Active Comparator|standard treatment of vancomycin|Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
89635870|NCT04739189|Experimental|Obese adolescent|
89635871|NCT01548599|Experimental|Multi-sectoral agricultural intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
89635872|NCT01548599|No Intervention|Control|Participants enrolled at one study location will receive the standard of care. At the end of the study, participants in this arm will be eligible for the finance training and those who pay the loan down payment will be eligible for a small loan to purchase a human powered water pump, hosing, fertilizer, and certified seeds.
89635873|NCT01548287|Experimental|AZD5213 doseA|AZD5213 doseA daily
89635874|NCT01548287|Experimental|AZD5213 doseB|AZD 5213 doseB daily
89635875|NCT01548287|Experimental|AZD5213 doseC|AZD5213 doseC daily
89635876|NCT01548287|Placebo Comparator|Placebo|Placebo daily
89635877|NCT04410185|Experimental|MEDITATION|Meditation sessions will take place over 12 weekly sessions of 1.5 hours. A retreat (3 hours) will be realized after the 9th session
89635878|NCT01546883|Experimental|Dabigatran|Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant
89635879|NCT01546649|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
89635880|NCT01546649|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
89635881|NCT02985983|Experimental|KHK4827|KHK4827 administered SC
89635882|NCT02985983|Placebo Comparator|Placebo|Placebo administered SC
89635883|NCT01544309|Experimental|Atorvastatin administration group|
89635884|NCT01544309|Experimental|Rosuvastatin administration group|
89635885|NCT01544153|Other|WEB only|Control group receiving no additional intervention
89635886|NCT01544153|Experimental|WEB+SN|WEB plus social network intervention.
89041961|NCT06235580||Controls|
89041962|NCT06235580||Unaffected related subjects|
89041963|NCT06235567|Experimental|Dextenza insert|"This is a prospective, open-label, single-center, randomized, investigator-sponsored clinical study to compare dexamethasone intracanalicular insert and corticosteroid drops for post-treatment in patients undergoing epithelium-off corneal collagen cross linking surgery. The participant's worse eye will be randomized to one of the two treatments, and the fellow eye will receive the alternate treatment when undergoing the procedure at a subsequent date at least three weeks later. There will be a baseline/screening visit, a surgical/ insertion visit for each eye, and follow up visits over 6 months, for a total of 10 visits per patient.~The study drug, DEXTNZA, is administered during the surgical procedure and the patient does not need to do any additional steps."
89057577|NCT01178671|Active Comparator|Sertraline and Sugar pill|Sertraline and Sugar pill for up to 24 weeks
89057578|NCT02886637||Acinetobacter baumannii infection|Critically ill patients infect with Acinetobacter baumannii
89635887|NCT01544153|Experimental|WEB+NRT|WEB plus nicotine replacement therapy product.
89635888|NCT01544153|Experimental|WEB+SN+NRT|WEB plus social network intervention and nicotine replacement therapy product.
89635889|NCT01543685|Experimental|Indomethacin 40 mg TID|
89635890|NCT01543685|Experimental|Indomethacin 40 mg BID|
89635891|NCT01543685|Experimental|Indomethacin 20 mg TID|
89635892|NCT01543685|Active Comparator|Celecoxib 200 mg|
89635893|NCT01543685|Placebo Comparator|Placebo|
89635894|NCT01541969|Experimental|CR Neuromodulation|Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device. Participants receive the intervention according to the manufacturer/funder training given to the study team.
89635895|NCT01541969|Active Comparator|Tinnitus masking|Participants will receive the same Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device, but it will NOT be programmed according to the therapeutic algorithm (0-12 weeks).
89635896|NCT04767737|Experimental|Topical lavender oil group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
89635897|NCT04767737|Placebo Comparator|Placebo group|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured, and then, 3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients. No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
89635898|NCT04767737|No Intervention|Control groups|Before the administration, pain level, blood pressure, respiratory rate, pulse rate, oxygen saturation level (SPO2), and blood glucose of all patients (topical lavender oil, placebo, and control groups) were measured.No application was applied to the control group. 5 minutes later, the insulin injection site was wiped with 10% povidone-iodine (baticonol) in all patients, and the injection was given. During the administration of the insülin, the pain levels of the patients were measured again. After giving the injection, blood pressure, respiratory rate, pulse rate, oxygen saturation level, and blood glucose of the patients were also measured again.
89635899|NCT01540565|Experimental|Treatment (veliparib)|Patients receive veliparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89041964|NCT06235567|Active Comparator|topical prednisolone acetate 1% (PredForte) eye drops|"This is a prospective, open-label, single-center, randomized, investigator-sponsored clinical study to compare dexamethasone intracanalicular insert and corticosteroid drops for post-treatment in patients undergoing epithelium-off corneal collagen cross linking surgery. The participant's worse eye will be randomized to one of the two treatments, and the fellow eye will receive the alternate treatment when undergoing the procedure at a subsequent date at least three weeks later. There will be a baseline/screening visit, a surgical/ insertion visit for each eye, and follow up visits over 6 months, for a total of 10 visits per patient.~The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week."
89041965|NCT06235554|Experimental|intervention|
89041966|NCT06235541|Experimental|GENA104|80 patients in total with histologically/cytologically confirmed unresectable, recurrent, or metastatic advanced solid tumors, for who no standard therapy exists, or standard therapy has failed will be enrolled in this study.
89041967|NCT06235515|Experimental|group I|conventional treatment As conventional treatment, patients will receive 20 minutes of hotpack and 20 minutes of TENS, 5 sessions a week for a total of 15 sessions for 3 weeks. Additionally, patients will be given cervical isometric exercises as a home exercise program.
89041968|NCT06235515|Experimental|group II|conventional treatment and virtual reality In addition to conventional treatment, virtual reality treatment will allow patients to play games in which they can perform neck movements in all directions for 30 minutes a day, 5 sessions a week for 3 weeks..
89041969|NCT06235502|Experimental|Home-based, longterm cycle-exercise|One year home-based cycle exercise on a exercise bike connected to a video app from where participants can cycle push videos forward when cycling.
89041970|NCT06235502|Active Comparator|Standard of Care|Standard of Care; exercise at fitness center, home-based exercise according to programme, self-initiated exercise
89041971|NCT06235489|Experimental|Palfique Bulk Flow bulk-fil flowable restorative material|Procedure: restoration of proximal cavities of primary molars with bulk-fil flowable composite removal of proximal caries of primary molars and restoration of the cavities prepared by Palfique bulk flow
89041972|NCT06235489|Active Comparator|Glass-hybrid added HVGIC Equia Forte HT Glass-hyrbid-added highly viscous glass ionomer cement|Procedure: Restoration of proximal cavities of primary molars with highly viscous glass ionomer cement removal of proximal caries of primary molars and restoration of the cavities prepared by the Equia forte HT
89041973|NCT06235476|Experimental|animal-based protein (WP)|Supplements and control (MPP, WP, CON) will be consumed as a drink or in a recipe for five subsequent weeks (30 g/day); four weeks preload and one week during the Four Days Marches. With this amount, we aim to increase the protein intake from <1.0g/kg/bw/d to >1.2g/kg/bw/d. Participants are allowed to dissolve the powder in a liquid of choice: we will provide several examples to the participants during the instructions.
89057579|NCT04532216|Experimental|Study group|
89057580|NCT04532216|Other|Control group|
89057581|NCT01649700|Experimental|Mesenchymal stem cells treatment|All subjects will receive autologous adipose-derived mesenchymal stem cells
89057582|NCT04532060|Experimental|Antimicrobial Photodynamic Therapy|Patients treated with Antimicrobial Photodynamic Therapy
89635900|NCT01540487|Experimental|linagliptin/metformin(high dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order
89635901|NCT01540487|Experimental|linagliptin/metformin(low dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order
89635902|NCT03027947|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.~Participants in this study receive spinal cord stimulation will be trans-tibial and trans-femoral amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
89635903|NCT03028181||1|Control group non-exposed to tobacco smoking
89635904|NCT03028181||2|Control group exposed to tobacco smoking
89635905|NCT03028181||3|Patients with acute pancreatitis non-exposed to tobacco smoking
89635906|NCT03028181||4|Patients with acute pancreatitis exposed to tobacco smoking
89635907|NCT01539317|Active Comparator|Topical liquid lidocaine|
89635908|NCT01539317|Placebo Comparator|Topical Saline|
89635909|NCT01539239|Experimental|Hydrus Aqueous Implant (Treatment)|Cataract surgery plus Hydrus Aqueous Implant
89635910|NCT01539239|Active Comparator|Cataract Surgery (Control)|Cataract surgery only
89635911|NCT01539083|Experimental|Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]|Bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
89635912|NCT01539083|Experimental|Thalidomide + Prednisolone [TP Consolidation]|Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.
89635913|NCT01539083|Experimental|Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]|Bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.
89635914|NCT01537211|Experimental|Microprocessor knee then Mechanical knee|
89635915|NCT01537211|Experimental|Mechanical Knee then Microprocessor knee|
89635916|NCT01537133|Experimental|Inhaled corticosteroid|Fluticasone (250 mcg/puff, one puff, twice a day)
89635917|NCT01537133|Placebo Comparator|Placebo|Placebo fluticasone (one puff, twice a day)
89635918|NCT01537133|No Intervention|Healthy Control|
88990992|NCT05903625|Experimental|Lysine and Phosphorus Group - Double Fortified Bread|This arm examines the combined effect of lysine and phosphorus in double fortified bread on glycemic response. Participants in this arm consume bread fortified with both lysine and phosphorus.
88990993|NCT05901870||Russian Adults (18+)|Russian adults who meet the inclusion criteria (described below) will be participants of RNHTS.
88990994|NCT05899101||1 - Opioid Only|Illicit and/or sustained prescription opioids only (no cannabis use)
88990995|NCT05899101||2 - OAT Only|Opioid agonist therapy (OAT) only (no cannabis use)
89635919|NCT01537133|No Intervention|Atopic Non-asthmatics|
89635920|NCT01536587|Other|Single Arm|Inhalation of salmeterol 50 µg twice daily over 4 weeks
89635921|NCT01536119|Experimental|Coparenting Breastfeeding Support Intervention|The intervention group will receive a in-hospital discussion, a video, a workbook,a breastfeeding booklet, access to a secure study website, two follow-up emails, and one telephone call.
89635922|NCT01536119|No Intervention|Usual Care Group|The usual care group will receive standard postpartum care in the hospital and in the community
89635923|NCT01535729||Cohort|
89635924|NCT02985905|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate,every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
89635925|NCT02985905|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment
89635926|NCT01535261|Experimental|Ranibizumab arm|Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN
89635927|NCT01534637|Experimental|Treatment (antiemetic, chemotherapy, and radiation therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy once daily on days 1-5 for 5.5 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes once weekly and either fluorouracil IV continuously or capecitabine PO twice daily on days 1-5.~PROPHYLACTIC THERAPY: Beginning 1 hour before chemoradiotherapy, patients receive aprepitant PO on days 1-3. Treatment repeats every 7 days for 5.5 weeks in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION CHEMOTHERAPY: Two to four weeks after completion of chemoradiotherapy and prophylactic therapy, patients without disease progression or a declining performance status receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
89635928|NCT02655016|Experimental|Participants receiving Niraparib|
89635929|NCT02655016|Placebo Comparator|Participants receiving Placebo|
89635930|NCT01533935|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
89635931|NCT01533935|Placebo Comparator|Placebo QD|placebo comparator for tiotropium + olodaterol
89635932|NCT01533935|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
89635933|NCT01533935|Experimental|Tiotropium + olodaterol low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in fixed dose combination once daily
89635934|NCT01533935|Experimental|Tiotropium + olodaterol high dose|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily
89041974|NCT06235476|Experimental|plant-based protein (MPP)|Supplements and control (MPP, WP, CON) will be consumed as a drink or in a recipe for five subsequent weeks (30 g/day); four weeks preload and one week during the Four Days Marches. With this amount, we aim to increase the protein intake from <1.0g/kg/bw/d to >1.2g/kg/bw/d. Participants are allowed to dissolve the powder in a liquid of choice: we will provide several examples to the participants during the instructions.
89041975|NCT06235476|Experimental|protein-rich food products (PFP)|PFP will receive digitally supported dietary intake counselling, with a focus on the use of protein-enriched food products in order to increase protein intake up to >1.2 k/kg/bw/d.
89041976|NCT06235476|Active Comparator|control (CON)|Supplements and control (MPP, WP, CON) will be consumed as a drink or in a recipe for five subsequent weeks (30 g/day); four weeks preload and one week during the Four Days Marches. With this amount, we aim to increase the protein intake from <1.0g/kg/bw/d to >1.2g/kg/bw/d. Participants are allowed to dissolve the powder in a liquid of choice: we will provide several examples to the participants during the instructions.
89041977|NCT06235463|Experimental|Osteopathic Pedal Pump|
89041978|NCT06235463|Sham Comparator|Light Touch Treatment|
89041979|NCT06235450|Experimental|Therapeutic iLIDS arm|Subjects apply iTEAR100 device with iLIDS100 accessory
89041980|NCT06235437|Experimental|ASD141|IV, Monotherapy
89041981|NCT06235320||Paracetamol group|
89041982|NCT06235320||Ibuprofen group|
89041983|NCT06234878|Experimental|Gait analysis|Gait analysis with the investigational and the reference devices
89041984|NCT06234202|Experimental|Bioactive Sleeve then Control Sleeve|Each pitcher will be instructed to sleep with the assigned sleeve on the throwing arm after each game that he pitches
89057583|NCT04532060|Experimental|Nystatin|Patients treated with Nystatin antifungal drug.
89635935|NCT01532999|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
89635936|NCT01532999|Sham Comparator|Present Centered Group Therapy|Present Centered Group Therapy (PCGT) serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
89635937|NCT02652676|Experimental|Reversible Pulmonary Artery Banding Procedure|"The addition of afterload Reversible Pulmonary Artery Banding to a normal-functioning right ventricle (in the setting of end-stage dilated cardiomyopathy) shifts the inter-ventricular septum toward the midline, thus significantly improving left ventricular geometry and function. It permits the infant or young child to operate from a much improved position on Starling's curve with gradual resolution of congestive heart failure and the potential for lethal ventricular dysrhythmia. An abundance of progenitor myocytes known to exist within the myocardium of this patient age group may then contribute to permanent left ventricular restoration."
89635938|NCT02554630||Preterm Neonate|Neonates of gestational age 24-37 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
89635939|NCT02554630||Term Neonates|Neonates of gestational age 37-42 weeks. Blood collection will be performed at the time of a clinically required heelstick or blood draw. Microfluidic techniques, utilizing whole blood, will be employed to characterize the baseline genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function. Meconium will be collected for microbiome analysis. Clinical outcomes will be recorded from the electronic medical record.
89635940|NCT02554630||Healthy Adult Control|Healthy Adult aged 18-55 years will undergo a single blood collection by the way of vein puncture. Microfluidic techniques, utilizing whole blood, will be employed to evaluate the genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function.
89635941|NCT01532921||Subjects with Tricuspid Valve Repair|All patients indicated for a Tricuspid Valve (TV) repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
89635942|NCT04341610|Active Comparator|ASC|100 million allogeneic adipose-derived mesenchymal stromal cell
89635943|NCT04341610|Placebo Comparator|Placebo|Saline
89635944|NCT04767425|Experimental|Experimental|
89635945|NCT01532687|Experimental|Arm I (gemcitabine hydrochloride and pazopanib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89635946|NCT01532687|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89635947|NCT04409717||Patients treated for type II endoleaks|Patients treated for type II endoleaks between the 01 January 2008 and the 31 March 2018 in the Cardiovascular and Thoracic Surgery Unit of Dijon Burgundy University Hospital
89635948|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635949|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635950|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635951|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635952|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635953|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635954|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635955|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635956|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
89635957|NCT03161730|Experimental|McGrath videolaryngoscopy|Participants attempt to perform three intubation using McGrath videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
89635958|NCT03161730|Experimental|Pentax videolaryngoscopy|Participants attempt to perform three intubation using Pentax videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
89635959|NCT03161730|Active Comparator|Macintosh laryngoscopy|Participants attempt to perform three intubation using Macintosh laryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
89635960|NCT03161886|Experimental|Pan-enteric capsule endoscopy (PCE)|Evidence of active disease by PCE prompted a change in therapy at the discretion of the treating clinician and according to current available pediatric guidelines. The definition of medical treatment adjustment after evidence of inflammation was: the introduction of steroids or enteral nutrition, the introduction or optimization of immunosuppressives; the introduction, optimization of biologics; or the introduction of both immunosuppressive agents and biologics. In case of a negative PCE and presence of symptoms, the magnetic resonance enterography (MRE) could help in guiding therapeutic decisions.
89635961|NCT02689518|Other|Treatment - On-Label|On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months
89635962|NCT03165474|Active Comparator|Control Arm|In the control group, children and parents will receive didactic health information and resources by email and/or text. The delivery mode of the health messages will be based on based on personal preference.
89635963|NCT03165474|Experimental|Intervention Arm|In the intervention group, children will have access to a web-based interactive nutrition comic and receive health messages from comic characters by email and/or text, while parents will receive weekly newsletters related to nutrition and health by email and/or text.
89635964|NCT03114774||grup 1|Ramsay Sedation Scale (RSS) Score monitoring
89635965|NCT03114774||Grup 2|The bispectral index (BIS) monitoring
89635966|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
89635967|NCT02681094|Active Comparator|Dapagliflozin+Saxagliptin placebo+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
89635968|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin placebo+metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
89635969|NCT03164304|Active Comparator|One gram magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 1 g of mgso4 to prevent and control of convulsions
89635970|NCT03164304|Experimental|Two grams magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 2 g of mgso4 to prevent and control of convulsions
89635971|NCT02689284|Experimental|Cohort 1: Margetuximab 10 mg/kg plus pembrolizumab 200 mg|margetuximab administered in combination with pembrolizumab
89635972|NCT02689284|Experimental|Cohort 2: Margetuximab 15 mg/kg plus pembrolizumab 200 mg|margetuximab administered in combination with pembrolizumab
89635973|NCT03165396|Experimental|Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0~2.5μg/ml ）for maintaining
89635974|NCT03165396|Experimental|1.2 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining
89635975|NCT03165396|Experimental|0.6 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining
89635976|NCT03165396|Experimental|Sevoflurane|administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining
89635977|NCT03164070||Patients with osteoarthritis|Patients with medium and large joint osteoarthritis
89635978|NCT03164070||Control group|Control group of healthy persons
89635979|NCT03164382|Experimental|HAIF group|FOLFOX regimen: oxaliplatin 130 mg/m2 on day 1 from hour 0 to 3; leucovorin 200 mg/m2 from hour 3 to 5, fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours, via hepatic artery, once every 3 weeks.
89635980|NCT03164382|Active Comparator|Sorafenib group|Sorafenib 200mg Tab, 400 mg twice per day orally. Treatment was given in 4-week cycles.
89635981|NCT03161340|Experimental|Treatment group|Rapamycin group
89635982|NCT03161340|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem
89635983|NCT03164148|Experimental|Case Evaluation by T-REX TRI00A|Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A
89635984|NCT04714320|Experimental|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered subcutaneously once-weekly for 12 weeks.
89041985|NCT06234202|Experimental|Control Sleeve then Bioactive Sleeve|Each pitcher will be instructed to sleep with the assigned sleeve on the throwing arm after each game that he pitches
89041986|NCT06234124|Experimental|Arm AB: Variable Friction Shoe Training, AFO Training|Baseline (T0), 12 weeks Variable Friction Shoe Training, Follow-up (T1), 2-week washout, Follow-up (T2), 12 weeks AFO Training, Follow-up (T3)
89041987|NCT06234124|Experimental|Arm BA: Ankle Foot Orthosis (AFO) Training, Variable Friction Shoe Training|Baseline (T0), 12 weeks AFO Training, Follow-up (T1), 2-week washout, Follow-up (T2), 12 weeks Variable Friction Shoe Training, Follow-up (T3)
89041988|NCT06233916|Other|[14C] D-1553 group|Single arm study
89041989|NCT06233903|Experimental|Neural crest tumors and sympathetically innervated organs undergoing tissue sampling|All subjects who undergo histopathologically established diagnosis of neuroblastoma and a scheduled clinical biopsy or surgery procedure within 21 days after 18F-mFBG PET imaging procedure; or be scheduled to have a clinical biopsy or surgery procedure that will yield a tissue specimen from an adrenergically-innervated organ or a non-neuroblastoma neural crest tumor within 21 days after 18F-mFBG PET imaging.
89041990|NCT06233357||N, no casirivimab / imdevimab or tocilizumab|No intervention
89041991|NCT06233357||C, treated with casirivimab / imdevimab|Active comparator
89041992|NCT06233357||T, Treated with Tocilizumab|Active comparator
89041993|NCT06233357||C + T, treated with casirivimab / imdevimab and tocilizumab|Active comparator
89041994|NCT06232850||Multiple sclerosis patient|According to EDSS should be between 0-3, not having had an attack in the last 3 months and without spasticity according to MAS in patient with MS will assesment KFORCE Sens® device and Purdue Pegboard Test.
89041995|NCT06232850||Healthy group|Healthy people of similar age who agree to participate in the study will evaluate the KFORCE Sens® device and the Purdue Pegboard Test.
89041996|NCT06232759|Experimental|Transarterial chemoembolization combined with Donafenib and Tislelizumab|Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Donafenib and Tislelizumab
89041997|NCT06232681|Experimental|Progressive relaxation exercise application|Progressive relaxation exercise practice Those who agree to participate in the study will be asked to fill in the Patient and Patient Relative Form, Cheltanhams Patient Classification Scale, Caregiving Burden Scale and Meaning and Purpose of Life Scale, which include personal information and information about the patient. Relaxation exercises will be explained and demonstrated by the researcher (Funda AKTÜRK) once a day for 1 month starting from the hospitalisation to the clinic and will be played on the computer. You will be asked to perform these exercises after listening to the video (CD). Relaxation exercises are exercises based on stretching and relaxing your muscles. Before the application, in the middle of the application (15th day) and at the end of the application, all forms except the introduction form will be filled in again.
89041998|NCT06232681|No Intervention|Control group|The participants in the control group also filled in the data collection tools without undergoing any intervention.
89041999|NCT06232629|Active Comparator|Active Low-Intensity Transcranial Focused Ultrasound|NeuroFUS device stimulation with 4-channel transducer Stimulation target = GPi Stimulation parameters = 5Hz and 10 Hz protocols at ISPPA=30 W/cm2
89635985|NCT04714320|Placebo Comparator|Placebo|IONIS-AGT-LRx-matching placebo will be administered subcutaneously once-weekly for 12 weeks.
89635986|NCT03161262|Experimental|SMS-based reminders|This group will receive consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site. They will also receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
89635987|NCT03161262|No Intervention|Control group|The control group will not receive medication reminders or questions regarding their pain or surgical site. This group will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
89635988|NCT02676882|Other|EnBrace HR for Prevention of Depressive Relapse (Group 1)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score </= 10.
89635989|NCT02676882|Other|EnBrace HR for Acute Treatment of Major Depression (Group 2)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score >/= 15.
89635990|NCT03161418|Experimental|KSP-910638G 0.4 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject.
89635991|NCT03161418|Experimental|KSP-910638G 1.2 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
89635992|NCT03161496||wild genotype|Through next generation sequencing, distinguish wild genotype of NOACs
89057584|NCT01649739|Experimental|Levitra|
89635993|NCT03161496||mutant genotype|Through next generation sequencing, distinguish mutant genotype of NOACs
89635994|NCT03161574|Experimental|FOLFOXIRI|patients with CRM positive who received FOLFOXIRI alone for 6 cycles before surgery
89635995|NCT03163914|Active Comparator|Epinephrine|Epinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
89635996|NCT03163914|Active Comparator|Norepinephrine|Norepinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
89635997|NCT03163914|Active Comparator|Phenylephrine|Phenylephrine will prepare as 100 µg/ ml and phenylephrine infusion rate will adjust 30 ml/h.
89635998|NCT03163914|Placebo Comparator|Control|Saline infusion will apply at equivalent volume till the surgical operation
89635999|NCT04700202||Retrospective Cohort|Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
89636000|NCT04693650|Experimental|Treatment group- UHF(+RF) stimulation|Patients implanted with leads and be administered with UHF stimulation
89636001|NCT04693650|No Intervention|Control group|Patients implanted with lead receiving fake stimulation (no stimulation but same device procedure with test group)
89636002|NCT04676724|Experimental|GSK3228836 for 24 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 24 weeks, followed by up to 24 weeks of PegIFN.
89636003|NCT04676724|Experimental|GSK3228836 for 12 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 12 weeks, followed by up to 24 weeks of PegIFN.
89636004|NCT03160950|Experimental|LuxaCrown|
89636005|NCT03160872||Women who undergo donor sperm insemination|Non infertile women who undergo donor sperm insemination cycle
89636006|NCT03163680||Low Dose PPI|patients with upper upper gastrointestinal bleeding were treated in low dose of proton Bump inhibitor meaning 40 mg twice daily
89042000|NCT06232629|Sham Comparator|Sham Low-Intensity Transcranial Focused Ultrasound|NeuroFUS device stimulation with 4-channel transducer Stimulation target = GPi and occipital cortex Stimulation parameters = for the passive sham protocol: GPi target (5Hz and 10 Hz protocols at 0 ISPPA) and for the active sham protocol: occipital target (5Hz and 10 Hz protocol at 30 ISPPA)
89042001|NCT06232538||gallbladder cancer|
89042002|NCT06232538||benign gallbladder diseases|
89042003|NCT06232148||Robotic ventral hernia repairs|
89636007|NCT05180448|Experimental|Coach Share On + Group Share On + Friend/Family Share On|
89636008|NCT05180448|Experimental|Coach Share On + Group Share On + Friend/Family Share Off|
89636009|NCT05180448|Experimental|Coach Share On + Group Share Off + Friend/Family Share On|
89636010|NCT05180448|Experimental|Coach Share On + Group Share Off + Group Share Off|
89636011|NCT05180448|Experimental|Coach Share Off + Group Share On + Friend/Family Share On|
89636012|NCT05180448|Experimental|Coach Share Off + Group Share On + Friend/Family Share Off|
89636013|NCT05180448|Experimental|Coach Share Off + Group Share Off + Friend/Family Share On|
89636014|NCT05180448|Experimental|Coach Share Off + Group Share Off + Friend/Family Share Off|
89636015|NCT03163836||double valve replacement group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) but did not received concomitant AF ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months. Exclusion criteria for consideration for concomitant AF ablation includes >70 years old, left atrium (LA) diameter >7 cm, or preoperative left ventricle (LV) ejection fraction < 40% and patients falls in these criteria were excluded from this group.
89636016|NCT03163836||surgical ablation group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) and received concomitant surgical ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months.
89636017|NCT03114696|Experimental|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
89636018|NCT03114696|Placebo Comparator|Placebo|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
89636019|NCT05675982|Experimental|Minimal residual disease assessment|
89042004|NCT06232148||Open ventral hernia repairs|
89042005|NCT06232148||Laparoscopic ventral hernia repairs|
89042006|NCT06231342|Active Comparator|Direct Laryngoscopy (DL)|Standard laryngoscope use to insert the endotracheal tube and removing the stylet without any rotation.
89636020|NCT05675904||Yes Textbook Outcome|Patients undergoing scheduled colon cancer surgery with a R0 resection, number of isolated nodes ≥12, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
89636021|NCT05675904||No Textbook outcome|Patients undergoing scheduled colon cancer surgery without any of the following items: R0 resection, number of isolated nodes ≥12, no Clavien-Dindo ≥IIIa complications, no prolonged stay, no readmissions, and no mortality in the first 30 days
89636022|NCT03114540|Experimental|GBT440 Dose 1:Mild hepatic impairment|Child Pugh A
89636023|NCT03114540|Experimental|GBT440 Dose 1:Moderate hep. impairment|Child Pugh B
89042007|NCT06231342|Active Comparator|Direct laryngoscopy (DLE) plus Endotracheal Tube (ETT) 180 maneuver|Standard laryngoscope use to insert the endotracheal tube and removing the stylet using a 180-degree rotation.
89042008|NCT06231342|Active Comparator|Video laryngoscopy plus Endotracheal Tube (ETT) 180 maneuver (VLE)|Video laryngoscope use to insert the endotracheal tube and removing the stylet using a 180-degree rotation.
89042009|NCT06230874|Experimental|HOME Protocol|Will receive the HOME Protocol Intervention
89042010|NCT06230874|Active Comparator|Control Journaling Protocol|Will receive the Control Journaling Protocol
89042011|NCT06230679|Experimental|Non-invasive Neuromodulation|Intervention with electrical stimulation: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
89042012|NCT06230679|Placebo Comparator|Placebo Non-invasive Neuromodulation|Intervention with electrical stimulation: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
89042013|NCT06228742|Experimental|Immobilized Leg|One leg of a young, healthy adult will be randomly assigned to undergo 5 days of immobilization using a rigid knee brace.
89636024|NCT03114540|Experimental|GBT440 Dose 1:Severe hepatic impairment|Child Pugh C
89636025|NCT03114540|Experimental|GBT440 Dose 1:Normal hepatic function|Healthy subjects
89636026|NCT03163524|Experimental|Treatment group (modified text)|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
89636027|NCT03163524|Sham Comparator|Control group (standard text)|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
89636028|NCT02674386|Other|Cohort 1|long-term observational study of subjects from tanezumab parent study
89636029|NCT04574232|Other|athletic subjects|athletic subjects who may need intra-articular knee infiltration
89636030|NCT03163290|Experimental|Posterolateral Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip abductors, lateral rotators and extensors. Posterolateral Hip Complex Exercises add extension knee in open kinetic chain, squat , abduction exercise, Clam exercise and external rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
89636031|NCT03163290|Active Comparator|Anteromedial Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip aductors, medial rotators and flexors. Anteromedial Hip Complex Exercises add extension knee in open kinetic chain, squat ,hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
89636032|NCT05064618|Experimental|Phase I study; 3+3 Design|"Phase I study; single-center, open-label, uncontrolled, dose-finding study~MIKE-1 (AM80, Tamibarotene) After the DLT assessment period, if there is no evidence of disease progression or unacceptable toxicity to the patient according to RECIST v1.1, the investigational drug in each dose group will continue to be administered orally twice daily after breakfast and dinner for up to 24 weeks.The dose of the study drug will not be reduced or increased in the same subject.~6 mg dose group (level 1).~8 mg dose group (level 2).~4 mg group (level 0). To be considered when two or more cases of DLT occur at level 1.~GEM/nab-PTX (Phase I / II study) GEM (1000mg/m2) and nab-PTX (125mg/m2) will be administered intravenously."
89636033|NCT05064618|Experimental|Phase II study; Single-centre, open-label, single arm, uncontrolled study.|The dose of MIKE-1 will be fixed at the clinically recommended dose determined in Phase I. MIKE-1 will be administered orally twice daily after breakfast and dinner, and treatment will be continued until the occurrence of intolerable toxicity or disease progression, up to a maximum of six courses, to confirm efficacy and safety (tolerability).
89636034|NCT03113838||Taking YXSF Capsule Group|The overall individuals taking YXSF Capsule and achieving the inclusion criteria.
89636035|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
89636036|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
89636037|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
89636038|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
89636039|NCT02680002|Experimental|90 mcg H5N1 (monobulk) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
89636040|NCT02680002|Experimental|90 mcg H5N1 (vials) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59
89636041|NCT04557384|Experimental|Ramucirumab|Participants received starting dose of 700 milligram (mg) ramucirumab loading dose (LD) subcutaneously (SC) followed, a week later, by 350 mg ramucirumab maintenance dose (MD) administered SC once a week.
89636042|NCT02673684|Sham Comparator|Sham Neurostim System (Sham NSS)|In this arm, the subject will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive a sham Neuro-Stim System device that will only be active for five minutes. Identical to the active device in placement, labeling, and packaging. It will remain on the subject's ear for 5 days at which point the subject may discard the device.
89636043|NCT02673684|Experimental|Working Neurostim System (Working NSS)|In this arm, the patient will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive an active Neuro-Stim System that generates electrical impulses that stimulate the neurovascular bundles in the ear. It will remain on subject's ear for 5 days at which point the subject may discard the device.
89636044|NCT05063448|Experimental|DadSpace Intervention|Participants will take part in a 12-hour educational discussion-based mentoring program intervention over 8 weeks. The intervention will be facilitated by a trained father facilitator and will include education and support on topics relevant to perinatal fathers. Topics include father identity, stress management, infant development, co-parenting, masculinity and caregiving, healthy communication, and work-life balance. Participants will additionally have access to a brief educational podcast series on related topics. Participants will also be invited to monthly follow-up daddy/baby drop-in groups.
89636045|NCT03161184|Active Comparator|Control (paper based)|"Women received prenatal household visits from CHWs who were trained on the Tanzania Ministry of Health and Social Welfare's National integrated Maternal, Newborn and Child Health (i-MNCH) paper-based protocols, i.e. received intervention SUSTAIN Paperbased training of CHW (SOC)"
88990996|NCT05899101||3 - Opioid and Cannabis|Illicit and/or sustained prescription opioids with concurrent cannabis use
88990997|NCT05899101||4 - OAT and Cannabis|Opioid agonist therapy (OAT) with concurrent cannabis use
89636046|NCT03161184|Experimental|Intervention (Smart phone assisted)|"Women received prenatal household visits from CHWs trained on the following:~A) National i-MNCH programme; and B) Smartphone-assisted counseling protocol: a smartphone application designed to assist with identification of danger signs during pregnancy, referral to health facilities, and MNCH counseling~, i.e. received intervention SUSTAIN Smartphone training of CHW (SP+)"
89636047|NCT02675634|Experimental|Test A, Test B, Subjects own product|The subjects first test Coloplast Test A, followed by Coloplast Test B and finally Subjects own product
89636048|NCT02675634|Experimental|Test A, Subjects own product, Test B|The subjects first test Coloplast Test A, followed by Subjects own product, and finally Coloplast Test B
89636049|NCT02675634|Experimental|Test B, Test A, Subjects own product|The subjects first test Coloplast Test B, followed by Coloplast Test A and finally Subjects own product
89636050|NCT02675634|Experimental|Test B, Subjects own product, Test A|The subjects first test Coloplast Test B, followed by Subjects own product, and finally Coloplast Test A
89636051|NCT02675634|Experimental|Subjects own product, Test A, Test B|The subjects first test Subjects own product, followed by Test A, and finally Coloplast Test B
89636052|NCT02675634|Experimental|Subjects own product, Test B, Test A|The subjects first test Subjects own product, followed by Test B, and finally Coloplast Test A
89636053|NCT05231850|Experimental|Tislelizumab|Tislelizumab
89636054|NCT03163212|Experimental|Lactoferrin/FOS 100mg/kg|100 mg/kg enteral administration daily for 30 days
89636055|NCT03163212|Experimental|Lactoferrin/FOS 200mg/kg|200 mg/kg enteral administration daily for 30 days
89636056|NCT03163212|Experimental|Lactoferrin/FOS 300mg/kg|300 mg/kg enteral administration daily for 30 days
89636057|NCT05007678|No Intervention|Standard of Care|The usual care will be offered as per current advice on management of hospitalised patients.
89636058|NCT05007678|Active Comparator|leflunomide|Patients admitted to the hospital COVID-19 positive and within 2 weeks of symptoms' onset will be treated with loading dose of 100 mg leflunomide for 3 days, followed by 20 mg once daily. Participants with ALT/AST levels 2 times above upper limits of normal reference range will receive 10mg instead of 20mg.
89636059|NCT03114384|Experimental|Healthy volunteers|
89636060|NCT03161106|Experimental|Nutrional Therapy Group|Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months
89636061|NCT03161106|Active Comparator|Lactulose Group|Lactulose - 20 mL thrice daily (maximum) for 6 months
89636062|NCT02671500|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
89636063|NCT03163056|Other|Cognitive-behavioral treatment (CBT)|The CBT treatment condition is implemented in group-based sessions carried out during 8 weeks. Components included: information about tobacco, behavioral contract whereby patients committed to attend sessions, self-monitoring and graphical representation of cigarette smoking, nicotine fading (a weekly reduction of 30% of nicotine intake from the first to the four week, and abstinence from the fifth week onwards), physiological feedback (CO in expired air and cotinine analyses) on cigarette intake, stimulus control, strategies for managing nicotine withdrawal symptoms, training in alternative behaviors, and relapse prevention strategies (e.g., problem solving techniques).
89636064|NCT03163056|Active Comparator|CBT+Behavioral Activation (BA)|This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
89636065|NCT03163056|Active Comparator|CBT+BA+ Contingency Management (CM)|This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
89636066|NCT04177290|Experimental|sintilimab (M1b) 200mg|
89636067|NCT04177290|Active Comparator|sintilimab (approved) 200mg|
89636068|NCT02671266|Experimental|Oxytocin, Then Placebo|Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).
89636069|NCT02671266|Experimental|Placebo, Then Oxytocin|Participants will first receive a placebo nasal spray containing a matching formulation as the oxytocin spray (without the active oxytocin ingredient). After a one-week washout period, participants will come back to the clinic and receive an oxytocin nasal spray (24 IU, 3 puffs per nostril).
89636070|NCT03160482||Papillary carcinoma, classical variant|
89636071|NCT03160482||Follicular carcinoma|
89636072|NCT03160482||Colloid nodule|
89636073|NCT03160482||Hyperplastic nodule|
89636074|NCT03160482||Adenomatoid nodule|
89636075|NCT03160482||Follicular adenoma|
89636076|NCT03160482||Papillary carcinoma, follicular variant|
89636077|NCT03160482||Medullary carcinoma|
89636078|NCT03160482||Lymphocytic thyroiditis|
89636079|NCT03160404|Experimental|EXERCISE|Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
89636080|NCT03160404|Active Comparator|ZOLPIDEM|10 mg/night during 6 weeks
89636081|NCT05676996|Experimental|attachment-based support group|"In addition to the routine follow-ups and trainings that the pregnant women in the intervention group can receive from the hospital, they will be included in the Attachment Based Support Program. Within the scope of the 1st stage of this support; A mobile application. There are 12 videos on connecting in the mobile application. These videos were shot by the researcher in a professional studio. 22nd-26th of pregnancy. The participants included in the study during the weeks of participation installed this mobile application on their phones during participation. It was requested to complete watching the videos by 36 weeks. In the second phase of Attachment-Based Support, breastfeeding and skin-to-skin contact support are provided to mothers on postpartum day 0."
89211979|NCT00992199|Experimental|IP Chemo arm|adjuvant system intravenous chemotherapy combined with adjuvant intraperitoneal chemotherapy
89211980|NCT04041986|Experimental|Site-Finding|Each subject will receive anodal, cathodal, and sham stimulation to both the ipsilesional and contralesional hemispheres in a series of six sessions (one condition per session), each separated by at least two days. During anodal and cathodal tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 mA using a 5x5 cm electrode. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. The participant will complete pre/post language testing at each session in order to determine if the subject is a tDCS responder and if so, which site produces the best transient language improvement in that individual. Subjects who do not respond to tDCS will not be invited to move forward to the treatment phase.
89211981|NCT04041986|Active Comparator|Real tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of real tDCS. During real tDCS sessions, subjects will receive stimulation for 20 minutes at a current of 2.0 mA with a 5x5 cm electrode at their optimal responder site previously determined.
89211982|NCT04041986|Sham Comparator|Sham tDCS|Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of sham tDCS. During sham tDCS, a 2.0 mA current will be delivered for approximately 30 seconds at the beginning of the sham condition before being extinguished over the course of seconds. Individuals randomized into the sham arm will be offered the option to crossover to real tDCS after their participation is complete.
89636082|NCT05676996|No Intervention|routine follow-up control group|The control group pregnants were left to the routine follow-up of the hospitals during their pregnancy and postpartum period. In this follow-up; When pregnant women apply to the outpatient clinic services of the hospital, appointments are made for their monthly routine follow-up. Information and practices that support mother-infant attachment in attachment-based support modules are not included in these trainings.
89636083|NCT04756518||COVID 19 group|The COVID 19 group will consist of peripheral blood smear slides from patients who are in the hospital who had qPCR results positive for COVID-19.
89636084|NCT04756518||CONTROL group|A control group will consist of i) peripheral blood smear slides from patients with no viral infection and ii) from those with a non-SARS-CoV-2 viral infection. Control group peripheral blood slides will be randomly selected from the laboratory slides archive within the facility. The laboratory slides used will be inclusive of slides archived prior to the emergence of COVID-19 infection in the United Kingdom.
89636085|NCT03162822|Active Comparator|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
89636086|NCT03162822|Active Comparator|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
89636087|NCT03162822|Active Comparator|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
89636088|NCT03162822|Active Comparator|Evaluative Conditioning Intervention|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
89636089|NCT03162744||Suicide attempt or ideas|Elderly patients who attempted suicide or who emitted suicidal ideas
89636090|NCT03162588|Experimental|multiple burrhole therapy and erythropoietin|pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed
89636091|NCT03320070|Experimental|Acthar Gel in DBT Then Acthar Gel in OLE|Participants received Acthar Gel as a 1 milliliter (mL) injection under the skin, twice weekly, for 24 weeks in the double-blind treatment (DBT) phase. Participants, who chose to continue into the optional OLE phase, then received Acthar Gel as a 1 mL injection under the skin, twice weekly, for another 24 weeks in the optional open-label extension (OLE) phase.
89636092|NCT03320070|Experimental|Placebo in DBT Then Acthar Gel in OLE|Participants received Acthar Gel matching placebo as a 1 mL injection under the skin, twice weekly, for 24 weeks in the DBT phase. Participants, who chose to continue into the optional OLE phase, then received Acthar Gel as a 1 mL injection under the skin, twice weekly, for another 24 weeks in the optional OLE phase.
89636093|NCT05675358|Experimental|virtual reality|In the study, Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used, and the Epic Roller Coasters train game, an application that would attract the attention of children, was determined by the researchers. The virtual reality application was started 2 minutes before the procedure and continued until the procedure was completed.
89636094|NCT05675358|No Intervention|control|The child in the control group did not receive any additional intervention.
89636095|NCT02667912|Experimental|Distal renal denervation|Endovascular denervation of segmental branches of renal artery
89636096|NCT02667912|Active Comparator|Conventional renal denervation|Endovascular denervation of main trunk of renal artery
89636097|NCT01373346|Experimental|Long limb Roux-en Y reconstruction|Long limb Roux-en Y reconstruction means that the length of Roux limb and biliopancreatic limb are longer than conventional reconstruction method after gastrectomy.
89636098|NCT04977336|Experimental|VX-548|Participants will be randomized to receive different dose levels of VX-548.
89636099|NCT04977336|Active Comparator|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will receive HB/APAP.
89636100|NCT04977336|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
89636101|NCT04915872||Participant|Critically Ill Patients with Open Abdomen and Negative Pressure Wound Therapy
89636102|NCT05675124|Experimental|Needlescopic laparoscopic adrenalectomy|Needlescopic laparoscopic surgery refers to the use of instruments with a diameter of less than or equal to 3 mm for laparoscopic surgery.
89211983|NCT00992277|Experimental|Facial|Skin rejuvenation treatments
89211984|NCT00856310|Active Comparator|Cohort 1|Dose 1 REGN475
89211985|NCT00856310|Active Comparator|Cohort 2|Dose 2 of REGN475
89211986|NCT00856310|Active Comparator|Cohort 3|Dose 2 of REGN475
89211987|NCT00856310|Active Comparator|Cohort 4|Dose 1 of REGN475
89211988|NCT00856310|Active Comparator|Cohort 5|Dose 2 of REGN475
89636103|NCT05675124|Active Comparator|conventional laparoscopic adrenalectomy|a 12 mm camera port ,and two additional (left anterior axillary line and left midclavicular line; for left tumors) or three additional(right anterior axillary line, right midclavicular line, and subxiphoid; for right tumors) 5 mm working ports along the ipsilateral subcostal were created regionally.
89636104|NCT03284424|Experimental|R/M cSCC cohort|Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
89636105|NCT03284424|Experimental|LA cSCC cohort|Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
89636106|NCT03273894||Paediatric patients undergoing surgery in general anesthesia|Paediatric patients undergoing surgery in general anesthesia with the expected duration over 30 minutes
89636107|NCT02674854|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
89636108|NCT02674854|Active Comparator|Netarsudil (AR-13324) ophthalmic solution 0.02%|Netarsudil 0.02% ophthalmic solution
89636109|NCT02674854|Active Comparator|Latanoprost ophthalmic solution 0.005%|Latanoprost 0.005 % ophthalmic solution
89636110|NCT03231150|Active Comparator|Anatomical injection|"Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to locate the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage."
89636111|NCT03231150|Experimental|Ultrasound Guided Injection|Once patient has been randomized, if placed in the USGI group, the patient will be scheduled for an ultrasound therapy in the radiology department at Penn Presbyterian Medical Center. In this setting, the patient will be informed that in order to keep them blinded, that all patients must have either injection performed in the radiology department and that the ultrasound machine utilized will either be on or off during the injection keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
89636112|NCT03133650|Experimental|Vascular-targeted photodynamic therapy (VTP) using WST11|Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
89636113|NCT04003272||Comprehensive Reverse Versa-Dial Titanium Glenosphere|Patients who have an allergy to typical cobalt chrome or other metal allergies had surgery to repair shoulder malfunction/disease.
89636114|NCT02667288|Experimental|A-101 Solution|A-101 Solution 40% administered once
89636115|NCT02670330|Experimental|Experimental: SD-101-6.0 cream|All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.
89636116|NCT02694822|Experimental|AGEN1884|anti-CTLA-4 antibody
89636117|NCT04479774|Experimental|Experimental Group (Group A)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
89636118|NCT04479774|Other|Control group: (Group B)|"Subjects were randomly assigned and informed consent was obtained, the subjects were educated about treatment and on the basis of functional ambulation scale 3,4 and 5 subjects were included, along with this the subjects of age group between 40-60 having ability to understand and follow instructions were included in study.~Results were obtained by using gait parameters including walk speed, cadence, step rate, stride length The tinetti POMA scale was utilized to record changes post treatment in gait , the weight bearing was recorded using Camry ZT-160 analog weight scale At the end of every week results were obtained."
89636119|NCT02388438|Experimental|Demineralized bone matrix|Applied demineralized bone matrix when investigator conduct hallux valgus surgery.
89636120|NCT02388516|Placebo Comparator|Group A|Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.
89636121|NCT02388516|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
89636122|NCT02388516|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
89636123|NCT02388516|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
89636124|NCT02388516|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week
89211989|NCT00856310|Active Comparator|Cohort 6|Dose 1 REGN475 subcutaneous administration
89211990|NCT00856310|Active Comparator|Cohort 7|Dose 2 REGN475 subcutaneous administration
89211991|NCT02773485|Active Comparator|Systemic Chemotherapy|Irrespective of arm allocation Baseline Positron Emission Tomography(PET) scan and hepatic function assessment will be done. Those randomized to this arm will receive systemic chemotherapy delivered on day 1 and 8 every 3 weekly, with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2. After first 4 cycles patients will undergo repeat Contrast Enhanced Computed Tomography(CECT)/PET scan. If CECT/PET scan shows stable/ responding disease then patients will continue to receive the same chemotherapy. In case of locally progressive/ systemic disease on chemotherapy patients may be considered for second line palliative chemotherapy or best supportive care. The use of radical chemoradiation is not allowed on disease progression in this arm. However palliative radiation may be used.
89636125|NCT02388360|Other|topical prostaglandin analogs|
89636126|NCT02669940||Participants With Chronic Hepatitis C Genotype 1|Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.
89636127|NCT03921216||Diabetic nephropathy, on hemodialysis|
89636128|NCT03921216||Chronic kidney disease, on hemodialysis|Chronic kidney disease of other causes than Diabetes.
89636129|NCT03921216||Chronic kidney disease, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
89636130|NCT03921216||Diabetic nephropathy, predialysis|Renal outpatients at Nephrology Unit, Karolinska University Hospital Huddinge
89636131|NCT02669862|Experimental|A-101 Solution 40|A-101 Solution 40% administered once per week
89636132|NCT02669862|Experimental|A-101 Solution 45|A-101 Solution 45% administered once per week
89636133|NCT02669862|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once per week
89636134|NCT02168868||Control Group of Children|2-12 years old age & sex-matched controls - typically developing (TD) children
89636135|NCT02168868||Children-Autism Spectrum Disorder|2-12 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00)
89636136|NCT02168868||Children-Autism Spectrum Disorder+SCT|2-12 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00) due to undergo stem cell transplantation therapy
89636137|NCT02168868||High-risk infants|Infants aged 10-18 months not diagnosed with ASD but with a sibling diagnosed with ASD
89636138|NCT02168868||Mothers of high-risk infants|Mothers of recruited infants aged 10-18 months not diagnosed with ASD but with a sibling diagnosed with ASD
89636139|NCT02388204|Experimental|Parkinson's disease patients|Group description: PD patients with locomotion problems as the primary complain with no interventions other than medication and rehabilitation therapies Intervention: Implantable spinal cord stimulation.
89636140|NCT02388204|Experimental|DBS Parkinson's disease patients|"Group description: PD patients with locomotion problems as the primary complain after cardinal symptoms are controlled by DBS.~Intervention: Implantable spinal cord stimulation."
89636141|NCT01531673|Placebo Comparator|Group 1-6d Combined: Placebo|All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.
89636142|NCT01531673|Experimental|Group 1: VX-661 10 mg qd|All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.
89636143|NCT01531673|Experimental|Group 2a: VX-661 30 mg qd|All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.
89636144|NCT01531673|Experimental|Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h|All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
89636145|NCT01531673|Experimental|Group 3a: VX-661 100 mg qd|All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.
89636146|NCT01531673|Experimental|Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h|All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
89636147|NCT01531673|Experimental|Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h|All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
89636148|NCT01531673|Experimental|Group 5a: VX-661 150 mg qd|All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.
89636149|NCT01531673|Experimental|Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h|All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
89636150|NCT01531673|Experimental|Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h|All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.
89636151|NCT01531673|Experimental|Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h|All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
89636152|NCT01531673|Placebo Comparator|Group 7: Placebo|All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
89636153|NCT01531673|Experimental|Group 7: VX-661 100 mg qd|All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
89636154|NCT01531205|Experimental|Drug and Hormonal Therapy with Salvage Surgery|Androgen Ablation (hormonal therapy before surgery), Cabazitaxel (chemotherapy before surgery), Salvage Surgery (radical prostatectomy), Post-operative Hormonal Therapy, Post-operative Follow-up
89636155|NCT02985671|Experimental|Experimental Drug & Voltaren Placebo|"Orphenadrine + acetaminophen + caffeine + diclofenac sodium & Placebo of Voltaren~01 tablet of experimental drug (orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg) + 01 tablet of placebo of Voltaren, to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
89636156|NCT02985671|Active Comparator|Voltaren® + Experimental Drug Placebo|"Voltaren & Placebo of Orphenadrine + acetaminophen + caffeine + diclofenac sodium~01 tablet of Voltaren + 01 tablet of placebo of experimental drug (orphenadrine, acetaminophen, caffeine and diclofenac sodium), to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
89636157|NCT04767269|Experimental|cuminum cyminum mouthwash|cuminum cyminum mouthwash in chronic gingivitis patients
89636158|NCT04767269|Active Comparator|herbal mouthwash|herbal mouthwash in chronic gingivitis patients
89636159|NCT01529645|Experimental|Group 1: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
89636160|NCT01529645|Experimental|Group 2: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
89042014|NCT06228742|Experimental|Non-immobilized leg|One leg of a young, healthy adult will remain active and not immobilized for 5 days.
89636161|NCT01529645|Experimental|Group 3: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
89636162|NCT01529645|Experimental|Group 4: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
89636163|NCT01529645|Experimental|Group 5: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
89636164|NCT01529645|Experimental|Group 6: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
89636165|NCT01529645|Experimental|Group 7: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
89042015|NCT06228573|Experimental|Active tDCS|"Active tDCS Arm:~In Week 1, participants in the Active tDCS arm will undergo five in-person visits for the administration of active transcranial Direct Current Stimulation (tDCS). Subsequently, from Weeks 2 to 9, participants will receive weekly active tDCS sessions preceding the scheduled yoga sessions.~For the active tDCS sessions, a constant current stimulator will be employed to deliver direct current through a pair of surface sponge electrodes (5×7 cm) soaked in saline. Participants will undergo anodal stimulation targeting the primary motor cortex (M1) contralateral to the most painful site (C3 or C4 based on the electroencephalogram 10/20 system). The cathodal electrode will be positioned on the supraorbital area contralateral to the anode. During active tDCS, a constant anodal current of 2 mA will be administered for 20 minutes, a duration known to enhance cortical excitability and alleviate pain. T"
89042016|NCT06228573|Sham Comparator|Sham tDCS|"Sham tDCS Arm:~tDCS: In Week 1, participants in the Sham tDCS arm will attend five in-person visits for the administration of sham transcranial Direct Current Stimulation (tDCS). From Weeks 2 to 9, participants will receive weekly sham tDCS sessions before the scheduled yoga sessions.~Constant current stimulator will be used to deliver direct current through a pair of surface sponge electrodes (5×7 cm) soaked in saline. Participants will undergo sham stimulation targeting the primary motor cortex (M1) contralateral to the most painful site (C3 or C4 based on the electroencephalogram 10/20 system).~During sham tDCS, the electrodes will be placed in the same montage as the active tDCS; however, current will only be applied for the initial and final 30 seconds of the 20-minute session. Consequently, participants will experience the sensation of current ramping up and down but will receive no current for the remaining stimulation period."
89042017|NCT06228482|Experimental|[177Lu]Lu DOTA-ABM-5G single dose therapy study|Patients will be undergo [68Ga]Ga DOTA-5G PET/CT scans to confirm eligibility for the [177Lu]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of [68Ga]Ga DOTA-5G PET/CT will be offered therapy.
89636166|NCT01529645|Experimental|Group 8: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
89636167|NCT01529645|Experimental|Group 9: TDaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
89636168|NCT01529645|Active Comparator|Group 10: Licensed TdaP booster|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart.
89636169|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
89636170|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
89636171|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.04%|1 drop to study eye once daily
89636172|NCT01528787|Placebo Comparator|AR-13324 Ophthalmic Solution Vehicle|1 drop to study eye once daily
89636173|NCT01528709|Experimental|High-dose statin therapy|Atorvastatin 80 mg daily
89636174|NCT01528709|Active Comparator|Moderate-dose statin therapy|Atorvastatin 10 mg daily
89636175|NCT01527383|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89636176|NCT01527383|Placebo Comparator|Placebo|Participants receive placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89636177|NCT01526057|Experimental|A - PF-05280586|
89636178|NCT01526057|Active Comparator|B - Rituximab EU|
89636179|NCT01526057|Active Comparator|C- Rituximab-US|
89636180|NCT01525901|Experimental|Insulin-Like Growth Factor-1 (IGF-1)|Injection
89636181|NCT01525901|Placebo Comparator|Normal saline|Injection
89636182|NCT00123123|Placebo Comparator|Placebo (Vehicle Control)|Delivered Twice a day
89636183|NCT00123123|Experimental|0.12% chlorhexidine gluconate oral rinse|Delivered twice a day
89636184|NCT00123123|Experimental|0.12% chlorhexidine oral rinse|Delivered once a day, placebo once a day
89636185|NCT04748393||Study cohort|Consecutive female patients between the ages of 18 and 50 with child bearing potential and objectivated, symptomatic VTE, who fulfil all the inclusion criteria and meet none of the exclusion criteria, are eligible for inclusion.
89636186|NCT00262509|Experimental|Egress Badge Performance|Blind subjects are walked into a building to a specific location, and then are asked to find their way out of the building.
89636187|NCT00262509|No Intervention|Baseline Egress Performance|Blind subjects are walked into a building to a particular location and then asked to find their way out of the building.
89636188|NCT00242385|Experimental|ARALAST Fr. IV-1|60 mg/kg
89636189|NCT00242385|Active Comparator|ARALAST|60mg/kg
89636190|NCT00242619|Experimental|Rosiglitzone|This group includes all 12 subjects who received rosiglitazone. Rosiglitazone was administered in addition to current antidepressant and/or mood-stabilizing medication at a dose of 4 mg/day for the first 4 weeks, with subsequent increase in dose to 9 mg/day for the remaining 8 weeks of the 12-week trial.
89636191|NCT01899027|Active Comparator|Rosuvastatin Group|Patients will be randomized to receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
89636192|NCT01899027|Placebo Comparator|Placebo group|Patients will be randomized to receive two overnight high doses of Placebo before RNA and another placebo dose 2 h before the procedure
89636193|NCT00264381|Active Comparator|Ibuprofen|Ibuprofen 800mg tid X 7 days + additional 7 days determined by protocol
89636194|NCT00243243|Experimental|rFVIIa|intravenous administration of rFVIIa (Novoseven; 90 micrograms/kg, IV push, given at start of first surgical incision and again at 1 hr after start of surgery)
89636195|NCT00243243|Placebo Comparator|Control|intravenous administration of placebo (sterile water, IV push, given at first surgical incision and again at 1 hr after start of surgery)
89636196|NCT02075775||MOON Shoulder Instability|Patients indicated for Shoulder Instability surgery
89636197|NCT00265473|Experimental|Allogeneic Islets of Langerhans|Islet infusion
89636198|NCT00246441|Experimental|Paroxetine|Active medication containing the drug Paroxetine
89636199|NCT00246441|Placebo Comparator|Placebo|A Placebo medication that appears just like the active medication but does not contain placebo
89636200|NCT00246519|Experimental|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
89636201|NCT00246519|Experimental|Hydrochlorothiazide (HCTZ)|HCTZ 12.5 mg then HCTZ 25 mg if BP < 120/70, then add atenolol 50 mg if BP < 120/70, then atenolol 100 mg if BP < 120/70.
89636202|NCT00125619|Active Comparator|Arm 1: Therapist assisted|Therapist assisted locomotor training (partial body-weight supported)
89636203|NCT00125619|Experimental|Arm 2: Robot-assisted|Robot-assisted locomotor training (partial body-weight supported)
89636204|NCT00248547|Active Comparator|Aprepitant|
89636205|NCT00248547|Placebo Comparator|sugar pill|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
89636206|NCT01525589|Experimental|PM01183|
89636207|NCT01524887|Experimental|IGIV, 10% at high dose (0.4 g/kg)|
89636208|NCT01524887|Experimental|IGIV, 10% at low dose (0.2 g/kg)|
89636209|NCT01524887|Placebo Comparator|Placebo control|
89636210|NCT00266799|Experimental|Pegylated liposomal doxorubicin|
89636211|NCT00266799|Active Comparator|Capecitabine|
89042020|NCT06227585|Experimental|Single Arm (Bevonescein)|All patients will receive a single administration of bevonescein 500mg via IV infusion and the REVEAL 475 system will be used on all patients.
89636212|NCT00248781|Experimental|Arm 1|exercise
89636213|NCT00248781|Other|Arm 2|health education
89636214|NCT04101071|Experimental|Modular ketogenic enteral feed|Ketogenic enteral feed to be administered continuously for 10 days.
89636215|NCT04101071|Active Comparator|Standard enteral feed|Standard enteral feed to be administered continuously for 10 days.
89042021|NCT06227130|Experimental|Intervention|Experimental: Intervention A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work. Each session lasts for about 20 minutes and the participant is encouraged to perform the session at least 3 times/week.
89042022|NCT06227130|Active Comparator|Waiting list|The first 6 weeks of the study, the participants will be controls. During week 6-12 they will then perform the intervention according to the description above.
89636216|NCT01522235|Active Comparator|IVIg group|Double blinded IVIg and single blinded IVIg
89636217|NCT01522235|Other|Placebo Group|Double blinded Placebo and single blinded IVIg
89636218|NCT00250497|Experimental|New Moves Intervention Group|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
89636219|NCT00250497|No Intervention|control group|Girls in the control group participated in an all-girls physical education class but did not receive additional components offered in the intervention such as individual coaching.
89636220|NCT00125931|Experimental|Pentazocine/Talwin|Talwin NX
89636221|NCT00267111|Experimental|Amethocaine gel 4% Group|1 g of topical amethocaine gel 4%
89636222|NCT00267111|Placebo Comparator|Placebo Group|
89636223|NCT01521923|Experimental|CZP 200 mg Q2W + Methotrexate|
89636224|NCT01521923|Experimental|CZP 200 mg Q4W + Methotrexate|
89636225|NCT01521923|Placebo Comparator|Placebo + Methotrexate|
89636226|NCT00128193|Experimental|A1-Ramping (MLSA-LAM)|5 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
89636227|NCT00128193|Experimental|C1-Target Population|80 subjects to receive: 1.0 mcg of MLSA-LAM, 1.0 mcg of MLCwA and 2TU Purified Protein Derivative/RT-23.
89636228|NCT00128193|Experimental|C-1b-Target Population (Low Dose)|80 subjects to receive: 0.1 mcg MLSA-LAM, 0.1 mcg MLCwA, 2 TU Purified Protein Derivative/RT-23.
89636229|NCT00128193|Experimental|B2-Full-Scale (MLCwA)|45 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
89636230|NCT00128193|Experimental|B1-Full-Scale (MLSA-LAM)|45 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
89636231|NCT00128193|Experimental|A2-Ramping (MLCwA)|5 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
89636232|NCT05240781|Active Comparator|Zotarolimus Eluting Stent|High Bleeding Risk patients to be treated with drug-eluting stents (DES). Includes both stable Coronary Artery Disease (CAD) and Acute Coronary Syndrome (ACS) patients undergoing elective PCI.
89636233|NCT05240781|Experimental|Sirolimus Eluting Stent|High Bleeding Risk patients to be treated with drug-eluting stents (DES). Includes both stable CAD and ACS patients undergoing elective PCI.
89636234|NCT01520987|Experimental|Caucasian 5 mg OPC|OPC, opicapone, BIA 9-1067
89636235|NCT01520987|Experimental|Caucasian 25 mg OPC|OPC, opicapone, BIA 9-1067
89636236|NCT01520987|Experimental|Caucasian 50 mg OPC|OPC, opicapone, BIA 9-1067
89636237|NCT01520987|Placebo Comparator|Caucasian Placebo|Placebo, PLC
89636238|NCT01520987|Experimental|Japanese 5 mg OPC|OPC, opicapone, BIA 9-1067
89636239|NCT01520987|Experimental|Japanese 25 mg OPC|OPC, opicapone, BIA 9-1067
89636240|NCT01520987|Experimental|Japanese 50 mg OPC|OPC, opicapone, BIA 9-1067
89042023|NCT06226909|Experimental|Shear-wave elastography-guided|based on the shear-wave elastography, the area with the highest elasticity value will be the target area to perform pleural biopsy for at least 6 times
89042024|NCT06226909|Active Comparator|B-mode ultrasound-guided|based on the B-mode transthoracic ultrasound, the area with the maximal thickness will be the target area to perform pleural biopsy for at least 6 times
89042025|NCT06226428|Experimental|Cyclo-ergonometry program group|"Mobility activities in bed (turning, pelvic elevation and sitting), standing, transfers and walking.~Progressive strength training of upper and lower limbs (2 days/week), by performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells.~Cycloergometry, using the MotoMed Letto 2 device, with a progressive pattern, starting with 5 minutes and lasting up to 30 minutes. It will be performed once a day, during working days (Monday to Friday) until discharge from the intensive care unit, and at a modified Borg intensity of 2-3 (Light)."
89042026|NCT06226428|Active Comparator|Usual treatment group|"Mobility activities in bed (turning, pelvic elevation and sitting), standing, transfers and walking.~Progressive strength training of upper and lower limbs (2 days/week), by performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells."
89042027|NCT06224569|Other|Series of n-of-1 trials administering black tea interventions|A series of n-of-1 trials in which participants will receive 'black tea', 'caffeine-only black tea', and 'placebo black tea'.
89042028|NCT06224569|Other|Series of n-of-1 trials administering green tea interventions|A series of n-of-1 trials in which participants will receive 'green tea', 'caffeine-only green tea', and 'placebo green tea'.
89042029|NCT06223113|Other|EyenableTM PA60AS1 IOL implanation|IOL implantation
89042030|NCT06222528|Experimental|Brief video intervention (Black Girl)|A brief social contact-based video with a Black girl protagonist
89042031|NCT06222528|Experimental|Brief video intervention (Black Boy)|A brief social contact-based video with a Black boy protagonist
89042032|NCT06222528|Experimental|Brief video intervention (Latinx Girl)|A brief social contact-based video with a Latinx girl protagonist
89042033|NCT06222528|Experimental|Brief video intervention (Latinx Boy)|A brief social contact-based video with a Latinx boy protagonist
89042034|NCT06222528|Experimental|Brief video intervention (White Girl)|A brief social contact-based video with a White girl protagonist
89636241|NCT01520987|Placebo Comparator|Japanese Placebo|Placebo, PLC
89636242|NCT00130923|Experimental|Risperidone Long Acting|Risperidone Long Acting; aka Risperdal Consta; injectable form
89636243|NCT00130923|Active Comparator|Oral Risperidone|Oral Risperidone; aka Risperdal; oral form
89636244|NCT04117581|Active Comparator|Vitamin D3 supplement|Participant will be asked to take one capsule of vitamin D3 supplement (5000 IU) (125 μg) daily for a total duration of 12 weeks.
89636245|NCT04117581|Placebo Comparator|Placebo|Participants will be asked to take one capsule of placebo (inert filler) daily for a total duration of 12 weeks.
89636246|NCT02103153|Experimental|Picosure Laser System|
89636247|NCT01899573|Experimental|Treatment|
89042035|NCT06222528|Experimental|Brief video intervention (White Boy)|A brief social contact-based video with a White boy protagonist
89636248|NCT02103309|Other|DACP, then 1DAM|Nelfilcon A contact lenses worn first, then etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
89636249|NCT02103309|Other|1DAM, then DACP|Etafilcon A contact lenses worn first, then nelfilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
89636250|NCT01897857|Experimental|DM kidney transplantation|patient with DM undergoing undergoing kidney transplantation
89636251|NCT01897857|Active Comparator|without DM undergoing kidney transplantation|patient without DM undergoing undergoing kidney transplantation
89636252|NCT00272337|Active Comparator|1|81 mg Aspirin
89636253|NCT00272337|Active Comparator|2|162 mg Aspirin
89042036|NCT06222528|Experimental|Brief video intervention (Nonbinary or transgender)|A brief social contact-based video with a nonbinary or transgender protagonist
89636254|NCT00272337|Active Comparator|3|325 mg Aspirin
89636255|NCT00272337|Active Comparator|4|650 mg Aspirin
89636256|NCT00272337|Active Comparator|5|1300 mg Aspirin
89636257|NCT01562275|Experimental|Dose escalation stage 1 (Arm A): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
89636258|NCT01562275|Experimental|Dose escalation stage 1 (Arm B): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
89636259|NCT01562275|Experimental|Stage 2 (Indication specific dose expansion cohort)|Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.
89636260|NCT01535053|Experimental|Arm I (dactinomcin)|Patients receive dactinomycin IV over 15 minutes on day 1.
89636261|NCT01535053|Active Comparator|Arm II (leucovorin calcium and methotrexate)|Patients receive methotrexate IM on days 1, 3, 5, and 7 and leucovorin calcium PO on days 2, 4, 6, and 8 OR single agent methotrexate IV on days 1-5.
89636262|NCT04410055|Active Comparator|Sitting|Three hours of sitting condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
89636263|NCT04410055|Active Comparator|Static standing|Four hours of static standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
89636264|NCT04410055|Active Comparator|Dynamic standing|Four hours of dynamic standing condition with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales were monitored.
89636265|NCT01534663|Placebo Comparator|Placebo|The placebo for fish oil will be safflower oil. For glutamine, soy powder will serve as the placebo.
89636266|NCT01534663|Active Comparator|Glutamine/Fishoil|3.285 g of EPA and 3.285 g of Docosahexaenoic acid (DHA) and L-alanyl-glutamine (8g/d).
89636267|NCT01520909|Experimental|Eltrombopag plus standard of care|Part 1, double-blind treatment group
89636268|NCT01520909|Placebo Comparator|Placebo plus standard of care|Part 1, double-blind treatment group
89636269|NCT01520909|Experimental|Eltrombopag plus standard of care (Part 2 open-label)|Part 2, open-label
89636270|NCT03027635|Experimental|PleurX|The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.
89636271|NCT03027635|Active Comparator|Large Volume Paracentesis|Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.
89636272|NCT03027713|Other|NAVA group with a specific catheter|The patients were allocated in the NAVA weaning protocol group
89636273|NCT03027713|Other|PSV group without a specific catheter|The patients were allocated in the PSV (pressure-support ventilation) weaning protocol group
89636274|NCT03027479|Experimental|Case group|women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples
89636275|NCT03027479|Other|Control group|women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples
89636276|NCT01520363|Active Comparator|Study drug-dextromethorphan (DM)|MECP2 mutation positive subjects randomized to receive DM
89636277|NCT01520363|Placebo Comparator|Placebo group|MECP2 positive subjects randomized to the placebo compound
89636278|NCT01578499|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
89636279|NCT01578499|Active Comparator|Methotrexate or Bexarotene|Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m^2, tablets, orally, once daily with meals for up to 48 weeks.
89636280|NCT01578187|Experimental|Hair2Go device|
89636281|NCT01561963|Experimental|Apremilast and Rifampin|"Participants received the following 3 treatment regimens:~A single oral dose of 30 mg apremilast on Day 1 (Period 1);~A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 (Period 2);~Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 (Period 3)."
89636282|NCT04852003|Experimental|SHR0410 Injection|
89636283|NCT04852003|Placebo Comparator|Placebo for SHR0410 Injection|
89042037|NCT06222528|Active Comparator|Control|A brief video control condition with psychoeducation on depression and help seeking
89042038|NCT06222489|Other|Patritumab Deruxtecan|5.6 mg/kg patritumab deruxtecan every 3 weeks
89636284|NCT04852003|Active Comparator|Morphine|
89636285|NCT01576783|Experimental|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
89042039|NCT06221943|Experimental|experimental group|ASD preschoolers who receive group-based NDBIs intervention (aged 2-6y)
89042040|NCT06221943|Active Comparator|active control group|ASD preschoolers who receive one-on-one NDBIs intervention (aged 2-6y)
89042041|NCT06218225|Experimental|Verum|Partecipants received a food supplement with the innovative IMMUREMEDY®-B complex and Lactobacillus rhamnosus CRL1505.
89042042|NCT06218225|Placebo Comparator|Placebo|Partecipants received a food supplement in the same primary packaging of the verum, but without active substances
89042043|NCT06214624|Experimental|12-week of aerobic high-intensity interval training (HIIT) exercise program|
89042044|NCT06214624|Experimental|12-week aerobic HIIT plus resistance exercise program|
89042045|NCT06214624|No Intervention|Usual care, Wait-list control group|The control group (as well as the 2 intervention groups) will be treated as usual in outpatient Phase III, which in Spain includes periodic medical revisions and medication control. In addition, for the control group, we will apply the wait-list strategy providing the supervised exercise program once all data collection for pre- and post-intervention assessment points have been finished.
89042046|NCT06211673||Patients and legal representatives|Minors and adults, without age limit, presenting with FOXP1 syndrome due to a genetic anomaly affecting the FOXP1 gene that has been identified, who have sought consultation at Necker-Enfants Malades Hospital, with at least one of the legal guardians or the legal representative being francophone.
89636286|NCT01576783|Placebo Comparator|Placebo|Corn oil supplement
89636287|NCT01534351|Experimental|Finasteride|Finasteride 5 mg taken orally once daily and tamsulosin-matching placebo taken orally once daily for 12 months. The tamsulosin-matching placebo will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
89636288|NCT01534351|Active Comparator|Tamsulosin|Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
89636289|NCT01534351|Experimental|Finasteride and Tamsulosin|Finasteride 5 mg orally once daily and tamsulosin 0.2 mg orally once daily for 12 months, taken concomitantly. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
89636290|NCT01534273|Placebo Comparator|Placebo|Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days
89636291|NCT01534273|Experimental|35 mg LY2886721|QD oral dosing for 14 consecutive days
89636292|NCT01534273|Experimental|70 mg LY2886721|Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days
89042047|NCT06209827|Experimental|Intervention for reducing benzodiazepines long-term use.|"It included the multiple components as follows:~(i) an exchange discussion with the patient describing the advantages, disadvantages and alternatives of benzodiazepines use and a tapering protocol with the support of educational material, (ii) the offer of a brief, if necessary, consultation with the family doctor, and (iii) a letter addressed to the patient supported by scientific societies."
89636293|NCT01534273|Experimental|140 mg LY2886721|Single oral dose
89042048|NCT06209827|No Intervention|Usual Care|Usual Care
89042049|NCT06207864|Experimental|Category 1 (biospecimens, surveys, interviews)|Cancer patients and survivors undergo collection of tissue, blood, saliva, and stool samples on study for genomic sequencing and microbiome analysis. Cancer patients and survivors also complete surveys and interviews on study pre and post intervention.
89042050|NCT06207305|Experimental|Phase I/Phase II|"Participants will be assigned to a study phase (Phase I or Phase II) based on when participants join this study. Up to 4 groups of at least 3 participants will be enrolled in Phase I of the study, and up to 15 participants will be enrolled in Phase II.~If you are enrolled in Phase I, the dose of paclitaxel you receive will depend on when the participants join this study. The first group of participants will receive the lowest dose level of paclitaxel. Each new group will receive a higher dose of paclitaxel than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of paclitaxel given intraperitoneally is found.~Participants who are enrolled in Phase II, participants will receive paclitaxel at the recommended dose that was found in Phase I."
89042051|NCT06199089|Experimental|Intervention (CM313)|30 from 45 enrolled subjects receive CM313: once a week x 8 doses
89636294|NCT01534195|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
89636295|NCT01534195|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
89636296|NCT04479384|Experimental|Intervention group|Thoracic manipulation T1-T5 if somatic dysfunction. Intrathoracic fascia stretch x 3. Recoil sternum x 3. Cranial base release - 4 steps.
89636297|NCT04479384|No Intervention|Control group|Supine position 10 minutes on the bench.
89636298|NCT03825588|Experimental|ASAP + BRITE + TAU (treatment as usual)|Participants in this arm receive the ASAP (As Safe As Possible) intervention, during their transition from inpatient to outpatient care, as well as the BRITE smart phone app for distress tolerance/emotion regulation and safety planning. Participants will also receive usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
89636299|NCT03825588|Experimental|BRITE + TAU (treatment as usual)|Participants in this arm will receive the BRITE smart phone app for distress tolerance/emotion regulation and safety planning as they proceed from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
89636300|NCT03825588|Experimental|ASAP + TAU (treatment as usual)|Participants in this arm will receive the ASAP (As Safe As Possible) intervention during their transition from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
89636301|NCT03825588|Active Comparator|TAU (treatment as usual) alone|Participants in this grouping are studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
89636302|NCT01560949|Experimental|Chemotherapy + Radiation|"SYSTEMIC PHASE: Chemotherapy with Oxaliplatin followed by Irinotecan followed by 5-FU. m FOLFIRINOX - oxaliplatin 75 mg/m2 d1 + irinotecan 150 mg/m2 d1 + 5-FUl 2,000 mg/m2 46h continuous infusion, every other week for 6 cycles (12 weeks).~CHEMORADIATION PHASE: This phase will start at least 2 weeks, but no more than 6 weeks after completion of the last cycle of mFOLFIRINOX. Chemoradiation with Gemcitabine: 350 mg/m2 IV over 35 minutes every week for 5 doses beginning day 1 (days 1, 8, 15, 22, 29)~Radiation: External beam radiation therapy will be delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions) to the GTV + 1.5 cm margin.~SURGERY- At least 4-6 weeks after last dose of Gemcitabine, if no local progression or distant metastasis. Patients whose scans show unequivocal local or distant progression are not candidates for surgery."
89636303|NCT03113448|Active Comparator|0.075% Capsaicin Lotion|0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
89636304|NCT03113448|Placebo Comparator|Placebo Lotion|Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
89636305|NCT01533493|Placebo Comparator|Placebo|Subjects randomized to receive memantine-matched placebo in addition to open-label OROS-Methylphenidate
89636306|NCT01533493|Active Comparator|Memantine|Subjects randomized to receive memantine in addition to open-label OROS-Methylphenidate
89636307|NCT04743102|Experimental|Biopsy cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, we add multi-points and full-thickness Biopsy to further improve the accuracy of cCR after neoadjuvant therapy for rectal cancer.
89636308|NCT04743102|Active Comparator|Conventional cCR|Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, to study accuracy of cCR after neoadjuvant therapy for rectal cancer.
89636309|NCT04439604||patient undergoing surgery under general anaesthesia|
89636310|NCT04479930|Experimental|HappyAir Group|The HappyAir app comprises two main parts: an educational program providing patients useful information and advice about their illness and data collection related to physical activity and disease.
89636311|NCT04479930|No Intervention|Control group|The control group only underwent the scheduled check-ups
89636312|NCT02388048|Experimental|Ibrutinib + Ofatumumab|"IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).~OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.~After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity."
89636313|NCT02388126|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
89636314|NCT02387892|Placebo Comparator|Control|Cheese & yogurt
89636315|NCT02387892|Experimental|Treatment|Cheese & yogurt + Vitamin D
89636316|NCT05581290|Experimental|Multi-Modal Sensor Patch Measurements|Subjects referred to Mayo Clinic in Arizona Cardiology Clinic who have an underlying cardiac structural condition will have a 15-minute data collection via the prototype device, AI-Flex, and standard of care electrocardiogram (ECG), temperature, and photoplethysmogram (PPG) measurements.
89636317|NCT05298540|Experimental|Home-based computerised cognitive training|Participants will be asked to complete 40 sessions (20 minutes / day, 5 days / week) of cognitive training over the 8-week intervention period (this will be assessed using automated data reports of user activity generated in collaboration with BrainHQ). Training will commence one week postoperatively to avoid the effects of sedatives, postoperative pain, sleep deprivation, and patient fatigue, and to improve adherence
89211992|NCT02773485|Experimental|Chemotherapy and radiation|In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
89211993|NCT04042220||GK + IT|Gamma Knife and immunotherapy
89636318|NCT00133575|Experimental|Group E: ACAM3000 MVA 10^7 ID|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intradermal route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
89636319|NCT00133575|Experimental|Group F: ACAM3000 MVA 10^8 IM|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
88990998|NCT05899101||5 - Nicotine Only|Nicotine users without opioid exposure
88990999|NCT05899101||6 - Cannabis Only|Cannabis-users without opioid exposure
88991000|NCT05899101||7 - Unexposed|Non-substance exposed healthy pregnancies
88991001|NCT05893121||Control|subjects who received information about MRI examination
88991002|NCT05893121||Experimental|Subjects who received information about MRI examination and one cardiac coherence session
88991003|NCT05891717|Experimental|Resistance training|Group A will receive resistance training. Twice per week for 8 weeks. Total 16 sessions will given.
88991004|NCT05891717|Active Comparator|Flexibility training|Group B will receive flexibility training. Twice per week for 8 weeks. Total 16 sessions will given.
88991005|NCT05887518|Experimental|EXPERIMENTAL GROUP|"In addition to the routine treatment and care practices of the operating theatre, the patients included in the study group will wear antiembolytic socks and warming socks to be developed with wearable technology. After the antiembolitic socks are put on the patients in the ward, the socks to be developed with wearable technology will be put on the study group before they are sent to the operating theatre and will be removed one day after the operation.~The socks to be used in the research (heating socks developed with wearable technology will be developed by the researchers and patent application will be made.~The application of socks to be developed with wearable technology in the research will be applied to all patients by the same executive. Verbal and written consent will be obtained from the patient/relative before the start of the study."
88991006|NCT05887518|No Intervention|CONTROL GROUP|"In the control group, the same looking sock will be worn before the patient is sent to the operating theatre and will be removed one day after the operation.~The sock to be used in the research will be developed by the researchers and a patent application will be made.~Verbal and written consent will be obtained from the patient/relative before the start of the study. The data obtained from the patients will be recorded in the Introductory Characteristics Form and Hypothermia Monitoring Form before the TUR. The application of socks to be developed with wearable technology will be carried out in accordance with the following application steps."
88991007|NCT05878600|Experimental|cervical spine strengthening group|"The participant will nod and chin tuck the head against the block with bands supporting the movement.~An air-filled pressure cushion is placed under the occiput behind the cervical spine and conforms to the subject's shape. With a head nod, the pressure on the cuff increases and is shown by the dial. 10 repetitions of 5 seconds hold will be performed for 8 weeks and strength is measured by sphygmomanometer"
88991008|NCT05878600|Active Comparator|Kendall exercise group|patient is seated and the exercises are performed which include stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up and performing arm abduction and external rotation; and (2) strengthening shoulder retraction, Strengthening the deep cervical flexors and Stretching the cervical extensors
89211994|NCT04042220||GK + IT + GC|Gamma Knife, immunotherapy and glucocorticoids
89636320|NCT00133575|Experimental|Group D: ACAM3000 MVA 10^8 SC|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via subcutaneous route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
89636321|NCT00133575|Experimental|Group B: ACAM3000 MVA 10^7 IM|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
89636322|NCT00133575|Experimental|Group A: ACAM3000 MVA 10^6 ID|10 subjects to receive ACAM3000 MVA dose 10^6 tissue culture infectious dose 50 (TCID50) via intradermal (ID) route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
89636323|NCT00133575|Experimental|Group C: ACAM3000 MVA 10^7 SC|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via subcutaneous (SC) route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
89636324|NCT00133809|Experimental|Islet Transplant|All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
89636325|NCT00134043|Experimental|Arm I|Patients receive oral suberoylanilide hydroxamic acid (SAHA) twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are then evaluated for disease response. Patients achieving a complete response receive an additional 2 courses of SAHA. Patients achieving stable disease or a partial response receive 4 additional courses of SAHA.After completion of study treatment, patients are followed within 4 weeks.
89636326|NCT01899495|Experimental|High sodium diet and low sodium diet|Each subject experiences both a high sodium and a low sodium diet.
89636327|NCT05177367|Experimental|Sequential Variety, Small Portion|3 courses each consisting of a different food served in a small portion.
89636328|NCT05177367|Experimental|Sequential Variety, Large Portion|3 courses each consisting of a different food served in a large portion.
89636329|NCT05177367|Experimental|Simultaneous Variety, Small Portion|3 courses each consisting of 3 foods served in small portions.
89636330|NCT05177367|Experimental|Simultaneous Variety, Large Portion|3 courses each consisting of 3 foods served in large portions.
89636331|NCT05177367|Experimental|Single Food, Small Portion|3 courses each consisting of the same food served in a small portion.
89636332|NCT05177367|Experimental|Single Food, Large Portion|3 courses each consisting of the same food served in a large portion.
89636333|NCT04389255||Healthy people|65 people will be included.
89636334|NCT01899651||Infants of 30-34 weeks gestation.|Inclusion criteria will be infants 30-34 weeks gestation. Exclusion criteria will be any infants with evidence of pre-existing skin condition, breakdown, rashes, or problems with skin integrity. Infants with a known neurological condition (hydrocephalus, Dandy Walker malformation, craniosynostosis, arteriovenous malformation) will be excluded as well. Also, secondary to the nature of the device and the surface area it takes up, infants on continuous positive airway pressure will be excluded as well.
89636335|NCT04751721|Experimental|CoronoVac Vaccine Group|
89636336|NCT03715998|Experimental|Group 1: firibastat 100 mg|Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.
89636337|NCT03715998|Experimental|Group 2: firibastat 500 mg|Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.
89636338|NCT03715998|Active Comparator|Group 3: ramipril 5 mg|Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.
89636339|NCT01790451|Active Comparator|peripheral ablation|an ablation of the peripheral area of the prostate
89636340|NCT01790451|Active Comparator|More central ablation|an ablation, more centrally, in proximity of the urethra
89636341|NCT01790529|Experimental|Early Prophylaxis|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)
89636342|NCT01790529|Active Comparator|Late Prophylaxis|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
89636343|NCT04751643|Experimental|TPE + usual treatments in intensive care unit according to the current state of knowledge.|"TPE + usual treatments in intensive care unit according to the current state of knowledge : 3 TPE sessions i.e. one per day during 3 consecutive days on day 1-3 (day 0 = inclusion Visit date)) + usual treatments in intensive care unit.~Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)"
89211995|NCT04042220||GK only|Gamma Knife without immunotherapy
89211996|NCT00992355|Active Comparator|Tobramycin 0.3% - Dexamethasone 0.1%|
89636344|NCT04751643|Active Comparator|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
89636345|NCT02387658||final TLG </=11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) < 11 mmHg regardless if revascularization is done or not.
89636346|NCT02387658||final TLG > 11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) > 11 mmHg regardless if revascularization is done or not.
89636347|NCT04717323|Experimental|Patients|Gait with and without pelvic assistance
89636348|NCT04717323|Experimental|Controls|Gait with no pelvic assistance
89636349|NCT01790607|Experimental|Subjects with moderate chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
89636350|NCT01790607|Experimental|Healthy subjects matched to moderate hepatic impaired subjects|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
89636351|NCT01790607|Experimental|Subjects with mild chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
89636352|NCT01790607|Experimental|Healthy subjects matched to mild hepatic impaired subjects|Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
89636353|NCT01790607|Experimental|Subjects with severe chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
89636354|NCT03644472|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
89636355|NCT03644472|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
89636356|NCT00278655|Experimental|Hematopoietic stem cell transplantation|All participants will undergo hematopoietic stem cell transplantation after receiving conditioning regimen.
89636357|NCT03113604||Patients with untreated CHC not sorafenib|
89636358|NCT03113604||Patients with non-sorafenib CHC|
89636359|NCT03113604||Patients with CHCs responding to sorafenib|
89636360|NCT01602432||High Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is ≥ 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~Based on this method, the model includes 5 predictive variables as follows:~Site of cancer: classified as very high-risk (+2 points) or high-risk (+1 point).~Platelet count: (>350 x 109/L) (+1 point)~Hemoglobin level (<100 g/L) and/or use of erythropoiesis stimulating agents (+1 point)~Leukocyte count (> 11 x 109/L)(+1 point).~body mass index (≥ 35 Kg/m2) (+1 point)."
89636361|NCT01602432||Low high Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is < 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~In order to confirm the patient low risk status, we will draw a blood sample to determine serum levels of D- dimer and soluble P selectin in patients of this low risk group according to Ay et al. (2010). If levels of D-dimer are ≥ 1.44 µg/mL and/or soluble P selectin ≥ 53.1 ng/mL, we will add one point for each one of the increased biochemical marker and the total score recalculated."
89636362|NCT01533181|Experimental|Arm I: OS-906 (linsitinib)|OS-906 daily, continuously, every 3 weeks.
89636363|NCT01533181|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes or PO QD on days 1-5. Patients may crossover to Arm I at the time of progressive disease.
89636364|NCT04641507|Active Comparator|Tamsulosin treated group|83 patient with lower ureteric stone will take tamsulosin 0.4 mg once daily .Therapy will be given for a maximum of 4 weeks.
89042052|NCT06199089|Placebo Comparator|Intervention (Placebo)|15 from 45 enrolled subjects receive placebo: once a week x 8 doses
89042053|NCT06189833|Experimental|D-VRd + ASCT + DVRD|"Participants will receive daratumumab, bortezomib, lenalidomide and dexamethasone (DVRD) for 4 induction cycles prior to and 2 consolidation cycles following autologous stem cell transplantation.~Daratumumab subcutaneously (SC), 1800 mg on days 1, 8, 15 and 22 of cycle 1 and 2, on days 1 and 15 of cycle 3-6 Bortezomib SC 1.3mg/m2 on days 1, 8, 15, 22 of cycle 1-6 Lenalidomide orally 25 mg once daily on days 1-21 of cycle 1-6 Dexamethasone 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22 and 23 of cycle 1-6"
89042054|NCT06185790|Experimental|LCHF diet|Participants will adhere to a low-carb high-fat diet for 12 weeks,defined by a carbohydrate intake of 50-100 grams per day.
89042055|NCT06185790|No Intervention|Control|Participants will follow their usual diet for 12 weeks.
89042056|NCT06174259|Experimental|Intermittent fasting|16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day) around standard neoadjuvant chemotherapy.
89042057|NCT06174259|No Intervention|regular diet|Regular diet around standard neoadjuvant chemotherapy
89042058|NCT06173635|Other|Maxi Move 5|24 healthy volunteers will evaluate all 5 devices
89042059|NCT06172075|Experimental|Brief video intervention (Black Woman)|A brief social contact-based video with a Black woman protagonist
89042060|NCT06172075|Experimental|Brief video intervention (Latinx Woman)|A brief social contact-based video with a Latinx woman protagonist
89042061|NCT06172075|Experimental|Brief video intervention (White Woman)|A brief social contact-based video with a White woman protagonist
89042062|NCT06172075|Other|Vignette Control|A brief vignette control condition
89042063|NCT06164743|Experimental|VVN461 1.0%|VVN461 Ophthalmic Solution, 1.0%
89042064|NCT06164743|Experimental|VVN461 0.5%|VVN461 Ophthalmic Solution, 0.5%
89636365|NCT04641507|Active Comparator|Tadalafil treated group|83 patients with lower ureteric stone will take tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
89042065|NCT06164743|Placebo Comparator|Vehicle|VVN461 Vehicle
89042066|NCT06159933|Experimental|Historic cohort (SUPINE POSITIONING)|According to our local protocol, until December 2021, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
89211997|NCT00992355|Active Comparator|Tobramycin-Dexamethasone plus Ketorolac tromethamine|
89636366|NCT04518969|No Intervention|Control|Standard medical therapy (ie: control group) : Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed……
89042067|NCT06159933|Experimental|Historic cohort (LATE PRONATION)|According to our local protocol, until December 2021, all patients developing PGD >1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
89042068|NCT06159933|Experimental|Prospective cohort (EARLY PRONATION)|On the contrary, starting from January 2022 our local protocol was updated and all LT recipients developing PGD >1 were routinely turned prone within 24 hours after the diagnosis ('early PP').Patients were placed in PP for at least 16 hours before being turned back to the supine position when meeting predefined criteria previously published by Guèrin et al
89636367|NCT04518969|Experimental|Cytosorb|"CytoSorb therapy (ie: study group): Adult intensive care patient admit in acute respiratory distress needing intubation with suspicion of under the CT Scan of Covid 19 confirmed by positive antigen or PCR technology N =12 -Mechanical ventilation, prone position if needed,fluid challenge if needed , vasopressors if needed, inotropic support in needed…… Plus patients will be on CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
89042069|NCT06158152|Active Comparator|Active arm|Patients who will receive the study treatment (AM3 Technology in combination with Probiotic SynBalance Metsyn)
89042070|NCT06158152|Placebo Comparator|Placebo arm|Patients who will receive placebo treatment, consisting of starch capsules
89042071|NCT06158152|Sham Comparator|Control arm|Patients to be treated with AM3 Technology capsules
89636368|NCT03113526|Active Comparator|Less than 30ml per 24-hour|Drain removed as early as day one as long as output less than 30ml per 24-hour
89636369|NCT03113526|Active Comparator|Less than 100ml per 24-hour|Drain removed as early as day one as long as output less than 100ml per 24-hour
89636370|NCT04489173|Experimental|Treatment|Treatment with TAS102
89636371|NCT02669082|Experimental|Ramelteon 8 mg|Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.
89636372|NCT00138645|Experimental|MicroDiet|Participants randomized to the MicroDiet group (1200 kcal/day) will be instructed by a Registered Dietitian to consume (one shake and 3 cookies; 240 kcal) for two meals each day for Months 1 through 3. They will be provided with meal plans for the meal that they do not replace with MicroDiet. During Months 4 through 6, participants in the MicroDiet group will be instructed to replace one meal per day with MD (the energy content of the meal plan will still be 1200 kcal/day). Participants will also be encouraged to eat or drink MD for snacks. The rest of the diet will consist of healthy foods, as outlined above. To help participants adhere to the MicroDiet regimen, they will meet with a registered dietitian for one hour at Week 0 and 30 minutes at Weeks 2 and 4, and every month thereafter.
89636373|NCT00138645|Active Comparator|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet. The Healthy Diet will consist of the same foods that are used in the meal plans for the MicroDiet group. The Healthy Diet group will be instructed not to use meal replacements such as shakes (e.g., Slim Fast®), nutrition bars (e.g., Balance Bar®), or portion-controlled meals (e.g., Healthy Choice entrees).
89636374|NCT00512070|Experimental|IIA (0.3mg day melatonin)|0.3mg day melatonin
89636375|NCT00512070|Experimental|IIB (3.0 mg/day melatonin)|3.0 mg/day melatonin
89636376|NCT00140205|Experimental|Fed state or fasting state|"1-day fed studies with administration of r-metHuLeptin at three different doses (0.01 mg/kg, 0.1 mg/kg, 0.3 mg/kg). All subjects participated in 3 studies in the fed condition (Part A) and 3 separate 72-hour fasting studies.~Intervention administered was-r-metreleptin in 3 different doses"
89042072|NCT06151652|Placebo Comparator|Group 1 (Control group, N = 175 patients)|which will include patients adopted to the hospital standard of care.
89042073|NCT06151652|Active Comparator|Group 2 (Test group, N = 175 patients)|which will include patients who will receive Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
89636377|NCT00279591|Active Comparator|Continuous Blood Pressure Monitoring|Patients received continuous blood pressure monitoring the entire time they were in med flight to the hospital.
89636378|NCT00279591|Placebo Comparator|Standard of care blood pressure monitoring|Patients received the normal standard of care for blood pressure monitoring during the course of the med flight to the hospital.
89636379|NCT03534102|No Intervention|Standard of Care|Standard instructions from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
89636380|NCT03534102|Experimental|Improved Instructions|Improved opioid-tapering instructions given upon discharge from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
89636381|NCT03534102|Experimental|Improved Instructions and Educator|Improved opioid-tapering instructions given upon discharge from hospital. Subject receives regular phone calls from educator for counseling in opioid tapering. Subjects record opioid tapering in diary.
89636382|NCT00141765|Experimental|Myeloablative Chemotherapy with Stem Cell Rescue|Myeloablative Chemotherapy, followed by stem cell rescue
89636383|NCT02668692|Experimental|LEO 80185 gel|
89042077|NCT06149689|Experimental|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin [70 mg per square meter of body surface area], irinotecan [130 mg per square meter], leucovorin [200 mg per square meter], and fluorouracil [2000 mg per square meter] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
89042078|NCT06148181|Experimental|Part 1, ABBV-141 (Intravenous [IV])|Western participants will receive a single IV dose of ABBV-141.
89042079|NCT06148181|Placebo Comparator|Part 1, Placebo for ABBV-141 (IV)|Western participants will receive a single IV dose of placebo for ABBV-141.
89042080|NCT06148181|Experimental|Part 1, ABBV-141 (subcutaneous [SC])|Western participants will receive a single SC dose of ABBV-141.
89042081|NCT06148181|Placebo Comparator|Part 1, Placebo for ABBV-141 (SC)|Western participants will receive a single SC dose of placebo for ABBV-141.
89636384|NCT02668692|Active Comparator|Dovobet ® ointment|
89636385|NCT01899807|Other|Single Arm|
89636386|NCT00281463|Experimental|Pushrim Activated Power Assist Wheelchair|Participants will be asked to propel both their own chair and a pushrim activated power assist wheelchair on a computer controlled wheelchair dynamometer.
89636387|NCT03106116|Experimental|Enhanced External Counterpulsation|Experimental: Enhanced External Counterpulsation (EECP) intervention on top of guideline- driven standard medical therapy for coronary heart disease
89636388|NCT03106116|Active Comparator|Control|Guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention
89636389|NCT03105882|Experimental|Neuro-Spinal Scaffold|
89636390|NCT00144963|Experimental|VSLI|Vincristine Sulfate Liposomes Injection (VSLI)
89636391|NCT02662764|Experimental|Zalviso™ 15 mcg|Zalviso™(sufentanil sublingual tablet system) 15 mcg
89636392|NCT01519817|Experimental|Yeast-Brachyury vaccine|Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
89636393|NCT01519661|Experimental|Tobramycin Inhalation Powder (TIP)|Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
89636394|NCT05549154|Experimental|High-dose vitamin D group|Vitamin D2 softgels 50,000 U/week
89636395|NCT05549154|Experimental|Low-dose vitamin D group|low-dose vitamin D group
89636396|NCT05549154|Placebo Comparator|Control group|Placebo
89636397|NCT05231538|Experimental|Neurodevelopmental Therapy|The treatment group received neurodevelopment treatment lasting for 3 months (3sessions per week). Additionally, for this study, the NDT programme included passive stretching of the lower limb muscles (e.g. hamstrings, gastrocsoleus), followed by techniques of reducing spasticity and facilitating more normal patterns of movement while working on motor functions. In each session, exercises included patients sustaining themselves on their forearms and hands, sitting, crawling, semi-kneeling, and in standing positions supported by the Physical therapist until tone reduction achieved. Balance and corrective reactions were developed by using a CP ball and tilt board.
89636398|NCT05231538|Active Comparator|Routine Physical Therapy|The control group underwent the exercises (stretching, passive range of motion, and active range of motion).
89636399|NCT01519427|Experimental|Treatment (selumetinib and Akt inhibitor MK2206)|Patients receive selumetinib PO BID on days 1-21 and Akt inhibitor MK2206 PO once weekly.
89636400|NCT02391792||patients|patients with septic shock
89636401|NCT02391792||control|patients without septic shock
89636402|NCT02391792||healthy volunteers|
89636403|NCT01518257|Experimental|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
89636404|NCT01518257|Placebo Comparator|Placebo|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
89636405|NCT02668302|Experimental|Treatment|Bilateral in-office placement of a steroid-eluting sinus implant following ethmoidectomy in addition to post-op standard of care, including debridement, irrigation, and topical steroids
89636406|NCT02668302|Active Comparator|Control|Post-op standard of care, including debridement, irrigation, and topical steroids
89636407|NCT03027401||Group A|Adult/pediatric with suspected or confirmed malignancy, family history of malignancy, undergoing surgery with no malignancy; tissues collected previously under CLIA or for research.
89636408|NCT02387424|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
89636409|NCT02387424|Active Comparator|OAR|Ongoing Assessment and Referral (OAR)
89636410|NCT02387346|Experimental|Real Stimulation|Participants in this group will receive Repetitive Transcranial Magnetic Stimulation, characterized by 900 pulses at 1Hz over the medial cerebellum at 120% resting motor threshold of the right first dorsal interosseous.
89636411|NCT02387346|Sham Comparator|Sham Stimulation|Participants will receive Sham Repetitive Transcranial Magnetic Stimulation by having the coil angled at 90 degrees to the scalp; this will allow adequate noise output from the stimulator in the absence on real magnetic stimulation.
89636412|NCT02387190|Experimental|Telenursing monitoring|The protocol for telenursing allows the realization of standardized professional contacts with the patient and educational approach It is possible through questions and answers coded, that indicate the need for educational intervention or reinforcement of appropriate health behavior.1) Contact the patient by telephone, weekly; 2) Distribution and explanation of the educational booklet; 3) Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
89636413|NCT02387190|No Intervention|Control group|Placebo is considered as standardized education
89636414|NCT02387034|Experimental|Physical activity on prescription (PAP)|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
89636415|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about being active with cardiovascular exercise such as walking, cycling or otherwise in 30 minutes three times a week and do strength training functional during the day such as walk in stairs and getting up from a chair without hand support.
89636416|NCT02391636|Experimental|Carbetocin arm|100 μg intravenous injection at delivery of the anterior shoulder
89636417|NCT02391636|Active Comparator|oxytocin arm|5 IU intravenous injection at delivery of the anterior shoulder
89636418|NCT01517867|Experimental|Intervention Chicago Parent Program arm|The Chicago Parent Program is a 12-session group-based parenting skills training program
88991009|NCT05876078|Experimental|ADHF patients|ADHF patients with insufficient response to diuretics treated with the Doraya catheter
89636419|NCT01517867|Active Comparator|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually tailored treatment for parents and children with behavior problems
89636420|NCT02386878|Experimental|Interpersonal Psychotherapy for Groups (IPTG)|The intervention consists of 16 weekly 60 to 90 minute psychotherapy sessions, implemented once a week by a trained lay facilitator.
89636421|NCT02386878|Experimental|Vhutshilo 2|The intervention consists of 13 group sessions, implemented once a week by a trained lay facilitator.
89636422|NCT02386878|Experimental|IPTG and Vhutshilo|Participants receive the IPTG intervention first, followed by Vhutshilo 2.
89636423|NCT02386878|No Intervention|No Intervention|No intervention
89636424|NCT04098107|Experimental|Throwing Device Phase 1|During Phase 1, subjects that have been recruited, consented, and enrolled will come to the biomechanics laboratory for throwing performance housed at the University of Pennsylvania (Human Motion Laboratory) on the day of their appointment. Subjects will be asked to wear the prototype device during a simulated baseball game (approximately 30-45 pitches), and then will perform a set of other baseball-specific movements while fitted with infrared markers for throwing analysis. This data will be used to develop and refine the algorithm for the prototype.
89636425|NCT01514357|Other|Nesiritide (BNP)|Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.
89636426|NCT01514357|Placebo Comparator|Placebo|Subjects will receive SQ placebo bid for seven consecutive days.
89636427|NCT02383212|Experimental|Monotherapy Cohort|Cemiplimab will be administered alone
89636428|NCT02383212|Experimental|Dual Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy~Doses of cemiplimab will be administered in combination with Cyclophosphamide~Doses of cemiplimab will be administered in combination with Docetaxel"
89636429|NCT02383212|Experimental|Triple Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus Cyclophosphamide~Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF~Doses of cemiplimab will be administered in combination with Carboplatin plus Paclitaxel~Doses of cemiplimab will be administered in combination with Carboplatin plus Pemetrexed~Doses of cemiplimab will be administered in combination with Carboplatin plus Docetaxel"
89636430|NCT02383212|Experimental|Quadruple Combination Cohorts|Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF plus Cyclophosphamide
89636431|NCT02387112|Experimental|Early VAD implantation|The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
89636432|NCT02387112|No Intervention|Emergency VAD implantation|The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.
89636433|NCT02386956|Experimental|Active stretching|10 minutes of Postural Global Reeducation for the posterior muscle chain
89636434|NCT02386956|Experimental|Dynamic Stretching|10 minutes of sciatic nerve manual movilization in two legs
89636435|NCT02386956|Placebo Comparator|Control|10 minutes with the patient lying on a machine off of magnetotherapy
89636436|NCT01532869|Placebo Comparator|Placebo|
89636437|NCT01532869|Experimental|Tocilizumab|
89636438|NCT02383290|Experimental|Decision support|This is a feasibility trial so all patients will give a saliva sample and the pharmacist/ Family Physician will use the decision support for generating prescription recommendations
89636439|NCT02391246||Positron Emission Tomography Imaging|Dual time point imaging with 250 MBq of 18F-Fluorodeoxyglucose (18F-FDG)
89636440|NCT02382978|Experimental|nurse-provided well child care visit|these children will be seen by a nurse only for their regular, pre-scheduled well child care visit
89636441|NCT02382900|Experimental|Cohort 1|11 year old boys enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Gustavo A. Madero, Iztacalco, Miguel Hidalgo, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
89636442|NCT02382900|Active Comparator|Cohort 2|Historical cohort of young women 18-24 years old recruited by Lazcano et. al. receiving a standard vaccination schedule (0-1-6 months). 500 subjects were recruited.
88991010|NCT05874479|Experimental|Active Portable Air Cleaner (PAC)|Using a double-blind randomized process, active PACs (with HEPA filters inside) will be assembled and placed in the bedroom of study participants. Initiation of the PAC devices will occur at baseline on Day 0. After completion of enrollment, consent and the placement of PACs, electricity monitors, and PurpleAir monitoring, the PAC will be turned on. Participants will be instructed to keep the PACs on in bedrooms during the study duration, closing bedroom doors at night and during the day, when possible. The PAC will run for 24 hours on Day 0 of the study protocol before the 30-day treatment period begins. A kilowatt meter will be installed with the PAC to monitor electricity usage as a measure of adherence.
88991011|NCT05874479|Sham Comparator|Sham PAC|Using a double-blind randomized process, sham PACs (with no filters inside) will be assembled and placed in the bedroom of study participants. Initiation of the PAC devices will occur at baseline on Day 0. After completion of enrollment, consent and the placement of PACs, electricity monitors, and PurpleAir monitoring, the PAC will be turned on. Participants will be instructed to keep PACs on in bedrooms during the study duration, closing bedroom doors at night and during the day, when possible. The PAC will run for 24 hours on Day 0 of the study protocol before the 30-day treatment period begins. A kilowatt meter will be installed with the PAC to monitor electricity usage as a measure of adherence.
88991012|NCT05865808|Experimental|Cervical spine mobilization|Subjects in this group will be treated with headache SNAGs
88991013|NCT05865808|Active Comparator|Rocabado 6x6 exercises|Rocabado 6x6 program includes 6 types of exercises which are- rest position of the tongue, TMJ rotation control, upper cervical distraction, axial extension of cervical spine, shoulder girdle retraction, and rhythmic stabilization technique.
89636443|NCT02382900|Active Comparator|Cohort 3|11 year old girls enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
89636444|NCT02386644|Experimental|Suspected Membrane Rupture Arm|Women with suspected membrane rupture will be subject to following interventions; Ultrasound amniotic fluid index measurement, ultrasound transperineal assessment, nitrazine test, speculum examination, PAMG-1 Immunoassay
89636445|NCT02386722|Experimental|Intervention group|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
89636446|NCT02386722|No Intervention|Control group|Patients in the control group will receive a Smartinhaler/POEMS, which only records their adherence. The alarm function of the devices will be switched off, and these participants will not be reminded to take their inhalers. This group will not receive any calls, if they do not comply with the prescribed medication schedule or if they use their rescue medication too frequently.
89636447|NCT01531387|No Intervention|Standard Therapy: Observation|Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
89636448|NCT01531387|Experimental|Hydroxyurea|Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
89636449|NCT01531153|Active Comparator|Sugar Pill|Sugar Pill will be compared with the active medication Galantamine
89636450|NCT01531153|Active Comparator|Galantamine|Comparing the active medication with the placebo medication to see if the self administration cocaine decreases.
89636451|NCT03027973|Experimental|UPA Treatment Group|UPA 5mg capsule daily + Placebo 2 capsules 4 times a day
89636452|NCT03027973|Active Comparator|TEA Treatment Group|TEA 500mg 2 capsules 4 times a day + Placebo 1 capsule daily
89636453|NCT01529749|Active Comparator|EFV/FTC/TDF|
89636454|NCT01529749|Experimental|EFV/FTC/TDF + Losartan|
89636455|NCT01529749|Experimental|FTC/TDF + MK-0518|
89636456|NCT01529749|Experimental|FTC/TDF+MK-0518+Losartan|
89636457|NCT01529515|Experimental|Paliperidone palmitate 3-month (PP3M)|
89636458|NCT01529515|Placebo Comparator|Placebo|
89636459|NCT01528969|Experimental|Xylitol|A half of the subjects will be randomly allocated into xylitol group.
89636460|NCT01528969|Active Comparator|Sorbitol|About 40 randomly allocated subjects will chew sorbitol chewing gum (1,5, g/pellet) three times a day
89636461|NCT01514201|Experimental|Treatment (veliparib, temozolomide, 3D-CRT, IMRT)|"DOSE-ESCALATION: Patients receive veliparib PO BID 5 days a week for 6-7 weeks. Patients also undergo concurrent 3D-CRT or IMRT QD 5 days a week for 6-7 weeks.~MAINTENANCE THERAPY: Beginning 3-4 weeks later, patients receive veliparib PO BID on days 1-5 and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
89636462|NCT02666664|Experimental|ETC-1002|ETC-1002 180 mg/day
89636463|NCT02666664|Placebo Comparator|Placebo|Placebo control
89636464|NCT01528735|Experimental|BI 207127 NA, BI 201335 NA(high dose), R|Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
89636465|NCT01528735|Experimental|BI 207127 NA,BI 201335 NA(low dose),RBV|Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
89636466|NCT02386332||umbilical cord blood transplant (UCBT)|Patients to receive umbilical cord blood transplant (UCBT) are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan and anti-thymocyte globulin.). Also receive GVHD prophylaxis with cyclosporine A and prednisone and Additional Supportive Care
89636467|NCT02386332||HLA-haploidentical hematopoietic stem cell transplantation|Patients to receive HLA-haploidentical hematopoietic stem cell transplantation are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan). Also receive GVHD prophylaxis with cyclophosphamide, cyclosporine A and mycophenolate mofetil and Additional Supportive Care
89636468|NCT02386410|Experimental|Group parent training|The intervention Group parent training for anxious parents is delivered in groups of about five, in 90 minutes per session, for eight consecutive weeks. The parent training is delivered by a licensed psychologist.
89636469|NCT02386410|Experimental|Internet delivered parent training|In the internet delivered parent training for anxious parents, parents are asked to work with one chapter each week, for eight consecutive weeks. Each chapter mirrors a session in the group format. Parents are able to e-mail a licensed psychologist during the intervention.
89636470|NCT02386410|No Intervention|Wait-list|Parents in the wait-list condition will receive the intervention after 12-month follow-up.
89636471|NCT02386488|Experimental|Vortioxetine 10 mg single dose|8 men and 8 women
89636472|NCT02386488|Experimental|Vortioxetine 20 mg single dose|8 men and 8 women
89636473|NCT02386488|Experimental|Vortioxetine 10 mg multiple dose|8 men and 8 women
89636474|NCT02386488|Experimental|Vortioxetine 20 mg multiple dose|8 men and 8 women
88991014|NCT05857657|Experimental|lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session
89636475|NCT02383446|Experimental|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
89636476|NCT02382822||HIV infected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
89211998|NCT00845312||Complicated hospitalization|"Patients 60 years old or younger, who were diagnosed with community acquired pneumonia (CAP) between March 1, 2005 and December 31, 2008 were retrospectively analyzed for risk factors for severe morbidity or mortality.~was defined as at least one of the following parameters: hospitalization longer than ten days, admission to intensive care unit and in- hospital mortality. Otherwise, the hospitalization was defined uncomplicated .The Rambam hospital Institutional Review Board approved the study."
89636477|NCT02382822||HIV uninfected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, blood sampling
89636478|NCT02661594|Experimental|ABCD|A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.
89636479|NCT02661594|Experimental|BDAC|B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;
89636480|NCT02661594|Experimental|CADB|C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg
89636481|NCT02661594|Active Comparator|DCBA|D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg
89636482|NCT02386566||natalizumab|natalizumab 300 mg intravenous (IV) every 4 weeks; according to the approved product label of Tysabri in Switzerland
89636483|NCT01528345|Experimental|Fulvestrant + Dovitinib active|Fulvestrant in combination with the study drug Dovitinib.
89636484|NCT01528345|Placebo Comparator|Fulvestrant + Dovitinib placebo|Fulvestrant in combination with a placebo matching Dovitinib.
89636485|NCT01513967|Experimental|Part A, SAD Treatment 1|RPh201 single dose (SAD Low Dose )
89636486|NCT01513967|Placebo Comparator|Part A, SAD Placebo 1|Placebo single dose (SAD Low Dose )
89636487|NCT01513967|Experimental|Part A, SAD Treatment 2|RPh201 single dose (SAD Mid Dose )
89636488|NCT01513967|Placebo Comparator|Part A, SAD Placebo 2|Placebo single dose (SAD Mid Dose )
89636489|NCT01513967|Experimental|Part A, SAD Treatment 3|RPh201 single dose (SAD High Dose )
89636490|NCT01513967|Placebo Comparator|Part A, SAD Placebo 3|Placebo single dose (SAD High Dose )
89636491|NCT01513967|Experimental|Part B, MAD Treatment 1|RPh201 multiple dose (MAD Low Dose )
89636492|NCT01513967|Placebo Comparator|Part B, MAD Placebo 1|Placebo multiple dose (MAD Low Dose )
89636493|NCT01513967|Experimental|Part B, MAD Treatment 2|RPh201 multiple dose (MAD Mid Dose )
89636494|NCT01513967|Placebo Comparator|Part B, MAD Placebo 2|Placebo multiple dose (MAD Mid Dose )
89636495|NCT01513967|Experimental|Part B, MAD Treatment 3|RPh201 multiple dose (MAD High Dose )
89636496|NCT01513967|Placebo Comparator|Part B, MAD Placebo 3|Placebo multiple dose (MAD High Dose )
89636497|NCT02099721|Active Comparator|Group A: Secondary prevention patients- device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects receive an ICD/CRT-D implant."
89636498|NCT02099721|No Intervention|Group B: Secondary prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects choose not to receive an ICD/CRT-D implant."
89636499|NCT02099721|Active Comparator|Group C: 1.5 Prevention patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects receive an ICD/CRT-D implant."
89211999|NCT04042064||Inhalation|Patient anesthetised with Inhalation anesthetic agents.
89212000|NCT04042064||TIVA (total intravenous anesthesia)|Patient anesthetised with total total intravenous anesthesia.
89636500|NCT02099721|No Intervention|Group D: 1.5 prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects choose not to receive an ICD/CRT-D implant."
89636501|NCT02099721|Other|Group E: Primary, non-1.5 patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects receive an ICD/CRT-D implant."
89636502|NCT02099721|No Intervention|Group F: Primary, non-1.5 patients - no device|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects choose not to receive an ICD/CRT-D implant."
89636503|NCT01511939|Other|Pennsaid, warfarin|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months
89636504|NCT01511939|Other|Pennsaid, dabigatran|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months
89636505|NCT01511939|Other|Pennsaid, aspirin and/or clopidogrel|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months
89636506|NCT02391480|Experimental|ABBV-075|Dose escalation cohorts of ABBV-075 monotherapy
89636507|NCT02391480|Experimental|ABBV-075 and venetoclax combination|Expansion cohorts of ABBV-075 and venetoclax combination therapy
89636508|NCT02391480|Experimental|ABBV-075 expansion|Expansion cohorts of ABBV-075 monotherapy
89636509|NCT01576705|Experimental|Thyroxin + folinic acid|
89636510|NCT01576705|Active Comparator|Thyroxin+folinic acid placebo|
89636511|NCT01576705|Active Comparator|Thyroxin placebo+ folinic acid|
89636512|NCT01576705|Placebo Comparator|Thyroxin placebo+ folinic acid placebo|
89636513|NCT02666430|Experimental|Mylan's insulin glargine|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
89636514|NCT02666430|Active Comparator|Lantus®|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
89636515|NCT01576549|Experimental|LY2127399|LY2127399 given subcutaneously (SC) at 240 milligrams (mg) as a loading dose in the first week followed by 120 mg SC every 4 weeks for up to 52 weeks.
89636516|NCT02382666|Experimental|Rolapitant Cohort 1|Investigational Product: Rolapitant Dose 1 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
89636517|NCT02382666|Experimental|Rolapitant Cohort 2|Investigational Product: Rolapitant Dose 2 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
89636518|NCT02382666|Experimental|Rolapitant Cohort 3|Investigational Product: Rolapitant Dose 3 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
89636519|NCT02382666|Experimental|Rolapitant Cohort 4|Investigational Product: Rolapitant Dose 4 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
89636520|NCT02382666|Experimental|Rolapitant Cohort 5|Investigational Product: Rolapitant Dose 5 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
89636521|NCT02382666|Experimental|Rolapitant Cohort 6|Investigational Product: Rolapitant Dose 6 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
89636522|NCT00145041|Experimental|VSLI|Single armed study; all subjects received VSLI
89636523|NCT01576159|Experimental|High-Impact Loading|Performed high-impact running exercise during intervention period.
89636524|NCT01576159|Experimental|Moderate-Impact Loading|Performed moderate-impact cycling exercise during intervention period.
89636525|NCT01576159|Experimental|Non-Impact Loading|Performed low-impact swimming exercise during intervention period.
89636526|NCT01576159|No Intervention|Control Group|Didn't participate any organized physical exercises
89636527|NCT02391012|Experimental|Fecal microbial l transplantation|patients with active colitis who will undergo treatment by fecal microbial transplantation
89636528|NCT02099799|Active Comparator|Pedometer and Internet Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
89636529|NCT02099799|No Intervention|Usual Care|Verbal instructions and written materials about exercise.
89636530|NCT04123561|Experimental|TLC599|TLC599 (1mL) IA injection
89636531|NCT04123561|Active Comparator|Dexamethasone sodium phosphate|DSP 4mg (1mL) IA injection
89636532|NCT04123561|Placebo Comparator|Normal Saline|Normal saline (1mL) IA injection
89636533|NCT01510769|Experimental|lesinurad 400 mg + febuxostat 80 mg|
89636534|NCT01510769|Experimental|lesinurad 200 mg + febuxostat 80 mg|
89636535|NCT01510769|Placebo Comparator|placebo + febuxostat 80 mg|
89636536|NCT04479228|Experimental|NAGI bi-flanged metal stent (BFMS)|The WON will be punctured using a standard 19-gauge FNA needle and the aspirate was sent for biochemical and microbial analysis. A 0.025-inch (Visiglide; Olympus Corporation, Tokyo, Japan) or 0.035-inch stiff guidewire (Jag Wire; Boston Scientific) passed through the needle into the cyst cavity to form at least 1 to 2 loops under fluoroscopic guidance. A 6F cystotome (Endo-flex GmbH Dusseldorf, Germany) will be passed over the guidewire for creating a fistula. Subsequently, a 6-mm balloon dilator (Hurricane; Boston Scientific Corporation or Titan balloon, Wilson Cook) will be used to further dilate the fistula tract. After this, the stent delivery catheter is advanced over the guidewire across the PFC wall and the BFMS (Nagi; Taewoong Medical, Gyeonggi-do, South Korea) deployed using sonographic, fluoroscopic and endoscopic visualization.
89636537|NCT04479228|Experimental|Plastic stents|Double-pigtail plastic stents will be used. A minimum of one 10Fr pigtail plastic stent will be placed. After initial EUS-guided access, the ostomy will be dilated first, using a cystotome, and secondly with a balloon dilation. The plastic stent will be inserted and delivered following the routine technique of each interventional endoscopist. The number of the plastic stents and the size of the balloon used to dilate the ostomy will depend on the WON size and content.
89636538|NCT05133648||Hip Surgery without COVID-19 infection|January to December 2021
89636539|NCT05133648||Hip Surgery with COVID-19 infection|January to December 2021
89042082|NCT06148181|Experimental|Part 2, ABBV-141 (IV)|Asian participants will receive a single IV dose of ABBV-141.
89042083|NCT06148181|Placebo Comparator|Part 2, Placebo for ABBV-141 (IV)|Asian participants will receive a single IV dose of placebo for ABBV-141.
89042084|NCT06148181|Experimental|Part 2, ABBV-141 (SC)|Asian participants will receive a single SC dose of ABBV-141.
89042085|NCT06148181|Placebo Comparator|Part 2, Placebo for ABBV-141 (SC)|Asian participants will receive a single SC dose of placebo for ABBV-141.
89042086|NCT06135259|Experimental|erythropoietin mucoadhesive thermosensitive hydrogel|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan (5%) and glycerophosphate (20%).
89042087|NCT06135259|Active Comparator|Triamcinolone Mucoadhesive gel|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
89042088|NCT06134154|Placebo Comparator|Air|
89042089|NCT06134154|Experimental|Carbondioxide|
89042091|NCT06127849|Placebo Comparator|Resistance Training + Placebo (Capsule) + Placebo (Sachet)|"A sachet of 20 gms of Placebo dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~One capsule of placebo to be taken 30 minutes after placebo sachet in the morning."
89042092|NCT06127849|Active Comparator|Resistance Training + Whey protein (40 gms) + Placebo (Capsule)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~One capsule of Placebo to be taken 30 minutes after whey protein in the morning."
89212001|NCT02545556|Experimental|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
89212002|NCT02545556|Placebo Comparator|control|liver cancer patients received traditional therapy
89212003|NCT04341909||Trainee Group|Patients who undergo ERCPs with trainee involvement
89212004|NCT04341909||control group|Patients who undergo ERCPs without any trainee involvement
89636540|NCT05133648||Hip Surgery pre-pandemic|January 2017 to December 2019
89636541|NCT02391090|Experimental|hypoxia|"The hypoxia group receives normobaric hypoxic air while sitting in a hypoxic chamber simulating 2800 meter above sea level.~Interventions: hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
89636542|NCT02391090|Sham Comparator|sham hypoxia|"The sham group receives normal air while sitting in a hypoxic chamber in about 360 meter above sea level (Graz, Austria).~Interventions: sham hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
89636543|NCT01575769|Experimental|1|
89636544|NCT02382354|Experimental|i-gel|I-gel insertion was attempted during propofol and remifentanil anesthesia .
89636545|NCT02382354|Active Comparator|laryngeal mask airway|LMA insertion was attempted during propofol and remifentanil anesthesia .
89636546|NCT01510145|Experimental|TRAVATAN® BAK-free|Travoprost 0.004% BAK-free, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks.
89636547|NCT03027167|Active Comparator|Aspirin and MCDs|ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery. ASA 325mg BID will be prescribed for a period of 6 weeks.
89636548|NCT03027167|Experimental|Aspirin only|ASA only- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will NOT receive MCDs after being discharged from hospital. ASA 325mg BID will be prescribed for a period of 6 weeks.
89636549|NCT02382198|Active Comparator|Active Group|This arm will receive the study drug glycopyrrolate.
89636550|NCT02382198|Placebo Comparator|Placebo Group|Control arm to receive placebo
89636551|NCT01528033|Experimental|Vacuum Assisted Closure®|Negative pressure wound therapy
89636552|NCT01528033|Active Comparator|Standard conventional wound therapy|According to institutional clinical standards
89636553|NCT02382432|Active Comparator|Pethidine 0.4mg/kg iv|interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
89636554|NCT02382432|Active Comparator|DEX. I|Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
89636555|NCT02382432|Active Comparator|DEX. II|Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
89636556|NCT02382432|Active Comparator|DEX III|Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
89636557|NCT01509287||Donnai-Barrow Syndrome (DBS)|Individuals affected with Donnai-Barrow Syndrome (DBS)
89636558|NCT01509287||Unaffected|Healthy family members of individuals affected with Donnai-Barrow Syndrome (DBS)
88991015|NCT05857657|Experimental|propriocepticve neuromuscular facilitation|:Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
89212005|NCT00852566|Active Comparator|Imatinib|Standard treatment Imatinib 400mg OD
89212006|NCT00852566|Experimental|dasatinib|Dasatinib 100mg OD
89212007|NCT00852722|Experimental|1. Low fat study diet|The low fat study diet arm will receive low fat diet training and followed for 12 months on the diet.
89636559|NCT00145587|Other|1|
89636560|NCT02390934|Experimental|Radium 223|Radium-223 (Xofigo®) will be supplied in vials as a ready-to-use solution for intravenous administration. The activity (administered radioactivity) will be 50 kBq/kg b.w., and multiple treatment activities up to 6 injections will be administered at intervals of 4 weeks.
89636561|NCT01560871|Sham Comparator|Low-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 15% PImax. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion (RPE) scale. Participants were encouraged to walk at 10 to 15 minutes, once to twice a day initially, then progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
89636562|NCT01560871|Experimental|High-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 60% PImax.~The walking program was the same as the one for the control group."
89636563|NCT04298463||COHORT A: dalbavancin|Patients hospitalized for at teast two days affected by ABSSSI and treated with dalbavancin.
89636564|NCT04298463||COHORT B: lipo and glyco-peptid drugs|Patients hospitalized for at teast two days affected by ABSSSI and treated with vancomycin, teicoplanin or daptomycin.
89636565|NCT02386020|Placebo Comparator|Placebo|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
89636566|NCT02386020|Active Comparator|Aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
89636567|NCT02381964|Placebo Comparator|Placebo|Matched placebo
89636568|NCT02381964|Experimental|1RDA+CoQ10|Supradyn® (1RDA+CoQ10) containing vitamins and minerals at levels up to 100% of the 2008 European Union recommended dietary allowances (RDAs), plus 4.5 mg CoQ10 (1RDA+CoQ10).
89636569|NCT02381964|Experimental|3RDA|Supradyn® (3RDA) containing vitamins and minerals at levels up to 300% of the 1990 European Union RDAs (3RDA).
89636570|NCT01509053|Experimental|Aripiprazole IM depot injection|Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.
89636571|NCT02100189|Experimental|Screening (esophageal cytology, FISH)|Participants swallow the capsule (Oesotest from Actimed) and then wait 10 minutes before the sponge is pulled out through the esophagus by gentle traction on the string. Cytology samples from the sponge are harvested and analyzed by FISH. Participants then undergo standard EGD or upper endoscopy.
89636572|NCT02390856|Active Comparator|Volar Plate|Patients in this group will undergo distal radius fracture fixation with a traditional volar plate.
89636573|NCT02390856|Experimental|Conventus DRS|Patients in this group will undergo distal radius fracture fixation with the Conventus DRS intramedullary fixation device.
89636574|NCT01560403|Experimental|Teduglutide|0.05 mg/kg/day
89636575|NCT02100579|Active Comparator|Active Group|Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine
89636576|NCT02100579|Placebo Comparator|Control Group|Ultrasound-guided sham block with 10 ml of preservative free normal saline
89636577|NCT04251351|Experimental|Arm 1|Paracetamol 15 mg/kg/dose 6 hourly for 72 hours
89636578|NCT04251351|Sham Comparator|Arm 2|Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.
89636579|NCT04748471|Experimental|18-45 years old|18 - 45 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
89636580|NCT04748471|Experimental|65-74 years old|65 - 74 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
89636581|NCT04748471|Experimental|At least 75 years old|At least 75 years old (60 volunteers), 2 injections of mRNA-1273, at day 1 and day 29
89636582|NCT05469282|Experimental|blood circulation treatment|Blood circulation treatment for the risk group for Deep Vein Thrombosis (DVT) and the ordinary person
89636583|NCT00147069||Controls|Non-smoking control subjects without lung disease
89636584|NCT00147069||Asthmatics|Non-smokers patients with asthma
89636585|NCT00147069||Non-COPD smokers|Current smokers without airways obstruction, FEV1 >80% predicted
89636586|NCT00147069||COPD smokers|Patients with COPD and cigarette smokers
88991016|NCT05857657|Active Comparator|propriocepticve neuromuscular facilitation with lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
88991017|NCT05856071|Experimental|clamshells exercises|
88991018|NCT05856071|Active Comparator|traditional physical therapy|
88991019|NCT05855005|Experimental|DTC Hearing Aid|
88991020|NCT05852574|Experimental|CP101|Extended Induction: Participants will receive the short induction dose of CP101 comprising 10 capsules daily for 5 days. Participants in this arm will then receive an extended induction daily dose of five CP101 capsules through Week 8.
88991021|NCT05852574|Placebo Comparator|CP101 + Placebo|Short Induction: Participants will receive the short induction dose of CP101 comprising 10 capsules daily for 5 days. Participants in this arm will then receive 5 capsules of placebo through Week 8.
88991022|NCT05852327||COPD|Subjects with COPD exacerbation
88991023|NCT05839314|Experimental|Huaier group|Patients will take Huaier granule and renin-angiotensin-aldosterone system inhibitors (RASI).
88991024|NCT05839314|Active Comparator|Ciclosporin soft capsules group|Patients will take Ciclosporin soft capsules and RASI.
88991025|NCT05838274|Active Comparator|Alcohol|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
88991026|NCT05838274|Placebo Comparator|Placebo|placebo beverage condition
88991027|NCT05835180|Experimental|TVB-2640 50 mg - normal hepatic function|Healthy subjects with normal hepatic function receive 50 mg PO daily from Day 1 to Day 4
88991028|NCT05835180|Experimental|TVB-2640 50 mg - mild hepatic function|Subjects with mild hepatic impairment will receive 50 mg PO daily from Day 1 to Day 4
88991029|NCT05835180|Experimental|TVB-2640 50 mg - moderate hepatic function|Subjects with moderate hepatic impairment will receive 50 mg PO daily from Day 1 to Day 4
88991030|NCT05835180|Experimental|TVB-2640 50 mg - severe hepatic function|Subjects with severe hepatic impairment will receive 50 mg PO daily from Day 1 to Day 4
88991031|NCT05834127|Experimental|Aerobic exercises|Group A will receive aerobic exercises. Treatment will be given 3 times a week for 1 month. Total number of sessions will be 12
88991032|NCT05834127|Active Comparator|Yoga exercises|"Group B will receive yoga. Treatment will be given for 40 min, 3 times a week for 1 month.~Total number of sessions will be 12"
89636587|NCT02382042|Active Comparator|Intensive Referral Intervention|
89636588|NCT02382042|No Intervention|Standard Care|
89636589|NCT02390700||Golimumab Intravenous|Participants with rheumatoid arthritis (RA) in Canada, will be observed for 24 months. Only data available from source documentation will be collected.
89636590|NCT00284739|Experimental|Alteplase|Multiple Alteplase injection into the abscess collection to improve percutaneous drainage
89636591|NCT00284739|Placebo Comparator|Saline|Multiple normal saline injection into the abscess collection to improve percutaneous drainage
89636592|NCT01527487|Experimental|Eribulin+Cyclophosphamide (ErC)|"Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
89636593|NCT01527487|Experimental|Docetaxel+Cyclophosphamide (TC)|"Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
89636594|NCT01506947|Experimental|Paricalcitol|"Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL.~Participants may have also received routine darbepoetin alfa to treat anemia."
89636595|NCT00149643|Active Comparator|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
89636596|NCT00149643|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
89636597|NCT02390622|Other|FMT treatment|Treat the patients by fecal microbiota transplantation
89636598|NCT04410289|Experimental|Intervention Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the intervention group were positioned using props horizontally aligning the external auditory meatus (EAM) with the sternal notch (SN) and the chin with the sinciput. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
89636599|NCT04410289|Active Comparator|Control Group|After induction of general anesthesia, and prior to direct laryngoscopy, patients in the control group were positioned freely according to the provider's preference. A lateral side-profile photograph was taken for latter analysis and an Intubation Difficulty Scale (IDS) score card completed.
89636600|NCT02381730|Experimental|Aflibercept|
89636601|NCT02390778|Experimental|Debrief Group|The debrief group participated in 3 consecutive face-to-face group debriefing sessions lasting 1.5-2 hrs each. Each session started with a fun ice-breaker to create a relaxed atmosphere and group cohesion. Session 1 focused on encouraging group participation, discussing primary trauma encountered and emotional reactions to these stories. Session 2 connected current experiences with the group members' own trauma histories and life experiences. The last session focussed on societal and community responses to violence, and employing personal agency to find constructive ways to address violence in communities.
89636602|NCT02390778|Placebo Comparator|Control Group|The control group was assigned to a leisure activity (film showing), for every session of debriefing undergone by the intervention group. The films were chosen for their light-hearted uplifting content and presented as a fun and relaxing activity.
89636603|NCT02665338|Sham Comparator|Sham rTMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
89636604|NCT02665338|Active Comparator|Active rTMS|Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% rMT, Total 60 trains, 15 minutes, Total pulses 3000.
89636605|NCT01506479|Sham Comparator|Control Group|Wait listed to moderate or vigorous exercise after 6 months of no exercise.
89636606|NCT01506479|Experimental|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
89636607|NCT01506479|Experimental|Moderate Exercise|Endurance exercise at 60-65% HR max, 4x/wk for 6 months.
89636608|NCT02382120||Patients undergoing cardiovascular surgery|Patients ASA 3-4 undergoing cardiac surgery.
89636609|NCT00149799|Experimental|Escitalopram|In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
89636610|NCT00149799|Placebo Comparator|Placebo|Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)
89636611|NCT02385942|Other|Tele-consultation system|compare the Live assessed wound size with the transmitted Smart phone-based wound size through Tele-consultation system
89636612|NCT02390544|Experimental|Melphalan in Patients Receiving HSCT|"The investigators will recruit approximately 30 patients who are scheduled to undergo allogeneic transplant with reduced intensity conditioning that includes melphalan. Approximately 10 patients who will receive melphalan as part of their conditioning regimen for an autologous transplant will also be recruited.~A test dose of melphalan will be administered prior to the start of the HSCT preparative regimen. The test dose will equal 10% of the standard dose. Blood samples will be drawn for pharmacokinetic measurement prior to and after the administration of the test dose and again around the full standard dose of melphalan. Urine samples will also be collected around the test dose and full standard dose of melphalan to measure markers of kidney injury."
89636613|NCT01506323|Experimental|Mantram Repetition Program (MRP)|"A portable meditation-based Mantram Repetition Program (MRP) will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms. For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma."
89636614|NCT01506323|Active Comparator|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping. For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.
89636615|NCT04204863||SE patients|
89636616|NCT02385630|Experimental|Esophagectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
88991033|NCT05834088|Experimental|Myofascial techniques with Thiele massage|Group A will receive myofascial techniques with Thiele massage. 12 treatment sessions will be given in 12 weeks
88991034|NCT05834088|Active Comparator|Myofascial techniques without Thiele massage|Group B will receive myofascial techniques without Thiele massage. 12 treatment sessions will be given in 12 weeks
88991035|NCT05833594||Experimental|Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
88991036|NCT05833594||Comparator|Whole-course nutrition Combined With Chemoradiotherapy±ICIs
88991037|NCT05829889|Experimental|FFR-guided Left Main PCI|
88991038|NCT05829889|Active Comparator|Angiography-Guided PCI|
88991039|NCT05828043|No Intervention|Usual care group|Provide conventional health educations in every three-month interval
88991040|NCT05828043|Experimental|Multidomain intervention group|The multidomain intervention program is designed as structural training sessions of 2-hour training sessions two times per week.
88991041|NCT05828004|No Intervention|standard care group|The standard care group is the routine care group, that is, under the current standard antitumor treatment and follow-up mode, the patients independently decided whether to carry out nutritional and psychological intervention after the advice from the medical care department of oncology
88991042|NCT05828004|Experimental|MDT care group|The MDT care group is the whole-course multidisciplinary care intervention group, which is conducted by a multidisciplinary team composed of the oncology department, nutrition department, mental health center and rehabilitation department.
89212008|NCT00852722|No Intervention|2. Regular diet group|The regular diet arm will be a wait-listed group that will receive no training in diet and will be advised to continue their regular (usual) diet as was prior to entry into the study, for the duration of the study. They will have a similar clinic follow up schedule as the treatment group. The regular diet group will be given identical instructions to exercise regularly similar to the treatment group.
89212009|NCT00856622|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
89212010|NCT00856622|Active Comparator|timolol 0.5% ophthalmic solution|one drop in the morning and evening
89636617|NCT02385630|Experimental|Gastrectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
89636618|NCT04157673|Experimental|Episodic Future Thinking introduced at 6 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 8-week period following a 6-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
89636619|NCT04157673|Experimental|Episodic Future Thinking introduced at 8 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 6-week period following a 8-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
89636620|NCT04157673|Experimental|Episodic Future Thinking introduced at 10 weeks|The intervention being researched is called episodic future thinking (EFT), which consists of imagining specific instances of one's future. In this study, participants will engage in EFT focused on imagining taking one's medication, guided by a research staff member in their intervention sessions in addition to weekly check-in calls across an 4-week period following a 10-week baseline period. The research staff member will conduct the intervention session using a semi-structured interview format in which they work to identify situations in which the participant encounters challenges with taking their medication and will ask questions to prompt the participant to imagine what successful medication adherence would consist of. Sessions may also involve imagining positive events resulting from successful medication adherence and the details surrounding those events.
89636621|NCT01790763|Active Comparator|Keramatrix|Keramatrix
89636622|NCT01790763|Active Comparator|Mepilex|Mepilex
89636623|NCT02381262|Experimental|Intervention|"At the 2 week post-surgical visit, subjects will receive and be trained in the use of the Fitbit and data interface and meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit."
89636624|NCT02381262|No Intervention|Control|"At the 2 week post-surgical visit, all subjects will then meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit.~The control group will receive a current version of the Fitbit device at the end of their completion of the 12 month visit."
89636625|NCT02381262|No Intervention|Historical Control|The investigators will extract historical control data from the electronic health record using electronic queries and manual data extraction. Historical controls will have surgery and 12-month follow-up completed prior to the start of the RCT.
89636626|NCT01790841||ICD system with DF4 connection|Iforia/Ilesto ICD with DF4 connection and Linox smart DF4 lead/ Protego
89636627|NCT01790841||ICD system with DF-1 connection|Ilesto/Iforia ICD with DF-1 connection
89636628|NCT01505387|Placebo Comparator|Placebo|Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
89636629|NCT01505387|Experimental|Litramine|Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
89636630|NCT02390232||NAFLD with simple steatosis|Patients with NAFLD with simple steatosis: collection of stools, blood sample and liver biopsy
89636631|NCT02390232||NAFLD with steatohepatitis|Patients with NAFLD with steatohepatitis: collection of stools, blood and liver biopsy
89636632|NCT01899885|No Intervention|historic control group|Standard treatment in the historic control group
89636633|NCT01899885|Active Comparator|Intervention group|"AHA (Acute Highrisk Abdominalsurgery): Optimized Course:~Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~GDT-LiDCO fluid management pre-, per- and postoperative~Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
89636634|NCT02381496|Experimental|Part A: Cohort A1: ACT-453859 1 mg|"ACT-453859 1 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
89212011|NCT00856622|Active Comparator|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
89212012|NCT00856700|Experimental|GLP-1 infusion|Patients with metabolic syndrome
89212013|NCT00618956|Experimental|1|
89212014|NCT00618956|Placebo Comparator|2|
89212015|NCT00845468||No treatment|
89212016|NCT00852800|Active Comparator|Standard regimen|Albumin in standard regimen (1.5 g/Kg IV on day 1 and 1 g/kg IV on day 3)with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
89212017|NCT00852800|Experimental|Dose reduced regimen|Albumin in dose reduced regimen (1 g/kg IV on day 1 and 0.5 g/kg IV on day 3) with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
89212018|NCT00845546|Experimental|1|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets of Ranbaxy
89636635|NCT02381496|Experimental|Part A: Cohort A2: ACT-453859 3 mg|"ACT-453859 3 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
89636636|NCT02381496|Experimental|Part A: Cohort A3: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
89636637|NCT02381496|Experimental|Part A: Cohort A4: ACT-453859 30 mg|"ACT-453859 30 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
89636638|NCT02381496|Experimental|Part A: Cohort A5: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo~After a washout period of 10-20 days subjects will return for a second study period to receive the same treatment received in the first session but under fed conditions"
89636639|NCT02381496|Experimental|Part A: Cohort A6: ACT-453859 300 mg|"ACT-453859 300 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
89636640|NCT02381496|Experimental|Part A: Cohort A7: ACT-453859 800 mg|"ACT-453859 800 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
89636641|NCT02381496|Experimental|Part B: Cohort B1: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
89636642|NCT02381496|Experimental|Part B: Cohort B2: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
89636643|NCT02381496|Experimental|Part B: Cohort B3: ACT-453859 800 mg|"ACT-453859 800 mg, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
89636644|NCT02381496|Experimental|Part C: Treatment Periods I & II: Setipiprant|"Setipiprant 500 mg, twice daily for 7 days, administered orally in Treatment Period I (TPI) and setipiprant 1000 mg, twice daily for 7 days, administered orally in Treatment Period II (TPII)~Four male subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~Four female subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~There will be a washout period of 10 days between TPI and TPII"
89636645|NCT01790919|Experimental|Cognitive Therapy plus Cognitive Support|Cognitive therapy for depression with cognitive support added
89636646|NCT01790919|Active Comparator|Cognitive therapy|Cognitive therapy for depression
89636647|NCT02385552||Experienced endoscopists|All of the experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rate every 3 months
89636648|NCT01790997|Experimental|Treatment I|1 tablet of DLBS1033 490 mg thrice daily, after meal
89636649|NCT01790997|Active Comparator|Treatment II|1 tablet of aspirin 80 mg once daily, after meal
89636650|NCT01790997|Active Comparator|Treatment III|1 tablet of clopidogrel 75 mg once daily, after meal
89636651|NCT02390388|Active Comparator|pudendal block group|nerve stimulated pudendal nerve block performed under general anesthesia
89636652|NCT02390388|Active Comparator|Caudal block group|caudal block performed under general anesthesia
89636653|NCT00324753|Experimental|Intervention|Communication sheet
89636654|NCT00324753|Other|Control|Standard of care brochures
89636655|NCT02385474|Experimental|38% SDF semi-annual|semi-annual application of 38% SDF
89636656|NCT02385474|Experimental|38% SDF annual|annual application of 38% SDF
89636657|NCT02385474|Active Comparator|12% SDF semi-annual|semi-annual application of 12% SDF
89636658|NCT02385474|Active Comparator|12% SDF annual|annual application of 12% SDF
89636659|NCT04439682|Experimental|Study group|Aerobic exercise will be performed for a single session
89636660|NCT04439682|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
89636661|NCT02390310|Active Comparator|Phase 1 - 7 Day Removal|Shang Ring No Flip Technique: Removal of Shang Ring and assessment of healing 7 days after circumcision with no-flip technique.
89636662|NCT02390310|Active Comparator|Phase 1 - Delayed Removal|Shang Ring No Flip Technique: Removal of ring or assessment of spontaneous detachment at more than 7 days to assess occurrence and safety following circumcision with the no-flip technique.
89636663|NCT02390310|Active Comparator|Phase 2 - Topical Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery using topical anesthesia.
89636664|NCT02390310|Active Comparator|Phase 2 - Injectable Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery when using injectable anesthesia.
89212019|NCT00845546|Active Comparator|2|(Claritin_D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
89636665|NCT02381184|Active Comparator|Clomiphene Citrate group (Group A)|Group A (n =68) assigned to receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
89636666|NCT02381184|Active Comparator|laparoscopic ovarian drilling (LOD) Group B|Group B (n =68) underwent LOD. Laparoscopy was performed under general anesthesia, using three-puncture technique. Each ovary was cauterized perpendicular to its antimesenteric border at four points, each for 4 seconds at 40 W with a mixed current, using a monopolar electrosurgical needle (Karl Storz, ND, Germany). Each puncture was about 4 mm in diameter and 6-8 mm in depth. The ovary was cooled by irrigation with normal saline solution. Any, intraoperative or postoperative complication was reported. The follow-up was started from the next cycle after ovarian drilling up to 6 months
89636667|NCT02381028|Experimental|Study area|Human milk and emollient: Apobase creme® (Actavis Norway AS)
89636668|NCT02381028|Active Comparator|Control area|Emollient: Apobase creme® (Actavis Norway AS)
89636669|NCT00326781|Active Comparator|Nicotine Nasal Spray|
89636670|NCT00326781|Active Comparator|Transdermal Nicotine patch|
89636671|NCT02385396|Placebo Comparator|Group I|60 patients diagnosed with PCOS, not myo-inositol treated undergoing ICSI
89636672|NCT02385396|Experimental|Group II|52 patients diagnosed with PCOS undergoing ICSI, taking Inofolic (myo-inositol + folic acid)
89636673|NCT02385396|Placebo Comparator|Group III|105 patients not diagnosed with PCOS undergoing ICSI, not taking myo-inositol
89636674|NCT02390466|Experimental|VAC-3S|32µg/ml corresponding to 16µg/vaccination
89636675|NCT00328263|Experimental|1|Bio-K Cl1285 Bio-K Cl1285 contains 50 billion of live bacteria.
89636676|NCT00328263|Placebo Comparator|2|placebo devoid of bacteria
89636677|NCT02390154|Experimental|Arm 1|Open label non-randomized non-controlled mass balance study in Cycle 1
89636678|NCT02390154|Experimental|Arm 2|Open label non-randomized non controlled multiple dose study in Cycle 2 and subsequent cycles
89636679|NCT01791075|Active Comparator|Tan Endoglide|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide.
89636680|NCT01791075|Active Comparator|Endosaver/serter|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Endosaver/serter injector.
89636681|NCT04710342|Experimental|CTO proximal cap crossing|To demonstrate that CapBuster breaks the proximal cap of CTO's
89636682|NCT02979405|Experimental|group 1|Phenylephrine 40 mcg/min, infusion during 5 minutes
89636683|NCT02979405|Placebo Comparator|group 2|Saline solution 21 cc, infusion during 5 minutes
89636684|NCT01791231|Experimental|Radiolabeled 14C-canagliflozin|Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1.
89636685|NCT01791309|Experimental|combination panitumumab and vemurafenib|This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
89636686|NCT03113682|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
89636687|NCT02389920|Experimental|Nilotinib|nilotinib 400mg BID for 12 months
89636688|NCT00329433|Active Comparator|Heparin|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
89636689|NCT00329433|Experimental|Desirudin (Iprivask™)|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
89636690|NCT03105726||Group I|Group managed by ventricular assist devices in first intention in Bad-Oeynhausen, Germany
89636691|NCT03105726||Group II|Group managed with medical therapy, heart transplantation, or both, in first intention,in Paris, France
89636692|NCT03105960|Experimental|garlic with lime juice mouthwash|"garlic with lime juice mouthwash is herbal antimicrobial .children were instructed to rinse for 14 days, twice daily, ,10 ml (undiluted) for 30 second and then expectorate .~To prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract."
89636693|NCT03105960|Active Comparator|chlorhexidine mouthwash|"chlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days. it is commercial mouthwash~."
89636694|NCT03105804|Experimental|FT21039 Group|7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
89636695|NCT03105804|Experimental|FT21041 Group|7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
89042093|NCT06127849|Active Comparator|Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~One capsule of EB0-PA to be taken 30 minutes after whey protein in the morning."
89042094|NCT06126991|Experimental|The Modified Sedation and Analgesia Regimen Group|midazolam, fentanyl, cetirizine
89042095|NCT06126991|Active Comparator|The Sedation and Analgesia Regimen Group|midazolam, fentanyl
89042096|NCT06126952|Experimental|Treatment A (Azelair)+Treatment B (Placebo)+Treatment C (Ryaltris), min. 14 days wash-out period|Cross-over design
89042097|NCT06126952|Experimental|Treatment B (Placebo)+Treatment C (Ryaltris)+Treatment A (Azelair), min. 14 days of wash-out period|Cross-over design
89042098|NCT06126952|Experimental|Treatment C (Ryaltris)+Treatment A (Azelair)+Treatment B (Placebo), min. 14 days of wash-out period|Cross-over design
89042099|NCT06126952|Experimental|Treatment A (Azelair)+Treatment C (Ryaltris)+Treatment B (Placebo), min. 14 days of wash-out period|Cross-over design
89042100|NCT06126952|Experimental|Treatment B (Placebo)+Treatment A (Azelair)+Treatment C (Ryaltris), min.14 days of wash-out period|Cross-over design
89636696|NCT03105804|Experimental|FT21044 Group|7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
89636697|NCT03105804|Experimental|FT21042 Group|7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
89636698|NCT02389842|Experimental|Palbociclib + Taselisib|The starting dose of palbociclib in combination with taselisib will be 100mg OD of palbociclib and 2mg taselisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
89636699|NCT02389842|Experimental|Palbociclib + Pictilisib|The starting dose of palbociclib in combination with pictilisib will be 100mg OD of palbociclib and 195 mg pictilisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
89042101|NCT06126952|Experimental|Treatment C (Ryaltris)+Treatment B (Placebo)+Treatment A (Azelair), min. 14 days of wash-out period|Cross-over design
89636700|NCT02385006|Other|Arm kidney transplanted|Arm kidney transplanted: all patients who receive kidney transplantation
89636701|NCT02385006|Other|Arm pancreas-kidney transplanted|Arm pancreas-kidney transplanted: all patients who receive pancreas-kidney transplantation
89042102|NCT06117670|Experimental|amniotic membrane graft|women with posterior vaginal prolapse will be enrolled and posterior colporrhaphy will be done with the application of sterilized (gamma irradiated) amniotic membrane as a graft.
89042103|NCT06114550|Experimental|High-intensity resistance training group (HIRT)|All subjects were instructed to conduct HIRT consisted of 4-5 sets of 12 repetitions at 80%1RM, with 1-2 minutes rests between each set.
89636702|NCT00289341|Placebo Comparator|Placebo|12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.
89042104|NCT06114550|Experimental|low-intensity resistance training group (LIRT)|All subjects were instructed to conduct LIRT consisted of 4-5 sets of 24 repetitions at 40%1RM, with same period) in random order.
89042105|NCT06112171|Other|Intravascular lithotripsy arm|Treatment with Lithotripsy system followed by Supera stent implantation in lesion segments with severe calcification.
89042106|NCT06112171|Other|Standard lesion preparation arm|Treatment with Balloon angioplasty with a conventional and/or high-pressure balloon angioplasty followed by Supera stent implantation in lesion segments with severe calcification.
89636703|NCT00289341|Experimental|DC/LNCaP|12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks
89042107|NCT06108427|Experimental|Renin-guided arm|Renin levels will be measured prior to each follow-up appointment and MRA therapy will be titrated to achieve renin unsuppression and normokalemia. Once this is achieved, any other class of antihypertensive drugs mais be used to achieve normal BP levels.
89042108|NCT06108427|No Intervention|Renin-blinded arm|No measurements of renin levels will be allowed during follow-up. MRA therapy will be titrated to achieve normokalemia. Once this is achieved, any other class of antihypertensive drugs mais be used to achieve normal BP levels.
89636704|NCT02389686|No Intervention|Without Radiotherapy|Patients just accept nipple-sparing mastectomy (NSM) without radiotherapy.
89636705|NCT02389686|Experimental|Intraoperative Radiotherapy|Followed by nipple-sparing mastectomy (NSM),INTRABEAM IORT was carried out with a single dose of 16 Gy for nipple-areola complex (NAC).
89636706|NCT04010175|Active Comparator|Control group|
89042109|NCT06105736|Experimental|Parents|In this 22-week almost completely remote study, following a 5-week control phase, parents will receive intensive treatment twice per week for 5 weeks followed by a one-time, 1-on-1 counseling session with an RT psychologist (week 11). Then, parents will use skill practice and application in the home environment for 10 weeks. Following this, a final interview is conducted (week 22).
89042110|NCT06105736|Experimental|Children|In this 22-week almost completely remote study, following a 5-week control phase, children will receive intensive group treatment, twice a week for 5 weeks delivered remotely. During the children's sessions, they will use child structured videos, the PlayPosit curriculum and learning rewards. The following assessments will be completed by the parents, regarding their children, at each phase; EDI, ABC-2, FS, BRIEF-2, CRS, PSI-4SF and CGI-I. Following the completion of group treatment, there will be a one-time, 1-on-1 counseling session with an RT psychologist.
89042111|NCT06105606|Experimental|AvuCure Microwave Ablation|"Participants will undergo study procedures as follows:~Baseline assessments~Hospital admission for bronchoscopy under general anesthesia and microwave ablation via standard of care.~Participants will be followed at 1, 3, and 6 months post-procedure."
89042112|NCT06104566|Active Comparator|Arm 1|Combination therapy
89042113|NCT06104566|Active Comparator|Arm 2|mono therapy
89042114|NCT06104540|Experimental|Experimental I Liquid Vaseline|Liquid vaseline will be applied to the Experimental I group twice a day according to the oil application protocol
89636707|NCT04010175|Experimental|Experimental group 1|Moderate frequency cognitive distance training
89636708|NCT04010175|Experimental|Experimental group 2|High frequency cognitive distance training
89636709|NCT00289653|Experimental|single open-label treatment arm|Adult smokers willing to quit were treated with escalating doses of transdermal nicotine patch (Nicoderm) and brief counselling if they continued to smoke over a 9-week treatment period.
89636710|NCT02380950|Other|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
89636711|NCT02380872|Active Comparator|Connective tissue graft|Connective tissue graft Soft tissue harvested from palatum of the subjects.
89636712|NCT02380872|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
89636713|NCT00290199|Experimental|Transcervical Foley Catheter|
89636714|NCT00290199|No Intervention|No Foley|
89636715|NCT02380794|Active Comparator|Danshen Gegen Capsule|3 capsules (500 mg per capsule) twice daily for 24 weeks
89636716|NCT02380794|Placebo Comparator|Placebo|3 capsules (500 mg per capsule) twice daily for 24 weeks
89636717|NCT00291135|Experimental|1|Oral Letrozole 2.5 mg daily for six months
89688537|NCT00920231|Experimental|Arm 1 initial system|"8 blind subjects are asked to use a prototype computer vision system to determine the challenges facing computer vision based indoor navigation.~Subjects are asked to travel through the hallways of a large hospital from the front entrance to a side entrance. The pathway consists of 9 segments including corners, four-way intersections, and doorways, and the total length of the route was approximately 200 meters. This challenging route was designed to stress the capabilities of the navigation system. It is a route that even sighted persons may find difficult to follow without practice. Pedestrian traffic was present throughout the route and lighting conditions could change in two of the segments where there were windows and doors."
89636718|NCT02389608|Experimental|1- tDCS 2--FES|"Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle. Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.~Functional electrical stimulation (FES) will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 µs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold. Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA."
89636719|NCT02103855|Experimental|belatacept|"Belatacept 5 mg/kg IVPB q 2 wks x 5 doses followed by 5 mg/kg IVPB q month. The belatacept dose will be infused IV over 30 minutes.~Day 14: Reduce tacrolimus dose by 25% Day 30: Reduce tacrolimus dose by additional 25% Day 45: Reduce tacrolimus dose by additional 25% Day 60: Stop tacrolimus."
89636720|NCT02380638|Experimental|DS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
89636721|NCT02380638|No Intervention|DS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
89636722|NCT02380638|Experimental|NONDS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
89636723|NCT02380638|No Intervention|NONDS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
89636724|NCT02380560||pPROM|50 women with preterm premature rupture of membranes with gestational age from 24 to 34 weeks assessed by ultrasound examination
89636725|NCT02380560||term non-labor control|25 term non-labor control (T-CTR, n=25) with gestational age from 37 to 41 weeks assessed by ultrasound examination
89636726|NCT02380560||preterm non-labor control|25 preterm non-labor control (P-CTR, n=25) with gestational age from 24 to 34 weeks assessed by ultrasound examination
89636727|NCT02104167||Operated Subjects|ROIC interbody cage with VerteBRIDGE plating
89636728|NCT02384694|Experimental|Intervention|Zumba dance intervention
89636729|NCT02389530||interventional group|All participants will receive the study intervention, intravenous administration of fluorescein dye prior to brain tumor removal.
89636730|NCT03706053|Placebo Comparator|Placebo|Investigational pharmacy formulated placebo. In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group)
89636731|NCT03706053|Experimental|Midodrine Hydrochloride 10 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
89636732|NCT03706053|Experimental|Midodrine Hydrochloride 20 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
89636733|NCT02384616|Active Comparator|Group High FiO2|Children will receive Fi02 100% during induction of anesthesia until end tidal oxygen concentration (Et 02) of 90% before intubation, anesthesia will be maintained with Fi02 of 80%. Then, shortly before the planned extubation, Fi02 will be increased to 100%.
89636734|NCT02384616|Active Comparator|Group Low FiO2|Children will receive Fi02 80% until Et 02 70% before intubation, anaesthesia will be maintained with Fi02 35%. Then, shortly before the planned extubation, Fi02 will be increased again to 80%.
89636735|NCT02018835|Other|patients of an insufficiency organic severe surgical mitrale|
89636736|NCT02018835|Other|insufficiency organic mitrale moderated in severe asymptomatic|
89636737|NCT02018835|Other|patients of an aortic bicuspidie|
89636738|NCT02018835|Other|patients of a syndrome of Marfan|
89636739|NCT02018835|Other|Healthy volunteers|
89636740|NCT02389296||Forensic Psychiatric Nurses in Mental Health Centers|Psychiatric nurses working in forensic wards in mental health centers
89636741|NCT02389296||Psychiatric Nurses in General Hospitals|Psychiatric nurses working in general hospitals
89636742|NCT03117699|Experimental|Hemiplegic subjects|"Testing of a new device for seated-standing passages after undergoing medical evaluation included Fugl Meyer scale, Berg scale and Bergego scale.~Phase 1 :~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
89636743|NCT03117699|Experimental|Healthy volunteers|"Testing of a new device for seated-standing passages .~Phase 1 :~3 seated-standing passages without help~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
89636744|NCT01504841|Experimental|Cohort I: Treatment experienced, 2 to 6 years of age|Children in this arm were at least 2 but younger than 6 years of age; they received the study drug etravirine (ETR) together with an optimized background regimen (OBR) consisting of one active boosted protease inhibitor (PI) and at least one other active antiretroviral (ARV) drug.
89636745|NCT01504841|Experimental|Cohort II: Treatment experienced, 1 to 2 years of age|Children in this arm were at least 1 but younger than 2 years of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
89636746|NCT01504841|Experimental|Cohort III: Treatment experienced, 2 months to 1 year of age|Children in this arm were at least 2 months but younger than 1 year of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
89636747|NCT02380170||Urosepsis|Sepsis derived from the urinary tract infection
89636748|NCT00330915|Experimental|A|
89636749|NCT02384304|Experimental|Choice|A self help program consisting of 8 modules. Patients will have access to therapist support through either messages or chat sessions
89636750|NCT02384304|Experimental|Messages|A self help program consisting of 8 modules. Patients will have access to therapist support through messages
89212020|NCT00852878|Active Comparator|Biofeedback|heart rate variability biofeedback
89042115|NCT06104540|Experimental|Experimental II Extra Virgin Olive Oil|Extra Virgin Olive Oil will be applied to the Experimental I group twice a day according to the oil application protocol
89636751|NCT02384304|Active Comparator|Self help|A relapse intervention program consisting of 8 modules. Patients will have no access to therapist support
89636752|NCT03026933|Experimental|Treatment|KI1107
89042116|NCT06104540|Experimental|Control group|No application will be made to the control group other than the institution's recommendations.
89042117|NCT06099652|Experimental|group A|611 300 mg Q2W, subcutaneous (SC) injection
89042118|NCT06099652|Experimental|group B|611 450 mg Q2W, subcutaneous (SC) injection
89042119|NCT06099652|Placebo Comparator|placebo group|placebo Q2W, subcutaneous (SC) injection
89042120|NCT06096818|Experimental|Experimental Group: Kegel exercises and abdominal exercises|Kegel exercises and abdominal exercises training has given to this group
89042121|NCT06096818|No Intervention|Control Group: Kegel exercises|Kegel exercises exercises training has given to this group
89042122|NCT06096519|Placebo Comparator|Information only control|The attention matched control arm will include information based text messages about general health and sexual health topics such as human immunodeficiency virus (HIV), sexually transmitted infections (STIs), relationships, and biomedical methods of HIV prevention (e.g., Pre-exposure prophylaxis (PrEP), Post-exposure prophylaxis (PEP)). No motivational or behavioral skill based text messages aimed at increasing HIV testing or reducing HIV risk behavior will be included. All participants will receive 8-10 messages/day for 6 weeks, with a 1 week booster. Participants in the control arm will have modified access to the interactive features such as quizzes, badges, an external chatbot feature, a website with sexual health resources and a group chat feature (a group of 3-4 total participants with whom participants can discuss program content).
89042123|NCT06096519|Experimental|Information, motivation, behavioral skills treatment arm|The active treatment arm consists of text messages with information, motivation, and behavioral skill based text messages aimed at increasing HIV testing, our primary outcome. Secondary outcomes include STI testing, PrEP uptake, condomless sex, and discussions with providers about PrEP/HIV care. Hypothesized mediators of HIV testing include testing/prevention information, motivation, and behavioral skills. All participants will receive 8-10 messages/day for 6 weeks, with a 1 week booster session following the intervention. In the active treatment arm, participants will have full access to interactive features such as quizzes, badges, an external chatbot feature, a website with sexual health resources, and a group chat feature (a group of 3-4 total participants with whom participants can discuss program content) to promote engagement and enhance learning and skills acquisition.
89042124|NCT06096116|Experimental|Low-dose Atenativ|
89636753|NCT03026933|Active Comparator|Control|Rosuvastatin calcium
89636754|NCT02389140|Experimental|Trigger point treatment|Trigger point release
89636755|NCT02389140|Sham Comparator|Ultrasound|Sham US at Trigger point
89636756|NCT02380482|Other|Traumatic brain injury|"Two dimensional and speckle tracking transthoracic echocardiography in traumatic brain injured patients~Glasgow score < or = 9 or~Glasgow score between 9 and 13 (included) and Following Traumatic Coma Data Bank Tomographic Damages:~diffuse injuries type III or IV or mass lesion over 25ml and/or neurosurgical injuries"
89636757|NCT02380482|Other|Controls|"Two dimensional and speckle tracking transthoracic echocardiography in control patients paired with traumatic brain injured patient on age, BMI and sex with the following criteria:~Intubated and mechanically ventilated~Undergoing urgent non severe surgery"
89636758|NCT01502423|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
89636759|NCT01502423|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
89042125|NCT06096116|Experimental|High-dose Atenativ|
89636760|NCT02388984|Experimental|Compound danshen dripping pills|Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.
89636761|NCT02388984|Placebo Comparator|Placebo|Placebo,20pills,tid. Duration: 24 weeks.
89636762|NCT01502033|Experimental|Transcranial Magnetic Stimulation|Open-label course of 30 daily treatments with repetitive transcranial magnetic stimulation (rTMS) at 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
89636763|NCT02380326||Lung transplant recipients|Lung transplant recipients with diffuse parenchymal abnormalities subjected to advanced endoscopic imaging modalities
89636764|NCT02380326||Diffuse intersitial lung disease|Patients suffering from diffuse intersitial lung disease without a certain diagnosis subjected to advanced endoscopic imaging modalities
89636765|NCT04861584|Experimental|Toripalimab+Gemcitabine/Cisplantin（GC）|Subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. . Toripalimab is given every 21 days for 4 doses starting C1D1. Subjects will then have consolidative surgery to remove their primary tumor within 6 weeks after their last dose of neoadjuvant therapy.
89636766|NCT02389062|Experimental|Placebo controlled group|This is a group of same number of subjects as in other arms, who will be given equivalent dose of placebo- cornstarch capsules i.e 5 capsules containing neutral substance- cornstarch(placebo) to be taken daily by mouth for a period of 12 weeks.
89636767|NCT02389062|Experimental|High dose gluten capsules|This group of subjects will be given high dose i.e 2.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
89636768|NCT02389062|Experimental|Low dose gluten capsules|This group of subjects will be given low dose i.e 0.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
89636769|NCT01500629|Experimental|C-1266-7|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-7. After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-6 (placebo).
89636770|NCT01500629|Experimental|Placebo|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-6 (placebo). After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-7.
89636771|NCT02384148||Healthy|Healthy volunteers with no inflammation diseases, no neoplasia, no allergy to lidocaine.
89636772|NCT02384148||Type 2 diabetic non obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index 19-30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
89636773|NCT02384148||Type 2 diabetic obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
89636774|NCT02384148||obese|Obese non diabetic patients with HbA1c<6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
89636775|NCT02388750|Other|No previous nausea and vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~No previous nausea and vomiting 24 hours prior to radiotherapy"
89636776|NCT02388750|Other|Previous nausea and/or vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~Previous nausea and/or vomiting 24 hours prior to radiotherapy"
89636777|NCT05231226|Experimental|Immediately CR group|Immediately open non-IRA after successful emergency PCI of IRA in STEMI patients with MVD
89636778|NCT05231226|Active Comparator|Staged (within 45 days) CR group|Strategy of opening non-IRA by stages after emergency PCI of IRA in STEMI patients with MVD
89636779|NCT02379936|Active Comparator|The NeoHilda Point of care method|Evaluating baby including lactate dehydrogenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
89636780|NCT02379936|Sham Comparator|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
89636781|NCT02388594|Experimental|ZFN Modified CD4+ T Cell|ZFN Modified CD4+ T Cell
89636782|NCT02388594|Experimental|ZFN Modified CD4+ T Cell with Cyclophosphamide|ZFN Modified CD4+ T Cell with Cyclophosphamide
89636783|NCT01500317|Active Comparator|Tapentadol|75 mg tapentadol tid
89636784|NCT01500317|Active Comparator|Oxycodone|5 mg oxycodone tid
89636785|NCT01500317|Placebo Comparator|Placebo|Placebo tid
89636786|NCT02379780|Active Comparator|USG guided Subcostal TAP block|after preparing the skin, ultrasound probe was placed obliquely on the upper abdominal wall along the subcostal margin near the midline. the rectus abdominis muscles, transversus abdominis muscles and the fascial plane (TAP) between rectus abdominis and transversus abdominis muscles were identified. after identification, the block needle was introduced anteriorly in the plane of the ultrasound beam. the needle was directed the transversus abdominis plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
89636787|NCT02379780|Active Comparator|USG guided Paravertebral Block|prior to start surgery, was performed in the left lateral position. after preparing skin, ultrasound linear probe was placed, 2-3 cm lateral of the T7 / T8 level in the midline. After determining the transverse process and ribs as hyperechoic, the paravertebral space was identified as an area wedge-shaped bounded by the pleura and above the internal intercostal membrane.after identification of the paravertebral space, the block needle was introduced in plane / out of plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
89636788|NCT02383914||Subscapularis rupture|
89636789|NCT02388672|Experimental|Drink high-CGA|Participants will drink once 250ml of decaffeinated coffee enriched with chlorogenic acid (CGA) (6g decaffeinated coffee (5 mg caffeine) with high total CGA (560 mg)).
89636790|NCT02388672|Placebo Comparator|Drink low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA (224 mg)
89636791|NCT02388672|Experimental|Capsules high-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee bean extract supplement with total CGA (560mg)
89636792|NCT02388672|Placebo Comparator|Capsules low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and placebo
89636793|NCT02388672|No Intervention|Control|No treatment control group
89636794|NCT02379468|Experimental|Pedyphar|Ointment
89636795|NCT02379468|Active Comparator|Panthenol|Ointment
89636796|NCT02388828||Subjects who have received lentiviral-based CARTmeso therapy|
89636797|NCT02379546|Experimental|BIS<50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values below 50.
89636798|NCT02379546|Active Comparator|BIS≥50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values above 50.
89636799|NCT00332163|Experimental|Pre-emptive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to chemotherapy.
89636800|NCT00332163|Experimental|Reactive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg Q2W or irinotecan and panitumumab 9 mg/kg Q3W. Participants were treated for each individual skin toxicity occurrence according to prespecified guidelines and based on the type and severity. Treatment could include emollient, sunscreen, topical or oral steroids, antibiotics, or antihistamines, as required.
88991043|NCT05825989|Experimental|Healthy Beat Acupunch Regimen|The intervention group will receive the instructor-led HBA regimen 3 times/week for first 6 months, followed by the DVD-led HBA regimen for another 6 months.
88991044|NCT05825989|No Intervention|Control group|The control group will continue their daily activities.
88991045|NCT05822765|Active Comparator|Group A|Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) Llidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter.
88991046|NCT05822765|Active Comparator|Group B|"Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter.~Lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter."
88991047|NCT05821127|Experimental|Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method|Patient education was provided in 3 sessions via telerehabilitation method, and exercises were provided with virtual reality support. It was requested that the exercises be done in 6 sets (30 repetitions) every day. Participants were given a splint, exercise brochure, and exercise diary for use at night.
88991048|NCT05821127|Active Comparator|Neurodynamic Exercises and Patient Education with Traditional Method|Participants were given a single session of face-to-face training on the same topics, and were given a splint, exercise brochure and exercise diary to be used at night.
89636801|NCT02377284|Experimental|Intervention (personalized chef card)|Restaurant employees received a personalized chef card, which included written information about a patron's food allergies and a photograph of the patron.
89636802|NCT02377284|No Intervention|Control (depersonalized chef card)|Restaurant employees received a depersonalized chef card, which included written information about a patron's food allergies, without a photograph of a patron.
89636803|NCT02379624|Placebo Comparator|EN group|5% glucose at a rate of 25 mL/h was given at day 1, followed with initial amount of EN (31.25g peptisorb dissolved in 250ml water) at 12.5 mL/h on day 2. From day 3 to day 6, the prescription is EN (62.5g peptisorb dissolved in 250ml water) at 12.5 mL/h. Since day 7, EN was began to advance to goal energy target as quickly as possibl
89636804|NCT02379624|Experimental|PEC/EN group|An additional amount of pectin was added 4 hours ahead of EN given from day 2 to day 6 (24g everday). Since day 7, EN was advanced to goal energy target as the same step
89636805|NCT02379312|Active Comparator|Very low energy aerated beverage|Very low energy aerated beverage
89636806|NCT02379312|Active Comparator|Normal energy aerated beverage 1|Normal energy aerated beverage 1
89636807|NCT02379312|Active Comparator|Normal energy aerated beverage 2|Normal energy aerated beverage 2
89636808|NCT02379312|Active Comparator|Normal energy aerated beverage 3|Normal energy aerated beverage 3
89636809|NCT02379000|Active Comparator|Transpupillary therapy alone|Transpupillary thermotherapy is performed as monotherapy. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. TTT could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid
89636810|NCT02379000|Active Comparator|TTT+Triamcinolone Acetonide|transpupillary thermotherapy followed by an intravitreal injection of triamcinolone. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. After an intravitreal injection of triamcinolone was perfomed under sterile conditions. TTT and triamcinolone injection could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid.
89636811|NCT04675398|Active Comparator|Open-loop deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving open-loop deep brain stimulation.
89636812|NCT04675398|Active Comparator|Randomized deep brain stimulation|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation at random time points.
89636813|NCT04675398|Active Comparator|Deep brain stimulation during contralateral limb movement|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of contralateral limb movement.
89636814|NCT04675398|Active Comparator|Deep brain stimulation during contralateral limb rest|Parkinson's disease patients implanted with Summit RC+S and brain lead implanted in the pallidal/striatal region receiving closed-loop stimulation during time of no movement for contralateral limb.
89636815|NCT00333177|Experimental|Cog Remediation, risperidone injection|Participants will receive cognitive remediation training plus risperidone, administered via injection.
89636816|NCT00333177|Active Comparator|Healthy Behavior Training, risperidone injection|Participants will receive health behavior training plus risperidone, administered via injection.
89636817|NCT00333177|Experimental|Cog Remediation, oral risperidone|Participants will receive cognitive remediation training plus risperidone administered orally.
89636818|NCT00333177|Active Comparator|Healthy Behavior Training, oral risperidone|Participants will receive health behavior training plus risperidone administered orally.
89636819|NCT02379234|No Intervention|Control|"All nurses received a 4 hours formation, called conventional formation, given by a professional trainer, that included 2 hours of theorical formation and 2 hours of practical training, based on CVVH generator demonstration. In addition, the trainer was present in the ICU during the first week of CVVH implementation, to answer any questions and to help nurses with their first CVVH sessions"
89636820|NCT02379234|Experimental|Simulated|The 'Simulated formation',used high fidelity mannequin and CVVH generator, is composed of 3 training sessions of 2 hours each one. This formation is associated with the 'conventional formation'.
89636821|NCT02379156|Experimental|Cool Temperature Exposure / No Drug|Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
89636822|NCT02379156|Experimental|Cool Temperature Exposure with Drug|Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).
89636823|NCT00333879|Other|Virtual Sound System|Efficacy of using a virtual sound system to simulate street crossing conditions.
89636824|NCT01792245|Active Comparator|NB-UVB|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
89688538|NCT00920231|Experimental|Arm 2 modified system|The system is redesigned in response to problems identified from the first phase of the study. The redesigned system is tested by a second set of 8 blind subjects in the same indoor path as used in Arm 1.
88991049|NCT05817708|Experimental|CX-4945 200mg QD|CX-4945 will be administered at 200mg QD for continuously 5 days.
89636825|NCT01792245|Active Comparator|Topical PUVA|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
89636826|NCT02383680||Patients under low dose methotrexate therapy|Patients with various underlying conditions (e.g. rheumatic diseases, dermatologic diseases) who have an indication for yellow fever vaccination
89636827|NCT02383680||Healthy controls|Healthy travelers who have an indication for yellow fever vaccination
89636828|NCT02383524||Chronic Low Back Pain (Lumbar Facet Joints Mediated Pain)|
89636829|NCT01899261|Experimental|Treatment (SBRT)|Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
89636830|NCT02383368|Experimental|ASP4132 dose escalation|"Subjects will receive a single dose of the study drug on Day -4 (Single-Dose Period), followed by PK sampling prior to Multiple-Dose Period where they will receive the same dose as they received in the Single-Dose Period on one of four schedules:~Continuous - daily dosing for 28 days, Intermittent: Schedule A: 3 days on / 4 days off; Schedule B: 1 days on / 6 days off; Schedule C: 3 days on / 11 days off."
89636831|NCT02383368|Experimental|ASP4132 dose expansion|Subjects in Part 2 will be treated with ASP4132 at the MTD and dosing schedule identified from Part 1.
89636832|NCT00335283|Active Comparator|Lansoprazole|
89636833|NCT00335283|Placebo Comparator|Sugar Pill|
89636834|NCT02372214|No Intervention|Group 1|30 patients/5 vascular surgery residents The residents of the last year of vascular surgery will perform the procedure under supervision of a senior surgeon
89636835|NCT02372214|Experimental|Group 2|30 patients/5 vascular surgery residents Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
89636836|NCT01500083|Experimental|Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with CLL will receive bendamustine at a dose of 100 mg/m2 on Days 1 and 2 in treatment cycles of 28 days for up to six cycles.
89636837|NCT01500083|Experimental|Patients with Indolent Non-Hodgkin's Lymphoma (iNHL)|Patients with iNHL will receive bendamustine at a dose of 120 mg/m2 on Days 1 and 2 in treatment cycles of 21 or 28 days for up to eight cycles.
89636838|NCT02779257|Experimental|Pasireotide|Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
89636839|NCT02371824||MRI Sequence|
89636840|NCT01890837|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
89636841|NCT01890837|Placebo Comparator|Placebo|Placebo TID
89636842|NCT02378922|Experimental|Treatment (gene-modified stem cells)|"CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.~STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant on day 0.~Note: Patients continue to receive HAART throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells."
89636843|NCT02377128|Experimental|Bilateral salpingectomy|Cesarean section with bilateral salpingectomy
89636844|NCT02377128|Active Comparator|Tubal ligation|Cesarean section with tubal ligation
89636845|NCT02377128|No Intervention|No intervention|Cesarean section with no additional intervention
89636846|NCT02709135||Pre-hospital HEART Score|All subjects included in this quality surveillance study will have had a HEART score, including POC troponin calculated by paramedics prior to arrival at the emergency department.
89636847|NCT02378688|Experimental|MT-1303|
88991050|NCT05817708|Experimental|CX-4945 200mg BID|CX-4945 will be administered at 200mg BID for continuously 5 days.
88991051|NCT05817708|Experimental|CX-4945 400mg BID|CX-4945 will be administered at 400mg BID for continuously 5 days.
88991052|NCT05817591||Patients with peripheral neuropathic pain and having an indication of capsaicin patches|"All patients will receive as part of routine care:~Three consecutive patches of 8% capsaicin in localized application for 30 to 60 minutes once every 3 months : at M0 (study inclusion), M3 and M6, or until pain scale < 4/10 (between 0 and 10),~Pain assessment every 1.5 months (+/-7 days), to evaluate clinical response,~8% capsaicin patches if the pain assessment rises again to pain scale > 4/10, after an initial response to treatment"
88991053|NCT05815888||Living donor nephrectomy patients|Patients who are scheduled for donor nephrectomy, and who will be operated in lateral position using laparoscopic techniques
88991054|NCT05813431|Active Comparator|Control - FRENCH grid only|
88991055|NCT05813431|Active Comparator|FRENCH grid + QuickSOFA|
88991056|NCT05813431|Active Comparator|FRENCH grid + QuickSOFA + Capillary Lactate|
88991057|NCT05812820|Placebo Comparator|Control|"Control group receives the routine treatment and uses distilled water (RO) water~Routine treatment at Department of Gastroenterology, Vietnam National Children's Hospital is as follows:~Antibiotics: oral (e.g. Zithromax® or Ciprofloxacin®) or intervention (ceftriaxone®, Ciprofloxacin®, Metronidazole®, Vancomycin®) drugs.~Oral rehydration Solution: Oremute~Zinc gluconate"
89042126|NCT06096116|Placebo Comparator|Placebo|Patients will receive a saline bolus dose
89636848|NCT02378688|Placebo Comparator|Placebo|
89636849|NCT02487147|Active Comparator|N95 Respirator|Participants in this arm will wear an N95 respirator and safety goggles during Live Attenuated Influenza Vaccine exposure.
89636850|NCT02487147|Experimental|Free Air Portable Air Powered Respirator|Participants in this arm will wear a Free Air PAPR and safety goggles during Live Attenuated Influenza Vaccine exposure.
89636851|NCT02378610||Observation in High-stressed|Saliva and fecal samples will be collected from High-stressed persons
89636852|NCT02378610||Observation in Low-stressed|Saliva and fecal samples will be collected from Low-stressed persons
89636853|NCT02371512|Experimental|Percutaneous mitral valve repair (MitraClip system )|Percutaneous mitral valve repair (simultaneous left atrial and ventricular pressure assessment suggested) with MitraClip system (Abbott)
89636854|NCT02371512|Active Comparator|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
89636855|NCT00295503|Experimental|1|cisplatin, pemetrexed, and bevacizumab
89636856|NCT02371590|Experimental|Lenalidomide-Obinutuzumab|All patients receive the combination of lenalidomide and obinutuzumab. There is no randomization or comparator arm.
89636857|NCT01791621|Experimental|Elimination/Challenge Diet|Once non-IgE mediated food allergy testing has been administered, study participants will follow food choices according to a pre-specified elimination diet for three weeks (Elimination phase). After the Elimination phase, study participants will introduce one food every three days (Challenge phase)and monitor their symptoms. Eight different foods will be introduced in the Challenge phase of the study.
89636858|NCT02371434|Experimental|Treatment arm|"Patients in ONEnTreg13 will be treated with four immunosuppressive agents, all of which are classified as an Investigational Medicinal Products (IMPs):~nTregs~Prednisolone~MMF~Tacrolimus"
89636859|NCT03105648||thyroid cancer|
89636860|NCT03105648||benign thyroid nodules|
89636861|NCT00335517|Experimental|10mg Depodur|
89636862|NCT00335517|Experimental|15mg DepoDur|
89636863|NCT02376816|Experimental|Cohort 1: Low Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 3E11 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
89636864|NCT02376816|Experimental|Cohort 2: High Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 1E12 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
89636865|NCT00298155|Active Comparator|Group 1|Goserelin + dutasteride
89636866|NCT00298155|Active Comparator|Group 2|Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
89636867|NCT00298155|Active Comparator|Group 3|Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
89636868|NCT01499849|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV) + dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
89636869|NCT01499849|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
89636870|NCT02371902|Active Comparator|ESWT Group|Focused Extracorporeal Shock Wave Therapy: 3 sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2
89636871|NCT02371902|Active Comparator|Cryo-US Group|Therapeutic cryoultrasound: 12 sessions was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each.
89636872|NCT02377050|Active Comparator|Higher Volume Feeding Goal|Infants randomized to this group will have higher volume feeding goals of 180-200 ml/kg/day.
88991058|NCT05812820|Experimental|DIA30|"DIA 30 group receives the routine treatment and uses distilled water plus B. subtilis, B. clausii and B. coagulans at 5 billion CFU/5 mL (LiveSpo® DIA 30)~Routine treatment at Department of Gastroenterology, Vietnam National Children's Hospital is as follows:~Antibiotics: oral (e.g. Zithromax® or Ciprofloxacin®) or intervention (ceftriaxone®, Ciprofloxacin®, Metronidazole®, Vancomycin®) drugs.~Oral rehydration Solution: Oremute~Zinc gluconate"
88991059|NCT05812820|Experimental|CLAUSY|"CLAUSY group receives the routine treatment and uses distilled water plus B. clausii at 2 billion CFU/5 mL (LiveSpo® CLAUSY)~Routine treatment at Department of Gastroenterology, Vietnam National Children's Hospital is as follows:~Antibiotics: oral (e.g. Zithromax® or Ciprofloxacin®) or intervention (ceftriaxone®, Ciprofloxacin®, Metronidazole®, Vancomycin®) drugs.~Oral rehydration Solution: Oremute~Zinc gluconate"
88991060|NCT05811429|Experimental|Aerobic exercises|Group A will receive aerobic exercises 2 sessions per week for 8 weeks total 16 sessions will be held.
88991061|NCT05811429|Active Comparator|Pilates exercises|Group B will receive pilates exercises 2 sessions per week for 8 weeks total 16 sessions will be held.
88991062|NCT05811299|Experimental|Abdominal Exercises and KT intervention|(Group A ) will receive kinesio taping with abdominal exercises. 8 sessions for 4 weeks and 2 session will be given in a week.
89636873|NCT02377050|No Intervention|Usual Volume Feeding Goal|Infants randomized to this group will have feeding goals of 140-160 ml/kg/day.
89636874|NCT00298233|Active Comparator|Standard Dose oseltamivir adult cohort|All participants >= 15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
89636875|NCT00298233|Active Comparator|Double Dose oseltamivir Adult cohort|All participants >= 15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
89636876|NCT00298233|Active Comparator|Standard Dose Oseltamivir child cohort|All participants <15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
89636877|NCT00298233|Active Comparator|Double Dose Oseltamivir child cohort|All Participants <15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
89636878|NCT02378376|Experimental|Wheat derived fiber fraction 1|Arabinoxylan oligosaccharides
89636879|NCT02378376|Experimental|Wheat derived fiber fraction 2|Dietary fiber enriched bran
89636880|NCT01499303|Experimental|Fostamatinib 200|200mg fostamatinib bid n=60
89636881|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
89636882|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
89636883|NCT02376972|Placebo Comparator|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
89636884|NCT02376972|Active Comparator|METROGEL VAGINAL|METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
89636885|NCT02378454||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
89636886|NCT02378454||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
89636887|NCT00298389||Non smokers|Non smokers included no history of respiratory or allergic disease, normal baseline spirometry
89636888|NCT00298389||Smokers|Smoking history of at least 10 pack years
89636889|NCT00298389||COPD|Patients with stable COPD
89636890|NCT02378532|Experimental|Radiotherapy/Temozolomide + Chloroquine|"Eligible patients will receive radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM.~Chloroquine will be escalated in 3 dose-levels (200mg, 400mg and 600mg) up each containing a minimum of 3 and a maximum of 6 patients. Based on the results of the DSMB, an additional level of 300mg was added."
89636891|NCT01498679|Active Comparator|fluticasone furoate/vilanterol trifenatate|Inhaled corticosteroid (ICS)/Long-acting beta2-agonist (LABA) combination
89636892|NCT01498679|Placebo Comparator|Placebo|placebo comparator
89636893|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 1|Therapy Setting 1
89636894|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 2|Therapy Setting 2
89636895|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 3|Therapy Setting 3
89636896|NCT02371122|Sham Comparator|RestoreSensor or RestoreUltra Setting 4|Therapy Setting 4
89636897|NCT02101437|Placebo Comparator|control|normal subjects.
89636898|NCT02101437|Active Comparator|clopidogrel|subjects received clopidogrel 75mg qd.
89636899|NCT02101437|Active Comparator|ticagrelor|subjects received ticagrelor 90mg qd.
89636900|NCT02101437|Active Comparator|cilostazol|subjects received cilostazol 100mg bid.
89636901|NCT02371200||Brain Sentinel Seizure Detection and Warning System|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
89636902|NCT01000467|Active Comparator|2|Group 2(probucol 500mg BID)
89636903|NCT01000467|Active Comparator|1|Group 1(Probucol 250mg)
89636904|NCT01000467|Active Comparator|3|Group 3(Probucol 500mg once daily)
89636905|NCT02370966|Placebo Comparator|Potato starch|Potato powder will be incorporated in the placebo product.
89636906|NCT02370966|Active Comparator|Berry powder|Several different berry powders including rose hip, bilberry, blackcurrant, sea buckthorn, and lingonberry will be prepared and studied.
89636907|NCT00434499|Active Comparator|placebo first|placebo first then crossover to EGCG
89636908|NCT00434499|Active Comparator|EGCG first|EGCG first then crossover to placebo
89636909|NCT02371278|Other|Higher daily protein|"Diets will provide protein intakes of 1.2 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
89636910|NCT02371278|Other|Lower daily protein|"Diets will provide protein intakes of 0.8 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
89636911|NCT01526785|Experimental|Alglucosidase alfa|Alglucosidase alfa (4000 L scale) intravenous (IV) infusion administered for 52 weeks as per physician's routine practice.
89636912|NCT02371044||Rivaroxaban|N=20
89636913|NCT02371044||Apixaban|N=20
89636914|NCT02371044||Dabigatran|N=20
89636915|NCT00198315|Active Comparator|Surgery Control|Patients will receive standard of care surgical removal of their tumor.
89636916|NCT00198315|Experimental|MedPulser EPT with Bleomycin|Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.
89636917|NCT02370732|Other|Roux en Y Gastric Bypass|"Participants recruited for this protocol will be those planning to undergo Roux-en-Y Gastric Bypass (RYGB). Upon study screening completion, participants will take part in a total of 4 laboratory assessment days where a fixed dose of alcohol will be given.~2 pre-surgery research appointments where participants will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day.~2 post-surgery (1 year) research appointments where you will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day."
89636918|NCT02370654|Experimental|Tai Chi|12 week Tai chi intervention, 3 sessions per week, 90 minutes per session
89636919|NCT02370654|Active Comparator|Conventional exercise|12 week conventional exercise intervention, 3 sessions per week, 90 minutes per session
89636920|NCT01559389|Experimental|Female Partners|This arm comprises female partners who receive up to 16 weeks of solifenacin treatment for their UUI symptoms
89636921|NCT01559389|No Intervention|Male Partners|This arm comprises healthy male partners
89636922|NCT02378142|Experimental|Arm 1|Pazopanib 800mg oral daily
89636923|NCT02376582|Experimental|DNA and protein|4mg DNA and 600 mcg protein formulated with Alum co-administration (IM) at Month 0, 1 and 6 in Schisto infected individuals
89636924|NCT02376582|Active Comparator|Vaccination without S. mansoni infection|DNA Protein
89636925|NCT02378064|Experimental|Fimasartan and vytorin|fimasartan(60mg,QD)+Vytorin(10mg,QD)
89636926|NCT02378064|Experimental|Fimasartan and rosuvastatin|fimasartan(60mg,QD)+rosuvastatin(5mg,QD)
89636927|NCT02378064|Active Comparator|amlodipine and vytorin|amlodipine(5mg,QD)+Vytorin(10mg,QD)
89636928|NCT02378064|Active Comparator|amlodipine and rosuvastatin|amlodipine(5mg,QD+rosuvastatin(5mg,QD)
89636929|NCT01526551|Experimental|Intervention Schools|High school students attending Wayne County and Monticello Ind. schools will be given opportunity to receive HPV Vaccine and HPV-related Health Education and Reduction of barriers to being vaccinated.
89636930|NCT00305565|Other|Low Dose|
89636931|NCT00305565|Other|Medium Dose|
89636932|NCT00305565|Other|High Dose|
89636933|NCT03113370|Experimental|Fish Oil|4 grams of fish oil per day
89636934|NCT03113370|Placebo Comparator|Placebo|4 grams of olive oil capsules per day
89636935|NCT02370576||control|Healthy women after elective cesarean section.Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
89636936|NCT02370576||emergency|Healthy women after emergency cesarean section. Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
89636937|NCT00343083|Experimental|Cetuximab comparison for Head and Neck Cancer|"To report the mature data of a prospective Phase II trial designed to evaluate the efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy of weekly paclitaxel/carboplatin (PC) and daily radiation therapy (RT).~Both chemotherapy and radiation will be given on a weekly basis (see interventions for details)."
89636938|NCT02370342|Experimental|Treatment (robot-assisted laparoscopic HIFU)|Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.
89636939|NCT02376426|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
89636940|NCT02376426|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
89636941|NCT02376426|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
89636942|NCT02376426|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
89042127|NCT06092879||Asciminib|Adult patients with Ph+ CML-CP previously treated with two or more tyrosine kinase inhibitors
89042128|NCT06088914|Experimental|Anodal tDCS group|Participants will receive anodal tDCS applied to the ipsilesional primary motor cortex.
89042129|NCT06088914|Sham Comparator|Sham tDCS|Participants will receive sham tDCS applied to the ipsilesional primary motor cortex
89042130|NCT06086912|Experimental|sequence 1|
89042131|NCT06086912|Experimental|sequence 2|
89636943|NCT00343785|Experimental|Treatment (conditioning regimen, transplant, GVHD prophylaxis)|Patients receive a conditioning regimen comprising cyclophosphamide IV on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2. Patients undergo allogeneic bone marrow transplantation on day 0. Patients then receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or PO twice daily on days -1 to 50, followed by a taper until 6 months after grafting.
89636944|NCT02370264|Experimental|Supportive care (musculoskeletal screening, quality of life)|Patients complete the DASH and FACT-B questionnaires over 30-45 minutes.
89636945|NCT02370108|Experimental|PD patient|Parkinson's disease patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
89636946|NCT02370108|Experimental|OT patients|others tremor patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
89636947|NCT00343863|Active Comparator|Dexamethasone + Ondansetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
89636948|NCT00343863|Experimental|Dexamethasone + Palonosetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
89636949|NCT02376504|Experimental|Treadmill workstation|Participants will be provided with a treadmill workstation to be more active at the workplace Active Workplace
89636950|NCT02376504|Experimental|Sit-to-Stand workstation|Participants will be provided with a sit-to-stand workstation to be decrease sitting time at the workplace Active Workplace
89636951|NCT02376504|No Intervention|Control|Participants will be asked to engage in three 10 min walking bouts each work day
89042132|NCT06086912|Experimental|sequence 3|
89042133|NCT06080685|Experimental|Intervention Group|Who receives intervention. Character strengths intervention will be administered in 5 sessions.
89042134|NCT06080685|Active Comparator|Waitlist Control Group|Who would receive the intervention after the study completion.
89636952|NCT02370030|Active Comparator|Intervention|Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
88991063|NCT05811299|Active Comparator|Abdominal exercises|(Group B) will receive abdominal exercises 8 sessions for 4 weeks and 2 session will be given in a week.
88991064|NCT05808270|Active Comparator|Nutrition care process|
88991065|NCT05808270|Placebo Comparator|Conventional nutritional intervention|
88991066|NCT05806541|No Intervention|control group|At the beginning of the study, data collection tools Personal Information Form, Academic Self-Efficacy Scale and Psychological Well-Being Scale will be applied to the control group. No intervention will be made in the control group. Measurement tools will be applied for the post-test.
88991067|NCT05806541|Experimental|experimental group|"Personal Information Form, Academic Self-Efficacy Scale and Psychological Well-Being Scale will be applied to all first-year nursing students studying at Sinop University Health Sciences in the spring term of 2022-2023.~Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. Psychological Well-Being Scale and Academic Self-Efficacy Scale will be applied again after the application and in the follow-up (after the application is over)."
88991068|NCT05805436|No Intervention|Control|Do not receive polyethylene glycol before surgery
88991069|NCT05805436|Experimental|Intervention|Receive polyethylene glycol before surgery
88991070|NCT05802953||Temporomandibular joint dysfunction group|The group will include patients with temporomandibular joint dysfunction.
88991071|NCT05796869|No Intervention|Control Group|"At the beginning of the study, data collection tools Personal Information Form, Premenstrual Syndrome Scale and Food Craving Scale will be applied to the control group.~No intervention will be made in the control group. Measurement tools will be applied for the post-test."
89521143|NCT02636881|Active Comparator|Autologous Chondrocyte Implantation|A diagnostic arthroscopy of the knee joint.The lesion is stabilized down to the subchondral bone, but not through it. Cartilage biopsy is taken from the medial femoral notch. The harvested cartilage is transported to the cell culture Laboratory and cultured for two weeks. The chondrocyte implantation: A mini-open arthrotomy is performed and the lesion is curetted down to subchondral bone, avoiding bleeding. The lesion is measured and a template of sterile aluminum foil is used to cut out a matching piece of collagen sheet which is used to contain the cells in the defect. The flap is sutured to the lesion and sealed with fibrin glue, leaving and opening at the upper part for injection of the cells. The last opening is then closed with a last stitch and fibrin glue.
89636953|NCT02370030|Placebo Comparator|Placebo|10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
89636954|NCT06307496|Experimental|Videos|Participants will be sent links to smoking cessation videos to watch.
89636955|NCT06307496|Active Comparator|NCI Pamphlet|"Participants will be sent links to NCI's Clearing the Air to read."
89636956|NCT06307444|No Intervention|medical treatment only|All patients will receive oral medication for antiviral therapy (800mg of acyclovir 5 times daily) at the time of diagnosis and supportive treatments, including acetaminophen (1gm 3times daily), and gabapentin (starting at 100mg three times daily) to be incrementally up titrated over time as needed by 100 to 300 mg every 3 to 5 days, to as high a dosage as 1800 to 3600 mg/day in 3 or 4 divided doses
89636957|NCT06307444|Experimental|Ultrasound-Guided Stellate Ganglion Block|Ten milliliters of a local anesthetic solution (bupivacaine (0.25%)+ 8 mg dexamethasone) is injected until the fluid spreads along the paravertebral fascia to the stellate ganglion.
89636958|NCT06307444|Experimental|Group III T2 T3 (High Thorathic) ErectroSpinae Plan Block|ocal anesthetic drugs(0.2-0.3ml/kg of bupivacaine 0.25% 8mg Dexamethazone) will be administered as standard in all patients aiming to distribute within the plane between the anterior fascia of the erector spinae muscle and the transverse process.
89636959|NCT06307418|Experimental|Internet-based support (Carer eSupport)|The internet-based support is developed in collaboration with clinical expertise within head and neck cancer care and an expert group of informal caregivers to patients with head and neck cancer. The support comprise text, lectures, films, discussion forum and real-time video meetings with clinical experts. The support will last for 18 weeks.
89636960|NCT06307418|No Intervention|Support as usual|Support as usual comprise a possibility for informal caregivers to contact a specified nurse with expertise in head and neck , at the head and neck or oncology clinic, to ask for support. Healthcare counsellors at the clinics is also available for ICs on request. Group support providing emotional and social support for ICs to patients with various cancer diagnoses may also be arranged at the clinics occasionally. Also, the Swedish healthcare is always responsible for recognizing the need for support for children (< 18 years) of patients with cancer.
89636961|NCT06307405||pulmonry infection group|50 cases of suspected pulmonary infection (based on clinical manifestations and imaging findings). These patients have collected two different samples of alveolar lavage fluid (BALF) and sputum and have undergone metagenomic next generation sequencing (mNGS) and routine pathogen detection, respectively.
89636962|NCT06307392|Experimental|Endotracheal tube plus bougie|
89636963|NCT06307392|Active Comparator|Endotracheal tube alone|
89636964|NCT06307379||Bronchoscopy under local anesthesia|Bronchoscopy under local anesthesia
89636965|NCT06307379||Bronchoscopy under anxiolysis|Bronchoscopy under anxiolysis
89636966|NCT06307379||Bronchoscopy under conscious sedation|Bronchoscopy under conscious sedation
89636967|NCT06307379||Bronchoscopy under general anesthesia|Bronchoscopy under general anesthesia
89636968|NCT06307366||(Future) parents with (a partner with) mental illness in the mood-psychosis spectrum|"The following participants will be included: (Future) parents with (a partner with) mental illness in the mood-psychosis spectrum (psychotic disorder, bipolar disorder, severe depression); ≥ 18 years old.~If including (future) parents with mental illness and their partners will turn out to be difficult given our timeframe, we will mitigate this by additionally including family members of people with mental illness, e.g. siblings or grandparents."
89636969|NCT06307340|Experimental|Adapted STAIR-NT Intervention|
89636970|NCT06307340|Active Comparator|Treatment as Usual (TAU)|
89636971|NCT06307301|Experimental|Phase I Study in ALS with Abatacept & IL-2|"Primary Objective:~1. To assess the safety and the tolerability of abatacept followed by IL-2 administration in ALS patients~Secondary Objectives:~To investigate the immunomodulatory effects of abatacept followed by IL-2, by monitoring the change in the number of Tregs~To investigate the immunomodulatory effects of abatacept followed by IL-2, by monitoring the change in the suppressive activity of Tregs on T effector proliferation.~To investigate the immunomodulatory effects of abatacept followed by IL-2, by monitoring in the level of cytokines secreted by PBMCs throughout the course of the study~Exploratory Objective:~1. To characterize the effects of abatacept followed by IL-2 on clinical outcome measures of ALS, including the Appel ALS Rating Scale (AALS) and ALS Functional Rating Scale-Revised (ALSFRS-R) scores, and the forced vital capacity (FVC) and maximum inspiratory pressure (MIP)."
89636972|NCT06307288|Experimental|minocycline treatment group|The patient was treated with oral minocycline capsules, 50mg each time, once a day, for 12 weeks.
89636973|NCT06307288|Experimental|tranilast treatment group|The patient was treated with oral tranilast capsules, 0.1g each time, three times a day, for 12 weeks.
89636974|NCT06307288|Experimental|tranilast combined with minocycline treatment group|The patient was treated with oral tranilast capsules, 0.1g each time, three times a day; oral minocycline capsules, 50mg each time, once a day, for 12 weeks.
89636975|NCT06307275|Active Comparator|Non Fasting|For four week: Participants will keep their normal food intake with no restrictions on when to eat. Participants will keep their normal weekly exercise routine.
89636976|NCT06307275|Experimental|Fasting|For four weeks: Fasting for 16 hours from participant last meal of the previous evening's meal to the first meal of the next day. Then for 8 hours, participant is able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.
89636977|NCT06307249|Experimental|Carrier First-line Combined Therapy Group C-FL-CT|This group of patients, who are carriers of the risk alleles, will receive combined therapy as the initial first-line treatment without prior chemotherapy.
89636978|NCT06307249|Experimental|Carrier Second-line Combined Therapy Group C-SL-CT|This group of patients, who are carriers of the risk alleles, will receive combined therapy after having undergone prior chemotherapy, making it the second-line treatment.
89636979|NCT06307249|Experimental|Non-carrier First-line Combined Therapy Group NC-FL-CT|This group of patients, who are non-carriers of the risk alleles, will receive combined therapy as the initial first-line treatment without prior chemotherapy.
89636980|NCT06307249|Experimental|Non-carrier Second-line Combined Therapy Group NC-SL-CT|This group of patients, who are non-carriers of the risk alleles, will receive combined therapy after having undergone prior chemotherapy, making it the second-line treatment.
89636981|NCT06307236|Experimental|Experimental|Group to be applied EFT
89636982|NCT06307236|No Intervention|Control|No application will be made
89636983|NCT06307223|Experimental|30% supramolecular salicylic acid combined with supramolecular active zinc treatment group|The patients received weekly application of 30% supramolecular salicylic acid in conjunction with daily application of topical supramolecular active zinc anti-dandruff lotion, for a duration of 8 weeks.
89636984|NCT06307210||age group 75-84|Inpatient rehabilitation included physiotherapy (30-60 min, 5 times/week), strength and endurance training (30-45 min, 3-5 times/week), occupational therapy (30 min, 2-3 times/week), and neuropsychological training (30 min, 2 times/week).
89636985|NCT06307210||age group 85-99|Inpatient rehabilitation included physiotherapy (30-60 min, 5 times/week), strength and endurance training (30-45 min, 3-5 times/week), occupational therapy (30 min, 2-3 times/week), and neuropsychological training (30 min, 2 times/week).
89636986|NCT06307197|Experimental|older adults|
89636987|NCT06307184||Natural proliferative phase frozen embryo transfer (NPP-FET)|When the endometrial thickness is at least 7 mm, vaginal micronized progesterone will be initiated at 400mg every 12 hours, as per standard clinical practice, when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are >80 pg/ml, and serum progesterone levels are <1.5ng/ml. One embryo will be transferred on the fifth day of progesterone supplementation under ultrasound guidance. Progesterone will be continued until the 11th week of pregnancy.
89636988|NCT06307184||Natural cycle frozen embryo transfer (NC-FET)|When the mean dominant follicle diameter was at least 17 mm and the endometrial thickness was at least 7 mm, serum E2, progesterone and luteinizing hormone (LH) were evaluated. If a spontaneously LH peak was detected (E2>80 pg/ml, LH peak >18 mIU/mL with progesterone level <1.5 ng/mL), vaginal micronized progesterone was started from the evening of ovulation at a dose of 200 mg every 12 hours. Conversely, whenever a LH peak was not detected (E2>80 pg/ml, LH <18mIU/ml and progesterone <1,5 ng/ml), r-hCG 250µg (Ovitrelle®) was administered subcutaneously, followed, 48 hours later, by daily administration of 200 mg micronized vaginal progesterone every 12 hours. One embryo was transferred 7 days after r-hCG administration or 6 days after LH peak detection. Progesterone was continued until the 8th week of pregnancy.
89636989|NCT06307171|Other|Leishmaniasis cases|Archived, cryo-preserved or prospectively collected samples from patients with clinically or laboratory confirmed leishmaniasis
89636990|NCT06307171|Other|Community Controls|Sera from uninfected subject archived, cryo-preserved serum sample,stored at the Tropica Biobank at the DITM, IRCCS Sacro Cuore Don Calabria Hospital, Negrar (Vr), from subjects from Italy and from Africa with negative results to two serological test for leishmaniasis. Archived, cryo-preserved serum sample from subjects with a confirmed diagnosis of Chagas' diseases, TB, leprosy, and malaria stored at the Tropica Biobank at the DITM, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona.
89636991|NCT06307171|Other|Validation CONTROLS (VC)|Serum samples stored in Tropica Biobank at the DITM from subjects that have been clinically diagnosed with Chagas's disease (n=15), or TB (n=15), or malaria (n=15) or leprosy (n=5).
89636992|NCT06307158||Intraoperative blood salvage and autotransfusion (IBSA) group|The study included patients who underwent adult-to-adult DDLT for HCC in China between January 2015 and December 2020. Exclusion criteria included: patients under 18 years of age, presence of extrahepatic metastasis, combined kidney transplantation, reduced-size or split liver transplantation, re-transplantation, and missing data on analyzed variables. The remaining recipients were 349 in IBSA group who received salvaged blood autotransfusion during the LT.
89636993|NCT06307158||non-intraoperative blood salvage and autotransfusion (non-IBSA) group|The study included patients who underwent adult-to-adult DDLT for HCC in China between January 2015 and December 2020. Exclusion criteria was as mentioned ahead. Recipients who did not receive salvaged blood autotransfusion during the LT were enrolled in non-IBSA group.
89636994|NCT06307132||test preparation|
89636995|NCT06307132||reference preparation|
89636996|NCT06307119|Experimental|Occupational Therapy and Relaxation Group|MOHO Based Intervention and Jacobson's Progressive Muscle Relaxation method
89636997|NCT06307119|Experimental|Relaxation Group|Jacobson's Progressive Muscle Relaxation method
89636998|NCT06307119|No Intervention|Control Group|No İntervention
89636999|NCT06307106|Experimental|group A: ketorolac and light marcaine injection|
89637000|NCT06307106|Experimental|group B: light marcaine injection|
89637001|NCT06307106|Experimental|group C: corticosteroids injection|
89637002|NCT06307106|Experimental|group D: topical diclofenac sodium|
89637003|NCT06307093|Experimental|RPH-075|"Pembrolizumab will be administered as an intravenous infusion every 3 weeks, at a fixed dose of 200 mg, for 30 minutes (it is permissible, but not desirable, to carry out an infusion in the range from 25 to 40 minutes).~Premedication before administration of pembrolizumab is not mandatory."
89637004|NCT06307093|Active Comparator|Keytruda®|"Pembrolizumab will be administered as an intravenous infusion every 3 weeks, at a fixed dose of 200 mg, for 30 minutes (it is permissible, but not desirable, to carry out an infusion in the range from 25 to 40 minutes).~Premedication before administration of pembrolizumab is not mandatory."
89637005|NCT06307080|Experimental|Multi-mode thermal ablation combined with intravenous anti-PD-1 and chemotherapy|Multimodal ablation therapy +PD-1 antibody combined with intravenous chemotherapy was performed (carreilizumab 200 mg IV D1+ gemcitabine 1000mg/㎡ IV+ albumin binding paclitaxel 125mg/㎡ IV D1.8Q3W; For 6 weeks)
89212021|NCT00852878|Active Comparator|Behavioral|Behavioral intervention will provide parent and child with a variety of pain management techniques such as relaxation, distraction, contingency management, and coping statements
89212022|NCT00852956|Experimental|Treatment|Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
89637006|NCT06307080|Active Comparator|Intravenous anti-PD-1 and chemotherapy|Intravenous chemotherapy was performed (carreilizumab 200 mg IV D1+ gemcitabine 1000mg/㎡ IV+ albumin binding paclitaxel 125mg/㎡ IV D1.8Q3W; For 6 weeks)
89637007|NCT06307067||Pre-intervention group|patients being treated according to the old method (no dipstick as diagnostic test)
89637008|NCT06307067||Post-intervention group|patients being treated according to the new method (dipstick as diagnostic test)
89637009|NCT06307054|Experimental|Anti CLL-1 CAR NK cells|
89637010|NCT06307041|Other|Test (HA group)|One side is HA gel impregnated dental floss usage
89637011|NCT06307041|Other|Control Group|One side is dental floss usage
89637012|NCT06307028|Experimental|SISTA-P Intervention|Participants will complete four sessions lasting up to three hours each over the course of one week. The sessions will be overseen by two facilitators and a technical monitor. Core elements of SISTA-P are: (1) small group discussions, modeling and role-play that facilitate repetition, reinforcement and sequential approximation; (2) skilled facilitators; (3) gender and culturally specific materials to enhance pride and self-worth; (4) teaching negotiation, self-advocacy; and (5) HIV prevention relevant skills; (6) discussing gender and culture-specific barriers and facilitators to prevention; and (7) enhancing HIV prevention norms and self-efficacy. Each discussion group will consist of 12- 15 participants and each cycle will consist of one group. Participants will be asked to complete a follow up survey and two booster sessions. They will also be asked to submit photo-confirmation of PrEP prescription to the research team.
89637013|NCT06307015|Active Comparator|Standard of care|Standard of care treatment for patients undergoing definitive chemoradiation for oropharyngeal squamous cell carcinoma
89637014|NCT06307015|Experimental|De-escalation|De-escalated radiation therapy for patients undergoing surgery to the primary site followed by chemoradiation to the primary site and neck for oropharyngeal squamous cell carcinoma
89637015|NCT06306989||High-risk groups|
89637016|NCT06306989||Low to medium risk group|
89637017|NCT06306963||Cirrhosis With Gastric Antral Vascular Ectasia|Patients with Gastric Antral Vascular Ectasia with cirrhosis will undergo gastric motor function testing. This will be measured by radioscintigraphy after overnight fast using a radiolabeled meal.
89637018|NCT06306963||Cirrhosis Without Gastric Antral Vascular Ectasia|Patients without Gastric Antral Vascular Ectasia with cirrhosis will undergo gastric motor function testing. This will be measured by radioscintigraphy after overnight fast using a radiolabeled meal.
89637019|NCT06306937||Periodontitis|Individuals diagnosed with periodontitis based on established clinical criteria. This group will include participants who exhibit signs and symptoms of periodontal disease, such as probing depth, clinical attachment loss, and bleeding on probing.
89637020|NCT06306937||Control|Individuals without any signs or history of periodontal disease. This group will consist of participants who do not have clinically diagnosed periodontitis and serve as the healthy control group for comparison with the periodontitis group.
89637021|NCT06306911|Experimental|Aronia Melanocarpa extract|a drink consisting of AME (Aronia Melanocarpa extract) and water.
89637022|NCT06306885|Experimental|AOMI-sleep|Observation and imagination of video-clips with motor contents before sleeping
89637023|NCT06306885|Active Comparator|AOMI-control|Observation and imagination of video-clips with motor contents in the morning
89637024|NCT06306885|Sham Comparator|Control|Observation and imagination of landscapes video-clips
89212023|NCT00852956|Active Comparator|Control|Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
89212024|NCT02545478||Infected Group|subjects with suspected infection
89212025|NCT02545478||Non-infected group|subjects without any infection
89212026|NCT00853034|Active Comparator|FOS-IN|prebiotic fructo-oligosaccharide enriched inulin
89212027|NCT00853034|Experimental|AXOS|arabinoxylan-oligosaccharides (AXOS)
89212028|NCT00857012||All patients|treated with Anastrozole as per SPC
89637025|NCT06306872|Other|Sequence A|Subjects in sequence A will be given ABSK-011 old formulation 220 mg (100 mg capsule *2 and 20 mg capsule *1) on an empty stomach in the morning of the first day of cycle 1 (C1D1) and ABSK-011 new formulation 200 mg (100 mg capsule *2) on an empty stomach in the morning of the first day of cycle 2 (C2D1).
89637026|NCT06306872|Other|Sequence B|Subjects in sequence B will be given ABSK-011 new formulation 200 mg (100 mg capsule *2) on an empty stomach in the morning of Cycle 1 day (C1D1) and ABSK-011 old formulation 220 mg (100 mg capsule *2 and 20 mg capsule *1) on an empty stomach in the morning of the first day of cycle 2 (C2D1).
89212029|NCT00716417|Experimental|A. BIBW 2992-cisplatin-paclitaxel|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel
89637027|NCT06306859|Experimental|SIKIDI group|The experimental arm will be given to access to m-health to monitor and education provision.
89637028|NCT06306859|Active Comparator|Comparator|The comparator group will be given standard care
89637029|NCT06306846|Experimental|experimental|"Step 1：neoadjuvant anti-PD-1 antibody and TP chemotherapy every 3 weeks 2 cycles~Step 2： SBRT with GTV expanded 3mm , 24Gy/3F, every other day within one week after the immunochemotherapy~Step 3：Subsequent surgery and adjuvant treatments.~Radical surgery will be performed within 4-6 weeks after the second cycle of immunochemotherapy，no matter the situation of the tumor regresses.~Patients with pathological MPR/CR were treated with PD-1 antibody every two weeks up to 6 cycles after surgery with no adjuvant chemoradiotherapy. Those not achieved MPR/CR will receive adjuvant radiotherapy or chemoradiotherapy according to NCCN guidelines."
89688539|NCT04737538|Experimental|Experimental Dentifrice|Participants assigned to this arm will apply full ribbon of toothpaste (containing sodium bicarbonate, sodium hyaluronate and sodium fluoride) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
89212030|NCT00716417|Experimental|B. BIBW 2992-cisplatin-5FU|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU
89212031|NCT02592863|Experimental|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
89688540|NCT04737538|Active Comparator|Positive control|Participants assigned to this arm will apply full ribbon of toothpaste (dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
89521144|NCT02636881|Sham Comparator|Arthroscopic Debridement|"The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. Lose bodies are removed, any meniscal pathology is addressed. Inflamed synovium is debrided. The lesion is stabilized by debridement around the edges and down to the subchondral bone using a ring curette, but not through it. Microfracture or any other cartilage treatment will not be performed.~No intra-articular local anesthetics will be used due to the possible harmful effect on cartilage [41-43].~All the operating surgeons will receive proper training in the operative procedure before study start."
89521145|NCT02594215|Experimental|Experimental|Experimental
89042139|NCT06072807|Experimental|ER Positive Breast Cancer Patients with Brain Metastases|A diagnostic intervention where this group will undergo an additional 18F- FES PET/CT scan in addition to their standard of care MRI and FDG PET/CT scan.
89042140|NCT06067178|Experimental|Health Dialogue Intervention|
89042141|NCT06067178|Experimental|Opportunistic Screening|
89042142|NCT06064825||patients received the investigational medicinal product acetaminophen in their first 5 days of life|This group of patients received the investigational product in their first 5 days of life during the Treocapa trial
89042143|NCT06064825||patients received the placebo (NaCl) in their first 5 days of life|This group of patients received the placebo in their first 5 days of life during the Treocapa trial
89042144|NCT06064591||Pilot study Belgium Patients|"Patients (P. falciparum-infected)~No intervention 6 ml of venous blood sampled at one time point"
89042145|NCT06064591||Pilot study Belgium Controls|Control non-infected individuals No intervention 6 ml of venous blood sampled at one time point
89042146|NCT06064591||Work package 1 Burkina Faso Asymptomatic|Asymptomatic (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point. 300µl of finger prick blood at four follow-up visits 24, and 48 and 72h and day 10 after the enrollment.
89042147|NCT06064591||Work package 1 Burkina Faso uncomplicated patients|uncomplicated patients (P. falciparum-infected) No intervention Venous blood sample (maximum of 8 ml) at 1 time point.
89042148|NCT06064591||Work package 1 Burkina Faso Controls|Control non-infected individuals No intervention Venous blood sample (maximum of 8 ml) at 1 time point.
89042149|NCT06064591||Work package 2 Mozambique Uncomplicated malaria patients|Uncomplicated malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.
89042150|NCT06064591||Work package 2 Mozambique Severe malaria patients|Severe malaria patients No intervention Venous blood sample (maximum of 6 ml) at 1 time point.
89042151|NCT06061952|Experimental|Customized Adherence Enhancement for Schizophrenia (CAE-S)|CAE is an adjunctive (to standard medication treatment) behavioral intervention delivered virtually (real-time one on one video-conferencing) in 6 individual sessions. All participants will receive content from the 4 currently existing CAE modules delivered over a 6-session series spaced out over approximately 6-10 weeks. The material from the 4 modules will be broken down into predetermined sub-sections and delivered in 6 sessions. The modules themselves are delivered in sections (thematic units within the module) and do not correspond to a specific session. The 4 CAE modules are Psychoeducation, Communication with Providers, Medication Routines, and Substance Use.
89212032|NCT02592863|Placebo Comparator|Placebo|Patients will take placebo 3 times per day for 12 weeks
89212033|NCT00719537|Placebo Comparator|Aspirin plus Placebo Oral Tablet|Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day
89521146|NCT03441763|Experimental|Normal participants|Emed foot device 3 times/measure to determine foot pressure in normal participants. .
89521147|NCT03441763|Experimental|Over weight participants|Emed foot device 3 times/measure to determine foot pressure in over weight participants.
89521148|NCT03441763|Experimental|Obese participants|Emed foot device 3 times/measure foot pressure in obese participants.
89521149|NCT02535325|Experimental|Treatment (pemetrexed, methoxyamine, cisplatin, RT)|"CYCLES 1-2: Patients receive pemetrexed disodium IV over 10 minutes and methoxyamine hydrochloride PO day 1; and cisplatin IV over 0.5-24 hours on day 3. Patients also undergo 3-D conformal RT or IMRT QD 5 days a week (3 days of week 1 and 4 days of week 4) for 30 fractions total.~CYCLES 3-4: Beginning at least 10 days after RT completion, patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 0.5-24 hours on day 1.~Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
89521150|NCT03441685|Experimental|Verb strategies|"The examiner labels each target word and performs the corresponding action six times in each condition. She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time. In the semantic cues condition, the examiner prompts the child to perform the target action twice. In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., I am X-ing, and See. I X.). In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences."
89521151|NCT04881175|Experimental|FlexSure Applicator|The TempSure FlexSure applicator will be used on the abdomen or flanks.
89521152|NCT03438175|No Intervention|Control|Families of Critically Ill will be informed about patients'clinical status only by oral communication during daily family meeting
89521153|NCT03438175|Experimental|Intervention|Families of critically ill patients will receive during the first ICU day of their loved one a brochure presenting the ICU and inviting them to visit a website specifically created for this project: www.intensiva.it Moreover, in the waiting room of the ICU will be placed 8 posters to improve comprehension and to legitimize emotions.
89521154|NCT03441607|Active Comparator|Drug|Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on second visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
89521155|NCT03441607|Placebo Comparator|Placebo|Intervention: 1cc of saline will be administered as a one time injection on visit 2, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
89042152|NCT06061952|Other|Enhanced Treatment as Usual (eTAU)|To optimize control intervention rigor, the eTAU participants will view a pre-taped series of 6 videos (based on NAMI or DBSA general wellness guidelines) 1:1 with a therapist who has similar credentials and competency as the CAE mental health clinician. The therapist will view the video with the participant and field questions the patient may have.
89042153|NCT06058832|Experimental|Low-intensity Shockwave Therapy|
89042154|NCT06058832|Experimental|Kegel Exercises|
89042155|NCT06058832|No Intervention|control group|
89637030|NCT06306846|Active Comparator|control|"Step 1：neoadjuvant anti-PD-1 antibody and TP chemotherapy every 3 weeks 2 cycles~Step 2：Subsequent surgery and adjuvant treatments.~Radical surgery will be performed within 4-6 weeks after the second cycle of immunochemotherapy，no matter the situation of the tumor regresses.~Patients with pathological MPR/CR were treated with PD-1 antibody every two weeks up to 6 cycles after surgery without adjuvant chemoradiotherapy. Those not achieved MPR/CR will receive adjuvant radiotherapy or chemoradiotherapy according to NCCN guidelines."
89637031|NCT06306846|Active Comparator|Cetuximab+immunochemo|"Step 1：neoadjuvant anti-PD-1 antibody and TP chemotherapy combined with cetuximab every 3 weeks for 2 cycles~step2: Subsequent surgery and adjuvant treatments.~Radical surgery will be performed within 4-6 weeks after the second cycle of immunochemotherapy，no matter the situation of the tumor regresses.~Patients with pathological MPR/CR were treated with PD-1 antibody and cetuximab every two weeks up to 6 cycles after surgery without adjuvant chemoradiotherapy. Those not achieved MPR/CR will receive adjuvant radiotherapy or chemoradiotherapy according to NCCN guidelines."
89042158|NCT06050811|Experimental|Prebiotic supplement|5 g 2'-Fucosyllactose per day
89042159|NCT06050811|Placebo Comparator|Placebo|5 g maltodextrin per day
89042160|NCT06045234|Experimental|Pesticide measurement|
89042161|NCT06043089|Placebo Comparator|Placebo group|Athletes received 7 days of placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
89042162|NCT06043089|Experimental|Beetroot group|Athletes received 7 days of beetroot juice (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK).
89042163|NCT06042114|Experimental|Listening to Surah Inshirah|Experimental group patients; A patient descriptive characteristics form will be applied, pretest VAS pain score and state anxiety scale will be applied. Then, the Surah al-Inshirah will be listened to and the final test VAS pain score and state anxiety scale will be applied.
89042164|NCT06042114|No Intervention|control group|Control group patients; A patient descriptive characteristics form will be applied, pretest VAS pain score and state anxiety scale will be applied. The posttest VAS pain score and state anxiety scale will be applied 10 minutes later, without any intervention.
89042165|NCT06041100|Experimental|Intervention|30 minutes of daily wearing an exoskeleton for 12-weeks
89042166|NCT06040710||Experimental: Intervention arm|All patients within the study are included in the intervention arm: polyp detected within these patients will be measured according to the study protocol using two different methods.
89042167|NCT06040541|Experimental|RMC-9805|Dose exploration and dose expansion
89042168|NCT06040255|Active Comparator|Arm A|Treat all children with suspected FCA with corticosteroids as soon as the diagnosis is made.
89042169|NCT06040255|Active Comparator|Arm B|Treat only the subset of children that develop evidence of FCA disease progression.
89042170|NCT06038591|Experimental|Sleep Intervention|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
89637032|NCT06306833|Experimental|sEMG Biofeedback Intervention|Participants in the intervention group will receive biofeedback surface EMG (sEMG) therapy as an alternative therapy to reduce chronic low back pain
89042171|NCT06038591|No Intervention|Comparison/control|The comparison arm is a no-contact control group. Parents and children will not receive any intervention. They will be placed on a wait-list, and then offered the sleep intervention once the post-assessments are complete.
89042172|NCT06030427|Experimental|Supportive care (virtual mindfulness and weight management)|Patients participate in a virtual behavioral weight management program with an integrated mindfulness component consisting of 12, 75-minute virtual group sessions over 12 weeks to help improve mood, coping strategies, stress management, and weight loss. Patents also receive patient education handouts, view behavioral educational PowerPoint presentations over 30 minutes, and wear a Fitbit on study.
89042173|NCT06029023|Active Comparator|MTA|Mineral trioxide aggregate MTA, The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
89042174|NCT06029023|Experimental|Nano propolis|Propolis is a resinous substance that honey bees collect from different plant species. The most important pharmacologically active constituents in propolis are flavonoids, phenolics, and aromatics.
89042175|NCT06029023|Experimental|Nano curcumin|Curcumin (CUR), 7-bis (4-hydroxy-3-methoxyphenyl)-1,6- heptadien-3, 5-dione
89042176|NCT06028074|Experimental|Intravenous administration of GIM-122|GIM-122
89042177|NCT06014255|Experimental|Enoblituzumab|Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV every 2 weeks for 12 weeks, followed by a radical prostatectomy on day 84, with follow-up visits 30 days, 90 days, 6 months, and 9 months post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.
89637033|NCT06306833|No Intervention|Control|Participants in the control group will receive usual care
89637034|NCT06306794|Experimental|experimental group|During the endotracheal aspiration procedure, the octopus will be given to experimental group 10 minutes before the procedure. Babies will be allowed to touch the octopus for 10 minutes during and after the procedure. Physiologic parameters of the infants before, during and after the procedure will be reported and recorded by camera. According to the video recordings, PIPP-R and PICS scale evaluations of the infants will be made by two research nurses other than the main researcher conducting the study.
89042178|NCT06014255|Active Comparator|Standard of Care|Patients will undergo standard of care radical prostatectomy within 4-8 weeks of randomization.
89637035|NCT06306794|No Intervention|control group|The routine aspiration application steps of the unit will be applied to the control group without any intervention. Physiologic parameters of the infants before, during and after the procedure will be reported and recorded by camera. According to the video recordings, PIPP-R and PICS scale evaluations of the infants will be made by two research nurses other than the main researcher conducting the study.
89637036|NCT06306781|Experimental|HCL001 cell injection (homologous allogeneic hepatocytes)|low/middle/high dose group
89637037|NCT06306768|Other|Remote Therapeutic Monitoring|Participants will receive 1 year of remote therapeutic monitoring via a connected health app and personal activity tracker to monitor their physical activity and exercise behaviors.
89637038|NCT06306755|Experimental|Sequential screening group|"The enrolled participants will undergo a questionnaire investigation and receive a risk assessment for esophageal and gastric malignancies based on two questionnaire-based diagnostic models. Participants identified as high-risk (i.e., with a top 50% risk level) for esophageal and/or gastric malignancy will receive the standard upper gastrointestinal endoscopy. Standardized diagnosis and treatment recommendations will be provided to patients with screening-detected malignant lesions, and green referral channels will be established for them. For participants with screening-detected premalignant lesions, the risk of progression will be evaluated based on endoscopic characteristics, pathological diagnosis, and biomarkers. Individualized reexamination and surveillance will be implemented accordingly."
89637039|NCT06306755|Active Comparator|Universal screening group|The enrolled participants will undergo a questionnaire investigation and receive the same standard upper gastrointestinal endoscopy as those in the sequential screening group, irrespective of the results of the risk assessment. Standardized diagnosis and treatment recommendations will be provided to patients with screening-detected malignant lesions, and green referral channels will be established for them. For participants with screening-detected premalignant lesions, the reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment.
89637040|NCT06306742|Active Comparator|OMT|"Participants will receive manual treatments. The treatment will include soft-tissue, joint mobilization techniques of the lumbar and sacral region. The treatment will also include the approach of the abdomen and lower limb with the same type of techniques.~Four treatments will be provided at 1, 2, 4 and 8 weeks."
89637041|NCT06306742|Experimental|Open-label placebo|This group will receive an open-label placebo. The manual treatment will be performed in the same areas of the active comparator but using a very light pressure. Additionally, before the start of the treatment, Four treatments will be provided at 1, 2, 4 and 8 weeks.
89637042|NCT06306742|No Intervention|Waiting list|Participants will receive no treatment.
89637043|NCT06306729||Standard Implantation|
89637044|NCT06306729||Rapid Deployment|
89637045|NCT06306716||Chronic and acute wounds|Subjects hospitalized due to chronic and acute wounds
89637046|NCT06306703|Experimental|group1, verbal instruction|
89637047|NCT06306703|Experimental|group 2, digital vaginal palpation|
89637048|NCT06306703|Experimental|group 3, perineometer|
89637049|NCT06306690||1. Patients with rhodopsin mutation (RHO)|Following a clinical diagnosis, patients undergo genetic testing. Patients with rhodopsin mutation (RHO) a mutation are categorised into subgroup 1.
89637050|NCT06306690||2. Patients with pre-mRNA factor 8 (PRPF8) mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with pre-mRNA factor 8 (PRPF8) mutation are categorised into subgroup 2.
89637051|NCT06306690||3.Patients a cone-specific phosphodiesterase, i.e. PDE6B, mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with a cone-specific phosphodiesterase, i.e. PDE6B, mutation are categorised into subgroup 3.
89637052|NCT06306690||4. Patients with Chromosome 2-Open (C2orf71) mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with Chromosome 2-Open (C2orf71) mutation are categorised into subgroup 4.
89637053|NCT06306690||5. Patients with Guanylate Cyclase (GUCY2D) mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with Guanylate Cyclase (GUCY2D) mutation are categorised into subgroup 5.
89637054|NCT06306690||6. Patients with RP- specific nuclear receptor (Nr2E3) mutation|Following a clinical diagnosis, patients undergo genetic testing. Patients with RP- specific nuclear receptor (Nr2E3) mutation are categorised into subgroup 6.
89637055|NCT06306664|Experimental|Group A|the patients will receive green filter of bioptron light therapy and conventional treatment((ice application+ exercise program)) for jumper knee three times a week for four weeks.
89637056|NCT06306664|Experimental|Group B|the patients will receive yellow filter of bioptron light therapy and conventional treatment for jumper knee three times a week for four weeks.
89637057|NCT06306664|Placebo Comparator|Control group|the patients will receive conventional treatment (ice application+ exercise program) for jumper knee three times a week for four weeks.
89637058|NCT06306638|Experimental|Phase I cohort 1 (I-PDT, EBUS)|Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 3 treatment sessions. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
89637059|NCT06306638|Experimental|Phase I cohort 2 (I-PDT, EBUS, palliative radiation therapy)|Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
89637060|NCT06306638|Experimental|Phase II (I-PDT, EBUS, palliative radiation therapy)|Phase II: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
89637061|NCT06306612|Experimental|Experimental group|The experimental group start with 6 cycles of induction chemohormonal therapy followed with cytoreductive prostatectomy and postoperative adjuvant radiotherapy if needed. All patients continued maintenance therapy.
89212034|NCT00719537|Active Comparator|Aspirin plus Progesterone|Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day
89212035|NCT00845624||1|Preterm infants <1500 grams or 32 weeks gestation.
89212036|NCT02591459|Other|Autism|Using the app to assist routine anticipation for autistic children in Android mobile devices
89042179|NCT06011031|Experimental|Novaloc attachment|"a newly developed device novaloc attachment systemmade of peek material and amorphous diamond like carbon."
89042180|NCT06011031|Active Comparator|locator attachment|a device with low-profile attachment used in cases of limited inter arch distance, provides excellent retention, possesses a self-aligning property and allow correction of implant divergence up to 20 degrees
89042181|NCT06010680|Experimental|[14C]SHR2554|
89042182|NCT06001918|Experimental|Treatment Arm|"Participants assigned to the treatment arm will undergo an endovascular procedure using the Nectero EAST System to deliver the Stabilizer Infusion Solution directly inside the aneurysm. This is a one-time local delivery of the product. Following treatment, surveillance of their AAA will be conducted using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.~Intervention: Drug: Stabilizer"
89637062|NCT06306612|Active Comparator|Control group|The control group start with 6 cycles of chemohormonal therapy followed by continued maintenance therapy.
89637063|NCT06306599|Experimental|Experiment|20 participants ultrasound scan five patients with thyroid nodules, and assess these nodules themselves, then with the AI-program, and at last they give a combined assessment.
89042183|NCT06001918|No Intervention|Control Arm|Participants assigned to the control arm will undergo surveillance of their AAA using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.
89042184|NCT05991596|Experimental|Psychodramatic Psychotherapy|"This experimental arm will include 12 patients with vitiligo (randomly assigned to this arm), attending the dermatology services of APSS Trento.~This experimental group will receive the drug treatment usually recommended for vitiligo, in addition to 6 months of psychodramatic psychotherapy."
89042185|NCT05991596|Active Comparator|Self-help activities|This is a control arm which will include 12 patients with vitiligo (randomly assigned to this arm), attending the dermatology services of APSS Trento. This control group will receive the drug treatment usually recommended for vitiligo, in addition to 6 months of self-help activities.
89042186|NCT05984667||C-SMART|C-SMART intervention will be provided via telehealth. Participants will complete in-person neurocognitive testing (baseline, post-intervention) as well as surveys (baseline, post-session, post-intervention) via secure email link. Exit interviews will be conducted by Zoom.
89042187|NCT05978492|Experimental|Dose-escalation part|TXN10128 will be administered orally once daily.
89042188|NCT05973890|Experimental|WhatsApp|Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
89042189|NCT05973890|Experimental|docudrama|Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
89637064|NCT06306586|Experimental|Digital Treatment for Adolescents With Eating Disorders|The digital treatment is guided by a therapist and comprises 8 modules, running over a span of 10 weeks.
89637065|NCT06306573||Primary Cohort|The Primary Cohort will include NYHA Class II heart failure subjects receiving a CardioMEMS PA Sensor implant in the commercial setting.
89637066|NCT06306573||Full Cohort|The Full Cohort will include both NYHA Class II and Class III heart failure subjects receiving a CardioMEMS PA Sensor implant in the commercial setting.
89637067|NCT06306560|Experimental|Immuno-cherapy for extensive small cell lung cancer|Adebrelimab in combination with famitinib and chemotherapy
89637068|NCT06306547||IMM patients with tumors|Patients with IMM will be grouped according to the type of positive myositis-specifc autoantibody,and then again according to whether and what type of tumor they had comorbid.
89637069|NCT06306547||IMM patients without tumors|Patients with IMM will be grouped according to the type of positive myositis-specifc autoantibody,and then again according to whether and what type of tumor they had comorbid.
89637070|NCT06306534|Experimental|Insert Array Into Auditory Nerve|
89637071|NCT06306521|Experimental|Enrollees|Enrolled infants will receive the BeginNGS test in addition to the state newborn screen.
89637072|NCT06306495||University students|Study data will be collected with the International Physical Activity Survey, Demographic Data Form, Sleep Hygiene Index, Distress Tolerance Scale and Pittsburgh Sleep Quality Index administered to all participants.
89042190|NCT05973890|No Intervention|control|standard of care for repeat blood donation
89042191|NCT05971381|Other|Study Treatment|Skin cell suspension prepared using the RECELL System will be applied to a prepared treatment area, followed by at-home NB-UVB phototherapy.
89042192|NCT05970263|Experimental|Breztri|"1. Interventional Arm: patients receive :~First dose of Breztri during hospitalization and discharge with 7-day Breztri inhaler~Breztri refills to cover 12-month follow-up period, mailed in 90-day supply from a central pharmacy. Emergency resupply is also available if needed."
89042193|NCT05970263|Other|External Comparator - Non-Triple|2. External Comparator Arm: patient who receive any non-triple inhaled therapy following a hospitalization for severe COPD exacerbation. This arm will be constructed of de-Identified patient.
89042194|NCT05967832|Experimental|Patients with type 1 narcolepsy|Patients with type 1 narcolepsy
89042195|NCT05967832|Active Comparator|Healthy volunteers|
89637073|NCT06306482||Group A|Patients with chronic obstructive lung disease, asthma, cystic fibrosis and bronchiectasis.
89637074|NCT06306482||Group B|Patients with diffuse parenchymal lung diseases
89637075|NCT06306482||control group|healthy aged matched individuals.
89637076|NCT06306469|Experimental|single Arm1|All practitioners had undertaken formal training on Pranic Healing, Meditation on Twin Hearts, and higher meditation practices at least six months prior to the retreat. Daily retreat practices, which lasted typically for 16-18 hours with occasional short breaks. These practices included combinations of specifically designed physical and breathing exercises to improve the energetic states and stillness. Exercises were followed by Pranic Healing and self-awareness practices. Meditations included Meditation on Twin Hearts, Arhatic Yoga meditations of Kundalini meditation, Arhatic Dhyan and Meditation on the Higher Soul .
89212037|NCT00853190|Experimental|A|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule
89637077|NCT06306456|Experimental|'GH21+Osimertinib'Group|GH21 Capsules Combined with Osimertinib Mesylate Tablets
89637078|NCT06306443|Experimental|extended-release buprenorphine (XR-B)|Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone. If they tolerate sl buprenorphine, on day 4 they will be administered an 8 mg dose of BRIXADI on day 5 (if they do not tolerate sl buprenorphine/naloxone we will extend sl dosing). During week two of dosing, they will receive 16 mg dose of BRIXADI will be given, based on the participant's response to the previous dose. During week three of dosing, they will receive a 24 mg dose of BRIXADI. During week four they will be administered a monthly dose of 64mg, 96mg, or 128mg. In all cases, the dose selected will be based on their response to the previous weeks' dose. We will endeavor to get you on the 96 mg or 128 mg monthly dose as there is a lack of opioid blockade data for the 64 mg monthly dose.
89637079|NCT06306443|Active Comparator|sublingual buprenorphine (SL-B)|Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone.
89637080|NCT06306430||PTB|Subjects with a pulmonary TB
89637081|NCT06306430||PNTM|Subjects with pulmonary NTM
89637082|NCT06306430||extraPTB|Subjects with extrapulmonary TB
89637083|NCT06306430||HC|Healthy controls donors
89637084|NCT06306417|Experimental|Experimental group|acupuncture
89637085|NCT06306417|Sham Comparator|control group|sham acupuncture
89637086|NCT06306404|Experimental|Hormones only|Participants will receive the standard care hormonal intervention.
89637087|NCT06306404|Experimental|Sleep intervention only|Participants will receive the sleep intervention, which includes cognitive behavioral therapy for insomnia, and circadian rhythm therapy.
89637088|NCT06306404|Experimental|Hormones and Sleep intervention|Participants will receive both the sleep intervention, which includes cognitive behavioral therapy for insomnia, and circadian rhythm therapy, and the standard care hormonal intervention.
89637089|NCT06306404|No Intervention|No intervention|The control group.
89637090|NCT06306378||ASD group|Diagnosed as ASD based on DSM-V diagnostic criteria and combined with clinical manifestations.
89637091|NCT06306378||Control group|Healthy children
89637092|NCT06306365|Experimental|Experimental|Subjects belonging to this group perform a modern board game-based learning.
89637093|NCT06306365|No Intervention|Control (no intervention)|Subjects belonging to this group not perform intervention.
89637094|NCT06306352|Experimental|Vibrotactile feedback|Participants will receive vibrotactile feedback in the ABLE Exoskeleton.
89637095|NCT06306339|Placebo Comparator|Placebo infusion|Placebo + SOC
89637096|NCT06306339|Experimental|Burfiralimab(hzVSF-v13) 200mg IV infusion|Burfiralimab (hzVSF-v13) 200mg/dose + SOC
89637097|NCT06306339|Experimental|Burfiralimab(hzVSF-v13) 600mg IV infusion|Burfiralimab (hzVSF-v13) 600mg/dose + SOC
89637098|NCT06306313|Experimental|Experimental|Conventional physiotherapy will be applied in a single session of 45 minutes a day, 3 days a week for 4 weeks, and in addition, robot-assisted therapy will be applied with the ReoGo Upper Extremity Exoskeleton Robot in a single session of 60 minutes a day, 5 days a week for 4 weeks. Evaluations will be made at the beginning and end of the treatment process.
89212038|NCT00853190|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
89212039|NCT02591225|Experimental|Dabigatranetexilate|Dabigatran capsula 150 mg; oral; bid; treatment period 12 months
89212040|NCT02591225|Active Comparator|Phenprocoumon|Phenprocoumon INR adjusted; oral; once daily; treatment period 12 months
89212041|NCT04085003||Intact abdominal aortic aneurysm|
89212042|NCT04085003||Ruptured abdominal aortic aneurysm|
89637099|NCT06306313|Active Comparator|Control Group|The control group will receive only conventional physiotherapy in a single session of 45 minutes a day, 3 days a week for 4 weeks. Evaluations will be made at the beginning and end of the treatment process.
89637100|NCT06306287|Experimental|ePACE Experimental Condition|The experimental intervention to be administered, ePACE, is a web-based brief intervention that includes personalization and youth-centered features. Feedback is provided based on youth's responses to activities, exercises, and quizzes to guide each individual's behavior change efforts.
89637101|NCT06306287|Active Comparator|eFACE Active Comparator Condition|The eFACE active comparator arm involves the eFACE intervention and includes content that is similar to the ePACE experimental intervention, but modules are offered in a fixed order with no tailoring features. No personalized feedback based on youth responses are provided to inform individual youth's behavior change efforts.
89637102|NCT06306287|No Intervention|Waiting List Comparison Group|"Youth in the waitlist comparison (WC) condition will not have access to the ePACE or eFACE modules until the final (6-month) assessment has been completed. Thus, the WC group will serve as a no intervention comparison group."
89637103|NCT06306274|Experimental|Active|
89637104|NCT06306274|Placebo Comparator|Placebo|
89637105|NCT06306261||patients in remission of the disease|UC patients will be subjected to a questionnaire every month about their habits.
89637106|NCT06306261||patients in reactivation of the disease|UC patients will be subjected to a questionnaire every month about their habits.
89637107|NCT06306248||MDD patients|"60 patients with a depressive episode in course of major depression (MDD) and treated with a chronobiological intervention including total sleep deprivation (TSD) + light therapy (LT).~Each subject will participate in the study for 6 months, will undergo MRI and clinical evaluation that will take overall about 2 hours at baseline (V0), after one week of chronobiological treatment and at 6 month follow-up."
89637108|NCT06306222|Experimental|Thulium fiber laser (TFL) lithotripsy|Lithotripsy with TFL is a recently introduced procedure, that will be tested in this study.
89637109|NCT06306222|Active Comparator|Holmium:YAG laser lithotripsy|Holmium:YAG laser lithotripsy represents the gold standard for this procedure since 30 years.
89637110|NCT06306209||MDD|80 patients with a depressive episode in course of major depression (MDD) and treated with SSRI's will be studied. The study does not include the evaluation of pharmacological treatments. The treatments will be administered in the judgment of the attending physician, independently of the experimental protocol.
89637111|NCT06306196|Experimental|Group A1 (Three doses of Hecolin®; HIV negative adults aged 18-45 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine administered at 0, 1 and 6 months to HIV negative participants, age 18-45 years old, 232 participants
89637112|NCT06306196|Experimental|Group A2 (Three doses of Hecolin®; HIV positive adults aged 18-45 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to HIV positive participants, age 18-45 years old, 178 participants
89637113|NCT06306196|Experimental|Group B1 (Three doses of Hecolin®; healthy adolescents aged 12-17 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 12-17 years old, 70 participants
89637114|NCT06306196|Experimental|Group B2 (Two doses of Hecolin®; healthy adolescents aged 12-17 years)|Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months) and one dose of Placebo, administered at 1-month timepoint, to age 12-17 years old, 70 participants
89637115|NCT06306196|Placebo Comparator|Group B3 (Placebo; healthy adolescents aged 12-17 years)|Three doses of Placebo, administered at 0, 1 and 6 months, to age 12-17 years old, 35 participants
89637116|NCT06306196|Experimental|Group C1 (Three doses of Hecolin®; healthy children aged 6-11 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 6-11 years old, 70 participants
89637117|NCT06306196|Experimental|Group C2 (Two doses of Hecolin®; healthy children aged 6-11 years)|Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0 and 6 months and one dose of Placebo, administered at 1-month timepoint, to age 6-11 years old, 70 participants
89637118|NCT06306196|Placebo Comparator|Group C3 (Placebo; healthy children aged 6-11 years)|Three doses of Placebo, administered at 0, 1 and 6 months, to age 6-11 years old, 35 participants
89637119|NCT06306196|Experimental|Group D1 (Three doses of Hecolin®; healthy children aged 2-5 years)|Three doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0, 1 and 6 months, to age 2-5 years old, 40 participants
89637120|NCT06306196|Experimental|Group D2 (Two doses of Hecolin®; healthy children aged 2-5 years)|Two doses of Hecolin® Recombinant Hepatitis E Vaccine, administered at 0 and 6 months and of Placebo, administered at 1-month timepoint, to age 2-5 years old, 40 participants
89637121|NCT06306196|Placebo Comparator|Group D3 (Placebo; healthy children aged 2-5 years)|Three doses of Placebo, administered at 0, 1 and 6 months, to age 2-5 years old, 40 participants
89637122|NCT06306183|Experimental|Acetaminophen and Vitamin C with Naproxen rescue|"900 mg vitamin C taken orally twice a day Extended-release acetaminophen 650 mg two pills every eight hours regularly~Naproxen 500 mg as a rescue medication"
89637123|NCT06306183|Placebo Comparator|Acetaminophen and Placebo with Naproxen rescue|"Placebo taken orally twice a day Extended-release acetaminophen 650 mg two pills every eight hours regularly~Naproxen 500 mg as a rescue medication"
89637124|NCT06306170||Gynecologic cancer patients|Gynecologic cancer patients treated with IGRT, IMRT, SBRT (advanced radiotherapy-ART)
89637125|NCT06306157|Placebo Comparator|Placebo sugar capsules|Half of all enrolled patients will be randomized to receive placebo sugar capsules. Neither the patient nor treating physician will be aware of the group in which the patient was randomized into until after study conclusion. All patients will be requested to take the respective daily dose and follow the titration schedule as instructed. All patients enrolled in the study, regardless of their randomization, will have standard of care treatment for CRPS according to their symptoms and the clinical judgment of the treating clinician.
89637126|NCT06306157|Experimental|Low dose naltrexone|Half of all enrolled patients will be randomized to receive capsules with the active low dose naltrexone (LDN) ingredient. LDN will be titrated over time to minimize potential side effects, with the initial dose starting at 1.5mg and eventually increasing up to 4.5mg. Neither the patient nor treating physician will be aware of the group in which the patient was randomized into until after study conclusion. All patients will be requested to take the respective daily dose and follow the titration schedule as instructed. All patients enrolled in the study, regardless of their randomization, will have standard of care treatment for CRPS according to their symptoms and the clinical judgment of the treating clinician.
89637127|NCT06306144|Experimental|Patients receiving the Psychoeducation Intervention|Patients will participate in a 6-week psychoeducation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of exercises set by the rehabilitation clinician
89637128|NCT06306144|Experimental|Patients receiving the Computerised Cognitive Stimulation Intervention|Patients will participate in a 6-week cognitive stimulation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of on-line exercises set by the rehabilitation clinician.
89042196|NCT05963984|Experimental|Arm A|Participants will receive 360 mg of samuraciclib on cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onwards in combination with fulvestrant administered monthly, plus an additional dose at Cycle 1 Day 15.
89042197|NCT05963984|Experimental|Arm B|Participants will receive 240 mg of samuraciclib on cycles of 28 days (Cycle 1 to 6), 56 days (Cycle 7 to 9) and up to 84 days (Cycles 10 onwards in combination with fulvestrant administered monthly, plus an additional dose at Cycle 1 Day 15.
89042198|NCT05963984|Experimental|Arm C|Participants will receive fulvestrant administered monthly, plus additional dose at Cycle 1 Day 15.
89637129|NCT06306144|Experimental|Patients receiving the Usual Care|Patients randomized to this group will complete the questionnaires and the cognitive tests but will receive no intervention
89637130|NCT06306131|Placebo Comparator|Placebo|The placebo is calcium carbonate 750 milligram (mg) known as TUMS. Each participant will take one tablet orally and repeat 48 hours later.
89637131|NCT06306131|Active Comparator|Levonorgestrel plus meloxicam|The active comparator is levonorgestrel 1.5 milligram (mg) and meloxicam 15 milligram (mg) taken together orally and repeated 48 hours later.
89688541|NCT04737538|Active Comparator|Negative control|Participants assigned to this arm will apply full ribbon of toothpaste (dentifrice containing 1100ppm fluoride as sodium fluoride [Crest Cavity Protection]) to cover the head of toothbrush provided and will brush their teeth for one timed minute twice a day (morning and evening).
89688542|NCT03403439|Experimental|All Subjects|Reference Treatment - BI 1015550 alone followed by Test Treatment (itraconazole + BI 1015550)
89637132|NCT06306092|Experimental|"Sleep on Schedule - sleep education at school"|The sleep training includes five lessons during school hours, and will be held by school staff (teachers, school nurses and school counsellors). The teaching consists of sleep education (sleep knowledge and good sleep routines), time management (e.g., planning homework without distraction, planning other activities, quiet time before bedtime), information to guardians, and discussions with peers in the classroom (e.g., rules regarding evening interaction via electronic media). Homework/exercises and behavioral experiments are also included. Data collection takes place in connection with the first and last lesson of Sleep on Schedule.
89637133|NCT06306092|Experimental|"TechRest - reduction of electronic media use before bedtime"|This intervention has been tested in Australia with a small sample of teenagers, and it was associated with promising effects. The data collection consists of a digital questionnaire regarding sleep habits, insomnia, motivation, physical and mental health, and electronic media use; a selection of students will use the actigraph for a week. After the first week, the participants will be instructed to stop using screens 1 hour before their usual bedtime. After one week has passed, participants in the Technology restriction intervention will be asked to complete the previously mentioned questionnaires as well as questions about the intervention itself: its applicability, compliance, and whether or not they will continue to limit their screen time before bedtime. One year after the intervention, they will be asked to complete the same questionnaire as at baseline. A selection of students will also wear a wrist actigraph.
89637134|NCT06306092|No Intervention|Control|School as usual
89637135|NCT06306079|Experimental|Feasibility intervention|The intervention will be foot insole (lateral wedge) insole, which has already been delivered in routine UK NHS and SA environments by at least one physiotherapist. Clinical testing will be done with 15-25 knee osteoarthritis subjects. These individuals will be assigned to a single intervention group for 4-6 weeks of re-gait training intervention. It involves a personalised gait retraining programme (sizable insole) for the KOA subjects to evaluate the impact on knee pain and improve function. It is set within 4-6 weeks of VAS and the WOMAC tools for knee pain & function outcome.
89637136|NCT06306053|Experimental|A Group|Only tDCS treatment
89637137|NCT06306053|Active Comparator|B Group|Only Motor Training
89637138|NCT06306053|Active Comparator|C Group|Both Treatment (tDCS+Motor Training)
89637139|NCT06306040|Experimental|• Group N (Nalbuphine group n=35 )|administrate nalbuphine 0.1 mg/kg nalbuphine diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery (injected once) dose
89637140|NCT06306040|Experimental|• Group M (Magnesium sulfate group n=35 )|administrate magnesium sulfate once 30 mg/kg Magnesium sulphate diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery
89637141|NCT06306040|Experimental|Group C (Control group n=35 ):|administrate 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery
89637142|NCT06306027|Experimental|Experimental|When patients come to the polyclinic for a check-up 15 days after discharge, the web-designed training program site will be promoted. The patient who accepts the research will be given a user name and password specifically created by the researcher. The patient will be explained practically how to log in to the system at home via phone. Patients will be asked to watch educational videos on the website at least twice a week for one month. Then, pre-test data, Personal Information Form, Self-Efficacy Scale, Self-Care Power Scale and Quality of Life Scale data will be collected. Patients who receive training for a month will be asked to fill out the self-efficacy scale, self-care power scale and quality of life scale for post-test data via the mobile application at the end of the month.
89637143|NCT06306027|No Intervention|Control Group|When patients come to the outpatient clinic for a check-up 15 days after discharge, they will be asked to fill out the Personal Information Form, Self-Efficacy Scale, Self-Care Ability Scale, and Quality of Life Scale by face-to-face information collection method.Patients will receive routine treatment, care and checks in line with the institutional policy. A web designed training program will not be implemented. One month after the pre-test data is collected, patients will be called and asked to fill out the self-efficacy scale, self-care ability scale and quality of life scale when they come to the outpatient clinic.
89637144|NCT06306014|Experimental|Part A (Open-Label EXL01)|
89637145|NCT06306014|Experimental|Part B (EXL01)|
89637146|NCT06306014|Placebo Comparator|Part B (Placebo)|
89637147|NCT06306001|Experimental|Methylene blue|Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
89637148|NCT06306001|Placebo Comparator|Placebo infusion|Subjects in the control arm will receive a placebo infusion (normal saline) at the same volumetric rate.
89637149|NCT06305975|Experimental|Blunt fascial entry|The blunt fascial entry technique will be used for patients in this arm
89637150|NCT06305975|Active Comparator|Veress needle entry technique|The Veress needle entry technique will be used for patients in this arm
89042199|NCT05957536|Experimental|D3L-001|"Part 1 Dose Escalation in subjects with HER2-positive advanced solid tumors~Cohort 1 (starting dose)~Cohort 2~Cohort 3~Cohort 4~Cohort 5~Part 2 Dose Expansion~Cohort A for subjects with HER2-positive advanced breast cancer~Cohort B for subjects with HER2-positive advanced gastric cancer/gastroesophageal junction cancer"
89042200|NCT05953090|Experimental|Feasibility|
89212043|NCT02590679|Experimental|PRAS|pulmonary regurgitation after surgical repair of congenital right ventricular outflow tract
89688543|NCT04346797|Experimental|Eculizumab|Eculizumab
89688544|NCT04346797|No Intervention|Standard of Care|Best standard of care
89042201|NCT05946239|Experimental|Manage My Pain App Intervention|Participants will have access to the MMP App and standard care for 60 days.
89042202|NCT05946239|No Intervention|Control Group|Participants will engage in standard care for 60 days.
89042203|NCT05939843|Active Comparator|Pain Coping Information|
89042204|NCT05939843|Experimental|Mindfulness Practice (alone)|
89042205|NCT05939843|Experimental|Mindfulness Introduction + Mindfulness Practice|
89042206|NCT05939843|Experimental|Pain Introduction + Mindfulness Introduction + Mindfulness Practice|
89042207|NCT05932654|Experimental|300 mg Monotherapy Cohort|BSI-045B 300 mg SC QW × 3 weeks, then BSI-045B 300 mg SC Q2W through Week 24
89042208|NCT05932654|Experimental|480 mg Monotherapy Cohort|BSI-045B 480 mg SC QW × 3 weeks, then BSI-045B 480 mg SC Q2W through Week 24
89042209|NCT05932654|Experimental|300 mg Add-on Therapy Cohort|BSI-045B 300 mg SC QW × 3 weeks, then BSI-045B 300 mg SC Q2W through Week 24; to be administered concomitantly with steady-state dupilumab
89042210|NCT05932654|Experimental|480 mg Add-on Therapy Cohort|BSI-045B 480 mg SC QW × 3 weeks, then BSI-045B 480 mg SC Q2W through Week 24; to be administered concomitantly with steady-state dupilumab
89042211|NCT05921045||time 0 and 6 months answers|questionnaire answers after first training and after re-training on shoulder dystocia model
89637151|NCT06305949|Experimental|Optimized transcranial Direct Current Stimulation|Patients receive optimized stimulation obtained from an individualized T1 MRI-based simulation of transcranial direct current stimulation for 30 minutes, once a day for 4 weeks, for a total of 20 sessions.
89042212|NCT05914961||Control Group|Chemotherapy without immunotherapy
89042213|NCT05914961||Experimental Group|Chemotherapy in combination with immunotherapy
89637152|NCT06305949|Sham Comparator|Sham transcranial Direct Current Stimulation|Patients receive sham stimulation for 30 minutes, once a day for 4 weeks, for a total of 20 sessions.
89042214|NCT05909683|Sham Comparator|Standard-of-care|These patients will receive antibiotics according to standard practice of the attending physicians. The central lab will feedback to attending physicians and investigators the results of the conventional blood cultures and AST according to the routine SOP. The attending physicians and investigators will be allowed to decide for any change of antimicrobial treatment based on the results of conventional blood cultures provided to them by the central lab or any other culture provided to them by their hospital. Antibiotics will be stopped according to the local standard practice. BCID2, Reveal Rapid AST and PCT will be performed in the samples of these patients, attending physicians will not be provided such information.
89637153|NCT06305923|Placebo Comparator|placebo cream|everyday using of placebo cream
89637154|NCT06305923|Active Comparator|colostrum cream|everyday using of colostrum cream
89637155|NCT06305910|Experimental|CD200AR-L|"Up to 3 dose levels (2.0, 3.75, and 5.0 micrograms/kg/dose) of CD200AR-L will be tested with a Dose Level -1 (1.0 microgram/kg/dose) in the event of toxicity at the 2.0 micrograms/kg/dose level. This will be given with fixed doses of 1mg GBM6-AD vaccine and topical imiquimod. A single dose of 300cGy re-irradiation will be given on Day 15. Patients with DMG/DIPG must have completed standard-of-care radiation before enrolling.~The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort. This study will first enroll patients ≥ 12 years of age into Dose Level 1 in order to acquire safety data prior to subsequent enrollment of study subjects aged 2-11 years."
89637156|NCT06305897|Experimental|Condition 1:|Sequence of cryogenic gas (EC14_4osc)
89637157|NCT06305897|Experimental|Condition 2:|Sequence of cryogenic gas (EC+05_1osc)
89637158|NCT06305897|Experimental|Condition 3:|Sequence of cryogenic gas (EC+05_2osc)
89637159|NCT06305884|Experimental|Diagnostic (BI, PPG)|"Participants undergo BIA and wear watch-like sensors and undergo PPG at rest and while active (pedaling an exercise bike) on study."
89637160|NCT06305871|Experimental|Ablation group|Patients with hyperthyroidism undergoing ultrasound-guided ablation
89637161|NCT06305858|Experimental|Partial denture surgical procedure|
89637162|NCT06305858|Active Comparator|Total denture surgical procedure with patellar resurfacing|
89637163|NCT06305845|Experimental|Digital crowns|"Crowns that are fabricated digitally by mean of CAD-CAM technology will be placed after preparation.~For tooth preparation, occlusal reduction was done by 1.5-2 mm. The proximal contacts will be opened and the entire clinical crown structure will be reduced by 0.8-1.0 mm , followed by a subgingival finish line . The resulting preparation was slightly converging occlusally.~Upper and lower arches will be scanned with intra oral scanner. A third scan of the occlusal bite is then performed in order to establish the patient's occlusion.~For The milling procedure, Brilliant Crios composite blocks will be used and milled with the CEREC MC X milling unit .~After the completion of the milling procedure, the inner surface of the crown was sandblasted with Al2O3 at two bar pressure followed by etching with 5% hydrofluoric acid for 60 seconds and then placed in an ultrasonic bath for 5 minutes."
89637164|NCT06305845|Active Comparator|Zirconia crowns|"Prefabricated zirconia crowns that are ready made and supplied in kits with their try-ins will be used in this arm.~Occlusal reduction of 1.5-2mm will be performed by a football diamond bur. The whole crown will be reduced by 0.8-1.0 mm by means of a tapered diamond stone . A shoulder finish line will be created. The try in crown will be tested. Then the shoulder finish line will be removed and the preparation will be extended subgingivally to feather-edge."
89637165|NCT06305832|Experimental|Rezvilutamide +ADT+ SRT|Rezvilutamide along with ADT for 6 cycles (28 days for each cycle) in combination with salvage radiation therapy (SRT) according to standard of care
89637166|NCT06305832|Other|ADT+ SRT|ADT for 6 cycles (28 days for each cycle) in combination with salvage radiation therapy (SRT) according to standard of care
89637167|NCT06305819|Experimental|Intervention|Participants assigned to intervention arm will receive the self-management support program. The program consists of 2.5-hour sessions and is delivered to groups of 5-7 participants. The intervention is provided over a period of eight weeks with one session per week and is delivered by a multidisciplinary team. A tele-health version of the intervention will be offered to those who prefer to participate via electronic devices.
89688545|NCT02798380|Experimental|HTS-519 Insert|Active treatment
89688546|NCT04377815||General Public cohort|General Public
89688547|NCT04377815||Hospital cohort|Medical records of patients hospitalised due to COVID-19
89057585|NCT04532138|Active Comparator|C-MAC Video laryngoscope awake intubation|In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using Videolaryngoscope (C-MAC) with Hyperangulated blade (D-blade) Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied.
89057586|NCT04532138|Experimental|VS-CMAC Rigid Fiberoptic Stylet awake intubation|"In this group, patients with severe predicted difficult airways scheduled for elective surgery receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.~Spontaneous breathing will be preserved in both groups of patients enrolled and the same protocol of sedation plus upper airways topical anesthesia will be applied."
89637168|NCT06305819|Active Comparator|Control|Participants assigned to the control group will receive the usual health and rehabilitation services provided in the municipality or other rehabilitation settings. These services will potentially vary greatly from no services to specialized or local rehabilitation teams. All services received by participants in the control group will be registered at the follow-ups.
89637169|NCT06305741|Experimental|Latino caregivers and the Latino older adults with cancer (OACs)|The intervention, MAC, is a seven-session (45- 60 minutes per session) psychotherapy intervention delivered via videoconference and/or telephone by licensed social workers. All sessions will be audio-recorded. MAC content, structure, and length are consistent with core components of cognitive behavioral therapy (CBT) (Freeman, 2004).
89637170|NCT06305728||High Risk Pancreatic Cystic Neoplasm|Participants will be diagnosed with a pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection
89637171|NCT06305715|Experimental|Radiation therapy followed by mutation-matched TKI treatment|Part 1 will enroll subjects who will be given radiation doses at the discretion of the treating physicians. Subjects with actionable driver mutation will continue to Part 2 and receive a standard-of-care TKI at the discretion of the treating oncologist.
89637172|NCT06305689|Active Comparator|Serial Casting|Repeated casts weekly until desired dorsiflexion range achieved
89637173|NCT06305689|Active Comparator|Surgery|Surgical procedure to the gastrocnemius and/or plantar fascia
89637174|NCT06305663|Experimental|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)|
89637175|NCT06305663|Active Comparator|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens|
89637176|NCT06305650|Experimental|Probiotic group|10 billion CFU/bag/day BBr60, before meals; Storage: Sealed, protected from light, placed in a cool and dry place.
89637177|NCT06305650|Placebo Comparator|Placebo group|Maltodextrin, one bag/day, before meals; Storage: Sealed, protected from light, placed in a cool and dry place.
89637178|NCT06305637|Experimental|Ketoconazole Shampoo, 2%|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
89637179|NCT06305637|Active Comparator|Ketoconazole Shampoo, 2% (Reference Standard)|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
89637180|NCT06305637|Placebo Comparator|Placebo Control|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
89637181|NCT06305598|Experimental|Treatment (Bipolar androgen therapy)|Patients receive testosterone IM on day 1 of each cycle. Cycles repeat every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also continue to receive standard of care leuprolide acetate SC per their standard schedule. Patients undergo CT scan, bone scan and may undergo MRI and tumor biopsy throughout the study.
89637182|NCT06305585|Experimental|Primal Reflex Release Technique|"The subject will lay on their back with their eyes closed. Palmar Reflex Release The subject will actively raise arms overhead (palm facing the floor) with a pen squeezed between their fingers.~Epicranial Release The clinician will grasp the subject's hair near the front of the hairline with one hand, just above the ear on the right side and gently pull.~Frontalis Release The clinician will instruct the subject to raise their eyebrows and keep them raised. The clinician will use their thumbs to gently flick downward on the inside portion of the subject's eyebrows.~Orbicularis Oculi Release The clinician will place their thumb below the eye resting on the cheek bone and with the other hand will lightly rest on the subject's eyelid The clinician will then gently and lightly attempt to quickly open the subject's eyelids~Suboccipital Release The participant will rest their head in clinicians hands while they provide a slight traction at the base of the skull"
89637183|NCT06305585|No Intervention|Control|For the control, the subject will watch another 5-minute video of fish in an aquarium.
89637184|NCT06305572||QFR group|Patients suspected with coronary artery disease undergoing diagnostic coronary angiography with an indication for to perform invasive FFR
89637185|NCT06305559|Experimental|Obicetrapib/Ezetimibe|obicetrapib 10 mg + ezetimibe 10 mg FDC daily
89637186|NCT06305559|Placebo Comparator|Placebo|Placebo on top of baseline lipid modifying therapy
89637187|NCT06305533|Other|Control|Root surface debridement only
89637188|NCT06305533|Active Comparator|Test group 1 (Biolase group)|Root surface debridement and laser disinfection, the diode Laser (Bolas) will be used to disinfect the inner layer of the pockets and thus reducing the microbial load.
89637189|NCT06305533|Active Comparator|Test group 2 (Quicklase group)|Root surface debridement and photodynamic therapy using a Indocyanine green photosensitizer activated with diode laser (Quicklase)
89637190|NCT06305481|Other|Imaging Device|Various scans will be captured
89637191|NCT06305195||Non-diabetic individuals|adults (18-70 Years) with glycated hemoglobin (HBA1C) <5.7 and/or Fasting blood glucose <100 mg/L and with no classic symptoms of hyperglycemia
89637192|NCT06305195||Pre-diabetic:|"adults (18-70 Years) who fulfil one of the American Diabetes Association (ADA) criteria :~glycated hemoglobin (HBA1C) =5.7-6.4%~Fasting blood glucose 100 mg/dL to 125 mg/dL. Fasting is deﬁned as no caloric intake for at least 8 hours."
89637193|NCT06305195||Diabetic patients :|"adults (18-70 Years) who fulfil one of the American Diabetes Association (ADA) criteria:~glycated hemoglobin (HBA1C) ≥6.5%~Fasting blood glucose ≥126 mg/dL.~A random plasma glucose ≥200 mg/dL. Random is any time of the day without regard to the meals."
89637194|NCT06305143|Experimental|intravitreal Conbercept|Participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.
89637195|NCT06304545|Experimental|Chemoradiotherapy combined with immunotherapy for early rectal cancer.|Radiotherapy and Chemotherapy combined with Camrelizumab
89637196|NCT06304012|Experimental|Intermittent Oro-esophageal Tube Feeding+Rehabilitation therapy|Both groups of patients were provided with routine treatments. Based on this, the patients were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
89637197|NCT06304012|Active Comparator|Nasogastric tube feeding+Rehabilitation therapy|Both groups of patients were provided with routine treatments The group was provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline
89637198|NCT06303999|Active Comparator|Nasogastric tube|The group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements.
89637199|NCT06303999|Experimental|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups
89637200|NCT06303973|Experimental|IOE group|IOE groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
89637201|NCT06303973|Active Comparator|PNG group|PNG groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
89637202|NCT06303934|Experimental|systemic therapy+Intermittent Oro-Esophageal Tube Feeding|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
89637203|NCT06303934|Active Comparator|systemic therapy+Persistent Nasogastric Tube Feeding|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.
89637204|NCT06303817|Other|Double knots group|The edge of the fascia was determined with a Kocher clamp. The fascia was closed starting from the opposite side with a synthetic absorbable multifilament suture in a continuous fashion up to the Kocher clamp and tied the knots with the same single suture.
89637205|NCT06303817|Other|Triple knots group|The edge of the fascia was fixed with the same suture material instead of the Kocher clamp, and the fascia was closed similarly, starting from the opposite corner via the second loop. Then the loops from the first suture were tied to the second suture.
89042215|NCT05909683|Experimental|MODIFY strategy|These patients will start antibiotics according to standard practice of the attending physicians. It is anticipated that attending physicians will be informed in maximum 5 hours after randomization about the results of BCID2 including carriage of resistance genes and of the Reveal Rapid AST in the case of Gram-negative isolates. Physicians and investigators receiving this information are obliged to change the empirically prescribed antibiotics according to the rule provided in Box 1. The attending physicians and investigators will be allowed to decide for any change of antimicrobial treatment based on the results of conventional blood cultures provided to them by the central lab or any other culture provided to them by their hospital. PCT will be measured on day 1 and then daily starting from day 5. Attending physicians will be advised to discontinue antimicrobials on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml.
89042216|NCT05909371|Experimental|Classical physiotheraphy|The Program Applied to the Classical Physiotherapy Group The Warm-Up The postural exercises Short Breathing exercises Strengthening exercises Don't sit up Daily Balance exercises Walking exercises Pre-cooling exercise An individual-specific standardized exercise program suitable for clinical characteristics will be applied to patients with a maximum of 1 set of 8-12 repetitions for 30-45 minutes for each exercise (Modified Borg scale 4-6 or maximum heart rate 60-70%).
89057587|NCT01178125|Experimental|DR-102|desogestrel/ethinyl estradiol 0.15/0.02 mg for 21 days then ethinyl estradiol 0.01 mg for 7 days
89057588|NCT01649778||Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
89637206|NCT06303791|Experimental|Digital Psychosocial Intervention group|The intervention group will be made up of five successive groups of 8 to 10 families that will receive 12 weekly 90-minute sessions in a synchronous virtual mode by zoom platform The integrity of the sessions will be guaranteed by a digital manual that clearly outlined all the procedures to be used in the intervention. Additionally, sessions will be audiotaped and reviewed by a team member through a checklist to ensure groups receive equivalent set of information.
89637207|NCT06303791|No Intervention|Control group|The control group of parents will be made up of another five successive groups of 8 to 10 families who will receive 12 sessions weekly 90 minutes. In these sessions these families will be encouraged to discuss their thoughts and share their experiences in a non-directive environment. The therapist will not be allowed to provide specific psychotherapy, psychoeducation or psychosocial techniques, nor any additional comments or information, but rather to guide the groups and allow everyone to express and give their personal point of view. The use of an active control group will ensure that the observed benefits are primarily due to the digitally supported psychosocial program only.
89637208|NCT06302686|Experimental|engAGE group|The experimental group will use the technological engAGE system for 6 months.
89637209|NCT06302686|Other|control group|To the control group will be given a booklet containing information and activities on well-being to do at home.
89637210|NCT06302257|Active Comparator|lidocaine alone|Bolus: 20mL MLAC% of lidocaine, administered as incremental test dose over 5 minutes; as in all routine epidurals by our hospital protocol, the incremental test dose is preferred to using classical surgical test doses (which expose the patient to excessive local anesthetic concentrations).
89637211|NCT06302257|Experimental|Chlorprocaine only|Bolus: 20mL MLAC% of chlorprocaine, administered as incremental test dose over 5 minutes; as above, no other test doses are used.
89637212|NCT06302257|Experimental|Lidocaine-chlorprocaine combination|Bolus: 10mL MLAC% of lidocaine plus 10mL MLAC% of chlorprocaine, mixed in a 20mL syringe, administered as incremental test dose over 5 minutes; as above, no other test doses are used.
89637213|NCT06302075|Experimental|One Day Rehabilitation|discharged home the day after the operation (24 hours) and carrying out outpatient rehabilitation according to the clinical standard
89637214|NCT06302075|Active Comparator|Fast Rehabilitation|discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
89637215|NCT06301126|Experimental|Virtual reality|Participants will receive VR for 20 minutes followed by conventional physical therapy program for 45 minutes, 5 days/ week for 8 weeks.
89637216|NCT06301126|Active Comparator|Control|Participants will receive conventional physical therapy program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
89637217|NCT06300658|Experimental|Stellate ganglion blockade|Patient will receive preemptive stellate ganglion blockade (SGB) just before spinal anesthesia.
89637218|NCT06300658|No Intervention|Control group|Patient will not receive preemptive stellate ganglion blockade (SGB).
89637219|NCT06300632||older adults|older adults Geriatric Locomotive Function Scale Tampa Kinesiophobia Scale Physical Activity Scale for the Elderly (PASE) Brief Physical Performance Battery Fatigue Severity Scale Montreal Cognitive Assessment Scale (MoCA)
89637220|NCT06300437|Experimental|Group jaw thrust|will include the children who will receive jaw thrusting during fiberoptic intubation.
89637221|NCT06300437|Active Comparator|Group control|will include the children who will not receive jaw thrusting (just sub laxed open mouth)
89637222|NCT06300190|Other|Biceps tenodesis alone|
89637223|NCT06300190|Other|Biceps tenodesis and repair labrum|
89637224|NCT06300112|Experimental|Experimental group|Yoga
89637225|NCT06300112|No Intervention|Control group|No Intervention
89637226|NCT06299449|Experimental|control group|conventional socket shield with conventional simultaneous implant placement
89637227|NCT06299449|Experimental|study group|computer guided implant placement combined with artificial intelligence-assisted socket shield.
89637228|NCT06299397|Experimental|Breastfeeding-Humor group|32 pregnant women were included in the experimental group determined by randomization method. Consent to participate in the study was obtained from these pregnant women. After obtaining consent, a pre-test was conducted. Afterwards, pregnant women were given breastfeeding education and humor practice. The application was applied once a week, twice a week. An interim test was administered 1 month after the application, and a final test was administered 3 months later.
89637229|NCT06299397|Sham Comparator|Control Group|After randomization, consent was obtained from the pregnant women determined that they agreed to participate in the study. The pregnant women in the control group were given a pre-test before starting the study, an interim test 1 month after the start, and a final test 3 months later.
89637230|NCT06299059|Experimental|the observation group|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups
89637231|NCT06299059|Active Comparator|the control group|the control group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements.
89637232|NCT06298617||Study group|
89637233|NCT06298253|Experimental|Behavioral economics-enhanced SWAP implementation strategy|Pantries assigned to the intervention group will receive behavioral nudges for implementing the SWAP nutrition program. These include: 1) invoice labeling with the food labeled as red, yellow, or green; 2) receipt of the SWAP toolkit at no cost; 3) pantry learning communities; 4)incentives to purchase SWAP implementation materials (e.g., shelves); 5) food bank recognition for SWAP implementation.
89637234|NCT06298253|Active Comparator|Basic SWAP implementation strategy|Pantries assigned to the control arm will receive email communication from the food bank dietitian providing them with information about SWAP, online links to SWAP implementation guides, and encouragement to purchase SWAP Toolkits on their own.
88991072|NCT05796869|Experimental|Experimental Group|All young women with a Premenstrual Syndrome Scale total score of 110 and above will be included in the study. Since all women who have a Premenstrual Syndrome Diagnostic Scale of 110 and above, volunteer to participate in the study and meet the inclusion criteria will be included in the study, no additional sample selection will be made. The application and control group will be determined on random.org among the group that constitutes the sample of the study. Laughter therapy sessions will be administered face to face to the application group once a week for 2 months by a researcher with a laughter therapy certificate. At the end of two months, the Personal Information Form, Premenstrual Syndrome Scale, and the Food Craving Scale will be administered again to both the application group and the control group.
88991073|NCT05794334|Experimental|Low Dye Taping|: There were 20 patients in group A which received the low dye taping technique. Low-dye is a classic taping method to reduces strain from plantar fascia and provide medial ankle arch support. If properly applied, reduces subtalar joint motion, pain, excessive pronation. Hence, it can be used in the treatment of ankle and foot.
89637235|NCT06295445|Experimental|Group A: Control group|About 54 patients that will undergo treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management.
89637236|NCT06295445|Experimental|Group B: Study group|About 54 patients that will undergo cardio-pulmonary ultrasound guided management.
89637237|NCT06288854|Experimental|Olanzapine|Olanzapine 5 mg oral OD
89637238|NCT06288854|Placebo Comparator|Placebo|Placebo
89637239|NCT06288685|Experimental|group1|percutaneous A1 pulley release with Triamcinolone injection
89637240|NCT06288685|Active Comparator|group0|percutaneous A1 pulley release alone
89637241|NCT06287086|Experimental|BRL-101|BRL-101 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the BCL11A gene. Subjects will receive a single infusion of BRL-101.
89637242|NCT06286358||Interventional treatment|Patients with severe aortic valve disease or thoracic aortic aneurysm in whom interventional treatment has been previously decided by the Heart Team (i.e. the multidisciplinary team of cardiologists and cardiac surgeons treating the patient, independently of the research team). The KCG measurements consecutive to the echocardiography and/or cardiac MRI will be carried out during the pre-operative assessment and post-operative assessment in Erasme hospital.
89637243|NCT06286358||Aortic valve disease of different severities|Patients with aortic stenosis and/or aortic regurgitation and/or bicuspidy of different severities. The KCG measurements consecutive to the echocardiography and/or cardiac MRI will be carried out during their clinical management in Erasme hospital.
89637244|NCT06286358||Control|Subjects matched to the two other groups according to their age, gender, body surface area and left ventricular ejection fraction (LVEF), without AVD or TAA. The KCG measurements will be made immediately after the echocardiography and/or MRI in Erasme hospital.
89637245|NCT06283966|Experimental|BGF arm|BGF MDI 320/14.4/9.6 μg BID
89637246|NCT06283966|Experimental|GFF arm|GFF MDI 14.4/9.6 μg BID
89637247|NCT06280352|Experimental|Custom made Total Knee Arthroplasty|Implant used is a patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
89637248|NCT06280352|Active Comparator|Functionally aligned robotically assisted total knee arthroplasty|Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker)
89637249|NCT06280066|Experimental|Children Intervention Group|Intervention Program Based on Strengthening Psychological Resilience for Children with Cystic Fibrosis and Their Mothers. The program will be implemented for 10 weeks, with a total of 10 sessions, 1 session per week (each session consists of 2 sessions).
88991074|NCT05794334|Experimental|Robert Debre Method|This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.
88991075|NCT05792332|Experimental|Telemonitoring|Patients are followed up by a nurse-telemonitoring
88991076|NCT05792332|Active Comparator|Standard-of-care|Patients are followed up only by the neurologist
88991077|NCT05792085|Active Comparator|Telehealth Model|Patient enrolled in the GDMT Telehealth HF improvement program in which hone BP cuff is provided and medication is initiated and titrated over the phone
88991078|NCT05792085|No Intervention|Control|Usual care, control group
88991079|NCT05787730|Other|Patients operated with TOT|The study is a retrospective cohort study. Between 2005 and 2008, a total of 54 patients were examined with ultrasound before and after TOT surgery. The collected data has not been previously published. Now these same patients are to be examined again with a more advanced ultrasound device.
88991080|NCT05787223|Active Comparator|Control Group|
88991081|NCT05787223|Experimental|Experimental Group|
88991082|NCT05787210|Active Comparator|Control group|
88991083|NCT05787210|Experimental|Strength|
88991084|NCT05784805|Experimental|Participants with ongoing non-convulsive or focal motor SE|Adult patients with ongoing non-convulsive or focal motor SE despite treatment with at least 2 ASMs and who are monitored with surface EEG will be screened and enrolled to receive up to 2 sessions of PLIFU.
88991085|NCT05783206|Experimental|MIR 19 ®|"MIR 19 ® was used in a single dose of 1.85 mg for 3 inhalations per day at intervals of 6-7 hours for 7 days in addition to standard therapy without use of any etiotropic drugs.~Standard therapy included:~- paracetamol - 1-2 tablets (500-1000 mg) 2-3 times a day (if body temperature ≥38.0°)"
88991086|NCT05783206|Active Comparator|Standard therapy|"Standard therapy included:~umifenovir (Arbidol®) - 200 mg 4 times per day for 7 days~interferon-α, intranasal forms (Grippferon®),spray - in accordance with the instructions.~paracetamol - 1-2 tablets (500-1000 mg) 2-3 times a day (if body temperature ≥38.0°)"
88991087|NCT05780918|Experimental|Best Case/Worst Case-ICU Communication Tool|Patients in the intervention group will receive care from a trauma team that routinely uses the Best Case/Worst Case-ICU communication tool.
88991088|NCT05780918|No Intervention|Usual Care|"Prior to implementation of the intervention, patients admitted to the trauma ICU will receive usual care. Usual care typically includes conversations focused on isolated problems, disarticulated from the patient's overall health trajectory. This is typified by the systems-base review, routinely summarizing each patient on rounds where the clinician lists each physiologic system, (e.g., neuro, cardiac, pulmonary…) with an assessment and plan to fix each abnormality with a new treatment. Deliberation about how these individual treatments align with patient preferences is typically prompted by major events like failure to liberate from a ventilator or imminent death. This pattern of usual care is well characterized and differs from daily scenario planning with the Best Case/Worst Case-ICU communication tool."
89637250|NCT06280066|Experimental|Mothers Intervention Group|Intervention Program Based on Strengthening Psychological Resilience for Children with Cystic Fibrosis and Their Mothers. The program will be implemented for 10 weeks, with a total of 10 sessions, 1 session per week (each session consists of 2 sessions).
89637251|NCT06280066|No Intervention|Children Controlled Group|No intervention.
89637252|NCT06280066|No Intervention|Mothers Controlled Group|No intervention.
89637253|NCT06269887||Male|Hand preference was evaluated with the Edinburgh Hand Preference Questionnaire, grip muscle strength with the Jamar dynamometer, dexterity with the Purdue Pegboard Test, and proprioception as joint position sense with the inclinometer.
89637254|NCT06269887||Female|Hand preference was evaluated with the Edinburgh Hand Preference Questionnaire, grip muscle strength with the Jamar dynamometer, dexterity with the Purdue Pegboard Test, and proprioception as joint position sense with the inclinometer.
89637255|NCT06267963|Experimental|Cohort 1|Participants will receive one dose of [14C] PF-07220060 by mouth
89637256|NCT06267963|Experimental|Cohort 2|Participants will take one dose of PF-07220060 by mouth and one dose as an IV (intravenous) infusion of [14C] PF-07220060.
89637257|NCT06267638|Experimental|ketamine group|Participant will receive intraoperative ketamine during total knee arthroplasty by Ketamine 0.5mg /kg loading then 0.25 mg/kg/hours until end of surgery
89637258|NCT06267638|Placebo Comparator|Placebo group|Participant will receive intraoperative normal saline during total knee arthroplasty
89637259|NCT06263842|Experimental|Immediate Implant Placement Using Socket Shield Technique alone|after insertion of immediate implant Using Socket Shield Technique, the bone defect between the socket shield and the implant fixture will be left ungrafted
89637260|NCT06263842|Experimental|Immediate Implant Placement Using Socket Shield Technique with xenograft|the shield/fixture jumping gap will be grafted with xenograft
88991089|NCT05780281|Experimental|VIR-7831 plus SOC|"VIR-7831 500 mg solution (2 vials of 250 mg); administered as a single IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
88991090|NCT05780281|Placebo Comparator|Placebo plus SOC|"Placebo administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
88991091|NCT05780268|Experimental|LY3819253 plus SOC|"LY3819253 7000 mg solution (10 vials of 20 mL solution containing 700 mg each); administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
88991092|NCT05780268|Placebo Comparator|Placebo plus SOC|"Placebo administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
88991093|NCT05772962||Children enrolled at CAC|Information regarding oral health will be gathered from the public dental health records of children enrolled at CAC.
88991094|NCT05772962||Children not enrolled at CAC|Information regarding oral health will be gathered from the public dental health records of children that have not been enrolled at CAC. This is a control group, matched by age and gender.
88991095|NCT05766007||Risperidone|Pregnant or breastfeeding women receiving the long acting injectable form of Risperidone and their babies
88991096|NCT05766007||Paliperidone palmitate|Pregnant or breastfeeding women receiving Paliperidone palmitate and their babies
88991097|NCT05766007||Flupentixol decanoate|Pregnant or breastfeeding women receiving the Flupentixol decanoate and their babies
88991098|NCT05766007||Zuclopenthixol decanoate|Pregnant or breastfeeding women receiving the Zuclopenthixol decanoate and their babies
88991099|NCT05766007||Fluphenazine decanoate|Pregnant or breastfeeding women receiving the Fluphenazine decanoate and their babies
88991100|NCT05761353|Experimental|Group A (endermologie group)|This group includes 34 patients who will receive 30 min Endermologie 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks.
89212044|NCT05302895||single-group|The health monitoring data of all the resident participants are measured using traditional device and the all-in-one health monitoring device on the same day for 12 weeks
89637261|NCT06263842|Experimental|Modified Elamrousy Approach for Immediate Implant Placement Using Socket Shield Technique|Immediate Implant Placement Using Socket Shield Technique with autogenous whole tooth graft after immediate implantation using Socket Shield Technique, the palatal root portion and the decoronated crown will be converted to autogenous whole tooth graft and used for grafting the defect between the socket shield and the implant fixture
89637262|NCT06261125|Experimental|Arm A|This arm includes the patients who previously had not received PD-1/PD-L1 antibody. Patients assigned to this arm will receive SBRT followed by adebrelimab and lenvatinib. The prescribed dose of SBRT is 33-48 Gy in 6 fractions over 2 weeks. Then all patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg) orally once daily in combination with adebrelimab 1200 mg every 3 weeks for up to 35 cycles. The first course of adebrelimab will be given within 1 week after completion of SBRT.
88991101|NCT05761353|Experimental|Group B (Negative pressure therapy group)|This group includes34 patients who will receive 30min negative pressure therapy 3 times per week in addition to their physical therapy program (active range of motion and elevation); hygiene and skin care for 6 weeks
89057589|NCT04532333|Experimental|Bivalirudin|Bivalirudin at full dose Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
89212045|NCT03951233||K-RAS and EGFR mutated|
89212046|NCT03951233||Wild type|
88991102|NCT05758688|Experimental|Adjuvant Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)|The study intervention is Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) as part of the definitive treatment of gynecologic cancers in the post-hysterectomy, adjuvant setting. Patients will be treated with doses of 45 or 50.4 Gy in 1.8 Gy daily fractions. The volume treated will include the whole pelvis according to Radiation Therapy Oncology Group post-hysterectomy pelvis guidelines.
89637263|NCT06261125|Experimental|Arm B|This arm includes the patients who had progressed after receiving PD-1/PD-L1 antibody. Patients assigned to this arm will receive SBRT followed by adebrelimab and lenvatinib. The prescribed dose of SBRT is 33-48 Gy in 6 fractions over 2 weeks. Then all patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg) orally once daily in combination with adebrelimab 1200 mg every 3 weeks for up to 35 cycles. The first course of adebrelimab will be given within 1 week after completion of SBRT.
89637264|NCT06258187|Experimental|Pedi-Cap|A Pedi-Cap will be connected to the T-piece resuscitator in between the T-piece and face mask. With effective gas exchange, carbon dioxide (CO2) is detected by the Pedi-cap and will demonstrate gold color change with each exhalation. If there is no CO2 gas exchanged, the Pedi-Cap color will remain purple. The color change will be used as one of the tools for the resuscitation team to determine if the infant has effective non-invasive positive pressure ventilation (PPV) during delivery room resuscitation. Other ways, in addition to the Pedi-Cap, to determine effective PPV include a rise in heart rate, improved infant color, chest rise, and improvement in oxygen saturation.
89637265|NCT06258187|No Intervention|No Pedi-Cap|There will be no Pedi-Cap attached to the t-piece resuscitator. Effective non-invasive positive pressure ventilation (PPV) during delivery room resuscitation will be assessed by a rise in heart rate, improved infant color, chest rise, and improvement in oxygen saturation.
89637266|NCT06254846|Other|Primary screening for UCC|Women aged between 30 and 65 who are candidates for primary screening for UCC will be included.
89637267|NCT06251128|Experimental|Self-management|This group of participants will be given education and will be taught about overcoming the barriers to a healthy lifestyle and medication adherence. No drugs or devices will be administered to the participants/
89637268|NCT06241950|Experimental|Delandistrogene Moxeparvovec after Imlifidase Infusion|Participants may receive 1 or 2 doses of imlifidase, depending on rAAVrh74 antibody titer results. Then, based on their rAAVrh74 antibody titer, eligible participants may receive 1 dose of delandistrogene moxeparvovec infusion.
89637269|NCT06238635|Experimental|Cohort A: Immunotherapy Naive|"10 Participants will complete study procedures as follows:~Baseline visit.~Imaging tests at baseline visit, at week 9, and then every 12 weeks.~Cycle 1 through End of Treatment (up to 2 years of treatment):~• Day 1 of 21 Day cycle: Dostarlimab 1x daily and Cobolimab 1x daily.~End of Treatment visit with blood tests and imaging tests.~Follow Up Period: Every 3 months for 2 years and then every 6 months for an additional 5 years. Includes imaging tests.~If >= 2 participants with objective responses, then 19 additional participants will be enrolled."
89688548|NCT04355065|Experimental|Cognitive Training with Virtual Reality Videogame|"The Secret trail of mon is a therapeutic video game that has been created for the cognitive training of patients with ADHD.~Five mechanisms have been designed to work on five cognitive functions that are deficient in ADHD: attention, memory, reasoning, planning and visuospatial ability.~Patients have to go to the hospital once a week for training sessions of approximately forty minutes duration during 12 weeks."
88991103|NCT05753735|Active Comparator|Standard perioperative antibiotics|The control group will be treated according to current standard perioperative antibiotic practice, and perioperative antibiotics will not exceed 24 hours postoperatively.
88991104|NCT05753735|Experimental|Extended antibiotic prophylaxis|The intervention group will receive an extended duration of current standard perioperative antibiotics, then converted to amoxicillin/clavulanic at discharge
88991105|NCT05752864|Experimental|spine manual therapy of sacroiliac joint|The group which treats spine manual therapy of sacroiliac joint
88991106|NCT05752864|Active Comparator|Superficial heat therapy|Group treated with superficial heat therapy for 20 minutes
88991107|NCT05751070|Active Comparator|Bowen Technique|BOWEN TECHNIQUE Hot pack TENS Cervical isometrics
88991108|NCT05751070|Experimental|Graston technique|GRASTON TECHNIQUE Hot pack TENS Cervical isometrics
88991110|NCT05747183|Experimental|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
88991111|NCT05747183|Active Comparator|ProTaper Gold files|Root canal preparation using ProTaper Gold files.
88991112|NCT05746390|Experimental|Home Alone Intervention|"Home Alone is a semi-structured intervention, tailored to address the individual needs and concerns of the older adult. The participant will engage in about seven psychoeducational coaching sessions, each lasting approximately one hour.~The intervention has two key foci:~increasing or maintaining home safety and comfort~increasing scheduled social engagements and activities.~Sessions are also designed to identify formal and informal services and supports to improve to increase assistance and ability to live independently for as long as safely possible. The sessions take place either in-person or remotely (via secure video conferencing or telephone). Ad hoc/ongoing sessions may be provided as needed."
88991113|NCT05741840|Experimental|PBT-A|PBT-A includes the elements of family based behavioral treatment for children with obesity, delivered exclusively to a parent via telehealth.
88991114|NCT05741840|Active Comparator|Health Education|This program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress delivered exclusively to a parent via telehealth.
88991115|NCT05740254|Experimental|Early Time Restricted Eating|early-day TRE (7:00 to 15:00 h)
89057590|NCT04532333|Active Comparator|Heparin|Heparin first dose at 0.6mg/kg(75U/kg) Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
88991116|NCT05740254|Experimental|Late Time Restricted Eating|late TRE (12:00 to 20:00 h)
88991117|NCT05738096|Experimental|TGN patients|Patients with TGN who will undergo rhizotomy surgery as the standard of care
88991118|NCT05738096|Active Comparator|Healthy volunteers|Healthy volunteers for whom TSEPS will be recorded in a lab setting
89057591|NCT01649817||Cohort|
89057592|NCT04538183|Experimental|WO 5000|Body lotion pH 4 for topical application
89057593|NCT04538183|Experimental|WO 5001|Body lotion pH 5.8 for topical application
88991119|NCT05736133|Experimental|Physiotherapist-led primary care model for hip and knee pain|The index intervention will incorporate a PT within the primary care team and make them available at the first point of contact for people with hip or knee pain. There will be 4 key components of this intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need (e.g., no insurance coverage for PT).
88991120|NCT05736133|Active Comparator|Usual physician-led primary care model for hip and knee pain|Participants will be seen by a primary care physician or a nurse practitioner, depending on the current practice at the clinic. Participants in both groups will be permitted to seek additional care outside of the primary care clinic.
88991121|NCT05731817||COVID-19 patients|COVID-19 patients
88991122|NCT05726344|Experimental|Lactulose group|"Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed.~The day before the study, the group receiving lactulose shall take 4 tablets of Bisacodyl (5 mg) the day before the study at 6pm. Then, at 8pm a bottle of 250 mL (162.5g lactulose) of lactulose shall be dissolved in 600 mL of water and all contents (850 mL) shall be taken in 2 hours. At 10pm they have to drink 2 liters still water."
88991123|NCT05726344|Experimental|Polyethylene glycol group|"Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed.~The day before the study, the group receiving polyethylene glycol (PEG) should take 4 tablets of Bisacodyl (5 mg) at 4pm. Then, at 6pm, 3 bottles of PEG (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) shall be dissolved in 3 liters of water (1 bottle per liter) and they shall take half the preparation, that is 1 liter and a half in 2 hours. At 10pm they shall take the remaining contents in 2 hours."
88991124|NCT05722704|Experimental|Cryotherapy|Final irrigation with cold saline (2.5C-4C) without occlusal reduction
88991125|NCT05722704|Active Comparator|Occlusal reduction|Normal room temperature saline irrigation protocol with occlusal reduction
88991126|NCT05722704|No Intervention|Control|Normal room temperature saline irrigation protocol without occlusal reduction
88991127|NCT05721170|Active Comparator|Beta-blockers continuation|Patients assigned in the beta-blockers continuation arm will be receiving per os beta blocker medication for at least 72 hours before TAVI without interruption after it.
88991128|NCT05721170|Active Comparator|Beta-blockers interruption|Patients assigned to interrupt the beta-blockers treatment will abstain from beta blockers for at least 7 days after TAVI.
88991129|NCT05719636|Active Comparator|Conventional treatment|
88991130|NCT05719636|Experimental|Progressive resistance exercise|
89042217|NCT05909371|Experimental|Motor cognitive exercise group|"The Program to be Applied in addition to the Physiotherapy Program to the Motor-cognitive Exercise Group .Remembering the word. Color/week/month/animal names counting/// girls boy names counting/// Country City names counting.~from 50 back to 2 bad, 3 er,// counting from 50 back to 4 er//counting from 100 back to 2 bad 2 bad 3 er 3 er and simple arithmetic problems with single digits.~Counting the months of the year// Counting the months of the year starting from any month// Counting the months of the year and 30 31 days."
89042218|NCT05902962|Experimental|Single arm dose escalation study of VP-001|
89042219|NCT05900115|Experimental|Web-based intervention|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
89042220|NCT05900115|Active Comparator|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
89042221|NCT05898568|Experimental|experimental: virtual reality|In addition to routine hand care programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days, 20 minutes) virtual reality based movement therapy program will be applied.
89637270|NCT06238635|Experimental|Cohort B: Immunotherapy Exposed|"14 Participants will complete study procedures as follows:~Baseline visit.~Imaging tests at baseline visit, at week 9, and then every 12 weeks.~Cycle 1 through End of Treatment (up to 2 years of treatment):~• Day of 21 Day cycle: Predetermined dose of Dostarlimab 1x daily. Predetermined dose of Cobolimab 1x daily.~End of Treatment visit with blood tests and imaging tests.~Follow Up Period: Every 3 months for 2 years and then every 6 months for an additional 5 years. Includes imaging tests.~If >= 2 participants with objective responses, then 23 additional participants will be enrolled."
89637271|NCT06233760||Patients with rheumatic diseases|All the rheumatic diseases outpatients from the National Institute of Medical Sciences
89637272|NCT06232616|Other|Single arm|In this single-arm designed study, participants with idiopathic epiretinal membranes with macular oedema were assigned a vitrectomy with an intravitreal dexamethasone implant.
89637273|NCT06230614|Active Comparator|Colistin 1 MU in normal saline 1 ml|1 MU of colistin in a total volume of 6 ml, diluted with a 1:1 ratio in normal saline (0.9%)
89637274|NCT06230614|Experimental|Colistin 1 MU in normal saline 2 ml|1 MU of colistin in a total volume of 12 ml, diluted with a 1:2 ratio in normal saline (0.9%)
89637275|NCT06225518|Experimental|Individualized physical activity management system|The mobile application will be downloaded to the smartphones of the participants in the experimental group and the application will be introduced by the nurse at the family health center. Participants will receive daily and weekly goals with personalized physical activity recommendations, using the exercise recommendations determined by the decision system by public health nursing and physiotherapy and rehabilitation experts in the mobile application. With the initial data collected, a personalized physical activity program will be created according to each participant's lifestyle, physical activity level and physical activity barriers. The physical activity program will include a daily step count goals, exercises and stretching movements for each participant, and this program will be offered to the participants via the mobile application. The exercises that the participants are expected to complete will be shown in the application as videos with animated characters.
89637276|NCT06225518|No Intervention|Control|The mobile application will be downloaded to the smartphones of the participants in the experimental and control groups and the application will be introduced by the nurse at the family health center to which the participants are affiliated. Participants in the control group will use the mobile application only to enter and track daily step counts and other data.
89637277|NCT06222697||Post-marketing surveillance cohort|Participants follow their usual medical visits with data collection occurs continuously in a 36-week observational period.
89637278|NCT06222463|Active Comparator|low tidal volume ventilation|Flow-controlled ventilation will be established with a PEEP of 5 cmH2O, peak pressure set to achieve a tidal volume of 7 ml/kg predicted body weight and the flow set to achieve normocapnia at an I:E ration of 1:1. Three consecutive measurements of power dissipation with 15 minutes in between will be obtained. Additionally secondary outcome parameters such as respiratory parameters and results of arterial blood gas analysis will be recorded at each measurement timepoint.
89042222|NCT05898568|Active Comparator|control:routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be implemented.
89042223|NCT05891223|Experimental|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"A breath break with kindness is practiced.~Encourage them to think about how threat, impulse and sedative systems have developed in their own lives.~A safe place application is made.~Courtesy meditation is done."
89042224|NCT05891223|Experimental|Session 2: Threat and Self-Compassion|"A breath break with kindness is practiced.~Building a compassionate relationship with resilience and kindness meditation: a benevolent practices are made.~A hand on your heart and a compassionate comrade practices are made."
89042225|NCT05891223|Experimental|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"Talk about homework.~A breath break with kindness is practiced.~Establishing a compassionate relationship with desire, guided meditation to discover the inner pattern, courtesy meditation: a good friend practices are made."
89042226|NCT05891223|Experimental|Session 4: Internalizing compassion|"Pretend-to-pretend practice is made for participants to observe themselves.~In addition to the previous practices, the practice of internalizing compassion is made in order to increase their expanded mindfulness.~Courtesy meditation: a neutral person, kindness towards your body, which is based on mindfulness practices and increases body awareness and mindful movement, is carried out. During the day, they will be informed that they should do the walking with kindness practice on their own."
89042227|NCT05891223|Experimental|Session 5: Me and others - Expanding the circle|"A compassionate letter application is made by asking participants to think about a situation they encountered recently or some time ago and is still causing distress. It is explained that they can gain insight with this application.~Courtesy meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices are made."
89057594|NCT04538183|No Intervention|No product use|Untreated control area
89057595|NCT04538105|Sham Comparator|Sham Injection|20cc of Normal Saline 0.9%
89057596|NCT04538105|Experimental|Articular Branch Block (ABB)|20cc of 0.5% Bupivacaine with epinephrine 1:200,000
89637279|NCT06222463|Experimental|individualized FCV|Flow-controlled ventilation will be individualized with compliance guided PEEP and peak pressure titration. The flow will be set to achieve normocapnia at an I:E ration of 1:1. Three consecutive measurements of power dissipation with 15 minutes in between will be obtained. Additionally secondary outcome parameters such as respiratory parameters and results of arterial blood gas analysis will be recorded at each measurement timepoint.
89637280|NCT06221904|Experimental|The observation group|The observation group is the only group.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Simple Gymnastics Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 30 minutes. Each training session will be conducted approximately at 9.00 a.m. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
89637281|NCT06221176|Experimental|Intervention Group|Being Brave
89637282|NCT06219941|Experimental|Sub Study 1 - AZD0901 MONOTHERAPY|Sub Study 1 will investigate AZD0901 monotherapy in order to evaluate the safety, tolerability, and efficacy of AZD0901.
89637283|NCT06219941|Experimental|Sub Study 2 - AZD0901 IN COMBINATION WITH ANTI-CANCER AGENTS|Substudy 2 will investigate the safety and efficacy of AZD0901 as first line systemic treatment used in combination with different chemotherapy agents
89637284|NCT06218251|Experimental|BOTOX|Participants will receive injections in the glabellar complex, in each of the lateral canthal area, and in the frontalis muscle on Day 1.
89637285|NCT06217705|Experimental|Project Calm|Project Calm is a ~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.
89637286|NCT06217705|Other|Delayed Receipt of Project Calm Control Condition|No intervention for first two months; will receive Project Calm after 2-months and become a second-wave intervention condition.
89637287|NCT06207786|Experimental|Povidone Iodine nasal swab|Patients undergoing Mohs micrographic surgery (MMS) for malignant cutaneous neoplasms will receive nasal povidone-iodine swabs prior to skin reconstruction.
89637288|NCT06207786|Other|Oral antibiotic prophylaxis protocol (usual care)|Patients undergoing Mohs micrographic surgery (MMS) for malignant cutaneous neoplasms will receive standard of care, including the provision of an oral anti-staphylococcal antibiotic per the standardized Antibiotic Prophylaxis protocol currently used for clinical decision making in Dermatologic Surgery at Mayo Clinic Rochester.
89637289|NCT06207630|Active Comparator|Standard dressing group|Use dry dressing, made with sterile compresses, then a glued dressing
89637290|NCT06207630|Experimental|NPWT 3/7d dressing group|Use of a PICO® dressing
89637291|NCT06207630|Experimental|NPWT 7d dressing group|Use of a PREVENA® dressing
89637292|NCT06207435|Experimental|West Philadelphia Residents|For eligible residents of West Philadelphia, patients are contacted by Community Support Program Representative and offered free Lyft transportation to and from appointment. If patient has other questions about their upcoming appointment (location, time, etc.), Patient Navigator assists in answering questions
89637293|NCT06207435|No Intervention|Non West Philadelphia Residents|For patients outside West Philadelphia, no contact is made and no free transportation is provided. Research coordinator logs their appointment attendance after the appointment date in question.
88991131|NCT05719428|Experimental|DRUID|Patients NGS profile will be analysed with DRUID system to generate recommendations based on predicted efficacy. Patients with available archival tissue will have gene expression analysis performed to optimise DRUID recommendation. Patients will subsequently receive single agent therapy based on DRUID recommendations and criteria for therapy choice.
88991132|NCT05717153|Experimental|Arm I (MRI, resection, DFMO, AMXT 1501)|Patients undergo magnetic resonance imaging (MRI) and surgical resection at baseline. Patients receive eflornithine PO in combination with AMXT 1501 PO on days 1-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
88991133|NCT05717153|Placebo Comparator|Arm II (MRI, resection, placebo, DMFO, AMXT 1501)|Patients undergo magnetic MRI and surgical resection at baseline. Patients receive placebo PO on days 1 and 2 post-surgery, and then receive eflornithine PO and AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
88991134|NCT05717153|Active Comparator|Arm III (MRI, resection, DMFO, AMXT 1501)|Patients undergo magnetic MRI and surgical resection at baseline. Patients receive eflornithine PO alone on days 1 and 2 post-surgery, then receive eflornithine PO in combination with AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.
88991135|NCT05711381|Experimental|Severe renal impairment|
88991136|NCT05711381|Experimental|Normal renal impairment|
88991137|NCT05711381|Experimental|Moderate renal impairment|
88991138|NCT05711381|Experimental|Mild renal impairment|
88991139|NCT05702216|Other|Cardiac rehabilitation|
88991140|NCT05702216|Other|Cardiac Tele-rehabilitation|Tele cardiac rehabilitation in hybrid form
89637294|NCT06206941||Cannabis User|Cancer patients being treated with immunotherapy and using cannabis
89637295|NCT06206941||Cannabis non-user|Cancer patients being treated with immunotherapy and not using cannabis
88991141|NCT05701917|Active Comparator|Interventional|Interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm).
88991142|NCT05701917|Active Comparator|Conservative Medical Management|Conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm).
88991143|NCT05699408|Experimental|INS068 injection|
88991144|NCT05699408|Active Comparator|Insulin Glargine|
88991145|NCT05697068|Active Comparator|Standard-of-Care|Patients who test positive will receive a call from the provider who conducted the test to notify them of the test result and provide standard-of-care counseling (e.g., health education, link them to resources). Index patients are entered into a COVID-19 patient registry in the Federally Qualified Health Center's electronic health record system (which also is linked to the clinic's COVID-19 dashboard) and monitored closely, with telemedicine follow-ups provided by skilled clinical staff every two-to-three days, and in-person follow-ups provided as needed.
89057597|NCT01649895|Experimental|D-Cycloserine|D-Cycloserine, 5 pills (50mg), once per week in 5 weeks.
89637296|NCT06205875|Experimental|Intervention group|Patients in the intervention group will receive a mixture of high-dose local anesthetic and epinephrine administered via a serratus anterior plane block.
89637297|NCT06205875|Active Comparator|Control group|Patients in the control group will receive a serratus anterior plane block with a low dose local anesthetic (based upon our primary trial).
89637298|NCT06202261|Experimental|TQB2930 for injection|TQB2930 for injection,10 mg/kg, quaque week (QW), 21 day as a treatment cycle; TQB2930 for injection, 20 mg/kg, quaque 2 weeks (Q2W), 28 day as a treatment cycle; TQB2930 for injection,30 mg/kg, quaque 3 weeks (Q3W), 21 day as a treatment cycle.
89637299|NCT06202261|Experimental|TQB2930 for injection 30mg/kg + Paclitaxel for injection (albumin-bound)|TQB2930 for injection 30mg/kg combined with paclitaxel (albumin-bound) for injection, 21 days for one treatment cycle
89637300|NCT06202261|Experimental|TQB2930 for injection+TQB3616 capsule for injection + fulvestrant injection|TQB2930 for injection 20mg/kg combined with TQB3616 capsule 120mg or 150mg or 180mg, and fulvestrant injection. Q2W, 28 days a cycle.
89637301|NCT06202261|Experimental|TQB2930 for injection + chemotherapy|TQB2930 for injection 30mg/kg combined with capecitabine tablets or vinorelbine tartrate injection or eribulin mesylate injection or gemcitabine hydrochloride for injection, 21 days a cycle.
89637302|NCT06201091|Experimental|the observation group|The observation group is the only group of the participants.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of systematic simple swallowing training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 15-30 minutes. Each training session will be conducted approximately one hour prior to meals. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
89637303|NCT06194396|Active Comparator|50 neonates using alcohol|Alcohol will be used as skin disinfectant before insertion of the central venous catheter, PICC line, and umbilical venous catheter and during its routine care
89637304|NCT06194396|Experimental|50 neonates using chlorhexidine|Chlorhexidine will be used as skin disinfectant prior to insertion of the central venous catheter, PICC line, and umbilical venous catheter and during its routine care
89637305|NCT06193928||Alagille syndrome (ALGS)|"A clinically and/or genetically confirmed ALGS diagnosis~Participant prescribed Livmarli"
89637306|NCT06193161|Experimental|Therapist-guided internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure comprising psychoeducation about PTSD, controlled breathing, imaginal exposure including processing, in vivo exposure and relapse prevention. The treatment will be delivered in a digital platform for eight weeks. Participants will have access to a therapist that will guide them through treatment in a text based format.
89637307|NCT06193161|No Intervention|Waiting list|Waiting list up for eight weeks and up until the 1-month follow up.
89637308|NCT06191861|Experimental|Most hoped for future self, 3 dose|Participants complete a writing task in which they think and write about their most hoped for future self, weekly for 3 weeks (i.e., at each session).
89637309|NCT06191861|Experimental|Most hoped future self, 1 dose|Participants complete a writing task in which they think and write about their most hoped for future self one time (on the third session).
89637310|NCT06191861|Experimental|Most feared future self, 3 dose|Participants complete a writing task in which they think and write about their most feared future self, weekly for 3 weeks (i.e., at each session).
89637311|NCT06191861|Experimental|Most feared future self, 1 dose|Participants complete a writing task in which they think and write about their most feared future self one time (on the third session).
88991146|NCT05697068|Experimental|Enhanced Standard-of-Care|In addition to the aforementioned standard-of-care actions, index patients in the enhanced standard-of-care group will receive tailored phone/mobile counseling (motivational interviewing) focused on implementing strategies to prevent immediate household spread of COVID-19, followed by weekly text messaging for a total of 6 weeks.
88991147|NCT05685290|Experimental|Intervention group|Pushing with saline technique
88991148|NCT05685290|Active Comparator|Control group|Traditional method
88991149|NCT05681988|Experimental|Study Intervention|Early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT performed within 24 hours after SSICH symptom onset.
88991150|NCT05681988|Active Comparator|Control Intervention|Best medical treatment i.e. active blood pressure control, seizure prophylaxis and care as according to the current guidelines.
88991151|NCT05681325|Active Comparator|green tea group|Mahmood Green Tea Sri Lanka. It will be given 2 cups / day for 30 days.
88991152|NCT05681325|Experimental|matcha tea group|Jade Leaf Organic Japanese Matcha, USA. It will be given 2 cups / day for 30 days.
88991153|NCT05672849|Experimental|Modified Devices in fetoscopic NTD repair|Single arm study. All patients will undergo fetoscopic NTD repair with the use of the modified devices.
88991154|NCT05671653|Experimental|Cohort 1: PF-07081532|Cohort 1 is an open-label, 9 period, fixed-sequence design to evaluate the effect of 2 steady state dose levels of PF-07081532 on the SD pharmacokinetics of midazolam and omeprazole, administered simultaneously, and an OC (LE/EE) in otherwise healthy obese adult female participants with a BMI ≥30 kg/m2.
88991155|NCT05671653|Experimental|Cohort 2: Semaglutide|Cohort 2 is an open label, 4-period, fixed-sequence design to evaluate the effect of steady state semaglutide on the SD PK of midazolam in obese adult female participants with a BMI ≥30 kg/m2
88991156|NCT05667584|Experimental|HPI|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and hypotension prediction index (HPI) derived from ClearSight are used for recording and monitoring. Blood pressure is monitored with ClearSight and HPI. Attending anesthesiologists controlled the blood pressure according to HPI values.~Maintain HPI below 85~HPI > 85 and heart rate > 60/min, IV bolus norepinephrine 5-10 mcg~HPI > 85 and heart rate < 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
89042228|NCT05891223|Experimental|Session 6: Growing happiness|"Revisiting the good practice is carried out to define the five sense organs for the participants.~Forgiveness, Asking for forgiveness, forgiving others, gratitude practices are carried out.~The practice is expanded as kindness meditation: groups and all beings."
89637312|NCT06191861|Experimental|Balanced self (hoped and feared self), 3 dose|Participants complete a writing task in which they think and write about their most hoped for and feared future self, weekly for 3 weeks (i.e., at each session).
89637313|NCT06191861|Experimental|Balanced self (hoped and feared self), 1 dose|Participants complete a writing task in which they think and write about their most hoped for and feared future self one time (on the third session).
89637314|NCT06191861|Placebo Comparator|Control, 3 dose|Participants in this condition complete a task in which they think and write about a trip to the zoo weekly for 3 weeks (i.e., at each session).
89637315|NCT06191861|Placebo Comparator|Control, 1 dose|Participants in this condition complete a task in which they think and write about a trip to the zoo one time (on the third session).
89637316|NCT06189482|Experimental|The observation group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients&#39; health condition. The observation group receives IOE for enteral nutrition support
89637317|NCT06189482|Active Comparator|The control group|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients&#39; health condition.The control group receives NGT for enteral nutrition support
89637318|NCT06189365||Amplatzer Amulet LAA occluder|Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
89637319|NCT06187701|Experimental|Co-Active Therapeutic Theatre (Co-ATT)|Drama therapy will be used to treat participants with co-occurring primary psychiatric and substance use disorders
89637320|NCT06187597|Experimental|The study group|Patients will receive radiotherapy with prescribed dose of 54 Gy in 27 fractions, concurrently with S-1 chemotherapy. Then patients in the study group will receive toripalimab as consolidation therapy for up to 12 months (16 cycles) after the completion of chemoradiotherapy.
89637321|NCT06187597|Active Comparator|The control group|Patients will receive radiotherapy with prescribed dose of 54 Gy in 27 fractions, concurrently with S-1 chemotherapy. Then patients will be receive routine follow-up.
88991157|NCT05667584|Active Comparator|ClearSight|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and HPI derived from ClearSight are used for recording, and HPI are masked for attending anesthesiologists. Blood pressure is monitored with ClearSight. Attending anesthesiologists controlled the blood pressure according to continuous arterial pressure values.~Maintain mean arterial pressure (MAP) above 65 mmHg~MAP < 65mmHg and heart rate > 60/min, IV bolus norepinephrine 5-10 mcg~MAP < 65mmHg and heart rate < 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
88991158|NCT05667584|No Intervention|NIBP|"Standard intraoperative monitor and non-invasive continuous arterial pressure waveforms (ClearSight) are set up in this group. ClearSight data and HPI derived from ClearSight are used for recording, and are masked for attending anesthesiologists. Blood pressure is monitored with conventional non-invasive blood pressure (NIBP). Attending anesthesiologists controlled the blood pressure according to continuous arterial pressure values.~Maintain mean arterial pressure (MAP) above 65 mmHg~MAP < 65mmHg and heart rate > 60/min, IV bolus norepinephrine 5-10 mcg~MAP < 65mmHg and heart rate < 60/min, IV bolus norepinephrine 5-10 mcg with atropine 0.01 mg/kg"
88991159|NCT05665738|Experimental|HDR brachytherapy|Participants will receive the same radiotherapy technique, methods, and delivery will as standard of care 3 hours apart instead of receiving the radiotherapy on separate days.
88991160|NCT05663905|Experimental|Ambroxol Arm|"Amboxol arm will be receiving standard therapy as per control group with the addition of IV ambroxol hydrochloride 30mg TDS as adjunct therapy for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour. The patients will be considered as drop-outs if ambroxol is discontinued due to its side-effects, or if the patient's duration of ICU stay is less than 24 hours."
88991161|NCT05663905|Other|Control Arm|"Control arm will be receiving standard therapy for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC).37 This includes antibiotics stewardship and supportive therapy."
88991162|NCT05661357|Experimental|Disitamab Vedotin combined with Fruquintinib|Single arm, prospective, exploratory clinical study of Disitamab Vedotin combined with Fruquintinib for advanced colorectal cancer with HER2 expression or mutation that has received at least two standard treatment failures
88991163|NCT05656885|Experimental|Lens A|All participants wore Lens A for 15 minutes (Period 1)
88991164|NCT05656885|Experimental|Lens B|All participants wore Lens B for 15 minutes (Period 2)
88991165|NCT05643950|Active Comparator|Control arm (Foley catheter)|When randomly allocated to this arm, a conventional Foley-type catheter will be inserted during all the study period (2 weeks). At day 14 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
88991166|NCT05643950|Experimental|T-Control arm|When randomly allocated to this arm, the T-Control catheter will be inserted during all the study period (2 weeks). At day 14 after inclusion, the patient will be called for a follow-up visit to remove the catheter.
88991167|NCT05632536|Active Comparator|GROUP ESP|Before the operation, under general anesthesia, group ESP (n=30) patients will be blocked with the sacral ESP block method. By giving the lateral decubitus position, the linear ultrasound probe will be placed in the sterilized area longitudinally on the midline of the sacrum. The erector spinae muscle and the sacral medial crest will be visualized. The 22 gauge, 50 mm needle will be advanced in the direction from cranial to caudal to reach the sacral crest. 0.25% bupivacaine from a dose of 1 mL kg-1 will be aspirated and injected every 2 mL under the erector spina muscle at the level of the median sacral crest at the level of the 4th sacral vertebra. (A test dose will be administered with 1 mL of saline.)
89637322|NCT06186726|Experimental|Study arm|The patients received 72GyE/18 fractions of carbon ion radiotherapy. Combined with platinum-containing schemes (including etoposide combined with cisplatin or carboplatin or loplatin or nedaplatin, paclitaxel combined with cisplatin or carboplatin or loplatin or nedaplatin, etc.); Docetaxel combined with cisplatin or carboplatin or loplatin or nedaplatin) for at least 4 cycles
89637323|NCT06186310|Active Comparator|Aquatic Therapy Group|in addition to the home programme exercises, aquatic exercises will be performed with a physiotherapist
89637324|NCT06186310|Active Comparator|Conventional Physical Therapy Group|Personalized exercises in the form of a home program will be demonstrated by the physiotherapist
89637325|NCT06176261|Experimental|Cohort A: Estrogen Receptor Positive HER2-Negative Metastatic Breast Cancer|"24 participants will be enrolled and will complete study procedures as outlined below:~Baseline visit with optional CSF collection via lumbar puncture and assessments.~CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.~Cycle 1 Through End of Treatment:~--Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.~End of Treatment:~Follow up every 6 months.~Optional CSF collection via lumbar puncture.~CT or MRI scans every 12 weeks."
89637326|NCT06176261|Experimental|Cohort B: Metastatic Triple-Negative Breast Cancer|"24 participants will be enrolled and will complete study procedures as outlined below:~Baseline visit with optional CSF collection via lumbar puncture and assessments.~CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.~Cycle 1 Through End of Treatment:~--Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.~End of Treatment:~Follow up every 6 months.~Optional CSF collection via lumbar puncture.~CT or MRI scans every 12 weeks."
89637327|NCT06176261|Experimental|Cohort C: HER2-Negative Metastatic Breast Cancer (any ER Expression) with Leptomeningeal Metastases|"Baseline visit with CSF collection via lumbar puncture and assessments.~CT or MRI scans every 6 weeks for 24 weeks, then every 9 weeks.~Cycle 1~--Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.~Cycle 2~Day 1 of 21 day cycle: Predetermined dose of Dato-DXd 1x daily.~Day 2 of 21 day cycle: CSF collection.~Cycle 3 Through End of Treatment:~--Day 1 of 21 day cycle: Predetermined dose of Datopotamab Deruxtecan 1x daily.~End of Treatment:~Follow up every 6 months.~Optional CSF collection via lumbar puncture.~CT or MRI scans every 12 weeks."
89637328|NCT06171230|Experimental|Eye Movement Desensitization and Reprocessing|Participants will undergo six 90-minute EMDR sessions. The EMDR treatment concludes when the selected target images attain a Subjective Units of Disturbance (SUD) score of 0 or when three consecutive sessions show no further decrease in the SUD. Between the baseline phase (phase A) and the intervention phase (phase C), an attention control phase is introduced (phase B). This phase controls for the non-specific effects of the intervention, such as attention, treatment contact, and social support.
89637329|NCT06167785|Experimental|Tislelizumab|Tislelizumab 200mg intravenously every 3 weeks - initial safety run-in period
89637330|NCT06167785|Experimental|Zanubrutinib|Zanubrutinib 160 mg oral twice daily - initial safety run-in period
89637331|NCT06167785|Experimental|Tislelizumab + Zanubrutinib|"Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks~Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle - expanded cohort"
89637332|NCT06167512||polytrauma patients|polytrauma patients
89637333|NCT06167512||healthy volunteers|healthy volunteers
89637334|NCT06165679|Active Comparator|Prilocaine group|
89637335|NCT06165679|Active Comparator|Bupivacaine GROUP|
89637336|NCT06161285|Other|Severe bronchiolitis|venous blood samples. Buccal, nasopharyngeal and rectal swabs
89637337|NCT06161285|Other|Non-hospitalized bronchiolitis|Capillary blood samples. Buccal, nasopharyngeal and rectal swabs
89637338|NCT06160518|No Intervention|Control|The children will receive the standard pharmacological treatment of the unit to manage pain and stabilize their physiological parameters throughout the three days of study.
89637339|NCT06160518|Experimental|Study group|The children will receive virtual reality intervention which will take place using a cell phone coupled with the three-dimensional image glasses. The cell phone will play three-dimensional games which will be downloaded for free. The options for images and games involved which children could choose freely, all games will be suitable for the age group of the study.
89637340|NCT06158594|No Intervention|Control|Children in this group will not receive a voucher to attend a pre-existing summer program
89637341|NCT06158594|Experimental|4-week voucher|Children in this group will receive a voucher to attend 4-weeks of a pre-existing summer program
89637342|NCT06158594|Experimental|6-week voucher|Children in this group will receive a voucher to attend 6-weeks of a pre-existing summer program
89637343|NCT06158594|Experimental|8-week voucher|Children in this group will receive a voucher to attend 8-weeks of a pre-existing summer program
89637344|NCT06157177|Active Comparator|Active M640|Metaxalone micronized 640 mg over encapsulated tablet Taken orally every 6 hours for 7 days
89637345|NCT06157177|Placebo Comparator|Placebo|Inactive placebo capsule 640 mg Taken orally every 6 hours for 7 days
89637346|NCT06143748|Experimental|The study group|Patients will receive 2 cycles of 3-weekly schedule of induction chemotherapy, consisting of paclitaxel 135 mg/m2, cisplatin 75 mg/m2, and cadonilimab 10 mg/kg on day 1 prior to CRT. Then all patients will receive standard fractionation radiation therapy scheme: 50.4 Gy in 28 fractions, concurrently with 2 cycles of cadonilimab. After the completion of radiotherapy, patients will then receive 12 additional cycles of cadonilimab.
89637347|NCT06143241|Experimental|Experimental Group|It consists of 20 children diagnosed with epilepsy who will receive inspiratory muscle training following routine medication use. The experimental group will receive inspiratory muscle training with the Thershold device for 30 minutes every day for 8 weeks.
89637348|NCT06143241|Active Comparator|Control Group|The control group consists of 20 children diagnosed with epilepsy who will only be followed up with routine medication.
89042229|NCT05891223|Experimental|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants are made to choose a day in their life and allow a few minutes to pause in a mindful way.~A breather for wise and compassionate action, calmness meditation and joy sharing meditation practices are carried out."
89637349|NCT06139991|Experimental|Treatment sequence ABB|Participants will receive Treatment A, followed by Treatment B, followed by Treatment B, all treatments as a single dose, with a washout period of minimum 3 days, but no longer than 7 days, between each study dose administration.
89057598|NCT01649895|Placebo Comparator|Placebo|Placebo: 5 pills for 5 weeks, once per week.
89637350|NCT06139991|Experimental|Treatment sequence BBA|Participants will receive Treatment B, followed by Treatment B, followed by Treatment A, all treatments as a single dose, with a washout period of minimum 3 days, but no longer than 7 days, between each study dose administration.
89637351|NCT06139991|Experimental|Treatment sequence BAB|Participants will receive Treatment B, followed by Treatment A, followed by Treatment B, all treatments as a single dose, with a washout period of minimum 3 days, but no longer than 7 days, between each study dose administration.
89637352|NCT06137365|Experimental|Active|"Cannabis gummy, starting at 2.5 mg THC and increased weekly by 2.5 mg increments up to a maximum target dose of 15 mg THC, administered once daily for duration of 6-month trial participation."
89637353|NCT06137365|Placebo Comparator|Placebo|"Placebo cannabis gummy, containing no active THC, administered once daily for duration of 6-month trial participation."
89637354|NCT06136741|Experimental|Arm A|Rezpegaldesleukin Dose Regimen A every 2 weeks during the induction period
89637355|NCT06136741|Experimental|Arm A1|Rezpegaldesleukin Dose Regimen A every 4 weeks during the maintenance period
89637356|NCT06136741|Experimental|Arm A2|Rezpegaldesleukin Dose Regimen A every 12 weeks during the maintenance period
89637357|NCT06136741|Experimental|Arm B|Rezpegaldesleukin Dose Regimen B every 4 weeks during the induction period
89637358|NCT06136741|Experimental|Arm B1|Rezpegaldesleukin Dose Regimen B every 4 weeks during the maintenance period
89637359|NCT06136741|Experimental|Arm B2|Rezpegaldesleukin Dose Regimen B every 12 weeks during the maintenance period
89637360|NCT06136741|Experimental|Arm C|Rezpegaldesleukin Dose Regimen C every 2 weeks during the induction period
89637361|NCT06136741|Experimental|Arm C1|Rezpegaldesleukin Dose Regimen C every 4 weeks during the maintenance period
88991168|NCT05632536|Sham Comparator|GROUP C|Group C (n=30) patients to whom caudal block will be applied will be placed in the lateral decubitus position and the linear ultrasound probe will be placed longitudinally in the sterilized area on the midline of the sacrum. A 2.5 cm 22 gauge needle will be inserted over the back skin of the sacral hiatus (located distal to the sacrum and formed by the two sacral cornua on its lateral edges) at a 90° position. The sacrococcygeal ligament will be crossed, the needle will be oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. After entering the sacral hiatus and confirming the location with negative aspiration method, 1 mL kg-1 0.25% bupivacaine will be injected by aspiration every 2 mL (test dose will be administered with 1 mL saline).
89637362|NCT06136741|Experimental|Arm C2|Rezpegaldesleukin Dose Regimen C every 12 weeks during the maintenance period
89637363|NCT06136741|Placebo Comparator|Arm D|Placebo every 2 weeks during the induction period
89637364|NCT06136741|Placebo Comparator|Arm D1|Placebo every 4 weeks during the maintenance period
89637365|NCT06136741|Experimental|Escape Therapy (open-label)|Rezpegaldesleukin Dose Regimen A every 2 weeks during the maintenance period
89637366|NCT06130410||COMIRNATY intramuscular injection for 6 months to 4 years old (monovalent, omicron XBB.1.5.)|
89637367|NCT06122480|Experimental|Treatment arm|"Eligible patients will undergo neoadjuvant FOLFIRINOX chemotherapy with the following order and dosing schedule:~Irinotecan hydrochloride trihydrate is administered intravenously over approximately 90 minutes at a dose of 180 mg/m^2.~Oxaliplatin is given intravenously over 2 hours at a dosage of 85 mg/m^2.~5-Fluorouracil is administered intravenously over approximately 46 hours at a dosage of 2400 mg/m^2. This treatment regimen is a modified FOLFIRINOX protocol."
89637368|NCT06120751|Experimental|Tetanus Vaccine, Adsorbed (TTVA)|1 dose of (TTVA) (0.5ml)
89637369|NCT06120751|Active Comparator|Tetanus Vaccine, Adsorbed (TT)|1 dose of (TT) (0.5ml)
89637370|NCT06116916|Experimental|Arm A|KHK4951 High dose
89637371|NCT06116916|Experimental|Arm B|KHK4951 Middle dose
89637372|NCT06116916|Experimental|Arm C|KHK4951 Low dose
89057599|NCT04527939|Active Comparator|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
89637373|NCT06116890|Experimental|Arm A|KHK4951 High dose
89637374|NCT06116890|Experimental|Arm B|KHK4951 Middle dose
89637375|NCT06116890|Experimental|Arm C|KHK4951 Low dose
89637376|NCT06115993|Experimental|Part Ia: dosing in healthy participants|Single ascending doses of 75 mg, 150 mg, 300 mg, 450 mg, and up to 600 mg (optional) AHB-137 and multiple ascending doses of 150 mg, 300 mg and up to 450 mg (optional) AHB-137 by 6 subcutaneous injections within a month in healthy participants
89637377|NCT06115993|Experimental|Part Ib: dosing in CHB patients|Multiple ascending doses of 150 mg, 300 mg, and up to 450 mg (optional) AHB-137 by 6 subcutaneous injections within a month both in CHB patients who are under stable nucleos(t)ide analogue (NA) therapy and in CHB patients who have not received any nucleos(t)ide analogue (NA) therapy
89637378|NCT06115707|Active Comparator|The lying flat group|Patients in lying flat intervention to be nursed lying flat (0°) after endovascular therapy is made and to remain in this position for 72 hours.
89637379|NCT06115707|Experimental|The head elevation group|Patients in the sitting up intervention should be nursed with their head elevated (30°) by raising the head of the bed (or using extra pillows or wedges) after undergoing endovascular therapy, and to remain in this position for 72 hours.
89637380|NCT06112951|Experimental|Treatment Group|Treatment group will receive extracorporeal photopheresis. First, a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
89637381|NCT06112951|No Intervention|Control Group|Control group will be observed and no active treatment will be administered. This is our standard of care in the studied clinical situation.
89637382|NCT06103383|Experimental|Donors with history of optimal ovarian response|IVIRMA Valencia donors between the ages of 18-35 years old, with normal ovarian function, with a history of optimal ovarian response (at least 10 total oocytes and/or 8 MII) and who have already completed all their donation cycles allowed by law.
89637383|NCT06100900|Experimental|BCX10013|Participants with PNH will receive BCX10013 daily for 4 weeks before dose escalation may occur.
89637384|NCT06098690|Experimental|Treatment|A tailored HPV psychoeducational multimedia intervention
89637385|NCT06098690|Active Comparator|Active Control|General/standard multimedia materials on HPV and HPV vaccine
89637386|NCT06098612|Experimental|evaluation of alpha synuclein aggregates in the brain|
89637387|NCT06098079|Active Comparator|Naltrexone/Bupropion (NB)|Patients will be randomly assigned to NB (naltrexone 8 mg and bupropion 90 mg) extended-release oral tablet.
89637388|NCT06098079|Placebo Comparator|Placebo|Patients will be randomly assigned to placebo.
89637389|NCT06097793|Experimental|KSD-101|Biological: Dendritic Cell Vaccine（Autologous monocyte-derived DCs pulsed with EBV Multi-antigen).
89637390|NCT06093191|Active Comparator|Combination group|Participants will receive inhaled 300mg of tobramycin solution twice daily for 12 weeks and oral 750mg of ciprofloxacin twice daily for 2 weeks
89637391|NCT06093191|Active Comparator|Tobramycin inhalation solution alone group|Participants will receive inhaled 300mg of tobramycin twice daily for 12 weeks and oral ciprofloxacin placebo twice daily for 2 weeks
89637392|NCT06093191|Active Comparator|Oral ciprofloxacin alone group|Participants will receive oral 750mg of ciprofloxacin twice daily for 2 weeks and inhaled saline twice daily for 12 weeks
89637393|NCT06093191|Placebo Comparator|Placebo group|Participants will receive inhaled saline twice daily for 12 weeks and oral ciprofloxacin placebo twice daily for 2 weeks
89637394|NCT06083142|Experimental|Active FMT|Active FMT (5 doses) over 7 days. Each dose contains 15 capsules.
89637395|NCT06079697|Experimental|Arm I (prehabilitation)|Patients wear a Fitbit beginning on day 1 and receive the prehabilitation exercise intervention consisting of 2000-4000 steps per day, sit-to-stand training 3 days per week, and standing therapeutic exercises 3 days per week beginning on day 2 for up to 2-5 weeks prior to surgery. Patients continue wearing the Fitbit from post-operative day 1 until hospital discharge or until 14 days post-surgery.
89637396|NCT06079697|Active Comparator|Arm II (usual care)|Patients wear a Fitbit beginning on day 1 up until day of surgery and then from post-operative day 1 until hospital discharge or until 14 days post-surgery.
89042230|NCT05891223|Experimental|Session 8: Living with the Heart|"The participants are told about the applications that they can apply for, where they need help to develop compassion towards self-healing skills, and the whole training is evaluated.~The river of life application, which evaluates mindfulness in depth, is carried out.~An overall summary of the 8-session study is made and feedback is received."
89042231|NCT05890300|Experimental|Intervention (INT)|Group receiving intervention
89042232|NCT05890300|No Intervention|Control (CON)|Group receiving no intervention
89042233|NCT05888922|Experimental|Active group|Oral minoxidil 1 mg (1 tablet, OD) + topical vehicle solution (1 ml, BID)
89042234|NCT05888922|Active Comparator|Control group|Oral placebo (1 tablet, OD) + topical 2% Minoxidil solution (1 ml, BID)
89042235|NCT05888922|Placebo Comparator|Placebo group|oral placebo (1 tablet, OD) + topical vehicle solution (1 ml, BID)
89042236|NCT05877599|Experimental|Dose Escalation|Dose Escalation of TCR T cell product
89042237|NCT05872425|Experimental|Treatment with DingKunDan(GuangYuYuan) combined with compound oral contraceptives|This arm is treated with DingKunDan plus compound oral contraceptives: Drospirenone and Ethinylestradiol Tablets (Ⅱ).
89042238|NCT05872425|Active Comparator|Treatment with compound oral contraceptives|This arm is only treated with compound oral contraceptives: Drospirenone and Ethinylestradiol Tablets (Ⅱ).
89042239|NCT05865535|Experimental|Cohort 1|IV infusion of AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
89042240|NCT05865535|Experimental|Cohort 2|IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
89042241|NCT05865535|Experimental|Cohort 3|IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
89042242|NCT05865535|Experimental|Cohort 4|IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
89212047|NCT02590445|Active Comparator|Active stimulation|Stimulator on followed by off
89212048|NCT02590445|Sham Comparator|Sham stimulation|Stimulator off followed by on
89637397|NCT06078332||Remote assessment first|Participants will perform the first neuropsychological assessment remotely via video conferencing. After 15 days, the participants will repeat the same neuropsychological tests (second assessment) face to face. Finally, participants and caregivers will complete online the satisfaction questionnaire about remote administration.
89637398|NCT06078332||Face-to-face assessment first|Participants will perform the first neuropsychological assessment in presence in the hospital. After 15 days, the participants will repeat the same neuropsychological tests (second assessment) remotely via video conferencing. Finally, participants and caregivers will complete online the satisfaction questionnaire about remote administration .
89637399|NCT06074510|Experimental|PYLARIFY PET|
89637400|NCT06072612|Experimental|Bria-IMT Regimen + CPI|"The Bria-IMT regimen:~Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site"
89637401|NCT06072612|Active Comparator|Treatment of Physician's Choice|TPC consists of eribulin, carboplatin, capecitabine, gemcitabine, vinorelbine or taxanes in accordance with the investigators' and institutional standard of care. The specific details of the selected regimen must include every detail of administration including frequency, sequencing (for multi-agent regimens), duration of infusion or oral administration, planned dose, dose prescribed, dose administered, dose adjustments after initial prescription or start of TPC treatment, and any other change in TPC from its initial election prior to randomization.
89637402|NCT06072612|Experimental|Bria-IMT Regimen Alone|"The Bria-IMT regimen:~Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site"
89637403|NCT06068868|Experimental|ABBV-787|Participants will receive increasing doses of ABBV-787 until the maximum tolerated dose (MTD) during the 3 year treatment period.
88991169|NCT05631574|Experimental|Escalation Phase|"Dose Escalation Phase will group all disease indications (NSCLC, PDAC, and CRC) together to assess the safety of each dose level.~Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose)."
88991170|NCT05631574|Experimental|Expansion Phase|"Dose Expansion Phase will enroll additional subjects independently in each disease indication:~Cohort 1: Participants with NSCLC~Cohort 2: Participants with PDAC~Cohort 3: Patients with CRC~Cohorts 1, 2, and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug."
88991171|NCT05626179|Other|[14C] IBI351|Recommended dose of [14C] IBI351
88991172|NCT05616533||focused group|Advanced gastric patients that will be treated with neoadjuvant therapy are enrolled. Every clinical decision such as regimen or dosage will be decided by their own doctors without any interventions. Tumor samples will be obtained before the first cycle of the treatment and will be transplanted to the zebrafish model. Compared results will be analyzed in future.
88991173|NCT05592067|Active Comparator|I tape technique|I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
88991174|NCT05592067|Active Comparator|Button hole technique|Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
88991175|NCT05592067|Other|exercises|exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
88991176|NCT05588856||Patients with Chronic Lung Disease|
88991177|NCT05588856||Healthcare professionals|
89637404|NCT06065241|Experimental|Experimental Group|Participants in this arm will receive a herbal capsule formulation, called LLP-01, consisting of 2 capsules taken once daily without food for 60 days. The capsules contain extracts from naturally occurring plant species, including Withania somnifera, Rosmarinus officinalis, Curcuma longa, Cotinus coggygria, Panax ginseng, Cordyceps militaris, Camellia sinensis, Cotinus coggygria, and Piper nigrum.
89637405|NCT06065241|Placebo Comparator|Placebo Group|Participants in this arm will receive Placebo capsules, which are visually identical to the capsules in the Experimental Group. These placebo capsules are filled with rice flour and a minor amount of Curcuma longa powder and should be taken in the same manner as the Experimental Group, with 2 capsules taken once daily without food for 60 days.
89637406|NCT06062433|Experimental|Pediatric Asthma Intervention Group|Along with clinical standard of care for asthma, subjects will have Asthma-Guidance and Prediction System (A-GPS) with AsthmaTuner (AT) integrated into care.
89637407|NCT06062433|No Intervention|Pediatric Asthma Control Group|Subjects will receive clinical standard of care for asthma.
89637408|NCT06062433|No Intervention|Clinician Control Group|Clinicians will provide clinical standard of care for pediatric asthma patients.
89637409|NCT06062433|Experimental|Clinician Intervention Group|Clinicians will integrate Asthma-Guidance and Prediction System (A-GPS) with AsthmaTuner (AT) into clinical standard of care for asthma.
89637410|NCT06062433|No Intervention|Asthma Care Coordinator Control Group|Asthma Care Coordinators will provide clinical standard of care for pediatric asthma patients.
89637411|NCT06062433|Experimental|Asthma Care Coordinator Intervention Group|Asthma Care Coordinators will integrate Asthma-Guidance and Prediction System (A-GPS) with AsthmaTuner (AT) into clinical standard of care for asthma.
89637412|NCT06058741||Venetoclax + Azacitidine Participants|Participants treated with venetoclax in combination with azacitidine in accordance with approved local label.
89637413|NCT06054464|Experimental|Part 1: PC14586 and rabeprazole|Healthy participants will receive a single, oral dose of PC14586 on day 1. On days 11-13, participants will receive an oral daily dose of rabeprazole. On day 14, participants will receive a co-administration dose of rabeprazole and PC14586. Rabeprazole will be given 1 hour prior to PC14586. Participants will be given a low-fat meal 30 minutes prior to PC14586 dosing.
88991178|NCT05583097|No Intervention|Selective cytology according to EU-TIRADS|All thyroid nodules are evaluated according to EU-TIRADS and cytology is performed according to EU-TIRADS criteria.
88991179|NCT05583097|Active Comparator|Non-selective cytology|All thyroid nodules are evaluated according to EU-TIRADS and cytology is performed on all nodules >1 cm. Cytology will also be performed on EU-TIRADS 5-nodules measuring between 0.5 and 1 cm.
89637414|NCT06054464|Experimental|Part 2: PC14586 and famotidine|Healthy participants will receive a single, oral dose of PC14586 on day 1. On days 11-13, participants will receive a twice daily, oral dose of famotidine. On day 14, participants will receive PC14586 two hours before a dose of famotidine. Participants will be given a low-fat meal 30 minutes prior to PC14586 dosing.
89637415|NCT06052761|Experimental|Making Toys from Medical Materials|"The purpose of the study will be explained to the children and their parents before the procedure, and verbal and written consent will be obtained from the parents who agree to participate in the study. Children's anxiety will be evaluated using the Children's State Anxiety Scale (CSA) before and after the procedure (half an hour after the first measurement), based on the statements of both the mother and the child."
89637416|NCT06052761|No Intervention|Control group|"The purpose of the study will be explained to the children and their parents before the procedure, and verbal and written consent will be obtained from the parents who agree to participate in the study. No procedures will be performed other than routine procedures performed in the hospital. Children's anxiety will be evaluated based on the statements of both the mother and the child, using the Children's State Anxiety Scale (CSA) after obtaining consent from the parents and half an hour after the first measurement."
89042243|NCT05865535|Experimental|Cohort 5|IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
89637417|NCT06051513|Experimental|colistin group|"For patients in this group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.~At the beginning of the intravenous use of Colistimethate Sodium for Injection，the load dose is 300mg CBA(about 9 million U)，and after 12-24 hours，the first maintenance dose should be given. The daily maintenance dose was 300-360mg CBA(9 million-10.9 million U), divided into two times (1/12h), for each time, 0.5-1 hour is needed to complete the infusion.~Drug: colistin, other name: Colistimethate Sodium for Injection"
89637418|NCT06051513|Active Comparator|control group|For patients in this group,best available treatment without colistin is used. Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.Dose of other drugs are listed below: 1-2g meropenem should be given every 8 hours，1g Imipenem every 8 hours or 6 hours，0.8g Amikacin everyday，2.5g ceftazidime-avibactam every 8 hours. A load dose of 200mg tigecycline is needed, followed by 100mg every 12 hours.
89637419|NCT06050694|No Intervention|Pola-R-CHP|"Protocol induction: Cycle 1-2~Low-risk group: Cycle 3-4 polatuzumab vedotin 1.8 mg/kg, cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 on day 1, prednisone 100 mg daily days 1-5, and rituximab 375 mg/m2 within 72 hours of polatuzumab vedotin~Cycle 5-6 rituximab 375 mg/m2 on day 1 of cycle 5 and cycle 6"
89637420|NCT06050694|Experimental|Pola-R-CHP and glofitamab|High-risk group: Cycle 3-6 polatuzumab vedotin 1.8 mg/kg, cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 on day 1, prednisone 100 mg daily days 1-5, rituximab 375 mg/m2 within 72 hours of polatuzumab vedotin and Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
89637421|NCT06048614|Experimental|Intervention Arm (Saline Enema Arm)|"After randomisation, infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) earliest at 48 to 72 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds"
89637422|NCT06048614|Active Comparator|Control Arm (Glycerin Suppository Arm)|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
89637423|NCT06045390|Experimental|App arm|The intervention is an in-office app that contains graphical and narrated information on a patient's specific drop regimen, and includes a quiz and a graphical print-out of their drop schedule. The patient will use the app during their clinic visit.
89637424|NCT06045390|No Intervention|Standard arm|The standard arm will be the standard of care, which involves a provider explanation of their drop regimen (using a phone interpreter if needed).
89637425|NCT06044857|Experimental|SAbR Every other day|SAbR given 2-3/week, at least every other day in spacing with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.
89637426|NCT06044857|Experimental|PULSAR every week|SAbR given 1/week, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.
89637427|NCT06044857|Experimental|PULSAR every 2 weeks|SAbR given every 2 weeks, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.
89637428|NCT06044857|Experimental|PULSAR every 3 weeks|SAbR given every 3 weeks, with long-term ADT (neoadjuvant ADT x 3months required) with experimental Illucix (PSMA-11 68Ga) PET before and during SAbR (between fraction 3 and 4) to assess and adapt to dominant intra-prostatic lesion boost dose.
89637429|NCT06041594|Experimental|Laguna Thrombectomy System|
89637430|NCT06041243|Experimental|Treatment|Game-based balance exercises on BoBo Home Balance Board
89637431|NCT06041243|No Intervention|Control|
89042244|NCT05863143|Experimental|Intervention Group|Subjects in the intervention group are required to involve in 12 sessions of nutrition education program and prescribed exercise program during the 12 weeks intervention period. Generally, respondents in the intervention group will received the developed educational materials and exercise diary as guide during this period.
89042245|NCT05863143|No Intervention|Control Group|"Subjects required to continue with usual lifestyle (eating habits and exercise pattern) for 12 weeks. Tips on healthy eating and active living, which are suitable for them will be provided.~When the study is completed (after 12 weeks), they will receive the same intervention activities as the intervention group."
89042246|NCT05860894|Experimental|Implantable ECG holter device|Adult patients with new onset atrial fibrillation occuring in the ICU will be implanted with an implantable ECG holter device (Biomonitor3, Biotronik) to monitor arrhythmia episodes up to 2 years after ICU discharge.
89042247|NCT05854537|Active Comparator|Sphenopalatine ganglion block using bupivacaine: xylocaine mixture for maxillofacial surgeries|Patients will have the cotton swab soaked in the LA medication (bupivacaine: lidocaine) introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication. Then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
89042248|NCT05854537|Placebo Comparator|Sphenopalatine ganglion block using normal saline for maxillofacial surgeries|Patients will undergo the same procedure but the cotton swab will be soaked into a normal saline solution, and the injection will be done by normal saline as well.
89057600|NCT04527939|Sham Comparator|magnification chromoendoscopy.|magnification chromoendoscopy.
89212049|NCT04086095|Experimental|Intervention Group|Surfactant administration will be done via videolaryngoscopy and the application aid Neofact in neonates with respiratory distress syndrome and airway support with CPAP. Alveofact is used as Surfactant in its standard dosage of 100 mg / kg
89212050|NCT05325827|Experimental|Group A: H-FICB under ultrasound guidance before general anesthesia|Group A was subjected to a high fascia iliaca compartment block under ultrasound guidance before general anesthesia.
89212051|NCT05325827|No Intervention|Group B: FBC combined with SBC under ultrasound guidance before general anesthesia|Group B was subjected to a femoral nerve block combined with a sciatic nerve block under ultrasound guidance before general anesthesia.
89212052|NCT00715949||Mild Traumatic Brain Injury (MTBI) admits|admitted pediatric patients with mild traumatic brain injury (concussion)
89212053|NCT04084535|Active Comparator|High intensity interval training|It will apply a HIIT program for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
89212054|NCT04084535|Active Comparator|Inspiratory muscle training|It will apply an inspiratory muscle training for 4 weeks, with 3 sessions per week of 30 min per session, including warm-up, recovery between intervals and return to calm.
89637432|NCT06036511|Experimental|Ketamine Assisted Psychotherapy [KAP]|A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.
89637433|NCT06030895|Experimental|Sorafenib group|100 patients diagnosed with HCC for whom Sorafenib therapy is prescribed (400 mg twice daily) or (200mg twice daily), will be recruited from Mansoura University Hospital, Mansoura, Egypt.
89637434|NCT06027515|Experimental|Prehabilitation Program|"30 participants will be enrolled and will complete study procedures as follows:~Enrollment at least 4 weeks prior to esophageal cancer surgery.~In-person clinic visit with dietitian and physical therapist for assessments, and completion of baseline questionnaires with study coordinator.~Adherence to daily physical function, dietary, and sleep recommendations and consumption of 5-day immunonutrition supplement.~Regular electronic/phone-call check-ins with study staff.~Telehealth appointment with physical therapist and dietitian prior to surgery.~After surgery and during hospital admission, final visit with dietitian and physical therapist for assessments, and completion of questionnaires.~6-month follow-up period."
89637435|NCT06025565||LET|Patients with tennis elbow.
89637436|NCT06020391|Experimental|Intervention group|Collaborative drug review.
89637437|NCT06020391|No Intervention|Control group|Usual care.
89637438|NCT06020235|Experimental|5% Nu-3 gel once daily|The 5% Nu-3 gel is applied once per day and placebo is applied once per day.
89637439|NCT06020235|Experimental|5% Nu-3 gel twice daily|The 5% Nu-3 gel is applied twice per day.
89637440|NCT06020235|Experimental|10% Nu-3 gel once daily|The 10% Nu-3 gel is applied once per day and placebo is applied once per day.
89637441|NCT06020235|Experimental|10% Nu-3 gel twice daily|The 10% Nu-3 gel is applied twice per day.
89637442|NCT06020235|Placebo Comparator|Placebo|The placebo is applied twice per day.
89637443|NCT06019988|Other|The Accountable Health Communities Health-Related Social Needs Screening Tool (AHC-HRSN)|Patients will be randomized to receive one of three social needs screening instruments. The AHC-HRSN is a 10-item tool developed by the Centers for Medicare and Medicaid Services to assess patient needs in 5 core domains, including housing instability, food insecurity, transportation problems, utility help needs, and interpersonal safety, with eight supplemental domains to collect information about financial strain, employment, family and community support, education, physical activity, substance abuse, mental health, and disabilities. The AHC-HRSN tool is designed to help physicians identify unmet needs and refer affected patients to appropriate community services.
89637444|NCT06019988|Other|Health Leads Social Screening Tool|Patients will be randomized to receive one of three social needs screening instruments. Health Leads is an 8-item survey with yes/no responses, which screens for food insecurity, utility needs, housing instability, childcare, financial resource strain, transportation challenges, education, and social isolation.
89637445|NCT06019988|Other|National Comprehensive Care Network (NCCN) Distress Thermometer and Problem List (DT + PL)|Patients will be randomized to receive one of three social needs screening instruments. The NCCN Distress thermometer is a single-item tool designed to measure patients' current level of distress. Patients are asked to rate their distress using a 10-point Likert scale, where 0=no distress and 10=extreme distress. The Problem List (PL) helps physicians identify the sources of patients' distress and direct patients to appropriate support services. The NCCN DT+PL is a widely used, validated tool for evaluating distress in patients diagnosed with or receiving treatment for cancer.
89637446|NCT06019988|Other|Chatbot|Patients who do not respond to the survey within 48 hours of being first administered via MyPennMedicine will be sent the same survey via one of two modality arms. The chatbot is a bidirectional text-based conversational agent administered via WaytoHealth. Patients will again have 48 hours to respond via chatbot.
89212055|NCT00503698|Experimental|Somatropin|Somatropin once daily from week 0 to end of trial
89212056|NCT00503698|Placebo Comparator|Placebo|Placebo once daily to end of trial
89212057|NCT03941015||patients with renal desaturation|Patients who underwent a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
89212058|NCT03941015||patients without renal desaturation|Patients who didn't undergo a decrease of SrtO2 measurement from the baseline value for more than 20% lasting for more than 60 s.
89212059|NCT02589899||Needle placement in different tissue types|Needle placement and impedance measurements in different tissue types
89212060|NCT00573794|Experimental|Adalimumab 40 mg EOW/EW|Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
89212061|NCT00715793|Experimental|Single Arm|
89042249|NCT05833646|Experimental|ShotBlocker Group|In control application, subcutaneous (SC) LMWH injection will be applied in patient's left abdomen with standard method on Post-op 0th day by the researcher. Intervention with ShotBlocker will be performed on the right abdomen site on post-op 1st day by the researcher. During subcutaneous LMWH injection with ShotBlocker, suitable injection site in right abdomen will be grasped by applying medium-weight pressure as ShotBlocker's obtuse touching points would touch the skin. In order to avoid ecchymosis and hematoma, it will be applied slowly for 10 seconds by entering from the middle point of ShotBlocker with a 90° angle. When injection is over, ShotBlocker will be removed 10 seconds will be waited. Removing the needle, the entry point will be applied light pressure with dry cotton for 10 seconds without any massage. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) within 1 minute after injection.
89042250|NCT05833646|Experimental|Virtual Reality Glasses (VRG) Group|"Standard LMWH application will be performed on the left side for control on Post-op 0th day by the researcher.~Intervention with VRG will be performed on the right abdomen site on post-op 1st day. The researcher will show the patient a video 5 minutes before the injection providing them with virtual reality glasses, which will continue till the end of the operation, after which the glasses will be removed. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) within 1 minute after injection."
89042251|NCT05833646|Experimental|Cold Application Group|Standard heparin application will be performed on left side for control on post-op 0th day by the researcher. Intervention with cold application will be performed on the right abdomen site on post-op 1st day. Prior to the intervention, cold silica gel pack which stayed in the freezer for at least 2 hours will be placed on patient's injection site by wrapping up with towel and will be applied on the site for 5 minutes. After 5 minutes, the cold gel pack will be removed from the site and subcutaneous LMWH injection will be applied by the researcher. Following the removal of the injector, cold application will continue for another 2 minutes. Patients' level of pain and satisfaction will be assessed by a nurse working in the clinic with visual analog scale (VAS) after injection.
89042252|NCT05831111|Experimental|Part A: mRNA-1195.1 Dose Level 1|Participants will receive 3 intramuscular (IM) injections of mRNA-1195.1 at Dose Level 1 on Days 1, 57, and 169.
89042253|NCT05831111|Experimental|Part A: mRNA-1195.2 Dose Level 1|Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 1 on Days 1, 57, and 169.
89042254|NCT05831111|Experimental|Part A: mRNA-1195.1 Dose Level 2|Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 2 on Days 1, 57, and 169.
89042255|NCT05831111|Experimental|Part A: mRNA-1195.2 Dose Level 2|Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 2 on Days 1, 57, and 169.
89042256|NCT05831111|Experimental|Part A: mRNA-1195.1 Dose Level 3|Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 3 on Days 1, 57, and 169.
89042257|NCT05831111|Experimental|Part A: mRNA-1195.2 Dose Level 3|Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 3 on Days 1, 57, and 169.
89042258|NCT05831111|Experimental|Part A: mRNA-1195.1 Dose Level 4|Participants will receive 3 IM injections of mRNA-1195.1 at Dose Level 4 on Days 1, 57, and 169.
89042259|NCT05831111|Experimental|Part A: mRNA-1195.2 Dose Level 4|Participants will receive 3 IM injections of mRNA-1195.2 at Dose Level 4 on Days 1, 57, and 169.
89042260|NCT05831111|Active Comparator|Part A: mRNA-1189|Participants will receive 3 IM injections of mRNA-1189 on Days 1, 57, and 169.
89042261|NCT05831111|Placebo Comparator|Part A: Placebo|Participants will receive IM injection of study drug-matching placebo on Days 1, 57, and 169.
89637447|NCT06019988|Other|Interactive Voice Response (IVR) System|Patients who do not respond to the survey within 48 hours of being first administered via MyPennMedicine will be sent the same survey via one of two modality arms. The interactive voice response (IVR) system is administered via phone through WaytoHealth. Patients will be called over the phone and will receive the screening tool through IVR. Patients will again have 48 hours to respond via IVR.
89637448|NCT06015906|Sham Comparator|socket|Tooth extraction socket filled only clot.
89637449|NCT06015906|Active Comparator|Socket associated with exposed absorbable membrane|Socket filled with clot and covered with the Plenum® Guide membrane exposed in the intraoral region.
89637450|NCT06015906|Active Comparator|Socket associated with covered absorbable membrane|Socket filled with clot and covered with the Plenum® Guide membrane and covered by mucosa (gingival tissue) in the intraoral region.
89637451|NCT06015906|Experimental|Socket filled with synthetic bone graft and covered absorbable membrane|Socket filled with synthetic bone graft and the Plenum® Guide membrane covered by gingival tissue in the intraoral region.
89637452|NCT06015906|Experimental|Socket filled with synthetic bone graft and exposed absorbable membrane|Socket filled with synthetic bone graft and Plenum® Guide membrane, where this membrane will be exposed in the intraoral region.
89637453|NCT06012929|Experimental|Arm I - Presurgical|Participants who will be undergoing surgery to remove their meningioma will receive two doses of ONC201 prior to their surgery. ONC201 is taken by mouth at 625 mg per dose. ONC201 will be taken once per week with the second dose taken approximately 24 hours prior to surgery.
89637454|NCT06012929|Experimental|Arm II - ONC201 treatment only|Participants will receive one dose of ONC201 per week until progression. ONC201 is taken by mouth at 625 mg per dose.
89637455|NCT06011187|Active Comparator|Routine care|"During the pre-implementation period, fluid therapy will be done as routine care.~Mean arterial pressure (MAP) will be maintained between 65-70 mmHg per standard of care"
89637456|NCT06011187|Experimental|Assisted fluid management system|"In the post-implementation period, fluid bolus administration will be guided by the AFM recommandation.~MAP will be maintained between 65-70 mmHg per standard of care"
89637457|NCT06010030|Experimental|HD-tDCS|Participants will be randomized to receive either anodal HD-tDCS or sham-tDCS.
89637458|NCT06010030|Experimental|Speech Therapy|Participants will be randomized to receive either phonologic-focused speech therapy or semantic-focused speech therapy
89637459|NCT06008288|Experimental|JAB-21822|Monotherapy
89637460|NCT06007976|Experimental|2 treatment|Subjects will receive 2 low-level laser therapy treatments of 20 minutes for low back pain.
89637461|NCT06007976|Experimental|4 treatment|Subjects will receive 4 low-level laser therapy treatments of 20 minutes over 2 weeks for low back pain.
89637462|NCT06007976|Experimental|6 treatment|Subjects will receive 6 low-level laser therapy treatments of 20 minutes over 3 weeks for low back pain.
89637463|NCT06007976|Experimental|8 treatment|Subjects will receive 8 low-level laser therapy treatments of 20 minutes over 4 weeks for low back pain.
89637464|NCT06005597|Experimental|Combination Therapy|once-daily obicetrapib 10 mg and ezetimibe 10 mg fixed dose combination tablet, placebo tablet, placebo capsule
89637465|NCT06005597|Experimental|Monotherapy obicetrapib|once-daily obicetrapib 10 mg, placebo tablet, placebo capsule
89637466|NCT06005597|Active Comparator|Monotherapy ezetimibe|once-daily ezetimibe 10 mg capsule, 2 placebo tablets
89637467|NCT06005597|Placebo Comparator|Placebo|once-daily placebo tablets (2), placebo capsule
89637468|NCT05995002|No Intervention|Control|Conventional drug treatment with a general recommendation for a healthy diet.
89637469|NCT05995002|Experimental|Anthocyanin-rich diet group|Conventional drug treatment with a weekly food plan aims to increase the consumption of anthocyanin-rich sources
89637470|NCT05989581|Experimental|BP goal <130/80mmHg|
89637471|NCT05989581|No Intervention|BP goal <140/90 (usual care)|
89637472|NCT05984836|Experimental|health education class|Those mothers receive Early Childhood Home-Related Injuries education regarding First Aid in Matrouh
89637473|NCT05984836|No Intervention|Control group|Those mothers not receive Early Childhood Home-Related Injuries education regarding First Aid in Matrouh
88991180|NCT05581706|Active Comparator|Regenerative endodontic treatment with calcium hydroxide|"Regenerative endodontic treatment (RET) performed with procedures of American Association of Endodontics (AAE) in two sessions. At the end of the first session, periapical tissue fluid samples (baseline samples) were collected.~Calcium hydroxide medicament was prepared by mixing with sterile distilled water and then placed in the coronal 1/3 of the root canals.~In the second session (14 days after first treatment), the medicaments in the root canals were carefully removed with 5 ml sterile distilled water irrigation. Periapical tissue fluid samples were obtained from the distal canal using the same protocol as described previously (final samples). Then RET was finished according to the treatment protocol of AAE."
88991181|NCT05581706|Active Comparator|Regenerative endodontic treatment with double antibiotic paste|"Regenerative endodontic treatment (RET) performed with procedures of American Association of Endodontics (AAE) in two sessions. At the end of the first session, periapical tissue fluid samples (baseline samples) were collected.~Double antibiotic paste (DAP) was prepared by mixing same amount of metronidazole and ciprofloxacin powdered antibiotics (1:1) and combined with sterile distilled water to form an ointment. DAP was introduced in roots canals using a lentulo to fill the entire root canal space.~In the second session (14 days after first treatment) after removal of DAP in the root canals, periapical tissue fluid samples were obtained the same protocol as described previously (final samples). Then RET was finished according to the treatment protocol of AAE."
88991182|NCT05581706|Active Comparator|Radiographic evaluation|"Pre-operative, post-operative and final recall (12th months follow up) standart digital radiographs were taken from patients with film holder. The radiographs saved and transferred to Image J software (version 1.47, National Institutes of Health, Bethesda, MD). The standardized radiographs were further aligned using the TurboReg plugin (Biomedical Imaging Group, Swiss Federal Institute of Technology, Lausanne, Switzerland) within the Image J toolkit to minimize any distortions caused by variability in the angulation.~All images were calibrated according to size #2 SPP (vertical dimension 31 mm, horizontal dimension 41 mm) using the ''set scale'' option in Image J. Thereafter, the root lengths, root width and radiographic root area were measured on both preoperative and final recall images to evaluate treatment outcomes."
88991183|NCT05581706|Active Comparator|Periapical tissue exudate sample collection and Immunofluorometric assay MMP-8|"At the end of the first session, periapical tissue fluid samples (baseline samples) were collected by introducing 3 sterile #45 paper points into the root canal until 2 mm passing through the root apex from the distal canal. After waiting for 1 min, the paper points were withdrawn, the tip was cut from 4 mm and were transferred to sterile Eppendorf tubes. At the beginnign of the second session periapical tissue fluid samples were obtained from the distal canal using the same protocol as described in the first session (final samples).~Baseline and final MMP-8 concentrations were determined by a time-resolved immunofluorometric assay (IFMA). The monoclonal MMP-8 specific antibodies 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as a catching antibody and a tracer antibody, respectively. The tracer antibody was labeled using europium-chelate"
88991184|NCT05568966|Experimental|Blood Draw|"Venous blood draw up to 24mL and/or 6 capillary fingersticks~Interventions:~Diagnostic Test: Venepuncture Diagnostic Test: Fingerstick"
89042262|NCT05831111|Experimental|Part B: mRNA-1195.1 or mRNA-1195.2 Low Dose|Participants will receive 3 IM injections of mRNA-1195.1 or mRNA-1195.2 (at a dose level selected based on the Part A interim analysis) low dose on Days 1, 57, and 169.
89637474|NCT05984758|Active Comparator|Standard care|Routine examination for uveitis with assessment of visual function followed by slit lamp examination
89637475|NCT05984758|Experimental|ASOCT imaging|Assessment of visual function followed by image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
89637476|NCT05979415|Active Comparator|Staccato Apomorphine|1mg, 2mg, 3mg, 4mg
89637477|NCT05979415|Placebo Comparator|Staccato Placebo|Placebo
89637478|NCT05975749|Experimental|Adjuvant Treatment of Serplulimab and Trastuzuma and Chemotherapy|
89637479|NCT05975749|Active Comparator|Adjuvant Chemotherapy only|
89637480|NCT05973955|Placebo Comparator|Education Control|A combination of alcohol education and sleep hygiene education comprised of four telephone-based sessions delivered over six weeks.
89637481|NCT05973955|Experimental|Insomnia Treatment|Cognitive-behavioral therapy for insomnia adapted to hazardous alcohol users comprised of four telephone-based sessions delivered over six weeks.
89637482|NCT05971303||Patient Questionnaire|Eligible patients will be matched to complete questionnaires in their specified preferred language. Questionnaire patient responses will also be in the patient's identified preferred language, and will be translated into English for study analysis by UHN Interpretation and Translation Services. The questionnaire will comprise of sections in multiple choice and free-text format, administered in an outpatient setting. Question domains will encompass patient demographics, comprehension of diagnosis and treatment, clinical trials, palliative care and overall experiences in the clinic from the perspective of a CALD oncology patient, including identification of any barriers to optimal care.
89637483|NCT05971303||Interpreter Questionnaire|Interpreters will be screened by investigators and approached for their willingness to complete the questionnaires. The questionnaire will comprise of several sections in rating scale and free-text format. Questionnaires will be delivered in English only. Question domains will encompass demographics, professional background, and overall experiences in the clinic setting from the perspective of a professional team member caring for the oncology patient with CALD background, including identification of any barriers to optimal care.
89637484|NCT05971303||Cancer Care Professional Questionnaire|Cancer Care Professionals will be screened by investigators and approached for their willingness to complete the questionnaires. The questionnaire will comprise of several sections in rating scale and free-text format. Questionnaires will be delivered in English only. Question domains will encompass demographics, professional background, and overall experiences in the clinic setting from the perspective of a professional team member caring for the oncology patient with CALD background, including identification of any barriers to optimal care.
89637485|NCT05965726|Experimental|Paxlovid 25 day dosing|Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days
89637486|NCT05965726|Experimental|Paxlovid 15 day dosing|Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 15 days then ritonavir 100mg plus nirmatrelvir-matching placebo x 10 days
89637487|NCT05965726|Placebo Comparator|Control|ritonavir 100mg plus nirmatrelvir-matching placebo bid x 25 days
89637488|NCT05955508|Experimental|Safety Run-In (Part 1)|Evaluation of initial safety and tolerability of the step-up regimen leading up to the start of full dose linvoseltamab.
89637489|NCT05955508|Experimental|Expansion (Part 2)|Linvoseltamab monotherapy according to the same dosing schedule established in the safety run-in part.
89637490|NCT05946707|Active Comparator|high oxygen: decremental FiO2 titration|Five minutes before lung isolation fraction of inspired oxygen will be increased to 1.0, representing the standard procedure for one-lung ventilation. 10, 20 and 30 minutes after OLV initiation paO2 obtained from arterial blood gas analysis will be measured and FiO2 titrated to achieve a paO2 of 75-120 mmHg.
89637491|NCT05946707|Experimental|low oxygen: incremental FiO2 titration|Before lung isolation fraction of inspired oxygen will be maintained as previously set to guarantee normoxia (SpO2 >92%). During OLV SpO2 will be continuously monitored and FiO2 adjusted to keep SpO2 >92%. Additionally after 10, 20 and 30 minutes after OLV initiation paO2 obtained from arterial blood gas analysis will be measured and FiO2 more precisely titrated to achieve a paO2 of 75-120 mmHg.
89637492|NCT05944926|Experimental|Healthy Activity Program (HAP)|HAP is a brief psychological treatment adapted from behavioral activation therapy, an empirically supported psychological treatment recommended by WHO.
89637493|NCT05944926|Experimental|Antidepressant medication (fluoxetine)|Fluoxetine is a selective serotonin reuptake inhibitors (SSRIs) and one of the safest medications used to treat depression. It is a routinely used medication and part of the Essential Drug List (EDL) in India.
89637494|NCT05943535|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
89637495|NCT05943535|Experimental|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
89637496|NCT05943119|Experimental|Experimental group: Radiotherapy in painting dose on histoscannographic mapping|
89637497|NCT05943119|Active Comparator|Control group: standard pan-sinus Radiotherapy|
89637498|NCT05938764|Active Comparator|Motivational Interviewing and Community Reinforcement Approach|A psychosocial intervention culturally tailoring the combination of motivational interviewing (approximately 1-3 individual therapy sessions) and the community reinforcement approach (could include maximum range of 15-19 individual therapy sessions). Two tribal members were hired and trained to deliver this intervention and were located separately from the other arm.
89637499|NCT05938764|Active Comparator|Treatment as Usual|Treatment as usual (TAU) included an intake session and could include individual counseling, group counseling, or cultural education. Treatment as usual was provided by staff at the reservation based outpatient treatment center. There was no limit on number of sessions provided.
89637500|NCT05933850|Experimental|Strong Family Programme Intervention|There will be 3 weekly group sessions of the strong family programme with caregivers and children (8-12 families per group).
89637501|NCT05933850|Active Comparator|Waitlist control group|This group will be on the waiting list and receive SF programme training sessions once the study will be completed.
89637502|NCT05923606|Experimental|Theta-nested gamma tACS applied during passive task epochs|Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during fixation periods between consecutive task trials. EEG will be acquired before and immediately after the intervention.
89637503|NCT05923606|Experimental|Theta-nested gamma tACS applied during memory delays|Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during memory delays. EEG will be acquired before and immediately after the intervention.
89212062|NCT04085549|Experimental|Berry Oil Cream|Study part 1: Administered to a chosen eczema lesion on randomized body half 1-2 times/d or more frequently (use reported to study logbook) for two weeks. Also administered to forearm (randomized body half) twice/d for two weeks. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
89212063|NCT04085549|No Intervention|Control|Study part 1: A chosen eczema lesion on randomized body half is an untreated control for two weeks. Also one forearm (on randomized body half) is a control with no treatment for two weeks.
89637504|NCT05923606|Experimental|Gamma tACS applied during memory delays|Participants will receive single-session administration of tACS during performance of a working memory task. tACS will be applied during memory delays. The stimulation will be phase locked to the peaks of ongoing theta rhythms of the participant. EEG will be acquired before and immediately after the intervention.
89212064|NCT04085549|Active Comparator|Reference cream|A commercial reference cream, not containing berry and plant oils. Study part 2: Administered to randomized body half 1-2 times/d for five weeks.
89212065|NCT00924014|Active Comparator|Conivaptan|Conivaptan will be given via IV bolus
89042263|NCT05831111|Experimental|Part B: mRNA-1195.1 or mRNA-1195.2 Middle Dose|Participants will receive 3 IM injections of mRNA-1195.1 or mRNA-1195.2 (at a dose level selected based on the Part A interim analysis) middle dose on Days 1, 57, and 169.
89042264|NCT05831111|Experimental|Part B: mRNA-1195.1 or mRNA-1195.2 High Dose|Participants will receive 3 IM injections of mRNA-1195.1 or mRNA-1195.2 (at a dose level selected based on the Part A interim analysis) high dose on Days 1, 57, and 169.
89042265|NCT05831111|Active Comparator|Part B: mRNA-1189|Participants will receive 3 IM injections of mRNA-1189 on Days 1, 57, and 169.
89042266|NCT05831111|Placebo Comparator|Part B: Placebo|Participants will receive IM injection of study drug-matching placebo on Days 1, 57, and 169.
89042267|NCT05827003|Active Comparator|Exercise|Individuals with a diagnosis of knee osteoarthritis who underwent supervised exercise under the guidance of a physiotherapist for 6 weeks, 2 days a week.
89042268|NCT05827003|Active Comparator|Exercise&Topical Agent|Individuals with a diagnosis of knee osteoarthritis who had supervised exercise under the guidance of a physiotherapist for 6 weeks, 2 days a week, and in addition to this program, they used diclofenac gel 2 times a day, 4 days a week.
89042269|NCT05827003|Active Comparator|Topical Agent|Individuals with a diagnosis of knee osteoarthritis using diclofenac gel twice a day, 4 days a week, for 6 weeks
89637505|NCT05923606|Placebo Comparator|Placebo tACS applied during task performance|Participants will receive single-session administration of placebo tACS during performance of a working memory task. EEG will be acquired before and immediately after the intervention.
89042270|NCT05824442|Experimental|Biological sample|Blood sample
89637506|NCT05923424|Experimental|Cohort 1 Mid IV Dose|Randomized 6:2 for single ascending dose
89637507|NCT05923424|Experimental|Cohort 3 High IV Dose|Randomized 6:2 for single ascending dose
89637508|NCT05923424|Experimental|Cohort 5 Higher IV Dose|Randomized 6:2 for single ascending dose
89637509|NCT05923424|Experimental|Cohort 6 Low IV Dose|Randomized 6:2 for single ascending dose
89637510|NCT05923424|Experimental|Cohort 2 Mid SC Dose|Randomized 6:2 for single ascending dose
89637511|NCT05923424|Experimental|Cohort 4 High SC Dose|Randomized 6:2 for single ascending dose
89637512|NCT05923424|Experimental|Cohort 7 Low SC Dose|Randomized 6:2 for single ascending dose
89637513|NCT05923424|Experimental|Expansion Cohort 1|Randomized 3:1 for single ascending dose
89637514|NCT05923424|Experimental|Expansion Cohort 2|Randomized 3:1 for single ascending dose
89637515|NCT05923424|Experimental|Expansion Cohort 3|Randomized 3:1 for single ascending dose
89042271|NCT05823441|Placebo Comparator|OS group|Half an hour after the volunteers inhaled 24 units of oxytocin spray, they watched the pre recorded video (attached with pictures and introductions of strangers) and underwent a pain test.
89042272|NCT05823441|Placebo Comparator|PS group|Half an hour after the volunteers inhaled the same amount of saline spray, they watched the pre recorded video (with pictures and introductions of strangers attached) and received a pain test.
89042273|NCT05823441|Experimental|OA group|Half an hour after the volunteers inhaled 24 units of oxytocin spray, they watched the pre recorded video (attached with pictures and introductions of acquaintances) and underwent a pain test.
89042274|NCT05823441|Placebo Comparator|PA group|Half an hour after the volunteers received the same dose of saline, they watched the pre recorded video (attached with pictures and introductions of acquaintances) and received the pain test.
89042275|NCT05822076||L - paravertebral block left|30 woman above 18 years of age qualified for elective breast surgery on the left side of the body
89042276|NCT05822076||P - paravertebral block right|30 woman above 18 years of age qualified for elective breast surgery on the right side of the body
89042277|NCT05814523|Experimental|Ganaxolone IV solution + SOC IV AED|
89042278|NCT05814523|Experimental|Placebo IV solution + SOC IV AED|
89637516|NCT05914376|Experimental|hV01 intratumoral injection|"Single-dose phase (3+3 design):~Participants will receive an intratumoral injection of hV01 at one of the dose levels from 1.0×10^7 PFU to 8.0×10^8 PFU on Day 1 of each treatment cycle. The MTD or MAD will be determined based on the safety and tolerability outcomes of this phase.~Multiple-dose phase (3+3 design):~Two doses per cycle: Participants will receive two intratumoral injections of hV01 at the dose level of sub-MTD or sub-MAD on Day 1 and Day 8 of each treatment cycle.~Three doses per cycle: Participants will receive three intratumoral injections of hV01 at the dose level of sub-MTD or sub-MAD on Day 1, Day 8 and Day 15 of each treatment cycle."
89637517|NCT05911776|Active Comparator|Group NP (nasal packing Dexmedetomidine)|Patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
89637518|NCT05911776|Active Comparator|Group IV (Intravenous Dexmedetomidine)|Patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg IV infusion Dexmedetomidine and nasal packing with saline.
89637519|NCT05911334|Experimental|Restorative Occupational Approaches for Disordered Eating (ROADE)|Novel Outpatient Occupational Therapy Intervention using chronic illness management strategies, yoga, meditation for disordered eating. 8-weeks with 2 visits per week each lasting 1 hour.
89042279|NCT05810194||StrataXRT|
89042280|NCT05810194||Standard of care|
89042281|NCT05807971|Experimental|SAD cohort|SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of ATH-063 (capsule) under fasting conditions at the planned dose levels.
89212066|NCT00924014|Active Comparator|Furosemide|Furosemide will be given via IV bolus
89637520|NCT05903196|Experimental|Mygen V-1000 RF system|The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation & ablation of vessel, tissue & bone
89637521|NCT05901688||Unselected population|Routine unselected populations at 20-22 weeks and 35-37 weeks
89637522|NCT05901688||High risk population|High-risk pregnancies attending the placental disorders clinic which have been deemed to be at risk of having adverse pregnancy outcomes.
89637523|NCT05901493|Experimental|Blocked Evening Only Training|One hour training in the evening, followed by a one hour training 24 hours later
89637524|NCT05901493|Experimental|Distributed Evening Training|One hour training in the evening, followed by a two 30 min trainings 12 and 24 hours later
89637525|NCT05901493|Experimental|Blocked Evening-Morning Training|One hour training in the evening, followed by a one hour training 12 hours later
89042282|NCT05807971|Experimental|MAD Cohort|MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of ATH-063 (Capsule) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.
89042283|NCT05807971|Experimental|Food Effect|An intermediary dose level that has already been administered in this study will be selected for the food-effect evaluation based on the available PK and safety data. This will be conducted under fasting and fed conditions.
89042284|NCT05807971|Placebo Comparator|SAD cohort (Placebo)|SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of placebo (Capsule identical to active ATH-063) under fasting conditions at the planned dose levels.
89042285|NCT05807971|Placebo Comparator|MAD cohort (Placebo)|MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of placebo (Capsule identical to active ATH-063) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.
89042286|NCT05798780|Experimental|ENHANCE Intervention Diet and Excerise|Participants will participate in 2 in-person supervised resistance training sessions every week for the 7 weeks (during radiation), followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks (after radiation). During radiation, participants will be provided 15 meals each week for 7 weeks. Participants will also attend weekly dietary coaching sessions. Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.
89042287|NCT05798780|Experimental|ENHANCE Intervention Diet Only|Participants will be provided 15 meals each week for 7 weeks that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals. Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.
89042288|NCT05798780|No Intervention|Usual Care + Fitbit|Participants will receive handouts with diet and exercise education. Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.
89637526|NCT05901493|Experimental|Blocked Morning Only Training|One hour training in the morning, followed by a one hour training 24 hours later
89637527|NCT05901493|Experimental|Distributed Morning Training|One hour training in the morning, followed by a two 30 min trainings 12 and 24 hours later
89637528|NCT05901493|Experimental|Blocked Morning-Evening Training|One hour training in the morning, followed by a one hour training 12 hours later
89637529|NCT05898555||Healthy individuals|Gait study protocol
89637530|NCT05894421|Experimental|TQB2223 injection+ Penpulimab Injection|intravenous injection of TQB2223 injection and Penpulimab injection for one times every three weeks, 21 days as a treatment cycle.
89637531|NCT05893914|Other|4 week baseline|Randomization to the first tier will include 4 weeks (28 days) of baseline measures (phase A), followed by 5 weeks of treatment and symptom monitoring (phase B)
89637532|NCT05893914|Other|5 week baseline|Randomization to the second tier will include 5 weeks (35 days) of baseline measures (phase A), followed by 5 weeks of treatment and symptom monitoring (phase B)
89637533|NCT05893914|Other|6 week baseline|Randomization to the third tier will include 6 weeks (42 days) of baseline measures, followed by 5 weeks of treatment and symptom monitoring (phase B)
89637534|NCT05893914|Other|7 week baseline|Randomization to the fourth tier will include 7 weeks (49 days) of baseline measure, followed by 5 weeks of treatment and symptom monitoring
89637535|NCT05892757|Experimental|Atogepant|Participants will receive single dose of atogepant on Day 1.
89637536|NCT05892757|Active Comparator|Ubrogepant|Participants will receive single dose of ubrogepant on Day 1.
89637537|NCT05890872|Experimental|Aliya PEF|Pulsed electric field treatment using the Aliya System
89637538|NCT05888194|Experimental|Mucogyne group|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
89637539|NCT05888194|No Intervention|Control group|Standard of care e.i no treatment
89637540|NCT05882045|Experimental|Retatrutide Dose 1|Participants will receive retatrutide subcutaneously (SC).
89637541|NCT05882045|Experimental|Retatrutide Dose 2|Participants will receive retatrutide SC.
89637542|NCT05882045|Placebo Comparator|Placebo|Participants will receive placebo.
89637543|NCT05881304|Experimental|Immediate SREC provision (iSREC)|Those randomized to the iSREC group will be provided a free 8-week supply of standardized research e-cigarettes (SRECs) and asked to try to switch completely to the SREC.
89637544|NCT05881304|Active Comparator|Delayed SREC provision waitlist control (WLC)|Those in the WLC condition will receive SREC provision after an 8-week delay.
89637545|NCT05880901|No Intervention|Control|does not attend afterschool or summer programing
89637546|NCT05880901|Experimental|After school|Attends after school programming for 32 weeks during the school year
89637547|NCT05880901|Experimental|Summer camp|Attends summer day camp programming for 8 weeks during the summer vacation from school
89637548|NCT05880901|Experimental|After school and Summer Camp|Attends after school programming for 32 weeks during the school year and summer day camp programming for 8 weeks during the summer vacation from school
89637549|NCT05873153|Experimental|Treatment Group|Participants will be given access to health education, home blood pressure monitor, and referral to a primary care provider.
89637550|NCT05873153|No Intervention|Control Group|Participants receive referrals only to a primary care provider (PCP) for blood pressure monitoring.
89637551|NCT05869643|Experimental|Cohort 1 STP0404|
89637552|NCT05869643|Placebo Comparator|Cohort 1|
89637553|NCT05869643|Experimental|Cohort 2 STP0404|
89637554|NCT05869643|Placebo Comparator|Cohort 2|
89637555|NCT05869643|Experimental|Cohort 3 STP0404|
89637556|NCT05869643|Placebo Comparator|Cohort 3|
89637557|NCT05861830|Experimental|Arm A|The combination of Dalpiciclib with physician-selected endocrine therapy
89637558|NCT05861830|Active Comparator|Arm B|Chemotherapy selected by the physician
89212067|NCT00924014|Active Comparator|conivaptan and furosemide|on day 3 subjects will receive both study drugs
89637559|NCT05857241|Experimental|Fasting mimicking diet (FMD)|patients aged 65 and over, institutionalized in Long Term Care Units (USLD) or Establishments for the elderly (EHPAD).
89637560|NCT05855733|Experimental|Radiofrequency|treatment of pilonidal disease according to the Fistura procedure
89637561|NCT05845671|Experimental|Dose Finding (Safety Lead-In) Cohort (<80 kg)|To estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in adult participants with advanced NSCLC with ALK, ROS1, and RET gene fusions.
89637562|NCT05845671|Experimental|Dose Finding (Safety Lead-In) Cohort (≥80 kg)|To estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in adult participants with advanced NSCLC with ALK, ROS1, and RET gene fusions.
89637563|NCT05845671|Experimental|Dose Expansion Cohort (<80 kg)|To estimate the objective response rate (ORR) of amivantamab in combination with common TKIs used in ALK, ROS1, and RET advanced NSCLC progressing on TKIs.
89637564|NCT05845671|Experimental|Dose Expansion Cohort (≥80 kg)|To estimate the objective response rate (ORR) of amivantamab in combination with common TKIs used in ALK, ROS1, and RET advanced NSCLC progressing on TKIs.
89637565|NCT05844423|Experimental|VAX-24 Low|Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
89637566|NCT05844423|Experimental|VAX-24 Mid|Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
89637567|NCT05844423|Experimental|VAX-24 Mixed|Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
89637568|NCT05844423|Active Comparator|PCV20|Participants will receive 4 doses of PCV20 administered as an intramuscular injection of the standard dose at 2, 4, 6, and 12-15 months of age.
89637569|NCT05843227||paediatric orthopaedic surgeons|"paediatric orthopaedic surgeons in the national territory who routinely treat idiopathic scoliosis in children and adolescents and who are members of the Société Française d'Orthopédie Pédiatrique (SoFOP) will be included.~questionnaire will be completed. ."
89637570|NCT05843175|Experimental|Pregnant women with type 1 diabetes|Participants will undergo 3 experimental conditions in random order at week of gestation 16 and 35 (experimental phases 1 and 2): pre-meal exercise, post-meal exercise, and non-exercise meal.
89637571|NCT05843175|Experimental|Non-pregnant women with type 1 diabetes|Participants will undergo 3 experimental conditions in random order after recruitment (experimental phase 1): pre-meal exercise, post-meal exercise, and non-exercise meal.
89637572|NCT05839041|Experimental|Part 1|Participants will receive a single intravitreal injection of AVD-104 at one of 4 escalating doses. All participants will be followed up for safety until Month 3. Participants from Part 1 will be offered the opportunity to receive monthly injections of high dose AVD-104 once the 6-month timepoint has been reached for 50% of the participants in Part 2. These participants will be followed for safety only.
89637573|NCT05839041|Active Comparator|Part 2: High dose AVD-104|100 participants will be randomized and treated with bimonthly intravitreal injections of high-dose AVD-104 for the first 12 months. They will continue bimonthly injections for months 13-24.
89637574|NCT05839041|Active Comparator|Part 2: Low dose AVD-104|100 participants will be randomized and treated with monthly intravitreal injections of low dose AVD-104 for 24 months.
89637575|NCT05839041|Active Comparator|Part 2: Avacincaptad|100 participants will be randomized to receive monthly injections of avacincaptad (2 mg. intravitreal)
89637576|NCT05838768|Experimental|A: HRO761 single agent|phase Ib (Dose finding (Escalation and Optimization) and expansion)
89637577|NCT05838768|Experimental|B: HRO761 + tislelizumab|phase Ib (Dose escalation and expansion)
89637578|NCT05838768|Experimental|C: HRO761 + irinotecan|phase Ib (Dose escalation and expansion)
89637579|NCT05838404|Experimental|MOMS on the Bayou Intervention Group|Participants complete intervention protocol.
89637580|NCT05836597|Experimental|Experimental|Experimental VR
89637581|NCT05836597|Sham Comparator|Sham|Sham VR
89637582|NCT05833113|Placebo Comparator|Gruop Control|The patients will be received an ultrasound-guided interscalene brachial plexus block and postoperative Placebo-TENS applied.
89637583|NCT05833113|Active Comparator|Group TENS|The patients will be received an ultrasound-guided interscalene brachial plexus block and postoperative TENS applied.
89637584|NCT05829109|Experimental|Fecal Microbiota Transplant (FMT)|Single arm of 16-18 subjects, all of whom will receive the interventional FMT.
89637585|NCT05820919|Other|Control (each NH acts as its own control):|Each nursing home serves as its own control. Control data will be collected for 1 week (then the intervention will begin).
89637586|NCT05820919|Experimental|Intervention (all NHs receive the intervention):|The intervention arm includes a ten-week active intervention phase, then a five-week sustainment phase.
89637587|NCT05803239|Experimental|First EBUS-TBCB and then EBUS-TBNA group|The patients will undergo first endobronchial ultrasound-guided transbronchial ultrasound-guided cryobiopsy（EBUS-TBCB) and endobronchial ultrasound-guided transbronchial needle aspiration（EBUS-TBNA)：Routine bronchoscopy was completed, and under the guidance of EBUS, combined with CT EBUS-TBNA was used to repeatedly aspirate the tissue for 3 times (One needle is 20-50 back and forth). After the end of puncture, EBUS-TBCB was performed again, and the frozen time was about 10-15s (1.1mm cryoprobe), and the frozen time was 2-3 times to obtain at least 2 samples with a diameter of more than 5mm.
89212068|NCT02591303|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of more than 3 nights a week, more than 3 months, affected daytime functioning, objectified low sleep quality (Sleep Efficiency <85%) with 10 days actigraphy
89042289|NCT05784753|Experimental|HEART Camp|Participants in the HEART Camp group will be provided paid, in-person access to the medical fitness center and in-person coaching by a trained coach.
89042290|NCT05784753|Experimental|HEART Camp Connect|Participants in the HEART Camp Connect group will be provided paid, virtual access to the medical fitness center and virtual coaching by a trained coach via videoconference. Participants will also receive automated, asynchronous motivational electronic messaging if they are below the weekly adherence threshold.
89042291|NCT05784753|No Intervention|Enhanced Usual Care|Participants in the Enhanced Usual Care group will be provided paid virtual access to the medical fitness center and virtual availability of the medical fitness center staff and study personnel for participant-initiated questions.
89042292|NCT05776979|Experimental|isatuximab plus lenalidomide after an autologous stem cell transplantation (ASCT)|Both isatuximab and lenalidomide are FDA approved and commercially available for the treatment of relapsed or refractory MM (MM that has come back or stopped responding to treatment). Participants will begin taking the study drugs about 60-180 days after your ASCT. Participants may receive the study drugs for about 3 years. After that, participants will have follow-up visits 1 time a year for the 3 years after your last dose of study drugs
89042293|NCT05770401|Experimental|Internet-Behavioral Cough Suppression Therapy|Participants will watch treatment-specific educational and training videos and perform the training exercises as recommended. There are a total of five videos ranging from 2-5 minutes in length. Participants will be asked to watch the videos at least once weekly. Daily training exercises will be discussed in the videos and should take no more than a few minutes to complete every day. All exercises are non-invasive and are not physically demanding. Each week participants will complete a progress check question that will take less than one minute to answer, indicating whether they are watching the videos and completing the exercises as recommended.
89057601|NCT04527783|Experimental|experimental group|"Each subject will perform a variety of VR exercises to reduce impairments in their finger range of motion, speed and strength.~It includes a glove-shaped sensor device and a software application."
89637588|NCT05803239|Experimental|First EBUS-TBNA and then EBUS-TBCB group|The patients will undergo first endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and then endobronchial ultrasound-guided transbronchial ultrasound-guided cryobiopsy (EBUS-TBCB): Routine bronchoscopy was completed, combined with CT, EBUS-TBNA needle was used to determine the puncture site, and the sheath tube was used to slightly enlarge the local needle hole for EBUS-TBCB. The freezing time was about 10-15 seconds (1.1mm cryoprobe), and the freezing time was 2-3 times. To obtain at least two pieces of samples with a diameter of more than 5mm. After TBCB, EBUS-TBNA was performed in the same lymph node with 3 repeated tissue aspirations (20-50 back and back per needle).
89637589|NCT05802186|Experimental|Treatment (AI-directed analysis, SBRT)|Patients undergo radiation planning with AI-directed analysis for dose recommendations with Deep Profiler + iGray software on study. Patients then undergo SBRT on study. Patients also undergo PET, CT, MRI, and/or x-ray imaging during screening and follow-up.
89637590|NCT05801029|Experimental|Osimertinib+Amivantamab|Participants will receive osimertinib and amivantamab.
89637591|NCT05799040||Self-developed pulmonary lobar ventilation detector|
89637592|NCT05799040||imported Chartis detection system|
89637593|NCT05795647|Experimental|Pentoxifylline|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
89637594|NCT05789225|Experimental|Fall prevention program + brochure|Fall prevention program and brochure about falls and fall risk factors
89637595|NCT05789225|Active Comparator|Brochure|Brochure about falls and fall risk factors
89637596|NCT05789212|Experimental|Personalized Trial ABCCBA|Participants in Arm 1 will receive a Personalized Trial comprised of three components delivered in a ABCCBA sequence over a total period of 12 weeks, where A-mindfulness, B-yoga, and C-guided walking. Participants in this arm will be prompted to complete 3 x 30-minute intervention sessions weekly during applicable treatment weeks. Interventions will be delivered by a virtual link to online videos recorded by an experienced wellness provider. Participants will be limited to three views of the study-provided intervention content each week.
89637597|NCT05789212|Experimental|Personalized Trial CBAABC|Participants in Arm 2 will receive a Personalized Trial comprised of three components delivered in a CBAABC sequence over a total period of 12 weeks, where A-mindfulness, B-yoga, and C-guided walking. Participants in this arm will be prompted to complete 3 x 30-minute intervention sessions weekly during applicable treatment weeks. Interventions will be delivered by a virtual link to online videos recorded by an experienced wellness provider. Participants will be limited to three views of the study-provided intervention content each week.
89057602|NCT04527783|Active Comparator|control group|Each subject will perform usual care rehabilitation aimed at improving manual dexterity
89637598|NCT05781659|Experimental|Ultrasound elastography guided pleural biopsy group|
89637599|NCT05781659|Experimental|Traditional ultrasound-guided pleural biopsy group|
89637600|NCT05780489|Experimental|DONORS UNDER CONTROLLED OVARIAN STIMULATION|Saliva samples will be analyzed using oestradiol and progesterone ELISA kits.
89637601|NCT05776641|Active Comparator|Active GENUS light and sound|The device is a light and sound device that delivers light stimulation using light-emitting diodes (LED) and sound stimulation through a speaker, with a centrally-mounted tablet that plays videos for entertainment. The device will be positioned on an easel such that the tablet is eye level with the participant while they are sitting 5 feet away. The active device delivers light and sound at 40Hz rate.
89637602|NCT05776641|Sham Comparator|Sham GENUS light and sound|The device is the same as the active device but it delivers light and sound at different frequencies.
89637603|NCT05776628|Active Comparator|Polydioxanone membrane|After flavectomy and manipulation of the spinal nerve and dura mater to resect the herniated intervertebral disk, the membrane will be placed on top of the dura mater.
89637604|NCT05776628|No Intervention|Control|The microdiscectomy procedure will be performed routinely, without the addition of any device over the dura mater.
89637605|NCT05775588|Experimental|Lung volume reduction surgery group|
89637606|NCT05766241|Experimental|Program group|Participants in this group will receive five weekly sessions of Sensory Strategies Training (SST), facilitated by a trained clinician or graduate/post-graduate student in a health-related field.
89637607|NCT05766241|No Intervention|Waitlist control group|Participants in the waitlist control group will not receive SST or any other PTSD or sensory-processing treatments for the duration of the study.
89637608|NCT05760352|No Intervention|Control group|Self-paced exercise
89637609|NCT05760352|Experimental|Intervention Group: eccentric cycling exercise|Received eccentric cycling exercise
89637610|NCT05760352|Experimental|Intervention Group: eccentric cycling exercise with helmet ventilation|Eccentric cycling exercise combined with helmet ventilation
89637611|NCT05760092|Experimental|Photobiomodulation Therapy|Institutional standard treatment for xerostomia and COVID Longa + PBM therapy
89637612|NCT05760092|Placebo Comparator|Placebo Photobiomodulation|Institutional standard treatment for xerostomia and COVID Longa + PBM placebo therapy
89637613|NCT05752760|Experimental|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (2 capsules) once daily for 12 weeks.
89637614|NCT05752760|Placebo Comparator|Placebo Control|Subjects will consume potato starch (2 capsules) once daily for 12 weeks.
89637615|NCT05750849||OPTIMAL SERUM P4 LEVEL|Serum progesterone levels on β-hCG day over the threshold point calculated
89637616|NCT05750849||SUB-OPTIMAL SERUM P4 LEVEL|Serum progesterone levels on β-hCG day below the threshold point calculated
89637617|NCT05750212||Cases|Cases are adult female patients with a diagnosis of pelvic floor disorder.
89637618|NCT05750212||Controls|Controls are adult female patients sampled from an outpatient primary care center
89637619|NCT05744960|Experimental|HPV vaccine communication training.|Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination.
89637620|NCT05744960|Experimental|HPV vaccine communication training and clinic-level financial incentive program|Staff in clinics randomized to this arm will receive the Announcement Approach Training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake.
89637621|NCT05737030|Experimental|L-ornithine-L-aspertate|L-ornithine-L-aspertate 18g per day
89637622|NCT05730829|Experimental|Pain Informed Movement and pain neuroscience education|Participants will receive a twice weekly, 8 week in-person group exercise program, consisting of exercise instruction (75 minutes) and pain neuroscience education (PNE) videos (20 to 30 minutes/week for the first 4 weeks). During the exercise sessions, the educational components and concepts such as mindfulness, muscle tension regulation, and breathing techniques will be applied by the instructor. A third home session (weekly) will be facilitated by exercise handout sheets. The exercise component will be delivered by an experienced yoga teacher that has been extensively trained. The PNE video component will cover the following topics: The purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.
89637623|NCT05730829|Active Comparator|Standard neuromuscular exercise and OA education|Participants in this group will receive an 8-week in-person group exercise program held twice weekly, in which they will receive exercise instructions (60 minutes) and standard osteoarthritis (OA) education (15 to 20 minutes/week for the first 4 weeks). A third home session (weekly) will be facilitated by exercise handout sheets. The exercise component (i.e., the specific movements) of this group will be similar to those of the other group without the added techniques of breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness. The standard OA education videos will cover the following topics: common OA symptoms, risk factors associated with knee OA, and the effects of exercise and self-management tips. The exercise and education components will be delivered by a physiotherapist in the research team.
89637624|NCT05730712|Experimental|Treatment (HP, enzalutamide)|Patients receive pertuzumab, trastuzumab, and hyaluronidase-zzxf SC and enzalutamide PO on study. Patients undergo ECHO, biopsy, CT, and MRI scans. Patients also undergo collection of blood and tissue samples.
89637625|NCT05729776||Overall eating pizza|All the patients that ate pizza
89637626|NCT05729776||Overall eating control meal|All patients that ate control mail (bread)
89637627|NCT05729776||Tandem patients eating pizza|All patients that ate pizza using Tandem Tslim system
89637628|NCT05729776||Medtronic 780 patients eating pizza|All patients that ate pizza using Medtronic 780 System
89637629|NCT05728489|Experimental|BI 765250 very low dose group|
89637630|NCT05728489|Placebo Comparator|Placebo group|
89637631|NCT05728489|Experimental|BI 765250 low dose group|
89637632|NCT05728489|Experimental|BI 765250 medium dose group|
89637633|NCT05728489|Experimental|BI 765250 high dose group|
89637634|NCT05723770|Experimental|Perfluorohexyloctane|
89637635|NCT05723341|Active Comparator|Paravertebral Block Group|In this group, preoperative ultrasound-guided paravertebral block will be performed ipsilateraly via peripheral block needle with 20 ml bupivacaine %0,25 in the paravertebral space.
89637636|NCT05723341|Active Comparator|Subcostal Transversus Abdominis Plane Block Group|In this group, preoperative ultrasound-guided subcostal transversus abdominis plane block will be performed ipsilateraly via peripheral block needle with 20 ml bupivacaine %0,25 into the fascial plane between erector spine muscle and transverse process
89637637|NCT05723341|Active Comparator|Intravenous Patient Controlled Analgesia|In this group, postoperative patient controlled analgesia with morphine will be preferred for postoperative analgesia method.
89637638|NCT05717686|Experimental|Part A: SAD in healthy participants|Part A: Single ascending doses of up to 450 mg AHB-137 by subcutaneous (SC) injection in healthy participants.
89637639|NCT05717686|Experimental|Part B: MD in healthy participants|Part B: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in healthy participants.
89637640|NCT05717686|Experimental|Part C: MD in CHB patients (open label)|Part C: Multiple doses of 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients.
89637641|NCT05717686|Experimental|Part D: MD in CHB patients in multiple centers|Part D: Multiple doses of 200 mg or 300 mg AHB-137 by subcutaneous (SC) injection in CHB patients (Multiple centers across multiple regions).
89057603|NCT04537754|Experimental|clinician|Comparison of LED and diode laser
89057604|NCT02217176||endotracheal intubation|
89637642|NCT05705414|Experimental|Treatment group Valine then EEA|Valine will be administered as two 4 gm packets administered on dialysis treatment day followed by a washout period and then EEA
89042294|NCT05770401|Sham Comparator|Sham Treatment|Participants will watch sham treatment-specific educational and training videos and perform the training exercises as recommended. There are a total of five videos ranging from 2-5 minutes in length. Participants will be asked to watch the videos at least once weekly. Daily training exercises will be discussed in the videos and should take no more than a few minutes to complete every day. All exercises are non-invasive and are not physically demanding. Each week participants will complete a progress check question that will take less than one minute to answer, indicating whether they are watching the videos and completing the exercises as recommended.
89637643|NCT05705414|Experimental|Treatment group EEA then Valine|EAA will be administered as one 12.5 gm packet administered on dialysis treatment day followed by a washout and then Valine
89637644|NCT05705167|Experimental|Plitidepsin 2.5 mg|"Best standard care (as per applicable local, institutional, national, supranational COVID-19 treatment guidelines) and plitidepsin (administered as a 60-minute intravenous (IV) infusion, every 24 hours for 3 consecutive days, at a dose of 2.5 mg) will be administered to participants of the following groups:~Group 1 - Participants receiving immune-suppression due to haematopoietic or organ transplantation.~Group 2 - Participants receiving B-cell depleting therapies.~Group 3 - Participants receiving other immune-suppressive therapies.~Group 4 - Other situations with immune deficiencies."
89637645|NCT05705167|No Intervention|Control|"Best standard care (as per applicable local, institutional, national, supranational COVID-19 treatment guidelines) ± other regulatory-approved antiviral (if clinically indicated) will be administered to participants of the following groups:~Group 1 - Participants receiving immune-suppression due to haematopoietic or organ transplantation.~Group 2 - Participants receiving B-cell depleting therapies.~Group 3 - Participants receiving other immune-suppressive therapies."
89637646|NCT05704621|Experimental|secondary cytoreductive surgery followed by chemotherapy|surgery arm
89637647|NCT05704621|Active Comparator|chemotherapy|no surgery arm
89637648|NCT05698524|Experimental|Single arm|"Patients will receive a combination of PCI-24781/Abexinostat and temozolomide. Patients will receive a loading dose of PCI-24781/Abexinostat prior to the start of Cycle 1; patients will take PCI-24781/Abexinostat by mouth twice a day starting 7 days prior to Cycle 1, Day 1 and ending 4 days prior to Cycle 1, Day 1.~Patients will continue taking PCI-24781/Abexinostat on days 1-4, 8-11, 15-18, and 22-25 of each 28 day cycle, starting with Cycle 1, Day 1. The initial dose level is 60 mg of PCI-2478/Abexinostat 1 by mouth twice daily. The dose level may be escalated based on results of interim data analysis.~Patients will additionally initiate metronomic temozolomide on Cycle 1, Day 1 at a dose of 50 mg/m2, taken by mouth twice daily. Patients will continue the PCI-24781/Abexinostat and metronomic temozolomide regimen until disease progression or intolerance."
89042295|NCT05767671|Other|Study Population Group|People in the ICU on mechanical ventilation due to a diagnosis of ARDS or any other diagnosis that requires mechanical ventilation (following surgery, sepsis without lung involvement, seizures)
89042296|NCT05763797|Experimental|Aim 1 (individual interview)|Participants will be interviewed
89042297|NCT05763797|Experimental|Aim 2 (supportive care program)|Participants will be assigned to one of two groups
89042298|NCT05763797|Experimental|Aim 3 (supportive care program)|Participants will be assessed regarding their program participation
89042299|NCT05763251|Experimental|Short-course therapy|pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy will receive no additional antifungal therapy
89042300|NCT05763251|No Intervention|Standard-course therapy|pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy will receive 7 additional days of systemic antifungal therapy
89637649|NCT05695352|Placebo Comparator|Placebo Comparator in Normal Ovulatory Women|The two arm placebo comparator study will use each participant as her own control with a placebo arm in the first menstrual cycle consisting of two placebo tablets taken at the time of the ovarian follicle measuring 17 mm in diameter and a second dose of two tablets 48 hours later.
89637650|NCT05695352|Active Comparator|Active intervention in Normal Ovulatory Women|The second menstrual cycle for each participant is an active intervention arm. Levonorgestrel 1.5 mg plus meloxicam 15 mg will be taken when the ovarian follicle reaches 17 mm in largest diameter. The two medications will be repeated 48 hours later.
89637651|NCT05692024|Active Comparator|Coffee|Participants in the active arm will take 15 capsules of coffee, each of which will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend (equivalent daily dose: three cups of coffee). Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
89637652|NCT05692024|Placebo Comparator|Placebo|Participants in the placebo arm will take 15 capsules of placebo. Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances. Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
89637653|NCT05691569|Experimental|doll therapy|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy"
89637654|NCT05691569|Other|non anthropomorphic object|non- anthropomorphic soft object
89637655|NCT05689762|Experimental|Health counselling plus E-health platform|Receive same information as controls plus health counseling and access to E-health platform
89042301|NCT05756556|Experimental|Phase 2a|T3011 given via intratumoral (IT) injection in combination with Cobimetinib via oral administration in patients with advanced melanoma.
89042302|NCT05746117|Experimental|Continuous Blood Pressure Monitoring (CBPM)|Participants will wear the Aktiia Bracelet for 6-months and potentially receive blood pressure medication titrations during the 6-month period.
89042303|NCT05746117|Active Comparator|Home Blood Pressure Monitoring (HBPM)|Participants will receive an upper arm cuff and standard hypertension care from their primary care physician.
89057605|NCT02217176||laryngeal mask airway|
89057606|NCT02217215||Negative and Referral Cytology Results|CNDS Advanced Cervical Scan Colposcopy
89637656|NCT05689762|No Intervention|Standard care|Receive (1) standard care advice based on general health benefits of healthy lifestyle habits (benefits of adherence to national guidelines about physical activity and dietary habits as well as limiting alcohol intake and smoking withdrawal), (2) feedback about current lifestyle habits and health status. Tobacco users and subjects with high alcohol consumption will be referred to specialized care.
89637657|NCT05684965|Experimental|Part 1A - XTX301 Monotherapy Dose Escalation|Part 1A Dose Escalation of XTX301 administered in ascending doses to patients with advanced solid tumors to assess the safety and tolerability and determine the recommended Phase 2 dose (RP2D).
89637658|NCT05684965|Experimental|Part 1B - XTX301 Monotherapy in Select Tumor Types|Part 1B XTX301 will contribute to the assessment of safety and feasibility of XTX301 and will additionally allow pharmacodynamic assessment of XTX301.
89637659|NCT05670587|Experimental|All participants|
89637660|NCT05662683|Experimental|Working Group 1|"From the preparation stage of the PAP-SMEAR removal procedure to the completion of the PAP-SMEAR removal procedure until the completion of the PAP-SMEAR removal procedure, after providing an internet connection with a smartphone for the image, clicking the youtube.com link and watching Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ) nature video virtual reality Goggles will be provided.~Virtual reality glasses to be used in the research are not a medical device."
89637661|NCT05662683|Experimental|Working Group 2|Distraction cards containing five optical illusion figures will be shown to the women by the researcher
89637662|NCT05662683|Experimental|Working Group 3|From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
89637663|NCT05662683|No Intervention|Control Group|The maintenance and applications in the routine PAP-SMEAR application will be done exactly.
89637664|NCT05662306|Experimental|Aripiprazole and Computerized Cognitive and Functional Skills Training Group|Participants in this arm will receive long-acting injectable aripiprazole every 2 months formulation for 12 consecutive months. Participants in this arm will also receive Computerized cognitive and functional skills training during the first 12 weeks of study participation.
89637665|NCT05659693|Experimental|Experimental Group|Digital literacy education specific to menopause will be given to this group.
89637666|NCT05659693|No Intervention|Control Group|no intervention will be applied to this group.
89637667|NCT05659069||Control group|10 patients with dental implant placement without inferior alveolar nerve lateralization
89637668|NCT05659069||Lateralization group|10 patients with dental implant placement with inferior alveolar nerve lateralization.
89637669|NCT05655819|Active Comparator|Glutamine Group|Subjects will receive glutamine for 28 days.
89637670|NCT05655819|Placebo Comparator|Placebo Group|Subjects will receive placebo for 28 days.
89637671|NCT05643001|Experimental|Electronic Health Record Notification|"For eligible patients presenting with an acute hemorrhagic stroke, a recommendation to measure low-density lipoprotein (LDL) and glycated hemoglobin A1c (HbA1c) together with their last measurement dates will be displayed in the patient's electronic health record through a best practice alert (BPA). The alert will display for the patient's provider when they first open the patient's chart. The provider may accept the automatically generated orders for both measurements displayed in the BPA, may modify one or both of the orders, or choose to dismiss the BPA.~For patients that follow-up with the out-patient stroke clinic and received the in-patient intervention, a second BPA will suggest referrals to sleep study and audiology. The alert will display for the patient's provider when they first open the patient's chart. The provider may accept one or both of the referrals suggested by the BPA, or may choose to dismiss the BPA."
89637672|NCT05638906|Experimental|single-arm study with intra-subject comparisons|Study eyes of subjects with uncontrolled (IOP > 20 mmHg) open-angle glaucoma (OAG), where IOP is not controlled when using maximum tolerated glaucoma medications.
89637673|NCT05638321|Experimental|Treatment Arm 1|Eyes of subjects with uncontrolled (IOP > 20 mmHg) open-angle glaucoma (OAG), where IOP is not controlled when using maximum tolerated glaucoma medications
89637674|NCT05638321|Experimental|Treatment Arm 2|Eyes of subjects with uncontrolled (IOP > 20 mmHg) open-angle glaucoma (OAG), who failed prior filtering procedure or had uncontrolled IOP on tolerated glaucoma medications [Treatment Arm 2 and Treatment Arm 3].
89637675|NCT05638321|Experimental|Treatment Arm 3|Two (2) inferonasal sclerostomies will be performed by the MIMS® system in the eyes of subjects who failed prior filtering procedure or had uncontrolled IOP on tolerated glaucoma medications (i.e., refractory glaucoma).
89637676|NCT05624450|Experimental|Tozorakimab|Approximately 2902 participants will be randomized in a 1:1 ratio. Arm 1 (n=approximately 1451) will receive a single dose of tozorakimab.
89637677|NCT05624450|Placebo Comparator|Placebo|Approximately 2902 participants will be randomized in a 1:1 ratio. Arm 2 (n=approximately 1451) will receive matching placebo.
89637678|NCT05619224|Experimental|GEO+N|Neurodevelopmental stimulation intervention programme combined with an oral stimulation programme. They recives 10 sesions of 15 minutes of stimulation.
89637679|NCT05619224|Experimental|GEO|Oral stimulation programme. They recives 10 sesions of 15 minutes of stimulation.
89637680|NCT05615896|Experimental|P200TxE Device First|
89637681|NCT05615896|Experimental|P200TE Device First|
89637682|NCT05610306||Inherited ichthyosis patients|Interviews
89637683|NCT05607979|Active Comparator|TRIAL INTERVENTION|Trial intervention is wound treatment with Lavior Diabetic Wound Gel.
89637684|NCT05607979|Active Comparator|CONTROL THERAPY|Control therapy is defined as Smith & Nephew Solosite Gel Hydrogel Wound Dressing, according to actual guidelines or local clinical standards. Standard therapy is defined as the currently accepted and widely used treatment for the respective wound type, based on the results of past research. Therapy options for standard wound care are treatments that experts agree to be appropriate, accepted, and widely used.
89637685|NCT05606341|Experimental|CpG 1018 0.1 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.1mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
89637686|NCT05606341|Experimental|CpG 1018 0.25 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.25 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
89637687|NCT05606341|Experimental|CpG 1018 0.5 mg/kg|"3 injections at Day 1, Week 4, and Week 8.~Treatment administered as morning injection of dose 0.5 mg/kg, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions."
89637688|NCT05606341|Placebo Comparator|Placebo|3 injections of sterile saline at Day 1, Week 4, and Week 8, followed by 1-hour post-dose observation period to check for injection site reaction and/or adverse reactions.
89637689|NCT05603338|Active Comparator|LSG|just laparoscopic sleeve gastrectomy without banding
89637690|NCT05603338|Experimental|LSG with omental band|laparoscopic sleeve gastrectomy with omental banding
89637691|NCT05598905|Experimental|Oxycodone + Pregabalin|Participants will visit twice. On one visit they will take a 10mg oxycodone tablet and 90 minutes later a 150mg pregabaline capsule.
89637692|NCT05598905|Experimental|Oxycodone + Lacosamide|Participants will visit twice. On one visit they will take a 10mg oxycodone tablet and 90 minutes later a 150mg Lacosamide capsule.
89637693|NCT05598905|Other|Oxycodone|"Amendment:~one open label arm.~In order to get an impression of the effect of 10 mg oxycodone per se, one open label arm of just 10 mg oxycodone as a visit 3 was added."
89637694|NCT05595369|Experimental|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
89637695|NCT05595369|Experimental|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
89637696|NCT05595369|Placebo Comparator|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
89637697|NCT05590494|Other|Repair a partially torn rotator cuff|Subjects will undergo an ultrasonic tenotomy to repair a partially torn rotator cuff per standard of care as clinically indicated
89637698|NCT05570708|Experimental|Personal experience of substance-assisted therapy using psilocybin, MDMA, and LSD|
89637699|NCT05570006|Experimental|ABBV-668|Participants will receive ABBV-668 twice daily approximately at same time each day for 16 weeks.
89637700|NCT05568940||Pre-menopausal women >18 years old with endometriosis and/or uterine fibroids|GnRH-a depot (11.25mg IM x 1) and daily Tibolone 2.5mg orally once a day for 2-3 months.
89637701|NCT05564299|No Intervention|Standard of Care|Point-of-care gram stain
89637702|NCT05564299|Experimental|Rapid STI Test|
89637703|NCT05561803||Radiodermatitis Case Group|40 patients on palliative care with grade 2 or grade 3 radiodermatitis after radiotherapy for the treatment of cancer submitted to a PBM therapy protocol
89637704|NCT05557838|Experimental|cohort 1|durvalumab in combination with tremelimumab
89637705|NCT05557838|Experimental|cohort 2|durvalumab in combination with tremelimumab
89637706|NCT05554510||Hospitalized Patients with Arterial Catheters|
89637707|NCT05547542|Experimental|Part A: Kappa Opioid Receptor (KOR) Cohort|"Participants will receive single dose of CVL-354, 25 mg, orally, on Day 1 along with [11C]-LY2795050, intravenous (IV) bolus injection of up to 20 millicurie (mCi) before the baseline and post-dose PET scans.~Based on the KOR receptor occupancy (RO) results from this cohort, dosing may be explored further in subsequent cohorts."
89637708|NCT05547542|Experimental|Part B: Mu Opioid Receptor (MOR) Cohort|"Part B will commence after Part A cohort is completed. Participants will receive single dose of CVL-354 150 mg, orally, on Day 1 along with [11C]-carfentanil, IV bolus injection of up to 20 mCi before the baseline and post-dose PET scans.~Based on the MOR RO results from this cohort, dosing may be explored further in subsequent cohorts."
89637709|NCT05543200||All Participants|All men who have a primary diagnosis of BPH with LUTS that are prescribed BPH medications or a surgical intervention.
89637710|NCT05542342|Experimental|Experimental arm|Patients will receive Sitravatinib 100 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until progression of disease, unacceptable toxicity, death, or consent withdrawal, whichever occurs first. Treatment may be continued after progression according to physician criteria (with previous consultation with Coordinating investigator) until patients no longer receive clinical benefit.
89637711|NCT05535972|Experimental|Participants receiving TRELEGY ELLIPTA|Participants will receive FF/UMEC/VI, inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) for 12 weeks.
89637712|NCT05527769||pre-pectoral prosthesis|breast cancer patients with an indication for total mastectomy + immediate breast reconstruction (IBR) by prosthesis using a pre-pectoral technique
89637713|NCT05527769||retropectoral prosthesis|breast cancer patients with an indication for total mastectomy + immediate breast reconstruction (IBR) by prosthesis using the retropectoral technique
89637714|NCT05526755|Experimental|Osimertinib|Participants will receive osimertinib (AZD9291).
89637715|NCT05517928|Experimental|Lactobacillus rhamnosus GG Group|Subjects will receive omeprazole daily for 56 days. After 28 days, subjects will receive Lactobacillus rhamnosus GG two capsules daily taken with a meal.
89637716|NCT05517928|Placebo Comparator|Placebo Group|Subjects will receive omeprazole daily for 56 days. After 28 days, subjects will receive placebo two capsules daily taken with a meal.
89637717|NCT05513742|Experimental|CTX-009 Treatment|
89637718|NCT05500443|Experimental|Active treatment|Tablets with vitamin k2 (Menaquinone-7 (MK-7)) 720 μg/day
89637719|NCT05500443|Placebo Comparator|Placebo|Tablets with placebo
89042304|NCT05736536|Experimental|Intervention Group|This group will receive a package of health education modules through Chance2Act website in addition to the existing health education being offered in the health clinic.
89042305|NCT05736536|No Intervention|Control Group|This group will receive the existing health education being offered in the health clinic.
89637720|NCT05499702|Experimental|Adults with type 2 diabetes|"20 subjects will be studied on one occasion, following 6 weeks of caloric restriction. They will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake. After this subjects will undergo a hyperglycemic clamp with 2 doses of glucagon infused."
89637721|NCT05485155|Experimental|Active Drug|Zemaira alpha-proteinase inhibitor
89637722|NCT05470985|Experimental|Ozanimod Dose Level 1|
89637723|NCT05470985|Experimental|Ozanimod Dose Level 2|
89637724|NCT05469919|Experimental|Ceralasertib monotherapy|This is a sequential group treatment/dose-escalation study with 2 cohorts with no masking.
89637725|NCT05463744|Experimental|Insulin Efsitora Alfa|Participants will receive insulin efsitora alfa by subcutaneously (SC)
89637726|NCT05463744|Active Comparator|Insulin Degludec|Participants will receive insulin degludec SC
89637727|NCT05459571|Experimental|Axicabtagene Ciloleucel|"Participant will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m^2/day and fludarabine 30 mg/m^2/day) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2.~Participant will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10^6 cells/kg."
89637728|NCT05452161|Active Comparator|Standard care|Control group receives the standard care in place in the service, a group information session about knee/hip arthroplasty surgery.
89637729|NCT05452161|Experimental|Standard care + individualized patient-centered preparation and education session|Intervention group A receives, in addition to standard care, an individualized patient-centered preparation and education session
89637730|NCT05452161|Experimental|Standard care + individualized patient-centered preparation and education session + remote follow-up|Intervention group B receives, in addition to standard care and an individualized patient-centered preparation and education session, a remote postoperative follow-up
89637731|NCT05445349||Asthma patients|Patients with proven record of asthma disease.
89637732|NCT05445349||COPD patients|Patients with proven record of COPD disease.
89637733|NCT05440422|Active Comparator|Patient|anifrolumab
89637734|NCT05440422|Placebo Comparator|Patient placebo|placebo
89637735|NCT05432583|Experimental|Part A - BNT163|Escalating dose levels
89637736|NCT05432583|Experimental|Part A - Placebo|Isotonic NaCl solution (0.9%)
89637737|NCT05432583|Experimental|Part B - BNT163 Dose 1|
89637738|NCT05432583|Experimental|Part B - BNT163 Dose 2|
89637739|NCT05408455|Experimental|EMST (Expiratory Muscle Streght Training) group|EMST at a pressure value between 50-75% will be applied for 8 weeks, 3 days a week and 24 sessions in total.
89637740|NCT05408455|Sham Comparator|Sham EMST Group|EMST without threshold loading will be applied for 8 weeks, 3 days a week and 24 sessions in total.
89637741|NCT05387018||Observation group (hyperbaric oxygen + routine rehabilitation treatment)|
89637742|NCT05387018||control group (routine rehabilitation treatment)|
89637743|NCT05384041|Active Comparator|Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)|The Fisher Wallace Stimulator provides cranial electrotherapy stimulation and is an active device.
89637744|NCT05384041|Placebo Comparator|Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)|The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
89637745|NCT05373108|Experimental|Intervention Arm|A consecutive subset of eligible patients based on inclusion/exclusion criteria will receive a 1-week course of Macitentan (10 mg po daily) prior to their routine 1-year coronary angiogram (7th and final dose of Macitentan will occur on the day of the angiogram).
89637746|NCT05371652|Experimental|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day)
89637747|NCT05365217|Experimental|Arm A - Nonacog beta pegol (On-demand/Prophylaxis)|Participants on on-demand treatment for 28 weeks, thereafter prophylactic treatment
89637748|NCT05365217|Experimental|Arm B - Nonacog beta pegol (Prophylaxis)|Participants on prophylactic treatment only
89637749|NCT05363865|Experimental|Virtual Community Intervention|Participants will participate in an online community with structured sessions as well as the ability to communicate freely with others.
89637750|NCT05363865|Active Comparator|Standard of Care|Participants will be exposed to what's disseminated within their communities
89637751|NCT05363813|Experimental|Laparoscopic Surgical Patients|"Adult subjects, male or female, ≥18 years old~Subjects who have been scheduled for a laparoscopic surgery using the clip~Subjects who had provided written informed consent form~Ability and willingness to comply with all study requirements to be evaluated for each study visit"
89637752|NCT05363553|Experimental|infant formula based on whole goat milk|
89637753|NCT05363553|Active Comparator|Infant formula based on cow milk proteins|
89637754|NCT05363553|No Intervention|Predominantly breastmilk|
89637755|NCT05362058|Experimental|Insulin Efsitora Alfa|Participants will receive insulin efsitora alfa subcutaneously (SC) once weekly.
89637756|NCT05362058|Active Comparator|Insulin Degludec|Participants will receive insulin degludec SC once daily
89637757|NCT05355701|Experimental|Monotherapy dose escalation (Part 1)|Participants will receive PF-07799933
89637758|NCT05355701|Experimental|Combination dose escalation (Part 2)|Participants will receive PF-07799933 in combination with binimetinib or cetuximab
89637759|NCT05355701|Experimental|Dose expansion (Part 3) - Tumor and mutation specific Cohort 1|Participants will receive PF-07799933
89637760|NCT05355701|Experimental|Dose expansion (Part 3) - Tumor and mutation specific Cohort 2|Participants will receive PF-07799933
89637761|NCT05334758|Experimental|At least 30 children between 2 - 13 years of age|Subjects less than 14 years of age, where the Parent or legal guardian collects a sample from their child (e.g., ages 2-13) and performs the Bio-Self COVID-19 antigen home test. The standard of care test and the RT-PCR test samples will be collected by the study team.
89637762|NCT05334758|Experimental|Subjects 14 - 90 years of age|The subject will self collect and test using the Bio-Self COVID-19 antigen home test. The standard of care test and the RT-PCR test samples will be collected by the study team.
89637763|NCT05333471|Experimental|Interventional|As this is a single arm study, this arm includes all participants. Participants will receive fecal microbiota transplantation (FMT) delivered by colonoscopy as a treatment for chronic granulomatous disease (CGD)-associated colitis (AC).
89637764|NCT05326087|Active Comparator|Antagonist group|Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
89637765|NCT05326087|Experimental|PPOS group|Women will receive oral MPA 10mg qd from Day 3 till the day of ovulation trigger.
89637766|NCT05302063|Experimental|Spinal Cord Stimulation (SCS)|Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
89637767|NCT05296395|Experimental|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (1 serving of GoodBelly fermented oat drink) once daily for 6 weeks
89637768|NCT05296395|Placebo Comparator|Heat-killed placebo control|Subjects will consume 1 serving of GoodBelly fermented oat drink that has been treated to heat kill all Lp299v once daily for 6 weeks
89637769|NCT05295290|Other|myocarditis/pericarditis following COMIRNATY|myocarditis/pericarditis following COMIRNATY within 28 days of dose
89637770|NCT05295290|Other|myocarditis/pericarditis following COVID-19 or MIS-C|myocarditis/pericarditis following COVID-19 or MIS-C without exposure to COMIRNATY
89637771|NCT05282459|Experimental|Enasidenib mesylat|Participants will self administer the enasidenib orally everyday.
89637772|NCT05278104|Experimental|Atomoxetine|
89637773|NCT05278104|Placebo Comparator|Placebo|
89637774|NCT05275400|Experimental|Insulin Efsitora Alfa|Participants will be given insulin efsitora alfa subcutaneously (SC).
89637775|NCT05275400|Active Comparator|Insulin Degludec|Participants with be given insulin degludec SC.
89637776|NCT05262361|Experimental|Office based Vergence and Accommodative Therapy immediately after enrollement|This arm will start immediately after baseline assessment. The participant will have two sessions of one hour each for 6 weeks (12 office-based vergence and accommodative therapy sessions). The first outcome measurement will be attained by a masked optometrist. Then, the participant will have 2 more weeks of therapy (4 office-based vergence and accommodative therapy sessions). The second and final outcome measurement will be attained. Assessments include a masked optometric vision exam, objective eye movement recordings and an functional MRI scan.
89637777|NCT05262361|No Intervention|Office based Vergence and Accommodative Therapy Delay 6 weeks post enrollment|This arm will start with a 6 week delay (no vision therapy) after baseline assessment to evaluate natural recovery. After 6 weeks, the first outcome assessment will be attained by a masked optometrist. The participant will have two sessions of one hour each for 8 weeks (16 office-based vergence and accommodative therapy sessions). The second and final outcome measurement will be attained. Assessments include a masked optometric vision exam, objective eye movement recordings and an functional MRI scan.
89637778|NCT05255224||Retrospective|Patients admitted to Mass Brigham Hospitals for cardiac surgery from 1st January 1998 to 31st December 2020
89637779|NCT05255224||Prospective|Patients admitted to Barts Health, Liverpool Heart and Chest Hospital, or Oxford University Hospitals NHS Foundation Trust for cardiac surgery between 1st October 2021 to 31st July 2023
89637780|NCT05254535|Other|Intervention|Up to 10 rural health systems will be participating in I-SITE implementation with cluster-randomization of the order of initiation for the intervention. All sites will receive usual care teleophthalmology prior to I-SITE implementation.
89637781|NCT05245812|Experimental|Treatment arm (SPrNSM)|Patients will undergo Single Port robotic Nipple Sparing Mastectomy (SPrNSM) with immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (Alloderm)
89637782|NCT05232916|Placebo Comparator|0.9% Normal Saline|0.9% normal saline in HLA-A*02 positive and HER2/neu positive subjects administered intradermally every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)
89637783|NCT05232916|Experimental|GLSI-100|GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects administered intradermally every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)
89637784|NCT05232916|Experimental|GLSI-100, Open-label|Open-label arm: GLSI-100 immunotherapy in non-HLA-A*02 positive and HER2/neu positive subjects administered intradermally every month for first 6 months then every 6 months for next 2.5 years (11 intradermal injections over 3 years)
89637785|NCT05227170|Experimental|Lp299v|Subjects will consume 20 billion colony forming units of Lp299v (2 capsules) once daily for 8 weeks.
89637786|NCT05227170|Placebo Comparator|Heat-killed placebo control|Subjects will consume potato starch (2 capsules) once daily for 8 weeks.
89637787|NCT05224414|Experimental|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program up to 12 sessions of a digital cognitive training targeting interpretation bias
89637788|NCT05224414|Sham Comparator|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program up to 12 sessions of digitized psychoeducation
89637789|NCT05216263|Experimental|Atogepant|Participants will receive atogepant once a day (QD) during the 24-week treatment period.
89637790|NCT05198310|Experimental|Cohort 1 KPL-404|KPL-404 2mg/kg Subcutaneous (SC) q2wk for 12 weeks
89637791|NCT05198310|Placebo Comparator|Cohort 1 Placebo|Placebo for KPL-404 SC q2wk for 12 weeks
89637792|NCT05198310|Experimental|Cohort 2 KPL-404|KPL-404 5mg/kg SC q2wk for 12 weeks
89637793|NCT05198310|Placebo Comparator|Cohort 2 Placebo|Placebo for KPL-404 SC q2wk for 12 weeks
89637794|NCT05198310|Experimental|Cohort 3 KPL-404|KPL-404 5mg/kg SC qwk for 12 weeks
89637795|NCT05198310|Experimental|Cohort 3 KPL-404 and Placebo|KPL-404 5mg/kg SC q2wk with alternating weekly administrations of KPL-404 or placebo SC for 12 weeks
89637796|NCT05198310|Placebo Comparator|Cohort 3 Placebo|Placebo for KPL-404 SC qwk for 12 weeks
89637797|NCT05198310|Experimental|Cohort 4 KPL-404|KPL-404 SC q4wk for 12 weeks: 600 mg loading dose at baseline followed by 400 mg at weeks 4 and 8.
89637798|NCT05198310|Placebo Comparator|Cohort 4 Placebo|Placebo for KPL-404 SC q4wk for 12 weeks
89637799|NCT05196867|Experimental|Arm 1: Immediate Intervention|participants will receive the 6 months intervention immediately
89637800|NCT05196867|Experimental|Arm 2: Delayed Intervention|participants will receive the intervention after the 6-month follow-up visit
89637801|NCT05170204|Experimental|Cohort A1: ALK-Positive (alectinib arm)|Participants will receive alectinib 600 mg orally twice daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
89637802|NCT05170204|Active Comparator|Cohort A1: ALK-positive (durvalumab arm)|Participants will receive 1500 mg of intravenous (IV) durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first
89637803|NCT05170204|Experimental|Cohort A2: ROS 1-positive (entrectinib arm)|"Participants will receive entrectinib 600 mg orally once daily until completion of treatment period (3 years), or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first.~Cohort A2 has been closed to enrollment."
89637804|NCT05170204|Active Comparator|Cohort A2: ROS 1-positive (durvalumab arm)|"Participants will receive 1500 mg of IV durvalumab every 4 weeks until completion of treatment period (1 year) or until disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death, whichever occurs first~Cohort A2 has been closed to enrollment."
89637805|NCT05164341|Active Comparator|metreleptin|Metreleptin [Recombinant-methionyl human Leptin; r-metHuLeptin] for daily injection is a sterile, white, solid lyophilised cake
89637806|NCT05164341|Placebo Comparator|placebo|Placebo for daily injection is a sterile, white, solid lyophilised cake
89637807|NCT05156398|Active Comparator|Rimegepant / BHV3000|Rimegepant 75mg or 50mg (2 X 25mg) ODT
89637808|NCT05156398|Placebo Comparator|Matching Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
89637809|NCT05144932|Experimental|StrokeAlarm use|This is a single arm study. All participants will be instructed to use the StrokeAlarm medical device for 1 month.
89637810|NCT05139784||Type 1 diabetes|As defined by the presence of hyperglycemia and/or islet auto-antibodies.
89637811|NCT05139784||Other forms of diabetes or autoimmune endocrinopathy|Type 2 diabetes, ketosis-prone diabetes, familial diabetes, secondary diabetes, immunotherapy-induced diabetes; and/or autoimmune endocrinopathies.
89637812|NCT05139784||No diabetes|No diabetes or impaired glucose tolerance; no cancer, infectious or immune pathologies; no other condition related to autoimmune and metabolic alterations that may bias the variables under study.
89637813|NCT05139784||Lymphadenectomy planned at the occasion of an abdominal surgery|Patients undergoing a lymphadenectomy during surgery for the treatment of their underlying pathology.
89637814|NCT05134740|Experimental|Experimental Arm|Patients receiving autologous TAA-specific cytotoxic CTLs
89637815|NCT05129592|Active Comparator|Nicotine corrective control|A factual message about nicotine that does not contain a causal explanation for what actually causes tobacco-caused disease or an explanation for why the misperception that nicotine causes cancer may have come to be believed.
89637816|NCT05129592|Experimental|Nicotine corrective with causal explanation|A factual message about nicotine that contain a causal explanation for what actually causes tobacco-caused disease: tar and chemicals created in tobacco smoke when tobacco is lit on fire.
89637817|NCT05129592|Experimental|Nicotine corrective with reason for misperception|A factual message about nicotine that contains an explanation for why the misperception may have come to be believed: that health messaging often discuses nicotine and tobacco-caused disease at the same time and people incorrectly make the connection that nicotine causes cancer.
89637818|NCT05129592|Experimental|Nicotine corrective with both components of coherence|A factual message about nicotine that contains both a causal explanation for what actually causes tobacco-caused disease and an explanation for why the misperception may have come to be believed.
89637819|NCT05128825|Other|Open-label with ZN-c3 (also known as azenosertib)|ZN-c3 (azenosertib) taken orally with food
89637820|NCT05124886|Active Comparator|Healthy Controls|
89637821|NCT05124886|Experimental|Enteric Hyperoxaluria|
89042306|NCT05729620|Experimental|STARgraft-3|Participants will be implanted with 6mm diameter STARgraft-3 grafts as an upper arm Brachial Artery to Axillary Vein shunt for hemodialysis access.
89042307|NCT05726396|Experimental|RMT group|16 patients will be randomized to Oral restorative microbiota therapy (RMT). Consenting eligible participants receive a loading dose of RMT capsules.
89042308|NCT05726396|Placebo Comparator|active placebo|participants in the placebo arm will receive an identical looking placebo capsules
89042309|NCT05721989|Experimental|Ziltivekimab B (manual syringe)|Participants will receive a single subcutaneous (s.c.) injection of 15 milligram (mg) ziltivekimab B (15 milligrams per milliliter [mg/mL]) by single-use pre-filled manual syringe on Day 1.
89637822|NCT05124392||Individuals with a family history of Prion disease|Individuals with a family history of Prion disease
89042310|NCT05721989|Experimental|Ziltivekimab D (manual syringe)|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
89042311|NCT05721989|Experimental|Ziltivekimab C (pen-injector)|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
89042312|NCT05715697|Experimental|Renal denervation and maintenance of heart failure medications|Renal denervation in patients with HFpEF and uncontrolled hypertension
89042313|NCT05715697|Sham Comparator|Sham intervention, maintenance of heart failure medications|Sham Treatment. After 1 year, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
89637823|NCT05116475|Experimental|Arm A|Arm A: ADT + Intensity-Modulated Image-Guided Radiation Therapy + Darolutamide ADT will be associated with LHRH agonists or antagonists for 24 months4. Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
89637824|NCT05116475|Placebo Comparator|Arm B|"Arm B: ADT + Intensity-Modulated Image-Guided Radiation Therapy + Placebo of Darolutamide~ADT will be associated with LHRH agonists or antagonists for 24 months4. Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months."
89637825|NCT05112536|Experimental|Trilaciclib plus chemotherapy|"Trilaciclib lead-in, followed by trilaciclib plus anthracycline/cyclophosphamide, then trilaciclib plus taxane chemotherapy:~Lead-in trilaciclib (240mg/m2) single dose monotherapy~Trilaciclib (240mg/m2) + doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) + pembrolizumab (per Investigator discretion; 400mg)~Trilaciclib (240mg/m2) + paclitaxel (80 mg/m2) + carboplatin (per Investigator discretion; AUC 1.5)"
89637826|NCT05108233||Observational (survey)|"COHORT 1-TP1: Patients complete surveys over 20 minutes on post-op day 3 and on day of discharge (or within 1 week).~COHORT 1-TP2: Patients complete surveys over 15 minutes at all regularly scheduled follow-up appointments (approximately 1 month, 3 months, 6 months, 12 months).~COHORT 2: Patients complete surveys over 15 minutes once."
89637827|NCT05103046|Experimental|Dose Finding as Monotherapy - Part 1|UCT-03-008 Dose Finding
89637828|NCT05103046|Experimental|Expansion as Monotherapy - Part 2|UCT-03-008 RP2D Expansion
89637829|NCT05091567|Experimental|Arm A: Atezolizumab+Lurbinectedin|"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle in combination with lurbinectedin on Day 1 of each 21-day cycle."
89637830|NCT05091567|Active Comparator|Arm B: Atezolizumab|"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle."
89637831|NCT05090995|Active Comparator|Self-Monitoring and Feedback|The intervention consists of subjects wearing a PPG device for 6 weeks. Subjects will monitor their own health and report their sleep behaviors daily during this time. On weeks two, four, and six subjects will receive personalized health feedback based on the PPG device data and sleep diaries.
89637832|NCT05090995|Placebo Comparator|Self-Monitoring|The intervention consists of subjects wearing a PPG device for 6 weeks. Subjects will monitor their own health and report their sleep behaviors daily during this time.
89637833|NCT05083442|Active Comparator|Group 1 - LLLT|Subject receive Laser treatments and Lifestyle Modifications
89637834|NCT05083442|Sham Comparator|Group 2 - SHAM|Subject receives Sham Laser treatments and Lifestyle Modifications
89637835|NCT05065450|Experimental|Brain Stimulation|Neurosurgical epilepsy patients that undergo placement of medial temporal electrode for seizure localizations will be recruited. All participants will view a series of images of emotionally-neutral objects on a computer screen. After each item presentation, they will randomly undergo either active-BLAES or sham-stimulation. Over subsequent days, free recall and recognition memory for these items, relative to new distractor items will be tested. Memory for items presented with and without stimulation will be compared. Brain activity recorded in the medial temporal lobe during item presentations will be used to predict subsequent memory. Such good and bad memory states (biomarkers) will be used to perform closed-loop stimulation when bad memory states are detected in order to enhance subsequent memory.
89637836|NCT05056597||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
89637837|NCT05056597||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype
89637838|NCT05056597||BN|Participants that meet DSM-V criteria for Bulimia Nervosa.
89637839|NCT05056597||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
89637840|NCT05052697|Experimental|SSA: mIRV A (dose level 1) + QIV|
89637841|NCT05052697|Experimental|SSA: mIRV A (dose level 2) + QIV|
89637842|NCT05052697|Experimental|SSA: mIRV A (dose level 3) + QIV|
89637843|NCT05052697|Experimental|SSA: mIRV A (dose level 4) + QIV|
89637844|NCT05052697|Experimental|SSA: mIRV B (dose level 1) + QIV|
89637845|NCT05052697|Experimental|SSA: mIRV B (dose level 2) + QIV|
89637846|NCT05052697|Experimental|SSA: mIRV B (dose level 3) + QIV|
89637847|NCT05052697|Experimental|SSA: mIRV B (dose level 4) + QIV|
89637848|NCT05052697|Experimental|SSA: bIRV AB (dose level combination 1) + QIV|
89637849|NCT05052697|Experimental|SSA: bIRV AB (dose level combination 2) + QIV|
89637850|NCT05052697|Experimental|SSA: bIRV AB (dose level combination 3) + QIV|
89637851|NCT05052697|Experimental|SSA: bIRV AB (dose level combination 4) + QIV|
89637852|NCT05052697|Experimental|SSA: QIV + mIRV A strain (dose level 4)|
89637853|NCT05052697|Experimental|SSA: qIRV (dose level 1) + QIV|
89637854|NCT05052697|Experimental|SSA: QIV + mIRV B strain (dose level 4)|
89637855|NCT05052697|Experimental|SSB: 2 doses of qIRV (dose level 1), 2-visit schedule|
89637856|NCT05052697|Experimental|SSB: 2 doses of QIV, 2-visit schedule|
89637857|NCT05052697|Experimental|SSB: QIV + bIRV AA (dose level combination 1), 2-visit schedule|
89637858|NCT05052697|Experimental|SSB: QIV + bIRV AA (dose level combination 2), 2-visit schedule|
89637859|NCT05052697|Experimental|SSB: QIV + bIRV AA (dose level combination 1), 1-visit schedule|
89637860|NCT05052697|Experimental|SSB: QIV + bIRV AA (dose level combination 2), 1-visit schedule|
89637861|NCT05052697|Experimental|SSB: qIRV (dose level 2, dose combination 1), 1-visit schedule|NOTE: Arm Description has not been entered.
89637862|NCT05052697|Experimental|SSB: qIRV (dose level 2, dose combination 2), 1-visit schedule|NOTE: Arm Description has not been entered
89637863|NCT05052697|Experimental|SSB: qIRV (dose level 3), 1-visit schedule|NOTE: Arm Description has not been entered
89637864|NCT05052697|Experimental|SSB: bIRV AA + bIRV BB (both dose level combination 1), 1-visit schedule|NOTE: Arm Description has not been entered
89637865|NCT05052697|Experimental|SSB: 1 dose of QIV, 1-visit schedule|NOTE: Arm Description has not been entered
89637866|NCT05052697|Experimental|SSB: qIRV (dose level 1), 1-visit schedule|NOTE: Arm Description has not been entered.
89637867|NCT05052697|Experimental|SSB: qIRV (dose level 2), 1-visit schedule|NOTE: Arm Description has not been entered.
89637868|NCT05036135|Experimental|Phase 2b low dose AV-101|
89637869|NCT05036135|Experimental|Phase 2b medium dose AV-101|
89637870|NCT05036135|Experimental|Phase 2b high dose AV-101|
89637871|NCT05036135|Placebo Comparator|Phase 2b Placebo|
89637872|NCT05036135|Experimental|Phase 3 dose AV-101 (Optimal dose selected in Phase 2b)|
89637873|NCT05036135|Placebo Comparator|Phase 3 Placebo|
89637874|NCT05033808|Placebo Comparator|Placebo|Administration of NaCl i.v. as placebo once.
89637875|NCT05033808|Experimental|Epirubicin Phase I|Administration of epirubicin i.v. 3.75 mg/m2 once.
89637876|NCT05033808|Experimental|Epirubicin Phase II|Administration of epirubicin i.v. 7.5 mg/m2 once.
89637877|NCT05033808|Experimental|Epirubicin Phase III|Administration of epirubicin i.v. 15 mg/m2 once.
89637878|NCT05019261|Experimental|Intervention|Multi-component Family Support Intervention
89637879|NCT05019261|No Intervention|Control|Usual ICU care
89637880|NCT05012878|Experimental|Cardiac rehabilitation - High intensity interval training (HIIT)|Patients attending cardiac rehabilitation randomized to HIIT.
89637881|NCT05012878|Active Comparator|Cardiac rehabilitation - Moderate intensity continuous training (MICT)|Patients attending cardiac rehabilitation randomized to MICT.
89637882|NCT05012878|Placebo Comparator|Cardiac rehabilitation - control|The control group (12 week period) will include participants who have declined cardiac rehabilitation.
89637883|NCT05012878|No Intervention|Healthy control group|Healthy age-matched adults without cardiovascular disease, who will complete baseline assessments only. No intervention period.
89637884|NCT05012878|Other|Cardiac rehabilitation - observational|This observational group will include patients who are completing an exercise-based cardiac rehabilitation program in line with standard care but are not part of the randomized exercise protocol groups (HIIT or MICT). Participants in this group will be combined with HIIT and MICT (as exercise-based cardiac rehabilitation group) for Aims 1b and 2b.
89637885|NCT05011838|Experimental|A multi-component intervention to improve hypertension care and control|The intervention will be implemented in Commune 2. It will integrate activities related to 1) Health services redesign, 2) Clinical staff training and 3) Patient and community engagement. The intervention activities will be implemented by health services staff with technical assistance from the investigation team.
89637886|NCT05011838|No Intervention|Routine Care|The Commune 6 was selected as control area, where routine care will be delivered.
89637887|NCT05005403|Experimental|Part 1 Dose Escalation: ABBV-514|Participants will receive ABBV-514.
89637888|NCT05005403|Experimental|Part 1 Dose Escalation: ABBV-514 + Budigalimab|Participants will receive ABBV-514 in combination with budigalimab.
89637889|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion.
89637890|NCT05005403|Experimental|Part 2 Dose Expansion: ABBV-514 + Budigalimab|Participants will receive ABBV-514 at recommended dose determined in Dose Escalation portion in combination with budigalimab.
89637891|NCT05004116|Experimental|Repotrectinib|"Phase 1:~Part A : TPX-0005 (Repotrectinib) will be given orally (without regard to food) once daily for 14 days, then increased to twice daily for remainder of cycles and concurrently administered with chemotherapy backbone described below. For patients less than 12 years old or less than 50kg, adult equivalent dosing (AED) will be used. Approximately 4-24 pediatric subjects will be enrolled into 2-4 dose levels (pending if DL-1 or DL-1b are utilized), with maximum of 6 subjects per dose level according to the 'rolling 6' design. Starting dose of TPX-0005 (Repotrectinib) will begin at dose level (DL) 1. Part B (combination therapy; patients less than 12 years old or ≤ 50kg): For 6 additional patients, a safety run-in will be conducted with TPX-0005 (Repotrectinib) and chemotherapy."
89637892|NCT05003180|Active Comparator|Surgical|"Surgical stabilization. Brace treatment will not be used postoperative. Early ambulation after surgery is encouraged. Surgery is to be performed within 2 weeks from the injury. The choice of supplier and brand of implants are based on the preference of each participating center.~Physiotherapy and other measures of rehabilitation are prescribed on an individual basis."
89637893|NCT05003180|No Intervention|Non-surgical treatment|"No surgical stabilization is performed. Early ambulation after treatment randomization is encouraged. Brace treatment is not required, but a standard three-point hyperextension brace may be offered up to 3 months for pain relief. The choice of supplier and brand of brace are based on the preference of each participating center. The brace will only be used upon mobilization. Brace use will be estimated by the patient at the 3-4 months follow-up.~Physiotherapy and other measures of rehabilitation are prescribed on an individual basis."
89637894|NCT04983901|Experimental|Group I (imipenem, cilastatin, relebactam)|Patients receive imipenem/cilastatin/relebactam IV over 30-60 minutes q6h for 2 days for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h. Patients may continue to receive imipenem/cilastatin/relebactam IVover 30-60 minutes for up to 14 days if clinically indicated by the assessment of the treating physician.
89637895|NCT04983901|Active Comparator|Group II (cefepime, meropenem, piperacillin/tazobactam)|Patients receive cefepime IV q8h for a minimum of 6 doses, meropenem IV q8h for a minimum of 6 doses, or piperacillin/tazobactam IV q6h for a minimum of 8 doses. Patients may also receive gram-positive therapy at the discretion of the primary team or emergency center physician consisting of vancomycin IV q12h or linezolid IV or PO q12h.
89637896|NCT04978428|Experimental|Epidiolex|Epidiolex (2.5 mg/kg twice daily for one week) followed by Epidiolex (5mg/kg twice daily for two weeks)
89637897|NCT04973228|Experimental|Roflumilast Foam 0.3%|Participants with seborrheic dermatitis apply roflumilast foam 0.3% once daily (QD) for 8 weeks.
89637898|NCT04973228|Placebo Comparator|Vehicle Foam|Participants with seborrheic dermatitis apply vehicle foam QD for 8 weeks.
89637899|NCT04957979||Nursing/Medical Model of Care Coordination|Someone with medical/nursing training coordinates involvement of various medical resources and provides patients with education, self-management support, and referrals to community resources.
89637900|NCT04957979||Medical/Social Model of Care Coordination|In addition to the services provided in the Medical/Nursing Model, a social worker by education has dedicated FTE as a member of the care team at the clinic, providing some direct services for care coordination patients and either spending some time on-site or in regular communication with its clinicians in addition to providing social work services.
89637901|NCT04952389|Experimental|Acupuncture Therapy Group|Subjects will undergo ten sessions of acupuncture therapy with a licensed acupuncturist in addition to the standard of care.
89637902|NCT04952389|Active Comparator|Standard of Care|Subjects will be treated with two times daily budesonide rinses and olfactory (sense of smell) training. This is considered the current standard of care in the treatment of olfactory dysfunction.
89637903|NCT04943354|Active Comparator|Study of single-nucleotide polymorphisms in women diagnosed with premature ovarian failure|Study of genes affecting single nucleotide polymorphisms: Reninangiotensin-aldosterone system (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), proinflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) in the study group of women diagnosed with premature ovarian failure.
89637904|NCT04943354|Active Comparator|Study of single-nucleotide polymorphisms in a control group of healthy women|Study of genes affecting single nucleotide polymorphisms: Reninangiotensin-aldosterone system (AGT, ACE), endothelial dysfunction (NOS3, EDN1), thrombosis-associated (ITGB3, ITGA2, FGB, GPIBA, SERPINE PAI1), pro-inflammatory (CRP, IL17A, IL2, IL10 1, IL10 2, TNFα, CRP 4, IL6, TLR2, TLR3, TLR4, TLR6, TLR9) in a control group of healthy women .
89637905|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 1|Multiple doses of ALN-AGT01 administered by subcutaneous (SC) injection during the 12-month DB treatment period.
89637906|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 2|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
89637907|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 3|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
89637908|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 4|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
89637909|NCT04936035|Placebo Comparator|Placebo + ALN-AGT01|Multiple doses of placebo administered by SC injection during the first 6 months of 12-month DB treatment period, followed by multiple doses of ALN-AGT01 administered by SC injection during the last 6 months of the 12-month DB treatment period.
89637910|NCT04931368|Active Comparator|Control treatment (Arm A)|Patients receive four courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) as induction treatment. Response assessment with gadolinium-enhanced brain MRI (centrally reviewed) takes place after course two and four. Patient with at least PR proceed to 3rd course of MATRix after first response assessment and to HCT-ASCT (BCNU 400 mg/m2, Thiotepa 4 x 5 mg/kg; i.v.) after second response assessment. Collection of autologous stem cells is planed after the second course of MATRix.
89637911|NCT04931368|Experimental|Experimental treatment (Arm B)|As induction treatment, patients receive one course of Rituximab/HD-Methotrexate (Rituximab 375 mg/m2, HD-Methotrexate 3.5 g/m2; i.v.). In the absence of clinical signs of progression, patients proceed to two courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) followed by a response assessment with gadolinium-enhanced brain MRI (centrally reviewed). Patients with at least PR will proceed to HCT-ASCT (BCNU 400 mg/m2, thiotepa 4 x 5 mg/kg; i.v.). Collection of autologous stem cells is planed after the first course of MATRix
89637912|NCT04930744|Active Comparator|Standard Tuberculosis Medicine|Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months.
89637913|NCT04930744|Experimental|Standard TB Medicines and Metformin|Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months. For this arm, they will also take Metformin hydrochloride one 500 mg tablet daily starting one week after the initiation of tuberculosis medicines, then increasing to one 500 mg table twice daily through study week-12 for a total 11 weeks of metformin exposure.
89637914|NCT04926324|Experimental|Cohort 1 (starting)|niraparib, 100 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
89637915|NCT04926324|Experimental|Cohort 2|niraparib, 200 mg orally once daily for up to 12 weeks dostarlimab, 500 mg infused (IV) once every 3 weeks for up to 12 weeks radiation therapy, 5 Gray (Gy) per day for 5 consecutive days
89637916|NCT04923724|Active Comparator|Tourniquet during surgery|Patients in this group get a tourniquet during surgery.
89637917|NCT04923724|Active Comparator|No Tourniquet during surgery|Patients in this group do not get a tourniquet during surgery.
89637918|NCT04899492|Active Comparator|Group 1:Nicotine Replacement Therapy (NRT)|Patients enrolled in group 1 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study
89637919|NCT04899492|Experimental|Group 2:Motivational Interviewing (MI)|Patients enrolled in group 2 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization
89637920|NCT04899492|Experimental|Group 3:Cognitive Behavioural Therapy (CBT)|Patients enrolled in group 3 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization and 6 sessions of CBT after Motivational Interviewing up to 6 months after
89637921|NCT04899492|Experimental|Group 4: Hypnotherapy|Patients enrolled in group 4 will receive a Nicotine Replacement Therapy (NRT) from the study entry to end of study and 1 to 3 Motivational Interviewing (MI) after randomization and about 3 sessions of hypnotherapy up to 6 months after
89637922|NCT04899102|Experimental|Time-Restricted, Intermittent Fasting Group|Special type of diet for 6 weeks, called time-restricted, intermittent fasting.
89042314|NCT05715242|Experimental|Condition 1|Calorie Goal (easier) + Step Goal (easier) + Eating Window Goal (easier) + Red Zone Food Goal (easier)
89042315|NCT05715242|Experimental|Condition 2|Calorie Goal (easier) + Step Goal (easier) + Eating Window Goal (easier) + Red Zone Food Goal (harder)
89212069|NCT02591303|Experimental|Control group|No sleep problems either self reported or objectified through actigraphy (Sleep Efficiency >85%)
89212070|NCT00853268|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
89042316|NCT05715242|Experimental|Condition 3|Calorie Goal (easier) + Step Goal (easier) + Eating Window Goal (harder) + Red Zone Food Goal (easier)
89212071|NCT00853268|Active Comparator|B|OxyContin® 40 mg tablet
89212072|NCT01011244|Experimental|ADIPOPLUS|patients with a fistula in Crohn's disease
89212073|NCT00853346|Experimental|1|Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
89042317|NCT05715242|Experimental|Condition 4|Calorie Goal (easier) + Step Goal (easier) + Eating Window Goal (harder) + Red Zone Food Goal (harder)
89042318|NCT05715242|Experimental|Condition 5|Calorie Goal (easier) + Step Goal (harder) + Eating Window Goal (easier) + Red Zone Food Goal (easier)
89637923|NCT04895436|Experimental|Cohort 1 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles.
89637924|NCT04895436|Experimental|Cohort 2 - venetoclax + obinutuzumab|Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.
89637925|NCT04869085|Experimental|e-PainSupport Condition|e-PainSupport is a self-administered, digital pain application. Over the course of the two weeks, caregivers and patients will record the severity of patient's pain and how much pain medicine they use to control patient's pain in the e-PainSupport application.
89637926|NCT04869085|No Intervention|Standard Care Condition|Patients and caregivers will be given a paper copy of the same list of resources for pain management included in the Education Module of the e-PainSupport condition at baseline.
89637927|NCT04866004|Experimental|Contingency Management - Cannabis|Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence.
89637928|NCT04861025||Users Group|Patients admitted to any Hospitalization Unit belonging to Geriatrics Department
89637929|NCT04861025||Health Professionals Group|All health professionals working at some Hospitalization Unit belonging to CSAPG Institution
89637930|NCT04858477|Other|Colonoscopy Patients + their Gastroenterology Fellows|Inpatient and outpatient colonoscopies performed by fellows at NYU Langone Health, NYU Langone Hospital Brooklyn, Bellevue Hospital Center, and Manhattan VA Medical Center from October 2020 - March 2021. These will include all colonoscopies with polyps done in adults age 45 and above.
89637931|NCT04853212|Active Comparator|SPA patient|Patients with SPA
89637932|NCT04853212|Sham Comparator|Subject without SPA|Health subjects without SPA, planned to undergo a digestive endoscopy.
89637933|NCT04841148|Experimental|HCQ|Patients will receive HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
89637934|NCT04841148|Experimental|Avelumab|Patients will receive Avelumab, 10 mg/kg, IV, D1 and D15 of each 28-day cycle.
89637935|NCT04841148|Experimental|Palbociclib and Avelumab|Patients will receive Palbociclib 125 mg daily, by mouth on D1-21 concurrently with Avelumab, 10 mg/kg IV on D1 and D15 of each 28-day cycle
89637936|NCT04841148|Experimental|Palbociclib and HCQ|Patients will receive Palbociclib 75 mg daily, by mouth on D1-28 concurrently with HCQ, 600 mg twice daily D1-28 of each 28-day cycle.
89637937|NCT04836559|Experimental|JNJ-40411813|Participants will receive JNJ-40411813 twice a day (bid) up to 12 weeks in double blind period. Up to 3 different doses (low, medium, high) of JNJ-40411813 will be administered in this study. Participants will also receive concomitant anti-epileptic drugs (AEDs) one of which must include levetiracetam or brivaracetam. Immediately after the last study drug intake by the participants in the double-blind period, participants will enter into a 2-year open label extension (OLE) period and continue receiving JNJ-40411813 as well as the AEDs during OLE period.
89637938|NCT04836559|Placebo Comparator|Placebo|Participants will receive JNJ-40411813 matching placebo (bid) up to 12 weeks. Participants will also receive concomitant AEDs one of which must include levetiracetam or brivaracetam during double blind period. Participants who had been receiving placebo in double blind period will start with the JNJ-40411813 dose in the OLE period.
89637939|NCT04828993|Experimental|Tafamidis treatment arm|Chinese patients diagnosed with ATTR-PN treated with tafamidis 20mg once daily oral administration for 72 weeks (18 months).
89637940|NCT04817007|Experimental|Part 1A: BMS-986158 + Ruxolitinib|
89637941|NCT04817007|Experimental|Part 1B: BMS-986158 + Fedratinib|
89637942|NCT04817007|Experimental|Part 2A1: BMS-986158 + Ruxolitinib|
89637943|NCT04817007|Experimental|Part 2B1: BMS-986158 + Fedratinib|
89637944|NCT04817007|Experimental|Part 2B2: BMS-986158 Mono and/or (BMS-986158 + Fedratinib), if applicable|
89637945|NCT04817007|Experimental|Part 2A2 Add-On: BMS-986158 + Ruxolitinib|
89637946|NCT04817007|Experimental|Part 2A3: BMS-986158 + Ruxolitinib|
89637947|NCT04805788|Experimental|Treatment (SBPT)|Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
89637948|NCT04793633||Patients at increased risk for developing pancreatic cancer|Patients being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes) or have signs or symptoms of disease and are undergoing other imaging diagnostic tests to determine if they have pancreatic cancer
89637949|NCT04774926|Experimental|Brolucizumab 6 mg|Participants will receive 3 monthly ocular injections followed by a q12w or q8w maintenance phase based on patient's disease activity (DA).
89637950|NCT04762368|Active Comparator|Active + Training|Participants in this arm will be exposed to active stimulation for the first 25 minutes of a roughly hour - long perceptual training procedure in which participants must verbally read sentences presented at various speeds and sizes.
89637951|NCT04762368|Sham Comparator|Sham + Training|Participants in this arm will be exposed to sham stimulation for the first 25 minutes of a roughly hour - long perceptual training procedure in which participants must verbally read sentences presented at various speeds and sizes.
89042319|NCT05715242|Experimental|Condition 6|Calorie Goal (easier) + Step Goal (harder) + Eating Window Goal (easier) + Red Zone Food Goal (harder)
89042320|NCT05715242|Experimental|Condition 7|Calorie Goal (easier) + Step Goal (harder) + Eating Window Goal (harder) + Red Zone Food Goal (easier)
89042321|NCT05715242|Experimental|Condition 8|Calorie Goal (easier) + Step Goal (harder) + Eating Window Goal (harder) + Red Zone Food Goal (harder)
89042322|NCT05715242|Experimental|Condition 9|Calorie Goal (harder) + Step Goal (easier) + Eating Window Goal (easier) + Red Zone Food Goal (easier)
89042323|NCT05715242|Experimental|Condition 10|Calorie Goal (harder) + Step Goal (easier) + Eating Window Goal (easier) + Red Zone Food Goal (harder)
89042324|NCT05715242|Experimental|Condition 11|Calorie Goal (harder) + Step Goal (easier) + Eating Window Goal (harder) + Red Zone Food Goal (easier)
89637952|NCT04749992||Non-Dreamers|Experimental Group
89637953|NCT04749992||Dreamers|Comparison Group
89042325|NCT05715242|Experimental|Condition 12|Calorie Goal (harder) + Step Goal (easier) + Eating Window Goal (harder) + Red Zone Food Goal (harder)
89637954|NCT04748432||Multi-drug resistant group (MDR)|Patients with resistant NFGNB isolate as MDR group
89637955|NCT04748432||Non-Multi-drug resistant group (Non-MDR)|Patients with sensitive NFGNB isolate as Non-MDR group
89637956|NCT04748432||Control group (Control)|Patients without suspicion of VAP and other signs of nosocomial infection as the control group
89637957|NCT04736706|Experimental|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 18 administrations (up to ~2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
89637958|NCT04736706|Experimental|Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (co-formulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered IV Q6W for up to 18 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
89637959|NCT04736706|Active Comparator|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 18 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
89637960|NCT04725513|Active Comparator|Physical Therapy Only|
89637961|NCT04725513|Experimental|Shockwave Therapy and Physical Therapy|
89637962|NCT04725513|Experimental|Photobiomodulation, Shockwave Therapy and Physical Therapy|
89637963|NCT04720534|Experimental|ARO-APOC3|ARO-APOC3 Injection
89637964|NCT04720534|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl)
89637965|NCT04711278|Experimental|hypnosis group|Mask-wearing as hypnosis method for patients in this arm.
89637966|NCT04711278|Sham Comparator|comparator group|No hypnosis for patients in this arm.
89637967|NCT04697628|Experimental|Tisotumab vedotin|Tisotumab vedotin monotherapy
89637968|NCT04697628|Active Comparator|Chemotherapy|Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
89637969|NCT04677166|Experimental|NPWT with Instillation|"NPWT coupled with instillation will be employed via use of V.A.C. VeraFlo device. The protocol to be used is as follows:~Instillation Solution: normal saline Dwell/Soak Time: 30 seconds Cycle Time: 4 hours Pressure: 125mmHg"
89637970|NCT04677166|Active Comparator|Standard NPWT|Standard NPWT with use of V.A.C. Ulta device employed at 125mmHg continuous suction.
89637971|NCT04668833|Experimental|Treatment (Autologous Lymphocyte Infusions)|The purpose of this study is to determine the safety and preliminary efficacy of un-manipulated autologous lymphocyte infusion (ALI) using the patient's own lymphocytes collected using apheresis, and infused after the completion of radiation/chemoradiation.
89637972|NCT04663620|Active Comparator|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
89637973|NCT04663620|Placebo Comparator|No Saving Babies Lives Programme|Control arm
89637974|NCT04662632|Experimental|Experimental|Local antibiotic irrigation via the VT-X7 (Vancomycin and Tobramycin Exchanged over 7 Days) Treatment System adjuvant to two-stage exchange arthroplasty per standard of care.
89637975|NCT04662632|Active Comparator|Control|Standard of care for treatment of chronic PJI - two-stage exchange arthroplasty: surgical removal of the infected implant, aggressive debridement, and exchange arthroplasty with administration of adjuvant systemic antibiotics and temporary antibiotic-impregnated cement spacer.
89637976|NCT04650698|Experimental|Tranexamic acid (TXA) Injection|Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) will receive two injections of TXA.
89637977|NCT04650698|No Intervention|Control - No Tranexamic acid (TXA) Injection|Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) won't receive any injections TXA.
89637978|NCT04646044|Experimental|Bempegaldesleukin IV + Standard of Care|
89042326|NCT05715242|Experimental|Condition 13|Calorie Goal (harder) + Step Goal (harder) + Eating Window Goal (easier) + Red Zone Food Goal (easier)
89637979|NCT04646044|Placebo Comparator|Placebo + Standard of Care|
89637980|NCT04645160|Experimental|1/ Phase I|Tivozanib, P.O. daily at 0.89 mg (given on Days 1-21 of every 28-day cycle) with intra-patient escalation to 1.34 mg daily (given on Days 1-21 of every 28-day cycle) and possible dose de-escalation to 0.89 mg every other day (without interruption for a 28-day cycle) if needed to determine RP2D
89212074|NCT00853346|Active Comparator|2|Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
89637981|NCT04645160|Experimental|2/ Phase II|Tivozanib at the RP2D established in Phase I
89637982|NCT04643431|Experimental|Carotid SHAPE estimation|The ultrasound contrast agent is infused (4-10 mL/min). An area within the plaque demonstrating internal flow is selected and a software based calibration algorithm is executed. After selecting the optimal acoustic output power 3D SHAPE volumes of the entire plaque (including the carotid artery) are acquired. Infusion is stopped and after microbubble clearance a second set of 3D SHAPE volumes (without contrast) are obtained.
89637983|NCT04630730|Experimental|Recombinant intravesical BCG|"The Intravesical recombinant BCG (Bacillus Calmette-Guérin - VPM1002BC) is used as an immuno-stimulating agent. The patient will receive 3 weekly BCG instillations as induction treatment.~4 cycles of atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1 inhibitor) will be administered in combination with the standard neoadjuvant chemotherapy cisplatin/gemcitabine.~After surgery atezolizumab will be administered in the adjuvant setting for 13 cycles."
89637984|NCT04618653||Early AA Attenders with Alcohol Use Disorder|observational study that includes three fixed assessments (Baseline, 3, and 6-month). Subset of participants will also provide daily EMA data.
89637985|NCT04618471|Experimental|WaveWriter Settings|
89042327|NCT05715242|Experimental|Condition 14|Calorie Goal (harder) + Step Goal (harder) + Eating Window Goal (easier) + Red Zone Food Goal (harder)
89212075|NCT00845780|Experimental|withdrawal amiodarone|withdrawal amiodarone afer at least 6 months of sinus rhythm maintenance on amiodarone therapy
89637986|NCT04602260||Prospective Cohort|The prospective cohort will assess patients upon admission to general internal medicine, at hospital discharge, and at 3, 6, 9, and 12-month follow-up.
89637987|NCT04602260||Retrospective Cohort|The retrospective cohort will assess patients at 3, 6, 9, and 12-months after being discharged from the hospital.
88991185|NCT05563038|Experimental|Scrambler Therapy Group 5 sessions|Patients undergoing treatment by Scrambler Therapy will begin by describing the areas and levels of pain along the Numerical Rating Scale (NRS) from 0-10. After the Scrambler treatment, patients will again be asked to describe the areas and levels of pain using the NRS. Each patient undergoing Scrambler Therapy will undergo this process for 5 consecutive days, following the same procedure every day of treatment. After completion of treatment, participants will be asked to complete monthly ratings of their pain for three months, and to follow-up in clinic at 3-6 month intervals (standard of care).
88991186|NCT05563038|Active Comparator|Scrambler Therapy Group 10 sessions|Patients undergoing treatment by Scrambler Therapy will begin by describing the areas and levels of pain along the Numerical Rating Scale (NRS) from 0-10. After the Scrambler treatment, patients will again be asked to describe the areas and levels of pain using the NRS. Each patient undergoing Scrambler Therapy will undergo this process for 10 consecutive days, following the same procedure every day of treatment. After completion of treatment, participants will be asked to complete monthly ratings of their pain for three months, and to follow-up in clinic at 3-6 month intervals (standard of care).
89637988|NCT04599855|Experimental|Esketamine 56 Milligram (mg)|Participants will receive nasal spray treatment with esketamine 56 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 Montgomery-Asberg Depression Rating Scale [MADRS] assessment).
89637989|NCT04599855|Experimental|Esketamine 84 mg|Participants will receive nasal spray treatment with esketamine 84 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
89637990|NCT04599855|Experimental|Placebo|Participants will receive nasal spray treatment with placebo twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
89637991|NCT04576104|Active Comparator|Arm I (megestrol acetate)|Prior to standard of care planned procedure, patients receive megestrol acetate PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on the day of planned procedure.
89637992|NCT04576104|Experimental|Arm II (megestrol acetate, metformin hydrochloride)|Prior to standard of care planned procedure, patients receive megestrol acetate PO BID and metformin hydrochloride extended-release PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on the day of planned procedure.
89637993|NCT04574960|Experimental|Neoadjuvant Chemotherapy Arm|Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. This will be followed by surgical intervention (nephroureterectomy or ureterectomy).
89637994|NCT04574960|Active Comparator|Adjuvant Chemotherapy Arm (Standard of Care)|"Patients will undergo surgical intervention (nephroureterectomy or ureterectomy) followed by adjuvant chemotherapy.~Patients with a GFR greater or equal to 60 mL/min will receive Gemcitabine/Cisplatin while those with a GFR greater or equal to 30 mL/min but less than 60 mL/min will receive Gemcitabine/Carboplatin.~Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles.~Gemcitabine/Carboplatin will be administered on a 3-week cycle for up to 4 cycles."
89637995|NCT04565925|Experimental|Sildenafil 20mg TID then Placebo TID|Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.
89637996|NCT04565925|Experimental|Placebo TID then Sildenafil 20mg TID|Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.
89637997|NCT04565067||1|COVID-19 recovered adult patients
89637998|NCT04558866|Experimental|ExBAT Arm|Testosterone Cypionate 400 mg IM on Day 1 and Darolutamide 1,200mg/day (two 300 tablets every 12 hours) p.o. for 28 days, from day 29 to day 56 followed by a washout period of 7 days (63-day cycles), until loss of benefit (disease progression and/or limiting toxicity).
89637999|NCT04558164|Experimental|Active TBS|Theta burst stimulation (TBS) will be delivered at 100% of motor threshold (MT).
89638000|NCT04558164|Sham Comparator|Sham TBS|Sham stimulation will be delivered at 0% of motor threshold (MT), with all other parameters matching the active TBS condition.
89638001|NCT04550377|Active Comparator|Cannabidiol Group 1|40 participants will be titrated to a maximum dose of oral cannabidiol 800 mg daily over 2 weeks for a total of 8 weeks treatment.
89638002|NCT04550377|Active Comparator|Cannabidiol Group 2|40 participants will be titrated to a maximum dose of oral cannabidiol 400 mg daily over 2 weeks for a total of 8 weeks treatment.
89638003|NCT04550377|Placebo Comparator|Placebo Group|40 participants will be given a placebo for a total of 8 weeks treatment.
89638004|NCT04550156|No Intervention|Control Arm|Patients are treated according to current local standards
89638005|NCT04550156|Experimental|Colorectal Bundle Arm|Patients are treated according to the colorectal bundle
89638006|NCT04549025|Experimental|JTX-4104|Drug: JTX-4014
89638007|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 1)|"Drug: JTX-4014~Drug: Vopratelimab Other Name: JTX-2011"
88991187|NCT05559502|Experimental|HFNO group|Patients will receive HFNO therapy during laryngomicrosurgery.
89638008|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 2)|"Drug: JTX-4014~Drug: Vopratelimab Other Name: JTX-2011"
89638009|NCT04541433|Experimental|AZD9833 monotherapy|Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer
89638010|NCT04536038|No Intervention|Opt-in|Patients randomized to opt-in framing will be instructed to visit the Way to Health website to enroll in the study, or to call or email the study coordinator with questions or for assistance in enrolling.
89638011|NCT04536038|Experimental|Opt-out|Patients randomized to opt-out framing will receive an email that frames participation in the study as part of the standard of care, and will be informed that a study coordinator will be calling them in the coming days to start enrollment in the study unless they opt out of participation.
89638012|NCT04529772|Experimental|acalabrutinib + R-CHOP|Acalabrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
89212076|NCT00845780|Active Comparator|continuation amiodarone|continuation of amiodarone after 6 months of sinus rhythm maintenance on amiodarone therapy
89638013|NCT04529772|Placebo Comparator|placebo + R-CHOP|Placebo plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
89638014|NCT04520698|Experimental|Nursing Home-level UPLIFT-AD intervention|The UPLIFT-AD intervention consists of three major components delivered at the level of the nursing home: 1) in-house PC champions trained to a) facilitate advance care planning conversations with residents with Alzheimer's Disease and Related Dementias and their surrogate decision-makers, b) screen and follow up on residents' Palliative Care needs and c) serve as a liaison to Palliative Care consultants; 2) specialty Palliative Care consultant support providing individual consults for residents with complex Palliative Care needs; and 3) education on primary Palliative Care offered to all clinical NH staff.
89638015|NCT04520698|No Intervention|Usual Care|
89212077|NCT00853424|Active Comparator|M|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
89212078|NCT00853424|Experimental|I|subjects receive an islet cell transplant in addition to all recommended medical treatment for diabetes and diabetic eye disease
89638016|NCT04520256|Experimental|Core Program Only|
89638017|NCT04520256|Experimental|Social Support|
89638018|NCT04520256|Experimental|Dysregulated Eating|
89638019|NCT04520256|Experimental|Social Support, Dysregulated Eating|
89638020|NCT04520256|Experimental|Exercise|
89638021|NCT04520256|Experimental|Social Support, Exercise|
89638022|NCT04520256|Experimental|Dysregulated Eating, Exercise|
89638023|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise|
89638024|NCT04520256|Experimental|Feedback|
89638025|NCT04520256|Experimental|Social Support, Feedback|
89638026|NCT04520256|Experimental|Dysregulated Eating, Feedback|
89638027|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback|
89638028|NCT04520256|Experimental|Exercise, Feedback|
89638029|NCT04520256|Experimental|Social Support, Exercise, Feedback|
89638030|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback|
89638031|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback|
89638032|NCT04520256|Experimental|VR|
89638033|NCT04520256|Experimental|Social Support, VR|
89638034|NCT04520256|Experimental|Dysregulated Eating, VR|
89638035|NCT04520256|Experimental|Social Support, Dysregulated Eating, VR|
89638036|NCT04520256|Experimental|Exercise, VR|
89638037|NCT04520256|Experimental|Social Support, Exercise, VR|
89638038|NCT04520256|Experimental|Dysregulated Eating, Exercise, VR|
89638039|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, VR|
89638040|NCT04520256|Experimental|Feedback, VR|
89638041|NCT04520256|Experimental|Social Support, Feedback, VR|
89638042|NCT04520256|Experimental|Dysregulated Eating, Feedback, VR|
89638043|NCT04520256|Experimental|Social Support, Dysregulated Eating, Feedback, VR|
89638044|NCT04520256|Experimental|Exercise, Feedback, VR|
89638045|NCT04520256|Experimental|Social Support, Exercise, Feedback, VR|
89638046|NCT04520256|Experimental|Dysregulated Eating, Exercise, Feedback, VR|
89638047|NCT04520256|Experimental|Social Support, Dysregulated Eating, Exercise, Feedback, VR|
89638048|NCT04517370|Active Comparator|Laser treatment|Each patient will be treated once every 20-40 days, for a total of 3 laser treatments. In every visit during the study, patients will undergo gynecological examination and will complete questionnaires evaluating GSM symptoms, using a visual analogue scale (VAS) for each symptom (vaginal dryness, dyspareunia, discharge, itching and/or stinging, vaginal bleeding and dysuria) as well as treatment induced pain and side effects.
89638049|NCT04517370|Sham Comparator|Sham treatment|"Each patient will be treated once every 20-40 days, for a total of 3 Sham treatments, in a similar procedure not using an active laser energy. Patients will be assessed in a similar manner.~Following 3 Sham-treatments patients in the placebo group will be offered the laser treatment in an open-label study ."
89638050|NCT04513665|Experimental|Stage 1|Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy. 16 participants will be accrued. If 2 or greater responses are seen, Stage 2 will accrue additional participants.
89638051|NCT04513665|Experimental|Stage 2|If 2 or greater responses are seen during Stage 1, Stage 2 will accrue an additional 9 participants. Participants will have recurrent endometrial carcinoma or carcinosarcoma with HER2 overexpression and 1-2 prior lines of chemotherapy.
89638052|NCT04508907|Experimental|Arm 1: Pre-emptive Treatment Arm|Single arm study were all recipients of HCV viremic organs will receive combination therapy.
89638053|NCT04498650|Placebo Comparator|Placebo|
89638054|NCT04498650|Experimental|300 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-24: 300 mg BID
89638055|NCT04498650|Experimental|600 mg|Dose in weeks 1 and 2: 50 mg once daily (evening) Dose in weeks 3 and 4: 50 mg BID Dose in weeks 5-8: 150 mg BID Dose in weeks 9-12: 300 mg BID Dose in weeks 12-24: 600 mg BID
89638056|NCT04497168|Experimental|Citalopram|20mg daily
89638057|NCT04497168|Placebo Comparator|Placebo|matching placebo pills
89638058|NCT04494945|Other|Screening (genetic testing)|Patients undergo collection of saliva samples for genetic testing. If genetic test is positive, patients receive genetic counseling.
89638059|NCT04488861||IVF-conceived|Those who have conceived by IVF (for whatever indication); target 80 participants of which it is anticipated 20 would have conceived by frozen embryo transfer IVF.
89638060|NCT04488861||Spontaneously conceived|Those who have conceived spontaneously (within 12 months and without use of hormonal or other contraception); target 20 participants
89638061|NCT04488861||Ovulation induction-conceived|Those who have conceived by ovulation induction (after more than 12 months); target 20 participants.
89638062|NCT04477837||direct oral anticoagulant (DOAC) No.1|Apixaban 5mg, oral, twice daily for at least four months
89638063|NCT04477837||direct oral anticoagulant (DOAC) No.2|Rivaroxaban 20mg, oral, once daily for at least four months
89638064|NCT04477837||direct oral anticoagulant (DOAC) No.3|Edoxaban 60mg, oral, once daily for at least four months
88991188|NCT05559502|Active Comparator|ET group|Endotracheal intubation was performed for general anesthesia
88991189|NCT05554302|Experimental|PET/CT, MRI|All patients will obtain an 18F-Fluciclovine PET/CT scan in addition to the planning MRI at the time of SRS treatment (approximately 2-4 weeks after resection). The value of 18F-Fluciclovine in addition to structural information from the MRI will be analyzed. Patients will continue to undergo 18F-Fluciclovine in addition to MRI during routine follow-up to determine the ability of 18F-Fluciclovine PET/CT to identify areas at risk for marginal failure, monitor resection beds for tumor control, identify patients at risk for disease recurrence, and detect patterns of failure.
88991190|NCT05553938|Experimental|Empagliflozin|Empagliflozin 10 mg daily for weeks 1-6
88991191|NCT05553938|Experimental|Placebo, Then Empagliflozin|Participants first receive matching placebo daily for weeks 1-6, then will receive Empagliflozin 10 mg daily for weeks 7-12
88991192|NCT05549921|Experimental|NY-ESO-1 TCR Specific T cell Therapy|This research is divided into two stages, Stage 1 and Stage 2, respectively. In Stage 1, 14 patients with advanced soft tissue sarcoma with positive expression of tumor antigen NY-ESO-1 and HLA-A*02:01 genotype were enrolled. A further 42 patients will be enrolled in Stage 2, where the primary efficacy analysis will be performed at 3 months after the completion of cell reinfusion in the last subject, with a target ORR of 25%.
89042328|NCT05715242|Experimental|Condition 15|Calorie Goal (harder) + Step Goal (harder) + Eating Window Goal (harder) + Red Zone Food Goal (easier)
89042329|NCT05715242|Experimental|Condition 16|Calorie Goal (harder) + Step Goal (harder) + Eating Window Goal (harder) + Red Zone Food Goal (harder)
89638065|NCT04477837||direct oral anticoagulant (DOAC) No.4|Dabigatran 150mg, oral, twice daily for at least four months
89638066|NCT04477408|Other|plantar exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
89638067|NCT04469192|Experimental|cryotherapy + education|intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
89638068|NCT04469192|Active Comparator|education alone|The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
89638069|NCT04468984|Experimental|Arm A: Navitoclax + Ruxolitinib|Participants will receive navitoclax tablets once daily and ruxolitinib tablets twice daily.
89638070|NCT04468984|Active Comparator|Arm B: Best Available Therapy (BAT)|Participants will receive one of the BAT options, per the investigator's discretion.
89638071|NCT04454437|Experimental|Sacituzumab Govitecan-hziy|Participants will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.
89638072|NCT04441034|Experimental|Anti-convulsant medication|The participants will be randomized to receiving an anti-convulsant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
89638073|NCT04441034|Experimental|Anti-depressant medication|The participants will be randomized to receiving an anti-depressant medication. Then using a patient centered approach, the participant and their treating pain provider will choose one medication within the class. Participants will continue the medications for at least 6 months provided that they can tolerate the side effects, consider the treatment effective, and are willing to continue the treatment. We are studying two classes of medications and specific names of medications do not apply.
89638074|NCT04426500|Placebo Comparator|Placebo/Local Anesthesia|Direct injection of 0.25% bupivacaine into surgical wounds
89638075|NCT04426500|Active Comparator|Ultrasound-guided transversus abdominus plane (UTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using ultrasound guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
89638076|NCT04426500|Experimental|Laparoscopic-guided transversus abdominus plane (LTAP) block|30mL of 0.25% bupivacaine will be administered to bilateral TAP using laparoscopic guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
89638077|NCT04419649|Experimental|KER-050 Cohort 1|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 4 cycles. Participants have the option to continue to receive KER-050 once 4 cycles have been completed for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
89638078|NCT04419649|Experimental|KER-050 Cohort 2|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 4 cycles. Participants have the option to continue to receive KER-050 once 4 cycles have been completed for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
89638079|NCT04419649|Experimental|KER-050 Cohort 3|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
89638080|NCT04419649|Experimental|KER-050 Cohort 4|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
89638081|NCT04419649|Experimental|KER-050 Cohort 5|Escalating doses of KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
89638082|NCT04419649|Experimental|KER-050 Dose Confirmation Cohort|Participants to receive KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles.
89638083|NCT04417257|Experimental|LAU-7b|Active drug as LAU-7b capsules
89638084|NCT04417257|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
89638085|NCT04414748|Active Comparator|Antagonist group|Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
89638086|NCT04414748|Experimental|PPOS group|Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
89638087|NCT04403620|Active Comparator|Conventionally fractionated radiotherapy|60 Gy in 30 fractions, 5 fractions/week
89638088|NCT04403620|Experimental|Hypofractionated radiotherapy|"Dose and fractionation determined by Phase I:~Level 1: 44.4 Gy in 12 fractions, 4 fractions/week~Level 0: 46.5 Gy in 15 fractions, 5 fractions/week~Level -1: 52 Gy in 20 fractions, 5 fractions/week~Level -2: 50 Gy in 20 fractions, 5 fractions/week"
89638089|NCT04401449||Acutely illl subjects|COVID-19 subjects treated at the Clinical Center, followed through recovery and into convalescence
89638090|NCT04401449||Recovered subjects|COVID-19 subjects who were treated at other hospitals, followed through recovery and into convalescence
89638091|NCT04367220||Patients with known or suspected cardiovascular disease|All patients with known or suspected cardiovascular disease are studied with a-priori stratification of specific disease-based cohorts.
89638092|NCT04360018|Active Comparator|arm one|participants receive alcohol beverage
89638093|NCT04360018|Placebo Comparator|arm two|Placebo
89638094|NCT04351178|Experimental|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0)
89638095|NCT04351178|Active Comparator|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
89638096|NCT04349033|Experimental|Emotional Disclosure and Brain Education|Patients are interviewed about stress and other emotional issues and are educated about how emotions and the brain influence pain.
89638097|NCT04349033|Active Comparator|Emotional Disclosure only|Patients are interviewed about stress and other emotional issues only.
89638098|NCT04349033|Placebo Comparator|Pain Information Control|Patients are interviewed about their pain history and experience.
89638099|NCT04343820||Breast reconstruction|Women who have had a mastectomy and want a secondary breast reconstruction by implant.
89638100|NCT04337034|Experimental|mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0)
89638101|NCT04337034|Active Comparator|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured
89638102|NCT04327557|Experimental|MBCP Childbirth Education Course|This arm will undergo the 9-week MBCP course.
88991193|NCT05534321|Active Comparator|Standard of Care Systemic Therapy or Surveillance|Patients randomized to arm 1 will undergo appropriate systemic therapy as determined by their oncology team. These patients will either continue the current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to arm 1, these patients may also undergo palliative radiation therapy for progressive or painful lesions (a skeletal related event as defined in the study) at the time of symptom development*(not upfront palliative radiation therapy)
88991194|NCT05534321|Experimental|Prophylactic Radiation Therapy|"Patients randomized to Arm 2 of the study will undergo upfront prophylactic radiotherapy to ≤ 5 highest risk bone metastases followed by standard of care, as defined by:~Bulkiest sites of disease ≥ 2cm (can include paraspinal disease extension)~Disease in junctional spine (Occ-C2, C7-T1, T12-L1, L5-S1)~Disease with posterior element involvement (facet(s), interspinous)~Compression Deformity > 50%"
88991195|NCT05532241|Experimental|metal + OH|fixed metal orthodontic appliance with regular oral hygiene (toothbrush + toothpaste with low concentration of fluorides 1450 ppm)
88991196|NCT05532241|Experimental|metal + CHX|fixed metal orthodontic appliance with antiseptic mouthwash one-month use (0.12% chlorhexidine digluconate)
88991197|NCT05532241|Placebo Comparator|non-metal + OH|fixed non-metal orthodontic appliance (ceramic brackets + nylon thread) with regular oral hygiene (toothbrush + toothpaste with low concentration of fluorides 1450 ppm)
88991198|NCT05532241|Active Comparator|non-metal + CHX|fixed non-metal orthodontic appliance (ceramic brackets + nylon thread) with antiseptic mouthwash one-month use (0.12% chlorhexidine digluconate)
88991199|NCT05528159||Robotic and Laparoscopic Urologic Surgery Group|Patients scheduled for robotic/laparoscopic urologic surgeries that will be performed under supine and trendelenburg position
88991200|NCT05524909|No Intervention|Control Group|The control group will receive a Fitbit device
88991201|NCT05524909|Experimental|Intervention Group - Genetic Risk Estimate|This intervention group will receive an estimated genetic risk and e-leaflet of type 2 diabetes in addition to the Fitbit .
89042330|NCT05703282|Experimental|Renal Impairment 1|Test Drug: AD-104-A
89638103|NCT04327557|Active Comparator|Non-MBCP Childbirth Education Course|This arm will undergo the TAU (treatment as usual) childbirth education course (one that does not have a huge mindfulness component).
89638104|NCT04323722|Experimental|Empty bladder|Planning CT scan and CBCTs with empty bladder after standard Planning CT scan and CBCTs with filling bladder
89638105|NCT04316546|Experimental|MK-7075 (miransertib)|This is a single-arm study. All study participants will be taking the experimental drug, MK-7075 (miransertib).
89638106|NCT04312516||Controls|Participants scheduled for surgery with MoCA score ≥ 26 preoperatively
89638107|NCT04312516||Patients|Participants scheduled for surgery with MoCA score < 26 preoperatively
89638108|NCT04297683|Experimental|Regimen A - Zilucoplan|Participants are randomized to receive either active zilucoplan or matching placebo.
89638109|NCT04297683|Experimental|Regimen B - Verdiperstat|Participants are randomized to receive either active verdiperstat or matching placebo.
89638110|NCT04297683|Experimental|Regimen C - CNM-Au8|Participants are randomized to receive either active CNM-Au8 or matching placebo.
89638111|NCT04297683|Experimental|Regimen D - Pridopidine|Participants are randomized to receive either active Pridopidine or matching placebo.
89638112|NCT04297683|Experimental|Regimen E - SLS-005 Trehalose|Participants are randomized to receive either active SLS-005 Trehalose or matching placebo.
89212079|NCT00853502|Active Comparator|testosterone cypionate|
89638113|NCT04297683|Experimental|Regimen F- ABBV-CLS-7262|Participants are randomized to receive either active ABBV-CLS-7262 or matching placebo.
89638114|NCT04297683|Experimental|Regimen G - DNL343|Participants are randomized to receive either active DNL343 or matching placebo.
89638115|NCT04295538|Experimental|Elezanumab|Participants will receive elezanumab dose A
89638116|NCT04295538|Placebo Comparator|Placebo|Participants will receive placebo for elezanumab
89638117|NCT04278521|Other|Unipolar Depression|Patients diagnosed with unipolar depression.
89638118|NCT04266912|Experimental|Treatment (avelumab, M6620)|Patients receive avelumab IV over 60 minutes on days 1 and 15, and M6620 IV over 60 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89638119|NCT04257097|Active Comparator|Group A - control group|25 patients will undergo bone regeneration with a titanium reinforced PTFE Mesh (RPM - Osteogenics Lubbock Texas USA), manually shaped and modeled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption (Vitala - Osteogenics Lubbock Texas USA)
89638120|NCT04257097|Experimental|Group B - Test group|25 patients undergo bone regeneration with a custom-made titanium mesh (Yxoss CBR - Reoss Filderstadt Germany), digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption (Bio-Gide - Geistlich Baden Baden Germany)
89638121|NCT04250155|Experimental|Phase 1a Dose Escalation|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
89638122|NCT04250155|Experimental|Phase 1a Dose Expansion|Participants will receive XmAb24306 until study treatment discontinuation or study termination.
89638123|NCT04250155|Experimental|Phase 1b Dose Escalation|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
89638124|NCT04250155|Experimental|Phase 1b Dose Expansion|Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.
89638125|NCT04231591||ACDH Pregnancy - Study group|Pregnant women with known adult congenital heart disease.
89638126|NCT04231591||Uncomplicated pregnancy - Control group|Healthy women with an uncomplicated pregnancy
89638127|NCT04158648|Experimental|Emicizumab|Participants with mild and moderate hemophilia A without factor VIII (FVIII) inhibitors will be enrolled to receive the emicizumab loading dose regimen followed by the participant's preference of one of 3 maintenance dose regimens.
89638128|NCT04158297|Active Comparator|ESWL|Extracorporeal shock wave lithotripsy for the treatment of pancreatic duct stones
89638129|NCT04158297|Active Comparator|SOPIL|Single Operator Pancreatoscopy and intraductal lithotripsy for the treatment of pancreatic duct stones
89212080|NCT00853502|No Intervention|bone monitoring|
89638130|NCT04152200|Experimental|Lumasiran|All patients will receive open-label lumasiran.
89638131|NCT04148560|Other|Study sample|Individuals who participate in this validation study
89638132|NCT04109066|Experimental|Arm A: Nivolumab combined with neoadjuvant CT and adjuvant ET|Nivolumab with paclitaxel followed by nivolumab with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab with adjuvant (post-surgery) endocrine therapy of investigator's choice
89638133|NCT04109066|Placebo Comparator|Arm B: Placebo combined with neoadjuvant CT and then adjuvant ET|Nivolumab placebo with paclitaxel followed by nivolumab placebo with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then adjuvant (post-surgery) endocrine therapy of investigator's choice
89638134|NCT04092270|Experimental|Treatment (peposertib, PLD)|Patients receive peposertib PO BID on days 1-21, days 1-28, or days 1-7 (depending on dose level) and pegylated liposomal doxorubicin hydrochloride IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection cycle 1 weeks 1 and 3. Patients also undergo CT scan or MRI during screening and every 8 weeks and after 6 months of study treatment, every 12 weeks. Patients undergo ECHO during screening and every 6 months. Starting in cycle 13, patients undergo ECHO or MUGA scan every 2 cycles.
89638135|NCT04086524|Experimental|Binocular cartoon treatment at home|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL at home. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
89638136|NCT04086524|Active Comparator|Control group|"Participants will patch for 2 hours every day at home. After 2 weeks, they will be given the option to crossover to the teratment group for an additional 2 weeks (total of 4 weeks). Patching is a common treatment for amblyopia, often considered the golden standard. It is the most common comparison as a control group in amblyopia and vision therapy literature."
89212081|NCT00853736|Experimental|A|Oxycodone hydrochloride tablet 30 mg
89212082|NCT00853736|Active Comparator|B|Roxicodone™ tablet 30 mg
89212083|NCT00857168|Active Comparator|Group 1|
89212084|NCT00857168|Active Comparator|Group 2|
89212085|NCT00857168|Active Comparator|Group 3|
89212086|NCT00857168|Active Comparator|Group 4|
89212087|NCT00857168|Active Comparator|Group 5|
89212088|NCT00857168|Active Comparator|Group 6|
89212089|NCT00857324|Experimental|ZMP|Combination with Vorinostat, Melphalan and Prednisone
89212090|NCT04043078|Other|Exercise|Exercise and respiratory muscle training before surgery
89212091|NCT00857402|Active Comparator|Peanuts|
89638137|NCT04086524|Experimental|Binocular cartoon treatment in office|Participants will view a dichoptic binocular cartoon (provided by BBC) on the Nintendo 3DS-XL in office. They will continue to watch the cartoon for 60 minutes, 4 times a week, for 2 weeks. After 2 weeks, they will be given the option to continue for an additional 2 weeks (total of 4 weeks). Watching the cartoon does not require any special glasses. They will discontinue patching during this time.
89638138|NCT04063267|Experimental|E cigarettes|
89638139|NCT04063267|Active Comparator|Nicotine Replacement Therapy|
89638140|NCT04051879||AN-R|Participants that meet Diagnostic And Statistical Manual Of Mental Disorders (DSM-V) criteria for Anorexia Nervosa restricting subtype.
89638141|NCT04051879||AN-BP|Participants that meet DSM-V criteria for Anorexia Nervosa binging/purging subtype.
89638142|NCT04051879||Healthy Controls|Participants that do not meet DSM-V criteria for any disorder.
89638143|NCT04029974|Experimental|Treatment|Progressive elevation (0 degrees, 25 degrees, 50 degrees, 75 degrees; x2 minutes in each position) while on robotic tilt-stepper at the cadence of 0, 40, and 80 steps/minute.
89638144|NCT04026178|Experimental|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI Patients (males and females) ≤ 40 kg: 0.06mg/kg Male patients > 40 kg: 2.5mg Female patients > 40 kg: 5mg
89638145|NCT03997383|Experimental|Patisiran|Participants will be administered multiple doses of patisiran in the double-blind and open-label extension period.
89638146|NCT03997383|Placebo Comparator|Placebo|Participants will be administered multiple doses of placebo in the double-blind period. In the open-label extension period, participants will be administered multiple doses of patisiran.
89638147|NCT03993353|Experimental|Tadalafil and Pembrolizumab|Tadalafil for up to 12 months and pembrolizumab for up to 24 months.
89638148|NCT03993262|Experimental|Interventional|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
89638149|NCT03993262|Placebo Comparator|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
89638150|NCT03972345||Paediatric patients with iGHD or SGA|Children with one of the following confirmed diagnoses: isolated growth hormone deficiency (iGHD) or small for gestational age (SGA)
89638151|NCT03951337|Experimental|64Cu ATSM|pretherapeutic 64Cu-ATSM PET/CT scan
89638152|NCT03944486|Other|On-Track|Stroke survivors receiving the OnTrack intervention for 12 weeks consisting of arm activity tracking and self-management coaching. Assessments are done before and after the intervention.
89638153|NCT03943875|Active Comparator|Females, 3 dose standard|Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
89638154|NCT03943875|Experimental|Females, 2 dose with delayed 3rd dose|Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
89638155|NCT03943875|Active Comparator|Males, 3 dose standard|Three doses of the 9-valent HPV vaccine to be administered to the comparison group (15-26 years of age) at 0, 2, and 6 months.
89638156|NCT03943875|Experimental|Males, 2 dose with delayed 3rd dose|Two doses of the 9-valent HPV vaccine to be administered to the experimental group (15-26 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
89638157|NCT03937817||1|Healthy volunteers and patients with hematologic and hemolytic diseases, including alpha and beta globin variants, sickle cell disease, malaria, or other diseases involving inflammation or endothelial dysfunction.
89638158|NCT03935425|Experimental|FitMi Plus|"Participants will perform targeted movement exercises by interacting with the FitMi Plus Functional modules at least 50% of the time they spend exercising.~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
89638159|NCT03935425|Active Comparator|FitMi Basic|"Participants will perform targeted movement exercises by interacting with the FitMi Basic pucks, as described and monitored on a computer.~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
89638160|NCT03925974|Experimental|HER2 overexpression|HER2 IHC 3+ or IHC2+ and ISH+
89638161|NCT03925974|Experimental|HER2 expression|HER2 IHC 2+ISH- or IHC 1+ and ISH+
89638162|NCT03923582|Experimental|Intervention Arm|A four-day comprehensive sexual health curriculum tailored for Africa.
89042331|NCT05703282|Experimental|Renal Impairment 2|Test Drug: AD-104-A
89042332|NCT05703282|Experimental|Renal Impairment 3|Test Drug: AD-104-A
89042333|NCT05703282|Experimental|Normal|Test Drug: AD-104-A
89638163|NCT03923582|No Intervention|Waitlist control|Participants in this arm completed a follow-up survey and were scheduled to receive the intervention after the end of the trial.
89638164|NCT03922893||Proband|First individual in a family to consent to this protocol
89638165|NCT03922893||Family Member Participants|Family members of the proband will be approached to consent to this protocol
89638166|NCT03911856|Experimental|Non-invasive assesment techniques|We hypothesize that non-invasive indices of right ventricular RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction pulmonary arterial hypertension and heart failure with preserved ejection fraction(PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
89638167|NCT03911856|Experimental|Efficacy of acute-oxygen therapy during exercise|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing pulse volume recording PVR, increasing RV functional reserve, increasing gas diffusion).
89638168|NCT03905694|Experimental|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
89638169|NCT03868930|Experimental|STEP-Home|The STEP-Home Arm involves a skills-based intervention focused on Emotional Regulation, Problem Solving, and Attention Training strategies.
89638170|NCT03868930|Active Comparator|PCGT|The Present Center Group Therapy (PCGT) Arm involves a nonspecific, supportive intervention, focused on identifying and discussing current life stressors.
89042334|NCT05689372||Participants with type 2 diabetes|Participants will be treated with Ozempic (solution for injection 1.34 milligrams per milliliter [mg/ml] (Semaglutide subcutaneous [s.c.]) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the Korean package insert (K-PI).
89042335|NCT05688215|Experimental|Treatment (zimberelimab, quemliclustat, chemotherapy)|Patients receive zimberelimab IV, quemliclustat IV, oxaliplatin IV, leucovorin calcium IV, and inrinotecan IV on study. Patients undergo collection of blood samples and CT throughout the trial. Patients with borderline-resectable pancreatic cancer undergo collection of tissue samples. Patients with locally advanced pancreatic cancer undergo core biopsy.
89638171|NCT03856086|Active Comparator|Enhanced usual care (EUC)|"ICs randomized to EUC following baseline questionnaire completion will be given instructions (Appendix I) on how to access or create an account to access the myMSK online portal IC Resources page (https://my.mskcc.org/login). If the caregiver does not wish to enroll in MyMSK, the research study staff will send them an email with sample referral material ( Appendix D. The IC Resources page includes links to extant MSK educational materials for ICs (e.g., A Guide for Caregivers [47]), contact information for psychosocial services (e.g., Caregivers Clinic in the MSK Counseling Center), and external resources (e.g., educational materials and services through the CSC, American Cancer Society, and others) (Appendix D,)."
89638172|NCT03856086|Experimental|CancerSupportSource-CG screening plus consultation (S+C)|"ICs randomized to S+C will complete the web-based CSS-CG (Appendix C) using a tablet immediately following baseline study measures. In case of technical issues, ICs may complete Appendix C with the guidance of a member of the research study team. The CSS-CG asks ICs to rate their level of concern for 33 different possible problems: if a need is rated as low (i.e., A little or less concern), after each problem is rated ICs will be prompted to request pertinent educational materials if they are interested. If a need is endorsed (i.e., Moderate or greater concern), ICs are asked through the web-based electronic platform (https://mskcc.mycarereport.com) whether they would like educational materials and/or to speak with someone about that need (i.e., receive a referral)."
89638173|NCT03834272|Experimental|1st Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo on surgical tissue.
89638174|NCT03834272|Experimental|2nd Tier Dose Level- LUM Imaging System|9 patients will be administered a single dose of LUM015 at 1.5 mg/kg. Imaging with the LUM imaging device will be performed in vivo on surgical tissue.
89638175|NCT03834272|Experimental|3rd Tier Dose Level- LUM Imaging System|6 patients will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo on surgical tissue.
89638176|NCT03834272|Experimental|Optimal Dose Arm|12 patients will receive LUM015 at the dose and timepoint selected based on the analysis of the data
89638177|NCT03774641||Taking Lamotrigine|Lamotrigine (Lamictal), dosage will be based on a reference concentration of blood-serum levels
89638178|NCT03760731|Experimental|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
89638179|NCT03760731|Active Comparator|Present Centered Therapy|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right. PCT could provide another treatment option that might be preferable to some Veterans and promote patient choice. Additionally, PCT would require less clinician training and specialization than ACT-MI. Using PCT as an active comparison condition will determine whether it is necessary to train clinicians in ACT-MI or if therapists with exposure to supportive problem-solving therapy approaches can lead a group that impacts functioning among Veterans reporting moral injury-related distress.
89638180|NCT03759665|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
89638181|NCT03759665|No Intervention|Post-Treatment Washout|After the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
89638182|NCT03755414|Experimental|Pilot Study: Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy~Stem cell transplantation on Day 0~Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
89638183|NCT03755414|Experimental|Expansion Phase: Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy~Stem cell transplantation on Day 0~Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
89638184|NCT03748966|Experimental|Adults with XLH|Adults with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
89638185|NCT03748966|Experimental|Children with XLH|Children (age 3-17) with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
89042337|NCT05683509|Active Comparator|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
89638186|NCT03745339||Abstinent OUD|Men and women with history of OUD, but abstinent for at least 3 weeks and not in agonist treatment
89638187|NCT03745339||Controls|Men and women with no history of a substance-use disorder (except nicotine, for matching purposes) and not using any drug for nonmedical purposes
89638188|NCT03745339||In-treatment OUD|Men and women with opioid use disorder (OUD) being treated with an agonist (buprenorphine or methadone)
89638189|NCT03697408|Experimental|Itacitinib and everolimus|
89638190|NCT03689114|Experimental|Low dose|Dosage is in mg: low dose carbamazepine, 300 ; low dose levetiracetam, 500; low dose valproate, 300; low dose zonisamide, 150; low dose oxcarbazepine, 600; low dose topiramate, 100; low dose lamotrigine, 100; low dose gabapentin, 450. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
89638191|NCT03689114|Active Comparator|Standard dose|Dosage is in mg: standard dose carbamazepine 600; standard dose levetiracetam 1000; standard dose valproate, 600; standard dose zonisamide 300; standard dose oxcarbazepine 1200; standard dose topiramate, 200; standard dose lamotrigine, 200; standard dose gabapentin 900. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
89638192|NCT03681262|Experimental|High frequency spinal cord stimulation|Implant of the device that can deliver high frequency waveform to spinal cord
89638193|NCT03681262|Experimental|Burst spinal cord stimulation|Implant of the device that can deliver burst waveform to spinal cord
89638194|NCT03646188|Placebo Comparator|Placebo-containing MNA|Placebo
89638195|NCT03646188|Experimental|25 µg Doxorubicin-containing MNA|D-MNA's containing 25 µg of doxorubicin hydrochloride
89638196|NCT03646188|Experimental|50 µg Doxorubicin-containing MNA|D-MNA's containing 50 µg of doxorubicin hydrochloride
89638197|NCT03646188|Experimental|100 µg Doxorubicin-containing MNA|D-MNA's containing 100 µg of doxorubicin hydrochloride
89638198|NCT03646188|Experimental|200 µg Doxorubicin-containing MNA|D-MNA's containing 200 µg of doxorubicin hydrochloride
89638199|NCT03629912|Experimental|Exercise + Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises AND health information on fall risks + diet/nutrition.
89638200|NCT03629912|Active Comparator|Exercise + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises ONLY.
89638201|NCT03629912|Active Comparator|Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating health information on fall risks + diet/nutrition ONLY.
89638202|NCT03629912|No Intervention|Bingo Only|Participants use the Bingocize app to play bingo only.
89638203|NCT03626688|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the highest tolerated dose.
89638204|NCT03626688|Placebo Comparator|Placebo|Matching placebo tablets (oral)
89638205|NCT03604783|Experimental|Single Arm TP-1287|TP-1287 by oral administration
89638206|NCT03593057|Experimental|Manual therapy protocol|Manual therapy protocol and self-care advice and body awareness. Three sessions of manual therapy will be applied, (at the beginning, at 2 weeks and at 3 weeks).
89638207|NCT03593057|Active Comparator|Control group.|Advice on self-care and body awareness.
89638208|NCT03585491|Experimental|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
89638209|NCT03585491|Experimental|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
89638210|NCT03582488|Experimental|Dementia with Lewy Bodies|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
89638211|NCT03580525|Experimental|nicotine saline infusion 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
89638212|NCT03580525|Experimental|nicotine infusion 0.24mcg/kg/s|0.24mcg/kg/s The day order will be randomized per day
89638213|NCT03580525|Experimental|nicotine infusion 0.096mcg/kg/s|0.096mcg/kg/s The day order will be randomized per day
89638214|NCT03580525|Experimental|nicotine infusion 0.048mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
89638215|NCT03580525|Experimental|nicotine infusion 0.024mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
89638216|NCT03549780|Other|Stomal Occlusion|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
89638217|NCT03523533|Experimental|Peripherally-inserted internal jugular catheter|All enrolled patients will receive a peripheral angiocatheter in the internal jugular vein, under dynamic ultrasound guidance.
89638218|NCT03520660|Experimental|Phase I|Phase I treatment
89638219|NCT03520660|No Intervention|Phase II after Phase I|Participants who achieved SVR12 in Phase I
89638220|NCT03520660|No Intervention|Phase II without Phase I|Participants who achieved SVR 24 previously
89638221|NCT03518216|Experimental|ADAPT|Participants randomized to ADAPT will complete Aim to Decrease Anxiety and Pain Treatment (ADAPT), a remotely delivered tailored intervention that integrates mindfulness meditation with cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions are interactive with a trained psychological provider and the following 4 sessions are web-based. Each web-based session is followed by therapist support.
89638222|NCT03518216|No Intervention|Waitlist Control|Participants randomized to waitlist control will receive medical treatment as usual. These participants will be given the opportunity to complete ADAPT upon completion of the post assessment.
89638223|NCT03489707|Experimental|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
89638224|NCT03489707|Active Comparator|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
89638225|NCT03478865|Experimental|Participants|Participants with age-related macular degeneration
89638226|NCT03462004|Experimental|Cohort 1: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^6.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
89638227|NCT03462004|Placebo Comparator|Cohort 1: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
89638228|NCT03462004|Experimental|Cohort 2: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^7.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
89212092|NCT00857402|Active Comparator|Daboqolo|
89638229|NCT03462004|Placebo Comparator|Cohort 2: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
89638230|NCT03442504|Other|FES PET/CT|"The images will be made immediately after the injection of the FES in a dynamic acquisition, of 30 minutes, centered on a positive FDG lesion. The imaging will then be completed 1 hour after the injection, after obtaining a urination, by an acquisition whole body (from the top of the skull to the root of the thighs or more if element on FDG or conventional imaging) which will be performed in the supine position with arms around the body. During the PET / CT scan, patients will breathe spontaneously. The acquisition will last 30 minutes."
89638231|NCT03435796|Other|Participants exposed to Gene-modified (GM) T cell therapy|
89638232|NCT03399110|Experimental|XELOX for 4 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery (five 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 4 months or progress of disease
89638233|NCT03399110|Active Comparator|XELOX for 6 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery(eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
89638234|NCT03388632|Experimental|lead-in doublet A|lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + ipilimumab (anti- CTLA-4) given IV on day 8 (IL-15 doses are limited to first 4 cycles only)
89638235|NCT03388632|Experimental|lead-in doublet B|lead-in doublet for initial safety evaluation: rhIL-15 given SC days 1-8 and 22- 29 + nivolumab (anti-PD1) given IV on days 8, 22, and 36 (IL-15 doses are limited to first 4 cycles only)
89638236|NCT03388632|Experimental|triplet|triplet combination
89638237|NCT03360838||CogCheck application|Performance in the application
89638238|NCT03337724|Experimental|Ipatasertib + Paclitaxel|
89638239|NCT03337724|Experimental|Placebo + Paclitaxel|
89638240|NCT03312569||Intracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an intracorporeal anastomosis due to begin or malignant Right Colon Disease.
89638241|NCT03312569||Extracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an extracorporeal anastomosis due to begin or malignant Right Colon Disease.
88991202|NCT05524909|Experimental|Intervention Group - Genetic Risk Estimate + Fitbit Functions|This intervention group will receive a Fitbit device, but have a Fitbit step goal set 10% higher than their baseline step count, and use its prompt functions, in addition to the genetic risk estimate and e-leaflet.
88991203|NCT05520047||COVID19-severe Patient|modified Medical Research Council dyspnea scale (mMRC), European Quality of Life 5 Dimensions and 5 Lines (EQ-5D-5L), the impact of event scale-revised (IES-R), The Hospital Anxiety and Depression Scale (HADS), the Montreal Cognitive Assessment (MoCA)- BLIND, Lawton instrumental activities of daily living (IADL) and Return to work scales
88991204|NCT05520047||family of COVID19-severe Patient|impact of event scale-revised (IES-R), The Hospital Anxiety and Depression Scale (HADS) scales
88991205|NCT05517603|Active Comparator|Experimental: AJ201|Subjects taking active drug AJ201 600mg/day for 12 weeks.
88991206|NCT05517603|Placebo Comparator|Placebo Comparator|Subjects taking placebo for 12 weeks.
88991207|NCT05515367|Experimental|Desidustat oral tablet|Oral administration of Desidustat from baseline (week 0) to Week 52
89042338|NCT05683509|Active Comparator|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane alone
89042339|NCT05675878|Experimental|Dietary Intervention Group|Subjects will undergo a 2-hour in-depth training via Zoom on how to follow the diet and will receive a binder with helpful information. They will be give the weekend to prepare and then will start the diet the following Monday, and will continue following it for 4 weeks before being reassessed in the lab.
89042340|NCT05675878|No Intervention|Waitlisted Control Group|The waitlisted control group will follow their usual diet for one month and then will be reassessed (as a comparator group) before being trained on the dietary intervention which they will then follow for the next month.
89638242|NCT03298061|Experimental|Subjects from clinical study MEA115921|Subjects who participated in clinical study MEA115921 and who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included. Eligible subjects will receive subcutaneously administered mepolizumab at a dose of 300 mg SC every 4 weeks.
89638243|NCT03260257|Experimental|Schizophrenia patients|Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
89638244|NCT03240900|Experimental|Electrical Stimulation Breast|Breast that will receive 1 hour of intraoperative electrical stimulation
89042341|NCT05675332|Placebo Comparator|no stress exposure|no threat stress
89212093|NCT00853814|Experimental|Reduced access to sedentary behaviors, High park access|
89212094|NCT00853814|Experimental|Usual access to sedentary behaviors, High park access|
89212095|NCT00853814|Experimental|Reduced access to sedentary behaviors, Low park access|
89638245|NCT03240900|Placebo Comparator|No Electrical Stimulation Breast|The contralateral breast of the patient will receive no electrical stimulation
89638246|NCT03229941|Experimental|Restrictive|Transfusion trigger: Hb<7gm/dl
89638247|NCT03229941|Experimental|Liberal|Transfusion trigger: Hb<10gm/dl
89638248|NCT03206086|Experimental|Group|Eltrombopag
89638249|NCT03205982|Sham Comparator|Control|WiseApp that delivers fitness reminders
89638250|NCT03205982|Experimental|Intervention|WiseApp that delivers medication adherence reminders
89638251|NCT03178552|Experimental|Cohort A: Alectinib 600 Milligrams (mg)|"This cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort A is complete."
89638252|NCT03178552|Experimental|Cohort B: Dose Finding Phase (DFP) Alectinib|"This cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study. Participants may receive 750 mg or 600 mg, if it is unsafe to pursue the higher starting dose.~Enrollment to Cohort B is complete."
89638253|NCT03178552|Experimental|Cohort B: Dose Expansion Phase (DEP) Alectinib|"This cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort B is complete."
89638254|NCT03178552|Experimental|Cohort C: Atezolizumab 1200 mg|"This cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort C is complete."
89638255|NCT03178552|Active Comparator|Cohort C: Pemetrexed, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care.~Enrollment to Cohort C is complete."
89638256|NCT03178552|Active Comparator|Cohort C: Gemcitabine, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D.~Enrollment to Cohort C is complete."
89638257|NCT03178552|Experimental|Cohort D: Entrectinib 600 Milligrams (mg)|"This cohort includes participants with c-ros oncogene 1 positive (ROS1+) NSCLC. Participants will receive entrectinib 600 mg orally once a day (QD) until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort D is complete."
88991208|NCT05514912|Experimental|Arm A (nab-paclitaxel, cisplatin, gemcitabine, infigratinib)|"While awaiting NGS molecular profile results, all patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8 of one 21-day cycle in the absence of disease progression or unacceptable toxicity.~Patients who are FGFR2 fusion/translocation positive receive infigratinib PO QD for days 1-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients whose cancer is stable or improved undergo surgery to remove the tumor within 8 weeks of completing preoperative therapy per standard of care."
88991209|NCT05514912|Active Comparator|Arm B (nab-paclitaxel, cisplatin, gemcitabine)|"While awaiting NGS molecular profile results, all patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8 of one 21-day cycle in the absence of disease progression or unacceptable toxicity.~Patients who are FGFR2 fusion/translocation negative continue receiving nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients whose cancer is stable or improved undergo surgery to remove the tumor within 8 weeks of completing preoperative therapy per standard of care."
88991210|NCT05514509|Active Comparator|Standard Implementation (SI)|PSPs will receive APRETUDE injection and could receive optional Cabotegravir tablets as oral lead in (OLI). The SI arm receives the standard toolkits that are anticipated to be available for APRETUDE that includes information resource for PSPs and SSPs.
88991211|NCT05514509|Experimental|Enhanced Implementation (EI)|PSPs will receive APRETUDE injection and could receive optional Cabotegravir tablets as OLI. The EI arm will receive all components of SI arm and additional provider-focused implementation strategies. Provider-focused strategies will include a patient-provider communication tool, Provider Education, and enhanced tool kit materials.
88991212|NCT05514509|Experimental|Enhanced Collaborative Implementation (ECI)|PSPs will receive APRETUDE injection and could receive optional Cabotegravir tablets as OLI. The ECI arm will involve implementation strategies to support patient activation and provider awareness. Clinics randomized to ECI will receive all components of SI and additional implementation strategies to support patient activation and ensure provider awareness. ECI strategies will include a patient information and product resources and peer support.
88991213|NCT05511337|Other|Control|Caloric restriction
89212096|NCT00853814|Experimental|Usual access to sedentary behaviors, Low park access|
89638258|NCT03178552|Experimental|Cohort E: Atezolizumab, Vemurafenib, and Cobimetinib|"This cohort includes participants with BRAF V600 mutation. Participants will receive: atezolizumab 1680 mg IV Q4W after the run-in period; cobimetinib 60 mg orally (PO) QD on Days 1-21 of each cycle during the run-in and triple-combination periods; and vemurafenib 960 mg PO twice daily (BID) on Days 1-21 of the initial run-in period, then 720 mg PO BID on Days 1-22 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.~Enrollment to Cohort E is complete."
89638259|NCT03178552|Experimental|Cohort F: Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed|"This cohort includes participants with EGFR exon 20+ NSCLC. Participants will receive atezolizumab + bevacizumab + carboplatin + pemetrexed for 4 or 6 induction cycles (cycle = 21 days). After induction therapy, participants will continue maintenance treatment with atezolizumab + bevacizumab + pemetrexed until disease progression, unacceptable toxicity, withdrawal of consent, or death.~Enrollment to Cohort F is complete."
89638260|NCT03178552|Experimental|Cohort G: GDC-6036 or Docetaxel|This cohort includes participants with KRAS G12C mutation. Participants will receive GDC-6036 PO QD or IV docetaxel Q3W (75 mg/m^2) until disease progression or unacceptable toxicity
89638261|NCT03115424|Placebo Comparator|Sleeve Gastrectomy Placebo|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
89638262|NCT03115424|Active Comparator|Sleeve Gastrectomy Saxenda|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
89638263|NCT03115424|Sham Comparator|RYGB|Twenty five subjects will be recruited from the Nutrition Clinic at Mayo Clinic Rochester prior to undergoing RYGB surgery.
89638264|NCT03089866||ASA Patients I or II|Participants are healthy (BMI <35), 55years and older, and have the ability to follow instructions. In this population we will quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
89638265|NCT03032406|Experimental|HCQ alone (Arm A)|
89638266|NCT03032406|Experimental|EVE alone (Arm B)|
89638267|NCT03032406|Experimental|combination HCQ and EVE (Arm C)|
89638268|NCT03032406|Experimental|observation (Arm D)|
89638269|NCT03027427||Patients|Patients with confirmation of, or suspicion of, a heritable gastric malignancy disorder
89638270|NCT02966756|Experimental|Cohort 1: Venetoclax|Participants with 17p deletion status will receive various doses of venetoclax once daily (QD).
89638271|NCT02966756|Experimental|Cohort 2: Venetoclax|Participants who have failed a B-Cell Receptor Signaling Pathway Inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status will receive various doses of venetoclax once daily (QD).
89638272|NCT02956473|Experimental|Supine MRI|"Standard MRI will be performed~Supine MRI will be performed~Participant will receive mammography and ultrasound~Breast Radiologist will take a brief survey.~Patients will undergo upfront surgery or receive Neoadjuvant Therapy per standard of care~Standard of care will be performed"
89638273|NCT02949830|Experimental|Givosiran|At the beginning of this study, participants received either givosiran 2.5 mg/kg subcutaneous (SC) injection once monthly(QM), givosiran 5.0 mg/kg SC injection QM, or givosiran 5.0 mg/kg SC injection once every 3 months (Q3M). Within a year, all participants were transitioned to givosiran 2.5 mg/kg SC injection QM.
89638274|NCT02913612|Experimental|0.25% Timolol Treatment|Subjects assigned to this arm will be randomized to 0.25% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol.
89638275|NCT02913612|Experimental|0.5% Timolol Treatment|Subjects assigned to this arm will be randomized to 0.5% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin an alternative treatment.
89638276|NCT02913612|No Intervention|Non-Intervention Group|Subjects assigned to this group will not receive treatment. The subject will only be photographed on the same schedule as the intervention group.
89638277|NCT02899052|Experimental|Venetoclax + Carfilzomib + Dexamethasone|"Part 1: Evaluate the safety and pharmacokinetic profiles while providing information to determine the appropriate doses of venetoclax and carfilzomib (VenKd) to be used in the VenKd combination in approximately 18 participants. The dose levels are Venetoclax 400 mg or 800 mg; Carfilzomib 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; Dexamethasone 40 mg~Part 2: Further evaluate the safety and efficacy profile of the VenKd combination selected after completion of Part 1 in approximately 22 additional participants. Participants may discontinue Kd but may continue receiving venetoclax once daily (QD) as monotherapy.~Part 3: Further evaluation of the efficacy of the VenKd combination after completion of Part 1 and Part 2 in 7 additional participants.~Part 4, An additional 65 participants t(11;14) positive will receive varying doses of the VenKd combination or carfilzomib and dexamethasone"
89638278|NCT02890095|Experimental|Arm A = Breast Cancer surgery|Arm A : women undergoing breast cancer surgery.
89638279|NCT02890095|Other|Arm B = Control (plastic surgery)|Arm B : women undergoing breast surgery for the purpose of plastic surgery
89638280|NCT02865408|Active Comparator|Group 1: Peptamen 1.5% via enteral only|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard EN Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d
89638281|NCT02865408|Active Comparator|Group 2: Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive the same enteral feeding as group 1 (Peptamen 1.5) but in addition will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/d
89638282|NCT02865408|Active Comparator|Group 3: Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids (Prosol 20%) in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/day.
89638283|NCT02795988|Experimental|Phase 1b|10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
89638284|NCT02795988|Experimental|Phase 2 - IMU 131 plus chemotherapy|50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
88991214|NCT05511337|Experimental|Intervention A|Caloric restriction and control oxalate and citrate food
89042342|NCT05675332|Active Comparator|stress exposure|exposure to stress threat
89212097|NCT00853892|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
89638285|NCT02795988|Experimental|Phase 2 - Chemotherapy only|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
89638286|NCT02762266|Active Comparator|Arm I (TACE)|Patients undergo TACE.
89638287|NCT02762266|Experimental|Arm II (SBRT)|Beginning within 2 weeks of the radiation set-up scan and within 4 weeks of fiducial seed implantation (if applicable), patients undergo image guided SBRT 3 fractions within 1 week or 5 fractions within 2 weeks.
89638288|NCT02737306|Placebo Comparator|Placebo|"In this study, 60 subjects will be randomized to receive either PRO 140 or placebo in a 1:1 ratio (i.e. 30 subjects per arm). PRO 140 or placebo will be administered as a 350 mg subcutaneous injection.~Placebo will be administered -2/-3 days before the stem cell infusion, on the day of stem cell infusion (Day 0) and thereafter on days 7, 14, 21, 28, 42, 56, 70, 84 and 98 as per the study schedule of assessments.~Each vial of the Placebo contains 5mM Histidine, 15 mM Glycine, 95 mM Sodium Chloride, 0.3% (w/v) Sorbitol, 0.005% (w/v) Polysorbate 20 at a pH of 5.5.~Each 350 mg dose of placebo consist of 2 SC injections of placebo (5mM Histidine, 15 mM Glycine, 95 mM Sodium Chloride, 0.3% (w/v) Sorbitol, 0.005% (w/v) Polysorbate 20 at a pH of 5.5) of 2 X 1 mL/inj. on opposite sides of abdomen."
89638289|NCT02737306|Experimental|350 mg Pro140|"In this study, 60 subjects will be randomized to receive either PRO 140 or placebo in a 1:1 ratio (i.e.,30 subjects per arm). PRO 140 or placebo will be administered as a 350 mg subcutaneous injection.~PRO 140 will be administered -2/-3 days before the stem cell infusion, on the day of stem cell infusion (Day 0) and thereafter on days 7, 14, 21, 28, 42, 56, 70, 84 and 98 as per the study schedule of assessments.~Each vial of the PRO 140 product contains 1.4 mL antibody at 175 mg/ml in a buffer containing 5 mM L-histidine, 15.0 mM glycine, 95 mM sodium chloride, 0.3% (w/v) sorbitol, 0.005% (w/v) polysorbate 20 (Tween 20®), and sterile water for injection, at pH of 5.5.~Each 350 mg dose of PRO 140 will consist of 2 SC injections of PRO 140 (2 X 1 mL/inj.) on opposite sides of abdomen."
89638290|NCT02736695|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive a Tau PET scan.
89638291|NCT02711553|Experimental|8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 8 mg/kg ramucirumab plus 25 mg/square meter (mg/m²) cisplatin and 1000 mg/m² gemcitabine intravenously (IV) on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for ramucirumab therapy).
89638292|NCT02711553|Placebo Comparator|Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable and equivalent volume to ramucirumab) plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
89638293|NCT02711553|Experimental|80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 80 mg merestinib orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for merestinib therapy).
89638294|NCT02711553|Placebo Comparator|Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable to merestinib) orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days. Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
89638295|NCT02700841|Experimental|Arm I (vaccine, CD34 transplant, DLI)|ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.
89638296|NCT02700841|Active Comparator|Arm II (vaccine, stem cell transplant)|Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.
89212098|NCT00853892|Active Comparator|B|OxyContin® 40 mg tablet
89212099|NCT02546336|Experimental|Ultrasound-Guided Hip Denervation|This is a pilot study. 15 Hip Osteoarthritis patients with chronic pain will be recruited in this pilot arm. These will undergo Ultrasound-Guided Cooled Radiofrequency Hip Denervation as intervention.
89212100|NCT00854126|Experimental|1|
89212101|NCT00857480|Experimental|Reference|No pre-treatment
88991215|NCT05511337|Experimental|Intervention B|Real-life intervention, control of oxalates and citrates without restriction of kilocalories.
88991216|NCT05511025|Experimental|Cohort 1|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC
88991217|NCT05511025|Experimental|Cohort 2|Participants will receive a single dose of AZD6234 via an SC injection and matching volume of the placebo as a solution via SC injection
88991218|NCT05511025|Experimental|Cohort 3|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
88991219|NCT05511025|Experimental|Cohort 4|Participants will receive single ascending doses of AZD6234 via IV injection and matching volumes of the placebo as a solution via IV injection
88991220|NCT05511025|Experimental|Cohort 5|One dose level for SC administration is planned to be investigated for Japanese participants only
88991221|NCT05511025|Experimental|Cohort 6|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
88991222|NCT05511025|Experimental|Cohort 7|Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection
88991223|NCT05511025|Experimental|Cohort 8|Participants will receive AZD6234 via SC injection and matching volumes of placebo as a solution via SC injection
88991224|NCT05507034||Breast cancer|Breast cancer patients following over time during cancer treatment
88991225|NCT05498610|Experimental|1.7 mg NNC0408-0389 plus 0.5 mg semaglutide|Participants will receive a single subcutanous dose of 1.7 mg of NNC0408-0389 in combination with a fixed dose of 0.5 mg semaglutide administered as separate injections
89212102|NCT00857480|Experimental|T1|Cloxacillin pre- and co-treatment
89212103|NCT00857480|Experimental|T2|UDCA pre-treatment
89212104|NCT00857558|Experimental|1|OPC-262 1mg
89638297|NCT02678741|Active Comparator|No clinical response|No clinical response (PD de novo) after a minimum of 3 months on CPI monotherapy
89638298|NCT02678741|Active Comparator|Develop PD|Develop PD after initial clinical response to CPI monotherapy
89638299|NCT02678741|Active Comparator|Stable Disease|Stable disease for at least 6 months on CPI monotherapy
89638300|NCT02659202|Experimental|Precision Spinal Cord Stimulator System|Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.
89638301|NCT02611180||Arm 1: Acute skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device.~Two optional skin biopsies. One on day 5-7 of treatment and one on day 28 from the start of treatment."
89638302|NCT02611180||Arm 2: Chronic skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device.~Two optional skin biopsies. One on day 5-7 of treatment and one on day 28 from the start of treatment."
89638303|NCT02587338|Experimental|Verum tDCS|Left frontal anodal stimulation, supraorbital right cathodal stimulation
89638304|NCT02587338|Experimental|Sham tDCS|sham stimulation, same electrode positions
89638305|NCT02584244|Experimental|Patients with colorectal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
89638306|NCT02584244|Experimental|Patients with esophageal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
89638307|NCT02584244|Experimental|Pancreatic cancer patients receiving neoadjuvant chemotherapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
89638308|NCT02584244|Experimental|Pancreatic cancer patients not receiving neoadjuvant chemo|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
89638309|NCT02584244|Experimental|Gastric cancer patients who have received neoadjuvant therapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
89638310|NCT02584244|Experimental|Patients with early stage gastric cancer or precancerous lesions|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
89212105|NCT00857558|Experimental|2|OPC-262 2.5mg
89212106|NCT00857558|Experimental|3|OPC-262 5mg
89212107|NCT00857558|Placebo Comparator|4|
89638311|NCT02567123|Experimental|Experimental|Runners are switched from a rearfoot strike running pattern to a forefoot strike running pattern.
89638312|NCT02567123|No Intervention|Control|Runners continue to use their normal rearfoot strike running pattern with no intervention in place.
89638313|NCT02546661|Experimental|Module A: AZD4547 Monotherapy|"AZD4547 will be given orally twice daily until disease progression.~Patients who receive AZD4547 as monotherapy will have the option to cross over to durvalumab as monotherapy at the point of objective progression, as long as the following criteria are met:~The investigator believes it is in the patient's interest to receive durvalumab;~The patient consents to the continued treatment;~It is clinically appropriate for the patient to continue on durvalumab treatment;~The patient satisfies the key eligibility criteria for receiving durvalumab treatment."
89638314|NCT02546661|Experimental|Module A: MEDI4736 (durvalumab) + AZD4547|AZD4547 will be given orally twice daily until disease progression. Patients will also receive MEDI 4736 (durvalumab) by IV infusion once every 4 weeks.
89638315|NCT02546661|Experimental|Module B: MEDI4736 (durvalumab) + Olaparib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Olaparib will be given orally twice daily.
89638316|NCT02546661|Experimental|Module C: MEDI4736 (durvaluamb) + AZD1775|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
89638317|NCT02546661|Experimental|Module D: MEDI4736 (durvalumab) monotherapy|MEDI 4736 (durvalumab) will be given by IV infusion once every 4 weeks.
89638318|NCT02546661|Experimental|Module E: MEDI4736 (durvalumab) + Vistusertib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Vistusertib will be given orally twice per day on an intermittent schedule (2 days on, 5 days off).
89638319|NCT02546661|Experimental|Module F: MEDI4736 (durvaluamb) + AZD9150|AZD9150 will be given as monotherapy on Days -7, -5, and -3 of a one week lead-in period. Combination dosing with IV AZD9150 followed by IV MEDI4736 (durvalumab) begins on Day 1 of each 28 day cycle. Thereafter AZD9150 is given weekly and MEDI4736 is given once every 4 weeks.
89638320|NCT02546661|Experimental|Module G: MEDI4736 + Selumetinib|
89638321|NCT02456389|Active Comparator|Standard perioperative management|Standard postoperative care
89638322|NCT02456389|Experimental|Risk-based, perioperative management|Preoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
89638323|NCT02412553|Active Comparator|Specific carbohydrate arm|The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient.
89638324|NCT02412553|Active Comparator|Elemental diet arm|The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet
89638325|NCT02367040|Experimental|Copanlisib + Rituximab|Combination of the Copanlisib and rituximab
89638326|NCT02367040|Placebo Comparator|Placebo + Rituximab|Combination of Copanlisib placebo and rituximab
89638327|NCT02292004|Experimental|ACL repair with MIACH scaffold|Patients will undergo ACL repair surgery using the newly developed MIACH scaffold
89638328|NCT02292004|Active Comparator|Standard ACL reconstruction|Patients will undergo a standard ACL reconstruction surgery
89638329|NCT02278120|Experimental|Ribociclib + NSAI/tamoxifen + goserelin|Ribociclib 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
89638330|NCT02278120|Placebo Comparator|Placebo + NSAI/tamoxifen + goserelin|"Placebo daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days).~Participants were unblinded once the final OS analysis was conducted and after the implementation of protocol amendment 6 (16-Jul-2019) and were given the option to crossover to treatment with ribociclib +NSAI/tamoxifen + goserelin."
89638331|NCT02257892||Patients|Affected patients, with symptoms or genetic mutation
89212108|NCT00857636|Experimental|Health Literacy|
89638332|NCT02257892||Unaffected/healthy relatives|Relatives without symptoms or genetic mutation
89638333|NCT02242942|Experimental|Safety Run-in Obinutuzumab + Venetoclax|Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
89638334|NCT02242942|Experimental|Obinutuzumab + Chlorambucil|Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
89638335|NCT02242942|Experimental|Obinutuzumab + Venetoclax|Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
89638336|NCT02242097|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib orally PO QD on days 1-28. Courses repeat every 28 days for up to 4 years in the absence of disease progression, unacceptable toxicity, or patient preference.
88991226|NCT05498610|Experimental|8.6 mg NNC0480-0389 plus 0.5 mg semaglutide|Participants will receive a single subcutanous dose of 8.6 mg of NNC0408-0389 in combination with a fixed dose of 0.5 mg semaglutide administered as separate injections
89212109|NCT00718523|Placebo Comparator|A|Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.
89638337|NCT02100891|Experimental|Allogeneic HCT + Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
89638338|NCT02089269||Cohort 1|2,200 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention
89638339|NCT02089269||Cohort 2|125 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention
89638340|NCT02048332|Experimental|Viral Specific VST Infusion|Viral reactivation or infection. VST Reinfusion required.
89638341|NCT01953926|Experimental|Neratinib monotherapy|"Neratinib monotherapy in HER2 mutated cancers including cervical, salivary gland, and lung cancers containing EGFR exon 18 mutations.~Cohorts closed to enrollment in prior amendments: HER2 mutant cancers including bladder/urinary, colorectal, endometrial, breast HR-positive, TNBC HR-negative, lung, gastroesophageal, biliary, and ovarian; HER3 mutant solid tumor NOS; HER4 mutant solid tumor NOS; fibrolamellar carcinoma and EGFR brain."
89212110|NCT00718523|Experimental|B|AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.
89638342|NCT01953926|Experimental|Neratinib and Trastuzumab|"Neratinib and Trastuzumab in HER2 mutated (TNBC, HR-negative) breast cancers.~Cohorts closed to enrollment in in prior amendments: colorectal, lung cancer HER2 mutant."
89212111|NCT02590367|Experimental|FOLFOX regimen&HD6610 Granule|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
89638343|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Randomized)|Neratinib, Fulvestrant and Trastuzumab or Fulvestrant and Trastuzumab or Fulvestrant alone in HER2 mutated (HR-positive with prior CDK4/6i) breast cancers.
89638344|NCT01953926|Experimental|Neratinib, Fulvestrant and Trastuzumab (Non-Randomized)|Neratinib, Fulvestrant and Trastuzumab in HER2 mutated (HR-positive with or without CDK4/6i) breast cancers.
89638345|NCT01953926|Experimental|Neratinib and Paclitaxel|Neratinib and Paclitaxel in HER2 mutated bladder/urinary tract cancers.
89638346|NCT01953926|Experimental|Neratinib and Fulvestrant|Neratinib and Fulvestrant in HER2 mutated (HR-positive) breast cancers.
89638347|NCT01948700|Other|Brief Intervention|Motivational Interviewing (MI)
89638348|NCT01948700|Other|Standard Intervention|Education
89638349|NCT01934660||Group 1|Healthy volunteers
89638350|NCT01934660||Group 2|Subjects diagnosed with diabetes
89638351|NCT01934660||Group 3|Subjects diagnosed cardiovascular disease
89638352|NCT01905826||Patient Relatives|Blood relatives of enrolled patients.
89638353|NCT01905826||Patients|Patients with known mutations in GATA2 or those with clinical and laboratory characteristics strongly consistent with GATA2 deficiency.
89638354|NCT01886794|Experimental|Postmenopausal, topical vaginal cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to estrogen cream.
89638355|NCT01886794|No Intervention|Pre-menopausal, no topical vaginal cream|Pre-menopausal, no topical vaginal cream. These women will be examined at different stages in their menstrual cycle in order to compare characteristics of the cycle at high and lower estrogen timepoints.
89638356|NCT01886794|Placebo Comparator|Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to placebo.
89638357|NCT01858168|Experimental|One|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Ewing sarcoma
89638358|NCT01858168|Experimental|Two|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle Irinotecan, given by IV once per day on days 1-7 of each cycle
89638359|NCT01858168|Experimental|Three|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Rhabdomyosarcoma
89638360|NCT01829958|Experimental|Pre-Phase Arm|They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
89638361|NCT01829958|Experimental|Geriatric Assessment (GA) only arm|Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
89638362|NCT01764451|Experimental|Simvastatin|20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
89638363|NCT01764451|No Intervention|No Treatment|
89638364|NCT01746238|Experimental|Treatment Arm|Bevacizumab, metronomic doxorubicin and radiation therapy
89638365|NCT01679535|Experimental|Intervention|nutrition and hygiene education by community health workers
89638366|NCT01613443||Control|Healthy volunteers without medication
89212112|NCT02590367|Placebo Comparator|FOLFOX regimen&HD6610 Granule placebo|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule
89638367|NCT01613443||Phenprocoumon|Patients receiving Marcumar having target INR 2-3
89638368|NCT01613443||Dabigatran|Patients receiving therapeutic dosis of Pradaxa
89638369|NCT01613443||Rivaroxaban|Patients receiving therapeutic dosis of Xarelto
89212113|NCT02590913|Experimental|group fructose|Volunteer was randomized into either group fructose or glucose
89212114|NCT02590913|Experimental|group glucose|After one-week washout period, volunteer was crossed over for either group glucose or fructose.
89212115|NCT02589743|Active Comparator|Fluroshield - F (Sealant)|Pit and fissure sealing using only sealant
89638370|NCT01593241|Experimental|Carboplatin|
89638371|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 1|
89638372|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 2|
89638373|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 3|
89638374|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 4|
89638375|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 5|
89638376|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 6|
89638377|NCT01409135|Experimental|ASG-22CE Expansion Cohort 1|Breast Cancer
89638378|NCT01409135|Experimental|ASG-22CE Expansion Cohort 2|Bladder Cancer
89638379|NCT01409135|Experimental|ASG-22CE Expansion Cohort 3|Lung plus other solid tumor cancers
89042343|NCT05672511|Experimental|İntervention group|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory.
89042344|NCT05672511|No Intervention|Control group|. The control group will not receive any simulation training
89042345|NCT05670509|Experimental|Nasal administration of midazolam in home group|treatment with intranasal midazolam in children with known seizure disorder who were prescribed midazolam by pediatric neurologist at home with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5mg/spray). If the volume to be administered exceeded 1 mL, then the dose was divided between both nostrils to avoid runoff and swallowing. children with known seizure disorder who were prescribed midazolam by pediatric neurologist
89042346|NCT05670509|Experimental|buccal administration of midazolam in home group|treatment with buccal midazolam in children with known seizure disorder who were prescribed midazolam by pediatric neurologist at home with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
89638380|NCT01407198|Experimental|Nilotinib/XRT|Nilotinib is administered 400mg PO BID for 2 weeks and then administered concurrently with daily radiation therapy until completion of radiation therapy. Participants can then undergo surgery if clinically possible. After either surgery or definitive radiation, participants have the option to continue on nilotinib therapy.
89638381|NCT01403857|Experimental|Whole Grain|Whole grain products as defined by the American Association of Cereal Chemists (AACC) given in a market basket that contains eight commonly used grain products over six weeks.
89638382|NCT01403857|Placebo Comparator|Refined Grains|Time control compared to experimental intervention.
89638383|NCT01330719|Experimental|Diseased periodontal treatment|Scaling and root planing along with systemic antibiotics (Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days).
89638384|NCT01330719|Active Comparator|Conventional periodontal treatment|Standard periodontal prophylaxis
89638385|NCT01272050|Active Comparator|Arm A: 64 Gy - Radiation Therapy|Arm A: 64 Gy (32 x 2 Gy) without hormonal treatment
89638386|NCT01272050|Active Comparator|Arm B: 70 Gy - Radiation Therapy|Arm B: 70 Gy (35 x 2 Gy) without hormonal treatment
89638387|NCT01214330|Experimental|Patient-Collected Cervical Pap Smear|women will receive a self Papanicolaou Smear test (SoloPap) in addition to their physician-collected Papanicolaou Smear
89638388|NCT01168739|Experimental|Quercetin|not necessary, contained in protocol
89638389|NCT01168739|Placebo Comparator|Placebo|not necessary, contained in protocol
89638390|NCT01027910|Experimental|PCI-24781 without mandated GCSF|PCI-24781 in combination with doxorubicin without mandated GCSF
89638391|NCT01027910|Experimental|PCI-24781 with mandated GCSF|PCI-24781 in combination with doxorubicin with mandated GCSF
89638392|NCT00978003||1/Healthy Volunteers|Adults age 18-55.
89638393|NCT00942877|Experimental|Cediranib (AZD2171) Treatment|"Adult participants will be treated with 30 mg by mouth once a day for 28 days (28-day cycles).~Pediatric participants (<16 years old) will be treated with 12 mg/m^2/day once a day for 28 days (28-day cycles)."
89638394|NCT00841334|Experimental|1|ACTION
89638395|NCT00841334|Active Comparator|2|Usual care
89638396|NCT00791635||Observational (questionnaires)|"RETROSPECTIVE PORTION: Patients who have undergone pelvic exenteration complete one set of QOL questionnaires.~PROSPECTIVE PORTION: Patients undergoing pelvic exenteration complete questionnaires over 20-40 minutes within 2 weeks before surgery, and at 4-12 weeks, 6 months, and 1, 2, 3, 4, 5, and 10 years after surgery regarding feelings, abilities, depression, coping, social support, sexual function and body image. Patients with cervical cancer may complete 1 additional questionnaire during each of these visits."
89638397|NCT00789009||Group 1|Consist of HIV positive patients recruited from the Washington DC metropolitan area who will receive long-term care for their HIV infection through the NIAID/CCMD HIV clinic
89638398|NCT00789009||Group 2|Patients with known or suspected HIV infection, referred to a NIAID/CCMD investigator for reasons such as testing to diagnose or exclude HIV disease or assistance with HIV-related problems.
89638399|NCT00534014|Placebo Comparator|A|0 mg of Vitamin C
89638400|NCT00534014|Active Comparator|B|250 mg Vitamin C
89042347|NCT05670509|Experimental|intramuscular administration of midazolam in home group|treatment with intramuscular midazolam in children with known seizure disorder who were prescribed midazolam by pediatric neurologist at home with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) administered via using 3 mm syringe in the front aspect of thigh
89212116|NCT02589743|Experimental|Single Bond and F (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
89212117|NCT02589743|Active Comparator|Helioseal Clear Chroma - H (Sealant)|Pit and fissure sealing using only sealant
89212118|NCT02589743|Experimental|Excite and H (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
89638401|NCT00534014|Active Comparator|C|500 mg Vitamin C
89638402|NCT00534014|Active Comparator|D|1000 mg Vitamin C
89638403|NCT00508599|No Intervention|1|Study 1 is the control arm in which participants continue with their normal activity.
89638404|NCT00508599|Experimental|2.|Study 2 consists of 48 hours of complete bed rest.
89638405|NCT00423722|Experimental|Hydration: Normal Saline (salt water)|Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily
89638406|NCT00423722|Placebo Comparator|Placebo: Lower Saline|Group 2: Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
89638407|NCT00362518|Placebo Comparator|1|Study Arm A - Control: no vitamins (placebo only).
89638408|NCT00362518|Active Comparator|2|Study Arm B - Low Dose: Vitamin C 250 mg, Vitamin E 200 IU
89638409|NCT00362518|Active Comparator|3|Study Arm C - Medium Dose: Vitamin C 500 mg, Vitamin E 400 IU
89638410|NCT00362518|Active Comparator|4|Study Arm D - High Dose: Vitamin C 1000 mg, Vitamin E 800 IU.
89638411|NCT00182858||1|Participants will be 18 years or older that are Healthy Volunteers or have been identified by the investigator and/or physician to have a condition of interest for exploratory studies related to the participant s illness or other feature that offers the possibility of creating information that leads to scientifically useful and important studies.
89638412|NCT00044174||Depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as exhibiting depressive symptoms
89638413|NCT00044174||Non-depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as not exhibiting depressive symptoms
89042348|NCT05670509|Experimental|Nasal administration of midazolam in ER group|treatment with intranasal midazolam in children presenting to ER with acute seizures with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5mg/spray). If the volume to be administered exceeded 1 mL, then the dose was divided between both nostrils to avoid runoff and swallowing.
89638414|NCT00344175|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
89638415|NCT00344175|Active Comparator|Simvastatin 40mg/80mg|Simvastatin 40 mg or 80 mg once daily
89042349|NCT05670509|Experimental|buccal administration of midazolam in ER group|treatment with buccal midazolam in children presenting to ER with acute seizures with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
89638416|NCT04406766|Experimental|Connected nutrition pump system|
89638417|NCT02376660|Experimental|Oats|70 grams oats
89638418|NCT02376660|Placebo Comparator|usual diet and exercise|usual diet and exercise
89638419|NCT02101515|Placebo Comparator|Usual Labor|Immediate delivery after 3 hours with epidural or 2 hours without epidural
89638420|NCT02101515|Experimental|Extended|"Immediate delivery after 4 hours with an epidural or 3 hours without an epidural~Intervention: one additional hour for the second stage of labor~Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural."
89638421|NCT02376270|Experimental|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
89638422|NCT02376270|Placebo Comparator|Maltodextrin|This group group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
89638423|NCT02376348|No Intervention|Control|Individuals receiving the standard Ministry of Health Package
89638424|NCT02376348|Experimental|Intervention|Individuals receiving the targeted demand creation strategy to increase adult men taking up VMMC
89638425|NCT02376114|Other|Ginkgo-Placebo|Patients receive Ginkgo biloba and then placebo afterwards.
89638426|NCT02376114|Other|Placebo-Ginkgo|Patients receive placebo and then Ginkgo biloba afterwards.
89638427|NCT02377596||Perceived Feeding Difficulties|To complete the study we will recruit at least 40 of the children perceived by their parents or guardian to have feeding difficulties.
89638428|NCT00345033|Experimental|1|Participants will take aripiprazole 15mg/day for 8 weeks.
89638429|NCT00345033|Placebo Comparator|2|Participants will take placebo for 8 weeks.
89638430|NCT02377518|Experimental|oncologic patients|"Prediction of postoperative pulmonary function.~Patients with an operable lung cancer: dual energy computed tomography with Krypton will be tested to estimate the postoperative FEV1"
89042350|NCT05670509|Experimental|Intramuscular administration of midazolam in ER group|treatment with intramuscular midazolam in children presenting to ER with acute seizures with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) administered via using 3 mm syringe in the front aspect of thigh
89212119|NCT00715559|Experimental|cysteamine bitartrate|Participants received cysteamine bitartrate by mouth up to 300 mg three times daily.
89638431|NCT02377518|Experimental|lung transplant recipients|"Detection of BOS~6 months+ lung transplant recipients will be tested using dual energy computed tomography with Krypton, with acquisition in the end-inspiratory and end-expiratory phase, in search of regional air trapping."
89638432|NCT00302055|Active Comparator|one-on-one lifestyle|Clinical referral to diabetes prevention lifestyle intervention at School of Medicine campus
89638433|NCT00302055|Experimental|group-based community lifestyle|Clinical referral to group diabetes prevention lifestyle intervention program in community
89638434|NCT01559311|Active Comparator|CRT-P OFF|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the absence of RVA pacing induced ventricular dyssynchrony were allocated to the DDDR standard therapy with CRT-P remained OFF"
89638435|NCT01559311|Experimental|CRT-P ON|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the presence of RVA pacing induced ventricular dyssynchrony were allocated to the CRT-P standard therapy with CRT-P turned ON"
89638436|NCT01559311|Active Comparator|DDDR|Patients randomized into the Control Group were implanted with a DDDR device (St. Jude Medical) standard therapy.
89638437|NCT00345969|Active Comparator|Transdermal Testosterone gel (1%)|Transdermal testosterone 1% gel (Androgel) provided as 2.5 gm and/or 5 gm gel packets with dose titration and monthly dose adjustments to achieve and maintain serum total testosterone level between 500-900 mg/dL. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
89638438|NCT00345969|Placebo Comparator|Placebo gel|Inactive topical gel identical in appearance to the active medication, provided in packets identical to the packaging for the active medication. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
89638439|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2|Less Intensive, Schedule A1 Dasatinib 100 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
89638440|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2|More Intensive, Schedule A2: Dasatinib 100 mg daily by mouth ; Decitabine ose 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
89638441|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
89638442|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib 140 mg daily by mouth ; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
89638443|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth; Decitabine e 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
89638444|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib140 mg daily by mouth; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
89638445|NCT01558297|Experimental|Motivational Interviewing|
89638446|NCT01558297|Active Comparator|Nutritional Counseling|
89638447|NCT01558297|Active Comparator|Treatment as usual|
89638448|NCT01525849|Active Comparator|Balloon Sinus Dilation|XprESS Multi-Sinus Dilation Balloon, FinESS Sinus Treatment
89638449|NCT01525849|Active Comparator|Functional Endoscopic Sinus Surgery|Traditional endoscopic sinus surgery (maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy) using cutting, grasping, and microdebrider tools.
89638450|NCT00308061|Experimental|FMP1/AS02A Vaccine|500 uL of FMP1/AS02A is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
89638451|NCT00308061|Active Comparator|Imovax Rabies Vaccine|1 mL of Imovax Rabies Vaccine is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
88991227|NCT05498610|Experimental|30 mg NNC0480 0389 plus 0.5 mg semaglutide|Participants will receive a single subcutanous dose of 30 mg of NNC0408-0389 in combination with a fixed dose of 0.5 mg semaglutide administered as separate injections
88991228|NCT05485103|Experimental|Modified bowel preparation method group|One day before the colonoscopy, only asol (or other intestinal nutrient solution) was taken. On the examination day (4 hours before), 1 bag of polyethylene glycol solution + (2 hours before) glycerin enema 110ml was taken
88991229|NCT05485103|Active Comparator|Traditional bowel preparation method group|Low residue diet 2 days before the colonoscopy, take 2 bags of polyethylene glycol solution the night before the examination and 1 bag of which on the examination day (4 hours before)
88991230|NCT05478759|Experimental|MMART and attention training|Training to recognize affect and prosodic expressions of emotions combined with attention training.
88991231|NCT05478759|Placebo Comparator|Brain Health Workshop and National Geographic Movies|an inactive arm that matches sessions of intervention. BHW is education about the brain and cognition. National Geographic movies are viewed with the clinician and the participant answers questions about the movies.
88991232|NCT05463692|Experimental|Single Arm - CAMELLIA Cohort|To better understand contextual factors among people who identify as women in Alabama that predict STI/HIV infection and PrEP use, we will refine an existing evidence-based mobile health app (HealthMpowerment or HMP) to optimally engage and retain a digital cohort of women at-risk for HIV infection (i.e. prior infection in the past 3 months with gonorrhea or syphilis). Using a sampling strategy based on geospatial analysis of HIV-risk, we will enroll and follow our factors associated with incident STI/HIV infection as well as utilization of PrEP through self-collected STI/HIV testing and survey assessments.
88991233|NCT05459233|Other|Doppler-echocardiography|Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements.
89638452|NCT01525615|Experimental|tiotropium+olodaterol low dose|once daily 2 puffs, fixed dose combination (FDC) solution for inhalation Respimat
89638453|NCT01525615|Experimental|tiotropium+olodaterol high dose|once daily 2 puffs, FDC solution for inhalation Respimat
89638454|NCT01525615|Placebo Comparator|placebo|once daily 2 puffs, solution for inhalation Respimat
89638455|NCT00309465|Experimental|1|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
89638456|NCT00309465|Active Comparator|2|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
89638457|NCT00309465|Experimental|3|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
89638458|NCT01791699|Placebo Comparator|Control group|"The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
89638459|NCT01791699|Active Comparator|Moxonidine group|"Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
88991234|NCT05459233|Other|Invasive hemodynamic measurements|Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording).
88991235|NCT05448118|Experimental|Virtual POC Toxicology Testing|Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
88991236|NCT05443568||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
88991237|NCT05443334||Participants with type 2 diabetes|Participants with type 2 diabetes and naive to injectable glucose-lowering treatment.
88991238|NCT05443191||Semaglutide|Participants with type 2 diabetes and naive to injectable glucose-lowering treatment.
88991239|NCT05438485||Methylmalonic Acidemia (MMA)|Approximately 60 subjects with Methylmalonic Acidemia
88991240|NCT05438485||Propionic Acidemia (PA)|Approximately 60 subjects with Propionic Acidemia
89638460|NCT00302133|Experimental|Naltrexone add on to valproate|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks add on to valproate
89638461|NCT00302133|Placebo Comparator|Placebo add on to valproate|Placebo comparator one capsule daily for 12 weeks add on to valproate
89638462|NCT01525225|Experimental|Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC|
89638463|NCT00346905|Experimental|Single Arm|Those receiving Enteryx treatment
89638464|NCT00304161|Active Comparator|Atomoxetine|Participants will receive 40-80mgs of atomoxetine orally once daily.
89638465|NCT00304161|Placebo Comparator|Placebo|Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.
89638466|NCT04398420|Active Comparator|TVERP|
89638467|NCT04398420|Active Comparator|TURis|
89638468|NCT04398420|Active Comparator|HoLEP|
89638469|NCT01524991|Experimental|Treatment|Gemcitabine 1000 mg/m2 Days 1 & 8 Cisplatin 70 mg/m2 Day 1 Ipilimumab 10 mg/kg Day 1 (start cycle 3)
89638470|NCT04039230|Experimental|Sacituzumab Govitecan+Talazoparib|"Sacituzumab Govitecan is administered on days 1 and 8 of a 21 day cycle.~Talazoparib is administered daily"
89638471|NCT01524913|Experimental|Hyaluronic acid|
89638472|NCT01524913|Active Comparator|Corticosteroid|
89638473|NCT01524913|Placebo Comparator|Saline|
89638474|NCT02376192|Experimental|Bolus Phenylephrine/Ephedrine Treatment'|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants who experience hypotension will receive bolus phenylephrine and/or ephedrine treatment as needed.
89638475|NCT02376192|Experimental|Phenylephrine Infusion Group|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
89638476|NCT03028285|Experimental|Unifusol 250 ml IV, 3 ml/mil|Twelve healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at a dose 250 ml and infusion rate 3 ml/min.
89638477|NCT03028285|Experimental|Unifusol 250 ml IV, 4.5 ml/min|Twenty-four healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 250 ml and infusion rate 4.5 ml/min
89638478|NCT03028285|Experimental|Unifusol 500 ml IV, 4.5 ml/min|Twelve healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 500 ml and infusion rate 4.5 ml/min
89638479|NCT03881137|Experimental|Intervention|Geriatric assessment with management
89638480|NCT03881137|No Intervention|Control|Patients receiving supportive care and follow up according to routine practice
89638481|NCT02369640|Experimental|Error-avoidance training|Study group 1: Error-avoidance training (Focusing on achieving the highest possible metrics score by avoiding errors).
89638482|NCT02369640|Experimental|Error-management training|Study group 2: Error-management training (Focusing on making errors and thinking of them in a positive way).
89638483|NCT02369718|Experimental|Implanted subjects|Listening to 12 Fournier's lists of words
89638484|NCT02369718|Active Comparator|Normal hearing subjects|Listening to 48 Fournier's lists of words
89638485|NCT02375958|Experimental|Triple Negative Breast Cancer|
89638486|NCT02375958|Experimental|Head and Neck Cancer|
89638487|NCT02375958|Experimental|Esophageal Cancer|
89638488|NCT02376036|Experimental|MGD010|Subjects will receive MGD010 through IV infusion.
89638489|NCT02376036|Placebo Comparator|Placebo|Subjects will receive placebo through IV infusion.
89638490|NCT02376036|Experimental|MGD010 and HepA vaccine|Subjects will receive MGD010 through IV infusion and HepA vaccine through an IM injection.
89638491|NCT02376036|Placebo Comparator|Placebo and HepA vaccine|Subjects will receive placebo through IV infusion and HepA vaccine through an IM injection.
89638492|NCT02375880|Experimental|150 mg DKN-01 Part A|Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
89638493|NCT02375880|Experimental|300 mg DKN-01 Part A|Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
89638494|NCT02375880|Experimental|MTD mg DKN-01 Part B|Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
89638495|NCT01524679|Experimental|Treatment group|pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
89638496|NCT01524679|No Intervention|Control group|ongoing nucleos(t)ide based treatment alone
89638497|NCT02365194|Other|Prehabilitation|physical conditioning and weight loss intervention done pre-operatively
89638498|NCT02365194|Other|Standard Counseling|initial clinic counseling
89638499|NCT02365272|Active Comparator|amikacin standard dose|amikacin in a single standard dose
89638500|NCT02365272|Active Comparator|amikacin dose for critical care patients|amikacin in a single dose for critical care patients
89638501|NCT02369328|Experimental|multimodal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for patients whom suffering stroke
89638502|NCT02369328|Active Comparator|multimocal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for healthy subjects
89638503|NCT02369250|Placebo Comparator|OFD+ PLACEBO GEL|furcation defect site is surgically debrid and placed a placebo gel
88991241|NCT05422209|Active Comparator|Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.|
88991242|NCT05422209|Active Comparator|Mesh-augmented sacrospinal fixation with posterior colporrhaphy.|
88991243|NCT05420831|Active Comparator|Sacrospinous fixation of the vaginal apex with the synthetic mesh|
88991244|NCT05420831|Active Comparator|Laparoscopic sacrocolpopexy|
88991245|NCT05416411|No Intervention|Usual Care|Patients who are candidates for thoracic resection surgeries will be advised to stay active and quit smoking.
88991246|NCT05416411|Active Comparator|Intervention group|Patients who are candidates for thoracic resection surgeries will be handed a flow resistive device that helps inspiratory muscle training (2*30 repetitions a day for 7 days) and will be advised to walk 5000 steps a day.
88991247|NCT05410392|Experimental|Combined physical and cognitive exercise intervention|Participants will receive both the physical exercise intervention and the cognitive exercise intervention for 3 months.
88991248|NCT05410392|Experimental|Physical exercise intervention|Participants will receive the physical exercise intervention for 3 months.
88991249|NCT05410392|Experimental|Cognitive exercise intervention|Participants will receive the cognitive exercise intervention for 3 months.
88991250|NCT05410392|Active Comparator|Control group|Participants will receive health education for 3 months.
88991251|NCT05398029|Experimental|Part A: Single Ascending Dose Escalation/Adaptive Design|Participants will receive a single dose of VERVE-101 in multiple dose-escalation cohorts.
89638504|NCT02369250|Active Comparator|OFD+ PRF + BONE GRAFT|Following surgical debridment of furcation site autologous PRF and bone graft is placed in defect as a competator drug used is platelet rich fibrin and porus hydroxyapatite bone graft
88991252|NCT05398029|Experimental|Part B: Single Dose Expansion|Participants will receive a single dose of VERVE-101 selected based on the doses studied in Part A.
88991253|NCT05394558|Experimental|Radiotherapy + AsiDNA|"Patients will receive the IMP which is the AsiDNA (etidaligide). AsiDNA will be administered intravenously as a 1-hour infusion. All patients will receive a loading dose for three consecutive days, with Day 1 being the start day of radiotherapy, followed by once weekly administrations during 11 weeks.~The infusion of AsiDNA should be administered between 4 and 6 hours before the planned start of radiotherapy.~After the administration of AsiDNA, Patients with DIBG will receive a total dose of 18 Gy, delivered in 10 fractions of 1.8 Gy, i.e. 5 fractions per week for 2 weeks, starting on Day 1. Patients with supratentorial non-DMG or DMG will receive a total dose of 36 Gy, delivered in 20 fractions of 1.8 Gy, i.e. 5 fractions per week for 4 weeks, starting on Day 1."
88991254|NCT05394558|Active Comparator|Radiotherapy|Patients with DIBG will receive a total dose of 18 Gy, delivered in 10 fractions of 1.8 Gy, i.e. 5 fractions per week for 2 weeks, starting on Day 1. Patients with supratentorial non-DMG or DMG will receive a total dose of 36 Gy, delivered in 20 fractions of 1.8 Gy, i.e. 5 fractions per week for 4 weeks, starting on Day 1.
89212120|NCT00620282|Experimental|Lira 1.8|Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
89638505|NCT02369250|Experimental|RSV1.2% gel + PRF+ BG|Following surgical debridment of furcation site Rosuvastatin 1.2% in situ gel combined with autologous PRF and bone graft is placed
89638506|NCT02369094|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
89638507|NCT02369094|Other|Waiting Control Group|"No acupressure therapy will be provided during the 1st 12 weeks' of study.The enrolled elderly will join a group activity, resembling the other group activities that held in that particular center, their caregivers will be requested to spend two 20 minutes sessions per week with the elderly doing homework assigned by the activity group and log down the timing in the log book.This arrangement is to account for the placebo effect of additional social interaction time and attention that the treatment group will receive during this period.~After completing the 1st 12 weeks' participation in the Waiting Control Group, the subject dyads in the waiting control group will receive the same training and treatment as the treatment group."
89638508|NCT01880541|Experimental|hypnosedation|hypnosedation
89638509|NCT01880541|Other|general anesthesia|general anesthesia
89638510|NCT02365428|Experimental|Control: Group 1|The control group will receive three standard Text4Baby messages per week at noon on Mondays, Wednesdays, and Fridays.
89638511|NCT02365428|Experimental|Group 2|Intervention group 1 will receive two physical activity messages and one standard Text4Baby message each week at noon on Mondays, Wednesdays, and Fridays.
89638512|NCT02365428|Experimental|Group 3|Intervention group 2 will receive six physical activity messages and one standard Text4Baby message per week at a random time per day.
89638513|NCT02365428|Experimental|Group 4|Intervention group 3 will receive six physical activity messages and one standard Text4Baby message per week at a time of the participant's choice per day.
89638514|NCT02365116|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will include components such as hope and belongingness.
89638515|NCT02365116|Active Comparator|Enhanced Usual Care|Patients will continue to receive usual care which typically consists of referral to an outpatient psychiatrist. Participants will also receive a phone call within 24-72 hours from a member of the inpatient unit clinical staff to assess barriers to follow-up care and safety. The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
89638516|NCT02368860|Experimental|OXIRI|OXIRI regimen: oxaliplatin, irinotecan, capecitabine
88991255|NCT05393869|Experimental|AR-Quit|Participants view messages with absolute risk and quit statements
88991256|NCT05393869|Experimental|AR-Switch|Participants view messages with absolute risk and switch statements
88991257|NCT05393869|Experimental|AR-Combination|Participants view messages with absolute risk and combination quit+switch statements
89638517|NCT02375646|Experimental|Continued Warfarin|continuous Warfarin therapy (aiming for therapeutic INR: 2-3) will be given throughout the study
89638518|NCT02375646|Active Comparator|LMW Heparin|Enoxaparin 1mg/kg SC bid (adjusted to renal function) will be given 5 days before the colonoscopy while withholding therapy with Warfarin. The day after procedure Warfarin therapy will be added, and Enoxaparin stopped when therapeutic INR will be reached
89638519|NCT02368782||ketamine group|ketamine 2mg/kg bolus IV once
89638520|NCT02368782||propofol group|propofol 2mg/kg ıv bolus once
89638521|NCT02368938||Several communities in the north of Shanghai|
89638522|NCT02368704||control|"control subjects with :~Nondiabetic subjects (blood glucose <7.0 mmol/l without hypoglycemic treatment).~The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2)."
89638523|NCT02368704||case|"Diabetic patients with :~Having type 2 diabetes for at least 6 months~HbA1c ≤ 8%~Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin~No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months"
89638524|NCT01524289|Experimental|Anacetrapib|Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment period.
89638525|NCT01524289|Placebo Comparator|Placebo|Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment period.
89638526|NCT02375490|Experimental|Intervention arm|The intervention arm will participate in Healthy Start.
89638527|NCT02375490|No Intervention|Control arm|Control arm will pursue daily activities at early childcare center as usual.
89638528|NCT01498289|Experimental|Arm I|FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89638529|NCT01498289|Experimental|Arm II|Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89638530|NCT02364882|Placebo Comparator|1|1 g (placebo) 0 mg sildenafil 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
89638531|NCT02364882|Active Comparator|2|1 g 50 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
89638532|NCT02364882|Active Comparator|3|2 g 100 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
88991258|NCT05393869|Experimental|RR-Quit|Participants view messages with comparative risk and quit statements
88991259|NCT05393869|Experimental|RR-Switch|Participants view messages with comparative risk and switch statements
88991260|NCT05393869|Experimental|RR-Combination|Participants view messages with comparative risk and combination quit+switch statements
88991261|NCT05393869|Other|Control|Participants view FDA regulatory messages
88991262|NCT05391581|Placebo Comparator|SAL-WAT|Saline infusion, saline injection, water ingestion
88991263|NCT05391581|Active Comparator|SAL-GLU|Saline infusion, saline injection, glucose ingestion
89638533|NCT02364882|Active Comparator|4|4 g 200 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
89638534|NCT05653830||Patients with chronic hepatitis B|Patients who meet the diagnostic criteria for chronic hepatitis B for long-term follow-up
89638535|NCT05653830||Patients with chronic hepatitis C|Patients who meet the diagnostic criteria for chronic hepatitis C for long-term follow-up
89638536|NCT05653830||Patients with chronic hepatitis D|Patients who meet the diagnostic criteria for chronic hepatitis D for long-term follow-up
89638537|NCT05653830||Patients with autoimmune liver disease（PBC\AIH\PSC）|Patients who meet the diagnostic criteria for autoimmune liver disease（PBC\AIH\PSC） for long-term follow-up
89638538|NCT05653830||Patients with NAFLD|Patients who meet the diagnostic criteria for NAFLD for long-term follow-up
89638539|NCT05653830||Patients with ALD|Patients who meet the diagnostic criteria for ALD for long-term follow-up
89638540|NCT02365038|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation
89638541|NCT02365038|Active Comparator|Conventional ventilation|Mechanical ventilation as proposed in the ARDSNet protocol.
89638542|NCT01524133|Active Comparator|Sertraline + enhanced medication management (SERT/EMM)|24 weeks of sertraline + enhanced medication management
89638543|NCT01524133|Active Comparator|Prolonged Exposure + sertraline (PE/SERT)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
89638544|NCT01524133|Active Comparator|Prolonged Exposure + placebo (PE/PLB)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
88991264|NCT05391581|Active Comparator|SAL-GIP|Saline infusion, GIP injection, water ingestion
89638545|NCT02368548|Experimental|Pharmaceutical care program|"Initiated in the Emergency Department (ED):~Review of home medication and medication reconciliation based on Primary Care data~Patient interview. Assessment of the patient's knowledge on the pharmacological treatment~Development of the pharmacological history and registration in the medical record~Adequacy of drug therapy. Identification of Drug Related Problems including reconciliation errors (DRP) and communication to medical team~Pharmacotherapy monitoring~Treatment validation and medication reconciliation at discharge~During the hospitalization (if admission from the ED):~Treatment review and medication reconciliation~Pharmacokinetics monitoring~Retrospective validation of prescriptions and assessment of drugs appropriateness. DRP identification and communication to medical team~Pharmacotherapy monitoring~Validation and medication reconciliation at discharge~Patient education at discharge"
88991265|NCT05391581|Active Comparator|SAL-GLP-2|Saline infusion, GLP-2 injection, water ingestion
88991266|NCT05391581|Experimental|GIA-WAT|GIPR antagonist infusion, saline injection, water ingestion
88991267|NCT05391581|Experimental|GIA-GLU|GIPR antagonist infusion, saline injection, glucose ingestion
88991268|NCT05391581|Experimental|GLA-WAT|GLP-2R antagonist infusion, saline injection, water ingestion
88991269|NCT05391581|Experimental|GLA-GLU|GLP-2R antagonist infusion, saline injection, glucose ingestion
89638546|NCT02368548|Other|Standard Care|"Stages:~Pharmaceutical care program in the episode at the Emergency Department:~a. There was no monitoring of the patient by the pharmacist. Retrospective validation of the prescriptions was not performed.~During the hospitalization (if admission from the ED):~Pharmacokinetics monitoring~Retrospective validation of prescriptions and assessment of drugs appropriateness."
89638547|NCT02368470|Active Comparator|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
89638548|NCT02368470|Experimental|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
89638549|NCT05800652|Experimental|Experimental|Experimental: First-year nursing students (mentees) undergoing a mentoring program 20 mentees were included in the experimental group.The mentoring program focuses on developing students' life skills. The mentoring program continued for 12 weeks. In the mentoring program, it was expected that the mentors would make individual meeting(s) with the mentee they were matched with, face to face, online or over the phone, and share information and support every week. The frequency and duration of individual interviews were determined by the needs of the mentee.
89638550|NCT05800652|No Intervention|Control|No Intervention: Control group 20 mentees were included in the control group. After the follow-up test was applied to the students in the experimental group, a three-week mentoring program was applied to the control group.
89638551|NCT05800548||postpartum women|The sample of the research is; puerperant women who applied to the hospital for delivery within the research dates and gave birth in a healthy way, did not have any risk for the mother and the baby, had no communication barriers and met the research criteria.
89638552|NCT05800535||JUMP Cohort|This study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day.
89638553|NCT05800522|Active Comparator|Control group|Various active treatments implemented in Norwegian frontline services. Treatments will include different measures varying in scope and intensity including eclectic counselling and other systematic and evidence-based interventions.
89638554|NCT05800522|Experimental|Intervention group|Transdiagnostic and preventive parent training intervention, Supportive parents - coping kids (SPARCK)
89638555|NCT05800509|Experimental|Experimental Group|"The participants and their partners will receive structured questionnaires respectively at 22nd and 35th week of pregnancy, and 3rd month and 6th month after delivery. The context of questionnaire includes basic information (age, level of education and occupation of the participant and her partner, household income, and status of marriage), marriage satisfaction, obstetrics and gynecological history (history of abortion, intended pregnancy , and artificial insemination), psychiatric history, family history of diabetes mellitus, height, pre-pregnancy weight, sleeping status, and basic knowledge of gestational diabetes mellitus.~A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners."
89638556|NCT05800509|Sham Comparator|Controlled group|"The participants and their partners will receive structured questionnaires respectively at 22nd and 35th week of pregnancy, and 3rd month and 6th month after delivery. The context of questionnaire includes basic information (age, level of education and occupation of the participant and her partner, household income, and status of marriage), marriage satisfaction, obstetrics and gynecological history (history of abortion, intended pregnancy , and artificial insemination), psychiatric history, family history of diabetes mellitus, height, pre-pregnancy weight, sleeping status, and basic knowledge of gestational diabetes mellitus.~A website of health education about gestational diabetes mellitus for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners."
89638557|NCT05800496|Experimental|SesZen-Bio™|SesZen-Bio™ is specially formulated for healthy hairs and healthy skin. Fortified with Sesbania Agati for 2X Hair Follicle Stimulation & Hair Fall Control, to Promote Shiny Hair, biotin that Supports Hair Growth.
89638558|NCT05800496|Placebo Comparator|Placebo (Tapioca based starch Capsules)|tapioca starch, is a starchy white flour that has a slight sweet flavor to it and is prepared by extrusion and coating process.
89638559|NCT05800483|Experimental|Healium|Healium is a web-based platform that employs a user-centric design and aims to appeal to a low health literate population. It features a simple language and layout, a large font size, contrasting text and background colors, bright color palette, and use of short labels and headings to describe content.
89638560|NCT05800483|No Intervention|Comparison (Healing Choices)|The Healing Choices program represents a virtual health center that patients visit to obtain disease and treatment-related information. The software was designed to be open to exploration with an intuitive layout, without restrictions in terms of order of access. Information is stored in virtual rooms, such as a library, a conference room showing videos by survivors who discuss their approach to treatment, and physician offices containing videos of physicians representing different treatment specialties. All information was extensively vetted by health education experts of the National Cancer Institute's Cancer Information Services (CIS).
89638561|NCT05800470|Experimental|Neurofeedback combined with MI (NFB-MI)|"Participants in both NFB-MI and MI groups will receive a total of 12 sessions of training in 3 weeks. At the first, 4th and 8th session, NFB-MI group will receive fNIRS-based neurofeedback during MI training in lab setting. Prior to each NFB-MI session during lab visit, participants will watch a video of a person executing balance tasks and walking in different environments. The explicit instruction will be given by the researcher. One trial of MI training consists of 30 seconds of imagery tasks and 20 seconds of rest, and the trial will be repeated 12 times. The training will take approximately 10 minutes. Visual feedback with a thermometer based on the changes of HbO concentration will be displayed on the screen during NFB-MI training.~In each training session, actual balance and gait tasks will be practiced for 20 min. The difficulty of the tasks will be modified individually for each participant."
89638562|NCT05800470|Active Comparator|Motor imagery|"Participants in both NFB-MI and MI groups will receive a total of 12 sessions of training in 3 weeks. At the first, 4th and 8th session, MI group will practice kinesthetic MI under supervision in lab setting. Prior to each NFB-MI session during lab visit, participants will watch a video of a person executing balance tasks and walking in different environments. The explicit instruction will be given by the researcher. One trial of MI training consists of 30 seconds of imagery tasks and 20 seconds of rest, and the trial will be repeated 12 times. The training will take approximately 10 minutes.~In each training session, actual balance and gait tasks will be practiced for 20 min. The difficulty of the tasks will be modified individually for each participant. The researcher will ensure the safety of executing each task during lab visit. Participants will be asked to practice at home and be checked by the daily phone call."
89638563|NCT05800457|Experimental|Total knee replacement with synovectomy|Patients in this arm will undergo synovectomy during total knee replacement surgery.
88991270|NCT05391438|Other|Meal-timing|All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period.
88991271|NCT05389709||Pharmacy based survey|Patients receive a questionnaire to fill out and return it the Contract Research Organization (CRO) or, alternatively to the pharmacy.
89638564|NCT05800457|No Intervention|Total knee replacement without synovectomy|Patients in this arm will not undergo synovectomy during total knee replacement surgery.
89638565|NCT05800418|Experimental|Ramucirumab injection|8mg/kg, Single intravenous infusion
89638566|NCT05800418|Active Comparator|Cyramza|8mg/kg, Single intravenous infusion
89638567|NCT05800340|Experimental|Toripalimab plus chemotherapy|3 cycles of neoadjuvant Toripalimab (240mg every 3 weeks) with nab-paclitaxel + carboplatin, or pemetrexed + carboplatin (decided by investigators; nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every 3 weeks; pemetrexed, 500mg/m2 d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including chemotherapy for 3-4 cycles or rare mutations-TKIs for up to 2 years or till disease progression or unacceptable toxicity.
89638568|NCT05800327|Experimental|LVL162 group|Levilimab 162 mg SC QW plus placebo starting from Week 0.
89638569|NCT05800327|Experimental|LVL324 group|Levilimab 324 mg SC Q2W plus placebo starting from Week 0.
89638570|NCT05800327|Experimental|LVL648 group|levilimab 648 mg IV Q4W plus placebo starting from Week 0.
89638571|NCT05800301|Active Comparator|Only WJ-MSCs|Consisted of 34 eyes of 32 RP patients treated with only WJ-MSCs, and it was applied only once following necessary preparations. After the inoculation of stem cells, the patients were followed up regularly on the 10th day, 3rd month, and every 6 months after that until 36 th months. For ethical reasons, the worse eye was selected to inject the stem cells instead of both eyes.
89638572|NCT05800301|Active Comparator|Only rEMS|Consisted of 32 eyes of 16 RP patients treated with only rEMS. rEMS was applied with a custom-designed helmet once a week for 30 min for 36 months. Both eyes are stimulated at the same time with the specially designed system for ophthalmologic use (MagnoVisionTM).
89638573|NCT05800301|Active Comparator|WJ-MSCs and rEMS combination|Consisted of 32 eyes of 16 RP patients treated with the WJ-MSCs and rEMS combination. WJ-MSCs were applied first into the deep subtenon space of both eyes after necessary preparations. rEMS application was started 10 days after the WJ-MSC application with a custom-designed helmet for 30 min. WJ-MSCs were inoculated only once, and rEMS was applied regularly once a week for 30 min for 36 months. Both eyes are stimulated at the same time with the specially designed system for ophthalmologic use (MagnoVisionTM).
88991272|NCT05386745|Experimental|Intervention|An online, asynchronous, self-paced, 10-week long, physical activity intervention.
88991273|NCT05386745|No Intervention|Control|A waitlist control; continue with life/activity as usual. Control participants will receive access to the intervention at 10 weeks following all measurements.
88991274|NCT05384535|Experimental|Bi-parametric Screening MRI|Bi-parametric MRI to be administered to High Risk males
88991275|NCT05384158|Active Comparator|Cognitive behavioral therapy|cognitive behavioral therapy for depression, anxiety, and/or anhedonia
88991276|NCT05384158|Active Comparator|Valuation with instruction|repeat laboratory sessions of a reward/loss learning computer game with specific instructions
88991277|NCT05384158|Active Comparator|Valuation without instruction|repeat laboratory sessions of a reward/loss learning computer game without specific instructions
88991278|NCT05379842|No Intervention|1- Non-intervention|Non-posterior intervention after randomization
88991279|NCT05379842|Active Comparator|2- Traditional advanced intervention model|Motivational workshops, every 3 months and with limited cost
88991280|NCT05379842|Active Comparator|3- E-learning advanced intervention model|Educational workshops, every 15 days, with videos -YouTube channel or WhatsApp/text message
88991281|NCT05375305|Experimental|Treatment group A：SHR8554 Injection|
88991282|NCT05375305|Experimental|Treatment group B：SHR8554 Injection|
88991283|NCT05375305|Placebo Comparator|Treatment group C：Saline Solution|
88991284|NCT05375305|Active Comparator|Treatment group D：Morphine|
88991285|NCT05374525|Experimental|Routine Implementation (RI)|PSPs will receive APRETUDE injection and optional Cabotegravir tablets as oral lead in (OLI) . PSPs and SSPs will have access to standard toolkits for APRETUDE to use as needed.
89212121|NCT00620282|Placebo Comparator|Placebo|Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
89212122|NCT00620282|Active Comparator|Glimepiride|Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12
88991286|NCT05374525|Experimental|Dynamic Implementation (DI)|PSPs will receive APRETUDE injection and optional Cabotegravir tablets as oral lead in (OLI). PSPs and SSPs will have access to enhanced toolkits, a digital health implementation strategy and implementation facilitation for APRETUDE to use.
89042351|NCT05658432|Experimental|Intervention|The experimental group will perform an exercise program including aerobic, range of motion, stretching exercises on zoom sessions of 45 minutes each, under the supervision of the investigator, following a prerecorded exercise video. They will exercise thrice a week for 8 weeks, in groups of five.
89638574|NCT05800301|No Intervention|The natural course|The natural course (control) group consisted of 32 eyes of 16 RP patients who received no treatment and were regularly followed until the 36th month. This group comprised patients who did not accept any treatment and/or were in good condition at baseline.
89638575|NCT05800262|Experimental|Dynamic stability exercise|A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
89638576|NCT05800236|Other|Gastric adenocarcinoma|patients who undergo gastrectomy
89638577|NCT05800223|Experimental|GroupA|Intracranial stereotactic radiotherapy (27-40 Gy/3-5f) was administered to all intracranial lesions on the first day of oral administration of Almonertinib
89638578|NCT05800223|Experimental|GroupB|Two successive MR enhancements after oral administration of Almonertinib suggest that intracranial lesions are maximally remission, and stereotactic body radiotherapy is given to all lesions (27-40Gy/3-5f)
89638579|NCT05800223|Experimental|GroupC|oral administration of Almonertinib
89638580|NCT05800132|No Intervention|L2 - Standard second read|Interpretation of mammograms done by a radiologist accredited to do second reading in France.
89638581|NCT05800132|Experimental|L2-AI - AI-assisted second read|Interpretation of mammograms done by the AI-based device. Mammograms deemed suspicious by the AI (i.e., receiving an AI global score higher than a defined threshold) will be interpreted by a radiologist accredited to do second reading in France. Mammograms assessed as negative or low suspicious by the AI won't be further interpreted by a radiologist.
89042352|NCT05658432|Active Comparator|Active control|Control group will have access to the same exercise video and guided for the first session. They will be asked to do the exercises at home, exact the same duration and frequency of the experimental group but without supervision, for 8 weeks.
89042353|NCT05651555|Experimental|N arm|
89042354|NCT05651555|Active Comparator|Control group|
89042355|NCT05649670|Experimental|Intervention (MSU)|Deployment of MSU + conventional ambulance
89042356|NCT05649670|No Intervention|Control (usual care)|Deployment of conventional ambulance
89638582|NCT05800106|Experimental|Sunitinib malate capsules generic product|Single dose of Sunitinib malate capsule under fed condition on Day 1 and Day 29, respectively.
89638583|NCT05800106|Active Comparator|Sunitinib malate capsules reference product|Single dose of Sunitinib malate capsule under fed condition on Day 1 and Day 29, respectively.
89042357|NCT05645003|Experimental|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily at a frequency of 10 HZ at 110% intensity of the motor threshold for 15 sessions.
89042358|NCT05645003|Sham Comparator|Sham rTMS Protocol|It was planned to apply daily sham rTMS to the dorsolateral prefrontal cortex for 15 sessions.
89042359|NCT05634278|Placebo Comparator|Mind wandering|
89042360|NCT05634278|Active Comparator|Preoperative Mindfulness|Participants will only listen to the guided meditation practice before surgery.
89042361|NCT05634278|Active Comparator|Preoperative and Postoperative Mindfulness|Participant will listen to the guided meditation practice before surgery and during their hospital stay after surgery.
89042362|NCT05631236|Placebo Comparator|BLT control|Bright light glasses that emit a non-therapeutic blue light.
89042363|NCT05631236|Active Comparator|BLT intervention|Bright light glasses that emit a more intense therapeutic blue light.
89042364|NCT05625204|Experimental|Center based attention control|Center based attention control
89042365|NCT05625204|Experimental|Center based HIIT|Center based HIIT
89042366|NCT05625204|Experimental|Home based HIIT|Home based HIIT
89042367|NCT05624918|Experimental|Investigational Group|"Nab-paclitaxel + gemcitabine + NovoTTF-200T(P) for 3 cycles (28 day cycles)~Participants who have stable disease or better after the first 3 cycles of treatment will undergo pancreatectomy within 8 weeks of receiving treatment. If the surgery yields R0 or R1 then patient will receive another 3 cycles of treatment regimen (within 8 weeks of surgery).~Those who do not undergo surgery will still be included in the evaluable patients for the objectives"
89042368|NCT05623306|Experimental|SEEG Guided DBS ON-OFF (Stimulation-Sham)|Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period.
89042369|NCT05623306|Sham Comparator|SEEG Guided DBS OFF-ON (Sham-Stimulation)|Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.
89638584|NCT05800080|Experimental|Single immunotherapy group；|one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy；
89638585|NCT05800080|Experimental|Double immune treatment group|one group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
89042370|NCT05622721||Pet owner|Pet owners
89042371|NCT05622721||Non pet owner|Non pet owners
89042372|NCT05617066|Active Comparator|therapy vs psychological support and usual care|Comparison between therapy groups vs psychological support and usual care. Only one group receive therapy.
89042373|NCT05617066|No Intervention|therapy and psychological support versus control group|Comparison between therapy groups vs psychological support and usual care. Only one group receive therapy.
89212123|NCT05684861|Active Comparator|Group I patients|90 patients with acne vulgaris Patients classified according to the global acne grading system(GAGS) into moderate, severe, and very severe cases
89638586|NCT05800067|Experimental|Axi-cel|Patients will receive a target dose of 2×10⁶ Axi-cel per kilogram of body weight after receiving a conditioning regimen. The conditioning regimen and dosage will be at investigator's discretion based on patient's status.
89638587|NCT05800054|Experimental|NST intervenes throughout the process|"Nutritionists formulate nutritional programs and manage them in a refined manner.~The nutritionist urges the patient to report daily to ensure that the patient's energy and protein are in place~Radiotherapy~chemotherapy"
89638588|NCT05800054|Experimental|Routine nutrition guidance group for esophageal cancer|"Patients perform their own nutrition regimen, and the nutritionist is not involved in management~Radiotherapy~chemotherapy"
89638589|NCT05800041|Experimental|Treatment group A|WTX221 low dose
89638590|NCT05800041|Experimental|Treatment group B|WTX221middle dose
89638591|NCT05800041|Experimental|Treatment group C|WTX221 high dose
89638592|NCT05799937||Group-A Smokers|smoker patients will be recruited in this group
89042374|NCT05616013|Placebo Comparator|Placebo to bimagrumab 30 mg/kg + no semaglutide|Participants will receive i.v. placebo at baseline and at Weeks 4, 16, 28 and 40 during the core treatment period and will switch during the extension period to receive bimagrumab 30 mg/kg at Weeks 52 and 64.
89042375|NCT05616013|Other|Placebo + semaglutide 1.0 mg|Participants will receive i.v. placebo at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.
89042376|NCT05616013|Other|Placebo + semaglutide 2.4 mg|Participants will receive i.v. placebo at baseline and at Weeks 4, 16, 28 and 40, 52 and 64, and s.c. semaglutide 2.4 mg weekly per the dose escalation schedule.
89042377|NCT05616013|Experimental|Bimagrumab 10 mg/kg to bimagrumab 30 mg/kg + no semaglutide|Participants will receive i.v. bimagrumab 10 mg/kg at baseline and at Weeks 4, 16, 28 and 40 during the core treatment period and will switch during the extension period to receive bimagrumab 30 mg/kg at Weeks 52 and 64.
89638593|NCT05799937||Group-B Non-Smokers|non smokers or patients who had quit smoking will be recruited in this group
89638594|NCT05799924|Experimental|Women with dysmenorrhea treated with TEAS|The transcutaneous electrical acupoint stimulator applied alternating current (including sine wave, pulse wave and modulation wave) with frequency of 2 ~ 100Hz and intensity of 10-20mA to stimulate corresponding acupoints through skin electrodes. The stimulated acupoints include Hegu acupoints, Luogong acupoints, Neiguan acupoints and Waiguan acupoints.
89638595|NCT05799924|Active Comparator|Women with dysmenorrhea receiving medication|Take NSAIDs or birth control pills every six hours during your period when you feel unbearable pain.
89638596|NCT05799885|Experimental|31 players with ankle instability|2 sessions per week for 8 weeks, total training time 30 min
89638597|NCT05799885|Experimental|30 players with ankle instability|2 sessions per week for 8 weeks, total training time 30-40 min
89638598|NCT05799859|Active Comparator|CAF + CM|Coronally advanced flap (CAF) and collagen matrix (CM)
89638599|NCT05799859|Experimental|CAF + CM +EMD|Coronally advanced flap (CAF), collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).
89638600|NCT05799846|Active Comparator|STANDARD Behavioral|This is a 12-month Internet-delivered behavioral weight loss (iBWL) program that has been used in numerous studies and is currently considered our 'standard' treatment. Participants are asked to adhere to calorie and physical activity (PA) goals and are required to self-monitor weight, intake, and PA daily via a study website. Participants will have a training session prior to beginning iBWL to learn about the website and their specific weight-related goals. The iBWL includes 3 months of weekly video lessons teaching skills to modify eating and PA behaviors. These lessons and individualized feedback to participants incorporate key BWL strategies. Participants will then have a 'refresher' training session at 3 months to discuss standard behavioral weight loss strategies and help control for contact across arms. For the remainder of the program (months 4-12) participants will have monthly lessons, self-monitoring (tracking calories and PA 1 wk/month) and feedback.
89638601|NCT05799846|Experimental|PREVENT|This is a 12-month Internet-delivered behavioral weight loss (iBWL) program in which participants are asked to adhere to calorie and physical activity (PA) goals and are required to self-monitor weight, intake, and PA daily via a study website. Additionally, PREVENT uses a future-oriented cognitive strategy featuring Episodic Future Thinking (EFT) to focus on long-term negative consequences of unhealthy choices. Participants will receive training in PREVENT strategies prior to beginning iBWL. The iBWL includes 3 months of weekly video lessons teaching skills to modify eating and PA behaviors. These lessons and individualized feedback to participants are framed according to PREVENT (i.e., focusing on avoiding long-term consequences of unhealthy choices) and include specific exercises and reminders to use the strategy. Participants will then have a 'refresher' training session at 3 months, followed by monthly lessons, self-monitoring (tracking calories and PA 1 wk/month) and feedback.
89638602|NCT05799846|Experimental|PROMOTE|This is a 12-month Internet-delivered behavioral weight loss (iBWL) program in which participants are asked to adhere to calorie and physical activity (PA) goals and are required to self-monitor weight, intake, and activity daily via a study website. Additionally, PROMOTE uses a future-oriented cognitive strategy featuring Episodic Future Thinking (EFT) to focus on long-term benefits of healthy choices. Participants will receive cognitive training in PROMOTE prior to beginning iBWL. The iBWL includes 3 months of weekly video lessons teaching skills to modify eating and activity behaviors. These lessons and individualized feedback to participants are framed according to PROMOTE (i.e., focusing on achieving long-term benefits of healthy choices) and include specific exercises and reminders to use the strategy. Participants will then have a 'refresher' training at 3 months, followed by monthly lessons, self-monitoring (tracking calories and PA 1 wk/month), and feedback.
89638603|NCT05799794|Active Comparator|Standard/As Usual CBT+/EBP Initiative Implementation|All CMHCs involved in the CBT+/EBP Initiative receive virtual clinician training, CBT-phone consultation options over 6-months, access to a supervisor monthly call, listservs (one supervisor-focused), and a yearly advanced clinical training and supervisor training. The Initiative is a program that has been ongoing since 2009.
89638604|NCT05799794|Experimental|Supervisor-led Implementation Coaching|The structure of this arm will depend on Aim 1. However, we imagine that peer supervisors leading implementation coaching, trained in Aim 1, will have 3-5 virtual meetings with supervisors and email communication. Meetings focus on orientation to the theory and rationale for Coaching and supervisors' role as frontline leaders to support EBP implementation. Meetings are likely over 6 months and focus on different implementation phases. Coaches will support supervisors in developing tailored workplans for implementation in their CMHCs. In each meeting, the coach will review the strategies in the workplan, provide examples of how the strategy could be specified, and then facilitate discussion among supervisors. The coach will support supervisors in building a tailored workplan for their CMHC. Supervisors in the Coaching condition receive Coaching plus standard Initiative Implementation support.
89042378|NCT05616013|Other|Bimagrumab 10 mg/kg + semaglutide 1.0 mg|Participants will receive i.v. bimagrumab 10 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.
89042379|NCT05616013|Other|Bimagrumab 10 mg/kg + semaglutide 2.4 mg|Participants will receive i.v. bimagrumab 10 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 2.4 mg weekly per the dose escalation schedule.
89042380|NCT05616013|Experimental|Bimagrumab 30 mg/kg + no semaglutide|Participants will receive i.v. bimagrumab 30 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64.
89212124|NCT05684861|Active Comparator|Control group|60 age-sex-matched healthy subjects as a control group
89212125|NCT02591069|Experimental|All patients will undergo the same procedure|
89212126|NCT03950375||cochlear implantation|"cochlear implantation group : patients undergoing cochlear implantation between December 2018 and June 2019 in the ENT service of Reims universitary hospital."
89212127|NCT04042688|Experimental|Treatment group|Patients were randomly allocated to one of two groups during preoperative preparation by computer-generated randomization. Treatment group; IA administration of TXA, control group; no TXA administration
89212128|NCT04042688|No Intervention|Control gorup|
89212129|NCT02590133|Experimental|Nedaplatin+5-Fu+Endostar|Drug: Recombinant Human Endostatin Injection (Endostar) Endostar, 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
89212130|NCT02590133|Active Comparator|Nedaplatin+5-Fu|Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
89638605|NCT05799781|Experimental|MPC Arm|Participants will use the MPC closed-loop system for 7 days using Fiasp insulin. The first 6 hours will be spent in clinic being trained on the system, then eating a meal. Then the participant will take the system home to continue using for 7 days.
89638606|NCT05799781|Active Comparator|Control IQ arm|Participants will continue their normal diabetes regimen which includes the t:slim X2 pump with Dexcom G6 CGM and Control IQ for 7 days. Participants will share their pump download and Dexcom Clarity data with study staff after the 7 days is complete.
89638607|NCT05799742|Active Comparator|Lichtenstein|Conventional approach
89638608|NCT05799742|Experimental|Laparoscopy|Experimental approach
89638609|NCT05799716|Experimental|IVIG|
89638610|NCT05799716|No Intervention|Sham|
89638611|NCT05799690|Experimental|DUAL-TASK+AOT-MI|Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) for six weeks.
89638612|NCT05799690|Active Comparator|DUAL-TASK|Dual-task gait and balance training with vision of landscape videos for six weeks.
89638613|NCT05799690|Experimental|DUAL-TASK+AOT-MI_DOUBLE|Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) repeated two times (twelve weeks: 6 + 6).
89638614|NCT05799690|Active Comparator|DUAL-TASK_DOUBLE|Dual-task gait and balance training with vision of landscape videos repeated two times (twelve weeks: 6 + 6).
89638615|NCT05799690|No Intervention|Healthy subjects|Age- and sex-matched healthy subjects recruited to compare gait, neuropsychological, serum and functional magnetic resonance imaging characteristics at baseline.
89638616|NCT05799664|Experimental|Experimental group|Patients will be treated with TLD and standard of care (per GOLD guideline).
89638617|NCT05799664|Sham Comparator|Control group|Patients will undergo sham TLD procedure and be treated with standard of care (per GOLD guideline).
89638618|NCT05799560|No Intervention|control group|no intervention
89638619|NCT05799560|Experimental|intervention|Reiki touch and terapotic touch will be done
89212131|NCT00848276||1|Hypogonadal Men before and after starting testosterone replacement therapy
89212132|NCT00848276||2|Post-menopausal women before and after starting Estrogen Replacement Therapy
89212133|NCT02590991||Prebiotics group|No intervention since is a follow-up study
89212134|NCT02590991||Prebiotics & Probiotics group|No intervention since is a follow-up study
89212135|NCT02590991||Control group|No intervention since is a follow-up study
89212136|NCT02590211|Other|non-poker players|(control group)
89212137|NCT02590211|Other|expert unproblematic poker players|(comparator)
89212138|NCT02590211|Other|pathological poker players|(comparator)
89212139|NCT00854438|Experimental|Active treatment arm|Reduction of anticholinergic drug effects by pharmacist review
89212140|NCT00854438|No Intervention|Control|No intervention
89212141|NCT00857870|Active Comparator|Metformin|
89212142|NCT00857870|Active Comparator|Insulin glargine|
89212143|NCT00848432|Experimental|1|Optimal therapeutic doses of risperidone continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months in clinically stable schizophrenia patients
89638620|NCT05799547|No Intervention|control group|
89638621|NCT05799547|Experimental|experimental group|
89638622|NCT05799534|Experimental|Rehabilitation|The duration for 4-week, three sessions per week. Each session will last for 45-60 minutes
89638623|NCT02365350|Experimental|STEINER-TAN Needle®|All visible follicles regardless of size in both ovaries will be aspirated and flushed three times by the STEINER-TAN Needle.
89638624|NCT02365350|Active Comparator|17G single lumen needle|In the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.
89638625|NCT05799469|Experimental|treatment arm|Participants receive envafolimab 150 mg subcutaneously (SC) on Day 1 of each week cycle (QW) for 8 cycles followed by envafolimab 300 mg SC on Day 1 of each 3-week cycle (Q3W) until disease progression, intolerable toxicity, investigator determines that the participant cannot continue to benefit, withdraws informed consent, or envafolimab treatment over 2 years. During the QW dosing period of envafolimab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 45 Gray Units (Gy)with the total duration of radiation treatment not to exceed 56 days.
89638626|NCT05799456||Bladder cancer|
89638627|NCT05799456||No evidence of disease|
89638628|NCT05799443|Experimental|SBRT followed by tislelizumab plus cetuximab and irinotecan|
89638629|NCT05799417|Experimental|Acoustic stimuli|Acoustic stimuli and comparison to within-subject baseline
89638630|NCT05799404||otosclerosis|otosclerosis patients
89638631|NCT05799404||chronic otitis media|otitis media with middle ear opacities
89638632|NCT05799404||controls|sudden ear loss, pre-implantatory imaging, vertigo, tympanic perforation
89042381|NCT05616013|Other|Bimagrumab 30 mg/kg + semaglutide 1.0 mg|Participants will receive i.v. bimagrumab 30 mg/kg at baseline, and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.
89042382|NCT05616013|Other|Bimagrumab 30 mg/kg + semaglutide 2.4 mg|Participants will receive i.v. bimagrumab 30 mg/kg at baseline and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 2.4 mg per the dose escalation schedule.
89042383|NCT05610150|Active Comparator|Myobrace functional Appliance|Thirteen patients with developing skeletal Class II malocclusion will be treated with Myobrace functional appliance for six months.
89042384|NCT05610150|Active Comparator|Twin Block Functional appliance|Thirteen patients with developing skeletal Class II malocclusion will be treated with Twinblock functional appliance for six months.
89042385|NCT05596058|Experimental|Dual task (active exercise and cognitive task)|"The dual task protocol is going to be in 15 one-hour sessions once a week in the headache free days.~This protocol will be set up in the clinic of physiotherapy degree (University of Trieste in the Department of Medical, Surgical, and Health Sciences).~The physical training tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises.~-"
89042386|NCT05596058|Active Comparator|active exercise only|The active exercise only intervention is going to consist of aerobic and flexibility training with a targeted duration of 1 hour, twice per week for 3 months.
89042387|NCT05596058|Active Comparator|Cognitive task trainig only|The Cognitive task training only engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).
89042388|NCT05590962|No Intervention|Control|"Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports.~Clinicians will receive no further interventions beyond usual practice."
89212144|NCT00848432|Experimental|2|Optimal therapeutic doses of risperidone continued for 26 weeks followed by a 50% dose reduction for at least another 6 months in clinically stable schizophrenia patients
89638633|NCT05799365||2 to 4 Years|The children with cerebral palsy between the age of 2 and 4. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
89638634|NCT05799365||4 to 6 Years|The children with cerebral palsy between the age of 4 and 6. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
89638635|NCT05799365||6 to 12 Years|The children with cerebral palsy between the age of 6 and 12. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
89638636|NCT05799365||12 to 18 Years|The children with cerebral palsy between the age of 12 and 18. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
89638637|NCT05799365||12 to 18 Years Young with Good Cognitive Levels|The children with cerebral palsy with good cognitive levels between the age of 12 and 18. GMFCS-FR Turkish adaptation was applied the childrens mother, father and clinical physiotherapist.
89638638|NCT05799352|Experimental|Endoscopic lung volume reduction|All the patients will have endobronchial valves insertion. We will evaluate before and 3 months after the evolution of the diaphragmatic strength and conformation.
89638639|NCT05799300||Hip fracture cohort|"Gender, Age, Racial and Ethnic Origin of Subjects Male and female adults over the age of 18 years; all origins, all races will be included.~Inclusion/exclusion criteria as below"
89638640|NCT05799248|Experimental|rhPSMA-7.3|Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management
89638641|NCT05799235|Experimental|Telerehabilitation TAR program using a mobile application (intervention group)|Participants in the intervention group will undergo the telerehabilitation TAR program and install and utilise the application on their mobile device, and self-administer the home exercises as prescribed by their physiotherapists. The mobile application uses novel deep learning algorithm on a mobile platform to detect key landmarks on the body for human pose estimation. Participants will be able to perform their rehabilitation exercise with real-time feedback allowing for proper execution of the exercises. The participants will be instructed on the installation and use of the mobile application and will be expected to perform the prescribed exercises independently (using the application) as instructed by their Physiotherapists. This application will be used for the initial 12 weeks of post-op rehabilitation.
89638642|NCT05799235|Active Comparator|Standard rehabilitation (control group)|Participants in the control group will attend standard in person rehabilitation sessions at the outpatient clinic. Participants will be prescribed a home exercise program as per standard care.
89638643|NCT05799222||Adults with overweight/obesity and pre-diabetes/diabetes and low income|Adults with overweight or obesity and pre-diabetes or type 2 diabetes who earn a low income.
89638644|NCT05799196||Microfracture|The patient with meniscus tear would be performed meniscus repair with additional microfracture
89638645|NCT05799196||Conventional|The patient with meniscus tear would be performed meniscus repair
89638646|NCT05799170|Experimental|intervention|Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment.
89638647|NCT05799170|No Intervention|usual care|usual care/standard of care no intervention implemented
89638648|NCT05799131||QBX (5F/6F) Peripheral Balloon Expandable Stent System|
89638649|NCT05799053|Experimental|Peppermint oil capsules (Tempocol®)|"Enteric-coated capsule containing 182mg of Peppermint Oil that release the oil in the small intestine, to be taken orally.~Age: 8-11 years old: 2 times daily for 8 weeks, if needed upped to 3 times daily after 4 weeks Age: 12-18: 3 times daily for 8 weeks, if needed upped to 3 times two capsules daily after 4 weeks"
89638650|NCT05799053|Placebo Comparator|Placebo|Capsule containing microcrystalline cellulose, to be taken orally. Age: 8-11 years old: 2 times daily for 8 weeks, if needed upped to 3 times daily after 4 weeks Age: 12-18: 3 times daily for 8 weeks, if needed upped to 3 times two capsules daily after 4 weeks
89638651|NCT05799053|Experimental|Peppermint sweets (Wilhelmina®)|"Wilhelmina® peppermints contain 9.2 mg of Menthae Piperitae Aetheroleum (peppermint oil), and 18.4 Kcal per mint and are to be taken orally.~Age: 8-11 years old: 2 times daily for 8 weeks, if needed upped to 3 times daily after 4 weeks Age: 12-18: 3 times daily for 8 weeks, if needed upped to 3 times two capsules daily after 4 weeks"
89638652|NCT05799027|Experimental|Raman spectrum analysis|The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
89638653|NCT05799014|Experimental|Traditional CT-guided percutaneous lung biopsy group|
89638654|NCT05799014|Experimental|Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology group|
89638655|NCT05798988|Experimental|Experimental group|Experimental group will follow 8 weeks of neurophysiology-based exercise program.
89638656|NCT05798988|No Intervention|Control group|Control group will receive no intervention. They will not change the movement habits.
89638657|NCT05798949|Active Comparator|Exposure in vivo-therapy|"In the first phase, patients with idiopathic small fiber neuropathy will receive exposure in vivo therapy for at least 4 weeks, 2 sessions/week.~In the second phase, the therapy will be expanded with either 4 weeks or 6 weeks, 2sessions/week, depending on the outcome of the first session."
89638658|NCT05798949|Active Comparator|Graded activity-therapy|"In the first phase, patients with idiopathic small fiber neuropathy will receive graded activity-therapy for at least 4 weeks, 2 sessions/week.~In the second phase, the therapy will be expanded with either 4 weeks or 6 weeks, 2sessions/week, depending on the outcome of the first session."
89638659|NCT05798949|Active Comparator|Acceptance and commitment therapy|"In the first phase, patients with idiopathic small fiber neuropathy will receive acceptance and commitment therapy for at least 4 weeks, 2 sessions/week.~In the second phase, the therapy will be expanded with either 4 weeks or 6 weeks, 2sessions/week, depending on the outcome of the first session."
89638660|NCT05798936|Experimental|Polidocanol group|Polidocanol is injected in the thyroid cyst under ultrasound guidance.
89638661|NCT05798936|Experimental|Alcohol group|Alcohol is injected in the thyroid cyst under ultrasound guidance.
89042389|NCT05590962|Experimental|Intervention|"Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports.~Clinicians in the intervention arm will receive an EHR nudge with option to opt-out for palliative care referral for any eligible high-risk patient."
89042390|NCT05581199|Experimental|Treatment Period 1: Cohort A, Dose 1|
89042391|NCT05581199|Experimental|Treatment Period 1: Cohort A, Dose 2|
89042392|NCT05581199|Experimental|Treatment Period 1: Cohort B, Dose 1|
89042393|NCT05581199|Experimental|Treatment Period 1: Cohort B, Dose 2|
89042394|NCT05581199|Experimental|Treatment Period 1: Cohort C, Dose 1|
89042395|NCT05581199|Experimental|Treatment Period 1: Cohort C, Dose 2|
89638662|NCT05798910|Active Comparator|Conventional Training Group (15 Participants)|The members of the conventional group had to complete pretest at the beginning of the study. Afterwards they had to take part at an interactive classroom based lecture about Advanced Life Support. The next step was the skills training with task trainers in order to teach them compression skills. Afterwards, the conventional group was divided into three blue code teams consisting of each 5 participants for the simulation session. Two independent instructors evaluated the video recordings in terms of technical and nontechnical skills. The final stage of the study were completing the post-test.
89638663|NCT05798910|Active Comparator|VR Group (14 Participants)|The members of the VR group had to complete pretest at the beginning of the study. Afterwards they had to play with the VR based serious game module for Advanced Life Support. The next step was the skills training with task trainers in order to teach them compression skills. Afterwards, the conventional group was divided into three blue code teams consisting of each 5 participants for the simulation session. Two independent instructors evaluated the video recordings in terms of technical and nontechnical skills. The final stage of the study were completing the post-test. The aprticipants of this group were also asked to fill a survey about their VR experience during the study.
89638664|NCT05798897|Experimental|Single Arm Study|Single arm study evaluating MT-601 investigational product at 200 million cells and 400 million cells per dose
89042396|NCT05581199|Experimental|Treatment Period 1: Cohort D, Dose 1|
89042397|NCT05581199|Experimental|Treatment Period 1: Cohort D, Dose 2|
89042398|NCT05581199|Experimental|Withdrawal Period 2: Cohort A, Dose 2|
89042399|NCT05581199|Experimental|Withdrawal Period 2: Cohort A, Placebo|
89042400|NCT05581199|Experimental|Withdrawal Period 2: Cohort B, Dose 2|
89042401|NCT05581199|Experimental|Withdrawal Period 2: Cohort B, Placebo|
89042402|NCT05581199|Experimental|Withdrawal Period 2: Cohort C, Dose 2|
89042403|NCT05581199|Experimental|Withdrawal Period 2: Cohort C, Placebo|
89042404|NCT05581199|Experimental|Withdrawal Period 2: Cohort D, Dose 2|
89042405|NCT05581199|Experimental|Withdrawal Period 2: Cohort D, Placebo|
89042406|NCT05581199|Experimental|LTE Period: With Relapse in Period 2: Dose 1 and Dose 2|Participants will receive Dose 1 for the initial 4 weeks only and Dose 2 for the remaining 48 weeks.
89042407|NCT05581199|Experimental|LTE Period: Without Relapse in Period 2: Dose 2|Participants will receive Dose 2 for all 52 weeks.
89042408|NCT05574491|Experimental|Super Skills for Life intervention group: traditional version|The Super Skills for Life program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/treatment.
89042409|NCT05574491|Experimental|Super Skills for Life intervention group: computerized version|"The Super Skills for Life program will be administered in-person as well by a trained therapist, as described in the section of intervention treatment.~The therapist will use the multimedia presentation of the program's contents as a tool for the better development of the sessions. The digital version of the program consists of an animation whose characters narrate examples that help the children better understand the contents. The therapist will have a password assigned to each child, and it will be the therapist who will guide the sessions and select the contents of the digital presentation that correspond to each session. The web address to access the programme is https://www.superskillsonline.com/."
89042410|NCT05574062|Experimental|Treatment Arm|AHCL therapy (780G system in Auto Mode with G4S sensor in the study phase and 780G BLE 2.0 system in Auto Mode with DS5 sensor in the continuation phase)
89042411|NCT05574062|Active Comparator|Control Arm|Predictive low-glucose suspend (780G system in Manual Mode with G4S sensor) in the study phase and AHCL therapy (780G system in Auto Mode with G4S sensor) in the continuation phase
89042412|NCT05571423|Active Comparator|Medical Play Intervention|This group of participants will be engaged in medical play before the dental exam visit.
89042413|NCT05571423|Placebo Comparator|Routine Play Intervention|This group of participants be engaged in routine play (coloring exercise) before the dental exam visit.
89638665|NCT05798884|Experimental|Electro-acupuncture group|The electro-acupuncture intervention will be conducted for 2 sessions per week for 4 consecutive weeks before and 8 weeks during the chemotherapy. In this study eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Disposable acupuncture needles (verum acupuncture needles Hwato 0.25 x 25mm matching the Streiterger sham needles) will be inserted at a depth of 10-25mm into the points. Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
89638666|NCT05798884|Sham Comparator|sham-acupuncture group|"For subjects assigned to the sham control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, and the stimulation will be a pseudo stimulation, which will be given by connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument.The credibility and validity of this system have been well demonstrated."
89638667|NCT05798871|Active Comparator|Subgingival erythritol air polishing|"The treatment will include the following therapy steps:~Supragingival debridement.~Subgingival erythritol air polishing by perioflow."
89638668|NCT05798871|Active Comparator|Conventional root planing|"The treatment will include the following therapy steps:~Supragingival debridement.~Subgingival root planing by curette."
89638669|NCT05798858|Active Comparator|Group A: NT+ NIPT|"Group A patients will undergo NT between 11+3 and 13+6 weeks. If the NT is <3.5 mm, the patient will be offered to continue the screening with NIPT.~If NIPT comes back as positive result, the result will be confirmed by an invasive procedure (amniocentesis/villocentesis); if, on the other hand, the NIPT will give a negative result, the screening is concluded and the patient will not undergo further tests."
89638670|NCT05798858|Active Comparator|Group B|"Combined test + NIPT (n=200) The patients of group A will undergo NT between 11+3 and 13+6 weeks, according to the same protocol foreseen for Group A.~If the NT is <3.5 mm, the patient will be offered continuation of the screening using the combined test.~In case of:~High risk (1:2-1:100), the patient will be offered an invasive procedure (amniocentesis/villocentesis) Intermediate risk (1:101-1:1000), the patient will be offered NIPT, according to the protocol already described for Group A. In the event of a positive result, the patient will undergo an invasive procedure (amniocentesis/villocentesis ); in the case of negative NIPT, the screening is concluded and the patient will not undergo further tests.~Low risk (>1:1000), screening ends and the patient will not undergo further tests."
89638671|NCT05798845|Experimental|Experimental: Arm A|Radiation: primary tumor SBRT, DT: 24Gy/3Fx, d1-3, d22-24; positive lymph nodes LDRT, DT: 2Gy/4Fx, d1-4, d22-25 (2 cycles) ; Drug: toripalimab 240mg ivgtt d5, d26 (2 cycles)
89638672|NCT05798845|Active Comparator|Conrol: Arm B|"Drug: Chemotherapy + toripalimab 240mg ivgtt d1, d22 (2 cycles)~Chemotherapy regimen:~Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum. Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum"
89638673|NCT05798832|Active Comparator|Active Comparator|The active control group was given traditional Basic Life Support, which already practiced in most schools.For the traditional BLS training group; basic life support was given a lesson in the classroom for 45 to 50 minutes, demonstrated on a model, and the training session was ended after a question and answer session. In terms of standardization of the trainings, the trainings were given by Derya ASLAN HUYAR.
89638674|NCT05798832|Experimental|experimental|Basic Life Support training with VR was given to the experimental group.For the VR BLS training group; The use of VR was introduced in the VR hall. The lexical meanings of the basic concepts of BLS were explained. The student received training on a scenario he chose in the training module, and then he was asked to perform the steps individually in the assessment mode. After the training was completed, a question-answer was made and the session was closed. In terms of standardization of the trainings, the trainings were made by Derya ASLAN HUYAR.
89638675|NCT05798819|Experimental|GLS-010+chemotherapy± bevacizumab|GLS-010 in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
89638676|NCT05798819|Placebo Comparator|Placebo+chemotherapy± bevacizumab|Placebo in combination with cisplatin or carboplatin and paclitaxel± bevacizumab
89638677|NCT05798767||PCI group|Patients with a Mini-Cog score of 3 or less were in the PCI group
89042414|NCT05570721|Experimental|Women with perimenopausal depression|Participants will undergo a social stress task (TSST)
89638678|NCT05798767||Normal group|Patients with a Mini-Cog score of 3 or 4 were in the normal group
89638679|NCT05798754|Active Comparator|Group LOR|The thoracic epidural space will be identified by the loss of resistance technique.
89638680|NCT05798754|Active Comparator|Group C|The thoracic epidural space will be identified by the CompuFlo® technology.
89638681|NCT05798728|Active Comparator|Inpatient Vaginal Misoprostol|These participants will receive intravaginal Misoprostol in the inpatient setting per our standard hospital protocol for cervical ripening.
89638682|NCT05798728|Experimental|Outpatient transcervical foley balloon|These participants will receive a catheter which will be placed by a physician present in the clinic, however, patient are discharged home for 12 hours until their time of induction of labor.
89638683|NCT05798715|Experimental|T test|1 tablet contains 1000 mg Metformin HCl & 50 mg Sitagliptin orally administrated with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing
89638684|NCT05798715|Active Comparator|R Reference|1 tablet contains 1000 mg Metformin HCl & 50 mg Sitagliptin orally administrated with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing
89042415|NCT05570721|Experimental|Women without perimenopausal depression|Participants will undergo a social stress task (TSST)
89042416|NCT05569317|Experimental|primary nursing|"The intervention group with patients who are cared with primary nursing (process-responsible nursing; PP) after elective thoracic and/or cardiovascular surgery are on the intervention ICU. Patients are assigned to the intervention group if they stay for at least 3 days on the ICU. PP take on~the responsibility of the nursing process~the daily care according to the individual patient case~direct communication with all professional groups involved in care~responsibility for the quality of care of the assigned patients over a fixed period of at least 14 and a maximum of 50 days - after that the primary nurse will change.~In this way, PP also take on the nursing anamnesis as well as the planning, implementation and evaluation of the nursing care. The nursing care ratio is at least 1:2"
89042417|NCT05569317|No Intervention|standard care|The control group with patients who are cared for according to the principle of standard care (area care or room care) is located on another ICU. There is no PP responsible for the target group and the allocation of nursing staff to patients is redefined at the start of each shift. The nursing care ratio is at least 1:2.
89042418|NCT05567588|Experimental|Pembrolizumab + RT (5 fractions, 8 Gy) + Pembrolizumab|"Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
89638685|NCT05796856|Experimental|Repeated low-level light therapy (wavelength: 810 nm)|"Participants will be treated with repeated low level light therapy (wavelength of 650 nm) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary."
89638686|NCT05796856|Active Comparator|Repeated low-level light therapy (wavelength: 650 nm)|"Participants will be treated with repeated low level light therapy (wavelength of 650 nm) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary."
89638687|NCT05795608|Experimental|intervention group|The intervention group received respiratory exercise with incentive spirometry before surgery
89638688|NCT05795608|No Intervention|control group|The control group were given standard preoperative care.
89638689|NCT05795491|Placebo Comparator|Group A|"This group includes 30 patients will receive routine medical treatment with antifungal, azole (vaginal route).~100 ml ( one Suppository ) at bedtime for three nights in a row"
89638690|NCT05795491|Experimental|Group B|This group includes 30 patients. The vulva and vagina will be exposed to 401 ± 5 nm ultraviolet A/ blue LED irradiation in a single session, divided into two applications.
89638691|NCT05794282||Group rTHA (robotic total hip arthroplasty)|the robot assisted total hip arthroplasty
89638692|NCT05794282||Group cTHA (conventional total hip arthroplasty)|the conventional total hip arthroplasty
89638693|NCT05788653|Active Comparator|Thiele Group|The group will be given Thiele Massage twice a week for 4 weeks. Thiele massage will be done with a stripping motion in the direction of the pelvic floor muscle fibers. Approximately 15-20 repetitions will be applied to each of the pelvic floor muscle groups for 30 minutes.
89638694|NCT05788653|Active Comparator|Transverse Friction Group|The group will be given Transverse Friction Massage twice a week for 4 weeks. Transverse friction massage will be applied to each tense muscle group and trigger points for 3-5 minutes, crossing the direction of the pelvic floor muscle fibers. Massage duration is approximately 30 minutes for each session.
89638695|NCT05788627|Placebo Comparator|Placebo arm / tap water enema arm|This arm will receive oral lactulose as per treatment protocol for hepatic encephalopathy i.e. 30ml twice daily. And will receive tap water enema as placebo i.e. 1000ml tap water enema twice daily.
89638696|NCT05788627|Experimental|Lactulose enema arm|This arm will receive oral lactulose in a dose of 30ml twice daily alongwith lactulose enema (300ml lactulose plus 700ml water) twice daily.
89042419|NCT05564429|Other|Only one arm|All subjects receive the same tests
89212145|NCT00848432|Experimental|3|Optimal therapeutic doses of risperidone continued for at least 1 year in clinically stable schizophrenia patients
89212146|NCT04043156|Experimental|High-precision RT|Study Arm: 18 x 2.33 Gy of high-precision RT in 3.5 weeks.
89638697|NCT05787964||Healthy participants|Healthy adults aged > 18 years
89638698|NCT05787964||Participants with haematological malignancies|Multiple myeloma patients receiving lenalidomide and smoldering multiple myeloma patients under observation.
89638699|NCT05787964||Participants with solid tumours|Stage IV non-small cell lung cancer patients treated with checkpoint inhibitor therapy +/- chemotherapy.
89638700|NCT05786833|Active Comparator|Dexmedetomidine Group|
89638701|NCT05786833|Active Comparator|Ketofol Group|
89638702|NCT05786833|Placebo Comparator|Control Group|
89638703|NCT05784883||Consecutive patients ≥60-year-old presenting to the echocardiography clinic|
89638704|NCT05780658|Experimental|Compass Course|Four groups of up to 12 participants (48 total) will receive the study intervention during Spring and Fall 2022. All participants will complete study questionnaires before and after the sessions.
89638705|NCT05777135|Experimental|Group I (Preloading with Ringer Lactate)|Preloading with Ringer lactate 30ml/kg over 30 minutes prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
89638706|NCT05777135|No Intervention|Group II (No preloading)|No preloading will be done and Propofol dose requirement for induction of anaesthesia will be noted
89638707|NCT05776849|Experimental|Experimental group|The trainer shared the training presentation, visuals and videos (his own video explaining the episiotomy application and repair and other videos shared with the traditional group) prepared on the subject of episiotomy with the students through the course information system, one week before the episiotomy application. It was accepted that the students came to the episiotomy application with the theoretical training. Afterwards, episiotomy was applied.
89638708|NCT05776849|No Intervention|No Intervention: Control group (Traditional education)|The students were given theoretical training. This training was implemented in two sessions, one lasting 50 minutes and the other 30 minutes. The content of the training; It included the definition of episiotomy, indications, risks, episiotomy application steps, materials used, episiotomy types, episiotomy repair and repair steps, suturing techniques and types, episiotomy care. Slide shows, related images and video presentations (3 videos showing episiotomy application and repair steps and suturing techniques) were used as teaching materials. A question-answer session was held at the end of the training. In addition, teaching materials were shared with the students after the application. Immediately after the training, episiotomy was applied.
89638709|NCT05774392||Disease Cohort|
89638710|NCT05774392||Engaged Cohort|
89638711|NCT05773742|Experimental|Low-volume irrigation|The patients will be instructed to irrigate once daily at a fixed time for 6 weeks. The patients will be instructed to use the irrigation 30 min after breakfast, capitalizing on the gastrocolic response; however, should this not fit in with the individual's lifestyle, then an alternative time of the day may be used. Preferably shortly after a large meal. The patients should fill the pump with 180 milliliters (a full pump) and irrigate with a volume of 160 milliliters of water.
89638712|NCT05771883|Experimental|DLBCL and other B-NHL patients such as FL, MZL, MCL, etc.|"In this study, lenalidomide was administered at a fixed dose, in which 25 mg was used for DLBCL patients,and 20mg was used for other B-NHL patients such as FL, MZL, MCL, etc. and daily oral therapy with IMM0306 was used on the 1~21st day of each repeat 28-day cycle.~The RP2D of the IMM0306 monotherapy trial was administered once a week (7 days ± 1 day) for intravenous infusion every 4 weeks"
89638713|NCT05768256|Experimental|Advanced cancer patients|
89638714|NCT05767892|Experimental|YK-029A Group (Arm A)|
89638715|NCT05767892|Active Comparator|Platinum-based Chemotherapy Group (Arm B)|
89638716|NCT05750355|Experimental|TPN171H|Subjects will receive TPN171H orally for single dose
89638717|NCT05750355|Placebo Comparator|Placebo|Subjects will receive Placebo orally for single dose
89638718|NCT05741320||public|Subjects older than 16 years of age and not working in any health sector will be included in the study.
89638719|NCT05737433|Experimental|[14C]-RCF 225mg|[14C]-rencofilstat, 225mg oral dose, self-micro-emulsifying drug delivery system, single dose
89638720|NCT05730816|Experimental|Magnesium Sulfate|The IV Mg will start at 1 g/hour (25 ml/hour) within one hour following induction of anesthesia and stabilization of the patient. The infusion will continue for 24 hours and serum Mg levels will be monitored every 4 hours (+/-1 hour) for 28 hours following initiation of the Mg. Dose adjustments to the Mg infusion will be made as necessary to reach target serum Mg levels (3-5 mg/dl).
89638721|NCT05730816|Placebo Comparator|Normal Saline|Patients randomized to placebo will receive an equal volume of normal saline (0.9% NS) placebo which will be administered as a continuous infusion at 25 ml/hour. The infusion will continue for 24 hours.
89638722|NCT05728840|Experimental|Rehabilitation intervention group|Each participant of the experimental group will undergo an initial cognitive screening (pre-training) and, in addition to their standard of care, they will have 20 additional sessions with the experimental rehabilitation program. Post-treatment cognitive screening will be completed at the end of the program, then 3-4 and 6-12 months later.
88991287|NCT05370534||Study Population|"The investigators anticipate validating two specific actions: a box jump and walking gait. Both will be captured in two planes, coronal and sagittal. Healthy patients without musculoskeletal complaints will be voluntarily enrolled to undergo motion capture with both methods, completed during the same visit to the UAMS Human Biomechanics Laboratory.~Each patient will perform a box jump and walking gait using each of the two modalities. We anticipate 4 hrs will be required for each patient: 1 hr for setup before the patient arrives, 1 hr for testing, and 2 hrs for data cleaning and initial processing. This work will be performed at the UAMS Human Biomechanics Laboratory (off campus on Aldersgate Road), which is equipped for this type of analysis."
88991288|NCT05357053||Anorexia nervosa patients|Anorexia nervosa patients
88991289|NCT05357053||Healthy normal weight controls|Healthy normal weight controls
88991290|NCT05354765|Experimental|"first type, called A Cohorts"|"The first type, called A Cohorts, corresponds to indications for which the treatment induces a high response rate (>30%). These patients will have a lymphapheresis before and during treatment with immunotherapy. In addition, a blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression."
88991291|NCT05354765|Experimental|"second type, called B Cohorts"|"The second type, called B Cohorts, corresponds to indications for which a role of the immune system is suspected. Only the so-called informative patients (responders or surprising evolution) will have one lymphapheresis during treatment. The lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment and depending on the clinical course determined by the clinicians in consultation with at least one immunologist (Olivier Lantz, Emanuela Romano, Cécile Alanio, Marion Alcantara)."
88991292|NCT05349552||Chest Wall Type|The lesion is directly adjacent (less than 1cm) or overlapped with the chest wall.
88991293|NCT05349552||Peripheral Type|The lesion is more than 1cm away from the chest wall and more than 2cm away from the bronchial tree.
88991294|NCT05349552||Central Type|The lesion is less than 2cm away from the bronchial tree.
88991295|NCT05349552||Ultral-central Type|The lesion is directly adjacent or overlapped with the mediastinal structure.
88991296|NCT05339529|Experimental|Thymosin alpha 1|1.6 mg q12h for 5 days
88991297|NCT05339529|Sham Comparator|Blank control|
89638723|NCT05728840|Active Comparator|Dose-match control group|Each participant of the experimental group will undergo an initial cognitive screening (pre-training) and, in addition to their standard of care, they will have 20 additional sessions of neuropsychological standard sessions. Post-treatment cognitive screening will be completed at the end of the program, then 3-4 and 6-12 months later.
89638724|NCT05728840|No Intervention|Retrospective standard of care group|Each participant of the retrospective group will be included retrospectively if they were hospitalized in the study's sites between 2012 and 2022, and followed standard neuropsychological rehabilitation of attention.
89638725|NCT05727345|Active Comparator|Interscalene|Right after general anesthesia induction and patient intubation, the patient will be placed in the semi-sitting position. Following sterile skin preparation, an interscalene block will be performed by the same anaesthesiologist under ultrasound guidance with an in-plane posterior approach approximately between C6-C7 nerve roots through a 22-gauge 50-mm insulated stimulating needle (StimuPlex Nanoline, Braun). Neurostimulation with an initial current of 0,5 mA, pulse width of 100ms, and a frequency of 2 Hz will be used as protection for intraneural injection, once the needle tip is in proximity to the brachial plexus. 15 mL local anesthetic solution (0.375 % bupivacaine anesthetic solution of 10 mL and 2 % lidocaine anesthetic solution of 5 mL) will be observed to disperse within the interscalene space.
89638726|NCT05727345|Experimental|SHAC|Right after general anesthesia induction and patient intubation, the patient will be placed in the semi-sitting position with the arm in extension and abduction. Following sterile skin preparation, a SHAC block will be performed by the same anaesthesiologist under ultrasound guidance by visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia and glenohumeral pericapsular space. A 22-gauge 50-mm insulated stimulating needle (StimuPlex Nanoline, Braun) will be used to give 1-3 mL of 5% Dextrose for the correct location and then 15 mL local anesthetic solution will be divided into 7,5 mL (0.375 % bupivacaine 5 mL and 2 % lidocaine 2,5 mL) for each target points as interfascial space and pericapsular space.
89638727|NCT05721677|Experimental|Tissue adhesive|Tissue adhesive application at the CVL exit-site, on all CVLs, PICCs during the patient LOS. Regular CLABSI preventive protocol. Regular preventive CVL dressings (Chlorhexidine >2mo).
89638728|NCT05721677|No Intervention|Control group|Regular CLABSI preventive protocol. Regular preventive CVL dressings (Chlorhexidine >2mo).
89638729|NCT05707611|Experimental|Running|Running on treadmill in moderate intensity for 30 minutes
89638730|NCT05707611|Experimental|Cycling|Cycling on ergometer in moderate intensity for 30 minutes
89638731|NCT05707611|Experimental|Swimming|Swimming in moderate in tensity for 30 minutes
89638732|NCT05707403|Experimental|Test treatment (T) followed by Reference treatment (R)|
89638733|NCT05705765|Experimental|Suspension|Exercise with suspension devices.
89638734|NCT05705765|Active Comparator|Balance|Exercise over instability surfaces.
89638735|NCT05702333||Vasoactive-inotropic drug use (VASO+)|All patients treated with vasoactive-inotropic drugs (epinephrine, norepinephrine, dobutamine, dopamine, and levosimendan) after 12 hours after Intensive Care Unit Admission were retrospectively classified in the VASO + cohort.
89638736|NCT05702333||No vasoactive-inotropic drug (VASO -)|Patients treated with vasoactive-inotropic drugs (epinephrine, norepinephrine, dobutamine, dopamine, and levosimendan) in the first 12 hours after Intensive Care Unit Admission (ICU) or patients never treated with such drugs in ICU were retrospectively classified in the VASO - cohort.
89638737|NCT05691205|Experimental|PEEP-LuTX|Within 48h after LuTX we will evaluate the effects of three levels of PEEP (14>10>6 cmH2O) upon: - lung and chest wall mechanics, - intrapulmonary shunt fraction; - distribution of ventilation and perfusion; - gas exchange.
89638738|NCT05682989||mesh surgery|Data obtained before the operation
88991298|NCT05336019|Experimental|"Diabetes self-management Coaching"|A 12-week Diabetes self-management Coaching program and the usual care
88991299|NCT05336019|Active Comparator|"Usual Care"|The control group will be assigned to 12 weeks usual care or routine diabetes service
88991300|NCT05332457|Active Comparator|Arm A|"Phase I : Participants will undergo first CPET (Day 0) at trough concentration of BB. After 7-day regular usage of BB, the second CPET(Day 7) will be performed at peak concentration of BB. Participants will enter the second phase if the results of CPET fulfill the pre-determined conditions as follows: (1) Chronotropic index < 0.8 at peak level of BB, (2) Resting HR < 110 bpm at trough level of BB, (3) Absent of unstable arrhythmia or unstable hemodynamics during CPET at trough level.~Phase II: BB dosage will be reduced. Daily blood pressure, heart rate and adverse event will be recorded. If participants remained clinically stable, the third CPET(Day 21) will be performed 14 days after the reduction of dosage. If participants' resting heart rate exceed 110 bpm, the dosage will be adjusted to the original level."
88991301|NCT05332457|Active Comparator|Arm B|"Phase I : Participants will undergo first CPET(Day 0) at peak concentration of BB. After 7-day regular usage of BB, the second CPET(Day 7) will be performed at trough concentration of BB. Participants will enter the second phase if the results of CPET fulfill the pre-determined conditions as follows: (1) Chronotropic index < 0.8 at peak level of BB, (2) Resting HR < 110 bpm at trough level of BB, (3) Absent of unstable arrhythmia or unstable hemodynamics during CPET at trough level.~Phase II: BB dosage will be reduced. Daily blood pressure, heart rate and adverse event will be recorded. If participants remained clinically stable, the third CPET(Day 21) will be performed 14 days after the reduction of dosage. If participants' resting heart rate exceed 110 bpm, the dosage will be adjusted to the original level."
88991302|NCT05329740|Experimental|Glucocorticoid group|
88991303|NCT05329740|No Intervention|Control Group|
88991304|NCT05324748|Placebo Comparator|Placebo Arm|
88991305|NCT05324748|Experimental|Intervention Arm|
88991306|NCT05318443|Experimental|Experimental|SIBP04 & Paclitaxel & Carboplatin
88991307|NCT05318443|Active Comparator|Control group|Avastin & Paclitaxel & Carboplatin
88991308|NCT05316662||Semaglutide|Participants with T2D will be assessed for clinical parameters associated with the once-daily use of oral semaglutide who have not previously been treated with injectable glucose-lowering medication in routine clinical practice.
88991309|NCT05313451|Experimental|Soluble fiber|Participants ingest 15 g daily of the experimental product for 2 months and receive the influenza vaccine at the end of the first month.
89638739|NCT05682989||Robotic-assisted sacrocolpopexy|Data obtained before the operation
89638740|NCT05682989||a hysterectomy with trans-vaginal mesh repair (Surelift®, Neomedic International, Barcelona, Spain)|Data obtained before the operation
89638741|NCT05671913|Active Comparator|Treatment|Intranasal Ketamine
89638742|NCT05671913|Placebo Comparator|Control|Normal Saline
89638743|NCT05668936|Experimental|Arm 1|Participants will receive cotadutide and will receive a single dose of moxifloxacin-placebo on Day 1 and Day 93.
89638744|NCT05668936|Experimental|Arm 2A|Participants will receive a single dose of moxifloxacin (Day 1) prior to initiating treatment with cotadutide-placebo for up to 13 weeks, followed by a single dose of moxifloxacin-placebo on Day 93.
89638745|NCT05668936|Experimental|Arm 2B|Participants will receive a single dose of moxifloxacin-placebo (Day 1) prior to initiating treatment with cotadutide-placebo for up to 13 weeks, followed by a single dose of moxifloxacin on Day 93.
89638746|NCT05657990|Experimental|Pre-operative Tamsulosin administration|Subjects will be provided with a prescription for Tamsulosin (generic) to be taken 7 days prior to scheduled surgery for thoracic cancer. Tamsulosin dose is set at 0.4mg/day and should be taken daily for seven days prior to their planned surgery date. Study subjects will also be given a diary to record their daily usage. Study subjects should take Tamsulosin on the day of the surgery with a sip of water.
89638747|NCT05655741||Delphi Panel|Participants who meet the inclusion criteria ,who are willing to complete the 3 questionnaires within the study.
89638748|NCT05650203|Experimental|JS009 as a monotherapy and JS009 Combine with Toripalimab and JS006|"JS009 as Monotherapy in first cycle of dose escalation and the triple combination therapy will be administered in subsequent cycles：5 proposed dose levels（18mg, 60mg, 180mg, 600mg, 1200mg).~The triple combination therapy in dose expansion：1 or 2 proposed dose levels, to be determined.~The triple combination therapy in indication expansion：4 or more cohorts, to be determined."
89638749|NCT05599568|Other|Exercise challenge|At baseline, subjects will perform the selected exercise challenge followed by blood samples collected at rest and 0, 2, 4, 24 hours and 4 days after end of exercise. Muscle soreness will be measured by asking the participant how sore their muscles in their thighs are on a visual-analog scale (1-10) at the same timepoints. After 4 weeks (+/- 3 days) of normal daily activity, the same test will be performed including blood samples.
89638750|NCT05587686||Intubated patient during their stay in the IUCPQ-UL emergency or intensive care department|
89638751|NCT05583539|No Intervention|Usual Care|Patients will receive usual care at the discretion of their providers.
89638752|NCT05583539|Experimental|Thromboelastography guided resuscitation|Patients will undergo thromboelastography testing that will be used by primary providers to guide blood product resuscitation.
89638753|NCT05571150|Experimental|Experimental intervention group|The dyad-focused strategy training intervention will be delivered to the treatment group. The intervention protocols of the dyad-focused strategy training were developed based on the strategy training guideline outlined by Skidmore et al, Bodenmann's framework of dyadic coping, and the self-efficacy theory.
89638754|NCT05571150|Active Comparator|Control intervention group|Participants in the control group will receive a dose-matched stroke education provided by a trained research therapist as an attention-control intervention. The therapist will provide in-person education to the dyad using an illustrated manual developed based on the stroke rehabilitation guidelines suggested by the American Heart Association/American Stroke Association .
89638755|NCT05565391||Elranatamab|Patients treated with elranatamab from the MagnetisMM-3 trial
89638756|NCT05565391||Standard of care|Patients treated with standard-of-care therapies from real-world data sources
89638757|NCT05563441||laparoscopic surgery|Patients over 70 years old underwent laparoscopic colorectal resection were enrolled.
89638758|NCT05563441||laparotomic surgery|Patients over 70 years old underwent laparotomic colorectal resection were enrolled.
89638759|NCT05559814|Experimental|Peppermint oil|1.6% peppermint oil solution 50 ml(Peppermint oil plus simethicone and tween)
89638760|NCT05559814|Placebo Comparator|Placebo|Placebo solution 50ml(Simethicone plus tween)
88991310|NCT05313451|Placebo Comparator|Placebo|Participants ingest 15 g daily of the placebo product for 2 months and receive the influenza vaccine at the end of the first month.
88991311|NCT05310526|Experimental|Intervention Group|"Distribution of the Brazilian cardioprotective diet manual to primary health care~Training to prescribe the cardioprotective Brazilian diet. the training consists of 5 face-to-face modules lasting 4 hours each, in addition to a virtual module and group exercises.~Audit feedback"
88991312|NCT05310526|No Intervention|Control Group|Distribution of the Brazilian cardioprotective diet manual to primary health care professionals
88991313|NCT05304416||Cardiovascular Surgical Patients Preoperative Exam|All enrolled participants will undergo a baseline Fiberoptic Endoscopic Evaluation of Swallowing (FEES) or a Simultaneous FEES and Videofluoroscopy instrumental swallowing exam before their surgery to determine baseline / preoperative swallowing function. Those with confirmed dysphagia will not be asked to complete the postoperative swallowing exam, given our desire to examine contributing risk factors for dysphagia development and mechanisms within cardiovascular surgical patients. In addition to the instrumental exam, systematic collection of demographic, medical, surgical, and intubation-related candidate predictor variables will be conducted over the entire perioperative period.
88999220|NCT03004404|Experimental|BA Part: T2/T1/R|"Participants were orally administered 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~Followed by 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
89638761|NCT05540938|Experimental|treatment group|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
89638762|NCT05540938|Active Comparator|control group|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
89638763|NCT05522140|Experimental|Intervention arm|"The intervention arm will undergo following steps:~Groups of 5-15 persons, who lives in Prague. Two trained facilitators support the group dynamics forstering empowerment.~Each participant will undergo an individual session with the facilitator(s) aimed at building relationships and trust, and getting to know the expectations and characteristics of the participants.~9 group activities with the aim to promote accessibility and engagement with the nature and outdoor activities available in their town. Collaborative mapping of nature-based community activities will direct the group to activities they want to approach and test."
89638764|NCT05522140|Active Comparator|Control arm|Participants randomly assigned to the control arm will receive usual care, which is a list of community resources in the city (Prague). Usual care is an appropriate comparison rather than placebo for complex interventions
89638765|NCT05520190|Experimental|All Participants|
89638766|NCT05492188|Experimental|Operant Conditioning of Cutaneous Reflexes|Each participant completes 6 baseline sessions and 30 conditioning sessions. In each of the 30 conditioning sessions, while the participant is standing nerves in the lower leg and ankle are stimulated to activate the reflex. The participant attempts to change the reflex activity based on visual feedback. In this way the cutaneous reflex (skin reflex) will be changed to decrease neuropathic pain resulting from spinal cord injury.
89638767|NCT05489432|Experimental|prehabilitation group|care as usual and pre habilitation intervention
89638768|NCT05489432|No Intervention|control group|care as usual
89638769|NCT05487326|Active Comparator|high thoracic ESPB group|Group where ESPB is performed at T2 with local anesthetic mixture 20 ml
89638770|NCT05487326|Active Comparator|cervical epidural group|Group where cervical epidural injection is performed at C6-7 or C7-T1 level
89638771|NCT05475704||Case group|Test-positive cases are study participants that meet the SARI case definition AND test positive for at least one SARS-CoV-2 diagnostic test, with specimens collected up to 14 days prior to ER visit or hospitalization or up to 24 hours thereafter
89638772|NCT05475704||Control group|Test-negative controls are study participants that meet the SARI case definition AND test negative for all SARS-CoV-2 diagnostic test with specimens collected up to 14 days prior to ER visit or hospitalization or up to 24 hours thereafter
89638773|NCT05469646|Experimental|Dose Group 1: BI 1819479 (Low dose)|
89638774|NCT05469646|Experimental|Dose Group 2: BI 1819479 (Middle dose)|
89638775|NCT05469646|Experimental|Dose Group 3: BI 1819479 (High Dose)|
89638776|NCT05469646|Placebo Comparator|Placebo|
89638777|NCT05439824|Experimental|20 μg dose of SYS6006 (Aged 18~59 years or 60 years or more)|20μg dose of SYS6006 vaccine IM, on day 0 and day 21.
89638778|NCT05439824|Experimental|30 μg dose of SYS6006 (Aged 18~59 years or 60 years or more)|30 μg dose of SYS6006 vaccine IM, on day 0 and day 21.
89638779|NCT05439824|Placebo Comparator|Placebo(Aged 18~59 years or 60 years or more)|placebo IM, on day 0 and day 21 .
89638780|NCT05402371|Experimental|Cohort A: Rencofilstat 75 mg|Eighty-four (84) biopsy-proven NASH F2/F3 subjects to complete study on Rencofilstat 75 mg daily.
89638781|NCT05402371|Experimental|Cohort B: Rencofilstat 150 mg|Eighty-four (84) biopsy-proven NASH F2/F3 subjects to complete study on Rencofilstat 150 mg daily.
89638782|NCT05402371|Experimental|Cohort C: Rencofilstat 225 mg|Eighty-four (84) biopsy-proven NASH F2/F3 subjects to complete study on Rencofilstat 225 mg daily.
89638783|NCT05402371|Placebo Comparator|Cohort D: Placebo|Eighty-four (84) biopsy-proven NASH F2 / F3 subjects to complete study on matching placebo.
89638784|NCT05384795||General anesthesia|
89638785|NCT05384795||Spinal anesthesia|
89638786|NCT05384795||Peripheral nerve block|
89638787|NCT05382481|Experimental|Peak value anti-Xa group (Group A)|The peak value of anti-Xa level of this group should be remain 0.3～0.5IU/mL. This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.
89638788|NCT05382481|Experimental|Trough value anti-Xa group (Group B)|The trough value of anti-Xa level of this group should be remain 0.1～0.2IU/mL. This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
89638789|NCT05382481|Placebo Comparator|Control group （Group C）|"The control group will not detect the value of anti Xa and not adjust the dose of LMWH.~This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day."
89638790|NCT05368987|Experimental|PTSD group|Participants will undergo a 3-day experimental paradigm. Before the experiment, participants will undergo a resting-state fMRI scan to determine the specific anatomical location of the TMS target for that particular individual (day 1). The resting-state scan will be about 10 minutes. Functional MRI scans will occur on days 1, 2, 3, and TMS on day 2. A blood draw will occur on experimental day 1 or, if needed due to scheduling, on any of the other experimental visits.
89638791|NCT05368987|Active Comparator|Healthy Control group|Participants will undergo a 3-day experimental paradigm. Before the experiment, participants will undergo a resting-state fMRI scan to determine the specific anatomical location of the TMS target for that particular individual (day 1). The resting-state scan will be about 10 minutes. Functional MRI scans will occur on days 1, 2, 3, and TMS on day 2. A blood draw will occur on experimental day 1 or, if needed due to scheduling, on any of the other experimental visits
89638792|NCT05364320||Men aged 50-64|
89638793|NCT05364320||Men aged 65 and over|
89638794|NCT05364320||Women aged 50-64|
89042420|NCT05551858|Placebo Comparator|Placebo|"Arm 1. Placebo for first 12 weeks. Placebo is a fiber filler called Avicel and is given by mouth three times daily.~Note: After 12 weeks on placebo, these subjects will receive proglumide 400 mg orally three times daily open labeled for 12 additional weeks."
89638795|NCT05364320||Women aged 65 and over|
89638796|NCT05354089|Experimental|Vaccine group 1|20 μg dose of SYS6006 vaccine IM, on day 0 and day 21.
89638797|NCT05354089|Experimental|Vaccine group 2|30 μg dose of SYS6006 vaccine IM, on day 0 and day 21.
89638798|NCT05354089|Placebo Comparator|Placebo|Placebo IM, on day 0 and day 21.
89638799|NCT05354063|Experimental|Vaccine group 1|20μg dose of SYS6006 vaccine IM, on day 0 and day 21.
89638800|NCT05354063|Experimental|Vaccine group 2|30μg dose of SYS6006 vaccine IM, on day 0 and day 21.
89042421|NCT05551858|Experimental|Proglumide|Proglumide therapy 400 mg by mouth three times daily for 12 weeks in a blinded fashion followed by continued proglumide 400 mg by mouth three times daily for 12 additional weeks in an open labeled fashion. Hence this arm receives proglumide for a total of 24 weeks.
89638801|NCT05354063|Placebo Comparator|Placebo|placebo IM, on day 0 and day 21 .
89638802|NCT05335369|No Intervention|Usual care|Usual care
89638803|NCT05335369|Experimental|UR-GOAL|UR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
89638804|NCT05323786|Experimental|The combined topical anesthesia induction group|Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
89638805|NCT05323786|Placebo Comparator|The routine induction group|Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
89638806|NCT05308316|Experimental|Impact of Sugar Content|Participants will be ask to attend 4 laboratory sessions during which they will be asked to smoke their usual brand (UB) cigarettes and then one of three study cigarettes with low, medium and high levels of sugar in separate sessions using a within-subject design with conditions counterbalanced determined by a Latin square. In each session, smokers will be asked to smoke a cigarette in a standardized manner (10 puffs,30 second interval between puffs) and 1 hour later, ad libitum. Each of the sessions will be separated by at least 48 hours but not more than 5 days.
89638807|NCT05291065|Experimental|Fasted exercise|Fasted prior to exercise
89638808|NCT05291065|Experimental|High protein breakfast exercise|High protein breakfast consumption prior to exercise
89638809|NCT05291065|Experimental|High carbohydrate breakfast exercise|High carbohydrate breakfast consumption prior to exercise
89638810|NCT05274516|Experimental|Single Ascending Doses, 6 dose levels|HRS-2261 oral tablet Matching placebo to HRS-2261
89638811|NCT05274516|Experimental|Multiple Ascending Doses, 3 dose levels|HRS-2261 oral tablet Matching placebo to HRS-2261
89638812|NCT05267925|Experimental|Intervention|All participants will be asked to take the dietary herbal supplement CuraLin for the duration of the study. All participants will take 2 capsules orally, three times per day following meals for 12 weeks.
89638813|NCT05262387|Experimental|Lyumjev|Lyumjev administered subcutaneously (SC) during a meal and following different approaches for basal reduction prior to exercise
89638814|NCT05262387|Active Comparator|Humalog|Humalog administered SC during a meal and following different approaches for basal reduction prior to exercise
89638815|NCT05262231|Experimental|Experimental|Study group intervention consists 1-session. A session takes approximately 1 hour. The pre-test will be applied just before the intervention. The final test will be administered immediately after the intervention.
89638816|NCT05262231|No Intervention|No Intervention|No intervention is applied to the control group.
89638817|NCT05255705||Patients undergoing Revascularisation at Barts Heart Centre|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients with coronary artery disease undergoing revascularisation.
89638818|NCT05221554|Experimental|Prospective Computer-Navigated Cohort|Patients in this arm will receive standard patient of care implants but navigation software will be used to plan optimal acetabular cup placement.
89638819|NCT05221554|Active Comparator|Cross-sectional Standard of Care Cohort|Patients in this arm will receive standard of care implants and undergo standard of care procedure for total hip arthroplasty.
89638820|NCT05200104|Experimental|PXL065|PXL065 22.5 mg QD
89638821|NCT05181098||Robotic-guided surgery group|Any pediatric, adolescent or adult patient undergoing robotic-guided spine surgery, ages 12-80.
89638822|NCT05162937|Experimental|Treatment group 1|Drug：GR1501 100mg
89638823|NCT05162937|Experimental|Treatment group 2|Drug：GR1501 200mg
89638824|NCT05162937|Experimental|Treatment group 3|Drug：GR1501 300mg
89638825|NCT05162937|Placebo Comparator|Treatment group 4|Drug：placebo
89638826|NCT05154838||Patients with Pilonidal Abcess|All adult (18+) patients presenting at surgical assessment unit requiring treatment for pilonidal abscess. Wounds will be drained, cleaned and packed as per usual clinical practice. Extra standard wound swabs will be collected for additional microbiological analyses. Control wound dressings will be placed on adjacent, unaffected area of skin for 24 hours.
89638827|NCT05119010|Experimental|A|patients will be asked to follow in a continuous way a very low-carbohydrate, high-fat diets, which strictly limit carbohydrate consumption (less than 40g / day) and allow unlimited consumption of high-fat foods, such as pork belly, butter, coconuts oils, fat meat, eggs and cheese, etc… (cf appendix A). Patients will be provided with 2 meals (lunch and dinner), every meal with 2 dishes (first course and main course) and bread for every day for 3 months (ELIOR partnership).
89638828|NCT05119010|Experimental|B|patients will be asked to follow in a discontinuous way (15 days on, 15 days off) a very low-carbohydrate, high-fat diets, which strictly limit carbohydrate consumption (less than 40g / day) and allow unlimited consumption of high-fat foods, such as pork belly, butter, coconuts oils, fat meat, eggs and cheese…etc (cf appendix A). Patients will be provided with 2 meals (lunch and dinner), every meal with 2 dishes (first course and main course) and bread for every day for the ketogenic diet period for 3 months (ELIOR partnership).
89042422|NCT05533866|Experimental|EB participants|Visits will include screening, pre-treatment (week 0), weeks 4 and 8, followed by a visit without use of the APR-TD011 for 4 weeks (week 12) for microbiome assessment off of therapy.
89042423|NCT05530889|Experimental|TEST/CONTROL|Eligible subjects who suffer from ocular allergies and who wear contact lenses will be randomized into the wear sequence (TEST/CONTROL) to wear the study lenses during each dispensing period (12-16 days).
89042424|NCT05530889|Experimental|CONTROL/TEST|Eligible subjects who suffer from ocular allergies and who wear contact lenses will be randomized into the wear sequence (CONTROL/TEST) to wear the study lenses during each dispensing period (12-16 days).
89638829|NCT05119010|Experimental|C|patients will receive oral liquid ketone supplement BHB monoester, 2 tablespoons three times per day (depending on patient weight: at least 1g/kg weight body/day) 15 days-on 15 days off during 3 months. We would recommend taking it at least 30 to 60 min before meal times and they will receive standard diet (without any diet restrictions).
89638830|NCT05119010|No Intervention|D|patients will receive standard diet (without any diet restrictions) and be followed up as in arms A, B, C.
89638831|NCT05100901|Experimental|Oral nutritional supplement|Oral nutritional supplement that contains MAG oil
89638832|NCT05046392|Experimental|mHealth Facilitated Adherence Coaching|
89638833|NCT05046392|Active Comparator|Control|
89638834|NCT05004402||Primiparous women|Primiparous women after vaginal delivery
89638835|NCT04998058|Placebo Comparator|Control (conventional graft procedure), bone substitute and saline solution.|one randomly assigned maxillary sinus grafted internally defined as control (bone substitute + saline solution) per subject.
89638836|NCT04998058|Experimental|Test (modified graft), bone substitute and concentrated culture medium (CM)|one randomly assigned maxillary sinus grafted internally defined as test (bone substitute + concentrated culture medium) per subject.
89638837|NCT04992494|Experimental|MBCT-T (Mindfulness-Based Cognitive Therapy - Telephone)|Mindfulness-based cognitive therapy delivered by Telephone
89638838|NCT04992494|Experimental|MBCT-V (Mindfulness-Based Cognitive Therapy - Video)|Mindfulness-based cognitive therapy delivered by Video
89638839|NCT04985500|Experimental|ESP group|Patient will receive ESP block with ultrasound guidance the transverse process of the vertebra at T7 is visualized and 20 mL of 0.25% bupivacaine will be injected between the transverse process and the erector spinae muscle on each side using a 21-gauge block needle.
89638840|NCT04985500|Experimental|PIF group|Patient will receive PIF block after intubation with ultrasound placed 1-2 cm lateral to the sternal border and the pectoralis major and external intercostal muscles are visualized at the level of ribs 3-4 where 10 mL of 0.25% bupivacaine will be injected on each side using a 21-gauge block needle.
89638841|NCT04985500|No Intervention|No Block group|Patient will not receive block.
89638842|NCT04973670|Experimental|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h
88991314|NCT05304416||Cardiovascular Surgical Patients Postoperative Exam|Participants without preoperative dysphagia will be seen for a postop exam within 72 hours of extubation. Simultaneous imaging using FEES and videofluoroscopy (or a FEES or VFSS exam in isolation) will be performed at the bedside, as well as a battery of clinical tests. Completion of these postoperative tests will indicate study completion for participants without evidence of dysphagia, while participants who demonstrate acute-phase postoperative dysphagia will continue to participate if they desire. During their standard of care one-month follow-up appointment, a third research evaluation will be offered for participants with previously identified postoperative dysphagia. During this exam, the same imaging and clinical tests from the previous research exam will be performed. Finally, participants with persisting dysphagia will be offered the opportunity to continue to be studied for a fourth and final research exam during their standard of care six-month follow-up clinic visit.
88991315|NCT05302388|Experimental|Experimental group|Drug: SIBP-R002 & Dexamethasone/Methyl prednisolone & Diphenhydramine Starting from the lowest dose, when the former dose does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD).
88991316|NCT05302388|Placebo Comparator|Placebo control group|Placebo control: The same volume of placebo as SIBP-R002 & Dexamethasone/Methyl prednisolone & Diphenhydramine The rule and dose of placebo were the same as SIBP-R002.
88991317|NCT05300594|Experimental|Audistim|The participants ingest the experimental product every day for 3 months. The experimental product contains a combination of plant extracts, vitamins and trace elements presented in 2 formulas: a day tablet (to be swallowed in the morning) and a night tablet (to be swallowed in the evening before going to bed).
88991318|NCT05300594|Placebo Comparator|Placebo|Participants ingest the placebo product every day for 3 months .The placebo is strictly identical in appearance to the experimental product and contains only excipients.
88991319|NCT05299151|Experimental|Vestibular Rehabilitation Group|A vestibular rehabilitation exercise program, which is determined based on the literature and personalized according to the functional disabilities of each patient, will be applied to the participants in the experimental group. An exercise session will be performed for a total of 40 minutes, with each exercise for 1-2 minutes. Exercise training will be applied 2 days a week for 8 weeks and they will be asked to do it at home once a week.
88991320|NCT05299151|Active Comparator|Standard Neurorehabilitation Group|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises will be applied. Each training session will be 40 minutes in total. Exercise training will be done in the clinical setting 2 days a week for 8 weeks, and they will be asked to do it at home once a week.
88991321|NCT05297656|Experimental|Experimental Group|"A total of 8 sessions of graston massage protocol will be applied to the patients in the experimental group for 4 weeks, 2 days a week for 5 minutes, at the hospital operating within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.~All patients will also receive home exercise therapy including stretching of the trapezius muscle and posture exercises"
88991322|NCT05297656|Sham Comparator|Sham Comparator Group|"A total of 8 sessions of sham graston massage protocol will be applied to the patients in the experimental group for 4 weeks, 2 days a week for 5 minutes, at the hospital operating within the body of Kırşehir Ahi Evran University Physical Therapy and Rehabilitation Center.~Sham graston massage is not a deep tissue massage, but will be performed with the device superficially, without applying pressure and mobilization.~All patients will also receive home exercises."
88991323|NCT05297656|Other|Control group|The volunteers in the control group will be only given home exercise therapy including stretching of the trapezius muscle and posture exercises
88991324|NCT05266846|Experimental|Pembrolizumab plus Bevacizumab and Chemotherapy|Pembrolizumab Plus Bevacizumab and Chemotherapy was used for ALK-rearranged NSCLC With Persistent 5'ALK.
88991325|NCT05265832|Experimental|Cataract surgery|Phacoemulsification cataract surgery
89638843|NCT04973670|Active Comparator|placebo|The same amount of NS containing only sivelestat sodium excipients
89638844|NCT04966858|Experimental|Individualized Caloric Refeeding (ICR)|Starting 50 kcal/kg/d, increasing by 200 kcal/d to goal
89638845|NCT04966858|Active Comparator|Higher Calorie Refeeding (HCR)|Starting 2000 kcal/d, increasing by 200 kcal/d to goal
89042425|NCT05529303|Experimental|Intervention group|The intervention group determined by the randomization method will be given the 'Feminine Identity Improvement Program', based on cognitive behavioral and expressive techniques, which is structured to be 90-120 minutes once a week for 10 weeks. The program to be applied to the intervention group has been created by the researcher in line with the literature review and the necessary expert opinions were obtained.
89042426|NCT05529303|No Intervention|Control group|No intervention will be applied to the control group during the study.
89042427|NCT05516628|Experimental|Surgery followed by Adjuvant Atezolizumab-Bevacizumab Therapy every 3-weekly|Patient will receive adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following surgery.
89042428|NCT05511519|Experimental|ATI-450|ATI-450 50mg oral tablet BID
89042429|NCT05511519|Placebo Comparator|Placebo|Placebo oral tablet BID
89042430|NCT05506670|Experimental|proved RSV infection (RSV positive patients|
89042431|NCT05506670|Experimental|suspected but not proved RSV infection (RSV negative patients)|
89042432|NCT05502549|Experimental|CB03-154 SAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state.
89042433|NCT05502549|Placebo Comparator|Placebo SAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state.
89042434|NCT05502549|Experimental|CB03-154 SAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state.
89042435|NCT05502549|Placebo Comparator|Placebo SAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state.
89042436|NCT05502549|Experimental|CB03-154 SAD 30mg|Participants will receive CB03-154 30mg orally once daily in a fasted state.
89042437|NCT05502549|Placebo Comparator|Placebo SAD 30mg|Participants will receive placebo 30mg orally once daily in a fasted state.
89042438|NCT05502549|Experimental|CB03-154 SAD 45mg|Participants will receive CB03-154 45mg orally once daily in a fasted state.
89042439|NCT05502549|Placebo Comparator|Placebo SAD 45mg|Participants will receive placebo 45mg orally once daily in a fasted state.
89042440|NCT05502549|Experimental|CB03-154 FE 20mg|Participants will receive CB03-154 20mg orally once daily in a fed state.
89042441|NCT05502549|Experimental|CB03-154 MAD 10mg|Participants will receive CB03-154 10mg orally once daily in a fasted state, for 14 consecutive days.
89042442|NCT05502549|Placebo Comparator|Placebo MAD 10mg|Participants will receive placebo 10mg orally once daily in a fasted state, for 14 consecutive days.
89042443|NCT05502549|Experimental|CB03-154 MAD 20mg|Participants will receive CB03-154 20mg orally once daily in a fasted state, for 14 consecutive days.
89042444|NCT05502549|Placebo Comparator|Placebo MAD 20mg|Participants will receive placebo 20mg orally once daily in a fasted state, for 14 consecutive days.
89042445|NCT05502549|Experimental|CB03-154 SAD 5mg|Participants will receive CB03-154 5mg orally once daily in a fasted state.
89042446|NCT05502549|Placebo Comparator|Placebo SAD 5mg|Participants will receive placebo 5mg orally once daily in a fasted state.
89042447|NCT05483803|Experimental|Qualitative sub-study 1 group|One group of caregivers (n = 20) will engage with the digital health solution during 1 month.
89042448|NCT05483803|Experimental|Quantitative sub-study 2 group|A different group of caregivers (n = 80) will engage with the digital health solution during 3 months.
89042449|NCT05483166|Experimental|ImPACT program|The ImPACT program consists of 8 weekly 1-hour sessions with homework between sessions.
89042450|NCT05482711|Other|Time Restricted Eating intervention|Participants will be asked to stop eating by 7 PM every day and to fast for a target of 16 hours per day for 8 weeks. During the first two weeks of the intervention, participants will gradually ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 8 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Additionally, they will be asked to keep a Fasting and Sleeping diary logging their eating habits and sleep quality.
89042451|NCT05480085|Experimental|School-based extracurricular intervention focusing on screen media use and time spent with friends|
89042452|NCT05479032|Experimental|Treatment group|Intensive care patients suffering from reduced consciousness not otherwise explained treated with Amantadine
89042453|NCT05477576|Experimental|Phase 1b - RYZ101|Part 1 is an uncontrolled dose de-escalation study to confirm the safety and determine the RP3D of RYZ101 based on Bayesian optimal interval design. Eligible participants will be enrolled in cohorts of 6 to receive RYZ101 up to 4 infusions every 8 weeks. If the initial dose level is not tolerated, the dose will be de-escalated; up to 3 dose levels will be assessed.
89042454|NCT05477576|Active Comparator|Phase 3 - RYZ101|Actinium 225 radiolabeled somatostatin analog (SSA) for injection
89042455|NCT05477576|Active Comparator|Phase 3 - Standard of Care|Investigator's choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide.
89042456|NCT05468892|Active Comparator|Arm A|Trifluridine-Tipiracil
89042457|NCT05468892|Experimental|Arm B|Panitumumab + Trifluridine-Tipiracil
89042458|NCT05453006|Experimental|Intervention|At the three intervention clinics, clinic providers or staff will offer women the option to perform HPV self-sampling as an alternative to cervical cancer screening by a clinician.
89042459|NCT05453006|No Intervention|Control|Control clinics will have passive participation and their only involvement will be that data will be pulled from these clinics. Women in the control clinics will be offered usual care cervical cancer screening by a clinician. The research team will not have any contact with women in the control clinics.
89042460|NCT05444244|Active Comparator|Brain Health Community Registry Recruitment|
89042461|NCT05444244|No Intervention|Standard Recruitment|
89042462|NCT05443256|Experimental|Theta Stim|To stimulate fMRI-informed individualized targets in dlPFC to diminish affective modulation of the RewP. Based on our working hypothesis, TMS Figure-8 coil stimulation should diminish affective modulation of RewP amplitude when compared to sham.
89042463|NCT05443256|Sham Comparator|Sham Stim|Sham stimulation. The Reward Positivity should be unaffected.
89042464|NCT05432596|Experimental|ATI-1777 topical solution 2.0% w/w (BID)|ATI-1777 topical solution 2.0% w/w, twice daily
89042465|NCT05432596|Experimental|ATI-1777 topical solution 1.0% w/w (BID)|ATI-1777 topical solution 1.0% w/w, twice daily
89042466|NCT05432596|Experimental|ATI-1777 topical solution 0.5% w/w (BID)|ATI-1777 topical solution 0.5% w/w, twice daily
89638846|NCT04929626|Active Comparator|Nebulized Ventolin|Nebulized Ventolin will given to 1st group after every 20 min for 1 hour
89638847|NCT04929626|Experimental|Nebulized Magnesium Sulphate + Ventolin|Dose of Nebulized Magnesium sulphate will vary in 3 subgroups.
89638848|NCT04908852||Cohort 1|This is a prospective, longitudinal, observational exploratory study. Ten subjects will be enrolled and will complete baseline and week 4 blood draws and symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
89638849|NCT04902196|Experimental|Group 1|persons with chronic low back pain of an non-specific origin
89638850|NCT04902196|Active Comparator|Group 2 (Control group)|"healthy persons (pain-free)"
89638851|NCT04840004|Other|PVT-1|One arm study.
89638852|NCT04826198|Experimental|AsiDNA in addition to Niraparib|Part A: AsiDN in addition to Niraparib (Safety evaluation) Part B: AsiDN in addition to Niraparib (Efficacy evaluation and Safety confirmation )
89638853|NCT04811833||Monoplus®|Adult patients undergoing an elective, primary surgery within the gastrointestinal tract with the need for anastomosis.
89638854|NCT04808934||Non-Valvular Atrial Fibrillation (NVAF) Adults|Adult patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban or VKAs between June 16, 2014 and December 31, 2018.
89638855|NCT04754230|Experimental|1,000mg IV Tranexamic acid|Participants in this arm will be given a 1,000mg dose of intravenous tranexamic acid via saline infusion 15 minutes prior to the completion of surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
89638856|NCT04754230|No Intervention|Normal saline|Participants in this arm will not be given any extra intervention over their routine anesthetic care. They will continue to receive their normal saline infusion during surgery. They will keep a bleeding diary with daily entries each day until their first routine scheduled postoperative follow-up clinic visit one week after surgery.
89638857|NCT04727086|Experimental|Medication (BP1.3656)|Participants will receive BP1.3656 in tablet form once daily at a dose of 30 µg/day for the first 4 days, followed by 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
89638858|NCT04727086|Placebo Comparator|Placebo pills|Participants will receive matching placebo pills for 14 days.
89638859|NCT04711759|Experimental|Sequence A: High flow nasal cannula - Standard oxygen therapy|Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of standard oxygen therapy.
89638860|NCT04711759|Experimental|Sequence B: Standard oxygen therapy - High flow nasal cannula|Once participants are extubated they will receive one hour of standard oxygen therapy followed by one hour of high flow nasal cannula.
89638861|NCT04659928|Experimental|High volume evacuation (HVE) suction only and hydrogen peroxide|
89638862|NCT04659928|Experimental|HVE suction and extraoral vacuum aspirator (EVA) and hydrogen peroxide|
89638863|NCT04659928|Experimental|HVE suction and external evacuation device (EED) and hydrogen peroxide|
89638864|NCT04653337|Experimental|Robot-assisted accelerated iTBS-1800 and Antidepressants|MDD patients with suicidal ideation will receive antidepressants combined with robot-assisted accelerated iTBS-1800(10 sessions per day over 5 consecutive days). This group is in order to determine the safety, tolerability and feasibility of accelerated iTBS protocol.
89638865|NCT04653337|Active Comparator|Robot-assisted accelerated iTBS-600 and Antidepressants|MDD patients with suicidal ideation will receive antidepressants combined with robot-assisted accelerated iTBS-600(6 sessions of iTBS with 30 min interval per day over 5 consecutive days).
89638866|NCT04653337|Sham Comparator|Sham accelerated iTBS-600 and Antidepressants|MDD patients with suicidal ideation and depression will receive antidepressants combined with sham accelerated iTBS-600(6 sessions of sham iTBS with 30 min interval per day over 5 consecutive days).
89638867|NCT04642417|Experimental|Experimental|intervention give experience dietary fiber literacy
89638868|NCT04642417|No Intervention|No Intervention|give standard education
89638869|NCT04641897|Other|Sequence A|Sequence A: Low RR for 12 hours - High RR for 12 hours
89638870|NCT04641897|Other|Sequence B|Sequence B: High RR for 12 hours - Low RR for 12 hours.
89638871|NCT04606303|Experimental|Toripalimab Combined With Platinum-containing Dual-agent.|Toripalimab combined with platinum-containing dual-agent as a neoadjuvant Therapy for Non-small Cell Lung Cancer.
89638872|NCT04541849||Critically ill patients|
89638873|NCT04539626|Experimental|Estrogen Therapy|"Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg~Dosage form: EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)"
89638874|NCT04539626|No Intervention|Control Group|Patients who will receive conventional COVID-19 treatment
89638875|NCT04531709||Recently diagnosed TGCT|
89638876|NCT04531709||Long-term survivors of TGCT|
89638877|NCT04516252|Experimental|Intervention|Half of the BodyWorks families will be randomized to the intervention group, and will receive a PAT for the children, the parents, and the dogs at the beginning of the cycle; the children will respond to EMA surveys using a cell phone; the children and the parents will receive the Canine health literacy module in addition to the BW curriculum.
89042467|NCT05432596|Placebo Comparator|Vehicle (BID)|Vehicle topical solution, twice daily
89638878|NCT04516252|Active Comparator|Control|Half of the BodyWorks participants will be randomized to the control group and will receive a PAT at the beginning of the cycle for the children, the parents, and the dogs, and the children will respond to EMA surveys using cell phones.
89638879|NCT04512534|Experimental|Sinitilimab+Chidamide|Anti-PD-1 antibody Sintilimab 200mg intravenously every 3 weeks; HDAC inhibitor Chidamide 30mg orally twice every week
89638880|NCT04504630|Active Comparator|Active HD-tDCS|Participants will receive 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting dorsal anterior cingulate region for 20 minutes) across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
89638881|NCT04504630|Sham Comparator|Sham HD-tDCS|Participants will receive 10 sessions of sham stimulation across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
89638882|NCT04442581|Experimental|Treatment (cabozantinib S-malate, pembrolizumab)|Patients receive cabozantinib S-malate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89042468|NCT05432596|Experimental|ATI-1777 topical solution 2.0% w/w (QD)|ATI-1777 topical solution 2.0% w/w, once daily
89042469|NCT05432596|Placebo Comparator|Vehicle (QD)|Vehicle topical solution, once daily
89042470|NCT05397951|Experimental|Wearing Biosensor Before & After Exercise|Each study participant will wear the bioelectronic sensors during a slow deep breath. Participants will wear the sensors and devices for 15 minutes before and after a brisk 6-minute walk.
89042471|NCT05397951|Experimental|Wearing Biosensor for an Extended Period|Each study participant will wear the bioelectronic sensors during a slow deep breath. Participants will wear the sensors and devices continuously for 2 hours.
89042472|NCT05394805||Participants treated with Humira (Adalimumab)|Participants prescribed Humira (adalimumab) for moderately to severely active crohn's disease (CD) in routine clinical practice.
89042473|NCT05394428||Patients with female sexual organs treated with pelvic radiotherapy|Patients with female sexual organs treated with pelvic radiotherapy.
89042474|NCT05386238|Experimental|Tailored treatment|6-months of group-based behavioral weight loss treatment tailored to men working in blue-collar occupations.
89042475|NCT05386238|Active Comparator|Standard of care treatment|6-months of group-based behavioral weight loss treatment following the Diabetes Prevention Program Group Lifestyle balance.
89638883|NCT04436731|Experimental|Hypoxia Exposure|A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions. The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).
89638884|NCT04423068|Experimental|Overall Study|
89638885|NCT04413214|Experimental|Test Group|The 3x3 dose escalation design will be adopted, including 200mg, 400mg and 600mg of Carrimycin; and three subjects at each dose level initially. If there is no DLT in the dose level of 200mg, the dose level of 400mg will be followed; if there is one DLT in the dose level of 200mg, another three patients will be added in the dose level of 200mg; if there is no DLT occurs in the another three patients, the dose level of 400mg will also be followed; if there is one DLT in the another three patients, the trial will be closed. The same condition to the dose level of 400mg and 600mg.
89638886|NCT04379570|Experimental|Arm I (TMR)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.
89638887|NCT04379570|Experimental|Arm II (MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.
89638888|NCT04379570|Experimental|Arm III (TMR + MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.
89638889|NCT04379570|Active Comparator|Arm IV (enhanced usual care)|Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.
89638890|NCT04376476|Experimental|Children group E1|Children with confirmed asymptomatic or pauci-symptomatic COVID infection will be recruited in pediatric emergency departments, among siblings of COVID-19+ pediatric patients or through the blood collection centers set up by the occupational health services. A single visit will be scheduled at the hospital (for clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
89638891|NCT04376476|Experimental|Children group E2|Children with confirmed COVID-19 infection requiring hospitalization will be recruited within participating centers (mostly in emergency and intensive care units). Data will be recorded (clinical examination, biology, immunology, virology measurements) during their hospital stay (day 0, day 7, in case of worsening) and a phone call performed at day 14 (or onsite visit if patient still hospitalized).
89638892|NCT04376476|Experimental|Children group E3|Children with confirmed non-COVID-19 viral infection requiring hospitalization will be recruited within participating centers (mostly in intensive care units). At inclusion, data will be recorded (clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
89638893|NCT04304534|Experimental|BAY 2433334 high dose|
89638894|NCT04304534|Experimental|BAY 2433334 medium dose|
89638895|NCT04304534|Experimental|BAY 2433334 low dose|
89638896|NCT04304534|Placebo Comparator|BAY2433334 matching placebo|
89638897|NCT04268706|Experimental|CD30 positive r/r classical Hodgkin Lymphoma|"Patients with relapsed or refractory classical Hodgkin Lymphoma who have failed 3 prior lines of treatment, which may include a prior autologous and/or allogeneic stem cell transplant.~Patients will be treated with autologous CD30.CAR-T cells."
89638898|NCT04250259|Placebo Comparator|Placebo|Alcoholic Cirrhosis on placebo
89638899|NCT04250259|Experimental|1,200 mg SAMe|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
89638900|NCT04250259|No Intervention|Non-drinking Controls|Non-drinking healthy controls
89042476|NCT05385484|Experimental|Mobile banking account with incentives to save|Participants in the savings intervention group will be provided with basic information on the importance of saving for the future, as well as (a) lottery-based incentives to save, (b) opportunities to develop savings goals, and (c) periodic reminders about the savings incentives and goals. Participants will receive assistance in opening and using a mobile savings account and will receive an education session that emphasizes the importance of saving for the future. Participants will be told about lottery-based incentives for saving money in their account.
89638901|NCT04223609|Experimental|Oxycodone, Then Placebo|Participants first receive initial dose of oxycodone 5 mg tablet followed by a 30-minute rest period to allow for onset of medication effect. This rest period will be followed by a standardized set of oculomotor testing for 40 minutes. After the initial testing, a second dose of oxycodone 5 mg tablet will be administered followed by a 30-minute rest period to allow for the onset of the second dose. The second rest period will be followed by a second round of standardized oculomotor testing for 40 minutes. Participants will then return approximately 4 to 6 days to repeat the standardized oculomotor testing with placebo.
89638902|NCT04223609|Experimental|Placebo, Then Oxycodone|Participants first receive initial dose of placebo 5 mg tablet followed by a 30-minute rest period to allow for onset of medication effect. This rest period will be followed by a set of standardized oculomotor testing for 40 minutes. After the initial testing, a second dose of placebo 5 mg tablet will be administered followed by a 30-minute rest period to allow for the onset of the second dose. The second rest period will be followed by a second round of standardized oculomotor testing for 40 minutes. Participants will then return approximately 4 to 6 days to repeat the standardized oculomotor testing with oxycodone.
89042477|NCT05385484|No Intervention|Basic health and financial education|Participants in the control group will be given basic information on the importance of saving for the future. In addition, health education curriculum developed by Impact Research & Development Organization (IRDO) will be provided to participants with standard health education on places to seek services for HIV and STI prevention and treatment, including information on alcohol and transactional sex as risk factors for HIV transmission.
89042478|NCT05384626|Experimental|Phase 1 dose escalation|NVL-655 oral daily dosing
89638903|NCT04194385|Active Comparator|Upper trunk block|In the supraclavicular region, UTB will be applied with 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
89638904|NCT04194385|Active Comparator|Costoclavicular brachial plexus block|In the infraclavicular region, CCBPB will be applied with 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
89638905|NCT04178304|Experimental|G1 patients receive prolotherapy|Intra and extra articular dextrose 25%
89638906|NCT04176458|Other|MBT in liver disease|Methacetin Breath test (MBT) intervention. We will use the MBT test to measure time from administration of 13C methacetin to obtaining the peak elimination of 13CO2.
89638907|NCT04137939|No Intervention|Control group|Ctrl group is instructed to maintain their original daily life
89638908|NCT04137939|Experimental|Smart Exercise group|SE group are instructed to perform one session of upper extremity ergometer and one session of lower extremity ergometer in a week, 30 minute per session, lasting for 12 weeks.
89638909|NCT04118920|Experimental|Topical insulin|Patients will receive topical insulin eye drops.
89638910|NCT04118920|Sham Comparator|Topical artificial tears|Patients will receive topical artificial tears.
89638911|NCT04089449|Experimental|PRT811|PRT811 will be administered orally
89638912|NCT04083144|Active Comparator|Deep rTMS active + Varenicline|Participants undergoing deep rTMS (active) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
89638913|NCT04083144|Sham Comparator|Deep rTMS sham + Varenicline|Participants undergoing deep rTMS (sham) for 4 weeks (5 sessions/week) along with 12 weeks of varenicline.
89638914|NCT04067180|Experimental|Haplo SCT|Allogeneic stem cell transplantation with a haplo-identical family donor graft.
89638915|NCT04067180|Active Comparator|URD SCT|Allogeneic stem cell transplantation with a matched unrelated donor graft.
89638916|NCT04055818|Experimental|Nicotinamide|Oral Nicotinamide 1000 mg twice daily
89638917|NCT04055818|Experimental|THU Decitabine|Oral 250 mg THU and 5 mg decitabine Once per week
89638918|NCT04047953|Experimental|Conversion Therapy|Paclitaxel (albumin-bound) +S-1+Oxaliplatin
89638919|NCT03981900||Rheumatoid arthritis|All participants with a diagnosis of moderate to severe active rheumatoid arthritis and treated with Tofacitinib
89638920|NCT03981107|Experimental|Chest Compression Only CPR (CO-CPR)|Instructions from a dispatcher at the dispatch center to trained bystanders to perform CO-CPR with chest compressions only.
89638921|NCT03981107|Active Comparator|Standard CPR (S-CPR)|Instructions from a dispatcher at the dispatch center to trained bystanders to perform S-CPR with chest compressions and rescue breaths in a 30:2 ratio.
89638922|NCT03947034||Metabolic toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of metabolic toxicities(such as hyperammonemia) of patient treated by a drug, with a chronology compatible with the drug toxicity
89638923|NCT03941548|Experimental|CTP-543 12 mg BID|Participants received 1 x 12 milligrams (mg) CTP-543 tablet and 1 x CTP-543 matching placebo tablet, twice daily (BID) for 24 weeks.
89042479|NCT05384626|Experimental|Cohort 2a|ALK+ NSCLC treated with 1 prior 2nd-generation ALK TKI therapy
89042480|NCT05384626|Experimental|Cohort 2b|ALK+ NSCLC treated with 2-3 prior 1st or 2nd-generation ALK TKIs
89042481|NCT05384626|Experimental|Cohort 2c|ALK+ NSCLC treated with 2-3 prior ALK TKIs, with lorlatinib in the 2nd or 3rd line
89042482|NCT05384626|Experimental|Cohort 2d|ALK+ solid tumors including patients with NSCLC not eligible for cohorts 2a-c, treated with ≥1 prior systemic anticancer therapy, or for whom no satisfactory standard therapy exists
89042483|NCT05382208|Experimental|Doxycycline|Doxycycline 100mg orally twice a day
89042484|NCT05382208|Placebo Comparator|Placebo|Matching placebo orally twice a day
89042485|NCT05374395|No Intervention|Usual Services|clinics will continue to deliver their normal outpatient services
89042486|NCT05374395|Experimental|Peer Recovery Support - Delivered Dropout Prevention + Usual Services|clinics will continue to deliver their normal outpatient services plus the peer recovery support-delivered dropout prevention enhancement
89042487|NCT05369715|Experimental|Morning|60 minutes cycling on cycle ergometer in the morning (11:30). Steady-state test at an intensity of 65% of participant's heart rate reserve.
89638924|NCT03941548|Experimental|CTP-543 24 mg QD|Participants received 24 mg (2 x 12 mg) CTP-543 tablets, once daily (QD) and after 12 hours, received 2 x CTP-543 matching placebo tablets, QD for 24 weeks.
89638925|NCT03928431|No Intervention|vaginally delivered|A non-randomized reference group of vaginally delivered infants.
89042488|NCT05369715|Experimental|Evening|60 minutes cycling on cycle ergometer in the evening (18:30). Steady-state test at an intensity of 65% of participant's heart rate reserve.
89638926|NCT03928431|Active Comparator|CS intervention|"A piece of gauze soaked with saline (0.9%) will be placed in the birth canal 2 hours before the CS by the study midwife, using sterile glows. Before the CS procedure begins, the gauze will be removed from the vagina and then immediately contaminated by a swab carrying maternal fecal microbiota. The swab is contaminated by introducing it 3 cm into the anal canal and by rotating it for 10-20 s.~Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding."
89638927|NCT03928431|Placebo Comparator|CS placebo|See above - the gauze will be exchanged to a clean gauze (soaked with saline). Immediately after birth, the study midwife will swab the neonate with the gauze in multiple body sites by a standardized manner and then swab maternal breasts and chest skin. The neonate will then be placed on the maternal chest to initiate breast-feeding.
89638928|NCT03925727|Experimental|1% Tavilermide ophthalmic solution|
89638929|NCT03925727|Experimental|5% Tavilermide ophthalmic solution|
89638930|NCT03925727|Placebo Comparator|Vehicle ophthalmic solution|
89638931|NCT03899922||Uveitis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of uveitis of patient treated by a drug, with a chronology compatible with the drug toxicity
89638932|NCT03858686|Active Comparator|400 mg FP-025 capsules|Based on a double-blind randomized schedule, 16 subjects will receive FP-025 capsules in Period 1 and matching placebo FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
89638933|NCT03858686|Placebo Comparator|FP-025 Placebo Capsules|Based on a double-blind randomized schedule, 16 subjects will receive matching placebo FP-025 capsules in Period 1 and FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
89638934|NCT03856671|Experimental|oral antibiotics+mechanical bowel preparation|Liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. A combination of neomycin 1g and metronidazole 0.2g every 6 hours was also administrated. Enteroclysis was conduted for patients on surgical morning.
89638935|NCT03856671|No Intervention|simple mechanical bowel preparation|Only liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. Enteroclysis was conduted for patients on surgical morning.
89638936|NCT03855982||myocarditis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity
89638937|NCT03840343|Experimental|Lower Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.
89638938|NCT03840343|Experimental|Higher Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose
89638939|NCT03833297||Hepatological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hepatological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
89638940|NCT03792061|Experimental|Strategy Training|Strategy training is an activity intervention training approach developed based on the theoretical tenets of metacognitive training. The purpose of strategy training is to guide individuals to generate problem-solving skills to address challenges that they identify in daily activities.
89638941|NCT03792061|No Intervention|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
89638942|NCT03786354|Experimental|Arm A (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy over 5 weeks.
89638943|NCT03786354|Experimental|Arm B (3DCRT)|Patients undergo 3-Dimensional Conformal Radiation Therapy over 5 weeks.
89042489|NCT05365477|Active Comparator|Empiric Therapy|Diet intervention and drug intervention not based on 24 hour urine results
89638944|NCT03743532|Experimental|E-Ciagrette|Participants will be asked to completely switch from cigarettes to e-cigarettes. They will receive an e-cigarette device and pods during the first 4 weeks following a scheduled switch date.
89638945|NCT03743532|Experimental|Financial Incentives + E-cigarette|Participants will be asked to completely switch from cigarettes to e-cigarettes, and they will receive an e-cigarette device and pods during the first 4 weeks following a scheduled switch date. Participants will also receive weekly financial incentives for biochemically-verified cigarette abstinence during the first 4 weeks following the switch date.
89638946|NCT03714503|Other|One day post-operative head positioning|patients will be assigned to remain a one-day post operative head positioning following retina re-attachment surgery
89042490|NCT05365477|Experimental|Selective Therapy|Diet intervention and drug intervention based on 24 hour urine results
89042491|NCT05361668|Experimental|40 mg Paltusotine|
89042492|NCT05361668|Experimental|80 mg Paltusotine|
89042493|NCT05354102|Experimental|BMC128 in combination with Nivolumab|"Four 28-day treatment cycles of the standard Nivolumab treatment protocol (480 mg on Day 1 of each cycle) together with a QD regimen of BMC128, followed by a Iong-term Nivolumab monotherapy.~Prior to starting this combination treatment, patients will undergo:~I. Native microbiota depletion stage - patients will be treated with oral Vancomycin 500mg in combination with Neomycin 1000mg, q6h for 72 hours.~II. BMC128 monotherapy induction stage - One BMC128 capsule will be administered once daily QD for a period of 14 days."
89042494|NCT05351489|Experimental|Dexmedetomidine 5 μg group (D5 group )|Dexmedetomidine 5 μg group (D5 group ): Patients will receive 2 mL heavy bupivacaine 0.5% and Dexmedetomidine 5 μg intrathecal.
89638947|NCT03696524|Experimental|Intervention Group|This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
89638948|NCT03696524|No Intervention|Usual Care|The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
89638949|NCT03662685|Active Comparator|Goeckerman Therapy|Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.
89638950|NCT03662685|Active Comparator|Phototherapy Only|Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.
89042495|NCT05351489|Active Comparator|Dexmedetomidine 10 μg group (D10 group )|dexmedetomidine 10 μg group (D10 group ): Patients will receive 2 mL heavy bupivacaine 0.5% and Dexmedetomidine 10 μg intrathecal .
89042496|NCT05348694|Active Comparator|Pendulum WBF-038|Pendulum WBF-038, a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
89042497|NCT05348694|Placebo Comparator|Pendulum Placebo|Pendulum Placebo containing Magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
89042498|NCT05342974|Experimental|Experimental: Atorvastatin followed by misoprostol|Oral dose of atorvastatin (80 mg) to be taken daily for seven days followed by misoprostol (800 mcg) on day 8. A second dose of misoprostol will occur 24 hours after the first dose if no significant bleeding (more than a regular period) has occurred.
89042499|NCT05338320|Active Comparator|General anesthesia and Ultrasound Guided Erector Spinae Plane Block|
89638951|NCT03662685|Active Comparator|Crude Coal Tar Only|Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.
89638952|NCT03651765|Experimental|Setmelanotide|Once daily subcutaneous injection
89638953|NCT03545906|Experimental|TEAM-UP Intervention Group|
89638954|NCT03545906|Active Comparator|Enhanced Care Comparison Group|
89638955|NCT03497780||ACL Tear|Patients with ACL tears
89638956|NCT03497780||Healthy Subjects|Healthy subjects
89042500|NCT05338320|Active Comparator|General anesthesia and intrathecal morphine|
89042501|NCT05338320|Other|General anesthesia using intravenous fentanyl (1µg/kg)|
89042502|NCT05335629|Active Comparator|Intervention arm|"30 patients will receive standard of care in addition to the SGLT2 Dapagliflozin 10 mg daily for 4 Weeks~Interventions:~Drug: Dapagliflozin 10 mg oral tablets Standard of care: Dual antiplatelet therapy, Statin, anticoagulation therapy"
89042503|NCT05335629|No Intervention|Control arm|30 patients will receive standard of care (Dual antiplatelet therapy, Statin, anticoagulation therapy) for 4 weeks
89042504|NCT05333289|Experimental|mRNA-1030 Dose Level A|Participants will receive mRNA-1030 at Dose Level A by intramuscular (IM) injection on Day 1.
89042505|NCT05333289|Experimental|mRNA-1020 Dose Level A|Participants will receive mRNA-1020 at Dose Level A by IM injection on Day 1.
89042506|NCT05333289|Experimental|mRNA-1030 Dose Level B|Participants will receive mRNA-1030 at Dose Level B by IM injection on Day 1.
89638957|NCT03468608||Phase 1: Instrument Development|An initial set of questionnaire items will be created based on the questionnaires noted in the literature review as well as the semi-structured interviews conducted with parents and healthcare team members in our facility.
89638958|NCT03468608||Phase 2: Pre-Test Evaluation|Parents and healthcare team members will be asked to comment on the quality of the draft questionnaire created in phase 1 of this study.
89638959|NCT03468608||Phase 3: Pilot|"Parents will be asked to complete the questionnaire developed during phase 2 of this study. Upon completing the questionnaire, parents will be asked to rate the overall face validity of the tool using a 5-point Likert scale.~Healthcare team members will be asked to rate the content validity of each item on the questionnaire."
89638960|NCT03468608||Phase 4: Validation|Parents will be asked to complete the questionnaire developed during phase 3 of this study.
89638961|NCT03461835|Active Comparator|M4|High risk classification if the chance of the PUL being an EP ≥5 %; a calculation based on the average value of the two hCG and the ratio of these two hCG (0 h/48 h). Otherwise a low risk classification is made and a predicted outcome of either an IUP or failed PUL is presented.
89638962|NCT03461835|Active Comparator|NICE|High risk classification if the change in rising hCG levels ≤ 63 % or the change in declining hCG ≤ 50 %. If these cut-offs are exceeded the PUL is classified as low risk and predicted to be either an IUP or failed PUL depending on rising or declining hCG levels.
89638963|NCT03461666|Active Comparator|Cognitive Behavior Therapy-Insomnia|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
89638964|NCT03461666|Active Comparator|Focus Of Attention|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
89638965|NCT03461666|Active Comparator|Combined-CBT-I and FOA Group|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
89638966|NCT03461666|Active Comparator|Sleep Hygiene|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
89638967|NCT03391934|Experimental|Cetuximab+ FOLFIRI|Cetuximab (Produced by CinnaGen Co.): 400 mg/m2 weekly in the first dose and 250 mg/m2 in the next doses Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
89638968|NCT03391934|Active Comparator|Cetuximab + FOLFIRI|Erbitux® (Produced by Merk Co.): 400 mg/m2 weekly Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
89638969|NCT03387150|Experimental|Group 1: VRC07-523LS|Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
89042507|NCT05333289|Experimental|mRNA-1020 Dose Level B|Participants will receive mRNA-1020 at Dose Level B by IM injection on Day 1.
89042508|NCT05333289|Experimental|mRNA-1030 Dose Level C|Participants will receive mRNA-1030 at Dose Level C by IM injection on Day 1.
89638970|NCT03387150|Experimental|Group 2: VRC07-523LS|Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
89638971|NCT03387150|Experimental|Group 3: VRC07-523LS|Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
89638972|NCT03387150|Experimental|Group 4: VRC07-523LS|Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
89638973|NCT03387150|Experimental|Group 5: VRC07-523LS|Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
89638974|NCT03387150|Experimental|Group T6 VRC07-523LS|Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
89638975|NCT03387150|Placebo Comparator|Group P6: Placebo|Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
89638976|NCT03325322|Experimental|Treatment|Fisetin 20 mg/kg/day, orally for 2 consecutive days
89638977|NCT03325322|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
89638978|NCT03289234|Experimental|mild hepatic impairment|
89638979|NCT03289234|Experimental|moderate hepatic impairment|
89638980|NCT03289234|Experimental|normal hepatic function|
89638981|NCT03289208|Experimental|mild renal impairment|
89638982|NCT03289208|Experimental|moderated renal impairment|
89638983|NCT03289208|Experimental|normal renal function|
89638984|NCT03281343|Experimental|MI-NAV|A study therapist will deliver a motivational interviewing session with participants while they are incarcerated and serve as a role of patient navigator post-release.
89638985|NCT03281343|Active Comparator|Standard of Care (SOC)|Approximates care currently provided at the prison.
89638986|NCT03276351|Active Comparator|Long-Stemmed with Hybrid Fixation|Participants will receive the Long-Stemmed revision implant with Hybrid Fixation during their surgery.
89638987|NCT03276351|Experimental|Short-Stemmed with Augmented Fixation|Participants will receive the Short-Stemmed primary implant with Augmented Fixation during their surgery.
89638988|NCT03244059|Experimental|Belimumab|"Subjects randomized to the experimental treatment arm will receive i.v. administrations of belimumab (10 mg/kg), consisting of three loading doses, two weeks apart, followed by five (5) more monthly infusions. The final assessment will be performed at month 8."
89638989|NCT03244059|Placebo Comparator|Placebo|"These subjects will be treated with identically appearing placebo i.v. on the same schedule as the experimental arm subjects (i.e., three loading doses, two weeks apart, followed by five more monthly infusions. Again, the final assessment will be performed at month 7 (210+10 days after treatment start)."
89638990|NCT03155854|Active Comparator|Pretendinous cord excision|Patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be excised
89638991|NCT03155854|Active Comparator|Division/manipulation of the cord|patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be incised.
89638992|NCT03036566|Experimental|Bridge|Three unit high strength ceramic (lithium disilicate/emaxCAD by Ivoclar) bridges replacing a single tooth.
89638993|NCT03010228|Active Comparator|VLA15 12 µg with Alum|VLA15 12 µg (microgram) with Alum has an injection volume of 100 µl (microliter). The amount of Alum per injection is 0.05 mg (milligram).
89638994|NCT03010228|Active Comparator|VLA15 12 µg w/o Alum|VLA15 12 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 100 µl (microliter).
89638995|NCT03010228|Active Comparator|VLA15 48 µg with Alum|VLA15 48 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter). The amount of Alum per injection is 0.2 mg (milligram).
89638996|NCT03010228|Active Comparator|VLA15 48 µg w/o Alum|VLA15 48 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter).
89638997|NCT03010228|Active Comparator|VLA15 90 µg with Alum|VLA15 90 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter). The amount of Alum per injection is 0.375 mg (milligram).
89638998|NCT03010228|Active Comparator|VLA15 90 µg w/o Alum|VLA15 90 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter).
89638999|NCT02927249|Experimental|Arm I (aspirin)|Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity.
89639000|NCT02927249|Placebo Comparator|Arm II (Placebo)|Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity.
89639001|NCT02890368|Experimental|TTI-621 Monotherapy Escalation|TTI-621 Escalation phase of single or multiple doses of TTI-621 delivered by intratumoral injections (various dose cohorts).
89639002|NCT02890368|Experimental|TTI-621 Monotherapy (Single Lesion)|TTI-621 Single Lesion Injection Expansion Cohort
89639003|NCT02890368|Experimental|TTI-621 Monotherapy (Multiple Lesions)|TTI-621 Multiple Lesion Injections Expansion Cohort
89639004|NCT02890368|Experimental|TTI-621 + PD-1/PD-L1 Inhibitor|Combination Therapy Expansion Cohort of TTI-621 plus PD-1/PD-L1 Inhibitor
89639005|NCT02890368|Experimental|TTI-621 + Pegylated Interferon-α2a|Combination Therapy Expansion Cohort of TTI-621 plus Pegylated Interferon-α2a
89639006|NCT02890368|Experimental|TTI-621 + T-Vec|Combination Therapy Expansion Cohort of TTI-621 plus T-Vec
89639007|NCT02890368|Experimental|TTI-621 + Radiation|Combination Therapy Expansion Cohort of TTI-621 plus Radiation Therapy
89639008|NCT02804828|Active Comparator|Arm 1|
89639009|NCT02804828|Sham Comparator|Arm 2|
89639010|NCT02754141|Experimental|Arm A-Monotherapy|BMS-986179, dose as specified
89042509|NCT05333289|Experimental|mRNA-1020 Dose Level C|Participants will receive mRNA-1020 at Dose Level C by IM injection on Day 1.
89639011|NCT02754141|Experimental|Arm B- Combination Therapy|BMS-986179 + nivolumab, dose as specified
89639012|NCT02754141|Experimental|Arm C-Combination Therapy|BMS-986179 + rHuPH20, dose as specified
89639013|NCT02659059|Experimental|Nivolumab+Ipilimumab|"Part 1~Specified Dose on Specified Days"
89639014|NCT02659059|Experimental|Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy|"Part 2~Specified Dose on Specified Days"
89639015|NCT02572427|Experimental|Education for intubation skills|Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
89639016|NCT02572427|Active Comparator|No added education for intubation skills|Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.
89639017|NCT02285530|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin:75 mg/m2 5-Fu:750 mg/m2/day"
89639018|NCT02285530|Other|surgery group|Radical resection of the primary lesion and full neck,radiotherapy was arranged 4 to 6 weeks after surgery
89639019|NCT02208388|Experimental|Computed tomography perfusion|Patients with Computed tomography perfusion
89639020|NCT02208388|Active Comparator|Fractional flow reserve|Patients with Fractional flow reserve
89639021|NCT02186470|Experimental|Treatment (image-guided intensity-modulated APBI)|Patients undergo image-guided intensity-modulated APBI twice daily (BID) in the prone position over a period of 5-10 days for a total of 10 treatment. Within 4-6 weeks post-APBI, patients undergo lumpectomy.
89639022|NCT02146950||LCS12|New users of LCS12
89639023|NCT02146950||Mirena|New users of Mirena
89042510|NCT05333289|Active Comparator|mRNA-1010|Participants will receive mRNA-1010 by IM injection on Day 1.
89042511|NCT05333289|Active Comparator|Active Comparator|Participants will receive an active comparator by IM injection on Day 1.
89042512|NCT05323396|Active Comparator|Parasite-positive arm|Participants will be evaluated for intestinal parasitic infection by stool microscopy, stool PCR and Strongyloides IgG from plasma. If positive by either of these, the participant will be treated for the detected parasitic infection. The biomarker levels of this parasite-positive group will be compared to the parasite-negative group. Additionally the parasite-positive pre-treatment biomarker levels will be compared to the parasite-positive post-treatment levels.
89042513|NCT05323396|No Intervention|Parasite-negative arm|"Participants will be evaluated for intestinal parasitic infection by stool microscopy, stool PCR and Strongyloides IgG from plasma. If negative by all of these tests on the initial sample collection, the participants will not receive treatment and will be in the parasite-negative/no intervention arm."
89042514|NCT05322993|Active Comparator|With artificial intelligence (AI)|Use of GI Genius artificial intelligence device during colonoscopy.
89042515|NCT05322993|Active Comparator|Without artificial intelligence|Use of standard colonoscopy equipment without GI Genius.
89042516|NCT05317234|Experimental|children with cerebral palsy|Patients between 2 and 15 years old, born after 34 weeks' gestation, with a diagnosis of cerebral palsy.
89057607|NCT04537676||DFU Participants|A cohort of 200 DFU patients who have been prescribed the Podimetrics System by their healthcare providers will be recruited upon providing informed consent. Potential participants will be asked to indicate their interest in participating in this patient empowerment study during their initial phone consultation for mat set-up with the Podimetrics care-management team. Participants will be followed for one year and answer a set of identical questionnaires at three time points: at baseline, at 6-month and at 12-month post enrollment.
89057608|NCT01649505|Experimental|Arm I (fibrin sealant)|Patients undergo sharp dissection technique with fibrin sealant closure.
89639024|NCT02146950||Copper IUD|New users of copper IUDs
89639025|NCT02146950||Kyleena|New users of Kyleena
89639026|NCT02146950||Other hormonal IUD (OHIUD)|New users of other hormonal IUDs (e.g. Levosert, Fibroplant)
89639027|NCT01907412|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
89639028|NCT01907412|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
89639029|NCT01788657|Experimental|Standard internet-based cognitive behavior therapy|Standard internet-based cognitive behavior therapy for depression with a written treatment material consisting of 60000 words (textmaterial only).
89639030|NCT01788657|Experimental|Condensed internet-based cognitive behavior therapy|Condensed internet-based cognitive behavior therapy for depression with a written treatment material consisting of 30000 words (available as text or audio).
89639031|NCT01722890||Cohort 1|TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.
89639032|NCT01722890||Cohort 2(Control Group)|TNM stage II-IV breast cancer patients with trastuzumab-refractory disease.
89639033|NCT01422421|Active Comparator|intensive control|systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl
89639034|NCT01422421|Active Comparator|standard control|systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
89639035|NCT01171573||Myositis Patients|Cases with myositis PM DM IBM Venepuncture
89639036|NCT01171573||Healthy controls|Control
89639037|NCT01164891|Experimental|Single Arm|
89639038|NCT00178932|Active Comparator|1 Outcome in schizophrenia with certain antipsychotic|clozapine
89639039|NCT00178932|Active Comparator|2 Outcome in schizophrenia with other Antipsychotics|Other Antipsychotics
89639040|NCT02375412||Pre-operative HRV group|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery.
89639041|NCT02375568||103024-F|For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation.
89639042|NCT02368392||Cardiac Arrest|Those who get in-hospital cardiac arrests
89639043|NCT02368392||Non Cardiac Arrest|Those who do not get in-hospital cardiac arrest
89639044|NCT02368626|Experimental|RF ablation treatment|'EndyMed Pro™ RF Micro-Needles' - RF ablation treatments for wrinkle appearance reduction
89639045|NCT02375256|Experimental|AERAS-402|3 x10^10 viral particles per 0.5 mL suspended in 10 mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL.
89639046|NCT02375256|Active Comparator|Placebo|1.0 mL sterile vaccine buffer containing 10mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL
89639047|NCT02375334||Observational (medical chart review)|Patient lab and visit dates are monitored by the Cancer Center ORIS and EPIC based systems during the 42 days of the concurrent temozolomide and radiation therapy.
89639048|NCT04439448||HIV+ non-obese|HIV+ adults on antiretroviral therapy with a body mass index <30 kg/m2
89639049|NCT04439448||HIV+ obese|HIV+ adults on antiretroviral therapy with a body mass index >=30 kg/m2
89639050|NCT04439448||HIV-negative obese|HIV-negative adults on antiretroviral therapy with a body mass index >=30 kg/m2
89639051|NCT02368080||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
89639052|NCT02368080||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
89639053|NCT02375178|Active Comparator|Sterile saline solution|sterile Saline solution 0,9%
89042517|NCT05312398|Experimental|single arm|"This is an open-label phase II study investigating the efficacy and safety of a bio-marker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line. Based on dynamic and longitudinal liquid biopsy assessment of RAS/BRAF status, that will be prospectively performed before each line of treatment, mCRC patients will be treated with cetuximab in combination with chemotherapy throughout three lines of therapy, as follows:~FOLFIRI plus cetuximab (first line);~FOLFOX plus cetuximab (second line);~irinotecan plus cetuximab (third line).~If at progression after the first line or after the second line, the liquid biopsy assessment indicates RAS and or BRAF mutant status, patients will be treated with FOLFOX plus bevacizumab as second line of therapy, or with regorafenib or with trifluridine-tipiracil (investigator's choice) as third line therapy."
89042518|NCT05306353|Placebo Comparator|VIB4920 Placebo with TNFi|Participants will receive VIB4920 placebo in a blinded fashion intravenously at weeks 0, 2, 4, 8, and 12 and continue all background disease-modifying RA therapy, including the TNFi, through the study period VIB4920 placebo consists of 0.9% normal saline in 250mL bags.
89042519|NCT05306353|Experimental|VIB4920 with TNFi|Participants will receive VIB4920 in a blinded fashion intravenously at a dose of 1500 mg at weeks 0, 2, 4, 8, and 12 and continue all background disease-modifying RA therapy, including the TNFi, through the study period
89639054|NCT02375178|Experimental|chlorhexidine|chlorhexidine 0,12% mouthwash
89639055|NCT02375178|Experimental|polyhexamethylene|polyhexamethylene biguanide 0,07% mouthwash
89639056|NCT02368236|Other|Intervention Group|Patients randomized to the intervention group will use CRIS. Then intervention group patients and their physicians will receive a tailored printout generated by the CRIS recommending risk-appropriate colorectal testing and ways to overcome perceived barriers to testing. A member of the research team will hand the patient a printout and will deliver the other printout to the physician.
89639057|NCT02368236|No Intervention|Comparison Group|Patients randomized to the comparison group will use CRIS, but receive a non-tailored standard information about multiple types of cancer screening (e.g., content from an American Cancer Society cancer screening brochure) while physicians receive standard electronic chart prompts indicating the patients were age-eligible but not currently adherent for colorectal cancer screening.
89639058|NCT02368236|No Intervention|True No-contact Control Group|A screening baseline for the true no-contact group will be established by conducting a retrospective chart review for patients who did not receive an invitation to participate in this study. The same randomization procedure will be used as the comparison and intervention groups. The purpose is to conduct analysis with the comparison and intervention group to see if individuals who participate in CRIS have a higher screening rate for colorectal cancer compared to the non-contact group.
89639059|NCT02364648|Experimental|MitoQ|4 week 20mg oral daily dose of MitoQ
89639060|NCT02364648|Placebo Comparator|Placebo|4 week 20mg oral daily placebo
89639061|NCT02375100|Active Comparator|Intrathecal bupivacaine&analgesics|Patients will be given standard care during perioperative period. They will undergo inguinal herniorraphy operation under spinal anesthesia (with 3ml of %0.5 hyperbaric bupivacaine intrathecally) and receive an parenteral pain regimen (acetaminophen for intravenous infusion in two doses routinely and intramuscular tramadol 50 mg when pain score is higher than 4) in postoperative period.
89639062|NCT02375100|Experimental|TAP Block with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive transversus abdominis plane block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
89639063|NCT02375100|Experimental|IlNB with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive Ilioinguinal nerve block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
89639064|NCT03105492||Pregnant women|Women who are pregnant
89639065|NCT02364414|Other|Cohort|Orthodontic patients, aged 11-18 who fulfill the inclusion/exclusion criteria and provide written informed consent to participate will undergo intra-oral scan. This will be repeated 2 weeks later.
89639066|NCT02364258|Experimental|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
89639067|NCT02364258|Experimental|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
89639068|NCT02368158|Experimental|Cardiologic Patient|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
89639069|NCT02368158|Experimental|Control Proband|"The same intervention as in arm cardiologic patients :Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors"
89042520|NCT05306353|Experimental|VIB4920 without TNFi|Participants will stop TNFi after randomization to this arm, and receive VIB4920 in an evaluator-blinded fashion intravenously at a dose of 1500 mg at weeks 0, 2, 4, 8, and 12 while maintaining all other background disease-modifying RA therapy (e.g., methotrexate, hydroxychloroquine, etc.) through the study period. This arm is evaluator blinded (not aware of treatment status), with the participant aware of treatment status but evaluator is not, due to not using a TNFi placebo for this study
89057609|NCT01649505|Active Comparator|Arm II (standard electrocoagulation)|Patients undergo standard electrocoagulation dissection technique.
89057610|NCT02279784|Experimental|Freeway|angioplasty with Freeway drug-eluting balloon
89639070|NCT02375022|Experimental|Endostar and icotinib|Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
89639071|NCT04439058|Active Comparator|Bupivacaine+lignocaine|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with10 ml of bupivacaine 0,25%+ 5ml lignocaine 1%(20 patients).~Under complete aseptic precautions an ultrasound guided left stellate ganglion block (paratracheal technique ) The patient placed in the supine position with the head in the neutral position and slightly extended.~The US probe placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia anterior to the C6 vertebral body and deep to the carotid artery. skin infiltration with local anesthetic, the needle inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
89042521|NCT05292651|Experimental|PSP technique|"The definitions of the PSP technique are:~Predilatation is mandatory with a balloon diameter equal to or maximally 0.5 mm less than the distal reference vessel diameter. We hypothesize that this lesion preparation and fracture of the calcium may result in better stent apposition, less recoil and higher minimal stent area (MSA) Also see endpoints.~The DES should be deployed at 2 atm. above the nominal pressure. This relatively low stent deployment pressure may prevent stent edge dissections.~The postdilatation is mandatory with a shorter length and (at least 0.25mm) larger diameter non-compliant balloon at 16 atm. The apposition, minimal stent area (MSA) and recoil may improve with this large, high pressure postdilatation. The slightly shorter balloon can prevent edge dissections."
89042522|NCT05292651|Active Comparator|Direct Stenting|• The DES is directly placed without any lesion preparation and deployed at a pressure at the discretion of the operator. Ideally a pressure would be achieved in which angiographic expansion of the DES is complete (without significant dog-boning)
89042523|NCT05291156|Experimental|Cetuximab + avelumab|"Cetuximab + avelumab (115 patients) - cetuximab at 400 mg/m2, as loading dose, and, subsequently, at 250 mg/m2 weekly, and avelumab was given intravenously at flat dose of 800 mg, once every 2 weeks.~Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST 1.1 if the subject's performance status has remained stable, and if in the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outlined in the protocol."
89042524|NCT05291156|Active Comparator|Cetuximab|Cetuximab only (58 patients) - cetuximab at 400 mg/m2 intravenously, as loading dose, and, subsequently, at 250 mg/m2 weekly. Treatment will continue until disease progression, significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled. Treatment may continue past the initial determination of disease progression per RECIST 1.1 if the subject's performance status has remained stable, and if in the opinion of the Investigator, the subject will benefit from continued treatment and if other criteria are fulfilled as outlined in the protocol.
89639072|NCT04439058|Other|Normal saline|"will receive ultrasound guided left stellate ganglion block just after induction of anesthesia with 15 ml of normal saline (20 patients).~US machine Mindray M5 (Shenzhen Mindray Bio-Medical Electronics Co., LTD. Shenzhen, China.) with a linear 38-mm high frequency 10-12 MHz transducer), with an imaging depth of 4 cm. A 50-mm short bevel 22-gauge insulated stimulating needle (PAJUNK® GmbH Medizin technologie, Deutschland"
89639073|NCT02374710|Experimental|ACL Reconstruction: Anterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed anterior (in front) of the 35% line.
89639074|NCT02374710|Active Comparator|ACL Reconstruction: Posterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed posterior (in back) of the 35% line.
89639075|NCT02364024||Arm A|Patients with no or low immune response (score 1 or 2) with linear quantification of CD3+ cells
89639076|NCT02364024||Arm B|Patients with high immune response (score 3 or 4) with linear quantification of CD3+ cells
89639077|NCT02367612|Experimental|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
89639078|NCT02367612|Placebo Comparator|Placebo|Placebo
89639079|NCT02367534|Experimental|Umbilical vein|umbilical vein catheterization
89639080|NCT01497899|Experimental|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks
89639081|NCT01497899|Active Comparator|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks
89639082|NCT01497899|Experimental|E/C/F/TAF Open-Label|"Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase.~Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase."
89639083|NCT02374866|No Intervention|Conventional monitoring|The control group will follow the current center: every four months for a year, combined with monitoring by email or regular mail during the year.
89639084|NCT02374866|Experimental|Closer monitoring|"The experimental group will follow a closer monitoring than the control group : every two months for one year in,stead of every 4 months for a year.~Follow by email or mail is identical to the control group."
89639085|NCT02363868||CML subjects receiving Dasatinib|CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs
89639086|NCT02363868||CML subjects receiving Nilotinib|CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs
89639087|NCT02363712|Experimental|APOS|APOS(All Phase Of Step)-shoe
89639088|NCT02363712|Sham Comparator|Sham APOS|Sham APOS(All Phase Of Step)-shoe
89639089|NCT02374788|Experimental|Group A|Participants in the intensive intervention group (A) receive a pedometer intervention and 12 group meetings over two years' time, with the majority of meetings being held in the first 6 months. The group meetings constitutes of a 30 min walk and 60 min group consulting based on techniques for behaviour change using an interactive program with positive feed-back following their steps on a website. One occasion is taking place at a gym with instruction for a home-based strength training program. Participants receive 10 individual consultations with a diabetes specialist nurse.
89639090|NCT02374788|Experimental|Group B|Participants in the pedometer group (B) receive a pedometer intervention. Henceforth they are left to continue by they own for two years.
89042525|NCT05289648|Experimental|Preoperative Niraparib|Single arm. Following the initial assessment and endometrial biopsy the participants will receive niraparib for 28 days. After the treatment period the patients will be surgically staged. All participants will receive the standard of care.
89057611|NCT02279784|Experimental|Lutonix|angioplasty with Lutonix drug-eluting balloon
89057612|NCT02217254|Active Comparator|two 3-minute cryoablations|two 3-minute cryoablations per pulmonary vein during an atrial fibrillation ablation procedure
89639091|NCT02374788|No Intervention|Group C|The control group (C) receive diabetes care as usual except for the extra measurements included in the study. Diabetes care as usual is meeting a diabetes specialist nurse and a general practitioner once a year receiving lifestyle advice and physical activity on prescription.
89639092|NCT01497275|Experimental|Zevalin + Velcade|"Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan~Other Names:~Rituxan Velcade Zevalin~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi."
89639093|NCT02363790|Other|Bridging LVHR|"Laparoscopic ventral hernia repair without closure of central defect (bridging repair)~Upon completion of the lysis of adhesions, the margins of the hernia defect will be measured and marked. The hernia defect size will be measured with the abdomen completely desufflated and insufflated at 15 mm Hg externally (on the skin).~A coated mesh with at least four cm of overlap on all sides will be placed. Mesh will be secured with at least four but no more than eight trans-fascial sutures. Titanium tacks will be placed in a double crown technique where tacks are placed every 1 cm on the periphery and every 3 cm along the fascial edge (bridged or closed)."
89639094|NCT02363790|Other|LVHR PFC|Ventral hernia repairs in the primary fascial group will be performed similarly except prior to placement of the mesh, the defect will be closed. After the defect size is measured, the mesh will be chosen based upon the unclosed defect size and size will not be adjusted. The hernia defect will be closed as described previously 9,10 with 0-prolene transfascial sutures placed every 1-2 cm. The two caudal-most and cranial-most sutures will be placed. The abdomen will be desufflated and these sutures will be secured. The abdomen will be reinsufflated to 15 mm Hg and the defect progressively closed. Upon completion of fascial closure, the mesh will be placed in the standard fashion as describe above. The lateral overlap will be increased due to the fascial closure.
89639095|NCT01557517|Experimental|Clobetasol|Patients will rinse oral cavity with 10cc of clobetasol 0.05% for 2 minutes 3 times a day.
89639096|NCT01557517|Placebo Comparator|Placebo|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
89639097|NCT02363556|Experimental|Misoprostol Alone|Subjects enrolled into this arm of the study will receive misoprostol 400-mcg only.
89639098|NCT02363556|Experimental|Dilapan with Misoprostol|Subjects enrolled into this arm of the study will receive Dilapan with 400-mcg misoprostol.
89639099|NCT01497197|Experimental|Gonal-f®+Luveris®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 1 until required recombinant human chorionic gonadotropin (r-hCG) level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
89639100|NCT01497197|Experimental|Gonal-f® Followed by Luveris®|GONAL-f® 300 IU per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 6 until required r-hCG level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
89639101|NCT01496885||Nonhemorrhagic Ischemic Stroke|Subjects obtained within 24 to 48 hours of a nonhemorrhagic ischemic stroke
89639102|NCT01557283||Plaque psoriasis patients|Plaque psoriasis patients treated with Enbrel after the approval of the new belgian reimbursement criteria
89639103|NCT00349713|Experimental|Cohort 1: 25ug FMP2.1 / AS02A|20 subject to receive 25ug of FMP2.1 vaccine in 0.25mL of GSK Biologicals' adjuvant AS02A
89639104|NCT00349713|Experimental|Cohort 2: 50ug FMP2.1 / AS02A|20 subjects to receive 50ug of FMP2.1 vaccine in 0.5mL of GSK Biologicals' adjuvant AS02A
89639105|NCT00349713|Active Comparator|Cohorts 1 and 2: Rabies vaccine (RabAvert)|"20 subjects to receive Rabies vaccine (RabAvert). 10 subjects from Cohort 1 and 10 subjects from Cohort 2~Rabies vaccine (RabAvert): RabAvert Rabies vaccine"
89639106|NCT02374632|Other|Low EBL|"Gastric bypass operated patients with low postoperative excess body weight loss (EBL) <50%.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
89639107|NCT02374632|Other|High EBL|"Gastric bypass operated patients with high postoperative excess body weight loss (EBL) >70% matched with respect to age, gender and preoperative BMI in the LowEBL group.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
89639108|NCT03372564|Experimental|Hip Capsule Repair|Patients in the intervention group (Hip capsule repair) will undergo initial diagnostic arthroscopy of the hip. Two to three standard portals (anterolateral, mid anterior, distal antero-lateral, posterolateral) will be used during the entire procedure to assess and treat the patient. After establishing standard portals, an interportal capsulotomy is completed to allow for complete evaluation of the central compartment of the hip. In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl). Three to four simples sutures will be placed and tied using arthroscopic technique.
89639109|NCT03372564|No Intervention|No Hip Capsule Repair (Control)|Patients in the control group (no hip capsule repair) have the same portals utilized and will have the same interportal capsulotomy performed. They will have all central and peripheral compartment pathologies addressed in the same way that the study group does. At the conclusion of the case, the hip capsule will be left open and not repaired.
89639110|NCT01523743|Experimental|Compact catheter|Compact intermittent catheter
89639111|NCT01523743|Active Comparator|Standard Care|Standard Care: Coated intermittent catheter normally used by subject
89639112|NCT04091633|Active Comparator|School Mental Health Program-Conventional (cSMHP)|The teachers of schools randomized to control arm will receive training in World Health Organization (WHO) School Mental Health Program (SMHP) by mental health experts at WHO collaborating center for mental health research and training, Institute of Psychiatry. The training of teachers will consist of a mix of both didactic and interactive training methodologies in the form of a workshop. The workshop will consist of lectures/presentations, incorporating group discussions/activities. Through didactic methods, teachers will be taught basic theoretical knowledge related to mental health in schools. Training will be followed by monthly supervision meeting of teachers for 9-months.
89639113|NCT04091633|Experimental|Enhanced-School Mental Health Program (eSMHP)|The teachers of schools randomized to intervention arm will receive online training in adapted version of School Mental Health Program. The online training in adapted School Mental Health Program consists of 4-5 hour, self-paced online training course for teachers. The teachers will register themselves in the online course in the form of a group of 4-5 teachers from each school. The teachers will complete the online training course in a group, with interactive group activities and role plays. Progress to the next module in the online training is conditional upon completion of post-module mental health literacy quiz. A certificate of training completion in adapted SMHP shall be awarded to those teachers who complete the post-test. Teachers will be supported online and in-person by the trainers who are trained in SMHP in monthly supervision meeting of teachers for 9-months.
89639114|NCT02363634|Active Comparator|Magnesium threonate (Magtein)|Those randomized to receive the Magtein
89639115|NCT02363634|Placebo Comparator|Placebo|Those randomized to placebo
89639116|NCT02363244||Pap group|Per speculum examination will be done.Pap test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for pap test will be collected and send to laboratory for further evaluation.
89639117|NCT02363244||HPVDNA GROUP|Per speculum examination will be done.HPVDNA test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for HPVDNA will be collected and send to laboratory for further evaluation.
89639118|NCT02374554|Other|Respiratory Rate Measurement Comparision|To demonstrate equivalence of the Thora-3Di Structured Light Plethysmography device and a Clinician Over-scored End Tidal C02 (COSC)derived from a BCI Capnograph 9004 (Smiths Medical) for measurement of Respiratory Rate
89639119|NCT02363400|Experimental|Adjuvant Chemotherapy|MEP followed by oral Tegafur-uracil
89639120|NCT02363400|No Intervention|control arm|closely followed with frequency similar to the experiemental arm
89639121|NCT02367222||Exposed to Arepanrix™ Cohort|All individuals with Manitoba Immunization Monitoring System (MIMS) record of H1N1 (Arepanrix™) and/or seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
89639122|NCT02367222||Unexposed to Arepanrix™ Cohort|All individuals registered with Manitoba Health (MH) during the study period but with no MIMS record for H1N1 (Arepanrix™) and seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
89639123|NCT00350025|Other|Cetuximab alone|Cetuximab 250mg/m2 IV weekly during each 28 day cycle. Arm A closed to accrual June 11, 2009 for lack of efficacy
89639124|NCT00350025|Other|Cetuximab with Paclitaxel|Paclitaxel 80 mg/m2 IV weekly for every 28 day cycle. Cetuximab 250mg/m2 IV weekly for every 28 day cycle.
89639125|NCT02367378||MIS|Those who received minimally invasive surgical procedures
89639126|NCT02367378||Control|Those who received treatments which include surgical resection, chemotherapy, and radiotherapy.
89639127|NCT01496807|Experimental|Yervoy with Sylatron|Participants are given Yervoy induction every 3 weeks for four doses, for 12 weeks, and all participants simultaneously receive Sylatron induction weekly, followed by Sylatron maintenance alone for up to 144 additional weeks (total 156 weeks = 3 years).
89639128|NCT02374320|Experimental|Exparel|20 mL liposomal bupivacaine injected once
89639129|NCT02374086|Experimental|Exercise Training|Subjects will exercise for 8 weeks
89639130|NCT01496183|Placebo Comparator|Placebo|
88991326|NCT05262920|Experimental|The BSM Intervention|"Guided by the Individual and Family Self-Management Theory, the Lucas team developed the Breastfeeding and BNP Self-Management (BSM) intervention. The BSM intervention uses a cloud-based platform, links to educational modules, and daily journaling, to provide women uniform best practice knowledge and skills for BF and BNP self-management.~Strategies include guided imagery, therapeutic breathing, mindfulness, relaxation, non-pharmacological interventions that are integrated within the self-management process such as goal-setting, self-monitoring, problem-solving, and social support through texting."
88991327|NCT05262920|Active Comparator|Attention Control|Attention control participants will receive equivalent attention as the BSM group. The fourth-trimester care based on the CDC HEAR HER campaign and infant health information modules will be provided through the REDCap link.
88991328|NCT05261711|Experimental|AB1|AB1 is the investigational product in this study taken orally, once daily, for 8 weeks. This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg.
88991329|NCT05260879|Experimental|Individuals|"This arm is composed of diabetic or hypertensive men and women who participate without joint participation of their spouse. The intervention consists of exposing participants to bi-monthly educational sessions on diet and exercise. Participants will be organized in groups of 15 led by one community health worker (CHW) assisted by a diabetes peer educator (PE). The basic format for the group sessions will follow the pattern developed with the DPP program, beginning with a discussion of success stories from the past weeks before proceeding to the didactic portion of the session. The sessions will mix the didactic portions facilitated by the PE with group discussions, activities and role plays, facilitated by the CHW."
88999221|NCT03004404|Experimental|BA Part: T1/R/T2|"Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~Followed by 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~Participants were orally administered 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
89639131|NCT01496183|Experimental|Olanzapine|
89639132|NCT01495793|Experimental|Rotigotine|In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.
89639133|NCT02363166||Acute Abscess Group|Adults and pediatric patients presenting to the UFHealth Shands Emergency Department with evidence of an acute abscess, or skin/soft tissue infection, which can be sampled for culture and sensitivity testing will be recruited.
89639134|NCT02362776||breast cancer patients|
89639135|NCT02362776||lung cancer patients|
89639136|NCT02362776||control subjects|
89639137|NCT02374008|Experimental|Combined nerve block|Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone
89639138|NCT02374008|Active Comparator|Local infiltrationanalgesia|Ropivacaine, Adrenalin and Ketorolac combined with systemic high dose dexamethasone
89639139|NCT04505280|Experimental|Active|%1 lidocaine injections to greater occipital nerve and cervical region once a week for 4 weeks
89639140|NCT02366988|Active Comparator|Endoscopic Biliary Stenting|Temporary self-expandable metallic covered stent
89639141|NCT02366988|Active Comparator|Surgical treatment|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
89639142|NCT02366832|Experimental|Cryoablation|Amputee subjects experiencing phantom limb syndrome (PLS) will receive cryoablation
89639143|NCT02366754|Experimental|Active rTMS|The intervention consists of 30 active rTMS sessions. Each session is comprised of 300 trains of paired pulses with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Pulse intensity will be set at 110% of each participant's motor threshold. Active rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left dorsolateral prefrontal cortex. Two Magstim-2002 units and a Bistim2 module will be used to administer active rTMS. Participants assigned to the active rTMS group will receive a total of 1.8 seconds of stimulation. Active rTMS will be administered 2 times daily with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
89639144|NCT02366754|Sham Comparator|Placebo rTMS|The intervention consists of 30 placebo rTMS sessions. Each session is comprised of 300 paired-pulse trains with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Placebo rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left DLPFC. Two Magstim-2002 units and a Bistim2 module will be used to administer placebo rTMS. The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. Participants assigned to the placebo rTMS group will receive 0 seconds of stimulation. Placebo rTMS will be administered with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
89639145|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 1|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
89639146|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 2|Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
89639147|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 3|Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
89639148|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 4|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
89639149|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 5|Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
89042526|NCT05274776|No Intervention|NVK Guidelines|The NVK guidelines use 8 maternal and 15 neonatal risk factors, each categorized as either red flag or non-red flag. These criteria guide clinicians on the management in case of suspected EOS. Briefly, antibiotic treatment is recommended if at least one red flag and, or, two or more non-red flags are present. An observation period of at least 12 hours is recommended if one non-red flag is present. Antibiotics are recommended when an infection is suspected during this observation. Newborns without EOS risk factors, with a good clinical condition, and a gestational age of more than 36 weeks will be discharged. If the guidelines recommend an observation period, the newborn with a good clinical condition is discharged after repeating physical examination. In case antibiotic treatment is started, discharge depends on the duration of treatment and the clinical course. At discharge, parents are instructed to call the hospital in case of signs of infection within the first 14 days of life.
89057613|NCT02217254|Active Comparator|One 3-minute cryoablation|One 3-minute cryoablation per pulmonary vein during an atrial fibrillation ablation procedure
89057614|NCT01178086||Participants With CLL|Participants with CLL who are being treated with intravenous (IV) rituximab in combination with chemotherapy, will be observed for 24 months including 6-month treatment period.
89057615|NCT04531865|Experimental|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
89057616|NCT04531865|Placebo Comparator|Rituximab Only|First course Course Rituximab at Randomization. Addition of Maintenance Placebo tablets matching Mycophenolate mofetil from 4 Month onwards.
89639150|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 6|Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
89639151|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 1|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639152|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 2|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639153|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 3|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639154|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 4|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639155|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 5|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639156|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 6|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639157|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 7|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639158|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 8|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639159|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 9|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
89639160|NCT03112746|Experimental|Cognitive Orientation to daily Occupational Performance|One group was submitted to the CO-OP approach to learn cognitive strategies to perform the chosen tasks.
89057617|NCT01683981|Experimental|L-Citrulline, Exercise Capacity|L-Citrulline malate, 1gr, oral, divided 3 times a day,for 2 weeks
89057618|NCT01177969|Experimental|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
89057619|NCT01177969|Placebo Comparator|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
89057620|NCT01643070|Active Comparator|XELOX RT|Concurrent XELOX-RT
89057621|NCT01643070|Active Comparator|Induction XELOX|Induction XELOX followed by XELOX-RT
89057622|NCT02216006|Active Comparator|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner."
89057623|NCT02216006|Active Comparator|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation the effect of preoxygenation is eliminated with an anti-preoxygenation maneuver."
89057624|NCT01688505||Visit-to-visit BP variability|The highest, intermediate, and the lowest visit-to-visit BP variability (Tertile grouping)
89057625|NCT04532021||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
89057626|NCT04532021||control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
89057627|NCT04531787||Vaccine, Pre-transplant|cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
89057628|NCT04531787||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
89057629|NCT04531787||Vaccine, Healthy Controls|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
89057630|NCT05140707|Experimental|Intervention|For the patients in this group, a virtual reality device was provided to the patients and patients wear it during the port catheter implantation and after the port catheter implantation when they felt pain.
89057631|NCT05140707|No Intervention|Control|For the patients in this group, there wasn't any specific intervention during or after the port catheter implantation.
89057632|NCT01684059||Single group|Single group: each participant receive same intervention (zinc sulfate) throughout study (non-randomized)
89042527|NCT05274776|Experimental|EOS Calculator|Using the EOS calculator application between 0-24 hours after birth, maternal EOS risk factors combined with the physical examination of the newborn are used to assign a risk category and accompanying clinical recommendation based on estimated EOS incidence for each newborn at-risk for an infection. The EOS calculator results are used to guide clinical management on performing either a diagnostic work-up and start of antibiotics for (suspected) EOS, or a conservative approach with routine controls of vital parameters every 3 hours. In case of routine controls, re-evaluation of physical appearance by a pediatric resident or pediatrician will take place within 24 hours postpartum. Newborns will be observed for at least 24 hours. In case antibiotics are started, the need for further treatment is depending on blood culture results, infection parameters, and clinical condition of the newborn. Discontinuation of antibiotics and discharge is at the discretion of the treating physician.
89042528|NCT05266937|Experimental|Single Arm|Single-arm study with the primary objective of providing preliminary evidence on the efficacy of atezolizumab plus carboplatin plus nab-paclitaxel as first-line therapy in metastatic triple-negative PD-L1 positive breast cancer patients as evaluated by % 2years OS.
89639161|NCT02366676|Experimental|treatment group|-Intervention: combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IALURIL®) ( 1st month: once a week, 2nd~5th month:once a month)
89639162|NCT03003780|Experimental|Mindful Steps|Web-based behavioral intervention
89639163|NCT03003780|No Intervention|Usual Care|
89639164|NCT03112668|Experimental|Supportive Care (ACT)|Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session.
89639165|NCT02373384|Experimental|Study group|"Eligible patients, who fulfilled the study criteria, will be instructed For;~Oral alkalinization~Potassium citrate 20 mEq three times daily~Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females), will receive Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.~Life style modification Adequate fluid intake in order to maintain urine volume between 2-3 L per day.~Dietary recommendations~In hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) ;~- Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables."
89639166|NCT01494467|Experimental|CD5024|CD5024 1% Cream
89639167|NCT01494467|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
89639168|NCT02362698|Experimental|electro-acupuncture|Receiving electro-acupuncture treatment once every other day, half an hour per treatment, 10 times as one treatment course, subjects received 2 courses of treatment.
89639169|NCT02362698|Active Comparator|psychological intervention|Receiving cognitive behavioral therapy once every four days, each time two hours. Five times intervention as one treatment course, subjects received 2 courses of treatment.
89639170|NCT02363088|No Intervention|No intervention, 24-29 years|No intervention, group 24-29 years. Women will receive the written invitation to screening only
89639171|NCT02363088|Experimental|Messenger text message reminder, 24-29|Messenger text message reminder, group 24-29 years.
89639172|NCT02363088|No Intervention|No intervention, 30-64 years|No intervention group 30-64 years, Women will receive the written invitation to screening only
89639173|NCT02363088|Experimental|Neutral text message reminder, 30-64|Neutral Text message, group 30-64 years
89639174|NCT02363088|Experimental|Messenger text message reminder, 30-64|Messenger text message reminder, group 30-64
89639175|NCT02363088|Experimental|Social Norms A reminder, 30-64|Social Norms (population proportion) text message reminder, group 30-64 years
89639176|NCT02363088|Experimental|Social Norms B reminder, 30-64|Social Norms (population total) text message reminder, group 30-64 years
89639177|NCT02363088|Other|Framed gain text reminder, 30-64|Framed gain text message reminder, group 30-64 years
89639178|NCT02363088|Experimental|Framed loss text reminder, 30-64|Framed loss text message reminder, group 30-64 years
89639179|NCT02362620||Docetaxel|Docetaxel 75mg/m2 IV every 3 weeks
89639180|NCT02362620||Cabazitaxel|Cabazitaxel 20-25mg/m2 IV every 3 weeks
89639181|NCT02366364|Placebo Comparator|Drug: Placebo|Single oral administration on Day 1
89639182|NCT02366364|Experimental|Drug: NRX-1074 375 mg|Single oral administration on Day 1
89639183|NCT02366364|Experimental|Drug: NRX-1074 500 mg|Single oral administration on Day 1
89639184|NCT02366364|Experimental|Drug: NRX-1074 750 mg|Single oral administration on Day 1
89639185|NCT02881086|Other|Stratification I - Standard Risk (SR)/ High Risk (HR)|Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16
89639186|NCT02881086|Other|Stratification I - Philadelphia (PH)+|Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16
89639187|NCT02881086|Active Comparator|Rand I - B-Lin + CNS Rad + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate
89639188|NCT02881086|Experimental|Rand I - B-Lin + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate
89639189|NCT02881086|Other|Stratification II - SR + MRD-neg|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone
89639190|NCT02881086|Other|Stratification II - HR + MRD-neg|Chemotherapy or stem cell transplantation according to randomisation II
89639191|NCT02881086|Other|Stratification II - SR/HR/PH+ + MRD-pos|Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine
89639192|NCT02881086|Active Comparator|Randomisation II - HR + MRD-neg-SCT|Stem cell transplantation
89639193|NCT02881086|Experimental|Randomisation II - HR + MRD-neg-SR-chemo|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine
89639194|NCT02362854|Active Comparator|Conventional peri-implantitis treatment|Peri-implantitis treatment according to the Cumulative interceptive supportive (CIST) therapy.
89639195|NCT02362854|Experimental|DL application in peri-implantitis|Adjunct Diode Laser application.
89639196|NCT02362932|Experimental|Intervention|Sanitation
89639197|NCT02362932|No Intervention|Control|No sanitation
89639198|NCT02362542|Experimental|Sham tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
89639199|NCT02362542|Experimental|Real tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
89639200|NCT01493687|Experimental|CD5024|CD5024 1% Cream
89639201|NCT01493687|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
89639202|NCT02362308||Adrenalectomy|Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism
89639203|NCT02362308||Medical Therapy|Subjects will undergo assessment before and after medical treatment of primary aldosteronism
89639204|NCT02373618|Experimental|Experimental: DN and Conventional PT|
89639205|NCT02373618|Active Comparator|Active Comparator: Conventional PT|
89639206|NCT02366208|Experimental|PEG-Tα1|PEG-Tα1 (1.6 mg/ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
89639207|NCT02366208|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
88991330|NCT05260879|Experimental|Couples|"Women recruited for the couples group will be asked to invite their husbands to participate, regardless of their husband's CVD status, and men whose wives do not have CVD similarly will be asked to enroll with their wife. The intervention consists in exposing them to bi-monthly educational sessions on diet and exercise. The intervention consists in exposing participants with bi-monthly educational sessions on diet and exercise. Participants will be organized in groups of 15 to 30, led by one community health worker (CHW) assisted by a diabetes peer educator (PE). The basic format for the group sessions will follow the pattern developed with the DPP program, beginning with a discussion of success stories from the past weeks before proceeding to the didactic portion of the session. The sessions will mix the didactic portions facilitated by the PE with group discussions, activities and role plays, facilitated by the CHW."
88991331|NCT05260879|No Intervention|Comparison|The comparison group is composed of diabetic or hypertensive individuals who agreed to participate in the study but who will not be exposed to the sessions.
88991332|NCT05259696|Experimental|Dose Escalation - Monotherapy|"Subjects will receive E-602 as monotherapy.~Planned monotherapy dose levels: 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg."
88991333|NCT05259696|Experimental|Dose Escalation - Combination|"Subjects will receive E-602 in combination with cemiplimab.~E-602 dose(s): Will be initiated at dose level(s) that have previously completed dosing and DLT assessments as monotherapy.~Cemiplimab dose: 350 mg."
88991334|NCT05259696|Experimental|Expansion - Monotherapy|Subjects will receive E-602 as monotherapy at the recommended Phase 2 dose determined in Phase 1.
88991335|NCT05259696|Experimental|Expansion - Combination|"Subjects will receive E-602 in combination with cemiplimab.~E-602 dose: Subjects will receive E-602 at the recommended Phase 2 dose determined in Phase 1 in combination with cemiplimab.~Cemiplimab dose: 350 mg."
88991336|NCT05250115||Evaluate the effectiveness, usage and patient characteristics of real-world use of Abrocitinib|"This is a 36-month, prospective, non-interventional, multicenter study to evaluate the effectiveness, usage and patient characteristics of real-world use of Abrocitinib in patients with moderate to severe AD in a real-world setting.~Eligible patients will be followed up from the date of first Abrocitinib prescription for 12 months. Patients who are switched from the initial Abrocitinib therapy to other therapies will be further followed. Patient documentation is expected quarterly as per standard clinical practice."
88991337|NCT05247918|Experimental|Digital-physical care group|Combination of digital and physical care.
88991338|NCT05247918|Active Comparator|Treatment as usual.|Treatment as usual in accordance with national guidelines.
88991339|NCT05238922|Experimental|Phase 1a Dose Escalation|"INCB123667 will be administered at a protocol defined starting regimen once daily (QD) orally in 28-day cycles.~Subsequent dose regimens will be determined during study conduct."
88991340|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 1|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants with gynecologic tumors (epithelial ovarian/fallopian/primary peritoneal carcinoma ) will enroll in this group.
88991341|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 2|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants with Endometrial/Uterine cancer will enroll in this group.
88991342|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 3|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants with gastric, Gastro Esophageal Junction (GEJ), and esophageal adenocarcinomas will enroll in this group.
88991343|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 4|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants with Triple Negative Breast Cancer(TNBC) will enroll in this group.
89057633|NCT04531748|Active Comparator|Toremifene + Melatonin|"100mg oral Melatonin on Days 1 & 2 (40mg in the morning and 60mg in the evening), 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).~60mg oral toremifene daily days 1-14."
89212147|NCT00854672||sarcoidosis patients|Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study
89639208|NCT00350337|Experimental|Pre-transfection F17|"4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine"
89639209|NCT00350337|Experimental|Post-transfection F17|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
89639210|NCT00350337|Experimental|Post-transfection F19|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
89639211|NCT00350337|Placebo Comparator|Placebo|A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine.
89639212|NCT02366052|Active Comparator|Nutritional Counseling|The nutritional counseling group will receive dietary counseling focusing on a reduction of fructose intake by a trained nutritionist for 12 weeks every 3 weeks.
89639213|NCT02366052|Experimental|Nutritional Counseling and LCS|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks in addition to the nutritional counseling every 3 weeks.
89639214|NCT02366052|Experimental|Lactobacillus Casei Shirota|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks.
89639215|NCT02365896|Other|TLDG or LADG|To complete the distal gastrectomy with Billroth-II reconstruction and D2 lymphadenectomy for locally advanced gastric cancer with TLDG or LADG
89639216|NCT02373462|Experimental|olmesartan group|olmesartan (20mg qd then 40mg qd for titrating BP <140/90 mmHg)
89639217|NCT02373462|Active Comparator|other group|other anti-hypertensive drug (titrating BP <140/90 mmHg)
89639218|NCT01523587|Experimental|Afatinib|Patients receive afatinib tablets once daily
89639219|NCT01523587|Active Comparator|Erlotinib|Patients receive erlotinib tablets once daily
89639220|NCT00310401|Experimental|Albuterol|Albuterol sulfate 5 mg dissolved in normal saline administered every 4 hours by nebulization
89639221|NCT00310401|Placebo Comparator|Saline|Saline administered every 4 hours by nebulization
89639222|NCT02373228|Experimental|Compressive signal processing algorithm|Participants compare music signals with preprocessing to the same music signals without compressive preprocessing.
89639223|NCT02365974|Active Comparator|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps (mA) will be adjusted depending on the sensitivity of each individual patient. The arrangement thereof will be parallel on each side of the C7 (channel 1) and T4 (channel 2) vertebral spinous processes.
89639224|NCT02365974|Sham Comparator|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment without be submitted to stimulation.
89639225|NCT02361996||Coronary Bypass Surgery|"inclusion criteria:~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery.~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extent of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
89639226|NCT02361996||Coronary Stenting|"inclusion criteria:~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting.~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extant of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
89639227|NCT02361996||Aortic Valve Replacement|"inclusion criteria:~presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extent of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
89639228|NCT00310791|Placebo Comparator|Sugar Pill|Placebo (sugar pill); identical to treatment medication capsule
89212148|NCT00854750|Experimental|ACTHAR- placebo first|Placebo, 20 mg, 40 mg, 80 mg
89212149|NCT00854750|Experimental|ACTHAR- placebo second|20mg, Placebo, 40 mg, 80mg
89042529|NCT05237999|Experimental|Intervention: KopOpOuders-PTSD|KopOpOuders-PTSD is a blended care (i.e., partially online and partially in person) intervention that addresses the enhancing of protective factors within the family setting (reducing negative parental self-perceptions; parent-child interaction quality, social support, child adaptive functioning/coping, and child understanding of the parent's illness) from a combination of transdiagnostic and PTSD-specific perspectives. It consists of 8 sessions (5 online self-help modules, 3 in-person sessions with a professional) to be completed in a maximum period of 9 weeks.
89042530|NCT05237999|No Intervention|Control: No intervention|The control group receives no parenting intervention during their participation.
89042531|NCT05225740|Active Comparator|Control|General stress reduction based on stress management training to help people cope with feelings of anxiety, used as an active control condition
89639229|NCT00310791|Experimental|DHEA + Hormone replacement therapy (estrogen/progestin)|Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).
89639230|NCT02362152||Ingenol mebutate|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
89639231|NCT02362152||5-fluorouracil|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
89639232|NCT02362152||Imiquimod|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
89639233|NCT02362152||Diclofenac|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
89639234|NCT01493531|Experimental|lesinurad 200 mg + allopurinol|
89639235|NCT01493531|Experimental|lesinurad 400 mg + allopurinol|
89639236|NCT01493531|Placebo Comparator|Placebo + allopurinol|
89639237|NCT02362074||Adalimumab subjects|Subjects starting Adalimumab treatment at time of enrollment.
89639238|NCT02105415|Active Comparator|Etomidate|weight based dose of 0.15mg/kg
89639239|NCT02105415|Experimental|Ketamine / Propofol Admixture|weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol
89639240|NCT01523275|Experimental|Mitomycin-C|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of MMC in the radial incisions.
89639241|NCT01523275|Placebo Comparator|Saline|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of isotonic saline in the radial incisions.
89639242|NCT00304707|Experimental|2|participants in this arm receive bupropion
89639243|NCT00304707|Placebo Comparator|1|placebo
89639244|NCT02038686|Active Comparator|Standard PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)
89639245|NCT02038686|Active Comparator|Long PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)
89639246|NCT04409483|Active Comparator|Standard Care|Standard care for COVID-19 according to the national guidelines of Niger
89639247|NCT04409483|Experimental|Standard Care plus lopinavir/ritonavir|Standard care for COVID-19 according to the national guidelines of Niger plus lopinavir/ritonavir
89639248|NCT02362230|Experimental|Icotinib|Icotinib 125 mg BID
89639249|NCT02365740|Experimental|Cases|gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus
89042532|NCT05225740|Active Comparator|Standard Exposure|Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and completion of questions about the exercises and the large-group aspect
89042533|NCT05225740|Experimental|Enhanced Exposure|Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and post-exposure processing aimed at emphasizing harm expectancy violation
89057634|NCT04531748|Active Comparator|Melatonin + Placebo|100mg oral Melatonin on Days 1 & 2 (40mg in the morning and 60mg in the evening) and 60 mg on Days 3-14, (20mg in the morning and 40mg in the evening).
89057635|NCT04531748|Placebo Comparator|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions
89639250|NCT02365740|Sham Comparator|Controls|gastric emptying test gut hormones determination
89639251|NCT01492439|Experimental|Cognitive Remediation and Supported Education|Participants in this group will receive cognitive remediation training in addition to supported education. Cognitive remediation has two components: computer-based cognitive exercise sessions held on a twice weekly basis for 10 weeks as well as 10 weekly group discussion sessions (approximately 60 minutes in duration).
89639252|NCT01492439|Active Comparator|Supported Education Only|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.
89639253|NCT02365662|Experimental|Arm 1|Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
89639254|NCT02365818|Experimental|CG0070|Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.
89639255|NCT03113214|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
89639256|NCT03113214|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
89042534|NCT05219175|Experimental|Co-occurring PTSD and OUD prior and after treatment with MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (~80 mg MDMA) to 140 mg MDMA HCL (~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (~100 mg MDMA) to 180 mg MDMA HCL (~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (~280 mg MDMA) to 500 mg MDMA HCL (~435 mg MDMA)"
89042535|NCT05212779||Females with Stage II-IV epithelial ovarian cancer|"All patients, as participation requirements in this study, are required to have blood drawn at the completion of their adjuvant treatment. Blood sample should be collected within 6 weeks of receiving the last cycle of adjuvant chemotherapy.~Other optional time points which will be encouraged but not required:~After debulking surgery~Serial draws every 3 months while on maintenance or surveillance."
89042536|NCT05211882|Experimental|Immediate|Participants in the intervention arm will start on the ENABLE program at point of randomization.
89042537|NCT05211882|Experimental|Wait-list (delayed)|Participants on wait-list will start ENABLE 6 months after randomization.
89042538|NCT05202678|Other|AGN1 LOEP|Subjects treated with AGN1 LOEP in proximal femur
89639257|NCT03113214|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
89639258|NCT03113214|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
89639259|NCT03113214|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
89639260|NCT03113214|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
89639261|NCT03113058|Experimental|study group|
89639262|NCT00313209|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: salmeterol 50 μg, twice daily, inhaled"
89639263|NCT00313209|Placebo Comparator|Placebo|"Placebo~underlying medication: salmeterol 50 μg, twice daily, inhaled"
89639264|NCT02372994|Experimental|Intervention Group|The randomization is at the level of attending healthcare professional who identifies patients for recruitment. For each participant in the intervention arm, a secure space (called a Patient Loop) is created in the online clinical communication system. A Patient Loop can be accessed by the patient, their caregiver, and the healthcare providers who have permission to do so through an algorithm of invitation, authentication and careful partitioning. In each Patient Loop, team members can post messages that can be read and responded to by the entire team. Each Patient Loop consists of a patient, their caregiver and at least two healthcare professionals.
89639265|NCT02372994|No Intervention|Control Group|Participants receive usual care.
89639266|NCT02361606|Experimental|Internet CBT intervention|Eligible candidates were offered to participate in an internet cognitive behavioral intervention.
89639267|NCT02373150|Experimental|Group A1|Dose 1 or placebo
89639268|NCT02373150|Experimental|Group A2|Dose 2 or placebo
89639269|NCT02373150|Experimental|Group A3|Dose 3 or placebo
89639270|NCT00313443|Experimental|Amiodarone, long-term|Unique arm: all patients were taking amiodarone for more than 6 months and all patietns underwent amiodarone dosage in blood and fat tissue samplings
89639271|NCT02361684|Experimental|Blended CBT treatment|
89639272|NCT02361684|Active Comparator|Treatment as usual|
89639273|NCT04271397|Other|Active tuberculosis|
89042539|NCT05176626|Experimental|Phentermine|Participants randomized to active treatment in LEAP will be provided with phentermine hydrochloride 8 mg scored tablets. This formulation of the drug is commercially available and marketed as Lomaira TM.
89042540|NCT05176626|Placebo Comparator|Placebo|Participants randomized to the control arm of LEAP will be provided with placebo tablets consisting of cellulose and corn starch and manufactured to have the same characteristics of the active drug, including size, shape, weight, and sensory perceptions.
89042541|NCT05174065|Experimental|Apremilast|Apremilast will be administered to participants twice daily (BID)
89042542|NCT05174065|Experimental|Placebo and Apremilast|Matching placebo will be administered to participants twice daily (BID) until week 16. After week 16, Apremilast will be administered to participants BID.
89639274|NCT04271397|Other|Latent tuberculosis infection|
89639275|NCT05267847|Experimental|Cryotherapy during inferior alveolar nerve block|
89639276|NCT05267847|Active Comparator|Inferior alveolar nerve block|
89639277|NCT05267457||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
89639278|NCT05267457||Healthy pregnant women|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
89639279|NCT02361840||Exposed cohort: TI>0.05ng/ml|We call Exposed group to increased TI > or = 0.05ng/ml We call Event to the onset of ARDS
89639280|NCT02361840||No Exposed cohort: TI<0.05ng/ml|We cal no Exposed group to increased TI (<0.05ng/ml) We call Event to the onset of ARDS
89639281|NCT02373306|Active Comparator|NIPS-sensitive group|Patients who had sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation.
89639282|NCT02373306|No Intervention|Control group|Patients who had no sustained or hemodynamically unstable arrhythmias induction during non-invasive programmed stimulation.
89639283|NCT00351039|Experimental|Bevacizumab, Erlotinib, Pemetrexed|Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer
89639284|NCT02361918||Anastomotic leakage|Patient had anastomotic leakage
89639285|NCT02361918||No anastomotic leakage|Patient had no anastomotic leakage
89639286|NCT02372916||Dry AMD|Patients with pre-existing GA secondary to AMD NOT requiring intravitreal injections (i.e. Dry AMD)
89042543|NCT05170737|Experimental|PART I: SINGLE ASCENDING DOSE (FIH-SAD)|Prospective, monocenter, double-blind, randomized, placebo-controlled, subsequent-group, Phase I investigation to assess the safety, tolerability and pharmacokinetics of AEF0217 administered orally in single ascending doses.
89042544|NCT05170737|Experimental|PART II: MULTIPLE ASCENDING DOSES (FIH-MAD)|Prospective, monocenter, double-blind, randomized, placebo-controlled, subsequent-groups, Phase I investigation to assess the safety, tolerability and pharmacokinetics of AEF0217 administered orally in multiple ascending doses.
89042545|NCT05170737|Experimental|PART III: FOOD EFFECT (FIH-FE)|Prospective, open-label single dose, two-condition (fed versus fasting), two sequences, crossover phase I investigation to assess the effects of food on the bioavailability of AEF0217.
89042546|NCT05167747|Active Comparator|Active Comparator|Dietary supplement
89042547|NCT05167747|Placebo Comparator|Placebo comparator|Placebo
89042548|NCT05153083||patient undergoing open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Subjects undergoing open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA) using cryoablation of intercostal nerves
89042549|NCT05147649|Active Comparator|non-OSAS patients|Patients without OSAS (Apnea-Hypopnea Index (AHI) < 15/h and absence of excessive daytime sleepiness with Epworth score <11)
89639287|NCT02372916||Wet AMD and treatment-naive|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and are treatment-naïve patients
89639288|NCT02372916||Wet AMD with history of intravitreal injections|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and have received previous intravitreal injections
89639289|NCT00351741|Experimental|High Frequency|Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation
89639290|NCT00351741|Active Comparator|Conventional|Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation
89639291|NCT02361528|Experimental|Leukine|Sargramostim: Leukine (Genzyme USA), 125µg/m2 , once per day during 5 days, by subcutaneous route
89639292|NCT02361528|Placebo Comparator|placebo|placebo, once per day during 5 days by subcutaneous route
89639293|NCT01572727|Experimental|BKM120 and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel.
89639294|NCT01572727|Active Comparator|Placebo and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel.
89639295|NCT01791777|Experimental|Purveyor|"The purveyor arm will include SafeCare Coaching that is conducted by a Training Specialists from the National SafeCare Training and Research Center (NSTRC), a GSU (Georgia State University)-Center that conducts training and research on the SafeCare model."
89639296|NCT01791777|Experimental|Local|"The the local are will receive SafeCare Coaching that is provided by a staff member who works for the local social service agency."
89639297|NCT02359266|Experimental|Vitamin D supplement|20,000 IU cholecalciferol p.o for the first 7 days, and weekly thereafter for 6 months
89639298|NCT02359266|No Intervention|Controls|These patients had normal vitamin D levels and did not receive any treatment with vitamin D.
89639299|NCT02359500|Experimental|68Ga-DOTATOC PET|patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)
89639300|NCT02372526||10 Roux-en-Y gastric bypass patients|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
89639301|NCT02372526||10 Healthy Control subjects|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
89639302|NCT00315627|Experimental|islet transplantation|Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
89639303|NCT02985697|Experimental|IN DEX|Group IN DEX will receive a placebo dose of flavored water followed by 3 mcg/kg intranasal dexmedetomidine in conjunction with 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or placebo will not be given.
89639304|NCT02985697|Experimental|MIDDEX|Group MIDDEX will receive 3 mcg/kg intranasal dexmedetomidine and 0.5 mg/kg oral midazolam and 100% oxygen at a calculated flow rate (oxygen administration to function as placebo for nitrous oxide). If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
89639305|NCT02985697|Experimental|NOMIDDEX|Group NOMIDDEX will receive 3 mcg/kg intranasal dexmedetomidine, 0.5 mg/kg oral midazolam, and 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
89639306|NCT02985697|Active Comparator|CTRL|The control group, Group CTRL, will receive a placebo dose of normal saline and 0.5 mg/kg oral midazolam and 50/50 nitrous oxide/oxygen at a calculated flow rate. Midazolam was chosen as the control due to its well documented history of use in pediatric procedural sedations. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
89042550|NCT05147649|Experimental|OSAS patients|Patients with severe OSAS with an Apnea-Hypopnea Index (AHI) > 30/h
89042551|NCT05141682|Experimental|Treatment (Oral Azacitidne)|Patients will receive CC-486 orally (PO) D1-14 of a 28-day cycle, in a similar fashion to the QUAZAR study for a minimum of 4 cycles. Patients that achieve a response (CR or PR) will remain on study for a maximum of 12 months. Patients without a response at 4 months will come off the study.
89212150|NCT00854750|Experimental|ACTHAR- placebo third|20 mg, 40 mg, Placebo, 80 mg
89212151|NCT00854750|Experimental|ACTHAR- placebo fourth|20 mg, 40 mg, 80 mg, Placebo
89639307|NCT02359188|Active Comparator|tVNS|Transcutaneous vagal nerve stimulation with 25 Hz
89639308|NCT02359188|Sham Comparator|Sham-tVNS|Sham transcutaneous vagal nerve stimulation with 1 Hz
89639309|NCT00315939|Experimental|Group A Order: SMBG, IBMF-1, IBMF-2|Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
89639310|NCT00315939|Experimental|Group B Order: IBMF-1, IBMF-2, SMBG|Group B began with Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.
89639311|NCT02361450|Experimental|Retrograde Colonic Irrigation with usual care|In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
89639312|NCT02361450|Active Comparator|Usual Care|In the comparator group, patients will receive conventional care, according to each clinical center habits.
89639313|NCT02982759|Other|Comparison Arm|The comparison group will receive 2 generic newsletters
89639314|NCT02982759|Experimental|Intervention Arm|The intervention arm will receive the multi-level intervention.
89639315|NCT02372760|Experimental|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V).
89639316|NCT02372760|Active Comparator|BA classic anesthesia|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
89639317|NCT02361294||Patient|Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Three blood samples are taken during the study period. A thrombophilia screening is carried out.
89639318|NCT02361294||Control|Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. One to two blood samples are taken during the study period.
89639319|NCT02361372|Experimental|Kefir and CaCO3|Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months
89639320|NCT02361372|Placebo Comparator|Placebo and CaCO3|Placebo and 1,500 mg of CaCO3 daily for 6 months
89639321|NCT00352911|Active Comparator|VGX-410 (Mifepristone)|150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days
89639322|NCT00352911|Placebo Comparator|Placebo for VGX-410 (Mifepristone)|150mg twice daily of placebo for VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of placebo for VGX-410 for 14 days
89639323|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose|ASP6858 arm
89639324|NCT02359032|Placebo Comparator|Part 1: Placebo single ascending dose|Placebo arm
89639325|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose (fasting cohort)|ASP6858 arm
89639326|NCT02359032|Experimental|Part 2, Sequence 1: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
89639327|NCT02359032|Experimental|Part 2, Sequence 2: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
89639328|NCT05267145|Experimental|the blood storage bag contains blood preservation solution III|a blood storage bag containing blood preservation solution III preserves the washed RBC
89639329|NCT05267145|No Intervention|empty blood bag to store washed RBC|an empty blood storage bag preserves the washed RBC
89639330|NCT02358954|Experimental|Vestibular Pain interactions|
89639331|NCT02358798|Experimental|Preschool aged children detected of CF in neonatal period|Preschool aged children detected of Cystic Fibrosis in neonatal period
89212152|NCT00858026|Other|1|Breastfed babies
89212153|NCT00858026|Active Comparator|2|Weaning with the standard milk
89212154|NCT00858026|Experimental|3|Weaning with the fermented milk
89212155|NCT00848666|Experimental|I|Patients with tinea pedis
89212156|NCT00858104|Active Comparator|1|Laser thermal ablation
89212157|NCT00858104|No Intervention|2|Follow-up
89212158|NCT00858182|Experimental|Group A|
89212159|NCT00858182|Experimental|Group B|
89212160|NCT00854984|Experimental|Self-help CBT|A nurse supported self-help CBT intervention in addition to usual care.
89212161|NCT00854984|No Intervention|Usual care|
89212162|NCT04123340|Experimental|Additional intraprocedural CT-scan|Additional intraprocedural CT-scan
89212163|NCT02545244|Experimental|Black Tea|0.5% Black Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
89639332|NCT00353301|Experimental|Erlotinib and Sirolimus|"Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day.~Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day."
89639333|NCT02372604|Active Comparator|Group1 : Regulatory dosage|"In a first time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time,and after primary endpoint assessment, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 3 and 4)."
89639334|NCT02372604|Experimental|Group 2 : fourfold dosage|"In a first time, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 3 and 4)."
89639335|NCT02372448|Other|ALK-positive|ALK positive analysis on CTCs detected by ISET
89639336|NCT02372448|Other|ALK-negative|ALK negative analysis on CTCs detected by ISET
89639337|NCT01792323|Experimental|1 bolus of insulin lispro with short bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 30 seconds
89042552|NCT05105256|Active Comparator|Corticosteroids|Lumbar facet joint injection with corticosteroids
89042553|NCT05105256|Experimental|PRP|Lumbar facet joint injection with PRP
89639338|NCT01792323|Experimental|1 bolus of insulin lispro with long bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 10 minutes
89639339|NCT02358642|Experimental|Angiotensin converting enzyme inhibitor|Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
89639340|NCT02358642|Placebo Comparator|Placebo|Placebo
89639341|NCT00318357||CRT in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued ot follow up the original CARE-HF CRT group patients."
89639342|NCT00318357||Control in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, almost all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued to follow up the original CARE-HF control group patients."
89639343|NCT01791933||CAM treatment|
89639344|NCT03160248|Experimental|Apremilast|Patients randomized to this arm will start Apremilast with a titration phase of 5 days, followed by 30 mg Apremilast tablets twice daily (BID) by mouth (PO) for a total of 32 weeks (including titration phase).
89639345|NCT03160248|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive identically matching placebo (including the titration phase) by mouth for first 16 weeks. Placebo participants will be switched to receive Apremilast 30 mg BID from beginning of Week 17 for another 16 weeks. In this arm Apremilast will be started without titration.
89639346|NCT02372370|Active Comparator|Interventions|All participants receive all interventions.
89639347|NCT01522651|Placebo Comparator|Placebo|Ranolazine placebo plus dronedarone placebo for 12 weeks.
89639348|NCT01522651|Experimental|Ranolazine 750 mg|Ranolazine 750 mg plus dronedarone placebo for 12 weeks.
89639349|NCT01522651|Experimental|Dronedarone 225 mg|Ranolazine placebo plus dronedarone 225 mg for 12 weeks.
89639350|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 225 mg|Ranolazine 750 mg plus dronedarone 225 mg for 12 weeks.
89639351|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 150 mg|Ranolazine 750 mg plus dronedarone 150 mg for 12 weeks.
89639352|NCT00318591|Experimental|SpeediCath|hydrophilic-coated intermittent catheter
89639353|NCT00318591|Experimental|Conveen Uncoated|uncoated urinary intermittent catheter
89639354|NCT02372292|Active Comparator|Group 1|Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
89639355|NCT02372292|Active Comparator|Group 2|Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
89639356|NCT01792011|Experimental|PVI|A new non-invasive device (Radical-7 pulse oximeter monitor, Masimo Corp.) has been introduced that continuously detects changes in the plethysmograph waveform and computes a Plethysmography Variability Index (PVI) reflecting alteration in preload and fluid management.
89639357|NCT02358486|Experimental|Acupuncture|Participants in this group are given 10 times of real acupuncture treatment for 4 weeks.
89639358|NCT02358486|Sham Comparator|Sham acupuncture|Participants in this group are given 10 times of sham acupuncture treatment for 4 weeks.
89639359|NCT05267067|Active Comparator|manual respirtory exercises|Using manual traditional respiratory exercises.
89639360|NCT05267067|Active Comparator|Respiratory exercises with respiratory pressure meter|Using pressure respiratory meter in exercises.
89639361|NCT02358564|Active Comparator|Healthy Volunteers|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
88991344|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 5|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants with HR+/HER2- breast cancer who have had disease progression on or been intolerant of a CDK4/6 inhibitor will enroll in this group.
88991345|NCT05238922|Experimental|Phase 1b: Dose Expansion Cohort Disease Group 6|INCB123667 will be administered at the recommended dose or doses for expansion (RDE[s]) for advanced or metastatic solid tumors. Participants with other tumor indications with CCNE1 amplification or cyclin E1 over-expression will enroll in this group.
88991346|NCT05236647|Experimental|Intravenous morphine infusion|"Morphine 10 mg/ml or morphine 20 mg/ml will be diluted with normal saline to 5 mg/ml or 10 mg/ml. Both active study medication and placebo will be prepared in 100 ml drug containers suitable for the infusion pump.~The patient will have two similar infusion pumps. Morphine infusion connected to an i.v. line, placebo (normal saline) connected to a s.c line. Bolus dose will initially be equal to dose/hour. The nurse will administer bolus doses on both pumps (placebo and morphine pump) simultaneously. Patient reported pain intensity (NRS 0-10) and whether the bolus dose was initiated by the patient or the nurse will be recorded before each bolus dose. Bolus dose will be equally increased if/when the infusion rate is increased. If the bolus dose is ineffective, the bolus dose can be increased in steps of 0.1 ml until an effective dose is reached."
88991347|NCT05236647|Active Comparator|Subcutaneous morphine infusion|"Morphine 10mg/ml or morphine 20 mg/ml will be diluted with normal saline to 5 mg/ml or 10 mg/ml. Both active study medication and placebo will be prepared in 100 ml drug containers suitable for the infusion pump.~The patient will have two similar infusion pumps. Morphine infusion connected to a s.c. line, placebo (normal saline) connected to a i.v. line. Bolus dose will initially be equal to dose/hour. The nurse will administer bolus doses on both pumps (placebo and morphine pump) simultaneously. Patient reported pain intensity (NRS 0-10) and whether the bolus dose was initiated by the patient or the nurse will be recorded before each bolus dose. Bolus dose will be equally increased if/when the infusion rate is increased. If the bolus dose is ineffective, the bolus dose can be increased in steps of 0.1 ml until an effective dose is reached."
88991348|NCT05231005|Experimental|4th dose BNT162b2 vaccine|The investigators will recruit 150-200 volunteers, who received the 3rd dose at least 4 months previously, and have a known serology history (showing an immune response (even if just a low response) to the three previous doses, but with a recent relatively low IgG (below 700 BAU). These volunteers will recieve a 4th dose (30 microgram) of the BNT162b2 vaccine
89042554|NCT05102279|Experimental|Early administration of high-phosphorus diet test group|Group A: 1500 mg phosphorus diet was given on day 1-2, 2500 mg phosphorus diet on day 3-5, 1500 mg phosphorus diet on day 6-7 and 500 mg phosphorus diet on day 8-10
89042555|NCT05102279|Active Comparator|Early administration of low-phosphorus diet test group|Group B: 1500 mg phosphorus diet was given on day 1-2, 500 mg phosphorus diet on day 3-5, 1500 mg phosphorus diet on day 6-7 and 3500 mg phosphorus diet on day 8-10
89042556|NCT05098483|Active Comparator|Conventional root canal treatment|The caries will be removed. An excavator will be used to remove the coronal portion of the dental pulp while the radicular portion will be cleaned using k- files. 2.5% Sodium hypochlorite will be used as irrigant solution.The canals will be filled with ZOE cement and a stainless-steel crown will be inserted to restore the tooth.
89042557|NCT05098483|Experimental|Regenerative endodontic treatment using MTA|"Access cavity will be prepared in each primary molar then each canal will be copiously irrigated by sodium hypochlorite. Triple antibiotic paste will be inserted in eash canal then sealed with temporary restoration till the second visit.~In the second visit canals will be irrigated with EDTA, after that induction of bleeding will be created by overinstumentation inside each canal. Finally sealed with MTA under the GIC restoration and S.S.C"
89639362|NCT02358564|Experimental|Irritable Bowel Syndrome Patients|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
89639363|NCT04389021|Experimental|VR|The intervention group will receive VR support upon the standard of care during the procedure.
89639364|NCT04389021|No Intervention|Control|The control group will have standard care without the VR support.
89639365|NCT02358330||EHR Enhanced Clinic Referral|"A set of standard EHR modifications will be implemented in 18 clinics as part of the MBD (multiple baseline design) experiment.The key new EHR functions that will be implemented and tested are: 1) a modified screen for smoking sta-tus to enhance the identification and documentation of all smokers visiting targeted primary care clinics; 2) a Smoker Registry to track smokers, document their receipt of treatment services, and organize direct-to-consumer communications; 3) a 1-click referral system to evidence-based smoking treat-ment with UW-CTRI case managers; 4) a closed-loop feedback feature to communicate to the clinician the fate of a referral, documenting receipt of the referral and treatment engagement; and 5) EHR-based communication options to inform smokers of treatment resources"
89639366|NCT02358330||Standard care (control) clinics|10 control clinics will also be inducted into the study. These clinics will use existing EHR resources to identify smokers (e.g., the expanded vital signs) and to document their smoking status, and then use the standard paper fax-to-quit methods to refer patients to the Wisconsin Tobacco Quit Line
89639367|NCT01792089||non-obese healthy subjects|subjects with BMI<25 and no known disease
89639368|NCT01792089||post-gastric bypass|post-obese subjects 12-48 months after Roux-en-Y gastric bypass
89639369|NCT01792089||matched control subjects|Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
89639370|NCT02358252||Orthostatic hypotension|"Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV).~Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension."
89639371|NCT02358252||Non-orthostatic hypotension|Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV) Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension.
89639372|NCT01554241|Experimental|vitamin D3 800 IU/day|recommended daily dosage of 800 IU/day D3
89639373|NCT01554241|Experimental|2000 IU/day D3|D3 2000 IU/day
89639374|NCT01554241|Experimental|vitamin D3 4000 IU/day|D3 4000 IU/day
89042558|NCT05098483|Experimental|Regenerative endodontic treatment using Biodentine|"Access cavity will be prepared in each primary molar then canals will be copiously irrigated by sodium hypochlorite. Mixture of Triple antibiotic paste will be introduced in eash canal then cavity will be sealed with temporary restoration till the second visit.~In the second visit canals will be irrigated with EDTA, after that bleeding will be created by overinstumentation inside each canal. Finally sealed with biodentine under the GIC restoration and S.S.C"
89042559|NCT05096260|Experimental|Intervention|Enrolled study participants receive Motivational Interviewing based SMS/MMS messages to increase COVID-19 vaccine uptake, and complete Baseline and Follow-up surveys.
89042560|NCT05096260|No Intervention|Control|Enrolled study participants receive a simple website and complete a Baseline and Follow-up survey, after which they will receive the interventional Motivational Interviewing based SMS/MMS messages to increase COVID-19 vaccine uptake.
89639375|NCT01554241|Experimental|50,000 IU/week D3|D3 50,000 IU weekly
89639376|NCT05266833|No Intervention|Control|Students in the control class received regular class instruction during the 5 weeks. This instruction did not deviate from regular instruction that was provided to all classes, including the intervention classes. During the intervention period, control group students completed the assessments once per week. The control class is considered a treatment-as-usual active control.
89639377|NCT05266833|Experimental|Self-Paced Breathing|The self-paced slow diaphragmatic breathing intervention provided guidance for participants to breathe at a slower pace than normal with brief, organic pauses after each inhale and exhale, and with exhales longer than inhales. Participants were guided to breathe at their own pace while following these principles of longer exhales and brief pauses after each inhale/exhale. They were invited to slow their pace when ready, both during each 5-minute session and over the course of the 5 weeks.
89639378|NCT05266833|Experimental|Guide-Paced Breathing|The guide-paced slow diaphragmatic breathing intervention comprised slow breathing with all exhales twice as long as the inhales; e.g., a 3-second inhale was followed by a 6-second exhale. Participants were instructed to breathe in sync with the guided pace. The breathing pace slowed over the 5 weeks: for weeks 1-2, the breath pattern comprised a 3-second inhale followed by a 6-second exhale; for weeks 3-4, the timing was 4 and 8, respectively; and was 5 and 10 for the last week.
89639379|NCT01792167|Experimental|Second Step|Second Step Curriculum
89639380|NCT01792167|No Intervention|Stories of Us|Stories of Us was provided to schools
89639381|NCT03027739|Experimental|Arm 1|CART-19 cells treated
89639382|NCT02361138|Experimental|Cohort SHR3824/Placebo 1.25 mg|SHR3824 1.25 mg/day or placebo for 10 days.
89042561|NCT05086315|Experimental|SAR443579|"Dose Escalation: SAR443579 administered intravenously at escalating dose levels.~Dose Expansion: SAR443579 administered intravenously at the recommended dose and schedule determined from the dose escalation."
89042562|NCT05084599|Placebo Comparator|left-tilt group|After spinal anesthesia, the patient was placed in a 15° left position until the fetus was delivered, and metaraminol was given at an initial rate of 2.00μg/kg/min throughout the process.
89042563|NCT05084599|Experimental|supine group|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
89042564|NCT05062083|Other|One arm|All particpants will receive the same tests
89042565|NCT05052398|Active Comparator|PSP NEURO SERUM|Active arm in which 26 patients will receive PSP NEURO SERUM in their hands three times a day for 28 days. Each application will consist of 1 g of PSP NEURO SERUM.
89042566|NCT05052398|Placebo Comparator|Placebo of PSP NEURO SERUM|Placebo arm in which 26 patients will receive Placebo PSP NEURO SERUM (same ingredients as PSP NEURO SERUM except for the active ingredient that is replace with water) in their hands three times a day for 28 days. Each application will consist of 1 g of Placebo PSP NEURO SERUM.
89042567|NCT05042258|Experimental|Dupilumab administration|dupilumab administered in weight based dosage for 12 weeks. The drug will be administered once a week during this time through a subcutaneous injection.
89042568|NCT05033886|Experimental|fezolinetant|Participants will receive 2 tablets of fezolinetant once daily for 24 weeks.
89042569|NCT05033886|Placebo Comparator|placebo fezolinetant|Participants will receive 2 tablets of matching placebo once daily for 24 weeks.
89042570|NCT05021757||Disrupt CAD III PAS Cohort|Patients in the CathPCI Registry who undergo a PCI procedure using a Shockwave C2 Coronary IVL catheter and meeting the eligibility criteria will be included in the PAS cohort.
89042571|NCT05000658|Experimental|group A|HSC one injection of 4 mL soluble Dexamethasone phosphate (16 mg) (equivalent to 100 mg Prednisone), followed by up to 16 mL saline (depending on tolerance)
89042572|NCT05000658|Placebo Comparator|group B|HSC one injection of 4mL of saline and then up to 16 mL of saline (depending on tolerance)
89042573|NCT04999462|Experimental|Full-fat fermented dairy|1 serving per day of full-fat yogurt and full-fat fermented cheese
89042574|NCT04999462|Active Comparator|Low-fat fermented dairy|1 serving per day of low-fat yogurt and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
89042575|NCT04999462|Placebo Comparator|Non-dairy, non-fermented foods|2 servings per day of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
89042576|NCT04990232|Placebo Comparator|Standard of care|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive 20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days.
89057636|NCT01177813|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose tablets once daily
89057637|NCT01177813|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose tablets once daily
89057638|NCT01177813|Placebo Comparator|Placebo|Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
89057639|NCT01177813|Active Comparator|Sitagliptin 100 mg|Patients receive Sitagliptin 100 mg tablets once daily
89057640|NCT01177813|Experimental|BI 10773 high dose open label|Patients receive BI 10773 high dose tablets open label once daily
89057641|NCT04537481|Experimental|Normal fertilization group|Sperm samples from the successful fertilization IVF cycles were collected.
89042577|NCT04990232|Experimental|Immunotherapy|Patients will receive the standard type of treatment decided by the attending physicians. They will also receive IV anakinra 200 mg three times daily (every eight hours) or sc rhIFNγ 100 μg once every other day. More precisely, patients randomized for hyper-inflammation will receive anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. Patients having immunoparalysis will receive IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days. Especially for patients with creatinine clearance lower than 30 ml/min anakinra will be given half dose (i.e. 100 mg three times daily). Creatinine clearance is calculated by the Cockcroft Gault equation [(140-age in years)/ (72 x serum creatinine in mg/dl) for men; this is multiplied by 0.85 for women.
89042578|NCT04989023|Experimental|Blood flow restriction (BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (80% limb occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
89639383|NCT02361138|Experimental|Cohort SHR3824/Placebo 2.5 mg|SHR3824 2.5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
89639384|NCT02361138|Experimental|Cohort SHR3824/Placebo 5 mg|SHR3824 5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
89639385|NCT02361138|Experimental|Cohort SHR3824/Placebo 10 mg|SHR3824 10 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
89639386|NCT02361138|Experimental|Cohort SHR3824/Placebo 25 mg|SHR3824 25 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
89639387|NCT02361138|Experimental|Cohort SHR3824/Placebo 100mg|SHR3824 100 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
89639388|NCT03840369|Experimental|rTMS to the Right Dorsolateral Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsolateral Prefrontal Cortex (DLPFC). The right DLPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
89639389|NCT03840369|Experimental|rTMS to the Right Dorsomedial Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsomedial Prefrontal Cortex (DMPFC). The right DMPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
89042579|NCT04989023|Sham Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training (knee)|Patients will perform slow open kinetic chain (OKC) knee extension (90°-0°) (2s con, 2s ecc, metronome). A modified pain monitoring will dictate the loading to ≤5 kg with maximum of 4/10 pain. Patients will complete 4 sets (1x30, 3x15 reps) with 30 s rest in between. If the patient fails to shadow the pace of the metronome or to fully extend the knee, the load will be reduced by 0.5Kg. The patients will exercise in sitting with an inflatable cuff of 10cm width and 75cm length will be attached to the most proximal part of the lower extremity. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, consisting of resistance training (3-4 sets, last set to volitional fatigue), core, and balance exercise. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
89057642|NCT04537481|Experimental|Low fertilization group|Sperm samples from the low fertilization IVF cycles were collected.
89057643|NCT04531826|Active Comparator|Group A|Five-strand hamstring autograft group
89057644|NCT04531826|Placebo Comparator|Group B|Quadripled hamstring autograft group
89057645|NCT01684137|Active Comparator|Joalis Bambi Bronchi & Joalis Bambi Analerg|10 days, 2 times per day 2,5/5 ml
89057646|NCT01684137|Placebo Comparator|Placebo & Placebo|10 days, 2 times per day 2,5/5 ml
89057647|NCT04531436|Experimental|Intervention|Brief mindful eating intervention
89212164|NCT02545244|Active Comparator|Green Tea|0.5% Green Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
89639390|NCT02353026|Experimental|Intravenous Artesunate|Intravenous Artesunate administered on Day 1 and 8 every 3 weeks
89639391|NCT01792401|Placebo Comparator|Placebo|Patients on enteral feeding in intensive care units are administered a placebo
89639392|NCT01792401|Active Comparator|Probiotics|Patients on enteral feeding in intensive care unit are given a probiotic
89639393|NCT02358096|Experimental|ASP8232|ASP8232 administered once daily
89212165|NCT02545244|Active Comparator|Chlorhexidine|0.12% Chlorhexidine Mouthwash 5mL to be used twice daily.
89639394|NCT02358096|Placebo Comparator|Placebo|Placebo administered once daily
89639395|NCT02982681|Experimental|Platelet rich Fibrin|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site secured with vicryl sutures.
89639396|NCT02982681|Active Comparator|Bioactive glass|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia and The control site were packed with the graft alone
89639397|NCT03827811||PandrTB cohort|endTB and endTB-Q study participants on experimental regimen
89639398|NCT01521559|Sham Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
89639399|NCT01521559|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.
89042580|NCT04989023|Experimental|Blood flow restriction (BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (60% of the limb complete occlusion pressure) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (maximum of 4/10 pain).
89057648|NCT01684176|Experimental|Complex tailored intervention|"The intervention consists of 3 elements:~Medication review with recommendations focused on antithrombotics and adherence to guidelines and patient´s adherence to medications.~Discharge consultation with an pharmacist using motivational interviewing techniques.~Follow-up telephone calls one week, two months and six months after discharge."
89057649|NCT01684176|Placebo Comparator|Usual care|Usual care
89057650|NCT01684254||Children with Cerebral Palsy (CP)|
89057651|NCT02216045|Active Comparator|Peginterferon ,Ribavirin|drug :Peginterferon, Ribavirin,
89639400|NCT02352870|Experimental|Computerised CBT with therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly plus they receive three telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future~In addition to completing the seven online sessions the intervention arm received three 30 minute telephone support calls at weeks two, four, and six to facilitate engagement and understanding of the contents of the website."
89639401|NCT02352870|Active Comparator|Computerised CBT without therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly but do not receive any telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future"
89639402|NCT04438980|Experimental|Methylprednisolone Arm|Standard of care plus Methylprednisolone
89639403|NCT04438980|Placebo Comparator|Placebo Arm|Standard of care plus placebo
89639404|NCT05266755|Placebo Comparator|Patiens who will receive stanrdar care after hip fracture|All the patients who will be on surgery after a hip fracture will receive after the hospital discharge the standar following we are doing now in our hospital
89639405|NCT05266755|Active Comparator|Patiens who will receive FLS following after the hip fracture|All the patients who will be on surgery after a hip fracture will receive after the hospital discharge a FLS following, multidisciplinary, with a web and mobile app aplication
89639406|NCT03827499|Experimental|Ex-HMB|HMB dietary supplementation and Multicomponent physical exercise program
89639407|NCT03827499|Experimental|NoEx-HMB|HMB Dietary supplementation
89639408|NCT03827499|Placebo Comparator|Ex-Plac|Multicomponent physical exercise program
89639409|NCT03827499|No Intervention|Controls|No intervention
89639410|NCT02358720|Experimental|A: single fraction IMRT with 1 x 24 Gy|single fraction IMRT with 1 x 24 Gy on bone metastasis
89639411|NCT02358720|Active Comparator|B: fractionated RT with 10 x 3 Gy|fractionated RT with 10 x 3 Gy on bone metastasis
89639412|NCT03824847|Active Comparator|Intervention group|Intervention group: clarithromycin 1 tablet (250mg) twice daily for three days
89639413|NCT03824847|Placebo Comparator|Placebo group|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days.
89639414|NCT01554163|Experimental|Etoricoxib 30 mg|Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks.
89057652|NCT02216045|Experimental|Peginterferon, Ribavirin, camel milk|drug :Peginterferon, Ribavirin, camel milk
89057653|NCT04531358|Active Comparator|Callergin|One puff (140 microliter) into each nostril
89639415|NCT01554163|Active Comparator|Celecoxib 200 mg|Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.
89639416|NCT02360826|Experimental|Pravastatin|Pravastatin 20mg tablet (age 8-13 years), 40mg tablet (>14 years); 1 time dose given per oral at at the start of the study day.
89639417|NCT02360826|Experimental|Simvastatin|Simvastatin 10mg tablet (ages 8-13 years), 20mg tablet (>14 years); 1 time dose given per oral at the start of the study day.
89639418|NCT02361060|Experimental|Sugammadex|sugammadex 4 mg/kg
89639419|NCT02361060|Active Comparator|Neostigmine + Atropine|Neostigmine 40µg/kg in combination with atropine 10µg/kg.
89639420|NCT04099927|Experimental|SHR0410|Experimental: SHR0410 dose escalation.
89042581|NCT04989023|Sham Comparator|Sham-Blood flow restriction (sham-BFR) with low load resistance training (shoulder)|Patients will perform slow full range dumbbell biceps curls (2s con, 2s ecc, metronome).Initial load approximately set to 5% of the participants body weight. Patients will complete 4 sets of biceps curls (1x30, 3x15 reps) with 30 s rest between sets.If the patient fails to shadow the pace of the metronome or to fully flex the shoulder, the load will be reduced by 0.5Kg. The patients will exercise in standing with an inflatable cuff of 6cm width and 60cm length will be attached to the most proximal part of the limb. The cuff will remain inflated (enough room for two fingers between the skin and the cuff) throughout the loading session. All participants will undergo a 45-min physiotherapy session, exercises of the scapula stabilizers, resistance exercises of the rotator cuff muscles (3-4 sets, last set to volitional fatigue), and functional and shoulder proprioception. A modified pain monitoring approach will dictate the selection of exercises and the training load (max of 4/10 pain).
89639421|NCT02360904|Experimental|start yoga classes immediately|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence concurrently with the start of chemotherapy.
89639422|NCT02360904|Active Comparator|Start yoga classes after 3 months|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence 3 months after start of chemotherapy
89639423|NCT01792479|Experimental|Arm A: BIND-014 every 3 weeks|
89639424|NCT01792479|Experimental|Arm B: BIND-014 weekly|
89639425|NCT02352792|Active Comparator|Standard therapy|Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)
89639426|NCT02352792|Experimental|dose escalation|Standard plus 10% dose escalation to the hypoxic volume
89639427|NCT02360982||propofol and esmeron(rokuronyum)|In group G, anesthesia was induced with iv propofol (2 mg.kg-1) and maintained with 2% sevoflurane in a mixture of 65 % nitrous oxide and 35 % oxygen with a total gas flow rate of 6 L min-1. Neuromuscular relaxation was induced with iv rocuronium (esmeron) (0.5 mg.kg-1). Intravenous infusion of 0.9% saline was administered at a volume of 5 mL/kg/h. Patients received morphine (0.1mg/kg) for postoperative analgesia 30 minutes before the end of the operation. Anesthesia was terminated and neuromuscular blockade was antagonized with neostigmine (0.05 mg.kg-1)and atropine sulphate (0.01 mg.kg-1).
89639428|NCT02360982||marcaine and fentanyl|"We inserted a 18-G Tuohy needle at the L3/L4 or L2/L3 intervertebral epidural space using an epidural loss of resistance technique and thus performed needle-through-needle technique for subarachnoid injection of 2 mL bupivacaine (marcaine)(0.5%) and fentanyl (25 mcg) by 27-G spinal needle. After subarachnoid injection, epidural catheter was advanced and fixed.~At the end of the surgery 5 mL of bupivacaine 0.5% plus morphine (1 mg), adding to 4 mL saline was injected via epidural catheter for postoperative analgesia.Epidural catheter was removed at 24th hours"
89639429|NCT03153774|Experimental|Heart failure patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
89639430|NCT03153774|Experimental|TAVI patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
89639431|NCT01790217||Cohort|
89639432|NCT02360748|Experimental|single|Pilot Study in which patients will be adding food items to improve their nutritional status
89639433|NCT01553851|Experimental|GSK1120212|GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
89639434|NCT02360670|Placebo Comparator|Control imaging (NCCT)|Standard imaging
89639435|NCT02360670|Experimental|additional multimodal imaging|CT + CTA + CTP
89042582|NCT04986553||50 subjects, male and female, at least 18 years of age|50 subjects who are candidates for surgery using the Arthrex Clavicle Plate for treatment of clavicle fractures.
89057654|NCT04531358|Active Comparator|Alpin Alpensalz|One puff (140 microliter) into each nostril
89057655|NCT04531358|Experimental|no treatment|Patients do not receive a treatment
89639436|NCT00355797|Active Comparator|Closed Loop Stimulation (CLS)|Pacemaker programmed with Closed Loop Stimulation rate adaptive technology for long-term follow-up data collection.
89639437|NCT00355797|Active Comparator|Standard Rate Adaptive Technology (R)|Pacemaker programmed with standard rate adaptive technology (R, accelerometer) for long-term follow-up data collection.
89639438|NCT00355797|Active Comparator|Non-rate adaptive pacing (DDD)|Pacemaker programmed with no rate adaption (DDD mode) for long-term follow-up data collection.
89639439|NCT02358174|Experimental|Group I|Patients with symptomatic hemorrhoids - Grade I to IV sec. Goligher. Grade III to IV underwent Hemorrhoidectomy. Blood sampling for MMPs and NGAL plasma levels evaluation will be performed. Tissue sampling (obtained during hemorrhoidectomy) for MMPs and NGAL tissue levels evaluation will be performed in grade III-IV patients.
89639440|NCT02358174|Experimental|Group II|Healthy subjects without hemorrhoids as control groups for MMPs and NGAL plasma evaluation will be performed by means of Blood sampling.
89639441|NCT02359344|Experimental|CNV1014802|CNV1014802 150mg three times a day (tid) 7 days plus a single dose on day 8
89639442|NCT02359344|Placebo Comparator|Placebo|Placebo tid 7 days plus a single dose on day 8
89639443|NCT03842163||Patients with LVH of unknown etiology|
89639444|NCT02357862||Mitral Valve Annuloplasty|All eligible patients
89639445|NCT02357628||Research Group I|Wound treatment with RO-NPT 40%
89639446|NCT02357628||Research Group II|Wound treatment with RO-NPT 60%
89639447|NCT02357628||Research Group III|Wound treatment with RO-NPT 40% and irrigation
89639448|NCT01552915|Experimental|Lisdexamfetamine Dimesylate|
89639449|NCT01552915|Active Comparator|Methylphenidate Hydrochloride|
89639450|NCT01552915|Placebo Comparator|Placebo|
89639451|NCT03112512|Experimental|EIT|PEEP titration is performed where EIT is measured at the same time. After PEEP titration, EIT data is analyzed. Global inhomogeneity index and regional compliance based on EIT are calculated. PEEP level is selected when ventilation distribution is most homogeneous.
89639452|NCT03112512|Experimental|G5 VENTILATOR|Protective Ventilation Tool by G5(MV) to determine the optimal PEEP on ARDS patients. The results are delivered by the ventilator automatically.
89042583|NCT04977271|Experimental|Treatment Group|"Starting dose of oral venlafaxine immediate release (IR) 37.5 mg BID, to be taken with food. The dosing will be increased at a rate of 75mg per week for 3 weeks, to reach a desired dose of 300mg per day, taken as 150mg BID.~For patients with hepatic impairment, severe renal impairment, or end-stage kidney disease, the starting dose is 37.5 mg once daily, and the dose is increased by increments of 37.5 mg per day, to a maximum of 187.5 mg per day, taken as 93.75 mg BID."
89042584|NCT04977271|No Intervention|Control Group|No intervention will be provided for this group
89042585|NCT04972786|Sham Comparator|Sham rTMS|Participants will receive sham rTMS for 10-20 minutes.
89639453|NCT03112122|Active Comparator|core decompression technique|The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
89639454|NCT03112122|Experimental|bone substitution (i-FactorTM)|i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
89639455|NCT03112122|Experimental|injections of autologous Bone Marrow Concentrate (BMC)|injections of autologous BMC.
89639456|NCT02360514|Experimental|hantaan virus vaccine|
89639457|NCT03027505|Experimental|MUAC<125mm|no medical complication
89639458|NCT02352714|Active Comparator|Paracervical Nerve Block|Ten milliliters of 1% lidocaine paracervical anesthetic will be injected at three cervical locations: 1 mL at the tenaculum site (12 o'clock on a clock face) and 4.5 mL each at the 4 o'clock and 8 o'clock positions. A 3 minute waiting period will be used between the administration of the paracervical nerve block and the insertion of IUS to allow the paracervical block to take effect.
89639459|NCT02352714|Sham Comparator|Sham Paracervical Block|To perform the sham cervical block, the cervix will be touched with the blunt end of a Q-tip at the three locations described above for the paracervical block. The cervical mucosa will not be broken during the sham block. A 3 minute waiting period will again occur between administration of the sham block and IUS insertion to be consistent with the procedure used for the nerve block.
89639460|NCT03027583|Experimental|Probiotic|63 subjects will be randomized to the experimental arm. The experimental product is a vegetable capsule containing a probiotic strain. Subjects will consume 1-2 capsules daily together with breakfast, equivalent to a dose of 50 bill CFU for 6 weeks.
89639461|NCT03027583|Placebo Comparator|Placebo|63 subjects will be randomized to the placebo arm.The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics. Subjects will consume 1-2 capsules daily with breakfast for 6 weeks.
89639462|NCT03911557|Experimental|Patients with moderate to high tumor mutational burden|Patients with recurrent or refractory disease in solid tumors naïve to anti-PD-1/PD-L1 or anti-CTLA-4 immunotherapy and have moderate to high tumor mutational burden (TMB)
89639463|NCT02357550|Placebo Comparator|Control|Saline infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
89639464|NCT02357550|Experimental|Hyperketonaemia|Ketone infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
89639465|NCT00356031|Experimental|Bevacizumab, Radiation, and Surgery|Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)
89639466|NCT03028441|Experimental|Group 1- low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day1 and at Day 29 for 25 subjects, placebo for 5 subjects
89639467|NCT03028441|Experimental|Group 2-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1 and at Day 85 for 25 subjects, placebo for 5 subjects
89639468|NCT03028441|Experimental|Group 3-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
89639469|NCT03028441|Experimental|Group 4 -high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1 and at Day 29 for 25 subjects, placebo for 5 subjects
89639470|NCT03028441|Experimental|Group 5-high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 85 for 25 subjects, placebo for 5 subjects
89639471|NCT03028441|Experimental|Group 6-dose-High Dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
89639472|NCT02352636|Active Comparator|Treatment arm 1|"Subjects will receive magnetotherapy (MAT). The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm. The experimental object will be applied to the reactive region of each of the six selected acupoints as detected by an acupoint detector. The justifications for selecting these acupoints are described below. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation prior to the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during therapy administration."
89639473|NCT02352636|Active Comparator|Treatment arm 2|Subjects will receive laser auriculotherapy (LAT). A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use12, 26. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection. Similarly, a plaster without magnetic pellets that mimics MAT treatment will be applied on these six acupoints after LAT.
89639474|NCT02352636|Experimental|Treatment arm 3|Subjects will receive a combined approach using MAT and LAT. LAT will be administered prior to the application of MAT on the selected auricular points, which would be implemented similar to the procedures in treatment arm 1 and 2.
89042586|NCT04972786|Active Comparator|Active rTMS|Participants will receive active rTMS for 10-20 minutes.
89042587|NCT04971707|Active Comparator|standard exercise training|The physical exercises intervention will include a standardized aerobic exercises training, three sessions per week for 3 months.
89042588|NCT04971707|Experimental|HRV-guided exercise training|The physical exercises intervention will include an individualized aerobic exercises training, three sessions per week for 3 months.
89042589|NCT04969978|Active Comparator|Arm I (Quitline eReferral)|Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.
89042590|NCT04969978|Experimental|ARM II (Quitline eReferral plus enhanced AD)|Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.
89042591|NCT04969744|Experimental|Intermittent Cold Exposure (ICE)|Stage 1- healthy volunteers aged 16-26 years will receive ICE for one day. stage 2a - controls aged 8-16 will receive ICE for one day. Stage 2b- NAFLD patients aged 8-16 years will receive ICE for one day or choose to continue for 5 days.
89639475|NCT02352636|Placebo Comparator|Placebo arm|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
89639476|NCT02038842|Experimental|MVA HIV-B and LIPO-5 vaccines|MVA HIV-B primes 0,5 milliliter (mL) Intramuscular at Week 0 and Week 8 LIPO-5 1mL Intramuscular boosts at Week 20 and Week 28
89639477|NCT02038842|Experimental|LIPO-5 and MVA HIV-B vaccines|LIPO-5 primes 1mL intramuscular at Week 0 and Week 8 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
89639478|NCT02038842|Experimental|GTU-MultiHIV B and LIPO-5 vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and LIPO-5 1mL intramuscular boosts at Week 20 and Week 28
89639479|NCT02038842|Experimental|GTU-MultiHIV B and MVA HIV-B vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
89639480|NCT01790139|No Intervention|Control|Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
89639481|NCT01790139|Experimental|Intervention-Oral Simethicone|Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.
89639482|NCT05266599|Active Comparator|MTA Fillapex group|Root canals were prepared with WaveOne Gold instruments and X-Smart Plus (Dentsply Maillefer, Switzerland) endodontic motor. Final irrigation was performed with 5 ml of 17% ethylene diamine tetraacetic acid (EDTA), 5 ml of 2.5% NaOCl, and distilled water. Then, the root canals were dried with the help of sterilized paper cones. MTA Fillapex sealer was mixed and applied to the root canals and the main gutta-percha cone. Then, the single cone technique was utilized for the obturation of the root canals.
89639483|NCT05266599|Active Comparator|AH Plus group|Root canals were prepared with WaveOne Gold instruments and X-Smart Plus (Dentsply Maillefer, Switzerland) endodontic motor. Final irrigation was performed with 5 ml of 17% ethylene diamine tetraacetic acid (EDTA), 5 ml of 2.5% NaOCl, and distilled water. Then, the root canals were dried with the help of sterilized paper cones. AH Plus sealer was mixed and applied to the root canals and the main gutta-percha cone. Then, the single cone technique was utilized for the obturation of the root canals.
89639484|NCT02360592|Active Comparator|1, conventional control group|Entecavir 0.5 mg po daily for 72 weeks
89639485|NCT02360592|Experimental|2, combination and sequential group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks
89639486|NCT02360592|Experimental|3, multitarget group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks plus interleukin 2 25 wIU qod iH for 12 weeks plus Hepatitis B Vaccine 60ug qm im for 48 weeks
89639487|NCT02360202|Experimental|Bullous pemphigoid patient treated with clobetasol propionate|Impedance analysis in patient with bullous pemphigoid treated by Clobetasol Propionate cream treatment.
89639488|NCT00322101|Experimental|Arm I (Nonmyeloablative regimen)|"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96."
89639489|NCT00322101|Experimental|Arm II (Myeloablative regimen)|"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.~Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.~Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.~TRANSPLANTATION: Patients undergo PBSC infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
89639490|NCT02360046|Other|Higher hydrocortisone dose|Established hydrocortisone replacement therapy plus 10mg of hydrocortisone
89639491|NCT02360046|Other|Lower hydrocortisone dose|Established hydrocortisone replacement therapy plus placebo
89639492|NCT02352480|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment plus usual and customary care, which can include any advanced therapeutics.
89042592|NCT04962776|Active Comparator|Low-concentration carbohydrate and nitrates group (CHON group )|
89042593|NCT04962776|Active Comparator|Low-concentration carbohydrate group (CHO group)|
89042594|NCT04962776|Placebo Comparator|W group|
89042595|NCT04961632|Experimental|Dose-determination|
89042596|NCT04961632|Experimental|Dose-confirmation|
89639493|NCT02352480|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.
89639494|NCT01552681|Experimental|Baminercept|Subcutaneous injections of 100 mg every week for 24 weeks
89639495|NCT01552681|Placebo Comparator|Placebo|Subcutaneous injections of matched placebo every week for 24 weeks
89639496|NCT02360358|Experimental|autologous cultured skin|autologous cultured skin patches (Tiscover) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size. Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new Tiscover patches.
89639497|NCT02360358|Active Comparator|acellular donor dermis|"acellular donor dermis (AS210) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size.~Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new AS210 patches."
89639498|NCT05266443|Placebo Comparator|Irritable bowel syndrome with normal mood receiving placebo|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R less than 16 will be supplemented with placebo drinks.
89639499|NCT05266443|Active Comparator|Irritable bowel syndrome with normal mood receiving probiotics|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R less than 16 will be given lactobacillus-containing cultured milk drinks.
89639500|NCT05266443|Placebo Comparator|Irritable bowel syndrome with subthreshold depression receiving placebo|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R of 16 or above will be supplemented with placebo drinks.
89639501|NCT05266443|Experimental|Irritable bowel syndrome with subthreshold depression receiving probiotics|A total of 35 patients diagnosed with IBS as per Rome IV criteria who scored CESD-R of 16 or above will be given lactobacillus-containing cultured milk drinks.
89639502|NCT02352402|Experimental|Ticagrelor|Ticagrelor 90mg twice daily for 1 year on top of ASA
89639503|NCT02352402|Placebo Comparator|Placebo|Placebo matching ticagrelor 90mg twice daily on top of ASA
89639504|NCT02357472|Experimental|High dose group|dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..
89639505|NCT02357472|Experimental|Standard dose group|dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.
89639506|NCT00322335|Experimental|Menitorix/Pediarix Group|Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
89639507|NCT00322335|Active Comparator|Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group|Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
89639508|NCT00322335|Active Comparator|Infanrix hexa/Meningitec Group|Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.
89639509|NCT05265897|No Intervention|Usual Care|Brief form letter with lung cancer screening results
89639510|NCT05265897|Experimental|CAQ|"Usual care, plus Commonly Asked Questions after Lung Cancer Screening informational document (CAQ)"
89639511|NCT03153852|Experimental|Combined peeling agents|Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides
89639512|NCT04751253|Active Comparator|1500 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 1500 J plus exercises.
89639513|NCT04751253|Active Comparator|3000 J + exercises|consist of 17 patients, they will receive the application of HILT with intensity 3000 J plus exercises.
89042600|NCT04926142||Patients planned for percutaneous PFO closure|Patients will undergo implantation of a Holter device (Reveal Linq Medtronic) 2 months prior to percutaneous PFO closure. Devices will be monitored by telemonitoring until the PFO closure procedure, and at 2, 12 and 24 months after the procedure.
89639514|NCT04751253|Sham Comparator|exercises + sham LASER|consist of 17 patients, they will apply exercises plus sham LASER.
89639515|NCT04751097|Experimental|Digital Platform|
89639516|NCT04751097|No Intervention|Routine Care|
89639517|NCT04320030|Experimental|[18F]-DPA-714|pretherapeutic [18F]-DPA-714 PET/CT scan
89639518|NCT02359734||Brigham and Women's Hospital.|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Brigham and Women's Hospital. In these unit, the intervention bundle was implemented.
89639519|NCT02359734||Johns Hopkins University Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Johns Hopkins University Hospital. In these unit, the intervention bundle was implemented.
89042601|NCT04909138|Active Comparator|DRG stimulation therapy at 20 Hz and 30 seconds ON, 90 seconds OFF|DRG stimulation therapy at 20 Hz (30 seconds ON, 90 seconds OFF)
89042602|NCT04909138|Active Comparator|DRG stimulation therapy at 5 Hz and 30 seconds ON, 90 seconds OFF|DRG stimulation therapy at 5 Hz (30 seconds ON, 90 seconds OFF)
89042603|NCT04908579|Active Comparator|- GROUP (I): 30 patients|
89042604|NCT04908579|Active Comparator|- GROUP (II): 30 patients|
89042605|NCT04908579|Active Comparator|- GROUP (III) (Control): 30 patients|
89042606|NCT04907461|Experimental|Laparoscopic guided TAP block|"The surgeon uses a laparoscopic technique to visualise the peritoneum from the inside of the abdomen and guides the hypodermic needle through the abdominal wall from the outside. When the needle point is visible through the peritoneum and almost enters the abdominal cavity, the surgeon retracts the needle around 5 mm. Then by deploying a test dose of the local anaesthetics a so called Doyle's bulge sign can confirm the right position in the nervous plane. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin."
89042607|NCT04907461|Active Comparator|Ultrasound guided TAP block|The anaesthesiologist uses ultrasound to identify the nervous plane in-between the external and transverse abdominal muscles. A dose of 20 cc 3,75 mg/ml of Ropivacain is administered on each side of the abdominal wall in the midaxillary line, just in between the crista and costal margin.
89639520|NCT02359734||Winchester Medical Center|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Winchester Medical Center. In these unit, the intervention bundle was implemented.
89639521|NCT02359734||Central DuPage Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Central DuPage Hospital. In these unit, the intervention bundle was implemented.
89639522|NCT02359734||Vanderbilt University|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Vanderbilt University Medical Center. In these unit, the intervention bundle was implemented.
89639523|NCT02359734||Massachusetts General Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Massachusetts General Hospital. In these unit, the intervention bundle was implemented.
89639524|NCT02359734||University of California, San Diego|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at University of California, San Diego. In these unit, the intervention bundle was implemented.
89639525|NCT02359734||Maricopa Integrated Health System|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Maricopa Integrated Health System. In these unit, the intervention bundle was implemented.
89639526|NCT02359734||Danbury Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Danbury Hospital. In these unit, the intervention bundle was implemented.
89639527|NCT02359734||Candler Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Candler Hospital. In these unit, the intervention bundle was implemented.
89639528|NCT02359656|Other|non operative treatment|specif non operative treatment protocol
89639529|NCT02359656|Other|operative treatment|dorsal atlanto-axial C1-C2 Arthrodesis
89639530|NCT01792557|Active Comparator|Phenol|Crystallized Phenol Group
89639531|NCT01792557|Active Comparator|Limberg|Limberg Flap Group
89639532|NCT01792557|Active Comparator|Modified Limberg|Modified Limberg Flap Group
89639533|NCT01792557|Active Comparator|Karydakis|Karydakis Flap Group
89639534|NCT02352246|Experimental|steady-state exercise (SSE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
89639535|NCT02352246|Other|high intensity intermittent exercise (HIIE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
89639536|NCT01792713|Active Comparator|Sertaconazole 2% cream|2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up
89639537|NCT01792713|Placebo Comparator|Placebo Arm|2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up
89639538|NCT03666507||Brain stem associated tumors|Brain stem associated tumors
89639539|NCT03666507||Tumors without brain stem assocation|Tumors without brain stem assocation
89042608|NCT04901741|Experimental|Arm 1: olaptesed pegol + pembrolizumab + nanoliposomal irinotecan + 5-FU + LV|
89042609|NCT04901741|Experimental|Arm 2: olaptesed pegol + pembrolizumab + gemcitabine + nab-paclitaxel|
89042610|NCT04896229|Experimental|Experimental: Intervention|Parent/student/dyads in the treatment condition will be sent program materials via mail and text or email, including smart-speaker hardware, wireless network bridges for wireless network connectivity, and web links to Talk STEM Familia, including set-up video tutorials, and graphic instructions. Intervention activities will take place in participants' homes over the 24-week intervention period and will include using the dual-language Talk STEM Familia technology to receive instruction, practice, and feedback on academic vocabulary.
89042611|NCT04896229|No Intervention|Treatment as usual|Parent/student dyads in this arm will receive treatment-as-usual (the vocabulary instruction regularly provided in their schools). They will receive the TSF technology after post-test data has been collected.
89639540|NCT02352168|Active Comparator|Budesonide nasal spray|Budesonide nasal spray ,64mcg/putt,1 spray/nostril, 2 times/day,for 12 consecutive weeks.
89639541|NCT02352168|Placebo Comparator|Placebo|Placebo:nasal placebo spray,1spray/nostril, 2 times/day,for 12 consecutive weeks.
89639542|NCT01792791||Single Arm|
89639543|NCT03154008|Experimental|Active Treatment|Group cognitive behavioral therapy (CBT) for 8 weeks.
89639544|NCT02359578|Experimental|Lymphatic occlusion pressure|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted.
89639545|NCT00323193|Experimental|Arm 1|The intervention group completes approximately 8 individual level sessions with a MOVE specialist as well as approximately 8 group level intervention sessions.
89639546|NCT00323193|No Intervention|Arm 2|The control group offers basic information about diet and exercise every month for six months.
89042612|NCT04844866|Experimental|CAR T-cell MB-CART2019.1|Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight.
89057656|NCT01684293|Experimental|Cognitive Rehabilitation|Occupational therapy-based cognitive rehabilitation
89057657|NCT01684293|Placebo Comparator|Psychoeducation/games|Psychoeducation/games
89639547|NCT02359422|Experimental|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health program developed based upon the Message Interpretation Processing model designed to increase critical thinking skills about media messages and reduce risky sexual behaviors.
89639548|NCT02359422|No Intervention|Wait-list control|
89639549|NCT02357316||All participants|All individuals visiting the museum who want to participate and sign a consent form.
89639550|NCT02357160|Experimental|Choice|Patients given choice over artwork on wall
89639551|NCT02357160|Active Comparator|No choice|Patients not given choice over artwork on wall
89639552|NCT02357160|Placebo Comparator|No artwork|Patients not receiving any artwork on wall
89639553|NCT02357004|Experimental|Carvedilol|Carvedilol CR 40 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to carvedilol CR 80 mg daily (subjects will take 2 of the study pills).
89639554|NCT02357004|Experimental|Chlorthalidone|Chlorthalidone 12.5 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to chlorthalidone 25 mg daily (subjects will take 2 of the study pills).
89639555|NCT02352012|Experimental|Autologous blood group A|Autologous blood was perfused to the target pulmonary segment
89639556|NCT02352012|Experimental|Bronchial plug group B|Bronchial plug was placed to the target pulmonary segment
89639557|NCT02352012|No Intervention|control group|Control group was given to continuous negative pressure drainage
89639558|NCT03152838||Autism Cases|"20 confirmed autism cases will be involved in this study.~The autism patients will be diagnosed according to:Gilliam Autism Rating Scale Arabic version: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score.~Fasting blood samples will be collected from autism children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
89639559|NCT03152838||Control|"20 age-gender matched typical development children that will be assigned to the normal control group.~Control children will be examined by a psychiatrist to exclude any sub-clinical autistic features.~Fasting blood samples will be collected from control children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
89639560|NCT02356926||Control|Usual care and routine management
89639561|NCT02356926||Cross checking|Systematic cross checking between emergency physicians at 11:30, 14:00 and 16:30
89639562|NCT02356848|Experimental|Tailored intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence.
89639563|NCT02356848|Placebo Comparator|Current Practice (CP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes including full EMR functionality, clinical reminders to improve care, and Patient-Centered Medical Home (PCMH) implementation with its benefits for diabetes care. To control for attention and preserve blinding, this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence to general health recommendations
89639564|NCT02356536|Experimental|Experimental|
89639565|NCT02356770|Experimental|Collagen Matrix 10808|Mucosal split-thickness flap in combination with the Collagen Matrix 10808.
89639566|NCT02356770|Other|Connective tissue graft (gold standard)|Mucosal split-thickness flap in combination with the connective tissue graft.
89042613|NCT04844866|Active Comparator|Standard of Care|"Immunochemotherapy will be administered from the following 2 predefined regimens: R-GemOx (8 cycles of 14 days each) or BR plus polatuzumab vedotin (6 cycles of 21 days each). BR plus polatuzumab vedotin will be capped at a maximum of 10% of participants; i.e. a maximum of 8 participants will be randomised to the BR plus polatuzumab vedotin regimen.~Participants from the SoC arm are allowed to be treated with CAR T-cell MB-CART2019.1 upon request by the investigator if at least one of the following criteria is confirmed by the IRC:~Relapse or progression occurring at any time within 1 year after randomisation.~Failure to achieve PR or CR at or beyond Week 8 after randomisation (after 4 cycles of R-GemOx or 3 cycles of BR plus polatuzumab vedotin) and the start of a new anti-lymphoma therapy is warranted."
89042614|NCT04840394|Experimental|BDB018 in Monotherapy|"A single subject will be enrolled at each dose level in the single agent arm.~Then dosage escalation will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB018 is reached."
89042615|NCT04840394|Experimental|BDB018 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.~When the MTD or RP2D of single agent BDB018 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, approximately twenty additional subjects will be enrolled in the expansion phase of the study."
89042616|NCT04833348|Experimental|Patients|Infants with spinal muscular atrophy cared by the Neuromuscular Reference Center at Necker Hospital and eligible for innovative therapy (gene therapy or pharmacogenetics)
89042617|NCT04832802|Experimental|ACCESS-Vets Intervention Group|This group will receive ACCESS-Vets, a customized employment intervention adapted for use in VA healthcare.
89639567|NCT01570387|Experimental|Phase I - cohort 1 (Pomalidomide 2mg) plus Dexamethasone|Pomalidomide 2 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
89639568|NCT01570387|Experimental|Phase I - cohort 2 (Pomalidomide 3mg) plus Dexamethasone|Pomalidomide 3 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
89042618|NCT04832802|Active Comparator|IPS (Usual Care) Group|This group will receive IPS (Individual Placement and Support), the usual evidence-based supported employment program in VA.
89639569|NCT01570387|Experimental|Phase I - cohort 3 (Pomalidomide 4mg) plus Dexamethasone|Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
89639570|NCT01570387|Experimental|Phase II Expansion- (Pomalidomide 4mg) plus Dexamethasone|"Expansion Phase:~Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle"
89639571|NCT03147846|Experimental|delayed cord clamping|"Keep the baby at the level or below the placenta for 45-60 seconds before clamping the cord.~Keep the room temperature at 23-25˚C and wrap the baby if possible"
89639572|NCT03147846|Active Comparator|cord milking|Do 4-5 strips from proximal (maternal) end of the cord (as proximal as possible) towards the baby abdomen with thumb and forefinger Wait for 2 seconds between each stripping Keep the baby at the level of placenta
89639573|NCT03147456|Experimental|Intervention group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
89639574|NCT03147456|Placebo Comparator|Control group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
89639575|NCT02348424|Experimental|Female solithromycin|14 females will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
89639576|NCT02348424|Experimental|Male solithromycin|14 males will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
89639577|NCT01570309|Active Comparator|Ergocalciferol|50,000 units of ergocalciferol once a week for 12 weeks
89639578|NCT01570309|Placebo Comparator|Sugar pill|
89639579|NCT03147300|Active Comparator|Östergötland region - Control group|
89639580|NCT03147300|Experimental|Östergötland region - Intervention group|
89639581|NCT03147534|Active Comparator|Children Age 1 month to 2 years|"Collecting temperatures on patients using the ARC InstaTemp MD and a Welch Allyn rectal thermometer."
89639582|NCT03147534|Active Comparator|Children > 2 to 5 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn rectal and Covidien tympanic thermometer."
89639583|NCT03147534|Active Comparator|Children > 5 to ≤ 10 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn oral and the Covidien tympanic thermometer."
89639584|NCT02356224|Experimental|Cohort 1|SHR3824 2.5 mg/day or placebo.
89639585|NCT02356224|Experimental|Cohort 2|SHR3824 5 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89639586|NCT02356224|Experimental|Cohort 3|SHR3824 10 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89639587|NCT02356224|Experimental|Cohort 4|SHR3824 25 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89639588|NCT02356224|Experimental|Cohort 5|SHR3824 50 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89639589|NCT02356224|Experimental|Cohort 6|SHR3824 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89639590|NCT02356224|Experimental|Cohort 7|SHR3824 200 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89639591|NCT02356146||All KT recipient|
89639592|NCT01519921|Experimental|PEG-IFN alfa-2a (Treatment naïve)|Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
89042619|NCT04832178|Placebo Comparator|Placebo|
89639593|NCT01519921|Experimental|PEG-IFN alfa-2a (YMDD mutant)|Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.
89042620|NCT04832178|Experimental|SUMOR|
89042621|NCT04823741||PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
89042622|NCT04818918||STEMI group|"Patients with anterior ST segment MI treated with percutaneous coronary intervention of the left anterior descending artery, at least 7 days prior to inclusion, and scheduled for new angiography to evaluate FFR of a lesion other than the infarct-related artery.~Absolute coronary flow and microvascular resistance will be measured in the LAD."
89639594|NCT02039154|Experimental|Aerobic and strength training group|
89639595|NCT02039154|Active Comparator|Balance and flexibility group|
89639596|NCT02356380|Experimental|Mobilization|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
89639597|NCT01519765|Experimental|Buccal misoprostol+placebo vaginal pill|
89042623|NCT04818918||Control group|"Patients undergoing non-urgent coronary angiography for stable angina or silent ischemia, with measure of FFR on one or more vessels (intermediate lesions <90% without proven ischemia). Absence of any signfiicant lesion on the left anterior descending artery (as evaluated by angiography or FFR value >0.8).~Absolute coronary flow and microvascular resistance will be measured in the LAD."
89042624|NCT04814368|Experimental|LNA043|Placebo to canakinumab + LNA043
89639598|NCT01519765|Active Comparator|Vaginal Misoprostol+placebo buccal pill|
89639599|NCT03147066|Experimental|Dezocine|0.1 mg/kg of intravenous dezocine 30 min before the end of surgery
89639600|NCT03147066|Active Comparator|Flurbiprofen axetil|1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery
89639601|NCT02351622|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
89639602|NCT02351622|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
89639603|NCT01552603|Experimental|Artificial Pancreas Control|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
89639604|NCT02351466||Children with Type 1 Diabetes|Subjects with T1 diabetes will undergo a physical exam and blood test as well as structural and functional brain MRI, neurocognitive testing and wear a continuous glucose monitor every 3 months for 24 months.
89639605|NCT02351466||Healthy Controls|Subjects will undergo a physical exam and blood test as well as structural and functional brain MRI at baseline and after 24 months.
89639606|NCT04824703|Active Comparator|Conservative oxygen therapy|"Spo2 alarm limit will be set as follow: - upper limit 94% and lower limit 88%~If spo2 >94% Unless fio2 is 0.21%, decrease fio2 by 0.10% at intervals no longer than 5 minutes till spo2 = 94%~If spo2 within target Decrease fio2 0.05% at intervals no longer than 30 min till fio2 0.21% reached or spo2 = 88 %~If spo2 < 88 % return to previous spo2 that achieve target spo2.~if an arterial blood gas demonstrate that the PaO2 is < 60 mmHg FiO2 will increased if clinically appropriate irrespective of the SpO2 reading ( target po2 60-100 mmhg )~During intubation, airway suction, tracheostomy, bronchoscopy, transportation outside of the ICU for radiological or other investigations or for procedures or operations, other critical situations such as hemodynamic collapse, patients will receive standard (non-study)treatment.~Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
89639607|NCT04824703|Placebo Comparator|Liberal oxygen therapy|"Spo2 target > 95%~No specific measures will be taken to avoid high fio2 or high po2~Use of upper alarm limit for spo2 will be prohibited~Echocardiography on randomization and at end of the study: we will calculate stroke volume according to Simpson's apical four view"
89639608|NCT02348190|Active Comparator|Lipid/heparin|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) lipid/heparin co-infusion for 8 hours.
89639609|NCT02348190|Placebo Comparator|Control|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and without (n=16) lipid/heparin co-infusion for 8 hours.
89639610|NCT02347956|Experimental|Reduced port group|
89639611|NCT01552369|Experimental|Preemptive Therapy|900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
89639612|NCT01552369|Active Comparator|Prophylaxis|900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88
89639613|NCT02356068||liver transplantation recepient|every patient who had a liver transplantation. 3 blood samples (2.7ml) for the ROTEM analysis
89042625|NCT04814368|Placebo Comparator|Placebo|Placebo to canakinumab
89042626|NCT04814368|Experimental|canakinumab + LNA043|canakinumab + LNA043
89042627|NCT04814368|Experimental|canakinumab|canakinumab
89042628|NCT04810572|Active Comparator|Group 1 - composition with Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition with Silymarin (Silybum marianum), in a diary dose of 140 mg for 180 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
89639614|NCT02355912|Experimental|Evaluate a real-time adaptive neural control system|The prosthesis will be tuned, for each subject: level-ground walking, walking up and down slopes and walking up and down stairs. We anticipate that participants will visit the laboratory approximately 6-9 times over 2 months (2-3 visits for socket duplications and modifications, 2-3 visits for control system tuning, and an additional 2-3 visits for practice using the tuned system). By the end of these visits, the goal is to have a properly fitting socket and for the subjects to ambulate proficiently with the powered prosthesis. After tuning, the subjects will complete 20 ambulation circuits (level ground walking, walking up and down slopes, up and down stairs). This will provide training data for our pattern recognition control systems.
89042629|NCT04810572|Active Comparator|Group 2 - composition without Silymarin (L5-Plus)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 180 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
89639615|NCT03149952|Other|Patient hospitalized for allogeneic haematopoietic stem cells|
89639616|NCT02348034|Experimental|Prevena Dressing|This group will receive prevena dressing after the elective colorectal surgery
89639617|NCT02348034|No Intervention|Conventional dressing|This group will receive conventional dressing after the elective colorectal surgery
89639618|NCT02351232|Experimental|Intervention|Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
89639619|NCT02351232|Placebo Comparator|Placebo|Placebo; daily subcutaneous injection; 1.8 mg; 6 months
89639620|NCT02355834|Experimental|Group 1 (IBD Nurse CONSULT + BOOKLET)|IBD nurse intervention-Will have 3-4 x 30 minute face-to-face sessions over 3 months with an IBD specialist nurse specifically focusing on bowel control. Participants completing at least 3 sessions will be considered to have completed the intervention. They will also be given a booklet and access to all usual care, including nurse-led IBD helpline
89639621|NCT02355834|No Intervention|Group 2 (BOOKLET alone)|Will receive the same booklet and access to usual care as Group 1.
89639622|NCT02355756|Experimental|Active|Intradermal injection of maxadilan solution
89639623|NCT02355756|Placebo Comparator|Placebo|Intradermal injection of placebo (=vehicle) solution
89639624|NCT03150030||Patients with type 2 diabetes|Insulin-treated type 2 diabetes with diabetic complications
89639625|NCT03150030||Healthy controls|Healthy control subjects
89639626|NCT02355678|Experimental|IV Dex|dexamethasone 0.5 mg/kg IV with placebo pre-incision infiltration
89639627|NCT02355678|Experimental|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 1.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 3 ml lidocaine 2%, 3 ml lidocaine 2% with epinephrine 1/200 000, 3 ml of bupivacaine 0.5%, 0.5 ml fentanyl 50 µg ml-1, and 0.3 ml clonidine 150 µg ml-1
89639628|NCT03146988|Experimental|RGB-02 6 mg SC (test product)|
89639629|NCT03146988|Active Comparator|Neulasta®|
89639630|NCT03149796||RA patients|"designated to be treated with tocilizumab and followed in rheumatology clinics.~Laboratory blood tests will be collected and analyzed"
89639631|NCT03149796||healthy controls|control Laboratory blood tests will be collected and analyzed
89639632|NCT02351310|Active Comparator|Betamethasone|Betamethasone: 12 mg given intramuscularly (IM), 24 hours apart or if as in some hospitals occasionally occurs and betamethasone is unavailable - • 4 doses of Dexamethasone IM 6 mg, 12 hours apart
89639633|NCT02351310|Placebo Comparator|Normal Saline|Quantity Sufficient (QS) of Normal Saline (NS) given intramuscularly (IM), 24 hours apart or if hospital is using Dexamethasone in place of Betamethasone then administer NS x 4 doses 12 hours apart
89639634|NCT02347878|Experimental|treatment arm|this treatment arm will received aprepitant 1 hour before lumbar puncture and intrathecal treatment.
89639635|NCT02347878|No Intervention|control arm|this arm will received nothing 1 hour before lumbar puncture
89639636|NCT02355522|Active Comparator|Lidocaine gel group|3ml of 2% lidocaine gel on the cervix and 5ml of intrauterine normal saline
89639637|NCT02355522|Active Comparator|Intrauterine lidocaine group|3ml of KY jelly on the cervix and 5ml of 2% intrauterine lidocaine
89639638|NCT02355522|Placebo Comparator|Placebo group|3ml of KY jelly on the cervix and 5mL of intrauterine normal saline
89639639|NCT02351388|Active Comparator|Active stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
89639640|NCT02351388|Sham Comparator|Sham stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
89042630|NCT04810572|Active Comparator|Group3 - Low-mineral composition without Silymarin (L5)|"This group compound with healthy and overweight/obese-I will receive the composition without Silymarin (Silybum marianum), in a diary dose for 180 days.~The formulation of the supplement/composition (Patent number: BR 10 2020 016156 3)."
89042631|NCT04800471|Active Comparator|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
89042632|NCT04800471|Placebo Comparator|Point of Care Glucose Group|Participants in this group will be monitored by point of care glucose values
89042633|NCT04796818|Experimental|Diagnostic (IVIM DWI)|Patients undergo IVIM DWI over 10 minutes during standard of care MRI within 30 days of starting chemotherapy and after 4-6 cycles of preoperative chemotherapy.
89042634|NCT04791371|Experimental|Type 2 Diabetes|Participants aged 30-55 with type 2 diabetes
89042635|NCT04791371|Experimental|Healthy overweight control|Participants aged 30-55 with BMI 25-40 without type 2 diabetes
89042636|NCT04789837|Experimental|Cilostazol|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
89042637|NCT04789837|Placebo Comparator|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
89042638|NCT04784130|Experimental|DHSMP core|Dietary Modification and Physical Activity
89042639|NCT04784130|Experimental|DHSMP core plus|Dietary Modification, physical activity and medication adherence
89042640|NCT04784130|Active Comparator|DHSMP control|enhanced usual care-3 hours of education plus materials.
89639641|NCT02355444|Experimental|High-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with high-dose blackberry polyphenols (250mL/day for 6 weeks).
89042641|NCT04783038|Active Comparator|Distance Reiki|Subjects will be scheduled for once a week session of distance Reiki for 4 weeks.
89042642|NCT04783038|Sham Comparator|Sham Reiki|Subjects will be scheduled for once a week session of Sham distance Reiki for 4 weeks.
89042643|NCT04783038|No Intervention|Standard of Care|Subjects will not receive any Reiki treatment
89042644|NCT04779125|Experimental|Gluteus plasty enhanced with Progrip self gripping mesh|All study patietns will have a gluteus enhanced plasty after abdominoperineal reconstruction.
89042645|NCT04772196|No Intervention|Control Group|Patients enrolled in the control group will receive standard of care.
89042646|NCT04772196|Experimental|Vitamin D Supplementation Group|Patients enrolled in the Vitamin D Supplementation Group will receive 50,000 IU Vitamin D3 weekly for 8 weeks.
89042647|NCT04761848|Experimental|Cilostazol|
89639642|NCT02355444|Placebo Comparator|Low-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with minimal blackberry polyphenols (250mL/day for 6 weeks).
89639643|NCT02355366|Experimental|Family Focused Therapy (FFT)|Participants will receive Family-Focused Therapy (FFT). It will consist of twelve, 1-hour long sessions, over a period of 4 months. The 12 sessions will include psychoeducation (sessions 1-4), training in communication enhancement (sessions 5-8) and training in relation to problem-solving skills (sessions 9-12).
89639644|NCT02355366|Active Comparator|Brief Educational Treatment|Participants will be receive 1-2 educational sessions which will include diagnostic feedback, recommendations for further treatment and crisis intervention if required.
89639645|NCT02347644|Experimental|Brief Motivational Interview|Given a brief motivational interview encouraging reduced use of alcohol and drugs.
89639646|NCT02347644|No Intervention|Youth Control Group|Given a brochure with all available organizations in the community for help with alcohol and drug problems.
89639647|NCT03146832|Experimental|Habituation|The habituation instruction focuses on changes of the initial physical fear-responses during exposure sessions. It is explained that the level of anxiety will gradually decrease, or habituate, each time someone faces a feared situation. Participants are then instructed to observe their own level of fear during the three practice trials with the thermode. Together with the experimenter, participants have to indicate their level of arousal on an 11-point scale (0= neutral, 10 = very high) in-between and after the three practice trials. After the practice trial, participants are instructed to reconsider their own development of physical responses. Participants are encouraged to remember the development of their level of arousal during the test trail with the thermode.
89639648|NCT03146832|Experimental|Expectation Violation|"The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. What did you learn?). Participants are encouraged to keep their own experience in mind during the test trail with the thermode."
89639649|NCT03146832|No Intervention|Control|"Participants in the control group are not provided with information about exposure therapy. Instead, participants listen to a newspaper article which reports on the daily work in a botanical garden. Together with the experimenter, participants are then asked to name the most interesting aspect in the article. Before the practice trails, participants have to rate how likely it is that they would further inform themselves about botanical gardens on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are provided with some further questions about the newspaper article (e.g. Did you find the newspaper article interesting?). This cognitive exercise does not cover any pain-related topics and, therefore, does not serve as a distraction instruction."
89639650|NCT02351154|Other|Atrophic gastritis|gastric glands (crypts) with atrophic gastritis were measured using the Cellvizio Viewer software
89639651|NCT03146520||Colorectal (CRC)|stage I-IV CRC subjects
89639652|NCT03146520||Polyps|subjects with adenoma or polyps
89639653|NCT03146520||Other cancers|subjects with other cancers
89639654|NCT03146520||Healthy|subjects with no evidence of CRC
89639655|NCT02355288|Active Comparator|Minimally Invasive Coronary Bypass|Minimally invasive bypass surgery (MICS CABG) would be conducted to treat the left anterior descending (LAD) artery disease in diabetic patients. This would be a surgical intervention, and differs from the stent procedure arm.
89639656|NCT02355288|Active Comparator|Percutenous Coronary Intervention|Percutaneous coronary intervention (PCI) with drug eluting stents would be used to treat left anterior descending (LAD) artery disease in diabetic patients. This would be an intervention induced by cardiology, and differs from the surgical intervention arm.
89639657|NCT02350842|Experimental|Triple-site biventricular pacing|Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance. Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.
89639658|NCT02350842|Active Comparator|Standard biventricular pacing|Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization. Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.
89639659|NCT02355132||Insurance Intervention Arm|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were randomly chosen to apply for insurance coverage via the Oregon Experiment
89639660|NCT02355132||Control|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were not chosen to apply for insurance coverage via the Oregon Experiment
89639661|NCT02354742|Active Comparator|Early Goal Directed Therapy (EGDT)|EGDT is currently standard of care in management of septic shock, so assignment to this treatment arm will confer no additional risk above that of standard of care. EGDT utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications. EGDT uses central venous catheter to assess central venous pressure and ScVO2.
89042648|NCT04761848|Placebo Comparator|Placebo|
89042649|NCT04757571|Experimental|Paroxetine|Paroxetine 20 mg daily plus standard therapy
89042650|NCT04757571|Placebo Comparator|Placebo|Placebo tablet daily plus standard therapy
89042651|NCT04749914|Experimental|150 Milligram (mg) Dabigatran Etexilate + 200mg Lasmiditan - Part 1|Participants received 150 mg dabigatran etexilate on Day 1 followed by 200 mg lasmiditan once daily (QD) on Days 8 and 9, and 150 mg of dabigatran etexilate along with 200 mg lasmiditan on Day 10. All treatments were administered orally
89042652|NCT04749914|Experimental|10 mg Rosuvastatin + 200 mg Lasmiditan - Part 2|Participants received 10 mg rosuvastatin on Day 1 followed by 200 mg lasmiditan QD on Days 8 and 9, and 10 mg of rosuvastatin along with 200 mg lasmiditan on Day 10. All treatments were administered orally.
89042653|NCT04746547|Other|Twice Daily DTG|Twice daily Dolutegravir (50mg) with Rifampicin containing TB treatment / Twice daily Dolutegravir (10mg) dispersible
89042654|NCT04740164|Experimental|Arm I (ERCP with LMA Gastro)|Patients undergo ERCP with LMA Gastro.
89042655|NCT04740164|Active Comparator|Arm II (ERCP with standard nasal cannula)|Patients undergo ERCP with standard nasal cannula.
89042656|NCT04722575|Experimental|ARM A|"Arm A BRAF mutated patients. Over a period of 6 weeks (1) + (2):~Vemurafenib 960 mg bid p.o. from week 1 to week 6.~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
89212166|NCT00858260||hemodialysis patients|Adult patients undergoing maintenance dialysis since at leat three months
89212167|NCT00855140|Placebo Comparator|Sham acupuncture|Sham acupuncture at non-active acupuncture points, using the Park Sham Device
89639662|NCT02354742|Experimental|Echo Guided Fluid Resuscitation|The echo arm also utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications, all of which are interventions found in standard care. The central venous pressure will not be monitored in this arm. Instead, decisions for giving fluids will be directed by the results of Echocardiography. Echocardiography poses no known risk to the patient, and it is non-invasive. The only risk of echocardiography is that of misdiagnosis.
89639663|NCT02347566|Experimental|Physical activity enhancing programme|Usual care + physical activity enhancing programme (PAEP) (Study group, [S]), which includes both pulmonary rehabilitation programme plus the PAEP using an activity monitor (DirectLife) with set targets of physical activity levels to stimulate and increase physical activity in daily life.
89639664|NCT02347566|Other|Control|Usual care (control, [C]) that includes only the pulmonary rehabilitation programme with the use of an activity monitor (DirectLife) in daily routine without any feedback or incentive to increase physical activity in daily life.
89639665|NCT04478448|Experimental|T test|Test drug (Flupirava) 1 tablet contains 200 mg Favipiravir
89639666|NCT04478448|Active Comparator|B reference|Reference drug (Avigan) 1 tablet contains 200 mg Favipiravir
89639667|NCT04478526|Experimental|e-CBT|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session were designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
89639668|NCT04478526|Experimental|Pharmacotherapy|Biweekly meeting with psychiatrist with GAD-7, DASS-42 and Q-LES-SF. Pharmacotherapy class decided according to protocol developed in accordance with Canada's best practice guidelines for GAD treatment. At second appointment, medication will be maintained and optimized, regardless of response. At third appointment, optimized if partial response or switched according to protocol if no response. Partial response is improvement of 20% or more in GAD-7. If switched, 6-week protocol will recommence with new medication. At fourth appointment, dosage optimized if responding well to medication and improvement greater than 50% within primary arm, or 20% if secondary arm, patient will remain on said medication for remainder of 12-week study. If not improving more than 20%, medication switched according to protocol and 6-week protocol will recommence. If primary arm and 20-50% improvement after six weeks on new medication, augmented with olanzapine, risperidone or benzodiazepines.
89639669|NCT04478526|Experimental|e-CBT + Pharmacotherapy|Participants will commence both treatments described above simultaneously.
89639670|NCT02350920|Active Comparator|Acceptance and Committment Therapy (ACT)|This group will consist of patients who will receive ACT therapy.This intervention will run with 8-12 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
89639671|NCT02350920|No Intervention|Control|The control group will consist of patients who will receive no ACT therapy during the 26 week st udy period
89639672|NCT01552057|Experimental|Duloxetine 60 mg|Duloxetine hydrochloride up to 60 milligrams (mg) orally for 15 weeks
89639673|NCT01552057|Placebo Comparator|Placebo|Placebo orally for 15 weeks
89639674|NCT03160014|Experimental|healthy volunteers|Drug: SHR3824 20mg/day, oral tablet, single dose
89639675|NCT03160014|Experimental|Mild Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
89639676|NCT03160014|Experimental|Moderate Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
89639677|NCT03160014|Experimental|Severe Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
89639678|NCT02350686|Experimental|capecitabine+oxaliplatin|XELOX every 3 weeks
89639679|NCT03160092|Experimental|Intervention|"Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).~The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).~The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.~The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim."
89639680|NCT03159078|Other|Polymyxin B monotherapy|Intravenous piggyback with Polymyxin B and control(Normal saline)
89639681|NCT03159078|Experimental|Polymyxin B plus Carbapenem|Intravenous piggyback with Polymyxin B plus Carbapenem
89639682|NCT01551745|Experimental|Vigil™ Vaccine|Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
89639683|NCT02350452|Experimental|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
89212168|NCT00855140|Experimental|Verum Acupuncture|Acupuncture following a specific TCM-based protocol
89212169|NCT00848900|No Intervention|Control|
89212170|NCT00848900|Experimental|Outdoor activity|Adding 1 hour outdoor time into school curricula
89212171|NCT00858416|Experimental|AB|First active then Sham
89212172|NCT00858416|Sham Comparator|BA|First sham then active
89212173|NCT00848978|Experimental|2|The experimental group will participate in the aerobic and strength training program.
89212174|NCT00848978|No Intervention|1|The usual care group will receive general physical activity guidelines.
89212175|NCT00858572|Experimental|Cohort|
89639684|NCT02350452|Active Comparator|Bipolar coaugulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
89639685|NCT02350530|Experimental|A (FOLFOXIRI + Bevacizumab)|FOLFOXIRI + Bevacizumab
89639686|NCT02350530|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
89639687|NCT01551355|Experimental|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
89639688|NCT01551355|No Intervention|children - control group|The control preschool facilities continued with their usual preschool curriculum
89639689|NCT02354664||Pompe subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
89639690|NCT02354664||Control subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
89639691|NCT01569841|Experimental|IDeg|
89639692|NCT01569841|Active Comparator|IGlar|
89639693|NCT03112356|Experimental|99mTc-Leukoscan® scintigraphy|Patients presenting a suspicions of infectious endocarditis on surgical materials and undergoing the 99mTc-Leukoscan® scintigraphy
89639694|NCT03146208||Coronary artery disease patients with type 2 DM|Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
89639695|NCT03146208||Coronary artery disease patients without type 2 DM|The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
89639696|NCT03146208||Healthy control group|we will include 54 age-matched patients with normal angiogram
89639697|NCT02350374|Other|carbohydrate counting|patients must fill their logbook during 28 days
89639698|NCT01569763|Active Comparator|hysteroscopic rollerball resection/ablation|
89639699|NCT01569763|Experimental|Aurora Endometrial Ablation|
89639700|NCT02354430|Active Comparator|Water-exercise|
89639701|NCT02354430|No Intervention|Control group|
89639702|NCT02039076|Experimental|avatrombopag|Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.
89639703|NCT02350296|Experimental|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release tablets 40 mg, corresponding to 25 mg of ketoprofen free acid
89639704|NCT02350296|Active Comparator|OKi® 80 mg|OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid)
89042657|NCT04722575|Experimental|ARM B|"Arm B BRAF mutated patients. Over a period of 6 weeks (1) + (2) + (3):~Vemurafenib 720 mg bid p.o. from week 1 to week 6.~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6. Week 4 off.~Atezolizumab 840 mg IV for 2 cycles (day 1 of week 4 and day 1 of week 7).~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
89639705|NCT03149718|Active Comparator|SMC (n=23)|Standard Medication Counseling.
89639706|NCT03149718|Experimental|BI-MTM (n=23)|Brief Intervention Medication Therapy Management.
89639707|NCT02354196||CCTA|Subjects who underwent a CCTA
89639708|NCT01550965|Experimental|Participants Receiving Adalimumab|Adults with active UC who had failed conventional therapy received Adalimumab 160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg every other week (EOW) starting at Week 4. Non-responders to adalimumab were to be discontinued from treatment at Week 8. After Week 8, dose escalation to 40 mg weekly was allowed for flare or non-response.
89639709|NCT02353884||MCIp,MCIs|progressive MCI：those convert to AD in two years, stable MCI
89639710|NCT02353884||MCI，HC|mild cognitive impairment, healthy control
89042658|NCT04722575|Experimental|ARM C|"Arm C BRAF WT patients. Over a period of six weeks (1) + (2):~Cobimetinib 60 mg qd p.o. from week 1 to week 3 and from week 5 to week 6,~Atezolizumab 840 mg IV for 2 cycles (day 1 of week 1 and day 1 of week 4).~After surgery and a second screening period (up to six weeks): Atezolizumab 1200 mg IV for 52 weeks"
89042659|NCT04708808|Experimental|MVA case undergone music therapy|case undergone manual vacuum aspiration are randomised to receive music therapy during the procedure.
89042660|NCT04708808|No Intervention|Control|Routine Care
89639711|NCT02354040|Experimental|Talking Rx|Assigned to receive Health Literacy and Reminder Updates via the IT based intervention Talking Rx, in addition to Usual Care for patients in the intervention group. The physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
89639712|NCT02354040|No Intervention|Usual Care, Prescriptions and Counselling|Assigned to receive a standard prescription and Counselling only, there are no cointerventions in this group
89639713|NCT02268474|Experimental|532nm KTP Laser vs 595nm Pulse Dye Laser|"This is a single-center prospective, randomized, controlled split-face study in 20 subjects diagnosed with Erythematotelangiectatic Rosacea and/or Papulopustular Rosacea.~This two arm, split-face study will consist of:~Treatment arm involving treatments with 532nm KTP laser~Active control arm involving treatments with 595nm Pulse Dye Laser (PDL)~Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of treatment (532nm KTP laser) and active control treatment (595nm PDL) arms will be determined by randomization."
89042661|NCT04693520|Experimental|Active treatment|ALZ-801 265 mg tablets once daily for two weeks and twice daily thereafter
89042662|NCT04687306||Females|15 females
89042663|NCT04687306||Males|15 Males
89639714|NCT02353962|Experimental|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. 5 sessions per week, 30-45 minutes per training for 3 weeks, with an intensity individually adjusted by the treating therapist according to the progress of the participating patient.
89639715|NCT03158766||Microdiscectomy|Patients with lumbar disc herniation who failed conservative treatment undergoing surgical treatment through microdiscectomy.
89639716|NCT03658629|Experimental|Dose A|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; in-clinic mix with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
89639717|NCT03658629|Experimental|Dose B|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; co-formulated with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
89639718|NCT03658629|Experimental|Dose C|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and B strain; co-formulated with 75 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
89639719|NCT03658629|Experimental|Dose D|Alternating deltoid injections of Quad-NIV (60 µg HA per A strain and 90 µg HA per B strain; co-formulated with 50 µg of Matrix-M1) on Day 0 and Placebo on Day 28.
89639720|NCT03658629|Experimental|Dose E|Alternating deltoid injections of Quad-NIV (60 µg HA per A and B strain without adjuvant) on Day 0 and Licensed 2018-2019 Influenza vaccine on Day 28.
89639721|NCT03658629|Experimental|Dose F|Alternating deltoid injections of 2018-2019 High-Dose Trivalent Vaccine on Day 0 and Placebo on Day 28.
89639722|NCT03658629|Experimental|Dose G|Alternating deltoid injections of 2018-2019 Quadrivalent Vaccine on Day 0 and Placebo on Day 28.
89639723|NCT03146364|Experimental|Hospitalization patients|patients in psychiatric hospitalization will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
89639724|NCT03146364|Experimental|Ambulatory patients|patients being treated in a clinic will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
89639725|NCT02347020|Experimental|Normal Sleep/ Normal Meal|sleep 0000-0800 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
89639726|NCT02347020|Experimental|Normal Sleep/ Late Meal|Ns/Lm: sleep 0000-0800 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
89639727|NCT02347020|Experimental|Late Sleep/ Normal Meal|sleep 0330-1130 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
89639728|NCT02347020|Experimental|Late Sleep/ Late Meal|sleep 0330-1130 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
89639729|NCT02346786|Experimental|Mineral Water|mineral water
89639730|NCT02346786|Active Comparator|Tap Water|usual water intake
89639731|NCT00323271|Experimental|Arm 1|Behavioral: Cognitive-behavior therapy
89639732|NCT00323271|Active Comparator|Arm 2|Interventional: Educational intervention
89042664|NCT04680403|Experimental|supervised exercise plan|patients will receive a tailored exercise regimen and behavior change techniques focused on adherence to the exercise program. These will be delivered by using a video platform, much liker telehealth clinic appointments. These telehealth visits will be over a 12-week period, occur 3 times a week, and last for 1 hour each.
89042665|NCT04674306|Experimental|Treatment α-lactalbumin and zymosan|"Participants diagnosed with triple negative breast cancer (TNBC) will be treated with successively higher doses of α-lactalbumin and zymosan in a traditional 3 + 3 phase I trial design. Treatment will involve a course of 3 vaccinations given every 2 weeks. Participants will be enrolled sequentially into 1 of 5 different dose levels each comprised of cohorts of 1-6 participants until the MTD has been identified (intra-patient dose escalation not permitted), after which the MTD will be expanded to 6 participants. Successively lower doses will be expanded to 6 participants until the lowest DL associated with immune response has been expanded.~Dose Level (DL) 1: 10 microgram (mcg) a-lactalbumin + 10 mcg Zymosan DL2: 100 mcg a-lactalbumin + 10 mcg Zyomsan DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan DL1b: 50 mcg a-lactalbumin + 10 mcg Zymosan DL1c: 50 mcg a-lactalbumin + 50 mcg Zymosan DL1d: 50 mcg a-lactalbumin + 30 mcg Zymosan (DL1d will only be utilized if 1c is too toxic)"
89639733|NCT02346864|Experimental|Three-stair-position group|The infants in the study group (n=72) received three-stair-position (TSP) intervention (head up 15°) for a week.
89639734|NCT02346864|Other|head elevated tilt position group|The control group(n=72)received head elevated tilt position (HETP) intervention (head up 15°) for a week．
89639735|NCT05265819|Active Comparator|Group A|Group A: Control group No intervention was provided for 12 weeks except thyroid hormone replacement therapy
89639736|NCT05265819|Experimental|Group B|Group B: Exergaming exercise The volunteers carried out 36 exergaming sessions
89212176|NCT00858650||Standard of Care|Hypogonadal males treated by standard of care, with or without testosterone replacement therapy
89639737|NCT05265819|Experimental|Group C|Group C: Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
89639738|NCT05265819|Experimental|Group D|Group D: Exergaming exercises and Mediterranean diet Exergaming exercises are used in addition to Mediterranean diet
89639739|NCT02346942||Patients who have no history of bDMARD therapy use|
89639740|NCT02346942||Patients who have a prior history of bDMARD therapy use|
89639741|NCT02346552|Experimental|Group 1|Procedures will be performed with the AutoLpap system used for holding and controlling the movement of the laparoscope.
89639742|NCT02346552|No Intervention|Group 2|Procedures will be performed with the assistance of human camera holder.
89639743|NCT00323427|Experimental|Arm 1|Group Aural Rehabilitation session, two hours in length, approximately 6 participants plus Group Facilitator
89639744|NCT00323427|Active Comparator|Arm 2|Veterans receive new VA issued digital hearing aids per Standard VA Audiology Hearing Aid services
89639745|NCT03146286|Placebo Comparator|Control|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
89639746|NCT03146286|Experimental|Saturated Fat|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.7 g/kg bodyweight palm stearin. 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
89639747|NCT03146286|Experimental|Fish Oil|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.45 g/kg bodyweight palm stearin and 0.25 g/kg bodyweight fish oil (n3PUFA). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
89639748|NCT03149406||Symptomatic patients|in the department with carotid plaque Comparing the expression of miRNAs
89639749|NCT03149406||Asymptomatic patients|in consultation with carotid plaque Comparing the expression of miRNAs
89639750|NCT02353260|Experimental|Ultrasound Hyperthermia+Chemotherapy|"Chemotherapy:~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)~The treatments will be administrated in accord with the guideline for other types of cancer.~Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles"
89639751|NCT02353260|Active Comparator|Chemotherapy|"Chemotherapy:~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2cycles)~The treatments will be administrated in accord with the guideline for other types of cancer."
89639752|NCT03148938|Experimental|Patients with Multiple Sclerosis|Patients will perform one or two visits at 15 days interval. Patients will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.
89639753|NCT03148938|Active Comparator|Healthy volunteer|Healthy volunteers will only perform one visit. Healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B).
89639754|NCT03158610|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 bid po qd
89639755|NCT03158610|Active Comparator|Capecitabine standard dosage chemotherapy|Capecitabine 1000mg/m2 bid po d1-d14,q3w
89639756|NCT02350140|Experimental|Text messaging from beginning|Half of the health facilities will be randomly allocated to receive the TextIT intervention during the first time period (six months), while the other half to continue with current standard care (first step)
89639757|NCT02350140|Active Comparator|Text messaging after 6 months of control|Half the facilities will receive standard of care for six months (first time period). After the first time period, the these facilities will then also receive the TextIT intervention (second step)
89639758|NCT00323739|Experimental|Bevacizumab and RAD001|Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
89639759|NCT02350218|Experimental|Eglandin 720㎍|Eglandin® (Alprostadil) 720㎍
89639760|NCT02350218|Active Comparator|Eglandin 360㎍|Eglandin® (Alprostadil) 360㎍
89042666|NCT04674306|Experimental|Preventitive a-lactalbumin and zymosan|"Participants with a genetic risk for developing TNBC who plan to undergo prophylactic mastectomy will be treated with α-lactalbumin and zymosan at doses based on the TNBC cohort. Treatment will involve a course of 3 vaccinations given every 2 weeks. Participants enrolled in the prevention cohort we will be enrolled at the dose level being used in the TNBC cohort if no DLTs above Grade 1 have been observed. If the TNBC cohort proceeds to the next dose level before another prevention cohort patient is enrolled, the next prevention patient will be enrolled on the next dose level along with the TNBC cohort.~Dose Level (DL) 1: 10 microgram (mcg) a-lactalbumin + 10 mcg Zymosan DL2: 100 mcg a-lactalbumin + 10 mcg Zyomsan DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan DL1b: 50 mcg a-lactalbumin + 10 mcg Zymosan DL1c: 50 mcg a-lactalbumin + 50 mcg Zymosan DL1d: 50 mcg a-lactalbumin + 30 mcg Zymosan (DL1d will only be utilized if 1c is deemed too toxic)"
89057905|NCT04529642||Stroke Group|Inclusion criteria were as follows: age above 18, Mini-Mental State Examination ≥ 24, ability to provide written informed consent and to understand the test instructions, and the presence of a single stroke. Exclusion criteria were as follows: more than one stroke, stroke area other than the cerebral cortex, or concomitant neurological disease and pathology of the locomotor system. This group has been analysed also dividing the subjects according to the stroke phase in 3 subgroups: Acute phase group, Subacute phase group, Chronic stroke group
89057906|NCT04529642||Healthy Group|Healthy subjects age matched with the stroke group
89057907|NCT01688271||Anesthesiologists|
89639761|NCT03157518|Experimental|Treatment Arm|Patients enrolled will receive probiotic supplementation following the first bronchoscopy for four weeks. A second bronchoscopy will be performed following probiotic administration.
89639762|NCT05242341|Experimental|app use teaching|"Intervention includes teach the subjects one-on-one to use the My Health Bank for 30 minutes (such as download, register, test, find information, etc.), and provide pre-recorded 1-minute instructional videos for viewing when needed at home. The intervention group also accepts to follow the use of My Health Bank app at home every two weeks for a period of two months. Both groups will receive pre- and post-evaluations, including knowledge of the disease, understanding of lab data, and knowledge of medication safety (prohibited medicines and concomitant medications)."
89639763|NCT05242341|No Intervention|B|will receive pre- and post-evaluations, including knowledge of the disease, understanding of lab data, and knowledge of medication safety
89639764|NCT03157284|Placebo Comparator|Placebo|Placebo Group will receive 7gr Maltodextrin
89639765|NCT03157284|Experimental|Intervention Rice Flour|The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
89639766|NCT03156192|Experimental|Caregivers of ICU patients|Caregivers (family member) aged over 20 who provides care to ICU patients
89639767|NCT02346318|Experimental|KS injection arm|Radiation and chemotherapy and compound Kushen Injection
89639768|NCT02346318|No Intervention|Control arm|Radiation and chemotherapy
89639769|NCT04121442|Experimental|Isunakinra monotherapy and in combination w PD-(L)1 Inhibitor|Patients will receive specified dose of Isunakinra as monotherapy for three weeks, followed by combination with a PD-(L)1 inhibitor
89057908|NCT01688349|Experimental|Cushing group|AT biopsy during partial nephrectomy
89042667|NCT04674306|Experimental|Standard of Care with a-lactalbumin and zymosan|"Participants undergoing chemo-immunotherapy for operable triple-negative breast cancer will be treated with α-lactalbumin concurrently with standard of care adjuvant pembrolizumab after having completed all pre- and postoperative chemotherapy and radiation therapy, with the exception of Xeloda/capecitabine at provider discretion. Treatment will involve 3 vaccinations given every 2 weeks. Participants enrolled in the Pembrolizumab cohort will be enrolled at the proper Optimal Immunologic Dose as defined by the TNBC and preventative cohorts and based on information available at the time of study entry.~Dose Level (DL) 1: 10 microgram (mcg) a-lactalbumin + 10 mcg Zymosan DL2: 100 mcg a-lactalbumin + 10 mcg Zyomsan DL3: 500 mcg a-lactalbumin + 10 mcg Zymosan DL1b: 50 mcg a-lactalbumin + 10 mcg Zymosan DL1c: 50 mcg a-lactalbumin + 50 mcg Zymosan DL1d: 50 mcg a-lactalbumin + 30 mcg Zymosan (DL1d will only be utilized if 1c is deemed too toxic)"
89042668|NCT04652843|Other|Idiopathic REM sleep behavior disorders|Group of 20 Patients with an Idiopathic REM sleep behavior disorder confirmed by video-polysomnography (International Classification of Sleep Disorders-3 criteria), not explained by a pathology (narcolepsy, brainstem injury, neurodegenerative disease)
89042669|NCT04652843|Other|Beginning Parkinson's disease|Group of 20 patients with Parkinson's Disease which has been progressing for less than 5 years and who have not received dopatherapy
89042670|NCT04652843|Other|Parkinson's disease state Phase|Group of 20 patients with Parkinson's Disease for more than 5 years
89042671|NCT04652843|Other|Control|Group of 20 patients undergoing coloscopy for family screening for digestive polyps
89042672|NCT04638413|Experimental|Walking regimen (W)|
89639770|NCT00390429|Experimental|Phase I, Group I (completed)|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride once on days 2, 9, and 16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
89639771|NCT00390429|Experimental|Phase I, Group II (completed)|Patients receive docetaxel as in group I and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
89639772|NCT00390429|Experimental|Phase II|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride at the MTD determined in group II of phase I once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then continue to receive erlotinib hydrochloride alone in the absence of disease progression or unacceptable toxicity.
89639773|NCT02349750|Active Comparator|endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed.
89639774|NCT02349750|No Intervention|Non endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group C received IUI without ESI and after 24 to 36 hours, IUI was performed.
89639775|NCT02349828|Active Comparator|Zovirax|Adult dose - 400 mg twice daily generic name: Acyclovir
89639776|NCT02349828|No Intervention|No treatment|standard of care
89639777|NCT02353416|Placebo Comparator|INRAM guidelines' diet|Intervention in this arm consists in some general dietary advice about healthy dietary components, serving size and frequency of servings following the Italian official guidelines.
89639778|NCT02353416|Active Comparator|Low Glycemic Index Mediterranean Diet|Intervention in this arm consists in a Low Glycemic Index Mediterranean Diet with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
89639779|NCT02353182|Experimental|Active open label single arm|"Dexmedetomidine- remifentanil- caudal based anaesthetic for lower abdominal/lower extremity surgery.~Dexmedetomidine (Precedex): loading dose: 1 mcg/kg over 10 minutes. Infusion: Start 1 mcg/kg/hr; titrate up or down within 50% of starting doses as needed~Remifentanil (Ultiva): loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed~Caudal- Bupivacaine (Marcaine) 0.175%-0.25% or Ropivacaine (Naropin) 0.2% with dose at discretion of anaesthetist"
89639780|NCT02353104|Experimental|Onion-Pumpkin Extract|Take two capsules, twice daily before breakfast and dinner
89639781|NCT04478916||Geriatric evaluation Group|Geriatric evaluation of the proportion of elderly patients in which the treatment is modified based on the complete geriatric assessment (CGA)
89639782|NCT04478916||Control Group|
89639783|NCT03145974||Hypoxemic Acute Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation, with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more, and with a FiO2 of 0.3 or more.
89639784|NCT03146130|Active Comparator|Patient treated with N-acetylcysteine|Patients randomise in the drug group
89639785|NCT03146130|Placebo Comparator|Patient treated with placebo|Patients randomise in the placebo group
89639786|NCT02349672||Healthy Control|The healthy control group will have 500-800uL (less than 1 mL) of blood collected. This sample will be obtained at the same time that the neonate is already having a standard blood screenings drawn at 24 and 48 hours of life.
89639787|NCT02349672||Clinical Control|The clinical control group will be healthy neonates that are being evaluated for jaundice, with multiple blood samples drawn between birth and 48 hours of life to monitor serum bilirubin. With these already scheduled lab draws, we will draw an additional 0.8-1 mL of blood.
89639788|NCT02349516|Experimental|Squalamine Solution BID 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
89639789|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% BID|Vehicle Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
89042673|NCT04638413|Experimental|Walking regimen + gamified inhibitory control training (W+PolyRules!)|
89639790|NCT02349516|Experimental|Squalamine Solution 0.2% QID|Squalamine Lactate Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
89639791|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% QID|Vehicle Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
89639792|NCT03155412||Offspring of type 2 diabetic patients|Group 1: 25 healthy lean men (age 30-45, BMI <28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
89639793|NCT03155412||Control subjects|Group 2: 25 healthy lean men (age 30-45, BMI <28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.
89639794|NCT03155256|Experimental|Coils + Cyanoacrylate Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils with cyanoacrylate
89639795|NCT03155256|Experimental|Coils Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils
89639796|NCT02349594|Active Comparator|treatment order A|Participants in this arm first receive 'Omegaven 10%' and after crossing over the 'Intralipid 20%'
89639797|NCT02349594|Active Comparator|treament order B|Participants in this arm first receive 'Intralipid 20%' and after crossing over the 'Omegaven 10%'
89639798|NCT02346084|Experimental|Female Participants - Arms 1A through 9A|"Female Participants 9 Arms (1A through 9A) 3 Product Sequences~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Rx3- MVC 1% gel PV~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC 1% gel PV Rx3- MVC tablet PO~Product Sequence 3 Rx1- MVC 1% gel PV Rx2- MVC tablet PO Rx3- MVC 1% gel PR~3 Biopsy Schedules D8- (~2-hr after the 8th dose) D9- (~24-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
89639799|NCT02346084|Experimental|Male Participants - Arms 1B through 4B|"Male Participants 4 Arms (1B through 4B) 2 Product Sequences 2 biopsy schedules~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC tablet PO~Biopsy Schedule D8- (~2-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
89639800|NCT03149250||Pregnant Preeclampsia|"Pregnant between 35th and 40th week of pregnancy Preeclampisa~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling"
89639801|NCT03149250||Pregnant No-Preeclampsia|Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling
89639802|NCT03149250||Not Pregnant|"Control group 2 Healthy and not pregnant control group~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling."
89639803|NCT02345928|Experimental|Part 1: Dose 1|Drug CNTO7160 or Placebo administered IV infusion Dose 1.
89639804|NCT02345928|Experimental|Part 1: Dose 2|Drug CNTO7160 or Placebo administered IV infusion Dose 2.
89639805|NCT02345928|Experimental|Part 1: Dose 3|Drug CNTO7160 or Placebo administered IV infusion Dose 3.
89639806|NCT02345928|Experimental|Part 1: Dose 4|Drug CNTO7160 or Placebo administered IV infusion Dose 4.
89639807|NCT02345928|Experimental|Part 1: Dose 5|Drug CNTO7160 or Placebo administered IV infusion Dose 5.
89639808|NCT02345928|Experimental|Part 1: Dose 6|Drug CNTO7160 or Placebo administered IV infusion Dose 6.
89639809|NCT02345928|Experimental|Part 1: Dose 7|Drug CNTO7160 or Placebo administered IV infusion Dose 7.
88991349|NCT05231005|No Intervention|Control|As controls, a sub-cohort of similar HCW, who are recruited to the Sheba COVID Cohort study (IRB 8008-20) and are followed monthly with serology tests, and are not receiving the 4th dose. The control group, all of whom signed an informed consent and allowed blood samples to be used for further immunologic studies, will be matched by age, gender, time from 3rd vaccine dose and IgG titers, and will be followed similarly
88991350|NCT05230953|Experimental|4th dose mRNA1273 vaccine|The investigators will recruit 150-200 volunteers, who received the 3rd dose at least 4 months previously, and have a known serology history (showing an immune response (even if just a low response) to the three previous doses, but with a recent relatively low IgG (below 700 BAU). These volunteers will recieve a 4th dose (50microgram) of the mRNA1273 vaccine
88991351|NCT05230953|No Intervention|Control|As controls, a sub-cohort of similar HCW, who are recruited to the Sheba COVID Cohort study (IRB 8008-20) and are followed monthly with serology tests, and are not receiving the 4th dose. The control group, all of whom signed an informed consent and allowed blood samples to be used for further immunologic studies, will be matched by age, gender, time from 3rd vaccine dose and IgG titers, and will be followed similarly
88991352|NCT05230953|Experimental|4th dose BNT162b2 vaccine|The outcomes will be compared to those participating in study IRB-8980-21, with a similar protocol, initiated 1 week earlier.
89639810|NCT02345928|Experimental|Part 1: Dose 8|Drug CNTO7160 or Placebo administered IV infusion Dose 8.
89639811|NCT02345928|Experimental|Part 1: Dose 9|Drug CNTO7160 or Placebo administered IV infusion Dose 9.
89639812|NCT02345928|Experimental|Part 2 (Asthma): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
89639813|NCT02345928|Experimental|Part 2 (Asthma): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
88991353|NCT05230615||Patients with type 2 diabetes|once-daily oral semaglutide in a real-world adult population with type 2 diabetes
89639814|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
89639815|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
89639816|NCT02353338|Experimental|Group A: Surgical|Individuals in Group A will receive surgery to correct their radial fracture
89639817|NCT02353338|Active Comparator|Group B: Conservative Treatment|Individuals in Group B will be immobilized in a cast, as per usual standard of conservative treatment.
89639818|NCT03149094|Experimental|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
89639819|NCT03149094|Active Comparator|CBSM-SMI control|The control group will receive an app called LifeSum, which focuses on healthy lifestyles.
89639820|NCT03149016|Experimental|Corticotomy-assisted Retraction|Corticotomy-assisted retraction will be performed in order to help in accelerating upper incisors' retraction
89639821|NCT03149016|No Intervention|Conventional Retraction|Conventional retraction will be used in this group of patients by sliding mechanisms
89639822|NCT02346006|Experimental|Physical activity|Subject from schools with more physical activity.
89639823|NCT03148782|Experimental|OST Intervention|12 weekly in-person sessions, each lasting approximately 1 hour, targeting 3 core organizational skills domains-Tracking Assignments, Managing Materials and Time Management
89639824|NCT00391443|Experimental|Bosentan|Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight > 40 kg) or bosentan 62.5 mg b.i.d. (if body weight < 40 kg)
89639825|NCT00391443|Placebo Comparator|Placebo|Subjects receive placebo matching the bosentan treatment regimen
89639826|NCT02343432|Experimental|Epidural Volume 10mL|Epidural Volume 10mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 10mL Intervention: Drug: Bupivacaine 12.5mg
89639827|NCT02343432|Experimental|Epidural Volume 15mL|Epidural Volume 15mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 15 mL Intervention: Drug: Bupivacaine 12.5mg
89639828|NCT02343432|Experimental|Epidural Volume 20mL|Epidural Volume 20mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 20 mL Intervention: Drug: Bupivacaine 12.5mg
89639829|NCT02343510||primary tubal cancer group|Paraffin blocks of cases of primary tubal cancer
89639830|NCT02343510||high grade serous ovarian cancer group|Paraffin blocks of cases of high grade serous ovarian cancer
88991354|NCT05220722|Experimental|SD-101|Three weekly doses of SD-101 given over two cycles via HAI using the PEDD method of administration.
88991355|NCT05206422|Experimental|ADHF patients|ADHF patients with insufficient response to diuretics treated with the Doraya catheter
88991356|NCT05203601|Experimental|SIBP-03(Recombinant anti-HER3 humanized monoclonal antibody injection)|"Stage 1: dose escalation stage Injection, first dose 2mg/kg, then 5mg/kg until the dose are no longer met the requirements of continuing the trial or up to 40 mg/kg.~Stage 2: joint extension stage:~① Group of advanced head and neck squamous cell carcinoma ：SIBP-03 & Cetuximab 5mg/kg dose level: Sibp-03, 5 mg/kg, Q3W Cetuximab, 400 mg/m2 (week 1), 250 mg/m2 (weekly follow-up), QW 10mg/kg dose level: Sibp-03, 10 mg/kg, q3W Cetuximab, 400 mg/m2 (week 1), 250 mg/m2 (weekly follow-up), QW~② Group of breast cancer：SIBP-03 & Trastuzumab & Docetaxel 5mg/kg dose level: Sibp-03, 5 mg/kg, Q3W Trastuzumab, first dose 8 mg/kg, maintenance dose 6 mg/kg, q3w+ Docetaxel 75mg/m2 q3w.~10mg/kg dose level: Sibp-03, 10 mg/kg, q3W Trastuzumab, first dose 8 mg/kg, maintenance dose 6 mg/kg, q3w+ Docetaxel 75mg/m2 q3w."
88991357|NCT05201638|Experimental|IMU-838|"IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH.~Formulation:~Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning."
88991358|NCT05201638|Placebo Comparator|Placebo|Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.
88991359|NCT05183321|No Intervention|Control Group|Group will not receive treatment: periodontal therapy
88991360|NCT05183321|Experimental|Periodontal therapy|Group will receive treatment: periodontal therapy
88991361|NCT05182008|Experimental|Decision Aid|Patients will be guided to an online interactive decision aid tool.
88991362|NCT05182008|Active Comparator|Usual Care|Patients will be guided to visit the clinic website of the Nova Scotia Women's Choice Clinic.
89639831|NCT02343510||Low Grade Serous Ovarian Cancer|Paraffin blocks of cases of low grade serous ovarian cancer
89639832|NCT02343510||normal tubes group|Paraffin blocks of tubes of hysterectomies due to non-oncologic causes
89639833|NCT02349282|Experimental|Calcifediol 10 ug/day|Capsule with 10 ug/day Calcifediol taken together with breakfast for a total period of 24 weeks.
89639834|NCT02349282|Experimental|Vitamin D3 20 ug/day|Capsule with 20 ug/day Vitamin D3 taken together with breakfast for a total period of 24 weeks.
89639835|NCT02349282|Placebo Comparator|Placebo|Capsule without active ingredients, taken together with breakfast for a total period of 24 weeks.
89639836|NCT02345694|Experimental|Effective CPAP|Continuous Positive Airway Pressure (RESMED S9™ Series), all the nights, during 8 weeks.
89639837|NCT02345694|Sham Comparator|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (RESMED S9™ Sham-Continuous Positive Airway Pressure System), validated placebo of Continuous Positive Airway Pressure, all the nights, during 8 weeks.
88991363|NCT05174026|Experimental|Diagnostic (18F-FDG PET-MRI)|Patients receive fludeoxyglucose F-18 IV over 1 minute, and then undergo PET-MRI over 1 hour, 30 days before radiation therapy, and 3 and 6 months after radiation therapy.
89057909|NCT01688349|Other|Controls1|normal weight metabolic healthy patients having partial nephrectomy with small AT Biopsy.
89639838|NCT05075421||Group 1 (high marker)|Patients with elevated serum markers
89639839|NCT05075421||Group 2 (normal marker)|Patients with normal value of serum markers
89639840|NCT02349204|Experimental|Exposure to music|The participants in this groups will have to complete the tasks on the intraocular surgery simulator while listening to Mozart's sonata for 2 pianos in D-440
89639841|NCT02349204|No Intervention|No exposure|The participants in this groups will have to complete the tasks on the intraocular surgery simulator in silence
89639842|NCT00391599|Experimental|Study Group|a fleet enema (250 cc of sodium biphosphate 16 gr and sodium phosphate 6 gr per 100 cc) the night before cesarean section
89639843|NCT00391599|Active Comparator|Control Group|no preoperative intestinal preparation.
89639844|NCT02345616|Experimental|Nitric oxyde|
89639845|NCT02343354|Experimental|Nutrition/physical activity intervention|There will be five in-person group sessions (3 to 4 weeks appart) with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website, telephone calls and phone applications.
89639846|NCT03148704||palonosetron palonosetron hydrochloride|A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
89639847|NCT02348970|Experimental|mandibular advancement devices ONIRIS®|The patients will use the mandibular advancement devices ONIRIS®
89639848|NCT02348970|Active Comparator|laboratory devices TALI|The patients will use the laboratory devices TALI
89639849|NCT01795287|Active Comparator|Spinal anesthesia|Spinal anesthesia
89639850|NCT01795287|Active Comparator|General anesthesia|General anesthesia with fentanyl, propofol and rocuronium and sevoflurane
89639851|NCT02342964|Other|MUCO-FIBRO|Measures of hepatic elasticity
89639852|NCT05013411||Healthcare workers|Healthcare workers with patient care experience and are willing to share their experience of current practices of obtaining patient observations.
89639853|NCT02343198|Experimental|Stimulation|Custom-built research muscle stimulator. Muscle stimulator is set to provide a comfortable stimulation when applied to the soleus muscle using two 5x5cm electrodes.
89639854|NCT02343198|Placebo Comparator|Placebo-control|Custom-built research muscle stimulator. Muscle stimulator is set to provide sensory stimulation but will not cause an active muscle contraction. Stimulation is also delivered to the soleus muscle through two 5x5cm electrodes.
89639855|NCT02345538||Women with Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women with chronic pelvic pain and determine if resting tone correlates with severity of pain.
89639856|NCT02345538||Women without Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women without chronic pelvic pain
89639857|NCT04976283|Active Comparator|Pioglitazone|The starting dose would be 15mg/day for pioglitazone and 500 to 1500mg per day for metformin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
89639858|NCT04976283|Active Comparator|Empagliflozin|The starting dose would be 500-1500mg/day of metformin, plus 5/10/12.5mg empagliflozin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.
89639859|NCT04976283|Active Comparator|Pioglitazone + Empagliflozin|The starting dose would be 15mg/day for pioglitazone and 500 to1500mg per day for metformin and 5/10/12.5mg/25mg/day empagliflozin and 50 to 100mg daily for DPP4 inhibitors depending on blood sugar levels.
88991364|NCT05173272|Experimental|Experimental: Neoadjuvant Therapy+CCRT|Patients will be treated with 2 cycles of neoadjuvant chemotherapy (Cisplatin 50 mg/m^2 d1 q21+ Paclitaxel 175 mg/m^2 d1 q21) combined with serplulimab （300mg d1 q21）. After that, weekly cisplatin 30mg/m^2 for 4 or 5 weeks is administered concomitant with external beam radiotherapy (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes. The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors. All radiotherapy should be completed within eight weeks.
88991365|NCT05173272|Experimental|Experimental: CCRT alone|weekly cisplatin 40mg/m^2 for 4 or 5 weeks is administered concomitant with external beam radiotherapy (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes. The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors. All radiotherapy should be completed within eight weeks.
88991366|NCT05172050|Experimental|Group 1: Raloxifene 60 mg|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing 60 mg of the active substance or placebo), a single daily oral dose of raloxifene 60 mg was administered; the treatment was taken by the patients for two weeks.
88991367|NCT05172050|Experimental|Group 2: Raloxifene 120 mg|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing 60 mg of the active substance or placebo), a single daily oral dose of raloxifene 120 mg was administered; the treatment was taken by the patients for two weeks.
88991368|NCT05172050|Placebo Comparator|Group 3: Placebo.|After an administration of two oral doses in the first day of treatment (one dose in the morning and one dose in the evening, each dose administered with 2 capsules containing placebo), a single daily oral dose of placebo (2 capsules guarantee the blinding design) was administered; the treatment was taken by the patients for two weeks.
88991369|NCT05165160|Experimental|Eligible patients|
89639860|NCT02345382|Experimental|20 mg BAY1143572|Subjects received 20 milligram (mg) BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
89639861|NCT02345382|Experimental|40 mg BAY1143572|Subjects received 40 mg BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
89639862|NCT02345382|Experimental|80 mg BAY1143572|Subjects received BAY1143572 80 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
89639863|NCT02345382|Experimental|120 mg BAY1143572|Subjects received BAY1143572 120 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
89639864|NCT02345382|Experimental|160 mg BAY1143572|Subjects received BAY1143572 160 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
89639865|NCT02345382|Experimental|200 mg BAY1143572|Subjects received BAY1143572 200 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
89042674|NCT04634071|Experimental|Group 1: Varenicline, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
89639866|NCT02345382|Experimental|240 mg BAY1143572|Subjects received BAY1143572 240 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
89639867|NCT02108223|Active Comparator|fix dose r-FSH (Gonal-f)|The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1
89639868|NCT02108223|Active Comparator|r-LH supplementation to r-FSH|On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.
89639869|NCT02108223|Active Comparator|r-FSH (Gonal-f)|Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.
89639870|NCT03148548||Patients with iliofermoral thrombosis without rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
89639871|NCT03148548||Patients with ilifermoral thrombosis with rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
89639872|NCT02345304|Experimental|Treatment 3|single dose of midazolam + BI drug
89639873|NCT02345304|Experimental|Treatment 4|single dose of probe drugs + BI drug
89639874|NCT02345304|Experimental|Treatment 5|single dose of digoxin + BI drug
89639875|NCT02345304|Experimental|Treatment 1|single doses of probe drugs
89639876|NCT02345304|Experimental|Treatment 2|single dose of digoxin
89639877|NCT01569295|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib plus bendamustine and rituximab
89639878|NCT01569295|Placebo Comparator|Placebo to match idelalisib+bendamustine+rituximab|Participants will receive placebo to match idelalisib plus bendamustine and rituximab
89639879|NCT03112278|Active Comparator|Ceramic restorations|Ceramic ultrathin occlusal veneers
89639880|NCT03112278|Active Comparator|Composite resin restorations|Composite resin ultrathin occlusal veneers
89212177|NCT00515086|Experimental|No Surgery (Everolimus 10 mg)|Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
89212178|NCT00515086|Experimental|Everolimus 10 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
89639881|NCT02108457||Proton subjects|
89639882|NCT02108457||IMRT subjects|
89639883|NCT03148626|Experimental|MINDI mindfulness curriculum|The intervention is a seven-session mindfulness curriculum to be delivered over six months to pediatric interns.
89639884|NCT03148626|Placebo Comparator|Control|Usual education.
89639885|NCT02345148|Experimental|Cohort 1|Elder participants will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
89639886|NCT02345148|Experimental|Cohort 2|Younger adults will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
89639887|NCT00394329|Experimental|Daily ICS + Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir®™ 90 mcg Inhalation Aerosol) rescue puffs as needed
89042675|NCT04634071|Experimental|Group : Varenicline, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
89639888|NCT00394329|Active Comparator|Daily ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
89639889|NCT00394329|Experimental|Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
89639890|NCT00394329|Placebo Comparator|Placebo|Albuterol sulfate administered via a hydrofluoroalkane (HFA) inhaler (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
89639891|NCT02342808|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
89639892|NCT02342808|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
89639893|NCT03148392||Cryo Balloon Ablation|Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
89639894|NCT03148392||Radiofrequency Ablation|Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
89639895|NCT02342730|Experimental|Weight Loss Referral|Patients are referred to a weight loss specialist for assistance with weight loss and medical chart reviews are performed at baseline and every 3 months for 24 months. Patients complete Quality-of-Life Assessment (EORTC- QLQ-C30 and EORTC-QLQ-EN24) at baseline, 12, and 24 months. Patients are also contacted at 90 days to determine whether they have initiated any weight loss interventions.
89639896|NCT02108691|Experimental|Glycin max(L.) Merr. pell extract|
89639897|NCT02108691|Placebo Comparator|Placebo|
89639898|NCT03146052|Experimental|Asymmetric split dose preparation|75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
89639899|NCT03146052|Active Comparator|Symmetric split dose preparation|50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure
89639900|NCT02109159|Experimental|emotional content|A short online video with emotional content, an interview with a postpartum hemorrhage survivor and her husband talking about their experience.
89639901|NCT02109159|Active Comparator|less emotional content|A short online video with less emotional content, the WOMAN trial coordinator talks about the experience of a postpartum hemorrhage survivor and her husband.
89639902|NCT01549951|Experimental|Orteronel+Prednisone|
89639903|NCT03145740|Experimental|Intensive F.O.T.T.®|Intensive F.O.T.T.® intervention was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Before and after the intervention, the patient was positioned in a standardized way in side lying for 10 minutes to rest. Here, the Electromyographic Bioimpedance Measuring device (EMBI) measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. In the intervention itself, the patient was facilitated with specific handling and interventions to swallow, according to F.O.T.T.®. The faciltation was embedded into a meaningful context for the patient, e.g. tooth brushing or eating small amounts of apple sauce, if safe.
89639904|NCT03145740|Placebo Comparator|Unspecific stimulation of face and mouth|The intervention in the control group was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Patients in the control group were before and after the intervention, positioned in a standardized way in side lying for 10 minutes to rest. The EMBI measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. The intervention included unspecific stimulation of the hands and the face, without therapeutic interventions directed towards facilitation of swallowing.
89639905|NCT02342652|Experimental|ASLAN003|Substance: ASLAN003 Administration route: Oral. Dosage form: Hard gelatine 50 mg capsules. Frequency: 100 mg (2 capsules) once daily for 14 consecutive days
89639906|NCT02342652|Placebo Comparator|Matched Placebo|Substance: Placebo Administration route: Oral Dosage form: Hard gelatine capsules Frequency: 2 capsules once daily for 14 consecutive days
89639907|NCT02342496|Placebo Comparator|Placebo|Powder consisting of maltodextrine, treated to resemble the Active product in appearance and taste.
89639908|NCT02342496|Active Comparator|Active, only probiotics|Powder consisting of freezedried bacteria at 10 billions cfu/daily dose and maltodextrine, treated to resemble the Active product in appearance and taste.
89639909|NCT02342496|Active Comparator|Active, blend of berries and probiotics|Powder consisting of freezedried berries , probiotics at 10 billions cfu/daily dose and maltodextrine.
89639910|NCT03148314|Other|hospital- based standard dose of vaginal misoprostol|
89639911|NCT03148314|Other|Home-based extended low dose of buccal/sublingual misoprostol|
89639912|NCT01517893|Experimental|Intervention arm|Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
89639913|NCT01517893|Placebo Comparator|Placebo Arm|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
89639914|NCT02342340|Active Comparator|Navy Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
89639915|NCT02342340|Active Comparator|Red Kidney Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked red kidney beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
89639916|NCT02342340|Active Comparator|Pinto Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked pinto beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
89639917|NCT02342340|Active Comparator|Black Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
89057910|NCT01688349|Other|Controls2|obese individuals already included and having biopsies of VAT and SCAT stocked.
89639918|NCT02342340|Active Comparator|Lentils (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked lentils. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
89639919|NCT02342340|Placebo Comparator|White Rice (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
89639920|NCT02344992|Experimental|Biochaperone Insulin Lispro|
89639921|NCT02344992|Active Comparator|Humalog®|
89639922|NCT01489891|Active Comparator|Lidocaine group|Blinded spraying 50 mg of pharyngeal topical lidocaine 180 seconds before sedated esophagogastroduodenoscopy (EGD)
89639923|NCT01489891|Placebo Comparator|Placebo|Excipients without lidocaine. The flavour taste is the same of active comparator ensuring the masking.
89639924|NCT02342574|Experimental|A active|Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
89639925|NCT02342574|Placebo Comparator|A placebo|Two subjects receiving F901318 placebo intravenously for eight days
89639926|NCT02342574|Experimental|B active|Six subjects receiving F901318 3 mg/kg intravenously for eight days
89639927|NCT02342574|Placebo Comparator|B placebo|Two subjects receiving F901318 placebo intravenously for eight days
89639928|NCT02342574|Experimental|C active|Six subjects receiving F901318 4 mg/kg intravenously for eight days
89639929|NCT02342574|Placebo Comparator|C placebo|Two subjects receiving F901318 placebo intravenously for eight days
89639930|NCT02342574|Experimental|D1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
89639931|NCT02342574|Placebo Comparator|D1 placebo|Two subjects receiving F901318 placebo intravenously for one day
89639932|NCT02342574|Experimental|E1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
89639933|NCT02342574|Placebo Comparator|E1 placebo|Two subjects receiving F901318 placebo intravenously for one day
89639934|NCT02342574|Experimental|F1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
89639935|NCT02342574|Placebo Comparator|F1 placebo|Two subjects receiving F901318 placebo intravenously for one day
89639936|NCT02342574|Experimental|D2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
89639937|NCT02342574|Placebo Comparator|D2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
89639938|NCT02342574|Experimental|E2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
89639939|NCT02342574|Placebo Comparator|E2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
89639940|NCT02342574|Experimental|F2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
89639941|NCT02342574|Placebo Comparator|F2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
89639942|NCT00360009|Active Comparator|STN DBS|Patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's disease (PD)
89639943|NCT00360009|Active Comparator|GPI DBS|Patients who underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi) to treat Parkinson's disease (PD)
89639944|NCT00360009|No Intervention|no DBS|non-DBS PD patient control group
89639945|NCT03148002|Active Comparator|Current Bowel Protocol|Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.
89639946|NCT03148002|Active Comparator|PEG Bowel Protocol|Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.
89639947|NCT02342262|Experimental|Probiotics|EcologicBarrier, 5x10E9 cfu/day
89639948|NCT02342262|Placebo Comparator|Placebo|carrier material of Ecologic Barrier, not containing bacterial strains
89639949|NCT02342184|Experimental|GB-0998|
89639950|NCT00360243|Experimental|flibanserin 25 mg b.i.d|25 mg twice daily for 24 weeks
89057911|NCT02216318|Placebo Comparator|red light|red light during the whole day
89057912|NCT02216318|Active Comparator|Blue light|Blue light during early day
89057913|NCT04822389|Experimental|Home-based telerehabilitation exercise|Exercise training is conducted in the patient's home conditions using modern technology to transfer medical data remotely - the participants receive a heart rate monitor and sensor. To know what to do and how to exercise, the first (1-2) exercise training sessions will be controlled by the physiotherapist in a rehabilitation clinic in the hospital, who creates individual exercise training for each patient. The patient's training data will be downloaded and updated regularly via the internet platform and clinicians will evaluate these results and provide patients with telephone feedback.
89057914|NCT02218073|Experimental|Treatment Sequence AB|Participants will receive 10 milligram (mg) JNJ-42756493 tablet orally on Day 1 of Period 1 and 100 microgram (mcg) of JNJ-61818549 as intravenous injection 2 hours after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 2.
89057915|NCT02218073|Experimental|Treatment Sequence BA|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 1 and JNJ-42756493 10 mg tablet orally on Day 1 of Period 2.
89057916|NCT05138523||Non-cirrhotic|Non-cirrhotic HCV patients; 12 weeks treatment
89057917|NCT05138523||Cirrhotic|Cirrhotic HCV patients; 24 weeks treatment
89057918|NCT02218112||OB - Bariatric surgery (gastric bypass)|Obese patients who will undergo a bariatric surgery (gastric bypass)
89057919|NCT02218112||OB- Control group|Obese patients who will not undergo surgery - Control group
88991370|NCT05164666|Experimental|TAK-103, Dose Escalation|TAK-103, Chimeric antigen receptor (CAR) (+) cells, intravenous infusion, will be administered at approximately 5 mL/min. There are 5 planned dose levels: 1x10^6, 3x10^6, 1x10^7, 1x10^8 and 5x10^8 CAR (+) cells/body. The level of dose in dose escalation will be guided by dose escalation schema based on the observed dose limiting toxicities (DLT) rate at each dose level.
88991371|NCT05143996|Experimental|Part A - Single ascending dose (SAD) design of IV administered CLN-049|Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration
88991372|NCT05143996|Experimental|Part B - Multiple ascending dose (MAD) design of IV administered CLN-049|Patients with relapsed/refractory AML or MDS will receive CLN-049 via IV administration
88991373|NCT05143996|Experimental|Part C - Multiple ascending dose (MAD) design of SC administered CLN-049|Patients with relapsed/refractory AML or MDS will receive CLN-049 via SC injection
88991374|NCT05136417|Experimental|left atrial appendage (LAA) occlusion with the WATCHMAN FLX device using (ICE)|100 patients undergoing LAA closure with the WATCHMAN FLX utilizing an intra-procedural ICE probe under moderate sedation.
88991375|NCT05134441|Experimental|IMU-838|"IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH.~Formulation:~Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning."
88991376|NCT05134441|Placebo Comparator|Placebo|Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.
88991377|NCT05131828|Experimental|Research arm: metformin and clemastine|
88991378|NCT05131828|Placebo Comparator|Control arm: placebos for both metformin + clemastine|
88991379|NCT05127980||patients with confirmed primary EBV infection|"40 patients with confirmed primary EBV infection as confirmed by the treating clinician and defined by:~- Compatible clinical (infectious mononucleosis symptoms including but not limited to malaise, headache, fever, tonsillitis, pharyngitis, cervical lymph nodes enlargement) and laboratory picture (lymphocyte count elevation, LUC cells, reactive lymphocytes in manual differential, elevated liver enzymes; of note, not all typically described features have to be fulfilled)~AND~- serology compatible with primary EBV infection (anti-EBNA IgG negative, anti-VCA IgG negative, anti-VCA IgM positive OR anti-EBNA IgG negative, anti-VCA IgG positive, anti- VCA IgM positive)"
88991380|NCT05127980||control patients|40 control patients (Clinical picture of upper respiratory tract infection (including but not limited to tonsillitis/pharyngitis, malaise, headache, cough, rhinitis, cervical node enlargement)) and/ or confirmed primary Cytomegalovirus (CMV) infection
88991381|NCT05124405|Experimental|Heart Rate Tracker (Fitbit)|continuous heart rate activity
88991382|NCT05124405|Experimental|Continuous Glucose Monitor (CGM)|monitoring daily exercise-related activities
88991383|NCT05121805|Experimental|EMR plus snare tip soft coagulation|Post procedural prophylactic coagulation of the entire margin of the resection site creating a 2-3mm rim.
88991384|NCT05121805|No Intervention|Standard EMR|No prophylactic coagulation
88991385|NCT05114837|Experimental|Phase I/II|Determine the maximum tolerated dose (MTD) of CAR19-tTreg. It will be administered in a single dose after high dose lymphodepleting chemotherapy to promote adoptive transfer. First dose of 1.0 x 10 6 CAR19-tTreg/kg recipient body weight (dose level 1).The subsequent doses are 3.0, 10.0 and 30.0 x 10 6 CAR19- tTreg/kg. PHASE II Expand trial on maximum tolerated dose (MTD) of CAR19-tTreg from Phase I. It will be administered in a single dose after high dose lymphodepleting chemotherapy to promote adoptive transfer.The CAR19-tTreg/kg dose is to be determined.
88991386|NCT05108974|Experimental|3 months choline bitartrate|Over the 9-month study, participants will receive a total of 3 months of choline bitartrate (19 mg/kg) and a total of 6 months of placebo
88991387|NCT05108974|Experimental|6 months choline bitartrate|Over the 9-month study, participants will receive a total of 6 months of choline bitartrate (19 mg/kg) and a total of 3 months of placebo
88991388|NCT05106920|Experimental|NMP 3 Hz|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
88991389|NCT05106920|Experimental|NMP 10 Hz|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 10 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
88991390|NCT05103293|Experimental|PTC group|Patients randomized into this group receiving PTC test and choose regimens according to this test results
88991391|NCT05103293|No Intervention|Control group|Patients randomized into this group receiving routine regimens according to subtypes
88991392|NCT05094934|Active Comparator|Normal renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
88991393|NCT05094934|Experimental|Mildly decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
88991394|NCT05094934|Experimental|Moderately decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
88991395|NCT05094934|Experimental|Severely decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
88991396|NCT05091073|Experimental|Fed group|Fed dosing conditions
88991397|NCT05091073|Experimental|Fasting group|Fasting dosing conditions
88991398|NCT05091073|Active Comparator|Reference group|Reference dosing conditions
88991399|NCT05089916|Experimental|Osimertinib plus Radiation|Osimertinib 80 mg Radiation as per SOC
88991400|NCT05086068|Other|Arthrosamid Inj|Single arm study - no comparator
89639951|NCT00360243|Experimental|flibanserin 50mg qhs|50 mg taken once daily at bedtime for 24 weeks
89212179|NCT00515086|Experimental|Everolimus 5 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
89212180|NCT00515086|Active Comparator|Everolimus 0 mg + Surgery|Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
89639952|NCT00360243|Experimental|flibanserin 50mg b.i.d.|50 mg twice daily for 24 weeks
89639953|NCT00360243|Placebo Comparator|placebo|twice daily for 24 weeks
89639954|NCT02342106||Poor responders|In order to define the poor response in IVF, at least two of the following three features must be present: (i) advanced maternal age or any other risk factor for poor ovarian response; (ii) a previous poor ovarian response; and (iii) an abnormal ovarian reserve test . Two episodes of poor ovarian response after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test. By definition, the term poor ovarian response refers to the ovarian response, and therefore, one stimulated cycle is considered essential for the diagnosis .
89639955|NCT02342106||Good responders|"Total number of antral follicles : 22-35 Normal (good) antral count, should have an excellent response to ovarian stimulation.Likely to respond well to low doses of FSH drugs.~Very low risk for IVF cycle cancellation. Some risk for ovarian overstimulation if a Lupron trigger is not used for final egg maturation injection.~Excellent pregnancy success rates."
89639956|NCT02039232|Experimental|CarboFix Pedicle Screw System|
89639957|NCT02344914|Experimental|receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
89639958|NCT02344914|No Intervention|do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
89639959|NCT02348892||With coordinator|Elderly patients, in complex situation, taken care by coordinator
89639960|NCT02348892||Without coordinator|Elderly patients, in complex situation, taken care by the classic plan
89639961|NCT03147924|Experimental|Attending Improvisation Group|Attended 3 or more Improvisation Group sessions
89639962|NCT00396201|Experimental|Participants with Hodgkin's Disease (HD)|Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
89639963|NCT02348814||normal weight|BMI 20-25
89639964|NCT02348814||overweight|BMI 25-30
89639965|NCT02348814||obese|BMI 30-35
89639966|NCT02348814||morbidly obese|BMI > 35
89639967|NCT02348814||non-diabetic|HgbA1c (<5.7%) and blood glucose (65-99 mg/dL) within normal range as defined at UCLA Clinical Lab
89639968|NCT02348814||diabetic|HgbA1c (>6.5%) and blood glucose (>100 mg/dL) as defined at UCLA Clinical Lab
89639969|NCT02348814||non-cirrhotic|Normal liver function tests (AST/SGOT, ALT, SGPT, alkaline phosphatase, bilirubin) as defined at UCLA Clinical Lab
89639970|NCT02348814||dyslipidemic|Abnormal lipid profile (Total cholesterol >170 mg/dL, LDL >100 mg/dL, HDL >130 mg/dL, triglycerides >150 mg/dL) as defined at UCLA Clinical Lab
89639971|NCT03145662|Active Comparator|high pressure balloon|randomized to have dialysis fistula or AV graft treated with high pressure balloon
89639972|NCT03145662|Active Comparator|cutting balloon|randomized to have dialysis fistula or AV graft treated with cutting balloon
89639973|NCT03145896|Active Comparator|IBD patients with Vitamin D treatment|
89639974|NCT03145896|No Intervention|IBD patients with no Vitamin D treatment|
89639975|NCT02341872|No Intervention|Control|The investigators won't do any application , the oral hygiene konwledge will be given only.
89639976|NCT02341872|Active Comparator|Fluoride + Calcium varnish|The investigators will do fluoride+ calcium varnish( Clinpro White Varnish) application on white spot lesions.
89639977|NCT02341872|Experimental|Polipeptide solution|The investigators will do polipeptide ( Curodont Repair) solution application on white spot lesions.
89639978|NCT02341872|Experimental|Fluoride + calcium + polipeptide|The investigators will do polipeptide ( Curodont Repair) solution and fluoride + calcium varnish (Clinpro White Varnish) application on white spot lesions.
89639979|NCT02342028||OSA|"The study group enrolled patients with OSA, fulfilling the following requirements~20~60 years ago, female or males~Agree participate the study and sign informed consent~Has not received any treatment for OSA~No obvious comorbidities (including autoimmune diseases)~No history of sarcoidosis and tuberculosis~No use of steroid and immunosuppressant"
89639980|NCT02342028||Control|"The control group enrolled age-, gender- and BMI-matched individuals without OSA, fulfilling the following requirements~20~60 years ago, female or males~Agree participate the study and sign informed consent~No obvious comorbidities (including autoimmune diseases)~No history of sarcoidosis and tuberculosis~No use of steroid and immunosuppressant"
89639981|NCT05255094|Experimental|AK102 regimen 1|
89639982|NCT05255094|Experimental|AK102 regimen 2|
89639983|NCT05255094|Placebo Comparator|Placebo 1|
89639984|NCT05255094|Placebo Comparator|Placebo 2|
89639985|NCT02348580|No Intervention|Treatment as usual|Schools in which regular curriculum is delivered and teachers do not receive any additional training in child centered methodologies.
89639986|NCT02348580|Experimental|Child centered teaching of life-skills|Training of teachers and weekly implementation of hour long sessions based on child centered teaching of life-skills education over the course of the school year in P6 and S3 classes as designed by Aflatoun Stichting Child Savings International and the Association of Microfinance Institutions in Rwanda (AMIR). The life-skills curriculum is known as Aflatoun's Child Social and Financial Education program. The training of teachers element of the intervention is known as Aflatoun Academy, which trains teachers in active learning, child centered methodologies as well as how to implement the life-skills curriculum of Aflatoun Child Social and Financial Education.
89639987|NCT02348736|Experimental|SensaScope|Time for tracheal intubation with the SensaScope
89639988|NCT02348736|Experimental|McGrath Series 5|Time for tracheal intubation with the McGrath Series 5
89639989|NCT00360399|Active Comparator|Escitalopram|Participants will receive treatment with escitalopram for 12 weeks
89639990|NCT00360399|Active Comparator|Duloxetine|Participants will receive treatment with duloxetine for 12 weeks
89639991|NCT00360399|Active Comparator|CBT|Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks
89639992|NCT02341794|Experimental|Rosuvastatin|
89639993|NCT02341950|Experimental|SCI Hard|This arm plays the SCI HARD game
89639994|NCT02341950|No Intervention|Control|Plays an alternate, publicly available game
89639995|NCT02344836|Active Comparator|Theory-based podcast|"Receive a 3-month weight loss intervention delivered via theory-based podcast (TBP) plus self-monitoring using a commercially-available calorie and weight tracking app (current most popular diet self-monitoring method).~Intervention: podcast + mobile diet app"
89639996|NCT02344836|Experimental|Theory-based podcast + Social POD|"Receive a 3-month weight loss intervention delivered via Theory-based Podcast (TBP) plus self-monitoring and social support/incentive points for participating with the Social POD app (TBP+Social POD).~Intervention: podcast + theory-based mobile diet app"
89639997|NCT00360555|Experimental|flibanserin|flibanserin 25 mg b.i.d
89639998|NCT00360555|Experimental|flibanserin 50mg|flibanserin 50mg qhs/b.i.d
89639999|NCT00360555|Experimental|flibanserin 100mg|flibanserin 50mg b.i.d./100mg qhs
89042676|NCT04634071|Experimental|Group 3: Varenicline, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive varenicline, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042677|NCT04634071|Experimental|Group 4: Varenicline, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive varenicline and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042678|NCT04634071|Experimental|Group 5: Buproprion, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042679|NCT04634071|Experimental|Group 6: Buproprion, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042680|NCT04634071|Experimental|Group 7: Buproprion, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive Buproprion, counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042681|NCT04634071|Experimental|Group 8: Buproprion, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive Buproprion and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042682|NCT04634071|Experimental|Group 9: Nicotine, Intense Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042683|NCT04634071|Experimental|Group 10: Nicotine, Intense Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042684|NCT04634071|Experimental|Group 11: Nicotine, Minimal Counselling and NRT|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch), counseling, and nicotine replacement therapy (PRN NRT). Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042685|NCT04634071|Experimental|Group 12: Nicotine, Minimal Counselling|Patients diagnosed with tobacco-related treatment will receive long acting nicotine replacement therapy (e.g. nicotine patch) and counseling. Dose and frequency will be based on patient preference, smoking history and other medical factors.
89042686|NCT04632433|Experimental|single arm|Patients will receive cemiplimab at a dosage of 350 mg every 3 weeks for two cycles prior surgery. Stage III stage must be documented at screening and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan (if clinically indicated) and Positron emission tomography (PET). Postoperatively, adjuvant immunotherapy with cemiplimab will be administered at a dosage of 350 mg every 3 weeks for one year.
89640000|NCT00360555|Placebo Comparator|placebo|placebo comparator
89640001|NCT03145506||Mohs Surgery Patients|Adult patients undergoing Mohs surgery for treatment of BCC or SCC
89640002|NCT02344602|Experimental|Febuxostat (trade name Uloric®)|Oral tablet, 80mg, OD, 8 weeks
89640003|NCT02348268|Active Comparator|Manual Therapy + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally this group was treated with manual therapy (for 15 minutes).
89640004|NCT02348268|Experimental|Myofascial Release + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally, this group was treated with myofascial release therapy (for 15 minutes).
89640005|NCT02337348|Experimental|OCT guided coronary intervention|Coronary angiography and optical coherence tomography imaging
89640006|NCT02337348|Active Comparator|Conventional coronary intervention|Coronary angiography
89640007|NCT00361257|Experimental|Arm 1: Minocycline|100 mg orally every 12 hours
89640008|NCT00361257|Placebo Comparator|Arm 2: Matching placebo|orally every 12 hours
89640009|NCT02344758|Experimental|Celiac adult|Patient >16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
89640010|NCT02344758|Experimental|Celiac child|Patient <16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
89640011|NCT02344758|Active Comparator|Healthy adult|Healthy individual > 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
89640012|NCT02344758|Active Comparator|Healthy child|Healthy individual < 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
89640013|NCT02344524|Experimental|Small bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using small bore chest drain
89640014|NCT02344524|Active Comparator|Large bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using large bore chest drain
89640015|NCT04062240||Additional BIS sensor|Many providers caring for cardiovascular surgical patients utilizes BIS monitoring to gauge depth of anesthesia. The current practice involves placement of the BIS sensor on the patient's forehead per the manufacturer's recommendation on arrival to the operating room. The intervention in this study will add an additional BIS sensor to the patient's forehead. After syncing the two monitors for time, and ensuring appropriate skin contact and signal quality of both sensors, BIS monitoring will commence. BIS readings will be available every 12 seconds during the duration of the study, yielding up to 240 points of comparison per enrolled patient.
89640016|NCT02344446|Experimental|Skilled Therapy|Differential physical therapy treatment, based on assessment results, with follow-up visits for PT treatment 1 - 2 times per week until patient achieves at least 1 primary outcome. They will pragmatically design an individualized and progressive treatment plan, including manual therapy (manipulation and/or mobilization), neuromotor control strategies, and vestibular rehabilitation techniques, depending on the findings at assessment and patient response. Therapists can also tailor education regarding mental and physical rest according to specific parameters provided by the treating physician. Patients may also be prescribed a home exercise program and exercise education. The precise treatment strategies will be recorded.
89640017|NCT01793571|Experimental|TAP block|20 ml Levobupivacaine 0,5%
89640018|NCT01793571|Active Comparator|Local wound infiltration|20 ml levobupivacaine 0,5%
89640019|NCT02341404|Experimental|Liproca Depot|A parenteral controlled release depot formulation of 2-hydroxyflutamide (2-HOF) is given as a single dose injection into the prostate gland within the lobe area where the tumour tissue is localized.
89640020|NCT04477980||Culture positive empyema|Patients with empyema confirmed by a positive pleural fluid culture, irrespective of its gross fluid appearance
89640021|NCT04477980||Culture negative empyema|Patients with empyema confirmed by a gross pus appearance AND a negative pleural fluid culture
89640022|NCT02341638|Experimental|Part A Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
89640023|NCT02341638|Experimental|Part A Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
89640024|NCT02341638|Experimental|Part A Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
89640025|NCT02341638|Experimental|Part A Panel 4: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
89640026|NCT02341638|Experimental|Part A Panel 5: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
89640027|NCT02341638|Experimental|Part A Panel 6: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
89640028|NCT02341638|Experimental|Part A Panel 7: BMS-986141|Single dose by mouth as specified
89640029|NCT02341638|Experimental|Part A Panel 8: BMS-986141|Single dose by mouth as specified
89640030|NCT02341638|Experimental|Part B Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
89640031|NCT02341638|Experimental|Part B Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
89640032|NCT02341638|Experimental|Part B Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
89640033|NCT02341638|Experimental|Part C Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
89640034|NCT02341638|Experimental|Part C Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
89640035|NCT02341638|Experimental|Part C Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
89640036|NCT02341638|Experimental|Part D Panel 1: BMS-986141 and Aspirin|BMS-986141 and Aspirin by mouth as specified
89640037|NCT02341638|Placebo Comparator|Part D Panel 1: Placebo matching BMS-986141 and Aspirin|BMS-986141 placebo and Aspirin by mouth as specified
89640038|NCT02341638|Experimental|Part E Panel 1: BMS-986141 and Itraconazole|BMS-986141 and Itraconazole by mouth as specified
89640039|NCT02337192|Experimental|Group 1|Negative control - Moutwash with 1,5mL of dimethyl sulfoxide at 5% (DMSO) in water solution - During 2 minutes.
89640040|NCT02337192|Experimental|Group 2|Mouthwash with Swish with Curcumin
89640041|NCT02337192|Experimental|Group 3|Moutwash with Swish with Curcumin + SDS
89640042|NCT02337192|Experimental|Group 4|Experiment use dental irradiation with blue light (LED) only.
89640043|NCT02337192|Experimental|Group 5|Antimicrobial Photodynamic Therapy (APDT) with blue light and Curcumin salt.
89640044|NCT02337192|Experimental|Group 6|Antimicrobial Photodynamic Therapy (APDT) with blue light, Curcumin salt and surfactant.
89640045|NCT02337192|Experimental|Group 7|Positive control - Use of mouthwash with Chlorhexidine only
89640046|NCT02344368|Experimental|0.2 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
89640047|NCT02344368|Experimental|0.5 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
89640048|NCT02349126|Experimental|Treatment Group|ARC-520 Injection
89640049|NCT02039310||≥ 65 years / opts for radical cystectomy|
89640050|NCT02344212|Experimental|ESENCIAL Para Vivir|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
89640051|NCT03111966||Spanish cohort with HCV treated with DAA|
89640052|NCT02341170|Experimental|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation (25 Gy in 10 fractions)
89640053|NCT02341170|No Intervention|Observation|Observation
89042687|NCT04622293|Experimental|Solriamfetol|Those who are receiving solriamfetol will receive 75 mg or 150 mg. Patients will begin at a 75 mg dose and then after three days titrate up or down as needed, determined by consultation visits with primary investigator. Solriamfetol will be taken orally.
89640054|NCT02341248||A) Newly diagnosed with Crohn's disease|"Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease [children who are found not to have Crohn's disease will not participate further].~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day] per day"
89640055|NCT02341248||B) Existing diagnosis of Crohn's disease|"Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day]"
89640056|NCT02341248||c) Healthy control group|Healthy children unrelated to Crohn's disease patients No intervention
89640057|NCT02340702||Patient with COPD and those without COPD|The participants of acute decompensated heart failure national registry would be stratified in to two group: those with COPD and those without COPD, to determine prognostic implication of COPD in participants with acute decompensated heart failure
89042688|NCT04622293|Placebo Comparator|Placebo|Those who are not receiving solriamfetol will receive the placebo drug, which will be encapsulated in matching capsules to reduce any bias or speculation with participants.
89042689|NCT04613999|Other|Single Arm|Subjects will receive regimens 50 mcg, 100 mcg and 150 mcg in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
89042690|NCT04608773|Other|Biotene Spray, followed by Refresh Spray|The Biotene Spray followed by Refresh Spray Arm will be asked to complete a 2 week trial using Biotene Spray first, then will be asked to complete a 2 week trial using Refresh Spray second. (after the appropriate 1 week washout periods have been completed)
89640058|NCT05254860|Experimental|Interrupted suture|
89042691|NCT04608773|Other|Refresh Spray, followed by Biotene Spray|The Refresh Spray, followed by Biotene Spray Arm will be asked to complete a 2 week trial using Refresh Spray first, then will be asked to complete a 2 week trial using Biotene Spray second. (after the appropriate 1 week washout periods have been completed)
89042692|NCT04601532|Active Comparator|Silver sulfadiazine|Topical management via dressings provide a barrier against microbial infection. The current gold standard for burn wound dressings is silver (nanoparticulate or ionic), and it has shown some efficacy in treating infections, but it does not demonstrate an ability to prevent infections and some treatment guidelines even recommend against its use. Although silver dressing is preferred for military use, a retrospective review spanning 10 years of use in military environments showed that silver was not more effective than other antimicrobial topical treatments, and a meta-analysis with over 2500 surgical patients found silver sulfadiazine was associated with increased infection rates and hospital length-of-stays were two days longer on average.
89640059|NCT05254860|Experimental|Continous suture|
89640060|NCT05254704||Group - assessment of reproductibility of TEX-Q-F|"This groupe will fill in the questionnaire twice :~at first before the anesthesia consultation~then, 7 days after the consultation (without further information) This group will be composed of 100 subjects.~We will then assess the influence of their answers on their recovery by collecting their answer of QoR-15 (quality of recovery) and EVAN-G (satisfaction) at 24 hours after the surgery."
89042693|NCT04601532|Experimental|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Synedgen has developed Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser. These products are Food and Drug Administration (FDA) 510(k) cleared wound care medical devices, formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure™ Wound Cleanser is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn™ Advanced Technology Hydrogel serves as a protective gel dressing. Together, these products reduce inflammation in wounds, aggregate bacteria and disrupt bacterial biofilms, and accelerate healing.
89042694|NCT04599660||Low Risk GISTs|This cohort include patients affected by primary GIST at very-low and low risk of recurrence/progression, referred to participating Institutions between January 2000 and February 2020.
89042695|NCT04590521|Experimental|Intervention|A standard 3-dose schedule (0, 2 and 6 months) of licensed HPV vaccine (Gardasil®, Merck) will be administered to all participants intramuscularly.
89042696|NCT04586270|Experimental|TAS0612 Escalation|TAS0612 administered orally
89042697|NCT04586270|Experimental|TAS0612 Expansion|TAS0612 administered orally
89042698|NCT04584801||COPD Patients|"Development Phase Any adult (≥18 years old) who has been diagnosed with COPD guide GOLD criteria (FEV1/FVC ratio post bronchodilator <0.70)~Cohort A (N=50): COPD stage 1~Cohort B (N=50): COPD stage 2~Cohort C (N=50): COPD stage 3~Cohort D (N=50): COPD stage 4"
89042699|NCT04584801||Healthy Smoker Subjects|• Cohort E (N=50): Healthy Smokers (≥35 years old, current or ex-smoker with a history of ≥10 pack-years (20 cigarettes smoked per day for 1 year)
89042700|NCT04574505|Experimental|NUT|1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks
89640061|NCT05254704||Group - assessment of the responsiveness of the questionnaire after information|"This group will also fill in the questionnaire twice :~at first before the anesthesia consultation~then, 7 days after the consultation and AFTER a phone interview (about 15 minutes) with an experienced practitioner to provide appropriate information concerning the anesthesia and the postoperative rehabilitation process.~This group will also be composed of 100 subjects.~We will then assess the influence of their answers on their recovery by collecting their answer of QoR-15 (quality of recovery) and EVAN-G (satisfaction) at 24 hours after the surgery."
89640062|NCT05254470||Pre-Low Intensity Continuous Ultrasound Treatment|Routine care for pain alleviation, range of motion and ability to return to work with traditional therapies from rehabilitation.
89640063|NCT05254470||Post-Low Intensity Continuous Ultrasound Treatment|Routine care of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies.
89640064|NCT02344134|Experimental|NBP607|cell culture-derived trivalent inactivated subunit influenza vaccine
89640065|NCT02344134|Active Comparator|Agrippal S1|egg-derived trivalent inactivated subunit influenza vaccine
89640066|NCT02343978|Experimental|KWA-0711 High dose|
89640067|NCT02343978|Experimental|KWA-0711 Low dose|
89042701|NCT04574505|Placebo Comparator|Placebo|1 tablet of Placebo per day + standard diet for 8 weeks
89042702|NCT04569331|No Intervention|Control group|"Patients undergoing anterior rectal resection with protective ileostomy will follow routine clinical practice.~During hospital admission for ileostomy closure surgery, the stoma therapist reinforces the information on the possibility of anterior resection syndrome (ARS) and hygienic-dietary measures. At the level of the ARS, the patient is informed of the possibility of increased frequency of bowel movements, evacuation dysfunction, such as urgency to defecate or feeling of incomplete emptying. At the level of diet, an astringent diet is recommended during the first week after ileostomy closure to avoid liquid stools. It is also recommended at the level of perineal hygiene to use a cleanser with a pH similar to that of the skin, applying the least possible force on the skin, dry gently after each bowel movement and apply a skin protection product to avoid dermatitis associated with incontinence."
89042703|NCT04569331|Experimental|Stimulation of efferent loop and rehabilitation pelvic floor|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened every 48-hours the first two weeks and once daily the thrid week.~Rehabilitation of pelvic floor: 3 months after the ileostomy closure surgery, patient will be referred to the pelvic floor unit for pelvic floor rehabilitation."
89042704|NCT04565145|Experimental|Kava Pharmacokinetics Group|75 mg kava dietary supplement capsules per day for one week.
89042705|NCT04565145|Placebo Comparator|Placebo|Three placebo capsule per day for one week
89042706|NCT04564963|Experimental|Cryotherapy|Cold therapy
89042707|NCT04564963|No Intervention|No cryotherapy|Standard practices for pain management
89042708|NCT04560894|Experimental|SCT-I10A+SCT510|
89640068|NCT02344056|Experimental|having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
89640069|NCT02344056|Experimental|skipping lunch/having lunch|no lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
89640070|NCT02343822|Experimental|Multiple PRP Injection|2 PRP Injections 2 months apart
89640071|NCT02343822|Experimental|Single PRP Injection|1 PRP Injection and Saline Injection 2 months apart
89640072|NCT02343822|Active Comparator|Saline Injection|2 Saline Injections 2 months apart
89640073|NCT02343744|Experimental|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
89640074|NCT02343588|Experimental|The Health Lifestyles Interventions|"Creating a supportive school, family and community environment;~Health lifestyles educational strategies;~Instruct and promote school physical education;~The monitoring and instruction of obesity related behaviors (focus group)"
89640075|NCT02343588|No Intervention|Receive no intervention|Usual practice
89640076|NCT02343666|Experimental|Treatment (gene modified HPSC)|See Detailed Description.
89640077|NCT04823676|Active Comparator|Probiotic composition|A capsule containing a mix of probiotic strains (1.5 x 10^9 CFU/capsule ) administered once daily for 4 months
89640078|NCT04823676|Placebo Comparator|Placebo|A capsule containing placebo administered once daily for 4 months
89640079|NCT02332278|Experimental|Early feeding|Early feeding (fluid diet), four hours after cesarean section.
89640080|NCT02332278|Active Comparator|Late feeding|Late feeding (fluid diet) 12 hours after cesarean section.
89640081|NCT04766268|Experimental|PAE group|Patients with BPH with moderate lower urinary tract symptoms fulfilling the inclusion criteria and exclusion criteria will be enrolled in the trial to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
89042709|NCT04560894|Active Comparator|Sorafenib|
89042710|NCT04550962||Participants with asthma|Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country
89042711|NCT04549311|Active Comparator|Antibiotic 1 arm (amoxicillin + clavulanic acid)|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~Patients randomized to the antibiotic 1 arm will receive a prescription for amoxicillin + clavulanic acid (875 mg amoxicillin and 125 mg clavulanic acid BID) PO for 7 days. Otherwise, all participants will be treated identically according to the institution's standard practices."
89042712|NCT04549311|Active Comparator|Antibiotic 2 arm (ciprofloxacin + metronidazole)|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~Patients randomized to the antibiotic 2 arm will receive a prescription for ciprofloxacin + metronidazole (ciprofloxacin 500 mg and metronidazole 500 mg BID) PO for 7 days. Otherwise, all participants will be treated identically according to the institution's standard practices."
89640082|NCT02340936|Experimental|LR-ESHAP (lenalidomide 5 mg)|Intervention: lenalidome 5mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 5 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
89042713|NCT04549311|No Intervention|No antibiotics|"Patients will undergo I&D of PA by the clinician as per standard of care. This may occur in the emergency department or operating room. Patients may or may not receive packing based on the clinician's standard practice and institutional routines.~In the comparator arm, patients will not receive any antibiotics. Otherwise, all participants will be treated identically according to the institution's standard practices."
89042714|NCT04548661|Experimental|Povidone-iodine solution|
89640083|NCT02340936|Experimental|LR-ESHAP (lenalidomide 10mg)|Intervention: lenalidome 10mg combined with R-ESHAP( 3 cycles of treatment every 21 days: lenalidomide 10 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
89640084|NCT02340936|Experimental|LR-ESHAP (lenalidomide 15mg)|Intervention: lenalidome 15mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 15 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
89640085|NCT02340936|Experimental|LR-ESHAP (lenalidomide 20mg)|Intervention: lenalidome 20mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 20 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
89640086|NCT02337114|Experimental|Intervention group|Treatment as Usual and Acceptance & Commitment Therapy
89640087|NCT02337114|Other|Comparison group|Treatment as Usual
89640088|NCT02340858|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
88991401|NCT05066503|Active Comparator|Delirious subjects receiving active study product|Subjects will ingest an oral amino-acid containing nutritional supplement twice daily for up to 4 days.
88991402|NCT05066503|Placebo Comparator|Delirious subjects receiving placebo|Subjects will ingest a flavored, sweetened, inactive drink twice daily for up to 4 days.
88991403|NCT05066503|No Intervention|Non-delirious control subjects who receive no intervention|Subjects receive no intervention and are observed for 2-3 days.
88991404|NCT05063955||Chronic Heart Failure|Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.
88991405|NCT05063955||Controls|Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.
88991406|NCT05060432|Experimental|Part 1A - EOS-448 + pembrolizumab|Participants will receive EOS-448 and pembrolizumab at every cycle
88991407|NCT05060432|Experimental|Part 1B - EOS-448 + inupadenant|Participants will receive EOS-448 at every cycle and inupadenant on an ongoing basis
88991408|NCT05060432|Experimental|Part 1C - EOS-448 + inupadenant|Participants will receive EOS-448 at every cycle and inupadenant on an ongoing basis
88991409|NCT05060432|Experimental|Part 1D - EOS-448 + dostarlimab|Participants will receive EOS-448 and dostarlimab at every cycle
89042715|NCT04548661|Placebo Comparator|Saline|
89640089|NCT02340858|No Intervention|Control|The patients without treatment
89640090|NCT02332122||COPD patients with bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
89640091|NCT02332122||COPD patients without bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
89640092|NCT02332044|Experimental|Erdosteine 300mg|
89640093|NCT02332044|Experimental|Bepotastine besilate 10mg|
89640094|NCT02332044|Experimental|Erdosteine 300mg + Bepotastine besilate 10mg|
89640095|NCT02337036|Experimental|Arm 1: Pharmacokinetic and Pharmacogenetic|Liver Transplant Children treated with tacrolimus
89640096|NCT02336880|Experimental|Intervention group|4 weeks guided internet-delivered cognitive behavioural therapy program. The program consists of psychoeducation, exposure to physical activity, and a breathing-based relaxation exercise
89640097|NCT02336880|No Intervention|Control group|Care as usual
89640098|NCT02336802||Healthy Control Group|Volunteers that meet no diagnostic criteria for mental disorders.
89640099|NCT02336802||Panic Disorder Group|Volunteers that meet diagnostic criteria for Panic Disorder.
88991410|NCT05060432|Experimental|Part 1E - inupadenant HCl + dostarlimab|Participants will receive dostarlimab at every cycle and inupadenant on an ongoing basis
88991411|NCT05060432|Experimental|Part 1F - EOS-448 + dostarlimab + inupadenant HC|Participants will receive EOS-448 and dostarlimab at every cycle and inupadenant on an ongoing basis
89042716|NCT04548661|No Intervention|No irrigation|Standard incision management
89640100|NCT02336802||Phobic Disorder Group|Volunteers that meet diagnostic criteria for a Phobic Disorder.
89640101|NCT02336802||PTSD group|Volunteers that meet diagnostic criteria for Post-Traumatic Stress Disorder
89640102|NCT03053310||Primary (P) - group|"Patients with a primary diagnosis~Patients treated with curative intent (stage I-IVb)"
89640103|NCT03053310||Relapse (R) - group|"Patients with a recurrent (loco)regional tumour~Patients treated with curative intent (stage I-IVb)"
89640104|NCT02340390|Experimental|Hip implant1|The Biomet G7 Acetabular System is a modular acetabular system, offering two types of acetabular shells. The shells are available in either a solid shell design, with an apical plug, or a limited hole with an apical plug and optional screw holes. Components are available in numerous designs and sizes intended for both primary and/or revision applications.
89640105|NCT02340390|Experimental|Hip implant2|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
89640106|NCT02336568|Experimental|intervention|intervention: Oxytoine treatments - 20 PTSD patients
89640107|NCT02336568|Placebo Comparator|Placebo treatments|Other: Placebo treatments- 20 PTSD patients
89640108|NCT02331732|Active Comparator|Control|Patients receive DOT as normal - involves patient going to polyclinic to be observed taking treatment every day
89640109|NCT02331732|Experimental|Treatment|Patients receive VOT - involves patient sending a video of themselves taking their treatment over M-health app which will be reviewed remotely by observers
89640110|NCT02336646|Experimental|Low Dose Allogenic MSC|Low dose allogenic mesenchymal stem cells with IM injection
89640111|NCT02336646|Experimental|High Dose Allogenic MSC|High dose allogenic mesenchymal stem cells with IM injection
89640112|NCT02336646|Placebo Comparator|Placebo|normal saline with Intramuscular injection
89640113|NCT05253612|Other|ISPOCD test battery|The participants will be randomized to start with ISPOCD test battery followed by Mindmore digitalized cognitive test battery with 2 weeks passing between the cognitive testing for both groups
89640114|NCT05253612|Other|Mindmore digitalized cognitive test battery|Strating with Mindmore digitalized cognitive test battery followed by ISPOCD test battery, with 2 weeks passing between the cognitive testing for both groups
89640115|NCT02039466|Active Comparator|volume controlled ventilation|volume controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
89640116|NCT02039466|Active Comparator|pressure controlled ventilation|pressure controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
89640117|NCT02340624|No Intervention|Control group|No intervention(control group)
89640118|NCT02340624|Experimental|condition 2|Intervention:Smokefreemoms texting
89640119|NCT02340624|Experimental|condition 3|Intervention: Quitline referral
89640120|NCT02340624|Experimental|condition 4|Intervention:Smokefreemoms texting and quitline referral
89640121|NCT02340624|Experimental|condition 5|Intervention: Brief intervention
89640122|NCT02340624|Experimental|condition 6|Intervention:Smokefreemoms texting and Brief intervention
89640123|NCT02340624|Experimental|condition 7|Intervention: Quitline referral and Brief intervention
89640124|NCT02340624|Experimental|condition 8|Intervention:Smokefreemoms texting, Quitline referral and Brief intervention
89640125|NCT02331888|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
89640126|NCT02331810|Experimental|SAR113244|Single subcutaneous dose of SAR113244
89640127|NCT02331810|Placebo Comparator|Placebo|Single subcutaneous dose of placebo
89640128|NCT04630938|Active Comparator|G-M|Received classic general Anesthesia, intrathecal (Bupivacaine 15 mg, morphine 4 microgram/kg) plus saline infusion intraoperative and postoperative.
89640129|NCT04630938|Active Comparator|G-ML|Received classic general Anesthesia, intrathecal morphine in a dose of 4 microgram/kg, and intravenous lidocaine in a loading dose of 1.5 mg/kg, then 2 mg/min with the saline infusion over the time of the operation and the next 4 hours postoperative.
89640130|NCT04630938|Placebo Comparator|G-0|Received General Anesthesia and Spinal anesthesia as previously described with saline infusion in the same design as in the previous two groups.
88991412|NCT05060432|Experimental|Part 1G - EOS-448 + dostarlimab + chemotherapies|Participants with 1L mNSCLC will receive EOS-448 and dostarlimab and chemotherapies at every cycle
88991413|NCT05060432|Experimental|Part 2C - EOS-448 + dostarlimab|Participants with 1L mHNSCC CPS ≥ 20 will receive EOS-448 and dostarlimab at every cycle
88991414|NCT05060432|Experimental|Part 2D - EOS-448 + dostarlimab|Participants with 1L mHNSCC 1 < CPS < 20 will receive EOS-448 and dostarlimab at every cycle
89640131|NCT04604262|Experimental|Treatment Group|Waterpik® in addition to the manual toothbrush
89640132|NCT04604262|No Intervention|Control|Manual toothbrush
89640133|NCT03111888|Experimental|Patient-Specific Tracheobronchial Stent|Observe and document the ability of a patient-specific tracheobronchial stent to improve a patient's quality of life and symptoms associated with airway stenosis.
89640134|NCT02336724|Experimental|Famitinib|25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
89640135|NCT02340234|Experimental|Lebrikizumab 250 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
89640136|NCT02340234|Experimental|Lebrikizumab 125 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
89640137|NCT02340234|Experimental|Lebrikizumab 125 mg Q4W + TCS Cream|Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
89640138|NCT02340234|Placebo Comparator|Placebo Q4W + TCS Cream|Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
89640139|NCT02331420|Experimental|Bariatric Surgery|Gastric bypass
89640140|NCT02331420|Active Comparator|Optimal Medical Therapy|planned visits, optimized hypoglycemic treatment, diet and lifestyle modification
89640141|NCT02336490|No Intervention|Usual Care|discharge medication prescriptions are printed or sent electronically to a patient's pharmacy of choice
89640142|NCT02336490|Active Comparator|Meds-in-Hand|discharge medication delivery service: discharge prescriptions are filled at the hospital pharmacy and delivered to patients before they leave the hospital
89640143|NCT02336412|Experimental|SMS reminder|Daily SMS medication reminder
89640144|NCT02336412|No Intervention|No SMS reminder|No daily SMS medication reminder
89640145|NCT02331654|Experimental|Experimental Treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes: the anode will be placed on the thoracic spinal cord (over the spinal process of the tenth thoracic vertebra) and the cathode (reference) above the right shoulder. Stimulating electrodes will be thick (6 mm), rectangular pieces of saline-soaked synthetic sponge. The sDCS polarity (anodal) will refer to the electrode over the spinal cord.
89640146|NCT02331654|Placebo Comparator|Placebo treatment|For sham sDCS (placebo), electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s.
89640147|NCT02336334|Experimental|With macular hole|"Inclusion of patients with macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch Closure rate of macular holes"
89640148|NCT02336334|Experimental|Without macular hole|"Inclusion of patients without macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch"
89640149|NCT04594746|Experimental|Oral Amiodarone|Amiodarone hydrochloride 2000 mg
89640150|NCT04594746|Placebo Comparator|Placebo|Oral placebo
89640151|NCT02790138|Placebo Comparator|Placebo IV|Vedolizumab placebo-matching intravenous (IV) infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
89640152|NCT02790138|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
89640153|NCT02339844|Active Comparator|antipsychotic treatment|individual doses of aripiprazole for all patients
89640154|NCT02339844|No Intervention|no treatment|no treatment for all healthy controls
89640155|NCT04492800|Other|Paxman Scalp Cooling Device|Patients will undergo scalp cooling via the Paxman Scalp Cooling device for the first 3 cycles of treatment. Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
89640156|NCT02339610||ATTUNE Primary, Cemented Total Knee Replacement|"Subjects will receive one of four available ATTUNE total knee implants:~(CR FB, CR RP, PS FB, PS RP)."
89640157|NCT00396981|Active Comparator|Matrix 2® Coils|Matrix 2® Coils for endovascular aneurysm occlusion
89640158|NCT00396981|Active Comparator|GDC® Coils|GDC® Coils for endovascular aneurysm occlusion
89640159|NCT02336100|Experimental|GERD patient|36 GERD patients without obviously abnormality were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
89640160|NCT02336100|Experimental|Control|18 control patients were were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
88991415|NCT05049369|Experimental|Polysomnography for all participants of the study|Polysomnography device is used to measure certain variables overnight when a participant is sleeping
88991416|NCT05041907|Active Comparator|Positive control: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|
88991417|NCT05041907|Experimental|AZD7442 (EVUSHELD™) [This arm is now closed to recruitment]|
88991418|NCT05041907|Experimental|Fluoxetine [This arm is now closed to recruitment]|
88991419|NCT05041907|Experimental|Molnupiravir [This arm is now closed to recruitment]|
88991420|NCT05041907|Experimental|Nitazoxanide|
88991421|NCT05041907|Other|Negative control group|
88991422|NCT05041907|Experimental|Ensitrelvir|
88991423|NCT05041907|Experimental|Molnupiravir and Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|
88991424|NCT05041907|Experimental|Sotrovimab [Pending addition]|
88991425|NCT05041907|Active Comparator|Positive control (REGN-COV2) [This arm is now closed to recruitment]|
88991426|NCT05041907|Experimental|Favipiravir [This arm is now closed to recruitment]|
88991427|NCT05041907|Experimental|Ivermectin [This arm is now closed to recruitment]|
88991428|NCT05041907|Experimental|Remdesivir [This arm is now closed to recruitment]|
88991429|NCT05041907|Experimental|Hydroxychloroquine [Pending addition]|
88991430|NCT05037942|Experimental|Blood flow-restricted exercise at 40% limb occlusion pressure (BFR-40)|Participants in BFR-40 will perform a lower-body exercise protocol under BFR set to 40% of the participants' relative limb occlusion pressure.
88991431|NCT05037942|Experimental|Blood flow-restricted exercise at 80% limb occlusion pressure (BFR-80)|Participants in BFR-80 will perform the same lower-body BFR exercise protocol as BFR-40; however, the occlusion pressure will be set to 80% of the participants' relative limb occlusion pressure.
88991432|NCT05037942|No Intervention|Control for BFR-40|Participants randomised to BFR-40 will perform the same exercise protocol without BFR with the contralateral leg.
88991433|NCT05037942|No Intervention|Control for BFR-80|Participants randomised to BFR-80 will perform the same exercise protocol without BFR with the contralateral leg.
88991434|NCT05034289|Experimental|PINPOINT Digital Educational Tool|Newly diagnosed Black cancer patients will be asked to access and engage with the educational website/intervention prototype before their clinic visit or in the clinic immediately before their appointment with their treating oncologist.
89042717|NCT04547868|Experimental|Coffee|Caffeinated coffee beverage
88991435|NCT05028504|Experimental|Penpulimab+Anlotinib|Penpulimab 200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
88991436|NCT05026710|Experimental|Silicone (Coloplast Imajin Hydro) ureteral stent|
88991437|NCT05026710|Experimental|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).|
88991438|NCT05025176||Surgery requiring Invasive arterial pressure monitoring|Patients undergoing elective surgery that requires Invasive arterial pressure monitoring as standard of care.
88991439|NCT05024409|Experimental|Orthotic + Occupational Therapy|
88991440|NCT05024409|Active Comparator|Occupational Therapy alone|
89640161|NCT02339688|Other|convential MS rehabilitation|Investigation of the quality (psychometric properties) and clinical utility of several measures of mobility
89640162|NCT00397839|Placebo Comparator|Placebo|
89640163|NCT00397839|Experimental|Ibandronate|
89640164|NCT03105024|Experimental|Exposure + self-efficacy enhancement|After the virtual exposure session, participants will receive instructions to recall the exposure session with a focus on the personal mastery experiences/achievements made during exposure.
89640165|NCT03105024|Active Comparator|Exposure + control intervention|After the virtual exposure session, participants will receive instructions to recall the exposure session
89640166|NCT03105024|No Intervention|Exposure only|Treatment as usual: no intervention after the exposure session will be given.
89640167|NCT03104946||Bronchopulmonary Dysplasia|
89640168|NCT03104946||Retinopathy|
89640169|NCT03104946||Severe Retinopathy|
89640170|NCT03104946||Neonatal Necrotizing Enterocolitis|
89640171|NCT03104946||Brain injury|
89640172|NCT03104946||sepsis|
89640173|NCT03104946||Patent Ductus Arteriosus|
89640174|NCT03104946||Respiratory Distress Syndrome|
89640175|NCT02336256|Experimental|TEP SILS|Procedures of hernia repair. Patients operated due to inguinal hernia using modified single incision laparoscopic surgery (SILS) methods.
89640176|NCT02336256|Active Comparator|Typical TEP|Procedures of hernia repair. Patients operated due to inguinal hernia using typical totally extra peritoneal.
89640177|NCT01793649|Experimental|Cross-Over Sequence 1|85 μg GS-5737 in 2.8% saline or 2.8% saline alone (blinded)
89640178|NCT01793649|Experimental|Cross-Over Sequence 2|2.8% saline alone or 85 μg GS-5737 in 2.8% saline (blinded)
89640179|NCT02331576|Placebo Comparator|rocaine|continuous femoral nerve block with ropivacaine alone.
89640180|NCT02331576|Active Comparator|rocaine with fentanyl|continuous femoral nerve block with combination of ropivacaine and fentanyl.
89640181|NCT01793727|Experimental|Glidescope intubation|Comparison of direct laryngoscopy and Glidescope videolaryngoscopy
89640182|NCT02339454|Active Comparator|Active treatment group|"Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.~During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions)."
89640183|NCT02339454|Placebo Comparator|Placebo group|This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.
89640184|NCT02339376|Experimental|Group 1|Low-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 1-Hz continuous stimulation at 95% resting motor threshold, with one session each day over 10 consecutive weekdays
89640185|NCT02339376|Experimental|Group 2|High-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 10-Hz continuous stimulation at 110% resting motor threshold, with one session each day over 10 consecutive weekdays
89640186|NCT02339376|Sham Comparator|Group 3|Sham repetitive transcranial magnetic stimulation: use of a specially fabricated coil that provides no magnetic stimulation but has a similar appearance and creates an auditory artifact that mimics TMS
89640187|NCT00400803|Experimental|Patients with Stage IIIb/IV Non-Small Cell Lung Cancer|Patients treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
89640188|NCT02335866|Experimental|Test groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
89640189|NCT02335866|Active Comparator|Control groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
89640190|NCT04681443|Active Comparator|Successful treatment|Patients with successfully treated pilonidal sinus disease
89640191|NCT04681443|Active Comparator|Treatment failure|Pilonidal sinus disease patients with treatment failure
89640192|NCT02339298|Active Comparator|Music group|music application
89640193|NCT02339298|Sham Comparator|Control group|only headphones
89640194|NCT02339142|Experimental|Combined radiotherapy and iv corticosteroid|"Therapy: iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 weeks~+ External beam radiotherapy: 100 Rads to each orbit x 10 doses"
89640195|NCT02339142|Active Comparator|iv Corticosteroid|iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 week No Radiotherapy administered
89640196|NCT04615299|Active Comparator|Auricular acupuncture|Auricular (Battlefield) acupuncture needles will be utilized in the test arm, location of needles and stickers will be placed according to 5 VA approved BFA auricular acupuncture points associated with PONV, pain, and anxiety respectively
89640197|NCT04615299|Sham Comparator|Sham acupuncture|The control arm will receive sham or placebo acupuncture via pressing of a blunt needle on the specified BFA locations and then application of adhesive stickers. In the control group simulating acupuncture, the needles will never enter the patients' skin and will give the impression to the patient that the procedure has taken place.
89042718|NCT04547868|Active Comparator|Decaffeinated coffee|Decaffeinated coffee beverage
89042719|NCT04547868|Placebo Comparator|Warm water|Warm water beverage
89042720|NCT04523766|Active Comparator|Mindfulness of Breath|
89640198|NCT02338908|Experimental|Experimental group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
89640199|NCT02338908|Active Comparator|Control group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
89640200|NCT02331264||MoM >7ppb|Patients with Metal on Metal hip implants and blood metal ions above the Medicines and Healthcare Products Regulatory Agency (MHRA) threshold of 7 parts per billion
89640201|NCT02331264||MoM <7ppb|Patients with Metal on Metal hip implants and blood metal ions below the MHRA threshold of 7 parts per billion
89640202|NCT02331264||Non MoM|Patients with non Metal bearing hip implants such as Ceramic on Ceramic or Plastic
89640203|NCT00362817|Experimental|Temozolomide & Intra-Arterial (IA) carboplatin|Patients will be administered Temozolomide orally once a day for 5 consecutive days and and will receive Intra Arterial Carboplatin
89640204|NCT02335554|Experimental|MoodHacker|Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.
89640205|NCT02335554|Active Comparator|Alternative Care|Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment
89640206|NCT00363675|Experimental|All study participants|Children with hand burns
89640207|NCT01792947|Active Comparator|Diet|Diet 1200 Kcal during 3 months
89640208|NCT01792947|Experimental|PENS associated to diet|Percutaneous electroneurostimulation of dermatome T6 associated to diet 1200 Kcal
89640209|NCT00400881|No Intervention|Continuous PAP (CPAP)|CPAP (continuous positive airway pressure). 5 cm H2O.
89640210|NCT00400881|Experimental|Automatic tube compensation (ATC)|ATC is a new mode of ventilation being compared with traditional one (CPAP). ATC is a mode of ventilation of the same device (mechanical ventilator), not a new device. The pressure in this modes varies according the mechanical parameters of the respiratory system that are automatically calculated by this mode. This is the intervention arm.
89640211|NCT01795365|Active Comparator|Epstein + (group I)|"Epstein + (Group I) PSA <10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;~% of tumor biopsy invasion <50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0"
89640212|NCT01795365|Experimental|Epstein - (group II)|"Epstein - (Group II) PSA <15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12~% of tumor biopsy invasion <50% and ≤8mm; mp MRI positive; T1-T2c N0 M0"
89640213|NCT02040792|Placebo Comparator|Placebo|Placebo
89640214|NCT02040792|Experimental|44 mcg|TD-4208
89640215|NCT02040792|Experimental|88 mcg|TD-4208
89640216|NCT02040792|Experimental|175 mcg|TD-4208
89640217|NCT02040792|Experimental|350 mcg|TD-4208
89640218|NCT02338830|Active Comparator|Progesterone group|Women received vaginal progesterone suppositories
89640219|NCT02338830|No Intervention|No treatment group|Women received no treatment
89640220|NCT00364377|Active Comparator|Sitagliptin|People with impaired fasting glucose randomized to treatment with sitagliptin 100 mg once daily.
89640221|NCT00364377|Placebo Comparator|Placebo|People with impaired fasting glucose randomized to treatment with placebo once daily.
89640222|NCT02338596|Experimental|Conventional stem|total hip replacement operated with conventional stem (Profile; DePuy, Leeds, United Kingdom)
89640223|NCT02338596|Active Comparator|Ultra-Short stem|total hip replacement operated with ultra-short stem (Proxima; DePuy, Leeds, United Kingdom)
89640224|NCT04271241|No Intervention|Control (Ctrl)|Ctrl group di not undergo any training
89640225|NCT04271241|Experimental|PS bilateral limbs (PSBil)|PSBil underwent 12 weeks of passive stretching on both the lower limbs
89640226|NCT04271241|Experimental|PS monolateral limb, stretched limb (PSMonoSL)|PSMonoSL underwent 12 weeks of passive stretching on just one lower limb (SL). Outcomes form this group were obtained from the stretched
89640227|NCT04271241|Experimental|PS monolateral limb, contralateral limb PSMonoCL|PSMonoCL involved the same participants as in PSMonoSL. Outcomes form this group were obtained from the contralateral not stretched limb (CL). Data from this limb helped in identify possible PS-induced crossover effects in the vasomotor response.
89640228|NCT02338674|Experimental|COM|COM group receives combination therapy of tenofovir and telbivudine (TDF and LdT) for at least 48 weeks
88991441|NCT05022433||Shukla|Shukla is a birth weight based formula to determine the insertional depth of the UVC
89042721|NCT04523766|Experimental|Mindful Interoceptive Mapping|
89640229|NCT02338674|Active Comparator|TDF|TDF group receives single therapy of tenofovir (TDF) for at least 48 weeks
89640230|NCT02338752|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
89640231|NCT02338752|Active Comparator|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
89640232|NCT01826838|Experimental|Dasatinib|Three dasatinib dose levels will be evaluated, 50 mg/day, 70 mg/day and 100 mg/day. Dasatinib will begin with day #1 of radiation and will be discontinued once radiation is completed.
89640233|NCT00365391|Experimental|Treatment (monoclonal antibody, enzyme inhibitor)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory studies to determine EGFR and phosphorylated-EGFR protein levels using initial diagnostic biopsy specimens by IHC for correlation with clinical outcome. Levels of proteins through which EGFR signals, including Akt, phosphorylated-Akt, MAPK, and phosphorylated-MAPK, are also determined using initial diagnostic biopsy specimens by IHC and correlated with clinical outcome. Total and free serum vascular endothelial growth factor levels are determined at the start of study and prior to course 3 by ELISA.
89640234|NCT03105180||0% dilution|Blood specimen which was diluted with 0% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
89640235|NCT03105180||10% dilution|Blood specimen which was diluted with 10% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
89640236|NCT03105180||20% dilution|Blood specimen which was diluted with 20% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
89640237|NCT03105180||40% dilution|Blood specimen which was diluted with 40% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
89640238|NCT02331030|Experimental|Combined (C)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml and Pecs II block with Ropivacaine 0.5% 10ml.
89640239|NCT02331030|Active Comparator|Supraclavicular (S)|Ultrasound-guided supraclavicular BPB with Ropivacaine 0.5% 20ml and sham block (grade 1)
89640240|NCT02331186||obese women who underwent bariatric surgery|obese women who underwent bariatric surgery
88991442|NCT05022433||UN-1|UN-1 is a body surface based formula to determine the insertional depth of the UVC
88991443|NCT05014204|Experimental|Interventional|All eligible patients will receive the endoscopic Endogenex procedure.
88991444|NCT05008419|Experimental|Discourse Treatment|Biweekly discourse treatment sessions.
89640241|NCT02639676||Group 1: Infants born to mothers with preeclampsia|Infants with expected delivery at 26+0 weeks gestation or greater .
89640242|NCT02639676||Group 2: Infants born to mothers with normotensive pregnancies|Infants with expected delivery at 26+0 weeks gestation or greater.
89640243|NCT04270929|Experimental|Oxaliplatin PEDD-PRVI|Two infusions of oxaliplatin (dose escalation: 20-40 mg) over the course of 4 weeks by Pancreatic Retrograde Venous Infusion (PRVI) utilizing Pressure Enabled Drug Delivery (PEDD) technology.
89640244|NCT02338440|Experimental|lipoprostaglandin E1 treatment arm|"lipoprostaglandin E1 1mcg/kg/day, continuous infusion~lipoprostaglandin E1 1.5mcg/kg/day, continuous infusion (for patients with elevating total bilirubin, hepatomegaly, right upper quadrant abdominal pain, unexplained weight gain)"
89640245|NCT01793961|Other|"Cannabis Arm"|patient addicted to cannabis
89640246|NCT01793961|Other|"Tobacco Arm"|patient addicted to tobacco
89640247|NCT01793961|Other|"Healthy volunteers"|no smokers
89640248|NCT00401817|Experimental|Study Treatment Arm|Bevacizumab-R-CHOP therapy included bevacizumab administered at 15 mg/kg on day 1, and standard dose R-CHOP on day 3, for six 21-day cycles
89640249|NCT04417179|Experimental|TAP block group|"the TAP block will be given by a high frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .~a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under direct ultrasound visualization, . After confirming the correct placement of the needle and the negative aspiration probe anaesthetic substance will be injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine(10) , and the dissection of the plane was observed. The block will be performed bilaterally."
89640250|NCT04417179|Experimental|ESP group|the Erector Spinae block will be given by a high-frequency linear ultrasound transducer of Siemens acuson x300 3-5MHz ultrasound .A blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be used under strict aseptic precautions until the tip is deep to erector spinae muscle, The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally
89640251|NCT02330796|Experimental|Arm A|Bucillamine (900 mg total dose over 7 days)
89640252|NCT02330796|Experimental|Arm B|Bucillamine (1,800 mg total dose over 7 days)
89640253|NCT02330796|Active Comparator|Arm C|Colchicine (1.8 mg total dose in 2 doses taken 1 hour apart)
89640254|NCT04410627|No Intervention|Standard of Care|
89640255|NCT04410627|Experimental|Standard of Care + HoPE|
89640256|NCT04270851||Borderline Resectability|Patients with colorectal liver metastases where the decision-making on technical resectability is difficult, i.e. 'borderline resectable,' where a group of liver surgeons might reasonably be expected to find the decision whether to operate to be challenging. A group of up to 20 such patients will undergo pre-operative LiMAx test and HepaT1ca pre-operative scanning. Recruited participants' data will be used to create anonymised online case scenarios to be used in a survey, assessing whether liver surgeons find these pre-operative assessments helpful in their decision-making on technical resectability.
88991445|NCT05008419|No Intervention|Treatment as Usual|No treatment. Participants will engage in their usual care.
88991446|NCT04997148||Cladribine|No intervention will be administered as a part of this study. Participants with Highly-active Disease Relapsing-remitting Multiple Sclerosis (HDA-RRMS), who completed at least Year 1 of treatment with cladribine tablets in routine clinical practice will be enrolled into this study and assessed up to maximum 5 years after cladribine tablets initiation.
88991447|NCT04997057|Other|Probiotics mixture|Daily supplementation with a mixture of probiotics for 12 weeks
88991448|NCT04992507|Experimental|Arm I (surgical resection with TIVA)|Patients undergo surgical resection with TIVA.
88991449|NCT04992507|Active Comparator|Arm II (surgical resection with inhaled volatile anesthetics)|Patients undergo surgical resection with inhaled volatile anesthetics.
88991450|NCT04989387|Experimental|Treatment Group A Dose Escalation and Expansion|INCA00186 will be administered as monotherapy every 2 or every 4 weeks.
88991451|NCT04989387|Experimental|Treatment Group B1 Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab. INCA00186 will be administered every 2 or 4 weeks and retifanlimab will be administered every 4 weeks.
88991452|NCT04989387|Experimental|Treatment Group B2 Dose Escalation and Expansion|INCA00186 will be administered in combination with INCB106385. INCA00186 will be administered every 2 or 4 weeks and INCB106385 will be administered once or twice daily.
88991453|NCT04989387|Experimental|Treatment Group C Dose Escalation and Expansion|INCA00186 will be administered in combination with retifanlimab and INCB106385. INCA00186 will be administered every 2 to 4 weeks, retifanlimab every 4 weeks and INCB106385 once or twice daily.
88991454|NCT04985968|Experimental|Cobitolimod 250 mg|"Dose of 250 mg cobitolimod~2 treatments during induction study and subsequently every third week"
88991455|NCT04985968|Experimental|Cobitolimod 500 mg|"Dose of 500 mg cobitolimod~2 treatments during induction study and subsequently every third week"
88991456|NCT04985968|Placebo Comparator|Placebo|"Dose of Placebo~2 treatments during induction study and subsequently every third week"
88991457|NCT04985695|Active Comparator|Thoracic epidural anesthesia|Epidural analgesia during midline laparotomy
88991458|NCT04985695|Experimental|Bilateral rectus sheath block|Bilateral rectus sheath block during midline laparotomy
89640257|NCT02330640|Experimental|ticagrelor|90mg Bid for 30days after first dose
89640258|NCT02330640|Active Comparator|clopidogrel|75mg Qd for 30days first dose
89640259|NCT02330640|Other|asprin|100mg Qd all patients will be given asprin 100mg Qd within 24hours after CABG
89640260|NCT01795443|Active Comparator|Healthy volunteers 1|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
89640261|NCT01795443|Active Comparator|Healthy volunteers 2|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
89640262|NCT01795443|Active Comparator|Healthy volunteers 3|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
89640263|NCT01795443|Active Comparator|Healthy volunteers 4|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
89640264|NCT01795443|Active Comparator|Healthy volunteers 5|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
89640265|NCT01795443|Active Comparator|Healthy volunteers 6|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
89640266|NCT01795443|Experimental|Back pain patients 1|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
89640267|NCT01795443|Experimental|Back pain patients 2|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
89640268|NCT01795443|Experimental|Back pain patients 3|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
89640269|NCT01795443|Experimental|Back pain patients 4|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
89640270|NCT01795443|Experimental|Back pain patients 5|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
89640271|NCT01795443|Experimental|Back pain patients 6|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
89640272|NCT02335632|Placebo Comparator|Placebo|For Probiotics, 7 days
89640273|NCT02335632|Active Comparator|Probiotics|Probiotics of 120 mg/day for 7days
89640274|NCT02330328|Experimental|No Telemetry Monitoring|The participants in this arm will be admitted to a bed without telemetry monitoring
89640275|NCT02330328|Active Comparator|Telemetry|The participants in this arm will be admitted to a bed with telemetry monitoring
89640276|NCT02335398|Experimental|methadone|single group
89640277|NCT02338206|Active Comparator|Long + Growth hormone|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously along with Growth hormone (Norditropin, Novo nordisk) co-treatment daily in a dose of 2.5 mg S.C. till the day of hCG administration.. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG and growth hormone, were continued till the day of hCG administration.
89640278|NCT02338206|No Intervention|Long protocol only|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG, were continued till the day of hCG administration.
89640279|NCT02338050|Experimental|Moxetumomab Pasudotox|Moxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox.
89640280|NCT02337816||Endometriosis|Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery.
89640281|NCT02337816||Controls|Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery.
89640282|NCT02330484|Experimental|incentives to physicians|Give incentives to physicians according to patients' HbA1c improvement
89640283|NCT02330484|Experimental|incentives to patients|Give incentives to patients according to their HbA1c improvement
89640284|NCT02330484|Experimental|incentives to both physicians and patients|intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement
89640285|NCT02330484|No Intervention|Group with no incentives|
89640286|NCT02330406|Active Comparator|Anagliptin|Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
89640287|NCT02330406|Active Comparator|Sitagliptin|Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed
89640288|NCT02330250|Experimental|Pharmaceutical Care|The patients will receive guidance from a pharmacist based on the Dader Method for Pharmaceutical Care, in addition to the medical care habitually delivered by the hospital.
89640289|NCT02330250|Sham Comparator|Control|The control group will receive the medical care habitually provided by the hospital, and the follow-up by a non-pharmacist professional.
89640290|NCT02335086||Stable angina patients|"Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.~Clinical and angiographic exclusion criteria as stated in the study protocol."
89640291|NCT02335086||NSTEMI patients|"Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :~Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:~Symptoms of ischaemia~Development of pathologic Q waves in the electrocardiogram (ECG)~New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.~Identification of an intracoronary thrombus by angiography.~Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality."
89640292|NCT02337972|Experimental|Diabetic patients|Patients with Diabetes Mellitus and macular edema who were determined by their treating physician to require at least 3 serial injections with an anti-Vascular epithelial growth factor (VEGF). Prior to each injection a use of povidone-iodine 4% drops will be performed to clean the conjunctival sac
89640293|NCT02337894|Experimental|Essential amino acids plus arginine|Children randomized to the intervention group will receive a supplement containing essential amino acids plus arginine in the form of a drink which they will have to take for 8 weeks. Measurement of liver lipid content, hepatic apoptosis, plasma lipids, apolipoprotein B-100 levels, hepatic fatty oxidation, whole body insulin sensitivity, body composition and whole body protein turnover will be compared with the the placebo group, and before and after the intervention.
89640294|NCT02337894|Placebo Comparator|Control drink|The control drinks will be indistinguishable from the intervention drinks in taste and volume, but will contain placebo rather than essential amino acids plus arginine.
89640295|NCT02337660|Experimental|Healthy, lean|"15 healthy, lean subjects.~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
89640296|NCT02337660|Experimental|Obese, otherwise healthy|"15 obese, otherwise healthy subjects~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
89640297|NCT02335164|Experimental|HA 45ug|recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses
89640298|NCT02335164|Experimental|HA 45ug+Advax1|recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
89640299|NCT02335164|Experimental|HA 45ug+Advax2|recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
89640300|NCT02335164|Experimental|HA 15ug+Advax1|recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
89640301|NCT02335164|Experimental|HA 15ug+Advax2|recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
89640302|NCT02335164|Experimental|HA 5ug+Advax1|recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
89640303|NCT02335164|Experimental|HA 5ug+Advax2|recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
89640304|NCT02335164|Experimental|HA 2.5ug+Advax2|recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
89640305|NCT02335164|Experimental|HA 15ug|recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses
89640306|NCT00365859|Experimental|De Novo|De novo participants (those who did not participate in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) assigned to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
88991459|NCT04965506|Experimental|IBI362 low dose|Participants receive low dose IBI362 by subcutaneous (SC) injection once a week.
88991460|NCT04965506|Experimental|IBI362 moderate dose|Participants receive medium dose IBI362 by subcutaneous (SC) injection once a week.
88991461|NCT04965506|Active Comparator|Dulaglutide|Participants receive Dulaglutide 1.5mg by subcutaneous (SC) injection once a week.
88991462|NCT04965506|Experimental|IBI362 high dose|Participants receive high dose IBI362 by subcutaneous (SC) injection once a week.
88991463|NCT04965506|Placebo Comparator|placebo|Participants receive placebo by subcutaneous (SC) injection once a week.
88991464|NCT04965038|Active Comparator|Thrombolysis (interventional study)|Alteplase (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
88991465|NCT04965038|Placebo Comparator|Placebo (interventional study)|Placebo (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
88991466|NCT04965038|No Intervention|Observational study|The prospective REVISION observational study will enroll patients within 12 hours of symptom onset
89057920|NCT04535570||Pre Transplant|All 20 patients will have the energy expenditure measured in the pre-transplantation in order to compare with post-transplant data.
89057921|NCT04535570||Post Transplant|All 20 patients will have the energy expenditure measured in the post transplantation in order to compare with the pre-transplant data.
89640307|NCT00365859|Experimental|Rollover Placebo|Participants who completed participation in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) on placebo treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
89640308|NCT00365859|Experimental|Rollover Aripiprazole|Participants who completed participation in protocol CN138-178 [NCT00332241] or CN138-179 [NCT00337571] on aripiprazole treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
89640309|NCT02337504|No Intervention|clinic-based care|Will receive HIV care at the clinic from the nurses and clinical officer on their regular schedule
89640310|NCT02337504|Active Comparator|Community-based care|Will receive HIV care in their community from a community health worker every month as part of a group of 6-10 people
89640311|NCT02337426|Experimental|Treatment (dimethyl fumarate, temozolomide, radiation therapy)|"CONCOMITANT THERAPY: Between 21 days (3 weeks) and 42 days (6 weeks) following the last surgical procedure, patients receive temozolomide PO QD for 42-49 days and dimethyl fumarate PO BID or TID continuously. Patients also undergo radiation therapy 5 days a week over 6 weeks for a total of 30 fractions~MAINTENANCE THERAPY: Patients continue to receive dimethyl fumarate PO BID or TID continuously. Four weeks after completing concomitant temozolomide and radiation therapy, patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
89640312|NCT02337582|Active Comparator|Intervention|
89640313|NCT02337582|Other|Control|
88991467|NCT04956393|Experimental|Immediate SOAR Program|Participants with a past sport-related knee injury randomized to the 'immediate intervention' group will complete an 8-week (weeks 1-8) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 physiotherapist counseling sessions, and optional weekly group-based exercise classes) followed by an additional 8 weeks (weeks 10-17) of home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and optional weekly group-based exercise classes. Consented trained physiotherapists will deliver the SOAR program throughout the study period to one or more immediate SOAR group knee injury participants.
88991468|NCT04956393|Other|Delayed SOAR Program|Participants with a past sport-related knee injury randomized to the 'delayed intervention' group will have a 9-week unstandardized delay before completing an 8-week SOAR program (weeks 10-17). During the delay (weeks 1-9) the delay comparison intervention will be unstandardized to reflect usual care in Canada. After the 9-week delay, these participants will complete an 8-week (weeks 10-17) SOAR program (Knee Camp, home-based exercise-therapy and physical activity with tracking, weekly 1:1 PT counseling sessions, and an optional weekly group-based exercise classes). Consented trained physiotherapists will deliver the SOAR program from week 10 to week 17 to one or more delayed SOAR group knee injury participants.
88991469|NCT04951947|Experimental|Arm A|Treatment arm
88991470|NCT04947319|Experimental|Tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A)|Patients with relapsed or refractory PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib monotherapy.
88991471|NCT04947319|Experimental|Tirabrutinib + MTR in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 1)|Patients with newly diagnosed treatment naïve PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib + methotrexate/temozolomide/rituximab (MTR)
88991472|NCT04947319|Experimental|Tirabrutinib + R-MPV in patients with newly diagnosed, treatment naïve PCNSL (Part B, Arm 2)|Patients with newly diagnosed treatment naïve PCNSL who meet eligibility criteria will be enrolled to receive tirabrutinib + rituximab/methotrexate/procarbazine/vincristine (R-MPV)
88991473|NCT04934865|Other|Patients treated for their lung cancer and Moovcare® Lung follow-up.|
88991474|NCT04927260||COHORTE PROSPECTIF|
88991475|NCT04927260||COHORTE RETROSPECTIF|
88991476|NCT04924062|Experimental|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
88991477|NCT04924062|Placebo Comparator|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
88991478|NCT04915014|Experimental|laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)|One arm benefiting from a laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)
88991479|NCT04915014|Sham Comparator|laparoscopic Roux-en-Y gastric bypass (RYGB)|One arm benefiting from a laparoscopic Roux-en-Y gastric bypass (RYGB)
88991480|NCT04912856|Experimental|Stage 1: Blinded Dose Transition/Titration|"24-day blinded transition/titration period. Subjects who received XEN496 in the preceding study will continue to receive XEN496 at the same dose, in a blinded manner, without any further titration. Subjects, who were allocated to placebo in the preceding study, will be titrated to a tolerated dose up to a maximum dose of 21 mg/kg/day, with a maximum daily dose of 672 mg/day. To maintain the blinded aspect of the study, placebo will be dispensed to all subjects during the transition/titration period to ensure the total number of capsules are consistent across all subjects.~Subjects who discontinue will be required to taper off study drug over a period of up to 15 days"
89057922|NCT05138484|Experimental|M. sylvestris mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
88991481|NCT04912856|Experimental|Stage 2: Open-Label Treatment|"Optimally-tolerated dose level established during the transition/titration period will be maintained throughout the duration of open-label period unless dose adjustment is required.~Subjects who discontinue or complete the study treatment will be required to taper off study drug over a period of up to 15 days."
89640314|NCT01795521|Experimental|Stereotactic Body Radiotherapy (SBRT)|All eligible patients will be offered Stereotactic Body Radiotherapy using Four-dimensional computed tomography (4D-CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks
89640315|NCT01794195|Experimental|apathetic patients with Parkinson's disease|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
88991482|NCT04906421|Experimental|TVB-2640 50 mg|Subjects will receive TVB-2640 PO QD for 52 weeks, with the first dose administered on Day 1.
88991483|NCT04906421|Placebo Comparator|Placebo|Subjects will receive matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.
88991484|NCT04906369||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, 2 weeks after the start of treatment, and at the beginning of each new treatment cycle.
88991485|NCT04898023|Experimental|zinc-green tea extract-ascorbic acid|Randomized patients will take three (3) capsules taken orally two (2) hours following a meal twice daily x5 days and be blinded to study assignment.
89640316|NCT01794195|Experimental|non apathetic paired patients|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
88991486|NCT04898023|Placebo Comparator|Placebo|Randomized patients will take three (3) capsules taken orally two (2) hours following a meal twice daily x5 days and be blinded to study assignment.
89640317|NCT01794195|Experimental|healthy paired control|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
89640318|NCT02334930||Patients|Patients who will have biopsy or surgery for Perivascular epithelioid cell tumor (PEComa) or vascular pediatric tumor (Rapidly Involuting Congenital Hemangioma (RICH), Non Involuting Congenital Hemangioma (NICH), hemangioma or pyogenic granuloma)
89640319|NCT04271319|Experimental|BEST™ Pro-Sport Ultra® microcurrent device|Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.
88991487|NCT04893018|Experimental|Treatment (efineptakin alfa)|Patients receive efineptakin alfa IM on day 1. Cycles repeat every 9 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
88991488|NCT04890301|Experimental|Puncture Template and CT group|Puncture Template assisted CT guided lung biopsy was performed.
88991489|NCT04890301|Active Comparator|CT group|Simple CT guided lung biopsy was performed.
88991490|NCT04889742|Experimental|Hyperthermia|Patients will receive 6-8 treatments additional loco-regional hyperthermia concurrent to re-irradiation. Hyperthermia will start on the third day of fractionated radiotherapy and will be given twice per week. According to site of recurrent disease either deep-regional, capacitive or superficial hyperthermia devices may be used.
88991491|NCT04889430|Experimental|Iptacopan 200 mg b.i.d|Single arm open-label with 50 adult patients receiving 200mg oral twice daily doses of iptacopan
88991492|NCT04886323|Experimental|cold atmospheric plasma treatment group|Patients are treated with a plasma device. Each treatment time was 3min per area based on the lesion size.The frequency of treatment is once a day. The duration of the treatment period is 2weeks.
88991493|NCT04886323|Active Comparator|Itraconazole capsules treatment group|Patients are treated with Itraconazole capsules, 200mg a day.The duration of the treatment period is 2weeks.
88991494|NCT04881279||Control|Trauma admissions in April-June 2016.
88991495|NCT04881279||Ransomware Group|Trauma admissions in April-June 2017.
89640320|NCT04271319|Sham Comparator|Electrical Stimulation - Sham Comparator|Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.
89640321|NCT02330016|Experimental|Voluma XC|Injections of Voluma will be accomplished using a serial puncture and fanning technique with the needle inserted to the periosteal plane as well as in the subcutaneous plane. The treatment area will include the medial and lateral chin as defined: lateral chin landmark is the depressor anguli oris.
89640322|NCT02329938|Active Comparator|Lichtenstein tension free reair|mesh repair of inguinal hernia
88991496|NCT04875806|Experimental|NC762 0.5mg/kg|Phase 1 Dose Escalation (Cohort 1): Subjects received NC762 IV at 0.5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991497|NCT04875806|Experimental|NC762 1.5mg/kg|Phase 1 Dose Escalation (Cohort 2): Subjects received NC762 IV at 1.5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991498|NCT04875806|Experimental|NC762 5mg/kg|Phase 1 Dose Escalation (Cohort 3): Subjects received NC762 IV at 5mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991499|NCT04875806|Experimental|NC762 10mg/kg|Phase 1 Dose Escalation (Cohort 4): Subjects received NC762 IV at 10mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991500|NCT04875806|Experimental|NC762 20mg/kg|Phase 1 Dose Escalation (Cohort 5): Subjects received NC762 IV at 20mg/kg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991501|NCT04872660|Experimental|GSATP group|Gushen Antai Pill (GSATP, 6g* 9 bags, Beijing boran Pharmaceutical Inc.) was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
89057923|NCT05138484|Active Comparator|CHX mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
89057924|NCT05138484|Placebo Comparator|Placebo mouthwash|using 10 ml, rinse for one minute, 1 time every 12 hours for 7 days.
89640323|NCT02329938|Active Comparator|Desarda's repair|non-mesh repair of inguinal hernia
89640324|NCT00406107|Active Comparator|Pegaptanib Sodium 0.3mg (Macugen)|Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
89640325|NCT00406107|Active Comparator|Pegaptanib Sodium 1 mg (Macugen)|Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
89640326|NCT02335008|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
89640327|NCT02335008|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
89640328|NCT02329782|Experimental|ARP intervention|Adherence counseling intervention
89640329|NCT02329782|No Intervention|usual care|no intervention, standard care practices regarding adherence support
89640330|NCT04290351||Band ligation and phlebotonic group|"Patients with rubber band ligation and the prescribed anti hemorrhoidal drug will be examined in this group.~(Note: The researcher has no contribution or intervention to the treatment method.)"
89640331|NCT04290351||Only phlebotonic group|"Patients who are prescribed the only 450mg of diosmin + 50mg of hesperidin as a treatment for bleeding internal hemorrhoids will be examined in this group.~(Note: The researcher has no contribution or intervention to the treatment method.)"
88991502|NCT04872660|Placebo Comparator|Placebo group|Placebo pill is made up of a certain amount of starch and glucose, and is shaped like GSATP according to the National Drug Standards of the State Food and Drug Administration of China. Placebo pill was required to be taken orally, 6g three times daily combined with vaginal progesterone (90 mg/day Crinone, Merck) from the day of embryo transfer until 10th gestational week.
88991503|NCT04870125|Experimental|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
88991504|NCT04870125|Placebo Comparator|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
88991505|NCT04859465|Experimental|Abraxane combined with liposomal doxorubicin|Abraxane combined with liposomal doxorubicin in the treatment of advanced or unresectable angiosarcoma
88991506|NCT04857164|Experimental|Pembrolizumab combined with Chemotherapy|"Chemotherapy regimen* is as follows, selected by the investigator, 3 weeks (21 days) is a cycle，combined with pembrolizumab 200 mg intravenously on day 1, every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated(Less than or equal to 35 cycle)~*1) Cisplatin(75 mg/m2) + albumin-bound paclitaxel(260 mg/m2) 2)Cisplatin(25 mg/m2,d1-d3) + albumin-bound paclitaxel(260 mg/m2) 3)Carboplatin(AUC5) + Albumin-bound Paclitaxel(260 mg/m2)"
88991507|NCT04847271|Experimental|Physical activity on prescription|Physical activity on prescription is a behaviour change intervention comprising 3 components: a person-centred pre-intervention dialogue, a written prescription for individually tailored physical activity, and a structured follow-up.
88991508|NCT04841291|Experimental|Virtual Simulation-Based Arm|Access virtual simulation-based diabetes foot care education once for 30 minutes plus the standard care.
88991509|NCT04841291|No Intervention|Standard Care Arm|Participants will continue utilizing the usual follow-up diabetes care which occurs every month.
88991510|NCT04835103|Other|Set a case management model for somatoform patients|Somatoform patients receiving case management, single group assignment, open label
88991511|NCT04835103|Other|Time-limited psychotherapy for somatoform patients|Somatoform patients receiving psychotherapy (based on cognitive-behavioral therapy and biofeedback therapy) vs treatment as usual, open label, non-randomized
88991512|NCT04826653|Experimental|Timing suture removal_1 week|
88991513|NCT04826653|Experimental|Timing suture removal_2 weeks|
88991514|NCT04826653|Experimental|Timing suture removal_3 weeks|
88991515|NCT04826484|Experimental|Liposomal Bupivacaine plus 0.25% Bupivacaine|Participants will receive local wound infiltration with sequential Liposomal Bupivacaine plus 0.25% Bupivacaine
88991516|NCT04826484|Active Comparator|0.25% Bupivacaine alone|Participants will receive local wound infiltration with 0.25% Bupivacaine alone.
88991517|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 30 mg|TAK-994 30 mg, twice daily (BID) tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
88991518|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 90 mg|TAK-994 90 mg, BID, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
89640332|NCT02334774|Experimental|Participants receiving an SOC Program|Participants following prolonged endotracheal intubation receiving a up to 14-day daily Swallowing and Oral Care Program.
89640333|NCT02327520||Colitis with CDI|Patients who diagnosed with CDI will be analysed
89640334|NCT00407355|Active Comparator|RBZ 0.3|RBZ at the 0.3 mg dose intravitreal injection
89640335|NCT00407355|Active Comparator|RBZ 0.5|RBZ dose level .5 for ITV injection
89640336|NCT02327208|Placebo Comparator|Control|3 Combat rations only per day. No additional experimental food items (those assigned to the active comparator groups will consume isoenergetic carbohydrate and protein-based food products).
89640337|NCT02327208|Active Comparator|Protein|Consume 4 whey protein-based snack-bars in addition to 3 combat rations each day during training.
89640338|NCT02327208|Active Comparator|Carbohydrate|Consume 4 carbohydrate-based snack-bars in addition to 3 combat rations each day during training.
89640339|NCT02334540|Other|purses or a calorie/protein matched smoothie|
89640340|NCT01793181||CRVO patients|Patients with a newly diagnosed CRVO. Maximum duration 3 months.
89640341|NCT01793181||Control patients|Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden
89640342|NCT02334462|Experimental|Group 1- Mali|Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530
89640343|NCT02334462|Experimental|Group 1-U.S|Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.
89640344|NCT02334462|Experimental|Group 2- Mali|Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530
89640345|NCT02334462|Experimental|Group 2-U.S|Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.
89640346|NCT02334462|Experimental|Group 3- Mali|Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530
89640347|NCT02334462|Experimental|Group 3- U.S.|Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.
89640348|NCT02334462|Active Comparator|Group 4- Mali|Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530
89640349|NCT02110485|Experimental|Patient Activation Tool|Patients and their caregivers will receive the patient activation tool in addition to standard consultation
89640350|NCT02110485|No Intervention|Standard Consultation|Patients and their caregivers will receive standard consultation alone
89640351|NCT03144882|Active Comparator|intervention|the trial group (n =35 )
89640352|NCT03144882|Placebo Comparator|placebo|control group
89640353|NCT01793259|Other|prefilled pen then prefilled syringe|weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks
89640354|NCT01793259|Other|prefilled syringe then prefilled pen|weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks
89640355|NCT02329548|Experimental|Alizarin Red|All participating patients will undergo the Alizarin Red intervention.
89640356|NCT04210245|Experimental|Daily 0.3 mg dose|Administered by subcutaneous injection
89640357|NCT04210245|Experimental|Daily 1 mg dose|Administered by subcutaneous injection
89640358|NCT04210245|Experimental|Daily 3 mg dose|Administered by subcutaneous injection
89640359|NCT04210245|Placebo Comparator|Placebo|Administered by subcutaneous injection
89640360|NCT02329626||Study population|"The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.~Intervention: PET CT 18 FDG"
89640361|NCT02334228|Experimental|In SHAPE Lifestyles|In SHAPE Lifestyle is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
89640362|NCT02334228|Active Comparator|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
89042722|NCT04517838||Observational Blood & Tissue Cohort|Patients with stage I-III disease undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence. Patients with stage IV disease undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of progressive disease. Patients with stage IV disease with no disease progression ≥ 2 years on the same line of therapy undergo collection of blood samples at baseline, 8 and 16 weeks after starting treatment, and at the time of invasive disease recurrence. For all patients, tissue samples from previous biopsy and/or surgical resection are also collected on study.
89042723|NCT04517838||Observational Tissue-Only Cohort|For patients with stage I-IV disease who received or previously completed anti-HER2 therapy, tissue samples from previous biopsy and/or surgical resection are collected on study.
89042724|NCT04507360|Experimental|Study 1, Generic response + Top Resources|"The Generic Response + Top Resources will feature the response-as-usual on MHA's website and the four most frequently visited resource pages on MHA's website.~Participants will be randomized into this condition, and also, participants who do not respond to the demographics survey or the Next Steps survey will be placed in this condition."
89042725|NCT04507360|Experimental|Study 1, Generic response + Tailored Resources by Demographics|This condition will feature the response-as-usual on MHA's website and resources tailored to two demographics. People who endorse being Lesbian, Gay, Bisexual, Transgender, or Queer (LGBTQ) will receive 4 resources associated with LGBTQ issues. People who endorse being 8-17, 18-24, 25-44, or 45+ years of age will receive the most common 4 resources used by people in those age groups. If someone enters both age and LGBTQ status, they will be provided with 2 resources tailored to age and 2 resources tailored to LGBTQ status, randomly chosen.
89640363|NCT02329704||Density Gradient processing|"Semen portion processed using Density Gradient (80/40 %) Spin on 1200 r.p.m./20min Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
89640364|NCT02329704||Swimming down Processing|"Semen portion processed using swimming down (100 %) 30 min at room temperature processing for swim down Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
89640365|NCT04200339||Adolescents|Adolescents between the ages of 12 and 17 years old (inclusive).
89640366|NCT04138173|Experimental|Tele coaching group|Coaching with daily interaction with the coaching application, based on an adaptive physical activity goal
89640367|NCT04138173|No Intervention|Usual care group|Usual care
89640368|NCT02329392||SPP|Patients undergoing cardiac surgery with perioperative monitoring of Skin Perfusion Pressure
89640369|NCT02034396|Other|Blood draw|One blood draw at enrollment
89640370|NCT02111187|Active Comparator|LDE225 (Arm1)|Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
89640371|NCT02111187|No Intervention|Observation Arm (Arm2)|Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
89640372|NCT02039544|Experimental|Xuebi formula|Xuebi formula , one dosage ,every day, treat 6 months.
89640373|NCT02039544|Placebo Comparator|Placebo|placebo,has the same taste and color as Xuebi formula one dosage ,every day, treat 6 months.
89640374|NCT02326740|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
89640375|NCT02326740|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
89640376|NCT02326740|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
89640377|NCT03111810|Active Comparator|Active|Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
89640378|NCT03111810|Placebo Comparator|Placebo Oral Tablet|Prednisolone 20mg once daily and placebo twice daily for 7 days.
89640379|NCT02334150|Experimental|CSEA group|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
89640380|NCT02334150|No Intervention|Control group|Women in the control group were not provided any analgesia during labor.
89640381|NCT02326428|Experimental|Thrombectomy|Thrombectomy arm consists of patients undergoing thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
89640382|NCT02326428|Active Comparator|Control|Control arm patients are treated with standard stroke care including IVT but do not receive Thrombectomy. Control arm consists of patients fulfilling criteria for thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reason.
89640383|NCT02329158||Arm: Exposed: Hydroxyethyl starch|Cardiac surgical patients exposed to 6% hydroxyethyl starch (130/0.4).
89640384|NCT02329158||Arm: Unexposed: Hydroxyethyl starch|Cardiac surgical patients not exposed to 6% hydroxyethyl starch (130/0.4).
89640385|NCT02333916|Experimental|Overfeeding + exercise pre/post training|"overfeeding + exercise pre-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - before training period.~fitness training: 10-week training period (3 times per week at a gym, 30-45 minutes cardio training and 15-30 minutes strength training).~overfeeding + exercise post-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - after training period."
89640386|NCT02329236||children with constitutional growth delay|
89042726|NCT04507360|Experimental|Study 1, Generic response + Tailored Resources by Desired Resources|"This condition will feature the response-as-usual on MHA's website and 4 resources tailored to a survey question that asks participants what they would like to do next on the website after screening is complete (e.g., Learn more about depression, Take another mental health screening)"
89042727|NCT04507360|Experimental|Study 1, Tailored Response + Top Resources|"This condition will feature a response tailored to screening status (above or below criteria for depression) and expressed need for mental health support (e.g., We're so glad to hear you're open to exploring how to improve your mental health. People who score with minimum or mild depression often notice that symptoms can get worse in the weeks after taking a Depression test. They will also receive the 4 top resources."
89042728|NCT04507360|Experimental|Study 1, Tailored Response + Tailored Resources by Desired Resources|"This condition will feature a response tailored to screening status (above or below criteria for depression) and expressed need for mental health support, and will receive resources tailored to a survey question that asks participants what they would like to do next on the website after screening is complete (e.g., Learn more about depression, Take another mental health screening)"
89042729|NCT04507360|Experimental|Study 1, Embedded single-question DIY|Participants who visit content pages on the MHA website after completing screening will receive stage 2 randomization into one of three content page conditions. In the embedded single-question DIY condition, a single DIY question will be embedded within the content page.
89042730|NCT04507360|Experimental|Study 1, Embedded full DIY within content page|Participants will be randomized into one of three content page conditions. In the embedded full DIY condition, the full DIY tool will be embedded within the content page.
89042731|NCT04507360|Experimental|Study 1, Single question plus full DIY|Participants will be randomized into one of three content page conditions. In the single question plus full DIY condition, a single question plus the full DIY tool will be embedded within the content page.
89042732|NCT04507360|Experimental|Study 1, Content-as-usual|The content page will not include any embedded DIY tool.
89042733|NCT04507360|Experimental|Study 2, Control|Participants in the DIY control group will receive psychoeducation materials in W0. They will view content as usual (no DIY) and will receive surveys from W1 to W4 and follow-up surveys in W5 and at the end of W8.
89640387|NCT02329236||children with Familial short stature|
89640388|NCT02333994|Experimental|GROUP A|EDUCATION PROGRAMME AND BALANCE TRAINING EXERCISES
89640389|NCT02333994|Active Comparator|GROUP B|BALANCE EXERCISES
89640390|NCT03144336|Experimental|Intervention group|"Participants in the intervention group will be able to accumulate rewards points for correctly answering weekly quizzes regarding the HIV prevention information; these reward incentives aim to encourage retention in the study and improve HIV prevention knowledge engagement and recollection.~Intervention 'Rewards for testing HIV-negative' Every three months those in the intervention group can win a prize based on testing HIV-negative at least once during that time period. The chance of winning will increase based on the number of reward points a participant accumulates by correctly answering questions on the weekly quizzes."
89640391|NCT03144336|Active Comparator|Control group|Intervention: Information provision: Participants in the control group will receive weekly information by SMS to encourage retention in the study and improve HIV prevention knowledge engagement and recollection. They are encouraged to come to the clinic every three months to test for HIV but do not receive any incentives for answering messages or for the HIV tests.
89640392|NCT03144414|Active Comparator|LAVH|Laparoscopic Assisted Vaginal Hysterectomy
89640393|NCT03144414|Active Comparator|LADH|Laparoscopic Assisted Doderlin Vaginal Hysterectomy
89640394|NCT04477590|No Intervention|NO EXERCISE TRAINING|25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).
89640395|NCT04477590|Experimental|EXERCISE TRAINING FED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).
89640396|NCT04477590|Experimental|EXERCISE TRAINING FASTED|2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).
89640397|NCT02326506|Experimental|Pump speed variation|VA-ELS pump speed variations
89640398|NCT02328690|Experimental|Music with BBT|Music embedded with special tones.
89640399|NCT02328690|Placebo Comparator|Music without BBT|Music not embedded with special tones.
89640400|NCT02326662|Experimental|Paraplegics Acute|Acute [1-6 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
89640401|NCT02326662|Experimental|Paraplegics Sub-chronic|Sub-chronic [6-12 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
89640402|NCT02326662|Experimental|Paraplegics Chronic|"Chronic [1- 5 years]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
89640403|NCT02326662|Experimental|Tetraplegics Acute|Acute [1-6 mo.] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
88991519|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 180 mg|TAK-994 180 mg, BID, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
88991520|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 30 mg|Following the Active Drug Extension Period, participants randomized to active treatment 30 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 30 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
89640404|NCT02326662|Experimental|Tetraplegics Sub-chronic|"sub-chronic [6-12 mo.] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
89640405|NCT02326662|Experimental|Tetraplegics Chronic|Chronic [1- 5 years]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation & Biomatrix
89640406|NCT02334072|Experimental|Classical|Laryngeal mask airway (LMA) is manufactured from medical grade silicone rubber and is reusable. It consists of 3 main components: An airway tube, inflatable mask and mask inflation line. The airway tube is slightly curved to match the oropharyngeal anatomy, semirigid to facilitate atraumatic insertion and semitransparent, so that condensation and regurgitated material is visible. The distal aperture of the airway tube opens into the lumen of an inflatable mask and is protected by two flexible vertical rubber bars, called mask aperture bars, to prevent the epiglottis from entering and obstructing the airway. The laryngeal mask classical application will be done following anesthesia induction.
89640407|NCT02334072|Experimental|I-Gel|I-Gel LMA is anatomically designed mask made of a gel-like thermoplastic elastomer. It has a drain tube for gastric aspiration. I-gel laryngeal mask application will be done following anesthesia induction.
89640408|NCT02334072|Experimental|Cobra|Cobra LMA consists of a translucent silicone airway tube with an inflatable cuff sited approximately two-thirds of the way to the tip, a 15-mm standard adapter and an expanded distal end with a smooth posterior surface. The cuff forms a seal in the upper pharynx and the distal end sits in the laryngopharynx. The distal grill is designed to sit over the laryngeal inlet.Cobra laryngeal mask application will be done following induction of anesthesia
88991521|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 90 mg|Following the Active Drug Extension Period, participants randomized to active treatment 90 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 90 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
88991522|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 180 mg|Following the Active Drug Extension Period, participants randomized to active treatment 180 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 180 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
88991523|NCT04820842|Placebo Comparator|Double-blind Randomized Withdrawal Period: Placebo|Following the Active Drug Extension Period participants meeting eligibility specification and received placebo-matching tablets for 4 weeks (from Day 57 to Day 84) in the Double-blind Randomized Withdrawal Period.
88991524|NCT04818216|Placebo Comparator|Placebo Group|Placebo capsules will be administered 2 capsules twice daily for 10 days
88991525|NCT04818216|Experimental|Nicotinamide Riboside Group|Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
88991526|NCT04810988|Active Comparator|Unsupported|"Participants in this arm will receive a 12-week Unified Protocol intervention delivered via the same web platform. Each week, participants will complete the following content:~depression survey,~anxiety survey,~information about their symptom change over time,~psychoeducational text~practice exercises,~home practice instructions,~writing exercise,~home practice worksheets.~In the first week, participants will receive an emailed welcome message followed by a link to the first week's content. For every following week, participants will receive an email at the start of the week with automatically generated feedback on intervention usage, behavior change, and symptom change, as well as the link to the new week's intervention content."
89640409|NCT02334072|Experimental|Supreme|The Supreme LMA is a single-use polyvinyl chloride supraglottic device. High oropharyngeal leak pressures are important as they indicate airway protection, feasibility of positive pressure ventilation and likelihood of successful LMA placement.Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia.
89640410|NCT02334072|Experimental|Proseal|The ProSeal LMA is the most complex of the specialized laryngeal mask devices.The primary design goal was to construct a laryngeal mask with improved ventilatory characteristics that also offered protection against regurgitation and gastric insufflation. The principal new features are a modified cuff and a drain tube.Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia.
89640411|NCT02328612|Experimental|First arm|250,000 cells/kg will be administered via intravenous infusion.
89640412|NCT02328612|Experimental|Second arm|1,000,000 cells/kg will be administered via intravenous infusion.
89640413|NCT02328612|Experimental|Third arm|4,000,000 cells/kg will be administered via intravenous infusion.
89640414|NCT02328612|Placebo Comparator|Fourth arm|Placebo (Ringer's lactate solution) volume according to subject's weight.
89640415|NCT02328924|Other|LH value in fixed group|LH value predictive of IVF in 104 patients entered in fixed protocol
89640416|NCT02328924|Other|LH value in flexible group|LH value predictive of IVF in 109 patients entered in flexible protocols
89640417|NCT02333838|Experimental|Reduced toxicity conditioning regimen|"Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.~The conditioning regimen will include:~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)~In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)"
89640418|NCT02326584|Experimental|Induction with SGN-CD33A|7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A
89640419|NCT02326584|Experimental|Consolidation with SGN-CD33A|High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)
89640420|NCT02326584|Experimental|SGN-CD33A Maintenance|SGN-CD33A Monotherapy (42-day cycles)
89640421|NCT02326584|Experimental|Induction and Consolidation with SGN-CD33A|7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A
89640422|NCT03111654|Other|Patients with pericardial closure of the auricle|
89640423|NCT03111654|Other|Patients without closure of the auricle|
89640424|NCT03111342|Experimental|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
89640425|NCT03111342|Sham Comparator|Dry-needling|A placement of thin needle into the cervix without substance injection
89640426|NCT03111342|No Intervention|No intervention|No intervention for pain relief prior to LNG-IUS insertion
89640427|NCT03111420|Experimental|Clopidogrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
89640428|NCT03111420|Experimental|Prasugrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
89640429|NCT03111420|Experimental|Ticagrelor|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
89640430|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 10 mcg, 1 capsule/day before breakfast, Duration: 6 months
89640431|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 15 mcg, 1 capsule/day before breakfast, Duration: 6 months
89640432|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
89640433|NCT02333682|Active Comparator|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
89640434|NCT02328534||Density Gradient semen|"ICSI Cases processed using DG semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
89640435|NCT02328534||Swimming down semen|"ICSI Cases processed using SD semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
89640436|NCT02328456|Other|SMS and free eye drops group|the patient after trabeculectomy surgery in the SMS associated with free eye drops group will receive free eye drops and a SMS reminder message about the revisit time.
89640437|NCT02328456|No Intervention|the control group|the patient after trabeculectomy surgery in the control group won't get any free eye drop and reminder message before the appointment.
89640438|NCT02326350|Experimental|Aspirin 75mg|Aspirin 75mg enterally once daily for a maximum of 14 days
89640439|NCT02326350|Placebo Comparator|Placebo|Lactose powder placebo enterally once daily for a maximum of 14 days
89640440|NCT02326194|Placebo Comparator|Placebo group (one shot)|one dose
89640441|NCT02326194|Placebo Comparator|Placebo group (two shots)|two doses, with one dose to each arm at a same time.
89640442|NCT02326194|Experimental|Low dose vaccine group|one dose, low dose Ebola Zaire vaccine (Ad5-EBOV)
89640443|NCT02326194|Experimental|High dose vaccine group|two doses, high dose, with one dose to each arm at a same time
89640444|NCT02326038|Experimental|Ritalin|Methylphenidate, capsule, 20 mg, single oral administration
89640445|NCT02326038|Placebo Comparator|Placebo|Placebo, capsule, single oral administration
89640446|NCT02328378|Active Comparator|Quadratus Lumborum block group (QL)|patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
89640447|NCT02328378|Placebo Comparator|Control Group|patients will receive a bilateral placebo block
89640448|NCT00970866|Active Comparator|Iron and Folic Acid (IFA)|
89640449|NCT00970866|Active Comparator|Multiple Micronutrient (MMN)|
89640450|NCT00970866|Active Comparator|Lipid-based Nutrient Supplements (LNS)|
89640451|NCT03145350|Active Comparator|High-fat, low-carbohydrate diet|Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks. This diet will include commonly eaten foods such as butter, cheese, and fatty meat products. Total fat intake in this intervention will be 40-45% total energy.
89640452|NCT03145350|Active Comparator|Low-fat, high-carbohydrate diet|Dietary intervention: Participants will consume a diet that is low in saturated fat (~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
89640453|NCT03145584|Active Comparator|Continuous Adductor Canal Saphenous Catheter|Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
89640454|NCT03145584|Sham Comparator|Single Shot Adductor Canal Saphenous Block|Participants in this group were randomly allocated NOT to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A SHAM CATHETER WAS PLACED ON THE SURFACE OF THE LEG AND COVERED BY AN OPAQUE DRESSING TO CONCEAL THE INSERTION SITE. ALL PATIENTS HAD THE PROXIMAL END OF THEIR CATHETER ATTACHED TO PORTABLE ELASTOMERIC PUMPS (PAJUNK FUSERPUMP 350 ML) CONCEALED IN OPAQUE BAGS TO PREVENT PATIENTS AND ASSESSORS FROM DETERMINING WHICH PUMPS WERE ACTUALLY FUNCTIONING. THESE PUMPS FUNCTION WITHOUT A MOTOR AND SO MAKE NO SOUND.
89640455|NCT03145194|Experimental|Ticagrelor|Patients will receive Ticagrelor 180mg (2 x 90mg tablets)
89640456|NCT03145194|Placebo Comparator|Placebo|Patients will receive Placebo (2 matching tablets)
89640457|NCT03145116|Experimental|509|
89640458|NCT03812250|Active Comparator|ERCP assisted trans-papillary drainage|ERCP assisted trans-papillary drainage for malignant biliary obstruction
89640459|NCT03812250|Active Comparator|EUS-guide biliary drainage|EUS-guide biliary drainage for malignant biliary obstruction
89640460|NCT03810378|Experimental|Mediterranean Diet (Med-Plus)|Participants will follow a Mediterranean-type diet (Med-Plus) for 12 weeks. This diet will maximize the intake of vegetables, legumes, fruits and nuts, whole intact grains/cereals and fish; and minimize the intake of meat, poultry, and dairy. It will exclude added sugars and refined grains.
89640461|NCT03810378|Experimental|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow a Well-Formulated Ketogenic Diet (WFKD) for 12 weeks. This diet will maximize the intake of non-processed beef, pork, and poultry (preferably organic/grass-fed), fish, heavy cream, low-lactose, high-fat cheeses, animal fats, oils (avocado, coconut, or other nut oils), non-starchy (above ground) vegetables and limited amounts of some fruits (berries). It will exclude legumes, grains, sugars, starchy (below ground) vegetables, most fruits, and polyunsaturated oils (soy, sunflower, peanut, cottonseed, canola, etc.). It will aim for an intake of 20 g of carbohydrates/day at start, with the goal to have no more than 50 grams/day to maintain ketosis.
89640462|NCT02328300||FLT PET/MR|"All participants will have known brain lesion in the central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board and will have the clinical question of radiation necrosis vs. recurrence.~All participants will receive a FLT PET/MR scan."
89640463|NCT03144492||self-reported healthy individuals|"Self-reported healthy individuals avoiding blood draw on the days participants are feeling under the weatheror sick. In that case, study team can delay the blood draw until the subject feels better, but this would not preclude anyone from participating."
89640464|NCT03144024|Experimental|band|
89640465|NCT03144024|Active Comparator|Rigid ring|
88991527|NCT04810988|Experimental|Partially Supported|Participants in the partially supported arm will receive all aspects of the intervention described above, with no differences between arms for the first seven weeks of the intervention (Modules 1-6). Participants will be introduced to their study therapist in week 8, at the start of Module 7 via email. During Module 7 (exposure; weeks 8-11), participants will receive four video therapy sessions. Session content will be based on principles of exposure therapy (developing a personalized exposure hierarchy, live demonstrations of exposure exercises, in-session exposure practices, post-exposure processing, home practice assignments, and therapist feedback).
88991528|NCT04798261||Patients with acute pulmonary embolism|
88991529|NCT04790305|Experimental|Huaier Granule + Conventional Treatment/visit|"Huaier Granule: oral administration, 20g each time, 3 times a day. The starting time of Huaier granule: from the beginning of adjuvant therapy to the end of adjuvant therapy, and within 60 days after the end of adjuvant therapy is also acceptable.~Conventional Treatment/visit：The postoperative adjuvant therapy and visit of TNBC are based on clinical routine."
88991530|NCT04790305|No Intervention|Conventional Treatment/visit|Conventional Treatment/visit：The postoperative adjuvant therapy and visit of TNBC are based on clinical routine.
88991531|NCT04777175||KRAS mutation|patients carry with KRAS mutation
88991532|NCT04777175||ALK fusion|patients carry with ALK fusion
88991533|NCT04777175||ERBB2 mutation|patients carry with ERBB2 mutation
88991534|NCT04777175||MET skipping/amplication|patients carry with MET skipping/amplication
88991535|NCT04777175||RET fusion|patients carry with RET fusion
88991536|NCT04777175||BRAF mutation|patients carry with BRAF mutation
88991537|NCT04775485|Experimental|Arm #1|Pediatric patients with low-grade glioma treated with DAY101 (Registrational Arm)
88991538|NCT04775485|Experimental|Arm #2|Expanded access arm of pediatric patients with low-grade glioma treated with DAY101
88991539|NCT04775485|Experimental|Arm #3|Pediatric patients with advanced solid tumors treated with DAY101
88991540|NCT04771208|Other|Pre-Post Trial|Native Hawaiian participants from Homestead and Group Assisted Living (N=110) will partake in a pre-post study design. Participants will receive a baseline survey (as described below), view the ACP video intervention, and receive a post-intervention survey, which includes the same items as the baseline survey. In-person or phone interviews will be done at three and six months.
89042734|NCT04507360|Experimental|Study 2, DIY tool without AI|Participants in the DIY tool without AI group will be instructed to use the DIY tool 3 times a week. They will receive surveys from W1 to W4 and follow-up surveys in W5 and at the end of W8.
88991541|NCT04771208|No Intervention|Randomized Clinical Trial: Control Group|In the ambulatory clinics we will conduct a randomized controlled trial (N=110), and randomize (1:1) to either the video (intervention) or usual care (control) arm. The control group will receive usual care. All participants will have a baseline survey, be randomized to intervention or control, and receive a post-intervention survey, which includes the same items as the baseline survey. Follow-up in person or by phone interviews will be done at three and six months.
88991542|NCT04771208|Experimental|Randomized Clinical Trial: Intervention Group|In the ambulatory clinics we will conduct a randomized controlled trial (N=110), and randomize (1:1) to either the video (intervention) or usual care (control) arm. The intervention group will use the ACP video decision aid. All participants will have a baseline survey, be randomized to intervention or control, and receive a post-intervention survey, which includes the same items as the baseline survey. Follow-up in person or by phone interviews will be done at three and six months.
88991543|NCT04768686|Experimental|FLX475 and pembrolizumab combination therapy|"Cohort 1: EBV negative / CPI naïve gastric cancer patient who has had a disease progression after at least 2 prior systemic treatments for advanced or metastatic gastric cancer~Cohort 2: EBV positive / CPI naïve gastric cancer patient (as determined by standard methods, e.g. EBER ISH or LMP-1 IHC) who had at least 1 prior systemic treatment for advanced or metastatic gastric cancer"
88991544|NCT04756505|Experimental|Treatment (bintrafusp alfa, NHS-IL12, radiation therapy)|Patients receive bintrafusp alfa IV over 1 hour on days 1 and 14 and immunocytokine NHS-IL12 SC on day 14. Beginning on day 14 of cycle 1, patients undergo radiation therapy QD for up to 4 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88991545|NCT04754451|No Intervention|Group P(placebo)|Attach two placebo patches for 12 hours, above and below the incision site.
88991546|NCT04754451|Experimental|Group L(lidocaine patch)|Attach two lidocaine patches for 12 hours, above and below the incision site.
88991547|NCT04748679|Experimental|Worry Intervention|The Worry Intervention uses cognitive-behavioral therapy (CBT) techniques to support the patient in reducing the amount of time they worry throughout the week. It is an 8-week manualized treatment with 5 modules. Each session is 45-60 minutes.
88991548|NCT04748679|Active Comparator|Befriending|Befriending therapy controls for the general factors of therapy (warmth, engagement) without any 'active' interventions. Individuals in the befriending arm will spend sessions talking with the therapist about things that interest them. It will also be conducted over 8-weeks with 45-60 minute sessions.
88991549|NCT04744285|Active Comparator|Condition 1 (normal cigarettes)|Participants receive regular package cigarettes for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection.
89640466|NCT03144102|Experimental|VR-based motor rehabilitation with tDCS|
89640467|NCT03144102|Active Comparator|Occupational Therapy with tDCS|
89640468|NCT03144102|Sham Comparator|VR-based motor rehabilitation with sham tDCS|
89640469|NCT03144102|Sham Comparator|Occupational Therapy with sham tDCS|
89640470|NCT03143946|Experimental|Vitamin supplement and diet advice|Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
89640471|NCT02039700|Experimental|Lesinurad and [14C]lesinurad|Single oral dose of lesinurad and single infusion of [14C]lesinurad
89640472|NCT02333214|Experimental|Exergame + conventional physiotherapy|This group will be submitted to 30 minutes of conventional physiotherapy and 20 minutes of therapy using interactive games Xbox 360 Video Game and Entertainment Microsoft System with Kinect sensor, intervention twice a week for 12 weeks. Each game has three difficulty levels that can be used according to the performance of each participant. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
89640473|NCT02333214|Active Comparator|Conventional physiotherapy|The control group will receive 50 minutes of conventional physiotherapy intervention twice a week for 12 weeks. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
89640474|NCT05076474|Experimental|TR1R2|T(Orlistat 60-mg) R1(Alli 60-mg) R2（Alli 60-mg×2）
89640475|NCT05076474|Experimental|R2TR1|R2（Alli 60-mg×2） T(Orlistat 60-mg) R1(Alli 60-mg)
89640476|NCT05076474|Experimental|R1R2T|R1(Alli 60-mg) R2（Alli 60-mg×2） T(Orlistat 60-mg)
89640477|NCT05076318|Experimental|Alanine-infusion|Alanine infusion taking place over a 3 hour period while monitorering metabolic changes in blood samples before and after dialysis
89640478|NCT05076240||Adults with ventilator associated pneumonia in COVID-19 ARDS|Patient hospitalized in intensive care unit for acute respiratory distress related to a Sars-Cov2 infection having contracted ventilator associated pneumonia. The diagnosis was made by culture but also with a FilmArray® multiplex PCR analysis.
89640479|NCT05076162||Group 1|Serum 25(OH)D levels <12 ng/ml
89640480|NCT05076162||Group 2|Serum 25(OH)D levels ≥12 ng/ml
89640481|NCT02328066|Experimental|NBI used by trained endoscopists|Assessment with NICE classification and NBI technology of colonic lesions (Paris classification type 0) greater than 1 cm found in a routine colonoscopy. This assessment was performed by previously trained endoscopists.
89640482|NCT02328144|Active Comparator|Metronidazole|22 patients received oral metronidazole 500mg 3 times for day for 7 days
89640483|NCT02328144|Placebo Comparator|Placebo|22 patients received oral placebo 500mg 3 times for day for 7 days
89640484|NCT02327988|Experimental|Cryotherapy|To the cryotherapy group a 1kg ice pack was strapped over the entire brachial biceps muscle and adjacent muscles of the arm under study using a bandage, and the application lasted 25 minute laser
89640485|NCT02327988|Experimental|Laser therapy|The laser therapy group received laser application to the muscle belly of the non-dominant upper limb brachial biceps at four different points.
89640486|NCT02327988|No Intervention|Control|The control group did not undergo any intervention and remained at rest for 25 minutes.
89640487|NCT02327676|Experimental|naive child CHB group|200 patients take generic emtricitabine capsule(200 mg one time per day) for 48 weeks
89640488|NCT02327832|Experimental|Autologous BMSCs|Infusion of cultured autologous bone marrow derived mesenchymal stem cells
89640489|NCT02035566|Experimental|Telehome Care Monitoring + Usual Care|
89640490|NCT02035566|No Intervention|Usual Care|
89640491|NCT02333058|Experimental|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
89640492|NCT03144960|Other|mechanical thrombectomy|The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset, mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption.
89640493|NCT03144726|Experimental|Negative pressure wound therapy|A vacuum assisted closure device will be applied in this arm
89640494|NCT03144726|Other|Standard dressing|Standard dressing will be applied to this arm
89640495|NCT03143634|Experimental|The Modular Protocol for Mental Health|"The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include:~M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation"
89640496|NCT03143634|Placebo Comparator|Treatment-as-usual|For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.
89640497|NCT02332746||Middle-aged women|Middle-aged women (35-64 years)
89640498|NCT03111186|Active Comparator|Opiate group|Group receiving oxycodone alone (oxycodone HCl 5 mg up to six times daily as needed for pain)
89640499|NCT03111186|Active Comparator|Non-opiate group|Group receiving ibuprofen and acetaminophen (acetaminophen 650 mg up to four times daily and ibuprofen 400 mg up to six times daily as need for pain)
89640500|NCT03144648||Cases|Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in five Latin American cities (Barretos, Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
89640501|NCT03144648||Controls|Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
89640502|NCT02332512|Experimental|Apatinib|Apatinib tablet administered orally, 750 mg,once daily until progression
89640503|NCT02332512|Placebo Comparator|Placebo|Placebo tablet administered orally, once a day until progression
89640504|NCT03143868|Experimental|Aerobic Exercise|
89640505|NCT03143868|Experimental|Resistance Exercise|
89640506|NCT03143868|Placebo Comparator|No Exercise|
89640507|NCT03143478|Experimental|M-MARK|Participants self administer rehabilitation exercises using the M-MARK device for 20 days.
89640508|NCT03143712|Experimental|Treatment A|GLPG1690 oral capsules after breakfast
89640509|NCT03143712|Experimental|Treatment B|GLPG1690 oral tablets after breakfast
89640510|NCT03143712|Experimental|Treatment C|GLPG1690 oral tablets after overnight fast
89640511|NCT03111264|Experimental|CHAMP group|Childcare centers randomly assigned the CHAMP group will receive an intervention that promotes physical activity in the classroom by developing gross motor skills through movement and enhances the nutritional environment in the centers by exposing preschoolers to new foods.
89640512|NCT03111264|Experimental|CHAMP+ group|These childcare centers, also randomly assigned, will have the same intervention as the CHAMP group in addition to a parenting intervention that promotes wellness and healthy behaviors within families.
89640513|NCT03111264|No Intervention|Control|This group will not receive theCHAMP intervention at the childcare center nor will this group receive the CHAMP+ parenting intervention.
89640514|NCT03143790|Active Comparator|ESWT|500 shockwave 3 different points on penis bilateral
89640515|NCT03143790|Placebo Comparator|Placebo|500 shockwave 3 different points on penis bilateral
89640516|NCT03111498|Other|theory-based training programme|theory-based training programme (oral presentation including a step-by-step guidance saying)
89640517|NCT03111498|Other|practice-based training|practice-based training programme (one-to-one teaching)
89640518|NCT02327754|Active Comparator|Active comparator|Topiroxostat, (Oral daily dosing for 28 weeks)
89640519|NCT02327754|Placebo Comparator|Placebo comparator|Placebo, (Oral daily dosing for 28 weeks)
89640520|NCT02327910|No Intervention|Conventional group|Conventional group:The patients of conventional group were extubated when standard criteria were met;
89640521|NCT02327910|Experimental|TOF group|TOF group: patients had a TOF ratio of greater than 0.90 as an additional extubation criterion;
89212181|NCT00849134|Placebo Comparator|Cohort 1,2 & 3|This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing the study drug. Effects will be compared to those seen when a placebo is taken. Up to 3 groups of 8 healthy male and female volunteers may be enrolled.
89212182|NCT00849134|Active Comparator|Cohort 4|If an investigation of food effect is not possible in Cohorts 2 or 3, this Cohort will be used to check if there is a difference in the blood levels of the study drug when taken with or without a high fat meal.
89212183|NCT00861224||Observed Subjects|Subjects that submitted bone marrow biopsy and aspirates.
89212184|NCT00861302|Experimental|Treatment group|This is the only group in the study. It consists of patients with chronic musculoskeletal pain who are receiving the treatment program
89212185|NCT01011322|Experimental|LT-02 Dose 1|0.2g IMP per dose
89212186|NCT01011322|Experimental|LT-02 Dose 2|0.4g IMP per dose
89212187|NCT01011322|Experimental|LT-02 Dose 3|0.8g IMP per dose
89212188|NCT01011322|Placebo Comparator|Sugar pill|placebo matching to 0g of IMP,
89212189|NCT00858806|Experimental|Intermittent Imatinib|"Imatinib will be given with the following schedule:~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
89212190|NCT02545088|Experimental|Study group Hybrid Assistive Limb (HAL)|
89640522|NCT02327910|Experimental|TOF unit TcPCO2 group|Qualitative TOF and transcutaneous partial pressure of carbon dioxide monitoring(Unite group):the patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
89640523|NCT04869930||Autism Spectrum Disorder (ASD)|Early childhood (pre-diagnosis) OR existing diagnosis of moderate/severe ASD
89640524|NCT04869930||Fragile X Syndrome (FXS)|Existing diagnosis of Fragile X Syndrome
89640525|NCT04869930||Healthy Controls|No diagnosed chronic conditions
89640526|NCT03111576||Normotensive|This group will include 50 pregnant women with normal blood pressure between 28 and 34 weeks.
89640527|NCT03111576||Pre-eclamptic|This group will include 50 pregnant women with diagnosis of pre-eclampsia between 28 and 34 weeks.
89640528|NCT02332434|Experimental|sleeve gastrectomy|bariatric surgery procedure based exclusively on the gastric restriction (the sleeve gastrectomy).
89640529|NCT02332434|Experimental|gastric bypass|bariatric surgery procedure associating a malabsorption (the gastric bypass).
89212191|NCT02545088|Active Comparator|1st control group|
89212192|NCT02545088|Active Comparator|2nd control group|
89212193|NCT00849368|Experimental|Azathioprine / Allopurinol|Single arm study: Dose escalations as described.
89212194|NCT02544932|Experimental|dabigatran 110mg or 150mg|After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)
89212195|NCT02544932|Experimental|ribaroxaban 20mg|After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)
89640530|NCT02327442||Volunteers|Healthy Volunteers undergo whole-body 68Ga-NOTA-NFB PET/CT scans 0, 0.5, 1.0, 2.0, and 3.0 hours after tracer injection. During the imaging period, 1 mL blood samples are obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, and 180 minutes after the injection, for time-activity curve calculations.
89640531|NCT02327442||Glioma Patients|Glioma Patients enrolled for the clinical study of diagnosing glioma are performed with both 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scans before surgery.
89640532|NCT02327442||Breast Cancer Patients|68Ga-NOTA-NFB PET/CT and 18F-FDG PET/CT scans will undergo in patients with breast cancer before and after neoadjuvant chemotherapy.
89640533|NCT06103539||1|Patients with an indication for left heart catheterization or cardiac resynchornization therapy
89640534|NCT06103500|Experimental|Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis|The planned intervention consists of a pharmacist-facilitated clinical decision support intervention, where pharmacists provide options and recommendations on empiric sepsis antibiotic selection to hospital providers.
89212196|NCT02544932|Active Comparator|warfarin|After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)
89212197|NCT02544854|Experimental|Ages 1 year - 3 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
89212198|NCT02544854|Experimental|Ages 4 years - 8 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
89212199|NCT02544854|Experimental|Ages 9 years - 11 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
89212200|NCT00861458|Experimental|PF-00868554|
89212201|NCT00861536|Experimental|ATG Fresenius|
89212202|NCT00861536|Active Comparator|Thymoglobuline Genzyme|
89212203|NCT00849446||Activity monitoring in CVA patients|
89212204|NCT00849446||Activity monitoring in healthy persons|
89212205|NCT02544776|Experimental|Clomifene citrate and Amlodipine|Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
89212206|NCT02544776|Active Comparator|Clomifene citrate|Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
89212207|NCT00859118|Experimental|Schedule A Cohort 1|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Baseline (days -3 to 0) Scan#2: Week 2 (between days 12-14) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
89640535|NCT06103500|No Intervention|Standard of Care|Non-intervention group. No decision support is provided. Patient care is routine.
89640536|NCT06103487||RGX-111 Recipients|Subjects who have received RGX-111 in a separate parent study.
89640537|NCT06103461|Experimental|Fat Grafting|It is an experimental study for effect of fat grafting on pigmentation of skin
89212208|NCT00859118|Experimental|Schedule A: Cohort 2|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Week 2 (between days 12-14) Scan#2: Week 3 (2 days after axitinib held) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
89640538|NCT06103422|Experimental|Streaming of patients and administration of tests|35 patients who met the inclusion criteria were divided into surgical groups. Patients with indications for upper jaw surgery were divided into Le Fort I operation, patients with lower jaw surgery were divided into Sagittal Split Ramus operation, and double jaw surgery groups. Localized taste tests and whole-mouth taste tests were applied to the patients.
89640539|NCT06103422|Experimental|Repetition of tests at certain intervals|Gustatory functions were evaluated by administering localized taste tests and whole mouth taste tests preoperatively and at postoperative 1st, 3rd, and 6th months.
89640540|NCT06103409|Experimental|Allogenic MSCs|All Patients will receive conservative treatment before transplantation of allogenic MSCs embedded in autologous platelet rich plasma clot.
89640541|NCT06103370|Experimental|Peer-educator-based network intervention|Indexes randomized to the intervention arm will complete a training program that emphasizes effective communication, frequent HIV testing, and awareness of evidence-based HIV prevention and treatment services. An important innovation to the network intervention will be training indexes to use and distribute HIV self-test kits and naloxone to their network members (NMs).
89640542|NCT06103370|No Intervention|Equal-attention control|This group will receive training sessions that will be focused on the opioid overdose epidemic and will not include any training to serve as a peer educator.
89640543|NCT06103279|Experimental|Empa Arm|"(Intervention group = 20 patients) >> will receive the standard chemotherapy protocol (DOX-based chemotherapy) plus Empagliflozin.~Empagliflozin dose and duration:~According to the Evidence-based doses of disease-modifying drugs in key randomized trials in patients with heart failure with reduced ejection fraction with or without diabetes, The recommended dose of empagliflozin is 10 mg once daily.~1 tablet once daily of continuously starting from 1 week before starting DOX till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol."
89640544|NCT06103279|No Intervention|Control Arm|(Control group = 20 patients) >> will receive the standard chemotherapy protocol (DOX-based chemotherapy) only.
89640545|NCT06103266|Experimental|Rivaroxaban monotherapy|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
89640546|NCT06103253|Placebo Comparator|Placebo group|a placebo 27 group (maltodextrin)
89640547|NCT06103253|Active Comparator|Probiotic group|a Bla80 group (maltodextrin + strain BLa80 in 10B /day)
89640548|NCT06103240|Active Comparator|Probiotic group|Bacterial count：100 billion CFUs Take one sachet per day for 4 weeks.
89640549|NCT06103240|Placebo Comparator|Placebo group|maltodextrin
89640550|NCT06103214|No Intervention|Control Group|In control group ，patients had undergone similar surgical and anesthesia procedures in the same time period but whose hemodynamic management was carried out according to the clinical decision of the attending anesthesiologist.
89640551|NCT06103214|Other|acute normovolemic hemodilution (ANH)|Before anesthesia induction, in the ANH Group, blood was withdrawn at a speed of 25-30ml/min from radial artery and stored in standard collection bags. The volume of blood to be removed during ANH was calculated using an established formula as follows: V = EBV (H0 - Ht) / H. During collection, a tilt rocker scale was used to rock, mix, and weigh the blood. To maintain euvolemia, half of the blood volume removed was replaced with 6% hydroxyethyl starch 130/0.4 with medium molecular weight at a 1:1 ratio and half was replaced with crystalloid at a 1:2 ratio. The autologous blood was returned to patients if the intraoperative transfusion trigger (Hb <8.0g/dl) was reached or at the completion of the operation.
89640552|NCT06103214|Other|acute hypervolemic hemodilution (AHH)|In AHH group, 15ml/kg Voluven was transfused at a speed of 30 ml/min to make Hct to drop to medium. In control group, the regular transfusion and infusion were conducted. Allogenic blood was only given after all autologous blood had been returned to the patient. The transfusion triggers (Hb <8.0g/dl) were used to determine the need for allogenic blood transfusions during the procedure in three groups.
89640553|NCT06103162|Active Comparator|group 1 rigid feeding plate|Heat cure polymerizing acrylic resin was used to fabricate the second appliance.
89640554|NCT06103162|Active Comparator|group 2 flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
89640555|NCT06103162|Active Comparator|special feeding appliance|special feeding bottle
89640556|NCT06103149|Experimental|MIED group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems
89640557|NCT06103149|No Intervention|Waitlist control group|
89640558|NCT06103136||Patients operated using the Maestro platform|
89640559|NCT06103136||Control|
89640560|NCT06103123||mRNA COVID-19 vaccine associated myocarditis|Participants who had developed myocarditis within 42 days of getting a mRNA COVID-19 vaccine
89640561|NCT06103123||mRNA COVID-19 vaccine associated pericarditis|Participants who had developed pericarditis within 42 days of getting a mRNA COVID-19 vaccine
89640562|NCT06103123||COVID-19 infection associated myocarditis|Participants who had developed myocarditis within 42 days of being infected with the SARS-COV-2 virus
89640563|NCT06103123||COVID-19 infection associated pericarditis|Participants who had developed pericarditis within 42 days of being infected with the SARS-COV-2 virus
89640564|NCT06103123||Alternative etiology myocarditis|Any participants with myocarditis that is not associated with the mRNA COVID-19 vaccine or SARS-COV-2 viral infection
89212209|NCT00859196|Experimental|Arm 1|
89212210|NCT00859196|Placebo Comparator|Arm 2|
89212211|NCT00849602|Placebo Comparator|1|
89212212|NCT00849602|Active Comparator|2|
89042735|NCT04507360|Experimental|Study 2, DIY tool with AI|Participants in the DIY tool with AI group will be instructed to use the DIY tool with AI 3 times a week. They will receive surveys from W1 to W4 and follow-up surveys in W5 and at the end of W8.
89042736|NCT04500665|Experimental|Colchicine|Colchicine 0.3 mg once daily
89042737|NCT04500665|Placebo Comparator|Placebo|Placebo once daily
89042738|NCT04498715|Active Comparator|OSTEOSYNTHESIS+SYSTEMIC ZOLEDRONIC ACID|After osteosynthesis, systemic Zoledronic acid 4mg (or any other bisphosphonate) will be given intravenously between day 7-14 post operation.
89042739|NCT04498715|Experimental|OSTEOSYNTHESIS+LOCAL CERAMENT BONE VOID FILLER (BVF)+SYSTEMIC ZOLEDRONIC ACID|During osteosynthesis, cerament BVF will be used for the augmentation of the screw. Then systemic Zoledronic acid 4mg (or any other bisphosphonate) will be given intravenously between day 7-14 post operation.
89042740|NCT04494347|Experimental|Treatment Group|This is not a randomized study. Patients who are clinically indicated for both procedures will be offered the option to enroll in this registry for a combined procedure. Otherwise, they will undergo TMVr and LAAO in two separate session as clinically indicated (standard of care).
89042741|NCT04488250|Other|Low-to-mid functioning HIV/AIDS patients|Low-to-mid functioning HIV/AIDS patients greater than 18 years of age with stroke co-morbidity.
89042742|NCT04488250|Other|Stroke survivors|Stroke survivors greater than 18 years of age with hemiplegia with and without HIV/AIDS.
89042743|NCT04482179|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
89042744|NCT04482179|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz sham TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
89042745|NCT04482140||Genta-Foil resorb®|Genta-Foil resorb® is a transparent collagen foil that forms a temporary barrier between the functional structures during the critical phase of wound healing. As a result, the ability of the tissue layers to slide against each other is retained. The absorbability of equine collagen means the foil can be left in place and does not require removal. The addition of the antibiotic Gentamicin is for self-protection since collagen implants are prone to bacterial contamination.
89042746|NCT04477356|Active Comparator|Swim-up technique (SU)|The SU method's principle is that the normal and highly motile sperm will move against the gravity and separate from the dead or abnormal sperms to swim up to the upper media culture layer.
89042747|NCT04477356|Active Comparator|Density gradient centrifugation technique (DG)|The DG method is based on the density in which mature and normal sperms are capable of passing through filtration layer to be isolated from dead or abnormal sperms in semen.
89640565|NCT06103110|Experimental|anterior repositioning appliance followed by Infra-red LED therapy|anterior repositioning appliance followed by Infra-red LED therapy
89640566|NCT06103110|Experimental|Infra-red LED therapy followed by anterior repositioning appliance|Infra-red LED therapy followed by anterior repositioning appliance
89640567|NCT06103110|Experimental|anterior repositioning appliance followed by Low level Laser therapy|anterior repositioning appliance followed by Low level Laser therapy
89640568|NCT06103110|Experimental|Low level Laser therapy followed by anterior repositioning appliance|Low level Laser therapy followed by anterior repositioning appliance
89640569|NCT06103097||Chohort of pediatric Liver transplant pacients|Patients under 18 years recipient of a Liver transplanbt followed in our Unit and under the follow-up liver biopsy protocol
89640570|NCT06103084|Experimental|Bahgina group|The Bahgina treatment group will be supplemented with Bahgina, a locally produced cereal based product for a maximum of six months at 200g/day.
89640571|NCT06103084|Experimental|SQLNS group|The small quantity lipid based nutrient supplements (SQLNS) group will be provided with 20g of SQLNS/day for a maximum of six months.
89640572|NCT06103084|No Intervention|Control|The control group will get nothing except the routine nutrition services and products provided by the local government sectors.
89640573|NCT06103071|Active Comparator|Sweeping group|Sweeping group include patients in which membrane sweeping started from 37 weeks and performed weekly till 40 weeks. Intervention is the sweeping of membranes from 37 weeks of gestational amenorrhea.
89640574|NCT06103071|No Intervention|Non sweeping group|Non sweeping group include patients in which no sweeping of membranes done. No intervention done.
89042748|NCT04475393|Experimental|Carmat TAH|Subjects implanted with Carmat TAH
89042749|NCT04474106|Experimental|ESWT|The extracorporeal shockwave therapy is applied once at the level of lesion and 5 segments above and below; or below the occiput (in lesions higher than C6) and above the sacrum (in lesions lower than T12). In addition, the ESWT is applied to the soles of both feet on the medial side of the plantar surface. The ESWT is applied as soon as possible within 48 hours post-injury.
89042750|NCT04474106|Sham Comparator|Control|In the control group, the same procedure is performed, but without the device emitting extracorporeal shock waves using a dummy head.
89042751|NCT04458584||Ligament Reconstruction - Tendon Interposition (LRTI)|Patients undergoing thumb basal joint arthroplasty using LRTI procedure as treatment of osteoarthritis.
89640575|NCT06103058||Positive for fibromyalgia|26.5% prevalence of fibromyalgia
89640576|NCT06103058||Negative for fibromyalgia|26.5% prevalence of fibromyalgia
89640577|NCT06103045|Experimental|unilateral mirror therapy (UMT)|Participants will receive 30 minutes unilateral mirror therapy and then 30 minutes conventional occupational therapy in each treatment session. there will be 20 consecutive sessions (5 times per week, lasting 4 weeks totally)
89640578|NCT06103045|Experimental|Bilateral Mirror Therapy (BMT)|Participants will receive 30 minutes bilateral mirror therapy and then 30 minutes conventional occupational therapy in each treatment session. there will be 20 consecutive sessions (5 times per week, lasting 4 weeks totally)
89640579|NCT06103045|Placebo Comparator|Conventional Occupational Therapy (COT)|Participants will receive 60 minutes conventional occupational therapy in each treatment session. there will be 20 consecutive sessions (5 times per week, lasting 4 weeks totally)
89042752|NCT04458584||Suture Suspensionplasty (SS)|Patients undergoing thumb basal joint arthroplasty using suture suspensionplasty (SS) procedure as treatment of osteoarthritis.
89042753|NCT04458584||Arthroscopic Trapeziectomy (AT)|Patients undergoing thumb basal joint arthroplasty using arthroscopic trapeziectomy (AT) procedure as treatment of osteoarthritis.
89042754|NCT04433741|Other|Oxytocin First, then Placebo|Oxytocin administered intravenously for the first half of the study and then will receive intravenous placebo for the second half.
89042755|NCT04433741|Other|Placebo, Then Oxytocin|Placebo administered intravenously for the first half of the study and then will receive intravenous oxytocin for the second half.
89042756|NCT04410341|Placebo Comparator|Placebo group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet once daily for 12 weeks
89640580|NCT06103032||a consecutive cohort of women with asymptomatic screen-detected non-palpable breast cancer|a consecutive cohort of women with asymptomatic screen-detected non-palpable breast cancer treated in Dept. Breast Surgery, PUMC Hospital from January 2003 to December 2017
89640581|NCT06102993||COPD GOLD 1|
89640582|NCT06102993||COPD GOLD 2|
89640583|NCT06102993||COPD GOLD 3|
89640584|NCT06102993||COPD GOLD 4|
89640585|NCT06102993||Control group|
89640586|NCT06102993||Exacerbated COPD|
89640587|NCT06102967||Non-delirious group|No postoperative delirium occurred
89640588|NCT06102967||Delirious group|Postoperative delirium occurs
89640589|NCT06102954|Experimental|Intervention group|"12-weeks active intervention session includes exercise and educational components.~9 months maintenance phase"
89640590|NCT06102954|No Intervention|Control group|No intervention for 12 months during intervention period.
89640591|NCT06102928|Experimental|Experimental group|Participants who met the study protocol were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day until disease progression or unacceptable toxicity. Anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily until disease progression or unacceptable toxicity occurs.
89640592|NCT06102863|No Intervention|control group|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or mirena +GnRHa 3.75mg subcutaneous injection monthly);
89640593|NCT06102863|Experimental|experimental group|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
89640594|NCT06102850|Experimental|Intervention Condition, CTI-YAMH|Participants receive the CTI-YAMH intervention in conjunction with rapid rehousing supports for the 6 month intervention
89640595|NCT06102850|No Intervention|Treatment as Usual Condition|Participants will be assigned to a housing program at another agency that provides rapid rehousing with usual supports
89640596|NCT06102837||glioma patients receiving tumor vaccine|
89640597|NCT06102837||glioma patients receiving conventional treatment|
89640598|NCT06102837||non-tumor patients|
89640599|NCT06102785||Fruquintinib combined with TAS102|Fruquintinib 4mg d1-21, q4w TAS102 35mg/m2，bid，d1-5，d15-19，q4w
89640600|NCT06102772||Adebrelimab, Fruquintinib combined with paclitaxel|Fruquintinib 4mg d1-14, q3w Paclitaxel 150mg/m2, d1, q3w / Albumin paclitaxel 125mg/m2, d1, d8, q3w PD-L1 antibody (Adebrelimab) 20 mg/kg, d1, q3w
89042757|NCT04410341|Experimental|Vildagliptin group|Escitalopram 20 mg tablet once daily for 12 week plus Vildagliptin 50mg tablet once daily for 12 weeks
89042758|NCT04403386||non-smokers|Participants who have never smoked or do not currently reside with a smoker
89042759|NCT04403386||Smokers|Participants who currently smokes and has smoked for at least 5 years
89042760|NCT04377386|Experimental|Intervention group: 1000 IU DV|The 75 participants assigned to the intervention group will take 1 DV capsule of 1000 IU daily for 15 weeks.
89042761|NCT04377386|Placebo Comparator|Control group: 200 IU DV|The 75 participants of the control group will take 1 DV capsule of 200 IU daily for 15 weeks, this dose being the minimum recommended for children. The above, considering that it is ethical for the control group to receive a minimum dose of supplementation.
89042762|NCT04375306|Active Comparator|angiography guided CABG|angiography guided CABG
89042763|NCT04375306|Experimental|RFR guided CABG|RFR guided CABG
89042764|NCT04368117|Active Comparator|Standard Therapy (ST)|Patients randomized to the ST group will receive standard of care, routine burn physical therapy.
89640601|NCT06102759||Adebrelimab, Fruquintinib combined with paclitaxel|Fruquintinib 4mg d1-14, q3w Paclitaxel 150mg/m2, d1, q3w / Albumin paclitaxel 125mg/m2, d1, d8, q3w PD-L1 antibody (Adebrelimab) 20 mg/kg, d1, q3w
89640602|NCT06102746||Sintilimab + Surufatinib + EP|Sintilimab: 200mg intravenously administered on day 1; Surufatinib: 200mg/ day orally, taken continuously; Etoposide: 1, 2, 3 days of continuous administration, 100mg/m2, intravenous infusion; Cisplatin: 75mg/m2 on day 1, or 25mg/m2 on day 1, 2, and 3, intravenous infusion;
89640603|NCT06102733||Adult chronic pain patients|Adult chronic pain patients with pelvic, inguinal or sacroiliac pain
89640604|NCT06102707|Experimental|Fluzopril Combined With Apatinib Group|
89640605|NCT06102655|Experimental|treatment group（Jiajian Guishen Formulation）|Jiajian Guishen Formulation is a traditional Chinese medicine, it will be used in POI patients for three menstrual cycles; their blood samples are collected before and after treatment.
89640606|NCT06102655|No Intervention|no-treatment control group|healthy people
89640607|NCT06102642|Experimental|Combining Free Gingival Graft with frenotomy procedure|evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
89640608|NCT06102629|Experimental|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of PCOS (|"We will take both blood and ovarian tissue samples used to diagnosis.~We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
89640609|NCT06102629|No Intervention|100 women undergoing surgery for gynaecological disorder|"We will take both blood and ovarian tissue samples used to diagnosis.~We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
89640610|NCT06102551||The primary group|
89640611|NCT06102551||The recurrent group|
89640612|NCT06102538|Active Comparator|Morbid obese adolescents with comorbidity|A weekly intervention of physical education, group psychological support, and nutrition education.
89640613|NCT06102538|No Intervention|Obese children who do not participate in this intervention|This group of adolescents will continue the routine treatment in the clinic
89640614|NCT06102525|Experimental|Part 1 Cohort 1|RZ-001 Dose 1 and VGCV
89640615|NCT06102525|Experimental|Part 1 Cohort 2|RZ-001 Dose 2 and VGCV
89640616|NCT06102525|Experimental|Part 1 Cohort 3|RZ-001 Dose 3 and VGCV
89640617|NCT06102525|Experimental|Part 1 Cohort 4|RZ-001 Dose 4 and VGCV
89640618|NCT06102525|Experimental|Part 1 Cohort 5|RZ-001 Dose 5 and VGCV
89640619|NCT06102525|Experimental|Part 2|RZ-001 Dose 6 and VGCV
89640620|NCT06102512|Experimental|[¹⁴C]-LOXO-783 (Part 1)|Single dose of [¹⁴C]-LOXO-783 administered orally
89640621|NCT06102512|Experimental|LOXO-783 + [¹⁴C]-LOXO-783 (Part 2)|Single dose of LOXO-783 administered orally followed by single dose of [¹⁴C]-LOXO-783 administered intravenously (IV)
89640622|NCT06102499||Pediatric population|Pediatric population < 18 years old (estimated 100 patients)
89640623|NCT06102499||Adult population|Adult population >or= 18 years old (estimated 100 patients)
89640624|NCT06102473|Experimental|Intervention group|The dyads (children and caregivers), will receive general nutritional education and also receive guidance on the use of front-of-package warning labels and awareness about the impact of the consumption of processed and ultra-processed foods on health.
89640625|NCT06102473|No Intervention|Control Group|The dyads (children and caregivers), will receive general nutritional education.
89640626|NCT06102460|Active Comparator|Casein Protein|Each participant will consume a serving of casein protein mix.
89640627|NCT06102460|Active Comparator|a-lactalbumin|Each participant will consume a serving of a-lactalbumin protein mix.
88815717|NCT01089062|Other|Treatment A, then Treatment C, then Treatment B|"The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
88991550|NCT04744285|Experimental|Condition II (cigarettes with neutral message)|"Participants receive cigarettes with neutral message Nothing about this product's color or name means that it will protect a smoker from the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection."
88991551|NCT04744285|Experimental|Condition III (cigarettes with compensation message)|"Participants receive cigarettes with compensation message This product has a ventilated filter. Filter vents increase how deeply a smoker inhales without them knowing, which can increase the health risks of smoking on package for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
88991552|NCT04744285|Experimental|Condition IV cigarettes with blocking message|"Participants receive cigarettes with blocking message This product has a ventilated filter. Be sure not to block the vent holes with your fingers or lips, which can increase the health risks of smoking for 2 weeks. Participants attend 3 video sessions over 0.5 hour each at baseline, 1, and 2 weeks respectively for data collection"
88991553|NCT04744116|Active Comparator|Arm 1 (ruxolitinib)|Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
88991554|NCT04744116|Experimental|Arm 2 (ruxolitinib, lower dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
88991555|NCT04744116|Experimental|Arm 3 (ruxolitinib, higher dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
88991556|NCT04742023|Experimental|Intervention Arm|
88991557|NCT04742023|Placebo Comparator|Control Arm|
89640628|NCT06102460|Active Comparator|Carbohydrate|Each participant will consume a serving of carbohydrate mix.
89640629|NCT06102460|Placebo Comparator|Placebo|Each participant will consume a serving of a placebo mix.
89640630|NCT06102447|Experimental|Treatment Group|
89640631|NCT06102434|Experimental|Psilocybin|25 mg psilocybin
89640632|NCT06102421||Symptomatic patellar tendon (patellar tendinopathy) treated by ESWT|"The included patients show signs of unilateral patellar tendinopathy and were included in the study in accordance with the inclusion and exclusion parameters. Data of clinical symptoms and morphological measures of symptomatic patellar tendons of enrolled participants are allocated to this group. Participants will receive a low-energy focused ESWT in accordance with study protocol.~ESWT will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines."
89640633|NCT06102421||Healthy tendon|"The asymptomatic tendons of enrolled patient are allocated to this group and are considered healthy based on clinical and ultrasound examination of the patellar tendon.~In this group, no specific treatment will be performed, only patellar tendon morphology will be monitored through time."
89640634|NCT06102356||Cohort 1|Patients diagnosed with Psoriasis referred to the outpatient clinics of Dermatology and Venereology of FPG already treated with a systemic biologic drug for at least one year.
89640635|NCT06102343|Experimental|acne scars treatment using the Alma Harmony platform with the ClearSkin applicator.|treatment of acne scars using the ClearSkin non-ablative ER:Glass 1540nm laser Module.
89640636|NCT06102317|Experimental|Intervention group|In the study, mobile application will be installed on the phones of the mothers in the initiative group and individual information will be provided about how the patients will use the smartphone application. . Information will be provided to patients for subsequent follow-ups. After the application is started to be used, notifications of the applications developed in Smart Mobile for the disease management process will be made to the mothers of the Initiative Group every two weeks for six months. In addition, the Initiative Group will continue to receive standard care practices such as examinations, examinations, tests, treatment, medical care and rehabilitation offered by the Home Health Services unit.
89640637|NCT06102317|No Intervention|control group|No attempts will be made to the control group. The control group will continue to receive the standard care practices offered by the Home Health Services unit.
89640638|NCT06102291|Experimental|Acupoint application with Yanqing Zhitong Ointment|"Acupoint selection: Ashi points, Shenshu (BL23), Guanyuanshu (BL26) Operation: Stick to each acupoint for about 4 hours. If there is a burning sensation or obvious itching or other discomfort on the part after application, it can be removed in advance.~Treatment Duration: Three times a week( Monday, Wednesday, and Friday), for four weeks"
89640639|NCT06102291|Active Comparator|Acupuncture|"Acupoint selection: Ashi points, Shenshu (BL23), Guanyuanshu (BL26) Operation: Disposable stainless steel needles (0.25mm×25mm) are used. The needles are retained for 20 mins afte Deqi.~Treatment Duration: Three times a week( Monday, Wednesday, and Friday), for four weeks"
89640640|NCT06102278||Training cohort|All cases were randomly grouped according to 7:3, with 70% defined as the training group
89640641|NCT06102278||Validation cohort|All cases were randomly grouped according to 7:3, with 30% defined as the validation group
89640642|NCT06102265||group 1|"In one arm of the study group, the surgeon changed the gown and the glove between each case with hand sterilization with alcohol before and after wearing the next glove.~Each keratome and MVR were used for multiple patients until they became blunt. We used the same IOL cartridge for every three cases and the same OVD in multiple patients. We immersed keratome, MVR, IOL cartridge, and cannulas of OVD in alcohol between cases.~As regard the phaco machine, we used Alcon Infiniti and Alcon Centurion and the same tip for all cases. The tip was immersed in a test chamber filled with alcohol between cases and not changed until we noticed a morphological change or they became blunt. Also, the same cassette was used in multiple surgeries and changed after collecting the plastic bag full of fluid."
89640643|NCT06102265||group 2|In another arm, we used the same steps except that the surgeon changed the glove only and used alcohol for hand sterilization before and after wearing the next glove. One gown was used for all the cases. As regard the intracameral antibiotic prophylaxis, a bottle of Vigamox, 5ml, was withdrawn, and each 1 ml was diluted with 5 ml saline. Using this dilution, 0.1 ml was injected intracamerally at the end of the operation. Finally, we did corneal hydration of the main wound and the side ports.
89640644|NCT06102252|Active Comparator|group A|will receive the TEC regimen: paclitaxel 150mg/m2 infused for 3 hours, epirubicin 50mg/m2 infused for 30 minutes, and carboplatin 4mg/ml/min for one hour on day 1 every 3 weeks.
89640645|NCT06102252|Active Comparator|group B|) will receive a ddTC regimen: paclitaxel 80mg/m2 for 3 hours on day 1,8,15. Carboplatin AUC 5 over one hour on day 1 repeated at 3-week intervals
89640646|NCT06102252|Active Comparator|group C|: paclitaxel 175 mg/m2 over 3 hours infusion on day 1-carboplatin AUC 5 over 1 hour on day 1 at 3 weeks intervals
89640647|NCT06102226||coronary artery disease group / non- coronary artery disease group|Recruited patients were categorized into a coronary artery disease group and a non-coronary artery disease group on the basis of coronary angiography findings, and the presence of CAD was defined as the presence of a coronary artery lesion with a stenosis
89640648|NCT06102200|Active Comparator|Standard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
89640649|NCT06102200|Experimental|Standard of care + CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
89640650|NCT06102200|Experimental|Standard of care + CBT4CBT+ RC|This condition will integrate the standard of care, CBT4CBT, and recovery coaching services with Assertive Community Engagement (ACE) model interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
89640651|NCT06102161|Experimental|Wedge resection|Wedge resection is performed for early-stage lung cancer to remove a wedge-shaped section of lung tissue.
89640652|NCT06102148|Experimental|PNF Group|
89640653|NCT06102148|Sham Comparator|Control Group|
89640654|NCT06102135|Other|Patients well established on tube feeds will act as their own control|Patients in the control group will switch from current feed to new tube feed to assess tolerance and acceptability.
89640655|NCT06102109|Active Comparator|Yamane Arm|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera.
89640656|NCT06102109|Active Comparator|"4-flanged Arm"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physiol Micropure 123) gets fixated in the sclera using 6.0 polypropylene suture
89640657|NCT06102070||Predisposition|individuals suffering of having previously suffered of severe infectious diseases
89640658|NCT06102044|Experimental|Zinc Supplementation|14-day regimen of twice-daily 5 mg elemental zinc supplements to be taken orally or by enteral feeding tube
89640659|NCT06102044|Placebo Comparator|Placebo|14-day regimen of twice-daily oral placebo supplements to be taken orally or by enteral feeding tube
89640660|NCT06102031|Experimental|Randomized Arm-Treatment Group|"Management of subjects based on lung fluid content derived from the ReDS™ system.~All subjects will receive ReDS™ test during hospitalization, at discharge, several home visits and 3 times outpatient follow-up.~For home visits frequency, ReDS™ tests will be performed every 7 days within 1 month of discharge; at the 2nd to 3rd month, ReDS™ test wil be performed every 15 days. Then ReDS™ test will be performed every 30 days from 4th to 12th months.~Patients will be followed up in outpatient at 3 months, 6 months, and 12 months after discharge."
89640661|NCT06102031|Sham Comparator|Randomized Arm-Control Group|"Management of subjects based on standard of care(signs, symptoms, weight, biomarkers, etc.) without lung fluid content information.~All subjects will receive ReDS™ test during hospitalization, at discharge, several home visits and 3 times outpatient follow-up.~For home visits frequency, ReDS™ tests will be performed every 7 days within 1 month of discharge; at the 2nd to 3rd month, ReDS™ test wil be performed every 15 days. Then ReDS™ test will be performed every 30 days from 4th to 12th months.~Patients will be followed up in outpatient at 3 months, 6 months, and 12 months after discharge."
89640662|NCT06102018||Breast cancer patients|No intervention. The patients who are diagnosed as breast cancer by postoperative pathological.
89640663|NCT06102018||Patients with benign breast lesions|No intervention. The patients who are diagnosed asbenign breast lesions by postoperative pathological.
89640664|NCT06102018||Healthy population|No intervention. The volunteers.
89640665|NCT06101966||cervical cancer patients with radiotherapy|The overall dose should be more than 75 Gy. patients received surgery should be excluded.
89640666|NCT06101953|No Intervention|Control|
89640667|NCT06101953|Experimental|Intervention|
89640668|NCT06101940||DM1 patients|Patient cohort
89640669|NCT06101888|Experimental|A single set of test|The experimental apparatus consisted of TaurusTrio™ Heart Valve (THV), Delivery Catheter & Introducer Sheath ,Loading Tools
89640670|NCT06101875|Experimental|Health Coaching|Patients will be assigned a health coach and be eligible to 8 sessions over a 12 week period.
89640671|NCT06101875|Active Comparator|Control|Patients will be enrolled onto the digital toolkit.
89640672|NCT06101849|Experimental|Cancer Pain Management Group|Participants in the study will attend a 6-week online pain management program (I-Can-Manage-Pain after cancer) that will cover the topics of understanding cancer pain, exercises to manage pain and psychological strategies to cope with pain. Questionnaires will be administered before and after the program
89640673|NCT06101836|Other|Interventional arm|All participant trainees will undergo the educational intervention, therefore there is only one arm since all participants will undergo the intervention. The intervention is a day where participants (the trainees) will undergo a full day of training in colonoscopy. Comparison of key performance measures in colonoscopy is made before and after the intervention.
89640674|NCT06101771||dyslipidemia|"Normal weight children more than 1 month and till age of 18 years that attend Assiut University children Hospital with Clinical manifestation:~Non-symptomatic accidentally discovered dyslipidemia.~Steatorrhea.~Fatty liver."
89640675|NCT06101758|Experimental|Muscular ultrasound assessment|Adult patients aged 18-69 years with a diagnosis of either liver cirrhosis, non-alcoholic fatty liver disease or hepatocellular carcinoma
89640676|NCT06101745|Active Comparator|Nizaracianine Triflutate Study Drug Arm|Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0, 2.5 or 5.0mg depending on trial phase.
89640677|NCT06101745|Placebo Comparator|Sugar Comparator Arm|In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo.
89640678|NCT06101719||Contrast Group|Inclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and received an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation,45 pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group
89640679|NCT06101719||No Contrast group|Inclusion criteria: children 1-20 years diagnosed with an adhesive small bowel obstruction by an attending pediatric surgeon and underwent a trial of nonoperative management (NOM) on hospital admission and who did not receive an enteral contrast challenge. Exclusion criteria included peritonitis, suspicion of incarcerated or internal hernia, active intra-abdominal malignancy, inflammatory bowel disease, <4 weeks since the most recent abdominal operation, pneumatosis, pneumoperitoneum, or known contrast allergy. If the attending surgeon made the decision to take a child directly to the operating room (OR) with no attempt at NOM, these children were excluded. Children under one year of age were excluded as the rate of successful NOM is lower in this age group
89640680|NCT06101706|Other|Psoriatic arthritis patients|
89640681|NCT06101706|Other|Cutaneous psoriasis patients|
89640682|NCT06101680||Children in intensive care with rhabdomyosis|
89640683|NCT06101615|Active Comparator|Group A|IASTM Group
89640684|NCT06101615|Active Comparator|Group B|Foam Rolling Group
89640685|NCT06101602|Experimental|With Floss Band|"Floss band made of natural rubber, black in color and 4 in width will be wrapped around the thigh, starting from the distally to superiorly with an overlap of 50%. Perform exercises:~• Multi-directional leg swing"
88991558|NCT04739761|Experimental|Trastuzumab Deruxtecan|Participants with or without BM at baseline will receive intravenous (IV) T-DXd, 5.4 mg/kg, every 3 weeks (21-day cycle) until Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined radiological progression outside central nervous system, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
88991559|NCT04737187|Experimental|Trifluridine/Tipiracil + Bevacizumab|Participants were administered 35 milligrams per square meter per dose (mg/m²/dose) trifluridine/tipiracil (FTD/TPI) orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on (Day 1 to 5 and Day 8 to 12) with 2 days off (Day 6 to 7 an Day 13 to 14), over 2 weeks, followed by a 14-day rest; with bevacizumab (5 milligrams per kilogram [mg/kg], intravenous [IV] infusion administered every 2 weeks (Day 1 and Day 15). This treatment cycle was repeated every 4 weeks.
88991560|NCT04737187|Active Comparator|Trifluridine/Tipiracil|Participants were administered 35 mg/m²/dose of FTD/TPI orally BID, within 1 hour after completion of morning and evening meals, 5 days on (Day 1 to 5 and Day 8 to 12) with 2 days off (Day 6 to 7 and Day 13 to 14), over 2 weeks, followed by a 14-day rest. This treatment cycle was repeated every 4 weeks.
88991561|NCT04737018|Experimental|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
88991562|NCT04737018|Sham Comparator|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
88991563|NCT04725110|Experimental|T3 Intervention|Participants in this arm will receive the experimental intervention.
88991564|NCT04725110|Placebo Comparator|Placebo Therapy|Participants in this arm will receive placebo therapy.
88991565|NCT04722939||Critical illness with acute kidney injury|See below for detailed inclusion/exclusion criteria
88991566|NCT04720989|Experimental|Bathing With Baby Cleanser|Skin cleansing products will be used in the first baths of the participants in this group.
88991567|NCT04720989|Experimental|Bathing With only Water|Only water will be used in the first baths of the participants in this group.
88991568|NCT04710784|Experimental|I-TEST Intervention Package|Each study site will begin in the baseline, pre-implementation phase, and then be randomized to implement the I-TEST intervention package for a duration of three months, followed by the post-implementation phase.
88991569|NCT04708431||Female subjects relatives who are carriers of the AR gene difference|We will enroll 50 female subjects relatives AIS subjects who are carriers of the AR gene difference
89042765|NCT04368117|Experimental|Active Therapy (STAT)|Patients randomized to the STAT group will receive an intensive, quantifiable, activity-based physical therapy prescription emphasizing four of the most active components of therapy: mobilization, strength training, aerobic training and functional training.
89042766|NCT04366973||Participants with Hepatitis C Virus With or Without Treatment|"This study includes 3 populations for analysis:~Target Population (TP): Defined as all participants enrolled in the study regardless of whether treated for HCV or not.~Core Population (CP): Defined as all participants of the TP who have been prescribed glecaprevir/pibrentasvir (G/P) and started treatment.~Safety Population (SP): Defined as all participants who received at least one dose of G/P."
89042767|NCT04358393|Experimental|APG-115 monotherapy|Monotherapy given in part 1
89042768|NCT04358393|Experimental|APG-115 + 5-azacitidine combination|Combination therapy given in part 2
89042769|NCT04356859|No Intervention|Crystalloid|Subjects in the crystalloid group will receive fluid resuscitation with Lactated Ringer's titrated each hour to achieve a urine output of 0.5-1mL/kg predicted body weight.
89042770|NCT04356859|Active Comparator|Colloid|Subjects in the colloid group will receive fluid resuscitation with Lactated Ringer's and 5% human albumin solution introduced no earlier than 8 hours post burn and no later than 12 hours post burn in a ratio by volume of 1/3 albumin to 2/3 Lactated Ringer's, and titrated each hour to achieve a urine output of 0.5-1mL/kg (milliliter/kilogram) predicted body weight.
89042771|NCT04351204|Other|MRL|radiotherapy on MR linac
89042772|NCT04334421||Mesh group|After resection, pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) and covered with subcutaneous flap.
89042773|NCT04332887|Experimental|Multidimensional Exercise Program|Patients in the intervention group received a 12-week multidimensional exercise programme that consisted of individual nursing consultation, an exercise program that included moderate intensity walking for 30-45 minutes per day, three days per week and combined resistance exercise, nutrition assessment and instructions, and support.
89042774|NCT04332887|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
89042775|NCT04332068|Active Comparator|Arm 1|Permethrin cream plus placebo tablets
89640686|NCT06101602|Active Comparator|Without floss Band|"Perform exercises without floss band.~• Multi-directional leg swing"
89640687|NCT06101576||Transurethral incision of the prostate (TUIP)|Patients who underwent TUIP using electrocautery or Laser.
89640688|NCT06101576||Transurethral resection of the prostate (TURP)|Patients who underwent TURP using monopolar or bipolar electrocautery.
89640689|NCT06101576||Prostate Vaporization|Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).
89640690|NCT06101576||Anatomical endoscopic enucleation of the prostate (AEEP)|Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.
89640691|NCT06101563|Active Comparator|Early|Patients will be managed by ureteroscopic lithotripsy 7 days after normalization of inflammatory indices (clinical and laboratory).
89640692|NCT06101563|Active Comparator|Delayed|Patients will be managed by ureteroscopic lithotripsy 2-4 weeks after normalization of inflammatory indices (clinical and laboratory).
89640693|NCT06101550|Experimental|partial pulpotomy in immature permanent teeth|partial removal of coronal pulp tissue
89640694|NCT06101550|Active Comparator|complete pulpotomy in immature permanent teeth|complete removal of pulp in pulp chamber
89042776|NCT04332068|Experimental|Arm 2|Ivermectin (200 µg/kg) plus placebo cream
89640695|NCT06101524|Experimental|Free Gingival greft Group|"Patients who are found to have keratinized mucosa insufficiency as a result of the examination, undergo free gingival graft to increase the keratinized mucosa. procedures will be done and you will be called for a check-up after 6 months.~The keratinized tissue volume formed after the procedure will be evaluated."
89640696|NCT06101524|Experimental|Gingival Unit Greft Group|"Patients who are found to have keratinized mucosa insufficiency as a result of the examination, undergo gingival unit graft to increase the keratinized mucosa. procedures will be done and you will be called for a check-up after 6 months.~The keratinized tissue volume formed after the procedure will be evaluated."
89640697|NCT06101485|Experimental|Telerehabilitation group|The telerehabilitation group (n=104) will participate in the FP-AF program for 16 weeks. The program is administered by the AF clinics and the healthcare centers (HC) in Viborg, Skive and Silkeborg Municipalities. After enrollment, the patients will have an individual meeting with the project nurse. Here the patient (and relatives, if necessary) will be instructed in the use of the technologies and an individual plan will be formulated for the AF patient's telerehabilitation. After participation in 16 weeks the patients start a 12 weeks follow-up period, where they will only measure steps and have access to the Heartportal on their own devices.
89640698|NCT06101485|No Intervention|Conventional rehabilitation|The control group (n=104) will follow the conventional care regime in the AF clinic and will not have contact to the project nurse. When the AF patients are in a stable condition, they will be followed by their general practitioner (GP). The control group will be in the study for 28 weeks.
89640699|NCT06101459||COPD patient with significant smoking history|"Patients with following conditions~smoking history more than 30 pack*year~FEV1/FVC ratio <0.7~No acute exacerbation history within 3 months"
89042777|NCT04332068|Experimental|Arm 3|Ivermectin (400 µg/kg) plus placebo cream
89042778|NCT04332068|Experimental|Arm 4|Ivermectin (800 µg/kg) plus placebo cream (Kenya and The Gambia sites)
89042779|NCT04326153|Experimental|experimental arm|Sintilimab+Albumin paclitaxel:+Carboplatin:
89042780|NCT04321200||Cross-sectional-150 infants (atypical vs typical)|Arm (Study)1: To assess the concurrent validity of a multimodal instrumented gym with existing clinical tools. Here, using 150 infants, we will focus on converting data from an instrumented gym into estimates of the standard clinical tests.
89042781|NCT04321200||Longitudinal cohort - 50 infants (atypical vs typical)|Arm (Study) 2: To discover the features related to long-term motor development. Here we will convert data collected longitudinally from 50 infants, using both instrumented gym and video recordings, into estimates standard clinical tests change over time and track features over developmental timescales.
89640700|NCT06101459||COPD patient without significant smoking history|"Patients with following conditions~smoking history less than 0.5 pack*year~FEV1/FVC ratio <0.7~No acute exacerbation history within 3 months"
89212213|NCT03997396||the DGM group|The subject recruitment was implemented in the obstetrics department of the First People's Hospital of Chongqing Liangjiang New Area, China. 255 pregnant women diagnosed with GDM by IADPSG2010 standard and their children will be enrolled into the GDM group.
89212214|NCT03997396||the Non-GDM group|In the obstetrics department of Chongqing First People's Hospital of Liangjiang New Area,China,the healthy pregnant women and delivery children in the same period were enrolled into the non-GDM group in a 1:1 ratio.
89212215|NCT00859274|Experimental|Budesonide|All patients receive this treatment to induce a change in asthma control
89212216|NCT00859352|Experimental|1|AZD1981 100mg and Midazolam
89640701|NCT06101459||Healthy smoker|"Patients with following conditions~smoking history more than 30 pack*year~FEV1/FVC ratio ≥0.7~No current use of medication for any chronic respiratory disease"
89640702|NCT06101446|Experimental|Lavander Aromatherapy|Lavender oil has been known to have calming properties and is one of the most effective aromatherapy oils. It reduces blood pressure and anxiety by stimulating the parasympathetic system.
89640703|NCT06101433|Placebo Comparator|The placebo group|Subjects in the placebo group, were advised to take two placebo tablets per day for 12 weeks along with life style modification such as physical activity of 30 minutes for 3 days per week with medium intensity and food intake consults provided by clinical guidelines of NIH and the North American Association for the Study of Obesity. The placebo tablets contained starch and they were similar to the soy isoflavone tablets in smell, taste, and appearance. The placebo tablets were made by Gol Daru Pharmaceutical Company, Isfahan, Iran.
89640704|NCT06101433|Active Comparator|The soy isoflavone group|In the soy isoflavone group, patients took 100 mg soy isoflavone in the form of two tablets per day for 12 weeks along with lifestyle modification. Each soy isoflavone 50 mg tablet contained 1.49 mg of genistein, 31.86 mg of genistin, 1.75 mg of daidzein, 13.21 mg of daidzin, 0.55 mg of glycitein and 1.14 mg of glycitin. The soy isoflavone tablets were made by Gol Daru Pharmaceutical Company, Isfahan, Iran.
89640705|NCT06101420|Experimental|Arm 1 Vonoprazn Triple Therapy Arm|Fifty eight participants.The patients received (Clarithromycin 500 mg tablets twice daily[BID]+ Amoxicillin 1gm capsules BID + Vonoprazan 20 mg tablets BID) for 14 days
89640706|NCT06101420|Active Comparator|Arm 2 Proton Pump Inhibitor Triple Therapy Arm|Fifty eight participants.The patients received the classic triple therapy (Clarithromycin 500 mg tablets BID + Amoxicillin 1gm capsules BID + Esomeprazole 20 mg tablets BID) for 14 days
89640707|NCT06101420|Experimental|Arm 3 Vonoprazan Quadruple Therapy Arm|Fifty eight participants.The patients received a non-bismuth quadruple therapy (Levofloxacin 500 mg tablets once daily[OD] + Vonoprazan 20mg tablets BID + Nitazoxanide 500mg tablets BID +Doxycycline 100mg capsules OD) for 14 days.
89640708|NCT06101420|Active Comparator|Arm 4 Proton Pump Inhibitor Quadruple Therapy Arm|Fifty eight participants.The patients received a non-bismuth quadruple therapy (Levofloxacin 500 mg tablets OD + Esomeprazole 20mg tablets BID + Nitazoxanide 500 mg tablets BID +Doxycycline 100mg capsules OD) for 14 days
89640709|NCT06101407||MG stage I|
89640710|NCT06101407||MG stage IIA|
89640711|NCT06101407||MG stage IIB|
89640712|NCT06101381|Experimental|CD19-directed CAR-T cell|After lymphodepletion, a single intravenous infusion of an academic, locally produced, autologous CD19-directed CAR-T cells will be administered.
89212217|NCT00859352|Experimental|2|AZD1981 500mg and Midazolam
89212218|NCT00861770|Other|1 - Control|All subjects will receive blood volume measurement immediately before and 30 minutes after ultrafiltration is completed. In the control group, the treating physician will not see the blood volume measurement results and treat according to standard of care.
89212219|NCT00861770|Experimental|2 - BVM|Ultrafiltration will be guided by blood volume measurement results.
89212220|NCT00849758||1|chemotherapy: elderly patients receiving 4x adjuvant taxotere cyclophosphamide adjuvant for breast cancer
89212221|NCT00849758||2|adjuvant hormone therapy: 40 patients receiving adjuvant aromatase inhibitor without chemotherapy
89640713|NCT06101368|Experimental|Physical Activity (Combined Aerobic and Resistance Training)|Group A will perform aerobic and resistance exercises at a moderate level. Brisk Walk on treadmill 5 days/week with 40-70% of Vo2max (maximal aerobic capacity) 150 min/week 50-55% humidity and a room temperature of 24-25 °C will maintain. The subject will wear insole proper fitted shoes. Aerobic exercise will be conducted for a total of 30 minutes per session for 5 days for 12 weeks. This protocol will be followed by a 10-minute warm-up and cool-down. Followed by 10-15 minutes of resistance-based exercises at a moderate intensity of three sets with 15 repetitions of upper and lower limbs respectively i.e. Dumbbell biceps curl, Standing dumbbell triceps extension, Dumbbell stiff-legged deadlifts and Dumbbell squats Resistance loads will be 40-50% of one repetition maximum. The resting interval between resistance training sets will be < 1 min.
89640714|NCT06101368|Other|Control Group|The control group will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
89640715|NCT06101355|Experimental|Telerehabilitation Group Based on Home Exercises|Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation.
89640716|NCT06101355|Active Comparator|Standard Home Exercise Group|Standard home based exercise group
89640717|NCT06101316|Experimental|CB06-036 Cohort 1|1.5 mg Day1, orally taken in the morning, on an empty stomach.
89640718|NCT06101199|Active Comparator|AIHH + tSCS-paired Strength Training|Participants will receive exposure to AIHH followed by transcutaneous spinal cord stimulation-paired respiratory and upper extremity strength training.
89640719|NCT06101199|Experimental|SHAM AIHH + tSCS-paired Strength Training|Participants will receive exposure to SHAM AIHH followed by transcutaneous spinal cord stimulation-paired respiratory and upper extremity strength training.
89640720|NCT06101199|Sham Comparator|SHAM AIHH + SHAM tSCS-paired Strength Training|Participants will receive exposure to SHAM AIHH followed by SHAM transcutaneous spinal cord stimulation-paired respiratory and upper extremity strength training.
89640721|NCT06101199|Experimental|AIHH + SHAM tSCS-paired Strength Training|Participants will receive exposure to AIHH followed by SHAM transcutaneous spinal cord stimulation-paired respiratory and upper extremity strength training.
89640722|NCT06101186|No Intervention|control group|Participants in the control group received standard nursing care provided by the institution where the research was conducted. After the study, we shared the materials developed for NPECP with the participants in the control group.
89640723|NCT06101186|Experimental|Experimental group|Nursing education and counseling practice to be applied to the experimental group was based on NSM. In the implementation of NPECP, the women were first met, and after the meeting, their informed consent was taken and they were included in the study. It was stated that the women in the experimental group were told that four scheduled interviews would be conducted online in a period of approximately 4 weeks. The women were given a telephone number where they could contact the researcher so that they could receive telephone/online counseling and were included in the whatsapp group with their permission.
89640724|NCT06101121||Urethral catherisation|Observation time will start with placement of catheter and will end with catheter removal or if any complication appears, whatever occurs first. In this case, the observational time will be 1 day when a bladder catheterization is undergone.
89640725|NCT06101121||Cytoscopy|Observation time will start with placement of catheter and will end with catheter removal or if any complication appears, whatever occurs first. In this case, the observational time will be the time which the catheterization lasts.
89640726|NCT06100419|Experimental|Block|This group consists of patients who underwent SPSIP block.
89640727|NCT06100341|Experimental|Head-mounted display (HMD)|The HMD system uses a commercially available virtual headset, the Oculus/Meta Quest 2, which allows a user to view a virtual environment in 360 degrees and to interact with the environment using hand-tracking technology (i.e., when a user's hand is projected into the virtual world to be used for interactions and gestures).
89640728|NCT06100341|Experimental|Semi-cave automatic virtual environment (semi-CAVE)|The semi-CAVE system uses projectors and projector screens to provide a 270-degree view of the virtual environment. These projectors are connected to a powerful workstation (desktop computer), which uses HTC Vive trackers and base stations to track user movements and interactions
89640729|NCT06099821|Experimental|Patients resistant to PD1/PDL1 blockade|Patients with microsatellite instability-high digestive system cancers resistant to PD-1/PD-L1 blockade
89640730|NCT06099613|Experimental|EG-COVII|
89640731|NCT06098586|Active Comparator|Self-managed exercise therapy program|Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
89640732|NCT06098586|Active Comparator|Partial wrist denervation|AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
89640733|NCT06098274|Experimental|Motivational interviewing group based on transtheoretical model|Smartphone addiction scale will be applied to nursing department students. Those who score 31 or more on the scale for men and 33 or more for women will be considered at risk and will be invited to the study. Those who meet the participation criteria and volunteer to participate will be included in the study. Participants will be homogeneously and randomly distributed into intervention and control groups.
89640734|NCT06098274|No Intervention|Group without transtheoretical model-based motivational interviewing (Control group)|No intervention will be made to the intervention group. After evaluating the final data, if the motivational interview and training program is found to be effective, a motivational interview and training program will also be carried out to the control group participants.
89640735|NCT06097455|Experimental|ARI0003|ARI0003 will be administered intravenously under a split regime. A total dose between 0.5 and 5 x106 cell/Kg will be administered in 3 administrations (fractions):
89640736|NCT06097351||Type 2 diabetes group|The group was based on the clinically confirmed diagnosis of type 2 diabetes
88991570|NCT04708431||Female subjects relatives who are not carriers of the AR gene|We will enroll 50 female subjects relatives of AIS subjects who are not carriers of the AR gene.
88991571|NCT04708431||Healthy male subjects relatives|We will enroll 50 healthy male subjects of AIS relative subjects
88991572|NCT04708431||Subjects with androgen receptor mutations|500 Subjects with confirmed androgen receptor mutations
88991573|NCT04689048|Other|PET/CT, MRI|In total, three 18F-fluciclovine PET/CT brain scans (pre-, interim-, and post-treatment) will be performed according to the study calendar. Generic name is Axumin and will be administered as an intravenous bolus. May administer diluted or undiluted. The maximum volume of undiluted 18F-fluciclovine is 5 mL. After administration, flush with normal saline to ensure full delivery of the dose.
88991574|NCT04668521||COHORT A|Women with a pelvic mass, symptomatic or asymptomatic.
88991575|NCT04668521||COHORT B|Women diagnosed with a pelvis mass undergoing genetic testing through our commercial offering.
88991576|NCT04668521||COHORT C|Subject must not have an identifiable adnexal mass and may, or may not, have a family history or a known familial genetic abnormality (germ line or identified in family cancer i.e. somatic DNA mutation) associated with ovarian cancer.
88991577|NCT04661644|Experimental|Test Group 1 (Low Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, which is divided into 1 cc pre-filled syringes and administered in 20 divided doses to 15-20 parts of the muscle in divided doses along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia so that the entire diluted solution is administered.
88991578|NCT04661644|Experimental|Test Group 2 (High Dose)|- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, then administered to 15-20 parts of the muscle along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia.
88991579|NCT04652726|Experimental|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
89212222|NCT00618410|Active Comparator|Carbon dioxide|nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge
89640737|NCT06097351||Diabetic nephropathy group|The group was based on the clinically confirmed diagnosis of type 2 diabetes.Patients were re-screened strictly according to the following admission criteria: persistent albuminuria and/or decreased eGFR, while other causes of chronic kidney disease (CKD) were excluded. When diabetes mellitus is identified as the cause of kidney damage and other primary and secondary glomerular diseases and systemic diseases are excluded, at least one of the following conditions can be diagnosed as DKD: (1) Urinary Albumin/Creatinine Ratio (UACR)≥30 mg/g or Urinary albumin excretion rate (UAER)≥30 mg/24 h, The UACR or UAER was checked again within 3 to 6 months, and 2 out of 3 times reached or exceeded the critical value; Eliminate other interfering factors such as infection; (2) eGFR&lt; 60 ml·min-1· (1.73 m2) -1 for more than 3 months; (3) Renal biopsy was consistent with DKD pathological changes
89640738|NCT06096766||Diminished Ovarian Reserve Group|women with DOR
89640739|NCT06096766||Premature Ovarian Insufficiency Group (POI)|women with premature ovarian insufficiency
89640740|NCT06096766||Control Group|women with normal menstruation and levels of sex hormones
89640741|NCT06095258|Experimental|Traditional Chinese medicine treatment group|Patients in this treatment group will receive individualized TCM syndrome differentiation treatment.
89640742|NCT06095258|Active Comparator|Western medicine control group|Patients in this control group will receive conventional Western medicine symptomatic treatment from general Western medicine practitioners.
89640743|NCT06089278|Experimental|300mg of TQH2722 injection|TQH2722 injection, 14 days as a treatment cycle.
89640744|NCT06089278|Experimental|600mg of TQH2722 injection|TQH2722 injection, 14 days as a treatment cycle.
89640745|NCT06089278|Placebo Comparator|TQH2722 injection matching placebo|TQH2722 injection matching placebo, 14 days as a treatment cycle.
89640746|NCT06089083||Newly diagnosed gynecologic cancer|Participants will undergo physical function assessments, complete surveys, and medical records every 3 months +/- 4 weeks prior to standard of care surgery (outside of this protocol). After surgery subjects will be followed for at least 3 months +/- 4 weeks for up to one year after diagnosis. Medical record reviews will occur periodically to examine for long-term follow up oncologic outcomes of progression free survival, overall survival, and chemotherapy delays for up to 10 years after enrollment.
89640747|NCT06085157||Ecological momentary assessment (EMA)|a repeated real-time data collection in real-world environment and allows modeling of within-person processes and temporal dynamics.
89640748|NCT06080997||Spinal surgery|"No intervention will take place Recruiting autumn 2023 until autumn 2024. All patients at Zealand University Hospital, who meet the inclusion criteria, undergoing spinal surgery during 1 year, will be invited to participate in the quantitative part of the study.~We estimate that 300 patients will be eligible for the quantitative part. For the qualitative part, we will include 10 - 15 patients undergoing spinal surgery."
89640749|NCT06072430|Experimental|VBI-S|Treatment with VBI-S
89640750|NCT06068192||28th day death group|Patient dies within 28 days after hospitalization
89640751|NCT06068192||non-28th day death group|The patient does not die within 28 days after hospitalization
88991580|NCT04652726|Placebo Comparator|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
88991581|NCT04641819|Experimental|Yangzheng Compound Mixture plus conventional treatment|"Yangzheng Compound Mixture: 10mL, 2 doses each time, 3 times a day, three weeks for a course of treatment. Investigators recommended that the participants of experimental group should use Yangzheng Compound Mixture for 2 courses at least.~Conventional treatment:~Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
88991582|NCT04641819|Other|conventional treatment only|"Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy.~The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine."
88991583|NCT04635423|Experimental|V503|Participants receive an intramuscular (IM) injection of V503 at Day 1, Month 2, and Month 6.
88991584|NCT04635423|Placebo Comparator|Placebo|Participants receive an IM injection of placebo at Day 1, Month 2, and Month 6.
88991585|NCT04630197|Experimental|e-CBT|16 weekly sessions will be conducted through OPTT and consist of approximately 30 slides and interactive therapist videos. The content and format will mirror in-person CBT for OCD. The connection between thoughts, behaviours, emotions, physical reactions, and the environment will be a focus. Moreover, mindfulness, body scanning, self-care, goal setting, thinking errors, the 5-part model, thought records, and ERP will be incorporated. Slides will highlight different topics each week and include general information, an overview of skills, and homework on that topic. The homework will be submitted through OPTT and reviewed by therapists with personalized feedback provided within 3 days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. After each completion of the e-CBT program, participants will be interviewed to investigate their experience using OPTT and their perception of how the treatment went.
89057925|NCT04535804|Active Comparator|Aspirin group|100 mg of low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
89212223|NCT00618410|Placebo Comparator|Placebo|nasal placebo administered 30 minutes prior to nasal challenge
89212224|NCT00861926|Experimental|Beclometasone/formoterol (100/6 µg)|Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
89212225|NCT00861926|Active Comparator|salbutamol|Ventolin : salbutamol sulphate 100 µg per metered dose
89640752|NCT06064721|Experimental|Buerger-Allen Exercise Group|"The researcher will conduct training sessions on the BAE for the study group (how to perform these exercises, duration, and frequency of exercise).~Firstly researcher practically demonstrate the BAE technique lasting 15-20 minutes, and secondly will encourage each participant to re-demonstrate the following technique.~The researcher will ensure that the study group practices the exercise until they demonstrate competence in its execution. Additionally, the study group will be provided with a photographic brochure illustrating the exercise.~The buerger Allen exercise will consist of three steps step 1. Elevation step 2. Dependency step 3. Horizontal The intervention group will continue for 14 days, with a 6-8 hour gap between the two sessions, in addition to receiving routine care.~To ensure exercise continuity, participants will receive reminders via phone calls/messages"
89640753|NCT06064721|No Intervention|Routine Care Group|the control group participants will receive routine care.
89640754|NCT06063161|Experimental|Music Therapy|Music therapy intervention will be administered for 30 minutes 3 times per week between Day 0 and Day 15 of inpatient hospitalization. Daily passive music listening will be required for 30 minutes twice a day, at least 4 days per week. This daily listening experience will consist of personalized playlists developed by the music therapist with specific purpose and goal.
89640755|NCT06063161|Active Comparator|Active Control|Daily passive music listening will be required for 30 minutes twice a day, at least 4 days per week. This daily listening experience will consist of non-personalized, auto-generated playlists based on popular genres. No interaction with a music therapist will occur.
89640756|NCT06063161|Placebo Comparator|Standard of care|Usual standard of care.
89640757|NCT06058429||2-3 months infants group|Subjects in this group had recieved three dose of sIPV as primay immunization, and about half of them recieved DTaP simultaneously.
89640758|NCT06058429||18 months children group|Subjects in this group had recieved one dose of sIPV as booster immunization, and about half of them recieved MMR or hepatitis A vacine(live-attenuated or inactivated) simultaneously.
89640759|NCT06056154||Patients undergoing routine clinical practice with ASQELIOTM monofocal LIO model QLIO130C.|Data will be extracted retrospectively from their medical records and prospectively in a single follow-up visit. All procedures performed are according to standard clinical practice.
89640760|NCT06055881||Observational|Patients undergo blood sample collection and complete questionnaires on study.
89640761|NCT06045299|Experimental|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution|Aceclidine+Brimonidine combination ophthalmic solution
89640762|NCT06045299|Experimental|LNZ100 (Aceclidine) ophthalmic solution|Aceclidine ophthalmic solution
89640763|NCT06045299|Placebo Comparator|Placebo (Vehicle) ophthalmic solution|Placebo (Vehicle) ophthalmic solution
89640764|NCT06044493|Experimental|Myreptic-N Tablet|Mycophenolate sodium
89640765|NCT06044493|Active Comparator|Myrept Tablet/Capsule|Mycophenolate mofetil
89640766|NCT06038721|Experimental|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children|The participants in this group will receive the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children (UP-C) in up to 15 sessions through a group format, attended over up to 24 weeks. Sessions will include parent and child strategies to manage strong emotions.
89640767|NCT06038721|Experimental|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents|The participants in this group will receive the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) in an individual format for up to 24 weeks.
89640768|NCT06028893|Experimental|Study group|All subjects will perform heart rhythm measurements with both diagnostic tests.
89640769|NCT06027307|Experimental|Enavogliflozin|Enavogliflozin 0.3 mg qd for 18 months
89640770|NCT06027307|Placebo Comparator|Placebo|Placebo qd for 18 months
89640771|NCT06023966||with HMGC|patients with gastric cancer who developed hepatic metastasis after curative gastrectomy
89640772|NCT06023966||without HMGC|patients with gastric cancer who did not developed hepatic metastasis after curative gastrectomy
89640773|NCT06020690|Experimental|Novabel bioabsorbable steroid-releasing stent|
89640774|NCT06020690|Active Comparator|marketed bioabsorbable steroid-releasing stent|
89640775|NCT06020677|Experimental|L-WebTIPS|
89212226|NCT04041518|Other|Intervention|Autotransplantation and intra-operative extraoral apicoectomy of a permanent tooth.
89212227|NCT00849836||Acute exacerbation|
89212228|NCT00849836||Stable disease|
89212229|NCT00849836||Healthy control|
89212230|NCT04041752|Experimental|Normal weight|30 healthy normal weight adults will be involved and will realize the three conditions
89212231|NCT04041206||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
89212232|NCT04041206||Healthy group|This group will include 40 healthy volunteers.
89212233|NCT00849914||1|Patients with actinic keratoses of the skin
89212234|NCT00849914||2|Patients with basal cell carcinoma of the skin
89212235|NCT00849914||3|Patients with squamous cell carcinoma of the skin
89640776|NCT06020677|No Intervention|L-WebINFO|
89640777|NCT06008964|Active Comparator|Ylang Ylang oil Group|GROUP 1
89640778|NCT06008964|No Intervention|Control Group|No intervention
89640779|NCT06008964|Active Comparator|Lavender oil|GROUP 2
89640780|NCT06003855|Experimental|Oxygen guided supervised exercise|Modified-SET parameters will be determined from resting StO2 during 10 minutes of sitting. The StO2 threshold will be set at 15% lower than baseline StO2 levels. After warm-up, the subjects will walk until they reach the StO2 threshold. The subjects will be instructed to stop walking once they reach the threshold and to rest until the StO2 level returns to the baseline level. Then, subjects will be instructed to begin walking again and this cycle will be repeated for 50 total minutes. The threshold was selected to be above the 31% drop associated with claudication onset time. If subjects experience pain earlier than the 15% drop, the threshold will be progressively decreased by 5%, as needed. Subjects will repeat this for up to 50 minutes (including walking and rest). Walking speed and treadmill incline will be adjusted to allow for 5-10 minutes of walking before reaching the threshold. Subjects will complete 3 sessions/week for 12 weeks.
89640781|NCT06003855|Active Comparator|Standard supervised exercise|After the warmup, subjects will walk until claudication pain becomes severe and needs to stop. Then subjects will rest until claudication pain subsides. Afterwards, subjects will walk again, repeating the cycle for up to 50 minutes (including walking and rest). Walking speed and treadmill incline will be adjusted during the SET session to allow individuals with PAD to walk for 5-10 minutes before claudication symptoms arise. Time at each speed and incline, along with rest times will be recorded during each exercise session. Subjects will complete 3 sessions/week for 12 weeks.
89640782|NCT06002971||Normotensive|Normotensive pregnant patients beyond the first trimester with systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg
89640783|NCT06002971||Hypertensive|"Hypertensive pregnant patients beyond the first trimester:~i) without proteinuria >300 mg in 24 h; and ii) with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg"
89640784|NCT06002971||Pre-Eclampsia|"Pre-eclampsia patients beyond the first trimester:~i) with proteinuria >300 mg in 24 h; and ii) with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg"
89640785|NCT05998824|Other|Adults With Sickle Cell Disease|Age 18 years or older
89640786|NCT05995366|Experimental|ABBV-903|Participants will receive ABBV-903 on Day 1.
89640787|NCT05987293||Supine group|Fifty-four patients undergoing elective surgery in general anesthesia for more than 2 hours with endotracheal tube applied in China-Japan Friendship Hospital will be enrolled (See in Sample Size calculation). Patients will be divided into two groups according to the surgery: supine position (Supine group)
89640788|NCT05987293||Flexion group|The high-risk positions (Flexion group) which include patients scheduled for surgery under the prone position, cervical traction position, and beach chair position.
89640789|NCT05985109|Experimental|Non-liver metastasis cohort|Arm A will include microsatellite-stable metastatic colorectal cancer patients who have no active liver metastasis. Patients are required to have received prior 5-Fu， oxaliplatin, and irinotecan treatment before enrollment.
89640790|NCT05985109|Experimental|BRAF V600E mutant cohort|Arm B will include microsatellite-stable metastatic colorectal cancer patients who have BRAF V600E mutation. Patients are required to have received prior 5-Fu， oxaliplatin, and irinotecan treatment before enrollment.
89640791|NCT05985109|Experimental|Front-line therapy cohort|Arm C will include microsatellite-stable metastatic colorectal cancer patients who are unable or refuse to receive standard first-line or second-line treatment.
89640792|NCT05978128|Experimental|Screening (electronic patient portal, patient navigation)|Participants access an electronic patient portal with educational materials at baseline, 1- and 2-year follow-ups, and also interact with a patient navigator on study. Patients also receive materials to share with their friends/family on benefits of breast and lung cancer screening on study.
89640793|NCT05975333|Experimental|Participants|Adolescents and young adults (AYA) patients aged 15-25 years currently receiving cancer-directed therapy at St. Jude Children's Research Hospital
89640794|NCT05972291|Experimental|Oral Glutamine|You will be asked to consume 5 grams of glutamine three times a day for 26 weeks. At week eight, you will be asked to return to the CRC to be assessed, and then to return every four weeks until week 26, which will be the conclusion of the study.
89640795|NCT05972291|Placebo Comparator|Whey Protein Powder|You will be asked to consume 5 grams of whey protein powder three times a day for 26 weeks. At week eight, you will be asked to return to the CRC to be assessed, and then to return every four weeks until week 26, which will be the conclusion of the study.
89640796|NCT05950919|Experimental|TASKPEN|"The TASKPEN intervention is a package of five evidence-based intervention (EBI) components that enhances WHO's Package of Essential Noncommunicable Disease Intervention for Primary Care (WHO-PEN) and includes a multi-faceted implementation strategy centred on service integration within routine HIV care settings. The EBI components and multi-faceted strategy have been adapted to the Zambian setting during recently completed formative work."
89640797|NCT05950919|No Intervention|Standard of Care|Screening, diagnosis, and treatment of cardio-metabolic NCDs are generally unavailable in the clinical departments where most PLHIV seek and receive health services. When these services are available, they tend to be siloed and offered only for hypertension in general outpatient medical settings that provide urgent care-like services. Healthcare workers do not have protocolized algorithms for NCD management in HIV service delivery settings. NCD equipment is often unavailable in ART and differentiated service delivery (DSD) clinics; most health facilities do not offer haemoglobin A1c or lipid panel testing; and fragmented NCD supply chain management systems mean that essential medications for the management of hypertension, diabetes, and dyslipidemia are often unavailable
89640798|NCT05941520|Experimental|Group 1 (acolbifene)|Patients receive acolbifene PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D mammography and collection of blood samples during screening and at the end of acolbifene treatment. In addition, patients undergo RPFNA during screening and during day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.
89640799|NCT05941520|Active Comparator|Group 2 (tamoxifen)|Patients receive tamoxifen PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D mammography and collection of blood samples during screening and at the end of tamoxifen treatment. In addition, patients undergo RPFNA during screening and day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.
89640800|NCT05934773|Experimental|Gait Rehabilitation|12-16 gait rehabilitation sessions on a robotic treadmill, emphasizing gait scaffolds: endurance, strength, speed, and balance. 3-4 sessions of training for each.
88991586|NCT04614662|Experimental|Intervention|"Participants enrolled at intervention sites will be prompted to complete symptom screening three times weekly via SPARK with corresponding feedback and links to symptom management care pathways sent to their healthcare providers.~Symptom screening using SPARK can be performed at any time and as often as desired, but screening will be prompted three times weekly for eight weeks.~Each day the participant completes symptom screening and has at least one severely bothersome symptom, the primary healthcare team will receive an email summarizing the symptom report and highlighting symptoms that are a lot or extremely bothersome.~Upon study activation, we will work with each of the 10 intervention sites to develop site-specific, adapted care pathways that consider relevant work flows, institutional culture and available resources."
89640801|NCT05933395|Experimental|Arm A- neratinib and fulvestrant|"Participants with a qualifying ERBB2 (HER2) mutation will be assigned to Treatment Arm A and given the combination of neratinib and fulvestrant until the end of the primary treatment phase.~Fulvestrant (500 mg) will be administered by intramuscular injection into the buttocks on Cycle 1 Day 1 and Day 15, and on Day 1 of subsequent Cycles.~Neratinib will initially be administered orally in 3 tablets (total dose of 120 mg) taken 1 time per day with food on Cycle 1 Days 1-7, in combination with fulvestrant starting on Cycle 1 Day 1 as described above. The dose of neratinib will be increased to 4 tablets (total dose of 160 mg) taken 1 time per day with food on Cycle 1 Days 8-14, and then increased further to 6 tablets (240 mg) taken once daily with food thereafter."
89640802|NCT05933395|Experimental|Arm B- alpelisib and fulvestrant|"If a participant does not have a qualifying ERBB2 (HER2) mutation, but they have a qualifying PIK3CA mutation, the subject will be assigned to Treatment Arm B and given the combination of alpelisib and fulvestrant until the end of the primary treatment phase.~Fulvestrant (500 mg) will be administered by intramuscular injection into the buttocks on Cycle 1 Day 1 and Day 15, and on Day 1 of subsequent Cycles.~Alpelisib will be administered orally in 2 tablets (total dose of 300 mg) taken 1 time per day with food, in combination with fulvestrant as described above."
89640803|NCT05933395|Experimental|Arm C- everolimus and fulvestrant|"If a subject does not have a qualifying ERBB2 or PIK3CA mutation, but they have a qualifying mutation/alteration in AKT1, MTOR, or PTEN, the subject will be assigned to Treatment Arm C and given the combination of everolimus and fulvestrant until the end of the primary treatment phase.~Fulvestrant (500 mg) will be administered by intramuscular injection into the buttocks on Cycle 1 Day 1 and Day 15, and on Day 1 of subsequent Cycles.~Everolimus will be administered orally in 1 tablet (10 mg per tablet) taken 1 time per day, in combination with fulvestrant as described above."
89640804|NCT05933395|Experimental|Arm D- abemaciclib and fulvestrant|"If a participant does not have a qualifying mutation/alteration for Arms A/B/C, and the participant does not have mutation or loss of RB1, the subject will be assigned to Treatment Arm D and given the combination of abemaciclib and fulvestrant until the end of the primary treatment phase.~Fulvestrant (500 mg) will be administered by intramuscular injection into the buttocks on Cycle 1 Day 1 and Day 15, and on Day 1 of subsequent Cycles.~Abemaciclib will be administered orally in 1 tablet (150 mg) taken 2 times per day, in combination with fulvestrant as described above."
89640805|NCT05928572|Experimental|Nutrition-Focused Approach (NFA)|NFA arm participants will receive introduction to CGM from a diabetes care provider with emphasis placed on using the CGM data to adjust food choices. The NFA will encourage food choices that align with evidence-based nutrition recommendations for People with Diabetes (PWD), and that achieve internationally recognized glucose targets (e.g. glucose 70-180 mg/dL, and Time In Range > 70%).
89640806|NCT05928572|Active Comparator|Self-Directed Approach (SDA)|The SDA arm participants will receive introduction to the CGM from a diabetes care provider using the CGM manufacturer-provided manuals and resources. The SDA will encourage participants to use the CGM device and apps in the way that feels most useful to them. The SDA is intended to reflect current CGM initiation practices, which focus on technical use of the CGM and a general review of CGM data.
89640807|NCT05916261|Experimental|Personalized neoantigen vaccine or neoantigen tumor vaccine + Pembrolizumab|In dose escalation phase, subject will only receive personalized neoantigen tumor vaccine. In dose expansion phase, subject will receive personalized neoantigen tumor vaccine combination with Pembrolizumab .
89640808|NCT05909800|Experimental|Phenofibrate|Phenofibrate in capsules received orally, daily, for 12 months.
89640809|NCT05909800|Placebo Comparator|Placebo|Capsules containing Microcrystalline cellulose 102,594 mg (99%) and Magnesium stearate 6 mg (1%) identical to those of the active product received orally, daily, for 12 months.
88991587|NCT04614662|No Intervention|Control|At control sites, usual care will be provided, which may or may not include symptom screening, access to CPGs or care pathways. Participants will complete SSPedi to obtain the primary outcome at weeks 0, 4 and 8 but the scores will not be revealed to providers and will not be linked to care pathways.
88991588|NCT04613128||Pediatric|Cystic Fibrosis pediatric patients (6-11 years old) prescribed ETI CFTR modulator Therapy.
88991589|NCT04592874|Experimental|AL002 Dose 1|AL002 every 4 weeks
88991590|NCT04592874|Experimental|AL002 Dose 2|AL002 every 4 weeks
88991591|NCT04592874|Experimental|AL002 Dose 3|AL002 every 4 weeks
88991592|NCT04592874|Placebo Comparator|Placebo|Placebo every 4 weeks
88991593|NCT04590235|Experimental|Selumetinib|All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m^2. Then, selumetinib 25 mg/m^2 oral twice daily will be administered continuously until disease progression or unacceptable drug-related toxicity, whichever occurs first.
88991594|NCT04584008|Experimental|Matched Targeted Agent|Matched Targeted Agent
88991595|NCT04584008|Active Comparator|Unmatched Therapy|Unmatched Therapy
88991596|NCT04574076||N8-GP|Patients with haemophilia A
88991598|NCT04569734||Experimental: Treatment Group|Determination for participation in the study is based on institutional standard of care practice for assessment of WATCHMAN eligibility. Patients that are being considered for LAA Closure with WATCHMAN device implant based on a history of non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHADS2VASc score >2 but have an appropriate rationale to seek a non-pharmacologic alternative to anti-thrombotic therapy due to risks of anti-thrombotic therapy. Patients should be able to tolerate the WATCHMAN device implant procedure without the need for general anesthesia.
89057926|NCT04535804|Placebo Comparator|placebo group|100 mg of placebo was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
89042782|NCT04321200||Cross-sectional-1500 infants (atypical vs typical)|Arm (Study) 3: To develop a computer vision-based algorithm to quantify infant motor performance from a single-camera video. Here using video data from 1200 infants, plus those gathered from Arm 1 and Arm 2, we will extract pose data from single-camera video recordings and convert these into kinematic features and relevant scores needed to classify infant movement.
89640810|NCT05905055|Experimental|co-administration of cefepime and nacubactam|co-administration of 2 g cefepime and 1 g nacubactam q8h (60 min. infusion)
89640811|NCT05905055|Experimental|co-administration of aztreonam and nacubactam|co-administration of 2 g aztreonam and 1g nacubactam q8h (60 min. infusion)
89640812|NCT05905055|Active Comparator|BAT|Best Available Therapy
89640813|NCT05901532|Experimental|Chinese herbal medicine|The bilateral nasal cavity was irrigated with a bottle of NeilMed containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day.
89640814|NCT05901532|Placebo Comparator|Placebo|The bilateral nasal cavity was irrigated with a bottle of NeilMed containing edible caramel dissolved in 240 ml of warm normal saline once a day.
89640815|NCT05834062|Experimental|Medication arm|"Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment at 3.75 mg/23 mg orally once in the morning for 14 days, which will then be increased to 7.5 mg/46 mg orally once daily in the morning for the remainder of the trial. Participants who are unable to tolerate the dosing regimen will be maintained at the maximally tolerated dose. To further safeguard the risk/benefit balance we will utilize a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants will be reduced to the lowest-dose level (3.75 mg/23 mg) for 12 weeks. If the BMI remains below 20 kg/m2 at the lowest dose after 12 weeks, active treatment will be fully withdrawn.~Participants at the end of the study will be down-titrated gradually with instructions to take the medication every other day for 7 days before stopping treatment altogether."
89640816|NCT05834062|Placebo Comparator|Placebo arm|"Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment with a placebo (to keep the blind) and be asked to up-titrate the placebo dose after the first 14 days and then maintain the placebo dose for the remainder of the study.~Individuals who are unable to tolerate the dosing regimen will have a down-titration protocol (to maintain the blind) as described in the medication arm. Likewise, we will employ a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants would be reduced to the lowest dose level of placebo for 12 weeks. If the BMI remains below 20 kg/m2 after 12 weeks, placebo treatment will be fully withdrawn.~Individuals in the placebo arm will also have a placebo-based down-titration with instructions to take the placebo every other day for 7 days before stopping treatment altogether, to maintain the blind."
89640817|NCT05831332|Experimental|BTL-785-7 Treatment|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
89640818|NCT05827302|Experimental|Device: Health Gauge AI-Based Wearable Device - Model: Phoenix|
89640819|NCT05793112|Experimental|INF108F|INF108F
89640820|NCT05793112|Placebo Comparator|Placebo|Placebo
89640821|NCT05782127|Experimental|Onureg + Venetoclax|"Onureg (CC-486, oral azacitidine) will be administered orally at 200 or 300 mg once daily for 7 or 14 consecutive days, beginning on Day 1 of repeated 28-day cycles.~Venetoclax will be administered orally at 400 mg once daily for 14 consecutive days on days 1 to 14, beginning on Day 1 of repeated 28-day cycles.~Patients will be treated up to 4 cycles and for a maximum of 24 cycles."
89640822|NCT05778227|Active Comparator|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
89640823|NCT05778227|Experimental|smearOFF|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
89640824|NCT05778227|Experimental|Etidronic acid/ Sodium Hypochlorite (HEBP/NaOCl)|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
89640825|NCT05778227|Experimental|Maleic acid (MA)|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
89640826|NCT05778227|No Intervention|Control group|Final irrigation of root canal treatment will be done with 0.9% saline.
89640827|NCT05753150||Tafenoquine (TQ)|Patients aged ≥16 years, G6PD activity ≥ 6.1 U/gHb, not pregnant or breastfeeding, will receive single-dose TQ in addition to chloroquine, the standard blood schizonticidal drug.
89640828|NCT05753150||Daily primaquine (PQ) for 14 days|Patients aged ≥16 years, G6PD activity ≥ 4.1 U/gHb, not pregnant or breastfeeding, will receive 14-day PQ in addition to chloroquine, the standard blood schizonticidal drug.
89640829|NCT05753150||Weekly primaquine (PQ) for 8 weeks|Patients aged ≥16 years, G6PD activity ≤ 4.0 U/gHb, not pregnant or breastfeeding, will receive 14-day PQ in addition to chloroquine, the standard blood schizonticidal drug.
89640830|NCT05738551|Experimental|STRESS BALL|Starting 5 minutes before the access to the vascular access, the patient will be asked to squeeze the stress ball in the palm until the blood collection is completed.
89640831|NCT05738551|Experimental|CHEWİNG GUM|Starting 5 minutes before the vascular access, the patient will be allowed to chew gum until the blood collection is completed.
89640832|NCT05738551|No Intervention|ROUTINE APPLICATION|Only within the scope of routine practice of the patient, vascular access will be provided and the blood collection process will be completed.
89042783|NCT04311788|Experimental|Intervention group|Prophylactic self gripping mesh (Program, Medtronic) will be placed in rectorectus space to prevent incisional hernia.
89042784|NCT04311788|Active Comparator|Control group|Abdomen of the patients in the control group will be closed by using small stitch closure with suture to wound length of 4:1 and slowly absorbable monofilament suture.
89042785|NCT04283916||Botox injection|30 consecutive patients will have 300 IU of botulinum toxin injected to six spots in abdominal wall to gain abdominal wall musculature relaxation.
89042786|NCT04282733|Experimental|Mindfulness Rounds|Participants will be exposed to thrice weekly Mindfulness Rounds education on the Unit; participation in the actual sessions is voluntary.
89640833|NCT05737420|Experimental|Interventional video call|All patients suspected of stroke in a prehospital setting are examined according to a prehospital stroke score. The emergency services personnel then contact the on-call neurologist and a live video stream is initiated. The on-call neurologist then examines the patient via the video-call.
89640834|NCT05737420|No Intervention|Control with standard care|All patients suspected of stroke in a prehospital setting are examined according to a prehospital stroke score. The emergency services personnel then contact the on-call neurologist by telephone. .
89640835|NCT05730582|Active Comparator|Generic Screening Invitation|Patients randomized to this study arm will receive the generic letter to inform them that they are at risk for T2D and that they are not up to date on screening. The letter also informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. The letter is signed by the patient's primary care provider and sent in both English and Spanish. This letter was previously developed and has been in use by the Parkland Diabetes Detection Program.
89640836|NCT05730582|Experimental|Targeted-Tailored Screening Invitation|Patients randomized to this study arm will receive the tailored letter, which uses messaging developed collaboratively by patients and clinical stakeholders under a prior NIH-funded research study (STU 2021-0743), in addition to available EHR data, to inform patients that they are at risk for Type 2 Diabetes based on specific clinical characteristics and that they are not up to date on screening. The letter also informs them that a screening test has been ordered, and requests that they fast and complete testing at their clinic lab within 60 days. Fasting instructions will specify nothing to eat or drink except water for at least 8 hours. The letter will be signed electronically by the patient's primary care provider and sent in both English and Spanish.
89640837|NCT05730582|No Intervention|Standard of Care|Patients randomized to this study arm will receive opportunistic screening based on routine clinical activities. Patients will be assigned a study number for tracking purposes, but no intervention activities via the Parkland Dysglycemia Detection Program will occur for this study arm.
89640838|NCT05722652|Experimental|Intervention Condition|
89640839|NCT05722652|Active Comparator|Waitlist Condition|Clinics in this condition will receive the intervention approximately 12 months after the intervention condition.
89640840|NCT05715203||Syndromic TAA|Subjets with clinical or genetic diagnosis of syndromic thoracic aortic aneurysms
89640841|NCT05715203||Non-syndromic TAA|Subjets without clinical or genetic diagnosis of syndromic thoracic aortic aneurysms
89640842|NCT05705817|Experimental|Treatment|
89640843|NCT05681806|Experimental|Treatment High Dose|Subjects consuming 1000mg LMP Creatine + 500mg Carnipure crystalline 1x/day
89640844|NCT05681806|Experimental|Treatment Low Dose|Subjects consuming 500mg LMP Creatine + 500mg Carnipure crystalline 1x/day
89640845|NCT05681806|Active Comparator|Active Control|Subjects consuming 5g creatine monohydrate 1x/day
89640846|NCT05666726|Experimental|1|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
88991599|NCT04569695|Experimental|Part 1: Cohort A: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 once daily (QD) on Day 1 followed by washout period of 4 days and then Dose 1 of JNJ-70033093 QD from Days 5 to 12.
88991600|NCT04569695|Experimental|Part 1: Cohort B: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 twice daily (BID) from Days 1 to 8.
88991601|NCT04569695|Experimental|Part 1: Cohort C: JNJ-70033093|Participants will receive Dose 2 of JNJ-70033093 BID from Days 1 to 8.
88991602|NCT04569695|Experimental|Part 2: Cohort D: JNJ-70033093|Participants will receive Dose 3 of JNJ-70033093 QD on Day 1 followed by washout period of 4 days and then Dose 3 of JNJ-70033093 BID from Days 5 to 12 in Cohort D. Dose escalation to Part 2: Cohort D will occur only after the safety and tolerability data of the Part 1 are assessed.
88991603|NCT04565483|Experimental|BENRALIZUMAB|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
88991604|NCT04565028|Experimental|Contingency Management (CM)|Mobile contingency management (CM) will be used to promote reductions in cannabis use among Veterans with PTSD who are heavy cannabis users. CM is an intensive behavioral therapy in which participants are paid to reduce substance use.
88991605|NCT04557046|Other|Group A: Sample Collection|Nasal Swab and Saliva Sample Collection
88991606|NCT04557046|Other|Group B: Sample Collection|Nasal swab, Capillary Blood (from fingerstick) and Saliva Collection
88991607|NCT04557046|Other|Group C: Sample Collection|Nasal Swab, Throat Swab and Saliva Sample Collection
88991608|NCT04557046|Other|Group D: Sample Collection|Nasopharyngeal Swab and Saliva Sample Collection
88991609|NCT04557046|Other|Group E: Sample Collection|Nasal swab
89042787|NCT04282733|No Intervention|Control|No intervention will take place on this Unit
89640847|NCT05666726|Experimental|2|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
89640848|NCT05666726|Experimental|3|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
89640849|NCT05666726|Experimental|4|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
89640850|NCT05666726|Experimental|5|within-subjects experimental study, where each subject will receive a neutral state and a negative state induction intervention in a cross-over design (counterbalanced order across participants).
89640851|NCT05650788|Experimental|Bipolar disorder group|Patients with a diagnosis of bipolar II mood disorder stabilized in remission, according to DSM 5 criteria, with mood stabilizer treatment (lithium, anticonvulsant or antipsychotic) at an effective dose, with possible antidepressant treatment (SSRI, SNRI, tricyclics )
89640852|NCT05650788|Experimental|Mood depressive disorder group|Patients with a diagnosis of unipolar mood disorder stabilized in remission, according to DSM 5 criteria, with or without antidepressant treatment (SSRI, SNRI, tricyclics)
89640853|NCT05650788|Experimental|Healthy volunteer|People for whom no psychiatric diagnosis can be retained, according to DSM 5 criteria and naïve to psychotropic treatments
89640854|NCT05650229|Experimental|KL1333|Twice daily
89640855|NCT05650229|Placebo Comparator|Matching Placebo|Twice daily
89640856|NCT05636904|Experimental|DLQ01 high dose|Twice daily application of DLQ01 high dose cutaneous solution in 30 subjects
89640857|NCT05636904|Experimental|DLQ01 low dose|Twice daily application of DLQ01 low dose cutaneous solution in 30 subjects
89640858|NCT05636904|Placebo Comparator|active ingredient-free vehicle solution to DLQ01|Twice daily application of DLQ01 vehicle cutaneous solution in 30 subjects
89640859|NCT05636904|Active Comparator|Minoxidil Solution 5%|Twice daily application of the comparator cutaneous solution in 30 subjects
89640860|NCT05633745|Experimental|NEU-723|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (7 days)
89640861|NCT05633745|Placebo Comparator|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (7 days)
89640862|NCT05630794|Experimental|Prevention (ONC201, biopsy, sigmoidoscopy, colonoscopy)|Patients receive ONC201 PO QW or Q3W for 12 weeks. Patients also undergo collection of blood, tissue biopsy, and sigmoidoscopy/colonoscopy throughout the study.
89640863|NCT05617326|Experimental|screening by a GP|Each patient in this group will have a screening for AAA performed by a trained general practitioner
89640864|NCT05617326|Other|screening by a radiologist (conventional)|Each patient in this group will have AAA screening performed by a radiologist
89640865|NCT05609032|Experimental|Intervention (App Arm)|Participants randomized to the intervention arm will receive access to the Sense2Quit App (A multi-component intervention that links a smartphone app to a smartwatch to provide real-time quit reminders to curtail relapses and avoid potential triggers), standard smoking cessation counseling, and nicotine replacement therapy.
89640866|NCT05609032|No Intervention|Control|Participants randomized to the control arm will receive standard smoking cessation counseling and referral to quitline.
89640867|NCT05599594|Experimental|Neroli oil|Neroli oil improves the quality of life by reducing premenstrual symptoms with relaxing and calming effect.
89640868|NCT05599594|Experimental|Lemongrass oil|Lemongrass oil improves the quality of life by reducing premenstrual symptoms with relaxing and calming effect.
89640869|NCT05598372|Experimental|shotblocker|infant pain during vaccination and mother anxiety
89640870|NCT05598372|Experimental|lullaby|infant pain during vaccination and mother anxiety
89640871|NCT05598372|No Intervention|CONTROL|not infant pain during vaccination and mother anxiety
89640872|NCT05590637|Active Comparator|quetiapine|Elderly patients with dementia-related psychosis will be treated with quetiapine, an atypical antipsychotic indicated for the treeatment of: schizophrenia, bipolar I manic episodes and bipolar depressive episodes.
89640873|NCT05590637|Active Comparator|pimavanserin|Elderly patients with dementia-related psychosis will be treated with pimavanserin, an atypical antipsychotic indicated for treatment of hallucinations and delusions associated with Parkinson's disease.
89640874|NCT05583721|Experimental|Stratum A|Sickle Cell patients with diastolic dysfunction
89640875|NCT05583721|Experimental|Stratum B|Sickle cell patients without diastolic dysfunction
89042788|NCT04274023|Experimental|TSR-042 arm|TSR-042 at a dose of 500 mg in IV infusion (given over t30-minutes) every 21 days for the first 4 doses, followed by 1.000 mg on day 1 of every 42 day.
89042789|NCT04264208|Experimental|68Ga-RM2 PET MRI then 68 Ga PMSA11 PET/MRI|Subjects will undergo either 68Ga RM2 PET/MRI followed within 2 weeks by 68Ga PMSA11 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
89042790|NCT04264208|Experimental|68Ga-PSMA-11 PET MRI then 68Ga-RM2 PET MRI|Subjects will undergo 68Ga PMSA11 PET/MRI followed within 2 weeks by 68Ga RM2 PET/MRI. Two x intravenous (IV) 68Ga-RM2 PET/MRI with a 68Ga dosage of 140 mBq (3.8 mCi), +/- 20%, Two x intravenous (IV) 68Ga-PMSA11 PET/MRI with a 68Ga dosage of 111 to 259 mBq (3 to 7 mCi)
89640876|NCT05583721|Experimental|Stratum C|Healthy controls
89640877|NCT05579782|Experimental|NIRAF Detection Technology (+)|Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
89640878|NCT05579782|No Intervention|NIRAF Detection Technology (-)|Parathyroid gland identification will be performed by the surgeon using only visual identification and without using PTeye - NIRAF detection technology in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND).
89042791|NCT04228120|Experimental|intervention group|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
89640879|NCT05565417|Experimental|IMT-009 Dose Escalation|Participants will receive an assigned dose level of IMT-009 monotherapy in dose escalation. Up to 44 Participants will be enrolled in the Phase 1 portion of the study.
89640880|NCT05565417|Experimental|IMT-009 Phase 2a Cohort (s)|Each Cohort will evaluate IMT-009 monotherapy in up to 25 Participants
89640881|NCT05564624|No Intervention|Control|No usage instructions. Continue regular eating habits for the duration of the study.
89640882|NCT05564624|Experimental|Fasting Mimicking Diet|Use the test products, ProLon(TM) Fasting Mimicking Diet, during the scheduled 5-day period in place of the usual meals (breakfast, lunch, dinner, snack) according to the instructions. Use the test product for 5 days for 3 cycles, beginning on day 1, day 30, and day 60.
89640883|NCT05559346|Experimental|Research Group|Diplegic Cerebral Palsy
89640884|NCT05559346|Active Comparator|Control Group|Diplegic Cerebral Palsy
89640885|NCT05541354||Stakeholder Interviews|Semi-structured, open-ended interviews will be conducted via Zoom with a purposive sample of surgeons, anesthesiologists and OR nurses and trainees to identify perceived OR ergonomics issues among stakeholders
89640886|NCT05541354||OR Observations|Live observation of OR teams by teams of two observers (an anthropologist and an ergonomics expert, such as a chiropractor or physiotherapist). This will be done, in addition to the interview studies, to identify unperceived and misperceived needs using an observation data collection tool. Each of the following 4 phases of surgery will be assessed individually: 1) OR preparation (team arrival to wheels-in), 2) wheels-in to incision, 3) incision to closure, and 4) closure to wheels-out.
89042792|NCT04228120|No Intervention|control group|routine care
89640887|NCT05541354||Curriculum Piloting|Participating OR teams will take part in piloting sessions of the developed simulation curriculum to determine if it meets the proposed content objectives and ensure environmental validity.
89640888|NCT05534737|Experimental|Intervention|Comprehensive and Person-Centered Care Model (AICP Model) +regular assistance from social services
89640889|NCT05534737|Other|Control|regular assistance from social services
89640890|NCT05497050|Experimental|Experimental group|Family education
89640891|NCT05497050|No Intervention|Control group|No training will be given.
89640892|NCT05495828||Orelabrutinib|Patients with relapsed or refractory B-cell lymphoma (including r/rCLL/SLL, r/rMCL) intolerant to ibrutinib/zanubrutinib or other BTK inhibitors who have decided to receive Orelabrutinib therapy
89640893|NCT05491044|Experimental|orelabrutinib|CLL/SLL patients who are slowly responding to ibrutinib are switched to orelabrutinib.
89640894|NCT05483088||Patients with KDIGO stage 2 or 3 AKI|
89640895|NCT05478213|Experimental|Monophasic Action Potential (MAP) Catheter|Participants undergoing ventricular tachycardia ablation per standard of care will also have cellular action potential of the ventricular myocardium assessed with the MAP catheter.
89640896|NCT05466487|Experimental|Active tACS|
89640897|NCT05466487|Sham Comparator|Sham tACS|
89640898|NCT05456529|Experimental|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
89640899|NCT05453396|Experimental|Treatment (loncastuximab tesirine)|Patients receive loncastuximab tesirine IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89640900|NCT05451654|Placebo Comparator|Placebo + SoC (N=30)|"This arm is composed by 30 patients.~Placebo: administration of 2 mL twice a day (morning and evening) by depositing 1 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Standard of care"
89640901|NCT05451654|Experimental|NanoManganese® + SoC (N=90)|"This arm is composed by 90 patients.~NanoManganese® + standard of care group:~NanoManganese®: administration of 2 mL twice a day (morning and evening) by depositing 1 mL in the gingivo-jugal groove of each cheek with the graduated pipette.~Standard of care"
89640902|NCT05442866|Experimental|Virtual reality (VR) dosing arm|All participants will proceed in this single arm, in which each participant will complete baseline measures, then receive 1 week of VR daily for 10 minutes per session, then 1 week of VR twice a day for 10 minutes per session, then 1 week of VR use as desired by the participant.
89640903|NCT05442606|No Intervention|Conservative medical therapy|Patients in this group received only medication prescribed by an Ear, Nose and Throat specialist.
89640904|NCT05442606|Experimental|Medication and Physiotherapy program|Patients in this group received medication prescribed by an Ear, Nose and Throat specialist, in addition to integrated Physiotherapy program
89640905|NCT05431855|Experimental|Engagement in biosensor wearing|A subset of the participants will receive the same interventions, namely the reciprocity messages, personalized feedback, or no prompt (as control condition), using micro-randomization procedure that randomly assign one of the condition in the morning and one of the condition in the evening.
89640906|NCT05417204|Experimental|Correction of abnormal somatic response to a meal|Biofeedback in patients with functional dyspepsia and abnormal somatic response to a probe meal
88991610|NCT04555044|Experimental|Clinolipid|Dosing based on American Academy of Pediatrics (AAP), American Academy Society for Parenteral and Enteral Nutrition (ASPEN), European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)/ European Society for Parenteral and Enteral Nutrition (ESPEN)/ European Society of Paediatric Research (ESPR)/ Chinese Society for Parenteral and Enteral Nutrition (CSPEN) guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
88991611|NCT04555044|Active Comparator|Intralipid|Dosing based on AAP, ASPEN, ESPGHAN/ESPEN/ESPR/CSPEN guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
88991612|NCT04542278|Active Comparator|Steroids|Participants randomized to the steroid arm will be given a prescription for prednisone 20mg daily for 7 days prior to surgery, otherwise, pre-operative standard of care
88991613|NCT04542278|No Intervention|No Steroids|Pre-operative Standard of Care
88991614|NCT04540081|Experimental|CLOVER arm|This arm will contain clinics that utilize the CLOVER intervention
88991615|NCT04540081|No Intervention|Standard of Care arm|This arm will contain clinics that do not utilize the CLOVER intervention
88991616|NCT04538638|Active Comparator|Mesenteric Sparing ileocolic resection|Standard procedure for CD, ileocolic resection without removal of the mesentery.
88991617|NCT04538638|Active Comparator|Central mesenterectomy ileocolic resection|Experimental procedure for CD: ileocolic resection in which the mesentery is taken up to the level of the ileocolic trunc.
88991618|NCT04535401|Experimental|Treatment (elimusertib, FOLFIRI)|Patients receive elimusertib PO QD on days 2, 3, 16, and 17 and irinotecan hydrochloride IV over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy during screening and on study and blood sample collection and imaging throughout the study.
89640907|NCT05417204|Active Comparator|Sham intervention in patients with normal somatic response to a meal|Biofeedback in patients with functional dyspepsia and normal somatic response to a probe meal
89640908|NCT05407844|No Intervention|Standard care|Standard cancer care
89640909|NCT05407844|Experimental|Standard care + DeCIDE PC intervention|Community health worker support and standard cancer care
89640910|NCT05402423|Experimental|JDome rehabilitation group|Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with the JDome System
89640911|NCT05402423|Active Comparator|control group|Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with standard exercise bike
89640912|NCT05401396|Experimental|Swimming immediately after eating|Two arms but all participants are performing both the intervention and the comparison.
89640913|NCT05401396|No Intervention|Swimming 30 minutes after eating|Two arms but all participants are performing both the intervention and the comparison.
89640914|NCT05385588|Experimental|Single arm|290 PLHIV, aged 55 to 76 years old
89212236|NCT00849992|Other|Imiquimod 5%|Patients randomized to this arm will receive treatment with imiquimod 5%
89640915|NCT05385224|Experimental|PillSense (Active)|This is a single-arm, non-randomized study.
89640916|NCT05382221|Experimental|Comprehensive Chronic Care|ongoing proactive outreach designed to provide support and information about evidence-based smoking treatment, with access to individually validated treatments that are appropriate for patients who are: 1) unwilling quit but willing to reduce; 2) ready to quit; and 3) recovering from an unsuccessful quit attempt
89640917|NCT05382221|Active Comparator|Standard Care|involves one offer of cessation treatment (8 weeks of nicotine patch plus referral to the tobacco quit line), annually
89640918|NCT05381090|Active Comparator|Healthy control|Venous blood collection
89640919|NCT05381090|Experimental|Parkinson's disease|Venous blood collection
89640920|NCT05381090|Experimental|Parkinson's disease dementia|Venous blood collection
89640921|NCT05381090|Experimental|Dementia with Lewy Bodies|Venous blood collection
89640922|NCT05381090|Experimental|Alzheimer's disease|Venous blood collection
89640923|NCT05365789|Active Comparator|Study Device and Standard of Care|"1 to 2 sprays per nostril of Sterimar Blocked Nose Baby for a minimum of 2 times (morning and evening) and, as needed, up to a maximum of 6 times per day (i.e. maximum 12 sprays per nostril each day) until nasal symptoms are resolved, up to a maximum of 10 days.~Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary."
89640924|NCT05365789|Other|Standard of Care|Standard of care consists of hydration, rest at home and antipyretic medication paracetamol as necessary.
89640925|NCT05364684|Other|Open-label Treatment|Open-label study of oral LUM-201 (ibutamoren mesylate) 25mg daily in otherwise healthy adults with BMI ≥25 kg/m2 and histologic or radiologic diagnosis of NAFLD.
89640926|NCT05363709|Experimental|Balstilimab|Participants will receive Balstilimab by vein over about 30 minutes on Days 1 and 15 of each cycle (every 2 weeks)
89640927|NCT05363319||Cohort 1|Patients who have initiated cemiplimab therapy for NSCLC under standard of care
89640928|NCT05362370||Cohort 1|Participants will receive a Stryker PEEK Customized Implant
89640929|NCT05360966|Experimental|AR-15512 Ophthalmic Solution (0.003%)|0.003% AR-15512 to be administered BID for 90 days. Both eyes will be treated.
89640930|NCT05360966|Placebo Comparator|Vehicle|AR-15512 vehicle to be administered BID for 90 days. Both eyes will be treated.
89640931|NCT05339022|Experimental|Arm I (ROAR-LCT intervention)|Patients receive ROAR-LCT intervention weekly for 12 weeks consisting of physical therapy visits and an exercise intervention. Patients also undergo progressive muscles relaxation exercises over 20 minutes for 12 weeks.
89640932|NCT05339022|Active Comparator|Arm II (standard of care)|Patients receive standard of care for 12 weeks.
89042793|NCT04219878|Active Comparator|Know@Home App or Website and Test Kit|Participants in this study arm will have access to Know@Home, a mobile HIV prevention app or website and will receive mail-out HIV self-testing kits.
89640933|NCT05329545|Experimental|XMT-1536 (upifitamab rilsodotin)|XMT-1536 (upifitamab rilsodotin)
89640934|NCT05329545|Placebo Comparator|Placebo|Saline placebo will be administered with same schedule and stopping rules as for the assigned interventions in the Experimental Arm.
89640935|NCT05312762|Experimental|MaxioCel|Microfiber wound dressing
89640936|NCT05312762|Active Comparator|AquaCel Extra|Hydrofiber dressing
89640937|NCT05312567|Experimental|Active Treatment (FP-101)|White to off-white extended-release, round tablets containing FP-101.
89640938|NCT05312567|Placebo Comparator|Matching placebo|White to off-white round tablets without the active ingredient but otherwise matching in size and appearance.
89640939|NCT05275205|Experimental|UBX1325|
89640940|NCT05275205|Active Comparator|Aflibercept (EYLEA ®)|
89640941|NCT05265416|Experimental|Piezosurgery|Piezocision will be applied in this group of patients using a piezosurgery knife.
89212237|NCT00849992|Other|Photodynamic therapy|Patients will be randomized to receive photodynamic therapy twice at a 2 week interval to the affected area.
89212238|NCT00859664||Neuroleptics|Children with autistic spectrum disorder, treated with neuroleptics
89212239|NCT00859742|Experimental|EBUS-TBNA|
89640942|NCT05265416|Experimental|Low-level laser therapy|Low-level laser therapy will be applied in this group of patients using a diode laser device.
89640943|NCT05265416|Active Comparator|Traditional treatment|No acceleration method will be performed in this group.
89640944|NCT05253495|Experimental|Cohort 1a|"Mature B-cell Non-hodgkin Lymphoma [MB NHL], GROUP B will receive reduction therapy with dexamethasone, vincristine and cyclophosphamide (DOC), then undergo disease assessment. If tumor reduction ≥ 20%, will get induction 1 and 2 with polatuzumab vedotin, cyclophosphamide, vincristine, methotrexate, rituximab, doxorubicin (Pv-COM3RA25D) 1 and 2, then Consolidation 1 with rituximab, cytarabine, methotrexate (R-CYM) . Patients will undergo disease assessment post Consolidation 1. If no residual disease, they proceed to receive Consolidation 2 with Pv-R-CYM (R-CYM 2).~Cohort Ia patients with < 20% tumor reduction post DOC will be assigned to Cohort Ib starting at Induction 1. Cohort Ia patients with residual disease post Consolidation 1 will be assigned to Cohort Ib starting at Consolidation 1 polatuzumab vedotin, rituximab, high dose cytarabine, cytarabine, high dose methotrexate, etoposide (Pv-R-CYVE 1)."
89640945|NCT05253495|Experimental|Cohort 1b|MB NHL, GROUP C will receive reduction therapy with DOC. Patients with < 20% tumor reduction will be off protocol. Patients with ≥ 20% tumor reduction get Induction 1 and 2 with cyclophosphamide, doxorubicin, dexamethasone, high dose methotrexate, polatuzumab vedotin, and triple intrathecal chemotherapy (M8A30D CPR) 1 and 2, then Consolidation 1 with Pv-R-CYVE 1. If no residual disease, they get Consolidation 2 (Pv-R-CYVE 2), followed by Maintenance (M) 1 with M8A30D CP, M 2 with Pv-cytarabine/etoposide, M 3 with cyclophosphamide, doxorubicin, dexamethasone and polatuzumab vedotin (A30D CP), and M 4 with Pv-cytarabine/etoposide. Cohort Ib patients with CNS disease will receive additional intrathecal chemotherapy and high dose methotrexate during Consolidation.
89640946|NCT05253495|Experimental|Cohort 2a|Classical Hodgkin lymphoma, INTERMEDIATE RISK will receive 2 cycles of brentuximab vedotin (Bv), doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-AVD-R 1 and 2). Response assessment with FDG-PET scan after 2 cycles of Bv-AVD-R. Rapid early responders (RER) will continue therapy with 2 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1 and 2). RERs will not receive radiation therapy. Patients deemed to be Slow Early Responders (SER) after 2 cycles of Bv-AVD-R will continue therapy with 4 cycles of Bv-NVD-R (Bv-NVD-R 1, 2, 3, and 4). Radiation therapy will be given at completion of therapy only for SER patients NOT achieving complete remission at the end of chemoimmunotherapy.
89640947|NCT05253495|Experimental|Cohort 2b|COHORT IIb (Classical Hodgkin lymphoma, HIGH RISK) Cohort IIb patients will receive 2 cycles of brentuximab vedotin (Bv), doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-AVD-R 1 and 2). Response assessment will be performed with FDG-PET scan after 2 cycles of Bv-AVD-R. Rapid early responders (RER) will continue therapy with 4 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1, 2, 3, and 4). RERs will not receive radiation therapy. Patients deemed to be Slow Early Responders (SER) after 2 cycles of Bv-AVD-R will receive 2 cycles of Bv, nivolumab, doxorubicin, vinblastine, dactinomycin, and rituximab (Bv-NAVD-R 1 and 2), followed by 4 cycles of Bv, vinblastine, dactinomycin, nivolumab, and rituximab (Bv-NVD-R 1, 2, 3, and 4). Radiation therapy will be given at completion of therapy only for SER patients NOT achieving complete remission at the end of chemoimmunotherapy.
89640948|NCT05224050|Experimental|Heart Rate Variability Biofeedback-Smoking Cessation Therapy (HRVB-SCT)|All participants in this open trial will receive individualized training in resonance breathing using biofeedback to help improve self-regulation (HRVB), cognitive-behavioral smoking cessation treatment (SCT), and up to 8-weeks of the transdermal nicotine patch (NRT).
89640949|NCT05220241|Other|Case : patient with 1st episode of COVID-19 and persistence of neurocognitive complaint|Patient with a 1st episode of COVID-19 in the 12 months preceding inclusion and presenting persistence of neurocognitive complaint beyond 4 weeks
89640950|NCT05220241|Other|Control : Patient with a 1st episode of COVID-19 cured and without neurocognitive complaint|Patient with a cured 1st episode of COVID-19 (without persisting symptoms beyond 4 weeks) in the 12 months preceding inclusion and without neurocognitive complaint
89640951|NCT05219149||Patients with CNS Tumors|feasibility study of family interviews of those who are making decisions about treatment for newly diagnosed or relapsed CNS tumors. For patients 12 years of age and younger, caregivers only will be included in the interviews. For patients 13-17 years of age, caregivers will have the option to include the patient in the interviews. For patients 18 years of age and older, patients will have the option to include their caregivers in the interviews.
89640952|NCT05196152|Active Comparator|MomMoodBooster Online|
88991619|NCT04524390|Experimental|Maralixibat|"Maralixibat chloride oral solution administered twice daily, up to 600* microgram per kilogram, for 26 weeks and in the OLE for all patients.~*equivalent to 570 mcg/kg/day maralixibat free base"
88991620|NCT04524390|Placebo Comparator|Placebo|Placebo oral solution for 26 weeks. All placebo participants who complete Week 26 and continue in the open label extension (OLE) will receive maralixibat after Week 26.
88991621|NCT04522908|Experimental|Cabozantinib - Single Arm|Single Arm with Cabozantinib starting dose 40 mg for 4 weeks and dose escalation to 60 mg afterwards.
88991622|NCT04519866|Experimental|Electroacupuncture|In addition to usual rheumatological care, patients in the electroacupuncture arm will undergo 2 courses of electroacupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
88991623|NCT04519866|Active Comparator|Manual acupuncture|In addition to usual rheumatological care, patients in the manual acupuncture arm will undergo 2 courses of manual acupuncture treatment. Each treatment course will consist of 10 acupuncture sessions held over 5 weeks. Patient will take a break of 5-7 days in between each course of acupuncture.
88991624|NCT04509037||Liposuction Assisted Breast Reduction|
88991625|NCT04509037||Open Incision Breast Reduction|
88991626|NCT04492722|Experimental|AZD5718 Dose 1 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 1 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
88991627|NCT04492722|Experimental|AZD5718 Dose 2 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 2 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
88991628|NCT04492722|Experimental|AZD5718 Dose 3 + Dapagliflozin 10 mg|Participants will receive once daily oral dose 3 of AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
88991629|NCT04492722|Placebo Comparator|Placebo + Dapagliflozin 10 mg|Participants will receive once daily oral dose of placebo matched to AZD5718 for 12 weeks, thereafter add-on therapy of 10 mg dapagliflozin for 8 weeks.
88991630|NCT04487405||Group A|Symptomatic with adnexal mass
88991631|NCT04487405||Group B|Asymptomatic with adnexal mass
88991632|NCT04487405||Group C|Women with a predisposition in developing ovarian cancer due to a positive, pathogenic variant
88991633|NCT04486352|Experimental|Atezolizumab and Bevacizumab Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with no specified gene signatures will be enrolled in this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
88991634|NCT04486352|Experimental|Atezolizumab and Ipatasertib Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with PIK3CA/AKT1/PTEN-altered tumors will be enrolled in this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
88991635|NCT04486352|Experimental|Atezolizumab and Talazoparib Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that have a ≥16%genomic loss of heterozygosity (LOH) will be assigned to this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
89042794|NCT04219878|Active Comparator|Mail-Out Testing Kit Only|Participants in this study arm will receive mail-out HIV self-testing kits.
89042795|NCT04214652|Experimental|IDP-126 Gel|
89042796|NCT04214652|Placebo Comparator|IDP-126 Vehicle Gel|
89042797|NCT04214639|Experimental|IDP-126 Gel|
89042798|NCT04214639|Placebo Comparator|IDP-126 Vehicle Gel|
89042799|NCT04213794|Experimental|Treatment (cytoreduction, HIPEC)|Patients undergo cytoreduction. Patients also undergo HIPEC over 60 minutes consisting of doxorubicin and cisplatin. Patients then receive sodium thiosulfate IV over 12 hours. Patients also undergo CT scan, MRI or PET/CT scan and blood sample collection throughout study.
89042800|NCT04207255|Experimental|Cohort 2: Opaganib with abiraterone|
89042801|NCT04207255|Experimental|Cohort 3: Opaganib with enzalutamide|
89042802|NCT04207255|Experimental|Cohort 1a: Opaganib with abiraterone|
89640953|NCT05196152|Experimental|MomMoodBooster + Coach|
89640954|NCT05195632|Experimental|Treatment arm (Safety Lead-in and Pivotal arm)|Encorafenib will be administered as a fixed, flat oral dose of 450 mg QD in combination with binimetinib as a fixed, flat oral dose of 45 mg BID.
89640955|NCT05183646|Experimental|DMX-200 (repagermanium)|"Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the treatment period (104 weeks)~OLE: Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the OLE period (108-212 weeks)"
89640956|NCT05183646|Placebo Comparator|Placebo|Patients will receive 120 mg immediate release capsules of Placebo twice daily
89640957|NCT05182658|Active Comparator|Empagliflozin group|Patients in the empagliflozin group will receive 10 mg of empagliflozin once daily for 12 months
89640958|NCT05182658|Placebo Comparator|Control group|Patients in the control group will receive placebo once daily for 12 months
89640959|NCT05172024||Participants with SARS-CoV-2 Infection|
89640960|NCT05172024||Participants without SARS-CoV-2 Infection|
89640961|NCT05162781|Experimental|CICT with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
89640962|NCT05162781|Experimental|CICT without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
89640963|NCT05162781|Active Comparator|BF-HELP with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
89640964|NCT05162781|Active Comparator|BF-HELP without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
89042803|NCT04207255|Experimental|Cohort 1b: Opaganib with enzalutamide|
89042804|NCT04201548|Active Comparator|Active Comparator|This is the constant-load Endurance Training (ET) group which will constitute the control group.
89042805|NCT04201548|Experimental|Long High Intensity Interval Training|This is the Long High Intensity Interval Training (Long-HIIT) group.
89042806|NCT04201548|Experimental|Short High Intensity Interval Training|This is the Short High Intensity Interval Training (Short-HIIT) group.
89042807|NCT04199403||Single Group|
89042808|NCT04196530|Experimental|Dose Escalation of BDB001 with atezolizumab|"This part of the study will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of BDB001 with atezolizumab is reached."
89042809|NCT04196530|Experimental|Dose Expansion of BDB001 with atezolizumab|"At the end of the dose escalation part of the study, the BDB001 dose to be used in combination with atezolizumab in the expansion part of the study will be established after thorough review of all available safety, preliminary efficacy, PK and PD data.~A biologically active dose will be selected that is either the MTD, if one was established in the escalation part, or an RP2D if no MTD was established. Approximately 20 additional subjects will initially be enrolled in the dose expansion part."
89042810|NCT04194346|Experimental|Determination of local pleural strain|The average Von Mises coefficient will be calculated for each recorded ultrasound loop using a non-invasive vascular elastography platform.
89057927|NCT04535765|Experimental|experimental group|The experimental group began to perform warm water sitz bath 6 hours after the operation (the day of the operation).Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
89640965|NCT05158075|Experimental|Neurocognitive training|The experimental group will: i) receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise); ii) receive an individualized diet and physical exercise planning for 6 weeks; iii) participate in 4 weekly group neurocognitive intervention sessions, that will last about 60-90 minutes each. Two neurocognitive sessions are intended to train impulsivity, and the other two neurocognitive sessions will focus on reflexive training. Participants will practice the content of each session daily at home.
89640966|NCT05158075|Sham Comparator|Sham cognitive training|The active control group will: i) receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise); ii) receive an individualized diet and physical exercise planning for 6 weeks; iii) participate in 4 weekly group sessions of sham intervention that mimic the neurocognitive sessions of the experimental group. Two neurocognitive sessions are intended to train impulsivity, and the other two neurocognitive sessions will focus on reflexive training. Participants will practice the content of each session daily at home.
89640967|NCT05158075|Other|Control|Participants in the control group will receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise) and will receive an individualized diet and physical exercise planning for 6 weeks.
89640968|NCT05154669|Active Comparator|Standard Smoking Cessation Coaching|Participants will receive 5 counseling sessions over approximately 8 weeks as per standard smoking cessation programs. Participants will receive 8 weeks of nicotine replacement therapy (patches, gum, and/or lozenges).
89640969|NCT05154669|Experimental|Integrated Financial-Smoking Cessation Coaching|The integrated intervention will provide 5 counseling sessions over approximately 8 weeks that integrates financial coaching into the smoking cessation program. Participants will receive 8 weeks of nicotine replacement therapy (patches, gum, and/or lozenges).
89640970|NCT05150106||Laryngeal dystonia|Patients with laryngeal dystonia (or spasmodic dysphonia)
89640971|NCT05150106||Voice tremor|Patients with voice tremor (essential or dystonic)
89640972|NCT05150106||Healthy controls|Healthy research volunteers
89640973|NCT05148234|Experimental|escalating dose of treatment for HR-MDS|escalating doses of BMS-986253 + DNMTi
89640974|NCT05148234|Experimental|escalating doses of treatment for LR-MDS|escalating doses of BMS-986253
89640975|NCT05148234|Experimental|phase II dose of BMS-986253 for HR-MD|phase II dose of BMS-986253 + DNMTi
89640976|NCT05148234|Experimental|phase II dose of BMS-986253 for LR-MDS|phase II dose of BMS-986253
89640977|NCT05131607|Experimental|Supine MRI|
89640978|NCT05130632|Experimental|The community working group|Female participants over the age of 15 randomized to the intervention group will participate in working group sessions over 12 weeks' time that addresses plastic waste and introduce strategies to reduce use, recycle, and repurpose plastic. Community members of participants in the intervention group will also be invited to participate in the working groups.
89640979|NCT05130632|No Intervention|Control Group.|No specific activities
89640980|NCT05124808|Experimental|Intensive glycemic targets|Participants in this arm will target a fasting blood glucose of <90 mg/dL and 1 hour post-prandial blood glucose values <120 mg/dL.
89640981|NCT05124808|Active Comparator|Standard glycemic targets|Participants in this arm will target a fasting blood glucose of <95 mg/dL and 1 hour post-prandial blood glucose values <140 mg/dL.
89640982|NCT05118503|Active Comparator|Customized education app|A customized URL-based platform will present brief education videos addressing a patients stroke etiology, risk factors, stroke prevention medications, and post-stroke lifestyle issues. This URL will be made available to the patient and caregiver.
89640983|NCT05118503|Placebo Comparator|Standard of care discharge education|Standard discharge education is performed by the bedside nurse at the time of hospital discharge.
89640984|NCT05109312|Experimental|Treatment Group 1 Cohort 1|HTX-011 + multimodal analgesic (MMA) regimen
89640985|NCT05109312|Active Comparator|Treatment Group 2 Cohort 1|Bupivacaine HCl + MMA
89640986|NCT05109312|Experimental|Treatment Group 1 Cohort 2|HTX-011 + MMA
89640987|NCT05109312|Active Comparator|Treatment Group 2 Cohort 2|Bupivacaine HCl + MMA
89640988|NCT05103566|Experimental|Treatment group|The gammaCore device supplies non-invasive stimulation to the cervical branch of the vagus nerve.
89640989|NCT05082519|Experimental|IDEAL2 intervention|"Focused and short-term intervention of diet and exercise during induction. Calorie goal is >=15% daily deficit as determined by each subject's estimated energy requirement. Fat intake will make up <25% of daily calories. Carbohydrate will make up <55% of daily calories consisting of low glycemic load foods (<100/2,000 kcal adjusted for daily calories). Protein will make up >=20% of daily calories. Subjects will also perform moderate exercise 5 days per week for 30 minutes/session (total = 150 minutes per week). Subjects will have a step goal to decrease sedentary behavior, with a starting goal of >=1000 steps/day and increasing by at least 1000 steps/day each week."
89640990|NCT05082519|No Intervention|Control - Standard of Care|One-time education of diet and exercise, which is the standard of care for ALL patients during induction.
89640991|NCT05076448||1|Group 1.Gonadal veins resection This group includes patients who underwent open retroperitoneal resection of the gonadal veins, endoscopic transperitoneal and retroperitoneal resection of the gonadal veins.
89640992|NCT05076448||2|Group 2. Gonadal veins embolozation This group includes patients who underwent embolization of the gonadal veins with coils.
89640993|NCT05076448||3|Group 3. Stenting of the common iliac vein with or without gonadal veins embolization This group includes patients who underwent isolated iliac vein stenting or iliac vein stenting combined with gonadal vein embolization.
88991636|NCT04486352|Experimental|Atezolizumab and Trastuzumab emtansine (TDM-1) Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that with an amplification of ERBB2/HER2 will be assigned to this cohort. Twenty participants will be enrolled. Once twenty participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
88991637|NCT04486352|Experimental|Atezolizumab and Tiragolumab Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumor type MSI-H and/or tTMB >=10 mut/mb will be assigned to this cohort. Twenty participants will be enrolled initially. Once twenty participants are enrolled, the cohort may be expanded if a positive signal is shown. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
89042811|NCT04186676||MINOCA patients|Prevalence, demographics, clinical profile, previous anginal status, presence of cardiovascular risk factors, management and outcomes in consecutive patients with Myocardial Infarction with Non-Obstructive Coronary Arteries admitted to study clinical sites
89042812|NCT04180488|Experimental|Study A Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
89640994|NCT05075200|Experimental|Group I|Participants with glomerular filtration rate (GFR) < 60 mL/min/1.73m2 (and dialysis)
89640995|NCT05075200|Experimental|Group II|Participants with GFR ≥ 60 mL/min/1.73m2
89640996|NCT05053854|Experimental|177Lu-DOTA-Octreotate + talazoparib|Patients will receive 4 cycles of 177Lu-DOTA-Octreotate every 8 weeks, the last 3 cycles combined with talazoparib on days 2-6 of each cycle.
89640997|NCT05030194|Experimental|Order 1 - Oral Nicotine product - ZYN and Electronic Cigarettes|Participants will use each product for up to a 30 minute interval But will also be permitted to stop use before the end of the 30-minute ad lib use period
89640998|NCT05030194|Experimental|Order 2 - Electronic Cigarettes and Oral Nicotine product|Participants will use each prodcut for up to 30 minutes but will also be permitted to stop use before the end of the 30-minute ad lib use period
89640999|NCT05022316|No Intervention|Control Arm|Control clinics will not receive an intervention.
89641000|NCT05022316|Experimental|Intervention Arm|Intervention clinics will have the CDS tools turned on in their EHR.
89641001|NCT05007717|Experimental|Data-informed Stepped Care (DiSC) arm|At intervention sites, HCW will assign ALHIV to different levels or intensity of HIV services depending on their current and anticipated health care needs. The stepped care framework is designed to be flexible, to accommodate variable individual and social support services available at each facility.
89641002|NCT05007717|No Intervention|Standard of care|Sites randomized to the control arm will continue with standard of care approaches for adolescent clinic visits (usually 1-3 monthly visits) regardless of health care needs and additional support as needed.
89641003|NCT04977466||Group #1 / Pregnant Female NIH Participants|Female NIH study participants.
89641004|NCT04977466||Group #2 / Male and Female Partners|Male or female partners of women who participated in NIH intramural clinical trials and that became pregnant.
89641005|NCT04977466||Group #3 / Pregnant Female Partners of Male or Female NIH Clinical Trial Partici|Female partners of NIH intramural clinical trial participants who became pregnant while their partner was or within 1 year after the last day of intervention after their partner was on a study.
89641006|NCT04977466||Group #4 / Neonate or Offspring of a Pregnant Female Participant or Pregnant Fe|Offspring from birth to 12 months of age and born to female participants / female partners.
89641007|NCT04957355|Experimental|Effect of functional electrical stimulation on reactive balance and laboratory falls|"All individuals will be assigned to the experimental group and will undergo the testing and training procedure across two separate sessions. During the first session, the participants will go through the complete initial screening process. If eligible for the study, the participants will perform the experimental training protocols during the second session.~Experimental Protocol The quadriceps, hamstrings, tibialis anterior, gastrocnemius, and the trunk muscle group on the stroke-affected side (weaker side) will be stimulated according to the participant's comfort and tolerance. The range of the intensity allowed by the device is 0-50milliamperes (mA). The frequency of the electrical stimulation device ranges from 1-60Hz."
89641008|NCT04937413|Experimental|Single dose of evolocumab|420 mg of evolocumab subcutaneous injection 7-14 days before scheduled surgery for malignant glioma
89641009|NCT04934969|Experimental|Use of lavender and peppermint essential oils pre and post|passive inhalation of either peppermint and lavender essential oil with pre and post test measure
89641010|NCT04927338|Experimental|BacoMind® 300mg/day|Participants randomized to the experimental arm will receive 12 weeks of 300 mg/day BacoMind® Bacopa monnieri standardized extract.
89641011|NCT04927338|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive 12 weeks of daily placebo identical to the experimental treatment in size, color, and shape.
89641012|NCT04901325|Experimental|Baricitinib for PG|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 30 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.
89042813|NCT04180488|Placebo Comparator|Study A Matched Placebo|placebo, on top of non-sedating H1-antihistamine
89042814|NCT04180488|Experimental|Study B Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
89042815|NCT04180488|Placebo Comparator|Study B Matched Placebo|placebo, on top of non-sedating H1-antihistamine
89042816|NCT04180488|Experimental|Study C Dupilumab|dose regimens, on top of non-sedating H1-antihistamine
89042817|NCT04180488|Placebo Comparator|Study C Matched Placebo|placebo, on top of non-sedating H1-antihistamine
89042818|NCT04173208|Experimental|Fecal microbial transplant|The participants of the experimental arm will receive an oral fecal microbial transplant after delivery
89042819|NCT04173208|Placebo Comparator|Placebo group|The participants of the placebo arm will receive an oral placebo after delivery
89057928|NCT04535765|Other|control group|The control group began to perform warm water sitz bath at 8:00 in the morning on the first day after the operation as usual.Warm water sitz bath temperature is 41-43 ℃, 3 times a day, 5 minutes each time.
89057929|NCT05138445|Experimental|Arm 1: FAME-W intervention|Four-week self-management education programme
89057930|NCT05138445|Active Comparator|Arm 2: FAME-W handbook|Self-guided FAME-W handbook
89057931|NCT04529603|Experimental|Arm 1|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
89641013|NCT04896606|Experimental|SARS-CoV-2 CTLS + Standard of Care|Patients will get family donor derived SARS-CoV-2 cytotoxic t-lymphocytes up to 5 times every 2 weeks along with Standard of care of COVID-19.
89641014|NCT04896606|Active Comparator|Standard of Care Only|Patients will NOT received COVID CTLs but will get standard of care.
89641015|NCT04880655|Experimental|Intervention|Dressed with WSD and petrolatum gauze
89641016|NCT04880655|Active Comparator|Control|Dressed with bacitracin and petrolatum gauze
89641017|NCT04861987|Experimental|PCS6422 + Capecitabine|Fixed dose of PCS6422 combined with various doses of Capecitabine administered in 14 day cycles
89641018|NCT04827056|Experimental|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
89641019|NCT04827056|Experimental|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL501 is a thin film formulation of dexmedetomidine (DEX) for sublingual (SL) administration. The product is a small, solid-dose film formulation, approximately 286 mm2 in area and 0.7 mm thick, designed to solubilize in the SL space within 1-3 minutes. At the time of dosing, subjects will be verbally instructed on how to take the investigational product sublingually, and that they should retain the investigational product in the sublingual cavity until dissolved.
89641020|NCT04827056|Placebo Comparator|Placebo|Placebo and study drug will look exactly the same in order to maintain the double-blind; study drug and placebo are administered exactly the same.
89641021|NCT04817488||Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound of patients with acute dyspnea will be performed with tele-supervision.
89641022|NCT04817488||Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound of patients with acute dyspnea will be performed without tele-supervision.
89641023|NCT04817475||Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
89641024|NCT04813601|Experimental|Robot Asissted Gait Training|The rehabilitation sessions will be carried out by a physiotherapist trained in rehabilitation with the ATLAS 2030 exoskeleton and will also have the technical supervision of personnel specialised in the handling of the laboratory and the robotic device.
89641025|NCT04807296|Active Comparator|TFLEP|Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.
89641026|NCT04807296|Active Comparator|m-HoLEP|The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.
89641027|NCT04777422|Experimental|Interventional|Defibrotide 6.25 mg/kg IV q6h
89641028|NCT04774289||1|Participants with NF1 seen at the NIH from 1/1/1998 to 1/1/2020
89641029|NCT04749329|No Intervention|Control Group|no mesh was used for end colostomy fashions
89641030|NCT04749329|Experimental|Mesh Group|Mesh of Bio A was used for end colostomy fashions
89641031|NCT04732026||Cases|150 infants with invasive serotype III GBS disease (isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
89641032|NCT04732026||Controls|450 infants exposed to serotype III GBS at birth - but who do not develop invasive GBS disease in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
89641033|NCT04725305|Experimental|BiZact|A bipolar electrosurgical device that employs radiofrequency(RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger
89641034|NCT04725305|Active Comparator|Standard of care|In electrocautery tonsillectomy (or diathermy) electric current from a radiofrequency generator is passed through the tissue between two electrodes. The resulting high temperature (400º-600ºC) cuts the tissue and simultaneously seals the blood vessels
89641035|NCT04724382|Experimental|Intervention|Intervention group consisting of culturally-tailored healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
89641036|NCT04724382|Active Comparator|Control|Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
89641037|NCT04710979|Experimental|Yoga Intervention Group|
89641038|NCT04710979|No Intervention|Control Group|Control participants will receive no guidance from the research staff to change their behavior.
89641039|NCT04707313|Placebo Comparator|Placebo (Cohorts 1 and 2)|
89042820|NCT04166019|Experimental|Peer-led self-management program|Peer-led self-management program (PLSMI) consists of 10 weekly/biweekly, 1.5-hour sessions (4 months), based on the modified Crisis-resolution-team Optimization and Relapse Prevention (CORE) program workbook/manual and psycho-education programs developed by the research team. The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being. Participants work through the workbook at their own pace, with the support from the peer support worker, to facilitate/support their recovery. They will meet in group with a trained peer support worker on 10 sessions, usually at 7-12 days intervals over 4 months.
89042821|NCT04166019|Active Comparator|Psycho-education group|Psycho-education groups (12-18 members/group; 10 two-hour sessions, weekly/biweekly), 4-month duration similar to the PLSMI, will be led by one trained advanced practice psychiatric nurse in each center experienced in psychiatric rehabilitation, and are guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psycho-education programs for psychosis.
89042822|NCT04166019|Other|Usual care only|Usual care (control) participants (and treatment groups) will receive routine psychiatric outpatient and community mental healthcare services.
89042823|NCT04122079||Clinical (outpatients)|Patients receiving mental health treatment at the three psychotherapeutic centers; two university clinics and a family mental health clinic
89042824|NCT04122079||Clinical (self-reported)|Students and community nonstudent participants who were receiving psychological or psychiatric treatment
89042825|NCT04122079||Non-clinical (Community)|Members of the community
89042826|NCT04122079||Non-clinical (Students)|University undergraduate students
89042827|NCT04120766|Experimental|Treatment|Nicorandil 20mg qd
89042828|NCT04120766|Placebo Comparator|Placebo|Matched placebo qd
89042829|NCT04114539|Experimental|Ecopipam|
89042830|NCT04097379|Experimental|LRX712 Arm 1|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
89042831|NCT04097379|Placebo Comparator|Placebo|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
89641040|NCT04707313|Experimental|PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID.
89641041|NCT04707313|Experimental|PF-06882961 80 mg BID, 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID.
89641042|NCT04707313|Experimental|PF-06882961 120 mg BID, 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID.
89641043|NCT04707313|Experimental|PF-06882961 160 mg BID, 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID.
89641044|NCT04707313|Experimental|PF-06882961 200 mg BID, 1-week titration (Cohort 1)|The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID.
89641045|NCT04707313|Experimental|PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2)|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID.
89641046|NCT04707313|Experimental|PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2)|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID.
89641047|NCT04707313|Experimental|PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2)|The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID.
89042832|NCT04097379|Experimental|LRX712 Arm 2|"Randomized in a 1:1:1 ratio:~LRX712 Arm 1:LRX712 Arm 2:placebo"
89641048|NCT04707313|Placebo Comparator|Placebo (Cohort 3)|
89641049|NCT04707313|Experimental|PF-06882961 80 mg BID, 4-week titration (Cohort 3)|The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 80 mg BID.
89641050|NCT04707313|Experimental|PF-06882961 140 mg BID, 4-week titration (Cohort 3)|The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 140 mg BID.
89042833|NCT04087473||Prior 2nd generation ALKi|
89042834|NCT04087473||Prior 1st and 2nd generation ALKi|
89042835|NCT04081701|Other|Meningioma|Cohort of 30 subjects with meningioma.
89042836|NCT04081701|Other|Non-Meningioma|"Cohort of 60 subjects with non-meningioma:~(esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma and SSTR-positive tumors metastatic to the brain)"
89042837|NCT04076423|Experimental|Experimental arm:|they will take 1 tablet (50 mg BIC + 200 mg FTC + 25 mg TAF), orally, once a day, from the moment of randomization.
89042838|NCT04076423|Active Comparator|Comparator arm|they will take 1 tablet of 50 mg of DTG orally, once a day + 1 tablet of 300 mg of 3TC orally, once a day, from the randomization moment.
89042839|NCT04056377||Black boys|240 black boys were included in the study (mean age 7.5 years)
89042840|NCT04056377||Black girls|339 black girls were included in the study (mean age 7.5 years)
89042841|NCT04056377||White boys|239 white boys were included in the study (mean age 7.4 years)
89042842|NCT04056377||White girls|224 white girls were included in the study (mean age 7.4 years)
89042843|NCT04027777|Experimental|Aktiia.product-P0|Main study arm including 85 subjects
89042844|NCT04027777|Experimental|Aktiia.product-P0 Diabetics|Second study arm including 40 diabetic patients
89042845|NCT04027777|Experimental|Aktiia.product-P0 Aged|Thirs study arm including 40 patients aged 65+
89042846|NCT04027647|Experimental|Treatment|Daily administration of oral Dacomitinib
89042847|NCT03984396|Experimental|Intervention - Patient and Clinician|Intervention educational materials provided to patient and family and clinician
89042848|NCT03984396|No Intervention|Delayed Intervention|Usual care
89057932|NCT04535739|Experimental|PCI group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy and prophylactic cranial irradiation。
89641051|NCT04707313|Experimental|PF-06882961 200 mg BID, 4-week titration (Cohort 3)|The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 200 mg BID.
89641052|NCT04705441|Experimental|SMART intervention|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions over 10-12 weeks. The intervention sessions are held over Zoom.
89641053|NCT04705441|No Intervention|Waitlist|Individuals randomized to WL will continue in their usual care. After they complete their 13-week and 6-month assessments, they will begin participating in the SMART program.
89641054|NCT04691986|Experimental|NR Supplementation|Participants in this group will receive NR supplementation at 1000 mg per day (given as 2x250mg capsules morning and 2x250mg at night).
89641055|NCT04691986|Placebo Comparator|Placebo supplementation|Participants in this group will receive placebo given as 2 pills in the morning and 2 pills at night. Placebo pills contain micro cellulose which is likewise found in NR containing capsules.
89641056|NCT04682639|Experimental|Etrasimod Dose 1|
89641057|NCT04682639|Experimental|Etrasimod Dose 2|
89641058|NCT04682639|Placebo Comparator|Placebo and Etrasimod|Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.
89641059|NCT04681144||Radium-223-dichloride (Xofigo, BAY88-8223)|Patients with metastatic castration-resistant prostate cancer (mCRPC)
89641060|NCT04641338|Experimental|Intervention group|
89042849|NCT03959176|Experimental|Group 1|"The right eye will receive a sham drop followed by 1 drop of Tropicamide 1%/Phenylephrine 2.5% five minutes after the sham drop is administered. A one minute wait will occur followed by a second drop of Tropicamide 1%/Phenylephrine 2.5%.~The left eye will receive 2 drops of Brimonidine 0.2% followed by a five minute wait time. One drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a one minute wait time. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered."
89042850|NCT03959176|Experimental|Group 2|"The right eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will be administered followed by a 15 second wait after which a sham drop will be administered.~The left eye will receive 1 drop of Tropicamide 1%/Phenylephrine 2.5% followed by a one minute wait. A second drop of Tropicamide 1%/Phenylephrine 2.5% will then be administered followed by a 15 second wait after which 2 drops of Brimonidine will be administered."
89641061|NCT04641338|Active Comparator|Control group|
89641062|NCT04575727|Experimental|Health Volunteers|In the first stage, five healthy human subjects will receive a microdose (10 µg) of [11C]MPC6827, immediately followed by whole body PET/CT to determine dosimetry and perform an initial safety evaluation of the radiotracer. A dose of 20 mCi [11C]MPC6827 will be administered and serial whole body PET scans will be acquired up to 2 hours post injection.
89641063|NCT04575727|Experimental|Patients with Neurodegenerative Disorders|Up to 30 patients with neurodegenerative disorders will receive a microdose (10 µg) of [11C]MPC6827 and be imaged dynamically for up to 90 minutes using PET/CT for research purposes.
89641064|NCT04569942|Active Comparator|Vasopressor|a restricted fluids and early vasopressor strategy
89641065|NCT04569942|Active Comparator|Fluids|a larger intravenous (IV) fluid volume and later vasopressor strategy
89641066|NCT04554225||Pulmonary disease patients|Patients with COPD or other pulmonary disease starting to use ambulatory oxygen therapy
89641067|NCT04551807|Active Comparator|Modified natural cycle|corpus luteum present
89641068|NCT04551807|Active Comparator|Programmed cycle|corpus luteum absent
89641069|NCT04541082|Experimental|ONC206|
89641070|NCT04533009|Active Comparator|tramadol/acetaminophen|Tramadol-paracetamol two tablets 37,5mg/325mg twice daily up to five days for patients undergoing spinal surgery
89641071|NCT04533009|Placebo Comparator|placebo|Placebo two tablets twice daily up to five days for patients undergoing spinal surgery
89641072|NCT04504903|Experimental|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will participate in 12 weekly group sessions to discuss thoughts, feelings, and behaviors that promote work success in the community
89641073|NCT04504903|Active Comparator|Psychoeducation|Veterans in the control group will participate in 12 weekly group sessions in which they will learn more about their mental health conditions.
89641074|NCT04491370|Experimental|Polatuzumab vedotin|"Evaluable patients for safety Patients receiving 1 dose of Polatuzumab Vedotin will be evaluable for safety.~Evaluable patients for response Only in patients who are in PR or SD prior to PV and received a minimum of 3 doses will be evaluable.~Evaluable patients for EFS, PFS, OS All patients who have completed conditioning and autoSCT will be evaluable for EFS, PFS, and OS."
89641075|NCT04478474||Eligible|Retrospective chart review of all pediatric patients who underwent allogeneic stem cell transplant between June 29, 2011 and December 31, 2019 at Westchester Medical Center (WMC). Children, adolescent, and young adult patients, ages 0-≤26 years, who have received an allogeneic stem cell transplantation on the pediatric bone marrow transplant service including matched unrelated donor, matched sibling donor, haploidentical donor, umbilical cord donor, who received ganciclovir prophylaxis for ≥14 days.
89641076|NCT04475692|Experimental|Intervention|"Conventional care will continue.~Participants (and proxy, where relevant) will be trained to use the intervention platform (GripAble). Participants will be loaned a GripAble device and advised to continue a self-selected training dose throughout the intervention period.~Weekly follow-up phone calls will be conducted, remote tech support will be available. Adherence with the intervention will be remotely monitored via an inbuilt data capture system.~At 3months post stroke, the intervention period will conclude, outcome measures will be implemented. Participants will be invited to complete a post intervention survey and interview. A purposive sample of participants will be invited to participate in an UL activity monitoring sub-study.~At 6months post stroke, follow-up outcome measures will be implemented. Participants will be invited to take part in a research implementation feedback survey."
89641077|NCT04475692|Active Comparator|Control|"Baseline data collection and outcome measures will be completed.~Conventional care will continue, no restrictions/specifications will be placed on this.~At 3months post stroke, UL outcome measures will be implemented. A purposive sample of participants will be invited to participate in an UL activity monitoring sub-study.~At 6months post stroke, follow-up UL outcome measures will be implemented. Participants will be invited to take part in a research implementation feedback survey."
89641078|NCT04470830||Participants With Essential Hypertension|Participants diagnosed with essential hypertension who have been treated with azilsartan medoxomil/chlorthalidone FDC as an early therapy for participants whose blood pressure is not properly controlled by monotherapy or who require administration of multiple drugs in order to reach the target blood pressure, will be observed prospectively over a period of 5 years.
89641079|NCT04470817||Participants With Essential Hypertension|Participants diagnosed with essential hypertension and whom have been prescribed azilsartan medoxomil as a monotherapy or taken concomitantly with other anti-hypertension therapies in a routine clinical practical setting, will be observed prospectively over a period of 6 years.
89641080|NCT04470050|Experimental|Cohort 1- Dexmedetomidine (30 Micrograms) vs. Placebo|Sublingual film containing 30 Micrograms Dexmedetomidine or Placebo Sublingual film
89641081|NCT04470050|Experimental|Cohort 2- Dexmedetomidine (60 Micrograms) vs. Placebo|Sublingual film containing 60 Micrograms Dexmedetomidine or Placebo Sublingual film
89641082|NCT04470050|Experimental|Cohort 3- Dexmedetomidine (90 Micrograms) vs. Placebo|Sublingual film containing 90 Micrograms Dexmedetomidine or Placebo Sublingual film
89641083|NCT04470050|Experimental|Cohort 4- Dexmedetomidine (120 Micrograms) vs. Placebo|Sublingual film containing 120 Micrograms Dexmedetomidine or Placebo Sublingual film
89641084|NCT04470050|Experimental|Cohort 5- Dexmedetomidine (180 Micrograms) vs. Placebo|Sublingual film containing 180 Micrograms Dexmedetomidine or Placebo Sublingual film
89641085|NCT04470050|Experimental|Cohort 6- Dexmedetomidine (240 Micrograms) vs. Placebo|Sublingual film containing 240 Micrograms Dexmedetomidine or Placebo Sublingual film
89641086|NCT04457258|Experimental|Diagnostic (68Ga-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable).
89042852|NCT03934021||Acute stroke patient group|"Consecutive patients diagnosed with acute ischaemic stroke during hospitalization in Prince of Wales Hospital will be recruited.~After an informed consent, stool will be collected from enrolled patients in their first bowel opening after hospitalization and stored in a freezer (-80 degree Celsius) within 24 hours for analysis. If a subject develops constipation, stool sampling will be facilitated by stool softener or laxatives. Stools samples will be stored at -80 degrees Celsius within 24 hours once it is collected.~Subjects will be followed up at 3 and 6 months after trial entry. NIHSS and mRS will be performed at each visit. Stool sample collection will be repeated in 6 months visit only."
89641087|NCT04456660||Control group|"Monitoring of pregnancy, including data on:~maternal age and other demographic characteristics;~ultrasound measurement of fetal heart rate (FHR) and crown-rump length (CRL)"
89641088|NCT04456660||sFlt-1, Doppler and NK cells types group|"Monitoring of pregnancy, including data on:~maternal age and other demographic characteristics;~ultrasound measurement of fetal heart rate (FHR) and crown-rump length (CRL), uterine arteries PI, and other parameters;~measurement of serum sFlt-1, PLGF, and glycodelin-A levels, as well as other parameters;~measurement of CD16+, CD56+, and other subpopulations of NK cells;"
89641089|NCT04452721||Retrospective cohort|340 to 400 patients
89641090|NCT04452721||Validation cohort|120 patients
89641091|NCT04451590|Experimental|VR-based Simulation (Intervention)|Students will receive training on traumatic airway management using VR-based simulation.
89042853|NCT03934021||Control group|Age and disease matched subjects will be invited to join the study as the control. Stool will also be collected for the comparison of gut microbiota with acute stroke patients to look for evidence of gut dysbiosis in acute stroke. We shall match the control cohort with the stroke cohort in terms of age, gender, smoking status, medical co-morbidities including hypertension, hyperlipidaemia, diabetes, (atrial fibrillation), use of medications in particular metformin, proton pump inhibitors and aspirin.
89042854|NCT03904290|Other|Pre-PFO closure|Subjects evaluated at 'baseline' prior to percutaneous closure of PFO, and re-evaluated at 3 months post percutaneous closure of PFO
89042855|NCT03900468|Experimental|Active Deep Brain Stimulation (DBS)|
89042856|NCT03891953|Experimental|DKY709|DKY709 monotherapy
89042857|NCT03891953|Experimental|DKY709 + PDR001|Combination therapy with DKY709 and PDR001
89042858|NCT03891238|Experimental|Avelumab Arm|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
89042859|NCT03888989|Other|Study Phase|Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
89042860|NCT03882034|Experimental|1|Intervention arm, Patient received pegvisomant
89042861|NCT03879161|Experimental|Device Arm|Study participants will be enrolled in the Device Arm and the Vu-Path™ Device will be used to access the femoral artery for intra-arterial chemoembolization.
89042862|NCT03878823|Experimental|ODM-209 Part 1 Dose escalation|
89042863|NCT03878823|Experimental|ODM-209 Part 2 Dose expansion|
89042864|NCT03831958||Family member|Family member of survivor of pediatric Cushing disease
89042865|NCT03831958||Subjects|survivor of pediatric Cushing disease
89042866|NCT03805477|Experimental|Nintedanib|Nintedanib 150 mg Kps bid (oral)
89042867|NCT03803774|Experimental|Treatment (IMRRT, birinapant)|Beginning on day 1, patients undergo IMRRT 5 days a week (Monday-Friday). Patients also receive birinapant IV over 30 minutes on days 2 and 9 of each cycle. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
89042868|NCT03799939|Active Comparator|Intervention group|Polyvinylidene fluoride mesh used in this trial (Dynamesh IPST) is synthetic mesh with central tube to accommodate bowel tightly and designed to prevent and treat parastomal hernia.
89641092|NCT04451590|Other|Mannequin-based Simulation (Control)|Students will receive training on traumatic airway management using mannequin-based simulation.
89641093|NCT04430894|Experimental|Induction|"All participants will receive 4 cycles of induction therapy. Based on the recommendation of investigators, participants may or may not proceed to an autologous stem cell transplant (SCT) after cycles 1-4. Each cycle is 28 days in length (see dosing details below.)~For patient undergoing upfront stem cell transplant (SCT): 4 cycles followed by stem cell collection, high-dose chemotherapy, and autologous SCT followed by 2 cycles (called consolidation).~For patients deferring SCT following collection: 4 cycles followed by stem cell collection followed by 4 additional cycles.~Carfilzomib: 56 mg/m2 IV on days 1, 8,15 Lenalidomide 25 mg orally (PO) on Days 1-21 Isatuximab: 10 mg/kg IV weekly for cycles 1-2 (days 1, 8, 15, 22), then every 2 weeks for cycles 3-6 (days 1 and 15), and monthly (day 1) thereafter Dexamethasone: 20 mg orally (PO) administered day of and day after carfilzomib and isatuximab (days 1, 2, 8, 9, 15, and 16; days 22 and 23 during cycles 1-2 only)."
89042869|NCT03799939|No Intervention|Control group|Participants in control group are operated with no preventive mesh.
89042870|NCT03798626|Experimental|Cohort A: 1st line colorectal cancer|Treatment for 1st line metastatic colorectal cancer (mCRC) with Gevokizumab, modified FOLFOX6, bevacizumab
89042871|NCT03798626|Experimental|Cohort B: 2nd line colorectal cancer|Treatment for 2nd line mCRC with Gevokizumab, FOLFIRI, bevacizumab
89042872|NCT03798626|Experimental|Cohort C: 2nd line gastroesophageal cancer|Treatment for 2nd line metastatic gastroesophageal cancer (mGEC) with Gevokizumab, paclitaxel, ramucirumab
89042873|NCT03798626|Experimental|Cohort D: 2nd or 3rd line renal cell carcinoma|Treatment for 2nd or 3rd line metastatic renal cell carcinoma (mRCC) with Gevokizumab, cabozantinib
89042874|NCT03795493|Experimental|Intervention Group|Standard chemotherapy treatment and oncology care plus short-term diet and exercise intervention.
89042875|NCT03795493|No Intervention|Control Group|Standard chemotherapy treatment and oncology care.
89042876|NCT03784313|Experimental|Perforators flaps (PF group)|
89042877|NCT03784313|Sham Comparator|Secondary intention wound healing|
89042878|NCT03768505|Experimental|Zandelisib (ME-401) open label|Subjects with relapsed/refractory FL or MZL will be administered 60 mg of ME-401 orally, once a day on an intermittent schedule (IS).
89042879|NCT03662308|Other|Heated Vest Safety & Comfort (able-bodied subjects)|Able-bodied controls will be fitted with an appropriately sized heated vest, while wearing only a standard cotton T-shirt and shorts, and will remain seated in a wheelchair. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for 2 hours with the heated vest on full power. Outcome Variables for Visit 1: Skin thermocouple temperatures, subjective ratings of thermal sensation.
89042880|NCT03662308|Experimental|Heated Vest Efficacy (persons with tetraplegia)|Subjects with tetraplegia, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized heated vest. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the self-regulating heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
89042881|NCT03662308|Active Comparator|Non-Heated Vest control condition (persons with tetraplegia)|The same subjects with tetraplegia from the experimental arm, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized, similarly insulated, but non-heated vest (control condition). Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the non-heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
89042882|NCT03651700|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
89641094|NCT04430894|Experimental|Maintenance-High Risk|"Only patients that have achieved a partial response (PR) or better after induction therapy with or without stem cell transplant will continue on to maintenance therapy. The treatment participants will receive for maintenance will be based on the biological features (or cytogenetics) of participants myeloma and categorized into two groups: Standard-risk and High Risk.~High Risk: subjects with high risk cytogenetics (deletion (del 17, translocation (t)(4:14), t(14;16), t(14;20), 1q duplications) will receive the following study treatment for up to two years (24 28-day cycles) until progressive disease (PD) or unacceptable toxicity:~Lenalidomide 10 mg orally (PO) Day 1-21 Carfilzomib 56 mg/m2 or last tolerated dose IV Days 1, 15 Isatuximab 10 mg/kg IV Day 1"
89057933|NCT04535739|Other|control group|patients received 4-6 circles of chemotherapy of EP or EC，and patients with complete remission or partial remission (more than 1 site) after chemotherapy，patients received thoracic radiotherapy。
89641095|NCT04430894|Experimental|Maintenance- Standard Risk|"Only patients that have achieved a partial response (PR) or better after induction therapy with or without stem cell transplant will continue on to maintenance therapy. The treatment participants will receive for maintenance will be based on the biological features (or cytogenetics) of participants myeloma and categorized into two groups: Standard-risk and High Risk.~Standard Risk: subjects without high risk cytogenetics (deletion (del 17, translocation (t)(4:14), t(14;16), t(14;20), 1q duplications) will receive the following study treatment for up to two years (24 28-day cycles) until progressive disease (PD) or unacceptable toxicity:~- Lenalidomide 10 mg orally (PO) Day 1-21"
89641096|NCT04428476|Other|Open-label arm|Open-label CAP-1002 will be administered to all subjects enrolled in the trial
89641097|NCT04390750|No Intervention|Treatment Group 1|Treatment Group 1 will receive a standard educational booklet, a clinical oral health evaluation and a smart electronic toothbrush with no instruction on oral hygiene technique. The study coordinator will download the toothbrush data for data collection. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided. The hygienist will provide basic instruction on proper use of the smart electronic toothbrush.
89641098|NCT04390750|Experimental|Treatment Group 2|Treatment Group 2 will receive a standard educational booklet, a smart electronic toothbrush, a clinical oral health evaluation with tailored instruction on oral hygiene technique and care partner coaching. The study coordinator will download the toothbrush data for data collection. The dental hygienist and interventionist will work together to fulfill the following intervention components: tailored instruction and coaching.
89641099|NCT04390750|No Intervention|Control Group|The Control group will receive a standard educational booklet and a clinical oral health evaluation with no instruction on oral hygiene technique. The dental hygienist will observe the participant's normal toothbrushing technique, interdental cleaning procedures and the cleaning of partial dentures. No instruction is provided.
89641100|NCT04386993|Experimental|IMRT|"-Five 5-Gy fractions of IMRT will be given to the pelvis with elective simultaneous boost to any suspicious lymph node or residual disease to 30 Gy.~-*Brachytherapy boost (at the discretion of the PI) within 2 weeks of radiation therapy completion. Once or twice weekly for three weeks"
89641101|NCT04375384|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once every week in the absence of disease progression or unacceptable toxicity.
89641102|NCT04369664|Experimental|Type 2 Diabetes group|All participants with type 2 diabetes will be given cholesterol-lowering medicine (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
89641103|NCT04369664|Other|Control group|The participants in the control group are subjects with elevated cholesterol who do not have diabetes. All participants will be given cholesterol-lowering medicines (evolocumab (PCSK9 inhibitor) plus atorvastatin (statin) or ezetimibe (zetia)) for 1 month with the same risk factors being measured following cholesterol reduction. They will be asked to undergo blood draw, to receive study medication, and to undergo additional optional vascular health testing including endothelial cell harvesting and glycocalyx (tongue probe).
89641104|NCT04349852|Experimental|BrainHQ Cognitive Training Arm|Participants will be randomized into the BrainHQ Cognitive Training modules which are 45 minute training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, and participants will be asked if they have a quiet space and noise cancelling headphones. Participants will complete the training protocols remotely and their performance will be tracked. Participants will complete the 40 training sessions remotely, but will meet with the study team member online prior to beginning the training and right after completing the training.
88991638|NCT04486352|Experimental|Inavolisib and Letrozole Cohort|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that with PIK3CA activating mutations in the absence of PTEN loss-of-function alterations or AKT1 activating mutations will be assigned to this cohort. Twenty-four participants will be enrolled. Once twenty-four participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
88991639|NCT04486352|Experimental|Giredestrant and Abemaciclib|Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumors that are RB1 intact with a local grade 1-2 estrogne receptor positive (ER+) are assigned to this cohort. Twenty-four participants will be enrolled. Once twenty-four participants are enrolled, the cohort will be closed to further enrollment. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
88991640|NCT04468360|Experimental|IV Allopregnanolone (Allo) for Extinction Retention (Expt. 1)|Arm 1 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after completion of extinction training.
88991641|NCT04468360|Placebo Comparator|IV Placebo for Extinction Retention (Expt. 1)|Arm 2 of Expt. 1 includes women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after completion of extinction training.
89641105|NCT04349852|Other|BrainHQ People Skills Arm|Participants will be randomized into the BrainHQ People Skills Modules which are 45 minute training sessions. There will be 40 training sessions. Since the intervention is presented both visually and verbally through the computer, and participants will be asked tocomplete the training in a quiet space and time to complete these activities. Participants will complete the 40 training sessions remotely, but will meet with the study team member online prior to beginning the training and right after completing the training.
89641106|NCT04344899||Historical|Retrospective Review
89641107|NCT04344899||ERAS Patients|Prospective Review
89641108|NCT04341194|No Intervention|Standard care with glucose|Control Group with standard care comprises facilitated tucking done by a nurse or the parent, oral glucose (300 mg/ml) and the opportunity to suck on a pacifier or on a parent's or a nurse's plastic gloved finger. The infant is placed on an examination table for the venipuncture.
89641109|NCT04341194|Experimental|Skin-to-skin contact|Skin-to-skin contact is a method widely used in neonatal care globally. The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
89641110|NCT04341194|Experimental|Skin-to-skin contact/breastfeeding/parental singing|Parent-driven interventions are skin-to-skin care, breastfeeding and multi-sensory stimulation like vocalisation. They are all a combination of multiple sensory inputs comprising auditory, tactile and olfactory recognition. Research has started to investigate breastfeeding in combination with Kangaroo-mother- care for example, which has shown to be an effective mix. A multimodal approach that includes a combination of non-pharmacological approaches is considered more effective during venipuncture than single strategies and provides greater pain relief.
89641111|NCT04337580|Experimental|Omeprazole Plus Standard of Care for Prostate Cancer Regimen|This intervention will be given on an outpatient basis. Omeprazole, 80 mg twice daily.
89641112|NCT04308330|Experimental|Vorinostat|"The first cycle of chemotherapy will not include the experimental agent vorinostat. This first cycle will be used to determine whether the patient can tolerate the chemotherapeutic backbone without developing a DLT.~Cycle 1~Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.~Temozolomide: 125 mg/m2/day PO Days 1-5.~Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.~Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.~Cycles 2-12~Vincristine: 1.5 mg/m2/day (maximum dose 2 mg) IV Days 1 and 8 over 1-15 minutes.~Temozolomide: 125 mg/m2/day PO Days 1-5.~Irinotecan: 50 mg/m2/day IV Days 1-5 over 60 minutes.~Cefixime: 8 mg/kg/day (maximum dose 400 mg) PO. Begin 2 days prior to irinotecan therapy and continue through Day 8.~Vorinostat: Dose per escalation schema daily Days 1-5.~Vorinostat will not be administered during Cycle 1."
89641113|NCT04278690|No Intervention|Usual Care|Current usual care includes standard discharge counseling by a nurse, with or without additional MD counseling.
89641114|NCT04278690|Experimental|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent.
89641115|NCT04278690|Experimental|HELPix+Tech|After parent receives usual care and HELPix (as above), trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app
89641116|NCT04254250||High risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
89641117|NCT04254250||Low risk recurrence group|Due to preoperative risk estimation each patient will be assigned to one of two groups - with high risk and low risk.
89641118|NCT04246346|Experimental|Interactive chatbot|A chatbot embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
89641119|NCT04246346|Active Comparator|Senior ophthalmologists|Senior ophthalmologists would communicate with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
89641120|NCT04245722|Experimental|FT596 Monotherapy, Lymphoma|FT596 monotherapy in adult subjects with r/r B-cell Lymphoma
89641121|NCT04245722|Experimental|FT596 in Combination with Rituximab, Lymphoma|FT596 in combination with Rituximab in adult subjects with r/r B-cell Lymphoma
89641122|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, Lymphoma|FT596 in combination with Obinutuzumab in adult subjects with r/r B-cell Lymphoma
89641123|NCT04245722|Experimental|FT596 Monotherapy, CLL|FT596 monotherapy in adult subjects with r/r CLL
89641124|NCT04245722|Experimental|FT596 in Combination with Obinutuzumab, CLL|FT596 in combination with Obinutuzumab in adult subjects with r/r CLL
89641125|NCT04204772|Experimental|Solution A Dose 1, Then Solution B Dose 2|Participants initially assigned to Solution A Dose 1 will complete the three day course (days 1-3) and switch to the Solution B Dose 2 arm to complete the three day course (days 8-10). The dose level for Solution A Dose 1 is 12 grams of medical grade oral AC mixed with 4 ounces of tap water. Participants will report on a daily basis and consume the assigned combination of oral AC.
89641126|NCT04204772|Experimental|Solution A Dose 2, Then Solution B Dose 1|Participants initially assigned to Solution A Dose 2 will complete the three day course (days 1-3) and switch to the Solution B Dose 1 arm to complete the three day course (days 8-10). The dose level for Solution A Dose 2 is 25 grams of medical grade oral AC mixed with 4 ounces of tap water. Participants will report on a daily basis and consume the assigned combination of oral AC.
89641127|NCT04204772|Experimental|Solution B Dose 1, Then Solution A Dose 2|Participants initially assigned to Solution B Dose 1 will complete the three day course (days 1-3) and switch to the Solution A Dose 2 arm to complete the three day course (days 8-10). The dose level for Solution B Dose 1 is 12 grams of medical grade oral AC mixed with 4 ounces of apple juice. Participants will report on a daily basis and consume the assigned combination of oral AC.
89641128|NCT04204772|Experimental|Solution B Dose 2, Then Solution A Dose 1|Participants initially assigned to Solution B Dose 2 will complete the three day course (days 1-3) and switch to the Solution A Dose 1 arm to complete the three day course (days 8-10). The dose level for Solution B Dose 2 is 25 grams of medical grade oral AC mixed with 4 ounces of apple juice. Participants will report on a daily basis and consume the assigned combination of oral AC.
89641129|NCT04197700|Other|Personalized Arm|"Personalized Arm: The target MAP will be defined as +/- 5% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements:~Pre-operative anesthesia or surgical consultation;~Other physician outpatient consultation (e.g. cardiology, family physician, internist) within 30 days of surgery;~Inpatient measurement the night before surgery;~Pre-anesthetic MAP~The order of the measurements prioritizes outpatient MAPs given that temporary pre-operative discontinuation of anti-hypertensive agents could potentially raise, while fasting and/or fluid restriction pre-operatively could potentially lower resting blood pressure.39 The lower and upper safety limits of personalized MAP targets will be 50mmHg and <90mmHg, respectively."
89641130|NCT04197700|Other|Protocolized Arm|"Protocolized Arm: The target MAP will be defined as 65 +/- 5mmHg. Pharmacologic and fluid treatment decisions will be at the discretion of the most responsible physician.~In both study arms, the blood pressure control period will extend from anesthetic induction until 12 hours after admission to the CSICU. As an additional safety metric, the anesthesiologist will be encouraged to utilize clinically-driven cerebral saturation monitoring to identify potential hypoperfusion. In cases with low bilateral saturations where the anesthesiologist feels low MAP may be the putative mechanism, the investigators will request that MAPs be raised in 5mmHg increments. Following completion of the study protocol, the MAP and/or systolic blood pressure targets will be at the discretion of the most responsible physician."
88991642|NCT04468360|Experimental|IV Allo for Reconsolidation Blockade (Expt. 2)|Arm 1 of Expt. 2 will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV Allo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
88991643|NCT04468360|Placebo Comparator|IV Placebo for Reconsolidation Blockade (Expt. 2)|Arm 2 of Expt. 2 will include will include women in the early follicular or mid-luteal phase of the menstrual cycle and men with PTSD who receive IV placebo immediately after reactivation of the conditioned fear memory by exposure to one conditioned stimulus (CS+).
88991644|NCT04467021|Experimental|Arm A (intensive systolic blood pressure management)|Patients receive intensive systolic blood pressure management for 6 months. Patients receive increased blood pressure medication every 2 weeks while systolic blood pressure is 120 mmHg or higher. Patients also monitor blood pressure at home 1 day a week (4 times in 1 day) every 2 weeks, and upload the recorded blood pressure readings to the provider and to a central blood pressure monitoring team. Patients with changes in blood pressure medications monitor blood pressure readings on 3 days in 1 week (4 times in 1 day).
88991645|NCT04467021|Active Comparator|Arm B (usual blood pressure management)|Patients receive standard blood pressure management for 6 months. Patients receive blood pressure medications per doctor's instruction. Patients also monitor blood pressure at home 1 day (4 times in 1 day) every 2 weeks, and upload the recorded blood pressures to a central monitoring team.
88991646|NCT04466865|Experimental|Best Case/Worst Case communication tool|The participant's enrolled nephrologist will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the participant.
88991647|NCT04466865|No Intervention|Usual Care|"Usual care conversations are typically focused on mode and timing of dialysis, management of electrolytes and scheduling of laboratory testing. Conservative management or a treatment option of no dialysis is rarely mentioned."
88991648|NCT04466618|Placebo Comparator|Saline|Saline infusion
88991649|NCT04466618|Active Comparator|Exendin-9,39|Exendin-9,39 infusion
88991650|NCT04466618|Active Comparator|Saline + Intralipid/Heparin|Induction of acute insulin resistance during Saline infusion
88991651|NCT04466618|Active Comparator|Exendin-9,39 + Intralipid/Heparin|Induction of acute insulin resistance during Exendin-9,39 infusion
89212240|NCT00618722|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received 0.5% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (1 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89641131|NCT04197596|Experimental|BK CTL|Eligible patients with refractory BK infection will receive up to 5 infusions of BK CTLs that are donor derived.
89641132|NCT04188873|Active Comparator|12-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
89641133|NCT04188873|Active Comparator|12-week Varenicline with 4-Week Preparation Varenicline and Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 12 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
89641134|NCT04188873|Active Comparator|24-week Varenicline with Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
89641135|NCT04188873|Active Comparator|24-week Varenicline with 4-Week Preparation Varenicline and Minimal Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 24 weeks post-TQD. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
89641136|NCT04188873|Active Comparator|12-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
89641137|NCT04188873|Active Comparator|12-week Varenicline with 4-Week Preparation Varenicline and Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 11 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
89641138|NCT04188873|Active Comparator|24-week Varenicline with Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 1 week prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 23 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
89641139|NCT04188873|Active Comparator|24-week Varenicline with 4-Week Preparation Varenicline and Intensive Counseling|Participants randomized to this intervention will receive one 0.5 mg pill for the first 3 days, starting 4 weeks prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily for the next 3 weeks pre-TQD and until 24 weeks post-TQD. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
89641140|NCT04188873|Active Comparator|12-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
89212241|NCT00618722|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received 1.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (2 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89641141|NCT04188873|Active Comparator|12-week C-NRT with 4-Week Preparation C-NRT and Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive a brief 15-30 minute phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
89641142|NCT04188873|Active Comparator|24-week C-NRT with Minimal Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
89641143|NCT04188873|Active Comparator|24-week C-NRT with 4-Week Preparation C-NRT and Minimal Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Then, starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
89641144|NCT04188873|Active Comparator|12-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges to use starting on their quit day. Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
89641145|NCT04188873|Active Comparator|12-week C-NRT with 4-Week Preparation C-NRT and Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 12 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
89641146|NCT04188873|Active Comparator|24-week C-NRT with Intensive Counseling|Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
89212242|NCT00618722|Experimental|Deoxycholic acid Injection 4 mg/cm²|Participants received 2.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (4 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89212243|NCT00618722|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89212244|NCT02546180|Experimental|YouTube Video Viewers|Subjects in this arm were randomized to viewing YouTube videos.
89212245|NCT02546180|Active Comparator|Standard Education|Subjects in this arm were randomized to standard preoperative education.
89212246|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 18 years and older|One dose of PCV13a vaccine will be given in aged 18 years and older
89212247|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 2-5 years old|One dose of PCV13a vaccine will be given in aged 2-5 years old
89641147|NCT04188873|Active Comparator|24-week C-NRT with 4-Week Preparation C-NRT and Intensive Counseling|Participants randomized to this intervention will receive 14 mg patches starting 4 weeks prior to the target quit day (TQD). Starting on the TQD, participants will receive 24 weeks of nicotine patches and nicotine mini-lozenges. Participants who smoke >10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants will receive four 15-20 minute phone or video counseling sessions (1 prior to the TQD, 1 during the first week post-TQD and during Weeks 2 and 4 post-TQD). The counseling is designed to produce intra-treatment support and skill training, consistent with the Public Health Service (PHS) Clinical Practice Guideline.
89641148|NCT04179409|Experimental|AMONDYS 45|This arm will involve the treatment of boys with DMD who have a duplication of exon 45, for which AMONDYS 45 will target skipping of this exon.
89641149|NCT04179409|Experimental|EXONDYS 51|This arm will involve the treatment of boys with DMD who have a duplication of exon 51, for which EXONDYS 51 will target skipping of this exon.
89641150|NCT04179409|Experimental|VYONDYS 53|This arm will involve the treatment of boys with DMD who have a duplication of exon 53, for which VYONDYS 53 will target skipping of this exon.
89641151|NCT04169906|Placebo Comparator|Placebo|
89641152|NCT04169906|Experimental|TS-142 10 mg|
89641153|NCT04169906|Experimental|TS-142 20 mg|
89641154|NCT04169906|Experimental|TS-142 30 mg|
89641155|NCT04169893|Placebo Comparator|Arm Title: Placebo (fasting)|fasting
89641156|NCT04169893|Placebo Comparator|Placebo (feeding)|after meal
89641157|NCT04169893|Experimental|TS-142, 1 mg|fasting
89641158|NCT04169893|Experimental|TS-142, 3 mg|fasting
89641159|NCT04169893|Experimental|TS-142, 10 mg (fasting)|fasting
89641160|NCT04169893|Experimental|TS-142, 10 mg (feeding)|after meal
89641161|NCT04169893|Experimental|TS-142, 30 mg|fasting
89641162|NCT04126603|Placebo Comparator|Group A Placebo|Metformin + Placebo.
89641163|NCT04126603|Active Comparator|Group B Active|Metformin + Placebo
89641164|NCT04099966|Experimental|alpha beta cell depletion|Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.
89641165|NCT04087707|Experimental|Step 1;TS-142|
89641166|NCT04087707|Experimental|Step 2;TS-142|
89212248|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 2, 4, 6 months|One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old
89212249|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 3、4、5 months|One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old
89212250|NCT00862160|Active Comparator|1|using minimized cardiopulmonary bypass circuit ROCsafeTM
89212251|NCT00862160|No Intervention|2|using standard cardiopulmonary bypass circuit
89212252|NCT00850148|Experimental|Melles|
89212253|NCT00850148|Experimental|Anwar|
89212254|NCT00862238|Experimental|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
89212255|NCT00862238|Other|Health Promotion|4-session education offering basic information about the prevention of hepatitis A, B & C
89212256|NCT00860054|Experimental|Medium Phytosterols|Diets with daily 400 mg of phytosterols
89212257|NCT00860054|Experimental|High Phytosterols Diet|Diet with 2000 mg of daily phytosterols
89212258|NCT00860054|Placebo Comparator|Low Phyto Diet|Diet with less than 100 mg of daily phytosterols
89641167|NCT04087707|Placebo Comparator|Step 2;Placebo|
89641168|NCT04053855||Renal mass patients|"Patients with renal mass requiring surgery (partial or total nephrectomy) will be included.~They will have an urinary sample."
89641169|NCT04053855||Control patients|Control patients (without renal mass) will be included. They will have an urinary sample.
89641170|NCT04043286|No Intervention|Control group|Healing abutments are connected on the implants on the day of surgery, which will be subjected to multiple disconnection and reconnection during the prosthetic phase
89641171|NCT04043286|Experimental|Test group|Definitive abutments connected to the implants on the day of surgery. No disconnection or reconnection during the prosthetic phase
89641172|NCT04023071|Experimental|FT516 Monotherapy|FT516 monotherapy in adult subjects with r/r AML.
89641173|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies|FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
89641174|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies on an Extended-Dosing Schedule|FT516 on an extended-dosing schedule in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
89641175|NCT04023071|Experimental|FT516 in Combination with Monoclonal Antibodies following Bendamustine Conditioning|Bendamustine conditioning followed by FT516 in combination with one of the following monoclonal antibodies in adult subjects with r/r B-cell lymphoma: rituximab or obinutuzumab.
89641176|NCT03991481|Experimental|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
89641177|NCT03991481|Active Comparator|Liquid-stored platelets|Platelets that have been liquid stored, with an expiry of 5 days.
89212259|NCT00850226|Experimental|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
89212260|NCT00850226|Experimental|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
89212261|NCT00860132||2|a group of consecutive hip fracture patients admitted to a dedicated comprehensive orthogeriatric ward and a group of similar patients admitted to an orthopedic ward and later on transferred to geriatric rehab center
89212262|NCT00862316|Experimental|Computer Navigational Unit Assistance|Oxford Unicompartmental Knee arthroplasty will be performed with the assistance of a computer navigational unit.
89212263|NCT00862316|Active Comparator|Non- Computer Navigational Unit Assisted|Oxford Unicompartmental Knee arthroplasty will be performed traditionally (without the assistance of a computer navigational unit).
89212264|NCT02544620||Total Hip arthroplasty|"Unselected primary THA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
89212265|NCT02544620||Total Knee arthroplasty|"Unselected primary TKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
89212266|NCT02544620||unicompartmental knee arthroplasty|"Unselected primary UKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
89212267|NCT02546258|Other|A Funagl Nail Treatment|Marketed treatment of Fungal Nail Follow instructions on pack
89212268|NCT00862394|Experimental|1|CHF 1535 Next DPI : BDP/Formoterol : 200/12 µg
89212269|NCT00862394|Active Comparator|2|CHF 1535 HFA pMDI : BDP/Formoterol : 200/12 µg
89212270|NCT00862394|Experimental|3|CHF 1535 Next DPI : BDP/Formoterol : 400/24 µg
89212271|NCT00862394|Active Comparator|4|CHF 1535 HFA pMDI : BDP/Formoterol : 400/24 µg
89212272|NCT02544542|Experimental|Rectum cooling system|Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
89212273|NCT02544542|Active Comparator|Hyper-hypothermia blanket|Let the patient sleep on the hyper-hypothermia blanket, set the target temperature to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by adjusting the target temperature of the device accordingly.
89212274|NCT00862472|Experimental|DuoTrav APS|DuoTrav APS QD AM
89212275|NCT00862472|Active Comparator|DuoTrav|DuoTrav QD AM
89212276|NCT00850304|Experimental|Arm one|
89521156|NCT03441529|Experimental|Treatment Sequence 1 (AB)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) on Day 1 of period 1 followed by Treatment B as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) together with piperacillin/tazobactam administered as three 30-minute Intravenous (IV) infusions of 4.5 gram (g) piperacillin/tazobactam (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
89521157|NCT03441529|Experimental|Treatment Sequence 2 (BA)|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
89521158|NCT03438019|Experimental|TIRE IMT|The TIRE IMT group will receive a tablet with the TIRE software installed and a PrO2® device through which they will train. Training consists of six levels (A-F) with six inspirations at each level for a total of 36 breaths. Recovery times between breaths range from 40 to 5 seconds as the subject advances each level. TIRE data will be stored in the tablet for subsequent interrogation and data retrieval.
89521159|NCT03438019|Experimental|Standard IMT group|The Standard IMT group will receive a Threshold® Inspiratory Muscle Trainer. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject. Subjects will be instructed to perform up to 36 breaths daily. To compare with TIRE training, we will ask participants to perform this within a 30-minute session.
89521160|NCT03438019|Sham Comparator|Sham IMT group|The Sham IMT group will also receive a Threshold® device and undergo the exact protocol of group 2 but with minimal resistance applied (7 cm H2O, the lowest in the device).
89521161|NCT04547569|Experimental|Adaptation to altered auditory feedback|fMRI measurement of brain activity during speech production under altered auditory feedback
89521162|NCT04547569|Experimental|Speech production|fMRI measurement of brain activity during normal speech production
89521163|NCT04547569|Experimental|Vibrotactile discrimination|fMRI measurement of brain activity during a vibrotactile discrimination task
89521164|NCT03441373|Experimental|XC8 20 mg and Placebo (Group A)|XC8 20 mg orally. 2 tablets of XC8 10 mg +2 tablets of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period
89521165|NCT03441373|Experimental|XC8 100 mg and Placebo (Group B)|"XC8 100 mg orally.~1 tablet of XC8 100 mg +2 tablets of Placebo 10 mg + 1 tablet of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period"
89521166|NCT03441373|Experimental|XC8 200 mg and Placebo (Group C)|XC8 200 mg orally. 2 tablets of XC8 100 mg +2 tablets of Placebo 10 mg (in total 4 tablets) once daily during 5 days of treatment period.
89521167|NCT03441373|Placebo Comparator|Placebo (Group D)|Placebo orally.
89521168|NCT03449797|Sham Comparator|Group A|AAVS performed with no intraprocedural rapid cortisol assay
89521169|NCT03449797|Experimental|Group B|AVS performed plus intraprocedural rapid cortisol assay
89042883|NCT03651700|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
89042884|NCT03612258|Experimental|Functional Magnetic Resonance Imaging|
89042885|NCT03611868|Experimental|APG-115+Pembrolizumab open label, two-part phase Ib/II|single arm dose escalation and dose expansion
89042886|NCT03610360|Active Comparator|Arm A|Arm A will receive the study drug MesoPher plus best supportive care
89042887|NCT03610360|No Intervention|Arm B|Arm B will follow best supportive care as deemed appropriate by the investigator.
89042888|NCT03593226|Experimental|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
89641178|NCT03965390|No Intervention|Classical care pathway|"Patients are following classical care pathway. Before brain surgery patients will be included after oral, medical and life quality evaluation.~After randomization in the control group, patients will be evaluated at 6 and 12months after surgery, during classical follow up visits."
89641179|NCT03965390|Experimental|Oral education|"Patients are following classical care pathway but combined at each visit with an oral education Before brain surgery patients will be included after oral, medical and life quality evaluation.~After randomization in the experimental group, patients will be evaluated at 6 and 12 months after surgery, during classical follow up visits. At each timepoint an oral education will be realized in parallel."
89641180|NCT03917173|Experimental|Experimental|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin
89641181|NCT03917173|Active Comparator|Comparator|Standard surgery
89641182|NCT03910738|Experimental|Testosterone treatment (Nebido®)|"Treatment/Nebido® arm: in this experimental arm, each patient will be injected intramuscularly with 1000 mg / 4 ml of testosterone undecanoate (Nebido®).~Treatment will be injected at baseline, week 6, 18, 30, 42 and 54"
89641183|NCT03910738|Placebo Comparator|Placebo|"Placebo arm: In this arm, each patient will be injected intramuscularly with 4 ml of placebo solution.~Placebo will be injected at baseline, week 6, 18, 30, 42 and 54"
89641184|NCT03869996|Active Comparator|fast track total knee arthroplasties|patients treated using fast track care protocol
89641185|NCT03869996|Active Comparator|standard care total knee arthroplasties|patients treated using standard care protocol
89641186|NCT03851601||ECP|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
89641187|NCT03841084|Active Comparator|Conservative Oxygen Management Strategy|Patients allocated to the conservative strategy will have the ECMO blender oxygen fraction (FbO2) will be titrated to achieve a post-oxygenator saturations of 92-96% (the FbO2 cannot be reduced to lower than 0.5). Post-oxygenator arterial blood gases (ABG's) will be taken to ensure safety and to allow for adjustments to be made. The ventilator FiO2 will be titrated to patient oxygen saturations (SpO2) of 92-96%.
89641188|NCT03841084|Active Comparator|Liberal Oxygen Management Strategy|Patients allocated to the liberal strategy will have the FbO2 set at 1.0 at all times. The ventilator FiO2 will be titrated to achieve a patient oxygen saturations (SpO2) of 97-100% (but not lower than 0.5).
89641189|NCT03785223|Experimental|Methylphenidate Hydrochloride Controlled-Release Capsules|Flexibly dosed at 25-100 mg per day
89641190|NCT03785223|Placebo Comparator|Placebo Capsules|1-4 capsules daily
89641191|NCT03779126|Experimental|Active comparator|Low frequency electrical stimulation for 60 minutes, three times a week during 60 days.
89641192|NCT03779126|Experimental|Other|High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
89641193|NCT03779126|Experimental|Experimental group|Low and High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
89641194|NCT03779126|Placebo Comparator|Placebo|Placebo electrical stimulation for 60 minutes, three times a week during 60 days. In the intervention groups will be used highest intensity tolerated by the individual, and in the sham will be maintained the minimum intensity after beginning of the perception of the electric current
89042889|NCT03575819|Experimental|FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
89042890|NCT03575819|Experimental|FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
89042891|NCT03565107||Female Patients|ICSI treatment because of male subfertility
89042892|NCT03563716|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
89042893|NCT03563716|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
89042894|NCT03540563|Other|blood draw|Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
89042895|NCT03538626|Experimental|Group 1: N6LS (5 mg/kg IV) single dose|N6LS (5 mg/kg) administered by intravenous (IV) infusion (Day 0)
89641195|NCT03779087|Experimental|10d TL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
89641196|NCT03779087|Active Comparator|10d AL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, amoxicillin 500 mg and metronidazole 250 mg q.i.d. for 10 days
89641197|NCT03779074|Active Comparator|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
89042896|NCT03538626|Experimental|Group 2: N6LS (5 mg/kg SC) single dose|N6LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
89042897|NCT03538626|Experimental|Group 3: N6LS (20 mg/kg IV) single dose|N6LS (20 mg/kg) administered by IV infusion (Day 0)
89042898|NCT03538626|Experimental|Group 4: N6LS (40 mg/kg IV) single dose|N6LS (40 mg/kg) administered by IV infusion (Day 0)
89042899|NCT03538626|Experimental|Group 5: N6LS (5 mg/kg SC) repeat dose|N6LS (5 mg/kg) administered by SC injection (Day 0, Week 12 and Week 24)
89042900|NCT03538626|Experimental|Group 6: N6LS (20 mg/kg IV) repeat dose|N6LS (20 mg/kg) administered by IV infusion (Day 0, Week 12 and Week 24)
89521170|NCT03449719|Active Comparator|Abiraterone|The treatment phase consists of systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist (control arm).
89521171|NCT03449719|Experimental|Abiraterone associated withAblative Radiation|"the patients in the experimental arm will receive SBRT to all metastatic lesions, concomitantly with abiraterone acetate.~SBRT will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations.~Considering an Alfa/beta of 3, a BED3 > 100 Gy is recommended"
89521172|NCT03449641|Other|Positive airway pressure (PAP) treatment|Positive airway pressure (PAP),which reverses upper airway obstruction, is effective in the majority of patients with stable obesity hypoventilation syndrome (OHS).
89521173|NCT02521519|Other|One side of the patient's back|medial branch block (MBB): Using sterile conditions, 25 gauge needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
89521174|NCT02521519|Other|Other side of the patient's back|These injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
89521175|NCT03437785|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-495 75mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 150mg, ,Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
89042901|NCT03538626|Experimental|Group 7: N6LS (5 mg/kg SC) + rHuPH20 (2000 U/ml SC) single dose|N6LS (5 mg/kg) + rHuPH20 (2000 U/ml) administered by SC injection (Day 0)
89521176|NCT03437785|Experimental|Experimental Group 2|Patients assigned to this group are treated with CKD-495 150mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
89521177|NCT03437785|Placebo Comparator|Placebo Group|Patients assigned to this group are treated with 4 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
89521178|NCT03437785|Active Comparator|Active comparator Group 1|Patients assigned to this group are treated with Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of the Rebamipide 100mg Tab.)
89521179|NCT03437785|Active Comparator|Active comparator Group 2|Patients assigned to this group are treated with Rebamipide 100mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.)
89521180|NCT03449563|Placebo Comparator|Placebo group (group G)|
89521181|NCT03449563|Active Comparator|Ultrasound-guided TPVB group (group U)|
89521182|NCT03449563|Experimental|open TPVB group(group E)|
89521183|NCT03437707|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
89521184|NCT03437707|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
89521185|NCT03437707|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
89521186|NCT03437629|Active Comparator|Calcium Hydroxide temporary cement|Cementation of a temporary crown with cement based on calcium hydroxide.
89521187|NCT03437629|Active Comparator|MTA temporary cement|Cementation of a temporary crown with cement based on Mineral trioxide aggregate .
89521188|NCT03437551||no intervention|Cross-sectional Observation study
89521189|NCT03437473|Active Comparator|Active stimulation QD|
89521190|NCT03437473|Active Comparator|Active stimulation QID|
89521191|NCT03437473|Sham Comparator|No stimulation|
89521192|NCT03441217|Experimental|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).
89521193|NCT03441217|Placebo Comparator|Saline solution|Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).
89042902|NCT03538626|Experimental|Group 8: N6LS (20 mg/kg SC) + rHuPH20 (2000 U/ml SC) single dose|N6LS (20 mg/kg) + rHuPH20 (2000 U/ml) administered by SC injection (Day 0)
89042903|NCT03535857|Active Comparator|Unilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on the ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
89042904|NCT03535857|Experimental|Bilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
89042905|NCT03532100|Experimental|Straight line walking|All participants will walk in a straight line while wearing the study prosthesis.
89042906|NCT03532100|Experimental|Circle walking with prosthesis inside|All participants will walk around a 1-meter radius circle with their prosthesis on the inside of the circle.
89042907|NCT03532100|Experimental|Circle walking with prosthesis outside|All participants will walk around a 1-meter radius circle with their prosthesis on the outside of the circle.
89042908|NCT03521154|Experimental|Osimertinib|Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule.
89042909|NCT03521154|Placebo Comparator|Placebo Osimertinib|Matching placebo for Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule
89042910|NCT03505398|Experimental|central vision disorder|
89521194|NCT03128515|Experimental|MTD Dose Escalation|Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
89521195|NCT03128515|Active Comparator|Fixed Dose|Fixed dose of Hydroxyurea, 20 mg/kg/day
89521196|NCT02521441|Experimental|F-627, 10 mg/dose|F-627 at dose of 10 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
89042911|NCT03505398|Experimental|peripheral vision disorder|
89042912|NCT03505398|Other|control|
89042913|NCT03496168|Experimental|mavacamten (MYK-461)|
89042914|NCT03487380|Experimental|Alzheimer with rapid DCR|
89042915|NCT03487380|Experimental|Alzheimer without rapid DCR|
89042916|NCT03487380|Sham Comparator|Control|
89042917|NCT03486301|Experimental|Single Agent BDB001|"A single subject will be enrolled at each dose level in the single agent arm until any ≥ Grade 2 treatment-emergent adverse event (TEAE) is observed in the first cycle.~Then dosage escalation will follow a traditional 3+3 dose escalation design.~Each successive group of patients will be enrolled at an incrementally higher dosage until the Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) of single agent BDB001 is reached."
89521197|NCT02521441|Experimental|F-627, 20 mg/dose|F-627 at dose of 20 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
89521198|NCT02521441|Experimental|Filgrastim, 5 mcg/kg/dose|Filgrastim of 5 mcg/dose administered by subcutaneous injection for up to two weeks, start from Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
89521199|NCT03433105||1/patients with tracheostomy tubes and prolonged MV use|Patients who have tracheostomy tubes and with prolonged mechanical ventilation
89521200|NCT03440983|Experimental|MRI data acquiring in healthy volunteers|MRI data acquiring in healthy volonteers
89521201|NCT03440827|Other|Child with slow-flow malformation|"Phase 1: Collect of experiences, perceptions, difficulties, needs and expectations of patients with slow-flow vascular malformation (for the age group of 11 to 15 years-old) using the focus group method.~Phase 2 : Administration of the scale of life's quality for validation."
89521202|NCT03440749|Experimental|Children with Cerebral Palsy (PC)|Serial reaction time task: repeating a sequence of movements according to the luminous stimuli
89521203|NCT03440749|Active Comparator|Control Group|Serial reaction time task: of movements according to the luminous stimuli
89521204|NCT03437317|Experimental|Active - MEG|Participants completed 1 session of 8 Perceptual Retraining blocks following an instructional presentation.
89521205|NCT03437317|Sham Comparator|Control - MEG|Participants completed 1 session of 8 blocks of Gender Discrimination Task.
89521206|NCT03437317|Experimental|Active - 3 Behavior/EEG|Participants completed 3 sessions of Perceptual Retraining following an instructional presentation. The first session included 6 blocks of perceptual training, and the second session included 12 blocks of perceptual training. No perceptual training was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
89521207|NCT03437317|Experimental|Active - 1 Behavior/MEG|Participants completed 1 session of 6 Perceptual Retraining blocks following an instructional presentation.
89521208|NCT03437317|Sham Comparator|Control - 3 Behavior/MEG|Participants completed 3 sessions of a Gender Discrimination Task. The first session included 6 blocks of gender discrimination task, and the second session included 12 blocks of the gender discrimination task. No gender discrimination task was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
89521209|NCT03437239|Experimental|Occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy to include occlusion training.
89521210|NCT03437239|No Intervention|Non-occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy without occlusion training (standard of care).
89521211|NCT03437083||Eribulin|Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m^2) (as eribulin 1.23 mg/m^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
89521212|NCT03436927|Experimental|Nintendo Wii Fit|Participants in the Nintendo Wii group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
89641198|NCT03779074|Experimental|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
89641199|NCT03779074|Experimental|14d high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
89641200|NCT03758066|Other|PlusCare|Patients and case managers who work with them will be given access to a web-/mobile-based application, PlusCare, to support various case management activities for one year.
89641201|NCT03754257|Experimental|Experimental Electrical Stimulation|Experimental Electrical Stimulation for 40 minutos + conventional physiotherapy, during seven days.
89641202|NCT03754257|Sham Comparator|Sham Electrical Stimulation|Sham Electrical Stimulation for 40 minutes + conventional physiotherapy, during seven days.
89641203|NCT03752515||case-ACS-MACE|ACS patients with poor prognosis
89641204|NCT03752515||control-ACS-MACE|ACS patients with good prognosis
89641205|NCT03752515||Health-control|general population without ACS
89042918|NCT03486301|Experimental|BDB001 in Combination with Pembrolizumab|"In the combination arm of the study, a standard 3+3 dose escalation design will be utilized for all dose levels.~When the MTD or RP2D of single agent BDB001 is reached, the first dose level cohort of the combination arm will begin. Once the MTD or RP2D in combination has been determined, twenty additional subjects will be enrolled in the expansion phase of the study."
89042919|NCT03477201|Experimental|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Intervention: 30 patients will undergo a robotic assisted laparoscopic inguinal hernia repair. This will be done using the DaVinci Robotic Platform by Intuitive Surgical. This an accepted safe method of repairing inguinal hernia. This platform uses special robotic ports produced and supplied by Intuitive Surgical required to dock the machine to the patient. Monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
89042920|NCT03477201|Active Comparator|Standard Laparoscopic inguinal hernia repair|Intervention: 30 patients will undergo a laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia. This platform uses standard laparoscopic ports. In our institution we use plastic ports made by Covidien, Boulder, CO. The operation will require two 5mm VersaPort (Covidien) and a Hassan Port. As in the robotic arm, monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
89042921|NCT03467373|Experimental|Part 1: Dose Escalation r/r NHL|"Dose finding in participants with r/r NHL: the study will explore different doses of glofitamab in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP every 3 weeks (Q3W). Participants with r/r NHL will receive 6 cycles of induction treatment (G/R-CHOP). Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) may optionally receive post-induction treatment (referred to as maintenance) with glofitamab alone.~The use of G versus R in Cycle 1 will be compared in parallel dose escalation cohorts."
89042922|NCT03467373|Experimental|Part 2: DLBCL G/R-CHOP|Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by G/R-CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
89042923|NCT03467373|Experimental|Part 2: DLBCL Pola-R-CHP|Participants with untreated DLBCL will receive Pola-R-CHP + glofitamab on Day 1 of each 21-day cycle for a maximum of 6 cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
89042924|NCT03459157|Other|HIV prevention package including PrEP|
89042925|NCT03450343|Experimental|Oral azacitidine + R-ICE|Patients will receive 7 days of oral azacitidine (CC-486) leading into cycle 1 day 1 of R-ICE chemotherapy. R-ICE chemotherapy may be administered as an inpatient or as an outpatient . Oral azacitidine will be administered on days 8-21 of cycles 1 and cycle 2. R-ICE will be administered per standard of care.
89042926|NCT03445936|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
89042927|NCT03445936|Active Comparator|Permacol|Permacol is a acellular porcine dermal implant used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
89641206|NCT03750786|Experimental|Group A|ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab
89641207|NCT03750786|Active Comparator|Group B|mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab
89641208|NCT03742414|Active Comparator|Control arm (Standard of care)|The study doctors will provide standard of care with routine reactive topical products for atopic dermatitis flares
89042928|NCT03430076|Experimental|Revascularization by (Propaten)®|Revascularization by PTFE with heparin bonded luminal surface (Propaten)®
89042929|NCT03430076|Active Comparator|Revascularization by Crude PTFE|
89042930|NCT03424941|Experimental|FFR-guided PCI and TAVI|FFR-guided PCI and subsequently TAVI treatment with the Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO
89042931|NCT03424941|Active Comparator|CABG and SAVR|CABG and SAVR
89042932|NCT03414567||Control Group|Non-smoker
89042933|NCT03414567||Study Group|Smoker
89641209|NCT03742414|Experimental|Active Intervention arm (proactive treatment)- Epiceram|Participants will receive proactive sequential skin care with the twice-daily use of a tri-lipid skin barrier cream (SBC). Clinically apparent eczema in this group will be managed with a short course of topical steroids (fluticasone propionate cream and/or hydrocortisone).
89641210|NCT03742414|Experimental|Active Intervention arm (proactive treatment)- Moisturizer|Participants will receive proactive sequential skin care with the twice-daily use of a moisturizer. Clinically apparent eczema in this group will be managed with a short course of topical steroids (fluticasone propionate cream and/or hydrocortisone).
89641211|NCT03736395|Active Comparator|Control|Schools in this condition will be provided a four-day training about Schoolwide Positive Behavioral Interventions and Supports, and bi-yearly feedback about progress monitoring and action planning.
89641212|NCT03736395|Experimental|I-RIM Intervention|Schools in this condition will be provided the same basic training as the control condition, plus the elements of the Idaho Rural Implementation Model (I-RIM).
89641213|NCT03728933|Experimental|2 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
89641214|NCT03728933|Experimental|3 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine (1 mg/24 h patch + 2 mg/24 patch at the same time), which is the assigned dose level throughout the 12-week Maintenance Period.
89641215|NCT03728933|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
89641216|NCT03719105|Experimental|Cohort 1|"Patients with aggressive NK cell leukemia or stage III or IV extranodal NK/T-cell lymphoma, nasal type.~Chemotherapy Regimen:~mSMILE: Methotrexate Day 1, Ifosfamide Days 2-4, Dexamethasone Days 2-4, Etoposide Days 2-4, calaspargase pegol Day 8. For patients in CR and no available allogeneic SCT can receive up to 2 additional cycles of mSMILE.~Pembrolizumab: For patients in PR/MR/NR/PD after 2 cycles of mSMILE.~Allogeneic Stem Cell Transplant if donor available and not in PD."
89641217|NCT03719105|Experimental|Cohort 2|"Patients with stage III or IV peripheral T-cell lymphoma-NOS, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma (other histologies will be considered after case-by-case discussion with Study Chairs and Executive Vice-Chairs).~Chemotherapy Regimen:~Cycle 1 & 2: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 3 & 5: Brentuximab vedotin Day 1, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 4 & 6: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Allogeneic Stem Cell Transplant if donor available and not in PD."
89641218|NCT03705819|Experimental|Healthy Volunteers|In Stage 1, five healthy volunteers will receive a microdose of [11C]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes post-administration. These image sets will be used to evaluate [11C]-NOP46 biodistribution and derive dosimetry estimates.
89641219|NCT03705819|Experimental|Individuals with Focal Pain|In Stage 2, up to 30 subjects with focal pain will receive a microdose of [11C]-NOP46 and undergo PET/CT scans for up to 60 minutes in length. The results of Stage 1 will inform the scanning parameters (uptake period, scan length, reconstruction parameters, etc.) for Stage 2.
89641220|NCT03694561||Late-Onset Pompe disease|Individuals with a confirmed diagnosis of Late-Onset Pompe disease via NBS
89042934|NCT03412760|Experimental|Exome sequencing|There is only one arm of this study. All enrolled participants with unexplained NIHF or other birth defect will be offered exome sequencing for the affected fetus or neonate. Please refer to the Study Design section for further details.
89042935|NCT03395210|Experimental|Rilzabrutinib (PRN1008) Daily|"Part A approximately 60 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension.~Part B approximately 25 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension"
89042936|NCT03388593|Placebo Comparator|Placebo|Placebo in addition to standard therapy
89042937|NCT03388593|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
89042938|NCT03361748|Experimental|Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 15 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy.
89042939|NCT03312699|Experimental|Group A IIV4|Group A: Up to 30 healthy volunteers 18-40 years old, will be given seasonal quadrivalent inactivated influenza vaccine (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89042940|NCT03312699|Experimental|Group B High Dose IIV3|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal high dose trivalent inactivated influenza vaccine (Fluzone High Dose) Fluzone® high dose vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89042941|NCT03312699|Experimental|Group B Fluad|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal adjuvanted trivalent inactivated influenza vaccine Fluad®. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89042942|NCT03312699|Experimental|Group A Hepatitis A (HepA)|Group A: Up to 30 healthy volunteers 18-40 years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89042943|NCT03312699|Experimental|Group B Hepatitis A|Group B: Up to 30 healthy volunteers 65 plus years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89641221|NCT03678935|Active Comparator|Low FODMAP diet (LFD)|The LFD wil receive advice on how to follow a low FODMAP diet. They wil follow this diet for 4 weeks. Thereafter they receive advice on how to reintroduce high FODMAPs again.
89641222|NCT03678935|No Intervention|Control|Control group. Participants follow their regular gluten-free diet (GFD), with no changes to their diet. They wil receive the same dietary advice as the LFD-group after the 4-week study.
89641223|NCT03663790|No Intervention|Control|No intervention
89042944|NCT03312699|Experimental|Group A Typhoid VI|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif®. This arm represents those randomized to Typhoid VI. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89042945|NCT03312699|Experimental|Group A Oral Typhoid|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine, Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif® (Oral Typhoid). This arm represents those randomized to Oral Typhoid. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8 (from date of last oral dose), Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89042946|NCT03312699|Experimental|Group B Typhoid VI|Group B: Up to 30 healthy volunteers 65 plud years old, will be given Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi® vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89042947|NCT03300310|Experimental|with nursing visit|a nurse visit is scheduled twice a week during 3 months at patient home.
89042948|NCT03300310|Experimental|without nursing visit|no nursing visit
89641224|NCT03663790|Experimental|Foot Progression|Participants will visualize a desired foot progression angle bandwidth in real-time that they should target with their foot angle
89641225|NCT03663790|Experimental|Trunk Lean|Participants will visualize a desired trunk lean angle bandwidth in real-time that they should target with their trunk lean angle
89042949|NCT03284242|Experimental|Autologous Treg Infusion|This will be a single intravenous (IV) infusion. A participant's own expanded regulatory T cells will be added to Albumin, and administered to them. The amount of the solution will be approximately 300 ml and the infusion will take about 3 to 4 hours.
89042950|NCT03280862|Active Comparator|Control|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned preferentially in a posterolateral, non-apical position
89042951|NCT03280862|Experimental|Intervention|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned according to the latest electrical activation in the CS
89042952|NCT03276221|Active Comparator|Abstinent|This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
89042953|NCT03276221|No Intervention|Monitoring|This group of cannabis users are not asked to change their cannabis use behavior.
89042954|NCT03276221|No Intervention|Non-Users|This is a group of adolescents with little to no cannabis use history and is non-randomized.
89042955|NCT03266770|Other|RELIEF stent placement|After meeting the inclusion criteria and being consented, patients will have the RELIEF stent inserted in the ureter during cystoscopy per standard of care for ureteral stent placement.
89042956|NCT03246932|Experimental|Peer-led psycho-education group|A structured, researcher-designed peer expert-led psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education and self-help, problem-solving programs by Chien et al. (2010) and Lehman et al. (2004).
89641226|NCT03649841|Active Comparator|Arm I (ADT, abiraterone, prednisone)|Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.
89641227|NCT03649841|Experimental|Arm II (ADT, abiraterone, prednisone, radiation therapy)|Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.
89641228|NCT03627026|Other|Patients treated with immune checkpoint inhibitor|
89641229|NCT03599713|Experimental|Retifanlimab: Chemotherapy: Naïve|
89641230|NCT03599713|Experimental|Retifanlimab: Chemotherapy: Refractory|
89641231|NCT03557372|Experimental|Mathematical Model-Adapted Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule
89641232|NCT03557281|Active Comparator|Rifafour e-275|All participants will receive a standard-of-care therapy (rifafour e-275) tablet, orally, once daily from Day 1 to Day 14. Participants will receive the standard treatment for tuberculosis (i.e. rifafour e-275 or equivalent generic alternative) once the study treatment (Day 1 to Day 14) is completed.
89641233|NCT03557281|Experimental|GSK3036656 1 mg|Participants will receive a loading dose of GSK3036656 3 milligram (mg), capsule, orally on Day 1, followed by maintenance dose of GSK3036656 1 mg, orally, once daily from Day 2 to Day 14.
89641234|NCT03557281|Experimental|GSK3036656 5 mg|Participants will receive a loading dose of GSK3036656 15 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 5 mg, orally, once daily from Day 2 to Day 14.
89641235|NCT03557281|Experimental|GSK3036656 15 mg|Participants will receive a loading dose of GSK3036656 30 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 15 mg, orally, once daily from Day 2 to Day 14.
89641236|NCT03557281|Experimental|GSK3036656 30 mg|Participants will receive a loading dose of GSK3036656 75 mg, capsule, orally on Day 1, followed by maintenance dose of GSK3036656 30 mg, orally, once daily from Day 2 to Day 14.
89641237|NCT03538041|Experimental|Parsaclisib 1 mg QD|Parsaclisib at 1 milligram (mg) once daily (QD) for 12 weeks followed by extension period, with a dose-increase option (to 2.5 mg QD) at Week 6 for participants who fulfill dose increase criteria.
89641238|NCT03538041|Experimental|Parsaclisib 2.5 mg QD|Parsaclisib at 2.5 mg QD for 12 weeks followed by extension period.
89641239|NCT03537196|Other|All patients|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
89641240|NCT03537196|Other|HIV/HCV co-infected patients|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day (sofosbuvir 400 mg and daclatasvir 90 mg)
89641241|NCT03537196|Other|Cirrhosis|In case of cirrhosis : ribavirin will be added to sofosbuvir / daclatasvir 12 weeks
89641242|NCT03537196|Other|Cirrhosis with ribavirin contra-indication|In case of cirrhosis with ribavirin contra-indication : sofosbuvir and daclatasvir for 24 weeks
89641243|NCT03525223|Active Comparator|dialysate [Na+] 138 mmol/l|Intervention: Change of dialysate [Na+] from 138 mmol/l to 142 mmol/l The dialysate [Na+] will be increased by 2 mmol/l per week and kept constant for 5 weeks (altogether 6 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
89641244|NCT03525223|Active Comparator|dialysate [Na+] 142 mmol/l|Intervention: Change of dialysate [Na+] from 142 mmol/l to 135 mmol/l The dialysate [Na+] will be decreased by 2 mmol/l per week for 3 weeks and by 1mmol/l for 1 further week. Afterwards the dialysate [Na+] will be kept constant for 5 weeks (altogether 8 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
89641245|NCT03515304|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
89641246|NCT03515304|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
89641247|NCT03502746|Experimental|Nivolumab + Ramucirumab|Nivolumab 240mg IV + Ramucirumab 8mg/kg IV
89641248|NCT03482310|Experimental|Cortical Control of Grasp Patterns|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
89641249|NCT03437993|Experimental|Recollect|Recollect is a video game which incorporates scientifically supported renditions of N-Back, Item Span, and Multiple-Identity tracking tasks. These tasks are independently shown to improve working memory in a manner that transfers to untrained tasks.
89641250|NCT03437993|Sham Comparator|Tetris|Tetris is a video game which has not been shown to have any benefits in the improvement of executive functioning.
89641251|NCT03384134|Experimental|Pain Buddy|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
89641252|NCT03384134|No Intervention|Control|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
89641253|NCT03345797|Experimental|Naive patients - ARM 1|TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel [Natesto] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2
89641254|NCT03345797|Experimental|Non-naive patients - ARM 2|TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage >/= 3, receiving Testosterone Nasal Gel [Natesto] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later
89641255|NCT03292458|Experimental|Clinical response to sodium oxybate|In contrast to placebo but similar to alcohol, sodium oxybate is expected to be most effective in reducing voice symptoms in alcohol-responsive SD and VT.
89641256|NCT03292458|Experimental|Primary markers of clinical response|The clinical outcome is expected to be determined by selective modulation of functional abnormalities in the brain regions controlling speech sensorimotor processing and integration in association with underlying gene variants.
89641257|NCT03287817|Experimental|AUTO3|Patient with relapsed or refractory DLBCL
89641258|NCT03260894|Experimental|Pembrolizumab + Epacadostat|
89641259|NCT03260894|Active Comparator|SoC (Sunitinib or Pazopanib)|Standard of care (SoC) (sunitinib or pazopanib monotherapy).
89641260|NCT03197935|Experimental|Atezolizumab and Chemotherapy|Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
89641261|NCT03197935|Placebo Comparator|Placebo and Chemotherapy|Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
89641262|NCT03136965|Experimental|Platelet-Rich Plasma (PRP)|Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
89641263|NCT03136965|Placebo Comparator|Dry Needling Procedure|Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
89641264|NCT03136965|Sham Comparator|Sham Procedure|Group 3 (sham) will undergo US-guided sham dry needling procedure.
89641265|NCT03115151|Experimental|Patient-Controlled Epidural Analgesia|Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
89641266|NCT03115151|Sham Comparator|Intravenous patient-controlled analgesia|Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone
89641267|NCT03042962||Patients with dystonia|Patients with dystonia (spasmodic dysphonia, singer's dystonia, writer's cramp, musician's focal hand dystonia) will undergo MRI of the brain and blood draw.
89641268|NCT03042962||Healthy volunteers|Healthy subjects without any neurological, psychiatric or otolaryngological problems will undergo MRI of the brain and blood draw.
89212277|NCT00850382|Experimental|Dasatinib|"Induction cycle(s):~Patients will receive in cycle 1 induction therapy with daunorubicin 60 mg/m2/day administered on days 1 through 3 and cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7). Patients will receive dasatinib 100 mg QD on days 8-21. Patients not achieving CR or CRi at the end of cycle 1 will be evaluable to receive a second induction cycle identical in schedule and dosage to the first induction cycle.~Consolidation Cycles 1, 2, 3, 4:~Patients achieving CR or CRi at the end of cycle 1 will receive consolidation therapy for 4 cy-cles. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours. Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
89212278|NCT00860366|Experimental|Uric Acid|Single intravenous infusion of 1 gram of Uric Acid dissolved in vehicle (500 ml of 0'1% Lithium Carbonate and 5% Mannitol).
89212279|NCT00860366|Placebo Comparator|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
89212280|NCT02544464|Experimental|Experimental group|ferric carboxymaltose 1000 mg
89212281|NCT02544464|Placebo Comparator|Control group|placebo
89212282|NCT00862550|Experimental|Group 1|Acupuncture (Areas known to help dry mouth)
89212283|NCT00862550|Experimental|Group 2|Acupuncture (Areas not known to help dry mouth)
89212284|NCT00862628|Experimental|Rebamipide|
89212285|NCT00507442|Experimental|VDR|VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
89641269|NCT03019757||Alzheimer's disease|Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
89641270|NCT03019757||Lewy Body dementia|Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
89641271|NCT03019757||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
89641272|NCT03001713|Active Comparator|Arm 1: Immediate implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system at the start of study year 2. Arm 1 CHCs will receive implementation support that will be pragmatically iterated to address any barriers to adoption / sustained use of the CDS that are identified through study activities. The investigators will apply these learnings to improve adoption rates in Arm 2.
89641273|NCT03001713|Active Comparator|Arm 2: Delayed implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system 18 months later than Arm 1. The investigators will measure the intervention's impact on CVD risk factor control in CHCs.
89641274|NCT02908685|Experimental|Part 1 Group A: Adolescents and Adults (Risdiplam)|Adolescent and adult participants aged 12-25 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
89641275|NCT02908685|Placebo Comparator|Part 1 Group A: Adolescents and Adults (Placebo)|Adolescent and adult participants aged 12-25 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
89641276|NCT02908685|Placebo Comparator|Part 1 Group B: Children (Placebo)|Children aged 2-11 years will receive placebo matching to risdiplam for at least 12 weeks. Once placebo-controlled period is completed, participants will be first switched to their cohort risdiplam dose. After the Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
89641277|NCT02908685|Experimental|Part 1 Group B: Children (Risdiplam)|Children aged 2-11 years will receive risdiplam for at least 12 weeks. Once the placebo-controlled period is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be treated in an open-label phase.
89641278|NCT02908685|Placebo Comparator|Part 2: Placebo|Participants aged 2-25 years will receive placebo matching to risdiplam for 12 months. After 12 months of treatment with placebo, participants will be switched to risdiplam (5 mg once daily for participants with a body weight (BW) >/=20kg or 0.25 mg/kg for participants with a BW <20) in a blinded manner and participants will continue with treatment until Month 24. After Month 24, participants will be offered the opportunity to enter the open-label phase.
89641279|NCT02908685|Experimental|Part 2: Risdiplam|Participants aged 2-25 years will receive risdiplam at the dose selected based on the results from Part 1 of the study (5 mg once daily for participants with a body weight (BW) >/=20kg or 0.25 mg/kg for participants with a BW <20 kg), for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the open-label phase.
89641280|NCT02845596|Active Comparator|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
89641281|NCT02845596|Active Comparator|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
89641282|NCT02778685|Experimental|Cohort 3 (letrozole, palbociclib, fulvestrant, pembrolizumab)|Patients receive either letrozole PO QD on days -28 to -1 and days 1-28, or fulvestrant on days -28, -14, and day 1 of subsequent cycles. Patients also receive palbociclib PO QD for 3 weeks. Cycles with palbociclib, and letrozole or fulvestrant repeat every 28 days in the absence disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89212286|NCT00507442|Experimental|VDCR|VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
89212287|NCT00507442|Experimental|VDC|VELCADE (bortezomib), dexamethasone, cyclophosphamide
89212288|NCT00507442|Experimental|VDC-mod|Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
89641283|NCT02778685|Experimental|Cohorts 1 and 2 (letrozole, palbociclib, pembrolizumab)|Patients receive letrozole PO QD on days 1-28 and palbociclib PO QD for 3 weeks. Cycles with letrozole and palbociclib repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89641284|NCT02772276|Experimental|Normal-CKD Stage 2/QuantumLeap|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may have received different doses.
89641285|NCT02772276|Experimental|CKD Stage 3-4/QuantumLeap|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-4), and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may have received different doses.
89641286|NCT02772276|Experimental|Normal-CKD Stage 2/Radiance|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Radiance ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89641287|NCT02772276|Experimental|CKD Stage 3-5/Radiance|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Radiance ORFM device. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89042957|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
89042958|NCT03246932|Active Comparator|Profession-led psycho-education group|A psycho-education group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
89641288|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance algorithm optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89641289|NCT02772276|Experimental|CKD Stage 3-5/Brilliance algorithm optimization|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89641290|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance sensor optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Sensor optimization of the Brilliance device was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89641291|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance sensor validation|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Validation of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89641292|NCT02772276|Experimental|CKD Stage 3-5/Brilliance sensor validation|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Validation of the Brilliance sensor was conducted. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89641293|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance (1-2 sensors)|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm received two doses of MB-102, 12 hours apart.
89042959|NCT03243422|Active Comparator|Successful aging health education intervention|Individual sessions on healthy aging topics
89042960|NCT03243422|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
89042961|NCT03238196|Experimental|Escalation|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
89042962|NCT03238196|Experimental|Expansion|"Fulvestrant - injection into muscle 1 time per month~Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken)~Erdafitinib tablet taken by mouth 1 time per day"
89042963|NCT03225989|Experimental|LOAd703|LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)
89042964|NCT03207373|Experimental|Stress ECG Test|The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
89042965|NCT03183609|Active Comparator|Gluten|30 grams of gluten flour daily in protein shake
89042966|NCT03183609|Placebo Comparator|Placebo|30 grams of rice flour daily in protein shake
89641294|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance (1-2 sensors and Brilliance 2-part sensor)|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors and 2-part sensor). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm received two doses of MB-102, 12 hours apart.
89641295|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance (1-2 sensors and Brilliance 2-part sensor) and 2 doses MB-102|Two doses of MB-102 administered to participants 12 hours apart, with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device (1-2 sensors and 2-part sensor). The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89641296|NCT02772276|Experimental|CKD Stage 3-5/Brilliance 1-2 sensors|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device was tested. Approximately half of the participants were to be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
89641297|NCT02733848|Experimental|DIET|A registered dietician (RD) will meet with and thoroughly review the patients diet. The patient will be counseled on a diet lower in refined carbohydrates and higher in protein.
89641298|NCT02733848|Active Comparator|Creon|Subjects will be provided Creon at a dose of 500 units/kg of lipase to be taken with meals and snacks to see if this decreases frequency and severity of hypoglycemia.
89641299|NCT02733848|Placebo Comparator|Placebo|Subjects will be provided placebo and advised to take it with meals and snacks to provide.
89641300|NCT02728661|Experimental|PACE|PACE participants will begin up to 6 weeks prior to their scheduled TKR and continue until 12 weeks after their TKR. Participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks (from up to 6 weeks pre-op to 12 weeks post-op). Further, participants may opt to receive regular text messages or emails from coaches if they prefer. At 12 weeks, PACE participants will enter a maintenance period and not have any contact with coaches.
89641301|NCT02728661|Experimental|Delayed PACE|After being notified of their randomized condition at baseline (up to 6 weeks prior to surgery), Delayed PACE participants will not have contact with coaches until 12 weeks after surgery. At 12 weeks after surgery, Delayed PACE participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks. Further, participants may opt to receive regular text messages or emails from coaches if they prefer.
89641302|NCT02676739|Placebo Comparator|Placebo|Capsule with no active medical ingredients to be taken orally once a day for 12 weeks.
89641303|NCT02676739|Active Comparator|Adderall XR 10mg|10mg Adderall XR capsule to be taken orally once a day for 12 weeks.
89641304|NCT02676739|Active Comparator|Adderall XR 20mg|20mg Adderall XR capsule to be taken orally once a day for 12 weeks.
89641305|NCT02675959|Experimental|Defibrotide prophylaxis|defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
89641306|NCT02668562|Experimental|Early CABG|Patients to undergo early CABG
89641307|NCT02668562|Active Comparator|Delayed CABG|Patients to undergo delayed CABG
89641308|NCT02646839|Experimental|KIR Favorable Transplant|To assess in a multi-center setting whether the disease-free survival (DFS) at one-year post-HCT for children with high-risk ALL, AML and MDS can be improved following favorably KIR-mismatched haplo-HCT using a graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells from CliniMacs TCR alpha-beta-Biotin system
89641309|NCT02644460|Experimental|Stratum A|Appropriate dose RT will be administered in 30-33 fractions over approximately 6 weeks for Stratum A patients. Treatment with abemaciclib (LY2835219) will start on the same day as RT and continue twice daily during and after RT for a maximum treatment duration of 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib (LY2835219) starting with dose level 1 (80% of adult dose). A cycle is defined as 28 days and the first 6 weeks of therapy will constitute the dose-limiting toxicity (DLT)-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
89641310|NCT02644460|Experimental|Stratum B - enrollment is closed for this study arm|Abemaciclib (LY2835219) will be administered orally on a twice daily basis continuously for 28 days, which defines one cycle. The maximum treatment duration will be 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib starting with dose level 1 (80% of adult dose). Dose escalation will be independent of Stratum A escalation. A cycle is defined as 28 days and the first 4 weeks of therapy will constitute the DLT-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
89212289|NCT00850616|Experimental|1|MRKAd6 Trigene 0.5x10^9 Ad6 vg
89641311|NCT02601313|Experimental|Axicabtagene ciloleucel/brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma (MCL) will receive conditioning chemotherapy (CTE) consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg on Day 0 or brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 CAR T cells/kg, with a maximum dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 1 or brexucabtagene autoleucel at a targeted dose of 0.5 x 10^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 2.
89641312|NCT02550652|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
89641313|NCT02550652|Placebo Comparator|Placebo|Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
89641314|NCT02547025|Experimental|rabeprazole+3 antibiotics|patients who have positive result of culture with equal to or more than three susceptible antibiotics are treated by non-bismuth quadruple therapy (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days
89641315|NCT02547025|Experimental|rabeprazole+bismuth+2 antibiotics|patients who have positive result of culture with one or two susceptible antibiotics are treated by bismuth-containing therapy (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days
89641316|NCT02547025|Active Comparator|rabeprazole+amox+tetr+levo|patients who have negative result of culture or whose culture data are unavailable will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days
89641317|NCT02491099|Experimental|Afatinib|Afatinib 40 mgs., Q 21 Day times 4 Cycles
89641318|NCT02484443|Experimental|Treatment (sargramostim and dinutuximab)|Patients receive sargramostim SC QD on days 1-14 and dinutuximab IV over 10 hours on days 4-7 (dinutuximab infusion may be extended up to a total of 20 hours per day for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
89641319|NCT02480374|Experimental|Single Arm|Carboplatin + Paclitaxel + IMNN-001
89641320|NCT02475707|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for ALL.
89641321|NCT02475707|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for ALL.
89641322|NCT02454907|Active Comparator|Control|One kind of communication with the clinic will be used.
89641323|NCT02454907|Experimental|Experimental|A different kind of communication with the clinic will be used.
89641324|NCT02422381|Experimental|MK-3475 + Gemcitabine|200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
89641325|NCT02371941|Experimental|Oral cromolyn|"Subjects randomized to the experimental arm will receive oral cromolyn sodium. The dose will be per current package insert for oral cromolyn:~Subjects 2-12 years of age - 100 mg (1 ampule) 4 times daily Subjects 13-18 years of age - 200 mg (2 ampules) 4 times daily"
89641326|NCT02371941|Placebo Comparator|Placebo|Subjects randomized to placebo will receive normal saline ampules Subjects 2-12 years of age - 1 ampule 4 times daily Subjects 13-18 years of age - 2 ampules 4 times daily
89641327|NCT02221310|Experimental|Gemtuzumab Ozogamicin|Conditioning therapy with Gemtuzumab Ozogamicin in combination with busulfan and cyclophosphamide chemotherapy followed by allogeneic stem cell transplantation.
89641328|NCT02140788|Active Comparator|Metformin|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added metformin will receive metformin 250 mg BID days 1-3, 500 mg BID days 4-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate a dose escalation will have the metformin dose reduced to the previously tolerated lower dose.
89641329|NCT02140788|Active Comparator|Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.
89641330|NCT02140788|Active Comparator|Metformin and Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will receive Metformin and Fish Oil as part of the study.
89641331|NCT02140788|No Intervention|No medication added|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will not receive Metformin or Fish Oil.
89212290|NCT00850616|Experimental|2|MRKAd6 Trigene 0.5x10^10 Ad6 vg
89212291|NCT00850616|Experimental|3|MRKAd6 Trigene 0.5x10^11 Ad6 vg
89212292|NCT00850616|Experimental|4|MRKAd5 Trigene 0.5x10^10 Ad5 vg
89212293|NCT00850616|Experimental|5|MRKAd5 Trivalent 1.5x10^10 Ad5 vg
89212294|NCT00850616|Experimental|6|MRKAd5+6 Trigene 1x10^9 Ad vg
89212295|NCT00850616|Experimental|7|MRKAd5+6 Trigene 1x10^10 Ad vg
89212296|NCT00850616|Placebo Comparator|8|Placebo
89212297|NCT00862706|Experimental|A|
89042967|NCT03173560|Experimental|Lenvatinib 14 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 14 mg once daily (QD) plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any >= Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (that is, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2 or later (cycle length equal to [=] 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
89042968|NCT03173560|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 18 mg QD plus oral everolimus 5 mg QD as the starting dose in Cycle 1 or later (cycle length =28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
89641332|NCT02117297|Experimental|Gemtuzumab Ozogamicin|Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is >1000/mm3 and platelet count is >40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later.
89641333|NCT02088554|Experimental|Model 400 aortic valve bioprosthesis|
89641334|NCT01894802|Experimental|Brain-Machine Interface Users|All participants enrolled in the study who meet eligibility criteria will be individuals implanted with microelectrodes in their brain to record neural activity. There is no control group.
89641335|NCT01863745|Experimental|nilotinib|16 patients who are currently enrolled in a Novartis- sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study receiving nilotinib and has fulfilled all their requirements in the parent study will be enrolled.
89641336|NCT01761422||SLE active flare|Patients who are having an active flare of their lupus confirmed by labs
89641337|NCT01703949|Experimental|Arm A (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89641338|NCT01703949|Experimental|Arm B (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89641339|NCT01617161|Active Comparator|PBT|Proton Beam Therapy
89641340|NCT01617161|Active Comparator|IMRT|Intensity Modulated Radiation Therapy
89641341|NCT01328977|Active Comparator|emails, book|
89641342|NCT01328977|Active Comparator|didactic teaching from experts|
89641343|NCT01328977|Experimental|personal coaching by development profs|
89042969|NCT03155425|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion.
89641344|NCT01307956|Experimental|Treatment (panitumumab, chemotherapy, radiation)|Patients receive panitumumab IV over 1 hour on day 1. Patients also receive oxaliplatin IV and leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1 (FOLFOX chemotherapy). Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Within 24 hours of the start of chemotherapy, patients undergo radiation therapy 5 days a week for 5.5 weeks. Patients then undergo surgery within 6-8 weeks after completion of radiation therapy. Patients with residual disease receive 4 additional courses of FOLFOX chemotherapy on days 1, 15, 29, and 42.
89042970|NCT03150329|Experimental|Vorinostat 100mg + Pembrolizumab 200mg|Patients receive Vorinostat 100mg PO BID on days 1-5 and 8-12 and pembrolizumab 200mg IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
89042971|NCT03150329|Experimental|Vorinostat 200mg + Pembrolizumab 200mg|Patients receive Vorinostat 200mg PO BID on days 1-5 and 8-12 and pembrolizumab 200mg IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
89042972|NCT03133208||Sepsis with AMS|Patients presenting to the ED with suspected sepsis who develop altered mental status
89641345|NCT01280669|Experimental|Group 1|Intravitreal injections of 440mcg sirolimus (low-dose monthly group)
89641346|NCT01280669|Experimental|Group 2|Intravitreal injections of 880mcg sirolimus (high-dose every other month group)
89641347|NCT01225913|Other|Asthma observational study arm|Asthmatics in this arm may be on varying dose of inhaled fluticasone 100-500mcg/salmeterol 50mcg bid via Advair MDI or equivalent dose via Diskus bid or Symbicort (budesonide 80-160mcg/formoterol 4.5mcg bid)or Dulera 100-200mcg mometasone/5 mcg formoterol bid, tiotropium 18mcg capsule daily. This is an observational study and additional pharmacologic intervention may include antibiotic and tapering doses of corticosteroids.
89641348|NCT01186341||Chronic Pain|New or existing patients of the center who are seeking their initial treatment at the Integrative Medicine center for chronic pain (chronic > 3 months) who report their average pain level over the past month to be at least a 4 of 10 on the Visual Analog Scale.
89641349|NCT01089101|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities. Patients undergo blood sample collection on study.
89641350|NCT01041027|Experimental|Treatment (paclitaxel, carboplatin, radiation therapy)|"CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15."
89641351|NCT00734513|Experimental|1|Partner-assisted Emotional Disclosure
89641352|NCT00734513|Active Comparator|2|Cancer Education
89042973|NCT03133208||Sepsis without AMS|Patients presenting to the ED with suspected sepsis without change in mental status
89042974|NCT03133208||Control|Patients presenting to the ED with no suspicion of systemic inflammation that need hospitalization (control category)
89042975|NCT03063606|Experimental|Cognitive-Behavioral Therapy (CBT)|"CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse."
89641353|NCT00669734|Experimental|Treatment (vaccine therapy, sargramostim)|Patients receive falimarev vaccine intratumorally using endoscopic ultrasound guidance on day 1. Patients also receive inalimarev vaccine SC on day 1 and sargramostim SC on days 1-4. Patients then receive falimarev vaccine SC on days 15 and 29 and sargramostim SC on days 15-18 and 29-32 in the absence of unacceptable toxicity. Beginning on day 43, patients with stable or improving pancreatic cancer receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity. Beginning on day 71, patients with no irreversible or dose limiting toxicity, receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity.
89641354|NCT00614887||2|Patients scheduled for elective cerebral aneurysmal surgery
89042976|NCT03063606|Active Comparator|Naltrexone/bupropion (NB) (on-going from acute stage)|Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.
89042977|NCT03057431|Placebo Comparator|Placebo|Once daily for 3 years
89042978|NCT03057431|Experimental|12.5 mg hydrochlorothiazide|Once daily for 3 years
89042979|NCT03057431|Experimental|25.0 mg hydrochlorothiazide|Once daily for 3 years
89042980|NCT03057431|Experimental|50.0 mg hydrochlorothiazide|Once daily for 3 years
89042981|NCT03053986|Active Comparator|Apple polyphenols|White capsule containing 300 mg of apple extract (Malus Domestica) with glycosilated polyphenols (≥90%) including glycosilated phloritzin (15-30%), chlorogenic acid (10-25%) and quercetin (15-25%)
89042982|NCT03053986|Placebo Comparator|Placebo|Indistinguishable capsules with similar dimension, colour, odour and taste
89042983|NCT03052127|Experimental|Single Low Dose Light-activated AU-011|Low dose Light-activated AU-011 followed by a single laser light application
89042984|NCT03052127|Experimental|Single Medium Dose Light-activated AU-011|Medium dose Light-activated AU-011 followed by a single laser light application
89042985|NCT03052127|Experimental|Single High Dose Light-activated AU-011|High dose Light-activated AU-011 followed by a single laser light application
89641355|NCT00614887||1|Patients with subarachnoid hemorrhage
89042986|NCT03052127|Experimental|2 Repeat Medium Dose Light-activated AU-011|2 repeat medium doses of Light-activated AU-011 each followed by a single laser light application
89042987|NCT03052127|Experimental|3 Repeat Medium Dose Light-activated AU-011|3 repeat medium doses of Light-activated AU-011 followed by a single laser light application
89641356|NCT00576069||asthma, quality of life, lung function|All Asthmatics will be treated with 1 of 3 long acting beta 2 agonist + corticosteroid using low or medium dose of inhaled (Advair) fluticasone or equivalent corticosteroid 200-500mcg/day plus salmeterol 100 mcg/day or (Symbicort) budesonide 320-640 mcg +formoterol 18 mcg/day or (Dulera) mometasone 400-800mcg + formoterol 20 mcg/day. In addition tiotropium 18ucg/day will be used. Additionally, albuterol 0.083%/ipratropium 0.02% solution or MDI HFA for acute exacerbation.Will measure lung function and asthma quality of life questionaire
89641357|NCT00501150|Experimental|Patients who fulfilled the study criteria|"IV to oral switch inclusion criteria used~Clinical status~Temperature less than 38°C for 24 hours~White cell count normalising~No unexplained tachycardia (Heart rate less than 100 beats per minute)~Sensitivity received (if microbiology positive)~Oral absorption~Patient tolerates oral fluids~No medical problems leading to reduced oral absorption (e.g. vomiting, diarrhoea, and gastrointestinal surgery)~No surgical operation scheduled within next 36 hours~IV to oral switch exclusion criteria used~Continuing sepsis~Temperature less than 36°C or more than 38°C~White cell count less than 4 × 109/L or more than 12 × 109/L~Unexplained tachycardia (Heart rate greater than 100 beats per minute in last 12 hours)~Oral route compromised~Vomiting or severe diarrhoea~Other ongoing or potential absorption problem"
89641358|NCT00389610|Experimental|Previously Vaccinated With GVAX Pancreas Vaccine|Participants receive booster vaccination every 6 months, given intradermally.
89641359|NCT00389610|Experimental|GVAX Pancreas Vaccine Naive|Participants will receive GVAX pancreas priming vaccinations once every month for a total of 3 months and every 6 months after that, given intradermally.
89641360|NCT00005533||Coronary Heart Disease Patients|
89641361|NCT05081778||Obese patient following a medical course|
89641362|NCT05081778||Obese patient following a surgical course|
89641363|NCT03142620|Active Comparator|Triple Therapy 10 days|Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
89641364|NCT03142620|Active Comparator|Triple Therapy 10 days+ vitamin D for 10|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 10 days"
89641365|NCT03142620|Active Comparator|Triple Therapy 10 days+vitamin D for 28|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 28 days"
89641366|NCT05077878||normal|Patients with non-orthodontic treatment and have no root resorption
89641367|NCT05077878||mild to moderate|Patients with orthodontic treatment and have mild to moderate root resorption
89641368|NCT05077878||severe|Child patients with non-orthodontic treatment and have severe root resorption
89641369|NCT05077644|Other|Participants who use Stella App|Participant experience in using the mobile application and EPDS results
89641370|NCT03140904|Other|Standard weekly visits|Standard weekly visits at the outpatient therapeutic feeding center until discharge
89042988|NCT03052127|Experimental|Single High Dose Light-activated AU-011 x 2 lasers|High dose Light-activated AU-011 followed by two laser light applications
89641371|NCT03140904|Other|Monthly visits|Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge
89641372|NCT03110952|Experimental|TDENV-PIV x2|2 doses of TDENV-PIV on Day 0 and Day 28
89641373|NCT03110952|Experimental|TDENV-F17/TDENV-PIV|1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
89641374|NCT03110952|Experimental|TDENV-PIV/TDENV-F17|1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
89641375|NCT03110952|Placebo Comparator|Placebo|2 doses placebo (phosphate buffered saline) Day 0 and Day 28
89641376|NCT03143400|Active Comparator|Healthy volunteers|Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
89641377|NCT03143400|Active Comparator|Ileostomized patients|Ileostomized patients will only take a unique dose of each probiotic. Each intake of a different probiotic will be separated from another by a 14-day wash-out period at least.
89641378|NCT03143244|Active Comparator|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
89641379|NCT03143244|Active Comparator|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
89641380|NCT03143244|Placebo Comparator|Control group (Normal Saline) (C)|Patients received same volume of normal slaine in two sets.
89641381|NCT02328222|No Intervention|CONTROL GROUP|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
89641382|NCT02328222|Experimental|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
89641383|NCT03838692|Experimental|Ponatinib Arm|Ponatinib tablets will be taken by mouth, continuously, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment can be taken with water, with or without food, at approximately the same time each day.
89641384|NCT03505944|Experimental|Treatment|Venetoclax+lenalidomide+rituximab
89641385|NCT05071950|Other|14 days continuous glucose monitoring|The participants started and completed the control period for continuous 7 days and followed with D-allulose period for 7 days
89641386|NCT01489189|Experimental|Anti-VEGF+Deferred PRP|Anti-VEGF= Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
89641387|NCT01489189|Active Comparator|Prompt PRP|PRP= Panretinal Photocoagulation. PRP alone.
89641388|NCT01549873|Active Comparator|Total intravenous anesthesia (TIVA)|
89641389|NCT01549873|Active Comparator|Inhaled anesthesia|
89641390|NCT01489111|Experimental|Surgery|
89641391|NCT04106401|Experimental|hypoxia & confinement|Participants exposed to high-altitude hypoxia and confinement during a one-year stay at Concordia station, Antarctica (3200 m)
89641392|NCT04106401|Active Comparator|confinement|Participants exposed to confinement during a one-year stay at Dumont d'Urville station, Antarctica (sea level)
89641393|NCT03871075|Experimental|IPC + exercise|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be helped to engage in home-based walking exercise therapy.
89641394|NCT03871075|Experimental|"IPC + no exercise control"|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be asked to participate in an educational/informational intervention consisting of an attention control intervention
89042989|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011|3 repeat high doses of Light-activated AU-011 each followed by a single laser light application
89042990|NCT03052127|Experimental|3 Repeat High Dose Light-activated AU-011 x 2 lasers|3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
89641395|NCT03871075|Active Comparator|sham control + exercise|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants in this group will be helped to engage in home-based walking exercise therapy.
89641396|NCT03871075|Active Comparator|"sham control + no exercise control"|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants will be asked to participate in an educational/informational intervention, designed as an attention control group.
89641397|NCT01488487|Experimental|Everolimus + pasireotide|Oral Everolimus 7.5 mg administered daily for 28 days per cycle, plus pasireotide Long Acting Release (LAR) 60 mg administered by intramuscular injection once per 28 day cycle on day 1.
89641398|NCT01488097|Experimental|Open-Label Sebelipase Alfa|Participants were administered sebelipase alfa once weekly (qw) as an intravenous (IV) infusion at the same dose received in Study LAL-CL01 (0.35, 1, or 3 milligrams per kilogram [mg/kg]) for 4 weeks. After the initial 4 qw doses, participants transitioned to dosing every other week (qow) at either 1 mg/kg (participants who initiated treatment at 0.35 or 1 mg/kg qw) or 3 mg/kg (participants who initiated dosing at 3 mg/kg qw). Subsequent modifications to the dose and dosing frequency were permitted for individual participants based on observed safety, tolerability, and clinical response to treatment. Participants could continue to receive treatment with sebelipase alfa for up to 5 years.
89641399|NCT03027115|Experimental|Treatment|treatment with a selective alpha1-adrenoceptor antagonist
89212298|NCT00860444|Active Comparator|1|Participants will take part in the basic educational and counseling program through their community health care center.
89641400|NCT03027115|No Intervention|Control|no treatment
89641401|NCT03026881|Experimental|Fluzoparib + Apatinib + Paclitaxel|
89641402|NCT01516879|Experimental|Evolocumab|Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
89641403|NCT01516879|Placebo Comparator|Placebo|Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
89641404|NCT01515865|Experimental|Midodrine HCl|
89641405|NCT01515865|Placebo Comparator|Placebo|
89641406|NCT01547299|Experimental|Enzalutamide alone|Enzalutamide 160 mg, orally, once daily
89042991|NCT03052127|Experimental|Expansion 3 Repeat High Dose Light-activated AU-011 x 2 lasers|Expansion of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications (up to 12 additional subjects)
89042992|NCT03052127|Experimental|Observation until Documented Growth of Tumor|Observation until documented growth of tumor and then treatment with 2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
89042993|NCT03052127|Experimental|2 Cycles of 3 Repeat High Dose Light-activated AU-011x2 lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications
89042994|NCT03052127|Experimental|Exp: 2 Cycles 3 Repeat High Dose Light-activatedAU-011x2lasers|2 cycles each of 3 repeat high doses of Light-activated AU-011 each followed by two laser light applications in subjects with evidence of documented tumor growth prior to study entry
89042995|NCT03020199|Experimental|Arm A1 (A1a and A1b): new-onset plaque psoriasis to be treated with secukinumab|80 patients (68 in Arm A1a and 12 in Arm A1b) with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 48 inclusive (treatment duration = 52 weeks).
89042996|NCT03020199|Active Comparator|Arm B1 (B1a and B1b): new-onset plaque psoriasis to be treated with nb-UVB|80 patients (68 in Arm B1a and 12 in Arm B1b) with new-onset psoriasis will receive 1 or 2 cycles of nb UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 will not receive a second treatment cycle). Only during the first 4 weeks of each cycle, nb-UVB treatment should be applied in combination with topical calcipotriol 50 µg/g and betamethasone 0.5 mg/g (treatment duration = 52 weeks).
89042997|NCT03020199|Experimental|Arm A2: new-onset plaque psoriasis to be treated with secukinumab|Eligible patients with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3 and 4 and then every 4 weeks until Week 100 inclusive (last dose administered at Week 100) (treatment duration = 104 weeks).
89042998|NCT03020199|Experimental|Arm C1: chronic plaque psoriasis to be treated with secukinumab|Eligible patients with chronic plaque psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3 and 4 and then every 4 weeks until Week 48 inclusive (last dose administered at Week 48) (treatment duration = 52 weeks).
89212299|NCT00860444|Experimental|2|Participants will take part in the comprehensive educational and counseling program through their community health care center.
89641407|NCT01547299|Experimental|Enzalutamide & Leuprolide & Dutasteride|Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily
89641408|NCT01515475|Active Comparator|Glasses|Glasses are prescribed at enrollment and worn per protocol throughout the duration of the study.
89641409|NCT01515475|Placebo Comparator|Observation|Glasses will not be prescribed unless the patient has confirmation of one or more deterioration criteria as described in the protocol.
89641410|NCT00408603|Experimental|All study patients|All patients will receive voreloxin injection
89641411|NCT04072107|Experimental|Arm I|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy + capecitabine AC. All patients will receive concurrent cisplatin (100 mg/m2) every 3 weeks, in a total of three cycles. All patients will receive low-dose metronomic capecitabine (650 mg/m2 bid, oral, d1-21, q3w) until disease progression, or intolerable toxicity or 6 months.
89641412|NCT04072107|Experimental|Arm II|Patients receive GP IC + IMRT concurrent with cisplatin chemotherapy and anti-PD-1 therapy (sintilimab) + anti-PD-1 therapy (sintilimab) AC. All patients will receive concurrent cisplatin (100 mg/m2) and sintilimab (200 mg, IV drop 30-60 min) every 3 weeks in a total of three cycles. All patients will receive adjuvant anti-PD-1 therapy (sintilimab, 200 mg, IV drop 30-60 min, q3w) in a total of nine cycles until disease progression, or intolerable toxicity or 6 months.
89641413|NCT04013061||Standard consultation|
89641414|NCT04013061||Pharmacist-anesthesiologist consultation|
89641415|NCT05288049|Experimental|Intervention aiming to enhance cognitive reserve (CR)|The psychological intervention to enhance cognitive reserve (CR) will be conducted in a group format (6-8 individuals). Each session will last approximately 60 minutes. The full psychological intervention will have 12 sessions (1 per week) and will last three months. Moreover, to remind the participants of the contents of the intervention, a follow-up session will be held every two months between the last session of the psychological intervention and the 12-month assessment. Most of the tasks of the psychological intervention will use pen and paper with audiovisual support. However, some sessions will use mobile apps and virtual reality. Virtual reality will be implemented for each patient in the sessions focusing on mindfulness training. The contents of the sessions are adapted to the different ages of the attendees. Groups with adolescents and those with young adults will be run separately.
89641416|NCT05288049|Active Comparator|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention. After the 12-month assessment, subjects in the support group will be offered the intervention although this will be out of the scope of this study.
89641417|NCT00409539|Placebo Comparator|1|Placebo run-in phase. 2 week duration.
89641418|NCT00409539|Placebo Comparator|2|To be taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
89641419|NCT00409539|Experimental|3|20mg dose of SMP-986 to be taken once daily for 8 week duration.
89641420|NCT00409539|Experimental|4|40mg dose of SMP-986 to be taken for 8 week duration.
89641421|NCT00409539|Experimental|5|80mg dose of SMP-986 to be taken for 8 week duration.
89641422|NCT00409539|Experimental|6|120mg dose of SMP-986 to be taken for 8 week duration.
89641423|NCT00411411|Placebo Comparator|Placebo|Placebo treatment, administered as tablets.
89641424|NCT00411411|Experimental|Januvia|Active treatment
89641425|NCT05287815||1|experimental(30 people) groups health education will be given by making a home visit
89641426|NCT05287815||2|control(30 people) no intervention
89641427|NCT05287659|Experimental|VLCKD group|patients followed a structured VLCKD protocol (800Kcal/die)
88991652|NCT04460326|Active Comparator|Group 1 insulin glargine and Novolog|Group 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal blood glucose (BG) is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care.
88991653|NCT04460326|Experimental|Group 2 insulin glargine and Fiasp|Group 2 will receive basal insulin glargine as dosed in Group 1. Meal insulin Fiasp dosing will be calculated the same way as Novolog dosing. If the premeal BG is ≥ 150 mg/dL, additional Fiasp will be administered based off the correctional scale at the same time as the prandial insulin.
89641428|NCT05287659|Active Comparator|VLCKD and Physical Training group|patients followed a structured VLCKD protocol (800Kcal/die) combined with interval training (IT), two times a week
89641429|NCT05287659|Active Comparator|LCD and Leucine supplementation group|patients followed a LCD regimen (1000 kcal/day) with supplementation of 18 g whey proteins which 4.1 g of leucine
89641430|NCT02107599|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.
89641431|NCT01794273|Experimental|ephedrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
88991655|NCT04446910|Experimental|SMS Text Messaging|SMS text messaging intervention for a period of 90 days to encourage attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.
89641432|NCT01794273|Experimental|phenylephrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
89641433|NCT02109939|Active Comparator|GeneSight Psychotropic Tested|Subjects being tested with GeneSight Psychotropic
89641434|NCT02109939|Placebo Comparator|Treatment As Usual|This group of subjects will not see their GeneSIght results or know whether or not they are in either arm until after week 12.
89641435|NCT01795599|Experimental|mifepristone/misoprostol|
88991656|NCT04446910|Active Comparator|Standard of Care Engagement Practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
88991657|NCT04439006|Experimental|Arm A (ibrutinib)|Patients receive ibrutinib PO QD on days 1-7. Treatment repeats every 7 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients who remain hospitalized or are re-admitted after 2 cycles may receive an additional 2 cycles per physician's discretion.
88991658|NCT04439006|Active Comparator|Arm B (usual care)|Patients receive usual care.
88991659|NCT04429217|Experimental|Arm-A|experimental post-operative rehabilitation intervention consisting in immediate weight-bearing
88991660|NCT04429217|Active Comparator|Arm-B|control post-operative rehabilitation intervention consisting in delayed weight-bearing
88991661|NCT04422249|Experimental|laparoscopic middle hepatic vein guidance hemihepatectomy|In theory, the advantages of anatomical hemihepatectomy guided by middle hepatic vein are as follows: 1) correctly guiding the transecting plane of the liver parenchyma can reduce the cross-sectional area of the liver and avoid damaging the vascular ducts of the pre-cut liver. so as to reduce the residue of necrotic tissue without blood supply and reduce the occurrence of postoperative complications. 2) active anatomy and exposure of hepatic vein can avoid uncontrollable bleeding after passive injury of hepatic vein, and laparoscopic anatomy has obvious advantage in exposing hepatic vein. 3) it may reduce the early recurrence rate of hepatocellular carcinoma after operation.
89212300|NCT00860522|Experimental|Phase I|Three patients will be enrolled at dose Level 1. If the patient does not completed the three infusion of JVRS-100 during cycle 1 for reason other than toxicity, another patient will be accrued at the same dose level.
89641436|NCT01795599|Active Comparator|misoprostol|
89641437|NCT01795599|Active Comparator|mifepristone|
89641438|NCT01794351|Experimental|Placebo then resveratrol|Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
89641439|NCT01794351|Experimental|Resveratrol then placebo|Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits
89641440|NCT01515319|Experimental|2mg Y242 (Part A)|Y242 single dose, subcutaneous
89641441|NCT01515319|Experimental|7.5mg Y242 (Part A)|Y242 single dose, subcutaneous
89641442|NCT01515319|Experimental|15mg Y242 (Part A)|Y242 single dose, subcutaneous
89641443|NCT01515319|Experimental|30mg Y242 (Part A)|Y242 single dose, subcutaneous
89641444|NCT01515319|Experimental|60mg Y242 (Part A)|Y242 single dose, subcutaneous
89641445|NCT01515319|Experimental|90mg Y242 (Part A)|Y242 single dose, subcutaneous
89641446|NCT01515319|Placebo Comparator|Placebo - Part A|0.9% saline
89641447|NCT01515319|Experimental|60mg Y242 (Part B1)|Y242 single subcutaneous dose, administered once a week for 5 weeks
89641448|NCT01515319|Experimental|90mg Y242 (Part B2-B4)|Y242 single subcutaneous dose, administered once a week for 5 weeks
89641449|NCT01515319|Placebo Comparator|Placebo - Part B|0.9% saline
89641450|NCT02110095|Experimental|Picosure Laser System|Picosure Laser System for the treatment of unwanted tattoos
89641451|NCT04409431|Experimental|Adrenal Artery Ablation|Patients in the Intervention group will be treated with endovascular chemical ablation of adrenal gland by endovascular injection of dehydrated alcohol.
89641452|NCT04409431|No Intervention|Spironolactone|Patients in this group will be treated with aldosterone 20-80mg daily according to blood pressure
89641453|NCT01794507|Experimental|ABT-199 + BTZ/Dex Dose Escalation Cohorts|Evaluate the safety and pharmacokinetics profile of ABT-199 administered with standard therapy bortezomib and dexamethasone in a dose escalation scheme in approximately 54 subjects.
89641454|NCT01794507|Experimental|ABT-199 + BTZ/Dex Safety Expansion Cohort|Safety expansion cohort to further evaluate recommended phase two dose (RPTD) of ABT-199 administered with standard therapy bortezomib and dexamethasone in approximately 12 subjects.
89641455|NCT00412425|Active Comparator|2 Days Palonosetron|2 Days Palonosetron 0.25 mg intravenous (IV)
89641456|NCT00412425|Active Comparator|3 Days Palonosetron|3 Days Palonosetron 0.25 mg IV
89641457|NCT01492361|Experimental|AMR101|AMR101 (icosapent ethyl) + statin therapy, daily
89641458|NCT01492361|Placebo Comparator|Placebo|Placebo + statin therapy, daily
89641459|NCT00415857|Experimental|PR1 + Imatinib|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Continue receiving imatinib by mouth at the same dose received during the last 6 months. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
89042999|NCT03020199|Experimental|Arm C2: chronic plaque psoriasis to be treated with secukinumab|Eligible patients with chronic plaque psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3 and 4 and then every 4 weeks until Week 100 inclusive (last dose administered at Week 100) (treatment duration = 104 weeks).
89641460|NCT00415857|Experimental|PR1 + Imatinib + Interferon|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
89641461|NCT03586635||Patients with Multiple Sclerosis|
89641462|NCT03529071|Experimental|CKD-Question Prompt Sheet|Study participants will receive the CKD-QPS.
89641463|NCT03529071|No Intervention|Control|Individuals will not receive any intervention or surveys.
89641464|NCT03491631|Experimental|2 drugs combination group|
89641465|NCT03491631|Experimental|3 drugs combination group|
89641466|NCT01794585|Experimental|Virtual Reality Based Exercise|
89641467|NCT01794585|Active Comparator|Standard Exercise|
89641468|NCT03464175|Active Comparator|Heated-humidifier left on during nebulization|
89641469|NCT03464175|Active Comparator|Heated-humidifier turned off 30 minutes before nebulization|
89641470|NCT03464175|Active Comparator|Use of a heat and moisture exchanger (HME) filter|
89641471|NCT03464175|Active Comparator|Use of a dry ventilator circuit specific for aerosol therapy|
89043000|NCT03008291||Heart Failure Group|Patients who have any QRS duration and left ventricular ejection fraction (LVEF) ≤ 50% will be enrolled in this arm. The primary care physician will have recommended either PM, CRT-D Implantation, CRT-P Implantation, HIBP or LBAP (including HIBP/LBAP for patients with HF, for patients who have failed CRT implant or patients who are CRT non-responders) . (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
89043001|NCT03008291||Atrioventricular Block/Bradycardia Group|Patients who have developed second or third degree atrioventricular block (AV block) or bradycardia will be enrolled in this arm. The primary care physician will have recommended dual chamber pacemaker implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
89043002|NCT03001414|Experimental|Placebo followed by Autologous EPCs transfected with eNOS|4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2
89043003|NCT03001414|Experimental|Autologous EPCs transfected with eNOS followed by Placebo|4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2
89043004|NCT03001414|Experimental|Autologous EPCs transfected with eNOS|4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)
89641472|NCT03442335||Recurrent miscarriage: 2+ miscarriages|Women who suffered 2 or more unexplained recurrent miscarriages.
89641473|NCT03442335||Extreme recurrent miscarriage: 5+ miscarriages|Women who suffered 5 or more unexplained recurrent miscarriages.
89641474|NCT00416793|Experimental|Treatment|Patients receive bortezomib IV on days 1, 4, 8, and 11 and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89641475|NCT00417417|Experimental|Rilonacept|Rilonacept 320 mg subcutaneous at each treatment visit
89641476|NCT00417417|Sham Comparator|Placebo|Normal saline subcutaneously at each treatment visit.
89641477|NCT05286723|Experimental|Multicomponent Training|"Traditional training. 3 times a week~Warm-up:~Main work:~Aerobic training Strength training Balance and coordination training Return to calm"
89641478|NCT00418977|Experimental|Family Based Therapy|Participants will receive family based therapy (FBT)
89641479|NCT00418977|Active Comparator|Individual Supportive Psychotherapy|Participants will receive individual supportive psychotherapy (ISP)
89641480|NCT05286645|Active Comparator|real stimulation|Participants will receive active tDCS once daily for two weeks. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes each day over 14 consecutive sessions.
89641481|NCT05286645|Placebo Comparator|sham stimulation|Participants will receive sham tDCS once daily for two weeks. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
89641482|NCT04271631|No Intervention|Control|Received conventional education group
89641483|NCT04271631|Experimental|Intervention 1|Received conventional education group and Mobile Application-Based Diabetes Education
89641484|NCT04271631|Experimental|Intervention 2|Received Mobile Application-Based Diabetes Education and Health Coaching
89641485|NCT02539563|Active Comparator|peanut ball|the peanut shaped birthing ball after labor analgesia will be utilized
89641486|NCT02539563|No Intervention|no peanut ball|the peanut shaped birthing ball will not be utilized during labor
89641487|NCT00419445|Active Comparator|GTS21 25 mg tid/Placebo 25 mg tid|
89641488|NCT00419445|Active Comparator|GTS21 75 mg tid/Placebo 75 mg tid|
89641489|NCT00419445|Active Comparator|GTS21 150 mg tid/Placebo 150 mg tid|
89641490|NCT00420147|Experimental|Wedged Orthosis|Subjects were given a wedged inshoe orthosis
89641491|NCT00420147|Placebo Comparator|Neutral Orthosis|Subjects were given a neutral inshoe orthosis.
89641492|NCT05286489|Experimental|group A|Qigong exercise program twice weekly for 8 weeks postmastectomy in addition to traditional medical and physical therapy treatment.
89641493|NCT05286489|Other|group B|traditional medical and physical therapy treatment only .
89641494|NCT00420459|Experimental|Aripiprazole|
89641495|NCT01514461|Experimental|LCQ908 20 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
89641496|NCT01514461|Experimental|LCQ908 40 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
89641497|NCT01514461|Placebo Comparator|Placebo|"In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
89641498|NCT00420771|Experimental|Gabapentin|gabapentin treatment 1200 mg three times daily
89641499|NCT00420771|Placebo Comparator|Placebo|Placebo condition received pills identical in appearance to experimental arm.
89641500|NCT00426153|Active Comparator|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
89641501|NCT00426153|Placebo Comparator|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
89641502|NCT01793415|Active Comparator|IodoCarb (r)|3 g iodinated activated charcoal, IodoCarb(r), daily for 28 +-2 days.
89641503|NCT01793415|Placebo Comparator|Placebo|3 g of non-iodinated activated charcoal daily for 28+-2 days.
89641504|NCT04750317|Experimental|Patients with reduced oxygen saturation ≤93% treated with tofacitinib|Patients with oxygen saturation ≤93% on admission treated with tofacitinib and standard of care treatment
89641505|NCT04750317|No Intervention|Patients with reduced oxygen saturation treated with SoC|Patients with oxygen saturation ≤93% on admission treated with standard of care only
89641506|NCT04750317|Experimental|Patients with preserved oxygen saturation >93% on admission treated with tofacitinib|Patients with oxygen saturation >93% on admission treated with tofacitinib and standard of care
89641507|NCT04750317|No Intervention|Patients with preserved oxygen saturation >93% on admission treated with SoC|Patients with oxygen saturation >93% on admission treated with standard of care only
89641508|NCT01996449|Active Comparator|Initial treatment with Amlodipine|The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
89641509|NCT01996449|Active Comparator|Initial treatment with Eplerenone|The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
89641510|NCT00426855|Experimental|Bendamustine and Bortezomib|Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section
89212301|NCT00860522|Experimental|Phase II|3 patients will be enrolled at a given dose level. If one of these patients experiences a dose limiting toxicity, an additional 3 patients will be enrolled at the given dose level. If the 1st 2 subjects enrolled and treated at a given dose experience dose limiting toxicities, no additional subjects will be enrolled at that dose. Dose escalation may proceed if < 2/6 patients at a given dose level experience a LDT. If ≥ 2/6 patients experience a DLT at a given dose level, the next lower dose level will be considered the RP2D. If a patient does not complete the 3 infusions of JVRS-100 during Cycle 1 for reasons other than toxicity, another patient will be accrued at the same dose level. Once the RP2D is established, the cohort will be expanded to a total of 12 patients.
89641511|NCT01491737|Experimental|Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy|"Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
89212302|NCT00850694||1|Obese female adolescents
89641512|NCT01491737|Active Comparator|Arm B: Trastuzumab + AI +/- Chemotherapy|"Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
89641513|NCT00427557|Experimental|Cellular Therapy with Cord Blood Cells|Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion
89641514|NCT01487863|Experimental|Concurrent Arm|Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
89641515|NCT01487863|Experimental|Sequential Arm|Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
89641516|NCT04088305|Experimental|Study group|Patients of study group will accept vancomycin strategies decided by a serum trough concentration model.
89641517|NCT04088305|No Intervention|Control group|Patients of control group will accept vancomycin dosages decided by attending physician.
89641518|NCT02982993||WTC responders participating in HCV infection study|Members of the World Trade Center Health Program cohort born from 1945 to 1965 who choose to participate in this research study on hepatitis C infection
89641519|NCT04088227|Active Comparator|Control Group|The control group will have a joint aspiration performed at an initial visit (within the first 10 days after injury), and at the time of surgery (within 4 weeks of injury).
89641520|NCT04088227|Experimental|Experimental Group|The experimental group will have a joint aspiration performed at an initial visit (within the first 10 days after injury) and receive an injection of leukocyte poor platelet rich plasma injection in their knee. At a second visit 5-12 days after the initial visit, the patient will receive a joint aspiration and platelet rich plasma injection. A final joint aspiration will be performed at the time of surgery (within 4 weeks of injury).
89641521|NCT04750629||SARS-Cov-2 RT-PCR AND CoviDx Rapid Antigen Testing|Sequentially enrolled symptomatic patients who present for COVID-19 testing and have a swab collected for high-sensitive, SARS-CoV-2 RT-PCR testing per Standard of Care AND a swab for CoviDx™ Rapid Antigen testing.
89641522|NCT00427791|Experimental|Etoposide + Total Body Irradiation + Rituximab|Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
89641523|NCT00427791|Experimental|Etoposide + Total Body Irradiation|Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days
89641524|NCT01487161|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
89641525|NCT01487161|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
89641526|NCT01487161|Experimental|FX006 60 mg|Single 3mL intra-articular (IA) injection Extended-Release Formulation
89641527|NCT01487161|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-Release Triamcinolone Acetonide
89641528|NCT00429507|Experimental|Samarium 153-EDTMP + Stem Cell Transplant|Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose. Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP. Questionnaires taking about 15 minutes to complete.
89641529|NCT01794897|Experimental|Valacyclovir treatment|Drug: Experimental: Valacyclovir treatment. Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either Valacyclovir (VAV) or placebo (PLA) group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
89641530|NCT01794897|Placebo Comparator|Placebo|Placebo comparator: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
89641531|NCT01795755|Experimental|Treat as usual + Horse assisted therapy ( HAT)|Treatment as usual means mentalization based inpatient treatment. Horse assisted therapy(HAT) is a structured program of 12 X 90 minute sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists.
89641532|NCT01795755|Active Comparator|Treatment as usual|Treatment as usual means mentalization based inpatient treatment.
89043005|NCT02991469|Experimental|Sarilumab|Participants will receive one of two ascending doses (or an additional intermediate dose based on available data) of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose once the selected dose is identified. Sarilumab will be given during 12-week core treatment phase followed by a 144- week extension treatment phase.
89641533|NCT00371631|Other|Arm 1|insertion of E. coli coated catheter
89641534|NCT00372957|Placebo Comparator|Placebo|Participants received two capsules of matching placebo orally once daily in the morning with 150 milliliter (mL) of water at least 15 minutes prior to breakfast for 7 Days.
89641535|NCT00372957|Experimental|GW823093C 15 mg|Participants received one 15 milligrams (mg) of GW823093C capsule and one placebo capsule orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
89641536|NCT00372957|Experimental|GW823093C 30 mg|Participants received 30 mg (2x15 mg) of GW823093C capsules orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
89043006|NCT02978521|Experimental|Intervention Group|"Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:~12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill."
89043007|NCT02978521|No Intervention|Control Group|CG will receive information and recommendations on physical activity
89212303|NCT02544386||Patients|Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan
89212304|NCT04041362|Active Comparator|Arm1 (Standard ART)|Standard ART
89641537|NCT00373269||Diabetic subject|Subjects with acute stroke, hyperglycemia and history of diabetes.
89641538|NCT00373269||Normoglycemic Control|Subjects with acute stroke and normal blood glucose.
89641539|NCT01794975|Active Comparator|Ketamine|Ketamine will be administered intravenously using a pseudo steady state infusion approach with a target plasma concentration of 300 ng/ml starting 15 minutes before the PET scan and continued throughout the scan.
89641540|NCT01794975|Active Comparator|Atomoxetine and the cold pressor test|An oral dose of approximately 1.2 mg/kg (range, 1.12-1.26 mg/kg) of atomoxetine is administered 1 h before the PET scans. A cold pressor test is employed as a physiological noradrenergic stimulus. The subject's foot is placed in a 8 °C water basin for the duration of the PET scan.
89641541|NCT01794975|Placebo Comparator|Placebo|Placebo capsules are given to mimic the atomoxetine treatment at each treatment visit except the atomoxetine visit. A baseline PET scan with [11C]ORM-13070 will be performed for all subjects with the placebo treatment only.
89641542|NCT01795989||Healthy Volunteers|Research only musculoskeletal (MSK) MRI for healthy volunteers.
89641543|NCT01795989||Clinical Efficacy|Clinically indicated musculoskeletal (MSK) MRI with sequences obtained using this pediatric elbow coil.
89641544|NCT05286021||Supine group|Children undergoing surgery in the supine position using the Ambu Auragain
89641545|NCT05286021||Prone group|Children undergoing surgery in the prone position using the Ambu Auragain
89641546|NCT05285787|Experimental|EPN-701, 10mg orally daily over 14 days|Single arm
89641547|NCT01491035|Experimental|Cohort CC1, 6 children|
89641548|NCT01491035|Experimental|Cohort CC2, 6 children|
89641549|NCT01491035|Experimental|Cohort CC3, 6 children|
89641550|NCT01491035|Experimental|Cohort CC4, 6 children|
89641551|NCT01491035|Experimental|Cohort AC1, 6 adolescents|
89641552|NCT01491035|Experimental|Cohort AC2, 6 adolescents|
89641553|NCT01491035|Experimental|Cohort AC3, 6 adolescents|
89641554|NCT01491035|Experimental|Cohort AC4, 6 adolescents|
89641555|NCT00375999|Experimental|docetaxel and epirubicin|salvage docetaxel and epirubicin
89641556|NCT04748315|Experimental|SEMT(1:1)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:1.
89641557|NCT04748315|Experimental|SEMPT(1:3)|Participants in this arm will perform an a speed endurance maintenance training consisted of work to rest ratio 1:3.
89641558|NCT04748315|No Intervention|Control|Participants in this arm will receive no intervention
89043008|NCT02967692|Experimental|Part 1: Safety run-in Cohort|In Part 1, participants are treated at different dose levels to determine the recommended Phase 3 regimen of spartalizumab in combination with dabrafenib and trametinib. The starting dose of spartalizumab is 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD).
89043009|NCT02967692|Experimental|Part 2: Biomarker cohort|In Part 2, participants are treated with spartalizumab 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD).
89043010|NCT02967692|Experimental|Part 3- Arm 1: Spartalizumab in combination with dabrafenib and trametinib|In Part 3, participants are randomized to receive spartalizumab at the RP3R identified in Part 1 (400 mg Q4W) in combination with approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD)
89043011|NCT02967692|Placebo Comparator|Part 3- Arm 2: Placebo in combination with dabrafenib and trametinib|In Part 3, participants are randomized to receive matching placebo in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD)
89212305|NCT04041362|Experimental|Arm 2 (ART plus UB-421)|ART plus weekly UB-421 IV infusion at 5 mg/kg dose level for 16 weeks
89641559|NCT04409327|Experimental|10 mg daily RTB101|TORC1 inhibitor
89641560|NCT04409327|Placebo Comparator|Placebo|Placebo
89641561|NCT01488071|Experimental|Vortioxetine 10 mg or 20 mg|
89641562|NCT01488071|Active Comparator|Agomelatine 25 mg or 50 mg|
89641563|NCT01487525|Placebo Comparator|PBFR-|double leg press without application of partial blood flow restriction to the upper leg
89641564|NCT01487525|Experimental|PBFR+|double leg press with application of partial blood flow restriction to the upper leg
89641565|NCT01486199|Experimental|CF pediatric|In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.
89641566|NCT01486199|Experimental|Controls adult|In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.
89641567|NCT01485887|Experimental|Venlafaxine ER|
89641568|NCT01546519|Experimental|1|Control cohort with normal renal and normal hepatic function
89641569|NCT01546519|Experimental|2|Severe renal impairment and normal hepatic function
89641570|NCT01546519|Experimental|3|Mild hepatic impairment and normal renal function
89641571|NCT01546519|Experimental|4|Moderate hepatic impairment and normal renal function
89641572|NCT01546519|Experimental|5|Severe hepatic impairment and normal renal function
89641573|NCT01484951|Experimental|AZARGA|Brinzolamide 1% and timolol 0.5% fixed combination eye drops, one drop administered to the study eye(s) twice daily (8:00 am and 8:00 pm) for up to 8 weeks.
89641574|NCT01484873|Experimental|Exenatide|All patients received exenatide 10mcg BID x 50 weeks
89641575|NCT01486927|Experimental|Recombinant Factor VIII (rFVIII)|
89641576|NCT00376935|Placebo Comparator|1|Participants will receive palifermin placebo injection on Days 1, 2, and 3
89641577|NCT00376935|Experimental|2|Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3
89641578|NCT00376935|Experimental|3|Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3
89641579|NCT00376935|Experimental|4|Participants will receive palifermin 60 mcg/kg injection on Days 1, 2, and 3
89641580|NCT04656925|Experimental|Contingency management A-B-A|All participants will be assigned a single arm where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods.
89641581|NCT04767451||Premature ovarian insufficiency (POI)|POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and low estradiol.
89641582|NCT04767451||Control group|The study population will consist of 50 women with POI as a study group and 50 patients with normal healthy women as a control group. A volunteer group of healthy women who will be visited the gynecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
89641583|NCT00379197|Experimental|Naltrexone|Naltrexone 50 mg will be taken orally once a day every day of a 28 day treatment course (cycle 1) and continue for another identical 28 day treatment (cycle 2) . PET scan will be performed after cycle 1 and cycle 2 complete.
89641584|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Interv.|Participants are randomized to motivational and family weight loss program plus the online intervention.
89641585|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Control|Participants are randomized to motivational and family weight loss intervention and then the online control program.
89641586|NCT01796067|Experimental|Basic Health Educ. & Online Interv.|Participants are randomized to the basic health education program and then the online intervention program.
89641587|NCT01796067|Active Comparator|Basic Health Educ. & Online Control|Participants are randomized to the basic health education program and then to the online control program.
89641588|NCT01513759|Experimental|EkoSonic® Endovascular System|Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.
89641589|NCT01484561|Active Comparator|Sequence 1|
89641590|NCT01484561|Placebo Comparator|Sequence 2|
89641591|NCT01546207|Other|catheter-based ablation|catheter ablation - a medical procedure used to treat some types of arrhythmia
89641592|NCT01513291|Experimental|MK-6096|Participants were randomized to receive double-blind MK-6096, two 5 mg tablets (10 mg dose), orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period were randomized 1:1 to receive double-blind MK-6096 or placebo once daily in the 2-week Run-out Period.
89641593|NCT01513291|Placebo Comparator|Placebo|Participants were randomized to receive double-blind placebo, two tablets, orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period continued to receive double-blind placebo once daily in the 2-week Run-out Period.
89641594|NCT01483937|Active Comparator|Usual care physical therapy only|Subjects will receive usual care physical therapy intervention provided by vestibular and balance specialists. Usual care physical therapy, in general, includes but is not limited to static and dynamic balance activities with or without head movements on firm floor or compliant surfaces.
89641595|NCT01483937|Experimental|Usual care physical therapy plus SEMD|"Subjects will receive usual care physical therapy intervention provided by vestibular balance specialists while using the Sensory Enrichment Multimodal Device (SEMD). SEMD protocols use visual, vibrotactile, and auditory cueing referenced to subject's Center of Gravity (COG) and/or Sum of Pressure (SOP) data collected from a force platform upon which the subject is placed. Static and dynamic balance activities with or without head movement are preformed while watching a computer screen; paced with an auditory metronome; and cued by touch vibration via coin tactors imbedded in a belt worn around the waist matching the COG/SOP data display."
89641596|NCT01483625|Experimental|tiotropium 18mcg|active
89641597|NCT01483625|Placebo Comparator|Placebo|placebo
89641598|NCT01485991|Experimental|TMC435/PR|
89641599|NCT01485991|Active Comparator|TVR/PR|
89641600|NCT00379821|Experimental|CQ Monotherapy|N=160: treat with Chloroquine (CQ) alone.
88991662|NCT04422249|Active Comparator|laparoscopic traditional anatomic hemihepatectomy|According to textbooks and the views of some scholars at present, traditional anatomical hepatectomy (non-hepatic vein-guided anatomical hepatectomy) has the following advantages: 1) avoiding exposure of hepatic vein can reduce the probability of injury to the trunk of hepatic vein, thus reduce the risk of massive bleeding during operation; 2) the difficulty of operation is relatively low, and a better short-term and long-term effect can be obtained.
88991663|NCT04405778|Experimental|TAK-102 Cohort 1|TAK-102, 1 × 10^7 Chimeric antigen receptor (CAR) (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 60 minutes.
89641601|NCT00379821|Experimental|CQ plus atovaquone proguanil|N=160: treat with CQ plus atovaquone proguanil.
89641602|NCT00379821|Experimental|CQ plus artesunate|N=160: treat with CQ plus artesunate.
89641603|NCT00379821|Experimental|CQ plus azithromycin|N=160: treat with CQ plus azithromycin.
89641604|NCT01482767|Experimental|HCV Treatment-Naive (Group A)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
89641605|NCT01482767|Experimental|HCV Treatment-Experienced (Group B)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
88991664|NCT04405778|Experimental|TAK-102 Cohort 2|TAK-102, 1 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 60 minutes.
88991665|NCT04405778|Experimental|TAK-102 Cohort 3|TAK-102, 1 × 10^9 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min and completed within 60 minutes.
88991666|NCT04401059|Experimental|Elemene plus First or Third generation EGFR-TKIs|Elemene Injectable Emulsion sequentially with Elemene Oral Emulsion plus First -generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib) or Third-generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib).
88991667|NCT04401059|Active Comparator|First or third generation EGFR-TKIs only|First-generation EGFR-TKIs (Gefitinib,Erlotinib, Icotinib) or third-generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib).
88991668|NCT04398485|Experimental|ION251|In Part 1, the dose escalation phase, increased amounts of ION251 will be administered at multiple time points by intravenous (IV) infusion during 28-day cycles. In Part 2, the determined RP2D of ION251 will be administered at multiple time points by IV infusion.
88991669|NCT04397432||Elemene plus TKIs|This is a real-world study, we just record the patient's medication who used Elemene Injectable Emulsion and/or Elemene Oral Emulsion plus TKIs. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
88991670|NCT04397432||TKIs only|This is a real-world study, we just record the patient's medication who used TKIs only. First, second or third generation TKIs were all available, such as Erlotinib, Gefitinib, Icotinib, Afatinib, Dacomitinib, and Osimertinib.
89043012|NCT02953457|Experimental|Treatment (olaparib, tremelimumab, durvalumab)|Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
89043013|NCT02939573|Experimental|Stage 1|Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint is response to treatment at month 6 (stage 1).
89043014|NCT02939573|Experimental|Stage 2|If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
89043015|NCT02925416|Experimental|Oritavancin/Oritavancin|On Day 1, participants were administered a single 1200-mg IV dose of oritavancin in 1000 milliliters (mL) diluted in 5% dextrose in water (D5W). On Day 7, an additional 1200-mg IV dose of oritavancin in 1000 mL of D5W was administered.
89641606|NCT00435591|Experimental|Dose Regimen 1|Placebo loading dose + 20mg/day continuous infusion conivaptan per ampoule
89641607|NCT00435591|Experimental|Dose Regimen 2|Conivaptan loading dose (20mg)+ 20mg/day continuous infusion conivaptan per ampoule
89641608|NCT00435591|Experimental|Dose Regimen 3|Placebo loading dose + 20mg/day continuous infusion conivaptan per premix bag
89641609|NCT00435591|Experimental|Dose Regimen 4|Conivaptan loading dose (20mg) + 20mg/day continuous infusion conivaptan per premix bag
89641610|NCT05258331|Experimental|Single Arm|CT303
89641611|NCT05244681|Other|People with chronic non-specific neck pain|Group of people with chronic non-specific neck pain who agreed to participate in a semi-structured interview about their experience using an immersive virtual reality serious game at home
89641612|NCT05241795|Active Comparator|Group A: Knee exercises then Ankle exercises|Patients will receive a rehabilitation protocol starting with knee training followed by ankle training.
89641613|NCT05241795|Experimental|Group B: Ankle exercises then Knee exercises|Patients will receive a rehabilitation protocol starting with ankle training followed by knee training.
89641614|NCT01482221|Experimental|1|
89641615|NCT01482221|Experimental|2|
89641616|NCT01482221|Placebo Comparator|3|
89641617|NCT01482065|Experimental|CPAP|"Patients with moderate to severe apnea will be randomized to CPAP or deferred CPAP. Those in the CPAP group will be sent home with an autoset CPAP device, which they will be instructed to utilize for 4 months. The CPAP device will be set in the auto mode so that it will automatically adjust the pressure at night to eliminate upper airway obstruction during sleep.~Criteria for OSA severity are specifically designed to target patients with nocturnal hypoxemia, which is hypothesized to contribute to NAFLD progression. According to the guidelines of the American Academy of Sleep Medicine, apnea will be defined as cessation of airflow for ≥ 10 sec. and hypopnea will be defined as decreased airflow for ≥ 10 sec. leading to oxyhemoglobin desaturation ≥ 4%. Mild, moderate and severe OSA will be diagnosed by an Apnea-Hypopnea Index (AHI) of 5-14.9, 15-29.9, and ≥ 30 events/hr, respectively."
89641618|NCT04649879|Experimental|Convalescent plasma treatment|"Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions.~If steroid therapy has not already been initiated, betamethasone 3 mg daily will be given concomitantly with steroid therapy or longer if clinically indicated but for a maximum of 10 days."
89641619|NCT04649879|Active Comparator|Control|Standard of care for COVID-19 patients.
89641620|NCT00439335|Experimental|H5 HA IM|Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.
89641621|NCT00439335|Experimental|H5 HA ID|Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.
89641622|NCT01545817|Experimental|Pazopanib followed by everolimus|First line pazopanib, followed by second line everolimus
89641623|NCT04408781|Experimental|Ridge expansion by osseodensifcation|Ridge expansion and osteotomy drilling by osseodensifcation in conjunction with simultaneous implant placement in narrow ridges
89043016|NCT02925416|Other|Oritavancin/Placebo|On Day 1, participants were administered a single 1200-mg IV dose of oritavancin in 1000 mL of D5W. On Day 7, a placebo was administered IV in 1000 mL of D5W.
89043017|NCT02882074|Other|Human albumin|Human albumin 5% during surgery.
89043018|NCT02882074|Other|Hydroxyethyl starch|Hydroxyethyl starch 6% (130/0.4) solution during surgery
89641624|NCT04408781|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
89641625|NCT00382785|Experimental|moderated online support|12-week online support led by a healthcare professional
89641626|NCT00382785|Experimental|peer-led support|12-week online support group in a peer-led format
89641627|NCT01512979|Experimental|linagliptin|patients receive linagliptin tablet once daily
89641628|NCT01512979|Experimental|linagliptin plus metformin|patients receive linagliptin tablet once daily and metformin tablets twice daily
89641629|NCT00383565|Experimental|Arm I|Patients receive FR901228 IV over 4 hours on days 1, 8, and 15.
89641630|NCT01512745|Experimental|apatinib|
89641631|NCT01512745|Placebo Comparator|placebo|
89641632|NCT01478321|Experimental|Treatment (radiation, chemotherapy, monoclonal antibody)|"CONCURRENT THERAPY: Patients undergo hypofractionated radiation therapy 5 days a week beginning on day 0. Patients also receive temozolomide PO QD and bevacizumab IV over 30-90 minutes once every 2 weeks beginning on days -3 to 0. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity."
89212306|NCT02546102|Experimental|1|Arm 1 will receive ICT-107 in combination with the standard of care, temozolomide (TMZ). ICT-107 will be given once a week for 4 weeks in the induction phase. During the maintenance phase, ICT-107 will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
89212307|NCT02546102|Placebo Comparator|2|Arm 2 will receive TMZ with a blinded control. Control will be given once a week for 4 weeks in the induction phase. During the maintenance phase, Control will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
89212308|NCT00860678|Active Comparator|A|Training group
89212309|NCT00860678|Other|B|Controls
89212310|NCT00860756|Experimental|1|Intervention Group
89641633|NCT01544491|Experimental|Investigational arm|Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
89641634|NCT01544491|Active Comparator|Control arm|MMF continuation (in combination with tacrolimus and standard dose steroids)
89641635|NCT00383643|Placebo Comparator|Placebo|Eligible subjects randomized to this arm received placebo as gelatin capsule and a liquid capsule to fully maintain the blind.
89641636|NCT00383643|Active Comparator|Zolpidem tartrate|Eligible subjects randomized to this arm received zolpidem as gelatin capsule and a placebo liquid capsule to fully maintain the blind.
89641637|NCT00383643|Active Comparator|Sodium oxybate|Eligible subjects randomized to this arm received placebo as gelatin capsule and a sodium oxybate capsule to fully maintain the blind.
89641638|NCT01478087|Other|Mysorba(single-arm)|
89641639|NCT00439413|Active Comparator|Selegiline Transdermal Patch|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received Selegiline Transdermal System, 6mg -20cm(2) patch, one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
89641640|NCT00439413|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received matched placebo 20cm(2) patch transdermal patch one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
89641641|NCT01477853|Experimental|Sitagliptin/Sitagliptin + Atorvastatin|In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
89641642|NCT01477853|Active Comparator|Atorvastatin/Atorvastatin + Glimepiride|In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.
89641643|NCT01477853|Experimental|Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin|In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
89641644|NCT00384813|Experimental|1: Home-based family intervention|Home-based family intervention
89641645|NCT00384813|Active Comparator|2: ETAU|Enhanced Treatment As Usual (1 home visit)
89641646|NCT03026855|Experimental|Autologous PRP Gel and PRP Injection|Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
89641647|NCT03026699||Intervention - Primary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of primary brain tumor patients.
89641648|NCT03026699||Intervention - Secondary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of secondary brain tumor patients.
89641649|NCT03026699||Control - Primary Brain Tumor|Questionnaires Only Control: Family caregivers of primary brain tumor patients.
89212311|NCT00850772|Experimental|Early post-operative enteral feeding|Standard post-operative care and diet together with early post-operative enteral feeding
89212312|NCT00850772|No Intervention|Standard post-operative care and diet|Standard post-operative care and diet only
89212313|NCT00850850|Active Comparator|Physostigmine|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 mg of physostigmine.
89641650|NCT03026699||Control - Secondary Brain Tumor|Questionnaires Only Control: Family caregivers of secondary brain tumor patients.
89641651|NCT00440505|Placebo Comparator|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
89641652|NCT00440505|Experimental|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
89641653|NCT00440505|Experimental|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
89641654|NCT01796535||PerX360º System™|Patients treated with PerX360º System™
89641655|NCT01511419|Experimental|LAIV H7N3|"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.~Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.~Dose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.~Route of administration: Intranasal aerosol.~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28."
89641656|NCT01511419|Placebo Comparator|Placebo|"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.~Dose: 0.5 ml; 0.25 ml/nare~Route of administration: Intranasal aerosol~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28"
89641657|NCT00441285|Active Comparator|I. ABZ + ABZ Placebo + PZQ|Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)
89641658|NCT00441285|Active Comparator|II.- ABZ + ABZ Placebo + PZQ Placebo|Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )
89212314|NCT00850850|Placebo Comparator|NaCl|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo).
89212315|NCT00860834|Experimental|1|Pediatricians and parents of children with asthma will participate in the asthma coaching program.
89212316|NCT00860834|Active Comparator|2|Children of parents enrolled in the study will receive usual asthma care from their pediatrician.
89212317|NCT00860912|Experimental|Intervention: Collagen matrix|Cystocele repair: Veritas reinforcing material implanted for reinforcement of cystocele repair with collagen matrix
89212318|NCT00860912|Other|Native tissue repair|Intervention: Cystocele repair performed: No reinforcing material used and routine performance of a cystocele repair using native tissues.
89212319|NCT00860990||1|SCI or disabled
89212320|NCT00860990||2|Able-bodied
89521213|NCT03436927|Experimental|Balance Trainer|Participants in the Balance Trainer group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
89521214|NCT03436927|No Intervention|Control|Patients in the 'Group III-control group' were included in the waiting list until the end of the study.
89521215|NCT03433027|Experimental|BB-401|BB-401 Intratumoral injection
89521216|NCT04451239|Other|COVID-19 keratoconjunctivitis|cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
89521217|NCT04406935|Active Comparator|475 KHz|NuEra device treatment using 475 KHz
89521218|NCT04406935|Active Comparator|1 MHz|Arm 2: NuEra device treatment using 1 MHz
89521219|NCT04406935|Active Comparator|2 MHz|NuEra device treatment using 2 MHz
89521220|NCT03440671|Experimental|Hutox Inj|Hutox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
89521221|NCT03440671|Active Comparator|Botox Inj|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
89521222|NCT03440593|Experimental|Measured Arm|Patients allocated to the measured energy expenditure (group M) will receive the intervention. Caloric delivery will target results of IC measurement.
89521223|NCT03440593|No Intervention|Estimated Arm|Patients allocated to the estimated energy expenditure (group E) will receive nutrition with caloric intake calculated based on the Penn State equation.
89521224|NCT03440515|Experimental|prednisone|prednisone 30mg/day 3weeks oral, if on rash or pruritus prednisolone 20mg/day 3weeks -> 10mg/day->7.5mg/day->5mg/day->stop
89521225|NCT02521597|Experimental|Cellscope|The intervention for this study will be the use of a smartphone otoscope attachment called CellScope Oto.
89521226|NCT02521597|Active Comparator|Traditional otoscope|The control group will be using a classic otoscope
89521227|NCT03996967||BA Group|The bacterial group: Patients will be assorted to this group if he/she has a bacterial pathogen culture of fluid from a normally sterile site (e.g. blood, pleural fluid)
89521228|NCT03996967||VI Group|"The viral group: Patients will be assigned to this group if they have negative bacteria microbiological tests, negative malaria blood slides, X-rays without endpoint pneumonia, no evidence of fungal infection, and positive PCR for a viral pathogen from nasopharyngeal swabs."
89521229|NCT03996967||MA Group|The malarial group: Patients will be assigned to this group if they have normal X-rays, no bacterial infection and >0 asexual P. falciparum parasites if they are aged < 1 year, or > 2,500 asexual parasites/µl of blood if they are aged > 1 year
89521230|NCT03432793|Experimental|TD-9855 + Fluvoxamine + Caffeine|Male smokers will receive TD-9855, fluvoxamine, and caffeine
89521231|NCT03432793|Experimental|TD-9855 + Itraconazole + Caffeine|Male non-smokers will receive TD-9855, itraconazole, and caffeine
89521232|NCT05121025||Helicobacter pylori patients|Patients with gastric biposies which was positive for Helicobacter pylori in culture
89521233|NCT05121025||Helicobacter pylori asymptomatic carriers|Healthy controls who are positive for Helicobacter pylori antigen in stool and have no symptoms of gastritis
89521234|NCT05121025||Healthy controls|Healthy controls who are negative for Helicobacter pylori antigen in stool and have no symptoms of gastritis
89521235|NCT03436849|Experimental|ESN364 dose-1 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
89521236|NCT03436849|Experimental|ESN364 dose-2 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
89521237|NCT03436849|Placebo Comparator|Placebo group in Part 1|Healthy male subjects will receive a single dose of Placebo.
89521238|NCT03436849|Experimental|Male ESN364 group in Part 2|Healthy male subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
89521239|NCT03436849|Experimental|Pre-menopausal female ESN364 group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
89521240|NCT03436849|Experimental|Post-menopausal female ESN364 group in Part 2|Healthy post-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
89521241|NCT03436849|Placebo Comparator|Male placebo group in Part 2|Healthy male subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
89521242|NCT03436849|Placebo Comparator|Pre-menopausal female placebo group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
89521243|NCT03436849|Placebo Comparator|Post-menopausal female placebo group in Part 2|Healthy post-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
89043019|NCT02806843|Experimental|Stroke survivors and healthy subjects|Stroke survivors greater than 18 years of age with hemiplegia and varying levels of impairment as well as healthy subjects greater than 18 years old with no motor disabilities will be asked to interact with a therapist. The Patient-Therapist interactions will be recorded using the Rehab Intercap System and 3D Kinect Device.
89043020|NCT02771236||Participants with cataracts|Participants with cataracts
89043021|NCT02771236||Participants with corneal dystrophies|Participants with corneal dystrophies
89043022|NCT02771236||Participants with glaucoma|Participants with glaucoma or other anterior chamber anomalies
89043023|NCT02771236||Participants with lens refractive errors|Participants with lens refractive errors including myopia and hyperopia
89043024|NCT02771236||Participants with retinal degenerations|Participants with retinal degenerations
89043025|NCT02705196|Experimental|Arm 1 Intratumoral LOAd703|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment.~The following LOAd703 doses will be evaluated:~Dose level 1: 5 X 10^10 viral particles per treatment Dose level 2: 1 X 10^11 viral particles per treatment Dose level 3: 5 X 10^11 viral particles per treatment"
89521244|NCT03436771||JCAR017-treated|Patients who received previous treatment with JCAR017
89521245|NCT03436771||JCARH125-treated|Patients who received previous treatment with JCARH125
89521246|NCT03436693|Experimental|Canagliflozin 100mg|
89521247|NCT03436693|Placebo Comparator|Placebo|
89521248|NCT03432637|Experimental|SV|undergoing thoracoscopic lobectomy under spontaneous ventilation (SV)
89521249|NCT03432637|Active Comparator|SLV|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation(SLV)
89521250|NCT03436537||Gingival recession (GR) group|GR group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
89521251|NCT03436537||Gingival enlargement (GE) group|GE group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
89521252|NCT03436537||periodontal healthy (H) group|H group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
89521253|NCT03436459|Active Comparator|Extracorporeal shock wave therapy group|Patients in the shock wave therapy group received total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute by using BTL-6000 SWT Topline Power® 3 times with a week's interval between the treatments.
89521254|NCT03436459|Active Comparator|Low Level Laser Therapy group|Patients in the laser therapy group received LLLT once a day for three weeks (altogether 15 working days) to the trigger points and around them in the upper trapezius. The type of laser used: PR999 4 Watt (W) scanning laser; Medical Italia®, around trigger points with 3 Joule /centimeter² (J/cm²), power 800 milliwatt (mW), frequency 2000 Hertz (Hz), on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot.
89521255|NCT03432559|Other|endoscopy|endoscopy of the upper GI tract
89521256|NCT03436381||Overweight and obese patients|Patient undergoing elective upper endoscopy or colonoscopy, body mass index equal or greater than 25 kg/m2.
89521257|NCT03432403||New LMA or Old LMA|newly designed LMA or older designed LMA
89521258|NCT03436303|Experimental|CEE 0.625 mg/MP 100mg|CEE 0.625 mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
89521259|NCT03436303|Experimental|CEE 0.3 mg/MP 100mg|CEE 0.3mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
89521260|NCT03436303|Experimental|CEE 0.625 mg/dydrogesterone 10mg|CEE 0.625 mg/dydrogesterone 10 mg daily for the last 12 days of every 28 days for two years
89521261|NCT03432169|Active Comparator|Yoga|Stretching with mindfulness
89521262|NCT03432169|Active Comparator|Stretching|Stretching exercises without mindfulness
89521263|NCT03436225|Other|Group one|Group one will receive dexamethasone orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
89521264|NCT03436225|Other|Group two|Group two will receive dexamethasone parenteral (0.15mg /kg /dose) twice daily for 3 to 5 days.
89521265|NCT03436225|Other|Group three|Group three will receive inhaled nebulized budesonide (1 mg/2ml) twice daily for 3 to 5 days.
89521266|NCT03436225|Other|Group four|Group four will receive symptomatic treatment in form of inhaled nebulized salbutamol(0.15mg/kg/ dose) daily every 6-8 hours.
89521267|NCT03440359|Other|# 1- no progesterone therapy|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7.Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination. No supplemental progesterone therapy in luteal phase
89521268|NCT03440359|Active Comparator|# 2 - Progesterone Vaginal Gel 8%|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7. Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination.Crinone 8% (progesterone) vaginal therapy was provided in luteal phase for 14 days .Administration was started the second day after intrauterine insemination or timed intercourse.
89521269|NCT03128749|Experimental|Mindfulness Based Intervention|"Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.~These patients will be also attending to their regular psychiatric visits for medication control."
89521270|NCT03128749|Active Comparator|Treatment as Usual (TAU)|Patients will be attending to their regular psychiatric visits during the whole trial period.
89521271|NCT03432013|Active Comparator|SUD-CBT|Standard cognitive behavioral therapy for substance use disorder
89521272|NCT03432013|Experimental|CUD-AMT|Experimental affective management training for cannabis use disorder specifically
89521273|NCT03440281||Preterm group|included pregnant females delivered prior to completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
89641659|NCT00441285|Active Comparator|III .- Albendazole + PZQ Placebo|"Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )~This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward."
89641660|NCT01796613|Active Comparator|Vaginal Ring - intermittent regimen|3 weeks ring use followed by one week of no ring use to allow menstruation
89641661|NCT01796613|Active Comparator|Vaginal Ring - continuous regimen|3 weeks of ring use with no off period. The next ring is immediately inserted after the previous one
89641662|NCT04388631||Exposed group|Male patient discharged with COVID-19
89641663|NCT04388631||Control group|Healthy male volunteers without COVID-19
89641664|NCT00442611|Experimental|Abatacept|Abatacept (dosed based upon weight) administered intravenously (IV) on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
89641665|NCT00442611|Placebo Comparator|IV fluid|Placebo to match abatacept (IV fluid) administered on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
89641666|NCT04388397|Experimental|Immediate-access Arteriovenous Grafts|Immediate-access Arteriovenous Grafts as a vascular access for hemodialysis patients
89641667|NCT04388397|Active Comparator|Standard Arteriovenous Grafts|Standard Arteriovenous Grafts as a vascular access for hemodialysis patients
89641668|NCT01511107|Active Comparator|Amoxicillin-Clavulanate, 10 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 10 days
89641669|NCT01511107|Other|Amoxicillin-Clavulanate, 5 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 5 days plus placebo, 2 divided doses, 5 days
89641670|NCT00387621|Experimental|Placebo First, then Nesiritide (Arm A)|In the first intervention period the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
89641671|NCT00387621|Experimental|Nesiritide First, then Placebo (Arm B)|In the first intervention period the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
89641672|NCT00442689|Experimental|1|oral contraceptive (35 mg ethinyl estradiol)
89043026|NCT02705196|Experimental|Arm 2: Intratumoral LOAd703 + atezolizumab|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment. A fixed dose of atezolizumab 1680 mg will be given every 4 weeks on day 1 of each chemotherapy cycle.~Patients will be assigned to the following LOAd703 doses:~Dose level 1: 1 X 10^11 viral particles per treatment Dose level 2: 5 X 10^11 viral particles per treatment"
89043027|NCT02700230|Experimental|Treatment (MV-NIS)|Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days, and at 6 weeks based on whether there is uptake on prior imaging studies. Patients also undergo MRI, ultrasound imaging, blood sample collection and tissue biopsy throughout the trial.
89043028|NCT02660125|Active Comparator|endometrial scratch injury|endometrial scratch done before ICSI cycle
89043029|NCT02660125|No Intervention|control|IcSI cycle without prior endometrial injury
89043030|NCT02658097|Experimental|Single Fraction Radiation Therapy (SFRT) + pembrolizumab|200mg Pembrolizumab by IV infusion on day 1 of each 3 week cycle. 8Gy will be given in a single fraction on the first day of treatment
89043031|NCT02646475|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
89043032|NCT02646475|Placebo Comparator|Saline|Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.
89043033|NCT02603276|Active Comparator|Plant sterols|Plant sterols 800 mg per dose, 1 liquid stick per day, per 8 weeks
89043034|NCT02603276|Active Comparator|Red Yeast Rice|Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
89043035|NCT02603276|Experimental|Red Yeast Rice plus Plant sterols|lant sterols 800 mg per dose + Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
89043036|NCT02564978|Experimental|Minocycline|Oral administration of minocycline.
89043037|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose A|Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
89043038|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose B|Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
89043039|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose C|Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
89043040|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose D|Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
89641673|NCT00442689|Experimental|2|Flutamide 250 mg twice daily
89641674|NCT00442689|Placebo Comparator|3|Placebo
89641675|NCT01484977|Experimental|Lacosamide|Lacosamide will be added to levetiracetam while withdrawing the sodium channel blocking antiepileptic drug (AED)
89641676|NCT00442767|Active Comparator|Rapid acting Insulin therapy - before meal|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal
89641677|NCT00442767|Experimental|Pre-meal Pramlintide and Post-meal Insulin therapy|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
89212321|NCT00619892|Active Comparator|Quetiapine XR|Our target daily dose for quetiapine XR was 200 mg/day. The detailed quetiapine XR dosing guidelines were as follows: 50 mg 1 tab po at HS × 3 days, then, if 50 mg tolerated, increase to 50 mg 2 tabs at HS × 4 days; at the beginning of week 2, if the last dose was tolerated increase to 50 mg 3 tabs at HS × 3 days, then, if 150 mg tolerated, increase to 4 tabs at HS; at the beginning of week 3, if no efficacy & the 200 mg dose was well tolerated, increase to one 300 mg tab at HS-otherwise remain at 200 mg one tab at HS; at week 4 if still no improvement, & 300 mg was tolerable, increase to 200 mg tablet 2 at HS. From the beginning of week 5 to the end of the trial, quetiapine XR doses were held. We used quetiapine XR tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
89212322|NCT00619892|Placebo Comparator|Placebo|Subjects received identical-appearing placebo tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
89212323|NCT00863018||Control|Eyes with glaucoma and on anti-glaucoma medication but without glaucoma surgery
89212324|NCT00863018||Implant surgery|Eyes underwent Ahmed glaucoma valve implantation
89212325|NCT00863018||Trabeculectomy|Eyes underwent conventional trabeculectomy with mitomycin-C
89212326|NCT00850928||Subjects|65 years and older scheduled for spine surgery will be undergoing serial assessments preoperatively and postoperatively over 6 time-points.
89212327|NCT04040972|Experimental|Rebalance - Group Compassion Focussed Therapy|
89641678|NCT00443547||1-level|Patients needing a single level cervical fusion with Vectra-T
89641679|NCT00443547||2-level|Patients needing cervical fusion at two consecutive levels with Vectra-T
89641680|NCT00443547||3-level|Patients needing cervical fusion at three consecutive levels with Vectra-T
89641681|NCT00443547||4-level|Patients needing cervical fusion at four consecutive levels with Vectra-T
89641682|NCT00445263|Experimental|Early Invasive strategy|Tirofiban and coronarography within 6 hours
89641683|NCT00445263|Active Comparator|Delayed invasive strategy|Coronarography after 6 hours
89641684|NCT00389493|Active Comparator|1|Participants will receive treatment with risperidone
89212328|NCT00507130|Experimental|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
89212329|NCT00507130|Experimental|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
89212330|NCT00507130|Experimental|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
89212331|NCT00507130|Placebo Comparator|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
89212332|NCT00863096||Gardasil|
89212333|NCT00863174|Experimental|1|SPARC147709
89212334|NCT00863174|Active Comparator|2|Reference147709
89212335|NCT00870272|Active Comparator|1|400mcg sublingual misoprostol
89212336|NCT00870272|Active Comparator|2|400mcg buccal misoprostol
89212337|NCT00863252|Experimental|1|MMF
89212338|NCT00863252|Active Comparator|2|Control
89212339|NCT00503308|Experimental|Abbreviated Consenting|
89212340|NCT00503308|No Intervention|Standard Consenting|
89212341|NCT00870350|Active Comparator|Td5ap|Group 1 receiving Td5ap as a single intramuscular injection.
89212342|NCT00870350|Active Comparator|Td1aP|Group 2 receiving Td1aP as a single intramuscular injection
89212343|NCT00870428||Preeclampsia Evaluation|Patients who are admitted for the evaluation of preeclampsia
89212344|NCT00863564|Active Comparator|Whey Isolate|
89212345|NCT00863564|Active Comparator|Caseine|
89212346|NCT00863564|Active Comparator|Cod|
89212347|NCT00863564|Active Comparator|Gluten|
89212348|NCT03893565|Experimental|GSK2831781-Double blind phase|Eligible participants will receive GSK2831781 intravenously in the double blind induction phase at different dose levels. Participants identified as Responders at Week 10 will then receive GSK2831781 subcutaneously during the double-blind ETP from Week 14 until Week 26
89212349|NCT03893565|Experimental|GSK2831781- Open label phase|Eligible participants will receive GSK2831781 intravenously in the open label induction phase. Participants identified as Non-Responders at Week 10 will receive GSK2831781 from Week 12 until Week 22. Participants identified as Responders at Week 22 will enter open label ETP to receive GSK2831781 from Week 26 until Week 38. Participants identified as Non- Responders at Week 22 will discontinue treatment.
89641685|NCT00389493|Active Comparator|2|Participants will receive exposure and ritual prevention therapy (EX/RP)
89641686|NCT00389493|Placebo Comparator|3|Participants will receive treatment with the placebo
89641687|NCT01795053|Experimental|playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and intensity and thereby reduce ADHD symptoms
89641688|NCT01795053|Placebo Comparator|open play session|the open play sessions are conducted in the same rooms, by the same staff and in the same time frame as the experimental sessions. The therapist plays with the child without structuring the sitauation through behavioral tecniques. The play situation is designed to be ineresting and comfortable for the child.
89641689|NCT04388709|Experimental|Peginterferon lambda-1a|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
89641690|NCT04388709|No Intervention|Best supportive care|Best supportive care
89641691|NCT00456807|Experimental|Cervarix Group|Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).
89641692|NCT00456807|Placebo Comparator|Placebo Group|Subjects who received 3 doses of placebo during the primary study (NCT00294047).
89641693|NCT00456885|Placebo Comparator|Exenatide First|Started on Exenatide, 3 week washout, start placebo
89641694|NCT00456885|Experimental|Placebo First|Started on placebo, 3 week washout, start exenatide
89641695|NCT01475825|Experimental|Regimen A: Mipomersen|Subcutaneous injection of mipomersen 200 mg once weekly
89641696|NCT01475825|Placebo Comparator|Regimen A: Placebo|Placebo matching subcutaneous injection once weekly.
89641697|NCT01475825|Experimental|Regimen B: Mipomersen|Subcutaneous injection of mipomersen 70 mg thrice weekly.
89641698|NCT01475825|Placebo Comparator|Regimen B: Placebo|Placebo matching subcutaneous injection thrice weekly.
89641699|NCT00457197|Placebo Comparator|Placebo|This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
89641700|NCT00457197|Active Comparator|Quetiapine|This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
89641701|NCT04408859||NACS|The patients with advanced gastric cancer who received neoadjuvant chemotherapy followed by surgery（NACS）.
89641702|NCT04408859||SA|The patients with advanced gastric cancer who received surgery alone.
89641703|NCT01484431|Experimental|Tadalafil|"Light Weight <25 kg Period 1: 2 milligram (mg) or 4 mg tadalafil administered once daily (QD) in oral suspension formulation for 5 weeks then 8 mg,10 mg,15 mg or 20 mg tadalafil was administered QD in oral suspension formulation for 5 weeks.~Middle Weight: 25 kg to <40 kg Period 1: 5 mg tadalafil tablet administered QD for 5 weeks then 10 mg, 15 mg or 20 mg tablet tadalafil administered QD for 5 weeks.~Heavy: ≥40 kg Period 1: 10 mg tadalafil tablet administered QD for 5 weeks then 20 mg or 40 mg tablet tadalafil administered QD for 5 weeks."
89641704|NCT00445887|Experimental|Arm I (levonorgestrel)|Patients receive oral levonorgestrel once daily.
89641705|NCT00445887|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily.
89641706|NCT02114307|Active Comparator|REVITIVE IX: actual device|Trial participants will receive the true Revitive IX device
89641707|NCT02114307|Sham Comparator|REVITIVE IX: sham device|Trial participants will receive a sham device
89641708|NCT01473953|Experimental|Cohort 1a: Lira-depot 2.25 mg|
89641709|NCT01473953|Experimental|Cohort 2a: Lira-depot 6.75 mg|
89641710|NCT01473953|Experimental|Cohort 3a: Lira-depot 15 mg|
89641711|NCT01473953|Experimental|Cohort 4a: Lira-depot 30 mg|
89641712|NCT01473953|Placebo Comparator|Placebo|
89641713|NCT04408703||Ulcerative colitis in clinical remission|Clinical remission with SCCAI <3 at baseline and stable remission for the last 3 months
89641714|NCT01510717|Experimental|Multifocal IOL|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
89641715|NCT01510717|Active Comparator|Monofocal IOL|AcrySof® IQ Monofocal IOL Model SN60WF, bilateral implantation
89641716|NCT00457977|Active Comparator|Pneumovax (PPSV23)|pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
89641717|NCT00457977|Active Comparator|Prevnar (PCV7)|diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose
89641718|NCT01473563|Experimental|Pemetrexed|500 milligrams per square meter (mg/m^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
89641719|NCT01795209|Experimental|Ranibizumab group|Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
89641720|NCT01795209|Sham Comparator|Standard of care group|Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.
89641721|NCT02115633|Experimental|Walkasins ON then OFF|Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.
89641722|NCT02115633|Experimental|Walkasins OFF then ON|Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.
89641723|NCT01484275|Experimental|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
89043041|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose E|Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
89043042|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose F|Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
89043043|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose G|Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
89043044|NCT02561962|Experimental|Dose Expansion: AMG 224 Dose H + prior CD38 targeting antibody treatment|Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose [MTD] based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
89641724|NCT01484275|Placebo Comparator|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
89641725|NCT01544335||BIS|Subjects evaluated using Bioimpedance Spectroscopy
89641726|NCT01484197|Experimental|75 µg Indacaterol (LB) + Placebo (PoS)|75 µg indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
89641727|NCT01484197|Experimental|75 µg Indacaterol (PoS) + Placebo (LB)|75 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
89641728|NCT01484197|Experimental|37.5 µg Indacaterol (PoS) + Placebo (LB)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
89641729|NCT01484197|Experimental|Placebo (LB) and Placebo (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
89641730|NCT01473407|Experimental|Epoetin Hospira|Epoetin Hospira
89641731|NCT01473407|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
89641732|NCT01472939|Active Comparator|SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI)|
89641733|NCT01472939|Active Comparator|SSP-002358 (0.5 mg) + PPI|
89641734|NCT01472939|Active Comparator|SSP-002358 (2.0 mg) + PPI|
89641735|NCT01472939|Placebo Comparator|Placebo + PPI|
89641736|NCT04082897|Experimental|Combination of Obinutuzumab, Atezolizumab and Venetoclax|"Obinutuzumab will be administered iv from cycle 1 to cycle 8 :~cycle1: 100 mg iv (day 1) and 900 mg iv (day 2) 1000mg iv (day 8 and day 15)~Cycle 2-8: 1000 mg iv on day 1~Atezolizumab will be administered iv at 1.200 mg fixed dose from C1 to C18:~Cycles 1: day 2~Cycle 2-18: day 1~Venetoclax will start from day 15 of cycle 1 on a weekly ramp-up basis:~week 1: 20 mg (from day 15 cycle 1) week 2: 50 mg (from day 1 to day 7 cycle 2) week 3: 100 mg (from day 8 to day 14 cycle 2) week 4 200 mg (from day 15 to day 21 cycle 2) week 5: 400 mg (from day 1 cycle 3) venetoclax will be thereafter continued until day 21 of cycle 35"
89641737|NCT01544179|Experimental|Gefitinib|Gefitinib and cisplatin plus pemetrexed combination chemotherapy
89641738|NCT01544179|Placebo Comparator|Placebo|Placebo and cisplatin plus pemetrexed combination chemotherapy.
89641739|NCT01483651|Experimental|Low, Medium and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
89641740|NCT01483651|Experimental|Low, High and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
89641741|NCT01483651|Experimental|Medium, Low and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
89641742|NCT01483651|Experimental|Medium, High and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
89641743|NCT01483651|Experimental|High, Low and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
89641744|NCT01483651|Experimental|High, Medium and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
89641745|NCT03027349||Study group|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~The exclusion criteria will be:~age younger than 18 years~renal and liver failure and insufficiency~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~any type of cancer~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption~transplantation~sarcoidosis~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~familial hypocalciuric hypercalcemia~hypophosphoremia sustained by genetic causes or secondary to other causes."
89641746|NCT03027349||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their parathyroid function and calcium metabolism state with results into the normal ranges.~The exclusion criteria will be:~age younger than 18 years~renal and liver failure and insufficiency~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~any type of cancer~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption~transplantation~sarcoidosis~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~familial hypocalciuric hypercalcemia~hypophosphoremia sustained by genetic causes or secondary to other causes."
89641747|NCT01464307|Experimental|IncobotulinumtoxinA (Xeomin) 400 Units|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
89641748|NCT01464307|Placebo Comparator|Placebo Comparator Arm|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
89641749|NCT03027193|Experimental|Group 1|Group 1 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^9 vp through intramuscular route.
89043045|NCT02561962|Experimental|Dose Expansion: AMG 224 Dose H + no prior CD38 targeting antibody treatment|Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
89043046|NCT02536118||Patients implanted with Micra System|Patients implanted with a Micra Transcatheter Pacing System are eligible for enrollment into the Micra PA Registry.
89043047|NCT02534168|Experimental|skin conductance|The skin conductance monitor will be applied to all study patient. There is no second arm to the study
89043048|NCT02519348|Experimental|Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg|Participants in Part 1A (safety run-in cohort) and Part 1 B (efficacy-gating cohort) will receive tremelimumab 1 mg/kg every 4 weeks (Q4W) 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
89043049|NCT02519348|Experimental|Parts 2 and 3: Durvalumab 1500 mg|Participants will receive durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
89043050|NCT02519348|Experimental|Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg|Participants will receive tremelimumab 300 mg 1 dose and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow, or development of other reason for treatment discontinuation, whichever occurs first.
89043051|NCT02519348|Experimental|Parts 2 and 3: Tremelimumab 750 mg|Participants will receive tremelimumab 750 mg Q4W 7 doses followed by every 12 weeks (Q12W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
89641750|NCT03027193|Experimental|Group 2|Group 2 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 2.5 x 10^10 vp through intramuscular route.
89641751|NCT03027193|Experimental|Group 3|Group 3 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^10 vp through intramuscular route.
89641752|NCT03027193|Experimental|Group 4|Group 4 volunteers (n= 3) will be administered MVA HAV, 5 x 10^7 pfu through intramuscular route.
89641753|NCT03027193|Experimental|Group 5|Group 5 volunteers (n= 3) will be administered MVA HAV, 2 x 10^8 pfu through intramuscular route.
89641754|NCT03027193|Experimental|Group 6|Group 6 volunteers (n= 10) will be administered ChAdOx2 HAV, 5 x 10^10 vp followed by MVA HAV, 2 x 10^8 pfu (8 weeks apart) through intramuscular route.
89641755|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 1: OPC-108459|To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
89641756|NCT01483183|Placebo Comparator|Persistent or Paroxysmal AF Part 1: Placebo|
89641757|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 2: OPC-108459|Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
89641758|NCT01483183|Placebo Comparator|Placebo Part 2|
89641759|NCT01483027|Experimental|Treatment group|Standard of care second-line chemotherapy plus TheraSphere
89641760|NCT01483027|No Intervention|Control group|Standard of care second-line chemotherapy with no added therapy
89641761|NCT01463683|Experimental|V232-2XP SC|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
89641762|NCT01463683|Active Comparator|V232-1XP SC|1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
89641763|NCT01463683|Experimental|V232-2XP IM|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6
89641764|NCT01482169|Active Comparator|Adenoscan|Subjects will have the FFR Measurement with IV Adenoscan®
89641765|NCT01482169|Experimental|Regadenoson|Subjects will have the FFR Measurement with IV Regadenoson
89641766|NCT01481779|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
89641767|NCT01481779|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
89641768|NCT04409587|No Intervention|NovoLog®-only|In the aspart-Only group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
89641769|NCT04409587|Active Comparator|Novolog® and Tresiba® Group|This study population will have an expertise in diabetes self-management with their insulin pump and Dexcom CGM. In the Novolog® and Tresiba® group, the subject will still take aspart via their pump for meals and correction boluses, but they will reduce the slow trickle (basal insulin) programmed in their pump to almost zero. Instead of receiving their normal basal insulin via CSII, the subject will injected degludec once or twice daily from an insulin pen for your basal insulin.
89641770|NCT04096261||Healthy controls|Healthy controls recruited through public advertisement.
89641771|NCT04096261||Siblings of people with Alzheimer's dementia|Siblings of people with Alzheimer's dementia recruited through public advertisement
89641772|NCT04096261||Subjective cognitive decline|Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
89641773|NCT04096261||Mild cognitive impairment|Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
89641774|NCT04096261||Dementia due to Alzheimer's disease|Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.
89641775|NCT01463527|Experimental|Open Capnography|
89641776|NCT01463527|Placebo Comparator|Capnography Blind|
89641777|NCT01509547|Experimental|varenicline|Participants >55 kg will take varenicline 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take varenicline 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
89641778|NCT01509547|Placebo Comparator|placebo|Participants >55 kg will take placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
89641779|NCT01509079|Experimental|Vitamin D3 4000 IU|
89641780|NCT01509079|Active Comparator|Vitamin D3 600 IU|
89641781|NCT01463293|Experimental|High-dose probiotic|Capsule containing 10 billion cfu B. lactis HN019
89641782|NCT01463293|Experimental|Low dose probiotic|Capsule containing 1 billion cfu B. lactis HN019
89641783|NCT01463293|Placebo Comparator|Placebo|Placebo capsule
89641784|NCT04650217|Active Comparator|L-DOPA + Exercise|N=20 subjects assigned to L-DOPA + Exercise will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive exercise training 4 times a week (exercise)
89212350|NCT03893565|Placebo Comparator|Placebo matching GSK2831781- Double blind phase|Eligible participants will receive Placebo in the double blind induction phase Participants identified as Responders at Week 10 will continue to receive Placebo subcutaneously during the double-blind ETP from Week 14 until Week 26.
89641785|NCT04650217|Active Comparator|LDOPA + Control|N=20 subjects assigned to L-DOPA + Control will receive L-DOPA three times daily for up to 450mg (L-DOPA) and also will receive a stretching and toning regime (Control).
89641786|NCT04650217|Placebo Comparator|Placebo + Exercise|N=20 subjects assigned to Placebo + Exercise will receive placebo three times daily and also will receive exercise training 4 times a week (exercise).
89641787|NCT04650217|Placebo Comparator|Placebo + Control|N=20 subjects assigned to Placebo + Control will receive placebo three times daily and also will receive a stretching and toning regime (Control).
89641788|NCT01479985|Experimental|CDM Tool|participants will be randomized to completing the CDM tool
89641789|NCT01479985|No Intervention|Control|Participants will fill out a computer survey similar to CDM tool without the decisive factors and computer print out
89641790|NCT02074345|Experimental|TAK-816 0.5 mL|Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.
89641791|NCT01462435|Experimental|Diclofenac Test (lower dose)|
89641792|NCT01462435|Experimental|Diclofenac Test (upper dose)|
89641793|NCT01462435|Active Comparator|Celecoxib|
89641794|NCT01462435|Placebo Comparator|Placebo|
89641795|NCT01472081|Experimental|Arm S: Nivolumab + Sunitinib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Sunitinib 50 mg capsule by mouth on Days 1-28 of 42 day cycle until Progressive disease (PD), toxicity or discontinue for other reasons"
89641796|NCT01472081|Experimental|Arm P: Nivolumab + Pazopanib|"Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons~Pazopanib 800 mg tablet by mouth daily until Progressive disease (PD), toxicity or discontinue for other reasons"
89641797|NCT01472081|Experimental|Arm I-1: Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg solution intravenously (IV) every 21 days during Induction phase and every 14 days during Maintenance phase until Progressive disease (PD), toxicity or discontinue for other reasons~Ipilimumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase (Ipilimumab will not be administered during Maintenance phase) until Progressive disease (PD), toxicity or discontinue for other reasons"
89641798|NCT01472081|Experimental|Arm I-3: Nivolumab + Ipilimumab|"Nivolumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
89641799|NCT01472081|Experimental|Arm IN-3: Nivolumab+Ipilimumab|"Nivolumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase~Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase"
88991671|NCT04388254|Experimental|Simufilam 100 mg oral tablets throughout|Simufilam 100 mg oral tablets administered twice daily (BID) for the full 24 months (including the randomized period Month 12 to Month 18)
89212351|NCT00863642|Experimental|Early|In patients who present with mild to moderate gallstone pancreatitis, those randomized to the early arm will undergo laparoscopic cholecystectomy within 48 hours of admission, regardless of laboratory values normalization and resolution of abdominal pain.
89212352|NCT00863642|Other|Control|In patients in the control arm, laparoscopic cholecystectomy is delayed until laboratory values normalize and abdominal pain resolves.
89641800|NCT01471691|Experimental|intravitreal ranibizumab 0.5mg|
89641801|NCT01471691|Experimental|intravitreal ranibizumab 1.0mg|
89641802|NCT01471379|Experimental|Group A (50mg - 100mg)|Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
89641803|NCT01471379|Active Comparator|Group B (50mg x12)|Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
89641804|NCT01471379|Placebo Comparator|Group C (Placebo - 50mg)|Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II
89641805|NCT01470989|Experimental|canakinumab|canakinumab 150 mg s.c.
89641806|NCT01470599|Experimental|5mg BID|
89641807|NCT01470599|Experimental|10mg BID|
89641808|NCT04409171||PD|pancreaticoduodenectomy
89641809|NCT04409171||DP|distal pancreatectomy
89641810|NCT01469819|Experimental|Lubiprostone|Lubiprostone 24 mcg by mouth twice a day (BID) for 2 weeks.
89641811|NCT04618523|Experimental|Artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days for children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
89641812|NCT04618523|Experimental|Artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
89641813|NCT01507831|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
89641814|NCT01507831|Experimental|Alirocumab|Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.
89641815|NCT01479595|Experimental|QBX258|Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
89641816|NCT01479595|Placebo Comparator|Placebo|Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.
89641817|NCT01462357|Experimental|Cervarix 2 dose Group|Subjects who received 2 doses of Cervarix vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
89212353|NCT00865358|Experimental|Yoga Group|A standardized hatha yoga protocol delivered in 12 weekly classes.
89212354|NCT00865358|No Intervention|Usual care|Participants continue to receive their usual medical care for their back pain
89212355|NCT00502996|Experimental|Rituximab|Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.
89212356|NCT00865436|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
89212357|NCT00865436|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
89641818|NCT01462357|Experimental|Gardasil 2 dose Group|Subjects who received 2 doses of Gardasil vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
89641819|NCT01462357|Experimental|Gardasil 3 dose Group|Subjects who received 3 doses of Gardasil vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
89641820|NCT03026569|Experimental|Orange juice|Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks.
89641821|NCT03026569|No Intervention|Control|Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks.
89641822|NCT01479439|Experimental|Sickle cell disease|The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.
89641823|NCT01478971|Experimental|peginesatide injection|In the first 6 months participants received standard of care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1-week erythropoiesis-stimulating agent (ESA)-Free Period, followed by peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).
89641824|NCT01507051|Experimental|Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939)|Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
89641825|NCT01507051|Placebo Comparator|Warfarin followed by Placebo|Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
89641826|NCT01507051|Active Comparator|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
89641827|NCT04079257||Patients with paroxysmal nocturnal hemoglobinuria|Patients are already treated with eculizumab. The only intervention is the collection of extra blood samples to measure peak concentrations of eculizumab
89641828|NCT01478347|Experimental|rMenB+OMV NZ|Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures (e.g. lab workers), were administered two injections of Recombinant meningococcal B (rMenB) + Outer Membrane Vesicle (OMV NZ) vaccine, 2 months apart, in part I of the study, were enrolled for optional blood draws and safety follow-up in part II of the study.
89641829|NCT01478113|Active Comparator|WBT + amphetamine/dextroamphetamine|In the active group, participants will receive treatment with Well-being therapy and amphetamine-dextroamphetamine.
89641830|NCT01478113|Placebo Comparator|WBT + placebo|In the placebo group, participants will receive treatment with Well-being therapy and pill placebo.
89641831|NCT01506271|Experimental|Relebactam 250 mg with imipenem/cilastatin|Participants randomized to receive relebactam 250 mg will be administered 250 mg doses of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
89641832|NCT01506271|Experimental|Relebactam 125 mg with imipenem/cilastatin|Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
89641833|NCT01506271|Placebo Comparator|Placebo to relebactam with imipenem/cilastatin|Participants randomized to receive placebo for relebactam will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
89641834|NCT01506193|Active Comparator|Group A|Subjects in this arm will receive MMRV vaccine at Visit 1 (Day 0) and MenC vaccine at Visit 2 (Days 35-49).
89641835|NCT01506193|Experimental|Group B|Subjects will receive MMRV vaccine and MenC vaccine at Visit 1 (Day 0).
88991672|NCT04388254|Placebo Comparator|Simufilam 100 mg oral tablets / Placebo / Simufilam 100 mg oral tablets|This placebo arm is only for Month 12 to Month 18. Day 1 to Month 12, as well as Month 18 to Month 24 are open-label treatment periods of simufilam 100 mg b.i.d. for all subjects.
89212358|NCT00870506|No Intervention|2|No intervention (control)
89212359|NCT00870506|Experimental|1|5-minute video on donation and transplantation
89212360|NCT00870662|Experimental|Automatic Fluid Shunt|
89212361|NCT01013584|Active Comparator|1,000 IU|1,000 IU/day of vitamin D3
89212362|NCT01013584|Active Comparator|5,000 IU|5,000 IU/day of vitamin D3
89212363|NCT01013584|Active Comparator|10,000 IU|10,000 IU/day of vitamin D3
89212364|NCT00863876||1|non-operated healthy eyes
89212365|NCT00863876||2|eyes 1 months following LASIK
89212366|NCT00863876||3|eyes 3-6 months following LASIK
89212367|NCT00863876||4|eyes with spherical monofocal IOLs more than 3 months postop
89212368|NCT00863876||5|eyes with aspherical monofocal IOLs more than 3 months postop
89212369|NCT00863876||6|eyes with toric monofocal IOLs more than 3 months postop
89212370|NCT00863876||7|eyes with diffractive multifocal IOLs more than 3 months postop
89043052|NCT02519348|Experimental|Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg|Participants will receive tremelimumab 75 mg Q4W 4 doses and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first. Participant recruitment to this arm was closed following protocol amendment 5.
89043053|NCT02519348|Experimental|Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg|Participants will receive durvalumab 1120 mg and bevacizumab 15 mg/kg every 3 weeks (Q3W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first
89043054|NCT02519348|Experimental|China Cohort: Durvalumab 20 mg/kg|Participants will receive durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
89043055|NCT02519348|Experimental|China Cohort: Tremelimumab 10 mg/kg|Participants will receive tremelimumab 10 mg/kg Q4W 7 doses followed by Q12W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
89043056|NCT02519348|Experimental|China Cohort: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg|Participants will receive tremelimumab 1 mg/kg Q4W 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
89043057|NCT02496156|Active Comparator|Usual Clinical Practice (UCP)|UCP participants will receive the same clinical and educational management for candidates for insulin pump or continuous glucose monitoring that is received by similar patients who are not enrolled in this study. The respective endocrinology practices at the enrolling sites all strive to meet or exceed the current American Diabetes Association Standards for Clinical Practice in the management of type 1 diabetes in this population. Thorough patient education is the cornerstone of that care, especially regarding the incorporation of insulin pumps and continuous glucose monitors into the treatment regimen for a given patient.
89043058|NCT02496156|Experimental|Shared Medical Decision Making (SMDM)|Participants randomized to SMDM receive all components of UCP supplemented with access to the decision aid website pertinent to the medical decision of interest (pump or CGM). Adolescents and parents will receive password-protected, secure access to the decision for their use until a decision is reached. The platform will then generate a summary report that the adolescent and parent will discuss with a diabetes nurse and then a visit with the treating endocrinologist will be scheduled to conclude the SMDM intervention for that adolescent and parent.
89641836|NCT01506193|Active Comparator|Group C|Subjects will receive Men C vaccine at Visit 1 (Day 0) and MMRV vaccine at Visit 2 (Day 35-49).
89641837|NCT01505881|Experimental|Dabigatran etexilate|Patient dose determined by dose allocated in 1160.113 and CrCl levels
89641838|NCT01505881|Active Comparator|warfarin|warfarin doses to maintain INR levels
89641839|NCT01462045|Experimental|Exercise Group|Participants who are screened positive for PTSD and participate in the series of 16 standardized, semiweekly 60-minute mindfulness-based exercise sessions. The intervention consists of stretching and balancing movements combined with breathing and a focus on mindfulness.Over the course of 8 weeks, the intensity of the exercise increases, but the sequence of the movements is the same.
89641840|NCT01462045|No Intervention|Control Group|Participants who are screened positive for PTSD but do not participate in the mindfulness-based exercise.
89641841|NCT01462045|No Intervention|Base Group|Healthy volunteers who are not screened positive for PTSD and do not participate in the mindfulness-based exercise.
89641842|NCT01505647|Experimental|ZOSTAVAX™ (AMP)|ZOSTAVAX™ manufactured with an alternative process
89043059|NCT02492464|Active Comparator|Red yeast rice|Red yeast rice extract 200 mg, containing 10 mg monacolin K per daily dose, 1 capsule per day, per 6 months
89043060|NCT02492464|Placebo Comparator|Placebo|Placebo 200 mg (neutral fibre), 1 capsule per day, per 6 months
89641843|NCT01505647|Active Comparator|ZOSTAVAX™|ZOSTAVAX™ manufactured with the current process
89641844|NCT01461811|Experimental|DAILIES® AquaComfort Plus® Toric|Nelfilcon A toric contact lenses (with comfort additives) worn in both eyes on a daily wear, daily disposable basis for three months
89641845|NCT01461811|Active Comparator|Focus® DAILIES® Toric|Nelfilcon A toric contact lenses worn in both eyes on a daily wear, daily disposable basis for three months
89641846|NCT01505491|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
89641847|NCT01505491|Active Comparator|adalimumab - US|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
89043061|NCT02488733|Experimental|Laparoscopic Sleeve Gastrectomy (LSG)|In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.
89212371|NCT00863876||8|eyes with phakic IOLs more than 3 months postop
89212372|NCT00863876||9|eyes with keratoconus
89212373|NCT00863954|Active Comparator|Output A|
89641848|NCT01505491|Active Comparator|adalimumab - EU|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
89641849|NCT04077775||Study group (group A):|"Study group (group ) Diagnostic Test: Study group (group A)24 women who have cyclic CPP~I) Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
89641850|NCT04077775||Study group(group B):|"included 20 women who have non-cyclic CPP and the other 16 women of the participants were normal I)~Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately. In contrast, the woman was in a standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer~Diagnostic Test: Study group (group A)"
89641851|NCT04077775||Control group (group C):|"16 women of the participants were normal and considered the control group~I) Pelvic tilt angle:~The physiotherapist stood beside the women and found the position of the anterior superior iliac spine (ASIS) and posterior superior iliac spine (PSIS) accurately while the woman was in standing position. Hence the therapist placed one end arm of PALM inclinometer on ASIS, and the other end arm was placed on PSIS. The pelvic sagittal inclination angle was the angle between the horizontal line and a line passing through the ASIS and PSIS that determined by the bubble level in the PALM inclinometer"
89641852|NCT01504867|Experimental|Aspirin|This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.
89641853|NCT01504867|Placebo Comparator|Placebo|This group received matching lactose powder filled capsules on days 1-7.
89641854|NCT01476475|Experimental|Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
89641855|NCT01476475|Active Comparator|Insulin glargine|Insulin glargine QD for 24 weeks. Dose individually adjusted.
89641856|NCT01475851|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet is administered orally once daily
89641857|NCT01460719|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89641858|NCT00527943|Placebo Comparator|Placebo|Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
89641859|NCT00527943|Experimental|Vorapaxar|Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
89641860|NCT00448227|Experimental|Famciclovir|Famciclovir was administered orally as a suspension in OraSweet® on Day 1. Patients received a single, individualized dose between 25-200 mg based on body weight.
89641861|NCT00529191|Experimental|Atorvastatin|Two out of every three patients will receive atorvastatin.
89641862|NCT00529191|Placebo Comparator|Placebo|One out of three subjects will receive a placebo.
89641863|NCT00459303|Active Comparator|intraocular lens|patients with bilateral clinical significant cataract reisiceved cataract surgeries and recieved spherial intraocuar lens(SA60AT, Alcon) in one eye and aspherical intraocular lens(Tecnis Z9000, AMO)in the other respectively.
89641864|NCT00459381|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
89641865|NCT00449007|Active Comparator|1|fluoxetine -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
89641866|NCT00449007|Active Comparator|2|bupropion -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
89641867|NCT00460551|Experimental|Zalutumumab 8 mg/kg|
89641868|NCT01468181|Experimental|LY2189265 + Sulfonylureas (SU)|"LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throughout the study."
89212374|NCT00863954|Active Comparator|Output B|
89641869|NCT01468181|Experimental|LY2189265 + Biguanides (BG)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study."
89641870|NCT01468181|Experimental|LY2189265 + alpha-glucosidase inhibitor (a-GI)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study."
88991673|NCT04382664|Experimental|UV1 vaccination + nivolumab and ipilimumab|UV1 vaccination + nivolumab and ipilimumab
88991674|NCT04382664|Active Comparator|Nivolumab and ipilimumab|nivolumab and ipilimumab
88991675|NCT04382404|Experimental|Sofosbuvir-Velpatasvir|Sofosbuvir-Velpatasvir
88991676|NCT04376502|Other|radiation therapy (RT)|RT for all subjects will consist of treating one tumor of the treating physician's preference (40 Gy in 5 fractions), and after a 1-week interval during which Immune checkpoint inhibitor (ICI) is continued alone, RT will be given to a second and separate tumor (30 Gy in 5 fractions).
89212375|NCT00863954|Active Comparator|Output C|
88991677|NCT04375982|Other|Blood collection|Venepuncture and fingerstick to obtain venous blood and capillary blood respectively
88991678|NCT04375891|Other|Radiotherapy|Radiotherapy alone
88991679|NCT04375891|Other|Radiotherapy plus radiofrequency ablation|Radiotherapy plus radiofrequency ablation / vertebral augmentation(Combination therapy)
89212376|NCT00863954|Active Comparator|Output D|
89212377|NCT00863954|Active Comparator|Output E|
89212378|NCT00863954|Active Comparator|Output F|
89641871|NCT01468181|Experimental|LY2189265 + Thiazolidinedione (TZD)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study."
89641872|NCT01468181|Experimental|LY2189265 + Glinides|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study."
89641873|NCT01693562|Experimental|Escalation Cohort (MEDI4736 0.1 mg/kg Q2W)|Participants will receive intravenous (IV) infusion of MEDI4736 (durvalumab) 0.1 mg/kg every 2 weeks (Q2W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641874|NCT01693562|Experimental|Escalation Cohort (MEDI4736 0.3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 0.3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89043062|NCT02488733|Other|Conventional medical therapy (CMT)|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.
89043063|NCT02486718|Experimental|Atezolizumab|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.
89641875|NCT01693562|Experimental|Escalation Cohort (MEDI4736 1 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 1 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641876|NCT01693562|Experimental|Escalation Cohort (MEDI4736 3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641877|NCT01693562|Experimental|Escalation Cohort (MEDI4736 10 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89043064|NCT02486718|Active Comparator|Best Supportive Care|Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.
89043065|NCT02477696|Experimental|Acalabrutinib|Participants will receive oral acalabrutinib 100 mg twice daily (BID) until disease progression (PD), or unacceptable toxicity, or other reasons for discontinuation, whichever occurs first.
89043066|NCT02477696|Active Comparator|Ibrutinib|Participants will receive oral ibrutinib 420 mg once daily (QD) until PD, or unacceptable toxicity, or other reasons for discontinuation, whichever occurrs first.
89043067|NCT02361944|Experimental|Normoxia|Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
89043068|NCT02361944|Active Comparator|Hyperoxia|Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
89043069|NCT02242773|Experimental|Active Surveillance|Participants in this group will receive a Multi-Parametric Magnetic Resonance Imaging (MP-MRI) of the prostate/pelvis and MRI-guided prostate biopsy at baseline (0-3 months from enrollment) and at the 12th, 24th and 36th month follow up.
89043070|NCT02133885|Active Comparator|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
89043071|NCT02133885|Placebo Comparator|Placebo Group|These subjects will start with placebo (this will look like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive a minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
89043072|NCT02021578|Experimental|Family Cognitive Behavioral Prevention|A family cognitive behavioral program for parents and children. Parents learn parenting skills and cognitive behavioral techniques for managing depression. Children learn coping skills.
89043073|NCT02021578|Active Comparator|Written Information|Families receive written materials about depression and the effects of parental depression on children.
89043074|NCT01988883|Placebo Comparator|Placebo|Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.
89043075|NCT01988883|Experimental|Modafinil|Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
89043076|NCT01988883|Experimental|Propranolol|Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
89043077|NCT01988883|Experimental|Modafinil plus Propranolol|Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.
89043078|NCT01955499|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO on days 1-21 and ibrutinib PO on days 1-28 (days 2-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89043079|NCT01829568|Experimental|Treatment (lenalidomide, ibrutinib, and rituximab)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 1 and once weekly at weeks 13, 21, 29, and 37.
89043080|NCT01818674|Experimental|Group A - Microclinic Behavioral Health Enhanced Program|Group A received the Microclinic Behavioral Health Full Program (structured social interactions + fully interactive classroom education curriculum; parallel clinical screenings)
89212379|NCT00864110|Experimental|99mTc EC-DG|99mTc-EC-DG with SPECT/CT imaging
89641878|NCT01693562|Experimental|Escalation Cohort (MEDI4736 15 mg/kg Q3W)|Participants will receive IV infusion of MEDI4736 15 mg/kg every 3 weeks (Q3W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641879|NCT01693562|Experimental|Exploration Durvalumab 20 mg/kg (Q4W)|Participants will receive IV infusion of MEDI4736 20 mg/kg every 4 weeks (Q4W) in the dose-exploration phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641880|NCT01693562|Experimental|Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89043081|NCT01818674|Experimental|Group B - Microclinic Behavioral Health Basic Program|Group B received the Microclinic Behavioral Health Basic Program (no social structured interactions; basic classroom education; parallel clinical screenings)
89641881|NCT01693562|Experimental|Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W)|Participants with non-SCCHN human papilloma virus positive (Non-SCCHN HPV+) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89043082|NCT01818674|No Intervention|Group C - Controls with Parallel Monitoring|Group C only received standard care, and only received parallel risk factor screening measurements; not participation in classroom or any social activities.
89043083|NCT01762839|Experimental|Oritavancin|Single-dose intravenous (IV) oritavancin diphosphate
89043084|NCT01762839|Placebo Comparator|Placebo|Single-dose IV placebo
89043085|NCT01762839|Active Comparator|Moxifloxacin|Moxifloxacin tablet
89641882|NCT01693562|Experimental|Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with non-small-cell lung cancer (NSCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641883|NCT01693562|Experimental|Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W)|Participants with hepatocellular carcinoma (HCC Total) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641884|NCT01693562|Experimental|Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with advance cutaneous melanoma (ACM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641885|NCT01693562|Experimental|Expansion UM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with uveal melanoma (UM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641886|NCT01693562|Experimental|Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with gastroesophageal cancer (GEC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641887|NCT01693562|Experimental|Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with triple-negative breast cancer (TNBC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641888|NCT01693562|Experimental|Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with pancreatic adenocarcinoma (PAC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89043086|NCT01693822|Experimental|Axitinib|Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg.
89043087|NCT01575834|Experimental|Romosozumab|Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
89043088|NCT01575834|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
89043089|NCT01509742|Experimental|NNC 90-1170|
89043090|NCT01509742|Placebo Comparator|Placebo|
89043091|NCT01385176|Experimental|Therapy|"Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.~The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.~Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
89043092|NCT01385176|Sham Comparator|Control|"Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
89043093|NCT01186328|Experimental|Single Arm|Patients will receive 2 doses of EZN-3042 (and intrathecal cytarabine, conditionally) prior to initiating systemic therapy with vincristine, doxorubicin, prednisone and PEG-asparaginase. Patients with CNS 1 or 2 will also receive intrathecal methotrexate, and patients with CNS 3 will also receive triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine).
89212380|NCT00864110|Active Comparator|18F FDG|18F FDG with PET/CT imaging
89641889|NCT01693562|Experimental|Expansion UC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with urothelial carcinoma (UC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641890|NCT01693562|Experimental|Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with glioblastoma multiforme (GBM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641891|NCT01693562|Experimental|Expansion OC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with ovarian cancer (OC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641892|NCT01693562|Experimental|Expansion STS Cohort (MEDI4736 10 mg/kg Q2W)|Participants with soft- tissue sarcoma (STS) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641893|NCT01693562|Experimental|Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with small-cell lung cancer (SCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641894|NCT01693562|Experimental|Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W)|Participants with microsatellite instability (MSI)-high cancer will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641895|NCT01693562|Experimental|Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with nasopharyngeal carcinoma (NPC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89641896|NCT00461097|Experimental|Egg Oral Immunotherapy (OIT)|Subjects ingest egg white solid (EWS) on Visit 1 (initial day dose escalation up to 50 mg), followed by a build-up phase (escalating daily egg doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects are on a maximally tolerated daily egg dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects are given a 5 gm Oral Food Challenge (OFC) using EWS to identify desensitized [1] subjects. Subjects/study staff are unblinded following this OFC and either continue on their egg OIT maintenance dose of 2 gm/day or are allowed to attempt escalation up to 2 gm/day for the remainder of the study (1-3 years). A 10 gm OFC to identify desensitized [1] subjects occurs at specified intervals under prescribed conditions (yrs 2 - 4). Subjects who pass this 1st 10 gm OFC stop study therapy for 4-6 wks, then have a 2nd 10 gm OFC. Subjects that pass this 2nd 10 gm OFC are considered tolerant [2], stop EWS dosing and add egg to their diet.
89641897|NCT00461097|Placebo Comparator|Control Group|Subjects ingest placebo (cornstarch) during Visit 1 (initial day of dose escalation up to 50 mg), followed by a build-up phase (escalating daily placebo doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects were on a maximally tolerated daily placebo dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects were given a 5 gm Oral Food Challenge (OFC) using egg white solid to identify desensitized [1] subjects. Subjects/study staff were unblinded following this initial 5 gm OFC. After unblinding, subjects discontinued further placebo dosing and continued on an egg-restricted diet. A 10 gm OFC was administered under prescribed conditions to subjects if their egg-specific serum IgE level was below 2 kUA/L. They were followed in the study up to 2 years. [1] Desensitized: Subject does not react to egg during OFC while taking daily doses of therapy. [2] Tolerant: Subject does not react to egg during OFC 4-6 wks after abstinence from egg consumption.
89641898|NCT01467713|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.
89641899|NCT01467713|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
89641900|NCT01467713|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
89641901|NCT01467713|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
89641902|NCT00531453|Experimental|1|bortezomib, dexamethasone, and thalidomide
89641903|NCT00531453|Experimental|2|bortezomib, dexamethasone, thalidomide, and cyclophosphamide
89641904|NCT00531843|Experimental|1A|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) >=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
89641905|NCT00531843|Active Comparator|1B|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS >=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
89641906|NCT00531843|Experimental|2A|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
89212381|NCT00864188|Placebo Comparator|1|Glucono-Delta-Lactone acidified milk containing no bacterial strains
89043094|NCT01130519|Experimental|1 - Bevacizumab and Erlotinib|All patients will be receiving fixed starting dose of bevacizumab (10 mg/kg intravenous (IV) every 2 weeks) and erlotinib (150 mg/day by mouth (PO)
89043095|NCT01054196|Experimental|all patients|subjects will receive daily doses of lenalidomide starting on Day -5 of transplant and melphalan on Days -2 and -1.
89043096|NCT01041508|Experimental|Related Donor Arm|Patients with related stem cell donors. Patients will receive Clofarabine in combination with 2Gy total body irradiation (TBI) as a preparative regimen for stem cell transplantation, in turn followed by cyclosporine and Mycophenolate Mofetil as GVHD prophylaxis.
89043097|NCT01041508|Experimental|Unrelated Donor Arm|Patients with unrelated stem cell donors. Patients will receive Clofarabine in combination with 2Gy total body irradiation (TBI) as a preparative regimen for stem cell transplantation, in turn followed by cyclosporine and Mycophenolate Mofetil as GVHD prophylaxis.
89043098|NCT00984490|Experimental|Metformin|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
89043099|NCT00859794|Experimental|Cognitive and Behavioral Testing|Participants will participate in cognitive tasks where brain recordings and task performance will be monitored and recorded.
89043100|NCT00648635||PET + QOL|Survey of how recurrent rectal cancer treatment affects well being + QOL
89043101|NCT00455858|Active Comparator|insulin detemir|
89043102|NCT00408005|Experimental|Group 0 Induction Therapy|All patients (T-ALL and T-LLy) receive cytarabine intrathecally (IT) on day 1; vincristine sulfate IV on days 1, 8, 15, and 22; prednisone IV or PO twice daily BID on days 1-28; pegaspargase IM (may give IV over 1 to 2 hours) on day 4, 5, or 6; daunorubicin hydrochloride IV on days 1, 8, 15 and 22; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease).
89043103|NCT00408005|Active Comparator|Group 1 Arm IV (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35.
89641907|NCT00531843|Active Comparator|2B|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).
89641908|NCT01693250|Experimental|fitbit ultra|Adolescents in the intervention group will receive a Fitbit Ultra and will download an app to their smartphone. Participants will be asked to wear the Fitbit device and use the app every day for three months.
89641909|NCT01693250|Active Comparator|Pedometer|After completion of the baseline assessments, adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
89641910|NCT02073461|Experimental|CD1579 2.5%|Benzoyl Peroxide 2.5%
89641911|NCT02073461|Experimental|CD1579 5%|Benzoyl Peroxide 5%
89641912|NCT02073461|Placebo Comparator|Vehicle|Vehicle
89641913|NCT04408547||soft catheter|Patients who underwent embryo transfer with a soft catheter
89641914|NCT04408547||stiff catheter|Patients who underwent embryo transfer with a stiff catheter because soft couldn't pass
89641915|NCT01590758|Placebo Comparator|Topical placebo control|
89641916|NCT01590758|Experimental|Topical pexiganan cream 0.8%|
89641917|NCT01590212|No Intervention|Care as usual|Participants received care in line with local guidelines
89641918|NCT01590212|Active Comparator|Mellow Bumps + care as usual|MB is a six week group-based antenatal programme designed to support families with additional health and social care needs. MB is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation.
89641919|NCT01590212|Active Comparator|Chill-out in Pregnancy + care as usual|CHiP is a relaxation programme that includes all the mother-centred components of Mellow Bumps but none of the baby or mother-baby relationship components. It runs for six weeks at two hours per week. It aims to decrease maternal stress levels.
89641920|NCT02985788||Video Instructions|Instructions on how to take a flexion/extension picture will be delivered in video format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
89641921|NCT02985788||Written instructions|Instructions on how to take a flexion/extension picture will be delivered in a written, on paper format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
89641922|NCT01692938||No Retinal Disease|
89641923|NCT01692938||Retinal Disease|
89641924|NCT00534417|Experimental|Capecitabine and fulvestrant|"Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 kg.~Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."
89641925|NCT01692782|Experimental|SEP-225289 4mg|SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses
89641926|NCT01692782|Experimental|SEP-225289 8mg|SEP-225289 8mg once daily taken as a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses
89641927|NCT01692782|Placebo Comparator|Placebo|4 capsules of placebo
89212382|NCT00864188|Experimental|2|Glucono-Delta-Lactone acidified milk containing one probiotic strain called Lactobacillus paracasei NCC2461.
89212383|NCT00864188|Placebo Comparator|3|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii subsp.bulgaricus.
89212384|NCT00864188|Experimental|4|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii and one probiotic strain called Lactobacillus paracasei NCC2461.
89641928|NCT01692626|Experimental|Pimecrolimus on Left vs. Placebo on Right|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
89641929|NCT01692626|Experimental|Pimecrolimus on Right vs. Placebo on Left|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
89641930|NCT00535587|Experimental|1|
89641931|NCT00535587|Experimental|2|
89641932|NCT00535587|Experimental|3|
89641933|NCT00535587|Experimental|4|
89641934|NCT01797237|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
89641935|NCT01797237|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
89641936|NCT01475461|Placebo Comparator|Placebo|
89641937|NCT01475461|Experimental|PF-04937319 - Dose 1|
89641938|NCT01475461|Experimental|PF-04937319 - Dose 2|
89641939|NCT01475461|Experimental|PF-04937319 - Dose 3|
89641940|NCT01475461|Experimental|PF-04937319 - Dose 4|
89641941|NCT01475461|Active Comparator|Sitagliptin|
89641942|NCT01589822|Experimental|EVICEL Fibrin Sealant: Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.
89641943|NCT01589822|No Intervention|Standard of Care|Standard surgical technique for GI anastomosis.
89641944|NCT01589822|Experimental|Experimental: EVICEL Fibrin Sealant: Non-Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
89641945|NCT01565642|Experimental|Decision support intervention|Decision aid and care plan meeting
89641946|NCT01565642|No Intervention|Control|Attention control information on dementia care
89641947|NCT01475071|Experimental|Metvix and daylight|
89641948|NCT01475071|Active Comparator|Metvix and lamp|
89641949|NCT01474993|Placebo Comparator|Placebo|inactive placebo.
89641950|NCT01474993|Experimental|Interventional|sulforaphane-rich Broccoli Sprout Extract.
89641951|NCT01691768|Experimental|Intervention|1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of Quality Improvement methodology to promote reliable service delivery
89641952|NCT01691768|Active Comparator|Control|monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
89641953|NCT01503229|Experimental|Treatment (abiraterone acetate and prednisone)|Patients receive abiraterone acetate orally once daily and prednisone orally twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89641954|NCT01691612|Experimental|D. pteronyssinus allergens|Single arm study exploring the role of Pin-1 enzyme in development of Asthma. Bronchoscopy before and 48 hours after installation of D. pteronyssinus allergens into the lung segments
89641955|NCT01565564|Active Comparator|The usual care arm|
89641956|NCT01565564|Active Comparator|The shared care arm|
89641957|NCT01460407|Experimental|LY2216684 + Clarithromycin|Participants will receive a single 18-mg oral dose of LY2216684 on Days 1 and 10. Clarithromycin (500 mg) will be administered twice a day (BID) on Days 6 through 13.
89641958|NCT01502371|Experimental|MF MDI 50 mcg BID|Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.
89641959|NCT01502371|Experimental|MF MDI 100 mcg BID|Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
89641960|NCT01502371|Experimental|MF MDI 200 mcg BID|Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
89641961|NCT01502371|Active Comparator|MF DPI 100 mcg QD|Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.
89641962|NCT01502371|Placebo Comparator|Placebo|Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
89641963|NCT01588496|Experimental|Part A: Evolocumab|Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
89641964|NCT01588496|Experimental|Part B: Evolocumab|Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
89641965|NCT01588496|Placebo Comparator|Part B: Placebo|Participants received double-blind placebo subcutaneously once a month for 12 weeks.
89212385|NCT00864188|Experimental|5|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii, one probiotic strain called Lactobacillus paracasei NCC2461 and Vitamin B2,B3, C and E, Beta Carotene and an Oil.
89212386|NCT05325749||unaffected|newborns without developmental features having no variations according to an inherited diseases screening;
89641966|NCT01502293|Experimental|Main Study: tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 3-month intervals until disease progression or unacceptable toxicity for up to 5 cycles.
89212387|NCT05325749||affected|newborns showing either phenotypic features or deviations according to MS screening
89212388|NCT05325749||refused families|parents refused to enroll their newborns to the study
89212389|NCT05325749||unaffected born prematurely|newborns without specific developmental features having no variations according to an inherited diseases screening, born before term
89212390|NCT05325749||unaffected wirh family history|newborns without developmental features having no variations according to an inherited diseases screening but with affected relative(s)
89521274|NCT03440281||Term group|Included pregnant females delivered after completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
89521275|NCT03440203||no Diabetic neuropathy|
89521276|NCT03440203||Diabetic peripheral neuropathy|
89521277|NCT03440203||Diabetic peripheral neuropathic pain|
89521278|NCT03440125|Experimental|Healthy|Healthy participants with no low back pain. 20 min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical) on the back will be administered.
89521279|NCT03440125|Experimental|LBP patients - CPC Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical).
89521280|NCT03440125|Experimental|LBP patients - CPC and ES/M Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical), and half of the subject also receiving 10 min electrical Stimulation and 10 min massage Treatment on the back.
89521281|NCT03435991||OAB patients|
89521282|NCT03435991||Healthy volunteers|
89521283|NCT03435913|Experimental|Standard PEEP ventilation|During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and 5 cmH20 of PEEP at every intra-abdominal pressure (IAP) step (8, 12 and 15 mmHg).
89521284|NCT03435913|Experimental|Matched PEEP Ventilation|"During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and a level of PEEP matched to every IAP step (8, 12 and 15 mmHg).~1 mmHg = 1,36 cmH20.~Between the standard and matched PEEP intervention there is a washout period that with a recruitment maneuver to re-establish baseline lung condition."
89521285|NCT03435757|Experimental|Test Group OFD+IMP+CPS|OFD+IMP+CPS; open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty (CPS)
89521286|NCT03435757|Active Comparator|Control group (OFD+IMP)|OFD+IMP;open flap debridement (OFD) and intramarrow penetration (IMP)
89521287|NCT03435679|Experimental|one-stage|one-stage surgical treatment of the infected knee arthroplasty
89521288|NCT03435679|Active Comparator|two-stage|two-stage surgical treatment of the infected knee arthroplasty with a interim period of 8-10 weeks between stages
89521289|NCT03435601|Experimental|Anifrolumab|Anifrolumab 300 mg IV administration Q4W, a total of 6 doses
89521290|NCT03435601|Placebo Comparator|Placebo|Placebo IV administration Q4W, a total of 6 doses
89521291|NCT04855825|Experimental|Robotic Exoskeleton Therapy|Gait rehabilitation provided using a wearable robotic exoskeleton
89521292|NCT04855825|Active Comparator|Conventional Gait Therapy|Gait rehabilitation provided using traditional gait therapy under the supervision of a licensed PT
89521293|NCT03435523|Experimental|Open lung approach|Recruitment maneuver during OLV in thoracic surgery
89521294|NCT03435445|Experimental|Online platform group|Online platform with diet, physical activity and behavior change recommendations for 24 weeks
89521295|NCT03435445|Experimental|Online dietitian coaching|Diet, physical activity and behavior change recommendations for 24 weeks and online sessions with a dietitian specialist for 12 weeks
89521296|NCT03435445|Active Comparator|Control group|Videos with diet, physical activity and behavior change recommendations for 24 weeks
89521297|NCT03435367|Experimental|Intervention Group (VR)|The patient will be allowed to 'try-out' the VR system (including all auditory and visual features) for ~5 minutes prior to the start of the procedure. In addition to usual care, consisting of child-life presence and topical analgesics if ordered by the treating medical team, children in the experimental condition will wear the VR HMD plus headphones and hold the VR controller.
89521298|NCT03435367|Active Comparator|Control Group (Standard Care - Video)|The patient will be allowed to watch an age-appropriate video on a tablet device. The patient will be offered to wear the same headphones as in the experimental condition. The patient will have the tablet and headphones for ~5 minutes prior to the start of the procedure. In addition, the patient will receive standard care consisting of a child life specialist and topical analgesics (if ordered by the treating medical team).
89521299|NCT03439969|No Intervention|Control|Dental appointment, one hour and included activities that are normally part of a SPT (Suportive Periodontal Treatment) consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon and Text Messages were not used.
89521300|NCT03439969|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
89521301|NCT03439969|Experimental|Mobile Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback.. Participants in the SMS group further received a total of 16 messages (SMS). One per week.
89641967|NCT01502293|Experimental|Addendum: Regimen A tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 8, and 15) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 9 cycles.
89641968|NCT01502293|Experimental|Addendum: Regimen B tavo EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 2 cycles.
89641969|NCT01474681|Experimental|HSC835|HSC835 infusion
89641970|NCT01459783|Active Comparator|Dementia care management in person|The dementia care management protocol will be delivered via face-to-face interactions in participants' homes or in mutually convenient locations between a trained care manager and the care recipient/informal family caregiver dyad, supplemented by telephone.
89641971|NCT01459783|Active Comparator|Dementia care management telephone only|The dementia care management protocol will be delivered via telephonic meetings only. Assessment, education, counseling, and social support procedures as well as referral and follow-ups will follow the same procedural content as stipulated for the face-to-face intervention, however, contact will not be planned in person.
89641972|NCT01588184|Experimental|Breast Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
89641973|NCT01588184|Experimental|Ovarian Cancer or Peritoneal Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
89641974|NCT01588184|Experimental|Renal Cell Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
89641975|NCT01588184|Experimental|Colorectal Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
89641976|NCT01588184|Experimental|Non-Squamous, Non-Small Cell Lung Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
89641977|NCT01588184|Experimental|Glioblastoma Multiforme|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
89641978|NCT01588106||Test group|patients using CONTOUR Next USB
89641979|NCT01588106||Control group|patients using standard CONTOUR
89641980|NCT01564862|Experimental|Vortioxetine (Lu AA21004) QD|Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
89641981|NCT01564862|Active Comparator|Duloxetine QD|Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
89641982|NCT01564862|Placebo Comparator|Placebo QD|Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
89641983|NCT01691378|Experimental|WtoH Intervention|Window to Hope: Psychotherapy consists of 10 2-hour sessions for a maximum dose delivered of 20 hours. Therapy consists of small groups of up to 2 participants.
89641984|NCT01691378|Other|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
89043104|NCT00408005|Active Comparator|Group I Arm I (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT. Patients with standard risk T-LLy received Arm I, and those with high risk T-LLy were randomized between Arm I and Arm II combination chemotherapy.
89212391|NCT05325749||unaffected wirh prenatal phenotype|newborns without developmental features at birth and on, having no variations according to an inherited diseases screening which had been observed to show signs of developmental features during prenatal ultrasound examination
89641985|NCT01467479|Experimental|T/PR + HAART Regimen (ATV/r-Based)|Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
89641986|NCT01467479|Experimental|T/PR + HAART Regimen (EFV-Based)|Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
89641987|NCT01467479|Experimental|T/PR + HAART Regimen (RAL-Based)|Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
89043105|NCT00408005|Active Comparator|Group I Arm I (Delayed intensification chemotherapy|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10). Standard risk T-LLy patients were assigned to Arm I and those with high risk were randomized between Arm I and Arm II.
89043106|NCT00408005|Active Comparator|Group I Arm I (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL), all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
89043107|NCT00408005|Active Comparator|Group I Arm I (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31. Patients with DS also receive leucovorin calcium PO 48 and 60 hours after each methotrexate IT dose (DS patients excluded as of 09/29/10).~Note: *Patients with an allergy to pegaspargase receive Erwinia asparaginase on days 2, 4, 6, 8, 10, 12, 22, 24, 26, 28, 30, and 32."
89057934|NCT04529525|Active Comparator|Ivermectin|"The dose of ivermectin in patients who are randomized to the active substance depends on the weight of the patient:~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
89641988|NCT01466387|Active Comparator|TF+YF|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
89641989|NCT01466387|Active Comparator|TF + YF + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
89641990|NCT01466387|Active Comparator|JE + Rabies|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
89641991|NCT01466387|Active Comparator|JE + Rab + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
89641992|NCT01466387|Active Comparator|Rabies|Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
89641993|NCT01466387|Active Comparator|MenACWY-CRM197 (Combined)|Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.
89641994|NCT00535743|Placebo Comparator|Arm A. Placebo; 3 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.
89641995|NCT00535743|Experimental|Arm B. 2 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89641996|NCT00535743|Experimental|Arm C. 4 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89641997|NCT00535743|Experimental|Arm D. 8 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89641998|NCT00535743|Experimental|Arm E. 12 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89641999|NCT00535743|Experimental|Arm F. 16 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89642000|NCT00535743|Placebo Comparator|Arm G. Placebo; 15 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89642001|NCT00535743|Experimental|Arm H. 2 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89642002|NCT00535743|Experimental|Arm I. 4 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89642003|NCT00535743|Experimental|Arm J. 8 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89642004|NCT00535743|Experimental|Arm K. 12 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89642005|NCT00535743|Experimental|Arm L. 16 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
89642006|NCT00535743|Placebo Comparator|Arm M. Placebo; 3 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642007|NCT00535743|Experimental|Arm N. 2 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642008|NCT00535743|Experimental|Arm O. 4 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642009|NCT00535743|Experimental|Arm P. 8 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89212392|NCT00864266|Experimental|1|After obtaining the biopsy, patients will be treated by standard chemotherapy (the regimen has to be in agreement with the ELCWP guidelines, available on the website www.elcwp.org)
89212393|NCT00918515|Experimental|AZD3043|Intravenous solution
89642010|NCT00535743|Experimental|Arm Q. 12 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642011|NCT00535743|Experimental|Arm R. 16 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642012|NCT00535743|Placebo Comparator|Arm S. Placebo; 15 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642013|NCT00535743|Experimental|Arm T. 2 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642014|NCT00535743|Experimental|Arm U. 4 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642015|NCT00535743|Experimental|Arm V. 8 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642016|NCT00535743|Experimental|Arm W. 12 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642017|NCT00535743|Experimental|Arm X. 16 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
89642018|NCT00535821|Experimental|MiCHO|A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
89642019|NCT00535821|Active Comparator|EGDT|A 6-hour resuscitation protocol utilizing CVP/ScvO2
89642020|NCT01564784|Experimental|Arm A|
89642021|NCT01564784|Active Comparator|Arm B|
89642022|NCT00536601|Experimental|Regimen CBV (patients with HL or NHL)|Patients receive etoposide intravenously (IV) continuously over 34 hours on day -8, cyclophosphamide IV over 2 hours on days -7 to -4, and carmustine IV over 2 hours on day -3. Patients undergo ASCT on day 0.
89642023|NCT00536601|Experimental|Regimen M200/M120 (patients with MM or amyloidosis)|Patients receive 200 or 120 mg/m^2 of melphalan IV over 30 minutes on day -2. Patients undergo ASCT on day 0.
89642024|NCT00536601|Experimental|Regimen BuC2iv (patients with ALL, AML, HL, or NHL)|Patients receive busulfan IV over 2 hours then every 6 hours on days -7 to -4 for 16 total doses and cyclophosphamide IV over 2 hours on days -3 and -2. Patients undergo ASCT on day 0.
89642025|NCT00536601|Experimental|Regimen CT6 (patients with ALL)|Patients receive cyclophosphamide IV over 2 hours on days -5 to -4. Patients then undergo TBI twice daily on days -3 to -1. Patients undergo ASCT on day 0.
89642026|NCT00536601|Experimental|Regimen CTtCp (patients with other solid tumors)|Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.
89642027|NCT00536601|Experimental|Regimen VCp (patients with testicular cancer)|Patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients then undergo a second ASCT on day 0.
89642028|NCT00536601|Experimental|Regimen TtC1500/ECpM (patients with NBL or SRBCT)|Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 2 hours on days -5 to -2. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive carboplatin IV continuously over 24 hours on days -7 to -4, etoposide IV continuously over 24 hours on days -7 to -4, and melphalan IV over 30 minutes on days -7 to -5. Patients undergo a second ASCT on day 0.
89642029|NCT00536913|Experimental|With Spacer|Budesonide/formoterol pMDI 40/2.25ug + spacer
89642030|NCT00536913|Experimental|Without Spacer|Budesonide/formoterol pMDI 40/2.25 ug
89642031|NCT00462423|Experimental|Single Arm, Open Label|Single Arm, Open Label trial of Abraxane and Avastin
89642032|NCT00461331|Active Comparator|Insulin 1|Either insulin Aspart or insulin Lispro were randomized to be insulin 1.
89642033|NCT00461331|Active Comparator|Insulin 2|Between insulin Aspart and insulin Lispro, the one that was not used as insulin 1 was then used as the second insulin for the second arm of the study.
89642034|NCT01564394|Experimental|Qigong|Qigong originated in China hundreds of years ago and has been practiced for centuries. It consists of a sequence of slow, flowing physical movements with concentration on the breath and awareness and may promote physical and mental relaxation and energy balance.
89642035|NCT01564394|Sham Comparator|Stretching control|The non-aerobic stretching will serve as an attention control group to control for non-specific factors; dose of attention and to mimic being in a group setting.
89642036|NCT00462735|Experimental|Advanced Head and Neck Cancer|Patients with stage IVA and IVB or high-risk stage III squamous cell carcinomas of the head and neck
89642037|NCT01690988|Experimental|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
89642038|NCT01690988|Placebo Comparator|Normal saline (placebo)|Intravenous normal saline
89642039|NCT01690988|Experimental|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
89642040|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
89642041|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
89212394|NCT04084223|Experimental|Active RA patients group|"64 active RA patients (DAS28>3,2 AND presence of ≥2 US synovitis with Power-Doppler≥2) with an inadequate response to methotrexate (MTX) starting a treatment with JAKi (tofacitinib ou baricitinib) will be evaluated at baseline, 1, 3 and 6 months in 5 centres.~A clinical joint assessment will be performed and CRP will be tested to calculate DAS28-CRP. Several PROs will be completed: RAPID3, HAQ, pain, and patient global assessment of disease activity on a VAS.~An US exam on 40 joints and 12 tendons will be performed by an independent investigator, looking for synovitis and tenosynovitis with B-Mode and Power Doppler. A Global US score (GLOESS) will be collected at each visit."
89212395|NCT00865670|Experimental|1|Azithromycin Monohydrate 600mg Tablets
89642042|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
89642043|NCT00463437|Active Comparator|Prevenar™ + Menitorix™|Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
89642044|NCT01466153|Active Comparator|Rituximab + Bendamustine|Rituximab was administered by IV infusion as 375 mg/m^2 on Day 2 of Cycle 1 and then 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.
89642045|NCT01466153|Experimental|MEDI-551 2 mg/kg + Bendamustine|MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
89642046|NCT01466153|Experimental|MEDI-551 4 mg/kg + Bendamustine|MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
89642047|NCT00464685|Experimental|700 µg Dexamethasone Implant and Laser Photocoagulation|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
89642048|NCT00464685|Sham Comparator|Sham Implant and Laser Photocoagulation|Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
89642049|NCT01474291||Tocilizumab|Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.
89642050|NCT01465997|Experimental|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
89642051|NCT01465997|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)
89642052|NCT00538863|Experimental|Fentanyl sublingual spray titration|Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.
89642053|NCT00538863|Experimental|Fentanyl sublingual spray maintenance|Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.
89642054|NCT00539253|Other|Gadobenate Dimeglumine (Multi Hance)|If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
89642055|NCT01465763|Experimental|tofacitinib 10 mg BID|
89642056|NCT01465763|Placebo Comparator|Placebo|
89642057|NCT00540579|Experimental|Intervention|All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
89642058|NCT00466323|Experimental|FMPO Condition|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
89642059|NCT00466323|Active Comparator|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
89642060|NCT04081727|Experimental|Test Article - Zip-stitch Clips|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
89642061|NCT04081727|Other|Reference Group - V-Loc Barbed Suture|Will not be comparative against the test article, but will be performed for reference and safety.
89642062|NCT01690520|Active Comparator|Arm I (standard of care)|"CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending physician: Patients receive fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose TBI BID on days -4 to -1 OR Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo middle intensity TBI QD on days -2 to -1.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour BID (adults) or TID (children) or PO on days -3 to 100 with taper beginning on day 101. Patients also receive MMF IV TID a day on days 0-7 then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then may begin a taper if there is no evidence of GVHD and are well-engrafted from one donor unit."
89642063|NCT01690520|Experimental|Arm II (experimental)|"CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending physician as in Standard of Care Arm.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0. Patients also undergo infusion of ex vivo-expanded cord blood progenitor cell infusion at least 4 hours after completion of UCB transplant.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO as in Standard of Care Arm."
89642064|NCT01796769|Experimental|Conventional|
89642065|NCT01796769|Active Comparator|Telemedicine|
89642066|NCT00541593|Experimental|NOTES pancreatic pseudocystgastrostomy|Patients who undergo pancreatic pseudocystgastrostomy via a NOTES technique.
89642067|NCT04081103|Experimental|Nexagon® (lufepirsen) High Dose Concentration|
89642068|NCT04081103|Experimental|Nexagon® (lufepirsen) Low Dose Concentration|
89642069|NCT04081103|Placebo Comparator|Vehicle|
89642070|NCT00541671|Placebo Comparator|1|Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
89642071|NCT00541671|Active Comparator|2|Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.
89642072|NCT01563536|Experimental|ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
89642073|NCT01563536|Experimental|ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
89642074|NCT03158337|Experimental|Aerobic exercise|Participants took part in a supervised 6-month long aerobic (walk/jog) training program held 3 days/week. Each session included a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cooldown, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise increased from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity is based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity builds from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
89642075|NCT03156465|Experimental|Hybrid L24 and Standard CI|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
89642076|NCT04163835|Experimental|Low-dose Group|The intervention is half-dose of Wenxin Granules (1/2 normal dose).
89642077|NCT04163835|Experimental|Medium-dose Group|The intervention is medium-dose of Wenxin Granules (normal dose).
89642078|NCT04163835|Experimental|High-dose Group|The intervention is twice-dose of Wenxin Granules (twice normal dose).
89642079|NCT04163835|Placebo Comparator|Placebo Group|The intervention is a placebo.
89642080|NCT01690130|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual.The brain stimulation techniques could theoretically improve the efficacy of smoking cessation. Treatment was standardized at 100% magnetic field intensity relative to the participant's resting MT, at 10 pulses per second (10 Hz) for 5 seconds, with an intertrain interval of 10 seconds. Treatment session lasted for 15 minutes with 3000 pulses.
89642081|NCT01690130|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rMT determination and DLPFC cortex localization, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes were connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device (Empi; St. Paul, MN, USA)
89642082|NCT04750161||Psoriasis Vulgaris|
89642083|NCT04750161||Atopic Dermatitis|
89642084|NCT04750161||Ichthyosis Vulgaris|
89642085|NCT04750161||Healthy Controls|
89642086|NCT01690052|Active Comparator|Cevimeline|Cevimeline vs Pilocarpine
89642087|NCT01690052|Active Comparator|Pilocarpine|Pilocarpine vs. Cevimeline
89642088|NCT02117193|Placebo Comparator|Alcohol intake|1 g/kg of etanol combined. Beer without alcohol in the same volume will be used to placebo condition.
89642089|NCT02117193|Active Comparator|sleep deprivation|one night of sleep deprivation will be compared to 8h of normal sleep.
89642090|NCT01689974|Other|Arm A: Ipilimumab|Ipilimumab administered alone Day 4, 25, 46, and 67
89642091|NCT01689974|Other|Arm B: Ipilimumab and Radiation|Radiation Therapy and Ipilimumab. Radiation treatment is administered for 5 fractions (sessions) over 1 week. On Day 4 treatment with Ipilimumab begins and continues on Days 25, 46, and 67.
89642092|NCT04750083|Experimental|phase II|Thirty-sixty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
89642093|NCT04750083|Experimental|phase III-experimental|Three hundred and twenty participants will receive HX008 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
89642094|NCT04750083|Experimental|phase III-control|Three hundred and twenty participants will receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W for another 31 cycles.
89642095|NCT02124603||single group|Patients undergone cataract surgery
89642096|NCT03092271|Active Comparator|Zero Suicide Quality Improvement (ZSQI)|Zero suicide best practices as implemented through a health system zero suicide quality improvement initiative
89642097|NCT03092271|Experimental|Stepped Care for Suicide Prevention|ZSQI plus a stepped care intervention that matches intensity of services to youth risk level.
89642098|NCT02954991|Experimental|Glesatinib and Nivolumab|Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
89642099|NCT02954991|Experimental|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
89642100|NCT02954991|Experimental|Mocetinostat and Nivolumab|Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks or 480 mg IV every 4 week
89642101|NCT02945787|Experimental|Extended Self-help|Spanish-Language Version of the Stop Smoking for Good: The Extended Self-help condition will comprise the 11 Stop Smoking for Good booklets and 9 supportive My Story pamphlets transcreated for Spanish speaking smokers.
89642102|NCT02945787|Active Comparator|Usual Care (UC)|NCI-Produced Spanish-language Self-help Booklet: The UC control condition enhances the external validity of the study by providing a comparison to an existing, credible intervention that a smoker could receive in a medical setting or elsewhere.
89642103|NCT02982837|Experimental|PEG-IFN & NUCLEOTIDE ANALOGUES|Peginterferon alfa-2a 180 Mcg infusion per week with ongoing NUCLEOTIDE ANALOGUES for 48 weeks.
89642104|NCT02982837|Active Comparator|NUCLEOTIDE ANALOGUES|Nucleoside same dose as they started the study.
89642105|NCT00469911|Experimental|Magnetic Resonance Spectroscopy|Patients will have Magnetic Resonance Spectroscopy to measure in vivo accumulation of triglycerides in myocardial tissue
88991680|NCT04375605|Active Comparator|Arm A (control arm)|Patients randomized in control arm A will receive four cycles of neoadjuvant chemotherapy with FLOT every two weeks (5-FU 2600 mg/m² d1, folinc acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) followed by surgical resection 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. 6-12 weeks after surgery adjuvant chemotherapy starts with 4 cycles of FLOT (total treatment period 25-32 weeks).
88991681|NCT04375605|Experimental|Arm B (experimental arm)|Patients randomized in experimental arm B will receive two cycles of neoadjuvant induction chemotherapy with FLOT (5-FU 2600 mg/m² d1, folinic acid 200 mg/m² d1, oxaliplatin 85 mg/m² d1, docetaxel 50 mg/m² d1) every two weeks (4 weeks of therapy) followed by radiochemo-therapy beginning at day 21 after day one of the last cycle of chemotherapy. Radiochemotherapy consists of oxaliplatin 45 mg/m² weekly (d1, 8, 15, 22, 29) and continuous infusional 5-FU 225 mg/m² plus concurrent radiotherapy given in 5/week fractions with 1.8 Gy to a dose of 45 Gy over 5 weeks. Resection is performed 4-6 weeks after last treatment with chemotherapy / radiation. Adjuvant treatment starts 6-12 weeks after surgery and consists of 4 cycles of FLOT (total treatment period of 26 - 33 weeks).
88991682|NCT04363359|Experimental|Quadrivalent influenza vaccine HD|Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.
88991683|NCT04363359|Experimental|Quadrivalent influenza vaccine LD|Participants randomized to receive two injections of 0.25 mL quadrivalent influenza vaccine at Day 0 and 28.
88991684|NCT04363359|Active Comparator|Trivalent influenza vaccine Victoria|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Victoria strain at Day 0 and 28.
89642106|NCT00469911|Experimental|Ex vivo heart biopsy|Patients will have their normal routine clinical heart biopsy of myocardial heart tissue.
88991685|NCT04363359|Active Comparator|Trivalent influenza vaccine Yamagata|Participants randomized to receive two injections of 0.25 mL trivalent influenza vaccine containing B/Yamagata strain at Day 0 and 28.
89642107|NCT00470301|Experimental|Arm I|Tipifarnib plus sequential weekly paclitaxel followed by doxorubicin plus cyclophosphamide
89642108|NCT00543777|Experimental|MRE + 2PD MRI|MRE - Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue. 2PD MRI - Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
89642109|NCT00544713|Experimental|Carboxymethylcellulose and Glycerin based artificial tear|Carboxymethylcellulose and Glycerin based artificial tear
89642110|NCT00544713|Active Comparator|Carboxymethylcellulose based artificial tear|Carboxymethylcellulose based artificial tear
89642111|NCT02126319|Experimental|Cognitive Affective Preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
89642112|NCT02126319|Active Comparator|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
89642113|NCT00545025|Experimental|GSK1247446A Group|Subjects aged between 18 and 60 years, having previously received one dose of the AS03-adjuvanted GSK1247446A vaccine in the primary study NCT00374842, received a single dose of GSK1247446A vaccine adjuvanted with a half dose of AS03 adjuvant at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Subjects in this group originated from either the GSK1247446A Formulation 1 or GSK1247446A Formulation 2 groups in study NCT00374862.
89642114|NCT00545025|Active Comparator|Fluarix Group|Subjects aged between 18 and 60 years, having previously received one dose of Fluarix™ vaccine during the primary study NCT00374842, received one dose of Fluarix™ vaccine at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltiod region of the non-dominant arm. Subjects in this group originated from the Fluarix Group in study NCT00374862.
89642115|NCT00545181|Experimental|Metronidazole plus gel|Receive metronidazole plus vaginal gel
89642116|NCT00545181|Active Comparator|Control- metronidazole alone|Oral Metronidazole antibiotic therapy alone
89212396|NCT00865670|Active Comparator|2|Zithromax (azithromycin dihydrate)600mg Tablets
89212397|NCT00864344|Experimental|A|Sertraline HCl 100 mg tablets, single dose
89212398|NCT00864344|Active Comparator|B|Zoloft® 100 mg tablets, single dose
89212399|NCT00870974|Experimental|Assess [18F]FPEB and PET imaging|To assess [18F] FPEB and PET imaging in subjects with neuropsychiatric conditions.
89212400|NCT02589431||Patients with severe sepsis|
89212401|NCT02589431||Controls|Healthy subjects
89212402|NCT00864422|Experimental|1|
89212403|NCT00864422|Active Comparator|2|
89212404|NCT00864500|Experimental|A|Clobetasol Propionate 0.05% lotion, single exposure
89212405|NCT00864500|Active Comparator|B|Clobex TM 0.05% Lotion, single exposure
89212406|NCT02588963|Experimental|Experimental Group 1|Children whose caregivers were subjected to a health education session
89212407|NCT02588963|Experimental|Experimental Group 2|Children who were subjected to nasal clearance protocol
89212408|NCT02588963|Experimental|Experimental Group 3|Children whose caregivers were subjected to health education session and who were subjected to respiratory physiotherapy protocol
89212409|NCT02588963|Placebo Comparator|Control Group|Children who were not subjected to respiratory physiotherapy protocol for nasal clearance and whose parents were not subjected to health education session
89212410|NCT00864656||1|Patients submitted to application of 1 drop of 10% phenylephrine
89212411|NCT00864656||2|Patients submitted to application of 2 drops of 10% phenylephrine
89212412|NCT00864656||3|Patients submitted to application of 4 drops of 10% phenylephrine
89212413|NCT00864734|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
89642117|NCT01797315|Active Comparator|Sirolimus|Patients who meet all inclusion criteria will be included into the study and randomised. If converted to Sirolimus (SRL), patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medication in the morning. The dose of SRL will be correlated to the former immunosuppressive therapy according to the study's conversion protocol.
89642118|NCT01797315|No Intervention|Standard therapy|Patients who will not receive SRL stay on their previous immunosuppressive therapy including one or more of the following drugs: azathioprine, cyclosporine, tacrolimus, mycophenolate-sodium and steroids.
89642119|NCT00471705|Experimental|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
89212414|NCT00864734|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
89212415|NCT04084691|Experimental|Single Arm|Every patient will undergo every combination of physical exercise/meal type (3x3 combinations), one following the other. Each combination is replicated three times.
89212416|NCT00864812|Experimental|1|tiotropium with fluticasone propionate/salmeterol (FSC)
89212417|NCT00864812|Active Comparator|2|tiotropium
89212418|NCT02590055|Experimental|Intervention arm|D1, 8 Gemcitabine 1000mg/m2 IV over 30 minutes D1, 8 Docetaxel 35mg/m2 IV over 1hr
89212419|NCT00864890|Experimental|A|Citalopram HBr 40 mg tablets, single dose
89212420|NCT00864890|Active Comparator|B|CelexaTM 40 mg tablets, single dose
89212421|NCT00919295|Placebo Comparator|placebo|placebo
89212422|NCT00919295|Placebo Comparator|mirtazapine 15|mirtazapine 15 mg
89212423|NCT00919295|Placebo Comparator|mirtazapine 30|mirtazapine 30mg
89212424|NCT00865748|Experimental|A|Metformin HCl 500 mg tablets, single dose
89642120|NCT00471705|Active Comparator|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
89642121|NCT00471705|Experimental|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
89212425|NCT00865748|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
89212426|NCT00865826||1|HIV-infected males and females who are not currently receiving ART
89212427|NCT00866060|Active Comparator|1|"10mg donepezil plus 20mg memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards"
89212428|NCT00866060|Placebo Comparator|2|"Placebo donepezil plus 20mg memantine~Participants in this arm will immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards. Donepezil dose will be reduced to 5mg daily in weeks 1 to 4 and replaced with placebo donepezil in week 5."
89212429|NCT00866060|Placebo Comparator|3|"10mg donepezil plus placebo memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence placebo memantine."
89212430|NCT00866060|Placebo Comparator|4|"Placebo donepezil plus placebo memantine~Participants in this arm will immediately commence placebo memantine dose escalation and will switch to donepezil 5mg daily in weeks 1 to 4, and replaced with placebo donepezil in week 5."
89212431|NCT00866138|Experimental|1|masitinib (AB1010)
89212432|NCT00502840|Experimental|1|
89212433|NCT00515008|Experimental|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi 18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
89642122|NCT01797861|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne ®) is administered, with an infusion time of 10 minutes. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first treatment with half-dose PDT), a second treatment with half-dose PDT will be performed (Treatment Visit 2)."
89642123|NCT01797861|Active Comparator|Micropulse laser (ML) treatment|"ML treatment with an 810 nm diode laser will be performed of the areas identified on mid-phase ICG angiography. Multiple laser spots will be applied, covering the leakage area on mid-phase ICG angiography. The area(s) that has to be treated is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein angiogram.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first ML treatment), a second ML treatment will be performed (Treatment Visit 2)."
89642124|NCT00472797|Active Comparator|1|Rebif New Formulation - Non Titrated
89642125|NCT00472797|Active Comparator|2|Rebif New Formulation - Titrated
89642126|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided twice daily (BID) in treatment-naïve participants with HCV genotype 1 infection.
89642127|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 2 infection.
89642128|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 3 infection.
89642129|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 1 infection.
89642130|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 2 infection.
89642131|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 3 infection.
89642132|NCT01464827|Experimental|Group A|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
89642133|NCT01464827|Experimental|Group B|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
89642134|NCT01464827|Experimental|Group C|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
89642135|NCT01464827|Experimental|Group D|Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
89642136|NCT01464827|Experimental|Group E|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
89642137|NCT01464827|Experimental|Group F|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
89642138|NCT01464827|Experimental|Group G|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
89642139|NCT01464827|Experimental|Group H|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
89043108|NCT00408005|Active Comparator|Group I Arm II (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35. Patients with high risk T-LLy were either randomized to Arm I or Arm II. Patients with T-LLy who failed induction therapy were assigned to Arm II.
89043109|NCT00408005|Active Comparator|Group I Arm II (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
89043110|NCT00408005|Active Comparator|Group I Arm II (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31.~Note: *Patients with an allergy to pegaspargase receive Erwinia asparaginase on Monday, Wednesday and Friday for two consecutive weeks starting the day of asparaginase substitution."
89642140|NCT01464827|Experimental|Group I|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
89642141|NCT01464827|Experimental|Group J|Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
89212434|NCT00515008|Placebo Comparator|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
89212435|NCT03326830|Active Comparator|Standard oxygen therapy|Standard oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system. The flow will be tapered to target an SpO2 ≥ 95%
89212436|NCT03326830|Experimental|High-flow nasal oxygen (HFNO)|Experimental: High-flow nasal oxygen (HFNO) group Device that delivers humidified and warmed high-flow oxygen at flows between 30-60L/min HFNO will be initiated at a flow rate between 30-60 L/min and FiO2 titrated for a target of SpO2 ≥ 95%.
89212437|NCT01013662|Active Comparator|glycemic control between 180 and 220 mg/dl|
89212438|NCT01013662|Active Comparator|glycemic control for levels between 80 and 110 mg/dl|
89212439|NCT01011790|Experimental|Stress Management Tool|All subjects will use the Healing Rhythms™ meditation program for 4 weeks.
89212440|NCT00514540|Experimental|First-Line/Second-Line Chemotherapy|"First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1. Repeated every 3 weeks.~Second-Line (EP) Chemotherapy: Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks."
89212441|NCT03121534|Experimental|Ibrutinib, Nivolumab and Blinatumomab|"2 (8week) cycles of ibrutinib, nivolumab and blinatumomab. 9 (4week) cycles ibrutinib and nivolumab. Maintenance with ibrutinib monotherapy until disease progression following completion of nivolumab.~Ibrutinib treatment will begin cycle 1, day 1 at 420mg/d. Nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.~blinatumomab continuous IV infusion, starting day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week blinatumomab treatment-free interval. Hospitalization in cycle 1 on day 15-31 (first 17 days of blinatumomab therapy). Blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28, followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days. Blinatumomab in cycle 2 will be administered at a dose of 112 mcg/day from day 1-28."
89212442|NCT01012102|Experimental|Group 1|EMD 640744 30μg and Montanide® ISA 51 VG
89212443|NCT01012102|Experimental|Group 2|EMD 640744 100μg and Montanide® ISA 51 VG
89212444|NCT01012102|Experimental|Group 3|EMD 640744 300μg and Montanide® ISA 51 VG
89212445|NCT01013818|Experimental|HGS1029|
89212446|NCT01013896|Active Comparator|Cystic Fibrosis Education|This intervention is designed to increase knowledge and enhance the skills needed to optimize CF-management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem-solving training to overcome barriers.
89642142|NCT01464827|Experimental|Group K|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
89642143|NCT01464827|Experimental|Group L|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
89642144|NCT01464827|Experimental|Group M|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
89642145|NCT01464827|Experimental|Group N|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
89212447|NCT01013896|Experimental|Motivational Interviewing|The Counselor's overarching goal for the intervention is to motivate and assist the participant to improve his/her adherence to the CF pulmonary medications. The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic-level figures showing the association between adherence and health outcomes.
89642146|NCT01463111|Other|Mood stabilizer|Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
89642147|NCT01463033|Active Comparator|Levetiracetam|66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
89642148|NCT01463033|No Intervention|No Intervention Control|60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.
89642149|NCT03026543|Experimental|Pulmonary recruitment maneuver|One minute of ventilator-piloted PRM at the end of laparoscopic cholecystectomy, intending to remove residual carbon dioxide (CO2) from the abdomen.
89212448|NCT01013974|Experimental|GSK573719 250 microgram (μg) arm|Each subject will receive the first dose of GSK573719 250 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
89642150|NCT03026543|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic cholecystectomy.
89642151|NCT01461707|Experimental|Mobile app plus activity monitor group|Participants in the group will receive the mobile phone-based physical activity program and an activity monitor
89642152|NCT01461707|Active Comparator|Activity monitor group|Participants in the group will receive an activity monitor
89642153|NCT01461551|Experimental|Sevoflurane|
89642154|NCT01461551|Experimental|Propofol|
89642155|NCT01461551|Experimental|Combine of sevoflurane and propofol|
89642156|NCT04077359|Experimental|nephrographic phase CT|the nephrographic phase will be evaluated alone by a radiologist blinded to the remaining series
89642157|NCT04077359|Active Comparator|gold standard|all series (unenhanced, corticomedullary, nephrographic and excretory phase) will be evaluated by a radiologist not involved in the experimental arm
89642158|NCT01461005|Experimental|Dynamic Stabilization System|Dynamic Stabilization System (DSS) System
89642159|NCT04599257|Experimental|Hip and thigh circumference changes|"The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits. All of the study subjects will receive the treatment with the subject device.~At the baseline visit, MRI imaging will be performed; the subject's weight and hip and thigh circumference will be recorded. Photos of the treated area will be taken.~The treatment administration phase will consist of four (4) treatments, delivered once a week. The applicator of the device will be applied over the treatment area. The device will induce visible muscle contractions along with heating of the subcutaneous fat.~At the last therapy visit, the subject's weight and hip and thigh circumference will be recorded, and photos of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire to fill in."
89642160|NCT01460381|Experimental|LY2216684 + Quinidine (CYP2C19 poor metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 poor metabolizer (PM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 was administered on Day 1.~Period 2 (Days 8-15): 300 mg quinidine sulfate controlled release was administered orally, once daily on Days 8-15. Additionally, a single, oral dose of 18 mg LY2216684 was administered on Day 11."
89642161|NCT01460381|Experimental|LY2216684 (CYP2C19 extensive metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 extensive metabolizer (EM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 administered on Day 1.~Period 2 (Days 8-15): EM participants did not participate in this period."
89642162|NCT02985359||Comparison district|Existing routine community health services by government
89642163|NCT02985359||Program district|In addition to existing routine community health services by the government, daily 20g Nutributter (Lipid-based Nutrient Supplement, LNS) will be provided to children 6 to 24 month of age and caregivers will participate in Social and Behavior Change Communications (SBCC) activities including the promotion of infant and young child feeding (IYCF) behaviors and water, sanitation and hygiene (WASH) behaviors will be conducted with caregivers.
89642164|NCT00546897|Experimental|Cohort 1|"Lenalidomide 50 mg/day oral for 14 days followed by 30 days of rest. Lenalidomide 50 mg/day oral for 21 days (this is Cycle 1 and Cycle 2).~If no progressive disease (PD) then lenalidomide 10 mg/day oral for 28 days for 12 cycles."
89642165|NCT00546897|Experimental|Cohort 2|"Cycle 1: Oral lenalidomide 50 mg/day x 28 days induction therapy. Treatment will then depend on the response to Cycle 1: if patients obtain a complete remission (CR) they will proceed to low dose lenalidomide therapy, if patients have a non-CR they will receive a second high dose cycle of lenalidomide 50 mg/day x 28 days (Cycle 2) Cycle 2 consists of lenalidomide 50mg/day x 28 days Further treatment will depend on the response to Cycle 2: if patients obtain a CR/partial remission (PR)/stable disease (SD) they will proceed to low dose lenalidomide therapy, if patients have PD they will be removed from the study.~Low Dose Cycles: low dose lenalidomide therapy consisting of 10 mg daily for a 28 day cycle.be 1) For patients that achieve a CR, 2 cycles of low dose lenalidomide will be administered, and then patients observed off therapy. For patients with PR/SD, low dose lenalidomide will continue for a total of 6 cycles and then patients will be observed off therapy."
89642166|NCT00474123|Active Comparator|Simvastatin 80 mg|Patients were treated with simvastatin 80 mg for 6 weeks
89642167|NCT00474123|Active Comparator|Ezetimibe 10 mg / Simvastatin 20 mg|Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
89642168|NCT00474201|Sham Comparator|Gemfibrozil PK without LPV/r|"Subjects received a single 600 mg dose of gemfibrozil without concurrent lopinavir-ritonavir 400mg/100mg; this is the control arm of a crossover study design."
88991686|NCT04361279|Experimental|SIBP-02|"Biological: SIBP-02, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.~Treatment cycle: 6 cycles, each cycle is 3 weeks."
88991687|NCT04361279|Active Comparator|Rituximab|"Biological: Rituximab, 375 mg/m2, intravenous infusion, administered on day1. Drug: Cyclophosphamide, 750 mg/m2, intravenous infusion, administered on day2. Drug: Doxorubicin Hydrochloride, 50 mg/m2, intravenous infusion, administered on day2.~Drug: Vincristine Sulfate, 1.4 mg/m2, intravenous infusion, administered on day2.~Drug: Prednisone Acetate Tablets, 100 mg, orally administered on day2-6, one time per day.~Treatment cycle: 6 cycles, each cycle is 3 weeks."
88991688|NCT04343560||patients with MACS|Patients with adrenal adenoma and dexamethasone suppression test >1.8 mcg/dl
88991689|NCT04343560||healthy controls|no history of adrenal and pituitary disease, no exogenous steroids
88991690|NCT04338191|Experimental|mFOLFOXIRI adjuvant chemotherapy|Patients will receive mFOLFOXIRI once every two weeks for 6 cycles as adjuvant chemotherapy
88991691|NCT04338191|Active Comparator|mFOLFOX6 adjuvant chemotherapy|Patients will receive mFOLFOX6 once every two weeks for 6 cycles as adjuvant chemotherapy
88991692|NCT04316117|Experimental|Diagnostic (FDG-PET/CT)|Patients receive FDG IV and undergo PET/CT scan over 15-30 minutes at baseline (within 21 days before start of standard systemic treatment) and at 12 weeks after start of standard systemic treatment in the absence of unacceptable toxicity.
88991693|NCT04308226|No Intervention|Usual care without patient navigation|Participants assigned to this arm will be given basic educational materials on general lung health and referred back to their primary care provider (PCP) for management as per usual practice.
89642169|NCT00474201|Experimental|Gemfibrozil PK after 2 weeks of LPV/r|Single dose (600 mg) Gemfibrozil pharmacokinetics (i.e. plasma concentrations collected over time to calculate area under the concentration vs. time curve) assessed after 14.5 days of lopinavir/ritonavir (400/100 mg twice daily) administration.
89642170|NCT03720327|Active Comparator|Get FIT|The Get FIT intervention
89642171|NCT03720327|Experimental|Get FIT+|The Get FIT+ intervention, which includes push-only personalized text messages from a health coach.
89642172|NCT01796847||PTEN, hyperglycemia|
89642173|NCT00548691|Experimental|Ferric Carboxymaltose (FCM)|Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.
89642174|NCT00548691|Active Comparator|Standard Medical Care (SMC)|SMC for IDA (as determined by the Investigator) for treating CKD related anemia.
89642175|NCT03431259|Experimental|Enrollment group|
89642176|NCT03431259|No Intervention|Information group|
89642177|NCT00549393|Experimental|1|Daily bathing with 2% chlorhexidine gluconate
89642178|NCT00549393|No Intervention|2|Standard bathing with soap and water basin or disposable cloth
89642179|NCT00549783|Active Comparator|Botulinum toxin type A 900kD|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
89642180|NCT00549783|Placebo Comparator|Placebo|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
89642181|NCT00475215|Experimental|Rocuronium + Sugammadex 2.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 2.0 mg/kg.
89642182|NCT00475215|Experimental|Rocuronium + Sugammadex 4.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 4.0 mg/kg.
89642183|NCT00477087|Experimental|GM-CSF Plus Mitoxantrone|GM-CSF at 250 micrograms/ m² / day subcutaneously 3 x week for 3 weeks. Participants will also receive mitoxantrone 14 mg/m² on Day 1 of each cycle. Each cycle of therapy consists 21 days.
89642184|NCT04409912|Experimental|Sirolimus coated balloon|The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the vessel wall by inflating the sirolimus coated balloons at 2 minutes at rated burst pressure (typically 12 to 14ATM). All the lesions within the dialysis circuit with sirolimus coated balloon.
89642185|NCT04409912|Placebo Comparator|Plain balloon|The plain balloon or placebo will not be coated. The plain balloon will be inflated at 2 minutes at rated burst pressure (typically 12 to 14 ATM). Plain balloon will be applied to all the narrowed segment of the dialysis circuit
89642186|NCT01473589|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
89642187|NCT01473589|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
89642188|NCT00478335|Experimental|Active Therapy|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, calcitonin, sildenafil
89642189|NCT00478335|Placebo Comparator|Placebo Control|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, placebo for calcitonin, placebo for sildenafil
89642190|NCT04085263|Sham Comparator|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
89043111|NCT00408005|Active Comparator|Group I Arm II (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
89043112|NCT00408005|Active Comparator|Group I Arm III (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT.
89212449|NCT01013974|Experimental|GSK573719 500 μg arm|Each subject will receive the first dose of GSK573719 500 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
89642191|NCT04085263|Experimental|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
89642192|NCT01500187|Active Comparator|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
89642193|NCT01500187|Experimental|3M Vanish Varnish|5% sodium fluoride varnish
89642194|NCT00478569||Parathyroid Hormone (PTH) (1-84)|PTH(1-84) was prescribed in accordance with the terms of the marketing authorization. Participants were observed for 24 months.
89642195|NCT01500031|Experimental|OffRoad Re-entry catheter|Participants treated with OffRoad Re-entry Catheter System
89642196|NCT03026491||Children with chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
89642197|NCT03026491||Children without chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
89642198|NCT04085185|Experimental|Phase Ia Dose-Escalation Stage:IBI110|Participants will be treated with escalating doses of IBI110 to determine the MTD.
89642199|NCT04085185|Experimental|Phase Ia Expansion Stage:IBI110|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in different cancer types.
89642200|NCT04085185|Experimental|Phase Ib Dose-Escalation Stage:IBI110+ Sintilimab|Participants will be treated with escalating doses of IBI110 in combination with a fixed dose of Sintilimab to determine the MTD.
89642201|NCT04085185|Experimental|Phase Ib Expansion Stage:IBI110+ Sintilimab|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI110 in combination with Sintilimab in different cancer types.
89642202|NCT00479037|Active Comparator|PTH(1-84)|
89642203|NCT00479037|Active Comparator|Strontium Ranelate|
89642204|NCT02985229|Experimental|All participants|All participants in the study will be given the option of home administration of 200 mg oral mifepristone and 800 μg buccal misoprostol for medical abortion.
89642205|NCT01473355|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm
89642206|NCT00479115|Experimental|AMD3100|
89642207|NCT01472965|Active Comparator|Treatment|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with 70% ethanol catheter lock therapy.
89642208|NCT01472965|Placebo Comparator|Control|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with heparin-saline placebo catheter lock therapy.
89642209|NCT00480987|Experimental|Oxaliplatin + Cytarabine + Fludarabine|Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6
89642210|NCT01457053|Active Comparator|Ultrafiltration|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretics (loop diuretics: furosemide, bumetanide, and/or torsemide). Patients in this arm are randomized to ultrafiltration.
89642211|NCT01457053|Active Comparator|Diuretic Therapy|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretic therapy ((loop diuretics: furosemide, bumetanide, and/or torsemide). The myocardial blood flow of patients treated with ultrafiltration will be actively compared to diuretic therapy with either furosemide, bumetanide, and/or torsemide.
89642212|NCT00481845|Experimental|Vandetanib + Anastrozole|Vandetanib and Anastrozole as neoadjuvant therapy
89642213|NCT00481845|Active Comparator|Anastrozole|Anastrozole as neoadjuvant therapy
89642214|NCT01472341||All Participants|Participants receiving routine care under a diabetologist.
89642215|NCT01472185|Placebo Comparator|Placebo|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
89642216|NCT01472185|Experimental|Ranolazine|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
89642217|NCT00482547|Experimental|Silver-coated catheter|Bard Hydrogel Silver Salts Coated Latex Urinary Catheter System
89642218|NCT00482547|Placebo Comparator|Silicone-coated catheter|Bard silicone elastomer coated latex catheter system
89642219|NCT00482625|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
89642220|NCT01456897|Experimental|OPC-34712|
89642221|NCT00553839|Other|Ketamine|Then a 2 mg/kg IV bolus of Ketamine hydrochloride will be given as part of general anesthesia for procedure
89642222|NCT01797393|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
89642223|NCT01797393|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .The mucosa was observed by inflating the bowel with air while withdrawing the colonoscope.All the patients were examined without sedation during the whole procedure.
89642224|NCT01797393|Experimental|" Air assisted water colonoscopy"|" Air assisted water injection colonoscopy: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.All the patients were examined without sedation during the whole procedure."
89642225|NCT01456195|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.
89642226|NCT01456195|Experimental|Fasiglifam 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.
89642227|NCT01456195|Experimental|Fasiglifam 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.
89642228|NCT00554463|Experimental|Combined Modality Therapy with Growth Factor Support|Concurrent radiation therapy, cisplatin, etoposide, and filgrastim followed by adjuvant cisplatin, etoposide, and pegfilgrastim.
89642229|NCT04748263||Fronto-Temporal Dementia (FTD)|10 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
89642230|NCT04748263||Alzheimer's Dementia (AD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
89642231|NCT04748263||Parkinson's Disease (PD)|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
89642232|NCT04748263||Healthy volunteers|20 subjects Standard neuropsychological evaluations. Standard Eye-Tracking paradigms.
89642233|NCT00554853|Other|Pioglitazone then placebo|Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
89642234|NCT00554853|Other|placebo then study drug (pioglitazone)|Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.
89642235|NCT00556491|Active Comparator|minocycline|
89043113|NCT00408005|Active Comparator|Group I Arm III (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10).
89043114|NCT00408005|Active Comparator|Group I Arm III (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine sulfate IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
89642236|NCT00556491|Placebo Comparator|placebo|
89642237|NCT05622513||cases|obesity / overweight children
89642238|NCT05622513||controls|normal weight children
89642239|NCT01797549||History of having sustained TBI|Males and females between 18 and 60 years who have a diagnosis of TBI
89642240|NCT01797549||Control group|Control group with no history of TBI or concussion. Gender and age matched non-TBI volunteers
89043115|NCT00408005|Active Comparator|Group I Arm III (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL) and all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
89043116|NCT00408005|Active Comparator|Group I Arm IV (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age); doxorubicin IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
89043117|NCT00408005|Active Comparator|Group I Arm IV (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
89212450|NCT01013974|Experimental|GSK573719 1000 μg arm|Each subject will receive the first dose of GSK573719 1000 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
89642241|NCT05622357|Experimental|Short course RT followed by full course of chemotherapy then surgery|Short course radiation therapy ( 25 Gy/ 5 fractions/ 1 week) , followed by 6 cycles of chemotherapy CAPOX, followed 4-6 weeks by surgery.
89642242|NCT02613819|Experimental|Stereotactic Ablative Body Radiotherapy|"Stereotactic Ablative Body Radiotherapy (SABR)~Treatment schedule 1: 26 Gray (Gy) in 1 fraction, for tumours of less than or equal to 4cm in size.~Treatment schedule 2: 42 Gray (Gy) in 3 fractions, for tumours of greater than 4cm in size"
89642243|NCT00485433|Active Comparator|Bupivacaine HCl 105mg|Bupivacaine HCl given during hernia repair
89642244|NCT00485433|Experimental|SKY0402 low dose|SKY0402 low dose given during hernia repair
89642245|NCT00485433|Experimental|SKY0402 Middle dose|SKY0402 middle dose given during hernia repair
89642246|NCT00485433|Experimental|SKY0402 High dose|SKY0402 high dose given during hernia repair
89642247|NCT02850081|No Intervention|Observational - Maximal Dose - ARM 1|Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for ~2 weeks before their CEA.
89642248|NCT02850081|Experimental|Less Than Maximal Dose - ARM 2|Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin <40mg without amlodipine and <20mg with amlodipine; Atorvastatin (<80mg) or Rosuvastatin (<20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for ~2 weeks before their CEA.
89642249|NCT02850081|Experimental|Statin Naive - ARM 3|Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for ~2 weeks before their CEA
89642250|NCT01456039|Experimental|Romidepsin|Patients will receive romidepsin intravenously for 4 hours on Days 1, 8, and 15 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, severe adverse events, or consent withdrawal.
89642251|NCT01455415|Experimental|1: Pregabalin|
89642252|NCT01455415|Placebo Comparator|2: Placebo|
89642253|NCT01471171|Experimental|Aclidinium bromide|3-week treatment periods
89642254|NCT01471171|Experimental|Placebo|3-week treatment periods
89642255|NCT01471093|Experimental|Solution|A single dose of OPC-12759 Ophthalmic solution for two-day treatment
89642256|NCT01471093|Active Comparator|Suspension|A single dose of OPC-12759 Ophthalmic suspension for two-day treatment
89642257|NCT01471015|Active Comparator|High dose Darbepoetin alfa|10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
89642258|NCT01471015|Active Comparator|Low dose Darbepoetin alfa|2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
89642259|NCT01471015|Placebo Comparator|Placebo|Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
89642260|NCT01497067|Experimental|CACHET|ACRYSOF CACHET Phakic Lens (L-series) previously implanted
89642261|NCT02334787|Experimental|0.3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
89642262|NCT02334787|Experimental|1% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
89642263|NCT02334787|Experimental|3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
89642264|NCT02334787|Placebo Comparator|Placebo in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
89642265|NCT02334787|Experimental|0.3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
89642266|NCT02334787|Experimental|1% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
89642267|NCT02334787|Experimental|3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
89642268|NCT02334787|Experimental|Placebo in the multiple administration period|In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
89642269|NCT01470469|Active Comparator|SPD503|
89642270|NCT01470469|Placebo Comparator|Placebo|
89642271|NCT04644367|Experimental|Tai Chi group|The Tai Chi (TC) group will receive or be taught TC in a class size consisting of about 5-12 students. Classes will be taught by a TC master with more than 4 years of experience practicing either Yang or Wu style TC. The participants will be allowed to practice TC at home and during their leisure time so long as they keep an activity log of their daily TC practice. This monitoring form (i.e. activity log or journal) will be distributed to all members of this group and collected weekly.
89642272|NCT04644367|Active Comparator|Regular Physical Activity (control) group|The regular physical activity (control) group will be asked to maintain or engage in at least 60 minutes of regular physical activity on their own for three times per week. The participants will be instructed as to the type of regular PA that they may engage in. These types of PA include: walking, cleaning or performing chores inside the home, and/or climbing the stairs. No restriction will be made to limit others forms of physical activity; individuals in the control group will be permitted to engage in organized sports, instructor-led class such as boxing, dance, etc. to ensure the participant recruitment process is feasible. Similar to the TC group, participants in this group will be asked to complete an activity log (or journal) that will be collected weekly to monitor their regular PA levels.
89642273|NCT01470001|Active Comparator|solifenacin|patients in this arm will receive drug
89642274|NCT01470001|Placebo Comparator|placebo|patients is this arm will receive placebo
89642275|NCT01469377|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
88991694|NCT04308226|Experimental|Usual care with patient navigation|Participants assigned to this arm will be informed about lung cancer screening (LCS), provided educational materials on LCS and patient navigation, and offered access to an LCS navigator who will partner with participants and primary care providers (PCPs) to facilitate low-dose computed tomography (LDCT) completion and follow-up.
88991695|NCT04305041|Experimental|Pembrolizumab + Quavonlimab + Vibostolimab|Participants will receive pembrolizumab intravenously (IV) plus quavonlimab IV plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.
88991696|NCT04305041|Experimental|Pembrolizumab + Quavonlimab + Lenvatinib|Participants will receive pembrolizumab IV plus quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
88991697|NCT04305041|Experimental|Pembrolizumab + all-trans retinoic acid (ATRA)|Participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days for a total treatment duration of up to approximately 2 years
88991698|NCT04300023|No Intervention|Study 1: Normal Care Control Group|Study 1: Normal Care Control Group [will crossover and complete the cycling intervention following the initial 6-months]
88991699|NCT04300023|Experimental|Study 1: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
88991700|NCT04300023|Experimental|Study 2: Social Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to 30 minutes of cycling while engaged in social interaction with a research staff member, thus providing a social/community aspect that would not otherwise be present.
89043118|NCT00408005|Active Comparator|Group I Arm IV (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
89043119|NCT00075946|Active Comparator|Arm A: Rituximab Retreatment|Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
89043120|NCT00075946|Experimental|Arm B: Rituximab Scheduled|Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
89043121|NCT04646291||Heterosexual Females with a Male partner|This cohort consists of heterosexual females with a male partner who have used the Mosie Baby Kit for insemination during at least one cycle
89043122|NCT04646291||Females in LGBTQ Relationships|This cohort consists of females in LGBTQ Relationships who have used the Mosie Baby Kit for insemination during at least one cycle.
89043123|NCT04646291||Solo parent|This generally will be a female without a partner who has used the Mosie Baby Kit for insemination during at least one cycle. However, it might also be a male who is using a surrogate female.
89043124|NCT02907684|Experimental|Almonds|Almond snacks
89043125|NCT02907684|Placebo Comparator|Control muffins/crackers|Muffin/Cracker snacks
89043126|NCT04646096|Experimental|Mako THA 4.0 group|Hip system used: femoral stem (Accolade II), acetabular cup (Trident II or MDM if necessary), femoral head (ceramic or metal head compatible with Accolade II), acetabular insert (X3 Trident II or MDM liner when using MDM cup). Mako THA 4.0 software also will be used.
89043127|NCT04681989|Experimental|MOVE-ABC intervention arm|"MOVE-ABC interventional group participants receive usual care plus the MOVE-ABC education instruction and materials. After the participant completes the baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~instructions on the education materials by a research staff member~a range of motion wand~a small ball~MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment. The follow-up phone calls are expected to take 20 - 30 minutes each time. During these follow-ups research staff will review material, and answer any questions the participant may have. All documentation of phone calls and questions asked by participants during these reviews will be captured in REDCap."
89043128|NCT04681989|No Intervention|Control/Usual Care arm|Control group participants will be measured at baseline and at 1 month follow-up. They receive usual care. Usual care does not include specialized, physical therapy-based education on recovery from breast cancer.
89043129|NCT04646447|Experimental|L-serine treatment|All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.
89043130|NCT04682184|Experimental|Wearable Biosensor Patch Device + Propranolol|Participants will wear the biosensor patch device followed by propranolol administered orally in one of three study periods.
89043131|NCT04682184|Experimental|Wearable Biosensor Patch Device + Pseudoephedrine|Participants will wear the biosensor patch device followed by pseudoephedrine administered orally in one of three study periods.
89043132|NCT04682184|Experimental|Wearable Biosensor Patch Device (Alone)|Participants will wear biosensor patch device (alone) during one of three study periods.
89043133|NCT02907450|Experimental|Clinical evaluation of the tolerance of the orthosis|
89043134|NCT04645901|Experimental|SYHA1805|Part 1: Subjects will receive a single dose of oral SYHA1805 tablets. Part 2: Subjects will receive single ascending doses of SYHA1805 tablets. Part 3: Subjects will receive a single dose SYHA1805 tablets in a fasted state and a single dose of SYHA1805 tablets after a high-fat, high-calorie meal, with sequence determined by randomization.
89043135|NCT04645901|Placebo Comparator|Placebo|Subjects will receive the matching placebo tablets.
89043136|NCT04645940|Experimental|Fed/Fasted|fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
89043137|NCT04645940|Experimental|Fasted/Fed|fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15. 40 mg rabeprazole from Day 23 to Day 29. On Day 29, fruquintinib 5 mg one hour after rabeprazole dose.
89043138|NCT02906280|Experimental|19 Ga EBUS-TBNA needle|needle aspiration by a flexible 19 Ga needle (Olympus)
89043139|NCT02906280|Active Comparator|22 Ga EBUS-TBNA needle|needle aspiration by a 22 Ga needle (Olympus)
89043140|NCT00558350||1|lobectomy / segmentectomy in patients with lung cancer
89642276|NCT01469377|Experimental|Cariprazine 1-2 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
89642277|NCT01469377|Experimental|Cariprazine 2-4.5 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
89642278|NCT01469221|Experimental|Apaziquone|Apaziquone (4 mg in 40 mL)
89642279|NCT01469221|Placebo Comparator|Placebo|Matching placebo (40 mL)
89642280|NCT01453855|Experimental|Travoprost 0.003%|Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months
89642281|NCT01453855|Active Comparator|TRAVATAN|Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months
89642282|NCT01469065|Experimental|PF-04991532|PF-04991532 experimental study medication
89642283|NCT01469065|Placebo Comparator|Placebo|PF-04991532 Matching Placebo
89642284|NCT01586624|Experimental|Dose Escalation Phase Cohort 1 (Steady state dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
89642285|NCT01586624|Experimental|Dose Escalation Phase Cohort 2 (Steady state dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
89043141|NCT02906085|Experimental|Endothelin-1|Intravenous infusion of pharmaceutical grade human endothelin-1
89043142|NCT02906085|Placebo Comparator|Placebo|Intravenous infusion of placebo (isotonic saline)
89043143|NCT02906124||Repatha® exposed|Females with familial hypercholesterolaemia (FH) exposed to Repatha® in the 15 weeks prior to or during pregnancy or during breastfeeding
89043144|NCT02906124||Non exposed to Repatha®|Pregnant females with familial hypercholesterolaemia (FH) not exposed to Repatha® and enrolled into this study, overall and stratified by lipid lowering therapy use
89043145|NCT00558506|Experimental|A|Abatacept
89043146|NCT02907411|Experimental|Quadrivas Therapy|Hands on therapy to improve all aspects of fat tissue including the vessels within. Each of 7 subjects receive 12 treatments in one month time.
89043147|NCT02907645|Experimental|Local educational|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
89043148|NCT02907645|Experimental|National educational|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
89043149|NCT02907645|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
89043150|NCT00558623|Placebo Comparator|1|Placebo
89043151|NCT02905968|Experimental|TTPLAR|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
89043152|NCT02905968|No Intervention|NORLAR|Tranditional low anterior resection without transanual tube placement or ileostomy.
89043153|NCT00558662|Active Comparator|1|Coban 2 Layer Compression System
89043154|NCT00558662|Active Comparator|2|Short-Stretch Bandage
89642286|NCT01586624|Experimental|Dose Escalation Phase Cohort 3 (Steady state dose of 100 mg OD Vandetanib + 75 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
89642287|NCT01586624|Experimental|Dose Escalation Phase Cohort 4 (Steady state dose of 100 mg OD Vandetanib + 100 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
89642288|NCT01586624|Experimental|Dose Escalation Phase Cohort 5a (Steady state dose of 100 mg OD Vandetanib + 125 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
89642289|NCT01586624|Experimental|Dose Escalation Phase Cohort 5b (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
89642290|NCT01586624|Experimental|Dose Escalation Phase Cohort 6 (Steady state dose of 300 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
89642291|NCT01586624|Experimental|Expansion Phase (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Expansion cohort at the recommended phase 2 dose of vandetanib and selumetinib defined in the escalation phase.
89043155|NCT02906046|Placebo Comparator|placebo Weight in Lower Limbs|placebo Weight in Lower Limbs
89043156|NCT02906046|Other|0,5 kg Weight in Lower Limbs|0,5 kg Weight in Lower Limbs
89043157|NCT02906046|Other|1,0 kg Weight in Lower Limbs|1,0 kg Weight in Lower Limbs
89043158|NCT00558740||healthy volunteers|
89043159|NCT02907528|Placebo Comparator|BONE Group|bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
89043160|NCT02907528|Active Comparator|BONE+EMD Group|mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland);
89043161|NCT02907528|Experimental|EMD Group|enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland)
89642292|NCT01586156|Active Comparator|Open Label Carvedilol|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
89642293|NCT01586156|Placebo Comparator|Placebo Arm|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight for the first-dose challenge of carvedilol. After one week run in phase, subjects will be placed on placebo. Subjects and Investigators will be blinded to the group assignment for the duration of the study.
89642294|NCT01459913|Experimental|Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)|Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.
89642295|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
89642296|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.
89642297|NCT01459913|Experimental|Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.
89642298|NCT04408391||COVID-19 patients with anosmia|Patients reporting loss of smell and scoring < 30 on a VAS 0-100 for ability to detect n-Butanol diluted 1/1000
89642299|NCT04408391||COVID-19 patients without anosmia|Patients reporting no loss of smell and scoring > 80 on a VAS 0-100 for ability to detect n-Butanol diluted 1/16000
89642300|NCT01458587|Experimental|ALA|
89642301|NCT01458587|Placebo Comparator|Vehicle|
89642302|NCT01458275|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
89642303|NCT01458275|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
89642304|NCT01458275|Placebo Comparator|Placebo|
89642305|NCT01458119|Experimental|Migalastat|Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.
89642306|NCT02334527|Other|Palbociclib Single Arm trial|Palbociclib
89642307|NCT01688726|Experimental|SYSTANE BALANCE|SYSTANE® BALANCE eyedrops, 1 drop 4 times a day for a continuous period of 1 month
89642308|NCT01688726|Active Comparator|Minims Saline|Minims® Saline 0.9% eyedrops, 1 drop 4 times a day for a continuous period of 1 month
89043162|NCT04645472||CT-Ultrasound group|
89043163|NCT02905890|Experimental|Norethisterone enanthate plus condoms|200 mg Norethisterone enanthate intramuscularly every eight weeks at enrolment, 2 and 4 months. Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
89043164|NCT02905890|Active Comparator|Condoms only|Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
89642309|NCT01585766|Experimental|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
89642310|NCT01585766|Experimental|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
89642311|NCT01585766|Experimental|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
89642312|NCT01585766|Experimental|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
89642313|NCT01585766|Experimental|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
89642314|NCT01585766|Placebo Comparator|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.
89043165|NCT02906163|Experimental|Thymalfasin biw plus SoC (tyrosine kinase inhibitor)|Twice weekly thymalfasin
89043166|NCT02906163|Experimental|Thymalfasin plus SoC (tyrosine kinase inhibitor)|5 times a week thymalfasin
89043167|NCT02906163|Active Comparator|SoC (tyrosine kinase inhibitor)|12 months
89043168|NCT04645745|Experimental|myo-inositol plus alpha-lactalbumin|Patients were treated with 2 g myo-inositol, 50 mg alpha-LA and 200 mcg of Folic Acid twice a day for 6 months. Controls were the same patients at baseline (t0)
89043169|NCT04645433||Favipiravir therapy|Favipiravir was advised to all patients with severe pneumonia and progressing pneumonia findings or worsening clinical manifestations except pregnant, breast feeding, postpartum woman. PCR results were not waited to start favipiravir in this group of patients and continued if it would be negative but tomography findings were consistent with COVID-19. Loading dose was 1600 mg twice a day. Maintenance dose was 600 mg per 12 hours for four days.
89043170|NCT04645433||Lopinavir-ritonavir therapy|Lopinavir-ritonavir therapy was used in selected ICU patients before widespread availability of favipiravir (23 March 2020) and/or if favipiravir was contraindicated. Combination of lopinavir 200 mg-ritonavir 50 mg tablet was the given form. It was given as double tablets twice daily for 10-14 days. Patients were accepted as under favipiravir therapy if they had incomplete course of lopinavir-ritonavir therapy (less than 5 days) and followed by favipiravir for 5 days.
89043171|NCT02907060|Experimental|Mechanical cervical ripening|mechanical cervical ripening with a Cook® Cervical Ripening Balloon
89043172|NCT02907060|Active Comparator|Pharmacological cervical ripening|pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)
89043173|NCT02905851|Placebo Comparator|Non Feedback|No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
89043174|NCT02905851|Active Comparator|Feedback group|"Feedback given to this group regarding their antibiotic use after baseline.~If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:~Continue current dose~Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily.~Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose."
89642315|NCT01562444|Other|TBE_R Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to rapid (R) schedule i.e., on days 0, 7 (+3) and 21 (+7) in the parent study (V48P7) and who were administered 1 booster dose of Encepur adults either 12-18 months after R schedule completion or in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination (for those subjects boostered before V48P7E1 study start, the blood draw occurred annually starting from >6 years up to >10 years after booster vaccination).
89642316|NCT01562444|Other|TBE_C Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to conventional (C) schedule i.e., on days 0, 28 (+10) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
89642317|NCT01562444|Other|TBE_AC Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to accelerated conventional (AC) schedule i.e., on days 0, 14 (+3) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
89642318|NCT01457339|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
89642319|NCT01457339|Placebo Comparator|Placebo|
89642320|NCT01456949|Other|Single Arm|Cryoablation
89642321|NCT01456169|Active Comparator|Azilsartan medoxomil 40 mg|Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.
89642322|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/12.5 mg|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
89642323|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/25 mg|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
89642324|NCT01454531|Experimental|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
89642325|NCT01454063|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
89642326|NCT01454063|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
89642327|NCT01453595|Experimental|BEZ235|"This is a single-institution, open label, single-arm Phase 1b/2 trial of BEZ235 in patients with advanced RCC. The study will be conducted in two phases:~Phase 1b: dose-escalation will be performed to determine the maximally tolerated dose (MTD) of twice daily BEZ235 to use in Phase 2 (RP2 dose).~Phase 2: subjects with clear cell who have experienced disease progression on prior first or second-line mTOR targeted therapy will be treated on the MTD of twice daily BEZ235."
89642328|NCT01453439|Experimental|Cognitive Behavioral Therapy|Group receiving Cognitive-Behavioral Therapy
89642329|NCT01453439|Active Comparator|Supportive Psychotherapy|Group receiving Supportive Psychotherapy
89642330|NCT01453361|Experimental|Vigil™ Vaccine|Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
89642331|NCT04530773|Experimental|GROUP1|
89642332|NCT04530773|Experimental|GROUP2|
89642333|NCT04530773|Experimental|GROUP3|
89642334|NCT04530773|Experimental|GROUP4|
89642335|NCT04530773|Experimental|GROUP5|
89642336|NCT01585298|Experimental|Fingolimod|Fingolimod 0.5 mg by mouth once daily for 7 days.
89642337|NCT04124198|Experimental|Transoral robotic surgery (TORS)|
89043175|NCT04645043|Experimental|US_Eso|US application on the participant
89043176|NCT02905695|Experimental|Group A|Chirocaine
89043177|NCT02905695|Placebo Comparator|Group B|Placebo
89043178|NCT04645238|Active Comparator|Static Hamstring Stretching|Static Hamstring Stretching
89043179|NCT04645238|Active Comparator|PNF Stretching|PNF Hamstring Stretching (Hold-Relax)
89043180|NCT02907333|Active Comparator|Intervention group|Women who are advised to use condom during the time period between diagnosis and follow-up
89043181|NCT02907333|No Intervention|Control group|Women who are not contacted with advise to use condoms
89043182|NCT00558779|Experimental|1|
89043183|NCT00558779|Active Comparator|2|
89043184|NCT02905773|Other|postoperative pain|postoperative pain
89642338|NCT04124198|Active Comparator|Intensity-Modulated Radiation Therapy (IMRT)|"Patients with clinical T1N0 stage are offered accelerated radiotherapy to 66 Gy/33fractions with concurrent nimorazole.~Patients with clinical T2N0 stage are offered either accelerated radiotherapy to 66 Gy/33fractions with the option of weekly cisplatin to fit patients or hyper-fractionated accelerated radiotherapy to 76 Gy/56fractions both with concurrent nimorazole.~Patients with clinical T1-T2, N1 stage are offered accelerated radiotherapy to 66 Gy/33 fractions and nimorazole with the addition of concurrent weekly cisplatin 40 mg/sqm to fit patients."
89642339|NCT01453205|Active Comparator|Rituximab+ ICE/DHAP|Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
89043185|NCT02905773|Other|intensity|intensity
89043186|NCT04644848|Experimental|Pre-sentinel node biopsy ultrasonographical tattooing|Preoperative ultrasonographical tattooing of the suspicious lymph nodes. Sentinel Lymph Node Biopsy (SLNB),
89642340|NCT01453205|Experimental|MEDI-551 2 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
89642341|NCT01453205|Experimental|MEDI-551 4 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
89642342|NCT01453049|Experimental|fix dose of rosiglitazone/glimepiride|4mg/1mg, 4mg/2mg, 4mg/4mg
89642343|NCT01453049|Active Comparator|glimepiride|1mg, 2mg, 4mg
89642344|NCT01452347|Experimental|Dabigatran etexilate|Patient dose dependent on screening CrCl levels and TT
89642345|NCT01452347|Active Comparator|warfarin|warfarin doses to maintain INR levels
89642346|NCT01451723|Experimental|Polyphenon E 400mg twice a day|Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
89043187|NCT02907294|Experimental|PBF-999|
89043188|NCT02907294|Placebo Comparator|Placebo|
89043189|NCT04644887|Experimental|Healthy diet CC genotype|The participants will follow the intervention diet during the 12-week intervention period.
89043190|NCT04644887|Active Comparator|Control diet CC genotype|The participants will follow the control diet during the 12-week intervention period.
89043191|NCT04644887|Experimental|Healthy diet GG genotype|The participants will follow the intervention diet during the 12-week intervention period.
89043192|NCT04644887|Active Comparator|Control diet GG genotype|The participants will follow the control diet during the 12-week intervention period.
89043193|NCT04644926|Experimental|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is performed at inclusion and repeated 12 h and 24 h later.
89043194|NCT04682262|Experimental|Cervical dilatation|Patients receive cervical dilatation up to 10 millimeter Hegar dilator under general anaesthesia. Patient undergo standard hysteroscopy operation.
89043195|NCT04682262|No Intervention|Expectant|Patients are scheduled for follow-up.
89043196|NCT02907138|Experimental|Medical Yoga|Medical Yoga Group therapy for eight weeks, 60 minutes per week, with the guidance of a physical therapist.
89043197|NCT02907138|Active Comparator|Treatment as Usual (physical therapy)|Treatment as Usual provided by physical therapist
89043198|NCT04644341||COVID survivors|Individuals who were infected by CPVID-19 and recovered.
89043199|NCT04681911|Experimental|Inetetamab Combined With Pyrotinib and Chemotherapy|"Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.~Pyrotinib: 400mg, oral, every day.~Chemotherapy: the choice of physicians，as the following regimens:~Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle Carboplatin, AUC = 6, 3-week cycle Albumin paclitaxel, 100 mg/m2, weekly Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle"
89642347|NCT01451723|Placebo Comparator|Placebo|Matching placebo capsules.
89642348|NCT01451645|Other|placebo|daily placebo dosing for 16 weeks with background allopurinol therapy
89642349|NCT01451645|Active Comparator|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks with background allopurinol therapy
89642350|NCT03026621|Placebo Comparator|Placebo|This will be an herbal tea the looks similar to the control.
89642351|NCT03026621|Experimental|Lignite Extract|This will be the Restore gut supplement
89043200|NCT04644263||Validity and reliability|
89043201|NCT04644302||non-COVID sepsis|Patients admitted to ICU with sepsis of non-COVID origin
89043202|NCT04644302||COVID sepsis|Patients admitted to ICU with sepsis of COVID origin
89043203|NCT02907255|Experimental|Oximetry monitor|"Standard care plus~Wireless respiratory monitoring~Covidien~Alarm triggers:~SpO2 ≤89% (heart rate) HR < 50 or > 120"
89043204|NCT02907255|No Intervention|Standard of Care|"• Standard care:~1:4 patient to nurse ratio~Vital signs every 4 hours~Respiratory rate and sedation scores every 2 hours for patients on the Acute Pain Service"
89043205|NCT00558857|Active Comparator|DSM|Treatment using DSM to guide ablation
89043206|NCT02905539|Experimental|Iron Isomaltoside 1000|Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
89043207|NCT02905539|Active Comparator|Ferric Carboxymaltose|Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
89043208|NCT02905734|Experimental|nicotine replacement patch|Single administration of a nicotine patch (14 mg or 21 mg, according to the Heaviness of Smoking Index)
89043209|NCT02905734|Placebo Comparator|placebo patch|Single administration of a placebo patch
89043210|NCT04644380|Experimental|Treatment Group|During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5 days vaginal incubation
89043211|NCT02899572|Experimental|Sexology consultation|specialized sexology consultation planned in the 15 days after inclusion. Randomisation is performed at D7 during a phone call to the patient.
89043212|NCT02899572|No Intervention|Leaflet concerning erectile disorders|leaflet explaining erectile disorders related to type 2 diabetes will be sent by post to the patients. Randomisation is performed at D7 during a phone call to the patient.
89043213|NCT04644146||SEVERE|Patients affected by SARS-CoV2 infection with severe lung dysfunction needing oxygen complementation and critical care supports - criteria 18-70yr old and without any comorbidities
89043214|NCT04644146||CONTROL|Patients affected by SARS-CoV2, as shown by PCR and/or antigen testing diagnosis and without any or minor clinical expression
89043215|NCT04644185|Experimental|SCTA01 Low Dose+BSC|SCTA01in a lower dose+best supportive care
89043216|NCT04644185|Experimental|SCTA01 High Dose+BSC|SCTA01in a higher dose+best supportive care
89043217|NCT04644185|Active Comparator|Placebo+BSC|SCTA01 excipients+best supportive care
89642352|NCT01450943|Active Comparator|Standard of care|debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape
89642353|NCT01450943|Experimental|Dermagraft|debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape
89642354|NCT01450943|Experimental|Oasis|debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape
89642355|NCT01450631|Active Comparator|Standard Dressing|Standard-of-care includes coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™) consistent with the national standard for dressing Cesarean section incisions.
89642356|NCT01450631|Experimental|Prevena™ (PIMS)|PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period.
89642357|NCT01450007|Experimental|Dexamethasone block|Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
89642358|NCT01450007|Active Comparator|Dexamethasone IV|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
89642359|NCT01450007|Placebo Comparator|Placebo|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline
89642360|NCT01496365|Experimental|DS-5565 5mg nighttime|DS-5565 5 mg/day (one 5 mg tablet at bedtime)
89642361|NCT01496365|Experimental|DS-5565 10 mg at bedtime|DS-5565 10 mg/day (one 10 mg tablet at bedtime)
89642362|NCT01496365|Experimental|DS-5565 15 mg at bedtime|DS-5565 15 mg/day (one 5 mg tablet plus one 10 mg tablet at bedtime)
89043218|NCT02899494|Other|Group A|Antenatal classes
89043219|NCT02899494|Experimental|Group B|Physical and psychic preparation
89043220|NCT02899260|No Intervention|Control|Subjects who are randomized to to the control group will labor without the use of the peanut ball in labor.
89642363|NCT01496365|Experimental|DS-5565 20 mg total per day|DS-5565 20 mg/day (one 10 mg tablet in the morning and one 10 mg tablet at bedtime)
89642364|NCT01496365|Experimental|DS-5565 30 mg total per day|DS-5565 30 mg/day (one 5 mg tablet plus one 10 mg tablet in the morning and one 5 mg tablet plus one 10 mg tablet at bedtime)
89642365|NCT01496365|Active Comparator|Pregabalin 300 mg total per day|Pregabalin 300 mg/day (two 150 mg capsules, in the morning and at bedtime)
89642366|NCT01496287|Experimental|Tube placement group|
89642367|NCT01495975|No Intervention|Usual Care|Usual care for diabetes in the 1 month after discharge.
89642368|NCT01495975|Experimental|Diabetes Transitions Tool Kit|Remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), in the 1 month after discharge.
89642369|NCT01468987|Active Comparator|Insulin Glargine + Insulin Lispro|"Participant-specific dose of Insulin Glargine will be administered subcutaneously (SC) once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial (pre-meal) and supplemental doses for 26 weeks."
89642370|NCT01468987|Experimental|LY2605541 + Insulin Lispro|"Participant-specific dose of LY2605541 will be administered SC once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial and supplemental doses for 26 weeks."
89642371|NCT01687712|Experimental|AFOLIA|One subcutaneous injection of 225IU AFOLIA (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
89642372|NCT01687712|Active Comparator|Gonal-f® RFF|One subcutaneous injection of 225IU Gonal-f® RFF (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
89642373|NCT01603628|Experimental|BOTOX® 4 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
89642374|NCT01603628|Experimental|BOTOX® 8 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
89642375|NCT01603628|Placebo Comparator|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
89642376|NCT04546412||Fresh oocytes|Sibling oocytes not subjected to vitrification prior to assessment
89642377|NCT04546412||Vitrified-thawed oocytes|Sibling oocytes subjected to vitrification using the Cryotop® - Open System and thawing prior to assessment
89642378|NCT01453153|Active Comparator|Gemcitabine|Gemcitabine + Placebo
89642379|NCT01453153|Experimental|PEGPH20|PEGPH20+Gemcitabine
89642380|NCT04767932|Experimental|control group|the control group will receive regular exercise training at same time.
89642381|NCT04113200|Experimental|F+ALG|An alginate containing feed: MerMed One (Kaneka Corporation). 300mls administered nasogastrically over one hour.
89642382|NCT04113200|Other|F-ALG|A standard enteral feed commonly used in practice. Nutricomp Soy Fibre (B.Braun). 300mls administered nasogastrically over one hour.
89642383|NCT01584440|Placebo Comparator|Placebo|Participants will receive placebo during Stage 1 and Stage 2 of the study.
89642384|NCT01584440|Experimental|AVP-923|Participants will receive AVP-923-20 and AVP-923-30 in a sequential manner during Stage 1 and Stage 2 of the study.
89642385|NCT01584440|Experimental|Placebo then AVP-923|Participants will receive placebo in Stage 1 followed by AVP-923 in Stage 2.
89642386|NCT01687478|Experimental|Olanzapine + Fluoxetine|"Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.~Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
89642387|NCT01687478|Placebo Comparator|Placebo + Fluoxetine|"Placebo matches the Olanzapine tablet for blinding.~Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
89642388|NCT01468909|Placebo Comparator|Arm I (paclitaxel and placebo)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89642389|NCT01468909|Experimental|Arm II (paclitaxel and pazopanib hydrochloride)|Patients receive paclitaxel as in arm I and pazopanib hydrochloride PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89642390|NCT01468597||One group|Emergency surgery
89642391|NCT01687166|Experimental|Blazer Open-Irrigated Ablation Catheter|Blazer Open-Irrigated Ablation Catheter and Ablation Catheter Cable used in conjunction with a compatible electroanatomic mapping system
89642392|NCT01687166|Active Comparator|FDA Approved Open-Irrigated Ablation Catheter|FDA approved Open-Irrigated Radiofrequency Ablation Catheter system and compatible electroanatomic mapping system for the treatment of paroxysmal atrial fibrillation.
89642393|NCT01561976|Active Comparator|Metformin hydrochloride prolonged release|1000mg in fasting state
89642394|NCT01561976|Active Comparator|metformin hydrochloride prolonged release|1000mg In fed state
89642395|NCT01561976|Active Comparator|Metformin hydrochloride sustained release/Glimepiride|1000/2mg In fed state
89642396|NCT01686932|Experimental|Vildagliptin followed by Sitagliptin|Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks
89642397|NCT01686932|Experimental|Sitagliptin followed by Vildagliptin|Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks
89642398|NCT01468207|Placebo Comparator|Placebo|Placebo for 12 weeks.
89642399|NCT01468207|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
89642400|NCT01468207|Experimental|Placebo/Adalimumab Every Week (EW)|Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
89642401|NCT01468207|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
89642402|NCT01468207|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
89642403|NCT01468207|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
89642404|NCT04530175||patients with hemodialysis|patient treated with intermittent hemodialysis for chronic renal failure
89642405|NCT03026725|Experimental|Tri-calcium Phosphate|clinpro tooth creme, i.e. Tri-calcium Phosphate, for 30 min/day after bleaching 4h with carbamide peroxide 20%
89642406|NCT03026725|Placebo Comparator|Placebo|a placebo creme will be applied for 30 min/day after bleaching 4h with carbamide peroxide 20%
89642407|NCT01494649|Active Comparator|Toothpaste containing 0.454% stannous fluoride|USA marketed toothpaste [test]
89642408|NCT01494649|Other|Toothpaste containing 0.76% sodium monofluorophosphate|USA marketed toothpaste [negative control]
89642409|NCT01686152|Experimental|Investigational Test Product|Imiquimod Cream, 3.75% (Teva)
89642410|NCT01686152|Active Comparator|Reference Listed Drug|Zyclara® (imiquimod Cream), 3.75% (Medicis)
89043221|NCT02899260|Experimental|Experimental/Peanut Ball|Subjects randomized to the intervention (peanut ball) arm will have the peanut ball planed between their upper legs for at least 30minutes during their labor. Time on the peanut ball will be quantified by the bedside nursing staff.
89642411|NCT01686152|Placebo Comparator|Vehicle|Vehicle of Test Product (Teva)
89642412|NCT04545632||Patients|Patients receiving chemotherapy with ethanol-containing docetaxel
89642413|NCT01452919|Experimental|LY2140023/LY2140023|"Open label phase: 40 milligram (mg) LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Current dose level at randomization will remain constant through the double blind phase.~Double blind phase: 40 mg or 80 mg LY2140023 administered orally; given twice daily for up to 3 weeks."
89642414|NCT01452919|Placebo Comparator|LY2140023/Placebo|"Open label phase: 40 mg LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time.~Double blind phase: placebo administered orally; given twice daily for up to 3 weeks."
89642415|NCT01582178|Experimental|Warm Water Immersion Colonoscopy|Colonoscopy using purely warm water (37°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
89642416|NCT01582178|Active Comparator|Cool Water Immersion Colonoscopy|Colonoscopy using purely room temperature water (20-24°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
89642417|NCT01561898|Experimental|Paliperidone extended-release (JNS007ER)|
89642418|NCT01685840|Experimental|Usual Care|Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
89642419|NCT01685840|Experimental|Biomarker-Guided Care|Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.
89642420|NCT01452529|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
89642421|NCT01452529|Placebo Comparator|Placebo|Placebo to match hydrocodone bitartrate once daily tablets
89642422|NCT01685606|Experimental|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor will be infused, irrespective of the number of CD34+ cells.
89642423|NCT01685372|Experimental|Fluzone High Dose|Fluzone High Dose 0.5 mL intramuscularly (IM) given once
89642424|NCT01685372|Active Comparator|Fluzone|Fluzone 0.5mL IM given once
89642425|NCT01685216|Experimental|velaglucerase alfa|IV infusion, 60 U/kg, every other week for 1 year
89642426|NCT01685138|Experimental|LDK378 (Ceritinib)|Participants on this arm took oral LDK378 750 mg once daily.
89642427|NCT01685060|Experimental|LDK378|Patients treated with ceritinib/LDK378 750 mg once-daily, fasted
89642428|NCT01582100|Experimental|GERD subjects with nausea|subjects with GERD and nausea will receive treatment with Reletex
89642429|NCT01579916|Experimental|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
89212451|NCT01013974|Placebo Comparator|Placebo|Each subject will receive GSK573719 matching placebo on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
89642430|NCT01579916|Placebo Comparator|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
89642431|NCT04410458|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors' life saving donation during 2019-nCoV epidemic.
89642432|NCT04410458|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
89642433|NCT04410458|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
89642434|NCT04410458|Placebo Comparator|SMS with thank-you note|SMS content in this group will be thank-you note for their previous donation(s) .
89642435|NCT01684202|Experimental|OPC-41061|
89642436|NCT01684046|Other|PureMoist - RevitaLens|Opti-Free® PureMoist® MPDS used first, followed by RevitaLens MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
89642437|NCT01684046|Other|RevitaLens - PureMoist|RevitaLens MPDS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
89642438|NCT01559090|Experimental|1|MEDI-546 100 mg IV
89642439|NCT01559090|Experimental|2|MEDI-546 300 mg IV
89642440|NCT01559090|Experimental|3|MEDI-546 1000 mg IV
89642441|NCT01683266|Experimental|HOE901-U300|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
89642442|NCT01683266|Active Comparator|Lantus|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
89642443|NCT01467661|Experimental|SPD422 (anagrelide hydrochloride)|
89642444|NCT01577186|Experimental|Paliperidone Extended Release (ER)|
89642445|NCT01559012|Other|clonidine first - placebo second|in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
89642446|NCT01559012|Other|placebo first - clonidine second|in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days
89642447|NCT01451827|Experimental|Tolvaptan MR 50 mg|Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
89642448|NCT01451827|Experimental|Tolvaptan MR 80 mg|Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
89642449|NCT01451827|Experimental|Tolvaptan IR 60/30 mg|Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
89642450|NCT01451827|Placebo Comparator|Placebo|Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
89642451|NCT01557920|Active Comparator|Propofol|The healthy subject will be anesthetized with Propofol. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
89642452|NCT01557920|Active Comparator|Sevoflurane|The healthy subject will be anesthetized with Sevoflurane. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
89642453|NCT04408261|Experimental|Buqitongluo Granule|Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.
89642454|NCT04408261|Placebo Comparator|Placebo|Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.
89642455|NCT01688882|Experimental|QGE031|QGE031 240 mg Q2W s.c.
89642456|NCT01688882|Placebo Comparator|Placebo|Placebo to Match Q2W s.c.
89642457|NCT01688882|Experimental|Open Label QGE031|Open Label QGE031 Q2W s.c.
89642458|NCT01467583|Experimental|Renal failure on intermittent dialysis|These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours
89642459|NCT01467583|Experimental|Renal failure-renal replacement therapy|These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours
89642460|NCT01467583|Experimental|Renal failure, not on dialysis|These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
89642461|NCT01576718|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89642462|NCT01576718|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89642463|NCT01576718|Experimental|Fp MDPI 200 mcg|"Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89043222|NCT04643756|Active Comparator|Conventional Physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound. Procedure/Device: Conventional Physiotherapy Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm2 and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
89043223|NCT04643756|Active Comparator|Conventional Physiotherapy + Kinesiotaping|Kinesiotaping application in addition to classical electrotherapy method consisting of tens, hotpack and ultrasound.It will be applied to reduce pain, increase proprioception and awareness. Kinesiotaping will be re-applicated every day. Space taping will be applied to the waist area. Space taping creates a vacuum effect on the skin, loosening the adhesions in the tissue layers. With this lifting effect, it creates a space under the skin, causing an increase in circulation and a decrease in pain. Four pieces of I-tape will be used for taping. The middle point of the first tape will be attached with maximum tension. The ends of the tape will be tensionless. The second tape will also be applied at a 90 degree angle. The third and fourth tapes will be taped at an angle of 45 degrees.
89043224|NCT02905461|Experimental|Intervention|Contraceptive text messages
89043225|NCT02905461|Placebo Comparator|Control|Text messages not about contraception
89043226|NCT04643873|Experimental|Experimental group 1|physical activity counseiling +pilates exercise group
89642464|NCT01576718|Experimental|Fp MDPI 400 mcg|"Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89642465|NCT01576718|Placebo Comparator|Placebo MDPI|"Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89642466|NCT01576718|Active Comparator|Flovent Diskus 250mcg|"Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
89642467|NCT03028610|Experimental|Acessa™ System|radiofrequency generator
89642468|NCT01493557|Other|Pradaxa (dabigaran etexilate)|Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
89642469|NCT01493557|Active Comparator|Pradaxa and pantoprazole|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
89642470|NCT01493557|Active Comparator|Pradaxa, 30 minutes after a meal|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
89642471|NCT01451749|Experimental|Shenwu Capsule|"Shenwu Capsule:1 capsule contains 451 mg of Shenwu extracts. 5 capsules/time, 3 times/day for 6 months.~Placebo: Placebo identical to donepezil tablets,1 placebo tablet/time, 1 time/day for 6 months."
89642472|NCT01451749|Active Comparator|Donepezil|"Donepezil: 1 tablet contains 5 mg of donepezil, 1 tablet/time, 1time/day for 6 months.~Placebo: Placebo identical to shenwu capsules,5 placebo capsules/time,3 times/day for 6 months"
89642473|NCT01576484|Placebo Comparator|Placebo Matched to Alirocumab|Participants who received placebo in parent study (NCT01576484), has received a subcutaneous injection of placebo matched to alirocumab every 2 weeks for 4 years in this study.
89642474|NCT01576484|Experimental|Alirocumab 150 mg|Participants who received alirocumab in parent study (NCT01576484), has received a subcutaneous injection of alirocumab 150 milligram (mg) every 2 weeks for 4 years in this study.
89642475|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Tacrolimus)|Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
89642476|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Cyclosporine)|Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
89642477|NCT01449929|Experimental|dolutegravir 50mg once daily (OAD)|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
89642478|NCT01449929|Active Comparator|darunavir 800mg OAD in combination with ritonavir 100mg OAD|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
89642479|NCT01451515|Experimental|Treatment|"Patients will undergo treatment as described in the intervention section. Interventions include:~Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine~Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine~Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine, methotrexate~Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide~All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22."
89642480|NCT01466881|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
89642481|NCT01576406|Experimental|A1: normal hepatic function|
89642482|NCT01576406|Experimental|A2: normal hepatic function|
89043227|NCT04643873|Experimental|Experimental group 2|only physical activity counseiling group
89043228|NCT04643873|No Intervention|Control Group|only followed by family physician
89642483|NCT01576406|Experimental|B: mild hepatic impairment|
89043229|NCT02899533||FES PET/CT scan|All subjects will receive an [18F]FES PET/CT scan.
89043230|NCT04643990||LDT Combined with TDF for Treatment|The patients take one tablet of LDTand one tablet of TDF every night and continue to 12 months.
89043231|NCT04643990||Only TAF treatment.|The patients take one tablet of TAF every night and continue to 12 months.
89212452|NCT04615624|Experimental|Furosemide|When patient meets inclusion criteria and is randomized to treatment drug, she receives 40mg /4 milliliters (mL) IV furosemide in addition to usual antihypertensive.
89642484|NCT01576406|Experimental|C: moderate hepatic impairment|
89642485|NCT01576406|Experimental|D: severe hepatic impairment|
88991701|NCT04300023|Experimental|Study 2: Solo Cycling Group|Exercise bike delivered to their home, custom fit to their needs and installed in a safe location, sessions will consist of up to cycling without a partner for a target duration and intensity.
88991702|NCT04271735|Placebo Comparator|Participants with mild to moderate Psoriasis receiving Placebo|Participants with mild to moderate Psoriasis receiving placebo (2 capsules) twice daily by mouth for 28 days.
88991703|NCT04271735|Experimental|Participants with mild to moderate Psoriasis receiving Nicotinamide Riboside|Participants with mild to moderate Psoriasis receiving Nicotinamide Riboside Chloride 500mg (2 capsules) twice daily by mouth for 28 days.
88991704|NCT04271384|Experimental|SABR + Nivolumab|"Pre-operative treatment with standard SABR (3 x 18 Gy or 5 x 10 Gy or 8 x 7.5 Gy) concomitant with nivolumab at 360 mg every 21 days x3 doses.~Standard-of-care surgery to be performed after 12 weeks from D1 of treatment."
88991705|NCT04266327|Experimental|I-125 Seed Implantation|All the enrolled patients were treated with ct-guided radioactive i-125 seed implantation assisted by 3D printing template.Prescription dose 110-130gy.
88991706|NCT04248959|Experimental|Multimodal Prehabilitation|Facility and home-based multimodal prehabilitation (aerobic exercise training, resistance exercise training, nutrition support, stress management and mindfulness training)
89212453|NCT04615624|Placebo Comparator|Placebo|When patient meets inclusion criteria and is randomized to placebo, she receives one dose of 4mL normal saline in addition to usual antihypertensive.
89642486|NCT01576172|Active Comparator|Arm I (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89642487|NCT01576172|Experimental|Arm II (abiraterone acetate, prednisone, and veliparib)|Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89642488|NCT01542788|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 12 weeks.
89642489|NCT01542788|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.
89642490|NCT01542632|Experimental|Group 1|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and placebo, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
89642491|NCT01542632|Experimental|Group 2|TDV, 0.5 mL, subcutaneous injection in one arm and TDV 0.5 mL, subcutaneous injection in the other arm on Day 0. Placebo, 0.5 mL, subcutaneous injection on Day 90.
89642492|NCT01542632|Experimental|Group 3|TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
89642493|NCT01542632|Experimental|Group 4|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
89642494|NCT01542632|Experimental|Group 5|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
89642495|NCT01542632|Experimental|Group 6|1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.
89642496|NCT01557842|Active Comparator|Treatment Group|This group receives radiofrequency catheter ablation and drug treatment.
89642497|NCT01557842|Experimental|Control Group|This group receives only drug treatment.
89642498|NCT01541930|Experimental|GK567|GK567: Metronidazole Gel 0.75% Once or twice daily, for 14 days, up to 30g
89642499|NCT01576016|Experimental|Lead Safety|Patient implanted with an Accent MRI system to evaluate safety of the Tendril MRI lead
89642500|NCT01576016|Experimental|Accent MRI system MRI Scan Group|Patient implanted with an Accent MRI system will receive an MRI scan to evaluate safety and efficacy of the Accent MRI system in an MRI environment
89642501|NCT03028298|Experimental|Low dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to low dose sildenafil citrate and will receive a 20mg oral dose and a subsequent 10mg intravenous dose of sildenafil citrate.
89642502|NCT03028298|Experimental|High dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to high dose sildenafil citrate and will receive a 60mg oral dose and a subsequent 30mg intravenous dose of sildenafil citrate.
89642503|NCT04122872||Patients with bone or soft tissue sarcomas or carcinosarcomas|Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone [GCTB], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
89642504|NCT02985944||Standard scope-short time|Standard colonoscopy with unmonitored withdrawal time
89642505|NCT02985944||FUSE scope-short time|Wide-angle colonoscopy with unmonitored withdrawal time
89642506|NCT02985944||Standard scope-long time|Standard colonoscopy with monitored withdrawal time
89642507|NCT02985944||FUSE scope-long time|Wide-angle colonoscopy with monitored withdrawal time
89642508|NCT04410536|Other|Symptomatic drugs - bridge theray - mindfu|"abrupt withdrawal of overuse symptomatic drugs, with possibility to use indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide i.m. injection in case of vomiting;~oral administration of a bridge therapy to reduce the withdrawal symptoms and rebound headache (prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day);~mindfulness practice daily with standard sessions by smartphone 6 minutes per day."
89642509|NCT04410614|Experimental|Free epithelial graft|Free epithelial graft at implant and teeth sites to increase the band of keratinized mucosa
89642510|NCT01540838|Experimental|Infusion with paracetamol|Cefotaxime is administered as 12 hourly infusions, together with high dose paracetamol (acetaminophen)
89642511|NCT01540838|Active Comparator|Bolus with placebo|Cefotaxime is administered as bolus q.i.d. with a placebo of paracetamol
89642512|NCT04109144|Experimental|Large Volume Paracentesis (LVP) with Fresh Frozen Plasma (FFP)|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the second drainage participants will receive 2 units, or about 500 ccs, of fresh frozen plasma intravenously, plus 1 bottle, or 50 ccs, of 25% albumin if more than 4 liters of fluid are removed
89642513|NCT04109144|Active Comparator|Large Volume Paracentesis (LVP) with Albumin|All participants who are scheduled for a LVP and meet the eligibility criteria will be monitored for 3 consecutive periods. At the first and third drainage participants will receive 1 bottle, or 50 ccs, of 25% albumin intravenously for every two liters of fluid removed
89642514|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 30 mg QD|Participants received MK-8242 30 mg once daily (QD) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
89642515|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 60 mg QD|Participants received MK-8242 60 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
89642516|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg QD|Participants received MK-8242 120 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
89642517|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg QD|Participants received MK-8242 250 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
88991707|NCT04244487|Experimental|intraoperative endoscopic variceal ligation group|intraoperative endoscopic variceal ligation group Every patient of vagus nerve-preserving group will receive the synchronous vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation procedure
88991708|NCT04244487|No Intervention|Non-intraoperative endoscopic variceal ligation group|Every patient of conventional group will receive single vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection without intraoperative endoscopic variceal ligation procedure
88991709|NCT04240561|Experimental|Hearing Aid Fitting Order A|Participants wear hearing aids with a high level of signal manipulation, followed by a low level of signal manipulation
88991710|NCT04240561|Experimental|Hearing Aid Fitting Order B|Participants wear hearing aids with a low level of signal manipulation, followed by a high level of signal manipulation
88991711|NCT04223960|Experimental|Part A: SAD, EA1080 Formulation A in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
88991712|NCT04223960|Experimental|Part A: SAD, EA1080 Formulation B in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation B or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
88991713|NCT04223960|Experimental|Part A: SAD, EA1080 Formulation C in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation C or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
88991714|NCT04223960|Experimental|Part A: SAD, EA1080 Formulation D in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation D or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).
88991715|NCT04223960|Experimental|Part A: SAD, EA1080 in Healthy Japanese Participants (Optional)|Healthy Japanese participants will receive any EA1080 formulation (Formulation A, Formulation B, Formulation C, and Formulation D) or matching placebo orally, once on Day 1 of SAD part of the study. There will be a maximum of six dose levels (three planned and three optional cohorts) per formulation.
88991716|NCT04223960|Experimental|Part A: FE and Optional BA in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 on Day 1 and Day 8 in selected formulations (Formulation A, Formulation B, Formulation C, and Formulation D) in fed and fasted states. These formulations may be tested in any order or combination up to eight- way crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 7 days will be maintained between the dosing days of each treatment periods.
88991717|NCT04223960|Experimental|Part A: FE and Optional BA, in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 on Day 1 and Day 8 in selected formulations (Formulation A, Formulation B, Formulation C, and Formulation D) in fed and fasted states. These formulations may be tested in any order or combination up to four-way crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 7 days will be maintained between the dosing days of each treatment periods.
88991718|NCT04223960|Experimental|Part A: MAD, EA1080 Formulation A in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
88991719|NCT04223960|Experimental|Part A: MAD, EA1080 Formulation B in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation B or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
88991720|NCT04223960|Experimental|Part A: MAD, EA1080 Formulation C in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation C or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).
89212454|NCT00713609|Experimental|1|Benzoyl peroxide/clindamycin gel + tazarotene cream
89642518|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg BID|Participants received MK-8242 120 mg twice daily (BID) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 120 mg was administered QD in the morning) in Part 1 Arm A.
89642519|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 170 mg BID|Participants received MK-8242 170 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 170 mg was administered QD in the morning) in Part 1 Arm A.
89642520|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 210 mg BID|Participants received MK-8242 210 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 210 mg was administered QD in the morning) in Part 1 Arm A.
89642521|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg BID|Participants received MK-8242 250 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 250 mg was administered QD in the morning) in Part 1 Arm A.
88991721|NCT04223960|Experimental|Part A: MAD, EA1080 Formulation D in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation D or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned dose level and three optional).
88991722|NCT04223960|Experimental|Part A: MAD, EA1080 in Healthy Japanese Participants (Optional)|Healthy Japanese participants will receive any EA1080 formulation (Formulation A, Formulation B, Formulation C, and Formulation D) or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned dose level and three optional) per formulation.
88991723|NCT04223960|Experimental|Part B: SAD, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
88991724|NCT04223960|Experimental|Part B: SAD, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
88991725|NCT04223960|Experimental|Part B: SAD, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
88991726|NCT04223960|Experimental|Part B: SAD, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).
88991727|NCT04223960|Experimental|Part B: SAD-FE, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo on Day 1 in fasted state followed by EA1080 Formulation E on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
88991728|NCT04223960|Experimental|Part B: SAD-FE, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo on Day 1 in fasted state followed by EA1080 Formulation E on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
89642522|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 300 mg BID|Participants received MK-8242 300 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 300 mg was administered QD in the morning) in Part 1 Arm A.
89642523|NCT01451203|Placebo Comparator|PBO + MTX|Participants who received placebo subcutaneously every two weeks (Q2W) at Weeks 0, 2, and 4; followed by placebo subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
88991729|NCT04223960|Experimental|Part B: SAD-FE, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo on Day 1 in fasted state followed by EA1080 Formulation F on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
88991730|NCT04223960|Experimental|Part B: SAD-FE, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation F or matching placebo on Day 1 in fasted state followed by EA1080 Formulation F on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.
89642524|NCT01451203|Experimental|CZP + MTX|Participants who certolizumab pegol (CZP) subcutaneously at a loading dose of CZP 400 mg every 2 weeks (Q2W) at Weeks 0, 2, and 4; followed by a dose of CZP 200 mg subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
89642525|NCT01556438|Experimental|100 mg Tabalumab+Bortezomib (BTZ)IV+Dexamethasone (Dex)|Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle, each cyle is 21 days. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.
89642526|NCT01556438|Experimental|300 mg Tabalumab+BTZ IV+Dex|Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
89642527|NCT01556438|Experimental|300 mg Tabalumab+BTZ SC+Dex|Cohort 2-SC. 300 mg tabalumab (LY2127399)IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, subcutaneously (SC) on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ. Cohort 2-SC was added per protocol amendment in February 2013.
89642528|NCT02073487|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.
89642529|NCT02073487|Active Comparator|Trastuzumab + Pertuzumab + Paclitaxel|Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.
88991731|NCT04223960|Experimental|Part B: FE/BA, in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.
89642530|NCT01554176|Experimental|Filorexant 10 mg (Treatment Phase)|Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
89642531|NCT01554176|Placebo Comparator|Placebo (Treatment Phase)|Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
89642532|NCT01554176|Experimental|Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
89642533|NCT01554176|Placebo Comparator|Filorexant 10 mg/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
89642534|NCT01554176|Placebo Comparator|Placebo/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.
89642535|NCT01466491|Placebo Comparator|4-site injection|The superior technique of Phase 1 will be compared to a 4-site technique (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
89642536|NCT01466491|Active Comparator|2-site Injection|The superior technique of Phase 1 will be compared to a 2-site technique (2 mL injected at the tenaculum site, 18 mL equally distributed between 4 and 8 o'clock) in a randomized fashion (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
89642537|NCT01466491|Placebo Comparator|4-Site PCB followed by 3-minute wait|Women will be randomized to receive a 4-site PCB followed by a 3-minute wait (PCB 20/4/3) prior to dilation
89642538|NCT01466491|Active Comparator|4-site PCB followed by no wait|Women will be randomized to receive a 4-site PCB followed by no wait (PCB 20/4/0).
89642539|NCT01466179|Experimental|Blinatumomab|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.
89642540|NCT01493089|Experimental|Zegerid|Treatment of heartburn with Zegerid
89642541|NCT01493089|Active Comparator|Losec|Treatment of heartburn with Losec
89642542|NCT03027037||Remitted Major Depression Group|Women in this group will have experienced at least one episode of major depression in their lifetime, but no episodes in the two months prior to study enrollment.
89642543|NCT03027037||Control Group|Women in this group will never have experienced any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Axis I psychological disorder.
89642544|NCT01450813|Sham Comparator|Group 1|Saline 0.06 ml/kg
89642545|NCT01450813|Active Comparator|Group 2|Rocuronium 0.2 mg/kg
89642546|NCT01450813|Active Comparator|Group 3|Rocuronium 0.4 mg/kg
89642547|NCT01450813|Active Comparator|Group 4|Rocuronium 0.6 mg/kg
89642548|NCT03026335|Experimental|Positive Action Curriculum|"A school-wide program was implemented in the experimental schools referred to as Positive Action and was integrated with the existing Health and Family Life Education curriculum."
89642549|NCT03026335|Active Comparator|Control/Comparison Group|Business as usual with students in non-intervened schools
89642550|NCT01539512|Active Comparator|Idelalisib + rituximab|Participants will receive idelalisib plus rituximab
89642551|NCT01539512|Placebo Comparator|Placebo + rituximab|Participants will receive placebo to match idelalisib plus rituximab
89642552|NCT01449955|Placebo Comparator|Placebo (e.g., sugar pill)|15 mg Placebo will be administered once, in pill form.
89642553|NCT01449955|Active Comparator|Rapamycin|15 mg of Rapamycin will be administered once, in pill form.
89642554|NCT01574612|Experimental|topical cream acyclovir/hydrocortisone|topical cream acyclovir/hydrocortisone used
89642555|NCT01573910|Experimental|Moxifloxacin|Moxifloxacin ophthalmic solution, 0.5%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
89642556|NCT01573910|Active Comparator|Ofloxacin|Ofloxacin ophthalmic solution, 0.3%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
89642557|NCT01491919|Experimental|Low Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
89642558|NCT01491919|Experimental|Medium Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
89642559|NCT01491919|Experimental|High Dose: Lisinopril|Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.
89642560|NCT01573442|Experimental|Arm I|Patients receive testosterone (0.264mL) topical application daily for six months.
89642561|NCT01573442|Placebo Comparator|Arm II|Patients receive placebo (0.264mL) topical application daily for six months.
89642562|NCT02319369|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules
89642563|NCT02319369|Experimental|Part 1A, Milademetan with 5-azacytidine (AZA)|Participants receive milademetan in combination with 5-azacytidine (AZA), with different dose schedules
89642564|NCT02319369|Experimental|Part 2, Cohort 1|Participants with refractory or relapsed acute myelogenous leukemia (AML) receive the recommended dose for Part 2 of milademetan or milademetan with5-azacytidine (AZA)
89642565|NCT02319369|Experimental|Part 2, Cohort 2|Participants with newly diagnosed acute myelogenous leukemia (AML) unfit for intensive chemotherapy receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
89642566|NCT02319369|Experimental|Part 2, Cohort 3|Participants with high-risk myelodysplastic syndrome (MDS) receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
89642567|NCT01491841|Experimental|Phase 1: Pixantrone, 55mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 55mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
89212455|NCT00713609|Active Comparator|2|Benzoyl peroxide/clindamycin gel + vehicle cream
89212456|NCT00713609|Active Comparator|3|Benzoyl peroxide gel + tazarotene cream
89642568|NCT01491841|Experimental|Phase 1: Pixantrone, 85mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 85mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
89642569|NCT01491841|Experimental|Phase 1: Pixantrone, 115mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 115mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
89642570|NCT00486447|Experimental|Imaging|General imaging subjects receiving CT exams
89642571|NCT04081441|Experimental|Inyenyeri clean cookstove/fuel|A tier 4 clean Mimi-moto cookstove/pellet system
89642572|NCT04081441|Experimental|I-ACT behavioral empowerment intervention|A culturally adapted 2-day personal empowerment workshop (based on the Individual, Agency-Centered Training (I-ACT) to women and modified, condensed 1-day training for their male partners, if applicable
89642573|NCT04081441|Experimental|Cookstove and I-ACT empowerment|Access to both the clean cookstove system and I-ACT empowerment training
89642574|NCT04081441|Other|I-ACT Waitlisted control|These households include those that were offered cookstoves after 6 months (from baseline) and are waitlisted to receive the I-ACT intervention
89642575|NCT04408573|No Intervention|Regular Continuous High Frequency|Patient remains 2 weeks in the currently chosen stimulation protocol.
89642576|NCT04408573|Experimental|Cycling High Frequency|Patient is stimulated with the same polarity, voltage/current, pulse width and frequency as the currently chosen stimulation protocol, but with cycling stimulation: 40sec On - 02 sec OFF
89642577|NCT04408573|Experimental|Continuous Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz). Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
89642578|NCT04408573|Experimental|Cycling Low Frequency|Patient is stimulated with the same polarity and pulse width as the currently chosen stimulation protocol, but with low frequency (80Hz) and cycling stimulation: 40sec On - 02 sec OFF. Voltage/current will be adjusted to maintain TEED similar to that on the regular stimulation protocol.
89642579|NCT01553318|Active Comparator|Active Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 26 of the 51 participants will assigned to this arm of the study.
89642580|NCT01553318|Placebo Comparator|Placebo for Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 25 of the 51 participants will assigned to this arm of the study. Subjects in this arm will receive the placebo drug.
89642581|NCT00486525|Experimental|Arm I: Yoga Therapy|Patients participate in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients are also encouraged to practice yoga at home using the appropriate DVD/video segments for the month.
89642582|NCT00486525|No Intervention|Arm II: Wait-List|Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.
89642583|NCT01572740|Experimental|Lira+Insulin|
89642584|NCT01572740|Placebo Comparator|Placebo+Insulin|
89642585|NCT01491607|Experimental|BioThrax (0.5 mL, on days 0, 14, and 28)|
89642586|NCT02338713|Experimental|Noncarbonated Water + Calcichew D3|Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period.
89642587|NCT00557349|Active Comparator|Omeprazole|40 mg Omeprazole daily
89642588|NCT00557349|Active Comparator|Famotidine|40 mg Famotidine daily
89642589|NCT01449721|No Intervention|Control|Standard medical care by the primary treatment team.
89642590|NCT01449721|Experimental|Interventional arm|Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization
89642591|NCT01553084|Experimental|Effectiveness of Nicotine patch only|
89642592|NCT01553084|Experimental|Effectiveness of Combination NRT|
89642593|NCT01553084|Experimental|Effectiveness of Varenicline [Chantix]|
89642594|NCT01536860|Placebo Comparator|Control Test Drink|control drink
89642595|NCT01536860|Experimental|Experimental Test Drink 1|control drink containing ingredient 1
89642596|NCT01536860|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
89642597|NCT01552928|Experimental|Anagrelide Therapeutic (0.5 mg)|
89642598|NCT01552928|Experimental|Anagrelide Supratherapeutic (2.5 mg)|
89642599|NCT01552928|Active Comparator|Moxifloxacin|
89642600|NCT01552928|Placebo Comparator|Placebo|
89642601|NCT01448707|Experimental|Darunavir monotherapy|Darunavir (DRV) + ritonavir (rtv): 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal. Following the primary efficacy analysis after Week 48, patients who entered the study with a nadir CD4+ count of <200 cells/μL will also receive 2 N[t]RTIs (ie, triple therapy) as soon as possible
89642602|NCT01448707|Active Comparator|Triple therapy containing darunavir|Darunavir (DRV) + ritonavir (rtv) + 2 N[t]RTIs: 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal in combination with 2 N[t]RTIs (an investigator-selected dual combination of either abacavir (ABC), lamivudine (3TC), zidovudine (AZT), tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)
89642603|NCT01536704|Experimental|Test nicotine lozenge (2 mg)|2 mg test nicotine lozenge to be chewed.
89642604|NCT01536704|Experimental|Test nicotine lozenge (4 mg)|4 mg test nicotine lozenge to be chewed.
89642605|NCT01536704|Active Comparator|Reference nicotine lozenge (2 mg)|2 mg reference nicotine lozenge to be chewed.
89642606|NCT01536704|Active Comparator|Reference nicotine lozenge (4 mg)|4 mg reference nicotine lozenge to be chewed.
89642607|NCT04108676|Experimental|single arm|Drug: Fluzoparib Drug: Omeprazole
89642608|NCT04121546|Experimental|Intervention Arm|Patients will receive the telecare intervention.
89642609|NCT04121546|No Intervention|Usual Care Arm|Patients will receive usual care.
89642610|NCT01552772|Experimental|Aripiprazole IM Depot|
89043232|NCT02905383|Experimental|Exercise|This group will perform a multi-component exercise program twice a week for 16 weeks. The multi-component exercise program consists of endurance training, progressive strength exercises and balance exercises. The intervention will be individualised, but performed in groups of four to ten patients. The participants are also expected to do exercises on their own, at least once weekly.
89043233|NCT02905383|No Intervention|Control|The participants in the control group will be encouraged to exercise on their own, according to the World Health Organization recommendations on physical activity for adults aged 65 and above.
89043234|NCT04643717||intensive care patients|
89043235|NCT02907840|Experimental|Recruitment|Lung aeration monitored by Swisstom BB2 during PEEP steps and recruitment maneuver
89043236|NCT02905344||1|Control, no anatomical model used for description
89642611|NCT01552694|Experimental|Sitagliptin|100 mg sitagliptin/day for 2 months
89642612|NCT01552694|Placebo Comparator|Placebo|Matching placebo daily for 2 months
89642613|NCT01464931|Experimental|Denosumab|Participants received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
89642614|NCT00560859|Active Comparator|Early AT Surgery|There will be removal of tonsils and adenoids that will be performed within 4 weeks of the baseline visit.
89642615|NCT00560859|Other|Watchful Waiting|Children will be closely monitored and re-evaluated for AT by an otolaryngologist after the primary 7 month monitoring period.
89642616|NCT03028376||Moderate TBI patients|GCS 9-13
89642617|NCT01536392|Experimental|Granisetron|Group A: 34.3 mg of granisetron formulated in transdermal patch replaced every 7 days. Transdermal patch placed/replaced prior to the intravenous (IV) infusion of cisplatin. At cycle 1, participants receive IV granisetron prior to IV cisplatin and prior to administration of transdermal patch.
89642618|NCT01536392|Experimental|Ondansetron|Group B: 8 mg of ondansetron orally thrice daily starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
89642619|NCT01464619|Experimental|Delayed Intervention|Those assigned to the delayed intervention arm will receive enhanced mental health referrals, monthly follow-up phone calls, and will be assigned to the parenting intervention 3-4 months after enrollment.
89642620|NCT01464619|Experimental|Intervention|Caregivers assigned to the intervention arm will be assigned to the Incredible Years parenting intervention immediately after enrollment. They will also receive enhanced mental health referrals and monthly follow-up phone calls.
89642621|NCT02123745|Experimental|Infiltrated Tissue|The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
89642622|NCT04767295|Experimental|Camrelizumab, Albumin Paclitaxel, Carboplatin|"ESCC participants in this study will be given intravenous administration of Camrelizumab (200mg/3w) combined with albumin paclitaxel (260 mg/m2) plus carboplatin chemotherapy. Every three weeks for a cycle of treatment, which will be conducted twice, and minimally invasive surgery within 5-8 weeks after the last administration.~Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment."
89642623|NCT00488865|Other|Intravascular Filter Device|
89642624|NCT02118441|Active Comparator|direct palpation|Radial artery catheter insertion will be conducted by direct palpation and use of anatomic knowledge by the Anesthesiologist.
89642625|NCT02118441|Active Comparator|Ultrasound|"Radial artery catheter insertion will be conducted by ultrasound guidance. A Sono-site ilook 25 Ultrasound (Sono-site, Inc., Bothell, WA, USA) with a 10-5 MHz linear array ultrasound transducer will be used.~At the discretion on the Anesthesiologist, an out-of-plane (i.e. needle plane at right angles to ultrasound plane) will be used. Colour flow doppler may also be used to identify the artery if necessary."
89642626|NCT02118831|Active Comparator|Aflibercept Blood Sample Collection|Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
89212457|NCT00713609|Active Comparator|4|Clindamycin gel + tazarotene cream
88991732|NCT04223960|Experimental|Part B: FE/BA, in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.
88991733|NCT04223960|Experimental|Part B: MAD, EA1080 Formulation E in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
89043237|NCT02905344||2|Anatomical model used for description
89043238|NCT04643522||Before COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed before the diagnosis of COVID-19.
89043239|NCT04643522||After COVID-19|The semen parameters and sex-related hormone levels of the patients which were performed after the diagnosis of COVID-19.
89043240|NCT02905305|Experimental|CA with dexamethasone base|Contour Advance electrode with controlled dose of dexamethasone base
89043241|NCT02905305|Active Comparator|Contour Advance|Standard Contour Advance electrode array
89043242|NCT02899182|Placebo Comparator|conventional group|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
89043243|NCT02899182|Experimental|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
89212458|NCT00713609|Active Comparator|5|Vehicle gel+ tazarotene cream
89642627|NCT02118831|Active Comparator|Bevacizumab Blood Sample Collection|Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
89642628|NCT02118831|Active Comparator|Ranibizumab Blood Sample Collection|Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
89642629|NCT03026179|Other|Intervention parents|Parents were asked to view 5-10 minutes of a program designed to educate about discipline.
89642630|NCT02119455|Experimental|Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
89642631|NCT02119455|No Intervention|No Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
89642632|NCT03026413|Experimental|PVAM|pulomonary vein antrum modification with contact force monitoring for AF
89642633|NCT03026413|Active Comparator|Control arm|pulmonary vein isolation without contact force
89642634|NCT02120001|Experimental|ETT cleaning maneuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
89642635|NCT02120001|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
89642636|NCT00490269|Active Comparator|Dronabinol|
89642637|NCT00490269|Placebo Comparator|Placebo|
89642638|NCT05621499|Experimental|experimental group1|HAIC
89642639|NCT05621499|Experimental|experimental group 2|Lenvatinib+Sintilimab
89642640|NCT05621421||Patients with long coronary artery lesions|Consecutive patients with functionally significant (FFR ≤ 0.8) long lesion requiring a stent length of ≥ 30mm to undergo FFR and IVUS guided PCI.
89642641|NCT05621343||Latent TB on treatment|"Treatment according to existing Swedish guidelines with:~Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months OR Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6 months"
89642642|NCT05621343||Latent TB not on treatment|Latent TB without indication for treatment OR patient who do not want to receive treatment
89642643|NCT05621343||Active TB with treatment|Treatment according to existing Swedish guidelines. Duration and choice of antibiotic therapy depending on the condition.
89642644|NCT05621343||Healthy control|Healthy
89642645|NCT01490125|Experimental|QVA149 + placebo to tiotropium|Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
89642646|NCT01490125|Active Comparator|Tiotropium + placebo to QVA149|Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
89642647|NCT01490125|Placebo Comparator|Placebo|Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
89642648|NCT05560503||significant liver fibrosis|According to the Scheuer scoring system, the degree of fibrosis S2-S4 as significant liver fibrosis.
88991734|NCT04223960|Experimental|Part B: MAD, EA1080 Formulation E in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
88991735|NCT04223960|Experimental|Part B: MAD, EA1080 Formulation F in Healthy Caucasian Participants|Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
88991736|NCT04223960|Experimental|Part B: MAD, EA1080 Formulation F in Healthy Japanese Participants|Healthy Japanese participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).
88991737|NCT04221373|Experimental|Exoskeletal-assisted walking training group|Participants will receive locomotor training provided with an Ekso™ powered exoskeleton according to the standard of care of AIR at Mount Sinai Hospital with the exception that the EAW training will be incorporated into the designated therapy times (3 hours of physical therapy (PT) and/or occupational therapy (OT)) which will be provided as determined by the clinical team from the earliest time they are identified to be able to safely stand, through discharge. The goal of EAW intervention is to complete three or more sessions of EAW training a week during the AIR period (after enrolling into the study until discharge).
88991738|NCT04221373|Active Comparator|Standard of care group|Participants will receive standard of care of acute inpatient rehabilitation which includes three hours of physical therapy and/or occupational therapy per day until they are discharged.
89212459|NCT00713609|Placebo Comparator|6|Vehicle gel + vehicle cream
89642649|NCT05560503||non-significant liver fibrosis|According to the Scheuer scoring system, the degree of fibrosis S0-S1 was defined as non-significant liver fibrosis.
89642650|NCT01446913|Active Comparator|Standard Intervention group|This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.
89642651|NCT01446913|Active Comparator|Enhanced CPAP intervention|This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.
89642652|NCT01446913|No Intervention|Usual Care|This group usual care after TIA/stroke and a sleep study at the end of the study.
89642653|NCT00491751|Experimental|Atorvastatin|Atorvastatin 40 or 80 mg/day
89642654|NCT00491751|Experimental|Ascorbic Acid|Ascorbic Acid 500 mg/day
89642655|NCT00491751|Placebo Comparator|Placebo|Placebo atorvastatin and Placebo ascorbic acid
89642656|NCT01420549|Experimental|Rosuvastatin + Ezetimibe|Participants received Rosuvastatin 10 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Rosuvastatin 20 mg+ Ezetimibe 10mg tablet orally once daily for more 4 weeks.
89642657|NCT01420549|Active Comparator|Simvastatin + Ezetimibe|Participants received Simvastatin 20 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Simvastatin 40 mg + Ezetimibe 10mg tablet orally once daily for more 4 weeks.
89642658|NCT00491829|Experimental|flibanserin|50 mg qhs
89642659|NCT00491829|Experimental|flibanserin 100mg|100 mg qhs
89642660|NCT00491829|Placebo Comparator|placebo|placebo qhs
89642661|NCT01440595|Experimental|Grazoprevir 200 mg + Peg-IFN + RBV|Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
89642662|NCT01440595|Experimental|Grazoprevir 400 mg + Peg-IFN + RBV|Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
89642663|NCT01440595|Placebo Comparator|Placebo + Peg-IFN + RBV|Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
89642664|NCT01440595|Experimental|Grazoprevir 800 mg + Peg-IFN + RBV|Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.
89642665|NCT05560347|Experimental|Experimental Group|Hot water will be applied to the participants in the experimental group at the 2nd and 6th hours postoperatively. During the hot water application, the feet of the individual will be immersed in the hot water application device and kept in the device for 20 minutes. At the end of the 20th minute, the feet of the individual will be removed from the device and dried with a towel for 10 minutes and the application will be completed. The data will be obtained by using the Introductory Information Form, Visual Analog Scale (VAS), Postpartum Comfort Scale and Post Cesarean Patient Evaluation Form.
89642666|NCT05560347|No Intervention|Control Group|Routine care will be given to the control group
89642667|NCT01440517|Experimental|Tc99m-Maraciclatide|
89642668|NCT05560269|Experimental|verbal and physical constraint group|○ Warm-up → pre-intervention measurement of joint angles with kettlebell swing → 30 seconds to 1 minute rest interval → 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the first part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval → Post-intervention measurement of joint angles with kettlebell swing
89642669|NCT05560269|Active Comparator|verbal constraint group|○ Warm-up → pre-intervention measurement of joint angles with kettlebell swing → 30 seconds to 1 minute rest interval → 15 repetitions of kettlebell swings using verbal cues to teach the first part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to combine both parts of the movement → 30 seconds to 1 minute rest interval → Post-intervention measurement of joint angles with kettlebell swing
89642670|NCT05560269|Experimental|physical constraint group|○ Warm-up → pre-intervention measurement of joint angles with kettlebell swing → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to teach the first part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval → Post-intervention measurement of joint angles with kettlebell swing
89043244|NCT02905227|Experimental|Adult Asthmatics|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult asthmatics
89043245|NCT02905227|Experimental|Adult Smokers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult smokers.
89043246|NCT02905227|Experimental|Adult Healthy Volunteers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult healthy volunteers.
89043247|NCT04643600|Active Comparator|Smokers|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients who are smokers will have recorded : the age of onset of smoking, the year of smoking experience and the average number of cigarettes smoked per day. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
89212460|NCT00513682|Experimental|Ultrase® MT20|
89212461|NCT00493012|Experimental|vitamin D oil|oil containing vitamin D (Vigantol oil)
89642671|NCT01440283|Experimental|Treatment|"Patients with high-risk abdominal neuroblastoma who receive any high-risk neuroblastoma treatment regimen will be eligible to enroll prior to surgical resection of the primary tumor. Following implantation of fiducial markers within the tumor bed and autologous hematopoietic rescue, patients will begin the planning process for abdominal irradiation.~Interventions: Intensity Modulated Radiation Therapy (IMRT)"
89642672|NCT05560035|Experimental|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
89642673|NCT05560035|Placebo Comparator|Normal saline|Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
89642674|NCT05559645|Experimental|Cohort 1: EGFR sensitizing mutations, T790M neg|
89642675|NCT05559645|Experimental|Cohort 2: EGFR sensitizing mutations|
89642676|NCT05559645|Experimental|Cohort 3: EGFR uncommon mutations|
89642677|NCT05559645|Experimental|Cohort 4: EGFR Exon20ins|
89642678|NCT05459259||Patients participants|Adults who have undergone elective knee arthroplasty with post-operative arthrofibrosis/stiffness who have undergone MUA in the previous 24 months or are currently listed for a MUA.
89642679|NCT05459259||Healthcare Professionals|Physiotherapists/Occupational Therapist/ Nurses and Orthopedic surgeons with clinical experience in the management of patients with arthrofibrosis following knee joint arthroplasty
89642680|NCT05418387|Experimental|Group A|Patients randomized to receive the Social Support Network intervention
89642681|NCT05418387|Active Comparator|Patient Navigation|Patients randomized to receive Usual Care (patient navigation)
89212462|NCT00493012|Placebo Comparator|placebo oil|oil not containg vitamin D (Migliol oil)
89212463|NCT00918593|Experimental|Electrochemotherapy|
89212464|NCT00918593|Active Comparator|radiotherapy|
89642682|NCT01440049||Eplerenone|
89642683|NCT00497055|Experimental|Aripiprazole|Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.
89642684|NCT00497055|Placebo Comparator|Placebo|Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.
89642685|NCT05559567|Other|Orthokeratology|Orthokeratology is fitting of a contact lens for overnight wear to flatten the cornea and correct myopia temporarily during the day. This procedure has also been shown to slow down the axial length growth in children.
89642686|NCT00497289|Experimental|1|Lipidem 20 %
89642687|NCT00497289|Active Comparator|2|Lipofundin MCT/LCT 20%
89642688|NCT05559333|Active Comparator|zirconomer|zirconia reinforced glass ionomer cement
89642689|NCT05559333|Active Comparator|Equia Fil|High viscosity glass ionomer cement
89642690|NCT05559333|Active Comparator|glass carbomer|glass ionomer cement containing nano sized- carbonized particles.
89642691|NCT05559333|Active Comparator|Tetric-evo ceram bulk fill|Bulk fill composite resin
89642692|NCT00498615|Experimental|Fasudil 80 mg|Subject is given a single dose of 80 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
89642693|NCT00498615|Experimental|40 mg Fasudil|Subject is given a single dose of 40 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
89642694|NCT00498615|Placebo Comparator|placebo|Subject is given a single dose of placebo( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
89642695|NCT05559177|Experimental|Treatment of recurrent or metastatic bladder cancer|Lack of conventional effective treatment, failure or recurrence of treatment with conventional methods (surgery, chemotherapy, radiotherapy, immune checkpoint inhibitors, targeted therapy, etc.), or refusal of conventional treatment
89642696|NCT00498927|Experimental|Temozolomide|Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
89642697|NCT00499473|Experimental|Stratum 1 (kinase inhibitor therapy)|Non-EIAC patients receive oral sunitinib malate once daily for 4 consecutive weeks followed by 2 weeks of rest.
89642698|NCT00499473|Experimental|Stratum 2 (kinase inhibitor therapy)|EIAC & OSU patients receive oral sunitinib malate as in stratum 1. Patients receive escalating doses of oral sunitinib malate until the maximum tolerated dose (MTD) is determined.
89642699|NCT01439971|Experimental|1|
89642700|NCT01439971|Experimental|2|
89642701|NCT01439971|Experimental|3|
89642702|NCT01439971|Experimental|4|
89642703|NCT01439971|Experimental|5|
89642704|NCT05555277||Anorexia Nervosa|Individuals aged 18 years and younger with anorexia nervosa who have beck depression inventory, beck anxiety inventory, eating attitude test-40 and EEG data in their patient file.
89642705|NCT05555277||Bulimia Nervosa|Individuals aged 18 years and younger with bulimia nervosa who have beck depression inventory, beck anxiety inventory, eating attitude test-40 and EEG data in their patient file.
89642706|NCT01797939||Erosive reflux disease (ERD)|
89642707|NCT01797939||Non-erovise reflux disease (NERD)|
89642708|NCT01797939||Functional heartburn (FH)|
89642709|NCT00501891|Experimental|Bevacizumab and Metronomic Temozolomide|Patients will receive up to 12 cycles of bevacizumab (Avastin) and metronomic temozolomide (Temodar), and each cycle is 28 days. Bevacizumab will be administered at 10 mg/kg every other week beginning a minimum of 7 days after a biopsy or 28 days after a craniotomy. Temozolomide will be dosed at 50 mg/m2 daily in a 28-day cycle.
89642710|NCT01798017|Experimental|Mifepristone-misoprostol|Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol
88991739|NCT04206605|Placebo Comparator|Placebo|Participants received placebo-matching lanadelumab subcutaneous (SC) injection once every 2 weeks (q2w) for up to 7 months.
88991740|NCT04206605|Experimental|Lanadelumab 300mg|Participants received 300 mg of lanadelumab solution in a prefilled syringe (PFS) as SC injection once (q2w) for up to 6 months.
88991741|NCT04187872|Experimental|Patients with Recurrent Brain Metastes|Adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis that have failed SRS treatment will receive LITT per standard of care in combination with Pembrolizumab 200mg IV every 3 weeks (+/-3 days) up to 2 years.
88991742|NCT04177212|Experimental|3 MRZF111 injection cycles|Enrolled subjects will receive 3 injection cycles in total at time points Day 1, Week 8, and Week 16.
88991743|NCT04177212|Experimental|2 MRZF111 injection cycles|Enrolled subjects will receive 2 injection cycles in total at time points Day 1, and Week 16.
89642711|NCT04808583|Active Comparator|Group (A)|conventional TLH with uterine artery ligation after the cornual pedicles
89642712|NCT04808583|Experimental|Group (B)|TLH with uterine artery ligation at its origin at the beginning of the operation
89642713|NCT02811003|Experimental|Treatment|Treatment with Rotation Medical Bioinductive Implant
88991746|NCT04161066|Experimental|Open-label|Psilocybin with facilitated counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
88991747|NCT04157920|Other|Patients treated with Medtronic CoreValve/ Evolut R/Pro|TAVI patients treated with Medtronic CoreValve /Evolut R - Evolut PRO Transcatheter Heart Valves, participated in the DIRECT trial
88991748|NCT04157920|Active Comparator|Patients treated with ACURATE neo/TF|TAVI patients treated with ACURATE neo/TF Transcatheter Heart Valve recruited prospectively.
89642714|NCT00502905|Experimental|Busulfan + Fludarabine|Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours immediately after Fludarabine 40 mg/m^2 over 1 hour.
89642715|NCT00505635|Experimental|Biochemotherapy with Temozolomide|Temozolomide 250 mg/m^2 every 4 hours Day 1; Biochemotherapy of Velban 1.5 mg/m^2 intravenous (IV) Days 1-4; Cisplatin 20 mg/m^2 IV Days 1-4; + Interleukin-2 9 MIU/m^2 IV over 24 Hours for 4 Doses Days 1-4; Intron-A 5 mu/m^2 subcutaneously daily Days 1-5; + Oral Thalidomide 400 mg daily.
89642716|NCT01842165|Other|177Lu-octreotate therapy|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
89642717|NCT00506025|Active Comparator|Cranberry 2xday|Cranberry juice (C) two times daily, a.m. and p.m.
89642718|NCT00506025|Active Comparator|Cranberry + Placebo|De-Activated Cranberry juice in the am, then placebo (P) in the pm
89642719|NCT00506025|Placebo Comparator|Placebo 2xday|Placebo in the form of juice two times daily in the a.m. and p.m.
89642720|NCT05395689|Experimental|Active substance|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae solution administered by the subcutaneous route for 12 months using a rush schedule
89642721|NCT05395689|Placebo Comparator|Placebo|Saline solution administered by the subcutaneous route for 12 months using a rush schedule
89642722|NCT05376657|Placebo Comparator|Placebo drink|
89642723|NCT05376657|Experimental|Cherry collagen drink|
89642724|NCT05365503|Experimental|Shamiri Intervention|The Shamiri intervention group will recieve a brief character strength intervention that will be delivered over the span of 4 weeks. There will be four sessions each lasting one hour each.
89642725|NCT04479813|Experimental|No conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
89642726|NCT04479813|Experimental|No conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests.
89642727|NCT04479813|Experimental|Remote pre-conditioning + placebo|Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
89642728|NCT04479813|Experimental|Remote pre-conditioning + moxonidine|Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests.
89642729|NCT04474899|Experimental|Phase 1|Moxonidine 0.4mg/daily
89642730|NCT04474899|Experimental|Phase 2|Amlodipine 5mg
89642731|NCT04436367||SAA patients with Monosomy 7|Severe Aplastic Anemia Patients who Developed High Risk Clonal Evolution with Chromosome 7 Abnormalities after Immunosuppressive Therapy
89642732|NCT00508521|Experimental|FES and Motor Learning Training|participants <6 months after first stroke who presented with arm dysfunction were trained using FES and Motor Learning
89642733|NCT00508521|Other|Control group|Subjects in this arm will receive standard care as prescribed by their physician and covered by their insurance
89642734|NCT04369989||Hydroxychloroquine - NO|Did not receive / are not receiving any Hydroxychloroquine
89642735|NCT04369989||Hydroxychloroquine - YES - started before|Hydroxychloroquine date started was before the date recorded for signs of respiratory distress
89642736|NCT04369989||Hydroxychloroquine - YES - started same|Hydroxychloroquine date started was the same as the date recorded for signs of respiratory distress
89642737|NCT04369989||Hydroxychloroquine - YES - started after|Hydroxychloroquine date started was after the date recorded for signs of respiratory distress
89642738|NCT05209659||Low Back Pain|Pragmatic Mobilization The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment)
88991749|NCT04151095|Experimental|BFR|
88991750|NCT04151095|Experimental|CTL|
88991751|NCT04147130|Experimental|MultiPAP Plus intervention|Complex intervention with general practitioners and patients
88991752|NCT04147130|Active Comparator|Usual care|Patients will recieve the usual clinical care
88991753|NCT04144569|Experimental|PD-1 Combined With Pyrotinib|PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
88991754|NCT04136457|Experimental|Endurance|Endurance training
88991755|NCT04136457|Experimental|Resistance|Resistance training
88991756|NCT04136457|Experimental|Sprint|Sprint training
88991757|NCT04110392|Experimental|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
88991758|NCT04110028|Experimental|Nicotinamide riboside 250 mg|One capsule of 250 mg each morning for three months
88991759|NCT04110028|Experimental|Nicotinamide riboside 500 mg|One capsule of 250 mg each morning and afternoon for three months
88991760|NCT04110028|Experimental|Nicotinamide riboside 1000 mg|Two capsules of 250 mg each morning and afternoon for three months
88991761|NCT04110028|Experimental|Nicotinamide riboside 2000 mg|Four capsules of 250 mg each morning and afternoon for three months
88991762|NCT04110028|Placebo Comparator|Placebo for 250 mg nicotinamide riboside|One capsule each morning for three months
88991763|NCT04110028|Placebo Comparator|Placebo for 500 mg nicotinamide riboside|One capsule each morning and afternoon for three months
88991764|NCT04110028|Placebo Comparator|Placebo for 1000 mg nicotinamide riboside|Two capsules each morning and afternoon for three months
88991765|NCT04110028|Placebo Comparator|Placebo for 2000 mg nicotinamide riboside|Four capsules each morning and afternoon for three months
89642739|NCT04234815|Experimental|CETA Short Session (CSS)|A single-session, 1.5-2 hour group workshop that includes psychoeducation, self-assessment, safety screening, and training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance. On this phone call they will also be asked about their use of the cognitive coping skill over the last week, and provided feedback if using it incorrectly.
89043248|NCT04643600|Active Comparator|Non - smokers|All patients will be maesured: body weight, height, BMI (body mass index), waist circumference, pulse (cp), saturation (SpO2), blood pressure, respiratory index and thoracic spine mobility index measured. All patients will do a 6-minute walk test and test on a bicycle erogometer. The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength. All patients will complete the CAT, IPAQ and DASS-21 questionnaire.
89043249|NCT02899455|Experimental|Experimental|HGP0904 + HGP0608 + HGP0816, once daily
89043250|NCT02899455|Active Comparator|Active Comparator1|HGP0904 placebo + HGP0608 + HGP0816, once daily
89043251|NCT02899455|Active Comparator|Active Comparator2|HGP0904 + HGP0608 + HGP0816 placebo, once daily
89043252|NCT04643561|Experimental|intervention|5 patients will recieve 5 days treatment with Travelan, blood samples will be taken prior and after intervention
89043253|NCT02898909|Experimental|16 pieces fragmentation|
89043254|NCT02898909|Active Comparator|8 pieces fragmentation|
89043255|NCT04643483|Experimental|Certolizumab pegol low dose arm|"Participants randomized to certolizumab pegol (CZP) who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 100 mg CZP subcutaneously (sc) every 2 weeks (Q2W).~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by placebo and a maintenance dose of 200 mg CZP sc Q2W."
89043256|NCT04643483|Experimental|Certolizumab pegol high dose arm|"Participants randomized to CZP who weigh ≥17 kg to <40 kg will receive placebo at Week 0 and a loading dose of 200 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 200 mg CZP sc Q2W.~Participants randomized to CZP who weigh ≥40 kg will receive placebo at Week 0 and a loading dose of 400 mg at Weeks 0, 2, and 4, followed by a maintenance dose of 300 mg CZP sc Q2W."
89642740|NCT04234815|Active Comparator|Enhanced Treatment as Usual (eTAU)|A single-session, approximately 1-hour group workshop that includes the same psychoeducation, self-assessment, and safety screening as the experimental condition, but no training in cognitive coping. Participants with at least moderate symptoms of distress will also receive a follow-up phone call to discuss next steps occurring within one week after workshop attendance.
89642741|NCT00511095|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) Intramuscular (IM) injection 0.5mL
89642742|NCT00511173|Experimental|Clinician dosing of warfarin|Warfarin dose based on clinician dosing without the use of warfarin pharmacogenetics
89642743|NCT05178771|Experimental|test site|The test site will receive ScRp in addition to PRF
89642744|NCT05178771|No Intervention|control sites|The control site will be treated by ScRp only
89642745|NCT01447927|Experimental|Arm I|Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.
89642746|NCT01447927|Placebo Comparator|Arm II|Patients receive extended-release placebo PO QD on week 1and BID on weeks 2-12 (QAM and QPM on week 3) in the absence of unacceptable toxicity or disease progression.
89642747|NCT04111185|Experimental|Receive Blood Volume Analysis Guided Treatment|The health care team will be provided with BVA results and may use the information to make decisions regarding the participant's treatment.
89642748|NCT04111185|No Intervention|Receive Standard of Care Treatment|The health care team will not be provided with the BVA results. The participant will receive the same treatment they would have received if they weren't in the study.
89642749|NCT04053387|Experimental|Tapinarof (DMVT-505) Cream Group|"Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study.~Subjects entering with a PGA ≥ 1 received treatment with tapinarof cream, 1% until they achieve a PGA = 0, at which time treatment was discontinued and subjects were monitored for durability of response (remittive response). If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved.~Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved.~This treatment and re treatment pattern of use was continued until the end of the study"
89642750|NCT04045743|Experimental|Bermekimab (MABp1)|
89642751|NCT04045743|Experimental|Placebo|
89642752|NCT01551758|Experimental|FF/VI|once daily via a Novel Dry Powder Inhaler
89212465|NCT04084847|Active Comparator|Barberry|Daily consumption of barberry in powder form.
89212466|NCT04084847|Placebo Comparator|placebo|Daily consumption of placebo powder.
89642753|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:~Long acting bronchodilator therapy alone~ICS alone or in combination with a long acting bronchodilator~Triple maintenance therapy"
89642754|NCT00513747|Experimental|Arm I|Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
89212467|NCT04084457|Placebo Comparator|Placebo|Matched for macronutrients, micronutrients and fibre
89212468|NCT04084457|Active Comparator|Wild Blueberry Powder|Formulation of a 100% blueberry (freeze-dried whole fruit) drink
89212469|NCT05163431|Experimental|Painful Hallux Valgus|
89642755|NCT00513747|Active Comparator|Arm II|Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
89642756|NCT00514137|Experimental|Treatment (kinase inhibitor therapy)|Patients receive 37.5 mg oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89642757|NCT00514215|Experimental|Sargramostim, Flow Cytometry, Biopsy. Cryosurgery|Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32
89642758|NCT05070819|Experimental|Cardiac surgery patients|"After admission to OR and arterial catheter is placed the pro-ANP probe is obtained.~After anesthesia induction, trachea intubation before Teboul' test pro-ANP is obtained~At the end of Teboul' test when lower limbs are lifted~30 minutes of CPB~End of CPB~End of volume transition from CPB circuit to patient~Before Teboul' test at the end of surgery~End of Teboul' test when lower limbs are lifted"
89642759|NCT03912909|Active Comparator|Phase 1|Empagliflozin 10mg daily or placebo
89642760|NCT03912909|Placebo Comparator|Phase2|Empagliflozin 10mg daily or placebo
89642761|NCT03903471|Experimental|22G-ProCore Group|The experimental group with 22G-ProCore needle is expected to enroll 300 patients. The 22G-ProCore needle has a 1.5mm long groove 2.5mm above the needle tip, which is expected to have the advantage of taking more biopsy tissues than the 22G-Standard needle.
89642762|NCT03903471|Active Comparator|22G-Standard Group|The control group of 22G-Standard needle is expected to include 300 patients, and there is no groove above the needle tip compared with 22G-ProCore needle.
89642763|NCT02130063|Experimental|iron isomaltoside 1000 (Monofer®)|iron isomaltoside 1000 (Monofer®)
89642764|NCT02130063|Active Comparator|iron sucrose (Venofer®)|iron sucrose (Venofer®)
89642765|NCT00515697|Experimental|Ramucirumab|Intravenous infusion at 8 milligrams per kilogram (mg/kg) on day 1 of every 14-day cycle.
89642766|NCT00516165|Experimental|RAD001|Patients will receive RAD001 10 mg/day orally (6 weeks/cycle). Patients will be continued on treatment until disease progression, limiting toxicity, patient withdrawal of consent, or death.
89642767|NCT04988061|Experimental|Counselling arm|Educating and Counselling are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
89642768|NCT04988061|No Intervention|standard arm|The information about hearing screening results and an appointment date are provided as a routine by either nurses or nurse assistances who perform the screening test.
89642769|NCT01798095|Experimental|Aplisol|To confirm the response of PPD materials
89642770|NCT01798095|Active Comparator|PPD Standard|Determine equivalent specificity for new material compared to standard material.
89642771|NCT02130999|Experimental|Sequence A|"Single oral dose of tasimelteon 20 mg on Day 1~Single I.V. dose of tasimelteon 2 mg on Day 6"
89642772|NCT02130999|Experimental|Sequence B|"Single I.V. dose of tasimelteon 2 mg on Day 1~Single oral dose of tasimelteon 20 mg on Day 6"
89642773|NCT00518349|Active Comparator|Prototype colonoscope|Colonoscopy using prototype colonoscope with passive bending function
89642774|NCT00518349|Placebo Comparator|Standard colonoscope|Colonoscopy using standard colonoscope with no passive bending function
89212470|NCT04083833|Experimental|Treatment Arm|(Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)
89212471|NCT04083833|Placebo Comparator|Control|"Treatment D:~(Period 1)A single matching-TTX placebo administered with a single oral moxifloxacin matching placebo~Treatment E:~(Period 2)A single matching-TTX placebo with a single oral 400 mg moxifloxacin~Treatment F:~(Period 3)A single matching-TTX placebo with a single oral moxifloxacin matching placebo~Treatment G:~(Period 1)A single matching-TTX placebo with a single oral 400 mg moxifloxacin~Treatment H:~(Period 2)A single matching-TTX placebo with a single oral moxifloxacin matching placebo~Treatment I:~(Period 3)A single matching-TTX placebo with a single oral 400 mg moxifloxacin"
89212472|NCT05155241|Experimental|Intervention|Participants will watch an online health promotion video tailored to their current stage of change related to SIV uptake once every two weeks for four times (at week 0, 2, 4, and 6)
89212473|NCT05155241|Active Comparator|Control|Participants will watch a same online video providing general advices related to SIV at week 0, 2, 4, and 6
89212474|NCT05144477|Experimental|FAID Fear Intervention|Family members of CA patients assigned to intervention will receive the ICU diary.
89212475|NCT05144477|No Intervention|Control condition - Usual Care|Family members of CA patients assigned to usual care will not receive the ICU diary.
89642775|NCT02132169|Experimental|AC-170 0.24%|
89642776|NCT02132169|Placebo Comparator|AC-170 0%|
89642777|NCT04065321||Control group|250 patients will be assigned into control group.
89642778|NCT04065321||Trial group|250 patients will be assigned into trial group.
89642779|NCT03193125|Experimental|Carnitine|500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.
89642780|NCT03193125|Placebo Comparator|Placebo|500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.
89642781|NCT03174405|Experimental|AVELUMAB|
89642782|NCT00522171||Electro Surgery|Electro Surgical instruments are used to cut and coagulate tissue using alternating electric current at the surgical site. In Electro Surgery, the patient is included in the circuit and current enters the patient's body.
89642783|NCT00522795|Experimental|PPX with cisplatin and radiation|PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation
89212476|NCT03938675||Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
89212477|NCT03938675||No Raw maternal own milk before day 7|"Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as exposed when they received any raw MOM before day 7, versus unexposed when they did not receive any raw MOM before day 7."
89212478|NCT05135663|Experimental|NS-089/NCNP-02 40 mg/kg|
89212479|NCT05135663|Experimental|NS-089/NCNP-02 80 mg/kg|
89212480|NCT05684237|Other|HiSMILE treatment option|HiSMILE treatment option
89212481|NCT02589587|Active Comparator|sleeve gastrectomy|Morbidly obese patients scheduled for sleeve gastrectomy will be examined by endoscopy before and 3 months after surgery. Biopsies will be taken from stomach and duodenum.
89212482|NCT02589587|Other|no intervention|Lean, healthy controls will undergo endoscopy and biopsies will be taken from stomach and duodenum.
89642784|NCT02913729|Experimental|radiotherapy in arm 1|pre-operative accelerated partial breast irradiation
89642785|NCT02913729|Active Comparator|radiotherapy in arm 2|post-operative accelerated partial breast irradiation
89642786|NCT02871687|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
89642787|NCT02871687|Active Comparator|Simvastatin|Subjects in the simvastatin arm will receive simvastatin 20 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of simvastatin is increased to 40 mg daily for the following 6 weeks.
89642788|NCT02871687|Active Comparator|Pravastatin|Subjects in the pravastatin arm will receive pravastatin 40 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of pravastatin is increased to 80 mg daily for the following 6 weeks.
89642789|NCT00525057|Experimental|Treatment (dalteparin)|Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
89642790|NCT00525135|Other|1|If a patient exhibits increased radioiodine uptake on the Thyrogen scan post valproic acid therapy, patients will then prepare for ablative treatment and will remain on valproic acid for a total of 16 weeks, until receiving RAI ablation.
89642791|NCT00525135|Other|2|If no increased uptake is seen, patients will continue on valproic acid for 6 additional weeks at an increased dosage, totaling an overall treatment time of 16 weeks as well.
89642792|NCT00525525|Experimental|Efficacy Group|Patients treated with the combination of radiation plus temozolomide (75 mg/m2 daily during radiotherapy) plus bevacizumab (10 mg/kg IV every two weeks during radiotherapy) plus tarceva (dose based upon use of EIAED, either 200 mg daily or 500 mg daily; given daily); all treatment begins at the start of radiotherapy and continues until tumor progression, death or excessive toxicity
89642793|NCT00525525|Other|Safety Lead-in Group|"Fractionated radiotherapy in daily doses of 1.8-2.0 Gy delivered 5 days per week over ~6 weeks, to a total dose of 59.4 to 60 Gy.~Adjuvant temozolomide 200 mg/m^2/d x 5 d per 28-d cycle; Erlotinib 150-200 mg/d (or 500-600 mg/d for patients on enzyme-inducing antiepileptic drugs) on a continuous basis 7 days per week; Bevacizumab 10 mg/kg every 2 weeks"
89642794|NCT00525603|Experimental|CFAR|CFAR = Cyclophosphamide 200 mg/m^2/day 3-5 intravenous (IV) 5-30 minutes, Fludarabine 20 mg/m^2/day 3-5 IV 5-30 minutes, Alemtuzumab 30 mg 1, 3,5 IV 2-4 hours, and Rituximab 375 mg/m^2/day 2 IV 4-6 hours
89642795|NCT00564447|Experimental|Azithromycin-30 minutes Post dose|
89642796|NCT00564447|Experimental|Azithromycin-2 hours post dose|
89642797|NCT00564447|Experimental|Azithromycin-12 hours post dose|
89642798|NCT00564447|Experimental|Azithromycin-24 hours post dose|
89642799|NCT00564447|Experimental|Moxifloxacin-30 minutes post dose|
89642800|NCT00564447|Experimental|Moxifloxacin-2 hours post dose|
89642801|NCT00564447|Experimental|Moxifloxacin-12 hours post dose|
89642802|NCT00564447|Experimental|Moxafloxacin-24 hours post dose|
89642803|NCT00564681|Active Comparator|botulinum toxin Type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
89642804|NCT00564681|Active Comparator|botulinum toxin Type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
89642805|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
89642806|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A Formulation 2|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A Formulation 2 for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
89642807|NCT00525837|Other|varenicline|open label varenicline
89212483|NCT05246813||Osteoporotic hip fracture patients|
89642808|NCT01798563||Tremor Dominant PD|Volunteers with predominantly tremor-related motor symptoms of PD
89212484|NCT05246813||Hip osteoarthritis patients|
89642809|NCT01798563||Postural Instability & Gait Difficulty PD|Volunteers with primarily walking & balance-related motor symptoms of PD.
89642810|NCT01798563||Healthy Controls|Healthy volunteers consisting of people of same age as PD volunteers, w/o a diagnosis of PD.
89642811|NCT00527475|Active Comparator|Group I|Group I will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year.
89642812|NCT00527475|Experimental|Group II|Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
89642813|NCT01798251|Experimental|XELOX-X|"XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.~X Maintenance: Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance."
89212485|NCT05238233|Experimental|Eye Dilation and Constriction|"Participants screened for hyperopia >+1 diopter using a phoropter, have their intraocular pressures measured using a tono pen, and have their iridocorneal angle measured with a gonio lens.~Proparacaine hydrochloride 0.5% eye drops will be used to numb the eyes before measuring intraocular pressures and prior to gonio lens.~The following day, the participant will receive one drop of tropicamide and one drop of 1% pilocarpine in the left eye.~If the left eye has no response to the 1% pilocarpine, or if the diameter of the pupil returned to baseline size, we will ask participants to come back to the clinic on another day to have the process repeated in the right eye."
89212486|NCT05685017||Metablic syndrome vs. non-metabolic syndrome|Obese adolescents were grouped on MetS vs. non-MetS based on The International Diabetic Federation criteria
89642814|NCT01798251|Active Comparator|XELOX|XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks, until progression/intolerance.
89642815|NCT00566943|Active Comparator|Control|"Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple lines including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine). intestine or mesentery.~Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without buttress at the GJ anastomosis. Linear buttress at the stomach/pouch staple line is required."
89642816|NCT00566943|Experimental|PSD Veritas|"Linear Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas used as a staple line buttress at the stomach/pouch.~In addition to buttress of the stomach/pouch, patients may have PSD Veritas linear buttress at any of the following staple lines: intestine, mesentery, or anastomosis junction (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine).~Circular Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas circular buttress used as a staple line buttress at the GJ anastomosis. Linear buttress at the stomach/pouch is required."
89642817|NCT01449461|Experimental|Brigatinib 30 mg QD/60 mg QD|Brigatinib 30 mg/60 mg, tablets, orally, once daily (QD) in each cycle of 28 days (Approximately up to 7.3 years).
89642818|NCT01449461|Experimental|Brigatinib 90 mg QD|Brigatinib 90 mg, tablets, orally, QD in each cycle of 28 days (Approximately up to 7.3 years).
89642819|NCT01449461|Experimental|Brigatinib 120 mg QD/60 mg BID|Brigatinib 120 mg, once daily or 60 mg, twice daily (BID), tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
89642820|NCT01449461|Experimental|Brigatinib 90 mg QD-180 mg QD|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days.
89642821|NCT01449461|Experimental|Brigatinib 180 mg QD/90 mg BID|Brigatinib 180 mg, once daily or 90 mg, BID, tablets, orally in each cycle of 28 days (Approximately up to 7.3 years).
89642822|NCT01449461|Experimental|Brigatinib 240 mg QD/120 mg BID/300 mg QD|Brigatinib 240 mg, QD or 120 mg, BID or 300 mg once daily, tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
89642823|NCT05363241|No Intervention|Conservative group (CG)|The patients will receive standard pharmacological treatment (oral analgesics, intra-articular injection with corticosteroids) and physiotherapy for 6 months, where the end of the study occurs. After this period, the patient is guaranteed to undergo the cooled radiofrequency procedure, with medical indication.
89642824|NCT05363241|Experimental|Radiofrequency cooled group with classical targets (CRF-CT)|The patients will undergo the CRF procedure using the classical therapeutic targets (medial superior genicular nerve, lateral superior genicular nerve, medial inferior genicular nerve). So that patients do not know in which group of the study they are included, the probe will be placed in the aforementioned genicular nerves and also in the recurrent fibular nerve and in the infra-patellar branch of the saphenous nerve, but will not receive radiofrequency in the recurrent fibular nerve nor in the infra-patellar branch of the saphenous nerve, receiving radiofrequency only in the genicular nerves. Oral analgesics will be prescribed for the patient to use if necessary.
89642825|NCT05363241|Experimental|Radiofrequency cooled group with revised targets (CRF-RT)|The patients will undergo the CRF procedure using the revised therapeutic targets (medial superior genicular nerve, lateral superior genicular nerve, medial inferior genicular nerve, recurrent fibular nerve and in the infra-patellar branch of the saphenous nerve). So that patients do not know in which group of the study they are included, the probe will be placed in all the aforementioned nerves and will receive radiofrequency in all of them. Oral analgesics will be prescribed for the patient to use if necessary.
89642826|NCT02121483|Experimental|empagliflozin high dose|Patient to receive a high dose of empagliflozin
89642827|NCT02121483|Experimental|empagliflozin medium dose|Patient to receive a medium dose of empagliflozin
89642828|NCT02121483|Experimental|empagliflozin low dose|Patient to receive a low dose of empagliflozin
89642829|NCT01572038|Experimental|Pertuzumab + Trastuzumab + Taxane|Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.
89642830|NCT01448213|Active Comparator|Fluorometholone 0.1% Solution|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
89642831|NCT01448213|Active Comparator|Prednisolone acetate 1% Solution|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
89212487|NCT00918905|Experimental|1 Telemonitor|Within 24 hours after the patient was discharged the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with a doctor. The patient was planned to have the equipment for approximately one week and had at least one follow-up phone call within the four weeks period. Telemonitoring video conferences could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period of time (hot-line).
89642832|NCT02122341|Experimental|BackStop|Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
89212488|NCT00918905|No Intervention|Control group|No tele-monitor at home. The COPD patients discharged after an acute exacerbation living outside Svendborg or Faaborg-Midtfyn municipalities in the recruiting area were included in the control group and assigned to conventional care.
89642833|NCT02122341|No Intervention|Control|Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
89642834|NCT01448057|Experimental|Combination Product|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
89642835|NCT01448057|Active Comparator|Paracetamol tablets|Paracetamol (500 mg) tablets
89642836|NCT05246631|Active Comparator|Dexamethasone|5 mg intravenous dexamethasone
89642837|NCT05246631|Active Comparator|Haloperidol|1 mg intravenous haloperidol
89642838|NCT05246553|Experimental|Modified cochlear implant recipients|"Patients suffering from severe to profound hearing loss and severe bilateral vestibulopathy implanted with a modified cochlear implant providing 1 to 3 extracochlear electrodes implanted in proximity to the ampullary branches of the vestibular nerve (vestibular electrodes).~All experiments will be carried out while the vestibular electrodes are inactive, and while electrical stimulation is delivered to one or several vestibular electrodes, with and without concurrent cochlear stimulation."
89642839|NCT05246553|Active Comparator|Cochlear Implant Patients (CI)|Unilateral or bilateral cochlear implant recipients with normal vestibular function documented within the clinical follow up of their cochlear implant, and without previous history of vestibular symptoms or complaints.
89642840|NCT05246553|Active Comparator|Bilateral vestibulopathy Patients (BV)|Patients with documented diagnosis of bilateral vestibulopathy, according to the guidelines of the Barany society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
89642841|NCT05246553|Active Comparator|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
89642842|NCT05246553|No Intervention|Healthy Subjects (HS)|Normal auditory functiona and without previous auditory or vestibular symptoms or complaints. Normal vestibular function documented with the video-head impulse test.
89642843|NCT01447433|Experimental|Calcium+D|Calcium supplements provide 600mg of calcium and 125IU vitamin D per day. A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
89642844|NCT01447433|Placebo Comparator|Control|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
89642845|NCT03624699|Experimental|Glaukos iStent inject®|Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.
89642846|NCT05363085||Mechanically ventilated neurosurgical patients|Observational study in mechanically ventilated neurosurgical patients
89642847|NCT05246475|Experimental|PET-MRI|Simultaneous 18F-EF5 PET and DW-MRI
89642848|NCT01446965|Experimental|Wearable defibrillator|subjects in the Device Group will receive a LifeVest® wearable cardioverter-defibrillator (manufacturer: ZOLL Medical Corporation) plus guideline-directed medical therapy for post-myocardial infarction patients
89642849|NCT01446965|No Intervention|Conventional treatment|subjects in the Control Group will only receive guideline-directed medical therapy for post-myocardial infarction patients
89642850|NCT03578211|Experimental|DAs group|Shared decision making using decision aids
89642851|NCT03578211|No Intervention|Control group|Standard oral explanation guided with booklets
88991766|NCT04106583||Single Arm|Single Arm - Patients with intracranial aneurysms treated with WAVE, as part of the Penumbra SMART COIL System
88991767|NCT04104841|Experimental|Behaviorally Enhancing Adolescents' Mood in Schools (BEAMS)|8-session modified behavioral activation program
89212489|NCT04083443||Patients with blood stream infections|Patients with a high probability of a blood stream infection and an indication for antimicrobial treatment. There will be an additional blood sampling for these patients, which is the only intervention in the study.
89642852|NCT01798875|Active Comparator|Metformin|oral metformin at a dose of 850mg twice daily
89642853|NCT01798875|Active Comparator|Oral contraceptive|oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)
89642854|NCT05362851|Experimental|YYC301-1, YYC301-2, YYC301-3 & Celecoxib placebo|"YYC301-1 is a capsule. It is composed of Celecoxib 200mg and Tramadol 37.5mg complex.~YYC301-2 is a capsule. It is composed of Celecoxib 200mg and Tramadol 75mg complex.~YYC301-3 is a capsule. It is composed of Celecoxib 200mg and Tramadol 150mg complex."
89642855|NCT05362851|Active Comparator|YYC301-1 placebo, YYC301-2 placebo, YYC301-3 placebo & Celecoxib|"Concomitant Drugs with Celecoxib 200mg and YYC301-1 placebo one capsule.~Concomitant Drugs with Celecoxib 200mg and YYC301-2 placebo one capsule.~Concomitant Drugs with Celecoxib 200mg and YYC301-3 placebo one capsule."
89642856|NCT04408235|Active Comparator|Low-Dose LMWH|Enoxaparin 4000 IU daily
89642857|NCT04408235|Experimental|High-Dose LMWH|Enoxaparin 70 IU/kg twice daily
89642858|NCT05362617|Experimental|FOLFIRI|"Irinotecan 180 mg/m2 I.V 30-90 min，D1；~LV 400 mg/m2 I.V.，D1；~5-FU 400 mg/m2 IVP，d1,1200 mg/m2/d×2 days（Total:2400 mg/m2，Continuous intravenous infusion,46~48 hours,）~Repeat Every 14 days"
89642859|NCT05362617|Active Comparator|mFOLFOX6|"Oxaplatin 85 mg/m2 I.V 120 min，D1；~LV 400 mg/m2 I.V.，D1；~5-FU 400 mg/m2 IVP，d1,1200 mg/m2/d×2 days（Total:2400 mg/m2，Continuous intravenous infusion,46~48 hours,）~Repeat Every 14 days"
89642860|NCT01446809|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
89642861|NCT01446809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
89043257|NCT04643483|Active Comparator|Adalimumab reference arm|"Participants randomized to adalimumab who weigh ≥17 kg to <40 kg will receive a loading dose of 80 mg at Week 0 and 40 mg at Week 2, followed by a maintenance dose of 20 mg sc Q2W.~Participants randomized to Adalimumab who weigh ≥40 kg will receive a loading dose of 160 mg at Week 0 and 80 mg at Week 2, 40 mg and placebo at week 4 followed by a maintenance dose of 40 mg sc and placebo Q2W."
89043258|NCT02905071|Experimental|Study 1 Group 1 G1 (n =50)|filling of Serenat at baseline (T1)
89043259|NCT02905071|Experimental|Study 1 Group 2 G2 (n=50)|Serenat at baseline T1 and 3 others questionnaires
89043260|NCT02905071|Experimental|Study 1 Group 3 G3 (n =50)|filling of Serenat at baseline T1 and T2 (one week after baseline).
89043261|NCT02905071|Experimental|Study 2 Ancillary study (n=50)|filling of Serenat, HADS, STAY-Y and BDI at baseline T1
89043262|NCT00559052|No Intervention|1|Baseline measurement. No drug with the liquid meal during perfusion procedure to establish baseline secretion.
89043263|NCT00559052|Experimental|2|The Viokase 16 is to be taken as 3 tablets with the liquid meal during perfusion procedure.
89642862|NCT05362539|Experimental|Hematuria patients|Voided urine was collected from consecutive patients presented with hematuria at our institute for urine cytology and DNA hypermethylation assay of the assigned genes using methylation-specific Polymerase Chain Reaction (PCR). Further assessment by office cystoscopy and imaging with subsequent inpatient cystoscopic biopsy for positive findings, was done. The diagnostic characteristics of DNA hypermethylation and urine cytology were assessed based on its capability to predict UBC noninvasively
89043264|NCT02899104||Radium-223 dichloride|Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.
89043265|NCT04643132|Placebo Comparator|Normal saline in patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
89043266|NCT04643132|Active Comparator|S-ketamine at low dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
89043267|NCT04643132|Active Comparator|S-ketamine at high dose in patients|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
89043268|NCT02904993|Other|L2 paravertebral block|regional anesthetic nerve blocks using an L2 paravertebral block with ropivacaine
89043269|NCT02904993|Active Comparator|periarticular injection group|periarticular local injection into the periarticular soft tissues at the time of hip replacement using a combination of ropivacaine, epinephrine, ketorolac and morphine sulphate (periarticular injection group).
89043270|NCT04643171|Experimental|Exercised group|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
89043271|NCT04643171|Active Comparator|group of electroacupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6, 5 times per week, for 12 week
89642863|NCT05246319||Patients with small intestine neuroendocrine tumors|Evaluation of preoperative abdominal imaging in patients who underwent an a resection for neuroendocrine tumors
89642864|NCT01446419|Experimental|Intracept Treatment|
89642865|NCT01446419|Sham Comparator|Sham Treatment|
89642866|NCT03353961|Experimental|Adjunctive Internet-delivered ERITA|Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community. The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
89642867|NCT03353961|Active Comparator|Treatment as usual|Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
89642868|NCT01736631|Experimental|Cognitive behavioural therapy|Cognitive behavioural therapy for social phobia in people with bipolar disorder
89642869|NCT04387929||IgG negative|No intervantion. Only antibody mesurment from blood sample
89642870|NCT04387929||IgG positive, viral load negative|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
89642871|NCT04387929||IgG positive, viral load positive|No intervantion. Only antibody mesurment from blood sample and viral load from nasopharyngeal swabs
89642872|NCT05361681|Experimental|interventional arm|Participants were charging full electric cars, using high power charging systems
89642873|NCT05361291|Active Comparator|Inferior Alveolar nerve block with 2% lidocaine with 1:80 000 epinephrine|An Inferior Alveolar nerve block was given with 2% lidocaine with 1:80 000 epinephrine
89642874|NCT05361291|Experimental|Inferior Alveolar nerve block with 2% lidocaine with 1:80 000 epinephrine with 2mg dexamethasone|An Inferior Alveolar nerve block was given with 2% lidocaine with 1:80 000 epinephrine mixed with 2mg dexamethasone
89642875|NCT05361291|Experimental|Inferior Alveolar nerve block with plain 2% lidocaine mixed with 2mg dexamethasone|An Inferior Alveolar nerve block was given with plain 2% lidocaine mixed with 2mg dexamethasone
89642876|NCT01445951|Experimental|Technosphere® Insulin with MedTone C Inhaler|Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry
89642877|NCT01445951|Active Comparator|Aspart Group|Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry
89642878|NCT01445951|Experimental|Technosphere ® Insulin-Gen2 Group|Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry
89642879|NCT05355285|Experimental|Baseline Euglycemia|"Subjects with T1DM (Groups 1 and 2): 1) receive a low dose insulin infusion to reduce their plasma glucose to euglycemia; 2) receive a continuous infusion of insulin at the rate of 0.25 milli-Units/kg/min to maintain euglycemia during a Baseline MRI scanning period.~Subjects without diabetes (Groups 3 and 4) are scanned during a Baseline MRI scanning period (no intervention is needed to maintain euglycemia in these subjects)."
89642880|NCT05355285|Experimental|Hyperglycemic Clamp|"Subjects with T1DM (Groups 1 and 2): 1) receive a primed variable glucose infusion to attain a target increase in glycemic level of +5.5 mmol/L; 2) receive a continuous infusion of insulin at the rate of 0.25 milli-Units/kg/min.~Subjects without diabetes (Groups 3 and 4): 1) receive a primed variable glucose infusion to attain a target increase in glycemic level of +5.5 mmol/L."
89642881|NCT05355285|Experimental|Hyperinsulinemic Euglycemic Clamp|Subjects without diabetes or depression (Group 3) have a second study visit at least 15 days after the Hyperglycemic Clamp visit. They receive a variable insulin infusion to match individual insulin levels to the levels attained during the Hyperglycemic Clamp and they receive a variable glucose infusion to maintain euglycemia.
89642882|NCT05245929|Active Comparator|Skeletally anchored Distal Jet appliance|
89642883|NCT05245929|Active Comparator|Skeletally anchored Hyrax screw distalizer|
89642884|NCT05354973||CAR T Cell Treatment|
89642885|NCT03187743|Experimental|Pharmacokinetics/dynamics|Blood samples at 3 visits
89642886|NCT05353725||COVID-19 ARDS|Patients with COVID-19 ARDS on veno-venous ECMO (vvECMO)
89642887|NCT05353725||Influenza ARDS|Patients with Influenza ARDS on vvECMO
89642888|NCT05353725||ARDS of Other Ethiologies|Patients with ARDS of Other Ethiologies on vvECMO
89642889|NCT03169101||HIV+|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment
89642890|NCT03169101||HIV-|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test
89642891|NCT03130023|Experimental|Test group|All subjects will be enrolled in the test group and will receive Pulse Oximeter with ORI.
89642892|NCT05344287||Typical American Diet|African American individuals who self-report adhering to a typical American diet prior to enrolling in the study.
89642893|NCT05344287||Plant-Based Diet|African American individuals who self-report adhering to a plant-based diet prior to enrolling in the study.
89642894|NCT00513435|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
89642895|NCT03064737|Other|This study is a non-drug one arm study|Skin biopsy for genetic analyze
89642896|NCT05263791|Experimental|Airmod|The experimental device are installed in the same patient as the reference device to compare the non-inferiority of the respiratory rate measurement.
89642897|NCT05214339|Experimental|TRIPLET|"Combination Product: Hepatic Arterial Infusion combined with Bevacizumab and Sintilimab Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Bevacizumab and Sintilimab for injection.~Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times. 2. Intravenous infusion of Bevacizumab 7.5mg/kg every 3 weeks on the 4th day. 3. On the 25nd day of treatment, namely the second session of HAIC, intravenous infusion of Sintilimab 200mg every 3 weeks. 4. The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
89212490|NCT04083677||Control GROUP|healthy adult fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
89642898|NCT03830463|Experimental|CTP-692|
89642899|NCT03830463|Placebo Comparator|Placebo|
89642900|NCT02730507|Experimental|PSR|Bras A : 167 patients in the experimental PSR group. Surgery with patient-specific rod, which are designed according to the preoperative surgical planning of the surgeon in collaboration with the manufacturer.
89642901|NCT02730507|Active Comparator|Conventional rod|Bras B: 167 patients in the experimental conventional rod group
89642902|NCT01444781|Experimental|Study Group 1|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of DTaP-IPV-Hep B-PRP~T vaccine + one dose of Prevenar™
89642903|NCT01444781|Active Comparator|Study Group 2|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™
89642904|NCT01444781|Experimental|Study Group 3|Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP~T + one dose of Prevenar™.
89642905|NCT05152641|Experimental|BGE-117 4mg|BGE-117 4mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
89642906|NCT05152641|Experimental|BGE-117 8mg|BGE-117 8mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
89642907|NCT05152641|Experimental|BGE-117 16mg|BGE-117 16mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
89642908|NCT05152641|Placebo Comparator|Placebo|Matching Placebo Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
89642909|NCT01444391|Experimental|Tympanostomy Tube Placement|
89642910|NCT02431845|Experimental|SSRIs treatment as usual OCD gruop|SSRIs treatment as usual fluoxetine 40~80 mg dose equivalent (fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine)
89642911|NCT01443923|Active Comparator|1-HCV|Hepatitis C Mono-infected
89642912|NCT01443923|Active Comparator|2 HCV/HIV|Hepatitis C and HIV co-Infected
89212491|NCT04083677||trauma GROUP|trauma patients fasting 8 hours before the operation sonographic examination of gastric antrum before anesthesia
89642913|NCT02196051|Experimental|Exercise Training|Participants will engage in a single bout of elliptical exercise for 45 minutes (3X15 spaced by 5 minutes rest) at baseline. Subjects will be studied before and after this one bout to measure hepatic de novo lipogenesis. Participants will then take part in six weeks of exercise training on an elliptical trainer 3 times per week each time for 45 minutes. Hepatic de novo lipogenesis will be compared pre and post to examine wether improving muscle glucose uptake will decrease hepatic de novo lipogenesis as the glucose is taken up by muscle and not directed to the liver.
89642914|NCT02121639|Experimental|AZD5363|AZD5363
89642915|NCT02121639|Placebo Comparator|Placebo|Placebo
89642916|NCT04847427|Experimental|Core exercises training|Participants will perform 4 core exercises
89642917|NCT04847427|Experimental|Structural exercises training|Participants will perform 4 structural (Olympic lifting) exercises
89642918|NCT04847427|Experimental|Accentuated eccentric exercises training|Participants will perform 4 exercises with eccentric loading
89212492|NCT00919373|Active Comparator|ICD-Implantation|Implantation of an Implantable Cardioverter Defibrillator (ICD) alone.
89212493|NCT00919373|Active Comparator|ICD + Ablation|Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation
89212494|NCT05314439|Experimental|ION904|Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection.
89212495|NCT05314439|Placebo Comparator|Placebo|Up to 4 monthly doses of placebo will be administered by SC injection.
89642919|NCT04847427|Experimental|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
89642920|NCT01585545||patients with NSCLC|
89642921|NCT01542177||Pancreatic cancer|
89642922|NCT04460703|Sham Comparator|Control|Control message about birdfeeding
89642923|NCT04460703|Active Comparator|Baseline message|These participants will be assigned a message about the benefits of vaccination. All other treatment arms include this baseline language.
89642924|NCT04460703|Experimental|Personal freedom|Experimental message arm.
89642925|NCT04460703|Experimental|Economic freedom|Experimental message arm.
89642926|NCT04460703|Experimental|Social benefit, self-interest|Experimental message arm.
89642927|NCT04460703|Experimental|Social benefit, community interest|Experimental message arm.
89642928|NCT04460703|Experimental|Economic benefit|Experimental message arm.
89642929|NCT04460703|Experimental|Social pressure- guilt|Experimental message arm.
89642930|NCT04460703|Experimental|Social pressure- embarrassment|Experimental message arm.
89642931|NCT04460703|Experimental|Social pressure- anger|Experimental message arm.
89642932|NCT04460703|Experimental|Trust in science|Experimental message arm.
89642933|NCT04460703|Experimental|Not bravery arm|Experimental message arm.
89642934|NCT01551212|Experimental|EVR/TAC|Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: < 5 ng/mL)
89642935|NCT01551212|Active Comparator|TAC|Tacrolimus (C0-h: 6-10 ng/ml)
89642936|NCT04381611||Primary Glaucoma|
89642937|NCT04381611||Glaucoma Surgery|
89642938|NCT04381611||Glaucoma Laser|
89212496|NCT00617708|Experimental|Arm I (erlotinib, gemcitabine, cixutumumab)|Patients receive erlotinib hydrochloride PO once daily on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89212497|NCT00617708|Active Comparator|Arm II (erlotinib, gemcitabine)|Patients receive erlotinib hydrochloride and gemcitabine hydrochloride as in arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89212498|NCT04083209|Experimental|Counseling group|"Patients randomized into the counseling group will be given a 1-2 minute presentation over the risks of opioid pain medications during their preoperative visit."
89642939|NCT04381611||Glaucoma Surgery Combined|
89642940|NCT04381611||Glaucoma treatment|
89642941|NCT04381611||Glaucoma imaging|
89212499|NCT04083209|No Intervention|Control group|The control group will undergo the standard preoperative evaluation by the senior author without any additional formal opioid counseling.
89212500|NCT02589119|Other|MSC-AFP|Single Treatment Group
89212501|NCT00864968|Experimental|A|Nabumetone 750 mg tablets, single dose
89212502|NCT00864968|Active Comparator|B|Nabumetone 750 mg tablets, single dose
89212503|NCT05227586||LA + RA ablation|Patients with persistent atrial fibrillation and right atrial enlargement received adjunctive right atrial ablation when left atrial ablation did not terminate atrial fibrillation.
89642942|NCT04381611||Glaucoma co-morbidity|
89642943|NCT04381611||Glaucoma untreated|
89642944|NCT04381611||Glaucoma Suspect|
89642945|NCT04381611||Secondary Glaucoma|
89642946|NCT00573261|Experimental|Pregabalin|Pregabalin medication
89642947|NCT00573261|Placebo Comparator|Placebo|Placebo
89642948|NCT04514211||Propofol|General anesthesia using propofol infusion
89642949|NCT04514211||Sevoflurane|General anesthesia using sevoflurane
89642950|NCT00574197|Other|Enteric-coated Mycophenolate Sodium (Myfortic)|1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months
89642951|NCT01798953||UC/PSC with IPAA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileal pouch-anal anastomosis
89642952|NCT01798953||UC with IPAA|Patients with ulcerative colitis reconstructed with ileal pouch-anal anastomosis.
89642953|NCT01798953||UC/PSC with IRA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileorectal anastomosis.
89642954|NCT01798953||UC with IRA|Patients with ulcerative colitis reconstructed with ileorectal anastomosis.
89642955|NCT00574587|Experimental|Vorinostat Plus Paclitaxel|Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks (and trastuzumab if HER2-positive), followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery
89642956|NCT04120220|Experimental|Heavy Cream|Participants will receive a meal containing 30 g of fat prepared with heavy cream.
89642957|NCT04120220|Experimental|Soybean Oil|Participants will receive a meal containing 30 g of fat prepared with soybean oil.
89642958|NCT00603993|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT 00235872]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan
89642959|NCT00575367|Active Comparator|AzaSite|
89642960|NCT00575367|Active Comparator|Vigamox|
89642961|NCT00604461|Experimental|Dose Escalation Followed by Maintenance Therapy|"A: Tiered Dose Escalation/Phase II Dose -~Tier -1: Carboplatin AUC 4 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 1: Carboplatin AUC 5 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 2: Carboplatin AUC 6 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~B: Maintenance Therapy -~Patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first."
89642962|NCT04417569||stimulated cycles|Patients will have blood drawn on five separate occasions: before and following hCG trigger on the day of final oocyte maturation and day of egg collection
89642963|NCT00576147|Experimental|CT scan|The standard head CT done to head trauma patients
89642964|NCT01550744|Experimental|Group 1: Approved q12w maintenance regimen|Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
89642965|NCT01550744|Experimental|Group 2: Subject-tailored fixed-interval maintenance regimen|Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.
89642966|NCT00577083|Experimental|Initial cap-fitted|Initial cap-fitted colonoscopy for the first insertion
89642967|NCT00577083|Active Comparator|Initial regular|Initial regular no cap on the end of the colonoscope for the first insertion
89642968|NCT00606489|Placebo Comparator|1|
89642969|NCT00606489|Experimental|2|
89642970|NCT00578331|Experimental|Olopatadine 0.6% Nasal Spray|2 sprays each nostril twice daily
89642971|NCT00578331|Placebo Comparator|Placebo Nasal Spray|2 sprays each nostril twice daily
89642972|NCT00607113|Experimental|Avastin|Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV)
89642973|NCT00607113|Experimental|Avastin + RAD001|Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks
89642974|NCT00607113|Experimental|RAD001|Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days
89642975|NCT00607269|No Intervention|Control|Control condition receiving minimal incentives for service program attendance and participation.
89043272|NCT02899143|Experimental|Group 5-days|5-days targeted antibiotic therapy
89642976|NCT00607269|Experimental|Contingency Management|Contingency management (Voucher-Based Reinforcement Therapy) intervention providing positive reinforcement for service program participation and attendance, enactment of prosocial/health behavior, and/or clean urine samples (i.e., no illicit drug use) and clean breathalyzer tests (i.e., BA < 0.05).
89642977|NCT01549964|Experimental|Fasiglifam (TAK-875) 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
89642978|NCT01549964|Experimental|Fasiglifam (TAK-875) 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
89642979|NCT01549964|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. TAK-875 placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
89642980|NCT01549964|Placebo Comparator|Placebo|Fasiglifam (TAK-875) placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
89642981|NCT00607815|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy
89642982|NCT00607815|Active Comparator|Present Centered Therapy|Present Centered Therapy
89642983|NCT00579111|Experimental|HLA-identical sibling transplant|Recipients of HLA identical sibling stem cell transplants
89642984|NCT00579111|Experimental|Unrelated Matched or Single Antigen Mismatched transplant|Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
89642985|NCT04363437|Active Comparator|Colchine|
89642986|NCT04363437|Active Comparator|Usual Care|
88991768|NCT04104841|Active Comparator|Usual Care|Referrals to usual care
88991769|NCT04099836|Experimental|atezolizumab and bevacizumab|Atezolizumab 1200 mg IV every 3 weeks and bevacizumab 15 mg/kg IV every 3 weeks (1 cycle=3 weeks)
88991770|NCT04094012|Active Comparator|3-months weekly RPT plus INH (3HP)|weekly RPT (900 mg for participants with body weight >50.0 kg; 750 mg for 32.1-50.0 kg; 600 mg for 25.1-32.0 kg; and 450 mg for 14.1-25.0 kg) plus INH (dose: 15 mg/kg, rounded up to nearest 150 mg; maximum 900 mg) for a total of 12 doses.
88991771|NCT04094012|Experimental|1-month daily RPT plus INH (1HP)|daily RPT (dose: 600 mg for participants with body weight ≥45.0 kg; 450 mg for <45.0 kg) plus INH (dose: 300 mg) for a total of 28 days.
88991772|NCT04084938|Active Comparator|Prostate operation|You will have a surgery to remove the prostate gland. The surgery will be done during general anesthesia. If your prostate gland is small the surgery will be done through a catheter into the penis. If your prostate gland is large the surgery will be through an incision in your lower abdomen.
89043273|NCT02899143|Other|Group 10-days|10-days targeted antibiotic therapy
89043274|NCT04643288|Experimental|OFD control group|open flap debridement for periodontal intrabony defects
89642987|NCT02138097||Glitazones|
89642988|NCT02138097||Linagliptin|
89642989|NCT02138097||Meglitinides|
89642990|NCT02138097||Metformin|
89642991|NCT02138097||Non-insulin injectables|
89642992|NCT02138097||Saxagliptin|
89642993|NCT02138097||Sitagliptin|
89642994|NCT02138097||Sulfonylurea|
89642995|NCT01570244|Experimental|Reference|multiple doses of Microgynon
89642996|NCT01570244|Active Comparator|Test|multiple doses of Microgynon + BI 201335
89642997|NCT00579813|No Intervention|1|Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects. Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model. These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition. There is no intervention.
89642998|NCT00579813|Active Comparator|2|Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. All of the studies described in arm 1 are repeated after treatment. The subjects in this group have impaired glucose tolerance. After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks. After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.
89642999|NCT00580671|Experimental|MET/CBT+CM/BPT|Integrated psychosocial counseling. 14 weekly session. Twice weekly urine testing. Abstinence-based incentives based on urine test results. 14 weekly behavioral parenting sessions.
89643000|NCT00580671|Experimental|MET/CBT+CM|Integrated psychosocial counseling. 14 weekly sessions. Twice weekly urine testing. Abstinence-based incentives based on urine test results.
89643001|NCT00580671|Active Comparator|MET/CBT|Integrated psychosocial counseling. 14 weekly sessions.
89643002|NCT01535222|Experimental|Cohort 1|3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
89643003|NCT01535222|Experimental|Cohort 2|3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
89643004|NCT01535222|Experimental|Cohort 3|6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
89643005|NCT01535222|Experimental|Cohort 4|6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
89643006|NCT01535222|Experimental|Cohort 5|6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
89643007|NCT01535222|Placebo Comparator|Placebo|8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
89643008|NCT01549886|Experimental|MGD + Rituximab + Y-90-Zevalin|"Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie / kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL."
89643009|NCT01549886|Active Comparator|Rituximab + Y-90-Zevalin|Day 1 Rituximab 250 mg/m^2 intravenous infusion. Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
89643010|NCT00610311|Experimental|ALVAC plus anti-gp100:154-162 TCR PBL + HD IL-2|"ALVAC plus anti-gp100:154-162 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin-2 (IL-2): ALVAC vaccine two hours prior to cell infusion patients will receive 0.5 ml containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6.4 to 107.9/mL of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL. This will be repeated on day 14.~Aldesleukin (IL2, Proleukin, Recombinant human interleukin 2)- 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)"
89643011|NCT04767230|Active Comparator|A heart-healthy diet + Flaxseed + Olive oil|A heart-healthy diet with a specified number of food servings from different food groups (including vegetables, fruits, grains, dairy products, meats) + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil (equivalent to 4 tablespoons; 2 tablespoons for lunch and 2 tablespoons for dinner) for 3 months
89643012|NCT04767230|Placebo Comparator|A heart-healthy diet|Recommendations for a heart-healthy diet, such as those of the American Heart Association for 3 months. These include eating at least 5 servings of vegetables and fruits daily, reduction in the consumption of sources of saturated and trans fats by avoiding the consumption of high-fat red meats and replacing them with low-fat meat or with poultry and fish, replacing low-fat dairy sources with regular or high-fat ones; consumption of regular vegetable oils such as canola and sunflower; reduction in salt consumption; and reduction in the consumption of simple sugars for 3 months
89643013|NCT00610701|Experimental|Anterior pin placement|Anterior pin placement
89643014|NCT00610701|Experimental|Lateral pin placement|Lateral pin placement
89643015|NCT04107506|Experimental|Filming Interactions to Nurture Development (FIND)|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly sessions lasting 30-45 minutes. The process begins with an initial session in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
89643016|NCT04107506|Active Comparator|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 sessions each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
89643017|NCT00581061|Experimental|Vesicare Treatment|
89643018|NCT04107272|Experimental|Experimental group|Real rTMS
89643019|NCT04107272|Sham Comparator|Control group|Sham rTMS
89643020|NCT01443845|Experimental|1|Roflumilast
89643021|NCT01443845|Placebo Comparator|2|Placebo
88991773|NCT04084938|Active Comparator|Prostate artery embolization|The embolization is done in the Department of Radiology. There will be placement of a catheter into the artery in one of the groins during local anesthesia. Through this catheter small particles will be injected into the arteries of the prostate gland. When finished, the hole in the artery will be closed.
88991774|NCT04082364|Experimental|Chemotherapy-free arm|margetuximab plus retifanlimab
89643022|NCT04754204||Patients indicated for Mobile Cardiac Telemetry Monitoring|Patients indicated for Mobile Cardiac Telemetry Monitoring while meeting inclusion/exclusion criteria and enrolled in sequential manner.
89643023|NCT01549652|Experimental|Prevention of Opioid Withdrawal|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days, and then will be randomized to take either ondansetron 8 mg or matching placebo thirty minutes prior to naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will return to their titrated morphine dose for one week and then return for the opposite pre-treatment followed by naloxone-induced withdrawal in clinic. Participants will then taper back to their original dose of morphine for one week.
89643024|NCT01549652|Experimental|Prevention of Physical Dependence|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days; during morphine treatment, participants will be randomized to take either ondansetron 8 mg or matching placebo three times daily along with the oral morphine treatment. After thirty days, participants will return to the lab to undergo naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will then taper back to their original dose of morphine for one week.
89643025|NCT04118504|Experimental|Intervention group|Lifestyle intervention on through mobile application
89643026|NCT04118504|No Intervention|Control group|Usual care
89643027|NCT01569464|Active Comparator|Rotigotine|Rotigotine patches titrated from 1 mg/ 24 hr - 3 mg /24 hr or until effective or maximum dose is reached.
89643028|NCT01569464|Placebo Comparator|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours~7 weeks"
89643029|NCT01534676|Active Comparator|Transfusion of Fresh blood|The recipient will receive one or two units of fresh blood <14 days old, as per their chronic transfusion schedule - on or off chelation therapy.
89643030|NCT01534676|Experimental|Transfusion of Stored blood|The recipient will receive one or two units of old blood >28 days old, as per their chronic transfusion schedule - on or off chelation therapy.
89643031|NCT01534676|Active Comparator|Transfusion of Cryopreserved Blood|The recipient will receive one or two units of cryopreserved (fresh/old) blood, as per their chronic transfusion schedule - off chelation therapy.
89643032|NCT01534676|Active Comparator|Transfusion of Washed Blood|The recipient will receive one or two units of washed (fresh/old) stored blood >28 days old, as per their chronic transfusion schedule - off chelation therapy.
89643033|NCT01442675|Experimental|Meningococcal vaccine Group|Participants must have received Menactra vaccine 4 to 6 years prior to enrollment
89643034|NCT01534520|Experimental|Group 1: Intravaginal 2% lidocaine gel|Intravaginal insertion of 4mL of 2% lidocaine gel
89643035|NCT01534520|Placebo Comparator|Group 2: Intravaginal placebo gel|Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
89643036|NCT00611325|Experimental|EIAED|Patients taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 2.5 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
89643037|NCT00611325|Experimental|Non-EIAED|Patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 1.7 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
89043275|NCT04643288|Experimental|n-HA bone graft intervention group|Nanocrystalline Hydroxyapatite (n-HA) bone graft substitute was added to periodontal intrabony defects
89043276|NCT02899026|Experimental|Part A: Sirukumab 100 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a 6-week oral prednisone taper regimen
89643038|NCT01798719|Placebo Comparator|Diet: Dietary Advice|Some general dietary advice about healthy dietary components, servings size and frequency of servings
89643039|NCT01798719|Experimental|Low glycemic index Mediterranean Diet|Low glycemic index Mediterranean Diet prescription with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
89643040|NCT00611403|Active Comparator|RESTASIS®|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
89643041|NCT00611403|Active Comparator|REFRESH ENDURA®|Artificial Tears (REFRESH ENDURA®)
89643042|NCT01534208|Experimental|Androxal 12.5 mg|Androxal 12.5 mg daily
89643043|NCT01534208|Experimental|Androxal 25 mg|Androxal 25 mg daily
89643044|NCT01548638|Experimental|Galantamine ER|The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.
89643045|NCT00581529|Experimental|Radiotherapy|IMRT (Intensity-modulated Radiation Therapy), 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
89643046|NCT00612339|Experimental|Avastin and Temozolomide|Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.
89643047|NCT02134119|Experimental|Echinacea-based dietary supplement|Echinacea-based dietary supplement 8,000mg/day or 16,000mg/day by mouth for 35-days
89643048|NCT02134119|Placebo Comparator|Sugar pill|Placebo given 8,000mg/day by mouth
89643049|NCT01533428|Experimental|Capsaicin 8%|Capsaicin 8% patch was applied for 30 minutes to the painful area(s) on Day 1
89643050|NCT01533428|Placebo Comparator|Placebo|Placebo patch was applied for 30 minutes to the painful area(s) on Day 1
89643051|NCT04066725|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 60 days
89043277|NCT02899026|Experimental|Part A: Sirukumab 50 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 50 mg SC q4w (with placebo SC injections q2w between sirukumab injections) for 52 weeks plus a 6-week oral prednisone taper regimen
89043278|NCT02899026|Placebo Comparator|Part A: Placebo SC + prednisone (52 week taper)|Eligible subjects will receive blinded placebo SC q2w for 52 weeks plus a blinded 52-week oral prednisone taper
89043279|NCT04643054|Experimental|Ovotransferrin|Dietary Supplement: Ovotransferrin
89043280|NCT04643054|No Intervention|Standard of care|Standard of care
89043281|NCT02904837|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
89043282|NCT02904837|Active Comparator|Control Group|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
89043283|NCT04643210|Experimental|F2F MoB EI and access to MoB Digital Platform (MoB DP) group|"The design of the face-to-face Management of my Bipolarity educational intervention (F2F MoB EI) will rely on the Colom & Vieta model, Cognitive- Behavioural techniques and the results of the relevant literature review and data acquired in the qualitative research of bipolar disease patients' educational needs. A textbook will be devised explaining in detail the step-by-step process and the techniques of the experimental educational method of the MoB F2F EI.~This group will also receive the technology-based intervetion, which regards access to the MoB DP. This is an ecosystem where the participants will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile."
89043284|NCT04643210|Active Comparator|The MoB DP group|This group will receive the technology-based intervention, which regards access to the MoB DP. The structure of the MoB DP has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
89043285|NCT02904798|Experimental|Polypodium Leucotomos Extract (PLE)|"Patient will serve as their own control and will be exposed to 4 doses of visible light on one side of their back prior to receiving PLE.~PLE 240mg will be dispensed to patient after evaluation of Pre-PLE visible light doses are evaluated to be taken by the patient for a total of 28 day followed by exposure of the opposite side of the back with the same 4 doses of visible light as above"
89043286|NCT04642703||COVID-19 ventilated patients subjected to tracheostomy|Patients who receive percutaneous or surgical tracheostomy due to prolonged mechanical ventilation. The indication is made by an experts team and based on national guidelines
89043287|NCT04642703||COVID-19 ventilated patients without tracheostomy|Patients supported with mechanical ventilation by 10 days or more in who an experts team of physicians decided do not perform a tracheostomy
89643052|NCT04066725|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 60 days.
89643053|NCT04066725|Placebo Comparator|Placebo|Participants will be given a placebo orally once daily for a total of 60 days.
89643054|NCT04047693|Experimental|ddMVAC|4 cycles of neoadjuvant chemotherapy using dose dense MVAC with G-CSF
89643055|NCT01517984|Experimental|Tacrolimus (CNI) Withdrawal|"Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal."
89043288|NCT02898831|No Intervention|Control/No Intervention|Standard clinical procedure with intrauterine device insertion involving no heated/cold compresses on the abdomen during insertion.
89043289|NCT02898831|Experimental|Cold Compress/Experimental|Cold compress (intervention) placed on abdomen just before IUD insertion and remains throughout insertion. Pain scale and survey completed following insertion regarding pre-procedure and intra-procedure pain.
89043290|NCT02904876|Experimental|Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
89643056|NCT01517984|Active Comparator|Standard Immunosuppressive Therapy|"Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur."
89643057|NCT00612573|Experimental|Doxycyline 0.6 mg/kg/day|Doxycycline dosed at 40 mg/day to subjects of appropriate weights
89643058|NCT00612573|Experimental|Doxycycline 1.2 mg/kg/day|Doxycycline dosed at 80 mg/day to subjects of appropriate weights
89643059|NCT00612573|Experimental|Doxycycline 2.4 mg/kg/day|Doxycycline dosed at 160 mg/day to subjects of appropriate weights
89643060|NCT00612573|Placebo Comparator|Placebo|
89643061|NCT01517750|Experimental|APAP with humidification|ICON Auto CPAP™ with Thermosmart heated tube
89643062|NCT01517750|Active Comparator|APAP without humidification|ICON Auto CPAP™ without Thermosmart heated tube
89643063|NCT00614445|Experimental|Diclectin®|Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet
89643064|NCT00614445|Placebo Comparator|Placebo|Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)
89643065|NCT01799187|Experimental|revascularization|revascularization is is an alternative new treatment of immature permanent teeth with necrotic pulp. The use of triple antibiotic paste is followed by Induction of bleeding from the apical root during this intervention.
89643066|NCT01799187|Active Comparator|apexification|apexification is a traditional therapy of immature permanent teeth with necrotic pulp.calcium hydroxide is served as medication to induce the developing of root .
89643067|NCT01548404|Placebo Comparator|Placebo|Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
89643068|NCT01548404|Experimental|Dupilumab 300 mg|Dupilumab 300 mg once weekly for 12 weeks by SC injection.
89643069|NCT01547780|Experimental|Baseline brain PET in acute TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to baseline brain positron emission tomography (PET) scan in Acute (< 5 months post-injury) traumatic brain injury (TBI) patients.
89643070|NCT01547780|Experimental|Repeat brain PET in acute TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to repeat brain positron emission tomography (PET) scan in Acute (< 5 months post-injury) traumatic brain injury (TBI) patients.
89643071|NCT01547780|Experimental|Single brain PET in Chronic TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to brain positron emission tomography (PET) scan in Chronic (5 months - 5 years post-injury) traumatic brain injury (TBI) patients.
89043291|NCT04642664|Experimental|Apatinib plus Camrelizumab|"Apatinib is a multi-target TKI, which selectively inhibits VEGFR-2.~Camrelizumabb is a anti-human PD-1 monoclonal antibody."
89043292|NCT04642742||Plant sterol chewable|
89043293|NCT02904759|Experimental|Desmopressin 25 µg|Desmopressin ODT
89043294|NCT02904759|Experimental|Desmopressin 50 µg|Desmopressin ODT
89043295|NCT02904759|Placebo Comparator|Placebo|Placebo ODT
89043296|NCT02898792|Experimental|targeted infusion of remifentanil untreated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
89043297|NCT02898792|Experimental|targeted infusion of remifentanil CPAP treated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
89043298|NCT02898792|Experimental|targeted infusion of remifentanil No OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
89043299|NCT02904642|No Intervention|Control|"All enrolled caregivers will receive a congratulatory text message at enrollment which indicates who is conducting the study and which also includes a general-health related saying, The greatest wealth is health. No additional text messages or travel subsidies will be sent to caregivers randomized to the control arm."
89043300|NCT02904642|Experimental|SMS reminder|At enrollment, participants will be told to expect 2 SMS reminders for measles vaccine; first, at 3 days before and second, on the day before the scheduled measles vaccine at 9 months of age. At most, enrolled caregivers will receive three text messages (two for the measles vaccine and one for welcoming mother to the study). Text messages will be sent in English, Kiswahili or Dholuo language, according to the mother's preference. These reminders will have information about the child's scheduled immunization date.
89043301|NCT02904642|Experimental|SMS reminder + Unconditional Incentive|Participants will receive SMS reminders as described in the SMS reminder arm. Additionally, participants will be sent a 150 Kenyan Shillings (KES) incentive to the mobile phone number they provided at enrollment. The incentive will be delivered three days before the child turns nine months (i.e. sent on the same day as the first SMS reminder). Caregivers will receive the mobile-money incentive unconditionally. The intent of the incentive is to help offset the costs associated with transportation to the clinic. The transaction costs associated with mobile-money transactions will be borne by the study such that mothers will receive the full 150 KES.
89043302|NCT04642313|Placebo Comparator|PLACEBO group|Placebo treatment: starch tablets (250 mg)
89643072|NCT01547780|Experimental|Single brain PET in healthy subjects|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to brain positron emission tomography (PET) scan in Healthy Subjects.
89643073|NCT00583011|Experimental|Local Anesthesia|Local anesthesia group. 2cc of 1% lidocaine with epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of 1% lidocaine to the depth of the peritoneum.
89643074|NCT00583011|Placebo Comparator|Placebo-Normal saline|Placebo normal saline group. 2cc of normal saline epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of normal saline to the depth of the peritoneum.
89643075|NCT01547390|Experimental|Aspirin|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
89643076|NCT01547390|Placebo Comparator|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
89643077|NCT01546922|Active Comparator|First low dose HC followed by high dose HC|First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
89643078|NCT01546922|Active Comparator|First high dose HC followed by low dose HC|First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight
89643079|NCT00615927|Experimental|Astrocytoma|Grade II Astrocytoma
89643080|NCT00615927|Experimental|Oligodendroglioma|Grade II Oligodendroglioma or oligoastrocytomas
89643081|NCT01532648|Experimental|Budesonide MMX|Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
89643082|NCT01532648|Placebo Comparator|Placebo|Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
89643083|NCT00617097|Active Comparator|paracervical block with lidocaine|Subjects who receive pain control using paracervical block with lidocaine during first trimester surgical abortion
89643084|NCT00617097|Experimental|paracervical block with ketorolac and lidocaine|Subjects who receive pain control using paracervical block with ketorolac and lidocaine during first trimester surgical abortion
89643085|NCT00617175|Experimental|Long NID|Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia
89643086|NCT00617175|Active Comparator|Short NID|Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia
89643087|NCT04022187||Bulbocavernosus reflex assessment|Patients over 18 years old, consulting in neuro-urology department for urinary, anorectal or genito-sexual disorders.
89643088|NCT01532570|Experimental|TA-650|
89643089|NCT00583713|Experimental|Renal Group|Patients with moderate renal impairment
89643090|NCT00583713|Active Comparator|Healthy volunteers|Healthy volunteers
89643091|NCT00583713|Experimental|Hepatic Group|Patients with mild/moderate hepatic impairment.
89643092|NCT01532414|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
89643093|NCT01532414|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
89643094|NCT01532414|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
89643095|NCT01441973|Experimental|Elotuzumab, 20 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1: Days 1 and 8. Cycle 2 and beyond: Day 1 only.
89643096|NCT01441973|Experimental|Elotuzumab, 10 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1 and 2: Days 1, 8, 15, and 22. Cycle 3 and beyond: Days 1 and 15.
89643097|NCT02074709|Active Comparator|TAP block|TAP block with plain bupivacaine
89643098|NCT02074709|Active Comparator|Wound infiltration|Wound infiltration with liposomal bupivacaine
89643099|NCT03571191|Experimental|1|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
89643100|NCT03475251|Experimental|CS1003|
89643101|NCT03475251|Experimental|CS1003 + regorafenib|
89643102|NCT01575899|Experimental|Levofloxacin-Amoxicillin/clavulanate|7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.
89643103|NCT01575899|Active Comparator|Clarithromycin-Amoxicillin|7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.
89643104|NCT01440881|Active Comparator|Nesiritide|infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours
89643105|NCT01440881|Placebo Comparator|Placebo|infuses at 0.01MCG/KG/min for 48 hours
89643106|NCT00620061|Experimental|All Participants|Lubiprostone: 24 mcg capsule twice daily (BID) for 36 weeks
89643107|NCT01575197|Active Comparator|Rotavirus Vaccine at age 6 & 10 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6 & 10 weeks of age.
89643108|NCT01575197|Experimental|Rotavirus vaccine at age 10 & 14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 10 & 14 weeks of age.
89643109|NCT01575197|Experimental|Rotavirus vaccine at age 6,10,&14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6, 10, & 14 weeks of age.
89643110|NCT00587769|Experimental|Bupropion SR & Varenicline|All 38 smokers will receive open-label bupropion SR and varenicline. Bupropion SR is an oral medication with recommended dosing of 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day. Varenicline is an oral medication with recommended dosing of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment. Subjects will quit on Day #8 after starting both medications.
89643111|NCT00621933||All Patients Receiving Cataract Surgery|All Patients Receiving Cataract Surgery
89043303|NCT04642313|Experimental|Magnesium group|Magnesium group: Magnesium gluconate (250 mg)
89043304|NCT04642313|Experimental|Potassium group|Potassium group: Potassium chloride (250 mg)
89043305|NCT04642313|Experimental|Magnesium + Potassium group|Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)
89043306|NCT04642157|Experimental|ELIOS group|In addition to receiving the same generic mental health resources as in the control group, the participants of the ELIOS arm will benefit from the intervention of the ELIOS team.
89043307|NCT04642157|Other|control group|Participants of the control arm will receive generic professional help contacts.
89043308|NCT02904525|Experimental|7T MRI + high resolution spectroscopy|Next to routine imaging, patients undergo an additional 7 tesla MRI for high resolution spectroscopy
89043309|NCT04642118|Experimental|Pulmonary recruitment maneuver 30 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 30 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
89043310|NCT04642118|Active Comparator|Pulmonary recruitment maneuver 40 cmH2O|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will be received positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist 5 times of setting pressure 40 cmH2O, 5 seconds per time to increase indirect abdominal pressure to release residual gas"
89043311|NCT04642118|No Intervention|Control|"After laparoscopic surgery has finished in operator room (before moving off trocar), patient will be set in Trenderlenberg position (Tilted head low) and then surgeon will compress abdomen to release residual gas after operation about 2 minutes.~The patients in this group will not be received any positive pressure from Pulmonary recruiment maneuver [balloon bag] from anesthesiologist."
89043312|NCT04641923|Experimental|Seprafilm|Antiadhesion barrier applied
89043313|NCT04641923|No Intervention|No seprafilm|No barrier applied
89043314|NCT02904564|Experimental|MMP with 5-FU infusion|MMP with 5-FU infusion using tattoo device
89043315|NCT02904564|Placebo Comparator|MMP with saline infusion|MMP with saline infusion using tattoo device
89043316|NCT04642040|Experimental|Pulmonary Rehabilitation|Patients are included in a personalized pulmonary telerehabilitation program consisting of patient education, respiratory and peripheral muscle training, and breathing strategies for 4 weeks. In the telerehabilitation program, exercises will be supervised by a physiotherapist two days a week, and patients will be asked to do the exercises themselves for the other 3 days. Patients will also receive instructional exercise videos for these 3 days.
89212504|NCT05227586||LA ablation only|Patients with persistent atrial fibrillation and right atrial enlargement received left atrial ablation only
89643112|NCT00623181|Experimental|Fluzone Intradermal First, Then Fluzone Intramuscular|
89643113|NCT00623181|Experimental|Fluzone Intramuscular First, Then Fluzone Intradermal|
89643114|NCT03433833|Experimental|Intervention|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.5-0.9 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
89643115|NCT03366051|Active Comparator|Sentinel Node Mapping plus Lymphadenectomy|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy
89643116|NCT03366051|Experimental|Sentinel Node Mapping|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm
89643117|NCT01574651|Experimental|QVA149 plus placebo to tiotropium and placebo to formoterol|QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
89643118|NCT01574651|Active Comparator|Tiotropium plus Formoterol and placebo to QVA149|Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
89643119|NCT05247411|Experimental|Educational intervention|a Skype-videoconference, which included a 30 min educational intervention, was held with each subject.
89643120|NCT03028649|Experimental|β-hydroxy-β-methylbutyrate (HMB)|"Group taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate.~Interventions:~The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
89643121|NCT03028649|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin.~Interventions:~The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
89643122|NCT03026231|Active Comparator|PRIM-DJ2727|Subjects with PD will be randomly assigned to receive PRIM-DJ2727 in orally administered enteric-coated capsules
89643123|NCT03026231|Placebo Comparator|Placebo|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
89643124|NCT02139969||GreenLight XPS Laser System|Treatment of BPH in men using the GreenLight XPS Laser System and the MoXy fiber
89643125|NCT03026309||depressed|un medicated diagnosed with major depression and scheduled to start SSRI treatment.
89643126|NCT03026309||healthy|healthy volunteers.
89643127|NCT01440803|Active Comparator|Teriparatide (Forteo)|Daily injection of Teriparatide for treatment of idiopathic osteoporosis
89643128|NCT01440803|Placebo Comparator|Placebo saline injection|Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.
89643129|NCT05247177|Experimental|Multimodal general anesthesia|General anesthesia maintained by co-administration of sevoflurane, dexmedetomidine and ketamine by using a predefined EEG density spectrum array pattern
89643130|NCT05247177|Active Comparator|Conventional general anesthesia|General anesthesia maintained by administration of sevoflurane alone to keep a bispectral index between 40-60
89643131|NCT01517282|Experimental|MOR103 0.5 mg/kg|6 doses of MOR103 0.5 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
89643132|NCT01517282|Experimental|MOR103 1.0 mg/kg|6 doses of MOR103 1.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
89643133|NCT01517282|Experimental|MOR103 2.0 mg/kg|6 doses of MOR103 2.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
89643134|NCT01517282|Placebo Comparator|Placebo|6 doses of placebo administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
89643135|NCT00624195|Experimental|CNS-targeted|"CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, under dosing).~Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
89043317|NCT02904486|Experimental|change behavior|Modified Health Belief Model Based Intervention and study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
89043318|NCT02904486|Experimental|lifestyle behavior|study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
89043319|NCT04642001|Other|Group G1|Photon Laser III-DMC (without radiation emission) + My First- Colgate
89043320|NCT04642001|Experimental|Group G2|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rápido Alívio/GSK
89043321|NCT04642001|Experimental|Group G3|Photon Laser III-DMC (with irradiation emission) + My First- Colgate
89043322|NCT04642001|Experimental|Group G4|Photon Laser III-DMC (with irradiation emission) + Sensodyne® Rápido Alívio/GSK
89043323|NCT02904408|Experimental|Experimental|experimental group (receiving psychotherapy and medical/surgical treatment)
89043324|NCT02904408|No Intervention|Control|control group (awaiting group) (receiving medical/surgical treatment)
89043325|NCT04641845|Experimental|Heel height increases|All participants consecutively walked with four heel height conditions (0 millimeter, 3 millimeter, 5 millimeter and 8 millimeter). The order of the heel height conditions was randomized.
89043326|NCT00559208||Children's Aid Societies|Comparing differential response (Wraparound) with usual care
89043327|NCT04641689|Active Comparator|Desk Only|Participants will receive a height-adjustable desk to use in their home work environment.
89043328|NCT04641689|Active Comparator|Program Only|Participants will receive 12 weeks of online content to support reductions in sedentary behavior while working from home. Content will be based on social cognitive theory.
89212505|NCT00876044|Experimental|1|4 mg/kg every 2 weeks
89212506|NCT00876044|Placebo Comparator|2|matching placebo
89212507|NCT04040114|No Intervention|Lead-in phase|During the lead-in phase treating clinicians will not be given the Molemap artificial intelligence diagnosis in real-time (i.e. in clinic with the patient).
89212508|NCT04040114|Active Comparator|Active phase|During the active phase treating clinicians will be given the Molemap artificial intelligence diagnosis in real-time.
89212509|NCT00876122|Experimental|1|
89212510|NCT00866216|Experimental|1|Azithromycin Monohydrate 600mg Tablets
89212511|NCT00866216|Active Comparator|2|Zithromax (Azithromycin Dihydrate) 600mg Tablets
89212512|NCT00871208|Experimental|1|Altabax (R) and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
89643136|NCT00624195|Active Comparator|non-CNS-targeted|"Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen (see list of FDA approved antiretrovirals listed below) designed to suppress plasma Viral Load, but not expected to have targeted CNS penetration.~Combinations of FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
89643137|NCT01440647|Experimental|NIPPV|Extubation to NIPPV (nasal intermittent positive pressure ventilation)
89643138|NCT01440647|Active Comparator|CPAP|After extubation this arm was placed on CPAP (continuous positive airway pressure) and was not offered NIPPV in the first month on life
89643139|NCT01799031|Experimental|Arm I (WISE)|Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
89643140|NCT01799031|Active Comparator|Arm II (control)|Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
89643141|NCT01516970|Experimental|DRV/r with 2 NRTIs|DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
89643142|NCT01516970|Active Comparator|Comparator standard of care HIV PEP|Comparator standard of care HIV PEP (as per German-Austrian Guidelines): Administration of the standard of care HIV PEP (postexposure prophylaxis) consisting of 2 NRTIs plus third partner.
89643143|NCT05247099||children with systemic diseases|Systemic diseases such as Nephritic syndrome, and other systemic diseases that can affect the eyes.
89643144|NCT05247099||healthy children|"The exclusion criteria for the subjects were eye diseases or other systemic diseases that can affect the quality or volume of tears or the secretion of tears. These included~eyelid diseases: eyelid entropion, eyelid ectropion, ptosis, and palpebral dyskinesia;~conjunctival diseases: pterygium and conjunctivitis;~history of ocular surface chemical injury;~history of eye surgery within 6 months or history of retinal laser photocoagulation;~systemic diseases: Sjogren syndrome, Parkinson's disease, rheumatoid arthritis, Grave's disease, systemic lupus erythematosus, and others."
89643145|NCT00625989|Placebo Comparator|Diluent|Inhalation challenge preformed with diluent.
89643146|NCT00625989|Active Comparator|Allergen|Inhalation challenge preformed with allergen.
89212513|NCT00871208|Active Comparator|2|Vehicle and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
89212514|NCT04039802||Test|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery
89212515|NCT04039802||Control|Historical control group, these patients already underwent BAHI insertion using two-stage surgery. The implant and abutment were inserted in two different procedures
89212516|NCT00876278|Other|*AT.Smart 46LC|The *AT.Smart 46LC is indicated for primary implantation for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
89212517|NCT04083521|Experimental|Treatment|Subjects received a once daily dose of Bacillus subtilis DE111® 1x10^9 CFU for 90-days.
89643147|NCT05247021|Experimental|erector spinae block group (E)|patients will receive bilateral ultrasound guided erector spinae block before the lumbar spine surgery starts.(20ml of bupivacaine 0.25%) after receiving general anesthesia
89643148|NCT05247021|No Intervention|control group (C)|patients will receive standard general anesthesia for lumbar spine surgery according to hospital protocol.
88991775|NCT04082364|Experimental|Margetuximab, retifanlimab, and chemotherapy arm|"margetuximab plus retifanlimab plus investigator choice of chemotherapy options.~Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)"
89212518|NCT04083521|No Intervention|Placebo|Subjects received a once daily dose of maltodextrin for 90-days.
89212519|NCT00871364|Experimental|A|VENLAFAXINE TABLETS 50 mg, single dose
89212520|NCT00871364|Active Comparator|B|Effexor® (venlafaxine HCl) Tablets equivalent to 50 mg venlafaxine, single dose
89212521|NCT00876356|Active Comparator|1|Conjugated Linoleic Acid 4.5g/day in three divided doses p.o. for 12 weeks
89212522|NCT00876356|Placebo Comparator|2|Olive oil 4.5g/day x 12 weeks.
89212523|NCT04083053|Experimental|Perianal Exam First|Perianal exam that is a part of anal cancer screening will be performed prior to the intraanal portion of the exam (high-resolution anoscopy with biopsy).
89212524|NCT04083053|Experimental|Perianal Exam Last|Perianal exam that is a part of anal cancer screening will be performed after the intraanal portion of the exam (high-resolution anoscopy with biopsy).
89212525|NCT05227274||MFM-Play|Neuromuscular disease patients completed MFM using MFM-Play
89043329|NCT04641689|Experimental|Desk + Program|Participants will receive a height-adjustable desk to use in their home work environment AND 12 weeks of online content to support reductions in sedentary behavior while working from home.
89043330|NCT04641689|No Intervention|Waitlist Control|Participants will receive the intervention (desk + program) after all follow-up data have been collected.
89043331|NCT02898753|Experimental|VAL-1221 3 mg/kg|"Part 1: Participants will receive VAL-1221 3 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 3 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 3 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 10 mg/kg and further to 30 mg/kg (after at least 12 weeks of dosing at 10 mg/kg), depending upon the pharmacodynamics, efficacy, and safety data."
89043332|NCT02898753|Experimental|VAL-1221 10 mg/kg|"Part 1: Participants will receive VAL-1221 10 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 10 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 10 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 30 mg/kg IV infusion, depending upon the pharmacodynamics, efficacy, and safety data."
89043333|NCT02898753|Experimental|VAL-1221 30 mg/kg|"Part 1: Participants will receive VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 30 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 30 mg/kg IV inufsion every other week."
89043334|NCT02898753|Active Comparator|rhGAA|"Part 1: Participants will be maintained on their current dose and regimen of Myozyme or Lumizyme.~Part 2: Participants from Part 1 of the study who were randomized to rhGAA can enter Part 2 of the study and receive VAL-1221 either 3 mg/kg, 10 mg/kg, or 30 mg/kg (based on the dose of VAL-1221 in respective cohorts to which they were randomized in Part 1) IV infusion every other week."
89043335|NCT04641572|No Intervention|Supine position|group A ( control ) will follow the hospital routine positions either supine or lateral during labor
89043336|NCT04641572|Experimental|Upright position|Group B (intervention) will follow the Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions. Then the researcher will register the time ( minutes/hours) that will be taken and which will be more preferable by the participant.
89043337|NCT02898324|Experimental|KiVa program full|The schools allocated in this arm will receive the Chilean adaptation of KiVa program with all its universal and indicated actions.
89643149|NCT02140593|Placebo Comparator|Standard neuromuscular blockade|Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
89643150|NCT02140593|Active Comparator|Deep neuromuscular blockade|Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.
89643151|NCT01516892|Experimental|BOTOX®|Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
89643152|NCT01798797||no treatment|non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months
89643153|NCT02863029|Other|Flexible Sigmoidoscopy|Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
89643154|NCT00668811|Experimental|Treatment Arm - Sutent|Sutent 37.5 mg/day will be given orally.
89643155|NCT02776605|Experimental|Ponatinib|"Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)~Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.~Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to day 7 before HSCT.~HSCT (performed ideally within 1 month from the end of consolidation).~Post HSCT therapy (MRD monitoring)"
89643156|NCT00627861|Experimental|Aliskiren and metoprolol succinate|
89643157|NCT00669279|Experimental|Carvedilol CR|
89643158|NCT00669279|Experimental|Atenolol|
89643159|NCT01516736|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
89643160|NCT01516736|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
89643161|NCT01546688|Active Comparator|Zonisamide at targeted daily doses of 100-500 mg/day|
89643162|NCT01546688|Placebo Comparator|Placebo administered to match daily doses of 100-500 mg/day|
89643163|NCT01516034|Experimental|Treatment|Cupola Tattoo Removal Device
89643164|NCT04409522|Experimental|Test Group|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
89643165|NCT04409522|Active Comparator|Control Group|Participants in this group will receive the usual treatment of COVID-19
89643166|NCT00672243|Experimental|Erlotinib + Sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of erlotinib and 5mg of sirolimus for patients not on concurrent Cytochrome P450, family 3 (CY3PA)-inducing anti-epileptics (EIAEDS) and 400 mg of erlotinib and 10 mg of sirolimus for patients on concurrent EIAEDS.
89643167|NCT04105946|Active Comparator|OFA Group|patients undergoing FESS under opiod free anesthesia
89643168|NCT04105946|Active Comparator|TIVA Group|patients undergoing FESS under total intravenous anesthesia
89643169|NCT01440569|Experimental|COBI-boosted DRV|Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
89043338|NCT02898324|Experimental|KiVa program w/o the digital component|The schools allocated in this arm will receive the Chilean adaptation of KiVa program without the digital component (online game)
89043339|NCT02898324|No Intervention|Control group|The schools allocated in this arm will not receive the KiVa program. If successful, these schools will receive the program the following academic year.
89043340|NCT04641533|Experimental|L-PRF + DPSC|Mandibular third molars were extracted and DPSC with L-PRF placed into the socket.
89043341|NCT04641533|Active Comparator|L-PRF|Mandibular third molars were extracted and L-PRF placed into the socket
89043342|NCT02898675|Experimental|Platelet Rich Fibrine|Platelet Rich Fibrine was applied with open flap debridement in test group.
89043343|NCT02898675|Active Comparator|Open Flap Debridement|Platelet Rich Fibrin was not applied to control groups. Only open flap debridement was applied to control groups.
89043344|NCT04641806||Lymphoma cases|Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. Past history of B-cell NHL in remission, active surveillance or during first-line or second-line treatment Affiliated with a social security, consenting to the study
89043345|NCT04641806||Controls|"Adults aged at least 18 years, with a Covid-19 confirmed by PCR, diagnosed between February and May 2020. No past history of lymphoma .~Affiliated with a social security, consenting to the study"
89043346|NCT02898558|Experimental|Magnification hand size|magnifying lenses used for 30 minutes daily for 14 days while completing a jigsaw puzzle
89043347|NCT04641494|Placebo Comparator|Placebo|28 subject received 2 capsules 3times a day for 12 weeks Each capsule contain 1gm (High Oleic Acid Safflower oils)
89043348|NCT04641494|Active Comparator|CLA group|Participants received 2 capsules3 times a day for 12 weeks Each capsule is 1 gm and it provided 0.75 gm CLA in a 50:50 mixture
89043349|NCT04641377|Experimental|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
89043350|NCT04641377|Active Comparator|Health education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
89043351|NCT02898441|Active Comparator|Screening Arm|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
89043352|NCT02898441|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care
89043353|NCT04641455|Experimental|A mucolytic solution|mucolytic solution - 100 ml of water + 600 mg of N-acetylcysteine (3 tablets of 200 mg ACC long), 320 mg of simethicone (8 ml of Espumisan sir. 40 mg / ml)administered 20-30 minutes prior to upper endoscopy
89043354|NCT04641455|Active Comparator|B mucolytic solution|mucolytic solution-100 ml water + 400 mg N-acetylcysteine (2 tablets 200 mg ACC long), 20 mg simethicone (0.5 ml Espumisan sir. 40 mg / ml) administered 20-30 minutes prior to upper endoscopy
89043355|NCT04641455|Placebo Comparator|C Water|100 ml of water 20-30 minutes prior to upper endoscopy
89043356|NCT04641455|No Intervention|D No intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
89043357|NCT02898480|Experimental|Remote ischemic conditioning|
89043358|NCT04641182||Prone position|Prone position per institutional protocol and as indicated by the treating physician
89043359|NCT04641182||No prone position|The control group will not be in prone position
89043360|NCT00559286|Experimental|A|treatment with 80 mg Telmisartan per day for 30 days
89043361|NCT00559286|Active Comparator|B|treatment with 20mg Telmisartan per day for 30 days
89043362|NCT00559403|Experimental|HIV/STD Sessions|The HIV/STD Risk-Reduction Intervention arm focuses on reducing the risk of STDs, including HIV.
89043363|NCT00559403|Active Comparator|Health Promotion Control Sessions|The Health Promotion Intervention arm focuses on physical activity, diet, and other behaviors linked to risk of heart disease, high blood pressure, stroke, diabetes, and certain cancers, which are all leading causes of morbidity and mortality among South Africans.
89043364|NCT02898285|Active Comparator|Personal time condition|"People randomized to this group will be asked to go on a night out with no kids (i.e. dinner, or a movie) once a month."
89043365|NCT02898285|Experimental|Individual sport condition|People randomized to this group will select an individual sport. They will be asked to participate in this individual sport for three months.
89043366|NCT02898285|Experimental|Team sport condition|People randomized to this group will select a team sport. They will be asked to participate in the team sport for three months (length of the team sport season).
89043367|NCT02898246||Patients with chronic heart failure|"Fear of physical activity (exposure) will be assessed in adult outpatients with diagnosed, chronic heart failure (with reduced ejection fraction or with preserved ejection fraction).~Hospitals provide medical data to assess patients' disease severity. Additional measures assessed via questionnaire include demographic characteristics, State and Trait depression and anxiety, heart failure related symptom distress, and coping dispositions relevant for coping with physical threat.~Fear of physical activity (FActS-HF 15) is reassessed after 4 weeks to evaluate the instrument's retest reliability.~After questionnaire completion, a subsample of participants will wear the MOVE III accelerometer for one week to objectively assess everyday physical activity and fill in an activity diary."
89212526|NCT00866450|Active Comparator|Western style diet|high-fat, low-calcium diet
89212527|NCT00866450|Active Comparator|Prudent diet|low-fat, calcium-sufficient diet
89212528|NCT03894969|Experimental|Sh_NTHi-Mcat_1 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.
89212529|NCT03894969|Experimental|Sh_NTHi-Mcat_3 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.
89212530|NCT03894969|Experimental|Sh_NTHi-Mcat_6 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.
89212531|NCT03894969|Active Comparator|NTHi-Mcat Group|Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.
89643170|NCT00629499|Experimental|Intervention|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment period of 12 weeks [84 days]). Patients with fluorescence in situ hybridization (FISH) HER2+ or IHC3+ breast cancer will also receive treatment with trastuzumab in addition to the nab paclitaxel / cyclophosphamide combination therapy. Maintenance therapy with trastuzumab will continue (for the HER2+ patients who are receiving trastuzumab) after the 12-week treatment period with combination nab paclitaxel/cyclophosphamide/trastuzumab. The total treatment time for trastuzumab will be 52 weeks rather than only 12 weeks.
89643171|NCT00631449|Active Comparator|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
89643172|NCT00631449|Placebo Comparator|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
89643173|NCT01546142|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89643174|NCT01546142|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89643175|NCT00632619|Active Comparator|1|Participants will receive stimulant medication therapy and referrals to community-based psychosocial treatments.
89643176|NCT00632619|Experimental|2|Participants will receive stimulant medication therapy and group-based behavior therapy.
89643177|NCT03027518|Other|Group 1|Group 1 will be active in the WILD 5 Wellness program the first 30 days and inactive the 2nd 30 days.
89643178|NCT03027518|Other|Group 2|Group 2 will be inactive in the WILD 5 Wellness program the first 30 days and active the 2nd 30 days.
89643179|NCT00633009|Active Comparator|LtSTA 15 ug|Naive volunteers tested with 15 ug injection of LtSTA. Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin tests were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
89643180|NCT00633009|Active Comparator|LtSTA 30 ug|Naive volunteers tested with 30 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
89643181|NCT00633009|Active Comparator|LtSTA 50 ug|Naive volunteers tested with 50 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
89643182|NCT01440101|Experimental|Double-blind Natalizumab 300 mg|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
89643183|NCT01440101|Placebo Comparator|Double-blind Placebo|IV infusions of placebo over 60 minutes every 4 weeks for 20 weeks
89643184|NCT01440101|Experimental|Open-label Natalizumab|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
89643185|NCT01530464|Active Comparator|Aminophylline|
89643186|NCT01530464|Active Comparator|Ambrisentan|
89643187|NCT01530464|Experimental|Aminophylline and ambrisentan|Treatment 3: Aminophylline, 500 mg plus Ambrisentan, 5 mg
89643188|NCT00633399|Experimental|1|Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Ziprasidone for 12 months.
89643189|NCT00633399|Placebo Comparator|2|Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Placebo for 12 months.
89643190|NCT01077843||Exposure|Ankylosing spondylitis patients currently exposed to anti-inflammatory treatments
89643191|NCT01077843||Non-exposure|Ankylosing spondylitis patients not currently exposed to anti-inflammatory treatments
89643192|NCT01799811||CLI patient's needing open bypass|Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open peripheral arterial revascularization.
89643193|NCT00633867|Active Comparator|Intubation c McGrath videolaryngoscope|Tracheal Intubation using McGrath video-laryngoscope
89643194|NCT00633867|Active Comparator|Intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
89643195|NCT00673959|Experimental|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
89643196|NCT00673959|Active Comparator|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
89643197|NCT04345809||GROUP A. MESH WITH OMEGA-3|Group A - 6.4-cm diameter circular prosthesis C-QUR V-Patch with an omega-3 coating
89643198|NCT04345809||GROUP B. MESH WITHOUT OMEGA-3|Group B - 6.4-cm diameter circular prosthesis BARD Hernia Patch , without omega-3 in its composition
89643199|NCT00635739|Active Comparator|A, 1|
89643200|NCT00635739|Placebo Comparator|A, 2|
89043368|NCT02898051||Venous Thromboembolism and cancer|"Patients hospitalized for Venous Thromboembolism and having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: three tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
89043369|NCT02898051||Venous Thromboembolism and non cancer|"Patients hospitalized for Venous Thromboembolism and not having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: 3 tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
89043370|NCT04640558||Group 1. Latent Myofascial Trigger Point Group|24 participants who will be clinically diagnosed with unilateral latent myofascial trigger point in the dominant side gluteus medius muscle.
89043371|NCT04640558||Group 2. Non-Latent Myofascial Trigger Point Group|24 participants who don't have latent myofascial trigger point.
89043372|NCT02898168|Experimental|WA|
89043373|NCT02898168|Active Comparator|Control|
89043374|NCT04640207|Experimental|Facial skin treatment|Facial skin treatment using the Alma Hybrid system.
89043375|NCT04640129|Active Comparator|TDF group|tenofovir 300mg taken orally per day.
89643201|NCT00635817|Experimental|Leuprolide acetate 11.25 mg|There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
89643202|NCT00635817|Experimental|Leuprolide acetate 30 mg|There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.
89643203|NCT01439945|Experimental|Arm I|Patients receive a low-dose of magnesium oxide orally (PO) daily (QD).
89643204|NCT01439945|Experimental|Arm II|Patients receive a high-dose of magnesium oxide PO QD.
89643205|NCT01439945|Placebo Comparator|Arm III|Patients receive a low-dose of placebo PO QD.
89643206|NCT01439945|Placebo Comparator|Arm IV|Patients receive a high-dose of placebo PO QD.
89643207|NCT00674115|Experimental|Single Dose Zegerid for 1 or 7 days|Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension
89643208|NCT00674115|Active Comparator|Single Dose Prilosec 1 or 7 days|Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet
89643209|NCT00674115|Active Comparator|Sodium Bicarbonate|Sodium Bicarbonate 1680 mg Oral Suspension
89643210|NCT02142153|Experimental|F901318 0.25 mg/kg|Single intravenous infusion over 4 hours
89643211|NCT02142153|Placebo Comparator|0.25 mg/kg placebo|Single intravenous infusion over 4 hours
89643212|NCT02142153|Experimental|F901318 0.75 mg/kg|Single intravenous infusion over 4 hours
89643213|NCT02142153|Placebo Comparator|Placebo 0.75 mg/kg|Single intravenous infusion over 4 hours
89643214|NCT02142153|Experimental|F901318 1.5 mg/kg|Single intravenous infusion over 4 hours
89643215|NCT02142153|Placebo Comparator|Placebo 1.5 mg/kg|Single intravenous infusion over 4 hours
89643216|NCT02142153|Experimental|F901318 mg/kg|Single intravenous infusion over 4 hours
89643217|NCT02142153|Placebo Comparator|Placebo 3 mg/kg|Single intravenous infusion over 4 hours
89643218|NCT02142153|Experimental|F901318 5 mg/kg|Single intravenous infusion over 4 hours
89643219|NCT02142153|Placebo Comparator|Placebo 5 mg/kg|Single intravenous infusion over 4 hours
89643220|NCT00674583|Experimental|Nimenrix Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Nimenrix™ vaccine into the non-dominant deltoid region, at Day 0.
89643221|NCT00674583|Active Comparator|Menjugate Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Menjugate® vaccine into the non-dominant thigh region, at Day 0.
89643222|NCT00637299|Active Comparator|Active osteopathic treatment (OMT+PR)|The examination was performed by osteopathic practitioners with emphasis on the neuromusculoskeletal system including palpatory diagnosis for somatic dysfunction and viscerosomatic change, in the context of total patient care. The examination was concerned with range of motion of all parts of the body, performed with the patient in multiple positions to provide static and dynamic evaluation.
89643223|NCT00637299|Sham Comparator|SOT + PR|Sham osteopathic treatment (manipulation)
89643224|NCT01420081|Experimental|B|PI3K Basal, IV Compound
89643225|NCT01420081|Experimental|C|PI3K Activated, Oral Compound
89643226|NCT01420081|Experimental|F|Japanese lead in cohort, IV compound
89643227|NCT01439867|Experimental|Cinacalcet|"Prior to the partial clinical hold, the starting dose was 0.25 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 4.2 mg/kg) based on plasma intact parathyroid hormone (iPTH), corrected serum calcium levels obtained monthly, and adverse signs and symptoms.~After the partial clinical hold the starting dose was 0.20 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 2.5 or 60 mg, whichever was lower) based on plasma iPTH, corrected serum calcium levels obtained monthly, weekly monitoring of ionized calcium levels, and adverse signs and symptoms.~All participants also received standard of care, which may have included vitamin D sterols."
89643228|NCT00637923|Experimental|1|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
89643229|NCT00637923|Placebo Comparator|2|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
89643230|NCT01439711|Experimental|letrozole + MRI + surgery|Patients receive letrozole (2.5 mg) one tablet each day after confirmation that the MRI is acceptable. There is a 3 and 6 month disease evaluation by MRI of both breasts. If the DCIS has grown, the patient will have surgery to remove it and will continue to take letrozole until the day before surgery. It is expected that decisions regarding any adjuvant treatment will be made individually based on best practice guidelines, using informed and shared decision making between the patient and provider.
89643231|NCT01439555|Experimental|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
89643232|NCT00674739|Experimental|imiquimod cream|2.5% imiquimod cream applied daily to wart area for up to 8 weeks
89643233|NCT00674739|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
89643234|NCT00674739|Placebo Comparator|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
89643235|NCT01544582||Boceprevir + PR|CHC genotype-1 participants included in study and prescribed boceprevir plus PR as routine clinical management.
89643236|NCT01544582||Telaprevir + PR|CHC genotype-1 participants included in study and prescribed telaprevir plus PR as routine clinical management.
89643237|NCT01544582||PR Alone|CHC genotype-1 participants included in study and prescribed PR alone as routine clinical management.
89643238|NCT00675909|Active Comparator|Oral Midazolam|Oral midazolam 0.5mg/kg
89643239|NCT00675909|Experimental|Aerosolized intranasal midazolam|Intranasal midazolam 0.3mg/kg
89643240|NCT00675909|Experimental|Aerosolized buccal midazolam|Buccal midazolam 0.3mg/kg
89643241|NCT01439165|Experimental|Adacel® Vaccine Group|Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)
89643242|NCT01439165|Active Comparator|Td Adsorbed Vaccine Group|Participants randomized to receive Subjects randomized to receive a Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine.
89643243|NCT03027908|Experimental|Fluoride Toothpaste 1|Toothpaste containing Sodium Fluoride at 1450 ppm F
89643244|NCT03027908|Active Comparator|Fluoride Toothpaste 2|Toothpaste containing Sodium Fluoride at 1450 ppm F
89643245|NCT03027986|Experimental|postural rehabilitation program based on sensory-motor control|
89643246|NCT03027986|No Intervention|Standard physiotherapy|
89643247|NCT03027752|Active Comparator|carotid endarterectomy patch angioplasty|Carotid endarterectomy with longitudinal incision carotid endarterectomy patch angioplasty
89643248|NCT03027752|Experimental|Carotid endarterectomy with autoarterial remodeling|Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery
89043376|NCT04640129|Experimental|peg-IFN-α plus TDF group|peg-IFN-α 180ug given subcutaneous injection per week combined with tenofovir 300mg taken orally per day .
89043377|NCT02898012|Experimental|Temozolomide and Bevacizumab|Single experimental arm with two drugs : Temozolomide and Bevacizumab
89043378|NCT04640324|No Intervention|NAFLD wild type control group|Consisted of not treated NAFLD wild type patients
89043379|NCT04640324|Active Comparator|NAFLD wild type treated group|Consisted of NAFLD wild type patients treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
89043380|NCT04640324|Experimental|NAFLD mutated treated group|Consisted of NAFLD patients carrying at least one mutation among PNPLA3, TM6SF2, MBOAT7 genes, treated with oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day six months
89043381|NCT02897895|Experimental|new strategy of immunosuppression monitoring|evaluation of calcineurin activity (CN-a) in combination with CNI blood levels
89043382|NCT02897895|Active Comparator|strategy of reference|CNI (inhibitor of Calcineurin) blood levels alone
89043383|NCT04640285|Experimental|Product Use Sequence 1|Period 1 - RELX ENDS Tobacco Flavor Period 2 - RELX ENDS Menthol Flavor Period 3 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 4 - Usual Brand Cigarette
89043384|NCT04640285|Experimental|Product Use Sequence 2|Period 1 - RELX ENDS Menthol Flavor Period 2 - Usual Brand Cigarette Period 3 - RELX ENDS Tobacco Flavor Period 4 - Nicorette White Ice Mint Nicotine Polacrilex Gum
89643249|NCT00638937|Experimental|Treatment (saracatinib)|Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
89643250|NCT03027830|Experimental|iFR pressure-wire|
89643251|NCT03027830|Active Comparator|Conventional|
89643252|NCT01529606|Active Comparator|Standard care|Fifty patients will be recruited into standard treatment group and they will receive composite resin restoration for all decayed teeth and standard preventive treatment (cleaning and fluoride varnish application) at baseline.
89643253|NCT01529606|Experimental|Plasma treatment|Fifty patients will be recruited into plasma treatment group and they will receive plasma treatment after cavity preparation, composite resin restoration, standard preventive treatment followed by plasma treatment for non-carious teeth.
89643254|NCT00639093|Experimental|1|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
89643255|NCT00639093|Active Comparator|2|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
89643256|NCT02985632|Experimental|Mild Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
89643257|NCT02985632|Experimental|Moderate Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
89643258|NCT02985632|Experimental|Healthy Subjects|Subjects given an oral dose of BMS-986141.
89643259|NCT01439009|Experimental|Tolvaptan|15 mg
89643260|NCT01439009|Placebo Comparator|Placebo|Placebo
89643261|NCT00675987|Active Comparator|Losartan|Losartan 100 mg 1 tab po QD
89643262|NCT00675987|Placebo Comparator|Placebo|Placebo 1 tab po QD
89643263|NCT01572389|Experimental|Arm 1: HOPE|The Healthy Outcomes through Patient Empowerment (HOPE) intervention group is the intervention arm which will employ behavioral health coaching telephone sessions. Tele-coaching is a theoretically grounded, structured processes guided by intervention manuals.
89643264|NCT01572389|Active Comparator|Arm 2: EUC|The Enhanced Usual Care (EUC) group will serve as a concurrent control group to compare to the intervention arm of the study. Participants are screened for diabetes self-management behaviors and control and for active depressive and anxiety symptoms. Primary care providers are alerted of the patients' status and given decision support to enhance care for these uncontrolled conditions.
89043385|NCT04640285|Experimental|Product Use Sequence 3|Period 1 - Usual Brand Cigarette Period 2 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 3 - RELX ENDS Menthol Flavor Period 4 - RELX ENDS Tobacco Flavor
89043386|NCT04640285|Experimental|Product Use Sequence 4|Period 1 - Nicorette White Ice Mint Nicotine Polacrilex Gum Period 2 - RELX ENDS Tobacco Flavor Period 3 - Usual Brand Cigarette Period 4 - RELX ENDS Menthol Flavor
89043387|NCT02898129|Experimental|Tube houses|Tube Houses. Group of 75-100 houses, with 4 inhabitants per house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
89643265|NCT00639717|Experimental|Etanercept and ECP|"Etanercept and ECP (Extracorporeal Photopheresis) in addition to standard GVHD prevention:~Etanercept will be given twice weekly by subcutaneous injection starting on the day of HSCT (Hematopoietic stem cell transplantation) conditioning until 8 weeks post transplant. ECP treatments will begin at once weekly starting at 4 weeks post transplant and continue at less frequent intervals until 6 months post transplant.~GVHD prophylaxis will consist of a standard two drug regimen: mycophenolate for 4 weeks and tacrolimus (titrated to a therapeutic level) for 8 weeks, then weaned over 4 months with discontinuation by 6 months post-transplant."
89643266|NCT01571453|Experimental|Vortioxetine (Lu AA21004)|
89643267|NCT01571453|Active Comparator|Venlafaxine extended release|
89643268|NCT04121195|Other|Dose escalation sequence (all participants)|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
89643269|NCT04120961|Experimental|prolonged continuous use of bivalirudine|A total of 165 patients are assigned to group with prolonged continuous use of bivalirudin after randomization schedule.
89643270|NCT04120961|Other|bivalirudin use during ePCI|A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.
89643271|NCT01446289|Experimental|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
89643272|NCT01446289|Placebo Comparator|Placebo|Pregnant women who received one injection of saline solution.
89643273|NCT04120649||endomterial cancer|All patients visiting the clinic at Women Health Hospital who having endometrial carcinoma with their diagnosis based on investigations (tumor marker ) , imaging, histopathology will have surgical staging consisted of total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
89643274|NCT01438541|Experimental|Window|WindowTM is a protective layer that may reduce the shear and friction on the skin and may help to prevent skin breakdown. Window TM provides instant tack adhesion that minimizes the requirement of extra pressure in order to fixate well. The product does not leave residues and the adhesion level does not increase over time.
89643275|NCT04410263||COVID-positive ICU patients|The collective of COVID-positive patients on the ICU
89643276|NCT01419769|Experimental|AXIOS Stent and Delivery System|
89643277|NCT01438307|Experimental|Schedule A|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
89643278|NCT01438307|Experimental|Schedule B|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258, different from Schedule A.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
89643279|NCT01444651|Active Comparator|Tadalafil|20 mg Tadalafil tablet taken by mouth once a day for 3 months
89643280|NCT01444651|Placebo Comparator|Placebo|Placebo tablet taken by mouth once a day for 3 months
89643281|NCT01570751|Experimental|IDeg followed by IGlar|
89643282|NCT01570751|Experimental|IGlar followed by IDeg|
89643283|NCT01419535|Experimental|Mifepristone, then Placebo|Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.
89043388|NCT02898129|Experimental|Apartment|Apartments. Group of 75-100 apartments, with 4 inhabitants per apartment. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
89043389|NCT02898129|Experimental|Rental Houses|Rental Houses. Group of 150-200 rental houses, with 2 inhabitants per rental house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
89043390|NCT02898129|Experimental|Rural houses|Rural Houses. Group of 40-60 rural houses, with 5 inhabitant per rural house. Expected number of participants: 200-300. Predicted number of non-smoker chronic respiratory disease of 12-18.
89043391|NCT00559442|Experimental|1|high altitude exposure without prior acclimatization
89043392|NCT02897739||TTC Patients|Patients diagnosed with Tako-tsubo cardiomyopathy.
89043393|NCT02897739||Health Volunteers|Participants who have normal hearts.
89043394|NCT00559520|Active Comparator|Impact|"patient receiving 3 drinks Impact a day during 5 days before surgery"
89043395|NCT00559520|Experimental|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
89043396|NCT01236352|Experimental|Phase 1 (Cohort 1): BMS-911543 (5 mg)|BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response
89643284|NCT01419535|Experimental|Placebo, then Mifepristone|Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.
89212532|NCT03894969|Experimental|Shingrix-Only Group|Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.
89643285|NCT01438151|Experimental|Remicade|Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
89643286|NCT02141451|Experimental|INCB7839 100 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
89643287|NCT02141451|Experimental|INCB7839 200 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
89643288|NCT02141451|Experimental|INCB7839 300 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
89643289|NCT02141451|Experimental|INCB7839 (Phase II)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
89643290|NCT01418365|Experimental|Metronidazole + MMX placebo|
89643291|NCT01418365|Experimental|Metronidazole + MMX Mesalazine/mesalamine|
89643292|NCT02075125|Experimental|Prasugrel 60 mg|Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
89643293|NCT02075125|Experimental|Ticagrelor 180 mg|Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose
89643294|NCT00676065||1|Women who take oral contraceptives containing drospirenone
89643295|NCT00676065||2|Women who take oral contraceptives containing levonorgestrel
89643296|NCT00676065||3|Women who take oral contraceptives containing other progestogens
89643297|NCT00678015|Experimental|1|
89643298|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 250/50 ug|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
89643299|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 100/50 ug|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
89643300|NCT01437995|Active Comparator|Fluticasone Diskus alone 250 ug|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
89643301|NCT00640653|Experimental|Abstinence-only|Participants will receive the abstinence-only HIV/STD risk-reduction intervention.
89643302|NCT00640653|Experimental|Safer-sex only|Participants will receive the safer-sex-only HIV/STD risk-reduction intervention.
89643303|NCT00640653|Experimental|Comprehensive-long|Participants will receive the 12-h long comprehensive HIV/STD risk-reduction intervention.
89643304|NCT00640653|Experimental|Comprehensive-short|Participants will receive the 8-h short comprehensive HIV/STD risk-reduction intervention.
89643305|NCT00640653|Active Comparator|Health-promotion control|Participants will receive the health promotion control intervention.
89643306|NCT04064879|Experimental|Deployment of AD-SVF|Administration of autologous adipose derived SVF
89643307|NCT00641745|Experimental|1|Lurasidone
89643308|NCT00641745|Active Comparator|2|Risperidone
89643309|NCT01799421||Non-haematologic cancer|
89643310|NCT01799109|Experimental|nebulization ms and albuterol|magnesium sulfate 150mg & albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
89643311|NCT01799109|Active Comparator|nebulized albuterol|albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
89643312|NCT01799109|Experimental|nebulized ms|magnesium sulfate 150mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
89643313|NCT00588159|Experimental|Gabapentin preoperatively|Preoperative gabapentin 600 mg orally within 2 hours prior to surgery.
89643314|NCT00588159|Placebo Comparator|Active placebo|Diphenhydramine 12.5 mg orally 2 hours preoperatively.
89643315|NCT01439347|Experimental|Vincristine Sulfate Injection (VSI)|VSI dosed at 1.4 mg/m^2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes.
89643316|NCT01439347|Experimental|Marqibo|Marqibo dosed at 2.25 mg/m^2 (without any dose cap) as an IV infusion over 60 minutes.
89643317|NCT00678249|Experimental|FLAIR|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
89643318|NCT00678249|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
89643319|NCT00678249|Experimental|FLAIR Roll-in Participants|Primary Patency followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
89643320|NCT00680823|Experimental|Ropivacaine Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
89643321|NCT00680823|Placebo Comparator|Normal Saline Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
89643322|NCT00680823|No Intervention|Observation|Observation for 30 minutes.
89643323|NCT00589329|Experimental|A|"roup A will be assigned to receive antibiotics:~Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days."
89043397|NCT01236352|Experimental|Phase 1 (Cohort 2): BMS-911543 (10 mg)|BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response
89043398|NCT01236352|Experimental|Phase 1 (Cohort 3): BMS-911543 (20 mg)|BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response
89043399|NCT01236352|Experimental|Phase 1 (Cohort 4): BMS-911543 (40 mg)|BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response
89043400|NCT01236352|Experimental|Phase 1 (Cohort 5): BMS-911543 (80 mg)|BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response
89043401|NCT01236352|Experimental|Phase 1 (Cohort 6): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
89043402|NCT01236352|Experimental|Phase 1 (Cohort 7): BMS-911543 (160 mg)|BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response
89043403|NCT01236352|Experimental|Phase 1 (Cohort 8): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
89043404|NCT01236352|Experimental|Phase 1 (Cohort 9): BMS-911543 (240 mg)|BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response
89043405|NCT01236352|Experimental|Phase 1 (Cohort 10): BMS-911543 (320 mg)|BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response
89643324|NCT00589329|Placebo Comparator|B|Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
89643325|NCT01438957|Placebo Comparator|Placebo|Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
89643326|NCT01438957|Experimental|Dexmedetomidine 0.067 mcg/kg|Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
89643327|NCT01438957|Experimental|Dexmedetomidine 0.25 mcg/kg|Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
89643328|NCT01438957|Experimental|Dexmedetomidine 0.5 mcg/kg|Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
89643329|NCT01438957|Experimental|Dexmedetomidine 1.0 mcg/kg|Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
89643330|NCT00589563|Experimental|Fludarabine/Melphalan Conditioning|"Fludarabine/Melphalan Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
89643331|NCT00589563|Experimental|FTBI/Cytoxan Conditioning|FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
89643332|NCT00589563|Experimental|FTBI/Etoposide Conditioning|"FTBI/Etoposide Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
89643333|NCT00645333|Experimental|MK-0752, Docetaxel, Pegfilgrastim|MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752
89643334|NCT00646581|Placebo Comparator|Placebo (1)|Subjects are given a one-time, single dose of placebo intranasal spray
89643335|NCT00646581|Experimental|Single-Dose Intranasal Insulin|Subjects are given a one-time, single dose of intranasal insulin
89643336|NCT00681291|Active Comparator|1|lightweight polypropylene mesh
89643337|NCT00681291|Active Comparator|2|Strattice
89643338|NCT00648375|Experimental|Propranolol|Participants will take propranolol for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
89643339|NCT00648375|Placebo Comparator|Placebo|Participants will take placebo for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
89643340|NCT01444417|Experimental|Romiplostim|Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
89643341|NCT01444417|Placebo Comparator|Placebo|Participants received weekly subcutaneous placebo for 24 weeks.
89643342|NCT00651573|Active Comparator|Blood transfusion triggers of 24% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 24%. When the hematocrit value falls to less 24%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 24%, no further transfusions will be administered.
89643343|NCT00651573|Active Comparator|Blood transfusion triggers of 28% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 28%. When the hematocrit value falls to less 28%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 28%, no further transfusions will be administered.
89643344|NCT00653133|Active Comparator|USPNB|Ultrasound imaging guided peripheral nerve block
89643345|NCT00653133|Active Comparator|NSPNB|Peripheral nerve stimulator guided peripheral nerve block catheter placement for continuous infusion of local anesthetic
89043406|NCT01236352|Experimental|Phase 2 (Cohort 11): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
89043407|NCT01236352|Experimental|Phase 2 (Cohort 12): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
89043408|NCT02897856|Active Comparator|Buccal midazolam|Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg
89043409|NCT02897856|Active Comparator|intramuscular midazolam|Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.
89043410|NCT00559559|Other|Control Group|Patient Notifier turned OFF
89043411|NCT00559559|Experimental|Treatment group|Patient Notifier turned ON
89043412|NCT02897817||Oral to Injectable|Patients treated with oral MTX and requiring a switch to injectable MTX
89043413|NCT02897817||Injectable to Injectable|Patients treated with injectable MTX and eligible for a change in MTX injection device.
89643346|NCT01444027|No Intervention|Attention Control|"This group receives standard care with the attention of social support/ friendly interactions and serves as an attention control group."
89643347|NCT01444027|Experimental|Intervention Group 1 (Face to Face)|This group receives Problem Solving Therapy in face to face visits.
89643348|NCT01444027|Experimental|Intervention Group 2 (Video)|This group receives Problem Solving Therapy via video.
89643349|NCT00654069|Placebo Comparator|Placebo|Tablet
89643350|NCT00654069|Active Comparator|Acurox 5/30mg|Oxycodone HCl 5mg/Niacin 30mg tablet
89643351|NCT00654069|Placebo Comparator|Acurox 7.5/30|Oxycodone HCl 7.5mg/Niacin 30mg tablet
89643352|NCT00654147|Active Comparator|Raltegravir & Lopinavir/ritonavir|Raltegravir 400 mg tablet and Lopinavir/ritonavir capsule by mouth, every 12 hours for 48 weeks
89643353|NCT00654147|Active Comparator|Raltegravir & emtricitabine/tenofovir|Raltegravir 400 mg tablet bu mouth, every 12 hours for 48 weeks and tenofovir/embritcitabine 200 mg/100 mg table by mouth, once daily for 48 weeks
89643354|NCT00654615|Active Comparator|1|"Intramedullary Radius Fixation (Micronail) - Group 1~A new device was developed to provide intramedullary distal radius fracture fixation. This new device allows the placement of the orthopaedic hardware inside the medullary canal of the radius."
89643355|NCT00654615|Active Comparator|2|"Volar Plate Fixation - Group 2~Volar locking plates provide rigid external fixation and are placed on the outside of the radius. Volar plates are placed directly on the distal radius using a metal plate contoured to the shape of the distal radius."
89043414|NCT02897661|Experimental|Early WMT and EEN|WMT (day1), EEN (day1-15)
89043415|NCT02897661|Experimental|Late WMT and EEN|WMT (day8), EEN (day1-15)
89643356|NCT01438489|Experimental|Anifrolumab (MEDI-546) 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
89643357|NCT01438489|Experimental|Anifrolumab (MEDI-546) 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
89643358|NCT01438489|Placebo Comparator|Matching Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
89643359|NCT04407949|Other|event detection|
89643360|NCT00655083|Experimental|1|Nepadutant 0.1 mg/kg
89643361|NCT00655083|Experimental|2|Nepadutant 0.5 mg/kg
89643362|NCT01418209|Active Comparator|Low-dose 17-ß-estradiol with progesterone taper|
89643363|NCT01418209|Active Comparator|Venlafaxine XR|
89643364|NCT01418209|Placebo Comparator|Placebo|
89643365|NCT00655473|Experimental|Dalcetrapib (RO4607381)|
89643366|NCT00655473|Placebo Comparator|Placebo|
89643367|NCT01570361|Experimental|Catheter Ablation|Radiofrequency catheter ablation treatment in subjects with Paroxysmal Atrial Fibrillation (PAF)
89643368|NCT01570361|Active Comparator|Drug Treatment|Drug therapy (either rate or rhythm control) using current AF management guidelines
89643369|NCT01417195|Experimental|Menopur and Bravelle combination|The initial daily dose consisted of 225 IU of gonadotropins, mixed in the same syringe and administered by subcutaneous (SC) injection for 5 days. The initial daily dose, based on the Investigator's judgment, consisted of either 150 IU of Menopur and 75 IU of Bravelle or 150 IU of Bravelle and 75 IU of Menopur. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and was always to include at least 75 IU of Menopur and 75 IU of Bravelle. Treatment could not continue beyond day 20.
89643370|NCT01417195|Active Comparator|Menopur alone|The initial daily dose consisted of 225 IU of Menopur administered by subcutaneous (SC) injection for 5 days. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and treatment could not continue beyond day 20.
89643371|NCT00655707|Experimental|Autologous CD34+ cells|Autologous Cluster Designation 34+(CD34+) cells
89043416|NCT03454685||NCSLC group|NSCLC patients,including stage I to stage IV.
89043417|NCT03454685||Healthy subjects|healthy subjects
89043418|NCT02897505|Experimental|Women enrolled in Empower Clinic|Women who are enrolled in the Empower Sanctuary will be asked to participate in a Music Workshop
89043419|NCT04639934||Breast cancer patients|Breast cancer patients being seen at SingHealth
89043420|NCT02897544|Experimental|Health Education Intervention|Study participants will attend Health Education sessions led by health educators over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
89043421|NCT04640090|Experimental|Smartphone app|All participants in this single-arm study will receive two months of subsidized, full access to the smartphone wellness application.
89643372|NCT00656487|Experimental|Cannabis-dependent rimonabant|Cannabis dependent young adults administered rimonabant 90 mg at Day 0 and followed for 28 days post.
89643373|NCT00656487|Placebo Comparator|Cannabis-dependent placebo|Cannabis dependent young adults administered matched placebo at Day 0 and followed for 28 days post.
89643374|NCT00656487|No Intervention|Non-cannabis using control|Non-cannabis using demographically similar young adults followed for 28 days.
89043422|NCT02897622|Other|Case management|Case management
89043423|NCT04639739|Experimental|anti-CD19 CAR NK cells|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage."
89043424|NCT04639700|Experimental|Psycho-educational intervention|All participants will receive receive 4 individual sessions with an interventionist in addition to the standard post-hospital HSCT information for patient follow-up care as provided by the patient's oncologist
89043425|NCT01236118|Experimental|30 milligrams (mg) LY2439821|Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
89643375|NCT00657657|Experimental|Group 1|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12, 60 (5 doses)
89643376|NCT00657657|Experimental|Group 2|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
89643377|NCT00657657|Experimental|Group 4|Neonates from mother HBsAg (+) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
89212533|NCT00871442|Active Comparator|No Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)"
89212534|NCT00871442|Active Comparator|Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 2: Basal Infusion: 10 ml/hr; Bolus 5 ml q 30min prn (5ml demand dose with 30min lockout)"
89212535|NCT00871520||Palliative Therapy|Patients referred to the oncology / radiation oncology departments for palliative therapy.
89212536|NCT02588729|Experimental|Pregnant+ app for smartphone (Gravid+)|The intervention consists of the Pregnant+app downloaded on women's smartphone. The app contains culturally adapted information about physical activity, diet and management of GDM. The Gravid+app will be available in Norwegain, Urdu and Somali. Women will have the opportunity to automatically transfer their blood glucose levels to their smartphones via Bluetooth.
89212537|NCT02588729|No Intervention|No admission to Pregnant+ app (Gravid+)|The control group will receive standard care at the outpatient departments. Participants to not receive the Pregnancy
89212538|NCT05355597|Experimental|Exparel Group|70 subjects will receive Exparel
89212539|NCT05355597|Experimental|Multi-Drug Cocktail Group|70 subjects will receive a Multi-drug Cocktail
89643378|NCT00657657|Experimental|Group 6|Neonates from mother HBsAg (-) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
89643379|NCT01799499|Experimental|Group A: 20 mg MMC mixed with 60cc TC-3|Group A: 20 mg MMC mixed with 60cc TC-3 hydrogel. (n=8)
89643380|NCT01799499|Experimental|• Group B: 40 mg MMC mixed with 60cc TC-3|• Group B: 40 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
89643381|NCT01799499|Experimental|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
89643382|NCT01443403|Placebo Comparator|Placebo|Participants received placebo orally once daily for 28 days.
89643383|NCT01443403|Experimental|Naldemedine 0.1 mg|Participants received 0.1 mg naldemedine orally once daily for 28 days.
89643384|NCT01443403|Experimental|Naldemedine 0.2 mg|Participants received 0.2 mg naldemedine orally once daily for 28 days.
89643385|NCT01443403|Experimental|Naldemedine 0.4 mg|Participants received 0.4 mg naldemedine orally once daily for 28 days.
89643386|NCT01438177|Experimental|Velcade+Cyclophosphamide+Chloroquine|"VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.~Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.~Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.~Each cycle is 42 days in length."
89643387|NCT04747717|Experimental|Mitomycin C and cisplatin regimen|mitomycin C at 10 mg/m2 and cisplatin at 100 mg/m2
89643388|NCT04747717|Active Comparator|Paclitaxel and carboplatin regimen|paclitaxel at 175 mg/m2 and carboplatin AUC5-6
89643389|NCT01416805|Experimental|Computerized Cognitive Behavioral Therapy|
89643390|NCT01416805|Active Comparator|Treatment as Usual|
89643391|NCT01437943|Active Comparator|Aliskiren|Aliskiren 150 mg daily for 180 days
89643392|NCT01437943|Placebo Comparator|Placebo|Placebo identical to Aliskiren drug daily for 180 days
89643393|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Prophylaxis|Cohort 1 prophylaxis: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
89643394|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Treatment|Cohort 1 treatment: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
89643395|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Prophylaxis|Cohort 2 prophylaxis: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
89643396|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Treatment|Cohort 2 treatment: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
89643397|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Prophylaxis|Cohort 3 prophylaxis: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
89643398|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Treatment|Cohort 3 treatment: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
89643399|NCT04064489|No Intervention|neutral|No specific instructions for prescribing prophylaxis or not
89643400|NCT04064489|Active Comparator|TRIPscore|calculation of the TRIPcast score and prescription of prophylactic or not according to the result (score > or = 7 : treatment (low molecular weight heparin or fondaparinux); score < 7 : no treatment)
89212540|NCT05684003|Experimental|Intervention group|Neuromuscular exercise based injury-prevention program
89212541|NCT05684003|No Intervention|Control group|Nonspecific warm-up including a combination of aerobic exercises and range of motion exercises.
89212542|NCT00866528|Experimental|Phase I|oral pazopanib once daily (Phase I starting dose 800 mg) and paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
89212543|NCT05355519|Active Comparator|Curriculum and Instructor-Led Course|Participants first complete an online cognitive assessment. Once complete, staff email the electronic curriculum for participants to read. On a specific day, participants will go to the designated center to participate in an instructor-led course and simulated medical scenarios and complete megapode and online cognitive assessment. After a washout period of six months, participants return to the designated center to participate in simulated medical scenarios and complete the online cognitive assessment again. After a second washout period of six months, participants will take the online cognitive assessment again.
89643401|NCT01436357|Experimental|Arm A (Stage I and II)|Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
89643402|NCT01436357|Placebo Comparator|Arm B (Stage I and II)|Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
89643403|NCT04512053|Experimental|TAS-303|
89643404|NCT04512053|Placebo Comparator|Placebo|
89643405|NCT01436201|Experimental|Digoxin + Dulaglutide|"Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.~Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15."
89643406|NCT01437397|Experimental|1|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/12μg
89643407|NCT01437397|Experimental|2|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/6μg
89643408|NCT01437397|Active Comparator|3|Aclidinium monotherapy 400 μg
89643409|NCT01437397|Active Comparator|4|Formoterol monotherapy 12 μg
89643410|NCT01437397|Placebo Comparator|5|Placebo
89643411|NCT01437319|Active Comparator|lotrafilcon A, comfilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to comfilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
89643412|NCT01437319|Active Comparator|lotrafilcon A, balafilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to balafilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
89643413|NCT01416571|Experimental|Influenza A (H5N1) Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
89643414|NCT04071691||Active LVV|Patients with active LVV
89643415|NCT04071691||Stable LVV|Patients with inactive LVV
89643416|NCT04070833|Active Comparator|Vitamin D + fish oil|
89643417|NCT04070833|Active Comparator|Vitamin D + fish oil placebo|
89643418|NCT04070833|Active Comparator|Vitamin D placebo + fish oil|
89643419|NCT04070833|Placebo Comparator|Vitamin D placebo + fish oil placebo|
89643420|NCT01442155||Capecitabine + Oxaliplatin|Participants with stage lll colon cancer, who were starting adjuvant chemotherapy with capecitabine in combination with oxaliplatin according to standard of care.
89643421|NCT01416181|Experimental|natalizumab|In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
89643422|NCT01416181|Experimental|Placebo|In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
89643423|NCT03026023|Experimental|Treatment with grazoprevir + elbasvir +/- ribavirin|12 to 16 weeks of treatment with combination tablet of grazoprevir + elbasvir +/- ribavirin
89643424|NCT04064515||Cervical Cancer|Participants with advanced or recurrent cervical cancer will provide 15 mL of whole blood. Participants will then be followed prospectively for three years to document oncologic outcome.
89643425|NCT04064515||Control|Participants without a history of cervical cancer or high grade pre-cancer of the cervix
89643426|NCT01441765|Active Comparator|CT-011|CT-011 3 mg/kg for 4 cycles of 6 weeks
89643427|NCT01441765|Active Comparator|CT-011 with DC/RCC fusion vaccine|CT-011 with DC/RCC fusion vaccine for subjects undergoing nephrectomy, resection of tumor tissue, or aspiration of malignant effusion
89643428|NCT01419665|Experimental|GP2013|Type: Biological/Vaccine
89643429|NCT01419665|Active Comparator|rituximab|Type: Biological/Vaccine
89643430|NCT04064333|Experimental|Slow-Stream Expiratory Muscle Strength Training|The therapy protocol consists of 12 sets of five breaths through the EMST150 device per week, in sessions of three or four sets (15 or 20 breaths). A typical schedule might be one 15 breath session four days per week, or one 20 breath session three days per week.
89643431|NCT01436305|Active Comparator|Tac maintenance|"Group 1 Study Therapy Regimen:Induction with alemtuzumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); long-term Prograf® (tacrolimus), or equivalent ; CellCept® (mycophenolate mofetil- MMF), or equivalent , and 4 day course of MEDROL® (methylprednisolone)"
89643432|NCT01436305|Experimental|Belatacept maintenance|"Group 2 Study Therapy Regimen: Induction with alemtuzumab and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); Nulojix® (belatacept); CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL®(Methylprednisolone)"
89643433|NCT01436305|Experimental|Basiliximab induction/Short-term Tac|"Short term = 3 months~Group 3 Study Therapy Regimen: Induction with 2 doses of basiliximab and tacrolimus for 84 days and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Simulect® (basiliximab); Nulojix® (belatacept); short-term course of Prograf® (tacrolimus), or equivalent; CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL® (methylprednisolone)"
89643434|NCT01436149|Experimental|Antidepressant + SPD489|
89643435|NCT01436149|Placebo Comparator|Antidepressant + Placebo|
89643436|NCT01415401|Experimental|AZARGA|Brinzolamide 1% / timolol 0.5% maleate fixed combination, 1 drop self-administered in study eye(s) twice daily for 8 weeks (8AM and 8PM)
89643437|NCT01414855|Experimental|obinutuzumab + CHOP|Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.
89643438|NCT01527500|Experimental|LFG316 higher dose|LFG316 10 mg/100 μL
89643439|NCT01527500|Sham Comparator|Sham|Sham injection
89643440|NCT01527500|Experimental|LFG316 lower dose|LFG316 5 mg/ 50 μL
89643441|NCT02074735|Placebo Comparator|Placebo|Placebo schedule will mimic the schedule of the active comparator citicoline. Placebo will be started at the randomization visit (week 0, mimicking 500 mg/day of citicoline), then increased at week 2 to mimic 1000 mg/day citicoline, then increased to mimic 1500 mg/day of citicoline at week 4, and then increased to mimic 2000 mg/day of citicoline at week 6 until the end of week 12.
89043426|NCT01236118|Experimental|80 mg LY2439821|Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
89643442|NCT02074735|Active Comparator|Citicoline|Citicoline will be started at 500 mg/day at the randomization visit (week 0), then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and then 2000 mg/day at week 6 until the end of week 12.
89643443|NCT01527110|Experimental|Intravenous (IV) zanamivir 600mg twice daily|600mg of IV zanamivir infusion twice daily
89043427|NCT01236118|Experimental|160 mg LY2439821|Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.
89643444|NCT01441063|Experimental|Tocilizumab|Tocilizumab 8 mg/kg on Day 1 of a 14 day cycle a maximum of 6 cycles. If indicated, zidovudine (AZT) and valganciclovir (VGC) will be administered concurrently with tocilizumab, with day 1 of the cycle being the day tocilizumab is administered.
89643445|NCT01436071|Experimental|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
89643446|NCT01436071|Placebo Comparator|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
89043428|NCT02897583|Experimental|YAG vitreolysis|A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician. Only one treatment session will be performed.
89043429|NCT02897583|Sham Comparator|Sham YAG vitreolysis|Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.
89043430|NCT04206631|Placebo Comparator|Doxycycline Group|Subjects were randomized to receive Doxycycline capsules. The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
89043431|NCT04206631|Active Comparator|Comedone Extraction Group|Subjects were randomized to receive comedone extraction. Comedone extraction were done three times, and evaluated every 2 weeks.
89643447|NCT03025399|Experimental|Tangwang Prescription|The prescription was composed five Chinese herbal medicines,every bag has 4.87g granules, take it one bag each time, two times a day.
89643448|NCT03025399|Placebo Comparator|Placebo|Placebo is a simulated drug of tangwang Prescription,every bag has 4.87g granules, take it one bag each time, two times a day.
89643449|NCT01514240|Experimental|D9421-C|D9421-C 9 mg once daily
89643450|NCT01514240|Active Comparator|Mesalazine|Mesalazine 1 g three times a day
89643451|NCT01435759|Experimental|Antidepressant + SPD489 10 mg|
89643452|NCT01435759|Experimental|Antidepressant + SPD489 30 mg|
89043432|NCT04639817||Levofloxacin targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received Levofloxacin from day of culture positivity (day 0) through day +7.
89043433|NCT04639817||TMP/SMX targeted therapy|Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received TMP/SMX from day of culture positivity (day 0) through day +7.
89043434|NCT05496634|Experimental|Exercise Group|An informative presentation will be made emphasizing the importance of physical activity during the pandemic process. Individuals in the exercise group also participated in pilates sessions that lasted 50 minutes, 2 days a week for 8 weeks.
89643453|NCT01435759|Experimental|Antidepressant + SPD489 50 mg|
89043435|NCT05496634|Experimental|Control Group|An informative presentation will be made emphasizing the importance of physical activity during the pandemic process.
89643454|NCT01435759|Experimental|Antidepressant + SPD489 70 mg|
89643455|NCT01435759|Placebo Comparator|Antidepressant + Placebo|
89643456|NCT04048057|Experimental|Modarete Intensity Continous Training|
89643457|NCT04048057|Experimental|High Intensity Interval Training I|
89043436|NCT02897193|Active Comparator|Dental implant with bone augmentation|patients will be installed with ICE Dental implant 4.2 mm diameter with Alpha-Bio's grafts horizontal bone augmentation
89043437|NCT02897193|Experimental|narrow implant|patients will be installed with NICE Dental implant 3.2 mm diameter
89043438|NCT04639856|Active Comparator|on-pump CABG|CABG using Cardiopulmonary Bypass Machine
89643458|NCT04048057|Experimental|High Intensity Interval Training II|
89643459|NCT01393405|Active Comparator|Methotrexate|25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
89643460|NCT01393405|Placebo Comparator|Placebo|Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
89643461|NCT01419197|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
89643462|NCT01419197|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
89643463|NCT01414075|Experimental|Arm A + E (Participants on HD): Roxadustat Only, No Iron|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally 3 times weekly (TIW) for 12 weeks.
89643464|NCT01414075|Experimental|Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
89643465|NCT01414075|Experimental|Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with approximately 60 mg IV iron (ferric gluconate complex in sucrose injection [for example, Ferrlecit®] or equivalent) once a week for 12 weeks.
89643466|NCT01414075|Experimental|Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on PD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
89643467|NCT04063007|Other|Ketogenic diet|The patients follow the ordinary treatment protocol for initiation and follow-up of the ketogenic diet
89643468|NCT04766905|Experimental|Issa1|Dr.A.Sayed Issa and his team
89043439|NCT04639856|Active Comparator|off-pump CABG|CABG without Cardiopulmonary Bypass Machine
89043440|NCT01236001||Vimpat® treatment|Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.
89043441|NCT04639349|Experimental|Exercised group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
89643469|NCT04408079|Experimental|TQB3558 Tablets|TQB3558 tablets administered orally once. Then TQB3558 tablet administered orally, once daily in 28-day cycle after 4 days of first administration.
89643470|NCT01434823|Experimental|Intervention - nocturnal coverage|Nocturnal coverage from intensivists will be randomized by week. The weeks that have intensivists in the MICU during the 7pm to 7am shift are the intervention weeks.
89643471|NCT01434823|No Intervention|Control - standard of care|The weeks that are not randomized, the intervention arm will retain the current standard of care in the HUP MICU: attending intensivist availability by phone (home call).
89643472|NCT01513460|Experimental|NVA237 + Fluticasone/Salmeterol (Flu/Sal)|NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
89043442|NCT04639349|Other|control group|The control group will not be trained
89043443|NCT02897466|Experimental|Direct Antimicrobial Susceptibility Testing|"At day 0: Direct antibiotic susceptibility testing performed directly (DAST) on the respiratory sample At day 1: both results of isolated GNB identification using mass spectrometry and DAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to change antimicrobial therapy in case of differences between CAST and DAST (2nd switch to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems)"
89043444|NCT02897466|No Intervention|Conventional Antimicrobial Susceptibility Testing|"At day 1 identification of isolated GNB bacilli using mass spectrometry will be given to the physician in charge (usual care in ICU involved) to adapt antibiotic regimen. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems."
89643473|NCT01513460|Active Comparator|Tiotropium + Flu/Sal|Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
89043445|NCT04639544|Placebo Comparator|Control group|Volunteers will take 1 capsule per day with maltodextrin for 6 months
89043446|NCT04639544|Experimental|Probiotic group|Volunteers will take 1 capsule per day with the Lactobacillus strain for 6 months
89043447|NCT02897232||Community Group Survey|Community members coming into the University Health Shreveport Ambulatory Care Facility.
89043448|NCT02897232||Physician Group Survey|Physicians affiliated with LSU Health Shreveport School of Medicine
89643474|NCT01513460|Placebo Comparator|Flu/Sal|Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
89643475|NCT01392547|Experimental|rFVIIa|
89643476|NCT01392547|Experimental|vatreptocog alfa|
89643477|NCT01435655|Experimental|open|tafamidis
89643478|NCT01434667|Active Comparator|APOE Genotype Non-Disclosure|Subjects will receive Alzheimer's disease risk disclosure. This assessment is based on age and MCI status alone.
89643479|NCT01434667|Experimental|APOE Genotype Disclosure|Subjects will receive both APOE genotype and Alzheimer's disease risk disclosure. The assessment is based on age, MCI status, and genotype.
89643480|NCT01513148|Experimental|Superluminous Light Diode Irradiation|Application of super luminous diodes light irradiation over the superficial radial nerve
89643481|NCT01513148|Placebo Comparator|Sham Superluminous Light Diode Irradiation|Sham Superluminous Light Diode Irradiation over the Superficial Radial Nerve for the same time period as the intervention group
89043449|NCT01229254|Experimental|Amiodarone|Participants on betrixaban 30 mg and concomitant baseline amiodarone
89043450|NCT01229254|Experimental|Betrixaban 60 mg|Participants with lower weights
89043451|NCT01229254|Experimental|Betrixaban 90 mg|Participants with higher weights
89043452|NCT04639232|Placebo Comparator|Control group|Volunteers will take 6 capsules per day for 28 days a capsule containing maltodextrin.
89043453|NCT04639232|Experimental|Prob-milk|Volunteers will take 6 capsules per day for 28 days a capsule containing the probiotics combination.
89043454|NCT04639232|Experimental|Voluntas-Prob|Volunteers will take 6 capsules per day for 28 days a capsule containing the combination of plant extracts and the inactivated probiotic strain
89643482|NCT01418339|Experimental|Aripiprazole|Aripiprazole was administered orally once a week (QW) for 8 weeks in a double-blind manner. Participants randomized to aripiprazole received aripiprazole tablets at a starting dose of 52.5 milligrams (mg) QW on Day 0. At Week 1, according to the investigator's discretion based on efficacy and tolerability, the dose of aripiprazole could remain at 52.5 mg QW or could be increased to 77.5 mg QW. The dose could be increased to 110 mg QW as early as Week 2. For the remainder of the study (up to Week 8), the dose was to be adjusted up and down among these three dose levels, as determined by the investigator.
89643483|NCT01418339|Placebo Comparator|Placebo|Participants randomized to placebo received aripiprazole-matching placebo, tablet, orally, QW for 8 weeks in a double-blind manner.
89643484|NCT01512368|Experimental|Supervised exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks to participants.
89643485|NCT01412983|Experimental|Bausch & Lomb Test Lens|Bausch + Lomb investigational soft contact lens
89643486|NCT01412983|Active Comparator|Ciba Vision soft contact lens|Ciba Vision Air Optix Aqua soft contact lens
89643487|NCT01417481|Active Comparator|Glycine|Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.
89043455|NCT02897388|No Intervention|Pre-intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from January 2015 through March 2015 (which is the period before any intervention started)who meet the enroll criteria
89643488|NCT01417481|Placebo Comparator|Placebo|Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.
89643489|NCT01392469|Experimental|Imatinib + Bosentan + Sildenafil|Participants received treatment with bosentan 125 milligrams (mg) twice daily and sildenafil thrice daily for 8 days in treatment period 1. Participants were on the same sildenafil dose level (20, 40, 50 or 60 mg) they had been at study entry which was well tolerated in conjunction with bosentan. Following treatment period 1, the participants received concomitant treatment of oral imatinib 200 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 2. Following treatment period 2, the participants received concomitant treatment of oral imatinib 400 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 3.
89643490|NCT01435577|Experimental|Tapentadol intravenous|Tapentadol will be given by intravenous infusion. Tapentadol will be administered every 4 hours. Ibuprofen 600 mg orally may be given as rescue medication for pain not controlled by Tapentadol alone.
89643491|NCT01435577|Placebo Comparator|Matching placebo intravenous|Placebo (0.9% sodium chloride and water for injection). Ibuprofen 600 mg orally may be given as rescue medication for pain.
89643492|NCT04039087|Active Comparator|Sildenafil|active sildenafil 40 mg p.o. three times per day
89643493|NCT04039087|Placebo Comparator|Placebo Arm|placebo three times per day
89643494|NCT04061369|Experimental|Meal 1|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
89643495|NCT04061369|Experimental|Meal 2|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
89643496|NCT04061369|Experimental|Meal 3|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
89643497|NCT04061369|Experimental|Meal 4|"A liquid meal, similar to a smoothie, that is high (60% of energy) in fat calories."
89643498|NCT01411891|No Intervention|Control|Patients assigned to this study group will not have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
89643499|NCT01411891|Experimental|Chlorhexidine impregnated patch.|Patients assigned to this study group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
89643500|NCT01416389|Experimental|LY2523355 + pegfilgrastim or filgrastim|LY2523355: Five milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Pegfilgrastim or Filgrastim: Dosage is determined by standard of care and is administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
89643501|NCT01416389|Active Comparator|ixabepilone|Forty milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
89643502|NCT04505969||SCD patients and healthcare professionals|
89643503|NCT04497155||Prehospital norepinephrine|Trauma patients that received norepinephrine in the prehospital setting or in the resuscitation unit .
89643504|NCT04497155||Prehospital no norepinephrine|Trauma patients that did not receive norepinephrine in the prehospital setting or in the resuscitation unit.
89643505|NCT01544348|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
89643506|NCT01544348|Active Comparator|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
89043456|NCT02897388|Experimental|intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from April 2015 through June 2016 who meet the enroll criteria. A series of breast milk consume promotion interventions would implemented during this intervention period, which including build local lactation team, set breast milk feeding room, train NICU staff etc.
89643507|NCT01544348|Experimental|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
89643508|NCT01544348|Experimental|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
89643509|NCT01544348|Experimental|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
89643510|NCT01544348|Experimental|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
89643511|NCT01544348|Experimental|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
89043457|NCT01235728|Experimental|Treatment Sequence 1|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
89043458|NCT01235728|Experimental|Treatment Sequence 2|Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
89643512|NCT01544348|Experimental|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
89643513|NCT04059965|Experimental|Intervention Arm|This cohort of patients will receive panel management through a customize software that integrates with the electronic health record
89643514|NCT04059965|Active Comparator|Control Arm|This cohort of patients will receive usual care
89643515|NCT01416155|Experimental|natalizumab|300 mg intravenous (IV) infusions of natalizumab every 4 weeks until product is approved in Japan or development is discontinued in Japan, whichever comes first.
89643516|NCT01415921|Experimental|Pyridostigmine Bromide|Forced titration protocol 15-60 mg every 8 hours as tolerated
89643517|NCT01415921|Placebo Comparator|Placebo|Matching placebo forced titration 15-60 mg as tolerated
89643518|NCT01415531|Experimental|1|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
89643519|NCT01415531|Placebo Comparator|2|Dose-matched placebo
89643520|NCT01544114|Experimental|VIMOVO|"Three VIMOVO strengths will be used in this study: 250 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 250/20), 375 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 375/20), and 500 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 500/20). The VIMOVO strength allocated to each participant will be determined by the participant's weight at baseline and based on investigator's discretion.~The target dose of the naproxen component will be within the range of 10-20 mg/kg/day divided twice daily (BID) with a maximum daily dose of 1000 mg."
89643521|NCT01435265|Active Comparator|Normal Nurse Education|Subjects receive normal nurse education materials provided by their physician.
89043459|NCT01235728|Experimental|Treatment Sequence 3|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
89043460|NCT01235728|Experimental|Treatment Sequence 4|Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
89043461|NCT01235728|Experimental|Treatment Sequence 5|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
89043462|NCT01235728|Experimental|Treatment Sequence 6|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
89043463|NCT01235728|Experimental|Treatment Sequence 7|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
89043464|NCT01235728|Experimental|Treatment Sequence 8|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
89643522|NCT01435265|Experimental|Additional Nurse Education-|Subjects will receive additional nurse education beyond the normal education materials provided by their physician
89043465|NCT02897310||critically ill patients|critically ill patients with acute kidney failure requiring renal replacement therapy
89043466|NCT04639271|Experimental|Pyrotinib Plus Trastuzumab And Abraxane|Pyrotinib Plus Trastuzumab And Abraxane
89043467|NCT02896764|Experimental|Eligible patients for cone-beam CT|A cone-beam CT will be offered to the patient undergoing a CT scan of the middle ear
89043468|NCT02896959|Experimental|25mmHg pressure|Pump pressure of 25mmHg during rotator cuff repair
89043469|NCT02896959|Experimental|45mmHg pressure|Pump pressure of 45mmHg during rotator cuff repair
89043470|NCT02896959|Experimental|65mmHg pressure|Pump pressure of 65mmHg during rotator cuff repair
89043471|NCT04639076|Active Comparator|Behavioral Weight Loss Group|Participants in this arm will receive a standard behavioral weight loss approach that recommends a calorie deficit based on starting weight, a standard activity minute goal progression based on baseline activity and standard behavioral weekly counseling.
89043472|NCT04639076|Experimental|Personalized Behavioral Weight Loss Group|Participants in this arm will receive a personalized weight loss approach that recommends either a low carbohydrate or low fat calorie reduced diet; personalized activity plan with either daily or weekly bout-related goals; and eating frequency of either 3 times per day or 5-6 times per day.
89043473|NCT02896725|Experimental|Keratin dressings|Wool-derived keratin matrix dressing applied with each change of the compression bandage until healing
89043474|NCT02896725|Active Comparator|Usual care dressings|Dressing chosen from study centres' formulary of non-medicated moist wound dressings applied with each change of the compression bandage until healing
89643523|NCT01433263|Experimental|30mg/kg BYM338|
89643524|NCT01433263|Placebo Comparator|Placebo / late 30mg/kg BYM338|
89643525|NCT01432951|Experimental|Enzastaurin|"Enzastaurin 500 mg, four 125-mg tablets administered orally once daily for 14 days. Dosing is held for 3 days, and resumes on Day 18. Participants may continue receiving optional enzastaurin for an additional 2 to 4 weeks.~Safety Extension: Participants had the option to continue receiving enzastaurin until disease progression or discontinuation criteria are met, as per the investigator's assessment."
89643526|NCT04407793||Diverticulitis Group|Patients with acute diverticulitis episode
89643527|NCT04407793||Diverticulosis group|Patients diagnosed with diverticulosis without any acute diverticulitis episode
89643528|NCT04407793||Non-diverticulosis|Patients without diverticulosis
89643529|NCT01432327|Placebo Comparator|Control group|This group receives no kind of feedback during the intervention period. The participants wear the SenseWear Armband for 4 weeks and results of the intervention are discussed after the 4 week intervention period.
89643530|NCT01432327|Experimental|Step Group|This group receives feedback about the daily amount of steps by means of a pedometer.
89643531|NCT01432327|Experimental|Display Group|Participants receive real time feedback on their energy expenditure, minutes of physical activity and step count by means of the SenseWear Display
89643532|NCT01432327|Experimental|Coaching Group|Participants receive real-time feedback on their energy expenditure, step count and minutes of physical activity by means of the SenseWear Display and weekly meet with a Personal Coach to discuss their progress
89643533|NCT01410799|Experimental|Growth Hormone Releasing Hormone (GHRH)|Drug: GHRH
89643534|NCT04407871|Experimental|acupuncture and CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after embryo transfer (ET). They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
89643535|NCT04407871|Placebo Comparator|acupuncture and placebo CHM|Women will receive acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
89643536|NCT04407871|Placebo Comparator|control acupuncture and CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
89643537|NCT04407871|Placebo Comparator|control acupuncture and placebo CHM|Women will receive control acupuncture three times a week 4 weeks prior to ovarian stimulation for IVF and during ovarian stimulation, and before and after ET. They will also take placebo CHM daily 4 weeks prior to IVF till the day of serum hCG testing. If the hCG testing is positive and a viable pregnancy is confirmed by transvaginal ultrasound, placebo CHM will be continued till 8 weeks of gestation. If the hCG testing is negative or spontaneous miscarriage is confirmed, the drug treatment will be stopped.
89643538|NCT01432171|Experimental|Arm I (lacosamide)|Participants receive lacosamide PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
89643539|NCT01432171|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
89643540|NCT04046263|Experimental|Intervention|Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.
89643541|NCT04034719|Experimental|Experimental group|"Newborn hospitalized in the neonatal department with their parent will be included.~They will have a portage scarf to help them to keep their child skin-to-skin"
89643542|NCT04034719|Active Comparator|Control group|"Newborn hospitalized in the neonatal department with their parent will be included.~They wont have a portage scarf."
89643543|NCT04496713|No Intervention|Telemedicine - Phone|Patients will continue with their telephone-based telemedicine visit as scheduled. There will be no change to their care. Patients will receive a survey by mail about the visit.
89643544|NCT04496713|Experimental|Telemedicine - Audio/Video|Patients will be given an internet-connected tablet to have their upcoming visit with their physician by audio/video. A survey can be completed on the tablet. The devices will be sent back to the research time after their single use.
89643545|NCT01435031|Other|CTO Treatment|"Subjects receiving at least 1 of the following for the treatment of CTO:~XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~HT PROGRESS and/or HT PILOT guide wires in recanalization~MINI-TREK Coronary Dilatation Catheter in predilatation"
89643546|NCT04490941|Experimental|Intervention group|
89643547|NCT04490941|Other|Control group|
89043475|NCT04639154|Placebo Comparator|control group|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of NaCl 0.9% will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB
89043476|NCT04639154|Active Comparator|tramadol 50|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 50 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
89043477|NCT04639154|Active Comparator|tramadol 100|patients will receive a solution of 28 ml of bupivacaine 0.25% and 2 ml of tramadol hydrochloride 100 mg will be added to the local anesthetic solution divided into two levels of injection T5 and T8 in ipsilateral ESPB.
89043478|NCT04681053|Active Comparator|Group (A) received both oral and inhaled ivermectin in addition to the standard of care.|use oral and inhaled ivermectin
89043479|NCT04681053|Active Comparator|B) received oral ivermectin in addition to the standard of care|receive oral ivermectin
89043480|NCT04681053|Active Comparator|c) received inhaled ivermectin in addition to the standard of care|received inhaled ivermectin
89043481|NCT04681053|No Intervention|Group (d) received the current standard of care only|received standard of care only
89043482|NCT04639193|Experimental|Placebo, then Dual-Therapy, then Single/Triple-Therapy|"Subjects will start with a 3-day PLACEBO regimen:~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day EXPERIMENTAL DUAL-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
88991776|NCT04082364|Experimental|Margetuximab, tebotelimab and chemotherapy arm|margetuximab plus tebotelimab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
88991777|NCT04082364|Experimental|Margetuximab and chemotherapy arm|margetuximab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
89212544|NCT05355519|Placebo Comparator|Placebo|On a specific day, participants will go to a designated center to complete an online cognitive assessment and participate in simulated medical scenarios. Once complete, study staff will email the electronic curriculum for participants to read. After a washout period of six months, participants will return to the designated center to participate in an instructor-led course and simulated medical scenarios and complete a megapode and online cognitive assessment. After a second washout period of six months, participants will take an online cognitive assessment again.
88991778|NCT04082364|Active Comparator|Trastuzumab and chemotherapy arm|Trastuzumab plus investigator choice of chemotherapy options. Chemotherapy options: capecitabine and oxaliplatin (XELOX) or modified 5-FU, leucovorin, and oxaliplatin regimen 6 (mFOLFOX-6)
89212545|NCT00871598|Placebo Comparator|Placebo|
89643548|NCT04767581|Active Comparator|KHK7791|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
89643549|NCT04767581|Placebo Comparator|Placebo|During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.
89643550|NCT01433549|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B worn first, with senofilcon A worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
89643551|NCT01433549|Other|Senofilcon A / Lotrafilcon B|Senofilcon A worn first, with lotrafilcon B worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
89643552|NCT01414205|Experimental|Obinutuzumab 1000 mg|Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
89643553|NCT01414205|Experimental|Obinutuzumab 2000 mg|Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
89643554|NCT01433471|Experimental|Trichuris suis ova followed by placebo|Subjects in this arm will receive Trichuris suis ova for 12 weeks, followed by placebo for 12 weeks after crossover
89643555|NCT01433471|Active Comparator|Placebo followed by Trichuris Suis Ova|Subjects in this arm will receive placebo for 12 weeks, followed by Trichuris suis ova for 12 weeks after crossover
89643556|NCT01433159|Experimental|HP011-101|
89643557|NCT01433159|Active Comparator|Various|Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
89643558|NCT02076425|Experimental|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
89643559|NCT02076425|No Intervention|Wait List|No intervention while subjects wait for PCIT-ED in the second phase of the study.
89643560|NCT01413503|Experimental|131I-MIBG|Patients received 131I-MIBG 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) diluted in 25 ml of normal saline. Patients were infused intravenously through a patient's peripheral or central line over 120 minutes
89643561|NCT01413191|Experimental|CixutumumabTreatment|Cixutumumab 10 mg/kg intravenous (IV) over 1 hour on days 1 and 15 for 4 week courses.
89643562|NCT05031000|Experimental|Subject POCT glucometer measurement|Blood glucose measurement POCT glucometer
89643563|NCT05069376|Experimental|The intraureteral placement of distal end of ureteral stent|Patients randomized to this group received 5-16/5-18 D-J stent with intraureteral placement of the distal end
89643564|NCT05069376|Active Comparator|The conventional placement of the distal end of ureteral stent|Patients randomized to this group received 5-22/5-24 D-J stent with bladder placement of the distal end
88991779|NCT04081649||Cardiac surgery|Patients undergoing non-emergent cardiac surgery for coronary bypass graft and/or valvular replacement
88991780|NCT04072497|Experimental|Zoster vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
89643565|NCT05006820||No intervention|
89643566|NCT04984512|Experimental|Mitizodone Phosphate tablet 10mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 8 weeks, then placebo,orally,once daily for 2 weeks.
89643567|NCT04984512|Experimental|Mitizodone Phosphate tablet 20mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 7 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then placebo,orally,once daily for 1 weeks.
89643568|NCT04984512|Experimental|Mitizodone Phosphate tablet 40mg|Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 40mg ,orally,once daily for 6 weeks, then Mitizodone Phosphate tablet 20mg ,orally,once daily for 1 weeks, then Mitizodone Phosphate tablet 10mg ,orally,once daily for 1 weeks.
88991781|NCT04072497|Active Comparator|Varicella vaccine, Live|live attenuated varicella-zoster virus vaccine (with live virus >=3.3 LgPFU per dose)
88991782|NCT04072497|Placebo Comparator|Placebo|Placebo with no live virus
89212546|NCT00871598|Experimental|Single 0.3|
89212547|NCT00871598|Experimental|Repeat 1.0|
89212548|NCT00871598|Experimental|Repeat 2.0|
89212549|NCT00871598|Experimental|Repeat 4.0|
89212550|NCT00871598|Experimental|Repeat 8.0|
89212551|NCT04082741|Experimental|Monotherapy SAD BMS-986318 or Placebo|Single Ascending Dose (SAD)
89212552|NCT04082741|Experimental|Monotherapy MAD BMS-986318 or Placebo|Multiple Ascending Dose (MAD)
89212553|NCT00992667|Experimental|Asthmatics|Ten nonsmoking patients, suffering from mild bronchial asthma participated in the study (mean age 30±9 years, 5 men, 5 women). Asthma was diagnosed based on GINA 2008 criteria. The patients were free of any medication, at least 7 days before, and had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study. Patients who did not meet these criteria were excluded from the study.
89212554|NCT00992745|Experimental|Previous ProstaScint®|Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
89212555|NCT00992745|Experimental|No Previous ProstaScint®|Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
89212556|NCT05171972||Relapsing-remitting Multiple Sclerosis|Enrolled subjects in this group will have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria of the relapsing-remitting form with an Expanded Disability Status Scale (EDSS) score of 0 to 5.5 and will be treated with Ofatumumab.
89643569|NCT04984512|Active Comparator|Placebo|Placebo,tablet,orally,once daily for 10 weeks.
89643570|NCT01412957|Experimental|Panitumumab + BSC|Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug.
89643571|NCT01412957|Other|BSC Alone|Participants received best supportive care until disease progression, withdrawal of consent, or death.
89643572|NCT04973826|Experimental|ATM-AVI treatment arm|Chinese healthy volunteers
89643573|NCT03025841|Other|Ceftaroline|Patients receive Ceftaroline 600mg BID
89643574|NCT05387460||Training cohort|The cohort of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology is a training cohort Intervention/treatment
89643575|NCT05387460||validation cohort|The cohort of Women's Hospital, School of Medicine, Zhejiang University is a validation cohort
89643576|NCT03091764||NMIBC Patient High Risk|"Any of the following:~T1 tumours~CIS (carcinoma in situ)~Multiple and recurring and large (>3cm) Ta, G1, G2 tumours (all these conditions must be presented)~(Patients requiring intravesical Bacillus Calmette-Guérin (BCG) (immunotherapy), which starts with 6 week induction treatment and continues with maintenance for 1 to 3 years)"
89643577|NCT03091764||NMIBC Patient Intermediate Risk|"All cases between High and Low Risk~(Patients requiring intravesical therapy which lasts between 6 weeks to 3 years)"
89643578|NCT03091764||NMIBC Patient Low Risk|"Primary, solitary, Ta, LG/G1, <3cm, no CIS~(Patients receiving frequent cystoscopies, possible tumour resections and single instillations of postoperative chemotherapy)"
89643579|NCT05064774|Active Comparator|control group|Patients who underwent arthroscopic rotator cuff repair surgery (n=10). They were implemented physiotherapy after the surgery once a week for 12 weeks. They were encouraged to do exercises 3 to 5 times every day.
89643580|NCT05064774|Experimental|myofascial release group|Patients who underwent arthroscopic rotator cuff repair surgery (n=10). They were implemented physiotherapy the same as the control group once a week for 12 weeks. In addition to physiotherapy they took myofascial release sessions twice a week for 4 weeks between 4 and 7 weeks.
89643581|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 50 mg/day|
89643582|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 100 mg/day|
89643583|NCT01432457|Placebo Comparator|Placebo|
89643584|NCT05062278|Experimental|Intravenous Vinblastine|Single dose intravenous vinblastine (6mg/m2) in bolous.
89643585|NCT05062278|Active Comparator|Oral Hydroxiurea|Patient will recieve oral hydroxiurea at a dose of 50mg/kg/day until response or administration of induction chemotherapy
89643586|NCT05026788||Intra-COVID lockdown|Any patients treated for orthopaedic trauma within the mandatory lockdown due to the pandemic.
89643587|NCT05026788||Pre/post-COVID lockdown|Any patients treated for orthopaedic trauma either before or after the imposition of lockdown induced by the pandemic.
89212557|NCT05171972||Healthy Control Subjects|Enrolled subjects must not have clinically definite Multiple Sclerosis as defined by the revised McDonald criteria, any other autoimmune disease, demyelinating co-morbidity, neurological disease or immune system altering disease.
89212558|NCT00992823|Active Comparator|Group 1:iron weekly supplementation|
89643588|NCT02823990|Experimental|Treatment TG4010 + nivolumab|Patients receive TG4010 SC once per week for courses 1-3 and every 2 weeks for courses thereafter and nivolumab IV over 30 minutes every 2 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89643589|NCT04873908|Other|conventional rehabilitation|
89643590|NCT04873908|Experimental|Modified constraint-induced therapy|
89643591|NCT04873908|Experimental|Proprioceptive Training|
89643592|NCT04835688|Experimental|Ventilation tube insertion|Ventilation tube insertion into the tympanic membrane.
89643593|NCT04835688|Sham Comparator|Sham-treatment|Sham-treatment. Manipulation of the tympanic membrane to simulate ventilation tube insertion without performing a ventilation tube insertion.
89643594|NCT04957602||Metastatic non-small cell lung cancer patients|Metastatic non-small cell lung cancer patients who have not initiated their treatment yet (osermertinib or chemotherapy (associated or not with immunotherapy)
89643595|NCT02427126|Experimental|Apixaban|Apixaban 5mg b.i.d. Study treatment: 12 months Follow-up: 30 days after last study drug intake
89643596|NCT02427126|Active Comparator|Aspirin|Acetylic Salicylic Acid 100mg o.d.; Study treatment: 12 months Follow-up: 30 days after last study drug intake
89643597|NCT04917120|Experimental|VRH (virtual reality hypnosis)|
89643598|NCT03143088||Medical clown|Medical clown will be present in the pediatric emergency department while assessing blood pressure during triage of patients.
89643599|NCT03143088||Blood pressure assessment|Blood pressure will be measured by the medical center protocols.
89643600|NCT04831554|Experimental|single chest tube group|
89643601|NCT04831554|No Intervention|multiple chest tubes group|
88991783|NCT04071418||I-125 Seeds Implantation|All the enrolled patients were treated with CT-guided radioactive I-125 seeds implantation assisted by 3D printing template. Prescription dose 140-160gy.
88991784|NCT04068207|Experimental|Minocycline|Tablets Minocycline 100mg po per day for 12 months
89643602|NCT04807920|Experimental|Intravesical OnabotulinumtoxinA|The treatment group will receive 100 units of BOTOX® reconstituted in 10mL of injectable preservative-free normal saline at the time of cystoscopy. An injection cystoscopy needle will be set to 3mm and used to inject 0.5mL reconstituted OnabotulinumtoxinA at each injection site, approximately 1cm apart along the posterior bladder wall, for a total of 20 injection sites (4 rows of 5 injection sites). This will be the only treatment.
88991785|NCT04065841|Experimental|Arm A: combination therapy|Combination therapy arm: tropifexor 140 mcg capsule + licogliflozin 30 mg tablet, once daily orally
88991786|NCT04065841|Experimental|Arm B: tropifexor monotherapy|Tropifexor monotherapy arm: tropifexor 140 mcg capsule (+ placebo matching licogliflozin tablet), once daily orally
88991787|NCT04065841|Experimental|Arm C: licogliflozin monotherapy|Licogliflozin monotherapy arm: licogliflozin 30 mg tablet (+ placebo matching tropifexor capsule), once daily orally
88991788|NCT04065841|Placebo Comparator|Arm D: Placebo|Placebo arm: placebo matching tropifexor capsule + placebo matching licogliflozin tablet, once daily
88991789|NCT04047030||Injured Cohort|Approximately 300 participants treated for a fracture of the tibial plateau, pilon, ankle or calcaneus will be enrolled from METRC civilian trauma centers and military treatment facilities over an 18 month period. Participating centers treat large numbers of severe orthopaedic injuries and have a proven track record for successfully recruiting and retaining participants in prospective studies in orthopaedic trauma. Participants will be enrolled following definitive treatment of their injury.
88991790|NCT04047030||Non-Injured Volunteers|Non-injured adults of similar age and gender distribution will be enrolled at two participating centers (Carolinas Medical Center and Womack Military Medical Center). The sample of non-injured volunteers will exclude individuals with history of lower extremity injury, vascular disease, or who require use of ambulatory aides to walk.
88991791|NCT04045132|Active Comparator|MoodGym Alone|The MoodGym program is an evidence-based online cognitive behavioral treatment program that has been shown to be effective at reducing depression symptoms in a meta-analysis of 11 trials (g=0.36, 95% CI 0.17-0.56). Moodgym contains five modules with interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files that can be completed online without therapist interaction.
88991792|NCT04045132|Experimental|Parenting Program + MoodGym|The social media-based parenting program consists of 8 weekly sessions using a Facebook platform with the following topics: depression psychoeducation and behavioral activation, infant temperament, play, feeding, safety, sleep, parent-child interactions, and shared book reading. Participants in the experimental arm will also be enrolled in the online depression treatment program, MoodGym.
88991793|NCT04038047||Core|Cystic Fibrosis patients prescribed elexacaftor, tezacaftor and ivacaftor CFTR modulator therapy (TCT).
88991794|NCT04016558|Experimental|StreamLine|Diabetes education, behavioral management
88991795|NCT04016558|Experimental|TunedIn|Diabetes distress reduction, emotion regulation techniques.
88991796|NCT04016558|Experimental|FixIt|Unified program combining diabetes education, behavioral management, diabetes distress reduction, and emotion regulation techniques.
88991797|NCT04002414|Active Comparator|Usually Active- Decrease|Participants who usually meet or exceed recommended levels of physical activity who will be asked to minimize activity during stimulation.
88991798|NCT04002414|Experimental|Usually Active- Maintenance|Participants who usually meet or exceed recommended levels of physical activity who will be asked to maintain usual level of activity during stimulation.
88991799|NCT04002414|Experimental|Usually Insufficiently Inactive- Increase|Participants who are usually inactive who will be asked to try to increase activity to the recommended level during stimulation.
88991800|NCT04002414|Active Comparator|Usually Insufficiently Inactive- Maintenance|Participants who are usually inactive who will be asked to maintain inactivity during stimulation.
88991801|NCT03995043|Experimental|Control Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.~Personal Support from community peer mentor to access counselling services through SRH"
88991802|NCT03995043|Experimental|Case Intervention|"Education about contraceptive use, reproductive health and family planning services through SMS messages on SRH.~Personal Support from community peer mentor to access counselling services through SRH~Access to Contraception and counselling and service provision will be provided by the mobile reproductive health team at contraceptive access points."
88991803|NCT03991000|Experimental|Intravenous iron|Intravenous iron administration in the form of ferric carboxymaltose will be carried out according to summary of product characteristics. Bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks (up to a total of 2000 mg which is in-label) according to approved dosing rules, followed by administration of 500 mg ferric carboxymaltose at months 4 and 8, except when haemoglobin is > 16.0 g/dL or ferritin is > 600 µg/L. To avoid unblinding in these patients a saline infusion will be administered.
88991804|NCT03991000|Placebo Comparator|Placebo|Administration of i.v. NaCl according to the dosing rules for intravenous iron.
88991805|NCT03989037|Experimental|SIBP-01 & Docetaxel & Carboplatin|SIBP-01→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; SIBP-01: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
88991806|NCT03989037|Active Comparator|Herceptin & Docetaxel & Carboplatin|Herceptin→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; Herceptin: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
89057935|NCT04529525|Placebo Comparator|Placebo|"The dose of placebo in patients who are randomized to the this depends on the weight of the patient:~More than 48 kg and less than 80 kg: Two tablets of 6 mg each (12 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 80 kg and less than 110 kg: Three tablets of 6 mg each (18 mg in total) at the time of inclusion and the same dose at 24 hours.~More than 110 Kg: Four tablets of 6 mg each (24 mg in total) at the time of inclusion and the same dose at 24 hours."
89057936|NCT02218346|Active Comparator|Treatment A (unfed)|Treatment A: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, following a 10-hour overnight fast.
89643603|NCT04807920|Placebo Comparator|Placebo|Subjects randomized to the placebo group will undergo the same procedure but will only receive 10mL of injectable preservative-free normal saline. This will be the only treatment.
89643604|NCT00658515|Experimental|Dalcetrapib (RO4607381)|
89643605|NCT00658515|Placebo Comparator|Placebo|
89643606|NCT04797312|Experimental|Opioid free anesthesia (OFA) protocol|
89643607|NCT04797312|Sham Comparator|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|
89643608|NCT05080374|Experimental|HVLA + exercise Group|Spinal manipulation (HVLA) + trunk exercise program
89643609|NCT05080374|Experimental|HVLA + kinesiotaping group|Spinal manipulation (HVLA) + Kinesiotaping (lumbar)
89643610|NCT05080374|Experimental|HVLA + Respiratory exercise group|Spinal manipulation (HVLA) + respiratory exercise program
89643611|NCT04470882|Experimental|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
89643612|NCT04470882|Active Comparator|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
89643613|NCT04470882|Experimental|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
89643614|NCT05080140||Simvastatin|
89643615|NCT05080140||Ezetimibe|
89643616|NCT05080140||Omega -3 fatty acids-|
89643617|NCT05080140||Simvastatin+ Ezetimibe|
89643618|NCT05080140||Simvastain + ezetimibe + omega|
89643619|NCT03142230|Experimental|non-nutritive suction with holed baby bottle nipple|A group using the holed baby bottle nipple
89643620|NCT03142230|Active Comparator|Simple non-nutritive suction with personal pacifier|A group using personal pacifier
89212559|NCT00992823|Active Comparator|Group 2: cycle supplementation|two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
89212560|NCT00871676|Active Comparator|1|Overweight/obese individuals being treated with lifestyle modification to facilitate weight loss.
89643621|NCT04426110||"Period 1 Control"|No Music. Wound stitches procedure conducted according to clinical practice.
89643622|NCT04426110||"Period 2 Music"|Music by headphones. Wound stitches procedure conducted according to clinical practice
89643623|NCT04413318|Experimental|electronic device followed by pneumatic device|Children receive continuous control of tracheal cuff pressure with the electronic device (VBM©) for 6-hours followed by continuous control of tracheal cuff pressure with the pneumatic device (Nosten©) for 6-hours.
89643624|NCT04413318|Experimental|pneumatic device followed by electronic device|Children receive the reverse sequence (continuous control using the pneumatic device (Nosten©) for 6-hours followed by the electronic device (VBM©) for 6-hours
89643625|NCT01390441|Experimental|Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MK-8808 (500 mg/m^2) administered intravenously (IV) on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open-label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, subcutaneously (SC), or intramuscularly (IM) for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
89643626|NCT01390441|Active Comparator|Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MabThera® (500 mg/m^2) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
89643627|NCT01390441|Experimental|Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MK-8808 (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) adminstered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
89643628|NCT01390441|Active Comparator|Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MabThera® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
89643629|NCT01390441|Experimental|Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of Rituxan® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
89643630|NCT03142386|Experimental|OMT group|Osteopathic manipulative treatment
89643631|NCT03142386|Active Comparator|Control Group|Physiotherapy
89643632|NCT03142464|No Intervention|IV fluids|Regular IV fluids (Glucose 5% and Sodium Chloride 10% or Ringer) at the surgeon description
89643633|NCT03142464|Experimental|No IV fluids|No IV fluids after the termination of the operation. T
89643634|NCT04280640||Metastatic Cancer Pts Receiving Molecularly Targeted Therapy|Metastatic cancer patients (with liver and/or lung metastasis) who will receive molecularly targeted therapy based on genomic testing data
89643635|NCT04280640||GI Cancer Pts|Gastrointestinal cancer patients (with liver and/or lung metastasis) who will receive 3rd line treatments or enrolled on a targeted therapy treatment trial
89643636|NCT04280640||Bladder Cancer Pts|Bladder cancer patients (with liver and/or lung metastasis) who will receive systemic treatment
89643637|NCT03142542|Experimental|Udenafil 75mg|Drug: Udenafil 75mg by mouth, once daily, for 32 weeks
89643638|NCT03142542|Placebo Comparator|Placebo|Drug: placebo by mouth, once daily, for 32 weeks
89643639|NCT04133688|Experimental|Mobile application (ASC)|mobile app / devise
89643640|NCT04133688|Active Comparator|Paper diary|paper diary
89643641|NCT04645290|Experimental|"Intervention group: Educational Intervention KARER"|General objective of the intervention: Implement self-care strategies and care actions aimed at people facing chronic diseases with disabilities, applying knowledge, ability and attitudes that allow them to act in a timely manner, reducing the risk of complications, improving well-being and the quality of life of the person cared for and of himself. Through face-to-face, virtual interdisciplinary educational actions (B-learning) and with simulation support.
89643642|NCT04645290|No Intervention|Usual Care|The people assigned to this group will receive their own responses from the institution providing care services to which they belong. These instructions consist of: information on the disease process and treatment received from the medical group, information on assistance by the nursing group and finally, the administrative procedures carried out by social work.
89643643|NCT02175576|Experimental|Vanguard XP Bicruciate Knee System|153 patients receive Vanguard XP Bicruciate Knee System
89212561|NCT00871676|Experimental|2|Lifestyle modification plus use of chewing gum to facilitate weight loss in overweight/obese persons.
89643644|NCT02175576|Active Comparator|Vanguard CR Knee System|153 patients receive Vanguard CR Knee System
89643645|NCT01412879|Experimental|Arm I|Course 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients then undergo stem cell collection after completion of course 2. Patients undergo stem cell collection after completion of course 2.
89643646|NCT01412879|Experimental|Arm II|Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment. Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.
89643647|NCT01431079|Experimental|Health belief model based education|This experimental arm will provide an educational intervention designed to modify constructs of health belief model regarding HPV vaccine acceptability.
89643648|NCT01431079|Active Comparator|Knowledge-based education|This comparison arm will provide education based on knowledge regarding HPV vaccine acceptability.
89643649|NCT03143010|Placebo Comparator|control group|intrathecal Dexmedetomidine received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline .
89643650|NCT03143010|Experimental|1.5 DEX|Dexmedetomidine 1.5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (1.5μg) dexmedetomidine
89643651|NCT03143010|Experimental|3 DEX|Dexmedetomidine 3 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (3μg) dexmedetomidine
89643652|NCT03143010|Experimental|5 DEX|Dexmedetomidine 5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (5μg) dexmedetomidine
89643653|NCT03142776|Placebo Comparator|Periodontal debridement|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
88991807|NCT03978429|Experimental|Intervention Arm|"Community-based Pre-eclampsia/Eclampsia Detection and Management~Strengthened Referral Network from Community to Referral hospital levels~Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.~Antenatal Care Nurses will receive bluetooth blood pressure monitors.~Community Health Workers within the intervention arm facilities will receive training in pre-eclampsia features and will be provided with smart phones and access to a smart phone application that will prompt them to initiate follow ups with pregnant women within the community and they will receive SMS/text messages reminders about pregnant women within the community who require follow up."
89643654|NCT03142776|Active Comparator|Periodontal debridement + CLM|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.
89643655|NCT03142776|Active Comparator|Periodontal debridement + PDT|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).
89643656|NCT03142776|Active Comparator|Periodontal debridement + CLM + PDT|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.
89643657|NCT01430611|Experimental|Sanofi Pasteur Meningococcal A+C Polysaccharide Vaccine|
89643658|NCT01430611|Active Comparator|Lanzhou Institute Meningococcal A+C Polysaccharide Vaccine|
89643659|NCT03142698|Experimental|Hepatic steatosis|Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)
88991808|NCT03978429|No Intervention|Enhanced Usual Care|"Antenatal Care Nurses will receive training on best practices for PE detection and management per Tanzanian Standard Treatment Guidelines.~Antenatal Care Nurses will be given smartphones and will be trained to complete Case Report Forms (CRF) to log key indicators and activities at each ANC visit, delivery and Postnatal Care visits of enrolled participants.~Antenatal Care Nurses will receive bluetooth blood pressure monitors."
88991809|NCT03976375|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.
88991810|NCT03976375|Active Comparator|Docetaxel|Participants receive docetaxel at 75 mg/m^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.
88991811|NCT03976375|Experimental|Lenvatinib Monotherapy|Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.
89212562|NCT00876746|Active Comparator|1. Supraclavicular|Patients will be randomized to placement of a nerve block in the supraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
89643660|NCT05079438|Experimental|CRT with Dendrobium huoshanense Suppository|"Dendrobium huoshanense Suppository: 1.7g rectal administration per day for 5 weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
89643661|NCT05079438|No Intervention|CRT with Placebo|"Placebo: 1.7g rectal administration per day for 5 weeks~Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2 (UGT1A1*28 and *6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1*28 and *6 ：7/7+GG or 6/6+AA or 6/7+GA）."
89643662|NCT04053127|Experimental|RAVANS|Electrodes will be placed in the auricle of the left ear. Electrical stimulation to these electrodes will be provided by a current-constant stimulator (Urostim, Schwa-Medico). Stimulation will be gated, with 1-second delay, after peak inhalation (i.e. during exhalation). Respiratory gating for stimulation will require real-time evaluation of the respiratory cycle. The study will use a belt system constructed in-house, and similar to the system used in several previous studies. A pneumatic belt will be placed around the subject's lower thorax. Once electrodes are set up, subjects will be asked to rate stimulation intensity on a NRS of 0 to 10 (0: no sensation, 10: pain detection threshold). Current intensity will be set to achieve moderate to strong (but not painful) sensation, and this current intensity will be used on subsequent stimulation runs.
89643663|NCT04053127|Sham Comparator|non-RAVANS|For sessions randomized to sham stimulation, the electrodes in the ear will remain as described above, but the leads will be disconnected from the stimulator. Subjects will be instructed that for this session they may or may not feel pulsing in their ear, and that the goal is to ensure that the stimulus was not painful.
89643664|NCT03140826||Meropenem arm|Patients receiving meropenem to treat an infection.
89643665|NCT03140826||Pip-Tazo arm|Patients receiving piperacillin-meropenem to treat an infection.
89643666|NCT01409707|Experimental|Healthy lifestyles sessions|Healthy lifestyles sessions is a structured 9-12 session intervention that provides education about a variety of health-related topics. Each therapy session was 50-60 minutes long. Sessions included the provision of information, discussing participants' understanding of information, and answering questions about the information provided.
89643667|NCT01409707|Experimental|Trauma-focused exposure therapy|Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
89643668|NCT01409707|Experimental|Motivational enhancement + trauma-focused exposure therapy|A one session, 90 min. trauma-focused motivational enhancement therapy session was provided prior to starting the trauma-focused exposure therapy. Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
89643669|NCT05079048|Active Comparator|conventional retentive element|The conventional group received implant-supported mandibular overdentures retained by metal housings and nylon retentive elements,
89643670|NCT05079048|Experimental|PEEK retentive element|PEEK group received implant-supported mandibular overdentures retained by PEEK housings ,
89643671|NCT04477278|Experimental|Audio-Guided Mindfulness Intervention|Brief, 8-minute, audio-guided mindfulness intervention delivered prior to osteopathic manipulation.
89643672|NCT04477278|Active Comparator|History of Osteopathy|Brief, 8-minute, audio-guided history of osteopathy delivered prior to osteopathic manipulation.
88991812|NCT03963739||Race: Non-Hispanic African American|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
88991813|NCT03963739||Race: Non-Hispanic White|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
88991814|NCT03963739||Income: Lower Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
88991815|NCT03963739||Income: Higher Income|Patients undergo an interview over 40-60 minutes at baseline and 3 and 6 months after treatment to describe and compare changes in ability to work and employment status/income.
89643673|NCT01389973|Experimental|Open-label: ustekinumab 90 mg|
89643674|NCT01389973|Experimental|Double-blind: ustekinumab 45 mg|
89643675|NCT01389973|Experimental|Double-blind: ustekinumab 90 mg|
89643676|NCT01389973|Experimental|Double-blind: ustekinumb 180 mg|
89643677|NCT01389973|Placebo Comparator|Double-blind: placebo|
89643678|NCT03506568|No Intervention|Control - no reminder|For Group 1, there will be no changes to their instructions or smart phone, which is the most common clinical situation.
89643679|NCT03506568|Experimental|Integrated daily reminder using the D3 app|For Group 2, they will have their D3 app turned on to deliver both a push notification reminder to their smart phone and audio and visual reminders to their D3 device.
89643680|NCT03025633|Other|Group A - PEARL|Group A will receive a combination of verbal and visual pre-treatment information via the use of PEARL.
89643681|NCT03025633|No Intervention|Group B - NON PEARL|Group B will receive verbal only pre-treatment information.
89643682|NCT03502278|Active Comparator|PTSD lay-led group treatment program|This group will go through the Islamic Trauma Healing Program
89643683|NCT03502278|No Intervention|Waitlist|Waitlist
89643684|NCT01389817|Experimental|Symptomatic LHON patients.|Study Arm 1) symptomatic LHON patients. Male and female LHON patients with treatable bilateral optic atrophy. Treat the worse of the 2 eyes if there is a measurable difference in subjective visual functions (visual acuity, peripheral vision).
89643685|NCT01389817|No Intervention|Asymptomatic LHON mutation carriers|Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.
89643686|NCT04529460||Previously COVID-19 positive|Previously confirmed PCR positive for COVID-19 And/or positive COVID-19 antibody test in the past six months
89643687|NCT04529460||Previously COVID19 negative|No previous symptoms of COVID-19
89643688|NCT04032067|Active Comparator|Control Group|"GV1001-Placebo ID injection administered every 2 weeks through Week 24~+ Proscar PO administered once a day through Week 24"
89643689|NCT04032067|Experimental|Study Group 1|"GV1001 0.56 mg ID injection administered every 2 weeks through Week 24~+ Proscar-placebo PO administered once a day through Week 24"
89643690|NCT04032067|Experimental|Study Group 2|"GV1001 1.12 mg ID injection administered every 2 weeks through Week 24~+ Proscar-placebo PO administered once a day through Week 24"
89643691|NCT03141996|Experimental|Vibration to upper posterior neck muscles|Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
89643692|NCT03141996|Active Comparator|Standard of care|Regular occupational therapy session
89643693|NCT00659295||Type 1 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
89643694|NCT00659295||Type 2 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
88991816|NCT03946072|Active Comparator|Transseptal Group|Transseptal Aortic Approach Catheter Ablation Procedure
88991817|NCT03946072|Active Comparator|Retrograde Group|Retrograde Aortic Approach Catheter Ablation Procedure
88991818|NCT03939923|Active Comparator|Neostigmine/Glycopyrrolate|Group 1: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on train of four (TOF) watch monitor reading recorded every 15 minutes. Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage).
88991819|NCT03939923|Active Comparator|Sugammadex|Group 2: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on train of four (TOF) watch monitor reading recorded every 15 minutes. Group 2 (treatment) will receive reversal with Sugammadex (2mg/kg).
88991820|NCT03928236|Experimental|Limited Benzodiazepine Policy|Policy of no routine use of any intraoperative benzodiazepines.
88991821|NCT03928236|Active Comparator|Liberal Benzodiazepine Policy|Policy for the administration of benzodiazepine as per clinical guidelines but no lower than 0.03 mg/kg (ideal body weight midazolam equivalent) to all patients undergoing cardiac surgery. Any benzodiazepine may be used.
88991822|NCT03918252|Experimental|Arm A Nivolumab Only|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
89643695|NCT03142854|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
89643696|NCT03142854|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
89643697|NCT01430455|Experimental|Tranylcypromine|Active, open-label tranylcypromine treatment
89643698|NCT02924220||Case patients|"Patients with culture-proven listeriosis. Case patients are classified in 3 groups :~Septicemic infections: isolation of Lm in blood cultures.~CNS infections: isolation of Lm in cerebrospinal fluid, or brain stereotaxic biopsy, or by isolation of Lm in the blood with concomitant meningitis, or radiological encephalitis, rhombencephalitis, brain abscess or meningitis.~MF infections: defined by isolation of Lm in any maternal/fetal/neonatal bacteriological sample.~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
89643699|NCT02924220||Control patients|"Patients without listeriosis but compatible clinical presentation. Control patients are divided in 3 groups.~Septicemic controls: febrile patient with same co-morbidities as septicemic cases.~CNS controls: patient with any neurological symptom leading to the empiric prescription of amoxicillin at meningeal dosage because of listeriosis presumption.~MF controls: febrile pregnant patient without obvious focal infection.~All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study."
89643700|NCT05078658|Experimental|Low-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
89643701|NCT05078658|Active Comparator|Recommended carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with 50% (+/- 5%) of the recommended energy from carbohydrates.
89043483|NCT04639193|Experimental|Dual-Therapy, then Placebo, then Single/Triple-Therapy|"Subjects will start with a 3-day EXPERIMENTAL DUAL-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg + Eszopiclone 2mg at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then cross-over to a 3-day PLACEBO regimen:~Day 1: Placebo (matching Acetazolamide 250mg) at bedtime at home.~Day 2: Placebo (matching Acetazolamide 500mg) at bedtime at home.~Day 3: Placebo (matching Acetazolamide 500mg + Eszopiclone 2mg) at bedtime in the sleep laboratory.~After a wash-out period of 4+ days, subjects will then undergo an OPEN-LABEL SINGLE/TRIPLE-regimen:~Day 1: Acetazolamide 250mg at bedtime at home.~Day 2: Acetazolamide 500mg at bedtime at home.~Day 3: Acetazolamide 500mg alone or Acetazolamide 500mg + Eszopiclone 2mg + Venlafaxine 50mg at bedtime in the sleep laboratory, if sleep apnea resolved or did not resolve with the dual regimen, respectively."
89043484|NCT01235689|Experimental|Tight Control Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI), high sensitivity C-reactive protein (hs-CRP), fecal calprotectin, and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified tight control criteria: At Key Visit 1 the success criteria were CDAI < 150, hs-CRP, < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone use. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria were CDAI < 150, hs-CRP < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone during the preceding week."
89043485|NCT01235689|Active Comparator|Clinically Driven Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI) and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine.~Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified failure criteria using less stringent criteria:~At Key Visit 1 the criteria for management of disease activity were a CDAI decrease ≥ 70 (CR-70) compared to Baseline or CDAI < 200 at 1 week prior to the visit. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria for a change in treatment were a CDAI decrease of ≥ 100 (CR-100) compared to Baseline or CDAI < 200, and absence of prednisone during the preceding week."
89043486|NCT04680819||Compared with given anatolian propolis group and do not use anatolian propolis group|According to the spectrophotometic analysis report of this anatolian group, there should be a minimum phenolic 106.0 mg gae per ml and 73.1 mg ke flavonoid content in each ml and a total content of 253.9 mg te / ml.
89043487|NCT04638764|Active Comparator|Aerobic interval training with high loads resistance training|"Patient to be randomised into combined aerobic training with high loads resistance training group."
89043488|NCT04638764|Active Comparator|Aerobic interval training with low loads resistance training|"Patient to be randomised into combined aerobic training with low loads resistance training group."
89043489|NCT04638764|Active Comparator|Aerobic interval training|"Patient to be randomised into aerobic training training group."
89043490|NCT04680858|No Intervention|Standard Communication|Endoscopic procedures performed by skilled endoscopic team with standard communication (no headset)
89043491|NCT04680858|Experimental|DECT enhanced Communication|Endoscopic procedures performed by skilled endoscopic team with enhanced communication tools ( DECT headset)
89643702|NCT04051957|Experimental|Isosorbide Mononitrate|
89643703|NCT04051957|Placebo Comparator|Placebo|
89643704|NCT00590889|Other|St. Jude Medical (SJM) Conventional|St. Jude Medical (SJM) Standard Masters Series Mechanical Heart Valve with Conventional Cuff
89643705|NCT00590889|Other|St. Jude Medical (SJM) Silzone|St. Jude Medical (SJM) Masters Series Mechanical Heart Valve with Silzone Coating
89643706|NCT05078424|Experimental|CBT Treatment group|This group receives CBT interventions that aim to improve mental well-being, depressive and anxiety symptoms in young people.
89643707|NCT05078424|No Intervention|Wait-list Control group|This group does not receive CBT intervention but will receive appropriate intervention after the CBT treatment group and follow-up phases complete.
89643708|NCT02859168|Experimental|Myofascial Induction session|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
89643709|NCT02859168|Placebo Comparator|Placebo session|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
89643710|NCT02784600||Partial or full-thickness rotator cuff tear|Rotation Medical bioinductive implant
89643711|NCT02458560|Experimental|single-arm|
89643712|NCT05387304||COVID-19 infections|SARS-Cov-2 RNA postive
89643713|NCT05387226|Experimental|Oncolytic Virus Injection(RT-01)|RT-01 will be administered intravenously
89643714|NCT04206150|Active Comparator|Group 1(femoral triangle apex)|the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal)
89643715|NCT04206150|Active Comparator|Group 2(femur length/15*2 cm above)|the adductor canal catheter is inserted femur length/15*2 cm above the location where the nerve block performed in group 1
89643716|NCT04206150|Active Comparator|Group 3(femur length/15 cm below)|the adductor canal catheter is inserted femur length/15cm below the location where the nerve block performed in group 1.
89643717|NCT05387070|Experimental|TransCon PTH|TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
89643718|NCT05387070|Placebo Comparator|placebo|Placebo for TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection
89643719|NCT00591123|Experimental|FOLFOX, plus 5-FU and Erlotinib|single arm
88991823|NCT03918252|Experimental|Arm B Nivolumab + Ipilimumab|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
88991824|NCT03912831|Experimental|Phase 1A: 1 x 10^6 KITE-439 (Cohort 1)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, intravenous (IV) infusion, once on Days -7 and -6 and fludarabine, 25 mg/m^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 1 × 10^6 E7 T-cell receptor (TCR) T cells/kg on Day 0 along with the interleukin-2 of 2,50,000 IU/kg, subcutaneous (SC) injection, once on Days 0 to 6.
88991825|NCT03912831|Experimental|Phase 1A: 3 x 10^6 KITE-439 (Cohort 2)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 3 × 10^6 E7 TCR T cells/kg on Day 0 along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
88991826|NCT03912831|Experimental|Phase 1A: 1 x 10^7 KITE-439 (Cohort 3)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 1 × 10^7 E7 TCR T cells/kg on Day 0 along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
88991827|NCT03912831|Experimental|Phase 1A: 3 x 10^7 KITE-439 (Cohort 4)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 3 × 10^7 E7 TCR T cells/kg on Day 0 along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
88991828|NCT03912831|Experimental|Phase 1A: 1 x 10^8 KITE-439 (Cohort 5)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 1 × 10^8 E7 TCR T cells/kg on Day 0 (maximum allowable dose is 5 × 10^9 E7 TCR T cells) along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
88991829|NCT03912831|Experimental|Phase 1A: 1 x 10^8 KITE-439 (Cohort 6)|Participants will receive conditioning chemotherapy of cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, up to 1 × 10^8 E7 TCR T cells/kg on Day 0 (maximum allowable dose is 1 × 10^10 E7 TCR T cells) along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
88991830|NCT03912831|Experimental|Phase 1B: KITE-439|Participants will receive cyclophosphamide 30 mg/kg, IV infusion, once on Days -7 and -6 and fludarabine, 25 mg/m^2, IV infusion, once on Days -7 to -3 followed by KITE-439 infusion, at a dose selected based on Phase 1A along with the interleukin-2 of 2,50,000 IU/kg, SC injection, once on Days 0 to 6.
88991831|NCT03879655|Experimental|VTS-270|Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via LP infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the participant, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.
89643720|NCT05311098|Experimental|Vestibule Group|Cryoablation
89643721|NCT01429441|Experimental|Ocriplasmin|
89643722|NCT01429441|Sham Comparator|Sham injection|
89643723|NCT04149990|Active Comparator|Entresto|Combination of valsartan and sacubitril titrated to 103+97 mg B.I.D. for 26 weeks
89643724|NCT04149990|Placebo Comparator|Placebo|Matching placebo B.I.D. for 26 weeks
89643725|NCT00591825|Placebo Comparator|Non-Phobic Control - Placebo|Participants without phobia will be given one placebo administration.
89643726|NCT00591825|Active Comparator|Non-Phobic Control - DCS|Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.
89643727|NCT00591825|Placebo Comparator|Spider-phobic Placebo|Participants with phobia will be given one placebo administration.
89643728|NCT00591825|Experimental|Spider-phobic DCS|Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.
89643729|NCT04120038|Experimental|SMART & Peer Support|
89643730|NCT01429285|Experimental|Hydromorphone|Hydromorphone protocol
89643731|NCT01429285|Active Comparator|Usual care|Usual care
89643732|NCT00592761|Experimental|Within subjects treatment, no-treatment|Within subject, treatment and no-treatment periods. Each participant served as his/her own control in this AABB/BBAA alternating treatment conditions design. Results were also compared across groups (treatment v. no-treatment).
89643733|NCT05084040|No Intervention|A|Porth-a-Cath maintenance with 60-day interval
89643734|NCT05084040|Experimental|B|Porth-a-Cath maintenance with 90-day interval
89643735|NCT00594009|Experimental|Venovenous CO2 Removal (VVCO2R) in COPD|All patients enrolled in the trial will receive VVCO2R which consists of a circuit with a centrifugal pump, tubing, double lumen intravenous catheter and hollow fiber oxygenator
89643736|NCT05083962|Active Comparator|Healthy Lifestyle Program Intervention Arm|
89643737|NCT05083962|No Intervention|Waitlist Control Group|
89643738|NCT03139812|Other|30-day SiH CW, No Daily Irrigation|Control group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines with no daily morning irrigation of the eyes with sterile saline solution
89643739|NCT03139812|Other|30-day SiH CW, Daily Irrigation|Treatment group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines, and also irrigated the eyes with sterile saline solution every morning upon awakening
89643740|NCT03141840|Experimental|Experimental|Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
88991832|NCT03873883|Experimental|1A Dose escalation EOS100850|Dose Escalation- EOS100850 Monotherapy: to confirm RP2D
88991833|NCT03873883|Experimental|1B Dose escalation EOS100850 and Pembrolizumab|EOS100850 and Pembrolizumab Combination Therapy: to confirm RP2D as combination
88991834|NCT03873883|Experimental|2A Dose Expansion- EOS100850|Dose Expansion- Monotherapy: to explore safety, PK, PD, and antitumor activity of inupadenant as monotherapy
88991835|NCT03873883|Experimental|2B Dose Expansion - EOS100850 and Pembrolizumab|Dose Expansion - EOS100850 and Pembrolizumab Combination Therapy: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with pembrolizumab in melanoma and CRPC patients
89643741|NCT03141840|Placebo Comparator|Control|Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
89643742|NCT00594945|Experimental|Intranasal Clonazepam 2 mg|
89643743|NCT00594945|Experimental|Intranasal Clonazepam 3 mg|
89643744|NCT00594945|Experimental|Intranasal Clonazepam both Dose Groups 2 mg & 3 mg|
89643745|NCT03110874|Experimental|Experimental group (one-way education)|"Experimental group (one-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~video based education"
89643746|NCT03110874|Active Comparator|Control group(two-way education)|"Control group(two-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~direct education"
89643747|NCT00595101|Experimental|PF-03187207 High Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
89643748|NCT00595101|Experimental|Latanoprost 0.005% and PF-03187207 Vehicle|A single drop of each, once daily in study eye for 28 days
89643749|NCT00595101|Experimental|PF-03187207 Medium Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
89643750|NCT00595101|Experimental|PF-03187207 Low Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
89643751|NCT05083650|Experimental|Amniotic membrane without internal limiting membrane peeling|The surgery performed will be phacoemulsification + vitrectomy using an amniotic membrane to plug the macular hole using air as tamponade.
89643752|NCT05083650|Active Comparator|Amniotic membrane with internal limiting membrane peeling|The surgery performed will be phacoemulsification + vitrectomy + internal limiting membrane peeling using an amniotic membrane to plug the macular hole using air as tamponade.
89643753|NCT04063566|Other|Total cohort|The study will consist of one group, one arm, all receiving the same screening procedures.
89643754|NCT00660075|Experimental|1|Sitagliptin 100 mg/d for 6 weeks
89643755|NCT00660075|Placebo Comparator|2|Placebo for 6 weeks
89643756|NCT05083494||Melanoma|
89643757|NCT05083494||clear cell renal cancer|
89643758|NCT05083494||Urothelial Carcinoma of the bladder|
89643759|NCT05083494||squamous cell carcinomas of the head and neck|
89643760|NCT05083494||non-small cell lung cancer|
89643761|NCT00682617|Experimental|Waitlist Control|Delayed intervention. 3 months on waitlist, crossover to intervention (3 additional months)
89643762|NCT00682617|Experimental|3 Month Exercise Program|3 month exercise program
89643763|NCT00595881||Ultrasound|One group of patients will undergo emergency bedside ultrasound in addition to the clinical examination.
89643764|NCT03140436|Experimental|sodium bicarbonate powders (65 µm)|sodium bicarbonate powders with grain size 65 µm
89643765|NCT03140436|Experimental|sodium bicarbonate powders (40 µm)|sodium bicarbonate powders with grain size 40 µm
89643766|NCT01429051|Experimental|Intranasal Fentanyl Spray (INFS)|All participants were step-wise titrated to an effective dose of 50, 100, 200 or 400 μg INFS in the Titration Phase (I). Participants titrated to 200 or 400 μg INFS in the Titration Phase were randomized to an 8-spray sequence in the Efficacy Phase (II); 6 BTP episodes were treated with 400 μg INFS and 2 BTP episodes with placebo in a random sequence. Participants entered the Tolerability Phase (III) either directly from the Titration Phase (with an effective dose of 50 or 100 μg) or from the Efficacy Phase (400 μg) and continued with this specific dose, unless adjustment was needed, for a total treatment time of 12 weeks.
89643767|NCT03968562|Active Comparator|2% Doxycycline Cream in Generic Aquaphor|2% Doxycycline Cream in Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Placebo Comparator
89643768|NCT03968562|Placebo Comparator|Generic Aquaphor|Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration. Will perform concurrent to Active Comparator.
89643769|NCT03425292|Active Comparator|1 SOC (closed to enrollment)|Standard conformal brain radiation therapy with concurrent and adjuvant temozolomide
89643770|NCT03425292|Experimental|2 Nivo|Nivolumab
89643771|NCT03425292|Experimental|3 Nivo-Ipi (closed to enrollment)|Nivolumab plus Ipilimumab
89057937|NCT02218346|Active Comparator|Treatment B (fed)|Treatment B: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
89643772|NCT03425292|Experimental|4 Nivo-Ipi-CCNU-TMZ|Nivolumab plus Ipilimumab plus Lomustine (CCNU) plus 5-day Temozolomide
89643773|NCT03425292|Experimental|5 Nivo-Ipi-TMZ|Nivolumab plus Ipilimumab plus 5-day Temozolomide
89643774|NCT03425292|Experimental|6 Nivo-Ipi-Bev-TMZ|Nivolumab plus Ipilimumab plus Bevacizumab plus 5-day Temozolomide
89643775|NCT00596271|Active Comparator|IC51 and Placebo|6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
89643776|NCT00596271|Active Comparator|HAVRIX and placebo|HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
89643777|NCT00596271|Active Comparator|IC51 and HAVRIX|IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)
89643778|NCT03139656|Experimental|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
89643779|NCT03139656|Experimental|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
89643780|NCT03139656|Experimental|Combined (Values Clarification & Planning)|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
89643781|NCT02320227|Experimental|Miami w/o frag Personal lubricant|Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
89643782|NCT03139422|Active Comparator|Tranexamic Acid|Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles
89643783|NCT03139422|Experimental|Calcium Dobesilate|Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.
89643784|NCT01428661|Experimental|tasimelteon|
89643785|NCT01428661|Placebo Comparator|placebo|
89643786|NCT05168670|Experimental|Study arm|Protection of eyes with tinted soft scleral eye shields followed by IPL administration directly on eyelids
89643787|NCT01799577||Gynecologist|Gynecologist can use laparoscopic surgery.
89643788|NCT02721381|Experimental|Self-Directed Group|Participants assigned to the self-directed group will receive access to the secure, password-protected, ImPACT Online web-based program for four months. The web application contains 12, self-directed lessons, each of which takes approximately 75 minutes to complete. Participants will be encouraged to complete one lesson per week and to practice the intervention techniques with their child between each lesson. Each lesson consists of a Narrated Slideshow with embedded video clips, a Written Manual, a self-check quiz, short interactive exercises, a Homework Plan, and reflection questions. Participants in the self-directed group may contact project staff via phone or email for assistance with technology-related problems (e.g., difficulty with logins, problems playing video). However, they will receive no assistance or support in learning the intervention from project staff outside of the self-directed web-based program.
89643789|NCT02721381|Experimental|Therapist-Assisted Group|"Participants assigned to the therapist-assisted group will be given access to the ImPACT Online web-based program for four months and will be encouraged to work through the program at the same pace as the self-directed group. Participants will also receive 2, 30-minute remote coaching sessions per week (24 total sessions) via video conferencing software by a trained therapist to assist them in learning the intervention. The first coaching session of the week will involve the coach and participant and will be used to help clarify the content of the relevant lesson and help the participant apply the lesson content to their own child. The second coaching session of the week will involve the coach, participant, and child and will be used to provide the participant with live feedback on their use of the intervention techniques as they practice with their child."
89643790|NCT02721381|No Intervention|Web-Based Information Control Group|Participants assigned to the web-based information control group will be given access the Resources page with links to the same ASD information websites, but will not receive access to other aspect of the ImPACT Online program. This condition will be used to control for participant maturation as well as the potentially confounding effect of having access to autism-related information via the internet.
89643791|NCT05083104||age and sex matched healthy control individuals.|controls divided into groups ,each group match in age and sex with cases
89643792|NCT05083104||mild and severe cases of COVID 19 patients|Covid 19 cases diagnosed by PCR , mild cases have symptoms as fever, dry cough, and diarrhea and severe cases admitted in ICU
89643793|NCT05163600|Experimental|COPD|Diagnosed COPD according to GOLD-guidelines
89643794|NCT05163600|Experimental|Healthy|Age ≥ 18 years Clinically healthy
89643795|NCT05144802|Experimental|group 1 : FreeStyle Libre 2 on right arm and Dexcom G6 on left arm|In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : FreeStyle Libre 2 will be applied on right arm and Dexcom G6 will be applied on left arm.
88991836|NCT03873883|Experimental|2D Dose expansion - EOS100850 and Chemotherapy in TNBC|Dose expansion - EOS100850 and Chemotherapy: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with chemotherapy SOC carboplatin and paclitaxel in patients with TNBC
89057938|NCT04535427|Placebo Comparator|Control|Participants in this arm will receive placebo per day.
88991837|NCT03873883|Experimental|3 EOS100850 in BMK-H participants|Dose expansion - EOS100850 Monotherapy : to evaluate the safety, PD, and antitumor activity of inupadenant as monotherapy at the mono-RP2D in BMK-H participants in 4 disease-specific cohorts: NSCLC; HNSCC; EC; and other forms of cancer
88991838|NCT03868618|Experimental|Genio Therapy|The Genio™ system is an implantable neurostimulation system comprised of one implanted device
88991839|NCT03861676|Experimental|Focal brachytherapy|"Drug: 18F-DCFPyl Other names: PET, PSMA~Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy"
88991840|NCT03848143|Experimental|BOTOX|"Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.~1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).~Each patient will receive 50 U of onabotulinum toxin A."
89643796|NCT05144802|Active Comparator|group 2 : 2 FreeStyle Libre 2 on left arm and Dexcom G6 on right arm|In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : Dexcom G6 will be applied on right arm and FreeStyle Libre 2 will be applied on left arm.
89643797|NCT01428583|Experimental|oxycodone HCl and naltrexone HCl extended-release capsules|
89643798|NCT05125848|Experimental|Hemodialysis Single Group Assignment|All enrolled subjects will be connected to the CM-1500 for monitoring during their hemodialysis session
89643799|NCT00683085|Experimental|Peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.
89643800|NCT05110950|Active Comparator|No suction EBUS-TBNA|In this technique the stylet is slowly removed without any kind of device in order to avoid active suction.
89643801|NCT05110950|Active Comparator|Passive suction through dedicated EBUS-TBNA syringe|After rapid stylet removal, suction is applied through a vacuteiner syringe, without active aspiration.
89643802|NCT05110950|Active Comparator|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|After rapid stylet removal, suction is applied through Cameco syringe pistol, that can apply active suction manually.
89643803|NCT00660543|Experimental|Ferumoxytol|Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.
89643804|NCT00660543|Active Comparator|Gadoteridol|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
89643805|NCT00660543|Active Comparator|Gadoteridol Leakage Corrected|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
89643806|NCT01428193|Experimental|Flutamide, estrace, progesterone|"For flutamide, subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission."
89643807|NCT03864276|Experimental|inhalation anesthesia (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
89643808|NCT03864276|Experimental|Total intravenous anesthesia (propofol) group|Anesthesia is induced and maintained with propofol and sufentanil
89643809|NCT01428115||Patients with severe active Crohn's disease|Patients with severe active Crohn's disease for whom adalimumab was prescribed in the usual manner in accordance with the terms of the local marketing authorization.
89643810|NCT05082792|Other|doppler US for native AVF in upper limb|creation of native arteriovenous fistula in upper limb in chronic kidney disease patients on hemodialysis
89643811|NCT03141918|Experimental|Curcumin group 1|Intervention will be with intake of curcumin, 1000mg per 30 days
89643812|NCT03141918|Placebo Comparator|Curcumin group 2|Intervention will be with placebo intake of curcumin, 1000mg per 30 days
89643813|NCT01427803|Experimental|Arm 1|
89643814|NCT04973202||Inpatients for alcohol detoxifications|French patients who were hospitalized for alcohol detoxification from 2011 to 2020
89643815|NCT01408537|Experimental|JEVAC|JEVAC 0.5 mL/ dose subcutaneously injected on upper thigh at D0, 1-4wk, and 1 year
89643816|NCT03139500|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral doses of JNJ-61803534 or placebo in the fasted or fed state.
89643817|NCT03139500|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-61803534 or placebo over a 14-day period.
89643818|NCT03139500|Experimental|Part 3: Drug-drug Interaction (DDI)|Participants will receive single oral doses of midazolam on Day 1 and Day 16 and will receive JNJ-61803534 daily from Day 3 through Day 16 for 14 days at a dose based on the data from the SAD and MAD part.
89643819|NCT00661479|Experimental|400 µg Brimonidine Tartrate Implant Group B|400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
89643820|NCT00661479|Experimental|200 µg Brimonidine Tartrate Implant Group B|200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
88991841|NCT03836859|Experimental|rhNGF 20μg/mL|rhNGF 20μg/mL eye drop solution, formulation containing L-methionine as excipient.
88991842|NCT03836859|Placebo Comparator|Placebo|Vehicle: formulation containing L-methionine as excipient.
89643821|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group B|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
89643822|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group A|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
89043492|NCT04680429|Experimental|RP7214, Single and multiple doses|"In Part 1 up to 3 cohorts with single ascending doses of RP7214 at 100 mg QD, 200 mg QD and 400 mg QD.~In Part 2 up to 2 cohorts with multiple ascending doses of RP7214 at 200 mg BID, 400 mg BID."
89043493|NCT04680429|Placebo Comparator|Placebo, Single and multiple doses|In Part 1 up to 3 cohorts and in Part 2 up to 2 cohorts with matching placebo to RP7214 tablet
89643823|NCT01408459|Active Comparator|Tomato product|Motivational telephone counseling weekly
89643824|NCT01408459|Placebo Comparator|Control|No Motivation telephone Counseling
89643825|NCT03139110||Control|Patients treated in emergency departments without the presence of a mediator.
89643826|NCT03139110||Mediation|Patients treated in emergency departments with the presence of a mediator.
89043494|NCT02896842|No Intervention|Control Arm|cohort 3: Imatinib through dosage ≥ 1000 ng/ml
89043495|NCT02896842|Active Comparator|Active comparator|Cohort 2 : Imatinib standard dose Imatinib through dosage < 1000 ng/ml
89043496|NCT02896842|Experimental|Experimental arm|Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage < 1000 ng/ml
89043497|NCT04638530|Other|Residents|All residents will participate in the activity
89043498|NCT00559715|Experimental|A|
89043499|NCT00559715|Active Comparator|B|
89043500|NCT02896998|Other|Control group|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
89043501|NCT02896998|Experimental|Intervention|The syndesmotic screw will only be removed in case of symptomatic implants (e.g. implants causing pain or restricted range of motion)
89043502|NCT00559832|No Intervention|Normoxia|Sleeping in normoxia for 14 nights prior to one night at 4500 m
89043503|NCT00559832|Experimental|Hypoxia|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
89043504|NCT02896803|Experimental|Experimental|mFLOX
89043505|NCT02897037|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
89043506|NCT02897037|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
89643827|NCT04476966|Experimental|T test|Test drug (Bladogra)1 extended release tablet contains 25 mg Mirabegron
89643828|NCT04476966|Active Comparator|B reference (first dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (first dose)
89643829|NCT04476966|Active Comparator|B reference (second dose)|Reference drug (Myrbetriq)1 extended release tablet contains 25 mg Mirabegron (second dose)
89643830|NCT00661557|Experimental|Mencevax Primed Group|Subjects who were previously vaccinated with meningococcal vaccine Mencevax ACWY in study NCT00227422 received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
89643831|NCT00661557|Active Comparator|Mencevax Naive Group|Subjects who did not receive (or had not received in the preceding 10 years) any meningococcal vaccination received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
89643832|NCT01408303|Placebo Comparator|Olive Oil|olive oil: 4 g/day + prescription statin
89643833|NCT01408303|Experimental|Epanova, 2 g|omega-3-carboxylic acids, 2g/day + prescription statin
89643834|NCT01408303|Experimental|Epanova, 4 g|omega-3-carboxylic acids, 4g/day + prescription statin
89643835|NCT00597675|Placebo Comparator|Placebo|Oat flour ingested daily as a placebo
89643836|NCT00597675|Active Comparator|Peanut OIT|Peanut flour ingested daily as oral mucosal immunotherapy
89043507|NCT00559871|Placebo Comparator|1|One placebo tablet administered tid from Day 1 to 28
89643837|NCT03821610|Active Comparator|Fludarabine / Melphalan / Alemtuzumab|Day -7 Fludarabine 30mg/m2 od IV Day -6 Fludarabine 30mg/m2 od IV Day -5 Fludarabine 30mg/m2 od IV Day -4 Fludarabine 30mg/m2 od IV Day -3 Fludarabine 30mg/m2 od IV Day -2 Melphalan 140mg/m2 od IV, Alemtuzumab 20 mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells
89643838|NCT03821610|Experimental|Cyclophosphamide / TBI (8Gy)|Day -6 Cyclophosphamide 50 mg/kg od IV , Mesna 20 mg/kg od IV, Mesna 76mg/kg od IV Day -5 Cyclophosphamide 50 mg/kg od IV, Mesna 20 mg/kg od IV, Mesna 76 mg/kg od IV Day -4 Rest Day -3 TBI (2Gy) bd Day -2 TBI (2Gy) bd, Alemtuzumab 20mg od IV (unrelated transplants only) Day -1 Alemtuzumab 20mg od IV Day 0 Infusion of sibling or unrelated donor peripheral blood stem cells or bone marrow
89643839|NCT01408147|Active Comparator|Treatment Group|This group will be allowed access to an online weight loss program. The program is designed to help low income women lose weight through lifestyle intervention.
89643840|NCT01408147|No Intervention|Standard WIC care|The control group will received Standard Care as provided through WIC.
89643841|NCT01407367||Phase I and Phase II|"Phase I (First 100 participants):~Medical alert bracelet/necklace, Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs~Phase II (Next 250 participants):~Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs"
89643842|NCT00683163|Active Comparator|A: 6 months both + 18 months oral only|Group A will receive 6 months of monthly oral ibandronate 150 mg, plus daily PTH 1-84, 1.4 mg; followed by 18 months of ibandronate only. Placebo injections will be given months 13-15. Calcium + Vitamin D supplements, plus multivitamins are provided.
89643843|NCT00683163|Active Comparator|B: (3 months injection + 9 months oral) x 2 years|Group B will receive 3 months of daily PTH 1-84, 1.4 mg; followed by 9 months of monthly oral ibandronate, 150 mg in year 1. In year 2, the group will receive another 3 months of daily PTH 1-84; followed by 9 months of monthly ibandronate. Placebo monthly pills will be given months 1-3 and months 13-15, and placebo injections will be given months 4-6. Calcium + Vitamin D supplements, plus multivitamins are provided.
89643844|NCT04044001|Experimental|Stage 1 - Cohort 1 (BTZ 250)|Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14
89643845|NCT04044001|Experimental|Stage 1 - Cohort 2 (BTZ 500)|Patients will receive 2 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (500 mg in total) from Day 1 through to Day 14
89643846|NCT04044001|Experimental|Stage 1 - Cohort 3 (BTZ 750)|Patients will receive 3 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (750 mg in total) from Day 1 through to Day 14
89643847|NCT04044001|Experimental|Stage 1 - Cohort 4 (BTZ 1000)|Patients will receive 4 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1000 mg in total) from Day 1 through to Day 14
89643848|NCT04044001|Experimental|Stage 1 - Cohort 5 (BTZ 1250)|Patients will receive 5 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1250 mg in total) from Day 1 through to Day 14
89643849|NCT04044001|Experimental|Stage 1 - Cohort 6 (BTZ 1500)|Patients will receive 6 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1500 mg in total) from Day 1 through to Day 14
89643850|NCT04044001|Experimental|Stage 1 - Cohort 7 (BTZ 1750)|Patients will receive 7 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1750 mg in total) from Day 1 through to Day 14
89643851|NCT04044001|Experimental|Stage 1 - Cohort 8 (BTZ 2000)|Patients will receive 8 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (2000 total) from Day 1 through to Day 14
89643852|NCT04044001|Experimental|Stage 2 - Arm 1 (BTZ high)|Patients will receive a higher dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
89643853|NCT04044001|Experimental|Stage 2 - Arm 2 (BTZ medium)|Patients will receive a medium dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
89643854|NCT04044001|Experimental|Stage 2 - Arm 3 (BTZ low)|Patients will receive a lower dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
88991843|NCT03809364|Experimental|START Together|Couples randomized to START Together will receive the manualized treatment to enhance women's medication adherence. The treatment is 5 sessions in length and conducted weekly. Sessions are 60 - 75 minutes. Couples have the option of completing up to 3 additional booster sessions. Total treatment therefore ranges between 5 to 8 sessions.
88991844|NCT03809364|No Intervention|Standard of Care (SOC)|Couples randomized to SOC will receive referrals to local HIV clinics to support medication adherence (for women) or other HIV-related issues (for men).
88991845|NCT03790800|Experimental|Intervention group|If systolic blood pressure>180:IV Urapidil 25mg If systolic blood pressure>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)
88991846|NCT03790800|No Intervention|control group|To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is >220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.
88991847|NCT03788369||Multivessel coronary artery disease|must include left anterior descending artery
88991848|NCT03787628|Active Comparator|Cannabidiol (CBD) 600 mg|Thirty participants who meet all eligibility criteria will be randomized to receive CBD (ATL5; Ananda Scientific) at a dose of 600 mg.
88991849|NCT03787628|Placebo Comparator|Placebo|Thirty participants who meet all eligibility criteria will be randomized to receive placebo.
88991850|NCT03719833||1-control group-T1-T2 N0 M0|"Breast cancer patients in T1 N0 M0 stage at the time of diagnosis who initially undergo surgical treatment (quadrantectomy/mastectomy + sentinel lymph node biopsy).~All patients will be followed for 5 years after surgery"
88991851|NCT03719833||2-T2-T3 N0 M0|"Breast cancer patients in the T2-T3 N0 M0 stage at the time of diagnosis who undergo neoadjuvant oncological treatment followed by surgery (quadrantectomy/mastectomy + sentinel lymph node biopsy). For the presence of any residual tumour in lymph node(s) at the final pathology report, ALND will be performed.~All patients will be followed for 5 years after surgery"
88991852|NCT03719833||3-T1-T3 N1-N2 M0|"Breast cancer patients in T1-T3 N1-N2 M0 stage at the time of diagnosis who undergo neoadjuvant oncological treatment followed by ultrasound reevaluation of axillary lymph nodes that indicate complete clinical axillary remission. The surgical procedure that would be performed is quadrantectomy/mastectomy + sentinel lymph node biopsy.~Before initiating neoadjuvant treatment biopsy (FNA) proven positive node will be marked with a titanium clip and at the time of surgery removed and pathologically examined regardless presenting as a sentinel node or not.~For the presence of any residual tumour in lymph node(s) at the final pathology report, ALND will be performed All patients will be followed for 5 years after surgery"
88991853|NCT03707574||Ancillary-correlative (genetic analysis)|Patients undergo collection of blood and tumor prior to starting treatment and upon disease progression (second collection of blood and tumor only for patients who do not continue to progress and achieve either an OR or SD after 6 months of treatment). Samples are banked and analyzed via next generation sequencing.
89043508|NCT00559871|Active Comparator|2|One 30-mg tablet of Fipamezole tid from Day 1 to 28
89043509|NCT00559871|Active Comparator|3|One 30-mg tablet of Fipamezole tid from Day 1 to 7; and one 60-mg tablet of Fipamezole tid from Day 8 to 28
89043510|NCT00559871|Active Comparator|4|One 30-mg tablet of Fipamezole tid from Day 1 to 7; one 60-mg tablet of Fipamezole tid from Day 8 to 14; and one 90-mg tablet of Fipamezole tid from Day 15 to 28
89212563|NCT00876746|Active Comparator|2. Infraclavicular|Patients will be randomized to placement of a nerve block in the infraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
89643855|NCT04044001|Active Comparator|Stage 2 - Arm 4 (control)|"Patients will receive a standard dose of Rifafour e-275® orally once daily according to body weight from Day 1 through to Day 14. Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.~The daily doses will be given to fasting patients, in accordance with South African Guidelines for treatment of TB. The total number of tablets will be based on the body weight at screening:~participants weighing 38 - 54 kg: 3 tablets~participants weighing 55 - 70 kg: 4 tablets~participants weighing >70 kg: 5 tablets"
89643856|NCT00684723|Experimental|Lovastatin 40 mg Tablet|A single dose of Lovastatin 40 mg administered under fed conditions.
89643857|NCT00684723|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered under fed conditions.
89643858|NCT00598689|Experimental|Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive 0.3% hypromellose ophthalmic solution prior to surgery.
89643859|NCT00598689|No Intervention|No Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive no intervention of 0.3% hypromellose ophthalmic solution prior to surgery
89643860|NCT01405027|Other|Group A - HCEE|Group A - CLDF Hepatology Centers of Educational Expertise (HCEE) are hepatologists experienced in educating health professionals about current developments in the management of chronic liver disease and with clinical trial experience using an HCV protease inhibitor. HCEE investigators provided patient education and management skills training during four (4) educational interventions to Community Site investigators.
89643861|NCT01405027|Other|Group B - Community Sites|Group B - community physicians treating HCV but without clinical trial experience with an HCV protease inhibitor received patient education and management skills training from Hepatology Centers of Educational Expertise (HCEEs) during four (4) educational interventions.
89643862|NCT00663039|Experimental|Oxytocin, then Placebo|Participants first received 24IU of Oxytocin administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received placebo.
89643863|NCT00663039|Experimental|Placebo, then Oxytocin|Participants first received a placebo (saline nasal spray) administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received Oxytocin.
89643864|NCT04387539|Active Comparator|Non-Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian non-cirrhotic experienced HCV GT4 participants for 12 weeks
89643865|NCT04387539|Active Comparator|Cirrhotic|SOF plus DCV/SMV/RBV regimen was administered to Egyptian cirrhotic experienced HCV GT4 participants for 12 weeks
89643866|NCT01412801|Experimental|HIVneg|HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of Group B streptococcus vaccine.
89643867|NCT01412801|Experimental|HIVposCD4HIGH|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count >350 cells/µL received one dose of Group B streptococcus vaccine.
89643868|NCT01412801|Experimental|HIVposCD4LOW|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but > 50 cells/µL received one dose of Group B streptococcus vaccine
89643869|NCT00663819|Active Comparator|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
89643870|NCT00663819|Other|Procedure/Surgery|Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement
89643871|NCT00664755|Experimental|Varenicline|Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
89643872|NCT00664755|Active Comparator|Transdermal Nicotine Patch|Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
89643873|NCT01525628|Experimental|Group A|Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
89643874|NCT01525628|Experimental|Group B|Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
89643875|NCT01525628|Experimental|Group C|Effect of Dual oral DAAs on tenofovir
89643876|NCT01525628|Experimental|Group D|Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
89643877|NCT01525628|Experimental|Group E|Effect of BI 201335 and BI 207127 on raltegravir
89212564|NCT03894813|Experimental|Probiotics and Metronidazole|Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
89212565|NCT03894813|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories(1 suppositories,qd,7 days )
89643878|NCT01412021||Humira|Participants with juvenile idiopathic arthritis who received Humira (adalimumab).
89643879|NCT04387383|Experimental|Acupuncture group|Electro-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
89212566|NCT04001361|Sham Comparator|Sham|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser inserted into knee joint but not turned on.
89212567|NCT04001361|Experimental|Laser Only|Under conscience sedation, a nick in the skin is made to mimic marrow aspiration. Laser fiber is inserted into knee over an 18 gauge needle and micro-channels are made into the damaged cartilage.
89643880|NCT04387383|Placebo Comparator|sham-acupuncture group|Sham-acupuncture will be conducted for 2 sessions per week over 6 consecutive weeks. Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
89643881|NCT01426789|Experimental|Secukinumab|10 mg/kg intravenous (I.V.)
89643882|NCT01426789|Placebo Comparator|Placebo|Placebo I.V.
89643883|NCT03141294|Placebo Comparator|sd-PDT group|The investigators applied the traditional standard dilation technique when operating tracheostomy on the standard group.
89643884|NCT03141294|Experimental|re-PDT group|The investigators applied the reformative dilation technique when operating tracheostomy on the re-PDT group.
89643885|NCT02320695|Placebo Comparator|Saline|0.9% Sodium Chloride Saline Solution (0.3 cc)
89643886|NCT02320695|Placebo Comparator|Isopropyl Alcohol|70% Isopropyl Alcohol (0.3 cc)
89643887|NCT02320695|Experimental|Pain Relieving Cream|Neosporin® Plus Pain Relieving Cream formula with pH balance technology (0.3 cc)
89643888|NCT02320695|Experimental|Antibiotic/Pain Relieving Ointment|Neosporin® Complete First Aid Antibiotic/Pain Relieving Ointment (0.3 cc)
89643889|NCT02320695|Experimental|Original Ointment|Neosporin® Original Ointment (0.3 cc)
89643890|NCT02320695|Experimental|Pain Relief Ointment|Neosporin® Plus Pain relief Ointment (0.3 cc)
89643891|NCT03632850||Doctors|This is a group of oncologists who have experience in treatment deliberations with patients of advanced cancer.
89643892|NCT03632850||Nurses|This is a group of clinical nurse specialists who have experience in treatment deliberations with patients of advanced cancer
89643893|NCT03632850||Patients|this is a group of adult patients who have been diagnosed with advanced pancreatic cancer
89643894|NCT03632850||Relatives|this is a group of adults who are involved in providing support for their loved ones who are diagnosed with advanced pancreatic cancer
89643895|NCT02078557|Experimental|MK-8892|Starting dose of 1 mg daily (oral); the dose may be titrated up on the 8th, 15th, and 22nd day of treatment to 2 mg, 3 mg, or 4 mg, respectively, for the duration of the study (28 days) as tolerated. For participants who reach one or more of the down-dosing criteria, there is an opportunity to decrease the dose back to a previously well-tolerated dose level, or to ½ of the starting dose.
89643896|NCT03554226|Experimental|AD Patients with NeuroPsychiatric Inventory Clinician (NPI-C)|The investigation aims to study the natural evolution of type A / A SPCDs in patients with AD. In this study, patients will receive optimized management based on existing best practice recommendations (HAS Recommendations 2009). It will therefore be a standard care study, since this survey applies the current recommendations on tools for the evaluation of SPCDs and the management of behavioral disorders in Alzheimer's disease (Recommendations HAS 2009).
89643897|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 via nebulizer (eFlow®)
89643898|NCT01426009|Active Comparator|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium bromide via (Spiriva® Handihaler®)
89643899|NCT01426009|Active Comparator|Ipratropium bromide Inhalation Solution|Ipratropium bromide Inhalation Solution via Handihaler® DPI
89643900|NCT01426009|Placebo Comparator|Placebo EP-101|Placebo
89643901|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 via nebulizer (eFlow®)
89643902|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 via nebulizer (eFlow®)
89043511|NCT02896920||Participants receiving adalimumab/ Humira®|Participants with HS for whom a change in treatment to Humira® is made by the treating physician
89643903|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 via nebulizer (eFlow®)
89643904|NCT00685659|Active Comparator|TAU only|Control condition that consists of treatment as usual, which is Intensive Outpatient Treatment (about 3 months long)
89643905|NCT00685659|Experimental|TMAC only|Adaptive telephone-based counseling
89643906|NCT00685659|Experimental|TMAC plus|Adaptive telephone-based counseling, plus incentives
89043512|NCT00559910|Experimental|PH-797804|PH-797804 at four dose levels
89643907|NCT01411319|Experimental|LEAD Radiation Therapy|Participants in this group will receive the LEAD Radiation Therapy on Day 1 followed by 38 daily standard IMRT beginning Day 2.
89643908|NCT03538860|Other|Method A first then Method B|Conventional in-person interview with a psychiatrist with a live human interpreter with crossover to asynchronous telepsychiatry
89643909|NCT03538860|Other|Method B first then Method A|Asynchronous telepsychiatry - that is, video-recorded interviews that are subsequently processed with automated speech recognition and machine translation technologies, with crossover to conventional in-person interview with a psychiatrist with a live human interpreter
89643910|NCT01543958|Experimental|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
89643911|NCT03537222||MyPOS|
89043513|NCT00559910|Placebo Comparator|Placebo|Placebo
89043514|NCT04680624|Other|Single Group|
89043515|NCT04638608|Other|EMBRACE (Relatives)|Feasibility test of a new palliative rehabilitation blended learning program for relatives of people with ALS/cognitive impairments
89043516|NCT04638608|Other|EMBRACE (Health care providers)|Feasibility test of a new palliative rehabilitation blended learning program health care providers helping people with ALS/cognitive impairments
89043517|NCT00553683|Experimental|poly ICLC|
89043518|NCT04638179||HF-PAC|(1) The experimental group is a patient who was managed by the NHIA 's acute post-care plan. Provide interdisciplinary comprehensive care in accordance with the norms and conduct health education during hospitalization. Hospitalized Chinese pharmacists, dietitians, physiotherapists and case managers participate in health education and will continue to be interviewed and have heart consultations within six months of discharge.
89043519|NCT04638179||HF-non PAC|(2)The control group received traditional health education in general care and routine health care.
89043520|NCT01229176|Experimental|Vi-CRM, Adults|Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine
89043521|NCT01229176|Active Comparator|Vi-PS, Adults|Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine
89643912|NCT04054895|Experimental|Physiological pacing|"Pacing the his-purkinje system.~Crossover to biventricular CRT will be allowed in the following situations: failed physiological pacing lead implantation; high thresholds (>3.5V / 1ms); no shortening of QRS (shortening <20%) or failure to meet non-selective HBP criteria [Europace. 2019 Oct 9. doi: 10.1093/europace/euz275]."
89643913|NCT04054895|Active Comparator|Biventricular resynchronization therapy|"Pacing from the right ventricular and coronary sinus leads. Electrocardiographic optimization with fusion-optimized intervals.~Crossover from biventricular CRT to physiological pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
89643914|NCT04880928|Experimental|injection solution|Mydrane, Tropicamid 0,02%, Phenylephrine 0,31%, Lidocain 1%, injection solution
89643915|NCT04880928|Active Comparator|Standard eye Drops|Phenylephrine 10% and Tropicamid 0,5% eye drops
89643916|NCT03496038|Experimental|Leukocyte and Platelet Rich Fibrin (L-PRF)|"For the test group the sub-sinus cavity will be filled with Leukocyte en Platelet Rich Fibrin (L-PRF).~Before starting the surgery, 8 tubes (9 ml) of venous blood will be collected from the patients. A centrifugation standard L-PRF protocol will be followed followed (12 minutes centrifugation, 2700 rpm/408g RCF).~After full centrifugation of the tubes, the L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA)."
89643917|NCT03496038|Active Comparator|Deproteinized Bovine Bone Mineral (DBBM)|For the test group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland).
89643918|NCT01411085|Experimental|Risperidone + Desipramine|All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated. The target dose of oral risperidone is 4mg though variations are allowed. The target dose of desipramine is 100mg.
89643919|NCT01543490|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
89643920|NCT01543490|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
89643921|NCT01404949|Experimental|Tretinoin and Arsenic Trioxide|This is a multicenter, phase II trial to study the efficacy of combined tretinoin and ATO in the treatment of newly diagnosed APL in an effort to reduce or eliminate the amount of standard chemotherapy required for long-term remission.
89643922|NCT03273816|No Intervention|Patients without sessions of sophrology|The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
89643923|NCT03273816|Experimental|Patients with sessions of sophrology|The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
89643924|NCT04758780|Experimental|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
89643925|NCT01431521|Experimental|MK-4074|Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
89643926|NCT01431521|Placebo Comparator|Placebo for MK-4074|Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
89643927|NCT01431521|Experimental|Pioglitazone|Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
89643928|NCT01431521|Placebo Comparator|Placebo for pioglitazone|Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
89643929|NCT04877652||ADHF patients|Patients with acute decompensated heart failure (ADHF) having insufficient response to diuretic therapy following a dose escalation protocol in keeping with AHA guidelines for the management of heart failure.
89643930|NCT04855188|Experimental|YVOIRE Y-Solution 540|
89643931|NCT04855188|Active Comparator|YVOIRE volume plus|
89643932|NCT05393856|Experimental|fed state in PART B|
89643933|NCT05393856|Experimental|fasted state in PART B|
89643934|NCT00601731|Experimental|Adjuvanted MenACWY vaccine group|Blood test
89043522|NCT01229176|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
89643935|NCT00601731|Active Comparator|Non-adjuvanted MenACWY vaccine group|Blood test
89643936|NCT04759326|Active Comparator|Hippotherapy treated group|The hippotherapy protocol will comprise three cycles. The first one consists of one session per day for 2 weeks allowing (i) to evaluate the patient and his neuro-functional skills, and (ii) to determine and carry out the treatment taking into account the silent barriers that may exist (PSTD, fatigue, pain, fear...) and strongly interfere with functional outcome (developing ways to overcome them). After a 9-week 'wash out' period (during which the patient consolidates the new patterns, translates them into daily activities and identifies new needs) where the patient continues his or her outpatient neurorehabilitation care, a further intermediate 1-week daily capacity building hippotherapy cycle follows. Then, after a second 9-week 'wash out' period (where the patient once again consolidates the new patterns, translates them into daily activities and identifies new needs), a final 1-week daily capacity building hippotherapy cycle will be carried out. Protocol will last 22 weeks.
89643937|NCT04759326|Placebo Comparator|Conventional neurorehabilitation treated group|Patients in the control group will receive standard outpatient rehabilitation treatment consisting of a program of physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support per week corresponding to the four weeks in which the treated group will be in hippotherapy. For the remaining 18 weeks, the treatment options for each patient, regardless of the group, will also include physiotherapy (motor training, functional training), occupational therapy, language therapy, psychological and social support.
89643938|NCT00601965|Experimental|CBT/Escitalopram|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
89043523|NCT01229176|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
89043524|NCT01229176|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
89043525|NCT01229176|Active Comparator|PNC13, Older infants|Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
89043526|NCT01229176|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
89043527|NCT01229176|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
89043528|NCT02896686|Active Comparator|Control|Abdominal wall closure will be done by continuous polydioxanone (PDS) suture following a SL:WL ratio of 4:1, and the skin will be closed using a subcutaneous purse-string closure
89043529|NCT02896686|Experimental|Reinforcement with Mesh|"Abdominal wall closure will be done by continous polydioxanone (PDS) suture following a SL:WL ratio of 4:1.~The incision is reinforced with onlay placement of a light polypropylene mesh (3 cm wide and the length corresponding to the incision), fixed to the aponeurosis with interrupted polyglactin (Vycril) suture.~The skin will be closed using a subcutaneous purse-string closure"
89043530|NCT04638101|Experimental|Intervention group (RCT)|Participants from the intervention group participated in the mindfulness-based intervention between Time 1 and Time 2.
89643939|NCT00601965|Active Comparator|No CBT/escitalopram|12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.
89643940|NCT00601965|Placebo Comparator|CBT/placebo|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
89643941|NCT00601965|Placebo Comparator|No CBT/placebo|"12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo~12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks."
89643942|NCT05393778|Experimental|Measured Technique|Patients in this group will have pre-operative planning done using the measured technique.
89643943|NCT05393778|Experimental|Navigated Technique|Patients in this group will have pre-operative planning done using the navigated technique.
89643944|NCT04751994|Experimental|Iron supplement/ ferrous sulphate syrup|administration of daily iron drops, 7.5mg/day iron as ferrous sulphate
89643945|NCT04751994|Placebo Comparator|supplement with placebo|administration of daily placebo drops
89643946|NCT05393700|Experimental|AOT-sleep|They will be asked to watch video-clips representing motor contents before sleeping.
89643947|NCT05393700|Active Comparator|AOT-control|They will be asked to watch video-clips representing motor contents at least 12 hours before sleeping.
89643948|NCT05393700|Sham Comparator|Control|They will be asked to watch video-clips representing landscapes before sleeping.
89643949|NCT00602043|Experimental|Diagnostic (FES)|Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.
89643950|NCT02998437|Experimental|Ilaprazole 10mg|"Period 1: Ilaprazole 10mg 1 tab.m one a day~Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day"
89643951|NCT02998437|Active Comparator|Clarithromycin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day"
89643952|NCT02998437|Active Comparator|Amoxicillin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day"
89043531|NCT04638101|Experimental|Waiting group (RCT)|Participants from the waiting group took part in the mindfulness-based intervention between Time 2 and Time 3.
89043532|NCT01228747|Placebo Comparator|Placebo|Matching placebo for 28 weeks
89043533|NCT01228747|Experimental|Levetiracetam|Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks
89043534|NCT02896413|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
89043535|NCT02896413|Placebo Comparator|Control Group|0.9% saline infusion
89043536|NCT01228591|Other|Acuvue Advance Plus/ Acuvue Advance|Acuvue Advance Plus contact lenses worn first period and Acuvue Advance contact lenses worn second.
89043537|NCT01228591|Other|Acuvue Advance/Acuvue Advance Plus|Acuvue Advance contact lenses worn first period and Acuvue Advance Plus contact lenses worn second.
89043538|NCT02896374|Experimental|Patients|Treated or hospitalized patients for schizophrenia.
89043539|NCT02896374|Experimental|Control|No schizophrenic participants, comparable to schizophrenia patients in age, gender, education level and socio premorbid verbal IQ.
89043540|NCT04638140||Healthy hip population|
89043541|NCT04638140||Hip defect population|
89043542|NCT00553722|Experimental|Eplerenone|Administer Eplerenone, 25 mg, orally twice daily for 4 weeks.
89043543|NCT00553722|Placebo Comparator|placebo|Administer a placebo tablet orally twice daily for 4 weeks
89043544|NCT01235338|Experimental|LDX (SPD489) + Venlafaxine XR (Effexor XR)|
89043545|NCT01235338|Experimental|Venlafaxine XR + LDX|
89043546|NCT04638296||Physicians|surgeons, anesthesiologists, and surgical residents
89043547|NCT04638296||Nurses|OR Nurses
89043548|NCT02896491|Experimental|GSM 900 MHz exposure|Radiation: Exposure with non-ionizing electromagnetic fields exposure with GSM 900 MHz (2W/kg)
89057939|NCT04535427|Experimental|Low dose L-arginine|Participants in this arm will receive 9g (3g tid) L-arginine per day.
89643953|NCT02618148|Experimental|ESTROGEN HERBALS 21|"Used for women who wish to monthly menstruation~Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
89643954|NCT02618148|Experimental|ESTROGEN HERBALS 28|"Used for women who do not wish to monthly menstruation~Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
89643955|NCT02998281|Active Comparator|Treatment Group|The treatment group received Inspiratory muscle training (IMT) at 40% of maximal mouth pressure (PImax) by using Threshold IMT and training loads were adjusted to maintain 40% of the PImax weekly. The PImax was measured at supervised sessions each week, and 40% of the measured value was determined as the new training work load.
89643956|NCT02998281|Sham Comparator|Control Group|The control group received sham Inspiratory muscle training (IMT) at a fixed work load, 5% of PImax by using Threshold IMT.
89643957|NCT02998359|Active Comparator|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
89643958|NCT02998359|Active Comparator|Total hip replacment|A cemented polished double taper stem arthroplasty inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
88991854|NCT03704207|Other|Nasal Nitric Oxide testing and collection of clinical data|Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data
88991855|NCT03696680|Experimental|FSRT Stereotactic radiation therapy|Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
88991856|NCT03675152|Experimental|Soft spinal brace|Soft spinal brace used 23 hours a day for 4 months.
88991857|NCT03675152|Active Comparator|thoracolumbar orthosis|Thoracolumbar orthosis used 23 hours a day for 4 months.
88991858|NCT03665285|Experimental|NC318 8mg|Phase 1 Dose Escalation (Cohort -1): Subjects received NC318 IV at 8mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991859|NCT03665285|Experimental|NC318 24mg|Phase 1 Dose Escalation (Cohort 1): Subjects received NC318 IV at 24mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
89643959|NCT04692714|Experimental|Experimental knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented without additional cement using the MAKO robot
89643960|NCT04692714|Active Comparator|Conventional knee prosthesis implantation|Patients included in this arm will have a total knee arthroplasty using a Triathlon prosthesis by STRYKER implemented with additional cement using the MAKO robot
89643961|NCT04683588|Experimental|intervention arm|"Polyclinic: Pre-tests (pain, anxiety, self-care and daily living activities), General coaching, 60 minutes~Before Surgery: Nursing coaching, 30-45 minutes~Surgery Day: Nursing coaching, 30-45 minutes~Postoperative 1st Day: Nursing coaching, 30-45 minutes~Postoperative 2nd Day: Nursing coaching practice, 30-45 minutes~Day of discharge: Nursing coaching, 30-45 minutes.~15 days after discharge: Nursing coaching, 60 minutes~45 days after the operation: Nursing coaching, 60 minutes.~90 days after surgery: Nursing coaching, 60 minutes."
89643962|NCT04683588|No Intervention|Control arm|Patients in the control group will receive routine postoperative nursing care.
89643963|NCT03140124|Other|Group 1|First session: worry stone, second session: exercise peddler
89643964|NCT03140124|Other|Group 2|First session: exercise peddler, second session: worry stone
88991860|NCT03665285|Experimental|NC318 80mg|Phase 1 Dose Escalation/Safety Expansion (Cohort 2): Subjects received NC318 IV at 80mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991861|NCT03665285|Experimental|NC318 240mg|Phase 1 Dose Escalation/Safety Expansion (Cohort 3): Subjects received NC318 IV at 240mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
89043549|NCT02896491|Experimental|TETRA 400 MHz exposure|"Radiation: Exposure with non-ionizing electromagnetic fields:~exposure with TETRA (6W/kg)"
89043550|NCT02896491|Sham Comparator|Sham exposure|Radiation: Exposure with non-ionizing electromagnetic fields: exposure with 0 W/kg
89043551|NCT01234675|Experimental|milnacipran|Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo
89643965|NCT04680936|Active Comparator|low dose dextrose arm (5% dextrose)|Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
89643966|NCT04680936|Active Comparator|high dose dextrose arm (15% dextrose)|Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
89043552|NCT01234675|Placebo Comparator|placebo|Drug: placebo 45-day placebo treatment before or after crossover to milnacipran
89043553|NCT02895984|Experimental|Brief Motivational Intervention (BMI)|The intervention recipients in the BMI group will receive a 1-hour single-session alcohol intervention (BMI) with personalized normative feedback.
89043554|NCT02895984|No Intervention|Natural History Control (NHC)|Students in the NHC group will receive no contact.
89043555|NCT04638452|Other|Epidemiology|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test Passing self and hetero questionnaires of temotion felt and perceived.
89043556|NCT02896101|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1 % (Glenmark Pharmaceuticals Ltd) topical application
88991862|NCT03665285|Experimental|NC318 400mg|Phase 1 Dose Escalation/Safety Expansion (Cohort 4): Subjects received NC318 IV at 400mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991863|NCT03665285|Experimental|NC318 800mg|Phase 1 Dose Escalation (Cohort 5): Subjects received NC318 IV at 800mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991864|NCT03665285|Experimental|NC318 1600mg|Phase 1 Dose Escalation (Cohort 6): Subjects received NC318 IV at 1600mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991865|NCT03665285|Experimental|Dose Expansion: 400mg Q2W|Phase 2 Dose Expansion (400mg): Subjects received NC318 IV at 400mg Q2W until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
88991866|NCT03665285|Experimental|Dose Expansion: 800mg QW|Phase 2 Dose Expansion (800mg): Subjects received NC318 IV at 800mg QW for 8 weeks, then Q2W thereafter until disease progression, withdraw of consent, or intolerable toxicity (whichever comes first).
89643967|NCT04680936|Active Comparator|Isotonic saline arm (0.9% NaCl)|Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
89643968|NCT05393544|Experimental|Intervention|The intervention utilizes an existing care coordination smartphone app to allow participants to engage with a recovery coach during and after an inpatient admission to an inpatient withdrawal management facility (i.e. detox).
88991867|NCT03654807|Experimental|High Intensity Walking|HIW (70-80% HRmax)
88991868|NCT03654807|Experimental|Casual Speed Walking|Self selected pace
89643969|NCT03140046|Experimental|Corneal Topography|we will do Corneal Topography for every patient before doing photorefractive keratectomy (PRK) and also after it , to measure the change in the quality of vision and measure the change in the quality of vision
89643970|NCT01404325|Experimental|Quadruple low level IS regimen|quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids
89643971|NCT01404325|Experimental|Centre specific triple IS regimen|centre specific CNI-based triple drug immunosuppression (IS)
89643972|NCT04407559||Groupe 1|Group 1: Rheumatoid arthritis seropositive for RF (+)
89643973|NCT04407559||Groupe 2|Group 2: Rheumatoid arthritis seronegative for RF (-)
89643974|NCT00602355|Placebo Comparator|1 (Placebo)|Participants receiving placebo pill with clinical management plus mothercrafting
88991869|NCT03647592||Cohorts 1|patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab
88991870|NCT03647111||Cohorts 1|
88991871|NCT03647098||Cohorts 1|Treatment plan
88991872|NCT03647098||Cohorts 2|brain metastases
88991873|NCT03647098||Cohorts 3|Concomitant KRAS mutation
88991874|NCT03646994||Cohorts 1|ROS1 fusion positive NSCLC patients who received crizotinib
88991875|NCT03646968|Experimental|Cohorts|Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
88991876|NCT03637660|Active Comparator|1|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly on Day 1, n=280
88991877|NCT03637660|Experimental|2|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly weekly for three successive weeks, n=280
88991878|NCT03631992|Experimental|Low Sweet|"Children in intervention group will be provided with daily snacks lower in added sugar and sweetness and their mothers will receive educational lessons on dental care, reading food labels, and nutrition that support the goals of reducing sweet exposure and added sugar intake."
88991879|NCT03631992|Sham Comparator|Regular Sweet|Children in the regular sweet control group will be provided with common snacks fed to children of this age and mothers will be given education lessons on portion size, physical activity, sleep, screen time and, at the end of the trial, dental care.
88991880|NCT03631290|Experimental|Deprescribing Intervention|
88991881|NCT03601806|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88991882|NCT03589924|Experimental|One step method|Immediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
89643975|NCT00602355|Active Comparator|2 (Sertraline)|Participants receiving active medication sertraline with clinical management plus mothercrafting
89643976|NCT00602355|Active Comparator|3 (IPT)|Participants receiving interpersonal psychotherapy (IPT) alone
89643977|NCT01425463|Experimental|Ferrous (II) Glycine Sulphate Complex|Ferrous (II) Glycine Sulphate Complex treatment with 567.7 mg three times a day (t.i.d.) for 12 weeks plus Placebo to Polyferose.
89643978|NCT01425463|Active Comparator|Polyferose|Polyferose treatment with 150 mg twice daily (b.i.d) for 12 weeks plus Placebo to Ferrous (II) Glycine Sulphate Complex.
89643979|NCT02144259|Active Comparator|DMPA group|Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.
89643980|NCT02144259|Active Comparator|Implanon group|Subjects randomized to receive Implanon immediately post-partum.
89643981|NCT02144259|No Intervention|Control group|Subjects selecting their own method of contraception or no contraception.
89643982|NCT04655586|Experimental|rNAPc2 Higher Dose|loading dose of 7.5 μg/kg SC on Day 1 followed by 5 μg/kg SC on Days 3 and 5
89643983|NCT04655586|Experimental|rNAPc2 Lower Dose|loading dose of 5 ug/kg SC on Day 1 followed by 3 ug/kg SC on Days 3 and 5
89643984|NCT04655586|Active Comparator|Heparin|heparin at either prophylactic or therapeutic doses per Standard of Care at Institution
89643985|NCT00689091|Experimental|BIS group|This group will have BIS values visible and will receive alerts when the value is >60.
88991883|NCT03589924|Active Comparator|Two step method|Immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
88991884|NCT03579394|Active Comparator|Interval Debulking Surgery (IDS)|Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)
89643986|NCT00689091|Active Comparator|MAC Alert|This group will receive an alert if total MAC (including intravenous infusions) is <0.5 age-adjusted.
89643987|NCT05082246|Other|Pre- and Post- Intervention|Data will be gathered in participants with pre-intervention and post-intervention comparison.
89643988|NCT04629690|No Intervention|Control Arm|The control group will obtain usual medical care in the Emergency Department and Acute Medical Assessment Unit
89643989|NCT04629690|Experimental|SOLAR arm|The SOLAR arm will obtain a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.
89643990|NCT05393154||Study Participant|Non-destructive imaging of biopsies using the Aquyre system
89643991|NCT05392998||Vivity patients|"The study will include patients >40 years old that undergo routine cataract surgery and implantation of Vivity ®. Exclusion criteria include corneal astigmatism ≥1.0 diopters (D ), amblyopia, previous ocular surgery and presence of ocular pathologies and abnormal iris. Patients with intra- or postoperative complications, with a postoperative best distance corrected visual acuity (BDCVA) < 20/20 and with postoperative refractive astigmatism > 0.50D will be also excluded .~Inclusion and exclusion criteria will be assessed by an ophthalmologic examination including refraction, screening for ocular conditions and/or systemic diseases, slit-lamp biomicroscopy and fundus examination."
89643992|NCT03141216|Experimental|VCV+PSV|volume controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
89643993|NCT03141216|Experimental|PCV+PSV|pressure controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
89643994|NCT01388647|Experimental|Eribulin, carboplatin, and trastuzumab|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
89643995|NCT03141138|Experimental|Group 1: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
89643996|NCT03141138|Experimental|Group 1: TDENV-LAV F17 on Day 180|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
89643997|NCT03141138|Experimental|Group 2: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
89643998|NCT03141138|Experimental|Group 2:TDENV-LAV F17 on Day 90|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
89643999|NCT03140982|Active Comparator|GR fast induction|propofol TCI effect site mode infusion using the PK Marsh model ke0 1,21 min-1 target 5.4 ug/ml (LOC EC95) util loss of consciousness (LOC) After LOC we maintain initial target during 10 min without intervention, except respiratory support if required.
89644000|NCT03140982|Active Comparator|GL slow induction|propofol infused at 10 mg/kg/h with CeCALC PK Marsh model ke0 1,21 min-1 same PK model After LOC we maintain the CeCALC observed al LOC during 10 min without intervention, except respiratory support if it was required.
89644001|NCT05392686|Experimental|Experimental: PD1 + PARP|"For the Induction Phase, participants receive 4 cycles:~PD1 200 mg, intravenous (IV) on Day 1 of each 21-day cycle PLUS carboplatin PLUS a taxane (either paclitaxel or nab-paclitaxel) for 4 cycles (21-day cycles). If the participant has a complete or partial response or stable disease to induction therapy, the participant to maintenance therapy.~For the Maintenance Phase, participants receive PD1 IV on Day 1 of each 21-day for up to 31 cycles PLUS maintenance oral PARP 100 mg twice daily. Until centrally verified progressive disease, physician decision or intolerable toxicity."
89644002|NCT05082168||Respiratory tract infection|Patients diagnosed with viral or bacterial pneumonia and admitted to ICU for mechanical ventilatory support
89644003|NCT05082168||Sepsis|Patients diagnosed with sepsis and admitted to ICU for mechanical ventilatory support
89644004|NCT05082168||Cardiac surgery|Patients admitted to ICU for mechanical ventilatory support following cardiac surgery
89644005|NCT00603291|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
89644006|NCT00603291|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
89644007|NCT00603291|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
89644008|NCT03140202|Experimental|Guide then blind|This group use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible) first, then have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask).
88991885|NCT03579394|Experimental|Retarded Interval Debulking Surgery (IDS)|Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)
88991886|NCT03538275||Unipolar depression cohort|Subjects with a known Dx of unipolar depression.
88991887|NCT03538275||Bipolar depression cohort|Subjects with a known Dx of bipolar disorder
88991888|NCT03538275||Healthy Control cohort|Subjects with no known unipolar or bipolar Dx.
88991889|NCT03534141|Experimental|Mild hypothermia & Esophageal cooling/warming device|The target core temperature is 34-35 °C.
88991890|NCT03534141|Active Comparator|Normothermia & Esophageal cooling/warming device|The target core temperature is 36.5-37.5 °C.
88991891|NCT03524612|Other|eltrombopag|Participants were treated with eltrombopag to induce sustained response off treatment to reach a target platelet count of >=100×10^9/L (CR), after 1st line steroids had failed.
88991892|NCT03519178|Experimental|Dose Escalation|Single Agent Dose Escalation
88991893|NCT03519178|Experimental|Dose Finding Endocrine Therapy 1 Combination|Part 1B PF-06873600 plus Endocrine Therapy 1
88991894|NCT03519178|Experimental|Dose Finding Endocrine Therapy 2 Combination|Part 1B PF-06873600 plus Endocrine Therapy 2
89644009|NCT03140202|Experimental|Blind then guide|This group have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask) first then use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible).
89644010|NCT03110796|Experimental|LU3103209 Dose 1|Dressing with LU3103209 Dose 1
89644011|NCT03110796|Experimental|LU3103209 Dose 2|Dressing with LU3103209 Dose 2
89644012|NCT03110796|Placebo Comparator|No LU3103209|Dressing without LU3103209
89644013|NCT00705003|Experimental|Active Drug Combination|BCI-024: over-encapsulated Buspirone tablet 15 mg at bedtime(QD) and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
89644014|NCT00705003|Active Comparator|BCI-024 (Buspirone)|BCI-024: over-encapsulated Buspirone 15 mg QD
89644015|NCT00705003|Placebo Comparator|Matching placebo|Placebo: 1 capsule QD
89644016|NCT05081856|Experimental|intervention group|The group mobilized for at least 20 minutes 6 times a day with a modular medical equipment carrying vehicle
89644017|NCT05081856|No Intervention|control group|The group mobilized for at least 20 minutes 6 times a day with a routin practice
89644018|NCT03110718|Experimental|ArmeoP+real MV|The patients underwent forty 1h Armeo-P training sessions (i.e. five times a week for eight consecutive weeks). During the first session, the device was adjusted to the patient's arm size and the angle of suspension. The working space and the exercises were selected once the UL had been fitted with the system. All the subjects in the arm received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air, wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude so that it was just below the threshold for perceiving an illusory movement. The investigators chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
89644019|NCT03110718|Active Comparator|ArmeoP+ Sham MV|"The patients underwent the same Armeo-P trainingas the experimental group. Only the vibration protocol was didderent. Indeed, in the control group a sham vibration was used, while in the experimental group, patients underwent a real one.~Sham vibration was delivered to the control group using the same procedure of the experimental group;however, vibration intensity was subthreshold (i.e. 50mBar below the threshold)."
89644020|NCT00690339|Experimental|1|Augmentation
89644021|NCT00690339|Experimental|2|Reconstruction
89644022|NCT00690339|Experimental|3|Revision-augmentation
89644023|NCT00690339|Experimental|4|Revision-reconstruction
89644024|NCT03110640|Experimental|CD9CAR-T transfer|All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T
89644025|NCT04368936||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 1-14 years
89644026|NCT04368936||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
89644027|NCT04368936||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
89644028|NCT04368936||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
89644029|NCT04368936||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed Epilepsia
89644030|NCT04368936||EFS: group of individuals with Epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
89644031|NCT00690495|Experimental|1|Modified propofol (Propofol 0.5%)
89644032|NCT00690495|Active Comparator|2|Propofol 1%
89644033|NCT04273386|Experimental|Evaluation|Cases will be evaluated for oral health and data will be recorded.
89644034|NCT00691197|Experimental|Carboxymethylcellulose sodium and Glycerin|Carboxymethylcellulose sodium and Glycerin based rewetting drop
89644035|NCT00691197|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium based rewetting drop
89644036|NCT02997969|Active Comparator|Group 1: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6. All injections are via needle and syringe.
89644037|NCT02997969|Active Comparator|Group 2: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, and 6. They will receive placebo in both deltoids at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6. All injections are via needle and syringe.
89644038|NCT02997969|Placebo Comparator|Group 3: Placebo|Participants will receive placebo in both deltoids at months 0, 1, 3, and 6. All injections are via needle and syringe.
89644039|NCT02997969|Active Comparator|Group 4: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine via Biojector in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6, via needle and syringe.
89644040|NCT02997969|Active Comparator|Group 5: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine at months 0, 1, and 6, and placebo at month 3, in the left deltoid via Biojector. They will receive placebo at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6, in the right deltoid via needle and syringe.
89644041|NCT02997969|Placebo Comparator|Group 6: Placebo|Participants will receive placebo in the left deltoid via Biojector, and in the right deltoid via needle and syringe, at months 0, 1, 3, and 6.
89644042|NCT04351230|Active Comparator|Arm A (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88991895|NCT03519178|Experimental|Dose Expansion Arm A|PF-06873600 as a Single Agent
89043557|NCT02896101|Active Comparator|Elidel®|Elidel® (Valeant Pharmaceuticals North America LLC) topical application
89043558|NCT02896101|Placebo Comparator|Placebo|Placebo of Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) topical application
89644043|NCT04351230|Experimental|Arm B (trastuzumab emtansine, abemaciclib)|Patients receive trastuzumab emtansine IV over 90 minutes on day 1 and abemaciclib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89644044|NCT02997891||intervention group|Patients with primary, unilateral hip osteoarthritis in inpatient orthopedic acute treatment, who have a medical indication of a necessary artificial hip replacement implantation.
89644045|NCT02997891||control group|Volunteers without chronic pain. As a control condition for comparing the variation in cognitive performance and everyday activity the investigators use a group of pain-free and mobility-unrestricted subjects, who do not receive or have an artificial hip.
89644046|NCT02997813||Cohort 1|All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor
89644047|NCT02997813||Cohort 2|All consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide
89644048|NCT00713427|Other|WallFlex Stent|All patients meeting eligibility criteria recieve the WallFlex™ Biliary Partially-Covered Stent, which has regulatory clearance in the areas in which the study is being conducted.
89644049|NCT04186650|Experimental|Autologous genetically modified tissue-engineered skin graft|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
89644050|NCT04175184|Experimental|Experimental group|"Exercise programme: 2-3 sets of 10-15 repetitions of shoulder girdle and glenohumeral strengthening exercises performed in different positions in addition to three stretching exercises.~Mobilisation with movement (MWM): the participant and physiotherapist will decide one movement more functionally relevant to the patient. Afterwards, attempts of MWM will be applied to different joints in order to identify one particular MWM that improves significantly the movement previously selected. Then, one set of six to ten repetitions will be applied. This process of pragmatically using MWM will be conducted in every session, but from the second session onwards, two to three sets of ten repetitions will be applied, with an interval of sixty seconds between sets. In case of failure to identify an MWM that improves the movement significantly, the patient decides which one seemed to be best and one set of six repetitions will be applied to the onset of discomfort."
89644051|NCT04175184|Sham Comparator|Placebo group|"The exercise programme is exactly the same as the experimental group.~Sham MWM: the participant and physiotherapist will decide together one movement that is more functionally relevant to the patient. Afterwards, a sham MWM (Delgado-Gil et al 2015) will be applied and the movement previously selected will be repeated six times in the first consultation. The participant will be informed that he/she should move to the onset of symptoms, if they occur.This process will be conducted in every session, but from the second session onwards, two to three sets of 10 repetitions will be applied, with an interval of sixty seconds between sets. In case the sham MWM failed to improve the movement significantly, one set of six repetitions will be applied only."
89644052|NCT02991105||Solid organ transplant recipients|National cohort = 85,410 solid organ transplant recipients receiving their transplant between January 1st 1985 to December 31st 2015
89644053|NCT02991183|Experimental|Acceptance and Commitment Therapy|Two half day (2.5 hours) group ACT sessions delivered one week apart followed by a third session 2 weeks following the second session.
89644054|NCT05392218|Experimental|motivational interviewing|
89644055|NCT05392218|Sham Comparator|attention group|
89644056|NCT04028388|Active Comparator|Docetaxel IV|This study arm will receive docetaxel at 75 mg/m2 given i.v. as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily.
89644057|NCT04028388|Experimental|ModraDoc006/r|This cohort will receive ModraDoc006/r 30 mg oral docetaxel in combination with 200 mg ritonavir in the morning and 20 mg oral docetaxel in combination with 100 mg ritonavir in the evening (7-12 hours after the morning dose), on Day 1, 8 and 15 of a 21-day cycle, plus 5 mg oral prednisone twice daily.
89644058|NCT04216056|Experimental|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI >=25 kg/m2, and/or waist circumference >=90 cm (male) or >=80 cm (female) during the 12-week study period.
89644059|NCT04216056|No Intervention|Control group|Subjects in the control group will be asked to maintain their usual diet and physical activity patterns over the 12 weeks.
89644060|NCT04205760|No Intervention|Control group|Standard Care as per local guidelines
89644061|NCT04205760|Experimental|Intervention|Oral nutrition support (ONS) and bed-cycling before surgery
89644062|NCT01402063|Experimental|radiation plus PPX(CT2103|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ intravenous PPX every week x 6 weeks for a total of 6 treatments"
89644063|NCT01402063|Active Comparator|radiation + Temozolomide|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days"
89644064|NCT05392140|Experimental|intervention group.|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
89043559|NCT04637789|Other|controlled group|
89043560|NCT04637789|Experimental|experimental group|
89043561|NCT04638218|Experimental|Augmented Reality|The system provides visual and audio feedback which makes the rehabilitation training process more relaxing, interesting and convenient to guide the patients performing appropriate upper-limb, lower-limb exercises and balance training.
89043562|NCT02896062|Experimental|Treatment group|In the treatment phase subjects receive a sleep-coaching
89057940|NCT04535427|Experimental|High dose L-arginine|Participants in this arm will receive 15g (5g tid) L-arginine per day.
89644065|NCT05392140|Active Comparator|non-intervention group|standard care practice will continue
89644066|NCT05392062|Other|Respiratory insufficiency|Subject with respiratory insufficiency
89644067|NCT01796301|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
89644068|NCT01796301|Active Comparator|Teriparatide|Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.
89644069|NCT03361410|Experimental|Grape Powder|
89644070|NCT03361410|Placebo Comparator|Placebo Powder|
89644071|NCT04118790||Minor Stroke patients|"Clinical Assessment~MRI scan session"
89644072|NCT04118790||TIA patients|"Clinical Assessment~MRI scan session"
89644073|NCT04118790||Healthy Controls|MRI scan session
89644074|NCT04095936|Experimental|AMG531|
89644075|NCT00868179|Experimental|Pradax|This is the only arm in the study and all will follow the same protocol for the study which is taking the pradax after total knee replacement
89644076|NCT01204905|Experimental|Open Label ART|Patients received raltegravir 400 mg PO BID and maraviroc 300 mg PO BID in combination for 48 weeks.
89644077|NCT03137940|Experimental|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator. The anode electrode is placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode is placed in the supraorbital region (SO) of the contralateral hemisphere.
89644078|NCT03137940|Sham Comparator|Sham tDCS|one-shot of sham tDCS session with BrainStim Stimulator (20 minutes). The montage of the electrodes will be placed as in the experimental session i.e.the anode electrode will be placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode in the supraorbital region (SO) of the contralateral hemisphere.
89043563|NCT02896062|Active Comparator|Waiting group control|The waiting group receives the treatment after a waiting period of up to 6 weeks
89043564|NCT04638257|Experimental|Lactobacilli|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14 Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14
89043565|NCT04638257|Placebo Comparator|Placebo|Receives placebo
89043566|NCT02896179|Experimental|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
89043567|NCT02896179|Active Comparator|Robot-assisted gait training group|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
89043568|NCT04637906|Experimental|L-arginine|Bioarginina®, 2 orally administered vials per day
89043569|NCT04637906|Placebo Comparator|Placebo|2 orally administered vials per day of Bioarginina® without L-arginine
89043570|NCT02896023|Active Comparator|pregnant|women with positive pregnancy test after induction of ovulation and ICSI
89043571|NCT02896023|Active Comparator|Not pregnant|women with negative pregnancy test after induction of ovulation and ICSI
89043572|NCT04637750|Experimental|Educational intervention|Randomised GPs will receive the low cost informative intervention composed by a practitioner-focused letter plus leaflet for patients
89043573|NCT04637750|No Intervention|Control group|GPs not receiving any informative intervention
89043574|NCT02896140||Type 2 diabetes in WhyWAIT Program|Patients with type 2 diabetes who are participating in Joslin Diabetes Center's 12-week intensive diabetes weight management program (WhyWAIT).
89043575|NCT04637633|Experimental|Cyclosporine A|All patients were treated with topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California) on twice daily dose, in addition to the topical preservative free artificial tears Q.I. D.
89644079|NCT03137706||Ancillary-correlative (tissue stiffness analysis)|Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.
89644080|NCT00691665|Experimental|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
89644081|NCT00691665|Active Comparator|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
89644082|NCT01388335|Experimental|warfarin + enzastaurin|"On Day 1 of Period 1, a single 5-milligram (mg) oral dose of warfarin will be given, followed by at least a 7-day washout.~Period 2: 500 mg enzastaurin administered orally once daily for at least 19 consecutive days and 5 mg warfarin administered as a single oral dose on Day 15.~Safety Extension: Participants are allowed to continue receiving enzastaurin alone until disease progression or other discontinuation criteria are met."
89644083|NCT03402282|Experimental|embolization|upper rectal artery embolization
89644084|NCT03402282|Active Comparator|surgical treatment|surgical repair through the classic technique (Milligan and Morgan technique)
89644085|NCT00713583|Experimental|Levodopa pharmacotherapy|Levodopa pharmacotherapy (800mg levodopa and 200mg carbidopa per day), cognitive behavioral therapy (CBT), and contingency management (CM).
89644086|NCT00713583|Placebo Comparator|Placebo|Placebo, cognitive behavioral therapy (CBT), and contingency management (CM).
89057941|NCT05138367|Experimental|UCA-PSC|Subsequent to isolation and culture of UCA-PSCs, UCA-PSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the National Institute for China Food and Drug Control) were injected into the ovaries of patients with hormone replacement treatment, which consisted of Premarin (0.625 mg/days on days 1 through 25) combined with Provera (10 mg/day for 10 days a month with monthly withdrawal bleeding).
89644087|NCT03359460|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
89644088|NCT03025243|Experimental|50 micron|surgical guide constructed with 3D printing with printing layer thickness 50 micron
89644089|NCT03025243|Active Comparator|100 micron|surgical guide constructed with 3D printing with printing layer thickness 100 micron
89644090|NCT00692211|Experimental|Arm 1: Fecal Immunochemical Tests|Mailed fecal immunochemical tests
89644091|NCT00692211|Experimental|Arm 2: Fecal Occult Blood Tests|Mailed fecal occult blood tests
89644092|NCT03025477|Active Comparator|Control arm|"Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.~The regimen of administration of the chemotherapy is as following:~Carboplatin AUC 6 - IV - Day (D) 1~Paclitaxel 80mg / m² - IV - D1, D8, D15~one cycle every 3 weeks"
89644093|NCT03025477|Experimental|Experimental arm|"Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.~Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.~Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.~The regimen of administration of the chemotherapy is as following:~Cisplatin 80mg / m² - IV or IP - D1~Epirubicin 60mg / m² - IV - D3~one Cycle every 3 weeks."
89644094|NCT03356652|Experimental|Tailor-made CRT delivery|Patient undergoes acute noninvasive electrical dyssynchrony study with various CRT configurations. CRT device is then implanted with optimal configuration.
89644095|NCT03025711||Pertuzumab|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
89644096|NCT03025711||Trastuzumab emtansine|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
89644097|NCT05391594|Experimental|Single Subject Design|The investigators will use a longitudinal design with baseline, immediate and post-intervention data collections. The intervention will include customized posture support in seated, standing or walking devices that will be used in the child's educational setting or home (for early intervention) to facilitate specific educational activities.
89644098|NCT03025321|Experimental|transcranial direct current stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for five consecutive days.
89644099|NCT03025321|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
89644100|NCT03147378|Experimental|arm A Fasting-Fed condition|ModraDoc006/r will be administered in fasting condition week 1 and in fed condition week 2
89644101|NCT03147378|Experimental|arm B Fed-Fasting condition|ModraDoc006/r will be administered in fed condition week 1 and in fasting condition week 2
89644102|NCT04466137|Experimental|YPEG-rhG-CSF 2mg|YPEG-rhG-CSF 2mg
89644103|NCT04466137|Experimental|YPEG-rhG-CSF 33μg/kg|YPEG-rhG-CSF 33μg/kg
89644104|NCT04466137|Active Comparator|Positive Control Group|rhG-CSF/PEG-rhG-CSF
89644105|NCT00713661|Experimental|TachoSil®|
89644106|NCT00159744|Active Comparator|Arm 1|Asenapine
89644107|NCT00159744|Active Comparator|Arm 2|Olanzapine
89043576|NCT02896218||Pharmacist consulting group|When physicians make the decision that patients need to prescribe vancomycin or need dose adjustment, they will call for a pharmacist consultation. Pharmacists will provide the initial regimen based on PPK methods if applicable, otherwise give the suggestion of the initial dosage according to guidelines. Also, pharmacists will give suggestions on the time of sampling for serum concentration measurement. For dosage adjustment, pharmacists will be informed the results of serum vancomycin concentration, and then make a calculation using Bayesian estimation to determine whether there is a necessity to change the dosing regimen. Pharmacists will follow the patients until they discharge.
89043577|NCT02896218||Usual care group|Empirical use of vancomycin without pharmacists consultation.
89644108|NCT00159744|Placebo Comparator|Arm 3|Placebo
89644109|NCT03125304|Experimental|treatment group|Treatment group will receive acupuncture at Sanyinjiao (SP 6), Zhaohai (KI 6) ,Taichong (LR 3) ,Qichong (ST 30) and Guanyuan.
89644110|NCT03125304|Placebo Comparator|control group|Control group will receive acupuncture at non-acupoints.
89644111|NCT01401361|Experimental|Treatment Arm|Atrial Flutter RF Ablation treatment with the Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement.
89644112|NCT03948516||Participants tested for Sickle cell disease|
89644113|NCT01401283|Active Comparator|Study group|intraoperative guidance of hemodynamics by measures of cardiac index and pulse pressure variation, measurement of cardiac output and pulse pressure variation, hemodynamic optimization according to cardiac index and pulse pressure variation
89644114|NCT01401283|No Intervention|Control group|hemodynamic management according to institutional clinical standards
89644115|NCT00693303|Experimental|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
89644116|NCT02914470|Experimental|carbo, cyclo, atezolizumab|The starting dose is carboplatin AUC 5mg/ml*min (d1), cyclophosphamide 600mg/m2(d1) and atezolizumab 840 mg (D1, 15), all administered intravenously
89644117|NCT00694473|Experimental|Freestyle Navigator|Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
89644118|NCT05383950|Experimental|smartphone application based 12-week pulmonary or cardiac rehabilitation|
89644119|NCT03137628||patients undergoing colectomy, GA and MV|venous blood samples collected from colorectal cancer patients undergoing selective colectomy with general anesthesia(GA) and mechanical ventilation(MV) before general anethesia and the third hour after
89644120|NCT03137628||healthy controls|donated venous blood samples from healthy people undergoing physical examination but not general anesthesia or mechanical ventilation.
89644121|NCT00856479|Active Comparator|1 Infuse|The patient will receive BMP 2 with allograft
89644122|NCT00856479|Active Comparator|2 Iliac crest autograft|Autograft from Patients Iliac Crest and allograft
89644123|NCT02409654|Active Comparator|Individualized stroke prevention|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
89644124|NCT02409654|Placebo Comparator|Routine Care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
89644125|NCT02990871||early rehabilitation|Patients started rehabilitative treatment during ICU hospitalization
89644126|NCT02990871||no-early rehabilitation|Patients started rehabilitative treatment after admission in Neuro-rehabilitation department
89644127|NCT05088330|Experimental|D-VRD|treatment with D-VRD in NDMM
89644128|NCT04387149||CSA-AKI|Patients that developed cardiac surgery-associated Acute Kidney Injury
89644129|NCT04387149||non CSA-AKI|Patients that did not developed cardiac surgery-associated Acute Kidney Injury
89644130|NCT03750006|Experimental|HIIT intervention|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
89644131|NCT03678324|Other|Fabry|Must be 18 or older and able to have an MRI.
89644132|NCT00695097|Active Comparator|1|Rituximab Group: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15) and followed up monthly for 1 year. Biopsy was done Baseline and Month 3 and other labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing). Physical exam and vital signs were done.
89644133|NCT00695097|Active Comparator|2|No Rituximab: received standard immunosuppression and was followed up monthly for 1 year. Labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing) vital signs, and physical exam was done.
89644134|NCT03139734|Other|Sacral neuromodulation|The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
89644135|NCT02997267|Experimental|Early closure|Closure of the ileostomy 14 days after the primary operation, in which it was created.
89644136|NCT02997267|Active Comparator|Late closure|Closure of the ileostomy more than 90 days after the primary operation, in which it was created.
89644137|NCT03138642|Experimental|RT|The patients are prescribed a EQD2of 65-70Gy to CTV1(high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper neck is is decided by radiation physicians and given a EQD2 of 70-77Gy to CTVnd (clinically negative lymph nodes), 50-55Gy to CTVn2（neck nodal regions). If there is residual tumor, a EQD2 of 70-77Gy is prescribed to GTV.
89644138|NCT01795911|Experimental|Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir|"Pegylated Interferon Lambda 180 μg Solution, Subcutaneous Once weekly for 12 weeks;~Ribasphere 1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg oral tablets per day [subjects should take either 400 mg for subjects < 75 kg or 600 mg ≥ 75 kg in the morning with food and 600 mg in the evening with food] for 12 weeks;~Daclatasvir 60 mg oral tablet Once daily for 12 weeks"
89644139|NCT03138408|Experimental|SC-004|
89644140|NCT03138408|Experimental|SC-004 and ABBV-181|
89644141|NCT03139890|Experimental|High-fat milkshake|
89644142|NCT03139890|Experimental|High-carbohydrate milkshake|
89644143|NCT03139890|Experimental|High-protein milkshake|
89644144|NCT03137238||Early_PD|People with Parkinson's disease in the early stages with low doses of antiparkinsonian medication and no motor fluctuations.
89644145|NCT03137238||Advanced_PD|People with advanced Parkinson's disease with motor fluctuations.
89644146|NCT03137238||Early_controls|Healthy participants matched for age and gender to the 'Early_PD' group.
89644147|NCT03137238||Advanced_controls|Healthy participants matched for age and gender to the 'Advanced_PD' group.
89644148|NCT01422889||ION Registry|The ION Registry population was designed to collect real world safety and clinical outcomes data. There were 1120 subjects were enrolled, however 9 subjects did not receive a study stent therefore 1111 subjects were eligible for follow up.
89644149|NCT03137082|Experimental|Guanfacine XR 3mgs/daily|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
89644150|NCT03137082|Placebo Comparator|Placebo (for guanfacine)|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
89644151|NCT03549468|Experimental|low level tragus stimulation (LLTS)|Patients with ischemic cardiomyopathy (left ventricular ejection fraction <35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).
89644152|NCT01400971||MOSAIc Participants|Participants enrolled in Multinational Observational Study Assessing Insulin use (MOSAIc) who had complete treatment data during the study.
89644153|NCT05230446|Other|Percutaneous Coronary Intervention|Interventional comparitor, compared to an optimal performance goal of 7% MACCE resulted from past CABG results
89644154|NCT05088174|Experimental|D1：hetrombopag single dose，D11-D15：cyclosporine,D16 combination use of hetrombopag and cyclosporine|
89644155|NCT03136614|Active Comparator|Preoperative|A single measurement with an Arteriograph is performed a day before an elective surgical intervention.
88991896|NCT03519178|Experimental|Dose Expansion Arm B|PF-06873600 as a Single Agent in Various Tumor Types
88991897|NCT03519178|Experimental|Dose Expansion Arm C|PF-06873600 in Combination with Endocrine Therapy 1
88991898|NCT03519178|Experimental|Dose Expansion Arm D|PF-06873600 in Combination with Endocrine Therapy 1
88991899|NCT03519178|Experimental|Dose Expansion Arm E|PF-06873600 in Combination with Endocrine Therapy 2
88991900|NCT03512470|Experimental|Sistema Prevena ™ (TVAC)|Negative topical pressure system (Sistema Prevena ™).
89644156|NCT03136614|Active Comparator|Intraoperative|An arteriograph is put on the patient for the time of operation. The device is set to measure in every 5 minutes.
89644157|NCT03136614|Active Comparator|Intensive Care Unit|Three separate measurements are performed on the subject with an Arteriograph throughout every dayshift for 3 days.
89644158|NCT01387789||Scheduled to start adalimumab therapy|Patients diagnosed with rheumatoid arthritis for at least 3 months that previously had not received prior anti-TNF agents.
89644159|NCT03455634|Active Comparator|Twin Block|Twin Block functional appliance
89644160|NCT03455634|Active Comparator|Sander|Sander bite jumping appliance
89644161|NCT03455634|No Intervention|Control|no intervention
89644162|NCT00695409|Experimental|Treatment (RIT, ZBEAM, ASCT)|RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan IV following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8*. NOTE: * Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity.
89644163|NCT03469050|Experimental|Rifaximin delayed released 800 mg b.i.d.|(i.e. 2 x 400 mg tablet twice a day; total daily dose: 1600 mg) for 10 consecutive days a month, for 12 months
89644164|NCT03469050|Experimental|Rifaximin delayed released 400 mg b.i.d|(i.e. 1x400 mg tablet plus 1 placebo tablet twice a day; total daily dose: 800 mg) for 10 consecutive days a month, for 12 months
89644165|NCT03469050|Placebo Comparator|Placebo b.i.d.|(i.e. 2 x placebo tablets twice a day) for 10 consecutive days a month, for 12 months.
89644166|NCT01400893|Experimental|CRRT + SCD|Patients with a diagnosis of AKI requires CRRT will be randomized
89644167|NCT01400893|No Intervention|CRRT alone|Patients with a diagnosis of AKI requires CRRT will be randomized
89644168|NCT03243318||Presence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the presence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
89644169|NCT03243318||absence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the absence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
89644170|NCT01794663|Experimental|OPN-305|
89644171|NCT01794663|Placebo Comparator|Matching placebo|
89644172|NCT05087706||Locally advanced patients with molecular-guided therapy|Locally advanced patient will be assigned to molecularly-guided therapy based on genomic profile.
89644173|NCT05087706||Advanced patients with molecular-guided therapy|Advanced patient will be assigned to molecularly-guided therapy based on genomic profile.
89644174|NCT02990637|Active Comparator|OLECOL|Olive leaf extract
89644175|NCT02990637|Placebo Comparator|Placebo|Maltodextrin
88991901|NCT03512470|Active Comparator|Standard medication|Standard medication with sterile gauzes and a TNT patch or medicated patch
88991902|NCT03495453|Active Comparator|CSI's DIAMONDBACK 360® Peripheral Orbital Atherectomy (OAS)|OAS (using CSI device) followed by Inpact Admiral drug coated balloon (DCB)
88991903|NCT03495453|Active Comparator|Medtronic's Hawkone Directional Atherectomy system (DAS)|DAS (using the Hawkone device) followed by DCB
88991904|NCT03490240|Experimental|BIPAMS|The behavioral intervention consists of two primary components, a dedicated Internet website and one-on-one video chats with a behavioral coach via Skype. The behavioral intervention focuses on the skills, techniques, resources, and strategies for becoming and staying physically active with MS, but it does not provide a prescription for exercise or physical activity itself.
88991905|NCT03490240|Active Comparator|WELLMS|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
88991906|NCT03433183|Experimental|Selumetinib and Sirolimus|A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNSTs. Both agents will be given orally on an empty stomach. Selumetinib will be given orally at a dose of 50mg twice daily continuously. Sirolimus will be given orally at a dose of 4mg once daily with a cycle 1 day 1 loading dose of 12mg. Each cycle will be considered 28 days.
88991907|NCT03427996||Coronary disease|
88991908|NCT03412435||Myocardial infarction|diagnosed as acute myocardial infarction and treated with medical treatment, coronary artery bypass surgery and percutaneous coronary intervention.
88991909|NCT03377881|Other|Standard arm (One testing with PSA and standard biopsy)|The traditional/control arm consists of PSA testing and if PSA>3ng/ml a systematic biopsy of the prostate is performed. Only one screening is offered for participants.
88991910|NCT03377881|Experimental|STHLM3+MRI/Fusion including repeat screening.|The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions. Participants with PSA<1.5ng/ml are reinvented for prescreen after 6 years. Remaining participants with no prostate cancer detected are reinvited for re-screen at 2-3 years.
88991911|NCT03359434|Experimental|Two measuring methods of blood pressure|
88991912|NCT03356236||Observation group 1|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe receive Huaier Granule are as observation group 1
88991913|NCT03356236||Observation group 2|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe not receive Huaier Granule are as observation group 2
88991914|NCT03331341|Experimental|Treatment (APVD)|"PART A: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine IV, and dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive doxorubicin hydrochloride IV, vinblastine IV, dacarbazine IV, and pembrolizumab IV as in part A, but undergo a total of 6 treatment cycles."
88991915|NCT03327064|Active Comparator|Renal Transplant subjects receiving UAB30|Generally healthy renal transplant subjects receive UAB30 for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
89644176|NCT03393936|Experimental|CCT301-59|The safety and efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
89644177|NCT03393936|Experimental|CCT301-38|The safety and efficacy of CCT301-38 will be evaluated for subjects with AXL positive but ROR2 negative biopsy in a standard 3+3 dose escalation approach. 3 CAR T dosage will be tested in this study: 1×10^5/kg, 1×10^6/kg, 1×10^7/kg CAR+ T cells.
89644178|NCT01799733|Active Comparator|LWT+AM BWL|Late-wake therapy in combination with morning bright white light
89644179|NCT01799733|Placebo Comparator|EWT+PM BWL|Early-wake therapy in combination with evening bright white light
89644180|NCT05087316|Active Comparator|Standard treatment|
89644181|NCT05087316|Experimental|Oral Appliance|
89644182|NCT05087160||semester pre pandemia in sub sectors of public health care in Uruguay|all birth in sub sectors of public health care between march 15 and September 30 of 2019, pre pandemia
89644183|NCT05087160||semester pre pandemia in sub sectors of private health care in Uruguay|all birth in sub sectors of private health care between march 15 and September 30 of 2019, pre pandemia
89644184|NCT05087160||semester with mitigation measures against COVID 19 in sub sectors of public health care in Uruguay|all birth in sub sectors of public health care between march 15 and September 30 of 2020, with mitigation measures against COVID- 19
89644185|NCT05087160||semester with mitigation measures against COVID 19 in sub sectors of private health care in Uruguay|all birth in sub sectors of private health care between march 15 and September 30 of 2020, with mitigation measures against COVID- 19
89644186|NCT02990403|Experimental|aspirin+LMWH group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd
89644187|NCT02990403|Experimental|aspirin+LMWH+immunoglobulin group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks
89644188|NCT02990403|Experimental|aspirin+LMWH+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd
89644189|NCT02990403|Experimental|aspirin+LMWH+IVIG+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd
89644190|NCT02990403|Other|dydrogesterone group|dydrogesterone 20-30mg/day, po, tid
89644191|NCT05087004|Experimental|Teen Council Pogram|Teens assigned to the intervention group received a 1-year long Teen Council Program.
89644192|NCT05087004|No Intervention|Control Group|Teens assigned to the control group did not receive any intervention.
89644193|NCT05086926|Experimental|Exercises and CSI|A corticosteroid injection in the lateral hip prior to performing an 8-week home exercise program
89644194|NCT03138174||Diabetes|One group consisting of diabetic subjects
89644195|NCT00697203|Experimental|Dalcetrapib 300mg|
89644196|NCT00697203|Experimental|Dalcetrapib 600mg|
89644197|NCT00697203|Experimental|Dalcetrapib 900mg|
89644198|NCT00697203|Placebo Comparator|Placebo|
89644199|NCT03325842||Cerebral palsy|ASKp will be submitted to children of 5 to 15 years with hemiplegia or diplegia due to Cerebral Palsy, with normal or slightly impaired cognitive level.
89644200|NCT03325842||Healthy individuals|ASKp will be submitted to children of 5 to 15 years with typical development
89644201|NCT05086848|Experimental|Treatment group:|Irinotecan liposome plus 5-fluorouracil, Leucovorin
89644202|NCT03295500||Experimental Group One|In this group ,the participants receive the dose fraction of 49Gy/7f (BED 83.3Gy) by cyberknife.
89644203|NCT03295500||Experimental Group Two|In this group ,the participants receive the dose fraction of 54Gy/6f(BED 102.6Gy) by cyberknife.
89644204|NCT03295500||Control Group|In this group ,the participants receive the dose fraction of 55Gy/5f(115.5Gy) by cyberknife.
89644205|NCT00830895|Experimental|RAD001|RAD001 10mg/day
89644206|NCT03136224|Experimental|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medikal, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
89644207|NCT03136224|Active Comparator|Plastic Clamping|Alisklamp (Alisklamp, Abagrup Health Services Ltd, Ankara, Turkey) was used in the plastic clamp technique. The clamp size was chosen according to the diameter of the penis of the patient. The clamp was inserted into the glans and then the skin and the mucosa were pulled to the appropriate size and clamped. The skin and mucosa were excised from the distal part of the clamp with the aid of a lancet. After the operation, the clamp was removed on the 4th day
89644208|NCT03136224|Sham Comparator|Surgical Circumcision|In classical surgical circumcision, foreskin was hung up with the clamp. The outer skin and secondly the mucosa was cut by using scissors. Following the hemorrhage intervention, the skin-mucosa integrity was sutured by using the 5/0 absorbable suture. Medical dressing was done.
89644209|NCT01158417|Placebo Comparator|Placebo|Placebo tablets
89644210|NCT01158417|Experimental|Resveratrol 40 mg oral three times a day|Resveratrol
89644211|NCT01158417|Experimental|resveratrol 500 mg oral once daily.|Resveratrol
89644212|NCT05086614|Experimental|Thymosin|Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.
89644213|NCT05086614|No Intervention|Observe|Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection.
89043578|NCT04637867|Other|RT-PCR confirmed COVID-19 patients|RT-PCR confirmed patients included in the NOSO-COR study are invited six and 12 months after the initial infection to provide blood (41.5mL in total), salivary and nasopharyngeal samples and to complete a questionnaire. Each visit is expected to take about one hour.
89043579|NCT01228318|Experimental|Zoledronic acid|Subjects in this arm will receive 5 milligram (mg) per 100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
89043580|NCT01228318|Placebo Comparator|Placebo|Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
89043581|NCT02895867|Experimental|Full fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
89043582|NCT02895867|Experimental|Low fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
89644214|NCT00698139|Active Comparator|Intervention first, then control|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, they will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. The rest of the protocol will be as described for the first encounter."
89644215|NCT00698139|Active Comparator|Control first, then intervention|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, the control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The rest of the protocol will be as described for the first encounter."
89644216|NCT00698139|Active Comparator|Intervention Only|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour."
89644217|NCT01400815|Experimental|X-22 Smoking Cessation Product|The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
89644218|NCT01400815|Active Comparator|Active Control Cigarette|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette."
89644219|NCT02990169|Active Comparator|Goldmann Tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
89644220|NCT02990169|Active Comparator|CATS tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
89644221|NCT05086536||early stage decompensation cohort|Patients occurred first decompensated events and initiating nucleoside analogs (NUCs) based treatment within 3 months were retrospectively included.
89644222|NCT02990325|Experimental|ABX464 150mg|ABX464, 50mg per Capsule Three Capsules per day for 28 days
89644223|NCT02990325|Experimental|ABX464 50mg for 28 days|ABX464, 50mg per Capsule One Capsule per day for 28 days
89644224|NCT02990325|Experimental|ABX464 50mg for 84 days|ABX464, 50mg per Capsule One Capsule per day for 84 days
89644225|NCT01793025|Experimental|ATAC Therapy|
89644226|NCT05086458|No Intervention|No intervention|the patients in this arm will not receive probiotics.
89043583|NCT02895867|Other|Control group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
89043584|NCT04637828|Experimental|GNS561 plus standard of care|All patients in this Arm will be treated with 200mg oral capsule of GNS561, once a day, for 10 days and with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
89043585|NCT04637828|No Intervention|standard of care|All patients in this Arm will be treated with any necessary measures based on the patient's condition and at the investigator's discretion and routine practices.
89043586|NCT04206475|Experimental|IM-FTP|rehabilitated over 1-month through IM-FTP, including physio-kinesis/occupational, speech, and neuropsychology treatments
89043587|NCT04206475|Active Comparator|standard rehabilitation|physio-kinesis, occupational, speech, and neuropsychology treatments
89043588|NCT05512624|Experimental|Intervention Arm|The course of Common Elements Treatment Approach (CETA - the intervention under study) is built to be flexible depending on need. Mild symptoms could result in fewer sessions (e.g., 5), while greater severity may require 8-12 sessions.
89043589|NCT05512624|No Intervention|Waitlisted Arm|The waitlisted arm will be offered the CETA approach upon conclusion of the endline data collection.
89043590|NCT02895828|Experimental|Core Stabilization Exercise (CSE)|The participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
89043591|NCT02895828|Experimental|General Strengthening Exercise (GSE)|The participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks.
89043592|NCT02895672||Weekly GLP-1 therapy: exenatide|Patients receiving weekly exenatide
89043593|NCT02895672||Daily GLP-1 therapy liraglutide|Patients receiving daily liraglutide
89043594|NCT04637711|Experimental|Specific surgical Intervention|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery
89043595|NCT04637711|No Intervention|Extensive lesion excision|
89043596|NCT02895516|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
89043597|NCT04637516|Active Comparator|Programme Version 60 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 60 sec"
89644227|NCT05086458|Experimental|Dietary Supplement|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks.
89644228|NCT01795131|Active Comparator|Vitamin B12|Supplementation group (N=60) that will receive 250 µg of vitamin B12 in addition to 60 mg of Fe and 400µg of folate.
89644229|NCT01795131|Placebo Comparator|Placebo|Placebo group (N=60) that will receive placebo tablets and 60 mg of Fe and 400µg of folate daily.
89644230|NCT02990247|Experimental|AMARS|Evaluation the resting ventilatory flow by applying a new technique called anharmonic morphological analysis of the respiratory signals (AMARS).
89644231|NCT03136458|Experimental|Real ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.
89644232|NCT03136458|Active Comparator|Dummy ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.
89644233|NCT02996643|No Intervention|Traditional method|The traditional brace design method will be used to design a spinal brace.
89644234|NCT02996643|Active Comparator|Intervention|A custom Providence brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
89644235|NCT01115283|Experimental|Perceptual learning|Patients will be asked to practice a range of visual discrimination tasks for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for ~1-6 months).
89644236|NCT01115283|Experimental|Occlusion therapy|The fellow sound will be covered with a standard eye patch for a period of time (1-2 hrs/day, 4-5 days/wk for ~1-3 months). The idea is to push the brain to use the weaker amblyopic eye.
89644237|NCT01115283|Experimental|Video game|Patients will be asked to play videogames for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for ~1-6 months).
89644238|NCT03137004|Experimental|biweekly DS|The biweekly DS regimen consisted of Docetaxel (50mg/m2) and S-1 (40mg/m2)
89043598|NCT04637516|Placebo Comparator|Programme Version 300 sec frequency|"This version of the program BlinkBlink has a presentation frequency of 300 sec"
89043599|NCT01227967|Experimental|Combination Therapy|Amantadine, Ribavirin, Oseltamivir
89043600|NCT01227967|Active Comparator|Oseltamivir monotherapy|Oseltamivir
89043601|NCT02895555|Active Comparator|Allograft group, standard treatment|Control group, standard treatment. Aprox 50 g pr level fused.
89043602|NCT02895555|Experimental|i-FACTOR|i-FACTOR putty in the operation site. Fda approved. Aprox 5 ml pr level fused.
89043603|NCT00560144|Experimental|1|
89043604|NCT00560144|Experimental|2|
89043605|NCT00560144|Experimental|3|
89043606|NCT02895477|Experimental|Intervention group|Hearing aid
89043607|NCT02895477|Experimental|Test group|Hearing aid
89043608|NCT04317391|Experimental|Pain management program|All enrolled patients participate in a 20 hour pain management program over a period of 8 weeks. The program is based on Mindfulness Based Stress Reduction with modifications to fulfill needs of the Taiwanese chronic pain population.
89043609|NCT04637477|Experimental|Virtual ELM|
89043610|NCT04637204||Subgroup 1|Patients with index treatment: cabozantinib treatment post vascular endothelial growth factor (VEGF)-targeted therapy in any line, except axitinib.
89644239|NCT00706407|Experimental|Fully integrated Uro-NIRS:UDS|
89644240|NCT03113994|Active Comparator|Rosuvastatin|
89644241|NCT03113994|Placebo Comparator|Placebo|
89644242|NCT00706485|Experimental|Dural brachytherapy plaque|Patients undergoing spine tumor resection will undergo dural plaque brachytherapy.
89644243|NCT02003742|Experimental|NX-1207|Subjects randomised to the NX-1207 group will receive a single NX-1207 (2.5 mg) TRUS-guided intraprostatic injection (under antibiotic prophylaxis), followed by a placebo QD oral treatment for 12 months.
89644244|NCT02003742|Active Comparator|Comparator|Subjects randomised to the comparative arm will undergo TRUS only (under placebo prophylaxis) and will continue the tamsulosin 0.4 mg QD oral treatment for 12 months
89644245|NCT01101555|Experimental|COHORT 1: CUMULATIVE DOSE 1.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 3 days, dose 0.3, 0.5, 0.7, four patients in cohort, one of which is on placebo, escalation increment N/A
89644246|NCT01101555|Experimental|COHORT 2: CUMULATIVE DOSE 3.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.5, 0.7, 1.0, 1.0 four patients in cohort, one of which is on placebo, escalation increment 2.3 fold.
89644247|NCT01101555|Experimental|COHORT 3: CUMULATIVE DOSE 6.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 7 days, dose 0.3, 0.7, 5 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.7 fold.
89644248|NCT01101555|Experimental|COHORT 4: CUMULATIVE DOSE 8.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.7, 1.0, 2 x 3.0 four patients in cohort, one of which is on placebo, escalation increment 1.33 fold.
89644249|NCT01101555|Experimental|COHORT 5: CUMULATIVE DOSE 10MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 10 days, dose 10 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.25 fold.
89644250|NCT01101555|Experimental|COHORT 6: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 15 days, dose 15 x 1.0 six patients in cohort, one of which is on placebo, escalation increment 1.5 fold.
89644251|NCT01101555|Experimental|COHORT 7: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 5 x 3.0 six patients in cohort, one of which is on placebo, escalation increment N/A
89644252|NCT03110016|Experimental|Smartphone Application|SPSRS is a smartphone application system designed to improve self-confidence in individuals with subthreshold depression. The application presents a motion picture that displays words every 5 s for improving self-confidence of the user.
89644253|NCT03134118|Experimental|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
89644254|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will be randomized at different timepoints to receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
89644255|NCT05085912|Experimental|Group A|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
89644256|NCT05085912|Active Comparator|Group B|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation
89644257|NCT05085912|Active Comparator|Group C|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
89644258|NCT02339415|Active Comparator|Treatment|Edoxaban 30mg daily
89644259|NCT02339415|Placebo Comparator|Placebo|Matching Placebo
89644260|NCT05085444|Experimental|Treatment of Scleroderma|Experimental：Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
89644261|NCT02998047|Experimental|IV infusion of Lintuzumab AC225|"Starting dose - 0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle with dose escalation 1 μCi/Kg and 1.5 μCi/Kg or de-escalation to 0.25 μCi/Kg.~1 cycle = 28 days, up to 3 to 8 cycles (depending on the cohort)."
89644262|NCT03110172|Active Comparator|KSS scale|Knee Society Score with Duloxetine Hydrochloride
89644263|NCT03110172|Active Comparator|HAMD-17 scale|Hamilton Depression Score with Duloxetine Hydrochloride
89644264|NCT03110172|Active Comparator|SF-36 scale|Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride
89644265|NCT03110172|Active Comparator|WOMAC scale|Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride
89644266|NCT02964546||Blood sample|
89644267|NCT00706563|Experimental|Fluarix Adult Group|Subjects who are 18-40 years of age received one dose of Fluarix™.
89644268|NCT00706563|Experimental|Fluarix Elderly Group|Subjects who are ≥ 60 years of age received one dose of Fluarix™.
89644269|NCT05084898|Active Comparator|Intervention|Far-UVC light as an additional method of disinfection
89644270|NCT05084898|Placebo Comparator|Placebo|"Inactive fluorescent light (no additional disinfection)"
89644271|NCT05084820|Experimental|Action observation treatment|Action observation treatment
89043611|NCT04637204||Subgroup 2|Patients with index treatment: axitinib treatment post VEGF-targeted therapy in any line, except cabozantinib.
89644272|NCT05084820|Active Comparator|conventional treatment|conventional treatment
89644273|NCT01400503|Experimental|Siltuximab|Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.
89644274|NCT05082324|Experimental|adapted physical activity|
89644275|NCT00706719|Experimental|25 mg Androxal no wash out|1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
89644276|NCT00706719|Active Comparator|Testim 1% (topical testosterone)|Testim 1% Gel applied topically for 6 months
89043612|NCT04637204||Subgroup 3|Patients with index treatment: cabozantinib treatment post axitinib by line of therapy (2L, 3L, 3L+)
89043613|NCT04637204||Subgroup 4|Patients with index treatment: axitinib treatment post cabozantinib by line of therapy (2L, 3L, 3L+)
89043614|NCT02895633|Experimental|Patients with bone or peripheral soft-tissue tumor|
89043615|NCT04637126||mechanically ventilated and sedated patients with sinus rhythm|all mechanically ventilated and sedated patients with sinus rhythm hospitalized in our ICU and fitted with an hemodynamic monitoring by thermodilution technique due to hemodynamic failure
89043616|NCT01227928|Experimental|pazopanib|experimental medication
89043617|NCT01227928|Placebo Comparator|placebo|placebo comparator
89043618|NCT02895438|Experimental|gluten|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
89644277|NCT00706719|Experimental|25 mg Androxal wash out|1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone
89644278|NCT05079672|Active Comparator|Group Dexmedetomidine|The patient will receive Dexmedetomidine, at the rate of 0,3μg/ kg/h, in continuous intravenous infusion from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
89644279|NCT05079672|Placebo Comparator|Group 0,9% Saline|The patient will receive a 0,9% saline, in continuous intravenous infusion, from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
89644280|NCT03138018|Active Comparator|Standard instruction|
89644281|NCT03138018|Experimental|Reduced threat instruction|
89644282|NCT01400425|Experimental|Subjects with Progressive Cognitive Decline|Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.
89644283|NCT03137862|Placebo Comparator|Arm A comparator|Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
89644284|NCT03137862|Experimental|Arm B|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of gluten friendly bread daily for 12 weeks."
89644285|NCT03137862|Experimental|Arm C|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
89644286|NCT02996331|Active Comparator|2 hour arm|All participants in this arm are assigned a 2-hour repositioning interval.
89644287|NCT02996331|Experimental|3 hour arm|All participants in this arm are assigned a 3-hour repositioning interval.
89644288|NCT02996331|Experimental|4 hour arm|All participants in this arm are assigned a 4-hour repositioning interval.
89644289|NCT04766827|Experimental|albumin-bound paclitaxel combined with cisplatin (AP regimen)|Paclitaxel (albumin combined type) 260 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; Cisplatin: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles;
89644290|NCT04766827|Active Comparator|docetaxel combined with cisplatin (TP regimen)|docetaxel: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; cisplatin: 75 mg/m2, d1 every three weeks for a cycle, a total of dosing 2 cycles;
89644291|NCT02960568|Experimental|Primaquine|Poor and Intermediate Metabolizers will receive 30 mg oral primaquine (PQ) and have peripheral blood draws over a 24-hour period to measure PQ pharmacokinetics
89644292|NCT02960568|No Intervention|No primaquine|Extensive and Ultra Metabolizers will not be eligible for the pharmacokinetic portion of the study and participation will be complete after receiving genotype information
89644293|NCT02996175|Experimental|SMART|"Treatment group targeting behavioral sleep problems for 5 weeks.~Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~Information on healthy sleep hygiene, preventative techniques, and use of visual supports~Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~Information on procedures for delayed sleep onset and problematic sleep associations~Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
89644294|NCT02996175|Active Comparator|WISE|Standard of care sleep treatment enhanced with psychoeducation. 1 Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome 2 Introduction to understanding and interpreting results from clinical evaluations 3 Introduction to educational planning, expectations, and transition planning 4 Introduction to lifespan development and advocacy and support services available 5 Feedback on current concerns and methods for obtaining services to manage concerns
89644295|NCT02948790|Experimental|Neuristim|Electrical stimulation with the Neuristim and auditory nerve electrical response measurements (wave V).
89644296|NCT02948790|Active Comparator|Digisonic SP EVO cochlear implant|Electrical stimulation with the patient's cochlear implant and auditory nerve electrical response measurements (wave V).
89644297|NCT02996409|Experimental|High-Volume Image-Guided Injection|HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
89644298|NCT02996409|Placebo Comparator|Low-Volume Image-Guided Injection|LVIGI: Injection of 2 cc (1.6 cc 0.9% Sodium chloride solution + 0.4 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
89644299|NCT02997111|Other|Energy drink|Single group study. Platelet function analyzed with PFA-100 before and 60 minutes after ingestion of 250 ml sugar-free energy drink
89644300|NCT02996565|Active Comparator|Best Practice Clinic-Based Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Best Practice Clinic-Based Care intervention.
89644301|NCT02996565|Active Comparator|Telehealth Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Telehealth Care intervention.
89644302|NCT01421719|Experimental|botulinum toxin treatment|botulinum toxin treatment Injection of Botox into urinary bladder for neurogenic symptoms.
89644303|NCT01421641|Active Comparator|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle.
89644304|NCT01421641|Active Comparator|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip (this amount of lidocaine will be measured out prior to procedure)
89043619|NCT02895438|Active Comparator|Placebo|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
89043620|NCT04637360|Experimental|Cinacalcet treatment|hyperparathyroid dialysis patients using cinacalcet and active vitamin D for 6 months
89043621|NCT04637360|Experimental|traditional therapy active vitamin D|hyperparathyroid dialysis patients using traditional therapy active vitamin D without use cinacalcet for 6 months.
89043622|NCT04317703|Experimental|Test: Gemigliptin/Metformin|Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg)
89043623|NCT04317703|Active Comparator|Reference: Gemigliptin and Metformin|Coadministration of Zemiglo Tablet 50 mg (Gemigliptin 50 mg) and Glucophage XR 1000 mg (Metformin Hydrochloride Prolonged Release 1000 mg)
89043624|NCT05656846|Experimental|Experimental: PulseNmore ES™|"Experimental: PulseNmore ES™:~The study population will be recruited between 12 and 14 weeks of gestation. These patients will be followed using a twice weekly virtual visit by a member of the study team. This visit will include a short survey of obstetrical complaints such as contractions leakage of fluid and decreased fetal movements, as well as a brief sonographic survey using the portable ultrasound device."
89043625|NCT05656846|Active Comparator|Control Standard Ultrasound|A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
89043626|NCT04317352||Multivisceral resection (MRV)|MVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
89212568|NCT04001361|Experimental|Laser plus Marrow|Under conscience sedation, a 10mL marrow aspiration is performed. Laser fiber is inserted into the knee over an 18 gauge needle and micro-channels are made into the damaged cartilage. After the channels are made, marrow aspirate is injected over the same 18 gauge needle.
89043627|NCT00624598|Experimental|SMART Group|The experimental group will have a nutrition program based solely on measured resting metabolic rate. The nutrition plan will be a specific calorie level that will promote a 1-2.5 lb per week weight reduction. No experimental participants' nutrition plan will be below 1200 Kcal/day for women or 1600 Kcal/day for men. Second, the experimental group will receive a downloadable copy of a computerized nutrition software program (BalanceLog: Microlife USA, Inc. Golden, CO) that functions s on a Windows 2000-XP or Palm operating system.
89644305|NCT01385995|Active Comparator|Continuous Positive Airway Pressure (CPAP)|
89644306|NCT01385995|Sham Comparator|Sham-Continuous Positive Airway Pressure (CPAP)|
89644307|NCT05068206|Experimental|AK105+Anlotinib+CapeOx|"Treatment period (6 cycles):~AK105 injection: intravenous drip on Day 1; Anlotinib hydrochloride capsule: oral administration, once daily(QD) ; Oxaliplatin for injection: intravenous infusion on Day 1; Capecitabine tablet:oral administration, twice daily (BID) .~Maintenance period:~AK105 injection: intravenous drip on Day 1; Anlotinib hydrochloride capsule: oral administration, once daily(QD) ; Capecitabine tablet:oral administration, twice daily (BID) . Every 3 weeks is as one cycle.Oxaliplatin is administered for 6 cycles, and AK105 can be administered continuously for 1 year but at most for 2 years. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
89644308|NCT05068206|Experimental|Anlotinib+CapeOx|"Treatment period (6 cycles) Anlotinib hydrochloride capsule: QD orally; Oxaliplatin for injection: D1 intravenous infusion on Day 1; Capecitabine tablet: BID oral administration.~Maintenance period:~Anlotinib hydrochloride capsule: QD orally; Capecitabine tablet: BID oral administration. Every 3 weeks is as one cycle, and Oxaliplatin is administered for 6 cycles. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
89644309|NCT05068206|Active Comparator|Bevacizumab+CapeOx|"Treatment period (6 cycles):~Bevacizumab D1 intravenous infusion; Oxaliplatin D1 intravenous infusion; Capecitabine BID oral administration.~Maintenance period:~Bevacizumab D1 intravenous infusion; Capecitabine BID oral administration. Every 3 weeks is as one cycle, and Oxaliplatin is administered for 6 cycles. Other cases continue to be administered until the treatment termination event specified in the plan occurs."
89644310|NCT05063370|Active Comparator|Levosimendan group|Patients will be admitted to ICU preoperatively and Levosimendan infusion will be started after insertion of an arterial line 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
89644311|NCT05063370|Other|Standard group|Patients will not receive Levosimendan perioperatively and will be managed with standard care according to our institutional protocol
89043628|NCT00624598|Active Comparator|Usual Care|Standard 1200 kcal/day diet (women) 1600 kcal/day diet (men) using a sample 3-day menu program. The diet will be follow current government based recommendations for carbohydrates (i.e. 55%), fat (30%), and protein (15%). Study participants will receive a standard paper-based food and exercise journal
89043629|NCT02895126|Experimental|"Appui Parental program (44 cases)"|
89043630|NCT02895126|Other|Regular parental support (44 cases)|Usual intervention
89043631|NCT04636892|Experimental|Severe aortic stenosis|"Patients with echocardiographic evidence of severe aortic stenosis as defined by:~Aortic Vmax ≥4 m/s or mean ΔP ≥40 mmHg AVA ≤1.0 cm2"
89043632|NCT04636892|Experimental|Severe mitral regurgitation|"Patients with echocardiographic evidence of severe mitral regurgitation as defined by:~Central jet MR >40% LA or holosystolic eccentric jet MR~Vena contracta ≥0.7 cm~Regurgitant volume ≥60 mL~Regurgitant fraction ≥50%~ERO ≥0.40 cm2~Angiographic grade 3 to 4+"
89043633|NCT04636892|Experimental|Heart Failure with Reduced EF <35%|Patients with echocardiographic evidence of left ventricular ejection fraction of < or = to 35%
89644312|NCT02590380|Active Comparator|treatment group (MESA)|Patients randomized to the treatment group will receive surgery with the MESA Rail Deformity System.
89644313|NCT02590380|Active Comparator|control group (USS II)|Patients randomized to the control group will receive surgery with the DePuy Synthes USS II System.
89043634|NCT04636892|Experimental|Pulmonary Hypertension|Patients with echocardiographic evidence of a mean pulmonary artery pressure (mPAP; supine and at rest) >20mmHg
89644314|NCT02553954|Experimental|Collection of healthy skin tissue|Collection of healthy skin tissue
89644315|NCT05377866||Study population|Patients undergoing percutaneus coronary intervention for chronic total occlusion. The procedures will all be done using mixed reality to enable remote proctoring. The study is a feasibility trial.
89644316|NCT01421017|Experimental|IMQ+RT|"This arm has been closed as of 6/4/2014.~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
89043635|NCT04636892|Experimental|Suspected coronary artery disease|Patients with plan to undergo elective left heart diagnostic catheterization for the assessment of coronary artery disease
89043636|NCT05656690||Healthy older Adults|Healthy older Adults: older adults without disability indicators
89043637|NCT05656690||Disability Older Adults|Disability Older Adults: older adults with disability indicators
89043638|NCT05656612|Experimental|The Group Given Training 1-2 Weeks Before The Procedure|Participants received breast biopsy procedure training once. 1-2 weeks before the breast biopsy procedure.
89043639|NCT05656612|Experimental|The group trained on the day of the procedure|Participants received one time breast biopsy procedure training. The day of the breast biopsy procedure.
89043640|NCT05656612|Experimental|Repetitive training group|Participants received twice breast biopsy procedure training. The first training is 1-2 weeks before the breast biopsy procedure. The second training is the day of the breast biopsy procedure.
89043641|NCT04636580|Experimental|anxious parent|Parents were divided into two groups anxious and non-anxious.
89644317|NCT01421017|Experimental|CTX/IMQ/RT|"Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
89644318|NCT01421017|Experimental|CTX/RT|"For patients with only non-skin metastatic sites~First cycle (Cycle 1):~Week -1 (day -7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
89644319|NCT05377710|Experimental|Glycobone|Patients will be implanted at T0 with Glycobone
89644320|NCT04988802|Active Comparator|Patients taking food supplement with levothyroxine|Patients will start taking food supplement with levothyroxine in the evening, and the other tablet of the food supplement in the evening for 8 weeks.
89644321|NCT04988802|Placebo Comparator|Patients taking placebo with levothyroxine|Patients will start taking placebo with levothyroxine in the evening, and the other tablet of the placebo in the evening for 8 weeks.
89644322|NCT00703053|Experimental|Group 1|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 7, A/Vietnam/04 90 mcg.
89644323|NCT00703053|Experimental|Group 9|100 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Vietnam/04 90 mcg.
89644324|NCT00703053|Experimental|Group 8|100 subjects: Day 0, A/Vietnam/04 90 mcg.
89644325|NCT00703053|Experimental|Group 7|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 180, A/Indonesia/05 90 mcg.
89644326|NCT00703053|Experimental|Group 6|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 180, A/Indonesia/05 90 mcg.
89644327|NCT00703053|Experimental|Group 5|50 subjects: Day 0, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg; Day 28, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg.
89644328|NCT00703053|Experimental|Group 4|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Indonesia/05 90 mcg.
89644329|NCT00703053|Experimental|Group 3|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 28, A/Indonesia/05 90 mcg.
89644330|NCT00703053|Experimental|Group 2|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 14, A/Vietnam/04 90 mcg.
89644331|NCT04980534|Experimental|Viusid Plus Asbrip Adjuvant|25 Patients who received standard therapy Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days AND Viusid (sachets with powder for dilution, oral administration) 1 sachet bid and Asbrip (liquid form, oral administration) 10 ml bid for the total duration of hospitalization. Time Frame: 21 days.
89644332|NCT04980534|Experimental|Viusid Plus Asbrip Monotherapy|25 Patients who did not receive standard antiviral therapy with the inclusion of food supplements Viusid (4.5 gr every 12 hours, oral administration) and Asbrip (10 mL every 12 hours, oral administration). Time Frame: 21 days.
89644333|NCT04980534|Active Comparator|Control|30 patients who received standard therapy (Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days), without the inclusion of food supplements Viusid and Asbrip.
89644334|NCT04962204|Active Comparator|Virtual visitation group|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
89644335|NCT04962204|No Intervention|Control group|Phone interview between physicians-caregivers once a day
88991916|NCT03327064|Placebo Comparator|Renal Transplant subjects receiving placebo|Generally healthy renal transplant subjects receive placebo for 28 days with increased risk of non-melanoma skin cancer as evidenced by a history of prior squamous or basal cell skin cancer, ongoing or history of actinic keratoses and presence at baseline of at least 8 actinic keratosis on the face, neck, scalp and arms.
88991917|NCT03300557|Experimental|Treatment (exemestane)|Patients receive exemestane PO QD over 21-42 days in the absence of disease progression or unaccepted toxicity. Patients undergo standard of care surgery between days 22-43.
88991918|NCT03256981|Experimental|SBRT and continued TKI therapy|"Patients will continue to receive background TKI treatment as prior to trial entry.~Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.~Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 5."
88991919|NCT03256981|Active Comparator|Continued TKI therapy alone|Continuation on the same background TKI treatment as prior to trial entry
88991920|NCT03250676|Experimental|H3B-6545 Arm 1: Dose escalation|
88991921|NCT03250676|Experimental|H3B-6545 Arm 2: Phase 2|
89644336|NCT05089968||Patient from the first wave of COVID-19|57 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 1st wave from January 24, 2020 to July 10, 2020
89644337|NCT05089968||Patient from the Second wave of COVID-19|211 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 2nd wave from July 11, 2020 to January 8, 2021
89644338|NCT05089890|Other|Sorbact® Compress|Patients already assigned to start treatment with Sorbact® Compress as it is judged by the investigator to be the most suitable for their wounds
89644339|NCT05089890|Other|Sorbact® Gel Dressing|Patients already assigned to start treatment with Sorbact® Gel Dressing as it is judged by the investigator to be the most suitable for their wounds
88991922|NCT03246334||Cohort|Critically ill patients admitted >12 hours to the ICU
88991923|NCT03226808|Other|Vivacit-E Liner|All subjects enrolled receive the study implant.
89644340|NCT05089890|Other|Sorbact® Ribbon Gauze|Patients already assigned to start treatment with Sorbact® Ribbon Gauze as it is judged by the investigator to be the most suitable for their wounds
89644341|NCT04931238|Experimental|JS016 treatment group|Standard therapy + JS016 injection Standard therapy including vital sign monitoring, supplementary oxygen and respiratory support in accordance with the patient's oxygen saturation and respiratory condition.
89644342|NCT04931238|No Intervention|Control group|Standard therapy Standard therapy includes vital sign monitoring, supplementary oxygen and respiratory support in accordance with the patient's oxygen saturation and respiratory condition.
88991924|NCT03212794|Experimental|Experimental|Subjects randomized to the experimental arm will be assigned to a recovery coach.In addition to being linked to a community buprenorphine or methadone treatment program, the recovery coach will work to meet weekly with the subject following discharge from the hospital to provide support.
89644343|NCT04543500|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
89644344|NCT04543500|Active Comparator|Sham Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left postcentral gyrus. Participants in this arm will receive sham feedback while attempting to modulate their neural activity during an emotional cognitive control task.
89644345|NCT05089578||Individuals with Covid-19|Interviews were conducted with individuals who had Covid-19, and their experiences with the integrative methods they used were determined.
89644346|NCT04927182|Experimental|Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|
89644347|NCT04927182|Experimental|Moderate Exercise Training (Age Group 2; 31 to 45 years)|
89644348|NCT04927182|Experimental|Moderate Exercise Training (Age Group 3; Above 45 years)|
89644349|NCT05089500|Experimental|Endoscopic injection sclerotherapy|
89644350|NCT05089500|Experimental|Endoscopic Band Ligation|
89644351|NCT05089422|Experimental|Children with exotropia|squint surgery
89644352|NCT04476888|Experimental|Treatment arm/CP recipient|"Patients with severe/critical COVID 19 who will receive 500 ml of Convalescent plasma (CP), obtained from donors who have been recovered from SARS-CoV-2 infection.~These patients may or may not get other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
89644353|NCT04476888|Other|Control arm|"Patients with severe/critical COVID 19 who will not receive Convalescent plasma (CP). These will be those who were recruited during the period before CP becomes available or for whom no compatible CP is available.~These patients will receive one or more of the other treatment modalities e.g. steroids,Tocilizumab, Azithromycin etc"
89644354|NCT05089344|Experimental|mild stimulation protocol + growth hormone adjuvant|"Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH antagonist protocol + Clomophine citrate.~Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian response .~. For those in the GH group, 8 IU recombinant human GH will be administered starting from Day 14 of the previous cycle Till administration of HCG for ovulation triggering"
89644355|NCT05089344|Active Comparator|Mild stimuation protocol|"Controlled ovarian hyperstimulation protocol will be held according to a flexible GnRH antagonist protocol + Clomophine citrate.~Ovarian stimulation will start with a fixed daily dose of 100 mg of Clomiphene citrate daily and recombinant FSH (Gonal-F®) will be started on day 2 of the menstrual cycle at a dose of 150 IU to be adjusted thereafter in a step up fashion every 2 to 4 days according to ovarian response .~."
89644356|NCT01420627|Experimental|Adagen/EZN-2279|Patients started on Adagen and crossed over to experimental EZN-2279 treatment after at least a 3 week Lead-in Period on Adagen
89644357|NCT04413630|Experimental|Study group|family workshop
89644358|NCT03136770|Experimental|A|CK-30 600 mg -> red ginseng extracts 2.94 g
89644359|NCT03136770|Experimental|B|red ginseng extracts 2.94 g -> CK-30 600 mg
89644360|NCT01400113|Experimental|Asenapine|This group received 10mg asenapine sl x 1 dose
88991925|NCT03212794|No Intervention|Control|Subjects randomized to the control arm will receive treatment as usual. This means subjects are linked to ongoing outpatient treatment with buprenorphine or methadone.
88991926|NCT03203850|Experimental|Deferasirox FCT Arm|randomized in a 2:1 ratio: Deferasirox or phebotomy
88991927|NCT03203850|Experimental|phlebotomy|randomized in a 2:1 ratio: Deferasirox or phebotomy
88991928|NCT03201848|Experimental|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight with treatment duration for 48 weeks
88991929|NCT03201848|Placebo Comparator|Placebo|Placebo given to subject will be adjusted by body weight After 24 weeks of placebo, change to Huaiqihuang Granule for another 24 weeks.
88991930|NCT03194958|No Intervention|Standard Quitline|Participants will receive standard Missouri quitline services
89644361|NCT01400113|Placebo Comparator|Placebo|This group received placebo sl x 1 dose
89644362|NCT05088954|Active Comparator|Patients diagnosed with metabolic syndrome|
89644363|NCT05088954|Active Comparator|Patients without a diagnosis with metabolic syndrome|
89644364|NCT01399723|Experimental|Amoxicillin 45mg/kg 12 hourly|
89644365|NCT01399723|Active Comparator|Benzyl Penicillin 50,000IU/kg 6 hourly|
89644366|NCT04787094|Experimental|Yoga Group|The sessions will begin with breathing exercises in standing, sitting, supine and prone positions, and these exercises will be applied for about 10 minutes. After the breathing exercises, the sudden relaxation technique, which will take 2-3 minutes, firstly contracting the whole body from the feet to the head and then completely relaxing it.
89644367|NCT04787094|Experimental|Spinal Stabilization Exercise Group|"Spinal stabilization exercises will be applied to the individuals in this group for 8 weeks / 2 days a week, approximately 50-60 minutes a day under the supervision of a physiotherapist.~Spinal stabilization exercises will be progressed in 3 phases by gradually increasing the difficulty."
89644368|NCT04726098|Active Comparator|Low dose group|Dexamethasone 6mg/day for 10 days
89644369|NCT04726098|Active Comparator|High dose group|Dexamethasone 20mg/day for 5 days + Dexamethasone 10mg/day for 5 days (Total 10 days)
89644370|NCT04712838|Experimental|group A|
89644371|NCT04712838|Experimental|group B|
89644372|NCT04712838|Experimental|group C|
89644373|NCT04712838|Experimental|group D|
89644374|NCT04712838|Experimental|group E|
89644375|NCT04712838|Experimental|group F|
89644376|NCT01385371|Experimental|SCH 697243|
89644377|NCT01385371|Placebo Comparator|Placebo|
89644378|NCT04697160||Patients who received systemic therapies for R/R DLBCL|
89644379|NCT01399099|Experimental|All Study Participants|Half of the abdomnioplasty incision was treated with the embrace device. Half of the abdomnioplasty incision was treated according to the investigator's standard of care. Participant served as his own control.
89644380|NCT01398787|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear
89644381|NCT01398787|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear
89644382|NCT04041115|Active Comparator|Control|personalized nutritional therapy + aerobic exercise
89644383|NCT04041115|Active Comparator|Non-alcoholic Beer|non-alcoholic beer + personalized nutritional therapy + aerobic exercise
89644384|NCT05088720|Experimental|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
88991931|NCT03194958|Experimental|Specialized Quitline|Participants will receive an enhanced version of the standard quitline services
88991932|NCT03194958|Experimental|Standard Quitline with Basic Needs Navigator|Participants receive standard quitline services with navigator
88991933|NCT03194958|Experimental|Specialized Quitline with Basic Needs Navigator|Participants receive enhanced quitline services with navigator
88991934|NCT03168516|Experimental|Experimental intervention|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
88991935|NCT03168516|No Intervention|Control intervention|Standard care, i.e. manual adjustments of the FiO2 only
88991936|NCT03141619||Respiratory failure and/or shock|All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
88991937|NCT03123783|Experimental|Phase 1b escalation 0.03 mg/kg|"Non-small cell lung cancer (NSCLC) or metastatic melanoma~APX005M 0.03 mg/kg and nivolumab 360 mg every 3 weeks"
88991938|NCT03123783|Experimental|Phase 1b escalation 0.1 mg/kg|"Non-small cell lung cancer (NSCLC) or metastatic melanoma~APX005M 0.1 mg/kg and nivolumab 360 mg every 3 weeks"
88991939|NCT03123783|Experimental|Phase 1b escalation 0.3 mg/kg|"Non-small cell lung cancer (NSCLC) or metastatic melanoma~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
88991940|NCT03123783|Experimental|Phase 2 expansion Cohort 1|"Immunotherapy naïve, metastatic or locally advanced NSCLC~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
88991941|NCT03123783|Experimental|Phase 2 expansion Cohort 2|"Metastatic melanoma progressing during treatment with anti-PD-1/PD-L1 therapy~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
88991942|NCT03123783|Experimental|Phase 2 expansion Cohort 3|"Metastatic or locally advanced NSCLC progressing during treatment with anti-PD-1/PD-L1:~Group A: best response of progressive disease or with stable disease < 16 weeks~Group B: tumor response or with stable disease ≥ 16 weeks"
88991943|NCT03118232|Active Comparator|Decolonization|Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
88991944|NCT03118232|No Intervention|Routine Bathing|Routine bathing per facility protocol.
89644385|NCT05088720|Active Comparator|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
89644386|NCT05365945|Experimental|The study group|
89644387|NCT05365945|Active Comparator|The control group|
89644388|NCT05377632|Active Comparator|Hybrid-Group|Laparoscopic and Robotic-assisted combined (partial) nephrectomy via the hybrid (trans-peritoneal and retroperitoneal) access route
89644389|NCT05377632|Active Comparator|Retroperitoneal-Group|Robotic-assisted laparoscopic (partial) nephrectomy via the retroperitoneal access route
89644390|NCT05088642|Experimental|Mild hepatic impairment (Child-Pugh Class A)|
89644391|NCT05088642|Experimental|Moderate hepatic impairment (Child-Pugh Class B)|
89644392|NCT05088642|Experimental|Normal hepatic function|
89644393|NCT01383499|Experimental|Treatment A|patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler
89644394|NCT01383499|Experimental|Treatment B|patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler
88991945|NCT03047629|Experimental|ENT-01|ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
88991946|NCT03047629|Placebo Comparator|Placebo Comparator|Placebo to be taken by mouth every day upon awakening
88991947|NCT03003962|Experimental|Arm 1: Durvalumab|Anti-PD-L1 monoclonal Antibody monotherapy
88991948|NCT03003962|Active Comparator|Arm 2: Standard of Care|Standard of Care Platinum-Based chemotherapy
88991949|NCT02968810|Experimental|Group I (simvastatin)|Patients receive simvastatin PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood on study and CT/MRI throughout the trial.
88991950|NCT02968810|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood on study and CT/MRI throughout the trial.
89644395|NCT01383499|Experimental|Treatment C|patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler
89644396|NCT01383499|Placebo Comparator|Treatment D|patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler
89043642|NCT04636580|Experimental|non-anxious parent|Parents were divided into two groups anxious and non-anxious.
89043643|NCT02895048||Chronic heart failure|
89644397|NCT05084118|Active Comparator|Landiolol group|Randomized patients receiving low dose landiolol after cardiac surgery
89644398|NCT05084118|Placebo Comparator|Placebo group|Randomized patients receiving 0,9% saline solution after cardiac surgery
89644399|NCT03025009|Experimental|LY3192767 (Part A)|Escalating doses of LY3192767 administered subcutaneously (SC).
89644400|NCT03025009|Placebo Comparator|Placebo (Part A)|Placebo matching LY3192767 administered subcutaneously (SC).
89644401|NCT03025009|Experimental|LY3192767 (Part B)|LY3192767 administered as a SC injection in one of three study periods.
89644402|NCT03025009|Active Comparator|Basal Insulin Peglispro (Part B)|Basal insulin peglispro administered as a SC injection in one of three study periods.
89212569|NCT02588183|Experimental|ArticFont Advance ST|Patients undergoing PV isolation with the ArticFont Advance ST Cryoenergy Balloon Catheter
89644403|NCT03025009|Active Comparator|Insulin Glargine (Part B)|Insulin glargine administered as a SC injection in one of three study periods.
89644404|NCT05075070|Experimental|Experimental Group|A total 400 HIV-infected subjects receive two doses inactivated COVID-19 vaccine with the interval of 21 days.
89644405|NCT03024853|Experimental|BPS PAST|Participants write down about themselves in a past when they displayed their best self. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
89644406|NCT03024853|Experimental|BPS PRESENT|Participants write down about themselves in in the present, focusing on what currently makes the best version of themselves (skills, features...). Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
89644407|NCT03024853|Experimental|BPS FUTURE|"Participants write down about themselves in the future after everything has gone as well as it possibly could. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.~This is the original BPS exercise (already validated in other studies)."
89644408|NCT03024853|Active Comparator|CONTROL|Participants write down the activities they did during the last 24 hours. Then, they visualize (imagine) the content. They practice the visualization exercise for 7 consecutive days.
89644409|NCT03135912|Experimental|Experimental Treatment|Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
89644410|NCT03135912|Placebo Comparator|Vehicle Control|Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
89644411|NCT03135912|Active Comparator|Active Comparator|Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
89644412|NCT05365321|Experimental|WP1122|Experimental drug with Concentration 100mg/mL - administered q12h PO for 10 days
89644413|NCT05365321|Placebo Comparator|placebo|Placebo Administered q12h PO for 10 days
89212570|NCT00876824|Experimental|Amphotericin B lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
89212571|NCT00876824|Active Comparator|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B
89644414|NCT03025555|Active Comparator|group 1|patients will receive partial denture constructed from breflex material.
89644415|NCT03025555|Experimental|group 2|patients will receive partial denture constructed from PEEK material.
89644416|NCT04507308|Experimental|Transdiagnostic Sleep and Circadian Intervention|All participants will undergo baseline assessment and then complete a brief, single-session sleep-focused intervention based on psychoeduation and handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth).
89644417|NCT01397461|Experimental|ozenoxacin 1% cream|1% cream
89644418|NCT01397461|Placebo Comparator|ozenoxacin placebo|cream
89644419|NCT01397461|Active Comparator|retapamulin 1% ointment|1% ointment
89644420|NCT04429464|Experimental|Non-randomized|All subjects will be treated using the Acutus Medical's AcQBlate Force Sensing Ablation Catheter in combination with the Qubic Force Sensing Module (AcQBlate Force Sensing System) to treat their arrhythmia.
88991951|NCT02962661|Experimental|Arm I (hMSCs IV)|Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
88991952|NCT02962661|Experimental|Arm II (hMSCs transendocardially)|Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
88991953|NCT02962661|Active Comparator|Arm III (standard of care)|Patients receive standard of care treatment for heart failure.
88991954|NCT02943408|Experimental|person-centered mental health intervention (PCMHI)|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
88991955|NCT02943408|Active Comparator|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
89212572|NCT00992979|Experimental|Therapeutic Massage|
88991956|NCT02913274|Experimental|"DEB arm"|dilation by a high-pressure conventional angioplasty balloon (sized to fit the reference native vein diameter) until disappearance of the stenotic obstructive area and achievement of technical success (possibility of changing balloon size or dilation pressure) then dilation by a DEB.
89212573|NCT00992979|Active Comparator|Relaxation Control|Relaxation Control Session
89212574|NCT00866684|Experimental|1|Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
89212575|NCT00866684|Active Comparator|2|Patients will stay on their previous immunosuppressive regimen.
89644421|NCT01382251||Patient|Patients undergoing ambulatory surgery
89644422|NCT01382251||Caregiver|Spouse, family members, or friends identified as the patient's primary source of support in the community.
89644423|NCT04335084|Experimental|Medical Workers|Medical workers who are exposed to COVID-19 and as such are at higher risk for infection.
89644424|NCT04335084|Placebo Comparator|Placebo|Medical workers who are exposed to COVID-19 and as such are at a higher risk for infection
89644425|NCT04386369||Airway Pressure Release Ventilation|Patients with COVID-19 ARDS requiring invasive mechanical ventilation in ICU, on Volume Assist Control ventilation (VAC) or Pressure Assist Control (PAC), are switched to airway pressure ventilation (APRV). If APRV doesn't lead to improvement in oxygenation the ventilatory mode is switched back to VAC or PAC ventilatory mode.
89644426|NCT02996019|Experimental|Part 1: Etrolizumab AI|Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
89644427|NCT02996019|Active Comparator|Part 1: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
89644428|NCT02996019|Experimental|Part 2: Etrolizumab AI|Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
88991957|NCT02913274|Active Comparator|"conventional angioplasty arm"|dilation will be performed by a conventional high-pressure balloon until technical success is achieved (possibility of changing balloon size or dilation pressure), then by a sham balloon i.e a conventional low-pressure balloon (placebo)
88991958|NCT02898818||symptomless|vaginal and oral swab sample, questionnaire
89212576|NCT05356455|Experimental|EXPERIMENT- active|Motivational interview technique
89212577|NCT05356455|No Intervention|control passive|just watched
89644429|NCT02996019|Active Comparator|Part 2: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
89644430|NCT02995785|Other|Experimental:simulation-based training|Experimental
89644431|NCT02995785|Other|Active comparatorr: traditional training|Traditional
89644432|NCT02994537||acute autoimmune hepatitis|Patients diagnosed autoimmune hepatitis(AIH) are divided into acute cohort or chronic cohort (acute-on-chronic and chronic were all included)by biochemical results, such as liver function and coagulation, then the investigators will compare the histological results, treatment effects and prognosis between the two groups. Further more, the investigators will study the pathogenesis of different forms of autoimmune hepatitis. Even more, the investigators want to explore drug induced AIH and viral hepatitis related AIH.
89644433|NCT02995395||Mucosal Impedance Balloon catheter|At the conclusion of the endoscopy, all fluids will be aspirated from the esophagus. The endoscope will then be left in place in the mid-esophagus and a custom Mucosal Impedance (MI) balloon assembly four axial arrays of 10 sensors (total of 40 sensors) will be positioned along the esophageal mucosal wall under direct visualization to directly measure MI at uniform intervals. Once in place, impedance readings will be recorded for a total of 2 minutes. At this point both the endoscope and impedance catheter will be withdrawn simultaneously.
89644434|NCT02992041|Experimental|Lower dose VVZ-149 Injections|
89644435|NCT02992041|Experimental|Higher dose VVZ-149 Injections|
89644436|NCT02992041|Placebo Comparator|Placebo|
89644437|NCT01396525|Experimental|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|
89644438|NCT02998827|Experimental|thalidomide|use thalidomide tablet by mouth, every night for at least 6 months
89644439|NCT02998827|Active Comparator|other treatment|the treatment include infliximab, azathioprine or enteral nutrition at least 6 months
89644440|NCT02991027|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be imaged using 2 different light sources using the DRI Triton
89644441|NCT02995707|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
89644442|NCT02849652|Experimental|ATTOC|Addressing Tobacco Through Organizational Change is a multi-phase organizational intervention to promote the treatment of tobacco dependence
89644443|NCT02849652|Other|Usual Care|Usual Care is the typical guideline based smoking cessation intervention
89644444|NCT02995473|Experimental|NP000888|Pharmaceutical form: Ointment
89644445|NCT02995473|Placebo Comparator|Vehicle|Pharmaceutical form: Ointment
89644446|NCT02995161|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89644447|NCT02990949|Experimental|Testing group|Timing of trigger at end of ovarian stimulation in an IVF cycle: trigger when 2 follicles reach 18mm, OR 1 follicle reaches 18mm AND 1 follicle is between 16-18mm.
89644448|NCT02990949|No Intervention|Control group|
89644449|NCT04234854||Carotid Artery Stenting|Consecutive patients older than 18 yrs with symptomatic carotid artery stenosis qualified for endovascular revascularization.
89644450|NCT02999139||ACL Return to Play|A specific training program, with emphasis on hamstring strengthening. There will also be a specificity on pivoting and jumping safely.
89644451|NCT02999139||Gait Retraining|Will receive training that is specific to running. Drills will help enforce a more efficient running form, as well as strengthening important muscle groups such as the hip abductors and adductors.
88991959|NCT02898818||vaginal discharge|vaginal and oral swab sample, questionnaire
88991960|NCT02898818||atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
88991961|NCT02898818||no atypical papa smear|vaginal and oral swab sample, questionnaire, papa smear
88991962|NCT02898818||lichen planus|vaginal and oral swab sample, questionnaire, papa smear
88991963|NCT02892682|Other|Arm 1 AE-Bk|Arm of the recurring angiodeme medié by the bradykinine: blood test
88991964|NCT02892682|Other|Arm 2 AE-Mast|Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test
89212578|NCT00993057|Active Comparator|Q1 hour protocol|change of insulin infusion every hour
89212579|NCT00993057|Active Comparator|Q30min protocol|change of insulin infusion every 30 minutes
89212580|NCT00866762|Experimental|1|Treatment with study drug approximately 6 months and follow-up for 3 months
89212581|NCT04001907|Experimental|exercise combined with β-hydroxy-β-methylbutyrate (HMB)|Resistance Exercise ( 3d/week) and HMB: 3g/d as three 1g capsules orally, for 9 weeks
89212582|NCT04001907|Placebo Comparator|exercise combined with placebo|Resistance exercise ( 3d/week) and placebo as 3g/d maltodextrin as three 1g capsules orally, for 9 weeks
89212583|NCT00876902|Experimental|1|Active Group: (18 subjects) YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One extra IV dose of 1 mg/kg will be given at the end of the procedure only to patients that have experienced an intraoperative blood loss of greater than 10 units.
89644452|NCT02999139||Private Training|Participants will receive a broad training program, targeting all major muscle groups. The goal is to increase muscle strength, mobility and aerobic capacity to reduce the risk of injury.
89644453|NCT02990715|Active Comparator|Up to 45 subjects|Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
89043644|NCT02895048||CCM treatment|Subjects with heart failure receiving OPTIMIZER system implant
89043645|NCT05656456||OCD patients|Patients with obsessive-compulsive disorder
89043646|NCT05656456||live-in family members|Live-in family members of OCD patients
89043647|NCT05656339|Sham Comparator|12 hours Fast - Fast Group|Participants will proceed in 12 hours fast condition for blood collection for laboratory assays
89043648|NCT05656339|Active Comparator|Carbohydrate plus whey protein supplement - CHO+WP group|After 12 hours fast participants will collect blood samples and immediately will drink an oral supplement containing carbohydrates plus whey protein. After 3 hours of ingesting the supplement blood samples will be collected again
89043649|NCT05656339|Placebo Comparator|Carbohydrate supplement - CHO group|After 12 hours fast participants will collect blood samples and immediately will drink an oral supplement containing carbohydrates alone without whey protein. After 3 hours of ingesting the supplement blood samples will be collected again
89043650|NCT04636541|Experimental|Goal Management Training|GMT modules were adapted for French-speaking patients with PD-MCI. Each session was reduced from nine 90-120-minute sessions (original GMT) to five 60-90-minute sessions, one session per week, in order to avoid fatigue. As for original GMT, participants were given exercises between sessions (mindfulness exercises and metacognitive reflections). In original-GMT, some information is repeated several times, but not in Adapted-GMT. Exercises demanding motor dexterity, such as card distribution, were removed. Adapted-GMT included information on PD-MCI and executive dysfunction (some psychoeducation). In addition, Adapted-GMT modules were administered individually with an iPad, as opposed to a power-point group presentation in original-GMT. A workbook was handed to participants, as in previous studies.
89043651|NCT04636541|Active Comparator|Psychoeducation sessions coupled mindfulness exercises|Five modules were designed as a discussion with patients and caregivers about various PD symptoms: module I-brain and motor symptoms; module II-autonomic symptoms; module III- psychological symptoms; module IV-brain and cognition; and module V-cognitive impairments in PD. Patients were handed the information book about the five modules at the beginning of the study. The objective was to improve their understanding of their condition and to discuss other components that could affect their cognitive abilities. After the 40-60-minute informative part, mindfulness exercises were offered for 20-30 minutes per session. Participants were not invited to practice exercises between sessions, but 3/6 participants reported they did.
89644454|NCT02990715|Experimental|Up to 25 subjects|Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
89644455|NCT01270035|Experimental|ADA 80 mg eow + MTX|
89644456|NCT01396447|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks.
89644457|NCT01396447|Experimental|Cariprazine 0.75 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
89644458|NCT01396447|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
89644459|NCT01396447|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.
89644460|NCT04792788|Active Comparator|NAVA/PSV/NAVA|6 patients
89644461|NCT04792788|Active Comparator|PSV/NAVA/PSV|6 patients
89644462|NCT00704379|Placebo Comparator|Placebo|Placebo will be given in a double blind fashion via an equal number of tablets (identical to the sertraline tablets) administered once daily.
89644463|NCT00704379|Experimental|Sertraline|Sertraline will be given in a double blind fashion via tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention.
89644464|NCT03110406|Experimental|whole-body vibration|The whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, semi-squat with knees at 15º flexion and upper limbs slightly flexed and supported on the platform. The exercises will be performed, in the first two weeks, for 10 minutes consisting of 60 seconds of low intensity with 30 seconds of rest standing in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. °
89644465|NCT03110406|Sham Comparator|Simulated whole-body vibration|The simulated whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, in semi-squat with knees at 15º of flexion and upper limbs slightly flexed and supported on the platform that presents a motor that simulates the noise of the platform But does not produce any therapeutic effect
89043652|NCT02895009|Other|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. In control group, TR Band deflation is commenced at the 2nd hour with successive 5 mL air released at 2 hours intervals until the bladder was empty at the 6th hour, and the TR Band is removed at the 24th hour.
89644466|NCT03825055||Young patients with MS|young adults (i.e., 18-45 years) newly diagnosed with MS (Case-Only)
89644467|NCT02991495|Active Comparator|Stamaril, Sanofi Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
89644468|NCT02991495|Experimental|Stamaril, Sanofi Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
89644469|NCT02991495|Active Comparator|Yellow fever vaccine, Bio-Manguinhos: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
89644470|NCT02991495|Experimental|Yellow fever vaccine, Bio-Manguinhos: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
89644471|NCT02991495|Active Comparator|Yellow fever vaccine, Institut Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
89644472|NCT02991495|Experimental|Yellow fever vaccine, Institut Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
89644473|NCT02991495|Active Comparator|Yellow fever vaccine, Chumakov Institute: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
89644474|NCT02991495|Experimental|Yellow fever vaccine, Chumakov Institute: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
89644475|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in Children|Subcutaneous administration of 1 dose of the yellow fever vaccine
89644476|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in Children|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
89644477|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in HIV+ adults|Subcutaneous administration of 1 dose of the yellow fever vaccine
89644478|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in HIV+ adults|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
89644479|NCT02994693||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
89644480|NCT04541706|Experimental|Lorlatinib|The recommended dosage of lorlatinib is 100 mg orally once daily, with or without food, until disease progression, unacceptable toxicity, or participant refusal/lost to follow-up. About 100 participants will be enrolled in this study.
89644481|NCT02997345||PPROM (Preterm Premature Rupture of Membranes)|PPROM / Preterm Premature Rupture of Membranes <37 weeks
89043653|NCT02895009|Experimental|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. In experimental group, TR Band deflation is commenced at the 1st hour with 3 mL air released, and at the 2nd hour with 5ml, and at the 3rd hour with the remainder air in the bladder, and the TR Band is removed at the 12th hour.
89043654|NCT04638959||GC|patients diagnosed with GC
89043655|NCT04638959||HC|patients diagnosed with chronic gastritis by histopathology
89043656|NCT00624637|Other|A|infants after craniofacial surgery receive one massage with aromatherapy three hours postoperatively
89644482|NCT04345185||Project Viva|Project Viva (1999-present) enrolled 2,341 pregnancies and followed 2,128 children at delivery, 6 months, then yearly from 1 year to 15 years of child age.
89644483|NCT04345185||Infant Feeding Practices Study II|The Infant Feeding Practices Study II (IFPS II, 2005-2007) enrolled 3,033 pregnancies with surveys in late pregnancy, neonatal (1 month), then monthly from 2 months (N=2,552) to 12 months of infant age, and at 6 years.
89644484|NCT05738070||Patients with acute ischemic stroke|All the patients with stroke admitted to the hospital from July 2021 to July 2022 were included in this study. Patients with the following criteria were included in the study: (1) anterior circulation stroke established by diffusion-weighted imaging (DWI), (2) MRI performed within 72 hours of stroke onset, (3) Patient with occlusion of the vessel on MRA (Magnetic Resonance Angiography). (4) MRI performed before or during intravenous thrombolysis (IVT) or mechanical thrombectomy (MT). Infarcts with hemor¬rhagic transformation cases were not included in the study due to suboptimal SVS quantification
89644485|NCT02990559||Iron Repletion|Subjects participating in the associated study under the Iron Repletion arm will also undergo MRI (Magnetic Resonance Imaging) scan/fMRI (functional Magnetic Resonance Imaging) scan on two occasions, while performing cognitive tasks.
89644486|NCT02990559||Placebo|Subjects participating in the associated study under the Placebo arm will also undergo MRI/fMRI scans on two occasions, while performing cognitive tasks.
88991965|NCT02892682|Other|ARM 3 AEI|Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test
88991966|NCT02892682|Other|ARM 4 US|Arm of superficial nettle rashes: blood test
88991967|NCT02875301|Experimental|150 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 150 minutes of exercise per week.
88991968|NCT02875301|Experimental|225 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 225 minutes of exercise per week.
88991969|NCT02875301|Active Comparator|Stretch and Tone|Participants engage in supervised 12 month non-cardiorespiratory activity intervention. This group has focus on improving balance, flexibility, and strength.
88991970|NCT02847624||ADPKD|
88991971|NCT02774421|Experimental|IT trastuzumab after subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab following 5-day course of subQ GM-CSF. Surgical resection should be planned (based on institutional surgical scheduling standards) for ideally 2-7 days after IT trastuzumab dosage.
88991972|NCT02774421|Experimental|IT trastuzumab in combination with subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab in combination with GM-CSF to establish a maximum tolerated dosage. GM-CSF will be administered at 250 mcg/m2/dose subQ daily for three (3) days prior to the IT trastuzumab dose.
88991973|NCT02770469|Active Comparator|Standard Intervention|The standard intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship.
88991974|NCT02770469|Experimental|Enhanced Intervention|The enhanced intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship as well as cognitive-behavioral stress management.
88991975|NCT02746458|No Intervention|Standard of Care Physical Therapy|This group will receive the standard of care physical therapy program for 6 weeks.
88991976|NCT02746458|Experimental|Blood Flow Restriction Plus Standard of Care Physical Therapy|This group will receive the same standard of care physical therapy program for 6 weeks plus blood flow restriction.
88991977|NCT02728102|Experimental|Lenalidomide, vaccine, and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will undergo leukapheresis and then will receive maintenance lenalidomide with myeloma vaccine and GM-CSF.
88991978|NCT02728102|Active Comparator|Lenalidomide and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide with GM-CSF.
88991979|NCT02728102|Active Comparator|Maintenance Lenalidomide|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide.
88991980|NCT02710786||Gastric bypass|Patients undergoing gastric bypass
89644487|NCT05737914|Active Comparator|Endoscopic thoracic T3 sympathectomy|
89644488|NCT05737914|Active Comparator|ThoracicT3 radiofrequency ablation|
89644489|NCT00714753|Experimental|Intervention Group|Protocol treatment consists of either two high dose-rate (HDR) brachytherapy implantation sessions or one HDR brachytherapy session followed by external beam radiotherapy (EBRT). Each HDR session consists of two 9.5Gy fractions. After the first HDR session of two fractions, patients express a preference for: (1) a second HDR brachytherapy implantation session, or (2) EBRT. The second HDR session or EBRT will begin 2-4 weeks after the first HDR brachytherapy session.
89644490|NCT04449042||COVID19 positive|a recently performed test which is positive for coronavirus infection
89644491|NCT04449042||COVID19 negative|a recently performed test which is negative for coronavirus infection
89644492|NCT04449042||COVID19 presumed positive|patients who do not have testing or who have negative testing but whose symptoms, history, physical exam, laboratory and imaging findings are consistent with infection with COVID19 and are treated as positive
89644493|NCT04449042||COVID19 presumed negative|patients who do not have testing, but based on symptoms, history, physical exam, laboratory and imaging findings are deemed to be low risk for COVID19 infection and are treated as negative
89644494|NCT02999997|Experimental|Ronnie Gardiner Method (RGM)|Exercising two times/week according to the RGM program in groups of 15 participants (2 groups).
89644495|NCT02999997|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
89644496|NCT03222648|Experimental|Structured Responsive Exercise Training|8 week twice weekly supervised structured responsive static-cycle based exercise training. Training protocol used the same as Loughney et al. 2016
89644497|NCT03222648|Active Comparator|Standard of Care Arm|Completion of outcome measures only
89644498|NCT00707343|Experimental|All patients|All participants enrolled.
89644499|NCT03852810||Receiving surgical intervention via XEN Gel Stent (XEN)|Patient Reported Outcomes (PRO) will be collected before and after this particular procedure
89644500|NCT03852810||Receiving surgical intervention via trabeculectomy|Patient Reported Outcomes (PRO) will be collected before and after this particular procedure
89644501|NCT04373616|Experimental|ACI-24|
89644502|NCT04373616|Placebo Comparator|Placebo|
89644503|NCT04341090|Experimental|Arm 1|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after low-fat meal, the third dose will be after high-fat meal
89644504|NCT04341090|Experimental|Arm 2|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after fasted, the third dose will be after low-fat meal
89644505|NCT04341090|Experimental|Arm 3|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after high-fat meal, the third dose will be after fasted
89644506|NCT04341090|Experimental|Arm 4|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after high-fat meal, the third dose will be after low-fat meal
89644507|NCT04341090|Experimental|Arm 5|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after fasted, the third dose will be after high-fat meal
89644508|NCT04341090|Experimental|Arm 6|Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after low-fat meal, the third dose will be after fasted
89644509|NCT04273854|Experimental|Intervention|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice.
89644510|NCT04273854|No Intervention|Control|The control arm will be managed as per usual NHS led care with assessment by their own health care professionals and adjustment of their medications as is needed. The BP of this group will be monitored and recorded at the same time-points and in the same manner as the intervention arm as will all other secondary outcome measures.
89644511|NCT02999607|Experimental|active transcranial direct current stimulation|Stimulation at three different intensities during FDG-PET scan
89644512|NCT02999607|Sham Comparator|Sham tDCS|Comparator to active arm
89644513|NCT04413396||Outpatient parenteral antimicrobial therapy|Patients with an infectious disease that receive an outpatient parenteral antimicrobial therapy
89644514|NCT04097964|Experimental|FaCES Intervention|Primary care providers will deliver anticipatory guidance for adolescents reporting no drug, alcohol or marijuana use in past year, an abbreviated brief intervention for adolescents who report using these substances one or twice in the past year, and a full brief intervention for adolescents who report using these substances monthly or weekly in the past year.
89043657|NCT00624637|Other|B|infants after craniofacial surgery receive one massage with carrier oil three hours postoperatively
89043658|NCT00624637|No Intervention|C|no intervention, standard postoperative care
89043659|NCT05656144|Experimental|Cadonilimab|Cadonilimab monotherapy
89644515|NCT04097964|Active Comparator|Treatment as usual|Usual care will be delivered by primary care providers during the clinic visit
89043660|NCT05656066|Experimental|The Vibration Intervention Group (VI)|After the injection area was determined in the VI group, the vibration device was held for 30 seconds in the area to be injected, then the injection was applied by pulling up 3 cm while the device was operating.
89043661|NCT05656066|Experimental|The Pressure Intervention Group|After the injection area was determined in the PI group, 30 seconds light pressure was applied with the thumb and then the injection was given
89043662|NCT05656066|No Intervention|The Control Group|The routine IM injection was applied to the children in the control group.
89043663|NCT04680663||Non-severe complications group|where the non-complicated patients is the patients running the normal postoperative course of surgery and without any need for intervention
89644516|NCT04089150|Active Comparator|Arm A|"Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)~Option 2: gemcitabine + nab-paclitaxel (3 cycles)~Resectable patients receive surgery 6 weeks post completion of initial chemotherapy~Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)~Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist~Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery~For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX~For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine"
89644517|NCT04089150|Experimental|Arm B|"Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)~Option 2: gemcitabine + nab-paclitaxel (3 cycles)~Stereotactic Radiotherapy (SBRT) to commence within 3 weeks of completing initial chemotherapy: 40 Gray (Gy) in 5 fractions over 2 weeks~Resectable patients receive surgery 6 weeks post completion of initial chemotherapy~Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)~Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist~Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery~For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX~For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine"
89644518|NCT02076919|Experimental|LHA510 Part 1|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1
89644519|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 1|Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1
89644520|NCT02076919|Experimental|LHA510 Part 2|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2
89644521|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 2|Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2
89644522|NCT01678560|Active Comparator|Usual Care|Monitoring every 3 months by face-to-face visits:These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
89644523|NCT01678560|Active Comparator|Wireless Care|Frequent remote monitoring:These patients will be monitored using wireless modems as the method to obtain adherence and efficacy data.
89644524|NCT02076997|Experimental|Individualized High Dose Methotrexate|Individualized high dose methotrexate given as a 24-hour infusion.
89644525|NCT03980574|Experimental|Crossover Group|The crossover group will be further randomly assigned (1:1) with 20 patients in each group. The two crossover arms of the study will follow the patients for 8 weeks. At the end of week 8, all crossover patients will have a 1 week wash out period. Thereafter, patients will be crossed-over to the opposing arm of the study for an additional 1+8 weeks (R Drink 8 oz 3-5x/day versus a placebo drink 8 oz 3-5x/day).
89644526|NCT03980574|Experimental|Non-crossover Group|The non-crossover group of the study will follow 20 patients for the entire 17 weeks and participants in this arm will not be crossed over, will not have a washout period, and will consume R Drink for the total duration of the study. If patients in this arm wish to continue on the R Drink, for 6 additional months they may do so. At the end of the optional 6 months these patients will have a repeat research transthoracic echocardiogram. Data collection will occur at baseline, week 8, and week 17. An additional 6 month data collection time point will occur for patients in the third arm opting to continue R Drink.
89644527|NCT05365165||sevoflurane|Standard anesthesia management will be applied in the induction and maintenance of anesthesia. In the induction of anesthesia 1mg/kg lidocaine , 1.5-2mg/kg propofol , 1 mcg /kg fentanyl citrate, 0.6 mg/kg rocuronium bromide will be administered. Sevoflurane for maintenance of anesthesia and propofol and fentanyl if needed bolus will be applied. BIS monitoring will be performed to control the depth of anesthesia.
89644528|NCT03925350|Experimental|Niraparib|Patients receive niraparib PO daily
89644529|NCT04890912|Active Comparator|Conventional Fractionation Pelvic Radiation|Patients randomized to the conventional fractionation arm will be treated with intensity-modulated or volumetric arc therapy technique as per standard protocol.
89644530|NCT04890912|Experimental|Stereotactic Hypofractionated Radiation|Patients randomized to hypofractionation will be treated the stereotactic hypofractionated technique.
89644531|NCT00707967|Experimental|Group A|Subjects receiving the candidate vaccine
89644532|NCT00707967|Placebo Comparator|Group B|Subjects receiving the adjuvant
89644533|NCT00707967|Placebo Comparator|Group C|Subjects receiving physiological saline
89644534|NCT04875780|Experimental|Digital diabetes prevention app intervention|Participants will receive web-based diabetes prevention curriculum, virtual social group support and digital tracking via the smartphone app.
89644535|NCT04875780|Active Comparator|Digital weight loss tracking app intervention|Participants will receive the same intervention as the digital diabetes prevention curriculum app group except the web-based diabetes prevention curriculum.
89644536|NCT04875780|Other|Wait-list control (usual care)|Participants will receive usual care in the form of an annual review and blood test, together with general lifestyle advice.
89644537|NCT02994381|Experimental|[14C]-RPC1063 Solution (0.1 g/mL)|1 mg; 10 mL [14C]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
89644538|NCT04874766|Experimental|Surgical face mask|Simulated hockey period with 2x20s Wingate tests; progressive-intensity on-ice sprint test while wearing a surgical mask
89644539|NCT04874766|Sham Comparator|Sham face mask|Simulated hockey period with 2x20s Wingate tests; progressive-intensity on-ice sprint test while wearing a sham mask
89043664|NCT04680663||severe complications group|any deviation from the normal post-operative course
89644540|NCT00716079|Other|Intensive BP lowering|Management policy to lower the systolic Blood pressure (BP) to a target of 140mmHg within 1 hour of randomization and sustained for 24 hours. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
89043665|NCT00560222|Active Comparator|A|This group will receive daily lactoferrin supplementation
89043666|NCT00560222|Placebo Comparator|B|placebo
89043667|NCT04316299||AKI|COVID-19 patients with acute kidney injury
89043668|NCT04316299||non-AKI|COVID-19 patients without acute kidney injury
89644541|NCT00716079|Other|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the American Heart Association (AHA) in 2007 and 2010. The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.
89644542|NCT04716504||Minimally invasive surgery for a benign or malignant pulmonary lesion.|"The patients will be divided in three categories depending on the Body Mass Index:~Category 1: 18,5 kg/m2 < BMI < 24,9 kg/m2 -Category 2: 25 kg/m2 < BMI < 29,9 kg/m2 /~Category 3: 30,0 kg/m2 < BMI < 34,9 kg/m2"
89644543|NCT04683510|No Intervention|Control Group|This group will receive no intervention before receiving the AMPLIFI Recruitment Call
89644544|NCT04683510|Other|Navigation|After receiving recruitment letter from AMPLIFI, participant randomized to this arm will receive a phone call from a Research Specialist who will discuss the importance of research participation for cancer survivors to increase research awareness and aid in recruitment. The information will focus on the importance of research and will be delivered from the perspective of either a researcher or a cancer survivor.
89644545|NCT04683510|Other|Brochure|After receiving recruitment letter from AMPLIFI, participant randomized to this arm will receive a brochure which will focus on the importance of research participation for cancer survivors in order to increase research awareness and aid in recruitment.
89644546|NCT04557696|No Intervention|Control Group|Standard oncology curriculum for medical trainees in oncology programs.
89644547|NCT04557696|Experimental|Reflective Group|Standard oncology curriculum with standardized patient simulation, in addition to the REFLECT Curriculum workshops for medical trainees in oncology programs.
89644548|NCT01270191|Experimental|Exenatide|In the exenatide therapy group, subjects will be instructed in the techniques for injection and be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months. If FPG still greater than 200 mg/dL after 4 weeks of exenatide treatment, they will use insulin for rescue therapy and will be withdrawn from this study.
89644549|NCT01270191|Active Comparator|Humulin-N|In the insulin therapy group (Humulin-N), subjects will be instructed in the techniques for insulin injection and home capillary glucose monitoring. The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
89644550|NCT04550754||Patients hospitalized for tramadol withdrawal|Patients hospitalized for tramadol withdrawal in Montpellier University Hospital and Nîmes University Hospital from 01/01/2015 to 31/12/2019
89644551|NCT02999919|Active Comparator|BMI ≥ 30|BMI ≥ 30
89644552|NCT02999919|Active Comparator|BMI < 30|BMI <30
89644553|NCT02994615||hypertrophic cardiomyopathy|
89644554|NCT02994615||Control|
89644555|NCT04526652|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine 1mcg/kg
89644556|NCT04526652|Placebo Comparator|Placebo|Intranasal normal saline equivalent to (1mcg/kg dose of dexmedetomidine)
89644557|NCT01270269|No Intervention|Patients (Controls)|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
89644558|NCT01270269|Experimental|Behavioral: Phys & Func Rehab|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
89644559|NCT01270269|Experimental|Behavioral: Cog/Phys/Func Rehab|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
89644560|NCT04500210|Placebo Comparator|Placebo|one capsule daily
89644561|NCT04500210|Active Comparator|Turmeric extract|one capsule daily
89644562|NCT04493190|Experimental|Scapular control training group|Participants in these group will be taught how to correctly movement arm overhead. And they will undergo series of movement tasks with mirror and also receive scapular-focused exercises. The difficulty of the movements protocol will increase weekly.
89644563|NCT04493190|Experimental|General exercise group|Participants in this group will receive a general strengthening exercise, focusing on the shoulder muscles. And the load will progressively increase weekly.
89644564|NCT04493190|No Intervention|Healthy subject group|No intervention.
89644565|NCT01381549|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
89644566|NCT01381549|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
89644567|NCT01381549|Active Comparator|imipenem-cilastatin|500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
89644568|NCT00159432|Experimental|Oxaliplatin, followed by Bevacizumab with Capecitabine|oxaliplatin 85 mg/m2 q 14 days, followed by bevacizumab 5 mg/kg q 14 days, with capecitabine 750 mg/m2 bid daily
89644569|NCT05737368|Experimental|Patients will receive the treatment of fractionated radiotherapy and Cadonilimab|fractionated radiotherapy (500cGy *5F, 600cGy*5F, 350cGy*10F, according to the tumor volume); within 14 days after receiving radiotherapy, Cardunizumab (10mg/kg, Q3W, d1)
89644570|NCT02969850|Experimental|Vitamin D Supplementation|Participant will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
89043669|NCT04317508|Active Comparator|Intervention group|Topicale® topical anesthetic gel patch (Benzocaine 18%)
89043670|NCT04317508|Placebo Comparator|control group|Opahl® topical anesthetic gel (Benzocaine 20%)
89043671|NCT05655988|Active Comparator|mesh migration after TEPP / fixation free mesh|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
89043672|NCT05655988|Active Comparator|mesh migration after TEPP / mesh with fixation|TEPP surgeries performed with mesh fixation
89644571|NCT02969850|Placebo Comparator|Placebo|Participant will receive a placebo. If subject has insufficient dietary calcium intake, calcium supplementation will be provided in the form of one 600mg CaCO3 pill to achieve a total calcium intake of 1200mg/day.
89644572|NCT02339766|Sham Comparator|Group 1|Group 1 will receive intrathecal morphine co-administered with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Sham Block be done with 25 mL of saline per side.
89644573|NCT02339766|Active Comparator|Group 2|Group 2 will receive an equivalent volume of intrathecal saline co-administered with the spinal anesthetic. After surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
89644574|NCT02339766|Active Comparator|Group 3|Group 3 will receive will receive intrathecal morphine with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
89644575|NCT05092464|Experimental|Single arm open label study|12 week-treatment of 5% natural lactic acid-enriched cream (BID)
89644576|NCT04287660|Experimental|BiRd combined with BCMA CAR T-cells infusion|
89644577|NCT04280016|Experimental|Exercise Added to Off-loading|Participants in this arm will participate in exercise at the healthcare facility one time a week (away from where wound care is provided) and be instructed in a home exercise program that they will be encouraged to perform at least three days per week with no more than two days between sessions. Wound care will continue at the facility as is standard, utilizing off-loading.
89644578|NCT04069104||ABCD training with standard feedback|Asymmetry, Border, Color, Diameter (ABCD) training message intervention with standard dermatological feedback
89644579|NCT04069104||ABCD training with motivational feedback|ABCD training message intervention with dermatological feedback and a motivational message
89644580|NCT04069104||ABCD training with no feedback|ABCD message intervention with no feedback
89644581|NCT04069104||UDS method training with standard feedback|Ugly Duckling Sign (UDS) method message intervention with dermatological feedback.
88991981|NCT02687464|Experimental|Non-operative treatment group|IV fluids, minimum 12 hrs IV antibiotics, minimum 12 hrs clear PO fluids only, regular clinical review. Discharge within 24 hrs after randomization, if study criteria met. If stable but not adequate improvement for discharge, non-operative management continues. If not improved by 48 hrs, appendectomy will be done. Discharge home once vital signs are within normal limits, light oral diet tolerated, adequate oral pain relief and mobile. Total 10 days of antibiotics (IV and oral) following randomization will be given. Antibiotics used vary between centers and will be current standard of care in that center; improving study feasibility and increased generalization of results.
89043673|NCT04636658|Active Comparator|Incentive spirometer training|Incentive spirometer training
89043674|NCT04636658|Experimental|diaphragmatic resistance exercises|Incentive spirometer training with diaphragm breathing with resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient
89043675|NCT05655910|Experimental|Group 1 (Not malnourished) - 3 products per day|Patients assessed as well-nourished based on AND-ASPEN criteria and randomized to receive 3 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
89043676|NCT05655910|Experimental|Group 1 (Not malnourished) - 1 product per day|Patients assessed as well-nourished based on AND-ASPEN criteria and randomized to receive 1 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
89043677|NCT05655910|Experimental|Group 2 (at risk/malnourished)|Patients assessed as at risk for malnourishment or malnourished based on AND-ASPEN criteria automatically assigned to receive 3 Ensure Surgery Immunonutrition shake per day during the days from consent to LVAD implantation.
89043678|NCT04636463|Experimental|Hand Surgery with Music|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) while listing to music
89043679|NCT04636463|No Intervention|Hand Surgery without Music (Control Group)|Participant undergoes surgery hand surgery using Wide Awake Local Anesthesia with no tourniquet (WALANT) without listening to music
89043680|NCT04636736||HIV POLISH (PL)|HIV infected people with polish nationality, who most probably acquired infection in Poland
89043681|NCT04636736||HIV MIGRANTS (M)|HIV infected people, originating from outside of Poland, where they were diagnosed with HIV infection
89043682|NCT04680702|Experimental|Metabolic Syndrome and Sims Score|
89644582|NCT04069104||UDS method training with motivational feedback|UDS message intervention with dermatological feedback and a motivational message.
89043683|NCT00560261|Experimental|1:Children with sickle cell disease|"NO-CO inhalation and expiration:~Children with sickle cell disease"
89043684|NCT00560261|Active Comparator|2: Healthy volunteers|"NO-CO inhalation and expiration:~Healthy volunteers"
89043685|NCT00560300|Experimental|1|Doxercalciferol + Calcium Carbonate
89043686|NCT00560300|Experimental|2|Doxercalciferol + Sevelamer
89043687|NCT00560300|Experimental|3|Calcitriol + Calcium Carbonate
89043688|NCT00560300|Experimental|4|Calcitriol + Sevelamer
89043689|NCT02895243|Experimental|Prehabilitation|
89043690|NCT02904369|Experimental|F/TAF 200/10|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/10 mg)
89043691|NCT02904369|Experimental|F/TAF 200/25|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/25 mg)
89043692|NCT02904369|Active Comparator|F/TDF 200/300|Emtricitabine (FTC) + Tenofovir Disoproxil Fumarate (TDF) (200/300 mg)
89043693|NCT02904330|Experimental|Single dose|The intervention is K1-70 intramuscular or K1-70 intravenous. This is a single, ascending, intramuscular or intravenous dose, sequential group study.
89043694|NCT00560378|Experimental|Tacrolimus Ointment 0.1%|
89043695|NCT00560456|Experimental|1|snorers
89043696|NCT00560456|Other|2|healthy volonters (control)
89043697|NCT00560456|Experimental|3|young subjects
89043698|NCT00560456|Experimental|4|mature subjects
89043699|NCT04636424|Experimental|spastic diplegic group|assessment of the speed and weight distribution during gait
89043700|NCT04636424|Experimental|hemiplegic group|assessment of the speed and weight distribution during gait
89043701|NCT04636346||COMPASS (Psychoeducational / Behavioral Program)|Group Acceptance and Commitment Therapy program as part of clinical service for cancer patients
89043702|NCT02895321|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity. The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense and Colgate Protection Caries and Placebo gel.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The effectiveness will be evaluated: immediately after application and after 2, 4, 8 weeks."
89043703|NCT04636112||control group|Patients hospitalized and diagnosed as non-AMI during the same time period were matched. All patients underwent coronary angiography and CAD was defined as at least one main coronary artery with > 50% narrowing of luminal diameter.
89043704|NCT04636112||AMI group|Patients were diagnosed as MI when a cardiac biomarker (preferably cardiac troponin) rose or fell at least one value in its 99th percentile upper reference limit and at least one of the following criteria was met, including ischemic symptoms, electrocardiogram (ECG) changes of new ischemia, pathologic Q waves in the ECG, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, identification of an intracoronary thrombus by angiography or autopsy.
89043705|NCT02894970||Healthy adults|Healthy adults for checking feasibility of Pulmonary PPG
89043706|NCT02894970||Healthy children|Healthy children for checking feasibility of Pulmonary PPG
89043707|NCT02894970||Healthy neonates|Healthy neonates for checking feasibility of Pulmonary PPG and in order to be a control group for neonates with pulmonary hypertension.
89043708|NCT02894970||Healthy preterm neonates|Healthy preterm neonates for checking feasibility of Pulmonary PPG and in order to be a control group for premature neonates with patent ductus arteriosus (PDA).
89043709|NCT02894970||Preterm neonates with PDA|Preterm neonates with hemodynamic significant PDA. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
89043710|NCT02894970||Neonates with pulmonary hypertension|Neonates with pulmonary hypertension. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
89043711|NCT02904174|Experimental|Healthy Living Programme|6 weeks program, with 45 minutes weekly session over 6 weeks.Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies.
89043712|NCT02894931|Sham Comparator|Control|Dietary Interventions: Control- water, Flavered Chilled water, will be administered once after O.N fasting.
89043713|NCT02894931|Active Comparator|Glucose|Dietary Interventions: Glucose, Monosaccharides, at the dose of 50 g, based on oral loading tests, once.
89644583|NCT04069104||UDS training with no feedback|UDS message intervention with no feedback.
89644584|NCT04069104||ABCD-F training with standard feedback|ABCD-F intervention with dermatological feedback.
89644585|NCT04069104||ABCD-F training with motivational feedback|ABCD-F intervention with dermatological feedback and a motivational message.
89644586|NCT04069104||ABCD-F training with no feedback|ABCD-F intervention with no feedback.
89644587|NCT04069104||No message intervention with standard feedback|No message intervention, but with dermatological feedback.
89644588|NCT04069104||No message intervention with motivational feedback|No message intervention, but with dermatological feedback and a motivational message.
89644589|NCT04069104||No message intervention with no feedback|No message intervention and no feedback. True control.
89644590|NCT01396057|Experimental|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally
89644591|NCT01396057|Sham Comparator|Dexamethasone|Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months
88991982|NCT02687464|Active Comparator|Appendectomy group|Laproscopic appendectomy within 18 hrs of randomization. IV antibiotics given from time of randomization and continued post-operatively per the standardized treatment regimen: children with visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue IV antibiotics for a minimum of 3 days and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group.
89644592|NCT02419560|Experimental|ABT-199 and Ibrutinib Combination|Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).
89644593|NCT05092308||Parents and their children with Behavioral insomnia|Parents and their children aged 6-36 months with sleep problems will be invited to participate into the study from Sleep Outpatient Clinic
88991983|NCT02660580|Experimental|MSB11022 (Core Treatment Period)|Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
88991984|NCT02660580|Active Comparator|EU-Humira|Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
88991985|NCT02660580|Experimental|MSB11022 (Extended Treatment Period)|Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
89644594|NCT05092308||Parents and their children without sleep problem|Parents and their children aged 6-36 months without sleep problems will be invited to participate into the study followed up in Well Child Clinic
89644595|NCT04540224||Luminal A|Breast cancer patients with Luminal A phenotype
89644596|NCT04540224||Luminal B|Breast cancer patients with Luminal B phenotype
89644597|NCT04540224||Triple Negative|Breast cancer patients with Triple negative phenotype
89644598|NCT04540224||Control|Healthy volunteers
89644599|NCT05091996|Experimental|Post-isometric muscle relaxation group|The post-isometric relaxation techniques were administered to the mandibular adductors and muscles responsible for lateral movements of the mandible.
89644600|NCT05091996|Experimental|Myofascial release group|The myofascial release procedure was performed successively in the area of the anterior parts of the temporal muscles, the superficial parts of the masseter muscles and the sternocleidomastoid muscles.
89644601|NCT05091840||patients requiring intubation at birth and subsequent surfactant administration|
89644602|NCT05091840||patients who receive surfactant by LISA|
89644603|NCT00704847|Active Comparator|1|SMC021 Oral Calcitonin
89644604|NCT00704847|Placebo Comparator|2|SMC021 Placebo
89644605|NCT01380769|Experimental|CRLX101|
89644606|NCT01380769|Other|Best supportive care|
89644607|NCT05091762|No Intervention|Blank control group|
89644608|NCT05091762|Experimental|Exercise group|
89644609|NCT05091762|No Intervention|Hyperlipidemia group|
89644610|NCT05091762|No Intervention|Hyperlipidemia and medication group|
89644611|NCT05091762|Experimental|Hyperlipidemia and exercise group|
89644612|NCT05091762|Experimental|Hyperlipidemia and medication and exercise group|
89644613|NCT05091762|No Intervention|Routine treatment group|
89043714|NCT02894931|Experimental|Fructose|Dietary Interventions: Fructose, Monosaccharides, at the dose of 50 g, once.
89043715|NCT02894931|Experimental|Galactose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
89043716|NCT02894931|Experimental|Mannose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
89043717|NCT02894931|Experimental|Maltose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
89043718|NCT02894931|Experimental|Sucrose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
89043719|NCT02894931|Experimental|Lactose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
89644614|NCT05091762|Experimental|Routine treatment and exercise group|
89644615|NCT03393468|Experimental|Sequence A: Dapivirine gel|Participants will receive 2.5 g of dapivirine gel administered rectally via an applicator, followed by a 2- to 4-week washout period. Participants will then receive a second dose of up to 10 g of dapivirine gel administered rectally via a coital simulation device.
89644616|NCT03393468|Experimental|Sequence B: Dapivirine gel|Participants will receive up to 10 g of dapivirine gel administered rectally via a coital simulation device, followed by a 2- to 4-week washout period. Participants will then receive a second dose of 2.5 g of dapivirine gel administered rectally via an applicator.
89644617|NCT02999685|Active Comparator|Home-base Pulm Rehab w/ Health Coaching|The intervention group starts with 8 weeks of Home-base Pulmonary Rehab with Health Coaching, followed by 8 weeks of observation.
89644618|NCT02999685|Active Comparator|Control/Wait|The Control/Wait group starts with 8 weeks of observation, followed by 8 weeks of intervention (Home-base Pulm Rehab w/ Health Coaching).
89644619|NCT02999529|Experimental|Education Group|Participants offered a consent for chemotherapy treatment will watch an educational video.
89644620|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 7.5 mcg H1N1v full MF59 adjuvant|
89644621|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 3.75 mcg H1N1v half MF59 adjuvant|
89644622|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 15 mcg H1N1v unadjuvanted|
89644623|NCT01012557|Active Comparator|Non-pregnant mothers, 7.5 mcg H1N1v full MF59 adjuvant|
89644624|NCT01395901|Experimental|Palonosetron and placebo to Ondansetron|Intervention: Drug: Palonosetron
89644625|NCT01395901|Active Comparator|Ondansetron and placebo to Palonosetron|Intervention: Drug: Comparator: Ondansetron
89644626|NCT02994147|Placebo Comparator|Placebo|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
89644627|NCT02994147|Experimental|AC-201CR 72mg|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
89644628|NCT03030534|Experimental|Experimental Group|Educational Package and software package
89644629|NCT03030534|Active Comparator|Control group|Health promotion tips
89644630|NCT04270539|Experimental|Experimental Group (nap)|The experimental group will be allowed to take a brief nap daily on school days during the study period.
89644631|NCT04270539|No Intervention|Control Group (no nap)|The control group will not be allowed to take daily nap on school days during the study period.
89644632|NCT02995239|Active Comparator|CJ-12420 formulation 1|CJ-12420 formulation 1
89644633|NCT02995239|Active Comparator|CJ-12420 formulation 2|CJ-12420 formulation 2
89644634|NCT02570100|Experimental|Biological collection|Before, during and after their treatment by chemotherapy, patients will undergo laboratory examinations.
89644635|NCT01395823|Other|ergocalciferol supplementation|
89644636|NCT01395823|Placebo Comparator|placebo|
89644637|NCT02993991|Experimental|Mocetinostat and Durvalumab|"Patients will start therapy with mocetinostat within 10 days of study enrollment. Mocetinostat will be given in 2 dose levels (n = 6 evaluable patients each) of 70mg three-times weekly and 90mg three-times weekly for 2 weeks.~Durvalumab will be given as a single infusion at a dose of 1500mg, over a period of 1-hour, on day 8 of the study."
89644638|NCT00158184|Active Comparator|Rx Opioid Abusers|Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.
89644639|NCT00158184|Active Comparator|Rx Opioid Non-Abusers|Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.
89043720|NCT02894931|Experimental|Saccharin|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
89043721|NCT02894931|Experimental|Aspartame|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
89644640|NCT02993913|Experimental|Simmiparib tablet monotherapy|Drug: Simmiparib tablet oral Qd or Bid
89644641|NCT02405520|Experimental|low dosage HPV Vaccine|Participants in this arm would receive low dosage of HPV vaccines.
89644642|NCT02405520|Experimental|medium dosage HPV Vaccine|Participants in this arm would receive medium dosage of HPV vaccines.
89644643|NCT02405520|Experimental|high dosage HPV Vaccine|Participants in this arm would receive high dosage of HPV vaccines.
89644644|NCT02405520|Placebo Comparator|Placebo|Participants in this arm would receive placebo (Aluminium Adjuvant).
89644645|NCT02356302|Experimental|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|The vicriviroc (MK-4176) IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
89644646|NCT02356302|Experimental|MK-2048 IVR|The MK-2048 IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
89644647|NCT02356302|Experimental|MK-2048A IVR|The MK-2048A IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
89644648|NCT02356302|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0), and it will be removed on Day 28.
89644649|NCT04270383||2019-nCoV infection group|Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019-nCoV infection group.
89644650|NCT04270383||Control group|Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019-nCoV infection group are classified as the control group.
89644651|NCT04270461|Experimental|Arms|NKG2D-based CAR T-cells Injection; Dosage:1-10x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time
89644652|NCT02999451|Experimental|snare group|snare-assisted POEM
89043722|NCT02894931|Experimental|Sucralose|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
89043723|NCT02894931|Experimental|Steviol|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
89043724|NCT02894931|Experimental|Leucine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
89644653|NCT02999451|Active Comparator|conventional group|knife-assisted POEM
89644654|NCT02993835|Active Comparator|Labeled iron salt (Fe54)|Labeled iron salt (Fe54) with bouillon
89644655|NCT02993835|Active Comparator|Labeled iron salt (Fe57)|Labeled iron salt (Fe57) with bouillon
89644656|NCT02993835|Experimental|Labeled iron salt (Fe58)|Labeled iron salt (Fe58) with bouillon
89644657|NCT05091138|Active Comparator|Mg and Bupivacaine|Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 150mg of Mg.
89644658|NCT05091138|Active Comparator|Buprenorphine and Bupivacaine|Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 300 mcg of buprenorphine.
89644659|NCT02993679|Other|double-bundle ACL reconstruction|surgical reconstruction of the anterior cruciate ligament
89644660|NCT02993679|Other|anterolateral ligament reconstruction|surgical reconstruction of the anterolateral ligament
89644661|NCT02989818||Lesion of the Gastrointestinal tract|Investigator will collect prospective data on the Endoscopic Submucosal dissection that is used as part of the subjects standard of care to remove the Gastrointestinal lesion
89644662|NCT02999295|Experimental|Phase 1|Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeks
89644663|NCT02999295|Experimental|Phase 2|Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks
89644664|NCT05094726|Experimental|Group A|the participant will received photobiomodulation session.
89644665|NCT05094726|Placebo Comparator|Group B|the participant will received placebo photobiomodulation session.
89644666|NCT05094648||group A|Covidpatient Who pass on high flow nasal therapy
89644667|NCT05094648||group B|Covidpatient who failed on high flow nasal therapy and need NIV
89644668|NCT02998905|Experimental|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban
89644669|NCT02998905|Active Comparator|Acetylsalicylic Acid|Acetylsalicylic acid
89644670|NCT02993367|Experimental|the Butylphthalide Soft Capsules group|600mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
89644671|NCT02993367|Placebo Comparator|the placebo group|60mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
89644672|NCT05094492|Experimental|Self assembling peptide P11-4 with fluoride|P11-4 forms a 3D matrix within subsurface of incipient carious lesions , allowing formation of new hydroxyapatite crystal facilitating guided regeneration of enamel lesions. Combination with fluoride will have a synergistic effect on remineralization potential
89644673|NCT05094492|Active Comparator|Fluoride varnish|Gold standard agent for remineralization of incipient carious lesions.
89644674|NCT01380691|Experimental|LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc|"Period 1: 18 milligrams (mg) LY2216684 (LY) administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic (Alc) beverage (with an alcohol dose of 0.6 grams per kilograms [g/kg] for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching (Pl-Match) alcoholic beverage, taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
89043725|NCT02894931|Experimental|Isoleucine|Dietary Interventions: The dose of the different BCAAs Amino acids - 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
89043726|NCT02894931|Experimental|Valine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
89043727|NCT04635956|Experimental|Study group|Patients will accept therapy consisting of platinum/etoposide/bevacizumab/camrelizumab
89043728|NCT02903979|Experimental|HVGIC|Restorations with only HVGIC in deep caries lesion of primary teeth.
89043729|NCT02903979|Active Comparator|Indirect pulp capping|Indirect pulp capping with calcium hydroxide cement, restored with HVGIC:
89043730|NCT04635488||Trainning group|70% of the whole participants would be randomly divided into the training group to build the predicition model.
89644675|NCT01380691|Experimental|Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
89644676|NCT01380691|Experimental|LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc|"Period 1: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
89644677|NCT01380691|Experimental|Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
89644678|NCT01270893|Experimental|Nilotinib and Surgical Resection|
89644679|NCT01270893|Experimental|Nilotinib and Potential Resection|
89644680|NCT02998515|Experimental|ESWT order: 1.liquid oxygen, 2. concentrator|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a portable liquid Oxygen device (Companion) and continue on the day after with ESWT by using supplemental Oxygen from a portable concentrator.
89644681|NCT02998515|Experimental|ESWT order: 1. concentrator, 2. liquid oxygen|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a concentrator and continue on the day after with ESWT by using supplemental Oxygen from a portable liquid Oxygen device.
89644682|NCT01271049|Placebo Comparator|Control Food Product|Consumption of placebo food product
89644683|NCT01271049|Experimental|Novel Food Product|Consumption of novel food product
89644684|NCT02998593|Experimental|extracted red Bahman and white bahman|500 mg of extracted red Bahman and white bahman that is used once a day.
89644685|NCT02998593|Placebo Comparator|Placebo|500 mg of placebo once time a day
89644686|NCT02993289|Active Comparator|Detoxification and pharmacological prophylactic treatment|Group A: Two months detoxification program combined with pharmacological prophylactic treatment from start.
89644687|NCT02993289|Active Comparator|Pharmacological prophylactic treatment|Pharmacological prophylactic treatment from start without detoxification.
89644688|NCT02993289|Active Comparator|Detoxification|Two months detoxification program with postponed pharmacological prophylactic treatment after ended detoxification.
89644689|NCT02993289|No Intervention|Control group 1: Episodic migraine|
89644690|NCT02993289|No Intervention|Control group 2: Healthy volunteers|
89644691|NCT04386447|Experimental|Oxytocin 40 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
89644692|NCT04386447|Experimental|Oxytocin 25 UI + SOC|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
89043731|NCT04635488||validation group|30% of the whole participant would be divided into the validation group to validate the model
89043732|NCT02895204|Experimental|Test group (F-MRP)|Fermented Maillard reacted whey protein (F-MRP) supplementation
89043733|NCT02895204|Placebo Comparator|Placebo group|Placebo supplementation
89043734|NCT02904135||first stage|During the first stage, the patient's baseline blood sample will be mainly used for validating and troubleshooting our instrument with clinical samples.
89644693|NCT04386447|Other|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~Oxygen supply or non-invasive ventilation to target peripheral blood saturation > 94%~Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~Prophylaxis for deep vein thrombosis~Steroids are not routinely recommended but may be considered in selected patients."
89043735|NCT02904135||second stage|During the second stage, 40 patients will be followed for up to three years after their baseline blood draw to obtain data on their survival status. The CTC results and follow-up data obtained from these samples will help to analyze any correlation with the patient's clinical outcome and further validate the prognosis ability of MiCareo's CTC platform for mBC patients.
89043736|NCT02894892|Active Comparator|(A)Bismuth|(A)Bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
89043737|NCT02894892|Active Comparator|(B)Bismuth|(B)Bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
89043738|NCT02894892|Active Comparator|(C)Bismuth|(C)Bismuth (120mg/tab) q.i.d. and endoscopy the next day
89043739|NCT02894892|Active Comparator|(D)Esomeprazole and Bismuth|(D)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
89043740|NCT02894892|Active Comparator|(E)Esomeprazole and Bismuth|(E)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
89043741|NCT02894892|Active Comparator|(F)Esomeprazole and Bismuth|(F)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) q.i.d. and endoscopy the next day
89043742|NCT02894892|Other|(G)Control|(G)These patients underwent endoscopy due to abdominal discomfort or other symptoms and did not have cancers in the digestive tract after series of workup.
89644694|NCT02993133|Experimental|60 patients will be used to build and validate the system|The first 30 patients will be used to build and validate the pharmacokinetic modeling of MPA in pemphigus.The 30 patients included later will provide additional data.
89644695|NCT02993055|Experimental|Ulimorelin|Active
89644696|NCT02993055|Placebo Comparator|Placebo|Placebo
89644697|NCT02992977|Experimental|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
89644698|NCT02114814|Experimental|Intervention group|Diabetes self-management and family support
89644699|NCT02114814|Active Comparator|Attention control group|General health information
89043743|NCT04635566|Active Comparator|Mebeverine|Mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
89043744|NCT04635566|Placebo Comparator|Placebo|Placebo one time/day at the evening.
89043745|NCT04635293|Active Comparator|patients who were administered levosimendan at a dose of 0.1µg/Kg/min for 24 hours prior to surgery|
89043746|NCT04635293|Placebo Comparator|patients who were not administered levosimendan prior to surgery|
89043747|NCT02894736|Experimental|Active tDCS|Soterix tDCS machine is used to administer active stimulation
89043748|NCT04635215||Participants|There are not multiple groups in this study
89043749|NCT02903862|Experimental|Intervention Arm|Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks. The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app. This arm will also take the study's psychological surveys.
89043750|NCT02903862|Other|Waitlist Control Arm|These participants will take psychological surveys and a usability questionnaire for the first 12 weeks of participation, then, for the 12 weeks following, take the psychological surveys along with DANA and a usability questionnaire.
89043751|NCT02894775||included in a clinical trial|
89043752|NCT02894775||not included in a clinical trial|
89043753|NCT01227889|Experimental|GSK2118436|Subjects in this arm will receive GSK2118436 150 mg twice daily.
89644700|NCT01380535|Experimental|ECP Methoxsalen + Standard of Care|Participants receive methoxsalen administered via ECP in addition to standard of care
89644701|NCT01380535|Active Comparator|Standard of Care|Participants receive standard of care only
89644702|NCT00725361|Experimental|Active|Ambrisentan
89644703|NCT05721612|Experimental|Study group|
89644704|NCT05721612|Active Comparator|Control gorup|
89644705|NCT04385979|Active Comparator|Curcumin|%2 Curcumin gel
89644706|NCT04385979|Active Comparator|Nanocurcumin|%1 NanoCurcumin gel
89644707|NCT05094024|Active Comparator|Central kitchen-prepared MDCF-2 arm|Children randomized to this arm will receive 25gm of kitchen-prepared version of MDCF-2 twice daily.
89644708|NCT05094024|Experimental|Ready-to-use supplementary food (RUSF) arm|Children randomized to this arm will receive 25g RUSF twice daily.
89644709|NCT05094024|Experimental|Freshly reconstituted MDCF-2 ingredients|Children randomized to this arm will receive individually packaged MDCF-2 ingredients, combined into 21.72g servings provided twice daily.
89644710|NCT05094024|Experimental|MDCF-2 shelf-stable foil pouch prototype with green banana powder|Children randomized to this arm will receive 21.77gm of shelf-stable foil pouch prototype with green banana powder twice daily.
89644711|NCT05094024|Experimental|MDCF-2 shelf-stable foil pouch prototype with sweet potato|Children randomized to this arm will receive 23.34gm of MDCF prototype with sweet potato twice daily.
88991986|NCT02660580|Active Comparator|EU-Humira/EU-Humira|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.
89644712|NCT02816424|Experimental|Brief Motivational Interviewing|Principles and skills of motivational interviewing will be used with participants assigned to brief intervention. These participants will receive feedback that they are at risk for unintended pregnancy. They will receive information on the likelihood of pregnancy given their self-reported frequency of unprotected sex. They will be given information regarding negative consequences associated with teen pregnancy. They will be provided with information on the chances of pregnancy with abstinence, condom use, oral contraceptives, and Long Acting Reversible Contraceptives (LARC). Following information exchange, participants who are high in readiness to change will engage in action planning, whereby a specific plan for reducing risk for unintended pregnancy will be collaboratively developed with the interventionist. Patients who are low in readiness to change will complete a motivational interviewing-based roadmap activity that is designed to strategically evoke motivational speech.
89644713|NCT02816424|No Intervention|Control|
89644714|NCT01275885|Active Comparator|Vitamin D3 10µg|
89644715|NCT01275885|Active Comparator|Vitamin D3 30µg|
89644716|NCT01275885|Active Comparator|Vitamin D3 40µg|
89644717|NCT01380379|Experimental|Life skills and self-defense training|Women will participate in a therapeutic group which covers education, skills, and empowerment activities.
89644718|NCT02794896|Experimental|Deep Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS 45 (group 1, deep anesthesia). Anesthesia depth was measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below or equal to a BIS level of 45 were counted.
89644719|NCT02794896|Experimental|Shallow Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a inter scalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
89644720|NCT01271283|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
89644721|NCT02985307|Experimental|Short Message Text Service|Participants receive short messages daily via their mobile phone
89644722|NCT02985307|Active Comparator|Standard Weight Management Group|Participants attend standard group weight management sessions
89644723|NCT05090670|Experimental|Germanium-Embedded Knee Brace|Following surgery the patients effected limb would be placed in an Germanium-Embedded Knee Brace
89644724|NCT05090670|Active Comparator|Replica Knee Brace|Following surgery the patients effected limb would be placed in a replica knee brace
89644725|NCT01275963||Control|Healthy individuals without structural heart disease
89644726|NCT01275963||CAD|Patients with coronary artery disease
89644727|NCT01275963||DCM|Participants with dilated cardiomyopathy
89644728|NCT01275963||HNCM|Patients with hypertrophic non-obstructive cardiomyopathy
89644729|NCT01275963||HOCM|Patients with hypertrophic obstructive cardiomyopathy
89644730|NCT01275963||RCM|Patients with restrictive cardiomyopathy
89644731|NCT01275963||Amyloidosis|Patients with cardiac manifestation of amyloidosis
89644732|NCT01275963||HFPEF|Patients with heart failure with preserved ejection fraction (diastolic heart failure)
89644733|NCT01276119|Experimental|Cohort A, CDP6038 0.001 mg/kg, iv|
89644734|NCT01276119|Experimental|Cohort B, CDP6038 0.01 mg/kg, iv|
89644735|NCT01276119|Experimental|Cohort C, CDP6038 0.03 mg/kg, iv|
89644736|NCT01276119|Experimental|Cohort D, CDP6038 0.1 mg/kg, iv|
89644737|NCT01276119|Experimental|Cohort E, CDP6038 0.3 mg/kg, iv|
89644738|NCT01276119|Experimental|Cohort G, CDP6038 1.0 mg/kg, iv|
89644739|NCT01276119|Experimental|Cohort I, CDP6038 3.0 mg/kg, iv|
89644740|NCT01276119|Experimental|Cohort K, CDP6038 10.0 mg/kg, iv|
89644741|NCT01276119|Placebo Comparator|Cohort A, Placebo, iv|
89644742|NCT01276119|Placebo Comparator|Cohort B, C, D, E, G, I, K, Placebo, iv|
89644743|NCT01276119|Experimental|Cohort F, CDP6038 0.3 mg/kg, sc|
89644744|NCT01276119|Experimental|Cohort H, CDP6038 1.0 mg/kg, sc|
89644745|NCT01276119|Experimental|Cohort J, CDP6038 3.0 mg/kg, sc|
89644746|NCT01276119|Placebo Comparator|Cohort F, H, J, Placebo, sc|
89644747|NCT01271439|Experimental|cetuximab|
89644748|NCT01271517|Active Comparator|Insulatard|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugars
89644749|NCT01271517|Active Comparator|Lantus|Treatment once daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
88991987|NCT02660580|Experimental|EU-Humira/MSB11022|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
88991988|NCT02629809|Experimental|Treatment (iFCG)|See Detailed Description.
88991989|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
89644750|NCT01271517|Active Comparator|Levemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
89043754|NCT01227889|Active Comparator|Dacarbazine (DTIC)|Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
89043755|NCT01227889|Experimental|Crossover|Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.
89043756|NCT02894814|Active Comparator|Basic intervention|Elements of One-Stop Dispensing (use of own medication, placed in bedside locker, partly or self-administration of medication during hospitalization)
89043757|NCT02894814|Active Comparator|Extended intervention|Elements of One-Stop Dispensing and focused dialogue with the patients about their medication during the hospitalization.
89043758|NCT02894814|No Intervention|Observational part of the study|Data collection on patients under the traditional medication system
89043759|NCT04635332|Experimental|Intervention|In the intervention arm, participants will be exposed to the developed intervention materials and face to face group sessions.
89043760|NCT04635332|Active Comparator|Control arm|In the control arm, participants will only be given the developed intervention materials. Face to face group sessions will not be held for the control arm.
89644751|NCT05090592||myopic children|Myopic children use overnight orthokeratology or 0.01% atropine eye drop per night for myopia control
89644752|NCT02992665|Experimental|Ca ionophore|Artificial activation of the oocytes using Calcium ionophore in the cases of severe male factor infertility.
89644753|NCT02992665|Experimental|Placebo|Placebo was used to control the group of Calcium ionophore
89644754|NCT05082636||case|54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital,
89644755|NCT05082636||control|besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).
89644756|NCT02992353|Active Comparator|Three-port pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
89644757|NCT02992353|Active Comparator|Single-port or two-port surgery|Treated by minimally invasive video assisted thoracoscopic single-port or two-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
89644758|NCT05093478|Experimental|Treatment|
89644759|NCT01380145|Experimental|recMAGE-A3 Protein + AS15 Adjuvant|Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
89644760|NCT05376072|Experimental|Experimental data|
89644761|NCT05367193|Experimental|pars plana vitrectomy performed using NGENUITY® 3D Visualization System (Alcon, TX, USA)|NGENUITY® 3D Visualization System (Alcon, TX, USA)
89644762|NCT05367193|Active Comparator|standard binocular microscope pars plana vitrectomy|standard binocular microscope pars plana vitrectomy
89644763|NCT00725751||PegIFN-2b/ribavirin with substitution therapy|Participants in this cohort received antiviral treatment and substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
89043761|NCT02894541|Experimental|CKD-519 tablet 100mg|CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
89043762|NCT02894541|Experimental|CKD-519 tablet 200mg|CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
89043763|NCT02894541|Experimental|CKD-519 soft capsule 100mg|CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
89644764|NCT00725751||PegIFN-2b/ribavirin without substitution therapy|Participants in this cohort received antiviral treatment but did not receive substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
89644765|NCT05364385|Experimental|S/B group- infants|Infants randomized to the study group (S/B group) will receive surfactant and Budesonide - 0.5 mg -1mL
89644766|NCT05364385|Placebo Comparator|S/P group- control / placebo comparator|Infants randomized to the control group (S/P group) will receive surfactant and placebo (Normal Saline -1mL)
89644767|NCT00726375|Experimental|Etanercept|a maximum of 8 SQ doses of 'Etanercept (Enbrel) at 0.4mg/kg per dose up to a maximum of 25 mg per dose
89644768|NCT05368597||Native vessel PCI|Native vessel PCI, which choose native coronary artery as the target vessel
89644769|NCT05368597||Bypass graft PCI|Bypass graft PCI, which choose the graft vessel as the target vessel
89644770|NCT01276275||Exposure Group 1|First time users of ticagrelor
89644771|NCT01276275||Exposure Group 2|First time users of clopidogrel
89043764|NCT02894541|Experimental|CKD-519 soft capsule 200mg|CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
89043765|NCT02888392|Experimental|Kiwifruit intervention|4 week intervention treatment with 2 fresh, whole green kiwifruit per day
89644772|NCT01276275||Exposure Group 3|First time users of prasugrel
89644773|NCT00710931|Experimental|ReSTOR +3 Multifocal Lens|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL)
89644774|NCT05363059||BS group|The group of bariatric surgery therapy in metabolic syndrome patients.
89644775|NCT05363059||MT group|The group of medical therapy in metabolic syndrome patients
89644776|NCT01271595|Active Comparator|acupuncture|12 sessions of acupuncture according to TCM
89644777|NCT01271595|Sham Comparator|sham acupuncture|superficial acupuncture at non acupuncture sites
89644778|NCT03420222|Experimental|AVP-786|Participants were to receive AVP-786-28 (deudextromethorphan hydrobromide [d6-DM] 28 milligrams [mg]/quinidine sulfate [Q] 4.9 mg) once daily (OD) for the first 7 days, followed by AVP-786-28 twice daily (BID) for the next 7 days. Beginning on Day 15, participants were to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) BID for 10 weeks.
89644779|NCT03420222|Placebo Comparator|Placebo|Participants were to receive placebo BID for 12 weeks.
89043766|NCT02888392|Active Comparator|Psyllium intervention|4 week intervention treatment with psyllium, matched for fibre content of 2 green kiwifruit / day for 4 weeks
89043767|NCT04635020|Experimental|Stable glaucoma iStent|Cataract surgery combined with iStent inject
89043768|NCT04635020|Experimental|Stable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
89043769|NCT04635020|Active Comparator|Stable glaucoma|Cataract surgery
89043770|NCT04635020|Experimental|Unstable glaucoma iStent|Cataract surgery combined with iStent inject
89043771|NCT04635020|Experimental|Unstable glaucoma SLT-laser|Cataract surgery combined with SLT-laser 1 month after surgery
89043772|NCT05655871|Experimental|Enterprise Group|"Elderly individuals were divided into 5 groups according to the stages of change in the TTM scale. According to the change phase, those in the non-thinking phase are at 10:00 on Mondays, Wednesdays and Fridays, those in the thinking phase are at 13:00 on Mondays, Wednesdays and Fridays, and those in the preparatory phase are at 15:00 on Mondays, Wednesdays and Fridays of the week. They were asked to come to the seminar hall at 00:00. It was explained that a training video about physical activity would be watched. Those in the preparation phase were asked to come to the activity hall at 10:00 on Tuesdays, Thursdays and Saturdays of the week, and at 14:00 on Tuesdays, Thursdays and Saturdays of the week, while wearing their comfortable clothes. It was said that a training and motivational video about physical activity would be watched and the exercises would be done under the supervision of the researcher with the show-and-make technique."
89043773|NCT05655871|Experimental|Control Group|"Data collection forms were applied to the control group in the pre-test. These forms are; Personal Information Form, Tinetti Balance and Gait Test, Exercise Change Stages Scale, Exercise Change Process Scale, Exercise Decision-Making Scale, Exercise Self-Efficacy Scale. In order to avoid an ethical dilemma between the individuals in the control and intervention groups, the videos will be watched by the individuals in the control group at the end of the study."
89043774|NCT04681716|Active Comparator|ELDOA GROUP|ELDOA position was instructed to this group
89043775|NCT04681716|Experimental|CONVENTIONAL PHYSIOTHERAPY|Hot pack,TENS and mobalization was given in this group
89043776|NCT04681521|Experimental|HOT THERAPY:GROUP A|Hot Compress Group
89043777|NCT04681521|Experimental|COLD THERAPY:GROUP B|Cold Compress Group
89043778|NCT04681521|Placebo Comparator|PLACEBO: GROUP C|Inoperative compress Group
89644780|NCT04766593|Experimental|Oncological functional reeducation program|"It will consist of the following actions:~Prescription of multimodal physical exercise: This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).~Retraining in activities of daily living: Gradation and simplification of activities and training in energy saving techniques (EAT).~Finally, an exhaustive daily record of the activity carried out by the patient will be carried out, from which it will be modified, adapting it to the clinical situation of the patient."
89644781|NCT04766593|Active Comparator|Prescription of multimodal physical exercise|This therapeutic measure will be carried out both in the individuals of the experimental group and in those of the control group. It will be held daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. The guideline will be to maintain a multimodal exercise to perform exercises of different characteristics, including aerobic exercises, balance exercises and low-load strength exercises for muscle groups, both in the upper quadrant and the lower quadrant. The sessions were structured according to the recommendations of the American College of Sports Medicine (ACSM) 18, with an initial warm-up (2-3 minutes), a main part (8-12 minutes) and a final cool-down and relaxation (5 minutes).
89644782|NCT04386291|Active Comparator|Anxiety Reduction Training (A.R.T.)|Participants will received biweekly on-line lessons that provide education and strategies to reduce stress and disturbing thoughts and improve healthy coping and sleep. .
89644783|NCT04386291|Experimental|ART and Kundalini Yoga|This combines ART with a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
89644784|NCT04386291|Experimental|ART and Meditation|This combines ART with a daily 15 minute meditation with stress reduction techniques and guided breathing.
89644785|NCT01394185|Active Comparator|Low Dose Dronabinol, High Dose Dronabinol, and placebo|Participants were administered dronabinol (0 mg/day, 120mg/day and 240mg/day) for 12 days each in a random order
89644786|NCT05032014|Experimental|probiotics group|"The oral probiotic (Lactobacillus rhamnosus Probio-M9,one times a day during the whole treatment) was isolated from healthy women's breast milk samples in 2017 and was identified as Lactobacillus rhamnosus by physiological and biochemical and 16S rRNA. It is listed as the List of Probiotics for Health Food in my country's List of Bacteria Available for Food, which can be directly applied to food production."
89644787|NCT05032014|Placebo Comparator|placebo group|Immunotherapy with placebo alone
89644788|NCT05032014|No Intervention|healthy control group|healthy control group
89644789|NCT00711711|Experimental|Manual lymphatic drainage|this arm will receive 5 manual lymphatic drainage treatments from day 2 to day 7 post surgery
89644790|NCT00711711|Placebo Comparator|Relaxation|This arm will receive 5 relaxation treatments from day 2 to day 7 post surgery
89644791|NCT05030376|Experimental|patients with ileostomy without type 2 diabetes|intraileal glucose or saline infusion via ileostomy
89644792|NCT05030376|Experimental|patients with ileostomy with type 2 diabetes|intraileal glucose or saline infusion via ileostomy
89212584|NCT00876902|Placebo Comparator|2|Placebo Control: (18 subjects) Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One additional infusion of 0.1 mL/kg placebo control (saline) will be given at the end of the procedure to patients that have experienced an intraoperative blood loss of greater than 10 units.
88991990|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)|Participants receive NNC0195-0092 (somapacitan) (0.08 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.
89644793|NCT04039165|Experimental|Intervention Group|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, and complete a group walk or indoor exercise during the group sessions. The investigators will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program. During times when in-person visits cannot happen (e.g., COVID-19), we will do virtual group sessions instead of meeting at the clinics, conducted via videoconference platform (i.e., Zoom), the group walks will not happen, and all exercise will be done individually to comply with social distancing measures.
89644794|NCT04039165|No Intervention|Wait-list Control Comparison Group|Participants in the waitlist control group will not receive any active intervention during the initial study period (weeks 1-9). At Week 10, this group will receive the same intervention and assessments as described in the active treatment group above.
89644795|NCT04000399|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinician trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE.; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
89644796|NCT01677936|Experimental|Raisin|Subjects randomized to the raisin treatment arm will consume raisins three times a day, prior to meals, and with a glass of water or non-caloric beverages (i.e. tea). Subjects will consume the raisins over a 12 week period.
89644797|NCT01677936|Active Comparator|Snack Group|Subjects randomized to the snack group will consume 100 calorie snack packs three times a day, before meals, and with water or other non-caloric beverages (i.e. tea). Subjects will consume the snack packs over a 12 week period.
88991991|NCT02616562|Experimental|Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)|Participants receive the same dose (0.16 mg/kg/week) of NNC0195-0092 (somapacitan) during all 4 trial periods.
88991992|NCT02616562|Active Comparator|Open labelled daily Norditropin® (0.034 mg/kg/day)|Participants receive Norditropin during the main trial, the extension period and the safety extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the long-term safety extension periods.
88991993|NCT02614911||Sick patients|Biological sampling of blood for all patients. Biological sampling of saliva, biopsies (skin and endoscopic), feces, for some patients
88991994|NCT02614911||Healthy relatives|Biological sampling of blood for all healthy relatives
88991995|NCT02610439||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
89644798|NCT04361851|Experimental|Single Arm|Pembrolizumab and Daratumumab
89644799|NCT04352179|Experimental|Virtual Education Simulation|All participants will have access to the virtual education simulations.
89644800|NCT04407715|Placebo Comparator|High Flow Anesthesia, Low Flow Anesthesia|. The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow. Group 1 (n = 40) was operated under high flow anesthesia with 50% O2 - 50% air at 2 L/min and desflurane at 1.1 MAC for the duration of the surgery. For anesthesia maintenance, Group 2 (n=40) was administered 50% oxygen - 50% air at 2 L/min and desflurane for 10-15 minutes. After reaching 1.1 MAC, it was switched to minimal flow with 50-60% oxygen- 40-50% air at 0.5 L/min and desflurane. 10 minutes before the end of the surgery, it was switched to high flow with 50% oxygen -50% air at 2 L/min.
89644801|NCT04407715|Active Comparator|Peroperetive Optic Nerve Sheath Diameter|Optic nerve sheath diameter measurements were performed by an experienced and the same anesthetist. In the measurements, the GE Healthcare Logiq e series USG device and 12-MHz linear probe were used. Longitudinal and transverse axis images were obtained on both eyelids while the patient was in the supine position. Measurements were taken 3 mm behind the optic nerve head
89644802|NCT00727857|Experimental|Pioglitazone 15 mg /Metformin 850 mg BID|
89644803|NCT00727857|Active Comparator|Pioglitazone 15 mg BID|
89644804|NCT00727857|Active Comparator|Metformin 850 mg BID|
89644805|NCT05095194|Experimental|High myopia patients who had cataract surgery with IOL and capsular tension ring implantation|The patients' axial length is over 26 mm and are diagnosed age related cataract The patients' age are over 50
89644806|NCT05095194|Experimental|High myopia patients who had cataract surgery with IOL implantation|The patients' axial length is over 26 mm and are diagnosed age related cataract The patients' age are over 50
89644807|NCT00217165|Placebo Comparator|placebo|cellulose
89644808|NCT00217165|Active Comparator|active drug|taurine
89644809|NCT04537728|Experimental|My Healthy Brain Version 2|an 8-week group program that directly targets multiple lifestyle factors associated with brain health and prevention of CD
89644810|NCT05092152|Active Comparator|Propofol|
89644811|NCT05092152|Experimental|Esketamina|
89644812|NCT05019066|Active Comparator|Herbal Combination Group|"Tablets of the herbal formulation will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/healthy-hair-tablets-10)~Each 500 mg tablet contains a proprietary blend of: Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa~Dose: subjects in this group will take 2 herbal formulation tablets twice per day for a total of 4 tablets per day"
88991996|NCT02610426||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
88991997|NCT02610413||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
88991998|NCT02606526|Experimental|Intervention arm: BCG at birth|Infants randomized to this arm will receive an intra-dermal administration of 0.05 ml of BCG vaccine within 24h of birth
89043779|NCT04634942|Experimental|Cold Spray Group|Cold spray group injection process step; In addition to the IM injection procedure steps, Cryos cold spray was applied to patients in this group after skin cleansing. Cryos cold spray sprayed 3 puffs from a distance of 20 cm to the skin, and the injection process was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
89043780|NCT04634942|Experimental|ShotBlocker Group|ShotBlocker group injection process step; In addition to the IM injection procedure steps, after cleansing the skin of the patients in this group, the protruding part of the ShotBlocker was placed in contact with the skin. ShotBlocker was pressed firmly against the skin and the injection was made through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
89043781|NCT04634942|No Intervention|Control Group|Control group injection process step; The individuals in this group were injected by following the routine IM injection procedure steps. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
89644813|NCT05019066|Placebo Comparator|Placebo Group|"Supplement appearing similar to the herbal combination formulation.~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 2 placebo tablets twice per day for a total of 4 tablets per day"
89644814|NCT05001360|Experimental|XBI-302 + Nivolumab|FMT capsules XBI-302 will be administered orally every two weeks for 12 weeks and then every four weeks for 12 weeks. Nivolumab will be intravenously infused every two weeks for 24 weeks.
89644815|NCT01276665|Experimental|Restrictive regimen group|treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.
89644816|NCT01276665|Active Comparator|Control group|treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses)
89644817|NCT04986150|Experimental|Milk Protein|4 daily 20-gram doses of milk protein (dairy yoghurt) consumed for 4 consecutive days after the exercise bout
89644818|NCT04986150|Placebo Comparator|Placebo|4 daily doses of low-protein placebo product (oat-based yoghurt) consumed for 4 consecutive days after the exercise bout
89644819|NCT00711867|Experimental|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
89644820|NCT00711867|Active Comparator|Bair Hugger|Arizant Bair Hugger temperature management system.
89644821|NCT01525550|Experimental|sunitinib|
89644822|NCT02991963||Case|Malaria patient defined by positive RDT or blood smear
89644823|NCT02991963||Control|Non-malaria patient defined by negative RDT or blood smear
89644824|NCT05016570|Experimental|Picture narrative lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format which uses text in combination with sequences of pictures to communicate a coherent message. The designs follow conventions from comics/graphic narratives and key stakeholders were involved during the design process.
89644825|NCT05016570|Active Comparator|Text with pictures lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format that uses text with non-narrative pictures for decoration. The pictures have been extracted from the picture narratives being used Arm 1.
89644826|NCT05016570|Active Comparator|Text-only lung screening information|Participants in this arm receive information about lung screening purpose, eligibility, benefits and risks in a format that uses text and no pictures.
89644827|NCT04730232|Experimental|Tislelizumab and Nab-Paclitaxel|Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
89644828|NCT04279197|Experimental|FZHY Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~Fuzheng Huayu tablets"
89644829|NCT04279197|Placebo Comparator|Placebo Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~placebo"
89644830|NCT04699032|Experimental|Severe Renal Impairment|eGFR (mL/min/1.73 m2): <30 not on hemodialysis
89644831|NCT04699032|Experimental|Normal Healthy Match|eGFR (mL/min/1.73 m2): ≥90
89644832|NCT04699032|Experimental|Moderate Renal Impairment|eGFR (mL/min/1.73 m2): ≥30 to 60
89644833|NCT04699032|Experimental|Mild Renal Impairment|eGFR (mL/min/1.73 m2): ≥60 to 90
89043782|NCT04634942|Placebo Comparator|Cold Spray Placebo Group|Cold spray placebo group injection procedure step; In addition to the IM injection procedure steps, the patients in this group were treated with tap water in a cold spray bottle after cleansing the skin. After spraying 3 puffs of tap water in a placebo bottle at a distance of 20 cm to the skin, the injection was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle entering the tissue on the VAS.
89644834|NCT00712179||Stroke Survivors|Subjects walked with or with therapists' assistance at different speeds and different amounts of body weight support across conditions.
89644835|NCT04540848|Experimental|Exparel plus supraclavicular block|
89644836|NCT04540848|Active Comparator|Bupivacaine HCL plus supraclavicular block|
89644837|NCT04540848|Active Comparator|supraclavicular block only|
89644838|NCT01271751|Experimental|GFT505 80mg|
89644839|NCT01271751|Placebo Comparator|Matching placebo|
89644840|NCT00211237|Experimental|Balloon Kyphoplasty (BKP)|The subjects assigned to this group will undergo the treatment with Balloon kyphoplasty for their painful VCFs.
89644841|NCT00211237|Active Comparator|Non Surgical Management|The subjects in this group will undergo the non-operative treatments aimed at alleviation of back pain and restoration of decreased function associated with VCFs.
89644842|NCT01271829|No Intervention|Control|While on the control arm subjects will be given a meal with no avocado.
89644843|NCT01271829|Active Comparator|Avocado supplement|While on the avocado supplement arm subjects will be given a meal in which a given amount of calories will be replaced by calories contributed by avocados.
89644844|NCT01271829|Active Comparator|Avocado included|While on the avocado included arm subjects will be given a meal in which the calories of avocado will be added to the calories of the control meal.
89644845|NCT04774146||triple air fluid exchange|those undergoing triple air fluid exchange
89644846|NCT04774146||irrigation|those undergoing vitreous chamber irrigation with comparable volume of BSS
89644847|NCT01489358|Experimental|Group 1|Group 1 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 10 mcg.
89644848|NCT01489358|Experimental|Group 2|Group 2 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 20 mcg.
89644849|NCT01489358|Experimental|Group 3|Group 3 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 40 mcg.
89644850|NCT04760028|Other|sevoflurane|Adjust sevoflurane concentration as required
89644851|NCT05366101|Active Comparator|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
89644852|NCT05366101|Active Comparator|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
89644853|NCT05366101|No Intervention|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
89644854|NCT04993560||Homologous booster|Two doses of BBIBP-CorV, followed by BBIBP-CorV
89644855|NCT04993560||Heterologous booster|Two doses of BBIBP-CorV, followed by BNT162b2
89644856|NCT05365555||Fascia Iliaca Compartment Block (FICB)|Participants with a radiologically verified hip fracture receiving a FICB using a blind technique guided by anatomical landmarks.
89644857|NCT05365555||Femoral Nerve Block (FNB)|Participants with a radiologically verified hip fracture receiving a FNB using ultrasound guidance for direct nerve visualisation.
89644858|NCT01525238|Experimental|Dapagliflozin 2.5 mg|
89644859|NCT01525238|Experimental|Dapagliflozin 5 mg|
89644860|NCT01525238|Experimental|Dapagliflozin 10 mg|
89644861|NCT05374356|Active Comparator|High spinal anesthesia|"Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).~Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated.~Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation."
89644862|NCT05374356|No Intervention|Control group|"Standard intraoperative monitors will include ECG, pulse oximetry, end-tidal CO2 and anesthetic gas measurement, quantitative EEG monitoring (BIS monitor), arterial line, central venous pressure line and any other monitor as clinically indicated.~Conduct of the general anesthetic will not be protocolized. It will be a pragmatic study. The attending anesthesiologist will attempt to have a BIS score of 20- 40 during the operation."
89644863|NCT00717405|Experimental|1|
89644864|NCT01276743||T1DM|Children and adolescents with T1DM
89644865|NCT01276743||Unaffected Population|Population not known to be affected by T1DM
89644866|NCT01276977|Experimental|Zolmitriptan 5 mg nasal spray|
89644867|NCT01276977|Active Comparator|Eletriptan 40 mg Tablet|
89644868|NCT05630599||ILD|ILD, or lung fibrosis, is one of a spectrum of fibrotic diseases, associated with ageing, obesity, diabetes and pollution, that are responsible for ~45% of premature deaths in Western Europe. Of >90,000 patients in the United Kingdom with ILD, ~30,000 have idiopathic pulmonary fibrosis, idiopathic pulmonary fibrosis, the most severe form. idiopathic pulmonary fibrosis is a disease of unknown aetiology that is more frequent in males presenting mainly in the sixth and seventh decades of life. There is no cure and median survival, just 3-5 years following diagnosis is worse than for many cancers.
89644869|NCT05630599||COPD|COPD is a common, long term condition of the lungs that is usually caused by cigarette smoking. In addition to daily symptoms and limitations in activities, patients are prone to developing chest infections called 'exacerbations'. Exacerbations are a significant problem: unpleasant for patients, and sometimes severe enough to cause hospital admission (and therefore National Health Service pressures) and death.
89644870|NCT05630599||COVID-19|Recovery from COVID19 has many unknowns, especially in the long term. Symptoms of COVID-19 have varied among those who have tested positive: some have displayed no symptoms, while others have developed severe pneumonia, progressing to lung injury and acute respiratory distress syndrome (ARDS) and, in the longer term, pulmonary fibrosis. Notably, the consequences of COVID-19 include effects on other organs including: heart, kidneys, and brain.
89644871|NCT01271985|Active Comparator|PolyPill|PolyPill once daily and Minimal Care
89644872|NCT01271985|Active Comparator|Minimal care|Minimal care.
89644873|NCT01271985|No Intervention|Usual care|Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.
89644874|NCT03832699|Experimental|Oral progesterone|
89644875|NCT03832699|Active Comparator|Vaginal progesterone|
89644876|NCT01272063||Dry AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
89644877|NCT00717873|Experimental|HFCWO Arm|Airway clearance provided by the Vest Airway Clearance System
89644878|NCT00717873|No Intervention|CPT Arm|Airway clearance provided by manual CPT
89644879|NCT02991885|Experimental|HAL-MPE1|HAL-MPE1 is an off-white to white liquid suspension containing modified peanut extract
89644880|NCT02991885|Placebo Comparator|HAL-MPE1 placebo|HAL-MPE1 placebo without modified peanut extract
89644881|NCT03997513|Experimental|Pulmonary Telerehabilitation Intervention Group|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
89644882|NCT03997513|No Intervention|Usual Care Group|Participants randomized to the usual care arm will also be enrolled in our institution's telehealth program, will receive an automatic blood pressure monitor, portable pulse oximeter, and scale and will be in regular contact with a telehealth provider. A study team member will meet with participants randomized to the usual care arm to discuss the importance of exercise and will encourage exercise (strength training, light aerobic activity such as walking or cycling) a minimum of 20-40 minutes three times per week at discharge.
89644883|NCT05369767|Experimental|SAD, SHR-2004|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 injection
89644884|NCT05369767|Placebo Comparator|SAD, SHR-2004 placebo|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-2004 placebo injection
89644885|NCT01277133||Cohort|
89644886|NCT05366803|Experimental|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults. Participants will wear the Zio patch monitor (electrocardiographic loop monitoring device) for 8 days at baseline, as well as at 6 months and again at one year, for a total of 3 times.
89644887|NCT05366803|No Intervention|Usual Activity Control|Participants will wear the Zio patch monitor (electrocardiographic loop monitoring device) for 8 days at baseline, as well as at 6 months and again at one year, for a total of 3 times. Participants carry about their normal activities during this period.
89644888|NCT01277289|Experimental|Ery-dex|Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
89644889|NCT01277289|Placebo Comparator|Placebo|placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.
89644890|NCT05630287|Experimental|[14C] Selpercatinib - Part 1|[14C] Selpercatinib administered as an oral solution
89644891|NCT05630287|Experimental|Selpercatinib and [14C] Selpercatinib - Part 2|Single oral dose of Selpercatinib followed 2 hours later by single dose of [14C] Selpercatinib administered as an intravenous (IV) push.
89644892|NCT04386915|Experimental|Single-dose experimental group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2 and Day4. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
89644893|NCT04386915|Placebo Comparator|Single-dose control group|50mg, 100mg, 200mg, 300mg, 400mg, 500mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
89644894|NCT04386915|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
89644895|NCT04386915|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups at 100 mg, 200 mg, 300 mg, and 400 mg. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
89644896|NCT04386915|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
89644897|NCT04386915|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day 2 and Day 4 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
89644898|NCT03599791|Experimental|Azelastine Hydrochl. + Fluticasone Prop.|Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
89644899|NCT03599791|Active Comparator|Azelastine hydrochloride|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
89644900|NCT03599791|Active Comparator|Fluticasone propionate|Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
89644901|NCT04386681|Experimental|RCBI|Receiving RCBI intervention, including BICS, ICAN, and RF.
89043783|NCT04634942|Placebo Comparator|ShotBlocker Placebo Group|ShotBlocker placebo group injection procedure step; In addition to the IM injection procedure steps, in patients in this group, the non-protruding part of the ShotBlocker was placed in contact with the skin after skin cleaning. ShotBlocker was pressed firmly against the skin and the injection was applied through the central opening of the ShotBlocker. ShotBlocker was removed from the skin after the injection was completed.
89043784|NCT01227577|Experimental|Nilotinib|Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.
89043785|NCT04681599|No Intervention|Nebulization without filter or scavenger|Subject will use a standard nebulizer
89043786|NCT04681599|Experimental|Nebulization with a filter or scavenger|Subject will use a nebulizer with a filter placed at the other end of nebulizer mouthpice or a scavenger outside the nebulizer mask
89043787|NCT04681599|No Intervention|High-flow nasal cannula|Subject will use high-flow nasal cannula at 40 L/min
89644902|NCT04386681|No Intervention|Treatment as usual- Control group|Not receiving the RCBI intervention
89043788|NCT04681599|Experimental|High-flow nasal cannula with a scavenger face tent|Subject will use high-flow nasal cannula at 40 L/min, with a scavenger face tent
89043789|NCT04681599|Active Comparator|High-flow nasal cannula with a surgical mask|Subject will use high-flow nasal cannula at 40 L/min, with a surgical mask over nasal cannula
89043790|NCT04635137|Experimental|Ablation and Cementoplasty|All patients undergoing thermal ablation and cementoplasty procedure for one or more painful bone lesion
89043791|NCT00624676|Experimental|A|LHA formulation
89043792|NCT00624676|Active Comparator|B|5% benzoyl peroxide
89644903|NCT04386525|Experimental|Omega-3|Fish oil will be administered to this group. We will administer 4g per day of fish oil in three times with meals for one month with monitoring the health status regularly
89644904|NCT04386525|No Intervention|Controle|for comparison with interventional arm
89043793|NCT04634903|Active Comparator|Supportive Therapy SSI (ST-SSI)|The web-based supportive therapy (ST-SSI) intervention, called the Sharing Feelings Intervention, is designed to mimic supportive therapy (ST). The goals of the ST intervention are to encourage participants to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions. The ST-SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the other SSIs.
89043794|NCT04634903|Experimental|Behavioral Activation SSI (BA-SSI)|The BA-SSI include 5 elements: (1) An introduction to the program's rationale: that engaging in value-based activities can combat sad mood and low self-esteem; (2) Psychoeducation about depression, including how behavior shapes feelings and thoughts; (3) A life values assessment, where youth identify key areas from which they draw enjoyment and meaning; (4) Creation of an activity hierarchy, where youth identify and personalize (in guided exercises) 3 activities to target for change; and (5) An exercise in which youths write about benefits that might result from engaging in each activity; an obstacle that might keep them from doing the activities; and a strategy for overcoming identified obstacles.
89043795|NCT04634903|Experimental|Growth Mindset SSI (GM-SSI)|"Program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
89043796|NCT02894385|Experimental|Part 1 - Subjects with severe renal impairment|Subjects with severe renal impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
89043797|NCT02894385|Experimental|Part 1 - Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
89644905|NCT01488578||Tolterodine tartrate.|Subjects taking Tolterodine tartrate.
89644906|NCT05632705|Experimental|Intervention arm|In this arm, prior to closing the sheath and skin, unused drapes, gloves and instruments will be used to close the sheath and the skin.
89644907|NCT05632705|No Intervention|Control arm|In this arm sheath and skin closure will be according to the standard protocol
89644908|NCT00720369|Experimental|CoEnzyme Q10|Open Label Study
89644909|NCT00720369|No Intervention|Healthy Controls|Healthy controls completed all study procedures completed by the CoQ10 group but did not receive any study medication.
89644910|NCT01277367|Active Comparator|A|These members will be offered no additional incentives
89644911|NCT01277367|Experimental|B|These members will receive regular communications by Discovery Vitality.
89644912|NCT01277367|Experimental|C|These members will nominate a charity which will benefit financially based on participants' level of physical activity.
89644913|NCT01277367|Experimental|D|These members are entered into a prize draw for a monthly cash prize if they achieve physical activity targets.
89644914|NCT01277367|Experimental|E|These members will receive a direct payment.
89644915|NCT01277367|Experimental|F|These members will be offered the opportunity to choose one of three incentive options at the time of enrollment in the study.
89644916|NCT01524770|Active Comparator|Manual syringe|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by manual syringe in one of two study periods separated by a 28-day minimum washout period.
89644917|NCT01524770|Experimental|Auto-injector|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by auto-injector in one of two study periods separated by a minimum 28-day washout period
89644918|NCT01277445|Placebo Comparator|Placebo|15g/day maltodextrin for 28 days
89644919|NCT01277445|Active Comparator|Prebiotic|Consumption of 15g/day of inulin-fructan for 28 days
88991999|NCT02606526|Active Comparator|Control arm: BCG at 14 weeks of age|Infants randomized to this arm will receive intra-dermal administration of 0.05 ml of BCG vaccine at 14 weeks of age
88992000|NCT02600897|Experimental|Dose-escalation Cohort: FL|Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
88992001|NCT02600897|Experimental|Dose-escalation Cohort: DLBCL|Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
88992002|NCT02600897|Experimental|Expansion Cohort: FL|Participants with R/R FL who received induction treatment with polatuzumab vedotin and lenalidomide, in addition to obinutuzumab and achieved CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 24-months maintenance regimen consisting of lenalidomide and obinutuzumab for first 12 months followed by obinutuzumab treatment for next 12 months. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
89644920|NCT03598231|Sham Comparator|Arm OFF-ON|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator for sacral neuromodulation is implanted.~Once the generator is placed it will be disconnected for 4 weeks. Then it will be continued to be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be turn ON for 4 weeks and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
89644921|NCT03598231|Active Comparator|Arm ON-OFF|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator sacral neuromodulation is implanted.~Once the generator is placed it will be turned ON for 4 weeks at the maximum subsensory stimulus. Then it will be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be kept OFF for 4 weeks. After this sequence it will be turned on again and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
89644922|NCT02991261|Experimental|SPARC001 type I|Treatment type I
89644923|NCT02991261|Experimental|SPARC001 type II|Treatment type II
89644924|NCT02991261|Active Comparator|Reference001 type I|Hydrocodone-Acetaminophen
89644925|NCT02991261|Active Comparator|Reference type II|Hydrocodone-Acetaminophen
89644926|NCT02991339|Experimental|Dexamethasone|Dexamethasone 10 mg iv on day 1 and day 2, then 5 mg iv on day 3. For the patients the serum total bilirubin did not decrease to 1.5 ULN, then 5 mg iv on day 4.
89644927|NCT02991339|No Intervention|control|Patients are not treated with glucocorticoids.
89644928|NCT04018495|Experimental|Interventional - Fitbit tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
89644929|NCT06123546|No Intervention|Usual discharge preparation|Discharge teaching according to the usual discharge preparation process in participating units
89644930|NCT06123546|Experimental|Teaching with a patient-oriented discharge summary|Discharge teaching with a patient-oriented discharge summary, using the teach-back technique and inclusion of caregivers
89644931|NCT06123520|Active Comparator|Ho-YAG Laser internal urethrotomy|consists of those who will undergo Ho-YAG laser internal urethrotomy only.
89644932|NCT06123520|Experimental|Ho-YAG Laser internal urethrotomy + Paclitaxel injection|those who will undergo Ho-YAG laser internal urethrotomy with circumferential submucosal paclitaxel injection at the stricture site.
89644933|NCT06123507|Experimental|Full educational intervention condition|The Full intervention condition included a perspective-taking workshop plus independent practice and video-feedback
89644934|NCT06123507|Active Comparator|Partial intervention condition|The Partial intervention condition involved video-feedback alone. In this condition, participants were provided with a link to the perspective-taking workshop after the study was complete.
89644935|NCT06123455|Experimental|Taurine + Sintilimab + investigator's choice chemotherapy|Taurine + Sintilimab + XELOX or Taurine + Sintilimab + SOX or Taurine + Sintilimab + FOLFOX
89644936|NCT06123455|Active Comparator|Sintilimab + investigator's choice chemotherapy|Sintilimab + XELOX or Sintilimab + SOX or Sintilimab + FOLFOX
89644937|NCT06123429|Experimental|Intervention group|All participants enrolled in the study will be enrolled in the Mindfulness-Based Stress reduction course. The MBSR course will consist of weekly sessions lasting two and a half hours, involving lecture, meditation, and self-reflection. The first MBSR course will be ready for 10-12 participants in November 2023. The following course will start every month thereafter. The courses will be held online over Zoom.
89644938|NCT06123377|Experimental|39 weeks|Patients with gestational hypertension and angiogenic factors (sFlt-1/PIGF) below 33 will be evaluated weekly until 39 weeks, when termination of pregnancy will be scheduled.
89644939|NCT06123377|Active Comparator|37 weeks|Patients with gestational hypertension and angiogenic factors (sFlt-1/PIGF) below 33 will be evaluated weekly until 37 weeks, when termination of pregnancy will be scheduled.
89644940|NCT06123312|Experimental|Single intervention arm: Tri-modality biopsy|Patients enrolled in this single arm will have lung nodules biopsied by Tri-modality (forceps biopsy, needle aspiration, and cryobiopsy)
89644941|NCT06123273|Experimental|Intervention group|The intervention group was given an exercise-oriented training
89644942|NCT06123273|No Intervention|Control group|The control group was given only routine recommendations
89644943|NCT06123234|Experimental|Verum 408|Partecipants received a food supplement with probiotics, chamomile, vitamin A, vitamin D in single-dose vials every day for 60 days.
89644944|NCT06123234|Placebo Comparator|Placebo 407|Placebo does not contain any active ingredients. Partecipants received placebo in single-dose vials every day for 60 days.
89212585|NCT04039646|Active Comparator|Standard postoperative care group|Patients received standard postoperative care as ususal.
89212586|NCT04039646|Experimental|ERAS group|Patients received postoperative ERAS treatment.
89644945|NCT06123221|Experimental|Osseodensification|Sinus floor elevation with osseodensification and concomitant implant installation
89644946|NCT06123221|Active Comparator|Lateral window|Sinus floor elevation with lateral window and concomitant implant installation
89212587|NCT00876980|Active Comparator|1|nasal Continuous Positive Airway Pressure treatment for 3 months
89212588|NCT00876980|No Intervention|2|controls have no treatment, being observed for 3 months
89212589|NCT00993213|Active Comparator|Liposuction|Standard of Care with Liposuction
89644947|NCT06123169|Active Comparator|Broad spectrum antibioprophylaxis|Antibioprophylaxis with Piperacillin-tazobactam during DPC.
89644948|NCT06123169|Experimental|Broad spectrum antibiotherapy|5 days Antibiotherapy (Piperacillin-tazobactam) from surgery.
89644949|NCT06123156|Active Comparator|Arm I (Sildénafil)|Sildénafil during 10 months (50mg daily), start 30 days after surgery
89644950|NCT06123156|Placebo Comparator|Arm II (Placebo)|Patients receive placebo during 10 month (1 platelet per day)
89644951|NCT06123091||Congenital ichthyosis patients|Questionnaires
89644952|NCT06123078|No Intervention|Control group|treatment as usual
89644953|NCT06123078|Experimental|Experimental group|CaCBT
89644954|NCT06123065|Experimental|Active|Immediately enrolled into Yoga intervention. Completed orientation and baseline measures then began 8-week yoga group intervention.
89644955|NCT06123065|Other|Waitlist|Delayed Intervention. Waitlist individuals attended orientation and completed baseline measures. After completion of re-assessment of measures 8 weeks later, then enrolled into Active arm.
89644956|NCT06122987|Experimental|Single Arm|Drug: Angiotensin II Other Names: Giapreza
89644957|NCT06122935|Experimental|Test Group|Plasma collection using a new plasma collection volume nomogram (software version 2.0) for the Aurora Xi Plasmapheresis System
89644958|NCT06122935|Active Comparator|Control Group|Plasma collection using the marketed (version 1.3) of AuroraXi Plasmapheresis System
89644959|NCT06122805|Experimental|Orthognathic Surgery Manual Toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~Intervention: Manual toothbrush."
89212590|NCT00993213|Sham Comparator|No Liposuction|Standard of Care without Liposuction'
89212591|NCT00993369||Healthy newborns conceived naturally|
89644960|NCT06122805|Experimental|Orthognathic Surgery Sonic toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~Intervention:Sonic toothbrush without activation of the dual light feature."
89644961|NCT06122805|Experimental|Orthognathic Surgery Sonic and dual light toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~Intervention:Sonic toothbrush with activation of the dual light feature"
89644962|NCT06122805|Experimental|Bone Graft Manual Toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~Intervention:Manual toothbrush."
89644963|NCT06122805|Experimental|Bone Graft Sonic Toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~Intervention:Sonic toothbrush without activation of the dual light feature."
89644964|NCT06122805|Experimental|Bone Graft Sonic and Dual-light Toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~Intervention:Sonic toothbrush with activation of the dual light feature"
89644965|NCT06122805|Experimental|No surgery, Manual Toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate 5, Intervention:Manual toothbrush."
89644966|NCT06122805|Experimental|No Surgery, Sonic Toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~Intervention:Sonic toothbrush without activation of the dual light feature."
89644967|NCT06122805|Experimental|No Surgery, Sonic and Dual-light Toothbrush|"Patient of record of the Craniofacial and Special Care Orthodontic Clinic at Children's Hospital Los Angeles~Between the ages of 6 and 20 years~Physical status of ASA I or II~Diagnosis of craniofacial and/or isolated, complete or incomplete, bilateral or unilateral cleft lip and palate~Intervention:Sonic toothbrush with activation of the dual light feature"
89212592|NCT00993369||Healthy newborns conceived with IVF|
89212593|NCT02588495|No Intervention|Fasting|Participant will remain fasted following initial gastric ultrasound
89212594|NCT02588495|Experimental|Food intake|Participant will ingest either 250mL of clear fluid (apple juice) or 250mL of coffee and a muffin following initial gastric ultrasound
89212595|NCT00871910|Experimental|2 Hour SCH 727965 infusion|Participants treated with 2 hour SCH 727965 IV infusion
89212596|NCT00871910|Experimental|8 Hour SCH 727965 infusion|Participants treated with 8 hour SCH 727965 IV infusion.
89212597|NCT00871910|Experimental|24 Hour SCH 727965 infusion|Participants treated with 24 hour SCH 727965 IV infusion.
89644968|NCT06122792|Active Comparator|Standard Therapy|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic hemostasis according to the center protocol.~Standard combined endoscopic and pharmacological therapy as secondary prophylaxis (carvedilol + repeated endoscopic injection of tissue adhesives until the eradication of the gastric varices)."
89644969|NCT06122792|Experimental|Preemptive TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic hemostasis according to the center protocol.~Performance of TIPS in the first 72 hours following initial endoscopic hemostasis."
88992003|NCT02600897|Experimental|Expansion Cohort: DLBCL|Participants with R/R DLBCL who received induction treatment with polatuzumab vedotin and lenalidomide in addition to rituximab and achieved CR or PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 6-month consolidation regimen consisting of lenalidomide and rituximab. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
88992004|NCT02399215|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88992005|NCT02365649|Active Comparator|Induction Period ABT-494 Twice Daily Medium/High Dose|Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
88992006|NCT02365649|Active Comparator|Extension Phase ABT-494 High Dose|Extension Phase ABT-494 High Dose orally dosed twice a day
88992007|NCT02365649|Placebo Comparator|Induction Period Placebo|Induction Period Placebo orally dosed twice a day
88992008|NCT02365649|Active Comparator|Induction Period ABT-494 Low Dose|Induction Period ABT-494 Low Dose orally dosed twice a day
88992009|NCT02365649|Active Comparator|Induction Period ABT-494 Once Daily Medium/High Dose|Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
88992010|NCT02365649|Active Comparator|Extension Phase ABT-494 Low Dose|Extension Phase ABT-494 Low Dose orally dosed twice a day
88992011|NCT02365649|Active Comparator|Induction Period ABT-494 High Dose|Induction Period ABT-494 High Dose orally dosed twice a day
88992012|NCT02365649|Active Comparator|Induction Period ABT-494 Low/Medium Dose|Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
88992013|NCT02365649|Active Comparator|Extension Phase ABT-494 Medium Dose|Extension Phase ABT-494 Medium Dose orally dosed twice a day
88992014|NCT02271919|Experimental|Group I (varenicline and placebo)|Patients receive varenicline PO QD or BID, placebo patches QD, and placebo lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
88992015|NCT02271919|Placebo Comparator|Group II (placebo, nicotine patch and lozenge)|Patients receive placebo tablets PO QD or BID, nicotine patches QD, and nicotine lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
88992016|NCT02225405|Experimental|Treatment (cisplatin, docetaxel, nintedanib)|"RUN-IN PHASE: Patients receive induction therapy comprising cisplatin IV over 2 hours on day 1, docetaxel IV over 1 hour on day 1, and nintedanib PO BID from day 2 of course 1 to day 7 of course 3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~EXPANSION PHASE: Patients receive single-agent nintedanib PO BID on days 1-28. Patients then receive 3 courses of induction chemotherapy and undergo surgery as above. Treatment continues even if patients experience disease progression, unless treatment is judged to be not in the best interest of the patient by the treating physician."
88992017|NCT02110225|Experimental|rhNGF 60µg/ml|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
88992018|NCT02110225|Experimental|rhNGF 180 µg/ml|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
88992019|NCT02110225|Placebo Comparator|Vehicle|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
89043798|NCT02894385|Experimental|Part 1 - Healthy subjects|Healthy subjects received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
89644970|NCT06122766||N-glycanase 1 (NGLY1) Deficiency|
89644971|NCT06122753|Active Comparator|Standard Therapy|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic hemostasis according to the center protocol.~Standard combined endoscopic and pharmacological therapy as secondary prophylaxis (carvedilol + repeated endoscopic variceal ligation until the eradication of the esophageal varices)."
89644972|NCT06122753|Experimental|Preemptive TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic hemostasis according to the center protocol.~Performance of TIPS in the first 72 hours following initial endoscopic hemostasis."
89644973|NCT06122727|Experimental|CUSTOM|patients will undergo primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with a design specifically based on each patient's real knee morphology and using PSI surgical technique and instrumentation.
89644974|NCT06122727|Active Comparator|TRADITIONAL|patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of the guided intramedullary femur and extramedullary tibia).
89644975|NCT06122701|Active Comparator|OCT1 deficient and wild type genotypes: 200 mg thiamin|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
89644976|NCT06122701|Active Comparator|OCT1 deficient and wild type genotypes: 50 mg thiamin|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
89644977|NCT06122701|Active Comparator|OCT1 deficient and wild type genotypes: 10 mg thiamin|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
89644978|NCT06122701|Active Comparator|OCT1 deficient and wild type genotypes: 5 mg thiamin|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
89043799|NCT05655715|Experimental|A SBRT + ipi/nivo|Stereotactic body radiotherapy of 8 Gray (Gy) x 3 on one soft tissue or bone metastasis + Nivolumab 3mg/kg IV every 3 weeks (Q3W) + Ipilimumab 1mg/kg IV Q3W for four doses, then Nivolumab 480 mg IV every 4 weeks (Q4W) for up to 52 weeks treatment in total
89043800|NCT05655715|Experimental|B ipi/nivo|Nivolumab 3mg/kg IV Q3W + Ipilimumab 1mg/kg IV Q3W for four doses, then Nivolumab 480 mg IV Q4W for up to 52 weeks treatment in total
89644979|NCT06122688|No Intervention|Care as usual|"All individuals within each site regardless of type of site or step period will begin with a control period of care as usual~Youth and parents within each site will have access to navigators who will share information about mental health and social services supports as well as referrals.~The duration of the control period (1, 2, or 3 years; collected via medical and/or other administrative records) will depend on the step period of the individual's site."
89644980|NCT06122688|Experimental|Implementation|In this stepped wedge design, following a period of care as usual as a control, sites will then cross over to the experimental arm, during which, all youth and their caregivers at the enrolled site are encouraged to download and use the wellness app for the duration of the implementation period. Navigators promote and support use of the app.
89644981|NCT06122675|Active Comparator|Effective stimulation|All participants will receive deep brain stimulation (DBS) in the cerebellum. For the first 20 weeks, every participant undergoes an open label phase to titrate stimulation and determine optimal stimulation settings. Following that phase, each participant starts three cycles of randomized, paired 8-week exposure periods, each pair including effective stimulation followed by sham stimulation, or vice versa. Effective stimulation will be the optimal stimulation settings determined during the open label phase.
89644982|NCT06122675|Sham Comparator|Sham stimulation|Sham stimulation will be settings at low amplitude (0.1mA) known to be ineffective.
89644983|NCT06122597|Experimental|Test arm: ConcenTrace|"Participants should follow this weekly dosing schedule:~Week 1 - Days 1-3: take 5 drops of ConcenTrace with 8 oz of water or flavored water. Days 4-7: take 5 drops of ConcenTrace 2x daily with 8 oz of water or flavored water.~Week 2: Take 10 drops of ConcenTrace 2x daily with 8 oz of water or flavored water.~Week 3: Take 15 drops of ConcenTrace 2x daily with 8 oz of water or flavored water.~Weeks 4-12: Take 20 drops of ConcenTrace 2x daily with 8 oz of water or flavored water."
89043801|NCT05655676|Experimental|89Zr-NY008|
89043802|NCT04634864|Active Comparator|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation
89043803|NCT04634864|Sham Comparator|sham tDCS|40 minutes of 0mA intensity. the session starts with a ramp up to 2mA, but machine is switched off after 2 minutes of stimulation.
89043804|NCT02887417||patients|glioblastoma patients
89043805|NCT02887417||controls|healthy controls
89043806|NCT04317235|Active Comparator|3 ml ropivacaine|interscalene block using 3 ml under ultrasound put medication on each nerve
89043807|NCT04317235|Active Comparator|5 ml ropivacaine|interscalene block using 5 ml under ultrasound put medication on each nerve
89043808|NCT00560690|Placebo Comparator|Placebo|standard treatment with pegylated interferon and ribavirin + placebo
89043809|NCT00560690|Experimental|Metformin|standard treatment with pegylated interferon and ribavirin + metformin
89043810|NCT01227421|Active Comparator|Nitazoxanide, Placebo|300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days
89043811|NCT01227421|Active Comparator|Nitazoxanide, Nitazoxanide|Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days
89043812|NCT01227421|Placebo Comparator|Placebo|2 placebo tablets twice daily for 5 days
89043813|NCT05655559|Experimental|Treadmill Group|Hemodynamic effects such as heart rate, blood pressure, oxygen saturation (SpO2), dyspnea and fatigue including muscle oxygenation, will be compared during treadmill exercises.
89043814|NCT05655559|Experimental|Cycle Group|Hemodynamic effects such as heart rate, blood pressure, oxygen saturation (SpO2), dyspnea and fatigue including muscle oxygenation, will be compared during cycling exercises.
89043815|NCT00560729|No Intervention|I|
89043816|NCT00560729|Active Comparator|II|oral nutrition
89043817|NCT00560729|Experimental|III|oral nutrition
89043818|NCT00560729|Experimental|IV|oral nutrition
89043819|NCT02903901|Placebo Comparator|Placebo|Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
89043820|NCT02903901|Active Comparator|Melatonin|Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
89043821|NCT00560768|Experimental|1|
89043822|NCT02904213|Experimental|Pentavalent vaccine|3 Dose, interval for each dose is 4 weeks. The first dose will be received at 8-10 weeks of age
89644984|NCT06122584|Experimental|[18F]PSMA-1007|Single intravenous administration of [18F]PSMA-1007 for Positron Emission Tomography (PET) scan
89644985|NCT06122571|Experimental|Test arm: ConcenTrace|"Participants will follow this weekly dosing schedule:~Week 1: Day 1-3: take 5 drops of ConcenTrace with 8oz of water or flavored water. Day 4-7: take 5 drops of ConcenTrace 2x per day with 8 oz of water or flavored water.~Week 2: Take 10 drops of ConcenTrace 2x per day with 8 oz of water or flavored water.~Week 3: Take 15 drops of ConcenTrace 2x per day with 8 oz of water or flavored water.~Week 4: Take 20 drops of ConcenTrace 2x per day with 8 oz of water or flavored water.~Weeks 5 - 12: Take 40 drops of ConcenTrace 1x per day with 8 oz of water or flavored water."
89644986|NCT06122558|Experimental|Probiotic|Probiotic Lactobacillus plantarum at 9 log CFU/day for 8 weeks
89644987|NCT06122558|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 8-weeks)
89644988|NCT06122545|Experimental|Greater Occipital Nerve Block|"Patients will receive greater occipital nerve block (GONB) either with local anesthetic (bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.~Ultrasound-guided Greater Occipital Nerve Block (GONB) will be performed to more accurately locate the nerve through searching for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process and injection will be done medial to the artery"
89644989|NCT06122545|Experimental|Medical Treatment|Patients who will receive medical treatment
89644990|NCT06122532|Experimental|Stem cell preparation combined with Reticular skin|
89644991|NCT06122532|Experimental|Stem cell preparation combined with MEEK skin|
89644992|NCT06122532|Experimental|Stem cell preparation combined with split-thickness skin|
89644993|NCT06122532|Placebo Comparator|autologous skin grafting|
89644994|NCT06122493|Other|chemotherapy-immunotherapy-radiotherapy|Carboplatin (AUC = 5, d1) and nab-paclitaxel (175 mg/m², day1) will be administered every 3 weeks for four cycles.Tislelizumab (200 mg) will be administered every 3 weeks for up to 12 months. Radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy over 28 fractions will be delivered.
89644995|NCT06122454|Active Comparator|Tenofovir alafenamide Fumarate tablets|TAF is taken orally under postprandial conditions, and subjects begin eating breakfast within 30 minutes of taking the drug. The 25mgQD group is given a single daily dose for 24 consecutive weeks, and continues to take the drug for 48 weeks after completing the 24-week treatment.
89644996|NCT06122454|Experimental|Hepenofovir Fumarate Tablets|After taking HTS tablets orally under postprandial conditions, subjects began to eat breakfast within 30 minutes before taking the drug. The 10mgQD and 20mgQD dose groups were administered once daily for 24 consecutive weeks, and continued to be administered for 48 weeks after completing the 24-week treatment. The 40mgQOD group was administered once every other day for 24 weeks, and continued to be administered for 48 weeks after completing the 24-week treatment.
89644997|NCT06122428||Group X: Ribohyal Group|Composed of 16 eyes (right or left) assigned for the use of modified hyaluronic acid, HAr® 0.1%, covalently linked to Riboflavin
89644998|NCT06122428||Group Y: (Control Group)|Composed of 16 eyes (right or left) assigned for the use of HA 0.1% alone
89644999|NCT06122402|Experimental|SECURE Care Bundle|The SECURE Care Bundle has been developed by researchers based on the latest evidence to prevent medical adhesive-related skin injuries associated with central venous catheter fixation in children. The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, correctly applying and removing medical adhesives and registering medical adhesive related skin injury.
89645000|NCT06122402|Active Comparator|Standart Care|No intervention will be applied to this group. No intervention will be applied to this group. The care provided in the clinic will continue to be provided in the same way.
89645001|NCT06122376|Experimental|U-shaped power toothbrush|U-shaped power toothbrush with fluoride toothpaste
89645002|NCT06122376|Placebo Comparator|Manual Toothbrush|soft manual toothbrush with fluoride toothpaste
89645003|NCT06122324||lidocaine group|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
89645004|NCT06122324||control group|The second group will receive standard anesthesia management as the control group.
89645005|NCT06122285||Hepatis Delta|Bulevirtide (BLV) at a dose of 2 mg/day subcutaneously
89645006|NCT06122246|Active Comparator|Remote Blood Pressure (BP) Management Program|Participants will receive a remote BP management program (RBPM) inclusive of home BP monitoring and telehealth visits with a nurse or pharmacist.
89645007|NCT06122246|Experimental|Remote Blood Pressure (BP) Management Program + Community Health Worker (CHW)|Participants will receive a remote BP management program (RBPM) inclusive of home BP monitoring and telehealth visits with a nurse or pharmacist plus a social model with a CHW.
89645008|NCT06122246|No Intervention|Usual Care|Participants will be monitored prior to any RBPM intervention.
89645009|NCT06122233|Experimental|REBUILD-SM Group|Participants randomised to REBUILD-SM will receive the self-management package as well as the RE-BUILD app. Structured self-management support via telephone or Zoom call will be provided 4 times during the 12-week intervention period.
89645010|NCT06122233|No Intervention|Standard Care Group|In the control arm, participants will receive standard care and a reduced capability version of the RE-BUILD app to be used for data-capture only. They will also receive phone/Zoom calls at the same frequency during the 12-week intervention period, but no health advice will be given. After 26 weeks, participants in this group will receive access to the fully functional RE-BUILD app.
89645011|NCT06122220|Experimental|Pre-eclampsia|Subjects admitted with severe pre-eclampsia, based on the criteria by the American College of Obstetricians and Gynecologists (ACOG)
89645012|NCT06122220|Active Comparator|Control|Subjects admitted for normal labor, without any criteria of pre-eclampsia
89645013|NCT06122168|Experimental|Intervention Group|"Standard induction handling plus mandala delivery. The standard management involves, upon admission, a verbal interview with the doctor and midwife regarding the labor induction procedure (Time 1) Time 1 will end with the signing of the consent to participate in the study. Time 2, shortly before the induction, there is a time dedicated to written informed consent relating to the induction, with explanations of possible complications.~Time 3: once the induction is complete, the patient will be invited to return to the hospital room and where the time for the intervention will start, with the delivery of the mandala and colours. During the phases preceding the start of labour, except for the time dedicated to coloring the mandala, the patient will be subjected to standard care management, as required by the ward induction protocol."
89645014|NCT06122168|Active Comparator|Control Group|Will follow all the standard management of hospitalization, informed consent and post-induction (time 1, 2 and 3) foreseen for the intervention group, but will not receive the mandala.
89645015|NCT06122090|Experimental|Treatment|Bimatoprost will be delivered to the scars using laser-assisted drug delivery in this arm
89645016|NCT06122090|Sham Comparator|Control|Saline control will be delivered to the scars using laser-assisted drug delivery in this arm
89645017|NCT06122051||GROUP A: no significant underlying lung condition|"No significant Underlying lung condition. An Asthma diagnosis requiring short-acting bronchodilators only will be eligible.~For Dynamic Chest - x-ray and simultaneous Spirometry"
89645018|NCT06122051||GROUP B: People with CF|Diagnosis of Cystic Fibrosis For Dynamic Chest x-ray and simultaneous spirometry. Retrospective review of Dynamic Chest-xray metrics and key clinical markers of CF as recorded by the annual review process
89645019|NCT06122038|Placebo Comparator|Placebo|Rice Flour. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
89645020|NCT06122038|Experimental|Tart Cherry Extract Powder|Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
89645021|NCT06122025|Active Comparator|Intervention [access to electronic healthcare records; EHR]|"For those in the intervention group, the participant will receive personalised access to their secondary electronic healthcare record (EHR) for 6 months. Individual access will be activated by the clinical team at the start of the study and will include views for;~Current problems~Current medication~Test requests~Letters~Consultations~Allergies~Immunisations"
89645022|NCT06122025|No Intervention|Control [no access]|For those in the control group, participants will not receive access to their electronic healthcare record for the 6 month period. After the study, participants in the control group will have the opportunity to have access to their healthcare records
89043823|NCT01227265|Experimental|Preladenant 2 mg|Participants received 2 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
89043824|NCT01227265|Experimental|Preladenant 5 mg|Participants received 5 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
89645023|NCT06122012|Other|HSK16149 capsule combined with L-carnitine hydrochloride|HSK16149 capsule (20 mg/ capsule) was administered orally, 1 capsule twice a day for 12 weeks. Acetyl-l-carnitine hydrochloride tablets (0.25g/ tablet) were administered orally after meals, 2 tablets 3 times a day for 12 weeks
89645024|NCT06122012|Other|Lipoic acid combined with L-carnitine hydrochloride|HSK16149 capsule (20 mg/ capsule) was administered orally, 1 capsule twice a day for 12 weeks. Lipoic acid tablets (0.3g/ tablet) were administered half an hour before breakfast, 2 tablets once a day for 11 weeks.
89645025|NCT06121973|No Intervention|control group|Pregnant women in the control group did not receive any intervention other than routine care.
89645026|NCT06121973|Experimental|Experimental group|Pregnant women in the intervention group received online video-assisted education which demonstrated first meeting of the mother-baby and first breastfeeding in addition to receiving counselling on breastfeeding.
89645027|NCT06121947|Experimental|The DBS electrodes are implanted into MLR.|The DBS electrodes are implanted into MLR.MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy, exercise training rehabilitation, and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide, and guide on rehabilitation training and electrical stimulation therapy. Device: GPi-DBS devices DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China).
89645028|NCT06121947|Active Comparator|The electrodes are implanted into the patient's vagus nerve|The electrodes are implanted into the patient's vagus nerve. A pre-surgery assessment was performed. Device implantation was done under general anesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunneled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
89645029|NCT06121895||Video Laryngeal Mask|Patients who are intubated using Video Laryngeal Mask for intubation purposes will be included.
89645030|NCT06121895||Fastrack Laryngeal Mask|Patients who are intubated using Fastrack Laryngeal Mask for intubation purposes will be included.
89645031|NCT06121869|Placebo Comparator|Placebo|Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
89645032|NCT06121869|Active Comparator|Leucine|Participants will supplement daily for 10 weeks with 2 grams rice leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
89645033|NCT06121869|Experimental|Dileucine|Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
89645034|NCT06121856||In-patients cardiothoracic intensive care|In-patients in the cardiothoracic intensive care department that were at least 16 years old and were fitted with an arterial line. There was no requirement to have diabetes but the study aimed to recruit a minimum of 20% subjects with diabetes.
89645035|NCT06121830|Experimental|DWP14012 20mg|Once daily with water regardless of meals without chewing or crushing for 4 weeks.
89645036|NCT06121830|Experimental|DWP14012 40mg|Once daily with water regardless of meals without chewing or crushing for 4 weeks.
89645037|NCT06121830|Placebo Comparator|Placebo|Once daily with water regardless of meals without chewing or crushing for 4 weeks.
89645038|NCT06121817|Experimental|Durian|250 g of durian aril (isocaloric)
89645039|NCT06121817|Other|Banana|417.6 g of banana (isocaloric)
89645040|NCT06121804||Patients with organ transplantation|Patients who underwent SOTs between 2002 and 2013, specifically, kidney (ICD-9-CM code V42.0), liver (ICD-9-CM code V42.7), or lung (ICD-9-CM code V42.6) transplants.
89645041|NCT06121804||Patients without organ transplantation|The general patients were enrolled as the comparison. We used propensity score matching (PSM) to establish a matched cohort.
89645042|NCT06121778||Home|Elderly people living at home
89043825|NCT01227265|Placebo Comparator|Placebo|Participants received preladenant-matching placebo as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extention trial or return for a follow-up visit two (2) weeks later.
89043826|NCT00560807|No Intervention|A|Zero treatment/3 weeks
89043827|NCT00560807|Active Comparator|B|Frequency of Mobilization:1/week Duration of Mobilization Treatment: 3 weeks
89043828|NCT00560807|Active Comparator|C|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 6 weeks
89043829|NCT00560807|Active Comparator|D|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 12 weeks
89043830|NCT00560807|Active Comparator|F|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 3 weeks
89645043|NCT06121739|Experimental|Child Mental health Literacy Program|Teachers from four schools will attend a nine-session workshop on mental health literacy. They will participate in face-to-face sessions and use an online platform.
89645044|NCT06121739|No Intervention|Control|Teachers from four schools will not receive any additional mental health training
89645045|NCT06121726||Ilioinguinal-Iliohypogastric nerve block|Patients will receive Ilioinguinal-Iliohypogastric nerve block as standard of care
89645046|NCT06121700|Experimental|Radiotherapy, Chemotherapy and anti-PD-1 Immunotherapy followed by Surgical Resection|Participants will receive short course hypofractionated radiotherapy (HFRT) for the primary lesion, HFRT or stereotactic body radiotherapy (SBRT) for metastatic lesions, combined with systemic chemotherapy and anti-PD-1 immunotherapy. For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. Then, surgical resections of primary and metastatic lesions are performed as much as possible. For patients who need a widely invasive surgical approach or are inoperable, local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) can be alternatives. For patients undergoing surgical resections, postoperative treatment includes chemotherapy, which is determined by the researcher, and PD-1 antibody, which will be maintained until one year after surgery.
89645047|NCT06121687|Experimental|Shaeer-I|Shaeer-I High Vein Ligation surgery will be performed. A hockey-stick or vertical incision encompassing the target point is cut, lateral to anal cleft. Subcutaneous fat is dissected down to the gluteus maximus, which is split along the direction of its fibers. The internal pudendal vein can be identified and ligated deep to the muscle, coursing between the pudendal nerve medially and the pudendal artery laterally.
89645048|NCT06121687|Active Comparator|PPI|Penile prosthesis implantation (PPI) will be performed.
89645049|NCT06121674|Experimental|Shaeer-II|"SHAEER-II targets ligation of the internal pudendal vein at the point where the vein exits Alcock's canal, and courses lateral to the ischial tuberosity.~Patient is oriented in the lithotomy position. The ischial tuberosity is marked. An incision is cut medial to the ischial tuberosity. Subcutaneous fat is dissected down to the neurovascular bundle harboring the internal pudendal vein. The vein is then ligated."
89645050|NCT06121674|Active Comparator|PPI|Penile prosthesis implantation (PPI) will be performed
89645051|NCT06121570|Experimental|Chemotherapy + LNL treatment|Participants receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by neoadjuvant LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.
89645052|NCT06121557|Experimental|LNL treatment + Camrelizumab + another anti-tumor drug|Participants receive LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive camrelizumab PLUS another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor at investigator's discretion.
89645053|NCT06121531|Active Comparator|Group I|Si-Hy (Samfilcon A)
89645054|NCT06121531|Experimental|Group II|Si-Hy (Otufilcon A)
89645055|NCT06121518|Experimental|Experimental Group|D064 and D702 Combination Therapy
88992020|NCT02098954|Experimental|experimental|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme(gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for 150mg/day, day 9-21 every cycle, after 4 cycles, erlotinib should be used daily), after 4 cycle of combined chemotherapy, patients will receive erlotinib for further treatment until progression disease.
88992021|NCT02065362|Experimental|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f
88992022|NCT02060344||Hispanic/Latinos residing in the US|The cohort consists of over 16,400 persons of Hispanic/Latino origin, ages 18-74, specifically Cuban, Puerto Rican, Mexican, and Central/South American, to be recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami.
88992023|NCT02016820|Experimental|Omeprazole (suspension)|Open-label, with all subjects receiving omeprazole
88992024|NCT02016820|Other|Lifestyle Modification|Treated with lifestyle modification (upright feeding, smaller meals, elevation of the head of the bed, etc.)
88992025|NCT01955460|Experimental|Treatment (chemotherapy, autologous T-cell immunotherapy)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and TGFb DNRII-transduced autologous TIL and NGFR-transduced autologous T lymphocytes IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
89645056|NCT06121518|Active Comparator|Comparator Group 1|D064 Monotherapy
89645057|NCT06121518|Active Comparator|Comparator Group 2|D702 Monotherapy
89645058|NCT06121154||PEX-positive patients|The criteria to diagnose Pseudoexfoliation syndrome (PEX) were, after pupillary dilatation, the presence of white fluffy dandruff-like material on one or more anterior segment structures, including the pupillary margin, the anterior lens capsule, or the angle in biomicroscopic examination. The patients were divided into two groups: solely based on PEX-positive (n=48) and PEX-negative (n=48) status
89645059|NCT06121154||PEX-negative patients|The criteria to diagnose Pseudoexfoliation syndrome (PEX) were, after pupillary dilatation, the presence of white fluffy dandruff-like material on one or more anterior segment structures, including the pupillary margin, the anterior lens capsule, or the angle in biomicroscopic examination. The patients were divided into two groups: solely based on PEX-positive (n=48) and PEX-negative (n=48) status
89043831|NCT00560807|Active Comparator|G|Frequency of Mobilization: 2/week Duration of Mobilization Treatment:6 weeks
89043832|NCT00560807|Active Comparator|H|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 12 weeks
89043833|NCT00560807|Active Comparator|J|Frequency of Mobilization: 3/week Duration of Mobilization Treatment: 3 weeks
89043834|NCT00560807|Active Comparator|K|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:6 weeks
89043835|NCT00560807|Active Comparator|L|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:12 weeks
89043836|NCT00560807|No Intervention|E|Zero treatment/6 weeks
89043837|NCT00560807|No Intervention|I|Zero treatment/12 weeks
89043838|NCT04319302||Paediatric biliary obstruction|This was a retrospective review of all paediatric patients who had undergone an IVGT graft procedure for biliary tract anatomical obstruction in the past five years. We looked at the indications for surgery, the demographic profile of the patients, outcomes following surgery and outlined the surgical technique used.
89043839|NCT04634981||Group general anesthesia (G)|patients will positioned with pelvic wedge on operating table and preoxygenated. Then rapid sequence induction with precalculated doses of propofol (2 mg/kg) and rocuronium (0.9 mg/kg) will followed by endotracheal intubation. After delivery of the baby, fentanyl will be administered. Later, anesthesia will be maintained with isoflurane (1%).
89043840|NCT04634981||Group Spinal anesthesia (S)|all parturients will co-loaded with 500 ml of colloid solution. In the left lateral position, the patients' back will be cleaned with povidone iodine. In the meantime, the spinal anesthetic drug and local anesthetic drug will be prepared. After wiping povidone iodine with alcohol, a rapid single shot of 2.5 ml of 0.5% hyperbaric bupivacaine will be administered intrathecally using 22 G spinal needle. Oxygen will be administered using simple face mask till the delivery of the baby.
89645060|NCT06121037|Experimental|Proximal group|proximal ultrasound-guided GON radiofrequency ablation
89645061|NCT06121037|Experimental|Distal group|distal ultrasound-guided GON radiofrequency ablation
89043841|NCT05655286|Experimental|Group A- immediately rinse mouth|Children are instructed to rinse their teeth with a cup of water containing about 50 ml immediately after SDF treatment. Afterwards, no post-treatment protocol is given to children.
89043842|NCT05655286|Experimental|Group B- not to rinse for at least 30 minutes|Children are instructed not to eat and drink for at least 30 minutes.
89043843|NCT02904252||Study group|Population : The participants are thalassemia patients who regularly visit Hematology Clinic, Department of Medicine, Faculty of Medicine Siriraj Hospital Clinical data, Laboratory data (Blood samples) and Transient elastography data will be collected from all participants, as previously described.
89043844|NCT04318990|Experimental|Distal radial artery access|Wrist rests on a comfortable underground which brings the wrist in passive ulnar flexion. Patient is asked to bring the thumb under the other four fingers. After disinfection, patient is covered with a sterile drape. Brachial drape is applied to the hand exposing the anatomical snuff box and the proximal radial. Under ultrasound guidance, local anesthesia applied by SC injection of 5cc of lidocaine filling the radial fossa. Puncture performed at the point of maximal pulsation proximal in the anatomical snuffbox. If fails, a puncture more distal, can be attempted. After successful anterior wall puncture a radial sheath wire is advanced. Proper position verified by fluoroscopy or by ultrasound to ensure the wire didn't traverse the palmar arch, followed by introduction of a hydrophilic sheath. After administration of a spasmolytic cocktail containing 200-400 mcg of nitroglycerin and 5 mg of verapamil, the operator can take up a position at the level of the patient's knees.
89645062|NCT06120803|Experimental|Esomeprazole 40 mg daily with thoracic radiation therapy and concomitant chemotherapy|Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy (TRT). TRT will be delivered as per the discretion of the treating physicians.
89645063|NCT06119438|Active Comparator|Saline group|Only saline solution was applied to the placebo group. The nebulizer was prepared and operated in the room where the prostate biopsy would be performed before the procedure. Patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure
89645064|NCT06119438|Active Comparator|Levander group|Levander oil was added to the nebulizer at a rate of 2%. The nebulizer was prepared and operated in the room where the prostate biopsy would be performed before the procedure. Patients were taken to the room 5 minutes before the procedure and the nebulizer was operated during the procedure.
89645065|NCT06119438|Active Comparator|Frankincense group|Frankincense oil was added to the nebulizer at a rate of 2%. Only saline solution was applied to the placebo group. The nebulizer was prepared and operated in the room where the prostate biopsy would be performed before the procedure. Patients were taken to the room 5 minutes before the procedure and the nebulizer was operated during the procedure.
89645066|NCT06119425|No Intervention|Control|Patients judged to be at average risk of CRC will be engaged in a conversation about CRC risk factors and standard of care (SOC) screening options. Patients who express a desire to be screened using the SOC options will be considered part of the control group.
89645067|NCT06119425|Experimental|Experimental|Patients judged to be at average risk of CRC will be engaged in a conversation about CRC risk factors and standard of care (SOC) screening options as well as the option to be screened with a blood-based test which is not currently standard of care. Patients who express a desire to be screened using the SOC options or the blood-based non-SOC option will be considered part of the experimental group.
89645068|NCT06119412|Other|group 1, starting with standard technique|According to block randomization, the 1st researcher will first apply the standard technique (60 seconds pause between palpation and auscultation), 1 minute break will be given, and the 2nd researcher will apply the alternative new technique (no break between palpation and auscultation) on the same person.
89645069|NCT06119412|Other|group 2, starting with alternative new technique|According to block randomization, Investigator 1 will first apply the alternative new technique (no pause between palpation and auscultation) to the people in the second group, and a 1-minute break will be given. The 2nd researcher will apply the standard technique (60 seconds break between palpation and auscultation) on the same person.
89645070|NCT06119399|Experimental|Breathing Exercises Plus Conventional Exercise Program for Chronic Neck Pain|Subjects will receive conventional exercise program for Chronic Neck Pain in addition to breathing exercises (diaphragmatic and pursed lip breathing) for (three sessions per week for six weeks).
89043845|NCT04318990|Active Comparator|Proximal radial artery access|Half of the patients enrolled in the study undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized proximal radial access for cardiac catheterization.
89043846|NCT04319107||Marfan Syndrome (MFS) patients|Patients who had a clinical diagnosis of MFS according to the revised Ghent criteria (ectopia lentis was not taken into account for the diagnosis), confirmed by FBN1 sequencing.
89645071|NCT06119399|Experimental|Doming of the diaphragm plus Conventional Exercise Program for Chronic Neck Pain|Patients in this arm will receive conventional physiotherapy treatment for Chronic Neck Pain in addition to doming of the diaphragm (three sessions per week for six weeks).
89645072|NCT06119386|Experimental|Group 1 - Treated Eye|Patients with treatment
89645073|NCT06119373|Experimental|Single daily icodextrin exchange group|For incident peritoneal dialysis (PD) patients assigned to the experimental arm, PD is initiated with single daily exchange of 2-liter icodextrin-based dialysis solution. The daily dwell time ranges from 8-24 hours per day, depending on the patient's clinical conditions. Additional exchange(s) of glucose-based dialysis solution will be added to increase uremic toxins and fluid removal if necessary during the follow-up.
89645074|NCT06119373|Active Comparator|Conventional PD group|For incident peritoneal dialysis (PD) patients assigned to this arm, PD is initiated with 2 to 3 exchanges of 2-liter glucose-based solution. The daily dwell time ranges from 8-24 hours per day, depending on the patient's clinical conditions. Additional exchange(s) of glucose-based dialysis solution will be added to increase uremic toxins and fluid removal if necessary during the follow-up.
89645075|NCT06119360|Other|Group Conventional|Conventional approach using group in lightwand intubation
89645076|NCT06119360|Other|Group Face-to-Face|Face-to-face approach using group in lightwand intubation
89645077|NCT06119347||AntiVEGF|cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF)
89645078|NCT06119347||ICIs|cancer patients receiving immune checkpoint inhibitors (ICIs).
89645079|NCT06119334|Experimental|Experimental|Sixteen weeks of phone-based counselling at a rate of 1 session/week and ongoing access to a online platform (Nex J Connected Wellness) that has health promotion text and videos readily accessed in combination with text messaging exchanges between counselor and participant. Participants receive a Fitbit which is connected to the Nex J Connected Wellness such that counselors can monitor steps/day.
89645080|NCT06119334|No Intervention|Wait list control|Participants wait for 16 weeks.
89645081|NCT06119321||Normal control group|
89645082|NCT06119321||Subclinical keratoconus|
89645083|NCT06119321||Keratoconus|
89645084|NCT06119308|Experimental|Benzodiazepine Medication Taper with Cognitive Behavioral Therapy|Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing
89645085|NCT06119256|Experimental|EBV-TCR-T cells|"Phase 1 trail:~The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10^5/kg to 1×10^6/kg EBV-TCR-T cells per dose.~Phase 2 trail:~According to the PK and response data, the dose escalation phase will be carried out."
89645086|NCT06119230|No Intervention|Sensors only|Participants will only wear the sensors for a one week period during the 4 different time points.
88992026|NCT01902173|Experimental|Treatment (uprosertib, dabrafenib, trametinib)|"Dabrafenib mesylate and uprosertib (Phase I): Patients receive dabrafenib PO BID and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, and blood sample collection throughout trial. Patients may also undergo a biopsy throughout the trial.~Dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib (Phase I and Phase II): Patients receive dabrafenib PO BID, trametinib PO QD, and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, and blood sample collection throughout trial. Patients may also undergo a biopsy throughout the trial."
88992027|NCT01872975|Active Comparator|Group 1A Lumpectomy: no regional nodal XRT with WBI|Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
88992028|NCT01872975|No Intervention|Group 1B Mastectomy: No regional nodal or chestwall XRT|Mastectomy patients do not undergo radiation therapy.
88992029|NCT01872975|Experimental|Group 2A lumpectomy: Regional nodal XRT with WBI|Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
88992030|NCT01872975|Experimental|Group 2B Mastectomy: Regional nodal XRT and chestwall XRT|Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks.
88992031|NCT01815957|Experimental|Ranalozine|After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
89645087|NCT06119230|Experimental|Sensors and Activity Counselling|Participants will wear the sensors for a one week period and receive a goal setting session with a physiotherapist at baseline, 3-and 7-weeks post discharge.
89645088|NCT06119217|Experimental|Arm 1|TTX-030 plus nab-paclitaxel and gemcitabine
89645089|NCT06119217|Experimental|Arm 2|TTX-030 plus budigalimab plus nab-paclitaxel and gemcitabine
89645090|NCT06119217|Active Comparator|Arm 3|Nab-Paclitaxel and gemcitabine
89645091|NCT06119152|No Intervention|Control|Usual Care
89645092|NCT06119152|Experimental|Intervention|The DESA Intervention will use a telehealth device to help the patient take blood pressure daily, and monitor blood pressure management.
89645093|NCT06119139|Active Comparator|1.8 ml 4% articaine buccal infiltration.|
89645094|NCT06119139|Experimental|3.6 ml 4% articaine buccal infiltration|
89645095|NCT06119113|Active Comparator|Group 1 (Vicryl suture™(Polyglactin 910))|The group whose skin incision was closed with Vicryl suture™ (Polyglactin 910) from patients who had cesarean section for the first time
89645096|NCT06119113|Active Comparator|Group 2 (Prolene suture™(polypropylene))|The group whose skin incision was closed with Prolene suture™ (polypropylene) from patients who had cesarean section for the first time
89645097|NCT06119113|Active Comparator|Group 3 (Monocryl suture™ (Polyglecaprone 25))|The group whose skin incision was closed with Tekmon suture™ (Polyglecaprone 25) from patients who had cesarean section for the first time
89645098|NCT06119087|Experimental|Mechanical insufflation|Participants will be asked to perform mechanical insufflation using the BiWaze cough device as 5 sets of 5 insufflations twice daily for 6 months.
89212598|NCT00871910|Experimental|2 Hour SCH 727965 infusions plus aprepitant in Cycle 1|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.
89212599|NCT00871910|Experimental|2 Hour SCH 727965 infusion plus aprepitant in Cycle 2|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.
89212600|NCT01564329|Experimental|endostar2|CT Perfusion Imaging(CTPI) at D0, D21 of the first cycle、D6, D14 of the second cycle, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
89212601|NCT01564329|Experimental|endostar1|CT Perfusion Imaging(CTPI) at D0，D6, D14, D21 of the first period, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
89212602|NCT00872066|Active Comparator|1) SmartSet® HV Bone Cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
89645099|NCT06119022|Experimental|CT-MPI guided without myocardial ischemia|There was no evidence of myocardial ischemia in patients with coronary heart disease by CT-MPI
89645100|NCT06119022|Experimental|CT-MPI guided with myocardial ischemia|There was positive evidence of myocardial ischemia in patients with coronary heart disease by CT-MPI
89645101|NCT06119022|Active Comparator|SPECT-MPI guided without myocardial ischemia|There was no evidence of myocardial ischemia in patients with coronary heart disease by SPECT-MPI
89645102|NCT06119022|Active Comparator|SPECT-MPI guided with myocardial ischemia|There was positive evidence of myocardial ischemia in patients with coronary heart disease by SPECT-MPI
89645103|NCT06119009||Non- Heart blocks|The number of patients who did not suffered the heart blocks in the postoperative 1-year period
89645104|NCT06119009||Heart blocks|The number of patients who suffered the heart blocks in the postoperative 1-year period
89645105|NCT06118996|Experimental|Patients at Risk of Breast Cancer|These patients will be imagined with an experimental device designed to acquire ultrasound in three dimensional volumes
89645106|NCT06118970||Patients with fibromyalgia syndrome|"Patients with fibromyalgia will be recruited at the UZ hospital in Brussels, at the Saint Luc hospital in Brussels, at local patient organisations (e.g. VLFP), at the Vrije Universiteit Brussel and via social media alerts.~This syndrome must be confirmed by a medical diagnosis. Patients with other diagnoses will be excluded from this study (e.g., osteoarthritis, rheumatoid arthritis, post-cancer pain, as well as patients with primary psychiatric/neurological conditions or psychopathological disorders). Subjects with a history of substance abuse or pathological gambling will also be excluded."
89645107|NCT06118970||Healthy controls|Healthy controls will be recruited through the University of Brussels or through social media alerts. Their exclusion criteria included, in addition to those specified for the fibromyalgia group, those who were suffering from fibromyalgia or had a severe rheumatic illness. Subjects should not have pain currently or have a recent history of pain (within the past 3 months).
89645108|NCT06118944|Experimental|ICB00 Group|ICB00 IOL
89645109|NCT06118944|Active Comparator|ZCB00 Group|ZCB00 IOL
89645110|NCT06118944|Active Comparator|CNA0T0 Group|CNA0T0 IOL
89645111|NCT06118931|Experimental|Early (7:00-16:00h) TRE|Participants will be asked to eat ad libitum between the hours of 7:00 - 16:00 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 7:00 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
89645112|NCT06118931|Experimental|Mid (9:30-18:30h) TRE|Participants will be asked to eat ad libitum between the hours of 9:30 - 18:30 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 9:30 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
89645113|NCT06118931|Experimental|Late (12:00-21:00h) TRE|Participants will be asked to eat ad libitum between the hours of 12:00 - 21:00 each day for seven days, and then only drink water or other no calorie beverages for the rest of the day. On the 8th day, they will consume one meal replacement beverage at 12:00 and be instructed to not consume anything else for two hours. After the two hours they will be instructed to return to their normal baseline eating habits.
89645114|NCT06118931|No Intervention|Control|During the first week of the study, participants will be asked to eat as they normally do, and to not make any changes regarding when they are stopping or starting eating.
89645115|NCT06118918|Experimental|The interventional arm (participants who will received the cardiac rehabilitation program|this arm will receive the cardiac rehabilitation program after completing the cardiac surgery and being assessed for eligibility.
89212603|NCT00872066|Active Comparator|2) SmartSet® GHV Bone Cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
89212604|NCT00877292||Down syndrome|Women having CVS or amniocentesis who, as a group, have a high prevalence of Down syndrome.
89212605|NCT00993525|Experimental|Intravitreal anti-VEGF|Intravitreal injection of 0.5 mg of ranibizumab
89645116|NCT06118918|No Intervention|the control arm (who will receive the usual care)|the control group will receive the usual care ( the usual instruction and general advice from the physicians and the nurses)
89645117|NCT06118879|Experimental|Sensory level stimulation with exercise|
89645118|NCT06118879|Sham Comparator|Sham stimulation with exercise|
88992032|NCT01810250||Abdominal Aortic Aneurysm (Challenging anatomy)|Endovascular aneurysm repair
89212606|NCT00993603|Experimental|Lifestyle programme.|8 month lifestyle programme.
89212607|NCT00993681|Experimental|1|900 subjects will receive a two vaccination regimen with an LT patch
89212608|NCT00993681|Placebo Comparator|2|900 subjects will receive a two vaccination regimen with a placebo patch
89212609|NCT03892707||NSAIDs group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors)
89645119|NCT06118879|Active Comparator|Exercsie alone|
89645120|NCT06118866|Placebo Comparator|placebo-Q2W|placebo, 0mg/vials
89645121|NCT06118866|Active Comparator|HMI-115-120mg-Q4W|HMI-115, 60mg/vials
89212610|NCT03892707||NSAIDs+Milgamma+Milgamma compositum group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum
89212611|NCT05132049|Experimental|Sequence A|
89212612|NCT05132049|Experimental|Sequence B|
89212613|NCT00993759|No Intervention|No treatment|
89212614|NCT00993759|Experimental|3804-250A lotion|
89212615|NCT00513604|Experimental|Cohort 1 - NMA, TIL, aldesleukin|"Cohort 1 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), & high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 1 = unselected TIL"
89645122|NCT06118866|Active Comparator|HMI-115-240mg-Q4W|HMI-115, 60mg/vials
89645123|NCT06118866|Active Comparator|HMI-115-240mg-Q2W|HMI-115, 60mg/vials
89212616|NCT00513604|Experimental|Cohort 2 - NMA, CD4+ TIL, aldesleukin|"Cohort 2 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 2 = CD4+ depleted (selected) TIL"
89645124|NCT06118840|Experimental|True-AI-integrated intracranial aneurysms diagnosis strategy|For patients who underwent head CTA and assigned to True-AI group, they will be diagnosed by a radiologist who are aided by the True-AI-integrated intracranial aneurysms diagnosis strategy.
89645125|NCT06118840|Sham Comparator|Sham-AI-integrated intracranial aneurysms diagnosis strategy|For patients who underwent head CTA and assigned to Sham-AI group, they will be diagnosed by a radiologist who are aided by the Sham-AI-integrated intracranial aneurysms diagnosis strategy. To mimic the True-AI, the Sham-AI had a sensitivity close to 0% and a similar specificity to the True-AI.
89645126|NCT06118827|Experimental|HS-10518 Dose 1|Dose level 1 of HS-10518, QD, orally, 7 days
89645127|NCT06118827|Placebo Comparator|Placebo Dose 1|Dose level 1 of matching placebo, QD, orally, 7 days
89645128|NCT06118827|Experimental|HS-10518 Dose 2|Dose level 2 of HS-10518, QD, orally, 7 days
89645129|NCT06118827|Placebo Comparator|Placebo Dose 2|Dose level 2 of matching placebo, QD, orally, 7 days
89645130|NCT06118827|Experimental|HS-10518 Dose 3|Dose level 3 of HS-10518, QD, orally, 7 days
89645131|NCT06118827|Placebo Comparator|Placebo Dose 3|Dose level 3 of matching placebo,QD, orally, 7 days
89645132|NCT06118827|Experimental|HS-10518 Dose 4|Dose level 4 of HS-10518, QD, orally, 7 days
89645133|NCT06118827|Placebo Comparator|Placebo Dose 4|Dose level 4 of matching placebo, QD, orally, 7 days
89645134|NCT06118814|Experimental|Body Awareness Therapy Group|
89645135|NCT06118814|Experimental|Virtual Reality Exercise Group|
88992033|NCT01805297|Active Comparator|Vitrectomy with Aflibercept Injection|Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection.
88992034|NCT01805297|Active Comparator|Standard Vitrectomy|Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.
88992035|NCT01764529||The BVMC FCCM cohort|"Aim 1: To investigate the relationship between lesion burden and outcomes in familial CCM.~Aim 2: To investigate the role of the gut microbiome in familial CCM disease severity.~Aim 3: To establish blood markers predictive of disease severity and progression for medical treatment of CCM."
89212617|NCT00513604|Experimental|Cohort 3 - NMA, total body irradiation|"Cohort 3 - Nonmyeloablative (NMA), total body irradiation (TBI):~Nonmyeloablative chemotherapeutic conditioning regimen and 2 gray units (Gy) of total body irradiation followed by cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL 2Gy (gray units) of total body irradiation (TBI) twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute using a linear accelerator in Radiation Oncology Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 3 = CD4 + depleted (selected) TIL + 600Gy radiation"
89645136|NCT06118814|Experimental|Core Stability Exercise Group|
89645137|NCT06118814|Active Comparator|Home Exercise Group|
89645138|NCT06118801|Experimental|Probiotic group|Mothers of premature babies in this group will be given breast milk and breastfeeding training immediately after birth in order to ensure that they can give only breast milk to their babies, and at the same time, 80 ml of probiotic supplements will be given once a day for 20 days.
89645139|NCT06118801|No Intervention|control group|There will be no intervention for mothers of preterm babies in this group, and they will be trained on breast milk and breastfeeding so that they can give only breast milk to the baby.
89645140|NCT06118775|Experimental|EaDyn weaning arm|In the EaDyn weaning arm of the study, dynamic arterial elastance (EaDyn) will be utilized as a specialized hemodynamic tool to guide the gradual reduction of vasopressor support in patients diagnosed with septic shock. EaDyn, a measure of the relationship between arterial pressure and stroke volume variation over the cardiac cycle, provides valuable insights into vascular tone and cardiac performance
89645141|NCT06118775|Active Comparator|PAM weaning arm|In the PAM (Mean Arterial Pressure) weaning arm of the study, mean arterial pressure (MAP) will be used as the primary parameter to guide the gradual reduction of vasopressor support in patients diagnosed with septic shock. Mean arterial pressure represents the average pressure in the arteries during one cardiac cycle and is a crucial indicator of perfusion to vital organs. Participants in this group will be monitored continuously for their MAP values, allowing real-time assessment of their hemodynamic status.
89645142|NCT06118762|Experimental|Fruquintinib combined with Raltitrexed group|Fruquintinib combined with Raltitrexed therapy
89645143|NCT06118736|Experimental|Adductor tenotomy + Temporary Medial Hemi-epiphysiodesis of the proximal femur|Standard care + intervention
89645144|NCT06118736|No Intervention|Adductor tenotomy|Standard care
89645145|NCT06118710|Experimental|Experimental premedication regimen|Local standard of care premedication regimen with an Histamine-1 antagonist (e.g. clemastine or cetirizine) without dexamethasone
89645146|NCT06118710|Active Comparator|Local standard of care premedication regimen|Local standard of care premedication regimen with an Histamine-1 antagonist (e.g. clemastine or cetirizine) with dexamethasone
89645147|NCT06118697|Experimental|Infants with Complex Feeding Difficulties|Weekly manometric esophageal stimulation as well as consistent nutritive oral feeding therapy
89043847|NCT04319107||Control patients|Relatives of MFS patients with none of the clinical features of MFS and in whom testing for the familial FBN1 mutation was negative.
89043848|NCT04319263|Experimental|intermediate and high risk non muscle invasive bladder cancer|
89645148|NCT06118671|Experimental|Intervention group|giving personalized lifestyle intervention suggestions through AI
89645149|NCT06118671|No Intervention|Control group|giving routine lifestyle suggestions
89645150|NCT06118658|Experimental|Chemotherapy-sequential tislelizumab adjuvant therapy|About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
89645151|NCT06118645|Experimental|cadonilimab combined +paclitaxel (albumin-bound)|cadonilimab combined +paclitaxel (albumin-bound)
89043849|NCT05655169|Experimental|Piezosurgery and low-level laser therapy|Piezocision will be applied in this group of patients using a piezosurgery knife and after six weeks of initial retraction, low-level laser therapy will be applied in this group of patients using a diode laser device.
89043850|NCT05655169|Experimental|Piezosurgery only|Piezocision will be applied in this group of patients using a piezosurgery knife
89043851|NCT05655169|Active Comparator|Traditional treatment without acceleration|In this group of patients, the en masse retraction will be conventional without any acceleration intervention.
89043852|NCT05658406|Active Comparator|Group A|intraoperative infusion of 15 mL/kg/hour Ringer's lactate.
89043853|NCT05658406|Active Comparator|Group B|intraoperative infusion of 10 mL/kg/hour Ringer's lactate
89043854|NCT05658406|Active Comparator|Group C|intraoperative infusion of 6 mL/kg/hour Ringer's lactate.
89043855|NCT05658406|Placebo Comparator|Group D|standard fluid management alone
89043856|NCT01226095||Osteoarthritic patients|Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis
89043857|NCT05658367|Active Comparator|Group 1|- Group I: The group applied arm massage with sesame oil
89043858|NCT05658367|Experimental|Group 2|- Group II: The group applied arm massage with a mixture of sesame-lavender oil
89043859|NCT05658367|Placebo Comparator|Group 3|- Group III (Control): The group applied arm massage with paraffin oil
89043860|NCT04319146|Other|robot-assisted radical prostatectomy|patient with a prostate cancer will be operated with a robot-assisted method. They will be supported on an outpatient basis
89043861|NCT04206592|Active Comparator|i Gel LMA|The sealing pressure of the igel laryngeal mask will be measured during pneumoperitoneum in elective laparoscopic cholecystectomy
89043862|NCT04206592|Active Comparator|Ambu Aura Gain|It will be compared the Ambu Aura Gain LMA vs iGel in elective laparoscopic cholecystectomy
89043863|NCT02894697|Active Comparator|Angiography-guidance|
89043864|NCT02894697|Experimental|OCT-guidance|
89043865|NCT04634474|Experimental|Pain on Endotracheal Suction|Before and after endotracheal aspiration, the pain of the patient will be evaluated according to the DAS and VAS scale. VAS scores will be compared with DAÖ scores. Aspiration process will be applied to all patients by the same nurse. According to the DAQ, the pain will be assessed by a volunteer nurse who is not a researcher.
89043866|NCT05469997|Experimental|MeDi(KD-MCT)|The participants in this arm will first undergo the MeDi-KD intervention followed by the MeDi-MCT intervention, after an 8-week washout period.
89043867|NCT05469997|Experimental|MeDi(MCT-KD)|The participants in this arm will first undergo the MeDi-MCT intervention followed by the MeDi-KD intervention, after an 8-week washout period.
89043868|NCT00560846|Experimental|Nutrition|Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
89043869|NCT00560846|No Intervention|Control|No immunonutrition, no glucose load, no early enteral immunonutrition
89043870|NCT04634006|Active Comparator|active tDCS 1|Anodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the cathode will be placed over the the vertex (Cz), using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
89043871|NCT04634006|Active Comparator|active tDCS 2|Anodal tDCS will be applied over the right IFG (1/3 of the distance between F8 and C6) according to the 10-20 EEG electrode systems and the cathode will be placed posterior to left mastoid, using square saline-soaked sponge pads 25 cm2. The current intensity of 1 mA will be used for 20 mins for a session. (N=25)
89043872|NCT04634006|Sham Comparator|sham tDCS|Anodal tDCS will be applied over the left DLPFC (N=13) or right IFG (N=12) according to the 10-20 EEG electrode systems and the cathode will be placed over vertex or posterior to left mastoid, respectively, using square saline-soaked sponge pads 25 cm2. Sham stimulation will be maintained for 19 min without current flow by increasing current for 30 s followed by a decrease for 30 s.
89043873|NCT04633850||Before implementation|Perineural bupivacaine without adjuvants.
89043874|NCT04633850||After implementation|Perineural bupivacaine with intravenous dexamethasone.
89043875|NCT02903472||Acute to first year after SCI|Individuals sustained SCI within a 1-year period
89043876|NCT02903472||Chronic|Individuals sustained SCI more than1 year ago
89645152|NCT06118580|Experimental|Oral alcohol drink|
89645153|NCT06118580|Placebo Comparator|Placebo (non-alcohol drink)|
89645154|NCT06118567|Active Comparator|Nitrous Oxide Inhalation|60 minute session inhaling Nitrous Oxide gas.
89645155|NCT06118567|Sham Comparator|Room Air|60 minute session inhaling Room Air.
89645156|NCT06118554|Active Comparator|Control group|The control group (CG) irrigated in the standard FDA consumer-recommended position, defined as leaning forward with a natural ear-to-shoulder head tilt.
89645157|NCT06118554|Experimental|Backfill group|Backfill group (BG) subjects irrigated with a head tilt of 90 degrees ear-to-shoulder and used the nostril closest to the ground.
89645158|NCT06118554|Experimental|Model group|Finally, the model group (MG) irrigated in an optimal position based on their 3D nasal replica. This patient-specific position was communicated to each MG patient with clear instructions during an in-person training session.
89645159|NCT06118541|Experimental|Vestibular Rehabilitation therapy|"The experimental group received a vestibular rehabilitation exercise program, The assessment tools used in this study included the Chinese version of the Dizziness Handicap Inventory (DHI), Dizziness Visual Analog Scale (DVAS), 16-item Post-Concussion Symptom Checklist (PCSC), Beck Anxiety Inventory (BAI), Traumatic Brain Injury Quality of Life (TBI-QOL) questionnaire, and a standing balance test. Measurements were taken at baseline and at weeks 2, 4, 8, and 12 post-intervention"
89645160|NCT06118541|Experimental|standard care|Monitor the patient's consciousness and limb muscle strength, give drugs according to the time point of administration, and educate the importance of early getting out of bed
88992036|NCT01756456|Experimental|1_rhNGF10_Phase 1_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
89645161|NCT06118528|Experimental|Blur Obfuscation|
89645162|NCT06118528|Experimental|Edge Obfuscation|
88992037|NCT01756456|Experimental|2_rhNGF20_Phase 1_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
89645163|NCT06118528|Experimental|Avatar Obfuscation|
89645164|NCT06118528|Experimental|No Obfuscation (Raw)|
89645165|NCT06118515|Experimental|Group 1|Neonates (</= 21 days) with symptomatic congenital Cytomegalovirus (CMV) disease will receive one dose of oral letermovir, using weight dose banding. All subjects also will receive valganciclovir as standard of care. A dose safety evaluation will occur to ensure the safety data support subjects proceeding. If the observed letermovir exposure is </= 100,000 ngxhr/mL, the subject will initiate a 14-day course of once-daily oral letermovir at the same dose as utilized on Study Day 0. If the observed letermovir exposure of the subject is > 100,000 ngxhr/mL, the once-daily oral letermovir dose that will be used will be adjusted down in 2.5 mg increments from the dose utilized on Study Day 0. N = 4
89645166|NCT06118515|Experimental|Group 2|Neonates (</= 28 days) with symptomatic congenital Cytomegalovirus (CMV) disease will initiate a 14-day course of once-daily oral letermovir, using weight dose banding. All subjects also will receive valganciclovir as standard of care. A dose escalation safety evaluation will occur to ensure the safety data support subjects proceeding. If the median of observed letermovir exposures of subjects in Group 1 is below 34,400 ngxhr/mL (or above 100,000 ngxhr/mL), then the subjects enrolled in Group 2 will receive once-daily oral letermovir at a dose that has been adjusted upward (or downward) in 2.5 mg increments. N=8
89645167|NCT06118476|Experimental|Group trained with 3D animation|The experimental group was followed by training with 3D animation videos every week.
89645168|NCT06118476|No Intervention|Control group|Lessons were taught with traditional learning method.
89645169|NCT06118450||high caIMR|caIMR≥25
89645170|NCT06118450||low caIMR|caIMR<25
89645171|NCT06118424|Experimental|deepfake group|The experimental group was trained and monitored with deep fake videos every week for 6 weeks.
89645172|NCT06118424|No Intervention|Control group|The control group was given a pre-test before the study and a post-test at the end of the study, without any intervention.
89645173|NCT06118398||Exposed group|Intravenous methylprednisolone (IVMP) plus Efgartigimod
89645174|NCT06118398||Control group|IVMP
89645175|NCT06118372|Experimental|Treatment with recombinant vWF|ECMO patients with major bleeding who are enrolled in the trial will receive treatment with recombinant von Willebrand Factor a single time. The dose will be 50 IU/kg and the drug will be given intravenously.
89645176|NCT06118320||Drug treatment group of uric acid stones（DT group）|Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/packet) were administered to patients with residual stones (>5 mm in diameter) after surgery or difficult-to-remove stones in the infrarenal calyces for a three-month intervention period. The medication was taken as follows: one packet after breakfast, one packet after lunch, and two packets after dinner. Participants were instructed to abstain from alcohol consumption, smoking, and the use of any probiotics or medications that lower uric acid levels during the therapeutic period.They were also instructed to monitor preprandial urine pH levels to maintain an effective range of 6.2-6.8.
89645177|NCT06118307||Ambispective patient cohort|Patients attending the oncology department require differential diagnosis of ovarian cancer.
89645178|NCT06118307||High-risk population cohort|Family members of ovarian cancer patients; family history of BRCA mutation-related disease; abnormal findings on ovarian cancer screening; history of ovarian disease and other risk factors.
89645179|NCT06118307||Healthy control cohort|Healthy women with normal health examination results.
89645180|NCT06118294|Experimental|Probiotics|daily ingestion of 2 capsules of probiotics (>30 billion CFU/capsule)
89645181|NCT06118294|Placebo Comparator|Placebo|daily ingestion of 2 capsules which only contained 425 ± 25 mg microcrystalline cellulose
88992038|NCT01756456|Placebo Comparator|3_vehicle group_Phase 1_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
88992039|NCT01756456|Experimental|4_rhNGF10_Phase 2_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
88992040|NCT01756456|Experimental|5_rhNGF20_Phase 2_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
88992041|NCT01756456|Placebo Comparator|6_vehicle group_Phase 2_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
88992042|NCT01744704|Experimental|rhNGF 0.5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
88992043|NCT01744704|Experimental|rhNGF 5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
88992044|NCT01744704|Experimental|rhNGF 60 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
88992045|NCT01744704|Experimental|rhNGF 20 µg/mL Sentinel|1 x 35 µL drop 3 subjects
89212618|NCT00513604|Experimental|Cohort 4 - NMA, young TIL, aldesleukin|"Cohort 4 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 4 = unselected TIL - it is the SAME as cohort 1"
89645182|NCT06118268|Active Comparator|Active iTBS|
89645183|NCT06118268|Sham Comparator|Sham iTBS|
89645184|NCT06118242|Experimental|Results Related to Ventilator-Associated Pneumonia in Patients|Use of 0.12% Chlorhexidine Gluconate,1% Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid.
89645185|NCT06118242|Experimental|Results Regarding the Oral Mucous Membrane Integrity of Patients|Use of 1% Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid.
89645186|NCT06118229||NSCLC patients wearing wearable smart devices|NSCLC patients wearing wearable smart devices while utilizing PROs for regular follow-up
89645187|NCT06118216|Placebo Comparator|Group-PCIA|
89645188|NCT06118216|Experimental|Group-IA+PCIA|
89645189|NCT06118203||Open label Semaglutide|Patients presenting with acute intermediate - high risk PE consenting to participation in drug arm of study
89645190|NCT06118203||Control|Patients presenting with acute intermediate - high risk PE consenting to participation in control arm of study
89645191|NCT06118190|Experimental|mesotherapy|All participants who received mesotherapy were monitored regularly for the following three months to assess their prognosis and ensure patient adherence to treatment.
89645192|NCT06118177||Test group|"20-ml blood samples were taken from the antecubital vein of the patient's right or left arm in one attempt. The blood was gently transferred to glass-coated plastic tubes free from anticoagulant agents without wasting time. The tubes were immediately centrifuged at 2800 rpm for 12 min with a centrifuge device.~After the subepithelial connective tissue graft harvesting from in the palate, obtained L-PRF was placed into donor site at the palate then incision line was suturedwith 5/0 synthetic, non-absorbable, sterile monofilament suture."
89645193|NCT06118177||Control group|After the subepithelial connective tissue graft harvesting from in the palate, the incision line was sutured with 5/0 synthetic, nonabsorbable, sterile monofilament suture. No additional material was performed into the donör area.
89645194|NCT06118151|Experimental|sentinel cohort 1|20 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 1 or dose 2 and half number of the participants in each age group also receiving the RIV4 control
89645195|NCT06118151|Experimental|sentinel cohort 2|20 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 3 or dose 4 and half number of the participants in each age group also receiving the RIV4 control
89645196|NCT06118151|Experimental|sentinel cohort 3|10 Participants in each age group will receive Influenza hemagglutinin mRNA vaccine candidate dose 5 with half of the participants in each age group also receiving the RIV4 control
89645197|NCT06118151|Experimental|main cohort 1|40 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 1 or dose 2 and half number of the participants in each age group also receiving the RIV4 control
89645198|NCT06118151|Experimental|main cohort 2|40 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 3 or dose 4 and half number of the participants in each age group also receiving the RIV4 control
89645199|NCT06118151|Experimental|main cohort 3|20 Participants in each age group will receive Influenza hemagglutinin mRNA vaccine candidate dose 5, and half number of the participants in each age group also receiving the RIV4 control
89645200|NCT06118125||2019|patients diagnosed in 2019
89645201|NCT06118125||2020|patients diagnosed in 2020
89645202|NCT06118112||Persons with- long-covid|Women and men diagnosed with persistent COVID according to WHO (World HEalth Organization) criteria: persistent symptoms three months after the acute manifestations of COVID-19 and lasting at least two months and cannot be explained by an alternative diagnosis.
89645203|NCT06118073|Active Comparator|Total knee replacement with Headspace|Participants scheduled for primary total knee replacement will be randomized to receive the mindfulness intervention (a smartphone-based mindfulness application).
89645204|NCT06118073|Active Comparator|Total knee replacement without Headspace|Participants scheduled for primary total knee replacement will not receive the mindfulness intervention.
89645205|NCT06118060|Experimental|acupressure group|After surgery, the patient is placed in a supine position, exposing both calves, and the operator sits on the edge of the bed and applies acupressure with the thumb or pressing tool (homemade).
89645206|NCT06118060|No Intervention|control group|usual care group
89645207|NCT06118047|Experimental|Intervention group|crisaborole ointment
89645208|NCT06118021|Experimental|HS-20094 5mg|Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
89645209|NCT06118021|Experimental|HS-20094 10mg|Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
89645210|NCT06118021|Experimental|HS-20094 15mg|Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
89645211|NCT06118021|Experimental|HS-20094 20mg|Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
89645212|NCT06118008|Experimental|HS-20094 5mg|"Drug: HS-20094 Administrated by subcutaneous injection~Drug: Placebo Administrated by subcutaneous injection~Drug: Semaglutide Administrated by subcutaneous injection"
89645213|NCT06118008|Experimental|HS-20094 10mg|"Drug: HS-20094 Administrated by subcutaneous injection~Drug: Placebo Administrated by subcutaneous injection~Drug: Semaglutide Administrated by subcutaneous injection"
89645214|NCT06118008|Experimental|HS-20094 15mg|"Drug: HS-20094 Administrated by subcutaneous injection~Drug: Placebo Administrated by subcutaneous injection~Drug: Semaglutide Administrated by subcutaneous injection"
89645215|NCT06118008|Experimental|HS-20094 20mg|"Drug: HS-20094 Administrated by subcutaneous injection~Drug: Placebo Administrated by subcutaneous injection~Drug: Semaglutide Administrated by subcutaneous injection"
89645216|NCT06117995||Infertile couples have indication of IUI|Infertile couples have an indication of IUI
89645217|NCT06117943||Pregnant women|Pregnant women who smoke personally or are passively exposed to cigarette smoke
89645218|NCT06117917|Experimental|S-ketamine and pregabalin|
89645219|NCT06117917|Placebo Comparator|Normal saline and placebo capsule|
89645220|NCT06117878|Experimental|Group A(low-dose group)|NK510 1×10^9 NK cells/dose.
89645221|NCT06117878|Experimental|Group B(medium-dose group)|NK510 3×10^9 NK cells/dose.
89645222|NCT06117878|Experimental|Group C(high-dose group)|NK510 9×10^9 NK cells/dose.
89645223|NCT06117878|Experimental|Group D(high-dose group，postoperative adjuvant treatmen)|NK510 9×10^9 NK cells/dose.
89645224|NCT06117865|Sham Comparator|Patient education|
88992046|NCT01744704|Experimental|rhNGF 20 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
88992047|NCT01744704|Experimental|rhNGF 180 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
88992048|NCT01744704|Placebo Comparator|Placebo Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
88992049|NCT01744704|Experimental|rhNGF 20 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 12 subjects
88992050|NCT01744704|Experimental|rhNGF 60 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
88992051|NCT01744704|Experimental|rhNGF 180 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
88992052|NCT01744704|Placebo Comparator|Placebo Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
88992053|NCT01734512|Experimental|Everolimus|Everolimus tablet will be taken daily by mouth with water. Twenty-eight days will constitute one course and subsequent courses will immediately follow with no break in the administration of the drug. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Patients will also be provided with a drug diary for everolimus. The maximum time on study is 24-months, but if there is no disease progression or adverse events, the patient may speak with a doctor about continuing the treatment off-study.
88992054|NCT01585675||Diagnosis/treatment of lung cancer|Specimen Banking
88992055|NCT01477333|Experimental|UT-15C SR BID|Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.
89645225|NCT06117865|Active Comparator|Behavioral therapy|
89645226|NCT06117865|Active Comparator|Low FODMAP-diet|
89645227|NCT06117865|Active Comparator|Combined treatment|Low FODMAP-diet and behavioral therapy
89645228|NCT06117800|Experimental|Team STEPPS and Patient Safety Culture|TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations. Patient safety culture means preventing unintended incidents or accidents that may happen in a certain period in serving health care to patients
89645229|NCT06117787||Subject use both KD-7920 Wrist Automatic Electronic BPM and mercury sphygmomanometers|
89645230|NCT06117709|Experimental|I-STAMP Testing|"Study procedures will be conducted as follows:~Activities 1-3: Data Collection for application development~Activity 4: To be added with future amendment"
89645231|NCT06117696||control group|Standard announcement system
89645232|NCT06117696||video reinforced announcment group|standard announcement system reinforced by animated videos
89645233|NCT06117657|Experimental|KL-HIV-Tri01 injection solution|Subjects will be dosed with three different dose of KL-HIV-Tri01 injection solution at 2.4x10^11 vg/kg to 2.4x10^12 vg/kg.
89645234|NCT06117644||Furmonertinib|The subjects will be treated with Furmonertinib (double dose, 160mg). The subjects were treated with drugs for 24 months until the tumor progressed (worsened) or died.
89645235|NCT06117631|Experimental|Group A: Centering Parenting|At each well-child check from 2- to 24-months, a trained bilingual facilitator from the CommUnityCare Centering Parenting program will present curriculum in person during 2-hour visits in a room with 3-8 mother-baby pairs per group. During each session, each mother-baby pair will be pulled out to a private medical room for a brief individual well child appointment with the pediatrician. During this appointment, infant measurements, physical exam, and discussion of unique concerns will take place before the pair returns to the session. There are 8 scheduled well child checks by the age of two, where regular parenting topics will be covered (i.e. discipline, safety, co-parenting, sibling relationships, childcare, development). Each Centering session is expected to last approximately 2 hours, for a total commitment of approximately 16 hours across 8 group sessions over the course of 22 months for each participant. Total time of enrollment should be approximately 22-24 months.
88992056|NCT01371630|Experimental|Arm I (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description Arm I
88992057|NCT01371630|Experimental|Arm II (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description Arm II
88992058|NCT01371630|Experimental|Arm III (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description Arm III
88992059|NCT01336803|Experimental|Feraheme|Intravenous injection of Feraheme, 5 mg Fe/kg
88992060|NCT01262625|Experimental|Group A: CCTA Diagnostic|Participants randomized to diagnostic evaluation using coronary computed tomographic angiography (CCTA) to determine therapeutic course of action.
88992061|NCT01262625|Active Comparator|Group B: SPECT MPI/ICA Diagnostic|Standard-of-care diagnostic assessment using single photon emission computed tomography myocardial perfusion imaging (SPECT MPI), possibly followed by diagnostic invasive coronary angiography (ICA) dependent on SPECT MPI results.
88992062|NCT01206465|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88992063|NCT00979693|Experimental|Full Dose|Participant will receive 25 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with each session scheduled seven to 14 days apart.
88992064|NCT00979693|Active Comparator|Active Placebo|The participant will receive 4 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with sessions scheduled seven to 14 days apart.
88992065|NCT00801489|Experimental|Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)|See Detailed Description
89043877|NCT02903784|Other|grade 2 glioma|Patient with grade 2 glioma use a neuropsychological examination and brain imaging (fMRI and tractography)
89645236|NCT06117631|Active Comparator|Group B: Bright by Text|This group will receive standard of care individual well child checks with their regular CommUnityCare pediatrician, with standard anticipatory guidance on feeding and sleep. Additionally, this group will be enrolled in a text-based parenting coaching program. The Bright by Text program will provide parenting tips two to three times weekly; tailored through community partner United Way of Central Texas offering local parent support and resources. The Bright by Text program is a message subscription program rather than an application. Participants may decide on their own how much to engage with the text-based program, so total time commitment cannot be estimated. Total time of enrollment should be approximately 22-24 months.
89645237|NCT06117631|No Intervention|Group C: Standard of Care|This group will receive standard of care individual well child checks with their regular pediatrician, with standard anticipatory guidance on feeding and sleep. Total time of enrollment should be approximately 22-24 months.
89645238|NCT06117566|Experimental|WX390 0.5 mg + Toripalimab 240mg|Participants will receive WX390 continuous oral dosing (0.5 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).
89645239|NCT06117566|Experimental|WX390 0.7 mg + Toripalimab 240mg|Participants will receive WX390 continuous oral dosing (0.7 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).
89645240|NCT06117566|Experimental|WX390 0.9 mg + Toripalimab 240mg|Participants will receive WX390 continuous oral dosing (0.9 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).
89645241|NCT06117540|Experimental|WX390|Participants will receive WX390 continuous oral dosing (1.1 mg once a day).
89645242|NCT06117514|Experimental|Sudapyridine 30 mg single dose|Participants received Sudapyridine 30 mg single dose orally.
89645243|NCT06117514|Experimental|Sudapyridine 100 mg single dose|Participants received Sudapyridine 100 mg single dose orally.
89645244|NCT06117514|Experimental|Sudapyridine 200 mg single dose|Participants received Sudapyridine 200 mg single dose orally.
89645245|NCT06117514|Experimental|Sudapyridine 200 mg multiple doses|Participants received Sudapyridine 200 mg orally for multiple doses.
89645246|NCT06117514|Experimental|Sudapyridine 300 mg multiple doses|Participants received Sudapyridine 300 mg orally for multiple doses.
89645247|NCT06117514|Placebo Comparator|Placebo 100 mg single dose|Participants received Placebo 100 mg single dose orally.
89645248|NCT06117514|Placebo Comparator|Placebo 200 mg single dose|Participants received Placebo 200 mg single dose orally.
89645249|NCT06117514|Placebo Comparator|Placebo 200 mg multiple doses|articipants received Placebo 200 mg orally for multiple doses.
89645250|NCT06117514|Placebo Comparator|Placebo 300mg multiple doses|Participants received Placebo 300 mg orally for multiple doses.
89645251|NCT06117462||Age above 60 eldery|group will be assessed using the Clinical Frailty Scale (CFS) giving patients who are very fit score one and those who are terminally ill score nine.
89645252|NCT06117462||age between 18:60 young|group will be assessed using the Clinical Frailty Scale (CFS) giving patients who are very fit score one and those who are terminally ill score nine.
89645253|NCT06117436|No Intervention|Control Group|patients will receive standard wound care and diabetes management (that includes bed rest with elevation, antibiotics, analgesics, and dressings).
89043878|NCT02903784|Other|healthy volunteers|healthy volunteers use a neuropsychological examination and brain imaging (fMRI and tractography)
89043879|NCT04633382|Experimental|Conducting research of enhanced recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.~Refusal from complete starvation. Carbohydrate drink 2 hours before surgery.~Refusal of cleansing enemas.~Refusal of premedication. NSAIDs 30 minutes before surgery~Prevention of thromboembolic complications~Multimodal analgesia: epidural catheter, paracetamol.~Minimally invasive access.~Prevention of hypothermia~Targeted infusion therapy.~Failure or limited time use of drainages: gastric, intra-abdominal, bile duct drainage.~Early activation of the patient.~Early enteral nutrition.~Prevention of nausea and vomiting."
89043880|NCT04633382|Placebo Comparator|Conducting research of traditional recovery after surgery|"Informing the patient about the course of the operation and the postoperative period. Psychological preparation.~Fasting for 2 days~Use of cleansing enemas. Bowel preparation~Premedication~Prevention of thromboembolic complications~Without multimodal analgesia~Traditional access.~Prevention of hypothermia~Targeted infusion therapy.~Use of drains: gastric, intra-abdominal, bile duct drainage.~Activation of patients within 2 days.~Enteral nutrition after 2 days after surgery.~Without the use of metoclopramide"
89043881|NCT02903628|Experimental|eye health education|
89043882|NCT04633733|Experimental|Single arm|"This single arm is conducted in fixed-sequence(Treatment A ->(washout period) -> Treatment B -> Treatment C -> Maintenance treatment).~Treatment A : tacrolimus 5mg po single dose, Treatment B : HL237 400mg bid for 4 days, Treatment C: tacrolimus 5mg po single dose and HL237 400 mg bid, Maintenance treatment : HL237 400mg bid for 2 days"
89043883|NCT04633265|Experimental|ECG-I Mapping and Ablation of drivers|ECG-I Mapping will be performed and drivers will be ablated as directed by ECG-I.
89043884|NCT05427942||Switch from adalimumab originator|
89043885|NCT05427942||Switch from adalimumab biosimilar 40 mg/0,8 mL|
89043886|NCT04632875|Experimental|Loving-Kindness Meditation|4-week guided Loving-Kindness Meditation training (administered online).
89043887|NCT04632875|Experimental|Relaxation Meditation|4-week guided Relaxation Meditation training (administered online).
89043888|NCT05427903|Experimental|Cryotherapy|
89043889|NCT05427903|Experimental|IANB plus buccal infiltration local anesthesia|
89043890|NCT05427903|Active Comparator|IANB|
89645254|NCT06117436|Active Comparator|Cilostazol Group|patients will receive Cilostazol 100 mg tablets per oral once daily in addition to standard wound care and diabetes management.
89043891|NCT04633109||normal weight|Normal weight adults with BMI ranging from 18.5-24.9; men and women; age range 18-69years; written informed consent
89043892|NCT04633109||obese|Subjects with obesity as defined by BMI >= 30; men and women; age range 18-69 years; written informed consent
89043893|NCT05427747|Experimental|cefotaxime|ceotaxime 2g iv /8hr
89043894|NCT05427747|Experimental|meropenem|meropenem 1g iv /8hr
89043895|NCT04633031||Group 1|Cheneau brace
89043896|NCT04633031||Group 2|Boston brace
89043897|NCT04632914|Experimental|trunk stabilizing exercise|trunk stabilizing exercises three times/week for four weeks
89645255|NCT06117436|Active Comparator|Cilostazol & Selenium Group|Cilostazol 100 mg tablets plus Selenium 200 mcg tablets per oral once daily, in addition to standard wound care and diabetes management.
89645256|NCT06117397|Experimental|Text4Moms|Texts will include video links that reinforce information relevant to Interpersonal Psychotherapy (IPT).
89645257|NCT06117397|No Intervention|Educational Control|The control condition will be limited to texts related to pregnancy, nutrition and sleep. We will avoid elements that have behavioral therapeutic effects. Although this condition is meant to constitute time and attention control, we will include material on recognizing depression and links to ways to attain depression treatment and suicide hotline information.
89645258|NCT06117371|Experimental|Monotherapy group 1|BEBT-607 tablets, 100mg/day,50mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
89645259|NCT06117371|Experimental|Monotherapy group 2|BEBT-607 tablets, 200mg/day,100mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
89645260|NCT06117371|Experimental|Monotherapy group 3|BEBT-607 tablets, 300mg/day,150mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
89645261|NCT06117371|Experimental|Monotherapy group 4|BEBT-607 tablets, 400mg/day,200mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
89645262|NCT06117371|Experimental|Monotherapy group 5|BEBT-607 tablets, 600mg/day,300mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
89645263|NCT06117371|Experimental|Monotherapy group 6|BEBT-607 tablets, 800mg/day,400mg each time, are administered once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days. 28 days is as a treatment cycle.
89645264|NCT06117371|Experimental|Monotherapy group 7|BEBT-607 tablets, 300mg/day,150mg each time, are administered twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days. 28 days is as a treatment cycle.
89645265|NCT06117371|Experimental|Monotherapy group 8|BEBT-607 tablets, 400mg/day,200mg each time, are administered twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days. 28 days is as a treatment cycle.
88992066|NCT00694655|Experimental|HLA-A202+: Yellow Fever Vaccine and Post-vaccination Blood Draws|HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws.
88992067|NCT00694655|Experimental|HLA-A202+: Yellow Fever Vaccine, Post-vaccination Blood Draws and Leukapheresis|HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws and leukapheresis.
88992068|NCT00694655|Experimental|HLA-A202+: Yellow Fever Vaccine, Post-vaccination Blood Draws and Fine Needle Aspirate|HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws and fine needle aspirate.
88992069|NCT00694655|Experimental|HLA-A202-: Yellow Fever Vaccine and Post-vaccination Blood Draws|HLA-A202- participants receiving Yellow Fever Vaccine plus post-vaccination blood draws.
88992070|NCT00642434|Active Comparator|1|study drug- carvedilol
88992071|NCT00642434|Active Comparator|2|study drug metorprolol
88992072|NCT00089245|Experimental|Radiolabeled Monoclonal Antibody Therapy|This is a Phase I trial designed to evaluate the Maximally Tolerated Dose (MTD) of intrathecal 131I-8H9. In order to find the MTD, a dose escalation scheme will be employed with patients entering in cohorts of 3 at each dose level from 10 mCi to 60 mCi and a cohort of 6 at each dose level from 70 mCi to 100 mCi.
88992073|NCT00004192|Experimental|Single Dose Filgrastim (SD/01)|Participants receive etoposide IV over 1 hour on days 1-4, cisplatin IV continuously on days 1-4, methylprednisolone IV over 15 minutes on days 1-5, and cytarabine IV over 2 hours on day 5. Treatment is repeated every 21 days for up to 4 courses. Arm I: Participants receive filgrastim-SD/01 subcutaneously (SQ) on day 6.
88992074|NCT00004192|Experimental|Daily Filgrastim (G-CSF)|Participants receive etoposide IV over 1 hour on days 1-4, cisplatin IV continuously on days 1-4, methylprednisolone IV over 15 minutes on days 1-5, and cytarabine IV over 2 hours on day 5. Treatment is repeated every 21 days for up to 4 courses. Arm II: Participants receive filgrastim (G-CSF) SQ daily beginning on day 6 and continuing for 12 days or until blood counts recover.
88992075|NCT00469885|Other|1|Usual care
88992076|NCT00469885|Other|2|Reduction
88992077|NCT04725669|Other|Seroprevalence of pertussis among children and adolescents in Croatia|For all patients participating in the study one serum sample will be collected for serological analysis.
88992078|NCT03271411|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
88992079|NCT03271411|Experimental|Progressive counting (PC) arm|
88992080|NCT00469924|Experimental|Alerting system ON|Alerting system is ON
88992081|NCT00469924|No Intervention|Alerting system OFF|Alerting system is OFF
88992082|NCT00157677|Experimental|1|Selective D-Dimer use
88992083|NCT00157677|Active Comparator|2|Uniform D-Dimer use
88992084|NCT00469963|Experimental|SIR-SPHERES|
88992085|NCT00470080|Experimental|1|venepuncture
88992086|NCT00470119|No Intervention|Control|
88992087|NCT00470119|Other|Caloric Restriction|Nutritionist-delivered weight loss intervention though diet modification with an aim of 10% weightloss over a year long intervention based on the DPP and LookAHEAD interventions. Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study.
89645266|NCT06117371|Experimental|Monotherapy group 9|BEBT-607 tablets, 600mg/day,300mg each time, are administered twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days. 28 days is as a treatment cycle.
89645267|NCT06117332|Experimental|Perception resulting from AI-powered artificial vision|The investigators will produce visual percepts in visual prosthesis patients either by directly stimulating electrodes (using FDA-approved pulse trains), or by asking them to view a computer or projector screen and using standard stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Informed by psychophysical data and computational models, the investigators will test the ability of different stimulus encoding methods to support simple perceptual and behavioral tasks (e.g., object recognition, navigation). These encoding methods may include computer vision and machine learning methods to highlight important objects in the scene or to highlight nearby obstacles and may be tailored to each individual patient.
89645268|NCT06117319|Experimental|Individual assistance|"5 sessions with individual assistance~The Virtual Reality (VR) activity will take the form of five (5) training sessions.~Session 1: Basics of VR.~Session 2: 1-multiplayer game mode.~Session 3: Playing with a library. Browsing a library~Session 4: 2-individual game mode.~Session 5: Game practice.~For each session, in small groups of 3 people, it will be proposed to test games requiring only movements of the upper limbs of low to moderate intensity. Sitting will be mandatory for the tests in order to avoid falls."
89645269|NCT06117319|Experimental|Collective assistance|"4 sessions with collective assistance and 1 session with individual assistance (session 5)~The Virtual Reality (VR) activity will take the form of five (5) training sessions.~Session 1: Basics of VR.~Session 2: 1-multiplayer game mode.~Session 3: Playing with a library. Browsing a library~Session 4: 2-individual game mode.~Session 5: Game practice.~For each session, in small groups of 3 people, it will be proposed to test games requiring only movements of the upper limbs of low to moderate intensity. Sitting will be mandatory for the tests in order to avoid falls."
89645270|NCT06117306|Experimental|Standard Dose|"Non-medicine sessions of PE + One Medicine Session with 3,4-methylenedioxymethamphetamine (MDMA)~PE Non-medicine sessions: 11 sessions~MDMA Medicine session:~Standard Dose: 120 mg MDMA HCl (~102 mg MDMA)"
89645271|NCT06117306|Experimental|Low Dose|"Non-medicine sessions of PE + One Medicine Session with 3,4-methylenedioxymethamphetamine (MDMA)~PE Non-medicine sessions: 11 sessions~MDMA Medicine session:~Low Dose: 40 mg MDMA HCl (~34 mg MDMA)"
89645272|NCT06117293|Experimental|Treatment Arm|Subjects will be treated up to 5 times with a 30- and 90-day post final-treatment follow-up. Subjects may be asked to participate in an elective biopsy collected from normal skin simultaneously.
89645273|NCT06117280|Experimental|Intervention (Dose One)|In this crossover trial, all participants will test both active comparators and the placebo comparator.
89645274|NCT06117280|Experimental|Intervention (Dose Two)|In this crossover trial, all participants will test both active comparators and the placebo comparator.
89645275|NCT06117280|Placebo Comparator|Placebo|In this crossover trial, all participants will test both active comparators and the placebo comparator.
89645276|NCT06117267|Experimental|Anatase Spine Surgery Navigation System|Using the navigation system during surgery
89645277|NCT06116747|No Intervention|No intervention Group|Group receiving care as usual
89645278|NCT06116747|Experimental|Intervention Group|Complex Intervention under development in collaboration with fathers' health care professionals in primary and secondary sectors.
89645279|NCT06116292|Experimental|Mobile application ESTOI for Asthmatic patients|The intervention group will receive the usual care, in addition to having access to the ESTOI application.
89645280|NCT06116292|No Intervention|Standard of care|The intervention group will receive the usual care
89645281|NCT06116032||Standard of Care Checkpoint|Patients receiving standard of care FDA approved immunotherapy
89645282|NCT06116032||Bone Marrow Transplant|Patients undergoing transplant for hematologic malignancy
89645283|NCT06116032||CAR T|Patients undergoing CAR T therapy
89645284|NCT06115980|Experimental|1 - An open label study|"This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~A total of 15 patients, who are scheduled for lead extraction, will be recruited in order to ensure a total of at least 10 patients finishing the study procedures and follow up."
89645285|NCT06115720|No Intervention|Standard video verbal consent process|The control group will undergo the standard video verbal consent process for both GA and RA for orthopaedic surgery. This will be delivered using a standardised video script that will be generated from existing certified material.
89043898|NCT04632914|Active Comparator|cardiac rehabilitation programe|cardiac rehabilitation program three times/week for four weeks
89043899|NCT05427591|Experimental|Group (1A)|"30 children with 60 primary molars underwent caries removal by the CMCR method BRIX3000® (the experimental group) on one molar (n = 30)."
89043900|NCT05427591|Active Comparator|Group (1C)|30 children with 60 primary molars underwent caries removal by the traditional surgical method (the control group) on the contralateral molar (n = 30).
89043901|NCT05427591|Experimental|Group (2B)|"30 children with 60 primary molars underwent caries removal by the CMCR method Carie-CareTM  (the experimental group) on one molar (n = 30)."
89043902|NCT05427591|Active Comparator|Group (2C)|30 children with 60 primary molars underwent caries removal by the traditional surgical method (the control group) on the contralateral molar (n = 30).
89043903|NCT04632602|Other|patients in prone position followed by dorsal decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
89043904|NCT04632602|Other|dorsal decubitus followed by prone decubitus|patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours.
89043905|NCT02903316||Fluid Therapy|Systematisation of fluids during CABG surgery
89043906|NCT00445367||Case|
89043907|NCT00445367||Control|
89043908|NCT02903199|Experimental|Whey Protein|Whey protein (18g) experimental supplement
89043909|NCT02903199|Experimental|Hydrolysed Protein|Hydrolysed whey protein (19.1g) experimental supplement
89043910|NCT02903199|Placebo Comparator|Placebo|Water placebo supplement
89043911|NCT02903433|Experimental|High Intake Group|"Throughout the entire study, this group will be provided with 14 avocados per week and will receive 12 bi-weekly home visits over a 6-month period during which they will receive specific brochures offering diet tips. This group will be given specific advice on avocado consumption. Each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
89043912|NCT02903433|Active Comparator|Low Intake Group|"This group will receive 3 avocados per week, as well as 12 bi-weekly home visits over a 6-month period during which they will be provided with the same educational materials (i.e., Diet Tips) as those assigned to the High intake group. Participants in this group will be encouraged to improve the quality of their diets, but will not be given specific advice on avocado consumption. However, each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
89043913|NCT00445445||Patients|Histologically confirmed breast cancer that was diagnosed between the years 2002-2004
89043914|NCT00445445||Healthy participants|Healthy participant who is receiving routine medical care (e.g., screening mammograms. Healthy participants are frequency-matched by age (± 2 years) and ethnicity.
89043915|NCT00445523|Experimental|1|TroVax® alone
89043916|NCT00445523|Experimental|2|TroVax® plus IFN-α
89043917|NCT05427357|Experimental|Diseased side of the patellofemoral pain syndrome (PFPS) group (40 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in diseased side of the PFPS group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
89043918|NCT05427357|Experimental|Healthy side of the patellofemoral pain syndrome (PFPS) group (40 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in healthy side of the PFPS group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
89645286|NCT06115720|Experimental|Video assisted consent process|The intervention group will also be shown the same pre-recorded standard verbal consent, but following this will additionally be shown a specifically recorded video of the anaesthetic process for both GA and RA.
89645287|NCT06115473|Active Comparator|E group for epinephrine|In Group (E) patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
89645288|NCT06115473|Placebo Comparator|Group (F)|In Group (F) patients will receive IV bolus isotonic fluid 500 ml as it is yet the standard method used before intubation
89645289|NCT06115460|Active Comparator|Oral sitagliptin 50 mg supplementation for three months|Intervention group includes: adolescents with diabetic nephropathy on advanced hybrid closed loop system receiving oral sitagliptin 50 mg for three months on a daily basis
89645290|NCT06115460|No Intervention|Control group ( No intake of oral sitagliptin 50 mg supplementation for three months)|Control group includes: adolescents with diabetic nephropathy on advanced hybrid closed loop system who did not take oral sitagliptin 50 mg for three months on a daily basis
89645291|NCT06114836|No Intervention|Natural maturation|Allows for time for infant maturation without treatment.
89645292|NCT06114836|Active Comparator|Proton Pump Inhibitor (PPI)|Omeprazole will be prescribed for 4 weeks using the dose of 1.5mg/kg/dose daily.
89645293|NCT06114836|Active Comparator|Added Rice (AR) Formula|Added rice formula will be ordered as the infant diet for the 4-week treatment period.
89645294|NCT06114810|Active Comparator|Arm A : 3 doses of nOPV2 and bOPV with IPV|Participants in arm A will receive the following polio vaccines: nOPV2 +bOPV (2 drops = 0.1 ml) @ 6, 10, 14 weeks and IPV (0.5 mL) @ 14 weeks
89645295|NCT06114810|Active Comparator|Arm B : 2 doses of nOPV2 and bOPV with IPV|Participants in arm B will receive the following polio vaccines: nOPV2+bOPV , (2 drops = 0.1 ml) @ 6, 10 weeks and IPV (0.5 mL) @ 14 weeks
89645296|NCT06114810|Active Comparator|Arm C: Single dose of bOPV, nOPV2, IPV|Participants in arm C will receive the following polio vaccines: bOPV ( 2 drops) @ 6 week , nOPV2 (2 drops) at 10 weeks and IPV ( 0.5mL) @ 14 weeks
89645297|NCT06114810|Active Comparator|Arm D: Single dose nOPV2, IPV|Participants in arm D will receive the following polio vaccines: nOPV2 (2 drops = 0.1 ml) at 6 and 10 weeks and IPV ( 0.5mL) @ 14 weeks
89645298|NCT06114602||Pre-Intervention|Patients who have a medical appointment with a urologist in HIBA but did not receive any reminder.
89645299|NCT06114602||Post-Intervention|Patients who have a medical appointment with a urologist in HIBA but did receive an email reminder of the appointment.
89645300|NCT06114472|Active Comparator|Group A aromatherapy|three drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
89645301|NCT06114472|No Intervention|Group B Control|No intervention
89645302|NCT06114368||Endoscopic Flexor Hallucis Longus transfer / Group 1|Patients with acute Achilles tendon rupture managed with Endoscopic Flexor Hallucis Longus transfer by one surgeon (A.E.) in one hospital (General Hospital of Naoussa, Naoussa, Greece), all of which followed the same rehabilitation protocol.
89645303|NCT06114368||Minimally Invasive Primary repair / Group 2|Patients with acute Achilles tendon rupture managed with Minimally Invasive Primary repair by one surgeon (P.S.) in one hospital (St. Luke's Hospital, Thessaloniki, Greece), all of which followed the same rehabilitation protocol.
89645304|NCT06114329|Experimental|AL01211 30 mg, once daily|9 subjects will first be enrolled in this arm, receiving 30 mg AL01211 treatment, once daily
89043919|NCT05427357|Other|Both side of the healthy control group (80 knees)|Non-selective close kinetic chain exercises and selective close kinetic chain exercises were applied for 6 weeks in side of the both side of the healthy control group. Thigh circumference measurement was performed 5-10 cm above the upper pole of the patella. In addition, evaluation was made with visual analog score (VAS) and Lysholm Knee score (LKS). Vastus medialis obliquus (VMO) and vastus lateralis (VL) muscles of the participants were measured with Shear Wave Elastography 1 day before the therapy and 6 weeks after therapy in hospital.
89043920|NCT02903082||Case|Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome
89043921|NCT02903082||Control|10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.
89043922|NCT02903004|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line)
89043923|NCT02903004|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28
89043924|NCT00445718||Observational|Patients undergo an abdominal CT or MRI scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. Urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. Patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. Patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy.
89043925|NCT04699175|Experimental|Treatment group A|
89043926|NCT04699175|Experimental|Treatment group B|
89043927|NCT04699175|Placebo Comparator|Treatment group C|
89043928|NCT03277781||Current smokers|
89043929|NCT03277781||Ex-smokers|
89645305|NCT06114329|Experimental|AL01211 60 mg, once daily|After enrolling into 30 mg arm is completed and preliminary data show good safety, 9 subjects will be enrolled in this arm, receiving 60 mg AL01211 treatment, once daily
89645306|NCT06114277||Patients with low ETCO2 levels|Intraoperative ETCO2 values between 26 and 34 in laparoscopic robotic prostatectomy patients were included in this group.
89043930|NCT03277781||Coronary heart disease|
89043931|NCT02902887|Experimental|Monitored CIAO therapy|Participants wear 3-hour CIAO therapy
89043932|NCT02902887|No Intervention|Observation|No intervention, just observation
89043933|NCT01225822|Experimental|BIBR 1048 50 mg bis in die(b.i.d)|BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
89645307|NCT06114277||Patients with high ETCO2 levels|Intraoperative ETCO2 values between 35 and 45 in laparoscopic robotic prostatectomy patients were included in this group.
89645308|NCT06113744|Experimental|Low-dose test vaccine, 1 dose|
89645309|NCT06113744|Experimental|Mid-dose test vaccine, 1 dose|
89645310|NCT06113744|Experimental|High-dose test vaccine, 1 dose|
89043934|NCT01225822|Experimental|BIBR 1048 150 mg b.i.d|BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
89043935|NCT01225822|Experimental|BIBR 1048 225 mg b.i.d|BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
89043936|NCT01225822|Experimental|BIBR 1048 300 mg quaque die(q.d)|BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
89043937|NCT01225822|Active Comparator|Enoxaparin 40 mg subcutaneous(s.c)|placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
89043938|NCT02903043||COPD patients|Quadriceps biopsies will be done. No drug administration.
89043939|NCT02903043||Healthy controls|Quadriceps biopsies will be done. No drug administration.
89043940|NCT00445835|Other|BA :Active arm|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
89043941|NCT00445835|Other|BC: Conservative arm|Conservative medical approach
89043942|NCT02902731|Placebo Comparator|placebo|PLACEBO + Usual use of tapering doses of oral prednisone
89043943|NCT02902731|Experimental|anakinra|"ANAKINRA : dose of anakinra is 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (W16). The dose of Anakinra will be adapted to that recommand according to renal function.~Intervention Anakinra in add on Therapy."
89043944|NCT00445913|Experimental|control dendritic cells|autologous dendritic cells that are not treated
89043945|NCT00445913|Experimental|AS ODN dendrtitic cells|autologous dendritic cells treated ex vivo with the mixture of the antisense oligonucleotides
89043946|NCT02902926|Experimental|Low FODMAPs Diet|"Instructed to low FODMAPs diet when patients signed the informed consent.~Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food."
89043947|NCT02902926|Placebo Comparator|Diet Instruction|1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
89043948|NCT01225549|Experimental|1|AZD5423 75ug
89043949|NCT01225549|Experimental|2|AZD5423 300ug
89043950|NCT01225549|Active Comparator|3|Budesonide 200 microgram
89645311|NCT06113744|Placebo Comparator|Placebo, 1 dose|
89645312|NCT06113744|Experimental|Low-dose test vaccine, 2 dose|
89645313|NCT06113744|Experimental|Mid-dose test vaccine, 2 dose|
89645314|NCT06113744|Experimental|High-dose test vaccine, 2 dose|
89645315|NCT06113744|Placebo Comparator|Placebo, 2 doses|
89645316|NCT06113744|Active Comparator|Active control vaccine, 2 doses|
89645317|NCT06113731|Experimental|Test vaccine dose 1, 2 dose|
89645318|NCT06113731|Experimental|Test vaccine dose 2, 2 dose|
89645319|NCT06113731|Active Comparator|Active Comparator, 2 dose|
89645320|NCT06113731|Experimental|Test vaccine dose 1, 1 dose|
89645321|NCT06113731|Experimental|Test vaccine dose 2, 1 dose|
89645322|NCT06113731|Active Comparator|Active Comparator,1 dose|
89645323|NCT06113432|Experimental|Helmet-CPAP then Mask-CPAP|CPAP via Helmet 40 minutes, then CPAP via full face mask 40 minutes
89645324|NCT06113432|Experimental|Mask-CPAP then Helmet-CPAP|CPAP via full face mask 40 minutes, then CPAP via helmet 40 minutes
89645325|NCT06113081||Patients enrolled|Patients affected by relapsed/refractory Cutaneous T cell Lymphoma who have received Mogamulizumab in real life setting
89645326|NCT06109961|Experimental|Active Hyperbaric Oxygen Therapy|The active Hyperbaric Oxygen Therapy (HBOT) arm will receive 100% oxygen at 2.0-2.5 atmospheres (ATM).
89645327|NCT06109961|Other|Standard of care treatment|The standard of care for perianal Crohn's disease (PCD) involves conventional therapies such as immunosuppressive agents and biologics, which can be used to induce and maintain fistula remission. Tumor necrosis factor (TNF) antagonists are considered the first-line therapy for PCD, and clinical trial evidence supports their efficacy in achieving short-term fistula remission.
89645328|NCT06105216|Experimental|Intervention Group|
89645329|NCT06105216|No Intervention|Control Group|
89645330|NCT06104527|Other|1.3 g/kg/day followed by 2.0 g/kg/day|Patients in this arm will, on their first test day, receive enteral nutrition containing 1.3 grams of protein per kg of body weight per day followed by 2.0 grams of protein per kg of body weight per day on their second test day.
89645331|NCT06104527|Other|2.0 g/kg/day followed by 1.3 g/kg/day|Patients in this arm will, on their first test day, receive enteral nutrition containing 2.0 grams of protein per kg of body weight per day followed by 1.3 grams of protein per kg of body weight per day on their second test day.
89645332|NCT06102980|Active Comparator|Liver steatosis|"Patients with requirements of screening following the European Association for the Study of the Liver (EASL) 2016 recommendations. The liver steatosis group will be compounded by patients with at least one of the following criteria:~Over fifty years old;~Body mass index (BMI) over 25 kg/m2;~Diabetes mellitus type 2;~Metabolic syndrome; or~Persistently elevated liver enzymes."
89645333|NCT06102980|Other|Controls|"Patients without requirements of screening following the European Association for the Study of the Liver (EASL) 2016 recommendations. The liver steatosis group will be compounded by patients who will not present any of the following criteria:~Over fifty years old;~Body mass index (BMI) over 25 kg/m2;~Diabetes mellitus type 2;~Metabolic syndrome; and~Persistently elevated liver enzymes.~To be a control participant does not mean that the patient is a healthy participant. The control participants are patients who request any type of endoscopy and fulfil the criteria not to screen for liver steatosis. For example, a 48-year-old male with 21 kg/m2 BMI, without diabetes mellitus type 2, any metabolic syndrome-related comorbidities, with normal liver enzymes and who refused an episode of persistently elevated liver enzymes, with persistent reflux disease after two months of proton pump inhibitor therapy,"
89645334|NCT06102720|Experimental|Colchicine Group|All patients in this arm will receive colchicine for 14 days in addition to standard medical care without clopidogrel (acetylsalicylic acid, lipid-lowering, antihypertensive, gastroprotective, hypoglycemic drugs if necessary, lifestyle recommendations, early rehabilitation activities).
89645335|NCT06102720|Active Comparator|Clopidogrel treatment group|All patients in this arm will receive standard treatment including clopidogrel.
89645336|NCT06100692||vit D and zinc group|will receive combination of oral vit D and zinc 30 patients
89645337|NCT06100692||placebo group|receive Placebo or no treatment 30 patients
89645338|NCT06100185|Active Comparator|Stimulation|Short duration repetitive (SDR-) tES with a frequency of 0.75Hz
89645339|NCT06100185|Sham Comparator|Sham Condition|Sham condition using a low current amplitude at 25 Hz.
89645340|NCT06099834|Other|Patient selection|Patient selection criteria were as follows: absence of any systemic disease; not being in American Society of Anesthesiologists (ASA) Class 3 or 4 according to the ASA Physical Status Classification System (Doyle, 2017); being older than 20 years of age; the existence of panoramic and dental volumetric tomography images of the area to be implanted; the presence of a suitable recipient bone for implantation with dental implants of the desired length and diameter.
89645341|NCT06099834|Other|Dental Implant Application|Bredent SKY® dental implants were applied at a torque level of 30 N.cm as recommended by the manufacturer. The surgery and all measurements were performed by the same surgeon.
89645342|NCT06099834|Other|Osseointegration and periodontal measurements|Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W&H, Sweden) devices. In accordance with the manufacturers' recommendations, the final implant stability quotient (ISQ) and Periotest values were determined by calculating the average of three measurements per implant. At the same time, periodontal index values of probing depth (PD-mm) and bleeding on probing (BOP-%) were recorded at the site of the dental implant at T4 and T12.
89043951|NCT01225549|Placebo Comparator|4|Placebo
89043952|NCT05469685|Experimental|10-day treatment group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 10 days
89043953|NCT05469685|Active Comparator|14-day treatment group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days
89043954|NCT02956772|Experimental|TACE plus Arsenic Trioxide|Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21). TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks. At least 3 cycles of arsenic trioxide are administrated.
89043955|NCT02956772|Active Comparator|TACE|Patients in this group are to receive a single dose of TACE treatment on day 1. TACE treatment is repeated every 9 weeks for 27 weeks.
89043956|NCT04680234|Active Comparator|Cryotherapy group|Patients underwent superficial cryotherapy using dimethyl ether and propane (DMEP) at -57C very 2 weeks for maximum six sessions
89043957|NCT04680234|Active Comparator|Microneedling group|Patients underwent microneedling 2 weeks for maximum six sessions
89043958|NCT01225159|Experimental|Tight glycaemic control (TGC)|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
89043959|NCT01225159|Placebo Comparator|Conventional glycaemic control (Control)|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
89043960|NCT00446069|Experimental|Egalet® morphine|
89043961|NCT00446069|Active Comparator|MST Continus®|
89043962|NCT02902692|Experimental|Brief Mindfulness|45 minute brief mindfulness intervention (lead by study investigator) on day 1 followed by 7 days of 30 minute mindfulness practice at home (without study investigator)
89043963|NCT05464459|Experimental|HAPY interposition elbow replacement|HAPY is a pyrocarbon sphere for use as an interposition joint replacement. In this study, the implant is being used as a novel procedure in the Elbow (outside approved label usage)
89645343|NCT06098872|Experimental|Experimental: Oral Trametinib|Participants will receive oral Trametinib once daily for up to 60 days prior to their elective surgery
89645344|NCT06096740|Experimental|Immediate Treatment|Those individuals randomized to immediate treatment will commence individual cognitive processing therapy (CPT) with an assigned study therapist, following the completion of baseline procedures.
89043964|NCT01224925|Active Comparator|Capping over carious exposure with Dycal|Total caries removal. In case of pulp exposure Direct Pulp capping with (Dycal®, Dentsply DeTrey GmbH, Konstanz, Germany)
89043965|NCT01224925|Experimental|Capping over carious exposure with WMTA|Total caries removal. In case of pulp exposure Direct Pulp capping with Mineral Trioxide Aggregate White ProRoot® (WMTA) (DENTSPLY, Tulsa Dental, Tulsa, OK, USA)
89645345|NCT06096740|Placebo Comparator|Delayed Treatment|Individuals randomized to the delayed treatment condition will be informed after randomization that their treatment will start in 6-8 weeks (the approximate period it will take for individuals in the immediate treatment arm to complete CPT and post-treatment assessments). During this period, the study postdoctoral fellow (who will be unblinded to treatment arm) will maintain regular contact with individuals through weekly phone and e-mail check-ins to maintain participant engagement and to ensure the participant is not experiencing a significant deterioration in mental health or functioning (e.g., developing suicidal ideation or behavior).
89645346|NCT06095908||'rectus sheath block'|Patients in Group I underwent postoperative USG-guided bilateral rectus sheath block at the T9-10 level with 20 ml of 0.25% bupivacaine (40 ml in total).
89645347|NCT06095908||'wound infiltration'|Group II (control group), 20 ml of 0.25% bupivacaine was applied subcutaneously to each wound lip (40 ml in total).
89645348|NCT06085833|Other|Human subjects requiring breast biopsy|All patients referred to participating study sites for a core needle or vacuum-assisted breast biopsy are eligible for this study. Upon consent, a diagnostic biopsy will be measured by the sponsor's device before returning to the standard of care pathway.
89645349|NCT06082713||Huntington Disease Carriers|
89645350|NCT06082713||Non-Huntington Disease Carriers|
89645351|NCT06080659|Experimental|DCS+|Patient with subjective cognitive decline, prodromal condition of Alzheimer's disease
89645352|NCT06080659|Experimental|TCL-MA|Patient with mild neurocognitive disorder linked to Alzheimer's disease
89645353|NCT06080659|Experimental|MPdn|early-stage or de novo Parkinson's disease patients with no cognitive deficits
89645354|NCT06080659|Experimental|TCL-MP|Patient with mild neurocognitive disorder linked to Parkinson's disease
89645355|NCT06080659|Active Comparator|Healthy volunteers|Healthy volunteers
89043966|NCT02902653|Experimental|Oral misoprostol|"Administration of oral misoprostol according to a 3x1 diagram, that is,3 oral doses (1 per hour) and then 1 hour without treatment"
89043967|NCT02902653|Active Comparator|Vaginal misoprostol|vaginal misoprostol, 25 microgs every 4 hours
89043968|NCT02902653|Active Comparator|Vaginal dinoprostone|vaginal dinoprostone, 10 mg during 24 hours (maximum)
89043969|NCT04680351|Experimental|phrenic stimulation|
89645356|NCT06080425|Other|Medical Nutrition Therapy|Medical Nutrition therapy is an intervention that will be administered to the participants for 6 months.
89645357|NCT06077630||Attended appointments|An appointment scheduled by a patient that was attended
89645358|NCT06077630||Not-attended appointments|An appointment scheduled by a patient that was not-attended, regardless of the cause
89645359|NCT06074003|Experimental|Females|Female participant group
89043970|NCT01223404|Experimental|Placebo, Nicotine, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
89043971|NCT01223404|Experimental|Nicotine, Placebo, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
89043972|NCT01223404|Experimental|Placebo, Mecamylamine, Nicotine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
89645360|NCT06074003|Experimental|Males|Male participant group
89645361|NCT06073509||Breast cancer patients treated with RT 5 years ago|Retrospective and cross-sectional data collection based on a medical questionnaire and screening for atrial fibrillation and other cardiac arrhythmias and diseases.
89645362|NCT06068218|Other|Patient Group|
89645363|NCT06068218|Other|Volunteer group|
89645364|NCT06066697|Experimental|SOVA Peer Ambassador Program|"Participants will be given login information for a website sova.pitt.edu. They will be given weekly emails notifications about new posts. The participant will be onboarded as a blogging peer ambassador. The participant will be expected to contribute content to the website at least once a month by~writing a blog article~sending information (de-identified photo or video or music) to post~• If they choose this option they will be encouraged to submit their own photo, video, or music to the website or they will be encouraged to write a response to a photo, video, or music piece.~being interviewed by the RA and then the RA ghostwriting an article about the interview which they pre-approve prior to it being posted."
89645365|NCT06066697|Active Comparator|attention control: brief psychoeducational independent assignments|Participants will be sent a REDCap form where they will receive a link to a SOVA article to read and a question for them to answer about what they read that will be accessible only to the study team. They will be asked to do this a couple times a month and will be reminded about their participation.
89645366|NCT06064071|Experimental|Experimental: Nordlys SWT IPL|Subjects will receive up to four study Nordlys SWT IPL treatments and MGX
89645367|NCT06064071|Sham Comparator|Control Group: Sham Treatment|Subjects will receive up to four sham study Nordlys SWT IPL treatments (device turned off) and MGX
89645368|NCT06063954|Experimental|Low-frequency continuous wave group|Low-frequency continuous wave EA In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
89645369|NCT06063954|Experimental|Intermittent wave group|Intermittent wave EA In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz intermittent wave will be used for 20 min.
89645370|NCT06063460||Ginigival health|The VAS scale will be filled about halitosis, smell and taste perception by patients diagnosed with gingival health during the exam.Patients will be called for a follow-up check in the 1st and 3rd months. Periodontal examinations will be repeated. The VAS scale will be filled in again with halitosis, smell and taste perception.
89645371|NCT06063460||Gingivitis|Patients diagnosed with gingivitis during will have the VAS scale filled in with halitosis, smell and taste perception. Phase 1 treatment will be applied. Patients will be called for a follow-up check in the 1st and 3rd months. Periodontal examinations will be repeated. The VAS scale will be filled in again with halitosis, smell and taste perception.
89645372|NCT06063460||Periodontitis|Patients diagnosed with periodontitis d will have the VAS scale filled in with halitosis, smell and taste perception. Phase 1 treatment will be applied. Patients will be called for a follow-up check in the 1st and 3rd months. Periodontal examinations will be repeated. The VAS scale will be filled in again with halitosis, smell and taste perception.
89645373|NCT06060691|Experimental|Kaempferol group|Kaempferol gel received the vaginal gel containing antioxidant extract every day for seven days. Then, the treatment continued for two months, twice weekly
89645374|NCT06060691|Placebo Comparator|Placebo group|Plain formulation received the vaginal gel containing antioxidant extract every day for seven days. Then, the treatment continued for two months, twice weekly
89645375|NCT06059508|Experimental|SHR-5495 for injection|
89645376|NCT06048965||Expert group|
89645377|NCT06047821||Children with Shigella Diarrhea|Children with Shigella identified by culture or quantitative PCR
89645378|NCT06047821||Children without Shigella Diarrhea|Children without Shigella identified by culture or quantitative PCR
89645379|NCT06042166|Experimental|Connecting and Reflecting Experience (CARE) Program|Participants will enroll in a 12-session CARE parenting group therapy.
89645380|NCT06039787|Experimental|moderate intensity continuous training|
89645381|NCT06039787|Experimental|High-intensity interval training|
89645382|NCT06039787|Placebo Comparator|Waiting condition|
89645383|NCT06028646|Experimental|Dynamic Airway CT scan (DA-CT)|All participants will have a DA-CT scan after flexible bronchoscopy has been performed.
89645384|NCT06028347|Experimental|sa-mRNA vaccine dose 1|
89645385|NCT06028347|Experimental|sa-mRNA vaccine dose 2|
89645386|NCT06028347|Experimental|sa-mRNA vaccine dose 3|
89645387|NCT06028347|Experimental|sa-mRNA vaccine dose 4|
89645388|NCT06028347|Placebo Comparator|Placebo|
89645389|NCT06026514|Experimental|Intranasal Vaccine|B/HPIV3/S-6P vaccine intranasally given in 2 doses, 56 days apart.
89645390|NCT06023719|Experimental|DISC Care|DISC Care implant
89645391|NCT06023524|Experimental|Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points.
89645392|NCT06023524|Sham Comparator|Sham Laser Acupuncture and Standard Medication|Sham Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
89645393|NCT06022913|Other|2 week wait|Participant waits for 2 weeks after their baseline assessment before commencing therapy.
89645394|NCT06022913|Other|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
88992088|NCT00470119|Other|Exercise Intervention|Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months
88992089|NCT00470119|Other|Caloric Restriction AND Exercise Intervention|Combined caloric restriction & exercise intervention
89645395|NCT06022913|Other|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
89645396|NCT06022913|Other|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
89645397|NCT06021301|Experimental|iPRF and Microneedling|First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.
89645398|NCT06018545||Readers|30 readers will be recruited across four NHS trusts including ten general radiologists, fifteen emergency medicine clinicians, and five CT radiographers of varying seniority. Readers will interpret each scan first without, then with, the assistance of the AI tool, with an intervening 4-week washout period. Using a panel of neuroradiologists as ground truth, the stand-alone performance of qER will be assessed, and its impact on the readers' performance will be analysed as change in accuracy, mean review time per scan, and self-reported diagnostic confidence. Subgroup analyses will be performed by reader professional group, reader seniority, pathological finding, and neuroradiologist-rated difficulty.
89645399|NCT06018545||Ground truthers|Two Consultant neuroradiologists will independently review the images to establish the 'ground truth' findings on the CT scans which will be used as the reference standard. In the case of disagreement, a third senior neuroradiologist's opinion will be sought for arbitration. A difficulty score will be assigned to each scan by the ground truthers using a 5-point Likert scale.
89645400|NCT06017102|Experimental|wired magnetic assisted capsule endoscopy|
89645401|NCT06017102|Other|esophagogastroduodenoscopy|
89645402|NCT06014164||Patients using psychedelic substances|Adult patients self-administering psychedelic substances in psychiatric disorders
89645403|NCT06013982|Experimental|Patients discharged following acute care stroke|Participation will last 3 months from enrollment. Demographic data will be retrieved from the electronic health record and the Generalized Anxiety Disorder-7 (GAD-7) Anxiety Questionnaire will be administered at baseline. Participants will repeat the GAD-7 in 3 months and an additional qualitative survey on their experience including an evaluation of the structured anxiety reduction program.
89645404|NCT06011928|Active Comparator|Motor imagery focused pelvic floor exercise (MOPEXE)|"Internal imagery technique, one of the imagery techniques, will be applied to the participants.~Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds."
89645405|NCT06011928|Active Comparator|Relaxation exercise (RE) group|One of the relaxation methods, Progressive Relaxation Exercises will be used.Exercises will be required to be applied 3 days a week, as 1 set of 10 repetitions per day.
89645406|NCT06011928|Active Comparator|Combined exercise group (CEG)|With the video home exercise program, the participants performed progressive relaxation exercises, respectively. then they will be provided with motor imagery focused pelvic floor exercises. A rest period of 5 minutes will be applied between two different exercise programs.
89645407|NCT06010875|Experimental|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89645408|NCT06010875|Experimental|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89645409|NCT06010862|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x106 cells/kg
89645410|NCT06010862|Experimental|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x106 cells/kg
89645411|NCT06003309|Active Comparator|The fully individualized form of iTBS (BOTH the frequency and E-field targeting approaches)|In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modeling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.
89645412|NCT06003309|Active Comparator|iTBS individualized using E-field targeting only (targeted-iTBS)|In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modeling and coordinate-based cortical targeting.
89645413|NCT06003309|Active Comparator|Standard iTBS treatment (i.e., typical iTBS localized to the DLPFC using the Beam F3 method)|The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA-approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
89645414|NCT06003075|Experimental|Combination Chemotherapy and Nivolumab and Surgery|Patients with lung cancer receiving combination therapy with surgery
89645415|NCT06003075|Experimental|Combination Chemotherapy and Nivolumab and Radiation|Patients with lung cancer receiving combination therapy with radiation
89645416|NCT05994261|Active Comparator|Cereset Research Tune-Up Intervention Group|All study participants will receive 4 initial CR sessions. Afterwards, they will be randomized, and this group will receive an additional tune-up (maintenance) session every 6 weeks for one year. There will be a CR session at weeks 6, 12, 18, 24, 30, 36, 42, and 48.
89645417|NCT05994261|Other|Cereset Research Control Group|All study participants will receive 4 initial CR sessions. Afterwards, they will be randomized, and this group will continue their current care for 1 year with no additional CR sessions.
89645418|NCT05993546|Active Comparator|vacuum-assisted sheath|
89645419|NCT05993546|Active Comparator|passive suction via conventional sheath|
89645420|NCT05990478||Participants with Breast Cancer|Participants will have a diagnosis of breast cancer
89645421|NCT05989256|Experimental|experimental hypoglycemia risk score is applied on a service which has already implemented EndoTool|Service where the experimental hypoglycemia risk score is applied on a service which has already implemented EndoTool
89645422|NCT05989256|Active Comparator|Service where EndoTool is applied without the experimental hypoglycemia risk score|Service where EndoTool is applied without our experimental hypoglycemia risk score
89645423|NCT05989256|Active Comparator|Standard of care glucose management|Service which has not yet implemented EndoTool - providers adjusting insulin and consulting the Glucose Management Team at their discretion
89645424|NCT05988749|Experimental|Device|Participants will receive usual care or usual care plus the American Heart Association's Digital Solution in patients with HFrEF. The Solution is a combination of the AHA/CHTI HF CarePlans and Education Content, delivered through and combined with the Biofourmis Platform.
89645425|NCT05988749|No Intervention|Routine Care|Routine care for heart failure management
89645426|NCT05986942||Dex|patients using dexmedetomidine infusion
89645427|NCT05986942||Fen|patients using fentanyl for induction
89645428|NCT05986253|Placebo Comparator|Control|0.6g/kg body mass maltodextrin in solution
89645429|NCT05986253|Experimental|Protein|0.6g/kg body mass maltodextrin PLUS 0.15g/kg body mass protein from Biodulse, in solution
89645430|NCT05985850|Experimental|Aurora 1:1 Drops (Indica)|"Aurora 1:1 Drops (Indica)~Balanced 1:1 ratio of THC and CBD packaged in a 30 mL bottle:~THC: 16.8 mg/g (+/- 15%) CBD: 16.8 mg/g (+/- 15%)~Induction and dosing will be ad libitum and sublingually self-administered. Initial dose will be 5 mg (equivalent to 0.25 mL)/day and participants will be able to titrate in increments of 2.5mg (0.125 mL)/day up to a maximum of 40 mg (2 mL)/day, in consultation with a study physician."
89043973|NCT01223404|Experimental|Nicotine, Mecamylamine, Placebo|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
89043974|NCT01223404|Experimental|Mecamylamine, Placebo, Nicotine|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
89043975|NCT01223404|Experimental|Mecamylamine, Nicotine, Placebo|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
89645431|NCT05985850|Placebo Comparator|Placebo|"Formulated using the same medium chain triglyceride (MCT) oil as Aurora 1:1 Drops (Indica)~Induction and dosing will be ad libitum and sublingually self-administered. Initial dose will be 5 mg (equivalent to 0.25 mL)/day and participants will be able to titrate in increments of 2.5mg (0.125 mL)/day up to a maximum of 40 mg (2 mL)/day, in consultation with a study physician."
89043976|NCT00446342|Experimental|Dose-escalation of SNS-032 injection|Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group.
89645432|NCT05980767|Active Comparator|Experimental Intervention|Standard of care plus therapy, which consists of a single, 1 hour dose of electrical stimulation.
89043977|NCT05657821|Experimental|pumpkin seed extract capsules|. In the intervention group, pregnant women received pumpkin seed extract capsules for 12 weeks
89645433|NCT05980767|No Intervention|Control|Standard of care only.
89645434|NCT05977894||Nurses and physicians|Nurses (registered, practitioner, and anesthetist) and physicians, employed at St. Elizabeth Youngstown Trauma Center, Mercy Health
89645435|NCT05963672|Sham Comparator|Usual Care|
89645436|NCT05963672|Experimental|EEG-guided sleep protection|
89645437|NCT05962346|Experimental|FETO Group|Participants will undergo fetal endoscopic tracheal occlusion (FETO) surgical procedure between 27 weeks 0 days and 29 weeks 6 days gestation.
89645438|NCT05962008|Active Comparator|Omega-3-phosphatidylserine derived from herring roe|Take 300 mg/day of omega-3-phosphatidylserine derived from herring roe.
89645439|NCT05962008|Active Comparator|Phosphatidylserine derived from soybean|Take 300 mg/day of phosphatidylserine derived from soybean.
89645440|NCT05962008|Placebo Comparator|Placebo|Take 0 mg/day of phosphatidylserine.
89645441|NCT05946382|Experimental|RNT-ACT protocol|Participants randomized to RNT-ACT will receive a total of 2 sessions of 60 minutes each as well as audio files to listen to between the occasions administered via internet. Previous studies have indicated that it doesn't make much of a difference whether the temporal distance between session 1 and session 2 is between 1 week and up to 3 months. At occasion 1, the time for occasion 2 is set. The temporal distance in days will noted for each patient. The treatment is inserted into the therapist's regular diary with 60 minutes session time and appropriate break before and after the treatment (e.g. at least 5-10 minutes) for preparation and post-administration where journal writing is included.
89645442|NCT05946382|Active Comparator|iCBT treatment|"The people randomized to Internet treatment will be offered based on M.I.N.I 7.0 a suitable iCBT program in the Stöd och Behandling (SoB) platform. The patients follow a structured self-help material which can be seen as a standard treatment option in Region Skåne, treatment as usual. The therapist has access to the material and the patient and the therapist can communicate via a chat function. The patients are matched to iCBT programs based on whether they are most likely to show symptoms of depression or anxiety. The main component of Internet processing consists of a structured self-help program in approximately eight modules, somewhat varying depending on which program in use. The program is based on proven CBT interventions for each problem area with a strong emphasis on psychoeducation but where different intervention elements is included."
89645443|NCT05945797|Experimental|Dexa Arm|Experimental arm patients will be receiving 2 ml (4mg) of dexamenthasone prior to undergoing ERCP.
89645444|NCT05945797|Placebo Comparator|NS Arm|Placebo arm patients will be receiving 2 ml of normal saline prior to undergoing ERCP.
89645445|NCT05940935||Group 1|Patients who have used Zonisamide or Topiramate
89043978|NCT05657821|Placebo Comparator|Iron tablets|the control group received iron tablets for 12 weeks
89043979|NCT00446381|Experimental|1|Patients with Proliferative Diabetic Retinopathy
89043980|NCT00446381|Experimental|2|Patients with Clinically Significant Macular Edema
89645446|NCT05940935||Group 2|Patients who have used Lacosamide
89645447|NCT05940935||Group 3|Patients who have used Carbamazepine
89645448|NCT05940935||Group 4|Patients who have used levetiracetam
89645449|NCT05940285|Experimental|Single arm study|Patients included in the study will undergo subsequently at 1-month after STEMI (ST-elevation Myocardial Infartion) Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
89645450|NCT05934955|Experimental|BI 1839100 low dose|
89645451|NCT05934955|Experimental|BI 1839100 medium dose|
89645452|NCT05934955|Experimental|BI 1839100 high dose|
89645453|NCT05934955|Placebo Comparator|Placebo|
89645454|NCT05929261||Study Group|Study group will be examined for outcome measurements.
89645455|NCT05929261||Control Group|Control group will be examined for outcome measurements.
89645456|NCT05928182|Experimental|Treatment Participants|Active treatment group participants
89043981|NCT04680273|Experimental|Part 1: [14C]-GDC-9545|Participants will be enrolled to receive a single dose of Carbon-14 labelled [14C]-GDC-9545.
89043982|NCT04680273|Experimental|Part 2: GDC-9545 Treatment Sequence BCD|Participants will be randomly allocated to one of two treatment sequences (BCD for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
89043983|NCT04680273|Experimental|Part 2: GDC-9545 Treatment Sequence BDC|Participants will be randomly allocated to one of two treatment sequences (BDC for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.
89043984|NCT00446420|Active Comparator|1|These patients will only receive intravenous propofol which will be titrated to an OAA/S score of 3. They will not receive fentanyl, midazolam or any other drugs
89043985|NCT00446420|Active Comparator|2|These patients will receive propofol plus midazolam and/or fentanyl. Midazolam and fentanyl will be given in fixed doses first and propofol will be titrated to effect. All drugs will be given intravenously.
89043986|NCT04679922|Active Comparator|Peri Implant mucosal thickness connective tissue graft|
89043987|NCT04679922|Experimental|Peri Implant mucosal thickness fascia lata graft|
89043988|NCT05426889|Other|Surgical|undergo surgery
89043989|NCT05426889|Other|non-surgical groups|no surgery
89043990|NCT02902419|Active Comparator|1|Wound dressing removal was performed between 12-30 hours postoperatively.
89043991|NCT02902419|Active Comparator|2|Wound dressing removal was performed between 30-48 hours postoperatively.
89043992|NCT02902341|Active Comparator|Control|Standard protocol nutrition.
89043993|NCT02902341|Experimental|Nutrition Therapy|Resting energy expenditure was measured using indirect calorimetry or calculated. A dietician assessed daily caloric intake during the entire hospitalization. Caloric deficits were calculated. According to a predefined flow-chart protocol, nutritional interventions were launched on different time points. Interventions varied from nutritional modifications to oral supplementation, tube feeding, and parenteral nutrition.
89043994|NCT03277664|Experimental|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
89043995|NCT03277664|No Intervention|control group|"All the device-monitored adherence data were downloaded from the background database and calculated weekly. However, feedback and reminders were not given to the caregivers. Caregivers were also asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
89043996|NCT02902302|Experimental|Ibuprofen 400 mg/10 mL oral suspension|Single dose of 1 ibuprofen 400 mg/10 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
89043997|NCT02902302|Active Comparator|MOMENT 400 mg coated tablet|Single dose of 1 MOMENT 400 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
89043998|NCT03277625||pancreaticoduodenectomy|patients undergoing pancreticoduodenectomy and having a soft, fragile and/or fatty pancreatic remnant, combined with small pancreatic duct having a Diameter <3 mm.
89043999|NCT02902458|Experimental|Psychological follow-up|Patients undergoing implantation of an ICD for primary prevention will have an individual interview with a qualified psychologist in addition to standard medical follow-up.
89044000|NCT02902458|No Intervention|Control|Patients undergoing implantation of an ICD for primary prevention will have standard medical follow-up.
89044001|NCT02957318|Experimental|FiberBind|
89044002|NCT02957318|Experimental|RG-I fiber|
89044003|NCT02957318|Placebo Comparator|Placebo|
89044004|NCT01223365|Experimental|Hydrocodone ER|Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period. Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
89044005|NCT05426850||ctDNA(+) Cohort|ctDNA(+) Cohort in pretreatment and posttreatment plasma samples was defined by accessing the presence of one or more mutations identified in match tumor samples.
89044006|NCT05426850||ctDNA(-) Cohort|ctDNA(-) Cohort in pretreatment and posttreatment plasma samples was defined by the absence of one or more mutations identified in match tumor samples.
89044007|NCT02956811|Active Comparator|Active|Dapagliflozin 10mg once daily for 12 months
89044008|NCT02956811|Placebo Comparator|Placebo|Placebo 10mg once daily for 12 months
89044009|NCT04319419|Experimental|Supplement with micronutrients|Nutrition education with a supplement
89044010|NCT04319419|Experimental|Nutrition education|Group received only nutrition education
89645457|NCT05925075||RDS|Infant born less than 32 weeks gestation with diagnosis of respiratory distress syndrome. Lung ultrasounds will be performed on day of life 7, 14, 21, 28 and at corrected gestational age of 36 weeks.
89645458|NCT05925075||PDA|In addition to being less than 32 weeks gestation, subject can qualify for study and receive a lung ultrasound scan at time of echo diagnosis of patent ductus arteriosus (PDA).
89645459|NCT05925075||Steroid|"Aims are :~A: To evaluate changes in LUS scores pre and post treatment with systemic steroid course.~B: To evaluate the predictive ability of LUS for successful extubation following course of systemic steroids.~Lung ultrasound scans will be done prior to initiation of post-natal steroid, day 1, day 3, day 7, day 10 of treatment and 1 week after steroid is discontinued."
89645460|NCT05923125|Experimental|Healthy Adults|Participants engage in a maximal exercise test. Before and after this test, blood samples are collected. At a separate, optional control visit, blood samples are collected as during the exercise visit, but participants do not participate in an exercise protocol.
89044011|NCT05657782|Experimental|Fixed Dose-Ranging|"The first, fixed dose-ranging module utilizes a classical 3+3 design. The name is derived from the typical cohort size at a given dose [3], and the typical expansion size at that dose [3] if 1 dose-limiting side effect is observed. This module will address the uncertainty regarding the relationship between dose and adverse events (AEs). A set of pre-specified doses (log10 values 6, 7, 8, 9, and 10) will be employed, based on animal experiments and other live OCV trials. Three participants will be administered each dose (15 participants total)."
89044012|NCT05657782|Experimental|Adaptive Dose-finding/Optimization|A modified continual reassessment method (CRM) adaptive design will guide the dose optimization module. CRM cohorts comprise 3 participants treated concurrently at each dose. All three subjects in each cohort will receive a single dose based on the CRM model fit to all the available dose-response data.
89044013|NCT05657782|Active Comparator|Expansion module - active product|The purpose of the expansion cohort is to gather additional clinical experience at the optimal dose of PanChol and increase the precision with which the rate of AEs is estimated. The expansion module will be randomized, double blind and placebo-controlled (20 receiving active product, 6 receiving placebo, 26 participants total).
89044014|NCT05657782|Placebo Comparator|Expansion module - placebo|The purpose of the expansion cohort is to gather additional clinical experience at the optimal dose of PanChol and increase the precision with which the rate of AEs is estimated. The expansion module will be randomized, double blind and placebo-controlled (20 receiving active product, 6 receiving placebo, 26 participants total).
89044015|NCT05426694|Experimental|Group A|The interventional group received stretching and strengthening exercises along with scapular clock exercises. For the first two weeks, only scapular clock exercises were performed by the patient actively. After 2 weeks, the subjects performed scapular clock exercises by using the thera-band.
89044016|NCT05426694|Active Comparator|Group B|The active control group received stretching and strengthening exercises only. The stretching and strengthening exercises include corner stretch, wall-washes and pectoralis minor muscle stretch.
89044017|NCT00446693|Experimental|I|Use of EndoFast Reliant System
89645461|NCT05921552|Experimental|Tele Health Exercise Prehabilitation|Participants will take part in an exercise program in which they will be encouraged to perform approximately 30 minutes of resistance training exercises approximately twice per week until they undergo surgery (Approximately 2-4 weeks). Participants will also be encouraged to perform moderate aerobic exercise such as brisk walking or using stationary aerobic equipment at least 3 times per week. Participants will wear a FitBit fitness watch to monitor aerobic exercise.
89645462|NCT05920681|Experimental|Transanal irrigation group|Transanal irrigation will be applied to patients who will enter the experimental group. The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
89645463|NCT05920681|Active Comparator|Best supportive care group|"The control group will receive best supportive care (diet modification, Loperamidum if needed, diapers, etc).~Loperamidum Dosage form: Loperamide Tablets (2mg of loperamide hydrochloride.). Dosage: Initial dose - 2 tablets immediately, then - 1 tablet after each loose stool, but not earlier than 2-3 hours after the initial dose. Do not exceed the maximum daily dose - no more than 6 tablets for adults (maximum daily dose 12 mg)."
89645464|NCT05920408|Experimental|EXS21546|EXS21546 Granule in Capsule for oral administration
89645465|NCT05918497||Group 1|patients who will switch at the beginning of Ramadan from standard daily L T4 to day after day.
89645466|NCT05918497||Group 2|patients who will switch to twice or thrice weekly dosing. Their weekly dose was divided equally into those doses, given at successive fixed days of the week
89645467|NCT05918497||Group 3|patients who will switch to once-weekly dosing.
89645468|NCT05918497||Group 4|patients who will continue to take L T4 on a standard daily basis.
89645469|NCT05914142|Experimental|Proton radiation therapy group|Experimental: single-arm objective performance criteria, OPC
89645470|NCT05909059|Experimental|Moderate Renal Dysfunction|Moderate renal dysfunction will receive a 20% dose reduction of fludarabine and no dose reduction for cyclophosphamide.
89645471|NCT05909059|Experimental|Severe Renal Dysfunction|Several renal dysfunction will receive a 40% dose reduction of fludarabine and no dose reduction for cyclophosphamide.
89645472|NCT05909059|Experimental|Dialysis Participants|Participants on dialysis will receive a 50% dose reduction of fludarabine and a 25% dose reduction of cyclophosphamide.
89645473|NCT05905523||3 year old participants|"In this study, your child will be asked to do the following things:~Play a drawing game on a tablet~Copy shapes using a pencil in a paper booklet~Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
89044018|NCT04319029|No Intervention|Non-intervention|Patients received a conventional pharmaceutical care plan, the patients offered optimal pharmacological therapy wit statin.
89645474|NCT05905523||4 year old participants|"In this study, your child will be asked to do the following things:~Play a drawing game on a tablet~Copy shapes using a pencil in a paper booklet~Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
89645475|NCT05905523||5 year old participants|"In this study, your child will be asked to do the following things:~Play a drawing game on a tablet~Copy shapes using a pencil in a paper booklet~Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
89645476|NCT05905523||6 year old participants|"In this study, your child will be asked to do the following things:~Play a drawing game on a tablet~Copy shapes using a pencil in a paper booklet~Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
89645477|NCT05905523||7 year old participants|"In this study, your child will be asked to do the following things:~Play a drawing game on a tablet~Copy shapes using a pencil in a paper booklet~Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
89044019|NCT04319029|Active Comparator|Intervention|The Patients offered to predesign pharmaceutical care plans aimed to improved patient's knowledge, adherence, satisfaction, and quality of life. The patients offered optimal pharmacological therapy wit statin.
89044020|NCT05657704|No Intervention|Tramadol|Patients treated with Tramadol, 100 mg every 8 hours according to clinical practice for the treatment of postoperative pain.
89044021|NCT05657704|No Intervention|Dexketoprofen|Patients treated with Dexketoprofen 25 mg every 8 hours according to clinical practice for the treatment of postoperative pain.
89044022|NCT05657704|Experimental|Experimental Group|"The patients in this group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype.~Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours"
89044023|NCT04319185|Experimental|Intervention|All patients who qualify for the study will receive the intervention
89044024|NCT00446732|Active Comparator|1|
89044025|NCT00446732|No Intervention|2|
89645478|NCT05905341|Experimental|Part 1 Dose Escalation-Dose Level 1|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
89645479|NCT05905341|Experimental|Part 1 Dose Escalation-Dose Level 2|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
89645480|NCT05905341|Experimental|Part 1 Dose Escalation-Dose Level 3|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
89645481|NCT05905341|Experimental|Part 1 Dose Escalation-Dose Level 4|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
89645482|NCT05905341|Experimental|Part 1 Dose Escalation-Dose Level 5|In Part 1, participants with locally recurrent/advanced or metastatic TNBC, platinum resistant ovarian cancer and other advanced solid tumors will receive PF-07224826 as a single agent. Participants with HR-positive HER2-negative advanced or mBC will receive PF-07224826 in combination with endocrine therapy. PF-07224826 will be administered orally, once daily, on a continuous basis.
89645483|NCT05905341|Experimental|Part 2 - Arm A|In Part 2 Arm A, PF-07224826 will be evaluated in combination with fulvestrant in HR positive HER2 negative advanced or mBC participants who have received prior CDK4/6 inhibitor. PF-07224826 will be administered orally, once daily, on a continuous basis.
89645484|NCT05905341|Experimental|Part 2 - Arm B|In Part 2 Arm B, PF-07224826 will be evaluated in combination with fulvestrant in HR-positive HER2-negative locally advanced or mBC participants whose disease has progressed on prior endocrine therapy and is naïve to CDK4/6 inhibitors. PF-07224826 will be administered orally, once daily, on a continuous basis.
89645485|NCT05903989||LAMA|
89645486|NCT05903989||LAMA plus LABA|
89645487|NCT05903989||ICS plus LABA|
89645488|NCT05896332|Experimental|Active, Open Label iTBS-rTMS|Individuals will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total). All will undergo clinical assessments and brain MRI at pre-treatment and at 1-week post-treatment, and clinical assessments at 4-weeks post-treatment. Weekly post-treatment online self-report assessments will be collected up to four weeks. Resting-state parcellations of pre- and post-fMRI will be completed for personalized targeting and network parcellations.
89645489|NCT05888883||Microbial Keratitis Participants|Up to 50 participants presenting with clinically suspected microbial keratitis will be recruited from the Princess Alexandra Eye Pavilion, NHS Lothian, Edinburgh
89645490|NCT05888883||Healthy Control Participants|Up to 20 participants with no history of microbial keratitis will be recruited.
89645491|NCT05887700||ASD subjects|Patients with a confirmed diagnosis of Atrial Septal Defect (ASD) and implanted with the investigational device.
89645492|NCT05882734|Experimental|Dosing Regimen 1 (Phase 1b): M1774 + Cemiplimab|
89645493|NCT05882734|Experimental|Dosing Regimen 2 (Phase 1b): M1774 + Cemiplimab|
89645494|NCT05882734|Experimental|Stratum A (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b|
89645495|NCT05882734|Experimental|Stratum B (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b|
89645496|NCT05882734|Experimental|Stratum C (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b|
89645497|NCT05880225|Active Comparator|Reciprocal Imitation Training (RIT)|Children (n=20) receive 30 sessions of Reciprocal Imitation Training (RIT), delivered in 40-60 minute sessions 2-3 times/week.
89645498|NCT05880225|Experimental|Music-Enhanced Reciprocal Imitation Training (meRIT)|Children (n=20) receive 30 sessions of music-enhanced Reciprocal Imitation Training (meRIT), delivered in 40-60 minute sessions 2-3 times/week.
89645499|NCT05874401|Experimental|Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m²|"Patients randomized 1:1 to trilaciclib. Patients receive trilaciclib (240 mg/m²) administered once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of trilaciclib on Days 1 to 5, patients receive topotecan (1.5 mg/m²)"
89044026|NCT01222507||Brain Speed Test|60 subjects who complete 60 Second Brain Game and Brain Speed Test
89044027|NCT01222078|Experimental|otelixizumab|otelixizumab
89044028|NCT03277586|Experimental|Probio'Stick|
89044029|NCT03277586|Placebo Comparator|Placebo|
89044030|NCT02902536||Myasthenia Positive Antibodies|Patients with Acetyl choline receptor (AChR) or muscle-specific kinase (MuSK) Positive Myasthenia
89044031|NCT02902536||Myasthenia Double Negative|Patients without AChR or MuSK antibodies
89044032|NCT02902536||Normal Controls|Patients without myasthenia
89645500|NCT05874401|Placebo Comparator|Placebo + Topotecan 1.5 mg/m²|"Patients are randomized 1:1 to placebo. Patients receive placebo administered once daily on Days 1 to 5 of each 21-day topotecan chemotherapy cycle.~Following administration of placebo on Days 1 to 5, patients receive topotecan (1.5 mg/m²)."
89645501|NCT05868668|Experimental|fSWT|Focused Shock wave treatments
89645502|NCT05868668|Active Comparator|rWT|Radial wave treatments
89645503|NCT05868668|Sham Comparator|Sham|Sham treatments
89645504|NCT05867472|Experimental|Inhaled sedation - volatile anesthetic|The ICU patient will receive either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
89645505|NCT05867472|No Intervention|IV sedation - standard of care|The ICU patient will receive standard of care, which is IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
89645506|NCT05866692|Experimental|TY-2699a|"Escalation stage: Multiple doses of TY-2699a as monotherapy for oral administration to find the maximum tolerated dose.~Expansion stage: an optimal dose of TY-2699a for cohort expansion."
89645507|NCT05863325|Experimental|HB1801|HB1801 will be given in 21-day cycles until documented disease progression, discontinuation due to toxicity, withdrawal of consent, initiation of a new antitumor therapy, loss of follow-up, death, or study completion, whichever occurs first.
89645508|NCT05863325|Active Comparator|Taxotere|Taxotere will be given in 21-day cycles until documented disease progression, discontinuation due to toxicity, withdrawal of consent, initiation of a new antitumor therapy, loss of follow-up, death, or study completion, whichever occurs first.
89044033|NCT04317157|Experimental|Caffeine Clinical Trial|Participants will ingest 6 mg.kg-1 of caffeine ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
89044034|NCT04317157|Placebo Comparator|Placebo Clinical Trial|Participants will ingest placebo ~45 minutes before the trial, in a double-blinded, randomized clinical trial fashion.
89044035|NCT04317157|Experimental|Placebo-deceived Caffeine|Participants will be lead to believe that they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
89044036|NCT04317157|Placebo Comparator|Placebo-deceived Placebo|Participants will be informed they are ingesting placebo ~45 minutes before the trial.
89044037|NCT04317157|Active Comparator|Control-Caffeine|Participants will be informed they are ingesting 6 mg.kg-1 of caffeine ~45 minutes before the trial.
89044038|NCT04317157|No Intervention|Control|Participants will perform a baseline trial with no intervention.
89044039|NCT04318873|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
89044040|NCT04318873|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
89044041|NCT04317079|Active Comparator|15mg of hydroxytyrosol|15 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given three times daily before main meals (totally 6 capsules daily) in combination with diet
89044042|NCT04317079|Active Comparator|5mg of hydroxytyrosol|5 milligrams of hydroxytyrosol given as 2 capsules containing 2.5mg of hydroxytyrosol each given in the morning and at night before meals and 2 capsules of placebo before lunch (totally 6 capsules daily) in combination with diet
89044043|NCT04317079|Placebo Comparator|placebo|2 capsules of placebo given 3 times daily before meals (totally 6 capsules daily) in combination with diet
89044044|NCT03277430|Experimental|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
89645509|NCT05857943|Experimental|AEYE-DS Software Device|An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy
89044045|NCT03277430|Experimental|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
89044046|NCT02902575|Experimental|Laparoscopic-assisted Gastrectomy|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
89044047|NCT05657431|Experimental|group 1 (Ylang ylang oil)|A square cotton ball impregnated with a drop of ylang-ylang oil was placed in the participants randomized to group I (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
89044048|NCT05657431|Experimental|group 2 (Lemon oil)|A square cotton ball impregnated with a drop of lemon oil was placed in the participants randomized to group 2 (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
89044049|NCT05657431|Placebo Comparator|group 3 (Control)|A square cotton ball impregnated with a drop of salin was placed in the participants randomized to group I (cervical dilatation ≥ 5) with the help of safety pins of pregnant women. One hour after the intervention (in the range of 5-7 cm cervical dilatation), pain levels were measured again with the VAS and anxiety levels were measured with the State Anxiety Scale. The essential oil was renewed as 1 drop every hour until the birth of the baby. When cervical dilatation was in the range of 8-10 cm, pain level was re-evaluated only with VAS. Spielberger Continuity Anxiety Scale was applied with face-to-face interview technique within 4-24 hours following the birth.
89044050|NCT04699214|Experimental|Endostar combined with chemotherapy AI|"Endostar: Endostar 45mg/d, D1-5 iv, Q3W, that is, continuous intravenous pump injection for 120 hours for 5 consecutive days, one cycle. Endostar uses 15 medicines per cycle, 15 Endostar medicines and a Baxter pump per single cycle. Subjects buy and use them at their own expense every two cycles.~AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W."
89645510|NCT05857371|Sham Comparator|Control group|"The surgeon trained to lipoaspiration procedure will perform lipoaspiration for the ADSVF cryopreservation under local anesthesia with sedation.~The patients of the control group benefices to urethrotomy (standard care) under general anesthesia. The surgical surgical technique necessitates performing three incisions with a cold endoscopic knife in the stenosis to obtain enlargement of urethral lumen on the length of the fibrosis at 3, 9 and 12 o' clock.~For patients randomised in the control group, lippoaspiration will be performed for cryopreservation of the autologous ADSVF and potential second administration of ADSVF in case of UrS recurrency. UrS recurrence or primary failure is defined as a recurrence without a period of post procedure improvement). Recurrence incoming before 21 months post experimental treatment will be treated according to the study in order to have a minimum follow-up of 3 months."
89044051|NCT04699214|Active Comparator|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W.
89044052|NCT04699214|Placebo Comparator|Observation group|"The dose of Endostar is not adjusted, and the specific adjustment plan of the chemotherapy regimen is adjusted according to the clinical experience of the investigator.~Patients with no disease progression (local tumor recurrence, distant metastasis, or the appearance of new lesions of the same tumor subtype) and the adverse reactions can be tolerated, continue to use the drug for 6 cycles, and cannot receive other anti-tumor treatments. In the course of medication, if the disease progresses or the researcher believes that the patient is not suitable for continuing medication, the medication will end."
89044053|NCT02902380|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
89044054|NCT02902380|Placebo Comparator|Control Group|0.9% saline infusion
89044055|NCT03277235|Experimental|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
89044056|NCT03277235|No Intervention|Control|Usual care
89044057|NCT01221727|Other|Midazolam|All 27 subjects will receive midazolam.
89044058|NCT01221727|Active Comparator|Denosumab|Eighteen (18) subjects will receive denosumab.
89044059|NCT03277157|Experimental|Probiotic|Bifidobacterium animalis ssp. lactis B94 at 15 billion CFUs per capsule
89044060|NCT03277157|Placebo Comparator|Placebo|Placebo veggie capsule.
89044061|NCT02902614|Experimental|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from opposite side to the 2nd polar body or from vegetal pole.
89044062|NCT02902614|Experimental|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from and side around the 2nd polar body and not the vegetal pole.
89044063|NCT05657392|Experimental|Inhibitory repetitive Transcranial Magnetic Stimulation|All patients will receive inhibitory repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency. The contralesional primary motor cortex region will be stimulated with a Neurosoft-Neuro MS/D device. There will be a total of 10 treatment sessions over a 2-week period. Before each intervention, the resting motor threshold (rMT) value will be determined. rMT will be detected by obtaining a motor-evoked potential of >50 μV amplitude on EMG recording of the contralateral first dorsal interosseous muscle in at least 5 out of 10 stimulations to the primary motor cortex. 90% of the motor threshold will be set in the stimulation. Each stimulation is planned for a total of 20 minutes and a total of 1200 pulses in the form of 1 Hz stimulation.
89044064|NCT03277118||Cardiac Surgery Cohort|Patients aged 18 years or older who are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass.
89044065|NCT01221181|Experimental|Eculizumab|Patients will receive Eculizumab and be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitides vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment.
89044066|NCT05657314|Active Comparator|Comparator|15 grams of pea protein dissolved in 12 ounces of water.
89044067|NCT05657314|Experimental|Active|15 grams of pea protein + probiotic blend (1 billion CFU/capsule - blend of Lactobacillus rhamnosus, Lactobacillus acidophilus, Saccharomyces boulardii, and Bifidobacterium breve) dissolved in 12 ounces of water.
89645511|NCT05857371|Experimental|Experimental group|"The surgeon trained to lipoaspiration procedure will perform lipoaspiration for the ADSVF cryopreservation under local anesthesia with sedation.~The patients of the control group benefices to urethrotomy (standard care) under general anesthesia. The surgical surgical technique necessitates performing three incisions with a cold endoscopic knife in the stenosis to obtain enlargement of urethral lumen on the length of the fibrosis at 3, 9 and 12 o' clock.~For theses patients -randomised in the experimental group - the experimental cell drug will be customised-made to each patient's lesion and included a dose between 16 and 56 million* viable nucleated cells (VNCs) of fresh or thawed autologous Adipose-derived -Stromal Vascular Fraction, resuspended in saline (0, 9%) - 5% human serum albumin (50 mg/mL) final packaged in 2 to 7 syringes of 1 mL at a concentration of 8 million CNV / mL, individually closed with a tamper-proof Luer Lock cap and labelled to ensure double-blindness."
89645512|NCT05857254||Chronic intestinal failure patient|Patient with chronic intestinal failure and with home parenteral nutrition treatment stable for at least 3 months and with home parenteral nutrition treatment for at least 6 months.
89645513|NCT05852054|No Intervention|Usual Care|Patients will receive the usual standard of care
89645514|NCT05852054|Active Comparator|STEP-UP|STEP-UP will promote linkage to primary care and ongoing chronic disease evaluation for postpartum women with prior GDM and/or HDP
89645515|NCT05844475|Active Comparator|Free gingival graft (FGG)|Conventional free gingival graft, involving the harvesting of an epithelialized graft from the hard palate, which is then stabilized/sutured to the recipient site (implant).
89645516|NCT05844475|Experimental|Buccal Strip Graft + Collagen matrix (bSG + CM)|Strip graft obtained from the buccal mucosa of a site showing abundant keratinized gingiva, combined with a collagen matrix. The bSG + CM graft is stabilized/sutured to the recipient site (implant).
89645517|NCT05841199||Controls|10 patients with unobstructed coronary arteries, normal microvascular function and normal LV function.
89645518|NCT05841199||Coronary artery disease|25 patients with severe, single-vessel coronary artery disease of the proximal LAD or proximal other dominant vessel awaiting PCI.
89645519|NCT05841199||Microvascular dysfunction|15 patients with without severe disease in any coronary artery, impaired microvascular function and normal LV function.
89645520|NCT05841199||Heart failure|20 patients with LV systolic dysfunction (LVEF<40%).
89645521|NCT05841004|Experimental|Investigational device - newly developed intermittent compact catheter|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (CH12 and CH14) for urinary drainage. The investigational device is for single use.
89645522|NCT05841004|Active Comparator|Hollister Infyna Chic|The comparator is Hollister Infyna Chic, a CE-marked single-use compact catheter.
89645523|NCT05837676|Experimental|PST-Concussion|Treatment arm. Six, approximately 30-minute telehealth treatment sessions comprised of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
89645524|NCT05837676|Other|Treatment as usual (TAU)|Control arm. Primary care treatment as usual. Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
88992090|NCT00470197|Experimental|Arm I|Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
88992091|NCT00149292|Experimental|LY2140023|40 mg LY2140023 BID for 28 days
88992092|NCT00149292|Active Comparator|Olanzapine|15 mg Olanzapine once daily (QD) for 28 days
88992093|NCT00149292|Placebo Comparator|Placebo|placebo for 28 days
88992094|NCT00470509|Experimental|Adalimumab|adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
88992095|NCT00470509|Placebo Comparator|Placebo|2 placebo injections on day 0 and 7
88992096|NCT05378906|Experimental|Treatment Sequence AB|Participants will receive a single oral dose of darunavir (DRV) and cobicistat (COBI) as one fixed dose combination (FDC) tablet dispersed in water (Treatment A [test]) in Treatment Period 1, followed by a single dose DRV suspension and COBI tablet (Treatment B [Reference]) in Treatment Period 2 on Day 1 of each Treatment Period under fed conditions. There will be a washout period of at least 7 days from dosing on Day 1 of each Treatment Period.
88992097|NCT05378906|Experimental|Treatment Sequence BA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2 on Day 1 of each Treatment Period under fed conditions. There will be a washout period of at least 7 days from dosing on Day 1 of each Treatment Period
88992098|NCT00470743|Experimental|Ibuprofen|Compare ibuprofen
88992099|NCT00470743|Placebo Comparator|Normal saline|Compared against ibuprofen -- placebo
88992100|NCT05370482|Experimental|MRI-guided focal laser ablation|
88992101|NCT00470821|Placebo Comparator|A - placebo|Identical tablets without the active principles. Each evening, nurses are requested to give 2 tablets at 8 PM and 12 PM
88992102|NCT00470821|Active Comparator|B - melatonin|Identical tablets containing melatonin 3 mg Nurses are requested to give two tablets daily, at 8 PM and 12 PM.
88992103|NCT05367830|Experimental|the bone@bc app|Intervention group patients with breast cancer using the app Bone@BC
88992104|NCT00470899|Experimental|placental drainage|
88992105|NCT00470899|No Intervention|no drainage of fetal blood|
88992106|NCT00149409|Placebo Comparator|Placebo|4 gelatine capsules/d
88992107|NCT00149409|Active Comparator|1g/d Omacor|
88992108|NCT00149409|Active Comparator|4g/d Omacor|
88992109|NCT00335998|Experimental|Treatment (triapine)|"Group 1: Patients undergo external-beam pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive 3-AP IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33 and cisplatin IV over 1½ hours on day 2, 9, 16, 23, and 30.~Group 2: Patients undergo external-beam pelvic radiotherapy and receive 3-AP as in group 1.~In both groups, patients undergo intracavitary or interstitial brachytherapy at least once weekly for 3-5 weeks during or after external-beam radiotherapy as per standard of care."
88992110|NCT00470977|Experimental|(Ranibizumab) Lucentis|(Ranibizumab)Lucentis 0.5%
89645525|NCT05832307|Active Comparator|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program, which will be comprised of the following core components: informatics and data analytic tools, evidenced-based education and communication, a multidisciplinary leadership team, and end-user engagement. Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative with lead site facilitation during the trial period.
89645526|NCT05832307|Active Comparator|Existing inpatient influenza vaccination practices|Usual care is defined as the inpatient influenza vaccination practices that currently exist at a given site.
89645527|NCT05829291|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89645528|NCT05829135|Experimental|Treatment group|All participants will be fit with Acuvue Oasys with Transitions.
89645529|NCT05829083|Experimental|Hypercapnic COPD patient - Asymmetric or conventional nasal high flow cannula|Patients with acute exacerbation of COPD and mild to moderate hypercapnic respiratory failure will be randomized to NHF oxygen therapy with asymmetric cannula OR conventional cannula
89645530|NCT05829083|Active Comparator|Hypercapnic COPD patient - Conventional or asymmetric nasal high flow cannula|Patients with acute exacerbation of COPD and mild to moderate hypercapnic respiratory failure will be randomized to NHF oxygen therapy with conventional cannula or Asymmetric cannula
89645531|NCT05826600|Experimental|OMX-0407|"A starting daily dose of 20 mg OMX-0407 per participant split into twice daily 10 mg.~Dose escalation will be determined by the safety monitoring committee. Capsule strengths 1, 5 and 20mg."
89645532|NCT05820672||Patients on SKYTROFA Treatment|Patients on SKYTROFA Treatment managed in USA with appropriate written Informed Consent
89645533|NCT05819138|Experimental|Semaglutide|"Participants will receive 0.25 mg once weekly semaglutide injection for 4 weeks.~Participants will receive 0.50 mg once weekly semaglutide injection for 4 weeks.~Participants will receive 1.0 mg once weekly semaglutide injection for 6 months."
89645534|NCT05819138|Placebo Comparator|Placebo|Participants will receive 0.25 mg once weekly placebo injection for 4 weeks. Participants will receive 0.50 mg once weekly placebo injection for 4 weeks. Participants will receive 1.0 mg once weekly placebo injection for 6 months.
89645535|NCT05818904||Healthy|Healthy group is recruited. They would not receive any intervention. The ultrasound imaging data will be collected to serve as the comparison for no fibrosis joint.
89645536|NCT05818904||Arthrosis of knee|People with arthrosis of the knee joint will be treated using the traditional intervention, which includes physical therapy. The ultrasound imaging will be collected before the intervention and at 3-month. The imaging data will be used to build a imaging model using the machine learning method.
89645537|NCT05818904||arthrosis of shoulder|People with arthrosis of the shoulder joint will be treated using the traditional intervention, which includes physical therapy. The ultrasound imaging will be collected before the intervention and at 3-month. The imaging data will be used to build a imaging model using the machine learning method.
89645538|NCT05817968|Experimental|Esophageal manometry using a solid state sensor vs. balloon catheter|Placement of both a solid state and balloon esophageal pressure (Pes) catheter. Pes recordings of these catheters will be acquired simultaneously during both controlled mechanical ventilation and assisted mechanical ventilation, for 10-15 minutes per phase. Ventilator settings/protocol will be as per standard-of-care.
89645539|NCT05814549||No previous history of diagnosed HPV-related head and neck cancer|Participants have no previous history of diagnosed HPV-related head and neck cancer
89645540|NCT05813717|Experimental|Cohort J1|
88992111|NCT05350592|Active Comparator|Tocilizumab + Dobutamine|Tocilizumab IV 280 mg (100mL/hour, 1 hour) Dobutamine IV 5 micrograms/kg/minute (5mL/hour, 24 hours)
88992112|NCT05350592|Active Comparator|Tocilizumab + Placebo|Tocilizumab IV 280 mg (100mL/hour, 1 hour) NaCl 0,9% IV (5mL/hour, 24 hours)
88992113|NCT05350592|Active Comparator|Placebo + Dobutamine|NaCl 0,9% IV (100mL/hour, 1 hour) Dobutamine IV 5 micrograms/kg/minute (5mL/hour, 24 hours)
88992114|NCT05350592|Placebo Comparator|Placebo + Placebo|NaCl 0,9% IV (100mL/hour, 1 hour) NaCl 0,9% IV (5mL/hour, 24 hours)
88992115|NCT00471055|Experimental|A|Capsaicin and placebo controlled,Cross-over design study
88992116|NCT00471055|Placebo Comparator|B|Capsaicin and placebo controlled,Cross-over design study
88992117|NCT00471094|Experimental|Ilaprazole 5 mg QD|
88992118|NCT00471094|Experimental|Ilaprazole 20 mg QD|
88992119|NCT00471094|Experimental|Ilaprazole 40 mg QD|
88992120|NCT00471094|Active Comparator|Lansoprazole 30 mg QD|
88992121|NCT00471133|Experimental|Xenogeneic Tyrosinase|
89645541|NCT05813717|Experimental|Cohort J2|
89645542|NCT05813717|Experimental|Cohort J3|
89645543|NCT05809921||Single-IVT strategy (SIS) cohort|The SIS cohort included patients with MeVO strokes who received a single conventional alteplase IVT (IVT-1).
89645544|NCT05809921||Dual-IVT strategy (DIS) cohort|"The DIS cohort included patients with alteplase-treated MeVO strokes for whom a repeat MRI (MRI-2) was planned 1-2h after alteplase IVT (IVT-1) to discuss a possible complementary IVT with tenecteplase (TNK-IVT-2).~Patients could be in the following situations: already recanalized at 1-2h post-alteplase IVT-1, persistent occlusion treated with TNK-IVT-2 or persistent occlusion but additional IVT contraindicated according to the study protocol."
89645545|NCT05809622|Experimental|Shoulder and scapular strengthening group|
88992122|NCT00336076||Participants evaluated for mastocytosis|Observational study of all patients referred for suspected mast cell disease. Collection of blood or bone marrow for analysis during diagnostic procedures.
88992123|NCT03271255|Experimental|Arm Apatinib|"Apatinib-FOLFIRI:~Apatinib Mesylate Tablets 500 mg po qd; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
88992124|NCT03271255|Active Comparator|Arm Bevacizumab|"Bevacizumab-FOLFIRI:~Bevacizumab Injection 5 mg/kg IV over 30 minutes,day 1; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
88992125|NCT00471289|Experimental|1|PTA with primary placement of Drug (paclitaxel) Eluting Stent
88992126|NCT00471289|Active Comparator|2|PTA
89645546|NCT05809622|Active Comparator|Control group|
89645547|NCT05805826|Experimental|C. difficile vaccine formulation 1, 2-month schedule (Phase 1)|Novel vaccine formulation 1
89645548|NCT05805826|Experimental|C. difficile vaccine formulation 2, 2-month schedule (Phase 1)|Novel vaccine formulation 2
89645549|NCT05805826|Experimental|C. difficile vaccine formulation 3, 2-month schedule (Phase 1)|Novel vaccine formulation 3
89645550|NCT05805826|Experimental|C. difficile vaccine formulation 1, 6-month schedule (Phase 1)|Novel vaccine formulation 1
89645551|NCT05805826|Experimental|C. difficile vaccine formulation 2, 6-month schedule (Phase 1)|Novel vaccine formulation 2
89645552|NCT05805826|Experimental|C. difficile vaccine formulation 3, 6-month schedule (Phase 1)|Novel vaccine formulation 3
89645553|NCT05805826|Active Comparator|C. difficile vaccine (previously studied formulation) (Phase 1)|Previously studied C. difficile vaccine formulation
89645554|NCT05805800|Experimental|5HT3RA+Olanzapine|Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.On day 1-4, Olanzapine is delivered orally after dinner.
89645555|NCT05805800|Active Comparator|5HT3RA+Olanzapine+Dexamethasone|Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.On day 1-4, Olanzapine is delivered orally after dinner.On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered.
89645556|NCT05803304|Experimental|PATH Intervention|Insufficiently active adults with obesity assigned to the PATH intervention.
89645557|NCT05803304|Active Comparator|Attention Control Group|Insufficiently active adults with obesity assigned to the attention control group. At the end of the 6-month study period, participants will receive access to the PATH program, with out the coaching component.
89645558|NCT05798468|Other|Control group|There will be two control groups. One control group will belong to the University of Malaga and the other will belong to the University of Cadiz. This group will follow the traditional teaching method. The total sample of the group will be approximately 96 students, ensuring a homogeneous distribution between the two groups.
89645559|NCT05798468|Experimental|Experimental group|There will be two experimental groups. One experimental group will belong to the University of Malaga and will use augmented reality using Zapworks software while the other experimental group will belong to the University and will use the Aumentaty platform. The sample will be made up of approximately 107 students, ensuring a homogeneous distribution between the two groups. Both the software and the platform mentioned above will work with augmented reality in the educational field, in this case in the university environment.
89645560|NCT05794503|Active Comparator|Neostigmine|One type of Neuromuscular Blockade Reversal Drug
89645561|NCT05794503|Active Comparator|Sugammadex|One type of Neuromuscular Blockade Reversal Drug
89645562|NCT05792553|Experimental|group I: bonded tongue tamers|25 cases with anterior open bite will be treated using bonded tongue tamers
89645563|NCT05792553|Experimental|group II: customized bonded spurs|25 cases with anterior open bite will be treated using customized bonded spurs
89645564|NCT05792553|Active Comparator|group III: conventional fixed palatal spurs|25 cases with anterior open bite will be treated using conventional fixed palatal spurs
89645565|NCT05783271||mpMRI|Multiparametric MRI of the bladder consists of :conventional (T1 weighted imaging and high resolution T2 weighted imaging) and functional sequences (diffusion-weighted imaging ,ADC), all data will be regrouped to evaluate the accuracy of each separate sequence and mp-MRI in distinguishing non-muscle invasive from muscle-invasive tumors, with VI-RADS score application and comparison with pathological findings, then interobserver agreement for detection of muscle invasion according to mp-MRI and VI-RADS scoring system findings will be calculated.
89645566|NCT05778695|Experimental|Parkinson Disease|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) three times daily (TID) as tolerated. KE dose will be titrated down to a tolerated level if necessary.
89044068|NCT03277079|Active Comparator|statin + ezetimibe|Low dose statin associated with ezetimibe
89044069|NCT03277079|Active Comparator|statin + ezetimibe + Nutraceuticals|Low dose statin associated with ezetimibe and Nutraceuticals
89044070|NCT05657236|Other|control group|
89044071|NCT05657236|Experimental|Experimental group|
89044072|NCT02902224|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
89044073|NCT02902224|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
89044074|NCT02902224|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
89044075|NCT01220557|Experimental|PRIMAS group|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
89044076|NCT01220557|Active Comparator|Control group|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
89044077|NCT04317001|Active Comparator|Active treatment with modafinil|active intervention
89044078|NCT04317001|Placebo Comparator|Placebo|placebo intervention
89044079|NCT03277040|Experimental|Intervention (CSA membership)|Employees will gain CSA membership - they will receive bi-weekly deliveries of fresh fruits and vegetables to a central location near their place of employment.
89044080|NCT03277040|No Intervention|Control (no CSA membership)|Usual care, usual employee benefits. Employees do not gain CSA membership.
89044081|NCT02887339|Experimental|Intervention Group|Tissue requesters from participating OPOs are randomly assigned to complete additional informed consent training through an interactive online training website.
89044082|NCT02887339|Experimental|Control Group|The control group of tissue requesters receive the standard training offered by their OPO and GTEx partners.
89044083|NCT05426499||Patients requiring cefotaxime treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
89645567|NCT05778695|Experimental|Parkinson Disease Dementia/Lewy Body Dementia|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) TID as tolerated. KE dose will be titrated down to a tolerated level if necessary.
89645568|NCT05778695|Experimental|Healthy Controls|Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) TID as tolerated. KE dose will be titrated down to a tolerated level if necessary.
89645569|NCT05777330|Other|Autoantibody-positive first-degree relatives of type 1 diabetes patients|
89645570|NCT05766891|Experimental|Group 1|Participants will receive hypnosedation before and during surgery as well as local anesthesia and pain/nausea medications during surgery
89645571|NCT05766891|Experimental|Group 2|Participants will receive hypnosedation before surgery and standard general anesthesia during surgery.
89645572|NCT05766891|Experimental|Group 3|Participants will receive standard general anesthesia alone. You will not receive hypnosedation.
89645573|NCT05763550|Experimental|HSK16149 20mg BID|
89645574|NCT05763550|Experimental|HSK16149 40mg BID|
89645575|NCT05763550|Active Comparator|Pregabalin 150mg BID|
89645576|NCT05762211|Experimental|Oral pooled fecal microbiotherapy - MaaT033|3 capsules per day
89645577|NCT05762211|Placebo Comparator|Placebo capsule|3 capsules per day
89645578|NCT05761522||Patients with septic shock for 24 hours or more|Adult patients suffering from septic shock, after 24 hours of their diagnosis. Presenting with Mean arterial pressure (MAP)<65 mmHg or the target MAP For whom the physician in charge decided to increase the norepinephrine dose
89645579|NCT05759910|Placebo Comparator|Placebo group|4 capsules per day containing 275mg of Maltodextrin
89645580|NCT05759910|Experimental|BrainPhyt High dose|4 capsules per day containing 275mg of BrainPhyt
89645581|NCT05756777|Experimental|gilteritinib + ivosidenib (Cohort 1)|Each patient will take the combination of gilteritinib/ ivosidenib (Cohort 1) , daily, in continuous 28-day cycles at the dose level that they are assigned.
89645582|NCT05756777|Experimental|gilteritinib + enasidenib (Cohort 2)|Each patient will take the combination of gilteritinib/enasidenib (Cohort 2) daily, in continuous 28-day cycles at the dose level that they are assigned.
89645583|NCT05755204||Apretude group|High-risk women who choose to initiate intramuscular q8week LA-CAB (Apretude) with or without oral lead in for HIV PrEP
89044084|NCT05426499||Patients requiring meropenem treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
89645584|NCT05755204||Truvada group|High-risk women who choose to initiate daily oral TDF/FTC (Truvada) for HIV PrEP
89645585|NCT05738746|Experimental|Pasteurized Akkermansia muciniphila|pasteurized A.muciniphila (Pasteurized, 3x10^10 bacteria per day) as supplement for 3 months,
89645586|NCT05738746|Placebo Comparator|Placebo|placebo administered for 3 months once a day
89645587|NCT05734313|Experimental|Unified Protocol for Cognitive Behavioral Therapy (UP-CBT) with Continuous Glucose Monitoring|Participants randomized to this arm will receive the Unified Protocol for Cognitive Behavioral Therapy (UP-CBT), enhanced by review of Continuous Glucose Monitoring (CGM) data. Participants will wear study-supplied CGM for the first 6 months of their participation in the trial.
89645588|NCT05734313|Active Comparator|Continuous Glucose Monitoring (CGM) Only|Participants randomized to receive Continuous Glucose Monitoring (CGM) will continue to receive their usual care and will also wear CGM throughout the first 6 months of their participation in the trial.
89645589|NCT05733507||Intravenous thrombolysis (IVT)|group of patients treated with IVT alone
89645590|NCT05733507||Tirofiban + IVT|groups of patients treated with simultaneous infusion of tirofiban and IVT
89645591|NCT05728736|Experimental|treatment|20 participants will be randomized to take lemborexant 25mg at h.s for two consecutive nights
89645592|NCT05728736|Placebo Comparator|placebo|10 participants will be randomized to take placebo at h.s. for two consecutive nights.
89645593|NCT05720312|Experimental|Dorsolateral Prefrontal Cortex (DLPFC)|36 sessions of high frequency (10Hz) rTMS
89645594|NCT05720312|Experimental|Ventromedial Prefrontal Cortex (vmPFC)|36 sessions of low frequency (1Hz) rTMS
89645595|NCT05708014|Experimental|Intervention|From baseline to 16-months, participants randomized to the intervention arm will have access to the LuvHub web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessments that will occur every 4 months (4, 8, 12, & 16-months).
89645596|NCT05708014|Experimental|Waitlist Control|"From baseline to 8-months, participants in the waitlist control condition will have access to the LuvHub web app for post-baseline assessments of 4 and 8 months, and the resources section.~From 8-months to 16-months, participants randomized to the waitlist control arm will then have access to the LuvHub web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessments that will occur every 4 months (12 & 16-months)."
89645597|NCT05706428|Active Comparator|Group I|Nasal high-frequency ventilation (NHFV) group (case group):
89044085|NCT05426499||Patients requiring fluconazole treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
89044086|NCT05426499||Patients requiring isavuconazole treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
89044087|NCT05426499||Patients requiring anidulafungin treatment|The treatment choice and the recommended dosage will depend on the isolated pathogen. Therapy will be based on the SmPC of the appropriate drug.
89044088|NCT05658094|Experimental|Exosome|Exosome (100e10 particle) injections with an interval of 14 days during two months.
89044089|NCT01220401|Experimental|ERRT-M|Exposure, Relaxation, and Rescripting Therapy for military populations. 4 sessions.
89044090|NCT00446810|Active Comparator|A1|Benfotiamine
89044091|NCT00446810|Active Comparator|A2|
89645598|NCT05706428|Placebo Comparator|Group II|Nasal CPAP group (control group):
89044092|NCT05426187||Group 1|Women who received the PRIMVAC Vaccine or Placebo during the phase 1b trial in Burkina Faso
89044093|NCT05426187||Group 2|Women of the same age and nulligravid who did not participate in the phase 1b trial
89044094|NCT05426187||Group 3|Women of the same age and primigravid who did not participate in the phase 1b trial
89044095|NCT00446888|Active Comparator|1|"these subjects will get a standard protein supplement milkshake during thei study."
89645599|NCT05694156|Experimental|Music-based cognitive training|Music-based cognitive training sessions are derived from two Neurologic Music Therapy techniques: Musical Attention Control Training (MACT) and Musical Executive Function Training (MEFT). MACT exercises will focus on sustained and selective attention to emphasise flexibility and adaptability of the auditory attention system. MEFT exercises will provide opportunity for decision making, problem solving, reasoning, comprehending, organising, initiating, inhibiting, evaluating, analysing, and creating.
89645600|NCT05689424|Placebo Comparator|HDV-bound Lispro 0%|Subjects will receive insulin lispro with 0% bound HDV
89044096|NCT00446888|Experimental|2|"these subjects will receive an enhanced protein supplement milkshake during their study. Product 4808."
89044097|NCT02887300|No Intervention|Passive control group|"After randomisation, 30 consenting, eligible study participants will be allotted a place in the passive, parallel control group. Participants will work as usual in the ED. Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
89044098|NCT02887300|Experimental|Planned intervention - mantra meditation|"After randomisation, 30 randomly chosen, ED staff members will be taught mantra meditation by an experienced meditator. Each 4 hour session will occur once every two weeks for 8 weeks (total of 4 sessions) and consist of guided meditation as well as discussions around prescribed texts on the meaning of health care.~In addition, participants will be asked to engage in home work (20 minutes of a guided mantra meditation on a twice daily basis). Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
89645601|NCT05689424|Active Comparator|HDV-bound Lispro 1%|Subjects will receive insulin lispro with 1% bound HDV
89645602|NCT05689424|Active Comparator|HDV-bound Lispro 10%|Subjects will receive insulin lispro with 10% bound HDV
89044099|NCT02901990||GMT-low-level group|low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
89044100|NCT02901990||GMT-high-level group|high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
89044101|NCT05657158||Brolucizumab|brolucizumab in routine clinical practice
89645603|NCT05689424|Active Comparator|HDV-bound Lispro 100%|Subjects will receive insulin lispro with 100% bound HDV
89645604|NCT05689021|Experimental|Treatment (CJNJ-67652000 and prednisone)|Patients receive CJNJ-67652000 PO and prednisone PO on study. Patients also undergo blood specimen collection, CT or MRI, and bone scan throughout the trial.
89645605|NCT05687838|Experimental|Relaxing Music Group|"The patients in this group will listen to specially composed MusiCure® compositions, which contain melodies with soft rhythm (60-80 bpm), including harp, cello, strings, and nature sounds (such as rain, bird, forest sound). The patients scheduled to receive chemotherapy for the first time, will be allowed to listen to music for at least one hour during chemotherapy with over-ear headphones (Sennheiser HD280) and an MP3 player. Anxiety and satisfaction levels of the patients will be recorded before and after the music application."
89645606|NCT05687838|Active Comparator|Turkish Makam Music Group|"The patients in this group will listen to the Rast Makam, which was created as a result of research conducted by the Turkish Music Research and Promotion Group (TÜMATA) and provides individuals with comfort and inner peace. The patients scheduled to receive chemotherapy for the first time, will be allowed to listen to music for at least one hour during chemotherapy with over-ear headphones (Sennheiser HD280) and an MP3 player. Anxiety and satisfaction levels of the patients will be recorded before and after the music application."
89645607|NCT05687838|No Intervention|Control Group|The patients in this group will not receive any musical interventions and will receive standard treatment and care during chemotherapy.
89645608|NCT05678387||Healthy participants|Participants without chronic pain and depression
89645609|NCT05678387||Chronic Widespread Pain participants|Participants with Chronic Widespread Pain
89645610|NCT05673629|Experimental|The treatment group-Utidelone in combination with AC|"Utidelone Injection at 30 mg/m2/d administered on days 1-5 of each cycle. Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2 administered once daily on day 1 of each cycle.~One treatment cycle has 21 days, and there are 6 cycles in total."
89645611|NCT05673629|Active Comparator|The control group-Docetaxel in combination with AC|"Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered on day 1 of each cycle.~One cycle has 21 days, and there are 6 cycles in total."
89645612|NCT05673590|Experimental|The treatment group-Utidelone monotherapy|Drug: Utidelone Injection Dose: 40 mg/m2/d intravenously Regimen: once daily on days 1-5 in a 21-day cycle
89645613|NCT05673590|Active Comparator|The control group-Docetaxel monotherapy|Drug: Docetaxel Injection Dose:75 mg/m2/d, administered intravenously Regimen: once on day 1 in a 21-day cycle
89645614|NCT05662124|Experimental|Remote Monitoring|"Patients in this arm will be asked to record their spirometry and oximetry three times weekly. This will be performed using a spirometer and oximeter which upload the results via bluetooth to the patientMpower app on their smartphones/tablets. These results are immediately available for review by their clinical teams who will be asked to review them at least once a fortnight.~All patients will be asked to complete surveys at baseline, 3, 6, and 12 months and for clinical outcome data during the observation period to be collected."
89044102|NCT01220167|Experimental|Sequence ABC|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
89044103|NCT01220167|Experimental|Sequence BCA|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
89044104|NCT01220167|Experimental|Sequence CAB|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
89044105|NCT02901912||Active|Women who perform at least 3h of physical activity per week
89044106|NCT02901912||Sedentary|Women who did not perform any kind of exercise
89044107|NCT00447044|Experimental|2|Subjects drink essential amino acid supplement 3x day for 2 days.
89044108|NCT00447044|Placebo Comparator|1|Subjects receive inert substance versus protein supplement.
89044109|NCT00447044|Experimental|3|Resistance exercise.
89044110|NCT02902185|Experimental|Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
89044111|NCT02902185|Placebo Comparator|Placebo-controlled|Placebo with the same taste and appearance like Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
89044112|NCT00447161|Experimental|1|Bacillus Clausii Multi ATB Resist
89044113|NCT00447161|Placebo Comparator|2|Placebo
89044114|NCT02901873|Active Comparator|Thyroid surgery|Electrical Impedance Spectroscopy in Thyroid surgery
89044115|NCT02901873|Active Comparator|Parathyroid surgery|Electrical Impedance Spectroscopy in parathyroid surgery
89044116|NCT00447317|Experimental|A|Intervention
89044117|NCT00447317|Other|B|Attention control, standard dietary education
89044118|NCT05425914|Active Comparator|Conventional Treatment|Receiving conventional dry eye treatment in the form of artificial tears four times per days for 90 days.
89044119|NCT05425914|Experimental|Vitamin D3 Supplementation|Receiving vitamin d3 supplementation 6000IU per day along with artificial tears for 90 days.
89044120|NCT02902068||Parturients undergoing cesarean section|Healthy parturients, hypertensive parturients and parturients suffering from preeclampsia above 18 undergoing cesarean section deliveries .
89044121|NCT00447395||GROUP 1|Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, normal or mild affected sperm, normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
89044122|NCT00447395||GROUP 2|•Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, oligozoospermia (1-5 mill/ml), normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
89044123|NCT00447395||GROUP 3|•Oligozoospermia (1-5 mill/ml), < 40 year-old-men, no recurrent miscarriages
89044124|NCT00447395||GROUP 4|•Healthy young sperm donors
89044125|NCT00447473|Other|A|GM-CSF given in combination with ketoconazole and mitoxantrone in patients with progressive prostate cancer despite androgen deprivation and prior taxane containing chemotherapy
89044126|NCT05425602|Experimental|MAX40279-01+KN046|"This is an open-label Phase I/II clinical study.~Drug: Stage1: Dose1:MAX40279-01 (35mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage1: Dose2:MAX40279-01( 50mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage1: Dose3:MAX40279-01( 70mg BID)+KN046 ( 5mg/kg Q3Week)~Drug: Stage2: Dose3:MAX40279-01( RP2D BID)+KN046 ( 5mg/kg Q3Week)"
89044127|NCT00553488|Active Comparator|1|Regular insulin SC at -17 mins
89044128|NCT00553488|Active Comparator|2|Regular insulin ID at -17 mins
89044129|NCT00553488|Active Comparator|3|Regular insulin ID at -2 mins
89044130|NCT00553488|Active Comparator|4|Insulin lispro given SC at -2 mins
89044131|NCT00553488|Experimental|5|Insulin lispro given ID at -2 mins
89044132|NCT00447551|Experimental|single group|
89044133|NCT00553527|Other|1|Patient will receive standard of care humeral stem replacement. Only a data collection study. There will be no changes in standard of care for diagnosis.
89044134|NCT00447668|Experimental|1|
89044135|NCT00447668|Active Comparator|2|Exercise
89044136|NCT00447668|Active Comparator|3|Self-care book recommendations
89044137|NCT05425407|Placebo Comparator|Placebo|Only whey protein will be provided
89044138|NCT05425407|Experimental|Collagen|A mix of whey protein and collagen peptides will be provided
89044139|NCT03455322|Active Comparator|norepinephrine|norepinephrine continuous intravenous infusion in a dose of 0.05-0.3ug/Kg/min. average7-10 days to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days.
89645615|NCT05662124|No Intervention|Usual Care|Patients in this arm will undergo usual clinical care as planned by their medical team. They will be asked to complete surveys at baseline, 3,6 and 12 months and for clinical outcome data during the observation period to be collected.
89645616|NCT05656573|Experimental|autologous CART-PSMA cells|
89645617|NCT05653700|Experimental|Arena Strive|The experimental intervention employed in this study will be a 12-week, multi-phased approach involving an asynchronous learning and coaching experience (6 weeks), and exploration phase (6 weeks).
89645618|NCT05653700|Other|Control Cohort|Participants randomized into the control cohort - the intervention is the survey at baseline and end of the study
89645619|NCT05653700|Other|Survey|end of the study
89645620|NCT05650736|Experimental|Abrocitinib 200 mg daily|6 months of treatment with abrocitinib 200 mg daily
89645621|NCT05639413|Other|COBRAF|"A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at the following timepoints:~At the starts of cycle 1, 2 and 3,~At 3 and 6 months after starting of each treatment line, if applicable.~At disease progression after second-line treatment with encorafenib combined with cetuximab, if applicable.~At disease progression after immunotherapy-based treatment in dMMR/MSI patients.~At most 390 mL of blood will be collected from each patient during the study."
89645622|NCT05636618|Experimental|Dose Escalation|"Dose Escalation to determine MTD/MFD in 32 patients receiving up to 4 administrations of [212Pb]VMT-α-NET approximately 8 weeks apart.~A dosimetry sub-study utilizing [203Pb]VMT-α-NET has been incorporated into the study."
89645623|NCT05636618|Experimental|Dose Expansion with RPh2D|Up to 20 patients with NET
89645624|NCT05632406||Adults without obesity|body mass index below 30 kg/m^2
89645625|NCT05632406||Adults with obesity|body mass index above 30 kg/m^2
89645626|NCT05630300|Experimental|Facility-based Ag-RDT COVID-19 testing - reactive|Out-patient department patients who utilized a COVID-19 Ag-RDT professional-use test in an OPD clinical setting with reactive test result
89645627|NCT05630300|Experimental|Facility-based Ag-RDT COVID-19 testing - non-reactive|Out-patient department patients who utilized a COVID-19 Ag-RDT professional-use test in an OPD clinical setting with non-reactive test result
89645628|NCT05630300|Experimental|COVID-19 Ag-RDT self-testing - agree to self-test|Participants who receive and take a COVID-19 Ag-RDT self-test (female sex workers, Boda boda drivers, household contacts)
89645629|NCT05630300|No Intervention|COVID-19 Ag-RDT self-testing - refuse to self-test|Participants who receive but refuse to take a COVID-19 Ag-RDT self-test (female sex workers, Boda boda drivers, household contacts)
89645630|NCT05624580|Experimental|Single Dose 1: NNC0582-0001 10 milligram (mg)|Participants will receive a single dose of NNC0582-0001 10 mg or matching placebo injection subcutaneously.
89044140|NCT03455322|Active Comparator|midodrine & octreotide|midodrine 5mg three times/day orally & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6hS.C. for 7-10 days
89044141|NCT05425368|Experimental|silver diamine fluoride group|partial caries removal will be carried out then Silver Diamine Fluoride will be applied as indirect pulp capping agent and rubbed for 1 minute followed by Glass ionomer filling
89044142|NCT05425368|Active Comparator|mineral trioxide aggregate group|partial caries removal will be carried out then mineral trioxide aggregate will be placed as indirect pulp capping agent followed by glass ionomer filling
89044143|NCT02901522|Active Comparator|Control|Spirometry (baseline) Spirometry (20 - 22weeks)
89044144|NCT02901522|Experimental|Telemedicine|Spirometry (baseline) Telemonitoring Teleconsultation Spirometry (20 - 22weeks)
89645631|NCT05624580|Experimental|Single Dose 2: NNC0582-0001 30 mg|Participants will receive a single dose of NNC0582-0001 30 mg or matching placebo injection subcutaneously.
89645632|NCT05624580|Experimental|Single Dose 3: NNC0582-0001 90 mg|Participants will receive a single dose of NNC0582-0001 90 mg or matching placebo injection subcutaneously.
89645633|NCT05624580|Experimental|Single Dose 4: NNC0582-0001 250 mg|Participants will receive a single dose of NNC0582-0001 250 mg or matching placebo injection subcutaneously.
89645634|NCT05624580|Experimental|Single Dose 5: NNC0582-0001 600 mg|Participants will receive a single dose of NNC0582-0001 600 mg or matching placebo injection subcutaneously.
89645635|NCT05624580|Experimental|Single Dose 6: NNC0582-0001 1000 mg|Participants will receive a single dose of NNC0582-0001 1000 mg or matching placebo injection subcutaneously.
89645636|NCT05610280|Experimental|Olezarsen|Participants will be randomized to receive multiple doses of olezarsen, once every 4 weeks by subcutaneous (SC) injection for up to Week 49.
89645637|NCT05610280|Placebo Comparator|Placebo|Participants will be randomized to receive olezarsen-matching placebo, once every 4 weeks by SC injection for up to Week 49.
89645638|NCT05609344|Experimental|SBIRT|Each intervention barbershop, will hold screening days, where a trained community health worker will be onsite to provide Screening, Brief Intervention, and Referral to Treatment (SBIRT).
89645639|NCT05609344|Other|Usual-care|Six months after completion of Time 1, barbershops in the usual-care arm will receive the intervention.
89645640|NCT05608681|Experimental|EP-104IAR 4 mg|4 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
89645641|NCT05608681|Experimental|EP-104IAR 8 mg|8 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
89645642|NCT05608681|Experimental|EP-104IAR 12 mg|12 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
89057942|NCT05138367|Experimental|WJ-MSC|Subsequent to isolation and culture of WJ-MSCs, WJ-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the National Institute for China Food and Drug Control) were injected into the ovaries of patients with hormone replacement treatment, which consisted of Premarin (0.625 mg/days on days 1 through 25) combined with Provera (10 mg/day for 10 days a month with monthly withdrawal bleeding).
89057943|NCT02218385||ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
89057944|NCT02216409|Experimental|Treatment (Hu5F9-G4)|Hu5F9-G4 monotherapy
89645643|NCT05608681|Experimental|EP-104IAR 16 mg|16 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
89645644|NCT05608681|Experimental|EP-104IAR 10 mg|4 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
89645645|NCT05608681|Experimental|EP-104IAR 20 mg|8 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
89645646|NCT05608681|Experimental|EP-104IAR 30 mg|12 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
89645647|NCT05608681|Experimental|EP-104IAR 40 mg|16 submucosal injections of EP-104IAR administered during an EGD procedure at the Baseline/Dosing visit.
89645648|NCT05605756|Experimental|Botox therapy effects on seizure|
89645649|NCT05593497|Experimental|Single Arm|neoadjuvant capivasertib combined with androgen receptor pathway therapy (leuprolide + abiraterone) prior to radical prostatectomy
89645650|NCT05587842|Active Comparator|Non-weightbearing Group|"At 0 weeks to 2 weeks post operation, subjects will be provided CAM (controlled ankle motion walking) boot and instructed to be non-weightbearing on the ankle, using crutches for assistance. During 2nd week, subject will visit clinic where staples/stitches will be removed, with instructions to continue non-weightbearing w/ crutches. Instructions for limited range of motion to be given, passive/active range of motion out of boot will be allowed. Between 2 to 6 weeks, the subject will continue with non-weightbearing and follow range of motion instructions. After 6 weeks, the subject will begin weightbearing as tolerated. Instructions for limited range of motion to be given, and be weaned from orthosis.~At each follow-up visit, as part of the subject's standard of care, a physical examination and radiographic assessments will be completed, and that data collected for research purposes. Subject will also be requested to complete outcome questionnaires during their participation."
89645651|NCT05587842|Experimental|Early weightbearing (as tolerated) Group|"At 0 weeks to 2 weeks post operation, subjects will be provided CAM (controlled ankle motion walking) boot and instructed to be non-weightbearing on the ankle, using crutches for assistance. During 2nd week, subject will visit clinic where staples/stitches will be removed, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given, passive/active range of motion out of boot will be allowed. Between 2 to 6 weeks, subject will continue with weightbearing as tolerated in orthosis, following range of motion instructions. After 6 weeks, the subject will continue with weightbearing as tolerated, and be weaned from orthosis.~At each follow-up visit, as part of the subject's standard of care, a physical examination and radiographic assessments will be completed, and that data collected for research purposes. Subject will also be requested to complete outcome questionnaires during their participation."
89645652|NCT05586269|Experimental|Meal Kits|Families receive weekly healthy meal kits with fresh ingredients and simple recipes (6 weeks duration), followed by a washout period of 2 weeks, and then receive a newsletter and food pantry referral.
89645653|NCT05586269|Experimental|Delayed Meal Kits|Families receive a newsletter and food pantry referral. After 8 weeks, families will receive weekly healthy meal kits with fresh ingredients and simple recipes (6 weeks duration).
89044145|NCT04681326|Experimental|Biological prosthesis|The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia to allow the positioning of the transfix stitches necessary to the mesh fixation. Successively the retro-muscular rectum muscles plane will be prepared by the separation of the rectum muscles from the posterior rectum-muscles fascia. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched placed at the cardinal and inter-cardinal points. The prosthesis will be placed with a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt (JP) 10 suction drain will be placed under the prosthesis. A JP 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate- reabsorbable-time suture. Another JP 10 suction drain will be placed over the anterior fascia. No subcutaneous suture. Skin stapler or interrupted stitches will be used to close.
89044146|NCT04681326|No Intervention|Standard of care|Normal abdominal wall closure
89044147|NCT02901600||Patients with colorectal cancer|Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
89645654|NCT05585775|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
89044148|NCT02901600||Patients with adenomatous polyps|Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
89044149|NCT02901600||Control patients|Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
89044150|NCT05425329|Experimental|Probiotic treatment|P. acidilatici, CECT 7483, L. plantarum CECT 7484, L. plantarum CECT7485 in a ration of 1:1:1 at a dose of 3b cfu/day.
89044151|NCT05425329|Placebo Comparator|Placebo treatment|Capsules indistinguishable from intervention containing maltodextrin.
89044152|NCT00448097|Other|Data not available PI relocated|No verifiable data available, PI relocated
89044153|NCT03455283||Clariscan 0.5 mmol/ml|Participants will receive Clariscan 0.5 mmol/ml injection as apart of clinical practice at the medical discretion of the prescribing physician.
89044154|NCT03455283||All Gadolinium-Based Contrast Agents (GBCAs)|Participants will receive GBCA as part of clinical practice at the medical discretion of the prescribing physician.
89044155|NCT00448214|Experimental|1|Low dose
89044156|NCT00448214|Experimental|2|Middle dose
89044157|NCT00448214|Experimental|3|High dose
89044158|NCT00448214|Active Comparator|4|
89044159|NCT02901639|Experimental|counseling group|will receive counseling about contraceptive methods using illustrations through postpartum interview with the study
89044160|NCT02901639|No Intervention|NO counseling|will not receive any counseling about contraceptive methods
89044161|NCT00448292|Experimental|1|PRX-00023 taken twice daily, escalating from 40 mg to 80 mg to 120 mg
89645655|NCT05585775|Active Comparator|Wellness for Wellbeing|Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
89044162|NCT00448292|Placebo Comparator|2|Placebo taken twice daily, escalating from 40 mg to 80 mg to 120 mg
89044163|NCT05425017||Low back pain group|Participants currently experiencing low back pain will have small accelerometers taped along spine and do a range of motions while accelerometers are recording back sounds. Subsequently, they will receive a chiropractic adjustment, then repeat the range of motions
89044164|NCT05425017||Healthy group|Participants will have small accelerometers taped along spine and do a range of motions while accelerometers are recording back sounds. Subsequently, they will receive a chiropractic adjustment, then repeat the range of motions
89044165|NCT00448331||positive screen, negative screen|Positive screens are those who received positive feedback regarding their answers to a mental illness screening assessment. Negative screens received feedback stating that they did not screen positive for any mental illness.
89044166|NCT02901561|Experimental|misoprostol 200|misoprostol 200 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
89044167|NCT02901561|Active Comparator|misoprostol 400|misoprostol 400 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
89044168|NCT00448409|Experimental|1|TroVax alone
89044169|NCT00448409|Experimental|2|TroVax plus GM-CSF
89044170|NCT02901678|Active Comparator|Intrusion by 200 g|Applying 200 g intrusive force for the maxillary posterior segment intrusion using miniscrews
89044171|NCT02901678|Experimental|Intrusion by 400 g|Applying 400 g of Intrusive force for the maxillary posterior segment intrusion using miniscrews
89044172|NCT03276884|Experimental|Experimental Infant Formula|Infant formula powder to be fed ad libitum
89044173|NCT03276884|Active Comparator|Control Infant Formula|Infant formula powder to be fed ad libitum
89645656|NCT05581056||CFTR modulators group|Children between 6 and 11 years old that will be treated by CFTR modulators.
89645657|NCT05580523|Experimental|Aspirin 75 mg and placebo|A capsule of 75 mg aspirin plus an aspirin identical-appearing capsule of placebo to be taken orally once per night from enrolment until 36 weeks' gestation and metformin identical-appearing placebo capsules to be taken orally twice per day from enrolment until delivery.
89044174|NCT02901366|Experimental|14C-FYU-981|14C-FYU-981, (Oral single dosing)
89044175|NCT03276806|Experimental|SDM + decision aid + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse, SDM and a decision aid.
89044176|NCT03276806|Active Comparator|LDCT brochure + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse and a LDCT informational brochure.
89044177|NCT03276767|Experimental|Online intervention with SMS reminder|"Reminders will be sendt by SMS-TEXTMESSAGE if users of Endre does not log on to an assigned online session by noon on the second day."
89044178|NCT03276767|Active Comparator|Online intervention with e-mail reminder|"Reminder will be sendt by E-MAIL if users of Endre does not log on to an assigned online session by noon on the second day."
89645658|NCT05580523|Experimental|Aspirin 150 mg and placebo|Two capsules of 75 mg aspirin to be taken orally once per night from enrolment until 36 weeks' gestation and metformin identical-appearing placebo capsules to be taken orally twice per day from enrolment until delivery.
89645659|NCT05580523|Experimental|Aspirin 75 mg and Metformin 1.5 g|A capsule of 75 mg aspirin plus an aspirin identical-appearing capsule of placebo to be taken orally once per night from enrolment until 36 weeks' gestation and metformin capsules (up to 750 mg) to be taken twice per day from enrolment until delivery
89044179|NCT05424666|Experimental|Patient going Oncoplastic Breast surgeries|Lipofilling After Oncoplastic Breast surgeries : Evaluation of Outcomes and Patient Satisfaction
89044180|NCT03276689|Experimental|Duloxetine|The patients will take 2 tab/d of duloxetine 60mg for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. For duloxetine, the morning dose will be a sham pill.
89044181|NCT03276689|Experimental|Pregabaline|The patients will take 2 tab/d of pregabaline 150mg x 2/day for 8 weeks.The initial 7-days dose of pregabaline will 75mg x 2.
89044182|NCT03276689|Experimental|Placebo|The patients will take 2 tab/d placebo for 8 weeks.
89044183|NCT03276650||critically ill AOSD patients|no intervention Data collection from hospitalisation reports (administrative, biological, clinical, outcome)
89044184|NCT02901132||Cancer group 1|Colorectal cancer patients, under 18 years old, no inflammatory disease, weight loss greater 10% habitual body weight, sarcopenic.
89645660|NCT05575830|Experimental|RZV or Shingrix®)|Recombinant Zoster Vaccine
89645661|NCT05570838|Experimental|FES + conventional treatment|60 minutes per session, 5 sessions per week with 30 minutes of task-specific training using Functional Electrical Stimulation applyed by Fesia Grasp device and 30 minutes of Robotic-Assisted Therapy using Amadeo robot for hand rehabilitation
89645662|NCT05570838|Active Comparator|Conventional treatment|60 minutes per session, 5 sessions per week with 30 minutes of task-specific training and 30 minutes of Robotic-Assisted Therapy using Amadeo robot for hand rehabilitation
89645663|NCT05568173|Experimental|Boxing Training|In the Boxing Training Group (BG) boxing training will be given. Additionally, stretching exercises and postural training will be applied.
89044185|NCT02901132||Control group|No cancer patients, under 18 years old, no inflammatory disease, no weight loss, no sarcopenic.
89057945|NCT02218580|Experimental|Massage therapy & standard care|"Massage therapy will be provided by caregiver for 15 minutes at bedtime at home, every night, for a 2-week period.~Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen."
89645664|NCT05568173|Experimental|Scapular Stabilization|In the Scapular Stabilization Group (SSG) scapular stabilization training will be given. Additionally, stretching exercises and postural training will be applied.
89645665|NCT05568173|No Intervention|Control|Individuals in this group will not receive any treatment. Evaluations will be made before treatment and after 8 weeks of treatment.
89645666|NCT05565521|Experimental|Treatment Arm|Concurrent dose-escalated chemoradiation with temozolomide (TMZ) on the MR-Linac with weekly adaptation
89645667|NCT05563974|Experimental|Women who agree to receive family led postnatal care|This group will receive Family-led Postnatal Care-FPNC
89645668|NCT05563974|No Intervention|Women who receive standard of care for postnatal care|Women will get the standard of care for postnatal care
89645669|NCT05558137||Elderly|patients aged 80 years or older
89645670|NCT05558137||Young|patients aged 18-40 years
89645671|NCT05556850|Experimental|Rehabilitation using STABL platform|Patients undergoing minor knee procedures (defined as meniscectomy and synovectomy) will be randomized to virtual rehabilitation using the STABL platform
89645672|NCT05556850|No Intervention|Rehabilitation using standard physical therapy|Patients undergoing minor knee procedures (defined as meniscectomy and synovectomy) will be randomized to standard physical therapy.
89645673|NCT05554393|Experimental|ARM I (daunorubicin, cytarabine, venetoclax)|Patients receive daunorubicin IV, cytarabine IV, and venetoclax PO on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
89645674|NCT05554393|Experimental|ARM II (azacitidine, venetoclax)|Patients receive azacitidine IV or SC and venetoclax PO on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
89645675|NCT05554393|Active Comparator|ARM III (daunorubicin, cytarabine)|Patients receive daunorubicin IV and cytarabine IV on study and undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated.
89645676|NCT05553743||Main Study|The purpose of this project is to collect and store breast milk samples and health information about moms and their babies in a Human Milk Biorepository at UCSD. Through these studies, researchers hope to understand more about the benefits of breast milk, and how it prevents or treats child health problems.
89645677|NCT05553743||Sub-study 100: COVID-19 Exposure|The purpose of this substudy is to learn how exposures to COVID-19 and breastfeeding may affect the development of the child. Women who contact the UCSD Human Milk Biorepository will be screened for possible COVID-19 infection or exposure. Women will be eligible to enroll in the COVID-19 sub-study if they are confirmed positive, are presumptive positive, are symptomatic but not tested, or have confirmed exposure but are asymptomatic.
89645678|NCT05553743||Sub-study 101: Antibiotic Exposure|The purpose of this substudy is to learn more about maternal use of antibiotics in women who do or do not breastfeed, and how this may influence infant and child health. Women who contact or are referred to the UCSD Human Milk Biorepository will be screened to participate in the Antibiotic Exposure sub-study. Women will be eligible to enroll in the Antibiotic Exposure sub-study if they are 18 years of age or older, have a singleton infant who is <3 months of age at the time of recruitment, and agree to all requirements of the study.
89645679|NCT05553314|Experimental|Carvedilol-group|Patients receiving carvedilol
89645680|NCT05553314|Placebo Comparator|Placebo-group|Patients receiving placebo
89645681|NCT05546346|Experimental|wearable magnet tracking system|
89645682|NCT05544071|Active Comparator|rTMS Active|Blinded Active TMS coil. Active repetitive Transcranial Magnetic Stimulation (rTMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.)
89645683|NCT05544071|Sham Comparator|rTMS Sham|Blinded Sham TMS coil. Sham Transcranial Magnetic Stimulation (TMS) and Sertraline (dosage form: pill, dosage: 50mg, frequency and duration: At the beginning of the treatment, the dose of 25mg/ was taken for 1-3 days and adjusted to 50mg/ days for 4-7 days. If there were no dose-limiting adverse events, the dose could be titrated to 100mg/ days in the second week. The dose could be flexibly adjusted within the range of 100~150mg/ days until a satisfactory clinical response was achieved. After that, the drug dose was kept unchanged as far as possible. Take it once a day, after a meal at a relatively fixed time in the morning.)
89645684|NCT05542420||Real world adult population with type 2 diabetes mellitus (T2DM)|
89645685|NCT05539443|Experimental|Intensive Clinic Management (ICM)|
89645686|NCT05539443|Experimental|Intensive tailored telehealth management (ITTM)|
89645687|NCT05534880|Active Comparator|Virtual Reality|Condition 01 - the participants will be induced to CS, they will be immersed in a roller coaster simulation video, lasting 10 minutes, there will be 03 sessions on alternate days with a 24-hour interval between each session, before and after each session will be applied the SSQ questionnaire subjective assessment and EEG objective assessment.
89645688|NCT05534880|Experimental|Virtual reality and binaural beats|Condition 02 - the participants will be induced to CS, they will be immersed in a roller coaster simulation video associated with audio with binaural beat, lasting 10 minutes, there will be 03 sessions on alternate days with a 24-hour interval between each session, before and after each session, the SSQ subjective assessment questionnaire and the objective assessment EEG will be applied.
89645689|NCT05533463|Experimental|HRS-4642|"In Dose Escalation:~HRS-4642 will be injected QW. Six dose levels are preset.~In Dose Expansion:~1 to 2 dose cohorts will be selected for dose expansion stage.~In Indication Expansion:~Enrollment into the dose expansion cohorts may be from any eligible solid tumor type."
89645690|NCT05523323|Experimental|Pembrolizumab with Lenvatinib|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
89212619|NCT00513604|Experimental|Cohort 5 - NMA, CD4+TIL, HD aldesleukin|"Cohort 5 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) tumor infiltrating lymphocytes (TIL), high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 5 = CD4 + depleted TIL - it is the SAME as cohort 2"
89212620|NCT00872144|Active Comparator|Sativex|
89212621|NCT05355129|Experimental|Dose 1|low dose
89212622|NCT05355129|Experimental|Dose 2|Middle dose
89212623|NCT05355129|Experimental|Dose 3|High dose
89212624|NCT05355129|Placebo Comparator|Placebo|
89645691|NCT05523323|Active Comparator|Pembrolizumab with Placebo|Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib-matching placebo will be administered until progressive disease or unacceptable toxicity.
89645692|NCT05522868|Other|Cohort 1|SB17170 initial dose: 300 mg/d per day, 3 to 6 subjects per cohort
89645693|NCT05522868|Other|Cohort 2|SB17170 dose: 600 mg/d per day, 3 to 6 subjects per cohort
89645694|NCT05522868|Other|Cohort 3|SB17170 dose: 1000 mg/d per day, 3 to 6 subjects per cohort
89645695|NCT05522868|Other|Cohort 4|SB17170 dose: 1500 mg/d per day, 3 to 6 subjects per cohort
89645696|NCT05522868|Other|Cohort 5|SB17170 dose: 2000 mg/d per day, 3 to 6 subjects per cohort
89645697|NCT05521919|Experimental|Stress (sympathetic nervous system activation)|"Stress will be induced using the socially evaluated cold pressor test.~Participants will complete three rounds of the socially evaluated cold pressor test.~The socially evaluated cold pressor test involves submerging one hand in ice-cold water for 3 minutes while participants' reactions are filmed on camera."
89645698|NCT05521919|Sham Comparator|No-stress|Participants will hold a hand in room temperature water for 3 minutes.
89645699|NCT05520762|Experimental|First choice supraglottic airway device, Then First choice endotracheal intubation|A strategy of 'first choice' supraglottic airway during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
89645700|NCT05520762|Active Comparator|First choice endotracheal intubation, Then First choice supraglottic airway|A strategy of 'first choice' endotracheal intubation during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
89645701|NCT05518812|Experimental|Hemabate|Dilute the 250mcg/mL vial with 25mL saline to create a solution of 10mcg/mL, and inject no more than 10mL of diluted solution at the base of the fibroid. The route of administration depends on the location of the fibroid.
89645702|NCT05516979|Experimental|100 mg AP1189|Treatment period of 12 weeks given as 1 tablet daily
89645703|NCT05516979|Placebo Comparator|Placebo|Treatment period of 12 weeks given as 1 tablet daily
89645704|NCT05514288|Other|Endoscopic sleeve gastroplasty/Transoral outlet reduction|
89645705|NCT05513378|Experimental|With Needle Guide|A needle guide adapted to a micro-convex ultrasound probe will be used in ultrasound-guided catheterisation of the subclavian vein using the long-axis approach with an in-plane needling technique
89645706|NCT05513378|No Intervention|Without Needle Guide|A micro-convex ultrasound probe without needle guide will be used in ultrasound-guided catheterisation of the subclavian vein using the long-axis approach with an in-plane needling technique
89645707|NCT05512871|Experimental|Group 1 (Intervention group)|Group 1 (Intervention group) :Oura ring with Oura App + HealthifySG App (receive lifestyle interventions via HealthifySG App)
89645708|NCT05512871|Other|Group 2 (Control group)|Group 2 (Control group) : Oura ring with Oura App alone (without lifestyle interventions)
89645709|NCT05512364|Experimental|Experimental arm|elacestrant 400 mg/day orally once daily on a continuous dosing schedule
89645710|NCT05512364|Active Comparator|Control arm|standard endocrine treatment - the same they were receiving at the time of ctDNA detection
89645711|NCT05502770||Natural cycle children|Children born from frozen embryo transfer with natural cycle protocol
89645712|NCT05502770||Modified natural cycle children|Children born from frozen embryo transfer with modified natural cycle protocol
89645713|NCT05502770||Artificial cycle children|Children born from frozen embryo transfer with artificial cycle protocol
89645714|NCT05491720|Experimental|tDCS group|TDCS intervention protocol consists of 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days. Anodal electrode will be placed over the left dorsolateral prefrontal cortex and cathodal electrode will be placed over the right supraorbital area.
89645715|NCT05491720|Experimental|Medication group|Participants in this group will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
89645716|NCT05491720|Placebo Comparator|Control group|Participants in this group undergo 10 daily sessions of sham tDCS concurrent with placebo tablets ( Galenus pharmaceutical company) for 10 consecutive days.
89645717|NCT05490485|Experimental|Camrelizumab|Camrelizumab (PD-1 MAB) combined with cisplatin for advanced cutaneous squamous cell carcinoma
89212625|NCT00872222|Other|Ceramic-on-Ceramic|Pinnacle™ Acetabular System with ceramic liner
89212626|NCT00877526||A|
89645718|NCT05485467||Heart transplant recipients|All patients will undergo coronary CT angiography and the presence of CAV will be defined in accordance with the ISHLT criteria. At the time of CT angiography, the patient will undergo a detailed clinical evaluation, and cardiac echo and we will also collect blood samples, perform extensive biochemical analysis and measure CD34+ cell count in peripheral venous blood
89645719|NCT05482334|Experimental|Sargramostim|Sargramostim 250 μg/m2/day subcutaneously (5 days per week)
89645720|NCT05482334|Placebo Comparator|Placebo Control - Saline|Placebo equivalent volume subcutaneously (5 days per week)
89645721|NCT05482321||Group 1|SOP (healthy) subjects. Part I of study (optimizing protocol).
89212627|NCT00867152|Experimental|Cohort 2|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
89212628|NCT00867152|Experimental|Cohort 1|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
89212629|NCT00993837|Experimental|conversion|
89212630|NCT00867230|Experimental|FTS (S-trans, trans-farnesylthiosalicylic acid)|
89645722|NCT05482321||Group 2|Control (healthy and autoantibody positive) subjects. Part II of study (cross-sectional study)
89645723|NCT05482321||Group 3|T1D subjects. Part II of study (cross-sectional study)
89645724|NCT05478863|Placebo Comparator|Oral placebo|Acute administration of oral placebo three times in study session (Time 0, 60, and 120).
89645725|NCT05478863|Experimental|Oral administration of 2.5 mg THC|Acute administration of oral THC (2.5 mg) three times in study session (Time 0, 60, and 120).
89645726|NCT05478863|Experimental|Oral administration of 2.5 mg THC + 60 mg caffeine|Acute administration of oral THC (2.5 mg) and oral caffeine (60 mg) three times in study session (Time 0, 60, and 120).
89645727|NCT05478863|Experimental|Oral administration of 2.5 mg THC + 60 mg caffeine + 35 mg CBD|Acute administration of oral THC (2.5 mg), oral caffeine (60 mg), and oral CBD (35 mg) three times in study session (Time 0, 60, and 120).
89645728|NCT05476523||Healthy Data Collection|As a part of the study, a group of up to 2000 healthy subjects will undergo a NeuraLight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye-tracking system (approx. 15 minutes). The oculometric evaluation will occur for every patient 1 time, and all subjects will be recruited over a period of 36 months. All assessments will be performed during a clinic visit unless authorized to be conducted remotely
89645729|NCT05474274||Post-Surgery data collection system|Subjects undergoing standard of care low-risk plastic surgery be provided with wearable sensors to take home and start recording heart rate, body temperature and body movements
89645730|NCT05473702||Cardiac health subjects|"Subjects over 18 years of age. Subject should satisfy any one of the following:~Healthy subject with no pre-existing conditions.~Subject with prehypertension~Subject with hypertension~Subject undergoing dialysis"
89645731|NCT05472584|Experimental|Experimental: Non-invasive spinal cord stimulation|This arm will receive 30 minutes of transcutaneous spinal cord stimulation as participants rest.
89645732|NCT05472584|Experimental|Experimental: Activity-based training|This arm will perform 30 minutes of activity-based training using leg movements.
89645733|NCT05472584|Experimental|Experimental: Activity-based training wtih non-invasive spinal cord stimulation|This arm will receive transcutaneous spinal cord stimulation as participants perform 30 minutes of activity-based training using leg movements.
89645734|NCT05472584|Experimental|Experimental: Non-invasive spinal cord stimulation and strength training|This arm will receive transcutaneous spinal cord stimulation as participants perform strengthening exercises.
89645735|NCT05472584|Experimental|Experimental: Non-invasive spinal cord stimulation and precision training|This arm will receive transcutaneous spinal cord stimulation as participants perform precision-control and dexterity exercises.
89645736|NCT05472584|Experimental|Experimental: Long-term activity-based training with non-invasive spinal cord stimulation|This arm will receive 4 weeks of activity-based training with transcutaneous spinal cord stimulation
89645737|NCT05466539|Experimental|Treatment Group|AbobotulinumtoxinA
89645738|NCT05466539|Placebo Comparator|Control Group|Normal Saline
89645739|NCT05465486|Experimental|Complete injury at cervical spine|Patients from Greece, 14 y.o. or oder, suffering from chronic complete injury at the cervical spinal cord level (ASIA Impairment Scale A)
89645740|NCT05465486|Experimental|Incomplete Injury at cervical spine|Patients from Greece, 14 y.o. or oder, suffering from chronic complete injury at the cervical spinal cord level (ASIA Impairment Scale B, C, D, E)
89645741|NCT05465486|Active Comparator|Healthy participants|Healthy participants, age and sex matched to the participants in the other two arms
89645742|NCT05461495|Experimental|Treatment Group|"Treatment group will receive 6 counseling sessions, participate in local support group and on-line chat group, and receive ad hoc' counseling."
89645743|NCT05461495|No Intervention|Control Group|Control group will participate in on-line chat group, and call the counselor for resource information and support as needed.
89645744|NCT05456360|Other|Intervention group|Participants will receive sleep enhancement intervention and will wear the ViSi Mobile device.
89645745|NCT05456360|Other|Control group|Participants will receive sleep enhancement intervention only. Participants in the control group will not wear the ViSi Mobile device.
89645746|NCT05456100|Experimental|Expressive Helping|Participants complete a 20-minute expressive writing session once per week for the first three weeks. During Week 4, participants complete a 20-minute peer support writing session.
89645747|NCT05456100|Active Comparator|Expressive Writing|Participants complete a 20-minute expressive writing session once per week for four weeks.
89645748|NCT05456100|Active Comparator|Factual Writing|Participants complete a 20-minute factual writing about their cancer diagnosis and treatment every week for four weeks.
89645749|NCT05449990|No Intervention|CONTROL GROUP: survey and Standard Care (SC)|150 (75 patients and 75 family members)
89645750|NCT05449990|Experimental|EXPERIMENTAL GROUP: participation in patient-and-family-centered interdisciplinary rounds (PFCC-IR)|150 (75 patients and 75 family members)
89645751|NCT05447988|Other|Two-stage reconstruction|136 participants will undergo two-stage reconstruction
89645752|NCT05446168|Experimental|Parkinson's Disease Tributyrin Intervention|Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
89645753|NCT05446168|Experimental|Healthy Control Tributyrin Intervention|Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
89044186|NCT04699370|Experimental|cognition-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to cognition-targeted exercise .~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.~For Cognition- targeted exercise , all standardized physical therapy exercises will be performed in a time-contingent rather than in a symptom-contingent way ."
89044187|NCT04699370|Active Comparator|symptom-targeted exercise|"The patients in this group will receive cognitive behavior therapy in addition to symptom-targeted exercise .~Cognitive behavior therapy will be designed on the basis of van Kessel's model . The main objective of this treatment will be challenging all external factors (e.g. behavioral, cognitive, and affective factors) envisioned to play a role in the development and persistence of fatigue in MS patients. The treatment sessions will be directed individually.~For symptom- targeted exercise, All Standardized physical therapy exercises will be performed in a symptom-contingent way (Stop or adjust the exercise when it hurts)."
89044188|NCT02901210|Experimental|Modified Delorme|Modified technique for delorme procedure done in mild to moderate rectal prolapse as the investigator destroy use the electrocautery to peal the mucosa with less intraoperative bleeding ,avoiding stripping of the mucosa done in classic delorme that induce major bleeding intraoperative .
89044189|NCT04699448|Active Comparator|High-protein hypocaloric diet|Composition of hypocaloric diet: protein:40%,carbohydrates:30% and fat:30%.
89044190|NCT04699448|Active Comparator|High-carbohydrate hypocaloric diet|Composition of hypocaloric diet: carbohydrate 60%, protein:18% and fat:22%
89044191|NCT01220128|Experimental|Cohort A-GSK2302024A Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of GSK2302024A according to the treatment schedule.
89044192|NCT01220128|Placebo Comparator|Cohort A-Placebo Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule.
89645754|NCT05444881|Experimental|Intervention|"10-20 minutes a day of mindfulness meditation practice through the Headspace app.~Participants will receive daily reminders to participate and receive weekly calls to assess adherence.~Participants will be briefed on the telephone on how to use the app and receive recommendations of possible meditations they can engage with throughout the 6 weeks of participation."
89645755|NCT05444881|No Intervention|Waitlist Control|Waitlist Control
89645756|NCT05438134|Experimental|SMART-3RP Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training upon enrollment.
89645757|NCT05438134|Active Comparator|Waitlist Control Group Intervention|Residents will participate in 9 structured weekly group sessions which incorporates stress management and relaxation training after the final survey time point.
89645758|NCT05437848|Experimental|Cotadutide|Those subjects who were randomized to cotadutide once daily SC will begin at 50 μg once daily, then up-titrated to 100 μg once daily a week later, after that up-titration will be done at 100 μg increment weekly, till to a maximum of 600 μg once daily.
89645759|NCT05437848|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
89645760|NCT05426356|Active Comparator|Non-Surgical Treatment|Non-surgical management (NSM) of sacral insufficiency or fragility fractures (SFIF)
89645761|NCT05426356|Experimental|Surgical Treatment|Surgical fixation of sacral insufficiency or fragility fractures (SFIF) with concomitant fusion of the sacroiliac (SI) joint
89645762|NCT05420753|Experimental|TIPS|Patients in this arm will undergo TIPS creation in addition to their current management.
89645763|NCT05420753|No Intervention|Standard of care|Patients in this arm will continue to be treated with their current management
89645764|NCT05419193|Placebo Comparator|Control group|Patients will receive usual care and drug use in hospital.
89645765|NCT05419193|Experimental|Propranolol group|Propranolol hydrochloride will be administered intravenously via pump at a initial dose of 5mg/day over a course of 7 consecutive days after randomization.
89645766|NCT05409183|Experimental|CRD-740|"Part A: Participants in Part A randomly assigned to this arm will take CRD-740 twice daily at two ascending dose levels over 12 weeks.~Part B: Participants in Part B randomly assigned to this arm will take CRD-740 twice daily at a single dose level over 12 weeks."
89645767|NCT05409183|Placebo Comparator|Placebo|"Part A: Participants in Part A randomly assigned to this arm will take placebo twice daily at two ascending dose levels over 12 weeks.~Part B: Participants in Part B randomly assigned to this arm will take placebo twice daily at a single dose level over 12 weeks."
89645768|NCT05406349|Other|Electrophysiological recordings in participants with intracranially implanted electrodes|All participants will perform behavioral tasks that test their spatial navigation and memory performance in self-navigation and observation tasks.
89645769|NCT05403307||Two doses or more of BNT162b2|Defined as ≥ 2 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
89645770|NCT05403307||One dose of BNT162b2|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
89645771|NCT05403307||One dose or more of BNT162b2|Defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
89645772|NCT05403307||Two doses of BNT162b2|Defined as 2 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset.
89645773|NCT05403307||Three doses of BNT162b2|Defined as 3 doses of BNT162b2 COVID-19 vaccine received with ≥7 days between receipt of the 3rd dose and acute respiratory illness (ARI) symptom onset.
89645774|NCT05403307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines according to Brazil National Immunization Program recommendations.
89645775|NCT05403307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
89645776|NCT05396001|Active Comparator|LowSalt4Life|
89044193|NCT01220128|Experimental|Cohort B-GSK2302024A Group|This group included breast cancer patients who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
89044194|NCT01220128|Placebo Comparator|Cohort B-Placebo Group|This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
89044195|NCT01220128|Experimental|Cohort C-GSK2302024A Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of GSK2302024A, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
89044196|NCT01220128|Placebo Comparator|Cohort C-Placebo Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
89044197|NCT01220128|Experimental|Cohort D-GSK2302024A-D14 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
89645777|NCT05396001|Experimental|LowSalt4Life + just-in-time adaptive intervention (JITAI)|
89645778|NCT05389488|Active Comparator|Control Arm|Subjects will receive standard of care intermittent compression therapy using the current devices used in the clinical space.
89645779|NCT05389488|Experimental|Study Arm|Subjects will receive compression therapy from the OsciPulse system.
89645780|NCT05387889|Experimental|Treatment Arm|"This treatment Arm will receive MMPH intervention first, while the wait-listed group waits until this group is complete.~Then the wait-listed group will receive the same intervention after the first group completes it."
89645781|NCT05387889|Active Comparator|Comparison Arm or Waited List Arm|This active comparator Arm will not receive MMPH intervention at the beginning. They will receive the intervention once the Treatment Group completed the intervention.
89645782|NCT05380583|Experimental|CRAFT-EP + TAU|Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) with 8 weekly sessions of 60-90-minute coaching + Treatment as Usual (TAU).
89645783|NCT05380583|Active Comparator|Treatment as Usual|Treatment as Usual
89645784|NCT05375760|Other|Arm A|600 mg AZD7442 following 300 mg AZD7442 every 3 months (5 doses totally)
89645785|NCT05375760|Other|Arm B|1200mg AZD7442 following 600 mg AZD7442 every 6 months (3 doses totally)
89645786|NCT05370352|Experimental|Mobile chat messaging|Standard smoking cessation treatment + Personalised chat messaging
89645787|NCT05370352|Active Comparator|SMS messaging|Standard smoking cessation treatment + Regular SMS text messaging generic information about the harms of smoking and the benefits of quitting
89645788|NCT05370196|Experimental|Test Product|Synthetic Male Condom
89044198|NCT04699409|Experimental|FAST|stroke education: FAST
89044199|NCT04699409|Experimental|STROKE 112|stroke education: STROKE 112
89044200|NCT05424588||Healthy male amateur Caucasian cyclists|Healthy male amateur Caucasian cyclists who attended the NC4000 4th edition underwent clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection.
89044201|NCT04698941|Experimental|Simvastatin + Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)
89044202|NCT04698941|Active Comparator|Albumin Paclitaxel|received intravenous infusions of Paclitaxel 260 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle (4 cycles)
89044203|NCT04206202|Experimental|PSI group|3D-printed patient-specific instrumentation (PSI) will be used in the total knee arthroplasty (TKA) of this group.
89044204|NCT02901288|Experimental|experimental group1|"The experimental group1 all oral regimen is consisted of isoniazid,rifampin, pyrazinamide, ethambutol and levofloxacin for 4.5 months.~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than 50kg,given once daily) or 800mg(more than 50kg,once daily)."
89044205|NCT02901288|Experimental|experimental group2|The experimental group2 all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol for 4.5 months. The dosage of isoniazid,rifampin, pyrazinamide, and ethambutol is as same as that of control regimen.
89057946|NCT02218580|Active Comparator|Standard care|Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen.
89645789|NCT05370196|Active Comparator|Control Product|Latex Male Condom
89645790|NCT05366933|Experimental|Supplemented with B-Complex|Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station
89645791|NCT05360784|Experimental|Brimonidine tartrate preservation-free|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
89645792|NCT05360784|Active Comparator|Lumify®|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
89645793|NCT05359016|Experimental|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
89645794|NCT05356715|Experimental|Group A|● Group A (n=110): will receive Ultrasound guided bilateral ESBP.
89645795|NCT05356715|Active Comparator|Group B|● Group B (n=110): will receive fentanyl IV infusion 2mic/kg/hr
89645796|NCT05333250|Experimental|Modafinil|One 200mg modafinil capsule once daily for one week
89645797|NCT05333250|Placebo Comparator|Placebo|One placebo capsule once daily for one week
89645798|NCT05332899|Experimental|Influenza Challenge Model with Influenza A H3N2 Strain|Participants exposed to a previously validated influenza challenge model with influenza A H3N2 strain (A/Perth/16/2009 H3N2).
89645799|NCT05324579|Experimental|Neurosurgical subjects|Subjects undergoing intracranial neurosurgical procedures
89044206|NCT02901288|Active Comparator|Control regimen group|"The control all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol during the intensive phase of treatment (2 months), followed by isoniazid and rifampin during the continuation phase (4 months).~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily).~."
89044207|NCT00448643|Experimental|Whole-Abdominal Radiation Therapy and Chemotherapy|
89645800|NCT05322213|Active Comparator|Active THC|Daily, inhaled, flexible dose of cannabis product with THC.
89645801|NCT05322213|Placebo Comparator|Placebo Cannabis|Daily, inhaled, flexible dose of cannabis product without THC.
89044208|NCT03276455|Experimental|Experimental|Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).
89044209|NCT02901327|Experimental|Lumbar Stabilisation Exercise|30 minute lumbar stabilization exercise, 3 times per week for 8 weeks.
89044210|NCT02901327|Active Comparator|Treadmill walk exercise|Walking exercise on a treadmill for a maximum of 30 minutes with increasing speed and inclination. 3 times/week for 8 weeks.
89044211|NCT03276416||150 children with concomitant asthma and rhinitis|Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry.
89044212|NCT05424393||RA Patients receiving routine treatment|During the induction phase, the dose of YISAIPU is 50mg/wk. Patients who achieved clinical remission or low activity after 24 weeks of induction treatment can enter the maintenance phase. Those who fail to succeed in induction treatment will not be followed up. During the maintenance phase, the dose of YISAIPU could be either 50mg/wk or 25mg/wk. Patients will be followed up regularly for 2.5 years.
89044213|NCT03276377||Exposed to VKA|VKA intake Patients who have been taking VKA for at least 3 months
89645802|NCT05321706|Active Comparator|Dapagliflozin|Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin (tablet) once daily for one year.
89044214|NCT03276377||Non-exposed to VKA|DOAC intake Patients who have been taking DOAC for at least 3 months
89044215|NCT05424354|Experimental|Transforming Powder Dressing|Half of the subjects will be randomized to Transforming Powder Dressing (TPD) to treat the burn wound(s). Subjects will be evaluated on Treatment Day 0, 3, 7, 10, 14, 21, and 28 (or sooner if the wound heals prior to end of study visit on Day 28). On each study visit, wound care will be performed. TPD will be applied directly on the burn wound, followed by another dressing (often called a secondary dressing).
89645803|NCT05321706|Placebo Comparator|Placebo|Participants will be randomized in a 1:1 fashion to receive a matching tablet once daily for one year.
89645804|NCT05313438|Experimental|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care.
89645805|NCT05306938|Experimental|Intervention|Adolescents in this arm will receive the Adolescent Wellness Visit intervention.
89645806|NCT05306938|No Intervention|Control|Adolescents in this arm will not receive the Adolescent Wellness Visit intervention.
89645807|NCT05298124|Experimental|Transcatheter edge-to-edge repair|The experimental arm includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support plus transcatheter edge-to-edge repair
89044216|NCT05424354|Active Comparator|Standard of Care Dressing|Half of the subjects will be randomized to Standard of Care (SOC) to treat the burn wound(s). Subjects will be evaluated on Treatment Day 0, 3, 7, 10, 14, 21, and 28 (or sooner if the wound heals prior to end of study visit on Day 28). On each study visit, wound care will be performed. The standard of care burn dressing will be applied directly on the burn wound, followed by another dressing (often called a secondary dressing).
89044217|NCT03276338|Experimental|Intervention|Participation in the HOLA intervention designed to prevention HIV
89044218|NCT03276338|No Intervention|Delayed-intervention|Delayed intervention with participation in HOLA intervention after follow-up data have been collected
89645808|NCT05298124|Active Comparator|Medical therapy|Medical therapy includes treatment in an intensive care unit with intravenous medications (e.g. vasopressors and inotropes), ventilatory support or mechanical circulatory support.
89645809|NCT05292222|Experimental|Intermittent theta burst stimulation|All subjects will receive treatment with intermittent theta burst stimulation (iTBS). There will be a total of 5 treatments over a 2-week period. All subjects will receive iTBS to the right TGd region. TBS treatment will also be provided for two additional sites within the large-scale brain networks (LSBNs) that is found to contain the greatest number of connectivity anomalies. Total participation will be 10-12 weeks.
89645810|NCT05289791|Experimental|ultrasonic activation of bioceramic sealer|ultrasonic activation of bioceramic sealer for 20 seconds
89645811|NCT05289791|Active Comparator|bioceramic sealer|bioceramic sealer
89645812|NCT05283928|Experimental|OsseoDensification (OD) protocol|
89645813|NCT05283928|Active Comparator|standard drilling (SD) protocol|
89645814|NCT05275855|Experimental|Part A: EDI048 or Placebo|Part A is a single ascending dose study
89645815|NCT05275855|Experimental|Part B: EDI048 or Placebo|Part B is a multiple ascending dose study
89645816|NCT05269667|Experimental|Cohort 1: treatment-naïve NMOSD patients|Patients will be treated with 120 mg satralizumab subcutaneously (SC) as monotherapy at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Week 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. All assessments (clinical, laboratory and imaging) should be performed before satralizumab administration. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
89645817|NCT05269667|Experimental|Cohort 2: NMOSD patients who are inadequate responders to previous treatment with RTX|Patients will be treated with 120 mg satralizumab subcutaneously (SC) as monotherapy at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Week 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. All assessments (clinical, laboratory and imaging) should be performed before satralizumab administration. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
89645818|NCT05267535|Experimental|Piromelatine 20 mg|Piromelatine 20 mg tablets once daily taken before going to bed, preferably between 2100h and 2300h, and after food consumption.
89645819|NCT05267535|Placebo Comparator|Placebo|Matched placebo tablets, with identical features to the piromelatine tablets, will be used as control treatment
89645820|NCT05258630|Experimental|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
89645821|NCT05258630|Active Comparator|Enhanced usual care|Brief diabetes educational session by a diabetes wellness coach.
89645822|NCT05253755|Active Comparator|DBI-001 Gel|"DBI-001 Gel: Topical application of DBI-001 gel on skin affected with atopic dermatitis.~(This study is a within-subject bilateral controlled study)"
89645823|NCT05253755|Placebo Comparator|Aqueous Gel|"Aqueous Gel: Topical application of aqueous gel on skin affected with atopic dermatitis.~(This study is a within-subject bilateral controlled study)"
89645824|NCT05247281|Active Comparator|Culture-based treatment|
89645825|NCT05247281|Active Comparator|Next Generation Sequencing (NGS) with Culture-based treatment|
89645826|NCT05246514|Experimental|T-DXd arm|Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle.
89645827|NCT05234658|Experimental|PHIT|Human artificial skin created by tissue engineering, composed of a sheet of autologous adult differentiated skin keratinocytes and fibroblasts expanded in a biological fibrin-agarose matrix (PHIT).
89645828|NCT05234658|Experimental|PHITAH|Human artificial skin created by tissue engineering, composed of a sheet of keratinocytes and differentiated autologous adult skin fibroblasts expanded in a biological fibrin-hyaluronic matrix (PHITAH).
89645829|NCT05234658|Active Comparator|Skin Autograft|Skin autograft.
89044219|NCT01219933|Experimental|1|
89044220|NCT05368441|Experimental|Midazolam-Group M|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room.
89044221|NCT05368441|Placebo Comparator|Control- Group S|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room.
89044222|NCT05657080||Cases|"This will include patients with:~existing diagnosis of proximal GIM undergoing endoscopic surveillance~a new diagnosis of proximal GIM requiring repeat endoscopy~a historical diagnosis of GIM retrieved from the pathology records through retrospective analysis and lost in follow up~gastric adenocarcinoma from upper GI multidisciplinary meeting."
89044223|NCT05657080||Controls|Controls will be patients with no known premalignant conditions of the upper GI tract and fit to undergo an upper endoscopy. They will be recruited via standard referral routes for upper GI endoscopy due to upper GI symptoms via standard referral routes. Individuals must be able to provide informed consent.
89044224|NCT02901015|Other|Schizophrenic patients group 1|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
89044225|NCT02901015|Other|Schizophrenic patients group 2|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
89044226|NCT04316845|Experimental|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT
89044227|NCT05423886|Experimental|Intervention arm|Participants receive a personalized screening invitation interval (1,2 or 3 years) based on their fecal Hemoglobin concentration of the negative fecal immunochemical test in previous round.
89645830|NCT05221385|Experimental|Experimental cohort|Gentulizumab monotherapy 0.1, 0.3, 1, 3, 10, 30, 45 mg/kg administered intravenously once every week.
89645831|NCT05218096|Experimental|ALXN2050: 180 mg|Participants will receive ALXN2050.
89645832|NCT05218096|Experimental|ALXN2050: 120 mg|Participants will receive ALXN2050.
89645833|NCT05218096|Placebo Comparator|Placebo|Participants will receive placebo followed by ALXN2050.
89645834|NCT05206877|Experimental|Low dose topical insulin|Group 1; N=6: 100 U/ml; 4 units of insulin per application, 1 drop done in clinic daily for 5 days
89645835|NCT05206877|Experimental|High dose topical insulin|Group 2; N=6: 500 U/ml; 20 units of insulin per application, 1 drop done in clinic daily for 5 days
89044228|NCT05423886|No Intervention|Control arm|Participants receive a standard screening invitation interval (2 years).
89044229|NCT01218802|Active Comparator|Rosuvastatin|Participants will take Rosuvastatin 10 mg. daily for 96 weeks
89044230|NCT01218802|Placebo Comparator|Sugar Pill placebo|Participants will take a placebo that appears on the exterior to be the same as active drug. They will take one capsule daily.
89044231|NCT00449267|Experimental|1|
89044232|NCT02887222|Active Comparator|PIEB volume of 7 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 7mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89044233|NCT02887222|Active Comparator|PIEB volume of 8 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 8mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89044234|NCT02887222|Active Comparator|PIEB volume of 9 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 9mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89645836|NCT05206877|Experimental|Longer-term topical insulin|Group 3 randomized; N=20: 10 subjects will receive the highest tolerated dose (e.g. from group 1 or group 2), 1 drop per day at home for 1 month, full testing pre- and post-treatment, and 10 subjects will receive 1/5 of the highest tolerated dose (either the lower dose, or if needed will dilute) 1 drop per day at home for 1 month, full testing pre- and post-treatment.
89645837|NCT05194358|Experimental|Cohort 1 SIAN|SIAN dose of 0.28 mg/kg (20 μL) will be administered from a single syringe-based spray device into left nostril.
89645838|NCT05194358|Experimental|Cohort 2 SIAN|SIAN dose of 0.73 mg/kg (50 μL) will be administered from a single syringe-based spray device into left nostril.
89645839|NCT05194358|Experimental|Cohort 3 SIAN|SIAN dose of 1.45 mg/kg (100 μL) will be administered from a single syringe-based spray device into left nostril.
89645840|NCT05194358|Experimental|Cohort 4 SIAN|SIAN dose of 2.18 mg/kg (150 μL) will be administered from a single syringe-based spray device into left nostril.
89645841|NCT05194358|Experimental|Cohort 5 SIAN|"SIAN dose of 2.90 mg/kg (200 μL) will be administered in two syringe-based spray devices, each containing 100 μL, with dose administered in left then right nostril, one device per nostril.~For doses of 2.90 milligram/kilogram (200 microliter) and higher, the dose will be split equally between the two nostrils to avoid drug overflow from the nose (using two syringe-based spray devices one immediately followed by the other). Lower doses will be administered by a single device to one nostril."
89645842|NCT05194358|Experimental|Cohort 6 SIAN|SIAN dose of 3.63 mg/kg (250 μL) will be administered in two syringe-based spray devices, each containing 125 μL, with dose administered in left then right nostril, one device per nostril.
89645843|NCT05194358|Experimental|Cohort 7 SIAN|SIAN dose of 4.35 mg/kg (300 μL) will be administered in two syringe-based spray devices, each containing 150 μL, with dose administered in left then right nostril, one device per nostril.
89645844|NCT05190588|No Intervention|Exercise|Quadriceps Strength 10 repetition in three-set, 5 times a week
89645845|NCT05190588|Active Comparator|Mesotherapy|Group 2: Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used. One time a week for a total of 3 times.
89645846|NCT05190549|Experimental|CAV Regimen Bridging to HSCT|
89645847|NCT05185180||Males with Category III Chronic Pelvic Pain Syndrome|Category III is subdivided into inflammatory (IIIa) and noninflammatory (IIIb) subtypes, based on the presence of white blood cells in expressed prostatic secretions (EPS). Category III prostatitis or chronic pelvic pain syndrome (CPPS) is the most common prostatitis observed in medical practice with a prevalence rate in the general population from 5% to 14.2%. CPPS is a poorly understood entity characterized by pelvic or perineal pain, irritative voiding symptoms, and sexual dysfunction.
89645848|NCT05185180||Control Group|The control group will consist of men with no history of Chronic Pelvic Pain or any underlying condition.
89645849|NCT05167227|No Intervention|Control|"The Control arm participates in monthly interactive webinars and quarterly short courses.~Monthly interactive webinars will offer brief didactic presentations by SMEs, examples of models of care, and a facilitated Q&A. These webinars will be convened to rapidly disseminate findings and emerging best practices to a large-scale, national audience.~Quarterly short courses will be developed to summarize key findings from past weekly teleECHO sessions. These quarterly short courses will be formatted as a learning module with the use of presentation slides and videos online that are accessible asynchronously."
89645850|NCT05167227|Experimental|Intervention|The Intervention arm participates in weekly teleECHO sessions with monthly interactive webinars and quarterly short courses.
89645851|NCT05166876|Experimental|Brequinar monotherapy|Brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met.
89645852|NCT05166876|Placebo Comparator|Placebo|Placebo matching brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met.
89645853|NCT05166876|Experimental|Brequinar-Dipyridamole Combination|Brequinar oral capsules will be administered once daily for 5 days using a dose-escalation approach. Planned doses include 50 mg, 100 mg, 150 mg, and 200 mg. Dosing will start at 50 mg and be escalated to the next higher dose if cohort stopping rules are not met. All subjects assigned to this arm will also receive dipyridamole 75 mg tablets TID.
89645854|NCT05161078||All Patients Enrolled|Patients will be treated with CARPEDIEM per standard of care.
89645855|NCT05159700|Experimental|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
89645856|NCT05144386|Experimental|EBT-101 Dose-Level 1|Cohort A: Participants will be administered dose-level 1 of EBT-101
89645857|NCT05144386|Experimental|EBT-101 Dose-Level 2|Cohort B: Participants will be administered dose-level 2 of EBT-101
89645858|NCT05144386|Experimental|EBT-101 Dose-Level 3|Cohort C: Participants will be administered dose-level 3 of EBT-101
89645859|NCT05143307|Experimental|Long Term Follow Up|Participants who received EBT-101 in a parent study will undergo long term follow up
89645860|NCT05126459|Active Comparator|Regimen 1|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration - Meperidine (1.5 -2 mg/kg) Oral administration - Midazolam (0.5- 0.75 mg/kg) Inhalation - Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2)
89645861|NCT05126459|Experimental|Regimen 2|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration- Meperidine (1.5 -2 mg/kg) Inhalation - Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) -
89645862|NCT05126459|Experimental|Regimen 3|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration - Midazolam (0.5- 0.75 mg/kg) Inhalation- Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2)
89645863|NCT05123118|Experimental|Integrated intervention|Integrated intervention of smoking cessation and breastfeeding
89645864|NCT05123118|Active Comparator|Attention placebo control group|Instructions on general pregnancy and infant care
89645865|NCT05120128|Experimental|TEST Lens|Eligible subjects who are habitual soft contact lens wearers will enter wearing their own lens, then given the TEST Lens for the remainder of the study.
89044235|NCT02887222|Active Comparator|PIEB volume of 10 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89044236|NCT02887222|Active Comparator|PIEB volume of 11 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 11mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89645866|NCT05114057|Other|PICU Patients|Prospectively enrolled patients admitted to the PICU will be assessed by the RAI calibration for sepsis in the PICU and including additional risk factors.
89645867|NCT05114057|Other|CICU Patients|Prospectively enrolled patients admitted to the CICU will be assessed by the RAI calibration specific to the CICU, especially post cardiac bypass
89645868|NCT05114057|Other|NICU Patients|Prospectively enrolled patients admitted to the NICU will be assessed by the RAI calibration for neonatal patients with sepsis or post abdominal surgeries
89645869|NCT05113771|Experimental|Liafensine 1mg|
89645870|NCT05113771|Experimental|Liafensine 2mg|
89645871|NCT05113771|Placebo Comparator|Placebo|
89645872|NCT05109195||MDD Participants with Insufficient Response to SSRI/SNRI (antidepressant)|Major Depressive Disorder (MDD) participants with insufficient response to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) (antidepressant) and starting an adjunctive therapy will be observed to create an external control arm (ECA) based on real world data (RWD) from electronic health records (EHR) data during routine medical care (standard of care [SOC]) combined with scheduled research assessments.
89645873|NCT05103475|Experimental|Rage Against the Pain (RAP)|The RAP program curriculum will mirror that of the Hatha Yoga classes, but will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the poses/movements (rather, poses will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the typical relaxation/meditation exercise used in yoga, referred to as savasana).
89645874|NCT05103475|Active Comparator|Treatment as Usual (i.e., yoga)|The 'treatment as usual' class will be conducted in the style of the yoga classes currently being offered to Veterans at the Hines VA Hospital, which is a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
89645875|NCT05100199|Placebo Comparator|Placebo|Placebo will be injected into the Glabellar Complex on Day 1.
89645876|NCT05100199|Experimental|OnabotulinumtoxinA X Dose A|OnabotulinumtoxinA X Dose A will be injected into the Glabellar Complex on Day 1.
89645877|NCT05100199|Experimental|OnabotulinumtoxinA X Dose B|OnabotulinumtoxinA X Dose B will be injected into the Glabellar Complex on Day 1.
89645878|NCT05100199|Experimental|OnabotulinumtoxinA X Dose C|OnabotulinumtoxinA X Dose C will be injected into the Glabellar Complex on Day 1.
89645879|NCT05096156|Experimental|All participants are fit with the study daily disposable lenses|All subjects are re-fit into their habitual monthly replacement contact lenses. Subjects are requested to wear the lenses for one week, for a minimum of at least 6 hours per day for 5 days. Upon return, subjects are refit into the daily disposable contact lenses.
89645880|NCT05081661|Experimental|Motor Imagery Group A|This group will follow a program of motor imagery.
89645881|NCT05081661|Placebo Comparator|Motor Imagery Group B|This group will follow a placebo program inspired from Bodyscan
89645882|NCT05080244|Experimental|Probiotics|Two probiotic strains will constitute the experimental arm (Probiotics). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
89645883|NCT05080244|Placebo Comparator|Placebo|Potato starch and magnesium stearate will constitute the comparator arm (Placebo). Participants will take two capsules per day (one closed capsule to swallow and one open capsule mixed with maple syrup) for 10 days and one closed capsule per day to swallow for the following 15 days. They will stop the treatment if they are admitted to the hospital. The treatment will last a maximum of 25 days.
89645884|NCT05080218|Experimental|Treatment Interruption - UPA|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
89645885|NCT05080218|No Intervention|Treatment Continuation|Treatment Continuation of All Immunomodulatory Therapy at the time of COVID Vaccine Booster
89645886|NCT05080218|Experimental|Treatment Interruption - ABA|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
89645887|NCT05080218|Experimental|Treatment Interruption - TOF|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
89645888|NCT05080218|Experimental|Treatment Interruption - SEC|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
89645889|NCT05080218|Experimental|Treatment Interruption - TNFi SQ|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
89645890|NCT05080218|Experimental|Treatment Interruption - CAN|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
89645891|NCT05080218|Experimental|Treatment Interruption - BAR|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
89645892|NCT05080218|Experimental|Treatment Interruption - IXE|Treatment Interruption of Immunomodulatory Therapy for 2 Weeks at the time of COVID Vaccine Booster
89645893|NCT05068843|Active Comparator|Arthroscopic partial meniscectomy|"In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy (APM) within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.~Other Names:~APM meniscal surgery surgery"
89044237|NCT02887222|Active Comparator|PIEB volume of 12 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 12mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89044238|NCT01218646|Experimental|Group 1: Investigational Quadrivalent Influenza Vaccine|Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
89044239|NCT01218646|Experimental|Group 2: Investigational Trivalent Influenza Vaccine|Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
89044240|NCT01218646|Active Comparator|Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
89044241|NCT01218646|Active Comparator|Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
89044242|NCT02901171|Experimental|Combined Treatment|ACT group treatment combined with smartphone application
89044243|NCT02901171|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT group treatment
89044244|NCT02901171|Active Comparator|Behavioural Support Programme|Group based Behavioural Support Programme
89645894|NCT05068843|Other|Physical therapy|The physical therapy program consisted of a physical therapist-led incremental exercise program containing of coordination/balance, closed kinetic chain strengths and cardiovascular exercises (see Appendix 1). The program was designed for 8 weeks with a total of 16 treatment sessions, each with a duration of 30 minutes. All 16 sessions were reimbursed. If knee symptoms persisted following the physical therapy program (e.g., knee pain, limitations in daily activities or mechanical dysfunction ), the patient could attend additional physical therapy sessions (not reimbursed by the study) or have meniscal surgery, depending on a shared decision after consultation with their orthopaedic surgeon.
89645895|NCT05065619|Experimental|MT-2766 High dose (3.75 µg)|
89645896|NCT05065619|Placebo Comparator|Placebo|
89645897|NCT05065619|Experimental|MT-2766 Low dose|
89645898|NCT05061862||CIED Indicated Subjects|Subjects indicated to receive a cardiac implantable electronic devices (CIEDs)
89645899|NCT05058911|Experimental|Internet-delivered exposure-based cognitive behavior therapy (Exp-CBT)|10-week self-help treatment delivered via a secure online platform, with regular therapist support.
89645900|NCT05058911|Active Comparator|Internet-delivered traditional cognitive behavior therapy (T-CBT)|10-week self-help treatment delivered via a secure online platform, with regular therapist support.
89645901|NCT05042102|Experimental|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
89645902|NCT05042102|Experimental|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
89645903|NCT05042102|Experimental|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
89645904|NCT05042102|Experimental|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
89645905|NCT05041101|Experimental|Treatment (grapiprant, eribulin mesylate)|Patients receive grapiprant PO BID on day 1-21 and eribulin mesylate IV over 5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89645906|NCT05039632|Experimental|Cohort I (NBTXR3, Abscopal, Anti PD-1 / PD-L1|COHORT I: Patients receive NBTXR3 intratumorally on day 1. Patients also receive ( anti-PD-1/L-1) intravenously (IV) on day 8. Beginning day 15, patients undergo Abscopal radiation therapy over 1-2 weeks. Cycles with ( anti-PD-1/L-1) repeat every 3-6 weeks per standard of care up to 2 years in the absence of disease progression or unacceptable toxicity.
89645907|NCT05039632|Experimental|Cohort II (NBTXR3, RadScopal, Anti PD-1 / PD-L1|COHORT II: Patients receive NBTXR3 intratumorally on day 1. Patients also receive ( anti-PD-1/L-1) IV on day 8. Beginning day 15, patients undergo RadScopal radiation therapy over 1-2 weeks. Cycles with ( anti-PD-1/L-1)repeat every 3-6 weeks per standard of care up to 2 years in the absence of disease progression or unacceptable toxicity.
89645908|NCT05029583|Experimental|routine screening group|consists of 4 clusters randomized into Group 1 (includes different clinic sites from Group 2)
89645909|NCT05029583|Active Comparator|physician-driven screening group|consists of 4 clusters randomized into Group 2 (includes different clinic sites from Group 1)
89645910|NCT05023161||Patient having a fetus with intra-uterine growth restriction diagnosis below the 3rd percentile|
89645911|NCT05019131|Experimental|Intervention arm|"Training: The investigators will develop a training for providers that addresses the following topics: Stress & positive coping mechanisms; Unconscious bias awareness and mitigation; Person-centered maternity care; Dealing with difficult situations; and Teamwork and communication;~Peer support and mentorship: The investigators will identify what works best for these groups in terms of group composition, size, and how the groups want to interact.~Leadership engagement: To ensure leadership buy in, support and sustainability of the intervention, the investigators will engage leadership of the County.~Embedded champions: To facilitate ongoing engagement, the investigators will identify local leaders, and invite them to training where they will be taught how to facilitate peer support groups and serve as champions."
89645912|NCT05019131|No Intervention|Control arm|Will not receive any training during the intervention period
89645913|NCT05011825|Experimental|Pregnant Moms' Empowerment Program|The PMEP is a 5-session program, delivered prenatally. The first three sessions address violence and mental health and the final two sessions address labor/delivery, infant health and early parenting.
89044245|NCT02900937|Experimental|Coronary Scaffold Implantation|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
89044246|NCT05423847||Benin1|Benin urban recruitment site National teaching hospital for tuberculosis, outpatient emergency department
89044247|NCT05423847||Mali1|Mali urban recruitment site University Hospital Bamako, outpatient emergency department
89044248|NCT05423847||South-Africa1|South-Africa rural recruitment site 1 Tintswalo hospital, outpatient emergency department
89044249|NCT05423847||South-Africa2|South-Africa rural recruitment site 2 Zithulele hospital, outpatient emergency department
89044250|NCT03276299|Active Comparator|test 1|six minute walking test
89044251|NCT03276299|Experimental|test 2|six minute walking test
89044252|NCT03276299|Experimental|test with encouragement|six minute walking test
89645914|NCT05011825|No Intervention|Control|Control group participants received information about community resources, but did not receive any study-related intervention.
89044253|NCT03276299|Active Comparator|test without encouragement|six minute walking test
89044254|NCT04680078|Active Comparator|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop. The sutures are removed 1 week after the surgery.
89044255|NCT04680078|Active Comparator|Conventional Triangular Three-snip Punctoplasty of the lower punctum|After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop.
89044256|NCT02900820|Experimental|Novel intervention group|Discontinuing antibiotic therapy.
89044257|NCT02900820|Experimental|Usual intervention group|Usual strategy of continuing antibiotic treatment.
89044258|NCT03276182|Experimental|cataract patients|cataract patients undergoing phacoemulsification
89645915|NCT05005689|Active Comparator|Mouthwash|Fluoride mouthwash (0.05%; 225ppm) 10ml for 1 minute daily
89645916|NCT05005689|Experimental|Tooth Mousse|"Tooth Mousse Plus (Recaldent™ CPP-ACP [casein phosphopeptide (CPP)-amorphous calcium phosphate (ACP)] and Sodium Fluoride 0.2% w/w; 900 ppm).~Tooth creme; 2ml smear daily"
89645917|NCT05004129|Experimental|Tideglusib|Weight adjusted tideglusib, orally, once daily
89044259|NCT01188772|Experimental|Sofosbuvir 200 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 200 mg (2 x 100 mg tablets)+placebo to match sofosbuvir (2 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
89044260|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
89044261|NCT01188772|Active Comparator|Placebo (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive placebo to match sofosbuvir (4 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
89044262|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 2/3)|Participants with genotype 2 or 3 HCV infection received sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks.
89044263|NCT04679883|Experimental|GLH8NDE 5% and GLH8NDE Placebo|Three times each 1 drop a day, total 6 times 1 drop of GLH8NDE 5% and GLH8NDE Placebo
89044264|NCT04679883|Experimental|GLH8NDE 5%|Total 6 times 1 drop of GLH8NDE 5%
89044265|NCT04679883|Placebo Comparator|GLH8NDE Placebo|Total 6 times 1 drop of GLH8NDE Placebo
89044266|NCT01188655||Treatment Group Enbrel|
89044267|NCT02900703||PATIENT|
89044268|NCT00449618|Active Comparator|1|Aspirin 100 mg on awakening
89044269|NCT00449618|Active Comparator|2|Aspirin 100 mg at bedtime
89044270|NCT00449618|Placebo Comparator|3|Placebo on awakening
89044271|NCT00449618|Placebo Comparator|4|Placebo at bedtime
89645918|NCT05000541||Armolipid-L/Armolipid Plus-L|Armolipid-L used for participants in Germany and Poland Armolipid Plus-L used for participants in Austria
89645919|NCT04998916|Experimental|Real TBS to the mPFC|For continuous theta burst stimulation (cTBS), participants will receive 3 sessions of stimulation per visit over the left medial prefrontal cortex (mPFC) (each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec, 600 pulses/session, 60 sec intertrain interval; 120% RMT, MagPro; 10-15 min inter session interval) using a figure 8 coil (Coil Cool-B65 A/P).
89645920|NCT04998916|Sham Comparator|Sham TBS to the mPFC|The MagVenture MagPro system has an integrated, active sham which passes current through two surface electrodes placed on the scalp. The electrodes will be placed on the left frontalis muscle for all sessions. A patient identification card will randomize participants to receive either real or sham stimulation. This system maintains blinding by a gyroscope in the coil which indicates to the clinical staff whether the coil should be rotated up or down for this participant once the card is entered into the machine. One side of the coil is active, the other is sham. The integrity of the double-blind procedure will be assessed by asking the patients and study personnel rate their confidence regarding whether they thought they received real or sham (scale 1-10).
89645921|NCT04998344|Experimental|Inactivated influenza vaccine group|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
89645922|NCT04998344|Active Comparator|Inactivated polio vaccine group|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
89044272|NCT01188538|Experimental|Epiduo gel|"Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
89645923|NCT04997473|Experimental|App Group|Participants will be receiving an addiction model based mobile health (mHealth) weight loss intervention with coaching for a total of 4 months duration
89645924|NCT04996498|Active Comparator|Group A (Oxytocin group):|30 women will undergo a hysteroscopic myomectomy with the use of 10 IU of oxytocin for every 1000 ml of the distending medium (1,5% Glycine ).
89645925|NCT04996498|Placebo Comparator|Group B (Placebo group):|30 women will undergo hysteroscopic myomectomy with the use of a sterile bacteriostatic water ampule in the distending medium (1,5% glycine).
89645926|NCT04995081|Active Comparator|Allogeneic HB-adMSCs.|"Biological/Vaccine: Allogeneic HB-adMSCs~Allogeneic HB-adMSCs will be administered intravenously to study participants who qualify.~Other Names: Allogeneic Hope Biosciences adipose derived mesenchymal stem cells."
89645927|NCT04995081|Placebo Comparator|Placebo|"Placebo will be administered intravenously to study participants who qualify.~Other Names: Sterile Saline Solution 0.9%"
89645928|NCT04992520|Experimental|Group 1A: S. sonnei 53G|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
89645929|NCT04992520|Experimental|Group 1B: S. flexneri 2a 2457T|"At least 3 months after challenging Group 1A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
89044273|NCT01188538|Active Comparator|BPO gel|"Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
89044274|NCT04316767|Experimental|App Intervention|Participants will download a mobile self-care app on their smartphones. The app guides users through exercises based on cognitive behavioral therapy principles. Participants will be able to use the app as frequently as desired throughout the course of the study.
89044275|NCT04316767|No Intervention|Control|Participants will receive usual supportive care provided to family members of ICU patients.
89645930|NCT04992520|Experimental|Group 2A: S. flexneri 2a 2457T (1500 cfu)|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
89645931|NCT04992520|Experimental|Group 2B: S. sonnei 53G|"At least 3 months after challenging Group 2A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
89645932|NCT04987372|No Intervention|Classical protocol|"Fentanyl Max. 15µg/kg IV Per-operative~Ultiva (Remifentanyl) 0.02-0.1µg/kg/h IV Post-operative~Paracetamol 4x1g /24h IV Post-operative~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in cas of break through pain~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
89645933|NCT04987372|Active Comparator|Multimodal protocol|"Lyrica (Pregabalin) 75mg PO 2 hours before the operation~Dexdor (Dexmedetomidine) 0.8µg/kg/h IV Per-operative / Post-operative~Ketalar (Ketamine) Bolus (0.5mg/kg) + 0.3mg/kg/h IV Per-operative until stop propofol~Linisol (Lidocain) Bolus (1.5mg/kg) + 1.3mg/kg/h IV Per-operatiive until 12h post-op~Magnesium Sulphate Induction (25mg/kg) + 25mg/kg weaning ECC IV Per-operative~Fentanyl 2.5µg/kg IV Per-operative~Paracetamol 4x1g /24u IV Post-operative~Tradonal (Tramadol) 100mg IV 4/d IV Post-operative in case of Break through pain~Oxynorm (Oxycodon) 5-10mg 4-6/d PO Post-operative in case of Break through pain"
89645934|NCT04977375|Experimental|Pembrolizumab with stereotactic radiation therapy and surgical resection|
89645935|NCT04977024|Experimental|Arm I (GEO-CM04S1)|Patients receive one dose of GEO-CM04S1 IM in the upper arm on days 0 and 28.
89645936|NCT04977024|Experimental|Arm II (SOC mRNA SARS-CoV-2 vaccine)|Patients receive one dose of SOC mRNA SARS-CoV-2 vaccine IM in the upper arm on days 0 and 28.
89645937|NCT04974671|Experimental|Stereotactic Body Radiation Therapy|
89044276|NCT04318444|Experimental|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
89044277|NCT04318444|Placebo Comparator|Placebo|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
89044278|NCT02900898|Experimental|Dynamic exercise and Mediterranean diet|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part.~MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation."
89044279|NCT02900898|Experimental|Dynamic exercise|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part."
89645938|NCT04968548||Cases Series|Subjects with confirmed lung cancer diagnosis
89645939|NCT04968548||Screening Series|Subjects undergoing LDCT for lung cancer screening
89645940|NCT04947254|Active Comparator|Group A (Apa, ADT, XRT)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
89645941|NCT04947254|Experimental|Group B (Apa, ADT, XRT, AAP, niraparib)|"PART 1 NEOADJUVANT PHASE (CYCLES 1-3): Patients receive PO QD on days 1-28, and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 2 RADIATION PHASE (CYCLES 4-6): Within 30 days of completing Part 1, patients undergo radiation therapy. Patients also receive apalutamide PO QD on days 1-28 and physician's choice ADT. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~PART 3 ADJUVANT PHASE (CYCLES 7 AND BEYOND): Patients receive abiraterone acetate PO QD, prednisone PO BID, physician's choice ADT, and niraparib PO QD. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
89645942|NCT04942353|Experimental|Home-based Exercise Rehabilitation|
89218001|NCT03878914|Experimental|Quick responders (Group A)|"Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.~CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group A (Total duration of therapy 8 weeks)~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 2 weeks~40mg/m2 or 1.5mg (maximum 40mg) every other day for 2 weeks.~Wean off in 4 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
89645943|NCT04942353|Active Comparator|Usual Care|
89645944|NCT04939701|Experimental|Phase 1 ASP0739 Monotherapy Dose Escalation|Participants with R/R solid tumors known to express NY-ESO-1 will receive ASP0739 on day 1 of each 28-day cycle for up to 6 doses, to determine the Recommended Phase 2 Dose (RP2D).
89645945|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Safety Lead-in|Participants with R/R SS, MRCL or ovarian cancer will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses in combination with pembrolizumab on Cycle 1 Day 1, and then every 6 weeks up to 4 doses during the treatment period to determine the RP2D of ASP0739 with pembrolizumab. A total of 17 doses of pembrolizumab may be available for qualifying participants.
89645946|NCT04939701|Experimental|Phase 2 ASP0739 Monotherapy Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer and other solid tumors known to express NY-ESO-1 (melanoma, NSCLC-adenocarcinoma, squamous cell, and ESCC) will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses.
89645947|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer will receive RP2D of ASP0739 with pembrolizumab on day 1 of each 28-day cycle for up to 6 doses, in combination with 4 doses of pembrolizumab administered on cycle 1 day 1, and then every 6 weeks during the treatment period. A total of 17 doses of pembrolizumab may be available for qualifying participants.
89645948|NCT04937868||Blunt trauma patients undergoing abdominopelvic computed tomographic imaging|"The study will be observational and not alter the care or management of blunt injury victims. Medical decisions will be made by treating physicians using current standards of care. Thus, to reduce the potential for bias, the study will seek to enroll all blunt injury victims who undergo A/P imaging as part of their ED trauma evaluation. This may include children, the elderly, all races, both sexes, and any other demographic or social groups that may present among blunt injury patients. An individual will become eligible for the study when the treating physician determines that A/P CT imaging is needed for their trauma evaluation. Inclusion or exclusion will not be based on age, gender, pregnancy or child-bearing potential, or racial/ethnic origin.~There will be no exclusion criteria."
89645949|NCT04925817|Experimental|Diagnostic (ultrasound microvessel imaging)|Patients undergo 3 D ultrasound microvessel imaging over 45 minutes. Patients' medical records are reviewed.
89645950|NCT04917055|Active Comparator|Active Treatment|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus distal iPACK (between femoral condyles) single shot with long acting local anesthetic (ropivacaine) plus dexamethasone
89645951|NCT04917055|Placebo Comparator|Placebo|Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus iPACK single shot with normal saline
89645952|NCT04911907|Experimental|Squamous cell carcinoma of head and neck: Utidelone Injection|Cohort 1 Squamous cell carcinoma of head and neck. Participants will be treated with utidelone monotherapy
89645953|NCT04911907|Experimental|Esophageal cancer: Utidelone injection|Cohort 2 Esophageal cancer. Participants will be treated with utidelone monotherapy.
89645954|NCT04911907|Experimental|Stomach cancer: Utidelone injection|Cohort 3 Stomach cancer. Participants will be treated with utidelone monotherapy.
89645955|NCT04911907|Experimental|Pancreatic cancer: Utidelone Injection|Cohort4 Pancreatic cancer. Participants will be treated with Utidelone monotherapy.
89645956|NCT04911907|Experimental|Ovarian cancer: Utidelone Injection|Cohort5 Ovarian cancer. Participants will be treated with Utidelone monotherapy.
89645957|NCT04911907|Experimental|Cholangiocarcinoma: Utidelone|Cohort 6 Cholangiocarcinoma. Participants will be treated with Utidelone monotherapy
89645958|NCT04911907|Experimental|Other solid tumors: Utidelone Injection|Cohort 7 Other solid tumors. Participants will be treated with Utidelone monotherapy
89645959|NCT04909801|Experimental|Arm 1: Abatacept + Methotrexate|
89645960|NCT04909801|Experimental|Arm 2: (Adalimumab + Methotrexate) followed by (Abatacept + Methotrexate)|
89645961|NCT04889144|Experimental|Arm I (PLAN intervention)|Patients participate in PLAN intervention, consisting of 3 coaching sessions over 45-60 minutes each with a health coach.
89645962|NCT04889144|Active Comparator|Arm II (Best practice)|Patients receive usual care.
89645963|NCT04877821|Experimental|Sintilimab + Anlotinib + Chemotherapy|Experimental: Sintilimab + Anlotinib + Chemotherapy Participants receive Sintilimab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + (Nab paclitaxel weekly + carboplatin (Q3W) x 4 cycles followed by epirubicin + cyclophosphamide Q3W x 4 cycles) as neoadjuvant therapy prior to surgery. After surgery, the subjects will continue to receive sintilimab treatment until one year has elapsed since the start of neoadjuvant therapy (that is, they will receive sintilimab treatment at least 17 times).
89645964|NCT04873037|Active Comparator|Emsella Chair Active Treatment|Active subjects will be asked to sit on the center of the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the reminder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
89044280|NCT02900898|Experimental|Mediterranean diet|MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation.
89044281|NCT02900898|Active Comparator|Control|This group will not carry out interventions.
89044282|NCT03276143|Active Comparator|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
89044283|NCT03276143|Active Comparator|Apixaban|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
89044284|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
89044285|NCT03276143|Experimental|BAY1213790 0.6 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
89645965|NCT04873037|Placebo Comparator|Emsella Chair Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (less than 10% power).
89645966|NCT04861896|Experimental|"My Guide (psychoeducation & self management program)"|Smartphone-based program plus standard clinical care.
89645967|NCT04858529|Experimental|THP|
89645968|NCT04858529|Active Comparator|TCHP|
89044286|NCT03276143|Experimental|BAY1213790 1.2 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
89044287|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
89044288|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
89044289|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.
89044290|NCT01188343|Experimental|Group 1|Participants will receive the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0 and Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 42
89044291|NCT01188343|Experimental|Group 2|Participants will receive Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 0, and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 42.
89044292|NCT01188343|Experimental|Group 3|Participants will receive the Measles, mumps, and rubella live attenuated virus vaccine (MMR) and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0
89044293|NCT00449774|Experimental|Subjects in Treatment regimen C|Subjects in treatment regimen C will receive 200 milligram (mg) orally disintegrating tablets (ODT) of lamotrigine disintegrate in mouth without water in fasting condition.
89044294|NCT00449774|Experimental|Subjects in Treatment regimen D|Subjects in treatment regimen D will receive 200 mg Immediate Release (IR) tablets of lamotrigine with water in fasting condition.
89044295|NCT00449774|Experimental|Subjects in Treatment regimen E|Subjects in treatment regimen E will receive 200 mg ODT disintegrate of lamotrigine in mouth without water in fed state.
89044296|NCT00449774|Experimental|Subjects in Treatment regimen F|Subjects in treatment regimen F will receive 200 mg ODT of lamotrigine, that subjects will swallow with water in fasting condition.
89044297|NCT02900742|Experimental|TCM granules plus Chemotherapy|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day until progression or unacceptable toxicity; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
89044298|NCT02900742|Placebo Comparator|Placebo granules plus Chemotherapy|Placebo granules: oral granules, oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
89044299|NCT00449813|Active Comparator|1.|40 mg Pantoprazole
89044300|NCT01188226|Experimental|Nano Hybrid Composite Denture teeth|Denture teeth are made of nano hybrid composite material
89044301|NCT05423067|Other|BUAO|"The study done in two phases:~Phase one from October 2011to May 2012 pilot study including twenty nine (29) premenopausal patients followed up for six months~Phase two from October 2012 till May 2014. Including Eighty nine (89) premenopausal patients"
89044302|NCT01218100|Experimental|1|Combination group - starting dose level nebivolol 5mg and lisinopril 10mg
89044303|NCT01218100|Active Comparator|2|Nebivolol monotherapy group - starting dose level nebivolol 5mg
89645969|NCT04857606|Experimental|AMG 609|Up to 7 cohorts ranging by various dose levels.
89645970|NCT04857606|Experimental|Placebo|Participants will receive the matching placebo.
89044304|NCT01218100|Active Comparator|3|Lisinopril monotherapy group - starting dose level lisinopril 10mg
89044305|NCT01218100|Placebo Comparator|4|Placebo group - starting dose is placebo
89044306|NCT02900508|Experimental|Exergaming training|Participants in the exergaming training group received a 4-week exergaming intervention.
89645971|NCT04855136|Experimental|Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone)|bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered at different doses and/ or schedules, depending on dose limiting toxicity (DLT) evaluation.
89044307|NCT02900508|Active Comparator|Control training|Participants in the control training group received a 4-week conventional training.
89044308|NCT02900196|Experimental|1 - Test|
89044309|NCT02900196|Placebo Comparator|2 - Placebo|
89645972|NCT04855136|Experimental|Arm B- bb2121 in combination with BMS-986405 (JSMD194)|"bb2121 will be administered at a target dose of 450 x 10^6 CAR+T cells. The combination agent will be administered during Month 1 starting from the day of bb2121 infusion~Enrollment is closed for this Arm"
89044310|NCT02900313|Other|Patients having cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
89044311|NCT00449852|Experimental|Interactive Voice Response Group|
89044312|NCT00449852|No Intervention|Usual Care Group|
89044313|NCT04681209|Experimental|DRT-Condition|This is the experimental group that engaged in the DRT-based intervention activity.
89044314|NCT04681209|Active Comparator|Empathy-Condition|This is the experimental group that engaged in the empathy-based intervention activity.
89044315|NCT02900235|Experimental|MT-3995|[14C]-MT-3995 after a single oral dose
89645973|NCT04823884|Active Comparator|open distal chevron osteotomy|Hallux valgus correction is provided by using the traditional open distal v-shaped chevron osteotomy.
89645974|NCT04823884|Active Comparator|minimally invasive distal chevron osteotomy|Hallux valgus correction is provided by using a minimally invasive distal v-shaped chevron osteotomy.
89645975|NCT04821830||Parkinson's disease patients who take levo-dopa as standard of care|Participants will undergo evaluation of the relationship between the LDR and movement vigor. All participants will undergo standard evaluation with standard clinical rating scales and three outcome measures: Tapping Speed Task - Measurement of Bradykinesia; Grip Strength Task - Measurement of Incentive-Outcome Coupling - Movement Vigor; Joystick Movement Task - Measurement of Incentive-Outcome Coupling - Movement Vigor. Some participants may opt in to an additional training and evaluation: Value Driven Attentional Oculomotor Capture.
89645976|NCT04802187|Other|RADx CHCs testing intervention strategy|Six Massachusetts community health center partnerships implementing both a common testing expansion implementation strategy plus tailored strategies designed for community partner needs.
89645977|NCT04802187|Other|Usual care control|
89645978|NCT04795648|Experimental|Spatial Repellent|Transfluthrin
89645979|NCT04795648|Placebo Comparator|Placebo|Inert ingredients
89645980|NCT04793035|Experimental|Enrolled patients|Single-arm study for enrolled GERD patients to be treated with an Omega-Cuff device
89645981|NCT04787848|Experimental|HIV negative without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
89645982|NCT04787848|Experimental|HIV negative with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
89044316|NCT00449969|Experimental|1. Extended feedback|
89044317|NCT00449969|Active Comparator|2. Limited feedback|
89044318|NCT00450008|Other|A|Combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA
89044319|NCT02900469|Experimental|Denosumab & surgery|"denosumab: 120 mg subcutaneous injection~Surgery: 2-4 weeks after denosumab"
89044320|NCT00450086|Experimental|A|
89044321|NCT00450086|Experimental|B|
89044322|NCT00450086|Placebo Comparator|C|
89044323|NCT05422911|Active Comparator|Abiraterone Acetate|
89044324|NCT05422911|Active Comparator|Standard of Care|
89044325|NCT00450125||Six-Minute Walk Test|Two Six-minute walk tests where total distance walked measured. Tests performed within 15 days of an exercise stress test.
89044326|NCT02900430||Patients without antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.
89044327|NCT02900430||Patients with antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.
89044328|NCT05422833||Before|"Children and adults with FD/MAS who visited at least once in our center (outpatient and hospitalized patients).~and with the first visit in the center included between 1996 and 2006 - before certification of our center."
89044329|NCT05422833||After|"Children and adults with FD/MAS who visited at least once in our center (outpatient and hospitalized patients).~and with the first visit in the center included between 2007 and 2019 - after certification of our center."
89044330|NCT02900040||patients with kidney transplantations|patients with kidney transplantations
89044331|NCT00450203|Experimental|ECX + Bevacizumab|ECX + Bevacizumab
89044332|NCT00450203|Active Comparator|Epirubicin, Cisplatin and Capecitabine|ECX chemotherapy
89044333|NCT00450203|Experimental|ECX + Lapatinib|ECX + Lapatinib
89044334|NCT05422677||single arm, single group(No interventional)|Observational
89044335|NCT00450281||Male, Never-smokers|Male subjects who smoked less than 100 cigarettes during their lifetime.
89044336|NCT00450281||Male, Ever-smokers|Male subjects who have smoked at least 100 cigarettes during their lifetime.
89044337|NCT00450281||Female, Ever-smokers|Female subjects who have smoked less than 100 cigarettes during their lifetime.
89044338|NCT00450281||Female, Never-smokers|Female subjects who have smoked at least 100 cigarettes during their lifetime.
89645983|NCT04787848|Experimental|HIV positive without chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
89645984|NCT04787848|Experimental|HIV positive with chronic widespread pain|50 Participants will be randomly administered saline or RELISTOR (Individuals weighing 38-<62 kg will receive an 8 mg dose; those weighing 62-114 kg will receive a 12 mg dose; Participants weighing more than 114 kg will receive 0.15 mg/kg) in counterbalance between visit 1 and visit 2.
89645985|NCT04787731|Active Comparator|Lidocaine|Lidocaine HCI (1.7mL) 2% concentration with epinephrine (1:100,000) is the control agent. It exists in liquid form in cartridges. Lidocaine is a FDA approved marketed anesthetic drug.
89645986|NCT04787731|Active Comparator|Bupivacaine|Bupivacaine HCI (1.8mL) 5% concentration, with epinephrine (1:200,000) is the investigational product. It exists in liquid form in cartridges. Bupivacaine is a FDA approved marketed anesthetic drug and meets IND Exemption.
89044339|NCT02900118||Group 1|Patients with breast cancer bone metastasis at the initial diagnosis.
89044340|NCT02900118||Group 2|Patients with breast cancer bone metastasis in a metastatic bone relapse.
89044341|NCT02900118||Group 3|Patients with breast cancer bone metastasis with a progression of bone metastasis.
89044342|NCT04699097||azytromycin|children who recieved azithromycin due to COVID 19 infection
89044343|NCT02900001|Active Comparator|Early invasive strategy|Patients undergo coronary angiography within 24 hours after admission and have percutaneous coronary intervention or coronary artery bypass grafting as soon as possible during the index hospitalization if appropriate.
89044344|NCT02900001|Experimental|Deferred invasive strategy|Patients undergo coronary angiography and appropriate revascularization after at lest 72 hours from admission in the index hospitalization.
89044345|NCT02899923||Autoimmune bullous dermatoses|Patients with autoimmune bullous dermatoses
89044346|NCT00450320|Active Comparator|Rapamycin|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen.
89044347|NCT05421234|Active Comparator|infertile men with post-COVID-19 (vaccinated or without vaccination)|15 infertile men with post-COVID-19 (vaccinated or without vaccination)
89044348|NCT05421234|Active Comparator|infertile men without post-COVID-19 (vaccinated or without vaccination)|15 infertile men without post-COVID-19 (vaccinated or without vaccination)
89044349|NCT05421234|Active Comparator|Control: 15 healthy men volunteers (no COVID-19, no other pathologies)|15 healthy men volunteers (no COVID-19, no other pathologies) as control group
89044350|NCT00450398|Experimental|1|YSPSL (rPSGL-Ig)
89044351|NCT00450398|Placebo Comparator|2|
89044352|NCT05421195|Experimental|Glucocorticoid therapy with olfactory training|olfactory training plus oral Glucocorticoid
89044353|NCT05421195|Other|Olfactory training|Olfactory training only
89044354|NCT00450515|Experimental|vinflunine + capecitabine|"Patients receive vinflunine IV over 20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed periodically for up to 5 years."
89044355|NCT02899845|Experimental|elderly people with walking difficulties|subjects with proven gait disturbance and balance will be recruited from a walking speed test and a standardized geriatric assessment by a geriatrician
89044356|NCT02899845|Active Comparator|elderly people without walking difficulties|subjects with no gait disturbance and balance disorders will be recruited from a walking speed test and a standardized geriatric assessment, once the subjects with gait disturbance and balance disorders have been recruited in order to make a match on the age criterion
89044357|NCT03276104|Active Comparator|IOL repositioning group|
89044358|NCT03276104|Active Comparator|IOL exchange group|
89645987|NCT04787523||Patients with pathological response to treatment|Response evaluated using the pathology report
89645988|NCT04783168|Active Comparator|Arm I (usual care)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting.
89645989|NCT04783168|Active Comparator|Arm II (usual care, Fitbit)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and early ambulation in the postoperative setting. Patients also receive a Fitbit to monitor step count
89044359|NCT03275987|Experimental|Mammography treatment|Mammography direct mail coupled with a financial incentive
89044360|NCT03275987|Active Comparator|Mammography control/delayed intervention|Usual care (for 15 months); Mammography direct mail coupled with financial incentive (after 15 months)
89044361|NCT03275987|Experimental|Colonoscopy treatment|Colonoscopy direct mail coupled with a financial incentive
89044362|NCT03275987|Active Comparator|Colonoscopy control/delayed intervention|Usual care (for 15 months); Colonoscopy direct mail coupled with financial incentive (after 15 months)
89044363|NCT02956850|Experimental|Part I: SAD in Healthy Volunteers|Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 milligrams (mg), 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, and 170 mg.
89044364|NCT02956850|Experimental|Part I: MAD in Healthy Volunteers|Healthy volunteers will receive RO7020531 (100 mg, 140 mg, and 170 mg as selected based on safety, pharmacokinetic (PK) and pharmacodynamic (PD) data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.
89044365|NCT02956850|Experimental|Part II: CHB Participants|CHB participants will receive RO7020531 (150 mg and 170 mg as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41, unless in Cohort 4 in case of once a week (QW) dosing as dose modification.
89044366|NCT04699019||Active Runners|All participants will be required to run unshod for a combination of four prescribed speeds (walking and up to 9 mph) and three different foot strike patterns (rearfoot, midfoot, and forefoot) on level ground.
89044367|NCT04698863||high flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 4 L/min for Group High flow rate.
89645990|NCT04783168|Experimental|Arm III (usual care, Fitbit, Fitbit app)|Patients receive usual care consisting of the clinician educating the patient on the importance of increasing exercise activity in the preoperative period and walking in the postoperative setting. Patients also receive a Fitbit device, install and use the Fitbit app on a smartphone. Postoperative step goals are as follows: Postoperative day (POD) 1: 25% of baseline. Subsequent days will be increased by 10% until patient reaches baseline daily step number. Five automatic daily reminders (delivered by the Fitbit Inspire HR^TM device itself) to meet a minimum of 250 steps an hour. Postoperatively, patients will be invited to participate in a private group with a leaderboard that consists of step numbers of other participants in the study in an anonymous fashion.
89645991|NCT04767347|Experimental|Fixed Work Rate|Participants will walk on a treadmill at 3 mph and the grade will be adjusted to elicit 430 W of metabolic heat production (the most common work intensity). This study will systematically examine the NIOSH recommendations for prescribing work-to-rest ratios with increasing environmental heat stress (defined as Wet Bulb Globe Temperature, WBGT) at this fixed rate of metabolic heat production on kidney function.
89645992|NCT04767347|Experimental|Fixed work-to-rest ratio|This study will systematically examine the NIOSH recommendations on changes in kidney function when the work-to-rest ratio is fixed at 30 min per hour (the most commonly prescribed work-to-rest ratio), but the rate of metabolic heat production and environmental heat stress differs (Figure 2). As described in Study 1, the appropriate rate of metabolic heat production will be elicited by having participants walk on a treadmill at 3 mph and the grade will be adjusted accordingly.
89645993|NCT04766879|Experimental|Spatial Repellent|Transfluthrin
89645994|NCT04766879|Placebo Comparator|Placebo|Inert ingredients
89645995|NCT04745910|Experimental|Treatment (pegloticase)|Patients receive pegloticase IV over 120 minutes. Patients whose serum uric acid does not drop below 6 mg/dL within 24 hours receive a second dose of pegloticase IV over 120 minutes on day 2. Patients whose serum uric acid does not drop below 6 mg/dL after two doses of pegloticase receive standard of care rasburicase IV QD for 5 days.
89645996|NCT04742361|Experimental|[18F]PSMA-1007|single intravenous administration of [18F]PSMA-1007 for Positron Emission Tomography (PET) scan
89645997|NCT04740034|Experimental|Dose Escalation|Sequential dose escalation cohorts are planned until maximum tolerated dose (MTD) is reached or recommended phase 2 dose (RP2D) is identified.
89645998|NCT04740034|Experimental|Dose Expansion|An expansion cohort in subjects with mCRPC will be enrolled after RP2D is established.
89645999|NCT04728087|Experimental|ACCEL|Participant will be treated with up to 2 bellows (10 grams nominal) of ACCEL®.
89646000|NCT04728087|Active Comparator|Gelfoam or SURGIFOAM|Participant will be treated with up to 12.5 cm x 8.0 cm of Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01) or SURGIFOAM® (Absorbable Gelatin Sponge, Manufacturer Part Number ETH1974).
89044368|NCT04698863||low flow rate|After intubation, patients had fresh gas flow with 50% O2/50% air for the first 10 minutes (3/3 L/min) and 6% desflurane. Then the flow rate was set to 1 L/min for Group Low flow rate.
89044369|NCT02899806|Placebo Comparator|Paper|Information about epidural analgesia by oral and paper sheep given by anesthesist in programed consultation
89044370|NCT02899806|Experimental|Video|Video information in addition to oral and written information gave by anesthesist in programed consultation
89044371|NCT05419713|Experimental|Visual scences|Lit target locations in visual environment will be varied and subjects' perceived locations will be measured.
89044372|NCT05419167|Experimental|STEP-COVID|Participants will participate online to the 6 sessions of the program addressing the psychological experience of pregnancy and supporting reflective capacities.
89044373|NCT05419167|No Intervention|Usual prenatal cares|Participants of the comparison group will receive usual prenatal cares (ex. prenatal classes)
89044374|NCT00450827|Experimental|Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab|Patients will be administered a therapeutic doses of intravenous (IV) 131I-3F8 given in a single dose per the dose escalation regimen on day 0 of study. This will be followed by blood draws for pharmacokinetic and dosimetry studies and by gamma camera scan, where feasible. Bevacizumab will be administered at a fixed dose of 15mg/kg on days 1 and 15. Thyroid protection is commenced 10 days prior to administration of 131I-3F8 and continued for 28 days after the therapeutic dose of 131I-3F8. ASCR will be carried out if ANC < 500/ul on day 28 (blood radioactivity will be confirmed to be <1 uCi/ml prior to ASCR). ASCR will be carried out sooner in the case of life-threatening infection in the setting of neutropenia (ANC<500). G-CSF can be used to maintain ANC>500/ul but should not be used for 24 hours immediately before and after ASCR. Blood product support will be provided with platelet and red cell transfusions as required.
89044375|NCT00450944|Experimental|Combination Therapy with Immunotoxins Imtox 19 Plus Imtox 22|
89044376|NCT05417607|Other|A+ Treatment/Feasibility participants|Total participation is expected to require a maximum of 20 weeks (plus optional remote follow-up at 16 week). Diagnostic/screening visits occur between 1 and 6 weeks prior to baseline and start of coaching. ESDM-informed parent coaching (~1 hour sessions) is delivered remotely (through telehealth) with a study clinician for 8 weeks and strategies are implemented within the child's typical daily routines by the caregiver. No medication is provided by the study team. Data is collected weekly and final assessment will be obtained at 16 weeks after baseline.
89044377|NCT02931812||Cirrhotic subjects|15 cirrhotic patients in end-stage in waiting a graft
89044378|NCT02931812||Chronic kidney disease subjects|15 chronic kidney disease patients in end-stage in waiting a graft
89044379|NCT02931812||Healthy subjects|30 healthy subjects to compare
89057947|NCT05126121|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy consisting of vonoprazan and three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, clarithromycin,levofloxacin,tinidazole,metronidazole.
89646001|NCT04722276|Active Comparator|fraction of inspired oxygen 80%|
89646002|NCT04722276|Experimental|Fraction of inspired oxygen 80% with positive end expiratory pressure|
89646003|NCT04702750|Experimental|Experimental group|
89646004|NCT04702672|Experimental|Type 2 diabetes|Adults with T2D. Hemoglobin A1C between 42-78 mmol/l. No use of insulin or once-weekly glucagon-like peptide-1 (GLP-1) or acarbose. No severe cardiovascular, kidney, liver, psychiatric or endocrine disease. No abuse of alcohol- or narcotics. No pregnancy or lactation.
89057948|NCT02218658|Experimental|WE 941 OD|
89646005|NCT04702672|Experimental|Non-diabetics|Adults without T2D. No severe cardiovascular, kidney, liver, psychiatric or endocrine disease. No abuse of alcohol- or narcotics. No pregnancy or lactation.
89646006|NCT04698538|No Intervention|Educational Materials|Caregivers in this arm will receive intervention material, but no coaching. The material consists of a self-guided module introducing caregivers to the developmental concepts of joint engagement, social communication, and play.
89646007|NCT04698538|Experimental|JASPER intervention|The caregivers randomized to intervention, will meet twice a week with UCLA staff to do session planning one day and JASPER remote, live coaching another day. The caregivers are expected to meet with the UCLA team twice a week.
89646008|NCT04696692|Other|Patient with histologically confirmed diffuse large B-cell lymphoma|
89044380|NCT03455127|No Intervention|Classic Public Works as Usual|Half of the sample will be eligible to receive or be receiving the Government of Rwanda's (GOR) flagship social protection programming, Vision 2020 Program (VUP). One component of this program is to provide cash for work opportunities for labor endowed vulnerable households, i.e. one able bodied adult. Vulnerable households are those in Poverty Level 1 category, the GOR's poverty classification system. Furthermore, this study will require households in the control group receiving classic public works as usual to have at least one child between the ages of 6 months to 36 months.
89044381|NCT03455127|Experimental|Classic Public Works + FSI ECD|Half of the sample will receive the FSI ECD home visiting parenting program alongside the GOR's classic public works programming. These households will be in Poverty Level 1 with an able-bodied adult, thus eligible to receive or be received the GORs public works programming. They will have a child between 6 and 36 months at enrollment. Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
89646009|NCT04685525|Experimental|Mycobiome Supporting Diet|Participants will be able to abide by the allowed and disallowed foods in MSD diet for at least four consecutive weeks prior to conditioning and up to 10 days after transplant. Participants will maintain a diary of foods they consume and any adverse effects they are experiencing and will self- collect fecal samples 28 days before transplant, 2 days before transplant and 10 days after transplant
89646010|NCT04683003|Experimental|Prophylactic Cohort: TAK-755|"All participants will receive prophylactic treatment with 40 IU/kg TAK-755 intravenous (IV) infusions once every week or once every other week for the duration of the study.~Participants who are naïve will receive an initial IV dose of 40 IU/kg TAK-755 to allow measurement of the pharmacokinetics of TAK-755, followed by prophylactic treatment with 40 IU/kg TAK-755 by IV infusion once every week or once every other week for the duration of the study."
89044382|NCT02931578|Active Comparator|Glucose100|Participants in this arm will randomly receive 100% glucose in the OGTT drink 3 out of 9 visits.
89044383|NCT02931578|Active Comparator|Glucose50|Participants in this arm will randomly receive 50% glucose in the OGTT drink 3 out of 9 visits.
89044384|NCT02931578|Active Comparator|Glucose42|Participants in this arm will randomly receive 42% glucose in the OGTT drink 3 out of 9 visits.
89044385|NCT02931344|Experimental|Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
89044386|NCT02931383|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg once daily (QD) and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
89057949|NCT02218658|Active Comparator|Brotizolam|
89646011|NCT04683003|Experimental|On-Demand Cohort: TAK-755|"Participants will receive daily IV infusions of TAK-755 when experiencing an acute thrombotic thrombocytopenic purpura (TTP) event until 2 days after the acute TTP event is resolved.~Participants will receive 40 IU/kg TAK-755 on the first day, followed by 20 IU/kg on Day 2, and then 15 IU/kg daily until 2 days after the acute TTP event has resolved. Upon resolution of the acute TTP event, participants may choose to move to the prophylactic cohort of the study or discontinue entirely from the study."
89646012|NCT04682561|Experimental|Supportive Trauma Exposure Preparation (STEP) Program|Nurses or personal support workers at Unity Health Toronto - Providence Healthcare will undergo the STEP Program Psychotherapy
89646013|NCT04680000|Active Comparator|Standard BCBT-CP|Brief Cognitive Behavior Therapy for Chronic Pain (BCBT-CP) is a seven-module intervention for chronic pain based on the efficacious specialty-care, ten-session version of this treatment called Cognitive Behavioral Therapy for Chronic Pain (CBT-CP).
89646014|NCT04680000|Experimental|Standard BCBT-CP with Telephone Booster|"Participants will receive standard BCBT-CP as described in the Standard BCBT-CP arm. They will also receive telephone or video teleconference booster contacts as follows:~BCBT-CP Booster Contacts are intended to refresh BCBT-CP content without introducing new skills. To accomplish this, Booster Contacts are manualized (see appended Booster Protocol form) to cover assessment of pain since last contact, review of most recent BCBT-CP module(s) and reminder about the next BCBT-CP appointment (if one is scheduled)."
89646015|NCT04677647|Experimental|OurChild|
89646016|NCT04665297|Experimental|Intervention arm|Subjects from intervention clusters will receive the GMCD intervention, delivered in monthly visits to the home by frontline health workers, for 24 months. 0-12 months represents the primary effectiveness study, and 12-24 months a secondary maintenance study.
89646017|NCT04665297|No Intervention|Control Arm|Subjects in control clusters will continue to receive usual care from their frontline health workers. After 12 months (primary effectiveness study) control will cross into the intervention for months 12-24.
89646018|NCT04663750|Experimental|Arm A - Surgery with aflibercept|Surgery with aflibercept at the end of surgery, with post-operative review day 1 and week 1 (day 7)
89646019|NCT04663750|Active Comparator|Arm B - Aflibercept monotherapy|Aflibercept monotherapy commencing at baseline.
89646020|NCT04648631|Experimental|ABWG|The participants in this group will be receiving the ABWG daily for 4 consecutive weeks.
89646021|NCT04645680|Experimental|Arm I (isocaloric high-fiber diet)|Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks.
88992127|NCT05331209|Active Comparator|Acupuncture only|Acupuncture treatments will take place at a frequency of once per week, with each session lasting between 30 to 45 minutes. At each session patients will be re-assessed by the study acupuncturist, with acupuncture points individualized in accordance with the principles of traditional Chinese medicine. At the same time, acupuncturists will include a set group of acupuncture points which have been used in the research of hot flashes: HT-6, Kid-3, Liv-3, SP-6.
88992128|NCT05331209|Active Comparator|Acupuncture-Acupressure|Patients randomly allocated to the acupuncture-acupressure arm of the study will first be treated by the study acupuncturist in accordance with the protocol described in the Acupuncture arm of the study. At the end of the first session, patients in this group will be taught by the study acupuncturist to self-treat at home with acupressure, on the acupressure points PC-7, ST-36, SP-9. Self-acupressure sessions will last between 3-5 minutes each, and will take place 3-4 times each day. At subsequent acupuncture treatments patients will receive reinforcement and guidance to ensure the fidelity of the self-acupuncture treatments
88992129|NCT04715971||Patients admitted ≤72 hours to an acute geriatric hospitalisation unit.|All patients aged ≥75 years, admitted to the acute geriatric hospitalisation units of the University Hospitals Leuven in Belgium, were consecutively screened for inclusion within 72 hours of admission in a 2 month period (between October 26 and December 18, 2015).
88992130|NCT00336193|Experimental|Home visitation|In the intervention condition, nurse home visitors receive enhanced training to improve delivery of parenting interventions to mothers
88992131|NCT00158028|Experimental|Risperidone|starting dose 0.25mg/day, titrated upward to 2mg/day over 9 weeks
88992132|NCT00158028|Placebo Comparator|Placebo|placebo match in identical tablets
88992133|NCT03271177|Experimental|7F Sheathless Guide Catheter|Patients in this arm will undergo their percutaneous coronary intervention using a 7F Sheathless guide catheter
88992134|NCT03271177|Placebo Comparator|6F Sheath/Guide Catheter Combination|Patients in this arm will undergo their percutaneous coronary intervention using a 6F Sheath/guide combination
89646022|NCT04645680|Active Comparator|Arm II (isocaloric diet)|Patients receive a standard whole foods diet recommended by the American Cancer Society for 11 weeks.
89646023|NCT04639466|Experimental|Phase I Arm I (COH04S1)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
89646024|NCT04639466|Active Comparator|Phase I Arm II (COH04S1, placebo)|Participants receive COH04S1 IM in the non-dominant upper arm on day 0 and placebo IM in the non-dominant upper arm on day 28 in the absence of unacceptable toxicity.
89646025|NCT04639466|Placebo Comparator|Phase I Arm III (placebo)|Participants receive placebo IM in the non-dominant upper arm on day 0 and day 28 in the absence of unacceptable toxicity.
89646026|NCT04639466|Experimental|Phase II Arm I (low dose COH04S1 booster)|Participants receive low dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.
89646027|NCT04639466|Experimental|Phase II Arm II (high dose COH04S1 booster)|Participants receive high dose COH04S1 booster IM in non-dominant upper arm on day 1 in the absence of unacceptable toxicity.
89646028|NCT04634604|Active Comparator|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by Occupational Safety and Health Administration (OSHA) and facility standards, will be followed.
89646029|NCT04634604|Experimental|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
89646030|NCT04631601|Experimental|Acapatamab and Enzalutamide: Dose Exploration|The dose-exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of Acapatamab in combination with enzalutamide.
89646031|NCT04631601|Experimental|Acapatamab and Enzalutamide: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with enzalutamide.
89646032|NCT04631601|Experimental|Acapatamab and Abiraterone: Dose Exploration|The dose exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of Acapatamab in combination with abiraterone.
89646033|NCT04631601|Experimental|Acapatamab and Abiraterone: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with abiraterone.
89646034|NCT04631601|Experimental|Acapatamab and AMG 404: Dose Exploration|The dose-exploration part of the study will estimate the MTD/RP2D of Acapatamab in combination with AMG 404.
89646035|NCT04631601|Experimental|Acapatamab and AMG 404: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with AMG 404.
89646036|NCT04631601|Active Comparator|AMG 404 Monotherapy|AMG 404 monotherapy is being conducted to evaluate the preliminary anti-tumor activity of PD-1 inhibition in the mCRPC population.
89646037|NCT04631601|Experimental|Acapatamab and Enzalutamide: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with enzalutamide for subjects in Asia.
89646038|NCT04631601|Experimental|Acapatamab and Abiraterone: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with abiraterone for subjects in Asia.
88992135|NCT03271294|Other|Exair transvaginal mesh surgery|This is a prospective study done in 80 consecutive subjects who underwent the Exair transvaginal mesh surgery from June 2013 to August 2015. The subjects were followed at 4 weeks, 6 months and 12 months post-operatively. All eligible subjects underwent a detailed urogynecologic history and examination including a Pelvic Organ Prolapse Quantification system assessment (POP-Q).
89044387|NCT02931383|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
89646039|NCT04631601|Experimental|Acapatamab and AMG 404: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with AMG 404 for subjects in Asia.
89646040|NCT04631601|Experimental|Acapatamab Monotherapy|Acapatamab monotherapy is being conducted to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of Acapatamab in subjects with mCRPC.
89646041|NCT04629833|Experimental|MC0518|Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
89646042|NCT04629833|Active Comparator|Best Available Therapy (BAT)|Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX).
89646043|NCT04628429||Episodic Migraine|All patients who have been diagnosed with migraine without aura or migraine with aura according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
89646044|NCT04628429||Chronic Migraine|All patients who have been diagnosed with chronic migraine (≥15 headache days per month 8 of which with migrainous features) according to the diagnostic criteria of the International Classification of Headache Disorders, third edition (ICHD-3) and have been unsuccessfully treated with first-line prophylactic medication
89044388|NCT02931422|Experimental|Low Financial Incentive|Conditional cash transfer upon HIV testing
89044389|NCT02931422|Experimental|Medium Financial Incentive|Conditional cash transfer upon HIV testing
89044390|NCT02931422|Experimental|High Financial Incentive|Conditional cash transfer upon HIV testing
89044391|NCT02931461|Experimental|needle Procore ®|
89044392|NCT02931461|Active Comparator|needle Cook®|
89044393|NCT04593641|Experimental|Cohort 1 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
89044394|NCT04593641|Experimental|Cohort 2 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
89044395|NCT04593641|Experimental|Cohort 3 will receive a dose of CT-P59 or matching placebo|"Drug: CT-P59~CT-P59 will be administered~Drug: Placebo~Placebo-matching CT-P59"
89044396|NCT04341441|Active Comparator|Study Drug - Daily Dose|The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
89044397|NCT04341441|Active Comparator|Study Drug - Weekly Dose|The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria.
89646045|NCT04628429||Healthy Control|Controls must be healthy (free of any diagnosed chronic disease, acute infection requiring medication, family history or personal history of migraine), chosen to be as similar as possible to migraine patients, in terms of age and sex.
89646046|NCT04623515||Surgery Only Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
89646047|NCT04623515||Surgery and Radiation Therapy Group|Participants will complete a questionnaires regarding demographics and medical history on a secured REDCap link.
89646048|NCT04621448|Experimental|Immediate Start|The Immediate Start group will participate in the 12-week Moving Together program after completing the baseline assessment. Moving Together is a gentle, live-streaming, group movement program designed specifically for people with memory loss (PWML) and caregivers (CG) to do together. It is based on the in-person Preventing Loss of Independence through Exercise (PLIÉ) and Paired PLIÉ programs. The program combines physical movements to help maintain daily function with mindful body awareness exercises and social interactions to provide a comprehensive, multi-domain program.
89044398|NCT04341441|Active Comparator|Placebo|All treatment groups will receive placebo pills to have the patients take 2 pills a day. The randomized placebo arm will receive placebo pills made to resemble the daily dosing of HCQ. Similarly, the once a week treatment arm will receive placebo pills for the days not on HCQ medication.
89044399|NCT04341441|Active Comparator|Non-Randomized Active Comparator|A non-randomized comparator group will be enrolled in the study comprising of healthcare workers and first responders who are chronically on oral hydroxychloroquine as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy.
89044400|NCT04525937||Patients with Severe Aortic Stenosis with Disparities|Patients will complete a survey and their aortic stenosis will be clinically followed at 30 days and one year
89044401|NCT04525937||Medical Providers with Disparities|Referring primary care providers complete a questionnaire on their referral practices for patients with severe aortic stenosis
89044402|NCT01187953|Experimental|LCP-Tacro|The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
89057950|NCT05125653|Experimental|NIR/ICG Arm|Indocyanine Green Fluorescent Cholangiography and Intraoperative Angiography will be done during the Laparoscopic Cholecystectomy
89646049|NCT04621448|Experimental|Delayed Start|A Delayed Start group will be encouraged to continue with their usual daily activities during the first 12 weeks of the study and will begin the Moving Together program after completing the mid-point assessment.
89646050|NCT04618172|Experimental|Exercising group|This group practises 30 minute long exercises twice a week besides filling out the questionnaires.
89646051|NCT04618172|No Intervention|Control group|This group fills out the questionnaires without practising 30 minute long exercises twice a week.
89646052|NCT04603066|Experimental|Ondansetron + Tariquidar|
89646053|NCT04603066|Placebo Comparator|Ondansetron + Placebo|
89646054|NCT04602026|Experimental|Arm I (physical therapy consultation, exercise intervention)|Patients undergo a physical therapy consultation and complete home exercises 3 days per week.
89646055|NCT04602026|Active Comparator|Arm II (best practice)|Patients receive standard of care.
89646056|NCT04585633||Low Risk|no complication develop within 30 days after the operation and high GOS value
89646057|NCT04585633||High Risk|"complication or complications develop within 30 days after the operation and low GOS value~Complications:~Moderate to severe intracerebral hemorrhage confirmed in a brain CT scan (Midline shift in brain imaging ≥ 3 mm),~İntracranial hypertension requiring post op surgical drainage,~Status epilepticus or seizures,~The need for tracheal intubation or use of mechanical ventilation after surgery,~Decrease in GKS,~Unmanageable agitation that requires restriction or sedation,~Need for respiratory failure and oxygen therapy,~Unexpected serious motor deficit~Died"
89646058|NCT04581200|Experimental|Lift mobile mindfulness program|Will receive standard dose Lift mobile mindfulness program intervention content, app-based response to elevated symptoms, and no introductory call from a therapist. This program lasts 1 month and includes 4 unique weeks' worth of audio, video, and text content.
89646059|NCT04581200|No Intervention|Usual care control|Usual care.
89646060|NCT04575142|Experimental|CO2 laser device group|Participants who will be undergoing laser treatment for their vocal nodes with a specific laser device. AcuPulse Duo, a CO2 laser is absorbed by water found in soft tissues and is independent of tissue color. It is very precise and causes less damage of the deep tissues, which results in less swelling and faster recovery. The absence of a long healing process means that most patients can resume their normal activities even on the same day The CO2 laser is the preferred laser for use in the operating room.
89646061|NCT04562714|Experimental|Intervention (FGM + DSME)|Study participants randomized to the intervention arm will be provided with a FreeStyle Libre flash glucose monitor (FGM) system to use for 16 weeks in Phase 1. Study participants will receive one training session on proper use of the FGM and encouraged to test at least 4 times per day: fasting and post-meals. Participants will also receive six diabetes self-management education (DSME) sessions, consisting of four individual in-clinic sessions and two telephone sessions.
89646062|NCT04562714|Other|Control (DSME alone)|Study participants in the control arm will receive six diabetes self-management education sessions matched to time and location of the intervention group. The sessions will consist of four individual in-clinic sessions and two telephone sessions over 16 weeks. Control participants will be encouraged to self-monitor blood glucose four times daily (fasting and post-meals) as per existing diabetes self-care guidelines
89646063|NCT04557124|Experimental|USS|social cognitive training
89646064|NCT04557124|Active Comparator|MovingForward|problem solving training
89646065|NCT04554420|Experimental|Youth Participatory Action Research-Mental Health Curriculum|Youth will be engaged with youth participatory approaches in learning about the intersection of mental health and systemic/community level issues.
89646066|NCT04553770|Active Comparator|Arm A (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
89646067|NCT04553770|Experimental|Arm B (trastuzumab deruxtecan, anastrozole)|Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 day 1 and 30 minutes on day 1 of each subsequent cycle and anastrozole PO QD on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
89646068|NCT04547309|Experimental|68Ga/18F-HER2 Affibody PET/CT scan|
89646069|NCT04544956|Experimental|Participants receiving 300 mg GSK3228836|Eligible participants on stable nucleos(t)ide therapy will receive GSK3228836 300 mg subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).
89646070|NCT04543357||All participants|Household contacts of a DMD patient in an interventional study of fordadistrogene movaparvovec.
89646071|NCT04535323|Experimental|Treatment of GSM (platelet rich plasma)|Patients receive platelet rich plasma via injection into the vaginal area.
88992136|NCT00471640|Active Comparator|1|dexamethasone
88992137|NCT00471640|Placebo Comparator|2|Placebo
88992138|NCT00471679|Experimental|Ethanol-Lock Treatment|Ethanol instillation and removal will be carried out by one of the investigating physicians, a pediatric surgical nurse practitioner, or a dedicated research nurse. Syringes containing a 70% ethanol solution will be pre-filled in the PDH pharmacy and dispensed to the nurse caring for a particular patient. The volume of ethanol to be administered into each lumen of the central line will be specific to each patient's catheter and will be determined at enrollment.
88992139|NCT00471952|Experimental|1|Maxalt 10mg with Caffeine 75mg
88992140|NCT00471952|Active Comparator|2|Maxalt 10mg plus Placebo
88992141|NCT00471952|Placebo Comparator|3|Double placebo
89646072|NCT04532346|Experimental|Hydroxychloroquine|Hydroxychloroquine in a dose of 10 mg/kg*d, p.o., bid for 12 months. The maximum daily dose is 400mg.
89646073|NCT04532346|No Intervention|control|control group which do not take hydroxychloroquine for treatment.
88992142|NCT00471991|Active Comparator|Arm 1|
88992143|NCT00471991|Experimental|Arm 2|
88992144|NCT03271099|No Intervention|Usual Care|Usual care
88992145|NCT03271099|Experimental|Navigator|Patient navigator services provided as part of survivorship care plan
88992146|NCT00472069|Experimental|A|transplantation of the squeletic muscular cells
88992147|NCT03271060|Active Comparator|Lumbar spondylolisthesis1|
88992148|NCT03271060|Active Comparator|Lumbar spondylolisthesis 2|
89057951|NCT05125653|Active Comparator|WL Arm|Conventional white light was used for Laparoscopic Cholecystectomy
89646074|NCT04529304|Experimental|Visual EEG|Individual dosing of anesthetic medications based on EEG AND other standardized clinical observations (BP, HR)
89646075|NCT04529304|Experimental|Blinded EEG|Individual dosing of anesthetic medications based on standardized clinical observations (BP, HR).
89646076|NCT04527146|Experimental|IMAGINE-PD/Virtual|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via virtual visit with a genetic counselor.
89646077|NCT04527146|Experimental|IMAGINE-PD/Telephone|Pre-test genetic counseling through the Interactive Multimedia Approach to Genetic counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) website. Genetic results disclosure via telephone with a genetic counselor.
89646078|NCT04527146|Experimental|Virtual/Telephone|Pre-test genetic counseling virtual visit with a genetic counselor. Genetic results disclosure via telephone with a genetic counselor.
89646079|NCT04527146|Active Comparator|Virtual/Virtual|Pre-test genetic counseling and genetic results disclosure via virtual visit with a genetic counselor.
89646080|NCT04520659|Experimental|Group 1: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
89646081|NCT04520659|Placebo Comparator|Group 1: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
89646082|NCT04520659|Experimental|Group 2: RSV LID/ΔM2-2/1030s|Participants will receive a single dose of RSV LID/ΔM2-2/1030s vaccine at study entry (Day 0).
89646083|NCT04520659|Placebo Comparator|Group 2: Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
89646084|NCT04501666|Experimental|Nemolizumab 30 milligram (mg)|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W) and participants >= 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W up to 24 weeks.
89646085|NCT04501666|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive matching placebo of two SC injections at baseline, then one SC injection Q4W and participants weighing >= 90 kg will receive matching placebo of two SC injections at baseline, then two SC injections Q4W up to 24 weeks.
89646086|NCT04497038|Experimental|Cabozantinib|Cabozantinib 20-60 mg by mouth once daily.
89646087|NCT04481243|Experimental|Pneumovax 23|Type 1 Diabetes subjects will receive Pneumovax 23-pneumococcal polysaccharide (PPSV23)
89646088|NCT04474301||Observational (survey administration)|Patients complete a survey over 10 minutes.
89646089|NCT04472260|Other|Sequence 1: PP->PP->V->V|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
89646090|NCT04472260|Other|Sequence 2: PP->V->V->PP|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
89646091|NCT04472260|Other|Sequence 3: V->PP->PP->V|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
89646092|NCT04472260|Other|Saquence 4: V->V->PP->PP|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
89646093|NCT04471779|Experimental|Disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity, family history of Alzheimer's disease, and their APOE genotype.
88992149|NCT03271138|Active Comparator|Bifidobacterium Infantis NLS Super Strain|Participants in the probiotic period will take two capsules of Bifidobacterium infantis NLS super strain (Natren LIFE START®2) three times per day for three weeks. Each capsule contains 2 x 10^9 colony-forming units (CFU) of Bifidobacterium infantis NLS super strain, for a total daily dose of 12 X 10^9 CFU. The probiotic will be kept refrigerated during transportation and throughout the study period.
88992150|NCT03271138|Placebo Comparator|Placebo|Participants in the placebo period will take two capsules of placebo three times per day for three weeks. The placebo capsules contain rice flour, hydroxypropyl and methylcellulose. The placebo will be kept refrigerated during transportation and throughout the study period.
88992151|NCT03270865|Experimental|Usability and Ergonomic Evaluation of Self-Positioning System|
88992152|NCT00472225|Experimental|1|Rituximab treatment arm
88992153|NCT00472264||Single arm study (Healthy volunteers & COPD subjects)|A single arm study PET imaging is carried out twice during the first week of the study and again 4 weeks later in both Healthy volunteers and COPD subjects.
88992154|NCT03270787|Placebo Comparator|Placebo Comparator|Placebo Comparator: controlled group Placebo,10pills,tid,po
89646094|NCT04471779|No Intervention|Non-disclosure|Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity and family history of Alzheimer's disease alone.
89646095|NCT04468919|Experimental|BCI-FIT multi-modal configuration|For this single case research design with alternating treatments without baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks with a standard P300 matrix speller layout and with the multi-modal configurations optimized from the BCI-FIT algorithms. Outcome measures are typing accuracy, typing speed and user experience.
89646096|NCT04468919|Experimental|Adaptive signal modeling|For this single case research design with alternating treatments without baseline, 5 participants with severe speech and physical impairment will complete copy spelling tasks with 3 signal adaptive modeling configurations. Outcome measures are typing accuracy, typing speed and user experience.
89646097|NCT04468919|Experimental|Active querying techniques|For this single case research design with alternating treatments without baseline, 5 control volunteers and 5 participants with severe speech and physical impairment who have AUC scores between 70-80% will complete copy spelling tasks with BCI-FIT active querying technique on and with BCI-FIT active querying technique off. Outcome measures are typing accuracy, typing speed and user experience.
89646098|NCT04468919|Experimental|Language modeling|For this single case research design with alternating treatments, 5 control volunteers and 5 participants with severe speech and physical impairment, each with a control partner for partner input will complete a story retell task with BCI-FIT language modeling features on and with BCI-FIT language modeling features off. Outcome measures are information transfer rate and user experience.
89646099|NCT04468230|Experimental|Nicotine Transdermal Patch Administration|Each patient will complete two 14-day treatment conditions, for 7 mg nicotine transdermal patch administration with a washout period in between (≥ 14 days and up to 21 days), then 14 mg nicotine transdermal patch administration (14 days).
89646100|NCT04467801|Experimental|Treatment|"Ipatasertib, 400 mg once daily, Oral, Days 1-14 of each 21 day cycle (2 weeks on and 1 week off).~Docetaxel, 75 mg/m2, Intra-venous, Day 1 of each 21 day cycle."
89646101|NCT04460937|Experimental|Treatment (radiation therapy, adavosertib)|Patients undergo radiation therapy QD 5 days per week for 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive adavosertib PO QD for 2-5 days (depending on dose level) during weeks 1 and 3 of radiation therapy in the absence of disease progression or unacceptable toxicity.
89646102|NCT04457362|Experimental|Experimental Cohort|Patients with clinically diagnosed wrist pathology undergoing wrist arthroscopy
89646103|NCT04456517|Experimental|Ranolazine, Then Placebo|- Participants first receive a Ranolazine 500 mg tablet twice daily for 12 weeks, they then receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
89044403|NCT01187953|Experimental|Prograf (tacrolimus)|Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Doses will be adjusted according to whole blood tacrolimus trough levels. In the initial post-transplant period, plasma trough levels will be measured at 24 and 48 hours. Study drugs will be adjusted to maintain the whole blood pre-dose (trough) concentration of tacrolimus in the target range of 6 - 11 ng/mL for the first 30 days, then 4 - 11 ng/mL for the remainder of the study.
89044404|NCT05381259|Other|hortitherapy intervention versus control|"Horticultural therapy refers to physical and psychic therapy by nature by focusing on the action of gardening on the body, intellect, psych and mind.~Horticultural in the form of therapeutic gardening serves as a support to help and treat various pathologies in the brain.~It is a form of curative treatment exploiting the planting and maintenance of garden. The term is a contraction of  horticultural  and  therapy."
89044405|NCT02900157|Experimental|MEDI9090|
89044406|NCT02931305|Experimental|Epimedium Prenylflavonoids Extract|Single oral doses of EP (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
89044407|NCT02931305|Placebo Comparator|Placebo|Single oral doses of Placebo (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
89646104|NCT04456517|Experimental|Placebo, Then Ranolazine|- Participants first receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks, they then receive a Ranolazine 500mg tablet twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
89044408|NCT04262817|Experimental|E-cigarette flavor|In this arm, participants will receive two experimental e-cigarette flavors
89044409|NCT04262817|Experimental|E-cigarette nicotine form|In this arm, participants will receive two forms of nicotine in an e-cigarette
89044410|NCT04679259|Experimental|Cardiac surgical patients|
89044411|NCT02931149|Experimental|Submucosal injection with PRP|All participants in the study received submucosal injection of PRP prior to endoscopic resection
89044412|NCT04679766|Experimental|Patients with non-restorable tooth in maxillary bi-cuspid region with labial/buccal plate dehiscence|
89044413|NCT01217944|Experimental|Ranibizumab driven by disease activity|Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
89044414|NCT01217944|Experimental|Ranibizumab driven by stabilization criteria|Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
89044415|NCT01217944|Active Comparator|Verteporfin PDT|Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.
89044416|NCT04238013|Active Comparator|Corticospinal Tract Excitability|During the Corticospinal Tract Excitability arm, corticospinal excitability will be assessed by measuring motor evoked potentials after transcranial magnetic stimulation pre-post each intervention in conjunction with other outcome measures.
89044417|NCT04238013|Active Comparator|Spinal Reflex Circuit Excitability|During the Spinal Reflex Circuit Excitability arm, spinal reflex circuit excitability will be assessed by measuring low frequency depression after Hoffmann-Reflex testing pre-post each intervention in conjunction with other outcome measures.
89044418|NCT04689737|Experimental|Experimental group|Doravirine (Pifeltro, MSD) will be added to participant's cART (100 mg once daily) for 5 days
89646105|NCT04450342|Experimental|ARCR augmented with REGENETEN™ Bioinductive Implant|During the ARCR procedure, the REGENETEN™ Bioinductive Implant is covering the tendon and attached to the bone and the tendon with small anchors.
89646106|NCT04450342|Sham Comparator|ARCR alone|The rotator cuff is repaired during arthroscopic standard procedure. No product is added for healing
89646107|NCT04450342|Other|ARCR revision group|ARCR revision group allows treatment of subjects having recurrent tears, ARCR supplemented with REGENETEN
89646108|NCT04446650|Experimental|Fedratinib Administration|The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.
89646109|NCT04446299|Experimental|BLI4900|Experimental bowel preparation solution for oral ingestion
89646110|NCT04446299|Active Comparator|FDA Approved Control|FDA approved bowel preparation solution for oral ingestion
89646111|NCT04439227|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89646112|NCT04439175|Experimental|Treatment (taselisib)|Patients receive taselisib 4 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89218002|NCT03878914|Active Comparator|Slow responders (Group B)|"CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group B: (Total duration of therapy ≥ 12 weeks)~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 4 weeks~40mg/m2 or 1.5mg (maximum 40mg) every other day for 4 weeks.~Wean off in 4-6 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
89646113|NCT04439136|Experimental|Treatment (afatinib dimaleate)|Patients receive afatinib dimaleate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646114|NCT04416334|Experimental|Colchicine plus symptomatic treatment (paracetamol).|"Patients in this arm will receive study medication colchicines 0.5 mg orally (PO) twice daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.~All patients should also receive best symptomatic treatment (mainly paracetamol), based on clinical practice."
89646115|NCT04416334|Active Comparator|Symptomatic treatment|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
89646116|NCT04416126|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
88992155|NCT03270787|Experimental|Compound danshen dripping pills|Compound danshen dripping pills Compound danshen dripping pills ,10pills,tid,po
88992156|NCT03270904|Experimental|Group 1 - Interventional Treatment|Participants in this group have been randomised to receive application of violet blue light administered by the hand held Microlight i:X device in addition to routine care of their foot ulcer. This intervention will be administered four times during the study.
88992157|NCT03270904|No Intervention|Group 2 - Usual care|This group receive routine care and no additional intervention.
89218003|NCT00727727||Parkinsonian patients|
88992158|NCT00336622|Experimental|Experimental|Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises
88992159|NCT00336622|Active Comparator|Control|Off-the-shelf splint
88992160|NCT00472381|Experimental|2|Insulin
88992161|NCT00472498||1|"Case:~Patients resuscitated after 2001"
88992162|NCT00472498||2|"Control:~Patients who suffer cardiac arrests after 2001."
88992163|NCT05279924|Experimental|Ivoirian Boys with severe Hemophilia A treated with Emicizumab|All Ivoirian boys with severe Hemophilia A (with and without inhibitors) on prophylaxis with Emicizumab
88992164|NCT00472810|Experimental|1|20 patients will be recruited according to the enrollment acceptance criteria.Randomisation is performed using a sealed envelope system, where 40 shuffled envelopes designating the surgery to either trabeculectomy with mitomycin-C (MMC) and trabeculectomy with ologen™ Collagen matrix must be open before surgery. Then, patients are allocated and trabeculectomy is performed.If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
88992165|NCT00472810|Active Comparator|2|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be randomised to trabeculectomy with mitomycin -C. Randomisation is performed. Then, trabeculectomy is performed
88992166|NCT00337051|Experimental|S|General Anesthesia with sevoflurane (inhalation) as hypnotic
88992167|NCT00337051|Active Comparator|P|General Anesthesia With Propofol TCI
88992168|NCT00149760|Active Comparator|Augmented Standard Medical Care|Participants will receive standard medical care augmented by a psychiatric consultation letter sent to the participants' primary care physician.
88992169|NCT00149760|Experimental|Cognitive-Affective Behavior Therapy|Participants will receive individually administered cognitive-affective behavior therapy as well as augmented standard medical care.
88992170|NCT04054492|Experimental|sIPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
88992171|NCT04054492|Active Comparator|sIPV+sIPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
88992172|NCT04054492|Active Comparator|sIPV+sIPV+sIPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
88992173|NCT05262452|Experimental|CureHIFUPanc|Patients diagnosed with locally advanced/borderline resectable pancreatic cancer through biopsy and CT/MRI imaging and planned to undergo anti-cancer treatment using FOLFIRINOX
89218004|NCT00907712|No Intervention|cardiovascular|cardiac echo
89646117|NCT04416126|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
89646118|NCT04415203|Experimental|TAVNS plus usual care|TAVNS on Erzhong and Xin (Auricular Acupuncture Point with Vagus nerve distribution); Usual Care: usual medicine treatment for PVCs.
89646119|NCT04415203|Placebo Comparator|Sham-TAVNS plus usual care|"Sham-TAVNS on Erzhong and Xin (Auricular Acupuncture Point); the same acupoints as the treatment group without any current.~Usual Care: usual medicine treatment for PVCs."
89646120|NCT04406038||Healthy adults|Healthy adults randomly sampled from the population of Saint Petersburg
89646121|NCT04404777||Patients with local recurrence|
89646122|NCT04383639|Active Comparator|1|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
89646123|NCT04383639|Experimental|2|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
89646124|NCT04383639|Experimental|3|All subjects will receive a high-fat high-sugar breakfast in three different days. They will not consume any additional product (1), they will receive the mixture of coca and carob together with breakfast (2) or they will receive the mixture of coca and carob 10 h before breakfast (3).
89646125|NCT04381416|Experimental|Cohort I: SEAD treatment|Following the first SEAD™ treatment, women who experience a sub-optimal treatment response (at least 3 months after the first treatment) will be eligible to receive a second SEAD™ treatment (see re-treatment criteria below), which will be performed during the first 1-3 days following the cessation of their menses immediately following decision to retreat.
89646126|NCT04381416|Experimental|Cohort II: Repeted SEAD treatment 1m post op|Following the first SEAD™ treatment, women will undergo a second SEAD™ treatment during the first 1-3 days following the cessation of their next menses.
89646127|NCT04377126|Active Comparator|Unacylated ghrelin|Participants randomized to unacylated ghrelin will self-administer 20 ug/kg unacylated ghrelin daily. Study drug is dispensed in syringes labeled with the participant's name, date of birth, expiration date, and instructions for administration. Syringes will NOT be labeled with the group assignment, ensuring that both the research team collecting data and study participants are blinded to group assignment (i.e. double blinded status). Study drug is stored and handled according to the University of Chicago Research Pharmacy Standard Operating Procedure (SOP).
89646128|NCT04377126|Placebo Comparator|Placebo|Participants randomized to placebo will self-administer an identical-appearing solution of bacteriostatic saline daily.
89646129|NCT04375436|Active Comparator|NTRX-07-SDD|NTRX-07-SDD at 0.3-8mg/kg; single dose
89646130|NCT04375436|Placebo Comparator|Control|Placebo control
89218005|NCT04720079|Active Comparator|Intercostobrachial nerve Infiltration|Preoperative infiltration of intercostobrachial nerve with 10ml of ropivacaine 0.5%
89218006|NCT04720079|Active Comparator|Ultrasound guided T2 paravertebral block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of ropivacaine 0.5%
89218007|NCT00909116||Chronic constipation - ODS|Adult Patients with ODS
89218008|NCT00729989|No Intervention|1|
89218009|NCT00729989|Experimental|2|
89646131|NCT04373343|Other|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
89646132|NCT04354961|Experimental|Almonertinib 110mg PO once daily|
89646133|NCT04354077|Experimental|NAc DBS|Subjects will receive bilateral DBS of the NAc
89646134|NCT04352972|Active Comparator|Hospital-based rehabilitation program|
89646135|NCT04352972|Experimental|Tele-monitored home exercise program|
89646136|NCT04340752|Experimental|Group 1:ICG 7.5 mg|Subjects in this group are randomized to receive 7.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
89646137|NCT04340752|Experimental|Group 2:ICG 12.5 mg|Subjects in this group are randomized to receive 12.5 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
89646138|NCT04340752|Experimental|Group 3: ICG 25 mg|Subjects in this group are randomized to receive 25 mg dose of Indocyanine Green (ICG) intravenously during the clinical surgery. ICG is a substance that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision.
88992174|NCT04715854|Active Comparator|Nasal canula (flexicare)|Patients will receive oxygen by classical nasal cannula
88992175|NCT04715854|Active Comparator|Intersurgical aerosol mask with one hole closed by tape|Patients will receive oxygen by classical nasal cannula associated with an aerosol mask partially closed (one lateral hole of the face mask closed by tape)
88992176|NCT04715854|Active Comparator|Intersurgical aerosol mask|Patients will receive oxygen by classical nasal cannula associated with an aerosol mask
88992177|NCT05210972||Diabetes|"Patients with level of HbA1c ≥ 6.5%, or Fasting blood glucose (FBG) ≥126 mg/dL, or a random plasma glucose (RBG) ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia.~In the absence of unequivocal hyperglycemia, diagnosis will be based on two abnormal test results, for FBG or RBG and HbA1c, from the same sample or in two separate test samples."
88992178|NCT05210972||Prediabetes|HbA1c 5.7-6.4% or FBG 110 mg/dL to 125 mg/dL The diagnosis will be based on two abnormal test results, for FBG or RBG and HbA1c, from the same sample or in two separate test samples.
88992179|NCT05210972||Normal glycemia|HbA1c <5.7% and FBG 110 mg/dL
88992180|NCT00158301|Experimental|1|Continuation phase cognitive behavioral therapy and drug therapy for 6 more months following acute treatment response
88992181|NCT00158301|Active Comparator|2|Continuation phase drug therapy only for 6 more months following acute treatment response
88992182|NCT04716049|Experimental|Protocol I|Powerade© Carbohydrates+Protein Cherry Juice Foam Roller Cold Water Immersion
88992183|NCT04716049|Experimental|Protocol II|Powerade@ Carbohydrates+Protein Stretching Intermittent Cold-Water Immersion
88992184|NCT00473122|Other|Delayed-Immediate Breast Reconstruction|Delayed-Immediate Reconstruction: If radiation therapy (XRT) not needed, immediate reconstruction. If XRT is needed, delayed reconstruction until XRT complete.
88992185|NCT00473200|Active Comparator|S-adenosylmethionine|S-adenosylmethionine
88992186|NCT00473200|Placebo Comparator|Placebo|Placebo
88992187|NCT00473239|Experimental|cholecalciferol|A single dose of 100,000 IU vitamin D
88992188|NCT00473239|No Intervention|Control|No drug was given
88992189|NCT00149916|Experimental|Mycophenolate sodium (enteric coated)|
88992190|NCT00473317|Experimental|1|All subjects in this study will be in the active arm
88992191|NCT05195762|Experimental|Patients receiving NFX-179 Gel|NFX-179 Gel 1.50% applied QD for 12 weeks
88992192|NCT00473356|Active Comparator|1|to receive amino acid supplement
88992193|NCT00473356|No Intervention|2|no amino acid supplement
88992194|NCT00158340|Experimental|1|Participants will receive guided self-help cognitive behavioral therapy
88992195|NCT00158340|Active Comparator|2|Participants will receive treatment as usual
88992196|NCT00473473|Experimental|1|potassium bichromate
88992197|NCT00473473|Placebo Comparator|2|placebo
88992198|NCT00405873|Experimental|AMT2003|
88992199|NCT00337480|No Intervention|conventional|This arm is the conventional way of taking care of patients after an acute coronary syndrome
88992200|NCT00337480|Active Comparator|structured|This arm is an active way to monitor and educate patients after their acute coronary syndrome, with the intervention of health members in a House of Education
88992201|NCT00337519|Experimental|1|see detailed description
88992202|NCT00337558|Experimental|1|Solifenacin succinate
88992203|NCT00337558|Experimental|2|Solifenacin succinate and simplified bladder training
88992204|NCT02964104|Experimental|Insulin 287 + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
88992205|NCT02964104|Active Comparator|Insulin degludec + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
88992206|NCT00337636|Experimental|HuCNS-SC|human central nervous system stem cells
88992207|NCT00509275|Experimental|1|W0027
88992208|NCT00509275|Experimental|2|W0027
88992209|NCT00509275|Experimental|3|W0027
88992210|NCT00509275|Placebo Comparator|4|Placebo
88992211|NCT00405080|Experimental|Treatment Period 1|Subject will receive single oral dose of 150 milligram (mg) of Casopitant. There will be wash out period of 7 days.
88992212|NCT00405080|Experimental|Treatment Period 2|Subjects will receive rifampin 600 mg once daily on Days 1 - 9. On Day 8 subjects will receive a single dose of oral casopitant 150 mg along with rifampin.
88992213|NCT00337714|Placebo Comparator|A|in this arm conventional CVCs will be inserted
88992214|NCT00337714|Active Comparator|B|group B will receive medicated silver nanoparticles CVC
88992215|NCT00337753|Active Comparator|Cognitive Behavioral Therapy|Weekly Cognitive Behavior therapy
88992216|NCT00337753|Other|Wait-list|Subjects in wait-list for six-weeks
88992217|NCT00337870|Experimental|Treatment|50% randomized to receive distraction intervention during painful procedure
88992218|NCT00337870|No Intervention|Control|50% RANDOMIZED TO RECEIVE NO INTERVENITON
88992219|NCT04715737|Experimental|Vasopressin|Vasopressin (20IU) intranasally
88992220|NCT04715737|Experimental|Oxytocin|Oxytocin (24IU) intranasally
88992221|NCT04715737|Placebo Comparator|Placebo|Placebo intranasally
88992222|NCT00337909|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
88992223|NCT00337909|Active Comparator|Active Control|Educational DVDs
88992224|NCT00337909|No Intervention|No Contact Control|
88992225|NCT00509431|Experimental|Erlotinib + Sirolimus|This is an open-label,phase I single-arm dose-escalation and phase II study of continuous, once daily doses of erlotinib administered orally in combination with sirolimus in adult patients with malignant glioma at first, second or third recurrence
88992226|NCT00509470|Active Comparator|telmisartan plus low-dose hydrochlorothiazide|12 week combination therapy with telmisartan plus low-dose hydrochlorothiazide
88992227|NCT00509470|Active Comparator|Amlodipine|Amlodipine is continuously administered.
88992228|NCT00150072|Experimental|imatinib|
88992229|NCT00509548|Experimental|1|Dose 1
88992230|NCT00509548|Experimental|2|Dose 2
88992231|NCT02953366|Experimental|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
88992232|NCT02953366|Active Comparator|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
88992233|NCT02953327|Experimental|Intervention arm|Intervention arm, these participants will receive BCG vaccination.
88992234|NCT02953327|Placebo Comparator|Placebo arm|The placebo arm will receive BCG solvent.
88992235|NCT02953288||Benign thyroid nodules|Benign thyroid nodules
88992236|NCT02953288||Thyroid Carcinoma|Thyroid Carcinoma
88992237|NCT02953210|Experimental|GF general free|pre induction midazolam 50ug.kg-1, clonidine 1ug.kg induction dexter ketamine 0.2mg.kg, lidocaine 1.5mg.kg, propofol 2mg.kg,rocuronium 0.6mg.kg maintenance isoflurane 1 CAM, lidocaine 2mg.kg.h
88992238|NCT02953210|Active Comparator|GBal general balanced|pre induction with midazolam 50 ug.kg induction fentanyl 3ug.kg, propofol 2mg.kg, rocuronium 0.6mg.k maintenance isoflurane 1 CAM and fentanyl as needed
88992239|NCT05151692|Experimental|Cohort 1: Nipocalimab|Participants will receive a single intravenous (IV) dose of nipocalimab Dose 1 on Day 1.
88992240|NCT05151692|Experimental|Cohort 2: Nipocalimab|Participants will receive a single IV dose of nipocalimab Dose 2 on Day 1.
88992241|NCT05151692|Experimental|Cohort 3: Nipocalimab|Participants will receive a single IV dose of nipocalimab Dose 3 on Day 1.
88992242|NCT02953249||Study group|The study group will include 30 subjects with type 1 diabetes mellitus who require extraction of 1 or more erupted teeth
88992243|NCT02953249||Control group|The control group will include 30 healthy subjects, without diabetes mellitus, in need of tooth extraction
88992244|NCT02953132|Experimental|Single ascending dose, MT-4129 or Placebo|
88992245|NCT02953132|Experimental|Multiple ascending dose, MT-4129 or Placebo|
88992246|NCT02953054|Active Comparator|DMTS|DMTS applied to the upper arm
88992247|NCT02953054|Placebo Comparator|Placebo|Placebo patches to match DMTS applied to the upper arm
88992248|NCT05110352|Experimental|Obstructive Sleep Apnea Syndrome patients with polysomnography planned|Apnea-Hypopnea Index (AHI) > 15
88992249|NCT00509743|Experimental|A|Low dose Diclofenac
88992250|NCT00509743|Experimental|B|High dose Diclofenac
88992251|NCT00509782|Experimental|ZIO-101|
89218010|NCT00903578||Kidney transplant recipients|
89218011|NCT00903656|Experimental|Caelyx/Lapatinib|
89646139|NCT04332016||COVID-19 infected patients|
89646140|NCT04325685|Placebo Comparator|Control group|
89646141|NCT04325685|Active Comparator|Antiseptic (Octenisept) group|
89646142|NCT04325685|Experimental|Bacteriophage (Sextaphag) group|
89646143|NCT04319276|Experimental|Dose-escalation Phase (500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
89646144|NCT04319276|Experimental|Dose-escalation Phase (1,000 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
89646145|NCT04319276|Experimental|Dose-escalation Phase (1,500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
88992252|NCT00509860|Experimental|Irinotecan|Irinotecan 16 mg/m2 by vein daily over 1 hour for 5 Days
88992253|NCT00509938|Experimental|1|5mg hLF1-11, single dose iv
88992254|NCT00338026|Experimental|ECO-4601|
88992255|NCT03459937|Experimental|Hatha Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Hatha Yoga.
88992256|NCT03459937|Experimental|Vinyasa Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Vinyasa Yoga.
88992257|NCT02958215|Placebo Comparator|Group A|This group will include patients with orthostatic hypotension and will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
88992258|NCT02958215|Active Comparator|Group B|This group will include patients with orthostatic hypotension and will be managed with prophylaxis single dose of phenylephrine, 50 ug IV, will be administered immediately before the spinal block then the patients will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
88992259|NCT02953171|Experimental|Raw sauerkraut+Probiotic capsule|75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
88992260|NCT02953171|Experimental|Raw sauerkraut+placebo capsule|75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.
88992261|NCT02953171|Experimental|Pasteurized sauerkraut+Probiotic capsule|75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
88992262|NCT02953171|Placebo Comparator|Pasteurized sauerkraut+Placebo capsule|75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.
88992263|NCT00158574|Placebo Comparator|Placebo|IPTi placebo
88992264|NCT00158574|Experimental|Sulphadoxine-pyrimethamine|IPTi SP
88992265|NCT00158574|Experimental|Mefloquine|
88992266|NCT00158574|Experimental|Chlorproguanil dapsone|
88992267|NCT00338182|Experimental|AZD1152|AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment)
88992268|NCT04695886|Experimental|CIME intervention|Community-delivered Integrated Malaria Elimination (CIME). The CIME intervention model integrates interventions for malaria, dengue, tuberculosis, childhood diarrhoea and RDT-negative fever.
88992269|NCT04695886|No Intervention|ICMV standard of care|Integrated Community Malaria Volunteer (ICMV) model - this is the current standard of care. This model involves malaria volunteers undertaking additional screening and referral services for a range of other diseases including: dengue, lymphatic filariasis, tuberculosis, HIV/AIDS and leprosy.
88992270|NCT00509977|Experimental|1|Light therapy
88992271|NCT00509977|Experimental|2|Laser Treatment
89646146|NCT04319276|Experimental|Dose-escalation Phase (2,000 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
89646147|NCT04319276|Experimental|Dose-escalation Phase (2,500 mg)|This is a 3 + 3 design. Participants will be entered sequentially. If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level. If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level. If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level. If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD). If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose. If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
89646148|NCT04319276|Experimental|Dose-expansion Phase|A minimum of six participants will be enrolled in the dose expansion phase for a total of 12 subjects at the recommended phase 2 dose.
89646149|NCT04311983|Active Comparator|Tobacco Quitline only|Smokers in this study group will be offered their state Tobacco Quitline programs
89646150|NCT04311983|Experimental|Tobacco Quitline plus Smoke Free Homes|Smokers in this study group will be offered their state Tobacco Quitline programs, but if they decline, they will be offered a Smoke Free Homes intervention
89646151|NCT04305691|Experimental|Treatment (ixazomib)|Patients receive ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response may continue treatment for an additional 12 cycles in the absence of disease progression or unacceptable toxicity.
89646152|NCT04299880|Other|Napabucasin monotherapy|Patients in this arm will receive napabucasin administered orally, twice daily
89646153|NCT04299880|Other|Napabucasin in combination with Gemcitabine and Nab-paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously once weekly, on 3 of every 4 weeks.
89646154|NCT04299880|Other|Napabucasin in combination with Nivolumab|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly nivolumab 3mg/kg administered intravenously over 60 minutes.
89646155|NCT04299880|Other|Napabucasin in combination with paclitaxel|Patients in this arm will receive napabucasin administered orally, twice daily in combination with weekly paclitaxel administered intravenously once weekly, on 3 of every 4 weeks.
89646156|NCT04299880|Other|Napabucasin in combination with FOLFIRI|Patients in this arm will receive napabucasin administered orally, twice daily in combination with biweekly FOLFIRI. Addition of bevacizumab, per Investigator choice, will be permissible.
89646157|NCT04280848|Experimental|Cohort A: UCPVax vaccine (patient with unmethylated MGMT status)|UCPVax
89646158|NCT04280848|Experimental|Cohort B: UCPVax vaccine + Temozolomide (patient with unmethylated or methylated MGMT status)|"UCPVax~+ Temozolomide according to standard of care"
89646159|NCT04257227|Experimental|rTMS Intervention Group|
89646160|NCT04256421|Active Comparator|Placebo + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
89646161|NCT04256421|Experimental|Tiragolumab + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
89646162|NCT04253171|Active Comparator|Lithoplasty lesion preparation|Balloon lithoplasty will be used as lesion preparation.
89646163|NCT04253171|Active Comparator|Conventional lesion preparation|Conventional and modified balloons will be used as lesion preparation.
89646164|NCT04252742|Experimental|Erenumab|"The 4-month DBTP has 2 phases:~Main double-blind treatment phase (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptan therapy as well as non-ictal burden."
89646165|NCT04252742|Experimental|Placebo|"The 4-month DBTP has 2 phases:~Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptan therapy as well as non-ictal burden."
89646166|NCT04237623|Experimental|GM-CSF post-transplant|Sargramostim (GM-CSF) will start on Day +5 and continue until ANC >1000 x3 days or >1500 x1 day. GM-CSF will be administered not less than 24 hours after the last dose of cyclophosphamide and will be given at a dose of 250mcg/m2/day as an infusion over 2 hours.
89646167|NCT04225884|Active Comparator|DTx for pain|Treatment A software
89218012|NCT00730067|Experimental|1|Sildenafil treatment
89218013|NCT00730067|Placebo Comparator|2|placebo
89646168|NCT04225884|Sham Comparator|Control|Treatment B software
89646169|NCT04225884|Other|Standard care|Pain medication
89646170|NCT04223401|Experimental|Prehabilitation group|Patients in the experimental group will undergo prehabilitation before the elective surgery for gastric cancer.
89646171|NCT04223401|No Intervention|Control group|Patients in the control group will not undergo prehabilitation.
89646172|NCT04218331|Experimental|JASPER only|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
89646173|NCT04218331|Active Comparator|JASPER + PROMPT|This group will consist of the child and therapist having one-on-one, JASPER sessions plus Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT), twice a week.
89646174|NCT04208321|Experimental|Cohort 1|40 mg (1 tablet of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
89646175|NCT04208321|Experimental|Cohort 2|80 mg (2 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
89646176|NCT04208321|Experimental|Cohort 3|160 mg (4 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
89646177|NCT04208321|Experimental|Cohort 4|320 mg (4 tablets of 80 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
89646178|NCT04208321|Experimental|Cohort 5|640 mg (8 tablets of 80 mg) of VT-1598 administered orally as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), while fasting on Day 1 in a double-blind manner.
89646179|NCT04208321|Experimental|Cohort 6|160 mg (4 tablets of 40 mg) of VT-1598 administered orally as a single dose, n=6, or matching placebo, n=2, after high-calorie, high-fat meal on Day 1 in a double-blind manner.
89646180|NCT04204902|Experimental|Test Treatment then Reference Treatment|Participants received a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in treatment period 1 followed by a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in treatment period 2. The treatment periods were separated by 21 day washout period.
89646181|NCT04204902|Experimental|Reference Treatment then Test Treatment|Participants received a single oral dose of reference treatment of tepotinib TF3 (2 * 250 mg) in treatment period 1 followed by a single oral dose of test treatment of tepotinib TF3 (5 * 100 mg) in treatment period 2. The treatment periods were separated by 21 day washout period.
89646182|NCT04197713|Experimental|Treatment (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-5 and 15-19 of each cycle and adavosertib PO QD on days 8-12 and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646183|NCT04195789||Sample population|Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.
89044419|NCT04689815|Experimental|Oral arsenic trioxide-Azacitidine|12 monthly cycles of oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle).
89044420|NCT05341557|Experimental|Dose Escalation|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).
89044421|NCT05341557|Experimental|Dose Expansion|"Oral capsules administered at recommended doses. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).~Cohort 1: Advanced NSCLC Cohort 2: Relapsed/refractory lymphoma Cohort 3: Advanced HCC Cohort 4: Other Advanced Solid Tumors"
89044422|NCT01187446|Experimental|TSEBT & Vorinostat|"Total skin electron beam therapy (TSEBT) will be performed per institution guidelines.~Vorinostat will be administered at a dose of 400 mg/day, starting one day prior to the initiation of TSEBT. During TSEBT, vorinostat should be taken in the morning and preferably prior to TSEBT."
89044423|NCT01187446|Active Comparator|TSEBT only|"Total skin electron beam therapy (TSEBT) will be administered according to the Stanford 6-field technique or equivalent technique per institutional standards. Patients will receive a planned total skin dose of 12 grey (Gy) fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks. Supplements will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions (1-2 Gy fractions to a total dose of 12 Gy). Discrete tumors may receive additional boost treatment not to exceed 12 Gy."
89044424|NCT02931110|Experimental|CBL0137 Dose Escalation|"Dose Level 1: 150mg/m2, IV~Dose Level 2: 180mg/m2, IV~Dose Level 3: 240mg/m2, IV~Dose Level 4: 320mg/m2, IV~Dose Level 5: 400mg/m2, IV~Dose Level 6: 540mg/m2, IV~Dose Level 7: 650mg/m2, IV~Dose Level 8: 780mg/m2, IV~Dose Level 9: 950mg/m2, IV~Dose Level 10: 1150mg/m2, IV~Dose Level 11: 1400mg/m2, IV~Dose Level 12: 1700mg/m2, IV~Dose Level 13: 2000mg/m2, IV~Dose Level 14: 2400mg/m2, IV~Dose Level 15: 2900mg/m2, IV~Dose Level 16: 3500mg/m2, IV"
89044425|NCT04224285|Experimental|Early Dayzz|Participants receive a Sleep Health and Wellness education session and download the Dayzz app. Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries.
89646184|NCT04181463|Experimental|Arm I (isopropyl alcohol)|Patients receive isopropyl alcohol via nasal inhalation.
89646185|NCT04181463|Placebo Comparator|Arm II (placebo)|Patients receive placebo via nasal inhalation.
89646186|NCT04176705|Experimental|Laser|
89646187|NCT04176705|Placebo Comparator|No laser|
89646188|NCT04169542||Observational (questionnaire)|Patients complete up to 4 electronic questionnaires over 15 minutes before surgery and at 6, 12, and 24 months after surgery.
89646189|NCT04167358|Experimental|Participants receiving linerixibat|Participants who previously participated in the Phase 2 studies (BAT117213 and 201000 GLIMMER [Group 1]) and Phase 3 study (212620 GLISTEN [Group 2]), will receive linerixibat.
89646190|NCT04166383|Experimental|1/Arm 1|Vascular Biogenics (VB)-111 and nivolumab
89646191|NCT04164004|Experimental|Routine Collection of Patient-Reported Health Status (KCCQ-12 Arm)|Patients in the KCCQ-12 arm will undergo KCCQ-12 assessment of patient-reported heart failure health status in the electronic health record at each heart failure clinic visit beginning at the start of the trial. Assessment results will be available to clinicians in the electronic health record when making treatment decisions during each clinic visit.
89646192|NCT04164004|Active Comparator|Usual Care|Patients in the usual care arm will not complete KCCQ-12 assessments in the electronic health record with clinic visits. They will complete a KCCQ-12 assessment at baseline that will not be available to the treating clinician.
89646193|NCT04163458|Experimental|MENOPUR liquid|MENOPUR liquid (including placebo to MENOPUR powder) initiated at a fixed dose of 225 international units (IU) for first five stimulation days. From stimulation Day 6, dosing could be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose was 450 IU/day and the minimum dose was 75 IU/day. The dosing could continue for a maximum of 20 days.
89646194|NCT04163458|Active Comparator|MENOPUR powder|MENOPUR powder (including placebo to MENOPUR liquid) initiated at a fixed dose of 225 IU for first five stimulation days. From stimulation Day 6, dosing could be adjusted as needed every second day by 75 IU per adjustment based on the participant's follicular response. The maximum dose was 450 IU/day and the minimum dose was 75 IU/day. The dosing could continue for a maximum of 20 days.
89646195|NCT04149522|Active Comparator|Medial Breast Tissue|Women assigned to the medial breast tissue arm, will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the medial breast tissue by clinically trained staff on day 1 of radiotherapy, the lateral segment will not be covered. The treatment area is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to the skin, then the paper frame is removed. Multiple sheets of non-overlapping film will be used to adequately cover the treatment area. During course of radiotherapy, new film may be applied by clinically trained staff in the event the film no longer adheres to the skin or comes off. Replacement of the film may be done as often as necessary. If there are signs of infection (e.g. redness, feeling warm or swollen), film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or clinically trained staff.
89646196|NCT04149522|Active Comparator|Lateral Breast Tissue|Women assigned to the lateral breast tissue arm will have the area of the breast visually divided into 2 equal parts; medial and lateral. The film will be applied to the lateral breast tissue only, by trained staff on day 1 of radiotherapy. The in-field ipsilateral axilla will be included with lateral breast segment to extent necessary to cover breast or chest wall only. The skin is cleaned with mild soap, rinsed with water, and dried. The film is applied, sticky side to skin and paper frame is removed. Multiple sheets of non-overlapping film will be used to cover the treatment area. During course of therapy, new film may be applied as often as necessary, by trained staff if film no longer adheres to skin or comes off. If there are signs of infection (e.g. redness, feeling warm or swollen), the film can be removed. The film will remain in place until one week following the last day of radiotherapy, where it will be removed by the physician or trained staff.
89646197|NCT04146428|Experimental|clinician-mediated JASPER|This group will consist of the child and therapist having one-on-one, JASPER sessions, twice a week.
89646198|NCT04146428|Experimental|parent-mediated JASPER|This group will consist of the therapist assisting the parent implement JASPER on the child twice a week.
89646199|NCT04144322|Other|Short Implant|17 patients will receive a 5 mm short implant.
88992272|NCT00510016|Experimental|Clonidine treatment|Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.
88992273|NCT05065580|Active Comparator|Low Somatic Symptom Score|"Patients meeting PHQ-9 (Patient health Questionnaire)-9 with score greater than 10 with Somatic Symptom Score less than 7.~These patients will receive the OMT treatment protocol and PHQ-9 and SSS scales will be recorded at 0, 4, and 8 weeks."
88992274|NCT05065580|Active Comparator|High Somatic Symptom Score|Patients meeting PHQ-9 (Patient health Questionnaire)-9 with score greater than 10 with Somatic Symptom Score 8 or greater These patients will receive the OMT treatment protocol and PHQ-9 and SSS scales will be recorded at 0, 4, and 8 weeks.
88992275|NCT04695964|Other|ICG-NIRF Imaging and objective perfusion rate|ICG-NIRF imaging is used to visualise the blood supply and the bowel perfusion rate in the area of the pouch anastomoses. An additional ingress and egress analysis at specific regions of interest is performed. This is to get an objective method of visualisation of the blood inflow and outflow over time and thus bowel perfusion at the anastomotic site.
88992276|NCT00338494|Experimental|1|
88992277|NCT02953015|Experimental|Manipulative articulatory and myofascial techniques Group|Manipulative and myofascial techniques
88992278|NCT02953015|Active Comparator|Transcutaneous Electrical Nerve Stimulation Group|Electrical Nerve Stimulation
88992279|NCT05020730|Experimental|PTM-001 400 mg daily for 12 weeks|
88992280|NCT05020730|Placebo Comparator|Placebo daily for 12 weeks|
88992281|NCT00158652|Active Comparator|1|
88992282|NCT00158652|Experimental|2|
88992283|NCT00158652|Experimental|3|
88992284|NCT00338572|Active Comparator|1|12-week exercise program
88992285|NCT00338572|Experimental|2|12-week combined exercise and diet program
88992286|NCT00338572|No Intervention|3|Non-intervention group
88992287|NCT04715698|Experimental|ICG-guided|anti-hypertensive drug selection based on physician's experience and hemodynamic profiling by measured ICG
88992288|NCT04715698|Active Comparator|Empirical|anti-hypertensive drug selection based on physician's experience only
88992289|NCT05004740||Lactating birthing persons delivering at Sinai Health System or from the general population|
88992290|NCT00338767|Experimental|Treatment|Participants receiving storefront directly observed therapy of anti-depressants (Fluoxetine)
88992291|NCT00338767|No Intervention|Control|Participants receiving referral to mental health follow-up with the UCSF AIDS Health Project
88992292|NCT00338845|Experimental|1|Participants will receive the Share Safer Sex counseling program
88992293|NCT00338845|Active Comparator|2|Participants will receive a standard didactic safer-sex counseling session
88992294|NCT00510094|Experimental|1|Participants will receive the Friend to Friend program
88992295|NCT00510094|Active Comparator|2|Participants will receive the psychoeducational attention control intervention
88992296|NCT04997915||Critical COVID-19|Critical COVID-19 patients admitted to the ICU
88992297|NCT00338923|Active Comparator|Treatment arm|One Arm - Active Compound (HO/03/03)
88992298|NCT00510172|Active Comparator|1|Active treatment
88992299|NCT00510172|Placebo Comparator|2|Placebo
88992300|NCT02952976|Active Comparator|Abthera|Patients with open abdomen submitted to treatment with the Abthera dressing
88992301|NCT02952976|Active Comparator|Barker|Patients with open abdomen submitted to treatment with the Baker dressing
89044426|NCT04224285|No Intervention|Late Dayzz|Complete monthly questionnaires for up to 9 months and 2 weeks of sleep diaries. At the end of nine months, participants have the opportunity to receive a Sleep Health and Wellness education session.
89044427|NCT02930993|Experimental|anti-mesothelin CAR T cells|"Dose escalation study aimed to assess the safety and efficacy of anti-mesothelin CAR T cells.~CAR T dosage ranging from 5×10^4 /kg to 1×10^7 /kg will be tested ."
89044428|NCT02931227|Experimental|Brain-injured group|
89044429|NCT02931227|Experimental|Hypothermia group|
89044430|NCT02931227|Experimental|Hyperthermia group|
89044431|NCT02931227|Experimental|PICCO group|
89646200|NCT04144322|Other|Long Implant|17 patients will receive a sinus lift procedure, bone graft, and 10 mm implant.
89646201|NCT04130971||Patients without neoadjuvant treatment|
89044432|NCT04191798|Experimental|KinexConnect|Rehab at Home Patients
89044433|NCT04191798|Active Comparator|Outpatient PT|In-person PT patients
89044434|NCT02931071|Experimental|plerixafor and filgrastim treatment|to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim
89044435|NCT02931032|Experimental|Patients of Student Dental clinic|"Enrolled patients of the student dental clinic in Hadassah Faculty of Dental Medicine, who came to receive scheduled dental treatment and agreed to participate in the trial.~The patients sampled will originate at the students' clinics, and the samples will be taken as part of their dental treatment, namely: removal of caries and infected dentin for future restoration, and dental calculus and plaque removal for the treatment of periodontal disease."
89044436|NCT01187407|Experimental|12 or 18 mg flexible dose LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to a 12 or 18 mg flexible dose of LY2216684.~During the AT Phase, participants first received 6 mg LY2216684 QD for 3 days, followed by 12 mg QD for the next 11 days. Then, based on efficacy and tolerability, dosage could be increased to 18 mg QD over the next 6 weeks. Participants on 18 mg QD could have had their dose decreased back to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
89044437|NCT01187407|Experimental|6 mg fixed dose LY2216684 + SSRI|"LY2216684: fixed dose of 6 mg, administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to 6 mg fixed dose of LY2216684.~During the AT Phase, participants received a 6 mg fixed dose of LY2216684 adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
89044438|NCT01187407|Placebo Comparator|Placebo + SSRI|"Placebo: administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to placebo.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
89044439|NCT02930681|Placebo Comparator|Placebo|Four capsules of placebo to be taken 30 mins before each test meal at the investigator's site
89646202|NCT04130971||Patients with short course radiotherapy|
89646203|NCT04130971||Patients with long course chemoradiotherapy|
89646204|NCT04130971||Patients with short course radiotherapy and deferred surgery|
89646205|NCT04130464|Experimental|Ropivacaine|Subjects will receive a continuous intraperitoneal infusion of ropivacaine
89646206|NCT04130464|Experimental|Ropivacaine + Ketorolac|Subjects will receive a continuous intraperitoneal infusion of ropivacaine + ketorolac
89646207|NCT04130464|Placebo Comparator|Normal Saline|Subjects will receive a continuous intraperitoneal infusion of normal saline
89646208|NCT04118348|No Intervention|Passive Control|Will consist of no alerts and will serve to examine lipid panel screening rates given the current standard of care. After 6 months, providers in this (and other conditions) will receive the alert(s) with the best demonstrated success in increasing screening rates.
89646209|NCT04118348|Experimental|Best Practice Alert (BPA-only)|Will consist of a BPA that fires for providers during a visit with an eligible 9-11 year-old patient. This is an active opt-in alert wherein the provider must respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test. The BPA will include a recommendation to administer the screen in combination with existing scheduled bloodwork.
89646210|NCT04118348|Experimental|Health Maintenance Topic (HMT-only)|Will consist of an HMT in Epic that is present for providers at their visit with an eligible patient. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
89646211|NCT04118348|Experimental|BPA+HMT|Will consist of both the BPA and HMT presented simultaneously in Epic.
89646212|NCT04108988|Experimental|InvestiDate Intervention|One Night Stan will be adapted as a multiplayer videogame called InvestiDate based on the card game prototype with a focus on a slightly younger age group.
89646213|NCT04108988|Placebo Comparator|Non-Health Related Game|Participants in the non-health related game group will play a multiplayer game unrelated to the content of InvestiDate.
89646214|NCT04108858|Experimental|Phase I, Phase II Arm I (copanlisib, trastuzumab, pertuzumab)|Patients receive copanlisib IV over 60 minutes on days 1 and 8. Patients also receive trastuzumab IV over 30-90 minutes and pertuzumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89646215|NCT04108858|Active Comparator|Phase II Arm II (trastuzumab, pertuzumab)|Patients receive trastuzumab IV over 30-90 minutes and pertuzumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89646216|NCT04108273|Experimental|OST Intervention|
89646217|NCT04108273|Other|Waitlist|
88992302|NCT00420940|Experimental|90 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
88992303|NCT00420940|Experimental|30 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
88992304|NCT00420940|No Intervention|control|control group (receiving no vibration)
88992305|NCT00425191|Experimental|1|
89646218|NCT04101656||Experimental: APBI (Accelerated Partial Breast Irradiation)|APBI 28 Gy in 5 fractions of 5.6 Gy, using external radiotherapy with modulated intensity technique (IMRT)
89646219|NCT04099615||Endovascular urgent stroke treatment group|Patients between 18 and 85 years old who have and acute cerebral stroke due to a demonstrated occlusion in the anterior circulation (M1 or M2 segment of middle cerebral artery with or without ipsilateral internal carotid artery (ICA), that undergo endovascular acute therapy fulfilling all inclusion criteria and with non exclusion criteria for that treatment. We also exclude patient with well-documented history of neuromuscular disorders, stroke or central nervous system tumors that could interfere in the SEPs assessment.
89646220|NCT04098237|Experimental|Standard of care treatment with Pancreaze (pancrelipase)|Pancrelipase capsules; 84,000 IU lipase units per main meal and 42,000 IU lipase units per snack; for 24 weeks
89646221|NCT04090762|No Intervention|Control|Women in the control arm will complete the baseline and follow up surveys but will not receive any intervention.
88992306|NCT00425191|Experimental|2|
88992307|NCT00425191|Experimental|3|
88992308|NCT04995926|Experimental|Labial mucosa epithelium grafting for corneal limbus substitution.|Surgery for treating limbal stem cell deficiency using a strip of the lip oral mucosa with trimmed off the substantia propria and grafted as a circular corneal limbus substitute.
88992309|NCT02952937|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF3 tablet 300mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
88992310|NCT02952937|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
88992311|NCT00339196|Experimental|1|5-azacytidine VALPROIC acid and ATRA
88992312|NCT04993391|Experimental|40mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per
88992313|NCT04993391|Experimental|80mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational per
88992314|NCT04993391|Experimental|160mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
88992315|NCT04993391|Experimental|240mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
88992316|NCT04993391|Experimental|320mg dose.|The subjects will receive a single dose at first in this stage, and be observed for 7 days subsequently, if tolerated, the subjects will enter the multi-dose study on oral AP-L1898 once per day for consecutive 21 days. The DLT observational pe
88992317|NCT00510211||olanzapine coated tablet|
88992318|NCT00510211||olanzapine orodispersable tablet|
88992319|NCT00339352||1|Cases
88992320|NCT00339352||2|Controls
88992321|NCT00339352||3|first-degree relatives of cases/controls
88992322|NCT02952547|Experimental|Test / Reference Drug|DWJ1366 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
88992323|NCT02952547|Experimental|Reference / Test Drug|Co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1366 Tab.
88992324|NCT00510250|Experimental|Cisplatin and Radiation in Combination with Sorafenib|
88992325|NCT00158769|Experimental|Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment as defined by a Child-Pugh score of 7-9 will be included. Subjects will be given GR270773 as a loading infusion of 25 milligram per kilogram per hour (mg/kg/hr) for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours.
88992326|NCT00158769|Experimental|Healthy subjects|Subjects will be matched as closely as possible to the group of moderate hepatic subjects for gender, age and body mass index (BMI). Subjects will be administered 25 mg/kg/hr GR270773 as a loading dose for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours. Following a washout period of 21 days, the subjects will then receive a loading dose of 75 mg/kg/hr for 2 hours followed by a maintenance dose of 12.5 mg/kg/hr of GR270773 for 70 hours.
88992327|NCT00339469|Other|2|Controlled feeding study.
88992328|NCT02952703|Active Comparator|First Breath|brief pre-natal smoking cessation counseling
88992329|NCT02952703|Experimental|Striving to Quit|Additional pre-natal counseling (in-person and telephonic); post delivery counseling (in-person and telephonic) and incentives
88992330|NCT00510367|Experimental|Multimodality Treatment|"Multimodality (chemotherapy, surgery and radiation therapy) treatment:~5-Fluorouracil + Doxorubicin + Cyclophosphamide (FAC)"
88992331|NCT04980716|Experimental|The early intervention group|"The early intervention group: evaluation and intervention based on impedance cardiography results at multiple timepoints. Specific intervention measures include:~cardiovascular drug treatment: based on the increase and decrease of the Golden Triangle~ACEI, perindopril tert-butyrate 4mg qd~β receptor antagonist, metoprolol succinate 47.5mg qd~Spironolactone 20mg qd~Drugs to improve myocardial metabolism: trimetazidine hydrochloride 35 mg bid~Other therapeutic drugs include: loop diuretics, ARNI, sinus node If current selection specific inhibitors, statins, antiplatelet aggregation and nitrate drugs, etc.~Exercise intervention: exercise prescription based on the initial cardiopulmonary exercise test results."
89646222|NCT04090762|Active Comparator|Risk information only|Women in the risk only arm who exhibit characteristics associated with a greater risk of a poor birth outcome will be informed that they possess these characteristics. Risk characteristics (identified from the medical and epidemiological literature) include age, prior pregnancy and birth history (e.g., previous stillbirth).
89218014|NCT00909194|Experimental|Intervention|Educational Seminar on Juvenile Primary Fibromyalgia Syndrome and CD-guided total body relaxation technique
89646223|NCT04090762|Active Comparator|Conditional Cash Transfer only|Women in this arm will be eligible to receive conditional cash transfers. To receive the transfer, pregnant women must attend prenatal care and give birth in a health facility.
89646224|NCT04090762|Active Comparator|Conditional Cash Transfer and risk information|Women in this arm will be provided with risk information at the time of baseline survey administration AND be eligible to receive conditional cash transfers, pending attendance at prenatal care and delivery at a health facility.
89646225|NCT04088981|Active Comparator|Low-fat, vegan diet|For a 22-week period, participants will be asked to follow a low-fat vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
89646226|NCT04088981|Active Comparator|Portion-controlled diet|For a 22-week period, participants will be asked to follow a portion-controlled diet which will include individualized diet plans that reduce daily energy intake by 500 kcal for overweight participants, and keep carbohydrate intake reasonably stable over time. It will derive 50% of total energy from carbohydrates, 20% from protein, and less than 30% from fat (≤7% saturated fat), with less than 200 mg/day of cholesterol/day.
89646227|NCT04084860|Experimental|CI-581a + MET/MBRP|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
89646228|NCT04084860|Experimental|CI-581a + Medication Management|Administration of CI-581a during weeks 1 and 6 at 0.71 mg/kg in the context of a 12 wk outpatient treatment ( no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
89646229|NCT04084860|Active Comparator|CI-581b + MET/MBRP|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (behavioral treatment combination of MET/MBRP will be provided)
89646230|NCT04084860|Active Comparator|CI-581b + Medication Management|Administration of CI-581b during weeks 1 and 6 at 0.0125 mg/kg in the context of a 12 wk outpatient treatment (no MET/MBRP sessions will be provided, only general check-ins and psychiatrist visits)
89646231|NCT04054154|Experimental|Device Feasibility (Millar Mikro-tip catheter, elastography)|Patients scheduled for an ultrasound-guided tumor biopsy undergo stiffness assessment of the tumor with shear wave elastography over 2 minutes and pressure measurements of the tumor using a Millar Mikro-tip catheter before and after the biopsy is collected.
89646232|NCT04051229|Experimental|Exercise Training Group|All 20 participants will be assigned to this arm. These individuals will participate in 6 weeks of a moderate supervised aerobic exercise training program.
89646233|NCT04049994|Experimental|Immunomodulation|Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).
89646234|NCT04049994|Placebo Comparator|Placebo|Oral placebo tablet once daily for 90 days.
89646235|NCT04042259|Active Comparator|Negative Pressure Wound Therapy|Standardized wound closure with negative pressure therapy.
89646236|NCT04042259|Other|Historic Cohort|Historic cohort have undergone a midline laparotomy and managed with an open abdomen for at least one day and have contaminated or dirty wound classification.
89646237|NCT04040387|Experimental|Treatment Arm|Intervention with NightWare Therapeutic System
89646238|NCT04040387|Sham Comparator|Sham Arm|NightWare system set to not provide any interventions
89646239|NCT04037605|Experimental|Control Condition|"8 am - Saline Solution for Injection~10 am - Placebo oral capsule~1 pm - Saline Solution for Injection~4 pm - Placebo oral capsule & start hourly blood sampling~7 pm- Gonadorelin (GnRH) and Corticorelin (CRH) injections~9 pm - Saline Solution for Injection & last blood sample"
89646240|NCT04037605|Experimental|Hypothalamic Condition|"8 am -Ganirelix~10 am - Placebo oral capsule~1 pm - Dexamethasone injection~4 pm- Placebo oral capsule and start of hourly blood sampling~7 pm - GnRH and CRH injections~9 pm - Saline Solution for Injection and last sample blood sample"
89646241|NCT04037605|Experimental|Pituitary Condition|"8 am - Saline Solution for Injection~10 am - Ketoconazole Pill~1 pm - Saline Solution for Injection~4 pm - Ketoconazole Pill & start of hourly blood sampling~7 pm - GnRH and CRH~9 pm - Hydrocortisone Injection and last blood sample"
89646242|NCT04037605|Experimental|Adrenal/Testis Condition|"10 pm - Ganirelix Injection & Dexamethasone Pills (night before)~8 am - Start of hourly blood sampling~10 am - Dexamethasone Pills~11 am - Last hourly blood sample taken~11:30 am - Start of blood sampling every 10 minutes~1 pm - Recombinant Human Luteinizing Hormone (rhLH) Injection~3 pm - rhLH Injection~5 pm - rhLH Injection~5 pm - Cosyntropin Injectable product~7 pm - GnRH and CRH Injections~9 pm - Last blood sample"
89646243|NCT04018937|Experimental|Reduced Intensity Conditioning with FAM|Children with SCD will received reduced intensity conditioning with fludarabine, alemtuzumab and melphalan (FAM) during HSCT with a HLA matched sibling donor
89646244|NCT04017936|Experimental|Anakinra|100 mg/0.67 mL daily subcutaneous injection for 4 weeks
89646245|NCT04017936|No Intervention|Standard of Care|Continue standard of care treatment
89646246|NCT04016389|Experimental|Neo-Adjuvant Chemotherapy, Surgery, and Adjuvant Chemotherapy|"Participants will receive neo-adjuvant treatment cisplatin or carboplatin with paclitaxel, intravenously, either once every cycle or once a week, for three (21-day) cycles.~After neo-adjuvant treatment, depending on their status, participants may have the trachelectomy done.~Adjuvant treatment may include standard chemotherapy and radiotherapy, or a hysterectomy may need to be done."
89646247|NCT04013841|Experimental|Oral preparation|The bowel preparation prior to colorectal resection will be conducted using oral-agents
89218015|NCT00909194|No Intervention|Control|Control Arm consisted of an educational seminar on skin care
89218016|NCT00509145|Experimental|Laquinimod|Laquinimod 0.6 mg, oral
89218017|NCT00509145|Placebo Comparator|Placebo|Matching placebo
89646248|NCT04013841|Experimental|Enema preparation|The bowel preparation prior to colorectal resection will be conducted using rectal enema
89646249|NCT04009668|Experimental|adalimumab|Adalimumab dose every other week (study weeks 0, 2, 4, 6, and 8), subcutaneously
89646250|NCT04006990|Experimental|Intervention|Subjects are given recliner chairs and education on the dangers of bedrest
89646251|NCT04006990|No Intervention|Control|Subjects are treated with standard care
89646252|NCT04003779|Other|Participant stability with various room configurations|Single-arm. Ergonomically exploring patient stability moving around various configurations of a hospital room.
89646253|NCT03993561|Experimental|TSSP Group|A one-hour treatment summary and survivorship care plan (TSSP) intervention specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists will be provided
89646254|NCT03987035|Experimental|BGP Stent Graft System|BGP Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms
89646255|NCT03985839||MICRORAPTOR™ REGENESORB™ Suture Anchor|MICRORAPTOR™ REGENESORB™ Suture Anchor
89646256|NCT03985839||MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
89646257|NCT03985839||MICRORAPTOR™ Knotless PEEK Suture Anchor|MICRORAPTOR™ Knotless PEEK Suture Anchor
89646258|NCT03985592|Other|Educational Intervention for ICU-Based Clinicians|ICU-based clinicians (e.g. physicians, RNs, and social workers) will be provided with educational modules related to bereavement support for family members. Following the modules a survey will be provided to participants to assess their perceived usefulness of the modules.
89646259|NCT03985592|Experimental|Educational material and personalized card of condolence|Members of the ICU team who cared for deceased ICU patients will be asked to send a letter of condolence to family members listed as the patient's primary contact and provide them with educational modules related to bereavement support for family members.
89646260|NCT03985592|Experimental|Virtual meeting with the care team to address unmet needs|At 8-12 weeks post-death, we will contact FMs and invite them to meet virtually with the care team. Our observational studies indicated that the most common need reported by bereaved FMs was the desire to meet with the care team to review events during the ICU stay and particularly the events that led to death, and that this was the type of support that ICU clinicians were most comfortable providing.
89646261|NCT03985592|Experimental|Offering a facilitated storytelling intervention session|At six months post-death, we will contact FMs and administer the Inventory of Complicated Grief-Revised (ICG-r), Brief Grief Questionnaire (BGQ), Impact of Events Scale - Revised (IES-r), Patient Health Questionnaire-9 (PHQ-9), and the Bereavement Dependency Scale (BDS). FMs who complete all questionnaires will be invited to participate in a 1-2-hour narrative exploration of their grief and bereavement experience, regardless of the severity of their symptoms. Those with severe symptoms will be notified of symptom severity, with a suggestion to participate in the narrative exploration of their grief and bereavement experience. Storytelling interventions require specialized resources but the results of Barnato et al., as well as the response to our qualitative interviews, suggest that this intervention may only be helpful for selected FMs. Storytelling interventions have been shown to reduce healthcare utilization and improve subjective health following a traumatic experience.
89646262|NCT03985020|No Intervention|Standard of Care|The control group will receive standard of care dietary advice for their solid food and beverage intake.
89646263|NCT03985020|Active Comparator|Water Intervention|We will order and deliver bottled water to the homes of subjects in the treatment group. We will provide each participant with a weekly supply of about 36 16.9 fl oz single-serving containers. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously.
89646264|NCT03985020|Experimental|Stevia Intervention|We will order and deliver a commercially-available stevia-sweetened soft drink Zevia (Los Angeles, CA) to each participant in the treatment group. We will provide each participant with a weekly supply of 24 12 fl oz single-serving containers. Zevia will be provided in an assortment of flavors for the first week, then catered to the preference of the participant for the remainder of the study. We will instruct subjects to notify us by calling a dedicated telephone line on occasions when a delivery is expected but not received so that the problem can be corrected expeditiously. Participants will also be asked to keep track of how many containers they consume using a sticker chart, and we will also phone parents weekly to verify the sticker charts
89646265|NCT03982940|Experimental|BGP+ Stent Graft System|Application of BeGraft Peripheral Plus (BGP+) Stent Graft System as bridging stent in Branched Endovascular Repair (BEVAR) for complex aortic aneurysms
89646266|NCT03958747|Experimental|Ultrasound|Undergo peripheral nerve ultrasound
89646267|NCT03943667|Experimental|GEMPAX|Gemcitabine + Paclitaxel until progression
88992332|NCT04980716|No Intervention|The control group|This group will be under observation. When cardiovascular events (including ischemic cardiomyopathy, heart failure, arrhythmia requiring treatment, pericardial disease requiring treatment, valvular disease, etc.) happen, a cardiovascular specialist assessment and intervention will be given.
88992333|NCT00339625|Experimental|1|low fat, high fiber, high fruit and vegetable eating plan
88992334|NCT00339625|No Intervention|2|Usual Diet
88992335|NCT00158886|Experimental|Subjects with rectal cancer|Subjects will be administered topotecan along with concomitant radiation for five days per week for five weeks. Topotecan doses will start at 0.25 milligrams per square meter (mg/m˄2) and will be escalated 0.15 mg/m˄2 for subsequent cohorts. To advance to the next dose level of topotecan, at least two subjects will have to complete therapy with oral topotecan without experiencing grade 3 or 4 toxicity for three weeks after the oral topotecan treatment.
89218018|NCT00907790|Experimental|Comprehensive Self-Management (CSM)|"Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS~--------------------------------------------------------------------------------"
89646268|NCT03943667|Active Comparator|Control|Gemcitabine alone until progression
89646269|NCT03941834|Active Comparator|BHV3000|
89646270|NCT03941834|Placebo Comparator|Placebo|
89646271|NCT03939858||Cognitive Function Analysis|Cognitive function will be evaluated using a customized cognitive battery designed for brain tumor patients. Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
88992336|NCT00339664||1/ patients|Patients on approved clinical trials
89646272|NCT03930251|No Intervention|Treatment as Usual|This is the standard coordinated specialty care treatment (without cognitive remediation) that is provided to OnTrackNY clients. This treatment involves psychiatric treatment, employment and educational support, substance abuse treatment, family education and support, CBT-informed individual psychotherapy, and cognitive health support services as needed.
89646273|NCT03930251|Experimental|Clinic-Based Cognitive Remediation|Clinic-based cognitive remediation consists of twice weekly group-based and clinician-led sessions.
89646274|NCT03930251|Experimental|Partial-Remote Cognitive Remediation|Partial-Remote cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
89646275|NCT03927833|Active Comparator|Continuous Phototherapy|Continuous phototherapy
89646276|NCT03927833|Experimental|Cycled Phototherapy|Cycled phototherapy at timed intervals, dependent upon total serum bilirum (TSB) levels.
89646277|NCT03923959|Active Comparator|Intervention|100 cc normal saline with 1g of tranexamic acid in solution
89646278|NCT03923959|Placebo Comparator|Placebo|100 cc normal saline
89646279|NCT03923374||Pregnant Mothers with Opioid Use Disorder|Planned recruitment of 200 pregnant (<16weeks) mothers who have opioid use disorder and are taking buprenorphine
89646280|NCT03923374||Pregnant Mothers|Planned recruitment of 100 pregnant (>16weeks) mothers who do not have any history of opioid use disorder.
89646281|NCT03923270|No Intervention|Thoracic Radiotherapy plus Durvalumab|This Arm is a standard of care Arm. Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 13 doses
89646282|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and 75mg Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 4 doses and 75mg intravenously of Tremelimumab every 4 weeks for up to 4 doses
89646283|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and Olaparib|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg orally of Olaparib twice a day
89646284|NCT03923270|Experimental|Thoracic Radiotherapy plus Durvalumab and 300mg Tremelimumab|Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg Tremelimumab IV x 1 (single dose)
89646285|NCT03916159|Experimental|Extrauterine Placental Transfusion EPT|Intervention group
89044440|NCT02930681|Experimental|Glucosanol 1000mg|Two capsules of placebo and two capsules of Glucosanol 500mg capsules to be taken 30 mins before each test meal at the investigator's site
89044441|NCT02930681|Experimental|Glucosanol 2000mg|Four capsules of Glucosanol 500mg to be taken 30 mins before each test meal at the investigator's site
89044442|NCT05310058|Active Comparator|12.5 g/d of C6 ketone di-ester|Low dose of ketone di-ester.
89044443|NCT05310058|Active Comparator|25 g/d of C6 ketone di-ester|Middle dose of ketone di-ester.
89044444|NCT05310058|Active Comparator|50 g/d of C6 ketone di-ester|Highest dose of ketone di-ester.
89044445|NCT05308576|Experimental|SCTV01E|one dose of SCTV01E on D0
89044446|NCT05308576|Placebo Comparator|Placebo|one dose of Placebo on D0
89044447|NCT02930876|Experimental|Resistance training at home|Participants will undergo training sessions at their own homes. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
89044448|NCT02930876|Experimental|Resistance training at the hospital|Participants will undergo training sessions at the hospital. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
89044449|NCT02930876|No Intervention|Controls|Participants will be given an information leaflet with the exercise recommendations of the Portuguese national ministry of health.
89044450|NCT05329311||ERATS protocol applied|Inflammatory parameters of the operated patients by applying the ERATS protocol will be investigated.
89044451|NCT05329311||ERATS protocol not applied|Inflammatory parameters of patients who were operated without the ERATS protocol will be investigated.
89646286|NCT03916159|Active Comparator|Delayed cord clamping DCC|Control group
89646287|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 0.3mg dose|Low dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
89646288|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 1 mg dose|Intermediate dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
89646289|NCT03913117|Experimental|pNGVL4aCRTE6E7L2 3 mg dose|High dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.
89646290|NCT03913117|Experimental|PVX-6|Selected dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0 and 4, and the TA-CIN protein is administered by intramuscular injection at week 8.
89646291|NCT03911466|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
89057952|NCT02278679||Anesthitized patient|First, it will be validated on 120 anesthetized patients undergoing prostate surgery comparing responses on the digital rectal exam clinical tool (DiRECT) from both expert and novice clinicians, with surgical pathology reports.
89646292|NCT03911466|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
89646293|NCT03910244|Experimental|Pomalidomide|Oral Pomalidomide will be provided as a capsule at 4 mg/day dose. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
89646294|NCT03910244|Placebo Comparator|Placebo|A placebo matching the study drug will be provided as a capsule. There will be 6 treatment cycles of 28 days (4 weeks) each. Total treatment phase duration will be 24 weeks.
89646295|NCT03904550|Active Comparator|Cisatracurium + Neostigmine|Patients in the cisatracurium/neostigmine group will receive 0.2 mg/kg of cisatracurium for neuromuscular paralysis during induction. Additional cisatracurium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
89646296|NCT03904550|Active Comparator|Rocuronium + Sugammadex|Patients in the rocuronium/sugammadex group will receive 0.6 mg/kg of rocuronium for neuromuscular paralysis during induction. Additional rocuronium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
89646297|NCT03895099|Experimental|A - Early follicular phase|Treatment by desogestrel at day 1 to day 3
89212631|NCT05093543|Experimental|Intervention|"The experimental group is based on a telematic multidisciplinary approach for CnsLBP. Scheduled and periodic telematic sessions will be performed. The multidisciplinary approach (to be carried out by telematic means) consists of a biopsychosocial rehabilitation program for patients with CnsLBP that includes physical rehabilitation/physiotherapy and psychosocial group sessions (performed by psychologists, social workers), which will be offered as part of the integrated program.~Patients assigned to the experimental group will receive a Google Meet® link by email, so that they may join the weekly 2-hour group sessions (every Tuesday at 9 a.m.). Google Meet® is a free real-time meeting app by Google that does not require download, has no session time limit, and neither limits the number of users per session. Patients assigned to the experimental group will receive a single-use link by email to access each online group session."
89646298|NCT03895099|Experimental|B - Medium follicular phase|Treatment by desogestrel at day 4 to day 7
89646299|NCT03895099|Experimental|C - Late follicular phase|Treatment by desogestrel at day 7 to day 11
89646300|NCT03895099|Experimental|D - Ovulatory Phase|Treatment by desogestrel at day 12 to day 15
89646301|NCT03895099|Experimental|E - Luteal phase|Treatment by desogestrel at day 16 to day 30
89646302|NCT03893370|Active Comparator|Treatment|RJA MCS
89646303|NCT03893370|Sham Comparator|Sham Control|Sham
89646304|NCT03883139|Active Comparator|JASPER|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing JASPER. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified JASPER for 4 hours a week (4 days, 1 hour per day)."
89646305|NCT03883139|Active Comparator|DTT|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing DTT. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified DTT for 4 hours a week (4 days, 1 hour per day)."
89646306|NCT03852550|Experimental|Usual Care + MyREADYTransition[TM] BBD App|Participants in the experimental Intervention group continue to get the same care they have been getting (their usual care) and they receive the MyREADY Transition[TM] BBD App e-health application. There are 19 parts in the App with videos and games to help youth learn and practice ways to manage their health. There are approximately 5-7 hours of content in total. Participants will be asked to wait at least one day between the parts. There is a timer in the App to help to moderate pace and align with how young people learn and digest information. Participants can choose how much time they want to take to do the App. It is recommended that participants make their own routine for using it. The recommended shortest and longest intervention exposure times are: 1 part each day (this will take 19 days to do all of the App), 1 part each week (this will take 19 weeks to do all of the App).
89646307|NCT03852550|No Intervention|Control Group: Usual Care|Participants in the no intervention Control group continue to get the same care they have been getting (their usual care). The researchers aim to supply the App to participants in both the intervention and control group for a limited time after participation in the study.
89646308|NCT03839342|Experimental|Binimetinib + Encorafenib|Binimetinib and encorafenib are administered orally on a twice daily or once daily schedule, respectively in 28-day cycles. Treatment will continue until it is discontinued due to unacceptable toxicity, clinical or radiological disease progression as per RECIST 1.1, investigator decision, and/or withdrawal of consent.
89646309|NCT03838978|Experimental|Calypso Knee System|Calypso Knee System
89646310|NCT03831594|Experimental|Standard Physiotherapy and Galvanic Vestibular Stimulation|Standard physiotherapy concurrently with Galvanic Vestibular Stimulation for 45 minutes a day for two weeks (five days per week)
89646311|NCT03831594|Active Comparator|Standard Physiotherapy|Standard Physiotherapy for 45 minutes a day for two weeks (five days per week)
89646312|NCT03808610|Experimental|Experimental (venetoclax, vincristine, cyclophosphamide)|See Detailed Description.
89646313|NCT03808103|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally twice a day for 15 days
89646314|NCT03808103|Experimental|Phage|Dose is 1mL of bacteriophage preparation given orally twice a day for 15 days
89646315|NCT03792516|Experimental|Artesunate ointment 40%, 1 cycle|Patients enrolled in this treatment group will receive one 5-day cycle of artesunate ointment applied topically to the vulva at week 0.
89646316|NCT03792516|Experimental|Artesunate ointment 40%, 2 cycles|Patients enrolled in this treatment group will receive two 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0 and 2.
89646317|NCT03792516|Experimental|Artesunate ointment 40%, 3 cycles|Patients enrolled in this treatment group will receive three 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0, 2, and 4.
89044452|NCT01186978|Other|Single arm|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve CR and have a negative post-chemotherapy PET scan following 4 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
89044453|NCT04506905|Experimental|Part 1 (Panel A) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg once daily (QD), orally, over a course of 7-day treatment.
89044454|NCT04506905|Experimental|Part 1 (Panel B) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated up to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panel.
89646318|NCT03783442|Experimental|Tislelizumab + Chemotherapy|"Tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days~Chemotherapy Doublet A: cisplatin 60-80 mg/m^2 or oxaliplatin 130 mg/m^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m^2 on Days 1 to 5 of each cycle Q3W;~Chemotherapy Doublet B: cisplatin 60-80 mg/m^2 or oxaliplatin 130 mg/m^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m^2 on Days 1 to 14 of each cycle, twice a day; or~Chemotherapy Doublet C: cisplatin 60-80 mg/m^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines"
89646319|NCT03783442|Active Comparator|Placebo + Chemotherapy|"Matched placebo administered IV on Day 1 of each cycle every 3 weeks (Q3W) plus one of the following until unacceptable toxicity, disease progression or withdrawal for other reasons; each cycle is 21 days~Chemotherapy Doublet A: cisplatin 60-80 mg/m^2 or oxaliplatin 130 mg/m^2 administered IV on Day 1 of each cycle Q3W and 5-fluorouracil IV 750-800 mg/m^2 on Days 1 to 5 of each cycle Q3W;~Chemotherapy Doublet B: cisplatin 60-80 mg/m^2 or oxaliplatin 130 mg/m^2 administered IV on Day 1 of each cycle Q3W and capecitabine orally 1000 mg/m^2 on Days 1 to 14 of each cycle, twice a day; or~Chemotherapy Doublet C: cisplatin 60-80 mg/m^2 administered IV on Day 1 or 2 or oxaliplatin 130 mg/m^2 administered IV on Day 1 of each cycle Q3W and paclitaxel 175 mg/m^2 IV on Day 1 of each cycle Q3W; cisplatin may be given in 3 divided doses on Days 1, 2, and 3 depending on local guidelines"
89646320|NCT03773822|Placebo Comparator|Placebo of hydrocortisone and placebo of fludrocortisone|Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days
89646321|NCT03773822|Experimental|Combination of hydrocortisone + fludrocortisone|Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days
89646322|NCT03764865|Experimental|day 3 embryo transfer|embryo transfer 3 days after fertilization
89646323|NCT03764865|Experimental|day 5 embryo transfer|embryo transfer 5 days after fertilization
89646324|NCT03756051||Cohort|This study will collect prospective longitudinal data to characterize rates and identify correlates of a) physical harms due to follow-up tests, b) financial harms, and c) inappropriate screening using electronic medical record data and manual chart review. The study will also use surveys and semi-structured interviews to characterize rates and identify correlates of screening-related psychological harms, e.g. cancer specific worry, situational anxiety, mood disturbances, and decisional regret. Lastly, investigators will create and disseminate a balance sheet of benefits and harms to inform patients, providers, healthcare organizations, payers, and policymakers about the role of hepatocellular carcinoma screening in patients with cirrhosis.
89646325|NCT03755401|Experimental|TFPP|TFPP is a manualized 16-24 session psychodynamic psychotherapy targeted on trauma symptoms of PTSD
89646326|NCT03755401|Active Comparator|TAU|TAU in this study is treatment for PTSD as currently delivered at the VA
89646327|NCT03747757|Experimental|Supportive Care (CBT)|Patients undergo CBT consisting of 7 counseling sessions, up to 45 minutes each over the phone.
89646328|NCT03745950|Experimental|Olaparib|"The Olaparib arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST (Response evaluation criteria in solid tumors) as assessed by the investigator, or unacceptable toxicity"
89646329|NCT03745950|Placebo Comparator|Placebo|"The placebo arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST as assessed by the investigator, or unacceptable toxicity"
89646330|NCT03734016|Experimental|Zanubrutinib|Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy
89646331|NCT03734016|Active Comparator|Ibrutinib|Participants received Ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy
89646332|NCT03730922|Experimental|A: Delayed-immediate reconstruction|"Primary Surgery: Skin sparing mastectomy (nipple sparing if appropriate) and axillary surgery according to guidelines or protocol. Reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix.~Delayed reconstruction: Final reconstruction with any reconstructive procedure - being it autologous or implant-based (one- or two-stage, +/- acellular dermal matrix (ADM)) - is performed 6-12 months after completion of chemotherapy and PMRT. Any contralateral procedure is allowed when doing the delayed surgery, but not in relation to the initial cancer surgery."
89044455|NCT04506905|Experimental|Part 1 (Panel C) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
89044456|NCT04506905|Experimental|Part 2 (Panel D) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
89646333|NCT03730922|Active Comparator|B: Delayed reconstruction|"Primary surgery: Total mastectomy and axillary surgery according to guidelines or protocol.~Delayed reconstruction: 6-12 months after completion of PMRT: final recon-struction with any reconstructive procedure - being it autologous or implant-based (one-or two-stage, +/- ADM). Any contralateral procedure is allowed at any time point after PMRT has been delivered This arm has been closed nov 2023"
89646334|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)|
89646335|NCT03728972|Experimental|Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)|
89646336|NCT03722680|Experimental|Riluzole|The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).
89646337|NCT03722680|Placebo Comparator|Placebo|Posology, administration and duration of treatment will be equivalent to riluzole group.
89646338|NCT03719079||Heart Failure Patients|Patients with primary diagnosis as heart failure
89646339|NCT03693300|Experimental|WHO/ECOG PS 0 to 1 Cohort|100-120 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
89646340|NCT03693300|Experimental|WHO/ECOG PS 2 Cohort|up to 30 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
89646341|NCT03679468|Sham Comparator|Cognitive Rehab & Sham Exercise|Cognitive Rehabilitation by computer based brain tasks, and Sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
89646342|NCT03679468|Sham Comparator|Sham Cognitive Rehab & Sham Exercise|Sham cognitive Rehabilitation will consist of basic internet searches and learning to use a computer, and sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
89646343|NCT03679468|Sham Comparator|Sham Cognitive rehab & Aerobic Exercise|Sham cognitive rehabilitation will consist of basic internet searches and learning to use a computer, and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
89646344|NCT03679468|Active Comparator|Cognitive Rehab & Aerobic Exercise|Cognitive Rehabilitation by computer based brain tasks and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
89646345|NCT03671564|Experimental|Milademetan (90 mg/Day)|Participants who received milademetan 90 mg daily (QD) Day 1 - 14 followed by 14-day rest in a 28-day cycle.
89646346|NCT03671564|Experimental|Milademetan (120 mg/Day)|Participants who received milademetan 120 mg daily (QD) Day 1 - 14 followed by 14-day rest in a 28-day cycle.
89646347|NCT03671564|Experimental|Milademetan (160 mg/Day)|Participants who received milademetan 160 mg daily (QD) Day 1 - 14 followed by 14-day rest in a 28-day cycle.
89646348|NCT03671213|Experimental|Calypso|Calypso Knee System
89646349|NCT03632720|Experimental|Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at 3 months and at 12 to 13 months of age, Bexsero® at 2, 4, and 12 to 13 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.
89646350|NCT03632720|Experimental|Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at 3 months and at 12 to 13 months of age, Bexsero® at 2 and 4 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.
89646351|NCT03632720|Active Comparator|Group 3: Bexsero® (2, 4, and 12 to 13 Months)|Participants aged 2 months (at the time of enrollment) received Bexsero® at 2, 4, and 12 to 13 months of age along with Infanrix hexa® vaccine at 2, 3, and 4 months of age; Rotarix® vaccine at 2 and 3 months of age; and Prevenar 13® vaccine at 2 and 4 months of age.
89646352|NCT03626857|Experimental|NMES+ECC|Neuromuscular electrical stimulation (NMES) and Eccentric Exercise (ECC). Patients randomized to the NMES+ECC group will first receive NMES for 2x/week for 8 weeks, beginning at the first post-operative visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive eccentric exercise 2x/week for an additional 8 weeks. For NMES, patients will have electrical stimulation delivered to their quadriceps. Fifteen isometric actions lasting 10 seconds each will be elicited during each session. For eccentric exercise, patients will train for 4 sets of 10 repetitions. This group will also receive standard of care ACL rehabilitation alongside the study interventions.
89044457|NCT04506905|Experimental|Part 2 (Panel E) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
89044458|NCT04506905|Experimental|Part 2 (Panel F) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
89044459|NCT04506905|Experimental|Part 2 (Panel G) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
89044460|NCT04506905|Placebo Comparator|Part 1 (Panels A, B, C) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
89044461|NCT04506905|Placebo Comparator|Part 2 (Panels D, E, F, G) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
89044462|NCT01186939|Experimental|Azacitidine|Azacitidine (study drug) plus best supportive care.
89044463|NCT04318483||Angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
89044464|NCT04318483||Without angio-oedema of extremities|Patients who had revealed IgE-mediated cow milk allergy with hands and feet oedema
89044465|NCT00554112|Active Comparator|1|Exercise
89044466|NCT00554112|Active Comparator|2|Exercise
89044467|NCT00554112|No Intervention|3|Control
89044468|NCT05463172|Experimental|pelvic floor muscles strengthening exercises|pelvic floor muscles strengthening exercises
89044469|NCT05463172|Experimental|abdominal strengthening exercises|abdominal strengthening exercises
89044470|NCT05461105|Experimental|Cohort A: rencofilstat 75 mg|1 rencofilstat 75 mg softgel capsule, 75 mg daily dose, QD 120 days
89044471|NCT05461105|Experimental|Cohort B: rencofilstat 150 mg|2 rencofilstat 75 mg softgel capsules, 150 mg daily dose, QD 120 days
89044472|NCT05461105|Experimental|Cohort C: rencofilstat 225 mg|3 rencofilstat 75 mg softgel capsules, 225 mg daily dose, QD 120 days
89044473|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
89044474|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
89044475|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
89044476|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
89044477|NCT04447040|Experimental|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
89044478|NCT04447040|Placebo Comparator|Placebo|Placebo tablets administered as a single two-tablet dose.
89044479|NCT01580540||Group A, subjects with colorectal cancer|Subjects between ages 50 and 84 identified to have CRC. Blood and stool specimens are collected and tested after colonoscopy and prior to surgery or other interventions.
89044480|NCT01580540||Group B, subjects without CRC|Subjects between ages 50 and 84 who provide stool and blood specimens prior to colonoscopy.
89044481|NCT02930642|Experimental|Mindful Eating|Participants in this arm will receive a 50 min mindful eating training with four pieces of food. They will practice mindful eating at home with two meals for a one-week duration.
89218019|NCT00907790|Other|Usual Care (Control Group)|Includes the usual care provided by the person and their health care provider.
89646353|NCT03626857|Placebo Comparator|NMES placebo + ECC placebo|"Neuromuscular electrical stimulation (NMES) placebo + Eccentric Exercise (ECC)placebo arm. Patients randomized to the NMES placebo + ECC placebo group will first receive NMES placebo for 2x/week for 8 weeks, beginning at the first post-operative physical therapy visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive an eccentric exercise placebo 2x/week for 8 weeks.~For the NMES placebo, patients will have NMES placebo delivered to their quadriceps 2x/week for 8 weeks beginning at the first post-operative visit. Fifteen isometric actions lasting 10 seconds each will be elicited during each session.~For the eccentric exercise placebo, patients will begin to receive eccentric exercise two times per week for 8 weeks. Patients will train for 4 sets of 10 repetitions."
89646354|NCT03624790|Experimental|Group 1: rRSV A/Maryland/001/11|Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).
89646355|NCT03624062|Other|33 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 33 ug IBC dose in 0.25 mL MAS-1 emulsion
89646356|NCT03624062|Other|109 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 109 ug IBC dose in 0.25 mL MAS-1 emulsion
89646357|NCT03624062|Other|327 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 327 ug IBC dose in 0.25 mL MAS-1 emulsion
89646358|NCT03624062|Other|TBD ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with the optimal IBC dose selected from the first 3 groups (either 33 µg, or 109 µg, or 327 µg IBC) in 0.25 mL MAS-1 emulsion
89646359|NCT03607370|No Intervention|Group 1|The cancer surgery is practice 8 weeks after neoadjuvant chemoradiotherapy
89646360|NCT03607370|Experimental|Group 2|The cancer surgery will be performed in 12 weeks after neoadjuvant chemoradiotherapy
89646361|NCT03606512|Experimental|Group 1: RSV Seronegative Toddlers (Ad26.RSV.preF)|Respiratory syncytial virus (RSV) seronegative toddlers will receive intramuscular (IM) injection of 2.5*10^10 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F-protein on Days 1, 29, and 57.
89646362|NCT03606512|Placebo Comparator|Group 2: RSV Seronegative Toddlers (Placebo/Nimenrix)|RSV seronegative toddlers will receive IM injection of placebo on Days 1, 29 and 57. Placebo can be replaced with Nimenrix on Day 57 in countries where applicable.
89646363|NCT03592238|Experimental|Aerobic Exercise Intervention|Participants will exercise on a motor-driven treadmill at a constant speed during the 23-min period.
89646364|NCT03592238|Active Comparator|Trier Social Stress Test for Children|The Trier Social Stress Test for Children consists of a speech task in which children must finish a story and a mental arithmetic task, completed in front of a camera and two neutral observers.
89044482|NCT02930642|Active Comparator|Nutrition Digital Video Disc (DVD)|Participants will watch a 50 min DVD on nutrition and receive four pieces of food. They will receive prompts twice a week to give one-word answers to questions about food.
89044483|NCT02930642|No Intervention|Control|Participants will receive four pieces of food. They will not receive any prompts during the one week.
89044484|NCT03455205|Experimental|shenqifuzheng injection|"Shenqifuzheng injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens:~Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio All test drugs should be covered with dark bags before infusion, and use a dark infusion to guarantee the implementation of the blind method."
89044485|NCT03455205|Placebo Comparator|0.9% sodium chloride injection|0.9% sodium chloride injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio No interventions have been included in Arm Description for '0.9% sodium chloride injection'
89044486|NCT02930954|Active Comparator|Gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received Gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
89044487|NCT02930954|Experimental|Gefitinib combined with chemotherapy|Gefitinib 250mg Qd combined with pemetrexed or gemcitabine plus carboplatin: Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days, Gemcitabine (1000 mg/m² days 1,d8, intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days
89044488|NCT02930954|Experimental|Gefitinib combined with antiangiogenesis|Gefetinib 250mg Qd combined with bevacizumab 7.5mg/kg per 21 days
89044489|NCT05290467|No Intervention|control group|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to the control group. Participants will be scheduled for 12 routine ANC visits.
89044490|NCT05290467|Experimental|experimental group|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to the experimental group. Participants will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Message, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
89044491|NCT02930759|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89044492|NCT03457649|Active Comparator|ARGX-113|SAD and MAD with test product at different increasing doses
89646365|NCT03592238|Placebo Comparator|Seated Rest|Participants will sit in a comfortable chair, placed in the same room as the motor-driven treadmill, for a period of 25-min.
89646366|NCT03587311|Experimental|GROUP I (anetumab ravtansine, bevacizumab)|Patients receive anetumab ravtansine IV over 1 hour on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646367|NCT03587311|Experimental|GROUP II (paclitaxel, bevacizumab)|Patients receive paclitaxel on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646368|NCT03539302|Experimental|Repeat dose inhaled flecainide acetate|"One 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used.~A subset of enrolled patients will be included in a sub-study in which a Hand Held ECHO device at bedside will be used to confirm eligibility by verifying absence of structural heart disease. Once eligibility is confirmed the treatment for this subset of patients will be the same as described above; one 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used."
89646369|NCT03537794||Treatment Resistant Depression|Unmedicated Individuals with Treatment Resistant Depression
89646370|NCT03537794||Major Depressive Disorder|Unmedicated Individuals with Major Depressive Disorder
89646371|NCT03537794||Healthy Control|healthy controls with no previous psychiatric disorders
89646372|NCT03530709|Experimental|Experimental|videoconferencing
89646373|NCT03530709|No Intervention|Control|Usual care
89646374|NCT03530384|Experimental|Cognitive training|Computerized cognitive training program targeting inhibitory control
89646375|NCT03530384|Sham Comparator|Control Training|A sensorial program with similar conditions, but targeting visual acuity, considered as neutral in the addiction field
89646376|NCT03525405|Experimental|Single Dose|
89646377|NCT03513562|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO daily on days 1-28 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 or 24 courses in the absence of disease progression or unacceptable toxicity. Participants with MRD negativity after 12 or 24 courses discontinue treatment, while participants with MRD positivity continue treatment with venetoclax in the absence of disease progression or unacceptable toxicity.
89646378|NCT03512314|Experimental|Tadekinig alfa|Active drug treatment during 26 weeks
89646379|NCT03490344|Experimental|Participants with Multiple Myeloma|Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.
89646380|NCT03489018|Active Comparator|Full dose PCV13 (2p+1 schedule)|Full dose PCV13 administration in 2p+1 schedule
89646381|NCT03489018|Experimental|40% dose PCV13 (2p+1 schedule)|Fractional (40%) dose PCV13 administration in 2p+1 schedule
89044493|NCT03457649|Placebo Comparator|Placebo|SAD and MAD with placebo at different increasing doses
89044494|NCT04141917|No Intervention|Standard influenza surveillance|Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing.
89044495|NCT04141917|Active Comparator|Point-of-care molecular testing and treatment of influenza|Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A & B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .
89044496|NCT02930525|Active Comparator|Standard care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
89044497|NCT02930525|Experimental|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
89044498|NCT04117659|Experimental|Phosphodiesterase-5 inhibitor withdrawal|In this single arm pretreatment with an oral phosphodiesterase-5 inhibitor will be discontinued
89044499|NCT02930798|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89044500|NCT04116606|Active Comparator|Active JNJ-54175446|JNJ-54175446 is an unlicensed drug currently being developed by Janssen Pharmaceuticals. The drug is presented in oral capsules, each capsule containing 50 mg of JNJ-54175446. Participants will be asked to self-administer one capsule daily for 8 weeks.
89044501|NCT04116606|Placebo Comparator|Matching placebo|
89646382|NCT03489018|Experimental|20% dose PCV13 (2p+1 schedule)|Fractional (20%) dose PCV13 administration in 2p+1 schedule
89646383|NCT03489018|Active Comparator|Full dose PCV10 (2p+1 schedule)|Full dose PCV10 administration in 2p+1 schedule
89646384|NCT03489018|Experimental|40% dose PCV10 (2p+1 schedule)|Fractional (40%) dose PCV10 administration in 2p+1 schedule
89646385|NCT03489018|Experimental|20% dose PCV10 (2p+1 schedule)|Fractional (20%) dose PCV10 administration in 2p+1 schedule
89646386|NCT03489018|Active Comparator|Full dose PCV10 (3p+0 schedule)|The current vaccine (PCV10) and schedule (3p+0) in use in the Kenyan routine immunisation programme as an additional comparison arm.
89044502|NCT02930603||Control|Control: Healthy child
89044503|NCT02930603||Experimental|Patients with Developmental Disabilities
89044504|NCT02930447|Experimental|Treatment group|Autologous glue will be prepared from the patient's own blood with RegenKit®-Surgery device and applied per-operatively by spraying in the undermining region space between fascia and skin.
89044505|NCT02930447|No Intervention|Control group|Patient from the control group will undergo abdominoplasty according to an identical procedure, but without application of autologous glue or any other treatment product before wound closure.
89044506|NCT04679571|Experimental|Targeted Albumin with Standard Medical Treatment|Patients with serum albumin <3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin >3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin >3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks
89044507|NCT04679571|Active Comparator|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year"
89044508|NCT02930369|Active Comparator|4PD diameter of ILM peeling in surgery|patients in this group was given 4papillary diameter (PD) diameter of internal limiting membrane (ILM) peeling in surgery
89044509|NCT02930369|Experimental|2PD diameter of ILM peeling in surgery|patients in this group was given 2PD diameter of ILM peeling in surgery
89044510|NCT02930486|Active Comparator|ZipTight|ZipTight suture endobutton
89646387|NCT03482778||AYA Patients - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA patients (n=36). AYA patients are eligible if they: (1) are 15 to 39 years of age, (2) were diagnosed with cancer at 15 to 39 years of age; (3) are able to read and understand English; (4) have a new cancer diagnosis and are receiving curative treatment OR are currently 0 to 5 years post-treatment. AYA patients will be excluded if they: (1) were diagnosed with basal cell skin cancer; (2) experienced a cancer recurrence; (3) are currently receiving palliative or hospice care; (4) had an infertility diagnosis prior to their cancer diagnosis, or (5) report a significant psychiatric history.
89646388|NCT03482778||AYA Providers - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with AYA providers (n=36). Providers will be health professionals who provide supportive care for AYAs to help address financial, body image, and fertility/future parenthood concerns or needs. Psychosocial providers (e.g., social workers, patient navigators, psychologists) will all be eligible to participate. We will also include reproductive endocrinologists, nurse practitioners, and other medical professionals who have expertise in the appropriate area of health-related quality of life (HRQOL). Additional inclusion criteria will be: (1) provision of care to AYAs; (2) ≥2 years practicing; (3) English-speaking.
89646389|NCT03482778||Content Experts - AIM1A|Qualitative data collection will occur through one-on-one semi-structured interviews with content experts (n=36). Content experts are a purposive sample of scientists and clinicians who have recognized expertise in each of the three domains of interest to this project - financial burden, body image, and fertility/future parenthood.
89646390|NCT03482778||AYA Patients - AIM1B|Five forms have been created for AYA patients (n=25). Each form consists of 25 to 30 items. Forms for AYA patients include an even number of items from the body image, financial burden, and fertility domains counterbalanced in order of administration to reduce the potential for order effects. Participants will also complete a sociodemographic form and, to evaluate literacy and reading grade equivalent, an interviewer-administered Wide Range Achievement Test (WRAT-5) will also be completed. Only the Word Reading portion of the WRAT-5 will be administered to the participants. Cognitive interviews will be conducted over 2 rounds with half the sample comprising each round. Items substantially revised from Round 1 will be re-evaluated in Round 2.
89646391|NCT03482778||AYA Caregivers - AIM1B|Two forms for AYA caregivers (n=10). Each form consists of 25 to 30 items. Forms for AYA caregivers only include items from the financial burden domain. Participants will also complete a sociodemographic form and, to evaluate literacy and reading grade equivalent, an interviewer-administered Wide Range Achievement Test (WRAT-5) will also be completed. Only the Word Reading portion of the WRAT-5 will be administered to the participants. Cognitive interviews will be conducted over 2 rounds with half the sample comprising each round. Items substantially revised from Round 1 will be re-evaluated in Round 2.
89044511|NCT02930486|Active Comparator|Syndesmotic screw|Tricortical 3.5 mm syndesmotic screw
89044512|NCT02930330|Experimental|Interval|"2x / week INT~2x / week CONT"
89044513|NCT02930330|Active Comparator|Continuous|4x / week CONT
89044514|NCT02929940||PiZZ|Observational
89044515|NCT02929940||PiMZ|Observational
89044516|NCT02929940||Other AATD variants|Observational
89044517|NCT02929940||PiMM (Control)|Observational
89044518|NCT02930057|Experimental|Celestone|all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.
89044519|NCT02930057|Other|Control|all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
89044520|NCT05238363|Experimental|HLX07|HLX07 1500mg ivgtt Q3W
89044521|NCT02930135|Experimental|Antibacterial Bond|"Indirect pulp capping using antibacterial bond and x-tra fil composite~Local anesthesia administration~Isolation of tooth with rubber dam~Opening of the cavity and the removal of undermined enamel~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~Partial removal of carious dentin on the pulp wall.~Washing the cavity and dryness~Apply antibacterial light-cure, self-etching bonding agent (Clearfil SE Protect, Kuraray America, Inc.)~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
89044522|NCT02930135|Active Comparator|Conventional Bond|"Indirect pulp capping using conventional bond and x-tra fil composite~Local anesthesia administration~Isolation of tooth with rubber dam~Opening of the cavity and the removal of undermined enamel~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~Partial removal of carious dentin on the pulp wall.~Washing the cavity and dryness~Apply conventional light-cure, self-etching bonding agent (Clearfil SE Bond, Kuraray America, Inc.)~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
89044523|NCT04080492||Hypertrophic Cardiomyopathy|Patients being seen for the first time at the Cleveland Clinic for Hypertrophic Cardiomyopathy.
89044524|NCT04080492||Thoracic Aortic Dilatation|Patients being seen for the first time at the Cleveland Clinic for Thoracic Aortic Dilatation.
89044525|NCT04080492||Radiation Induced Heart Disease|Patients being seen for the first time at the Cleveland Clinic for Radiation-Induced Heart Disease.
89646392|NCT03469986||Autism Spectrum Disorder|Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
89044526|NCT02930096||pulsatility index mesured with doppler ultrasound|
89044527|NCT04049721|Active Comparator|Standard of Care without HBO|Intravenous access and fluid resuscitation (standard of care treatment)
89044528|NCT04049721|Experimental|HBO + Standard of Care|Ten daily treatment sessions of HBO at 2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks
89044529|NCT02930252|Experimental|Niti-S Biliary ComVi Stent|"Device:~Niti-S Biliary ComVi Stent is a hollow cylindrical stent fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure. A plurality of interlocked points allow each of the inside and outside stent bodies to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction. A hollow polytetrafluoroethylene (PTFE) membrane tube is closely fitted between the inside and outside stent bodies, with each of overlapped ends of the PTFE membrane tube and the inside and outside stent bodies integrated into a single structure."
89044530|NCT02930252|Active Comparator|Niti-S Stent (D-type)|"Device:~The Niti-S Stent (D-type) maintains a desired bent shape corresponding to the specific target lesion. It is comprised of a hollow cylindrical stent body fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure with a plurality of interlocked points capable of allowing the stent body to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction of the stent body.~The wires are made of a shape memory alloy through a process of shaping the alloy then heat-treating the wires to allow restoration of the original shape at a predetermined temperature."
89218020|NCT02538224|Active Comparator|experimental(case): group A|Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
89646393|NCT03469986||Non-autism Spectrum Disorder|Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
89646394|NCT03461497||Patients Cohort|Patients undergoing abdominal surgery
89646395|NCT03455439||Rivaroxaban|Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment with rivaroxaban at least 4 months prior to inclusion
89646396|NCT03453359|Experimental|BIS|Group of patients (90) in whom sedation is adjusted using as main parameters the information obtained by the BIS sedation monitor (BIS VISTA, Aspect Medical Systems, USA).
89646397|NCT03453359|Active Comparator|Ramsay|Group of patients (90) in whom sedation is based on subjective monitoring of the level of sedation, using the Ramsay scale as a reference.
89646398|NCT03450018|Experimental|SLC-0111 + Gemcitabine|"Dose Level 1 - SLC-0111 (500 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)~Dose Level 2 - SLC-0111 (750 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)~Dose Level 3 - SLC-0111 (1000 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)"
89646399|NCT03435718|Experimental|OXF6|Patients receive a single 6 mg/kg dose of oxfendazole administered orally.
89646400|NCT03435718|Experimental|OXF15|Patients receive a single 15 mg/kg dose of oxfendazole administered orally.
89646401|NCT03435718|Experimental|OXF30|Patients receive a single 30 mg/kg dose of oxfendazole administered orally.
89646402|NCT03435718|Experimental|OXF15x3|Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.
89646403|NCT03435718|Active Comparator|ALB400|Patients receive a single 400 mg/kg dose of albendazole administered orally.
89646404|NCT03434392|Active Comparator|Healthy Controls|"Subjects with no pancreatic disease and no abdominal pain.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
89646405|NCT03434392|Active Comparator|Suspected CP|"Suspected Chronic Pancreatitis patients.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
89646406|NCT03434392|Active Comparator|Definite CP|"Definite Chronic Pancreatitis patients.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires.~A subset of these patients who undergo endotherapy as per clinical recommendation from clinical provider independent of this study will be followed for 6 months after their clinical intervention for repeat Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3 and questionnaires."
89646407|NCT03434392|Active Comparator|Sphincter of Oddi Dysfunction or Functional Dyspepsia|"Patients with Sphincter of Oddi Dysfunction Type 1 or Type 2, or who have a prior diagnosis of Functional Dyspepsia.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
89646408|NCT03426865||Axumin PET scan|Only one arm is being evaluated--the arm receiving PET scan
89646409|NCT03417739|Experimental|BVD-523|BVD-523 is administered at the RP2D of 600mgs taken twice daily orally for 28 consecutive days (1 cycle). Planned does may modified based on toxicity.
89044531|NCT04017000|Active Comparator|BlaST study|"Patients scheduled for Urodynamic clinic will be offered to participate in the study. Once consented to participate, the participant will be scheduled for a bladder shape test clinic at least one week in advance of their Urodynamic appointment. At their blast clinic, participants will attend a clinical room with a portable bladder scanner. Participants will be asked to consume up to 1000 mls of water over a 20-30 period until their bladder is full. The participant will have their bladder scanned at 10 minute intervals during the filling phase and after prompted voiding.~The participants Urodynamic clinic will run according to routine care."
89218021|NCT02538224|Sham Comparator|control: group B|Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
89646410|NCT03406338|Active Comparator|Surgical fasciectomy|Fasciectomy according to usual care (surgery), implying excision of Dupuytren's cords and tissues to release the finger joint contractures
89646411|NCT03406338|Experimental|Collagenase Clostridium Histolyticum|Injection of 0.8 mg collagenase clostridium histolyticum into multiple spots in the Dupuytren cords followed by finger manipulation 1-2 days later to release the finger joint contractures
89646412|NCT03395236|Experimental|Treatment|StellarexTM 0.014 OTW Drug-coated Angioplasty Balloon (Stellarex Balloon)
89646413|NCT03376880||Obese Boys|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
89646414|NCT03376880||Obese Girls|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
89646415|NCT03376880||Normal Weight Boys|Normal weight boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
89646416|NCT03376880||Normal Weight Girls|Normal weight girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
89646417|NCT03376880||Obese Boys Misdiagnosed with Asthma|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
89646418|NCT03376880||Obese Girls Misdiagnosed with Asthma|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
89646419|NCT03367845|Experimental|Control|Phone contacts with content not focusing on sensitivity or couples' relationships
89646420|NCT03367845|Experimental|Sensitivity Intervention|Home visits to enhance mother-infant and father-infant parental sensitivity; with COVID-19, we now conduct remote visits using Zoom
89646421|NCT03367845|Experimental|Couples Intervention|Home visits to enhance constructive couples' communication; with COVID-19, we now conduct remote visits using Zoom
89646422|NCT03367845|Experimental|Sensitivity and Couples Intervention|Home visits combining sensitivity and couples' interventions; with COVID-19, we now conduct remote visits using Zoom
89646423|NCT03348631|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans and MRI on study.
89646424|NCT03323099|Experimental|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
89646425|NCT03323099|Placebo Comparator|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
89646426|NCT03323034|Experimental|Treatment (pevonedistat, temozolomide, irinotecan)|Patients receive pevonedistat IV over 60 minutes on days 1, 8, 10, and 12, temozolomide PO daily on days 8-12, and irinotecan IV over 90 minutes on days 8-12 of cycle 1. Beginning cycle 2, patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, temozolomide PO daily on days 1-5, and irinotecan IV over 90 minutes on days 1-5. Treatment repeats every 28 days for cycle 1 and 21 days for subsequent cycles for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
89646427|NCT03315910|Experimental|Motivational Interviewing( MI) (Yes vs. No)|Participants will receive two motivational informed cessation sessions; the first delivered face to faceor via telephone by the SC during the patient's initial lung cancer screening visit or during the shared decision making discussion or within about 1 week following their screening visit, and the second session delivered by telephone by the SC approximately 4 to 8 weeks after the first MI session.
89646428|NCT03315910|Experimental|Nicotine Replacement Therapy (NRT) Patch (Yes vs. No)|Participants will receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day and written instructions to use the patch daily starting on date they mutually agreed upon with their site coordinator. Participants who smoke fewer than 10 cigarettes per day will receive 4-weeks of the 14mg patch (2 boxes), and 2-weeks of the 7mg patch (1 box). Those who smoke 10 or more cigarettes per day will receive 4-weeks of the 21mg patch (2 boxes) and 2-weeks of the 14mg patch (1 box). Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment.
89218022|NCT04018781||MR group|Patients who benefit from a full process of medication reconciliation (entrance and discharge) before being discharged to home.
89044532|NCT04017000|Other|Calibration Sub Study|"Any patients who are not eligible or decline participation in the main study will be offered the chance to participate in the calibration sub study.~Participants will be scheduled for their clinically indicated Urodynamic appointment where they will have their bladder imaged by portable ultrasound.~Participants will consent for these images to be used as part of the calibration of the technology being used to measure bladder shape change."
89044533|NCT04007406|Experimental|DP13 low|DP13 for 8 weeks
89044534|NCT04007406|Experimental|DP13 middle|DP13 for 8 weeks
89044535|NCT04007406|Experimental|DP13 high|DP13 for 8 weeks
89044536|NCT02929901|Active Comparator|caffeine and chlorogeinc acid|caffeine (200 mg) 1 capsule / day for 6 months plus chlorogenic acid (200 mg) 1 capsule / day for 6 months
89044537|NCT02929901|Active Comparator|caffeine|caffeine (200 mg) 1 capsule / day for 6 months plus placebo (200) mg 1 capsule / day for 6 months
89044538|NCT02929901|Active Comparator|chlorogenic acid|chlorogenic acid (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
89044539|NCT02929901|Placebo Comparator|placebo|placebo (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
89044540|NCT05237661|Experimental|Dietary supplement|Dietary supplement: Moon Balance
89646429|NCT03315910|Experimental|NRT Lozenge (Yes vs. No)|Participants will receive will receive 6 packs of NRT 2mg lozenge and written instructions to use the lozenge PRN to help manage acute nicotine withdrawal. Participants will be instructed to use the NRT lozenges no more than every 1-2 hours as needed. Participants will receive their study medications from their site coordinator on the day of their screening appointment or via mail from Arrowhead Promotion & Fulfillment.
89044541|NCT02929784|Experimental|Intervention|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Affected hemisphere anodal stimulation of the hand area of the primary motor cortex (C3/C4), Intensity of 2 mA (milliampere) for duration of 20 minutes. A total of 10 sessions: 5 sessions a week for 2 weeks.
89044542|NCT02929784|Sham Comparator|Sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
89044543|NCT02929784|No Intervention|no HSP|Patients hospitalized in the Loewenstein department of neurologic rehabilitation after first clinical stroke who do not have hemiplegic shoulder pain.
89646430|NCT03315910|Experimental|Message Framing (Gain vs. Loss)|Overall, a robust body of health communication literature demonstrates that gain-framed messages may be more effective than loss-framed or non-framed (neutral) messages for encouraging smoking cessation. In other words, quitting messages that promote smoking cessation are more persuasive if they emphasize the benefits of quitting (gain-framed) rather than the risks (loss-framed) of persistent smoking (25, 26). Included with the written communication of their LDCT-LCS results, participants will receive a printed individualized quitting message that emphasizes either the benefits of quitting (gain-framed) or the risks of continuing to smoke (loss-framed).
89212632|NCT05093543|No Intervention|Control|Explanation for choice of comparators {6b} The telematics multidisciplinary approach (experimental group) will be compared to Standard of Care (SoC) (control group). SoC consists of a patient's follow up according to the usual clinical practice. In Bellvitge University Hospital's setting, the treatment protocol for CnsLBP indicates physical rehabilitation/physiotherapy as the first treatment step, and Pain Clinic evaluation as a second step for those who did not improve. For patients who did not improve with the previous steps and that still demand a solution for their CnsLBP, a third step would be to refer the patient for surgical evaluation - a spine surgeon would, then, evaluate, alongside with the patient, whether a surgical approach would be appropriate for his/her case. If the surgery is ruled out by the spine surgeon, the patient may be referred, once more, to physical rehabilitation/physiotherapy and/or to the Pain Clinic, at the surgeon's discretion.
89646431|NCT03307252|Experimental|Treatment Reference 1|
89646432|NCT03307252|Experimental|Treatment Reference 2|
89044544|NCT02929706|Experimental|intervention group|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
89044545|NCT02929706|No Intervention|control group|optimize the thiopurine use by coventional strategy without konwing NUDT15 genotype
89044546|NCT02929628|Experimental|Patients with Various Frequency Stimulation|Patients are in the condition of Various Frequency Stimulation
89044547|NCT02929628|Sham Comparator|Patients With Traditional Frequency Stimulation|Patients in the condition of Sham Comparator are Traditional Frequency Stimulation
89044548|NCT00553878|Placebo Comparator|dutasteride|
89044549|NCT04407689|Experimental|CYT107|Intra-muscular administration of CYT107 twice a week for a total of 5 administrations
89044550|NCT04407689|Placebo Comparator|Saline|Intramuscular (IM) administration of saline at the same volume and same time for a total of 5 administrations
89044551|NCT05225064|No Intervention|Control|No vaccine or mask promotion, but access to vaccines increased to match access in intervention villages
89044552|NCT05225064|Experimental|Village-level vaccine clinics with monetary, non-monetary, or no incentive|Village-level vaccine clinics with monetary, non-monetary, or no incentive. Villages are cross-randomized to grocery coupon, food ration, no incentive, or grocery coupon to both community member and community health worker after the community member has received a vaccination.
89044553|NCT05225064|Experimental|Household-level vaccination with monetary or no incentive|Household-level vaccination with monetary incentive or no incentive. Villages are cross-randomized to grocery coupon or no incentive upon receiving vaccination
89646433|NCT03307252|Experimental|Treatment Reference 3|
89646434|NCT03307252|Experimental|Treatment 1|
89646435|NCT03307252|Experimental|Treatment 2|
89646436|NCT03307252|Experimental|Treatment 3|
89646437|NCT03307252|Experimental|Treatment 4|
89646438|NCT03307252|Experimental|Treatment 5|
89646439|NCT03307252|Experimental|Treatment 6|
89646440|NCT03286504|No Intervention|Standard-of-care|Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
89212633|NCT03840824||Cancer Survivor|Pre-menopausal women who are cancer survivors ages 18-45 years with normal menstrual cycles.
89212634|NCT03840824||Similar aged healthy controls|Pre-menopausal, healthy women ages 18-45 years with normal menstrual cycles
89212635|NCT03840824||Late Reproductive Age|Pre-menopausal, healthy women of late reproductive age
89212636|NCT00993993||"group early intervention"|
89212637|NCT00993993||"group late intervention"|
89212638|NCT04039958|Experimental|T test|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
89212639|NCT04039958|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
89212640|NCT04039958|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
89212641|NCT00534105||Gestational Diabetics|Patients with Gestational Diabetes
89212642|NCT00534105||2|Normal pregnant women without gestational diabetes
89212643|NCT00872378|Active Comparator|Exenatide|Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program
89212644|NCT00872378|Placebo Comparator|Placebo|Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program
89212645|NCT00877682|Experimental|Cryotherapy|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
89646441|NCT03286504|Experimental|FANMI - Cohort Care|Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-10 peers. The entire visit will take ~ 2 hours.
89646442|NCT03275168|Active Comparator|Control|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention
89646443|NCT03275168|Experimental|Intervention|Participants will receive individual evidence-based STI/HIV prevention intervention (Sister to Sister Teen for female participants and Focus on the Future for male participants) for STI prevention plus dyadic counseling and negotiation practice with partner
89646444|NCT03274219|Experimental|bb21217 Experimental Arm|
89646445|NCT03253081|Active Comparator|PARENT focused intervention|The PF condition will consist of a 90-minute parent group session twice per week. The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent.
89646446|NCT03253081|Active Comparator|CHILD focused intervention|In the CF condition both parent and child will attend the 90-minute session twice weekly. The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist.
89212646|NCT05084885|Experimental|Online treatment|The participants will receive counseling over the internet.
89212647|NCT05084885|No Intervention|Non-treatment|Participants who did not participant in the group were asked to complete the 12ve month followup questionnaire (but not the post treatment questionnaire).
89212648|NCT00994149|Experimental|Diazoxide|Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours
89212649|NCT00994149|Placebo Comparator|Ora-plus|Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.
89212650|NCT00573248|Experimental|4|
89212651|NCT00994227|Experimental|surgery|
89212652|NCT04039880|Experimental|Cohort A (mass balance)|evaluation of mass balance and metabolite profiling
89212653|NCT04039880|Experimental|Cohort B (biliary evaluation)|evaluation of biliary elimination
89646447|NCT03247088|Experimental|Treatment (sorafenib, busulfan, fludarabine, HSCT)|"PRE-STEM CELL INFUSION: Patients receive sorafenib orally PO QD or BID on days -24 to -5, busulfan IV over 3 hours on days -20 and -13 and -6 and -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.~STEM CELL INFUSION: Patients receive allogeneic HSCT IV in the absence of disease progression or unacceptable toxicity.~POST-STEM CELL INFUSION: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus PO BID beginning day 5 for about 50 days, filgrastim SC on day 7 and sorafenib PO BID beginning between days +30 and +120 for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with matched unrelated donor receive mycophenolate mofetil PO TID or IV over 2 hours TID beginning on day 5 for up to 90 days for longer."
89646448|NCT03233139|Experimental|Cemiplimab|Part 1
89212654|NCT04083989||Multimodal treatment for AN|Adolescent patients with AN attending an integrative medicine-based inpatient treatment program
89212655|NCT04083989||Healthy controls|Healthy volunteers assessed once to collect comparative data
89212656|NCT00994305|Active Comparator|N-acetylcysteine|N-acetylcysteine 600 mg bid po 0-7 PO
89212657|NCT00994305|Sham Comparator|control|No treatment: standard care provided. No N-acetylcysteine administration.
89212658|NCT00877760|Experimental|ETV + pegIFN|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. From week 24 to week 48, they also receive pegylated-interferon a-2a in a dose of 180 μg per week s.c. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
89218023|NCT04018781||Control group|Patients who benefitted from a medication reconciliation at entrance only before being discharged to home.
89646449|NCT03233139|Experimental|Cohort A|Part 2
89646450|NCT03233139|Experimental|Cohort B|Part 2
89646451|NCT03233139|Experimental|Cohort C|Part 2
89646452|NCT03233139|Experimental|Cohort D|Part 2
89646453|NCT03233139|Experimental|Cohort E|Part 2
89646454|NCT03221777||AFOTS - Medical Illness Cases|"Patients who have AF detected for the first time in the setting of an acute non-cardiovascular medical (i.e. non-surgical ).~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
89646455|NCT03221777||Medical Illness Controls|"Patients without a history of AF who are hospitalized for an acute non-cardiovascular medical (i.e. non-surgical) and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
89646456|NCT03221777||AFOTS - Non-cardiac surgery Cases|"Patients who have AF detected for the first time following non-cardiac surgery.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
89044554|NCT05225064|Experimental|Village-level vaccination without incentive, plus mask promotion|Individuals are encourage to attend village-level vaccine clinics but not given any incentive. Mask distribution and reinforcement activities are conducted in villages at a similar time as vaccine promotion.
89044555|NCT05225064|Experimental|Village-level vaccination without incentive|Individuals are encourage to attend village-level vaccine clinics but not given any incentive.
89044556|NCT05222919|Active Comparator|Bare performance supplement|Dietary supplement
89044557|NCT05222919|Placebo Comparator|Placebo|Placebo
89044558|NCT02929862|Experimental|Single Agent 55716|
89044559|NCT04381052|Experimental|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum C-reactive protein (CRP) will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
89044560|NCT04381052|Placebo Comparator|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
89044561|NCT03956940|Experimental|Intplex test|In vitro diagnostic device
89044562|NCT00624325|Experimental|1|12 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
89646457|NCT03221777||Non-cardiac Surgery Controls|"Patients without a history of AF who are hospitalized after non-cardiac surgery and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
89646458|NCT03213002|Experimental|Capecitabine amd Temozolomide|Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.
89646459|NCT03209154|Experimental|Study Group|Study Group intervention: Therapeutic drug monitoring.
89646460|NCT03209154|Active Comparator|Control Group|Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
89646461|NCT03191786|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death.
89646462|NCT03191786|Active Comparator|Single Agent Chemotherapy (Vinorelbine or Gemcitabine)|Participants will receive single agent chemotherapy; either vinorelbine oral or IV, or gemcitabine IV, according to the label based on investigator's choice.
89646463|NCT03176394|Experimental|BLASTX Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
89044563|NCT00624325|Experimental|2|9 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
89044564|NCT00624325|Experimental|3|6 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
89044565|NCT02929745|Experimental|10 HLA-Cw6+|HLA-Cw6+ patients will donate blood and skin samples
89044566|NCT02929745|Experimental|10 HLA Cw6-|HLA-Cw6- patients will donate blood and skin samples
89044567|NCT02929745|Experimental|Healthy Skin|Healthy patients will donate blood and skin samples
89044568|NCT05204823|Experimental|Experimental Product 1|Consumption of 221.24 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
89044569|NCT05204823|Experimental|Experimental Product 2|Consumption of 282.81 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
89044570|NCT05204823|Experimental|Experimental Product 3|Consumption of 589,62 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
89044571|NCT05204823|Experimental|Experimental Product 4|Consumption of 573,39 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
89044572|NCT05204823|Active Comparator|Control product|Consumption of 25g of glucose. Subjects will take this amount only on the day of the visit that they are to consume this product.
89044573|NCT03934398||ReNEW Clinical Cohort|Individuals evaluated in the ReNEW Clinic at Johns Hopkins University who join the ReNEW Clinic Cohort Study are eligible for this cross-sectional study. Tests will be done for all participants which includes Cardiovascular Assessments, Actigraphy and Laboratory assessments.
89044574|NCT02929550||Well-controlled cohort (LDL-C ≤ 1.8 mmol/L)|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation with well-controlled LDL-cholesterol
89646464|NCT03176394|Placebo Comparator|McKesson Jelly Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.
89688549|NCT04355065|Experimental|Cognitive Training with Therapeutic chess|"The training in Therapeutic chess consists of four sections:~Video tutorial: Weekly videos have been recorded in which a chess board and the image of the psychologist explaining the lesson appear. Each week a chess concept will be explained.~Traditional chess exercises Therapeutic chess exercises: The exercises use the elements of chess but it is not necessary to know how to play chess to perform them. The purpose of the exercise is to work on a specific cognitive area each week.~Playing online games: The patient must play a minimum of 2 online games on the chess platform chess24.es . The psychologist will follow the progress of each patient.~At the end of the week, the patient should send an email to the psychologist with the completed exercises and then they will receive a personalised email. This group carries out all the treatment online from their home."
89044575|NCT02929550||Non-controlled cohort|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation and with not well-controlled LDL-C
89044576|NCT02929511|Experimental|Reciproc Blue|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc Blue single-file system (VDW, Germany). The intervention is root canal treatment with the Reciproc Blue single-file system.
89646465|NCT03174938|Other|COHORT A: Cognitively healthy younger individuals (40-65 y)|"We will recruit 300 cognitively healthy individuals from the Malmö Offspring study, which is an epidemiological study. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline.~An auxiliary cohort (termed Cohort A2) of 40 healthy individuals aged 20-40 years of age will also be included."
89646466|NCT03174938|Other|COHORT B: Cognitively healthy elderly individuals (66-100 y)|"We will recruit 300 cognitively healthy individuals from the Malmö/Lund region, where we will aim to include as many individuals as possible that did participate in the Malmö Diet and Cancer study during the early 1990's. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE 4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline."
89646467|NCT03174938|Other|COHORT C: SCD and MCI|"750 patients with either subjective cognitive decline or mild cognitive impairment will be recruited in a consecutive fashion from the Skåne University Hospital and Ängelholm Hospital. We will only include cases where the medical doctor believes that the cognitive symptoms are caused by an incipient neurocognitive disorder. For example, all cases with evidence of brain amyloid pathology (i.e. an abnormal CSF Aβ42/40 ratio) will be included.~FOLLOW-UP FOR 6 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done every 2 years. Amyloid PET will be performed at baseline and after 4 years.~A auxiliary cohort (Cohort C2) 150 cases with SCD/MCI where the doctor does not suspect incipient neurocognitive disorder, will undergo the same baseline investigations, but they will be followed up clinically only after 2, 4 and 8 y."
89646468|NCT03174938|Other|COHORT D: Dementia due to Alzheimer's disease|"400 patients with mild to moderate dementia due to Alzheimer's disease (AD) will be recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. We will include at least 50 cases aged 40-65 years of age, at least 200 cases aged 66-79 years of age and at least 50 cases aged 80-100 years of age.~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
89646469|NCT03174938|Other|COHORT E: Other dementias|"Patients with primary neurodegenerative disorders other than Alzheimer's disease will be recruited:~160 cases with Frontotemporal dementia (FTD)-related disorders, including behavioral variant of FTD (bvFTD), Progressive nonfluent aphasia (PNFA), semantic dementia (SD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD).~50 cases with subcortical Vascular dementia (VaD).~200 cases with either Parkinson's disease (PD), Parkinson's disease with dementia (PDD), Dementia with Lewy Bodies (DLB), Multiple system atrophy (MSA).~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
89646470|NCT03170518|Experimental|Single-blind run-in Period: Placebo|Participants will receive 1 placebo tablet matching canagliflozin 100 milligram (mg) once-daily during the 2-week single-blind placebo run-in period.
89212659|NCT00877760|Active Comparator|ETV|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
89212660|NCT04083911|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in elderly newly diagnosed AML patients.
89646471|NCT03170518|Experimental|Double-blind Treatment Phase: Canagliflozin or Placebo|Canagliflozin 100 mg/matching placebo once-daily during first 12 weeks. At Week 13, participants who have glycated hemoglobin (HbA1c) of greater than or equal to (>=)7.0 percent (%), estimated glomerular filtration rate (eGFR) >=60 milliliter/minute/1.73 meter square (mL/min/1.73 m^2) will be re-randomized to either remain on canagliflozin 100 mg/matching placebo or up-titrate to canagliflozin 300 mg/matching placebo till Week 52.
89646472|NCT03169075|Experimental|ARM A: A|Supervised physical exercise programs (SPEP)
89646473|NCT03169075|Active Comparator|ARM B: B|Adapted physical activity (APA)
89212661|NCT05354895|Experimental|Intervention: Transcranial Infrared Laser Stimulation (TILS)|Participants receive 10 minutes of TILS treatment to the right prefrontal cortex once a week for 6 weeks. TILS will use an FDA-cleared 1064-nm laser (CG-5000, Cell Gen Therapeutics, LLC, Dallas, TX). The irradiance will be 0.25 W/cm2, and fluence, 60 J/cm2.
89212662|NCT00995241|Experimental|Raltegravir 800 mg / 24 hours|Raltegravir 800 mg / 24 hours
89212663|NCT00867542||past IUGR|3-4 y old children with past IUGR
89044577|NCT02929511|Experimental|OneShape|In this group, OneShape rotational single-file system (Micro Mega, France) will be used as single-file system according to the manufacturer's instruction.
89044578|NCT02929511|Active Comparator|Protaper|As a control group, Protaper (Dentsply, Mailleffer, Switzerland) will be used according to the manufacturer's instruction.
89044579|NCT03934281|Active Comparator|HAS dressing|"Patients included in the HAS dressing arm will receive the best available dressing according to the HAS recommendations. HAS is the french National Authority for Health (HAS) ."
89646474|NCT03148821||Healthy volunteer participants|The investigators propose a snap shot study in a group of healthy volunteers of varying BMIs, laying on surfaces a patient would be exposed to during their hospital stay. Participants will lie on a variety of surfaces they may find themselves on during an emergency admission to hospital, including an operating table, in a variety of positions. Participants pressure distributions in each scenario will be measured with a pressure sensing mattress.
89646475|NCT03145077|Experimental|Cohort 1 (DCE-MRI)|Patients with newly diagnosed tumors undergo DCE-MRI within 4 weeks prior to the first radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation. Patients who were previously irradiated and are at various stages of oncologic follow-up undergo DCE-MRI for a total of 2-5 times at baseline and at 6, 12, 24, 36, and/or 48 months post radiation. Patients in the third or subsequent years post treatment may undergo subsequent yearly imaging studies.
89646476|NCT03145077|Experimental|Cohort 2 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to the first re-radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation.
89646477|NCT03145077|Experimental|Cohort 3 (DCE-MRI)|Patients undergo DCE-MRI before and at 2 and 6 months post ORN treatment. Patients may undergo DCE-MRI during the mid-ORN treatment.
89646478|NCT03145077|Experimental|Cohort 4 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to and at 5-10 weeks and 12 months post surgery.
89646479|NCT03138733|Experimental|Ceftobiprole medocaril|Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril)
89646480|NCT03138733|Active Comparator|Daptomycin|Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards), with or without aztreonam
89646481|NCT03121001|Experimental|Subject treatment|Patients will receive the following conditioning regimen: ATG, fludarabine (6 days before stem cell infusion), cyclophosphamide, and total body irradiation. The stem cell product will be infused according to BMT unit policy. Patients will also receive GVHD prophylaxis which will consist of cyclophosphamide, sirolimus, and mycophenolate mofetil according to the protocol. Post-transplant evaluation will be done as per standard care with study data collected at days 30, 60, 100, 180, 365, and annually thereafter.
89646482|NCT03077685|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
89646483|NCT03077685|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
89646484|NCT03077685|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume
89646485|NCT03077685|Experimental|Second Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.
89646486|NCT03077685|Experimental|Third Phase: NanoPac® at Best Dose|Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.
89646487|NCT03057054|Experimental|Arm I (Lactobacillus plantarum, alloHCT)|Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
89646488|NCT03057054|Placebo Comparator|Arm II (placebo, alloHCT)|Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
89646489|NCT03037528|Experimental|Positive Affect, Mindfulness, Tracking|Participants will receive information about positive affect and mindfulness, in addition to being asked to actively track what they eat and receiving the core program
89646490|NCT03037528|Experimental|Mindfulness, Tracking|Participants will receive information about mindfulness, be asked to actively track what they eat, and receive the core program.
89646491|NCT03037528|Experimental|Positive Affect, Tracking|Participants will receive information about positive affect, be asked to actively track what they eat, and receive the core program.
89646492|NCT03037528|Experimental|Tracking|Participants will be asked to actively track what they eat in addition to receiving the core program.
89646493|NCT03037528|Experimental|Positive Affect, Mindfulness|Participants will receive information about positive affect and mindfulness in addition to the core program.
89646494|NCT03037528|Experimental|Positive Affect|Participants will receive information about positive affect in addition to the core program.
89646495|NCT03037528|Experimental|Mindfulness|Participants will receive information about mindfulness in addition to the core program.
89646496|NCT03037528|Experimental|No Extras|Participants will receive the core program.
89646497|NCT03035292||Children attending eye clinic|"Children 1 month to 5 years of age attending paediatric ophthalmology clinic with and without cataracts. Children who had previously had intra-ocular surgery were excluded.~One eye of each child was assessed by an inexperienced screener (medical student) by red-reflex assessment using direct ophthalmoscope and infrared-reflex using a new device (CatCam). CatCam is a modified smart phone camera which images the reflection of co-axial infrared light from the ocular fundus. A cataract appears as a black silhouette on the white infrared-reflex imaged by the camera.~Sensitivity and specificity for red-reflex and infrared-reflex assessment compared to gold standard dilated ophthalmic examination by a specialised were compared."
89688550|NCT04355065|Active Comparator|Control Group|This group corresponds to the control group. The control group continues with their prescribed pharmacological treatment without any cognitive intervention. The participants of this group are contacted by telephone once a week to follow up on possible difficulties and/or side effects.
89212664|NCT00867542||control|3-4 y old healthy children
89212665|NCT00872612|Experimental|A|Endosonography arm
89646498|NCT03020030|Other|Initial Low Risk (Initial LR)|"Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.~Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
89646499|NCT03020030|Other|Initial High Risk (Initial HR)|"Meets at least one of the following criteria: Age >=15 years, WBC >=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1~And: No VHR characteristics~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
89646500|NCT03020030|Other|Initial Very High Risk (Initial VHR)|"Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
89646501|NCT03020030|Other|Final Low Risk (Final LR)|"Initial Low Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
89646502|NCT03020030|Other|Final Intermediate Risk (Final IR)|"Initial High Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
89688551|NCT02917642|Experimental|Passive Ultrasonic Irrigation Protocol|ultrasonic activation of antimicrobial solutions
89688552|NCT02917642|Active Comparator|Non-Ultrasonic Irrigation Protocol|no-activation of antimicrobial solutions
89044580|NCT03934281|Experimental|Honey dressing|"the honey used in this study is the Melectis G dressing. This is a combination of thyme honey (99.8%) and hyaluronic acid (0.2%).~The patient will benefit from the honey dressing until complete healing and/or until the end of the study (maximum 12 months)."
89044581|NCT04689893|Experimental|68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT scan|Patients of Tumor-induced osteomalacia PET/CT imaging: The patients were subcutaneously injected with 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 and underwent PET/CT scan 20~40min after the injection in two consecutive days.
89044582|NCT03922854||Mobile Monitor Group|Participants are recruited to this study if they have been monitored during their labour with a monica AN 24 monitor
89044583|NCT05184426||Exposed: Positive anti-HLA antibodies|Heart transplant patients who have developed antiHLA antibodies after transplant
89044584|NCT05184426||Non-exposed: Negative anti-HLA antibodies|Heart transplant patients without antiHLA antibodies with similar transplant date to its correspondent case.
89044585|NCT04689425|Experimental|MNC+PRP|The combination of PRP and MNC
89044586|NCT04689425|Active Comparator|PRP|PRP alone.
89044587|NCT05184192|Experimental|Gabapentin|"This arm will be given the active treatment, oral Letco (gabapentin) gelatin capsules of 300mg each.~Up to the first four weeks will be a titration period (week 1 300mg TID, week 2 600mg TID, week 3 900mg TID, week 4 1,200mg TID) as tolerated. If intolerable adverse reactions occur, the dosage will be decreased to prior tolerable dose (e.g., if 900mg TID is intolerable, dose will be decreased to 600mg TID).~The following eight weeks will be fixed dose, the highest tolerable dose from the titration period.~Up to two weeks will be a taper down tailored to the maximum dose the participant reached during the titration and fixed periods.~A maximum 14 weeks will mark the end of active treatment. Follow-up assessments will be conducted 4 weeks after completion of the taper-down period."
89044588|NCT05184192|Placebo Comparator|Placebo|"Placebo gelatin capsules that look, smell, and taste like gabapentin capsules will be given to the placebo arm.~To preserve double-blinding of the study, subjects will receive one capsule TID the first week, the second week two capsules TID, the third week three capsules TID, and fourth week four capsules TID as tolerated. If intolerable, the dose will be decreased to prior tolerable dose.~The next eight weeks will be a fixed amount of placebo based on the highest tolerable amount from the titration period.~Subjects will then taper-down placebo to imitate the gabapentin arm for maximum two weeks based on highest dose achieved during study.~4 weeks after completion of taper-down, follow-up assessments will be conducted."
89044589|NCT04689581|Experimental|Bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
89044590|NCT04689581|Experimental|Modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
89044591|NCT03887676|Active Comparator|Arbaclofen|
89044592|NCT03887676|Placebo Comparator|Placebo|
89044593|NCT04689620|Experimental|HELIUM NEON LASER plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
89044594|NCT04689620|Experimental|GALLIUM ARSENIDE plus regular ulcer care|laser scanning the wound with 9.6 jole/cm2 then regular dressing
89044595|NCT04689620|Active Comparator|regular ulcer care|dressing for the ulcer
89044596|NCT02929472|Experimental|Physical Exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
89212666|NCT00872612|Active Comparator|B|Conventional bronchoscopy arm
89044597|NCT02929472|Other|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
89044598|NCT02929433|Experimental|Cycloergometer group|Training at home with the cycloergometer per 20 minutes twice a day. The protocol suggested a continous use of the cycloergometer for a period of 6 months after 2 weeks of rehabilitation as outpatient.
89044599|NCT02929433|No Intervention|Control group|Usual care after a period (2 weeks) of rehabilitation as outpatient.
89044600|NCT04291469|Placebo Comparator|Control group|Identical-appearing Placebo (maltodextrin tables) ,oral, daily for 14 weeks
89044601|NCT04291469|Experimental|Probiotics group|Combined Bifidobacteria+lactobacillus+maltodextrin tables, each table contain more than 1.0*10^9 colony forming units, oral, daily for 14 weeks
89044602|NCT04291469|Experimental|Prebiotics group|Combined inulin+maltodextrin tables, oral, daily for 14 weeks
89044603|NCT03882294|Experimental|Probiotics|Subjects in probiotic group will receive fermented milk containing live cultures Lactobacillus casei Shirota (LcS), 3 x 10^10 CFU/bottle (80 ml)
89044604|NCT03882294|Placebo Comparator|Placebo|Subjects in placebo group will receive milk drink without LcS (80 ml).
89044605|NCT02929121|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
89044606|NCT02929121|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
89044607|NCT00553917||1|Pregnant women currently taking Prozac for the treatment of depression
89044608|NCT00553917||2|Pregnant women currently taking Zoloft for the treatment of depression
89044609|NCT00553917||3|Pregnant women not currently using medication for the treatment of depression
89044610|NCT00553917||4|Pregnant women with no history of, symptoms of, or treatment for depression
89044611|NCT02929277|Other|single arm study|
89646503|NCT03020030|Other|Final High Risk (Final HR)|"Initial Low Risk or Initial High Risk with High MRD (>=0.0001) at first time point (Day 32) but low MRD (<0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
89646504|NCT03020030|Other|Final Very High Risk (Final VHR)|"Initial VHR or any patient with high MRD (>=0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase [by direct assignment], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission."
89646505|NCT03020030|Active Comparator|Fixed Dose Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
89646506|NCT03020030|Experimental|Reduced Dose (PK-Adjusted) Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL. Closed to Enrollment.
89646507|NCT03020030|Other|Direct Assignment|All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
89646508|NCT02989636|Experimental|Arm I (nivolumab)|Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
89044612|NCT03871998|Experimental|Interventional arm|Skin barrier protection in the first 2 months of life.
89044613|NCT03871998|No Intervention|Control arm|Standard skincare advice. No moisturiser in the first 2 months.
89044614|NCT02929394|Active Comparator|investigational treatment|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity.
89044615|NCT02929394|No Intervention|observation|Observation through clinical and radiological follow-up until disease progression (RECIST 1.1).
89646509|NCT02989636|Experimental|Arm II (nivolumab, SRS)|Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.
89688553|NCT04364581|Active Comparator|Letrozole group|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
89688554|NCT04364581|Placebo Comparator|Placebo group|Women will be treated with placebo for 10 days before hysteroscopic intervention
89044616|NCT05159037|Experimental|Active GC-MRT Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will have been trained with prior to a stressful speech task.
89044617|NCT05159037|Placebo Comparator|Control Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will not have been trained with but ranked as highly liked prior to a stressful speech task.
89044618|NCT02929316|Experimental|Vedolizumab|Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6
89044619|NCT03841539|Experimental|Mediterranean Diet|Follow a Mediterranean eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
89044620|NCT03841539|Active Comparator|Low-fat Diet|Follow a low-fat eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
89044621|NCT02929238|Experimental|Polypropylene Suture Right Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
89044622|NCT02929238|Experimental|Polypropylene Suture Left Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
89044623|NCT05152836|Experimental|Vibrotactile stimulation atdifferent settings|All participants receive vibrotactile stimulation at three different stimulation settings as well as one sham condition. Specifically, stimulation is applied at (1) brief bursts of 80Hz that occur at the individual tremor frequency, (2) 80Hz bursts at tremor frequency*1.5, and (3) continuous stimulation at 80Hz. The sham condition does not involve any stimulation. All of the stimulations will be applied under three different contextual manipulations: during rest, posture and cognitive coactivation (serial subtraction task). Within each context, stimulation/sham conditions are applied in random order.
89044624|NCT02929199|Active Comparator|group A|Pressable E- max, an all ceramic crown
89044625|NCT02929199|Experimental|Group B|BIO-Hpp hybrid crown
89044626|NCT03791112|Experimental|50mg QD|Participants received 50 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
89044627|NCT03791112|Experimental|100mg QD|Participants received 100 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
89044628|NCT03791112|Experimental|200mg QD|Participants received 200 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
89044629|NCT03791112|Experimental|300mg QD|Participants received 300 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
89044630|NCT03791112|Experimental|400mg QD|Participants received 400 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
89044631|NCT03791112|Experimental|500mg QD|Participants received 500 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
89044632|NCT02929355||diabetic patients with carotid assessment|Patients with diabetes and a carotid assessment by duplex ultrasonography in 2012 in a monocentric diabetic unit
89044633|NCT02929043||Dentine hypersensitivity subjects|
89044634|NCT02928926||Thrombolysis|Acute ischaemic stroke patients who receive intravenous thrombolysis
89044635|NCT02928926||non thrombolysis|Acute ischaemic stroke patients who admitted to the hospital within the timeframe for intravenous thrombolysis but contraindicate to receive intravenous thrombolysis
89044636|NCT05099211|Experimental|Patients muscle strengthening|
89044637|NCT05099211|Experimental|Aerobic Training Patients|
89044638|NCT05099211|Active Comparator|Healthy patients|
89044639|NCT02928809|No Intervention|TMD control|Patients with diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
89044640|NCT02928809|Experimental|TMD LLL|Patients with diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
89044641|NCT02928809|No Intervention|Without TMD control|Patients without diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
89044642|NCT02928809|Experimental|Without TMD LLL|Patients without diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
89646510|NCT02955290|Experimental|Phase I (CIMAvax, nivolumab)|"LOADING PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.~MAINTENANCE PHASE I: Patients who do not experience a DLT receive CIMAvax every 4 weeks and nivolumab every 2 weeks."
89646511|NCT02955290|Experimental|Phase II Study A and B (CIMAvax, nivolumab)|PHASE II STUDY A and B: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for nivolumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients in Study A with antibody titer >= 1:4000 at the end of the loading phase may receive CIMAvax IM every 8 or 12 weeks during the maintenance phase.
89646512|NCT02955290|Experimental|Phase II Study C, D & E (CIMAvax, pembrolizumab)|PHASE II STUDY C, D & E: Patients with PD-L1 expression >= 50% receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for pembrolizumab repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
89688555|NCT04363723||patients with an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that developed an acute exacerbation during a pulmonary Rehabilitation program but continued the Rehabilitation program
89044643|NCT02928809|Placebo Comparator|TMD placebo|Patients with diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
89044644|NCT02928809|Placebo Comparator|Without TMD placebo|Patients without diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
89044645|NCT02928731||Children with cancer|"Children met the criteria below were invited to fill in the questionnaires set 1.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, (3) they should have been diagnosed with cancer for at least 2 months and be currently undergoing active treatment, and (4) they should aware of their diseases (cancer)."
89212667|NCT00877994|Active Comparator|Immediate|This group will receive the nurture group therapy immediately after enrolling in the study.
89646513|NCT02955290|Experimental|Phase II Study D (CIMAvax, pembrolizumab)|PHASE II STUDY D: Patients with PD-L1 expression < 50% after 4 cycles of induction chemotherapy with pembrolizumab, receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
89646514|NCT02924311||Previously treated patient|Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
89646515|NCT02924311||Naïve patient|Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
89646516|NCT02924311||Entire study population|Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept
89646517|NCT02921893|Experimental|Group I (ixazomib citrate, lenalidomide, dexamethasone, ASCT)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 cycles of treatment.
89646518|NCT02921893|Experimental|Group II (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
89646519|NCT02905240|Experimental|nSTRIDE APS|Autologous Protein Solution prepared using the nSTRIDE APS Kit
89646520|NCT02905240|Other|Saline|Saline control
89646521|NCT02901275|Placebo Comparator|Placebo + Placebo|Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
89646522|NCT02901275|Active Comparator|Hydromorphone (oral) 4mg + Placebo|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
89646523|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 2.5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 2.5mg. Order of dose randomized session days 2-5.
89646524|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 5.0mg. Order of dose randomized session days 2-5.
89646525|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 10mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 10mg. Order of dose randomized session days 2-5 but was never the first hydromorphone 4mg + dronabinol combination dose.
89646526|NCT02896452||Women diagnosed with PCOS without IIH|Women diagnosed with polycystic ovary syndrome without idiopathic intracranial hypertension
89646527|NCT02896452||Women diagnosed with PCOS and IIH|Women diagnosed with polycystic ovary syndrome and idiopathic intracranial hypertension
89646528|NCT02896452||Women diagnosed with IIH without PCOS|Women diagnosed with idiopathic intracranial hypertension without polycystic ovary syndrome
89646529|NCT02896452||Women without PCOS or IIH|Women age and body mass index match controls without polycystic ovary syndrome or intracranial hypertension
89646530|NCT02893917|Experimental|Arm A (olaparib, cediranib)|Patients receive olaparib PO BID and cediranib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646531|NCT02893917|Active Comparator|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646532|NCT02854527|Experimental|R1 (Reference 1) Digoxin|1 tablet (0.25 mg) digoxin as single dose
89646533|NCT02854527|Experimental|R2 Furosemide|0.1 mL (1 mg) furosemide oral solution as single dose
89646534|NCT02854527|Experimental|R3 Metformin hydrochloride|0.1 mL (10 mg) metformin oral solution as single dose
89646535|NCT02854527|Experimental|R4 Rosuvastatin|1 tablet (10 mg) rosuvastatin as single dose
89646536|NCT02854527|Experimental|T (Test)|1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')
89646537|NCT02839707|Experimental|Arm I (PLD, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15. (Closed to accrual as of February 09, 2021)
89646538|NCT02839707|Experimental|Arm II (PLD, bevacizumab, atezolizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15. Patients also undergo CT on study.
89646539|NCT02839707|Active Comparator|Arm III (PLD, bevacizumab)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also undergo CT on study.
89646540|NCT02830477||BAY81-8973|Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis
89646541|NCT02828592|Experimental|Flu/Cy/TBI|Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 & 4.
89646542|NCT02811432|Experimental|Kangaroo mother care|Skin-to-skin care initiated as soon as possible following randomisation
89646543|NCT02811432|Active Comparator|Standard care|Incubator or radiant warmer
89212668|NCT00877994|Active Comparator|Delayed|This group will receive the nurture group therapy 16 weeks after enrolling in the study.
89212669|NCT02588417|Active Comparator|dexamethasone|dexamethasone 4 mg administered intrathecally during active stage of labor once only in combination with levobupivacaine
89218024|NCT02538302|Experimental|Minirin|120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
89044646|NCT02928731||Healthy children|"Children met the criteria below were invited to fill in the questionnaires set 2.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, and (3) they should not have cancer or any other chronic illness."
89044647|NCT02928965|Experimental|Minocycline|Participants will receive capsules containing 100mg of minocycline (modified release), two per day for the first two weeks of the trial and then three per day for the remainder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
89044648|NCT02928965|Placebo Comparator|Placebo|Participants will receive placebo capsules entirely matching minocycline, two per day for the first two weeks of the trial and then three per day for the reminder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
89044649|NCT04679220|Active Comparator|Non-heated Resin Composite group|Patients received Non-heated nanofilled resin composite on one side of the mouth
89044650|NCT04679220|Placebo Comparator|Preheated Resin Composite group|Patients received preheated nanofilled resin composite on the other side of the mouth
89044651|NCT02928692|Placebo Comparator|Placebo|Placebo administered before surgery
89044652|NCT02928692|Experimental|Minocycline|Minocycline was administrated before surgery
89646544|NCT02800486|Experimental|Intra-arterial Cetuximab with Re-Irradiation|Mannitol 20% 12.5ml over two minutes for blood brain barrier (BBB) disruption followed by Cetuximab administered intra-arterially for three doses at a dose of 250 mg/m2 combined with hypofractionated re-irradiation
89646545|NCT02779725|Active Comparator|Group 1 SCC/SSR|This arm includes self-care coaching (SCC) message during daily self-reported symptom severity report (SSR) calls to the automated system.
89646546|NCT02779725|Active Comparator|Group 2 NP/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. These alerts are monitored and follow-up care is given by a nurse practitioner.
89044653|NCT02928692|No Intervention|Volunteers|Health people for calculate the incidence of POCD
89044654|NCT04679142||Adult patients starting a treatment with Baclocur®|Baclofen(Baclocur®) 10mg, 20mg, 30mg, 40mg.
89044655|NCT02928653|Active Comparator|Sucrose Sweetened Beverage|100-140 g sucrose/day
89646547|NCT02779725|Active Comparator|Group 3 NP/DSS/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. Nurse practitioner follow-up calls utilize the evidenced based SCH decision support system (DSS) when symptoms exceed alert thresholds
89646548|NCT02779725|Active Comparator|Group 4 Full Intervention SSR/SCC/NP/DSS|Complete intervention with all components used in prior efficacy study (Symptom Severity Report (SSR)+Self Care Coaching (SCC) +Nurse Practitioner (NP) +Decision Support System (DSS))
89646549|NCT02779725|Active Comparator|Group 5 SSR/SCC/AT|Symptom severity reporting (SSR), automated self-care coaching (SCC) based on daily symptom reporting plus activity tracker (AT)
89646550|NCT02772081|Experimental|Curosurf LISA|"Single dose of poractant alfa 200 mg/kg via brief insertion of a thin catheter (CHF 6440) into the trachea in neonates with RDS.~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
89646551|NCT02772081|Active Comparator|Curosurf Endotracheal Tube|"Single dose of poractant alfa 200 mg/kg via the conventional intubation with endotracheal tube in neonates with RDS.~A second surfactant dose at 100 mg/kg will be administered with the same technique as the first dosage administration if needed.~After the first and second surfactant administration, neonates could receive a third surfactant dose at 100 mg/kg through a standard technique if needed."
89646552|NCT02742623||Rivaroxaban|Female and male patients with active cancer and treated with rivaroxaban after a diagnosis of DVT/ and/or PE
89646553|NCT02713022||Breast Cancer|DEXA scan will be carried out 1 to 30 days prior to mastectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
89646554|NCT02713022||Prostate Cancer|DEXA scan will be carried out 1 to 30 days prior to radical prostatectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
89646555|NCT02705859|Other|Single Arm|"This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial.~Patients with HER2-positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8)."
89646556|NCT02699697|Experimental|ARM I (palliative radiation therapy)|Patients undergo 1 fraction of EBRT over 30 minutes.
89646557|NCT02699697|Experimental|ARM II (palliative radiation therapy)|Patients undergo 2 fractions of EBRT over 30 minutes. The 2 fractions will be separated by 3-7 days.
89688556|NCT04363723||patients without an acute exacerbation during Rehabilitation|Patients with severe chronic obstructive pulmonary disease awaiting lung Transplantation that did not develop an acute exacerbation during a pulmonary Rehabilitation program and completed the Rehabilitation program regularly.
89044656|NCT02928653|Experimental|Aspartame Sweetened Beverage|0.541-0.757 g aspartame Sweetened Beverage/day
89044657|NCT02928653|Experimental|Saccharin Sweetened Beverage|0.300-0.455 g saccharin Sweetened Beverage/day
89044658|NCT02928653|Experimental|Sucralose Sweetened Beverage|0.167-0.233 g sucralose Sweetened Beverage/day
89044659|NCT02928653|Experimental|Rebaudioside A Sweeteened Beverage|0.250-0.350 g rebaudioside A Sweetened Beverage/day
89044660|NCT02928419|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
89044661|NCT02928419|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
89212670|NCT02588417|Active Comparator|levobupivacaine|levobupivacaine 2.5 mg in 2 ml administered intrathecally during active stage of labor once and alone and then epidural levobupivacaine 7ml of 2.5 mg concentrationis administered till the end of labor
89044662|NCT02928614|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
89044663|NCT02928614|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
89044664|NCT02928458|Active Comparator|Omnipaque|Arm 1
89044665|NCT02928458|Active Comparator|MD-Gastroview|Arm 2
89044666|NCT03685500|Active Comparator|Arm 1|Patients who postpone switching from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) four weeks
89044667|NCT03685500|Experimental|Arm 2|Patients who switch from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) during the baseline visit
89646558|NCT02697487||No Treatment|This is a longitudinal observational study involving individuals who are depressed, depressed with other comorbidities and non-depressed individuals. The primary aim of this study is to describe the longitudinal course of illness and real world treatment outcomes for depressed patients receiving routine care from their providers. Health outcomes and biospecimens along with the functional and economic burden of depression will be characterized and compared amongst three groups: (1) depressed patients, (2) depressed patients with comorbid illnesses, and (3) non-depressed patients.
89646559|NCT02664883||Group I (no cancer or hematuria)|Patients with no evidence of cancer and no hematuria undergo collection of blood and urine samples at baseline and 2 months for analysis via the Flow Cytometry MDSC Clinical Assay
89646560|NCT02664883||Group II (localized RCC)|Patients diagnosed with localized renal cell carcinoma undergo collection of blood and urine samples at baseline and after nephrectomy for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI within 30 days after nephrectomy.
89646561|NCT02664883||Group III (metastatic RCC)|Patients diagnosed with metastatic renal cell carcinoma undergo collection of samples prior to baseline and then after 4 months of systemic treatment for analysis via the Flow Cytometry MDSC Clinical Assay. Patients also undergo CT or MRI after completion of 4 months of systemic treatment.
89646562|NCT02639559|Experimental|Arm 1: Donors|-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10^6 CD34+ cells/kg and at least ≥ 2 x 10^6 CD34+ cells/kg from the combined collections.
89646563|NCT02639559|Experimental|Arm 2: Recipients|-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0
89646564|NCT02633137|Experimental|Chemotherapy|Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months. Patients will be followed on active follow up for three years after completion of therapy. After the active followup period, survival, relapse, and new anti-lymphoma therapy information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 6 months until death, loss to follow up or consent withdrawal, whichever comes first.
89646565|NCT02605512|Other|Breast cancer patients with 3DCRT|Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'
89646566|NCT02584478|Experimental|Phase 3 -Active Treatment Arm|"Phase 3: AL3818 8 mg once daily in combination with one background chemotherapy in 21-day cycles. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~Pegylated liposomal doxorubicin (PLD)~Topotecan"
89646567|NCT02584478|Other|Phase 3-Control Treatment Arm|"Control Treatment Arm: Background chemotherapy treatment alone. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~Pegylated liposomal doxorubicin (PLD)~Topotecan"
89646568|NCT02584478|Experimental|Phase 1b: AL3818 plus carboplatin and paclitaxel|Phase 1b: Sequential deescalating dosing evaluation to determine the recommended Phase II dose (RP2D). For 21-day treatment cycles, cohort 1 (3 subjects) will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at an initial dose of 12 mg/day.
89688557|NCT01049009|Active Comparator|Nebivolol followed by Metoprolol XL|Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
89688558|NCT01049009|Active Comparator|Metoprolol XL followed by Nebivolol|Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.
89044668|NCT02928575|Experimental|Sunitinib, Temozolomide and Radiation Therapy|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
89044669|NCT05052918|Active Comparator|Exercise|"Patients with prediabetes undergoing a 12-week exercise program~(1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks)"
89212671|NCT00867620||1|case group: patients with urothelial carcinoma
89646569|NCT02584478|Experimental|Phase 2a: AL3818 plus carboplatin and paclitaxel|Phase 2a: subjects will receive chemotherapy and oral AL3818 for 6 cycles (18 weeks, 21-day cycles of treatment) followed by continuous maintenance treatment of oral AL3818 for up to 12 months. Subjects will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at the RP2D found in Phase 1b.
89646570|NCT02581891|Experimental|Early-start T&E / Arm 1|Early-start T&E arm: test group, early treatment individualization
89646571|NCT02581891|Active Comparator|Late-start T&E / Arm 2|Late-start T&E arm; per label, control group, treatment individualization after Year 1
89646572|NCT02576535|Experimental|Fractionated stereotactic radiosurgery|The radiation dose will be delivered by the standard, FDA approved Leksell gamma unit (Gamma knife; Elekta Instruments, Atlanta, GA). Treatment dose and volume will be determined using the Gamma Plan software provided with the unit (Elekta Instruments, Atlanta, GA).
89646573|NCT02574845|Experimental|R (Reference) Rosuvastatin|1film-coated tablet as single dose, fasted
89646574|NCT02574845|Experimental|T1 (Test 1) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
89646575|NCT02574845|Experimental|T2 (Test 2) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
89646576|NCT02574845|Experimental|T3 (Test 3) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
89646577|NCT02574845|Experimental|T4 (Test 4) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
89646578|NCT02574845|Experimental|T5 (Test 5) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
89646579|NCT02530593||Patients with colon cancer|All patients presenting with a newly diagnosed colon cancer regardless of tumour stage
89212672|NCT00867620||2|control group: those without previous history of any malignancy
89646580|NCT02523534|Experimental|Recurrence Mapping|Participant undergoing their first ablation that fit our inclusion/exclusion criteria will undergo new atrial fibrillation mapping techniques to help identify the sources of atrial fibrillation. The participant will have an MRI and ECG prior to a clinically indicated ablation.
89646581|NCT02521844|Experimental|Dose Escalation|ETC-1922159 + pembrolizumab
89646582|NCT02521844|Experimental|Dose Expansion|ETC-1922159 as single agent until disease progression, then in combination with pembrolizumab at the recommended dose (RD) identified in the dose escalation segment
89646583|NCT02445443||LEGION Hinge Knee System|This group will be receiving the LEGION Hinge device.
89646584|NCT02432326|Experimental|Arm A|
89646585|NCT02404285|Placebo Comparator|Vehicle|"Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
89044670|NCT05052918|No Intervention|Control|Patients with prediabetes with no intervention
89044671|NCT05052918|No Intervention|Metformin|Patients with prediabetes using metformin
89212673|NCT00872690||Group 1|OEF/OIF veterans with polytrauma who have been referred by the Tampa VA Polytrauma Rehabilitation Center (PRC) to the VA VR&E Regional Office in St. Petersburg, Florida for Chapter 31 (IL) services.
89212674|NCT00872690||Group 2|Caregivers of the veterans who enroll in the study
89212675|NCT00532935|Experimental|1|Sitagliptin phosphate (+) metformin hydrochloride
89212676|NCT00532935|Active Comparator|2|pioglitazone
89212677|NCT00878150|Experimental|Telephone-based CBT|- 12 counseling sessions over 16 weeks over the telephone
89212678|NCT00878150|Experimental|In-person CBT|- 12 counseling sessions over 16 weeks at either Harborview Medical Center or the University of Washington Medical Center in Seattle, WA
89212679|NCT00878150|No Intervention|3: Usual care|- No counseling sessions as part of this study, however you are free to pursue regular medical care and counseling outside of this study
89646586|NCT02404285|Active Comparator|NAG (Next Science Acne Gel)|"Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
89646587|NCT02387905|Active Comparator|Arm I (standard of care)|Patients undergo stereotactic spinal radiosurgery per standard of care.
89646588|NCT02387905|Experimental|Arm II (vertebral body cement augmentation)|Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery.
89646589|NCT02344355|Experimental|ascorbate, radiation, temozolomide|"Concomitant therapy:~Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions~Adjuvant therapy:~Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions"
89646590|NCT02289924||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy
89646591|NCT02279537||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC)
89646592|NCT02270359|Other|MI without obstructive CAD|MI without obstructive CAD, with OCT and CMR imaging
89646593|NCT02256865|Placebo Comparator|Placebo and Drug Group 2|Placebo pills and gel is used in place. Placebo for Ketoconazole is taken 4 times a day Placebo for Hydrocortisone is taken 3 times a day Placebo for testosterone gel is applied once a day.
89646594|NCT02256865|Active Comparator|Drug and Placebo Group 1|Ketoconazole is taken 4 times a day Hydrocortisone is taken 3 times a day Testosterone gel is applied once a day
89646595|NCT02208141||lean and obese children and adolescents|study cohort may be stratified for lean (definded as BMI <1.28 SDS) and overweight/obese (definded as BMI>= 1.28 SDS) children for posthoc analyses no intervention
89044672|NCT02928302|Experimental|TVU CL screening|TVU CL screening: single TVU CL at 18 0/7 to 23 6/7 every week
89044673|NCT02928302|No Intervention|no screening|no TVU CL screening
89044674|NCT02928263||Patients treated with IV agents|Metastatic renal cell carcinoma patients treated with IV agents
89212680|NCT00878306|Active Comparator|Disulfiram|Disulfiram
89646596|NCT02193191|Experimental|Plerixafor|Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.
89646597|NCT02188329||Households with children under 13|Interviews were conducted with the parent or guardian of a child or children under age 13.
89646598|NCT02188329||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own.
89646599|NCT02188329||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
89646600|NCT02188329||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
89646601|NCT02162849|Experimental|Varenicline + Placebo Patch|"Varenicline dosing follows the recommended 12 week course: 0.5 milligram mg/day by mouth for Days 1-3, 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter. Participant takes Varenicline 1-10 days after Visit 1.~Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day.~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo. Some of the counseling sessions may be recorded by video and/or audio tape.~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
89646602|NCT02162849|Experimental|Nicotine Patch + Placebo Tablet|"Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.~Starting on Day 8, and then every day after that, participant applies 1 nicotine patch.~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo.~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
89646603|NCT02122913|Experimental|Tumor patients_Dose 1|Adult patients with solid tumors receiving 50 mg of BAY2757556 once daily (dose escalation cohort).
89646604|NCT02122913|Experimental|Tumor patients_Dose 2|Adult patients with solid tumors receiving 100 mg of BAY2757556 once daily (dose escalation cohort).
89646605|NCT02122913|Experimental|Tumor patients_Dose 3|Adult patients with solid tumors receiving 100 mg of BAY2757556 twice daily (dose escalation cohort).
89646606|NCT02122913|Experimental|Tumor patients_Dose 4|Adult patients with solid tumors receiving 200 mg of BAY2757556 once daily (dose escalation cohort).
88992337|NCT03459586|Experimental|9zest app facilitated exercise|App to facilitate exercises for 3 times a week for 12 weeks. The app includes physical therapist-designed exercises that are modified using an algorithm to the participants physical capabilities and PD status. Exercises include strengthening, balance, range of motion, and endurance type exercise.
88992338|NCT04965428|Experimental|Fear-focused Self-Compassion Therapy|Experimental group receives group face-to-face Fear-focused Self-Compassion Therapy for eight weeks.
88992339|NCT04965428|No Intervention|Usual care|The no intervention group receives usual care supported by hospital or coming from elsewhere for eight weeks.
88992340|NCT00339703||Control|Subjects between the ages of 18 and 65 without a diagnosis of asthma or other inflammatory disease were enrolled from the patient population at Wilford Hall Medical Center. Subjects underwent a single blood draw and spirometer.
88992341|NCT00339703||Mild to Moderate Asthma|Subjects between the ages of 18 and 65, who were previously diagnosed with moderate to severe persistent asthma as defined by the National Asthma Education and Prevention Program (NAEPP), were enrolled from the Allergy and Immunology clinic at Wilford Hall Medical Center. Subjects on inhaled corticosteroids or other controller medications were allowed in the study, but subjects on oral corticosteroids were excluded. Subjects underwent a single blood draw and spirometer.
88992342|NCT00510406|Placebo Comparator|A|
88992343|NCT00510406|Active Comparator|B|
88992344|NCT00510406|Active Comparator|C|
88992345|NCT00510406|Active Comparator|D|
88992346|NCT00510406|Active Comparator|E|
88992347|NCT00510406|Active Comparator|F|
88992348|NCT00510406|Active Comparator|G|
88992349|NCT00510406|Active Comparator|H|
88992350|NCT00339742||Clinic Referral controls|Controls referred by the endoscopy clinic
88992351|NCT00339742||Esophageal Cancer cases|Histologically confirmed squamous cell cancer of the esophagus
88992352|NCT00339742||Neighborhood controls|Controls recruited from the neighborhood
88992353|NCT02952664|Experimental|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
88992354|NCT00339859||1|The population controls are collected from DMV records in the Baltimore region of MD. The cases are patients at the University of Maryland Medical System, including the associated Veterans' Association Hospital.
88992355|NCT02952625|Other|Single arm imaging study|Single arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position
88992356|NCT02952859||historic control group|Work-up and follow-up of the historic control will be performed through similar means by contacting primary care physicians and/or medical oncologists, if information cannot be received, the patient will be directly contacted. In case the patient cannot be reached and no other information can be received on patients outcome, the death registry will be contacted.
88992357|NCT02952859||comparator group|All patients with potentially and borderline resectable pancreatic cancer are potentially candidates for IRE and will be considered for this treatment. Patient will be recruited/referred through daily clinical practice from the Inselspital Bern. Final inclusion into the study will be performed by the responsible investigators at the Inselspital Bern. Patients will be included according to the inclusion/exclusion criteria mentioned.
89646607|NCT02122913|Experimental|Tumor patients_Dose 5|Adult patients with solid tumors receiving 150 mg of BAY2757556 twice daily (dose escalation cohort).
89646608|NCT02122913|Experimental|Tumor patients_Dose 6|Adult patients with solid tumors receiving 200 mg of BAY2757556 twice daily (dose escalation cohort).
88992358|NCT02952196|Placebo Comparator|placebo|
89646609|NCT02122913|Experimental|Tumor patients_Expansion|"Adults patients with solid tumors and neurotrophic tyrosine kinase (NTRK) genes or proteins of types 1 - 3 (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of BAY2757556 as determined in the dose escalation part."
88992359|NCT02952196|Experimental|cannabinoid dose 1|
88992360|NCT02952196|Experimental|cannabinoid dose 2|
88992361|NCT00511732|Experimental|Technosphere Insulin|
88992362|NCT00511732|Placebo Comparator|Technosphere Inhalation Powder|
88992363|NCT00510445|Experimental|Single Arm Trial|Patients will be enrolled in the order of confirmation of eligibility. Dose cohorts will be filled sequentially with a minimum of 3 patients. Once assigned to a dose cohort, each patient will continue to be treated at the same dose level throughout the course of the study.
88992364|NCT04937387|Experimental|Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler|
88992365|NCT04937387|Experimental|Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler|
89646610|NCT02101905|Experimental|Group A (lapatinib ditosylate, surgery)|Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646611|NCT02101905|Active Comparator|Reference Group (surgery, lapatinib ditosylate)|Patients undergo surgery on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646612|NCT02070549|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89646613|NCT02048371|Active Comparator|Cohort A: Liposarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
89646614|NCT02048371|Placebo Comparator|Cohort A: Liposarcoma, Placebo|"21 days on and 7 days off~Placebo"
89646615|NCT02048371|Active Comparator|Cohort B: Osteosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
89646616|NCT02048371|Placebo Comparator|Cohort B: Osteosarcoma, placebo|"21 days on and 7 days off~Placebo"
89646617|NCT02048371|Active Comparator|Cohort C: Ewing sarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
89646618|NCT02048371|Active Comparator|Cohort D: Rhabdomyosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
89646619|NCT02048371|Active Comparator|Cohort E: Mesenchymal Chondrosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
89646620|NCT02022514|Experimental|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
89646621|NCT02022514|Active Comparator|Conventional medical treatment|Conventional medical treatment
89646622|NCT01957436|Active Comparator|Arm A|androgen deprivation therapy + docetaxel
89646623|NCT01957436|Experimental|Arm B|androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone
88992366|NCT04937387|Experimental|Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler|
88992367|NCT04937387|Experimental|Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler|
88992368|NCT00510562|Experimental|1|Assessment for cranial strain patterns, followed by indirect osteopathic treatment of dysfunctions found on assessment, followed by reassessment.
88992369|NCT00510562|Sham Comparator|2|Assessment for cranial strain patterns, followed by laying on of hands, followed by reassessment.
88992370|NCT00510601|Experimental|1|
88992371|NCT00511849|Experimental|1|
89044675|NCT02928263||Patients treated with oral agents|Metastatic renal cell carcinoma patients treated with oral agents
89646624|NCT01957436|Experimental|Arm C|Arm A + radiotherapy
89646625|NCT01957436|Experimental|Arm D|Arm B + radiotherapy
89646626|NCT01946139|Experimental|Screening (HSIL detection)|Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
89646627|NCT01896973|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
89646628|NCT01886885||MBCPM|There is just one group of participants of no more than 20 people.
89646629|NCT01860261|Experimental|Aerobic and Strength Training|Participants in the Aerobic and Strength Training intervention group will receive a standardized aerobic and strength training exercise program for 12 weeks, including paid gym membership, personal training, and 3 workshops in ChiWalkRun technique.
89646630|NCT01860261|No Intervention|Control (delayed onset of intervention)|After 12 weeks of active observation, this group will receive a modified version of the exercise intervention consisting of a free gym membership for 12 weeks, with limited personal training.
89646631|NCT01783925||Group 1|
89646632|NCT01737619|Experimental|Diagnostic (PET/CT, lymph node mapping)|Patients undergo PET/CT prior to surgery. Patients then undergo intraoperative lymph node mapping with indocyanine green solution, given via superficial and deep cervical injection during full lymphadenectomy.
89646633|NCT01730781||Schizophrenia|Patients diagnosed with schizophrenia both on medication and off medication
89646634|NCT01730781||Cannabis dependence|Frequent users of cannabis
89646635|NCT01730781||Family history of alcoholism|Healthy volunteers with a first degree relative with alcoholism
89646636|NCT01730781||Prodrome for psychotic illness|Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms
89646637|NCT01730781||Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
89646638|NCT01730781||PTSD-Post Traumatic Stress Disorder|Patients diagnosed with Post Traumatic Stress Disorder
89646639|NCT01730781||Opioid Use Disorder|Patients diagnosed with Opioid Use Disorder
89646640|NCT01685008|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
89646641|NCT01624805|Experimental|Treatment (methylprednisolone, hATG, cyclosporine, G-CSF)|Patients receive methylprednisolone IV over 10 minutes on days 1-4 and IV or PO with taper over days 5-30. Patients also receive horse anti-thymocyte globulin IV over 8 hours daily on days 1-4, cyclosporine PO BID on days 1-180, and pegfilgrastim or pegfilgrastim biosimilar SC on day 5 and/or filgrastim SC beginning on day 5 and continuing until absolute neutrophil count recovers. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
89646642|NCT01605123||Lean children|n=100 (anticipated), n=70 currently Age: 6-25 years BMI-SDS: -1.88 to +1.23 , currently -0.25±0.77; Height-SDS: > - 2 SDS, currently 0.03±1.07;
89646643|NCT01605123||Obese children|n=106 Age: 6-25 years BMI-SDS: >1.23 , currently 2.41±0.52; Height-SDS: > - 2 SDS, currently 0.80±1.18;
89646644|NCT01605123||Obese Exercise Group|Obese children will engage in increased physical activity (one to two lessons per week) at 40-60 and 60-80% of maximal exercise capacity (n=50 each anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
89646645|NCT01605123||Classical Lifestyle Intervention|Obese children will receive a classical lifestyle intervention, including dietary, activity and psychosocial counselling (n=50 anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
89646646|NCT01587352|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID for 3 days weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88992372|NCT00510640|Experimental|Sunitinib|Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.
88992373|NCT00511927||GHD|Patients with Growth Hormone Deficiency
88992374|NCT00511927||non-GHD|Patients with CHF, without coexisting growth hormone deficiency
88992375|NCT03459508||Primary antiphospholipid syndrome women|"Informed consent~Detailed history emphasizing on~a. obstetric complications related to antiphospholipid syndrome: i. Recurrent miscarriage ii. Fetal demise iii. Fetal growth restriction iv. Severe pre-eclampsia or eclampsia v. Placental insufficiency vi. Placental abruption b. Systemic vascular complications related to antiphospholipid syndrome: i. Arterial thrombosis ii. Venous thrombosis iii. Small-vessel thrombosis~Revision of diagnosis of primary antiphospholipid syndrome:~Exclusion of antiphospholipid syndrome secondary to SLE and other autoimmune diseases by: antinuclear (ANA), anti-Smith (Sm) and anti-double stranded DNA (dsDNA) antibodies.~Ophthalmological examination:"
88992376|NCT00165633|Experimental|1|
88992377|NCT00165633|Experimental|2|
88992378|NCT00165633|Placebo Comparator|3|
88992379|NCT02952469|Experimental|(68Ga)PSMA-HBED-CC|Intervention: positron emission tomography / computed tomography (PET/CT) scan using a experimental radiotracer for imaging prostate-specific membrane antigen
88992380|NCT03459430|Experimental|Low Intensity training group|Low Intensity training group will complete a 6 week core stability training program with low intensity/oscillation exercises
88992381|NCT03459430|Experimental|High Intensity training group|High Intensity training group will complete a 6 week core stability training program with high intensity/oscillation exercises
88992382|NCT03459430|No Intervention|Control group|Control group will have 6 weeks with no intervention before post-test
88992383|NCT00510757||Males|
88992384|NCT00510757||Females|
88992385|NCT04907591|Experimental|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band for 12 months.
88992386|NCT04907591|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
88992387|NCT00510796||High Risk Group|Colon and/or Endometrial Cancer
88992388|NCT02952742|Experimental|Black Cohosh Therapy|Black Cohosh will be provided in 250mg capsules. Subjects will take 2 capsules by mouth daily for a total daily dose of 500 mg. Subject's will remain on this study arm for 8 weeks.
88992389|NCT02952742|Placebo Comparator|Placebo|Subjects will take 2 capsules, identical to the Black Cohosh capsules, by mouth each. Subject's will remain on this study arm for 8 weeks.
88992390|NCT04903301|Experimental|Study Group|Contoura Vision LASIK using Phorcides Analytic Software
88992391|NCT03459391|Experimental|XC221 60 mg|Cohort 1:16 subjects were randomized in a 3:1 ratio to be treated either with 60 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
89044676|NCT02928146|Active Comparator|Lichtenstein technique|Lichtenstein inguinal hernia repair
89212681|NCT00878306|Experimental|Disulfiram + Efavirenz|Efavirenz alone, then in addition with Disulfiram
89646647|NCT01556490|No Intervention|Control group|Standard-of-care sorafenib, with no added therapy
89646648|NCT01556490|Experimental|Treatment group|Standard-of-care sorafenib plus TheraSphere
89646649|NCT01453660||Cisplatin-Based Chemotherapy Group|GCT patients who are planned to start cisplatin-based chemotherapy will be identified within the genitourinary oncology service clinics and offered inclusion in the trial.
89646650|NCT01453660||Surgery-Only Group|GCT patients who have been treated with surgery and who do not require chemotherapy or radiation will be used as a comparison group to confirm that there is not a significant change in endothelial function among GCT patients treated with surgery alone.
89212682|NCT00878306|Experimental|Disulfiram + Atazanavir|Atazanavir alone, then in addition with Disulfiram
89212683|NCT00878306|Experimental|Disulfiram + Ritonavir|Ritonavir alone, then in addition with Disulfiram
89212684|NCT00995319||radiation patients|cancer patients with radiotherapy concerning the head and neck area/oral cavity
89212685|NCT00878384|Active Comparator|Rate control|Strategy of 'rate-control': acceptance of atrial fibrillation, and dose-adjusted drug therapy as needed to control ventricular rate.
89646651|NCT01434316|Experimental|Treatment (veliparib and dinaciclib)|"PART 1A: Patients receive veliparib PO BID on days 1-28 and dinaciclib IV over 2 hours on days 8 and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PART 1B: Patients receive veliparib and dinaciclib as patients in Part 1A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PART 1C: Patients receive veliparib PO BID on days 1-7 of cycle 0. Patients then receive veliparib PO BID on days 1-21 and dinaciclib IV over 2 hours on days 1, 4, 8, and 11 or days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89646652|NCT01351896|Experimental|Arm A (Concurrent PCV13 and lenalidomide)|Patients receive low-dose lenalidomide PO once daily on days 1-28. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive PCV13 IM on day 1 of courses 3 and 5.
89646653|NCT01351896|Experimental|Arm B (Sequential PCV13 and lenalidomide)|Patients receive PCV13 IM on days 1 and 78 (cycles 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 1 of course 4. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity.
89646654|NCT01347294|Experimental|Bleomycin + Fibrovein|"1) Fibrovein 3% foamed with air 50/ 50. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.~2) wait 5 minutes~3) Bleomycin 1000 iu / ml. Injected volume same as volume of Fibrovein foam."
89646655|NCT01347294|Active Comparator|Bleomycin|Bleomycin 1000 iu/ ml. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.
89646656|NCT01347294|Experimental|Natrium Tetradecyl Sulphate (Fibrovein )|Fibrovein 3% foamed with air 50/ 50. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.
89646657|NCT01281176|Experimental|Arm I (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive high-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3 of all subsequent courses.
89646658|NCT01281176|Experimental|Arm II (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat and low-dose vorinostat as in Arm I. After 5 days, patients receive lower-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3.
89646659|NCT01281176|Experimental|Arm III (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat PO QD on days 1-3 and high-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive vorinostat and carboplatin as in Arm I.
89646660|NCT01281176|Experimental|Arm IV (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat and high-dose vorinostat as in Arm III. After 5 days, patients receive vorinostat and carboplatin as in Arm II.
89646661|NCT01281176|Experimental|Arm V (low- and mid-dose vorinostat and paclitaxel)|Patients receive low-dose vorinostat PO QD on days 1-3 and mid-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive mid-dose vorinostat PO QD on days 1-3 and paclitaxel IV over 3 hours on day 3.
89646662|NCT01281176|Experimental|Arm VI (mid- and low-dose vorinostat and paclitaxel)|Patients receive mid-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10. After 5 days, patients receive vorinostat and paclitaxel as in Arm V.
89646663|NCT01181947||patients undergoing TEVAR|Those with a thoracic aortic aneurysm/dissection
89646664|NCT01133990|Active Comparator|FOLFIRI|The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 and Day 15 of each 28-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional). The 5-FU IV bolus (400 mg/m2) and CIV infusion (2400 mg/m2) over 46 hours is repeated on Days 15 and 16 of each cycle.
89646665|NCT01133990|Experimental|E7820|E7820 is administered orally in tablet form once daily, every day of each 28-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Phase II portion, the dose will be the MTD recommended Phase IB dose in combination with FOLFIRI, as determined during the Phase Ib portion of the study.
89646666|NCT01133990|Experimental|FOLFIRI plus Bevacizumab|Bevacizumab at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle
89212686|NCT00878384|Active Comparator|Catheter Ablation|Strategy of 'rhythm control' by catheter ablation: patients will undergo catheter ablation with the intention of restoring sinus rhythm.
89212687|NCT04082975|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
89212688|NCT04082975|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
89212689|NCT00994617|Experimental|Combination Therapy|Patients treated with combination therapy of Hydrochlorthiazide plus Losartan. Losartan will be force-titrated from 50 to 100mg, Hydrochlorothiazide will be force-titrated from 12.5mg to 25mg
89212690|NCT00994617|Active Comparator|Monotherapy|Initial monotherapy Hydrochlorothiazide 12.5mg -25mg Crossed over with Losartan 50 -100mg at 8 weeks
89212691|NCT00995397|Experimental|Dexchlorpheniramine 1% lotion|
88992392|NCT03459391|Experimental|XC221 200 mg|Cohort 2: 16 subjects were randomized in a 3:1 ratio to be treated either with 200 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
88992393|NCT03459391|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (4 subjects from each cohort).
89212692|NCT00995397|Active Comparator|Dexchlorpheniramine 1% cream|
89212693|NCT00919451|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
89212694|NCT05684393|Experimental|Anatomy based fitting|
89646667|NCT01115387||ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who have at least one parent with age related maculopathy.~These individuals with ARM-affected parents and relatives have a substantially higher risk (6-12 fold) of developing ARM than the general population. They will be followed prospectively with fundus photography every two years and questionnaires (distributed over six month intervals) to assess external risks for ARM development in order to investigate genotype-phenotype correlations of early onset clinical features of ARM."
89212695|NCT05684393|Active Comparator|Standard fitting|
89646668|NCT01115387||Partners/Spouses of ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who are the spouses/partners of individuals with ARM affected parents.~We will invite the partners or spouses to participate in order to compare their risk of developing ARM with those individuals with an increased risk of ARM based on a positive family history."
89646669|NCT01115387||ARM affected individuals and relatives.|"Individuals who have experienced vision loss from ARM and have at least one brother or sister who also has experienced vision loss from ARM can participate in the study. They also need to have at least one adult child (from 49 to 65 years old) who wishes to participate in this study.~We will allow for additional recruitment to compensate for additional family members (such as parents, aunts and uncles) who wish to participate as well as to address potential drop out and those who may be deemed ineligible based on review of their medical and/or eye records. As many as 4000 individuals in this group will be allowed to enroll."
89646670|NCT01004952||screening questionnaire|This study will involve two phases. Guided by EDTM, we will first build models of decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing)using in-home ethnographic interviews with 25 melanoma FDRs (Phase I). In Phase II, we will test the validity of each composite model. This will be completed using EMA data collection with 60 different melanoma FDRs from Phase I who will report on their sunscreen use, shade-seeking, use of hat, and use of UVR protective clothing and decision-making regarding these outcomes via interactive voice response (IVR) system and audio narrative diaries (using a digital voice recorder). We will examine the validity of each model and examine the influence of theory-driven affective and cognitive predictors of UVR protection maintenance across time.
89646671|NCT00910429|Experimental|Arm 1|
89646672|NCT00879853|Experimental|Interpersonal Therapy|
89646673|NCT00879853|No Intervention|Wait List Control|
89646674|NCT00863681|Experimental|Arm 1|
89688559|NCT04363645|Experimental|Multicontext approach (Intervention) Arm|Participants received 30-minute sessions of strategy and self-monitoring practice within the context of everyday activities. These sessions were delivered either daily or twice a day. The total number of sessions varied depending on the participant's length of stay in acute rehabilitation.
89688560|NCT02918656|Experimental|Infographics|Infographic presentation of health information
88992394|NCT03459352|Experimental|ePRO|There is no therapeutic intervention. Patients will use ePRO system to report systems. We will describe use in patients to determine compliance in reporting symptoms.
88992395|NCT02952274|Active Comparator|locater attachment|mandibular overdenture retained with single midline implant using locator attachment
88992396|NCT02952274|Active Comparator|ball attachment|mandibular overdenture retained with single midline implant using ball attachment
88992397|NCT04695925|Active Comparator|osimertinib monotherapy|osimertinib 80 mg po qd.
88992398|NCT04695925|Experimental|combination of osimertinib and chemotherapy|osimertinib 80 mg po qd plus pemetrexed 500 mg/m2 and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by maintenance osimertinib and pemetrexed until disease progression
88992399|NCT00510991|Experimental|A|NIPPV
88992400|NCT00165750|Experimental|1|
88992401|NCT04888949|Experimental|Mesenchymal stem cell|4 times dose of Mesenchymal stem cell
88992402|NCT04888949|Placebo Comparator|Placebo|Saline
88992403|NCT00511186|Experimental|Bovine Intestinal AP|"Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10 bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)"
88992404|NCT00511186|Placebo Comparator|2|"Placebo Intravenous administration of 10 bolus and 48h continuous infusion"
88992405|NCT00511225|Active Comparator|1|Will receive 10,000 IU of cholecalciferol weekly
88992406|NCT00511225|Placebo Comparator|2|Will receive a identical appearing placebo weekly
88992407|NCT00511420|Placebo Comparator|1|Cocoa and other ingredients (product type 1). This product is a control of type 2.
88992408|NCT00511420|Placebo Comparator|2|Cocoa plus hazelnuts and other ingredients (product type 2). This product is a control of type 3 and 4.
88992409|NCT00511420|Active Comparator|3|Cocoa plus hazelnuts and other ingredients (cocoa product type 3).
88992410|NCT00511420|Active Comparator|4|Cocoa, hazelnuts and other ingredients called LMN (cocoa product type 4).
88992411|NCT00165828|Experimental|1|
88992412|NCT00165828|Experimental|2|
88992413|NCT00511498|Placebo Comparator|Placebo Arm|Placebo nightly
88992414|NCT00511498|Active Comparator|Drug|Sildenafil 50mg nightly
88992415|NCT00511576|Active Comparator|Part 1|In Part 1, cohorts of three to six subjects will receive doses of MGCD0103 administered orally three times per week (TIW) in combination with 60 mg/m2 IV docetaxel administered as a 1-hour infusion on Day 1 of each 3-week (21-day) cycle. The starting dose of MGCD0103 in Part 1 will be 50 mg (approximately 25 mg/m2).
88992416|NCT00511576|Active Comparator|Part 2|Part 2 will begin once the MTD for MGCD0103 in combination with 60 mg/m2 IV docetaxel has been determined and further evaluated in the expansion phase. In Part 2, cohorts of three to six subjects will receive escalating doses of MGCD0103 administered orally TIW in combination with 75 mg/m2 docetaxel administered as a 1-hour IV infusion on Day 1 of each cycle. The starting dose of MGCD0103 administered in combination with 75 mg/m2 IV docetaxel will be the MTD from Part 1 minus 25 mg.
88992417|NCT00511615||1|Patients with cervical cancer scheduled to be treated with the LEEP procedure.
88992418|NCT00511654|Experimental|Subjects in Group 1 receiving GW823296|Subjects will receive single dose of GW823296 on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered GW823296 for 28 days in the repeat dosing period.
88992419|NCT00511654|Placebo Comparator|Subjects in Group 1 receiving placebo|Subjects will receive single dose of placebo on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered placebo for 28 days in the repeat dosing period.
89218025|NCT02538302|Active Comparator|Oxybutynin|5 mg Oxybutynin twice a daily for 6 months
88992420|NCT00511654|Experimental|Subjects in Group 2 and 3 receiving GW823296|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered GW823296 on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of GW823296 for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
88992421|NCT00511654|Placebo Comparator|Subjects in Group 2 and 3 receiving placebo|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered placebo on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of placebo for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
88992422|NCT00511693|Experimental|1|hospitals randomly allocated to receive physician and patient osteoporosis recommendations from the regional coordinator
88992423|NCT00511693|Active Comparator|2|hospitals randomly allocated to receive falls prevention advice
88992424|NCT02952235|Other|SPF50+|SPF 50+ assigned to Left side of face SPF 100+ assigned to Right side of face
88992425|NCT02952235|Other|SPF100+|SPF 100+ assigned to Left side of face SPF 50+ assigned to Right side of face
88992426|NCT02952391||Parkinson's disease patients|patients with Parkinson's disease, between the ages of 45 and 65, with a disease duration of 3 - 10 years
88992427|NCT02952391||healthy control subjects|Healthy control subjects, between the ages of 45 and 65
88992428|NCT03459274||VR-Biofeedback Feedback Sharers|These participants would express either interest or a lack of interest in trying biofeedback/virtual reality therapy. They will be instructed on how to use the virtual reality equipment and program. Then, they will have the option to participate in the biofeedback/virtual reality experience, if they choose to do so, before sharing their feedback.
88992429|NCT02952430||Frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of greater than or equal to five.~This group will then be observed after intervention to review outcomes."
88992430|NCT02952430||Not frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of less than five.~This group will then be observed after intervention to review outcomes."
88992431|NCT04797728|Experimental|Elacestrant|400 mg given orally (PO), once a day, in a continuous schedule (QD). 4 weeks (+/- 2 days) of elacestrant treatment
88992432|NCT02951806|Active Comparator|(R) Rapid spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 15 seconds then 10 mg hyperbaric bupivacaine.
88992433|NCT02951806|Active Comparator|(S) Slow spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
88992434|NCT00512980|Active Comparator|1|
88992435|NCT00512980|Active Comparator|2|
88992436|NCT00513058|Experimental|lapatinib + vinorelbine|"starting with loading dose of lapatinib per os for 7 days~then, combining lapatinib (oral daily continuous) + vinorelbine (intravenous, day 1 and 8 every 3 weeks)"
88992437|NCT00513097|Experimental|Smoking Prevention & Cessation Program|
88992438|NCT00513136|Active Comparator|I|10 week group-based mind body medicine intervention
88992439|NCT00513136|Experimental|II|Group-based mind body medicine intervention with a family focus
88992440|NCT02951962|Experimental|Twynsta 80/5mg|Day 1 ~ Day 9 : Twynsta 80/5mg / Day 10 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
88992441|NCT02951962|Experimental|Crestor 20mg|Day 1 ~ Day 5 : Crestor 20mg / Day 6 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
88992442|NCT02952040|Experimental|ASP1517 alone period preceding group|Subjects will receive a single oral dose of ASP1517 alone in period 1, then subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 2.
88992443|NCT02952040|Experimental|ASP1517+lanthanum period preceding group|Subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 1, then subjects will receive a single oral dose of ASP1517 alone in period 2.
88992444|NCT02952118|Experimental|one night with the device and one night without the device.|"The study duration with each patient will be 48 hours (two nights); at the first night the sleep study will be with PAT device, with snoring recording and without the Forrest epic device. In the second night the sleep study will be with PAT device, with snoring recording and with the Forrest epic device. The order of the sleep studies (with and without the epic device) will be randomly determined by computerized ahead prepared list. The research duration for patients that did not have a sleep study over the last year, will take place for 3 nights; the sleep study will be performed in order to make sure the patient does not suffer from obstructive respiratory disorder during sleep. The sleep studies will take place in a sleep laboratory (Millennium Sleep Labs LTD, Beer Sheva) or as an ambulatory study, at home."
88992445|NCT00513214|Active Comparator|XOMA 052|
88992446|NCT00513214|Placebo Comparator|Placebo|
89646675|NCT00846742|Experimental|Treatment|Participants receive Stanford V Chemotherapy with or without radiation therapy. Patients receive doxorubicin hydrochloride IV and vinblastine IV on day 1 of weeks 1, 3, 5, and 7; mechlorethamine hydrochloride IV on day 1 of weeks 1 and 5; vincristine sulfate IV and bleomycin IV on day 1 of weeks 2, 4, 6, and 8; etoposide IV on day 1 of weeks 3 and 7; and prednisone orally (PO) three times daily every other day of weeks 1-8. Beginning 2-3 weeks after completion of chemotherapy, patients not achieving complete response undergo radiation therapy to individual nodal sites (tailored fields)
89646676|NCT00802230|Active Comparator|1|Carvedilol IR
88992447|NCT04777058||Patients|Patients admitted to the intensive care unit, treated with isavuconazole intravenously for treatment of invasive fungal infections
88992448|NCT00513331||Algorithm #1|Patients without visable lesions
89646677|NCT00802230|Active Comparator|2|Metoprolol Succinate
89646678|NCT00795080||1|Normal volunteers who do not have malformations in their cerebral spinal fluid (CSF)
89646679|NCT00795080||2|Patients with incidentally discovered Chiari 1 DVS malformation of the cerebral spinal fluid (CSF)
89646680|NCT00795080||3|Patients with known Chiari or any other CVJ malformations undergoing a workup prior to surgery. Research images will be added to the clinically ordered exams ordered at 3 months and 1 year after surgery.
88992449|NCT00513331||Algorithm #2|Patients with a visable lesion that is less than 1cm
88992450|NCT00513331||Algorithm #3|Patients with a visable lesion greater than 1cm
89044677|NCT02928146|Active Comparator|TAPP|Transabdominal preperitoneal (TAPP) approach for inguinal hernia repair
89646681|NCT00734149|Experimental|Bortezomib+Melphalan+Prednisone|Bortezomib 1.3 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 4, 8, and 11 of a 28 day cycle. Six cycles are planned. On days when both melphalan and bortezomib are given, melphalan is given at least one hour prior to bortezomib. Melphalan 6 mg/m2 is administered orally on an empty stomach daily on days 1-7 of each cycle. Prednisone 60 mg/m2 is administered orally daily on days 1-7 of each cycle.
89646682|NCT00587431|Experimental|1|
89646683|NCT00587431|Active Comparator|2|
89646684|NCT00514618|Active Comparator|1|patients will be treated with misoprostol 50 mcg PO
89646685|NCT00514618|Placebo Comparator|2|patients will receive placebo (Vitamin C)
89646686|NCT00496119|Experimental|70 Gray (Gy) Proton Beam Therapy|Participants treated to 70 cobalt Gray equivalent (CGE) only (the standard treatment).
89646687|NCT00496119|Experimental|Photon Beam Therapy|Proton beam therapy combined with photon radiation therapy where combination improves final dose distribution.
89646688|NCT00097786|Experimental|Valsartan 160 mg + nateglinide 60 mg|For the first 2 weeks of treatment, patients took the combination of nateglinide 30 mg (3 times daily, ante cibum [ac] before meals) and valsartan 80 mg (once daily [od] in the morning). After 2 weeks, patients were up-titrated to nateglinide 60 mg ac and valsartan 160 mg od.
89646689|NCT00097786|Experimental|Valsartan 160 mg + nateglinide placebo|For the first 2 weeks of treatment, patients took valsartan 80 mg capsules (once daily [od] in the morning). After 2 weeks, patients were up-titrated to 160 mg valsartan od. Patients also received nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals).
89044678|NCT02928146|Active Comparator|TEP|Totally extraperitoneal (TEP) approach for inguinal hernia repair
89044679|NCT02928068|Experimental|Occupational Performance Coaching (OPC)|This group received approximately 12 sessions of the telehealth intervention. The intervention consisted of parent-therapist conversations via telehealth to increase child function and participation.
89044680|NCT02927951|Experimental|pregabalin at 150 mg bid|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
89044681|NCT02927951|Placebo Comparator|Placebo|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
89044682|NCT02927678||Diabetic patients with osteomyelitis|Patients with a clinical and radiological diagnosis of osteomyelitis were included in two diabetic centers
89044683|NCT03457532|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
89646690|NCT00097786|Experimental|Nateglinide 60 mg + valsartan placebo|For the first 2 weeks of treatment, patients took nateglinide 30 mg tablets (3 times daily, ante cibum [ac] before meals). After 2 weeks, patients were uptitrated to 60 mg nateglinide ac. Patients also received valsartan placebo capsules (once daily [od] in the morning).
89646691|NCT00097786|Placebo Comparator|Placebo|Patients took 3 nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals) and 1 valsartan placebo capsule (once daily [od] in the morning).
89646692|NCT01524692|Experimental|Single ARM Dovitinib treatment|Single ARM Dovitinib treatment
89646693|NCT01277679|Other|Healthy Volunteer|Healthy Volunteer cohort
89646694|NCT01277679|Other|Heart Failure|Heart Failure cohort
89646695|NCT04018105|Experimental|taking metformin 30 or 60 minutes before the OGTT|
89646696|NCT04018105|Placebo Comparator|No metformin before OGTT|
89646697|NCT02991417|Experimental|CDVAX|
89646698|NCT05366647|Active Comparator|Canaloplasty|Canaloplasty ab externo
89646699|NCT05366647|Active Comparator|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
89044684|NCT02927600|Experimental|Low GI Rice Breakfast|Intake of low GI breakfast
89044685|NCT02927600|Experimental|High GI rice Breakfast|Intake of High GI breakfast
89044686|NCT02927600|Experimental|Low GI Rice Dinner|Intake of low GI dinner
89044687|NCT02927600|Experimental|High GI Rice Dinner|Intake of High GI dinner
89044688|NCT05045547||Patients with febrile illness|Febrile patients attending village malaria workers (VMWs)
89044689|NCT05045547||Health centre staffs|Health centre staffs from 12 rural health centres
89057953|NCT02278679||Standardized patients|During a standardized patient exercise focusing on digital rectal exam in the University of Virginia School of Medicine curriculum, 160 second-year medical students will be given the DiRECT to document their examination. An attending physician will also attend the standardized patient exercise and document their examination for comparison with the medical students.
89646700|NCT05632549|Placebo Comparator|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
89646701|NCT05632549|Experimental|L-carnitine|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
89646702|NCT05632549|Experimental|Biotin|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
89646703|NCT00721539|Other|Transoral Robotic Surgery|Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.
89646704|NCT00721617|Active Comparator|Obese subjects|Obese normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
89646705|NCT00721617|Active Comparator|Lean subjects|Lean normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
89646706|NCT03993613|Experimental|human apotransferrin|Patients will receive an intravenous dose of human apotransferrin every two weeks for 14-18 weeks.
89646707|NCT03597997|Experimental|Group P|The patients in group (P) will be anaesthetized using total intravenous propofol.
89646708|NCT03597997|Sham Comparator|Group S|Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.
89646709|NCT01277835|Experimental|Lidocaine Infusion|
89646710|NCT01277835|Placebo Comparator|Placebo|Saline Infusion
89646711|NCT01431287|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
88992451|NCT02951611|Sham Comparator|Sham stimulation|Put the electrodes on SI3, SJ6, PC6 and LI4 without stimulation.
88992452|NCT02951611|Experimental|Treatment: Acupuncture stimulation|Stimulate the SI3, SJ6, PC6 and LI4 since 30 minutes before anesthesia induction until the end of operation. Stimulate again at above acupoints at 6 and 24h after operation, for 30 minutes each time. The stimulation frequency is 2/100Hz. The stimulation current is two to three times of the lowest current that the patient can feel.
89646712|NCT01431287|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
88992453|NCT04759547|Experimental|Handheld ultrasound-assisted technique|Participants will be received labor combined epidural-spinal analgesia using handheld ultrasound
88992454|NCT04759547|Active Comparator|Conventional palpation-guided technique|Participants will be received labor combined epidural-spinal analgesia using conventional landmark-guided technique
89646713|NCT01431287|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
88992455|NCT04695496|Experimental|Theta bust stimulating group|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
88992456|NCT02951689|Experimental|Probiotic|Multi-strain probiotic
88992457|NCT02951689|Placebo Comparator|Placebo|Maltodextrin placebo
88992458|NCT02951572|Other|Patients with RLD initiating NIV|Patients with RLD initiating NIV according to Belgian Health guidelines are followed-up before and after NIV initiation
88992459|NCT04695535||Chemotherapy with Anlotinib|Patients received chemotherapy with Anlotinib.
88992460|NCT00513565|Placebo Comparator|placebo arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
88992461|NCT00513565|Experimental|GSK561679 arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
88992462|NCT00513565|Active Comparator|lorazepam arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
88992463|NCT00403949|Active Comparator|Azelaic acid 15% Gel|Azelaic acid 15%
88992464|NCT00403949|Placebo Comparator|Placebo|Non-active base from Azelaic acid 15% gel
88992465|NCT00513643|Experimental|1|6 U insulin aspart
88992466|NCT00513643|Experimental|2|12 U insulin aspart
88992467|NCT00513643|Experimental|3|24 U insulin aspart
88992468|NCT00513643|Active Comparator|4|6 IU human regular insulin
88992469|NCT00513643|Active Comparator|5|12 IU human regular insulin
88992470|NCT00513643|Active Comparator|6|24 IU human regular insulin
88992471|NCT00513721||III|Prostate specimens with positive surgical margins.
88992472|NCT00513760|Experimental|1|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
88992473|NCT00513760|Active Comparator|2|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
88992474|NCT00513760|Placebo Comparator|3|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
88992475|NCT00513877|Experimental|Bortezomib 1.6mg/m2|
88992476|NCT04695613|Active Comparator|aminoacid group|patients received an IV amino acid infusion 150 ml/kg/hr starting just before and during anesthesia
89646714|NCT01431287|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
89646715|NCT01431287|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
89646716|NCT05632159|Placebo Comparator|conventional anaesthesia group|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
89646717|NCT05632159|Active Comparator|Mg sulphate group|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
89646718|NCT00722007|Experimental|Cormet Hip Resurfacing Post-PMA Group|hip resurfacing
89688561|NCT02918656|Active Comparator|Plain Language Summary|PLS presentation of health information
89688562|NCT02918656|Active Comparator|Scientific abstract|Scientific abstract presentation of health information
88992477|NCT04695613|Active Comparator|magnesium sulfate group|patients received an IV magnesium sulphate bolus and infusion 40 mg/kg starting just before and during anesthesia
88992478|NCT00151047|Experimental|Docetaxel and Capecitabine|
88992479|NCT00513916|Experimental|Arm I|"Participants partake in a high soy diet consisting of 2 daily soy servings (approximately 50mg isoflavones).~The choice of soy foods will include ½ cup of tofu, ¾ cup of soy milk, or ¼ cup of soy nuts. Replacement of currently consumed foods with soy foods will be encouraged."
88992480|NCT00513916|Active Comparator|Arm II|Participants will be asked to keep their soy intake below 3 servings per week. The participants will also receive general nutrition counseling.
88992481|NCT00513955|Experimental|Bortezomib plus CHOP|"Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.~Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.~After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter."
88992482|NCT04735796|Experimental|LM102 Dose Escalation Level 1, 3mg/kg|LM102 Dose Escalation Level 1, 3mg/kg, enrolled CLDN 18.2 positive advanced solid tumors
88992483|NCT04735796|Experimental|LM102 Dose Escalation Level 2, 10mg/kg|LM102 Dose Escalation Level 2, 10mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
88992484|NCT04735796|Experimental|LM102 Dose Escalation Level 3, 20mg/kg|LM102 Dose Escalation Level 3, 20mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
88992485|NCT04735796|Experimental|LM102 Dose Escalation Level 4, 30mg/kg|LM102 Dose Escalation Level 4, 30mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
88992486|NCT04735796|Experimental|LM102 Dose Escalation Level 5, 40mg/kg|LM102 Dose Escalation Level 5, 40mg/kg,enrolled CLDN 18.2 positive advanced solid tumors
88992487|NCT00513994|Active Comparator|1|
89218026|NCT00727883||1|Post menopausal women treated with adjuvant TAM for breast cancer
88992488|NCT00514033||Group A|PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.
89646719|NCT04017013|Active Comparator|Epidural Analgesia|"The placement of the thoracic epidural catheter will be located depending on surgical incision as follows:~Surgery of the upper abdomen: T7-T8.~Surgery of lower abdomen: T8-T9. The epidural catheter placement technique will be determined by the treating anesthesiologist. However, once the epidural space is located and the respective catheter is inserted, the correct location of the catheter should be tested with lidocaine at 2% CE 5 cc and a sensitivity test with temperature should be performed on the target dermatomes. A negative test for an adequate location of the catheter indicates that the procedure should be repeated until the epidural space is correctly located. Once this is achieved, the catheter will be left 4 cm away from the skin. The catheter will be fixed according to the institutional protocol."
89646720|NCT04017013|Experimental|Lidocaine Infussion|Intravenous lidocaine
89646721|NCT01277913|Experimental|Vitamin D 1000 IU|vitamin D will be given 1000 IU for 12 months
89646722|NCT01277913|Active Comparator|Vitamin D 500IU|vitamin D 500 IU will be given for 12 months once daily
89646723|NCT04385901|No Intervention|Standard of Care|These are patients who were diagnosed with COVID19 and recovered with usual care prior to implementation of the rehabilitation program developed by MUHC therapists. These patients will be selected in such a way as to match the approximate demographics that exist within the treatment group. These patients received education and supportive care only.
89646724|NCT04385901|Experimental|Rehabilitation Group|These are patients who were diagnosed with COVID19 and participated in the physical and pulmonary rehabilitation program developed at MU Healthcare as described in the study design.
88992489|NCT00514072|Experimental|Arm I|Patients receive ONY-P1 vaccine with BCG intradermally on days 1 and 15. Patients then receive ONY-P1 vaccine alone on day 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
88992490|NCT00514072|Placebo Comparator|Arm II|Patients receive placebo vaccine intradermally on days 1, 15, and 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
88992491|NCT04735640|Experimental|Nurse-led teleconsultation group|9-month nurse-led telephone-based personalized behavioural intervention.
88992492|NCT04735640|Active Comparator|SMS group|Behavioural intervention by means of short text messages.
88992493|NCT02951650|Experimental|Cyberonics VNS|Cyberonics VNS
88992494|NCT00514111||HVC Patients|HVC patients attended in SAE e HD.
88992495|NCT00151086|Experimental|Estramustine and Vinorelbine|Treatment will consist of 28-day cycles with estramustine at a dose of 140mg orally 3 times per day on days 1-3 and 8-10 and vinorelbine orally on days 2 and 9 beginning at dose 50mg/m^2.
88992496|NCT00514150|Active Comparator|1|1075 cc of 154 mEq/L solution of NaCl 0.9% , prepared by adding 75 cc of 154 mEq/L NaCl 0.9 % to 1000 cc of 154 mEq/L NaCl 0.9%
88992497|NCT00514150|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate 8.4% to 1000 cc of 154 mEq/ L NaCl 0.9%.
88992498|NCT00514189|Experimental|Autologous Dendritic Cells|
88992499|NCT00514228|Experimental|Continuous sunitinib treatment|
88992500|NCT04695418|Placebo Comparator|Placebo|an isocaloric wheat germ-based supplement
88992501|NCT04695418|Active Comparator|Rice Germ|
88992502|NCT00514306|Experimental|Schedule 1|OSI-906 days 1-3 every 14 days
88992503|NCT00514306|Experimental|Schedule 2|OSI-906 days 1-5 every 14 days
88992504|NCT00514306|Experimental|Schedule 3|OSI-906 days 1-7 every 14 days
88992505|NCT00514423|Experimental|2|Psychoeducation by peer-moderators
88992506|NCT00514423|Experimental|1|Psychoeducation by professionals
88992507|NCT00514423|Experimental|3|Video-education
88992508|NCT00514423|Placebo Comparator|4|Control group
88992509|NCT00514462|Experimental|A|low level laser instrument (Painless Light PL-830, Advanced Chips & Products Crop., USA)
88992510|NCT04695574|Experimental|Volunteer young adults|Healthy young adults
88992511|NCT00151125|Experimental|A|rhIL-11 (Interleukin-11, Neumega) 25 mcg/kg subcutaneously daily for 7 days
88992512|NCT00151125|Experimental|B|rhIL-11 (interleukin-11, Neumega) 50 mcg/kg subcutaneously daily for 7 days
88992513|NCT00151125|Experimental|C|rhIL-11 (Interleukin-11, Neumega) 10 mg/kg subcutaneously daily for 7 days
88992514|NCT00514579|Other|Myeloablative double unit UCBT|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
88992515|NCT00514657|Placebo Comparator|P|
88992516|NCT00514657|Experimental|L|low dose (0.03 %)
88992517|NCT00514657|Experimental|M|medium dose (0.1 %)
88992518|NCT00514657|Experimental|H|high dose (0.3 %)
88992519|NCT00514696|Experimental|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
88992520|NCT04655261||Participants Treated With Venetoclax + Obinutuzumab|Participants will receive venetoclax (Venclexta) in combination with Obinutuzumab according to local label.
88992521|NCT00514774|Experimental|A|
88992522|NCT00514774|Experimental|B|
88992523|NCT00514774|Placebo Comparator|C|
88992524|NCT02951221|Experimental|Cohort 1|Treatment sub groups A and B
88992525|NCT02951221|Experimental|Cohort 2|Treatment sub groups C and D
88992526|NCT02951260|Experimental|Metformin|17 days metformin treatment
88992527|NCT02951260|Placebo Comparator|Placebo|17 days placebo treatment
88992528|NCT02951299|Experimental|pentoxifylline group|Received oral pentoxifylline (400 mg) three times a day for 14 days.
88992529|NCT02951299|No Intervention|no treatment group|No intervention.
88992530|NCT02951065|Experimental|Bristle-less brush|Subjects will be assigned to use a bristle-less manual tooth brush with short, rubbery cones for one year twice daily
88992531|NCT02951065|Active Comparator|Soft bristle brush|Subjects will be assigned to use a soft, nylon-bristled tooth brush for one year twice daily
88992532|NCT02951026||0.03mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.03mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
89646725|NCT03992677||Brugada VF|Confirmed Brugada Syndrome by either Spontaneous or drug induced Type 1 ECG, confirmed cardiac arrest or appropriate ICD therapy for potentially lethal arrhythmia.
89646726|NCT03992677||Brugada relative|Relatives of Brugada syndrome patients with proven no pathology by Ajmaline challenge
89646727|NCT03992677||Ventricular ectopy|Patients undergoing ablation with ECGi system for other arrhythmias -these patients will be similar to our original controls and provide a repeat set of controls.
89646728|NCT03992677||Ischaemic VF|Out-of-hospital cardiac arrest primary PCI with full recovery of left ventricular function and full revascularisation (n=10) - the purpose of this group is to confirm that the changes detected in our SCD group are not secondary to the SCD event. These are patients who have had a cardiac arrest secondary to coronary occlusion, but have made a full recovery with normal LGE-MRI and no indication for ICD.
89646729|NCT00729807|Experimental|Pentamidine|
89646730|NCT03590119|Experimental|Intra-arterially treated liver lobe|Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.
89646731|NCT03590119|Active Comparator|'Intravenously' treated liver lobe|The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.
89646732|NCT04385511|Experimental|supraglottic jet ventilation group|Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will put the Wei NASAL JET（WNJ）into one's nose to give the supraglottic jet ventilation with the driving pressure 0.01-0.03 megapascal (MPa), respiratory rate 15 beats per minute（BPM）, inspiratory/expiratory rate 1-1. 5.Check blood gas,stomach-ultrasound after 3 min, then do the tracheal intubation guided by visual laryngoscope.Stop jet ventilation during intubation.
89646733|NCT04385511|No Intervention|mask pressurized ventilation group|"Check blood gas before induction without preoxygen. Take stomach-ultrasound. Induction with Midazolam 0.02 mg/kg, sufentanil 0.3 ~ 0.5 ug/kg, propofol 2-2.5 mg/kg, rocuronium 0.6 mg/kg.After patients fall asleep and can't be woke up ,the investigators will give them 1 min mask pressure respiration, by pressure control V - E technique after muscle relaxant. Check blood gas,stomach-ultrasound after 2 min, then do the tracheal intubation guided by visual laryngoscope."
89646734|NCT01272297|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
89044690|NCT05045547||Key stakeholders|"Key stakeholders , for example health managers and health professionals:~the director, deputy-directors, and technical officers at the National Malaria Control Program;~the directors and deputy-directors of the Provincial Health Departments in Battambang and Pailin province;~health officers actively involved in community-based (malaria) programmes at the district levels in Battambang and Pailin provinces;~health workers (i.e., nurses or doctors) actively involved in community-based (malaria) programmes in Battambang and Pailin provinces;~community representatives and village malaria workers from villages in both Battambang Pailin province."
89212696|NCT03016312|Experimental|Atezolizumab + Enzalutamide|Participants will receive atezolizumab along with enzalutamide until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
89646735|NCT05366023|No Intervention|No contact|0 hours of activities during intervention period of study
89646736|NCT05366023|Experimental|TDD1|10 hours of top-down driven cognitive training games
89646737|NCT05366023|Experimental|TDD2|10 hours of top-down driven cognitive training games
89646738|NCT05366023|Experimental|TDD1 + TDD2|20 hours of top-down driven cognitive training games
89646739|NCT05366023|Experimental|BUD1|10 hours of bottom-up driven cognitive training games
89646740|NCT05366023|Experimental|BUD2|10 hours of bottom-up driven cognitive training games
89646741|NCT05366023|Experimental|BUD1 + BUD2|20 hours of bottom-up driven cognitive training games
89646742|NCT05366023|Experimental|BUD2 + TDD2|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
89646743|NCT05366023|Experimental|BUD1 + TDD1|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
89646744|NCT05366023|Experimental|BUD2 + TDD1|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
89646745|NCT05366023|Experimental|BUD2 + TDD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
89646746|NCT05366023|Experimental|BUD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
89646747|NCT05366023|Experimental|BUD1 + TDD1 + TDD2|10 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
89646748|NCT05366023|Experimental|BUD1 + BUD2 + TDD2|20 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
89646749|NCT05366023|Experimental|BUD1 + BUD2 + TDD1|20 hours of bottom-up driven cognitive training games plus 10 hours of top-down driven cognitive training games
89646750|NCT05366023|Experimental|BUD1 + BUD2 + TDD1 + TDD2|20 hours of bottom-up driven cognitive training games plus 20 hours of top-down driven cognitive training games
89646751|NCT05366023|Active Comparator|CSA10|10 hours of cognitive stimulating activities
89646752|NCT05366023|Active Comparator|CSA20|20 hours of cognitive stimulating activities
89646753|NCT05366023|Active Comparator|CSA30|30 hours of cognitive stimulating activities
89646754|NCT05366023|Active Comparator|CSA40|40 hours of cognitive stimulating activities
89646755|NCT01278147|No Intervention|controle|patient without fatigue education program
89646756|NCT01278147|Experimental|Education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
89646757|NCT01272453||Control Group|Data from patients in the control group will be obtained retrospectively from patient medical records and stored image data
89212697|NCT03016312|Active Comparator|Enzalutamide|Participants will receive enzalutamide alone until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
89212698|NCT05061953||EDSS 0-2.0|Confirmed diagnosis of MS with an EDSS score between 0 and 2.0.
89212699|NCT05061953||EDSS 2.5-4.0|Confirmed diagnosis of MS with an EDSS score between 2.5 and 4.0.
89212700|NCT05061953||EDSS 4.5-6.0|Confirmed diagnosis of MS with an EDSS score between 4.5 and 6.0.
89212701|NCT05061953||EDSS 6.5-8.0|Confirmed diagnosis of MS with an EDSS score between 6.5 and 8.0.
89212702|NCT05061953||Healthy Control|Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
89212703|NCT05059223|Experimental|AXS-12 (reboxetine)|Up to 5 weeks
89212704|NCT05059223|Placebo Comparator|Placebo|Up to 5 weeks
89212705|NCT00919607|Active Comparator|1|quetiapine fumarate extended-release 300mg,administered once-daily Day1~5
89212706|NCT00919607|Experimental|2|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2~6,administered once-daily
89212707|NCT00919607|Experimental|3|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3~7,administered once-daily
89646758|NCT01272453||Prospective Patient Group|Data from patients in the Flash group will be obtained prospectively from scanner consoles and medical records.
89646759|NCT05631691|Experimental|Experimental Group|school students
89646760|NCT05631691|No Intervention|Comparison Group|school students
89646761|NCT03990805|Experimental|JOINTSTEM|Autologous Adipose Tissue derived MSCs
89646762|NCT03990805|Placebo Comparator|saline|saline
89646763|NCT03595501||Hematology Analyzer - OLO|The investigational device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples.
89646764|NCT03595501||Hematology Analyzer - Predicate|The predicate device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical and reference laboratories.
89646765|NCT03592693|Experimental|Vitamin-Steroid|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
89646766|NCT03592693|Placebo Comparator|Control|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
89646767|NCT02079025|Active Comparator|LR-TRUS|Low-resolution transrectal ultrasound guided prostate biopsy (standard of care)
89646768|NCT02079025|Experimental|UHR-TRUS|Ultra-high resolution transrectal ultrasound guided prostate biopsy
89646769|NCT00730353|Experimental|1|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.~Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.~Sunitinib malate 37.5 mg orally, daily. After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion."
89646770|NCT03595423||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
89646771|NCT03595423||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
89646772|NCT01272531||lithium|All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.
89646773|NCT01272531||valproate|Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.
89212708|NCT05188391|Other|Positive Group (Rupture and Gap Sign are both positive)|Rupture and Gap Sign are both positive
89212709|NCT05188391|Other|Rupture Positive Group (Rupture positive but Gap Sign is negative)|Rupture positive but Gap Sign is negative
89646774|NCT03595345||Training set|2200 HCC cases from East and West centres enlisted for LT and then delisted or transplanted
89212710|NCT05188391|Other|Gap Sign Positive Group (No rupture exists but Gap Sign is positive)|No rupture exists but Gap Sign is positive
89212711|NCT05188391|Other|Negative Group (Rupture and Gap sign are both negative)|Rupture and Gap sign are both negative
89212712|NCT01014130|Active Comparator|Arm 2|Conventionally Fractionated Radiotherapy (ConRT) - Standard of Care
89212713|NCT01014130|Experimental|Arm 1|Hypofractionated radiotherapy (HypoRT) - Investigational
89212714|NCT05187221||Control Group|The participants will respond to CVS-F4 questionnaire online via SurveyMonkey to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. This group will contains participants with no CVS complains.
89212715|NCT00512902|Experimental|Group 1|SSc patients receiving Imatinib (Gleevec, up to 600 mg) QD PO for up to 1 year.
89212716|NCT01014364|Experimental|Corticosteroids|Hydrocortisone
89212717|NCT01014364|Placebo Comparator|Control|isotonic saline
89212718|NCT04082351|Active Comparator|Magnalife|the group of patients receiving the nanotechnology structured water
89212719|NCT04082351|Placebo Comparator|Ordinary water|the group of patients receiving ordinary water
89646775|NCT03595345||West validation set|630 HCC cases from a Western centre enlisted for LT and then delisted or transplanted
89646776|NCT03595345||East validation set|300 HCC cases from a Eastern centre enlisted for LT and then delisted or transplanted
89646777|NCT03025685|Experimental|TRUST technique + Coronary Stenting|PCI with coronary stenting using TransRadial Ultra Support technique for support improvement
89646778|NCT03025685|Active Comparator|Anchoring technique + Coronary Stenting|PCI with coronary stenting using Wire Anchoring Pass technique for support improvement
89646779|NCT01272609|Experimental|LCP + Timolol|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5 ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
89646780|NCT01272609|Active Comparator|LCP|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure © spaced out of 1 month.
89646781|NCT04489667|Other|+STEP Implementation|All patients will receive +STEP as new standard of care at their clinic. This intervention will include staff training, PROs as part of routine care to screen for substance use and mental health disorders, and telemedicine for health care delivery.
89646782|NCT04407091|Experimental|[14C]AZD4831 Oral Solution|One 10 mg dose of [14C]AZD4831 Oral Solution
89646783|NCT03595189|Experimental|Cilastatin Dose 1|Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.
89646784|NCT03595189|Experimental|Cilastatin Dose 2|Dose escalation Single intravenous administration during 3 hours.
89646785|NCT03595189|Experimental|Cilastatin Dose 3|Dose escalation Single intravenous administration during 3 hours.
89646786|NCT03595189|Placebo Comparator|Placebo|Saline solution for infusion
89646787|NCT00749931|Active Comparator|SOC|Standard of Care arm - standard of care lumpectomy procedure
89646788|NCT00749931|Experimental|Device + SOC|Use of the device in addition to the standard of care lumpectomy procedure.
89646789|NCT05631145|Experimental|Morita therapy (MT) combined with Xingnao Kaiqiao self-administered acupressure (XKSA)|MT combined with XKSA for 2 weeks.
89646790|NCT05631145|Placebo Comparator|Morita therapy (MT)|MT alone for 2 weeks
89646791|NCT01274715|Experimental|Behavioral Health Coaching arm|This is a single-arm, pilot study of a health behavior coaching intervention to consist of 12 sessions of coaching over a 3 month period. There is no control arm for this pilot study.
89646792|NCT03595111|Experimental|Myocardial biopsy|The specimens were classified into three categories: normal, focal hydropic change and diffuse hydropic change.
89646793|NCT01410227|Experimental|PK 80 Arm (minimum of 22 subjects with severe VWD)|PK assessment (80 IU/kg rVWF) + 12-month treatment period
89646794|NCT01410227|Experimental|PK 50 Arm (14 subjects with type 3 VWD)|Two single-blinded PK assessments (50 IU/kg rVWF + rFVIII/placebo) + 12-month treatment period
89646795|NCT01410227|Experimental|PK 50 Only Arm (minimum of 7 subjects with type 3 VWD)|PK assessment (50 IU/kg rVWF) only, no treatment of bleeding episodes
89646796|NCT01410227|Experimental|Treatment Only (up to 7 subjects independent of VWD subtype)|Treatment of bleeding episodes for a total of 12 months
89646797|NCT03595033|Experimental|Intervention Phase|Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
89646798|NCT03989713|Experimental|MRD-triggered arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)~Consolidation therapy: Patients receive one cycle of HAM and are further allocated based on the MRD-results assessed by flow cytometry with a cut of level of 0.1%: if the MRD is negative they remain in the MRD-triggered arm, whereas MRD positive patients cross over to the prophylactic arm.~(Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)~Observation: No treatment will be given in the MRD-triggered arm. (Duration: 48 weeks in total.)~Safety follow-up and observational follow-up"
89646799|NCT03989713|Experimental|Prophylactic Arm|"Salvage therapy: All patients are randomized upfront and receive one cycle Q-HAM salvage therapy. All patients achieving CR or CRi are allocated according to randomization to either MRD-triggered or prophylactic arm.~(Duration: one cycle á 21 days followed by up to 3 weeks recovery period if needed, 22-42 days in total)~Consolidation therapy: Patients may receive up to two cycle of Q-HAM. (Up to 2 cycles. Duration: two cycles á 28 days each followed by up to two weeks recovery period if needed, 56-84 days in total.)~Maintenance therapy: Quizartinib will be given as single-agent therapy. The dose of quizartinib is aimed to be increased during maintenance therapy. (Up to 12 cycles. Duration: four times three cycles á 28 days, 48 weeks in total.)~Safety follow-up and observational follow-up"
89646800|NCT01274559|Experimental|Extended-release niacin/laropiprant|ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant.
89646801|NCT01274559|Placebo Comparator|Placebo|Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks)
89646802|NCT03594721|Experimental|Fitzpatrick Skin Types I-III|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
89646803|NCT03594721|Experimental|Fitzpatrick Skin Types IV-V|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
89646804|NCT01409993|Experimental|sildenafil Aim 1|sildenafil 25 mg p.o. tid
89646805|NCT01409993|Placebo Comparator|placebo Aim 1|matching placebo p.o. tid
89646806|NCT01409993|Experimental|sildenafil Aim 2|sildenafil 25 mg p.o. tid
89646807|NCT01409993|Placebo Comparator|placebo Aim 2|matching placebo p.o. tid
88992533|NCT02951026||0.07mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.07mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
89212720|NCT04082507||Non_adherent plcenta|placenta separated within 15 minutes after delivery of fetus
89212721|NCT04082507||Adherent placenta|placenta dosenot separated within 15 minutes after delivery of fetus
89212722|NCT01015378||Diverticulitis of the sigmoid colon - first episode|
89212723|NCT01015456|Experimental|1|Oral mycophenolate sodium 1440 mg per day for 12 months
89646808|NCT01278381||Pancreaticoduodenectomy (PD)|Patients undergoing PD from 2002 to 2010
89646809|NCT03988855|Experimental|Part 1|10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days.
89646810|NCT03988855|Experimental|Part 2|30 subjects with severe or non-severe CDI will be enrolled to receive DNV3837. Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total daily dose of 1.5 mg/kg actual body weight(BW)/day DNV3837. Infusions will be administered once daily for 10 consecutive days
89646811|NCT01273623|Experimental|Patients with PAD|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
89646812|NCT03599401|Active Comparator|Aspirin Group (Group I)|14 Patients in Group I underwent scaling and root planing using ultrasonic scalers after which 75 mgms of Aspirin was administered orally, once daily for 3 months
89646813|NCT03599401|Active Comparator|Omega 3 Fatty acid Group (Group II)|14 Patients in Group II were given 500 mgms of Omega 3 Fatty Acid orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
89646814|NCT03599401|Placebo Comparator|Placebo Group (Group III)|14 Patients in Group III was given Placebo, which was administered orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
89646815|NCT01409915|Experimental|Sagramostim (Leukine)|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
89646816|NCT01409915|Placebo Comparator|Control Group|Saline -- placebo comparator. Given as a subcutaneous injection.
89646817|NCT01272921|Active Comparator|Bupivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
89646818|NCT01272921|Active Comparator|Ropivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
89646819|NCT01409837|Placebo Comparator|Sugar pill|Started with Placebo until the crossover.
89646820|NCT01409837|Experimental|Lisinopril|Started with Lisinopril until the crossover
89646821|NCT00750165|Experimental|Titration Night|Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device
89646822|NCT01278459|Experimental|Atorvastatin first|Participants receive 4 week treatment with atorvastatin 20mg/day, followed by 4 week washout, followed by 4 week treatment with placebo.
89646823|NCT01278459|Experimental|Placebo first|Participants receive 4 week treatment with placebo, followed by 4 weeks washout, followed by 4 weeks treatment with atorvastatin 20mg/day.
89646824|NCT04407169||Patients without chronic respiratory disease|All patients hospitalized for severe CoVid-19 without chronic respiratory disease
89646825|NCT04407169||Patients with chronic respiratory diseas|Patients hospitalized for severe CoVid-19 with one chronic respiratory disease
89646826|NCT00731055|Experimental|Intervention 1|"Each participant participates in 4 consecutive interventions in random order.~Placebo, 1 capsule before the session~0.5 mg varenicline, 1 capsule before the session 3.1 mg varenicline, 1 capsule before the session~4. 2 mg varenicline, 1 capsule before the session"
89646827|NCT00731055|Experimental|Intervention 2|Each participant participates in 4 consecutive interventions in random order. 1.0.5 mg varenicline, 1 capsule before the session 2. 1 mg varenicline, 1 capsule before the session 3.2 mg varenicline, 1 capsule before the session 4. Placebo, 1 capsule before the session
89646828|NCT00731055|Experimental|Intervention 3|Each participant participates in 4 consecutive interventions in random order. 1.1 mg varenicline, 1 capsule before the session 2. 2 mg varenicline, 1 capsule before the session 3.Placebo, 1 capsule before the session 4. 0.5 mg varenicline, 1 capsule before the session
89646829|NCT00731055|Experimental|Intervention 4|Each participant participates in 4 consecutive interventions in random order. 1.2 mg varenicline, 1 capsule before the session 2. Placebo, 1 capsule before the session 3. 0.5 mg varenicline, 1 capsule before the session 4. 1 mg varenicline, 1 capsule before the session
89646830|NCT03594643||electronic cigarette|patient using electronic device, electronic cigarette
88992534|NCT02951026||0.23mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.23mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
89646831|NCT03594643||control|patient not smoking nor using electronic cigarette
89646832|NCT03024541||LASA study|
89646833|NCT03024541||InterRAI consortium|
89646834|NCT03594565|Experimental|Local steroids prior to CGMS insertion|"topical spraying of fluticasone propionate nasal spray (nsFP) on the skin area of CGMS placement prior to sensor insertion in a group of pediatric T1D patients who had mild to severe local skin reactions to CGMS adhesives.~Dosage: 2 puffs."
89646835|NCT01430585|Experimental|A|
89646836|NCT01430585|Experimental|B|
89646837|NCT01430585|Active Comparator|C|
89646838|NCT04005859|Active Comparator|CONTROL: IV Lido|CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)
89646839|NCT04005859|Experimental|EXPERIMENTAL: Exparel|EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)
89646840|NCT04052945|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
89212724|NCT01015456|Active Comparator|2|Intravenous cyclophosphamide monthly for 6 months
89212725|NCT00919841||Postpartum women|Women who deliver a singleton vaginally
89212726|NCT02589041|Experimental|Intraneural|Using an Up-and-down methodology, the first patient receives 15 ml ropivacaine 1% intraneural injection. If unsuccessful, following patient will receive an increased dose of LA (2 ml). If successful, following patient will be randomized to have either the same LA dose (9 out of 10 probability) or 2 ml reduction of LA dose (1 out of 10 probability)
89212727|NCT00492232|Experimental|Ramelteon 8 mg QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
89044691|NCT02927405|Placebo Comparator|TAP Block plus placebo|Patients will only receive a TAP block procedure and then morphine consumption will be recorded.
89646841|NCT04052945|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
89646842|NCT03594331|Experimental|Gluten Exposure Group 1|This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
89646843|NCT03594331|Experimental|Gluten Exposure Group 2|This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.
89646844|NCT03594331|Experimental|Gluten Exposure Group 3|This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
89646845|NCT05633719||Pediatric solid cancer|
89646846|NCT03594097|Experimental|Treatment cookies|
89646847|NCT03594097|Active Comparator|Control cookies|
89646848|NCT01408901|Experimental|A: GM-CSF + supervised treadmill exercise therapy|
89646849|NCT01408901|Active Comparator|B: GM-CSF + attention control group|
89646850|NCT01408901|Active Comparator|C: placebo + supervised exercise therapy|
89646851|NCT01408901|Placebo Comparator|D: placebo + attention control group|
89646852|NCT04182763|Experimental|CoA-Z dose 1|6 months of CoA-Z at the highest assigned dose followed by 18 months of CoA-Z at dose 2
89646853|NCT04182763|Experimental|CoA-Z dose 2|6 months of CoA-Z at the medium assigned dose followed by 18 months of CoA-Z at dose 2
89646854|NCT04182763|Experimental|CoA-Z dose 3|6 months of CoA-Z at the lowest assigned dose followed by 18 months of CoA-Z at dose 2
89646855|NCT04182763|Placebo Comparator|Placebo|6 months of placebo, followed by 18 months of CoA-Z at dose 2 (medium dose)
89646856|NCT04182763|Experimental|Open-label arm|Up to 24 months of CoA-Z at dose 2
89646857|NCT05633485|Experimental|Experimental|An animation-supported training based on the health promotion model for COVID-19 disease and prevention measures was given to the participants.
89646858|NCT05633485|No Intervention|Control|No intervention was applied to the participants in the control group.
89646859|NCT05633251|Experimental|School 1|
89646860|NCT05633251|Experimental|School 2|
89646861|NCT05633251|Experimental|School 3|
89646862|NCT03594019|Placebo Comparator|Control Group|Patients in the control group will follow the conventional treatment protocol combined with connective tissue graft. Briefly, hopeless tooth will be extracted atraumatically. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. Then, connective tissue graft will be harvest from palatal and fixed between bucall mocosa and bucall bone. Healing abutment will placed and collegan sponge will be used to seal the wound. After 4 months, implant impression and crown delivery will be finished.
89646863|NCT03594019|Experimental|Test Group|Patients in the test group will receive conventional immediate implant placement combined with socket shield technique. Briefly, the hopeless teeth will be splited from mesial and distal, the buccal part will be preseved and the palatal part will extracted. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. After 4 months, implant impression and crown delivery will be finished.
89646864|NCT03593863|No Intervention|"PE as Usual Control Group"|The Control Group will be asked to continue with their normal PE lessons
89044692|NCT02927405|Experimental|TAP Block plus gabapentin|Patients will receive a TAP block procedure and take pre-operative oral Gabapentin and morphine consumption will me recorded after surgery.
89044693|NCT02927444|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
89646865|NCT03593863|Experimental|Intervention Group|Physical Education (PE) Programme
89646866|NCT02080195|Experimental|Nonmyeloablative Conditioning and BMT|Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.
89646867|NCT04044131|Experimental|Treatment Arm|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
89646868|NCT04044131|Placebo Comparator|Placebo Arm|Subjects will take a mixture of placebo as powder dissolved in water by mouth.
89646869|NCT04748081||Surgery cohort|Patients who underwent hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4) between 2000 and 2012 were identified as the surgery cohort.
89646870|NCT04748081||Control cohort|Patients without any record of hepatectomy between 2000 and 2012 were defined as the control cohort.
89646871|NCT03599011||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
89646872|NCT03599011||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
89646873|NCT03599011||Non exposure|Non-pharmacological treatment (psychotherapy)
89646874|NCT03024307|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
89646875|NCT03024307|No Intervention|usual care only|Patients were provided with usual care.
89646876|NCT01428713|Active Comparator|Group A-Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
89646877|NCT01428713|Active Comparator|Group B-Combined oral contraceptive pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
89646878|NCT02985385||Abnormal Fetal Ultrasounds|"Abnormal fetal ultrasounds:~Those consistent with lethal malformations are provided with palliative management without providing respiratory support. Are given feeding and oxygen~Those compatible with life are managed by full investigation and given standard care for each case"
89212728|NCT00492232|Placebo Comparator|Placebo QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
89212729|NCT02587871|Experimental|Treatment (cytarabine, G-CSF mobilized peripheral blood cells)|Approximately 4-6 weeks after completion of induction chemotherapy, patients receive cytarabine IV over 1-3 hours BID on days -7 to -2 and G-CSF mobilized peripheral blood cells (microtransplant) IV over 15-20 minutes on day 0. Treatment repeats every 8-10 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
89212730|NCT02587793||Barcelona Clinic Liver Cancer (BCLC) staging|The tumor stages of the patient are classified as BCLC stage 0, A, B, C, or D.
89646879|NCT02985385||Normal Fetal Ultrasounds|Given normal care
89646880|NCT01408277|Active Comparator|Santyl|2mm Santyl applied once daily.
89646881|NCT01408277|Active Comparator|Control|Standard Care
89646882|NCT01408043|Experimental|Treatment (stem cell supermobilization)|Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.
89646883|NCT03598855|Experimental|IPC intervention|Participants will self administer IPC of the upper arm daily for 7 days.
89646884|NCT03598855|No Intervention|Control|
89646885|NCT03593785|Experimental|Cohort 1|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 1 injection (6 subjects) or matching placebo (2 subjects).
89646886|NCT03593785|Experimental|Cohort 2|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 2 injection (6 subjects) or matching placebo (2 subjects).
89646887|NCT03593785|Experimental|Cohort 3|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 3 injection (6 subjects) or matching placebo (2 subjects).
89646888|NCT03593785|Experimental|Cohort 4|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 4 injection (6 subjects) or matching placebo (2 subjects).
89646889|NCT03593785|Experimental|Cohort 5|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 5 injection (6 subjects) or matching placebo (2 subjects).
89646890|NCT03984175|Experimental|Patients with ARDS at three Intermountain tertiary hospitals|
89646891|NCT03023995|Experimental|CAF with Platelet Rich Fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it.
89646892|NCT03023995|Active Comparator|CAF with connective tissue graft|In control group, connective tissue graft harvesting was carried out which was followed by placement of connective tissue graft on the recipient site. The connective tissue graft was placed on the recipient site and secured in position with 5-0 vicryl sutures
89646893|NCT03598621|Experimental|Cohort 1: Semaglutide 0.25 mg|Participants will receive a single dose of semaglutide 0.5 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
89646894|NCT03598621|Experimental|Cohort 2: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 1.0 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
89646895|NCT03598621|Experimental|Cohort 3: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 2.0 mg/mL using NovoPen®4 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
89646896|NCT05632783|Experimental|chondroitin sulfate 800 mg tablets|oral chondroitin sulfate 800 mg tablet
89646897|NCT05632783|Placebo Comparator|placebo|oral placebo tablets matching the IP tablets
89646898|NCT01524224|Experimental|LY2495655|"Administered intravenously (IV) every 2 weeks (14 days) for four (4) 14 day cycles. Participants receiving clinical benefit may continue to receive treatment until one or more of the discontinuation criteria are met.~Starting dose in Part 1 (dose escalation) will be 2 mg. The dose will be subsequently increased to 7 mg, 21 mg, 70 mg, 210 mg, and 700 mg. The dose administered in Part 2 (dose confirmation) will be determined from Part 1."
89646899|NCT05630443|No Intervention|ERAS|Ordinary ERAS treatment postoperatively without any prone position or voicetraining
89646900|NCT05630443|Active Comparator|+prone position|Ordinary ERAS treatment adding the prone position and voicetraining in short intervals
89646901|NCT00219349|Experimental|Escitalopram|12 weeks of open label escitalopram, 10-20 mg/day (after 14 weeks of cognitive behavioral therapy
89212731|NCT04082273|Experimental|Femtosecond Laser for Cataract Surgery|Capsulotomy, lens fragmentation and Clear Corneal Incisions with FEMTO LDV Z8, followed by ultrasound phacoemulsification and IOL implantation.
89646902|NCT03593239|Experimental|Tobacco flavored JUUL 1.7% ENDS|Tobacco flavored JUUL 1.7% ENDS (10 puffs)
89646903|NCT03593239|Experimental|Tobacco flavored JUUL 5% ENDS|Tobacco flavored JUUL 5% ENDS (10 puffs)
89646904|NCT03593239|Experimental|Mint flavored JUUL 1.7% ENDS|Mint flavored JUUL 1.7% ENDS (10 puffs);
89646905|NCT03593239|Experimental|Mint flavored JUUL 5% ENDS|Mint flavored JUUL 5% ENDS (10 puffs)
89646906|NCT03593239|Experimental|Fruit Medley flavored JUUL 1.7% ENDS|Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)
89646907|NCT03593239|Experimental|Fruit Medley flavored JUUL 5% ENDS|Fruit Medley flavored JUUL 5% ENDS (10 puffs)
89646908|NCT03593239|Experimental|Crème brulee flavored JUUL 1.7% ENDS|Crème brulee flavored JUUL 1.7% ENDS (10 puffs)
89212732|NCT04082273|Active Comparator|Conventional Cataract Surgery|Clear Corneal Incisions, conventional capsulorhexis and ultrasound phacoemulsification and IOL implantation. Control treatment where the clear corneal incisions and capsulorhexis are performed manually and the lens fragmentation is performed with the phacoemulsification device.
89646909|NCT03593239|Experimental|Crème brulee flavored JUUL 5% ENDS|Crème brulee flavored JUUL 5% ENDS (10 puffs)
89646910|NCT03593239|Experimental|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs
89646911|NCT03593239|Experimental|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs
89646912|NCT01523756|Experimental|test product 1 first|"own product (baseline) - test product 1 - test product 2~test product 1 = New ostomy base plate. Due to company confidentiality the product is just called test product 1"
89646913|NCT01523756|Experimental|test product 2 first|"own product (baseline) - test product 2 - test product 1~test product 2 = New ostomy base plate. Due to company confidentiality the product is just called test product 2"
89646914|NCT00218257|Active Comparator|Progesterone|200mg progesterone twice daily
89646915|NCT00218257|Placebo Comparator|Placebo|Placebo twice daily
89646916|NCT01523366|Experimental|Ticagrelor|
89646917|NCT01523366|Active Comparator|Clopidogrel|
89646918|NCT03024697|Active Comparator|PECs Block|Patients randomised to receive pectoral plane blocks and a sham local anaesthetic infusion wound catheter
89646919|NCT03024697|Active Comparator|LA Infusion|Patients randomised to receive a local anaesthetic infusion wound catheter; No sham pectoral plane block performed as patients usually under general anaesthetic at time of block.
89646920|NCT03024697|Active Comparator|PECs Block & LA Infusion|Patients randomised to receive pectoral plane blocks and a local anaesthetic infusion wound catheter.
89646921|NCT04407403|Experimental|Tai Chi tailored for lowering blood pressure (PRESSURE)|During the 12-week Tai Chi intervention, participants in the PRESSURE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the PRESSURE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
89646922|NCT04407403|Experimental|Tai Chi tailored for improving balance (BALANCE)|During the 12-week Tai Chi intervention, participants in the BALANCE group attended supervised Tai Chi sessions led by a certified Tai Chi instructor for 3 sessions/week, 60 minutes/session for 12 weeks. In addition, participants in the BALANCE group were instructed: 1) to maintain their regular level of physical activity outside of the supervised Tai Chi exercise sessions, and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed.
89646923|NCT04407403|No Intervention|control group (CONTROL)|During the 12-week Tai Chi intervention, participants in the CONTROL group performed their regular daily activities. In addition, participants in the CONTROL group were instructed: 1) to maintain their regular level of physical activity and diet during the study; and 2) to inform the researchers when there is a change(s) in a medical condition or medication prescribed. Of note, both PRESSURE and BALANCE were offered to participants assigned in the CONTROL group after data collection was completed.
89646924|NCT03593161|Experimental|Humor therapy|After baseline assessment (before start of conditioning), patients assigned to the experimental study arm will receive the standard psychosocial care plus weekly clown visits over the course of their inpatient stay for allogeneic stem cell transplantation.
89646925|NCT03593161|No Intervention|Treatment as usual|Patients assigned to the control arm will receive the standard psychosocial care over the course of their inpatient stay for allogeneic stem cell transplantation.
89646926|NCT01427933|Experimental|Ramucirumab and Eribulin|"Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle~Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle"
89646927|NCT01427933|Active Comparator|Eribulin Monotherapy|Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle
89646928|NCT03024073||SG|Study group (patients who underwent pseudophakic presbyopic correction with bilateral bifocal lenses implantation
89646929|NCT03024073||CG|Control group (age-matched participants without pseudophakic presbyopic correction)
89646930|NCT03024385||Mothers of healthy infants|Mothers of young infants presenting for well child visits between the ages of 0-2 years of age
89646931|NCT04043273||Whole cohort|The whole cohort will be divided into clusters according to patients expectations and preferences regarding their treatment
89646932|NCT03593083|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
89646933|NCT03593083|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
89646934|NCT00217087|Other|Endoscopic Mucosal Resection|Patients will undergo endoscopic mucosal resection at time of endoscopy if indicated.
89646935|NCT00217087|Other|Photodynamic Therapy|Patients will have endoscopic mucosal resection with photodynamic therapy.
89646936|NCT03598543||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
88992535|NCT02951026||Placebo (previously injected)|"Subjects in this group received a single intra-articular injection of placebo into the target knee during the parent study prior to enrolling in this observational study."
89646937|NCT03598543||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
89646938|NCT03593005|Experimental|Order A|The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)
89646939|NCT03593005|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
89646940|NCT01406873|Active Comparator|Mexiletine|20 subjects will be randomized (assigned) to receive Mexiletine. Mexiletine is available on the market for the treatment of cardiac arrhythmias, but it is not currently approved for the treatment of myotonia or myotonic dystrophy.
88992536|NCT00514891|Active Comparator|1|Vitamin A supplementation
88992537|NCT00514891|Placebo Comparator|2|Placebo
88992538|NCT00515047||Eczema Herpeticum (EH)|Participants with AD who currently have or have had EH
88992539|NCT00515047||Non-EH|Participants with AD who do not have and have never had EH
88992540|NCT00515047||Healthy Controls|Healthy participants without a history of AD
88992541|NCT00515125|Other|Dietary Advice|Dietary Advice
88992542|NCT00515125|Other|Oral Nutritional Supplements|Oral Nutritional Supplements
89044694|NCT02927444|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
89044695|NCT02927288||Military subjects with mTBI|mTBI/concussion only Group: Participants must have been clinically diagnosed with mTBI/concussion according to criteria outline by the World Health Organization (WHO; Holm et al., 2005) and be at least three month post-injury. Participants in the mTBI/concussion only group must not have a concurrent diagnosis of PTSD and must score below 25 on the Post-traumatic stress Check List for Civilians (PCL-C).
89044696|NCT02927288||Military subjects with PTSD|Participants in the PTSD only group must have a clinical diagnosis of PTSD, following criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR). Proof of diagnosis will be obtained from participants via a request for release of pertinent medical records. Participants in this group must not have a history of mTBI or concussion.
89646941|NCT01406873|Placebo Comparator|Sugar pill|20 subjects will be randomized (assigned) to receive placebo (sugar pill). This control group is necessary to definitely establish the antimyotonic efficacy and safety of mexiletine.
89044697|NCT02927288||Military subjects with mTBI and PTSD|Participants in the mixed group must meet criteria for mTBI/concussion and PTSD as outlined above.
89646942|NCT01406795|Experimental|Venous Stent Arm|The study is a single treatment arm study and the venous stent will be placed in all eligible participants.
89646943|NCT01406717|Experimental|SPIL1033|
89646944|NCT01406717|Placebo Comparator|Placebo|
89646945|NCT01406015|Active Comparator|Spironolactone|
89646946|NCT01406015|Placebo Comparator|Placebo|
89646947|NCT00215683|Experimental|Degarelix 80 mg|Participants who completed the CS12 study in the Degarelix 80 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
89646948|NCT00215683|Experimental|Degarelix 120 mg|Participants who completed the CS12 study in the Degarelix 120 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
89646949|NCT00215683|Experimental|Degarelix 160 mg|Participants who completed the CS12 study in the Degarelix 160 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
89646950|NCT00215137|Experimental|Open Label Escitalopram 10-20 mg/daily|Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
89646951|NCT00215137|Placebo Comparator|Randomizationn Placebo 10-20 mg daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
89646952|NCT00215137|Active Comparator|Randomization Escitalopram 10-20 mg/daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
89646953|NCT04406779||Patients with breast cancer|Patients with breast cancer
89646954|NCT04406779||Control|Healthy patients without breast cancer
89646955|NCT00214201|No Intervention|1|Standard of Care CNI immunosuppression
89646956|NCT00214201|Experimental|2|Calcineurin inhibitor withdrawal
89646957|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide intravenous infusion 120 micrograms over 20 minutes
89646958|NCT03598075|Other|CGRP|CGRP intravenous infusion 30 micrograms over 20 minutes
89646959|NCT03592615|Experimental|Cataract group|All participants in this arm undergo cataract surgery for the purpose of vision correction.
89646960|NCT03592615|Experimental|Refractive error group|All participants in this arm undergo corneal refractive surgery for the purpose of vision correction.
89646961|NCT03597919|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
89646962|NCT03597919|Experimental|Two-dose schedule for Sabin IPV|Subjects vaccinate first dose IPV at 4 months, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
89646963|NCT04001413|No Intervention|Arm A: Observational|No intervention, observational arm.
89646964|NCT04001413|Experimental|Arm B: Durvalumab Alone|Durvalumab will be administered as an IV Infusion.
89646965|NCT04001413|Experimental|Arm C: MEDI0457 and Durvalumab|MEDI0457 is an injection. Durvalumab will be administered as an IV Infusion.
89646966|NCT03592459|Experimental|Device feasibility (Macy catheter, opioids)|Patients undergo placement of rectal catheter and receive opioids through the Macy catheter.
89646967|NCT03597763||Moderate to severe traumatic brain injury|Patients who have suffered a moderate to severe traumatic brain injury, with confirmed intracranial damage.
89646968|NCT01486784|Experimental|Phase 1 DL1|26mg/m2/dose IV once per week x 3 weeks of 4 week cycle
89044698|NCT02927288||Military healthy control|Participants in the military control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above. Participants in this group will include service members on Active Duty and those currently serving with National Guard or Reserve forces.
89646969|NCT01486784|Experimental|Phase 1 DL-1|17mg/m2 IV/dose once per week x 3 weeks of 4 week cycle
89646970|NCT01486784|Experimental|Phase 1 DL-1a|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
89646971|NCT01486784|Experimental|Phase 1 DL-1b|17mg/m2/dose IV three times per week x 3 weeks of 4 week cycle
89646972|NCT01486784|Experimental|Phase 1 DL-1c|22mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
89646973|NCT01486784|Experimental|Phase 1 DL-1d|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
89646974|NCT03592381|Experimental|Ridge expansion by osseodensification|Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
89646975|NCT03592381|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
89646976|NCT03592303||Control|Any pregnant patient with a normal pregnancy is eligible for possible participation in the study.
89646977|NCT03592303||PPH group|Women with PPH requiring biological evaluation of hemostasis
89646978|NCT01521884||RA Patients treated with SC anti-TNF|
89646979|NCT03592147|Other|Relaxation|This is a within-subject pilot study, where each participant received, in random order, five different relaxation therapies (Guided Imagery Relaxation Tape, Music Listening, Relaxation Lighting, Meditation and Relaxation Light, and Music and Relaxation Light) and one Control/Silence state spanning across 3-6 weeks.
89044699|NCT02927288||Civilian healthy control|Participants in the civilian control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above.
89044700|NCT02927483|Experimental|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
89044701|NCT02927483|Active Comparator|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
89044702|NCT02927210|Placebo Comparator|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
89646980|NCT03597451||Multiple sclerosis|Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS)
89646981|NCT03597451||Control|Healthy individuals of similar age and sex to patients
89646982|NCT03027596|Experimental|Remote ischemic conditioning|Four cycles of 5 min occlusion and reperfusion in an extremity using a tourniquet.
89646983|NCT03027596|No Intervention|Control group|no intervention
89044703|NCT02927210|Experimental|Dimethandrolone Undecanoate|Single doses of DMAU administered via injection intramuscularly (IM - 80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC - 50 mg, 100 mg and 200 mg)
89044704|NCT04679649|Experimental|Trial A - Intervention Group (manual mobilisation)|Participants will continue to receive routine care and 13 sessions of manual spinal mobilisation will be administered over a 6 months period to compare routine care vs routine care plus manual spine mobilisation physiotherapy.
89044705|NCT04679649|No Intervention|Trial A - Control Group (routine care)|Participants in control group will continue to receive routine care, and routine care measurements for axial spondyloarthritis will be taken at baseline, 3 months and 6 months plus follow up.
89044706|NCT02927522|Placebo Comparator|Control|Placebo was administrated
89044707|NCT02927522|Experimental|Donepezil|Donepezil (5mg/ day for 7 days) was administrated
89044708|NCT02927093||Case|neonates with NH reaching exchange transfusion threshold
89044709|NCT02927093||Control|neonates with NH within moderate threshold of the phototherapy charts
89044710|NCT04679493|Experimental|XC7 100 mg single|Cohort 1 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 100 mg (3 subjects) or placebo (1 subject, see placebo single arm)
89646984|NCT01677858|Experimental|Carfilzomib|"In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.~In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study.~Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study."
89646985|NCT03027362|Experimental|Cognitive behavioral therapy (CBT) and medication|Following clinical ketamine treatment, the intervention includes sixteen CBT sessions over 14 weeks. In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or by a psychiatrist unaffiliated with the trial. Participants will remain on the medication they were prescribed when they entered the study and will be expected not to adjust the medication unless clinically urgent.
89646986|NCT03027362|Active Comparator|Psychoeducation and medication|Following clinical ketamine treatment, the intervention includes psychoeducational sessions over 14 weeks.In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or a by psychiatrist unaffiliated with the trial.
89646987|NCT04198441|Active Comparator|Omeza Value-based Bundle Test|The Omeza value-based bundle consists of lidocaine lavage, flowable collagen matrix and skin protectant products.
89646988|NCT04198441|Active Comparator|Standard Wound Care Control|Standard wound care control is saline wound wash and wet to dry dressing.
89044711|NCT04679493|Experimental|XC7 200 mg single|Cohort 2 - 4 subjects will be randomized in a 3:1 ratio to be treated either XC7 200 mg (3 subjects) or placebo (1 subject, see placebo single arm)
89044712|NCT04679493|Placebo Comparator|Placebo single|Placebo comparator arm will consist of 2 subjects (1 subject from Сohorts 1 and 2)
89044713|NCT04679493|Experimental|XC7 200 mg multiple|Cohort 3 - 6 subjects will be randomized in a 6:2 ratio to be treated either XC7 200 mg (6 subjects) or placebo (1 subject, see placebo multiple arm)
89044714|NCT04679493|Placebo Comparator|Placebo multiple|Placebo comparator arm will consist of 2 subjects from cohort 3
89044715|NCT02927132|Experimental|Alcohol-Guilt Condition|"In this condition, participants are asked to write about an incident in which they drank heavily and experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
89212733|NCT00919919|Experimental|Progesterone vaginal tablet|Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.
89646989|NCT03027284|Experimental|Merestinib (Part A Dose Level 1)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
89646990|NCT03027284|Experimental|Merestinib (Part A Dose Level 2)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
89044716|NCT02927132|Experimental|Distress-Guilt Condition|"In this condition, participants are asked to write about an upsetting incident where they experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
89044717|NCT02927132|Experimental|Alcohol-No Guilt Condition|"In this condition, participants are asked to write about a negative drinking incident that they had experienced.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
89044718|NCT02927132|Experimental|Distress-No Guilt Condition|"In this condition, participants are asked to write about an upsetting experience that has affected their life.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
89044719|NCT02927132|No Intervention|Neutral Control Condition|"In this condition, participants are asked to write about the laboratory room in which they are seated.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
89646991|NCT03027284|Experimental|Merestinib + Cisplatin + Gemcitabine (Part B)|Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles.
89057954|NCT02278679||Clinic patient|The third phase includes 8 residents and up to10 attendings in the Urology clinic, who will independently complete the DiRECT documenting their DRE in the course of usual care.
89646992|NCT03592069|Active Comparator|10 day concomitant|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~- Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid."
89646993|NCT03592069|Active Comparator|14 day hybrid|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days."
89646994|NCT03027128|Experimental|haNK™ for Infusion|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous Infusion
89646995|NCT03591991|Active Comparator|treatment group|Patients will be randomized into two groups after enrolled. In Empagliflozin Group, the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin .After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths. The procedure will double blind to patients and investigators.
89646996|NCT03591991|Placebo Comparator|Placebo group|Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
89646997|NCT03592927|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
89646998|NCT03592927|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
89646999|NCT04673058|Experimental|Spinal Manipulation Group|After the patients were evaluated in terms of somatic dysfunction, the appropriate techniques of Cervical Upglide Thrust, Cervical Downglide Thrust, Cervical Traction Thrust, Cervical Rotation Thrust, Cervico-Thoracic Distraction Manipulation, Cervico-Thoracic Lateral Glide (Spinous Push) Manipulation, Supine Screw Thoracic Thrust, Prone Thoracic Thrust, and Lumbar Spine Rotation Manipulation will be applied to patients.
89647000|NCT04673058|Sham Comparator|Sham Manipulation Group|A treatment will be applied which is very similar to active treatment but aimed to have minimal therapeutic effect. For this, the practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position. In this way, the movement will be imitated without reaching the elastic zone and a stronger similarity will be provided compared to sham treatments such as light touch or massage.
89647001|NCT04673058|No Intervention|No Intervention Group|These patients will receive only their pharmacological treatments.
89647002|NCT03597373||reintubation|Reestablish of invasive mechanical ventilation
89647003|NCT03597373||not reintubation|Favourable respiratory function
89647004|NCT03591913|Experimental|study group|will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
89647005|NCT03591913|Active Comparator|control group|will receive sublingual misoprostol immediately after skin closure
89647006|NCT04198519|Active Comparator|Poor Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Poor cardiovascular health is considered for two or less metrics.
89647007|NCT04198519|Active Comparator|Ideal-intermediate Cardiovascular Health|Cardiovascular health is said to be ideal by the presence of optimal health behaviors (non-smokers, adequate BMI, physical activity level and healthy eating pattern) and ideal health factors (blood pressure, total cholesterol and blood glucose). Ideal cardiovascular health is considered for those with five or more metrics within this qualification, and intermediate for the presence of three or four metrics.
89057955|NCT01199068|Experimental|CS-7017+Erlotinib|Drug: CS-7017 from 0.25 mg to 0.50 mg twice a daily Drug: Erlotinib 150 mg once daily
89044720|NCT02927132|Experimental|Personalized Normative Feedback|Participants in the PNF condition will be given gender-specific personalized feedback regarding their alcohol use. Participants will be presented with the drinking estimates that they previously gave in addition to average gender-specific drinking estimates provided by 1124 students at the University of Houston. Feedback will be provided for drinking frequency (i.e., number of drinking days per week), and drinking quantity (i.e., the number of drinks consumed per week and number of drinks consumed per typical drinking occasion). Participants will also receive a printed a copy of the feedback for their records. PNF participants will receive feedback immediately after the baseline assessment. We also wanted to control for any differences that might be attributed to attention. Thus, participants will be scheduled to come in to the lab for two more sessions, during which time they will write about the laboratory room in which they are seated.
89044721|NCT02927054|Other|Internal Medicine Residents|Sepsis education provided to internal medicine residents
89044722|NCT02927054|Other|Emergency Medicine Residents|Sepsis education provided to emergency medicine residents
89044723|NCT02927054|Other|Orthopedic Residents|Sepsis education provided to orthopedic residents
89044724|NCT02927054|Other|Neurosurgery Residents|Sepsis education provided to neurosurgery residents
89044725|NCT02927054|Other|General Surgery Residents|Sepsis education provided to general surgery residents
89044726|NCT04938648|Experimental|Intervention|"The intervention consists of the following:~mailing deprescribing educational materials to care partners and people living with dementia (PLWD);~dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences;~pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP."
89044727|NCT04938648|Active Comparator|Delayed Intervention (wait list control)|"The delayed intervention consists of the following:~mailing deprescribing educational materials to care partners and people living with dementia (PLWD);~three months after mailing the deprescribing educational materials, dyads will receive a telehealth visit with a clinical pharmacist to discuss the benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences.~pharmacist- primary care provider (PCP) communication in which the pharmacist provides tailored deprescribing recommendations to the PCP."
89044728|NCT02926976|Active Comparator|risperidone with clozapine|risperidone, dosage form: 1 mg, dosage and frequency:3.0~6.0 mg/d; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
89044729|NCT02926976|Active Comparator|aripiprazole with clozapine|aripiprazole, dosage form: 5 mg, dosage and frequency:15~30 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
89044730|NCT02926976|Active Comparator|sodium valproate with clozapine|sodium valproate, dosage form: 250 mg, dosage and frequency:600~1200 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 3 months.
89044731|NCT02926976|Active Comparator|clozapine|only clozapine, dosage and frequency:300~600 mg/d;
89044732|NCT02926976|Active Comparator|Modified electroconvulsive therapy with clozapine|10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
89647008|NCT01486316|Other|Control arm|Subjects in the Control arm will be observed between implant and month 12. During this time, the standard device diagnostic suite will be used as it would normally, in the office using the programmer, or by data transmission from the patient's home (or another remote location). At month 12 through study close (month 18), study doctors for the all subjects will have access to the risk status.
89647009|NCT01486316|Experimental|Risk Status Guided|Study doctors will have access to the experimental IDENTIFY-HF Risk Status for subjects in the Guided arm between months 6 and 18. At all times during the study, study doctors will also be able to use the standard device diagnostics in the office using the programmer, or by data transmission from the patient's home (or another remote location).
89647010|NCT03591835|Active Comparator|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
89647011|NCT03591835|Active Comparator|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear.
89044733|NCT02926976|Active Comparator|Magnetic seizure therapy with clozapine|10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
89044734|NCT04917393|Experimental|Multi-organ denervation|Multi-organ (Hepatic and Renal) denervation with the Integrated Radio Frequency (iRF) Denervation System
89647012|NCT04850898|Placebo Comparator|Normal Saline Placebo Control|Placebo control dosed 1 time via intravenous infusion
89647013|NCT04850898|Experimental|SAB-176 - 25mg/kg|Investigational Medicinal Product dosed 1 time at 25 mg/kg on day 1 via intravenous infusion
89647014|NCT04198285|Experimental|Retrograde filled|This arm will contain patients who had retrograde bladder filling upon completion of surgery with 200 milliliters (mL) of sterile saline.
89647015|NCT04198285|No Intervention|Control|This arm will contain patients who simply had the urinary catheter removed upon completion of surgery, and were left with an empty bladder.
89647016|NCT04198129|Experimental|Treatment|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.
89647017|NCT04198129|Active Comparator|Control|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care.
89647018|NCT01486238|Experimental|IVMac q6 Arm|Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.
89647019|NCT01486238|Experimental|IVMac q4 Arm|Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.
89647020|NCT03591757|Experimental|Tolcapone|Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
89647021|NCT04438434|Experimental|Hydrogen Peroxide and Hyaluronic acid mouthwash (BMG0703)|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
89647022|NCT04438434|Active Comparator|Chlorhexidine 0.2% mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
89647023|NCT04438434|Placebo Comparator|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
89647024|NCT04198051|Experimental|treatment group|
89647025|NCT03596983|Experimental|Short Sleep Patients|
89647026|NCT04462146|Experimental|Internet-based intervention|Internet-based Self Applied Treatment Program. Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
89647027|NCT04462146|Active Comparator|Face-to-face treatment by videoconference|Face-to-face Intervention by videoconference applied by a therapist: Main components: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
89647028|NCT03591679|Experimental|study group|patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
89647029|NCT03591679|Active Comparator|control group|patients at risk of uterine atony undergoing cesarean section received oxytocin only.
89044735|NCT04917393|Sham Comparator|Control Arm|Subjects will recieved the sham procedure
89044736|NCT03455166|Other|Psoriasis|
89044737|NCT03455166|Other|Psoriatic arthropathy|
89044738|NCT02927015|Experimental|Purple Majesty potato chips|Purple Majesty potato chips
89044739|NCT02927015|Experimental|Mountain Rose potato chips|Mountain Rose potato chips
89044740|NCT02927015|Experimental|White potato chips|White potato chips
89044741|NCT02927015|Experimental|Crackers|Crackers
89044742|NCT02926820|Experimental|Cognitive training|Participants will undergo five weeks of cognitive training using the Cogmed QM program. All patients complete the same intervention.
89044743|NCT04910412|Experimental|Anodal tDCS with gait training|Anodal tDCS will be applied over the primary motor cortex (M1) (anodal or active electrode on M1 area, cathodal or reference electrode on supraorbital area) for 20 mins with 2 mA intensity before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
89044744|NCT04910412|Active Comparator|Sham tDCS with gait training|Sham tDCS will be applied over the primary motor cortex for 20mins before 50-minute of gait training with external cue and feedback for 5 consecutive sessions
89044745|NCT02926781|Experimental|osteotome technique|transcrestal sinus floor elevation using osteotomes
89044746|NCT02926781|Active Comparator|drills|transcrestal sinus floor elevation using drills
89044747|NCT00553956|Experimental|1|Intervention group A treatment combination of Narrative Exposure Therapy and Interpersonal Psychotherapy (5 individual sessions NET in addition to 3 individual sessions IPT)
89044748|NCT00553956|No Intervention|2|Waiting list control
89044749|NCT04887246||UNISALUD population|Refers to all affiliated members or beneficiaries of the UNISALUD entity, who got any of tthe COVID-19 vaccines available in Colombia
89057956|NCT05103891|Experimental|Binimetinib 15 mg / Binimetinib 45 mg|2 periods
89057957|NCT05103891|Experimental|Binimetinib 45 mg / Binimetinib 15 mg|2 periods
89647030|NCT03969043|Experimental|Young volunteers|"Volunteers between 18 ans 45 years old~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
89647031|NCT03969043|Experimental|Older Volunteers|"Volunteers between 60 ans 85 years old~Interventions: task scans (n=4), anatomical MRI, Resting state functional scan, Diffusion Tension Imaging, Perfusion imaging."
89647032|NCT04039932|Experimental|Intervention|
89212734|NCT00919919|Other|Activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
89647033|NCT04039932|No Intervention|Standard of Care|
89647034|NCT03596827|Active Comparator|1E10 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
89647035|NCT03596827|Experimental|1E9 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E9 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
89647036|NCT03596827|Experimental|1E8 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E8 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
89647037|NCT03596827|Experimental|1E7 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E7 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
89647038|NCT03596827|Experimental|1E6 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E6 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
89647039|NCT04197817|Active Comparator|JS002|JS002, Subcutaneous or intravenous injection
89647040|NCT04197817|Placebo Comparator|Placebo,|Placebo,Subcutaneous or intravenous injection
89647041|NCT05375682|Experimental|Integrated care program|ICP intervention consists of several core intervention components.
89647042|NCT03591601|Active Comparator|Manual therapy protocol|Treatment based on manual therapy with proven evidence.
89647043|NCT03591601|Experimental|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
89647044|NCT03591601|Placebo Comparator|Placebo Control|Placebo treatment based on the placement of the hands on the head without intention to treat.
89647045|NCT04615338||Homicidal group|The group of patients presented with homicidal open neck injuries
89647046|NCT04615338||Suicidal group|The group of patients presented with suicidal open neck injuries
89647047|NCT04615338||Accidental group|The group of patients presented with accidental open neck injuries
89647048|NCT04197661|Active Comparator|Elderly groupⅠ|Elderly groupⅠ 65 years or older 0.2 mg/kg HSK3486
88992543|NCT00515164|Experimental|Group 1|Treatment will be administered in 2 treatment sessions.
88992544|NCT00515164|Experimental|Group 2|Treatment will be administered in a single treatment session.
88992545|NCT02950948|Experimental|Progesterone|25 mg of progesterone will be administered daily by subcutaneous injection.
88992546|NCT02950948|Placebo Comparator|Placebo|25 mg of progesterone will be administered daily by subcutaneous injection.
88992547|NCT00515242|Experimental|1|Therapeutic massage
89647049|NCT04197661|Active Comparator|Elderly group Ⅱ|Elderly group Ⅱ 65 years or older 0.3 mg/kg HSK3486
89647050|NCT04197661|Active Comparator|Elderly group Ⅲ|Elderly group Ⅲ 65 years or older 0.4 mg/kg HSK3486
89647051|NCT04197661|Active Comparator|Non-elderly group IV|Non-elderly group IV 18 to 64 years 0.4 mg/kg HSK3486
89647052|NCT04065984|Experimental|Neuro-Muscular electrical stimulation treatment arm|Active muscle stimulation with a view that this will lead to muscle preservation through muscle fibre recruitment
89647053|NCT04065984|Sham Comparator|Neuro-Muscular electrical stimulation Placebo arm|Stimulator set at a sub therapeutic threshold so as to not recruit muscle fibres
89647054|NCT04197895|Experimental|test group|Socket preservation with APRF
88992548|NCT00515242|Active Comparator|2|Thermotherapy
88992549|NCT00515242|Placebo Comparator|3|Relaxation
88992550|NCT00515320|Experimental|Fluoxetine|
88992551|NCT00515320|Placebo Comparator|Placebo|
88992552|NCT00515398||1|Group 1 (all subjects)
88992553|NCT00515554|Active Comparator|A|8 cycles BEACOPPesc
88992554|NCT00515554|Experimental|B|8 cycles BEACOPPesc plus rituximab
88992555|NCT00515554|Active Comparator|C|8 cycles BEACOPPesc
88992556|NCT00515554|Experimental|D|4 cycles BEACOPPesc
88992557|NCT04620200|Experimental|ARM A|2 courses of nivolumab 3 mg/kg in week 0 and 2 prior to standard of care
88992558|NCT04620200|Experimental|ARM B|2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course of ipilimumab 1mg/kg in week 0 prior to standard of care
88992559|NCT00515632|Experimental|Balaglitazone 10 mg per day|
88992560|NCT00515632|Experimental|Balaglitazone 20 mg per day|
88992561|NCT00515632|Active Comparator|Pioglitazone 45 mg per day|
88992562|NCT00515632|Placebo Comparator|Placebo|
88992563|NCT00515710||1|Prior gene therapy study subjects receiving AAV2-hFIX16.
88992564|NCT02950909|Experimental|Emphasized exercise group|Patients in the emphasized exercise group performed exercises emphasizing the deep cervical extensor muscles applying a resistance at the level of the vertebral arch of C4 either therapeutically with the therapist's fingers or as a home exercise with the aid of a towel or belt. These exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, a dynamic exercise was added moving the head from maximal flexion to maximal extension keeping the gaze fixed at an object lying between both elbows hoping to activate more the extensors in the lower cervical spine.
89647055|NCT04197895|Active Comparator|control group|natural healing
89647056|NCT03591523||Suspicion of vascular pathology|Subjects indicated to quantitative MR angiography and duplex sonography for suspicion of cervical or intracranial vascular pathology
88992565|NCT02950909|Experimental|General exercise group|Patients in the general exercise group performed exercises targeting all cervical extensor muscles including the superficial ones applying resistance at the head pushing against a wall or the therapist's hand or as a home exercise with the aid of a towel. As in the other group, these exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, the same dynamic exercise was added as in the other group with the only difference that the gaze was fixed at an object lying between both hands hoping to activate all cervical extensors
88992566|NCT02957565|Experimental|Video 1: No EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
88992567|NCT02957565|Experimental|Video 1: No EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
88992568|NCT02957565|Experimental|Video 2: With EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
88992569|NCT02957565|Experimental|Video 2: With EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
88992570|NCT00515788|Experimental|DepoCyt + Temozolomide|DepoCyt Starting 50 mg Intrathecal Day 1 every 14 days for 12 weeks (6 treatments), then every 28 days for 40 weeks (10 treatments). Temozolomide 100 mg/m^2 by mouth daily for 7 days every 14 days.
88992571|NCT02950870|Experimental|group treated|this group will be treated with Ombitasvir-Paritaprevir-Ritonavir (12,5 mg/75 mg/50 mg) and Dasabuvir ( 250 mg) with or without Ribavirina every day , for 12 weeks.
88992572|NCT02950870|No Intervention|group untreated|Control group
88992573|NCT02950792|Experimental|ViewRay MRI-IGART|"ViewRay MRI-Image-Guided Adaptive Radiation Therapy (IGART):~Daily MRI on ViewRay 5 days per week for 4 weeks in combination with weekly standard of care chemo-radiation.~Daily MRI on ViewRay during Week 5 in combination with Stereotactic Body Radiation Therapy boost for daily for up to 1 week.~Continued standard of care consolidation chemotherapy every 21 days for 3 cycles, beginning 4 - 6 weeks after completion radiation therapy, ."
88992574|NCT00515866|Experimental|1|Gemcitabine + KU-0059436
88992575|NCT02950714|Experimental|LIN_NOW|Participants from CaNIOS centres randomized to the NOW group will be provided immediate access to the lupus interactive navigator (LIN), a web-based program developed to promote engagement and self-care in lupus.
88992576|NCT02950714|Active Comparator|LIN_WAIT|Participants from CaNIOS centres randomized to the WAIT group will have usual care for three months prior to crossing over to access to the LIN.
88992577|NCT00166257|Active Comparator|Medical antitrhombotic treatment|
88992578|NCT00166257|Experimental|Device Implant|Percutaneous closure of patent foramen ovale
88992579|NCT02950675||Normal Adult|Control:Normal Adult
88992580|NCT02950675||Burn Patient|The burn patient will be identified according to the diagnoses (ICD-9-CM code: 940-949).
88992581|NCT00516022|Experimental|Investigator product|The patients randomized to this arm will receive the IP injections at home 3 times a week (the patients will inject the IP themselves).
88992582|NCT00516022|Other|Control|The patients randomized to this arm will continue to receive chemotherapy as usual without further treatment (unless prescribed by the Doctor).
88992583|NCT00151242|Active Comparator|1|
88992584|NCT00151242|Experimental|2|
88992585|NCT02950636|Experimental|Restorative Yoga|Subjects will participate in a structured restorative yoga program. Subjects will attend a 60 minute restorative yoga class twice a week for 8 weeks in a yoga studio.
88992586|NCT02950519|Active Comparator|As needed Cuff Pressure Checks|Cuff pressure checks upon intubation and after any manipulation of ET tube
88992587|NCT02950519|Experimental|Cuff Pressure checks every 8 hrs|Cuff pressure checks upon intubation, after manipulation of ET tube, and minimum of 8 hr interval
88992588|NCT02950402|Experimental|Two Dried Plums per day|Two Dried Plums per day is approximately 14 g.
88992589|NCT02950402|Experimental|Six Dried Plums per day|Six Dried Plums per day is approximately 42 g.
88992590|NCT03459118|Experimental|Function Focused Care|FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the champion and stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
88992591|NCT03459118|Placebo Comparator|Education Only|Education only sites are exposed to Step II of the Four step approach described under the treatment arm. They receive baseline education of staff.
88992592|NCT04695184|Other|ICG-NIRF Imaging|ICG-NIRF imaging is used intraoperatively to visualise precisely the blood supply and bowel perfusion rate in the area of ileal pouch formation and the ileal pouch-anal anastomosis.
89057958|NCT04535375|Other|Preterm infants < 28 weeks gestational age|For infants born before 28 0/7 weeks, standard of care consists of brain ultrasound performed on admission, day 1, day 2, day 3, day 7, and then weekly until discharge.
89647057|NCT03785574|Active Comparator|A:chemotherapy immediately|Treated with chemotherapy immediately. First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
89647058|NCT03785574|Experimental|B:follow up|"B1: follow up until hCG level met FIGO diagnostic criteria of GTN, then chemotherapy.~B2: follow up until hCG level declined to normal spontaneously."
89647059|NCT04197427|Experimental|Experimental Oral Rinse|"In this arm the test article,oral rinse, a proprietary formulation of agents including xylitol, Caffeine, Essential oils, Monk fruit extract, which can reduce the plaque formation Subjects rinse twice a day with 10 mL of the oral rinse for 2 minutes for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
89044750|NCT02926703||GTCS patients|Patients with generalized tonic-clonic seizures (GTCS) and whose serum lactate and creatine kinase (CK) concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers
89044751|NCT02926703||Syncope patients|Patients with syncope and whose serum lactate and CK concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers.
89044752|NCT04878549||Febrile Adults|1200 adult participants (15 to 45 years old) with a febrile illness without localising features and reported duration of 3-14 days.
89044753|NCT04878549||Controls|400 afebrile, healthy adult participants (15 to 45 years old).
89044754|NCT04878549||Febrile Children|400 child participants (2 to 14 years old) with a febrile illness without localising features and reported duration of 3-14 days. This is an exploratory arm of the study.
89044755|NCT02926625|Active Comparator|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, ie. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
89044756|NCT02926625|Experimental|Systematic follow-up arm|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should come back for a systematic follow-up visit after 2 days, even if the child has recovered.
89044757|NCT02926547||CCIS|
89044758|NCT02926547||invasive breast cancer|
89044759|NCT02926508|Experimental|Prebiotic (Bimuno)|Bimuno (B-GOS, Galacto-oligosaccharides, produced and provided by Clasado BioSciences Ltd)
89044760|NCT02926508|Placebo Comparator|Placebo|Maltodextrin
89044761|NCT02926469|No Intervention|Standard Care|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions. Afterwards they will answer pain and anxiety questionnaires.
89647060|NCT04197427|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
89647061|NCT04585854|Other|Control|Control population who will undergo two cardiovascular magnetic resonance exams: one at rest and one after drinking caffeine.
89647062|NCT04562220|Experimental|Vibration Group|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
89647063|NCT04562220|Active Comparator|Control Group|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions.
89647064|NCT04471038|Experimental|Cohort 1|1 mg/mL SAB-176 in normal (0.9%) Saline; concentration 1 mg/mL (0.1%)
89647065|NCT04471038|Experimental|Cohort 2|10 mg/kgSAB-176 in normal (0.9%) Saline; concentration 4 mg/mL (0.4%)
89647066|NCT04471038|Experimental|Cohort 3|25 mg/kgSAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
89647067|NCT04471038|Experimental|Cohort 4|50 mg/kg SAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
89647068|NCT04471038|Placebo Comparator|Cohort 5|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
89647069|NCT03481842|Experimental|Vaginal Suppositories|"Daily single administration of vaginal suppository in diagnosed endometriosis. Duration of admission-five days, two days-off. The total duration of treatment is 6 weeks. General course -30 vaginal suppositories ELTA~The composition of the suppository:~Axitinib (inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit) in a minimally sufficient therapeutic dose~Afatinib (BIBW2992) EGFR / HER2 including EGFR (wt), EGFR (L858R), EGFR (L858R / T790M) and HER2 inhibitor - minimally sufficient therapeutic dose~Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose"
89647070|NCT04197739|Experimental|Fixed dose|patients will receive a fixed, single daily dose of amikacin, 500 mg, a day.
89647071|NCT04197739|Active Comparator|Adjusted body weight dose|patients will receive a weight adjusted dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram.
89647072|NCT04197505|Experimental|Acute fracture specific|The FLIR E95 camera will be used for the study. The injured extremity will be scanned with the thermal camera and a second scan will be performed on the non-injured extremity to provide an internal control for any differences in room temperature and humidity. Prior to scanning, both the injured and non-injured extremity will remain uncovered for 10 minutes, about the length of an average office visit, and the areas to be scanned will remain free from contact by the patient or interviewer during this time period. The camera will be held 2 feet away from the extremity at a 90º angle to limit reading contamination from objects other than the patient.
89647073|NCT04197349|Experimental|Part A Cohort 1-8|ALD1910/Placebo; Single Dose IV infusion on Day 1
89647074|NCT04197349|Experimental|Part B Cohort 9|ALD1910/Placebo+Sumatriptan; Single Dose IV infusion on Day 1
89647075|NCT04197349|Experimental|Part B Cohort 10|ALD1910/Placebo; Single dose subcutaneous injection on Day 1
89044762|NCT02926469|Experimental|Virtual Reality|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions while using immersive Virtual Reality.Afterwards they will answer pain and anxiety questionnaires.
89044763|NCT04680195|Experimental|Thalidomide treatment Group|"Induction period:~Thalidomide tablets: 50-100 mg/d, qn, po.~Maintenance period:~Thalidomide tablets: 50-75 mg/d qn, po."
89044764|NCT02926313|No Intervention|Existing Seating conditions|This group of participants received the standard care - they continue to sit in the seating system (chair and cushion) as provided by the nursing home facility staff; selected from whatever seats the facility had available.
89044765|NCT02926313|Experimental|Individualized Seating provision|This group of participants were provided with a seating system that was specifically configured to match their individual postural care needs.
89044766|NCT04864431|Active Comparator|Vitamin D group|Daily vitamin D3 2000 IU on day 1 through day 180 Intervention: vitamin D3 2000 IU
88992593|NCT04694989|Experimental|Sequence 1|"Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition"
89647076|NCT04429854|Experimental|Convalescent Plasma|"4 units of convalescent plasma:~2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~2 units of plasma should be administered between 24h and 36h after the first infusion"
89647077|NCT04429854|Other|Standard of Care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive. Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
89647078|NCT04197271||Patients with acutely symptomatic abdominal wall hernia|Patients presenting to emergency surgical services with acutely symptomatic abdominal wall hernia (excluding parastomal).
89647079|NCT03422094|Experimental|Cohort A: NeoVax+Nivolumab (start at time of progression)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning at time of progression"
89647080|NCT03422094|Experimental|Cohort B: NeoVax+Nivolumab (start with Cycle 2)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of each cycle beginning with Cycle 2 (start of boosting phase)"
89647081|NCT03422094|Experimental|Cohort C: NeoVax + Nivolumab (start with Cycle 1)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Nivolumab 480 mg i.v. given on Day 1 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)"
89647082|NCT03422094|Experimental|Cohort D: NeoVax+Ipilimumab+Nivolumab (start with Cycle 3)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Ipilimumab 1 mg/kg i.v. given on Days 1 and 22 of Cycle 1 (priming phase)~Nivolumab 480 mg i.v. given on Day 1 of Cycle 3 and then on Day 1 of each subsequent cycle"
88992594|NCT04694989|Experimental|Sequence 2|"Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition"
88992595|NCT00166413|Experimental|CC5013|Assess the proportion of confirmed hematologic responses (HCR, HPR) resulting from treatment with CC5013 after 3 months in patients with primary systemic amyloidosis.
88992596|NCT00516178|Placebo Comparator|Placebo|Saline (No lipid emulsion)
88992597|NCT00516178|Experimental|Fish oil emulsion|3 infusions of 0.2 g/kg omega-3 PUFA within 24 hours in cardiac surgery (continuous infusion post-PTCA)
88992598|NCT04515290|Experimental|TSG-01-H|Two tablets of TSG-01 per time.
88992599|NCT04515290|Experimental|TSG-01-L|One tablet of TSG-01 and One tablet of Placebo per time.
88992600|NCT04515290|Placebo Comparator|Control|Two tablets of Placebo per time.
88992601|NCT00516256|Experimental|CHESS System|CHESS System - Internet-based computer program for 6 months.
88992602|NCT00516256|Experimental|Cancer Information Mentor|Cancer Information Mentor - Phone calls to the patient for 6 months.
88992603|NCT00516256|Experimental|CHESS System + Cancer Information Mentor|CHESS System + Cancer Information Mentor
89647083|NCT03422094|Experimental|Cohort E: NeoVax+Ipilimumab+Nivolumab (day 1&15 each cycle)|"NeoVax given on Days 1, 8, 15, and 22 of Cycle 1 (priming phase), and then on Day 1 of each subsequent cycle (boosting phase)~Ipilimumab 1 mg/kg i.v. given every 6 weeks beginning on Day 1 of Cycle 1 (C1D1, C2D15, C4D1, C5D15, C7D1, C8D15 …)~Nivolumab 3 mg/kg i.v. given on Days 1 and 15 of each cycle (q2w) beginning on Day 1 of Cycle 1"
89647084|NCT03596593|Experimental|Experimental group|A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
88992604|NCT02950441|Experimental|Nicotinamide Riboside|1000mg (2x250mg tablets twice daily)
88992605|NCT02950441|Placebo Comparator|Placebo|Two tablets twice daily
88992606|NCT02950246|Experimental|2% alcoholic chlorhexidine group|"Skin preparation Use of 10 ml of 2% alcoholic Chlorhexidine drug for disinfection in place of povidone iodine without scrubing device Wait at least 30 secondes for drying Perineural catheterization implementation Ultrasonography use"
88992607|NCT02950246|Active Comparator|povidon iodine group|"Skin preparation Use of 10 ml of povidone iodine drug for disinfection with scrubing device Wait at least 30 seondes for drying Perineural catheterization implementation Ultrasonography use"
88992608|NCT02950324|Experimental|Prehabilitation|Patients in this (intervention) arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'.
88992609|NCT02950324|Active Comparator|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
88992610|NCT02950129|Other|measurements of gait|all subjects will undergo 6 tests to assess gait before and after SIJ; SIJ pain diagnostic tests
88992611|NCT02950168||Edoxaban|All patients treated with edoxaban with a planned or unplanned diagnostic or interventional procedure
88992612|NCT04510688||Managed Access Program (MAP) patients|Patients with RCC treated with cabozantinib under a Managed Access Program (MAP) prior to Cabometyx® marketing authorization
88992613|NCT04510688||Real World (RW) patients|Patients with RCC treated with cabozantinib as routine clinical prescription (Real World), with treatment started after Cabometyx® marketing authorization
88992614|NCT04695223|Experimental|Arsenic Trioxide|Arsenic Trioxide (0.16mg/kg,d1-5,ivgtt,28days as a duration) for injection
88992615|NCT00508807|Experimental|RTA 402|5 mg PO daily x 21 days
88992616|NCT00508846||HNPCC Patients|
88992617|NCT00508885|Experimental|1|Niacinamide starting at 250 mg twice daily titrated up to 750 mg twice daily
88992618|NCT00508885|Placebo Comparator|2|Placebo
88992619|NCT00516802|Experimental|1|DTIC + KU-0059436
88992620|NCT05861466|Active Comparator|Group A|Patients with eyes with non ischemic diffuse center involving DME will be assigned to receive IVI of ranibizumab without Anterior Chamber Paracentesis.
89212735|NCT04082195|Experimental|Fooya mobile game|An arm that receives a mobile-app-based treatment.
89647085|NCT03225378||Acute circulatory failure|Mechanically ventilated patients displaying acute circulatory failure in whom the physician decides to perform a fluid challenge (fluid loading of 500 mL of crystalloid solution) and a passive leg raising test to predict fluid responsiveness.
89647086|NCT03596515|Experimental|Received sensory integration therapy|Participants in the experimental group received 16 sessions (45 minutes each) of individualized Ayres Sensory Integration intervention.
88992621|NCT05861466|Active Comparator|Group B|Patients with eyes with non ischemic diffuse center involving DME will be assigned to receive IVI of ranibizumab with Anterior Chamber Paracentesis.
89647087|NCT03596515|No Intervention|Waitlist control group|Participants in the control group received Ayres Sensory Integration according to the usual clinical scheduling. It is after the post- assessment outcome at the same time of the experimental group.
89647088|NCT03591367|Other|Hematuria due to suspicious superficial bladder tumor|MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
89647089|NCT04356534|Active Comparator|Control group|local standard of care which include antivirals and supportive care
89647090|NCT04356534|Experimental|Intervention group|convalescent patient plasma 400ml given as 200ml over 2 hours in 2 consecutive days, plus routine local standard of care
89647091|NCT03591289|Active Comparator|Deep NMB|Deep NMB: Intervention: Rocuronium will be given as a continuous infusion for deep block. TOF will be maintained at 0 (zero) with at least one PTC. Patients' paralysis will be continued through the anesthesia period. At the end of surgery, patients will receive 4 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
89647092|NCT03591289|Active Comparator|Moderate NMB|Moderate NMB: Intervention: Rocuronium will be used as bolus doses to achieve a moderate block. TOF will be maintained between 1 to 3 twitches. PTC will not be counted. Paralysis will be continued throughout the anesthesia period. At the end of surgery, patients will receive 2 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
89647093|NCT03596437|Experimental|Ehlers-Danlos Syndrome|Intima-media thickness by ultrahigh frequency vs standard ultrasound
89647094|NCT03596437|Experimental|Fibromuscular Dysplasia|Triple signal by ultrahigh frequency vs standard ultrasound
89647095|NCT03023917|Active Comparator|umbilical cord clamping immediately|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
89647096|NCT03023917|Experimental|umbilical cord milking|preterm baby were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
89647097|NCT03591211|Experimental|Qigong Training|
89647098|NCT03591211|Active Comparator|Cognitive Training|
89647099|NCT03596359|Experimental|Test group|Self-care behaviors training with Teach-Back method within 15 to 45 minutes was done on the Test group
89647100|NCT03596359|Active Comparator|Control group|The control group received routine treatment
89647101|NCT02696382|Active Comparator|Usual Care (UC)|"Participants in the Usual Care (UC) group will receive standard, low-intensity physical therapy following discharge from acute hospitalization."
88992622|NCT05861414|Experimental|Experimental group|21 days of emotional working memory training
88992623|NCT05861414|No Intervention|control group|
88992624|NCT05861401|Active Comparator|control|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
88992625|NCT05861401|Active Comparator|cases|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
88992626|NCT05861388|Active Comparator|cobalt chrome implant framework|the participants received Co-Cr based screw-retained implant supported prosthesis at one side of the lower jaw
88992627|NCT05861388|Experimental|Bio-Hpp implant framework|The participants received Bio-Hpp based screw-retained implant-supported prosthesis at the other side
88992628|NCT05861362|Experimental|FAST|5:2 intermittent fasting group
88992629|NCT05861310|Experimental|Metronidazole 1% Group|Metronidazole 1% cream is applied to the entire face twice a day. Giving cream in the morning and at night. Evaluation will be carried out on days 28 and 56.
88992630|NCT05861310|Experimental|Placebo Group|Placebo cream (without the drug substance) is applied to the entire face twice a day. Giving cream in the morning and at night. Evaluation will be carried out on days 28 and 56.
88992631|NCT05861297|Active Comparator|Control group|The first (control )group includes patients with confirmed diagnosed who received IV pulse (High Dose-Dexamethasone) therapy
88992632|NCT05861297|Experimental|PSL - AZA group|The second group includes patients with confirmed diagnosed who received Prednisolone -Azathioprine therapy
89647102|NCT02696382|Experimental|Progressive High Intensity Therapy|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization."
89647103|NCT03023761|Active Comparator|low level laser|A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group
89647104|NCT03023761|Placebo Comparator|laser sham|In the control group patients received placebo laser to eliminate the probable psychological effects of laser.
89647105|NCT02471118|Experimental|1st 50 subjects to Enter the Study|"At Baseline, subjects will be randomized (1:1) to receive study drug (Adalimumab or placebo). The study drug will be provided as a subcutaneous injection (pre-filled syringe) either Adalimumab (ADA) 40 mg/0.8 mL,every other week (EOW) or matching placebo for Adalimumab every other week for 16 weeks. Efficacy will be assessed at Week 16 while the safety of the study drug will be monitored throughout the study.~At Week 16 all subjects will begin to receive open label ADA 40 mg EOW and will continue to receive open label ADA up to Week 50. An End of Study visit will be done at Week 52. A Telephone Follow-up will be done at Week 62 to review Adverse Events and Concomitant Medications."
89212736|NCT04082195|Active Comparator|Uno board game|An arm that receives a non mobile-app-based treatment.
89212737|NCT04807595||Retrospective cohort|Patients with confirmed diagnosis of HER2-neg, unresectable and/or mBC regardless of hormone status dating back from 31 December 2017 - but no older than 01 January 2015 - who progressed on any systematic anti-cancer therapy will be involved in this study.
89212738|NCT02587091|No Intervention|Control Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. There was no advertisement of portable ultrasound.
89647106|NCT02471118|Experimental|2nd group of 50 subjects|At Baseline, subjects will be randomized (1:1) to receive either adalimumab 40 mg every other week or placebo for 16 weeks. All subjects will begin to receive open label adalimumab 40 mg every other week from week 16-week 30, with An End of Study visit at Week 32. A Telephone Follow-up will be done at Week 42 to review Adverse Events and Concomitant Medications.
89647107|NCT03590977|Experimental|licorice extract mouthwash|administration of a mouthwash containing licorice as a preventive measure to high caries risk patients (faculty of pharmacy, cairo university)
89647108|NCT03590977|Placebo Comparator|chlorohexidine mouthwash|administration of chlorohexidine 0.2% in 1:1 diluation mouthwash that is broad spectrum antimicrobial activity to high caries risk patients
89647109|NCT04197115|No Intervention|Phase 1|Septic patients admited to ICU whick will be treated as specified in current guidelines.
89647110|NCT04197115|Active Comparator|Phase 2|"Septic patients admitted to ICU which will be treated as specified in current guidelines adding:~Vitamin C Hydrocortisone B complex (Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg)"
89647111|NCT02579850|Experimental|CHF 5993 + Ultibro matched placebo|"Fixed triple therapy with BDP/FF/GB 100/6/12.5 mcg (CHF 5993) administered 2 puffs twice daily via pMDI + Fixed combination of indacaterol and of glycopyrronium (Ultibro® Breezhaler®) matched placebo administered once daily via DPI for 52-week treatment.~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments Saint George's Respiratory Questionnaire EXACT-pro questionnaire"
89647112|NCT02579850|Active Comparator|Ultibro + CHF 5993 matched placebo|"Fixed combination of indacaterol 85 mcg and of glycopyrronium 43 mcg (Ultibro® Breezhaler®) administered once daily via DPI + Fixed triple therapy with BDP/FF/GB (CHF 5993) matched placebo administered 2 puffs twice daily via pMDI for 52-week treatment.~Patient used to take pMDI medication using a spacer will be provided with a new spacer for the study.~7 study visits including : central spirometry tests, Local laboratory, COPD assessment test (visit 1 only), Local laboratory Assessments, Saint George's Respiratory Questionnaire, EXACT-pro questionnaire"
89647113|NCT04196881|Experimental|Training|group will receive training about ADHD
89647114|NCT04196881|No Intervention|Control|group will not receive training about ADHD
89647115|NCT03590665|Other|Individuals with Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
89647116|NCT03590665|Other|Individuals without Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
89647117|NCT04196725|Experimental|Physical therapy treatment|
89647118|NCT04196725|Experimental|Lifestyle treatment|
89647119|NCT04196725|No Intervention|Control|Parallel control group, not undertaking any treatment and not part of the cross-over design
88992633|NCT05861297|Experimental|The RTX group|The third group includes patients with confirmed diagnosed who received Prednisolone -Azathioprine therapy
89212739|NCT02587091|Experimental|Intervention Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. In addition, it was advertised that portable ultrasound would be provided free of charge in addition to standard comprehensive antenatal care.
89212740|NCT00491764|Experimental|Posaconazole 100 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
89212741|NCT00491764|Experimental|Posaconazole 200 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
89212742|NCT00491764|Experimental|Posaconazole 400 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
89212743|NCT00491764|Experimental|Posaconazole 400 mg QD for 12 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
89212744|NCT00491764|Active Comparator|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
89212745|NCT00491764|Placebo Comparator|Placebo|Placebo for 24 weeks.
89647120|NCT03024151|Active Comparator|T4/T3 combination replacement|Comthyroid
89647121|NCT03024151|Active Comparator|T4 mono replacement|Synthroid
89647122|NCT01118676|Experimental|Cilengitide with standard radiochemotherapy|Cilengitide (4 dose levels are defined :12, 18, 27 et 40 mg /hour) concomitant with radiotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction) and cisplatin and vinorelbine based chemotherapy.
89647123|NCT03595969||acute leukemia group|150 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
89647124|NCT03595969||Control group|The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
89647125|NCT02467452|Experimental|BDP/FF/GB|Drug: BDP/FF/GB Other name: CHF 5993 pMDI 100/6/12 mcg
89647126|NCT02467452|Active Comparator|FlF/VI + Tiotropium|FlF/VI + Tiotropium Other name: Relvar DPI 100/25 mcg + Spiriva 18 mcg capsule
89647127|NCT03590587||1|patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
89647128|NCT05375526|Experimental|Primary staging laparotomy for suspicion of early stage EOC|In case of a primary staging laparotomy the diagnosis of malignancy is based on a frozen section of the resected adnexa, followed by the sentinel node technique during the same procedure.
89647129|NCT05375526|Experimental|Secondary staging laparotomy for EOC|On the other hand, in some cases early stage EOC is only diagnosed after the primary surgery, when the surgeon resects the ovary with the suspicion of benign disease. If the adnexa are already removed before the diagnosis of malignancy, a secondary staging laparotomy is required and, in this case, a single step approach for SLN is not feasible.
89647130|NCT05375448|Experimental|Intervention|"Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient."
89647131|NCT03945565|Active Comparator|FiO2 0.3|Patients allocated to this group are going to receiving FiO2 of 0.3 during surgery
89647132|NCT03945565|Active Comparator|FiO2 0.8|Patients allocated to this group are going to receiving FiO2 of 0.8 during surgery
89647133|NCT03590431|Other|bioavailability iodine milk (extrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine in milk, low protein-bound fraction)
89044767|NCT04864431|Placebo Comparator|Control group|Daily placebo (saccharum lactis) on day 1 through day 180 Intervention: placebo
89044768|NCT02926118|Experimental|Low glycemic load|Low glycemic load
89044769|NCT02926118|Experimental|High glycemic load|High glycemic load
89044770|NCT00553995|Experimental|Salsalate|Salsalate
89044771|NCT00553995|Placebo Comparator|Placebo|Placebo
89044772|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1|Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
89647134|NCT03590431|Other|bioavailability iodine milk (intrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine in milk, high protein-bound fraction)
89647135|NCT03590431|Other|bioavailability water iodine solution|300 ml water iodine solution delivering ≈ 200 µg iodine (water iodine solution)
89647136|NCT05102604|Active Comparator|Avocado|one avocado per day
89647137|NCT05102604|Placebo Comparator|Habitual Diet|maintain habitual diet
89044773|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2|Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
89647138|NCT03980665|Experimental|Arsenic trioxide combined with cART|Receiving intravenous arsenic trioxide, 0.16mg/kg/day, no more than 10 mg per-day , two to four weeks, combined with continuous cART after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
89647139|NCT03980665|No Intervention|Without arsenic trioxide therapy|Only receiving cART without arsenic Trioxide after attaining plasma HIV-1 suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
89647140|NCT05102526|Experimental|"Young Millie prevention program, active teachers"|"The Young Mili program will be delivered to teens ages 10-12, over 3 months. The program contains nine 90-minute weekly sessions focusing on media literacy, self-esteem, self-esteem and physical self-esteem. Teachers will also participate by delivering planned activities to their students in addition to each week's theme, in parallel with an externally delivered program. All participants will complete a self-report questionnaire at the beginning of the study, after the end of the program and three months after the end of the program."
89647141|NCT05102526|Active Comparator|"Young Mili prevention program, passive teachers"|"The Young Mili program will be delivered to teens ages 10-12, over 3 months. The program contains nine 90-minute weekly sessions focusing on media literacy, self-esteem, self-esteem and body image. Teachers will not participate in the program, they will be present in class only during the program on transfer abroad. All participants will complete a self-report questionnaire at the beginning of the study, after the end of the program and three months after the end of the program."
89647142|NCT04438122|Active Comparator|Red Wine group|Participants of this group consumed 200ml of red wine along with a meal (lunch or dinner) every day for 8 weeks.
89044774|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
89044775|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
89044776|NCT02926430|Experimental|Placebo (Day 1 and Day 365): Group 5|Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).
89044777|NCT04798287||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
89044778|NCT04798287||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
89044779|NCT02926157|Experimental|Life Style and Sleep Group|Participants randomized into this group will undergo a 4 week sleep hygiene course (classes 1x/week for 1.5 hours), followed by a 20 week lifestyle activation program. During the 20 week lifestyle activation program, participants wear a Fit Bit and receive a call from a fitness professional every other week for motivation and recommendations, and receive a bright light therapy program from a sleep expert based on their initial sleep results at the baseline measurement session.
89044780|NCT02926157|No Intervention|Wait-list Control|Participants randomized into this group will complete all measurement sessions. After completion of the final measurement session (6 months), participants will be offered an abbreviated version of the Life Style and Sleep Group intervention including the sleep hygiene course, consultation with sleep expert to go over individual sleep patterns and be given recommendations, along with physical activity recommendations from a fitness expert.
89647143|NCT04438122|Active Comparator|Ethanol group|Participants of this group consumed 69mL of tsipouro along with a meal (lunch or dinner) every day for 8 weeks.
88992634|NCT05861297|Experimental|The ELTRO group|The fourth group includes patients with confirmed diagnosed who received E therapy
89647144|NCT04438122|No Intervention|Control group|Participants of this group consumed no alcohol along with a meal (lunch or dinner) every day for 8 weeks
89647145|NCT03595813|Experimental|Patients treated with Immune Checkpoint Blockade|
89647146|NCT03595735|Experimental|Treatment Group|Receives treatment with the Zenflow Spring System
89647147|NCT05102448|Experimental|Tofacitinib|Partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
89647148|NCT05102448|Active Comparator|Methotrexate|Participates would be given tablets of methotrexate (2.5mg per tablet) 15mg each week, the treatment duration will last 12 months during the whole follow-up period.
89647149|NCT03855696|Experimental|MG1113|"Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody~Each vial contains 1mL of study drug~The doses planned in healthy subjects are 0.5 mg/kg, 1.7 mg/kg, and 3.3 mg/kg by SC injection; 3.3 mg/kg by IV injection. In hemophilia patients, 1.7 mg/kg and 3.3 mg/kg will be administered by SC injection."
89647150|NCT03855696|Placebo Comparator|Placebo of MG1113|"Placebo of MG1113~Each vial contains 1mL of study drug"
88992635|NCT05861297|Experimental|The ROMP group|The fifth group includes patients with confirmed diagnosed who received Romiplostim therapy
88992636|NCT05861219|Experimental|chronic kidney disease patients stage 3 and 4|50 chronic kidney disease patients stage 3 and 4 will perform mild exercise and water immersion
88992637|NCT05861206|Active Comparator|GT-MW group (5% Green tea), WT-MW group (5% White tea), EO-MW group (Listerine mouthrinse)|"Chronic gingivitis patients whose mechanical plaque control was supported with 5% Green tea. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks.~Chronic gingivitis patients whose mechanical plaque control was supported with 5% White tea. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks.~Chronic gingivitis patients whose mechanical plaque control was supported with Listerine mouthrinse. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks."
88992638|NCT05861206|Active Comparator|CHX-MW group (0.12% CHX, as a positive control group)|Chronic gingivitis patients whose mechanical plaque control was supported with 0.12% CHX. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks.
88992639|NCT05861193|Experimental|Cases|Patients belonging to the intervention group presented abfraction lesions in upper and/or lower premolars. These abfraction lesions consist of a loss of dental hard tissue at the cervical level of more than 1 mm, and are associated with type 1 gingival recession of the Cairo classification.
88992640|NCT05861180||normal group|no text neck
88992641|NCT05861180||mild text neck|
88992642|NCT05861180||moderate text neck|
89647151|NCT04196179|Experimental|SAD|"A1 Day 1 ANG-3070 50 mg (n=6) / Placebo (n=2) Oral~A2 Day 1 ANG-3070 100 mg (n=6) / Placebo (n=2) Oral~A3 Day 1 ANG-3070 200 mg (n=6) / Placebo (n=2) Oral~Day 15 ANG-3070 200mg (n=6) / Placebo (n=2) Oral~A4 Day 1 ANG-3070 400 mg (n=6) / Placebo (n=2) Oral~A5 Day 1 ANG-3070 600 mg (n=6) / Placebo (n=2) Oral~D1 Single Dose Food Effect: Day 1 ANG 3070 600 mg *with and without food* (n=6)/ Placebo (n=2) Oral"
89647152|NCT04196179|Experimental|MAD|"B1 ANG-3070 50 mg BID (n=6) / Placebo (n=2)~B2 ANG-3070 100 mg BID (n=6) / Placebo (n=2)~B3 ANG-3070 250 mg BID (n=6) / Placebo (n=2)~B4 ANG-3070 500 mg, BID (n=6)/ Placebo (n=2)~C1 ANG-3070 400 mg, QD(n=6)/ Placebo (n=2)~C2 ANG-3070 600 mg, QD (n=6)/ Placebo (n=2)"
89647153|NCT05098158|Experimental|Single arm pain treatment|Arm includes usual pain care plus the chosen two telehealth interventions x 6 weeks
89647154|NCT04195711||blinq screened|Patients screened by new birefringent screener
89647155|NCT03599323||Clotrimazole 1% (Empecid L Cream, BAYB5097)|Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.
88992643|NCT05861180||severe text neck|
88992644|NCT05861154|Experimental|Photobiomodulation|
88992645|NCT05861154|Active Comparator|Topical anesthesia|
88992646|NCT05861063|Placebo Comparator|control group|The patients were divided into 3 groups based on different dosages of Dezocine injection, with 35 patients in each group: Group 1: Dezocine low-dose group, Group 2: Dezocine high-dose group; Group 3: Blank control group (normal saline).
88992647|NCT05861063|Experimental|Dezocine low dose group|The patients were divided into 3 groups based on different dosages of Dezocine injection, with 35 patients in each group: Group 1: Dezocine low-dose group, Group 2: Dezocine high-dose group; Group 3: Blank control group (normal saline).
88992648|NCT05861063|Experimental|Dezocine high dose group|The patients were divided into 3 groups based on different dosages of Dezocine injection, with 35 patients in each group: Group 1: Dezocine low-dose group, Group 2: Dezocine high-dose group; Group 3: Blank control group (normal saline).
88992649|NCT05860946|Experimental|RIC group|Patients in RIC group and control group will achieve RIC intervention and sham RIC intervention three times daily from 5 days before operation and 7 days post operation
88992650|NCT05860946|Sham Comparator|Control group|Patients in control group, bilateral upper arm cuffs were inflated to a pressure of 60 mm Hg for 5 minutes, followed by 5 minutes of relaxation of the cuffs
88992651|NCT05860907|Experimental|Huaier Granule+Standard treatment|The subject is administered according to the clinical dosage and method of medication until disease progression occurs or the subject is unable to tolerate treatment.Subjects receiving routine diagnosis and treatment simultaneously.
88992652|NCT05860907|No Intervention|Standard treatment|Subjects receive routine diagnosis and treatment without taking Huaier granules.
88992653|NCT05860868|Experimental|2 cycles|2 cycles induction + concurrent chemoradiotherapy
89647156|NCT01602744|No Intervention|Controll|The medications in this arm will not be screened.
89647157|NCT01602744|Active Comparator|Intervention screening medication group|STOPP/START screening tools are used for medication intervention
89647158|NCT04195867|Experimental|Salmeterol|Subjects receive a 3-day treatment and collect urine from 2 days before first administration to 24 hours post-administration.
89647159|NCT05102058||Conventional group (GC)|Not receive perioperative additional medication.
89647160|NCT05102058||Magnesium-dexmedetomidine therapy group (GMD)|Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively.
89647161|NCT04195165|Experimental|SIT|Subject will be asked to take <3,000 steps for two intervention days prior to an oral glucose tolerance test on the third day.
89647162|NCT04195165|Experimental|SIT+EX|Subject will be asked to take <3,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
89044781|NCT04798209|Experimental|Part A (single ascending dose) Dose A1|Single dose A1 of ACT-777991.
89044782|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A2|Single dose A2 of ACT-777991.
89044783|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A3|Single dose A3 of ACT-777991.
89044784|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A4|Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.
89044785|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A5|Single dose A5 of ACT-777991.
89044786|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A6|Single dose A6 of ACT-777991.
89044787|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A7|Single dose A7 of ACT-777991.
89044788|NCT04798209|Experimental|Part A (single ascending dose arm) Dose A8|Single dose A8 of ACT-777991.
89044789|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B1|Multiple doses B1 of ACT-777991.
89044790|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B2|Multiple doses B2 of ACT-777991.
89044791|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B3|Multiple doses B3 of ACT-777991.
89044792|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B4|Multiple doses B4 of ACT-777991.
89647163|NCT04195165|Experimental|ACTIVE+EX|Subject will be asked to take >10,000 steps for two intervention days. On the evening of the second intervention day, the subject will cycle for one hour at 65% of VO2peak. The subject will undergo an oral glucose tolerance test on the morning of the third day.
89647164|NCT05097690||Case|Case (Fatal Suicide)
89647165|NCT05097690||Control|Control (Non-Fatal Suicidal Behavior)
89647166|NCT03956797|Experimental|-15 degrees Celsius for 10 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 10 seconds.
89647167|NCT03956797|Experimental|-15 degrees Celsius for 15 seconds|Cooling anesthesia device applied to the eye at -15 degrees Celsius for 15 seconds.
89647168|NCT05327166|No Intervention|Usual Care|Participants assigned to this arm will receive usual care.
89647169|NCT05327166|Experimental|ED-LINC Intervention|Patients assigned to the ED-LINC intervention will receive 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
89647170|NCT05101512|Experimental|Patient with critical ischemia of the lower limb|Patient eligible and scheduled for bypass in venous allograft stored at + 4 ° C with distal anastomosis below the knee
89647171|NCT03598777|Experimental|Dysport - Dose Escalation stage 1|Intramuscular injection of Dysport on day 1 of each cycle.
89647172|NCT03598777|Placebo Comparator|Placebo - Dose Escalation stage 1 and Dose Expansion stage 2|Intramuscular injection on day 1 of cycle 1.
89647173|NCT03598777|Active Comparator|Dysport - Dose Expansion stage 2|Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.
89647174|NCT04192123|Experimental|Experimental|"All patients will receive an occlusive patch per test treatment as follows:~Treatment 1: HM242-Solution~Treatment 2: HM242-Gel~Treatment 3: HM242-Solution and HM242-Gel~Treatment 4: Irritant control (sodium lauryl sulfate (SLS))~Treatment 5: Negative control"
89647175|NCT04195243|Experimental|Dapagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Dapagliflozin capsules, 10 mg 1 time daily 5 minutes before the first meal"
89647176|NCT04195243|Experimental|Empagliflozin|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Empagliflozin capsules, 25 mg 1 time daily 5 minutes before the first meal"
89647177|NCT04195243|Placebo Comparator|Placebo|"Individuals with T2DM controlled with metformin; with no hypertension neither treated with insulin.~Dapagliflozin capsules, 400 mg 1 time daily 5 minutes before the first meal"
89044793|NCT04798209|Experimental|Part B (multiple ascending dose) Dose B5|Multiple doses B5 of ACT-777991.
89044794|NCT04798209|Experimental|Part A (single ascending dose) Absolute Bioavailability|Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.
89044795|NCT04798209|Experimental|Part B (multiple ascending dose) ADME|Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.
89044796|NCT02926274||Whole Blood|Adult male trauma patients presenting with systolic blood pressure <100 will receive up to 6 units of whole blood when available.
89044797|NCT02926274||Component therapy|Adult female patients presenting with systolic blood pressure <100, as well as adult male patients with systolic blood pressure <100 during periods when whole blood is not available, will receive component therapy (1:1:1 packed red blood cells: plasma:platelets) for transfusion.
89044798|NCT04784013|Active Comparator|Conventional group|
89044799|NCT04784013|Active Comparator|90W-group|
89044800|NCT04783350|Experimental|Transcranial alternating current stimulation (tACS)|Participants (Ps) will undergo 20min of daily home-based tACS intervention at 40Hz over the left angular gyrus for 4 weeks by trained administrators (As) (phase 1). In case of cognitive and mental improvement participants will undergo further 10 weeks of 20 minutes session of tACS daily (phase 2). Additionally, those P/A pairs who completed the 14 weeks of home-based tACS intervention and express an interest in an open label extension may be enrolled in further 34 weeks of 20 minutes tACS sessions.
89647178|NCT04195321|Active Comparator|norepinephrine group|patients will receive NE infusion at a starting of rate of 1 ml/min of 8 mcg/ml solution (prepared by diluting 4 mg NE in 500 ml normal)
89647179|NCT04195321|Active Comparator|phenylephrine|patients will receive PE infusion at a starting rate of 1 ml/min of 100 mcg/ml solution (prepared by diluting 10 mg of PE in 100 ml normal saline)
88992654|NCT05860868|Active Comparator|3 cycles|3 cycles induction + concurrent chemoradiotherapy
89647180|NCT04195087||Non-hypotension|Patients with a mean arterial pressure reduction of less than 20% and/or systolic arterial pressure above 80 mmHg after spinal anesthesia.
89647181|NCT04195087||Hypotension|Patients with a 20% reduction in mean arterial pressure and/or systolic arterial pressure below 80 mmHg after spinal anesthesia.
89647182|NCT04194931|Experimental|Mixed BCMA/CD19 CAR-T Transfer|Subjects with BCMA/CD19+ multiple myeloma will be infused with CD19-targeting CAR T Cells and BCMA-targeting CAR T Cells in one time or in parts
89647183|NCT04023643|Experimental|CPAP + PS|Weaning from mechanical ventilation using CPAP + PS
89647184|NCT04023643|Active Comparator|SIMV + PS|Weaning from mechanical ventilation using SIMV+PS
89647185|NCT06012682|Experimental|metformin|patients randomized to received metformin
89647186|NCT06012682|Placebo Comparator|placebo|patients randomized to received placebo
89647187|NCT06012682|No Intervention|group without intervention|
89647188|NCT06012630||group 1: RA without CTS|Rheumatoid arthritis patients without a diagnosis of CTS based on clinical findings and physical examination
89647189|NCT06012630||group 2: RA with CTS|Rheumatoid arthritis patients with a diagnosis of CTS based on clinical findings and physical examination
89647190|NCT06012630||group:3 Healthy Control|Healthy Control without rheumatologic disease and Carpal tunnel syndrome
89647191|NCT06012617||UCP group|children with hemiplegia due to stroke
89647192|NCT06012604|Experimental|allogeneic mesenchymal stromal stem cells|Application of allogeneic mesenchymal stromal stem cells (MSC, derived from umbilical cord tissue) under ultrasound guidance into both parotid and submandibular glands.
89647193|NCT06012565|Experimental|KAND567|
89647194|NCT06012565|Placebo Comparator|Placebo|
89647195|NCT06012552|Experimental|Stady group|The study group will receive oral tianeptine in a dose of 3x 12.5 mg per day (patients younger than 70) or 2x 12.5 mg per day (patients older than 70) for 16 weeks. In addition, the subjects will participate in group psychotherapy and neurological rehabilitation.
89647196|NCT06012552|Placebo Comparator|Control group|The control group will receive oral placebo in a dose of 3x 12.5 mg per day (patients younger than 70) or 2x 12.5 mg per day (patients older than 70) for 16 weeks. In addition, the subjects will participate in group psychotherapy and neurological rehabilitation.
89647197|NCT06012526||OSA group|The group of patients who had sleep disordered breathing
89647198|NCT06012526||No OSA group|The group of patients who had not sleep disordered breathing
89647199|NCT06012500||Control|Healthy Controls
89647200|NCT06012500||ILD|Participants with diagnosed ILD
89647201|NCT06012474|Experimental|inspiratory muscle training group|30 patients will receive inspiratory muscle training by Power breath device once daily for 7 days.
89647202|NCT06012474|Active Comparator|diaphragmatic breathing exercise group|20 patients will receive program of diaphragmatic breathing exercise by incentive spirometer once daily for 7 days.
89647203|NCT06012448|Experimental|Dupilumab|All patients will receive dupilumab.
89647204|NCT06012422|Other|Individuals aged 65 and over who were screened for sarcopenia|Persons aged 65 and over will be evaluated only once and the assessment will be made through a face-to-face interview.
89647205|NCT06012396|Experimental|Exercise group|
89647206|NCT06012396|No Intervention|Daily life group|
89647207|NCT06012383||NanoAlvand Bortezomib|1.3 mg/m2 Bortezomib, IV infusion
89647208|NCT06012370|Other|Stress incontinence patients|PRP injection
89647209|NCT06012344|Experimental|Group A|20 participant randomly allocated they were administered in first phase with post facilitation stretch , 3rd phase with post isometric relaxation and then in 5th phase hamstring Nordic lower
89647210|NCT06012344|Experimental|Group B|20 participant randomly allocated they were administered in first phase with post isometric relaxation 3rd phase with hamstring Nordic lower and then in 5th phase post facilitation stretch
89647211|NCT06012344|Experimental|Group C|20 participant randomly allocated they were administered in first phase hamstring Nordic lower 3rd phase with post facilitation stretch and then in 5th phase post isometric relaxation
89647212|NCT06012318||Monoimmunotherapy group|
89647213|NCT06012318||Chemoimmunotherapy group|
89647214|NCT06012292||Group A Not addicted to mobile phone|Addicted to mobile phone less than four hours per day.
89647215|NCT06012292||Group B addicted to mobile phone|Addicted to mobile phone more than four hours per day.
89647216|NCT06012214|Experimental|Robot-assisted minimally invasive esophagectomy|Participants will received neoadjuvant therapy followed by robot-assisted minimally invasive esophagectomy within 8 weeks.
89647217|NCT06012214|Placebo Comparator|Thoraco-laparoscopic minimally invasive esophagectomy|Participants will received neoadjuvant therapy followed by thoraco-laparoscopic minimally invasive esophagectomy within 8 weeks.
89647218|NCT06012201||low normal protein intake|the patient in this group will intake enteral protein feeding from 0.8- 1.5 gm /kg/day
89647219|NCT06012201||high normal protein intake|the patient in this group will intake enteral protein feeding from 1.6 - 2.2 gm /kg/day
89647220|NCT06012188|Experimental|Experimental group|Children in the experimental group will be given a sleeping companion toy.
89647221|NCT06012188|No Intervention|Control group|No intervention will be made on the control group.
89647222|NCT06012097|Active Comparator|active comparator|Diclofenac gel Splint of the thumb and wrist
89647223|NCT06012097|Experimental|Experimental Group|Aromatherapy Gel Splint of the thumb and wrist
89647224|NCT06012045|Experimental|Enhanced Cue Exposure Therapy|This is the experimental arm. Participants will receive the 6-session enhanced cue exposure therapy.
89647225|NCT06012045|Active Comparator|Behavioral Lifestyle Intervention|This is the active control arm. Participants will receive the 6-session behavioral lifestyle intervention.
89647226|NCT06012006|Experimental|pulmonary rehabilitation|COPD patients will be admitted for pulmonary rehabilitation, the duration and modalities of which vary from center to center.
89647227|NCT06011980|Experimental|Group A|Participants in this group will take growth inhibitors for 5 days after endoscopic treatment.
89647228|NCT06011980|No Intervention|Group B|Participants in this group will not take growth inhibitor treatment after endoscopic treatment.
89647229|NCT06011967|Active Comparator|Group A : 90 degree|In this group patients were intubated using a 90 degree angled stylet with C-MAC D- Blade videolaryngoscope
89647230|NCT06011967|Active Comparator|Group B : 80 degree|In this group patients were intubated using a 80 degree angled stylet with C-MAC D- Blade videolaryngoscope
89647231|NCT06011967|Active Comparator|Group C: 60 degree|In this group patients were intubated using a 60 degree angled stylet with C-MAC D- Blade videolaryngoscope
89647232|NCT06011941|Experimental|modified laparoscopic transcystic biliary drainage|A 7-Fr triple-lumen 30-cm central venous catheter was adopted to replace conventional 5-Fr ureteral catheter. Then we developed a continued suture and circling manner by the V-Loc closure device, which simultaneously covered and anchored the C-tube. Furthermore, the catheter was introduced through the abdominal wall located at 3 cm below the costal margin on the midaxillary line/the posterior axillary line, which was traditionally performed at the point below the midclavicular line on the right side.
89647233|NCT06011837|Experimental|Altered Auditory Feedback|Participants in this arm will use the Mumble Melody application over the course of 1 month
89647234|NCT06011811||Patients with episodic or chronic cluster headache|Patients with a diagnosis of episodic or chronic cluster headache, as diagnosed by a health care professional and to be confirmed by questions on the study survey.
89647235|NCT06011759|Experimental|Intervention|A multi-faceted implementation intervention including qualitative interviews and feedback and optional delivery of Academic Detailing and/or LEAP.
89647236|NCT06011759|Experimental|Control|Control sites will be selected to match intervention sites on baseline referral rates.
89647237|NCT06011720||Stroke Patients July 1st 2015 - June 30th 2017|Stroke patients that have undergone hospitalization within the time frame July 1st 2015 - June 30th 2017 to be used as a baseline.
89647238|NCT06011720||Stroke Patients January 1st 2018 - December 31st 2019|Stroke patients that have undergone hospitalization and undergone improvements to transition of care within the time frame January 1st 2018 - December 31st 2019.
89647239|NCT06011707|Experimental|OPT-IN intervention|
89647240|NCT06011707|Active Comparator|Psychoeducational control|
89647241|NCT06011694||No Intervention|Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
89647242|NCT06011668|Experimental|distraction method|video game playing
89647243|NCT06011668|Experimental|distraction|kaleidoscope
89647244|NCT06011668|Experimental|distraction methods|virtual reality glasses
89647245|NCT06011642||Clinical sample|Participants will be recruited from families in Bochum who receive treatment or wait for the treatment to begin at the Forschungs- und Behandlungszentrum (FBZ; outpatient treatment center).
89647246|NCT06011642||Nonclinical sample|Participants will be recruited from families in Bochum who take part in experiments and studies at the Department of Clinical Child and Adolescent Psychology at the Ruhr-University. The Department of Clinical Child and Adolescent Psychology maintains a database of families interested in participating in research.
89647247|NCT06011590||Study Cohort|All patients treated at the Department of Internal Medicine at the Medical University of Innsbruck between 01.01.2000 and 31.07.2022, in whom a 10 second 12-lead ECG is available from clinical routine.
89647248|NCT06011564|Experimental|Intervention|Reminder function
89647249|NCT06011564|No Intervention|control|No reminder
89647250|NCT06011538|Experimental|On-line SDD LH website resource (intervention)|Patients allocated the experimental arm will be provided with the link to the SDD LH patient information website (https://www.mydaycasehysterectomy.com).The option of this educational material will be in addition to the standard verbal and written patient information provided by the BWCH.
89647251|NCT06011538|Active Comparator|Standard practice for information provision (control)|Patients allocated the control group will receive standard BWCH information only.
88992655|NCT05860855|Active Comparator|Decompressive hemicraniectomy|The procedure of hemicraniectomy is performed in the same way as the augmentative craniotomy from skin incision to dural augmentation. Then, the myo-cutaneous flaps are reapproximated and sealed and the operculum is secured. Then, cranioplasty with autologous bone will be performed within 6-months after the hemicraniectomy.
88992656|NCT05860855|Experimental|Augmentative craniotomy|"Surgical incision according to Kempe is performed to obtain a better vascularization of the myo-cutaneous flap, to guarantee a larger surgical exposition and to facilitate the closure. The incision starts from widow's peak and arrives 1 cm upon the inion and it is performed parallel to the midline, 3 cm from it. Then a second incision is performed from the center of the first one and it will be extended inferiorly to the tragus. Burr holes will be performed in the frontal-basal region (keyhole), temporal region and superior and medial to the inion. Supplementary burr holes can be performed. Then, a large frontal-temporal-parietal-occipital craniotomy not smaller than 12x15 cm is performed. Then dural augmentation is performed with the positioning of a dural patch. The operculum is repositioned through the application of 5 titanium clamps secured with screws 1 cm above the margin of the craniotomy. The myo-cutaneous flaps are reapproximated and sealed."
88992657|NCT05860816||Primary Care Physiotherapists working in the Spanish public health system|A sample of primary care physiotherapists fill out a survey on their knowledge of chronic pain management and the approach they use to treat patients with chronic pain.
88992658|NCT05860777|No Intervention|Control|This is the control group who receive standard of care
88992659|NCT05860777|Experimental|Intervention|This is the group in units who are identified via AI model and in which interpreter services are actively reaching out to clinicians
88992660|NCT05860764||vascular amputees and healthcare professionals|participants who have undergone an amputation due to peripheral arterial disease and healthcare professionals who treat these participants
88992661|NCT05860751|Experimental|Exercise and dry needling|Subjects will complete a 5 day a week exercise program and 1 session per week standard of care dry needling for 4 weeks.
89044801|NCT02925767|Experimental|The 311-nm Ti:Sapphire laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
89044802|NCT02925767|Active Comparator|The 308-nm excimer laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
89044803|NCT04764708|Active Comparator|Control Group|Cognitive behavioral therapy plus standard psychopharmacological treatment.
89044804|NCT04764708|Experimental|Experimental Group|A Third Wave Cognitive Therapy that integrates Compassion Focused Therapy and Metacognitively Oriented Psychotherapy.
89044805|NCT02925962|Experimental|Clinical Decision Support System (CDSS)|"PCPs get a notice the CKD Clinical Decision Support System (CDSS) is available.~CDSS overview:~The study MDs order CKD triple marker tests~Patients will go to the lab as per usual clinical care~Lab results are returned to PCPs clinical results folder as per usual clinical workflow with information about CKD and link to KDIGO guidelines~Results will also be sent to the Study MD's for monitoring~At the patient's next visit, if the labs are completed, the full CDSS launches for the PCP~If the labs are not completed by the next visit, a Best Practice Alert (BPA) will launch for the PCP notifying them that the labs have been ordered, but the patient hasn't done them yet"
89044806|NCT02925962|Experimental|Clinic Decision Sup System + Pharmacist|"The Clinical Decision Support System + Pharmacist follow-up call extends beyond the CDSS alone.~CDSS Plus overview:~At the visit in which the CDSS launches, the PCP will hand a study card with pharmacist information to their patient notifying them that a pharmacist will be calling to follow-up after the visit~The pharmacist will use MyChart and/or phone calls to schedule a follow-up call within two weeks of the visit~On the follow-up phone call, the pharmacist will discuss understanding of CKD, medication review and adherence assessment, home BP checks, and the importance of NSAID avoidance~A second follow-up call will only be scheduled if the patient is non-adherent with their medications and makes an active plan for adherence with the pharmacist, or if the patient requests an additional call from the pharmacist"
89044807|NCT02925962|No Intervention|Usual Care|Patients continue to receive usual care by their provider.
89044808|NCT02925845|Experimental|Neuromuscular electrostimulation|Patients assigned to the group NMS, following the visit Day Hospital, in the first two hours of each HD session will perform a program of neuromuscular electrostimulation of the limb with the RC-AVF performed in the reference position of the flexors and extensors forearm at the tip intervened in each HD session on the stage previously established in the protocol (duration according to established program).
89044809|NCT02925845|No Intervention|Isometric exercises|They will perform isometric exercises operated limb on an outpatient basis (repeated pressure rubber balls, heavy lifting 1-2 kg).
89647252|NCT06011525|Active Comparator|standard cold-cap|"Patients will benefit from the prevention of chemo-induced alopecia using the standard cold cap device throughout the course of anthracycline- and taxane-based chemotherapy.~This device will be supplemented by a compression bandage to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the effectiveness of the device."
89647253|NCT06011525|Experimental|scalp-cooling technique|Patients will benefit from the prevention of chemo-induced alopecia using the standard cold cap device throughout the course of anthracycline- and taxane-based chemotherapy.
89647254|NCT06011486|Experimental|Lymphocyte infusion|Patients with CMV disease or reactivation will be included for receiving donor-CMV-specific cells
89647255|NCT06011460||Patients' name|Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-5. Age from 18 to 65 years old.
89647256|NCT06011447||Patients with diabetes and wound ulcers|
89647257|NCT06011434||Patient: Conversation Aid On Mammography Screening|"Participants will complete study procedures as follows:~Pretest questionnaires.~PCP Appointment with introduction to conversation aid website.~Post-test questionnaires within two weeks of PCP visit."
89647258|NCT06011434||Family: Conversation Aid On Mammography Screening|"Caretakers/Family members to participants will complete study procedures as follows:~Pretest questionnaires.~Attend with participant PCP Appointment with introduction to conversation aid website.~Post-test questionnaires within two weeks of PCP visit."
89647259|NCT06011434||Clinician: Conversation Aid On Mammography Screening|"Clinicians will complete study procedures as follows:~Pretest questionnaires.~Post-test questionnaires."
89647260|NCT06011382|Active Comparator|patients treated with amda®|two different treatment groups will be evaluated, from initiation of treatment until completion of maxillary molar distalization.
89647261|NCT06011382|Active Comparator|patients treated with buccal mini-implants|from initiation of treatment until completion of maxillary molar distalization.
89647262|NCT06011343|Placebo Comparator|Placebo and Sbv|Eleven CL patients will receive meglumine antimoniate by EV route at 20mg/kg/day, for 20 days.
89647263|NCT06011343|Experimental|Tofacitinib and Sbv|Eleven CL patients will receive oral tofatinib (10mg daily for 30 days) associated to meglumine antimoniate by EV route at 20mg/kg/day, for 20 days.
89647264|NCT06011252|Other|Solia S lead with any BIOTRONIK Pacemaker|"Name: Solia S lead with any BIOTRONIK Pacemaker~Model: Solia S45/S53/S60~Manufacturer: BIOTRONIK SE & Co. KG~Method of use: LBBAP implantation for all bradycardia indications.~Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony.~Device category and grade: E3610 Cardiovascular devices, Class III"
89647265|NCT06011174||post-stroke patient|"Being 18 years of age or older,~being diagnosed with hemorrhagic or ischemic stroke,~No cooperation and communication problems~Being able to walk independently"
89647266|NCT06011161|Experimental|Brief Relationship Checkup|Couples in the experimental condition will participate in three joint sessions of the Brief Relationship Checkup (BRC; Cordova 2014; Cigrang et al., 2016). This program has been tested in Air Force Primary Care but we do not know if veterans with mental health concerns will be able to attend it (feasibility), complete it safely (tolerability), and enjoy it (acceptability).
89647267|NCT06011122||Zimmer Biomet|Patients who were operated with a Zimmer Biomet plate
89647268|NCT06011122||Newclip Technics|Patients who were operated with a Newclip Technics plate
89647269|NCT06011122||Stryker|Patients who were operated with a Stryker plate
89647270|NCT06011122||Medartis|Patients who were operated with a Medartis plate
89647271|NCT06011122||Medartis Footprint|Patients who were operated with a Medartis Footprint plate
89647272|NCT06011122||Synthes|Patients who were operated with a Synthes plate
89044810|NCT04679454|Experimental|Preoperative Radiation Treatment|
89647273|NCT06011096|Experimental|the group with skin-to-skin contact and delayed cord clamping|In this arm, skin-to-skin contact and delayed cord clamping are performed between mother and baby.
89647274|NCT06011096|Experimental|The group without skin-to-skin contact and early cord clamping|In this arm, skin-to-skin contact and delayed cord clamping are not performed between mother and baby.
89647275|NCT06011083|Active Comparator|Group A|20 patients who were treated with Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm twice daily as a monotherapy for 3 months over a selected psoriatic plaque
89647276|NCT06011083|Active Comparator|Group B|20 patients who were treated with fractional CO2 laser sessions once per month followed by application of the same Topical Ointment twice daily for 3 months over a similar psoriatic plaque
89044811|NCT02925728|Experimental|Nutrition with Finger-Food|Nutrition with Finger-Food
89044812|NCT02925728|Active Comparator|Nutrition without Finger-Food|Nutrition without Finger-Food
89044813|NCT02925884|Experimental|Gunnar OTC Glasses Condition|Intervention: Gunnar Over-The-Counter Glasses with lens (subjects will wear the glasses with lens while performing visual tasks on computers.
89044814|NCT02925884|No Intervention|Control Condition|Subjects will be wearing an identical frame without any lens while performing visual tasks on computers.
89044815|NCT04744974|Experimental|Mediterranean diet|Participants will be given dietician counseling on a Mediterranean diet
89044816|NCT04744974|Experimental|DASH diet|Participants will be given dietician counseling on a DASH diet
89044817|NCT04242251|No Intervention|Usual Care|Management by primary oncologist. Referral to existing palliative care service initiated by primary oncologist if needed.
89044818|NCT04242251|Experimental|SPARKLE intervention group|Regular symptom monitoring and treatment of problems identified. Referral to existing palliative care services can also be initiated by the SPARKLE nurse if identified problems require follow up.
89044819|NCT04725786|Experimental|Case group|The intervention of the research corresponds to the realization of a thoracic echography.
89044820|NCT04723524|Experimental|Treatment group|150 Cases, treated with Jinhua Qinggan (JHQG) Granules
89044821|NCT04723524|Placebo Comparator|Control group|150 Cases, Placebo treated
89044822|NCT02925806||ER/LA opioids included in the class REMS|
89647277|NCT06011044|Experimental|Intercostal nerve block with ropivacaine（0.5%）|This group of patients will be further divided into 2 groups. Group A (incision-specific multi-site injection) received intraoperative 3-8 intercostal nerve block with 0.5% ropivacaine. Group B (single injection) received intraoperative 3-5 intercostal nerve block with 0.5% .After completing lung surgery, fully exposing the lateral and posterior chest wall. From the inside view of the chest cavity, the intercostal nerve enters the correlated intercostal space between the posterior intercostal membrane and the parietal pleura. The needle of the 1ml syringe was held with a thoracoscopic ovale forceps and the target intercostal nerves were confirmed. It is only necessary to puncture the parietal pleura at the side of the intercostal nerve to perform the block. Inject ropivacaine(1ml, 0.5%) into the target nerve. At the same time, we recorded patients' mental status and vital signs to avoid systemic toxicity.
89044823|NCT02925806||IR Opioids|
89044824|NCT02925806||Celecoxib|
89044825|NCT02925806||Benzodiazepines|
89044826|NCT04706754||Prospective|Confirmed ALK, EGFR, ROS1, ERBB2 (HER2), exon 20 EGFR mutation, MET and BRAF cancer patients from across participating sites/cancer centers across Canada.
89044827|NCT04689308|Experimental|Part A: Dose Escalation and Determination of RP2D|Part A: Dose Escalation and determination of RP2D, multiple dose levels of MH048 to be evaluated
89044828|NCT04689308|Experimental|Part B: Dose Expansion in Selected Relapsed/Refractory B-cell Malignancies|Part B: Selected relapsed/refractory B-NHL subjects with at least 1 prior systemic OR standard-of-care therapy.
89044829|NCT04672122|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity will be at 2 mA (sham mode). The scope of intervention is to investigate effect of sham tDCS on muscle strength.
89044830|NCT04672122|Experimental|Cathodal-tDCS 1 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 1 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
89044831|NCT04672122|Experimental|Cathodal-tDCS 1.5 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 1.5 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
89044832|NCT04672122|Experimental|Cathodal-tDCS 2 mA|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) and Anode on the supraorbital area of contralateral side. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of cathodal tDCS on muscle strength.
89044833|NCT04689191|Experimental|Experimental Vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
89044834|NCT04689191|Active Comparator|Active Comparator Vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
89044835|NCT04671498||Ancillary-correlative (biospecimen collection) (Breast Cancer patients)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
89044836|NCT04671498||Ancillary-correlative (biospecimen collection) (Volunteer)|Participants undergo collection of blood sample for the Droplet-BC test. All participants' medical records are also reviewed.
89647278|NCT06011044|No Intervention|no intercostal nerve block.|This group of patients will not receive intraoperative intercostal nerve block with 0.5% ropivacaine. After completing lung surgery, fully exposing the lateral and posterior chest wall. From the inside view of the chest cavity, the intercostal nerve enters the correlated intercostal space between the posterior intercostal membrane and the parietal pleura. The needle of the 1ml syringe was held with a thoracoscopic ovale forceps and the target intercostal nerves were confirmed. Inject physiologic saline(1ml) into the target nerve.
89647279|NCT06011005|Experimental|(Group A) Ethyl Chloride (EC)|Topical application for 30 sec.
89647280|NCT06011005|Active Comparator|(Group B) Benzocaine gel 20% (BC)|BC 20% Topical gel application for 30 sec and left for 1 minute.
89647281|NCT06010992|No Intervention|Group 1|35 Patients with type 2 diabetes receiving treatment with metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin).
89647282|NCT06010992|Experimental|Group 2|35 Patients with type 2 diabetes receiving nitazoxanide 500 mg orally twice daily in addition to metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin).
89647283|NCT06010979||conventional group|Conventional instrument-assisted knee arthroplasty
89647284|NCT06010979||CAS group|computer navigation assisted knee arthroplasty
89647285|NCT06010979||RAS group|robotic system assisted knee arthroplasty
89647286|NCT06010979||PSI group|patient-spercific instrumentation assisted knee arthroplasty
89647287|NCT06010940|Active Comparator|control group|Control group (A) was treated by nasogastric tube and oral care.
89647288|NCT06010940|Experimental|study group|Study group (B) was treated as the control group in addition to a designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
89647289|NCT06010888|Experimental|Fruquintinib+mFOLFOX6/FOLFIRI|
89647290|NCT06010771|No Intervention|Control Group|Routine aspiration will be applied to the control group. No action will be taken.
89647291|NCT06010771|Experimental|Experimental Group|During the aspiration process, the experimental group will listen to fairy tales and watch cartoons.
89647292|NCT06010745|Active Comparator|Active capsules|Dietary ingredient standardized to deliver 10 mg of biotin and 10 mg of silicon per serving (1 capsule/serving).
89647293|NCT06010745|Placebo Comparator|Placebo capsules|The placebo comparator contains only inert ingredients (1 capsule/serving)
89647294|NCT06010745|Other|open label|Open-label arm that will involve men who only receive the active dietary ingredient capsules. This arm will run in parallel with the blinded study conducted in women.
89647295|NCT06010537|Experimental|polyglucose superparamagnetic iron oxide injection 2.5 mg/kg|Intravenous injected polysaccharide superparamagnetic iron oxide injection at 2.5 mg/kg dose;
89647296|NCT06010537|Experimental|polyglucose superparamagnetic iron oxide injection 3.0 mg/kg|Intravenous injected polysaccharide superparamagnetic iron oxide injection at 3.0 mg/kg dose;
89647297|NCT06010368|Experimental|Group 1: Tranexamic acid group|In TXA group (n=25): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
89647298|NCT06010368|Experimental|Group 2: oxytocin group|to the oxytocin group (n = 25): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
89647299|NCT06010186|Experimental|Ultrasound measurement of the diaphragm and intercostals|"The specific research procedures correspond to the addition of :~Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes)."
89647300|NCT06010121|Experimental|Liposomal Vitamin D|Daily oral dose of liposomal vitamin D for 4 weeks
89647301|NCT06010121|Active Comparator|Traditional Vitamin D|Daily oral dose of traditional vitamin D for 4 weeks
89647302|NCT06010043|Experimental|"Dumpling suture for ileostomy"|The stoma is fixed with sutures in a skin fold method, and the incision is progressively reduced in a process similar to the process of folding and pinching the Chinese small dumplings. This procedure may reduce stoma complications by progressively reducing the incision and realizing the effect of hiding the skin incision.
89057959|NCT04535375|Other|Preterm infants born between 28 0/7 and 31 6/7 weeks|For infants born between 28 0/7 and 31 6/7 weeks, brain ultrasound is performed on admission, once between day 1 and 3, once between day 7 and 10, and then 2-weekly until discharge or transfer.
89647303|NCT06010043|Other|Traditional suture for ileostomy|The stoma was fixed at the skin using traditional sutures. The incision is narrowed by 2-3 interrupted sutures at the distal and proximal ends of the skin incision on the abdominal wall. The stoma is then fixed at the right lower abdominal incision with sutures.
89647304|NCT06009640|Experimental|Intraoperative neurophysiological monitoring for decompression surgery|we integrated intraoperative neuromonitoring system into laparoscopic lumbosacral plexus nerve decompression surgery and simultaneusly recorded nerve roots from lumbar 5 to sacral 4 during the operation. Diseases that cause pelvic nerve compression such as abnormal vascular conflict, aberrant priformis muscle, and endometriosis have settled in hard-to-reach deep areas of the pelvis. These areas can be accesed more easily with by laparoscopy, which provides better magnification and visualization. Sacral and sciatic nerves might be damaged when performing decompression surgery in these deep pelvic areas. Patients who gave informed consent and underwent surgical treatment for a proven diagnosis of lumbosacral plexus nerve entrapment were included in the study.
89647305|NCT06009289|Active Comparator|Standard of care|One hour of daily bright light exposure beginning one hour after wake time.
89647306|NCT06009289|Experimental|Stepped care|One hour of daily bright light exposure in the afternoon
89647307|NCT06008990||Pregnant Mothers with Opioid Use Disorder|Planned recruitment of 20 mothers with Opioid Use Disorder who are on Buprenorphine at the time of screening.
89647308|NCT06008990||Pregnant Mothers|Planned recruitment of 20 mothers who do not have any history of opioid use disorder.
89647309|NCT06008002|Active Comparator|Group M|ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block
89057960|NCT01198873|Experimental|Dronedarone|Dronedarone 400 mg twice a day
89647310|NCT06008002|Active Comparator|Group E|Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block
89647311|NCT06008002|Active Comparator|Group P|Patient-controlled analgesia with tramadol
89647312|NCT06007885|Experimental|Community-based activity program|Engagement in 8-week community-based activity program.
89647313|NCT06007456||Patients at onset of juvenile arthritis|New diagnosis of JIA
89647314|NCT06007456||Patients with juvenile arthritis in follow up|Subjects with JIA already followed at Rheumatologic Service
89647315|NCT06007196||Continuous non-invasive Hemodynamic Monitoring|Continuous non-invasive Hemodynamic Monitoring (Task Force CORE(R) and Task Force CARDIO(R)) will be compared to invasive thermodilution cardiac output measurements in all patients.
88992662|NCT05860712|Active Comparator|Sodium hypochlorite Irrigation|standardized pulpectomy procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, and a sharp spoon excavator will remove pulpal tissues to the orifice level , the working lengths of root canals were estimated by apex locator and Cleaning and shaping of the root canals was done by rotary files .The pre - irrigation sample were collected after debridement of the radicular pulp tissues by a sterile paper point ,then Second microbial sample : The canals were irrigated with Sodium hypochlorite Irrigation (group A) .All the microbiological culturing procedures were carried out in the Microbiology and Immunology Department , the plates were examined and the colonies were directly counted using colony forming unit .
88992663|NCT05860712|Sham Comparator|Cinnamon extract Irrigation|standardized pulpectomy procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, and a sharp spoon excavator will remove pulpal tissues to the orifice level , the working lengths of root canals were estimated by apex locator and Cleaning and shaping of the root canals was done by rotary files .The pre - irrigation sample were collected after debridement of the radicular pulp tissues by a sterile paper point ,then Second microbial sample : The canals were irrigated with cinnamon Irrigation (group B) . All the microbiological culturing procedures were carried out in the Microbiology and Immunology Department , the plates were examined and the colonies were directly counted using colony forming unit .
88992664|NCT05860699|Experimental|Placebo|add-on placebo (Echo Pharmaceutical, BV) for 10 days during their inpatient stay
88992665|NCT05860699|Experimental|Half-dose|add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
89647316|NCT06006312||Elderly population|The elderly population is defined as those over 60 years of age and residing in retirement home. Excluding people with critical conditions, mental disorders that prevent them from cooperating with the study, and those who are unable to defecate due to intestinal obstruction or other illnesses.
89647317|NCT06006312||Community population|This group is the resident population of the community. Excluding people with critical conditions, mental disorders that prevent them from cooperating with the study, and those who are unable to defecate due to intestinal obstruction or other illnesses.
89647318|NCT06006312||Chronic pancreatitis|Patients with chronic pancreatitis are considered as study subjects. If a CP patient has diabetes mellitus (exclude type 1 diabetes mellitus), a blood test will be performed to assess glycemic control.
88992666|NCT05860699|Experimental|Full dose|add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
88992667|NCT05860686|Active Comparator|No rinsing|
88992668|NCT05860686|Experimental|Monoject rinsing|
88992669|NCT05860621|Experimental|Brief Physical Activity Counselling|The brief physical activity counselling (PAC) group will receive a group-based, light-touch, motivational counselling program to promote physical activity.
88992670|NCT05860621|Experimental|Structured Exercise Program|The structured exercise group will receive a group-based supervised multi-component exercise program, with progressive intensity.
88992671|NCT05860621|No Intervention|Waitlist control|Patients allocated to the control group (i.e., waiting list) will keep daily routines and standard medical care. At the end of the study, the control group will be offered the structured exercise program.
88992672|NCT05860608|Experimental|ACTIVE investigational arm (NT-proBNP + AI-ECHO)|NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent; those with elevated NT-proBNP (≥125pg/ml) will undergo an Us2.ai (AI-enabled report) handheld echocardiogram within one month of NT-proBNP testing. A standard echocardiographic study will be performed if the AI-echo is non-diagnostic.
88992673|NCT05860608|Other|CONTROL routine care arm|Patients randomized to usual care will undergo standard clinical follow-up, with NT-proBNP and conventional echocardiography prescribed only as per usual practice.
88992674|NCT05860582|Experimental|[14C]GB491|
89057961|NCT01198873|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day
89647319|NCT06006312||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus are considered as study subjects.
89647320|NCT06003023|Active Comparator|Living Well with Congenital Heart Disease (LIV-CHD) Intervention|In LIV-CHD, participants will receive a Fitbit and a tailored exercise prescription, as devised from their baseline exercise stress test results. They will also meet with a health coach for 9 virtual sessions over a period of 20 weeks. The content will focus on how to use the Fitbit along with health education pertinent to living a healthy lifestyle (e.g., sleep hygiene, stress management). Goal-setting and other cognitive behavioral strategies for health behavior change will not be discussed in this arm. Participants in the attention control arm will also receive text messages reminding them to wear their Fitbit.
89647321|NCT06003023|Experimental|Congenital Heart Disease Physical Activity Lifestyle (CHD-PAL) Intervention|In CHD-PAL, participants will receive a Fitbit and a tailored exercise prescription, as devised from their baseline exercise stress test results. They will also meet with a health coach for 9 virtual sessions over a period of 20 weeks. The content will focus on cognitive behavioral strategies, grounded in the Theory of Planned Behavior, to increase physical activity and healthy living. Participants in the intervention arm will also receive text motivational messages relevant to session content, as well as reminders to wear their Fitbit.
89647322|NCT06001463|Experimental|reduce the severity, and enhance healing of radiation dermatitis|The patient received part of the breast/neck skin CSMed® dressing or clinical routine skin care.
89647323|NCT05998369|Experimental|Empowered Relief for Youth|Empowered Relief for Youth is a single-session pain management class focused on pain science education and teaching self-regulatory skills for pain management based on the evidence-based adult ER class.
89647324|NCT05993000|Experimental|Grup 1(Music + mobilization + exercise was applied)|In this group, hot packs and TENS (Transcutaneous Electrical Nerve Stimulation) were applied to the patients simultaneously, while they were listening to 432 hertz frequency music through headphones. Subsequently, shoulder mobilization was applied in appropriate positions. The exercises were conducted by the physiotherapist during the session and the manageable exercises were given to the patients as a home program.
89647325|NCT05993000|Experimental|Grup 2 ( music + exercise)|In this group, hot packs and TENS (Transcutaneous Electrical Nerve Stimulation) were applied to the patients simultaneously, while they were listening to 432 hertz frequency music through headphones. The exercises were conducted by the physiotherapist during the session and the manageable exercises were given to the patients as a home program.
89647326|NCT05993000|Active Comparator|Grup 3 (mobilization + exercise)|After applying hot packs and TENS(Transcutaneous Electrical Nerve Stimulation) to the patients, shoulder mobilization was performed in suitable positions.The exercises were conducted by the physiotherapist during the session and the manageable exercises were given to the patients as a home program.
89647327|NCT05993000|Active Comparator|Grup 4 (exercise)|After the application of hot packs and TENS (Transcutaneous Electrical Nerve Stimulation) to the patients, the physiotherapist administered specific exercises during the session. Additionally, customized exercises were prescribed as a home program for the patients to continue their rehabilitation outside of the clinic setting.
89647328|NCT05989464||Human Papilloma Virus (HPV) Self swab|Enrolled participants will be instructed to perform a self swab for genital Human Papilloma Virus (HPV) infection. Additionally, a short survey will be administered to collect demographic information, evaluate knowledge of HPV/cervical cancer, and assess acceptability of HPV self swab.
89647329|NCT05982236||PCOS patients|
89647330|NCT05982080|Experimental|FP002 Injection|Dose escalation: FP002
89647331|NCT05979077|Experimental|MyChart Questionnaire (Intervention Group)|Participants within the intervention group will complete the patient-facing EHR-enabled MyChart® questionnaire.
89647332|NCT05979077|No Intervention|Standard Clinical Care (Control Group)|Participants within the control group will undergo standard clinical care with no study intervention.
89647333|NCT05974449|Experimental|C1, C2 dosing group|C1 and C2 dosing groups: The drug is administered on the day of the C1 and C2 chemotherapy cycles for 10 days, washing the vulva and placing the drug deep into the vagina, once a night, 1 capsules each time.
89647334|NCT05974449|Experimental|C3, C4 dosing group|C3 and C4 dosing groups: The drug is given on the day of the C3 and C4 chemotherapy cycles and is administered for 10 days. The drug is placed deep into the vagina after washing the vulva, once a night, 1 capsules each time.
89647335|NCT05967637|Experimental|Whole-body vibration|Standard patient education and exercise training + whole body vibration
89647336|NCT05967637|Sham Comparator|Sham-whole-body vibration|Standard patient education and exercise training + sham whole body vibration
89647337|NCT05962385|Experimental|Healthy control|All participants receive the same procedures
89647338|NCT05935774|Experimental|Treatment (atezolizumab, trabedersen)|Patients recieve atezolizumab IV on day 1 and trabedersen continuous IV on days 1-4 and days 15-19 of each cycle. Cycles repeat every 28 days for 104 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI during screening and every 8 weeks for the first 24 weeks and then every 12 weeks thereafter. Patients undergo blood sample collection prior to initiation of therapy, on day 4 of cycles 1-4, prior to weeks 4 and 8 of therapy, and at time of progression. Patients may also undergo biopsy during screening and/or 6-8 weeks after initiation of therapy.
89647339|NCT05926440|Experimental|SCB-2023 arm|Participants will receive one booster dose with SCB-2023 vaccine on Day 1
89647340|NCT05926440|Active Comparator|SCB-2019 arm|Participants will receive one booster dose with SCB-2019 vaccine on Day 1
89647341|NCT05912400||NF1 Group|This study will look to enroll 40 to 45 adults over 18 years old diagnosed with NF1.
89647342|NCT05912400||Control Group|This study will look to enroll 10 to 15 adults over 18 years old without NF1.
89647343|NCT05908461|Experimental|Intervention Group|Participants will receive the Early Childhood Friendship project intervention (8x10-min puppet shows, 7x5-min gross motor activities7x5-min passive activities, up to 3x1-hour in-vivo behavioral reinforcement periods).
89057962|NCT04535388|Other|LK scleral lens|LK scleral lens (Lucid Korea LTD, Seoul, Republic of Korea) are worn for 12 weeks.
89057963|NCT01198795|Experimental|1|Flexible-dose 10mg-20mg once-daily oral (10mg tablets) dose of escitalopram
89647344|NCT05908461|No Intervention|Control Group|Participants will not receive the Early Childhood Friendship project intervention.
89057964|NCT04535024|Experimental|Treatment Arm|"A total of 60 MSS oligometastatic colorectal cancer patients will receive multisite SABR followed by Sintilimab within one week from completion.~The dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal."
89057965|NCT04535336|Experimental|Vitality acupunch (VA)|The VA program took 40 minutes to complete and included 3 phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allowed the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands were used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group received the VA program led by the instructors, who were trained an certified by the PI, 3 times per week and 40 minutes per session for 6 months.
89647345|NCT05904561|Active Comparator|Group (A) (Study group A)|It will be consisted of 16 women complaining from mild to moderate Carpel Tunnel Syndrome after 6 weeks from delivery diagnosed by electrophysiological study. They will receive low level laser therapy, for 10 minutes, three times per week for 4 weeks (total of 12 sessions), in addition to wrist exercises and home advices.
89647346|NCT05904561|Experimental|Group (B) (study group B)|It will be consisted of 16 women complaining from mild to moderate Carpel Tunnel Syndrome after 6 weeks from delivery diagnosed by electrophysiological study. They will receive pulsed ultrasound therapy, for 10 minutes, three times per week for 4 weeks (total of 12 sessions), in addition to wrist exercises and home advices
89647347|NCT05904561|Active Comparator|Group (C) (control):|It will be consisted of 16 women complaining from mild to moderate Carpel Tunnel Syndrome after 6 weeks from delivery diagnosed by electrophysiological study. They will receive wrist exercises (strengthening exercises for thenar muscles, wrist flexors. Extensors, grip strengthening, stretching, nerve glide, neurodynamic technique and tendon glide) for 15 minutes, three times per week for 4 weeks (total of 12 sessions) and home advices only.
89647348|NCT05896917|Experimental|Experimental|This group will receive 3D Printed Foot Orthoses
89647349|NCT05896917|Active Comparator|Control|This group will receive Prefabricated Foot Orthoses
89647350|NCT05873478|Experimental|Experimental (High Intensity Interval Training)|High Intensity Interval Training for 8 weeks, which include lunges, squatting sprinting and other exercises.
89647351|NCT05873478|No Intervention|Control (No Intervention)|Control Group received no intervention they all will be engaged in normal daily routines.
89647352|NCT05869162|Experimental|SY-3505-Phase II|SY-3505 single agent, 600 mg oral capsules, QD, continuously
89647353|NCT05859828||Head and Neck Cancer patients|Participants with incurable advanced head and neck cancer. Participants will have histologically or cytologically confirmed squamous cell carcinoma of the head and neck
89647354|NCT05859828||Patient Caregivers|Caregivers to participants in the patient cohort
89647355|NCT05853640|Active Comparator|Usual care|Participants in this group will undergo usual care at the orthopedic department and will get a recommendation for physical therapist-led treatment in primary care.
89647356|NCT05853640|Experimental|HIPSTER|Participants in this group will undergo usual care at the orthopedic department and will also receive a semi-structured intervention according to the HIPSTER treatment model.
89647357|NCT05834595|Experimental|Sequence 1|"Period 1: D064, D701 - A single oral dose of 2 tablets~Period 2: CKD-828 - A single oral dose of 1 tablet~Period 3: D064, D701 - A single oral dose of 2 tablets~Period 4: CKD-828 - A single oral dose of 1 tablet"
89647358|NCT05834595|Experimental|Sequence 2|"Period 1: CKD-828 - A single oral dose of 1 tablet~Period 2: D064, D701 - A single oral dose of 2 tablets~Period 3: CKD-828 - A single oral dose of 1 tablet~Period 4: D064, D701 - A single oral dose of 2 tablets"
88992675|NCT05860491||patients with pre-dialysis hyperkalemia|To investigate the dietary fiber intake of hemodialysis patients with pre-dialysis hyperkalemia. Use a retrospective analysis method. Analyze the relationship between dietary fiber intake and hyperkalemia.
88992676|NCT05860491||patients without pre-dialysis hyperkalemia|To investigate the dietary fiber intake of hemodialysis patients without pre-dialysis hyperkalemia. Use a retrospective analysis method. Analyze the relationship between dietary fiber intake and hyperkalemia.
88992677|NCT05860478|Experimental|wearable device plus standard care|
88992678|NCT05860478|No Intervention|standard care|
88992679|NCT05860413|Experimental|Intermittent energy restriction (IER)|Intermittent fasting using a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week
88992680|NCT05860413|Experimental|Time-restricted eating (TRE)|Intermittent fasting using an 8-hour eating period.
88992681|NCT05860374|Experimental|R130 Treatment Group|Every 7-14 days,1-4 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors
88992682|NCT05860335|Experimental|Toripalimab +AP-induced chemotherapy|Study drug: toripalimab JS001 dosage：240mg Drug administration plan and mode：Intravenous infusion of 30min (not less than 20min and not more than 60min), followed by observation of 60min (only the first 2 cycles), once every 3 weeks (Q3W).
88992683|NCT05860322|Experimental|Inulin group|Patients randomized to the intervention group will receive inulin supplementation for 14 days, preceding the surgery. Inulin will be given at a dosage of 10g/day divided in two doses.
88992684|NCT05860322|Placebo Comparator|Control group|Patients randomized to the control group will receive a placebo for 14 days, two times a day.
88992685|NCT05860309|Active Comparator|preoperative quadratous lumborum block|patients weill recieve preoperative ultrasound guided quadratous lumborum block at lateral position before start of surgery after induction of general anesthesia
88992686|NCT05860309|Active Comparator|postoperative quadratous lumborum block|patients weill recieve postoperative ultrasound guided quadratous lumborum block at lateral position at the end of surgery before recovery from general anesthesua
89057966|NCT04535336|Active Comparator|Control|Participants in the control group continued with their daily activities as usual.
89647359|NCT05819320||ALdakhla general hospital patients|patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease in renal unit of internal medicine of Eldakhla general hospital in New Vally
89647360|NCT05819320||Assuit University hospital adult renal unit|patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease in renal unit of internal medicine of Assuit University hospital (adult renal unit ) .
89647361|NCT05819320||Assuit University hospital pediatric renal unit|patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease in renal unit of internal medicine of Assuit University hospital (pediatric renal unit ).
89647362|NCT05811936|No Intervention|Usual Care|Caregiver- Survivor Dyads in this group will receive routine follow-up care in the HNC clinic. Current standard of care is an Advanced Practice Provider (Physician Assistant or Nurse Practitioner)-delivered survivorship visit after treatment. This visit will take place according to UC in the clinic. UC dyads will also receive printed caregiving and survivorship materials.
89647363|NCT05811936|Experimental|SNAP|Caregiver- Survivor Dyads in this group will receive a two-session intervention spanning 3 months, with a caregiver module within 1-2 weeks of the end of RT and a dyadic module at 3 months. Each session will include a needs- assessment, a tailored care plan with a goal setting discussion, and referrals for unmet needs. Each session follows with a supportive mobile app for 6 weeks.
89647364|NCT05809089|Active Comparator|(High flow nasal cannula (HFNC)|"This arm should have the interventionHigh flow nasal cannula (HFNC) assigned to it."
89647365|NCT05809089|Active Comparator|Noninvasive ventilation (NIV)|"This arm should have the intervention Noninvasive ventilation (NIV) assigned to it."
89057967|NCT04535180||Hemophilia|
89057968|NCT02216448|Other|simulator training|Training knee simulator in Lab
89647366|NCT05802693|Experimental|The dose increase phase of this study adopts a 3+3 half-step design|"The main research objective of active comparator is to observe the efficacy and safety of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T cells(EGFRvIII CAR-T cells) injected by local administration (Omaya capsule administration) in the treatment of Glioblastoma(GBM).~Initial dose 22 × 10^6 cells will adopt accelerated titration (ATD); 60 × 10^6 cells，160 × 10^6 cells and 220 × 10^6 cells will use the BOIN method to increase the dose. The planned dose increase scheme is divided into accelerated titration stage (ATD) and BOIN stage"
89647367|NCT05799521|Experimental|Treatment|subjects on Treatment arm will get study drug
89647368|NCT05799521|Placebo Comparator|Placebo|subjects on Treatment arm will get placebo
89647369|NCT05784870|Experimental|Shengxuening Tablets|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
89647370|NCT05784870|Active Comparator|ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
89647371|NCT05767684|Experimental|Arm 1: DCs monotherapy|DCs injection on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
89647372|NCT05767684|Experimental|Arm 2: DCs with booster of anti-VEGF/anti-PD-1.|DCs injection on day 1, 8, 15, 29, 85, 141, 197, 253 and 309 plus lenvatinib 10mg QD on day 43-77 and nivolumab 3mg/kg on day 43, 57 and 71.
89647373|NCT05762302|Experimental|Adults with suspected Lower Respiratory Track Infection (LRTI)- The MeMed BV arm|ED and urgent care center patients over the age of 18 years , with clinical suspicion of Lower Respiratory Track Infection. clinician will receive the BV result, this will include a recommendation regarding antibiotic treatment. A telephone FU call will be done at 28 (+/- 3) days after the day of consent to complete a short questionnaire regarding your current illness
89647374|NCT05762302|No Intervention|Adults with suspected Lower Respiratory Track Infection (LRTI)- The control arm|ED and urgent care center patients over the age of 18 years , with clinical suspicion of Lower Respiratory Track Infection. clinician will not receive the BV result, and will treat according to standard of care. A telephone FU call will be done at 28 (+/- 3) days after the day of consent to complete a short questionnaire regarding your current illness
89647375|NCT05758246|Experimental|Fisetin- dose 1|Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis, will be given the first dose of fisetin.
89647376|NCT05758246|Experimental|Fisetin- dose 2|Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis, will be given the 2nd does of fisetin.
89647377|NCT05758246|Placebo Comparator|Placebo|Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis will receive placebo treatment.
89647378|NCT05756829|Experimental|High frequency, low-touch virtual health care|"Participants in this arm will receive a high frequency, low-touch virtual health care intervention through the Maple application, as an adjunct to usual T1D care. High-frequency visits will occur every 2 +/- 1 weeks for a total of 6 months.~Participants will also receive access to a virtual library to support T1D self-learning and as a guided educational tool."
89647379|NCT05756829|No Intervention|Standard Care|Participants in this arm will receive the standard of care offered for their condition and by their clinic.
89647380|NCT05751603|No Intervention|Control group|Routine anesthetic process; sugammadex is administered when spontaneous respiration is returned (before extubation)
89647381|NCT05751603|Experimental|Experimental group|sugammadex is administered just after extubation.
89647382|NCT05734794|Experimental|Rituximab Group|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days).
89647383|NCT05734794|Active Comparator|Steroid Group|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks.
89647384|NCT05705128|Active Comparator|dexamethasone group|patients will receive dexamethasone with bupivacaine before general anaesthesia
89647385|NCT05705128|Active Comparator|dexmedetomidine group|patients will receive dexemedetomidine with bupivacaine before general anaesthesia
89647386|NCT05695092|Experimental|Experimental group|PMR session will be provided a night before competition
89647387|NCT05695092|Sham Comparator|Control group|Simple ROM for upper limbs and lower limbs
89647388|NCT05684666|Experimental|SBE Group|Slow Breathing Exercise (SBE) was performed by the participants of SBE group. Sixteen participants included in this group.
89647389|NCT05684666|Experimental|PMR Group|Progressive Muscle Relaxation (PMR) Technique was performed by the participants of the PMR group. It included 16-participants for the study.
89647390|NCT05684666|Experimental|Combined Group|Sixty participants from the combined group performed both Slow Breathing Exercise and Progressive Muscle Relaxation technique in this study.
89647391|NCT05684666|No Intervention|Control Group|No intervention was received/performed by the sixteen participants of the control group in this study.
89647392|NCT05669053|Experimental|Super U Story intervention|Participants in this condition will be asked to play the Roblox video game, Super U Story with the goal of reaching the end of the game (approximately 20-30 minutes)
89647393|NCT05669053|Active Comparator|Alternative Roblox game|Participants in this condition will be asked to play the Roblox video game, Rainbow Friends Story (Color Story) with the goal of reaching the end of the game (approximately 20-30 minutes)
89647394|NCT05669053|Active Comparator|Online word search|Participants in this attention control condition will be asked to complete as many online word searches on the topic of animals as they can in 20-30 minutes.
89647395|NCT05650333|Experimental|Ritlecitinib 20 mg|Participants will receive Ritlecitinib 20 mg by mouth once daily (QD).
89647396|NCT05630859|Experimental|Phase 1:1a Low dose Group|Participants randomized to the 1a Low dose Group receive 2 doses of NgG low dose investigational vaccine.
89647397|NCT05630859|Placebo Comparator|Phase 1:1b Placebo Group|Participants randomized to the 1b Placebo Group receive 2 doses of placebo.
89647398|NCT05630859|Experimental|Phase 1: 2a Medium dose Group|Participants randomized to the 2a Medium dose Group receive 2 doses of NgG medium dose investigational vaccine.
89647399|NCT05630859|Placebo Comparator|Phase 1: 2b Placebo Group|Participants randomized to the 2b Placebo Group receive 2 doses of placebo.
89647400|NCT05630859|Experimental|Phase 1: 3a High dose Group|Participants randomized to the 3a High dose Group receive 2 doses of NgG high dose investigational vaccine.
89044837|NCT04689113|Experimental|Intervention Group|ıntervention group After determining the women according to the research criteria, they were randomized into intervention and control groups.Firstly, Pre-tests were applied to the women in the experimental group. The Incontinence Health Belief Development Program was applied to the women in the experimental group as 5 sessions.This program includes the following topics; urinary system anatomy and physiology, urinary incontinence and risk factors, definition of kegel exercise and its place in urinary incontinence treatment, kegel exercise applied expression, health motivation. A WhatsApp group was established to remind women in the intervention group about the kegel exercise 3 times a day for 3 months to increase their self-efficacy. In addition, a facebook group was opened and posts about urinary incontinence and kegel exercises were made. Posttests were made 3 months after the training ended
89044838|NCT04689113|No Intervention|Control Group|Firstly, Pre-tests were applied to the women in the control group. No intervention was applied to this group.Posttests were made 3 months after pre-test.
89044839|NCT02925572|Experimental|Concentric cycling exercise (CON)|40 obese adolescents will be randomized into 2 groups: CON or EXC
89044840|NCT02925572|Experimental|eccentric cycling exercise (EXC)|40 obese adolescents will be randomized into 2 groups: CON or EXC
89044841|NCT04664673|Experimental|HABIT-ILE|HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) intervention during two weeks adapted for adults stroke survivors
89044842|NCT04664673|Active Comparator|Regular care|Usual customary treatment for adults stroke survivors during two weeks
89044843|NCT02925377|Experimental|Neuromuscular|Neuromuscular warm-up
89647401|NCT05630859|Placebo Comparator|Phase 1: 3b Placebo Group|Participants randomized to the 3b Placebo Group receive 2 doses of placebo.
89647402|NCT05630859|Experimental|Phase 2: 4a HTD Group|Participants randomized to the 4a highest tolerated dose (HTD) Group receive 2 doses of NgG highest tolerated dose selected from Phase 1.
89647403|NCT05630859|Experimental|Phase 2: 4b dose below HTD Group|Participants randomized to the 4b dose below HTD Group receive 2 doses of NgG dose below the highest tolerated dose selected from Phase 1.
89647404|NCT05630859|Placebo Comparator|Phase 2: 4c Placebo Group|Participants randomized to the 4c Placebo Group receive 2 doses of placebo.
89647405|NCT05603624|Active Comparator|Sterile glove|Sterile glove is usually the standard of care
89647406|NCT05603624|Experimental|Clean glove|Clean glove is usually not used or in the event of an emergency or lack of access to sterile gloves in the United States.
89647407|NCT05586958|Experimental|Tigulixostat 100mg|Tigulixostat 100mg, Once a day (QD) for up to 6 months
89647408|NCT05586958|Experimental|Tigulixostat 200mg|Tigulixostat 200mg, Once a day (QD) for up to 6 months
89647409|NCT05586958|Experimental|Tigulixostat 300mg|Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 6 months
89647410|NCT05586958|Placebo Comparator|Placebo|Placebo, Once a day (QD) for up to 6 months
89647411|NCT05575518|No Intervention|No intervention|Standard of care according to the National TB Programmes which is a weight-banded rifampicin, isoniazid, pyrazinamide, and ethambutol for weeks 0-8 followed by rifampicin and isoniazid for weeks 9-26.
89647412|NCT05575518|Experimental|Experimental Arm 1|Optimised dose of rifampicin. The rifampicin 35mg/kg alongside standard weight-banded doses of isoniazid, pyrazinamide, and ethambutol, once daily
89647413|NCT05575518|Experimental|Experimental Arm 2|Optimised dose of rifampicin and moxifloxacin. The rifampicin 35mg/kg and moxifloxacin 400mg alongside standard weight-banded doses of isoniazid and pyrazinamide, once daily.
89647414|NCT05573672|Experimental|Immediate Start|Dietary Counselling (7 bi-weekly sessions) plus omega-3 supplementation
89647415|NCT05573672|No Intervention|Waitlist Control|Participants will wait 12 weeks and then complete the same intervention as the Immediate Start arm.
89647416|NCT05563415|Other|Medicare AWV Toolkit|This is a stepped-wedged study. All practices will receive the intervention.
89647417|NCT05558436||Cancer group|Patients with colorectal cancer.
89647418|NCT05558436||Control group|Patients with benign colorectal disease.
89647419|NCT05547022||Critical Limb ischemia patients with tissue loss|CLI patients with minor and major tissue loss who had endovascular revascularisation
89647420|NCT05530213|Experimental|Healthy adults UZ Gent|A group of 30 healthy adults aged 18-65years old will carry out a 3D gait analysis at UZ Gent within a week of the 3D gait analysis at UHasselt and/or UMaastricht.
89647421|NCT05530213|Experimental|Healthy adults UHasselt|The same group of 30 healthy adults aged 18-65years old will carry out a 3D gait analysis at UHasset within a week of the 3D gait analysis at UZGent and/or UMaastricht.
89647422|NCT05530213|Experimental|Healthy adults UMaastricht|The same group of 30 healthy adults aged 18-65years old will carry out a 3D gait analysis at UHasset within a week of the 3D gait analysis at UZGent and/or UZGent.
89647423|NCT05472987|Active Comparator|Open Ventral Hernia Repair|These patients will undergo open retromuscular ventral hernia repairs
89647424|NCT05472987|Active Comparator|Robotic Ventral Hernia Repair|These patients will undergo robotic retromuscular ventral hernia repairs.
89044844|NCT02925377|Active Comparator|Control|Standard warm-up
89044845|NCT04654299||standard PD (ST-PD)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and standard hepaticojejunostomy
89044846|NCT04654299||PD with external biliary stent(PD-BS)|Pancreacoduodenectomy with pancreatic-enteric reconstruction and hepaticojejunostomy with external biliary stent for externalization of bile fluid
89057969|NCT02216448|Other|OR training|Training in the OR - 2 knee arthroscopies.
89212746|NCT04082039|Active Comparator|1-channel PCA|Ch-1: fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline) Ch-2: 100ml normal saline only (for blinding)
89647425|NCT05458050|Other|PU Sensor examination|Device:PU Sensor will assess the microcirculation in sacrum with and without pressure (subject will lay on side and after that on back) the total measurement time is 5-10 minutes
89647426|NCT05442983|Experimental|PanCytoVir™ 500 mg twice daily|
89647427|NCT05442983|Experimental|PanCytoVir™ 1000 mg twice daily|
89647428|NCT05442983|Placebo Comparator|Placebo twice daily|
89647429|NCT05404945|Experimental|Fit Cohort|Three 6-week cycles of 400 mg intravenous pembrolizumab + intravenous AVD (q 2 weeks).
89647430|NCT05404945|Active Comparator|Non-Fit Cohort|Three 6-week cycles of 400 mg intravenous pembrolizumab and concurrent (q 3 week) intravenous brentuximab vedotin (BV).
89647431|NCT05344859|Experimental|Arm 1|Adaptive Rewards + Weekly automated coaching
89647432|NCT05344859|Experimental|Arm 2|Adaptive Rewards + Weekly human coaching
89647433|NCT05344859|Experimental|Arm 3|Fixed Reward + Weekly automated coaching
89647434|NCT05344859|Experimental|Arm 4|Fixed Reward + Weekly human coaching
89044847|NCT02925299|Experimental|24/7 closed loop insulin delivery|The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system used in the US is FlorenceM (Medtronic 640G pump and Guardian3 sensor). The name of this closed-loop system in the UK is FlorenceX (DANA pump and Dexcom sensor). Half of the individuals taking part in the study will use the closed-loop study system for 6 months.
89044848|NCT02925299|Active Comparator|Insulin pump therapy|Half of the Subjects will continue using their own insulin pump for 6 months.
89044849|NCT02925533|Experimental|B-701 and Pembrolizumab|"B-701 will be administered every 3 weeks intravenously~Pembrolizumab will be administered every 3 weeks intravenously"
89044850|NCT02925260||Patients with normal ileal pouches|"Inclusion Criteria~Ileal pouch reservoir in situ~Greater than three years since closure of ileostomy~Normal pouch function as defined by Orësland score of <4~Never had a diagnosis of pouchitis~Never had treatment for pouchitis~No evidence of pouchitis on rigid pouchoscopy~CRP <10"
89044851|NCT02917889|Experimental|Caffeine protocol|300 mg in pills
89044852|NCT02917889|Experimental|Placebo protocol|300 mg in pills
89044853|NCT02917811||ICU patients|
89044854|NCT04564092|Experimental|DaTSCAN™ ioflupane (123I) injection|Participants will receive a single intravenous (IV) injection of DaTSCAN™ ioflupane (123I) injection into an arm vein, followed by planar whole-body imaging at prespecified time points over a period of 48 hours after administration. Brain SPECT imaging will be acquired at 3 and 6 hours after administration.
89044855|NCT02917967|Experimental|BTX injection group|Botulinum toxin injection group
89044856|NCT04536909||Non-surgical|A non-surgical group for comparison, they will conduct a training program tailored for the kyphoscoliotic patients. The inclusion criteria is the same as for the surgical group.
89647435|NCT05337852|Experimental|Experimental group|"To the pregnant women in the experimental group;~Emotional freedom technique was applied online with the researcher twice a week.~PUQE, PRAQ-2 tests will be applied before the intervention,~SUE and PUQE will be applied before and after each session,~After 2 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
89647436|NCT05337852|No Intervention|Control group|"After each intervention applied to the experimental group, SUE and PUQE will be applied to the control group over the phone, simultaneously.~After 1 week, post-test data will be obtained with PUQE, SUE, PRAQ-2."
89647437|NCT05321134|Experimental|Single Port Robotic Surgery Arm|Study subjects will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the Intuitive Da Vinci Single Port SP system
89647438|NCT05318235||Children|Children between 6 weeks and 4 years of age who have a older sibling or attend day care
89647439|NCT05314361|Experimental|Treatment - 1 Day CBT-Based Workshop|Participants assigned to the treatment arm will attend a day long CBT-based workshop delivered by two trained public health nurses in addition to receiving usual care.
89647440|NCT05314361|No Intervention|Control - usual care|Participants assigned to the control arm will continue to receive standard postnatal care from their healthcare providers.
89647441|NCT05307185|Experimental|Tritordeum-based Food (TBD)|A controlled TBD will be provided to each patient. The daily menu will be breakfast, mid-morning snacks, lunch, afternoon snacks, and dinner. This intervention diet implies that each patient in the study has to consume flour, bread, breakfast biscuits, taralli, and pasta prepared exclusively with Tritordeum. The diets will be designed by matching basal metabolism and daily energy consumption with anthropometric data of all patients to assign suitable and tailored dietary regimens. The software utilized to assess the daily intake of macronutrients (50% carbohydrates, 30% lipids, and 20% proteins) will be the same as LFD.
89044857|NCT04536909||Surgical|Patients operated with correction of kyphotic- or scoliotic deformity.
89044858|NCT04688840||study results and satisfaction with telemedicine|the investigators designed a group on WhatsApp for all patients included in the study. The questionnaires were sent on the group to be filled by the patients in addition to a request for routine x ray follow up. Also, the investigators used the group to send any announcement, schedule of routine visits and some instructions about how to answer the questionnaires. To keep the privacy of patients' informations, every patient was asked to resend the file and x- ray pictures to the surgeon private account. the investigators collected data received by all patients and reviewed all x-rays. If there was any serious complain or major radiological finding the investigators asked the patient for immediate clinical visit.
89044859|NCT04688840||study results and satisfaction with routine follow up|the investigators asked the patients to come for routine follow up visit (RV) and reevaluate them clinically and radiologically. the investigators asked patients to calculate total time needed for completion of the questionnaires, time needed for x-ray and the investigators added time needed for reviewing these files. The same was done at the RV including time of transportation
89044860|NCT04688879||According to the degree of occlusion, 13 patients were divided into complete and incomplete groups.|Seven patients were complete occlusion and 6 patients were incomplete occlusion and all underwent thrombolysis with intra-arterial urokinase and the outcome was analysed..
89044861|NCT04688957|Active Comparator|osteotome sinus lifting|
89044862|NCT04688957|Experimental|oseodensification sinus lifting|
89044863|NCT04517721|Experimental|Treatment group|"The 4C's-TBuRP for adult burn survivors comprises of two phases:~Phase 1: Discharge planning/ preparation and day of discharge (Comprehensive assessment and evaluation, Education, guidance, and counselling, Treatment and procedures, Case management (referral for nursing follow-up), multi-disciplinary follow-up and Surveillance)~Phase 2: Follow-up Phase (2 WeChat Telehealth, 6 structured telephone follow-ups and daytime patient/ family-initiated telephone service; home visit based on meeting criteria) over an 8-week follow-up with delivery of rehabilitation care across the spectrum by trained nurse case managers ongoing assessment, intervention using the Omaha System and delivery of evidence-based care."
89044864|NCT04517721|Active Comparator|Control group|Participants in the control group will receive the care at the discharge planning phase and thereafter continue to utilise the exiting service available at the hospital, that is, medical review in the hospital.
89044865|NCT02917733|Experimental|Radiolabelled LY3039478|Single dose of radiolabelled LY3039478 administered orally.
89044866|NCT02917655|Experimental|Educational Program Associated (EPA)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital on months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; on month 4 for a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
89044867|NCT02917655|Other|Educational Program Isolated (EPI)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA.~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
89044868|NCT02917538|Experimental|Intervention group|In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters.
89044869|NCT02917538|Active Comparator|Control group|In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters.
89647442|NCT05307185|Active Comparator|Low-FODMAPs diet (LFD)|A personalized LFD will be assigned after reviewing a food diary and having a one-on-one personal consultation with a nutritionist. Diet will match the basal metabolic rate and daily energy expenditure. A detailed weekly structured menu based on three meals (breakfast, lunch, and dinner) and two snacks (morning and afternoon) will be provided. Patients also will receive a booklet detailing what foods are allowed, which foods to avoid and which foods to reduce based on the classifications used by Monash University and cut-off values for each FODMAPs subgroup. Nutritionists have already created a leaflet for patients in the study with details on where to buy specific products. Besides, nutritionists will guarantee adequate fiber intake, also offering advice on cooking without onions and garlic and other high-FODMAP foods. Drinking alcohol will not be recommended, although it is not high in FODMAPs.
89647443|NCT05307185|Active Comparator|Specific dietary advice for IBS|"According to NICE BDA Irritable bowel syndrome dietary advice, a controlled diet will be provided. All the food items (bread, pasta, taralli - local salty biscuits, and breakfast biscuits) will be prepared using durum wheat flour commercially available and anonymized to guarantee masking. Dietary recommendations include eating slowly, limiting alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoiding chewing gums and sweeteners containing polyols; small and frequent meals, stressful conditions."
89647444|NCT05305989|Experimental|Arm A: belumosudil 200 mg QD|The assigned arm is per the previous study KD025-213 or study KD025-208
89647445|NCT05305989|Experimental|Arm B: belumosudil 200 mg BID|The assigned arm is per the previous study KD025-213 or study KD025-208
89647446|NCT05305989|Experimental|Arm C: belumosudil 400 mg QD|The assigned arm is per the previous study KD025-213 or study KD025-208
89647447|NCT05279456|Experimental|Spikogen vaccine - accelerated arm|Spikogen vaccine 25 micrograms by intramuscular injection on study months 0, 1 and 2
89647448|NCT05279456|Experimental|Spikogen vaccine - standard arm|Spikogen vaccine 25 micrograms by intramuscular injection on study months 0, 1 and 4
89647449|NCT05276830|Experimental|40 micrograms|Sublingual film containing 40 micrograms Dexmedetomidine
89647450|NCT05276830|Experimental|60 micrograms|Sublingual film containing 60 micrograms Dexmedetomidine
89647451|NCT05276830|Experimental|Placebo|Sublingual Placebo film
89647452|NCT05218109|Experimental|tVNS + mindfulness|Transcutaneous vagus nerve stimulation plus behavioral: mindfulness
89647453|NCT05218109|Sham Comparator|Sham + mindfulness|Sham transcutaneous vagus nerve stimulation plus behavioral: mindfulness
89647454|NCT05218109|Active Comparator|Mindfulness only|
89647455|NCT05218109|Active Comparator|Control|Control number puzzle task delivered via mobile device
89647456|NCT05211596|Other|Single Intervention Arm (Main Intervention)|Main Intervention
89647457|NCT05205928|Active Comparator|Placebo + closed-loop insulin system|
89647458|NCT05205928|Experimental|Semaglutide, Ozempic® (at maximum tolerated dose) + closed-loop insulin system|Semaglutide is a Glucagon-Like Peptide 1 Receptor Agonist. It stimulates GLP1 in the body, which allows for increased satiety, reduced glucagon levels, delayed gastric emptying, and in some, increased insulin secretion. It is a once per week subcutaneous injection.
89044870|NCT04485273|Active Comparator|Dexmedetomedine Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected, in addition to dexmedetomedine.
89647459|NCT05205356||Neonates and Parents/Caregivers|"Providers caring for newborns that meet eligibility criteria will approach parents to assess interest. The VIGOR study staff will remotely contact parents to complete consent for genomic sequencing (GS). We will also invite 1 additional primary caregiver (e.g. father, co-mother etc.) to participate even if that caregiver is not biologically related to the child.~We will administer surveys at baseline enrollment to assess sociodemographics, obstetrical history, family genetic history & mental health; within 1 week of disclosure of findings to assess satisfaction & mental health; & at 3 & 6 months to further assess mental health & newborn clinical outcomes. We will approach a subset of the families for qualitative interviews to assess satisfaction with VIGOR & receipt of GS results with their physician in more detail."
89647460|NCT05205356||Clinicians|Following focus groups at each of the participating sites to assess the feasibility & needs of each site, the care teams will receive basic training in genomics and how to disclose GS results with VIGOR support. Study orientation will be completed as part of the training. Focus groups will be conducted within 1 year post implementation & again between year 4 & the completion of the study, to assess feasibility & appropriateness of VIGOR. We will administer brief surveys to the care providers before & after receipt of genomic education to assess their baseline knowledge & comfort with genomic medicine in newborns. Surveys will be repeated within a week of disclosure to families regarding feedback on the process & satisfaction with VIGOR. After approximately 3-5 disclosure events, study staff will approach the clinical care team members to participate in a qualitative interview to assess their perspectives in more depth.
89647461|NCT05203068|Experimental|Recombinant tuberculosis allergen (CFP10-ESAT6)|RTA (CFP10-ESAT6) 0.2 µg/0.1 mL RTA given intradermally on the middle of the forearm
89647462|NCT05200845|Experimental|Conditioned Stimulus+ (CS+) and High Fat Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose first. They will also undergo the high fat meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucralose and the high carbohydrate test meal session.
89647463|NCT05200845|Experimental|Conditioned Stimulus+ (CS+) and High Carbohydrate Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucrose first. They will also undergo the high carbohydrate meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucralose and the high fat test meal session.
89647464|NCT05200845|Experimental|Conditioned Stimulus- (CS-) and High Fat Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucralose first. They will also undergo the high fat meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucrose and the high carbohydrate test meal session.
89647465|NCT05200845|Experimental|Conditioned Stimulus- (CS-) and High Carbohydrate Test Meal First|Participants will undergo exposure sessions with flavored beverage solutions containing sucralose first. They will also undergo the high carbohydrate meal test session inside the metabolic chamber first. Then, they will undergo exposure sessions with flavored beverages containing sucrose and the high fat test meal session.
89647466|NCT05194735|Experimental|TCR-T Cell Drug Product|"Phase I: Dose-escalation of TCR-T Cell Drug Product~Phase II: Single dose of TCR-T Cell Drug Product after MTD/RP2D determine in Phase I portion of the study"
89647467|NCT05194735|Experimental|TCR-T Cell Drug Product with Aldesleukin (IL-2)|"Phase I: Dose-escalation of TCR-T Cell Drug Product with Aldesleukin (IL-2)~Phase II: Single dose of TCR-T Cell Drug Product with Aldesleukin (IL-2) after MTD/RP2D determine in Phase I portion of the study"
89647468|NCT05182554|No Intervention|Control|No intervention in this arm; the study team will examine publicly available county- and zip code-level outcomes in this group.
89647469|NCT05182554|Experimental|Treatment 1: Direct|Facebook users in the area receive ads which include videos of health professionals telling them to get vaccinated. The health professionals answer common questions about Covid-19 vaccines (e.g. are they safe / are they free).
89647470|NCT05182554|Experimental|Treatment 2: Friends|Facebook users in the area receive ads which include videos of health professionals encouraging them to help their friends to get vaccinated. There is also a link in the ad to a website build by the study team. This website hosts videos which answer common questions about vaccination (the same videos which are directly served to Facebook users in Treatment 1).
89044871|NCT04485273|Placebo Comparator|Control Group|Laryngeal mask airway is inserted and anesthesia is maintained with sevoflurane. Subtenon's block is performed and local anesthetic solution is injected.
89044872|NCT02205528|Placebo Comparator|Treatment Period: Placebo QD|Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.
89044873|NCT02205528|Experimental|Treatment Period: NNC0090-2746 QD|Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.
89044874|NCT02205528|Active Comparator|Treatment Period: Liraglutide QD|Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.
89044875|NCT03532022|Experimental|Chronocort|Hydrocortisone modified release capsules - Chronocort®. 66 subjects will be randomised to this group using an interactive web response system (IWRS).
89044876|NCT03532022|Active Comparator|Standard Care|Subjects participating in this arm will continue to receive their normal, standard care (hydrocortisone, dexamethasone, prednisone, prednisolone) once enrolled on the study. 66 subjects will be randomised to this arm using an interactive web response system (IWRS).
89044877|NCT02205099|Experimental|SKL15508 High Dose|SKL15508 High Dose
89044878|NCT02205099|Experimental|SKL15508 Medium Dose|SKL15508 Medium Dose
89044879|NCT02205099|Experimental|SKL15508 Low Dose|SKL15508 Low Dose
89044880|NCT02205099|Placebo Comparator|Placebo|Placebo
89044881|NCT02200380|Experimental|CDX-301|
89044882|NCT02200380|Experimental|CDX-301 and plerixafor|
89044883|NCT02196792|Active Comparator|E-Poly/32 mm|E-Poly polyethylene liner in a titanium cup with a stem with 32 mm cobalt-chromium (CoCr) femoral head.
89044884|NCT02196792|Active Comparator|E-Poly/36 mm|E-Poly polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
89044885|NCT02196792|Active Comparator|ArComXL/32 mm|ArComXL polyethylene liner in a titanium cup with a stem with 32 mm CoCr femoral head.
89044886|NCT02196792|Active Comparator|ArComXL/36 mm|ArComXL polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
89044887|NCT02917499|Experimental|TMS|The experimental group will be treated with transcranial magnetic stimulation for 4 weeks.
89647471|NCT05182554|Experimental|Treatment 3: Gossips|Facebook users in the area receive ads which include videos of health professionals encouraging them to nominate their most influential friends to help their friends get vaccinated. The difference from Treatment 2 is that the health professionals call on Facebook users to get their most influential friends to do the convincing about the vaccine. There is also a link in the ad to a website built by the study team. This website hosts videos which answer common questions about vaccination (the same videos that are directly served to Facebook users in Treatment 1).
89647472|NCT05182320||OrthoPath|
89647473|NCT05182320||Control|
89647474|NCT05172791|No Intervention|Usual care|Clinical teams will decide on antibiotic duration for patients with possible pneumonia without external prompting
89647475|NCT05172791|Experimental|Electronic alert|An electronic alert will be displayed within the electronic medical record of eligible patients that notes that the patient's respiratory rate and oxygenation are within the normal range and will advise stopping antibiotics prescribed for possible pneumonia
89647476|NCT05172791|Experimental|Pharmacist|Pharmacists will contact the treating teams of eligible patients to note that the patient's respiratory rate and oxygenation are within the normal range and will advise stopping antibiotics prescribed for possible pneumonia.
89647477|NCT05150821||experimental|patients during lockdown
89647478|NCT05150821||control group|patients before lockdown
89647479|NCT05131815|Experimental|Virtual Group-Based Physical Activity (BurnAlong) and Discussion Board|Participants will be asked to complete a 12 week virtual physical activity program delivered by the BurnAlong app, participate in a discussion board, and engage in live physical activity sessions with an exercise physiologist.
89647480|NCT05071027|Experimental|App Medication Reminder Group|Patients in this group will receive dual antiplatelet medication reminders.
89647481|NCT05071027|No Intervention|Non-app Using Group|Patients in this group receive the same standard of care [i.e. endovascular stent-based treatment of unruptured aneurysms] as the other group, but do not receive app dual antiplatelet reminders.
89647482|NCT05070663||Participants with severe asthma|Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study.
89647483|NCT05070364|Experimental|Peginterferon Lambda for 48 weeks|Peginterferon Lambda 180 mcg once weekly for 48 weeks with 24 weeks follow-up
89647484|NCT05070364|No Intervention|No treatment for 12 weeks|No treatment for 12 weeks followed by Peginterferon Lambda 180 mcg once weekly for 48 weeks and 24 weeks follow-up
89647485|NCT05060068|Placebo Comparator|Placebo group|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
89647486|NCT05060068|Experimental|Low-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
89647487|NCT05060068|Experimental|High-dose ketamine group|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
89647488|NCT05056844|Experimental|Diagnostic (CESM, DBT)|Patients receive iodine-based contrast agent IV then undergo CESM over 10-15 minutes. Patients who have not undergone standard of care DBT within 3 months from the study, also undergo DBT.
89647489|NCT05043350|Experimental|Interventional group|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
89647490|NCT05043350|Active Comparator|Control group|107 patients will receive standard drug therapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company)
89044888|NCT02917499|No Intervention|noTMS|The control (no intervention) group will be treated as usual (with pharmacotherapy). These patients will receive TMS treatment after data collection is ended.
89044889|NCT02191878|Experimental|Phase 1 Escalation / Phase 2 Expansion|"Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.~Phase 2 - dose expansion at the MTD."
89044890|NCT03411083||Knee replacement|Patients assigned for total or unicompartmental knee replacement surgery
89647491|NCT05010109|Experimental|Standard Treatment Plan (Cohort One)|Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.
89647492|NCT05010109|Experimental|Model Based Personalized Treatment Plan (Cohort Two)|Patients undergo SPECT/CT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.
89647493|NCT04985266|Active Comparator|Standard endocrine therapy|"Standard endocrine therapy will continue for up to 24 months on trial.~Standard endocrine therapies include tamoxifen, and aromatase inhibitors (letrozole, anastrazole, exemestane)."
89647494|NCT04985266|Experimental|Palbociclib and fulvestrant|"Treatment with palbociclib plus fulvestrant will continue for a maximum of 24 months.~Palbociclib will be given orally once a day on days 1-21 of each 28 day cycle.~Fulvestrant 500 mg will be administered on cycle 1 days 1 and 15, cycle 2 day 1 and then every 28 days thereafter (plus or minus 3 days) as two intramuscular injections of 250mg fulvestrant at each visit."
89647495|NCT04967274|Experimental|Spinal cord injured subjects|
89647496|NCT04949776|Experimental|Double reading of all cases with and without Transpara software|Double reading of all cases with and without Transpara software
89647497|NCT04929288|Experimental|Males|Participants in this group will be adult male drinkers.
89044891|NCT02187003|Experimental|Rivipansel Treatment Arm|
89044892|NCT02187003|Placebo Comparator|Placebo Treatment Arm|
89044893|NCT03330509|Experimental|Cluster 1|Control: 1-4 months; SPARK intervention: 5-20 months
89044894|NCT03330509|Experimental|Cluster 2|Control: 1-8 months; SPARK intervention: 9-20 months
89647498|NCT04929288|Experimental|Females|Participants in this group will be adult female drinkers. Data will be segregated by menstrual cycle phase.
89647499|NCT04896697|Experimental|Part 1A - XTX101 Monotherapy Dose Escalation|Part 1A Dose Escalation of XTX101 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 dose (RP2D).
89647500|NCT04896697|Experimental|Part 1B - Pharmacodynamic (PD) Dose Expansion|Part 1B XTX101 at the RP2D will be administered to further examine XTX101 as monotherapy in patients with select advanced solid tumors.
89647501|NCT04896697|Experimental|Part 1C - XTX101 Dose Escalation in Combination with Atezolizumab|Part 1C will receive a labeled dose of atezolizumab in combination with XTX101.
89647502|NCT04862468|Experimental|Treatment|
89647503|NCT04862468|Sham Comparator|Control|
89647504|NCT04860323|Experimental|Analytical Treatment Interruption|Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 703/HPTN 081 (NCT02568215).
89647505|NCT04858451|Experimental|All participants|"In Part 1a, up to 48 patients will be administered single ascending doses of RESP301 (1-6ml; 8 patients per dose cohort). Provided that individual stopping criteria are not met in ≥3 participants, and there are no serious adverse events that are at least possibly related to RESP301, the next dose cohort can be enrolled. Patients can be enrolled into more than one dose cohort provided they did not meet individual stopping criteria.~In Part 1b, 8 participants will receive RESP301 at MTD determined in Part 1a, with short-acting bronchodilator administered 10min prior to RESP301.~In Part 2, a minimum of 150 patients will be enrolled. This may include patients who took part in Part 1. At least the first 50 patients will receive a test dose of RESP301 before enrolment into the dormant phase. Patients who experience flare-up symptoms while in the dormant phase, may proceed to the treatment phase where they will self-administer RESP301 at home for 7 days."
89647506|NCT04849975|Experimental|Pelvimetry group|The participants oh this group will successively perform MRI pelvimetry and EOS imaging.
89647507|NCT04825015||OLTx|Liver insufficiency patients undergoing transplantation surgery
89647508|NCT04814927|Active Comparator|Copper IUD|The copper IUD contains approximately 176 mg of copper wire wrapped around a vertical stem. It is FDA approved for pregnancy prevention for 10 years.
89647509|NCT04814927|Active Comparator|Etonogestrel Implant|The ETG implant is a single, radiopaque, rod shaped implant containing 68 mg of etonogestrel. It is FDA approved for pregnancy prevention for 3 years.
89647510|NCT04814927|Active Comparator|Levonorgestrel IUS|The LNG IUS contains approximately 52 mg. of LNG. It is FDA approved for pregnancy prevention for 5 - 6 years.
89647511|NCT04814927|Active Comparator|DMPA Sub-cutaneous|DMPA contains 104 mg of medroxyprogesterone acetate in 0.65 mL of fluid, administered by subcutaneous injection in the abdominal fat, thigh or skin over the deltoid muscle. It is FDA approved for pregnancy prevention for 14 weeks.
89647512|NCT04774861||CCTA Group|This is an all-comers group, of all ages and ethnicities who have been evaluated with a CCTA from 2017-2020.
89647513|NCT04772482||All Participants|All participants will undergo path testing to determine skin sensitivity to certain compounds.
89647514|NCT04747912|Experimental|Treatment Arm - Induction/Consolidation Phase - All Participants|"All participants in this arm will receive the same first round of treatment as part of induction/consolidation therapy. This treatment will use inotuzumab ozogamicin combined with anti-cancer drugs. The additional treatment that participants receive after this first round of treatment will vary based on the participant's response to induction therapy. This phase of treatment will last for 60 days. All participants in this arm will receive the following treatment:~Treatment Course I (Induction Phase, 28 days):~Dasatinib 140mg daily continuous~Dexamethasone 10mg/m^2 PO or IV Days 1-7 and Day 15-Day 22~InO 0.8mg/m2 Day 8; 0.5mg/m2 D15, 0.5mg/m2 Day 22~Intrathecal methotrexate 15mg Day 1, Day 28~Treatment Course II (Consolidation Phase, 28 days):~Dasatinib 140mg daily continuous~InO: If in CR/CRi 0.5mg/m2 Day 1, Day 8, Day 15; If not in CR/CRi 0.8mg/m2 on Day 1, 0.5mg/m2 Day 8 and Day 15~Intrathecal methotrexate 15mg Day 1, Day 28"
89647515|NCT04747912|Experimental|Treatment Arm - Interim/Maintenance Phase - Participants in CMR|"This study arm is for participants who no longer show any detectable signs of BCR-ABL1 (a cancer-causing gene) in response to the previous phase of induction/consolidation treatment (also known as being in complete molecular remission or CMR). Participants in this arm will receive 3 courses of interim/maintenance treatment using dasatinib combined with other anti-cancer drugs. Inotuzumab ozogamicin will be added during the fourth course of treatment. These treatments will be given in 28-day and 84-day cycles.~If the participant achieves complete molecular remission (no signs of BCR-ABL gene) after 60 days (or more) of treatment, then the treating physician may take the participant off the study for allogenic stem cell transplantation surgery.~If the participant does not undergo allogeneic stem cell transplantation after achieving complete molecular remission, they will complete 3 additional courses of maintenance treatment."
89647516|NCT04747912|Experimental|Treatment Arm - Interim/Maintenance Phase - Participants Not in CMR|"This study arm is for participants whose cancer responded to induction/consolidation treatment, but still shows detectable signs of BCR-ABL1 (a cancer-causing gene), so they are not in complete molecular remission. Participants in this arm will receive 3 courses of treatment using ponatinib combined with other anti-cancer drugs. Inotuzumab ozogamicin will be added during the 4th treatment course. These treatments will be given in 28-day and 84-day cycles.~If the participant achieves complete molecular remission (no signs of BCR-ABL gene) after 60 days (or more) of treatment, the treating physician may take the participant off the study for allogenic stem cell transplantation surgery.~If the participant does not undergo allogeneic stem cell transplantation after achieving complete molecular remission (CMR), they will complete 3 additional courses of maintenance treatment.~If the participant doesn't achieve CMR after 4th treatment course, they will be removed from the study."
89647517|NCT04732780||Questionnaire group|Individuals who attend the type 1 diabetes clinic will complete a number of self-report questionnaires and a survey.
89647518|NCT04612465|Experimental|ASC (test arm)|(Autologous Adipose-derived Mesenchymal Stem Cells)
89647519|NCT04612465|Placebo Comparator|Fibringlue|Standard comparator
89044895|NCT03330509|Experimental|Cluster 3|Control: 1-12 months; SPARK intervention: 13-20 months
89044896|NCT03330509|Experimental|Cluster 4|Control: 1-16 months; SPARK intervention: 17-20 months
89647520|NCT04603911|Active Comparator|Control|Control arm will receive standard of care solution for the ESPB block
89647521|NCT04603911|Active Comparator|Liposomal Bupivicaine|Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block
89647522|NCT04597424|Experimental|doxycycline and Bexsero® vaccine|-doxycycline will be taken by participants as PEP (prophylaxy post exposition) and participants will received Meningococcal B vaccine (Bexsero®) at D0 and M2
89647523|NCT04597424|Experimental|doxycycline|-doxycycline will be taken by participants as PEP (prophylaxy post exposition)
89647524|NCT04597424|Experimental|Bexsero® vaccine|-Meningococcal B vaccine (Bexsero®) at D0 and M2
89647525|NCT04597424|No Intervention|No treatment|-no doxycycline and no Bexsero® vaccine
89647526|NCT04590703||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
89647527|NCT04590703||Vehicle sheet|Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-301
89647528|NCT04569409|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
89044897|NCT00554814|Experimental|3|Blédilait Biofer® milk (1,1mg/100kcal)
89044898|NCT00554814|Experimental|1|Blédilait Biofer® milk (2mg/100kcal)
89044899|NCT00554814|Active Comparator|2|Milk supplemented with ferrous sulphate (2mg/100kcal)
89044900|NCT02917382||Waiting list for liver transplant|Patients on the waiting list for liver transplant treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
89044901|NCT02917382||Undergoing liver transplantation|Patients undergoing liver transplantation treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
89044902|NCT02161419|Active Comparator|BAY1000394|Roniciclib 5 mg bid 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
89044903|NCT02161419|Placebo Comparator|Placebo|Matching placebo 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
89044904|NCT02917616|Experimental|Alkaline water|Two liters (minimum) daily of alkaline drinking-water (pH=9) for 14 days
89044905|NCT02917616|Active Comparator|Neutral Water|Two liters (minimum) daily of neutral drinking-water (pH=7) for 14 days
89044906|NCT02160678|Active Comparator|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
89044907|NCT02160678|Other|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
89044908|NCT02160678|Placebo Comparator|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
89044909|NCT02917304|Experimental|GC3110A vaccine group|Participants administered a single dose of GC3110A(Quadrivalent Influenza Vaccine).
89044910|NCT02917226|Experimental|Clinical decision support and monitoring system|
89044911|NCT02917226|No Intervention|Control Group|
89044912|NCT02153502|Experimental|AVP-786|
89044913|NCT02153502|Placebo Comparator|Placebo|
89044914|NCT02917343|Experimental|intervention arm|participants received 4 weeks of mirror therapy and repetitive task training
89044915|NCT02917148||aGVHD|Patient who undergo allogeneic transplant with clinical and/or biopsy-proven diagnosis of aGVHD within the first 100 days post-transplant.
89044916|NCT02917148||non aGVHD|Patients who undergo allogeneic transplant but do not develop aGVHD.
89044917|NCT02151474|Experimental|INCB047986 4 mg QD|INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
89647529|NCT04569409|Placebo Comparator|Vehicle sheet|Hydrogel sheet without allogenic mesenchymal stem cell
89647530|NCT04554901|Other|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
89647531|NCT04546477|Other|Single Arm|"135 patients stratified into 2 groups:~FEM-POP patients: SFA-P1~Isolated POP Patients: P1, P2, P3 only~It is expected the majority of enrolled patients to be FEM-POP category. In case sufficient Isolated POP patients are enrolled, a sub-analysis will be performed on this group of patients."
89647532|NCT04501978|Experimental|ACTIV-3 Drug plus SOC|Participants in this study will be randomized to receive one of the ACTIV-3 drug treatments plus Standard of Care (SOC) or placebo plus SOC
89647533|NCT04501978|Placebo Comparator|Placebo plus SOC|The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
89044918|NCT02151474|Experimental|INCB047986 8 mg QD|INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
89044919|NCT02151474|Experimental|INCB047986 12 mg QD|INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
89044920|NCT02151474|Experimental|INCB047986 placebo QD|INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
89044921|NCT02917070||Patients|Patients who have chronic kidney diseases
89044922|NCT02917070||Healthy controls|Healthy subjects
89044923|NCT02144181|Active Comparator|Group A|Subjects will receive two low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one low-density Ulthera System Treatment.
89044924|NCT02144181|Active Comparator|Group B|Subjects will receive three low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two low-density Ulthera System Treatments.
89044925|NCT02144181|Active Comparator|Group C|Subjects will receive two high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one high-density Ulthera System Treatment.
89044926|NCT02144181|Active Comparator|Group D|Subjects will receive three high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two high-density Ulthera System Treatments.
89044927|NCT02917109|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
89212747|NCT04082039|Experimental|2-channel PCA|Ch-1: fentanyl 16 µg/kg (total volume 100 ml with normal saline) Ch-2: ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
89647534|NCT04472442|Experimental|High Intensity Training with Intermittent Hypoxia|The primary goal will be provide acute intermittent hypoxia (9% PO2; 1 min on 1 min off) prior to stepping training while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
89647535|NCT04472442|Sham Comparator|High Intensity Training with Sham Hypoxia|The primary goal will be provide sham intermittent hypoxia (20% PO2) prior to performing continuous stepping while maintaining HR within 70-85% maximum predicted HR (if patients are deconditioned, PTs will gradually increase intensity to desired levels as tolerated). Sessions will be divided into ~10 minute increments (~25% of sessions) between speed-dependent treadmill training (described above for treadmill stepping), skill-dependent treadmill training, overground training, and stair climbing.
89647536|NCT04453475|Experimental|Partial digital group: depression|"Burg~Online depression session as a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
89647537|NCT04453475|Experimental|Partial digital group: social work (social medicine)|"NOR~Online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
89647538|NCT04453475|Experimental|Partial digital group: depression + social work|"JUL~Online depression session as a flipped classroom and an online lecture with socio-medical content and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
89647539|NCT04453475|Active Comparator|Control group: only digital training before rehabilitation|"MOE~Online tobacco cessation a flipped classroom and voluntary low-threshold communication trainings as well as training on rehabilitation goals"
89647540|NCT04348591|Experimental|Misophonia Group|Participants who endorse Misophonia will undergo a neuroimaging session to identify different neurostimulation targets. Then Misophonic participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
89647541|NCT04348591|Active Comparator|Emotional Dysregulation Clinical Group|Participants who self report high emotional dysregulation and who meet diagnostic criteria for a DSM disorder will undergo a neuroimaging session to identify different neurostimulation targets. Then these participants will be exposed to aversive and neutral sounds while receiving real or sham neurostimulation over different pre-established neural targets.
89647542|NCT04342819|Experimental|SGLT2i|Empagliflozin 25 mg per oral once daily
89647543|NCT04320381||Group A|subjects in the hypertonic saline study randomized to discontinue or maintain therapy
89647544|NCT04320381||Group B|subjects in the dornase alfa study randomized to discontinue or maintain therapy
89647545|NCT04320381||Group C|subjects who were randomized but withdrew early from the SIMPLIFY Study.
89647546|NCT04320381||Group D|subjects in the hypertonic saline study randomized to discontinue or maintain therapy with FEV1% predicted between 40 and <60%
89647547|NCT04320381||Group E|caregiver participants (parents and legal guardians of eligible patient participants less than 18 years of age who were randomized in the SIMPLIFY study)
89647548|NCT04280341|Experimental|RC48-ADC in combinaton with Anti-PD1 Monoclonal Antibody|RC48-ADC(Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate) JS001(Recombinant Humanized Anti-PD1 Monoclonal Antibody)
89647549|NCT04279223|Active Comparator|5 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
89647550|NCT04279223|Sham Comparator|10 mm trocar group|A study with 107 patients was planned to compare the development of trocar site hernia.
89647551|NCT04263727||Asthma|Non-Interventional. Patients with asthma will be screened and enrolled into the active Asthma disease-specific cohort.
89647552|NCT04263727||Chronic Obstructive Pulmonary Disease (COPD)|Non-Interventional. Patients with COPD will be screened into the inactive COPD disease-specific cohort.
89044928|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 1|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: visit to out-patient clinic,CT scan of pulmones."
89647553|NCT04263727||Idiopathic Pulmonary Fibrosis (IPF)|Non-Interventional. Patients with IPF will be screened into the inactive IPF disease-specific cohort.
89647554|NCT04250597|Experimental|Part 1 Dose Escalation|Drug: GNX102 Dose Escalation: 21 day dosing interval
89647555|NCT04250597|Experimental|Part 2 Dose Escalation|Drug: GNX102 Dose Escalation: 7 day dosing interval
89044929|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 2|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: withdrawal of blood sample for DNA analyses,"
89044930|NCT02916914|Other|Q2 feeding|feeding intervals: 2 hours
89044931|NCT02916914|No Intervention|Q3feeding|feeding intervals: 3 hours
89044932|NCT02130687|Active Comparator|Amlodipine|Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
89044933|NCT02130687|Experimental|Ramipril|Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
89044934|NCT02130687|Active Comparator|Valsartan|Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
89044935|NCT02916836||With TDC sheet|Use of therapeutic drug conciliation sheet (TDC) by the hospital and transmitted to the family practitioner with other usual documentation
89044936|NCT02916836||Without TDC Sheet|transmission of usual documentation only to the family practitioner
89044937|NCT02916758|Experimental|Let's Go Community Mobility Program|Participation in 4 week program
89647556|NCT04250597|Experimental|Part 3 Expansion|Drug: GNX102 Expansion: Selected dose level(s) and schedule(s) in expanded cohort(s)
89647557|NCT04250571|Experimental|No treatment group|Participants will receive no pills and will be told that they are in the no treatment group
89647558|NCT04250571|Experimental|Imaginary pill (IP) group|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence)
89647559|NCT04250571|Experimental|Open label placebo group|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo)"
89647560|NCT04228523|Experimental|Therapeutic education workshop|Two group receive therapeutic education workshop already existing in Toulouse University Hospital
89647561|NCT04228523|Other|Speaking Therapy|One group receive speaking therapy already existing in Toulouse University Hospital
89647562|NCT04222569|Experimental|T-piece and PSV 7 PEEP 0 and PSV 0 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
89647563|NCT04222569|Experimental|T-piece and PSV 0 PEEP 0 and PSV 7 PEEP 0|First T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
89647564|NCT04222569|Experimental|PSV 0 PEEP 0 and PSV 7 PEEP 0 and T-piece|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
89647565|NCT04222569|Experimental|PSV 0 PEEP 0 and T-piece and PSV 7 PEEP 0|First PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min.
89647566|NCT04222569|Experimental|PSV 7 PEEP 0 and T-piece and PSV 0 PEEP 0|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min.
89647567|NCT04222569|Experimental|PSV 7 PEEP 0 and PSV 0 PEEP 0 and T-piece|First PSV 7 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, PSV 0 cmH2O and PEEP 0 cmH2O trial for 15 min. After 10 min of rest, T-piece trial for 15 min.
89647568|NCT04169243|Experimental|Intervention|Women randomized to the New Nordic Diet meet the study dietician at week 30 for 1.5 hr of individual diet treatment according to the New Nordic Diet and a cognitive behavioral approach. The diet advice include evenly distributed meals over the day, foods low in fat and rich in fibre, 500 g fruit and vegetables daily, fish 2-3 times a week and keyhole foods. Participants will prepare their own food but are provided with recipes and food bags containing ingredients and foods to be consumed during the two-week intervention At gestational age 32 weeks, women meet with a dietitian and will be instructed to continue with the New Nordic Diet diet throughout pregnancy on their own.
89647569|NCT04169243|Active Comparator|Control|The control women receive diet advice according to usual care.
89647570|NCT04156087|Experimental|MIMIPAC|Intervention: MIS-MWA plus immunotherapy using the combination of durvalumab with tremelimumab
89647571|NCT04140097||COPD patients with acute exacerbation|
89647572|NCT04140097||COPD patients without acute exacerbation|
88992687|NCT05860244|Experimental|Salbutamol|"Salbutamol 2mg/5ml syrup : 2mg TID salbutamol for 3 months, then 4 mg TID for 3 months~For each investigated dose (6 mg then 12 mg), the treatment will be titrated during a 4 days period:~At beginning of the first 3-month period : Month 0 D1: 2mg in the morning; D2-D3: 2 mg in the morning and 2mg in the evening for two days; From D4 and until the end of first 3-month period (until the M3 follow-up visit): 2mg in the morning, at noon and in the evening~At beginning of the second 3-month period : Month 3 D1: 4mg in the morning, 2mg at noon, 2 mg in the evening; D2: 4 mg in the morning, 2 mg at noon and 4mg in the evening; J4 and for 3 months (until the M6 follow-up visit) : 4mg in the morning, at noon and in the evening."
88992688|NCT05860244|Placebo Comparator|placebo of salbutamol|"Placebo syrup : 2mg TID salbutamol for 3 months, then 4 mg TID for 3 months~For each investigated dose (6 mg then 12 mg), the treatment will be titrated during a 4 days period:~At beginning of the first 3-month period : Month 0 D1: 2mg in the morning; D2-D3: 2 mg in the morning and 2mg in the evening for two days; From D4 and until the end of first 3-month period (until the M3 follow-up visit): 2mg in the morning, at noon and in the evening~At beginning of the second 3-month period : Month 3 D1: 4mg in the morning, 2mg at noon, 2 mg in the evening; D2: 4 mg in the morning, 2 mg at noon and 4mg in the evening; J4 and for 3 months (until the M6 follow-up visit) : 4mg in the morning, at noon and in the evening."
88992689|NCT05860218|Other|advices|• Group I (control) will receive advices only.
89647573|NCT04112212|Other|No administration of vedolizumab-800CW|Patients did not receive vedolizumab-800CW but underwent a Fluorescence molecular imaging procedure to serve as a control group and compare results with patients receiving the tracer
89647574|NCT04112212|Experimental|4.5 mg vedolizumab-800CW group|Patients received 4.5 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
89647575|NCT04112212|Experimental|15 mg vedolizumab-800CW group|Patients received 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
88992690|NCT05860218|Experimental|exercises plus advices|• Group II (experimental) will receive a suggested functional exercise program plus advises
88992691|NCT05860205|No Intervention|No treatment condition|Group 1 (no treatment condition) will only receive educational materials through email and a weekly phone call from Coordinator to reduce dropouts for 12 weeks.
89647576|NCT04112212|Experimental|75 mg vedolizumab + 15 mg vedolizumab-800CW group|Patients received 75mg vedolizumab + 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
89647577|NCT04112212|Experimental|300mg vedolizumab + 15mg vedolizumab-800CW group|Patients received 300mg vedolizumab + 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
89647578|NCT04112212|Experimental|> 14 weeks of vedolizumab therapy + 15 mg vedolizumab-800CW group|Patients received 300mg vedolizumab + 15 mg vedolizumab-800CW after >14 weeks vedolizumab therapy and subsequently underwent a Fluorescence molecular imaging procedure
89647579|NCT04107077|Experimental|Drug Administration Period|
89647580|NCT04080128|Other|Contact lens|Depending upon the study lens proven to be the most effective in the BLINK Study, this contact lens will be used for the first two years of the study. The last year of the study, all subjects will be wearing single vision contact lenses.
89647581|NCT04057001||Patients who received a HCV+ liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C+ virus positive tested liver transplant.
89647582|NCT04057001||Patients who received a HCV- liver transplant|Patients on a wait list for a liver transplant who agree to receiving a hepatitis C- virus positive tested liver transplant.
89647583|NCT04051320|Experimental|Hormone Sensitive Women (HS+)|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
89647584|NCT04051320|Experimental|Hormone Insensitive Women (HS-)|Participants will take leuprolide acetate (lupron) via intramuscular injection, for 2 months. Participants will take 2 mg of estradiol twice daily and 200 mg of progesterone twice daily for 2 weeks.
89647585|NCT04046250|Experimental|TK112690|TK112690 treatment
89647586|NCT04046250|Placebo Comparator|Placebo|TK112690 formulation
89647587|NCT03990961|Experimental|Pembrolizumab Treatment|
89647588|NCT03875729|Experimental|teplizumab|Sterile solution for injection.
89647589|NCT03875729|Placebo Comparator|Placebo|Sterile solution for injection
89212748|NCT02586311|Experimental|CKD-330 16/5mg + Amlodipine 5mg placebo|CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.
89647590|NCT03861910||extensively hydrolyzed casein formula+LGG|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
89044938|NCT01228656|Experimental|-mometasone furoate associated with salicylic acid|
89044939|NCT01228656|Active Comparator|-mometasone furoate|
89044940|NCT02916641|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
89647591|NCT03861910||extensively hydrolyzed whey formula;|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
89044941|NCT02916641|Active Comparator|Monotherapy|UDCA monotherapy
89044943|NCT02916368||with surgery|
89044944|NCT02916368||with chemotherapy or radiotherapy|
89044945|NCT02125266|Experimental|Low Dose V404 PDS|Sustained intravitreal delivery of methotrexate (0.6 mg)
89044946|NCT02125266|Experimental|High Dose V404 PDS|Sustained intravitreal delivery of methotrexate (2.3 mg)
89044947|NCT02916524|Experimental|Model-based|Semantic Feature Analysis training will be provided in the language that was selected by the computational model.
89647592|NCT03861910||hydrolyzed rice formula|subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
88992692|NCT05860205|Active Comparator|Multiple component mobile-aid pain reduction intervention + sham osteopathic manipulation treatment|Group 2 will receive the new intervention and sham osteopathic manipulative treatment for 12 weeks.
88992693|NCT05860205|Active Comparator|Multiple component mobile-aid pain reduction intervention + osteopathic manipulation treatment|Group 3 will receive both the multiple component mobile-aid pain reduction intervention and actual osteopathic manipulation treatment for 12 weeks.
88992694|NCT05860153|Experimental|Group (A)|• Group (A) will receive oral levetiracetam at a dose of 15-20 mg/kg/day twice daily at the onset of fever (temperature >37.5 c) for 48h after subsiding of fever.
88992695|NCT05860153|Experimental|Group (B)|• Group (B) will receive diazepam at a dose of 0.3 mg/kg/dose was given every eight hours for 48h after subsiding of fever Children were followed up for 12 months to find out seizure frequency associated with febrile events and febrile seizure recurrence rate during 12 months follow-up
89044948|NCT02916524|Active Comparator|Model-opposite|Semantic Feature Analysis training will be provided in the language opposite to that which was selected by the computational model.
89647593|NCT03861910||soy based formula|subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
89647594|NCT03861910||amino-acid based formula|subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
89647595|NCT03841526|Experimental|CRC Phase: Glucagon RTU With Insulin Pump Reduction|CRC Phase: 2-arm randomized double-blind crossover, Glucagon RTU Injection 30 microliters of 0.15 mg injection with 50% reduction in the insulin pump
88992696|NCT05860114|Experimental|Givinostat (single-dose and multiple-dose)|On day 1, givinostat 50 mg as oral suspension was administered as a single dose, in the morning. On Days 5-12 givinostat 50 mg as oral suspension was administered twice-daily, in the morning and in the evening, as a multiple dose. On day 13 givinostat 50 mg as oral suspension was administered as a single dose, in the morning.
88992697|NCT05860101|Other|1 week waitlist|
88992698|NCT05860101|Other|2 week waitlist|
88992699|NCT05860075|Experimental|IMM01 in subjects with hematologic malignancy|"The escalation dosing were 3µg/kg, 10µg/kg, 50µg/kg, 150µg/kg, 500µg/kg, 1.0mg/kg, 1.5mg/kg and 2.0mg/kg.~The extend cohorts were Hodgkin's lymphoma, B-cell lymphoma,NK/T-cell lymphoma,AML,MDS and MM cohorts"
88992700|NCT05860062|Placebo Comparator|calcium+topiramate/amitriptyline|Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).
88992701|NCT05860062|Experimental|vitamin D3/calcium+topiramate/amitriptyline,|Patients with prophylactic treatment (amitriptyline, topiramate) + Vitamin D and calcium supplementation: 1 Tablet every 24 hours containing: Calcium carbonate 1666.670 mg (600 mg calcium) + Vitamin D3 6.2 mg (400 IU).
88992702|NCT05860062|Active Comparator|vitamin D+topiramate/amitriptyline|Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)
88992703|NCT05860023|No Intervention|Control Group|In this group, mothers will only take routine gynecologic. No additional treatment will be applied to the mothers in this group.
89647596|NCT03841526|Placebo Comparator|CRC Phase: Vehicle for Glucagon RTU With Insulin Pump Reduction|CRC Phase: 2-arm randomized double-blind crossover, Vehicle for Glucagon RTU Injection 30 microliters vehicle with 50% reduction in the insulin pump
89647597|NCT03841526|Experimental|Outpatient Phase: Glucagon RTU With Insulin Pump Reduction|Outpatient Phase: 3-arm randomized comparison (2-arm double-blind, 1-arm open-label), Glucagon RTU Injection 30 microliters of 0.15 mg injection with 50% reduction in the insulin pump (double-blind arm)
89212749|NCT02586311|Active Comparator|CKD-330 16/5mg placebo + Amlodipine 5mg|CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.
89647598|NCT03841526|Placebo Comparator|Outpatient Phase: Vehicle for Glucagon RTU With Insulin Pump Reduction|Outpatient Phase: 3-arm randomized comparison (2-arm double-blind, 1-arm open-label), Vehicle for Glucagon RTU Injection 30 microliters vehicle with 50% reduction in the insulin pump (double-blind arm)
89647599|NCT03841526|Experimental|Outpatient Phase: Glucagon RTU Without Insulin Pump Reduction|Outpatient Phase: 3-arm randomized comparison (2-arm double-blind, 1-arm open-label), Glucagon RTU Injection 30 microliters of 0.15 mg injection without a reduction in the insulin pump (open-label arm)
89647600|NCT03834506|Experimental|Pembrolizumab+Docetaxel|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m^2 by IV infusion Q3W for a maximum of 10 cycles (approximately 7 months). Participants also receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each docetaxel cycle.
89647601|NCT03834506|Placebo Comparator|Placebo+Docetaxel|Participants receive placebo by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to a maximum of 35 cycles (approximately 2 years) PLUS docetaxel 75 mg/m^2 by IV infusion Q3W for a maximum of 10 cycles (approximately 7 months). Participants also receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours, and 1 hour prior to docetaxel administration and prednisone 5 mg by oral tablets twice daily during each docetaxel cycle.
89647602|NCT03808441|No Intervention|Standard Arm|"Dabrafenib + Trametinib~Switch to N+I at first progression"
89647603|NCT03808441|Active Comparator|ctDNA Guided Switch|"Dabrafenib + Trametinib~Switch to N+I when ctDNA levels in the blood have dropped by ≥80%."
89647604|NCT03800108|Other|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
89647605|NCT03792659||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
89647606|NCT03659123|Experimental|Intervention|"The intervention is designed to be implemented at different times of patients' care~During the prehabilitation time:~Nutritional care~Total-body rehabilitation~Pharmaceutical conciliation During peri-operative time~Management of enhances rehabilitation of the elderly. During rehabilitation time~Nutritional, medication conciliation and functional follow-up During hospital-home transition time~Nutritional and functional follow-up~Optimisation of symptoms management: abdominal pain, nausea, vomiting…"
89647607|NCT03637569||Cancer patients|Newly diagnosed pancreatic, bile duct or GB cancer patients at samsung medical center.
89647608|NCT03626467|Experimental|Arm 1|Men infected by HIV who have sex with men
89647609|NCT03616431||Demographic cohort|A prospective cross-sectional assessment of the prevalence of PEI-related symptoms in up to n=150 patients with pancreatic malignancy.
89647610|NCT03616431||Diagnosis cohort|"A sub-set (up to n=50) of the Demographic cohort patients will be tested to elucidate the most efficient diagnostic panel for PEI in pancreatic malignancy.~An extra assessment for PEI diagnosis consisting of a breath test (Pancreo-KIT breath test) will be carried out during the following 1-2 weeks after the first appointment (which takes around six hours to complete and involves the administration of bread spread with 13C butter followed by collection of the patient's breath in small plastic vials at timed intervals. The vials will subsequently be analyzed for 13C quantity; details in Appendix 6). Following these diagnostic tests, patients will complete an acceptability questionnaire to assess their opinion regarding the burden that these diagnostic tests may add."
89647611|NCT03616431||Follow-up cohort|Validation of the diagnostic panel designed and tested in Step-1 of this study and evaluation of dietician intervention (including Pancreatic Enzyme Replacement Therapy; PERT) and its impact in weight loss, symptom evolution, chemotherapy receiving rate, quality of life and overall survival.
89647612|NCT03610698|Experimental|Facilitated Intervention|Intervention arm facilitated by a trained team member, delivering the 8 positive emotion skills over 5 weeks.
89647613|NCT03610698|Experimental|Self-Guided Intervention|Intervention arm that is self-guided on an online platform, delivering the 8 positive emotion skills over 5 weeks.
89647614|NCT03610698|Active Comparator|Emotion Reporting Control|Participants in the emotion reporting control condition will be reporting their emotions daily for the same length as the intervention.
89647615|NCT03585660|Experimental|Interventional Arm|Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.
89647616|NCT03558438||HIV patients older than 50 years|Spanish cohort of patients with HIV infection older tha 50 years old.
89647617|NCT03554785|No Intervention|Control/Usual Care|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~Option to view 60 minute online webinar Do Ask, Do Tell: Collecting Data on Sexual Orientation and Gender Identity at Health Centers"
89647618|NCT03554785|Active Comparator|Intervention|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~CHC staff leadership key informant interviews (up to 5 at each site)~Tailored Educational Clinician and Non-clinician staff training intervention and technical assistance follow-up"
89044949|NCT02916524|No Intervention|Sub-Study: Computational Modeling for Bilingual Dementia and Semantic Decline|This is a sub-study aimed at building a computational model to simulate bilingual dementia and semantic decline.
89044950|NCT02116998|Experimental|GEN-004 with Aluminum Hydroxide|
89212750|NCT02586467|Experimental|Gain-Framed|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products).
89647619|NCT03535740|Experimental|Brigatinib 90 mg/180 mg with Optional Dose Escalation to 240 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity. Participants who experienced progression on the 180 mg dose and had not experienced toxicities greater than Grade 2 had the option to receive brigatinib 240 mg QD based on investigator's discretion, up to 20 months until data cut-off: 30 September 2020. Participants who experienced progression on any doses but judged as still benefiting from the study treatment by the investigator may continue to use the current dose, up to study end.
89647620|NCT03518060||Subjects receiving Juluca|Approximately 250 virologically suppressed HIV positive subjects on a stable antiretroviral regimen as indicated in local SmPC of Juluca will be included in the study. The subjects will be followed for approximately 3 years during routine clinical practice.
89647621|NCT03477669|Experimental|chamomile/probiotic arm|Infant will receive 5 drops of the study product once per day with a feeding at midday.
89647622|NCT03477669|Placebo Comparator|Placebo of chamomile/probiotic arm|Infant will receive 5 drops of a placebo product once a day at midday.
89647623|NCT03474744|Experimental|Experimental Arm|"Induction Phase:~Cycle 1-6 (28 days cycle):~Copanlisib: 60 mg i.v. fixed dose days 1, 8, 15. Rituximab: 375 mg/m2 day 1 i.v.~Maintenance:~Start 2 months after start of the last induction cycle for patients at least achieving a stable response after induction.~Copanlisib: 60 mg i.v. fixed dose day 1 and day 15 every 4 weeks for a maximum of 12 cycles or until progression or study drug-related intolerable toxicity (month 2 to month 13 after end of induction).~Rituximab: 375 mg/m2 i.v. day 1 every 8 weeks for a maximum of 12 infusions or until progression or study drug-related intolerable toxicity (month 2 to month 24 after end of induction)"
89647624|NCT03432481|Experimental|Knee Arthroplasty using BUKS|Unicompartmental Knee Arthroplasty Surgery
89647625|NCT03370874|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
89647626|NCT03370874|Placebo Comparator|Vehicle Sheet|Hydrogel sheet without Allogenic mesenchymal stem cell
89647627|NCT03367871|Experimental|Pembrolizumab, Chemotherapy, Bevacizumab|On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5; and Bevacizumab 15mg/kg (IV).
89647628|NCT03359889||patients administered with PraxbindTM|
89647629|NCT03351049|Experimental|Reactive, Low air loss support surface|Participants in this arm will use a reactive support surface with a low air loss feature
89647630|NCT03351049|Active Comparator|Reactive, non-low air loss|Participants in this arm will use a reactive support surface without a low air loss feature
88992704|NCT05860023|Experimental|Aerobic Exercise Group|This group will attend to seven days aerobic exercise program with 65% to 75% of their maximum heart rate monitored with pulse oximeter. Aerobic exercise will take 30 minutes consisting of 5 minute warm up, 20 minute jogging and 5 minute cool down. Prior to discharge pulse oximeter will be given to the participants for self monitorization. Their compliance to exercise will be questioned with daily phone calls.
89647631|NCT03340064|Experimental|Levetiracetam|"Subjects aged 1 month to <6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to <4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day.~At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months or by LEV 20 mg/kg/day for subjects aged 6 months to <4 years at 2-week intervals to 0 mg/kg/day."
88815718|NCT01089062|Other|Treatment B, then Treatment A, then Treatment C|"The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
88992705|NCT05860023|Experimental|Pelvic Floor Muscle Strengthening Group|This group will attend to seven days pelvic floor muscle strengthening programme with moderate intensity consisting of 6 exercises recommended by the national association for incontinence. Prior to discharge exercise sheets will be given to the participants. Their compliance to exercise will be questioned with daily phone calls.
88992706|NCT05860010|Placebo Comparator|control|Bupivacaine will be administered in the caudal space
88992707|NCT05860010|Active Comparator|dexmedetomidine|caudal with dexmedetomidine
88992708|NCT05860010|Active Comparator|epinephrine|caudal with epinephrine
88992709|NCT05859984|Experimental|Low dose group|1 bottle of recombinant human interferon ω spray and 1 bottle of placebo（recombinant human interferon ω spray mimics）+base drugs（Xiao'er Changui Tuire granules and Xiao'er Feire Kechuan granules). Each bottle of medication is sprayed once, twice a day. After using the medication, no food or water can be consumed for 20 minutes. Follow the doctor's instructions for use of the base drugs. This treatment course can last up to 7 days.
88992710|NCT05859984|Experimental|High dose group|2 bottle of recombinant human interferon ω spray +base drugs（Xiao'er Changui Tuire granules and Xiao'er Feire Kechuan granules). Each bottle of medication is sprayed once, twice a day. After using the medication, no food or water can be consumed for 20 minutes. Follow the doctor's instructions for use of the base drugs. This treatment course can last up to 7 days.
88992711|NCT05859984|Placebo Comparator|Placebo group|2 bottle of placebo（recombinant human interferon ω spray mimics）+base drugs（Xiao'er Changui Tuire granules and Xiao'er Feire Kechuan granules). Each bottle of medication is sprayed once, twice a day. After using the medication, no food or water can be consumed for 20 minutes. Follow the doctor's instructions for use of the base drugs. This treatment course can last up to 7 days.
88992712|NCT05859919|Experimental|"The main group receiving the drug Rutan 0.1 and"|"The main group will receive the drug Rutan 0.1"
88992713|NCT05859919|Other|The control group not receiving Rutan 0.1|The control group will not be given the study drug Rutan 0.1
89044951|NCT02116998|Placebo Comparator|Placebo|
89647632|NCT03304262|Active Comparator|Cathodal tDCS + rTMS then Anodal tDCS + rTMS then Sham tDCS + rTMS|Participant will receive 10 minutes of cathodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2. After 1 week washout, participant will receive 10 minutes of anodal tDCS and rTMS for 900 1Hz pulses at 0.85 RMT. After 1 week washout, participant will receive 10 minutes of sham tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT.
89647633|NCT03304262|Active Comparator|Anodal tDCS + rTMS then Sham tDCS + rTMS then Cathodal tDCS + rTMS|Participant will receive 10 minutes of anodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2. After 1 week washout, participant will receive 10 minutes of sham tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT. After 1 week washout, participant will receive 10 minutes of cathodal tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT.
89647634|NCT03304262|Sham Comparator|Sham tDCS + rTMS then Cathodal tDCS + rTMS then Anodal tDCS + rTMS|Participant will receive 10 minutes of sham tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2. After 1 week washout, participant will receive 10 minutes of cathodal tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT. After 1 week washout, participant will receive 10 minutes of anodal tDCS and rTMS for 900 1 Hz pulses at 0.85 RMT.
89647635|NCT03288506|Experimental|Google Hangout (VC) group|This group receive peer led support for depression via Google Hangouts for 8-weeks
89647636|NCT03288506|No Intervention|Waiting list control group|Waiting list
89647637|NCT03277638|Experimental|Pembrolizumab injections 7 days before surgery|Patients will have intravenous pembrolizumab 7 days before surgery with Laser Interstitial Thermotherapy
89647638|NCT03277638|Experimental|Pembrolizumab injections 14 days after surgery|Patients will have intravenous pembrolizumab 14 days after surgery with Laser Interstitial Thermotherapy
88992714|NCT05859906||Group 12 mmHg|All patients in this group will be operated with an insufflation pressure of 12 mmHg during laparoscopic cholecystectomy surgery.
88992715|NCT05859906||Group 14 mmHg|All patients in this group will be operated with an insufflation pressure of 14 mmHg during laparoscopic cholecystectomy surgery.
88992716|NCT05859893|No Intervention|No Intervention: Control|
88992717|NCT05859893|Experimental|Intervention|"Behavioral: Interactive livestreamed classical Turkish music sessions with a professional music band.~The sessions, which lasted approximately one and a half hours, twice a week, have been completed within one month."
88992718|NCT05859841|Experimental|Music listening|Music listening under instruction by music therapist, min 3 hours daily
88992719|NCT05859841|Placebo Comparator|Control|Standard treatment, care and rehabilitation
88992720|NCT05859802|Experimental|Drug Group|
88992721|NCT05859802|Placebo Comparator|Placebo Group|
88992722|NCT05859789|Active Comparator|control group: Kegel exercise group|"will receive Kegel exercise (3 sessions /week for 12 weeks)- Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A&B).~Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises."
88992723|NCT05859789|Experimental|study group: Kegel exercise combined with Mediterranean diet regimen for 12 weeks.|kegel and Mediterranean diet regimen :kegel ex same as controlled group in addition toMediterranean diet. The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will
88992724|NCT05859763|Experimental|Patients diagnosed with pulmonary fibrosis|Patients of Pulmonary Fibrosis SPECT/CT imaging: The patients were subcutaneously injected with 99mTc-HFAPI and underwent SPECT/CT imaging.
88992725|NCT05859750|Experimental|AK104 6mg/kg and chemotherapy|
88992726|NCT05859750|Experimental|AK104 10mg/kg and chemotherapy|
88992727|NCT05859711|Experimental|thyme honey|oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
88992728|NCT05859711|Active Comparator|Saline|oral rinses with saline 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy.
88992729|NCT05859646|Experimental|Probiotics|Group A-Probiotics group: Patients who started using probiotic drops after general anesthesia procedure
88992730|NCT05859646|No Intervention|Control|Group B-Control group: Patients who did not use any probiotics after general anesthesia procedure
88992731|NCT05859633||patients with acute pancreatitis|any patient suffers from acute pancreatitis
88992732|NCT05859607|Active Comparator|Easy cholecystectomy|easy procedure with no complications
88992733|NCT05859607|Active Comparator|moderate severe cholecystectomy|moderate severity with prolonged time or complication .
88992734|NCT05859607|Active Comparator|difficult cholecystectomy|very prolonged time , complication or conversion to open cholecystectomy .
88992735|NCT05859581|Experimental|Suspected positive RPRM on MRI|
88992736|NCT05859568|Experimental|Microphone Location versus Microphone Algorithm Comparison|Comparing performance and subjective feedback for pinna-located microphone versus a pinna-simulated microphone algorithm.
88992737|NCT05859542||Group A|The group A included 18 trainees, who started the session with videolaryngoscope followed by the direct laryngoscope.
88992738|NCT05859542||Group B|The group B included 17 trainees, who started the session with the direct laryngoscope followed by the videolaryngoscope.
88992739|NCT05859516||Experimental: Ultrasound|
88992740|NCT05859438|Experimental|Intervention group|
88992741|NCT05859399|Experimental|Experimental (laughter yoga) group|The intervention group will receive 12 online laughter yoga sessions, only one session per week for 12 weeks. In this study, the number of laughter yoga sessions was determined in line with the studies in the literature. Each laughter yoga session is planned to last approximately 40-45 minutes. Each session of laughter yoga consists of clapping and warm-up exercises, deep breathing exercises, childlike play and laughter.
89647639|NCT03277638|Experimental|Pembrolizumab injections 35 days after surgery|Patients will have intravenous pembrolizumab 35 days after surgery with Laser Interstitial Thermotherapy
89212751|NCT02586467|Experimental|Loss-Framed|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products).
89212752|NCT02586467|Experimental|Self-Regulatory Efficacy|Participants receive messages that provide them with tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.)
89212753|NCT02586467|Experimental|Gain-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
89647640|NCT03265613|Experimental|AD-MSCs group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks.
89647641|NCT03250351|Experimental|Neural mobilization group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program (described in Torres Lacomba M) plus neurodynamic techniques consisting of neural tissue longitudinal glide using the Upper Limb Neurodynamic Test 1 (ULNT1), the neurodynamic test sequence for the median nerve, described by Butler and adapted by de la Rosa. With participants in the supine position, the shoulder was abducted and externally rotated, the scapula depressed, the forearm supinated, and the wrist and fingers extended. Mobilization was applied by depressing the scapula, flexing the elbow, and elevating the scapula, extending the elbow, within a pain-free range. The mobilization was applied for 2 minutes. Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
89647642|NCT03250351|Active Comparator|Control group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program (described in Torres Lacomba M). Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
89647643|NCT03183661||ALLO-ASC-CD injection|Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
89647644|NCT03180684|Experimental|VGX-3100 + EP|Participants with histologically confirmed vulvar high-grade squamous intraepithelial lesion (HSIL) associated with human papilloma virus (HPV) 16 and/or 18, received four doses of 6 mg VGX-3100 as an intramuscular (IM) injection on Day 0, Week 4, Week 12, and Week 24 followed by electroporation (EP) using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52.
89647645|NCT03180684|Experimental|VGX-3100 + EP + Imiquimod|Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52. In addition, participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
89647646|NCT03161652|Placebo Comparator|DME lactose pill|Patients with DME will be randomized to take a lactose pill (placebo).
89647647|NCT03161652|Experimental|DME levosulpiride|Patients with DME will be randomized to take levosulpiride.
89647648|NCT03161652|Placebo Comparator|DR lactose pill|Patients with non-proliferative DR will be randomized to take a lactose pill (placebo)
89647649|NCT03161652|Experimental|DR levosulpiride|Patients with non-proliferative DR will be randomized to take levosulpiride
89647650|NCT03161652|Placebo Comparator|DR, vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take a lactose pill (placebo).
89647651|NCT03161652|Experimental|DR, vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take levosulpiride.
89647652|NCT03161652|Placebo Comparator|DME plus ranibizumab lactose pill|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take a lactose pill (placebo)
89647653|NCT03161652|Experimental|DME plus ranibizumab levosulpiride|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take levosulpiride
89647654|NCT03131037|Experimental|Study Arm|CAN-2409 + valacyclovir
89647655|NCT03083561|Experimental|LY3337641 Multiple Dose|Multiple doses of 30 mg LY3337641 tablet administered orally every day for two weeks, with a two week follow-up period.
89647656|NCT03083561|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered orally every day for two weeks, with a two week follow-up period.
89647657|NCT03083561|Experimental|LY3337641 Single Dose|Single dose of 5 mg, 80 mg and 160 mg LY3337641 tablet administered orally, with a two week follow-up period.
89647658|NCT03083561|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally, with a two week follow-up period.
89218027|NCT00903734|Experimental|Erlotinib Hydrochloride|Those eligible for umbrella of studies and have not received Erlotinib hydrochloride in past, will first receive Erlotinib hydrochloride alone.
89647659|NCT02992457|Active Comparator|Sof-Riba|Sofosbuvir ribavirin 6 months.
89647660|NCT02992457|Active Comparator|Sof- Riba- Pegylated interferon|Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months
89647661|NCT02992457|Active Comparator|Sof- Olysio|Sofosbuvir and simeprevir for 3 months.
89647662|NCT02992457|Active Comparator|Sof- Dacla|Sofosbuvir and Daclatasvir for 3 months.
89647663|NCT02992457|Active Comparator|Harvony|Sofosbuvir and ledipasvir for 3 months
89647664|NCT02992457|Active Comparator|Ritaprevir, paritaprevir, ombetasvir|Querevo for 3 months
89647665|NCT02992457|Active Comparator|Salvage therapy|sofosbuvir, daclatasvir, simeprevir,ribavirin or sofosbuvir and querevo
89647666|NCT02914379|Experimental|20mg [¹⁴C]-LY3337641|Participants received 20 milligrams (mg) oral dose of LY3337641 containing 120 microcuries of radioactivity.
89647667|NCT02896751|Experimental|3D Printed NIV Mask|3D imaging and use of a custom mask from 3D printer
88992742|NCT05859399|No Intervention|Control group|The control group will receive no intervention for 12 weeks.
89044952|NCT02916329|Experimental|68Ga-ZEGFR: EGFR++|Patients in this group had EGFR-activating mutant and EGFR high expression tumors and did not receive any treatment before this study.
89044953|NCT02916329|Experimental|68Ga-ZEGFR: EGFR+|Patients in this group had EGFR-activating mutant and EGFR medium expression tumors and did not receive any treatment before this study.
89218028|NCT04603079|Experimental|Currently practicing nurses who will receive intervention|An intervention for COVID-19 preventive protocols will be delivered to the nurses in the experiment group.
88992743|NCT05859373|Experimental|TQB3728 tablets+chemoradiation, sequential maintenance with TQB2450 injection|TQB3728 tablets combined with sequential or concurrent chemoradiation, 21 days as a treatment cycle. After 4~6 cycles, sequential maintenance therapy of TQB2450 injection.
88992744|NCT05859373|Experimental|TQB3728 tablets+chemoradiation, sequential maintenance with TQB3728 tablets and TQB2450 injection|TQB3728 tablets combined with sequential or concurrent chemoradiation, 21 days as a treatment cycle. After 4~6 cycles, sequential maintenance with TQB3728 tablets and TQB2450 injection for 4 cycles. Then sequential maintenance with TQB2450 injection monotherapy；
88992745|NCT05859373|Active Comparator|Sequential or concurrent chemoradiation, sequential maintenance with TQB2450 injection.|Sequential or concurrent chemoradiation, 21 days as a treatment cycle. After 4~6 cycles, sequential maintenance with TQB2450 injection；
88992746|NCT05858918|Active Comparator|clopidogrel|patient post elective angioplasty and stenting receiving aspirin 80 mg and clopidogrel 75 mg PO daily
88992747|NCT05858918|Active Comparator|ticagrelor|patient post elective angioplasty and stenting receiving aspirin 80 mg and ticagrelor 90 mg PO twice daily
88992748|NCT05858281||Online Survey|
88992749|NCT05858281||Focus group|
88992750|NCT05858281||Interviews|
88992751|NCT05856942|No Intervention|Standard care|Patients will receive standard PrEP care in the clinic including in-person visits for triannual (every 4 months) HIV & STI screening and comprehensive sexual health care.
88992752|NCT05856942|Experimental|Home-based care|Patients will have the option to complete their PrEP care from home including 1) self-collection of blood specimens for HIV, syphilis and creatinine; 2) self-swabs for extragenital GC/CT screening; and 3) telehealth follow-up. A maximum of two triannual follow-up visits per year may be conducted remotely; one visit per year must be in person. Participants also have the option to attend visits in person and are otherwise eligible to continue receiving comprehensive sexual health services in the clinic.
88992753|NCT05856877|Active Comparator|Nasal insulin spray|
88992754|NCT05856877|Placebo Comparator|Placebo spray|
88992755|NCT05856864|Experimental|Cadonilimab in Combination With Ramucirumab|Cadonilimab Injection 10mg/kg, intravenous drip ,q2w,
88992756|NCT05856279|Experimental|mulligan SNAG|Patients in this group will receive mulligan SNAG from sitting position and McGill stabilization exercises.The glide will be performed six repetitions for three sets for one session and McGill stabilization exercises as a home program: 7 days a week and 10 repetitions of each exercise for 2times per day and a rest interval of 2 minutes between exercises
89647668|NCT02829424|Active Comparator|Experimental group|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the control group and according to the Summary of Product Characteritics (SmPC) MTX: 15 mg a week orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX will be initiated within 7 days after the start of the anti TNF alpha agent
88992757|NCT05856279|Experimental|mulligan lion position|Patients in this group will receive mulligan modified lumbar SNAG lion position and McGill stabilization exercises.Modified lumbar SNAGs (lion position) will be applied in a quadruped position (lion position)six repetitions for three sets for one session . McGill stabilization exercises as a home program: 7 days a week and 10 repetitions of each exercise for 2times per day and a rest interval of 2 minutes between exercises The therapist stands to one side of the patient and applies (SNAG) centrally to the spinous process of the involved segment. The medial border of the hand is hooked under the chosen segment while the other arm encircles the trunk to stabilize the upper body. The therapist maintains the glide while the patient sits back towards their heels (for flexion) .
88992758|NCT05850741|Experimental|Device|"The following procedure steps will take place:~The study system is installed in the room before patient arrival~The patient needs to fully undress the upper body before lying on the bed~The 3 ECG electrodes are placed~Ultrasound gel is applied on the ultrasound probe"
88992759|NCT05850286|Experimental|VRD-based Regimen Combined With CART-ASCT-CART2|"Autologous BCMA-directed CAR-T cells, Double infusion intravenously at a target dose of 2-4 x 10^6 anti-BCMA CAR+T cells/kg respectively.~Participants will receive VRD-based regimen induction, first CAR-T infusion, consolidation, ASCT and second CAR-T infusion. Maintenance therapy was initiated on day 100 and entered the follow-up period."
88992760|NCT05848726||A Group|Group of patient who underwent laparoscopic cholecystectomy using Airseal
88992761|NCT05848726||S Group|Group of patient who underwent laparoscopic cholecystectomy using a standard insufflation
88992762|NCT05848154||ctDNA detection group|ctDNA detection, WES and RNA-seq will be performed on blood samples of all patients in this group.
88992763|NCT05842083|Active Comparator|Intervention|Each oncologist will have a total of three intervention days with a psychologist sitting in and observing the doctor-patient consultations and subsequently providing feedback.
88992764|NCT05842083|No Intervention|Control|Oncologists in the control group will conduct consultations as usual.
88992765|NCT05829187|Experimental|Dihydro artemisinin Piperakuin (Fixed Dose Combination) and Primaquine|Fixed Dose Combination content in the form of 40 mg dihydroartemisinin and 320 mg piperaquine administered for 3 days with a dose of dihydroartemisinin 2-4 mg/Kg body weight, piperaquine at a dose of 16-32 mg/Kg body weight in the form of a combination set out in the table based on body weight and age. Primaquine dose of 0.25 mg/Kg body weight is given only on the first day. Dihydroartemisinin-piperaquine was local product by PT Mersi Pharmaceuticals, batch No 220610, produced on Jun/22 and expiring on Jun/24. primaquine was local product by PT Phapros Indonesia, Batch No 56386001, produced on Jan/22 and expiring date jan/25.
88992766|NCT05829187|Experimental|Extract Capsul Momordica Charantia|Momordica Charantia 325 mg in 500 mg capsules is given to patients with uncomplicated plasmodium falsiparum malaria as one capsule per day for three days for body weight less than 60 kg. Patients with a body weight of more than 60 kg are given two capsules per day for three days.
88992767|NCT05823233|Experimental|Study group|Cold application+Deep friction+Home exercise+Eccentric stretching
88992768|NCT05823233|Experimental|Control Group|Cold application +Deep friction +Home exercise
88992769|NCT05818384|Experimental|Wait List Control|Participants in the Wait List group will be randomly assigned to start the intervention 3 months later in the Summer.
88992770|NCT05818384|Experimental|Wakaya (Immediate Group)|Participants in the immediate group will be randomly assigned to start the intervention immediately in the Spring.
88992771|NCT05779696||Group 1|We will recruit a diverse range of participants to take part and therefore have a limited inclusion/exclusion criteria. Participants must be over 18 years old and be able to a computer/mobile device to access the survey or video conference software (Zoom, as used by the Centre of Ethnic Health Research). Participants can come from a range of cultural communities and religious groups. Participants do not need to have any prior knowledge to participate in the virtual focus groups or the survey.
88992772|NCT05779644|Experimental|Liraglutide group|Liraglutide is injected once a day.
88992773|NCT05779644|Experimental|Semaglutide group|Semaglutide is injected once a week.
88992774|NCT05779644|Experimental|Metformin group|Metformin is taken orally daily.
88992775|NCT05776381|Experimental|Shared Decision Making (SDM)|Patients with an unexpected malignant colorectal polyp where a decision needs to be made concerning the management of care.
89212754|NCT02586467|Experimental|Loss-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
89212755|NCT00491608|Experimental|1|rThrombin
89212756|NCT04081415||Group with FPIES|Not yet healed children with FPIES
89212757|NCT01018888|Experimental|Keratoprosthesis|
89212758|NCT04678583|Experimental|A - Anatomical resection|removal of the entire, tumor-bearing liver segment(s)
89212759|NCT04678583|Active Comparator|B - Non-anatomical resection|metastasectomy with a margin of healthy liver tissue irrespective of segmental borders
89212760|NCT03996928|Experimental|Eccentric exercise by physiotherapist|"A physiotherapist will apply (in this order) a plan of stretching exercises, warm-up exercises and eccentric exercises of epicondylar muscle,according to a program of 10 sessions of 20 minutes each, during two weeks.~Before exercise, ultrasounds will be applied at intensity of 0.1 wat/cm2, which is considered as a placebo, in order to achieve greater adherence and monitor the treatment."
89218029|NCT04603079|No Intervention|Currently practicing nurses who will not receive intervention|No intervention for COVID-19 preventive protocols will be delivered to the nurses in the control group.
89218030|NCT00903812||A|No intervention - observational study
89647669|NCT02829424|Placebo Comparator|Control group|"Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent~All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the experimental group and according to the SmPC Placebo-MTX orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX-placebo will be initiated within 7 days after the start of the anti TNF alpha agent"
89647670|NCT02740920|Experimental|Pembrolizumab|200mg IV Day 1 every 3 weeks.
89647671|NCT02692846||Control participants with connective tissue disease|Not have a diagnosis of WS. Have a clinical or molecular diagnosis of connective tissue disease, between the ages of 1 and 70 years old
89647672|NCT02692846||Unaffected Control participants|Not have a diagnosis of WS or other connective tissue disease, between the ages of 1 and 70 years old
89647673|NCT02692846||WS participants|Have diagnosis of WS, between the ages of 5 and 70 years old. Be able to tolerate blood pressure measurements.
89647674|NCT02619851|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
89647675|NCT02619851|Active Comparator|Conventional Therapy|Typical therapy conducted for burn injury patients
89647676|NCT02580617|Experimental|ALLO-ASC|Group 1: 5.0 x 10^7 cells Group 2: 7.5 x 10^7 cells Group 3: 10.0 x 10^7 cells
89647677|NCT02579369|Experimental|ALLO-ASC-DFU|
89647678|NCT02579369|Active Comparator|Conventional Therapy|
89647679|NCT02515227|Experimental|6MHP (6 Melanoma helper peptide) vaccine + Pembrolizumab|6MHP (200 mcg each peptide) will be administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) will be administered intravenously every 3 weeks for up to 2 years, beginning on day 1.
89647680|NCT02455375||Cases|"Case group = group of patients positive with reference tests including serological (ELISA, IF neutralization) and/or molecular assays:~detection of PUUV RNA in plasma collected at admission.~or/and detection of IgM and IgG against PUUV in serum collected at admission,~or/and detection of a seroconversion in IgG against PUUV from admission and late sera"
89647681|NCT02455375||Controls|Control group = group of patients who do not have the criteria listed above
89647682|NCT02430467|Active Comparator|Caregiver-guided pain management training protocol (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques
88992776|NCT05776381|No Intervention|Historical data arm|Historical data on the management of patients with an unexpected malignant colorectal polyp from February 2018 to the end of 2022 retrieved through the Danish Colorectal Cancer Group Database, the National Pathology database and the National Patient Register.
89647683|NCT02430467|Active Comparator|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
88992777|NCT05775016|Placebo Comparator|Placebo|Placebo (Resistant Dextrin) (n=40)
88992778|NCT05775016|Experimental|750 mg/day Mitoburn (L-BAIBA)|750 mg/day Mitoburn (L-BAIBA)
88992779|NCT05775016|Experimental|1,500 mg/day Mitoburn (L-BAIBA)|1,500 mg/day Mitoburn (L-BAIBA)
88992780|NCT05766904|Experimental|Intervention|Intramuscular injection of 2 doses of 0.5mL 4CMenB vaccine 1 month apart
89647684|NCT02369458|Experimental|Cohort A: p16+ OPSCC|"Mitomycin C given on Day 1 every 5 weeks (each cycle is 5 weeks).~Pegfilgrastim will be given on Day 2 of each cycle (subcutaneous injection)"
88992781|NCT05766904|Placebo Comparator|Control|Intramuscular injection of 2 doses of 0.5mL placebo 1 month apart
88992782|NCT05749211|Experimental|Huaier granule|Huaier granule is supplied as 20-g granule. Huaier granule will be administered as 20 g orally tid x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. In the absence of intolerable toxicity, a patient may continue to receive treatment with Huaier granule until disease progression, or until 24 months have elapsed.
88992783|NCT05748093|Experimental|Cohort 1: Adjusting osimertinib treatment plans with concomitant pk-boosting|Feasibility of using pharmacokinetic boosting and TDM to individualize treatment plans and dosage for osimertinib, in patients with advanced NSCLC with mutated EGFR. In this cohort, patients will receive cobicistat for pharmacokinetic boosting of standard osimertinib treatment. Afterwards, they will receive personalised treatment plans, guided by therapeutic drug monitoring.
88992784|NCT05748093|Experimental|Cohort 2: Improving osimertinib CNS penetration in patients with neurometastases|Assessing whether pharmacokinetic boosting can improve CNS penetration of osimertinib, in patients with advanced NSCLC with mutated EGFR with asymptomatic CNS oligoprogression. Patients who experience progressive disease intracranially, are sometimes dose-escalated to try and improve osimertinib intracranial exposure. This study will look to demonstrate the feasibility of using a PK-booster instead, potentially providing patients the benefits of higher intracranial treatment efficacy, without needing to take extra osimertinib.
88992785|NCT05741645|Experimental|Study group|Study group consists of 15 participants, where the elastic kinesiotaping is applied and evaluations are made before and after.
88992786|NCT05741645|Sham Comparator|Control Group|To the participants in the control group, the elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
88992787|NCT05731596|Active Comparator|Group 1 (Rosuvastatin group)|Patients will receive Rosuvastatin 20mg/day orally for 3 months
88992788|NCT05731596|Experimental|Group 2 (CoQ10 group)|Patients will receive Coenzyme Q10 100 mg/day orally for 3 months
88992789|NCT05730270|Experimental|Stress reduction program 1|Participants will complete stress reduction lessons for two weeks
88992790|NCT05730270|Experimental|Stress reduction program 2|Participants will complete stress reduction lessons for two weeks
89647685|NCT02369458|Experimental|Cohort 2: p16- HNSCC|"Mitomycin C given on Day 1 every 5 weeks (each cycle is 5 weeks).~Pegfilgrastim will be given on Day 2 of each cycle (subcutaneous injection)"
89647686|NCT02316392||Post transplant subjects|Hyperpolarized Helium-3 MRI. Subjects who have had or are scheduled to have a lung transplant
89647687|NCT02122172|Experimental|Treatment (afatinib)|Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89647688|NCT02056132||Cystic Fibrosis patients.|Patients with Cystic Fibrosis. Results of Exhaled Breath Condensate lab.
89647689|NCT02056132||Control Subjects|Individuals without Cystic Fibrosis or signs of current respiratory infection. Results of Exhaled Breath Condensate lab.
89647690|NCT02052609|Experimental|KHK4827 140mg SC|
89647691|NCT02052609|Experimental|KHK4827 210mg SC|
89647692|NCT02031939|Active Comparator|Standard chemoradiotherapy|Standard chemoradiotherapy (Capecitabine 825mg/m2 combined with radiotherapy )
89647693|NCT02031939|Experimental|induction and gap chemotherapy|induction chemotherapy (Capecitabine 2000mg/m2 +oxaliplatine 130mg/m2) + 2 cycles of chemoradiotherapy (Capecitabine 2000mg/m2 +oxaliplatine 100mg/m2 combined with radiotherapy) + gap chemotherapy (Capecitabine 2000mg/m2 + oxaliplatine 130mg/m2)
89647694|NCT01997190|Experimental|Study Arm|AdV-tk + valacyclovir
89647695|NCT01925040|Experimental|Venus Pearl|Placement of restoration using Venus Pearl in carious teeth or as a replacement of a defective previous restoration.
88992791|NCT05730270|No Intervention|Waitlist|Participants will have an opportunity to complete one of the two programs of stress reduction lessons after data collection is completed
88992792|NCT05726006||Non-pregnant adult patients with group B streptococcal infection|all non-pregnant adult patients from the selected hospitals whom group B streptococcus will be isolated from their clinical samples from sterile sites.
88992793|NCT05714852|Experimental|Intervention|
88992794|NCT05714852|No Intervention|Control|
88992795|NCT05713318|Experimental|Treatment Group 1|
88992796|NCT05713318|Experimental|Treatment Group 2|
88992797|NCT05713318|Placebo Comparator|Control Group 3|
88992798|NCT05713318|Placebo Comparator|Control Group 4|
88992799|NCT05710328|Experimental|Diagnostic (FDG-PET/CT scan)|Patients receive FDG IV, undergo PET/CT, receive standard of care chemotherapy, and undergo standard of care surgery on study.
88992800|NCT05699707|Experimental|Ketone monoester|0.75 g/kg body mass of ketone monoester to be consumed within 5 minutes with venous blood samples obtained pre-ingestion, and 30-, 60- and 90-minutes post-ingestion.
88992801|NCT05690009||Patients with albuminuria|Patients aged 40 or older without preexisting diagnoses of chronic kidney disease, type 1 diabetes, and type 2 diabetes with positive albuminuria by dipsticks and/or microalbuminuria test or albumin-to-creatinine ratio in a single urine sample.
88992802|NCT05684744|Experimental|Roflumilast|oral roflumilast in a dose of 500 mcg per day
88992803|NCT05684744|Active Comparator|Methotrexate|oral methotrexate in a dose of 0.2- 0.4 mg/kg/week
88992804|NCT05679986||Recent small subcortical infarction within 72 hours from stroke onset to admission|Recent small subcortical infarction (RSSI) is defined as small deep infarctions in the territory of perforating arteries with maximum axial diameters (MAD) of less than 20 mm. In this study, RSSIs in the territories of lenticulostriate area, pons are enrolled.
88992805|NCT05678114|Experimental|Hyperandrogenic PCOS|
88992806|NCT05678114|Experimental|Non-hyperandrogenic PCOS|
89647696|NCT01925040|Active Comparator|control resin-based filling material|Placement of restoration using a control resin-based filling material in carious teeth or as a replacement of a defective previous restoration.
89647697|NCT01776190|Experimental|UVA1 treatment|Low-dose UVA1 will be applied to active cutaneous lupus lesions three times a week for 10 weeks.
89647698|NCT01736202|Active Comparator|Palm oil orally|oral fat load
89647699|NCT01736202|Active Comparator|Canola oil orally|Oral fat load
89647700|NCT01736202|Placebo Comparator|Water orally|oral water administration as control
88992807|NCT05676827||Study group|Participants with masticatory muscle pain lasting for over 3 months.
88992808|NCT05676827||Control group|Participants without masticatory muscle pain in last 6 months.
88992809|NCT05675787|Experimental|Experimental group|MPA + Atorvastatin
88992810|NCT05675787|No Intervention|Control groups|MPA
88992811|NCT05661812||Patients|173 patients aged 18-75 years with self-reported allergic airways symptoms during autumn, primarily in August and September.
89647701|NCT01447147|Placebo Comparator|Placebo (Group A)|
89647702|NCT01447147|Experimental|CCX140-B (Group B)|
89647703|NCT01447147|Experimental|CCX140-B (Group C)|
89647704|NCT01440699|Experimental|Treatment|For ALLO-ASC 1xE7 cells/ml,3 patients are to be enrolled. If there is no safety issue, 3 more patients will be enrolled to be treated with ALLO-ASC 3xE7 cells/ml.
89647705|NCT01440257|Placebo Comparator|Placebo (Group A)|
89647706|NCT01440257|Experimental|Active study medication (Group B)|CCX140-B
89647707|NCT01370278|Active Comparator|Normal Saline|Normal saline sprayed into stent/airway tubes then suctioned out through bronchoscope.
89647708|NCT01370278|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate sprayed into stent/airway tubes then suctioned out through bronchoscope.
89647709|NCT01242917|Placebo Comparator|Placebo|
89647710|NCT01242917|Experimental|CCX354-C 100mg twice daily|
89647711|NCT01242917|Experimental|CCX354-C 200mg once daily|
89647712|NCT01113268|Other|1:cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
89647713|NCT01028963|Placebo Comparator|Placebo|
89647714|NCT01028963|Active Comparator|Active control|
89647715|NCT01028963|Experimental|Active Study Medication (Group C)|CCX140-B
89647716|NCT01028963|Experimental|Active Study Medication (Group D)|CCX140-B
89647717|NCT01027728|Experimental|CCX354-C|
89647718|NCT00754845|Experimental|Letrozole|Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
89212761|NCT03996928|Active Comparator|Illustrated booklet|A physiotherapist will train the patient an exercise plan equivalent to the one above explained with the help of illustrations. Now, in order to achieve palmar flexion at the same time the patients will contract their epicondylar muscles (the eccentric effect), and elastic band is used.
89212762|NCT02586545|Experimental|Shared care model|Four visits a year: one annual comprehensive check-up at the outpatient diabetes clinic and three quarterly visits at the general practitioner.
89647719|NCT00754845|Placebo Comparator|Placebo|Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
89212763|NCT02586545|No Intervention|Mono sectorial care|Treament as usual including four visits a year with the diabetes team at the outpatient clinic: an annual comprehensive check-up, identical to the one received by the intervention group, and three quarterly visits.
89647720|NCT00751270|Experimental|A|Arm A for unresectable malignant glioma was closed due to poor accrual.
89647721|NCT00751270|Experimental|B|Arm B for resectable malignant glioma completed the Phase I accrual and long term follow up continues. A follow on study at dose level 3 was opened as a Phase 2a study (see BrTK02).
89647722|NCT00638612|Experimental|A resectable|Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
89212764|NCT04932785|Active Comparator|Regular Diet|Patient randomized to regular diet will begin with a regular diet.
89647723|NCT00638612|Experimental|B locally advanced|"Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir.~Enrollment has been completed for Arm B."
89647724|NCT00634231|Experimental|AdV-tk|AdV-tk + valacyclovir in combination with standard of care radiation
89647725|NCT00555555|Experimental|Coagulation FVIII/VWF|Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT
89647726|NCT00540657|Experimental|1|
89647727|NCT00540657|Placebo Comparator|2|
89647728|NCT00319228|Experimental|Antithrombin III|
89647729|NCT00312039|Experimental|A|
89647730|NCT00312039|Active Comparator|B|
89647731|NCT00306215|Experimental|1|Blinded study arm
89647732|NCT00306215|Experimental|2|Blinded study arm
89647733|NCT00306215|Experimental|3|Blinded study arm
89647734|NCT00306215|Experimental|4|Blinded study arm
89647735|NCT00083174|Other|Exemestane|one 25 mg tablet daily in am
89647736|NCT00066573|Experimental|Exemestane|Patients receive oral exemestane (25 mg) once daily for 5 years.
89647737|NCT00066573|Active Comparator|Anastrozole|Patients receive oral anastrozole (1 mg) once daily for 5 years.
89647738|NCT03965845|Experimental|Cohort 1: Telaglenastat 600 mg and Palbociclib 75 mg|
89647739|NCT03965845|Experimental|Cohort 2: Telaglenastat 800 mg and Palbociclib 75 mg|
88992812|NCT05661812||Controls|114 controls aged 18-75, healthy, non-allergic individuals.
88992813|NCT05652738|Active Comparator|Group I: (passive cooling group)|
88992814|NCT05652738|Placebo Comparator|Group II: (Blanket roll III cooling group)|
89212765|NCT04932785|Active Comparator|Clear Liquid Diet|Patient randomized to clear liquid diet will begin with a clear liquid diet.
89212766|NCT02587715|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
89212767|NCT04777721|Experimental|Group 1: 1 x 10^4 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^4 cfu aerosol inhaled BCG. All Group 1 volunteers will have a bronchoscopy 14 days post challenge.
89212768|NCT04777721|Experimental|Group 2: 1 x 10^5 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^5 cfu aerosol inhaled BCG. All Group 2 volunteers will have a bronchoscopy 14 days post challenge.
89647740|NCT03965845|Experimental|Cohort 3: Telaglenastat 800 mg and Palbociclib 100 mg|
89647741|NCT03965845|Experimental|Cohort 3: Telaglenastat 800 mg and Palbociclib 125 mg|
89647742|NCT03965845|Experimental|Part 2: Expansion|The recommended phase 2 dose (RP2D) determined from Part 1 will be the treatment for all cohorts in expansion Part 2.
89647743|NCT03594955|Experimental|SAR440234|SAR440234 was administered as intravenous infusion once weekly for 6 weeks per Cycle. Per plan, participants were to receive first 2 to 3 doses as Lead-in doses followed by a fixed dose until the end of treatment or unless the dose needs to be decreased for safety reasons. Due to early study termination, all participants received only 1 treatment cycle at a dose of 1 nanogram per kilogram (ng/kg) once weekly.
89647744|NCT03593551|Experimental|relaxation and control|All participants will attend five relaxation treatments and one control. The order of treatments and control will be randomised allocated to participants.
89647745|NCT04194697|Experimental|Exercise group|Participants will conduct exercise programs provided by the app 3 times a week for 12 weeks. Except for the exercise program provided by the app, the amount of activity and exercise in daily life will not change from before the study.
89647746|NCT04194697|Other|Non-exercise group|Participants will not change the amount of activity or exercise in daily life from before the study.
89647747|NCT04766359|Experimental|Albumin-Bound paclitaxel combined with radiotherapy|"Albumin paclitaxel (100mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
89647748|NCT04766359|Experimental|Cisplatin combined with radiotherapy|"Cisplatin (40mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.~Radiotherapy: The total dose is 66-70Gy, divided into 33-35 times to complete."
89647749|NCT04027621|Active Comparator|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
89647750|NCT04027621|Placebo Comparator|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
89647751|NCT03023293||gestational diabetes mellitus|The investigators plan to establish a prospective GDM cohort and collect n-3 PUFAs consumption and irisin information at 24-28 weeks'gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum, respectively.
89647752|NCT03954145|Active Comparator|PUMICING GROUP|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle.Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors"
89647753|NCT03954145|Experimental|SANDBLASTING GROUP|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
89647754|NCT04194463|Experimental|ChemoFit exercise prehabilitation intervention|Exercise intervention consisting of walking and increasing daily step count. This is monitored by wearing a pedometer device. Other part of intervention are 5 simple strengthening exercises.
89647755|NCT04193839||Paper Order Entry cohort|Patients admitted to the NICU during the pre-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the pre-intervention period will be handled with the paper order entry
89647756|NCT04193839||CPOE + BCMA cohort|Patients admitted to the NICU during the post-intervention phase, enrolled in the study after parental consent. The medications prescribed to the patients enrolled during the post-intervention period will be handled with the Computerized Provider Order Entry + Bar Code Medication Administration (BCMA)
89647757|NCT04020601|Active Comparator|PRE-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through the interscalene catheter
89647758|NCT04020601|Sham Comparator|POST-GA|10 ml of 5% dextrose injection before the start of surgery and 1% ropivacaine injection at the end of surgery through the interscalene catheter
89044954|NCT02916329|Experimental|68Ga-ZEGFR: EGFR-|Patients in this group had no EGFR expression tumors and did not receive any treatment before this study.
89044955|NCT02916329|Experimental|68Ga-ZEGFR: EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
89044956|NCT02916329|Experimental|68Ga-ZEGFR:unknown EGFR status|Patients without the EGFR status measurement results and did not receive any treatments were classified in this group.
89044957|NCT02916329|Experimental|68Ga-ZEGFR: EGFR|Patients in this group had EGFR expression tumors and had receive some treatment before this study.
89044958|NCT02110368|Active Comparator|AndroGel|AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg
89044959|NCT02110368|Experimental|Testosterone Gel|Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
89044960|NCT02916485|Experimental|Bioresorbable scaffold|Percutaneous coronary intervention (PCI) with a sirolimus-eluting resorbable coronary magnesium scaffold
89044961|NCT01709214|Experimental|Cebranopadol (GRT6005) Low-Dose Range|Once daily GRT6005, flexible dosing 200, 300 or 400 micrograms, and once daily Placebo; oral administration for 15 weeks
89044962|NCT01709214|Experimental|Cebranopadol (GRT6005) High-Dose Range|Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, and once daily Placebo; oral administration for 15 weeks
89044963|NCT01709214|Placebo Comparator|Placebo|Twice daily Placebo, oral administration for 15 weeks
89044964|NCT01709214|Active Comparator|Oxycodone CR|Twice daily Oxycodone CR, flexible dosing 10, 20, 30, 40 or 50 milligrams; oral administration for 15 weeks
89044965|NCT02916602|Experimental|Treatment|HCP1401
89044966|NCT02916602|Active Comparator|Reference|HCP0605
89044967|NCT02110212|Active Comparator|U/S Surgery and CCC|Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
89044968|NCT02110212|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.
89044969|NCT02916797|Experimental|Stepping training with feedback|Subjects stand in a step standing position with placing the affected leg on the load cells of the VWTM and the non-affected leg slightly backward outside the load cells, look forward to light bars of the displayed section which will be set at their eye level. Then subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can. Subjects repetitively practice the task for 30 minutes with a period of sufficient rest as required.
89044970|NCT02916797|No Intervention|Stepping training without feedback|Subjects will be trained and instructed the same as the experimental group but without using the displayed section, for approximately 30 minutes/day (excluding rest periods), 5 days/week, for 4 week. Then, every subject will be trained to walk overground with or without a walking device for 10 minutes in order to promote transferability of the part-task practice to the whole/target task. Subjects still receive routine treatments from other rehabilitation professionals as needed during participation in the study.
89647759|NCT04198597|Experimental|Unified Protocol, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
89647760|NCT04198597|Experimental|Unified Protocol, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
89647761|NCT04198597|Experimental|Process-based treatment, 2 week baseline|Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
89647762|NCT04198597|Experimental|Process-based treatment, 4 week baseline|Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
89647763|NCT04029805|Experimental|Combination of a Plant Extract and a Probiotic|Volunteers will take twice at day for 12 weeks a capsule containing the combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6
89647764|NCT04029805|Placebo Comparator|Placebo|Volunteers will take twice at day for 12 weeks a capsule containing maltodextrin.
89647765|NCT04193995|Experimental|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday and fasting is terminated at 0800 on Monday and Thursday.
89647766|NCT04193761|Active Comparator|Control|
89647767|NCT04193761|Active Comparator|Chronic hepatitis|
89044971|NCT02916290|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
89044972|NCT02916290|Active Comparator|Monotherapy|UDCA monotherapy
89044973|NCT01708551|Active Comparator|Group A|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
89044974|NCT01708551|Active Comparator|Group B|Subjects who were non-responders to a prior Ultherapy™ treatment for hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
89044975|NCT01708551|Active Comparator|Group C|Subjects will receive one double-density Ulthera System treatment; dual depth treatment at 4.5mm and 3.0mm.
89044976|NCT01708551|Active Comparator|Group D|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and standard energy level.
89044977|NCT01708551|Active Comparator|Group E|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and adjusted energy level.
89044978|NCT02916251|Experimental|ZP4207(dasiglucagon)|Intervention: ZP4207(dasiglucagon) glucagon analogue (4 mg/mL) planned doses: 0.03, 0.08, 0.2 and 0.6 mg at euglycemic and hypoglycemic conditions.
89044979|NCT02916251|Active Comparator|Glucagon (Native glucagon)|Intervention: Glucagon (Native glucagon) 1 mg/mL as active comparator planned doses: 0.03, 0.08 and 0.2 mg at euglycemic conditions.
89044980|NCT01707264|Experimental|NEOD001|NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.
89044981|NCT02916095|Experimental|Kanitinib|Subjects will be enrolled in cohorts at different dose levels in order to evaluate the safety,tolerability and determine the maximum tolerated dose and recommended phase II dose of kanitinib.
89044982|NCT02106546|Experimental|Veliparib + Carboplatin + Paclitaxel|Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
89647768|NCT04193761|Active Comparator|Cirrhosis|
89647769|NCT04193761|Active Comparator|Hepatocellular carcinoma|
89647770|NCT03965221|Experimental|LYNX|LYNX is developed using IMB model and engages youth through entering sexual diary data, earning badges, and calculating a personalized sexual protection (Sex Pro) score, which informs and motivates youth around HIV/STI testing and PrEP uptake. Behavioral skills are built through HIV/STI testing reminders, presenting options for home HIV testing and/or linkage to nearby testing services, and access to an online chat with support for HIV/STI testing and PrEP referral.
89044983|NCT02106546|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
89044984|NCT02916173|Experimental|Human chorionic gonadotrophin group|Patients will receive Human chorionic gonadotrohpin injection 5000 unit
89044985|NCT02916173|Active Comparator|Human chorionic gonadotrophin + agonist group|patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate
89044986|NCT02916134|Active Comparator|Operative Intervention|Laparoscopic +/- open appendicectomy, with antibiotics at induction and 3 further doses of intravenous antibiotics. Co-amoxiclav, or cefuroxime and metronidazole if previous rash-allergy to penicillin.
89647771|NCT03965221|Experimental|MyChoices|"MyChoices is adapted from an app for adult MSM, HealthMindr, developed using SCT. The app aims to increase HIV testing and PrEP uptake by increasing self- regulation, self-reflection, and self-efficacy around HIV testing and PrEP uptake. Brief surveys about sexual risk and protective health behaviors within the app are used to assist users in tracking and self-monitoring their behaviors and creating a personalized HIV testing plan. Quizzes, videos and infographics as well as Help me Choose, Ordering, and geofencing functions are used to maximize self-efficacy around HIV prevention and uptake of PrEP."
89647772|NCT03965221|No Intervention|Standard of Care|Provision of referrals to local HIV/STI testing and PrEP resources.
89647773|NCT04194073|Experimental|Pulse oximeter calibration population|All subjects within this single arm of the study will undergo the calibration experiment as described in the Detailed Description
89044987|NCT02916134|Experimental|Antibiotic Treatment|Intravenous antibiotics until clinical improvement and then 5 further days of oral antibiotics. Co-amoxiclav, or if rash-allergy to penicillin, cefuroxime and metronidazole.
89044988|NCT02916212|Experimental|Experimental|Hospital units where alarms have been optimized
89044989|NCT02916212|No Intervention|Control|Hospital units where alarms remain unchanged
89044990|NCT04688606||Two groups|"Initial diagnosis of suspected hepatocellular carcinoma;~patients undergoing liver transplantation, radical resection or ablation of liver cancer"
89044991|NCT02104245|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
89044992|NCT02104245|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
89044993|NCT04688489|Active Comparator|Intervention|The intervention consists of a supplement of maltodextrin at training episodes combined with added dietary carbohydrates at all meals
89044994|NCT04688489|No Intervention|Control|The control receives no intervention. Standard treatment will be administered.
89044995|NCT01699737|Experimental|JTT-851 Dose 1|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
89044996|NCT01699737|Experimental|JTT-851 Dose 2|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
89044997|NCT01699737|Experimental|JTT-851 Dose 3|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
89044998|NCT01699737|Active Comparator|Glimepiride Dose 1|Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
89647774|NCT03369444|Experimental|FLT180a, 6x10e^11 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 6x10e^11 vg/kg
89044999|NCT01699737|Placebo Comparator|Placebo active & Placebo comparator|Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks
89045000|NCT04688723|Active Comparator|Dabigatran/Clopidogrel|Patiënt receive standard care, with dabigatran + clopidogrel 75mg once daily up to 12 months.
89045001|NCT04688723|Experimental|Dabigatran/Ticagrelor|Patiënt receive standard care, with dabigatran + ticagrelor 90mg twice daily up to 12 months.
89045002|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.7%|AR-12286 Ophthalmic Solution 0.7%, both eyes
89045003|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% both eyes
89045004|NCT01699464|Active Comparator|Timolol maleate ophthalmic solution 0.5%|Timolol maleate ophthalmic solution 0.5% both eyes
89045005|NCT04688645|Experimental|Balanced crystalloid solution|Balanced crystalloid solution - Plasmalyte.
89045006|NCT04688645|Active Comparator|Normal saline|0.9% sodium chloride solution.
89045007|NCT00555282|Experimental|1|coated central venous catheter
89045008|NCT00555282|Active Comparator|2|standard central venous catheter
89045009|NCT04688372||Inpatient encounters with COVID-19 present-on-admission|See Study description above
89647775|NCT03369444|Experimental|FLT180a, 2 x 10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 2 x 10e^12 vg/kg
89647776|NCT03369444|Experimental|FLT180a, 1x10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 1 x 10e^12 vg/kg
89647777|NCT03369444|Experimental|FLT180a, 1.3x10e^12 vg/kg solution for infusion|Participants receiving gene therapy vector at a dose of 1.3 x 10e^12 vg/kg
89647778|NCT04029727|Experimental|Combination of Plant Extracts (BSL_EP025)|The volunteers will take two capsules daily with a combination of plant extracts (BSL_EP025)
89647779|NCT04029727|Placebo Comparator|Placebo|The volunteers will take two capsules daily with maltodextrin.
89647780|NCT04193683|Sham Comparator|Sham-Ultrasound|Intervention will include one session sham-ultrasound application to both lower extremities of participant. The total time will be 15 minutes.
89647781|NCT04193683|Experimental|Myofascial Release Technique+Sham-Ultrasound|In addition to one session sham-ultrasound, the intervention will include one session myofascial release technique to both lower extremities of participant. The total time will be 30 minutes.
89045010|NCT02104050|Placebo Comparator|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
89045011|NCT02104050|Experimental|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
89045012|NCT02915861||EXPa|Scrub typhus patients: Group A
89045013|NCT02915861||EXPb|Scrub typhus patients: Group B
89045014|NCT02915861||EXPc|Scrub typhus patients: Group C
89045015|NCT02915861||EXC|Control group
89045016|NCT01694277|Experimental|Masitinib|Participants receive masitinib (12 mg/kg/day), given orally twice daily.
89045017|NCT01694277|Active Comparator|Sunitinib|Participants receive sunitinib, given at 50 mg/day for 4 consecutive weeks out of 6 weeks, orally
89045018|NCT02100150|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
89045019|NCT02100150|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and water
89045020|NCT03103490|Other|18F-FSPG|Patients receive 18F-FSPG for detection of Cardiac Sarcoidosis or Inflammation
89045021|NCT01669980|Experimental|Ceftaroline fosamil|
89647782|NCT04029571|Experimental|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
89647783|NCT04029571|Active Comparator|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
89647784|NCT04029571|No Intervention|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
89647785|NCT01677624|Experimental|E7040|
89647786|NCT03318666|Active Comparator|Enhanced Usual Care (EUC)|Both arms will receive this intervention
89647787|NCT03318666|Experimental|Supporting Our Valued Adolescents (SOVA)|This arm will receive the SOVA intervention in addition to Enhanced Usual Care
89647788|NCT03913039||transperineal protocol|"Transperineal biopsy approach with avoidance of rectal flora~MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~Multi-antibiotic prophylaxis~Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
89647789|NCT03913039||Traditional biopsy|"Transrectal approach~Standard 12-core template~Surgeon-specific antibiotic prophylaxis~Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
89647790|NCT05097378|Experimental|EncoBini Arm|Oral encorafenib 450mg once daily and oral binimetinib 45mg twice daily for 8 weeks pre-operative and for up to 44 weeks post-operative.
89647791|NCT05097378|Active Comparator|Standard Arm|Immediate surgery followed by Investigator's choice of standard adjuvant therapy to commence within 12 weeks of surgery and to continue for up to 52 weeks.
89647792|NCT05097300|Experimental|Manual therapy and vagus nerve stimulation group|Patients will recibe 4 sessions, each of the duration of 20 minutes. Manual therapy consist in: suboccipital inhibition (during 10 minutes) and ischemic pressure and passive stretching of three muscles (superior trapezius, temporal muscle and sternocleidomastoid muscle). Vagus nerve stimulation will be performed through a diaphragmatic breathing exercise, during 5 minutes, adding neural tension of median nerve.
89647793|NCT05097300|Active Comparator|Manual therapy group|Patients will recibe 4 sessions, each of the duration of 20 minutes. Manual therapy consist in: suboccipital inhibition (during 10 minutes) and ischemic pressure and passive stretching of three muscles (superior trapezius, temporal muscle and sternocleidomastoid muscle).
89647794|NCT05085600|Active Comparator|Exercise Group|20-minute session, composed of 2 blocks of 10 repetitions, holding each exercise for 10 seconds, a 40-second rest between each repetition and 2 minutes between blocks.
89647795|NCT05085600|Experimental|Exercise + Manual Therapy Group|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
89647796|NCT04199845|Experimental|PS128|PS128 will be given twice daily for 8 weeks Active capsule containing 300 mg of probiotics, equivalent to 3 x10^10 CFU of Lactobacillus plantarum PS128.
89647797|NCT04199845|Placebo Comparator|placebo|Placebo containing starch will be given twice daily for 8 weeks.
89647798|NCT05084664|Experimental|group A|premodulated current
89647799|NCT05084664|Experimental|group B|diadynamic current
89647800|NCT04193137||Primary Aldosteronism(PA)|plasma aldosterone /renin ratio (ARR)>10 pg/μIU and plasma aldosterone concentration(PAC) post-FST≥60pg/ml；or PAC>200 pg/ml，plasma renin concentration(PRC)<2.5μIU/ml，with hypokalemia
89647801|NCT04193137||non Primary Aldosteronism|ARR<10 pg/μIU or ARR>10 pg/μIU and PAC post FST<60pg/ml
89647802|NCT05060484|Active Comparator|Healthy Women Aged 18 to 26 Years|1200 healthy women aged18 to 26 years are in this arm. Middle dose SCT1000 : hight dose SCT1000:Gardasil®9 : placebo =1:1:1:1. SCT1000 and Gardasil®9 will be immunized at 0, 2, and 6 months, respectively.
89647803|NCT05060484|Active Comparator|Healthy Women Aged 27 to 45 Years|600 healthy women aged 27 to 45 years are in this arm. Middle dose SCT1000 : hight dose SCT1000:Gardasil® : placebo =1:1:1:1. SCT1000 and Gardasil®9 will be immunized at 0, 2, and 6 months, respectively.
89647804|NCT04193059|Active Comparator|PANSY-1: EC-T|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+ cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of T (docetaxel 100 mg/m^2 ivgtt d1, 21 days per cycle)
89647805|NCT04193059|Experimental|PANSY-1: PCb|6 cycles of weekly PCb (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15+ carboplatin Area Under Curve (AUC)=2 ivgtt d1, d8, d15, 28 days per cycle)
89647806|NCT04193059|Active Comparator|PANSY-2: EC-TH(P)|4 cycles of EC (epirubicin 90 mg/m^2 ivgtt d1+cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle), followed by 4 cycles of TH(P) (docetaxel 100 mg/m^2 ivgtt d1 + trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). After 8 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
89647807|NCT04193059|Experimental|PANSY-2: PCbH(P)|6 cycles of weekly PCbH(P) (paclitaxel 80 mg/m^2 ivgtt d1, d8, d15 + carboplatin AUC=2 ivgtt d1, d8, d15 + trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle, with pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle for participants receiving dual-targeted therapy). Participants may also choose to receive trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy. After 6 cycles of chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks), with pertuzumab (420mg ivgtt every 3 weeks) for participants receiving dual-targeted therapy.
89647808|NCT05289882|Experimental|PASS Program Condition|Participants in this condition will take part in weekly physical activity, augmented with built-in opportunities to socially connect, and be directed to veteran-specific support services and resources.
88992815|NCT05638672|Experimental|Treatment group|Huashi Baidu Granule+Monapiravir simulant
89647809|NCT05289882|No Intervention|Waitlist Control|Those randomized to the wait-list control condition will go about their daily lives for the duration of the 6-month assessment period (following randomization). They will be asked to complete the same measures (and will be remunerated in the same way as those in the PASS program condition, based on the completion of study measures). At the end of the 6-month trial, participants in this condition will have the opportunity to participate in the PASS program.
89647810|NCT04199611|Experimental|Integrated Therapy Group|Both liposuction and psychological therapy are delivered to the participants in this group.
89647811|NCT04199611|Active Comparator|Liposuction Group|This group experiences only liposuction and do self-help care after the liposuction.
89045022|NCT01669980|Active Comparator|IV Ceftriaxone and Vancomycin|
89647812|NCT04199611|Active Comparator|Psychological Therapy Group|This group experiences only cognitive behavioral therapy (CBT; psychological therapy) during the intervention period.
89647813|NCT04199611|No Intervention|Self-help Group|This group do not receive any interventions and do self-help care.
89647814|NCT04028791|Experimental|AS and AA|Participants will be submitted to 45 minutes of exercise on ergocycle.
89647815|NCT04438200||Adolescents|Individuals aged 10-19 years
89647816|NCT04438200||Young Adults|Individuals aged 20-39 years
89647817|NCT04438200||Elderly Adults|Individuals aged 40+ years
89647818|NCT04199923|Experimental|15 Day immobilisation|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 15 continuous days
89647819|NCT04199923|Experimental|5 Day immobilisation young|The dominant leg of young healthy patients (18-40 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
89647820|NCT04199923|Experimental|5 Day immobilisation old|The dominant leg of aged patients (65-80 years without serious comorbidities) will be immobilised using a fixed knee brace and aircast boot for 5 continuous days
88992816|NCT05638672|Active Comparator|Control group|Monapiravir+Huashi Baidu Granule Simulator
88992817|NCT05605353||Colorectal|Patients with rectal or colon cancer
88992818|NCT05605353||Gynaecological|Patients with uterine, ovarian or cervical cancers
88992819|NCT05605353||Urological|Patients with bladder or prostate cancers
88992820|NCT05604404|Experimental|Positional Changes|The patient will begin in a supine position with the head-of-bed (HOB) at zero (0) degrees. The patient will remain in this position for five (5) minutes while pressure data is collected every fifteen (15) seconds. Next, the HOB will be adjusted to thirty (30) degrees. The patient will remain in this position for five (5) minutes while pressure data is collected every fifteen (15) seconds. Lastly, the HOB will remain at thirty (30) degrees and the foot-of-bed (FOB) will be adjusted to place the patient's leg in a dependent position. The patient will remain in this position for five (5) minutes while pressure data is collected every fifteen (15) seconds.
88992821|NCT05600725|Experimental|Pacing intervention|A novel atrial pacing approach will be delivered using the subject's already implanted pacemaker, ICD or BiV/ICD while the subject is in a semi-recumbent position and while hemodynamic and symptom data is collected. This will be repeated once daily, 3d/wk over 4 weeks.
88992822|NCT05600725|Sham Comparator|Sham pacing|Subjects in this arm will be treated identically to the subjects in the pacing intervention arm but their already implanted pacemaker, ICD or BiV/ICD will have programming changes simulated but not actually implemented.
88992823|NCT05582343|No Intervention|HEAR|Participants who are identified as having moderate to high risk of suicide, as identified by suicide risk on the ISP, will be contacted by a mental health counselor who will engage them through the HEAR encrypted interface online. The mental health counselor will offer counseling online through encryption or on the phone. Where indicated, the mental health counselor will provide the crisis hotline, and encourage participants to use their insurance provider and/or Employee Assistance Program to obtain treatment. The mental health counselor will offer to help with referrals and will bridge high-risk participants into treatment. Participants who are not identified as having moderate to high risk of suicide will be thanked for their time.
88992824|NCT05582343|Active Comparator|HEAR plus MINDSTRONG|Participants identified as having a moderate to high risk of suicide based on ISP screening will then be randomized. Participants randomized to the MINDBODYSTRONG© program (intervention) will receive the 8-session online interactive program. Reminders will be sent weekly to complete the next MINDBODYSTRONG© session and a MINDBODYSTRONG© trained coach will check in with participants by phone at baseline, weeks 3 and 5 of the on-line program to reinforce key program concepts and assess whether participants are completing the weekly skills building activities. Nurses assigned to the control group will only receive the HEAR program alone (aforementioned) and will be contacted for follow-up surveys.
88992825|NCT05576792||ranibizumab 0.2 mg|Intravitreal ranibizumab 0.2 mg for the treatment of ROP
88992826|NCT05574673||Ovarian cancer patients|Newly diagnosed patients with ovarian cancer, fallopian tube cancer or primary peritoneal cancer
88992827|NCT05574517|Experimental|Experimental group(group 1)|Without reverse insertion of a ureteral catheter in tubeless percutaneous nephrolithotomy.
88992828|NCT05574517|No Intervention|Control group(group 2)|Traditional tubeless percutaneous nephrolithotomy need reverse insert a ureteral catheter.
88992829|NCT05569395|Experimental|Study group|Median nerve neuro mobilization group
88992830|NCT05569395|Sham Comparator|Control Group|Sham median nerve neuro mobilization group
88992831|NCT05564689||Patients with or in need of CRT, left bundle branch block, without ischemic heart disease|
88992832|NCT05546333||Patients receiving CTA|Patients who will receive a CTA due to clinical need will be imaged with electrical impedance tomography in addition to the CTA.
88992833|NCT05539378|Experimental|Auditory Stimulation|Auditory Stimulation during sleep
88992834|NCT05539378|Sham Comparator|No Auditory Stimulation|Playing no tones during sleep but still recording brain activity
89647821|NCT04029103|Active Comparator|used m-DAKBAS|"m-DAKBAS application was downloaded to the mobile phones of the participants who met the research criteria and accepted to participate in the study; the participants were given a username and a password for the confidentiality. They were instructed how to use the application after a number of trials.~The participants were asked to send their blood sugar levels each time they measured it and foot observations daily through the application. Using the admin panel, the researcher followed the participants' frequency of using the application and the data they sent throughout 24 weeks and tried to find solutions to the problems experienced (for example: hyperglycaemia, insulin dosage adjustments). The participants were provided with feedback in line with these data; SMS reminders were sent if the tasks were not completed."
89647822|NCT04029103|Experimental|not used m-DAKBAS|The participants who met the research criteria and accepted to participate in the study were given training via verbal instruction about the information in the content of m-DAKBAS (definition of Diabetic Foot, risk factors, protective precautions, daily foot care)
89647823|NCT04028869||Glycyrrhizin preparation treatment group|Clinical effect of glycyrrhizic acid preparation for 144 weeks of autoimmune liver disease and safety during treatment
89647824|NCT04028635|Experimental|Cognitive-behavioral therapy plus VR-based body exposure|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, six sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which the they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions, until a healthy BMI value is reached.
89647825|NCT04028635|Active Comparator|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the centre in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
89647826|NCT02080273|Placebo Comparator|Colgate Cavity Protection toothpaste|Brush whole mouth 2x/day with Colgate Cavity Protection toothpaste. This study treatment is currently marketed/sold in Poland
89647827|NCT02080273|Active Comparator|Colgate Total toothpaste|Brush whole mouth 2x/day with Colgate Total toothpaste . This study treatment is currently marketed/sold in Poland
89647828|NCT02080273|Active Comparator|Parodontax|Brush whole mouth 2x/day with Parodontax toothpaste. This study treatment is currently marketed/sold in Poland.
88992835|NCT05525494|Active Comparator|Text Fixed R/R Messages with Direct Appointment Schedule Link + Text Pre-Appointment Reminders|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
88992836|NCT05525494|Active Comparator|Text Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
88992837|NCT05525494|Active Comparator|Portal Pre-Commitment Prompt, Tailored R/R Messages w/ Direct Scheduling + Pre-Appointment Reminders|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
88992838|NCT05525494|Active Comparator|Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
88992839|NCT05525494|Active Comparator|Portal Fixed R/R Messages with Direct Appointment Schedule Link + Portal Pre-Appointment Reminder|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment. Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
88992840|NCT05525494|Active Comparator|Portal Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
88992841|NCT05525494|No Intervention|No R/R Message or Pre-Appointment Reminder|Participants do not receive any flu vaccine R/R message or Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment during the specified flu season.
88992842|NCT05524610|No Intervention|Pre-Implementation of Routine Sexual Function Screening (Baseline)|This arm will include patients with and surviving cancer who are seen during the Pre-Implementation study period. It will include patients diagnosed prior to age 18 years and 15-24 years old at the time of study. Patients will be approached by research personnel at the end of each visit for participation in a survey. The pre-implementation survey will assess sexual function communication and patient satisfaction. In addition, medical record data abstraction of clinical care related to sexual health and function will be collected.
88992843|NCT05524610|Experimental|Post-Implementation of Routine Sexual Function Screening|This arm will include patients with and surviving cancer who are seen during the Post-Implementation study period, once the routine sexual function screening intervention has been implemented. It will include patients diagnosed prior to age 18 years and 15-24 years old at the time of study. Patients will be approached by research personnel at the end of each visit for participation in a survey. The post-implementation survey will assess sexual function communication and patient satisfaction, as well as measures of acceptability, feasibility, and appropriateness of the intervention. In addition, medical record data abstraction of clinical care related to sexual health and function will be collected.
88992844|NCT05516381|Other|Restricted Invers Kinematic Knee Alignment Technique|Restricted Invers Kinematic Knee Alignment Technique
88992845|NCT05516381|Other|Mechanical Knee Alignment Technique|Mechanical Knee Alignment Technique
89045023|NCT02915666|Experimental|Digoxin combination for Melanoma|Drugs: Dabrafenib 150mg PO 2x daily, Trametinib 2 mg PO daily, and Digoxin 0.25 mg PO daily for 8-week cycles.
89647829|NCT03131466|Experimental|PRF Group|This group will undergo 42°C high-voltage pulsed radiofrequency treatment.
89647830|NCT03131466|Active Comparator|Nerve Block Group|This group will undergo nerve block treatment with steroid and local anesthesia.
89647831|NCT03060174|Other|monitoring and non-medical prophylaxis of delirium|The treatment group will receive monitoring and prophylaxis of delirium. The study arm designed to prevent delirium incorporates reorientation (watches, calendar, family photos, use of hearing aids, glasses and dentures, cognitive stimulation (newspaper, magazines, radio, television), early mobilisation, early enteral nutrition, early removal of drains or catheters, normalizing sleep-awake-rhythm.
89647832|NCT03060174|No Intervention|Standard|The standard group will receive standard monitoring and standard treatment. The indication, choice and dosage of the medication used to treat delirium will be at the discretion of the ward doctor and will not be influenced by this study. The chosen medication as well as its dosage will be documented.
89647833|NCT04192279||lactate group|Lactate early guide resuscitation
89647834|NCT04192279||control group|early guide resuscitation without lactate
89647835|NCT04199377|Experimental|hip or knee replacement|total hip or knee replacement
88992846|NCT05507684|Experimental|Nature-based social prescribing group intervention|"Groups of 5-12 persons will formed from one assisted living facility. All of them will undergo an individual interview to assess their wishes for the nature-based activities.~Participants meet in a closed group 9 times for once a week for 10 weeks. All 2-4 hour sessions will include nature-based activities and mutual discussions about the experiences of nature and loneliness.~2 professionals will facilitate and observe the group more thoroughly, give feedback to each other, and make use of group dynamics. They write diaries on each session and receive feedback from their trainers. The groups are objective oriented (aiming to alleviate loneliness, to improve participants' self-efficacy), client oriented and aim with favorable group dynamics to mature, self-directing group in which the participants have made friends with each other and want meet with each other without the facilitators after the official group intervention is over."
88992847|NCT05507684|No Intervention|Control|The control arm will receive individually usual care in assisted living facility (e.g. the existing social prescription as available) Usual care is the appropriate comparison rather than a placebo for complex interventions.
88992848|NCT05500079|Active Comparator|Wrist splint group|The group to be treated with a wrist splint
88992849|NCT05500079|Active Comparator|Transcutaneous pulsed RF group|The group to be treated with transcutaneous pulsed RF
88992850|NCT05496283|Experimental|Corega|Complete denture patients given Corega denture adhesive.
88992851|NCT05496283|Experimental|OlivaFix|Complete denture patients given OlivaFix denture adhesive.
88992852|NCT05496283|Experimental|Sea.Bond|Complete denture patients given Sea.Bond denture adhesive.
88992853|NCT05491278|Experimental|Fospropofol disodium for injection|Fospropofol disodium continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for analgesia.The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
88992854|NCT05491278|Active Comparator|propofol|Propofol continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for analgesia. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
88992855|NCT05491148||medical workers|medical workers of the resuscitation and intensive care unit of newborns
88992856|NCT05485935|Experimental|Investigational device - intermittent catheter with micro-hole zone|Ready-to-use, sterile, hydrophilic coated intermittent male catheter (sizes CH12 and CH14) with a flexible tip and a micro-hole zone for urinary drainage. The investigational device is for single use.
88992857|NCT05485935|Active Comparator|Comparator device - standard intermittent catheter|Single-use, hydrophilic coated intermittent male catheters (sizes CH12 and CH14) with sleeves: SpeediCath Flex, VaPro, VaPro Pocket, VaPro Plus and VaPor Plus Pocket.
88992858|NCT05480527|Active Comparator|Patients with bilateral neuropathic pain which treating active electrode|30 patients which treating with transcutaneous pulsed radiofrequency. All patients have diabetic polyneuropathy and confirmed with electroneuromyography.
88992859|NCT05480527|Sham Comparator|Patients with bilateral neuropathic pain which applied sham electrode|Sham electrodes will be applied to 30 patients. All patients have diabetic polyneuropathy and confirmed with electroneuromyography.
88992860|NCT05472064||Group 1|Primary care doctor persona with direct messages
88992861|NCT05472064||Group 2|Breast cancer survivor persona with direct messages
88992862|NCT05472064||Group 3|Primary care doctor with indirect messages
88992863|NCT05472064||Group 4|Breast cancer survivor persona with indirect messages
88992864|NCT05472064||Group 5|Control
88992865|NCT05457582|Placebo Comparator|Placebo plus high-intensity statin|Participants received placebo subcutaneous injections once every 2 weeks (Q2W) plus high-intensity statin treatment (Rosuvastatin, 20 mg, once daily)
88992866|NCT05457582|Active Comparator|PCSK 9 Inhibitor plus high-intensity statin|Participants received PCSK 9 Inhibitor Q2W subcutaneous injections
88992867|NCT05436626|Experimental|Early BDI reconstruction without abdominal sepsis control|BDI reconstruction within 6 weeks after the injury without controlling the abdominal sepsis
89647836|NCT04199455|Experimental|Integrative Treatment Group|Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
89647837|NCT04199455|Placebo Comparator|Control Group|Patients randomly assigned to the control group will receive recipe simulators as placebo, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.
89647838|NCT04191343|Experimental|The control group|
89647839|NCT04199143|Experimental|healthy voluntary controls|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
89647840|NCT04199143|Experimental|Depressive Patients|A single Non-blinded One-hour administration of 50% Nitrous oxyde (N2O) 50%oxygen (O2) Gas Mixture
89647841|NCT04616274||Venetoclax|Adult CLL patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from July 2020 to December 2025.
89647842|NCT04613622||Venetoclax|Adult patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from August 2020 to December 2025.
89647843|NCT04022629|Active Comparator|Treatment Group 1|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
89647844|NCT04022629|Active Comparator|Treatment Group 2|Patients aged between 18-35 years who have sustained a first-time traumatic anterior dislocation of the shoulder.
89647845|NCT04604340|Active Comparator|transfemoral access|control
89647846|NCT04604340|Active Comparator|transradial access|case
89647847|NCT04027933|Active Comparator|Experimental|Education Based on Standard Patient Simulation was given to this group
89647848|NCT04027933|No Intervention|Control|Control group
89647849|NCT04021303|Experimental|Experimental Cereal|Experimental cereal with probiotics, prebiotic fiber and low carbohydrates through all the duration of the study.
89045024|NCT02915822|Experimental|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique to surgically correct Hallux Valgus
89647850|NCT04021303|Active Comparator|Conventional cereal|Conventional gluten free cereal between 4 and 6 months old, and conventional gluten cereal between 7 and 12 months old.
89647851|NCT04021225|Active Comparator|Ectoin® Allergy Eye Drops 2%|"20 Patients:~- Ectoin® Allergy Eye Drops 2% (bitop AG)"
89647852|NCT04021225|Active Comparator|Ectoin® Eye Spray Colloidal|"20 Patients:~-Ectoin® Eye Spray Colloidal (bitop AG)"
89647853|NCT04021225|Active Comparator|Tears Again® Eye Spray|"20 Patients:~- Tears Again® Eye Spray (Optima Pharmazeutische GmbH)"
89647854|NCT05097066||Elective neurosurgery|Any elective neurosurgical procedure.
89647855|NCT05097066||Non-elective neurosurgery|Any non-elective neurosurgical procedure.
89647856|NCT04021147|Experimental|Action Observation|
89647857|NCT04021147|Experimental|Motor Imagery|
89647858|NCT04021147|Experimental|Visual mirror feedback|
89647859|NCT04021147|Active Comparator|Orofacial exercise|
89647860|NCT05096910|Active Comparator|Monofilament Suture Group|Monofilament sutures will be used for uterine closure.
89647861|NCT05096910|Active Comparator|Polyfilament Suture Group|Polyfilament sutures will be used for uterine closure.
89647862|NCT04027387|Experimental|TMB-365 400 mg- Group 1|Single dose of TMB-365 400 mg or matching placebo by intravenous infusion
89647863|NCT04027387|Experimental|TMB-365 800 mg- Group 2|Single dose of TMB-365 800 mg or matching placebo by intravenous infusion
89045025|NCT02915822|Active Comparator|Open Scarf/Akin osteotomy|Open technique to surgically correct Hallux Valgus
89045026|NCT02098473|Experimental|RPC4046 Low Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
89045027|NCT02098473|Experimental|RPC4046 High Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
89045028|NCT02098473|Placebo Comparator|Placebo|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks
89045029|NCT02915627|Active Comparator|Healthy participants|Non chronic kidney disease (CKD) participants. Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
89045030|NCT02915627|Active Comparator|CKD patients not on dialysis|CKD 4/5 patients not on Dialysis- Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
89647864|NCT04027387|Experimental|TMB-365 1600 mg- Group 3|Single dose of TMB-365 1600 mg or matching placebo by intravenous infusion
89647865|NCT05096676|Experimental|Adolescents diagnosed with Autism spectrum disorder|Participants in the ASD group received oxytocin and placebo in a randomized, double-blind placebo-controlled manner.
89647866|NCT05096676|No Intervention|Typically developing adolescents|Control participants were recruited using online ads. This group did not receive oxytocin or placebo due to ethical constraints in Israel.
89647867|NCT04027543||Neoadjuvant chemoradiotherapy|Patients who had chemoradiotherapy before surgery.
89647868|NCT04027543||Neoadjuvant chemotherapy|Patients who had chemotherapy before surgery.
89647869|NCT04027543||Surgery alone|Patients who only had oesophagectomy. Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic. The appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
89647870|NCT04497324|Experimental|Experimental group|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
89647871|NCT04497324|No Intervention|Control group|Standard of care
89647872|NCT03948763|Experimental|V941 Monotherapy|V941(mRNA-5671/V941) administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles
89647873|NCT03948763|Experimental|V941 + Pembrolizumab|V941(mRNA-5671/V941) administered IM Q3W for 9 cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles
89647874|NCT04896840|Experimental|Treatment group|Telerehabilitation and motor learning principles will be applied.
89647875|NCT04896840|Experimental|Control Group|Motor learning principles will be applied in the clinic.
89688563|NCT02850874|Experimental|HIPEC|Immediately following laparoscopy for diagnosis and staging of disease, closed neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) will be performed using the anatomical site of the laparoscopic procedure in the same operative encounter. Perfusion will be initiated with 4-6 L of 1.5% dextrose at a 500 mL/min flow rate with manual agitation of the abdominal wall. Once the temperature in the abdomen becomes stable above 40°C, perfusate volume will be reduced to 1.5 L/m sq, and gemcitabine (GEMZAR®) will be instilled into the abdomen (1000 mg/m sq) for 90 min. Neoadjuvant chemotherapy with gemcitabine will be administered prior to open pancreaticoduodenectomy by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy with gemcitabine will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional protocol.
89212769|NCT04777721|Experimental|Group 3: 1 x 10^6 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^6 cfu aerosol inhaled BCG. All Group 3 volunteers will have a bronchoscopy 14 days post challenge.
89647876|NCT05096520|Active Comparator|radiofrequency group|the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.
89647877|NCT05096520|Active Comparator|control group|The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.
89647878|NCT04191109||1|Subacute stroke patients admitted to an inpatient rehabilitation facility.
89647879|NCT03948529|Experimental|eltrombopag|Eligible patients will receive the investigational drug eltrombopag
89647880|NCT04856592|Experimental|VICI Stent|
89647881|NCT03023605|No Intervention|Pre-intervention PE Diagnosis|Patients visited in Emergency Department, with suspected Pulmonary Embolism, before the training intervention.
89647882|NCT03023605|Experimental|Post-intervention PE Diagnosis|"Patients visited in Emergency Department, with suspected Pulmonary Embolism, after the training intervention.~Training intervention centered on emergency department staff, regarding the application of clinical probability scores (Wells and Geneva scores) to guide the determination of D-dimer and the performance of pulmonary CT in patients with suspected pulmonary embolism."
89647883|NCT04020757|Other|Bicarb Variation|Variation in dialysis bicarbonate, lowered to 30 mEq/L for week 2 of 3
89647884|NCT05095974||A (main group)|29 Consecutive patients with a singleton pregnancy complicated by severe PE will be included in the study at hospital admission. Assessment will be done by lung ultrasound , echocardiography and thoracic bioimpedence device
89647885|NCT05095974||B (control group)|29 Consecutive healthy patients with a singleton pregnancy (control group) will be included in the study at hospital admission. Assessment will be done by lung ultrasound , echocardiography and thoracic bioimpedence device
89647886|NCT03022669|Experimental|Text Message Group|"The TM group will use the VA Annie text messaging program to remind patients to take antiplatelet medications. The content for the text messages will be determined through preliminary focus groups that will be conducted prior to the RCT."
89647887|NCT03022669|Experimental|Application Group|"The App group will use a mobile application to remind patients to take antiplatelet medications. The commercially available mobile app will be selected by participants through preliminary focus groups that will be conducted prior to the RCT."
89647888|NCT03022669|Experimental|Website-Control|"The Website-Control group will will be offered the American Heart Association patient education website (My Life Check - 7 Steps To Healthy Living) and will serve as an attention-control. The website will be offered to participants in all three groups. The 7 small steps to big changes are to manage blood pressure, control cholesterol, reduce blood sugar, get active, eat better, lose weight, and stop smoking."
89647889|NCT03832465|Experimental|Intraluminal Levofloxacin powder therapy|Group A Crashed powder of film-coated Levofloxacin Tablet (1 gm) for the Intraluminal therapy
89647890|NCT03832465|Active Comparator|Intraluminal Levofloxacin solution therapy|Group B Intravenous solution of Levofloxacin (1 gm) for the Intraluminal therapy
89647891|NCT04437966|Experimental|Self-management Group|"The intervention consists of three levels - (1) chronic disease self-management workshops, (2) distribution of and teaching on the use of medication pill boxes and (3) use of social media (WhatsApp version 2.0) to encourage medication adherence.~We combine the Stanford Chronic Disease Self-Management Curriculum, add medication adherence tools and social media use to develop a novel intervention aimed at better blood pressure control. The CDSMP focuses on enhancing skills through problem solving and brainstorming activities. In the workshop we discuss: blood pressure control, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control. Pill boxes will be distributed to all individuals in the intervention group. Post workshop, participants will be sent twice weekly reminders to use their high blood pressure medications via the social media tool WhatsApp. These will be sent for one month."
89647892|NCT04437966|No Intervention|Usual care group|Controls will receive educational material at baseline and one didactic session (on importance of medication adherence to hypertension control) lasting 1 hour delivered by a health care professional.
89647893|NCT04190407|Other|Pediatric patients scheduled for day case surgery|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
89212770|NCT04777721|Experimental|Group 4: 1 x 10^7 cfu aerosol inhaled BCG|3 historically BCG-vaccinated volunteers will receive 1 x 10^7 cfu aerosol inhaled BCG. All Group 3 volunteers will have a bronchoscopy 14 days post challenge.
89212771|NCT00615836|Experimental|Desmopressin Melt 10 μg|Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).
89212772|NCT00615836|Experimental|Desmopressin Melt 25 μg|Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
89212773|NCT00615836|Experimental|Desmopressin Melt 50 μg|Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
89212774|NCT00615836|Experimental|Desmopressin Melt 100 μg|Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
89212775|NCT04040270|Experimental|Live drama+DVD+Worksheets|Primary school students watched an interactive live drama in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
89212776|NCT04040270|Experimental|DVD+Worksheets|Primary school students were given DVD and worksheets and they were asked to watch the DVD and finish the worksheets with their parents. After the study finished, the students watched the live drama.
89212777|NCT04040270|No Intervention|Waitlist control|Primary school students received no intervention during the 4-week study period. After the study finished, the students watched the live drama, and DVD with worksheets were distributed to students and they were encouraged to share with their parents.
89647894|NCT04605432|Experimental|PEG-FFI prep|"On the day before colonoscopy, an experienced researcher would go to the ward to have a face-to-face conversation with the patient to know if patients have the risk factors for bowel preparation failure.~The bowel preparation regimens for patients with risk factors would be optimized. In addition to drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min, the patient also drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at 20:00- 21:00 hours on the day before the colonoscopy. Patients without risk factors drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.~Patients would received a booklet to explain the details of diet restriction, preparation method and the pictures of bowel preparation of results.The researcher would give a detailed oral explanation of the booklet."
89647895|NCT04605432|Active Comparator|PEG-nonFFI prep|Patients in the PEG-nonFFI group would only receive routine patient education on bowel preparation of colonoscopy, which was completed by ward nurse. all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 3L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
89647896|NCT04190173|Experimental|Prucalopride|Prucalopride (Trade name: Resolor) 2 mg oral or tube feeding once daily 5 consecutive days Decrease dose to 1 mg once daily in patient with end stage kidney disease or Cirrhosis Child Pugh C
89647897|NCT04190173|Placebo Comparator|Placebo|Placebo tablet to mimic Prucalopride made by starch
89647898|NCT04190095|Experimental|User Interaction with Device|A user will wear motion sensors and VR device to interact with object or another user in VR environment
89647899|NCT04020679|No Intervention|Control arm|Participants will not receive GOCI materials
89647900|NCT04020679|Experimental|Intervention|Participants will receive GOCI materials and clinicians will receive training.
89647901|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)|
89647902|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)|
89212778|NCT00872924|Experimental|1|sumatriptan succinate 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan) of OHM laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA).
89212779|NCT00872924|Active Comparator|2|IMITREX® 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan)
89647903|NCT01272219|Placebo Comparator|Liraglutide Placebo, no Pre-diabetes|
89647904|NCT01272219|Experimental|Liraglutide 3.0mg, Pre-diabetes|
89647905|NCT01272219|Placebo Comparator|Liraglutide Placebo, Pre-diabetes|
89647906|NCT05230836|Experimental|30 kilohertz|Alternating current stimulation at 30 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
89647907|NCT05230836|Experimental|40 kilohertz|Alternating current stimulation at 40 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
89647908|NCT05230836|Experimental|50 kilohertz|Alternating current stimulation at 50 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
89647909|NCT05230836|Sham Comparator|Sham stimulation|Sham stimulation via transcutaneous, 15 minutes each intervention, following the same procedures as 30, 40 and 50kHz HFAC groups.
89647910|NCT01510028|Experimental|Cohort 1 (10 mg)|6 patients treated with HGT-1110 10 mg EOW by IT injection
89647911|NCT01510028|Experimental|Cohort 2 (30 mg)|6 patients treated with HGT-1110 30 mg EOW by IT injection
88992868|NCT05436626|Experimental|Early BDI reconstruction with abdominal sepsis control|BDI reconstruction within 6 weeks after the injury after controlling the abdominal sepsis
89212780|NCT00867776|Experimental|AAHC Excercise Program Support Group|Participants taking part in the AAHC Exercise Program Support Group (the intervention).
89212781|NCT00878540|Experimental|mirtazapine|
89212782|NCT04039334|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 5 days a week for 8 week. All exercise sessions will be performed at home.
89212783|NCT04039334|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive creative dance based exercise training for 60 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised in a clinic per week.
89647912|NCT01510028|Experimental|Cohort 3 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
89647913|NCT01510028|Experimental|Cohort 4 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
89647914|NCT05104164|Experimental|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 3 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include 11 exercises that must be administered bilaterally. A mobile application will be developed where each patient will be able to observe the exercises to be carried out.
88992869|NCT05436626|Active Comparator|Delayed reconstruction|BDI reconstruction after 6 weeks after the injury a
89647915|NCT05104086|Active Comparator|evaluate the value of ultrasound elastography in dignosis of endometriomas|evaluation of endometrioma by ultrasound elastography and will be repeated after 4 weeks
89647916|NCT05104086|Active Comparator|evaluate the value of ultrasound elastography in ovarian hemorrhagic cysts|revaluation of ovarian hemorrhagic cyst by ultrasound elastography and noticing the change of values
89647917|NCT04020991||Doctors working in a tertiary hospital|Doctors working in a tertiary hospital
89647918|NCT05104008|Active Comparator|Lateral wedge insoles with home exercises group(Group 1)|In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
89647919|NCT05104008|Active Comparator|Traditional physiotherapy with home exercises group (Group 2)|Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors & abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
89647920|NCT04020211||HF10|SCS stimulation with HF10 therapy
89647921|NCT04577820|Experimental|garetosmab|
89647922|NCT04097600|Experimental|Sequence 1|Current form 3 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
89647923|NCT04097600|Experimental|Sequence 2|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
89647924|NCT04097600|Experimental|Sequence 3|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by current form 14 mg in treatment period 3
89647925|NCT04097600|Experimental|Sequence 4|New form 2.4 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by current form 14 mg in treatment period 3
89647926|NCT04097600|Experimental|Sequence 5|New form 2.4 mg in treatment period 1, followed by current form 7 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
89647927|NCT04097600|Experimental|Sequence 6|Current form 3 mg in treatment period 1, followed by new form 5.6 mg in treatment period 2, followed by new form 11.2 mg in treatment period 3
89647928|NCT04020367|Other|patients with biopsy|
89647929|NCT04096820|Experimental|Open Label|Uromune will be taken by the participant for 90 days.
89647930|NCT04766203|No Intervention|Global screening of high-performance athletes for REDS|This arm collects data with an online survey to assess prevalence and signs and symptoms of REDS in elite female and male elite and recreational athletes and para-athletes over the age of 15 years across the world.
89647931|NCT04766203|No Intervention|Basic screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline blood sample and potentially (where abnormalities are present) a follow-up 6 months later.
89647932|NCT04766203|No Intervention|Advanced screening of Canadian high-performance athletes for REDS|In this study arm, varsity level to elite Canadian athletes and para-athletes will complete a baseline test for bone density (DXA scans), resting metabolic rate and exercise testing. Potentially (where abnormalities are present) a follow-up 6 months later.
89647933|NCT04766203|Experimental|Treatment of Canadian athletes with REDS: a holistic intervention arm|In this arm, varsity level to elite Canadian athletes and para-athletes with REDS will participate in a nutritional intervention aiming to improve energy availability and thus, REDS status.
89647934|NCT04409756|Other|postassessment of the SRQ-T test|the SRQ -T will be obtained to all patients three days after the first assessment
89647935|NCT04194229||Group 1|Patients that receive Cytoflavin® medication i/v drop infusion at a dose of 10 ml of solution for injection per 200 ml of 0.9 % sodium chloride solution for 10 days in addition to a set of neurorehabilitation activities
89647936|NCT04194229||Group 2|Patients that subjected to the standard set of neurorehabilitation activities for 10 days without being prescribed Cytoflavin® medication
89647937|NCT01272765|Placebo Comparator|Control Group|
89647938|NCT01272765|Experimental|Risperdal Group|Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
89647939|NCT01272765|Experimental|Seroquel Group|Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
89647940|NCT01272765|Experimental|Zyprexa Group|Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
89647941|NCT05103852|Experimental|Patients with right cardiac catheterization|
89647942|NCT04020133|Active Comparator|the control group|this group will receive post-operative saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
89647943|NCT04020133|Active Comparator|the intervention group|this group will receive popliteal plexus block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg in addition to standard saphenous nerve block by 1mg/kg plain bupivacaine 0.5% plus epinephrine 0.05 mg.
89647944|NCT04565574|Experimental|Part A: E7090 35 mg (Fasted + Fed + Fed)|Participants will receive E7090 35 milligram (mg) tablet, orally on Day 1 of Treatment Period 1 in fasted state, followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fed state (high-fat meal). A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
89647945|NCT04565574|Experimental|Part A: E7090 35 mg (Fed + Fasted + Fed)|Participants will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 1 in fed state (high-fat meal), followed by E7090 35 mg tablet, orally on Day 1 of Treatment Period 2 in fasted state. A wash out period of 5 days will be maintained between Treatment Periods 1 and 2. Further participant will receive E7090 35 mg tablet, orally on Day 1 of Treatment Period 3 in fed state (low-fat meal).
89647946|NCT04565574|Experimental|Part B: E7090 35 mg + Rabeprazole 20 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rabeprazole 20 mg tablets, orally, once daily on Days 7 to 10, and then followed by E7090 35 mg tablet and rabeprazole 20 mg tablets, orally on Day 11 in fasted state.
89647947|NCT04565574|Experimental|Part C: E7090 35 mg + Rifampin 600 mg|Participants will receive E7090 35 mg tablet, orally on Day 1 in fasted state, followed by a wash out period of 5 days, further followed by rifampin 600 mg capsules, orally, once daily on Days 7 to 12, then followed by E7090 35 mg tablet and rifampin 600 mg capsules, orally on Day 13 in fasted state, and then by rifampin 600 mg capsules, orally, once daily on Days 14 to 18.
89647948|NCT00731211|Experimental|Pazopanib|800 mg of pazopanib orally each day continuously
89647949|NCT04192513|Active Comparator|Cohort 1 DBI-001 Gel and placebo|Cohort 1 DBI-001 Gel with low dose CFU's of J. lividum and placebo
89647950|NCT04192513|Active Comparator|Cohort 2 mid dose DBI-001 Gel and placebo|Cohort 2 DBI-001 Gel with mid dose CFU's of J. lividum and placebo
89647951|NCT04192513|Active Comparator|Cohort 3 high dose DBI-001 Gel and placebo|Cohort 3 DBI-001 Gel with high dose CFU's of J. lividum. Drug: J. lividum and placebo
89647952|NCT01521494|Experimental|PA21 750 mg/day|
89647953|NCT01521494|Experimental|PA21 1500 mg/day|
89647954|NCT01521494|Experimental|PA21 2250 mg/day|
89647955|NCT01521494|Experimental|PA21 3000 mg/day|
89647956|NCT01521494|Placebo Comparator|Placebo|
89647957|NCT04026919|Experimental|to analyze the effectiveness of Ok en Casa Zaindoo|The multicomponent online programme is composed of the components explained in the detailed study description:
89647958|NCT01270971|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
89647959|NCT01270971|Placebo Comparator|Solution Vehicle|Solution Vehicle
89647960|NCT05103774||Group A: children exposed to any type of radiation or contrast|Group A: children exposed to any type of radiation or contrast
89647961|NCT05103774||Group B : children not exposed to an type of radiation or contrast|Group B : children not exposed to an type of radiation or contrast
89647962|NCT04026841|Experimental|PD-1 Antibody Sintilimab|Patients receive the treatment of PD-1 antibody Sintilimab
89647963|NCT04128774||GBM-dexa|Participants with clinical diagnosis of GBM, that require dexamethasone due to neurological deficits. Dose is based on the clinical judgement of the treating physician but should be given at least two weeks. Dexamethasone is given once a day.
88992870|NCT05434234|Experimental|Dose escalation|All participants enrolled in the dose escalation part
88992871|NCT05434234|Experimental|Dose expansion|All participants enrolled in the dose expansion part
88992872|NCT05427110||asymptomatic|Runners without iliotibial band syndrome
88992873|NCT05427110||Iliotibial band syndrome|Runners with iliotibial band syndrome
88992874|NCT05415033|Other|BREAST-Q|
88992875|NCT05406011|Experimental|Age groups|Participants grouped by their age (Age group I: patients aged between 18-30, age group II: patients aged between 31-45).
88992876|NCT05406011|Experimental|Groups by toothbrush change|Half of the group change the toothbrush after scaling and the other half not.
88992877|NCT05406011|Experimental|Experimental period|"Control: Control period without sour cherry chewing gum usage, with saliva sampling on fixed appointments (between 12:00 and 14:00, 0th, 4th and 7th day of the week) of the week. At the beginning oral and basic periodontal examinations performed. Plaque and calculus index at every sampling occasions.~Prevention: After a full mouth scaling sour cherry chewing gum usage, for a week. Saliva sampling on the same days. Plaque and calculus index at every sampling occasions.~Therapeutic: Sour cherry chewing gum usage, for one more week. Saliva sampling on the same days. Plaque and calculus index at every sampling occasions.~Control (without sour cherry chewing gum usage), prevention and therapeutic periods takes 3 weeks together."
88992878|NCT05399615|Experimental|Hospitalized Patients|"Patients hospitalized in internal ward at Poriya Medical Center"
88992879|NCT05399615|Experimental|Controls|Healthy volunteers
88992880|NCT05388734|No Intervention|Before group|Patients in the before group are recruited during the first 4 months of the study and will not benefit from the alternative medicine education consultation
88992881|NCT05388734|Active Comparator|After Group|Patients in the front group are recruited from the 5th month of the study and will benefit from the alternative medicine education consultation
88992882|NCT05383859|Experimental|Intervention Group (IG)|"Completing the consent and the pre-intervention questionnaires, anthropometric and HbA1c measurements.~Dietary and/ or physical activity: face to face plus written material~3 months later: motivational phone call."
89647964|NCT04128774||GBM-control|Participants with clinical diagnosis of GBM not requiring dexamethasone treatment.
89647965|NCT04027855|Other|collection of PBMC from healthy donors|"Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
88992883|NCT05383859|No Intervention|Control group (CG)|"Completing the consent and the pre-intervention questionnaires, anthropometric and HbA1c measurements.~Usual care"
89647966|NCT04192669||Anxio-depressive patients|Patients with a depressive or anxious disorder going to the Psychiatry Department of the CHU Brugmann Hospital.
88992884|NCT05383586|Experimental|Creative Music Therapy|20 minutes of infant-directed singing in lullaby-style accompanied with the monochord for preterm infant and parent during kangaroo-care
89647967|NCT00732225|Active Comparator|DisCoVisc|Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)
89647968|NCT00732225|Active Comparator|DuoVisc|Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)
89647969|NCT00732225|Active Comparator|BioVisc|Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)
89647970|NCT00732225|Active Comparator|Healon5|AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)
89647971|NCT00732225|Active Comparator|Amvisc Plus|Bausch & Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)
88992885|NCT05375916|Experimental|Sustained-release opioid|3mg of sustained-release hydromorphone three times a day
88992886|NCT05375916|Active Comparator|Short-acting opioid|1-4 mg of short-acting hydromorphone 2-4 times a day as needed
89647972|NCT05103462|Experimental|Telehealth Physical Therapy|Weekly sessions of education, advice and exercise instruction provided by a licensed physical therapist using real-time, interactive video conferencing platform.
89647973|NCT01270503|Experimental|Menactra® Group 1|Participants aged 2 to 11 on enrollment
89647974|NCT01270503|Experimental|Menactra® Group 2|Participants aged 12 to 17 on enrollment
89647975|NCT01270503|Experimental|Menactra® Group 3|Participants aged 18 to 55 on enrollment
89647976|NCT04026763|Experimental|Males with Prostate Cancer|Each participant will receive standard of care prostate biopsy as well as a US guided prostate biopsy and a MR/TRUS Fusion Guided prostate biopsy guided prostate biopsy.
89647977|NCT04026685|Active Comparator|Phenylephrine infusion only|Phenylephrine infusion only
89647978|NCT04026685|Active Comparator|Phenylephrine infusion and Ringer-Acetate bolus|Phenylephrine infusion and Ringer-Acetate bolus
89647979|NCT04024033|Active Comparator|capsule|patinets receiveing pine cone extract tablets
89647980|NCT04024033|Placebo Comparator|placebo capsule|patinets receiving placebo
89647981|NCT04026061|Experimental|FMA group|Receiving the FMA training and tool
89647982|NCT04026061|Placebo Comparator|control group|Receiving a simple tablet training and some websites
89647983|NCT00751179|Active Comparator|Rocuronium - Sugammadex|Rocuronium - Sugammadex 4.0 mg/kg
89647984|NCT00751179|Active Comparator|Succinylcholine|Succinylcholine 1.0 mg/kg
89647985|NCT04766281|Active Comparator|MLC901 (NeuroAiD II)|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
89647986|NCT04766281|Placebo Comparator|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
89647987|NCT01273233|Experimental|Group 1: 200U EV71 vaccine|12 adults received 3 doses of 200U EV71 vaccine 14 days apart
89647988|NCT01273233|Experimental|Group 2: 400U EV71 vaccine|12 adults received 3 doses of 400U EV71 vaccine 14 days apart
89647989|NCT01273233|Placebo Comparator|Group 1: Placebo|6 adults received 3 doses of placebo 14 days apart
89647990|NCT01273233|Placebo Comparator|Group 2: Placebo|6 adults received 3 doses of placebo 14 days apart
89647991|NCT01278693|Other|placebo|it is as like as L-carnitine in shape
89647992|NCT01278693|Other|L-carnitine|it is kind of supplement
89647993|NCT01277211|Experimental|ENG-EE (NuvaRing)|Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
89647994|NCT01277211|Active Comparator|DRSP-EE|Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.
89647995|NCT04022161|Placebo Comparator|Nitrogen|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
89647996|NCT04022161|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled nitric oxide (iNO) will be weaned and discontinued.
89647997|NCT01676220|Experimental|HOE901-U300|
89647998|NCT01676220|Active Comparator|Lantus|
89647999|NCT04027231||Ahlback I|
88992887|NCT05368467||1|All consecutive consenting patients diagnosed with PH according to specific hemodynamic criteria at participating institutions.
88992888|NCT05359354|Experimental|Personalized neoantigen vaccine or neoantigen tumor vaccine + PD-1|In dose escalation phase, subject will only receive personalized neoantigen tumor vaccine. In dose expansion phase, subject will receive personalized neoantigen tumor vaccine combination with PD-1.
89648000|NCT04027231||Ahlback II|
89648001|NCT04027231||Ahlback III|
89648002|NCT04027231||1 year following TKA|
89648003|NCT04027231||TKA revision|
89648004|NCT04026997|Experimental|Cohort 1|CIN-102 tablets by mouth twice daily for 14 days
89648005|NCT04026997|Placebo Comparator|Cohort 1 - Placebo|Placebo tablets by mouth twice daily for 14 days
89648006|NCT04026997|Experimental|Cohort 2|CIN-102 tablets by mouth twice daily for 14 days
89648007|NCT04026997|Placebo Comparator|Cohort 2- Placebo|Placebo tablets by mouth twice daily for 14 days
89648008|NCT04026997|Experimental|Cohort 3|CIN-102 tablets by mouth twice daily for 14 days
89648009|NCT04026997|Active Comparator|Cohort 3- Placebo|Placebo tablets by mouth twice daily for 14 days
89648010|NCT01275105|Other|Vehicle|
89648011|NCT01275105|Active Comparator|Brimonidine Tartrate 0.01%|
89648012|NCT01275105|Active Comparator|Oxymetazoline HCl 0.025%|
89648013|NCT01275105|Active Comparator|Brimonidine Tartrate 0.025%|
89648014|NCT01273389|Experimental|CNTO 136|CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.
89648015|NCT01273389|Placebo Comparator|Placebo|
89648016|NCT04026139|Experimental|experimental group|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
89648017|NCT04026139|Active Comparator|control group|The control group underwent active joint range-of-motion exercises and isometric contraction exercises.
89648018|NCT00734409|Experimental|RASS plus (BIS)|Participants in this arm will receive sedation assessment with the RASS scale augmented with Bispectral Index (BIS) Monitor
89648019|NCT00734409|No Intervention|RASS only|Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution
89648020|NCT04026373|Experimental|modified Prolonged Exposure|
89648021|NCT04026373|Active Comparator|Treatment as usual|
89648022|NCT05102838||Hepatitis B cohort|"Patients with HBsAg and/or HBV DNA positive;~Patients without cirrhosis."
89648023|NCT05102838||Hepatitis C cohort|"Patients with anti-HCV and/or HCV RNA positive;~Patients without cirrhosis."
89648024|NCT05102838||Cirrhosis cohort|"Patients diagnosised with cirrhosis;~Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive."
89648025|NCT05102838||Liver cancer cohort|"Patients diagnosised with liver cancer;~Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive."
89648026|NCT04029649|Experimental|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|This group received capsule contains 180 mg Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum with dose 3x1 capsule a day for 90 days
89648027|NCT04029649|Placebo Comparator|Placebo|This group received empty capsule with dose 3x1 capsule a day for 90 days
89648028|NCT01270347|Experimental|Aeroquin|Aeroquin, Inhaled Levofloxacin (MP-376)
89648029|NCT01270347|Active Comparator|TIS|Tobramycin Inhalation solution (TIS) [TOBI® Novartis Pharmaceuticals]
89648030|NCT03608436|Experimental|Low pressure PNP, deep NMB|Low pressure pneumoperitoneum of 8 mmHg with deep neuromuscular block (post tetanic count of 1-2) reached by titration with continuous infusion of Rocuronium bromide.
89648031|NCT03608436|Active Comparator|Normal pressure PNP, moderate NMB|Normal pressure pneumoperitoneum of 12 mmHg with moderate neuromuscular block (TOF count of 1-2) reached by titration with bolus or continuous infusion of a low dose of Rocuronium bromide.
89648032|NCT03947281|Experimental|Almond snack|The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.
89648033|NCT03947281|Experimental|Cereal-based snack|The cereal-based intervention will be a mixture of dry cereal, pretzels, and bread sticks prepared by the Western Human Nutrition Research Center (WHNRC). The caloric value is approximately 350 kcals.
89648034|NCT03486678|Experimental|SHR1210+GEMOX|This is a single arm trial. Participants will receive SHR1210 + GEMOX treatment.
89648035|NCT01271673||Women undertaking Breast Self Examination|Women attending Preventive Oncology Clinic during the month of November- December 2010,and undertaking BSE training whose Residential address mentioned as Mumbai and whose Contact number is available.
89648036|NCT03652285|Experimental|Esophageal stent implantation (UAS-RBS implantation)|Esophageal stent implantation (UAS-RBS implantation) at J0, removal after 6 months and follow-up for 6 months
89648037|NCT04154046|Experimental|Tenotomy|Patients allocated to this arm receive tenotomy treatment of affected toes, and standard care including offloading treatment
89648038|NCT04154046|No Intervention|standard care|Patient who are randomized to this arm receive standard care including offloading treatment
89648039|NCT04025671|Experimental|Nasal Spray Naloxone|This arm will be randomized to administer a nasal spray naloxone device in a simulated overdose setting.
89648040|NCT04025671|Active Comparator|Intramuscular|This arm will be randomized to administer a intramuscular naloxone device in a simulated overdose setting.
89648041|NCT04025671|Active Comparator|Improvised Nasal Atomizer|This arm will be randomized to administer an improvised nasal atomizer naloxone device in a simulated overdose setting.
89648042|NCT01273467|Experimental|001|CNTO 0007 or placebo (Stage A) a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
89648043|NCT01273467|Experimental|002|CNTO 0007 or placebo (Stage B) a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
89212784|NCT04018274|Experimental|Sequence 1|In Treatment Sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into Period 2 where they will receive PF-06651600 PO for 9 days followed by administration of a single dose of OC on the morning of Day 10.
89648044|NCT03412188|Experimental|group 1 Eltrombopag arm|"Group 1 (eltrombopag arm n=20 patients): Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy. patients will receive a total daily dose of eltrombopag of (25-50mg/d). Dose adjustments may be made based on platelets count with an increment of 25mg once per day at 2 weeks intervals (Maximum dose: 75 mg orally once a day).~Patients, who responded poorly to eltrombopag in 6 months or developed adverse effects, were asked to discontinue the medication. Those who responded were followed for further 6 month period."
89648045|NCT03412188|Active Comparator|group 2 conventional Treatment|"Group 2 (n=20 patients) Patients who are currently receiving other lines of treatment (steroids, IVIG, azathioprine, and rituximab).~patients will continue on the conventional line of treatment"
89648046|NCT01273545||001|PRILIGY (dapoxetine hydrochloride) The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists and in Italy by urologists
89648047|NCT04146727||ICU Duration|The total study duration is determined by their length of stay in the ICU.
89648048|NCT04146727||Transplant through 1 month at Home|Time from surgery through 1 month at home. Maximum duration is length of stay in the ICU plus 1 month at home.
89648049|NCT00734799|No Intervention|2|Usual Care/Wait-List Control
89648050|NCT00734799|Experimental|1|Sleep Intervention for PTSD (SIP)
89212785|NCT04018274|Experimental|Sequence 2|In Treatment Sequence 2, Period 1, participants will be dosed with PF-06651600 PO QD for 9 days and administered a single dose of OC on the morning of Day 10. After a washout period of at least 10 days, participants will continue into Period 2 and will receive an additional single dose of OC.
89648051|NCT01278849|Experimental|ASA404 + standard therpy|
89648052|NCT04146805|Experimental|Part 1SAD/Part 2 MAD:Active Treatment(BLD-0409)|For each cohort in both study parts, 6 subjects will be randomized to active (BLD-0409). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s)
89648053|NCT04146805|Placebo Comparator|Part 1SAD/Part 2 MAD:Control(Matched Placebo)|For each cohort in both study parts, 2 subjects will be randomized to control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
89648054|NCT04007094|Experimental|Study Arm|Participants will be entered into the single armed study in which one side of the fusion will be coated with milled local autograft bone and the opposite fusion side will be supplemented with an equal volume of Depuy Synthes ViviGen.
89648055|NCT01273701|Experimental|TSTSU-N|TSTSU-N stands for Treatment for Schedule Two Substance Use, No Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-N will not receive telephone reminding before each visit.
89648056|NCT01273701|Experimental|TSTSU-T|TSTSU-T stands for Treatment for Schedule Two Substance Use, Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-T will receive telephone reminding before each visit.
89648057|NCT01273701|Active Comparator|OPD|OPD stands for Outpatient Department. Subjects in this arm will be methamphetamine users who voluntarily visit psychiatric clinics for treatment of mental disorders in National Taiwan University Hospital, Yunlin Branch. They will be referred to this study by their treating psychiatrists.
89648058|NCT04020289|Experimental|"BalancingMySwing"|"Psychoeducational Program BalancingMySwing for bipolar disorder"
89648059|NCT04020289|Other|treatment as usual (TAU)|Patients received treatment as usual
89648060|NCT04949412||non-severe COVID19|Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types or A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura.
89648061|NCT04949412||Severe Covid19|Severe pneumonia was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR ≥30 times/minute; ii) hypoxia: oxygen saturation (resting state) ≤93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) ≤ 300 mmHg (millimeters of Mercury); or iv) the occurrence of respiratory or other organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
89648062|NCT04385355|Other|Control Group|Control group will receive an intermediate transmucosal abutment with conventional diameter and 3mm height, once the implants are placed.
89648063|NCT04385355|Experimental|Test Group|Test group will receive an intermediate transmucosal abutment with a TCP design, narrower than the conventional one, of 3mm height, once the implants are placed
89648064|NCT04023175|Active Comparator|In office|Patients will undergo our standard in office preoperative counseling.
89648065|NCT04023175|Experimental|Virtual visit|Patients will undergo preoperative counseling using telemedicine virtual visits.
89648066|NCT04914858|Experimental|Education group|Education
88992889|NCT05357976|Active Comparator|Patients with a BMI of 18-24.9 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
89648067|NCT04914858|No Intervention|Control group|No Intervention
89648068|NCT04022473|Experimental|Bafiertam|oral capsules administered twice daily
89648069|NCT04022473|Active Comparator|Tecfidera|oral capsules administered twice daily
89648070|NCT05375058||pandemic group (2020)|includes patients who presented to the hospital during the period of acute restrictions and shutdowns extending from the 17th of March to the 6th of June 2020
89648071|NCT05375058||pre-pandemic group (2019)|which represents the same period in the previous year
88992890|NCT05357976|Active Comparator|Patients with a BMI of 25-29.9 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
88992891|NCT05357976|Active Comparator|Patients with a BMI of 30-40 kg/m2|The needle will be advanced to the paravertebral area with an ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
88992892|NCT05491421|Experimental|A (ZT002)|"Drug: ZT002~Dose level:~SAD dose (Cohort 1-4)~0.03 mg/kg, 0.09 mg/kg, 0.18 mg/kg, 0.3 mg/kg;~MAD dose (Cohort 1-3)~Cohort 1: 7.0mg, 10mg, 20mg;~Cohort 2: 10 mg, 20mg, 40mg;~Cohort 3: To be decided post safety review meetings~Dose: Subcutaneous Injection"
88992893|NCT05491421|Placebo Comparator|B (Placebo)|"Dose level:~SAD dose (Cohort 1-4)~0.03 mg/kg, 0.09 mg/kg, 0.18 mg/kg, 0.3 mg/kg;~MAD dose (Cohort 1-3)~Cohort 1: 7.0mg, 10mg, 20mg;~Cohort 2: 10 mg, 20mg, 40mg;~Cohort 3: To be decided post safety review meetings~Dose: Subcutaneous Injection"
88992894|NCT05352243|Active Comparator|Expressive Disclosure|Participants will be instructed to write about their deepest thoughts and feelings surrounding their bereavement experience.
88992895|NCT05352243|Experimental|Expressive Helping|Participants will be instructed to write about their deepest thoughts and feeling surrounding their bereavement experience in their first two essays and to provide advice and support for someone who recently experienced a loss in their final essay.
88992896|NCT05352243|Sham Comparator|Fact-Writing|Participants will be instructed to write objectively about different time frames (e.g., routine for getting up in the morning, routine for going to sleep at night).
88992897|NCT05352230|Active Comparator|Continue Glucose Monitoring (CGM)|External diabetes device glucose sensor that measures interstitial glucose levels every minute
88992898|NCT05352230|Other|Glucometer|Device that measures capillary blood glucose levels
89045031|NCT02915627|Active Comparator|CKD patients on Dialysis|Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility-Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
89648072|NCT03972696|Active Comparator|BA3S|Radiotherapy (RT) will be administered, in the breast or thoracic wall, axillary levels I, II and III, and supraclavicular node areas, with optimization of the technique Intentional irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast and nodal areas (axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
89648073|NCT03972696|Experimental|BA2|RT will be administered, in the breast or thoracic wall and axillary levels I and II, with optimization of the technique Incidental irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
89648074|NCT02705911|Experimental|Isometric Handgrip training|Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
89648075|NCT02705911|Active Comparator|Aerobic endurance training|Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
89045032|NCT02915588|Active Comparator|Primary Active|Early postoperative isometric activation of the rotator cuff
89045033|NCT02915588|Active Comparator|Primary Passive|Standard postoperative passive movement rehabilitation protocol
89045034|NCT02915510|Experimental|GMP|Single arm designed, 3 day baseline, 28day on GMP
89045035|NCT02098278|Experimental|CAT-2003 or Placebo|All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
89045036|NCT02915471|Experimental|Virtual Peer-to-Peer Support Mentoring|n addition to standard medical care, adolescents in the experimental group will receive the iP2P support program, a manualized peer-mentorship program that will provide mentoring and reinforcement by peers (young adults with cancer aged 16-25 years who have learned to function successfully with their cancer to the mentored participants).
89045037|NCT02915471|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the iP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
89045038|NCT04677894||Group Direct Laringoscopy|Group DL: Group of patients intubated using a Macintoch blade laryngoscope.
89045039|NCT04677894||Group Videolaringoscopy|Group VL: Group of patients intubated using a McGrath video laryngoscope.
89648076|NCT02705911|No Intervention|Control|Participants are asked to continue with their daily routine and not to perform extra exercise.
89648077|NCT03845946||Hereditary angioedema type I/II|Hereditary angioedema with C1Inh deficiency
89648078|NCT03845946||Acquired angioedema|Angioedema with acquired C1Inh deficiency
89648079|NCT03845946||Drug induced angioedema|Angioedema associated with ACEi used
89648080|NCT03845946||Mast cell induced angioedema|Spontaneous mast cell induced isolated angioedema
89648081|NCT03845946||Hereditary angioedema with nC1Inh|Hereditary angioedema with normal C1Inh and with F12, PLG, ANGPT2 mutations
89648082|NCT01485614|Experimental|Sitagliptin|Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
89648083|NCT01485614|Placebo Comparator|Placebo/Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
89045040|NCT02915276|Active Comparator|Blastocentisis|The blastocoelic fluid will be aspirated from the embryonic cavity on day 5 or 6 of development and will be subjected to genetic analysis
89045041|NCT02915276|Active Comparator|Trophectoderm biopsy|Throphectoderm cells will be removed from the embryo on day 5 or 6 of development and will be subjected to genetic analysis
89045042|NCT02915315||Baseline survey period|All subjects will continue a normal diet for 3 days in which questionnaire design and anthropometric measurements will be implemented.
89045043|NCT02915315||Low-salt diet|All subjects will be instructed to maintain a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day).
89045044|NCT02915315||High -salt diet|After washout period, all subjects will be instructed to maintain a 18g of salt or 307.8mmol of sodium per day.
89045045|NCT02092935|Experimental|SMT19969|200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
89045046|NCT02092935|Active Comparator|Vancomycin|125 mg capsule four times a day for 10 days
89045047|NCT02915237|Experimental|Low Dose - Concord grape juice|Daily dietary supplementation with 4 oz. of a commercially available Concord grape juice.
89045048|NCT02915237|Experimental|Moderate Dose - Concord grape juice|Daily dietary supplementation with 8 oz. of a commercially available Concord grape juice.
89045049|NCT02915237|Experimental|High Dose - Concord grape juice|Daily dietary supplementation with 16 oz. of a commercially available Concord grape juice.
89045050|NCT02915237|Placebo Comparator|Low dose - placebo beverage|Daily dietary supplementation with 4 oz. of a placebo beverage
89045051|NCT02915237|Placebo Comparator|Moderate Dose - placebo beverage|Daily dietary supplementation with 8 oz. of a placebo beverage
89045052|NCT02915237|Placebo Comparator|High Dose - placebo beverage|Daily dietary supplementation with 16 oz. of a placebo beverage
89045053|NCT01666977|Experimental|Arm A|Arm A: AMG 386 placebo IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
89045054|NCT01666977|Experimental|Arm B|Arm B: AMG 386 15 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
89045055|NCT01666977|Experimental|Arm C|Arm C: AMG 386 30 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
89045056|NCT02915354|Experimental|Etanercept, AS|The patients were diagnosed with ankylosing spondylitis and obtained the ASAS20 response after etanercept treatment. Then they were discontinued to etanercept and received no treatment except DMARDs or NSAIDs which had used before.
89212786|NCT00873002|Active Comparator|LBH589|This study utilizes a sequential dose-escalation design to define the MTD of LBH589 when combined with standard doses of sorafenib.
89212787|NCT00491530|Experimental|ABT-335 + rosuvastatin calcium|
89212788|NCT00491530|Experimental|ABT-335 + simvastatin|
89045057|NCT01661634|Experimental|Ularitide|Ularitide, lyophilizate for i.v. infusion, 15 ng/kg BW/min, for 48 hours
89212789|NCT00491530|Experimental|ABT-335 + atorvastatin calcium|
89521302|NCT03439969|Experimental|Intra Oral Camera and Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.Participants also received SMS a total of 16 messages (SMS). One per week.
89045058|NCT01661634|Placebo Comparator|Placebo|Placebo lyophilizate for i.v. infusion
89045059|NCT02915393||Healthy Volunteers (BC)|Healthy Volunteers with Balanced Constitution(n=10).
89045060|NCT02915393||Healthy Volunteers(QC)|Healthy Volunteers with Qi Deficiency Constitution(n=10).
89045061|NCT02915393||Healthy Volunteers(DC)|Healthy Volunteers with Damp-heat Constitution(n=10).
89045062|NCT02915393||Superficial Gastritis(SDS)|Superficial Gastritis with Spleen-qi Deficiency Syndrome(n=10).
89045063|NCT02915393||Superficial Gastritis(DS)|Superficial Gastritis with Damp-heat Syndrome(n=10).
89045064|NCT02915393||Atrophic Gastritis(SDS)|Atrophic Gastritis with Spleen-qi Deficiency Syndrome(n=10).
89045065|NCT02915393||Atrophic Gastritis(DS)|Atrophic Gastritis with Damp-heat Syndrome(n=10).
89045066|NCT02915393||Gastric Cancer(SDS)|Gastric Cancer with Spleen-qi Deficiency Syndrome(n=10).
89521303|NCT03431701|Experimental|Group chlorhexidine|Patients will receive chlorhexidine abdominal and vaginal scrubbing
89521304|NCT03431701|Active Comparator|Group iodine|Patients will receive iodine abdominal and vaginal scrubbing
89521305|NCT03431623|Experimental|CKD-11101(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
89521306|NCT03431623|Active Comparator|NESP(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
89521307|NCT04451395|Experimental|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet..The supplement is provided within the parent trial.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
89045067|NCT02915393||Gastric Cancer(DS)|Gastric Cancer with Damp-heat Syndrome(n=10).
89521308|NCT04451395|No Intervention|Standard of care|Daily iron and folic acid supplementation provided through the existing public health system.
89521309|NCT03439813|Experimental|TASK-CBT|Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
89521310|NCT03439813|Active Comparator|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
89521311|NCT04451005||Elderly patients with sarcopenia|Elderly patients with sarcopenia
89521312|NCT04451083|Experimental|FOY-305|
89521313|NCT04450849|Experimental|collagen membrane associated to anorganic bone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio) associated to anorganic bovine bone matrix + collagen (Bio-Oss® Collagen) . The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
89521314|NCT04450849|Active Comparator|collagen membrane alone|Complete debridement of the osseous defects and thorough scaling and root planing using mini curettes and ultrasonic scalers were performed. The sites were randomly selected for treatment with resorbable collagen membrane (Bio-Gide® Perio). The membranes were trimmed to cover the lesions and extended to the adjacent bone between 2 to 3 mm apically and laterally. They were then placed in position, 2 mm below the CEJ, and fixed in position using sling 5-0 vicryl sutures. The flaps were coronally positioned until completely covering the membranes without tension and sutured with 5-0 nylon sutures
89521315|NCT03431389|Active Comparator|Decannulated group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Trial of decannulation was considered successful, if there was no need to reapply tracheostomy within 6 months of decannulation.
88992899|NCT05352100|Experimental|Hospitalized patients|This phase will recruit hospitalized bedridden patients who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. They may receive multiple 5 minute episodes of various vibration frequencies.
88992900|NCT05346562|Experimental|Cannabidiol, then Placebo|Participant receive cannabidiol: 225 to 300 mg split over three times daily for the initial 2.5 weeks and 375 to 450 mg split over three times for the following 2.5 weeks. After two week washout, participant receives Placebo for five weeks (matching Cannabidiol tablets)
88992901|NCT05346562|Experimental|Placebo, then Cannabidiol|Participant receive placebo tablets (matching Cannabidiol pills) for five weeks. After two week washout, Participant receive cannabidiol: 225 to 300 mg split over three times daily for the initial 2.5 weeks and 375 to 450 mg split over three times for the following 2.5 weeks.
88992902|NCT05344430|Other|cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy|Cone beam Computed Tomography (CBCT) with Navigational software guidance for percutaneous transthoracic needle biopsy
88992903|NCT05344430|Other|multidetector computed tomography (MDCT) for percutaneous transthoracic needle biopsy|Multidetector Computer Tomography for percutaneous transthoracic needle biopsy
88992904|NCT05339854||ECPR survivor|Adult patient who survived therapy-refractory cardiac arrest with extracorporeal cardiopulmonary resuscitation (ECPR).
89521316|NCT03431389|Active Comparator|Failure of decannulation group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Decannulation trail was considered failed if there was a need to reapplication of tracheostomy at the time of decannulation or within six months of decannulation the duration of follow up.
89521317|NCT03435289|Other|CPI-613, Gemcitabine and Nab-paclitaxel|CPI-613 in Combination With Gemcitabine 1000mg/m2 iv and Nab-paclitaxel 125mg/m2 iv
89521318|NCT03435133|Active Comparator|Prasugrel|
89521319|NCT03435133|Active Comparator|Ticagrelor|
89521320|NCT03431311|Experimental|Adoptive Cell Therapy (ACT)|"The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.~Escalating dose per week, from 1 x108 cells (week 1) to 2x109 cells (week 4 onwards) using a central venous catheter. The doses listed indicate the maximum number of T cells per injection at any given time point."
89521321|NCT03439579|Experimental|Home weight loss program|Participants will be instructed to daily monitor their body weight, minutes of activity, number of steps, and calories consumed for the duration of the pilot study, and they will receive recorded individualized feedback on this self-monitored data from Weight Management Center clinicians (registered dietitians, exercise psychologists, and behavioral specialists).
89521322|NCT03431233|Experimental|Group 1|protein enriched bar->commercial cereal bar->water
89521323|NCT03431233|Experimental|Group 2|protein enriched bar->water->commercial cereal bar
89521324|NCT03431233|Experimental|Group 3|commercial cereal bar->protein enriched bar->water
89521325|NCT03431233|Experimental|Group 4|commercial cereal bar->water->protein enriched bar
89521326|NCT03431233|Experimental|Group 5|water->protein enriched bar->commercial cereal bar
89521327|NCT03431233|Experimental|Group 6|water->commercial cereal bar->protein enriched bar
89521328|NCT03431155|Experimental|Experimental group|Nursing intervention
89521329|NCT03431155|No Intervention|Control Group|- Receive routine nursing care
89521330|NCT03434899|Experimental|Intervention group|Health care plan including physical exercise and online support during the entire study
89521331|NCT03434899|Active Comparator|Control Group|Health care plan including physical exercise
89521332|NCT03431077|Experimental|LJPC-501|Angiotensin II administered via continuous infusion (1.25 - 40 ng/kg/min) for 24 hours up to 168 hours.
89521333|NCT03430999|Experimental|Group 1 (Japanese) Calmangafodipir|
89521334|NCT03430999|Placebo Comparator|Group 1 (Japanese) Placebo|
89521335|NCT03430999|Experimental|Group 2 (Caucasian) Calmangafodipir|
89521336|NCT03430999|Placebo Comparator|Group 2 (Caucasian) Placebo|
89521337|NCT04450615|Experimental|Training group|"The first part of the program aims in pelvic and hip mobility and includes the following exercises, glute bridge, single-leg glute bridge, side-lying clam, side plank and side plank with hip abduction, on stable surface.~The second part consists of exercises for deep and superficial trunk muscles. In the first exercise the participants learn to activate the transversus abdominis muscle from the crook-lying position, by performing abdominal hollow. Other exercises include the front plank, trunk curl-up, trunk curl-up on stable surface and curl-up on unstable surface (Swiss ball).~The third part of the program consists of exercises for strengthening the lumbar multifidus muscle. The participants will perform prone trunk extension, superman exercise, quadruped diagonal arm and leg lift, single leg supine bridge and supine bridge on unstable surface (Swiss ball)."
89521338|NCT04450615|No Intervention|Control group|The participants of this group will follow their typical daily routine
89521339|NCT04450537|Experimental|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
89521340|NCT04450537|No Intervention|Sun Safety Control|Participants will be exposed 10 sun safety messages
89521341|NCT03860311|Experimental|Bladder Ultrasound|The bladder ultrasound group will undergo point-of-care ultrasound upon enrollment, and bladder ultrasound will be repeated every 30 minutes, unless the patient's bladder is full at time of initial scan.
89521342|NCT03860311|Active Comparator|Standard of Care|Bladder (Urethral) Catheter group. The standard of care group will undergo placement of a urethral bladder catheter to allow retrograde filling of the bladder.
89521343|NCT03434743|Experimental|Rehabilitative Intervention|Experimental rehabilitative intervention consists of non-nutritive sucking on emptied breast, one time per day for 10 minutes.
89521344|NCT03434743|Active Comparator|Control Intervention|Control active comparator intervention consists of non-nutritive sucking on a pacifier, one time per day for 10 minutes.
89521345|NCT03434665|Other|Recruited patients|Transradial celiac artery angiography
89648084|NCT01485614|Active Comparator|Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
89648085|NCT01485614|Placebo Comparator|Placebo/Sitagliptin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
89648086|NCT00722553|Other|Dietary Supplement Vitamin B12 & Folic Acid (Vitamin B9)|"Vitamin B12 : 1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.~Folic Acid: 1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
89648087|NCT03022747|Active Comparator|Standard maintenance therapy|Standard maintenance therapy with 6 mercaptopurine and methotrexate
89648088|NCT03022747|Experimental|Allopurinol treatment|The second 12 week phase during which allopurinol is added to oral 6-mercaptopurine and methotrexate therapy
89648089|NCT04853082|Active Comparator|Limonene capsules(marketed product in China)|Limonene capsules(marketed product in China) donate by pharmaceutical company
89648090|NCT04853082|Placebo Comparator|Limonene capsules(Placebo)|Same smell, color and shape as limonene capsules(marketed product in China), without limonene in capsules
89648091|NCT03928015|Experimental|Adjunctive dronabinol|Dronabinol 5mg BID and adjusting within the range of 2.5mg - 10mg BID, as an adjunct to systemic analgesics
89648092|NCT03928015|Active Comparator|Systemic analgesics|Systemic analgesics only
89648093|NCT03831906|No Intervention|Control|"All children admitted in the hospital and presenting with WHO-defined severe pneumonia will be immediately managed as part of routine care per the WHO Standard of Care (SOC), including broad spectrum antibiotics, oxygen therapy if required, additional supportive care and specific therapies for comorbidities such as HIV infection.~For research purposes, children will benefit from HIV testing, malaria testing, and complete blood count (CBC) if not systematically performed as routine care in the country/hospital, as well as from a digitalized chest X-ray (CXR). Additionally, samples will be collected for future biomarkers studies (biobank)."
89648094|NCT03831906|Experimental|Interventional|Children will benefit from the WHO SOC and additional strategies for research purposes (HIV and malaria testing, CBC, CXR, and biobank) as described in the control arm, plus the study intervention.
89648095|NCT04792164|Experimental|The experimental group will receive US guided nerve block|The experimental group will receive US guided nerve block by lidocaine before open inguinal hernia repair.
89648096|NCT04792164|Other|The control group will receive usual infiltration|The control group will receive usual infiltration by lidocaine before open inguinal hernia repair.
89648097|NCT04386213|Experimental|Paclitaxel Drug-coated Balloon|
89648098|NCT04386213|Active Comparator|SeQuent® Please Paclitaxel Drug-coated Balloon|
89648099|NCT04025437|Experimental|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
89648100|NCT04025437|Active Comparator|Neoadjuvant radiotherapy plus hepatectomy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
89648101|NCT03229512|Experimental|Intervention|Topical 1% Sildenafil Cream
89648102|NCT01279083|Experimental|Concentration 1|
89648103|NCT01279083|Experimental|Concentration 2|
89648104|NCT01279083|Experimental|Concentration 3|
89648105|NCT01279083|Experimental|Concentration 4|
89648106|NCT01279083|Placebo Comparator|Vehicle Solution|
89648107|NCT01279083|Active Comparator|Timolol Maleate Ophthalmic Solution|
89648108|NCT03022201|Experimental|DA-9701|In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
89648109|NCT03022201|Active Comparator|Domperidone|(This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.
89648110|NCT04716114|Experimental|SKLB1028|Subjects will receive 150 mg orally twice daily (BID) in continuous 28-day cycles
89648111|NCT04716114|Active Comparator|Salvage Chemotherapy|"Chemotherapy will be given in 28-day cycles. Subjects on low-dose cytarabine (LoDAC) will receive 10 to 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injections for 7 to 14 days.~Subjects on azacitidine will receive 75 mg/m^2 daily by SC or IV, for 5 to 7 days.~Subjects on homoharringtonine (HHT), cytarabine and aclarubicin (HAA) will receive 2 mg/m^2 of HHT by IV, for 7 days (day 1 to 7) (or HHT 2 mg/m^2, twice daily, day 1 to 3); 100~200 mg/m^2 of cytarabine by IV for 7 days (day 1~7) and 20 mg/d of aclarubicin by IV for 7 days (day 1 to 7).~Subjects on fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (FLAG) will receive 30 mg/m^2 of fludarabine daily by IV for 5 days (day 2 to 6), 1000~2000 mg/m2 of cytarabine daily by IV for 5 days (day 2 to 6), and 300 g/m^2 of G-CSF daily by SC or IV for 5 days (days 1 to 5). After completion of chemotherapy, G-CSF will be administered continually until ANC>0.5 x 10^9 / L."
89648112|NCT00752973|Experimental|Treatment arm|MALG treatment
89648113|NCT04025593|Active Comparator|RCHOP|
89648114|NCT04025593|Experimental|RCHOPX|
89648115|NCT02709967|Active Comparator|Material support|Writing materials
89648116|NCT02709967|Experimental|Economic support|Writing materials and economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9).
89648117|NCT02709967|Experimental|Combined intervention|Writing materials, economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9) and community dialogue (youth club meetings, community and parent meetings)
89648118|NCT01279707|Experimental|A: Veltuzumab and chemotherapy|Veltuzumab and modified UKALL XII chemotherapy
89648119|NCT01279707|Experimental|B: epratuzumab and chemotherapy|epratuzumab and modified UKALL XII chemotherapy
89648120|NCT01279707|Experimental|C: veltuzumab and epratuzumab and chemotherapy|Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
89648121|NCT02976714|Other|CF patients|CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care.
89648122|NCT04146415|Experimental|Cardiac amyloidosis patients|
89648123|NCT00736125|Active Comparator|1|
89648124|NCT00736125|Active Comparator|2|
89648125|NCT02957292|Experimental|Levonorgestrel IUD|13,5 mg Levonorgestrel intrauterine device
89648126|NCT02957292|Active Comparator|Copper IUD|Copper (380mm2) intrauterine device
89648127|NCT04146181|Experimental|SCT-I10A|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
89648128|NCT03021889|Experimental|Nutritional therapy group|The group nutritional therapy intervention was subjected to a protocol that included: nutritional counseling and weekly phone calls for 12 weeks.
89648129|NCT03021889|Other|Control group|The control group received conventional care consisting of usual medical care. The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
89648130|NCT00753363|Experimental|Arm 1|6 months of aerobic exercise training
89648131|NCT00753363|Experimental|Arm 2|6 months of weight loss
89648132|NCT04437420||T-ALL|
89648133|NCT04437420||B-ALL|
88992905|NCT05328934|Experimental|Initial Assignment: SoftHand Pro|This arm of the crossover design will begin the trial using the SoftHand Pro.
88992906|NCT05328934|Active Comparator|Initial Assignment: Ossur i-Limb|This arm of the crossover design will begin the trial using the i-Limb.
88992907|NCT05327374||AHF-group|patients with AECOPD and acute heart failure
89648134|NCT02984917|Experimental|anterior transversalis fascia approach|Patients with inguinal hernia will undergo inguinal hernia repair via the anterior transversalis fascia approach.
89648135|NCT02984917|Experimental|preperitoneal space approach|Patients with inguinal hernia will undergo inguinal hernia repair via the preperitoneal space approach.
89648136|NCT01273779|Placebo Comparator|Placebo|
88992908|NCT05327374||non AHF-group|patients with AECOPD without acute heart failure
88992909|NCT05298098|Active Comparator|Hypertonic Saline Solution|50 ml of intravenous Hypertonic Saline Solution over 1 hour + 250mg of IV furosemide over 1 hour
88992910|NCT05298098|Placebo Comparator|5% Dextrose solution|50ml of 5% Dextrose solution over 1 hour + 250mg of IV furosemide over 1 hour
89648137|NCT01273779|Experimental|Talactoferrin alfa|
89648138|NCT01485536|Experimental|AUY922|AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.
89648139|NCT02658630|Experimental|Device: Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
89648140|NCT01484912|Experimental|STA-2|"STA-2 250 mg capsule, each containing 100 mg green tea polyphenols.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
89648141|NCT01484912|Placebo Comparator|Placebo|"Placebo capsule, containing non-active ingredients.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
89648142|NCT03022123|Experimental|pegylated liposomal doxorubicin|PL-doxorubicin 35-40 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
89648143|NCT03022123|Active Comparator|Epirubicin|Epirubicin 70 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
89648144|NCT01279005||20-50 YEARS OLD MSM|
89648145|NCT04024969||Clinically isolated syndrome|Those presenting for diagnositic evaluation of multiple sclerosis, not currently meeting the 2017 McDonald criteria.
89648146|NCT01520870|Experimental|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end. Patients at first recurrence will be enrolled onto 1 of 2 cohorts that will be recruited and analysed independently. Cohort A will include patients who have EGFRvIII mutations. Cohort B will include patients who have EGFR gene amplification but no EGFRvIII mutations.
89648147|NCT01279161||diabetes|The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from Poland (Białystok, Warszawa, Łódź, Gdańsk, Wrocław, Katowice).
89648148|NCT01279161||control|Reference group will be made of 1500 children from the above mentioned Clinics and Departments in whom type 1 diabetes was excluded. In these children diagnostics procedures will be conducted for reasons other than body weigh related diseases (excluding simple obesity). The children will not receive any treatment that might influence their body weight.
89648149|NCT05100576|Experimental|Active group|This group gets the telemedicine system, with the devices, and gets life-style guide by telephone consultation/ visits, during 3 months
89648150|NCT05100576|No Intervention|Comparator group|This group gets the normal, evidence based therapy, without extra visits.
88992911|NCT05287633|Active Comparator|A : Proton Pump Inhibitors|Patients are given proton pump inhibitors tablets once a day
88992912|NCT05287633|Placebo Comparator|B: Placebo|Patients are given a placebo instead of proton pump inhibitors active drug
88992913|NCT05285449|Active Comparator|Dietary Supplement: Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate
88992914|NCT05285449|Placebo Comparator|Dietary Supplement: CBD matching Placebo|Matching Placebo
88992915|NCT05282693|Experimental|ReMag|Liquid Lemon flavor drink containing 300 mg magnesium chloride (Regmag) consumed twice daily for 9 days
88992916|NCT05282693|Placebo Comparator|ReMag Placebo|Liquid Lemon flavor drink placebo comparator consumed twice daily for 9 days.
89648151|NCT01520714|Experimental|Medtronic passive fixation LV lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
89648152|NCT01520714|Experimental|Medtronic 4195 Active Fixation LV Lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
89648153|NCT05100498|Experimental|Web-based oncofertility support tool|"User-centered design practices were used to develop an oncofertility support website for women with breast cancer before treatment. The steps of the Ottawa Decision Support Framework were used throughout the development process. A multidisciplinary steering group was assembled, and the input was provided. Guidelines from the International Patient Decision Aid Standards were applied to test the quality of the oncofertility support website.~Three steps included:~Identify the supportive needs of a patient;~Guide the development of support interventions;~Evaluate the quality of web-based oncofertility support."
89648154|NCT00722865|Other|Avastin (Bevacizumab)|single-arm, open-label
89648155|NCT02700529|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
89648156|NCT02700529|Placebo Comparator|placebo|matched placebo capsules TID, administered orally for a total of 24 weeks
89648157|NCT02659098|Experimental|Open-Label Safety Run-in Phase: Treatment Group|Participants will receive CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL). CNTO 2476 will be delivered using the custom-designed Delivery System.
89648158|NCT04025047||Transvaginal mesh|Patients who undergo pelvic reconstruction surgery using trans-vaginal mesh (commercial mesh kits or self-cut synthesized mesh).
89648159|NCT00723099|Experimental|Treatment (chemotherapy, transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower dose of TBI on day -1.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.~IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96."
89648160|NCT01508936|Placebo Comparator|Placebo|Placebo intravenous injection every 4 weeks for a total of 4 doses.
89648161|NCT01508936|Experimental|Reslizumab 3.0 mg/kg|Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.
89648162|NCT04146259||group A|Control
89648163|NCT04146259||Group B|Post-surgical hypoparathyroidism
89648164|NCT04437342||Maternal Group|Pregnant women in labour (vaginal delivery or caesarean section) that are admitted to the hospital. Pre-labour 3 different questionnaires are administered to evaluate depression, general anxiety disorder and the association to the covid-19 pandemic. 40 days post delivery via telephone contact 2 questionnaires are administered, one in order to assess the postpartum disorder the other to assess depression.
89648165|NCT05100186|Experimental|Dexamethasone Ophthalmic Insert|Day of surgery, in OR placement versus Day 1 Post-Op, In-office (HOPD)
89648166|NCT04323462|Experimental|Intensive Glucose Control|"Intensive Glucose control Insulin ≥3 times per day; Goals: prePBG 80-130 & post PBG <180 (60% of all readings); HbA1c <8% at 3 months SMBG at least 14 readings/week (3-5 FBG, rest PPBG) and/or CGMS readings Reexamined weekly for 1 month; then fortnightly for 3 months and then monthly till 6 months~Intensive subgroup will receive a standard glucometer with strips as one-week supply or CGMS for glycemic monitoring. They will receive a diabetic monitoring log/chart for home use. The chart and glucometer will have to be shown at each week of follow up. Number of hypoglycemic events in past week will be checked for each patient. This sub group will receive instructions to use 3 times bolus (regular/analogue) and single time basal insulin (glargine). Treatment goals will be conveyed at first contact and reinforced at each visit. Insulin dose modulation will be done telephonically. Patients will be reviewed weekly for 1 month and then fortnightly."
89648167|NCT04323462|Active Comparator|Conventional Glucose control|Fixed dosage of oral anti-diabetic drugs/insulin per week as patient is receiving prior; Insulin <3 times per day SMBG <3 times per day
89648168|NCT04145947||triple negative breast cancer|triple negative breast cancer patients with age ≤ 60 years old
89648169|NCT00723177|Placebo Comparator|Placebo|This group will receive placebo drug
89648170|NCT00723177|Experimental|Low-dose AV411|This group will receive a low dose of AV411
89648171|NCT00723177|Experimental|High-dose AV411|This group will receive a high dose of AV411
89648172|NCT04318392||Patients with suspected sarcoidosis|Patients presenting with suspected sarcoidosis.
89045068|NCT02915081|Experimental|Blue light|Subjects will be exposed to 24 hours of bright (1700 lux) blue (peak 442 nm) spectrum light the day prior to operative intervention and for the 24 hours after the operative intervention.
89648173|NCT04318392||Healthy controls|Healthy controls matched for age and gender. Recruitment of spouses and partners will also take place where possible.
89648174|NCT04698434|Active Comparator|0.5mg/kg esketamine group|0.5mg/kg esketamine group will be given a single intravenous 0.5mg/kg esketamine
89648175|NCT04698434|Active Comparator|.75mg/kg esketamine group|0.75mg/kg esketamine groupwill be given a single intravenous 0.75mg/kg esketamine
89648176|NCT04698434|Active Comparator|1.0mg/kg esketamine group|1.0mg/kg esketamine group will be given a single intravenous 1.5mg/kg esketamine
89648177|NCT04146025|Experimental|Nature Coach Intervention|The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.
89648178|NCT04146025|No Intervention|Control Group|Education only
89648179|NCT01273935||Responder|Responder versus Non-Responder as a result of platelet function test
89648180|NCT01273935||Non-Responder|According to the result of platelet function test
89648181|NCT04142749|Active Comparator|Oltipraz|Oltipraz 30mg
89648182|NCT04142749|Placebo Comparator|Placebo|Placebo 30mg
89648183|NCT01508702|Experimental|lesinurad 400 mg|
89648184|NCT01508702|Placebo Comparator|placebo|
89648185|NCT01279239||Poly trauma|20 Patients suffering from poly trauma who meet inclusion criteria would be recruited
89648186|NCT01279239||Healthy control|20 healthy volunteers would be recruited to obtain basal metabonomics fingerprinting
89648187|NCT05100108|No Intervention|Control group|They will be on a waiting list. They will be assessed before and after the 8 week program but will not take part in it.
89648188|NCT05100108|Experimental|Experimental group|Participants in this group will take part in the 8 sessions of dog-assisted therapy. They will be assessed before and after the 8 week program.
89045069|NCT02915081|No Intervention|Ambient light|Subjects will be exposed preoperatively to the lighting conditions of their living environment and postoperatively to the standard, white fluorescent lighting environment of the hospital.
89648189|NCT00723645||PEG IFN alfa-2b + RBV|Adult participants with chronic hepatitis C who were treated for the first time with pegylated interferon alfa-2b plus ribavirin and achieved end-of-treatment response prior to the study. Participants received no treatment during this study.
89648190|NCT05099796|Active Comparator|Transforaminal epidural steroid injection (TESI) group|"This procedure was applied only once.~1 to 2 cc of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 40 mg (1mL) of triamcinolone acetonide, 2 cc of physiological saline, and 2 cc (0.5%) of bupivacaine was injected."
89648191|NCT05099796|Active Comparator|Caudal epidural steroid injection (CESI) group|"This procedure was applied only once~1 to 2 cc of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized which showed bilateral L5-S3 distribution without vascular flow. A mixture of 40 mg (1mL) of triamcinolone acetonide, 7 cc of physiological saline, and 2 cc (0.5%) of bupivacaine was injected. A total of 10 cc mixture was used for CESI."
89648192|NCT04022395|Experimental|stress cardiac MRI|"To optimize the scan protocol and the sequence parameters~To investigate the clinical compliance of stress induced cardiac MRI in pediatric patients~To test the ability of stress cMRI to visualize coronary arteries morphological irregularities, the corresponding wall motion abnormalities and perfusion - viability features"
89648193|NCT02337270|Experimental|Group 1 Aerosol|Receive 10^6 Ad5Ag85A by aerosol at day 0
89648194|NCT02337270|Experimental|Group 2 Aerosol|Receive 2x10^6 Ad5Ag85A by aerosol at day 0
89648195|NCT02337270|Experimental|Group 3 Intramuscular|Receive 10^8 Ad5Ag85A by intramuscular injection at day 0
89648196|NCT01484834|Experimental|Exercise and Education|Company A received intervention of exercise in the workplace, posters with tips on health and quality of life computer software. The interventions with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
89648197|NCT01484834|Active Comparator|Exercise|The intervention with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
89648198|NCT01484834|Active Comparator|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
89648199|NCT01484834|Placebo Comparator|Control Company|No intervention
89648200|NCT04024813|Placebo Comparator|Placebo (N=25)|Placebo for the remainder of the study
89648201|NCT04024813|Experimental|Seladelpar 5 mg (N=25)|5 mg seladelpar daily for the remainder of the study
89648202|NCT04024813|Experimental|Seladelpar 10 mg (N=25)|10 mg seladelpar for the remainder of the study
89648203|NCT04024813|Experimental|Seladepar 25 mg (N=25)|25 mg seladelpar for the remainder of the study
89648204|NCT04145791|No Intervention|No Ice|Patients will receive standard postoperative pain control methods as defined by the participating institution
89648205|NCT04145791|Experimental|Ice|Patients will receive ice packs to the abdomen, in addition to standard postoperative pain control methods as defined by the participating institution
89648206|NCT01484132|Experimental|Composite|
89648207|NCT01276041|Experimental|pertuzumab in combination with trastuzumab and paclitaxel|This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.
89648208|NCT04150770|Experimental|Patients with Childhood Uveitis|5mg/kg/dose of infliximab IV initially two weeks, then 4 weeks and then every 6-8 weeks
88992917|NCT05279144|Experimental|Experimental|Ventrogluteal region IM injection will be applied to the children in the intervention group, which is recommended by the literatureIn order to ensure that the children in the groups are similar in terms of two factors (same drug, same nurse) in the assignment, they will be assigned to the groups first by stratified sampling method and then by simple random sampling (http://www1.assumption.edu/users/avadum/applets/RandAssin/Groupgen). .html). In the case of a 5% margin of error and an effect width of 0.70 at 80% power, the total number of patients, including 40 control and 40 intervention groups, who met the inclusion criteria of the study, was determined as 80.
88992918|NCT05279144|No Intervention|No Intervention|Vastus Lateralis IM injection, which is the routine practice of the clinic, will be applied to the children in the control group of the study. In order to ensure that the children in the groups are similar in terms of two factors (same drug, same nurse) in the assignment, they will be assigned to the groups first by stratified sampling method and then by simple random sampling (http://www1.assumption.edu/users/avadum/applets/RandAssin/Groupgen). .html). In the case of a 5% margin of error and an effect width of 0.70 at 80% power, the total number of patients, including 40 control and 40 intervention groups, who met the inclusion criteria of the study, was determined as 80.
89045070|NCT02914847|Experimental|Immediate Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery training (FIT) immediately.
89045071|NCT02914847|No Intervention|Delayed Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery Training (FIT) after a 3 month delay.
89688564|NCT02850874|Other|Historical Control|Case-matched historical controls will have received neoadjuvant chemotherapy with gemcitabine prior to open pancreaticoduodenectomy (PD) by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy (SCT) with gemcitabine will be administered for 6 mo (including period of neoadjuvant therapy) according to established institutional protocol.
89688565|NCT01047683|Placebo Comparator|Placebo|
89688566|NCT01047683|Experimental|AMR101 (ethyl icosapentate) - 2 g/day|
89045072|NCT01661166|Experimental|Fesoterodine 4mg|Fesoterodine 4mg, Oral once daily for three months
89045073|NCT01661166|Placebo Comparator|Placebo|Placebo Oral once daily for three months
89648209|NCT03717961|Experimental|" BTX-A group"|"BOTOX® solution~Saline serum~lidocaine/prilocaine cream~Nitrous oxide/oxygen (50%/50%)~Intervention Description :~BOTOX 100 UNITES (Allergan, Courbevoie, France, and São Paulo, Brazil) Single injection schedule of BOTOX® in both hands, diluted in 2 ml of sterile serum saline, with a dosage of 50 UI (1 ml) by hand. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site)~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
89648210|NCT03717961|Placebo Comparator|Placebo group|"Saline serum~lidocaine/prilocaine cream~Nitrous oxide/oxygen (50%/50%)~Intervention Description :~Sterile saline solution Single injection schedule of 2 ml (1 ml by hand) of serum saline, in both hands. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site).~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer of the lidocaine cream.~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
89648211|NCT04026438|Experimental|Intervention Arm - potassium phosphate injection|
89648212|NCT04026438|No Intervention|Control Arm|
89648213|NCT01275339|Active Comparator|Tadalafil in Diabetic Cohort|
89648214|NCT01275339|Placebo Comparator|Placebo in Diabetic Cohort|
89648215|NCT01275339|Active Comparator|Tadalafil in Non-Diabetic Cohort|
89648216|NCT01275339|Placebo Comparator|Placebo in Non-Diabetic Cohort|
89648217|NCT05104320|Experimental|MICS-CABG|Patients undergoing MICS-CABG.
89648218|NCT05104320|Active Comparator|sternotomy CABG|Patients undergoing thoracotomy OPCABG.
89648219|NCT01520402|Experimental|Warfarin|Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.
89648220|NCT04145557|Placebo Comparator|skaling root planing|
89648221|NCT04145557|Active Comparator|skaling root planing and diode laser|
89648222|NCT05099406|Active Comparator|Transcranial direct current stimulation (tDCS)|Fifteen stimulation sessions applied with a daily frequency during an uninterrupted period of time which comprises just over two weeks. Current intensity of 2mA is applied during 20 minutes at the left M1, with anodal electrode placed in C3 and cathodal in FP2, following the International 10-20 EEG System. Ramp-up and ramp-down comprises 15 seconds at the beginning and end of the stimulation period.
89648223|NCT05099406|Active Comparator|Transcranial alternant current stimulation (tACS)|Fifteen stimulation sessions applied with a daily frequency during an uninterrupted period of time which comprises just over two weeks. Two electrodes will be placed at F3 and F4 and connected together for 10-Hz tACS (or the frequency which shows best sensitivity or specificity), and one electrode at Pz will be the return electrode. This setting is used to stimulate the somatosensory cortical region. Stimulation will last for 20 minutes, with a ramp-up and ramp-down of 15 seconds at the beginning and end of the session.
89648224|NCT05099406|Placebo Comparator|Sham stimulation|The electrode montage will be either the tDCS (for half of the participants) or the tACS montage (for the other half), and we will just apply the current at the ramps terms, but no current in the interval between the ramps which practically comprises the whole session. As for the two other group, fifteen sham stimulation sessions will be daily scheduled in a non-interrupted period of two weeks.
89648225|NCT00738543|Experimental|Whole group of 48 volunteers|The arm is composed of 48 human volunteers to test 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City), Hypochlorite 10% of electrochemical production (Exsept 10% ®, Pisa, Guadalajara, Mexico), and control.
89648226|NCT03924973|Experimental|Experimental group|"Children below the age of 3 in this group received 2 years of ESDM intervention for 12 hours per week, and then treatment as usual for the 3 following years.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community."
89648227|NCT03924973|Other|Control group|"Children in this group received treatment as usual delivered in the community for the 2 years of IDEA.~Participants will still receive treatment as usual delivered in the community during IDEA-2, in the 3 years following IDEA."
89648228|NCT01520324|Experimental|Patients with UC undergoing colonoscopy|
89648229|NCT03832231|Experimental|Ventilator liberating trial|The diaphragmatic function of patients undergoing a ventilator liberating trial will be determined with transient shear wave elastography.
89648230|NCT01279473|Experimental|Nilotinib|
89648231|NCT05111730|Experimental|The shockwave Group|Group (A) study group received medical care and standard chemotherapy and shock wave, three times / week for three successful months.
89648232|NCT05111730|No Intervention|the traditional treatment group|group (B) control group received medical care and standard chemotherapy only.
89648233|NCT04145713|Experimental|Probiotic group|
89648234|NCT04145713|Placebo Comparator|Placebo group|
89648235|NCT01519934||Ulthera-treated subjects|All enrolled subjects will have received an Ulthera treatment prior to enrollment.
89648236|NCT05108220||R-101|CBD oil, 30 mg CBD per serving, 0% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
89648237|NCT05108220||R-102|CBD oil, 20 mg CBD per serving, 0% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
89648238|NCT05108220||R-103|CBD oil, 30 mg CBD per serving, <0.3% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
89648239|NCT05108220||R-104|CBD oil, 20 mg CBD per serving, <0.3% THC per serving, medium-chain triglyceride dilution, carbon dioxide extraction method
89648240|NCT05108220||R-105|CBD capsule, 15 mg CBD per serving, 0% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
89648241|NCT05108220||R-106|CBD capsule, 25 mg CBD per serving, 0% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
89648242|NCT05108220||R-107|CBD capsule, 15 mg CBD per serving, <0.3% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
89648243|NCT05108220||R-108|CBD capsule, 25 mg CBD per serving, <0.3% THC per serving, Rice Powder and Piperine dilution, carbon dioxide extraction method
89648244|NCT05108220||Control|Waitlist control; no product
89648245|NCT04145479|Experimental|low-resistance|women will perform low-resistance physical activity
89648246|NCT04145479|Experimental|aerobic|women will perform aerobic physical activity
89648247|NCT05107986||Patients diagnosed with complicated groin hernia|
89648248|NCT01484054|Other|EAPVPDE/EADE|etafilcon A with embedded print and PVP lens for dark eyes worn daily during the first period of 7-9 days, then etafilcon A control lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
89648249|NCT01484054|Other|EADE/EAPVPDE|etafilcon A control lens worn daily during the first period of 7-9 days, then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
89648250|NCT03711799|No Intervention|Resource Only Group|Families randomized to the resource only condition will have access to training materials in web-based and paper formats. The will receive the internet address to access web-based trainings, handouts and materials, including instructions for each activity and they will receive a binder that includes the information that is available on line so they can access the information even if they do not have internet access. Families in the resource only condition will not have access to a peer coach through the program. They will not have access to the on-line support community.
89648251|NCT03711799|Experimental|Peer Coaching Group|Families randomized to peer coaching will receive assistance with navigating the training program and accessing the system from a trained peer parent coach. Peer coaches will, as much as possible, be culturally and language-matched with the participant family.
89648252|NCT03027674|Experimental|10% nifedipine cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of 10% nifedipine cream in one hand and 5 grams of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
89648253|NCT03027674|Active Comparator|5% sildenafil cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of topical10% nifedipine cream in one hand and 5 grams of topical 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
89648254|NCT03945799|Experimental|Anlotinib|Administration Anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
89648255|NCT04024345|Experimental|Psychometric assessment group|Arms to whom the psychometric assessment will be administered
89648256|NCT04436874|Experimental|Han ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Han ethnic by endoscopy
89648257|NCT04436874|Experimental|Han ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Han ethnic by endoscopy
89648258|NCT04436874|Experimental|Dai ethnic-UC|Ulcerative colitis subjects will be treated with bacterial solution from Dai ethnic by endoscopy
89648259|NCT04436874|Experimental|Dai ethnic-CD|Crohn's disease subjects will be treated with bacterial solution from Dai ethnic by endoscopy
89648260|NCT02080507|Active Comparator|Active Neuronetics rTMS stimulator|Device: Active Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the active group, magnetic power output will be delivered to the subject through the coils.
89648261|NCT02080507|Sham Comparator|Inactive Neuronetics rTMS stimulator|Device: Inactive Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
89648262|NCT01507298||Capsule endoscopy|
89648263|NCT01507298||24 hour oesophageal pH study|
89648264|NCT04023721|Experimental|Cohort 1 - Inarigivir Soproxil Alone|Cohort 1, 400 mg Inarigivir daily for 24 weeks and after treatment discontinuation will be followed for a further 18 months.
89648265|NCT04023721|Experimental|Cohort 2 Arm A - Inarigivir Soproxil and NUC|Cohort 2, Arm A, 400 Inarigivir daily in addition to their prestudy nucleoside/nucleotide (NUC) analogue inhibitors for 48 weeks. At Week 48 subjects will stop both inarigivir and the NUC and be followed for a further 48 weeks off treatment.
89648266|NCT04023721|Experimental|Cohort 2 Arm B - Inarigivir Soproxil and NUC|Cohort 2, Arm B, 400 mg Inarigivir daily plus prestudy nucleoside/nucleotide (NUC) analogue inhibitors for at least 24 weeks and up to 48 weeks. After treatment discontinuation of both inarigivir and the NUC, subjects will be followed off treatment up to Week 96.
89648267|NCT04023877|Experimental|E2027|Participants will receive approximately 130 microcurie (μCi) of [14C]E2027 as a single 50 milligram (mg) (free base), capsule, orally on Day 1.
89648268|NCT04023955||Intervention|Twitter messages delivered over 1 month period
89648269|NCT02412540|No Intervention|Weight Loss Surgery|Adolescents who will have Weight Loss Surgery and had biopsy-confirmed NASH. The Weight Loss Surgery is not part of the study. The investigators are following the adolescents after the surgery.
89648270|NCT02412540|Experimental|Comprehensive Lifestyle Intervention|Comprehensive Lifestyle Intervention - Dietary, activity and behavioral interventions. Adolescents who have biopsy-confirmed NASH and wish to participate in a Comprehensive Lifestyle Intervention (26+ contact hours) including individual meetings with a study dietitian, group nutrition classes, behavior management modules and physical activity goals.
89648271|NCT04145245|Experimental|Intervention or group a|Diabetic neuropathy patients with antidiabetic therapy in addition with l-carnitine supplementation
89648272|NCT04145245|Placebo Comparator|Placebo or group b|Diabetic neuropathy patients with antidiabetic treatment in addition with placebo
89688567|NCT01047683|Experimental|AMR101 (ethyl icosapentate) - 4 g/day|
89688568|NCT02919826|Experimental|DBT Group|Adapted Dialectical Behaviour Therapy
89688569|NCT02919826|No Intervention|Control Arm|People in this group will receive treatment as usual
88992919|NCT05266209|Experimental|Experimental (coconut oil group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Moisturizers are applied to the thorax, back, arms and legs by massage, respectively, and the skin is absorbed. If it is to be applied for the first time, it is applied to a small area of the body under the control of a doctor. If there is no reaction, it is applied by massaging other areas. Since the babies to be included in the sample group are borderline and moderately premature (34-37W), 3-4 ml/kg (coconut oil)moisturizer will be applied.~Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday). Routine care will be applied to the skin of the newborns in the control group in the hospital. The control group will be evaluated using the NSCE form 3 days a week (Monday, Thursday, Sunday)."
88992920|NCT05266209|Other|Experimental (sunflower oil group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Moisturizers are applied to the thorax, back, arms and legs by massage, respectively, and the skin is absorbed. If it is to be applied for the first time, it is applied to a small area of the body under the control of a doctor. If there is no reaction, it is applied by massaging other areas. Since the babies to be included in the sample group are borderline and moderately premature (34-37W), 3-4 ml/kg (sunflower oil) moisturizer will be applied.~Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday)."
89521346|NCT04689295|Other|experiment group|Three dimensional scoliosis therapy method (Schroth) will be applied to the participants for 6 weeks. It consist of 15 different exercises combined with rotational breathing exercise.
89521347|NCT04689295|Other|control group|Traditional scoliosis exercises will be applied to the participants for 6 weeks. It consist of 6 different exercises
89521348|NCT03434587|Experimental|Syndactyly|Syndactyly
89521349|NCT03434587|Active Comparator|Reduction and inmobilization|Closed reduction and splint inmobilization
89521350|NCT03430765|Experimental|Acceptance and Commitment Therapy|Standard breast cancer treatment plus a single 2 hour individual Acceptance and Commitment Therapy coping skills session.
89521351|NCT03430765|No Intervention|Treatment as Usual|Standard breast cancer treatment.
89521352|NCT03439501|Other|avelumab|"1 Cycle: 10mg/kg Avelumab administered via IV every 2 weeks (1st, 15th)~Interval of 1 cycle: 28 days ③ Administration schedule: Repeated until disease progression or unacceptable toxicity and dose adjustments may be permitted based on the toxicity that occurs every cycle."
89521353|NCT03430687|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec intravesically (10ml of 10^6 PFU/mL) on days 1, 8, 15, 22, 29, and 36 or days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
89521354|NCT04255381|Experimental|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Use Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP) system
89521355|NCT03757897|Experimental|Dexmedetomidine induced sleep patients|All subjects will be measured for CSF volume, diffusion parameters and mechanical 'stiffness' of the brain during wakefulness and during sleep-induced with dexmedetomidine (DEXM).
89521356|NCT03434197|Experimental|SFPP (Esflurbiprofen plaster)|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
89521357|NCT03434197|Active Comparator|Diclofenac gel|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
89521358|NCT03439111|Placebo Comparator|Placebo|Intervention : Placebo + Standardized Lycium chinense Fruit Extract (LCF) capsules Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment 3 week wash-out Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment
89521359|NCT03439111|Experimental|Experimental|Intervention : Standardized Lycium chinense Fruit Extract (LCF) capsules + Placebo Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment 3 week wash-out Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment
89521360|NCT03757429||RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.
89521361|NCT03757429||Non-RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.
89521362|NCT03430609|Active Comparator|Bipolar tweezers Astus Medical©|Laparoscopic treatment for endometrioma Astus© will use Bipolar coagulation (bipolar tweezers, Astus Medical ©, Copyright 2015, Tampa FL, USA) with 30 W power and a Valleylab generator (Medronic ©, Copyright 2017, Medtronic Parkway, Minneapolis, USA); the number of coagulated points will be counted, and the time for coagulation will be measured in seconds. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
89521363|NCT03430609|Active Comparator|2-0 Vicryl® Suture|Laparoscopic treatment for endometrioma Vicryl® will use suturing with simple suture (2-0/Vicryl polyglactin absorbable synthetic suture; Ethicon Inc., New Jersey, USA); the number of sutures will be recorded. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
89521364|NCT03430609|Active Comparator|Surgicel®|Laparoscopic treatment for endometrioma Surgicel® will use Hemostatic matrix (Surgicel® Original Absorbable Hemostat, Ethicon, USA). Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
89521365|NCT03438955|Experimental|Cohort A|Administration of omacor soft capsule 4000mg for 16 days, and followed by omacor soft capsule 4000mg and Pritor tablet 40mg in combination for 7 days.
89521366|NCT03438955|Experimental|Cohort B|Administration of Pritor tablet 40mg for 7 days, and followed by Pritor tablet 40mg and Omacor soft capsule 4000mg in combination for 16 days.
89521367|NCT03433963|Experimental|L-Arg supplement group|Study participants in the group will take L-Arg supplement during the trial.
89212790|NCT04313062|Experimental|Intervention|"The intervention group will receive the PM ACTIVAS' intervention model. This intervention will be done by a member of the technical staff (previously trained) at the patient's home (house call). In the house call, the trainee will perform a multidimensional assessment of the patient's falling risks factor (internal and external), deliver a  Falling Prevention Kit  and lastly establish together (with the patient and their family) a plan to change the hazards in their home. The patients will receive a telephone follow-up by the same technical staff member until the final house call, which will be 12 months after the recruiting. Finally, 12 months after recruitment, they will receive a last house call where the trainee will assess with the patient and the family the plan, ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period), and conduct the final survey."
89212791|NCT04313062|No Intervention|Standard care|"The control group will receive the standard care from the community health center. They will not receive a telephone follow-up. They will receive a house call 12 months after recruitment by a trainee, who will conduct the final survey and ask for the  Falls and Events Calendar  given at recruitment (where the older person and/or their family registered every trip or fall during the 12-month period). Lastly, they will receive an abbreviated intervention for falling prevention and be given the  Falling Prevention Kit ."
89212792|NCT00867854||Experimental|25 evaluable subjects from the experimental arm of ATN 061 who undergo de-intensification to boosted atazanavir (ATV) with VL suppression of < 100 copies/ml and CD4+ T cells > 350 cells/mm3 at week 48 and maintain VL suppression to < 400 copies/ml with stable CD4+ T cell counts after week 48.
89521368|NCT03433963|Placebo Comparator|Control group|Study participants in the group will take placebo during the trial.
89521369|NCT03128437|Experimental|Aerobic Exercise Condition|6 aerobic exercise exposures will be completed over the course of 2 weeks.
89521370|NCT03128437|No Intervention|Assessment Only Condition|"Participants randomly assigned to the control condition will complete assessments at the same time intervals as the active condition, but will not participate in exercise sessions.~Assessments will take place at baseline, week 2, week 4, and week 8."
89521371|NCT04240249|Experimental|Constructive self-assertiveness with guidance|10 weeks of internet-based treatment with weekly assignments. The homework is commented on by the guide using electronic communication.
89521372|NCT04240249|Experimental|Constructive self-assertiveness without guidance|10 weeks of internet-based treatment with weekly assignments. The homework is NOT commented on by any guide. Hence, same treatment as group 1 but without guidance.
89521373|NCT04240249|No Intervention|Waitlist control|No treatment, no guidance, just waiting for 10 weeks. After the ten weeks the participants will receive the treatment.
89521374|NCT04655911||ABO-101|Participants from prior interventional trials involving the administration of ABO-101.
89521375|NCT03430453|Experimental|Patient with ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed.
89521376|NCT04450303|Experimental|Telehealth Therapy|
89521377|NCT03430375|Active Comparator|Alternating air then static air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the alternating air wheelchair cushion for 32 minutes and then the static air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes.
89521378|NCT03430375|Active Comparator|Static air then alternating air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the static air wheelchair cushion for 32 minutes and then the alternating air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted.
89521379|NCT03438799||Cordio|Cordio R&D database to develop the Cordio System
89521380|NCT03433885||Progressors|Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
89521381|NCT03433885||Nonprogressor|Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.
89521382|NCT03430141|Experimental|Intervention for all participants|Nutritarian Diet-style: Intervention for all participants: All participants are exposed to the same nutrition treatment/intervention protocol.
89521383|NCT03433729|Experimental|Patient Agenda Form|Patient Agenda form: Patients receive an agenda form to use before their consultation.
89521384|NCT03433729|No Intervention|Usual care|Patients' appointment continues as usual.
89521385|NCT04219735|Experimental|Minocycline|Minocycline 100 mg BID
89521386|NCT04219735|Placebo Comparator|Placebo|Placebo capsules identical to experimental arm
89521387|NCT03433651|Experimental|creatine monohydrate|Experimental will take by mouth 5 grams a day of creatine monohydrate powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
89521388|NCT03433651|Placebo Comparator|Placebo|Placebo will take by mouth 5 grams a day of placebo powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
89521389|NCT03438565||Participants with intracranial large vessel occlusive stroke|50 patients who have been treated with the Asahi Chikai Black 18 neurovascular guidewire.
89521390|NCT03438565||Historical Control Group|The historical control will include 50 retrospective consecutive patients (who fulfill inclusion and exclusion criteria) treated for acute anterior circulation large vessel occlusive stroke prior to the initiation of the Sure -18 registry.
89648273|NCT04145323|Experimental|ICG microangiography for necrotic tissue determination|During flap procedure, the study area of the patient will be imaged with a white light digital camera prior to a 5 mg dose of ICG as per FDA approved protocol for use of SPY device in microangiography. Following ICG injection, the study area will undergo fluorescence imaging using the SPY system to obtain microangiography perfusion data (baseline imaging - Standard of Care). During the standard postoperative evaluation (approximately 4 hours after baseline) and 24 hours after baseline, the study area will undergo repeat digital photography and fluorescence imaging using SPY for necrosis avid detection of ICG (Research only session). This evaluation with digital photography and fluorescence imaging will continue every 24 hours for the first 3 days after surgery or one day prior to discharge(Research only session).
89648274|NCT01483118|Active Comparator|Cinnamon Extract Arm|PCOS patients receiving abstract of cinnamon
89648275|NCT01483118|Placebo Comparator|Placebo Arm|PCOS patients receiving placebo capsules
89648276|NCT05106972|Experimental|UC-MSC infusion|UC-MSC infusion by intravenus, 1*10^8 cells/dose, 2 doses (apart from 24weeks)
89648277|NCT04146337|Experimental|Fecal microbiota transplantation (FMT)|FMT regimen: Patients will be given capsulized FMT 15 capsules a day for two consecutive days after a fast of 8 hours before FMT. Stool will be collected before and after the intervention for genomic analysis of CRE strains, analysis of microbiome and metabolome.
89648278|NCT04146337|No Intervention|Control|Routine follow-up
89648279|NCT04094948|Experimental|clenbuterol|The initial dose of clenbuterol will be 40 mcg per oral each morning for one week, followed by 40 mcg twice per day (BID) for the next 5 weeks until Week 6. If the 40 mcg BID per oral is well tolerated, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID for the next 5 weeks until the Week 12 visit. If 80 mcg BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
89648280|NCT04094948|Placebo Comparator|placebo|Initially, one capsule each morning for one week, followed by one capsule BID for the next 5 weeks until Week 6. If tolerated, the dose will be increased to two capsules each morning and 1 capsule each evening for one week, followed by two capsules BID for the next 5 weeks until the Week 12 visit. If two capsules BID is tolerated at Week 12, the subject will continue on that dose until Week 52.
89648281|NCT04023565|Experimental|perindopril + moxonidine|perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).
89648282|NCT05106504||Parkinson's disease patients|Parkinson's disease patients receiving medical cannabis for pain related to the disease
89648283|NCT04149847|Experimental|Nylon darn repair|a nylon #1 suture to be used to reconstruct the posterior inguinal wall
89648284|NCT04149847|Experimental|polypropylene mesh repair|a commercially available 7.5cm x 15cm sheet of polypropylene mesh to be trimmed to fit the posterior inguinal wall
89648285|NCT05111496||Patient requiring intervention (complex coronary dilation or coronary recanalization)|Patient requiring intervention with a predicted risk of exceeding the radiological threshold (Air Kerma> 3Gy): complex coronary dilation, coronary recanalization
89648286|NCT04144855|Experimental|TQB3474 injection|Participants receive TQB3474 injection by intravenous (IV) infusion on Day 1, 8, 15, 22 of each 28 day cycle.
89648287|NCT01506908|Active Comparator|Nicotine Polacrilex mint mini lozenge|
89648288|NCT01506908|Placebo Comparator|placebo|mint mini lozenge with no active
89648289|NCT04144777|Experimental|Treatment|Subjects will be administered one daily dose of Solarplast (100mg), in a capsule, for 45 days.
89045074|NCT02915003|Experimental|E-health website intervention|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
89045075|NCT02915003|No Intervention|Control|usual health insurance navigation, and ACA materials provided by social service agencies and clinics where individuals seek services.
89045076|NCT01659138|Experimental|SAR339658|SAR339658 at Weeks 0, 2, 4, and 6
89045077|NCT01659138|Placebo Comparator|Placebo|Placebo at Weeks 0, 2, 4, and 6
89045078|NCT02915042|Experimental|Experimental group|Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
89045079|NCT02915042|Placebo Comparator|Placebo group|Intervention group 2: placebo
89045080|NCT01658826|Experimental|AIC316, Then Valacyclovir|Participants first received AIC316 100 mg once daily for 28 days. After a washout period of 28 days, they then received Valacyclovir 500 mg once daily for 28 days.
89045081|NCT01658826|Active Comparator|Valacyclovir, Then AIC316|Participants first received Valacyclovir 500 mg once daily for 28 days. After a washout period of 28 days, they then received AIC316 100 mg once daily for 28 days.
89045082|NCT02914769|Placebo Comparator|placebo|patients receiving a passive placebo
89045083|NCT02914769|Experimental|Ayahuasca|patients receiving Ayahuasca
89045084|NCT04677582|Experimental|Intervention Group|The intervention group will receive weekly education sessions about nutrition, exercise, and behavioral health.
89045085|NCT02914925|Experimental|ArmeoSpring/CIT|Group will receive ArmeoSpring and CIT therapy
89045086|NCT02092077|Experimental|TV-1106 0.554 mg|
89045087|NCT02092077|Experimental|TV-1106 0.924 mg/kg|
89045088|NCT02092077|Experimental|TV-1106 1.20 mg/kg|
89648290|NCT04144777|No Intervention|Placebo|Subjects will be administered one daily dose of maltodextrin (100mg), in a capsule, for 45 days.
89648291|NCT04164654|Experimental|Experimental-Immediate Access to the Nod app|The experimental group will have immediate access to all content in the Nod app and will be free to engage with it as much or as little as they like for four weeks. They will retain access to the Nod app for an additional four weeks.
89648292|NCT04164654|Other|Waitlist Control-Delayed Access to the Nod app|The waitlist control group will have full access to the Nod app approximately four weeks after the experimental group gains access.
89648293|NCT04149769|Other|Interventional|Walking in an exoskeleton within the home and community.
89648294|NCT01519778|Experimental|TR-701 FA|
89648295|NCT05106660|Experimental|Ambulatory Care Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy as ambulatory care procedure with same-day discharge
89648296|NCT05106660|Active Comparator|Next Day Discharge Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy with next day discharge
89648297|NCT04023097|Experimental|Toothwave contraindicated subject|"the Toothwave toothbrush is contraindicated for people in certain conditions, e.g. pregnant or nursing women, people with pacemaker and more.~This arm is assembled from contraindicated subject, who should exclude themselves from use of the device, based on the user manual and box sleeve."
89648298|NCT04023097|Active Comparator|potential users of the Toothwave device|The control arm is assembled from people who can use the toothbrush and should recognize themselves as potential users.
89648299|NCT05111340|Experimental|Adult patients undergoing sedation with or without associated local anesthesia|
89648300|NCT04149067||Dapagliflozin cohort|Patients diagnosed with type 2 diabetes that started dapagliflozin treatment at least 6 months before the beginning of the study.
89648301|NCT04149067||Sitagliptin cohort|Patients diagnosed with type 2 diabetes that started sitagliptin treatment at least 6 months before the beginning of the study.
89648302|NCT05066022|Experimental|Experimental: CT0590 CAR T cells|Dose-escalated CAR T cells infusion
89648303|NCT04148755||Elastography guided FNA|Those patients are going to have EUS elastography guided FNA
89648304|NCT04148755||EUS. FNA|From records we are going to compare them with patients who had EUS without elastography guided FNA
89648305|NCT05111106||Non-Pathology Eyes|Cataract Surgery with implantation of Symfony IOL in eyes without pre-existing pathology..
89648306|NCT05111106||Glaucoma Eyes|Cataract Surgery with implantation of Symfony IOL with pre-existing glaucoma.
89648307|NCT05111106||Retinopathy Eyes|Cataract Surgery with implantation of Symfony IOL in eyes with pre-existing retinal pathology..
89648308|NCT04022941|Experimental|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5days.
89045089|NCT02092077|Active Comparator|somatropin 0.033 mg/kg/day|Dosages may be adjusted according to findings and as necessary
89045090|NCT01651143|Experimental|SAR100842|"Core part: SAR100842 300 mg, oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
89045091|NCT01651143|Placebo Comparator|Placebo|"Core part: Placebo (for SAR100842), oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
89045092|NCT02914886|Experimental|Group 1|Daily use of insulin Apidra in insulin pump. The dosis will be according to the patient's former dosing scheme.
89045093|NCT02914886|Active Comparator|Group 2|Daily use of current insulin in insulin pump.The dosis will be according to the patient's former dosing scheme.
89045094|NCT01650051|Placebo Comparator|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|
89045095|NCT01650051|Experimental|Phenazopyridine Hydrochloride Tables, USP 200 mg|
89045096|NCT01643226|Experimental|riboflavin solution and KXL System|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by UVA irradiation for 4 minutes
89045097|NCT01643226|Placebo Comparator|placebo solution and KXL System|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by UVA Irradiation for 4 minutes
89045098|NCT02089425|Placebo Comparator|Placebo|Placebo patch: 0% indomethacin
89045099|NCT02089425|Experimental|K-103-IP|K-103-IP: 0.5% indomethacin
89045100|NCT02914652|Experimental|Operated VSD's|Through the use of Electronic Patient Journal (EPJ), the investigators have identified a total of 182 children who underwent surgical closure of a congenital VSD at Aarhus University Hospital, Denmark between 1990 and 1995. After thorough review of all charts, 117 patients were excluded from participation. Exclusion criteria were coexistence of other congenital heart defects (n=89), associated syndromes, e.g. Down's (n=14), operation through a ventricular approach (n=7), missing chart (n=6) and documented arrhythmia requiring pacemaker (n=1). The remaining 68 patients represent a homogeneous group comparing surgeons, anaesthetists, surgical procedure and post-surgical period. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
89045101|NCT02914652|Experimental|Un-operated VSD's|Using EPJ, this project identified a total of 481 children born between 1985 and 1998 who had a small VSD, confirmed through diagnosis codes, that was not closed, neither spontaneously nor surgically. Exclusion criteria were lack of medical record, suffering from coronary disease, other congenital cardiac abnormalities than VSD, spontaneous closure of the ventricular septal defect at inclusion date, magnetic implants, pregnancy, lack of Danish language skills, suffering from lung disease requiring continuous medical treatment. The remaining patients represent a homogenous group of patients with isolated persistent ventricular septal defects. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
89045102|NCT02914652|Experimental|Healthy controls|Will function as a control group. Controls will be recruited through www.forsoegsperson.dk and www.sundhed.dk. Current group receives salbutamol or norflouran, blinded.
89045103|NCT02081703|Experimental|AYX1 Injection 660 mg / 6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
89045104|NCT02081703|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
89045105|NCT02081703|Experimental|AYX1 Injection 1100 mg / 10 mL|Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
89045106|NCT02081703|Placebo Comparator|Placebo Injection 10 mL|Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
89045107|NCT02914691|Active Comparator|Active|Dapagliflozin 10 mg once daily tablet treatment
89045108|NCT02914691|Placebo Comparator|Placebo|Identical once daily tablet treatment
89045109|NCT02081118|Experimental|HM11260C (8 mg)|Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
89045110|NCT02081118|Experimental|HM11260C (12 mg)|Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
89045111|NCT02081118|Experimental|HM11260C (16 mg)|Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
89045112|NCT02081118|Placebo Comparator|Placebo|Monthly administration of placebo by subcutaneous injection for 16 weeks
89045113|NCT02078310|Experimental|ITI-007 Part 1|Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007
88992921|NCT05266209|No Intervention|No Intervention (Control group)|"Before moistening, the skin of newborns is evaluated using the Newborn Skin Condition Evaluation Form form.~Routine maintenance of the intensive care unit will be implemented. Evaluation with NSCE form: Evaluations will be made using the NSCE form 48-72 hours after each application (Monday, Thursday, Sunday). Routine care will be applied to the skin of the newborns in the control group in the hospital. The control group will be evaluated using the NSCE form 3 days a week (Monday, Thursday, Sunday)"
88992922|NCT05256576|No Intervention|Control Group 1|Historic control group from both study sites: patients who took part in the FRAILTY study at Charité University hospital Berlin, as well as patients who were treated for OC at Evangelische Kliniken Essen Mitte during the same time period. Retrospective analysis looking at some of the main outcome variables will be conducted.
88992923|NCT05256576|No Intervention|Control Group 2|Prospective control group: patients who undergo treatment for OC at both sites. Main outcomes are determined while under standard hospital care before start of the change management and implementation of the new intervention.
88992924|NCT05256576|No Intervention|Control Group 3|Control group for health economical analysis to determine the cost-effectiveness of the new intervention.
88992925|NCT05256576|Experimental|Intervention Group|Intervention Group undergoing the new multi-modal perioperative care pathway, including the implementation of ERAS pathway, in combination with a tri-modal prehabilitation program following a comprehensive frailty assessment.
88992926|NCT05256277|Experimental|CT101a|1 dose infusion
88992927|NCT05246735|Other|MR-guided NIR|"Women with breast abnormalities will undergo an optical exam (NIR) in combination with MRI where the NIR light imaging system illuminates the breast from multiple positions covering the area of interest.~A total of 60 women will be evaluated: 20 with breast abnormalities receiving gadolinium (Gd) contrast enhancement, 20 with breast abnormalities receiving both Gd-contrast enhancement and indocyanine green (ICG) contrast enhancement, and 20 healthy volunteers not receiving any contrast agents."
88992928|NCT05240417|Experimental|Study group|"Pontic-shield will be performed as ridge preservation technique."
88992929|NCT05240417|Active Comparator|Positive control (ridge preservation)|Deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction.
88992930|NCT05240417|No Intervention|Negative control (fresh socket)|No intervention will be performed after tooth extraction. Blood clot will be maintained after extraction.
88992931|NCT05238597|Experimental|A197 Ophthalmic Solution, High Dose|
88992932|NCT05238597|Experimental|A197 Ophthalmic Solution, Low Dose|
88992933|NCT05238597|Placebo Comparator|A197 Vehicle Control|
88992934|NCT05238597|Active Comparator|Active Comparator|
88992935|NCT05218005|No Intervention|Observation|Those admitted in the first 6 months of the study that meet the inclusion criteria. Patients will be treated according to the normal standard of care for acute coronary syndrome.
88992936|NCT05218005|Experimental|Active-testing|Those admitted between 6-18 months of the study meeting the inclusion criteria. Saliva samples will be collected for DNA testing.
88992937|NCT05216913||Endometrial cancer survivors|
88992938|NCT05216900|Experimental|Neoadjuvant radiotherapy group|Twenty breast cancer patients will be included after they have given informed consent. Patients are eligible if they have an indication for mastectomy and RT, and a wish for an immediate reconstruction, either implant-based or autologous, in MUMC, UMCU, Alexander Monro hospital and Amsterdam UMC.
88992939|NCT05207657|Experimental|Lentiviral vector transduced CD34+ cells|The investigational product is patient-specific and corresponds to cryopreserved autologous CD34+ cells transduced ex vivo with the pCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.
88992940|NCT05188118|Experimental|Patients with metastatic or unresectable clear cell renal cell carcinoma|Patients with metastatic or unresectable clear cell renal cell carcinoma to receive same sequential treatment strategy. (Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x4 over 12 weeks, then subsequent therapies depending on treatment response for another 12 weeks [Nivolumab for CR/PR/SD, Cabozantinib or Lenvatinib/Everolimus for PROG]).
89212793|NCT00867854||Control|25 evaluable subjects from ATN 071 will also be enrolled. These subjects will have initiated HAART according to current DHHS guidelines (CD4+ T cells < 350 cells/mm3), had viral load suppression to < 100 copies/ml at 24 through 48 weeks on HAART and maintained suppression to < 400 copies/ml through week 80.
89212794|NCT00873158|No Intervention|Physical Therapy Group|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
89648309|NCT04022941|Placebo Comparator|Placebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
89648310|NCT05087862|Active Comparator|Pericapsular nerve group block|Twenty milliliters of bupivacaine 0.5% (100 milligrams) with epinephrine 5 ug/mL will be deposited in the anterior aspect of the iliac bone between its periosteum and the tendon of the iliopsoas muscle. Additionally, ketorolac 30 mg will be administered intravenously.
89648311|NCT05087862|Experimental|Periarticular local anesthetic infiltration|Sixty milliliters of 0.25% bupivacaine (150 milligrams), 5ug/mL epinephrine, and ketorolac 30 mg will be deposited at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
89648312|NCT04022863||ovarian tumor benign|all pathological proven benign ovarian tumors
89648313|NCT04022863||ovarian tumor borderline|all pathological proven borderline ovarian tumors
89648314|NCT04022863||ovarian tumor malignant|all pathological proven malignant ovarian tumors
89648315|NCT05111028|Active Comparator|Period 1|Each research subject will participate in two study periods that will crossover from one storage product to the other storage product (Cold Stored Platelets vs Room Temperature Platelets) based on the randomization assignment. In Period 1 subjects will undergo an apheresis platelet collection, aspirin dosing, transfusion of their autologous platelets, and followed by platelet response testing and safety assessments. This is repeated in Period 2 using the other storage product. CSP is the the experimental comparator and RTP is the active comparator.
89648316|NCT05111028|Experimental|Period 2|Each research subject will participate in two study periods that will crossover from one storage product to the other storage product (Cold Stored Platelets vs Room Temperature Platelets) based on the randomization assignment. In Period 1 subjects will undergo an apheresis platelet collection, aspirin dosing, transfusion of their autologous platelets, and followed by platelet response testing and safety assessments. This is repeated in Period 2 using the other storage product. CSP is the the experimental comparator and RTP is the active comparator.
89648317|NCT04022707|Experimental|High-Velocity Resistance Circuttraining (HVRCT)|The participants will perform three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three weeks from 1 to 3 circuits.
89648318|NCT04022707|Experimental|Educational Control (CON)|A supervised program will be provided to the participants that includes lectures on health and fitness.
89648319|NCT05110716|Experimental|Gains, Ascending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary gains in an ascending order of bundle size.
89648320|NCT05110716|Experimental|Gains, Descending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary gains in a descending order of bundle size.
89648321|NCT05110716|Experimental|Losses, Ascending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary losses in an ascending order of bundle size.
89648322|NCT05110716|Experimental|Losses, Descending Bundle-Size Order|Participants will complete the choice bundling adjusting-amount task for monetary losses in an ascending order of bundle size.
89648323|NCT04144699||Wheezing 3~11months|Patient has wheezing, age 3 to 11 months
89648324|NCT04144699||Wheezing 12~23months|Patient has wheezing, age 12 to 23 months
89648325|NCT04144699||Wheezing 24~35months|Patient has wheezing, age 24 to 35 months
89648326|NCT04144699||Wheezing 36~107months|Patient has wheezing, age 36 to 107 months
89648327|NCT04144699||No wheezing 3~11months|Patient do not have wheezing, age 3 to 11 months
89648328|NCT04144699||No wheezing 12~23months|Patient do not have wheezing, age 12 to 23 months
89648329|NCT04144699||No wheezing 24~35months|Patient do not have wheezing, age 24 to 35 months
89648330|NCT04144699||No wheezing 36~107months|Patient do not have wheezing, age 36 to 107 months
89648331|NCT05106114|Experimental|Intensive gait training rehabilitation protocole|"Functional gait training~Strengthening interventions~High intensity interval training"
89648332|NCT01519700|Experimental|EP2006|Eligible patients will be teated with EP2006
89648333|NCT01519700|Active Comparator|Filgrastim|Eligible patients will be teated with Filgrastim
89212795|NCT00873158|Experimental|Dynasplint Group|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
89648334|NCT04144075|Experimental|Mindful Self-Compassion|Protocolized training program in mindfulness and self-compassion skills.
89648335|NCT04144075|Active Comparator|Cognitive Behaviour Therapy Group|A control intervention designed to develop a control group suitable for comparison with experimental groups receiving interventions based on mindfulness and compassion.
89212796|NCT00617240|Experimental|1|metformin in doses from 250mg to 2000mg/day for 26 weeks
89212797|NCT00617240|Placebo Comparator|2|Matched placebo to metformin, doses between 250/0mg and 2000/0mg per day
89648336|NCT04144075|Placebo Comparator|Treatment as Usual|Es variable según las características clínicas y personales del paciente.
89648337|NCT04143997||PPCM with Diastolic Dysfunction & Normal Systolic Function|The patient population examined will include patients diagnosed with peripartum cardiomyopathy who have diastolic dysfunction and normal systolic function.
89648338|NCT05110560|No Intervention|control group|step counts will be followed
89648339|NCT05110560|Experimental|intervention group|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
89648340|NCT04143685|Active Comparator|misoprostol|misoprostol 50 mcg tablet by mouth every four hours for maximum dosage of six
89688570|NCT02920918|Active Comparator|Canagliflozin|Canagliflozin will be administered orally in pill form at 100 mg, daily for 12 weeks.
89648341|NCT04143685|Active Comparator|oxytocin|Oxytocin 10 IU in 1000 mL Standard solution. Starting with 10 mL/hr infusion rate and increasing by 10mL/hr every 20 minutes until achieving 3-5 regular uterine contractions every 10 minutes (as recorded by cardiotocography)
89648342|NCT05082090||Implanted with Orthofix Spinal products|Study will include 2000+ subjects implanted with Orthofix Spine devices including spine fixation systems and motion preservation systems (i.e. M6-C artificial cervical disc and M6-L artificial lumbar disc)
89648343|NCT04148599|Active Comparator|dexmedetomidine|dexmedetomidine ( precedex) infusion will be administered preoperatively and continued intraoperatively
89648344|NCT04148599|Active Comparator|lidocaine|Lidocaine (Xylocaine) infusion will be administered preoperatively and continued intraoperatively
89648345|NCT04148599|Placebo Comparator|placebo|saline infusion will be administered preoperatively and continued intraoperatively
89648346|NCT04143763|Active Comparator|Intervention group|receive mobile messages supporting caregivers' psychological well-being, according to the participants' preferences in intervention group.
89648347|NCT04143763|No Intervention|Control group|receive general health information through a mobile message.
89045114|NCT02078310|Placebo Comparator|Placebo Part 1|Part 1: Healthy geriatric volunteers with placebo given
89045115|NCT02078310|Experimental|ITI-007 Part 2|Part 2: Geriatric patients with dementia with ITI-007 given
89045116|NCT02078310|Placebo Comparator|Placebo Part 2|Part 2: Geriatric patients with dementia with placebo given
89045117|NCT02914574|Other|healthy control|Healthy control group will attend one visit and functional performance, muscle strength and flexibility, quadriceps AMI, patellar position and posture will be measured. No intervention will be applied.
89045118|NCT02077881|Experimental|Indoximod and Gemcitabine + Nab-paclitaxel|"Phase 1 portion:~Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.~Phase 2 portion:~Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
89045119|NCT02914418|Experimental|Active iTBS|iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. The hand representation of the primary motor cortex will targeted using a circular coil held over the vertex of skull. Intensity will be set to 80% of Resting Motor Threshold (RMT), which will be determined visually by the lowest percentage of stimulator output which can cause upper limb motor twitch in at least 5 out of 10 attempts.
89045120|NCT02914418|Sham Comparator|Sham iTBS|Sham iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. Intensity will be set at 80% RMT. Circular coil will be held over vertex of skull but angled away to ensure no neural stimulation.
89045121|NCT04677699||Birth Cohort|Newborns less than 8 months old and born in the state of Washington.
89045122|NCT04677699||Kids Cohort|Children ages 4-7 years and born in the state of Washington.
89045123|NCT02074410|Experimental|OMS643762 Low Dose without food|Orally administering OMS643762 low dose daily without food for 28 days
89045124|NCT02074410|Experimental|OMS643762 Medium Dose without food|Orally administering OMS643762 medium dose daily without food for 28 days
89045125|NCT02074410|Experimental|OMS643762 Medium Dose with food|Orally administering OMS643762 Medium dose daily with food for 28 days
89045126|NCT02074410|Placebo Comparator|Placebo|Orally administering placebo daily for 28 days
89045127|NCT02914340|Experimental|Treatment|The treatment algorithm is complete occlusion of one lobe of the lung by using valves to occlude all segments of the lobe. The lobe will be selected based on imaging with high resolution computed tomography (HRCT). The lobe to be treated will have severe heterogeneous emphysema based on visual exam. The selected lobe will also have an intact fissure separation with the ipsilateral lobe. An intact fissure will be estimated visually to be ≥ 90% complete after viewing the HRCT in 3 dimensions. If more than one lobe meets criteria, the investigator will determine a primary lobe to treat based on fissure completeness, heterogeneity, disease severity, and the anatomy of the airways that will be treated.
89045128|NCT02914262|Experimental|Experimental:Cohort 1-6 Experimental|Intervention AKB 4924 Six subjects per cohort will receive single doses of 20 to up to 480 mg of AKB 4924 orally in a dose escalation format
89045129|NCT02914262|Placebo Comparator|Placebo:Cohort 1-6|"Intervention Placebo:~Two subjects per cohort will receive single oral doses of placebo"
89045130|NCT02915900|Experimental|Intervention|Hormone dosage is calculated by using the new method Gonadotropin removal test.
89648348|NCT04143841|Active Comparator|Single treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
89648349|NCT04143841|Sham Comparator|Single sham treatment|A single treatment will be administered for both eyes for each subject. The treatment will be administered for 11 minutes per treated eye.
89648350|NCT04930458|Experimental|Nanosilver fluoride group|Nanosilver fluoride will be applied on carious lesion
89045131|NCT02915900|Active Comparator|Routine IVF method|Hormone dosage is chosen by the clinician according to standard clinical routine.
89045132|NCT01632228|Experimental|Onartuzumab + Bevacizumab|All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
89045133|NCT01632228|Active Comparator|Placebo + Bevacizumab|All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
89648351|NCT04930458|Active Comparator|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate group|Sodium fluoride with casein phosphopeptides_Amorphous calcium phosphate will be applied on carios lesion
89648352|NCT04930458|Active Comparator|Sodium fluoride varnish group|Sodium fluoride varnish will be applied on carios lesion
89045134|NCT02914223|Experimental|Treatment and observation period|On Day 1, subjects will receive a single oral dose of 2 mg 14C-radiolabeled cenerimod. Subjects will be followed for 21 days during which blood, urine, feces, and expired air samples will be collected
89212798|NCT04775927|Experimental|education group|marriage preparation training
89648353|NCT03021811|Other|LumiHeal|Treatment of chronic wounds with KLOX LumiHeal BioPhotonic System
89648354|NCT03021733||Non-operative|Patients whom elected non-operative treatment
89648355|NCT03021733||Operative|Patients whom elected operative treatment
89648356|NCT04917588|Experimental|Saypha® FILLER HQ|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma HQ Facility in order to correct moderate to severe deficiency of lip volume.~The treatment will be administered at the Baseline visit (Day 0)."
89648357|NCT04917588|Active Comparator|Saypha® FILLER C1|"Eligible subjects will undergo bilateral lip augmentation treatments with Saypha® FILLER Lidocaine manufactured in the Croma Pharma C1 Facility in order to correct moderate to severe deficiency of lip volume.~The treatment will be administered at the Baseline visit (Day 0)."
89648358|NCT03021577|Active Comparator|Orbital Atherectomy System (OAS) Group|Subjects randomized to OAS. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
89648359|NCT03021577|Active Comparator|Rotational Atherectomy (RA) Group|Subjects randomized to RA using the Rotablator Rotational Atherectomy System. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
89648360|NCT04022317|Experimental|Biocon Insulin R|0.3 IU/kg Dose per administration, subcutaneous Route of administration
89648361|NCT04022317|Active Comparator|Humulin® R (regular insulin human)|0.3 IU/kg Dose per administration, subcutaneous Route of administration
89648362|NCT05105724|Experimental|PRP|ovarian injections of PRP were administered to the patients
89648363|NCT05105724|No Intervention|No ovarian puncture or injection|no ovarian puncture or injection was used in the patients
89648364|NCT04021849|Experimental|Intervention|Participants will be gathered in a classroom with computers to receive an asynchronous virtual class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
89648365|NCT04021849|Sham Comparator|Control|Participants will be gathered in a classroom with computers to receive a face-to-face class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
89648366|NCT05099250|Placebo Comparator|Control group: Bupivacaine Group (B group)|Included patients who received 17 mL of 0.25% bupivacaine + 3 mL saline 0.9% in a total volume of 20 ml on each side
89648367|NCT05099250|Active Comparator|Magnesium Group (M group)|Included patients who received 17 mL of 0.25% bupivacaine + 3 mL of 75 mg magnesium sulfate diluted in 0.9% saline in a total volume of 20 ml on each side.
89648368|NCT03942913||dual therapy|including 1 antiplatelet treatment aspirin or clopidogrel associated with 1 anticoagulant treatment VKA or NOAC.
89648369|NCT03942913||triple therapy|"including 2 antiplatelet treatments (aspirin and clopidogrel) associated with 1 anticoagulant treatment VKA or NOAC.~In VKA class, 2 different drugs are commonly prescribed: warfarin and fluidinione. In NOAC class, 3 different drugs are commonly prescribed: rivaroxaban, apixaban, dabigatran."
89648370|NCT04764006|Experimental|Surufatinib plus Sintilimab|Drug: Surufatinib plus Sintilimab Surufatinib will be given orally. Sintilimab will be given intravenously
89648371|NCT04143451|Active Comparator|IQ|"Year 1: a single dose ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream~Year 2: randomised into 3 subgroups. Group IQ1: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream Group IQ2: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IQ3: ID normal saline vaccination with pre-treatment of the injected skin with imiquimod (Aldara) cream.~Year 3: IQ1 and IQ2 same treatment as second year. IQ3 same as first year."
89648372|NCT04143451|Active Comparator|IM|"Year 1: a single dose IM QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream~Year 2: randomised into 3 subgroups. Group IM1: IM QIV (15 µg of hemagglutinin per strain with pre-treatment of the injected skin with aqueous cream. Group IM2: ID QIV (15 µg of hemagglutinin per strain) with pre-treatment of the injected skin with imiquimod (Aldara) cream. Group IM3: IM normal saline vaccination with aqueous cream pretreatment.~Year 3: IM1 and IM2 same treatment as second year. IM3 same as first year."
89688571|NCT02920918|Active Comparator|Sitagliptin|Sitagliptin will be administered orally in pill form at 100 mg, daily for 12 weeks.
88992941|NCT05185934|Active Comparator|Food supplement Endocalyx|Thirty patients with COVID-19 infection will randomized to receive 4 capsules a day of the food supplement Endocalyx for 4 months.
88992942|NCT05185934|Placebo Comparator|Placebo|Thirty patients with COVID-19 infection will randomized to receive 4 capsules a day of the placebo for 4 months.
88992943|NCT05184699|Active Comparator|Food supplement Endocalyx|Thirty patients with psoriatic disease will randomized to receive 4 capsules a day of the food supplement Endocalyx for 4 months
88992944|NCT05184699|Placebo Comparator|Placebo|Thirty patients with psoriatic disease will randomized to receive 4 capsules a day of the placebo for 4 months
88992945|NCT05182099|Other|Conventional image reconstruction|Gd-EOB-DTPA enhanced liver MRI images are reconstructed using a conventional image reconstruction algorithm. It is automatically generated from a MRI console after the examination.
88992946|NCT05182099|Active Comparator|Deep learning image reconstruction|"Gd-EOB-DTPA enhanced liver MRI images are reconstructed using a deep learning based image reconstruction algorithm (AIRTM). It is additionally generated aside from the conventional images.~For obtaining the images, we will use the same MRI raw data which is used for conventional image reconstruction."
89045135|NCT02914223|Experimental|Extended observation period|In case, radioactivity recovery does not meet the stopping criteria described in the protocol, the subjects will have to come for a maximum of 7 24-h in-clinic visits during which blood, urine, feces, and expired air samples will be collected
89212799|NCT04775927|No Intervention|control group|No intervention
89212800|NCT04039490|No Intervention|Ultrasound-only Pediatric Vessel Cannulation|The standard of care for vessel cannulation currently employed at CNMC
89648373|NCT04143451|Active Comparator|HD|"Year 1: a single high-dose IM TIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream~Year 2: Group HD1: IM QIV (60 µg of hemagglutinin per strain) with pre-treatment of the injected skin with aqueous cream. Group HD2: IM normal saline vaccination with aqueous cream pretreatment.~Year 3: Group HD1 same treatment as second year. HD2 same as first year."
89648374|NCT05105646||Patients|"• All patients undergoing primary total knee arthroplasty for osteoarthritis of the knee reported in the Dutch Arthroplasty Register.~and~• Patients who filled out the EQ-5D-3L anxiety/depression score."
89648375|NCT04143529|Experimental|Personalized acceptance-based mindfulness exercise|The purpose of this study is to identify whether a brief 60-second acceptance based mindfulness intervention at specific time points will reduce state trait anxiety, Mini-Mental Adjustment to Cancer Scale score, pain intensity, distress, anxiety, depression and anger
89648376|NCT04143529|Placebo Comparator|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 second at specific timepoints.
89648377|NCT05080062|Experimental|Painrehabilitation + Demand and ability protocol|Will receive pain-rehabilitation and the intervention ( an interview called Requirements and functional Schedule, with the patients employer and an occupational therapist)
89648378|NCT05080062|Active Comparator|Painrehabilitation|Will receive pain-rehabilitation
89648379|NCT05105412|Experimental|Lenalidomide and Gemcitabine|Lenalidomide and Gemcitabine
89648380|NCT04766047|Active Comparator|DEXMEDETOMIDINE AND AKI|The patients of the group undergoing EVAR under general anesthesia will receive dexmedetomidine intraoperatively.
89648381|NCT04766047|No Intervention|CONTROL AND AKI|The patients of the group undergoing EVAR under general anesthesia will not receive dexmedetomidine intraoperatively.
89648382|NCT04662294|Experimental|T-ALL|
89648383|NCT04662294|Experimental|T-NHL|
89648384|NCT04662294|Experimental|AML|
89648385|NCT04021927|Experimental|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
89648386|NCT04021615|Experimental|Group A (study group)|Twenty five patients will receive comprehensive rehabilitation program combined with inspiratory muscle training.
89648387|NCT04021615|Active Comparator|Group B (Control group)|Twenty five patients will receive traditional chest physical therapy combined with inspiratory muscle training.
89648388|NCT05061498|Other|Additional Pacing maneuvers|In all study participants additional pacing maneuvers (cycle lenght and output) are performed
89648389|NCT03940261|Experimental|High Intensity Interval Training|
89212801|NCT04039490|Experimental|SCENERGY-guided Pediatric Vessel Cannulation|The addition of the SCENERGY guidance combined with the ultrasound for pediatric vessel cannulations.
89648390|NCT03940261|Active Comparator|Continuous Moderate Intensity Training|
89648391|NCT04633668|Experimental|CBT-p|cognitive behavioral therapy, Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
89648392|NCT04633668|Active Comparator|Self-monitoring|Monitoring of sleep through sleep diaries, nightmare experiences, and actigraphy
89648393|NCT04596228|Experimental|Experimental|Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device
89648394|NCT04747951|Experimental|total neoadjuvant therapy|Total neoadjuvant therapy consisted chemoradiotherapy with capecitabine and nine weeks of consolidation chemotherapy with XELOX prior to surgery and adjuvant therapy if necessary.
89648395|NCT04747951|Active Comparator|standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
89648396|NCT04148677||Protoves M1® syrup|A combination of two alkaloid, Protopine and Nuciferine
89648397|NCT04148677||No treatment|Patients will not receive a treatment
89648398|NCT04515888||target population|The target population of the study consists of breast cancer female patients over 50 years old followed for an invasive carcinoma expressing hormone receptors, non metastatic, undergoing adjuvant hormone therapy.
89648399|NCT04515888||control population|The control group will be composed of patients followed for an in situ carcinoma treated by surgery +/- radiotherapy, without hormone therapy.
89648400|NCT04149613||Colorectal Cancer Patients|Newly diagnosed stage IV colorectal cancer patients
89648401|NCT04149613||Controls|cancer free
89648402|NCT04148053||Active TB|"Subjects met the following:~Either Pulmonary or Extra-pulmonary tuberculosis patients~TB Bacteriological evidence obtained by culture or Xpert MTB/RIF from at least 1 specimen."
89648403|NCT04148053||Latent TB|"Subjects met the following:~TB Contact in history.~Chest X-ray suggestive of non-TB.~without any symptoms suggestive of TB.~TST and/or IGRA positive."
89648404|NCT04147975||Patients Suspected of Bloodstream Infection|No intervention(s) to be administered.
89648405|NCT04148209|Experimental|Treatment|Participants receiving PF-07081532
89648406|NCT04148209|Placebo Comparator|Placebo|Participants receiving Placebo
89648407|NCT04147897|Active Comparator|Internal Facilitation|mHealth specialist is a trained clinician embedded in the clinical team offering the mHealth intervention, FOCUS.
89648408|NCT04147897|Active Comparator|External Facilitation|mHealth specialist is a trained clinician external to the clinical team offering the mHealth intervention, FOCUS.
89648409|NCT04458792|Experimental|Experimental: Biological collection|"For all the patients include in the study :~Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue)~MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery~circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery~radiotherapy toxicity : Blood samples collected before the radiotherapy~In parallel to this biological collection, standardized clinical data will be entered into a database"
89648410|NCT04765891|Experimental|Positional Release Therapy|Participants were randomly assigned the positional release therapy treatment group. The participants underwent the treatment.
89648411|NCT04765891|Experimental|Therapeutic Massage|Participants were randomly assigned the therapeutic massage treatment group. The participants underwent the treatment.
89648412|NCT05104944|Experimental|Arm A (Intervention - Standard Care and Serial MRIs)|Immobilisation discontinued on the basis of MRI defined disease resolution at 3, 6, 9 or 12 months. In the intervention arm participants will receive additional MRIs at 3, 6, 9 and 12 months. Patients randomised to serial MRI will not undergo further MRI once remission has been diagnosed i.e. if remission is diagnosed at 6 months the MRI at 9 and 12 months will not occur.
89648413|NCT05104944|No Intervention|Arm B (Control - Standard Care and one additional MRI)|Immobilisation discontinued on the basis of clinical remission determined by skin temperature measurement and MRI. In the standard care arm participants will receive one additional MRI when the temperature measurements, X-ray and/or signs and symptoms indicate to the clinical team that the foot is in remission. A temperature difference of ≤ 2ºC which is maintained or improves on two separate consecutive occasions for a period of ≥4weeks will be the indicator to arrange the second MRI, to confirm the diagnosis of remission. If participants in either arm of the trial have not reached remission at the end of the 12 month active phase of the study they will exit the study. Ongoing standard care will be provided by their clinical team.
89648414|NCT02080819|No Intervention|Healthy Control|Non drug using healthy controls
89648415|NCT02080819|Placebo Comparator|Placebo|Placebo BID for 7 weeks
89648416|NCT02080819|Experimental|Medication|Levodopa/carbidopa 400/100 BID for 7 weeks
89648417|NCT05104788|Experimental|Icotinib with platinum-based chemotherapy|Icotinib 125 mg TID plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
89648418|NCT04405843|Experimental|Ivermectin|Ivermectin, 300 micrograms / kg, once daily for 5 days
89648419|NCT04405843|Placebo Comparator|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
89648420|NCT04316364|Experimental|Treatment group A|Neoadjuvant setting: Drug: SHR-1316 and carboplatin and Paclitaxel (Albumin Bound) 3 cycles; Adjuvant setting: Drug: SHR-1316 up to 16 cycles
89648421|NCT04316364|Experimental|Treatment group B|Neoadjuvant setting: Drug: SHR-1316 and platinum-based dual chemotherapy 3 cycles; Adjuvant setting: Drug: SHR-1316 up to 16 cycles
89648422|NCT04316364|Placebo Comparator|Treatment group C|Neoadjuvant setting: Drug: Placebo and platinum-based dual chemotherapy 3 cycles; Adjuvant setting: Drug: Placebo up to 16 cycles
89648423|NCT04142671|Experimental|Individualised Gait Modification Intervention|"Patients will carry out several walking trials to test the efficacy of an individualised gait modification intervention.~Pre-intervention over ground walking, pre-intervention treadmill walking, intervention treadmill walking with real-time biofeedback on their knee loading, intervention treadmill walking with no feedback, and post-intervention over ground walking."
89648424|NCT04142827|Experimental|Therapy with high flow humidification|The patients will be activated after enrollment with myAirvo2 device at home for 6 months before first observations
89648425|NCT04142827|No Intervention|Therapy with usual care|The patients will be under usual care for observational
89648426|NCT04147741|Experimental|Pre-Workout Supplement|A 60 g dose of a commercially available pre-workout supplement providing 159 kcal including carbohydrates 15 g, essential amino acids 12 g, citrulline 3.5 g, Arginine, 3.5 g Taurine 1 g, L-Tyrosine 1 g, yerba mate 0.3 g and caffeine 0.4 g. With 250 ml of water.
89648427|NCT04147741|Placebo Comparator|Maltodextrin Supplement|A isoenergetic Maltodextrin supplement will be administered as placebo. With 250 ml of water.
89648428|NCT04972500|Experimental|Pre-op|Nutricia Pre-op, 400 milliliters, per os
89648429|NCT04972500|No Intervention|Control|No intervention
89648430|NCT04142359||Cohort A: CIS (either study)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
89045136|NCT01628094|Experimental|A: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
89045137|NCT01628094|Experimental|B: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
89045138|NCT01628094|Experimental|C: GT1a 2DAA|including RO5466731, RO5190591, ritonavir and ribavirin [Copegus]
89045139|NCT01628094|Experimental|D: GT1b 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
89648431|NCT04142359||Cohort B: High-Grade Ta/T1 Papillary Disease (either study)|Patients with histologically confirmed presence of BCG-unresponsive high-grade Ta/T1 papillary disease
89648432|NCT04142359||Cohort C: CIS (QUILT-3.032)|Patients with histologically confirmed presence of BCG-unresponsive CIS, [with or without Ta/T1 papillary disease].
89648433|NCT04406155||Patients with suspicion of rectosigmoid endometriosis|
89648434|NCT04918212|Experimental|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
89648435|NCT04781478|Active Comparator|Biorepair Gel (Q1-Q3) and Chlorhexidine 1% gel (Q2-Q4)|The patients receive Biorepair Gel application in quadrants Q1 and Q3, whereas they receive chlorhexidine 1% gel in quadrants Q2 and Q4.
89648436|NCT04781478|Active Comparator|Chlorhexidine 1% gel (Q1-Q3) and Biorepair Gel (Q2-Q4)|The patients receive chlorhexidine 1% gel in quadrants Q1 and Q3, whereas they receive Biorepair Gel application in quadrants Q2 and Q4.
89648437|NCT04436562|Experimental|Poziotinib|A single oral dose of 8 mg poziotinib as a capsule formulation (as the hydrochloride salt) containing approximately 100 μCi of [14C]-poziotinib
89648438|NCT05104398||Baseline therapy|Group 1 (n=29) continued to receive standard treatment.
89648439|NCT05104398||Basic therapy + Efferon CT|group 2 (n=13) received HP procedure once, for 3-4 hrs, using Efferon CT adsorbers containing mesoporous SDC beads uptaking 6-60 kD molecules followed by continuous veno-venous hemodiafiltration. Group 2 included more severe patients requiring HP support.
89648440|NCT04141969|Active Comparator|RLP|ReaLife+
89648441|NCT04141969|Placebo Comparator|Inert|Inert brown powder to look similar to RLP
89648442|NCT04141969|No Intervention|Control|Not given RLP or the placebo
89648443|NCT03935113|Experimental|KT group|The paretic upper limb is a common consequence of stroke that increases activity limitation.
89648444|NCT04018872|Experimental|Itraconazole|Itraconazole capsule 300mg twice daily for 6-8 weeks following chemoradation.
89648445|NCT04141735||patients from September 2016 to September 2018|all patients underwent allogeneic hematopoietic stem cell transplantation
89648446|NCT03978078|Experimental|Biological collection|"For all the patients include in the study :~- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment~In parallel to this biological collection, standardized clinical data will be entered into a database"
89648447|NCT04147429|No Intervention|Usual care|Newborns randomized to the usual care group will receive standard education about safe sleep practices, measuring temperatures and newborn feeding needs. This information will be accompanied by printed instructions that will be added to the family's discharge instructions. This reflects current practice in the Duke Hospital Newborn Nursery.
89648448|NCT04147429|Experimental|Intervention|In addition to usual care, families randomized to the intervention group will receive an early literacy intervention, delivered by a trained research assistant. To ensure intervention and delivery fidelity, the PI will meet with research assistants at bi-weekly intervals to review procedures and perform structured observations of intervention delivery.
89648449|NCT04147507|Experimental|Music Therapy|
89648450|NCT04147507|Other|Control|Life style Modification.
89648451|NCT03915691|Active Comparator|Isthmus targeted approach using Ripple Mapping|Intervention: Isthmus targeted approach using Ripple Mapping catheter ablation of atrial tachycardia.
89648452|NCT03915691|Active Comparator|Conventional Mapping|Intervention: conventional catheter ablation of atrial tachycardia.
89648453|NCT04141345||Heart failure with chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
89648454|NCT04141345||Heart failure without chronic lung disease|Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. HF patients who did not have chronic lung disease were assigned as a non-CLD group.
89648455|NCT04140877|Other|Visu OD, Control OS|Contralateral eye study
89648456|NCT04140877|Other|Control OD, Visu OS|Contralateral eye study
89648457|NCT05581459|Experimental|63 Hz vibration group|Vibration of 63 Hz frequency was applied.
89648458|NCT05581459|Active Comparator|42 Hz vibration group|Vibration of 42 Hz frequency was applied.
89648459|NCT05581459|Sham Comparator|Sham vibration group|No actual vibration was applied.
89648460|NCT04868136|Experimental|Warm-up, then no warm-up|Participants' visit 2 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session. Participants' visit 3 consisted of the 30 minute exercise session without a warm-up.
89648461|NCT04868136|Experimental|No warm-up, then warm-up|Participants' visit 2 consisted of the 30 minute exercise session without a warm-up. Participants' visit 3 included 10 minutes of gradually increasing intensity prior to the 30 minute exercise session.
89648462|NCT04141189|Experimental|weekly|weekly fetal surveillance
89648463|NCT04141189|Active Comparator|bi-weekly (twice-weekly)|bi-weekly fetal surveillance
89648464|NCT05078268|Experimental|Combined group|Participants in combined group will receive both HRV biofeedback training and self-help CBT-I concurrently.
89648465|NCT05078268|Active Comparator|Self-help CBT-I only group|Participants in self-help CBT-I only group will receive self-help CBT-I only.
89648466|NCT05076786|Experimental|Chidamide + Etoposide + Cisplatin/Carboplatin|Experimental arm will be treated by chidamide combined with etoposide and cisplatin/carboplatin regimen for 4-6 cycles.
89648467|NCT04141033|Other|saliva neopterin levels|assessment of saliva neopterin levels in pre and post-menopausal women
89648468|NCT04141033|Other|GCF neopterin levels|assessment of GCF neopterin levels in pre and post-menopausal women
89648469|NCT03588949|Experimental|Active Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)
89648470|NCT03588949|Placebo Comparator|Control Dietary Supplement|Dietary Supplement with 50% RDA of beta-carotene
89648471|NCT03476317|Experimental|Group 1-Fluconazole|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
89648472|NCT03476317|Placebo Comparator|Group 1-Placebo|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
89648473|NCT03476317|No Intervention|Group 2|Collect stool samples for calprotectin in patients undergoing colonoscopy for clinical care to evaluate effect of bowel lavage alone on calprotectin.
89648474|NCT02658084|Experimental|Phase 1: T-DM1 + Vinorelbine|One cycle of Trastuzumab Emtansine (T-DM1)/Vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). The recommended (starting) dose of trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion on Day 1 of every 21-day cycle. The starting dose of Vinorelbine is 22.5 mg/m2 given as a direct intravenous push over 6-10 minutes on day 1 and day 8 of every 3-week (i.e. 21-day) cycle. Participants will be treated until documented disease progression or other criteria for discontinuation. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose (RP2D).
89648475|NCT02658084|Experimental|Phase 2: T-DM1 + RP2D Vinorelbine|One cycle of trastuzumab emtansine (T-DM1)/vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). Participants will receive the recommended Phase 2 Dose (RPSD) of Vinorelbine with the fixed dose (3.6 mg/kg) of Trastuzumab Emtansine. Participants will be treated until documented disease progression or other criteria for discontinuation. Up to 35 patients will be treated at the RP2D (MTD) including 6 patients treated at RP2D in phase I.
89648476|NCT03588871|Experimental|Group A|Dental bleaching with PaintOn Plus, HP 6%, 6x10min, two sessions
89648477|NCT03588871|Experimental|Group B|Dental bleaching with Opalescence GO, HP 6%, 10x60min
89648478|NCT03588871|Experimental|Group C|Dental bleaching with Opalescence PF, CP 16%, 14x60h
89648479|NCT04548882|Experimental|Calypso Knee System|Calypso Knee System
89648480|NCT04140643|Experimental|Ozone therapy|Oral hygiene instructions given by dental hygienist and home daily use of ozonated water delivering system.
89648481|NCT04140643|Active Comparator|Only oral hygiene instructions|Oral hygiene instructions given by dental hygienist.
89648482|NCT03021655|Experimental|Adventure-based intervention group|Adventure-based intervention group included 1 day-camp and will be divided into 2 parts: (1) physical activity such as wall climbing, ropes course etc, (2) health education delivering about the relationship of self-efficacy, self-esteem, emotion and smoking abstinence. The training will be held before the 6-month follow-up. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
89648483|NCT03021655|Experimental|WhatsApp intervention group|For WhatsApp intervention group, not more than 8 subjects with same gender will be assigned into a group. Messages about mood and stress management will be sent to the group per week and the group will last for 6 months. It aims to relieve their pressure and emotion by sharing their unhappy things with other subjects. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
89648484|NCT03021655|Other|Control group|For the control group, the subjects will receive telephone counseling on quitting smoking at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
89648485|NCT03345186|Experimental|Nurse led plus standard of care|Nurse Led Patient Management Programme to Improve Outcomes in Gout and Standard of care for gout patients, including nurse delivered patient education and follow up
89648486|NCT03345186|No Intervention|Standard of care|Standard of care for gout patients
89648487|NCT03588715|Experimental|Pegylated Interferon alpha 2b + bNAbs|Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)
89648488|NCT03588715|Experimental|bNAb only|bNAb (3BNC117 + 10-10-74) only
89648489|NCT03588559|Experimental|BPM, TMB-1591-A-002 and Reference Device|DUT: Transtek Blood Pressure Monitor TMB-1591-A-002 Reference Device: Baumanometer Desk Mercury Sphygmomanometer. Blood Pressure Measurement with the Transtek BPM TMB-1591-A-002 and with reference device.
89648490|NCT04528758|Experimental|Dosimetry group|Patients in the dosimetry group will be imaged with the radio-pharmaceutical Rhodamine 6G at different time points. 0-120, 30-150, 60-180
89648491|NCT04528758|Active Comparator|Stable Heart Patients|Stable heart patients will be given a rest/stress PET/CT with Rhodamine 6G myocardial perfusion study to determine myocardial blood flow
89648492|NCT04140409|Experimental|Treatment|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
89648493|NCT04452474|Experimental|Olokizumab 64 mg|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Olokizumab on Day 1, in addition to standard therapy
89648494|NCT04452474|Placebo Comparator|Placebo|Subject randomized to receive subcutaneous single injection of 0,4 ml solution of Placebo on Day 1, in addition to standard therapy
89648495|NCT04527510||Conventional-reading|
89648496|NCT04527510||Second-reading|
89648497|NCT04527510||Concurrent-reading|
89648498|NCT04527510||Tow-view-reading|
89648499|NCT04527510||Handheld US-screening|
89648500|NCT03588403||Arm A:Tomotherapy|Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
89648501|NCT03588403||Arm B: IMRT|Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
89648502|NCT05580835|Experimental|PET MRI - PSMA|Patients with an imaging diagnosis of HCC and submitted to PET MRI - PSMA
89648503|NCT04436718|Experimental|Daily POCUS|Patients are assessed by facility experts with daily chest ultrasound and findings of interstitial syndrome and IVC measurement are reported to primary care providers.
89648504|NCT04436718|No Intervention|Usual care|Patients are assessed daily by primary care providers per usual care.
89648505|NCT04879290|Active Comparator|Control Group FiO2=1|FiO2 = 1 (100%) 10mn before emergence of general anesthesia
89648506|NCT04879290|Experimental|Intervention Group FiO2 0.5|Fi02 = 0.5 (50%) 10mn before emergence of general anesthesia
89045140|NCT01628094|Experimental|E: GT1b 2DAA|including RO54664731, RO5190591, ritonavir and ribavirin [Copegus]
89045141|NCT01628094|Experimental|Part II|
89648507|NCT03912805|Placebo Comparator|Vehicle|Vehicle, topical liniment, administered once at baseline
89648508|NCT03912805|Experimental|ET-01 1610U|botulinum toxin, Type A, topical liniment, administered once at baseline
89212802|NCT00878618|Experimental|HAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with heavy breakfast
89648509|NCT03909685|Experimental|the intervention arm|During the course of the study, the participants in the intervention arm will use the Ask RoSE application daily. Participants will receive weekly in-person psychotherapy for a total of four sessions over four weeks. Licensed therapists will provide the in-person psychotherapy
89648510|NCT03909685|No Intervention|a waitlist control arm|The participants in the waitlist arm will serve as controls unless there is attrition from the intervention group at which time waitlist participants will be offered a spot in the intervention arm
89648511|NCT04642950|Experimental|NPC-26|Sargramostim (125 μg) will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
89648512|NCT04642950|Placebo Comparator|NP-26 Placebo|Physiological saline will be administered by inhalation twice daily for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment.
89648513|NCT05110092|Experimental|The exercise group|The exercise group received usual care and breathing-based leg resistance exercise program for 12 weeks.
89648514|NCT05110092|No Intervention|The control groups|The control group received usual care
89648515|NCT05109936|Experimental|Experimental arm|Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), urate-lowering treatment, for a period of 2 x 6 weeks.
89648516|NCT05109936|No Intervention|Standard care arm|Prescription deferred to 6 weeks (42 days +/- 3 days) of ADENURIC 80 mg / day (febuxostat): hypouricemic treatment, for a period of 6 weeks.
89648517|NCT04472208|Experimental|Ambulatory Monitoring Solution|The evaluable device is a secondary monitoring device and no decisions/diagnosis will be made from these devices.
89648518|NCT04522440|Experimental|Inpatients in hospice Ward|Inpatients in hospice Ward with pain control problems
89648519|NCT04427982|Experimental|Experimental Group|All participants will attend a 2-month weekly light-to-moderate intensity dance workshop followed by a brief diabetes education and discussion session.
89648520|NCT04374240|Experimental|AdNRGM followed on day 2 by CB1954|The proposed dose levels for AdNRGM are 10^10, 3x10^10, 10^11, 3x10^11, 10^12 vp while the prodrug CB1954 will be given at a standard dose of 24 mg/m^2
89648521|NCT05109468||Anal cancer patients|Non-metastatic squamous anus cancer with the presence of an HPV infection authenticated on the biopsy
89648522|NCT05109390|Experimental|Part 1: Danicopan plus Cyclosporine|"Participants (N=14) received danicopan and cyclosporine in a fixed sequence over 2 periods:~Treatment A (Period 1): 300 milligrams (mg) cyclosporine administered on Day 1.~Treatment B (Period 2): 200 mg danicopan administered 3 times daily (TID) on Days 1-7 with 300 mg cyclosporine coadministered on Day 5.~There was a washout period of 3 days between the dose of cyclosporine in Period 1 and the first dose of danicopan in Period 2."
89648523|NCT05109390|Experimental|Part 2: Danicopan plus Tacrolimus|"Participants (N=28) received danicopan and tacrolimus in a fixed sequence over 2 periods:~Treatment C (Period 1): 2 mg tacrolimus administered on Day 1.~Treatment D (Period 2): 200 mg danicopan administered TID on Days 1-10 with 2 mg tacrolimus coadministered on Day 5.~There was a washout period of 7 days between the dose of tacrolimus in Period 1 and the first dose of danicopan in Period 2."
89648524|NCT05109390|Experimental|Part 3: Danicopan plus Antacids and Omeprazole|"Participants (N=30) received danicopan, calcium carbonate, aluminum/magnesium hydroxide/simethicone, and omeprazole in fixed sequences over 2 periods:~Treatment E1 (Period 1): 200 mg danicopan administered TID on Days 1-4. Treatment E2 (Period 1): 200 mg danicopan coadministered with 1 gram calcium carbonate on Day 5.~Treatment F1 (Period 1): 200 mg danicopan administered TID on Days 1-4. Treatment F2 (Period 1): 200 mg danicopan coadministered with 200 mg aluminum hydroxide/200 magnesium hydroxide/25 mg simethicone on Day 5.~Note: Participants were randomized in a 1:1 ratio to receive either Treatment E2 or F2 coadministered with danicopan on Day 5.~Treatment G1 (Period 2): 40 mg omeprazole administered once daily (QD) on Days 1-4.~Treatment G2 (Period 2): 40 mg omeprazole administered QD with 200 mg danicopan administered orally TID on Days 5-8.~There was a washout period of 2 days between the last dose of danicopan in Period 1 and the first dose of omeprazole in Period 2."
89648525|NCT04783974||Patients assuming SSRI|Patients treated with dental implants and assuming selective serotonin reuptake inhibitors
89648526|NCT04783974||Patients assuming PPI|Patients treated with dental implants and assuming proton pump blockers
89648527|NCT04783974||Patients assuming Anti-inflammatory drugs|Patients treated with dental implants and assuming anti-inflammatory drugs
89648528|NCT04783974||Patients assuming Anti-hypertensive drugs|Patients treated with dental implants and assuming anti-hypertensive drugs
88992947|NCT05172908|Active Comparator|Group Dexa|"After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively.~The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study"
88992948|NCT05172908|Sham Comparator|Group S|"After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 50 mL normal saline in a 50 ml syringe will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively.~The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study"
88992949|NCT05140512|Experimental|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
88992950|NCT05140512|Active Comparator|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
88992951|NCT05139927|Experimental|Condition 1|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - ON Component D: Navigation
88992952|NCT05139927|Experimental|Condition 2|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - ON Component D: Self-test kit
88992953|NCT05139927|Experimental|Condition 3|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - ON Component D: Navigation
88992954|NCT05139927|Experimental|Condition 4|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - ON Component D: Self-test kit
88992955|NCT05139927|Experimental|Condition 5|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Navigation
88992956|NCT05139927|Experimental|Condition 6|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Self-test kit
89212803|NCT00878618|Experimental|HBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with heavy breakfast
89648529|NCT04783974||Control group - Patients not assuming the studied drugs|Patients treated with dental implants and not assuming any of the following drugs: selective serotonin reuptake inhibitors, proton pump blockers, anti-inflammatory drugs, anti-hypertensive drugs
89648530|NCT04030182||Level of vitamin D|Level in blood sample of vitamin D for each patient
89648531|NCT05109000|Experimental|Normal Saline|This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject. In this arm, the subject will receive a 10 mL subcutaneous injection of normal saline into either their left or right anterior thigh. The side will be determined by randomization protocol.
89648532|NCT05109000|Experimental|Bacteriostatic Saline|This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject. In this arm, the subject will receive a 10 mL subcutaneous injection of bacteriostatic saline into either their left or right anterior thigh. The side will be determined by randomization protocol.
89648533|NCT05108610|Active Comparator|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
89648534|NCT05108610|Experimental|Shi-style manipulations|Shi-style manipulations is a cervical manipulation for cervical spondylosis.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
89648535|NCT05108532||Patients after revisional bariatric surgery.|This cohort will include patients, who underwent revisional bariatric surgery.
89648536|NCT03876990|Experimental|Multiplex PCR + Current strategy|Results of the multiplex PCR will be send as soon as possible to the infectious disease phycian for quick adaptation of antibiotic treatment. Positive blood cultures will also undergo current diagnosis strategy for bacteremia and fungemia.
89648537|NCT03876990|Active Comparator|Current strategy alone|Current diagnostic strategy based on the identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
89648538|NCT03799380|Active Comparator|Control - Standard of Care|Standard of care nutritional support
89648539|NCT03799380|Experimental|Experimental - Gatorade|Standard of care nutritional support with the addition of daily Gatorade G2
89648540|NCT03952494|Experimental|Intervention group|Intervention group will have the PGx test results available via Epic, three days after the biospecimen is received.
89648541|NCT03952494|Experimental|Control group|"The control group will be considered in TAU(treatment as usual) group but will have the PGx test results available after 24 weeks.~Note: Patient in both the groups will be followed for 24 weeks and will take questionnaires every other week."
89648542|NCT05098314||EHPAD with personalized interventions|EHPAD with personalized interventions.
89648543|NCT05098314||EHPAD without personalized interventions|EHPAD without personalized interventions
89648544|NCT03680196|Experimental|cerebral palsy patients|cerebral palsy patients who have GMFCS level3,4,5 and 2 years old and under 10 years old apply an A injection of medication Botulinum A injection
89648545|NCT04814472|Experimental|Oral Solution vs. Tablet Formulation|"There will be 3 treatments, each single dose administered based on the treatment sequence with at least a 3 day washout between treatments:~Treatment A: 750 mg BLD-0409 oral solution formulation (solution) under fasting conditions.~Treatment B: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fasting conditions.~Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablets) under fed conditions."
89648546|NCT04814472|Experimental|Tablet Formulation Dose Proportionality|"There will be 4 treatments, each single dose administered under fed conditions (standard meal) based on the treatment sequence with at least a 3 day washout between treatments:~Treatment A: 250 mg BLD-0409 tablet formulation (1 x 250 mg tablet).~Treatment B: 500 mg BLD-0409 tablet formulation (2 x 250 mg tablet).~Treatment C: 750 mg BLD-0409 tablet formulation (3 x 250 mg tablet).~Treatment D: 1000 mg BLD-0409 tablet formulation (4 x 250 mg tablet)."
89648547|NCT03661632|Experimental|Dose Escalation|"Part 1: BMS-986310 + Nivolumab Combination Dose Escalation~Sub-Study A: A cohort of Cisplatin Ineligible Muscle Invasive Bladder Cancer patients will receive either monotherapy BMS-986310, or BMS-986310 + Nivolumab, or Nivolumab monotherapy.~Sub-Study B: A cohort of PD[L]1 relapsed / refractory tumor cancer patients will be treated with monotherapy BMS-986310 followed by BMS-986310 + nivolumab"
89648548|NCT03661632|Experimental|Cohort Expansion|"Part 2: Cohort Expansion will initiate upon consideration of the totality of data from Part 1.~BMS-986310 + Nivolumab combination will be administered in specific patient populations."
89648549|NCT04748250|Experimental|Acupuncture Group|This group will receive acupuncture therapy for 30 minutes, three times per week for six months using the internationally recognized standard acupuncture needle which is 3 cm long with diameter o.3 mm, pushing it with twisting movement to the required depth until the De Qi sensation will be obtained.
89648550|NCT04748250|Experimental|Soy Group|This group will receive soy products for six months which including: Soy milk: 100 millilitre of soy milk every day, every bottle of original soy milk contains 300 millilitre or Soy beans: 100 gram of cooked soy beans per day.
89648551|NCT04748250|Experimental|Acupuncture and Soy Group|Every patient in this group will receive acupuncture therapy sessions in abdominal acu-points as in group (A) for 30 minutes, three times per week for six months in addition to administration of soy products in the form of soy milk or soy beans daily in breakfast for three months as in group (B).
89648552|NCT04726878|Placebo Comparator|Controlled|Standard care without regional block. General anesthesia. After the end of the surgery, the patient-controlled analgesia with oxycodone.
89648553|NCT04726878|Experimental|ESP block|After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.375% ropivacaine will be performed. Then, the patient will be treated as in the controlled group.
89648554|NCT04726878|Sham Comparator|Sham block|After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.9% saline will be performed. Then, the patient will be treated as in the controlled group.
89212804|NCT00878618|Experimental|LAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with light breakfast
89648555|NCT04525638|Experimental|177Lu-DOTATATE + Nivolumab|Patients will receive 240 mg flat dose of nivolumab intravenously as a 30-minutes infusion and 7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
89648556|NCT04164342|Experimental|Single ARM|This is an observational study, all patients will be followed at 3, 6 and 12 months by phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done).
89648557|NCT04701216|Experimental|Experimental: SHR8735 cohort 1|The subjects will receive a multiple dose of SHR8735 (low dose).
89648558|NCT04701216|Experimental|Experimental: SHR8735 cohort 2|The subjects will receive a single dose of SHR8735 (medium dose).
89648559|NCT04701216|Experimental|Experimental: SHR8735 cohort 3|The subjects will receive a single dose of SHR8735 (high dose).
89648560|NCT04663230||Pulmonary arterial hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
89648561|NCT04663230||Chronic thromboembolic pulmonary hypertension|Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
89648562|NCT04663230||Control|Patients with invasive exclusion of pulmonary hypertension (mean pulmonary arterial pressure below 25 mmHg) undergoing diagnostic CMRI due to the evaluation of dyspnoea.
89648563|NCT04706364||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder
89648564|NCT04706364||Healthy Control|Typically developing individuals without a history of autism
89648565|NCT01482962|Experimental|Alisertib|Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
89648566|NCT01482962|Active Comparator|Pralatrexate, or Romidepsin, or Gemcitabine|Pralatrexate 30 mg/m^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
89648567|NCT04701060|Experimental|Camrelizumab combined with apatinib|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
89648568|NCT05116098|Active Comparator|100 pulmonary positive patients on tb protocol adding to supplement zinc 50 mg 400 mg once daily|
89648569|NCT05116098|Placebo Comparator|control group 100 patients only on tuberculosis national protocol|
89648570|NCT04464408|Experimental|Favipiravir|Favipiravir: 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (Maximum days of therapy is 7 days)
89648571|NCT04464408|Placebo Comparator|Placebo|9 tablets by mouth twice daily for one day, followed by 4 tablets twice daily (Maximum days of therapy is 7 days).
89648572|NCT04587570|Experimental|Group 1: Infiltration of PRP|The proband gets Platelet Rich Plasma injected in the thumb saddle joint.
89648573|NCT04587570|Experimental|Group 2: Infiltration of Fat|The proband gets fat injected in the thumb saddle joint.
89648574|NCT04587570|Experimental|Group 3: Infiltration of PRP and Fat|The proband gets a mixture of Platelet Rich Plasma (PRP) and Fat injected in the thumb saddle joint.
89648575|NCT04587570|Placebo Comparator|Group 4: Infiltration of NaCl|The proband gets NaCl injected in the thumb saddle joint.
89648576|NCT04585620|Active Comparator|BTX-A|"Onabotulinum toxin A is reconstructed with 4 ml of normal saline in a vial containing 100 U (Allergen Units).~At a single treatment session, test subjects receive a series of subcutaneous injections with 2,5 U Onabotulinum toxin A equivalent to 0,1 ml of solution after reconstruction. One injection is given per 1 square centimeter in the painful area in relation to the scar on the chest wall. The maximum number of subcutaneous injections is 40, equivalent to a maximum dose of 100 U of Onabotulinum toxin in a total volume of 4 ml solution. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes."
88992957|NCT05139927|Experimental|Condition 7|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Navigation
88992958|NCT05139927|Experimental|Condition 8|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - ON Component D: Self-test kit
88992959|NCT05139927|Experimental|Condition 9|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Navigation
88992960|NCT05139927|Experimental|Condition 10|Component A: motivational interviewing counseling - ON Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Self test kit
88992961|NCT05139927|Experimental|Condition 11|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Navigation
88992962|NCT05139927|Experimental|Condition 12|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - ON Component C: Peer education - OFF Component D: Self test kit
88992963|NCT05139927|Experimental|Condition 13|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Navigation
88992964|NCT05139927|Experimental|Condition 14|Component A: motivational interviewing counseling - ON Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Self test kit
88992965|NCT05139927|Experimental|Condition 15|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Navigation
89045142|NCT02914106||Control group|Sixty-90 year-old subjects were randomly selected and distributed in two experimental groups: 1) a control group, involving subjects without physical or psychiatric illness, and 2) an Acute Ischemic Stroke group (AIS group).
89045143|NCT02914106||Acute Ischemic Stroke group|Patients with diagnosis of AIS within the 24 hours of their neurovascular event.
89045144|NCT01627314|Experimental|ProHema-CB with MAC Preparative Regimen|ProHema-CB and Wash-Only CB Unit with myeloablative conditioning regimen (MAC)
89045145|NCT01627314|Experimental|ProHema-CB with RIC Preparative Regimen|ProHema-CB and Wash-Only CB Unit with reduced intensity conditioning regimen (RIC)
89648577|NCT04585620|Placebo Comparator|Placebo|At a single treatment session, test subjects receive a series of subcutaneous injections with one injection per 1 square centimeter in the painful area in relation to the scar on the chest wall with an inert solution, i.e. 0.1 ml injections of normal saline up to a total volume of 4 ml, depending on the area of the painful area. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes.
89648578|NCT02655666||Medtronic MiniMed Paradigm® REAL-Time System|Medtronic MiniMed Paradigm® REAL-Time System consisting of Paradigm 722 Insulin Pump (MMT-722), Medtronic MiniLink® REAL-Time Transmitter (MMT-7703) and Sof-Sensor® (MMT-7003) Glucose Sensor
89648579|NCT05115708|Active Comparator|Kahook dual blade ab-interno Trabeculotomy|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
89648580|NCT05115708|Active Comparator|ab externo viscotrabeculotomy|In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group.
89648581|NCT04339218|Experimental|Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin|Cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
89648582|NCT04339218|Active Comparator|Arm pembrolizumab-pemetrexed-carboplatin|Combination of Pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
89648583|NCT04253808|Experimental|Arm A|The experimental arm (N=6) were provided a CRHF diet with enough calories to maintain body weight for appoximately 2 weeks neoadjuvantly (during radiotherapy preparation) and adjuvantly during primary oncology treatment for ~6.5 weeks. The CRHF diet was composed of 45% fats (mostly) unsaturated fats, 25% proteins, and 30% carbohydrates.
89648584|NCT04253808|Active Comparator|Arm B|"Arm B (N=7) were provided a regular composition diet prescribed with enough calories to maintain body weight for approximately 2 weeks neoadjuvantly (during radiotherapy preparation) and adjuvantly during primary oncology treatment for ~6.5 weeks.~The regular composition diet was composed of ~50-52% carbohydrates, ~30% fats, and 18-20% proteins,"
89648585|NCT04253808|No Intervention|Control group|The control group (N=26) followed applicable eligibility criteria but did not receive any intervention.
89648586|NCT05115318||Adult Tourette syndrome patients|Patients will be assessed before (baseline), 4 (visit 2) and 12 weeks (visit 3) after use of Medical cannabis via inhaled dried buds or sublingual oil extract. The percentage of THC and CBD were pre-set to 10% and 2%, respectively. All patients received the same general instructions for treatment titration, which was to start with 1 drop or puff a day and increase by 1 drop or puff as needed. There was no fixed schedule for the incremental increases, thus each patient freely raised the dose as well as number of daily consumptions until clinical benefit was achieved or SE emerged over a follow-up period of 12 weeks.
89648587|NCT05115162|Experimental|elerehablitation home exercise group|"Telerehabilitation home exercise group received indoor walking and general exercise program for 6 weeks.~Indoor walking was performed 3 days a week, for 30 minutes. General exercise program was consisted of flexibility, strengthening the shoulder and trunk muscles, bridge exercises, lying on the back, cycling and squatting exercises. All of the general exercises were repeated 3 days a week, 2 sets and each set with 10 repetitions.~Two synchronized exercise education sessions were performed with the exercise group. In the first of these sessions, the content of the exercise program was explained. In the second, it was checked whether the exercises were done correctly. After synchronous education sessions, an asynchronous home exercise program, consisting walking and general exercise program continued for 6 weeks."
89648588|NCT05115162|No Intervention|Control Group|This group did not participate in any exercise program for 6 weeks.
89648589|NCT01506596|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
89648590|NCT04474860||Malignant Hyperthermia|Samples from Chinese whose malignant hyperthermia susceptibility had been confirmed after a positive clinical manifestation of malignant hyperthermia and samples from their blood relations will receive genetic testing.
89045146|NCT01627314|Placebo Comparator|Control Arm with MAC Preparative Regimen|Two Wash-Only CB Units (Untreated CB) with myeloablative conditioning regimen
89648591|NCT03895801|Experimental|Group A Experimental + active comparator|IFX-1 + reduced dose GC
89648592|NCT03895801|Active Comparator|Group B Placebo + active comparator|Placebo-IFX-1 + standard dose GC
89648593|NCT03895801|Placebo Comparator|Group C Experimental + placebo comparator|IFX-1 + Placebo-GC
89648594|NCT04469478|Experimental|Virtual Reality for imaging review|Each participant (patient and caregiver(s)) will undergo standard 2D imaging review on a computer screen, followed by 3D imaging review in virtual reality during their radiation oncology consultation
89648595|NCT05114928||Progression Group (P-group)|Eyes that showed progression of the disease after trans-epithelial corneal collagen cross-linking during the 5 years of follow-up, (number of eyes = 7 eyes).
89648596|NCT05114928||No Progression Group (NP-group)|Eyes that showed no progression of the disease after trans-epithelial corneal collagen cross-linking during the 5 years of follow-up, (number of eyes = 11 eyes).
89648597|NCT05114772|Active Comparator|Recurrent Atrial fibrillation|patients developed Recurrent Atrial fibrillation catheter ablation
89045147|NCT01627314|Placebo Comparator|Control Arm with RIC Preparative Regimen|Two Wash-Only CB Units (Untreated CB) with reduced intensity conditioning regimen
89212805|NCT00878618|Experimental|LBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with light breakfast
89212806|NCT05102942|Experimental|Group A: a gamified AACTP smartphone application + treatment as usual (TAU)|
89212807|NCT05102942|Placebo Comparator|Group B: a gamified AACTP sham-control application + TAU|
89212808|NCT05102942|No Intervention|Group C: only TAU|
89212809|NCT02587559|No Intervention|Control|usual medical advice regarding symptomatic control and activity modification
89212810|NCT02587559|Experimental|Experimental|Six visits of physical therapy to provide manual therapy and therapeutic exercise
89212811|NCT02587169|Experimental|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
89212812|NCT00873236|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.
89212813|NCT00873236|Experimental|Arm II|Patients receive bevacizumab as in arm I and low-dose recombinant interferon alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.
89212814|NCT00873236|Experimental|Arm III|Patients receive bevacizumab as in arm I and standard-dose recombinant interferon alpha-2a SC 3 times weekly beginning on day 0.
89648598|NCT05114772|Active Comparator|NO Recurrent Atrial fibrillation|patients didn't develop Recurrent Atrial fibrillation catheter ablation
89648599|NCT03021421|Sham Comparator|Group USA|(Marcain Heavy 0.5%; AstraZeneca®, London, UK) using a 25-G Quincke spinal injector (B. Braun®, Melsungen, Germany).
89648600|NCT03021421|Active Comparator|Group PCS|"(Stimupleks A; B. Braun®, Melsungen AG, Germany) to lumbar plexus in psoas muscle compartment (injected material 20 ml local anaesthetic mixture5 ml of 2% lidocaine + 15 ml of 0.5% bupivacaine)~%2 Aritmal ampul (Osel İlaç,Turkey) and Marcaine %0.5 flacon (AstraZeneca®, London, UK)"
89648601|NCT04521582|Experimental|Active Group|Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within ~1 week and measure blood pressure again. If found high, the participant will be referred to the nearest Health Post. At the Health Posts, if FB-CHWs confirms the diagnosis of hypertension, they will prescribe amlodipine 5 mg/d according to the study protocol and ask the patient to return in ~2 weeks. If blood pressure is controlled (<140/90 mmHg) after ~2 weeks, FB-CHWs will refill amlodipine 5 mg/d for 3 months. If not, FB-CHWs will increase the dose to 10 mg/d and follow up in ~2 weeks. If still not controlled with amlodipine 10 mg, FB-CHWs will refer the patient to the Regional Hospital in Pokhara. In addition, FCHVs will visit patients' homes 3 times (at 3-, 6-, and 9-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment.
89648602|NCT04521582|Active Comparator|Comparison Group|"Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within a week or so and measure the blood pressure again. If found high, the participant will be referred to a healthcare facility (the usual care) which can diagnose and manage hypertension. In addition, FCHVs will visit patients' homes once (around 3-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment."
89648603|NCT03588169||patients hospitalized at the Dijon University Hospital|Patients hospitalized in the endocrinology, digestive surgery, pneumology and geriatric units of the Dijon University Hospital with a prescription for ONS
89648604|NCT01482884|Experimental|1|tralokinumab (CAT-354) sc injection
89648605|NCT01482884|Placebo Comparator|2|placebo sc injection
89648606|NCT03588091|Experimental|arm1|Pyrotinib Plus trastuzumab and docetaxel
89648607|NCT03588091|Placebo Comparator|arm2|placebo plus trastuzumab and docetaxel
89648608|NCT04140253|Active Comparator|Standard Duloxetine treatment|Peroral treatment with duloxetine at a dose of 40 mg twice a day
89648609|NCT04140253|Experimental|Standard Duloxetine treatment with PFMT|Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.
89648610|NCT05114304||Pulmonary Langerhans cell histiocytosis (PLCH)|Adults with pulmonary Langerhans cell histiocytosis
89648611|NCT01518374|Experimental|Florbetapir-PET Scans|
89648612|NCT04359654|Experimental|Dornase alfa treatment|Best available care and nebulised dornase alfa [2.5 mg BID] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of ventilatory failure
89648613|NCT04359654|No Intervention|Best available care|Best available standard of care
89648614|NCT03588013|Experimental|Moderate/severe malnourishment|Pakistani children from age 0 to 6 months with weight for height Z score (WHZ) < -2 at the time of enrollment. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth. Those participants who remain WHZ < -2 despite interventions are eligible for medical evaluation for more advanced workup of malnutrition, including UGI endoscopy and biopsy.
89648615|NCT03588013|Active Comparator|Well nourished children|Pakistani children from age 0 to 6 months who would be growing normally, with WHZ > 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
89212815|NCT04039724|Experimental|Sequence A|"Period 1 : HCP0605+HGP0816~Period 2 : HCP1305"
89212816|NCT04039724|Experimental|Sequence B|"Period 1 : HCP1305~Period 2 : HCP0605+HGP0816"
89212817|NCT00878696||Tinnitus|Tinnitus patients
89212818|NCT00878774|Experimental|Cohort 1|ToleroMune Ragweed, subjects to receive either active or placebo comparator
89212819|NCT00878774|Experimental|Cohort 2|ToleroMune Ragweed or placebo comparator
89212820|NCT00878774|Experimental|Cohort 3|ToleroMune Ragweed or placebo comparator
89212821|NCT00878774|Experimental|Cohort 4|ToleroMune Ragweed or placebo comparator
89212822|NCT00878774|Experimental|Cohort 5|ToleroMune Ragweed or placebo comparator
89212823|NCT00868010|Experimental|1: donepezil|Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
89045148|NCT03026504|Experimental|Baricitinib Therapy|4 milligrams oral Baricitinib daily for 52 weeks
89045149|NCT02073123|Experimental|Indoximod + Ipilimumab|"Indoximod will be administered at 1200mg BID by mouth.~Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.~Indoximod and ipilimumab will be dosed concurrently. Indoximod will be dosed twice daily on all days of each 21 day cycles (segment 1). Ipilimumab will be dosed on the 1st day of each 21 day cycle for the first 4 cycles. Indoximod dosing will continue after all 4 doses of ipilimumab are administered (segment 2, 28-day cycles).~Patients will continue until they experience disease progression or limiting toxicity."
89045150|NCT02073123|Experimental|Indoximod + Pembrolizumab|"Indoximod will be administered at 1200mg BID by mouth.~Pembrolizumab administered intravenously at 2 mg/kg every three weeks."
89045151|NCT02073123|Experimental|Indoximod + Nivolumab|"Indoximod will be administered at 1200mg BID by mouth.~Nivolumab administered intravenously at 240 mg every 2 weeks."
89045152|NCT02914145|Other|Participants|Any individual from the study area who participates and is medicated with DHAp in the mass drug administration campaign
89648616|NCT03588013|No Intervention|US children with celiac disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
89648617|NCT03588013|No Intervention|US children with Crohn's disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. As some differentially expressed ileal gene signatures for Crohn's disease bear remarkable similarities to individual gene expression patterns previously reported for EE, children under the age of 10 years with newly diagnosed Crohn's disease per endoscopy at CCHMC will be enrolled to study these similarities and any differences
89648618|NCT03588013|No Intervention|Healthy age-matched US children|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Number of upper gastrointestinal endoscopies performed in children less than 2 years old are limited in Pakistan, therefore US age-matched controls will be used; healthy children < 3 years old will be enrolled, who will undergo endoscopy at CCHMC as part of a diagnostic workup for digestive symptoms, but whose biopsies and diagnoses are not supportive of eosinophilic esophagitis, celiac disease, or inflammatory bowel disease, and who were not treated with antibiotics ≤ 4 weeks prior to endoscopy.
89648619|NCT04436172|No Intervention|pre intervention|Before intervention
89648620|NCT04436172|Experimental|post intervention|Received soinal anesthesia
89648621|NCT03446989|Experimental|Case management|Those who did not agree to participate in the NLCM were enrolled into the control group and received the standard care: visits to their RA physicians on a regular basis with health education administered by a ward nurse during each visit. The education sessions lasted for approximately 15 minutes and consisted of consultation about disease symptoms, related treatments, and disease management.
89648622|NCT04740060|Experimental|Augmented Feedback without Virtual Reality(VR)|
89648623|NCT04740060|Experimental|Augmented Feedback with Non-Game based VR|
89648624|NCT04740060|Experimental|Augmented Feedback with Game based VR|
89648625|NCT01481324||Functioning Pressure Sensor Group|This group will have a functioning pressure sensor placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
89648626|NCT01481324||Non-Functioning Pressure Sensor Group|This group will have a non-functioning pressure sensor (a placebo) placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
89648627|NCT01481324||No Sensor Group|This group will not have a pressure sensor placed on the foot ankle orthosis.
89648628|NCT04080986|No Intervention|Standard Arm|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
89688572|NCT03403049|Experimental|Arm 1|Dose-escalation phase I clinical study. In the initial dose levels, 'dose-escalation' refers to an increase in the radiotherapy dose delivered using carbon ion radiotherapy along with a corresponding decrease in the dose delivered using photons.
89045153|NCT02913989||Doctors from Medical Specialities|Doctors from Medical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
89045154|NCT02913989||Doctors from Surgical Specialities|Doctors from Surgical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
89045155|NCT00554892|Active Comparator|1|Bowel preparation
89045156|NCT00554892|Experimental|2|without bowel preparation
89045157|NCT01626573|Experimental|Itacitinib 400 mg twice a day|Itacitinib 400 mg twice a day
89045158|NCT01626573|Placebo Comparator|Itacitinib 400 mg placebo twice a day|Itacitinib 400 mg placebo twice a day
89045159|NCT01626573|Experimental|Itacitinib 100 mg twice a day|This dose group will be studied twice during the study.
89045160|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo twice a day|This dose group will be studied twice during the study.
89045161|NCT01626573|Experimental|Itacitinib 100mg once a day|Itacitinib 100mg once a day
89045162|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo once a day|Itacitinib 100 mg placebo once a day
89045163|NCT01626573|Experimental|Itacitinib 200 mg twice a day|Itacitinib 200 mg twice a day
89045164|NCT01626573|Placebo Comparator|Itacitinib 200 mg placebo twice a day|Itacitinib 200 mg placebo twice a day
89045165|NCT01626573|Experimental|Itacitinib 300 mg once a day|Itacitinib 300 mg once a day
89045166|NCT01626573|Placebo Comparator|Itacitinib 300 mg placebo once a day|Itacitinib 300 mg placebo once a day
89045167|NCT01626573|Experimental|Itacitinib 600 mg once a day|Itacitinib 600 mg once a day
89045168|NCT01626573|Placebo Comparator|Itacitinib 600 mg placebo once a day|Itacitinib 600 mg placebo once a day
89648629|NCT04080986|Active Comparator|Double Sequential Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
89648630|NCT04080986|Active Comparator|Vector Change Defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
89648631|NCT03587779|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
89648632|NCT03587779|Experimental|Desflurane|Anesthesia is maintained with desflurane.
89648633|NCT05580211|Other|Investigational Stimulation Pattern 1-Randomized|
89648634|NCT05580211|Other|Investigational Stimulation Pattern 2-Randomized|
89648635|NCT05580211|Other|Investigational Stimulation Pattern-Open Label|
89648636|NCT05580133||Peroneus Longus Tendon autograft|All-Inside Single-Bundle for ACL Reconstruction with Full Thickness of the Peroneus Longus Tendon
89648637|NCT05580133||six-strand-hamstring autograft|All-Inside Single-Bundle for ACL Reconstruction with six-strand-hamstring autograft
89648638|NCT04688502|Experimental|high intensity interval training wearing a face mask|high intensity interval training wearing a face mask
89648639|NCT04688502|Active Comparator|high intensity interval training wearing no face mask|high intensity interval training wearing no face mask
89648640|NCT04688502|Experimental|continuous exercise training wearing a face mask|continuous exercise training wearing a face mask
89648641|NCT04688502|Active Comparator|continuous exercise training wearing no face mask|continuous exercise training wearing no face mask
89648642|NCT03587545|Experimental|Healthy probiotic group LGG|Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
89648643|NCT03587545|Experimental|Healthy probiotic group LAMBR2|Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
89648644|NCT03587545|Placebo Comparator|Healthy placebo group|"Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.~Placebo nasal spray."
89648645|NCT03587545|Experimental|CRS probiotic group LGG|Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
89648646|NCT03587545|Experimental|CRS probiotic group LAMBR2|Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
89648647|NCT03587545|Placebo Comparator|CRS placebo group|Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.
89648648|NCT04188756|Other|Exercise|Group under exercise training for 15 weeks with High intenstiy interval training under medical control
88992966|NCT05139927|Experimental|Condition 16|Component A: motivational interviewing counseling - OFF Component B: Text message intervention - OFF Component C: Peer education - OFF Component D: Self test kit
88992967|NCT05128682|Other|Urodynamic testing with and without pudendal nerve stimulation|"The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with the stimulation sets turned off and then turned on. At the end of the UDT the settings will be returned to the previously set therapeutic values. The neuromodulation settings constitute the dose and can include the voltage/current amplitude, frequency, pulse width, on time/off time duration and electrode polarity assignments. These parameters are limited by the available ranges of the approved neurostimulation device and will be adjusted during the study by the principal investigator to stay within the safe and comfortable levels for each individual study subject."
88992968|NCT05119465||Group|Hospitalized Patients with Corona virus disease
89648649|NCT04188756|No Intervention|Control|Group with standard care according to current guidelines
89648650|NCT03587467||health|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~smooth and soft stool like sausage or snake~Voluntary participate in this study"
89648651|NCT03587467||chronic hepatitis b carrier|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic HBV infection in EASL 2017 Clinical Practice Guidelines on the management"
88992969|NCT05115929|Active Comparator|Decompressive Craniectomy Group|participants with severe TBI randomly assigned as described in the study protocol
88992970|NCT05115929|Active Comparator|Decompressive Laparotomy Group|participants with severe TBI randomly assigned as described in the study protocol
88992971|NCT05111548|Experimental|Active stimulation + cognitive training|Participants receive 10 sessions of 'active' non-invasive brain stimulation (tDCS) with concurrent cognitive training (BrainHQ).
88992972|NCT05111548|Sham Comparator|Inactive stimulation + cognitive training|Participants receive 10 sessions of 'inactive' non-invasive brain stimulation (tDCS) with concurrent cognitive training (BrainHQ).
89648652|NCT03587467||chronic hepatitis b|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
89648653|NCT03587467||decompensated cirrhosis|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
89648654|NCT04688190||Transcatheter Mitral Valve Implantation (TMVI)|Patients with successful TMVI screening, who underwent Transcatheter Mitral Valve Implantation subsequently. All devices may be included.
89648655|NCT04688190||Interventional mitral valve edge-to-edge repair (E2E)|Patients with TMVI screening failure, who subsequently underwent interventional mitral valve edge-to-edge repair.
89648656|NCT04688190||Mitral valve surgery (Surgery)|Patients with TMVI screening failure, who subsequently underwent mitral valve surgery (i.e., mitral valve repair or replacement).
89648657|NCT04688190||Medical therapy (OMT)|Patients with TMVI screening failure, who subsequently underwent conservative or optimal medical therapy (OMT).
89648658|NCT04405921|Experimental|Hydroxychloroquine associated to azithromycin|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. Azithromycin: 500 mg at day 1 then 250 mg/day for 4 days. with standard of care in association to treatments.
89648659|NCT04405921|Active Comparator|Hydroxychloroquine with placebo|Hydroxychloroquine: 200 mg twice a day orally or via gastric tube (total 400 mg/day) for 5 days. with standard of care in association to treatments.
89648660|NCT05113836||Any patient hospitalised in intensive care for a COVID-19 infection.|Any patient hospitalised in intensive care for a COVID-19 infection. The health emergency of this pandemic and the potential therapeutic action of HDL particles justify the choice of this population for study.
89648661|NCT05583565|Experimental|study group|receiving sensory integration approach
89648662|NCT05583565|Active Comparator|control group|receiving conventional physical therapy
89648663|NCT04516902|Experimental|100 μg LSD + MDMA placebo|100 μg LSD + MDMA placebo
89648664|NCT04516902|Experimental|LSD placebo +100 mg MDMA|LSD placebo +100 mg MDMA
89648665|NCT04516902|Experimental|100 μg LSD + 100 mg MDMA|100 μg LSD + 100 mg MDMA
89648666|NCT04516902|Placebo Comparator|LSD placebo+ MDMA placebo|LSD placebo+ MDMA placebo
89648667|NCT03581149|Active Comparator|Citrafleet®|Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
89648668|NCT03581149|Active Comparator|MoviPrep®|Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
89648669|NCT05113602|Experimental|Simultaneous acquisition of EEG signals|
89648670|NCT05113134|Experimental|Transvaginal natural orifice specimen extraction (NOSE)|The outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who underwent multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder
89648671|NCT04406077|Experimental|Intervention|Patients suffering from hydrocele, underwent treatment using Ligasure device.
89648672|NCT04405531|Experimental|task-oriented training(TOT)|The first phase of the TOT, functional activity analysis, was performed for the activities, for which performance problem was determined by Canadian Occupational Performance Measure (COPM) and Functional Independence Measure for Children (WeeFIM). In the second phase, the occupational performance, fatigue and functional independence levels that prevent the realization of the activity were determined by functional activity analysis. These designated occupational performance, fatigue and functional independence levels constitute the task of this study, as we aim to improve children's functionality. In the third phase, various functional activities including these tasks were executed. The TOT was practiced by following the above mentioned steps for each performance area. All the activities were designed for the inpatient settings of children.
89648673|NCT04405531|Experimental|conventional occupational therapy (COT)|The treatment efficacy determined by the therapist was provided by considering the functional level in order to achieve the desired goal by the participant. The COT included functional activities based on the client-centered principles of the neuro-developmental approach. All the sessions started with relaxation training combined with breathing exercises. At the end of approximately 10 minutes of application time, individualized functional activities were implemented.
89648674|NCT02487420|Other|Arm 18m|arm 18m: 6 months between step 1 and step 2; 6 months between step 2 and step 3, 3 months between all other steps step by step gradual introduction of egg containing food products during 18 months, unless next step can not be taken
89648675|NCT02487420|Other|arm 30 m|arm 30m: 9 months between step 1 and step 2; 9 months between step 2 and step 3, 6 months between all other steps step by step gradual introduction of egg containing food products during 30 months, unless next step can not be taken
89648676|NCT05583409|Experimental|Osimertinib plus SBRT|SBRT with photon and dose is 40Gy/5F after three months after Osimertinib treatment
89648677|NCT05583409|Active Comparator|Osimertinib|Osimertinib 80mg, po, Qd
89648678|NCT04405453|Active Comparator|Trapezius Muscle İnjection (TMI) group|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
89648679|NCT04405453|Active Comparator|Erector Spina Plane Block (ESPB) group|ESPB group in the 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive. Pain severity of the patients will evaluate by visual analog scale before (week 0) and after (week 1,2,3,4) the injections
89648680|NCT05112588|Experimental|Individual and digital support Intervention (IDSI)|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit according to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
89648681|NCT05112588|No Intervention|Care as usual|One arm including in women with gestational diabetes who will be subject to care as usual at the Health care unit.
89648682|NCT05112588|No Intervention|Control|One arm with women with normal glucose tolerance as control. Will be examined carefully at the same time-point as women in the intervention.
88992973|NCT05110170|Experimental|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
89648683|NCT03020953|Experimental|Exercise + Estrogen|Strength training 3 times a week for 12 weeks. Estrogen patches which provide 100 um pr. 24 hours.
89648684|NCT03020953|Active Comparator|Exercise + Placebo|Strength training 3 times a week for 12 weeks. Placebo patches.
89648685|NCT05112510||event group|The patients with nasopharyngeal carcinoma developed distant metastasis or recurrence after standard treatment.
89648686|NCT05112510||non-event group|The patients with nasopharyngeal carcinoma did not develop distant metastasis or recurrence after standard treatment.
89688573|NCT00944047|Experimental|Intervention Arm|Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
89688574|NCT03402971||healthy pregnant+healthy fetus|healthy pregnant women with suspected healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
89045169|NCT01621152|Other|Conventional management arm|Patients with AKI receive standard of care in the conventional manner by the primary clinicians
89045170|NCT01621152|Active Comparator|AKI sniffer instigated AKI management|primary clinicians for the AKI patients in this arm receive a verbal alert and reminder of KDIGO guidelines.
89045171|NCT02914028|Active Comparator|Tramadol and paracetamol|subjects were administered intravenous analgesia (control group) Tramadol 100 mg and paracetamol 1000 mg at the end of the surgery
89648687|NCT05112354|Experimental|the main group|"Management plan~If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator"
89648688|NCT03580993||SBT Completers|Those patients who successfully complete a spontaneous breathing trial of 2 hours.
89648689|NCT03580993||SBT Non-completers|Those patients who fail to complete a spontaneous breathing trial of 2 hours.
89648690|NCT03580915|Experimental|Functional Literacy Intervention|The intervention group will receive the functional literacy program in which, in small groups, participants learn literacy skills in the context of daily life activities such as shopping, meal preparation, and transportation use.
89648691|NCT03580915|Active Comparator|Functional Literacy Control|The control group will not receive intervention but the Usual Care Management Services.
89648692|NCT05109624|No Intervention|group(A) control group|pronation cycles each last for 16 hours every 24 hours
89648693|NCT05109624|Active Comparator|group(B)|pronation cycles each last for 24 hours followed by 6 hours supine position
89648694|NCT05105334|Experimental|Nonablative fractional laser alone|
89648695|NCT05105334|Experimental|Nonablative fractional laser alternating with microneedling with radiofrequency|
89648696|NCT03587155||Mutation|Embryo or infant with ASNS mutation.
89648697|NCT03587155||Control|Embryo or infant without ASNS mutation.
89648698|NCT03639324|Experimental|Dose Combination 1-1|idelalisib + venetoclax
89648699|NCT03639324|Experimental|Dose Combination 1-2|idelalisib + venetoclax
89648700|NCT03639324|Experimental|Dose Combination 1-3|idelalisib + venetoclax
89648701|NCT03639324|Experimental|Dose Combination 1-4|idelalisib + venetoclax
89648702|NCT03639324|Experimental|Sub-Trial Dose Combination 2-1|idelalisib + venetoclax
89648703|NCT03639324|Experimental|Sub-Trial Dose Combination 2-2|idelalisib + venetoclax
89648704|NCT05583253|Active Comparator|Vitrectomy group with previous refractive surgery|Cases with primary retinal detachment that are prepared for pars-plana vitrectomy with previous history of refractive surgery.
89648705|NCT05583253|Active Comparator|Vitrectomy group with no previous intraocular surgery|Subjects with primary retinal detachment that are prepared for pars-plana vitrectomy with no previous history of intraocular surgery.
89045172|NCT02914028|Active Comparator|transversus abdominis plane block|patients that applied transversus abdominis plane block at the end of the surgery after given intravenous analgesia
89045173|NCT02913911|Experimental|Feedback|Subjects will be trained using the sit-to-stand weight-taking machine. Prior to the training, subjects sit in a standard sitting position. Then they will be instructed to take most of their body-weight onto the legs while they standing up where the light bars will be gradually lightened from the red, yellow and green zones according to the level of LLL. Then they stand up, hold a standing position for 3-5 seconds and sit-down with always maximize their body-weight onto their legs during performing the task in which the green zone will always be lightened.
89045174|NCT02913911|Sham Comparator|No feedback|Subjects will be trained using the same instruction and protocol as the experimental group, but without the provision of external feedback.
89045175|NCT02065284|Active Comparator|Walking-Rhythmic Auditory Stimulation|Walking daily with Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
89045176|NCT02065284|Active Comparator|Walking- only|Walking daily with no Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
89045177|NCT02065284|Active Comparator|Rhythmic Auditory Stimulation (RAS)only|Listening to based music only daily for 4 weeks
89045178|NCT02913833|Experimental|Daily pain evaluation|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
89045179|NCT02913833|No Intervention|Control|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
89648706|NCT03571386||Mild to Moderate Depression|Patients who currently have mild to moderate severity of depression symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
89648707|NCT03571386||Mild to Moderate Anxiety|Patients who currently have mild to moderate severity of anxiety symptoms are who are receiving Mindfulness-Based Cognitive Therapy (MBCT) in a group setting as standard of care will be recruited for this arm.
89648708|NCT03571386||High Stress|Patients with a history of reported stress who are receiving Mindfulness-Based Stress Reduction (MBSR) in a group setting as standard of care will be recruited for this study. All patients are eligible.
89648709|NCT05099562|Experimental|Acupuncture group|This is a one-arm study. Breast cancer patients with peripheral neuropathy were measured using the FACT/ GOG-Ntx and EORTC QLQ-CIPN20 scales. Our clinical study included breast cancer patients diagnosed with peripheral neurotoxicity caused by taxanes-based drugs who would receive acupuncture treatment. Neurotoxicity was identified based on NCI-CTCAE 5.0 for daily or almost daily numbness in the hands and feet, tingling, and other symptoms of peripheral neuropathy over the past two to three weeks. Blood samples were collected from patients to detect SNP associated with neurotoxicity.
89648710|NCT03542994|Other|Cohort 1|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 66 mg, capsule, once daily, 15 days
89648711|NCT03542994|Other|Cohort 2|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 15 days
89045180|NCT02913755|Experimental|Intervention group|Repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
89045181|NCT02913755|Active Comparator|Lagged Control Group|2 week period of treatment as usual followed by repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
89045182|NCT02064426|Experimental|Molidustat (BAY85-3934)|
89648712|NCT03542994|Other|Cohort 3|12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 15 days
89648713|NCT03542994|Other|Cohort 4|12 subjects with mild to moderate psoriasis; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days
89648714|NCT03542994|Other|Cohort 5|24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days
89648715|NCT03542994|Other|Cohort 6|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 660 mg, capsule, once daily, 29 days"
89648716|NCT03542994|Other|Cohort 7|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
89648717|NCT03542994|Other|Cohort 8|up to 24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3g, capsule, once daily, 29 days
89648718|NCT03542994|Other|Cohort 9|"up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo.~Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days"
89648719|NCT03586843|Experimental|Part A: Treatment Sequence ABC: JNJ-64565111|Participants will receive Treatment A (JNJ-64565111 subcutaneous [SC] administration in the upper arm in fasted condition) on Day 1 of Treatment Period 1; followed by Treatment B (JNJ-64565111 SC administration in the thigh in fasted condition) on Day 1 of Treatment Period 2 and then Treatment C (JNJ-64565111 SC administration in the abdomen in fasted condition) on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last pharmacokinetic (PK) sample collection and dosing on Day 1 of subsequent treatment period.
89648720|NCT03586843|Experimental|Part A: Treatment Sequence ACB: JNJ-64565111|Participants will receive Treatment A on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
89648721|NCT03586843|Experimental|Part A: Treatment Sequence BAC: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment C on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
89648722|NCT03586843|Experimental|Part A: Treatment Sequence BCA: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
89648723|NCT03586843|Experimental|Part A: Treatment Sequence CAB: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
89648724|NCT03586843|Experimental|Part A: Treatment Sequence CBA: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment B on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
89648725|NCT03586843|Experimental|Part B: JNJ-64565111|Participants will receive a single SC ascending doses of JNJ-64565111 on Days 1, 8, 15, 22, 29 and 36.
89648726|NCT05582863|Experimental|Intervention group.|"The experimental group attended a VR exercise routine twice a week for 12 weeks.~Device:1 computer virtual reality online software and 3 large projectors were used to project videos on the wall in a wrap-around state."
89648727|NCT05582863|No Intervention|Control group.|Participants in the control group received no intervention and had normal daily activites.
89648728|NCT03580681|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
89648729|NCT03580681|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
89648730|NCT03580603|Experimental|Antibiotic visualization tool|Provider will answer microbiological sensitivity questions using a new antibiotic visualization tool.
89648731|NCT03580603|No Intervention|Standard practice|Provider will answer microbiological sensitivity questions using standard medical record tools.
89648732|NCT03437616|Experimental|Tulppa rehabilitation|8-10 weekly 3-hour group sessions and two follow-up sessions (6 and 12 months).
89648733|NCT03437616|No Intervention|Control group|Control group does not receive Tulppa rehabilitation during the study.
89648734|NCT03586765||Experimental group|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
89648735|NCT03407040||1/Cancer Patients|Patients with a cancer diagnosis enrolled on protocol 03-C-0277
89648736|NCT03580447|Experimental|Citrus extract|During this period participants receive daily citrus extract supplements for four weeks
89648737|NCT03580447|Placebo Comparator|Placebo|During this period participants receive daily maltodextrin supplements for four week
89045183|NCT02064426|Active Comparator|Epoetin alfa/beta|
89045184|NCT00899301||Patients with Breast Cancer|
89045185|NCT00899301||Patients without breast cancer|
89045186|NCT02913677|Active Comparator|group 1|prolonged minimal enteral nutrition
89045187|NCT02913677|Placebo Comparator|group 2|slowly advancing enteral nutrition
89648738|NCT03177421|Experimental|Bedtime media use and sleep problems|This arm will receive screening for and associated clinical decision support on sleep problems and bedtime media use.
89648739|NCT03177421|Other|Sleep problems only|This arm will receive screening for and associated clinical decision support on sleep problems only.
89648740|NCT03100578|Experimental|PLASTIC STENT|"Endoscopic double pigtail plastic stent, with formal indication on pancreatic collection, according to the instruction forms of the manufacturer.~Interventions associated:~EUS-guided transmural drainage of pancretic collection: PLASTIC STENT."
89648741|NCT03100578|Active Comparator|SELF EXPANDABLE METALLIC STENT|"Lumen apposing metal stent with formal indicaction on pancreatic collection, according to the manufacturer instruction forms.~Interventions associated:~EUS-guided transmural drainage of pancretic collection: METALLIC STENT."
89648742|NCT03069300|Experimental|prednisolone+NAC|40mg prednisolone once a day for 28 days and 30 minutes of intravenous NAC at 150mg/kg in 250ml 5% dextrose solution followed by 4 hours of intravenous NAC at 50mg/kg in 500ml 5% dextrose solution, followed by 16 hours of intravenous NAC at 100 mg/kg in 1000ml 5% dextrose solution, followed by 4 days of intravenous NAC at 100mg/kg/day in 1000ml 5% dextrose solution
89648743|NCT03069300|No Intervention|prednisolone|40mg prednisolone for 28 days
89648744|NCT05582317|Active Comparator|Biodentine|20 primary molars were treated by Biodentine
89648745|NCT05582317|Active Comparator|Simvastatin|20 primary molars were treated by Biodentine
89648746|NCT05582317|Active Comparator|combination of Biodentine and Simvastatin|20 primary molars were treated by Biodentine
89648747|NCT03977064|Experimental|Intensive treatment group|The intensive treatment group will pass a life-style intervention program including consequent escalation of measures to reach sustained reduction of 10% of initial body weight at minimum.
89648748|NCT03977064|No Intervention|Standard treatment group|Patients will be taken care of by general physician without lifestyle program.
89648749|NCT03891355|Experimental|Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D)|"Carfilzomib (K) (maximum period of treatment= 24 cycles)~K on days 1-2, 8-9, 15-16 during cycles 1-12. The dosage of K will be 20 mg/m2 10' iv infusion on day 1 and 2 during cycle 1 and then 27 mg/m2 10' iv infusion thereafter;~K: on days 1-2, 15-16 during cycles 13-24. The dosage of K will be 27 mg/m2 10' iv infusion. Lenalidomide (R) (maximum period of treatment= 24 cycles)~R: 25 mg/daily on day 1 to 21 of a 28 days course; for patients with creatinine clearance ≥ 30 mL/min but < 50 mL/min the dosage of R will be 10 mg/daily on day 1 to 21 of a 28 days course.~Dexamethasone (D) (maximum period of treatment= 24 cycles) PO or IV D on days 1-2, 8-9, 15-16, 22-23. The dosage will be 20 mg between 30 minutes and 4 hours prior to K. For patients older than 75 years the dosage may be reduced at 10 mg."
89648750|NCT03580291|Experimental|Mesenchymal stem cells|"The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.~Dexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.~A sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort."
89648751|NCT03580291|Active Comparator|Mycophenolate Mofetil|The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
89648752|NCT03898284||Impulse Oscillometry|Patients with Idiopathic Pulmonary Fibrosis. The objective is to determine whether another lung function technique, impulse oscillometry, is of interest to identify disease progression before changes in forced vital capacity can be ascertained.
89648753|NCT05028738|Active Comparator|Intermittent Theta Burst Stimulation (iTBS)|iTBS to the L-DLPFC
89648754|NCT05028738|Active Comparator|Low Frequency Right (LFR)|1Hz stimulation to the R-DLPFC
89648755|NCT02936388|Experimental|Arm A|SIRT: Transarterial radioembolisation with Yttrium-90-bearing resin microspheres (SIR-Spheres®)
89648756|NCT02936388|Active Comparator|Arm B|DSM-TACE: Transarterial chemoembolisation with Cisplatin and EmboCept® S starch microspheres (PharmaCept GmbH)
89648757|NCT03586141|Other|noninvasive measurement of hemoglobin|All participating patients are measured by the Pronto® hemoglobin measurement tool
89648758|NCT03020563|Active Comparator|Liposomal Bupivacaine|Time release Bupivacaine
89648759|NCT03020563|Placebo Comparator|Bupivacaine|Immediate Acting Bupivacaine
89648760|NCT04591626|Experimental|1.5 Milligrams (mg) Dulaglutide|Participants received 1.5 mg Dulaglutide administered once weekly (QW) subcutaneously (SC) as add-on to titrated treat-to-target (TTT) dose of Insulin Glargine given SC, along with metformin and/or acarbose.
89648761|NCT04591626|Placebo Comparator|Placebo|Participants received placebo administered QW SC as add-on to titrated TTT dose of insulin glargine given SC, along with metformin and/or acarbose.
89648762|NCT05702203|No Intervention|Standard Care|Infants allocated to the control group will receive standard care during admission. Standard care includes involvement of a multi-professional team consisting of medical and nursing team, psychologists/psychiatrists, social workers, breastfeeding counsellor, speech therapist, nutritional counsellor and physiotherapists
89648763|NCT05702203|Experimental|Creative Music Therapy|A certified, well-trained and experienced music therapist will formulate an individualized, culturally adapted treatment plan based on an initial infant-parent assessment, which includes assessment of parental needs, musical heritage, culture, context, and parental integration in the therapeutic process. During hospitalization 3 times per week 20 minutes of creative music therapy sessions will be performed, a minimum of 10 therapy session. After discharge, every other two weeks a music therapy session will be performed at home until the age of six months.
89648764|NCT03580135|Experimental|Propolis powder|"resin (50%),~vegetable Balsam, wax~essential aromatic oils (30%)~salivary secretions (10%)~pollen(5%)~other substances (5%) including amino acids~,ethanol vitamin A, B complex, and E, minerals, steroids~ﬂavonoids. The most important pharmacologically active constituents in propolis are ﬂavonoids, which are well-known compounds which have antioxidant, anti-bacterial, antifungal, antiviral, and anti-inﬂammatory properties.~Other ingredients: carob powder (free flow agent). Contains no yeast, salt, sugar, starch, milk, preservatives or colors."
89648765|NCT03580135|Active Comparator|Mineral Tri Oxide|"Consists of calcium oxide and silicon dioxide.When these raw materials are blended, they produce tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite.~A radiopacifier (bismuth oxide) is added to the cement for dental radiological diagnosis."
89648766|NCT03379272|Active Comparator|GOLD STANDARD|RECORDING WITH EEG GOLD STANDARD
89648767|NCT03379272|Experimental|NEURONAUTE|RECORDING WITH THE NEURONAUTE
89648768|NCT01890252|Experimental|Hyper CL|Hyper osmotic contact lens
89648769|NCT01890252|Experimental|Hyper CL + Saline solution|combined treatment of hyper osmotic contact lens+ hypertonic solution
89648770|NCT01890252|Active Comparator|saline solution|hypertonic solution
89648771|NCT04765579||4in1|4in1 block will be applied in the operation room
89648772|NCT04765579||medical|medical analgesics will be applied in the service
89648773|NCT04369482|Active Comparator|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
89648774|NCT04369482|Active Comparator|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
89648775|NCT03585985||Group 1|10 patients aged above 70 years with typical geriatric multimorbidity or aged above 80 years otherwise, patient in the hospital Franziskushospital Aachen on the ward of geriatric medicine
89648776|NCT03585985||Group 2|10 healthy elderly people above 70 years, healthy
89648777|NCT03585907|Experimental|Modified Atkins Diet (MAD)|A diet that can produce ketones
89648778|NCT03585907|Active Comparator|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND). A diet that has been indicated to be helpful in preventing or decreasing cognitive decline.
89648779|NCT03585829|Active Comparator|hydrocortisone|hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner
89648780|NCT03585829|Active Comparator|prednisolone|Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner
89648781|NCT03587389|Experimental|Rotavirus vaccine|"The Rotarix vaccine package consist of 1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1.~The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix is for oral use only and should under no circumstancies be injected.~All participating infants will receive two doses of Rotarix vaccine following the standard Rotarix immunization protocol."
89648782|NCT03585751|Active Comparator|Triple antibiotic paste|Pulpectomy for primary molars, triple antibiotic mix is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
89648783|NCT03585751|Experimental|3mixstatin|Pulpectomy for primary molars, 3 Mixstatin ( mix of simvastatin and triple antibiotic mix ) is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
89648784|NCT03585751|Experimental|simvastatin|Pulpectomy for primary molars, simvastatin is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
89648785|NCT03583333|Experimental|IMI/REL FDC|Imipenem/cilastatin/relebactam (IMI/REL) administered intravenously (IV) as a fixed-dose combination (FDC) at a dosage of 500 mg IMI/250 mg REL, once every 6 hours for a minimum 7 days, up to 14 days. At the start of IMI/REL treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
89648786|NCT03583333|Active Comparator|PIP/TAZ FDC|Piperacillin/tazobactam (PIP/TAZ ) administered IV as a FDC at a dosage of 4000 mg PIP/500 mg TAZ once every 6 hours for a minimum 7 days, up to 14 days. At the start of PIP/TAZ treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
89648787|NCT03585673|Experimental|Docetaxel-PM+Oxaliplatin|"Docetaxel-PM 35mg/m2 D1, 8 I.V.~Oxaliplatin 120mg/m2 D1 I.V. Every 3 weeks till progression"
89648788|NCT01602510|Experimental|Lamotrigine CD|lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg
89648789|NCT01602510|Placebo Comparator|Placebo|Placebo
89648790|NCT04952142|Experimental|minimal water exchange|We suctioned the lumen and infused water by constant pressure on the air-water valve button of the endoscope at the rectum to open the lumen.
89648791|NCT04952142|No Intervention|traditional water exchange colonoscopy|The water exchange colonoscopy reached the cecum through continuous infusion and suction of water in the whole colon via an additional flushing pump.
89648792|NCT03887533|Experimental|VTS-270 at 500 mg/kg|Participant received dose of 500 mg/kg of intravenous VTS-270 administered over 2 hours monthly for 12 months. Participant also received 900 mg intrathecal VTS-270 therapy monthly for 18 months.
89648793|NCT03887533|Experimental|VTS-270 at 1000 mg/kg|Participant received 1000 mg/kg of intravenous VTS-270 over 4 hours monthly for 12 months. Participant also received 900 mg intrathecal VTS-270 therapy monthly for 18 months.
88992974|NCT05110170|Active Comparator|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
88992975|NCT05098145|Experimental|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood cells and delivered as a single infusion with a nonmyeloablative conditioning regimen.
89045188|NCT02913716|Experimental|Defactinib treatment|Single dose of 400 mg [14C]-defactinib, oral suspension
89045189|NCT02063997|Experimental|Arhalofenate 600 mg|
89045190|NCT02063997|Experimental|Arhalofenate 800 mg|
89045191|NCT02063997|Active Comparator|Allopurinol 300 mg; colchicine 0.6 mg|
89045192|NCT02063997|Active Comparator|Allopurinol 300 mg|
89045193|NCT02063997|Placebo Comparator|Placebo|
89045194|NCT02913443|Experimental|Introductory Cohort - 400 μg RO7051790|Introductory cohort to ensure participant safety, prior to the dose escalation study. 400 μg of RO7051790 was administered to two (2) participants followed by a 21-day DLT observation period.
89045195|NCT02913443|Experimental|Dose Escalation - 1000 μg RO7051790|1000 μg of RO7051790 was administered to six (6) participants once every 3 weeks (Q3W).
89045196|NCT02913443|Experimental|Dose Escalation - 1300 μg RO7051790|1300 μg of RO7051790 was administered to seven (7) participants once every 3 weeks (Q3W).
89648794|NCT04511754|Experimental|Experiential Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the experiential training condition, the trainees will receive information about the skills with examples and will have opportunity to practice using short video clips of actors portraying clients. The trainees will be asked to respond to the short clips using the skills they learned. A trainer (a graduate student in clinical psychology) will pause and process the trainees' reactions after they respond to each practice video clip and will provide feedback to the trainees about their performance on the practice.
89648795|NCT04511754|Active Comparator|Standard Training Condition|Trainees will be taught the following skills during a single session: 1) Therapist in-session emotional-awareness and self-regulation; 2) Facilitating client disclosure of traumas and other difficult experiences; and 3) Helping clients access and experience adaptive emotions. In the standard training condition, the trainee will receive a lecture about the skills including rationale and research background, examples, and opportunities to ask questions. The standard training condition will not include opportunities for practice or live discussion and feedback from the trainer.
89648796|NCT03585439||Single cohort of operated patients|One group of patients: isthmic spondylolisthesis operated in our center using a double approach technique
89648797|NCT04945512|Experimental|Study group; Epidural catheter and PCA|Epidural catheter will be placed in the preoperative period. After induction, 10 ml of 0.25% bupivacaine will be administered through the epidural catheter and bupivacaine PCA will be started.
89648798|NCT04945512|No Intervention|Control group; No block, IC PCA|Postoperative pain control will be achieved with intravenous morphine PCA.
89648799|NCT04934982|Experimental|1|the group of LRH
89648800|NCT04934982|Active Comparator|2|the group of ARH
89648801|NCT03581071|Experimental|Step1:1mg in non-dialysis subject|
89648802|NCT03581071|Experimental|Step2-1:1mg in hemodialysis subjects|
89648803|NCT03581071|Experimental|Step2-2:6mg in non-dialysis subject|
89648804|NCT03581071|Experimental|Step3-1:11㎎ in hemodialysis subjects|
89648805|NCT03581071|Experimental|Step3-2:11㎎ in non-dialysis subject|
89648806|NCT04306458|Experimental|Robot assisted minimally invasive esophagectomy|Robot assisted minimally invasive esophagectomy
89648807|NCT04306458|Active Comparator|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
89648808|NCT04501926||Controls|Asthma patients who did not report asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
89648809|NCT04501926||Cases|Asthma patients that reported asthma exacerbations in the 12 months prior recruitment, defined by one of the following events because of asthma: oral corticosteroids use, emergency room visits, and/or hospitalizations.
89648810|NCT04161378||RHB-SG 01|Patients with early mobilization (< 2 days after the onset of symptoms)
89648811|NCT04161378||RHB-SG 02|Patients with delayed mobilization after AMI (>2 days after the onset of symptoms)
89648812|NCT05701813|Experimental|INOSITOLS|4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
89648813|NCT05701813|Placebo Comparator|PLACEBO|Cellulose 4.3 grams once a day for 90 days.
89648814|NCT03586921|Experimental|Enhanced usual care + group intervention|Intervention patients received enhanced primary care plus a 9-session group intervention. The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party. The patients from the intervention arm also received additional outreach from the Family Health Teams, including home delivery of psychotropic medication when needed and active outreach and engagement by community workers if patients missed group sessions.
89648815|NCT03586921|Active Comparator|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
89648816|NCT03586219|No Intervention|Control Arm|Standard preoperative and postoperative instructions will be provided to the study subjects
89648817|NCT03586219|Experimental|Intervention Arm|Intervention: Study subjects will receive opioid-specific educational patient pamphlets in addition to standard preoperative and postoperative instructions
89648818|NCT01675596|Experimental|Test|SAPIEN XT™ valve with the NovaFlex and NovaFlex+ delivery systems.
89648819|NCT03585361|Experimental|Intervention|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Also, health centers conduct data reviews of PPFP counseling, intra-facility referrals and uptake data. At community level, HEWs provide PPFP counseling and services throughout continuum of care, volunteers (Development Army) promote PPFP, and HEWs and volunteers track PPFP method choice and uptake.
89648820|NCT03585361|Active Comparator|Comparison|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Health centers conduct data reviews.
89648821|NCT05118984|Active Comparator|Azithromycin group|Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12 hrs on empty stomach for 3 days).
89688575|NCT03402971||non healthy pregnant|non healthy women with suspected healthy or unhealthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
89045197|NCT02913443|Experimental|Dose Escalation - 1900 μg RO7051790|1900 μg of RO7051790 was administered to three (3) participants once every 3 weeks (Q3W).
88992976|NCT05082922|No Intervention|No treatment waiting period|Participants are randomized to a 4, 5, or 6 week waiting period. Weekly measurements are collected throughout this period.
88992977|NCT05082922|Experimental|Hybrid treatment|Hybrid treatment. Weekly measurements are collected throughout treatment.
88992978|NCT05078164|No Intervention|Treatment as Usual|Youth who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
89648822|NCT05118984|Placebo Comparator|Placebo group|placebo capsules (manufactured in pharmacy department with the same shape, color and consistency as Azithromycin capsule every 12hrs for 3 days). A single pharmacist will be responsible for manufacturing of placebo capsules and packing all medications into sterile boxes and labelling of them as 1 or 2.
89648823|NCT03585283|Experimental|Myofascial Group|Myofascial release will be applied by physiotherapist two times a week for four weeks which is a manual therapy technique includes stretching and compression of soft tissues according to fascial chains.Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
89648824|NCT03585283|Sham Comparator|Sham Group|Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
89648825|NCT01927770||WES/WGS|Eligible adults (or parents of eligible children) consenting to enroll in an NIH study thatincludes WES/WGS.
89648826|NCT03583645|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
89648827|NCT03583645|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
89648828|NCT03585127|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy comprises of nine weekly sessions of an hour.
89648829|NCT03585127|Experimental|Avatar Therapy|Avatar Therapy consists of 9 weekly sessions: one avatar creation session and 8 therapeutic sessions of one hour.
89648830|NCT04514328|Experimental|one group|patients with mild or moderate Alzheimer disease
89648831|NCT03115723||Group 1 : Percutaneous coronary intervention|All the patients who underwent percutaneous coronary intervention, in 9 invasive cardiology centers in the Aquitaine Region, France.
89648832|NCT03115723||Group 2 : Coronary angiography|All the patients who underwent coronary angiography, in 9 invasive cardiology centers in the Aquitaine Region, France
89648833|NCT02802852|Experimental|Calf Compression, Filgrastim injection|All patients enrolled in the study will undergo pneumatic calf compression though use of the Art Assist device as well as stem cell mobilization through administration of Filgrastim 10 mcg/kg subcutaneously, every 3rd day for 30 days.
89648834|NCT04405609|Experimental|ArmAssist group|"The post-stroke patients who participate in the study, are classified in differents stages (3 patients in each stage).~Group 1: subacute, between 2 - 6 months Group 2: chronic of short evolution, between 6 - 12 months Group 3: long-term chronic, more than 12 months.~The system is tested in a clinical (training) and patients' home setting. The ArmAssist system includes the ArmAsist 2.0 device (without motors), the tele rehabilitation platform based on serious games and Antari's HomeCare tele-care platform for the clinicians."
89648835|NCT00886548||Ultrasound performed|Single arm study.
89648836|NCT03159325|No Intervention|Usual Care|The usual care group will receive all standard treatment, instructions and information for patients with cardiovascular disease, but no Healing Circles program.
89648837|NCT03159325|Experimental|Healing Circles|Healing Circles is an evidence-based and patient-informed novel self-management platform designed to support patients with CVD. It uses a private, secure social network that helps connect patients to one another, to personalized, disease management information , and provides functions to assist patients in self-management via evidence-based principles of behaviour change.
89648838|NCT00409266|Other|Functional flexion axis of the knee|The functional flexion axis of the knee can be established by computer-assisted intra-operative data, through range of motion techniques, not specific landmarks such as epicondyles.
89648839|NCT04405375|Experimental|treatment arm|gemcitabine 1.25g/㎡ d1, pegaspargase 2500IU/㎡ d1 (max dose =<3750IU) etoposide 75mg/㎡ d1-3 dexamethasone 20mg d1-4 repeated every 21 days, up to 6 cycles.
89648840|NCT05118438|Experimental|Nursing intervention|The recruited participants were clients of a self-sufficiency support center for sexually exploited women located in South Korea, recruited through snowball sampling after obtaining permission from the director of the support center.
88992979|NCT05078164|Experimental|Bridging the Gap (BTG)|Youth randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 3-months of community case management and a firearm counseling program.
88992980|NCT05075967|Experimental|Integrated Strategy|"Black MSM living in intervention communities will have access to the HPTN 096 integrated strategy in addition to standard HIV prevention and care services available in their communities.~The integrated strategy includes a combination of four community-, organizational-, and interpersonal-level components designed to impact individual-level outcomes."
88992981|NCT05075967|Other|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
88992982|NCT05072717|Experimental|Patients with a meniscal tear requiring surgery|Patients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an arthroscopic imaging system.
88992983|NCT05060978|Active Comparator|Watch your Weight During the Holidays Program|
88992984|NCT05060978|Active Comparator|Relative 5:2 Fasting|
88992985|NCT05060978|Placebo Comparator|Control Group|
88992986|NCT05042323|Experimental|TF-CBT-Skills|Step 1: 4-5 sessions with stabilization/skill building Step 2: 4-5 sessions with narrative and cognitive processing
88992987|NCT05042323|Active Comparator|TF-CBT-Narr|Step 1: 4-5 sessions with narrative and cognitive processing Step 2: 4-5 sessions with stabilization/skill building
89648841|NCT03583801|Experimental|aromatherapy group|"The patient has to choose an essential oil among the 3 proposed :~sweet orange (Citrus sinensis L. Persoon)~fine lavender (Lavandula angustifolia P. Miller)~little seed from the mandarin tree (Citrus reticulata blanco)"
89648842|NCT03583801|Placebo Comparator|without aromatherapy|
89648843|NCT05106348||Wheelchair Rugby Group|wheelchair rugby players, elite athletes, national team athletes
89648844|NCT03584503|Active Comparator|Group SA|Group SA intubated with Suction Above Cuff Endotracheal Tube
89648845|NCT03584503|No Intervention|Group C|Group C intubated with classic endotracheal tube
89648846|NCT03587857|Experimental|Arm 1: Intervention|All YLWH who choose to enroll in the study will receive access to WYZ, the mobile health application. The participants will be asked to use the app for 6 months, during which the investigators will assess the feasibility and acceptability of WYZ. Based on this initial data, the investigators will refine and release a new version of the app (WYZ 3.0).
89648847|NCT02776488|Experimental|ELI Arm|Infusion of exogenous sodium lactate as supplemental fuel within 48 hours of TBI
89648848|NCT02776488|Placebo Comparator|Placebo|Placebo infusion of normal saline in Part 2 RCT
89648849|NCT03158857||Hepatitis C monoinfection|"Sofosbuvir 400 mg tablet once a day + Daclatasvir 60mg tablet once a day~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
89648850|NCT03158857||Hepatitis C and HIV co-infection|"Sofosbuvir tablet 400 mg once a day + Daclatasvir tablet 90 mg once a day (increased dose in patients receiving efavirenz. Patients on an alternative HIV drug regimen will receive standard dose i.e. 60 mg)~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
89648851|NCT03584425|Experimental|Healthy Controls|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
89648852|NCT03584425|Experimental|Stroke Participants|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
89648853|NCT03029611|Experimental|Treatment (chemotherapy, IGFBP-2 vaccine)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour followed by IGFBP-2 vaccine ID 2 weeks later. Treatment repeats every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. After completion of 3 cycles, patients then undergo cytoreductive surgery.
89648854|NCT03020173||BMI above 30|Oocytes and granulosa of infertile women with BMI above 30
89648855|NCT03020173||BMI below 30|Oocytes and granulosa of infertile women with BMI above 30
89648856|NCT05701579||Patients with ACL Degeneratio Mucosa|Patients with ACL Degeneratio Mucosa
89648857|NCT03159949|Experimental|PR- REHIIT|"PR-REHIIT participants (Sprint Snacks) will participate in 3 separate training session per day on 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
89648858|NCT03159949|Experimental|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second sprints with three minutes rest in between, and a one-minute cool-down.
89648859|NCT04765501||Patients group|Individuals with headache
89648860|NCT03584035|Experimental|Sensory motor integration group|Sensory-motor integration exercises with 3 progressive steps, 30 minutes per sessions, 3 sessions per week for 6 weeks.
89648861|NCT03584035|Active Comparator|Conventional group|Conventional exercises include simple passive and active exercises and lower extremities strengthening exercises for balance and ambulation. The exercise session will last 30 minutes for 3 sessions per week. The total intervention period is 6 weeks.
89648862|NCT03583723|Experimental|Radiotherapy Group|Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.
89648863|NCT03589495|Active Comparator|N acetylcysteine group|N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
89648864|NCT03589495|Placebo Comparator|placebo group|received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
89648865|NCT03159559|Experimental|Treatment group|In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;
89648866|NCT03159559|No Intervention|Control group|In the control group, patients received conventional therapy only.
89648867|NCT03159403||Oritavancin|Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
89648868|NCT03583567|Placebo Comparator|0.9% Normal Saline|Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL
88992988|NCT05039710|Experimental|Cohort 1: JNJ-75220795 or Placebo|Participants will receive single subcutaneous (SC) dose of JNJ-75220795 Dose 1 or matching placebo on Day 1 in Cohort 1.
88992989|NCT05039710|Experimental|Cohort 2: JNJ-75220795 or Placebo|Participants will receive single SC dose of JNJ-75220795 Dose 2 or matching placebo on Day 1 in Cohort 2.
89648869|NCT03583567|Experimental|Chlorpheniramine and ranitidine|Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)
89648870|NCT03583489|Placebo Comparator|Placebo|
89648871|NCT03583489|Experimental|APD421|
89648872|NCT03583489|Experimental|APD421 + ondansetron|
89045198|NCT02913287|Placebo Comparator|Placebo|Maltodextrin
89045199|NCT02913287|Experimental|Aquamin/Aquamin MG|Aquamin/Aquamin MG mix
89045200|NCT02063685|Other|GROUP 1 - STANDARD|R-CHOP or R-bendamustine + Standard Maintenance
89045201|NCT02063685|Experimental|GROUP 2|FDG-PET POSITIVE (score 4-5) patients (High risk) R-CHOP or R-bendamustine + Ibritumomab Tiuxetan + Maintenance
89045202|NCT02063685|Experimental|GROUP 1a|FDG-PET NEGATIVE (score 1-3) AND MRD NEGATIVE R-CHOP or R-bendamustine + Observation
89045203|NCT02063685|Experimental|GROUP 1b|FDG-PET NEGATIVE (score 1-3) AND MRD POSITIVE R-CHOP or R-bendamustine + Maintenance weekly x4
89045204|NCT02913365||Patients presenting with hemoptysis|Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
89045205|NCT02913248|Experimental|Conventional periodontal treatment|35 subjects diagnosed with manifest periodontitis, which will all receive standardized treatment according to protocol. In brief, this treatment includes professional tooth cleaning and thorough instruction in self-performed oral hygiene procedures. Clinical registrations and collection of microbiological samples (subgingival and saliva) will performed at baseline and 2, 6 and 12 weeks after treatment.
89648873|NCT03159871|Experimental|Stratafix suture|
89648874|NCT03159871|Active Comparator|Vicryl suture|
89045206|NCT02063295|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
89045207|NCT02063295|Experimental|ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
89212824|NCT00868010|Placebo Comparator|2. placebo|Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
89521391|NCT04450147|Experimental|Tai Chi and Qigong|50mins x 12 weeks of virtually-delivered group tai chi/qigong
89521392|NCT04450147|Active Comparator|Walking and Stretching|50mins x 12 weeks of virtually-delivered group walking and stretching
89521393|NCT03438409|Experimental|Single Arm Study|This study has a single arm with repeated baseline measures. This arm will complete the robotic gait training.
89521394|NCT03433573|Experimental|Intervention|Abbott Sensor Based Glucose Monitoring System
89521395|NCT03128125|Experimental|High intellectual potential|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in children with high intellectual potential.
89521396|NCT03128125|Other|Control|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in control children with no particularities.
89521397|NCT03433495|Active Comparator|Melodic Intonation Therapy|The duration of therapy was 12 sessions performed over a 6-week period. Each session lasted 30 minutes. They were performed individually by a speech-experienced therapist previously trained in Melodic Intonation Therapy.
89521398|NCT03433495|No Intervention|Waiting list|No intervention
89521399|NCT04070365||FLEX Vessel Prep followed by angioplasty|
89521400|NCT03128281|Experimental|Conventional Insufflation System (CIS)|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery."
89521401|NCT03128281|Experimental|ConMed AirSeal Insufflation System (AIS) at Low Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
89521402|NCT03128281|Active Comparator|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
89521403|NCT03429751|Experimental|Liberal fluid group|received 30 ml/Kg/h crystalloid for maximum 3 hours.
89521404|NCT03429751|Active Comparator|Restrictive fluid group|received 10 ml /Kg/h crystalloids for maximum 3 hours.
89521405|NCT04449757|Experimental|bicarbonated ringer's solution|We apply bicarbonated ringer's solution as resuscitation fluid to patients with septic shock.
89521406|NCT04449757|Experimental|lactated ringer's solution|We apply lactated ringer's solution as resuscitation fluid to patients with septic shock.
89521407|NCT04008745|Experimental|Intervention Group|Patients in the intervention group will perform foot-related exercises described in an educational booklet three times/week at home. In the follow-up period, patients will follow the same schedule set by the project till the end of the study (16-weeks).
89521408|NCT04008745|No Intervention|Control Group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
89521409|NCT03429673||Patients with surgeries|Pathologically diagnosed elderly early Chinese patients with non-small cell lung cancer who received lobectomy or segment/wedge dissection
89521410|NCT04449601||Group 1 (with hypertension )|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
89521411|NCT04449601||Group 2( without hypertension)|Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
89521412|NCT03621553|Experimental|Low vit-D, Ergocalciferol|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
89521413|NCT03621553|Placebo Comparator|Low vit-D, Placebo|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
89648875|NCT03589261|Other|MRI (magnetic resonance imaging)|Hepatic blood flow baseline will be measured using MRI. Fluid challenge of 500 ml of NaCl 0.9% will be administered during 10 minutes. Before and After fluid challenge, MRI will be performed to compare flow changes.
89648876|NCT03583411||acute coronary syndrome (ACS) patients|ACS subjects hospitalized in the Cardiology 1 - UTIC department of ASST Grande Ospedale Metropolitano Niguarda between 2014 and 2017
89648877|NCT03020485|Experimental|Isomaltulose|50g of isomaltulose dissolved in 250ml of water
89648878|NCT03020485|Experimental|Sucrose|50g of sucrose dissolved in 250ml of water
89648879|NCT03159169|Experimental|study patients|Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
89648880|NCT03158935|Experimental|Advanced metastatic melanoma (Cohort 1)|Cyclophosphamide and fludarabine followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
89648881|NCT03158935|Experimental|Advanced ovarian cancer (Cohort 2):|Cyclophosphamide followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
89648882|NCT04965168|Active Comparator|controls|phacoemulsification and IOL implantation
89648883|NCT04965168|Active Comparator|diabetic without pseudoexfoliation|phacoemulsification and IOL implantation
89648884|NCT04965168|Active Comparator|non-diabetic with pseudoexfoliation|phacoemulsification and IOL implantation
89648885|NCT04965168|Active Comparator|diabetic with pseudoexfoliation|phacoemulsification and IOL implantation
89648886|NCT03158623|Experimental|Platelet Rich Plasma|30cc of PRP was administered at closure of wound
89648887|NCT03158623|Experimental|Cellerate (Activated Collegen)|1gm of Cellerate was administered at closure of wound
89648888|NCT03158467||Phase 1|
89648889|NCT03158467||Phase 2|
89648890|NCT05117580|Experimental|Active group|The active group get telemedicine devices, and lifestyle interventions.
89648891|NCT05117580|No Intervention|Comparator Group|The comparator group get the evidence based treatment.
89648892|NCT03583177||healthy volunteers|
89648893|NCT03583177||cancer patients|
89648894|NCT03583177||undergoing chronic hemodialysis patients|
89648895|NCT02653326|Experimental|Telerehabilitation|In addition to routine care, patients in this arm will receive a telerehabilitation strategy comprised by a portable EKG monitor and a smartphone application.
89648896|NCT02653326|Active Comparator|Routine Care|Patients allocated to routine care will receive care as enforced by current practice guidelines. This care included nutritional counseling, depression screening, drug therapy for the management of comorbidities and physical exercise without telemonitoring.
89648897|NCT03158545|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
88992990|NCT05000021|Experimental|Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring|Participants randomized to this arm will receive Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD), enhanced by review of Continuous Glucose Monitoring (CGM) data. Participants will wear study-supplied CGM for the first 6 months of their participation in the trial.
88992991|NCT05000021|Active Comparator|Continuous Glucose Monitoring (CGM) Only|Participants randomized to receive Continuous Glucose Monitoring (CGM) will continue to receive their usual care and will also wear CGM throughout the first 6 months of their participation in the trial.
88992992|NCT04975620|Experimental|Franseen needle with three symmetric cutting edges|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using the Franseen needle (Acquire FNB needle; Boston Scientific): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
89648898|NCT03158545|Active Comparator|EPA-rich|3 x 1 g capsules daily containing EPA-enriched oil
89648899|NCT03158545|Active Comparator|DHA-rich|3 x 1 g capsules daily containing DHA-enriched oil
89648900|NCT04818372|Experimental|Dose escalation|"Subjects enrolled in this arm will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.~Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 4 dose levels (0.006mg/kg, 0.06mg/kg, 0.3mg/kg and 1.0mg/kg) and then traditional 3+3 dose escalation design will be used for the following levels (2.0mg/kg, 4.0mg/kg, 8.0mg/kg, 16mg/kg and 24mg/kg)."
89648901|NCT04818372|Experimental|Dose expansion _Cohort 1|This cohort will comprise subjects with RRMM. Subjects will receive the CM313 in combination with dexamethasone.
89648902|NCT04818372|Experimental|Dose expansion _Cohort 2|This cohort will comprise subjects with RRMM and NDMM. Subjects will receive the CM313 in combination with Rd regimen.
89648903|NCT03158077||Raltegravir + ABC/3TC|Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study
89648904|NCT01462578|Experimental|Azacytidine|Azacytidine injection: 75 mg/m²/d, subcutaneous
89648905|NCT04601844|Experimental|Cohort 1|Cemdisiran at dose 1 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
89648906|NCT04601844|Experimental|Cohort 2|Cemdisiran at dose 2 SC single dose on day 1 followed by pozelimab at dose 1 SC single dose on day 29
89648907|NCT04601844|Experimental|Cohort 3|Cemdisiran at dose 2 SC single dose and pozelimab at dose 2 SC single dose, both administered on day 1
89648908|NCT03059173|Experimental|Myo-Inositol + Levomefolic acid|The experimental group will receive the dietary supplement: 4 g of MYO + 0.736 mg of 5-MTHF, glucosamine salts per day per os (in 2 bags per day) in addition to the standard therapy (Clomiphene Citrate).
89648909|NCT03059173|Placebo Comparator|Placebo|The control group will receive the standard therapy ( Clomiphene Citrate) and a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
89648910|NCT05117268|Experimental|Silver Diamine Fluoride|In the experimental group, 44 children will be provided with SDF application, after gross debris removal to allow better contact of SDF. The entire dentition will be treated with sodium chloride fluoride varnish to prevent caries.
89648911|NCT05117268|Placebo Comparator|Glass Ionomer Restoration|In placebo control group n= 44 participants will be enrolled. High viscosity glass ionomer restoration will be placed after complete caries excavation using high-speed handpiece and air/water coolant. Patient will be dispensed with clear postoperative instructions.
89648912|NCT05117268|Active Comparator|Hall Technique|In active comparator group, n= 44 study participants will be enrolled. Pre-formed metal crowns will be selected according to the tooth size and filled with low viscosity glass ionomer cement and seated using digital/ finger pressure.
89648913|NCT05122338|Placebo Comparator|Normal saline in transversus abdominis plane block|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
89648914|NCT05122338|Active Comparator|Ropivacaine in transversus abdominis plane block|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
89648915|NCT05122338|Active Comparator|Compound lidocaine in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
89648916|NCT05122338|Active Comparator|Compound lidocaine and esketamine in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine and 0.4mg/kg esketamine are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
89648917|NCT03157843||Medical Patients|Medical patients who received, at admission and during all the length of recovery, antithrombotic drugs (low-molecular-weight heparin at prophylactic dosage ).
89648918|NCT03157843||Control Group|Medical patients not treated with antithrombotic drugs during the recovery. Subjects age, sex and comorbidities matched.
89648919|NCT04386174|Other|Group A|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
89648920|NCT04386174|Other|Group B|Participants will be shown information about brain activity while trying different thinking strategies to change their experience of pain. Both groups will be shown brain activity, but the source of the brain activity information will differ between the groups.
89648921|NCT04014894|Experimental|ET019003-T Cells|The trial will enroll 9 patients with leukemia and 9 patients with lymphoma. Each disease has 3 dose-levels.
89648922|NCT05121870|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|standard of care (SOC) plus UC-MSCs
89648923|NCT05121870|Placebo Comparator|Placebo|SOC plus placebo.
89648924|NCT03589027|Experimental|Rilpivirine arm|All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
89648925|NCT03589027|Experimental|Darunavir arm|All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
89648926|NCT03918486||Caretaker|Comparing blood pressure obtained using routine blood pressure sphygmomanometer to a non-invasive device that continuously monitors central blood pressure (CareTaker).
89648927|NCT03156673|Experimental|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
89648928|NCT03874494|Experimental|Brexpiprazole|2-4 mg/day, once daily for 6 weeks, oral administration
89648929|NCT03874494|Active Comparator|Aripiprazole|10-20 mg/day, once daily for 6 weeks, oral administration
89648930|NCT03156439|Experimental|BIS-001 ER|The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.
89648931|NCT05113992|Experimental|Intervention group massaged with frankincense and myrrh oil|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm. Individuals who did not develop any reaction after thirty minutes and who met other inclusion criteria were included in the study. At the beginning of the study, the patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. Then, in accordance with the massage application protocol, a back massage was applied for a total of 15 minutes, using 4% massage oil. Then EPS was applied to the individuals. VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
89688576|NCT03402971||non healthy fetus|healthy or non healthy pregnant women with suspected non healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
89688577|NCT02921386|Other|Breakfast A - Fasting|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
89688578|NCT02921386|Other|Breakfast B - 15 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
89688579|NCT02921386|Other|Breakfast C - 30 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
88992993|NCT04975620|Experimental|Multi-blade needle with three-prong tip with one tip longer than the other two|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using a multi-blade three-prong tip needle (Trident; Microtech): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
88992994|NCT04971499|Experimental|Dose Selection|Dapansutrile starting at 500 mg PO BID plus Pembrolizumab 200 mg IV every three weeks. Dose escalation is planned to a maximum of 1000 mg BID of dapansutrile + pembrolizumab.
88992995|NCT04971499|Experimental|Dose Expansion|Dapansutrile at the RP2D plus Pembrolizumab 200 mg IV every three weeks
88992996|NCT04918017|Experimental|Treatment based on subtypes: Epigastric Pain Syndrome (EPS)|EPS: treat with esomeprazole 40mg OD (proton pump inhibitor)
88992997|NCT04918017|Experimental|Treatment based on subtypes: Post Prandial Distress Syndrome (PDS)|PDS: treat with itopride 50mg TDS (prokinetic)
89648932|NCT05113992|Sham Comparator|. Placebo group massaged with jojoba oil,|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm. Individuals who did not develop any reaction after 30 minutes and who met other inclusion criteria were included in the study. At the beginning of the study, a patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. Then, in accordance with the massage application protocol, a back massage was applied for a total of 15 minutes, using jojoba fixed oil. Then EPS was applied to the individuals. VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
89648933|NCT05113992|No Intervention|Control group|At the beginning of the study, a patient information form, VAS for back pain severity, and GCQ for comfort evaluation were applied by face-to-face interview method before the intervention. No intervention was applied to individuals in the control group. In order to ensure standardization between the groups, after 15 minutes of verbal communication, they were taken to the EPS process. After the procedure, VAS and GCQ were applied again at the 4th hour, which is the ambulation hour.
89648934|NCT04436328|Experimental|Surgical treatment|Surgical treatment of native vertebral osteomyelitis followed by antimicrobial therapy
89648935|NCT04436328|Active Comparator|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only
89648936|NCT04223466|Experimental|Subxiphoid group|Subxiphoid procedure for thymectomy.
89648937|NCT04223466|Active Comparator|VATS group|Video-assisted thoracoscopic thymectomy through chest wall.
89648938|NCT03156283|Experimental|SleepWell24 Application|A mobile health smartphone application based on evidence-based health behavior change theory and interventions to promote adherence to positive airway pressure therapy
89648939|NCT03156283|Other|Usual Care Plus Activity Monitor|Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
89648940|NCT05044806|Experimental|Ultrasound-guided-RIC group|Patients in the ultrasound-guided-RIC group will receive percutaneous coronary intervention (PCI), usual pharmacotherapy and pre-, per-, and post-operative ultrasound-guided remote ischemic conditioning (RIC). The pressure applied during cuff inflation is total occlusion pressure (TOP) determined with ultrasound measurement.
89648941|NCT05044806|Experimental|Traditional RIC group|Patients in the traditional RIC group will receive PCI, usual pharmacotherapy and pre-, per-, and post-operative traditional RIC. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
89648942|NCT05044806|Other|Control group|Patients in the control group will receive PCI and usual pharmacotherapy.
89648943|NCT03156517|Active Comparator|Deep Brain Stimulation in VIM|Patients receive stimulation in the VIM-nucleus of the thalamus
89648944|NCT03156517|Active Comparator|Deep Brain Stimulation in PSA|Patients receive stimulation in the posterior subthalamic area
89648945|NCT03156361|Experimental|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
89648946|NCT03156361|Active Comparator|Insulin Lispro 100 UNIT/mL|Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
89648947|NCT05690035|Experimental|patients with mCRC|Tislelizumab 200mg ivdrip every 3 weeks; Fruquintinib 5mg qd day 1-14, every 3 weeks
89648948|NCT03156049|Active Comparator|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
89648949|NCT03156049|Active Comparator|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
89648950|NCT03156127|Experimental|BR-UPS 5 mg tablet|
89648951|NCT03156127|Active Comparator|Inisia 5 mg tablet|
89648952|NCT05002530|Experimental|Aerosolized 13 cis retinoic acid and Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
88992998|NCT04918017|Experimental|Treatment based on subtypes: Overlapped EPS/ PDS|Overlapped EPS/PDS: treat with itopride 50mg TDS first and add esomeprazole 40mg OD (if partially responded) or change to esomeprazole 40mg OD (if not responded)
89648953|NCT05002530|Experimental|Aerosolized All trans retinoic acid and Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized all trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
89648954|NCT05002530|Placebo Comparator|Standard therapy|Standard therapy
89648955|NCT05700487|No Intervention|Control Group|Patients in this group continued their routine medicaltreatmentprogram without any treatment
89648956|NCT05700487|Experimental|Intervention Group|Pelvic floor exercises (PTE) training in the preoperative period, regular PTE was performed three times a day for 6 months in the postoperative period, and the continuity of the exercises was checked by telephone
89648957|NCT04975464||Control|eGFR ≥ 60 ± 5 ml/min/1.73m2 at the first baseline visit in BRINK 1.0. Non-CKD population.
89648958|NCT04975464||Mild CKD|eGFR 45 - <60
89648959|NCT04975464||CKD|eGFR < 45
89648960|NCT04975464||Dialysis/Transplant|active dialysis for dialysis participants or kidney transplant for transplant participants
89648961|NCT03583021|Experimental|sugammadex group|Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
89648962|NCT03583021|Placebo Comparator|neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
89648963|NCT05113914|Experimental|Healthy, physically fit men|All participants underwent a single CPET test with pre- and post-exercise blood measurements.
88992999|NCT04918017|Active Comparator|Treatment with Proton Pump Inhibitor regardless of subtype|Treat with esomeprazole 40mg OD (proton pump inhibitor) regardless of subtype of functional dyspepsia
88993000|NCT04914754||Long COVID with mild exercise impairment|Patients with prior serological or clinical diagnosis of CoV-2 infection and a referred to the UCLH Long-COVID clinic for persistent fatigue or exercise intolerance.
88993001|NCT04914754||Healthy Control|Healthy sex-matched and age-matched to within 5 years of Long Covid participants were recruited from UCL staff and students.
88993002|NCT04914754||Long COVID with severe exercise impairment|Patients with prior serological or clinical diagnosis of CoV-2 infection and a referred to the UCLH Long-COVID clinic for persistent fatigue or exercise intolerance and an abnormal walk test criteria included: peripheral oxygen desaturation, <85% predicted walk distance, a lactate rise> 1.0 from baseline or a Borg score > 5 for breathlessness or fatigue at end of test.
89212825|NCT05683301|Experimental|Arm 1|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Amlodipine 5 mg and Perindopril 4 mg once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Amlodipine 10 mg and Perindopril 8 mg once daily, orally
88993003|NCT04898231|Active Comparator|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
88993004|NCT04898231|Active Comparator|Methylprednisilone (steroids)|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
88993005|NCT04898231|Active Comparator|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
88993006|NCT04887558|Active Comparator|NCI QuitGuide and NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free NRT.
88993007|NCT04887558|Experimental|Smart-T Mental Health and NRT|Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive NRT.
88993008|NCT04887558|Experimental|Smart-T Mental Health+ and NRT|Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. During the pre-quit and post-quit period, the app will also send messages that encourage the use of the nicotine patch and lozenges according to recommended practices. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free NRT.
88993009|NCT04849026|Experimental|Group A|"Period 1: WID-CLZ18~Period 2: Clozaril 100 mg (Clozapine)"
88993010|NCT04849026|Experimental|Group B|"Period 1: Clozaril 100 mg (Clozapine)~Period 2: WID-CLZ18"
88993011|NCT04841980|Active Comparator|Antibiotics|
88993012|NCT04841980|Active Comparator|Dietary based therapy|
89648964|NCT04937322||Interventional Endoscopy procedures|All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations for pancreatico-biliary disorders since June 2011 and extending forward through June 2023.
89648965|NCT03582787|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
89648966|NCT03582787|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
89648967|NCT04235244|Experimental|left lower abdominal region|5 minutes before and after application to the right upper abdominal region. local cold application
89648968|NCT04235244|Experimental|right upper abdominal region|Thermomechanical-analgesia device will be operated 30 seconds before the injection in the right lower abdominal region and the device will be injected by sliding the device to the side of the selected region during the injection,
89648969|NCT04235244|Experimental|left upper abdominal region|Coolant spray will be applied to the upper left abdominal region for 15 sec.
89648970|NCT04235244|No Intervention|right lower abdominal region|SC injection will be applied to the left lower abdominal region without any cold application.
89648971|NCT03156205|Experimental|Interactive Music Therapy|
89648972|NCT03156205|Other|passive music listening|
89648973|NCT03156205|Other|passive earphone-use|
89648974|NCT04885608|Experimental|PReGe|Group that will perform the intervention with therapeutic exercise.
89648975|NCT03155971|Experimental|PCB group|Prospective, single center, single-group clinical study. Interventions: Patients in the PCB group will be treated (angioplasted) with Paclitaxel-Coated Balloon (SeQuent ® Please; B.Braun, Melsungen, Germany)
89648976|NCT03157765|Experimental|EMB intervention|These patients receive and endometrial biopsy
88993013|NCT04831736|Experimental|Treatment|
88993014|NCT04831736|Placebo Comparator|Control|
89648977|NCT03157765|No Intervention|Routine care|These patient receive routine care
89648978|NCT03582319|Experimental|Biodentine|Regenerative material for pulp therapy
89648979|NCT03582319|Active Comparator|Formocresol|Fixative agent for pulp therapy
89648980|NCT03157375|Other|0°|Implantation of the intraocular lens Vivinex p261 on axis 0°
89648981|NCT03157375|Other|45°|Implantation of the intraocular lens Vivinex p261 on axis 45°
89648982|NCT03157375|Other|90°|Implantation of the intraocular lens Vivinex p261 on axis 90°
89648983|NCT03157375|Other|135°|Implantation of the intraocular lens Vivinex p261 on axis 135°
89648984|NCT00307242|Active Comparator|Direct switch to Adefovir Dipivoxil from Lamivudine|
89648985|NCT00307242|Active Comparator|Overlapping Lamivudine and Adefovir Dipivoxil for 3 months followed by ADV monotherapy|
89648986|NCT05120778|Experimental|conventional medical treatment|Volunteers will maintain habitual medical treatment.
89648987|NCT05120778|Experimental|exercise training + conventional medical treatment|Volunteers will maintain habitual medical treatment and will participate in a 16-week exercise training based on high-intensity interval training (stationary bikes), and strength training (weight-bearing exercises).
89648988|NCT03157297|Experimental|Enrolled|Subjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
89648989|NCT05120700|Experimental|Stromal vascular fraction|Treatment of cartilage injury with a tissue engineering construct.The patients will be adults diagnosed with a single, 3 to 6 cm2 full-thickness cartilage lesion, symptomatic and with no improvement with non-operative treatment.
89648990|NCT04512768|Active Comparator|Standard ICBT|Participants in the Standard ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia.
89648991|NCT04512768|Experimental|Sleep-Enhanced ICBT|Participants in the Sleep-Enhanced ICBT condition will receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. In addition, participants in the Sleep-Enhanced ICBT condition will also receive a newly developed lesson designed to target insomnia.
89648992|NCT02653170|No Intervention|Usual Care|Patients in this group will receive the hospitals' usual transitional care approach.
89648993|NCT02653170|Experimental|SCM|"One intervention is provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services."
89648994|NCT02653170|Experimental|SCM and VSSP|"Two interventions are provided:~SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:~VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource."
89648995|NCT03582007|Experimental|Murepavadin|Murepavadin + ertapenem
89648996|NCT03582007|Active Comparator|Anti-pseudomonal antibiotic|One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
89648997|NCT02895373|Experimental|Alprostadil|heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
89648998|NCT02895373|Placebo Comparator|Placebo|heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
89648999|NCT05087784|Experimental|Intervention:|Complex, technology supported survivorship intervention using wearable devices for patients, supportive patient apps and physician apps for risk prediction. Increased Cardio-oncology visits assigned to risk patients as predicted by the app.
89649000|NCT05087784|No Intervention|Control arm:|Wearable device for patients together with a basic patient app providing feedback on the wearable device records and patient information material.
89649001|NCT03155815||Derivation Cohort|Eligible respondents to the combined 2001, 2003, 2005 and 2007 Canadian Community Health Surveys, conducted by Statistics Canada.
89649002|NCT03155815||Validation Cohort|Eligible respondents to the 2008/2009 Canadian Community Health Survey.
89649003|NCT03157141||Control group, CG|For the purpose of the study, forty subjects for each group will be recruited. The control group (CG group) (so-called healthy subjects) CG will be recruited following the recruitment of the AA group and of the TAR group, as a sex, age and BMI matched design will be pursued. Inclusion criteria for the CG group are no history of orthopaedic lower limb surgery and absence of any known neurological or systematic disease.
89649004|NCT03157141||Total ankle replacement group (TAR group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects.
89649005|NCT03157141||Ankle arthrodesis group (AA group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects
89649006|NCT05230056|Experimental|PG|
89649007|NCT05230056|Active Comparator|CTRL|
89649008|NCT05698771|Experimental|NR|A total of 6 individuals comprising 3 males and 3 females will receive NR 1200 mg daily (600 mg x 2) for 8 days, with a total measurement/assessment period of 20 days. These will be the same individuals as in the NMN-arm. The individuals will enter the two arms sequentially and with a washout period of 14 days.
89649009|NCT05698771|Experimental|NMN|A total of 6 individuals comprising 3 males and 3 females will receive NMN 1200 mg daily (600 mg x 2) for 8 days, with a total measurement/assessment period of 20 days. These will be the same individuals as in the NR-arm. The individuals will enter the two arms sequentially and with a washout period of 14 days.
89649010|NCT04207320|Experimental|Stage I|Stage I will include eligible subjects between the ages of 10-25 years.
89649011|NCT04207320|Experimental|Stage II|Stage II will include eligible subjects between the ages of 2-25 years.
89649012|NCT03581929|Experimental|Memormax|2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
89649013|NCT03581929|Placebo Comparator|Placebo|2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
89649014|NCT04205604|Experimental|Single Arm,|Patients with clinically diagnosed congenital hyperinsulinism
89649015|NCT03156907|Experimental|Chronic pain patients|The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (HDB) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.
89649016|NCT03156829|Experimental|Splint alone|
89649017|NCT03156829|Experimental|Cortico-steroid alone|
89649018|NCT03156829|Experimental|Splint and cortico-steroid combined|
89649019|NCT03581851|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
89649020|NCT03581851|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
89649021|NCT05229276|Experimental|Sternum Guard|The treatment of interest was Sternum GuardTM application during sternotomy.
89649022|NCT05229276|Active Comparator|Bone wax|The 'bone wax' arm was the control group of active comparator as the widely-used materials during sternotomy.
89649023|NCT03581773|Active Comparator|Treatment arm|5 mg of folic acid (1 tablet) per day for 12 weeks.
89649024|NCT03581773|Placebo Comparator|Placebo arm|PLACEBO (1 tablet) per day for 12 weeks.
89649025|NCT04425174||QL|QL = 30 patients representing the case group receiving QL block.
89649026|NCT04425174||EP|EP = 30 patients representing the control group receiving epidural anesthesia.
89649027|NCT05119452|Other|Assisted monitoring|In the Assisted monitoring arm, C-reactive protein and musculoskeletal ultrasound information will be made available to the clinical assessors who, at each time-point will use this information, along with information from the clinical examination, to identify patients experiencing recurrence of inflammation which will then be counted as subclinical flare according to predefined criteria.
88993015|NCT04830462|Other|LTBI and DM|Participants with LTBI and DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
89688580|NCT02921386|Other|Breakfast D - 45 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
88993016|NCT04830462|Other|LTBI without DM|Participants with LTBI without DM will be treated with Rifampicin or Isoniazid at the treating physicians discretion
88993017|NCT04829851||Health Care Professionals|Registered health care professional, such as a General Practitioner/ Dietitian/ Nutritionist/ Registered Exercise Professional (REPs) etc. who sees clients for assistance with weight management and / or iron deficiency or diet quality.
88993018|NCT04829851||Adults who are Overweight|Adults (> 18 years) who are considered to be overweight (25 - 30 kg/m2) but are otherwise in good physical health and a regular android smart phone/ tablet user.
88993019|NCT04829851||Adults with Iron Deficiency Anaemia|Adults (> 18 years) who have been diagnosed with Iron deficiency anaemia but are otherwise in good physical health and a regular android smart phone/ tablet user.
88993020|NCT04829851||Adults with Low- Fruit/ Vegetable Intake|Adults ( > 18 years) with a low fruit and vegetable intake (2-3 portions/ d) but are otherwise in good physical health and a regular android smart phone/ tablet user.
88993021|NCT04797403|Experimental|Intervention|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
88993022|NCT04797403|No Intervention|Enhanced Usual Care|Enhanced usual care will include an education session on the ACC/AHA hypertension guideline to providers and proper BP measurement to providers and staff at enhanced usual care clinics.Otherwise, no active intervention will take place, and all usual care clinics will follow their routine clinic practice.
88993023|NCT04776473|Experimental|Open (i.e. surgical) treatment|"This includes reduction and internal fixation of the fracture (ORIF) performed using the preferred surgical approach and bone implants of the including centre that could be associated with one or several items among the following:~physical therapy based on exercises done by the patient himself~physical therapy performed by a specialized/non-specialized physical therapist~arch bars / screws / splint use for transient MMF~arch bars / screws / splint use for passive mobilization of the mandible"
88993024|NCT04776473|Other|Closed (i.e. conservative) treatment|"To date, there is no consensus on which procedures should be used in case of conservative treatment, which may vary between centres and, for a same centre, between patients. This includes one or several items among the following:~physical therapy based on exercises done by the patient himself~physical therapy performed by a specialized/non-specialized physical therapist~arch bars / screws / splint use for transient maxillo-mandibular fixation (MMF) (15 days max)~arch bars / screws / splint use for passive mobilization of the mandible"
88993025|NCT04776291|Experimental|Recruitment and image processing|
88993026|NCT04775381|Experimental|Vitamin D|During preoperative visit (Month -2) patients will receive a cholecalciferol supplementation added to a fruit juice.
88993027|NCT04775381|No Intervention|Fruit juice|During preoperative visit (Month -2) patients will receive only fruit juice.
88993028|NCT04770181|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
88993029|NCT04770181|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
89521414|NCT03621553|Other|Normal vit-D, control|"Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
89521415|NCT03423511|Experimental|MiStent II Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
89521416|NCT03423511|Active Comparator|Xience or Promus Coronary Artery Stents|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
89521417|NCT01559363|Experimental|Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing|Participants received tesevatinib 50 milligrams (mg) tablet orally once daily (QD) for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum duration: up to 36 months).
89521418|NCT01559363|Experimental|Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing|Participants received tesevatinib 100 mg tablet orally QD for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 36 months).
89521419|NCT01559363|Experimental|Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing|Participants received tesevatinib 150 mg tablet orally QD for 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 36 months).
89521420|NCT01559363|Experimental|Phase 2a: Cohort 4: Tesevatinib: Bi-weekly Dosing|Participants received tesevatinib 150 mg tablet orally bi-weekly in alternative dosing schedules on Monday and Thursday for initial 25 days. After initial 25 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
89649028|NCT05119452|Other|Clinical monitoring|In the Clinical monitoring arm, the results of C-reactive protein and musculoskeletal ultrasound information will be recorded but will not be made available to the clinical assessor who at each time-point will make the decision on whether the patient is experiencing or has experienced a clinical flare according to predefined criteria based on information from the clinical examination.
89649029|NCT02788591|Other|Proton Pump Inhibitor (PPI) Therapy|2x daily Proton Pump Inhibitor (PPI) Therapy for 8 weeks
89649030|NCT02788591|Other|Sucralfate|4x daily Sucralfate slurry, 1g, for 8 weeks
89649031|NCT02785471|Active Comparator|Screening for Mental Health only|Participants in the Screening for Mental Health only (control) group will complete the online depression and suicide screening and receive immediate feedback and referrals.
89649032|NCT02785471|Experimental|Screening for Mental Health & Man Therapy|Participants assigned to Screening for Mental Health & Man Therapy (intervention) group will be offered the Man Therapy program in conjunction with Screening for Mental Health.
89649033|NCT01670305|Experimental|Residual pocket - PDT|Photosensitizer plus diiodo laser
89649034|NCT01670305|Placebo Comparator|Residual pocket - Photosensitizer|Photosensitizer alone
89649035|NCT01670305|Active Comparator|Residual pocket - SRP|scaling and root planing alone
89649036|NCT01670305|Experimental|Furcation - PDT+SRP|Photosensitizer plus diiodo laser associated with scaling and root planing
89649037|NCT01670305|Active Comparator|Furcation - SRP|Photosensitizer associated with scaling and root planing
89649038|NCT05108142|Experimental|Control meal|Participants were asked to visit the lab and consume the control meal (hot, freshly cooked pasta)
89649039|NCT05108142|Experimental|Resistant starch meal|Participants were asked to visit the lab and consume the resistant starch meal (re-heated pasta)
89649040|NCT03581617||Infertile women|Inclusion criteria for the study group will be as follows: 21-38 years old, primary infertility (no live birth), regular menstrual cycle (24-35 days), body mass index (BMI) ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/ml on day 2-3 of the menstrual cycle. They will be recruited at admission for tubal patency assessment.
89649041|NCT03581617||Fertile women|Inclusion criteria for control group will be as follows: 21-35 years old, almost one live birth, regular menstrual cycle (24-35 days), BMI ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/mL on day 2-3 of the menstrual cycle. Women with endometritis, endometriosis, tubal factor, ovulatory dysfunction, anatomical uterine pathologies will be excluded.
89649042|NCT05102994||VRL patients group|Presenting clinical features suggestive for VRL with positive finding in laboratory exam
89649043|NCT05102994||uveitis group|Even if characterized as clinical features of presumed VRL, no positive laboratory investigations for lymphoma and well response to IMT
89649044|NCT01670461|Experimental|FACE Advance Care Planning|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
89649045|NCT01670461|Other|Standard of Care (SOC) Control|Standard of Care Control: Advance Directive Information Booklet plus Advance Directive Checklist.
89649046|NCT03155503|Active Comparator|Single ascending dose|Single dose of SUVN-911 or placebo in healthy male subjects
89649047|NCT03155503|Active Comparator|Multiple ascending dose|Multiple doses of SUVN-911 or placebo in healthy male subjects
89649048|NCT04405687||Severe head and face deformity|
89649049|NCT03581539|Active Comparator|Group #1|Transverses Abdominis Plane (TAP) block
89649050|NCT03581539|Active Comparator|Group #2|Quadratus Lumborum (QL) block
89649051|NCT03581539|Active Comparator|Group #3|Surgeon Infiltration using Exparel
89649052|NCT03155113|Other|patients with chronic HCV infection|"Patients with chronic HCV infection to be treated with any of the available DAA (without associated PEG-IFN) in daily clinical practice.~Intervention: Blood Drawing.Before starting therapy a blood sample will be collected from any subject."
89649053|NCT01670695||IgG4-RD|Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
89649054|NCT03076164|Experimental|Trametinib 1.5mg + Erlotinib 75mg|Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.
89649055|NCT03157609|Experimental|Thermometry with SpotOn|Application of SpotOn sensor on forehead.
89649056|NCT03157609|Active Comparator|Thermometry with oesophageal probe|Nasal insertion of oesophageal temperature probe in the lower fourth of the oesophagus.
89649057|NCT03155893|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 15 and 16 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 2 orally under fed conditions.
89649058|NCT03155893|Experimental|Panel 1: Treatment B|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2 and 15 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 16 orally under fed conditions.
89045208|NCT02913209||Multiple Sclerosis Fatigue (MSF) Cohort|Participants will complete study assessments over 4 visits to the DC VAMC. Disease severity will be assessed by the EDSS, and a cognitive battery will be completed. Peak torque assessment for the knee flexors and extensors will be performed on an isokinetic dynamometer (Biodex System 4). Muscle morphology measures of the rectus femoris will be obtained using diagnostic musculoskeletal ultrasound. The sonographic measures will include muscle thickness and echogenicity. Isokinetic and isoinertial mode fatigue measures for the knee extensors will be assessed on separate visits (at least 48 hours apart). Performance-based measures of function will include an assessment of patient mobility and the 25-foot walk test. Muscle power will be estimated by the timed sit to stand test. Subjective measures of fatigue and quality of life include the MSQoL, MFIS, and Neurology Quality of Life Adult Fatigue Bank (AFB).
89045209|NCT02913170|Experimental|Nattokinase group|A nattokinase group composed of 50 individuals who consumed a 300mg nattokinase capsule (100mg of nattokinase and 200mg of maltodextrin) daily after meal.
89045210|NCT02913170|Placebo Comparator|Placebo group|A placebo group composed of 50 individuals who consumed a 300mg placebo capsule (300mg of maltodextrin) daily after meal.
89045211|NCT02057172|Experimental|HM11260C (0.3 mg)|Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
89045212|NCT02057172|Experimental|HM11260C (1 mg)|Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
89649059|NCT03155893|Experimental|Panel 1: Treatment C|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily on Day 1 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2, 15 and 16 along with ODV 25 mg (1*25 mg tablet) and SMV 150 mg (2*75 mg capsule) once daily on Day 2 to 16 and AL-335 1200 mg (3*400 mg tablet) single dose on Day 15 orally under fed conditions.
89649060|NCT03155893|Placebo Comparator|Panel 2: Treatment E|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2; ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) on Days 3 to 7; and ODV placebo (matching 100 mg ODV [2*50 mg tablets] on Days 8 to 14, orally once daily under fed conditions.
89649061|NCT03155893|Experimental|Panel 2: Treatment F|Participants will receive ODV 200 mg (4*50 mg tablets) on Days 1 and 2; ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) on Days 3 to 7, and ODV 100 mg (2*50 mg tablets) on Days 8 to 14, orally once daily under fed conditions.
89045213|NCT02057172|Experimental|HM11260C (2 mg)|Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
89045214|NCT02057172|Experimental|HM11260C (3 mg)|Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
89045215|NCT02057172|Experimental|HM11260C (4 mg)|Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
89045216|NCT02057172|Placebo Comparator|Placebo|Weekly administration of placebo by subcutaneous injection for 12 weeks
89045217|NCT02057172|Active Comparator|Liraglutide|Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
89045218|NCT02913404|Experimental|ACL Reconstruction|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia."
89045219|NCT02913404|Experimental|ACL Recon. extra-articular-tenodesis|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia. ACL-R+EAT will be performed as described by Marcacci with doubled hamstring tendon left attached at the pes anserinus, an anatomic tibial tunnel, staple fixation in the over the top position, routing of the graft superficial to the LCL, and staple fixation at Gerdy's tubercle. Concomitant tears to the menisci and their roots will be repaired as indicated."
89045220|NCT02053116|Experimental|PF-05175157|
89045221|NCT02053116|Placebo Comparator|Placebo|
89045222|NCT02912975|Experimental|Mirror treatment|Five minutes treatment period twice a day for three weeks
89045223|NCT02912975|Active Comparator|Tactile treatment|Tactile massage twice a day for three weeks
89649062|NCT01670773|Experimental|CAT-1004 Dose #1|Single dose #1
89649063|NCT01670773|Active Comparator|Salsalate + DHA|Single dose #2
89649064|NCT01670773|Placebo Comparator|Placebo|Single Dose #3
89649065|NCT05228418|Experimental|Participant|All participants who meet inclusion criteria will be offered oral naltrexone in the ED, a bridge prescription for oral naltrexone, and be referred to outpatient MAT clinic where participants will be offered monthly IM naltrexone injections.
89649066|NCT01676233|Experimental|Sequence 1|Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal
89649067|NCT01676233|Experimental|Sequence 2|Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal
89649068|NCT01670851||Strattice|eLAPE
89212826|NCT05683301|Experimental|Arm 2|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Perindopril 4 mg and Indapamide 1.25 mg once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Perindopril 8 mg and Indapamide 2.5 mg once daily, orally
89649069|NCT04078776||Lean Individuals|waist circumference ≤94 cm (men) and 80 cm (women) and BMI ≥ 21.0 kg/m2
89649070|NCT04078776||Obese Individuals|waist circumference ≥102cm (men) and 88 cm (women) and BMI ≥ 30.0kg/m2
89649071|NCT01670929|Active Comparator|Progesterone group|progesterone (400 mg pessary, once daily)
89649072|NCT01670929|Placebo Comparator|Placebo group|Placebo (pessary, once daily)
89649073|NCT02673996||Postural Tachycardia Syndrome (POTS)|Patients with postural tachycardia syndrome; patients will receive both IV phenylephrine and IV isoproterenol
89649074|NCT02673996||Healthy (control) Subjects|Healthy volunteers that are gender and age-matched (by groups) to the POTS patients; healthy subjects will receive both IV phenylephrine and IV isoproterenol
89649075|NCT03925272|Experimental|Patients with Suppurated Hidradenitis|"Human biological samples :~Whole blood and derived products (DNA, RNA), urine, stool, saliva, tears, skin and mouth swabs, lesion samples: swab for microbiological analyzes, cutaneous biopsies (lesion skin and peri-lesional healthy skin), surgical lesion excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~bio-clinical data: Ethno-geographical, family and personal antecedents and current events in particular related to Verneuil's disease and any associated diseases (chronic auto-inflammatory ...)"
89649076|NCT03925272|Experimental|Patients with Alzheimer disease|"Human biological samples :~stool, blood (20 ml), nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~bio-clinical data: healthy or sick status,cognitive, memory and psychometric abilities evaluated by different tests example: MMSE (for Alzheimer's) and MST (minor memory disorders), Psychometric abilities assessed by the Geriatric Depression Scale GDS, Nutritional status assessed by the MNA test"
89649077|NCT03925272|Experimental|Patients with familial adenomatous polyposis|"Human biological samples :~whole blood (30 to 100 mL), optional stool collection~bio-clinical data: Age, Gender, Ethnicity, Personal and Family Medical History, Current Treatment, Type of PAF Mutation"
89649078|NCT03925272|Experimental|Patients with chronic inflammatory diseases (SPA, Crohn, ...)|"Human biological samples :~whole blood and derived products (DNA, RNA, PBMC, plasma, serum), (100 mL), stool; as part of the treatment, occasionally: lesions, urine, saliva, tears~Bio-clinical data :~Ethno-geographical origin, Personal and family history, History of the disease, Associated or concomitant diseases, Treatments in progress."
89649079|NCT03925272|Experimental|Healthy cases|"Human biological samples :~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~Bio-clinical data :~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
89649080|NCT03925272|Experimental|Healthy cases relatives|"Human biological samples :~whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions, nasal swab, oro-pharyngeal swab, nasopharyngeal swab.~Bio-clinical data :~ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ..."
89649081|NCT03925272|Experimental|Subjects vaccinated against COVID-19|"Human biological samples :~whole blood and derived products: serum, DNA, PBMCs, saliva, nasopharyngeal swab~Bio-clinical data :~ethno-geographical origin, family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases, specific history of otorhinolaryngology and broncho-pulmonary and treatments, specific COVID-19 history, risk factor for a severe form of COVID-19, symptoms of COVID-19 or positive test for SarsCov-2 positive"
89649082|NCT04746937|Placebo Comparator|Control Group|They will receive standard therapy plus placebo
89649083|NCT04746937|Active Comparator|Nitazoxanide Group|They will receive standard therapy plus nitazoxanide
89649084|NCT04588350|Experimental|i-SEP autotransfusion system|Use of i-SEP autotransfusion system during the surgery
89649085|NCT05220319|Placebo Comparator|Placebo|"100 ml of NaCl 0,9%, not containing corticosteroids, given at induction of anaesthesia, before surgery.~If a patient will receive cardiopulmonary bypass (CPB) during his operation, a repeat dose of 100 ml of NaCl 0,9% will be administered at the beginning of CPB."
89649086|NCT05220319|Active Comparator|Methylprednisolone|"250 mg of methylprednisolone made up with 100 ml NaCl 0,9%, given at the induction of anaesthesia, before surgery.~If a patient will receive cardiopulmonary bypass (CPB) during his operation, a repeat dose of 250 mg methylprednisolone will be administered at the beginning of CPB."
89649087|NCT05615077|Experimental|Combined exercise-education intervention group|Combined exercise-education intervention by fall risk state for 12 months during intervention period.
89649088|NCT05615077|No Intervention|Control group|No intervention for 12 months during intervention period.
89649089|NCT04555902|Active Comparator|Standard Mailer and Small Gift|A postcard encourages mammograms and includes a small gift.
89649090|NCT04555902|Experimental|Mailer with Loss Frame, Risks, and Small Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; a small gift is included.
89649091|NCT04555902|Experimental|Mailer with Loss Frame, Risks, and No Gift|The postcard is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; the small gift is not included.
89649092|NCT01676389|Experimental|OMM Hands-On Treatment|The Osteopathic Manual Medicine (OMM) Hands-On Treatment group will be receiving an osteopathic structural exam along with 7 gentle, non-thrusting techniques during each treatment session that lasts 20-30 minutes. The Sham treatment group will be receiving only an osteopathic structural exam that will be slowed down in order to be a similar duration to the full treatment group session (approximately 20-30 minutes).
89649093|NCT01676389|Placebo Comparator|Sham OMM|Sham Osteopathic Manual Medicine (OMM)
89649094|NCT05227872||Decompensated HF|
89649095|NCT05227872||Compensated HF|
89649096|NCT04499352|Experimental|treatment arm A|
89649097|NCT04499352|Experimental|treatment arm B|
89649098|NCT03155035|Experimental|Intervention|Albendazole 200 mg 2 tablets single dose
89649099|NCT03155035|Placebo Comparator|Placebo|Calcium 400 mg + vitamin D 2.5 mcg 2 tablets single dose
89649100|NCT01671163||Subjects requiring fiducial placement|Endoscopic Ultrasound (EUS) for fiducial placement
89649101|NCT03154879||Comatose cardiac arrest survivors|
89649102|NCT01463696|Experimental|MK-8242 60 mg BID|In Cycle 1, participants received MK-8242 60 mg administered orally (PO) twice a day (BID) on Days 1-6 and PO once daily (QD) in the morning on Day 7 of the 21-day cycle to accommodate pharmacokinetic (PK) sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 60 mg PO BID on Days 1-7 of each 21-day cycle.
89649103|NCT01463696|Experimental|MK-8242 120 mg BID|In Cycle 1, participants received MK-8242 120 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 120 mg PO BID on Days 1-7 of each 21-day cycle.
89688581|NCT02921386|Other|Breakfast E - High Fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
89045224|NCT02913014|Active Comparator|Arm 1- No AAD post Ablation|Subjects will not resume their Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation.
89045225|NCT02913014|No Intervention|Arm 2-Resume AAD post Ablation|Subjects will resume their pre-ablation Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation, during the 90 day blanking period following the ablation.
89521421|NCT01559363|Experimental|Phase 2a: Cohort 5: Tesevatinib: Tri-weekly Dosing|Participants received tesevatinib 150 mg tablet orally tri-weekly in alternative dosing schedules on Monday, Wednesday and Friday for initial 26 days. After initial 26 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
89521422|NCT01559363|Experimental|Phase 2a: Safety in Larger Kidneys (SILK) Cohort: Tesevatinib 50 mg Once Daily Dosing|Participants with autosomal dominant polycystic kidney disease (and Baseline estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 35 milliliters per minute per 1.73 square meter (mL/min/1.73 m^2) and less than or equal to (<=) 80 mL/min/1.73 m^2, and height-adjusted total kidney volume (htTKV) >=1000 mL were enrolled and received tesevatinib 50 mg tablet orally QD for initial 28 days. After initial 28 days treatment, at the investigator's discretion, participants continued to receive tesevatinib for a total of 24 months (since treatment initiation) or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant, or investigator decision (maximum exposure duration: up to 28 months).
89521423|NCT03423433|No Intervention|Control condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography.~During the second two visits, participants will have either undergo a 180 minute seated protocol or a 180 minute heel raising protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes in both protocols, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout the 180 minutes. EMG will record muscle activation during heel raises after each 30 minutes.~Ten weeks after these sessions have been completed, participants will return to the laboratory for follow-up a session assessing resting measures in an identical protocol to the first visit."
89521424|NCT03423433|Experimental|Experimental (heel raise) condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography. During the second two visits, participants will have undergo a 180 minute seated or a 180 minute heel raise protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout. EMG will record muscle activation during heel raises after each 30 minutes.~Participants in this arm will be prescribed a ten-week heel-raise programme involving hourly heel raises. Ten weeks later, participants will return to the laboratory for follow-up sessions assessing resting measures in an identical protocol to the first visit."
89045230|NCT02913053|Active Comparator|Aerobic exercise|
89045231|NCT02913053|Active Comparator|Stretching and Toning|
89045232|NCT02913053|No Intervention|Usual care: Control Group|
89045233|NCT02894112|Experimental|Oral glucose tolerance test|100 g of glucose in a fruit punch flavored 8 oz drink
89045234|NCT02894112|Experimental|High fat tolerance test|single high fat load determined by body weight.
89045235|NCT01186744|Experimental|Active Treatment (10 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
89045236|NCT01186744|Experimental|Active Treatment (10 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
89045237|NCT01186744|Experimental|Active Treatment (5 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
89045238|NCT01186744|Experimental|Active Treatment (5 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
89045239|NCT02912936|Experimental|Ketogenic medium chain triglyceride drink|Lactose-free skim milk drink containing 25 g of MCT oil per 250 ml.
89045240|NCT02912936|Placebo Comparator|Placebo|Lactose-free skim milk drink containing high-oleic sunflower oil in the equivalent amount of energy as the active arm.
89521425|NCT03127969|Other|Fluidotherapy treatment|Patients who received fluidotherapy and joint protection and exercise
89521426|NCT03127969|Other|Joint protection and exercise|Patients who received joint protection and exercise
89521427|NCT01504919|Experimental|Health Education (HE)|HE of brief counseling and self-help materials addressing 3 risk behaviors, referrals to available resources, and a home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed.
89521428|NCT01504919|Experimental|Motivation and Problem Solving (MAPS)|HE counseling, self-help materials, and resource referrals, and home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed. Plus 9 proactive, telephone counseling sessions over the 18 month period.
89521429|NCT03540121|Experimental|Video education + adherence contract|electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
89521430|NCT03540121|No Intervention|Standard education|standard of care education provided at each transplant center (control emails will be provided at intervention time points)
89521431|NCT02732327|Experimental|CAZ-AVI + Vancomycin or Linezolid|Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care [SOC]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
89212827|NCT05683301|Experimental|Arm 3|(Arm 1 compare to Arm 2 compare to Arm 3) - Treatment Period 1 (Enrollment - 2 months) - Single Pill Combination of Amlodipine 5 mg and Indapamide 1.5 mg sustained release once daily, orally Treatment Period 2 (2 months - 6 months) - Single Pill Combination of Amlodipine 10 mg and Indapamide 1.5 mg sustained release once daily, orally
89212828|NCT05081648|Experimental|Intervention group: Multiple Single Cannulation Technique (MuST)|
89212829|NCT05081648|Other|Control group: Rope-ladder cannulation technique (RL)|
89212830|NCT05068856|Experimental|HRS2543|
89212831|NCT04770467|Experimental|BRII-196 and BRII-198 in adult subjects with severe COVID-19|
89521432|NCT02732327|Active Comparator|Standard of Care+Vancomycin or Linezolid|Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.
89521433|NCT03428503|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
89521434|NCT03428503|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
89212832|NCT04770467|Placebo Comparator|Placebo in adult subjects with severe COVID-19|
89212833|NCT04770467|Experimental|BRII-196 and BRII-198 in adult subjects with mild-moderate COVID-19|
89212834|NCT04770467|Experimental|Placebo in adult subjects with mild-moderate COVID-19|
89212835|NCT00873314|Experimental|Bed rest|
89212836|NCT00873314|Placebo Comparator|Activity restriction|
89212837|NCT00878852|Active Comparator|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
89212838|NCT00878852|Experimental|Experimental|Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
89521435|NCT03421535|Active Comparator|Sleeper stretch group|A certified athletic trainer supervised and observed the athlete as he performed the sleeper stretch on his dominant shoulder.
89521436|NCT03421535|Experimental|Opposite SI joint Stretch|A certified athletic trainer supervised and observed the athlete as he performed the SI joint stretch opposite his dominant shoulder.
89521437|NCT03428425|Experimental|apatinib paclitaxel S-1|
89521438|NCT03417089|Experimental|falciform ligament suspension|routine suspension of falciform ligament during mini gastric bypass,
89521439|NCT03417089|Active Comparator|No suspension|working without suspension of the falciform ligament
89521440|NCT03534583|Active Comparator|Health Enhancement Program (HEP)|The Health-Enhancement Program (HEP) is structurally equivalent to a SKY intervention, with similar-sized groups, meeting for 3 consecutive days for 1.5-3 hours. There will then be a a gap of 4 days where participants will practice what they have learned, followed by 3 consecutive days of 1.5-3 hours of instruction. Starting the following week participants will attend once weekly follow up sessions (60-90 min/wk) for 3 weeks and then bimonthly sessions for the next 8 weeks. Participants will be asked to complete 25 min/day of course homework. Participants will learn about health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation. In HEP, which has been manualized, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes, HEP will be delivered by a trained social worker (or equivalent).
89521441|NCT03534583|Experimental|Sudarshan Kriya Yoga (SKY)|The SKY PTSD program is a mind-body resilience building program developed for persons with PTSD. Through SKY breathing, interactive discussions, journaling, yoga and guided meditations, the workshop builds a framework for resilience and empowerment, and develops self-awareness, connectedness and community, and a positive outlook. SKY training will take place in group-format (6-8 participants). During the first week participants will attend three 2.5-3 hour sessions on three consecutive days. There will then be a gap of 4 days where participants can apply the tools provided, followed by three more consecutive days of 1.5-3 hours of instruction. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period (up to 26 weeks) and log practice frequency.
89521442|NCT03416777|Active Comparator|Meat-based diet (MBD)|Behavioral intervention with diet including 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat.
89521443|NCT03416777|Experimental|Meat-based alpha-tocopherol (MBD-T)|Behavioral intervention including diet with 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat with a dietary supplement of 100 mg/day of alpha-tocopherol in the form of tablet
89521444|NCT03416777|Experimental|Pesco-vegetarian (PVD)|Behavioral intervention with diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish
89521445|NCT03533725|Experimental|Intervention group|Breastfeeding counseling and education services using mHealth tools
89521446|NCT03533725|No Intervention|Comparative control group|No intervention, only standard of care
89521447|NCT03429595|Experimental|Group 1: ATx201 GEL 2%|
89521448|NCT03429595|Experimental|Group 2: ATx201 GEL 4%|
89521449|NCT03429595|Experimental|Group 3: ATx201 GEL 4% plus vehicle|
89521450|NCT03429595|Experimental|Group 4: ATx201 GEL 4% plus vehicle|
89521451|NCT03429595|Placebo Comparator|Group 5: Vehicle|
89521452|NCT01256255||influenza infection|Patients with the diagnosis of influenza infection by standard laboratory technique
89521453|NCT03428347|Experimental|Group 1|1.4 mg/kg body weight
89521454|NCT03428347|Experimental|Group 2|7 mg/kg body weight
89521455|NCT03428347|Experimental|Group 3|14 mg/kg body weight
89045241|NCT02044341|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
89045242|NCT02044341|Placebo Comparator|Glycerin ear drops|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
89045243|NCT00555399|Experimental|Ph I: Arm 1|Vorinostat plus isotretinoin
89649104|NCT01463696|Experimental|MK-8242 170 mg BID|In Cycle 1, participants received MK-8242 170 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 170 mg PO BID on Days 1-7 of each 21-day cycle.
89649105|NCT01463696|Experimental|MK-8242 250 mg BID|In Cycle 1, participants received MK-8242 250 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 250 mg PO BID on Days 1-7 of each 21-day cycle.
89649106|NCT01463696|Experimental|MK-8242 300 mg BID|In Cycle 1, participants received MK-8242 300 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 300 mg PO BID on Days 1-7 of each 21-day cycle.
89649107|NCT01463696|Experimental|MK-8242 350 mg BID|In Cycle 1, participants received MK-8242 350 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 350 mg PO BID on Days 1-7 of each 21-day cycle.
89649108|NCT01463696|Experimental|MK-8242 400 mg BID|In Cycle 1, participants received MK-8242 400 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 400 mg PO BID on Days 1-7 of each 21-day cycle.
89649109|NCT01463696|Experimental|MK-8242 500 mg BID|In Cycle 1, participants received MK-8242 500 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 500 mg PO BID on Days 1-7 of each 21-day cycle.
89649110|NCT03154723|Experimental|Vitamin A Group|In vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
89649111|NCT01671397|Experimental|Diet, exercise, sleep hygiene counseling|Subjects will meet with a dietitian and a physician and receive counseling on diet restriction, exercise goals, and good sleep hygiene. Subjects will identify goals in each domain and keep a calendar of the success with achieving these goals.
89649112|NCT01671397|Active Comparator|Diet and exercise counseling|Subjects will meet with a dietitian and a physician and receive counseling on calorie restriction and exercise. They will identify goals in each domain and keep a calendar to determine their success with achieving these goals.
89649113|NCT04080908|Experimental|Ferumoxytol injection treatment|
89649114|NCT04409678|Experimental|activity|
89649115|NCT04409678|No Intervention|bed rest|
89649116|NCT01671553|Experimental|Counseling group|Study participants in the intervention group were received an intensive smoking cessation telephone counselling with 2-weeks free and 6-weeks discount nicotine replacement therapy (NRT).
89649117|NCT01671553|No Intervention|Control group|Study participants in the control group were not received any quitting assistance other than the self-help materials provided by Hong Kong Council on Smoking and Health (COSH).
89649118|NCT02653482|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg daily
89649119|NCT02653482|Placebo Comparator|Dapagliflozin matching placebo|Dapagliflozin matching placebo 10 mg daily
89045244|NCT00555399|Experimental|Ph I: Arm 2|Temozolomide plus isotretinoin
89045245|NCT00555399|Experimental|Ph I: Arm 3|Vorinostat plus isotretinoin plus temozolomide
89045246|NCT00555399|No Intervention|Ph II: Arm 1|Non-Surgical
89045247|NCT00555399|Other|Ph II: Arm 2|Surgical Arm
89045248|NCT03454932||Rheumatoid Arthritis|Patients with Rheumatoid Arthritis
89045249|NCT03454932||Psoriatic Arthritis|Patients with Psoriatic Arthritis
89045250|NCT03454932||Spondylarthritis|Patients with Spondylarthritis
89045251|NCT02912663|Experimental|Verapamil and Magnesium Sulfate|10mg of verapamil in 10 cc of normal saline and 1000mg of magnesium sulfate in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
89045252|NCT02912663|Placebo Comparator|Placebo|Control group will receive saline only
89045253|NCT02026401|Experimental|NGM282 Dose 1|NGM282 Dose 1
89045254|NCT02026401|Experimental|NGM282 Dose 2|NGM282 Dose 2
89649120|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (neutral)|
89649121|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (marijuana)|
89045255|NCT02026401|Placebo Comparator|Placebo|Placebo
89045256|NCT02912741|Experimental|Vanish xt Extended Contact Varnish|Vanish xt Extended Contact Varnish is a resin modified glass ionomer cement and fluoride varnish used to treat white spot lesions to be more resistant to early caries progression.
89649122|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (neutral)|
89649123|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (marijuana)|
89649124|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (neutral)|
89649125|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (marijuana)|
89649126|NCT01676467||Smoking asthma on steroids|Smokers with persistent asthma on background steroid therapy
89649127|NCT01676467||Smoking asthma steroid naïve|Smokers with persistent asthma, steroid naive
89649128|NCT01676467||asthma on steroids|Non-Smokers with persistent asthma on background steroid therapy
89649129|NCT01676467||asthma, steroid naïve|Non-smokers with persistent asthma, steroid naive
89649130|NCT01676467||Healthy smoking|Healthy smoking control subjects
89521456|NCT03423043||Distal Radius Fracture Patients|Adult patients who have sustained a Distal Radius Fracture.
89521457|NCT02521129|Experimental|Ablation|Intervention: ablation of biopsy needle track with a new device
89521458|NCT03429517||Patients|ACS Lipogram
89521459|NCT03429517||Controls|Normal LDL-C level Lipogram
89521460|NCT03429439|Experimental|IMT Combined with Antiviral Therapy|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved a 6 times intestinal microbiota transplant and the time interval is generally 2 weeks.~Interventions:~Procedure: Intestinal Microbiota Transplantation Procedure: antiviral therapy"
89045257|NCT02912741|Active Comparator|Resin infiltration|Resin infiltration is a low viscous resin infiltrates into small pores of white spot lesions to block entrance of bacteria into dentinal tubules of the tooth and more resistant to early caries progression.
89045258|NCT04318522|Experimental|Stimulation Group|
89045259|NCT04318522|Sham Comparator|Control Group|
89045260|NCT02894151|Active Comparator|LNG-IUS|"LNG IUS was hormonal containing IUD relased LNG at constant rate through out 5 year period.~It was inserted only first time entry in the study."
89045261|NCT02894151|Active Comparator|DMPA|DMPA was given in trimonthly intramuscular injection.
89045262|NCT02912858|Experimental|geko plus R-2|neuromuscular electrostimulation
89521461|NCT03429439|Other|Antiviral Agents|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved 12 months antiviral therapy.~Interventions:~Procedure: antiviral therapy"
89521462|NCT03422965|Active Comparator|Type 1 Diabetes Mellitus|Cohort of Type 1 DM patients
89521463|NCT03422965|Sham Comparator|Healthy controls|Cohort of Healthy controls
89521464|NCT03422887|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
89521465|NCT03422887|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
89521466|NCT03422887|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
89521467|NCT03428269|Experimental|simulation by gaming group|In the simulation by gaming group, the students will individually play with two cases of the LabforGames Warning game (postoperative hemorrhage case and brain trauma in elderly case). After each case, a debriefing to which with all players will participate will be conducted by an instructor.
89521468|NCT03428269|Active Comparator|traditional education group|In traditional education group, the students will individually work on the two same cases but the two vignettes and adjoining questions will be presented and answered by the student on a paper sheet. Then a global review of the two cases and the major messages to be retained will be presented by a teacher.
89521469|NCT02521207|Experimental|Part 1 OXP001|OXP001 formulation containing 800mg ibuprofen single dose
89521470|NCT02521207|Active Comparator|Part 1 Ibuprofen control|Ibuprofen control 800mg single dose
89521471|NCT02521207|Experimental|Part 2 OXP001|OXP001 formulation containing 800mg ibuprofen three times per day
89521472|NCT02521207|Experimental|Part 2 Ibuprofen control|Ibuprofen control 800mg three times per day
89521473|NCT03173053|Active Comparator|Search and destroy (SD) strategy|"A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.~Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
89521474|NCT03173053|Active Comparator|Continuous suppression (CS) strategy|"A repeated, continuous, topical decolonization treatment of S. aureus~Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
89521475|NCT03429127||Normal saline fluid group|The patients in this group will receive up to 2000 ml of normal saline during neurosurgical operation.
89521476|NCT03429127||Balanced fluid group|The patients in this group will receive up to 2000 ml of balanced fluids during neurosurgical operation.
89521477|NCT03422575|Experimental|Test|Etoricoxib 120Mg film-coated Tablet at single dose was given to subjects in this arm.
89521478|NCT03422575|Active Comparator|Reference|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) was given to subjects in this arm.
89521479|NCT03422497||Male hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have male sex listed in their discharge abstract
89521480|NCT03422497||Female hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have female sex listed in their discharge abstract
89521481|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 3 mg|Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
89521482|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 4 mg|Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.
89521483|NCT02412722|Experimental|Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2|Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.
89045263|NCT02894229|No Intervention|No intervention wait-list|This arm will receive no intervention for approximately the first 4 months. At the conclusion of the 4-month period, this group will receive a 6-week cognitive-behavioral therapy (CBT) group
89045264|NCT02894229|Active Comparator|Mindfulness Based Stress Reduction(MBSR)|This arm will receive 6 weekly, 2-hour groups that focuses on mindfulness meditation for stress reduction
89045265|NCT02894229|Active Comparator|Cognitive Behavioral Therapy (CBT) Group|This are will receive 6 weekly, 2-hour groups that focus on cognitive-behavioral skills for stress
89045266|NCT02021370|Experimental|BAY85-3934 (25mg OD)|25 mg once daily (OD) of BAY85-3934 Morning: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo Evening: 3 tablets matching placebo
89045267|NCT02021370|Experimental|BAY85-3934 (50mg OD)|50 mg OD of BAY85-3934 Morning: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo Evening: 3 tablets matching placebo
89045268|NCT02021370|Experimental|BAY85-3934 (75mg OD)|75 mg OD of BAY85-3934 Morning: 3 tablets BAY85-3934 25 mg Evening: 3 tablets matching placebo
89649131|NCT01676467||Healthy non-smoking|Healthy non-smoking control subjects
89649132|NCT02707939||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
89649133|NCT02707939||Controls|Patients with no developmental diagnoses
89649134|NCT04310748|Active Comparator|Total Intravenous Anesthesia(TIVA)|Anesthesia is maintaining with TIVA (Group 1)
89649135|NCT04310748|Active Comparator|Inhalation Anesthesia|Anesthesia is maintaining with inhalation anesthesia (Group 2)
89649136|NCT03154645|Active Comparator|Ibuprofen|ibuprofen, 600mg, three times a day, through to ascent to high altitude
89649137|NCT03154645|Active Comparator|acetazolamide|acetazolamide, 125mg, two times a day, through to ascent to high altitude
89649138|NCT02464098||Group 1|Participants with diagnosis of hematological malignancy or solid tumor.
89649139|NCT02464098||Group 2|Participants undergoing hematopoietic stem cell transplantation (HSCT).
89649140|NCT01671631||Acute Coronary Syndrome|Patients with Acute Coronary Syndrome and multivessel coronary artery disease undergoing functional evaluation of non-culprit lesions.
89649141|NCT01671709|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
89649142|NCT01671709|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
89649143|NCT01189422|Experimental|Segment 1: 3 Arms|
89649144|NCT01189422|Experimental|Segment 2: 4 Arms|
89649145|NCT04302636|Experimental|The hypoglycemic index diet group|"Patients in the experimental group ate two portions of food each day.This diet will last for 12 weeks.~Food provided by the canteen: one egg for breakfast;Lunch and dinner are 50g of rice with all the dishes.~Dietary nutrition and supplementary food: according to the weight and height of the patient, the daily energy required was calculated, which was divided into six levels: 1400kcal, 1600kcal, 1800kcal, 2000kcal, 2200kcal and 2400kcal.The six corresponding nutritional auxiliary food powders are: 20g-30g-40g-50g-60g-70 g.The suspension was prepared in the proportion of 160ml warm water poured into 55 grams and given to the patient."
89649146|NCT04302636|No Intervention|General diet group|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
89649147|NCT05222256|Experimental|Group (L) levosimendan group|Patients in this group will receive levosimendan (0.1 μg/kg/min) during re-warming of the patients.
89649148|NCT05222256|Active Comparator|Group (A) Adrenaline group|Patients in this group will receive Adrenaline (0.05 μg /kg/min) during re-warming of the patients.
89649149|NCT01671787|Experimental|GS-7340 8mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
89649150|NCT01671787|Experimental|GS-7340 25mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
89649151|NCT01671787|Experimental|GS-7340 40mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
89649152|NCT01671787|Experimental|GS-7340 120mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
89649153|NCT01671787|Experimental|Tenofovir disoproxil fumarate 300mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
89649154|NCT04074876||patients with femur fracture|"Group is composed of patients more of 65 years of age with femur fracture undergoing urgent orthopedic surgery.~During normal pre-operative evaluation and classification based on principal scores and laboratory data, patients will be subjected to bedside pulmonary ultrasound.~Pulmonary ultrasound will evaluate the presence of one of four patterns (normal pattern, isolated B lines, coalescent B lines and consolidation) defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient.~These patients will be later subjected to spinal anaesthesia and orthopedic surgery.~They will be follow for evaluation of MACE (major adverse cardiovascular events: atrial fibrillation, flutter, acute heart failure and non-fatal acute myocardial infarction)"
89649155|NCT05229510|Experimental|50 mg/mL Virazole (10 ml total volume)|50 mg/mL Virazole (10 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 20 minutes).
89045269|NCT02021370|Experimental|BAY85-3934 (25mg BID)|25 mg twice daily (BID) of BAY85-3934 Morning and evening: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo
89045270|NCT02021370|Experimental|BAY85-3934 (50mg BID)|50 mg BID of BAY85-3934 Morning and evening: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo
89045271|NCT02021370|Placebo Comparator|Placebo BID|Placebo BID Morning and evening: 3 tablets of placebo matching BAY85-3934 25 mg
89649156|NCT05229510|Experimental|50 mg/mL Virazole (20 ml total volume)|50 mg/mL Virazole (20 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 40 minutes).
89521484|NCT02412722|Experimental|Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2|Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
89521485|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 20 mg|Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.
89649157|NCT05229510|Experimental|100 mg/mL Virazole (10 ml total volume)|100 mg/mL Virazole (10 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 20 minutes).
89649158|NCT05229510|Experimental|100 mg/mL Virazole (20 ml total volume)|100 mg/mL Virazole (20 ml total volume) aerosolized and administered until solution depleted (approximate time of treatment is 40 minutes).
89649159|NCT05229510|Placebo Comparator|Placebo|Placebo aerosolized and administered until solution depleted
89649160|NCT04372381|Active Comparator|Supra-Annular transcatheter heart valve|Medtronic Evolut Pro Valve implantation
89649161|NCT04372381|Active Comparator|Annular transcatheter heart valve|Edwards Sapien 3 Ultra implantation
89649162|NCT01671943|Experimental|Breast carcinoma up to 2.0 cm|
89649163|NCT01672021|Other|PET/MRI|PET/MRI
89649164|NCT01362348|Experimental|pazopanib eye drops|pazopanib topical ocular administration
89649165|NCT03154489|Other|Acenocoumarol|
89649166|NCT03154489|Other|control group|
89649167|NCT04248036|Other|Circle Of Security Parenting, COS-P|Pilot study, assessing eligibility, outcome measures and compliance to Group intervention
89649168|NCT04371055|Experimental|Risk-adapted ECG monitoring for atrial fibrillation|"Intervention Group with high Risk for AF:~Continuous Rhythm Monitoring using an implantable cardiac Monitor~Intervention group with low risk for AF:~7-day Holter ECG at baseline, after 3 and 12 months and then annually until the end of the study or the first occurrence of atrial Fibrillation"
89649169|NCT04371055|Other|Standard of Care|Standard of care rhythm monitoring
89649170|NCT04228848|Active Comparator|Healthy adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
89649171|NCT04228848|Experimental|ACL adult|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
89649172|NCT04228848|Active Comparator|Healthy adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer
89649173|NCT04228848|Experimental|ACL adolescent|Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video.Legs muscle strength will be assessed using hand held dynamometer
89649174|NCT04052724|Experimental|Intervention group LINGI|Trans-diagnostic, 8 module, 8 week long internet intervention for reducing informal caregiver burden
89649175|NCT04052724|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention
89649176|NCT04336033|Experimental|Counseling + Renal Diet App|Subjects in the intervention group will receive an individualized dietetic counseling from the researcher aided with the newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients
89649177|NCT04336033|Placebo Comparator|Counseling + Printed Nutrition Pamphlet|Individualized dietetic counseling aided with printed nutrition pamphlet prepared by Ministry of Health, Malaysia
89649178|NCT00698022|Experimental|Risperidone plus mifepristone|risperidone plus mifepristone daily for 28 days
88993030|NCT04733053|Experimental|Diet plus exercise|The initial physiotherapy consultation for participants in this group will last 75 minutes, with 30 minutes for the exercise component and 45 minutes for the diet component. Thereafter, consultations will last 50 minutes, with 20 minutes for the exercise component and 30 minutes for the diet component. The exercise component will be the same as that described for the exercise alone group.
89649179|NCT00698022|Placebo Comparator|Risperidone plus mifepristone-matched placebo|risperidone plus mifepristone-matched placebo daily for 28 days
88993031|NCT04733053|Active Comparator|Exercise|Physiotherapy consultations for participants in this group will last 30 minutes initially and then 20 minutes thereafter, consistent with clinical practice. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate and a personalised physical activity plan.
88993032|NCT04721873|Experimental|Intervention|
88993033|NCT04721873|Placebo Comparator|Placebo|
88993034|NCT04721015|Experimental|Part 1: ABBV-637 Monotherapy|Participants will receive escalating doses of ABBV-637 in 28-day cycles.
88993035|NCT04721015|Experimental|Part 2a: ABBV-637 + Docetaxel|Participants will receive escalating doses of ABBV-637 in combination with docetaxel in 28-day cycles.
89649180|NCT00698022|Placebo Comparator|Risperidone-matched placebo plus mifepristone|risperidone-matched placebo plus mifepristone daily for 28 days
89649181|NCT01672099|Active Comparator|nutrient enriched dairy|Yoghurt product which contains vitamin K2 and extra dairy nutrients; all in a concentration of 15% of the recommended allowed daily intake (RDI)
89649182|NCT01672099|Placebo Comparator|Basic dairy|2 basic yoghurt products
89649183|NCT01672177|No Intervention|Control|Individuals in the control group will not receive any training.
89649184|NCT01672177|Experimental|Intervention|Individuals in the intervention group will receive two hour long weekly training sessions for seven to eight months. The content of the training focuses on health promotion, health seeking behaviours and chronic disease management.
89649185|NCT02570503|Experimental|ROP/KET/CLON/EPI/SAL|Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
89649186|NCT02570503|Placebo Comparator|Placebo|0.9% Sodium Chloride- 100ml
89649187|NCT01672333|Experimental|Pathological Response|
89649188|NCT02492269|Experimental|Dexmedetomidine|Dexmedetomidine in addition to 15 µg/kg of fentanyl
89649189|NCT02492269|Placebo Comparator|Placebo|Normal saline as a placebo in addition to 15 µg/kg of fentanyl
89649190|NCT01672567|Experimental|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
89649191|NCT01672567|Experimental|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
89649192|NCT01672567|Experimental|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
89649193|NCT00617994|Experimental|Group A|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA.
89649194|NCT00617994|Experimental|Group B|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1.
89649195|NCT00617994|Experimental|Group C|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 2.
89649196|NCT04405219|Sham Comparator|smokers (S)|
89649197|NCT04405219|Active Comparator|non smokers (NS)|
89649198|NCT05046366||Lung cancer group|Participants with lung cancer/pulmonary nodules
88993036|NCT04721015|Experimental|Part 2b: ABBV-637 + Docetaxel|Participants will receive ABBV-637 at dose determined in Part 2a in combination with docetaxel in 28-day cycles.
88993037|NCT04721015|Experimental|Part 3a: ABBV-637 + Osimertinib|Participants will receive escalating doses of ABBV-637 in combination with osimertinib in 28-day cycles.
88993038|NCT04721015|Experimental|Part 3b: ABBV-637 + Osimertinib|Participants will receive ABBV-637 at dose determined in Part 3a in combination with osimertinib in 28-day cycles.
88993039|NCT04701086|Experimental|Cationorm Pro|Cationorm Pro is an ophthalmic sterile unpreserved eye drops emulsion (N=40) Posology: One Drop in each eye 4 times daily for 84 days
88993040|NCT04701086|Active Comparator|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
88993041|NCT04685109|Experimental|Alocross|Cross-linked HA 0.2% + Aloe Vera 0.1% solution (N=40) Posology: One Drop in each eye 4 times daily for 84 days
88993042|NCT04685109|Active Comparator|Vismed|HA 0.18% hyaluronic solution (N40) Posology: One Drop in each eye 4 times daily for 84 days
88993043|NCT04681274||patient with hepatocellular carcinoma|Phenotype signature database building Image features extraction and clustering
88993044|NCT04634162|Experimental|Cangrelor|Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
88993045|NCT04634162|Placebo Comparator|Placebo|Ticagrelor loading dose followed after 1 hour by placebo infusion
88993046|NCT04630860|Experimental|56mg dose group|
88993047|NCT04630860|Experimental|84mg dose group|
88993048|NCT04630860|Experimental|112mg dose group|
88993049|NCT04616196|Experimental|Dose Escalation of NKTR-255 with Cetuximab|Establish RP2D, of NKTR-255 with cetuximab.
88993050|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort A|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with HNSCC.
88993051|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort B|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with CRC.
88993052|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort C|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with cSCC.
88993053|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort D|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with ASCC.
88993054|NCT04616196|Experimental|Dose Expansion of NKTR-255 with Cetuximab - Cohort E|The RP2D of NKTR-255 will be evaluated as monotherapy and in combination with cetuximab in patients with cervical cancer.
88993055|NCT04602949|Experimental|COVID-19 patients|subjects who were found as COVID-19 positive patients by swab RT-PCR
88993056|NCT04602949|Other|Healthy controls|subjects who were found as COVID-19 Negative, by swab RT-PCR
88993057|NCT04601948|Experimental|Intervention|Participants will receive a Fitbit activity monitor and access to the mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
88993058|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Lower Trapezius group|Rotator cuff tears excluding the subscapularis muscle repaired using Lower Trapezius tendon
88993059|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Latissimus Dorsi group|Rotator cuff tears excluding the subscapularis muscle repaired using Latissimus Dorsi tendon
88993060|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Pectoralis group|Rotator cuff tears involving the subscapularis muscle repaired using Pectoralis tendon
88993061|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Latissimus Dorsi group|Rotator cuff tears involving the subscapularis muscle repaired using Latissimus Dorsi tendon
89649199|NCT05046366||Pulmonary tuberculosis group|Participants with pulmonary tuberculosis
89649200|NCT05046366||COIVD-19 group|Participants with COIVD-19
89649201|NCT03153943|Experimental|Workbook support group|Printed educational workbook and pedometer.
89649202|NCT03153943|Experimental|HIP Mobile e-Monitoring support group|Remote monitoring via smart shoe insoles and a coaching with enabling educational electronic program accessed through a tablet.
89649203|NCT05561179|Experimental|GERD + HA injections|This group is comprised by patients with GERD, assessed previously through 24-Hour pH impedance test and esophageal manometry. The patients are submitted to HA injections at the lower esophageal level.
89649204|NCT05561179|Placebo Comparator|GERD without HA injections|This group is comprised by patients with GERD assessed previously through 24-Hour pH impedance test and esophageal manometry. The patients are submitted to sodium chloride at the lower esophageal level.
89649205|NCT03154021|Experimental|Gingivitis Test|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and Next Science Over the Counter (OTC) Oral Rinse with Essential Oils.
89649206|NCT03154021|Placebo Comparator|Gingivitis Placebo|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and OTC Oral Rinse Control.
89649207|NCT03754309|Experimental|KY1005 lower dose|Low dose KY1005
89649208|NCT03754309|Experimental|KY1005 higher dose|High dose KY1005
89649209|NCT03754309|Placebo Comparator|Placebo|Matched placebo
89045272|NCT02912702|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin hydrochloride liposome injection 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
89045273|NCT02912702|Active Comparator|HLH-94 regimen|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
89045274|NCT02894073|No Intervention|control group|PVC placement performed in the usual manner: visual inspection of the patient's anatomy
89045275|NCT02894073|Experimental|visualisation group|a skin transilluminator (such as the VeinViewer®Vision) is used to guide PVC placement
89045276|NCT02912585|Experimental|Own mother's colostrum|Oropharyngeal administration of own mother's colostrum.
89045277|NCT02912585|Placebo Comparator|Placebo|Oropharyngeal administration of sterile water.
89045278|NCT02912585|Active Comparator|Donor human milk|Oropharyngeal administration of donor human milk.
89045279|NCT02016534|Experimental|Single arm|AMG 337 Monotherapy
89045280|NCT02912429|Other|Inlay|specific technical type of patellofemoral arthroplasty
89045281|NCT02912429|Other|Onlay|specific technical type of patellofemoral arthroplasty
89045282|NCT02010333|Experimental|Ha44 Gel 0.74% w/w|Open label, one arm
89045283|NCT02912390|Active Comparator|Cerclage|- Macdonald cerclage placed in standard fashion
89045284|NCT02912390|Active Comparator|Expectant management|- Patient is placed on activity restrictions
89045285|NCT02894346||Teachers|Public school teachers in Denmark - across age, gender, subject, class and experience.
89045286|NCT02912273||Fall Risk Assessment Group|-Participants will complete baseline primarily self-administered cancer-specific geriatric assessments and measures of neuropathy and pain, an abbreviated geriatric assessment with each follow-up clinic visit (generally every 3-4 weeks in patients receiving systemic therapy) for 6-months of follow-up and a final end-of-study assessment.
89045287|NCT02008344|Active Comparator|favipiravir|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
89045288|NCT02008344|Placebo Comparator|placebo|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
89045289|NCT02912546|Active Comparator|Control group|Eighteen healthy subjects and eighteen hypertensive patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
89521486|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 30 mg|Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.
89521487|NCT03422419|Experimental|TIPS+Anticoagulation|
89521488|NCT03422419|Active Comparator|Anticoagulation|
89521489|NCT03077815|Other|arm movement more than a total of at least 30 minutes a day|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day
89521490|NCT03077815|Other|arm movement and local press strength 50 mmHg at the upper arm|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day with Elbow proximal 4 (2~6) local press strength 50 mmHg at the upper arm
89521491|NCT03428893|Experimental|Mobile Application Group|The mobile app group will receive physical therapy as determined by the physical therapist and agree to receive the home exercise prescription using a mobile app on their phone or personal tablet
89521492|NCT03428893|No Intervention|Control|The control group will receive physical therapy as determined by the physical therapist based on clinical practice guidelines and will receive the home exercise program in the traditional way through paper exercise handouts
89521493|NCT04449289|Active Comparator|Intravenous lidocaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+intravenous lidocaine infusion for the first 48 hours postoperative
89521494|NCT04449289|Active Comparator|Epidural ropivacaine|Patients will be subjected to anesthesia with sevoflurane+fentanyl+epidural ropivacaine infusion for the first 48 hours postoperatively
89521495|NCT03074695|Experimental|Dural Puncture Epidural (DPE)|Women who have analgesia initiated with a DPE technique
89521496|NCT03074695|Experimental|Standard Epidural (EPL)|Women who have analgesia initiated with an epidural technique
89521497|NCT03128203|Experimental|Oxytocin|
89521498|NCT03128203|Placebo Comparator|Placebo|
89521499|NCT03422341|Experimental|GenePOC testing|"The swab will be used for the testing on the revogene using the GenePOC Strep A, C/G assay.~Intervention will be the Comparison between GenePOC CR and Reference Method."
89521500|NCT03422341|Active Comparator|Reference Method|"The swab will be used to detect the presence or absence of Strep A, C/G using standard microbiology method.~Intervention will be the Comparison between GenePOC CR and Reference Method."
89521501|NCT03422263||Patients with T2DM under new therapy with SGLT-2-Inhibitors|Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
89521502|NCT03422263||Patients with T2DM without SGLT-2-Inhibitors.|Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
89521503|NCT03422263||Patients without T2DM manifesting similar comorbidities|Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)
88993062|NCT04583956|Active Comparator|Remdesivir + Placebo|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab placebo infusion (300-mg x 4 vials) once on Day 1. N=100.
88993063|NCT04583956|Experimental|Remdesivir + Risankizumab|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab infusion (300-mg x 4 vials) once on Day 1. N=100.
88993064|NCT04562207|Experimental|Patients|Addition of a nasopharyngeal swab before surgery
89521504|NCT03469999|Experimental|Dysport Injectable Product|All participants will participate in baseline data collection of energy expenditure, gait analysis, and lower limb spasticity assessment. All participants will receive single event multi level chemoneurolysis with Dysport and will have repeat data collection at 4 weeks and 12 weeks post injection.
89521505|NCT02379728|Experimental|PrenaBelt|"Participants will be instructed to use the PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
89521506|NCT02379728|Experimental|PrenaBelt with Body Position Sensor|"Participants will be instructed to use the PrenaBelt (with integrated body position sensor (BPS)) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
89521507|NCT02379728|Sham Comparator|Control|"Participants will be instructed to use the sham-PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
89521508|NCT02379728|Sham Comparator|Control with Body Position Sensor (BPS)|"Participants will be instructed to use the sham-PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the sham-PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
89521509|NCT03422107||TAVI|Transcatheter Aortic Valve Implantation
89521510|NCT03422107||cAVR|Conventional Valve Replacement
89521511|NCT03422107||rCABG|minimally invasive coronary artery bypass graft
89521512|NCT03422107||cCABG|Conventional Coronary Artery Bypass Graft
89521513|NCT02935309|Experimental|Pre-Surgery Chemotherapy/Radiotherapy|Pre-surgery chemotherapy and external radiation therapy. Dose escalation of Lenvatinib; fixed dose Capecitabine; Radiotherapy. Lenvatinib and capecitabine will be started on day 1 with radiation and will be discontinued on the last day of radiation. Surgical resection should occur between 6 - 10 weeks after the participant completes preoperative lenvatinib, capecitabine, and radiation therapy. Postoperative chemotherapy after surgery will be given at investigator's discretion.
89521514|NCT03428113||ICU patient unable to void for 6 hours|ICU patients unable to void after 6 hours after a indwelling urinary catheter is removed or since time of admission
89521515|NCT03428113||renal failure with low urine volume|ICU patients with renal failure, acute kidney injury or acute on chronic with minimal urine output without an indwelling urinary catheter
89521516|NCT04900922||Healthy tennis players|Participants in this group need to perform arm elevation in the scapular plane three times and successful flat tennis serve three times before and after a fatigue protocol. Surface electromyography on infraspinatus, pectoralis major, anterior deltoid ,and latissimus dorsi will be used to detect muscle activity related to fatigue.
89521517|NCT03463993|Experimental|Group A|Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
89521518|NCT03463993|Active Comparator|Group B|Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
89521519|NCT04899440|Experimental|Test Regimen|Oral Irrigator + Manual toothbrush + toothpaste Subjects will brush their teeth twice daily and will use the oral irrigator once in the evening daily
89521520|NCT04899440|Sham Comparator|Control Regimen|Manual toothbrush + toothpaste Subjects will brush their teeth twice daily
89521521|NCT02412488|Experimental|Out of CathLab setting|Out of cathlab insertion
89521522|NCT03419143||Cohort 1|naïve of abatacept, other biologic agents and Targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs)
89521523|NCT03419143||Cohort 2|"naïve of abatacept, who previously failed one tumor necrosis factor inhibitor (TNFi), but are naïve of any other biologic agent and tsDMARDs"
89521524|NCT03419143||Cohort 3|naïve of abatacept, who previously failed treatment with tsDMARDs and/or biologic agents** other than a single TNFi
89521525|NCT03417271|Active Comparator|30us stimulation then 60us stimulation|All patients will receive both types of stimulation in a randomised crossover design. This arm will receive 30us stimulation for 4 weeks then will be switched to 60us stimulation for 4 weeks.
89521526|NCT03417271|Active Comparator|60us stimulation then 30us stimulation|All patients will receive both types of stimulation in a randomised crossover design.This arm will receive 60us stimulation for 4 weeks then will be switched to 30us stimulation for 4 weeks.
89521527|NCT03422029|Experimental|177Lu-Dotatate PRRT|177Lu-Dotatate A maximum of 8 cycles of 1000mCi 177Lu-Dotatate, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 8 cycles, every 8 weeks
89521528|NCT03421873||Intervention (Implementation) group|Chest pain patients enrolled during a 10 month period after a change in routine care, i.e. the implementation of a 0h/1h hs-cTnT protocol
89521529|NCT03421873||Control group|Chest pain patients managed at the 3 intervention EDs during the corresponding 10 months of the previous year (intervention hospitals acting as their own controls) as well as chest pain patients managed during the corresponding before-and-after period at EDs not implementing the protocol (concurrent controls).
89521530|NCT03417037|Experimental|Arm A|BMS-986205 and Nivolumab administered in combination
89521531|NCT03417037|Experimental|Arm B|BMS-986205 and Nivolumab administered in combination with chemotherapy
89212839|NCT05226806||Healthy adults|"Inclusion criteria: both, mals and female, age 45 years and older. Exclusion criteria: Medical contraindications for a maximum stress test and endurance test by the attending physician~Pathologies in the context of the preliminary examinations:~Acute and chronic cardiovascular diseases except arterial hypertension (systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg in untreated and drug-treated participants) and minor valve insufficiency~Acute and chronic lung diseases~Liver and kidney diseases~diabetes mellitus~Alcohol (> 30g / day) or drug abuse~Obesity from grade 2 (body mass index> 35 kg / m²)~Orthopedic diseases with reduced physical performance~Existing pregnancy"
89212840|NCT05671367||Artery without microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR<2.5 mmHg*s/cm is defined as no microvascular resistance.
89521532|NCT03417037|Active Comparator|Arm C|Chemotherapy administered alone
89521533|NCT02378480|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
89521534|NCT02378480|Active Comparator|Linezolid|Linezolid IV; Linezolid tablets
88993065|NCT04544358|Experimental|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
89521535|NCT03109639|Active Comparator|Group A|This group will undergo tissue acquisition using the conventional EUS-FNA needle followed by the experimental Acquire EUS- FNB needle
89521536|NCT03109639|Active Comparator|Group B|This group will undergo tissue acquisition using the experimental Acquire EUS- FNB needle followed by the conventional EUS-FNA needle
89521537|NCT03421795|Experimental|Let's Talk About Pain Training|Participants complete pre-, post- and follow-up measures, and receive a pain training program. The pain assessment and management training will be based on a training previously developed and piloted by Genik et al. (2017). The training will be facilitated by the same researcher (L.G.) throughout the study.
89521538|NCT03421795|Sham Comparator|Family Centered Care Training|Participants complete all of the same measures as those in the intervention, but receive a training about family centered care. This training will be facilitated by Andrea Cross (PhD Candidate) from CanChild and will be related to the F-words of childhood disability (function, family, fitness, fun, friends, future; Rosenbaum & Gorter, 2012) .
89521539|NCT03421717|Experimental|Test|Treatment/maintenance of implants postsurgically performed by the use of chitosan brushes
89521540|NCT03421717|Active Comparator|Control|Treatment/maintenance of implants postsurgically performed by the use of titanium curettes
89521541|NCT02411396||Patients With SCD|Patients treated for uncomplicated VOC in ICs and EDs.
89521542|NCT03428035|Experimental|Modified Package Insert|Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.
89521543|NCT03428035|No Intervention|Verbal Information|The patient is informed verbally about side effects and does not receive any package insert.
89521544|NCT03428035|Active Comparator|Control|Package insert according to EU Directive 2001/83 / EC (usual package insert)
89521545|NCT03427957|Experimental|New hysteroscopic grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the new grasper with knurled terminal end and cutting jaws.
89521546|NCT03427957|Active Comparator|Classic spoon grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic spoon grasper.
89521547|NCT03427957|Active Comparator|Classic alligator grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic alligator grasper.
89521548|NCT03427879|Placebo Comparator|Low flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, low flavonoid, sports nutrition recovery beverage 14 days.
89521549|NCT03427879|Active Comparator|High flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, high flavonoid, sports nutrition recovery beverage 14 days.
89521550|NCT03427801||Treatment Group|Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent
89521551|NCT03427801||Control Group|Chronic kidney disease patient receiving palliative care without erythropoiesis-stimulating agent
89521552|NCT03416803|Experimental|Radiotherapy|Patients in the experimental group, who were at high risk for lymph node metastasis, underwent radiotherapy in the lymphatic drainage area. Radiotherapy was started in lymphatic drainage areas about 1 month after HCC surgery. The range of radiotherapy was hepatic portal area, pancreas circumference, celiac trunk and abdomen Around the aortic lymph drainage area, the dose of radiation 45Gy, conventional segmentation.
89521553|NCT03416803|No Intervention|Blank control|Patients in the control group , who were at high risk for lymph node metastasis，were followed up.
89521554|NCT03416725||Patients with chronic suppurative otitis media.|patients of the age group 18-60 years with Chronic suppurative otitis media (CSOM) planned for tympanoplasty.
89521555|NCT01483105|Experimental|DVD self-hypnosis|This group will receive standard care, and parents/children in this group will receive in the mail a set of questionnaires and the DVD self-hypnosis training program. Parents will be asked to review these materials and practice the training at home with their children for one week leading up to the procedure Parents will also be asked to try to use these techniques with their child during his or her upcoming VCUG procedure.
89521556|NCT01483105|No Intervention|Standard care|Children in this arm will receive standard care and parents/children will be mailed a set of questionnaires to complete before and after your child's upcoming VCUG.
89521557|NCT01329757|Active Comparator|GH|Administration of a daily dose of GH (0.4mg)for 1 year
89521558|NCT01329757|Placebo Comparator|Placebo|Administration of a daily dose of placebo for 1 year
89521559|NCT03427723|Active Comparator|Standard care|visualization and palpation
89521560|NCT03427723|Experimental|Accuvein|system uses an infrared laser beam to project the image of superficial veins to the skin
89521561|NCT03416647|Experimental|SMAS patients|
89521562|NCT03427645|No Intervention|Control Surrogate Arm|Usual care control group will complete baseline and follow-up questionnaires with standard decision making techniques. This group will not be asked to use the decision making tool.
89212841|NCT05671367||Single artery with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg*s/cm is defined as microvascular resistance. There is only one of three major coronary arteries in 3 that meets this condition.
89212842|NCT05671367||Multiple arteries with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg*s/cm is defined as microvascular resistance. Two of the three major coronary arteries meet this condition.
89212843|NCT05671367||Three arteries with microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg*s/cm is defined as microvascular resistance. All three major coronary arteries meet this condition.
89521563|NCT03427645|Experimental|Surrogate Decision Tool Arm|This group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
88993066|NCT04544358|No Intervention|Control|Randomized to wait list, received BAILAMOS© program after data collection.
89521564|NCT03416569|Experimental|Nicotine-Prazosin Interaction Study|Over four test days, each participant will be tested with placebo, nicotine alone, prazosin alone, and nicotine + prazosin, in a double-blind sequence.
89521565|NCT01004029|Placebo Comparator|Vehicle|Castor Oil
89521566|NCT01004029|Active Comparator|Hydroxyprogesterone Caproate Injection (HPC), 250 mg/mL|HPC 250 mg/mL in oil
89521567|NCT03416491|Experimental|NC_30|Non-cirrhotic subjects were medicated with KW-136 capsules 30 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
89521568|NCT03416491|Experimental|NC_60|Non-cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
89521569|NCT03416491|Experimental|LC_60|Cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
89521570|NCT03427567||Sublobar dissection|Chinese NSCLC patients who received sublobar dissection
89521571|NCT03416257||WIHS|Women's Interagency HIV Study
89521572|NCT03416257||MACS|Multicenter AIDS Cohort Study
89521573|NCT03427489||Coronary heart disease|Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
89521574|NCT03427489||Controls|Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.
89521575|NCT03427333|Experimental|The Rook® Epicardial Access Kit|The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.
89521576|NCT03421405|Experimental|Intervention Arm|All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
89521577|NCT03421327||Families at-risk for HD|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
89521578|NCT03421327||Families at-risk for hereditary cancer|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
89521579|NCT03421327||Genetic Counselors|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
89521580|NCT03421249|Active Comparator|Group A - Intervention|Submitted to knee and hip muscle strengthening exercises and electromagnetic field therapy with Magnetron ® (Meditea - ARG) using the coplanar technique
89521581|NCT03421249|Active Comparator|Group B - exercises|Performed exercises to strengthen the hip and knee muscles
89521582|NCT03421249|Placebo Comparator|Group C - Placebo|Performed hip and knee strengthening exercises and electromagnetic field therapy with the coplanar Magnetron® technique, but with the device switched off
89521583|NCT03421249|Active Comparator|Group D - Apparatus|Only use electromagnetic field therapy with the coplanar Magnetron® technique
89521584|NCT04596475|Experimental|Treatment Arm|
89521585|NCT03421093||Surgeries and adjuvant therapies|Surgeries or surgeries plus adjuvant therapies
89521586|NCT03421015||case group|patients with biochemical recurrence and positive imaging (case group)
89521587|NCT03421015||Control Group|patients without biochemical recurrence (control group)
89521588|NCT03420937|Experimental|Deep Neuromuscular Block|"Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min.~Intervention: Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
89521589|NCT03420937|Experimental|Moderate Neuromuscular Block|Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Intervention: Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9.
89212844|NCT05671367||Significant microcirculation resistance|The angiographic microvascular resistance (AMR) index was analyzed by interventional laboratory platform image analysis software (AngioPlus 2.0). AMR≥2.5 mmHg*s/cm is defined as microvascular resistance. The sum of AMR of the three main arteries is greater than 7.5mmHg*s/cm
89649210|NCT05409937|Experimental|Improved Hot Weather Combat Uniform|Wearing the Improved Hot Weather Combat Uniform; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
89649211|NCT05409937|Experimental|Army Combat Uniform|Wearing the Army Combat Uniform; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
89649212|NCT05409937|Experimental|Army Combat Uniform + Silk Weights|Wearing the Army Combat Uniform + a base layer of silk weights; Asked to perform 60 min of standing with minimal movement, 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, 60 min weight (38.5lb) treadmill walking at 2.5mph, up to 4% grade.
89649213|NCT05409937|Experimental|Army Combat Uniform- XR|Wearing the Army Combat Uniform; Asked to perform 60 min weighted (38.5lb) treadmill walking at 2.0mph, up to 4% grade, followed by 60 min of standing with minimal movement
89649214|NCT03153397|Experimental|Nutraflora scFOS|prebiotic fiber-containing formula (Nutraflora scFOS)
89649215|NCT03153397|Active Comparator|Osmolite|non-prebiotic fiber containing formula (Osmolite)
89649216|NCT02467153|Experimental|RET + vitamin D3|Resistance Exercise Training (RET) + vitamin D3 given orally as tablets at a dosage of 800 International Units (IU)/day for 6 months.
89649217|NCT02467153|Placebo Comparator|RET + placebo|Resistance Exercise Training (RET) + placebo given orally as tablets; 1 tablet per day for 6 months.
89649218|NCT03719521|Experimental|Intervention Arm|"Community-based provision of an integrated package of services over a 24 month period.~For all those aged 16-24 years residing in the intervention clusters: HIV testing, Sexual and reproductive health services (condoms, menstrual hygiene management, contraception, syndromic sexually transmitted infection (STI) treatment, referral for voluntary medical male circumcision, cervical screening), General health information and counselling. For those who are aged 16-24 years and test HIV-positive (or known HIV positive) within the intervention clusters: ART initiation and community-based treatment, adherence support."
89649219|NCT03719521|Active Comparator|Control Arm|Routine existing services
89649220|NCT03153007||Subjects with DFU|Adult male or female subjects, 18 years of age or over and currently receiving treatment for a diagnosis of DFU or have received treatment for a past foot ulcer within the last 6 months, will be recruited from up to three clinical sites. They will undergo concept elicitation interviews over the telephone or in-person by trained and experienced interviewers.
89649221|NCT01676545||Chronic Periodontitis|
89649222|NCT01676545||Control|
89649223|NCT04933903|Experimental|Protocol Therapy|Ipilimumab: 1mg/kg IV day 1. Nivolumab: 3mg/kg IV days 1, 15, 29. SBRT delivered as 1-2 fractions to the gross primary tumor and nodal disease following day 1 infusion and completed by day 3 (7Gy x 1; 4Gy x 2).
89649224|NCT03153163|Experimental|Trastuzumab Emtansine|Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.
89649225|NCT03153085|Experimental|TBI-1401(HF10) + Ipilimumab|1x10^7 TCID50/mL TBI-1401(HF10) administered to a single or multiple eligible tumors in a total volume up to 5.0 mL (injection volume will be adjusted based on the size of tumor mass) by intratumoral injection and 3 mg/kg ipilimumab administered by intravenous infusions.
89649226|NCT03463525|Experimental|[11C]osimertinib + oral osimertinib|IV microdose administrations of [11C]osimertinib co-administered with 80 mg daily oral osimertinib.
89212845|NCT00868088|Active Comparator|ALA + PDT|Topical ALA will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
89212846|NCT00868088|Placebo Comparator|placebo + PDT|Topical placebo will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
89212847|NCT00873392|Experimental|1|Experimental drug
89212848|NCT00873392|Active Comparator|2|Usual treatment
89212849|NCT04039256|Experimental|PVR implantation group|Patients enrolled receive PVR intervention
89212850|NCT02587013|Experimental|In situ uterine repair|The uterus is repaired in situ within the abdominal cavity, without exteriorization; intra-abdominal repair
89649227|NCT01673269|Experimental|ERCP with direct examination of the CBD|
89649228|NCT03438643||Patient|Patients treated with ECP and corticosteroid as first-line treatment for cGVHD
89649229|NCT01675128|Experimental|Phase I Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 started 800 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
89649230|NCT01675128|Experimental|Phase I Dose Level II|Irinotecan 180 mg/m^2 every other week; ISIS 183750 1000 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
89649231|NCT01675128|Experimental|Phase II Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 1000mg every week will be administered as an intravenous infusion every week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be re-staged every 8 weeks.
89649232|NCT02626507|Experimental|Gedatolisib ER+/HER2- Breast Cancer|"Gedatolisib at escalating doses of 180, 215 and 260 mg via a 3-6 dose-escalation scheme is administered once weekly on the first day for each of the four weeks during the four 4-week cycles.~Faslodex at 500 mg is administered IM into the buttocks slowly (over 1 - 2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of Cycle 1 and on Day 1 of the remaining three 4-week treatment cycles.~Palbociclib at 125 mg is administered PO with food daily on Days 1-21 for each of the four 4-week cycles~Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment."
89649233|NCT03243175|Experimental|Direct Oral Anticoagulant (DOAC)|Apixaban 5MG twice daily
89649234|NCT03243175|Experimental|Left Atrial Appendage Closure (LAAC)|Devices will be chosen by local teams.
89649235|NCT03243175|No Intervention|Control|avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug
89649236|NCT04995510||Chronic Obstructive Pulmonary Disease Group|Individuals diagnosed with chronic obstructive pulmonary disease by ''Bolu Abant Izzet Baysal University'' Faculty of Medicine, Department of Chest Diseases and referred to the Physiotherapy and Rehabilitation Department of Bolu Abant Izzet Baysal University Health Sciences Faculty
89649237|NCT04995510||Healthy Group|Volunteer healthy individuals with similar demographic characteristics and without any diagnosed disease will be recruited
89649238|NCT04764877|No Intervention|Standard Care|Standard teaching and physical exam for any patient that would be seen at our Hilltop Primary Care center asthma clinic. This included baseline PFTs. FOR THIS STUDY a second set of PFTs were obtained at the end of the visit
89649239|NCT04764877|Experimental|OMT arm|As above BUT with the addition of standardized OMT focusing on lung functionality. OMT provided by either our OMM attending at that time (Dr Wolf) or residents trained by her for this study (Drs. Regan, Jones, Pe and Bryant)
89649240|NCT04764955|Placebo Comparator|Group A (Placebo)|Prenatal Period 0 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
89649241|NCT04764955|Experimental|Group B (4200:0 IU/week)|Prenatal Period 4200 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
89649242|NCT04764955|Experimental|16800:0 IU/week|Prenatal Period 16800 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
89649243|NCT04764955|Experimental|28000:0 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 0 IU/week (delivery-6 months postpartum)
89649244|NCT04764955|Experimental|28000:28000 IU/week|Prenatal Period 28000 IU/week (17-24 weeks gestation - delivery) ; Postpartum Period 28000 IU/week (delivery-6 months postpartum)
89649245|NCT04511208|Experimental|Cooling vest, then without cooling vest, then without cooling vest, then cooling vest (ABBA)|Surgeons first performed one surgery with the cooling vest. On another day, they then performed one surgery without the cooling vest. Then on another day, they performed another surgery without the cooling vest. Then they finally performed one surgery with the cooling vest.
89649246|NCT04511208|Experimental|Without cooling vest, then cooling vest, then cooling vest, then without cooling vest (BAAB)|Surgeons first performed one surgery without the cooling vest. On another day, they then performed one surgery with the cooling vest. Then on another day, they performed another surgery with the cooling vest. Then they finally performed one surgery without the cooling vest.
89649247|NCT04511208|Experimental|Cooling vest, then cooling vest, then without cooling vest, then without cooling vest (AABB)|Surgeons first performed one surgery with the cooling vest. On another day, they then performed another surgery with the cooling vest. Then on another day, they performed one surgery without the cooling vest. Then they finally performed another surgery without the cooling vest.
89649248|NCT04511208|Experimental|Without cooling vest, then without cooling vest, then cooling vest, then cooling vest (BBAA)|Surgeons first performed one surgery without the cooling vest. On another day, they then performed another surgery without the cooling vest. Then on another day, they performed one surgery with the cooling vest. Then they finally performed another surgery with the cooling vest.
89045290|NCT02912546|Active Comparator|Stroke patients|Eighteen stroke patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
89649249|NCT01673581||Low risk prostate cancer|
89649250|NCT03152851|Experimental|Pressure stimulus group by ultrasound probe|A pressure stimulus would be applied once using a device (ultrasound probe) to the anteroposterior wall of the bladder until the anterior & posterior wall meet if the measured diameters (AP x T) is 2 X 2 or more by ultrasound
89649251|NCT03152851|No Intervention|Non-pressure stimulus group|No pressure stimulus would be given
89212851|NCT02587013|Active Comparator|Exteriorization of the uterus|The uterine incision is repaired with the exteriorization of the uterus; extra-abdominal repair
89649252|NCT01770067|Experimental|Infected CIED and Infection-Prone Patients Prior to CIED Implantation|Administration of high-dose antibiotics (CITA)
89649253|NCT01770067|Active Comparator|Infected CIED extraction|Extraction of infected CIED
89649254|NCT03152695|Experimental|High-intensity focused ultrasound therapy|Abdominal MRI will be used to target the tumor, and the tumor will be divided into slices with 5mm separation using MR images. By scanning the HIFU beam in successive sweeps from the deep to the shallow regions of the tumor.
89649255|NCT03028597|Experimental|Intervention Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
89649256|NCT03028597|Active Comparator|Control Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
89045291|NCT02912156|Experimental|Vaway FC Tablets|Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
89045292|NCT02912156|Active Comparator|VFEND FC Tablets|VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
89045293|NCT03455049|Experimental|Normal subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
89045294|NCT03455049|Placebo Comparator|Normal subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
89045295|NCT03455049|Experimental|Prediabetes subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
89045296|NCT03455049|Placebo Comparator|Prediabetes subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
89045297|NCT02912234|Experimental|Apixaban and Clarithromycin|
89649257|NCT03152461||Surgical patients|Patients undergoing elective cardiac or vascular surgery involving bypass, or major spine surgery, or surgical patients presenting with acute bleeding in a post-surgical unit.
88993067|NCT04541407|Experimental|Exon 19 deletions or L858R point mutations in exon 21|Will include patients with exon 19 deletions or L858R point mutations in exon 21 of the epidermal growth factor receptor (EGFR) gene. Temozolomide plus Osimertinib will be the study drug combination administered. Osimertinib will be given at a fixed dose of 80 mg daily for dose level 1, with a potential to increase to 160 mg daily for dose level 2. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level.
88993068|NCT04541407|Experimental|Patients with anaplastic lymphoma kinase (ALK) fusions|Will include patients with anaplastic lymphoma kinase (ALK) fusions. Temozolomide plus Lorlatinib will be the study drug combination administered. Lorlatinib will be given at a fixed dose of 100 mg daily. Temozolomide will be started at a dose of 150 mg/m2 on days 1-5 of a 28 day cycle for cycle 1 and if tolerated will be increased to 200 mg/m2 on days 1-5 of a 28 day cycle for cycles 2+. There will be a -1 dose level depending on tolerability.
88993069|NCT04552795|Experimental|Open-Label 3TC|12 subjects will receive 3TC, 300-mg, daily for 24 weeks.
89649258|NCT04404673||Open rectal resection|
88993070|NCT04497025|Experimental|Immersive virtual reality-based vestibular training.|"Subjects in this group will receive the same intervention than the other group of study, but they will wear a 3D head mounted display (Oculus Quest glasses) and will receive real-time gaming feedback in terms of visual and audio output while using the training system.~Participants will receive a total of 20 sessions (3 sessions of 50 minutes per week, 7 weeks). These sessions will be divided in 10 initial sessions (based on the three first blocks of Cawthorne-Cooksey protocol) and 10 advanced sessions in which vestibular exercises are gradually get more complicated by modifiying the following exercise parameters: base of support width, standing on unstable surface, alternatives single leg support, tandem position, increased velocity of head movements, higher head range motion and coordinated movements with arms and trunk.~Same location, tailoring parameters and physical therapist supervision than conventional vestibular training."
89045298|NCT04676139|Experimental|Fluoxetine|patients will undergo maintenance therapy selective serotonin reuptake inhibitors, fluoxetine, 10 mg capsules once daily for 12 weeks
89045299|NCT04676139|Placebo Comparator|Placebo|patients will undergo maintenance therapy Placebo for 12 weeks
89045300|NCT01999764|Placebo Comparator|Placebo (for QLT091001)|Placebo is supplied to mimic QLT091001 oral solution.
89045301|NCT01999764|Experimental|QLT091001 - first oral dose|Subjects will receive an oral dose of 10mg/m2 of QLT091001.
89045302|NCT01999764|Experimental|QLT091001 - second oral dose|Subjects will receive an oral dose of 40 mg/m2 of QLT091001.
89649259|NCT04404673||Laparoscopic rectal resection|
89649260|NCT04404673||Robotic rectal resection|
89649261|NCT04404673||Trans-anal TME (Ta-TME)|
89649262|NCT03150121|Experimental|Ovarian cancer patients|High grade ovarian/fallopian tube/primary peritoneal carcinoma patients with current active disease, at any stage and histological type, who have not yet undergone debulking surgery.
89649263|NCT03150121|Active Comparator|Non-malignant controls|Patients with non-malignant gynecological conditions indicating surgical procedure, either salpingo-oophorectomy, hysterectomy or hysteroscopy.
89649264|NCT03150121|Experimental|High risk population|Healthy women with genetically high risk for developing ovarian cancer, who have not undergone risk reducing procedure.
89649265|NCT01673971||Natural History|
89649266|NCT01673971||Treatment|
89649267|NCT02081365|Experimental|High Anxiety Computerized Dental Anxiety Treatment|Computer based CBT intervention before the scheduled dental appoinment (1.5 hours)
89649268|NCT02081365|No Intervention|High Anxiety Wailist Control|
89649269|NCT01674049|Experimental|Exercise and Immediate Nutrition|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk immediately after the exercise bout
89649270|NCT01674049|Active Comparator|Exercise and Nutrition 3 hours Post-Bout|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk three hours after the exercise bout
89649271|NCT01674127|Experimental|Methyldopa|In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
89649272|NCT01674127|Placebo Comparator|placebo|
89649273|NCT02081443|Experimental|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
89649274|NCT02081443|Active Comparator|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
89649275|NCT03725449|Experimental|Phase I (user testing)|Participants complete telephone-based usability testing of the online program. Participants complete between 1-5 user testing sessions of the mySmartCheck program (about 45-60 minutes per session) to provide feedback on acceptability, satisfaction, comprehension, and usability.
89649276|NCT03725449|Experimental|Phase II Group I (mySmartCheck)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive access to mySmartCheck program, and continue to receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
89649277|NCT03725449|Experimental|Phase II Group II (standard of care)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
89649278|NCT01674205|Experimental|Group 1 (Inpatient, H2N3 MO 2006/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.2 mL being delivered by Accuspray device (0.1 mL per nostril).
89649279|NCT01674205|Experimental|Group 2 (Inpatient, H9N2 G9/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.5 mL being delivered as nose drops (0.25 mL per nostril) using a sterile, needle-less tuberculin syringe.
89649280|NCT01674205|Experimental|Group 3 (Outpatient, seasonal LAIV [FluMist®])|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
89649281|NCT01674205|Placebo Comparator|Group 4 (Both inpatient and outpatient, placebo)|Participants will receive either the L-15 placebo delivered by nose drops or the FluMist® placebo delivered as a nasal spray.
89212852|NCT04040036|Experimental|VR-Rollercoaster|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, individuals feel as if they are getting on and riding a rollercoaster. The rollercoaster speeds up and slows down.
89212853|NCT04040036|Experimental|VR-Ocean Rift|The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Ocean Rift Group, individuals can take an underwater tour with 12 different marine animals with slow music.
89212854|NCT04040036|No Intervention|Control|They would be monitored during the procedure if their informed consent was received. Control group children did not receive any distraction techniques.
89649282|NCT03157063||Inactive, normal weight|Less than 30 minutes per day of moderate to vigorous physical activity (MVPA), and body mass index percentile (BMI%) between 5th to 75th percentile.
89649283|NCT03157063||Inactive, overweight/obese|Less than 30 minutes per day MVPA, BMI% between 85th and 99th.
89649284|NCT03157063||Active, normal weight|More than 60 minutes per day MVPA, BMI% between 5th and 75th.
89649285|NCT03157063||Active, overweight/obese|More than 60 minutes per day MVPA, BMI% between 85th and 99th.
89649286|NCT03154411|Experimental|ABY-029|ABY-029 will be administered prior to surgery and tissue will be examined ex vivo to determine binding with EGFR positive tumor tissue.
89649287|NCT01674283|Experimental|Glucagon|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.~The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer."
89649288|NCT01674283|Placebo Comparator|Sodium chloride 0.9%|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.~The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer."
89649289|NCT04404517|Active Comparator|40mg1w|Adalimumab at an administration of 40 mg weekly for 6 weeks, followed by Adalimumab at an administration of 80 mg every two weeks
89649290|NCT04404517|Active Comparator|80mg2w|Adalimumab at an administration of 80 mg every two weeks
89649291|NCT04688905||Dyspnea explained by heart failure with preserved ejection fraction|All patients fulfilling invasive criteria for heart failure with preserved ejection fraction
89649292|NCT04688905||Dyspnea not explained by heart failure with preserved ejection fraction|All patients not fulfilling invasive criteria for heart failure with preserved ejection fraction
89649293|NCT01674517|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
89212855|NCT00879008||Group 1|
89212856|NCT04081181|Experimental|CT_ guided percutaneous microwave ablation|The procedure will be done under anaesthesia by interventional radiologist
89212857|NCT00873470|Experimental|Stimulation|All patients included have the stimulation
89212858|NCT00873548||PFNA_Asia treated|
89212859|NCT02586935|Active Comparator|Tideglusib|
89212860|NCT02586935|Placebo Comparator|Placebo|
89212861|NCT00868400|Experimental|1|High-carbohydrate
89212862|NCT00868400|Placebo Comparator|2|Placebo
89212863|NCT00868400|No Intervention|3|Control
89212864|NCT04079699|Experimental|Liquid Biopsy|"Experimental arm where the liquid biopsy decides whether to perform an prostate biopsy or not"
89212865|NCT04079699|Other|Standard Biopsy|Standard arm, where every patient receives a standard prostate biopsy
89212866|NCT00919997||Specimen collection|Single group study. Blood, saliva, anal cytology, and penile cytology samples, and questionnaire responses will be collected from participants at a single study visit.
89212867|NCT02586779|Experimental|whatsApp messages|consultations in the experimental group will be generated with whatsApp. Patients' all radiographies, laboratory results, electrocardiographs, tomography images, wound images and/or extremity pictures will be sent to consultant physician via whatsApp.
89649294|NCT01674517|Active Comparator|SINGULAIR®|SINGULAIR®(containing Montelukast sodium) chewable tablets 4mg and 5mg of Merck Sharp & Dohme Ltd., USA
89649295|NCT03159793|Active Comparator|Group A|Live Modelling
89649296|NCT03159793|Active Comparator|Group B|Filmed Modelling
89649297|NCT03159793|No Intervention|Group C|No Modelling
89649298|NCT01923649|Experimental|Lanreotide slow release 90 mg|Patients receive lanreatide slow release (Somatuline autogel) 90 mg every four weeks via a deep subcutaneous injection, three times. After a wash out period of 4 weeks they receive a similar placebo every for weeks, three times.
89649299|NCT01923649|Placebo Comparator|Placebo|Patients receive a deep subcutanous injection of placebo every four weeks, three times. After a wash out of three weeks, they will receive somatuline 90 mh via a deep subcutanous injection every four weeks, three times.
89649300|NCT01670071|Experimental|Paliperidone extended-release|
89649301|NCT01670071|Active Comparator|Risperidone immediate-release|
89649302|NCT01674751|Experimental|Immediate intervention|Group begins the 4 week Pre-Ordering Program intervention immediately following a 4-wk baseline period.
89649303|NCT01674751|Other|Wait-listed control|Group begins the 4 week Pre-Ordering Program intervention following an 8-wk baseline period.
89649304|NCT01427309|Experimental|High Dose Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
89649305|NCT01427309|Active Comparator|Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of the Trivalent Inactivated Influenza vaccine
89649306|NCT01674907||Cohort|
89649307|NCT04747093|Experimental|ITNK group|
89649308|NCT01674985|Experimental|Decitabine and cytarabine|induction therapy：decitabine 25mg/m2 daily for 4 days with cytarabine 150 mg/m2 daily for 7 days consolidation：decitabine 25mg/m2 daily for 4 days with cytarabine 2g/m2 q12h for 3 days
89649309|NCT01426373|Experimental|Deoxycholic Acid 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89649310|NCT04763785||Patients with keratoconus corneas|Corneal tomography on patients with keratoconus diagnosis
89649311|NCT04763785||participants with healthy corneas|Corneal tomography on healthy participants
89649312|NCT04763785||retrospective part|fully anonymised Picture data of existing 4500 patients
89649313|NCT04043117||Clinical Group|Group is composed by 12-19 years adolescents with a tumor (excluding brain tumor). Every patient included in the group complete the assessment including: evaluation of self-esteem (TMA test) and body image (BUT test, I-BICI test and Human Figure Drawing).
89649314|NCT03885817|Experimental|Exercise training and nutritional guide|Standard recommendations regarding physical activity and nutrition. An individually tailored exercise program and nutritional guide during adjuvant chemotherapy.
89649315|NCT03885817|Active Comparator|Standard follow-up care|Standard recommendations regarding physical activity and nutrition.
89649316|NCT03858751|Placebo Comparator|Placebo|Placebo capsule before bedtime
89649317|NCT03858751|Experimental|LTM1201AZ|LTM1201AZ capsule before bedtime
89649318|NCT03858751|Experimental|LTM1201AT|LTM1201AT capsule before bedtime
89649319|NCT03858751|Experimental|LTM1201AG|LTM1201AG capsule before bedtime
89649320|NCT03858751|Experimental|LTM1201AD|LTM1201AD capsule before bedtime
89649321|NCT01426217|No Intervention|Control|Control arm using standard of care operating room procedures and equipment
89649322|NCT01426217|Experimental|Problem Solving Innovations (PSI) Experimental|Implementation of the passive bundle including HubScrub and DocIt
89649323|NCT01675375|Experimental|Eye shield|Eye shield place on post Laser Vision Correction eye
89649324|NCT04042415|No Intervention|Free diet controls|Patients on free diet
89649325|NCT04042415|Experimental|Caloric restriction|Patients will be treated with a mild caloric restriction (15-20% caloric restriction)
89649326|NCT04042415|Experimental|Caloric restriction without cow's milk and gluten|Patients will be treated with a mild caloric restriction (15-20% caloric restriction) with exclusion of cow's milk, its derivatives and gluten
89649327|NCT03856099|Experimental|TTAC-0001|TTAC-0001 with dose assigned to each dose group will be administered
89649328|NCT01425749|Experimental|Arm A|Intramuscular injections of recMAGE-A3 + AS15 ASCI.
89649329|NCT01425749|Experimental|Arm B|Intradermal/Subcutaneous injections of recMAGE-A3 + AS15 ASCI. Requires an injection site biopsy at Day 8 and Day 50.
89649330|NCT03852901|Experimental|Single Arm|Single group
89649331|NCT01675687|Experimental|Internet|"Participants of this intervention group get follow up support via Internet.~They have access to new inputs biweekly consisting of~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~News and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be available each month.~Tailored feedback of their behaviour will be given by documentation on spreadsheets."
89649332|NCT01675687|Experimental|Printed Manual|"Participants of this intervention group get follow up support via a printed manual.~The manual consist of all the same inputs as are available to the Internet follow up group.~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~All inputs will be given at once at the beginning of the follow up intervention, only news and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be sent per mail each month.~There is no tailored feedback of their behaviour as the paper-pencil documentation on spreadsheets can't be monitored by the psychologists."
89649333|NCT01403987|Active Comparator|Control Arm|Control group will receive standard teaching by the Residency Program regarding management of ascites and performance of paracentesis.
89045303|NCT02911961|Experimental|Acetaminophen|Subjects will take extra strength acetaminophen (4g/day) for the three days prior to the embolization procedure.
89045304|NCT02911961|No Intervention|Observational - No Acetaminophen|Subjects will take no acetaminophen containing products prior to the embolization procedure.
89045305|NCT01998828|Experimental|Momelotinib 100 mg PV|Participants with polycythemia vera will receive 100 mg of momelotinib.
89045306|NCT01998828|Experimental|Momelotinib 200 mg PV|Participants with polycythemia vera will receive 200 mg of momelotinib.
89649334|NCT01403987|Experimental|Intermediate Education Arm|In addition to the teaching provided by the residency program, the intermediate education group will receive a dedicated lecture by a gastroenterology fellow designed to teach consensus guidelines and their rationale in management of ascites. They will also receive a pocket card noting specific indications for paracentesis, and a brief summary of guidelines.
89649335|NCT01403987|Experimental|"Intensive Education Arm (Pager Arm)"|This group will receive the residency teaching, the specialist lecture, the pocket card, and have access to a pager carried by a gastroenterology fellow for personal assistance in performing paracentesis.
89045307|NCT01998828|Experimental|Momelotinib 100 mg ET|Participants with essential thrombocythemia will receive 100 mg of momelotinib.
89045308|NCT01998828|Experimental|Momelotinib 200 mg ET|Participants with essential thrombocythemia will receive 200 mg of momelotinib.
89649336|NCT01675843|Experimental|Group A|controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI)
89649337|NCT01675843|No Intervention|Group B|Controlled ovarian hyperstimulation (COH)+ Timed Intercourse (TI)
89649338|NCT03876847||Spontaneous Coronary Artery Disection|The spontaneous coronary artery disection (SCAD) diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by three cardiologists. The determination will be evidence of linear luminal defect (intimal flap) detection, luminal narrowing or occlusion confirmed to be a dissection on further imaging, or by clinical judgment classifying it as definite SCAD.
89649339|NCT03876847||Control|A set of controls will be used for genetic analysis. These controls will pulled from subjects in the INSPIRE registry that had coronary angiography at Intermountain Medical Center for stable angina and meet inclusion/exclusion criteria.
89649340|NCT01675921|No Intervention|Control|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to this study website at the start and at the end of the study."
89649341|NCT01675921|Experimental|Facebook group|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to the study website at all times throughout the study.~Participants will have access to the secret study group on Facebook for 12 months.~Participants will take the ACT survey once a month for 12 months."
88993071|NCT04497025|Active Comparator|Conventional vestibular training.|"Subjects in the control group will receive a total of 20 sessions of 50 minutes (3 sessions per week, 7 weeks). They will receive traditional Cawthorne-Cooksey vestibular rehabilitation exercises. This program improves vestibular compensation through a mechanism of neuroplasticity known as adaptation, habituation and substitution. Just like the virtual reality intervention it will be divided in 10 initial sessions and 10 advanced sessions. For the advanced phase of intervention exercises parameters were the same described for the virtual vestibular rehabilitation intervention.~A physical therapy with at least two years of expertise in vestibular rehabilitation will adjust the difficulty level. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain)."
88993072|NCT04478162|Experimental|Experimental|All phases of the FICare model have been implemented. Parents in the intervention group were included in a one-week training program within the scope of the Family Integrated Care model. A maximum of four couples attended the training in each session. A training program was also organized at weekend for those who could not attend it during the week. Training subjects consisted of the importance of breast milk, breastfeeding positions, hygienic care practices (eyes, nose, mouth, ears, skin, diaper change), bathing, nail clipping, kangaroo care, drug administration, first and emergency support, safe sleep, doctor check-up times, and vaccine follow-ups. Care practices were first shown on the model infant, and parents were asked to practice on the model. When the clinical stabilization of their infants was achieved, parents were asked to attend at least three caregiving sessions and stay in the hospital for an average of six to eight hours.
88993073|NCT04478162|No Intervention|Control Groups|Individuals received usual care provided by nurses from the time the premature infant was admitted to the NICU until discharge. The usual care process is carried on between the nurse and the mother. Mothers are allowed to perform limited care practices (bottom cleaning, breastfeeding) that the nurse considers appropriate. Mothers of babies who are planned to be discharged start staying in the hospital approximately 2 days before. Fathers are not included in the care and process. They are not allowed to stay in the hospital. Fathers are only informed and not included in the care.
88993074|NCT04472884|Experimental|mWACh-PrEP|
88993075|NCT04472884|Other|Standard of Care|
88993076|NCT04463680|Experimental|Intervention|Will receive 2 week regimen of rifampin 600mg per day
89649342|NCT01675999|Experimental|1|"Perioperative simplified FOLFOX-4 chemotherapy~- Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by simplified FOLFOX-4 (8 cycles)."
89649343|NCT01675999|Experimental|2|Perioperative FOLFOX4+Cetuximab chemotherapy Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h)+ Cetuximab (IV 500 mg/m2 every 2 weeks) for 4 cycles followed by colectomy (3 to 5 weeks after), followed by simplified FOLFOX-4 + Cetuximab (8 cycles).
89649344|NCT01675999|Other|3|Surgery followed by FOLFOX4 chemotherapy No preoperative chemotherapy Colectomy (maximum 4 weeks after randomization) followed by simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 12 cycles.
89649345|NCT01425359|Placebo Comparator|Placebo|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks."
89649346|NCT01425359|Experimental|Ranolazine|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks."
89649347|NCT02082145|No Intervention|Control|Treated according to local protocol for diabetic peripheral neuropathy
89649348|NCT02082145|Experimental|NMES|Treated with neuromuscular stimulation of both legs, for 10 weeks
89649349|NCT03846895|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following:~Power: 40 watts,~Dwell time:1000μs,~Spacing 1000 μm,~Depth: SmartStak parameter 3~D-pulse mode."
89649350|NCT03846895|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following:~Power: 0.5 watts,~Dwell time:1000μs,~Spacing 1000 μm,~Depth: SmartStak parameter 1,~Smart-pulse mode."
89649351|NCT04764409||Group 1|This group includes patients who underwent chemoembolization of hepatic arteria
89649352|NCT04764409||Group 2|This group includes patients who underwent chemoinfusion of hepatic arteria
89649353|NCT04764565|Experimental|Nuun Instant|2 servings of Nuun instant in 1 liter water
89649354|NCT04764565|Placebo Comparator|Control|1 liter of water
89649355|NCT04764565|Experimental|Nuun Electrolyte|2.1 servings of Nuun Electrolyte in 1 liter water
89649356|NCT04404751|Active Comparator|Arm 1|
89649357|NCT04404751|Active Comparator|Arm 2|
89649358|NCT04404751|Sham Comparator|Arm 3|
89649359|NCT01403051|Experimental|Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), calcium carbonate and vitamin D3 4000 IU.
89649360|NCT01403051|Experimental|Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), a placebo for calcium carbonate, and a placebo for vitamin D3.
89649361|NCT03873337|Experimental|NRT + Persistence Targeted Smoking Cessation in SMI|Participants will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of task persistence focused cessation counseling delivered via telehealth.
89045309|NCT02912000|Experimental|Intervention|The intervention group will receive the TEACH intervention - an electronic tablet screening in waiting room for the modifiable risk factors
89649362|NCT04404829|Experimental|Informational Manual Therapy|It is an integral no orthopedic and very soft manual therapy
89649363|NCT01676155||Patient with active tuberculosis|
89649364|NCT01676155||Patients with diagnosis of latent tuberculosis infection|
89045310|NCT02912000|No Intervention|Control|Care as usual: No electronic tablet in waiting room
89045311|NCT04675944|Experimental|BIA 5-1058 / treprostinil|Three treatment periods separated by a washout period of at least 10 days
89045312|NCT02911766|Active Comparator|Corsodyl, 0.2% mouthrinse|"The comparator solution was Corsodyl, 0.2% Chlorhexidine mouthrinse,~Intervention Rinsing 60 sec with Comparator solution twice daily for 21 days"
89045313|NCT02911766|Experimental|FluxProKlorhexidine 0.12% mouthrinse|"The experimental solution was FluxProChlorhexidine 0.12% mouthrinse~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
89045314|NCT02911766|Experimental|Corsodaily 0.06% mouthrinse|"The second experimental solution was Corsodaily, 0.06% chlorhexidine mouthrinse.~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
89045315|NCT01993641|Experimental|Pracinostat added to HMA|Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
89045316|NCT00555516|Active Comparator|1|"The chemotherapy regimen of group 1 is restricted to AC or CAF during the first cycle~Group 1 will receive EW02 for 15 consecutive days during the second cycle~will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle."
89045317|NCT00555516|Placebo Comparator|2|"The chemotherapy regimen of group 2 is restricted to AC or CAF during the first cycle~Group 2 will receive 15 consecutive days of Placebo~Group 2 will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle"
89045318|NCT01991184|Experimental|Dose-escalation|
89045319|NCT02911727|Experimental|Fast-track discharge|Intention to discharge within 28 hours after elective cesarean section including a home visit by a nurse or midwife from the postnatal ward.
89045320|NCT02911727|No Intervention|Standard discharge|Discharge at least 48 hours after elective cesarean section.
89045321|NCT02911883||Normal|Not having glaucoma or retinal pathology
89045322|NCT02911883||Glaucoma|Having glaucoma.
89649365|NCT01676155||Patient without latent tuberculosis or active tuberculosis|
89649366|NCT04747639|Active Comparator|verum 500|500 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
89649367|NCT04747639|Placebo Comparator|control 500|500 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
89649368|NCT04747639|Active Comparator|verum 250|250 ml low sugar apple juice manufactured from conventional apple juice via a series of enzymatic reactions that end up in a final content of free glucose less than 0,5 g/l.
89649369|NCT04747639|Placebo Comparator|control 250|250 ml conventional apple juice produced by a general apple juice production process (free glucose 17g/l)
89649370|NCT03873259|Experimental|Treatment Group|Subjects in this arm receive the 10-minute burst wave lithotripsy intervention dose during their standard-of-care lithotripsy procedure.
89045323|NCT02911883||Retina|Having retinal pathology
89045324|NCT04675905||PACORUS-D Main cohort|Eligibility, Endpoints as described above
89045325|NCT04675905||PACORUS-D Delirium-Subcohort|Eligibility: patients aged >= 65 years undergoing noncardiac nonneurosurgical procedures (definition see above); Endpoints as described above; additional explanatory variable: postoperative Delirium detected by CAM on postoperative day 1 and 2
89045326|NCT02911649|Experimental|Wearable Device Only|Participants will be allowed to choose one of three wearable devices (FitBit, Garmi or Polar), for the wearable technology intervention. Once the participant has chosen their wearable device they will be oriented to their chosen device, platform to obtain information from the device, as well as a guide with ideas for reducing sedentary behaviour. Participants will be asked to wear the devices every day during waking hours.
89045327|NCT02911649|Experimental|Online Educational Workshop Only|The Online Educational Group will be asked to participate in 6 online workshops that will occur during the 12-week intervention. Adobe connect software will be used to implement these workshops which allows for interaction between participants and leader. Workshops will focus on specific aspects related to reducing sedentary behaviours and increasing PA time. Each workshop will be developed by study coordinator/author (MO) and constructed using Social Cognitive Theory (SCT), ensuring the themes such as self-efficacy, self-control and reinforcements are within each topic. EDU topics will include motivation, goal setting, and activities and ways to reduce sedentary behaviour.
89045328|NCT02911649|Experimental|Wearable Device+Online Edu Workshop|Both the wearable technology intervention and Online Educational Group intervention simultaneously.
89649371|NCT03871231|Experimental|Unpinning Termination Therapy Arm|Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia
89649372|NCT04115748|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
89649373|NCT04115748|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg + PTM adalimumab for up to 16 weeks.
89649374|NCT04115748|Active Comparator|Adalimumab (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + adalimumab 40 mg injection for up to 16 weeks.
89649375|NCT04115748|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg + PTM adalimumab injection for up to 16 weeks.
89649376|NCT04115748|Experimental|Filgotinib 200 mg (Long Term Extension [LTE])|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 34 weeks.
89649377|NCT04115748|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 34 weeks.
89649378|NCT04747015|Active Comparator|Cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus
89649379|NCT04747015|Active Comparator|Active management|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
89649380|NCT03755713|Experimental|ASP0892 Low Dose (Cohort A)|Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
89649381|NCT03755713|Experimental|ASP0892 High Dose (Cohort B)|After all participants in cohort A complete study procedures, the DMC will review the safety and tolerability data and provide recommendations depending on the nature, frequency and severity of the safety profile reviewed. Recommendations will be to proceed with escalation to the next higher dose or stop dose escalation (i.e., no further dosing with study drug).
89649382|NCT03755713|Placebo Comparator|Placebo|Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
89649383|NCT04403815||right radial access|"diagnostic coronary angiography and/or PCI performed through right wrist and distal (snuffbox) radial access"
89649384|NCT04403815||left distal radial access|"diagnostic coronary angiography and/or PCI performed through left distal (snuffbox) radial access"
89649385|NCT04747171|Active Comparator|magnesium intrathecal|
89649386|NCT04747171|Active Comparator|dexamethasone intrathecal|
88993077|NCT04459000|Active Comparator|STARs Only|Consenting research participant who receive prenatal care services in the STAR clinic, but are not randomized to receive mABC home visiting services.
88993078|NCT04459000|Experimental|STARS + mABC|Consenting research participant who receive prenatal care services in the STAR clinic, and are randomized to receive mABC home visiting services.
88993079|NCT04459000|No Intervention|Control Group/CHOUM Only|These are research participants who were eligible to receive care in the STAR clinic, but did not opt to receive that care.
88993080|NCT04454970|Experimental|Urethral catheterisation device (UCD)|First attempt of urethral catheterisation using the Urethrotech(R) Urethral catheterisation device (UCD)
88993081|NCT04454970|Active Comparator|Bardia Aquafil Foley catheter|First attempt of urethral catheterisation using the Bardia Aquafil Foley catheter
88993082|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD|Eligible participants on stable nucleos(t)ide treatment will receive 300 milligrams (mg) GSK3228836 once weekly for 24 weeks along with loading dose (LD) of 300 mg GSK3228836 on Day 4 and Day 11.
88993083|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
88993084|NCT04449029|Experimental|Cohort 1: GSK3228836 300 mg + LD/ Placebo|Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
88993085|NCT04449029|Experimental|Cohort 1: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants on stable nucleos(t)ide treatment will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
88993086|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 24 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11.
88993087|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
89649387|NCT04747171|Active Comparator|dexmedetomidine intrathecal|
88993088|NCT04449029|Experimental|Cohort 2: GSK3228836 300 mg + LD/ Placebo|Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
88993089|NCT04449029|Experimental|Cohort 2: Placebo/ GSK3228836 300 mg + Placebo LD|Eligible participants not currently on nucleos(t)ide therapy will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
88993090|NCT04438655|Experimental|Oral + Parenteral prophylaxis|"Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.~Systemic antibiotic drugs:~Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
88993091|NCT04438655|Sham Comparator|Only parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
89045329|NCT02911649|No Intervention|Control Group|Participants in this group will receive usual care
89045330|NCT01989429|Active Comparator|Daivonex|topical application
89649388|NCT02082769|Experimental|Febuxostat 40 mg QD|Febuxostat 40 mg, orally, once daily for up to 24 weeks
89649389|NCT02082769|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, orally, once daily for up to 24 weeks
89649390|NCT02082769|Active Comparator|Allopurinol 100mg QD|Allopurinol 100mg, orally, three times daily for up to 24 weeks
89649391|NCT03751423|Active Comparator|PO Morphine & IV Placebo|One third of study participants will be randomized to this local standard of care arm.
89045331|NCT01989429|Placebo Comparator|vehicle|topical application
89649392|NCT03751423|Active Comparator|IV Fentanyl & PO Placebo|One third of study participants will be randomized to this current gold standard of care arm.
89649393|NCT03751423|Experimental|IV Ketamine & PO Placebo|One third of study participants will be randomized to this experimental arm.
89649394|NCT04972188|Experimental|ZYIL1|Capsule administration. Six subjects will be recruited in each cohort. safety data up to day 14 will be evaluated. Single dose will be administered in ascending manner starting from 12.5 mg.
89649395|NCT01676623|Active Comparator|Comparison area, only standard government services|This intervention arm will receive the standard government services offered at CHCs all over Vietnam. In addition, participants in this arm will be exposed to the nationwide mass media campaign.
89649396|NCT01676623|Experimental|A&T Franchise|In this arm, the 20 CHCs will offer Alive & Thrive branded franchise services with enhanced quality of IYCF counseling through interpersonal contact between health workers at the commune level and clients who use the commune health services. In addition, the clients could also be exposed to the mass media campaign.
89649397|NCT03745729|Experimental|Treatment group|
89649398|NCT03745729|Placebo Comparator|Control group|
89649399|NCT04904952|Active Comparator|Experimental|This arm includes 30 OCD patients receiving SSRIs
89649400|NCT04904952|Placebo Comparator|Control|This arm includes 30 OCD patients receiving SSRIs
89649401|NCT04763863||Ostomates|Ostomates with leakage issues and stoma created at least 3 months ago
89649402|NCT03661411|Experimental|Aspirin+ clopidogrel|aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
89649403|NCT03661411|Active Comparator|Alteplase|intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.
89649404|NCT04756596||Study group|70 patients with normal vision (NVG) 30 patients with low vision (LVG) These patients will be tested on the DDVIT
89649405|NCT03827941|Active Comparator|1 Hz group|1 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
89649406|NCT03827941|Active Comparator|20 Hz group|20 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 20 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
89649407|NCT04706520|Experimental|Group 1: Vinegar|Participants will consume 400 mL/day vinegar beverage providing 1,500 mg/day acetic acid [200 mL vinegar beverage, twice per day (prior to breakfast and dinner)] for 12 weeks.
89649408|NCT04706520|Experimental|Group 2: Vinegar/Placebo Combination|Participants will consume 200 mL/day vinegar beverage and 200 mL/day placebo beverage providing 1,200 mg/day lactate [200 mL placebo beverage 1x/day] and 750 mg/day acetic acid [200 mL vinegar beverage 1x/day] (prior to breakfast and dinner) for 12 weeks.
89649409|NCT04706520|Placebo Comparator|Group 3: Placebo|Participants will consume 400 mL/day placebo beverage containing 1,250 mg/day lactate [200 mL placebo beverage, and 200 mL placebo beverage (prior to breakfast and dinner) for 12 weeks.
89649410|NCT03742297|Active Comparator|VMP x 9 + Lenalidomida-dexamethasone x 9|Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose
89649411|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethasone regimen|carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle
89649412|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethason with daratumumab|Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22. Daratumumab 1800mg SC Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18
89649413|NCT01677403|Active Comparator|Nebulised Tobramycin|Nebulised Tobramycin
89045332|NCT01989429|Experimental|M518101|topical application
89045333|NCT02911532|Experimental|Optical Coherence tomography|
89045334|NCT01989234|Placebo Comparator|Placebo Comparator|Placebo Comparator
89045335|NCT01989234|Experimental|YKP10811 High Dose|YKP10811 High Dose
89045336|NCT01989234|Experimental|YKP10811 Mid Dose|YKP10811 Mid Dose
89045337|NCT01989234|Experimental|YKP10811 Low Dose|YKP10811 Low Dose
89649414|NCT01677403|Placebo Comparator|Nebulised 0.9% Saline|Nebulised 0.9% Saline
89649415|NCT03629652|Experimental|Head down position|head-down position treatment combined with conventional rehabilitation.
89649416|NCT03629652|Sham Comparator|Conventional Rehabilitation|Conventional rehabilitation treatment
89649417|NCT03441750|Experimental|metformin plus standard lifestyle intervention|Metformin starting dose is 850mg/d, it will be titrated to 850mg twice daily after 2 weeks and maintained until the last subject completes 2 years' intervention.
89649418|NCT03441750|Other|Standard lifestyle intervention|Standard lifestyle advice will be united for all subjects by providing special booklet.
89649419|NCT04527744|Experimental|the Yonsei point group|Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point.
89649420|NCT04527744|Active Comparator|the levator labii superioris alaeque nasi muscle group|For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
89649421|NCT04976010||CKD G3-5|Patients with CKD and an estimated eGFR < 60ml/min not yet on dialysis
89649422|NCT04976010||End stage kidney disease (ESKD) CKD G5 Hemodialysis|Patients on hemodialysis for at least 3 months
89649423|NCT04976010||Normal kidney function|Patients enrolled with normal kidney function and/or CKD G1 and an estimated eGFR > 90ml/min
89045338|NCT02911493|Experimental|Sedentary Group-Experimental|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
89649424|NCT04503954|Experimental|Self-management group|Self-management group Chronic disease self-management program is conduct training skills, person how to live together with personal chronic disease to make life quality better.
89649425|NCT04503954|Placebo Comparator|Control group|Control group will continue general psychiatric intervention.
89649426|NCT03198468|Experimental|Vapor Ablation|
89649427|NCT03741751|Experimental|active rTMS with computerized cognitive training|Participants will receive 6 sessions of active rTMS followed by a computerized cognitive training session over 2 weeks.
89649428|NCT03741751|Sham Comparator|sham rTMS with computerized cognitive training|Participants will receive 6 sessions of sham rTMS followed by a computerized cognitive training session over 2 weeks.
89649429|NCT03179748||turoctocog alfa|Patients with haemophilia A
89649430|NCT04868292|Experimental|SPR206|Healthy subjects meeting eligibility criteria will receive a total of three 100 mg SPR206 intravenous doses administered every 8 hours.
89649431|NCT03657433|Experimental|Ferumoxyltol|"Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
89649432|NCT03657433|Active Comparator|Ferrous Sulfate|"Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
89649433|NCT04351386||Atrial Fibrillation (AF)|Patients diagnosed with AF during reference ECG
89649434|NCT04351386||Normal Sinus Rhythm (NSR)|Patients with NSR during reference ECG
89649435|NCT04351386||Other Arrythmia|Patients diagnosed with an arrhythmia other than AF during the reference ECG
89649436|NCT01676935|Experimental|ABT-126|ABT-126 Open-label dose
89649437|NCT03821155|Active Comparator|Neuritis vestibularis (group 1)|"Corticosteroid (prednisolone)"
89649438|NCT03821155|Experimental|Neuritis vestibularis (group 2)|"Corticosteroid (prednisolone) + vestibular rehabilitation"
89649439|NCT04803552|Experimental|Contactless sleep apnea screening vs respiratory polygraphy|
89649440|NCT03819283|Other|Hepatic evaluation|
88993092|NCT04438031|Experimental|Navigation Intervention Prenatal 1.0 (arm closed and modified to 2.0 design. Data will not be used)|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits (using prenatal navigation version 1.0), establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
88993093|NCT04438031|Other|Control Intervention|Brief educational information will be provided about pregnancy (provided prenatally) and child development at 12, 24, and 36 months.
88999222|NCT03004404|Experimental|BA Part: T1/T2/R|"BA Part: T1/T2/R Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~Participants were orally administered 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~Followed by 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
89649441|NCT03651895|Active Comparator|Treatment Group|Metformin 500mg bd
89649442|NCT03651895|Placebo Comparator|Placebo Group|Placebo
89649443|NCT04760184||COVID19 positives after autologous stem cell transplantation|All Swedish citizens treated with ASCT for malignant disease in Sweden from 1st January 2020 until 31st December 2020 who has tested positive for SARS-CoV-2 from start of conditioning until the end of the study period 31st March 2021.
89649444|NCT03650491|Experimental|Experimental: FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
89649445|NCT03650491|Experimental|Experimental: FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
89649446|NCT03867396|Active Comparator|Cochlear Implant and Hearing Aid|Subject wears a hearing aid on the contralateral side of the cochlear implant. Subject will use a clinic-loaned Naida hearing aid for listening tests.
88999223|NCT03002597|Experimental|Blind Children|Children between the ages of 4 and 17 who are blind (documented visual acuity of light perception or worse) in both eyes from an eye care provider.
88999224|NCT03002597|Experimental|Sighted Children|Children between the ages of 4 and 17 who are sighted in both eyes.
88999225|NCT02985749|Experimental|Oxytocin- Participants ages 12-17|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
88999226|NCT02985749|Experimental|Oxytocin- Participants ages 18-55|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
89649447|NCT03867396|Active Comparator|Cochlear Implant alone|Subject only uses the cochlear implant; hearing on the contralateral side is unaided.
89649448|NCT03867396|Experimental|Cochlear Implant and CROS|Subject wears the CROS device on the contralateral side of the cochlear implant. Subject will use a clinic-loaned CROS device.
89649449|NCT04183530||SCOPD|Participants with stable COPD diagnosed according to GOLD criteria and hasn't encountered acute exacerbations in the past six months, generally include outpatient clinical patient and community patients.
89649450|NCT04183530||AECOPD|Participants with COPD diagnosed according to GOLD criteria and suffered from acute exacerbations, characterized by worsening clinical symptoms(such as acute worsening of dyspnea, and/or cough and sputum production, and/or increased sputum purulence) and positive laboratory biomarkers suggesting AECOPD (such as serum CRP and serum neutrophilia or eosinophilia) at the time of registering into the group, particularly include inpatient.
89649451|NCT04183530||Smoking healthy controls|Participants with a smoking history of more than ten years and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
89212868|NCT02586779|Other|control group|consultations in the control group will be generated without whatsApp.
89212869|NCT04079777||Clinical diagnosis of severe acute pancreatitis|"1, with typical clinical manifestations, such as abdominal pain or nausea and vomiting, accompanied by epigastric tenderness or peritoneal irritation.~2. Pancreatin content in serum, urine or abdominal cavity puncture fluid increases.~3. Image examination (ultrasound, CT) showed pancreatic inflammation or pancreatic inflammation seen by surgery or confirmed by autopsy pathology.~4, can except other similar clinical manifestations of lesions."
89649452|NCT04183530||Non smoking healthy controls|Participants without a smoking history and was in good health, characterized by negative chest radiograph and negative laboratory tests for cardiac, pulmonary or hematologic disorders, and so on.
89649453|NCT00003469|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89649454|NCT04748640|Experimental|Treatment group|Participants will undergo a thalamotomy contralateral to their previous treatment with Gamma Knife using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
89649455|NCT04670484|Other|Healthy subjects wearing masks|Subjects wearing masks to prevent coronavirus infection spread in COVID19 pandemic
89649456|NCT03648463|Experimental|arthroscopy with removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
89649457|NCT03648463|Active Comparator|arthroscopy without removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
89649458|NCT04657926|Experimental|APPA|"APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) & 2-hydroxy-4-methoxyacetophenone (2H4MA) administered to 75 participants as 2 x 400mg capsules b.d. for 28 days~."
89649459|NCT04657926|Placebo Comparator|Placebo|2 capsules b.d. for 28 days
89649460|NCT04070898|No Intervention|control group|Bladder catheter removal 24 hours after surgery
89649461|NCT04070898|Experimental|experimental group|Removal of the bladder catheter after the surgical intervention
89649462|NCT04000620||cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as positive for cancer cell involvement by imaging based deep learning.
89649463|NCT04000620||no cancer cell involvement predicted by deep learning|the participants with lesions of lung, lymph node or other sites predicted as negative for cancer cell involvement by imaging based deep learning.
89649464|NCT03807037|Experimental|Treatment|Mixed tocotrienols 200mg, twice daily (400mg/day)
89045339|NCT02911493|Active Comparator|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
89045340|NCT04675671||Pregabalin group (Group P)|Group pregabalin patients will be received 75 mg of pregabalin twice daily for 2 days before surgery
89045341|NCT04675671||Control group (Group C)|The Control group will be received plasebo capsule mg at the same point in time
89045342|NCT02911298|Experimental|Mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation is administered to subject in fasted state
89045343|NCT02911298|Active Comparator|Non-mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation is administered to subject in fasted state
89045344|NCT01984788|Active Comparator|BCX4161|400 mg TID for 28 days
89045345|NCT01984788|Placebo Comparator|Placebo|TID for 28 days
89045346|NCT02911337|Experimental|Lifestyle modification|Lifestyle modification
89045347|NCT01983306|Experimental|SP-333 1 mg|1 mg SP-333 orally once daily for 4-week Treatment Period
89045348|NCT01983306|Experimental|SP-333 3 mg|3 mg SP-333 orally once daily for 4-week Treatment Period
89045349|NCT01983306|Experimental|SP-333 6 mg|6 mg SP-333 orally once daily for 4-week Treatment Period
89045350|NCT01983306|Placebo Comparator|Placebo|Placebo orally once daily for 4-week Treatment Period
89045351|NCT02911220|Other|blood sample for genetic evaluation|a blood sample is collected once for genetic analysis
89045352|NCT02911454|Experimental|Healthy infants: fully or partly formula fed|
89045353|NCT01982175|Experimental|Alemtuzumab|Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.
89045354|NCT01975818|Experimental|Molidustat (BAY 85-3934)(25mg)|Starting dose of 25 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
89649465|NCT03807037|Placebo Comparator|Control|Matching Placebo (Placebo oral capsule)
89649466|NCT03638791||Healthy controls|Matched Controls without treatment
89649467|NCT03638791||OCD|Exposure and response inhibition
89649468|NCT03805399|Experimental|pyrotinib with capecitabine|If patients were LAR subtype with HER2 gene activated mutation
89649469|NCT03805399|Experimental|AR inhibitor with CDK4/6 inhibitor|If patients were LAR subtype without HER2 gene activated mutation, but had PIK3CA mutation, enter into arm B1; If patients were LAR subtype without HER2 gene activated mutation or PIK3CA mutation, enter into arm B2;If B2 was closed, enter into B4;
89649470|NCT03805399|Experimental|anti PD-1 with nab-paclitaxel|If patients were IM subtype(CD8 positive T cell more than 20%)
89521590|NCT02900443|Experimental|Mycophenolate mofetil|The intervention group will receive oral mycophenolate mofetil for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
89521591|NCT02900443|Active Comparator|Azathioprine|. The control group will be treated with azathioprine (standard of care) for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
89521592|NCT02881255|Other|Subcutaneous ICD|Patient will receive a subcutaneous implantable cardioverter defibrillator (Boston Scientific EMBLEM)
89521593|NCT02881255|Other|Transvenous ICD|Patient will receive a single-chamber, transvenous implantable cardioverter defibrillator (from any manufacturer) which as the capability for remote monitoring.
89521594|NCT04449445|Other|Standard enteral tube feeds|Patients will be instructed to continue a normal diet before surgery. Post-operatively, patients will receive standard of care isocaloric and iso-nitrogenous standard enteral tube feeds
89521595|NCT04449445|Experimental|Nestle IMPACT AR|Patients will be encouraged to continue their regular diet until their surgery day. In addition, beginning 5 days before surgery, subjects will be instructed to drink three, 6 ounce cartons of Nestle IMPACT AR each day until their surgery. Post operatively patients who are able to eat orally, will be given three, 6 ounce cartons of Nestle IMPACT AR to drink each day for 5 days. Patients who are not able to tolerate an oral diet will be given Nestle IMPACT via a continuous tube feeding for 5 days through a temporary nasogastric feeding tube placed per standard post-operative care. Dosing of the tube feeding will be based on weight at a rate of approximately 70-75 cc/hour.
89521596|NCT04594213|Experimental|MP: NT 201 (incobotulinumtoxinA): UFL|Intramuscular injection
89521597|NCT04594213|Experimental|MP: NT201 (incobotulinumtoxinA): GFL/HFL; Placebo: LCL|Intramuscular injection
89521598|NCT04594213|Placebo Comparator|MP: Placebo: UFL|Intramuscular injection
89521599|NCT04594213|Experimental|OLEX: NT201 (incobotulinumtoxinA): UFL|Intramuscular injection
89521600|NCT04449367||Randomized and Single-Arm Trials|a sham comparator (no intervention)
89521601|NCT04449133|Experimental|Treatment Group 1|AD128 for 7 days, then, after a wash-out period of 7-10 days, placebo for 7 days
89521602|NCT04449133|Experimental|Treatment Group 2|Placebo for 7 days, then, after a wash-out period of 7-10 days, AD128 for 7 days
89521603|NCT03420703|Active Comparator|Block group|Erector espine plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively
89521604|NCT03420703|Sham Comparator|control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
89521605|NCT03416023|Experimental|Single|
89521606|NCT03415945|Experimental|CRT implantation|In cardiac resynchronization therapy (CRT), biventricular pacing is performed by pacing the right ventricle (RV) and epicardium of the left ventricular (LV) posterolateral wall.
89521607|NCT03420547|Experimental|Intervention group|Group of participants receiving the RISE intervention
89521608|NCT03420547|No Intervention|Standard Care (waitlist)|Group receiving no intervention in first 6 weeks.They will have the option of participating in the RISE program after their second assessment at week 6.
89521609|NCT03109171|Other|Expert rater|Pulmonologist or Otolaryngologist with experience in laryngopharyngeal sensory evaluation: who has made more than 50 laryngopharyngeal sensory tests.
89521610|NCT03109171|Other|Non-expert rater|"Pulmonologist or Otolaryngologist inexperienced in laryngopharyngeal sensory evaluation: who has made minimum 5 and maximum 50 laryngopharyngeal sensory tests.~Pulmonologist fellow who has completed the training provided for a Pulmonologist Fellow in bronchoscopy and who has performed minimum 5 and maximum 50 laryngopharyngeal sensory testing."
89521611|NCT03420469|Experimental|Baseline CYP2D6 activity|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).
89521612|NCT03420469|Experimental|CYP2D6 activity with single dose of bupropion|The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.
89521613|NCT03420469|Experimental|CYP2D6 activity after treatment with bupropion to steady sate|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).
89521614|NCT03415789||80 patients non ischemic DCM|"A cohort of 80 patients with nonischemic dilated cardiomyopathy in sinus rhythm with left ventricle ejection fraction (EF) less than 45%.~In the first 24 hours after enrollment a coagulation blood test, an electrocardiogram, a Doppler echocardiogram exam and a clinical examination (including neuropsiquiatric evaluation) will be performed.~A cardiac magnetic resonance and a brain magnetic resonance will be performed within 10 days after the enrollment."
89521615|NCT03420391|Placebo Comparator|Placebo PBMT|Participants will be treated with placebo PBMT in different time-points before the eccentric exercise protocol (5 minutes, 3 hours, 6 hours or 24 hours). Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
89521616|NCT03420391|Active Comparator|5 Minutes|"Participants will be performed the eccentric exercise protocol 5 minutes after PBMT.~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
89521617|NCT03420391|Active Comparator|3 Hours|"3 hours: Participants will be performed the eccentric exercise protocol 3 hours after PBMT.~Assessments will be performed before at baseline, 1 minute, 1 hour and 24, 48 hours after the end of exercise protocol."
89521618|NCT03420391|Active Comparator|6 Hours|"6 hours: Participants will be performed the eccentric exercise protocol 6 hours after PBMT.~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
89521619|NCT03420391|Active Comparator|24 hours|24 hours: Participants will be performed the eccentric exercise protocol 24 hours after PBMT. Assessments will be performed before at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
89521620|NCT03420391|No Intervention|Control|Participants will not receive intervention. Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
88993094|NCT04438031|Experimental|Navigation Intervention Prenatal 2.0|This program recruits mothers in OB/GYN offices. Mothers are offered visits from a Navigator prenatally and postnatally (12-, 24-, and 36-months). During visits, the Navigator works with the mother to identify family needs, establishes connections between the family and community providers, and follows up one month later to confirm these referrals. Navigators assess and support family needs across 13 factors: caregiver health, infant health, healthcare plans, childcare plans, parent-child relationship, management of infant crying/behavior, household safety/material supports, family/community violence, history of parenting difficulties, parent well-being, substance use, parent emotional support, and other needs not related to first 12 factors. Navigation 2.0 is a revision of 1.0 in which adjustments to the protocol were made to improve guidance for Community Navigators and aid their assessments of family needs.
89212870|NCT04079777||mtDNA|"Mitochondrial DNA is the genetic material in mitochondria. Mitochondria can produce energy (ATP) for cells, which is a special form of ribonucleic acid found in mitochondria of cells. Mitochondria are organelles that provide energy (ATP) to cells. There are usually many DNA molecules in a mitochondria.~They carry their own DNA--mtDNA, and mutations in these genes can cause mitochondrial diseases. Although the symptoms of the disease are changeable, organs that consume more energy, such as brain, muscle and heart, are usually affected. Since mitochondria are transmitted through egg cells, related diseases will be inherited from the mother."
89212871|NCT04079543|Other|Strict NPO|NPO after midnight. No solids or liquids after midnight.
89212872|NCT04079543|Other|Liberal NPO|No solids after midnight. Clear liquids up to 2 hours prior to surgery.
89212873|NCT02585687|Experimental|liver Perfusion MRI|liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments
89212874|NCT00920543|Active Comparator|Fluticasone propionate|
89212875|NCT00920543|Active Comparator|Fluticasone propionate/salmeterol combination|
89212876|NCT04731155|Active Comparator|standard group|
89212877|NCT04731155|Experimental|experiment group|
89212878|NCT04080011|Experimental|NP-PWD application|All patients enrolled into the study will have the negative pressure- platform wound device applied to their surgical incision.
88993095|NCT04433351|Experimental|SE cohort|Patients in the SE cohort will carry out first the simple rehabilitation protocol (S, 4 weeks) followed by enriched rehabilitation (E, 4 weeks).
89521621|NCT03427021|Experimental|Arm A|will be treated with consistent exposure to oral ice
89521622|NCT03427021|Active Comparator|Arm B|Will not be treated with consistent exposure to oral ice.
89521623|NCT03415711|Experimental|Mesalamine plus high-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 12 months.
89521624|NCT03415711|Experimental|Mesalamine plus low-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets twice a day (1800 billion of bacteria per day) for 12 months.
89521625|NCT03415711|Active Comparator|Mesalamine plus Placebo|Mesalamine 2.4 g/day in once daily administration plus placebo for 12 months.
89521626|NCT03420313|Experimental|Interim Buprenorphine Treatment|"Interim Buprenorphine Treatment includes (a) Maintenance treatment with Buprenorphine/ naloxone sublingual tablets with bi-monthly clinic visits for observed dosing and the remaining doses dispensed at home via a secure computerized portable device (Med-O-Wheel, Addoz, Finland).~(b) nightly calls from an automated Interactive Voice Response (IVR) phone system to assess any drug use, withdrawal and craving, (c) IVR-generated random call-backs for urinalysis and pill counts, and (d) HIV+Hepatitis education delivered via iPad. (e) monthly follow-up assessments"
89521627|NCT03420313|No Intervention|Waitlist Control|Waitlist Control participants will remain on the waitlist for their treatment of choice but complete the same monthly assessments.
89521628|NCT03415633|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
89521629|NCT03415633|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
89521630|NCT03420235|No Intervention|Control group|Control group will receive standard care alone.
89521631|NCT03420235|Experimental|Home monitoring group|Intervention will consist of a home monitoring program added to standard care.
89521632|NCT03420157||Focus Group 1 & 2|Each Focus Group of 10 women will be led by a psychologist according to a semi-directive interview pattern. This interview guideline specifies in details the ideal proceedings of Focus Group, as well as the various predetermined topics to be addressed in the form of questions and / or relaunches. The interview guideline is divided into 2 parts: the accompanying letter and the leaflet explaining how to perform the vaginal self-sampling.
89521633|NCT03415477|Experimental|denosumab (Xgeva) treatment|Patients with aneurismal bone cysts received perioperative denosumab(Xgeva).
89521634|NCT03127735|Experimental|BAY1436032|"Dose escalation:~Various doses of study drug will be tested on a small number of patients/dose with the goal of identifying the most appropriate dose(s) for further evaluation in dose expansion. The MTD of the study drug may or may not be identified. It is anticipated that 3-4 patients will be treated at each dose of study drug to be tested and that 15-20 total patients will be treated in this part of the trial.~Dose expansion:~Up to 2 different doses of study drug will be tested on up to 30 patients/dose with the goal of identifying the most appropriate RP2D for further clinical development. The doses to be evaluated in this part of the trial will be selected based on information obtained during dose escalation."
89521635|NCT02345252|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus FTC/RPV/TDF placebo for at least 96 weeks.
89521636|NCT02345252|Active Comparator|FTC/RPV/TDF|FTC/RPV/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
89521637|NCT02345252|Experimental|Open Label Extension Phase|After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF, and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
89521638|NCT03415399|Experimental|i.v. arm|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
89521639|NCT03415321|Experimental|Intervention group|Postpartum Mobile Support Application
89045355|NCT01975818|Experimental|Molidustat (BAY 85-3934)(50mg)|Starting dose of 50 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
89045356|NCT01975818|Experimental|Molidustat (BAY 85-3934) (75mg)|Starting dose of 75 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.,
89649471|NCT03805399|Experimental|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation
89649472|NCT03805399|Experimental|BLIS with anti-VEGFR included therapy|If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation
89649473|NCT03805399|Experimental|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation
89649474|NCT03805399|Experimental|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation
89649475|NCT02652624|Experimental|B/F/TAF|Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.
89649476|NCT02652624|Active Comparator|Baseline Regimen|Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.
89649477|NCT02652624|Experimental|Extension Phase|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.
89649478|NCT03852966|Experimental|CBT-i/ADHD|Behavioral treatment for sleep problems in ADHD
89649479|NCT03724903|Experimental|Ductal lavage|Ductal lavage and breast massage for two weeks.
89649480|NCT03724903|Active Comparator|Corticosteroids therapy|Oral corticosteroids therapy for 6 months.
89649481|NCT03722017|No Intervention|Control--usual care|"Medication History: All participants / surrogates will receive a structured interview and chart review by the study Pharmacist or Nurse Practitioner at enrollment to determine:~Medications: Medications will include ANY medication with the potential for continuation at the time of hospital discharge to include pre-hospital medications, [OTC medications] and active in-hospital medications. Pre-hospital [and OTC] medications will be confirmed by Veteran/surrogate interview and pharmacy refills. If a Veteran is admitted from SNF (short-term stay), the investigators will request a copy of the Medication Administration Record (MAR) for the past 30 days. Current medications will be defined as those taken within 30 days prior to the index (enrollment) hospitalization event."
89649482|NCT03722017|Experimental|Intervention--deprescribing protocol|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
89649483|NCT04348279|Active Comparator|custom made acrylic stent|the donor sites of the participants were covered with custom made acrylic stent
89649484|NCT04348279|Experimental|propylene mesh|in the test group, the donor sites received propylene mesh.
89649485|NCT03637075|Placebo Comparator|Placebo|Intranasal placebo administration
89649486|NCT03637075|Active Comparator|Intranasal insulin|Intranasal insulin administration
89649487|NCT04403503|Active Comparator|Gelatine Sponge|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA)
89688582|NCT03402815|Experimental|A|Patients received Maraviroc 300 mg/day in addition to current ART for 24 weeks. At the end of the first 24-week period patients were switched to ART with no additional treatment.
89045357|NCT01975818|Experimental|Molidustat (BAY 85-3934) (150mg)|Starting dose of 150 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, 150 and 200 mg once daily
89045358|NCT01975818|Active Comparator|Epoetin alfa/beta|Starting dose at the subject's current weekly dose. Administered IV or SC 3 times per week. Doses will be titrated at the scheduled dose control visits according to the local label. Titration will be based on the subject's Hb response and tolerability of the prior dose. Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.
89045359|NCT02911259|Experimental|Group 1|Post-operative suction is set to -2 cmH2O.
89045360|NCT02911259|Active Comparator|Group 2|Post-operative suction is set to -10 cmH2O (standard treatment).
89045361|NCT04676919|Experimental|pulsed mode phonophoresis group|Phonophoresis therapy with pulsed mode ultrasound.
89045362|NCT04676919|Experimental|continuous mode phonophoresis group|Phonophoresis therapy with continuous mode ultrasound.
89045363|NCT04676919|Sham Comparator|sham group|Sham ultrasound
89521640|NCT03415321|No Intervention|Control Group|Routine care
89521641|NCT03420079|Experimental|Dose escalation cohort of FCN-411|"FCN-411 will be orally administrated at five sequential dose levels, which are 4 mg, 8 mg, 16 mg, 24 mg, and 32 mg.~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
89649488|NCT04403503|Active Comparator|Gelatine sponge +Cyanoacrylate|After local anesthesia (2% articaine HCl with epinephrine 1:100,000) administration, palatal thickness was measured by perpendicularly inserting a Michigan-O periodontal probe from the corners of the rectangular donor area and mean value was recorded as 'palatal tissue thickness (PTT)'. Epithelialized gingival graft was harvested with the method described by Zucchelli et al.19 After a rectangular shaped initial incision, graft with 1-1.5 mm thickness was harvested approximately 1.5 to 3 mm away from gingival margins of upper teeth. After harvesting, excess fatty tissues were removed and de-epithelialization was performed to obtain DGG. Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group)
89649489|NCT00249795|Experimental|Irbesartan|150 mg for 2 weeks, then up-titrated to 300 mg up to final follow-up visit
89649490|NCT00249795|Placebo Comparator|Placebo|Matching placebo up to final follow-up visit
89649491|NCT04404127|Placebo Comparator|No induction Arm|
89649492|NCT04404127|Active Comparator|Induction with basiliximab|
89649493|NCT04763629|Experimental|Interval Training (IT)|Patients randomized to this group will perform 45 minutes of exercise on treadmill, alternating intervals of ten minutes at 50-60% of VO2 peak and two intervals five miutes at 85-90% of VO2 peak
89649494|NCT04763629|Experimental|Compbined Training (CT)|Patients randomized to this group will perform 45 minutes of exercise in which they will perform aerobic continuous training on tradmill (20 minutes) and resistance training (25 minutes)
89649495|NCT04763473|Placebo Comparator|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
89649496|NCT04763473|Experimental|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
89649497|NCT02651220|Experimental|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w|
89649498|NCT02651220|Active Comparator|Epiduo® Forte Gel 0.3%/2.5% w/w|
89649499|NCT02651220|Placebo Comparator|Placebo (vehicle) Topical Gel|
89649500|NCT00724347|Experimental|Arm 1|Hearing impaired listeners with hearing aids underwent two months of consonant identification training in their homes.
89649501|NCT03719287||Hospital #1|Patients who meet inclusion criteria in the first of three participating Brazil hospitals
88993096|NCT04433351|Experimental|ES cohort|Patients in the ES cohort will carry out first the enriched rehabilitation protocol (E, 4 weeks) followed by simple rehabilitation (S, 4 weeks).
88993097|NCT04392193|Experimental|Proton Particle Therapy for Cardiac Arrhythmia|Subjects who have an ICD with recurrent VT, VF, or VT storm who have failed one prior standard catheter-based ablation after device implantation, will subsequently undergo particle-based extracorporeal ablation.
88993098|NCT04304014|Experimental|L. reuteri|"Group that will receive L. reuteri one dose per day in an oral suspension~Intervention: Dietary Supplement: L. reuteri"
88993099|NCT04304014|Experimental|B. longum and P. Pentosaceus|"Group that will receive B. longum and P. Pentosaceus one dose per day in an oral suspension.~Intervention: Dietary Supplement: B. longum and P. Pentosaceus"
88993100|NCT04300231|Active Comparator|Thoracic epidural|1. Thoracic epidural- epidural bupivacaine 0.05%/hydromorphone 0.05mg/ml mix will be given throughout the duration of their epidural analgesia.
88993101|NCT04300231|Active Comparator|Rectus Sheath Block|2. Rectus Sheath Block - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected into 4 locations below the rectus abdominis muscle.
88993102|NCT04300231|Active Comparator|Surgeon Infiltration with Liposomal Bupivacaine (LB)|3. Surgeon infiltration with Liposomal Bupivacaine (LB) - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery, prior to abdominal wall closure.
88993103|NCT04300231|Active Comparator|Surgeon Infiltration|4. Surgeon infiltration with Standard Bupivacaine (SB) - 60ml of 0.25% bupivacaine will be diluted with 40ml of saline for a total of 100ml. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery.
88993104|NCT04261543|Experimental|High Protein and Early Exercise|High protein is defined as a protein prescription of ≥2.2 gram/kg body weight; Early exercise is defined as exercise by using cycle ergometry for 45 minutes per day within 24 hours of randomization
88993105|NCT04261543|Active Comparator|Usual Care|Usual care has a protein prescription of ≤1.2 gram/kg body weight and exercise prescription as per the discretion of attending clinicians
88993106|NCT04253327||BOT|Patients diagnosed and treated by surgery for borderline ovarian tumor
88993107|NCT04253327||controls|Patients after surgical treatment of benign ovarian tumor
89649502|NCT03719287||Hospital #2|Patients who meet inclusion criteria in the second of three participating Brazil hospitals
89649503|NCT03719287||Hospital #3|Patients who meet inclusion criteria in the third of the three participating Brazil hospitals
89649504|NCT04271943|Active Comparator|COMPUTER BASED EXERCISES|
89649505|NCT04271943|Active Comparator|AEROBIC EXERCISES|
89649506|NCT04580004|Experimental|Medication Optimization Group|Patients randomized to the medication optimization group will receive an evidence-based medication recommendation intervention.
89649507|NCT04580004|No Intervention|Control Group|Patients in the control group will receive the same intervention, delayed 2 weeks after the intervention group. During those initial 2 weeks they will act as a control.
89649508|NCT01279551|Experimental|GTN|In this arm the investigators administer local application of 0.4% nitroglycerin ointment and ketorolac tromethamine 10 mg
89649509|NCT01279551|Active Comparator|Control|In this arm the investigators administer local application of lidocaine cloridrato 2.5% and ketorolac tromethamine 10 mg.
89649510|NCT00780403|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
89649511|NCT00780403|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
89649512|NCT01274091|Experimental|P/S-ratio 1.0|"Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:~polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0."
89045364|NCT02911415||the dosage of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.25 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015.
89045365|NCT02911415||the dosage of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.5 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015
89649513|NCT01274091|Experimental|P/S-ration 0.3|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
89649514|NCT04436094|Experimental|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
89649515|NCT04436094|Active Comparator|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
89649516|NCT01677013|No Intervention|Oral medication treatment|type 2 diabetics with only oral medications
89649517|NCT01677013|Experimental|Oral medication plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
89649518|NCT01677013|No Intervention|Oral medication plus insulin treatment|Type 2 diabetics who need insulin therapy with oral medications
89649519|NCT01677013|Experimental|Oral medication plus insulin plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
89649520|NCT00741273|Experimental|Proellex 25 mg healthy|Proellex 25 mg in healthy females
89649521|NCT00741273|Experimental|Proellex 25 mg Impaired|Proellex 50 mg in hepatically impaired females
89649522|NCT03630601|Experimental|Diagnostic (photoacoustic imaging)|Participants undergo PAI on different parts of the body over 20 minutes for up to 5 imaging sessions for 6 months.
89649523|NCT01979796|Experimental|Ecig 24 mg nicotine|Ecig 24 mg nicotine
89649524|NCT01979796|Sham Comparator|Ecig 0 mg nicotine|Ecig 0 mg nicotine
89649525|NCT01979796|Placebo Comparator|Nicotine free inhalator|Nicotine free inhalator
89045366|NCT02910947|Experimental|quadratus lumborum|
89045367|NCT02910947|Experimental|TAP(Transversus abdominis plane)|
89045368|NCT01973049|Experimental|A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks"
89045369|NCT01973049|Experimental|A2: DCV/ASV/BMS-791325 + RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200mg tablet orally twice a day for 12 weeks"
89045370|NCT01973049|Experimental|A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks"
89045371|NCT01973049|Experimental|A4: DCV/ASV/BMS-791325 + RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If < 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening"
89649526|NCT03797989|Experimental|Phase A: Group 1|Each volunteer will receive one vial of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
89649527|NCT03797989|Experimental|Phase A: Group 2|Each volunteer will receive a fifth of a vial (1:5 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
89649528|NCT03797989|Experimental|Phase A: Group 3|Each volunteer will receive one twentieth of a vial (1:20 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
89649529|NCT03797989|Experimental|Phase B: Group 4|The six volunteers from Groups 1, 2 and 3 in will undergo secondary challenge using the optimal inoculum, as determined in Phase A of the study. They will constitute 'Group 4' in Phase B. This will occur approximately eight months (and up to nine months) later after their primary challenge.
89649530|NCT03797989|Experimental|Phase B: Group 6|Three new malaria naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls to Group 4.
89649531|NCT03797989|Experimental|Phase C: Group 5|The six volunteers from Group 4 in Phase B will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 5 in Phase C. This will occur approximately sixteen months (and up to twenty months) later after their secondary challenge.
89649532|NCT03797989|Experimental|Phase C: Group 7|The three volunteers from Group 6 who underwent primary challenge in Phase B undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will now form Group 7 in Phase C. This will occur approximately six months (and up to nine months) later after their primary challenge.
89649533|NCT03797989|Experimental|Phase C: Group 9|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 5 and 7.
89649534|NCT03797989|Experimental|Phase D: Group 8|The three volunteers from Group 7 in Phase C will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 8 in Phase D. This will occur approximately five months (and up to ten months) after their secondary challenge.
89649535|NCT03797989|Experimental|Phase D: Group 10|The four to eight volunteers from Group 9 in Phase C will undergo secondary challenge, using the optimal inoculum as determined in Phase A, and form Group 10 in Phase D. This will occur approximately six months (and up to nine months) later after their primary challenge.
89649536|NCT03797989|Experimental|Phase D: Group 12|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 8 and 10.
89649537|NCT03797989|Experimental|Phase E: Group 11|The four to eight volunteers from Group 10 in Phase D will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 11 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
89649538|NCT03797989|Experimental|Phase E: Group 13|The four to eight volunteers from Group 12 in Phase D will undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 13 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
89649539|NCT03797989|Experimental|Phase E: Group 15|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 11 and 13.
89649540|NCT03797989|Experimental|Phase F: Group 14|The four to eight volunteers from Group 13 in Phase E will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 14 in Phase F. This will occur approximately five months (and up to ten months) after their secondary challenge.
89649541|NCT03797989|Experimental|Phase F: Group 16|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Group 14.
89649542|NCT00247611|Other|Control|Participants will receive the control condition
89649543|NCT00247611|Experimental|Intervention|Participants will receive the LifeWindows Intervention sessions
89649544|NCT04532190|Experimental|Active rTMS|Active repetitive TMS parameters will be intensity 120% resting motor threshold (RMT), 40 pulses over 4 seconds (frequency 10Hz), inter-trial interval of 26 seconds, 75 trains, 3000 pulses/session to the right superior frontal gyrus, duration of 37.5 minutes per session.
89649545|NCT04532190|Sham Comparator|Sham rTMS|For sham rTMS, set-up, duration, and sound (i.e. clicking sound) will be the same, but no magnetic field will be emitted from the rTMS coil.
89649546|NCT04202874|Experimental|Bupivacaine|Administration of 20ml of bupivacaine 0.25% on each side, for a total of 40ml.
89649547|NCT04202874|Placebo Comparator|Saline|Administration on 20ml of normal saline on each side, for a total of 40ml.
88993108|NCT04242134|Experimental|PS-DCB|"For PS-DCB group~NC balloon dilating ostial side branch (SB) (1:1 ratio).~DCB dilating SB. Specifically, the DCB, which had to be 2-3 mm longer on each side than the predilatation balloon, was inflated at nominal pressure for 30~ 60 s. The ratio of the DCB diameter to the nominal diameter of the SB was recommended to be between 0.8 and 1.0. DCB should be delivered to the lesion within 2 min after entering human body.~Kissing inflation using 2 noncomplian balloons.~Stenting side branch with T and protrusion (TAP) technique if any of the following issues was observed after kissing balloon inflation: >type C dissection or thrombolysis in myocardial infarction (TIMI) flow <3.~Final kissing inflation and proximal optimal technique (POT)."
88993109|NCT04242134|Active Comparator|PS-NCB|"For PS-NCB group~NC balloon dilating ostial SB (1:1 ratio).~Kissing inflation using 2 NC balloons.~Stenting side branch with TAP technique if any of the following issues was observed after kissing balloon inflation: >type C dissection or thrombolysis in myocardial infarction (TIMI) flow <3.~Final kissing inflation and proximal optimal technique (POT)."
88993110|NCT04236739|Experimental|IMPACT|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) during one surgical procedure.
88993111|NCT04236739|No Intervention|Control|Optional physical therapy or pain medication, according to participants' desire for 9 months.
88993112|NCT04218422|Experimental|Treatment|2 treatments of battlefield acupuncture to the bilateral ears spaced one week apart
88993113|NCT04218422|Sham Comparator|Control|2 treatments with sham acupuncture to the bilateral ears at acupuncture points not associated with pain relief (2 liver and 1 stomach)
88993114|NCT04209985|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach will call patients up to five times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
88993115|NCT04209985|No Intervention|Usual care|Patients assigned to usual care have access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
88993116|NCT04201600||Middle-aged and Older adults with Prediabetes|Middle-aged and Older adults with Prediabetes
89649548|NCT00742053|Experimental|1|Male or female inpatients, age ≥ 18 and ≤ 80 years, who are in normal sinus rhythm and do not have a pacemaker or other indwelling intracardiac device and require PICC insertion for their routine care will be studied. Intervention: ECG-guided Power PICC placement.
89649549|NCT03628339|Experimental|Midazolam (Reference Treatment)|Participants received single oral dose of 7.5 milligrams (mg) midazolam tablet on Day 1 of treatment period 1. The washout period between midazolam administrations in Period 1 and Period 2 was 12 days.
89649550|NCT03628339|Experimental|Tepotinib + Midazolam (Test Treatment)|All participants who received 7.5 mg midazolam tablet in treatment period 1 received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 along with 7.5 mg midazolam tablet on Day 11 in treatment period 2.
89649551|NCT03433950||Fluctuator|Parkinson's subjects with rises in systolic blood pressure exceeding 50% of baseline during motor off periods to select for subjects with severe blood pressure fluctuations.
89649552|NCT04412694|Experimental|supplementation group|Patients will receive preoperative oral supplementation of 8mg of dexamethasone (Dexamethasone Krka tablets (8mg), Warsaw, Poland) in a single dose taken once one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
89649553|NCT04412694|Placebo Comparator|placebo group|Patients will receive preoperative oral supplementation of sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria) taken once in a single dose one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated.
89649554|NCT03628261|Other|physical therapy then serious games|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
89649555|NCT03628261|Other|serious games then physical therapy|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
89649556|NCT03613038|Other|Phonetic complexity effects|Conduct a comprehensive kinematic assessment using state-of-the art 3D speech tracking technology on individuals with ALS and PD as well as healthy talkers to identify articulatory motor disturbances as a function of phonetic complexity and dysarthria severity. Phonetic complexity will be experimentally manipulated using the consonant and vowel complexity classification system proposed by Kent (1992) that takes into account the underlying articulatory motor adjustments required to produce various speech sounds.
89649557|NCT03627715|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks propagermanium and 12 weeks placebo separated by a 6 week washout period."
89649558|NCT03627715|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks placebo and 12 weeks propagermanium separated by a 6 week washout period."
89649559|NCT00246753|Other|Single Arm Trial|Single Arm Trial where each patient receives GW572016 (lapatinib ditosylate) at a dose of 1500mg daily initially until disease progression or unacceptable toxicity.
89649560|NCT02083861|Experimental|Active ultrasound device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
89649561|NCT02083861|Placebo Comparator|Placebo ultrasound device|Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
89649562|NCT03600480|Experimental|NNC0174-0833+Semaglutide|Participants will receive increasing doses of NNC0174-0833 along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
89649563|NCT03600480|Active Comparator|Placebo (NNC0174-0833)+Semaglutide|Participants will receive placebo (NNC0174-0833) along with semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
89045372|NCT01185964|Experimental|Phase 1b: Olaratumab + doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
89045373|NCT01185964|Experimental|Phase 2: Olaratumab and doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
89045374|NCT01185964|Active Comparator|Phase 2: Doxorubicin: Optional Olaratumab After Progression|"All cycles are 21 days.~Cycles 1-8: doxorubicin 75 mg/m2 on day 1 until disease progression.~At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression."
89649564|NCT03624361|Experimental|Stand-alone|"Patients will receive MINIject Glaucoma implant in a stand-alone procedure.~MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention."
89649565|NCT00246129|Active Comparator|Campath-Tacrolimus|Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
89045375|NCT02910869||Successful weight loss|Patients who have lost =>5% of their weight after completing MOVE! or TeleMOVE!
89045376|NCT02910869||Unsuccessful weight loss|Patients who have lost <5% of their weight after completing MOVE! or TeleMOVE!
89045377|NCT01972854|Experimental|riboflavin solution and KXL System|The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
89045378|NCT01972854|Placebo Comparator|placebo solution and KXL System|The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
89045379|NCT01217476|Active Comparator|Trafermin 0.01% spray|
89045380|NCT01217476|Placebo Comparator|Matching placebo spray|
89649566|NCT00246129|Experimental|Daclizumab-Tacrolimus-Mycophenolate|Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy
89649567|NCT04131972|Experimental|Single arm 1|Each patient will be planned to perform 7 study visits and at the second visit excision / lumpectomy and REGENERA implant will be performed during the same surgical intervention.
89649568|NCT03789253||AS cohort with progression|AS cohort with tumor progression
89649569|NCT03789253||AS cohort without progression|AS cohort without tumor progression
89649570|NCT02980848||Screening group|Women without a history of breast cancer undergoing screening digital mammography, screening digital breast tomosynthesis, or screening breast magnetic resonance imaging.
89045381|NCT04677075||mastectomy group|patients with breast cancer and eligible for mastectomy
89045382|NCT04318756||Italian patients suffering from mucinous neoplasms|Italian patients suffering from mucinous neoplasms will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
89045383|NCT04318756||Italian patients with familiarity/genetic predisposition|Italian patients with familiarity/genetic predisposition will follow a brief interview made by a psychologist. The interview of pilot group will be record to allow us to investigate and track detail that will highlight the comprehension of cancer worry scale and participants' suggestion. Moreover during the session will be ask to patients to fill inn Irritability-Depression-Anxiety Scale and Patient Health Questionnaire-9 to evaluate other psycho-emotional information about fear of cancer
89045384|NCT02888002|Experimental|Internet-based treatment|"Guide to better alcohol habits online. An Internet-based treatment program with online counselor support."
89045385|NCT02888002|Experimental|Face-to-face treatment|"Guide to better alcohol habits F2F: Face-to-face treatment with 5 individual counselor sessions at the clinic."
89045386|NCT04675437|Experimental|Frail patients (CABG, HF or mini-AVR)|12-weeks cardiac exercise program (3 sessions per week) consisting of aerobic exercises (ergometer, treadmill and arm ergometer).
89045387|NCT04677192|Experimental|Microwave Ablation Combined with Chemotherapy|All patients will receive microwave ablation of oligohepatic metastasis and chemotherapy according to NCCN guidelines,and the efficacy was evaluated every 8 weeks until the disease progressed or the patient could not tolerate it.
89045388|NCT02550470||Randomized to Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
89521642|NCT03420079|Experimental|Dose expansion cohort of FCN-411|"FCN-411 will be orally administrated at MTD.~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
89521643|NCT03420001||VBAC|secundiparous women after one vaginal birth after caesarean section
89521644|NCT03420001||controls|women after one vaginal delivery
89521645|NCT03415165|Active Comparator|green tea buccal tablet|buccal tablet 3 times aday
89521646|NCT03415165|Sham Comparator|corticosteroids topical|topical steroids 3 times aday
89521647|NCT03419923|Placebo Comparator|saline flushes|saline flushes with 250 mL were carried out every 30 min.
89521648|NCT03419923|Active Comparator|one stage regional citrate|one stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
89521649|NCT03419923|Experimental|two stage regional citrate|two stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
89521650|NCT03419845|Experimental|Step Right Buddy arm|To use modified walking frame using the Step Right Buddy
89521651|NCT03426553|Experimental|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
89521652|NCT03426553|Active Comparator|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
89521653|NCT03415087|Active Comparator|sequential intrathecal injection of fentanyl and bupivacaine|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV,once drug: hyperbaric bupivacaine 0.5%10 mg IV,once both syringes were injected slowly sequentially
89521654|NCT03415087|Experimental|rapid sequential intrathecal injection of fentanyl and bupiva|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV, injected rapidly and mixed by CSF, once drug: hyperbaric bupivacaine 0.5%10 mg IV injected slowly once.
89521655|NCT02833753|Experimental|Dose Escalation|"Single arm dose finding for intraperitoneal Oxaliplatin. All patients will receive experimental treatment.~The first cohort of 3 patients will receive dose level 1. The second cohort of 3 patients will receive dose level 2. The Third cohort of 3 patients will receive dose level 3. The fourth cohort of 3 patients will receive dose level 2."
89521656|NCT03419767|Active Comparator|surgery with melatonin|Patients under carotid revascularization surgery with melatonin taken during perioperative period.
89521657|NCT03419767|Sham Comparator|surgery with blank control|Patients under carotid revascularization surgery with nothing unnecessary taken during perioperative period
89521658|NCT03415009||HCV genotype 1 and genotype 2/3|DNA extracted from whole blood sample will be used as template for real-time PCR amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for rs12979860 and TT/GT/GG for rs8099917).
89521659|NCT03426397||Study population|
89521660|NCT03414931|Experimental|NMDAE|An NMDA enhancer
89521661|NCT03414931|Active Comparator|SSRI|Sertraline
89521662|NCT03414931|Placebo Comparator|Placebo|Placebo
89521663|NCT03414853||With algorithm use|
89521664|NCT03414853||No algorithm use|
89521665|NCT03426319||Primary adrenal insufficiency|Patients with primary adrenal insufficiency on hormone replacement therapy with hydrocortisone.
89521666|NCT03426241||smoking chronic periodontitis|
89521667|NCT03426241||non-smoking periodontitis|
89521668|NCT03426241||smoking healthy|
89521669|NCT03426241||non-smoking healthy|
89521670|NCT03033823|Experimental|Intervention|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
89649571|NCT02980848||Women with breast cancer|Women diagnosed with stage 0-III breast cancer undergoing pre-operative work-up with diagnostic mammography alone or diagnostic mammography plus pre-operative breast magnetic resonance imaging.
89649572|NCT01676779|Experimental|Arm A dendritic cell therapy|Arm-A, patients will receive Dendritic Cell therapy during one year following randomization.
89649573|NCT01676779|Experimental|Arm B Dendritic cell therapy|Arm-B, patients will initiate Dendritic Cell therapy only after documented recurrence of the melanoma that cannot be salvaged by local therapy.
89649574|NCT04345575|Experimental|VR Group|VR group participants were mailed an Oculus Go Virtual Reality headset preloaded with VR software developed by AppliedVR. Treatment content consisted of a variety of 21 sessions to support participants in learning cognitive and behavioral self-management skills based on evidence-based CBT principles and skills, biofeedback and mindfulness strategies used in pain management. The program was designed to improve self-regulation of cognitive, emotion, and physiological response to stress and pain.
89649575|NCT04345575|Active Comparator|Audio Group|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the Audio program included didactic and experiential content that was not identifical but was closely matched to the VR content (sans references to visual imagery that would be confusing in the absence of visual content). Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
89649576|NCT02848716|Active Comparator|Standard of care arm|Standard chemoradiation based on FluoroDeoxyGlucose-Positon Emission Tomography (FDG-PET) imaging status of the pelvic nodes
89649577|NCT02848716|Experimental|Experimental arm|Pretherapeutic paraaortic lymphadenectomy followed by tailored chemoradiation. Pretherapeutic lymphadenectomy will be performed via the laparoscopic extraperitoneal or transperitoneal approach
89649578|NCT01274247|Active Comparator|Topical Benzocaine|For infants treated with topical benzocaine prior to the procedure
89649579|NCT01274247|No Intervention|no benzocaine|No benzocaine applied
89649580|NCT02738034|Experimental|Adaptive training group|The intervention group will be composed of hypertensive participants with cognitive decline that will be submitted to the training program (Cogmed) for approximately 10 weeks. Across training, task difficulty was adjusted as a function of individual performance.
89649581|NCT02738034|Active Comparator|Active control Group|In the control group, hypertensive patient will be submitted to a set of online games available on the internet and previously determined. In this way, the control group will receive the same motivation, as well as will be engaged in computerized activities, in the same way as the experimental group. The difference is that these varied games do not provide any type of intense and adaptive training, at the same time as they do not stimulate any specific cognitive function.
89649582|NCT01279629||Tazarotene 0.1%|
89649583|NCT01279629||Calcipotriol 0.005%|
89649584|NCT04762849|Experimental|laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR)|Laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. A ring with shape memory put on the gastric pouch
89649585|NCT04762849|Active Comparator|laparoscopic one anastomosis gastric bypass (MGB/OAGB) without band: standard surgery|Laparoscopic one anastomosis gastric bypass (MGB/OAGB) include the creation of a gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
89649586|NCT01274325|Experimental|Sereflo|Sereflo (25/125)
89649587|NCT01274325|Active Comparator|Seretide|Seretide (25/125)
89649588|NCT04502394|Experimental|Cohort 1 (R/R DLBCL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
89649589|NCT04502394|Experimental|Cohort 2 (R/R CLL)|"KRT-232 will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.~Acalabrutinib at 100 mg twice a day (BID) continuously starting on Day 1 in a 28-day cycle."
88993117|NCT04193202|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
88993118|NCT04193202|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
88993119|NCT04173715||General Group|All those who are over 65 years old and capable of walking by themselves.
88993120|NCT04173715||Low Physical Function Status Group.|All those who present a low physical function status will be included in this group.
88993121|NCT04173715||Medium Physical Function Status Group.|All those who present a medium physical function status will be included in this group.
88993122|NCT04173715||High Physical Function Status Group.|All those who present a high physical function status will be included in this group.
88993123|NCT04171050|Active Comparator|Group 1: Local Anesthesia|Standard of care with local anesthesia used during surgery
88993124|NCT04171050|Active Comparator|Group 2: Local Anesthesia plus Pudendal Nerve Block|Pudendal Nerve Block (PNB) in addition to local anesthesia used during surgery
88993125|NCT04159935|Experimental|iLux® treatment|The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.
88993126|NCT04159935|Experimental|Delayed iLux® treatment|Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.
88993127|NCT04155619|Active Comparator|No change in eating or light exposure habits|
88993128|NCT04155619|Experimental|Early Time-Restricted Feeding|
88993129|NCT04155619|Experimental|Timed Light Therapy|
89649590|NCT01677481||Femoral|Coronary angiography procedures performed using transfemoral access
89649591|NCT01677481||Left radial access|Coronary angiography procedures performed using left radial access site.
89649592|NCT01677481||Right radial Access|Coronary angiography procedures performed using Right radial access site.
89649593|NCT02984839||Intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
89649594|NCT02984839||Non-intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective non intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
89649595|NCT00746187|Experimental|ASTRA TECH Implant System; Fixture ST|Ø 4.5 cm in lengths 9-13 mm
89649596|NCT00746187|Experimental|Biomet 3i; Osseotite® Implants|Ø 4.0 cm in lengths 8.5-13 mm
89649597|NCT01677091|Active Comparator|Control group|This group will benefit from conventional rehabilitation
89649598|NCT01677091|Experimental|Cervical vibration|This group will benefit from a daily 20 minutes session, with vibration of neck muscles during 10 minutes
89649599|NCT01677091|Experimental|Prism adaptation|This group will benefit from a daily 20 minutes session, with prism adaptation during 10 minutes
89649600|NCT01677091|Experimental|Cervical vibration + Prism adaptation|This group will receive a daily 30 minutes session, with cervical vibration during 10 minutes + prism adaptation during 10 minutes
89649601|NCT01274403|Experimental|Melphalan, prednisone plus Thalidomide|
89649602|NCT01274403|Active Comparator|Melphalan and Prednisone|
89649603|NCT03182868|Experimental|Repeatability Group|Healthy participants perform goggle testing on two consecutive days to determine if the testing results are repeatable. Testing will be between 10 am and 2 pm and testing on the two sessions will be within 30 minutes of the same time. Sessions can be on two consecutive days or separated by up to 4 days.
89649604|NCT03182868|Experimental|Time of Day Group|Healthy participants perform goggle testing at two different times of day to determine if time of day affects goggle testing performance. One quarter of the participants in this arm will undergo one test at 8 am on the first session and 10 am on the second session. A second quarter will undergo the tests at 10 am on first session and 8 am on the second session. A third quarter will undergo one test at 3 pm on the first session and 10 am on the second session. The fourth quarter will undergo the tests at 10 am on first session and 3 pm on the second session. In all these cases the sessions can be on consecutive days or separated by up to 4 days.
89649605|NCT03182868|Experimental|Learning Affect Group|Healthy participants perform goggle testing back to back on the same day to determine if performance on second test changes from first test suggesting a learning affect.
89649606|NCT03182868|Experimental|MSQ Group|Healthy participants perform goggle testing and upon completion of each goggle testing session will complete a Motion Sickness Questionnaire (MSQ) to determine if they show any signs of motion sickness.
89649607|NCT03182868|Experimental|OKN Only Group|OKN Only Group is for exploratory aims only. Healthy participants will undergo goggle testing limited to Optokinetic Nystagmus (OKN) recordings at two stimulus speeds (20 and 60 deg/s) in both the counterclockwise and clockwise directions.
89649608|NCT03700099|Other|Study cohort|Docetaxel 75 mg/m2 i.v. every 3 weeks for 6-10 cycles. Upon disease progression after docetaxel, participants will receive enzalutamide 160 mg p.o. daily until limiting toxicity or disease progression.
89649609|NCT01274481|Experimental|Iloprost|All patients will have their response to Iloprost compared to baseline pre-treatment.
89649610|NCT03782467|Experimental|ATOR-1015|ATOR-1015 administered by intravenous infusions every 2 weeks until confirmed progressive disease, unacceptable toxicity or withdrawal of consent.
89649611|NCT00754377||PBLI Curriculum group|To evaluate preliminary data on a PBLI curriculum grounded on QI system projects.
89045389|NCT02550470||Randomized to Drager 800 Absorbent|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
89649612|NCT00754377||Comparison group|Received a different curriculum.
89649613|NCT03779269|Experimental|color meditation|only color meditation
89649614|NCT03779269|Experimental|Sound meditation|Only sound mediation
89649615|NCT03779269|Experimental|Color and sound combined meditation|Combined group
89649616|NCT03779269|No Intervention|Control group|Only control group
89649617|NCT00245583|Experimental|Topiramate|25mg to 300mg daily dose
89649618|NCT00245583|Placebo Comparator|Placebo|placebo equivalent tablets
89649619|NCT01379989|Active Comparator|Carboplatin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.
89649620|NCT01379989|Experimental|Trabectedin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.
89649621|NCT04129320|Experimental|Experimental Arm 1|Enoblituzumab plus MGA012
89649622|NCT04129320|Experimental|Experimental Arm 2|Enoblituzumab plus MGD013
89649623|NCT04053426||"Population before"|Patient included before implementation of care algorithm.
89649624|NCT04053426||"Population after"|Patients included after the implementation of care algorithm and training of health professionnals
89649625|NCT04012242||NAFLD patients who are scheduled for liver biopsy|
89649626|NCT04762303|Experimental|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
89649627|NCT04762303|No Intervention|No MedReviewRx|During the control phase, MedReviewRx will not be accessible to health care professionals at the nursing homes. This serves to obtain baseline deprescribing levels for each nursing home.
89649628|NCT04348903|Experimental|Virtual Reality Distraction|Virtual reality refers to a human-computer interface that completely immerse the child in a simulated environment. It integrates multiple perceptual senses including; the visual, auditory and kinaesthetic stimulation modalities. Virtual reality diverts children's attention away from the negative feelings associated with unpleasant experience.
89688583|NCT03402815|Experimental|B|Patients received ART with no additional treatment for 24 weeks. At the end of the first 24-week period patients were switched to Maraviroc 300 mg/day in addition to current ART.
89649629|NCT04348903|Experimental|Positive Pre-Visit Imagery Intervention|Positive pre-visit imagery is one of the superior cognitive- behavioral interventions. It is kind of psychological preparation that is designed to provide children with a step-by-step explanation of the dental local anaesthesia injection in an attractive approach
89649630|NCT00893178||CHF with elevated PAP|CHF patients (LVEF > 35%) with elevated mean pulmonary pressure( > 20 mmHg ) measured by pa catheter
89649631|NCT00893178||CHF patient without elevated PAP|CHF patients (LVEF > 35%) with normal mean pulmonary pressure
89649632|NCT00893178||Normal EF with elevated PAP|Patients with normal LVEF < 60% with elevated mean pulmonary pressure
89649633|NCT04506528||Patients with COVID-19|Analyses of the cohort data will include (1) all patients, or (2) hospitalized patients meeting specific inclusion criteria.
89649634|NCT03775291||Low pre-test likelihood for sleep apnea|Subjects at low risk for having sleep apnea due to lack of known risk factors and no complaints of symptoms related to sleep apnea (e.g., excessive daytime sleepiness)
89649635|NCT03775291||High pre-test likelihood for sleep apnea|Suspected sleep apnea patients who are undergoing sleep tests as part of normal medical care or are also known to be non-compliant with therapy.
89649636|NCT02652156|Active Comparator|Single Injection of Bupivacaine|Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.
89649637|NCT02652156|Active Comparator|Single Injection of Exparel®|Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane
89649638|NCT02652156|Active Comparator|Continuous infusion of Ropivacaine|Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump
89649639|NCT03699865|Experimental|Purple|Participants will receive cigarettes with intermediate or very low nicotine content in purple packaging
89649640|NCT03699865|Experimental|White|Participants will receive cigarettes with intermediate or very low nicotine content in white packaging
89649641|NCT03699865|Experimental|Black|Participants will receive cigarettes with intermediate or very low nicotine content in black packaging
89649642|NCT00754923|Experimental|Treatment: Sorafenib|Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
89045390|NCT02550470||Randomized to Drager Free|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
89045391|NCT04688216||MDRO|
89045392|NCT04688216||Non-MDRO|
89649643|NCT00746421|Experimental|1|Quetiapine XR 200-400 mg/day
89649644|NCT00746421|Placebo Comparator|2|Placebo one pill per day matching 200, 300, or 400 mg
89649645|NCT00755235|Experimental|1|Participants will receive depression care management by secure messaging.
89649646|NCT00755235|No Intervention|2|Participants will receive their usual care, with no additional education or care management services.
89649647|NCT02117076|Active Comparator|gabapentin immediate release|Gabapentin IR is the immediate release form of the medication. Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
89649648|NCT02117076|Active Comparator|gabapentin enacarbil extended release|Horizant is the extended release form of gabapentin enacarbil. Subjects randomized to Horizant will take 600mg at 5 pm. After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted. Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.
89649649|NCT00724477||Subjects treated with INEGY|Subjects suffering from primary hypercholesterolemia that are not controlled by statins as a monotherapy, and are treated with INEGY
89649650|NCT01573650||group 1|Group 1a (standard): Epineural Suture Group 1b (experimental): Epineural suture and Fibrin Wrap
89649651|NCT01573650||group 2|Group 2a (standard): Epineural suture and autologous nerve transplantation from lateral antebrachial cutaneous nerve (LACN) Group 2b (experimental): Epineural suture and Fibrin Conduit
89649652|NCT01274793|Active Comparator|Mosapride|In the control group were orally administered 5 mg mosapride citrate tablet s three times a day for 4 continu ous weeks if no severe adverse effects were found.
89649653|NCT01274793|Experimental|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
89649654|NCT01274793|Experimental|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
89649655|NCT03763578|Experimental|Licorice|licorice is one of the natural products that is listed by the Food and Drug Administration (FDA) as GRAS (generally regarded as safe) when used as food flavoring and sweetening agent which has an antimicrobial, anti-inflammatory and antiviral activity.
89688584|NCT02245555||Patients with benign prostatic hyperplasia|
89045393|NCT04675359|Active Comparator|Enzymatic digestion group|A group treated with a stromal vascular fraction (SVF) with mesenchymal stromal cells (MSC) injection in the knee joint after an enzymatic digestion of autologous adipose tissue
89045394|NCT04675359|Active Comparator|Mechanical fragmentation group|A group treated with a mechanically fragmented (using Lipogems device) autologous adipose tissue injection in the knee joint
89045395|NCT04675203||Normal tooth eruption|
89045396|NCT02910518|Experimental|Insulin glulisine (U300) - Test formulation|Insulin glulisine (U300) will be given as a single subcutaneous (SC) dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
89045397|NCT02910518|Active Comparator|Insulin glulisine - Reference formulation|Insulin glulisine (U100) will be given as a single SC dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
89045398|NCT01217437|Experimental|Arm I (temozolomide, irinotecan hydrochloride)|Patients receive temozolomide PO and irinotecan hydrochloride IV over 90 minutes on days 1-5.
89045399|NCT01217437|Experimental|Arm II (temozolomide, irinotecan hydrochloride, bevacizumab)|Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
89045400|NCT02910479|Experimental|temperature measurements with 4 devices|temperature measurements with e-device Celsius, esophageal probe and a rectal probe and vital sense capsule
89045401|NCT02910596|Experimental|A|"Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~In bethanechol chloride arm arm should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~Remove urethral catheter on 5thpostoperative day. Void volume and postvoid residual urine were record. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
89521671|NCT03033823|Placebo Comparator|Control|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
89521672|NCT04669639|Experimental|The block group (a)|Patients were randomized in a 1:1 :1ratio, group (a) will receive SSN. The nerve blocks The procedure will be performed after induction of anaesthesia and endotracheal intubation.
89521673|NCT04669639|Experimental|The block group (b)|Patients were randomized in a 1:1:1 ratio. group (b) will receive the Erector spinae plane block. The procedure will be performed after induction of anesthesia and endotracheal intubation.
89521674|NCT04669639|Placebo Comparator|control group|Patients were randomized in a 1:1:1 ratio. this group will receive general anesthesia (GA) only
89521675|NCT03414697|Other|Control group|Routine rehabilitation treatments
89521676|NCT03414697|Experimental|Intravenous UC-MSCs group|Injection of UC-MSCs via the peripheral vein.
89521677|NCT03414697|Experimental|Intrathecal UC-MSCs group|Injection of UC-MSCs via the intrathecal route.
89521678|NCT03414697|Experimental|Intranasal UC-MSCs group|Injection of UC-MSCs via the nasal route.
89521679|NCT03419611|Experimental|Multi-Modal|3 Times Per Week for 4 weeks - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component followed by more treatment for 12 weeks
89521680|NCT03419611|Experimental|Multi-Modal + High Intensity Multi-Modal|3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 4 weeks, increasing to 5 times per week for 12 weeks
89521681|NCT03419611|Placebo Comparator|Treatment as Usual|Teacher provided with word list for 4 weeks followed by more treatment as usual for 12 weeks
89521682|NCT03419611|Experimental|Treatment as Usual + Multi-Modal|Teacher provided with word list for 4 weeks followed by 3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 12 weeks
89521683|NCT03419611|Experimental|Treatment as Usual + High Intensity Multi-Modal|Teacher provided with word list for 4 weeks followed by Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 5 times per week for 12 weeks
89521684|NCT04448821|Experimental|Sequence A|Period 1: metformin; Period 2: metformin + nilotinib
89521685|NCT04448821|Experimental|Sequence B|Period 1: metformin + nilotinib; Period 2: metformin
89521686|NCT03414619|Experimental|Intrusive Thoughts Group|Clinically significant intrusive thought in the domain of obsessions, worries, or depressive ruminations with a score above the clinical mean (≥ 37) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
89521687|NCT03414619|Experimental|Non-psychiatric Control Group|A score 1 SD below the community mean (≤ 15) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will also receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
89521688|NCT04448509|Other|Healthy donor|Healthy donor
89521689|NCT03414541|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
89521690|NCT03414541|Experimental|500mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
89521691|NCT03414541|Experimental|1000mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
89521692|NCT04448899|Active Comparator|Ivabradine|"Patients administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.~Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study."
89521693|NCT04448899|Placebo Comparator|Control|Patients administered a placebo twice daily. Patients were followed up after 1 week of initiation of the study then monthly till the end of the study.
89521694|NCT03419377|Experimental|Standard care and sexological counseling|Standard care including gynecological examination and 6-8 sexological consultations.
89521695|NCT03419377|No Intervention|Standard care|Standard care including gynecological examination.
89521696|NCT03414307|Experimental|Intracerebral hemorrhage|Patients with ICH meeting inclusion/exclusion criteria undergo ROSA stereotactic robot-assisted intracerebral catheter placement to evacuate intracerebral or intracranial hemorrhage
89521697|NCT03419299||Pre- Application|Patients admitted prior to use of tube feeding application
89521698|NCT03419299||Post- Application|Patients admitted when tube feeding application was being used.
89521699|NCT03414151||Observational - Case Arm|All participants will be placed in this arm or group if they have an eligible psychiatric diagnosis as a case (there is no randomization procedure)
89649656|NCT03763578|Active Comparator|Chlorhexidine|"The gold standard of oral therapeutics is Chlorhexidine due to its prolonged broad- spectrum antimicrobial effect."
89649657|NCT03763578|No Intervention|Control Group|Participants in this group will follow only the standard preventive measures which is brushing twice a day after breakfast and before bed time and daily flossing interdentally before bed time. (No Mouthwash is used)
89649658|NCT00746889|Active Comparator|Corticosteroid Injection|40 mg of intraarticular triamcinolone acetonide
89649659|NCT00746889|Placebo Comparator|Placebo Injection|Intraarticular injection of 0.9% saline
89649660|NCT01675050|Experimental|Cyproheptadine first then Placebo|4 weeks of cyproheptadine or placebo with crossover to the other
89649661|NCT01675050|Experimental|Sugar Pill first then Cyprotheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
89649662|NCT00756093|Experimental|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each one time
89649663|NCT00756093|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
89649664|NCT00756093|Active Comparator|Blink Tears|Blink Tears 1 drop each eye one time
89649665|NCT00756093|Active Comparator|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops 1 drop each eye one time
89649666|NCT00816582|Experimental|PET/CT Guided FES Therapy|All subjects will be seen at baseline and then monthly until month 6 of fulvestrant therapy unless clinical or radiological progression or unacceptable toxicity earlier than month 6.
89649667|NCT01279785||Prostate Cancer Patients|Male participants who are scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center and have evidence of a recent (within 12 months of study entry) trans-rectal biopsy documenting adenocarcinoma of the prostate.
89649668|NCT05128188||Patients on haemodialysis|5 patients on haemodialysis will be recruited. The study involves a single dialysis session and two MRI scans (one prior and one following dialysis) and collection of clinical data.
89649669|NCT01274871||lung cancer surgery|
89649670|NCT05127798||Adult from 18 to 70 years old AML in first line|Patients >/= 18 years old with recent diagnosis of AML who receive treatment with intensive chemotherapy according to our local guidelines.
89649671|NCT00244881|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89649672|NCT03701958|Other|Exalt DScope 01|Subjects will have a clinically indicated per standard of care ERCP procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
89649673|NCT04763395||non-severe COVID19|"Patients with mild symptoms (i.e., fever, cough, expectoration, and other upper respiratory tract symptoms), and without abnormalities, or with mild changes on chest radiography, were classified as non-severe types.~A mild change in chest radiography is defined by multiple small patchy shadows and interstitial changes, mainly in the outer zone of the lung and under the pleura."
89649674|NCT04763395||Severe Covid19|Severe COVID19 was defined by the presence of any of the following conditions: i) significantly increased respiration rate (RR): RR >-30 times/minute; ii) hypoxia: oxygen saturation (resting state) <-93%; iii) blood gas analysis: partial pressure of oxygen/fraction of inspired oxygen (PaO2) /FiO2) <- 300 mmHg (millimeters of Mercury), or iv) the occurrence of respiratory or another organ failure that require Intensive care unit (ICU) monitoring and treatment, or shock
89649675|NCT03446508|Experimental|Active frontal|Active HD-tDCS
88993130|NCT04155619|Experimental|Early Time-Restricted Feeding and Timed Light Therapy|
88993131|NCT04151251|Active Comparator|Sleep Kit Alone|Patients who are not randomized into the I-SLEEP intervention will receive a sleep kit that includes an eye mask, earplugs, and headphones.They will still receive the usual standard of care provided by clinicians which includes measures to reduce unnecessary nighttime disruptions and limiting excessive noise within the hospital setting.
88993132|NCT04151251|Experimental|Sleep Kit + Empowerment|"A short video will be shown on iPads and a brochure will be given that both describe the importance of good sleep and how to facilitate it with good sleep hygiene.~The video will show a few reasons why someone might not get optimal sleep while in a hospital, and offer advice to address this from a doctor. The brochure will be kept to no higher than a 6th grade reading level, considered optimal for health education materials. Text will be kept brief and to the point. To account for vision problems, we will use >12-point font & leave a large portion of each page empty. Visual Aids & graphics will be employed when possible.~All of this is given in addition to the usual standard of care provided by clinicians."
88993133|NCT04126369|Experimental|mindfulness intervention|12 mindfulness sessions for 3 months (1 session per week)
88993134|NCT04126369|Active Comparator|Psycho educative programme|12 psycho educative sessions for 3 months (1 session per week)
88993135|NCT04116489|Experimental|Wildlife Immersion Activity|We will use a crossover design in which each participant receives an introductory forest walk followed by 3 wildlife immersion activity experiences in different settings .
88993136|NCT04098081|Experimental|galeterone|galeterone orally once daily
88993137|NCT04098081|Experimental|galeterone+gemcitabine|daily dose galeterone and weekly dose of gemcitabine
89649676|NCT03446508|Experimental|Active parietal|Active HD-tDCS
89649677|NCT03446508|Sham Comparator|Sham control|Sham HD-tDCS
89649678|NCT03767491|Experimental|Smartphone-delivered CBT for OCD|12-week Smartphone delivered CBT for OCD.
89649679|NCT03767491|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for OCD following the 12-week waitlist control).
89649680|NCT00530517|Experimental|1|
89649681|NCT05404698|Experimental|Aerobic intradialytic exercise|10 patients will perform Aerobic exercise with the cycle ergometer prototype (EXALT) during hemodialysis
89649682|NCT05404698|Experimental|Standard care|10 patients will receive hemodialysis treatment (usual care)
89649683|NCT01274949|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
89649684|NCT03686605||Cancer pain patients|
89688585|NCT03402737|Experimental|Stereotactic body radiotherapy + IM|Single arm phase I trial with 3 Stereotactic Body Radiation Therapy dose-escalation arms.
89688586|NCT04378673||parental involvement group|n=46
89688587|NCT04378673||parental presence group|n=42
89649685|NCT05404620|Experimental|Schroth exercises|"Mobilization in the spine between ribs will be performed to increase the mobility of joints. To strengthen the muscles such as erector spinae, iliopsoas, and the quadratus lumborum, muscle activation will be done. Then the four exercises of the Schroth method which are the 50 x Swiss ball exercise, Prone exercise, Sail exercise, and the Muscle-cylinder exercise will be performed. This will be followed by hot pack and static stretching of muscles."
89649686|NCT05404620|Experimental|PNF technique|This technique involves the specific program and pattern of PNF that are deep breathing, pelvic posterior tilting, DI flexion & Extension of UL and D2 flexion, and extension of LL. + Hot pack + static stretching of the involved muscles.
89649687|NCT05404464||Infertile couples|Infertile couples who came to the hospital for ART treatment
89649688|NCT03683095||Lymphovenous bypass|Patients with extremity lymphedema treated with lymphovenous bypass.
89649689|NCT04435938|Experimental|Stereotactic Body Radiotherapy (SBRT)|The dose prescribed in the study will be 45Gy in 5 fractions, delivered once every 3-4 days, such that treatment is completed within 15 days. (e.g. treatment given on Monday/Thursday/Mon/Thurs/Mon) (Exceptions: treatment duration of up to 18 days will be allowed to account for cancer centre closures and unforeseen patient issues.)
89649690|NCT02820012|Other|Scoliosis|"Preoperative data: demographics, clinical diagnosis and etiology, relevant prior medical treatment, x-rays, and patient questionnaire will be completed in the database.~The self-questionnaire (SAQ parents, patients, SR22) provided will assess the state of health and disability of patients.~After surgery: the clinical questionnaire will be completed by the investigator to collect the parameters of the operation and the patient's clinical data Immediate Postoperative visit: J1 to S1: radiological and clinical examinations .~Visit Month 1 to M3, M 12, M 24 , M 36 , M 60 : During these visits, clinical and radiological examinations will be realized."
89649691|NCT03765853|Other|Stretching Postural®|
89649692|NCT03765853|No Intervention|Control|
89649693|NCT04366362|Active Comparator|Convetional reconstruction group|Patients will undergo ACL reconstruction based on conventional ACL surgery
89649694|NCT04366362|Experimental|Individualised reconstruction group|Patients will undergo ACL reconstruction based on their special anatomical and functional characteristics and with the use of a navigation system
89649695|NCT05123976|Experimental|Treatment A|Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)
89649696|NCT05123976|Active Comparator|Treatment B|Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
89649697|NCT03762421|Experimental|Psychosocial skills development workshops based on PM plus|A number of psycho-social skills development workshops will be conducted for newly inducted civil servants, based on the problem management plus intervention. Problem Management Plus is a brief low-intensity, trans-diagnostic psychological intervention that helps with existing psychological problems as well as building resilience against future adversity. It addresses a range of psychological and practical problems that participants identify as relevant to their lives, including common mental health problems (WHO, 2016; Dawson, et al., 2015). The workshops will be integrated into the routine induction sessions for trainee civil servants.
89649698|NCT03762421|Active Comparator|Control Arm|The control group will receive 5 routine training induction sessions.
89649699|NCT05127096||Cohort A|Cohort A will include subjects with a recent diagnosis of colorectal cancer and/or advanced adenoma requiring additional endoscopic or surgical resection (surgery).
89649700|NCT05127096||Cohort B|Cohort B will include subjects undergoing routine screening colonoscopies will be enrolled in the screening cohort.
89649701|NCT03762343|Experimental|Greater occipital nerve block group (group GONB)|Patient in this group will receive 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
89649702|NCT03762343|Placebo Comparator|Control group (group C):|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
89649703|NCT05126940||nurses|ED nurses trained to perform LUS and blinded to the final diagnosis
89649704|NCT05126940||emergency physician|"certified emergency physician who had accomplished a full mentoring program for Ultra-Sound Life Support."
88993138|NCT04079634|Experimental|Treatment|Placement of study device (EnsoETM) for temperature management
88993139|NCT04079634|Active Comparator|Control|Placement of standard temperature probe
88993140|NCT04068935|Experimental|Buddy taping|Buddy taping of the fractured finger to ist neighbouring uninjured finger.
88993141|NCT04068935|Active Comparator|splint immobilization|A forearm-based palmar Hand Splint in an intrinsic plus Position, enclosing all fingers without the thumb.
88993142|NCT04045600|Experimental|Mult FCT/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules (mult FCT) to evaluate the effects of mult FCT on renewal, super-resurgence, and reinstatement.
88993143|NCT04045600|Experimental|Mult FCT + Stimulus Fading/Trad FCT|Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules and stimulus fading (mult FCT + stimulus fading) to evaluate the effects of mult FCT and gradual fading of contextual stimuli on renewal, super-resurgence, and reinstatement.
89649705|NCT02724072|Experimental|Thoraflex™ Hybrid Device.|Plexus™ 4 and Ante-Flo™ configurations will be included in this study.
89649706|NCT00005803|Experimental|Treatment (tandem transplantation)|See Detailed Description
89649707|NCT05123898|Other|1 group|The patients underwent implant placement in combination with an increase in the thickness of soft tissues using a free connective tissue graft from the tuber region on the upper jaw.
89649708|NCT05123898|Experimental|2 group|"The patients underwent implant placement in combination with an increase in the thickness of soft tissues using collagen matrix Fibromatrix"
89649709|NCT03760315||Sepsis|All enrolled patients
89649710|NCT01676857||CP/CPPS group|The Study population will include patients diagnosed with CPPS (equal numbers of CPPS IIIa and CPPS IIIb) at least 18 years of age, recruited from Northwestern urology clinical site practices. All CPPS participants will be male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise the patient population
89649711|NCT01676857||Control group|Adult male volunteers who are male, at least 18 years of age and meet inclusion and exclusion criteria
89649712|NCT03680131|Active Comparator|EB01 Cream Placebo|EB01 Cream containing 0% EB01 w/w applied BID
89212879|NCT02584439|Other|ivabradine-placebo|Volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
89649713|NCT03680131|Experimental|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
89649714|NCT03680131|Experimental|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
89649715|NCT03680131|Experimental|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
89649716|NCT03679195|Experimental|NO Ultra (Nitric Oxid Ultra Capsules)|764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline. Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
89649717|NCT03679195|Placebo Comparator|Placebo (Cellulose Capsules)|Participants will consume cellulose capsules that are similar in shape and size to the NO ultra product, i.e. 2 capsules between breakfast and lunch and 2 other capsules between lunch and dinner.
89649718|NCT03593629|No Intervention|Standard of Care|Participants receive standard of care for PrEP, including 3-months of PrEP supply and HIV testing at clinic every three months
89649719|NCT03593629|Experimental|Blood-based HIV self-testing|Participants receive 6-months of PrEP supply and blood-based HIV self-tests for quarterly HIV testing.
89649720|NCT03593629|Experimental|Oral fluid HIV self-testing|Participants receive 6-months of PrEP supply and oral fluid HIV self-tests for quarterly HIV testing.
89649721|NCT03757741||AF-SG 01|Study subjects with atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
89649722|NCT03757741||AF-SG 02|Study subjects without atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
89649723|NCT03592849|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring
89649724|NCT02649894|Experimental|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
89649725|NCT02649894|Active Comparator|Approved Uncoated PleurX Indwelling Pleural Catheter|Approved Uncoated PleurX Indwelling Pleural Catheter
89649726|NCT03591055|Experimental|Intervention Group|Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment. Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment. All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
89649727|NCT03591055|No Intervention|Control group|Participants in the control group will receive the usual standard care and regular referrals.
89649728|NCT01279941|No Intervention|Testing Only|
89649729|NCT01279941|Experimental|Testing & Intervention|
89649730|NCT03556969||Propofol sedation after SA|Participants who undergo propofol sedation after spinal anesthesia
89212880|NCT02584439|Other|placebo-ivabradine|Volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
89649731|NCT01275027|Experimental|Nutralin|Individuals with Type 2 Diabetes
89649732|NCT01275027|Placebo Comparator|Placebo|Individuals with Type 2 Diabetes
89649733|NCT04185012|Experimental|Benralizumab|Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
89649734|NCT04185012|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks
89649735|NCT01276899||Neoadjuvant setting|
89649736|NCT01276899||Metastatic setting|
89649737|NCT05126706|Experimental|Digital lifestyle management group|In the experimental group (digital lifestyle management group), 54 patients are randomly assigned to the digital lifestyle management group. The patients use this application for the first 4 months with Noom applications with 1:1 personalized coaching intervention, and then, use this app by self-help program without coaching intervention. In order to monitor the psychological state of the patients, all the patients are given daily assessment online questionnaires and additional questionnaires to evaluate the quality of life at the baseline, 4 months, and 6 months after surgery. To assess the nutritional status of the patients, we collect blood laboratory data, bioimpedance analysis for each visit.
89649738|NCT05126706|No Intervention|Non-digital lifestyle management group|In the control group (Non-digital lifestyle management group), 26 patients are randomly assigned to the control group (Non-digital lifestyle management group). The patients follow conventional postoperative care protocol after total thyroidectomy for thyroid cancer without using Noom application. All patients are given questionnaires to evaluate the quality of life at the baseline, 4 months, and 6 months after surgery. To assess the nutritional status of the patients, we collect blood laboratory data, bioimpedance analysis for each visit.
89649739|NCT01275183|Experimental|Raltegravir and cisplatin|
89649740|NCT05126628|Active Comparator|Active Comparator: Proxalutamide + Usual Care|Proxalutamide + usual care as determined by care provider
88993144|NCT04036409|Experimental|Intensive Control of Systolic Blood Pressure (SBP)|Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP <120 mm Hg.
89649741|NCT05126628|Placebo Comparator|Placebo Comparator: Placebo + Usual Care|Placebo + usual care as determined by care provider
89649742|NCT01273077||Evaluation of Rotarix Program|All infants in Nova Scotia DHA 9 and PEI born after October1, 2010 until September 30, 2012 will be eligible for Rotarix immunization as part of the publicly funded immunization program. New Brunswick will serve as the non-intervention control location.
89649743|NCT01273077||Retrospective Surveillance|All laboratory- confirmed cases of rotavirus gastroenteritis and all cause diarrhea admitted to the trial hospitals from 2008-2010 will be entered in the database.
89649744|NCT01273077||Prospective Surveillance|Will begin on December 1, 2010. Data will be collected to identify hospitalizations for all cause diarrhea and rotavirus gastroenteritis at all 3 sites through the first two consecutive rotavirus seasons following vaccination.
89649745|NCT01273077||Safety Intussusception|Each trial hospital will identify cases of severe diarrhea and intussusception in Rotarix vaccine recipients through the first two consecutive rotavirus seasons following vaccination.
89649746|NCT01273077||ED Rotavirus Snap Shot Study|During rotavirus peak season, a prospective study of a sample of children under the age of 2 years presenting with diarrhea with or without vomiting to the ER of participating trial centers will be conducted in year one. In year 2 and 3 of the project:, systematic stool sampling will be carried out for cases of gastroenteritis in children < 5 years of age presenting to the ED departments.
89649747|NCT01273077||KAB Questionnaire for HCP and Parents|Data will be collected by a validated survey given to Parents, Healthcare providers and Program organizers throughout the 2 year program.
89649748|NCT05126394|Experimental|Group A ( SAPB) group|this group of patients receives serratus anterior plane block, just after induction of anesthesia.
89649749|NCT05126394|No Intervention|Group B: control group|this group of patients does not receive any blockade, they receive conventional IV analgesics.
89649750|NCT03676543|Experimental|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
89649751|NCT01677169|Experimental|59 mL noni juice|Ingestion of 59 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) twice daily (118 mL daily total) for 30 days.
89649752|NCT01677169|Placebo Comparator|Placebo|Ingestion of 59 mL of placebo (mixture of grape and blueberry juices and natural cheese flavor) twice daily (118 mL daily total) for 30 days.
89649753|NCT01677169|Experimental|29.5 mL noni dose|Ingestion of 29.5 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) daily for 30 days.
89649754|NCT04762615||Patients with renal pathology treated with immunosuppressive drugs|Female in reproductive age suffering from renal disease that is or was previously treated with immunosuppressive drugs
89649755|NCT04762615||Patients with renal pathology without treatment|Control group
89649756|NCT04762615||Patients after renal transplantation taking immunosuppressive drugs|Female in reproductive age after renal transplantation taking immunosuppressive drugs
89649757|NCT05126004|No Intervention|Control group|receive supportive care
89212881|NCT04729049|Experimental|Erector spinae plane block + patient controlled analgesia (PCA) with intravenous morphine|"Preoperative bilateral ESP block with ropivacaine 0,4% + dexamethasone 4 mg, 20 mL per side, at the median spinal level of intervention.~End-surgery: acetaminophen 1 g ev + 4 mg morphine ev before the end of the intervention.~PCA: morphine 1 mg, max every 30 minutes. Rescue: ketoprofen 100 mg ev, max three times per day."
89649758|NCT05126004|Experimental|AZA+NAC group|AZA 50mg Subcutaneous daily d1-d5 + NAC 600mg oral bid d1-28， 28 days for one cycle
89649759|NCT05125926|Experimental|low-dose LYB001 in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
89649760|NCT05125926|Placebo Comparator|Placebo comparator Ⅰ in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
89649761|NCT05125926|Experimental|high-dose LYB001 in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
89649762|NCT05125926|Placebo Comparator|Placebo comparator Ⅱ in participants aged 18-59 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
89649763|NCT05125926|Experimental|low-dose LYB001 in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
89649764|NCT05125926|Placebo Comparator|Placebo comparator Ⅲ in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
89649765|NCT05125926|Experimental|high-dose LYB001 in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
89649766|NCT05125926|Placebo Comparator|Placebo comparator Ⅳ in participants aged over 60 years|Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56
89649767|NCT01278615|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity
89649768|NCT05125770||new crown vaccination|Collect all the couples who gave birth in Ditan Hospital or one of the mothers and newborns who were injected with the new crown vaccine during the peri-pregnancy period as the observation group
89649769|NCT05125770||non new crown vaccination|Collect the pregnant women and newborns who were not vaccinated with the new crown vaccine during the peri-pregnancy of the couples who gave birth in our hospital during the same period as the control group
89649770|NCT05123430|Experimental|MitraClip operated patients suffering from serious mitral insufficiency|
89649771|NCT00350701|Experimental|androgel 5g|androgel 5g
89649772|NCT00350701|Experimental|androgel 10g|androgel 10g
89649773|NCT00350701|Placebo Comparator|placebo|placebo
89649774|NCT01275261|No Intervention|Foley catheter|Usual care - patients will have a Foley catheter placed on admission.
89649775|NCT01275261|Experimental|Nursing protocol to avoid Foley Catheter|No catheter will be placed on admission, and a nursing order protocol will be followed to avoid catheterization and avoid complications.
89649776|NCT05123352||Standard intensive chemotherapy|Patients with acute myeloid leukemia in this cohort will receive standard induction chemotherapy that combines seven days of cytarabine and three days of anthracycline (7+3 regimen).
89649777|NCT05123352||Bcl-2 inhibitor-based targeted therapy|Patients with acute myeloid leukemia in this cohort will receive Bcl-2 inhibitor-based targeted therapy, such as combination of bcl-2 inhibitor plus decitabine/azacitidine with or without sorafenib.
88993145|NCT04036409|Active Comparator|Standard Control of Systolic Blood Pressure|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg
88999227|NCT02905591|Experimental|ChemoRT + Ascorbate|Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)
88999228|NCT02845063|Experimental|concentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
89649778|NCT01275417||adult|100 volunteers age ranged 18-80 years old
89649779|NCT01275417||children|60 children under 10 years old.
89649780|NCT03585205||cognitive load with/ without stress induction|"Participants will engage in demanding cognitive load computerized tasks (such as N-back and Stroop tasks). They will engage in these tasks once in a non-stressful (neutral condition), and once in a stressful condition.~Psychological stress will be induced by the following methods:~Limiting time for task completion~Providing negative feedback on participants' performance in relation to others~Presentation of sudden, loud sounds during task"
89649781|NCT01677325|Experimental|Chinese herb|Chinese herb
89649782|NCT04435860||Ankylosing Spondylitis|Patients with ankylosing spondylitis meeting the inclusion and exclusion criteria
89649783|NCT04435860||Healthy Controls|Healthy individuals meeting the exclusion criteria
89649784|NCT04277247|Experimental|Botulinum Toxin Type A Treatment|Injections
89649785|NCT04277247|Placebo Comparator|Placebo|Injections
89649786|NCT03541213|Other|Control group|"Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
89649787|NCT03541213|Other|Iron deficiency group|"Patients with iron deficiency who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
89649788|NCT03541213|Other|Iron treated group|"Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
89649789|NCT01505114|Experimental|Arm 1|MVC 300 mg plus FTC placebo and TDF placebo orally once daily
89649790|NCT01505114|Experimental|Arm 2|MVC 300 mg plus FTC 200 mg and TDF placebo orally once daily
89649791|NCT01505114|Experimental|Arm 3|MVC 300 mg plus FTC placebo and TDF 300 mg orally once daily
89649792|NCT01505114|Experimental|Arm 4|MVC placebo plus FTC 200 mg and TDF 300 mg orally once daily
89649793|NCT04276077|Experimental|High-frequency electrical muscle stimulation|
89649794|NCT04276077|Experimental|Low-frequency electrical muscle stimulation|
89649795|NCT04276077|No Intervention|Control|
89649796|NCT04177524|Experimental|Arm 1|Participants alternate between using the Manual Mode of the app for 2 weeks and Auto-Detect Mode of the app for 2 weeks, for a total of 4 periods (8 weeks).
89649797|NCT04177524|Experimental|Arm 2|Participants use the Auto-Detect Mode of the app for 4 weeks, followed by the Manual Mode for 4 weeks.
89649798|NCT04177524|Experimental|Arm 3|Participants use the Background Mode of the app for 4 weeks, followed by the Auto-Detect Mode of the app for 4 weeks.
89649799|NCT00006151|Experimental|Accu Drops (AD&C)|The experimental group (N=30) will be prescribed active Accu Drops (AD&C) plus behavioral therapy.
89649800|NCT00006151|Placebo Comparator|Placebo|The control condition (N=30) will be prescribed placebo Accu Drops (PD&C) plus behavioral therapy.
89649801|NCT00747747|No Intervention|Control|No coadiuvant treatment. The subject is treated with the antibiotic only and forbidden to take any coadiuvant medicine as a remedy for the symptoms during the period of the study.
89649802|NCT00747747|Active Comparator|Saline solution|Saline solution sprayed according to the product indication. Only one brand/specific product has been selected.
89649803|NCT00747747|Experimental|Sinuclean treatment|Sinuclean DM Spray.
89649804|NCT05125692|Other|women with symptomatic post cesarean Istmocele|vaginal surgical repair of post cesarean symptomatic isthmocele using conventional low cost surgical techniques
89649805|NCT04761757|Active Comparator|Control Arm|
89649806|NCT04761757|Active Comparator|Intervention Arm|
89649807|NCT01275573|Other|healthy volunteers|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
89649808|NCT01275573|Other|painful Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
89649809|NCT01275573|Other|painless Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
89649810|NCT01275651||Ancillary-Correlative (AR activity in CRPC)|Previously collected bone marrow tissue and blood samples are analyzed for AR activity, AR splice variations, expression of androgen transport/synthesis/metabolism genes, AKR1C3 protein levels, and testosterone and dihydrotestosterone levels via RT-PCR, SNP microarrays, IHC, gene expression analysis, and mass spectrometry methods.
89649811|NCT05111184|Other|Internvention group|
89649812|NCT01277757|Experimental|Treatment (Akt inhibitor MK-2206)|Akt Inhibitor MK-2206 mg orally once a week on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89649813|NCT00245271|Experimental|1|OMS103 Irrigation Solution
89649814|NCT00245271|Placebo Comparator|2|Balanced Salt Solution (BSS)
89649815|NCT00243867|Experimental|Arm A|(Taxoprexin® + carboplatin)
89649816|NCT00243867|Active Comparator|Arm B- Paclitaxel and carboplatin|(Paclitaxel and carboplatin)
89649817|NCT01679899|Experimental|Vildagliptin|Vildagliptin 50 mg bid for 12 months
89649818|NCT01679899|Active Comparator|Gliclazide MR|Gliclazide MR 60 or 120mg once a day for 12 months
89649819|NCT01276821|Placebo Comparator|Standard Treatment|L-Epinephrine and Normal Saline (0.9%)
89649820|NCT01276821|Active Comparator|Study Treatment|L-Epinephrine and Hypertonic Saline (3%)
89649821|NCT03461419|Experimental|Microcannula Harvest Adipose Stroma|Acquisition of AD-tSVF via closed syringe microcannula
89688588|NCT04378673||parental absence group|control group, n=32
89045402|NCT02910596|Experimental|B|"Early bladder training Start on 3rd - 5th postoperative day~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
89045403|NCT02910596|Experimental|C|"Early bladder training and Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
89045404|NCT02910596|Other|D|-Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative
89045405|NCT04316377|Active Comparator|Treatment|Chloroquine therapy in addition to standard of care
89649822|NCT03461419|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration closed system to create cellular stromal vascular fraction (cSVF)
89649823|NCT03461419|Experimental|Sterile Normal Saline IV|Re-suspension of cSVF pellet in Sterile Normal Saline Intravenous Delivery
89045406|NCT04316377|No Intervention|No Treatment|Standard of care
89045407|NCT04677036||TUH Staff|Staff within Tallaght University Hospital - anonymised
89045408|NCT04677036||ASIT Members|Members of the Association of Surgeons in Training - anonymised
89045409|NCT02886988|Experimental|Botulinum toxin type A|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
89045410|NCT02886988|Placebo Comparator|Normal Saline|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.0.1ml normal saline will be injected along the wound edges.
89045411|NCT02887144|Experimental|SenSura test product 1pc|"Subjects randomized to treatment sequence 1test:~SenSura test product~SenSura"
89045412|NCT02887144|Experimental|SenSura 1pc|"Subjects randomized to treatment sequence 2 test:~SenSura~SunSura test product"
89045413|NCT06227468||Greek population|The enrolled subjects will be managed as a single group.
89649824|NCT04403269|Experimental|IgIV|The experimental arm is human immunoglobulins. 2 infusion at D1 and D2. (0.8 g / kg by IV infusion)
89649825|NCT00245037|Experimental|Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)|Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
89649826|NCT04402879|Experimental|Prone Positioning (PP)|The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day.
89649827|NCT04402879|No Intervention|Control - usual management|The control group will consist of standard medical care with no instructions or prompts to change positioning to staff or patients.
89649828|NCT00241839|Active Comparator|A|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, Allopurinol 300mg daily was added for 8-10 weeks at which time testing was repeated.
89649829|NCT00241839|Placebo Comparator|B|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, a Placebo,matched in appearance to Allopurinol, was added daily for 8-10 weeks, at which time testing was repeated.
89649830|NCT03529903|No Intervention|Control Group|*Complete an online survey and intake appointment with a trained Health Coach (HC), who will measure their height, weight, and blood pressure, assess their current health habits (sleep, nutrition, exercise) and work with they to set realistic, achievable health goals. *Wear a Fitbit device daily to track physical activity and weight (members of the MyLife study team can access their data during throughout the program and de-identified, anonymous, data will be shared with Fitbit as part of a research partnership). *Complete another online survey and telephone check-in with their HC at the halfway point to monitor their progress toward reaching their goals. *Complete a final online survey and outtake appointment with their HC to re-check their measurements and discuss their progress.
89649831|NCT03529903|Experimental|Experimental Group|*Complete survey/ intake appointment with a HC, who will measure their height, weight, and blood pressure, assess their health habits and set achievable health goals. *Wear a Fitbit to track their daily physical activity and weight *Set a weekly active minutes goal and record their weight weekly. *Receive motivational text messages 4x per week, one will ask for their weekly active minutes goal and weight and another will ask for goal progression.*Complete photo food diaries biweekly (send pictures of everything they eat/drink to their HC). *Complete surveys/telephone check-ins with their HC every 2 weeks to monitor their progress toward reaching their goals. *Complete final survey/outtake appointment with their HC to for final measurements and to discuss goal progression (about 2 hours).
89649832|NCT03529435|Active Comparator|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
89688589|NCT03904771|Active Comparator|Food for Mind -intervention group|Nutrition counselling + peer support
89649833|NCT03529435|Experimental|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
89649834|NCT05347381|Experimental|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
89649835|NCT02651688|Experimental|Enclomiphene 12.5 mg|Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
89649836|NCT02651688|Experimental|Enclomiphene 25 mg|Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
89649837|NCT02651688|Placebo Comparator|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
89649838|NCT05347615||EDOF|Eye after EDOF lens Implantation
89649839|NCT05347615||Monofocal|Eye after Monofocal lens Implantation
89649840|NCT03528109|Experimental|patient-centered home CBT|60 minute office-based exposure therapy with a PhD psychologist once per month and a 90 minute community-based CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week)
89649841|NCT03528109|Active Comparator|Provider-centered|60 minute office-based exposure therapy with a PhD psychologist four times per month (once per week)
89649842|NCT03528109|Experimental|patient-centered telehealth CBT|60 minute telehealth exposure therapy with a PhD psychologist once per month and a 90 minute telehealth CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week). Patient-centered telehealth was closed when the recruitment goal was met in May 2021.
89649843|NCT01276353|Experimental|1|
89649844|NCT01276353|Active Comparator|2|
89649845|NCT03578029|Experimental|RGN-137|It is formulated as a gel for topical administration.
89649846|NCT03578029|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-137 formulation without the active ingredient.
89649847|NCT03525847|Active Comparator|contrast enhanced FNA endosonography|First passage in the solid pancreatic tumor using FNA endosonography then with the contrast enhanced FNA endosonography
89649848|NCT03525847|Active Comparator|FNA standard endosonography|First passage in the solid pancreatic tumor using contrast enhanced FNA endosonography then with the FNA endosonography
89649849|NCT03807921|Experimental|Warfarin|"Warfarin will be started 48-72h after aortic valve replacement. Dose will be 5 mg daily in order to obtain an Internation normal ratio (INR) of 2-3. Warfarin treatment will continue for 3 months.~Aspirin will be administered 100 mg daily."
89649850|NCT03807921|Active Comparator|Aspirin only|Aspirin will be started 48-72h after aortic valve replacement. Dose will be 100 mg daily. Patients who undergo coronary artery revascularization will receive 325 mg daily.
89649851|NCT00762021|Experimental|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT
89649852|NCT00762021|Active Comparator|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF
89649853|NCT01675609|Placebo Comparator|Placebo|
89649854|NCT01675609|Experimental|Brimonidine Tartrate 0.025%|
88993146|NCT04033952|Experimental|Assigned Interventions|The OPASS program will be delivered to the intervention group. The intervention protocols of the OPASS program were developed based on the strategy training guidelines developed by Skidmore et al. and based on the findings identified from the feasibility study. Trained research therapists will take the responsibility for delivering the intervention to participants. The program consists of four critical ingredients: self-selected goals, self-evaluation of performance, strategy development, and implementation, and therapeutic guided discovery.
88993147|NCT04033952|No Intervention|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
88993148|NCT04028986||Surgery group|patients treated by surgery before starting the IVF/ICSI treatment
88993149|NCT04028986||Ulipristalacetate group|patients treated by ulipristalacetate before starting IVF/ICSI treatment
88993150|NCT04009122|Experimental|IGEN-0206|a sachet after each meal, preferably (3 sachets per day)
88993151|NCT04009122|Placebo Comparator|Placebo|a sachet after each meal, preferably (3 sachets per day)
88993152|NCT04009122|No Intervention|group C|standard treatment
88999229|NCT02845063|Experimental|eccentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
89649855|NCT01673659|Experimental|Test product|Mometasone furoate 50 mcg/actuation Nasal Spray
89649856|NCT01673659|Active Comparator|Reference product|Nasonex Nasal Spray
89649857|NCT01673659|Placebo Comparator|Placebo Nasal Spray|vehicle of the test product
89649858|NCT00762177|Placebo Comparator|A -Control|fluoride toothpaste
89649859|NCT00762177|Experimental|B Experimental toothpaste|Stannous fluoride toothpaste
89649860|NCT00762177|Active Comparator|C- positive control|fluoride/triclosan/copolymer toothpaste
89649861|NCT04403659|Experimental|Intervention|Use of a telemonitoring/telemedicine suite (including a sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph) as a support to the routine clinical care
89649862|NCT04403659|No Intervention|Control|Routine clinical care, following European Society of Cardiology 2016 Guidelines on Heart failure and Good Clinical Practice guidelines
89649863|NCT03807687||Patient with pancreatic disease|Patients diagnosed with pancreatic disease evaluated at this institution.
89688590|NCT03904771|Active Comparator|Befriending group -control group|Social activation + peer support
89688591|NCT01724801|Experimental|icotinib|icotinib administered orally at a dose of 125 mg 3 times daily
89649864|NCT02536794|Experimental|Treatment (MEDI4736, tremelimumab)|Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity. Patients achieving PD or clinical benefit (CR, PR, or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks.
89649865|NCT00749073|Other|Percutaneous Lumbar Decompression procedure|mild percutaneous lumbar decompression procedure
89649866|NCT00777855|Experimental|warfarin then warfarin plus rifampin|
88999230|NCT02845063|Active Comparator|concentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
88999231|NCT02845063|Active Comparator|eccentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
88999232|NCT02838069|Experimental|2x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
88999233|NCT02838069|Experimental|10x106 ASC intra-articular injection|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
88999234|NCT02838069|Placebo Comparator|Placebo|0.5% glucose in saline with 4.5% albumin
88999235|NCT02635672|Experimental|Dose escalation of VIP152 (BAY 1251152) / PART 1 (Completed)|Investigating VIP152 (BAY 1251152) in a dose escalation cohort in patients with solid tumors and aggressive NHL
88999236|NCT02635672|Experimental|Dose expansion of VIP152 (BAY 1251152) / PART 2|Investigating VIP152 (BAY 1251152) in a dose expansion cohort in patients with solid tumors and aggressive NHL
88999237|NCT02635672|Experimental|Dose escalation of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 3|Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose escalation cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.
88999238|NCT02635672|Experimental|Dose expansion of VIP152 (BAY 1251152) in combination with Keytruda® (pembrolizumab) / PART 4|Investigating combination VIP152 (BAY 1251152) and Keytruda® (pembrolizumab) in a dose expansion cohort in patients with advanced cancer. All subjects must be eligible to use pembrolizumab per USPI.
88999239|NCT02589600|Experimental|Active Medication Group|Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
88999240|NCT02589600|Placebo Comparator|Placebo Group|Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
88999241|NCT02565199|Experimental|Single motor training only|For a pilot experiment, healthy, right-handed subjects will complete one testing session. During the testing session, subjects will complete motor training. The results of this experiment will determine the motor training protocol used in the main experiment.
88999242|NCT02565199|Experimental|Repetitive TMS during motor training|Healthy, right-handed subjects will complete five testing sessions. During each testing session, subjects will complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Subjects will receive a different rTMS protocol at each testing session. By the end of the study, each subject will have received all rTMS protocols.
88999243|NCT02450604|Other|Patients with chronic pains of unknown aetiology|
88999244|NCT02335268|Experimental|Group 1|"Stratification into group 1 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are +3~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
88999245|NCT02335268|Experimental|Group 2|"Stratification into group 2 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -1 or -2~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
88999246|NCT02335268|Experimental|Group 3|"Stratification into group 3 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -6~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
88999247|NCT02222155|Active Comparator|CCX168 low dose plus standard of care|Capsule, 10 mg, twice daily + standard of care for 12 weeks
88999248|NCT02222155|Active Comparator|CCX168 high dose plus standard of care|Capsule, 30 mg, twice daily + standard of care for 12 weeks
88999249|NCT02222155|Placebo Comparator|Placebo, twice daily + standard of care|Capsule, placebo, twice daily + standard of care for 12 weeks
88999250|NCT02020070|Experimental|Ipilimumab & Degarelix With Radical Prostatectomy|"Week 1: Degarelix SQ injection (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose) and Ipilimumab at 3 mg/kg intravenously (IV). Surgery Radical prostatectomy (RP)will be performed during week 3 ± 1 week or after recovery to grade ≤ 1 adverse events experienced during the induction period related to treatment. Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose)~Week 11, 14, 17 or after sufficient wound healing and recovery post RP:~Ipilimumab 3 mg/kg IV Follow-up Twelve week intervals until Week 87."
88999251|NCT02020070|Experimental|Ipilimumab & Degarelix With Prior With Radical Prostatectomy|Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 3 mg/kg intravenously (IV) Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ Week 4,7,10: Ipilimumab 3mg/kg IV Follow-up Twelve week intervals until Week 81, with MD visits at weeks 52 and 84 (12 and 20 months).
88999252|NCT01936272|Active Comparator|Chhabra Shunt Placement|The shunting arm will comprise a standard frontal approach ventriculoperitoneal shunt using a silastic Chhabra system.
88999253|NCT01936272|Active Comparator|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) arm will comprise a standard frontal approach with flexible endoscopy.
89649867|NCT05125536|Experimental|Experimental group|"Before the application, the Descriptive Characteristics Data Form and Assessment Scale of Adaptation Difficulty in Elderly were administered to the experimental group by the investigator through face-to-face interviews. A cd containing songs in Nihavent theme (instrumental), computer and sound system were used during the application. The patients in the experimental group were informed about the music session in advance. The sessions lasted 12 weeks in total and there were two sessions per week (Monday and Wednesday), and each session took approximately 50 minutes to complete. One week after the last music session (end of 12th week), the Assessment Scale of Adaptation Difficulty in the Elderly was re-administeredto the experimental group ."
89649868|NCT05125536|No Intervention|Control group|No intervention was performed for the patients in the control group.
89649869|NCT03523429|Experimental|blinatumomab|blinatumomab administered during the early consolidation phase in patients ≤ 55 years with high-risk Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukaemia (ALL) with MRD < 0.1% (< 1×10-3) after induction therapy.
89649870|NCT03802851|Experimental|Holmium Laser Enucleation of Prostate (HoLEP)|Patients in this arm will undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS). Patients will undergo HoLEP one time and will return for standard of care follow up.
89649871|NCT03802851|No Intervention|Control Arm|Patients in this arm will undergo no additional interventions and will not undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms and instead follow standard of care treatment and follow up.
89649872|NCT04403035||ID NOW vs. Acccula arm|Each patient serves as his or her own control. The ID NOW test is the one that is being currently used (i.e. the control) and the Accula test is the newer test being evaluated.
89649873|NCT03807609|Experimental|CON .|The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
89649874|NCT03807609|Experimental|EX -30.|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
89649875|NCT03807609|Experimental|EX-180|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their appetite feelings will be assessed at regular intervals.
89649876|NCT02403193|Experimental|PBF-509_80 mg|
89649877|NCT02403193|Experimental|PBF-509_160 mg|
89649878|NCT02403193|Experimental|PBF-509_320 mg|
89649879|NCT02403193|Experimental|PBF-509_640 mg|
89649880|NCT02403193|Experimental|PBF509_160 mg +PDR001|
89649881|NCT02403193|Experimental|PBF509_320 mg+PDR001|
89649882|NCT02403193|Experimental|PBF509_640 mg +PDR001|
89649883|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno naïve|Immunotherapy naïve patients will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
88993153|NCT04000971|Active Comparator|Integrated Stroke Practice Unit (ISPU)|ISPU personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge. This will be supplemented by a more integrated model designed to increase coordination through team-based initiatives across the continuum of care for stroke - from acute and in-hospital care through 12 months post-discharge. Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, increase understanding, and build positive behavior change for patients and caregivers. Primary outcomes will be assessed by phone at 3, 6, and 12 months; secondary outcomes will be assessed at 3, 6, and 12 months.
88993154|NCT04000971|Active Comparator|Comprehensive or Primary Stroke Center (CSC/PSC)|CSC/PSC personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge, follow-up clinic visits as recommended by their outpatient provider, and other clinic visits initiated by the patient when issues arise. Primary outcomes will be assessed by phone at 3, 6, and 12 months; secondary outcomes will be assessed at 3, 6, and 12 months.
88993155|NCT03985501||newborn screening for sickle cell disease|Newborns with a targeted neonatal screening for sickle cell disease carried out at the University Hospital of Lyon
88993156|NCT03972163|Experimental|SPECTORx Educational Intervention|The program intervention is based on a combination of 3 existing, complementary, educational programs that, together, equip hospice staff to create a comprehensive, patient-centered, medication management care plan.
88993157|NCT03972163|Active Comparator|Attention Control|"As the attention control, we will refer staff in control offices to the National Institute of Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
88993158|NCT03972124|Active Comparator|CBD 100 mg OD|The lower dose CBD group will start with CBD capsules 10 mg OD, then increase the dose every 4 days until on the target dose of 100 mg OD.
89649884|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno treated|Patients previously treated with immunotherapy (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
89649885|NCT03807297|Other|TIVA - total intravenous anaesthesia|only intravenous type of anaesthesia using Injection propofol, 10 mg and Injection dexmedetomidine drug infusion will be infused for maintenance of anaesthesia
89649886|NCT03807297|Other|Inhalational anaesthesia|In this group, both nitrous oxide and sevoflurane will be given for maintenance of anaesthesia
89649887|NCT05387148|Experimental|Cannabidiol (CBD)|For a total of three days, so that both study participants and staff are blind to treatment condition
89649888|NCT05387148|Placebo Comparator|Placebo|For a total of three days, so that both study participants and staff are blind to treatment condition
89649889|NCT03807219|Active Comparator|Magnox Comfort|80 subjects will be on the Magnox Comfort arm.
89649890|NCT03807219|Placebo Comparator|Placebo|80 subjects will be on the Placebo arm.
89649891|NCT03569917|Experimental|patient under Ceftriaxone treatment|
89688592|NCT01724801|Active Comparator|Whole brain irradiation|Whole brain irradiation 30Gy/3Gy/10 fractions plus concurrent or sequential chemotherapy for 4-6 cycles
89045414|NCT06227455|Sham Comparator|Ti PTFE|TI PTFE is pre-bent and adapted over a 3D printed model for the alveolar defect area after virtual augmentation then used intra-operative over the mixture of Autogenous and xenograft particles.
89045415|NCT06227455|Active Comparator|Customized zirconia Barrier|After virtual augmentation of the defect area, a customized 3D zirconia barrier is designed on a specialized software (Autodesk Meshmixer). The exported STL file of the designed barrier is milled and sterilized. Intra-operatively, the initial try-in of the zirconia barrier is done to allow for adjustment and ensuring a proper fit and tension-free primary closure.
89045416|NCT06227442||Group A|will include 48 RA patients without renal affection.
89045417|NCT06227442||Group B|will include 48 RA patients with renal affection.
89045418|NCT06227442||Group C|will include 48 healthy control.
89045419|NCT06227416|No Intervention|Ex-vivo samples from already excised SCC and BCC areas from mohs surgery|
89045420|NCT06227416|Experimental|Ex-vivo samples from punch biopsy from patients with AKs|
89045421|NCT06227403|Experimental|Leadership, Engagement, and youth Activism Program with Mindfulness|The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP-M) consists of 14 sessions focused on youth civic engagement, leadership, and mindfulness.
89045422|NCT06227403|Active Comparator|EnvisionIT|EnvisionIT is a college and career-readiness program designed for students in grades 6-12. The EnvisionIT program will be delivered over 14 sessions, and focus on skills and career/college readiness.
89045423|NCT06227390|Experimental|MTA and stainless-steel crown|
89045424|NCT06227390|Experimental|Biodentine® and stainless-steel crown|
89045425|NCT06227390|Experimental|TheraCal PT® and stainless-steel crown|
89045426|NCT06227390|Experimental|MTA and glass ionomer restoration|
89045427|NCT06227390|Experimental|Biodentine® and glass ionomer restoration|
89045428|NCT06227390|Experimental|TheraCal PT® and glass ionomer|
89045429|NCT06227364||MCI patients|patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment
89045430|NCT06227364||Metabolic patients|patietns with obesity and metabollic dysfunction submitted to haematological tests, psychological and neuropsychological evaluations and endocrinology assessment
89045431|NCT06227351|Active Comparator|completely limiting computer generated surgical three-dimensional guide|patients in this group will receive zygomatic implant placed in a completely fully guided technique using surgical guide,keys and sleeves.
89521700|NCT03414151||Observational - Healthy Control Arm|All participants will be placed in this arm if they are healthy controls (there is no randomization procedure)
89521701|NCT03419065|Other|Relaxation Intervention|Women hospitalized on bed-rest for high risk pregnancy participated in Relaxation Interventions.
89521702|NCT04649047|Experimental|Intervention|All participants will be assigned to the experimental group and receive a 3-weekly intervention via web and individual health coaching. The educational topics cover stress management, healthy eating, and physical activity
89521703|NCT02835157|Experimental|Balanced crystalloid or multiple electrolyte solution group|After enrollment, a fluid bolus comprising of 'multiple electrolyte solution (Plasma-Lyte P)' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children.
89521704|NCT02835157|Active Comparator|0.9% saline or saline group|After enrollment, a fluid bolus comprising of 'saline' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children.
89521705|NCT03418831|Active Comparator|Raloxifene|Raloxifene Hydrochloride
89521706|NCT03418831|Placebo Comparator|Placebo|placebo tablet
89521707|NCT04448587|Experimental|Sitagliptin|
89521708|NCT02770183||Consecutive patients|"Consecutive patients waiting to have elective cardiac surgery will be eligible. Each week the principal investigator will track patients in the operating program. The day of the consultation or the day before the operation, one of the investigators will have a talk with the patient to provide information and clarify doubts, also allowing the patient to read and look good all the details before giving its approval. For the screening, the principal investigator will use the criteria of inclusion and exclusion to select patients for the study. The screening uses clinical, laboratory or without other biological information.~To minimize confounding factors, it will be taken consecutive patients, that will also be analyzed regarding all known variables that can affect the systolic function, as non-modifiable (age, cardiovascular risk factors, heart-rate variability and preoperative basal systolic function) and modifiable."
89521709|NCT02737189|Experimental|Endovascular Arm|"Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration~Best Medical Treatment and maximum supportive care"
89521710|NCT02737189|Other|Control Arm|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
89521711|NCT03426163|Experimental|VR group|Application of virtual reality 12 hours before arthroscopic surgery
89521712|NCT03426163|No Intervention|Non-VR group|Application of knee MRI 12 hours before arthroscopic surgery
89521713|NCT03426085|Placebo Comparator|Placebo|Same formulation as active medication minus the active ingredient. Patients will start with 0.1 mL of liraglutide placebo and will escalate the dose every week in 0.1 ml increments until the 0.3 ml dose is reached. Escalation will be done according to patients' tolerance and glucose control
89521714|NCT03426085|Experimental|Liraglutide 6 mg Solution for Injection|After randomization, patients will undergo a treatment dose escalation phase. Liraglutide will be started at 0.6 mg SQ QD for 1 week, increased to 1.2 mg subcutaneous, per day (SQ, QD) for 1 week, and then increased and maintained on 1.8 mg SQ QD or maximally tolerated dose if self monitored blood glucose (SMBG) is at goal. Escalation will be done according to patients' tolerance and glucose control
89521715|NCT03127657|Experimental|Cock's comb extract 0.01%|25 Patients Cock's comb extract 0.01% Applied topically twice daily for 12 weeks
89521716|NCT03127891|Experimental|pranayama yoga|yoga breathing exercise
89649892|NCT03807375|Other|CPAP|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O. The process will continue until the end-tidal O2 concentration ≥ 90% is removed.
89649893|NCT03807375|No Intervention|standard preoxygenation|During the preoxygenation, the ventilator device will be put in spontaneous mode and the procedure will continue until the End-tidal O2 concentration ≥90% is removed without additional pressure.
89521717|NCT03127891|Placebo Comparator|control group|no intervention
89521718|NCT03426007|Experimental|Uterine Lavage|Embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
88993159|NCT03972124|Experimental|CBD 200 mg OD|The higher dose CBD group will start with CBD capsules 10 mg OD and will increase every 4 days until on a target dose of 200 mg OD.
88993160|NCT03972124|Placebo Comparator|Placebo|
88993161|NCT03970070|Experimental|Health service research (Periop-OSMT)|Patients and/or support persons/family caregivers complete Periop-OSMT session in-person or via telephone over 20-40 minutes before surgery and before hospital discharge and group telehealth session over 1.5-2 hours at weeks 1-3, 4, 5, 6, and 7 post discharge
88993162|NCT03944668|Experimental|Intervention|Exercise intervention
88993163|NCT03915418|Experimental|Connected tools|1 night at home with connected tools only and 1 night at hospital with connected tools and PSG.
88993164|NCT03914612|Active Comparator|Arm I (placebo, paclitaxel, carboplatin)|"COMBINATION PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive placebo IV over 30 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan throughout the study.~On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm 1 will not receive additional placebo infusions."
88993165|NCT03914612|Experimental|Arm II (pembrolizumab, paclitaxel, carboplatin)|"COMBINATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle, paclitaxel IV over 3 hours on day 1 of each cycle, and carboplatin IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease may continue treatment for up to a total of 10 cycles (if deemed necessary by the treating physician) in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 6 weeks for up to 14 cycles in the absence of disease progression or unacceptable toxicity.~Patients undergo CT scan throughout the study."
88993166|NCT03914482|Other|Patients at risk of FLD|Patients who choose to participate in the study that meet the inclusion criteria
88993167|NCT03898804|Experimental|BCI and FES|Surgical implantation of the device and testing for 13 months with an optional 5 year extension study.
88993168|NCT03896880||blood culture positive|hematological malignancy patients with positive blood culture
88993169|NCT03883542||serous BOT|simple serous BOT ovarian tissue
88993170|NCT03883542||serous BOT with non-invasive implants|BOT ovarian tissue presenting with non-invasive implants
88993171|NCT03883542||sBOT with micropapillary grow pattern|BOT ovarian tissue presenting with micropapillary grow pattern
88993172|NCT03883542||serous BOT with invasive implants|sBOT ovarian tissue presenting with invasive implants at the time of diagnosis
88993173|NCT03871543|Other|Part 1|All eligible subjects enrolled into Part 1 will be fit and dispensed with Test Lens 1
88993174|NCT03871543|Other|Part 2|All eligible subjects (based on CLDEQ responses) enrolled into Part 2 will be fit and dispensed with Test Lens 2 and will follow the same procedures as Part 1.
88993175|NCT03862963|Active Comparator|Standard of Diabetes Care|Standard of diabetes care in the Marshall Islands
88993176|NCT03862963|Experimental|Lifestyle Intervention|Plant-based, whole foods diet with moderate exercise
89521719|NCT03418597|Experimental|Deep local anesthesia + Virtual reality|Pre-medication procedures and lidocaïne injection are the same as in the current practice. During the intervention delay, the patient will also experience hypnosis through a virtual reality procedure .
89521720|NCT03418597|Active Comparator|Deep local anesthesia alone|The musculoskeletal biopsy is performed according to the standard practice using a deep local anesthesia with premedication and lidocaïne.
89521721|NCT03414073|Sham Comparator|Group A Phase 1|"Conventional flossing technique using commercially available Reach® Floss One third of sample are randomly assigned to Group A and are to utilise conventional finger flossing technique in the first phase of 4-weeks. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
89521722|NCT03414073|Active Comparator|Group B Phase 1|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss One third of sample are randomly assigned to Group B and are to utilise knotted floss technique in the first phase of 4-weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
89521723|NCT03414073|Sham Comparator|Group C Phase 1|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes One third of sample are randomly assigned to Group C and are to utilise conventional interdental brushing technique in the first phase of 4-weeks twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
89649894|NCT05076084||Patients aged 0 to 18 years followed for Vernal keratoconjunctivitis|Treated (or having been treated) with tacrolimus 0.1% ophthalmic solution previously treated with ciclosporin 2% ophthalmic solution with treatment failure.
89649895|NCT03809637|Experimental|pemetrexed+cisplatin|Patients with metastatic sarcoma who underwent one chemotherapy regimens are treated with the combination of pemetrexed and cisplatin, and the treatment is repeated until the disease progression. pemetrexed 500 mg / m2 (day 1) and cisplatin 75 mg / m2 (day 1) are intravenously injected. 21 days is one cycle, and it is carried out by co-administration up to 6 cycles. After 7 cycles, intravenous injection of pemetrexed alone at intervals of 3 weeks until disease progression.
89649896|NCT03513445|Experimental|Lumbar Spine Surgery with Injection|Patients undergoing lumbar spine surgery will receive a peri-incisional injection of pain medications (morphine, epinephrine, and ropivacaine) during their surgery.
89649897|NCT03513445|No Intervention|Lumbar Spine Surgery without Injection|Patients undergoing lumbar spine surgery will NOT receive a peri-incisional injection of pain medications during their surgery.
89649898|NCT03802071|Experimental|Durvalumab+doxorubicin combination|
89649899|NCT05071404||Cases|Patients treated with infliximab sc.
89649900|NCT01677637||All measurements|Total measured population
89649901|NCT05057832||Cases|Patients treated with Ustekinumab.
89649902|NCT05124756|Experimental|Bioelectric stimulation|Bioelectric stimulation on quadriceps muscle and kidneys: 45 minutes, 3 times/week, 8 weeks, 24 sessions.
89649903|NCT05124756|No Intervention|Control|No intervention.
89649904|NCT00758667|No Intervention|Standard treatment|Standard treatment
89649905|NCT00758667|Experimental|Use of Mesna|Standard surgical procedure with Mesna
89649906|NCT04412772|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen.
89649907|NCT04412772|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
89649908|NCT03509857|Placebo Comparator|normal standard of care infusion of propofol without analgesia|normal standard of care infusion of propofol without analgesia
89649909|NCT03509857|Experimental|infusion of propofol with application of vibration analgesia|infusion of propofol with application of vibration analgesia
89649910|NCT00758745|Active Comparator|Model SN60WF|Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)
89649911|NCT00758745|Active Comparator|Model MA60AC|Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)
89649912|NCT05124600|Experimental|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
89649913|NCT05124600|No Intervention|Waiting list|Participants will be on the waiting list.
89649914|NCT05041920|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design.
89649915|NCT03802461|Active Comparator|Fecal Microbiota Transplantation (FMT)|Bowel lavage preparation followed by FMT administered by enema, given on 3 occasions. Fecal filtrate for FMT will be prepared from 50 g of healthy donor stool, homogenized, and diluted in 300 mL sterile normal saline.
89649916|NCT03802461|No Intervention|Standard of Care|Patients in this arm will not receive intervention and will be on standard of care .
89649917|NCT03984786|Experimental|ICBT for alcohol misuse: Assessment Interview/Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.~Participants randomized to this arm will then receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
89649918|NCT03984786|Experimental|ICBT for alcohol misuse: Assessment Interview/No Guidance|"In this arm, an interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization during the initial telephone screen, where the interviewer will use the AUD section from SCID-5.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
89649919|NCT03984786|Experimental|ICBT alcohol misuse: No Assessment Interview/Guidance|"The client will not receive any assessment interview during the telephone screen.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse with guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT."
89649920|NCT03984786|Experimental|ICBT for alcohol misuse: No Assessment Interview/No Guidance|"The client will not receive any assessment interview during the telephone screen.~Participants randomized to this arm will receive the 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no guidance from a health educator will be provided. Clients will be monitored by providing brief measures on alcohol and depression each week. However, clients will only be contacted if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms of depression and suicidal ideation)."
89649921|NCT03508219|Experimental|BiOSS LIM C|The treatment strategy consists of contemporary PCI of the left-main bifurcation, using the BiOSS LIM C stent system, following diagnostic angiography demonstrating significant distal unprotected left main disease and local Heart Team discussion applying the anatomic SYNTAX Score.
89649922|NCT05032716|Active Comparator|Balance exersices group|received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance
89688593|NCT04354441|Experimental|hydroxychloroquine|10-day course of hydroxychloroquine 200 mg tablet twice a day. To be taken orally.
89649923|NCT05032716|Active Comparator|Balance exersices and treadmill group|received the same traditional physical therapy program as the same applied in group of balance exercise (30 min), in addition to treadmill training (30 min)
89649924|NCT03807453||Psoriasis Vulgaris patients-Lesion|
89649925|NCT03807453||Psoriasis Vulgaris patients-Lesion free|
89649926|NCT03807453||Seborrheic Dermatitis-Lesion|
89649927|NCT03807453||Seborrheic Dermatitis-Lesion free|
89649928|NCT03807453||Control Group|
89649929|NCT03506113|Active Comparator|Gram stain-guided therapy group|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
89649930|NCT03506113|Active Comparator|Guidelines-based therapy group|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs
89649931|NCT04413084|Experimental|Gaze stability exercises|Group I will receive Gaze stability exercises.
89649932|NCT04413084|Experimental|Brandt-Daroff Exercises|Group II will receive Brandt-Daroff Exercises.
89649933|NCT04412850|Experimental|Control group|Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. The regiment chosen for this study is designed to double serum magnesium concentration to twice physiological concentration for therapeutic effects in humans, Serum levels between 4.8mg/dl-6mg/dl are considered to have an optimal neuroprotective effect.
89649934|NCT04412850|Placebo Comparator|placebo group|Normal Saline in equal volume as the control group.
89649935|NCT00778167|Experimental|Arm I (Enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.
89649936|NCT00778167|Experimental|Arm II (Enzyme inhibitor and monoclonal antibody therapy)|Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1 hour on days 1, 8, and 15.
89649937|NCT05124444|Experimental|Cases (tolerant patients)|
89649938|NCT05124444|Experimental|Controls|
89649939|NCT03807141|Experimental|Diet arm|"Modified Atkins diet will be administered with carbohydrate restriction to 10 grams per day. Proteins will be allowed unrestricted and fats will be actively encouraged.~The ongoing antiepileptic medication will be continued unchanged"
89649940|NCT03807141|No Intervention|Control|The control group will continue their anti-epileptic medication unchanged with no additional dietary input
88993177|NCT03843125|Experimental|2 mg Baricitinib|Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).
88999254|NCT01823237|Active Comparator|rTMS|rTMS condition, rTMS will be applied at 0.1-0.5 Hz frequency at a subthreshold intensity
89212882|NCT04729049|Active Comparator|Patient controlled analgesia (PCA) with intravenous morphine|"End-surgery: acetaminophen 1 g ev + 4 mg morphine ev before the end of the intervention.~PCA: morphine 1 mg, max every 30 minutes. Rescue: ketoprofen 100 mg ev, max three times per day."
89212883|NCT04722107|Experimental|Single arm|All patients enrolled in the study will receive a single subretinal injection of ZVS101e in one eye
89649941|NCT03957330|Experimental|Community Mental Health Clinic|In this arm, clients will be assigned to therapists working in a community mental health clinic in Saskatchewan where the focus of the setting is primarily on face-to-face treatment and ICBT makes up a small component of the workload in the clinic.
89649942|NCT03957330|Experimental|Once a week therapist contact|In once a week treatment, therapists will email their clients once a week on a pre-determined day.
89649943|NCT03957330|Experimental|Reflection Questionnaire|"In the reflection questionnaire, patients will be asked to complete the following questions five times during the treatment period (beginning lesson 2-5 and then at the point they complete post-questionnaires):~How much of the lesson were you able to review?~How much effort were you able to put into the lesson?~How difficult was the lesson?~Please share any difficulties you had with the lesson.~How understandable was the lesson?~How helpful did you find the lesson?~Please describe an example of what you learned.~To what extent have you continued to use strategies from previous lessons~If applicable, please provide an example of what you are working on from previous lessons~Please indicate which Additional Resources you reviewed this week.~If applicable, please share any skills you are working on from the Additional Resources."
89649944|NCT03957330|Experimental|Specialized Internet Therapy Clinic|In this arm, clients will be assigned to therapists working in a specialized internet therapy clinic where the therapists only deliver ICBT.
89649945|NCT03957330|Experimental|Twice a week therapist contact|In twice a week treatment, therapists will email their clients twice a week on pre-determined days.
89649946|NCT03957330|Experimental|No Reflection Questionnaire|In this arm, no reflection questions will be asked of clients receiving ICBT.
89649947|NCT03809559||Biliary Conditions|Participants who have a history of a biliary tree related condition
89649948|NCT03809559||Liver conditions|Participants who have a history of a non-biliary tree related liver condition
89649949|NCT03809559||Healthy Volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
89649950|NCT05124366|Experimental|Study group|Nanovitamin E, nanovitamin C and propolis extract gel
89649951|NCT05124366|Placebo Comparator|Placebo|Gel without nanovitamin E, nanovitamin C and propolis extract
89649952|NCT03809403||"No touch group:"|Patients with left sided colic adenocarcinoma who underwent left colectomy with an early ligation of mesenteric vessels
89649953|NCT03809403||"Mobilisation first group"|patients with right colic adenocarcinoma who underwent right colectomy with early mobilisation of the tumor followed by the ligation of the vessels.
89649954|NCT03916848|Experimental|Combined Micro-Macro SEEG Electrodes|Implanting SEEG electrodes with combined micro-macro electrodes capable of recording clinical data and experimental micro electrode single unit data
88993178|NCT03843125|Experimental|4 mg Baricitinib|Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.
88993179|NCT03843125|Experimental|Placebo to 2 mg Baricitinib|Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.
88993180|NCT03843125|Experimental|Placebo to 4 mg Baricitinib|Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.
88993181|NCT03842670|Active Comparator|Cognitive-Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein & McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking.
88993182|NCT03842670|Active Comparator|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz & Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual.
88993183|NCT03828786|Active Comparator|Endometrial scratching group|Endometrial scratching will be done with a Pipelle in uterus.
89649955|NCT00778869|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
89649956|NCT05118594|Experimental|Pre-treatment recommendations|Therapists receive automatized feedback at the beginning of the treatments with recommendations regarding the most appropriate interventions to use with their patients based on a machine learning algorithm developed on a previous study.
89649957|NCT05008536|Experimental|Anti-BCMA CAR-NK Cells|After preconditioning with chemotherapy, the Anti-BCMA CAR-NK Cells will be evaluated
89649958|NCT00779103|Experimental|Histrelin Subcutaneous Implant (50 mg)|Subcutaneous implant designed to deliver histrelin continously for 12 months.
89649959|NCT05373420||All individuals tested for COVID-19 in Belgium|All individuals of 18 years old and over tested for COVID-19 at least once in Belgium until the 31st of August 2021
89649960|NCT04345419|Experimental|Remdesivir|Remdesivir with standard of care treatment standard of care treatment
89649961|NCT04345419|Placebo Comparator|Standard of care|Standard of care treatment alone.
89649962|NCT04841070|Experimental|Persistent pulmonary hypertension of the newborn.|Children aged 1 to 5 years who have been hospitalized in pediatric resuscitation service for the treatment of persistent pulmonary hypertension of the newborn.
89649963|NCT01480076|Experimental|(BIIB041) Fampridine|All participants take 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, a participant continues 10 mg fampridine twice daily for 44 weeks. Treatment non-responders can continue without treatment by completing quality of life questionnaires.
89649964|NCT04830774|Other|COVID-19 patients with new-onset AF|Consecutive patients with a confirmed diagnosis of COVID-19 with a first clinical episode of AF at admission or during hospitalization.
89649965|NCT00759525|Active Comparator|1|Glycyrrhetic Acid
89649966|NCT00759525|Placebo Comparator|2|Placebo
89649967|NCT03606876|Experimental|BAT1806 injection|BAT1806 injection: 4 mg/kg, intravenous infusion over 60 min
89649968|NCT03606876|Active Comparator|Actemra(EU-licensed)|Actemra(EU-licensed): 4 mg/kg, intravenous infusion over 60 min
89649969|NCT03606876|Active Comparator|Actemra(US-licensed)|Actemra(US-licensed): 4 mg/kg, intravenous infusion over 60 min
89649970|NCT00759603|Experimental|Lenalidomide + Rituximab|Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.
89649971|NCT03599934|Experimental|LiFE training and home safety assessment|The participants will receive Lifestyle Integrated Functional Exercise Program and Home safety assessment
89649972|NCT03599934|No Intervention|Control group|The control group will continue their usual daily routine.
89649973|NCT03809325||Participants with Schizophrenia|No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.
89649974|NCT04759014||Group 1|21 patients using non-articulated dynamic foot (non-articulating ankle, NAA)
89649975|NCT04759014||Group 2|21 patients using dynamic foot with hydraulic ankle (articulating hydraulic ankle, AHA)
89649976|NCT03510390|Experimental|Metformin|Participants will be orally administered 850 mg of metformin twice daily between the therapeutic decision of the tumor board and the surgical resection of the tumor. The duration of the treatment is 9-14 days
88993184|NCT03828786|No Intervention|Control group|This group will proceed with intrauterine insemination without endometrial scratching according to clinic's standard procedure
88993185|NCT03815019|Experimental|Megestrol|"Megestrol is a steroid and progestational drug FDA approved for treating anorexia or weight loss in patients with acquired immunodeficiency syndrome. Its use in the current protocol is off label to stimulate appetite in tube-fed infants and toddlers who are weaning from tube feedings and learning to eat. The precise mechanism of action that leads to increased appetite and weight gain is unknown, but is probably related to megestrol's glucocorticoid effect.~The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable."
88999255|NCT01823237|Placebo Comparator|rTMS sham|Placebo condition will use a sham coil and apply a very small magnetic stimulus
89649977|NCT03505099|Experimental|onasemnogene abeparvovec-xioi|One-time intravenous infusion of onasemnogene abeparvovec-xioi at 1.1 X 10^14 vg/kg
89045432|NCT06227351|Active Comparator|Partially limiting computer generated surgical three-dimensional guide|patients in this group will receive zygomatic implant placed in a partially guided technique using surgical guide.The first drill only will be used with the guide then the guide will be removed and the whole procedure with the remaining drills will be completed in a free hand technique.
89045433|NCT06227325|Experimental|treatment group|Neoadjuvant therapy:RC48 combined with Sintilimab and XELOX repeat every 2 weeks or every 3 weeks for a total of 3 cycles Adjuvant therapy: RC48 combined with Sintilimab and XELOX repeat every 2 weeks or every 3 weeks for a total of 5 cycles
89045434|NCT06227312|Experimental|warm-up intervention|"Each participant performed all warm-up variants one week apart, without the possibility of repeating:~CTRL 5 sets of 30 s calf raises on the platform but without vibration with 30 s rest intervals between sets; WBV 5 sets of 30 s calf raises on the vibration platform with 30 s rest intervals between sets; DJ 6 modified drop jump with a 30 s rest interval between sets (DJ); WBV + DJ 5 sets of 30 s calf raises on the vibration platform followed by 6 drop jumps with a 30 s rest interval between sets"
89045435|NCT06227299||Glaucoma patients|Patients with glaucoma
89045436|NCT06227273|Active Comparator|H2 Standard Dose|This condition will schedule 1-5 glasses of hydrogen water a day for 16 weeks.
89649978|NCT03806829|Active Comparator|Water + Meal|250 ml Water and a high calorie, high fat meal (>900 kcal, 50g fat)
89649979|NCT03806829|Experimental|Red Wine + Meal|250 ml Red Wine and a high calorie, high fat meal (>900 kcal, 50g fat)
89649980|NCT03806829|Experimental|Green Tea + Meal|250 ml Green Tea and a high calorie, high fat meal (>900 kcal, 50g fat)
89649981|NCT03806829|Experimental|Orange Juice + Meal|250 ml Orange Juice and a high calorie, high fat meal (>900 kcal, 50g fat)
89649982|NCT03496194||Head of Post Anaesthesia Care Unit|The chief physician of PACUs at all Danish Anaesthesia departments will receive electronic survey on postoperative pain treatment
89649983|NCT03806673|Active Comparator|primipara|primipara subjected to their first epidural block
89649984|NCT03806673|Active Comparator|multipara|multipara subjected to their repeated epidural block.
89045437|NCT06227273|Active Comparator|H2 Standard Dose followed by Higher Dose H2|This condition will schedule 1-5 glasses of hydrogen water a day for 8 weeks followed by 4-5 glasses of hydrogen water for 8 weeks.
89649985|NCT03807063|Experimental|Treatment (rivogenlecleucel)|Each subject may receive up to 3 IV infusions of rivogenlecleucel at intervals no less than 28 days apart. Subjects who meet protocol-specified severity criteria for acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia or encephalopathy will be treated with rimiducid infusion(s).
89649986|NCT04553562|Experimental|Acupuncture group|For acupuncture group, sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads. The participants will be treated three times a week, on alternate days, for 6 successive weeks; 18 sessions for each patient in total.
89649987|NCT04553562|Sham Comparator|Sham acupuncture group|For the sham acupuncture group, aterile adhesive pads will be placed after skin disinfection on the acupoints and needles with a blunt tip will be inserted at the same acupoints in the acupuncture group without penetrating the skin.No manipulation of needles will be conducted. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
89649988|NCT04553562|No Intervention|Waiting list group|For the waiting list group, patients will receive no treatment in the first 6 weeks and will receive the same treatment used in the acupuncture group according to patients' preference.
89649989|NCT03809871|Experimental|Biomarker group|These participants will receive information about cardiometabolic biomarkers pre and post weight management course
89649990|NCT03809871|No Intervention|Control group|They will receive the same weight management programme as the experimental group, but they will not have biomarker information.
89649991|NCT03291990|Experimental|5 fraction radiotherapy with standard temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
89649992|NCT00087919||Maywood|The were 743 subjects were sampled from Maywood, Il. There was no intervention.
89649993|NCT00087919||Nigeria|There were 1188 Nigerian sampled from Igbo-Ora and Ibadan, Nigeria. There was no intervention.
89649994|NCT03806595|Experimental|Intranasal lidocaine|1mL of lidocaine 2% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
89649995|NCT03806595|Placebo Comparator|Intranasal normal saline|1mL of saline 0.9% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
89649996|NCT03808935|Experimental|Medical cannabis|Capsules containing cannabis extract, dissolved in high-oleic sunflower oil, and CBD/THC in a 16:1 ratio.
89649997|NCT03808935|Placebo Comparator|Placebo Control|"Capsules containing a high-oleic sunflower oil, calorie-equated to the active treatment. There will be no active compounds in the placebo treatment.~Following treatment with placebo, all participants in this group will begin treatment with medical cannabis."
89649998|NCT05170698|Experimental|coalition excision and arthroereisis|Talocalcaneal bar excision is done and then arthroereisis implant is applied in subtalar joint to correct rigid pes planovalgus in adolescent
89212884|NCT02585765|Experimental|Pioglitazone|Subjects will receive 8 weeks of daily pioglitazone (30mg/day).
89649999|NCT05170698|Experimental|coalition excision and corrective osteotomies|Talocalcaneal bar excision is done and then according to degree of deformity either medial displacement calcaneal osteotomy or evans or cotton osteotomy is done or combined together to correct rigid pes planovalgus in adolescents
89650000|NCT03455959|Experimental|Allergic Asthmatic or Healthy Control Adults|Allergic Asthmatic or Healthy Control Adults will undergo Bronchoscopy/BAL and airway brushing
89650001|NCT03807999|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel 125 mg/m2 as 30- to 40-minute infusion (maximum infusion time not to exceed 40 minutes) once weekly for 3 weeks followed by a week of rest. plus Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) once weekly for 3 weeks followed by a week of rest.
89688594|NCT04354441|Placebo Comparator|Placebo|An identical appearing placebo. To be taken orally twice a day for 10-days.
88993186|NCT03815019|Placebo Comparator|Placebo|Subjects randomized to the placebo protocol will receive a placebo syrup identical in taste and smell to megestrol at the same intervals as those in the megestrol group but the syrup will contain no active ingredients.
88993187|NCT03800407||EFV-based ART|ART-naïve HIV-infected children aged 3 - 14 years who initiate EFV-based ART
88993188|NCT03800407||Concurrent EFV-based ART plus anti-TB therapy|ART-naïve HIV-infected children aged 3 - 14 years with TB coinfection who initiate EFV-based ART while receiving first-line anti-TB therapy
88993189|NCT03796078|Active Comparator|Bimaxillary surgery (MMA)|Bimaxillary Orthognathic Surgery. MMA
88993190|NCT03796078|Active Comparator|monomaxillary surgery (Isolated MaxS)|Monomaxillary surgery (Isolated MaxS)
88993191|NCT03796078|Active Comparator|monomandibullary surgery (Isolated MandS)|Monomandibular surgery (Isolated MandS)
88993192|NCT03770650|Experimental|IVUS-guided DK crush stenting|"In the IVUS-guided DK crush stenting group, IVUS will be before side branch stenting, after rewiring side branch, after 1st kissing balloon inflation, after rewiring side branch, after 2nd kissing balloon inflation.~For LM bifurcation lesions involving ostial LAD and LCX: minimum stent are (MSA) should be ≥10mm2 (LM), 7 mm2 (LAD), and 6 mm2 (LCX), with stent expansion index ≥90% (CSA≥90% of distal reference lumen area in LCX) and symmetry index >0.8.~For non-LM bifurcation lesion involving the MSA should be ≥6 mm2 in the main vessel; and the MSA in the ostial side branch should be ≥5 mm2 and ≥90% of distal reference lumen area; and symmetry index should be >0.8."
88993193|NCT03770650|Active Comparator|Angiography-guided DK crush stenting|In the Angiography-guided DK crush stenting group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of ≥Type B dissection.
88993194|NCT03767218|Experimental|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH > 10 IU/L, till day of trigger.
88993195|NCT03767218|Active Comparator|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
88993196|NCT03755375|Active Comparator|E-stim Group|TENS group was treated with biofeedback, manual therapy, andtranscutaneous electrostimulation (TENS), a peripheral neuromodulation to promote analgesia in pain areas, using two transcutaneous self-adhesive electrodes Axelgaard 5 cm x 5 cm with 2 cm of distance between them. The parameters used were frequency = 100 Hz, pulse width = 50-100 µs, and current intensity according to the patient's sensitivity.
88993197|NCT03755375|Active Comparator|Postural Group|Postural group was treated with biofeedback, manual therapy, and postural exercises , which promoted pelvic mobility and functional training associated with respiratory exercises increasing the diaphragmatic excursion.Postural exercises consisted of 10 repetitions of breathing exercises in the lay-down position, 10 repetitions of hip anteversion and retroversion in the sitting position, and 10 repetitions of hip anteversion, retroversion, and lateral movement in the stand-up position.
89212885|NCT02585765|Placebo Comparator|Placebo|Subjects will receive 8 weeks of daily placebo capsules.
89045438|NCT06227260|Active Comparator|Study 1: Thai massage|Participants were randomized to receive an arm. In this arm, participants received Thai massage without any oil for 1 hour/day, 1 day/week for 12 weeks. Massage was performed at Burapha University by an expert.
89045439|NCT06227260|Active Comparator|Study 1: Thai massage with pure coconut oil|Participants were randomized to receive an arm. In this arm, participants received Thai massage with pure coconut oil which is a popular oil used in spa for 1 hour/day, 1 day/week for 12 weeks. Massage was performed at Burapha University by an expert.
89045440|NCT06227260|Experimental|Study 1: Thai massage with oil mixed with Snake fruit extract|Participants were randomized to receive an arm. In this arm, participants received Thai massage with oil mixed with Snake fruit extract for 1 hour/day, 1 day/week for 12 weeks. Massage was performed at Burapha University by an expert.
89045441|NCT06227260|Experimental|Study 2: Facial mask with Snake fruit extract|Participants were randomized to receive an arm. In this arm, participants received home-based program facial mask with Snake fruit extract for 30 min/day, 2 days/week for 12 weeks.
89045442|NCT06227260|Active Comparator|Study 3: Control jelly|Participants were randomized to receive an arm. In this arm, participants consumed with control jelly at 3.5 g/kg body weight. Consumption was taken at Burapha University.
89045443|NCT06227260|Experimental|Study 3: Jelly with Snake fruit juice|Participants were randomized to receive an arm. In this arm, participants consumed with jelly with Snake fruit juice at 3.5 g/kg body weight. Consumption was taken at Burapha University.
89045444|NCT06227221|Experimental|Sorafenib|
89045445|NCT06227221|Placebo Comparator|Placebo|
89650002|NCT03807999|Experimental|Gemcitabine|Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
89650003|NCT05403918|Active Comparator|conventional physiotherapy|15 patients will receive conventional physiotherapy including a hot pack, TENS, therapeutic ultrasound, shoulder anteroposterior, posteroanterior, and inferior glides followed by active and active-assisted range of motion exercises, isometric exercises, Codman's pendulum exercises, wand, pulley, and finger ladder exercises.
89650004|NCT05403918|Experimental|scapular stabilization exercises along with conventional physiotherapy|15 participants will receive conventional treatment along with scapular stabilization exercises program consisting of strengthening exercises (Middle Trapezius, Lower Trapezius, Serratus Anterior, and Rhomboid Muscles) and stretching exercises (Pectoralis Minor, Levator Scapulae, Upper Trapezius, Teres Major). Appropriate exercises will be given to patients according to the type of Scapular Dyskinesia.
89650005|NCT03808857|Experimental|GB226|Geptanolimab Injection,3mg/kg once per 2 weeks
89650006|NCT03558451|Experimental|EXIMe intervention|In addition to the usual assistance, women will receive a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
89650007|NCT03558451|Active Comparator|Usual care|Usual care according to available protocols applicable to the women and the health service standardized portfolio
89650008|NCT04427280||Arm A|Suspected acute COVID-19 infection
89650009|NCT04427280||Arm B|Asymptomatic patients with no clinical suspicion of COVID-19
89650010|NCT03808701|Experimental|low dose group|Initially, 9.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 12.0mg/kg of SCT200 will be administered every two weeks until disease progression.
89650011|NCT03808701|Experimental|HIGH dose group|Initially,12.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 15.0mg/kg of SCT200 will be administered every two weeks until disease progression.
89650012|NCT03499951|Other|Wheelchair Skills Trainers|Individuals will receive remotely delivered wheelchair skills training, after which they will be assessed on their ability to teach the Wheelchair Skills Trainees a series of wheelchair skills in a one-on-one environment. The intervention for this group is Wheelchair Skills Training - Remote.
89650013|NCT03499951|Other|Wheelchair Skills Trainees|Individuals will receive one-on-one wheelchair skills training from the Wheelchair Skills Trainers. The intervention for this group is Wheelchair Skills Training - In Person.
89650014|NCT03498625|Other|Clinical remission CD|
89650015|NCT04762147|Experimental|Paracetamol group-P|Paracetamol 15mg/Kg was dministered 30 minutes before the start of surgery
89650016|NCT04762147|Active Comparator|Fentanyl group-F|Fentanyl 2mcg/kg was administered at the time induction of anaesthesia
89650017|NCT05005338|Experimental|Cohort A|
89650018|NCT05403840||MVRR: Patients due to undergo surgical MV repair/replacement|
89045446|NCT06227208||Opioid-naive patients|Opioid-naive patients are defined as the absence of any documented opioid use in the available preoperatively medical records, and are receiving opioids postoperatively
89045447|NCT06227208||Chronic opioid patients|Chronic opioid patients were defined as current or previous use of the following medications, re-gardless of the duration of use: morphine, tramadol, tapentadol, fentanyl, oxycodone, ketobe-midone, methadone, or buprenorphine. This was verified through patients' preoperative medical records. All chronic opioid users received postoperative opioids.
89045448|NCT06227208||Control group|Patients who did not receive pre- or postoperative opioids were served as the overall control group.
89650019|NCT05403840||TMVI: Patients due to undergo transcatheter MV intervention|
89650020|NCT04273737|Experimental|Amantadine|Daily regimen of amantadine hydrochloride tablets for 6 weeks: dosing of 5mg/kg divided by two daily doses (max daily dose of 300 mg)
89650021|NCT03808779|Experimental|Radiofrequency Ablation|Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
89650022|NCT03808779|Active Comparator|Conventional Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
89688595|NCT04378595||During Pandemic|During Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. If a positive response is given, the investigators will ask if the food insecurity began or worsened during the pandemic in the past 1 to 2 months.
89650023|NCT04183062|Experimental|Chemotherapy plus BIO-11006|Patients will receive BIO-11006 in addition to GemTax chemotherapy. The BIO-11006 inhalation solution will be given by mouth inhalation twice daily. BIO-11006 will be given during the first three cycles of GemTax and then will be stopped. Subjects will continue with GemTax treatment for three additional cycles. If the patient shows lung progression (either clinical or on imaging) at any point after cycle 4 has been given, but had shown at least a partial response during the tumor assessment after cycle 3, BIO-11006 may be re-started at the discretion of the investigator and continued for the duration of the GemTax treatment.
89650024|NCT04325880|Placebo Comparator|Placebo arm|Patients in this arm will receive a placebo formula
89650025|NCT04325880|Active Comparator|Mirabegron arm|Patients in this arm will receive Mirabegrone 50 mg once daily
89650026|NCT04325880|Active Comparator|Tamsulosin arm|Patients in this arm will receive tamsulosin o.4 mg once daily
89650027|NCT04325880|Active Comparator|Solifenacin arm|Patients in this arm will receive solifenacin 10 mg once daily
89650028|NCT00780741|Active Comparator|Immediate Office Probing|Probing to be performed in the office setting using topical anesthesia and infant restraint. Probing to be performed either the same day as randomization or within two weeks.
89650029|NCT00780741|Active Comparator|Deferred Facility Probing|Probing to be performed in a surgical facility under general anesthesia within four weeks after completion of the 26-week visit if any of the clinical signs persist.
89650030|NCT02943954|Other|Angiography guided PCI|Revascularisation of non-culprit lesions guided by PCI
89650031|NCT02943954|Other|FFR guided PCI|Revascularisation of non-culprit lesions guided by FFR measurement
89650032|NCT04385043|Experimental|plasma-hyperimmune|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with plasma hyperimmune add on to the standard therapy
89650033|NCT04385043|Active Comparator|standard therapy|enrolled patients (n=200) with severe Covid-19 infection will receive a treatment with the standard therapy
89650034|NCT04862442|Experimental|Group 1=Video-conference based Qigong exercises|After initial result evaluation, participants of Group A will perform Qigong exercises for 40 to 45 minutes per session for 3 days a week for 6 weeks via the online video conference method.
89650035|NCT04862442|Experimental|Group 2=A-synchronized video Qigong exercises|"Group B will perform the same routine via a-synchronized video sections for 6 weeks.~Basic Qigong exercises will be performed by volunteers for 6 weeks and progression will be logged."
89650036|NCT04846608||Nursing home residents with behavioural problems|Nursing home residents from Grand Nancy aged 75 and over referred to emergency departments for disorientation, agitation, dementia or behavioural problems during the study period
89650037|NCT04846608||Nursing home residents with other problems|Nursing home residents from Grand Nancy aged 75 and over referred to emergency departments for other reasons
89650038|NCT04846218|Active Comparator|Group 1|They will receive a single dose of 0.2 mg triptorelin (Decapeptyl® Ipsen Pharmaceutical Company, France) and follow up with daily 125 IU HCG injections
89650039|NCT04846218|Active Comparator|Group 2|They will receive a single dose of HCG 10000 IU was given followed by progesterone supplementation with 100mg IM (Prontogest®).
89045449|NCT06227182||Healthy individuals|Healthy individuals between 18 and 70 years old.
89045450|NCT06227182||Patients with FSHD|Individuals with clinically and genetically proven FSHD type 1 or type 2.
89650040|NCT03808233||Spinal Muscular Atrophy Type 1|Non rolling infants or children with SMA
89045451|NCT06227156|Experimental|Disitamab Vedotin|Disitamab Vedotin Q2W or Q3W arm
89650041|NCT03808233||Non Rolling Function matched control|Non rolling typically developing infant
89650042|NCT04152486|Experimental|Intervention arm|The vaccine Ad26.ZEBOV (5x10^10 viral particles (vp)) will be given as the first dose and the vaccine MVA-BN-Filo (1x10^8 infectious units (Inf U)) will be given as the second dose 56 (-14 day +28 day) days later.
89650043|NCT02512692|Experimental|90Y TARE with Gemcitabine and Cisplatin|"90Y TARE will be given on day 3 or 4 of cycle 1 and start at 75% of the dose calculated by the body surface area formula and escalated by 25% per cohort in combination with cisplatin 25 mg/m2 and gemcitabine 300 mg/m2 in cycles 1 and 2.~Once the 90Y TARE has reached the 100% dose level, the gemcitabine dose will increase to 600mg/m2 in dose level 3 and 1000mg/m2 in dose level 4. The cisplatin dose will remain at 25/mg/m2.~For all dose levels, from cycle 3 to cycle 8, the cisplatin dose will be 25mg/m2 and the gemcitabine dose will be 1000mg/m2."
89650044|NCT03933072|Experimental|patients with complete spinal cord injury|the planned interventions have been described in the section below
89650045|NCT04807998||Group EA|Serum and Urine samples were collected before anesthesia and immediately after surgery from children who enrolled in part I and undergoing the adenoidectomy or adenotonsillectomy. A PAED score of 12 or greater was defined as EA. The serum and urine samples were analyzed by UHPLC-Q-TOF/MS separately.
89650046|NCT04807998||Group non-EA|Serum and Urine samples were collected before anesthesia and immediately after surgery from children who enrolled in part I and undergoing the adenoidectomy or adenotonsillectomy. A PAED score less than 12 was defined as non-EA. The serum and urine samples were analyzed by UHPLC-Q-TOF/MS separately.
89650047|NCT04499664||Blood donors|Healhy young male bloddonors, aged 30-45
89650048|NCT03458988|Other|All patients|Nellcor™ Adult SpO2 Sensor
89650049|NCT01594398|Experimental|entinostat C1D1 fed|Entinostat: Beginning C1D1 fed; C1D15 fasted. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
89650050|NCT01594398|Experimental|entinostat C1D1 fasted|Entinostat: Beginning C1D1 fasted; C1D15 fed. Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd. Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
89650051|NCT04682106|Experimental|LY3493269|Multiple doses of LY3493269 administered orally.
89650052|NCT04682106|Placebo Comparator|Placebo|Placebo administered orally.
89045452|NCT06227104|Experimental|Online hemodiafiltration (OL HDF)|Prescription: Nikkiso DBB-05 or Fresenius 5008 machine, high-flux polysulfone dialyzer, BFR 200-300, DFR 500, duration 4 hrs
89045453|NCT06227104|No Intervention|Intermittent hemodialysis (IHD)|Fresenius 4008 hemodialysis machine, low-flux polysulfone (Elisiio 170L) dialyzer, minimum BFR 200-300, DFR 500, duration 4 hrs
89045454|NCT06227091|Experimental|Beetroot juice|beetroot juice with high concentration of nitrates ( 800mg)
89045455|NCT06227091|Placebo Comparator|Depleted beetroot Juice|beetroot juice with low concentration of nitrates
89650053|NCT05403606|Experimental|Experimental Group (GASPARD®)|Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
89650054|NCT05403606|No Intervention|Control group:|Spinal cord injured patient with traditional follow-up with therapeutic education at discharge from initial care
89650055|NCT00782379|Experimental|Myeloablative Haploidentical Transplant|All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.
89650056|NCT04572828|Active Comparator|Group 1: Waiting 1 Minute After Paracervical Block|
89650057|NCT04572828|Active Comparator|Group 2: Waiting 3 Minute After Paracervical Block|
89650058|NCT04572828|Placebo Comparator|Group 3: Control Group|
89650059|NCT04572828|Active Comparator|Group 4: Waiting 60 Minute After Taking Oral NSAIDs|
89650060|NCT05316597|Experimental|Terpenes On|"Forest bathing intervention with no filtration of terpenes from inhaled air (terpenes on)"
89650061|NCT05316597|Active Comparator|Terpenes Off|"Forest bathing intervention with filtration of terpenes from inhaled air (terpenes off)"
89650062|NCT05318391||Group/Cohort|Retrospective Cohort： Participants who diagnosed with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients and treated with BTK inhibitor or lenalidomide and its biosimilars.
89650063|NCT05134350|Experimental|Arm A (LOXO-305 - Fasted)|LOXO-305 administered orally while fasting
89212886|NCT02584361|Active Comparator|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
89650064|NCT05134350|Experimental|Arm B (LOXO-305 - Fed)|LOXO-305 administered orally with standard meal
89650065|NCT05134350|Experimental|Arm C (Omeprazole + LOXO-305 Fasted)|Omeprazole + LOXO-305 administered orally while fasting
89650066|NCT05129826|Experimental|older adult|Subjects who has aged ≥ 60 years old.
89650067|NCT05134194|Experimental|Arm A|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
89650068|NCT05134194|Experimental|Arm B|Capecitabine or eribulin or gemcitabine or vinorelbine
89650069|NCT05129514|Experimental|Manual Lymphatic Drainage (MLD)|
89650070|NCT00761007|Experimental|Ibodutant 10 mg|
89650071|NCT00761007|Experimental|Ibodutant 30 mg|
88993198|NCT03755375|Active Comparator|Conventional Group|Conventional group was treated with biofeedback for pelvic floor relaxation and manual therapy to release the tension in the suprapubic, pelvic, and intravaginal areas. The manual therapy consisted of a myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas. Biofeedback consisted of pelvic floor muscle coordination and relaxation exercises using intravaginal probes. The training program was initiated with 10 fast contractions with 5 seconds of relaxation between them followed by 10 sustained contractions of 5 seconds with 10 seconds of relaxation between them. Finally, one minute of pelvic floor relaxation was performed.
88993199|NCT03740282|Experimental|Lapiplasty|All study participants receiving Lapiplasty procedure
88993200|NCT03739645|Experimental|Eye position and tense arousal over time a metrics for sustained attention in conditioned fear.|After conditioning the conditioned stimulus induces autonomic metrics like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after conditioning. Activity across blocks in the conditioning stage demonstrates that the skin conductance can produce a progressive decrease in skin conductance over the conditioning stage of our fear conditioning protocol. The decline is not apparently related to habituation or changes in the skin conducting electrodes or recording system. It does correspond to the decrease in performance of a visual fixation task which is part of the fear conditioning during the conditioning stage; and to an increase in the unpleasant psychologic activation termed tense arousal over the same stage. If both these changes are found he then we may conclude that sustained task related attention is produced during fear conditioning
88993201|NCT03709563|Active Comparator|Oral Nutraceutical Supplement|
88993202|NCT03709563|Placebo Comparator|Placebo|
88993203|NCT03681678||fCO2 Laser Therapy Group|Women treated with the fCO2 laser
88993204|NCT03667781||Patients Interviewed|Patients in cardiology clinic with uncontrolled hypertension despite being on 2 medications
88993205|NCT03667781||Providers Interviewed|Providers in cardiology clinic
89212887|NCT02584361|Active Comparator|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA)
89650072|NCT00761007|Experimental|Ibodutant 60 mg|
89650073|NCT00761007|Placebo Comparator|Placebo|
89650074|NCT00761085|Active Comparator|Methadone-Children|Methadone comparison to standard of care for pain management
89650075|NCT00761085|Active Comparator|Morphine-Children|Morphine standard of Care pain management
89650076|NCT00761085|Active Comparator|Methadone-Adults|Methadone comparison to standard of care for pain management
89650077|NCT00761085|Active Comparator|Morphine-Adults|Morphine standard of Care pain management
89650078|NCT02650128|Experimental|Lithoplasty System|Shockwave Coronary Rx Lithoplasty® System is a lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement
89650079|NCT02145039|Experimental|Haploidentical stem cell transplant|This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
89650080|NCT03806049|Experimental|A: triplet|chemotherapy-free combination of niraprib + bevacizumab + Dostarlimab
89650081|NCT03806049|Experimental|B: Doublet|chemotherapy-free combination of niraparib + bevacizumab
89650082|NCT03806049|Active Comparator|C: standard of care|Standard of care chemotherapy: Carboplatin + paclitaxel
89650083|NCT04397562|Experimental|LVL group|Single subcutaneous administration of levilimab at a dose of 324 mg in combination with standard therapy
89650084|NCT04397562|Placebo Comparator|Placebo group|Single subcutaneous administration of placebo in combination with standard therapy
89650085|NCT02147301|Experimental|DEB-TACE|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
89650086|NCT01362270|Experimental|Verum Acupuncture|Subjects will receive acupuncture using real acupuncture needles.
89650087|NCT01362270|Sham Comparator|Sham acupuncture|Subjects will receive sham acupuncture therapy using the Streitberger needle at the same points and on the same schedule as patients in the treatment group. Streitberger needles are blunt tipped and retract into themselves rather than penetrating the skin.
89650088|NCT04902612|Experimental|HM242-Solution|
89650089|NCT04902612|Active Comparator|Saline|
89650090|NCT02147613|Experimental|High intensity interval training|High intensity interval training - 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
89650091|NCT02147613|Active Comparator|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
89650092|NCT04413006|Experimental|Treatment Arm|Participants who will receive the 6-session Group-Based Virtual Self-Compassion for Chronic Pain treatment
89650093|NCT02147769||Preterm infants monitored with NIRS|All infants enrolled in the study will be monitored with cerebral near-infrared spectroscopy (NIRS monitoring) to measure cerebral oxygenation levels in the first 96 hours of life. Mean arterial blood pressure will simultaneously be monitored.
89650094|NCT04940676|Active Comparator|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
89057970|NCT02278757|Placebo Comparator|Low protein diet (LPD)|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
89650095|NCT04940676|Placebo Comparator|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding of 5 minutes after breakfast and dinner for 7 days
89650096|NCT00089479|Experimental|1|
89650097|NCT00089479|Active Comparator|2|
89650098|NCT05057052|Experimental|Cryoablation in combination with Sintilimab plus regorafenib|
89650099|NCT01463306|Experimental|Open|Pregabalin open label flexible dose
89650100|NCT05055726|Experimental|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|"Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A., is assigned to the patients for radiation-induced oromucositis.~The patients take at home 15 ml (1 tablespoon) of concentrated or diluted (with water) mouthwash 2-3 times a day, but not more than 5 times a day, washing the mouth and throat for 20-30 seconds, according to the Investigator's indications and the local product's SmPC.~In Hungary, the therapy should started with diluted product (15 ml of water + 15 ml of concentrated solution). After that, gargling can be continued with 15 ml (1 tablespoon) of concentrated mouthwash, generally 2-3 times a day, but not more than 5 times a day.~In Poland, the solution is used 2 to 3 times daily; at a single time, it should be used approximately 15 ml of concentrated or diluted mouthwash with a small amount of water and wash the mouth and throat for 20 to 30 seconds."
89650101|NCT04916106|Experimental|One parameter TEA group for 4 weeks|Choose two acupoints,give 25Hz electrical stimulation for 4 weeks.
89650102|NCT04916106|Experimental|Another parameter TEA group for 4 weeks|Choose two acupoints,give 100 Hz electrical stimulation for 4weeks.
89650103|NCT04916106|Experimental|Sham-TEA group for 2 weeks, and the random TEA for the next 2 weeks.|Choose two non-acupoints，give 25Hz and 100Hz electroacupuncture stimulation respectively for the first 2 weeks. Then give supplement TEA treatment as described above for the next 2 weeks.
89650104|NCT00765375|Experimental|Botox and Placebo on each side of face|Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)
89650105|NCT03451591|Active Comparator|Isosorbide Mononitrate XL (ISMN)|Oral Isotard® 25mg XL (Isosorbide Mononitrate) tablets. Oral Isotard® 25mg XL: Day 1-5 / 25mg daily morning dose. Day 6 to week 52 / 50mg daily morning dose. Week 53 / 25mg daily morning dose. Week 54 / NIL dose. Or Oral Isosorbide mononitrate (ISMN) non-XL 20mg tablets: Day 1-5 / 20mg daily evening dose. Day 6 to week 52 / 20mg twice daily morning & evening. Week 53 / 20mg daily morning dose. Week 54 / NIL dose.
89650106|NCT03451591|Active Comparator|Cilostazol|Oral Cilostazol 100mg tablets. Day 1-5 / 50mg daily evening dose. Day 6-10 / 50mg twice daily morning & evening. Day 11-15 / 50mg daily morning dose & 100mg daily evening dose. Day 16 to week 52 / 100mg twice daily morning & evening. Week 53 / 50mg twice daily morning & evening. Week 54 / NIL dose.
89650107|NCT03451591|Active Comparator|ISMN XL and Cilostazol|Oral Isotard® 25 mg XL (ISMN) and oral Cilostazol 100mg tablets. Day 1-5 / ISMN - 25mg daily evening dose / Cilostazol - NIL. Day 6-10 / ISMN - 50mg daily morning dose and Cilostazol - NIL. Day 11-15 / ISMN - 50mg daily morning dose / Cilostazol - 50mg daily evening dose. Day 16-20 / ISMN - 50mg daily morning dose and Cilostazol - 50mg twice daily morning & evening. Day 21-25 / ISMN - 50mg daily morning dose and Cilostazol - twice daily, 50mg morning & 100mg evening dose. Day 26-30 ISMN - 50mg daily morning dose and Cilostazol 100mg - twice daily morning & evening. Day 30 to week 52 / ISMN 50mg morning dose and Cilostazol 100mg - twice daily morning & evening. Week 53 / ISMN 25mg daily morning dose and Cilostazol 50mg twice daily morning & evening. Week 54 / NIL dose
89650108|NCT03451591|Placebo Comparator|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol is administered for the entire duration of the study.
89650109|NCT05744115|Experimental|Ga-68-PSMA-11 PET/CT|Administration of Ga-68-PSMA-11 and acquisition of PET/CT
89650110|NCT01677559|Experimental|Dose Level 0|"MLN8237 20 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
89650111|NCT01677559|Experimental|Dose Level 1|"MLN8237 30 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
89650112|NCT01677559|Experimental|Dose Level 2|"MLN8237 40 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
89650113|NCT01677559|Experimental|Dose Level 3|"MLN8237 50 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
89650114|NCT01677559|Experimental|MTD Expansion Phase|"MLN8237 as determined during the dose escalation phase on Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
89650115|NCT04496232|No Intervention|Normal SDF|Using routine semen processing method
89650116|NCT04496232|Active Comparator|Physiological ICSI (PICSI)|Sperm selection using PICSI dishes for selecting sperm with lower DNA fragmentation index for ICSI
89650117|NCT04496232|Active Comparator|Second ejaculate|Using the second ejaculate as a way of reducing SDF in the semen sample used for ICSI
89650118|NCT05744037|Experimental|CAR-T Cell Infusion|After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
89650119|NCT04409132|Experimental|Triferic AVNU infusion pre-dialyzer|Patients will receive one (1) 6.75 mg Fe dose of Triferic AVNU by continuous infusion over 3 hours into the predialyzer blood line.
89650120|NCT04409132|Experimental|Triferic AVNU for injection at T=0 and T= 3 hours|Patients will receive two (2) doses of Triferic AVNU 3.4 mg IV (2.25 mL) at T=0 and T=3 hours of hemodialysis into the venous drip chamber.
89650121|NCT04409132|Experimental|Triferic AVNU for injection at T=0|Patients will receive one (1) dose of Triferic AVNU 0.08 mg/kg IV, up to 6.75 mg Fe, at T=0 of hemodialysis into the venous drip chamber.
89650122|NCT04409132|Experimental|Triferic AVNU for injection at T=0, T=1.5 and T= 3 hours|Patients will receive three (3) doses of Triferic AVNU 2.25 mg Fe (1.5 mL) at T=0, T=1.5 and T=3.0 hours of hemodialysis into the venous drip chamber.
89650123|NCT05132946|Active Comparator|Group (B): will receive erector spinae plane block.|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
89650124|NCT05132946|No Intervention|• Group (C): will not receive any block.|
89650125|NCT05132712|Experimental|Use of ACE inhibitor|losartan potassium will be administered 25 mg daily
89650126|NCT05132712|Placebo Comparator|placebo group|matched for age and gender
89650127|NCT02149173|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
89650128|NCT04886700|Experimental|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
89650129|NCT04789434|Experimental|PD-1 Inhibitor maintenance|PD-1 Inhibitor Tislelizumab maintenance therapy dose：200mg frequency：1 time for 2 months duration：2 years
89650130|NCT04789434|No Intervention|No intervention|No intervention
89650131|NCT03805503|Experimental|chloroprocaine 1% injectable solution|"Prospective, up-down sequential allocation : first patient receives 50mg intrathecal chloroprocaine 1%.~An effective result will decrease the test dose of chloroprocaine with 2 mg for the next patient in this study.~An ineffective result will increase the test dose of chloroprocaine with 2 mg for the next patient in this study."
89650132|NCT04736082|Experimental|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive the following infant formula: Infant formula manufactured from extensively hydrolyzed proteins and containing pre- and probiotics.
89650133|NCT04736082|Active Comparator|Control Group: Infant Formula with intact protein|Infants will receive the following infant formula: Infant formula manufactured from intact proteins and containing pre- and probiotics.
89650134|NCT04736082|No Intervention|Breast Fed Group|Exclusively breast milk
89650135|NCT01504412|Experimental|DS-5565 Low Dose|DS-5565 10mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
89650136|NCT01504412|Experimental|DS-5565 Middle Dose|DS-5565 20mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
89650137|NCT01504412|Experimental|DS-5565 High Dose|DS-5565 30mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
89650138|NCT01504412|Placebo Comparator|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day.
89650139|NCT01504412|Active Comparator|Pregabalin|Pregabalin capsules 300mg/day administered in 2 doses
89650140|NCT04702464|Experimental|Treatment Administration|"Day 1: Single dose of 100 mg fedratinib~Days 10 to 23, inclusive: Single dose of 400 mg fluconazole on Day 10 and once daily (QD) doses of 200 mg fluconazole on Days 11 to 23, inclusive~Day 18: Single dose of 100 mg fedratinib coadministered with the 200-mg fluconazole dose."
89650141|NCT00784095|Experimental|Preparation and Completion|"Subjects in the first group (treatment) met with the facilitator three times for a period of forty-five minutes to one hour to discuss issues of life completion and preparation. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects discussed issues of heritage and legacy."
89650142|NCT00784095|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
89650143|NCT00784095|No Intervention|True Control|"Subjects in the third group (true control) were exposed to no intervention or attention control."
89650144|NCT04776174|Experimental|standard and telerobotic ultrasound|Included patients will have both ultrasound examination: standard ultraosound (abdominal, cardiac or pulmonary depending on the prescription and telerobotic ultrasound
89650145|NCT01503164|Active Comparator|Positive pressure therapy (PAP)|Positive airway pressure(PAP) therapy is the standard of care for patients with obstructive sleep apnea. During sleep, a mask is worn over the nose and connected to the PAP machine.
89650146|NCT01503164|Sham Comparator|Lifestyle counseling|
89045456|NCT06227078|Active Comparator|Active Kinesiotaping + Physiotherapy|"The application of kinesiotaping for grade 2 osteoarthritis involves the application of an anchor strip at one end of the affected joint, typically with no stretch. Apply the kinesiotape with the desired amount of stretch, usually around 50-80% of its maximum stretch capacity. Direct the tape along the muscle or joint in a specific pattern, such as I, Y, or X depending on the therapeutic goal. Finish with an anchor strip at the opposite end, with no stretch to secure the tape in place.~Physiotherapy:~Apply TENS: Low-frequency TENS (2-10 Hz) that produces a tingling or buzzing sensation without causing discomfort or pain. TENS sessions may last between 20 to 30 minutes per session.~Strengthening exercises:~Quadriceps Sets:~Straight Leg Raises:~Seated Leg Press:~Hamstring Curls:~Calf Raises:~Repeat the exercises for 10 times, 3 sets in a session for 8 weeks."
89045457|NCT06227078|Placebo Comparator|Placebo Kinesiotaping + Physiotherapy|"The application of kinesiotaping for grade 2 osteoarthritis involves the application of an anchor strip at one end of the affected joint, typically with no stretch. Apply the kinesiotape without stretch, Direct the tape along the muscle or joint in a specific pattern, such as I, Y, or X depending on the therapeutic goal. Finish with an anchor strip at the opposite end, with no stretch to secure the tape in place.~Physiotherapy:~Apply TENS: Low-frequency TENS (2-10 Hz) that produces a tingling or buzzing sensation without causing discomfort or pain. TENS sessions may last between 20 to 30 minutes per session.~Strengthening exercises:~Quadriceps Sets:~Straight Leg Raises:~Seated Leg Press:~Hamstring Curls:~Calf Raises:~Repeat the exercises for 10 times, 3 sets in a session for 8 weeks."
89045458|NCT06227065|Experimental|Epirubicin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Epirubicin.
89045459|NCT06227065|Experimental|Mitomycin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Mitomycin.
89045460|NCT06227065|Experimental|Gemcitabine|Patients in that PDOs show highest response to this drug in-vitro will be treated with Gemcitabine.
89045461|NCT06227065|Experimental|Docetaxel|Patients in that PDOs show highest response to this drug in-vitro will be treated with Docetaxel.
89045462|NCT06227052|Placebo Comparator|Natures Tears|This is the placebo arm. Participants in this arm will receive Natures Tears spray during their gynecologic procedure. They will receive the spray on their cervix right before the paracervical block. Natures Tears is normal saline, which is sprayed from a canister similar to the Num vapocoolant.
89045463|NCT06227052|Experimental|Num Vapocoolant Spray|This is the intervention arm.
89650147|NCT03805425|Experimental|Photorefractive intrastromal corneal crosslinking (PiXL)|Patients undergo PiXL where the UVA light is delivered in customized patterns and corneal changes are achieved. For hyperopia, a ring shape irradiation is used to steepen the central cornea. An oxygen mask is used to enhance the crosslinking efficacy. A dedicated riboflavin formulation penetrates the corneal stroma. Pulsed UVA light with oxygen triggers the covalent bonds of collagen strands in riboflavin soaked cornea.
89650148|NCT04719858|Experimental|Intervention|Intervention group that will install the #LIFEGOALS app.
89650149|NCT04719858|No Intervention|Control|Control group that will not receive any intervention.
89650150|NCT00088465|Experimental|Intramuscular Olanzapine Depot|Intramuscular (IM) olanzapine depot flexible dosing and flexible interval
89650151|NCT05094180|Other|Face-to-face consultation|
89650152|NCT05094180|Active Comparator|Teleconsultation|
89650153|NCT05094180|Active Comparator|Video consultation|
89650154|NCT04086446|Active Comparator|active tDCS|Cathode transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
89650155|NCT04086446|Sham Comparator|sham tDCS|The sham transcranial direct current stimulation over the right OFC will be applied once a day, 5 days a week, for 2 weeks.
89650156|NCT03805347|Experimental|Medication|Extract of Helminthostachys zeylanica(L.)Hook in capsule, 1gm/time, 3 times daily
89650157|NCT03805347|Placebo Comparator|Starch|Starch in capsule，1gm/time, 3 times daily
89650158|NCT04653636||Adhesive capsulitis|Patients presenting to the physical medicine and rehabilitation department [tertiary care] of Cochin Hospital with a clinically diagnosis of severe adhesive capsulitis for whom first-line medical treatment is not effective.
89650159|NCT03804957|Active Comparator|CT-guided core needle biopsy (CNB)|18 gauge ct-guided lung biopsy
89650160|NCT03804957|Experimental|CNB followed by ABPI.|17 gauge coaxial needle for a 18g ct-guided lung biopsy followed by autologous blood patch injection
89650161|NCT00784641|Experimental|Novel Bausch & Lomb Contact Lens|Novel Bausch & Lomb daily disposable contact lenses
89650162|NCT00784641|Active Comparator|SofLens|Bausch & Lomb SofLens daily disposable contact lenses
89650163|NCT00784641|Active Comparator|Acuvue|Johnson and Johnson 1-Day Acuvue Moist contact lenses
89650164|NCT04560738|Experimental|Administration of [14C]-CC-92480|[14C]-CC-92480 will be administered as an oral solution. A single oral dose of [14C]-CC-92480, containing approximately 2 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
89650165|NCT04550208||Healthy basketball or volleyball players|Basketball and volleyball players Landing biomechanics of different landing tasks is investigated in a population of volleyball and basketball players
89650166|NCT00793611|Active Comparator|Behavioral therapy|"Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)"
89650167|NCT00793611|Experimental|hypnotherapy|patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder
89650168|NCT04405674|Experimental|Tislelizumab plus chemotherapy|Tislelizumab plus Carboplatin/Nab-paclitaxel as induction treatment and followed by Tislelizumab plus pemetrexed as maintenance treatment.
89650169|NCT04405674|Experimental|Tislelizumab plus chemotherapy plus Bevacizumab|Tislelizumab plus Nab-paclitaxel and Bevacizumab as induction treatment and followed by Tislelizumab plus Bevacizumab as maintenance treatment.
89650170|NCT00088153|Experimental|Physiologic estrogen replacement|"Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month).~Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study"
89650171|NCT00088153|Placebo Comparator|Placebo|Placebo patches or pills
89650172|NCT04478682|Experimental|WhatsApp Messaging Application|Continuous breastfeeding support will be provided for the first 6 months through WhatsApp messaging application. Mothers will be contacted once a week through WhatsApp and feedback will be received on the breastfeeding process. The questions of the mother regarding breastfeeding will be answered by text / voice message or video call.
89650173|NCT04478682|No Intervention|Standard breastfeeding support|She will receive standard breastfeeding support after delivery. Breastfeeding will not receive continuous breastfeeding support for the first 6 months after discharge.
89650174|NCT04470960|Experimental|participating community centers|Training course for the community center health coordinators Professional guidance for the CC health coordinators
89650175|NCT02074358|Experimental|Treatment A: Apixaban + Placebo (Saline solution)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by Saline solution (placebo) 0 IU/kg infusion for 30 min Intravenously
89650176|NCT02074358|Experimental|Treatment B: Apixaban + Cofact (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
89650177|NCT02074358|Experimental|Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
89650178|NCT04405518|Active Comparator|Control group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.~Formula: 8mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
89650179|NCT04405518|Experimental|intervention group|"The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy.~Formula: 11mm - A10FIBTEM registered in mm) x 1.1 = fibrinogen dose required"
89650180|NCT05743725|Active Comparator|A: Dexmedetomidine|Brain tumor excision under general anesthesia. This group will receive dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery.
89650181|NCT05743725|Active Comparator|B: Magnesium sulphate|Brain tumor excision under general anesthesia. This group will receive a 2 gm magnesium infusion for 30 minutes.
89650182|NCT04912518|Active Comparator|Dexmedetomidine (DEX) group|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
89650183|NCT04912518|Placebo Comparator|Placebo (Saline) group|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX group.
89650184|NCT04094558|Active Comparator|IBS-D|Participant diagnosed with Irritable Bowel Syndrome, diarrhea predominant, confirmed by study doctors using Rome IV criteria.
89650185|NCT04094558|Active Comparator|IBS-C|Participant diagnosed with Irritable Bowel Syndrome, constipation predominant, confirmed by study doctors using Rome IV criteria.
89650186|NCT04094558|Active Comparator|Healthy Control|Participant with no ongoing medical conditions affecting GI health.
89650187|NCT05153460||Single Arm Study (Cohort)|"All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simulataneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device)."
89650188|NCT01502228|Experimental|62Cu-ETS PET assessment|CT scan for attenuation correction; 15O-water administered by intravenous injection and 6-minute dynamic PET imaging; 62Cu-ETS administered by intravenous injection; Dynamic PET acquisition for 6-minutes; Whole-body PET acquisition from 6-20 minutes post-62Cu-ETS injection
89650189|NCT05011812|Experimental|Part 1, Treatment A|Dose level 1 of PBI-0451
89650190|NCT05011812|Experimental|Part 1, Treatment B|Dose level 2 of PBI-0451
89650191|NCT05011812|Experimental|Part 1, Treatment C|Dose level 3 of PBI-0451
89650192|NCT05011812|Experimental|Part 1, Treatment D|Dose level 4 of PBI-0451
89650193|NCT05011812|Experimental|Part 2, Treatment E|PBI-0451 =/< Dose level 1
89650194|NCT05011812|Experimental|Part 2, Treatment F|PBI-0451 =/< Dose level 2
89650195|NCT05011812|Experimental|Part 2, Treatment G|PBI-0451 =/< Dose level 3
89650196|NCT05011812|Experimental|Part 2, Treatment H|PBI-0451 =/< Dose level 4
89650197|NCT05011812|Experimental|Part 3, Treatment J|PBI-0451 + ritonavir (a CYP450 3A inhibitor)
89650198|NCT05011812|Experimental|Part 3, Treatment K|PBI-0451 + ritonavir
89650199|NCT05011812|Experimental|Part 3, Treatment L|"PBI-0451 dose TBD~+ midazolam (a sensitive CYP450 3A substrate)"
89650200|NCT05011812|Experimental|Part 1, Treatment M|Dose level 2 of PBI-0451 with food
89650201|NCT05011812|Experimental|Part 2, Treatment I|PBI-0451 =/< Dose level 5
89650202|NCT05011812|Experimental|Part 1, Treatment N|Dose Level 5 of PBI-0451
89650203|NCT05535231|Experimental|Turmeric test product|Turmeric
89650204|NCT05535231|Active Comparator|Turmeric comparator|Turmeric
89650205|NCT01502072|Experimental|Inhaled Ribavirin|Group 1: Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.
89650206|NCT01502072|Experimental|Oral Ribavirin|Group 2: Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.
89650207|NCT01502072|No Intervention|No Ribavirin|Group 3: No Ribavirin treatment.
89650208|NCT04662450|Experimental|Affective pain stimuli group|affective/neutral word pairs
89650209|NCT04662450|Experimental|Sensory pain stimuli group|sensory/neutral word pairs
89650210|NCT04662450|Placebo Comparator|Control group|affective/neutral and sensory/neutral word pairs
89688596|NCT04378595||Post-Pandemic|Post-Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. The investigators will assess if food insecurity has stopped or lessened after the pandemic.
89650211|NCT01462370|Experimental|Etoricoxib+placebo ibuprofen then placebo etorcoxib+ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
89650212|NCT01462370|Experimental|Ibuprofen+placebo etoricoxib then etoricoxib+placebo ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
89650213|NCT03804489|Experimental|Decision aids group|Shared decision making using decision aids,
89650214|NCT03804489|No Intervention|Control group|Standard oral explanation with booklet.
89650215|NCT05743257||Experimental group|Volunteers living in a deprived neighborhood with urban transformations in Paris (France)
89650216|NCT05743257||Control group|Volunteers living in a deprived neighborhood without urban transformations in Paris (France).
89650217|NCT03804567|Experimental|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
89650218|NCT03804567|Active Comparator|Routine low back pain management|Normal accepted physiotherapy treatment for persistent low back pain.
89650219|NCT01479764|Experimental|Sugammadex|Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
89650220|NCT01479764|Active Comparator|Neostigmine/glycopyrrolate|Participants receive neostigmine/glycopyrrolate per usual practice
89650221|NCT04383405|Experimental|Sequential Preparotory Approach|
89650222|NCT04383405|Active Comparator|Conventional|
89650223|NCT01479530|Placebo Comparator|Placebo|
89650224|NCT01479530|Experimental|Azilect®|
89650225|NCT04383483||CoVID patients admitted to ICU|Patients admitted to the intensive care unit with the diagnosis of COVID
89650226|NCT04383561|Active Comparator|stage 3 periodontitis|GCF and serum samples were collected before and after treatment from periodontitis patients.
89650227|NCT04383561|Placebo Comparator|Periodontally healthy controls|GCF and serum samples were collected from periodontally healthy controls at baseline for once.
89650228|NCT01479374|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop to each eye, 3 nonconsecutive days
89650229|NCT01479374|Placebo Comparator|Vehicle|AL-4943A vehicle, 1 drop to each eye, 3 nonconsecutive days
89650230|NCT01479374|Active Comparator|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop to each eye, 3 nonconsecutive days
89650231|NCT00087529|Experimental|1|
89650232|NCT00087529|Placebo Comparator|2|
89650233|NCT00794313|Experimental|Amantadine|
89650234|NCT00794313|Experimental|Amantadine plus Topiramate|
89650235|NCT00794313|Placebo Comparator|Sugar Pill|
89650236|NCT00794469||Water|obese children (body mass index > 95th percentile for age and sex) that will drink cold water
89650237|NCT05743101|Experimental|Levofloxacin group|Levofloxacin 200mg twice per day is administrated.
89650238|NCT05743101|Placebo Comparator|Levofloxacin simulant group|Levofloxacin simulant 200mg twice per day is administrated.
89650239|NCT01500434|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
89650240|NCT00087139|Experimental|Arm I|"Patients are stratified according to prior chemotherapy (none vs 1 prior taxane-containing regimen vs 2 prior cytotoxic regimens).~Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89650241|NCT00794547|Experimental|1|In the Phase I part of the study, we will test the safety of calcitriol along with standard chemotherapy. In addition, the goal is to see what effects (good and bad) it has on you and your type of Non-Small Cell Lung Cancer. This study is ongoing. In this portion of the study, we are testing increasing doses of calcitriol in combination with standard chemotherapy. If 2/3 patients at any dose level experience side effects that are limiting, we will call the dose level below that dose the maximum tolerated dose.
89650242|NCT00794547|Experimental|2|In the Phase II part of the study, we will find out the response of subjects' cancer has to the combination of a fixed dose of calcitriol (determined in the phase I study) with standard chemotherapy.
89650243|NCT03804645|Experimental|Cohort 1|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
89650244|NCT03804645|Experimental|Cohort 2|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
89650245|NCT03804645|Experimental|Cohort 3|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
89650246|NCT03804645|Experimental|Cohort 4|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
89650247|NCT03804645|Experimental|Cohort 5|In Part B, each subject will receive one formulation from Part A chosen for further development, dose under fed conditions, followed by dose under fasted condition.
89650248|NCT00786825|Experimental|somatostatin|Type 1 diabetes and Hypoglycemia unawareness
89650249|NCT00786825|No Intervention|2|Healthy control subjects
89650250|NCT03492229|Experimental|tDCS+AMT|TDCS in combination with movement training before treadmill training
89650251|NCT03492229|Active Comparator|tDCS|tDCS only before treadmill training
89650252|NCT03492229|Active Comparator|AMT|Movement training only before treadmill training
89650253|NCT03492229|Sham Comparator|Control|No priming before treadmill training
89650254|NCT05743023|Experimental|Consciousness-based Ayurvedic lifestyle Intervention|In the intervention group, each participant will receive a structured education and be asked to follow a 12-week personalized diet and daily routine protocol based on the assessment of their current Ayurvedic mind-body state. Participants will be asked to complete the self-reported questionnaires at baseline, 6, and 12-week.
89521724|NCT03414073|Active Comparator|Group A Phase 2|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group A will use the knotted floss technique in the second phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
89650255|NCT05743023|Active Comparator|Waitlist control|Participants in the waitlist control group will not receive any intervention. They will continue usual care and will be asked to complete the self-reported questionnaires at baseline, 6, and 12-week. Participants n this group receive their personalized protocol at the end of 12 weeks after completing all the data collection.
89650256|NCT04348513|Experimental|T3 solution for injection|T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).
89650257|NCT04348513|Placebo Comparator|Placebo|Composition identical apart from the active substance. Same dosage.
89650258|NCT04402255|Experimental|behcet group|this group includes 16 patients with behçet
89650259|NCT04402255|Experimental|fmf group|this group includes 16 patients with fmf
89650260|NCT04402255|Active Comparator|healty control|this group includes 16 healthy control
89650261|NCT00768261|No Intervention|Very Mild to Mild DAT Untreated|Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine
89650262|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/ Donepezil|Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with Donepezil (Aricept®).
89650263|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/Combination|Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of Donepezil (Aricept®) and Memantine (Namenda®)
89650264|NCT00768261|No Intervention|Nondemented Comparison Subjects|Group 4) nondemented comparison subjects.
89650265|NCT05346991|Experimental|Intervention arm|Implementation of the Tobacco-Free Teachers, Tobacco Free Society program in government schools in Bihar, India
89650266|NCT05346991|No Intervention|Control arm|Delayed intervention - control arm schools receive the program after all data collection is complete
89650267|NCT01677715|Active Comparator|"Yili Mei Yi Tian lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
89650268|NCT01677715|Placebo Comparator|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
89650269|NCT04279275||Survey|Knowledge survey
89650270|NCT05742867||Cohort 1|High-risk Muscle-Invasive Bladder Cancer (MIBC) participants following radical cystectomy
89650271|NCT03804723|Experimental|GC withdrawal|
89650272|NCT03804723|Placebo Comparator|non GC withdrawal|
89650273|NCT03804411|Experimental|Treatment chosen by automated decision-making system|Group A: type 2 diabetic patients randomized to receive antidiabetic drugs according to predictors chosen with developed automated decision-making system: subgroup 1A- addition of vildagliptin 100 mg/day, subgroup 2A - addition of sitagliptin 100 mg/day, subgroup 3A- addition of dapagliflozin 10 mg/day, subgroup 4A- addition of empagliflozin 10 mg/day, subgroup 5A- addition of liraglutide 1,2-1,8 mg/day, subgroup 6A- addition of exenatide 20 μg/day, subgroup 7A - addition of glimepiride, subgroup 8A - addition of gliclazide.
89650274|NCT03804411|Experimental|Treatment based on standard recommendations|Group B: type 2 diabetic patients randomized to receive antidiabetic drugs according to standard recommendations : subgroup 1B- addition of vildagliptin 100 mg/day, subgroup 2B - addition of sitagliptin 100 mg/day, subgroup 3B- addition of dapagliflozin 10 mg/day, subgroup 4B- addition of empagliflozin 10 mg/day, subgroup 5B- addition of liraglutide 1,2-1,8 mg/day, subgroup 6B- addition of exenatide 20 μg/day, subgroup 7B - addition of glimepiride, subgroup 8B - addition of gliclazide.
89650275|NCT00797277|Experimental|IM olanzapine|Patients of this arm received 10 mg IM olanzapine after randomization
89650276|NCT00797277|Active Comparator|IM haloperidol plus lorazepam|Patients of this arm received 5 mg IM haloperidol plus 2 mg IM lorazepam after randomization
89650277|NCT03837015|Active Comparator|Estring alone|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.
89650278|NCT03837015|Active Comparator|Estring and vaginal RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will also be instructed to insert one RepHresh Pro-B capsule vaginally twice daily, morning and night, until day 30
89650279|NCT03837015|Active Comparator|Estring and oral RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will be instructed to take one RepHresh Pro-B capsule orally twice daily until day 30.
89650280|NCT03837015|Active Comparator|Vaginal RepHresh Pro-B|Participants will be given a 30 days supply of RepHresh Pro-B and instructed to insert one capsule vaginally twice daily until day 30.
89650281|NCT03830853||Successful CTO PCI achieved|Patients will have successful CTO PCI (chronic total occlusion percutaneous coronary intervention) followed by physiological and intracoronary imaging. These measurements will be repeated at a 3 month follow up angiogram procedure.
89650282|NCT03804333|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
89650283|NCT03804333|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
89650284|NCT01500278|Active Comparator|Certolizumab Pegol + Methotrexate (CZP + MTX)|
89650285|NCT01500278|Active Comparator|Adalimumab + Methotrexate (ADA + MTX)|
89650286|NCT01500278|Active Comparator|CZP + MTX followed by ADA + MTX|Those subjects who received Certolizumab Pegol (400 mg at Weeks 0, 2, 4 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) at Baseline and are Non-Responders at Week 12, switch to Adalimumab (40 mg) + Methotrexate (ADA + MTX) after Week 12.
89650287|NCT01500278|Active Comparator|ADA + MTX followed by CZP + MTX|Those subjects who received Adalimumab (40 mg + Placebo at Weeks 0, 2, 4 followed by 40 mg ADA every two weeks) + Methotrexate (ADA+ MTX) at Baseline and are Non-Responders at Week 12, switch to Certolizumab Pegol (400 mg at Weeks 12, 14, 16 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) after Week 12.
89650288|NCT00086281|Experimental|1|Xyrem 9 grams given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later
89650289|NCT00086281|Active Comparator|2|Zolpidem 10 mg + placebo were given at bedtime and placebo given 2.5 to 4 hours later.
89650290|NCT00086281|Experimental|3|Xyrem 9 g + modafinil 200 mg (Xyrem 9 g was given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later; modafinil was given at 8 am on the morning of Xyrem treatment).
89650291|NCT00086281|Placebo Comparator|4|Placebo was given at bedtime and again 2.5 to 4 hours later.
89650292|NCT00086047|Experimental|Coping Skills|Patients will receive 8 weeks of behavioral training in pain coping strategies
89650293|NCT00086047|Active Comparator|Education|Patient will receive 8 weekly sessions of education about fibromyalgia syndrome.
89650294|NCT00787761|Experimental|ATG, Cytoxan, Bu/Flu based Allogeneic Transplant|All patients will receive an ATG, Cyclosphosphamide, Busulfan and Fludarabine based Allogeneic Transplant
89650295|NCT01478828|Experimental|Lovastatin|After informed consent and central pathology review of the core prostate biopsy, eligible patients who decide to undergo prostatectomy at Johns Hopkins will be scheduled to receive po lovastatin following a four times a day schedule, at the starting dose of 20 mg/kg/day. Following an initial period of monitoring for safety at this entry dose level of one month, we will then accrue patients to dose de-escalation (to 1, and 10 mg/kg/day) cohorts.
89650296|NCT00085423|Experimental|IL-2, CTX, fludarabine, GM-CSF|Aldesleukin (IL-2), cyclophosphamide, fludarabine phosphate, sargramostim
89650297|NCT04079192|Experimental|Biolimus A9™ Drug Coated Balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Biolimus A9™ Drug Coated Balloon
89650298|NCT04079192|Active Comparator|Sequent ® Please Paclitaxel coated balloon|Patients who meet the eligibility criteria and who are randomised to this arm, will receive treatment with the Sequent ® Please Paclitaxel coated balloon
89650299|NCT05742555|Experimental|Experimental Group|
89650300|NCT05742555|No Intervention|Control Group|
89650301|NCT01677793||Child and adolescent population|
89650302|NCT03087877|Other|CGM Users|Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.
89650303|NCT01677871|Experimental|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
89650304|NCT01677871|Active Comparator|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
89650305|NCT01677871|Experimental|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
89650306|NCT01677871|Active Comparator|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
89650307|NCT03447379|Experimental|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
89650308|NCT03447379|Active Comparator|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
89650309|NCT03837093|Experimental|dose A|ILT-101
89650310|NCT03837093|Experimental|dose B|ILT-101
89650311|NCT03837093|Experimental|dose C|ILT-101
89650312|NCT03837093|Experimental|dose D|ILT-101
89650313|NCT03837093|Experimental|dose E|ILT-101
89650314|NCT03837093|Experimental|Placebo|
89650315|NCT00084487|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89650316|NCT03087565|Active Comparator|subtotal hystrectomy|"Careful examination under anesthesia. Catheterization by N. 18 Foley's catheter . A transverse lower abdominal incision (Pfannenstiel incision) . the corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination ."
89650317|NCT03087565|Active Comparator|Total hyterectomy|examination under anesthesia. Catheterization by N. 18 Foley's catheter A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Blunt dissection is done . Sharp dissection using Metzenbaum scissors is performed in patients with previous cesarean sections Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination .
89650318|NCT05740449|Experimental|sub-study A - Epigenetic approach|"Decitabine / Venetoclax and Navitoclax.~Each cycle lasts 28 days.~Cycle 1: Decitabine is given 10 mg/m2 intravenous, once a day on 5 consecutive days (Day 1 - 5), venetoclax 400 mg adult equivalent dose, once a day, Day 1 - Day 28 orally, with a ramp-up dose on day 1 and navitoclax once a day, Day 3 - 28 orally depending on the weight of the patient (dose level 1).~Cycle 2: Decitabine is given 10 mg/m2 intravenous, once a day on 5 consecutive days (Day 1 - 5), venetoclax 400 mg adult equivalent dose, once a day, Day 1 - Day 28 orally and navitoclax once a day, Day 1 - 28 orally depending on the weight of the patient (dose level 1).~Patients in dose level 2: will receive decitabine 20 mg/m2 intravenous once a day on 5 consecutive days (Day 1 - 5).~Patients in dose level -1: will receive venetoclax 200 mg adult equivalent dose, once a day, Day 1 - Day 28 orally.~All patients receive age adapted intrathecal chemnotherapy."
89650319|NCT03087799|Experimental|Brief Behavioral Treatment for Sleep|
89650320|NCT03087799|No Intervention|Wait List Control|
89650321|NCT01677949|Experimental|ALL patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute lymphoblastic leukemia (ALL) along with Clofarabine, Etoposide and Cyclophosphamide.
89212888|NCT02584283|Experimental|Dual hypothermic oxygenated perfusion|The liver is procured with a segment of supratruncal aorta. The intervention is restricted to the liver graft after arrival in the transplant center and before implantation. The donor liver is subjected to 2 hours of hypothermic oxygenated perfusion via the portal vein and the supratruncal aorta applied by the Liver Assist®. Before perfusion, the liver is flushed via the portal vein with 1 L Belzer machine perfusion solution. The perfusion is pressure controlled and set to a mean of 25 mmHg (arterial) and 5 mm Hg (portal). The perfusion fluid is 4 L Belzer machine perfusion solution with additional 3 mmol/L glutathione. The perfusion fluid is 12°C, when the temperature is set at 10°C. The oxygen flow is set at 0.5 mL/min of 100% oxygen on each of the two membrane oxygenators.
89212889|NCT02584283|No Intervention|Care as usual|The donor liver is procured with a segment of 5 cm circular supratruncal aorta left attached to the coeliac trunc. The patients randomized to the control group will receive a liver graft preserved by conventional SCS without any further intervention.
89212890|NCT04080401|Experimental|Fun-Knee Mobile Application|Participants will use a mobile application paired to a knee sleeve with embedded inclinometer sensors. The sensor system will compute knee movement, and feed towards game-based rehabilitation exercises for Total Knee Arthroplasty rehabilitation. game-based and supported on mobile device running on Android or Inter-network Operating System platforms. The mobile apps is able to capture the angle and position data from the two inclinometers on smart knee sleeve.
89212891|NCT04080401|Active Comparator|Conventional Exercise Brochures|Participants will be guided to do their Total Knee Arthroplasty rehabilitation exercises using conventional, paper-based exercise brochures.
89650322|NCT01677949|Experimental|AML patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute myeloid leukemia (AML) along with Clofarabine, Etoposide and Cyclophosphamide.
89650323|NCT05738889||Group 1: Patients with fixed lingual retainers applied with Bis-GMA containing composite|In the maxilla and mandible, the lingual surfaces of the anterior six teeth, including the canines, were roughened and bonded by applying 37.5% phosphoric acid for 30 seconds. Then, the retainer wire was adhered to the lingual surfaces of the teeth between the canine-canines in the maxilla and mandible, where a fixed lingual retainer will be applied, with a flowable composite adhesive containing Bis-GMA, with 10 seconds of illumination for 60 seconds for each tooth.
89650324|NCT05738889||Group 2: Patients with fixed lingual retainers applied with Bis-GMA-free composite|The lingual surfaces of the anterior six teeth, including the canines, in the maxilla and mandible were roughened by the application of 37.5% phosphoric acid for 30 seconds. Since the applied composite system is one-stage, no additional bond application was done. Fixed lingual retainer wire was applied with a Bis-GMA-free flowable composite adhesive with 60 seconds exposure for 10 seconds for each tooth.
89650325|NCT05738889||Group 3: Patients with vacuum-formed retainers|Impressions were taken with alginate impression material from the maxilla and mandible of the volunteers whose treatment was completed, and a model was obtained with a hard cast. On the models obtained, vacuum formed retainers were prepared with a vacuum forming machine. The use and care instructions of vacuum formed retainers were explained to the patient orally. vacuum formed retainers were used by the patient for 22 hours.
89650326|NCT05738889||Group 4: Patients with hawley retainers|Impressions were taken with alginate impression material from the volunteers in the Hawley retainers group and a model was obtained with hard plaster. Wire elements were made on the model obtained and the appliance was prepared from transparent acrylic material. After the leveling and polishing processes were completed, the hawley retainers was attached to the mouth. It is stated that the appliance is used for 22 hours in 1 day. The use and care instructions of the Hawley retainers are explained to the patient.
89650327|NCT03087331|Experimental|Pharmacist intervention|Within the pharmacist intervention arm, pharmacists will do medication reviews, assessment, recommendations, education.
89650328|NCT05349669|No Intervention|Conventional CPB|Elective cardiopulmonary bypass (CPB) procedures with an expected time >120 minutes for each extracorporeal procedure.
89650329|NCT05349669|Experimental|CPB with Jafron|Elective cardiopulmonary bypass (CPB) procedures with Jafron use with an expected time >120 minutes for each extracorporealprocedure.
89650330|NCT03483883|Experimental|Single Arm|
89650331|NCT05737875||Distal pancreatectomy|Patients who have undergone a distal pancreatectomy, retrospective analysis of post pancreatectomy fistula risk factors
89650332|NCT04384185|Experimental|Group A: Exercise therapy|Group A: will perform an exercise protocol to improve the stability of the spine muscle of low-back
89650333|NCT04384185|Experimental|Group B. Manual therapy and exercises|Group B: Will be treated with manual therapy in the diaphragm muscle and the same protocol of therapeutic exercise applied in group A
89650334|NCT00799227|Experimental|700 µg Dexamethasone Implant|700 µg dexamethasone implant in the study eye at Day 1
89650335|NCT03439423||Patients who underwent EVAR|
89212892|NCT04634669|Experimental|AXS-05 (dextromethorphan-bupropion)|
89650336|NCT03439267|Active Comparator|Proactive Current National Guidelines Group|Standard Interventional Control Group. Will receive treatment recommendation according to the current National guidelines for statin initiation and follow-up.
89650337|NCT03439267|Experimental|Proactive CAC Group|Investigational Interventional Group. Will undergo coronary artery calcium screening and will receive statin recommendation based on the cardiovascular risk algorithm.
89650338|NCT05737017|Experimental|The ClearCoajet group|During the endoscopic resection procedures, the ClearCoajet will be used for injection and initial hemostasis for intraprocedural bleeding.
89650339|NCT05737017|Active Comparator|The control group|During the endoscopic resection procedures, the conventional injector will be used for injection.
89650340|NCT03087097|Experimental|Fecal Microbiota Transplant|FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
89650341|NCT03087097|No Intervention|Standard of Care|Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines
89212893|NCT02585531|Experimental|HS3% group|Administration of nebulized hypertonic saline for 4 days. Hypertonic Saline 3% 3 ml.
89212894|NCT02585531|Active Comparator|ED group|Administration of nebulized epinephrine and dexamethasone for 4 days. Epinephrine 1:1000 solution. Dexamethasone solution 8mg/2ml.
89650342|NCT00770133|Experimental|Ketotifen/naphazoline|Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
89212895|NCT04572503|Experimental|Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty In Management of Mild and Moderate Obstructive Sleep Apnea Syndromea using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
89212896|NCT00920153|Experimental|Group 1 (favorable prognosis)|Patients receive ABVD and VABEM chemotherapy.
89212897|NCT00920153|Experimental|Group 2 (intermediate prognosis)|Patients receive ABVD and VABEM chemotherapy.
89650343|NCT00770133|Placebo Comparator|Vehicle|Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
89650344|NCT00770133|Active Comparator|Naphazoline|Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
89650345|NCT00770133|Active Comparator|Ketotifen|Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
89650346|NCT05317065|Experimental|Mindfullness Based Stress Reduction|Mindfullness Based Stress Reduction (MBSR) therapy
89650347|NCT05317065|No Intervention|Control|Control
89650348|NCT03836547|Experimental|Multicomponent Intervention for weight loss|12-week intervention that consists of Weight Watcher on-line program, Garmin Fitness Tracker, blue-tooth scale, and telephonic health coaching.
89650349|NCT03836547|Active Comparator|Wait-list Control|The participant will receive usual care for 12 weeks and then will compassionately be offered the active intervention.
89650350|NCT00800865|Other|Biomarker Evaluation Group I|Biomarker evaluation before and after dosing with cytotoxic agent(s)
89650351|NCT00800865|Other|Biomarker Evaluation Group II|Biomarker evaluation before and after dosing with cytotoxic agent(s)
89650352|NCT00770757|Experimental|CC-4047 Arm|CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).
89650353|NCT03803319|Active Comparator|Fibre 1 (combined fibres)|Ingestion of 150mls water with 7.5g fibre (two times a day)
89650354|NCT03803319|Active Comparator|Fibre 2 (natural fibres)|Ingestion of 150mls water with 15g fibre (two times a day)
89650355|NCT03803319|Placebo Comparator|Dietary Supplement (placebo)|Ingestion of 150mls water with 7.5g (two times a day)
89650356|NCT01425281|Active Comparator|XIENCE™|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
89650357|NCT01425281|Experimental|ABSORB BVS™|Experimental: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
89650358|NCT00789867|Experimental|20ml pGM169/GL67A|Received a nebulized dose 20ml via an breath-actuated nebulizer
89650359|NCT00789867|Experimental|10ml pGM169/GL67A|Received a nebulized dose 10ml via an breath-actuated nebulizer
89650360|NCT00789867|Experimental|5ml pGM169/GL67A|Received a nebulized dose 5ml via an breath-actuated nebulizer
89212898|NCT00920153|Experimental|Group 3 (poor prognosis)|Patients receive VABEM, CEO, BEAM, and MINE chemotherapy. Patients also undergo allogeneic or autologous stem cell transplantation.
89212899|NCT04080713|Experimental|Budesonide|
89212900|NCT04080557||AAA patients that went to the ICU postoperatively|An retrospective cohort study was conducted that included all patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
89212901|NCT02585453|Experimental|Patients with dry eye syndrome 1|20 Patients with dry eye syndrome
89212902|NCT02585453|Active Comparator|Patients with dry eye syndrome 2|20 Patients with dry eye syndrome
89212903|NCT02585453|Active Comparator|Patients with dry eye syndrome 3|20 Patients with dry eye syndrome
89212904|NCT02586701|Active Comparator|Prehabilitation Plus|Patients in this group will be enrolled in a multimodal program before surgery involving supervised exercise, nutrition counseling and relaxation strategies. Supervised exercise is provided once a week for four weeks before surgery as well as during the hospital stay post surgery. Patients are to continue with a home-based exercise program for 8 weeks after discharge.
89650361|NCT04384653|Experimental|Treatment A|Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 1 and IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 2
89650362|NCT04384653|Experimental|Treatment B|IV Furosemide Injection, USP (80 mg) by IV bolus for Treatment Period 1 and Furosemide Injection Solution for subcutaneous administration (80 mg) over 5 hours for Treatment Period 2
89650363|NCT02648724|Experimental|Part 1: 6 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 6 mg/kg. A substitute or an additional dose level could potentially be evaluated.
89650364|NCT02648724|Experimental|Part 1: 12 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 12 mg/kg. A substitute or an additional dose level could potentially be evaluated.
89650365|NCT02648724|Experimental|Part 1: 18 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 18 mg/kg. A substitute or an additional dose level could potentially be evaluated.
89650366|NCT02648724|Experimental|Part 1: 24 mg/kg|Sym015 was tested in four dose titration cohorts. Patients in this cohort received 24 mg/kg. A substitute or an additional dose level could potentially be evaluated.
89650367|NCT02648724|Experimental|Part 2: Basket Cohort|Patients with KRAS WT advanced solid tumor malignancies with MET-amplification were to receive Sym015 at the RP2D. Included in this group was a subset of patients who have received prior therapy with a MET-targeting TKI.
89650368|NCT02648724|Experimental|Part 2: NSCLC MET-Amplified Cohort|Patients with advanced NSCLC with MET-amplification were to receive Sym015 at the RP2D. Patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.
89650369|NCT02648724|Experimental|Part 2: NSCLC METex14del Cohort|Patients with advanced NSCLC with METex14del were to receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.
89650370|NCT04199130|Experimental|Intervention Group 1|This arm will receive BrainHQ for the first four weeks of the study, and Goal Management Training for the second four weeks.
89650371|NCT04199130|Experimental|Intervention Group 2|This arm will receive Goal Management Training for the first four weeks of the study, and BrainHQ for the second four weeks.
89650372|NCT04199130|No Intervention|Treatment-as-usual|
89045464|NCT06227039|No Intervention|No treatment|This arm will be the current standard of care
89650373|NCT04487028||Thoracic Surgical Patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
89650374|NCT04113720|Experimental|Group A|children will receive levobupivacaine 0.25% by peritonsillar infiltration after intubation 3- 5 min before the start of surgery.
89650375|NCT04113720|Active Comparator|Group B|children will receive levobupivacaine 0.25% plus dexmedetomidine 1µg/kg diluted in 4 ml saline 0.9% and given by peritonsillar infiltration (2 ml per tonsil), after intubation 3- 5 min before the start of surgery.
89650376|NCT03803241|Experimental|PVE + CD133|preop portal vein embolization + stem cells infusion
89650377|NCT03803241|Sham Comparator|PVE|only preop portal vein embolization
89650378|NCT01402817|Experimental|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
89650379|NCT04449744|Active Comparator|MySafeRx Group A-(coaching + medication dispenser)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
89650380|NCT04449744|Experimental|MySafeRx Group B-(coaching + dispenser based on clinical need)|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a manual lockbox, and a standardized protocol for supervising self-administration of medication via videoconferencing. Participants will be assessed bi-weekly by their clinical team for substance abuse, coaching and medication adherence, compliance with urine drug screen policies, safety/ risk or mental health concerns, and diversion. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study.
89650381|NCT04374084|Experimental|Moxibustion plus Cupping|"Moxibustion plus cupping and basic therapy (rehabilitation direction and basic breathing exercise) once a day for 4 weeks (28 sessions).The moxibustion plus cupping treatments were divided into 2 alternating formulas:~A: Monday, Wednesday, Friday and Sunday: moxibustion on bilateral Fengmen (BL12), Feishu (BL13) and Pishu(BL20) B: Tuesday, Thursday and Saturday: moxibustion on Zhongwan (RN12), Qihai (RN6), bilateral Tianshu(ST25) and Zusanli(ST36) + cupping on bilateral Feishu(BL13) Geshu(BL17) Pishu(BL20) The 2 formulas were used alternatively every other day, 7 times per week, for 4 weeks. Moxibustion acupoint addition: profuse sweating added Fuliu (KI7), insomnia added Shenmen(HT7) anxiety or depression added Neiguan (PC6)."
89650382|NCT04374084|No Intervention|Basic therapy|Basic therapy: rehabilitation direction and basic breathing exercise.
89650383|NCT04142424|Experimental|Cohort 1 healthy subjects: AZD2693 Dose 1|Subjects will receive a subcutaneous (SC) injection of single dose 1 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650384|NCT04142424|Experimental|Cohort 2 healthy subjects: AZD2693 Dose 2|Subjects will receive a SC injection of single dose 2 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650385|NCT04142424|Experimental|Cohort 3 healthy subjects: AZD2693 Dose 3|Subjects will receive a SC injection of single dose 3 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650386|NCT04142424|Experimental|Cohort 4 healthy subjects: AZD2693 Dose 4|Subjects will receive a SC injection of single dose 4 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650387|NCT04142424|Experimental|Cohort 5 healthy subjects: AZD2693 Dose 5|Subjects will receive a SC injection of single dose 5 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650388|NCT04142424|Experimental|Cohort 6 healthy subjects: AZD2693 Dose 6|Subjects will receive a SC injection of single dose 6 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650389|NCT04142424|Experimental|Cohort 7 healthy Japanese subjects: AZD2693 Dose 7|Subjects will receive a SC injection of single dose 7 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650390|NCT04142424|Experimental|Cohort 8 healthy Japanese subjects: AZD2693 Dose 8|Subjects will receive a SC injection of single dose 8 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650391|NCT04142424|Experimental|Cohort 9 healthy Chinese subjects: AZD2693 Dose 9|Subjects will receive a SC injection of single dose 9 of AZD2693 or placebo matched to AZD2693 on Day 1.
89650392|NCT03926910|Experimental|VESAP|patient receiving stimulation test to detect hypovolemia
89650393|NCT01425203|Experimental|RGT BOC + PR|Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
89650394|NCT01425203|Placebo Comparator|PBO + PR (Control)|Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
89650395|NCT01425203|Experimental|Crossover Arm|Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.
89650396|NCT04215120|Active Comparator|Desidustat oral tablet|Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
89650397|NCT04215120|Experimental|Epoetin Injection|Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.
89045465|NCT06227039|Experimental|Vibroacoustic|This arm will use the vibroacoustic device to provide a mechanical stimulus to the patient as treatment to reduce pain and anxiety. Augmented reality glasses will be worn but will be turned off.
89045466|NCT06227039|Experimental|Augmented Reality|This arm will use the augmented reality game to provide a visual stimulus to the patient as treatment to reduce pain and anxiety. Vibroacoustic device will be worn but will be turned off.
89045467|NCT06227039|Experimental|Combination vibroacoustic and augmented reality|This arm will use both the augmented reality game and vibroacoustic device to provide a visual stimulus to the patient as treatment to reduce pain and anxiety.
89212905|NCT02586701|No Intervention|Rehabilitation|Patients in this group are provided with in-hospital supervised exercises with a kinesiologist post surgery until discharge. Patients, upon discharge are provided with a home-based exercise program, nutritional counseling and relaxation strategies for 8 weeks.
89650398|NCT00081289|Experimental|Neoadjuvant chemoradiation with irinotecan|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1200mg/m^2/day 5 days/week during RT, and irinotecan 50 mg/m^2 IV for 1 hour days 1, 8, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
89650399|NCT00081289|Experimental|Neoadjuvant chemoradiation with oxaliplatin|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1650mg/m^2/day 5 days/week during RT, and oxaliplatin 50 mg/m^2 IV for 2 hours days 1, 8, 15, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
89650400|NCT03917160|Experimental|EMS treatment|Subjects will undergo treatment with EMS and measurements
89650401|NCT03917160|No Intervention|Control|Subjects will undergo measurements only
89650402|NCT01478594|Experimental|Tivozanib + mFOLFOX6|Participants received 1.5 mg of tivozanib orally once daily beginning on Day 1 of each cycle for 21 days followed by 7 days off treatment. Participants also received modified FOLFOX6 (mFOLFOX6) chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
89650403|NCT01478594|Active Comparator|Bevacizumab + mFOLFOX6|Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
89650404|NCT01424813|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
89650405|NCT01424813|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
89650406|NCT03815916|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89650407|NCT03815916|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89650408|NCT03815916|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89650409|NCT03815916|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89650410|NCT03859128|Active Comparator|Group A|TORIPALIMAB 240mg ,Q3W, up to 16 cycles
89650411|NCT03859128|Placebo Comparator|Group B|Placebo 240mg Q3W, up to 16 cycles
89650412|NCT03086941|Active Comparator|Group B(blibd)|group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
89650413|NCT03086941|Active Comparator|Group C(control)|group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
89650414|NCT05202522|No Intervention|Control Group|During the study. participants in the control group will not receive the virtual GERAS DANCE intervention. However, they will receive the virtual GERAS DANCE intervention following study completion for equal opportunity to participate in the program.
89650415|NCT05202522|Experimental|Virtual GERAS DANCE Group|Virtual GERAS DANCE will be delivered for 1-hr twice weekly for 6 weeks.
89650416|NCT01678105|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
89650417|NCT03479827||Experimental|Subjects will undergo three Wavefront measurements, once with no contact lens, once with a monofocal contact lens and once with a bifocal contact lens.
89650418|NCT03389022|Active Comparator|Treatment1|0,15 mg/kg (LBM) of intravenous pre-incisional single bolus injection of ketamine given for bariatric patients in the operating room.
89650419|NCT03389022|Active Comparator|Treatment2|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection of ketamine given for bariatric patients in the operating room.
89650420|NCT03389022|Active Comparator|Treatment3|0,15 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
89650421|NCT03389022|Placebo Comparator|Control|The same amount of intravenous single pre-incisional injection of saline for bariatric patients in the operating room.
89650422|NCT03389022|Active Comparator|Treatment4|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
89650423|NCT01678183|Experimental|Monthly Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension, and hypercholesterolemia at the pharmacy on time. The intervention is the cash incentive.
89650424|NCT01678183|Experimental|Monthly and Final Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension and hypercholesterolemia at the pharmacy on time, as well as an additional financial incentive for each full percentage point of decrease in their hemoglobin A1c over the eight-month course of the study. The two cash incentives are the intervention.
89212906|NCT04079309|No Intervention|No Intervention|No mist will be diffused into the environment.
89212907|NCT04079309|Active Comparator|Lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
89212908|NCT04079309|Active Comparator|Orange|0,3 ml orange oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
89650425|NCT01678183|No Intervention|Control|These subjects will complete the enrollment process for the study but will be randomized to a group that receives usual care.
89650426|NCT03715686|Experimental|Wire localization|Intervention: procedure: wire localization
89650427|NCT00080899|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
89650428|NCT03086785|Experimental|apatinib|apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w
89650429|NCT03714516|Experimental|Online psychological intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
89045468|NCT06227013|Experimental|interventional group|Whistleblowing intervention
89045469|NCT06227013|No Intervention|control group|no intervention
89045470|NCT06226987||Fabry Disease with cardiac involvement|
89045471|NCT06226948|Experimental|Intervention group 1|Patients will use a continuous blood glucose monitoring and visualization of CVDs risk.
89045472|NCT06226948|Experimental|Intervention group 2|Patients will use a continuous blood glucose monitoring.
89045473|NCT06226948|Experimental|Intervention group 3|Patients will use a visualization of CVDs risk.
89650430|NCT04987398||Intubation for respiratory reasons|All patients who were intubated for respiratory reasons (i.e. acute respiratory distress syndrome, pneumonias, pleural effusions for example)
89650431|NCT04987398||Intubation for neurological reasons|All patients who were intubated for neurological reasons (i.e. stroke, intracranial bleeding, cervical fracture with tetraparesia for example)
89650432|NCT04987398||Intubation for other reasons|All patients who were intubated for other reasons than respiratory or neurological (i.e. intubation before surgery, cardiac arrest, hemodynamic instability and polytraumatism without respiratory distress or neurological pathology necessitating intubation)
89650433|NCT03259698|Experimental|ARM 1 = TEXT MESSAGING SUPPORT|"PEP will be delivered by ID physician and participants will receive weekly text message check-ins and optional automated text appointment reminders via the WelTel system."
89650434|NCT03259698|Experimental|ARM 2 = NO TEXT MESSAGING SUPPORT|"PEP will be delivered according to the standard of care by an infectious diseases physician. Participants will not receive text message reminders or check-in."
89650435|NCT03259698|Experimental|ARM 3 = NURSE-LED nPEP|PEP will be delivered by a sexual health clinic nurse operating under a medical directive.
89650436|NCT03259698|Active Comparator|ARM 4 = ID PHYSICIAN-LED nPEP,|PEP will be delivered according to the standard of care by an infectious diseases physician.
89650437|NCT02576184|Experimental|Biologic Mesh|Biologic mesh placed in retromuscular position
89045474|NCT06226948|No Intervention|Control group|No intervention.
89045475|NCT06226922||PCIA-PONV Group|Patient-controlled intravenous analgesia (PCIA) will be used after surgery. Patients will receive dedicated follow-up. Routine bedside visits will be conducted twice daily after surgery to assess postoperative nausea and vomiting (PONV). The severity of nausea will be evaluated using the Visual Analogue Scale (VAS), where 0 indicates no nausea and vomiting, and 10 represents the most unbearable nausea and vomiting. When the PONV score is >0 or vomiting occurs, it is defined as the PCIA-PONV group.
89045476|NCT06226922||None PCIA-PONV Group|Patient-controlled intravenous analgesia (PCIA) will be used after surgery. Patients will receive dedicated follow-up. Routine bedside visits will be conducted twice daily after surgery to assess postoperative nausea and vomiting (PONV). The severity of nausea will be evaluated using the Visual Analogue Scale (VAS), where 0 indicates no nausea and vomiting, and 10 represents the most unbearable nausea and vomiting. When the PONV score is 0, it is defined as the None PCIA-PONV Group.
89045477|NCT06226844||Control group : PEMA SHAM|Patients receiving the usual management
89045478|NCT06226844||Experimental group : PEMA BeatMove|Patients on rehabilitation using the BeatMove device
89045479|NCT06226831||MS with LUTS|Patients with multiple sclerosis with LUTS symptoms.
89045480|NCT06226831||MS without LUTS|Patients with multiple sclerosis without LUTS symptoms.
89045481|NCT06226805|Experimental|BB-031|A single dose of BB-031 will be administered via IV push over 1-3 minutes.
89045482|NCT06226805|Placebo Comparator|Placebo|A single dose of matching placebo will be administered via IV push over 1-3 minutes
89045483|NCT06226779|Experimental|Baduanjin|Parcipants will practice baduanjin exercise.
89045484|NCT06226779|Active Comparator|Brisk walking|Parcipants will perform brisk walking activities.
89045485|NCT06226779|Other|health education|Parcipants will receive health education classes and watch sport related videos.
89212909|NCT02583503||Hindfoot alignment view x ray|Patients undergoing TKR for osteoarthritis will have an additional x ray (hindfoot alignment view) as well as the standard hip knee ankle x ray extended to include the heel.
89212910|NCT03928769||Control Group|Patients with traumatic vascular injury, ultimately corresponding to control patients
89650438|NCT02576184|Experimental|Synthetic Mesh|Synthetic mesh placed in retromuscular position
89650439|NCT02576184|No Intervention|No Mesh|No mesh
89650440|NCT00089635|Experimental|Panitumumab|Panitumumab was administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease, were unable to tolerate investigational product, or discontinued for other reasons.
89650441|NCT03445728|Experimental|Treatment arm|Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);
89650442|NCT03445728|Placebo Comparator|Placebo arm|Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.
89650443|NCT02795520|Experimental|OTS167IV|
89688597|NCT02802514|Experimental|With Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will undergo off-therapy MRI scan Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI. In session 2, subject will receive single dose each of albiglutide placebo on Day 1 (Week 9) and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
89212911|NCT03928769||Atheroma Group|"Patients will be included either in the atheromatous group (patients with atheromatous pathology) or in the control group (patients without atheromatous pathology), according to the clinical evaluation.~In the atheromatous group, subjects must have a clinically significant atheromatous pathology.~The investigator must specify the site (s) affected by the atheroma: carotid artery, coronary artery, aorta, renal artery, mesenteric artery or lower limb artery."
89212912|NCT02584205|Experimental|Powerbreathe|We will use the powerbreathe Classic light resistance in this intervention (inspiratory muscle training). Both groups will receive the equipment, but the intervention group will do the training with a load 40% of the maximum inspiratory pressure.
89212913|NCT02584205|Placebo Comparator|Control|"This group will also receive the equipment (powerbreathe classic light) but will do the training with a load less than 10% of the maximum inspiratory pressure (insufficient charge to train the muscles)."
89212914|NCT02585297||Control- semen|Semen of fertile men
89212915|NCT02585297||Control- vaginal discharge|Vaginal discharge of partners of fertile men
89212916|NCT02585297||Case-semen|Semen of infertile men
89212917|NCT02585297||Case- vaginal discharge|Vaginal discharge of partners of infertile men
89650444|NCT03435835|Experimental|Sham, then heat therapy|Participants were fitted with liquid-circulating trousers. In the sham-treatment session, water at 33℃ was circulated through the trousers for 90 min using a water pump (HTP-1500, Adroit Medical, Louden, Tennessee, United States). At least 72 hrs after completion of the sham treatment session, participants returned to the laboratory and received the heat therapy (HT) treatment. In the HT session, water at 43℃ was circulated through the tube-lined trousers using a heated bath circulator (HT; Aqua Relief Systems, Akron, Ohio, United States) with the goal of increasing leg skin temperature to 37-38ºC.
89650445|NCT03435835|Experimental|Heat therapy, then sham|Participants were fitted with liquid-circulating trousers. In the HT session, water at 43℃ was circulated through the tube-lined trousers using a heated bath circulator (HT; Aqua Relief Systems, Akron, Ohio, United States) with the goal of increasing leg skin temperature to 37-38ºC. At least 72 hrs after completion of the sham treatment session, participants returned to the laboratory and received the sham treatment. In the sham-treatment session, water at 33℃ was circulated through the trousers for 90 min using a water pump (HTP-1500, Adroit Medical, Louden, Tennessee, United States).
89650446|NCT03159000|Experimental|GONB of lidocaine/bupivacaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
89650447|NCT03159000|Placebo Comparator|Placebo injection of 1/3 saline|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion bilaterally. The subject will remain in the office for 30 minutes after injection, and receive a questionnaire to be filled out at 10 and 30 minutes, and 2 and 24 hours post-injection. Subjects who are not improved after 2 hours will be allowed to use their abortive treatment.
89650448|NCT00086671|Experimental|ABT-874 200 mg weekly|
89650449|NCT00086671|Placebo Comparator|Placebo|
89650450|NCT00086671|Experimental|ABT 874 QOW|
89650451|NCT02010606|Experimental|Cohort A: Patients with newly diagnosed glioblastoma|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
89650452|NCT02010606|Experimental|Cohort B: Patients with recurrent glioblastoma|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
89650453|NCT00084253|Active Comparator|1|
89650454|NCT00084253|Active Comparator|2|
89650455|NCT01678261||1a Turner syndrome 45,X|Blood from 50 persons with Turner syndrome an karyotype 45,X
89650456|NCT01678261||1b Controls for TS 45,X|50 healthy aged female controls matched to the TS 45,X cohort
89650457|NCT01678261||2a Turner syndrome 45,X mosaics|Blood from 50 persons with Turner syndrome an karyotype 45,X mosaics
89650458|NCT01678261||2b Controls for TS 45,X mosaics|50 healthy aged female controls matched to the TS 45,X mosaics cohort
89650459|NCT01678261||3a Paraffin embedded aortic tissue TS|3a Paraffin embedded samples of aortic tissue from 10 persons with TS
89650460|NCT01678261||3b Paraffin embedded aortic tissue from 10 controls|3b Paraffin embedded samples of aortic tissue from 10 controls who did not die from aortic aneurism
89650461|NCT01678261||4a 70 47,XXY men|4a Blood from 70 men with Klinefelter syndrome (47,XXY)
89650462|NCT01678261||4b 70 controls matching group 4a|4b 70 male controls matching group 4a with respect to age.
89650463|NCT01678261||5a 5 persons with double Y-syndrome|5a Blood from 5 persons with double Y-syndrome (47,XYY)
89650464|NCT01678261||5b 20 controls matching 5a|5b 20 healthy controls matching group 5a with respect to age
89650465|NCT01678261||6a 5 persons with triple X-syndrome|6a Blood from 5 persons with triple X-syndrome (47,XXX)
89650466|NCT01678261||6b 20 controls matching 6a|6b 20 healthy controls matching group 6a with respect to age.
89650467|NCT01678261||7 10 biological parents of cohort 1a.|7 Blood from 10 biological parents of individuals in cohort 1a
89212918|NCT02584127|Experimental|High reinforcement cessation program|The High Reinforcement (HR) condition included five monthly, online interim surveys with financial incentives for these assessments and also for program completion. All participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
89650468|NCT01678339||1|
89650469|NCT02951364||LDV/SOF|Adult Korean participants and pediatric Korean participants aged 12 to <18 years with genotype 1, 2, 4, 5, and 6 chronic HCV infection who are initiating commercial Harvoni regimen
89650470|NCT01678417|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
89650471|NCT01500200|Experimental|ALKS 5461|
89650472|NCT01500200|Placebo Comparator|Placebo|
89650473|NCT00083941|Experimental|TroVax and IL-2|TroVax: Intramuscular into the deltoid muscle of the upper arm, 10x dose (6.83 x 108 pfu/ml). IL 2: High dose IL 2, 600,000 IU/kg intravenously every 8 hours up to a maximum of 15 injections.
89650474|NCT01678495|Experimental|Sonothrombolysis + microbubbles|"rtPA+ sonovue. SonoVue sulphur hexafluoride microbubbles 8 microlitres/ml Powder and solvent for dispersion for injection 1 vial containing 25 mg lyophilized powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection~1 pre-filled syringe containing sodium chloride 9 mg/ml (0.9%) solution for injection~1 Mini-Spike Plus 6/8 (CE 0123) transfer system.~1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles."
89650475|NCT01678495|Active Comparator|Standard intravenous thrombolysis|Patients in thecontrol group will use thehelmetbut without U.S continuous U.S wave emission. Serial monitoring of the status ofrecanalizationaccording to theschedule set will be carried out according to theestablished schedule
89650476|NCT04969848||eMSGait|Record of IGP using IMU sensor (Metamotion R mbientlab) during T25FW.
89650477|NCT01512810|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
89650478|NCT01512810|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
89650479|NCT05131932|Experimental|Inlet patch|Patients found to have an inlet patch on upper endoscopy
89650480|NCT05131932|No Intervention|Controls|Patients without an inlet patch on upper endoscopy
89650481|NCT01678573|Experimental|Sequence 1: abiraterone acetate|"Randomly assigned participants in Sequence 1 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule ABC under fasted conditions."
89045487|NCT06226740|Experimental|Cold Lateral Compaction (Control group)|After the root canal preparation was completed, the working length was checked with the master cone and periapical radiography. The master cone was then covered with root canal sealer and placed in the root canal. Then, a gap was created for the .02 angled lateral cones using #30, 25 and 20 finger spreader. The obturation process continued until the spreader went 2 mm beyond the level of the canal orifice. Next, a hot excavator removed the coronal gutta-percha 1 mm below the canal orifice.
89045488|NCT06226740|Experimental|Warm Vertical Compaction|After the root canal preparation was completed, the working length was checked with the master cone and periapical radiography. Root canal sealer was applied to the root canal walls using a master cone. HeatPlugger connected to the down-pack unit of the obturation system was adjusted to be 4 mm shorter than the working length. The master cone was cut 1 mm shorter than the working length with a heated plugger and applied to the root canal. Then, the heated plugger was advanced in the apical direction, and the apical region was obturated. Obturation was completed in 2 stages with gutta-percha in the gutta-percha cartridge connected to the remaining root canal cavity back-fill unit and heated to 200 °C. Heated gutta-percha was vertically condensed with HeatPlugger to 1 in the first stage and 2 in the second. The root canal obturation was completed by removing the gutta-percha 1 mm below the canal orifice.
89045489|NCT06226740|Experimental|Gutta Core|After the root canal preparation was completed, the working length was controlled with the master cone and periapical radiography. Root canal sealer was applied to the root canal walls using a master cone. Root canal obturation was completed with heated gutta-percha according to the manufacturer's instructions. The heated gutta-percha was slowly inserted into the canal up to the working length. After cutting the handle of the obturators at the level of the canal orifice with a hot excavator, it was condensed into the canal using a gutta-percha plugger. The coronal gutta-percha was removed 1 mm below the canal orifice using a hot excavator.
89045490|NCT06226714|Experimental|ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)|Intramuscular injection, 0.5ml
89650482|NCT01678573|Experimental|Sequence 2: abiraterone acetate|"Randomly assigned participants in Sequence 2 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule BAC under fasted conditions."
89650483|NCT01678573|Experimental|Sequence 3: abiraterone acetate|"Randomly assigned participants in Sequence 3 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule CBA under fasted conditions."
89650484|NCT01478360|Experimental|AIN457|AIN457 10 mg/kg
89650485|NCT01478360|Placebo Comparator|Placebo|Placebo intravenous injection
89650486|NCT01678651|Active Comparator|Human FSH|Human FSH
89650487|NCT01678651|Active Comparator|Recombinant FSH|Recombinant FSH
89650488|NCT04684446|Experimental|Arm 1|AZD1222 on Day 1 followed by rAd26-S on Day 29
89650489|NCT04684446|Experimental|Arm 2|rAd26-S on Day 1 followed by AZD1222 on Day 29
89650490|NCT04094090|Experimental|Pulsed, accelerated|4 mW, 10-15 sec on, 10-15sec off, 45 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
89650491|NCT04094090|Experimental|Pusled, accelerated|8 mW, 10-15 sec on, 10-15 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
89650492|NCT04670796|Experimental|HLX02|patient receive one dose of HLX02
89650493|NCT04670796|Active Comparator|EU-sourced Trastuzumab (Herceptin®)|patient receive one dose of EU-sourced Trastuzumab (Herceptin®)
89650494|NCT04670796|Active Comparator|US-licensed Trastuzumab (Herceptin®)|patient receive one dose of US-licensed Trastuzumab (Herceptin®)
89650495|NCT03856268||ARM 1: 'Surgical Menopause' Group|Premenopausal women having an oophorectomy.
89650496|NCT03856268||"ARM 2: Drug-Induced Menopause'"|Premenopausal women with gonadal suppression
89650497|NCT03856268||'Comparative (Control)' Group|Premenopausal women with regular cycles.
89650498|NCT03083977|Experimental|Intervention group|This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days
89650499|NCT05130918|Experimental|Phenolmicin P3 and Bosexil|Group in which patients were administered Phenolmicin P3 and Bosexil suppositories twice a day for 5 days, then once a day for other 10 days after thulium laser enucleation of prostate was performed.
89650500|NCT05130918|No Intervention|Controls|Group in which patients were not administered Phenolmicin P3 and Bosexil suppositories after thulium laser enucleation of prostate was performed.
89045491|NCT06226714|Active Comparator|ACYW135 Group Meningococcal Polysaccharide Vaccine (MPSV4)|Subcutaneous iniection, 0.5ml
89650501|NCT04402021|Experimental|Aerobic Exercise|Participants randomized to the aerobic exercise group will complete 30 minutes of outdoor walking at a moderate intensity, defined as 50% heart rate reserve from the American College of Sports Medicine (ACSM) exercise prescription recommendations. A 5-minute warm-up and cool-down will occur before and after the 30-minute bout. A Polar H10 heart rate monitor will continuously monitor exercise intensity during the session. Ratings of Perceived Exertion (RPE) will be assessed using the Borg scale (i.e., 6-20 rating system) to indicate perceived exercise effort every 5 minutes during the exercise session. Each session will last approximately 50 minutes.
89650502|NCT04402021|Other|Quiet Rest|Participants randomized to this condition will be instructed to watch a nature documentary void of topics related to sleep or exercise. A Polar H10 heart rate monitor will continuously monitor heart rate during the session to mimic the aerobic exercise condition. Participants will not be permitted to complete homework or work during the allotted time to reduce the chance of unintended stimuli. The quiet rest sessions will be 50 minutes in length.
89650503|NCT01019616|Experimental|Chemotherapy|
89650504|NCT01019616|No Intervention|Control|
89650505|NCT03086395|Experimental|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab.
89650506|NCT00735384||Patients with critical illness myopathy|Patients with,e.g., sepsis, with secondary myopathy
89650507|NCT00735384||Patients with Primary Myopathies|Patients with primary myopathy, e.g., Duchenne Muscular Dystrophy, Myotonia
89650508|NCT03083197|Active Comparator|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
89650509|NCT03083197|Active Comparator|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
89650510|NCT03083197|Active Comparator|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
89650511|NCT03086239|Experimental|Part A: Rovalpituzumab tesirine|Part A Dose Escalation: Rovalpituzumab tesirine intravenous (IV) (various doses and dose regimens) on Day 1 of each 6-week cycle
89650512|NCT03086239|Experimental|Part B: Rovalpituzumab tesirine|Part B Dose Expansion: Rovalpituzumab tesirine dosed at regimen(s) previously demonstrated in Part A to not to exceed the maximum tolerated dose (MTD).
89650513|NCT04761445|Experimental|Straumann Standard Plus (SP)|Patients receiving Straumann SP implants of 4.1 mm in diameter and length of 10 mm.
89650514|NCT04761445|Experimental|JDental care Octa (JD Octa)|Patients receiving JD Octa implants of 4.3 mm in diameter and 10 mm in length.
89650515|NCT05136768|Experimental|Single arm|Sintilimab combined with platinum-based chemotherapy and SBRT
89650516|NCT01678963|Experimental|Squalamine|Squalamine eye drop 0.2%
89650517|NCT01678963|Placebo Comparator|Vehicle Control|Eye drop vehicle control
89650518|NCT00790335|Experimental|A-Intervention|PCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
89650519|NCT00790335|No Intervention|B-Control|Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed
89650520|NCT03086083|Experimental|EMDR standard protocol|Standard EMDR protocol, once.
89650521|NCT03086083|Active Comparator|protocol without brain stimulation|Standard EMDR protocol without brain stimulation, once
89650522|NCT05136534|Experimental|group A|subarachnoid anesthesia wit hyperbaric prilocaine
89650523|NCT05136534|Active Comparator|group B|local anesthesia + mild sedation
89650524|NCT03086161|Active Comparator|Treatment-as-usual|Treatment-as-usual alone provided in the context of a multi-disciplinary teen pregnancy clinic providing wrap-around medical, nutrition, and social work care.
89650525|NCT03086161|Experimental|Interpersonal Psychotherapy|Treatment-as-usual plus a six-session interpersonal psychotherapy program delivered as individual sessions by a trained facilitator every 2-3 weeks throughout pregnancy.
89650526|NCT05136378|No Intervention|Control Arm|Wait and Watch.
89650527|NCT05136378|Experimental|Low Dose Selenious Yeast|Receive 200μg Selenious Yeast per day.
89045492|NCT06226701|Experimental|Impact of cryolipolsis on hormonal profile in obese women with pcos|The patients will receive cryolipolysis session in abdomen for 45minute ,session every two week and 1200kcal diet and exercise for 3 months
89650528|NCT05136378|Experimental|High Dose Selenious Yeast|Receive 400μg Selenious Yeast per day.
89650529|NCT05135832|Experimental|Patient-reported outcomes arm (experimental arm)|"This arm will be assigned to intervention by weekly electronic reporting of symptoms and side effects in an app. A specifically developed alert-algorithm will in real-time guide the patient to adjust supportive care or contact the hospital.~The reported symptoms are sent to the hospital to a healthcare professional - depending on the severity of the reported symptoms the healthcare professional can schedule a visit at the clinic.~The patient will also receive a health-related quality of life questionnaire (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire) including the Physical Function domain in the app each month.~Patient satisfaction regarding the patient-reported outcomes will be measured with the validated Patient-Reported Experience Measurement questionnaire at termination of participation."
89650530|NCT05135832|No Intervention|Standard of care|"This arm will continue standard procedure regarding side effect registration and handling.~The patients will receive a health-related quality of life questionnaire (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, EORTC QOL-C30) at baseline, after 1, 3, and 6 months of participation in the study."
89650531|NCT05135520|Active Comparator|Transabdominal specimen extraction|The outcomes of transabdominal specimen extraction in a classic way in patients who underwent multiport laparoscopic surgery for resection of kidney
89650532|NCT05135520|Experimental|Transvaginal natural orifice specimen extraction (NOSE)|The outcomes of transvaginal natural orifice specimen extraction (NOSE) in patients who underwent multiport laparoscopic surgery for resection of kidney
89650533|NCT01461980|Active Comparator|MCV4 + Tdap+ rLP2086|Group 1 - MCV4 + Tdap + rLP2086
89650534|NCT01461980|Active Comparator|MCV4 + Tdap + saline|Group 2, MCV4 + Tdap+ saline
89650535|NCT01461980|Placebo Comparator|Saline + saline + rLP2086|Group 3- rLP2086 + saline
89650536|NCT03088111|Other|Obiltoxaximab|"This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.~The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA)."
89650537|NCT03087955|Experimental|Acoziborole (SCYX-7158)|Acoziborole (SCYX-7158), in 320-mg tablets, administered by the oral route to patients in the fasting state according to the following dosing regimen: 960 mg (3 tablets) in a single intake on Day 1.
89650538|NCT05135442|Experimental|bortezomib group|On the basis of standard single membrane plasma exchange (2L/d) and hormone therapy (1mg/kg prednisone or equivalent methylprednisolone), bortezomib was given intravenous injection of 1.3mg/m2 d1, 4, 8, 11 (total 4 doses).
89650539|NCT01424501|Experimental|Group A|Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
89650540|NCT01424501|Placebo Comparator|Group B|Subjects from TB-treated cohort will receive 2 doses of physiological Saline.
89650541|NCT01424501|Experimental|Group C|Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
89650542|NCT01424501|Placebo Comparator|Group D|Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.
89650543|NCT01424501|Experimental|Group E|Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
89650544|NCT01424501|Placebo Comparator|Group F|Subjects from TB-naive cohort will receive 2 doses of physiological Saline.
89650545|NCT00771537|No Intervention|Arm 1. Control PLUS Control|
89650546|NCT00771537|Experimental|Arm 2. Control PLUS 1-Sided|No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650547|NCT00771537|Experimental|Arm 3. Control PLUS 2-Sided Trivial|No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
89650548|NCT00771537|Experimental|Arm 4. Control PLUS 2-Sided Major|No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
89650549|NCT00771537|Experimental|Arm 5. 1-Sided PLUS Control|1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
89650550|NCT00771537|Experimental|Arm 6. 1-Sided PLUS 1-Sided|1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650551|NCT00771537|Experimental|Arm 7. 1-Sided PLUS 2-Sided Trivial|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650552|NCT00771537|Experimental|Aim 8. 1-Sided PLUS 2-Sided Major|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650553|NCT00771537|Experimental|Arm 9. 2-Sided Trivial PLUS Control|2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
89650554|NCT00771537|Experimental|Arm 10. 2-Sided Trivial PLUS 1-Sided|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650555|NCT00771537|Experimental|Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650556|NCT00771537|Experimental|Arm 12. 2-Sided Trivial PLUS 2-Sided Major|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650557|NCT00771537|Experimental|Arm 13. 2-Sided Major PLUS Control|2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
89650558|NCT00771537|Experimental|Arm 14. 2-Sided Major PLUS 1-Sided|2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650559|NCT00771537|Experimental|Arm 15. 2-Sided Major PLUS 2-Sided Trivial|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
89650560|NCT00771537|Experimental|Arm 16. 2-Sided Major PLUS 2-Sided Major|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
88993206|NCT03667781||Patients Blood Draw|Patients seen in interventional clinic for post PCI followup will have a venous blood draw which will be sent for therapeutic drug monitoring
88993207|NCT03661437|Experimental|Arm I (BWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
89212919|NCT02584127|Experimental|Low reinforcement cessation program|Participants in the Low Reinforcement (LR) condition participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
89650561|NCT05130684|Experimental|Neo-CRT|"Nivolumab 240 mg, 30-min IVF, Q2W on days -14, 1, 15, and 29;~Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8, 15, 22, and 29;~Cisplatin 30 mg/m2,1h-IVF,on days 1, 8,15, 22, and 29;~RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy)."
89650562|NCT04402411|Active Comparator|Control Group|Patients will receive general anesthesia with intravenous opioid
89650563|NCT04402411|Experimental|Quadratus lumborum|Patients will receive bilateral quadratus lumborum block
89650564|NCT04402411|Experimental|Transversus abdominis plane|Patients will receive bilateral transversus abdominis plane block
89650565|NCT05135364|Experimental|Camrelizumab+HAIC+TKI*|*For patients who have not received molecular targeted therapy in the past, lenvatinib is recommended; For patients who have received sorafenib or lenvatinib in the past, regorafenib is recommended.
89650566|NCT03089515|Active Comparator|Healthy Controls|
89650567|NCT03089515|Experimental|Survivors|
89650568|NCT05265507|Experimental|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
89650569|NCT05265507|Active Comparator|Ondansetron|Ondansetron (4mg) was intravenously given at the ending of the surgery.
89650570|NCT05130372|Active Comparator|Static Stretching Group|The static stretching method was actively applied while standing.The person was positioned facing the wall, supporting the wall with both hands, with the dominant foot behind. The point where a feeling of tension in the plantar flexor muscles was created and held in this position for 30 seconds. Afterward, a 15-second rest break was given. After completing 3 repetitions (3x30sec) in total, measurements were started.
89650571|NCT05130372|Active Comparator|PNF Stretching Method Group|The person was positioned supine, and the ankle joint was dorsiflexed by the physiotherapist to the point where the tension was felt. Then, while the person was trying to push the foot towards the plantarflexion direction for 10 seconds, the movement was prevented by the physiotherapist and isometric contraction was achieved at 20% of the maximum voluntary contraction. After 10 seconds, the person was asked to relax slowly and passive stretching was applied to the plantar flexors for 20 seconds. The contract-relax technique was applied for 30 seconds and completed with 3 repetitions (3x30sec) with 15-second rest intervals.
89650572|NCT05130372|Active Comparator|Myofascial Relaxation Method Group|A comfortable position was achieved by placing a rolled towel on the front of the ankle. The roller was massaged along with the plantar flexors for 30 seconds. The movement of the cylinder from bottom to top and from top to bottom was done for a second. Three repetitions were completed (3x30sec) with a 15-second rest break. For the pressure of the roller to be stable during the application, the numbered pain scale was shown to the participants, and attention was paid to ensure that the perceived severity was 7/10 according to the numbered pain scale. Participants with dry skin in the application area were asked to moisturize with cream beforehand to avoid complications.
89650573|NCT01679353|Placebo Comparator|placebo group|normal saline 0.5ml
89650574|NCT01679353|Experimental|magnesum group|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
89650575|NCT05135286|Experimental|BRIMOCHOL™ PF|A single drop in each eye at a visit.
89650576|NCT05135286|Active Comparator|Carbachol PF|A single drop in each eye at a visit.
89650577|NCT05135286|Placebo Comparator|Vehicle|A single drop in each eye at a visit.
89650578|NCT05260203|Experimental|App RITA|The interventional study group will use the Device Rita, an application that allow the oncological and onco-hematological patients to receive and communicate information about the quality of life and about the treatment related adverse events, providing a support in the therapy management. The access to the app functionalities is granted when the physician habilitates the personal profile. The app can be also used from people designated from the patient as caregiver, who can view the data inserted by the patient and, if enabled, they can insert the data for the patient.
89650579|NCT05260203|No Intervention|Retrospective Historical|This clinical trial has no control intervention; on the other hand, the clinical outcomes of this treatment will be compared with the retrospective clinical data obtained from a historical group of comparison. The historic control used in this clinical trial is specifically selected to reflect the endpoints. According to a feasibility phase of this study, the information on the date of start and end of treatments is routinely collected in the medical records of patients, and for this reason, these data are potentially already available for the historical control group.
89650580|NCT03470857||Patients|Oncological patients: lymphomas (Hodgkin's, DLBCL), breast and ovarian cancers, brain gliomas.
89650581|NCT03470857||Control|The number at most half as large as the patients' group, composed of healthy people at similar age and the same sex as patients.
89650582|NCT03085381|Experimental|HPV vaccine|Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
89650583|NCT03085381|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
89650584|NCT05134896|Experimental|normal healthy group|Spatial light modulator
89650585|NCT01679509|Experimental|Single-port surgery group|Single-port laparoscopic adnexal surgery
89650586|NCT01679509|Active Comparator|Three-port surgery group|Three-port laparoscopic adnexal surgery
89650587|NCT05137470||Newly HD patients|Newly admitted patients with uremia who started hemodialysis treatment
89650588|NCT05137470||MHD patients|Maintenance hemodialysis patients
89650589|NCT01679665|Experimental|320U /0.5ml in children (from 2 to 5 years old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28
89650590|NCT01679665|Placebo Comparator|0/0.5ml placebo in children (from 2 to 5 years old)|0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28
89212920|NCT00501046|Placebo Comparator|Placebo|
89212921|NCT00501046|Experimental|AST-120|
89212922|NCT02585219||High-grade Glioma Patients|"Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy).~Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded.~The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination."
89212923|NCT01018966|Experimental|Ixabepilone|
89212924|NCT01019044||Rectal mucosa biopsy|Rectal mucosa samples collection
89650591|NCT05710575|Experimental|probiotic group|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
89650592|NCT05710575|Experimental|placebo group|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
89650593|NCT03089671|Experimental|Vitamin B|Vitamin B: Patients in this arm will receive 100mg of riboflavin (vitamin B2) 60 to 120 minutes prior to surgery for the purpose of turning the urine bright yellow to see if this helps with detection of ureteric jets during cystoscopy which will be done using normal saline.
89650594|NCT03089671|Active Comparator|D5W (5% dextrose in water)|5% Dextrose in Water: Patients in this arm will receive a placebo in the pre-operative area (for the purpose of blinding the surgical team) 60 to 120 minutes prior to surgery. Intraoperative cystoscopy will then be performed using D5W to see if this helps with detection of ureteric jets.
89650595|NCT05136924|Experimental|OC-01|(varenicline 1.2mg/ml) nasal spray
89650596|NCT05136924|Placebo Comparator|Placebo|(vehicle) nasal spray
89650597|NCT03085459||Nurse level N0|who got college degree or above, nurse qualification certificate and working time less than one year
89650598|NCT03085459||Nurse level N1|who got nurse qualification certificate and working time between 1~3 years
89650599|NCT03085459||Nurse level N2|who got nurse qualification certificate and working time between 3~5 years
89650600|NCT03085459||Nurse level N3|who got nurse qualification certificate and working time more than 5 years
89650601|NCT05134818|Experimental|group OT +|In this group (OT +), the resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
89650602|NCT05134818|No Intervention|group OT-|In this group (OT-), the resident will not use the observer tool and will observe other residents to insert a CVC on the simulator without any physical support.
89650603|NCT03089593|Experimental|Extract of ginger|Healthy and eutrophic women will receive two capsules of 200 mg of ginger extract (5% gingerols) to be taken along with a standardized breakfast.
89650604|NCT03089593|Placebo Comparator|Cellulose|Healthy and eutrophic women will receive two capsules of 200 mg of placebo (cellulose) to be taken along with a standardized breakfast.
89650605|NCT05134506|Experimental|Dance for PD® classes|Dance for PD® was developed by the Brooklyn Parkinson Group (BPG) in collaboration with the Mark Morris Dance Group (MMDG) in 2001. It was designed to introduce people with PD to techniques used by dancers to control movement and it integrates different dance genres while participants dance individually and in groups rather than partnered.
89212925|NCT04546061|Experimental|Project Uplift Intervention|A 6-month long intervention for young adult sexual and gender minorities, ages 18-35.
89650606|NCT05115240|Experimental|Audio-guided mindfulness-based intervention (body scan)|
89650607|NCT05115240|Experimental|Enhanced Audio-guided mindfulness-based intervention (body scan)|Participants undergo the same audio-guided body scan intervention. However, in this arm the instruction focuses on the positive effects of mindfulness-based interventions and body scan aiming to optimize participants' interventions outcome expectations of the intervention. The idea of this arm is to assess whether the effects of the mindfulness-based intervention can be augmented by boosting participants positive expectations prior to the intervention.
89650608|NCT05115240|Active Comparator|Audio-Book|Participants in this group listen to an audio-book for the same duration as the participants in the two experimental groups.
89650609|NCT05066646|Experimental|CT103A in relapsed and refractory multiple myeloma patients|CT103A autologous CAR-T cells will be infused at RP2D of 1.0 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
89688598|NCT02802514|Experimental|Without Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 and exenatide placebo on Day 4 followed by a post-dose MRI scan. In session 2, Day 1 (Week 9) subject will undergo off-therapy MRI scan. Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
89212926|NCT04078685|Active Comparator|CONVENTIONAL group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a standard (non-contact-force sensing) ablation catheter
89212927|NCT04078685|Experimental|CONTACT-FORCE group|Patients with supraventricular tachycardia treated with radiofrequency ablation using a Contact-Force-sensing ablation catheter
89212928|NCT05519189|Active Comparator|Peri-anal infiltration of Ropivacaine|
89212929|NCT05519189|Experimental|Failure to perform peri-anal ropivacaine infiltration|
89212930|NCT04080323|Experimental|dinoprostone 3 mg|60 minutes before the surgery 3 mg of dinoprostone inserted vaginally
89650610|NCT00791037|Experimental|Treatment (vaccine therapy)|"Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.~Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals."
89650611|NCT04403191||Group A|received ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours
89650612|NCT04403191||Group B|received isopropyl alcohol 70% inhalation every 15 min for 4 times then repeated after 6 hours
89650613|NCT04403191||Group C|received intravenous normal saline at rate of 20 ml/kg over 30 minute and repeated by the same dose after 6 hours.
89650614|NCT05123508|Experimental|Treatment Arm|2940nm laser and BBL treatment
89650615|NCT05123508|Experimental|Control Arm|One side of the treatment area will act as a control. No treatment on the control side.
89650616|NCT03084913|Active Comparator|Prostate Cancer Foundation diet|Intervention: 8-weeks of a Prostate Cancer Foundation diet
89650617|NCT03084913|Experimental|plant- based, olive oil diet|Intervention: 8 weeks of a plant-based, olive oil diet
89650618|NCT04383093||Combination Therapy|"Patients initial assessment included age, waist circumference, blood pressure, clinical laboratory parameters, digital rectal examination. LUTS were evaluated with total IPSS, focusing also on storage, voiding IPSS sub-scores, and IPSS QoL, and Overactive Bladder questionnaire (OAB-q), while ED with IIEF-515. Each patient underwent uroﬂowmetry and postvoid residual volume (PVR) was measured with abdominal ultrasound immediately after voiding. All patients reporting any intake of therapies for LUTS or ED underwent a 4 weeks treatment-free washout period.~All subjects were treated with tadalafil 5 mg/die plus tamsulosin 0.4 mg/die for 12 weeks. The medications were self-administered every day at the same time, before the night rest, without any limitations or variations of sexual activity timing or food intake. Patients were re-evaluated after 12 weeks of treatment with Uroflowmetry and PVR, IPSS, IPSS QoL, OAB-q and IIEF-5"
89650619|NCT05301660|Experimental|Experimental group|People with schizophrenic disorders: receiving nicotine transdermal patches.
89650620|NCT05301660|Placebo Comparator|Control group|People with schizophrenic disorders: receive placebo treatment.
89650621|NCT01401959|Experimental|Cohort A: Triple-negative breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
89650622|NCT01401959|Experimental|Cohort B: ER/PR+ /HER2- breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
89650623|NCT01401959|Experimental|Cohort C: HER2+ breast cancer|"Eribulin 1.4 mg/m^2 intravenously (IV)~Trastuzumab 6mg/kg intravenously (IV)"
89650624|NCT01679821||Dental students|Seventy dental students of State University of West of Paraná - UNIOESTE. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. A questionnaire and a clinical examination were employed.
89650625|NCT01679821||Removable partial denture|Seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous). Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary were not included in the research. A questionnaire and a clinical examination were employed.
89650626|NCT01679821||Double complete denture|Seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Patients wearing just one complete denture were not included in the research. A questionnaire and a clinical examination were employed.
89650627|NCT05621031|Experimental|PDExperimental|This group will receive usual care (physical therapy) and whole body vibration sessions.
89650628|NCT05621031|Active Comparator|PDControl|This group will receive usual care (physical therapy) and placebo whole body vibration session.
89650629|NCT05105490||Chronic Discogenic Low Back Pain|"Patient is skeletally mature and between 21 and 60 years of age.~Patient has Degenerative Disc Disease (DDD) at one or more levels~between L1 and S1 but must have a single level identified as the pain generator.~Patient has adequate disc height (6mm) at the level to be treated~Patient is not responsive to conservative, non-surgical treatment for back pain."
89650630|NCT00791817|Experimental|200 mg PG 760564, Subjects Fasted|200 mg PG 760564, Subjects Fasted, single dose
89650631|NCT00791817|Experimental|200 mg PG 760564, Subjects Fed|200 mg PG 760564, Subjects Fed high fat meal
89650632|NCT03084835|Active Comparator|UC|Usual Care
89650633|NCT03084835|Active Comparator|WEB+TXT|Digital Intervention
89650634|NCT03084835|Active Comparator|WEB+TXT+TTS|Digital plus Counseling Intervention
89650635|NCT04767035|Active Comparator|MELT-100 3/25|MELT-100 3mg midazolam / 25 mg ketamine
89650636|NCT04767035|Active Comparator|MELT-100 2 x 3/25|MELT-100 2 doses of 3mg midazolam / 25mg ketamine
89045493|NCT06226701|Experimental|Impact of cryolipolysis in hormonal profile in obese women with pcos|All patient will receive same diet 1200kcal diet ,and exercise for 3 months
89045494|NCT06226675|No Intervention|Group Control|
89045495|NCT06226675|Active Comparator|Group PENG|
89045496|NCT06226675|Active Comparator|Group PENG+LFCN|
89212931|NCT04080323|Placebo Comparator|placebo|60 minutes before the surgery 1 tablet of placebo inserted vaginally
89650637|NCT04767035|Active Comparator|ketamine IV 18mg|
89650638|NCT04767035|Active Comparator|Midazolam IV 3.5mg|
89650639|NCT05125614||Developement set|Gastric cancer patients who did not receive adjuvant chemotherapy after curative gastrectomy from 2009 to 2016 at Seoul St.Mary's Hospital
89650640|NCT05125614||Validation set|Gastric cancer patients who did not receive adjuvant chemotherapy after curative gastrectomy from 2009 to 2016 at St.Vincent''s Hospital
89650641|NCT04402177|Experimental|Hypersensitivity Pneumonitis patients showing lung fibrosis|hypersensitivity Pneumonitis patients that shows lung fibrosis after CT scan ( fibrotic patients ) methyl prednisolone 0.5mg/kg /day orally for 8 weeks
89650642|NCT04402177|Active Comparator|hypersensitivity Pneumonitis patients without lung fibrosis|hypersensitivity Pneumonitis patients that doesn't show lung fibrosis after CT ( non-fibrotic patients ) will be given also methyl prednisolone 0.5mg/kg /day orally for 8 weeks
89650643|NCT03084991||OCT group|1500 AMI patients with OCT imaging guidance during PCI
89650644|NCT03084991||CAG group|3000 AMI patients without OCT imaging guidance during PPCI
89650645|NCT05073900|Experimental|Rhomboid intercostal block|Ultrasound guided rhomboid intercostal block
89650646|NCT05073900|Active Comparator|Erector spinae plane block|Ultrasound guided erector spinae plane block
89650647|NCT03081169|Active Comparator|Early (24 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 24 hours after injury if CT head is stable.
89650648|NCT03081169|Active Comparator|Late (72 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 72 hours after injury if CT head is stable.
89650649|NCT03803163|Experimental|TransCon Treprostinil|
89650650|NCT03084679|No Intervention|Conventional Clinical Care - HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
89650651|NCT03084679|Other|Supervised Exercise Training- HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
89650652|NCT03084679|No Intervention|Conventional Clinical Care - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
89650653|NCT03084679|Other|Supervised Exercise Training - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
89650654|NCT05287308|Experimental|AC followed by albumin-bound paclitaxel|A (doxorubicin, epirubicin or pirarubicin) and C (cyclophosphamide) for 4 cycles followed by albumin-bound paclitaxel for 4 cycles.
89650655|NCT05287308|Active Comparator|AC followed by taxanes|A (doxorubicin, epirubicin or pirarubicin) and C (cyclophosphamide) for 4 cycles followed by paclitaxel or docetaxel for 4 cycles.
89650656|NCT00801723|Experimental|1: Budesonide MMX® 6 mg|One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.
89650657|NCT00801723|Placebo Comparator|2: Placebo|One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.
89650658|NCT03089437|Experimental|Prolonged Standing|Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
89650659|NCT03089437|Experimental|Prolonged Sitting|Subject sit for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
89650660|NCT03084289|Experimental|Group 1|Group 1 will receive ChAd63-METRAP at the dose of 5x10^8 vp i.v.
89650661|NCT03084289|Experimental|Group 2|Group 2 will receive ChAd63-METRAP at the dose of 5x10^9 vp i.v.
89650662|NCT03084289|Experimental|Group 3|Group 3 will receive ChAd63-METRAP at the dose of 5x10^10 vp i.v.
89650663|NCT03084289|Experimental|Group 4|Group 4 will receive ChAd63-METRAP at the dose of 5x10^10 vp s.c.
89650664|NCT03084289|Experimental|Group 5|Group 5 will receive ChAd63-METRAP at the dose of 2x10^11 vp s.c.
89650665|NCT03084289|Experimental|Group 6|Group 6 will receive MVA METRAP at the dose of 2 x 10^6 pfu i.v.
89650666|NCT03084289|Experimental|Group 7|Group 7 will receive MVA METRAP at the dose of 2 x 10^7 pfu i.v.
89650667|NCT03084289|Experimental|Group 8|Group 8 will receive MVA METRAP at the dose of 2 x 10^8 pfu i.v.
89650668|NCT05346211|Experimental|Curcumin Single|"The Single dose group will consume 1 placebo sachet and one curcumin sachet per day.~Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.~The placebo is a sachet containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
89650669|NCT05346211|Experimental|Curcumin Double|"The double dose group will consume two sachets per day of curcumin.~Curcumin supplementation will be from YourZooki, the supplement in question is commercially offered to the public in a tangerine flavour. The sachets will be in 750mg hydrolysed format.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
89650670|NCT05346211|No Intervention|Placebo|"Placebo sachets containing the same ingredients mentioned above minus the curcumin. The sachets will be in 750mg hydrolysed format.~Participants will consume two sachets per day.~Supplementation will be administered and commence 48-hours prior to the first testing day and will be consumed twice a day (8am & 8pm)."
89650671|NCT05694897|Active Comparator|Erector spinae block using a combination of bupivacaine and magnesium sulfate|Ultrasound guided erector spinae block at the level of T10 using a combination of 20 ml bupivacaine 0.25% and 3.75ml magnesium sulfate for treatment of postoperative pain
89650672|NCT05694897|Active Comparator|Erector spinae block using a combination of bupivacaine and dexmedetomidine|Ultrasound guided erector spinae block at the level of T10 using a combination of 20 ml bupivacaine 0.25% and 1ug/kg dexmedetomidine for treatment of postoperative pain
89650673|NCT01478048|Experimental|Arm A: Elotuzumab + Bortezomib + Dexamethasone|On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
89650674|NCT01478048|Active Comparator|Arm B: Bortezomib + Dexamethasone|
89650675|NCT04576494|Experimental|5q-SMA type 2 and type 3 adults|5q-SMA type 2 and type 3 adults
89650676|NCT03081091|Active Comparator|Intervention group (A) Acupuncture|The treatments performed will be personalized and the treatment criteria will be based on the use of the Yuan and Luo points. In clinical practice, the Yuan (source) points and the Luo (connecting) points can be used jointly, linking the two associated meridians (external-internal) in such a way that, after assessing the state of a meridian's path, its Yuan point will be combined with the Luo point of its coupled meridian and vice versa; all this depending on the condition of the muscle fibres and on the path that wants to be treated for these.
89650677|NCT03081091|Sham Comparator|Control group (C) Sham Acupuncture:|"The course of action with the patient from the group that will use sham acupuncture will be the same as in the group that receives real treatment: patient in supine position, cleaning of the treated area, use of eye mask during the treatments and selection of points following the previously described Yuan and Luo points' criteria, based on traditional Chinese medicine.~The difference of sham acupuncture will lie on the way of performing the acupuncture technique. It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body."
89650678|NCT01424189|Experimental|ReSTOR Toric IOL|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
89650679|NCT01424189|Active Comparator|ReSTOR IOL|AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation
89650680|NCT05306106|Other|Glucose|The control product, said to be the reference product, is an oral solution of 50 g of glucose.
89650681|NCT05306106|Other|a truffle match|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
89650682|NCT05306106|Other|a hazelnut chocolate cookie|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
89650683|NCT05306106|Other|a Paris Brest style eclair|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
89650684|NCT05306106|Other|a hazelnut chocolate finger|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
89650685|NCT05306106|Other|a lemon finger|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
89650686|NCT05306106|Other|a elderflower madeleine|The products evaluated are pastries from the Mademoiselle Desserts range, namely a truffle match, a hazelnut chocolate cookie, a Paris Brest style eclair, a hazelnut chocolate finger, a lemon finger and an elderflower madeleine.
89650687|NCT03831789|Active Comparator|Unilateral cerebellar rTMS|
89650688|NCT03831789|Experimental|Bilateral cerebellar rTMS|
89650689|NCT03081247|Experimental|BGF 320/14.4/9.6 µg MDI BID|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
89650690|NCT03081247|Experimental|BFF 320/9.6 µg MDI BID|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
89650691|NCT05205993|Experimental|Intrauterine infusion of antibiotics|Thirty women will receive only intrauterine infusion of antibiotics for 30 days.
89650692|NCT05205993|Experimental|Combination of intrauterine infusion and oral administration of antibiotics|Thirty women will receive a combination of intrauterine infusion and oral administration of antibiotics for 30 days.
89650693|NCT05205993|Active Comparator|Oral administration of antibiotics|Thirty women will receive only oral administration of antibiotics for 30 days.
89650694|NCT04585776|Experimental|LY900014 + Insulin Degludec|LY900014 (100 units/milliliter (U/mL)) is a prandial insulin administered subcutaneously (SC) 0-2 minutes before meals. Insulin degludec (100 U/mL) is a basal insulin administered once daily SC. Participants received individually adjusted insulin doses during the 35-day titration period. The target glucose values were: fasting glucose 80-110 milligrams per deciliter (mg/dL), overnight glucose excursion (the difference between bedtime and prebreakfast glucose levels) < or = +/- 30 mg/dL, postprandial glucose peak <140 mg/dL or <20% increase from premeal level. Following the titration period, there was an 11-day maintenance period during which the doses were kept unchanged unless for safety reasons.
89650695|NCT03080857|Experimental|Virtual Platform|Patients will be provided with a computer simulated tool to assist with education and support relating to atrial fibrillation.
88993208|NCT03661437|Experimental|Arm II (DWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
89650696|NCT01401647|Active Comparator|Amiodarone|Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.
89650697|NCT01401647|Active Comparator|Lidocaine|IV or IO administration of lidocaine if VF/pulseless VT reoccurs after initial defibrillation.
89650698|NCT01401647|Placebo Comparator|Normal saline|IV or IO administration of normal saline if VF/pulseless VT reoccurs after initial defibrillation.
89650699|NCT01499810|Experimental|Renal denervation|All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.
89650700|NCT04401631||Interventions|"A minimum of 20 subjects with targeted levels of total IgE are needed to participate in the Operator-to-Operator whole blood study.~A minimum of 20 subjects with targeted levels of allergen-specific and total IgE are needed to participate in the capillary whole blood between-run imprecision study in the POL environment.~A minimum of 40 subjects with targeted levels of Fel d 1-specific IgE and total IgE are needed to participate in the sample type comparison study. These subjects will be recruited, and their samples analyzed at 1 POL.~A minimum of 300 subjects (approximately 100 subjects enrolled and evaluated at each of three sites) and with targeted levels of total IgE are needed to participate in the method comparison study."
89688599|NCT02802514|Experimental|With Off therapy MRI in S1:Exenatide-S1 & Albiglutide-S2|In session 1, Day 1 subject will undergo off-therapy MRI scan Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan In session 2, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 (Week 9) and exenatide placebo Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
89045497|NCT06226649|Experimental|Digital Dyadic Empowerment|The intervention group (Digital Dyadic Empowerment) will utilize LINE, a prominent instant messaging App in Taiwan, to assist in lifestyle modification, along with support from the significant other.
89045498|NCT06226649|No Intervention|Control group|The control group receives routine education and care.
89045499|NCT06226636|Experimental|intervention|intervention given
89045500|NCT06226610|Active Comparator|ARM 1 - Dupixent|Two subcutaneous injection of 300mg Dupixent at visit 1 and every two weeks (+/- 2 days) for a total of 6 administrations. Injections may be administered in the thigh, lower abdomen or upper arm. The initial dose (two 300 mg doses) will be given in two different injection sites. There are not restriction or guidance regarding dose administration related to meals. No dose modifications will occur during study participation.
89045501|NCT06226610|Placebo Comparator|ARM 2 - Placebo|Two subcutaneous injection of the placebo at visit 1 and every two weeks (+/- 2 days) for a total of 6 administrations. Injections may be administered in the thigh, lower abdomen or upper arm. The initial dose (two doses) will be given in two different injection sites. There are not restriction or guidance regarding dose administration related to meals. No dose modifications will occur during study participation.
89045502|NCT06226597|Experimental|Fitbit monitoring|Individuals in this arm will wear a fitbit device consistently throughout the duration of their pregnancy, and monitor fitbit data using a platform that connects to their phone. The remainder of prenatal care will be per standard procedure.
89650701|NCT05305716|Experimental|online pilates group|Online pilates training was done for a total of 8 weeks, 2 days a week for 1 hour. Microsoft Teams program was used to perform the exercises online. The investigators divided the individuals in the online pilates exercise group into seven smaller groups of 3 or 4 to verify whether they correctly did the exercises. A program including 15 minutes of warm-up, 30 minutes of Pilates exercises and 15 minutes of cooling and stretching exercises was arranged for the online pilates group and the exercises were performed as 10 repetitions. The exercise program recommended by the Australian Pilates and Physiotherapy Institute during pregnancy was used in the online training.
89650702|NCT05305716|Active Comparator|control group|The control group was given breathing and relaxation exercises, which they would do two days a week for eight weeks, in the form of a home program. Diaphragmatic breathing and respiratory control were given as breathing exercises.
89650703|NCT03080701|No Intervention|Group 1 - Automated Mailing|The mailing process will be identical to those used in the SOS study. Mailing 1 includes an introductory letter on CRC screening and a pamphlet on CRC testing choices (colonoscopy every 10 years, FIT testing yearly, or flexible sigmoidoscopy every 10 years combined with interval FIT testing), and pros and cons of each. The letter will state that they will soon be receiving a FIT kit in the mail, and a number to call if they prefer another option. Mailing 2 includes a brief letter reaffirming the importance of screening, a FIT kit (the one used by Group Health), pictograph instructions, and a postage-paid return envelope. Mailing 3 a reminder letter, is sent to participants not completing the FIT kit after 3 weeks. The intervention for Group 1 includes no incentive.
89650704|NCT03080701|Experimental|Group 2 - Auto Mailing Plus Money|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will receive a monetary thank you gift for completing testing (FIT colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the monetary thank you gift for CRC screening completion. Mailing 4 will include the money with a thank you letter for those who complete the screening
89650705|NCT03080701|Experimental|Group 3 - Auto Mailing Plus Lottery|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will have a 1 in 10 chance of winning money (FIT, colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the 1 in 10 chance of winning the lottery for CRC screening completion. Mailing 4 will include a thank you letter with money for those who complete their screening and win the lottery. Participants who do not win the lottery will receive a thank you letter.
89650706|NCT05282862|Active Comparator|Freehand|Conventional bone augmentation using a particulate graft material (DBBM) and a collagen barrier membrane.
89650707|NCT05282862|Experimental|Guided|Bone augmentation performed using the materials as in the Freehand group, but using a surgical guide to help define the shape of the guide.
89650708|NCT03084211|No Intervention|Control Group|The control group will be instructed to gradually return to activities.
89650709|NCT03084211|Experimental|Prescribed Light Exercise Group|Intervention: Prescribed Light Exercise Group will receive discharge instructions prescribing 30 minutes of light exercise (ie: walking).
89650710|NCT01423253|Experimental|Lurasidone 20, 40, 60 mg|Lurasidone 20, 40, or 60 mg/day flexibly dosed
89650711|NCT04383249||Pathology result|Pathology result of the hernia sac
89650712|NCT05305326||Control|Singleton pregnancies undergoing elective pre-labour CS at gestational age (37+0 to 40+0) that are healthy
89650713|NCT05305326||Gestational diabetes|Singleton pregnancies complicated with gestational diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
89650714|NCT05305326||Type 1 diabetes with pregnancy|Singleton pregnancies complicated with Type 1 diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
89045503|NCT06226597|No Intervention|Routine prenatal care|Individuals in this arm will receive standard prenatal care without the addition of wearing a fitbit device.
89045504|NCT06226584|Experimental|multiple-strain probiotics|
89045505|NCT06226571|Experimental|SNDX-5613|"Dose Escalation:~Induction: Sequential cohorts of escalating dose levels of SNDX-5613 with chemotherapy regimen.~Consolidation: Cohorts will receive high-dose cytarabine (HiDAC) chemotherapy followed by SNDX-5613.~Maintenance Monotherapy: Cohorts will receive SNDX-5613.~Dose Expansion:~Induction: SNDX-5613 at tolerated dose level with chemotherapy regimen.~Consolidation: Cohorts will receive SNDX-5613 with chemotherapy regimen and HiDAC.~Maintenance Monotherapy: Cohorts will receive SNDX-5613."
89045506|NCT06226558||Category 1: Confirmed cCMV infection identified by NYS newborn screen|Infants who have both a positive cCMV NYS newborn screen AND are positive for cCMV on confirmatory testing
89650715|NCT05305326||Type 2 diabetes with pregnancy|Singleton pregnancies complicated with Type 2 diabetes undergoing pre-labour CS at gestational age (37+0 to 40+0) that are otherwise healthy
89650716|NCT03088891|Experimental|Antioxidant-rich snacks|The participants received antioxidant-rich snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included fruits and vegetable smoothies, dark chocolate, walnuts, dried fruits and berries.
89650717|NCT03088891|Placebo Comparator|Control snacks|The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
89650718|NCT03802929||Derivation Cohort|"Derivation Cohort of Diagnostic Prediction Model:~Participants will be recruited from the emergency department of five general urban hospitals in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; from March 1, 2019. The investigators will randomly assign 70% participants to a derivation cohort.~Derivation Cohort of Prognostic Prediction Model:~Patients with VTE from 5 thrombosis centers in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; between January 2014 and December 2018."
89650719|NCT03802929||Validation Cohort|"Validation Cohort of Diagnostic Prediction Model:~The investigators plan to randomly assign 30% participants for developing the diagnostic prediction model to a Validation cohort.~Validation Cohort of Prognostic Prediction Model:~New individuals selected by the same inclusion and exclusion criteria as the derivation cohort of prognostic prediction model from the same institutions as a validation cohort of prognostic prediction model will be recruited from January 2019."
89650720|NCT02984527|Active Comparator|water and soap first day|Intimate hygiene performed with water and soap first day and disposable wet wipes second day
89650721|NCT02984527|Active Comparator|disposable wet wipes first day|Intimate hygiene performed with wet wipes first day and water and soap second day
89045507|NCT06226558||Category 2: Confirmed cCMV infection NOT identified by NYS newborn screen|Infants who have both a NEGATIVE cCMV NYS newborn screen AND are found to have cCMV on confirmatory testing
89045508|NCT06226558||Category 3: False-positive cCMV NYS newborn screen|Infants who have both a positive cCMV NYS newborn screen AND are NEGATIVE for cCMV on confirmatory testing
89045509|NCT06226558||Category 4: Premature infants with confirmed CMV infection on late positive NBS|Infants who are: (a) born prior to 37 weeks gestation AND (b) cCMV positive on any NYS newborn screen collected prior to 44 weeks gestational age AND (c) Have a positive cCMV confirmatory test obtained within 14 days of a positive NYS newborn screen
89045510|NCT06226545|Experimental|Low-dose LASN01|
89045511|NCT06226545|Experimental|High-dose LASN01|
89045512|NCT06226545|Placebo Comparator|Placebo|
89045513|NCT06226532|Experimental|Group SL|10%lidocaine spray total 8 puffs at laryngoscopes blade and endotracheal tube cuff, 4 puffs each.
89045514|NCT06226532|Active Comparator|Group IL|2% lidocaine intravenous 1.5 mg/kg, not exceed 80 mg equally to spray group.
89045515|NCT06226506|Experimental|Test (T)-Reference (R)|In this trial, 24 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group A: Test (T)-Reference (R), The washout period (dosing interval) between doses will be at least 7 days. After fasting for at least 10 hours.
89650722|NCT04564014|Experimental|ISSS Intervention|The intervention group will receive 5 weekly ISSS sessions in addition to the information about mental health, depression, anxiety and available treatment and community resources also recived by the control group.
89650723|NCT04564014|Active Comparator|Wait-list control group|Members will receive information about mental health, depression, anxiety and available treatment and community resources but not ISSS during the intervention period.
89650724|NCT03025451|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
89045516|NCT06226506|Experimental|Reference (R)-Test (T)|In this trial, 24 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group B: Reference (R)-Test (T), The washout period (dosing interval) between doses will be at least 7 days. After fasting for at least 10 hours.
89045517|NCT06226454|Experimental|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-993.
89045518|NCT06226454|Placebo Comparator|Part A: Placebo|Participants will be randomized to receive placebo matched to VX-993.
89045519|NCT06226454|Experimental|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A.
89045520|NCT06226454|Placebo Comparator|Part B: Placebo|Participants will be randomized to receive placebo matched to VX-993.
89045521|NCT06226441|Active Comparator|CRRT group|Patients receiving aminoglycosides and submitted to CRRT
89045522|NCT06226441|No Intervention|no-CRRT group|Patients receiving aminoglycosides and no CRRT
89045523|NCT06226402|No Intervention|Control group|Patients will receive the standard pharmacotherapy of Acute Respiratory Distress Syndrome (ARDS) patients.
89045524|NCT06226402|Experimental|Inhalational group|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
89045525|NCT06226402|Experimental|Intravenous group|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
89045526|NCT06226389|Experimental|4 Different bulk-fill composite|Bulk-fill composite will be applied in different 4 posterior cavities with 3-4 ml in depth
89045527|NCT06226389|Experimental|Aging|For long term follow up
89045528|NCT06226376|Active Comparator|EXOPULSE Mollii Suit Stimulation Active.|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
89212932|NCT00533949|Active Comparator|60 Gy RT|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
89212933|NCT00533949|Experimental|74 Gy RT|74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
89650725|NCT03802617|Experimental|MR13A9 low dose|
89650726|NCT03802617|Experimental|MR13A9 medium dose|
89650727|NCT03802617|Experimental|MR13A9 high dose|
89650728|NCT03802617|Placebo Comparator|Placebo|
89650729|NCT03084055|Experimental|eMotion intervention|Subjects randomised to the intervention arm will receive eMotion for two months. eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity.
89650730|NCT03084055|No Intervention|Waiting list control|Subjects in the waiting list control group will be given no intervention for two months; the control group will then be able to access eMotion if they wish but this will not form part of the research project
89650731|NCT03025529|Experimental|Active Cerebellar rTMS|Cerebellar rTMS will be carried out in ET subjects using a MagPro stimulator with a double cone coil at 1Hz (1 pulse every second) for 3 minutes on the left and 3 minutes on the right, at the cerebellar location indicated by resting state functional connectivity MRI analysis. Subjects with ET will undergo 5 consecutive daily sessions of cerebellar rTMS at either the connectivity map generated target or sham rTMS and then crossover to the other target after 2 weeks. Subjects will be blinded to the treatment order assignment. The intensity of the stimulation will be determined as 90% of the resting motor threshold, to be determined at the beginning of the first visit.
89650732|NCT03025529|Sham Comparator|Sham Cerebellar rTMS|In sham rTMS, the same parameters and procedures as Treatment Procedures 4-8 will be used, except that the coil will be angled 90 degrees from the scalp, resting on one wing of the coil.
89650733|NCT03025529|No Intervention|Healthy control pilot|This pilot phase is done to assess feasibility of obtaining MRI and cerebellocortical inhibition measures in healthy control subjects.
89650734|NCT03088735|Experimental|Blastocyst-stage embryo transfer strategy|
89650735|NCT03088735|Active Comparator|Cleavage-stage embryo transfer strategy|
89650736|NCT01477892|Experimental|low dose remifentanil|continuous infusion of remifentanil 0.1mcg/kg/min
89650737|NCT01477892|Active Comparator|high dose remifentanil|continuous infusion of remifentanil 0.25mcg/kg/min
89650738|NCT03080779||ADP Group|Index group includes participants who have suffered an accidental dural puncture with a 16 gauge Tuohy needle
89650739|NCT03080779||Non-ADP group|Control group includes participants who received an uneventful epidural analgesia with a 16 gauge Tuohy needle
89650740|NCT00801801|Experimental|Metronomic Docetaxel + Sorafenib|"Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.~Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle."
89650741|NCT03395041||ATD - SG 01|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event revealed the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
89650742|NCT03395041||ATD - SG 02|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event did not reveal the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
89650743|NCT05273502|Experimental|Citizen Science Behavioral Intervention|The intervention group (IG) participants will receive the whole citizen science intervention of the project, and participants will be assessed at baseline and end-of-study.
89650744|NCT05273502|No Intervention|Control group|The controls group (CG) participants will not receive any kind of intervention, and participants will only be assessed at baseline and end-of-study.
89650745|NCT01422239|Experimental|Tailored behavioral counseling|"The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. The last 5 counseling sessions will be based on perceived risks of quitting."
89650746|NCT01422239|Active Comparator|Standard behavioral counseling|"The focus of the first three sessions for participants receiving the standard treatment will be the benefits of quitting smoking. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. All participants will receive identical counseling sessions during week 4-8 based on material from the Mayo Clinic manual."
89650747|NCT01499576|Experimental|Acetic acid spraying|
89650748|NCT03080233||Pakistani adult|"Men and women aged 18 years or above,presenting with neurological deficit consistent with stroke in the Emergency Department at Aga Khan University Hospital~Consenting to participate in the study"
89650749|NCT00802113|Experimental|Arm A - Family Donor|Fludarabine and Busulfan: Patients who have a matched family (allogeneic) donor will go on to receive non-ablative therapy, followed by an infusion of donor stem cells; this is called an allogeneic peripheral blood stem cell transplant. The non-ablative therapy will be busulfan and ﬂudarabine, Usually large (myeloablative) doses of these drugs are used for an allogeneic transplant. However, in this study lower doses (non-ablative) of chemotherapy will be given. In patients who still have evidence of disease after allogeneic transplant, additional donor immune cells (donor lymphocyte infusion) (DLI) will be given twice to further treat the lymphoma.
89212934|NCT00533949|Experimental|60 Gy RT + Cetuximab|60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
89212935|NCT00533949|Experimental|74 Gy RT + Cetuximab|74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
88993209|NCT03648541|Experimental|All Patients|1 arm solution for injection Spesolimab will be used for all patients. Those who did not respond to previous induction treatment or experienced disease flare will need i.v. re-induction treatment also
88993210|NCT03643354|Experimental|Evaluation of prevalence of BPPV|Epley/Barbeque maneuver will be performed using the Rotundum Device to assess if subject has BPPV, patient will thereafter be treated for it using the Rotundum Device.
88993211|NCT03603509|Active Comparator|Fluad vaccine|Subjects receive a single dose of the Fluad influenza vaccine.
88993212|NCT03603509|Active Comparator|Fluzone vaccine|Subjects receive a single dose of the Fluzone High-Dose influenza vaccine.
88993213|NCT03567993|Active Comparator|Comparison|The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
88993214|NCT03567993|Experimental|Intervention|The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
88993215|NCT03536871|Active Comparator|Multinutrient Supplement|Participants will be allocated in a randomized double-masked manner to receive a multi-nutrient supplement (protein and creatine sachet and omega-3 oil) or placebo during a 12 week home-based exercise program and we will assess the influence on the primary and secondary outcomes.
88993216|NCT03536871|No Intervention|Age biological and chronological|The primary and secondary outcomes will be compared between the younger and older age groups as a function of both exercise and nutritional supplementation.
88993217|NCT03536871|No Intervention|Sarcopenia grades|The baseline primary and secondary outcomes will be compared for each of the 3 older adults males groups as a function of muscle mass (healthy active, mild sarcopenia and moderate sarcopenia).
88993218|NCT03536871|Experimental|Exercise - home based programme|Each of the older participants will undergo a 12 week home-based exercise program (endurance = increased steps; resistance = body weight and elastic band exercise) to determine the effects on the primary and secondary outcomes.
88993219|NCT03487471|Active Comparator|Real-time elastography|98 patients with breast lesion will a receive breast ultrasound (real time elastography)
88993220|NCT03487471|Active Comparator|Shear Wave|98 patients with breast lesion will a receive breast ultrasound (shear wave elastography)
88993221|NCT03452813||ischemic stroke or intracerebral hemorrhage patients|patients discharged from hospital to home or discharged to rehab will be called at 30 day and 90 day to monitor their transition of care outcomes.
88993222|NCT03428932|Active Comparator|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
88993223|NCT03428932|Active Comparator|Closed-Loop|Subjects will transition from their current treatment (insulin pump or injections) onto the Medtronic 670G insulin pump (intervention arm as a comparator) and will have close contact with the study team. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
89045529|NCT06226376|Sham Comparator|EXOPULSE Mollii Suit Stimulation Sham.|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
89045530|NCT06226363|Experimental|LNF1901 monotherapy|
89045531|NCT06226350|Experimental|F520 monotherapy|
89045532|NCT06226337|No Intervention|No intervention: control group|No intervention was applied to the control group other than routine practice.45 women were assigned to the control group
89045533|NCT06226337|Experimental|Experimental group|45 women to the experimental group. In the study, the experimental group Acemaşiran makam was played to the women as music during hysterosalpingography.
89045534|NCT06226324||SLE with neuropsychiatric symptoms|"Neuropsychiatric symptoms meeting the 1999 ACR definition~Ages 18-55y~Female~Right-handed~Can cooperate with MRI and neuropsychiatric examination"
89045535|NCT06226324||SLE without neuropsychiatric symptoms|"Patients who meet the 2019 ACR diagnostic criteria for SLE~Patients without neuropsychiatric symptoms~Age 18-55y~Female~Right-handed~Able to cooperate with MRI and neuropsychiatric examination"
89045536|NCT06226324||Healthy control group|"Age and gender matched the case group~Right-handed~No cerebrovascular, neurological or mental diseases~Can cooperate with MRI and neuropsychiatric examination"
89045537|NCT06226311||Children of IoMum pregnants cohort|IoMum participants without congenital malformations or gestational diabetes, with a singleton pregnancy with live birth, who provided contact and a T1 urine sample, will be invited to participate under signed informed consent.
89045538|NCT06226298|Experimental|Xiaxi|The experimental group will lie in the Xiaxi postural hammock for 10 minutes for 5 days.
89045539|NCT06226298|Active Comparator|Control|The control group will lie on a mat on the floor for 10 minutes, 5 days of intervention.
89045540|NCT06226285|Experimental|Informal caregivers|Informal caregivers will participate in a participatory process of development, testing and validation of a technological platform aimed at improving their quality of life, impact of care, occupational balance, self-management of health and empowerment.
89045541|NCT06226272||S-S-102-A: Cervical Sub-Protocol|The study population includes subjects who are surgically treated with a Stryker device for a cervical condition per the specific device cleared IFUs and Surgical Technique Guides (STGs), by a participating investigator and are willing to complete patient-reported questionnaires at the study-specific time points.
89045542|NCT06226272||S-S-102-B: Thoracolumbar Sub-Protocol|The study population includes subjects who are surgically treated with a Stryker device for a thoracic/lumbar condition per the specific device cleared IFUs and STGs, by a participating investigator and are willing to complete patient-reported questionnaires at the study-specific time points.
89045543|NCT06226272||S-S-102-C: Adult Spinal Deformities|The study population includes subjects who are surgically treated with a Stryker device for a spinal deformity condition per the specific device cleared IFUs and STGs, by a participating investigator and are willing to complete patient-reported questionnaires at the study-specific time points.
89045544|NCT06226233|Experimental|Juniver intervention group|Immediate access to the Juniver program
89045545|NCT06226233|No Intervention|Wait list control|Access to the Juniver program after 12 weeks
89045546|NCT06226220|Experimental|3-day trial|Patients randomized to the 3-day trial arm will undergo a 3-day PNE trial phase for sacral neuromodulation. Participants will have the PNE placed in the office and return on day 3 for PNE removal.
89045547|NCT06226220|Active Comparator|7-day trial|Patients randomized to the73-day trial arm will undergo a 7-day PNE trial time for sacral neuromodulation. Participants will have the PNE placed in the office and return on day 7 for PNE removal.
89045548|NCT06226181|Active Comparator|Conventional dacryocystorhinostomy|Patients undergoing conventional dacryocystorhinostomy using external approach.
89650750|NCT00802113|Experimental|Arm B - Unrelated Cord Blood or Adult|Fludarabine, Busulfan and ATG: For patients who don't have a matched family donor, a cord blood search and unrelated adult search will be done at all of the cord blood banks and adult donor registries in the world. If a closely matched cord blood donor or unrelated adult donor is found, non-ablative chemotherapy with busulfan, ﬂudarabine and antithymocyte globulin (ATG) followed by the infusion of matched unrelated cord blood cells or adult donor stem cells or bone marrow to restore the bone marrow will be given.
89045549|NCT06226181|Experimental|Dacryocystorhinostomy using amniotic membrane|Patients undergoing conventional dacryocystorhinostomy using external approach and adding amniotic membrane over the osteotomy, fixed with sutures.
89045550|NCT06226142|Experimental|Ultrasound guided percutaneous tracheostomy|The PDT will be performed by the attending physician exclusively with the aid of the ultrasound.
89045551|NCT06226142|Active Comparator|Bronchoscopy guided percutaneous tracheostomy|The PDT will be performed by the attending physician exclusively with the aid of the bronchoscope.
89045552|NCT06226142|Active Comparator|Ultrasound-bronchoscopy guided percutaneous tracheostomy|The PDT will be performed by the attending physician with the aid of the ultrasound and bronchoscope.
89650751|NCT03084601|Active Comparator|calcium hydroxide iodoform paste|intervention administered to control group is a combination of drugs as follow: ciprofloxacin 500mg, cefixime 500 mg, metronidazole 500 mg, simvastain 40mg. all are mixed, placed in pulp chamber only one time and tooth is restored
89650752|NCT03084601|Experimental|3-mixtatin|intervention administered to experimental group is a ready made mixture of calcium hydroxide and iodoform, placed in pulp chamber only one time and tooth is restored
89650753|NCT01476722|Experimental|OPTI-FREE PureMoist|OPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days
89650754|NCT03084133|Experimental|Therapeutic Education Strategy|"Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.~Intervention 'Therapeutic Education Strategy'"
89650755|NCT03084133|No Intervention|Control group|Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice
89045553|NCT06226129|Experimental|Gadopiclenol|Gadopiclenol in dose, route of administration, and indication that is FDA-approved.
89045554|NCT06226116|Experimental|socket preservation with autologous dentin|
89045555|NCT06226116|Placebo Comparator|extract teeth socket|only stabilized blood clot
89650756|NCT04535778|Experimental|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. Participants will also have access to the standard charity resources.
89650757|NCT04535778|Active Comparator|Standard charity resources|Participants will be directed to the standard resources provided by the charities involved in the study.
89045556|NCT06226103|Experimental|Interventional Group (Aerobic Exercise and Computerized Cognitive Training)|"Aerobic Exercise (AE) included walk briskly, increasing intensity and duration progressively. The first week they had to walk 30 min per day, 3 days per week, up to 9-10 on the Borg Rating of Perceived Exertion Scale (BRPES; Borg, 1982) perceived as light intensity; during the second week, the duration was increased to 45 min and the intensity 9-10 and frequency (3 days per week) were maintained; the following 10 weeks they maintained the duration (45 min) and frequency (3 days per week) and increased the intensity up to 12-14 on BRPES perceived as moderate-high effort.~Computerized Cognitive Training (CCT) included a multidomain computer-based cognitive training using the brainHQ software in sessions of 45 min, 3 days per week for 12 weeks. Cognitive tasks targeted attention, recognition, colour and shape, identification, calculation, visual perception, visual spatial processing, memory, and executive function)."
89045557|NCT06226103|Active Comparator|Control Group|Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks.
89045558|NCT06226090|Experimental|TG103 7.5 mg|
89045559|NCT06226090|Placebo Comparator|Placebo 7.5 mg|
89045560|NCT06226090|Experimental|TG103 15 mg|
89045561|NCT06226090|Placebo Comparator|Placebo 15 mg|
89045562|NCT06226090|Experimental|TG103 22.5 mg|
89045563|NCT06226090|Placebo Comparator|Placebo 22.5 mg|
89650758|NCT00791973|Active Comparator|Veramyst, then Placebo|fluticasone furoate (Veramyst) nasal spray once daily for a week, then one week washout period followed by placebo nasal spray once daily for a week
89650759|NCT00791973|Active Comparator|Placebo, then Veramyst|placebo nasal spray once daily for a week, then one week washout period followed by fluticasone furoate (veramyst) nasal spray once daily for a week
89650760|NCT01476644|Other|Glaucoma Patients|Moderate glaucoma patients with a minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or pseudoexfoliation glaucoma were included to complete annual visits over a 4 year period. Each visit included (1) Clinical evaluation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance based measures: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related quality of life (VRQoL) (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).
89650761|NCT04533360||Community Cohort 1|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
89650762|NCT04533360||Community Cohort 2|1000 Participants from the community will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
89650763|NCT04533360||Healthcare Provider Cohort 1|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 1.
89650764|NCT04533360||Healthcare Provider Cohort 2|500 hospital employees will be recruited to undergo serological testing for SARS-CoV2 Antibodies at time point 2.
89650765|NCT00802503|Experimental|SPN group|"experimental arm: Supplemental Parenteral Nutrition (SPN) is added to enteral nutrition (EN) to reach 100% of their predicted energy needs from ICU day 4.~In the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line. Nutritional products as currently used in our institution. SPN is composed of EN and PN, both techniques being currently used in our institution."
89650766|NCT00802503|No Intervention|Control gr|EN : start EN at 20-30 ml/h per day up to maximal 150 ml/h per day; or day1: 500 ml, day2: 1000 ml, day3: 1500 ml of EN dependant on gastrointestinal tolerance (gastric residue volume more than 500ml). Nutritional products as currently used in our institution.
89650767|NCT04402333||Robotic interval debulking surgery|Surgery will commence with an initial assessment with a camera inserted though the belly button. This visual assessment will be used to determine whether it is feasible to proceed with surgery robotically or whether full debulking surgery to zero macroscopic residual disease would be best carried out through an open surgical approach. If an open surgical approach is considered the optimum treatment for the patient and they have consented for this, then this will be done. If there is disease that cannot be removed Robotically after starting by this route, but can be removed via an open incision the surgery will be converted to an open procedure if it is safe to do so. If there are any complications, we may also need to convert to open surgery. The aim of the surgery whether by robotic or open is to remove all visible disease safely.
89650768|NCT04402333||Open interval debulking surgery|Standard Care. Following initial laparoscopic assessment patients not deemed suitable for minimally invasive robotic surgery will proceed with standard open interval debulking surgery through an extended midline incision. These patients will also be followed up to assess recovery, complication rate and quality of life.
89650769|NCT03425539|Experimental|Lucerastat|
89650770|NCT03425539|Placebo Comparator|Placebo|
89650771|NCT04490616|Experimental|RR-GR|MCI patients with social cognition deficits will receive 4 weeks of rTMS stimulation
89650772|NCT04490616|Other|SR-GR|MCI patients with social cognition deficits will receive 2 weeks of placebo treatment, followed by 2 weeks of real rTMS stimulation
89650773|NCT05304624|Active Comparator|Group 1: ErCr:YSGG laser|"Waterlase iPlus,Biolase-USA Er,Cr:YSGG laser (2780nm) was set at frequency 50Hz, power of 2.5W and 1562.5 W/cm2. MZ6 (400µm fiber tip) was used in contact mode for de-epitelization procedure.~Another visit of laser ablation was performed after 7 days to remove the remaining pigmentation. The same laser settings were used."
89650774|NCT05304624|Experimental|Group 2: Diode laser|"Ilase, Biolase-USA Diode laser (940nm) was set at power of 1.2W and 750 W/cm2. 400µm fiber tip was used in contact mode and continuous-wave for de-epitelization procedure.~Another visit of laser ablation was performed after 7 days to remove the remaining pigmentation. The same laser settings were used."
89650775|NCT03080389||Extended urine culture|Each patient will be their own control and two specimens will be obtained from each participant. The first will be a catheterized urine sample to be sent for routine culture and the second will be collected from the same catheterized specimen and sent for extended culture.
89650776|NCT00773955|Experimental|Treatment (R-(-)-gossypol)|Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89650777|NCT03080623||Suspicious breast lesions|women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasound，patients will be assigned to breast biopsy or follow-up
89650778|NCT03088501|Experimental|Interactive Voice Response System|Through IVRS, women will receive a 2-3 minute call that informs them about their lab test, next follow-up visit, breastfeeding, introduction of solid foods, immunization, motor development, and sleep.
89650779|NCT03088501|Experimental|Mother and Baby Affairs (MBA) workshops|"This will involve antenatal workshop and counselling for parents.~Brief talk by health professionals.~Role-plays"
89045564|NCT06226077|Experimental|sleep extension intervention arm|sedentary and short sleep (=<6 hrs/night) African American adults with overweight/obesity randomized to the sleep extension intervention.
89045565|NCT06226077|Active Comparator|education contact control arm|sedentary and short sleep (=<6 hrs/night) African American adults with overweight/obesity randomized to contact control intervention.
89650780|NCT03088501|No Intervention|Control Arm|The participants in this group do not get any specific interventions but would receive standard instructions to attend follow-up.
89650781|NCT05231772|Experimental|Probiotics|Patients in the Test arm will receive Saccharomyces boulardii (Saccharomyces), (Enterol), Biocodex Ltd, France, registration number LP-000622 from 21.09.2011 at a dose of 250 mg 2 times a day for 3 months.
89650782|NCT05231772|Placebo Comparator|Placebo|Patients in the Placebo arm will receive the placebo at a dose of 250 mg 2 times a day for 3 months.
89650783|NCT03083899|Experimental|Diatast|Free patient-initiated use of out-patient services
89650784|NCT03083899|Placebo Comparator|Control|Scheduled diabetes control
89650785|NCT01421459|Experimental|LY2963016 + OAMs|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) [alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)] administered per standard of care for 24 weeks
89650786|NCT01421459|Active Comparator|Lantus + OAMs|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks
89650787|NCT01498952|Experimental|Phase 1b Cohort A|Participants will receive MEDI-573 10 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
89650788|NCT01498952|Experimental|Phase 1b Cohort B|Participants will receive MEDI-573 45 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
89650789|NCT01498952|Experimental|Phase 1b Cohort C|Participants will receive MEDI-573 30 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
89650790|NCT01498952|Experimental|Phase 2 Arm 1|Participants will receive recommended dose of MEDI-573 from Phase 1b IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
89650791|NCT01498952|Active Comparator|Phase 2 Arm 2|Participants will receive sorafenib 400 mg orally twice daily until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
89650792|NCT03802539|Experimental|Glass Liner|Tooth restoration with a glass ionomer liner material under a nanohybrid composite resin
89650793|NCT03802539|No Intervention|No liner|Tooth restoration without a glass ionomer liner material under a nanohybrid composite resin
89650794|NCT05304312|Experimental|Women with Kegel Exercises book|"We gave the patient the Kegel Exercises guidebook for them to study, follow, and keep track of their exercise.~The Kegel Exercises regiment was 10 each slow and fast-twitch muscle contraction for a session. Three sessions a day needed to be done every day for 12 weeks."
89045566|NCT06226064|Experimental|VES001 (Healthy Participants)|Part A: Ascending single doses and Part B: Multiple ascending dose (seven days of treatment), for healthy volunteers.
89650795|NCT05304312|No Intervention|Women without Kegel Exercises book|We did not give the Kegel Exercises guidebook for the patients We taught the same Kegel Exercises regiment that was 10 each slow and fast-twitch muscle contraction for a session. Three sessions a day and needed to be done every day for 12 weeks
89650796|NCT03393637|Experimental|M-O-M-S Intervention|M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
89650797|NCT03393637|No Intervention|Routine Prenatal Care|Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines
89650798|NCT03083743|Experimental|Recombinant human Apo-2 ligand|Recombinant human Apo-2 ligand for Injection
89650799|NCT03083743|Placebo Comparator|Placebo|Mimetic agent for recombinant human Apo-2 ligand for injection
89045567|NCT06226064|Placebo Comparator|Placebo (Healthy Participants)|Part A: Ascending single doses and Part B: Multiple ascending dose (seven days of treatment), for healthy volunteers.
89045568|NCT06226038|Experimental|With magnet|
89045569|NCT06226038|Sham Comparator|Without magnet|
89045570|NCT06226012|Experimental|Group A|Group (A) received Pulsed magnetic field therapy in addition to traditional exercise program
88993224|NCT03417531|Active Comparator|Protein Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a simple home exercise strength program (3x30 minutes/week)
88993225|NCT03417531|Active Comparator|Protein-free Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a simple home exercise strength program (3x30 minutes/week)
88993226|NCT03417531|Active Comparator|Protein Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a joint flexibility home exercise program (3x30 minutes/week)
88993227|NCT03417531|Sham Comparator|Protein-free Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a joint flexibility home exercise program (3x30 minutes/week)
88993228|NCT03386487|Active Comparator|PF-04457845|Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks
88993229|NCT03386487|Placebo Comparator|Placebo|Subjects will be randomized to placebo
89650800|NCT04608266|Experimental|Camostat mesylate|Camostat mesylate, oral administration 600mg/day
88993230|NCT03375918|Other|Healthcare Trainees - Cluster 1|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
88993231|NCT03375918|Other|Healthcare Trainees - Cluster 2|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
88993232|NCT03375918|Other|Healthcare Trainees - Cluster 3|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
88993233|NCT03375918|Other|Healthcare Trainees - Cluster 4|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
88993234|NCT03375918|Other|Healthcare Trainees - Cluster 5|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
88993235|NCT03361345|Experimental|Right Side of Face|Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
88993236|NCT03361345|Sham Comparator|Left Side of Face|Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
88993237|NCT03312686||Eosinophilic Esophagitis patients|PPI treatment
88993238|NCT03256201|Experimental|Standard Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
88993239|NCT03256201|Experimental|Enhanced Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
88993240|NCT03245866||Aneurysmal Subarachnoid hemorrhage|Patients suffering from a ruptured cerebral aneurysm are included in the study.
88993241|NCT03216187|Experimental|Pregabalin|Pregabalin 150 mg twice daily, starting from the evening before surgery, continuing with two times 150mg per day for 12 days, and ending with one 150mg capsule every evening for the final 3 days.
88993242|NCT03216187|Placebo Comparator|Placebo|Identical placebo capsules twice daily, starting from the evening before surgery, continuing with two capsules per day for 12 days, and ending with one capsule every evening for the final 3 days.
89650801|NCT04608266|Placebo Comparator|Placebo|Placebo tablets, oral administration
89650802|NCT05304156||Standard of Care in patients with AML|"Standard of Care including a first course containing one of the following backbones without addition of third agent before day 8 of induction (approved drugs such as midostaurine or investigational agents administered beyond day 8 are allowed) :~7+3 induction 3+7 with daunorubicin (or idarubicin) and cytarabine~CPX-351 induction"
89650803|NCT03839901|Experimental|isometric training programme|'Home exercise programme' consisting of isometric exercises with participants followed up at week 1, 4, 6 and 8.
89650804|NCT03839901|Experimental|isotonic training programme|'Home exercise programme' consisting of isotonic exercises with participants followed up at week 1, 4, 6 and 8.
89650805|NCT04489134|Experimental|A D B C|Period n°01: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°03:Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°04:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
89650806|NCT04489134|Experimental|B A C D|Period n°01: Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°02:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
89650807|NCT04489134|Experimental|C B D A|Period n°01: Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°03:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°04:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
89650808|NCT04489134|Experimental|D C A B|Period n°01:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°02:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a 2 mg dose of LCP-tacro (Envarsus®)
88993243|NCT03195270|Experimental|Single Arm|[18F]FDG PET/MRI
88993244|NCT03172754|Experimental|Phase I patients|Phase I patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
89650809|NCT05685355||Gingivitis samples|"Inclusion criteria:~Adult subjects attending PPDH can give informed consent.~Subjects who are diagnosed to have gingivitis only and have 24 or more teeth.~Subjects who are otherwise medically healthy.~Subjects who can attend multiple dental visits.~Exclusion criteria~Subjects who are in acute dental infection or in pain.~Subjects who have oral mucosal diseases that preclude retraction of soft tissues for photos.~Subjects who are in the fixed appliance for orthodontic treatment.~Subjects who are pregnant, or medically unfit for periodontal charting or require antibiotic coverage (e.g. risk of infective endocarditis)"
89650810|NCT00774267||1|
89650811|NCT00774267||2|
89650812|NCT00774267||3|
89650813|NCT00774267||4|
89650814|NCT05213130|Experimental|Information group|In this group, blood donors will receive a questionnaire 15-25 days after their blood donation, i.e., after their blood has been sent to the hospital and be transfused by patients. The questionnaire contains items measuring empathy, altruism, subjective well-being, etc., as well as a clear reminder to inform donors that their blood has saved patient's life.
89650815|NCT05213130|No Intervention|Non-information group|In this group, blood donors will receive a questionnaire 15-25 days after their blood donation, i.e., after their blood has been sent to the hospital and be transfused by patients. The questionnaire contains items measuring empathy, altruism, subjective well-being, etc., but there will be no reminder to inform donors that their blood has saved patient's life.
89650816|NCT04400851|Experimental|Sintilimab in advanced childhood cancer patients|
89650817|NCT05191056|Placebo Comparator|Placebo drink|
89650818|NCT05191056|Experimental|MelaGene drink|
89650819|NCT01461044||Cohort|
89650820|NCT03080155|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
89650821|NCT00774579||1|Patients with growth hormone (GH) deficiency starting GH replacement.
89650822|NCT00774579||2|Patients with growth hormone (GH) deficiency not starting GH replacement.
89650823|NCT03080077|Active Comparator|Epi-Off CXL|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
89650824|NCT03080077|Experimental|Epi-On CXL|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
89650825|NCT04041869|Experimental|MapTrek|
89650826|NCT00793455|Experimental|Intervention Group|Received Educational Outreach
89650827|NCT00793455|No Intervention|Usual Care Control Group|Participants in this arm will receive normal care until outcome assessment is performed at 6 months following the placement of the order for the preventive service. They will be sent a letter reminding them to obtain the ordered preventive service test.
89650828|NCT01421303||AS patients who are working and treated with Enbrel|
89650829|NCT04279639||qigong practice|Patients in this arm participated in qigong as part of their treatment at the Pain Management Unit
89650830|NCT04279639||control|Patients attend the pain management unit but do not undertake qigong practice.
89650831|NCT05303922|Experimental|DECT and MRI|Patients will be scanned with both DECT and MRI.
89650832|NCT04348201|Active Comparator|foot reflexology|foot reflexology session which takes about 20 minutes.
89650833|NCT04348201|Active Comparator|dietary modification|diet must be rich in vitamins.
88993245|NCT03172754|Experimental|Phase II patients: cohort 1|Phase II cohort 1 patients must have received at least 1 prior tyrosine kinase inhibitor for RCC.
89650834|NCT03027050|Experimental|Titanium-prepared platelet rich fibrine|T-PRF was applied with open flap debridement in test group.
89650835|NCT03027050|Active Comparator|Open Flap Debridement alone|T-PRF was not applied to control groups. Only open flap debridement was applied to control groups.
89650836|NCT05303766|Experimental|RFT group|The treatment of the patients in the radio frequency thermo-coagulation of the genicular nerves was conducted under the guidance of C-arm X-ray machine . The C-arm machine showed that the radiofrequency cannula needle was advanced percutaneously towards the periosteal areas connecting the shaft of the femur to bilateral epicondyles and the shaft of the tibia to the medial epicondyle while the lateral image showed that the depth of the needle insertion was about 50% of the diameter of the femur or tibia. The radiofrequency electrodes were connected and tested. These induced abnormal pain around the knee joint at 50 Hz and 0.1-0.3 V, but did not induce contraction of the muscles of the knee joint at 2 Hz and > 2.0 V. The location of the needle tip was confirmed by the C-arm, and 0.5 mL of 1% lidocaine was used for local anesthesia. The temperature of RFT was increased gradually to 70°C for 180 seconds.
89688600|NCT02802514|Experimental|Without Off therapy MRI in S1: Exenatide-S1 & Albiglutide-S2|In session 1, subject will receive single dose each of albiglutide placebo on Day 1 and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. In session 2, subject will undergo off-therapy MRI scan on Day 1 (Week 9). Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI scan.. There will be 6-9 week washout period between Session 1 and Session 2
89688601|NCT00944671|Active Comparator|A|Famotidine/antacid combination tablet with water
89688602|NCT00944671|Experimental|B|Famotidine/Antacid EZ Chew tablet without water
89688603|NCT00944671|Experimental|C|Famotidine/Antacid EZ Chew tablet with water
88993246|NCT03172754|Experimental|Phase II patients: cohort 2|Phase II cohort 2 patients must not have received prior systemic therapy for advanced RCC.
89688604|NCT02922868|Experimental|EndoSheath CST-5000 Scope|Cogentix Medical CST-5000 Flexible Video Cystoscope with Slide-On® EndoSheath® Technology. EndoSheath CST-5000 Scope.
88993247|NCT03123913|Experimental|Combination therapy|Testosterone Enanthate and Somatropin
88993249|NCT03066258|Experimental|Cohort 1|3E9 GC (genome copies)/eye of RGX-314 (E means the exponential constant)
88993250|NCT03066258|Experimental|Cohort 2|1E10 GC/eye of RGX-314
88993251|NCT03066258|Experimental|Cohort 3|6E10 GC/eye of RGX-314
88993252|NCT03066258|Experimental|Cohort 4|1.6E11 GC/eye of RGX-314
88993253|NCT03066258|Experimental|Cohort 5|2.5E11 GC/eye of RGX-314
88993254|NCT03054155|Experimental|Treatment Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
88993255|NCT03054155|No Intervention|Control Arm|For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
88993256|NCT03039985|Experimental|Bruxism + lithium disilicate crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
88993257|NCT03039985|Experimental|No bruxism + lithium disilicate crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
88993258|NCT03039985|Experimental|Bruxism + zirconia crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from zirconia.
88993259|NCT03039985|Experimental|No bruxism + zirconia crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from zirconia.
88993260|NCT03028831|Active Comparator|Resistant Starch|70g high-amylose maize starch which contains 42g of type 2 resistant starch
88993261|NCT03028831|Placebo Comparator|Digestible Starch|70g of fully digestible starch comprised of amylopectin corn starch.
88993262|NCT03024255|Experimental|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
88993263|NCT03024255|Experimental|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
88993264|NCT03024255|Experimental|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
88993265|NCT03024255|Placebo Comparator|Vehicle|Placebo, applied once to each axilla daily
88993266|NCT03007238|Experimental|Supportive care (aldesleukin and ECP)|Patients receive aldesleukin SC daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop.
88993267|NCT02902198|Placebo Comparator|Placebo preoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
88993268|NCT02902198|Placebo Comparator|Placebo postoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
88993269|NCT02902198|Active Comparator|Glucose preoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
88993270|NCT02902198|Active Comparator|Glucose postoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
88993271|NCT02902198|Active Comparator|Monosodium glutamate preoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
88993272|NCT02902198|Active Comparator|Monosodium glutamate postoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
88993273|NCT02902198|Active Comparator|Quinine preoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
88993274|NCT02902198|Active Comparator|Quinine postoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
88993275|NCT02858869|Experimental|Arm A (pembrolizumab, SRS 6 Gy, CLOSED):|Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat Q3W for at least 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo 5 SRS fractions between days 2-15 of course 1.
88993276|NCT02858869|Experimental|Arm B (pembrolizumab, SRS 9 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 3 SRS fractions between days 2-15 of course 1.
88993277|NCT02858869|Experimental|Arm C (pembrolizumab, SRS 18-21 Gy)|Patients receive pembrolizumab IV as in Arm A. Patients undergo 1 SRS fraction between days 2-3 of course 1.
88993278|NCT02852031||Hypoplastic Left Heart Syndrome|Infants diagnosed with Hypoplastic Left Heart Syndrome (HLHS)
88993279|NCT02849717|No Intervention|Standard Care|Subjects are advised to maintain their normal level of activity
88993280|NCT02849717|Active Comparator|Home-Based Exercise|Progressive walking and resistance exercise treatment
88993281|NCT02811523|Experimental|Doxorubicin 5 mcg/ml|Doxorubicin 5mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
88993282|NCT02811523|Experimental|Doxorubicin 7 mcg/ml|Doxorubicin 7mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
88993283|NCT02811523|Experimental|Doxorubicin 9 mcg/ml|Doxorubicin 9mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
88993284|NCT02811523|Experimental|Doxorubicin 7 mcg/ml - expansion|Expansion group at ideal dose
89045571|NCT06226012|Experimental|Group B|Group (B) received Low level laser therapy in addition to traditional exercise program
89045572|NCT06225986|Experimental|LMH-4-DCP Intervention|
89688605|NCT02922868|Active Comparator|Olympus Visera Elite OTV-S190 Scope|Olympus HD Flexible Cysto-Nephro Videoscope (CYF-VH) with Olympus Visera Elite Platform, including OTV-S190 Video Processor CLV-S190 Xenon Light Source. Olympus Visera Elite OTV-S190 Scope.
89688606|NCT00944749|Experimental|Single Arm|
89688607|NCT02763202|No Intervention|Usual Care Group|Participants assigned to the usual care group will continue have the current standard of care including any discharge services for example those usually arranged by case managers, hospitalists, and primary care physicians.
88993285|NCT02800551|Experimental|SBRT (Arm A)|"dose-intensified image-guided SBRT using simultaneous integrated boost:~in the case of no epidural involvement: 40 Gy and 20 Gy in 5 fractions to the high-dose and conventional-dose target volume, respectively.~In the case epidural involvement: 48.5 Gy and 30 Gy in 10 fractions to the high-dose and conventional-dose target volume, respectively."
88993286|NCT02800551|Active Comparator|Conventional Radiation Therapy (Arm B)|"External 3-dimensional conformal radiotherapy (3D-CRT):~Homogeneous irradiation of the affected vertebra delivering either~20 Gy in 5 fractions or~30 Gy in 10 fractions."
88993287|NCT02800551|Experimental|SBRT (prospective observational)|Patients eligible for the prospective observational arm will be treated according to the investigational arm (arm A) of the randomised arm of the trial.
88993288|NCT02774694||observational cohort|patients undergoing interventional pain management procedures
88993289|NCT02751138||Isocitrate dehydrogenase - 1 mutated|Immunophenotype of Glioblastoma and correlation with outcome
88993290|NCT02751138||Isocitrate dehydrogenase - 1 wild type|Immunophenotype of Glioblastoma and correlation with outcome
88993291|NCT02750319|Placebo Comparator|Amiodarone + Placebo|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading matching placebo; 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 NAC matched placebo continuously for 48 hours.
88993292|NCT02750319|Experimental|Amiodarone + N-Acetylcysteine|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading: 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 and then continuously for 48 hours.
88993293|NCT02690766|Other|Physical Activity Group|The Success Study's Standard Behavioral Weight Change Intervention consists of 75 minute group sessions held monthly which include 30 minutes of physical activity with a licensed Physical Activity Instructor. Web Lessons that include information on Physical Activity, Nutrition and Healthy Behaviors will also be provided to participants on the study's website.
89650837|NCT05303766|Experimental|IAPRF group|The puncture site was selected in the middle of the medial or lateral edge of the patella. After local anesthesia was administered with 0.5% lidocaine, the radiofrequency cannula needle was inserted slowly between the patella and femoral condyles. The needle was gradually inserted into the joint cavity, and then a small volume of saline was administered using a syringe. If any resistance was encountered, which indicated that the needle tip was located in a ligament or tendon, the surgeon readjusted the needle tip until the injection proceeded without any significant resistance. After entering the joint cavity, the C-arm x-ray is used confirm that the cannula needle was located in the middle of the joint space. Subsequently, sensory stimulation using 50 Hz/2 Hz was performed at > 2 V, to prevent inducing pain or muscle contraction. Then, an automatic PRF mode ≤ 45 V (≤ 42°C, 2 Hz, pulse width of 20 ms) was administered for 300 seconds.
88993294|NCT02688699|Experimental|EndoClot|spraying of Endoclot powder after EMR or ESD
88993295|NCT02688699|No Intervention|control|
89650838|NCT05303766|Experimental|IAS group|The puncture procedure was similar to that for the IAPRF group. After the cannula needle was inserted to the articular cavity, 1 mL compound betamethasone (2 mg betamethasone sodium phosphate and 5 mg betamethasone dipropionate) was injected. Then, the needle was withdrawn, and the puncture site was dressed aseptically.
89650839|NCT03703375|Experimental|Administration of Oral Azacitidine (CC-486)|Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
89650840|NCT03703375|Active Comparator|Investigator's choice therapy - Romidepsin|Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)
89650841|NCT03703375|Active Comparator|Investigator's choice therapy - Gemcitabine|Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
89650842|NCT05080725|Experimental|Generalized sarcopenia group|Older adults will be recruited from local community centers, physician offices, and retirement communities via flyers. Participants will complete 16 sessions of standard of care swallowing exercises 2 times per week for 8 weeks. All sessions will be conducted via Webex. During each session, a series of standard of care swallow exercises will be performed following a demonstration from a trained speech-language pathologist.
89650843|NCT05303688|Experimental|Drug: Dexketoprofen Tremetamol|50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, Istanbul, Turkey) were administrated 30 minutes before incision in the treatment group (deksketoprofen trometamol n= 15)
89650844|NCT05303688|Placebo Comparator|Drug: Steril Salin (control)|iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15)
89650845|NCT03083509|Other|Group1 (Resistance trained individuals)|Resistance trained individuals (>3 sessions per weeks for ≥2 years with a minimum of 1 session per week including leg-based exercises)
89650846|NCT03083509|Other|Group 2 (Trained cyclists)|Trained cyclists (competing at a minimum of Category 3 road racing/estimated 10 mile TT of <25 minutes and a training history of ≥5 hours per week for ≥2 years)
88993296|NCT02669056|Experimental|preterm babies|preterm babies (less than 28 weeks)
88993297|NCT02669056|Other|term babies|term babies with blood test prescription
88993298|NCT02637102||Patients undergoing cardiac or vascular surgery|
88993299|NCT02611258|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
88993300|NCT02512939|Experimental|Contacts of TB cases|Blood test, not yet marketed, development phase
89650847|NCT03083509|Other|Group 3 (Team sports players)|Team sports players (minimum of University 1st team level e.g. soccer, rugby union, rugby league, hockey and basketball, playing competitively ≥1x per week for ≥2 years)
89650848|NCT04383717|Active Comparator|Proposed treatment group|Levamisole and isoprinosine
89650849|NCT04383717|Active Comparator|Control group|hydroxychloroquine and azithromycin
89650850|NCT04077788||Study group (group A):|It consisted of fifteen subjects who received muscle energy technique (Mitchell relaxation osteopathic technique). Two sessions per cycle for three cycles before menstruation by one week and after the end of menstruation by one week. In addition to their medical treatment non-steroidal anti-inflammatory drugs (NIAIDS).
89650851|NCT04077788||control group (group B):|It consisted of fifteen subjects who took their medical treatment only (non-steroidal anti-inflammatory drugs (NIAIDS)).
89650852|NCT01400243|Placebo Comparator|Placebo Patch|Placebo patch for 15-day quit period
88993303|NCT02230124|Experimental|MRE|
89650853|NCT01400243|Active Comparator|Nicotine Patch|7 mg Habitrol nicotine patch-15 day quit period
89650854|NCT03083119|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
89650855|NCT03083119|Placebo Comparator|Placebo Comparator|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
89650856|NCT00809055|Experimental|High dose caffeine|Loading dose 40mg/kg IV caffeine citrate, followed 12 hours later by 20mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate.
89650857|NCT00809055|Active Comparator|Standard dose caffeine|Loading dose 20mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo, followed 12 hours later with 10mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo.
89650858|NCT05303454|Experimental|Cartoons|Reduce Pain and Fear Levels of Children
89650859|NCT05303454|Experimental|Musical-moving Toys|Reduce Pain and Fear Levels of Children
89650860|NCT05303454|No Intervention|CONTROL|NOT Reduce Pain and Fear Levels of Children
89650861|NCT01475162|Experimental|Tocilizumab|"Drug: Tocilizumab~Other Names:~Actemra~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response."
89650862|NCT01421225|Active Comparator|Standard Insulin Pump Therapy first, then Closed Loop|Standard therapy day 1, Closed-Loop therapy day 2.
89650863|NCT01421225|Active Comparator|Closed Loop first, then Standard Insulin Pump Therapy|Closed-loop therapy day 1, standard therapy day 2.
89650864|NCT05189496|Experimental|hyperbaric oxygen therapy group|30-40 times hyperbaric oxygen therapy
89650865|NCT05189496|No Intervention|control group|No hyperbaric oxygen therapy
89650866|NCT04386798|Other|survey application to mothers|In the neonatal intensive care, the information form, postpartum specific anxiety scale, and neonatal intensive care unit parent-father stress scale will be filled in for the mothers who have a baby.
89650867|NCT00803751|Experimental|Truview intubation|Receive laryngoscopy with Truview first and is immediately followed by laryngoscopy and intubation with Macintosh
89650868|NCT00803751|Active Comparator|Macintosh intubation|Macintosh blade will be used first followed by laryngoscopy and intubation with the truview
89650869|NCT04279015|Active Comparator|Conventional rehabilitation treatment|Conventional physiotherapy program, consisting of standardised active (exercise) and passive (hotpack, ultrasound, conventional TENS) physical therapy methods, was applied by the same physiotherapist.
89650870|NCT04279015|Active Comparator|Kinesio tape procedure|In addition to the conventional physiotherapy program Kinesio tape was performed every day of conventional treatment immediately after the session ended by the same physiotherapist.
89650871|NCT01498640|Experimental|XIAFLEX/XIAPEX MP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord
89650872|NCT01498640|Experimental|XIAFLEX/XIAPEX PIP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord
89650873|NCT03366727|Experimental|DCB group|this group treated with drug coated balloon catheter, Orchid
89650874|NCT03366727|Experimental|PTA group|this group treated with plain balloon catheter, Admiral Xtreme
89650875|NCT04386330|Experimental|Narrative Exposure Therapy|Firefighters will receive distance-delivered NET administered by a paraprofessional.
89650876|NCT04279717||Subjects with von Willbrand Disease Acquired|
89650877|NCT04279717||Subjects with von Willbrand Disease Congenital|
89650878|NCT04371120||Brain Injury Survivors|Traumatic or acquired brain injury survivors, patients of RHI
89650879|NCT03801603|Experimental|HPV Vaccination Training and Education|Participants will be educated on the importance of HPV vaccination.
89650880|NCT03082885|Experimental|Thymosin-α1 group|Patients receive treatment based on standard Therapy with additional Thymosin-α1
89650881|NCT03082885|No Intervention|control group|Patients receive treatment based on standard Therapy
89650882|NCT04382781||COVID-19 infection|Consecutive patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who showed clinical and analytical data suggestive of macrophage activation syndrome during admission until March 30, 2020 .
89650883|NCT05688787|Active Comparator|Perineural injection arm|"30 patients will be received 4 sessions of perineural injection~1 week a part with optional additional sessions per the physician recommadation and the patient preference .injections are done with a 27 gauge half 1/2 needle directed perpendicular to the skin and going~1/ to the skin surface delivering 1_2 cc of buffered 5% dextrose solution in the subcutaneous superficial perineural tissue we will be targeting the most triggering points for each patient emphasizing on pain located in thoraco-dorsal fascia, the fascia of the erectorspinae muscles along T10 to L2 dorsal rami, interspinoustenderness from medial branches of dorsal rami, superiorcluneal nerve at 7-8 cm from middle line cross the iliac crest &amp; T10 cross over iliac crest at a distance 8-10cm"
89650884|NCT05688787|No Intervention|Standard treatment|will be received standard of care treatment of fibromyalgia
89650885|NCT04861935|Placebo Comparator|ultrasound evaluation of sacral region in normal pediatric patients|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
89650886|NCT04861935|Active Comparator|ultrasound evaluation of sacral region in patients with sacral dimple|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
88993304|NCT02218996||Psychosocial treatment|Children and adolescents with anxiety disorders
89045573|NCT06225986|Active Comparator|Attention Control Arm|
89650887|NCT01498484|Experimental|HCT EBV+ PTLD R/R Rituximab|Patients with Epstein-Barr virus positive (EBV+) posttransplant lymphoproliferative disorders (PTLD) hematopoietic cell transplant (HCT) who were relapse/refractory (R/R) to rituximab will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89650888|NCT01498484|Experimental|SOT EBV+ PTLD R/R Rituximab|Patients with EBV+PTLD solid organ transplant (SOT) who were R/R to rituximab or R/R to rituximab and chemotherapy will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After 3 week observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89650889|NCT01498484|Experimental|EBV+ AID-LPD|Patients with EBV+ acquired immunodeficiency (AID) lymphoproliferative disorder (LPD) will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity
89650890|NCT01498484|Experimental|EBV+ PID-LPD|Patients with EBV+ primary immunodeficiency (PID) LPD will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89650891|NCT01498484|Experimental|EBV+ Viremia|Patients with EBV+ viremia will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89650892|NCT01498484|Experimental|EBV+ Leiomyosarcoma|Patients with EBV+ leiomyosarcoma (LMS) will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89650893|NCT01498484|Experimental|EBV+ Lymphoma|Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89650894|NCT01498484|Experimental|EBV+ NPC|Patients with EBV+ nasopharyngeal carcinoma (NPC) will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89650895|NCT01498484|Experimental|EBV+ Other Solid Tumor|Patients with EBV+ other solid tumors will receive IV infusion of tabelecleucel 2 × 10^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
89650896|NCT03016104|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
89650897|NCT03016104|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
89650898|NCT05688631||Diabetic participants (case group)|Participants diagnosed with type 2 diabetes mellitus
89650899|NCT05688631||Healthy participants (control group)|Participants not diagnosed with type 2 diabetes mellitus or any other chronic diseases
89650900|NCT04849221||Patients|Head trauma, patient operated on for an intracranial lesion, or other condition (hemorrhagic stroke)
89650901|NCT04849221||healthy subjects|No otologic or neurological history
89650902|NCT04348032|Active Comparator|PLD|PLD 40 mg/m2 D1 ivgtt q4w
89650903|NCT04348032|Experimental|PLD + Apatinib|PLD 40 mg/m2 D1 ivgtt q4w + Apatinib 250mg po qd
89650904|NCT05682235|Experimental|Therapeutic Exercise AND Pain Neurophysiology Education|"Therapeutic exercise:~Therapeutic exercise is the systematic and planned execution of posture movements and physical activities to correct or prevent alterations, improve or enhance physical functioning, prevent risk factors for solid and optimize overall health status.~Pain Neurophysiology Education:~Education in pain neurophysiology consists in describing to the patient the neurobiology and neurophysiology of his nervous system pain to improve the processing of it and diminish the threatening meaning of pain."
89650905|NCT05682235|Sham Comparator|Sham Comparator|Talks about healthy habits
89650906|NCT03083275|Experimental|Resistance Training|
89650907|NCT03083275|No Intervention|Control|
89650908|NCT04343352|Experimental|In application group; Mobile Epilepsy Training Program Impleme|"Mobile epilepsy training program will be introduced to the parents in the application group and pre-tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale).~The participants will only use the mobile epilepsy training program application.~Parents in the application group will be monitored for 3 months using the mobile epilepsy training program. The researcher will follow the participants' use of the mobile application with the interface of the mobile epilepsy training program.~During the monitoring phase, the Epilepsy Information Questions screen will be given once every 15 days, and the training module will be reopened automatically on missing or incorrect answers and the parent's information on this subject will be renewed.~- At the end of the 3rd month, posttests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale) will be applied face-to-face."
89521725|NCT03414073|Sham Comparator|Group B Phase 2|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group B will use the conventional interdental brushing technique in the second phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
89045574|NCT06225934||congenital muscular torticollis|Babies diagnosed with congenital muscular torticollis (CMT) who agree to participate in the study and meet the inclusion criteria will be included in the study without using any sample selection method, since it is a single-arm study. The parents of each baby will first be informed about the content of the study and will read and sign the consent form stating that they participate in the study voluntarily.
89650909|NCT04343352|No Intervention|In the control group|"- The purpose of the project will be shared with the parents in the control group, and the pre-tests Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied.~There is no structured training program in the outpatient functioning. Routine practice of the hospital; is the education and information provided by the physician to the family during the outpatient clinic.~At the end of the 3rd month, the final tests (Parent Epilepsy Knowledge Scale for Parents and Parental Anxiety Scale for Seizures Scale). will be applied face to face.~After the work is completed, the mobile application will be installed on the phones of the control group, the application will be taught and applied."
89650910|NCT03082807|Experimental|Study group I|Study group I (18 participants) received the NCD with exercise (NCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
89650911|NCT03082807|Experimental|Study group II|Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
89650912|NCT01474772|Experimental|Pregabain|
89650913|NCT01474772|Placebo Comparator|Placebo|
89650914|NCT04341012||Normal|No known medical conditions
89650915|NCT04341012||Liver Cirrhosis|Clinically diagnosed with cirrhosis
89650916|NCT04341012||COVID-19 tested|Persons with known test results for COVID-19 RNA
89650917|NCT04341012||Other|Persons with other medical diagnosis, no known liver disease, negative for COVID-19
89650918|NCT03082339||Neurology|Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (>=40mg/d)
89650919|NCT03082339||Pulmonology|Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (>=40mg/d)
89650920|NCT03801759|Experimental|Vadadustat, digoxin|Arm 1: Subjects will receive a single oral dose of digoxin 0.5 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of digoxin 0.5 mg.
89650921|NCT03801759|Experimental|Vadadustat, adefovir|Arm 2: Subjects will receive a single dose of oral adefovir 10 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of adefovir.
89650922|NCT03801759|Experimental|Vadadustat, Furosemide|Arm 3: Subjects will receive a single dose of oral furosemide 40 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone, and in combination with a single dose of furosemide 40 mg.
89650923|NCT05688553|Experimental|Flexi-bar group|
89650924|NCT05688553|Active Comparator|balance and strength group|
89650925|NCT03801681||myocarditis|patients with clinically suspected myocarditis
89650926|NCT01421147|Experimental|LY2963016 + Insulin Lispro|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
89650927|NCT01421147|Active Comparator|Lantus + Insulin Lispro|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
89650928|NCT03082417|No Intervention|Pre-Implementation|"Medical records of patients with a fracture visiting the Emergency departments will be reviewed.~Data will be collected as a baseline prior to the intervention regarding how nurses and physicians working at Emergency Departments manage acute pain in targeted population."
89650929|NCT03082417|Experimental|Implementation|"In this stepped-wedge trial design, the experimental arm refers to the time period during patients advertising and educational interventions. It consists in:~Informing patients visiting Emergency department for fracture about Pain Management Nurses and physicians working at the Emergency Departments will receive an educational interventions focused on optimal acute pain management in older adults with fracture."
89650930|NCT03082417|No Intervention|Post-Implementation|Data will be collected after the intervention regarding how the intervention impacted nurses' and physicians' work in the pain management in older adults with fracture visiting Emergency Departments manage acute pain in older adults.
89650931|NCT03082573|Active Comparator|Group A|"Will be receiving the same background medications and H.P. Acthar gel 40 units twice weekly for 12 weeks.~Patients in group A, can be cross over to group B on week 13 if disease is uncontrolled for continuation until week 24. If their disease is under control then they will continue with the same dosage until week 24.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
89650932|NCT03082573|Active Comparator|Group B|"Will be receiving the same background medications and H.P. Acthar gel 80 units twice weekly for 12 weeks.~if the disease is not under control, will continue with same dosage until week 24. If the disease is under control, will be given the option to reduce the dosage to 40 units twice weekly only if patient is suffering from H.P. Acthar gel related adverse effects.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
89650933|NCT05129124|Experimental|T01: +6.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
89650934|NCT05129124|Experimental|T02: +6.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
89650935|NCT05129124|Experimental|T03: -3.00-2.75 x180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
89650936|NCT05129124|Experimental|T04: -3.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
89650937|NCT05129124|Experimental|T05: -9.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
89045575|NCT06225908|No Intervention|Group Control|
89045576|NCT06225908|Active Comparator|Group SPSİPB|
89650938|NCT05129124|Experimental|T06: -9.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
89650939|NCT05129124|Experimental|T07: -12.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
89650940|NCT05129124|Experimental|T08: -12.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
89650941|NCT05129124|Active Comparator|C01: +6.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
89650942|NCT05129124|Active Comparator|C02: +6.00-2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
89650943|NCT05129124|Active Comparator|C03: -3.00-2.75 x180|Commercially available Ultra for Astigmatism Contact Lenses
89650944|NCT05129124|Active Comparator|C04: -3.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
89650945|NCT05129124|Active Comparator|C05: -9.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
89650946|NCT05129124|Active Comparator|C06: -9.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
89650947|NCT00809523|Experimental|Inactivated negative ion generator|Equivalent exposure to inactivated Negative Ion Generator
89650948|NCT00809523|Experimental|LED light treatment device|Light-emitting photodiode light treatment device, used for 30 min before 8 am
89650949|NCT05302362|Sham Comparator|Sham tDCS Group|Sham transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 1.5mA, 0mA stimulation for 19 min 30 sec.
89650950|NCT05302362|Active Comparator|Conventional tDCS Group|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 1.5mA, continuous 1.5mA stimulation for 19 minutes, ramp-down 30sec to 0mA.
89650951|NCT05302362|Experimental|Tailored tDCS Group|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea); ramp-up 30sec to 2.0mA, continuous 2.0mA stimulation for 19 minutes, ramp-down 30sec to 0mA.
89650952|NCT03839979||HCV positive patients|Patients tested positive for the hepatitis c virus antibodies by BIOLINE HCV kits.
89650953|NCT03839979||HCV negative patients|Patients tested negative for the hepatitis c virus antibodies by BIOLINE HCV kits.
89650954|NCT05679271|Experimental|venous stenting|"Venous stenting associated to antiaggregation protocol:~Venous stenting: venous approach can be performed via femoral, brachial or jugular puncture. Autoexpansible stent should delivered at the level of the fistulous sinus. If distal access catheter is wide enough, stent can be delivered directly through it. After partial deployment of the stent, Labbe vein's flow may be restricted. If necessary, several stents can be used in the same procedure to cover the whole length of fistulous sinus area. After stent deployment, ballon angioplasty is compulsory and must be performed using a ballon of equivalent size to the stent. The procedure ends after stent deployment and angiographic arterial post-op controls.~Antiaggregation protocol: aspirin (160mg for 3 months) + clopidogrel (75mg/d 5 days before stenting and 75mg/d for 1 month after stenting) OR ticagrelor (180mg 2h before stenting and 90mg twice a day for 1 month) in case of clopidogrel platelet resistance."
89650955|NCT05679271|Active Comparator|no treatment|standard care (no treatment)
89650956|NCT01497938|Experimental|Low Glucose Suspend feature (LGS)|According to randomization, Low Glucose Suspend (LGS) will be turned ON in the treatment arm of the study
89650957|NCT01497938|Experimental|Control Arm|The Low Glucose Suspend feature will not be available to subjects in the control arm
89650958|NCT04401787|Active Comparator|laparoscopic anterior resection (LAR)|LAR group included 88 patients, 17 patients converted to open
89650959|NCT04401787|Active Comparator|open anterior resection|Open anterior resection for 56 patients
89650960|NCT03092154|Experimental|Exposed|Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks
89650961|NCT03092154|No Intervention|No intervention|Patients will not receive artovastatin (lipid-lowering agents)
89650962|NCT04301310|Experimental|Treatment Group|
89650963|NCT03026894|Active Comparator|CD group|Panoramic Radiographs and T-Scan III occlusal system
89045577|NCT06225895|Placebo Comparator|control group|patients will receive a sham block
89650964|NCT03026894|Active Comparator|IOD group|Panoramic Radiographs and T-Scan III occlusal system
89650965|NCT00804609|Active Comparator|DepoDur following epidural lidocaine|Epidural DepoDur was administered 60 minutes after an epidural Lidocaine top-up for surgical anesthetic in cesarean section patients.
89650966|NCT00804609|Active Comparator|DepoDur following spinal anesthetic|Epidural DepoDur was administered 60 minutes after a standard spinal anesthetic. No prior epidural local anesthetic was used prior to DepoDur in this group assignment.
89650967|NCT03082183|Experimental|All participants|BI 425809 given alone in first period, then in combination with Rifampicin in second period
89650968|NCT04291404|No Intervention|Standard of Care (Control) Arm|Standard of care treatment, which may include a combination of the following, at the discretion of the treating team and family: parent/ caregiver support, child life services, healthcare provider support, etc.
89650969|NCT04291404|Experimental|Intervention Arm|Addition of distraction via an immersive, interactive VR experience to Standard of Care
89650970|NCT03801291|Active Comparator|Transvaginal repair|Repair of anterior rectocele via the vagina
89650971|NCT03801291|Active Comparator|Transperineal repair|Repair of anterior rectocele via the perineum
89650972|NCT05302206|Experimental|patients with ileostomy without type 2 diabetes|colonic glucose or saline infusion via ileostomy
89650973|NCT05302206|Experimental|patients with ileostomy with type 2 diabetes|colonic glucose or saline infusion via ileostomy
89650974|NCT03801135|No Intervention|Electrolyte&Albumin Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.
89650975|NCT03801135|Experimental|Fibrinogen Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.
89650976|NCT03801135|Active Comparator|FFP Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.
89650977|NCT05301738|Experimental|Plyometric exercise group|Participants in this group received the plyometric training program
89045578|NCT06225895|Active Comparator|E group|patients will receive Erector spinae plane block
89045579|NCT06225895|Active Comparator|R group|patients will receive rhomboid intercostal nerve block
89650978|NCT05301738|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program
89650979|NCT00804999|Placebo Comparator|Placebo 1|Subjects that have never worn contacts with no ocular problems were selected. A baseline HRT was performed. Trial contact lenses were soaked in clear care solution for 10 hours. After 10 hours of the lenses soaking in clear care the subject returned. The contacts lenses that were soaked in clear care were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contact lenses were removed. An HRT was performed immediately after removing the contact lenses. The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
89650980|NCT00804999|Active Comparator|Renu|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in ReNu contact solution for 10 hours. After 10 hours of the lenses soaking in ReNu the subject returned. The contacts were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contacts lenses were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
89650981|NCT00804999|Active Comparator|Optifree|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in Optifree Replenish contact solution for 10 hours. After 10 hours of the lenses soaking in Optifree Replenish the subject returned. The contacts were inserted onto the patients eyes. The patient wore contacts the for two hours. After two hours the contacts were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
89650982|NCT05688319|Experimental|experimental group|The participants in the experimental group were divided into five groups of eight participants each according to the number of days they visited the center. The training was conducted face to face in the meeting room of the special education and rehabilitation center. Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks . The duration of each training session was 60-90 minutes. The weekly training sessions for all the experimental groups were completed on the same day.
89650983|NCT05688319|No Intervention|control group|The control group did not receive any training, and there was no interaction between the experimental group and the control group during the training period.
89650984|NCT04486404||Group 1|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra and Ec.
89650985|NCT04486404||Group 2|Online survery to healtcare personnel and other professionals in the front-line from Col, Bra, Ch and Ec.
89650986|NCT04401397|Experimental|Early mobilization group|Immediately after ICU extubation, enrolled patients will receive an intensive 30-45 minutes, implemented twice a day early mobilization protocol containing psychological empowerment, detailed informative education of patients and close relatives, close monitoring of the recovery course, frequent parameter protocol configuration, high intensity active progressive pulmonary and musculoskeletal exercises and mobility techniques, close monitoring for early identification and measures for prevention and treatment of complications.
89650987|NCT04401397|Active Comparator|Standard care group|Enrolled patients will receive the standard hospital mobilization protocol after their admission to the ward, containing standardized basic pulmonary and mobilization techniques of 15 minutes, once a day.
89650988|NCT05095818|No Intervention|Standard of Care with EMR Enhancements|Participants in this arm will receive Standard of Care with EMR Enhancements.
89650989|NCT05095818|Experimental|Standard of Care with EMR Enhancements and PrEP-RN|Participants in this arm will receive Standard of Care with EMR Enhancements and PrEP-RN.
89650990|NCT03082105|Experimental|Winter snow|First test series breathing in dry snow in winter
89650991|NCT03082105|Experimental|Intermediate snow|Second test series breathing in dry/wet snow in intermediate season
89650992|NCT03082105|Experimental|Spring snow|Third test series breathing in very wet snow in spring
89650993|NCT00810303|Experimental|whole study group|A study with a duration of 34 days with 4 periods (= 4 pharmakokinetics) on 12 healthy subjects.
89650994|NCT05656729|Placebo Comparator|Placebo|Placebo 8-week daily administration
89650995|NCT05656729|Active Comparator|Multistrain probiotic|Dietary Supplement: Multistrain Probiotic 12-week daily administration
89650996|NCT03081871|Experimental|Web and mobile app access|Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
89650997|NCT03081871|Active Comparator|Web app only access|Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
89650998|NCT03801057|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
89650999|NCT03801057|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
89651000|NCT04272840|No Intervention|Standard Care|Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record).
89651001|NCT04272840|Experimental|Low Glycemic Index|Standard care + Glycemic Index. Participants will attend a 30-45 min workshop. Trainees will review Diabetes Canada Clinical Practice Guidelines Job Aids (Just the Basics, the Handy Portion Guide, and Basic Carbohydrate Counting) and teach data provision skills (how to complete a three day diet record). Diabetes Canada and Dietitian's Canada resources on glycemic index will also be reviewed: the Glycemic Index Food Guide, Flip Cards, and Recipes.
88999256|NCT01484093|Experimental|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|This is a phase I/phase II multi-institution trial. The phase I part of the trial will determine the MTD of cytarabine. The phase II part of the trial will examine the efficacy of the proposed regimen by evaluating the 3-year event-free survival (EFS) in patients with untreated mantle cell lymphoma. All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR.
89651002|NCT03800901|Active Comparator|Control|The Control arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will not be offered Continuing Medical Education (CME) or American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
89651003|NCT03800901|Experimental|CME|The CME arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will be offered Continuing Medical Education (CME) and American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
89651004|NCT04401085||Population area cohort - Control Cohort|A population cohort of asymptomatic individuals (only adults). This is a representative sample of the population, which are part of the research project of Institute for Clinical and Experimental Medicine and Czech Academy of Sciences. The second subsample included individuals from the official household survey of Czech Statistical Office. This cohort allowed better comparative analysis of other population cohorts from specific geographical areas.
89651005|NCT04401085||Population cohort from specific geographical areas|"This cohort is based on epidemiologically defined demographic parameters. These are populations from the following geographical areas:~Brno and the South Moravian Region; Praha; Olomouc; Litoměřice; Litovel and Uničov."
89651006|NCT04401085||Chronically ill patients cohort|A cohort of chronically ill people enrolled by Institute for Clinical and Experimental Medicine with chronic cardiovascular problems, hypertension, or diabetes.
89651007|NCT05073042|Experimental|Morning exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
89651008|NCT05073042|Experimental|Evening exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
89651009|NCT05073042|Active Comparator|Time of choice exercise|Participants will have a daily exercise goal, receive nightly surveys, receive weekly emails, and wear a physical activity sensor daily.
89651010|NCT05073042|No Intervention|No exercise period|"During the two-week washout (i.e., break) periods between the exercise interventions, participants will not have an exercise goal. Participants will continue to receive weekly emails and wear a physical activity sensor daily."
89651011|NCT03081793||Patients with sinus Rhythm|Patients with sinus rhythm at the beginning of monitoring
89651012|NCT03081793||Atrial fibrillation|Patients with atrial fibrillation at the beginning of monitoring
89651013|NCT04239456|Experimental|Group A|Receive intervention 2 weeks after group assignment.
89651014|NCT04239456|Other|Group B|Wait List - Receive intervention 3 months after initial testing.
89651015|NCT00810459|Experimental|Trilogy ventilator|Trilogy ventilator
89651016|NCT00810459|Active Comparator|Standard of Care|Participants currently prescribed ventilator
89651017|NCT04229940|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
89651018|NCT04229940|Active Comparator|No bridging|The hernia defect is left without closure prior to application of the mesh.
89651019|NCT04227756|Experimental|LSD-100|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
89651020|NCT04227756|Active Comparator|Psilocybin-20|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
89651021|NCT04227756|Active Comparator|Mescaline-300/500|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
89651022|NCT04227756|Placebo Comparator|Placebo|Cross-over within-subject design with all treatment conditions, separated by a wash-out phase of at least 10 days
89651023|NCT01460342|Placebo Comparator|Placebo|Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
89651024|NCT01460342|Experimental|Tadalafil|Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
89651025|NCT00810771|Experimental|Preference-tailored (PT) intervention|"Intervention:~Behavioral: Standard Information Behavioral: Preference-tailored Information"
88999257|NCT01465100|Experimental|Hepatocyte Transplantation|See Below.
89651026|NCT00810771|Active Comparator|Standard information (SI) intervention|Behavioral: Standard Information
89651027|NCT00810771|No Intervention|Usual Care|Due to budget and time constraints this group was not powered as a true study arm but was used to assess the impact of our baseline physician information letter and to control for any other interventions of system-wide initiatives that may occur during the study timeframe and impact rated of CRC screening. Data was not collected on every participant in this arm.
89651028|NCT05345977|Experimental|Unified Protocol|The psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
89651029|NCT05639335|Other|No Character Control|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing no characters.
89651030|NCT05639335|Experimental|Character|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing their respective brand characters (e.g., Tony the Tiger) and a licensed character recently featured on these cereal brands (e.g., Buzz Lightyear).
89651031|NCT00775671|Active Comparator|Nebivolol|Nebivolol 5mg by mouth daily for 12 weeks.
89651032|NCT00775671|Active Comparator|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
89651033|NCT03800745|No Intervention|No Medication|No intervention is assigned in Arm A.
89651034|NCT03800745|Experimental|Colace|This is Arm B. Docusate sodium(Colace) is prescribed as100mg twice daily orally. Patients will be instructed to begin taking this the evening of surgery through postoperative day five.
89651035|NCT03800745|Experimental|Miralax|This is Arm C. Miralax 17 grams oral powder pack daily is prescribed to be taken with breakfast. Patients will be instructed to begin taking this the morning after surgery through postoperative day five.
89045580|NCT06225882||Lumasiran|Patient with primary hyperoxaluria type 1 who has been treated with Lumasiran, since the beginning of the ATU (temporary authorization for use) and in post-marketing.
89045581|NCT06225830|Experimental|Ekso mediated gait training|"Ekso mediated gait training will take place twice per week for 8 weeks . An Ekso Robotic Eksoskeleton will be used during each treatment session; this device can physically assist leg movements along a customized path or resist or amplify movements the participant makes. Each session will be 60 minutes and will be 3 rounds of 15 minutes of Ekso mediated gait training.~Four (4) study related Assessment sessions will be conducted and include a series of physical tests and a written questionnaire. This will be done at the Evaluation/ 1st visit, then the re-evaluation at visit 9, at discharge or visit 17, and finally at a 3-month follow-up."
89045582|NCT06225791|No Intervention|Standard MMS delivery with two 90-count bottles|Pregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with standard MMS delivery strategy (MMS orientation only). (1 sub-district within each of the 13 districts with high- or moderate-intensity evaluation).
89045583|NCT06225791|Active Comparator|Enhanced MMS delivery with two 90-count bottles|Pregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC). (1 sub-district within each of the 13 districts with high- or moderate-intensity evaluation).
89651036|NCT01459796|Experimental|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 51.
89651037|NCT01459796|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 51.
89651038|NCT04908501||Intervention group|Services of the non-transversal clinical departments of the Bordeaux University Hospital willing to participate to the programme.
89651039|NCT04908501||Control group|Services of the non-transversal clinical departments of the Bordeaux University Hospital not willing to participate to the programme.
89651040|NCT04721691|Active Comparator|IP|Epidiolex (Cannabidiol) is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe.The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Epidiolex at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
89651041|NCT04721691|Placebo Comparator|Placebo|Placebo is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe. The starting dosage is 2.5 mg/kg twice daily, or 5 mg/kg/day. After one week, the dosage can be increased to a maintenance dosage of 5mg/kg twice daily, or 10 mg/kg/day. Patients who are tolerating Placebo at 10mg/kg per day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance. Dosage of 10mg/kg twice daily (20mg/kg/day), in weekly increments of 2.5 mg/kg twice daily(5mg/kg/day), as tolerated. For patients in whom a more rapid titration from 10 mg/kg/day to 20 mg/kg/day is warranted, the dosage may be increased to no more frequently than every other day administration of the 20 mg/kg/day. Dosage resulted in somewhat greater reductions in seizure rates than the recommended maintenance dosage of 10 mg/kg/day, but with an increase in adverse reactions.
89651042|NCT04207788|Experimental|Intervention|HIP-REP programme offers elderly with hip fracture add on activity-focused interventions.
89651043|NCT04207788|Active Comparator|Usual care|The elderly with hip fracture in the control group will receive usual care.
89651044|NCT04760821|No Intervention|Usual Care|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2. Usual Care means the clinical protocol approved by the enrolling center.
89651045|NCT04760821|Experimental|Trimetazidine|Patients ascribed to the Usual Care group will receive the standard of care for the management of patients admitted with moderate to severe acute respiratory distress syndrome due to SARS-CoV2 plus trimetazidine.Usual Care means the clinical protocol approved by the enrolling center.
89651046|NCT04382079|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
89651047|NCT04382079|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
89651048|NCT04382079|No Intervention|control|Routine care to encourage oral care three times a day.
89651049|NCT03355105|Experimental|Objective adjustment of the MI/E exsuflation pressure|Objective adjustment of the MI/E exsuflation pressure based on the flow-volume curve generated during the cough.
89651050|NCT03355105|Active Comparator|Subjective adjustment of the MI/E exsuflation pressure|Subjective adjustment of the MI/E exsuflation pressure based on the clinical judgment of the therapist and the patient.
89651051|NCT03081559|Experimental|Intervention|Healthy Divas intervention
89651052|NCT03081559|No Intervention|Control|Treatment as usual
89651053|NCT00776295|Experimental|adeno virus vectored p53|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
89651054|NCT05688007||Cases|pregnant women with established preterm labor - gestational age: (28-36 weeks), having: Regular uterine contractions are at least 3 in 10 min each lasting 40 seconds. Progressive cervical dilatation (at least 4 cm).
89651055|NCT05688007||Controls|pregnant women not in labor - gestational age: (28- 36 weeks)
89651056|NCT03081715|Experimental|Experimental Group|"Peripheral blood lymphocytes will be collected and Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and reinfused back into patients. To avoid allergic reactions, 50 mg hydrocortisone was intravenously injected into the patient 30 min before cells infusion every time. Best supportive care was also provided for patients.~A total of 1 to 10 x 10^9 PD-1 Knockout T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent."
89651057|NCT01459718|Experimental|Deferasirox / Deferasirox + Deferoxamine (DFO)|During Phase A, the induction treatment at entry, participants received Deferasirox -DFO combination. During Phase B, when participants transitioned to less intensive chelation therapy, participants received Deferasirox monotherapy.
89651058|NCT04154826|Experimental|low dose|CYT107 10µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 10µg/kg/week for 4 weeks (wk9-12)
89651059|NCT04154826|Experimental|high dose|CYT107 20µg/kg/week for 4 weeks (wk1-4) followed by no treatment during 4 weeks (wk 5-8) CYT107 20µg/kg/week for 4 weeks (wk9-12)
89651060|NCT03081481|Experimental|PRX302|intraprostatic administration
89651061|NCT04918407|Experimental|Empagliflozin|Adding 25mg Empagliflozin on Insulin
89651062|NCT04918407|Active Comparator|Insulin alone|Just contriling the blood glucose with Insulin
89651063|NCT04916769|Experimental|Bosutinib capsule contents mixed with applesauce|Bosutinib capsule contents mixed with applesauce to healthy participants
89651064|NCT04916769|Experimental|Bosutinib capsule contents mixed with yogurt|Bosutinib capsule contents mixed with yogurt to healthy participants
89651065|NCT04916769|Active Comparator|Bosutinib intact capsules|Bosutinib intact capsules to healthy participants
89651066|NCT04989660|Experimental|Treatment Group|6% aqueous phenol, 1.5 mL per target site
89651067|NCT04989660|Placebo Comparator|Placebo Group|Isotonic saline, 1.5 mL per target site
89651068|NCT04008069|Experimental|Open-Label Sarilumab (pre-randomization)|On entering the study, all participants receive open-label sarilumab every two weeks for 16 weeks.
89651069|NCT04008069|Experimental|Double-Blind Sarilumab (post-randomization)|After completing the open-label period, participants are randomized in blinded fashion to receive sarilumab every two weeks for 12 weeks.
89651070|NCT04008069|Placebo Comparator|Double-Blind Placebo (post-randomization)|After completing the open-label period, participants are randomized in blinded fashion to receive placebo every two weeks for 12 weeks.
89651071|NCT05621863|Experimental|Aim 1 Group 1|"Order of Treatments:~Meal Challenge 1, Meal Challenge 2, Meal Challenge 3"
89651072|NCT05621863|Experimental|Aim 1 Group 2|"Order of Treatments:~Meal Challenge 1, Meal Challenge 3, Meal Challenge 2"
89651073|NCT05621863|Experimental|Aim 1 Group 3|"Order of Treatments:~Meal Challenge 2, Meal Challenge 3, Meal Challenge 1"
89651074|NCT05621863|Experimental|Aim 1 Group 4|"Order of Treatments:~Meal Challenge 2, Meal Challenge 1, Meal Challenge 3"
89651075|NCT05621863|Experimental|Aim 1 Group 5|"Order of Treatments:~Meal Challenge 3, Meal Challenge 1, Meal Challenge 2"
89651076|NCT05621863|Experimental|Aim 1 Group 6|"Order of Treatments:~Meal Challenge 3, Meal Challenge 2, Meal Challenge 1"
89651077|NCT05621863|Experimental|Aim 2 Typical American Diet|
89651078|NCT05621863|Experimental|Aim 2 Typical American Diet Plus Test Foods|
89651079|NCT05621863|Experimental|Aim 2 Dietary Guidelines for Americans Diet Plus Test Foods|
89651080|NCT00811317|Experimental|Closed-loop|Type 1 diabetic subjects under closed-loop blood glucose control
89651081|NCT03800589|Active Comparator|phaco and Ex-Press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to phacoemulsification with implantation of the Ex-Press
89651082|NCT03800589|Active Comparator|deep sclerectomy, phaco and Ex-press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to deep sclerectomy, phacoemulsification, ExPress implantation
89651083|NCT03081325|Experimental|lymphocyte immunotherapy on uRM and RIF|Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
89651084|NCT05687851|Experimental|treatment arm|Participants receive candonilimab at a dose of 10 mg/kg, Q3W (Day 1 of each 21 day treatment cycle) via IV infusion, until disease progression, intolerable toxicity, investigator determines that the participant cannot continue to benefit, withdraws informed consent, or candonilimab treatment over 2 years. During the q3w dosing period of candonilimab, participants receive radiotherapy including external beam radiotherapy (EBRT) and followed by brachytherapy.
89651085|NCT03081403|Other|Subjects with sensitive skin|Subjects with a score greater than 50 on the sensitive scale
89651086|NCT03081403|Other|Subjects without sensitive skin|Subjects with result lower than 20 on the sensitive scale
89651087|NCT05687773|Experimental|Leap Motion Controller on Flat display - Non-Immersive Group|
89651088|NCT05687773|Experimental|Leap Motion Controller on Head-Mounted Display - Immersive Group|
89651089|NCT03353701|Other|Adults with or without HIV infection|Participants will be asked to stop drinking for at least 30 and up to 90 days. The study will use Contingency Management (CM) with financial incentives to encourage participants to maximally reduce alcohol consumption.
88999258|NCT01436656|Experimental|LGX818 - Dose escalation|
88999259|NCT01436656|Experimental|LGX818 - Dose Expansion at MTD or RP2D|
89651090|NCT04384731|Experimental|Surfactant arm|patient receiving the surfactant
89651091|NCT04384731|No Intervention|Control arm|patient not receiving the surfactant
89651092|NCT04483362|Experimental|Physical Activity|Behavioural change techniques to promote physical activity
89651093|NCT02984605|Experimental|Interventional group|"Arm：Hypoglycemic agents + Nutrition meal replacement & exercise prescription~Hypoglycemic agents in combined with 1 times a day with bags of nutritional meal replacement and exercise"
89651094|NCT02984605|No Intervention|Control group|"Arm：Hypoglycemic agents~without take nutrition meal replacement & exercise prescription"
89651095|NCT04803435|Active Comparator|Adult patients with acute gastrointestinal infection - telemedicine before face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have undergone telemedicine consultation before face-to-face evaluation
89651096|NCT04803435|Active Comparator|Adult patients with acute gastrointestinal infection - only face-to-face evaluation|Adult patients who sought in person the screening of the Morumbi Emergency Care Unit of HIAE with symptoms suggestive of GECA (diarrhea with or without other symptoms of the digestive tract and infectious) who have only face-to-face evaluation
89651097|NCT04972890|Placebo Comparator|Control group|with 2cc saline/NaCl 0,9% solution once at baseline
89651098|NCT04972890|Experimental|Stem Cell Group|with umbilical cord stem cells 15x10^6 cells in 2 cc saline/NaCl 0,9% solution once at baseline
89651099|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 1 and test drug 2|
89651100|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 3 and test drug 4|
89651101|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 5 and test drug 6|
89651102|NCT04793295|Experimental|MT-7117 Drug-drug interaction with test drug 7|
89651103|NCT05042466|Experimental|Plant Medicine On Boarding|The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every M/W/F with a tailored dose of plant medicine psilocybin in the enhanced micro dose levels or 0.15g. to 0.33g with a monthly dose of 1 gram to 1.5 grams. Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
89651104|NCT05042466|Experimental|Participant|0.15g. thru 0.33g. tailored to participant, then Monthly a 1 time dose of 1gram to 1.5 grams dose of non-synthesized plant medicine psilocybin.
89651105|NCT05042466|Experimental|Psychiatrist|Psychiatrist QC scaling back SSRI's replacing with psilocybin.
89651106|NCT05042466|Experimental|On-Boarding Plant Medicine Specialist|The On-Boarding Provider will control dosage of the plant medicine via Telehealth.
89651107|NCT04791891||Low Back Pain (LBP)|"Adult women and men with self-reported LBP.~Inclusion Criteria for potential LBP participants~At least 18 years old;~Internet access;~Fluent in English or French;~Self-reported LBP.~Exclusion Criteria: No exclusion criteria will be adopted in this study.~No exclusion criteria will be adopted in this study"
89651108|NCT05052684|Experimental|Leaflex™ Performer|
89651109|NCT05615467|Experimental|LY3556050 + Metformin + Iohexol|LY3556050 administered orally in combination with metformin given orally and iohexol given intravenously (IV).
89651110|NCT04756869||Health Care Workers at Risk for COVID-19|Health care workers at risk for COVID-19 will be monitored using wearing sensors and smartphone technology.
89651111|NCT05687617|Experimental|Gastric cancer with ICG|Patient to receive IV ICG during diagnostic laparoscopy.
89651112|NCT04279873||Adults with nosocomial pneumonia|Diagnostic procedures on pulmonary secretion collected by tracheal suctioning and bronchoalveolar lavage.
89651113|NCT04541043|Experimental|active treatment|Nefecon 16 mg once daily by mouth for 9 months
89651114|NCT03800433|No Intervention|control|23 patients will receive their usual dose of erythropoietin stimulating agents and their routine treatment.
89651115|NCT03800433|Experimental|test|23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of erythropoietin stimulating agents and their routine treatment.
89651116|NCT03395899|Active Comparator|Atezolizumab alone|1200mg of Atezolizumab D1 C1
89651117|NCT03395899|Experimental|Atezolizumab + Cobimetinib|Atezolizumab (1200mg IV D1 C1) + Cobimetinib (60mg PO D1 - 21 of C1)
89651118|NCT03395899|Experimental|Atezolizumab + Ipatasertib|Atezolizumab (1200mg IV D1 C1)+ Ipatasertib (400mg OD D1 - 21 of C1)
89651119|NCT03395899|Experimental|Atezolizumab + Ipatasertib + Bevacizumab|Atezolizumab (1200mg IV D1 C1)+ Cobimetinib (60mg PO D1 - 21 of C1) + Bevacizumab (10mg/kg IV D1 C1)
89651120|NCT03800511||repeated caesarean section|full term pregnant women with singleton baby with a history of at least previous one caesarean section
89651121|NCT05470543|Experimental|Nurse-led Supportive Care Group|
89651122|NCT05470543|No Intervention|Control Group|The control group received only usual care. They did not receive any intervention during the study period.
89651123|NCT05687461||People at high risk for VTE|Patients who are admitted to the hospital for acute medical illness or surgery operations.
89651124|NCT05687461||People diagnosed with VTE|Patients who were clearly diagnosed with deep vein thrombosis or pulmonary thromboembolism.
89651125|NCT04608201|Experimental|NICOTINE transdermal patch|NICOTINE 7 mg / 24h, transdermal patch
89651126|NCT04608201|Placebo Comparator|Placebo of NICOTINE transdermal patch|Placebo of nicotine patch
89651127|NCT04955652|Active Comparator|Standard of Care|A health maintenance topic, actionable sidebar item, and a single-click best practice alert are presented.
89651128|NCT04955652|Experimental|Silent Best Practice Alert|A health maintenance topic and an actionable sidebar item are presented. The best practice alert is set to be silent and will not appear in the patient's chart.
89651129|NCT04110444||sildenafile group A|received sildenafil citrate orally 20mg every 8 hours based on previous studies18,21 (Respatio tablet, pharma Egypt group) in addition to low molecular weight heparin daily according to the bodyweight at the booking visit (Clexane 20,40,60 mg, Sanofi eventis company) plus small dose of aspirin 75 mg (Aspocid 75mg tablet, CID pharmaceutical) once daily
89651130|NCT04110444||control group B|received low molecular weight heparin as subcutaneous injection once daily plus low dose aspirin 75mg orally once daily in addition to placebo three times daily prepared by a local pharmacy from a domestic manufacturer
89651131|NCT04951986|Experimental|High dose Rifampicin plus Levofloxacin|Standard TB treatment plus additional Rifampicin 35 mg/kg/day PLUS Levofloxacin for 14 days
89651132|NCT04951986|Experimental|Prednisone|Prednisone 1.5 mg/kg for 14 days
89651133|NCT04951986|Active Comparator|Standard TB treatment|High dose rifampicin/levofloxacin comparator
89651134|NCT04951986|Placebo Comparator|Placebo|Prednisone comparator
89651135|NCT04278859|Experimental|0.3mg/kg repeat dose every 21 days up to 2 years|
89651136|NCT04278859|Experimental|1 mg/kg repeat dose every 21 days up to 2 years;|
89651137|NCT04278859|Experimental|3 mg/kg repeat dose every 21 days up to 2 years;|
89651138|NCT04278859|Experimental|10 mg/kg repeat dose every 21 days up to 2 years;|
89651139|NCT03322813|Experimental|ExAblate 4000 - Type 2|ExAblate BBBD
89651140|NCT01474538|Active Comparator|Insulin Lispro, then Insulin Aspart|Insulin lispro [100 units/milliliter (U/mL)] administered by continuous subcutaneous insulin infusion (CSII) pump for 16 weeks in Treatment Period 1, followed by insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
89651141|NCT01474538|Active Comparator|Insulin Aspart, then Insulin Lispro|Insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 1, followed by insulin lispro (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
89651142|NCT04278703|Active Comparator|15 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
89651143|NCT04278703|Active Comparator|25 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
89651144|NCT04278703|Active Comparator|35 opioid tablets perscribed|For this treatment arm, patients will be given a prescription of 15 tablets of Oxycodone which they may take to alleviate post-operative pain
89651145|NCT04907058|Experimental|Treatment with CO2|Patients were treated with an effective lowest concentration of CO2 delivered by the novel CO2 supply system.
89651146|NCT04449003||Adolescents with Tourette Syndrome|Adolescents (aged 13-17 years) with Tourette Syndrome
89651147|NCT04449003||Adolescents without any neurologic or psychiatric diagnoses|Adolescents (aged 13-17 years) without any history of tics
89651148|NCT04402281||suPAR algoritm control|Control arm (Meilahti hospital): Samples are collected and suPAR measured but no algorithm is implemented.
89651149|NCT04402281||suPAR algoritm intervention|"Intervention arm (Jorvi Hospital).~According the algorithm when admitting a patient with suPAR below 3 ng/ml, physician should answer the following question~Are you sure it is the right decision to admit this patient? Please discuss this with a senior physician.~If discharging a patient with suPAR above 6 ng/ml, physician should answer the following question~Are you sure it is the right decision to discharge this patient? Please discuss this with a senior physician."
89651150|NCT02647788|Active Comparator|Acetaminophen/Ibuprofen|Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg
89651151|NCT02647788|Active Comparator|Acetaminophen/Codeine|Group 2: Acetaminophen 300mg, Codeine 30 mg
89651152|NCT04408742||females with Multiple Sclerosis|patients with a confirmed diagnosis of MS according to the McDonald criteria, physician-administered Expanded Disability Status Scale (EDSS) range of 1-3.5, having regular menstrual cycle (between 21-35 days), and cognitive levels to give history and following the instructions
89651153|NCT04382703|Experimental|Intervention|Given the associated questionnaire which has the embedded self-affirmation exercise.
89045584|NCT06225791|Active Comparator|Enhanced MMS delivery with one 180-count bottle|Pregnant women are provided with one 180-count bottle of MMS along with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 with MMS orientation with expanded BCC). (1 sub-district with each of the 13 districts with high- or moderate-intensity evaluation).
89045585|NCT06225778|No Intervention|Control Group|Control group
89045586|NCT06225778|Experimental|Exercise Group|6-week online exercise group
89045587|NCT06225765|Experimental|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Test group receiving surgery under transoral endoscopic thyroidectomy vestibular approach (TOETVA)
89045588|NCT06225765|Active Comparator|Traditional open surgery|Control group receiving traditional open thyroidectomy
89045589|NCT06225726||Experimental : Urothelial bladder tumour|Patient with an indication of transurethral resection of the bladder. Following the Urology consultation, the patient will be called for a trans-urethral bladder resection within 1 month. The patient will be admitted to the Urology Department of the Tours University Hospital the previous day.
89045590|NCT06225687|Experimental|Heat Application|Heat will be applied to the abdominal/lumbar area for 15 minutes.
89045591|NCT06225687|No Intervention|Control Group|No intervention will be made.
89651154|NCT04382703|Active Comparator|Control|Given the associated questionnaire without the embedded self-affirmation exercise.
89651155|NCT01459016|Experimental|Imaging Biomarkers|
89045592|NCT06225661|Experimental|SAFE Intervention|This group will receive the SAFE individual youth and family-based intervention.
89045593|NCT06225661|Active Comparator|NAV (Telephone Navigation)|This group will receive telephone-based case navigation.
89045594|NCT06225635|Experimental|Test|Ezerosu tablet(double layer tablet)
89045595|NCT06225635|Active Comparator|Control|Ezerosu tablet(monolayer tablet)
89045596|NCT06225609|Experimental|Ghost ileostomy|Laparoscopic or robotic surgery with ghost ileostomy
89045597|NCT06225609|Active Comparator|No ileostomy|Laparoscopic or robotic surgery with no ileostomy
89651156|NCT04382859|Active Comparator|TAP block with liposomal bupivacaine|Active comparator
89651157|NCT04382859|Other|TAP block with 0.25% bupivacaine|Standard comparator
89045598|NCT06225570|Experimental|Isotretinoin|Weekly isotretinoin (at 1-1.5 mg/kg per week) dose preceded by a 5-day daily loading dose (0.5-1 mg/kg/day). The weekly dose will be given once a week for 4 months.
89045599|NCT06225570|Active Comparator|Tetracycline|Daily oral doxycycline (weight-based dosing with maximum dose 200mg daily) or other tetracycline class antibiotic for a 4-month treatment period.
89045600|NCT06225544|Experimental|Lumasiran, treatment arm|
89045601|NCT06225544|Placebo Comparator|Placebo|Placebo injection with 0.9% sodium chloride
89045602|NCT06225440|Active Comparator|Levagen+® Palmitoylethanolamide (PEA)|Levagen+® Palmitoylethanolamide (PEA) - 700mg/day, containing not less than 600 mg PEA.
89045603|NCT06225440|Placebo Comparator|Placebo|Placebo - Microcrystalline Cellulose
89045604|NCT06225414|Experimental|Arm A: Enhanced Usual Care|Usual Care + Brief Educational Material
89045605|NCT06225414|Experimental|Arm B: Empower Latinx|"PCP notifications of patients' LCS eligibility (addressing provider time constraints and barrier in identifying eligible patients);~Patients' education (addressing knowledge barriers);~Patients' referral to financial navigation resources (addressing health-related social risks)~Patients' reminder to discuss LCS during PCP visit."
89045606|NCT06225401|Experimental|Simcapture PRE|In the PRE intervention group (before the traditional teaching) students will practice in pairs, with the same low fidelity simulator, the blood collection technique without a teacher in the classroom. In the SimCapture for Skills interface, the procedure of how to perform the technique (sequence of actions) will be developed in checklist format for the student to check step by step. They will be provided with the same material and classroom time as in traditional teaching (2h).
89651158|NCT03318133|Experimental|GA group|"general anesthesia(GA) group:~Open peripheral vein fluid infusion, radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring~Propofol (1.5-3mg/kg), cis-atracurium(0.1-0.15mg/kg) and sulfentanyl(0.2-0.6μg/kg) anesthesia-induced intubation, mechanical ventilation to maintain normal PETCO2~Use sevoflurane, propofol and sulfentanyl to maintain anesthesia, and add cis-atracurium as needed~Transfer to ICU after surgery"
89651159|NCT03318133|Experimental|CLSB group|"combined lumbar plexus and sacral plexus block(CLSB) group:~Open peripheral vein fluid infusion~In lateral position (affected side upward), ultrasound-guided lumbar plexus block (0.375% ropivacaine, Lumbar 2-3 or/and 3-4vertebral space level, 25ml), then sacral plexus block (0.375% ropivacaine, 20ml)~Radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring, and blockade effectiveness was evaluated 30min after nerve block~After reaching satisfactory blockade, target-controlled infusion of propofol was used to maintain Ramsay sedation score between 5-6 points, monitoring PETCO2 through nasopharyngeal airway, maintain autonomous respiration, and add small-dose fentanyl (10-20μg/time) as needed~Transfer to ICU after surgery"
89651160|NCT02800434|Experimental|hand allograft|
89651161|NCT04382547|Experimental|mesenchymal stem cells|Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells
89651162|NCT04382547|Active Comparator|control|Patients with Covid-19 associated pneumonia receiving standard treatment
89651163|NCT05687227|Experimental|EXPERIMENT GROUP|The trainings were held in groups of 4-6 people. The trainings, which were held in three sessions, were held on the days and times that were convenient for the participants. Since the participants were required to attend all sessions, additional session/sessions were held in case of not being able to attend the trainings. Participants in the control and experimental groups were called and the day they would come for the control was determined, and they went to the gynecology outpatient clinic. The post-test questionnaire was applied to the participants in the control and experimental groups in the first 3 months. Until the end of the research, the participants were told that they could reach the researcher at any time and ask questions. Finally, at the 6th month, a post-test form was applied to the participants.
89651164|NCT05687227|No Intervention|CONTROL GROUP|No training or counseling was given to the control group. Participants in the control and experimental groups were called and the day they would come for the control was determined, and they went to the gynecology outpatient clinic. The post-test questionnaire was applied to the participants in the control and experimental groups in the first 3 months. Finally, at the 6th month, a post-test form was applied to the participants.
89651165|NCT04134663|Experimental|vasoconstrictor + intranasal oxytocin group|subjects receive the vasoconstrictor followed by oxytocin
89651166|NCT04134663|Active Comparator|vasoconstrictor's placebo + intranasal oxytocin group|subjects receive the vasoconstrictor's placebo followed by oxytocin
89651167|NCT04134663|Placebo Comparator|vasoconstrictor + intranasal oxytocin placebo group|subjects receive the vasoconstrictor followed by intranasal oxytocin's placebo
89651168|NCT05431998|Experimental|The use of demineralized autogenous tooth graft in the jumping gap of the immediate implant|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high-speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill (Gold Bone Mill, MCT Bio, Korea). Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid (Chemajet Chemicals, Egypt) for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the bone defect around the immediately placed implant.
89651169|NCT05431998|Active Comparator|The use of autogenous bone graft in the jumping gap of the immediate implant|A horizontal vestibular incision will be placed below the mucogingival junction and a mucoperiosteal flap will be reflected then autogenous bone particles will be collected from the participants using Automatic Bone Collector Bur (ACM Bur) by NeoBiotch, from the mandibular retro-molar region, speed 300rpm, torque 30Ncm, with irrigation.
89651170|NCT04112433||PURE EP 2 Group|Enrolled and consented patients who are indicated for and receive an elective cardiac ablation procedure using the PURE EP 2 system for monitoring and collection of intracardiac electrogram signals.
89651171|NCT05431764|Experimental|Camrelizumab Plus Stereotactic Body Radiotherapy|Patients were treated with gemcitabine, cisplatin and camrelizumab for 6 cycles, followed by whole-target radiotherapy (IMRT for locoregional lesion and SBRT for oligometastatic lesions) and camrelizumab maintenance therapy.
89651172|NCT04311411|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
89651173|NCT04311411|Placebo Comparator|Placebo|Placebo administered SC.
89651174|NCT04311411|Active Comparator|Liraglutide|Liraglutide administered SC.
89651175|NCT05431530||Ovarian cancer|Tumor involving rectosigmoid colon
89651176|NCT03383107||Cohort 1a - Prostate Cancer|Standard fractionation RT to 81 Gy in 45 fx over 9 weeks
89651177|NCT03383107||Cohort 1b - Prostate Cancer|Hypofractionated RT to 36.25 Gy in 5 fx over 1-2 weeks
89651178|NCT03383107||Cohort 2a - Breast cancer|Standard fractionation breast and nodal RT to 50 Gy in 25 fx over 5 weeks
89651179|NCT03383107||Cohort 2b - Breast Cancer (Partial Breast )|Partial breast RT to 30 Gy in 5 fx over 2 weeks
89651180|NCT00843531|Experimental|RAD001 and erlotinib|"Each 28 day cycle:~RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)"
89651181|NCT04383015|Other|Carbohydrate (CHO)-only|Carbohydrate dose of 0.3g/kg/hr given every 30 minutes of exercise if blood glucose is in range with usual basal insulin infusion
89651182|NCT04383015|Other|50 Percent Basal Rate Reduction (BRR)|A 50 percent basal rate reduction set 90-minutes pre-exercise and throughout exercise
89045607|NCT06225401|Experimental|Simcapture POST|In the POST intervention group (after the traditional teaching) the students will practice in pairs, with the same low fidelity simulator, the blood collection technique without a teacher in the classroom. In the SimCapture for Skills interface, the procedure of how to perform the technique (sequence of actions) will be developed in checklist format for the student to check step by step. They will be provided with the same material and classroom time as in traditional teaching (2h).
89045608|NCT06224855|Experimental|Experimental|Dose Escalation DXC006, Cohort Expansion DXC006
89045609|NCT06224725||The Cohort of 60-year-olds (60YO): case-cohort study design|"The project is an observational study and will employ a case-cohort design using two cohorts Swedish cohorts- The Cohort of 60-year-olds (60YO) and the Swedish Mammography Cohort (SMC).~A sub-cohorts will be randomly selected from the full cohorts (aprox n = 450 around 5 %-of the baseline population in 1997-1999, for 60YO, and 2003-2009, for SMC). All the cases of each of the diseases under investigation occurring outside the sub-cohorts will be included. The cases will include participants free of any diagnosis of each of the diseases investigated at the time of sampling. Incident cases of the diseases under investigation will be identified through linkage to the Swedish National Cancer Register, National Patient Register, Cause of Death Register and Swedish registry for cognitive/dementia disorders till the end of follow-up (2022 for both cohorts)."
89045610|NCT06224725||The Swedish Mammography Cohort (SMC)|"A case-cohort design will be employed as for 60YO cohort (see cohort label 60YO)"
89045611|NCT06224595|Experimental|CS32582 Cohort 1|Subjects receive a single dose of 3 mg CS32582 or matching placebo
89045612|NCT06224595|Experimental|CS32582 Cohort 2|Subjects receive a single dose of 6 mg CS32582 or matching placebo
89045613|NCT06224595|Experimental|CS32582 Cohort 3|Subjects receive a single dose of 12 mg CS32582 or matching placebo
89045614|NCT06224595|Experimental|CS32582 Cohort 4|Subjects receive a single dose of 24 mg CS32582 or matching placebo
89045615|NCT06224595|Experimental|CS32582 Cohort 5|Subjects receive a single dose of 36 mg CS32582 or matching placebo
89651183|NCT04383015|Other|Combo|The combination of a 50 percent basal rate reduction and carbohydrate dose of 0.3g/kg/hr (given every 30 minutes) both at exercise onset
89651184|NCT00812877|Active Comparator|Mineral Trioxide Aggregate|Pulp capping agent, Mineral Trioxide Aggregate used as a direct pulp cap
89651185|NCT00812877|Active Comparator|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide used as a direct pulp cap
89651186|NCT00813111|Experimental|SKY0402|A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)
89651187|NCT00813111|Active Comparator|Bupivacaine HCl|A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)
89651188|NCT04292847|Experimental|Geriatric Assessment|Participants fill out the geriatric assessment during a clinic visit and receive recommendations based on results
89651189|NCT00845481|Experimental|all patients apply all products|
89651190|NCT03641001|Experimental|Intervention|Intervention group will receive child feeding counselling, food voucher for recipe, WASH and home fortification
89651191|NCT03641001|No Intervention|Control|Control will receive usual health messages from government and NGO
89651192|NCT03627507|Experimental|Hepa B|79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
89651193|NCT03627507|Active Comparator|Engerix B|79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.
89651194|NCT01458392|Experimental|Dalantercept|dalantercept
89651195|NCT01421069|Experimental|1|
89651196|NCT04276233|Experimental|Participants with severe eosinophilic asthma|Participants with severe eosinophilic asthma will receive Mepolizumab 100 mg subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses). Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
89651197|NCT04093622||Genetically engineered NK Cell - treated|Long term follow-up of subjects who have received lentivirus-mediated genetically engineered NK Cells.
89651198|NCT04681430|Experimental|convalescent plasma (CP)|Administration of 2 units of CP (neutralizing anti-SARS-CoV-2 antibody titer of at least 1:160) on day 1
89651199|NCT04681430|Other|Standard of Care|Standard of care allowed
89651200|NCT04681430|Experimental|Camostat Mesilate|Tablets 600 mg per day in 3 doses over 7 days
89651201|NCT04681430|Placebo Comparator|Placebo camostat|Placebo Tablets in 3 doses over 7 days (blinded)
89651202|NCT00848367|Experimental|High attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
89651203|NCT00848367|Experimental|Low attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
89651204|NCT05345665|Other|Echography|For the neuronal blockade of the patient, anesthesiologists used an echography.
89651205|NCT05345665|Other|Neurostimulation|For the neuronal blockade of the patient, anesthesiologists used neurostimulation.
89651206|NCT05345665|Other|Active mobilization|For the neuronal blockade of the patient, anesthesiologists used active mobilization.
89651207|NCT00814671|Experimental|RPT450|Rifapentine 450mg daily
89651208|NCT00814671|Active Comparator|RIF 600|Rifampin 600mg daily
89651209|NCT00814671|Experimental|RPT 600|Rifapentine 600mg daily
89651210|NCT03379051|Experimental|Ublituximab + Umbralisib + Venetoclax|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose
89651211|NCT03379051|Experimental|Ublituximab + Umbralisib + Lenalidomide|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions; Umbralisib and Lenalidomide both administered days 1 - 21 of every 28 days
89651212|NCT01473836|Experimental|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium
89651213|NCT03340909|Experimental|Prednisolone|Prednisolone tablets 5 mg
89045616|NCT06224595|Experimental|CS32582 Cohort 6|Subjects receive a single dose of 54 mg CS32582 or matching placebo
89651214|NCT03340909|Placebo Comparator|Placebo|Placebo tablets with identical appearance to the experimental drug.
89651215|NCT00815685|Experimental|Eicosapentaenoic Acid|
89651216|NCT00850473|Experimental|Positron Emitting Image|Patient will have a PET/CT imaging study to determine cardiac stenosis, F-18 FDG and heparin/intralipid infusion and Contrast Dye.will be administered.
89651217|NCT05552209||Orthosis group 1|Use of Elbow Mid 500 device during sport practice
89045617|NCT06224595|Experimental|CS32582 Cohort 7|Subjects receive a single dose 12 mg CS32582 in either the fasted or fed state for two periods
89651218|NCT05552209||Control group 1|Control group of the Elbow Mid 500 group - no medical device used during sport practice
89651219|NCT05552209||Orthosis group 2|Use of Elbow Strap device during sport practice
89651220|NCT05552209||Control group 2|Control group of the Elbow Strap group - no medical device used during sport practice
89651221|NCT04239027|Experimental|RTH258/Brolucizumab|This is a single-arm study in which all patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment from Week 16/Week 20 up to Week 40/Week 44.
89651222|NCT05540041|Experimental|Bubble breathing play therapy|Children in intervention group 2 will be given a bubble breathing play therapy intervention. With this intervention, it is aimed to teach the child and parent to breathe correctly and deeply, to relax them, to reduce their anxiety and fears, to relax, to direct their attention to something other than pain. In the intervention pediatric surgery service, investigative coaching will be applied 30 minutes before premedication. The procedure time is planned to be at least 5-10 minutes. The intervention will be implemented with a ready-made foam bubble toy. The toy will be provided by the researcher and given to the children as a gift.
89651223|NCT05540041|Experimental|Tell-show-do play therapy|Tell-show-do play therapy initiative will be applied to children included in intervention group 1. The initiative will be applied to children without disturbing the parent-child relationship. The intervention will be applied for 10-15 minutes. The tell-show-do play therapy initiative will be implemented using the directed play therapy method and therapeutic play tools. Amigurumi dolls, medical toys (surgical shirt, movable toy bed) and real medical materials such as stethoscope, patient armband, bone, mask, degree will be used as therapeutic play tools.
89651224|NCT05540041|Other|No intervention|The participants in the control group will be given routine nursing care.
89651225|NCT03839589|Experimental|MBSR-A|Intervention Mindfulness Condition: MBSR is a structured intervention delivered through an 8-week course. Mindful breathing, awareness, walking, and attention are core activities taught and practiced during and outside of the course.
89651226|NCT03839589|Placebo Comparator|Wait-listed MBSR-A|The MBSR-A Wait-listed group: This wait-listed group will be followed with the same outcome assessments as the MBSR- A immediate group but will receive no intervention until after outcomes from group 1 are collected at 3 months, when they will also receive the MBSR-A
89651227|NCT05686915||Revision Total Hip Arthroplasty|Patients who received a revision total hip surgery utilizing a ceramic femoral head with a titanium sleeve
89651228|NCT00815997|Sham Comparator|6-Fr TRI (transradial coronary intervention)|TRI will be performed using a 6-Fr guiding catheter.
89651229|NCT00815997|Active Comparator|4-Fr TRI|TRI will be performed using a 4-Fr guiding catheter.
89651230|NCT03674151|Active Comparator|Device: Silver Nylon dressing|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
89651231|NCT03674151|Active Comparator|Device: Manuka-Honey|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
89651232|NCT03674151|Active Comparator|Device: Povidone-Iod (PVP-Iod)|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
89651233|NCT03674151|Active Comparator|Device: Hydrogel|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
89651234|NCT03376633|No Intervention|Control group|These youth will not receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2] or after, and will not have contact with WOW clinicians. Control youth will be able to receive all other services available through their school as they normally would, such as access to the school counselor and after school programs.
89651235|NCT03376633|Experimental|WOW Group and Individual Counseling|These youth will receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2]. These young women will participate in weekly group therapy and skill-building sessions, led by master's level clinicians, and will also receive individual support and therapy from their clinicians as-needed.
89651236|NCT03643965|Experimental|Nefecon|Nefecon 16 mg once daily by mouth for 9 months.
89045618|NCT06224595|Experimental|CS32582 Cohort 8|Subjects receive 3 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.
89045619|NCT06224595|Experimental|CS32582 Cohort 9|Subjects receive 6 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.
89651237|NCT03643965|Placebo Comparator|Placebo oral capsule|Placebo oral capsule once daily by mouth for 9 months.
89651238|NCT01473758|Active Comparator|Roflumilast|added on to standard therapy for acute COPD exacerbations
89651239|NCT01473758|Placebo Comparator|Placebo|added on to standard therapy for acute COPD exacerbations
89045620|NCT06224595|Experimental|CS32582 Cohort 10|Subjects receive 12 mg CS32582 or matching placebo for 10 days, once daily from Day 1 to Day 10.
89045621|NCT06224595|Experimental|CS32582 Cohort 11|Subjects receive 12 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.
89045622|NCT06224322||Cerebral Palsy Patients Parent|Parents of patients who underwent knee and hip surgery for cerebral palsy
89045623|NCT06224023||Patients with chronic liver failure and ascites|
89651240|NCT05533801|Experimental|Treatment A: Lecanemab 720 mg|Participants will receive a single SC dose of lecanemab 720 milligram (mg) in the lower abdomen using a vial and syringe on Day 1.
89651241|NCT05533801|Experimental|Treatment B: Lecanemab 720 mg|Participants will receive a single SC dose of lecanemab 720 mg in the lower abdomen using AI on Day 1.
89651242|NCT01420679|Experimental|Pralatrexate|Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.
89651243|NCT01420679|No Intervention|Observation|Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.
89651244|NCT00851409|Other|Recombinant Human C1 Inhibitor|Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor
89651245|NCT03902535||Group I (geriatric and quality of life assessments)|Patients complete comprehensive geriatric and quality of life assessments within 1-4 weeks of treatment (either upfront surgery which may be followed by radiation with or without chemotherapy or upfront radiation which may include CRT) initiation (baseline), and at 1, 3, and 6 months following CRT completion.
89651246|NCT03902535||Group II (quality of life assessment)|Family caregivers complete quality of life assessment at baseline, and at 1, 3, and 6 months following patient radiation or CRT completion.
89651247|NCT04401007|Experimental|Group 20/30|Two different local anesthetic volumes will be investigated: 20 mL of 1.5% lidocaine (300 mg lidocaine) at one study visit and 30 mL of 1.5% lidocaine (450 mg lidocaine) at the other study visit. Volunteers will be randomized to one of two intervention groups: (1) Group 20/30: A unilateral ESP block with 20 mL of local anesthetic at the first visit, and 30 mL of local anesthetic at the second visit
89651248|NCT04401007|Experimental|Group 30/20|(2) Group 30/20: a unilateral ESP block with 30 mL of 1.5% lidocaine with 1/200,000 epinephrine at the first visit, and 20 mL of the same local anesthetic solution at the second visit. This crossover design allows subjects to serve as their own control.
89651249|NCT01496846|Active Comparator|IANB Articaine|IANB Articaine: Inferior alveolar nerve block (IANB) anesthesia with articaine local anesthetic.
89651250|NCT01496846|Active Comparator|SUP Articaine|SUP Articaine: Supplemental buccal anesthesia (SUP) with articaine local anesthetic after unsuccessful IANB.
89045624|NCT06223854|Active Comparator|Iodized salt|Refined iodized salt containing 35 ppm iodine as potassium iodate
89045625|NCT06223854|Experimental|Iodized salt with lower-dose folic acid fortification|Refined iodized salt containing 35 ppm iodine as potassium iodate and 33 ppm folic acid (to provide an estimated 200 microgram folic acid per day to women consuming the previously determined average amount of discretionary salt in the study communities)
89045626|NCT06223854|Experimental|Iodized salt with higher-dose folic acid fortification|Refined iodized salt containing 35 ppm iodine as potassium iodate and 99 ppm folic acid (to provide an estimated 600 microgram folic acid per day to women consuming the previously average amount of discretionary salt in the study communities)
89045627|NCT06221813|Experimental|Cohort 1 (first 60 subjects) PHV02 high dose|
89045628|NCT06221813|Experimental|Cohort 1 (first 60 subjects) PHV02 medium dose|
89651251|NCT01496846|Active Comparator|SUP Lidocaine|SUP Lidocaine: Supplemental buccal anesthesia (SUP) with lidocaine local anesthetic after unsuccessful IANB.
89651252|NCT00964002|Experimental|Efavirenz|"Patients will receive efavirenz 600 mg daily as oral tablets at bedtime and in fast condition (1-2 hours far from dinner) until objective biological, radiological or clinical disease progression or study discontinuation (withdrawal of consent or when the patient meets one criterion for treatment discontinuation).~Individual dose escalation will be possible: if biological progression occurs at month 3, dose could be increased to 1200 mg/day in asymptomatic and non radiological progression patients (by step of 200 mg every 15 days)."
89651253|NCT00818337|Active Comparator|Aspirin 81mg|Resistant
89651254|NCT02695368|Experimental|Exposed patients: Plasma-filter on|"Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into:~regular operating theater~ultra-Clean operating theaters"
89651255|NCT02695368|Experimental|Unexposed patients: Plasma-filter off|Those with Novaerus NV800 off for at least 2 Days prior to index surgery
89651256|NCT02695368|Experimental|Mixed patients: Plasma-filter on or off|Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.
89651257|NCT02718807||Post-partum Women|Post-partum women following an atraumatic pregnancy.
89651258|NCT02718807||Co-Parents|Co-parents to post-partum women following an atraumatic pregnancy.
89651259|NCT02688660||ADAPT Study Population|This cohort will be subjects from the ADAPT study who had an acute MRI scan which has been uploaded into the ADAPT database from all participating sites.
89651260|NCT02688660||Follow-Up MRI|This cohort will include patients from ADAPT sites who choose to participate in this option and obtain a follow-up MRI approximately 1 year after the TBI.
89651261|NCT02688660||Healthy Controls|This cohort will have one MRI to be used in comparison of the above cohorts.
89651262|NCT02577120|No Intervention|Low TEWL|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects will be be discontinued from the study.
89651263|NCT02577120|No Intervention|High TEWL - No treatment|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
89651264|NCT02577120|Experimental|High TEWL - Epiceram skin barrier function|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
89651265|NCT02577120|Experimental|High TEWL - Ceramiseal|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site
89651266|NCT02577120|Placebo Comparator|High TEWL - Vaseline Petroleum Jelly|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
89651267|NCT01399697|Experimental|A|
89651268|NCT01399697|Active Comparator|B|
89651269|NCT00853671|Experimental|Adenosine Stress Dual-source CTP|A multiphase adenosine Stress Dual-source stress perfusion computed tomography imaging test, as described above, will be performed in all patients.
89651270|NCT02565030||CTEPH surgical disease, operated|Patients with proximal CTEPH who have undergone Pulmonary Endarterectomy (PEA) surgery
89651271|NCT02565030||CTEPH surgical disease, not operated|"Patients with proximal CTEPH with operable distribution of disease& have not undergone PEA surgery due to the following reasons:~Multiple co-morbidities~Patients choice~Mild disease /symptoms~Awaiting Surgery"
89651272|NCT02565030||CTEPH non surgical|Patients with distal CTEPH with inoperable distribution of disease inaccessable to surgery.
89651273|NCT02565030||IPAH|Patients with IPAH as per European Society of Cardiology(ESC) criteria
89651274|NCT00818805|Experimental|Olopatadine 0.1% one eye|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
89651275|NCT00818805|Experimental|Tranilast 0.5% one eye|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
89651276|NCT00818805|Placebo Comparator|Placebo (Olopatadine)|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
89651277|NCT00818805|Placebo Comparator|Placebo (Tranilast)|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
89651278|NCT03025607|No Intervention|Control|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes as well as a list of resources for mHealth tools for monitoring diet, physical activity, and weight.
89651279|NCT03025607|Experimental|JOOL-Only|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, and will receive the JOOL Health mobile phone application.
89651280|NCT03025607|Experimental|JOOL-Plus|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, the JOOL Health mobile phone application, a digital scale, and a Fitbit.
89651281|NCT00854061|Experimental|T-Pred|Tobramycin prednisolone acetate combination
89651282|NCT00854061|Active Comparator|Pred Forte|Prednisolone acetate
89651283|NCT01473602|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
89651284|NCT01473602|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
89651285|NCT03336073|Experimental|carfilzomib, dexamethasone and cyclophosphamide|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles
89651286|NCT03336073|Active Comparator|carfilzomib and dexamethasone|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 , in 28 days cycles
89651287|NCT05523427|No Intervention|Standard treatment of IBS|"Mebeverine 135 mg Sulpiride 25 mg Simethicone 200 mg~They were administered in a single capsule, three time daily before meals."
89651288|NCT05523427|Experimental|Probiotics + Standard treatment of IBS|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
89045629|NCT06221813|Experimental|Cohort 1 (first 60 subjects) PHV02 low dose|
89045630|NCT06221813|Placebo Comparator|Cohort 1 (first 60 subjects) Placebo|
89045631|NCT06221813|Experimental|Cohort 2 (next 60 subjects) PHV02 high dose|
89045632|NCT06221813|Experimental|Cohort 2 (next 60 subjects) PHV02 medium dose|
89045633|NCT06221813|Experimental|Cohort 2 (next 60 subjects) PHV02 low dose|
89651289|NCT04760197||patient under cancer immunotherapy with inflammatory ophthalmological manifestations|patient(>18 years old) under cancer immunotherapy with inflammatory ophthalmological manifestations
89045634|NCT06221813|Placebo Comparator|Cohort 2 (next 60 subjects) Placebo|
89045635|NCT06220916||Greek National School of Dance - GNSD|All the GNSD undergraduate students with written consent for participating into the study
89045636|NCT06220916||Higher Vocational Dance School of Maria Grigoriou - Choros|All the Choros undergraduate students with written consent for participating into the study
89045637|NCT06220916||Higher Vocational Dance School Chorochronos|All the Chorochronos undergraduate students with written consent for participating into the study
89045638|NCT06220916||Higher Vocational Dance School of Moragemou|All the Moragemou undergraduate students with written consent for participating into the study
89045639|NCT06220916||Higher Vocational Dance School Aktina|All the Aktina undergraduate students with written consent for participating into the study
89651290|NCT03334045||Stress patients|Patients diagnosed with work-related Adjustment disorder
89651291|NCT03334045||Controls|Healthy controls
89651292|NCT01496612|Experimental|Study Phase|
89651293|NCT01496612|Placebo Comparator|Alternate Study Phase|
89651294|NCT03303391|No Intervention|Standard Care|This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist
89651295|NCT03303391|Experimental|IBPS Group|This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.
89651296|NCT00790218|Experimental|CF102 1mg|An open-label trial in 28-day cycles.
89651297|NCT00790218|Experimental|CF102 5mg|An open-label trial in 28-day cycles.
89651298|NCT00790218|Experimental|CF102 25mg|An open-label trial in 28-day cycles.
89651299|NCT05349019||Part A/Sub Cohort A1|15 healthy participants 18-35 years of age
89045640|NCT06220916||Higher Vocational Dance School of Maro Marmarinou|All the Maro Marmarinou undergraduate students with written consent for participating into the study
89045641|NCT06220916||Higher Vocational Dance School of Athens Conservatoire|All the Athens Conservatoire undergraduate students with written consent for participating into the study
89045642|NCT06220916||Higher Vocational Dance School of Marias Chatzimihali Charlafti|All the Marias Chatzimihali Charlafti undergraduate students with written consent for participating into the study
89045643|NCT06219252|Experimental|ORA group|the intraocular lens calculation in this group will be optimized by the intraoperative aberrometer (ORA)
89045644|NCT06219252|Active Comparator|Control group|Barrett universal II will be used in the control group.
89045645|NCT06219226|Experimental|Chlorine dioxide mouthwash|Participants will rinse once with hyper-pure ClO2 (0.003%) mouthwash.
89045646|NCT06219226|Active Comparator|Chlorhexidine mouthwash|Participants will rinse once with chlorhexidine-containing mouthwash (0.2%).
89045647|NCT06219031||valid group（CR/PR）|CR/PR
89045648|NCT06219031||invalid group（SD/PD）|SD/PD
89045649|NCT06218836|Active Comparator|Intubation with pre-inflated ETT|Patient's trachea will be intubated using pre- inflated endotracheal tube (ETT)
89045650|NCT06218836|Active Comparator|Intubation with non-inflated ETT|Patient's trachea will be intubated using non-inflated ETT
89045651|NCT06218238|Experimental|Ossur Power Knee|Subjects will be fitted with the Ossur Power Knee, which has powered flexion and extension.
89045652|NCT06218238|Active Comparator|Ossur Rheo XC Knee|Subjects will be fitted with the Ossur Rheo XC Knee, which is a conventional microprocessor-controlled knee joint that modulates the amount of damping during flexion and extension.
89651300|NCT05349019||Part A/Sub Cohort A2|15 healthy participants 65-80 years of age
89045654|NCT06213779||One group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
89045655|NCT06213766|Active Comparator|Cognitively healthy subjects|"Participants aged between 20 and 85 years old with no cognitive impairment (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15), affiliated or entitled to a social health insurance, having been informed and having given written consent to the study.~As part of the study, cognitively healthy subjects will :~Undergo a cognitive assessment;~Answer several questionnaires on their demographic data, lifestyle habits, quality of sleep, cognitive reserve, concomitant treatment and comorbidities;~Complete a cognitive spatial navigation task with eye-tracking;~Have a blood sampling for plasma biomarker and genetic risk factor for Alzheimer's disease."
89045656|NCT06213766|Experimental|Patients suffering from Alzheimer's disease|"Patients aged between 50 and 85 years old, undergoing memory clinic consultation for prodromal or mild Alzheimer's disease with mild or moderate cognitive decline (Mini-Mental State Examination ≥20/30) affiliated or entitled to a social health insurance, having been informed and having given written consent to the study.~As part of the study, patients suffering from Alzheimer's disease will :~Undergo a cognitive assessment;~Answer several questionnaires on their demographic data, lifestyle habits, quality of sleep, cognitive reserve, concomitant treatment and comorbidities;~Complete a cognitive spatial navigation task with eye-tracking;~Have a blood sampling for plasma biomarker and genetic risk factor for Alzheimer's disease."
89045657|NCT06212349|Experimental|Experimental|They will receive therapeutic-educational physiotherapy, which will combine therapeutic exercise with a pain education program,
89045658|NCT06212349|Other|Control|They will receive the pain education program.
89651301|NCT05349019||Part A/Sub Cohort A3|Control group age and sex matched to the PD participants in Part B of the study
89651302|NCT05349019||Part B|60 participants with a confirmed diagnosis of Parkinson's disease and a heterozygous G2019S mutation in the LRRK2 gene
89651303|NCT02497950||HeartMate 3|This registry will include all patients that receive the HM3 LVAS in the post-market setting
89651304|NCT03333655|Other|Checkpoint Inhibitor Therapy|Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible.
89651305|NCT03333265|Experimental|100mg Berberine hydrochloride group|Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months
89651306|NCT03333265|Experimental|300mg Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months
89651307|NCT03333265|Placebo Comparator|Placebo oral tablets|identical-appearing placebo tablets by mouth, two times per day for 6 months
89651308|NCT04849260|Experimental|Pexa-Vec combined with ZKAB001|"The combined treatment group is divided into two dose groups. The principle of 3+3 is adopted to determine RP2D, and RP2D will be used in subsequent patients in this cohort."
89651309|NCT04849260|Active Comparator|ZKAB001 monotherapy|ZKAB001 monotherapy.
89651310|NCT00818961|Other|Hematopoietic Stem Cell Transplantation|All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type
89045659|NCT06208592||Anaconda Group|Use of Anaconda devide at any point during the initial follow up (7 days) additional of conventional intravenous sedation
89045660|NCT06208592||Non-Anaconda Group|Use on conventional intravenous sedation, not using Anaconda device
89651311|NCT05431218|No Intervention|normal vitamin D levels|Patients with normal vitamin D levels (30-100ng/ml) No interference is implied. Observation only
89651312|NCT05431218|Active Comparator|Mild vitamin D deficiency|Patients with mild vitamin D deficiency (20-29 ng/ml)They will receive 4000 IU of cholecalciferol per day for 3 months
89651313|NCT05431218|Active Comparator|Moderate vitamin D deficiency|Patients with moderate vitamin D deficiency (10-19 ng/ml) will receive cholecalciferol at a dose of 5000-6000 IU daily for 3 months
89651314|NCT05431218|Active Comparator|Severe vitamin D deficiency|Patients with moderate vitamin D deficiency (10-19 ng/ml) will receive cholecalciferol at a dose of 7000-8000 IU daily for 3 months
89045661|NCT06206460||Open Label Placebo with Treatment Rationale|
89045662|NCT06206460||Open Label Placebo without Treatment Rationale|
89045663|NCT06206005||Group1 with Haemoglobin A1c ≤6.5%|This group represents a well-controlled type 2 Diabetics mellitus.
89045664|NCT06206005||Group 2 with Haemoglobin A1c >6.5%|This group represents a poorly controlled type 2 Diabetics mellitus.
89045665|NCT06205628|Experimental|PART 1 - Active ADX-850 administered to patients with hypertension|"For Cohort 1 in Part 1 (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-850) : 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.~For Cohort 2, the option either to enroll 8 or expand to 16 patients in a 3:1 ratio will be made following review of Cohort 1. For Cohorts 3 and 4, 16 patients will be randomized in a 3:1 ratio; 12 patients to active (ADX-850) : 4 patients to control (matched placebo)."
89212936|NCT00485134|Experimental|Stage 1: Group A, Dolphin 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of lipopolysaccharides (LPS). 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
89651315|NCT05431062|Active Comparator|Thoracic paravertebral block|USG guided TPVB will be performed with 0.5 mL/kg %0.25 Buvicaine in the paravertebral space.
89651316|NCT05431062|Active Comparator|Erector spinae plane block|USG guided ESPB will be performed with 0.5 mL/kg %0.25 Buvicaine into the facial plane between erector spine muscle and transverse process
89651317|NCT05431062|Active Comparator|Serratus anterior plane block|USG guided ESPB will be performed with 0.5 mL/kg %0.25 Buvicaine into the facial plane between serratus anterior muscle and external intercostal muscles
89651318|NCT05430984|Active Comparator|Laparoscopic TAPP inguinal hernia repair with mesh fixation|the mesh will be fixed to the abdominal wall using suture, spiral tacks.
89651319|NCT05430984|Active Comparator|Laparoscopic TAPP inguinal hernia repair without mesh fixation|the mesh will be left as it is and the operation will be concluded
89651320|NCT00819507|Experimental|Vanos Cream|glucocorticoid cream
89651321|NCT03371875|Experimental|Transition Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. Physicians will then be given reminders based on the subject's deficiencies in transition management, and given the opportunity to intervene.
89651322|NCT03371875|No Intervention|Control Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. No reminders will be provided to providers for care transition.
89651323|NCT03696121|Experimental|Intervention|Desmopressin injection
89651324|NCT03696121|Placebo Comparator|Control|Normal Saline
89651325|NCT01171950|Other|All Patients|All patients meeting the patient selection criteria will be treated with the CentriMag device.
89651326|NCT03297541|Experimental|m-health approach|All dyads will receive the m-health approach.
89651327|NCT00820443|Experimental|Ceramic on metal prosthesis|Ceramic on metal prosthesis
89651328|NCT01457924|Experimental|Cohort 1|Placebo and one dose of Ofatumumab 3mg over 24 weeks
89651329|NCT01457924|Experimental|Cohort 2|Two doses of Ofatumumab 3mg over 24 weeks
89651330|NCT01457924|Experimental|Cohort 3.1|Two doses of Ofatumumab 30mg over 24 weeks
89651331|NCT01457924|Experimental|Cohort 3.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 30mg over 24 weeks
89651332|NCT01457924|Experimental|Cohort 4.1|Two doses of Ofatumumab 60mg over 24 weeks
89651333|NCT01457924|Experimental|Cohort 4.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 60mg over 24 weeks
89651334|NCT01457924|Experimental|Cohort 5.1|Six doses of Ofatumumab 60mg over 24 weeks
89651335|NCT01457924|Experimental|Cohort 5.2|Conditioning dose of Ofatumumab 3mg at randomization, six doses of Ofatumumab 60mg over 24 weeks
89651336|NCT04400773|Experimental|Plyometric Group|This group will receive a 6-week upper body plyometric exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
89651337|NCT04400773|Experimental|Strength Group|This group will receive a 6-week upper body strength exercise protocol. Sessions will last for 65 minutes, three times per week. Each week the exercises will be progressed and all sessions will be supervised by an exercise professional.
89651338|NCT01307631|Experimental|Treatment (Akt inhibitor MK2206|Patients receive Akt inhibitor MK2206 PO once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89651339|NCT03291535|Placebo Comparator|Control|This arm will consist of the usual care of management of hypertension by a clinical pharmacist.
89651340|NCT03291535|Active Comparator|Intervention|This arm will consistent of usual care plus the addition of a blood pressure cuff that will allow patients to upload data to the electronic health record via a secure portal.
89651341|NCT04279405|Experimental|YY-20394|treatment with YY-20394 will be continued until tumor progression or development of unacceptable toxicity.
89651342|NCT05237115|Experimental|Clostridium butyricum group|given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
89651343|NCT05237115|Experimental|Bacillus clotting group|given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
89651344|NCT05237115|Active Comparator|bismuth quadruple therapy|given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
89651345|NCT01399619|Experimental|BI201335 12W|patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
89651346|NCT01399619|Experimental|BI 201335 24W|patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
89651347|NCT01399619|Experimental|BI 201335 24 W|patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks
89651348|NCT01496456|Placebo Comparator|Preventative measures|Caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
89045666|NCT06205628|Placebo Comparator|PART 1 - Placebo administered to patients with hypertension|"For Cohort 1 in Part 1 (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-850) : 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.~For Cohort 2, the option either to enroll 8 or expand to 16 patients in a 3:1 ratio will be made following review of Cohort 1. For Cohorts 3 and 4, 16 patients will be randomized in a 3:1 ratio; 12 patients to active (ADX-850) : 4 patients to control (matched placebo)."
89045667|NCT06205628|Experimental|PART 2 - Active ADX-850 administered to patients with hypertension|This will be initiated at the dose level determined by the Safety Review Committee from SAD in Part 1. The treatment of hypertension patients is an open-label study.
89045668|NCT06205628|Experimental|PART 2 - Active ADX-850 plus ARB therapy administered to patients with hypertension|Following ADX-850 dosing in Part 2, patients with remaining elevated blood pressure will additionally receive regular dosing of an angiotensin receptor blocker as an as-indicated concomitant therapy.
89045669|NCT06205407|Active Comparator|Treatment A|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets manufactured at Viatris.
89045670|NCT06205407|Experimental|Treatment B|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets manufactured at Neolpharma.
89045671|NCT06205368|Other|Combine app with all features except the ability to order self-test kits|Participants will receive a modified standard of care which consists of the Combine app with all features except the ability to order self-test kits. The HIV/STI testing locator in the app will be available.
89045672|NCT06205368|Other|Combine app + motivational interview|In addition to the other Combine app features, participants will receive a motivational interview within 4 weeks of downloading the app.
89045673|NCT06205368|Other|Combine app + ability to order up 2 free HIV/STI self-test kits|In addition to the other Combine app features, participants in this arm will be able to order up to two HIV/STI self-test kits at no charge during each year of follow-up.
89045674|NCT06205368|Other|Combine app + motivational interview + ability to order HIV/STI test kits via the app|In addition to the other Combine app features, participants in this arm will receive both the motivational interview and the ability to order HIV/STI test kits via the app.
89045675|NCT06203847|Experimental|Intervention group|"Combined drug treatment: includes epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial).~The method of administration is as follows: after the first administration of epinephrine (Adrenaline® 1mg/vial) to patients with cardiac arrest before hospital arrival, vasopressin (Pitressin® 20Unints/vial) and methylprednisolone (Solu-Medrol® 40mg/vial) are given simultaneously; thereafter, every 3 minutes, 1 mg (1 dose) of (Adrenaline® 1mg/vial) is given, along with 20 Units (1 dose) of vasopressin (Pitressin® 20Unints/vial) up to a maximum of 4 doses (a total of 80 Units) of vasopressin can be given before hospital arrival."
89651349|NCT01496456|Active Comparator|Lesion infiltration|Resin infiltration of caries lesion in addition to caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
89651350|NCT03327649|Sham Comparator|Sham control|Patients will receive 1 hour of sham transcutaneous low level vagal stimulation daily for 3 months
89651351|NCT03327649|Experimental|Active treatment|Patients will receive 1 hour of active transcutaneous low level vagal stimulation daily for 3 months
89651352|NCT05236959|Experimental|Mindfulness-Based Cognitive Therapy|A group-based treatment combining intensive training in mindfulness mediation and elements of cognitive therapy (see further above).
89651353|NCT05236959|Other|Treatment as Usual|Participants in this group continue with their usual care and follow the regimes suggested by their GP or mental health professionals (see further above).
89651354|NCT05487547|Experimental|Study arm|Subjects will receive 4 treatments at 2-weeks intervals. Each treatment will consist of IPL administered on the malar region, followed by RF administered around the eye, followed by Meibomian gland expression (MGX). Follow-up will be conducted at 4 weeks after the 4th treatment session.
89651355|NCT04040621|Experimental|Ceftazidime-avibactam|This arm includes 4 cohorts
89651356|NCT05486533|Experimental|Experimental|The experimental group will be given acupressure.
89651357|NCT05486533|No Intervention|Control|It will only take routine treatment and care.
89651358|NCT00856791|Experimental|ON 01910.Na|3200 mg ON 01910.Na administered intravenously over 2 hours on days 1, 4, 8, 11, 15, and 18 of 28-day cycle
89651359|NCT03289273||uHCC patients treated with regorafenib|Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)
89651360|NCT03326713|Experimental|Telephone Counseling & Navigation (TCN)|Telephone Counseling
89651361|NCT03326713|Active Comparator|Mailed Targeted Print (TP)|Mailed Targeted Print
89651362|NCT03326713|Other|Usual Care (UC)|Control
89651363|NCT00857493|Experimental|Group 1|
89651364|NCT00857493|Experimental|Group 2|
89651365|NCT04399915||Hyperoxalemia/Hyperuricemia Group|
89651366|NCT04399915||Hyperoxalemia/Hyperuricemia-free Group|
89651367|NCT04399915||Healthy Subjects|
89651368|NCT05236569|Experimental|Tranexamic acid|The intervention was 1 ml of 10 mg/ml of tranexamic acid solution which was given intradermally.
89651369|NCT05236569|Placebo Comparator|Placebo|The placebo was 1 ml of 0.9% normal saline which was given intradermally.
89651370|NCT00857727|Experimental|Drug|Dexmedetomidine
89651371|NCT00857727|Placebo Comparator|Control|Normal Saline IV solution
89651372|NCT03275545||Anorexia Nervosa, Weight Restored|Individuals with a recent diagnosis of anorexia nervosa (within the past 6 months), who currently have their weight in a healthy range (BMI > or = 18.5 kg/m2)
89651373|NCT03275545||Non-eating disorder Control|Individuals without a history of an eating disorder and no current DSM-5 psychiatric diagnoses.
89651374|NCT05087173|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
89045676|NCT06203847|Active Comparator|Control group|Standard drug treatment: epinephrine (Adrenaline® 1mg/vial). According to international resuscitation guidelines ( Advanced Cardiac Life Support, ACLS), patients with cardiac arrest before hospital arrival are given 1 mg (1 dose) of epinephrine (Adrenaline® 1mg/vial) every 3 minutes.
89045677|NCT06202040|Active Comparator|Group 1:OSTAPand RSB|Group 1 will consist of patients who received general anesthesia, and just before the surgery started, bilateral OSTAP and RSB will be performed.
89045678|NCT06202040|No Intervention|Group 2: Intravenous analgesia|Group 2 will include patients who received general anesthesia and were administered intravenous analgesia approximately 30 minutes before the end of the operation.
89045679|NCT06199466|Experimental|Dose Escalation|Participants will be assigned to a dose level of YL-13027 in combination with gemcitabine and nab-paclitaxel based on when you join this study.
89045680|NCT06199466|Experimental|Dose Expansion|Participants will receive YL-13027 in combination with gemcitabine and nab-paclitaxel at the recommended dose that was found in the Dose Escalation part.
89045681|NCT06199297||ABTH|Atezolizumab plus bevacizumab combined with TACE-HAIC
89045682|NCT06199297||SBTH|Sintilimab plus bevacizumab combined with TACE-HAIC
89045683|NCT06192563||Adolescents with AD|Adolescent (aged 12 to 17 years) participants who suffer from severe AD with EASI score < 16, eligible for systemic dupilumab treatment according to Italian reimbursement criteria.
89045684|NCT06192017||Post-menopausal women with AUB|"The patients will be divided into different study groups: Control and cases or EC, the latter could be subdivided and analyzed in separate groups related to their prognosis. The Control patients are those patients with symptoms compatible with endometrial cancer but who are diagnosed with benign and / or healthy pathology; while EC patients present associated symptoms and are diagnosed with endometrial cancer."
89045685|NCT06174480|No Intervention|Control Group|Participants will not undergo cryostimulation exposure but will only receive 2 1-hour hypoxia sessions at FiO2 13.5% for 1 hour, at 2-week interval
89045686|NCT06174480|Experimental|Cryostimulation Group|Participants will be exposed to cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks and will undergo 2 hypoxia sessions at FiO2 13.5% for 1 hour, at 2-week interval
89045687|NCT06169072|Other|Sentinel node detection with 0.1mL SPIO and Technetium99|An intradermal injection of SPIO (MagTrace®), according to the pre-specified dose of 0.1mL, will be performed 7 days, up to the day of surgery. The injection should be in the skin over the tumour, or at the border of the areola. All patients will also receive technetium per routine.
89651375|NCT00857961|Experimental|3 mL (30 mg) of 1% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
89651376|NCT00857961|Experimental|1.5 mL (30 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to one axilla. All study participants are randomized to each of the 4 study treatments.
89045690|NCT06154824|Experimental|1st pruritogen|The study takes place over two sessions over a period of 7 days. The duration of the sessions is approx. 4 hours in total. In the 1st session, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject. The two areas will be randomly treated with one of the following substances: cowhage, histamine, BAM 8-22 or vehicle. Each substance will be applied for 10 minutes, during which the pain/itch following the substance application will be monitored. Twenty minutes after each application, the measurements with FLPI will be conducted. Then the measurements of alloknesis and mechanically evoked itch, will be conducted. This procedure will be repeated three times for each substance; so in total each substance will be applied three times, each application lasting 10 minutes.
89045691|NCT06154824|Experimental|2nd pruritogen|The study takes place over two sessions over a period of 7 days. The duration of the sessions is approx. 4 hours in total. In the 1st session, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject. The two areas will be randomly treated with one of the following substances: cowhage, histamine, BAM 8-22 or vehicle. Each substance will be applied for 10 minutes, during which the pain/itch following the substance application will be monitored. Twenty minutes after each application, the measurements with FLPI will be conducted. Then the measurements of alloknesis and mechanically evoked itch, will be conducted. This procedure will be repeated three times for each substance; so in total each substance will be applied three times, each application lasting 10 minutes.
89045692|NCT06148974|Experimental|Polar lipid 1|15 g Plant polar lip 1 consumed with a white wheat bread including 50 g available carbohydrates
89045693|NCT06148974|Experimental|Polar lipid 2|15 g Plant polar lipids 2 consumed with a white wheat bread including 50 g available carbohydrates
89651377|NCT00857961|Experimental|3 mL (60 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
89651378|NCT00857961|Experimental|4.5 mL (90 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days by three doses to both axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla). All study participants are randomized to each of the 4 study treatments.
89651379|NCT03839433|Active Comparator|ciclesonide positive|"Half of the Mannitol positive patients were given ciclesonide. Half of the Mannitol negative patients were given ciclesonide. All patients in the ciclesonide positive arm received ciclesonide."
89651380|NCT03839433|Placebo Comparator|Placebo|"Half of the Mannitol positive patients were given a placebo. Half of the Mannitol negative patients were given a placebo. All patients in the placebo arm received placebo."
89651381|NCT05035537|Experimental|Group 1 (PGDT)|Group 1(PGDT, intervention group) where minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide a goal directed fluid administration protocol
89651382|NCT05035537|No Intervention|Group 2 (control)|Group 2 (control) managed according to local and international best practice guidelines using standard hemodynamic monitoring
89651383|NCT05236101|Experimental|CD:H Scale|Pictures drawn using the CD:H Scale were evaluated.
89045694|NCT06148974|Active Comparator|non-polar lipids|15 g commonly consumed non-polar lipids consumed with a white wheat bread including 50 g available carbohydrates
89045695|NCT06148974|Placebo Comparator|no lipids|A white wheat bread including 50 g available carbohydrates
89045696|NCT06141369|Experimental|mRNA-0523-L001|individualized mRNA neoantigen vaccine (mRNA-0523-L001)
89045697|NCT06132360|Experimental|cohort 1|or placebo
89045698|NCT06132360|Experimental|Cohort 2|or placebo
88993305|NCT02172651|Experimental|Vitamin D3 - Blinded Registration|One capsule of vitamin D3 10,000 IU orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative vitamin D3 for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
88993306|NCT02172651|Placebo Comparator|Placebo - Blinded Registration|One placebo capsule orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative placebo for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
88993307|NCT02144857|Active Comparator|Anti-TNFa regimen|Etanercept 50 mg
88993308|NCT02144857|Active Comparator|Anti IL12/23 regimen|ustekinumab 45 mg
89212937|NCT00485134|Experimental|Stage 1: Group B, Dolphin 480 µg|480 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
89212938|NCT00485134|Experimental|Stage 1: Group C, Dolphin 690 µg|690 Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
89212939|NCT00485134|Other|Stage 1: Group D, Pipette 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. These subjects received 200 μL the vaccine via electronic pipette. This group is for lot bridging only, not included in dose-finding study.
89212940|NCT00485134|Other|Stage 2: Immunized / Challenge|The selected dose was to be administered with the Dolphin™ using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
89212941|NCT00485134|Placebo Comparator|Stage 2: Controls|A control was to be administered with the DolphinTM using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
89212942|NCT05514353|Experimental|PBI-100 Topical Cream|"SAD: 4 cohorts of subjects are planned to receive a single dose of PBI-100 topical cream in one of three dosage strengths, administered once or twice daily~MAD: 3 cohorts of subjects are planned to receive one of three dosage strengths of PBI-100 administered once or twice daily for periods of 14 consecutive days"
89212943|NCT05514353|Placebo Comparator|Vehicle|
89651384|NCT00823797|Experimental|Treatment (bendamustine hydrochloride)|Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
89651385|NCT05686057||single vessel diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
89651386|NCT05686057||2 vessels diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
89651387|NCT05686057||multivessels diseased patients|sST2 level will be withdrawn at the baseline and after successful PCI
89651388|NCT05686057||non-ischemic control patients|sST2 level will be withdrawn at the baseline
89651389|NCT00858507|Experimental|Personal Health Assessment/RN Brief Intervention|RN-based medical outreach, administration of a personal health assessment and brief intervention
89651390|NCT00858507|Placebo Comparator|Social Work-Administered Outreach|Social work based outreach (usual care)
89651391|NCT05685901|Experimental|High polyphenolic olive oil|Participants were required to take 2 mL of early harvest olive oil (normal early harvest olive oil) twice a day for three months and went through a clinical questionnaire at days 15, 30, 60 and 90. Participants were sent an envelope closed with instructions and informed consent. The primary outcome was to determine the effect of high polyphenolic olive oil on Coronavirus disease incidence, duration and severity. This study was approved by the independent ethic committee of the Hospital Nuestra Señora del Prado in Talavera de la Reina, belonging to the National Health System in Spain, and conducted in accordance with Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from all patients. This questionnaire consisted in asking about having symptoms of SARS-CoV-2 infection, fever, low fever, malaise, headache, loss of smell, runny nose, sore throat.
89651392|NCT05685901|No Intervention|No intervention|Participants were required to complete a questionnaire at days 15, 30, 60 and 90 of the study. This questionnaire consisted in asking about having symptoms of SARS-CoV-2 infection, fever, low fever, malaise, headache, loss of smell, runny nose, sore throat.
89651393|NCT02150109|Experimental|Persons With Diabetes|Untrained subjects WITH Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
89651394|NCT02150109|Experimental|Persons With and Without Diabetes|Untrained subjects WITH/WITHOUT Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
89651395|NCT00824733|Experimental|Arm I: Treatment (PF03512676 in combination with Trastuzumab)|12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
89651396|NCT03288727|Experimental|Negative IF result|
89651397|NCT03288727|Experimental|Positive IF result|
89651398|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus placebo HFA|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
89651399|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus levalbuterol|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
89651400|NCT03287947|Experimental|A|Nintedanib
89651401|NCT03282955|Experimental|Lipidem|i.v. lipid emulsion containing fractionated fish oil (n-3 fatty acid triglycerides)
89651402|NCT03282955|Active Comparator|Lipofundin MCT|i.v. lipid emulsion
89651403|NCT05685667|Experimental|Laser-induced microjet injector (Mirajet)|The left/right assignment was sealed in a nontransparent envelop.
89651404|NCT05685667|Active Comparator|Needle injection (control)|The left/right assignment was sealed in a nontransparent envelop.
89651405|NCT05007535||HD-IVUS-guided primary PCI|Prospective, single arm, observational
89651406|NCT04999657|Active Comparator|Active|Device: Non-invasive low-frequency tibial nerve stimulator
89212944|NCT02585141|Experimental|aspiration|Aspiration of perianal abscess(MEDIPLAST® 13 G, 2,5 x 110 mm) under general anesthesia followed by antibiotic treatment with Clindamycin tablet 300 mg 3 times daily for 7 days
89651407|NCT04999657|Sham Comparator|Sham|Device: Non-invasive low-frequency tibial nerve stimulator (same device operation without real current output)
89651408|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh A|
89651409|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh B|
89651410|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh C|
89651411|NCT00859053|Active Comparator|BMS-790052 in Healthy Subjects|
89651412|NCT00859131|Active Comparator|Thymoglobulin|Subjects receiving Thymoglobulin as induction agent in renal transplantation
89651413|NCT00859131|Active Comparator|Zenapax|subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
89651414|NCT00859833|Experimental|myocardial perfusion reserve|Myocardial perfusion reserve will be measured by quantifying myocardial blood flow using MRI at rest and then with each of 2 coronary vasodilators. Measurements are performed with first pass gadolinium perfusion (i.v. bolus injection of 0.02 or 0.03 mmol/kg of gadolinium). Each of the 2 drugs is given sequentially (30 minutes apart) in the same sequence in every patient. The shorter acting drug (adenosine) is given first so it has time to wear off before giving the second drug. It is ideal to measure MPR with each drug during the same imaging session so that there are no other clinical variables that change between the administration of the 2 agents. See below.
89651415|NCT02154477|Active Comparator|diabetes|All patient will receive insulin at one visit and saline at another visit
89651416|NCT02154477|Active Comparator|control|All patient will receive insulin at one visit and saline at another visit
89651417|NCT00860379|Placebo Comparator|Placebo|Placebo
89651418|NCT00860379|Experimental|Selenium1|Subject will receive 2 ug/kg of IV selenium per day
89651419|NCT00860379|Experimental|Selenium2|Subject will receive 4 ug/kg of IV selenium per day
89651420|NCT00860457|Experimental|Chemotherapy|Fludarabine/Rituximab followed by Lenalidomide
89651421|NCT00860535|Experimental|Ph+ CML or Ph+ ALL|GFS biomarker evaluation
89651422|NCT00827073|Active Comparator|Tetracaine 0.5% drop|Tetracaine 0.5% drop of betadine will be used on the operative eye after Tetracaine has been administered
89651423|NCT00827073|Active Comparator|Lidocaine 2% Jelly|Lidocaine 2% Jelly drop of betadine will be used on the operative eye after Lidocaine 2% Jelly has been administered
88993309|NCT02144857|Active Comparator|Cyclosporine regimen|Cyclosporine 2.5-3 mg/kg
88993310|NCT02144857|Active Comparator|anti-interleukin 17 A regimen|secukinumab 300 mg
88993311|NCT02144857|Active Comparator|inhibitor of phosphodiesterase-4|apremilast 30mg
88993312|NCT02095184|Active Comparator|Cohort 1: Normal Weight Anastrozole|Cohort 1: Patients with BMI < 25.0 kg/m2 treated with anastrozole
88993313|NCT02095184|Active Comparator|Cohort 2: Overweight Anastrozole|Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
88993314|NCT02095184|Active Comparator|Cohort 3: Obese|Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
88993315|NCT02095184|Active Comparator|Cohort 4: Normal Weight Letrozole|Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
89651424|NCT05235477|Experimental|Tube technique.|"The excavator is used to do the same on the palatal aspect. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect. To harvest the graft, the incision is made parallel to and 2 mm away from the gingival margin. A thin flap containing the keratinized tissue is separated, then the second incision is made parallel to the gingival margin, but perpendicular to the alveolar bone. With a sharp periosteal elevator, the graft is raised with the periosteum and released at its anterior and posterior ends, and then from its base ."
89651425|NCT05235477|Active Comparator|Hyaluronic acid.|The product used in this trial is Restylane Lidocaine (Restylane-Lidocaine cross-linked Hyaluronic Acid Filler, Galderma S.A, Sweden). Restylane was the first FDA-approved HA filler in 2003. Restylane is a non-animal stabilised cross-linked HA filler with an HA concentration of 20 mg/ml. It is a minimally invasive non-surgical injection of hyaluronic acid that observed to overcome the major limiting factor in most surgical techniques regarding the limited blood supply and the small working space. Supported by a recent study conducted by Jinng etal. 2019, who reported significant increase in the height of the gingival papilla and reduction of the area of the black triangle between baseline and 3 or 6 months in a group with thick gingival biotype after injection with hyaluronic acid, that was adding possible maximum effect with minimal postoperative hazards.
89651426|NCT04997785|Experimental|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
89651427|NCT04997785|Active Comparator|Intravenous Morphine|Dosage of intravenous morphine was determined according to 0.1 mg per kg; EPs were instructed to aim to reduce the pain by 50% or per patient request.
89651428|NCT00860847|Active Comparator|Aged Garlic Extract and Coenzyme Q10|"AGE (1200 mg) and CoQ10 (120 mg)~This is a combination of aged garlic extract and co-enzyme Q10"
89651429|NCT00860847|No Intervention|Placebo|placebo pills will be given
89651430|NCT05235243|Experimental|The Full Intervention (FI) group|The full intervention (FI) group received a psycho-education module about MD and its addictive behavior mechanism, a motivation enhancement module based on motivational interviewing, mindfulness modules, and self-monitoring modules.
89651431|NCT05235243|Active Comparator|The partial intervention (PI) group|The partial intervention (PI) group received an intervention identical to the FI group (a psycho-education module about MD and its addictive behavior mechanism, a motivation enhancement module based on motivational interviewing, mindfulness modules) with the exclusion of the self-monitoring modules.
88993316|NCT02095184|Active Comparator|Cohort 5: Overweight Letrozole|Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
88993317|NCT02095184|Active Comparator|Cohort 6: Obese Letrozole|Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
88993318|NCT02081157||Breast Mastopexy with or without reduction using GalaFlex Mesh|Breast mastopexy with or without reduction, using GalaFLEX mesh
88993319|NCT01950234|Experimental|ACTH|ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month
88993320|NCT01950234|Placebo Comparator|Placebo|Placebo subcutaneous injections administered on 3 consecutive days per month
89212945|NCT02585141|Active Comparator|incision|Surgical incision of perianal abscess under general anesthesia.
89212946|NCT04443101||Group（SN6CWS）|Group（SN6CWS）：Implant SN6CWS intraocular lens
89651432|NCT05235243|No Intervention|Waiting List (WL) group|Waiting List (WL) group did not undergo any intervention during the study period. However, WL participants were told that the program will commence in three months. During their waiting time participants were instructed to reduce their daydreaming activity to the best of their ability. Since all participants were recruited for this study from an online support forum (that is not part of this research design), the investigators labeled WL as the Internet Support as Usual (ISAU) group.
89651433|NCT04347733|Experimental|Group A|Intra-articular injection, 20 mg (0.5 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.5 mL of normal saline
89651434|NCT04347733|Experimental|Group B|40 mg (1 mL) of triamcinolone acetonide mixed with 2 mL of 2% lidocaine and 7.0 mL of normal saline
89651435|NCT04347733|Active Comparator|Group C|20 mg (0.5 mL) of triamcinolone acetonide and 1 mL of hyaluronidase mixed with 2 mL of 2% lidocaine and 6.5 mL of normal saline
89651436|NCT02155101|Active Comparator|ART with 2 NRTIs plus LPV/r (or ATV/r)|2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
89651437|NCT02155101|Experimental|Darunavir|"Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side."
89651438|NCT05317507|Experimental|Randomization order 1|Participants receive placebo at visit 1, 50 mg CBD at visit 2, and 100 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
89651439|NCT05317507|Experimental|Randomization order 2|Participants receive placebo at visit 1, 100 mg CBD at visit 2, and 50 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
89651440|NCT05317507|Experimental|Randomization order 3|Participants receive 50 mg CBD at visit 1, placebo at visit 2, and 100 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
89651441|NCT05317507|Experimental|Randomization order 4|Participants receive 50 mg CBD at visit 1, 100 mg CBD at visit 2, and placebo at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
89651442|NCT05317507|Experimental|Randomization order 5|Participants receive 100 mg CBD at visit 1, 50 mg CBD at visit 2, and placebo at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
89651443|NCT05317507|Experimental|Randomization order 6|Participants receive 100 mg CBD at visit 1, placebo at visit 2, and 50 mg CBD at visit 3 followed by a 4-week period of at home use of 100 mg CBD daily.
89651444|NCT02155257|Active Comparator|Modafinil|Modafinil 200 mg will be administered orally one time
89651445|NCT02155257|Placebo Comparator|Placebo|A placebo will be administered orally one time
89651446|NCT02155257|Active Comparator|Gabapentin|Gabapentin 900 mg will be administered orally one time
89651447|NCT03243019|Experimental|SIROLIMUS|
89651448|NCT04382625|Experimental|Hydroxychloroquine (HCQ)|Initial dose: HCQ 400mg x 2 (800mg) then 200mg by mouth, three times per day (600mg/24hr period) starting 8 hours after the initial dose for a total of 14 doses over 5 days Plus Usual Care (See below for full description)
89651449|NCT04382625|No Intervention|Usual Care|The care of hospitalized patients with covid-19 is evolving with hospital guidelines arising across the U.S. with several commonalities. Patients receive clinical assessment, chest x-ray, covid-19 testing, basic labs (WBC, CMP), and additional labs based on protocol or clinical judgment (ABG, CRP, LDH), antibiotics for possible bacterial pneumonia, acetaminophen for fever, supplemental O2, and consideration for mechanical ventilation. Early intubation over escalating noninvasive support. Low tidal volume ventilation and prone positioning are lung protective strategies used in critically ill covid-19 patients that are based on management of acute respiratory distress syndrome generally. Conservative fluid replacement is used to avoid worsening oxygenation.
89651450|NCT04631809|Active Comparator|invasive Coronary Angiography alone|
89651451|NCT04631809|Experimental|CT-Coronary Angiography + invasive Coronary Angiography|
89651452|NCT01673646|Experimental|Pasireotide LAR 20mg|Enrolled patients were randomized to 20mg pasireotide LAR.
89651453|NCT01673646|Experimental|Pasireotide LAR 40mg|Enrolled patients were randomized to 40mg pasireotide LAR.
89651454|NCT01673646|Experimental|Pasireotide LAR 60mg|Enrolled patients were randomized to 60mg pasireotide LAR.
89651455|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD1222|Previously vaccinated with AZD1222, dosing on day 1
89651456|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD2816|Previously vaccinated with AZD1222, dosing on day 1
89045699|NCT06132360|Experimental|Cohort 3|or placebo
89212947|NCT04443101||Group（MI60）|Group（MI60）：Implant MI60 intraocular lens
89212948|NCT04443101||Group（Aspira-aA）|Group（Aspira-aA）：Implant Aspira-aA intraocular lens
89212949|NCT04079231|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
89212950|NCT04079231|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
89651457|NCT04973449|Other|mRNA booster: one dose of AZD1222|Previously vaccinated with an mRNA vaccine, dosing on day 1
89651458|NCT04973449|Other|mRNA booster: one dose of AZD2816|Previously vaccinated with an mRNA vaccine, dosing on day 1
89651459|NCT04973449|Other|2 doses of AZD1222, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
89651460|NCT04973449|Other|2 doses of AZD2816, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
89651461|NCT04973449|Other|2 doses of AZD2816, 12 weeks apart|Previously unvaccinated. First dose day 1, second dose day 85
89651462|NCT04973449|Other|one dose of AZD1222 + one dose AZD2816, 4 weeks apart|Previously unvaccinated. Dose of AZD1222 on day 1, dose of AZD2816 on day 29
89651463|NCT04042584|Experimental|Visio conference device evaluation|Neurological tele-evaluation by a neurologist
89651464|NCT04278391|Experimental|A (RT)|Period 1 : Reference drug (DWC201903) Period 2 : Test durg(DWJ1421)
89651465|NCT04278391|Experimental|B (TR)|Period 1 : Test durg(DWJ1421) Period 2 : Reference drug (DWC201903)
89651466|NCT00717132|Experimental|Individual Behavioral Modification|Individual behavioral weight control treatment; parent and child are treated separately for 15 total sessions.
89045700|NCT06132360|Experimental|Cohort 4|or placebo
89045701|NCT06132256|Experimental|Axatilimab|Participants will receive axatilimab every 2 weeks during the 26-week Treatment Period.
89045702|NCT06132256|Placebo Comparator|Placebo|Participants will receive placebo every 2 weeks during the 26-week Treatment Period.
89045703|NCT06109662||Healthy volunteers|Normal renal function with no kidney disease. Participants with other comorbidities can be included as long as not listed on the exclusion criteria. They will have body composition measured, and eGFR measured.
89045704|NCT06109662||Chronic Kidney Disease Stage 3|People with CKD Stage 3 (eGFR 30-59). They will have body composition measured, and eGFR measured.
89045705|NCT06109662||Chronic Kidney Disease Stage 4|People with CKD 4 (eGFR 15-29). They will have body composition measured, and eGFR measured.
89045706|NCT06109662||Chronic Kidney Disease Stage 5|People with CKD 5 (eGFR <15), but not on dialysis. They will have body composition measured, and eGFR measured.
89651467|NCT00717132|Active Comparator|Family-based Behavioral Modification|Family-based behavioral weight control treatment; parent and child are treated together for 15 total sessions.
89651468|NCT00862563|Experimental|Zonisamide|Encapsulated zonisamide with a target maintenance doses of 400 mg/day administered as 4 capsules per day.
89651469|NCT00862563|Experimental|Levetiracetam|Encapsulated levetiracetam with a target maintenance doses of 2000 mg/day administered as 4 capsules per day .
89651470|NCT00862563|Active Comparator|Topiramate|Encapsulated topiramate with a target maintenance doses of 300 mg/day administered as 4 capsules per day .
89651471|NCT00862563|Placebo Comparator|Sugar Pill|Encapsulated sugar pill with a target maintenance dose administered as 4 capsules per day.
89651472|NCT05430672|Other|Subjects with aortic dissection|Subjects receive endovascular treatment.
89651473|NCT04822662|Experimental|Experimental Group: Epilepsy education program|The training prepared for epilepsy will be held in 3 main modules and 5 sessions with two weeks intervals. Each session will last 25 minutes. Trainings will be given to adolescents and their parents online.
89651474|NCT04822662|No Intervention|Control Group|The control group will receive standard epilepsy treatment without any training intervention. The group did not receive any other intervention.
89651475|NCT04278937|Active Comparator|Azithromycin group|women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
89651476|NCT04278937|No Intervention|Control group|women will receive routine antenatal care without antibiotic prophylaxis after cerclage.
89651477|NCT05235789|Experimental|Intervention group|The social workers in each center of primary care held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
89651478|NCT05235789|Active Comparator|Control group|The control group (GC) in each center of primary care will take the usual medical care for depression, according with up-dated national and international guidelines.
89651479|NCT02647944|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
89651480|NCT02647944|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
89651481|NCT03839277|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
89651482|NCT03839277|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
89045707|NCT06104371||Node negative|Clinically node negative before neoadjuvant chemotherapy
89045708|NCT06104371||Node positive|Clinically node positive before neoadjuvant chemotherapy
89651483|NCT05272735|Experimental|Hepatitis B Vaccine (Recombinant)|Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
89651484|NCT04278469|Active Comparator|Patients with chemotherapy|
89045709|NCT06101264|Experimental|Virtual Reality Intervention|Participants will receive a post-operative virtual reality intervention following corrective surgery for idiopathic scoliosis.
89045710|NCT06090370|Experimental|Baseline Survey: Silicosis and Personal Protective Equipment|
89045711|NCT06090370|Experimental|Design of Personal Protective Equipment Training Workshop|
89045712|NCT06090370|Experimental|Pilot Study: Personal Protective Equipment Training Program|A small training program will be offered to brick kiln workers to determine preferred PPE type, feasibility in the work environment and proper usage of PPE.
89045713|NCT06090370|Experimental|Feedback Workshop on Pilot Personal Protective Equipment Training Program|
89045714|NCT06087302|No Intervention|control group|the control group wouldnot receive the CPRT for caregivers/parents
89045715|NCT06087302|Experimental|CPRT intervention group|intervention group would receive the CPRT for caregivers/parents
89045716|NCT06066944|Experimental|Group B|The experimental group will receive a Self-Thai Foot Massage on every alternate day for 15 days for 30 minutes.
89651485|NCT04278469|No Intervention|Patients without chemotherapy|
89651486|NCT05430516||Families|Patients with confirmed SARS-Cov-2 infection and their household members of all ages can be enrolled in the study, if at least one household member is a child age under 18.
89651487|NCT04278547|Experimental|Experimental group|Preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis;
89651488|NCT04278547|No Intervention|Control group|Standard of care, universal prophylaxis with valgancyclovir for 3 months).
89651489|NCT00863109||PEG + RBV (Standard Clinical Practice)|Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.
89651490|NCT03265015|Experimental|cTBS|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern.
89651491|NCT03265015|Active Comparator|iTBS|Transcranial Magnetic Stimulation delivered in an intermittent Theta Burst Stimulation (iTBS) pattern.
89651492|NCT05425836|Active Comparator|Oxygen supplementation in the conventional arm|will be delivered by nasal cannula. At 5 minutes prior to sedation the flow rate would be kept a 5 L/minute.; The flow will be increased to 6-8 L/minute to maintain SPO2 ≥92% during the procedure, up to a maximum of 15 L/minute, depending on the patient tolerance.
89651493|NCT05425836|Experimental|Oxygen supplementation in HFNC arm|HFNC (OptiFlowTM; Fisher & Paykel, Auckland, New Zealand) will be started 5 minutes before the sedation at a flow rate of 30 Litres/minute and at a fraction of inspired oxygen (FiO2) of 0.30, which will be titrated by increments of 10 liters/minute depending on oxygen demand to keep SPO2 ≥92% during the procedure. The flow rate will be maintained between 30- and 70-liters minute, depending on the patient tolerance.
89651494|NCT05210673|Experimental|group A|non ERAS pathway
89651495|NCT05210673|Active Comparator|group B|ERAS pathway
89651496|NCT03238807|Experimental|Intervention Group|Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
89651497|NCT03238807|No Intervention|Control Group|Control Group
88993321|NCT01924455||HBV-HIV coinfected subjects|HBV-HIV coinfected subjects seen at one of 7 participating centers.
88993322|NCT01623076||Neuromyelitis Optica Spectrum Disorder|Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included
88993323|NCT01623076||Transverse Myelitis and Optic Neuritis|Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.
88993324|NCT01623076||Healthy Controls|patients without a history of CNS inflammation
88993325|NCT01623076||Neuromyelitis Optica|patients diagnosed with NMO
88993326|NCT01555905|Experimental|Exercise|Threshold PEP or IMT device Phillips-Respironics
88993327|NCT01252953|Experimental|Anacetrapib|
88993328|NCT01252953|Placebo Comparator|Placebo anacetrapib|
88993329|NCT01234480|Experimental|Participants with Cervical Disease|Participants positive for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
88993330|NCT01234480|Experimental|Participants without Cervical Disease|Participants negative for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
88993331|NCT01183078|Other|Free-hand technique|Free-hand technique utilized to find screw holes.
88993332|NCT01183078|Other|Wand technique|Wand technique is utilized to find screw holes.
88993333|NCT00957489|Experimental|Functional appliance-Dynamax|
88993334|NCT00957489|Other|Functional appliance- twin block|Conventional treatment
88993335|NCT00937131|No Intervention|no comparator|
88993336|NCT00877851|Experimental|1 Computer-based Program|Use of Computer-based Program for 12 weeks
88993337|NCT00877851|No Intervention|2 Control|Usual care and list of useful websites
88993338|NCT00837616|Active Comparator|Group A|Group A will receive the oral estradiol for 12 months
88993339|NCT00837616|Active Comparator|Group B|Group B will receive the transdermal estradiol for 12 months
88993340|NCT00610051|Active Comparator|trial arm|6 months central continuous infusion with Alp_1 by infusion pump.
88993341|NCT00610051|Placebo Comparator|Placebo arm|6 months central infusion with NS by infusion pump with exact infusion rat as trial arm.
88993342|NCT00476060|Experimental|A|
88993343|NCT00476060|Placebo Comparator|B|
88993344|NCT00176254|Experimental|Induction chemotherapy and radiation|Induction chemotherapy with low dose radiation
89212951|NCT05350293|Active Comparator|Molded abutment|A plastic abutment that is provided by the implant manufacturer will be used. This abutment will be modified using wax, and then it will be dismantled, wedged, and poured using a Ni-Cr mixture. A plastic abutment that the implant manufacturer provides will be used. This abutment will be modified using wax, and then it will be dismantled, wedged, and poured using a Ni-Cr mixture.
89651498|NCT05142345|Experimental|CONTINUUM Intervention Post-Hospital Discharge|Participants will receive CONTINUUM intervention visit with a nurse practitioner within three business days of hospital discharge and complete questionnaires about their cancer and care.
89651499|NCT05142345|Active Comparator|Usual Care Post-Hospital Discharge|Participants will receive standard oncology care following hospital discharge with follow-up appointments scheduled per primary team and participant preferences. Participants will complete questionnaires about their cancer and care.
88993345|NCT02950090|Experimental|MobilWise|MobilWise will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) via Fitabase to: allow a remote coach to view and collect physical activity data generated by the personal monitor, and use that data to formulate and provide tailored behavioral support, using motivational interviewing. The coach has a phone conversation weekly x 12 using motivational interviewing with participants to set goals and encourage activity. Coaches mention patient use of treatment elements (accountability) and will be positively reinforcing for adherent participants, or will include positive statements for those who are not adherent (supportive).Participants are also encouraged to use all the features of Fitbit (social networking, challenges, email reminders).
88993346|NCT02950090|Active Comparator|Fitbit Only|will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) to monitor their own progress and physical activity level without coaching support. Participants are again encouraged to use all the features of Fitbit (social networking, challenges, email reminders) to achieve activity levels.
88993347|NCT02950090|No Intervention|Waitlist Control|Participants in the waitlist arm have exposure to the usual wellness supports provided by the company: Motiva is the internal corporate wellness program that is under the direction of the Chief Medical Officer. Initiated in 2000, Motiva is staffed by two full- time health professionals and two full-time healthy lifestyle professionals. Motiva provides wellness programming year round on a BCBSIL intranet web page plus an individual page called myMotiva, where self- assessment of health risks, including weight and physical activity behavior, is encouraged. Participating in myMotiva allows individuals to earn up to $200 per year in an incentive program called Wellness Rewards
89651500|NCT05246371|Experimental|propofol and dexmedetomidine|Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine
89651501|NCT05246371|Experimental|desflurane|Patients will receive maintenance of general anesthesia by desflurane.
89651502|NCT03104790|Experimental|naive|Children who have never received any influenza vaccine (The two groups are defined by immunisation history, all receive the same intervention in the study)
89651503|NCT03104790|Experimental|prior vaccinees|Children who have received at least two doses of Fluenz Tetra previously (The two groups are defined by immunisation history, all receive the same intervention in the study)
89651504|NCT00863265|Experimental|Crossover order ABC|The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).
89651505|NCT00863265|Experimental|Crossover order BCA|The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).
89651506|NCT00863265|Experimental|Crossover order BAC|The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)
89651507|NCT00863265|Experimental|Crossover order ACB|The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).
89651508|NCT00863265|Experimental|Crossover order CAB|The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).
88993348|NCT02950285|Experimental|Baseline alert|For patients randomly selected for the baseline alert arm, their physicians will be alerted via email that a patient(s) under their care has atrial fibrillation, is at high risk of stroke, and is not currently anticoagulated. Physicians will also be asked to complete a survey related to anticoagulation for each patient and will be provided with educational resources and consultation services.
88993349|NCT02950285|No Intervention|3-month alert arm|For patients randomly selected for the 3-month alert arm, their physicians will not be notified during the 3-month study follow-up period. Instead, PCPs will be sent alerts after 3-months via email for these patients.
88993350|NCT02949895|Experimental|Dose Escalation Dose 1|BMS-986012 Dose Escalation Dose 1
88993351|NCT02949895|Experimental|Dose Escalation Dose 2|BMS-986012 Dose Escalation Dose 2
88993352|NCT02949895|Experimental|Chemotherapy Combination|BMS-986012 + Cisplatin + Etoposide
88993353|NCT02949622|Experimental|Multimodal intervention program|The intervention program will be in group format, with a size of 10 to 12 patients per group and with an extension of 12 sessions. The treatment program will feature sessions with psychoeducation of metabolic syndrome and treatment model, problem solving, stress management, anger management, social skills, self-efficacy and social support.
88993354|NCT02949622|Active Comparator|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
88993355|NCT02949544|Other|water immersion|patients with heart failure will be immersed to the neck for 15 minutes
89651509|NCT00863265|Experimental|Crossover order CBA|The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).
88993356|NCT02949661|Experimental|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block using levobupivacaine
88993357|NCT02949661|Active Comparator|Local wound infiltration|Patients will receive local wound infiltration with levobupivacaine after the conclusion of surgery
88993358|NCT02949583|Experimental|Punica granatum Linn.|The childrens used the mouthwash contain pomegranate 6,25% twice daily for 14 days.
88993359|NCT02949583|Active Comparator|chlorhexidine|The childrens used the mouthwash contain chlorhexidine 0.12% twice daily for 14 days.
88993360|NCT00516841|Experimental|volociximab|15 mg/kg volociximab once weekly
88993361|NCT04694599|Experimental|Early intervention|The experimental group will receive oxygen supplementation when oxygen saturation decreases according to the monitoring of wearable devices.
88993362|NCT04694599|Active Comparator|Typical|The control group will receive oxygen supplementation when oxygen saturation decreases according to typical periodical monitoring.
89651510|NCT04900519|Experimental|STI-6643|STI-6643 will be provided in a single use 10-mL high borosilicate type 1 glass vial at a concentration of 500mg/10 mL (50 mg/mL) administered intravenously weekly for 4 weeks, then biweekly for Cycles 2 and up.
89651511|NCT03942744|No Intervention|high-flux hemodialysis|high-flux hemodialysis cut-off membrane above 50
89651512|NCT03942744|Active Comparator|on-line hemodiafiltration|postdilutional on-line hemodiafiltration with a convective transport above 21 liters
89651513|NCT04895449|Experimental|≥ 1 x 10E7 IU (low dose) in seronegative subjects|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
89651514|NCT04895449|Experimental|≥ 5 x 10E7 IU (middle dose) in seronegative subjects|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
89651515|NCT04895449|Experimental|≥ 1 x 10E8 IU (high dose)in seronegative subjects|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: MVA-SARS-2-ST vaccinations (days 0 & 28) in seronegative subjects
89651516|NCT04895449|Experimental|≥ 1 x 10E7 IU (low dose)|≥ 1 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
88999260|NCT01368588|Active Comparator|Arm I|Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)* or 3D-conformal radiation therapy (3D-CRT)* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (I 125 or Pd 103 may be used as the radioisotope).
88999261|NCT01368588|Experimental|Arm II|Patients undergo whole-pelvic radiotherapy (WPRT)* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.
89651517|NCT04895449|Experimental|≥ 5 x 10E7 IU (middle dose)|≥ 5 x 10E7 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
89651518|NCT04895449|Experimental|≥ 1 x 10E8 IU (high dose)|≥ 1 x 10E8 IU MVA-SARS-2-ST Intervention: Biological: Single MVA-SARS-2-ST vaccination in mRNA vaccinated subjects
89651519|NCT04891471|Experimental|SRS/SBRT arm|Patients with five or more brain metastasis assigned by randomization to Stereotactic RadioSurgery (SRS) or Stereotactic Body RadioTherapy (SBRT) will be treated with a highly-conformal metastasis-directed single dose between 15 and 24 Gy or fractionated dose (e.g. 27 Gy in 3 fractions), respectively, depending on lesion size, while sparing clinically negative brain. The treatment will be delivered using five non-coplanar arcs and a mono-isocentric technique.
89651520|NCT04891471|Active Comparator|WBI arm|Patients with five or more brain metastasis assigned by randomization to Whole Brain Irradiation (WBI) will be treated using a 3D-Conformal RadioTherapy technique for a uniform dose delivery of 30 Gy in 10 daily/fractions to the target, that is entire brain.
89651521|NCT00863343||All|Anyone presenting with influenza-like-illness
89651522|NCT04489758|Experimental|Constrictive Bronchiolitis|Veterans with surgical lung biopsy-proven constrictive bronchiolitis
89651523|NCT04489758|Active Comparator|Controls|Control patients with minimal smoking history and no chronic lung disease or respiratory symptoms
89651524|NCT05238805|Other|Observational heart and kidney metabolism|Participants will have a PET scan with 11C-Acetate followed by a TEP Scan with 11C-Acetoacetate all in the same day.
89651525|NCT03880578||surgery (withdrawn, not continuing recruiting)|thyroid patients receiving replacement treatment with levothyroxine (LT4) after thyroidectomy
89651526|NCT03880578||radioiodine|thyroid patients receiving replacement treatment with levothyroxine (LT4) following radioiodine treatment
89651527|NCT03880578||control|thyroid patients followed without surgery or radioiodine treatment
89651528|NCT05252689|Active Comparator|monolithic zirconia single posterior crowns with deep chamfer finish line|monolithic zirconia single posterior crowns with deep chamfer finish line fabricated by cad cam machine and cemented by self adhesive resin cement.
89651529|NCT05252689|Experimental|monolithic zirconia single posterior crowns with vertical finish line|monolithic zirconia single posterior crowns with vertical finish line fabricated by cad cam machine and cemented by self adhesive resin cement.
89651530|NCT04878289|Experimental|TOTAL Intervention|TOTAL video and participate in three one-on-one, 30-minute motivational sessions via VVC at 1-week, 6-months, and 12-months
89651531|NCT00831675|Experimental|Infants <12 Months|Participants aged ≥ 6 to < 12 months at enrollment and received 2 doses of Fluzone® Vaccine
89045717|NCT06066944|No Intervention|Group A|Participants in the control group will continue with the standard treatment regimen prescribed by the physician at the diabetic clinic. Baseline data will be collected as conducted for the experimental group. After the completion of the study, if the intervention will prove effective, the Self-Thai foot massage will be taught to the control group.
89045718|NCT06066047|Experimental|TOUCH ATTENTIVE TREATMENT|15 minutes of osteopathic treatment with operator's touch attention
89045719|NCT06066047|Sham Comparator|AUDITORY ATTENTIVE TREATMENT|15 minutes of osteopathic treatment with operator's auditory attention
89045720|NCT06066047|No Intervention|CONTROL|The volunteers lay for 15 minutes in the same environment as the volunteers in the other two groups, without being touched in any way.
89651532|NCT00831675|Experimental|Toddlers ≥12 Months|Participants aged ≥ 12 to < 36 months at enrollment and received 2 doses of Fluzone® vaccine
89651533|NCT04399447||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
89651534|NCT04399447||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
89651535|NCT04399447||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
89651536|NCT04399447||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
89651537|NCT04399447||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
89651538|NCT04399447||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of tissue motion tracking of mitral annular displacement will be obtained.
89651539|NCT01397825|Experimental|Safety Lead-in|Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
89651540|NCT01397825|Experimental|Dose Escalation, Alisertib 30 mg|Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
89045721|NCT06063720||AI group|AI monitoring of effective withdrawal time
89045722|NCT06059651||Cohort 1|Cohort #1 (within-subject) will enroll up to 10 women with class III obesity who plan to undergo Roux-en-Y metabolic and bariatric surgery as a standard of obesity care. Subjects will complete study measures preoperatively and one year postoperatively.
89045723|NCT06059651||Cohort 2|Cohort #2 (between-subject) will enroll up to 10 women with a history of class III obesity who underwent Roux-en-Y metabolic and bariatric surgery as a standard of obesity care approximately one year before enrollment. Subjects in this cohort will be matched on demographic and clinical variables to those in Cohort #1.
89212952|NCT05350293|Experimental|3D printed abutment|The customised abutment will be made using a laser printer with a Cr-Co mixture after being designed using a special computer program.
88999272|NCT00546260|Placebo Comparator|1|Placebo for each Dose cohort: 10, 20, 40, and 60 mg
88999273|NCT00546260|Experimental|2|Experimental drug for each Dose cohort: 10, 20, 40, and 60 mg
89651541|NCT01397825|Experimental|Dose Escalation, Alisertib 40 mg|Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
89651542|NCT01397825|Experimental|Dose Escalation, Alisertib 50 mg|Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
89651543|NCT01397825|Experimental|Phase 2: Alisertib|Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV on Days 1 & 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.
89651544|NCT03865914||Type 2 diabetic nephropathy|The cohort will be followed for at least 10 years. The cohort will be divided into 2 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
89651545|NCT05353764|Experimental|SNB group|patients in the SNB group will receive general anesthesia combined with scalp nerve block and intercostal nerve block with 0.5% ropivacaine.
89651546|NCT05353764|No Intervention|control group|patients in control group will receive general anesthesia without nerve block.
89651547|NCT00831753|Experimental|Group 1|DTaP-IPV-Hep B-PRP~T vaccine group
89651548|NCT00831753|Active Comparator|Group 2|Infanrix® Hexa vaccine group
89045724|NCT06048744|Active Comparator|external oblique intercostal block|"After induction of general anesthesia, external oblique intercostal blocks will be performed with patients positioned in the supine position with their ipsilateral arm abducted.~A 14-15 MHz linear ultrasound transducer (Sono-Site) was placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib.~30 ml of bupivacaine 0.25% will be administered incrementally. The drug will be injected after a negative aspiration into the plane deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles."
89045725|NCT06048744|Active Comparator|Erector Spine Block|After induction of general anesthesia, patients will be positioned in the lateral position . A linear ultrasound transducer will be placed on the midline to identify the T8 spinous process. From this position, the ultrasound transducer was moved 2-3 cm laterally to visualize the hyperechoic line of the T8 transverse process with its associated acoustic shadow inferiorly, and the overlying erector spinae muscle superiorly. 30 ml 0.25% bupivacaine will be injected.
89045726|NCT06048718|Experimental|T-DXd|Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous (IV) infusion every three-weeks (Q3W) until disease progression, unacceptable toxicity, death, or discontinuation from the study.
89651549|NCT01397747||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer.
89651550|NCT04399759|Experimental|A-IADL Group|Approach-Instrumental Activities of Daily Living in home
89651551|NCT04399759|Active Comparator|Control group|Home health education
89651552|NCT00831987|Experimental|Fluzone® Vaccine Group - Age 18-59 Years|Participants aged 18 to 59 years at enrollment and received 1 dose of Fluzone® Vaccine
89651553|NCT00831987|Experimental|Fluzone® Vaccine Group - Age ≥ 60 Years|Participants aged at least 60 years or older at enrollment and received 1 dose of Fluzone® Vaccine
89651554|NCT05222269|Experimental|68Ga-PTF|150 (+/-50) Megabecquerel (MBq) 68Ga-PTF will be injected intravenously at three timepoints during the course of the standard of care treatment.
89651555|NCT05306262|Active Comparator|hypnotic trance|Hypnosis session of comfort for 20 minutes
89651556|NCT05306262|Experimental|hypnotic trance + catalepsy|Catalepsy + Hypnosis session of comfort for 20 minutes
89651557|NCT04863157|Experimental|Survivor-SHIP|Parents/guardians will take part in 3 education sessions over a one month period. During the sessions, they will learn more about common sleep problems following cancer treatment and ways to understand their child's unique patterns. They will then be educated about behavioral changes they can make to improve their child's sleep.
88999262|NCT01364857|Other|PWS cohort|search for polymorphisms of RASA1 gene
88999263|NCT01029002|Experimental|Vitamin D 50000 IU|Patients randomized to this arm will receive 50,000 IU of ergocalciferol in one unmarked pill once weekly.
88999264|NCT01029002|Placebo Comparator|Placebo|Patients randomized to this arm will receive a placebo pill once weekly.
88999265|NCT01011478|Placebo Comparator|Group 1: placebo|Patients receive oral placebo once daily for 5 years.
88999266|NCT01011478|Experimental|Group 2: rosuvastatin|Patients receive oral rosuvastatin once daily for 5 years.
88999267|NCT00876174||Patients|20 patients with genotype 1, chronic hepatitis C who are to undergo standard antiviral therapy
88999268|NCT00876174||control|Group 2, (control): 10 healthy family members or significant others of patients who are to undergo standard antiviral therapy
88999269|NCT00799864|Experimental|Rilpivirine (TMC278)|The patients received rilpivirine with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as a background regimen in cohort 1 [aged greater than or equal to (> =) 12 to less than (<) 18 years] for up to 240 weeks which is already completed and recruitment closed and will receive this treatment in cohort 2 (children aged > = 6 to < 12 years) for up to 48 weeks. The NRTIs include zidovudine, abacavir, or tenofovir disoproxil fumarate in combination with lamivudine or emtricitabine.
88999270|NCT00756795|Experimental|Attention Control|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Patient will be taught how to keep the Activity diary to record walking and physical activities.~Structured Interview will be conducted at baseline and post-intervention. All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis"
88999271|NCT00695279||Participants|Venipuncture
89651558|NCT04802538|Experimental|Study Group|All patients will begin the study by using their normal ostomy pouching equipment for 28 days. This will be followed by a transition to using the OstoRing® for 28-47 days.
89651559|NCT05239884|Experimental|Product usage order EFDGCHBA|Subjects will use each of the 8 products (EFDGCHBA) during an evaluation period, followed by a 4 hour Test Session
89651560|NCT05239884|Experimental|Product usage order HAGBFCED|Subjects will use each of the 8 products (HAGBFCED) during an evaluation period, followed by a 4 hour Test Session
89651561|NCT05239884|Experimental|Product usage order CDBEAFHG|Subjects will use each of the 8 products (CDBEAFHG) during an evaluation period, followed by a 4 hour Test Session
89651562|NCT05239884|Experimental|Product usage order DECFBGAH|Subjects will use each of the 8 products (DECFBGAH) during an evaluation period, followed by a 4 hour Test Session
89651563|NCT05239884|Experimental|Product usage order FGEHDACB|Subjects will use each of the 8 products (FGEHDACB) during an evaluation period, followed by a 4 hour Test Session
89651564|NCT05239884|Experimental|Product usage order BCADHEGF|Subjects will use each of the 8 products (BCADHEGF) during an evaluation period, followed by a 4 hour Test Session
89651565|NCT05239884|Experimental|Product usage order ABHCGDFE|Subjects will use each of the 8 products (ABHCGDFE) during an evaluation period, followed by a 4 hour Test Session
89651566|NCT05239884|Experimental|Product usage order GHFAEBDC|Subjects will use each of the 8 products (GHFAEBDC) during an evaluation period, followed by a 4 hour Test Session
89651567|NCT00832767|Active Comparator|SILS Port|SILS™ Port Laparoscopic Cholecystectomy
89651568|NCT00832767|Active Comparator|Four Port|Four Port Laparoscopic Cholecystectomy
89651569|NCT04599829||Orthosis Group 1|Use of AnkleSTRONG100 device
89651570|NCT04599829||Control Group 1|Control Group of the AnkleSTRONG100 Orthosis Group - No use of the device
89651571|NCT04599829||Orthosis Group 2|Use of AnkleSTRONG500 device
89651572|NCT04599829||Control Group 2|Control Group of the AnkleSTRONG500 Orthosis Group - No use of the device
89651573|NCT04599829||Orthosis Group 3|Use of AnkleSTRONG900 device
89651574|NCT04599829||Control Group 3|Control Group of the AnkleSTRONG900 Orthosis Group - No use of the device
89651575|NCT05216341|Experimental|Stage 1: Arm 1 (OLP-1002, 1 μg)|"Participants will receive once single dose of 1 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
89651576|NCT05216341|Experimental|Stage 1: Arm 2 (OLP-1002, 3 μg)|"Participants will receive once single dose of 3 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
89651577|NCT05216341|Experimental|Stage 1: Arm 3 (OLP-1002, 10 μg)|"Participants will receive once single dose of 10 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
88993365|NCT04694716||Covid-19 group (Group I)|Patients diagnosed with Covid-19 will be enrolled in this group.
88993366|NCT04694716||Control group (Group II)|Healthy individuals will be enrolled in this group.
88993367|NCT04694677|Active Comparator|women receiving tranexamic acid|
88993368|NCT04694677|Active Comparator|women receiving misoprostol|
88993369|NCT00516958|Experimental|1|Topical Dermacyn
88993370|NCT00516958|Active Comparator|2|Topical Dermacyn and levofloxacin
88993371|NCT00516958|Active Comparator|3|Topical saline and levofloxacin
88993372|NCT00517036|Experimental|A|Participants will take EPA
88993373|NCT00517036|Experimental|B|Participants will take DHA
88993374|NCT00517036|Placebo Comparator|C|Participants will take placebo
88993375|NCT00517387|Active Comparator|1|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
88993376|NCT00517426|Experimental|Active Acetazolamide|
89651578|NCT05216341|Experimental|Stage 1: Arm 4 (OLP-1002, 25 μg)|"Participants will receive once single dose of 25 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
89651579|NCT05216341|Experimental|Stage 1: Arm 5 (OLP-1002, 50 μg)|"Participants will receive once single dose of 50 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
89651580|NCT05216341|Experimental|Stage 1: Arm 6 (OLP-1002, 80 μg)|"Participants will receive once single dose of 80 μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
89651581|NCT05216341|Experimental|Stage 2: Arm 1 (OLP-1002, 1μg)|"Participants will be randomised to receive single dose of 1μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
89651582|NCT05216341|Experimental|Stage 2: Arm 2 (OLP-1002, 2μg)|"Participants will be randomised to receive single dose of 2μg OLP-1002 on Day 1~Mode of Administration: subcutaneously injection"
89651583|NCT05216341|Placebo Comparator|Stage 2: Arm 3 (Placebo)|"Participants will be randomised to receive single dose of Placebo on Day 1~Mode of Administration: subcutaneously injection"
88993377|NCT00517465|Experimental|1|
88993378|NCT00517465|Experimental|2|
88993379|NCT00517465|Experimental|3|
88993380|NCT00517465|Placebo Comparator|4|
88993381|NCT00517582|Experimental|HOE-140|Administration of HOE-140 (icatibant) 30 mg at time 0 and at 6 hours
88993382|NCT00517582|Placebo Comparator|Placebo|Administration of placebo at time 0 and 6 hours
88993383|NCT00517738|Experimental|Physical training - No encephalopathy|Patients randomized to the physical training program and diet intervention
89651584|NCT05114967||Patients undergoing surgery|Patients undergoing surgery during the 4th wave of the pandemic for 1 month duration in the University Hospital of Larissa
89651585|NCT03836352|Experimental|Arm 1 (All cohorts)|DPX-Survivac, Cyclophosphamide, Pembrolizumab
89651586|NCT03836352|Experimental|Arm 2 (Ovarian cohort only)|DPX-Survivac, Pembrolizumab
89651587|NCT00833781|Active Comparator|mRNA-transfected dendritic cells|Participants in this arm/group received mRNA-transfected autologous dendritic cells
89651588|NCT00833781|Placebo Comparator|Dendritic cells without mRNA|Participants in this arm/group received autologous dendritic cells with no mRNA transfection
89651589|NCT01397201|Experimental|BI 54903 - low dose|Respimat inhaler containing low dose BI 54903 plus placebo matching hydrofluoralkane (HFA) metered dose inhaler (MDI)
89651590|NCT01397201|Experimental|BI 54903 - medium dose|Respimat inhaler containing medium dose BI 54903 plus placebo matching HFA MDI
89651591|NCT01397201|Experimental|BI 54903 - high dose|Respimat inhaler containing high dose BI 54903 plus placebo matching HFA MDI
89651592|NCT01397201|Active Comparator|Fluticasone propionate|Fluticasone HFA MDI containing ICS plus placebo matching Respimat inhaler
89651593|NCT01397201|Placebo Comparator|Placebo|Placebo matching Respimat inhaler plus placebo matching HFA MDI
89651594|NCT04845919|Experimental|5-ALA mediated sonodynamic therapy|
89651595|NCT03835338|Experimental|Test Group|The test group will receive Pulmonary Vein Isolation, LAA Isolation and LAA Occlusion with the WATCHMAN LAAC Device
89651596|NCT03835338|Active Comparator|Control Group|The control group will receive Pulmonary Vein Isolation
89651597|NCT00834171||1|Loteprednol etabonate ophthalmic suspension 0.5%
89651598|NCT00834171||2|Loteprednol etabonate (0.5%) and tobramycin (0.3%)
89651599|NCT02985437|Experimental|Surfactant|Alveofact® (Bovine Lung Surfactant), 0.5 mg/ml per day (solution) all two days maximal eight times
89651600|NCT02985437|Active Comparator|Saline|0.9% Sodium chloride solution (NaCl solution), 2 ml per day (solution) all two days maximal eight times
89651601|NCT04839367|Experimental|Cohort 1 - 100 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 100 MBq 64Cu-SAR-bisPSMA.
89651602|NCT04839367|Experimental|Cohort 2 - 150 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 150 MBq 64Cu-SAR-bisPSMA.
89651603|NCT04839367|Experimental|Cohort 3 - 200 MBq 64Cu-SAR-bisPSMA|Participants will receive a single administration, a bolus injection of 200 MBq 64Cu-SAR-bisPSMA.
89651604|NCT00834483|Experimental|1|Knotless suture for wound closure
89651605|NCT00834483|Active Comparator|2|Layered traditional wound closure (monocryl)
89651606|NCT04982289|Experimental|ALXN1830 Dosing Arm 1|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
89651607|NCT04982289|Experimental|ALXN1830 Dosing Arm 2|Participants will receive ALXN1830. Treatment will be received for 16 weeks followed by an Observation Period (no treatment) for 8 weeks.
89651608|NCT04982289|Experimental|ALXN1830 Dosing Arm 3|Participants will receive placebo for 8 weeks, then ALXN1830 for 8 weeks, followed by an Observation Period (no treatment) for 8 weeks.
89521726|NCT03414073|Sham Comparator|Group C Phase 2|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the conventional finger flossing technique in the second phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
89651609|NCT05200039||Study group|Older men who were treated for localized or locally advanced prostate cancer with curative intent at the age of 70 years or more
89651610|NCT05200039||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019, matched on age and education
89651611|NCT01393613|Experimental|Dose 3 OPC 34712|Higher dose, tablet, once daily, for six weeks
89651612|NCT01393613|Experimental|Dose 2 OPC 34712|Middle dose, tablet, once daily, for six weeks
89651613|NCT01393613|Experimental|Dose 1 OPC 34712|Lower dose, tablet, once daily, for six weeks
88993384|NCT00517738|Active Comparator|Control - No encephalopathy|Patients not allocated to exercise program, but undergoing diet intervention
88993385|NCT00517738|Experimental|Physical training - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grade 1-2) randomized to the physical training program
89651614|NCT01393613|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
89651615|NCT04830553|Experimental|Music-based couple therapy.|"Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks."
89651616|NCT04830553|No Intervention|Waiting list.|Each couple will go through an initial waiting period before the treatment phase. Duration of the waiting period: five weeks.
89651617|NCT00835185|Experimental|IMC-11F8 (necitumumab) /mFOLFOX-6 regimen|Participants will receive IMC-11F8 (necitumumab) once every 2 weeks in combination with the mFOLFOX-6 regimen (oxaliplatin/5-FU/FA)
89651618|NCT05196685||Group Vertigo|Patients who have Carotid Doppler Ultrasonography and Vertigo screening test scores of 1 and above will be sent to ENT
88993386|NCT00517738|Active Comparator|Control - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grades 1-2) not allocated to the physical training program, but undergoing diet intervention
89651619|NCT05196685||Group control|Patients who have Carotid Doppler Ultrasonography and Vertigo screening test score below 1
89651620|NCT04399525|Experimental|Sequence 1|Desloratadine 5 mg Levocetirizine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
89651621|NCT04399525|Experimental|Sequence 2|Desloratadine 5 mg Levocetirizine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
89651622|NCT04399525|Experimental|Sequence 3|Levocetirizine 5 mg Desloratadine 5 mg Levocetirizine 2x5 + 2x5 mg Desloratadine 2x5 + 2x5 mg
89651623|NCT04399525|Experimental|Sequence 4|Levocetirizine 5 mg Desloratadine 5 mg Desloratadine 2x5 + 2x5 mg Levocetirizine 2x5 + 2x5 mg
89651624|NCT00864123|Active Comparator|Cognitive-behavioral therapy + placebo|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of placebo. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
89651625|NCT00864123|Experimental|Cognitive-behavioral therapy + D-cycloserine|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of D-cycloserine. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
89651626|NCT04817995|Experimental|Intervention group|The intervention group will get a 6-week internet-based stress recovery intervention.
89212953|NCT02584985|Other|ETAP : Endoscopic Transanal Proctectomy|"Primary transanal approach :~Careful positioning in Lithtomy, dilatation and anal exposure with standard retractor. Mucosa incision and internal sphincter dissection according to tumor extension. Primary conventional dissection up to circumferential exposure of fascia recti. Secondary implantation of transanal endoscopic device Begin mesorectal endoscopic dissection postero-anteriorly, then laterally with nerve-sparing dissection. Level assessment of posterior dissection (vertical segment). End with peritoneal opening anteriorly (Douglas).~Secondary transabdominal approach :~Type of laparoscopic approach multiport or singleport. Level of arterial section, extension of colonic mobilization, site for specimen extraction (transanal / transabdominal), type of colonic reconstruction."
89212954|NCT02584985|Other|Standard Transabdominal Laparoscopic proctectomy|Primary transanal conventional dissection (sphincter preservation assessment) or not, type of laparoscopic approach multiport or singleport, level of arterial section, extension of colonic mobilization, conditions of mesorectal excision and nerve preservation, site for specimen extraction (transanal / transabdominal) and type of colonic reconstruction.
89651627|NCT04817995|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
89651628|NCT04054947|Experimental|Suicide Prevention Program|
89651629|NCT04054947|No Intervention|Usual Care|
89651630|NCT03858465|Active Comparator|25 mg of ephedrine|participants who will receive intravenous 1,25mg/min ephedrine during 20 minutes (total dosage is 25 mg of ephedrine).
89651631|NCT03858465|Active Comparator|0,3 mg of phenylephrine|participants who will receive intravenous 0,015mg/min phenylephrine during 20 minutes (total dosage is 0,3mg of phenylephrine).
89651632|NCT02417805|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
89651633|NCT02417805|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
89651634|NCT02417805|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
89651635|NCT02417805|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
89651636|NCT03230149||Molecular and genetic tests|Measurements of the alpha-GAL enzyme activity will be performed knowing that for male patients with alpha-GAL activities below the cut-off value and all female patients, a blood sampling for full genetic sequencing of all seven exons including promotors of the a-GAL gene will be done
89651637|NCT00836433|Active Comparator|FALLS only|Traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
89651638|NCT00836433|Experimental|CONNECT and FALLS|CONNECT educational intervention is designed to improve relationship-building and communication. The intervention includes 2 in-class session, group mapping exercise, individual relationship mapping exercises, Self-monitoring of interactions, individual staff coaching sessions. FALLS is a traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
89651639|NCT00867789|Experimental|Trimethoprim-sulfamethaxazole|Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)
89651640|NCT00867789|Placebo Comparator|Sugar pill|Incision and drainage of the abscess and treatment with oral placebo (100 patients)
89651641|NCT04399681|Other|Suspected COVID-19 Group|Patients who admitted to emergency department with suspicion of COVID 19 pneumonia will be evaluated with POCUS/ bedside lung ultrasound.
89651642|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] High Dose|Higher Dose, tablet, once daily, for six weeks
89651643|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Middle Dose|Middle Dose, tablet, once daily, for six weeks
89651644|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Low Dose|Lower Dose, tablet, once daily, for six weeks
89651645|NCT01396421|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
89651646|NCT00868101|Experimental|Preconditioning|Children who received the preconditioning stimulus
89651647|NCT00868101|No Intervention|Control|Children who did not receive the preconditioning stimulus
89651648|NCT04797013|Active Comparator|rhTNK-tPA (0.25mg/kg)|rhTNK-tPA (0.25mg/kg) is given as a single, intravenous bolus (within 5-10 seconds) immediately upon randomization. Maximum dose 25mg.
89651649|NCT04797013|Active Comparator|rt-PA (0.9mg/kg)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the remainder in 1 hour. Maximum dose 90mg.
89651650|NCT00837447|Active Comparator|NexGen CR knee prosthesis|side of knee operated with total knee replacement with Nexgen CR prosthesis
89651651|NCT00837447|Active Comparator|NexGen CR-Flex knee prosthesis|side of knee operated with total knee arthroplasty using Nexgen CR-flex prosthesis
89651652|NCT00838695|Experimental|African Americans|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
89651653|NCT00838695|Experimental|Caucasians|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
89651654|NCT00839241|Experimental|Autologous Blood Transfusion|
89651655|NCT00839241|Active Comparator|Allogenic Blood Transfusion|
89651656|NCT03664297|Experimental|SHR1459|Oral administration, once a day, 28 days for a cycle, until the disease progression or the intolerable toxicity occurs.
89651657|NCT01396265|Experimental|Afatinib alone (Reference)|Tablet, Oral administration with 240 mL of water
89651658|NCT01396265|Experimental|Rifampicin + Afatinib (Test)|Tablet, Oral administration with 240 mL of water
89651659|NCT04760431|Active Comparator|Group A|Trastuzumab, Taxanes and Pertuzumab
89651660|NCT04760431|Experimental|Group B|Trastuzumab, Taxanes and TKIs
89651661|NCT04560283|Experimental|Experimental group receiving HYALOGYN®|
89651662|NCT04560283|Placebo Comparator|Control group undergoing expectant management|
89651663|NCT04750213||Participants Receiving Humira (Adalimumab)|Participants receiving Adalimumab for Pyoderma Gangrenosum (PG).
89651664|NCT00839319|Experimental|Acyline plus Placebo|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
89651665|NCT00839319|Experimental|Acyline plus 15 IU hCG|Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
89651666|NCT00839319|Experimental|Acyline plus 60 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
89651667|NCT00839319|Experimental|Acyline plus 125 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
89651668|NCT00839319|Experimental|Acyline plus Testosterone gel|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days
89651669|NCT04746313||Patients with systemic sclerosis|The study will be systematically offered to any scleroderma patient seen in scheduled hospitalization
89651670|NCT04746313||Healthy subjects|Healthy subjects who will donate blood to the French Blood Establishment (EFS) and matched to scleroderma patients on age (+/- 5 years) and sex
89651671|NCT00890721|Experimental|SKY0402|During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.
89651672|NCT00890721|Placebo Comparator|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
89212955|NCT02585063||Dual assessment|Where there is time and space, participants will be allocated to have a clinical assessment by the IP optometrist during their wait for the clinical assessment with the ophthalmologist. Both clinical assessments are needed to obtain measurement of agreement. There is no intervention. but participants have two clinical assessments rather than just one.
89651673|NCT04277767||mild cognitive impairment (MCI)|observational
89651674|NCT04277767||Patients with mild to moderate AD|observational
89651675|NCT04277767||Normal controls|observational
89651676|NCT00868959|Experimental|lurasidone|
89651677|NCT03210103|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
89651678|NCT03210103|Experimental|Arm 2, TOS + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
89651679|NCT03209869|Experimental|Single arm|All subjects will receive Ex vivo Expanded and Activated Haploidentical Donor NK Cells + hu14.18-IL2
89651680|NCT03209791||Alcoholic Steatosis|This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed
89651681|NCT03209791||Cirrhosis|This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed
89651682|NCT03209791||Steatohepatitis|This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed
89651683|NCT03209791||controls|This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed
89651684|NCT02647866|Experimental|KHK4083 Cohort 1|Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
89651685|NCT02647866|Experimental|KHK4083 Cohort 2|Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
89651686|NCT02647866|Experimental|KHK4083 Cohort 3|Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
89651687|NCT02647866|Experimental|KHK4083 Cohort 4|Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
89651688|NCT02647866|Placebo Comparator|Placebo|Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
89651689|NCT03838887||control group|"Pregnant women:~Age between 18-35 years~Parity: primigravidas and multiparas.~Have no history of preeclampsia or eclampsia.~Have no history of chronic hypertension.~Not diabetic.~Not have antiphospholipid syndrome.~Not have autoimmune disease such as SLE"
89651690|NCT03838887||High risk group|"Pregnant women with:~History of preeclampsia -Eclapmsia~Chronic hypertension~Diabetic~Antiphospholipid syndrome.~Autoimmune syndrome such as SLE."
89651691|NCT02246127|Active Comparator|Sequence A, drug: everolimus first|Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).
89651692|NCT02246127|Experimental|Sequence B, drug: STZ - 5FU first|STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)
89651693|NCT04277923|Experimental|SMOF lipid emulsion|the SMOF lipid emulsion is SMOFlipid.
89651694|NCT04277923|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin.
89651695|NCT00869349|Experimental|IFS Intervention Group|
89651696|NCT00869349|Active Comparator|Education Group|
89651697|NCT04783662||Robust|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal to 0
89651698|NCT04783662||Pre Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is 1 or 2
89212956|NCT00920465|Experimental|one-visit|
89212957|NCT00920465|Active Comparator|two-visit|
89651699|NCT04783662||Frail|Patients ≥65 years, undergoing elective non cardiac surgery which Fried phenotype score is equal or greater than 3
89651700|NCT00870363|Active Comparator|1|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
89651701|NCT00870363|Active Comparator|2|maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
89651702|NCT00870363|Active Comparator|3|efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
89651703|NCT00870363|No Intervention|4|HIV-negative
89651704|NCT03104634|Experimental|Active arm|Aclidinium bromide/formoterol fumarate dihydrate 400 mcg/12 mcg Twice daily (once in the morning, once in the evening) 7-days
89045727|NCT06044311|Experimental|Vactosertib + Chemoradiotherapy|Vactosertib orally, 200 mg twice daily for five days a week for 2 weeks, followed by standard of care chemoradiotherapy, followed by Vactosertib for 4 weeks after standard of care chemoradiotherapy
89045728|NCT06007521||Patients with alternating hemiplegia|Patients with alternating hemiplegia, from 0 to 99 years old
89651705|NCT03104634|Placebo Comparator|Placebo arm|Placebo Twice daily (once in the morning, once in the evening) 7-days
89651706|NCT03104712|Other|Glucose #1|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
89651707|NCT03104712|Active Comparator|Spaghetti|50 grams of available carbohydrate from spaghetti will be cooked according to package instructions and consumed as a test meal
89651708|NCT03104712|Active Comparator|Rice|50 grams of available carbohydrate from white rice will be cooked according to package instructions and consumed as a test meal
89045729|NCT06004037|Experimental|delpazolid|In addition to background therapy for MABC, patients will be given orally three tablets (400 mg/tablet) of LCB01-0371 for 12 weeks.
89045730|NCT05991817||Adults 30-50 years|
89651709|NCT03104712|Active Comparator|Spaghetti + tomato sauce|50 grams of available carbohydrate from spaghetti plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
89651710|NCT03104712|Active Comparator|Rice + tomato sauce|50 grams of available carbohydrate from white rice plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
89651711|NCT03104712|Active Comparator|Spaghetti + Pesto|50 grams of available carbohydrate from spaghetti plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
89651712|NCT03104712|Active Comparator|Rice + Pesto|50 grams of available carbohydrate from white rice plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
89651713|NCT03104712|Other|Glucose #2|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
89651714|NCT03104712|Other|Glucose #3|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
89651715|NCT00871143|Experimental|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
89651716|NCT00871143|Active Comparator|Non Specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
89651717|NCT05179746|Active Comparator|With electrolytic cleaning|Mechanical debridement with ultrasonics (plastic tip) and plastic curettes
89651718|NCT05179746|Placebo Comparator|Without electrolytic cleaning|Mechanical debridement with ultrasonics (plastic tip) and plastic curettes
89651719|NCT04933188||control|Lean health controls with a BMI<25kg/m2
89651720|NCT04933188||overweight|patients with a BMI of 25-30kg/m2
89651721|NCT04933188||obesity|patients with a BMI of over 30kg/m2
89651722|NCT04738890|Experimental|MBCT-PCCFA plus TAU|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing, plus treatment as usual.
89651723|NCT04738890|Other|TAU control|Treatment as usual control group
89651724|NCT01396187|Experimental|Treatment|
89651725|NCT01396187|Placebo Comparator|Placebo|
89651726|NCT00871689|Experimental|UCBT With Post-Transplant IL-2|Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
89651727|NCT02084797|Experimental|all study participants|All study participants received all interventions. V2R Antagonist: 30mg Tolvaptan tablet ingested 2 hours before exercise. V2R agonist: 0.2mg DDAVP tablet ingested 2 hours before exercise Placebo
89651728|NCT03104166|Experimental|MCO|Patients will be treated thrice weekly with Medium Cut-Off Dialysis membranes.
89651729|NCT03104166|Active Comparator|High-Flux|Patients will be treated thrice weekly with High-Flux Dialysis membranes.
89651730|NCT00871845|No Intervention|LEAN (non obese, naive)|Patients naive to hepatitis C therapy with body mass index (BMI) <25
89045731|NCT05987033|Experimental|NVDX3 implant|
89651731|NCT00871845|Other|OVERWEIGHT (obese, naive, control)|Patients naive to hepatitis C therapy with BMI ≥ 25, received Dietary and Lifestyle modification educational sessions (one-time 15 minute weight loss instruction and pamphlet and enrolled into weight management program with 5 weekly one-hour nutrition and physical exercise education sessions after initial evaluation followed by monthly follow up.)
89651732|NCT04738110||KCH patients|75 high grade glioma patients from KCH
89651733|NCT04738110||NHNN patients|75 high grade glioma patients from NHNN
89651734|NCT00872079|Active Comparator|Genomics|"Aim 1: Collect historical data on warfarin dosing in subjects at the VA. Aim 2: Collect genotype information on up to 300 subjects receiving warfarin anticoagulation.~Aim 3: Develop a computer model incorporating the information from Aim 1 and 2. Aim 4: Conduct randomized clinical trial."
89651735|NCT03816449|Active Comparator|experimental group|Experimental group will include postmenopausal women who will practice following exercise program:aerobic exercise, resistance training and balance exercise. Aerobic exercise will be conducted as a dose walk, 3-5 km / h, approximately 70% of maximal heart rate, about 50 minutes per day, five days per week, for 12 weeks. Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions with straps. Frequency of training will be 3 times per week, will last 70 minutes per day, for 12 weeks.
89651736|NCT03816449|Placebo Comparator|control group|Control group will include about postmenopausal women who will not practice exercise program (aerobic exercise, resistance training and balance exercise) .They will continue to carry out activities of daily living, which are conducted daily before inclusion in the study. These patients will be asked to not include in any other program of physical activity and exercise during the research period (12 weeks). After this period, patients will be offered to participate in the same exercise program that had patients from the experimental group.
89651737|NCT03104244||Youth Football|5th and 6th grade tackle football players will be enrolled in 2016. They will be followed as a cohort, participating in the study each year they play tackle football, through 8th grade. Total enrollment is expected to reach 70 players.
89651738|NCT03104244||High School Football|Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
89651739|NCT00873327|Active Comparator|1|Open label -- 6 interval doses
89651740|NCT04816890|Experimental|M1 Pram P037|Multi daily administration of M1 Pram P037 by subcutaneous injection
89651741|NCT04816890|Active Comparator|Insulin lispro|Multi daily administration of insulin lispro (Humalog®) by subcutaneous injection
89651742|NCT03205579|Experimental|Video group|Video cancer pain education (10 minutes ) the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
89651743|NCT03205579|Active Comparator|Conventional group|Face to face cancer pain education by trained nurse (10 minutes)the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
89651744|NCT01392677|Experimental|Dapagliflozin 10 mg tablet|
89651745|NCT01392677|Placebo Comparator|matching placebo tablet|
88993387|NCT04481165||Adolescents with anorexia nervosa|Adolescents from 12 to 25 year old, cared for anorexia nervosa at the Maison de Solenn (Cochin hospital, Paris, France) et for whom antidepressive agents have been prescribed
88993388|NCT02949856|Experimental|Tapered|Mallinckrodt, COVIDIEN
88993389|NCT02949856|Active Comparator|Cylindrical|Endotracheal tube, Unomedical
88993390|NCT02949817|Experimental|IMU sensor training group(intervention group)|video-game based rehabilitation therapy system training group
88993391|NCT02949817|Active Comparator|Conventional OT group (control group)|conventional training group (control group)
88993392|NCT00517777|Experimental|1|continuous positive airway pressure ventilation + dietary and life style recommendations
88993393|NCT00517777|Active Comparator|2|dietary and life style recommendations
88993394|NCT00517816|Experimental|1|
88993395|NCT00517816|Experimental|2|
88993396|NCT00517816|Experimental|3|
88993397|NCT00517816|Experimental|4|
88993398|NCT00517816|Experimental|5|
88993399|NCT00517816|Experimental|6|
88993400|NCT00517816|Experimental|7|
88993401|NCT00517816|Experimental|8|
88993402|NCT00151515|Experimental|1|Topical 5% minoxidil foam formulation used twice daily
88993403|NCT04478981||SELENON- or LAMA2-related muscular dystrophy|Participants diagnosed with congenital myopathy/muscular dystrophy due to mutations in the SEPN1 (SELENON) or LAMA2 gene
88993404|NCT00518050||Specific Aim 1- Focus Group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~Screening, skin self-examination, sun protection, and other cancer preventive practices;~Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
89212958|NCT04078919|Active Comparator|Low calorie diets with nuts|Low calorie diet in which 20 percent of daily calories will be provided from nuts
89212959|NCT04078919|Placebo Comparator|Low calorie diet|Low calorie diet
89212960|NCT02583035|Other|Nurse telephone contact|3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate
89212961|NCT00994773|Experimental|Simvastatin|Simvastatin orally
89651746|NCT04102410|Experimental|Experimental group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program composed of two 2 training strategies.
89651747|NCT04102410|Sham Comparator|Control group|Patient with acute coronary syndrome will be included. They will have sprints, vertical jumps, questionary Short Form-12 (SF-12), activity actigraph and program of usual practice.
89651748|NCT00841269|Experimental|Uridine|Uridine 500 mg by mouth twice daily for 6 weeks
89651749|NCT00841269|No Intervention|Healthy Comparison|Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.
89651750|NCT03927001|Other|Intervention|NeVa Stent Retrievers
89651751|NCT03104088||SPG4 patients|
89651752|NCT03104088||Healthy controls|
89651753|NCT00841971|Experimental|anidulafungin|anti-fungal agent
89651754|NCT00841971|Active Comparator|Fluconazole|anti-fungal agent
89651755|NCT04399135|Active Comparator|Normal Patients|All patients admitted to Qassim dental clinics, who need root canal treatment would be screened for possible involvement in this study
89651756|NCT04399135|Active Comparator|Periodontitis Patients|All patients who need root canal treatment would be screened to determine the periodontal condition for possible involvement in this study. the periodontitis patients would be categorized according to the new periodontitis classification 2017 world workshop.
89651757|NCT00842751|Placebo Comparator|Testosterone Undecanoate + placebo finasteride|Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
89651758|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 0.5mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
89651759|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 1mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)
89651760|NCT03104010|Experimental|PEG-rhGH-1|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.
89651761|NCT03104010|Experimental|PEG-rhGH-2|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.
89651762|NCT03103854|Active Comparator|Control|"Patients in the Control arm of the study performed Moderate Intensity Continuous Training (MICT) and did not receive text message reminders."
89651763|NCT03103854|Experimental|BURST|"Patients in the BURST arm of the study performed BURST physical activity and did not receive text message reminders"
89651764|NCT03103854|Experimental|Text Message Reminders|"Patients in the Text Message Reminders arm of the study performed Moderate Intensity Continuous Training and received text message reminders."
89651765|NCT03103854|Experimental|BURST and Text Message Reminders|"Patients in the BURST and Text Message Reminders arm of the study performed Burst physical activity and received text message reminders"
89651766|NCT04399213|Experimental|Group A|From cubital fossae to wrist: 50 - 15 - 5 µg histamine dihydrochloride
88993405|NCT00518050||Specific Aim 2- Survey Study|A separate random sample of melanoma survivors will complete the pilot questionnaire. To enhance completion rates, survey instruments will be developed to be both self-administered and interviewer-administered. The survey will include questions from existing surveys, regarding demographics, sun sensitivity, eye and hair color, color of untanned skin, sun exposure, skin selfexamination, sun protection practices and frequency of sunburns, psychosocial/cognitive factors: skin cancer knowledge, skin awareness, cancer worry, perceived risk of recurrence, cancer risk and screening behaviors, and access to health care and insurance.
88993406|NCT00518128|Active Comparator|1|Surgical OSA Treatment Group: Moderate to Severe OSA patients who are unable to tolerate PAP (Positive Airway Pressure) and elect to proceed with surgical treatment (surgical cohort).
88993407|NCT00518128|Active Comparator|2|Positive Airway Pressure Therapy Comparison Group: Moderate to Severe OSA patients who tolerate PAP (Positive Airway Pressure).
88993408|NCT02949778|Active Comparator|Ropivacaine 3.75mg/mL|QL-block using 20 mL ropivacaine 3.75mg/mL
88993409|NCT02949778|Placebo Comparator|Sodium chloride 9 mg/mL|QL-block using 20 mL sterile sodium chloride 9 mg/mL
88993410|NCT00518245|Experimental|1|
88993411|NCT00518245|No Intervention|2|
88993412|NCT00518362|Experimental|immunosuppressor|Valsartan,160mg/d,TW 120mg/d
88993413|NCT00151554|No Intervention|Control group|
88993414|NCT00151554|Experimental|Intervention group|
88993415|NCT02957903|Experimental|Treatment A|"Injection around the lateral femoral cutaneous nerve:~8 ml Ropivacaine 0.75 %."
88993416|NCT02957903|Placebo Comparator|Treatment B|"Injection around the lateral femoral cutaneous nerve:~8 ml isotonic Saline."
88993417|NCT00518479|Experimental|1|Neurohormonal stimulatory arm
88993418|NCT00518479|Experimental|2|Neurohormonal inhibitory arm
88993419|NCT04694755|Placebo Comparator|Heart lung qi deficiency syndrome placebo group|Buyixinfei placebo was given.Tianjiang brand formula granules were used. One dose a day, two times orally, five days a week.
88993420|NCT04694755|Placebo Comparator|Deficiency of lung and Kidney Qi placebo group|Tonifying kidney and protecting lung prescription placebo was given. Tianjiang brand granule was used as the drug, one dose a day, twice orally, five days a week.
88993421|NCT04694755|Experimental|Heart lung qi deficiency syndrome drugs group|Buyixinfei formula was given. Tianjiang brand granule was used as the drug, one dose a day, twice orally, five days a week.
89651767|NCT04399213|Experimental|Group B|From cubital fossae to wrist: 15 - 5 - 50 µg histamine dihydrochloride
89651768|NCT04399213|Experimental|Group C|From cubital fossae to wrist: 5 - 50 - 15 µg histamine dihydrochloride
89651769|NCT02154243|Experimental|Midodrine|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV<15 will be given oral midodrine, 10 mg, once.
89651770|NCT02154243|Experimental|Intravenous fluid bolus|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV>=15 will be given intravenous fluid bolus, 15 cc/kg, once.
89651771|NCT02154243|No Intervention|Control (no intervention)|Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.
89651772|NCT03995004|Experimental|Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Normal Saline (1mL) on induction and continued q12h for 4 more doses."
88993422|NCT04694755|Experimental|Deficiency of lung and Kidney Qi drugs group|The prescription of invigorating the kidney and protecting the lung was given. The drug was Tianjiang brand granule, one dose a day, two times orally, five days a week
88993423|NCT00518518|Active Comparator|1|
88993424|NCT00518518|Placebo Comparator|2|
88993425|NCT00518557|Experimental|1|All patients of this arm are treated by TACE together with Andostatin.
88993426|NCT00518557|Active Comparator|2|All patients of this arm are treated by TACE alone: only mixture of Epirubicin and Lipiodol is injected into the feeding arteries of the tumor, without injection of Andostatin.
88993427|NCT00518596|Experimental|Probiotic Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, given L. plantarum preparations orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
88993428|NCT00518596|Placebo Comparator|Control Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, receiving placebo preparations (a control solution of sterile 2.0 cc 5% dextrose-saline)orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
88993429|NCT00151593|Experimental|1|Celsior preservation solution
88993430|NCT00518635|Experimental|A|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
88993431|NCT02949505|Experimental|Intervention arm|12-week home prehabilitation program
88993432|NCT00518752|Active Comparator|A|Standard Oral Care
88993433|NCT00518752|Experimental|B|Comprehensive Oral Care
88993434|NCT00151632|Experimental|MMF+FK|Low doses of tacrolimus in association with mycophenolate mofetil
88993435|NCT00151632|Active Comparator|FK|Full recommended doses of tacrolimus
88993436|NCT00518791|Experimental|I|Multidisciplinary Care
88993437|NCT00518791|Other|II|Usual Care
88993438|NCT00518830|Experimental|PND-MCI|The multi-component intervention involved a psychoeducational group, treatment adherence support, and pharmacotherapy if needed
88993439|NCT00518830|Active Comparator|usual care|'Usual care' included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
88993440|NCT02949232|Experimental|Prednisolone|Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
88993441|NCT02949232|Placebo Comparator|Placebo Oral Tablet|Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm
88993442|NCT02949154||Metastatic melanoma patients|All patients >18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
88993443|NCT00151671|Experimental|1|Perioperative Oral Nutritional Supplementation
88993444|NCT00151671|Placebo Comparator|2|Placebo of Perioperative Oral Nutritional Supplementation
88993445|NCT04694326||Inpatients|Patients who were inpatients of units other than internal medicine services and internal medicine side-branch services
88993446|NCT04694170|Experimental|Experimental group|Patients with musculoskeletal pain in the lumbar region. Patients with typical symptoms of functional dysfunction of kidney undergo conventional physiotherapy and an alternative approach by yoga set exercising and regimen restriction according to traditional Chinese medicine.
88993447|NCT04694170|Active Comparator|control group|Patients with musculoskeletal pain in the lumbar region. Patients with kidney dysfunction symptoms treated by conventional physiotherapy only.
88993448|NCT00518908|Experimental|Sevoflurane|Sevoflurane for pharmacological postconditioning
88993449|NCT00518908|Experimental|Propofol|Anesthesia maintenance with propofol instead of Sevoflurane postconditioning
88993450|NCT00518947|Active Comparator|1|Continued-Lithium
88993451|NCT00518947|Experimental|2.|Verapamil
88993452|NCT00518947|Experimental|3.|Verapamil plus Lithium
88993453|NCT02949466|Experimental|triamcinolone and hyaluronic acid group|combined triamcinolone (Triamcinolone 10 mg 1cc) and hyaluronic acid (2 cc) injections: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
88993454|NCT02949466|Active Comparator|hyaluronic acid group|hyaluronic acid (2cc) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
88993455|NCT00519064|Active Comparator|Arm 1|
88993456|NCT00519064|Active Comparator|Arm 2|
88993457|NCT00519103|Experimental|1|Active resistive excercise for 7 weeks
89651773|NCT03995004|Active Comparator|Dexamethasone|"Placebo capsules at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
89651774|NCT03995004|Experimental|Dexa_Melatonin|"Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.~IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses"
89651775|NCT01392443|Experimental|Ruxolitinib|Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count >200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.
89651776|NCT03103776|Other|Patients who have Graves disease|
89651777|NCT03103776|Other|Patients having a goiter|
89651778|NCT03870607|Experimental|Prebiotics and probiotics group|This group will receive standard nutritional guidance from the institutional routine and prebiotics in combination with probiotics, starting one week before the start of Ch-RT and daily throughout the treatment up to 6 to 8 weeks post Ch-RT at the time of evaluation response (primary outcome).
89651779|NCT03870607|No Intervention|Control group|This group will lead nutritionally based just before starting Ch-RT.
89651780|NCT03216681||Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
89651781|NCT03216681||Tanakan 40mg|Administered orally three times a day, one tablet each time, for 45 days.
89651782|NCT01391819|Other|Study cohort|Children age 5 to 13 years at the time of enrollment, selected from schools in Fortaleza.
89651783|NCT03216291|Active Comparator|Home Biofeedback|Patients will be given home biofeedback device (InTone) to take home and practice biofeedback exercises at least twice a day for six weeks of therapy. Intervention: Home device biofeedback training.
89651784|NCT03216291|Active Comparator|Office biofeedback|Patients with fecal incontinence will receive traditional office biofeedback, once weekly, over six weeks. Intervention: Regular office biofeedback training with assistance of biofeedback person..
89651785|NCT03216369||carotid artery stenting and carotid endarterectomy|Symptomatic patients with unilateral ICA severe stenosis by magnetic resonance angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI before and after CAS and CEA.
89651786|NCT03216447|Experimental|Experimental Arm|Switch from Prograf to Advagraf on POD 15
89651787|NCT03216447|Active Comparator|Control Arm|Continue Prograf treatment
89651788|NCT04669938||Patients hospitalized for COVID-19|
89651789|NCT03845023|Placebo Comparator|2-Night at Home|An initial 2-night, at-home blinded baseline period in which all subjects received placebo
89651790|NCT03845023|Experimental|3-Night Run In|AD036 Dose 1 (Low Dose: 25/5) or Placebo
89651791|NCT03845023|Experimental|7-Night|A 7-night treatment period in which subjects received the treatment to which they were randomized, i.e., 1 of the 3 different fixed-dose combinations of drugs, or placebo
89651792|NCT03845023|No Intervention|End of Study|End of Study Visit
89651793|NCT03957876|Experimental|intravenous CPX-351 with potential maintenance therapy|Single agent CPX-351 administered at the standard FDA approved dose of 44 mg/m2 intravenously on days 1, 3, 5 of the induction cycle. If participants achieve complete remission (CR), complete remission with incomplete count recovery (CRi) or partial remission (PR), they will be eligible to continue on to maintenance therapy, which will consist of CPX351 at a dose of 15.4 mg/m2 every 28 days. Participants can receive up to 4 cycles of maintenance therapy.
89045734|NCT05948293|Experimental|Intervention arm|In the intervention arm the first dose of FSH will be assigned by a machine learning model called IDoser.
89045735|NCT05948293|Active Comparator|Control arm|In the control arm the first dose of FSH will be determined by the clinician following standard practice.
89045736|NCT05947071|Experimental|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|Two doses of SD-QIV (0.5 mL; 15µg of each influenza antigen) 28-42 days apart
89045737|NCT05947071|Experimental|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|Two doses of HD-QIV (0.7 mL; 60µg of each influenza antigen) 28-42 days apart
89651794|NCT02454114|Active Comparator|Standard Hospital Care (SHC)|All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. Patients receiving SHC will be discussed at weekly case note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
89651795|NCT02454114|Active Comparator|HOMEFIRST|"Patients randomised to HOMEFIRST care will initially receive up to twice daily visits for the first 48 hours. After this, the frequency and duration of visits will depend on clinical need but not exceed 5 days. The study nurse will establish the need for the involvement of other MDT members. Laboratory tests will be performed as clinically indicated. Venepuncture will be performed for clinical purposes as needed.~Patients will be discussed at a weekly case-note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.~Patients are either discharged from HOMEFIRST, readmitted or handed over to their community care team at the end of the intervention."
89045738|NCT05946733|Experimental|Group A|subcostal TAP block
89651796|NCT03216135||(GERD) with no Barrett's Esophagus|Squamous epithelium from patient with gastroesophageal reflux disease (GERD) with no BE or EAC diagnosed will be collected and a control sample (area with no disease).
89651797|NCT03216135||Barrett's Esophagus|BE/columnar epithelium from patient diagnosed with BE and a control sample (area with no disease).
89651798|NCT03216135||Cancer Tissue|Cancer tissue, and a control squamous epithelium from the same patient.
89045739|NCT05946733|Experimental|Group B|lateral TAP block.
89045740|NCT05946733|Other|GroupC|will receive postoperative morphine by patient-controlled analgesia (PCA).
89045741|NCT05931796|Active Comparator|Group A|NON-ERAS pathway All patients received best of care practice, with standardization of preoperative and postoperative care
89651799|NCT04512924|Active Comparator|Group 1|
89651800|NCT04512924|Experimental|Group 2|
89651801|NCT03249103|Experimental|All subjects|Up to 24 subjects will receive placebo, NYX-2925 20 mg QD, and NYX-2925 200 mg QD for sequential 2 week treatment periods, then go into Follow-up for 1 week.
89651802|NCT03216213|No Intervention|Control|Vignette contains no extra information
89651803|NCT03216213|Experimental|Frame|Vignette is framed in a particular manner
89651804|NCT03216213|Experimental|Norms|Vignette contains extra information about norms
89651805|NCT03216213|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
89651806|NCT03215979|Experimental|PEP-Arm|In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.
89651807|NCT03215979|Placebo Comparator|Placebo-Arm|This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.
89651808|NCT03837925|Experimental|ATORVASTATIN|Atorvastatin 40mg caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG, to evaluate the pharmaco-metabolomic effects of the Statine
89651809|NCT03837925|Placebo Comparator|PLACEBO|Placebo caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG to compare the pharmaco-metabolomic effects of the Statine between atorvastatin arm and placebo arm
89651810|NCT00873873||Persistent obstruction|(pattern of asthma progression)
89651811|NCT00873873||Late obstruction|(pattern of asthma progression)
89651812|NCT00873873||Late normal|(pattern of asthma progression)
89651813|NCT00873873||Persistent normal|(pattern of asthma progression)
89651814|NCT04398589|Experimental|SSNB and ANB c DEX|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for SSNB and ANB.
89651815|NCT04398589|Placebo Comparator|SSNB and ANB c saline|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for SSNB and ANB.
89651816|NCT00874887|Active Comparator|Vigamox®|moxifloxacin 0.5% (m mg/mL), boric acid, sodium chloride, and purified water
88993458|NCT02949388|Placebo Comparator|Placebo|Placebo Comparator: Placebo daily Two (2) placebo capsules given twice daily (AM and PM) for 84 (± 2 days
88993459|NCT02949388|Active Comparator|300 mg (150 mg BID)|Active Comparator: 300 mg of Prurisol daily One (1) capsule containing 100 mg Prurisol and one (1) capsule containing 50 mg of Prurisol given twice (AM and PM) for 84 (± 2) days
88993460|NCT02949388|Active Comparator|400 mg (200 mg BID)|Active Comparator: 400 mg of Prurisol daily Two (2) capsule each containing 100 mg Prurisol given twice daily (AM and PM) for 84 (± 2) days
88993461|NCT02949310|Placebo Comparator|Control|Placebo use instead of nefopam
88993462|NCT02949310|Experimental|Nefopam|Intraoperative use of nefopam 40 mg
88993463|NCT00519220||I|Patients will answer symptom questionnaires and have their charts reviewed for relevant medical information.
88993464|NCT02949349|Experimental|MMF 500mg|Mycophenolate mofetil 500mg, PO BID
88993465|NCT02949349|Experimental|MMF 750mg|Mycophenolate mofetil 750mg, PO BID
88993466|NCT02949349|Active Comparator|AZA|Azathioprine 1mg/kg, PO BID
88993467|NCT02949193|Experimental|evogliptin|evogliptin 5mg qd add-on to metformin
88993468|NCT02949193|Active Comparator|sitagliptin|sitagliptin 100mg qd add-on to metformin
88993469|NCT00519298|Experimental|1|
88993470|NCT00519298|Placebo Comparator|2|
88993471|NCT00519298|Active Comparator|3|
88993472|NCT00519337|Active Comparator|1|Ascorbic acid
88993473|NCT00519337|Placebo Comparator|2|Identical placebo
88993474|NCT00519415|Experimental|A|
88993475|NCT00519415|Experimental|B|
88993476|NCT00519454||Female Lupus patients|Females who are still childbearing age, not on hormones, with Systemic Lupus Erythematosus, still cycling.
88993477|NCT00519493|Active Comparator|Suture|A keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
88993478|NCT00519493|Active Comparator|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
88993479|NCT00519571|Experimental|1|
88993480|NCT00166881|Experimental|A, 2, III|Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL
88993481|NCT00519610||I|Patients will have charts reviewed for relevant medical information before and after surgery to assess patient outcome after placement of H-graft shunt for the treatment of portal hypertension.
88993482|NCT02948998|No Intervention|control|The participants in control group do not take spironolactone.
88993483|NCT02948998|Experimental|spironolactone|The participants in spironolactone group take 10-20mg spironolactone orally and daily.
89651817|NCT00874887|Active Comparator|Zymar®|gatifloxacin 0.3% (3 mg/mL), benzalkonium chloride 0.005%, edetate disodium; purified water and sodium chloride
89651818|NCT04657315|Other|The investigational drug into the Intratumoral administration|The investigational drug in the amount of 1x10^7, 3x10^7cells per dose into the tumor or the tumor removal site using a syringe during surgery
89651819|NCT04695132|Experimental|Illness Management and Recovery treatment programme (intervention group)|These patients receive the Illness Management and Recovery treatment. Treatment takes place during 2 Group sessions and 1 individual session per week.
89651820|NCT04695132|No Intervention|Treatment as usual (control group)|These patients receive treatment as usual consisting of the standard treatment given at the respective inpatient forensic mental health facility where they are admitted.
89651821|NCT00875277|Experimental|LEO 29102 cream|LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks
89651822|NCT00875277|Placebo Comparator|LEO 29102 Cream Vehicle|LEO 29102 cream vehicle applied topically twice daily for 4 weeks.
89651823|NCT00875277|Experimental|Betamethasone Dipropionate Cream|Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
89651824|NCT00875277|Experimental|LEO 29102 Plus Calcipotriol Cream|LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.
89651825|NCT00875277|Experimental|LEO 29102 Plus Betamethasone Dipropionate|LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
89651826|NCT00875277|Active Comparator|Daivobet® Ointment|Daivobet® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.
89651827|NCT03245983|Experimental|Patient willing to participate|
89651828|NCT03757182||Wearable activity monitor|Continuous activity monitoring with Fitbit Charge HR from baseline to up to 1 year from end-of-study.
89651829|NCT01323309||Individual Meaning-Centered Psychotherapy (IMCP)|
89651830|NCT01323309||standard Individual Supportive Psychotherapy (ISP)|
89651831|NCT01323309||enhanced usual care (EUC)|
89651832|NCT03215745|Experimental|Delirium prevention program|Delirium prevention program involved a non-pharmacologic preventive interventions that will be focused in: Delirium prevention program includes individualized non-pharmacological interventions such as multisensory stimulation, cognitive stimulation, activate the functional and family involvement.
89651833|NCT03215745|No Intervention|Control group|Usual care
89651834|NCT04457245|Active Comparator|Arm I (dRT)|150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.
89651835|NCT04457245|Experimental|Arm II (18F-DCFPyL, PET/CT, dRT)|162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.
89651836|NCT03103464|Experimental|Intervention Group|Patients to receive standard-of-care physical therapy + sit-to-stand therapy using the Movi chair 3x/wk.
89651837|NCT03103464|Active Comparator|Control Group|Patients to receive standard-of-care physical therapy 3x/wk.
89651838|NCT03637231|Other|Standard and ultra-low-dose CAC scoring|
89651839|NCT00875589||Control|Control subjects with no Mild Traumatic Brain Injury (MTBI) and no Post-Traumatic Stress Disorder (PTSD)
89651840|NCT00875589||MTBI|Subject with a diagnosis for Mild Traumatic Brain Injury (MTBI)
89651841|NCT03368118|Experimental|ABX464 Treatment arm|All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.
89651842|NCT03611946|Experimental|rZIKV/D4Δ30-713 (10^3)|Participants will receive a single dose of rZIKV/D4Δ30-713 at study entry (Day 0).
89651843|NCT03611946|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
89651844|NCT03611946|Experimental|rZIKV/D4Δ30-713 (10^4)|Participants will receive a single dose of rZIKV/D4Δ30-713 or placebo at study entry (Day 0).
89651845|NCT02311621|Experimental|A: 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
89651846|NCT02311621|Experimental|B: 3rd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
89651847|NCT02311621|Experimental|C: Long Spacer 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
89651848|NCT01395017|Active Comparator|Group 1|One arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus dasatinib 100 mg by mouth once daily (QD).
89651849|NCT01395017|Placebo Comparator|Group 2|The other arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus matched placebo by mouth once daily (QD).
89651850|NCT04444453|Experimental|Pedometer|Admitted patients who receive a pedometer to wear during their hospital stay to measure steps ambulated
89045742|NCT05931796|Active Comparator|Group B|ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
89045744|NCT05923333|Active Comparator|B. infantis Rosell®-33|Participants will receive 8 x 109 CFU B. infantis Rosell®-33 per dose (single microbial active ingredient) and carrier material (maltodextrin) for 28 days from day 1-3 of life.
89045745|NCT05923333|Placebo Comparator|Placebo|Participants will receive placebo (containing all materials besides B. infantis Rosell®-33) for 28 days from day 1-3 of life.
89045746|NCT05921955|No Intervention|air group|the patients of the air group receive the 2L/min with air pattern by the Optiflow high-flow nasal cannula system from anesthesia to fetal delivery.
89045747|NCT05921955|Experimental|HFNO group|For HFNO group, a flow rate of 40L/min, with 100% oxygen concentration and a temperature of 37℃ by the Optiflow high-flow nasal cannula system from anesthesia to fetal delivery.
89045748|NCT05919472|Experimental|Pre-treatment group|Participants assigned to this group will receive 200 mg oral iron on alternate days on study days 1-56.
89045749|NCT05919472|Experimental|Simultaneous treatment group|Participants assigned to this group will receive placebo on alternate days on study days 1-28 and 200 mg oral iron on alternate days on study days 29-56.
89045750|NCT05919472|Placebo Comparator|Control group|Participants assigned to this group will receive placebo on alternate days on study days 1-56.
89212962|NCT00994773|Experimental|Simvastatin and tenofovir|Simvastatin combined with tenofovir
89651851|NCT04444453|No Intervention|Control|Patients admitted to hospital who do not receive a pedometer, but receive all other usual standard of care
89212963|NCT00994773|Experimental|Simvastatin and entecavir|Simvastatin combined with entecavir
89212964|NCT05405543|Experimental|Arm 1|
89212965|NCT05405543|Experimental|Arm 2|
89212966|NCT05405543|Experimental|Arm 3|
89651852|NCT04276753|Experimental|Terminalia Chebula fruit extract|"The test product is an emulsion. It contains Terminalia Chebula fruit extract.~Test product will be applied topically on full face twice a day for 8 weeks."
89651853|NCT04276753|Placebo Comparator|Placebo|"The placebo product is an emulsion with same appearance as the experimental product but without Terminalia Chebula fruit extract.~Placebo emulsion will be applied topically on full face twice a day for 8 weeks."
89651854|NCT03670134|Experimental|Volumetric laser Endomicroscopy (VLE)|Volumetric laser Endomicroscopy (VLE) is a second-generation optical coherence tomography platform that can image the human esophagus in cross-section at microscopic resolution this will performed by using the Nvision VLE Imaging System.
89651855|NCT03235986|Experimental|nCPAP+ Nebulised Curosurf®|Curosurf® administered through nebulization
89212967|NCT05405543|Experimental|Arm 4|
89212968|NCT00995631|No Intervention|Premenopausal, Control|Premenopausal women randomized to Control (delayed liposuction surgery)
89212969|NCT00995631|Active Comparator|Premenopausal, Surgery|Premenopausal women randomized to surgery (femoral lipectomy)
89212970|NCT00995631|No Intervention|Postmenopausal, Control|Postmenopausal women randomized to Control (delayed liposuction surgery)
89651856|NCT03235986|Other|nCPAP alone (control)|Standard of care, respiratory support used also during experimental arms
89651857|NCT03630822|Experimental|beneficiary of the advance directive program|
89212971|NCT00995631|Active Comparator|Postmenopausal, Surgery|Postmenopausal women randomized to surgery (femoral lipectomy)
89651858|NCT03630822|Active Comparator|beneficiary of standard Support|
89651859|NCT03137394||Spinal Cord Injury|Participants with SCI in the acute, in-patient rehabilitation phase.Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury;
89651860|NCT03137394||Able-bodied control|Age- and gender-matched able-bodied individuals (matched to SCI group). Control group data will be collected at baseline and at the 1-year follow-up.
89651861|NCT03606798|Experimental|Multidisciplinary and personalized care|Personalized care and proposals bring by a team of experts : neurologists ; geriatrician ; psychologist.
89651862|NCT03606798|No Intervention|Reference care|Standard clinical evaluations of patient with Frontotemporal Lobar Degeneration.
89651863|NCT04488354|Experimental|CLBR001 treated patients|Patients who have been administered with CLBR001
89651864|NCT03600090|Experimental|Arm EOC202 + Paclitaxol|"Biological: EOC202 This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Two EOC202 dose levels (6 mg and 30 mg) will be evaluated in two cohorts of 18 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 48 weeks (12 s.c. injections in total), separated by 13-day intervals free of EOC202 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
89651865|NCT05148858||Cases|Patients affected by COVID-19 infection
89651866|NCT05148858||Control|Normal subjects not affected by COVID-19 infection
89651867|NCT03103230|Experimental|Motor Evoked Potentials|Patients with aphasia after a stroke
89651868|NCT04479852|Experimental|SP-624|Daily oral capsule, 20 mg/day
89651869|NCT04479852|Placebo Comparator|Placebo|Daily oral capsule
89651870|NCT02912988|Experimental|Letrozole group|"Letrozole + standard treatment:~Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration."
89651871|NCT02912988|No Intervention|Control group|"Standard treatment:~Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration."
89651872|NCT03102840||Children nasal swab only|Pneumococcal nasopharyngeal carriage in children aged 6-48 months who have previously received PCV13
89651873|NCT03102840||Children nasal swab + serum|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
89651874|NCT03103074|Experimental|Botulinum B Toxin|Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
89651875|NCT03103074|Placebo Comparator|Placebo|Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention
89212972|NCT00995787|Experimental|AZD1656|
89212973|NCT00995787|Placebo Comparator|Placebo|
89212974|NCT04079153|Active Comparator|25% of maximal mandibular advancement|25% of maximal mandibular advancement of individual protrusion range
89212975|NCT04079153|Active Comparator|50% of maximal mandibular advancement|50% of maximal mandibular advancement of individual protrusion range
89212976|NCT00994851|Experimental|SENNA+ CASSIA|Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days
89212977|NCT00994851|Placebo Comparator|Placebo|Daily administration (capsule) of placebo at bedtime, during 30 days
89212978|NCT04411745||Parturition|Healthy women who are carrying a healthy singleton pregnancy, but have not yet gone to labor at 40 weeks of gestation or who are at term and admitted to hospital for any sign of labor.
89212979|NCT04001127|Experimental|High Intensity Functional Training|Intervention group assigned to 16 weeks of group-based high intensity functional training supervised by physiotherapists.
89651876|NCT04882644|Experimental|Aerobic Exercise Intervention Group|The subjects receive an intensive aerobic exercise for 3 months and a health education content for 12 months.
88993484|NCT00519688|Experimental|Thalidomide plus Tegafur/Uracil1|Thalidomide plus Tegafur/Uracil
88993485|NCT02948803|Experimental|Intervention group|smartphone based intervention with Active Coach app: participants in the intervention group will use a newly developed smartphone app in combination with a Fitbit Charge activity tracker for 9 weeks. The app aims to promote an active lifestyle.
88993486|NCT02948803|No Intervention|control group|participants in the control groups only receive a flyer with standard information about an active lifestyle
88993487|NCT02948920|Experimental|Ephedrine|Intravenous 9 mg of ephedrine (3 ml) given at finishing local anesthetic administration for spinal anesthesia
88993488|NCT02948920|Placebo Comparator|NSS|Intravenous normal saline 3 ml given at finishing local anesthetic administration for spinal anesthesia
88993489|NCT02948764|Other|single-arm study|This project is designed as a one-armed diagnostic study. Every patient included in the study will undergo the same diagnostic test, the vacuum-assisted biopsy, after NACT and before surgery according to guidelines.
88993490|NCT00519727|Experimental|A|50 mg ISIS 325568 vs Placebo, s.c. injection
88993491|NCT00519727|Experimental|B|100 mg ISIS 325568 vs Placebo , s.c. injection
88993492|NCT00519727|Experimental|C|200 mg ISIS 325568 vs Placebo , s.c. injection
88993493|NCT00519727|Experimental|D|400 mg ISIS 325568 vs Placebo, s.c. injection
88993494|NCT00519727|Experimental|AA|50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
88993495|NCT00519727|Experimental|BB|100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
88993496|NCT00519727|Experimental|CC|200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
88993497|NCT00519727|Experimental|DD|400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
88993498|NCT00151827|Experimental|Olmesartan medoxomil|Olmesartan oral tablets 20 mg or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
88993499|NCT00151827|Experimental|Losartan|Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.
88993500|NCT00519883|Active Comparator|A|Arm A: Standard Supportive Care (no supervised exercise)
88993501|NCT00519883|Experimental|B|Arm B: Exercise Intervention
88993502|NCT00519922|Experimental|1|KBA = Kinesthesia, Balance, Agility Exercise Training
88993503|NCT00519922|Active Comparator|2|Standard Lower Extremity Strength Training
88993504|NCT04457180|Experimental|treatment|"In phase A, subjects receiving a single dose of Repaglinide orally on day 1 , a single dose of Bupropion orally on day 2 and wash-out for 10 days, then apatinib once daily will be conducted on D5 through D16~# In addition, In phase B, subjects receiving a single dose of Repaglinide (in combination with apatinib) orally on day 12 , a single dose of Bupropion (in combination with apatinib) orally on day 13."
88993505|NCT00519961|Experimental|A|
88993506|NCT00519961|Experimental|B|
88993507|NCT00520000|Active Comparator|Weekly Arm|Carboplatin day 1, abraxane days 1, 8, 15 every 28 day cycle
88993508|NCT00520000|Experimental|Every 3 week Arm|Carboplatin day 1, abraxane day 1, every 21 day cycle
88993509|NCT00520000|Experimental|Arm C|Carboplatin day 1, abraxane day 1, 8 every 21 day cycle
88993510|NCT04453982||Human milk donors|
88993511|NCT00520117||negative pap-smear|
88993512|NCT00520117||positive pap-smear|
88993513|NCT02949115|Experimental|70 mL red beetroot juice|70 mL red beetroot juice naturally containing 300 mg nitrate.
88993514|NCT02949115|Active Comparator|70 mL placebo drink plus potassium nitrate|70 mL calorie-matched placebo control drink containing 489 mg potassium nitrate to deliver 300 mg nitrate.
89651877|NCT04882644|No Intervention|Control Group|The subjects do not change their physical activity routine and receive a health education content for 12 months.
89651878|NCT03577938|Experimental|Chinese herbal medicine|One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).
88993515|NCT02949115|Active Comparator|70 mL red beetroot juice without nitrate|70 mL red beetroot juice per day without nitrate.
88993516|NCT02949115|Placebo Comparator|70 mL placebo drink|70 mL calorie-matched placebo control drink devoid of nitrate, vitamins, minerals, and polyphenols.
88993517|NCT00520273|Experimental|A|
88993518|NCT02949037|Experimental|Intervention|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, integrated with the mobile health care environment (MHCE) system. The MHCE system will provide tailored behavioral messages triggered by clinical values and survey responses.
88993519|NCT02949037|No Intervention|Control|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, NOT integrated with the mobile health care environment (MHCE) system.
88993520|NCT00520429|Other|1|This study is an open pilot; therefore all participants were given the opportunity to receive treatment.
88993521|NCT00520507|Experimental|1|
88993522|NCT00520507|Placebo Comparator|2|
88993523|NCT04694404|Experimental|S-1 Plus Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-10, q2w)
88993524|NCT04694365|Experimental|Normal Hepatic Function|
88993525|NCT04694365|Experimental|Mild Hepatic Impairment|
88993526|NCT04694365|Experimental|Moderate Hepatic Impairment|
88993527|NCT04406597|Experimental|the New Tissue Containment System group|Using the New Tissue Containment System during Laparoscopic Ovarian Cystectomy
88993528|NCT04406597|No Intervention|Open group|Without any protection system during Laparoscopic Ovarian Cystectomy
88993529|NCT02948413||Single Group of patients with Cancer|Patients with cancer (lymphoma, leukemia, prostate cancer, and mesothelioma) on clinical trials at the NIH Clinical Center.
88993530|NCT00151983|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 27.5mg, 41.3mg, 55mg, and 82.5mg patches applied daily for 8 weeks
88993531|NCT00151983|Placebo Comparator|Placebo patch|Placebo patch applied daily for 8 weeks
88993532|NCT04392674|Experimental|using the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
88993533|NCT02948374||Delirium positive|Patients with a positive CAM-ICU test
88993534|NCT02948374||Delirium negative|Patient without delirium determined with the CAM-ICU test
88993535|NCT00520624|Experimental|1|Treatment 1, for those with high degree of EIL
88993536|NCT00520624|Experimental|2|Treatment 2, for those with high degree of EIL
88993537|NCT00520624|No Intervention|3|Control group of those with high degree of EIL
88993538|NCT00520624|Experimental|4|Treatment 1, for those with low degree of EIL
88993539|NCT00520624|No Intervention|5|Control group of those with low degree of EIL
88993540|NCT00520663|Experimental|Healthy male subjects|Each subject will receive a single oral dose of 14C-SB649868 (containing approximately 70 microcuries of radiocarbon and 30 milligrams of SB649868).
88993541|NCT03459001||Tube Fed Malnourished Outpatients|Outpatients that are malnourished or at risk of malnutrition and have been placed on a nutritional care plan, which includes a complete tube feeding formula as sole source nutrition
88993542|NCT00520702|Active Comparator|3D CRT|3-Dimensional Conformal Radiation Therapy (3D CRT)
88993543|NCT00520702|Active Comparator|IMRT|Intensity-Modulated Radiation Therapy (IMRT)
88993544|NCT00520780|Experimental|1|
88993545|NCT00520780|Placebo Comparator|2|
88993546|NCT04723797|No Intervention|Control group|The participants in the control group will be asked to maintain their lifestyle as before the study.
88993547|NCT04723797|Experimental|Moderate-intensity group|Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 150min/week. This at a moderate intensity, which means a slightly increased heart rate and breathing also talking is possible.
88993548|NCT04723797|Experimental|Vigorous-intensity group|Participants will be asked to perform a physical activity program, consisting of cycling and/or running for 6 weeks of at least 75min/week. This at a vigorous intensity, which means increased heart rate and breathing also talking is possible.
88993549|NCT00520858|No Intervention|C|
88993550|NCT00520858|Active Comparator|RE|Resistance Exercise
88993551|NCT00520858|Active Comparator|AE|Aerobic Exercise
88993552|NCT00520858|Active Comparator|RAE|Resistance and Aerobic
88993553|NCT00520897|Experimental|MK0518 + cART|Raltegravir + standard of care combined antiretroviral therapy
88993554|NCT00520897|Placebo Comparator|Placebo + cART|Placebo + standard of care combined antiretroviral therapy
88993555|NCT00521092|Experimental|Arm I|Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
88993556|NCT04376606|Experimental|Left atrial appendage closure group|
88993557|NCT04376606|Experimental|Radiofrequency ablation group|
88993558|NCT04376606|Experimental|LAAC combined with radiofrequency ablation group|
88993559|NCT04694092|Experimental|Intensive rate control with landiolol|Intensive heart rate control using landiolol with the goal to achieve HR<115 during the first 2 hours.
88993560|NCT04694092|Active Comparator|Standard therapy|Standard heart rate control with therapy other than landiolol
88993561|NCT04376489|Experimental|Brief cognitive/behavioral strategies|
88993562|NCT04376489|Experimental|Effortful self-regulatory activities|
88993563|NCT04376489|No Intervention|No activities|
88993564|NCT04424147|Experimental|HVA treatment|All patients with rrAML are treated with HVA regimen
89212980|NCT04078607|Experimental|Distraction|Distraction during eating using the Rapid Visual Information Processing task as the distraction
89212981|NCT04078607|Placebo Comparator|Control|No distraction during eating
89651879|NCT03577938|Other|Control (blank)|Patients in the control group only receive the standard medical treatment (SMT), no control drug with CHM.
89651880|NCT03103308|Experimental|Walk training and transplant|Multidirectional walk training with activity monitoring after bone marrow transplant
89212982|NCT05198505|Experimental|TQB2868 Injection|The drug was administered once every 3 weeks (administration time window: ± 3 days), the dose of each administration was 1.5-600 mg, and 3 weeks was a treatment cycle until the disease progressed or the investigator judged that it was not suitable to continue the drug use.
89651881|NCT03103308|Experimental|Activity Monitoring and transplant|Activity monitoring alone after bone marrow transplant.
89651882|NCT00876915|Experimental|High Risk for VTE recieving dalteparin|Patients assigned at random to receive prophylactic dalteparin injections
89651883|NCT00876915|No Intervention|High Risk for VTE No therapy|No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
89651884|NCT00876915|No Intervention|Low Risk for VTE|Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples
89212983|NCT04078841|Active Comparator|ReaLife+ (RLP)|Dietary Supplement: ReaLife+ (RLP) RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids
89651885|NCT03573414|Experimental|Healthy men and women|"Intervention:~2*breakfast containing 40 g of raspberry powder, 30 g milled flax seeds and 250 mL of soy Milk."
89651886|NCT03555942|Active Comparator|Early follicular phase protocol|On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
89651887|NCT03555942|Experimental|Luteal phase protocol|Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
89651888|NCT03103386|Experimental|Fermented Rye Bran group|Intake of food product with a patented fermented rye bran: A patented fermented rye bran ingredient for food purpose has been produced through a process where a specific Lactobacillus curvatis strain was incubated with rye bran by Kampffmayer Food Innovation GmbH, Germany. The dried fermented rye bran was incorporated into a whole grain rye crisp bread product (25% on weight basis) commercially available in Sweden and in a novel extruded whole grain rye product (20%) developed by Lantmännen.Two crisp rye bread pieces (2 x 12g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily. Rye puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily. Total energy: 518 kcal/day.
89212984|NCT04078841|Placebo Comparator|Inert Brown Powder|"Brown powder~Inert brown powder to look similar to RLP"
89212985|NCT04078841|No Intervention|Control|Control
89212986|NCT03742869||Patients with HPV integration|The HPV integration status will be checked by GWAS.
89212987|NCT03742869||Patients without HPV integration|The HPV integration status will be checked by GWAS.
89212988|NCT02583191|Experimental|Rivaroxaban|Arm A: Rivaroxaban
89212989|NCT02583191|Active Comparator|low-molecular heparine|Arm B: standard treatment with low-molecular heparine
89212990|NCT04000893|Experimental|Resistance exercise session|Acute isometric session, about 20 minutes.
89212991|NCT04000893|Active Comparator|Aerobic exercise session|Acute aerobic session, about 20 minutes.
89212992|NCT04078217|Experimental|Jintronix|Jintronix Rehabilitation System uses Microsoft Kinect cameras to track patient's movements in 3D during exercises. They are programmed as games that are visualized on a TV and for which performance feedback is provided to the participant. Individualized asynchronous supervised home-base exercise program using the Jintronix System, 3 times/week for 12 weeks (36 sessions). A trained kinesiologist will install the system and supervise the exercise program, in person and remotely.
89212993|NCT04078217|Active Comparator|Control|Participants in this group will follow an individualized non-supervised home-based exercise program (booklet format). The exercise program will include 3 sessions per week for 12 consecutive weeks, as for Jintronix group. Actually, all movements of the booklet program are selected to match the exercise-games of the technology (similar movement, muscles engagement, etc.). A trained kinesiologist will explain and supervise the exercise program for the first sessions. The communication frequence will be the same as the Jintronix group.
89212994|NCT02582723|Active Comparator|High protein/high fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
89212995|NCT02582723|Active Comparator|High protein/low fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
89212996|NCT02582723|Experimental|Low protein/high fat creme cheese|Served for breakfast together with bread, juice and coffee, tea or water
89212997|NCT05347329|Placebo Comparator|Control Arm 1|Placebo (starch) in 3 capsules size 1 (0 mg of active ingredient), administered orally once daily on empty stomach with plenty of water.
89212998|NCT05347329|Experimental|400 mg Tongkat Ali+ 200 mg Maca (Experimental Arm 2)|The content of 2 capsules of Tongkat Ali Maca (600 mg of active ingredient), Plus is equally distributed and inserted into 3 capsules size 1 (low dose), administered orally once daily with plenty of water.
89212999|NCT05347329|Experimental|600 mg Tongkat Ali+ 300 mg Maca ( Experimental Arm 3)|The content of 3 capsules of Tongkat Ali Maca Plus (900 mg of active ingredient), is equally distributed and inserted into 3 capsules size 1 (high dose), administered orally once daily with plenty of water.
89213000|NCT02582567|Experimental|Exercise intervention|3 times per week from the 17th week of gestation until delivery
89213001|NCT02582567|No Intervention|Control group|Usual care (control) group
89213002|NCT05347017|Experimental|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using HCL acid as demineralized dentin block graft and inserted in the extraction socket
89213003|NCT05347017|Active Comparator|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non-restorable teeth, then autogenous bone block will be harvested from the maxillary tuberosity and reshaped and inserted in the extraction socket
89213004|NCT04403009||the nonsevere Coronavirus Disease 2019 Patients|
89651889|NCT03103386|Placebo Comparator|Refined Wheat group|Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
89651890|NCT04381845|Other|psychiatric patient|patients who are hospitalized in psychiatric department
89651891|NCT02854488||Women Exposed to Yervoy (ipilimumab) During Pregnancy|Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
89651892|NCT03102528||Cardiac Surgery Patients|All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015
89651893|NCT03102606|Active Comparator|Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin|
89651894|NCT03102606|Experimental|Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim|
89651895|NCT03102684|No Intervention|No exposure|No exposure to secondhand exposure to aerosols produced by e-cigarettes
89651896|NCT03102684|Experimental|Low exposure|Secondhand exposure to e-cigarette aerosols (low)
89651897|NCT03102684|Experimental|High exposure|Secondhand exposure to e-cigarette aerosols (high)
89651898|NCT04380909|Experimental|Internet-based self-help|The self-help program consists of six text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
89651899|NCT04380909|Other|Waiting control group|Access to internet-based intervention after 3 weeks.
89651900|NCT00896181|Experimental|Chemoradiation for Nasopharyngeal Carcinoma|"INDUCTION THERAPY: Patients receive docetaxel intravenously (IV) over 60 minutes on Day 1; cisplatin IV over 1 to 3 hours (or carboplatin IV over 30 minutes) on Day 1; and fluorouracil IV continuously over 24 hours on Days 1 to 5. Each cycle is 21 days, with treatment consisting of up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMO-RADIOTHERAPY: Beginning within 3 to 6 weeks after initiating the last course of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily for 6.5 to 7 weeks. Patients also receive cisplatin IV over 1 hour (or carboplatin IV over 30 minutes) once weekly in weeks 1 to 6 in the absence of disease progression or unacceptable toxicity."
89651901|NCT02647320|Experimental|DS-8500a 25mg|One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose
89651902|NCT02647320|Experimental|DS-8500a 50 mg|Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose
88993565|NCT00521248|Active Comparator|Oral morphine solution|Oral morphine solution
89213005|NCT04403009||the severe Coronavirus Disease 2019 Patients|
89213006|NCT00998907|Active Comparator|PDS II|PDS II® loop suture is used for abdominal wall closure
89213007|NCT00998907|Experimental|PDS plus|"antibacterial coated PDS plus is used for abdominal wall closure"
89651903|NCT02647320|Experimental|DS-8500a 75 mg|Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose
89651904|NCT02647320|Placebo Comparator|Placebo|Three placebo tablets and one placebo capsule in a once-daily oral dose
89651905|NCT02647320|Active Comparator|Sitagliptin 100 mg|Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose
89651906|NCT05311137||Closed-loop Group|Groups of Patients Adhering to Closed-Loop Therapy.
89651907|NCT05311137||No Closed-loop Group|Patients who have not undergone closed-loop treatment or patients who have not undergone standard surgery and medication.
89651908|NCT05311137||Exchange Group|Groups of patients with delayed compliance with closed-loop therapy for atrial fibrillation.
88993566|NCT00521248|Experimental|Buprenorphine|Sublingual buprenorphine
88993567|NCT00521287|Other|Early (E)|Early stage cancer
89213008|NCT03084237|Experimental|HLX02+docetaxel|
89213009|NCT03084237|Active Comparator|Herceptin®+docetaxel|
89213010|NCT02584907|Experimental|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
89213011|NCT02584907|No Intervention|Standered Enteral Nutrition|Diet in standard group will be 20% from protein, 30% from fat and 50% from carbohydrate
89213012|NCT04620629||control group|Late premature and term babies without any disease
89213013|NCT04620629||probiotic group|Babies whose probiotic support is started and continues because they cannot receive breast milk, and whose antibiotic treatment is started in the neonatal period.
89213014|NCT04620629||antibiotic group|Babies who receives antibiotic treatment in the neonatal period and does not receive probiotic support before.
89213015|NCT00996021|Experimental|Arm 1|This is a three way crossover study with 3 periods. Subjects will receive a single dose of either GSK1349572 250 mg suspension, placebo suspension or moxifloxacin 400 mg tablet in each of the three periods. The order in which the treatments are given will be randomized. There is a screening visit within 30 days prior to the first dose of study drug and a follow-up visit within 10-14 days after the last dose of study drug.
89213016|NCT00996099|Active Comparator|CGM-eMPC|
89213017|NCT00996099|Other|Control|
89213018|NCT02582645|Experimental|OWT - open window technique|In this arm, a palatally impacted canine will be exposed surgically and left for max 9 months. No traction will be applied during this time.
89651909|NCT03215355|Experimental|Participants receiving Primovist|Because this is a proof of concept study, only one arm will be considered which is the patients that receive the one time contrast injection prior to their first treatment. The intervention is that although this drug is approved, an off label dosing regiment is being used to improve a separate imaging modality than what it was approved for. Based on preliminary phantom experiments and toxicity results in the literature, four times the dose was deemed safe and required to use for CBCT.
89651910|NCT03837795|Experimental|Neurofeedback therapy group|
89651911|NCT03830697|Experimental|Menstruation situation TCM symptom score standard|
89651912|NCT03830697|Placebo Comparator|Sham intervention|
89651913|NCT04381065|Experimental|PKG+ Group|For subjects in the PKG+ Group, participants will wear the PKG watch prior to all study visits in which the study investigator will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment.The PKG will be used to determine if the subject is in the target range or out of the target range based on scores provided by the PKG.
89651914|NCT04381065|Placebo Comparator|PKG- Group|For subjects in the PKG- Group, participants will wear the PKG watch prior to all study visits, however the investigator will not have access to the PKG report and will use standard of care to determine clinical treatment plans.
89651915|NCT03457896|Experimental|Arm 1|"Guardant360 test on blood from select patients with known HER2 status.~Prior to assignment to Arm 1, HER2 test on blood obtained from Quadruple Wild-Type patients who received anti-EGFR therapy. Patients with HER2 amplified, HER2 Wild-Type or HER2 mutated will recieve:~• Neratinib daily + Trastuzumab weekly until disease progression"
88993568|NCT00521287|Other|Advanced (A)|Advanced stage cancer (Stage IV without treatment)
88993569|NCT00521287|Other|Terminal (T)|Terminal stage cancer (Stage IV with chemotherapy)
89651916|NCT03457896|Experimental|Arm 2|"Patients with HER2 Wild Type or HER2 amplified with no prior anti-EGFR therapy will receive:~• Neratinib daily + Cetuximab weekly until disease progression"
89651917|NCT04380597||Patients with nail psoriasis|Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.
88993570|NCT00521326||A|Patients with an acute coronary syndrome that are candidates for coronary angiography. Doppler results will be compared to angiographic findings.
88993571|NCT04370990|Active Comparator|Active|Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
88993572|NCT04370990|No Intervention|controle|Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously
88993573|NCT02948491|Experimental|Music therapy|First. Recording of the voice of the mother singing the song to the child. (To choose this option, the song must be sung to the child during pregnancy at least 2 to 3 times per week. Second. The mother's favorite song, obtained externally. (To choose this option, the mother must bring the song that she that she listened to frequently, at least 5 times per week). Third. Pre-determined lullaby. (This option refers only to the lullaby melody or Brahms lullaby, edited to obtain stable volumes and normalization of the audio, with the effect of progressively appearing and fading for the first and last 10 seconds of the intervention with music therapy, so there are no drastic acoustic changes in the intervention. Audacity editing software will be used.)
88993574|NCT02948491|No Intervention|Without sound emission|"The infant does not receive any sound emission because the baffle will be turned off.~One of the three intervention options are chosen. The parents are told that their child may be randomly assigned to either the therapeutic or control group."
88993575|NCT00521443||Normal|Embryos derived from morphologically normal MII oocytes
88993576|NCT00521443||Irregular Shapes|Embryos derived from irregularly shaped oocytes.
88993577|NCT00521443||Large PVS|Embryos derived from oocytes with large perivitelline space.
88993578|NCT00521443||Dark Zona|Embryos derived from oocytes with dark zona pellucida
88993579|NCT00521443||Dark cytoplasm|Embryos derived from oocytes with dark cytoplasm
88993580|NCT00521443||Vacuolar cytoplasm|Embryos derived from oocytes with vacuolated cytoplasm
88993581|NCT00521443||Central granulation|Embryos derived from oocytes with centrally granulated cytoplasm
88993582|NCT00521443||Double extra|Embryos derived from oocytes with double extracytoplasmic abnormalities
88993583|NCT00521443||Double combined|Embryos derived from oocytes with any combination of one extracytoplasmic and one cytoplasmic anomaly
88993584|NCT00521443||Double cytoplasmic|Embryos derived from oocytes with any two cytoplasmic anomalies
88993585|NCT00521443||Triple extra|Embryos derived from oocytes with triple extracytoplasmic anomaly
88993586|NCT00521443||Triple combined|Embryos derived from oocytes with triple combined anomalies
88993587|NCT00167154|Experimental|risperidone|risperidone
88993588|NCT00167154|Placebo Comparator|placebo|placebo comparator
88993589|NCT04320563|Active Comparator|Full power treatment 4|These group of participants will receive the full power treatment 4
88993590|NCT04320563|Placebo Comparator|Comparative Power 1|These group of participants will receive the comparative power 1 treatment
88993591|NCT00521482|Active Comparator|A|Temozolomide 75 mg/m2 daily for 21 days during each 28-day cycle until tumor progression.
88993592|NCT00521482|Experimental|B|Temozolomide 200 mg/m2 for 5 days during each 28-day cycle plus Thalidomide 100 mg for 2 weeks, thereafter 200 mg daily continuously until tumor progression.
89651918|NCT00879255|Experimental|Videoteleconferencing CPT|"The experimental arm is the group condition that received the CPT treatment via videoteleconferencing modality as compared to the experimental condition which is via face-to-face traditional modality.~Cognitive Processing Therapy Group Videoteleconference is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference."
89651919|NCT00879255|Active Comparator|Face-to-Face CPT|"The control arm is the group condition that received the CPT treatment via face-to-face traditional modality as compared to the experimental condition which is via videoteleconferencing modality.~Cognitive Processing Therapy Group In-Person is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference."
89651920|NCT04546698||Multiple Sclerosis patients with an acute relapse|Multiple Sclerosis diagnosed according to Mc Donald's criteria with an acute relapse
89045751|NCT05918094|Experimental|Modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W. After 6 cycles of treatment, patients could choose capecitabine + sintilimab maintenance with a maximum treatment duration of 2 years.
89045752|NCT05918094|Active Comparator|Standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W. After 6 cycles of treatment, patients could choose capecitabine + sintilimab maintenance with a maximum treatment duration of 2 years.
89045753|NCT05905068|Active Comparator|Cohort 1 will be 25 mg RN0191 (or placebo)|
89045754|NCT05905068|Active Comparator|Cohort 1 will be 100 mg RN0191 (or placebo)|
89045755|NCT05905068|Active Comparator|Cohort 1 will be 300 mg RN0191 (or placebo)|
89045756|NCT05905068|Active Comparator|Cohort 1 will be 500 mg RN0191 (or placebo)|
89045757|NCT05900245|Active Comparator|Group H：IoC1 60-70|This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg， following by mask pressurized oxygen supply，dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 60 and 70. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System，manufacturer：SOMATICS, USA；Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.
89045758|NCT05900245|Active Comparator|Group M: IoC1 50-60|This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg， following by mask pressurized oxygen supply，dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 50 and 60. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System，manufacturer：SOMATICS, USA；Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.
89045759|NCT05900245|Active Comparator|Group L：IoC1 40-50|This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg， following by mask pressurized oxygen supply，dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 40 and 50. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System，manufacturer：SOMATICS, USA；Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.
89045760|NCT05898607|Active Comparator|Group A|Patients will receive Loading dose of 20 ml 0.25% bupivacaine then continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative
89045761|NCT05898607|Active Comparator|Group B|Patients will receive Loading dose of 20 ml 0.25% bupivacaine then continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
89045762|NCT05892744|Other|Sertraline hydrochloride, up to 200mg/day or maximum tolerable dose|Established FDA-approved treatment for major depressive disorder
89045763|NCT05873439|Experimental|Arm A: RSI predicts dose ≤ 60 Gy|Participants will receive standard RT dose of 60Gy in 30 fractions targeting the primary tumor and any involved regional lymph nodes.
89045764|NCT05873439|Experimental|Arm B: RSI predicts dose > 60 Gy|Participants will receive treatment with RxRSI guided boost to the primary tumor up to 81Gy (2.7Gy/fraction).
89045765|NCT05873439|Experimental|Arm C: unable to calculate RSI|Participants in will receive standard RT dose of 60Gy in 30 fractions targeting the primary tumor and any involved regional lymph nodes.
89045766|NCT05864118|Experimental|Saliva passive drool|Participant is asked to spit saliva, through a straw, into a micro centrifuge tube. This specimen will undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing.
89651921|NCT04546698||Multiple sclerosis pataients treated with Natalizumab|Multiple Sclerosis patients diagnosed according to Mc Donald's criteria and treated with Natalizumab since 6 cures
89651922|NCT04546698||Healthy people|
89651923|NCT03458325|Experimental|Furoscix Infusor Prospective Treatment|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
89651924|NCT03458325|No Intervention|Propensity-Matched Historical Control|The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.
89045767|NCT05864118|Experimental|Oral Capsule saliva|Participant is asked to chew on a study device (Oral Capsule) with their molar teeth which will draw saliva into the device's internal specimen chamber. This specimen will undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing.
89045768|NCT05864118|Experimental|NP saline wash by study device|Participant will receive a nasopharyngeal wash with sterile saline. The irrigation saline is recollected into the device's internal specimen chamber. This specimen will undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing.
89651925|NCT04382157|Experimental|Mablet|Mablet 360 mg. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
89651926|NCT04382157|Placebo Comparator|Placebo|Placebo. Twice daily for 4 weeks. If tolerated trice daily for following 20 weeks. Treatment for 24 weeks in total.
89651927|NCT00880425||Participants with continuous headache|
89651928|NCT00880425||Participnts with non-continuous headache|
89651929|NCT03214965|Active Comparator|Facebook group|Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
89045769|NCT05864118|Experimental|Blood by standard finger stick method|Participant is asked to provide approximately 60 uL of blood via a capillary finger stick. This specimen will undergo COVID-19 antibody testing.
89045770|NCT05860036|Experimental|VRd-based regimen Combined With BCMA CART|"VRd：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle.~Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10^6 anti-BCMA CAR+T cells/kg.~Participants will receive VRD induction, BCMA CAR-T infusion, VR consolidation, R maintenance."
89045771|NCT05850013||Sub Protocol 1|Sub protocol 1 - Blood pressure measured in participants who are able to cooperate and are relatively still Within each study session, compliant participants will have their blood pressure measured using standard-of-care equipment and methods during the same 60 seconds that their other vital signs are measured
89045772|NCT05850013||Sub protocol 2|OPTIONAL Sub protocol 2: Electrocardiogram (ECG) for measurement of Heart rate variability This sub-protocol is relevant for children who would benefit from having a 3-lead ECG to capture beat to beat variability. This will be done in a subset of the participants, and ideally on a subsequent that is representative of the full cohort of participants in terms of age profile, skin tone distribution and illness.
89045773|NCT05850013||Sub protocol 3|The questionnaire will ask questions related to vital sign monitoring habits and preferences, or not, of Lifelight®-type technologies for measuring vital signs instead of standard-of-care methods.
89045774|NCT05847582|Experimental|mSTARS|Participants randomized to the mSTARS condition will receive standard inpatient care while hospitalized at Duke. They will also receive an intervention that combines inpatient skills training and the mHealth telephone app. Inpatient emotional regulation skills training will be completed while participants are receiving inpatient treatment at Duke. Upon discharge from Duke, patients will download the mHealth app on their personal phones to use in their personal environments for 30 days. The app is designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.
89045775|NCT05847582|Active Comparator|Treatment As Usual|Participants randomized to the treatment-as-usual condition will receive standard inpatient care provided at Duke.
89045776|NCT05847582|Active Comparator|Treatment As Usual + Skills Training|Participants randomized to this condition will receive standard inpatient care and inpatient emotional regulation skills training.
89651930|NCT03214965|No Intervention|Control group|Patients of the kidney transplantation group that do not receive specific educational interventions.
89045778|NCT05836090|Experimental|Family Spirit Strengths (FSS)|FSS participants will receive 4-16 (average of 6-8) intervention visits covering topics related to their mental and behavioral health. The number of sessions each participant receives varies and depends on their unique needs. To guide this process, all intervention participants will take a brief, in-session survey to screen for current challenges they may be facing. Their answers will help determine the content and dose of future sessions.
89651931|NCT03214731|Experimental|low dose Art|25mg bid Artesunate and standard of care was given to patients
89213019|NCT02582645|Active Comparator|CWT - closed window technique|In this arm, a palatally impacted canine will be exposed surgically, an attachment will be bonded to the tooth and traction will be applied after healing period is complete (1-2 weeks).
89651932|NCT03214731|Experimental|high dose Art|50mg bid Artesunate and standard of care was given to patients
89651933|NCT03214731|Placebo Comparator|placebo|Placebo and standard of care was given to patients
89651934|NCT02604108|Experimental|Physical Exercise|Physical Exercise: Participants will receive training and health messages on positive psychology and healthy living style focusing on physical activity.
89651935|NCT02604108|Experimental|Healthy Diet|Healthy Diet: Participants will receive training and health messages on positive psychology and healthy living style focusing on healthy diet.
89651936|NCT00897897|Other|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure receive a treatment with the Philips MRI-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
89651937|NCT00858078||Previously referred|Previously-enrolled subjects from NCI Protocol 01-C-0009
89651938|NCT00858078||Self-referred|Self-referred women at increased familial risk of breast and ovarian cancer were recruited through an hereditary breast/ovarian cancer advocacy group
89651939|NCT04424862|Experimental|Multitarget Therapy|The combined therapy with prednisone, ciclosporin and mycophenolate mofetil.
89651940|NCT04424862|Active Comparator|Control|Ponticelli Regimen
89651941|NCT05310513||ICU group|patients admitted to ICU with PRES.
89651942|NCT05310513||Non-ICU group|patients not admitted to ICU with PRES.
89651943|NCT04368780|No Intervention|Control group|Individuals who provide home care to an elderly person who is dependent on the bed
89651944|NCT04368780|Experimental|Experimental group|Individuals who provide home care to an elderly person who is dependent on the bed. It is planned that the exercises will be conducted two days a week with the researcher and on the other days by the caregiver herself for a total of eight weeks.
89651945|NCT04333602|Experimental|Screening and Treatment of Asymptomatic Bacteriruria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. If we detect asymptomatic bacteriuria specific treatment will be instituted.
89651946|NCT04333602|No Intervention|Screening and NO treatment of Asymptomatic Bacteriuria|All patients assigned to this arm will be screen with urine culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. No treatment will be instituted.
89651947|NCT03214575|Active Comparator|Conventional method|For the Conventional method of ultrasound guided central venous catheter insertion,we use the ultrasound machine, eZono 4000 and linear array transducer L3-12NGS (3-12 MHz)
89651948|NCT03214575|Experimental|GPS method|For the GPS method, we use the ultrasound machine, eZono 4000 with built-in adaptive needle recognition software called eZGuide (eZono, Jena, Germany) and linear array transducer L3-12NGS (3-12 MHz).
89651949|NCT05073666||pulmonary embolism|Patients with a recent pulmonary embolism event will be followed for 6 months and will benefit of routine tests (Lung scintigraphy, venous echo doppler, d- dimers measurement) in order to determine chronic thrombo-embolic disease prevalence and its risk factors.
89651950|NCT00882687|Experimental|0.1% Lifitegrast|
89651951|NCT00882687|Experimental|1.0% Lifitegrast|
89651952|NCT00882687|Experimental|5.0% Lifitegrast|
89651953|NCT00882687|Placebo Comparator|Placebo|
89651954|NCT05073198|Experimental|Experiment|Giving educational brochures about testicular cancer and Testicular Self-Examination to the students in the experimental group
89651955|NCT05073198|No Intervention|Control|No intervention
89651956|NCT02467374|Active Comparator|Immediate Behavior Therapy|If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
89651957|NCT02467374|Active Comparator|Waitlist Behavior Therapy|Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
89651958|NCT05310123|Experimental|AC-11|6 months of treatment with AC-11
89651959|NCT02644122|Experimental|SF1126|SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.
89651960|NCT04313166|Experimental|Cu(II)ATSM|copper-containing synthetic small molecule
89651961|NCT00883233|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
89651962|NCT00883233|Experimental|2|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
89651963|NCT00883233|Experimental|3|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
89651964|NCT00883233|Active Comparator|4|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
89651965|NCT04197726|Experimental|sbeIIa/b white bread|sbeIIa/b white bread with high resistant starch content
89651966|NCT04197726|Active Comparator|Control white bread|Reference white bread (wild-type)
89651967|NCT01394939|Experimental|Single Agent_ Cohort 1|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: Recombinant Vaccinia Granulocyte-Macrophage Colony-Stimulating Factor (RAC VAC GM-CSF) Cohort 1: JX-594 3 x 10^8 plaque forming unit (pfu), Days 1, 8,15, 22, and 29"
89651968|NCT01394939|Experimental|Single Agent_Cohort 2|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: RAC VAC GM-CSF Cohort 2: JX-594 1 x 10^9 pfu, Days 1, 8,15, 22, and 29"
89651969|NCT01394939|Experimental|Combination_Cohort 3|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF Irinotecan: 180 mg/m2 IV every 2 weeks. JX-594 3 x 10^8 pfu Day 1,8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
89651970|NCT01394939|Experimental|Combination_Cohort 4|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF JX-594 1 x 10^9 pfu Day1, 8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
89651971|NCT00883389||Safe Kidney Care|Patients with Chronic Kidney Disease (eGFR < 60 ml/min/1.732)and not expected to need dialysis within 6 months of enrollment
89651972|NCT00880581|Experimental|PF-3512676|Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
89651973|NCT04193514|Experimental|Acceptance and Commitment Therapy|
89651974|NCT04193514|No Intervention|Treatment as Usual|
89651975|NCT01394627|Experimental|Eplerenone|hypoglycemia (50 mg/dl) with pretreatment with two doses of eplerenone (100 mg of eplerenone per dose)
89651976|NCT01394627|Placebo Comparator|placebo|hypoglycemia of 50 mg/dl plus placebo
89651977|NCT02288377|Experimental|lanreotide|In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
89651978|NCT02288377|Placebo Comparator|placebo|In this arm, patients will receive placebo every 28 days until disease progression
89651979|NCT03214497|Active Comparator|Protector group|All patients collocated randomly to the Protector Group Primary and secondary outcome Parameters are studied
89651980|NCT03214497|Placebo Comparator|Supreme group|All patients collocated randomly to the Supreme Group, Primary and secondary outcome Parameters are studied
89651981|NCT04147338|Experimental|Reference Device: Guselkumab|Participants will receive subcutaneous (SC) injections of guselkumab in reference device.
89651982|NCT04147338|Experimental|Test Device 1: Guselkumab|Participants will receive SC injections of guselkumab in test device 1.
88993593|NCT00521521|Active Comparator|docetaxel and cisplatin|
88993594|NCT00521521|Experimental|docetaxel|
88993595|NCT00521560|Experimental|1|
89651983|NCT04147338|Experimental|Test Device 2: Guselkumab|Participants will receive SC injections of guselkumab in test device 2.
89651984|NCT04133532|Experimental|metoprolol-no metoprolol|After a washout period of one month following discontinuation of preceding beta-blocker medication patients will be given metoprolol 50 mg daily. The effect will be evaluated after three months of treatment. After that, another one-month washout period will commence followed by three months without metoprolol medication. Then, a final reevaluation will be performed.
89651985|NCT04133532|Experimental|no metoprolol-metoprol|After a one-month washout period following discontinuation of preceding beta-blocker medication patients will continue another three months without a metoprolol medication. After that, an evaluation will be performed. Then they will be given metoprolol 50 mg daily for three months followed by a reevaluation.
89213020|NCT02584751|Active Comparator|Able-Bodied non-GERD|Able-bodied patients who are not diagnosed with GERD during screening will act as controls.
89213021|NCT02584751|Active Comparator|SCI non-GERD|SCI patients who are not diagnosed with GERD during screening will act as controls
89213022|NCT02584751|Experimental|SCI GERD|For those SCI subjects who are identified with GERD, they will undergo a 8week treatment of Omeprazole to reduce GERD
89651986|NCT03214185|Experimental|With PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,conventional embryo morphology evaluation and trophectoderm biopsy before blastocyst cryopreservation. Preimplantation genetic screening (PGS) will be performed to select euploid embryo. The patients will go through up to three times of frozen-thawed transfers of euploid blastocysts until ongoing pregnancy or live birth is acquired. Only one euploid blastocyst will be transferred at a time.
89651987|NCT03214185|Active Comparator|Without PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,and conventional embryo morphology evaluation before blastocyst cryopreservation. The patients will go through up to three times of frozen-thawed transfers of good quality blastocysts until ongoing pregnancy or live birth is acquired. Only one good quality blastocyst will be transferred at a time.
89651988|NCT01391663|Experimental|Alogliptin 12.5 mg QD|
89651989|NCT01391663|Experimental|Alogliptin 25 mg QD|
89651990|NCT01391663|Experimental|Alogliptin 50 mg QD|
89651991|NCT05072106|Active Comparator|Single agent lurbinectedin cycle|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
89651992|NCT05072106|Active Comparator|Bosentan co-administration cycle|"Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).~Lurbinectedin: 3.2 mg/m² as a 1-hour i.v. infusion on Day 1 in first three patients. Dose for remaining five patients will depend on PK and safety outcomes in first three patients."
89651993|NCT03102372|Experimental|Protein group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program. Whey protein supplementation 0.4g/kg before sleep.
89651994|NCT03102372|Placebo Comparator|Placebo group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program
89651995|NCT03102216|No Intervention|Current workflow pathway|In the Current (normal) Workflow Pathway, after a patient is triaged, they are reviewed by the doctor. It is routine for the doctor to then order diagnostic tests/investigations that include blood tests, which are analysed at the laboratory, x-rays, which are performed in the Radiology department, and an ECG, which is performed by an ECG technician. Once the results of those tests are ready, the doctor will then review the patient a second time with all the results. The decision for patient disposition will then be made
89651996|NCT03102216|Experimental|Enhanced workflow pathway iSTAT|Patients will receive i-STAT point-of-care troponin, INR (International Normalised Ratio), CG4(blood gas analysis) and chem8 tests prior to seeing the doctor.
89651997|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as a CBC prior to seeing the doctor.
89651998|NCT03102216|Experimental|Enhanced workflow pathway ECG|Patients will receive a 12lead, v1R-v6R(right sided ECG leads) and V7-V9 ECG prior to seeing the doctor.
89651999|NCT03102216|Experimental|Enhanced workflow pathway Lodox|Patients will receive a supine AP and lateral lodox (low dose x-ray) of their chest and abdomen prior to seeing the doctor.
89652000|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
89213023|NCT02584751|Active Comparator|Able-bodied GERD|For those AB subjects who are identified with GERD will act as controls. Note they will not receive treatment for GERD in this study. We will notify their primary care physician during the study so that they may receive treatment.
89213024|NCT00999219|Experimental|FK199B-first group|
89213025|NCT00999219|Experimental|Zolpidem-first group|
89652001|NCT03102216|Experimental|Enhanced workflow pathway iSTAT, CBC ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests, CBC and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
89652002|NCT03102216|Experimental|Enhanced workflow pathway iSTAT lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests and Lodox prior to seeing the doctor.
89652003|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC and Lodox prior to seeing the doctor.
89652004|NCT03102216|Experimental|Enhanced workflow pathway ECG Lodox|Patients will receive LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
89652005|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor
89652006|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC ECG Lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC, LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
89652007|NCT05315895||general population|general population in a specific area and specifc time range.
89213026|NCT02583971||Patients with AF|"Split into 3:~Those patients on treatment for AF involving blood thinning medicines (anticoagulants) +/- heart rate limiting drugs such as B blockers or digoxin. 100 patients in this group.~Patients undergoing direct current cardioversion (DCCV) to temporarily restore normal (sinus) rhythm. 100 patients in this group.~Patients undergoing an AF ablation to permanently restore sinus rhythm. 300 patients in this group."
89213027|NCT00996177|Experimental|IONSYS|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
89213028|NCT00996177|Active Comparator|Patient-Controlled Analgesia|IV Morphine Patient-Controlled Analgesia (IV PCA)
89213029|NCT04079933|No Intervention|Group 1: Continue Smoking|Subjects were asked to continue smoking their own brand of cigarettes ad libitum for 4 weeks
89652008|NCT03213717|Experimental|Procedure 1|Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is because it has been considered that the effect may be transmitted by weight loading of the lower extremities.
89652009|NCT03213717|Active Comparator|Procedure 2|Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.
89045779|NCT05836090|Active Comparator|Family Spirit Nurture|Participants enrolled in nutrition education comparison group will receive 6 educational lessons related to promoting early childhood healthy growth. Lessons will be delivered bi-weekly for no longer than 4-months total. The lessons are from the evidence-based Family Spirit Nurture curriculum.
89045780|NCT05815160|Experimental|Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin|Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
89045781|NCT05815160|Experimental|Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin|Participants will receive Debio 0123 RP2D determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
89045782|NCT05806294|Experimental|Single-arm pilot trial|The Digital Metabolic Rehabilitation is a single-arm pilot trial that assesses Canadian Digital Technology's feasibility in preventing and managing MetS in patients living with COPD for a 6-month program.
89045783|NCT05805852||patients with surgical intervention|
89045784|NCT05805852||patients with no surgical intervention|
89045785|NCT05805384|Experimental|Cochlear Implant Users|Participants will complete up to 4 experiments evaluating the use of the Speech Enhancement using Dynamic thresholding Approach (SEDA) algorithm. Each testing session will take between 4-6 hours to complete. Testing sessions will continue until the completion of the experiments.
89652010|NCT03213717|Active Comparator|Procedure 3|Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a control group without loading of the lower extremities. This is also the normal working position for many sedentary jobs (e.g. office workers) and why this is of special interest for further investigation. There is a large body of investigative literature showing the negative health consequences of the sitting working position.
89652011|NCT03102060|Experimental|Prevention (gluten free diet)|Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.
89652012|NCT03213483|Active Comparator|Subepithelial connective tissue graft|Patients will receive a coronally advanced flap surgery with a subepithelial connective tissue graft for recession coverage.
89652013|NCT03213483|Experimental|De-epithelialized free gingival graft|Patients will receive a coronally advanced flap surgery with a de-epithelialized free gingival graft for recession coverage.
89652014|NCT03213561|Experimental|Stable and Independent Communication Brain-computer Interfaces|Each arm will receive the same intervention.
89652015|NCT00886899|Experimental|BridgePoint Medical System|Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire
89652016|NCT02281500|Experimental|Single|Human Plasma-Derived Fibrinogen Concentrate Grifols (FIB Grifols)
89652017|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts <350 cells/µL|Intervention to be administered: Prevenar13
89652018|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts ≥350 cells/µL|Intervention to be administered: Prevenar13
89652019|NCT02205450||Children under 2 years with Prader-Willi Syndrome|
89652020|NCT02180178||Consecutive patients undergoing coronary angiography|Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
89652021|NCT05071482|Experimental|flumatinib arm|600 mg QD oral administration, fasting (2 hours before administration and 1 hour after administration).
89652022|NCT05071482|Active Comparator|imatinib arm|600 mg QD oral administration, with a meal
89652023|NCT04477746||Standard Laparoscopy group (LS)|7 surgeons performing surgical procedures using the standard laparoscopic approach
89652024|NCT04477746||Robot- assisted laparoscopic group (RALS)|6 surgeons performing surgical procedures using the robot-assisted laparoscopic approach
89652025|NCT03213249|Active Comparator|Arm 1: Intraoperative pocket irrigation with NS|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket."
89652026|NCT03213249|Active Comparator|Arm 2: Intraoperative pocket irrigation with NS + antibiotics|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin"
89652027|NCT03213093|Other|Diabetic patients with a risk of diabetic foot ulcer|
89652028|NCT03838341||Included|The consecutive patients with atrial fibrillation assigned to totally thoracoscopic stand-alone left atrial appendage occlusion using AtriClip® for stroke prevention.
89652029|NCT03317067|Experimental|dexmedetomidine|Patients in the Dexmedetomidine (interventional) group will be treated with a continuous infusion of dexmedetomidine in case of agitated delirium.
89652030|NCT03317067|Placebo Comparator|Normal Saline (NaCl 0.9%)|Patients in the Normal Saline (control) group will be treated with a continuous infusion of normal saline in case of agitated delirium.
89652031|NCT02641392|Experimental|GED-0301 (160 mg) followed by Placebo intermittent 160 mg|GED-0301 160 mg once daily (QD) for 12 weeks, followed by alternating Placebo (PBO) QD for 4 weeks with GED 0301 160 mg QD for 4 weeks, up to 208 weeks, if the subject previously received Placebo in the prior GED-0301 Study
89652032|NCT02641392|Experimental|Intermittent GED-0301 160 mg and placebo|Alternating GED-0301 160 mg once daily (QD) for 4 weeks with placebo (PBO) QD for 4 weeks, up to 208 weeks, depending on previous response in the prior GED-0301 study
89652033|NCT02641392|Experimental|Intermittent placebo and GED-0301 40 mg|Alternating PBO once daily (QD) for 4 weeks with GED-0301 40 mg QD for 4 weeks with, up to 208 weeks, depending on previous response in the prior GED-0301 study
89045786|NCT05798650|Experimental|instagram user images of attractive smiles|the experimental group had 60 instagram user images of attractive smiles. The first author shortlisted 100 pictures with a hashtag #smile from Instagram. The photographs were of people with full attractive smile and well aligned teeth. These pictures were chosen from public profiles on Instagram. The photographs had an equal proportion of celebrity and non-celebrity faces and the age group was also similar to the people participating in the study (18-35 years).
89045787|NCT05798650|Placebo Comparator|instagram images of nature|the control group had 60 appearance- neutral Instagram images of nature. The neutral images for the control group were chosen with a hashtag nature on Instagram. These images only had nature and no people in them.
89045788|NCT05794555|Active Comparator|Enhanced usual care group|Participants will be in stage 1 for approximately 12 weeks and then be re-randomized for stage 2.
89045789|NCT05794555|Experimental|Treatment (Lactulose) group plus enhanced usual care|Participants will be in stage 1 for approximately 12 weeks and then be re-randomized for stage 2.
89652034|NCT02641392|Experimental|Continuous GED-0301 40 mg|GED-0301 40 mg once daily (QD) for up to 208 weeks
89652035|NCT02641392|Experimental|Intermittent placebo and GED-0301 160 mg|Alternating PBO QD for 4 weeks with GED-0301 160 mg QD for 4 weeks, through Week 208
89652036|NCT04380675|Active Comparator|Music during ESWL|Patients listen to music during ESWL
89652037|NCT04380675|No Intervention|ESWL without music|Patients don't listen to music during ESWL
89045790|NCT05794555|Active Comparator|Enhanced usual care group followed by investigator recommended exercise|This is considered stage 2 for 12 weeks (for re-randomized participants).
89045791|NCT05794555|Experimental|Treatment (Lactulose) plus enhanced usual care then TeleTai-Chi exercise classes|This is considered stage 2 for 12 weeks (for re-randomized participants)
89045792|NCT05794555|Experimental|Enhanced usual care group followed by Tele-Tai Chi exercise classes|This is considered stage 2 for 12 weeks (for re-randomized participants)
89045793|NCT05794555|Experimental|Treatment (Lactulose) plus enhanced usual care then recommended exercise|This is considered stage 2 for 12 weeks (for re-randomized participants)
89045794|NCT05794022|Other|Cohort group|patient with ST-segment elevation myocardial infarction.
89045795|NCT05792020|Experimental|Excitatory tFUS parameters effect on Motor Evoked Potentials|All participants will receive three sessions of Focused Ultrasound Stimulation to their motor hotspot. This stimulation cycle will operate at a 50% duty cycle.
89045796|NCT05792020|Experimental|Inhibitory tFUS parameters effect of Motor Evoked Potentials|All participants will receive three sessions of Focused Ultrasound Stimulation to their motor hotspot. This stimulation cycle will operate at a 5% duty cycle
89045797|NCT05792020|Sham Comparator|Sham tFUS parameters effect of Motor Evoked Potentials|All participants will receive three sessions of Focused Ultrasound Stimulation to their motor hotspot. This stimulation cycle will utilize an air-filled spacer to block stimulation from reaching the brain
89652038|NCT04440007|Experimental|Abivertinib with Standard of Care|STI-5656 (abivertinib maleate) capsule administered orally 200 mg QD up to 28 days or until hospital discharge, in addition to standard of care
89652039|NCT04440007|Active Comparator|Standard of Care|Standard of care treatments for COVID-19 as determined appropriate by the Investigator
89652040|NCT05312541|Placebo Comparator|Opioid Based Anesthesia|Pre induction of general anesthesia with placebo 1 h before surgery. induction of general anesthesia with fentanyl1ug/kg/ iv then infusion of 1 ug/kg/h
89652041|NCT05312541|Active Comparator|opioid free anesthesia|Pre induction of general anesthesia with gabapentin 300 mg tab 1 h before surgery. induction of general anesthesia with ketamine 0.5 mg/kg iv, Lidocaine 1 mg/kg iv then continuous infusion with 2 mg/kg/hr, dexamethasone 0.1 mg/kg.iv, magnesium sulfate 20 mg/kg.iv
89652042|NCT03194269|Experimental|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
89652043|NCT04398823|Active Comparator|Foam sclerotherapy,FS|Participants in this arm will receive the enteroscopic treatment with the sclerosing foam of lauromacrogol.
89045798|NCT05791032|Experimental|AtaCor EV-ICD Lead System|Subjects implanted with the AtaCor EV-ICD Lead
89045799|NCT05787106|Experimental|PAtients withdrawn from alcohol|
89045800|NCT05773989|Experimental|Genotype guided P2Y12 monotherapy|Patients will be tested for the CYP2C19 genotype. Patients without a loss-of-function (LOF) allele will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
89045801|NCT05773989|Active Comparator|Standard DAPT|Patients will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
89045802|NCT05763004|Experimental|IOS-1002 Monotherapy|
89045803|NCT05763004|Experimental|IOS-1002 Combination Therapy with KEYTRUDA® (pembrolizumab)|
89045804|NCT05760794|Experimental|Non-barbed delayed absorbable suture|Participants assigned to Non-barbed delayed absorbable suture group will have Non-barbed delayed absorbable suture used for vaginal mesh attachment at time of SCP
89045805|NCT05760794|Experimental|Barbed delayed absorbable suture|Participants assigned to Barbed delayed absorbable suture group will have Barbed delayed absorbable suture used for vaginal mesh attachment at time of SCP
89045806|NCT05756725|Other|All Pilot Sites|All community health centers participating in the study will implement the new population health management tools utilizing tailored implementation strategies
89045807|NCT05751941|Experimental|Sipuleucel-T with NHA|Participants will continue taking New Hormonal Agents (NHA) while receiving sipuleucel-t as standard of care.
89045808|NCT05751941|Experimental|Sipuleucel-T without NHA|Participants will discontinue use of New Hormonal Agents (NHA) while receiving sipuleucel-t as standard of care.
89045809|NCT05746897|Experimental|NM1F Injection/pembrolizumab Injection|NM1F monotherapy dose escalation(Phase 1a) NM1F dose escalation in combination with a fixed dose of pembrolizumab(Phase 1b)
89045810|NCT05741528|Experimental|SEP-363856|
89652044|NCT04398823|Placebo Comparator|Liquid sclerotherapy,Ls|Participants in this arm will receive the enteroscopic treatment with the liquid of lauromacrogol.
89652045|NCT03213015|Experimental|Experimental|Measurement of ankle dorsiflexion ROM (range of motion) with iHand app (smartphone)
89045811|NCT05741060|Experimental|Equol Arm|S-equol - 10 mg per day tablet for 24 months.
89045812|NCT05741060|Placebo Comparator|Placebo Arm|10 mg per day for 24 months of tablets that will be of the same size/shape/color as the experimental tablet.
89045813|NCT05729477|Active Comparator|Group 1 Phaco Subject Cohort|The Group 1 Phaco subject cohort will begin enrolling subjects sequentially in the first initial arm of the study with up to 250 eyes total.
89045814|NCT05729477|Active Comparator|Group 2 miCOR System Subject Cohort|The Group 2 MICOR System subject cohort, non-use of miLOOP will enroll subsequently with up to 250 eyes total.
89045815|NCT05729477|Active Comparator|Group 3 miCOR System Subject Cohort|The Group 3 MICOR System subject cohort, use of miLOOP optional will enroll subsequently with up to 250 eyes total.
89045816|NCT05726305|Experimental|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
89045817|NCT05726305|Experimental|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
89045818|NCT05721144|Experimental|Experimental: Treatment Group|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room. The physician will follow their own institutional weaning protocols.
89045819|NCT05721144|No Intervention|Sham Comparator: Control Group|The delivery system will be set up anyway without studying gas administration
89652046|NCT05071638|Experimental|ACBMNC infusion group|Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion. Cell dose for all patients was targeted at 5×107 cells per kilogram.
89652047|NCT05071638|No Intervention|control group|The control group received standardized treatment without special treatment.
89652048|NCT04410913|Experimental|Visual Healing Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Visual Healing Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
89045820|NCT05709132|Experimental|iPeer2Peer Program|
89045821|NCT05709132|No Intervention|Standard of Care Waitlist Control Group|
89045822|NCT05708859|Active Comparator|Tirzepatide|Tirzepatide 15mg Prefilled pen for weekly subcutaneous injection over 52 weeks
89045823|NCT05708859|Placebo Comparator|Placebo|Placebo Prefilled pen (volume matched) for weekly subcutaneous injection over 52 weeks
89652049|NCT04410913|Active Comparator|Standard Set and Setting|Participants in this group will receive a single 25 mg dose of open-label psilocybin along with the Standard Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water. Four weeks later all participants will undergo a second open-label psilocybin 25 mg session where participants will choose to receive Visual Healing or standard Set and Setting procedures. All participants will receive Prep and Integration counseling.
89652050|NCT03101670|Experimental|filgotinib|
89652051|NCT03101670|Placebo Comparator|placebo|
89652052|NCT05312463|Experimental|Tongjiang granule group|Experiment group: oral administration of Tongjiang granule with warm water after meal for 1 bag each time for three times a day. The medication period was 4 weeks.
89045824|NCT05699525|Experimental|Personalized|Participants receive the personalized Maya app intervention for 6 weeks
89045825|NCT05699525|Active Comparator|General Non-Personalized|Participants receive the general MAYA app intervention for 6 weeks
89045826|NCT05698199|Experimental|Participants with Newly Diagnosed Glioblastoma (GBM)|Ten participants with histopathological diagnosis of WHO grade IV glioma (Glioblastoma; GBM) and have undergone a gross/near gross total surgical resection of tumor by analysis of residual enhancing tumor remnant on the immediate post-operative MRI
89045827|NCT05693558|Experimental|NVD-003 bone graft implant|"The study includes 2 important surgical procedures, the Adipose Tissue Collection (ATC) and the Grafting Surgery (GS) and 3 stages~Stage 1: A screening, adipose tissue collection & NVD 003 manufacturing period.~Stage 2: Grafting surgery and 12-month post-GS follow-up period.~Stage 3: long-term safety follow-up period (from post-month 12 to month 24)."
89045828|NCT05687903|Experimental|TAK-861 Dose 1|Participants will receive TAK-861 dose 1, orally, from Day 1 up to Weeks 8 or 12.
89045829|NCT05687903|Experimental|TAK-861 Dose 2|Participants will receive TAK-861 dose 2, orally, from Day 1 up to Weeks 8 or 12.
89045830|NCT05687903|Experimental|TAK-861 Dose 3|Participants will receive TAK-861 dose 3, orally, from Day 1 up to Weeks 8 or 12.
89045831|NCT05687903|Experimental|TAK-861 Dose 4|Participants will receive TAK-861 dose 4, orally, from Day 1 up to Weeks 8 or 12.
89045832|NCT05687903|Placebo Comparator|Placebo|Participants will receive TAK-861 matching placebo tablets, orally, from Day 1 up to Weeks 8 or 12.
89045833|NCT05673460|Experimental|Nemtabrutinib|Participants receive nemtabrutinib at specified dose orally once daily (QD) until progressive disease (PD) or discontinuation
89045834|NCT05670405|Experimental|Trauma PORTAL Intervention|The treatment group will complete the Trauma PORTAL intervention in 9 weeks. The participants will be asked to complete clinical measures at baseline, 8 weeks, and 16 weeks.
89045835|NCT05670405|No Intervention|Care-as-Usual|The control group will receive care-as-usual, remaining on the waitlist for the regular TTP R&R groups. Participants in the CUC group will be asked to complete clinical measures at time points corresponding to the ITC group's baseline (prior to starting week one) and post-intervention (i.e. primary endpoint, end of week 8). Both groups will complete the clinical measures eight weeks later (16-week time point).
89045836|NCT05664243|Experimental|1) Autologous: Phase 2 Arm A|Arm A subjects with newly diagnosed disease will receive autologously derived, genetically modified gamma-delta T cells administered with maintenance temozolomide.
89045837|NCT05664243|Experimental|2) Allogeneic: Phase 1b|Phase 1b subjects with relapsed disease will have allogeneic derived, genetically modified gamma-delta T cells administered with temozolomide
89652053|NCT05312463|Placebo Comparator|Tongjiang granule simulant group|Control group:oral administration of Tongjiang granule simulant with warm water after meal for 1 bag each time for three times a day. The medication period was 4 weeks.
89652054|NCT05070936|Other|vestibular rehabilitation group|Vestibular rehabilitation was performed. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backwards both open and closed eyes, and walking on tandem both open and closed eyes. Exercise program was applied for 8 weeks. Patients were observed in the hospital every two weeks. The exercises given in the session were given as home exercises, 3 times a day, for 10 repetitions.
89045838|NCT05664243|Experimental|3) Allogeneic: Phase 2 Arm B|Arm B subjects with relapsed disease will have allogeneic derived, genetically modified gamma-delta T cells administered with temozolomide
89045839|NCT05664243|Experimental|4) Allogeneic: Phase 2 Arm C|Arm C subjects with newly diagnosed disease will receive allogeneic derived, genetically modified gamma-delta T cells administered with maintenance temozolomide.
89045840|NCT05661734|Experimental|VX-548|Participants will receive VX-548 every 12 hours (q12h) up to 14 days.
89045841|NCT05656196|Experimental|Dry eye syndrome (DES)|Dry eye syndrome (DES) will received Chinese herbal tea VGHTPE-DESJS-1 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
89045842|NCT05656196|Experimental|Sjögren's syndrome (SJS)|Sjögren's syndrome (SJS) will received Chinese herbal tea VGHTPE-DESJS-1 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
89045843|NCT05656196|Experimental|Non DES SJS Healthy Controls (NHC)|Non DES SJS Healthy Controls (NHC) will received Chinese herbal tea VGHTPE-DESJS-1 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation. And we could use the Schirmer's test, Tear breakup time, Ocular Surface Disease Index (OSDI), EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Pittsburgh Sleep Quality Index (PSQI), Ford Insomnia Response to Stress Test (FIRST), cytokine markers, Whole-genome genotyping, TCM pattern, Traditional Chinese Medicine (TCM) tongue diagnosis, TCM pulse diagnosis, and TCM heart rate variability for this purpose.
89045844|NCT05654883||HIV-negative, SQ-SQ, short interval|HIV-negative patients who received two subcutaneous mpox vaccinations with an interval of <7 weeks between primer and booster doses.
89045845|NCT05654883||HIV-positive, SQ-SQ, short interval|HIV-positive patients who received two subcutaneous mpox vaccinations with an interval of <7 weeks between primer and booster doses.
89652055|NCT03212703|Active Comparator|Waitlist control (WLC)|Observation surveys over an 8-week period.
89652056|NCT03212703|Active Comparator|Mindfulness-Based Skills Training (MBST)|Attendance at weekly 1.5-hour group sessions and surveys over an 8-week period.
89652057|NCT02013336|Experimental|MM-398 + cyclophosphamide|MM-398+cyclophosphamide
89045846|NCT05654883||HIV-negative, ID-ID, short interval|HIV-negative patients who received two intradermal mpox vaccinations with an interval of <7 weeks between primer and booster doses.
89045847|NCT05654883||HIV-positive, ID-ID, short interval|HIV-positive patients who received two intradermal mpox vaccinations with an interval of <7 weeks between primer and booster doses.
89045848|NCT05654883||HIV-negative, SQ-SQ, SQ-ID, ID-SQ or ID-ID, long interval|"HIV-negative patients who received either:~subcutaneous primer and booster mpox vaccinations, OR~intradermal primer and booster mpox vaccinations, OR~subcutaneous primer followed by intradermal booster mpox vaccination OR~intradermal primer followed by subcutaneous booster mpox vaccination~with the booster dose being taken after an interval of ≥7 weeks."
89045849|NCT05654883||HIV-positive, SQ-SQ, SQ-ID, ID-SQ or ID-ID, long interval|"HIV-positive patients who received either:~subcutaneous primer and booster mpox vaccinations, OR~intradermal primer and booster mpox vaccinations, OR~subcutaneous primer followed by intradermal booster mpox vaccination OR~intradermal primer followed by subcutaneous booster mpox vaccination~with the booster dose being taken after an interval of ≥7 weeks."
89045850|NCT05654883||SQ-ID or ID-SQ, short interval|"subcutaneous primer and intradermal booster mpox vaccinations, OR~intradermal primer and subcutaneous booster mpox vaccinations~with the booster dose being taken after an interval of <7 weeks."
89045851|NCT05654883||1st Dose Only|Participants who receive a 1st dose of the mpox vaccination but elect not to take 2nd dose.
89652058|NCT04397653|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
89652059|NCT04397653|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
89652060|NCT03212781|Experimental|intravenous iron|patients will receive intravenous iron as total dose infusion
89652061|NCT03212781|Active Comparator|oral iron|patients will receive oral iron
89652062|NCT04397965|Experimental|Experimental: Continuous Monitoring|Intervention: Device: Cascade Continuous Glucose Monitoring System
89652063|NCT04435236|Active Comparator|Cervical ESP block group|Cervical ESP block will be performed as described by Elsharkawy at al. (7).
89652064|NCT04435236|Sham Comparator|ISB Block group|ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
89652065|NCT03212937|Experimental|Selinexor and ICE Chemotherapy|
89045852|NCT05654883||Convalescent, No Vaccination|Participants who are convalescent from mpox infection who do not receive mpox vaccination.
89045853|NCT05654883||Convalescent, Vaccination Post-Infection|Participants who are convalescent from mpox infection who receive mpox vaccination after infection.
89045854|NCT05654883||BT after Vaccinations|Participants who experienced breakthrough (BT) mpox infections following mpox vaccination.
89652066|NCT04397497|Experimental|Mavrilimumab|Single dose of IV Mavrilimumab
89652067|NCT04397497|Placebo Comparator|Placebo|Single dose of matching IV placebo
89652068|NCT05312073|Other|Patients with ichtyosis|
89652069|NCT05312073|Other|Patients without ichtyosis|
89045855|NCT05653999||Normal Hearing|Group 1 will consist of approximately 20 infants with normal hearing. This cohort will have passed their newborn hearing screenings and will pass audiologic measurements on the day of testing. Audiologic measurements include tympanometry to determine middle ear function and otoacoustic emissions testing to determine cochlear integrity.
89652070|NCT04397341|Experimental|biweekly TPF induction|Docetaxel: 50 mg/m2 Cisplatin : 50 mg/m2 5-fluorouracil : 2,500 mg/m2 for 40-48 hrs Leucovorin: 250 mg/m2
89652071|NCT01391507|Placebo Comparator|Placebo|
89045856|NCT05653999||Hearing Loss|Group 2 will consist of approximately 20 infants with diagnosed bilateral sensorineural hearing loss ranging from mild to severe. These infants will also pass audiologic measures on the day of testing (tympanometry as described in group 1), currently use bilateral air-conduction hearing aids, and are enrolled in early intervention services.
89652072|NCT01391507|Experimental|20 mg COR-1|
89652073|NCT01391507|Experimental|80 mg COR-1|
89652074|NCT01391507|Experimental|160 mg COR-1|
89652075|NCT04412382||covid-19|Study population: Covid-19 patients aged ≥ 18 years admitted to the Covid sections of the Verona University Hospital. Based on the ongoing epidemic emergency and the lack of specific therapy, we believe that to date this should be the only INCLUSION CRITERION.
89652076|NCT04412382||control|Control group: medical doctors and nurses working in the University Hospital of Verona without known autoimmune diseases nor cancer.
89652077|NCT04398511|Experimental|L brevis|Lactobacillus brevis CD2 in lozenges containing 4 billion CFU. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
89652078|NCT04398511|Placebo Comparator|Placebo|Placebo in lozenges, identical to those of L brevis. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.
89652079|NCT03212313|Active Comparator|Healthy Subjects|Study dose of 120 mg
89652080|NCT03212313|Experimental|Mild Hepatic Impairment|Study dose of 120 mg
89652081|NCT03212313|Experimental|Moderate Hepatic Impairment|Study dose of 120 mg
89652082|NCT03212313|Experimental|Severe Hepatic Impairment|Up to a maximum study dose of 120 mg
89652083|NCT03101436|Experimental|Lean Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
89652084|NCT03101436|Experimental|Obese Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
89652085|NCT03212391|Experimental|Diet+Walking|52 weeks of Diet+26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
89652086|NCT03212391|Experimental|Diet+Nordic Walking|52 weeks of Diet+26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
89652087|NCT03734887|Active Comparator|Private Feedback|Participants will receive a smart pill bottle that will collect data on their medication usage and provide real-time data about adherence to study staff. Study staff will provide participants with private feedback about adherence in the form of meeting with a pharmacist. Feedback will be provided at the start of the study. A semi-structured interviews will be performed among a random sub-sample of participants afterwards.
89652088|NCT03734887|Experimental|Social Network Intervention|Participants will receive the same treatment as the Private Feedback arm but they will additionally have Social Network Feedback. A biweekly feedback text messages will be sent to both the participant and a designated loved-one or friend of the participants for 12 weeks.
89652089|NCT05311995|Active Comparator|Group 1|trocar entry areas:Periumblical, left lower quadrant, suprapubic
89652090|NCT05311995|Active Comparator|Group 2|trocar entry areas: Periumblical, left lower quadrant, right lower quadrant
89652091|NCT05311995|Active Comparator|group 3|trocar entry areas: Periumblical, right lower quadrant, suprapubic
89652092|NCT05311995|Active Comparator|Group 4|trocar entry areas: Periumblical, left lower quadrant, left upper quadrant
89652093|NCT03940326|Experimental|Levetiracetam|
89652094|NCT03940326|Active Comparator|Valproate|
89652095|NCT05311293||Patients with simple diarrhea-predominant irritable bowel syndrome|
89652096|NCT05311293||Patients with irritable bowel syndrome accompanied by anxiety and depression|
89652097|NCT05311293||Healthy Volunteers|
89652098|NCT03212235|Experimental|Hypofractionated radiation therapy|"Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.~After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles."
89652099|NCT01964508||Thyroid nodule|Patients with thyroid nodules undergoing FNA.
89652100|NCT04347889|Experimental|Hydroxychloroquine|Oral loading dose of 800 mg followed by once weekly oral hydroxychloroquine 400 mg for 3 months
89652101|NCT04347889|Active Comparator|Vitamin C|Oral Vitamin C 1,000 mg daily for three months
89652102|NCT03211845|Experimental|Nutritional telemonitoring|Nutritional telemonitoring including self-measurements of body weight, nutritional status, appetite, diet quality and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
89652103|NCT04759963||Group A|follow up for 6 women who gave birth through a cesarean delivery with Midline approach epidural anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
89652104|NCT04759963||Group B|follow up for 13 women who gave birth through a cesarean delivery with Midline approach spinal anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
89652105|NCT04759963||Group C|follow up for 7 women who gave birth through a cesarean delivery with general anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
89652106|NCT04759963||Group D|follow up for 12 women who are the control group (who did not experience any pregnancy or anesthesia. They will perform all assessment procedures: Visual analog scale (VAS) and Oswestry Disability Index (ODI).
89652107|NCT01473524|Experimental|DB OCA 5-10 mg|OCA 5 milligram (mg) for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.
89652108|NCT01473524|Experimental|DB OCA 10 mg|OCA 10 mg for 12 months during the DB phase.
89652109|NCT01473524|Placebo Comparator|DB Placebo|Matching placebo for 12 months during the DB phase.
89652110|NCT01473524|Experimental|LTSE OCA|After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg. Participants who were previously titrated above 10 mg OCA daily were down-titrated to ≤10 mg OCA daily.
89652111|NCT01905384|Active Comparator|U-SEMS group|Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific).
89652112|NCT01905384|Active Comparator|C-SEMS Group|Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific)
89652113|NCT03211923||Nemaline myopathy type 6 (NEM6)|Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
89652114|NCT03211923||Myotonic dystrophy type 2 (DM2)|Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
89652115|NCT03211923||McArdle disease (McA)|Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
89652116|NCT03211923||Healthy controls|14 male and 10 female healthy subjects were measured in a previous study
89652117|NCT03211923||Controls with positive muscle phenomena|9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
88993596|NCT04694209|Experimental|Fixed implant supported prosthesis|the prosthesis is an all-on-four prosthesis composed of a hybrid prosthesis. a metal framework, acrylic resin denture base and acrylic resin teeth
88993597|NCT04694209|Active Comparator|Removable implant supported prosthesis|the prosthesis is an all-on-four prosthesis composed of a telescopic retained overdenture, both primary and secondary copings are custom made. the secondary copings are conncetd via a metal framework
88993598|NCT00521638|Experimental|1|
88993599|NCT00521677|Experimental|1|Procedure: Use of protocol that use special suction connected toothbrush to clean the teeth and the oral cavity, use of non alcoholic antiseptic solution and lubrication of the lips and the oral cavity.
88993600|NCT00521677|Active Comparator|2|The traditional method of oral care with cleaning of the oral cavity with a sponge soaked with antiseptic non alcoholic solution
88993601|NCT00521716|Experimental|A|
88993602|NCT00521755|Experimental|A|
88993603|NCT00521833|Experimental|1|Temporal (right eye)
88993604|NCT00521833|Experimental|2|Nasal (Left eye)
88993605|NCT00521911|Active Comparator|1|Cognitive Behavioural Therapy
88993606|NCT00521911|No Intervention|2|Treatment as Usual
88993607|NCT04273412|Experimental|lifestyle intervention (LI)|moderate-intensity lifestyle intervention (Individualised counseling on diet, physical activity, and target weight gain) by license dietitian
88993608|NCT04273412|No Intervention|usual standard care group (UC)|standard antenatal care as per usual clinic protocol
88993609|NCT00522067|Experimental|Arm 1|FLUAD
88993610|NCT00522106|Experimental|A|Behavioral graded activity
88993611|NCT00522106|Active Comparator|B|Exercise therapy
88993612|NCT00522184|Experimental|1|patient receiving etanercept intra-articular injection
88993613|NCT00522184|Active Comparator|2|patient receiving steroid intra-articular injection
88993614|NCT00522223||Questionnaire|Questionnaire
88993615|NCT00522262|Experimental|Exercise|Women randomized to the exercise intervention arm completed a one year aerobic exercise intervention of 225 minutes/week.
88993616|NCT00522262|No Intervention|Control|Women randomized to the control arm were asked to maintain their regular lifestyle which meant no changes to their exercise or dietary intake. Women eligible for this trial were inactive and hence were expected not to increase their levels of physical activity in the control arm.
88993617|NCT00522340|Experimental|Aerobic Exercise Program|
88993618|NCT00522340|No Intervention|Usual Care|
88993619|NCT03458923|Active Comparator|Group A|15 eyes will receive 0.1 ml containing 500µg of diclofenac intravitreally, repeated monthly for 3 months.
88993620|NCT03458923|Active Comparator|Group B|15 eyes will receive 0.5 mg Ranibizumab intravitreally, repeated monthly for 3 months.
88993621|NCT00522535|Active Comparator|Open Surgical Repair|Open surgical repair of abdominal aortic aneurysm. All patient enrollment and 2-year follow-ups completed.
88993622|NCT00522535|Experimental|Endovascular Repair|"Endovascular treatment arm of 160 patients having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. Use of stent grafts in aortic angles greater than 60° has not been approved for other devices available in the US. As a result, a minimum of 120 patients in this arm will have an aortic angle between 60° and 90°.~Patient recruitment completed; 5-year follow-up evaluations continue."
88993623|NCT00522535|Experimental|Continued Access|"Endovascular treatment arm of 50 patients maximum having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. This Arm will provide active sites with ongoing device access while FDA reviews the PMA.~Patient recruitment completed; 5-year patient follow-ups continue."
88993624|NCT04186013|Experimental|Experimental arm|Atezolizumab 1200 mg intravenous infusion every 3 weeks for a total of 6 doses combined with External Beam Radiation Therapy (EBRT) (dosage: 60 Gy in 30 fractions overs 6 weeks at 2Gy/day)
88993625|NCT00152139|Other|1|
88993626|NCT00522652|Experimental|Investigational Drug|Dose Escalation
88993627|NCT04725162||Epilepsy patients|Pediatric patients with focal epilepsy.
88993628|NCT04725162||Control|Age-matched controls who underwent 18F-FDG PET/CT examination for diseases outside brains.
88993629|NCT04725162||Validation|Children who underwent 18F-FDG PET/MRI to examine extracranial tumors.
88993630|NCT00522691|Experimental|A: sacral first|Phase 1: sacral nerve stimulation crossover Phase 2 : sham stimulation
89045857|NCT05646121||wounds at risk of infection|Ideally 71 patients with wounds at risk of infection (W.A.R. Score ≥ 3) to be included.
89045858|NCT05646121||infected wounds|Ideally 28 patients with infected wounds (TILI Score ≥ 5) to be included.
89045859|NCT05630885|Experimental|CVC arm (Arm A)|Participants with pre-existing ART regimen of EFV will take CVC 300 mg. Participants with all other pre-existing ARTs will take CVC 150 mg.
89045860|NCT05630885|Placebo Comparator|Placebo for CVC arm (Arm B)|Participants with pre-existing ART regimen of EFV will take placebo for CVC 300 mg. Participants with all other pre-existing ARTs will take placebo for CVC 150 mg.
89045861|NCT05625698|Other|MagTrace only|Cohort 1: Clinically node negative patients undergoing neoadjuvant chemotherapy. This cN0-group will receive MagTrace injections before start of neoadjuvant chemotherapy followed standard routine technetium-99 injections after neoadjuvant chemotherapy to facilitate surgery. Nodes containing Magtrace will be detected by finding the magnetic signals using the SentiMag probe. No other interventions during chemotherapy treatments
89045862|NCT05625698|Other|MagTrace and Magseed|Cohort 2: Clinically node positive patients undergoing neoadjuvant chemotherapy. This N+ group will receive MagTrace injection in the breast to mark sentinel nodes and Magseed will be inserted into the index metastatic node before the start of neoadjuatnt chemotherapy followed by standard routine technetium-99 injections after neoadjuvant chemotherapy to facilitate surgery. Nodes containing Magtrace / Magseed will be detected by finding the magnetic signals using the SentiMag probe. No other interventions during chemotherapy treatments
89045863|NCT05612425|Experimental|Safety Behavior Fading|Individuals randomly assigned to the safety behavior fading condition will receive instructions to decrease or eliminate their endorsed appearance-related safety behaviors. In addition, they will receive daily reminders via text message to decrease these behaviors, along with a safety behavior monitoring checklist in which the participant indicates the extent to which they decreased and/or eliminated each safety behavior over the previous day.
89045864|NCT05612425|Active Comparator|Unhealthy Behavior Fading|Individuals randomly assigned to the unhealthy behavior fading condition will receive instructions to decrease or eliminate unhealthy behaviors that are unrelated to appearance. They will also receive daily reminders via text message to decrease these behaviors, along with a behavior monitoring checklist in which the participant indicates the extent to which they decreased and/or eliminated each behavior over the previous day.
89045865|NCT05612100||Observational (alopecia questionnaires and surveys)|Patients complete alopecia questionnaires and surveys on study.
89652118|NCT03211923||Brody disease|4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study
89652119|NCT01390649|Experimental|IgPro10|
89652120|NCT03696355|Experimental|Stratum A1|"Dose Escalation Phase:~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive single-agent oral GDC-0084 at one of the 4 dose levels once daily in cycles of 28 days. During cycle 1 only, a single dose of GDC-0084 will be withheld on day 2, for a total of 27 doses. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.~Dose Expansion Phase~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive the MTD dose established in the Stratum A dose escalation phase. Subjects who completed the first course of therapy may take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity."
89652121|NCT03696355|Experimental|Stratum A2|Four to 12 weeks after the completion of standard RT, subjects will received the MTD dose established in the Stratum A1 dose escalation phase. Subjects who are unable to swallow capsules will initially be enrolled until the Stratum A1 expansion cohort is filled. Once the Stratum A1 expansion cohort has been filled, both subjects who are able to swallow capsules and those unable to swallow capsules may be enrolled. Subjects who are unable to swallow capsules will take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Subjects who have completed the first course of therapy and are able to swallow capsules may take GDC-0084 as capsules. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
89652122|NCT03212001||Telehomecare patients (matched cohort study)|COPD and HF patients in Telehomecare program (followed up to 18 months)
89652123|NCT03212001||Usual-care patients (matched cohort study)|COPD and HF patients in 'usual care' (followed up to 18 months)
89652124|NCT03212001||Telehomecare patients (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess patient experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
89652125|NCT03212001||Informal caregiver (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess caregiver experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
89652126|NCT03212001||Healthcare providers (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess provider experience with Telehomecare program."
89652127|NCT03212001||Administrators and Decision Makers (observations, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess administrator/decision-maker experience with Telehomecare program."
89652128|NCT03212001||Technician (observation, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess technician experience with Telehomecare program."
89652129|NCT03882996|Experimental|Ezetimibe 10 mg + Atorvastatin|Ezetimibe 10 mg plus atorvastatin 10 to 80 mg daily for up to 12 months
89652130|NCT04383691|Experimental|Lurasidone|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
89652131|NCT04383691|Placebo Comparator|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
88993631|NCT00522691|Experimental|B: sham first|Phase 1: sham stimulation crossover Phase 2: sacral nerve stimulation
88993632|NCT00405431|Active Comparator|1|Patients received restasis eyedrops during 6 month post-operative period
88993633|NCT00405431|Placebo Comparator|2|Patients receive artificial tears (Endura) during 6 month post-operative period
88993634|NCT00522730|Experimental|1|Parenteral nutrition
88993635|NCT00522730|Active Comparator|2|Enteral nutrition
88993636|NCT00167232|Active Comparator|Naltrexone 150mg/day|
88993637|NCT00167232|Placebo Comparator|Placebo Sugar Pill|
88993638|NCT00522769|Active Comparator|Delayed Intervention|1/2 of participants are randomized to immediate intervention that starts within a week of randomization. The other 1/2 of the participants are randomized to delayed intervention which starts 6 months after randomization.
89045866|NCT05601414|Experimental|BIO-Z vs. Finapres Nova|Participants will have blood pressure in both arms measured three times using standard methods. The investigators will then fit the Bio-Z watch onto the non-dominant hand's wrist and the Finapres Nova® on the middle finger of the arm with the Bio-Z device. Participants will be asked to perform different exercises and blood pressure readings will be recorded during the exercise and recovery. Each exercise will be repeated three times. 15 Participants will have the option to complete study procedures twice more, spaced one week apart, for a total of three weeks of participation. Each visit will take at most 2 hours to complete study exercises for a total of 6 hours of study time if all the three visits are completed.
89045867|NCT05581602|Experimental|Hemiparetic post-stroke subjects|Stroke patients with motor sequelae in the upper limb.
89045868|NCT05581602|Other|Healthy subjects|Subjects without stroke.
89045869|NCT05571579||brain tumors|
89045870|NCT05569551|Experimental|Adhesive pouch|Experimental group will be applied with Wondaleaf adhesive pouch to cover up the umbilical stump
89045871|NCT05569551|No Intervention|Conventional care|Control group will not be applied with Wondaleaf adhesive pouch, but the umbilical stump is managed with conventional care, by cleaning with antiseptic.
89045872|NCT05550376||HHT1|Mutations in the ENG (endoglin) gene
89045873|NCT05550376||HHT2|Mutations in the ALK-1 (activin receptor-like kinase) gene
89652132|NCT05070468|Active Comparator|Group A|Prescribing Vaginally Dexamethasone tablets to the Group A
89045874|NCT05540717|Experimental|PQ Grass|6 subcutaneous injections of active treatment (900, 2700, 6000, 6000, 6000 and 6000 SU sequentially) to achieve a cumulative nominal dose of 27600 SU
89045875|NCT05540717|Placebo Comparator|Placebo|6 subcutaneous injections of placebo
89045876|NCT05536752|Experimental|QA102 200mg group|Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months
89045877|NCT05536752|Experimental|QA102 400mg group|Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months
89652133|NCT05070468|Placebo Comparator|Group B|Prescribing Vaginally placebo tablets to the Group B
89652134|NCT01390181|Experimental|Losartan|
89652135|NCT03689491|Experimental|rTMS+visual feedback|10-minute rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
89652136|NCT03689491|Active Comparator|sham rTMS+visual feedback|10-minute sham rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
89652137|NCT03689491|Active Comparator|sham rTMS+traditional training|10-minute sham rTMS and then a 30-minute traditional rehabilitation training,3 times a week, for 4 weeks
89652138|NCT05311059|Experimental|Ovarian drilling|Drilling needle was introduced and connected by monopolar current, held against ovarian surface for 4 seconds using a power of 40 watt, 4 puncture was done in each ovary with putting into consideration that the puncture must be not superficial and it must go deep through the main substance of the ovary
89652139|NCT02641080|Active Comparator|Aspirin|Participants randomized to aspirin alone will be advised to take a 325mg per day as their outpatient DVT/PE prophylaxis.
89652140|NCT02641080|Active Comparator|Aspirin with portable Compression Device|Participants randomized to the compression device group are asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an 325mg aspirin per day as their outpatient DVT/PE prophylaxis.
89652141|NCT01964209||No treatment|This is a psychometric study of a screening tool for ADHD, so we will not be administering any treatments or interventions.
89652142|NCT03212079|No Intervention|Control|The participant will self motivate hi/herself to increase physical activities.
89652143|NCT03212079|Experimental|Mycoach Smart Text|The participant will receive personalized smart text messages to encourage him/her to increase physical activities
89652144|NCT03212079|Experimental|MyCoach via Amazon Alexa|The participant will interact with intelligent coach on Amazon Alexa (a digital voice assist) to help him/her become more active
89652145|NCT03101280|Experimental|Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab|Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
89652146|NCT03101280|Experimental|Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab|"Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)].~Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles."
89652147|NCT03211767|Active Comparator|Aged garlic extract|2 capsules per day containing aged garlic extract
89652148|NCT03211767|Placebo Comparator|Placebo|2 capsules per day without aged garlic extract
89652149|NCT04015739|Experimental|Bevacizumab, Olaparib and Durvalumab|Single arm study
89652150|NCT03867318|Experimental|Atorvastatin Monotherapy|Participants receive double-blind atorvastatin 10 mg once daily (QD) via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 80 mg (10 mg open label plus 70 mg double blind).
89652151|NCT03867318|Experimental|Ezetimibe + Atorvastatin|Participants receive double-blind ezetimibe 10 mg QD via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 40 mg (10 mg open label plus 30 mg double blind).
88993639|NCT00522769|Experimental|Immediate intervention|Immediate intervention starts within two weeks of randomization. Delayed interventions starts 6 months after randomization.
88993640|NCT00167271|Experimental|Experimental|Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
88993641|NCT00167271|Active Comparator|Control|Subjects given pamphlets from the Arthritis Foundation
88993642|NCT00522964|Experimental|Intervention|
88993643|NCT04083560|Experimental|Intervention group|Group A Intervention: 360 pregnant women will receive 250 mcg of B-12 daily orally from 1st trimester to 6 months postpartum
88993644|NCT04083560|Active Comparator|Control group|Group B- Control: 360 pregnant women will receive 50 mcg of B-12 daily orally from 1st trimester to 6 months post partum
88993645|NCT00511966||001|
88993646|NCT00511966||002|
88993647|NCT00152178|Experimental|1|UFT (uracil, tegafur) and tamoxifen
88993648|NCT00152178|Active Comparator|2|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
88993649|NCT02948140|Experimental|Stroke|
88993650|NCT02948179|Experimental|Preimplantation genetic diagnosis group|ADPKD patients will complete the whole process of preimplantation genetic diagnosis with healthy baby without pathogenic gene inheritance.
88993651|NCT02948179|No Intervention|Natural pregnancy group|ADPKD patients, pathogenic mutations in PKD1, have natural pregnancy without preimplantation genetic diagnosis.The investigators will perform genetic tests on the blood or umbilical cord blood of infants born between January 2014 and June 2020.
88993652|NCT00523081|Experimental|Experimental|Teens in the experimental group will meet with a research counselor for five to nine individual, 50-minute weekly sessions. They will learn ways to deal with stress and feel better. The study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
88993653|NCT00523081|Active Comparator|Active Control|
88993654|NCT00523120|Active Comparator|1|voltaren ophta
88993655|NCT00523120|Active Comparator|2|dexotic
88993656|NCT04725279|Experimental|Type of rehabilitation treatment|Depending on whether the cervical pain associated with vertigo in the patients associated pain radiating to the arms or not, treatment with conventional physiotherapy or electrotherapy was prescribed. In addition, both groups had a control group that performed exercises at home prescribed by a physician.
89652152|NCT01876771|Experimental|[177]Lu-DOTA-TATE Therapy|"Nominal, induction stage dose of 150 mCi (5.55 GBq) [177]Lu-DOTA-TATE every 10 - 14 weeks for 4 treatments.~Nominal maintenance stage dose of 75 mCi (2.78 GBq) [177]Lu-DOTA-TATE every 22 - 40 weeks, up to a maximum of 8 treatments."
89652153|NCT02274987|Experimental|Treatment|The treatment plan for each patient is individualized and different depending on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
89652154|NCT05070234||short stature children born small for gestational age|This group was defined as a group of children whose birth weight and/or birth length equal or less than -2 SD for sex and gestational age, and who had failed to catch up in growth, remaining short after 2 years old.
89652155|NCT04760119|Active Comparator|Vein bypass surgery first strategy|
89652156|NCT04760119|Active Comparator|Endovascular treatment first (drug coated balloon angioplasty) strategy|
89652157|NCT03722550|Active Comparator|Control Group|Standard Starter Infant Formula, Standard Follow-up Formula, and Standard Growing-up Milk
89652158|NCT03722550|Experimental|Test Group 1|Starter Infant Formula (same as Control Group) supplemented with 1.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
89652159|NCT03722550|Experimental|Test Group 2|Starter Infant Formula (same as Control Group) supplemented with 2.5g/L of Human Milk Oligosaccharides, Follow-up Formula (same as Control Group) supplemented with 0.5g/L of Human Milk Oligosaccharides, and Growing-up Milk (same as Control Group) supplemented with 0.4g/L of Human Milk Oligosaccharides
89652160|NCT03722550|Active Comparator|Breastfed Group|Non-randomized Breastfed reference group
89652161|NCT04381377|Experimental|Polyoxidonium|Polyoxidonium will be administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
89652162|NCT04381377|Placebo Comparator|Placebo|Placebo will be administered (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).
89652163|NCT04033289|Experimental|experimental group|
89652164|NCT04033289|No Intervention|control group|
89652165|NCT03211611||Patients with BRCA ½ mutation|Women with BRCA 1 / 2 mutation with or without cancer Age over 18
89652166|NCT03211611||GP|GP of the patients with BRCA 1 / 2 mutation
89652167|NCT05070000||US|Ultrasound
89045878|NCT05536752|Placebo Comparator|Placebo group|Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months
89045879|NCT05507580|Experimental|Double-Blind Treatment Period Dose A|Participants will be administered updadacitinib Dose A once daily (QD) for 12 weeks.
89045880|NCT05507580|Experimental|Double-Blind Treatment Period Dose B|Participants will be administered updadacitinib Dose B once daily (QD) for 12 weeks.
89045881|NCT05507580|Experimental|Single-Blinded Treatment Period Arm A|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
89045882|NCT05507580|Experimental|Single-Blinded Treatment Period Arm B|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
89045883|NCT05507580|Experimental|Single-Blinded Treatment Period Arm C|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
89045884|NCT05507580|Experimental|Single-Blinded Treatment Period Arm D|Participants will be administered updadacitinib once daily (QD) for 12 weeks.
89045885|NCT05502315|Experimental|Experimental Group|"40 mg of cabozantinib taken orally every day (days 1-28) of a 28 day cycle~480 mg of nivolumab given intravenously on the first day (day 1) of each 28 day cycle"
89045886|NCT05493241|Other|Open trial|In Aim 2, all 10 participants will receive the ACTIVaTE intervention.
89652168|NCT05070000||CT|Computed tomography
89652169|NCT05070000||US after CT|Ultrasound after Computed tomography
89652170|NCT01457846|Experimental|AZD4547|AZD4547 taken orally in tablet formation, 80mg b.d., in a 2 week on, 1 week off schedule
89652171|NCT01457846|Active Comparator|Paclitaxel|Paclitaxel - 80mg/m² as a 1 hour infusion given weekly on days 1, 8 and 15 of a 28 day cycle (up to the maximum number of cycles per local practice)
89652172|NCT03211689|Experimental|Exercise Group|Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
89652173|NCT03211689|No Intervention|Control Group|Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
89652174|NCT01275846|Experimental|Health Guide using AHA protocols|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
89652175|NCT05310825|Experimental|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850 W for 50 seconds in a microwave oven which will be brought by the researcher. After heating, the temperature of the cleaning towels will be measured with an infrared thermometer. The reason for heating the wipes is to bring them to the same temperature as the bath water and thus to prevent any factors arising from a temperature difference.
89688608|NCT02763202|Experimental|CHS-TS Group|Participants assigned to the Carolinas Healthcare Services Transition Services (CHS-TS) group will be introduced to a patient navigator prior to discharge from the hospital and if interested enter the CHS-TS pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support.
89688609|NCT01047293|Experimental|All patients|All participants enrolled.
89652176|NCT05310825|Other|Traditional Body Wiping Bath|Before bathing, two basins will be filled with a suitable amount (2/3 of the basin) of water at a suitable temperature (43°C). Water temperature will be measured by the researcher with a water thermometer. This thermometer will be used to bring the bath water to the correct temperature. Neutral soap will be added to the water of one basin, while the water of the other basin will be used for rinsing. The neutral soap to be used will not dry the skin or cause chafing or irritation, and it will be noon-allergenic. At the same time, soap with these characteristics is one which is routinely used for patient hygiene in the intensive care unit where the study will be conducted. The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water.
89213030|NCT04079933|Experimental|Group 2: OTDN|Subjects were allowed to continue smoking their own brand of cigarettes ad libitum and provided the option to use an OTDN (specifically, VERVE® Discs Blue Mint) also under ad libitum conditions
89652177|NCT04032119|Experimental|Epinephrine|0.2ml 1:10000 epinephrine diluted into each 20ml of the original solution for submucosal injection
89652178|NCT04032119|Active Comparator|Non-epinephrine|No epinephrine would be added into the solution
89652179|NCT04011137|No Intervention|Control|No exercise - 30-min of rest
89652180|NCT04011137|Experimental|High-intensity interval training|8 x 60 s intervals at 70% peak power output (intersperesed with 60 s recovery intervals at 10% peak power output)
89652181|NCT04011137|Experimental|Moderate-intensity continous training|25 min at 45% peak power output
89652182|NCT03211455|Placebo Comparator|Control|"intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.~Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection."
89652183|NCT03211455|Experimental|Lidocaine|Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
89652184|NCT03172819|Experimental|OBP-301+Pembrolizumab|OBP-301+Pembrolizumab
89652185|NCT01496066|Experimental|LAL|LAL implanted
89652186|NCT01496066|Active Comparator|Monofocal control|Monofocal control IOL implanted
89652187|NCT01389323|Experimental|Arm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin|
89652188|NCT03170557|Active Comparator|Traditional chinese acupuncture|Traditional chinese acupuncture. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
89652189|NCT03170557|Sham Comparator|Aspecific needle skin stimulation|Aspecific needle skin stimulation. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
89652190|NCT04084262||All Study Participants|Phantom® Intramedullary Nail combined with a supinating reduction technique
89652191|NCT03831763|Active Comparator|ColdZyme|
89213031|NCT00996255|Experimental|Dose-Escalation|
89652192|NCT03831763|No Intervention|Optional care only|
89652193|NCT01389245|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
89652194|NCT03170401|No Intervention|no protein supplementation|trauma subjects receiving enteral nutrition without any protein supplementation
89652195|NCT03170401|Active Comparator|protein supplementation|trauma subjects receiving enteral nutrition with additional protein supplementation
89652196|NCT01494818|Experimental|CLEAR CARE/AOSEPT Plus|Hydrogen peroxide-based contact lens care system used per manufacturer's instructions
89652197|NCT01494818|Active Comparator|ReNu MultiPlus|PHMB-containing contact lens solution used per manufacturer's instructions
89652198|NCT03559465|Experimental|patient with Scs|patients with SSc, (10 diffuse forms and 20 limited forms)
89652199|NCT03559465|Sham Comparator|healthy subject|
89652200|NCT04031417|Other|Placebo|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
89652201|NCT04031417|Other|soy isoflavones|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
89652202|NCT04031417|Other|soy isoflavones & cocoa polyphenols|Spend 2 hours in an environmental chamber at sea level conditions (temperature : 23c, oxygen concentration 21 %, humidity 45%) Spend 2 hours in a simulated flight (temperature 23c, oxygen concentration 15%, humidity 15%)
89652203|NCT03839043|Experimental|"Quit for a bit"|"Brief behavioral intervention (~5 min) that focus on quitting smoking from the morning of surgery until one week after surgery + Quit for a bit SMS program."
89652204|NCT03839043|Active Comparator|"Quit for good"|"Brief behavioral intervention (~5 min) that focus on quitting smoking permanently for as long as possible + Quit for good SMS program."
89652205|NCT02638389|Experimental|Patients with vascular malformations|Patients with venous, lympathic or complex vascular malformations (KTS, PTEN, etc.) will receive sirolimus after completion of inclusion criteria
89652206|NCT03550573|Experimental|hypertrophic cardiomyopathy without sudden death history|
89652207|NCT03550573|Experimental|hypertrophic cardiomyopathy with sudden death history|
89652208|NCT01494584|Experimental|ezogabine/retigabine|ezogabine dose escalation
89652209|NCT03211143|Experimental|A|"TR group~Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days~Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days"
89652210|NCT03211143|Experimental|B|"RT group~Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days~Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days"
89652211|NCT01388543|Active Comparator|CYP3A5 Expressors|A pre-screening genetic test determines CYP3A5 expressor status
89652212|NCT01388543|Active Comparator|CYP3A5 Non-expressors|A pre-screening genetic test determines CYP3A5 non-expressor status
89652213|NCT03211299||IHL <5%|overweight and obese humans with a liver fat percentage <5%
89652214|NCT03211299||IHL 5-10%|overweight and obese humans with a liver fat percentage 5-15%
89652215|NCT03211299||IHL >15%|overweight and obese humans with a liver fat percentage >15%
89652216|NCT03211377||neoadjuvant therapy group|Preoperation chemotherapy treatment for patients up to four cycles
89652217|NCT03211377||adjuvant therapy|Postoperation chemotherapy treatment for patients up to six cycles
89652218|NCT03211377||Perioperative therapy|Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
89652219|NCT03216603|Experimental|Health literacy intervention group|Health literacy intervention group will receive self-management help using a motivating interviewing technique delivered by nurses trained on motivating interviewing technique and COPD.
89652220|NCT03216603|No Intervention|Usual care group|Usual care group will receive usual follow up
89652221|NCT03837561|Experimental|Cunox|Cunox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
89652222|NCT03837561|Active Comparator|Botox|Botox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
89652223|NCT04380285|Active Comparator|Group 1. Custom heel pads and modified soft molded orthotics|Modified soft custom orthotics supported in the medial longitudinal arches and medial shock absorbing heel pads with customized cutout at the point corresponding to the heel pain
89652224|NCT04380285|Active Comparator|Group 2. Custom hard orthotics|Custom hard orthotics made from a positive mold of a foot in neutral position, with arch support and medial heel postings.
89652225|NCT03837249|Placebo Comparator|Passive Personal Sleep Monitoring|Wears personal sleep monitor but does not actively self-monitor (will have access to the sleep data and self-monitoring after 4 weeks).
89652226|NCT03837249|Active Comparator|Individual Personal Sleep Monitoring|Wears personal sleep monitor and actively self-monitoring sleep and using data to self-manage sleep.
89652227|NCT03837249|Active Comparator|Socially Supported Sleep Monitoring|Wears a personal sleep monitor, actively self-monitoring using sleep data to self-manage sleep and shares data for supportive self-management.
89652228|NCT03210597|Experimental|hydro-aerobic|Water aerobics exercise
89652229|NCT03210597|Experimental|hydro-power|Resistance water exercise
89652230|NCT03210597|Experimental|hydro-combined|Water aerobics and resistance water exercise
89652231|NCT00900237|Active Comparator|Eslicarbazepine acetate|Eslicarbazepine acetate (ESL) 600 mg QD morning from Day 1-3 and 1200 mg ESL QD morning from Day 4-9
89652232|NCT00900237|Active Comparator|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 and oxcarbazepine 600mg BID from Day 4-9
89652233|NCT00893997|Experimental|PR-1 vaccine|4 injections of 0.5 mg PR1 peptide vaccine every 3 weeks.
89652234|NCT04381767||Concussion Evaluation|Adult athletes receiving a clinical evaluation for a suspected concussion after head injury
89652235|NCT00512317|Experimental|ganaxolone|active experimental drug
89652236|NCT03210909|Experimental|BMS-986231 Intravenous Infusion|A single continuous intravenous infusion of BMS-986231
89652237|NCT00901017|Active Comparator|Straumann BoneCeramic|Straumann BoneCeramic
89652238|NCT00901017|Active Comparator|Bio-Oss|Geistlich Bio-Oss
89652239|NCT01494506|Experimental|MM-398|MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
89652240|NCT01494506|Active Comparator|5 Fluorouracil and Leucovorin IV|5 Fluorouracil and Leucovorin IV
89652241|NCT01494506|Experimental|MM-398, 5-FU and Leucovorin|MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.
89652242|NCT03219801|Experimental|mesenchymal stem cells|Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed.
89652243|NCT05361317|Other|Hallux valgus correction|Hallux valgus correction for all patients : intervention during intraoperative visit, with Nexis® PECA Bunion Implantable Osteosynthesis Medical Device
89652244|NCT03210207||GASTROPLICATURE|"The procedure begins with division of the greater curve vessels from 4 to 5 cm proximal to the pylorus to the angle of His. Either ultrasonic energy or bipolar cautery is appropriate for this step.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum"
89652245|NCT04468529|Experimental|Investigational drug group|Injectable Neucardin + standard basic therapeutic medication
89652246|NCT04468529|Placebo Comparator|Placebo group|placebo + standard basic therapeutic medication
89652247|NCT03210285||NF2-associated VS|Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue
89652248|NCT03210285||Sporadic VS|Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue
89688610|NCT01045967|Experimental|Invesigational Test Product|Lansoprazole 30 mg delayed-release Capsules
89688611|NCT01045967|Active Comparator|Reference Listed Drug|Prevacid® 30 mg delayed-release Capsules
89652249|NCT03024905|Experimental|Division 1|"The first division receives baseline data collection for 6 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
89652250|NCT03024905|Experimental|Division 2|"The second division receives baseline data collection for 9 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
89652251|NCT03024905|Experimental|Division 3|"The third division receives baseline data collection for 12 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
89652252|NCT03024905|Experimental|Division 4|"The fourth division receives baseline data collection for 15 months then experiences interventions for the remainder of the trial.~nterventions are behavioural and device: Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
89652253|NCT01830387||Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump. All subjects enrolled in the study will have their medical chart reviewed from consent to 30 days post operatively.
89652254|NCT01830387||Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy during a one year time span by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
89652255|NCT05630573|Experimental|TNM001 Injection dose 1 or placebo|low dose administered
89652256|NCT05630573|Experimental|TNM001 Injection dose 2 or placebo|medium dose administered
89652257|NCT05630573|Experimental|TNM001 Injection dose 3 or placebo|high dose administered
89652258|NCT02643420|Experimental|Arm 1: SPI-2012 and Docetaxel + Cyclophosphamide (TC)|Participants received SPI-2012 13.2 milligram (mg)/0.6 milliliter (mL) (3.6 mg Granulocyte Colony-Stimulating Factor [G-CSF]) fixed-dose subcutaneous (SC) injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy was administered on Day 1 of each cycle and included Docetaxel 75 mg/m^2 intravenous (IV) infusion and Cyclophosphamide 600 mg/m^2 IV infusion per institute's standard of care.
89652259|NCT02643420|Experimental|Arm 2: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)|Participants received pegfilgrastim 6 mg SC injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy on Day 1 of each cycle included Docetaxel 75 mg/m^2 IV infusion and Cyclophosphamide 600 mg/m^2 IV infusion per institute's standard of care.
89652260|NCT01830465|Experimental|Bortezomib + Rituximab|Single arm. Patients will be treated with Bortezomib, 1,3 mg/m2 intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of 21 day cycle for 6 cycles and Rituximab 375 mg/m2 intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
89652261|NCT04408937|Experimental|tropifexor AM 200 micrograms and Placebo (PM)|Tropifexor 200 μg (AM) and Placebo (PM) once daily each
89652262|NCT04408937|Experimental|tropifexor PM 200 micrograms and Placebo (AM)|Tropifexor 200 μg (PM) and Placebo (AM) once daily each
89652263|NCT03210363|Experimental|Guiana population|"Human Biological samples from Guiana population :~Two serum tubes of blood will be collected"
89652264|NCT03025373||Patients - prolonged ICU stay (> 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
89652265|NCT03025373||Heart surgery patients (< 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
89652266|NCT00894465|Experimental|Versed|Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
89652267|NCT00894465|Placebo Comparator|Placebo|Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.
89652268|NCT01456130|Experimental|Alogliptin|Alogliptin 25 mg (or 12.5 mg for participants with moderate renal dysfunction) tablets, orally once daily and a rapid-acting insulin secretagogue as prescribed by the Investigator for up to 52 weeks.
89652269|NCT03832751|Experimental|vitiligo patients|Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
89652270|NCT03832751|Active Comparator|Healthy controls|Tissue levels of human beta-defensin 1 in healthy controls
89652271|NCT04398277|Active Comparator|Initial Low dose|Participants will receive only one daily positive emotion prompt in the first seven days of the toolkit use.
89652272|NCT04398277|Active Comparator|Initial high dose|Participants will receive two daily positive emotion prompts in the first seven days of use.
89652273|NCT03219489|Experimental|Intervention|Clinics randomized to intervention will use the electronic medical record alert for progesterone, informed by guidelines and the foundational meta-analyses demonstrating its efficacy.
89652274|NCT03219489|No Intervention|Control|Clinics randomized to control will not use the electronic medical record alert for progesterone. The control group will receive the usual prenatal care.
89652275|NCT04479540|Experimental|Hospitalized SARS Cov-2|Hospitalized patients diagnosed with SARS Cov-2 infection
89652276|NCT03219645|Active Comparator|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
89652277|NCT03219645|Placebo Comparator|aspirin|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
89652278|NCT04435314|Experimental|nitazoxanide|Subjects will receive nitazonanide 600 mg TID.
89652279|NCT04435314|Placebo Comparator|Placebo|Subjects will receive placebo TID.
89652280|NCT03210129|Experimental|Motivational interviewing|Patients of the motivational interviewing group will receive standard care alongside motivational interviewing to change their behavior regarding physical activity.
89652281|NCT03210129|No Intervention|Control Group|Patients of the control group will receive standard care alone.
89652282|NCT03102450|Experimental|Benzalkonium Chloride Spermicide Cream|Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)
89652283|NCT01456052|Experimental|Low Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally once daily (QD).
89652284|NCT01456052|Experimental|High Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally three times daily (TID).
89652285|NCT01456052|Placebo Comparator|Placebo|Matching placebo administered orally.
89652286|NCT03210051|Experimental|RIC & ET|Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
89652287|NCT01387607|Experimental|Pregabalin|
89652288|NCT01387607|Placebo Comparator|Placebo|Matched placebo
89652289|NCT05069454|Active Comparator|Exposure group|Healthcare workers vaccinated by any of the available COVID19 vaccine;
89652290|NCT05069454|Active Comparator|Control group|Have not received any doses of any form of COVID-19 vaccine
89652291|NCT04408274|Experimental|Computerized Tests|
89652292|NCT04408274|Placebo Comparator|Placebo Control|
89652293|NCT05069688|Experimental|Dolutegravir PK during standard and high-dose rifampicin|This is a single arm study: all patients are started on HIV/TB cotreatment considered standard of care and then for two weeks (study weeks 20-21) high-dose rifampicin is given during which safety and pharmacokinetics are examined.
89652294|NCT03219255||Subjects receiving RELVAR 100 ELLIPTA|Subjects with a diagnosis of COPD, for which RELVAR is indicated, who are naive to RELVAR will be included.
89652295|NCT01830777|Experimental|Experimental Arm|Brentuximab Vedotin + MEC
89652296|NCT05069064|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
89652297|NCT05069064|Other|non-music group|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
89652298|NCT03568344||Community based tx seeking: baseline|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities during baseline period (no QA RAS administration).
89652299|NCT03568344||tx seeking @ referral facility: baseline|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility during baseline period (no QA RAS administration).
89652300|NCT03568344||Community based tx seeking: Post RAS|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities after QA RAS roll-out (after pre-referral QA RAS administration).
89652301|NCT03568344||tx seeking @ referral facility: Post RAS|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility after QA RAS roll-out ( no QA RAS administration).
89652302|NCT03218631|Other|Oxandrin|Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
89652303|NCT03451045|Experimental|Lenabasum 20 mg BID|
89652304|NCT03451045|Experimental|Lenabasum 5 mg BID|
89652305|NCT03451045|Placebo Comparator|Placebo BID|
89652306|NCT03100032|Experimental|NVD-001|Autologous osteogenic cells in ECM with DBM
89652307|NCT03100032|Active Comparator|Standard of Care|Best standard of care in surgical practice
89652308|NCT03212859|Experimental|Coach2Move Intervention Group|Coach2Move Intervention Group
89652309|NCT03212859|Active Comparator|Usual Care|Usual care physiotherapy among older adults
89652310|NCT01831011|Experimental|mildronate|infusion of mildronate
89652311|NCT01831011|Active Comparator|cinepazide maleate|infusion of cinepazide maleate
89652312|NCT03218709|Experimental|High-dose multi-vitamins with minerals|Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
89652313|NCT03218709|Experimental|Low-dose multi-vitamins with minerals|Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
89652314|NCT03218709|Active Comparator|Hypouricemic tablets|Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months
89652315|NCT03218709|Placebo Comparator|Placebo|Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months
89652316|NCT04277065|Experimental|Bulldog tourniquet in laparoscopic Hepatectomy|The bulldog tourniquet , a reusable vessel occlusion instrument forblocking the liver inflow-blood in laparoscopic liver resection, was uniformly employed in all patients randomized to Bulldog laparoscopic hepatectom group in the present study.
89652317|NCT04277065|Active Comparator|cotton tourniquet in laparoscopic Hepatectomy|The cotton tourniquet ,a reusable vessel occlusion instrument for blocking the liver inflow-blood in laparoscopic liver resection
89652318|NCT03218553|Experimental|Dexamethasone|Standard cares plus postoperative administrations of glucocorticoid
89045887|NCT05493241|Experimental|ACTIVaTE intervention|In Aim 3, 24 participants will be randomized to receive the ACTIVaTE intervention.
89652319|NCT03218553|Placebo Comparator|placebo|Standard cares plus postoperative administrations of placebo
89652320|NCT01831167|Experimental|dynamic light|dynamic light
89652321|NCT01831167|No Intervention|reference|normal light
89652322|NCT03102294|Active Comparator|Experimental: IMT|inspiratory muscle training (PowerBREATHE) with ~50% of maximum inspiratory pressure
89652323|NCT03102294|Placebo Comparator|Placebo: SHAM|inspiratory muscle training (PowerBREATHE) without inspiratory load
89652324|NCT03099876||7 days treament group|7 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
89652325|NCT03099876||10 days treatment group|10 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
89652326|NCT03219567|Experimental|Normals|Normal subjects will be imaged with the OCT system to ensure the imaging range of the system.
89652327|NCT03219567|Experimental|Patients with a history of cataract surgery or high myopia|Subjects will be imaged with both the OCT system and MRI. Reconstructions of the eye from each modality will then be compared.
89652328|NCT03099642|Experimental|Ultrasound assisted lumbar puncture|The intervention of interest will be the ultrasound-assisted lumbar puncture (UALP). To do this, the treating physician will perform a bedside ultrasound of the spine to identify and mark the level of the conus medullaris and preferred puncture site prior to LP
89652329|NCT03099642|No Intervention|Standard lumbar puncture|The control group will have a standard landmark-based lumbar puncture
89652330|NCT01386125|Experimental|Mometasone Furoate Nasal Spray (MFNS)|Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks
89652331|NCT01386125|Placebo Comparator|Placebo|Participants receive matching placebo nasal spray BID for 16 weeks
89652332|NCT03218865|Experimental|ViE High flux dialyzer|vitamin E coated polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for the patient suffering from acute or chronic renal failure
89652333|NCT03218865|Active Comparator|Leoceed H high flux dialyzer|polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for patient suffering from acute or chronic renal failure
89652334|NCT05630261|Experimental|Self-help CBT-I|Participants assigned to the CBT-I group will receive the self-help CBT-I intervention for six weeks (i.e., participants will access the intervention every day, for 42 days).
89045888|NCT05493241|Active Comparator|Attention control|In Aim 3, 24 participants will be randomized to an attention control arm.
89045889|NCT05489926|Experimental|Pamiparib|
89652335|NCT05630261|Active Comparator|Self-help CBT-D|Participants assigned to the CBT-D group will receive the self-help CBT-D intervention for six weeks (i.e., participants will access the intervention every day, for 42 days).
89652336|NCT05068986|Other|single arm intervention|
89652337|NCT05094258|Active Comparator|mobile insert|Unicondylar knee arthroplasty with mobile insert was applied to 30 patients determined by randomization. The patients were followed for 1 year.
89652338|NCT05094258|Active Comparator|fixed insert|Unicondylar knee arthroplasty with fixed insert was applied to 30 patients determined by randomization. The patients were followed for 1 year.
89652339|NCT01830309|Experimental|Sequence 1|Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition
89652340|NCT01830309|Experimental|Sequence 2|Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition
89652341|NCT01831323||mesalazine|10 female patients with first diagnosis of SUDD will take mesalazine 1,6g per day for 14 days (1 tablet 800mg twice daily)
89652342|NCT01831323||VSL#3|10 female patients with first diagnosis of SUDD will take VSL#3 2 sachets a day for 14 days (1 sachet twice a day, for a total of 900 billion bacteria per day)
89652343|NCT01831323||Rifaximin|10 female patients with first diagnosis of SUDD will take 800mg/day of rifaximin (2 tablets of 200mg twice a day)
89045896|NCT05479643|Experimental|Patients with Aphonia or Dysphonia|Participants with Aphonia or Dysphonia will be asked to recite phrases with sEMG attached to articulatory muscles.
89045897|NCT05479643|Placebo Comparator|Healthy Volunteers|Healthy Volunteer will be asked to recite phrases with sEMG attached to articulatory muscles.
89652344|NCT01831323||fiber|10 female patients with first diagnosis of SUDD will take fibers for 14 days (psyllium 10grams per day)
89652345|NCT03221400|Experimental|Phase 1a PEN-866 Sodium (Single Agent)|Dose escalation of PEN-866 Sodium administered intravenously
89652346|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Flurouracil + Folinic Acid|Dose escalation of intravenous administration of PEN-866 Sodium in combination with fluorouracil and folinic acid
89652347|NCT03221400|Experimental|Phase 2a PEN-866 Sodium (Single Agent)|Intravenously administered PEN-866 Sodium at the Recommended Phase 2 Dose
89652348|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Niraparib|Dose escalation of intravenous administration of PEN-866 Sodium in combination with niraparib
89652349|NCT01831401|Experimental|0° Head Down (horizontal) & Standard Introducer.|Operating table position 0° head down (horizontal) & standard straight acetabular component introducer without alignment guide.
89652350|NCT01831401|Experimental|0° Head Down (horizontal) & Modified 35° Introducer.|Operating table position 0°head down (horizontal) & modified 35° acetabular component introducer.
89652351|NCT01831401|Experimental|0°Head Down (horizontal) & Inclinometer-assisted Introducer.|Operating table position 0°head down (horizontal) & standard straight acetabular component introducer without alignment guide.
89652352|NCT01831401|Experimental|7° Head Down & Standard Introducer.|Operating table position 7° head down & standard straight acetabular component introducer without alignment guide.
89652353|NCT01831401|Experimental|7° Head Down & Modified 35° Introducer.|Operating table position 7° head down & modified 35° acetabular component introducer.
89652354|NCT01831401|Experimental|7° Head Down & Inclinometer-assisted Introducer.|Operating table position 7° head down & inclinometer-assisted acetabular component introducer.
89045898|NCT05478681|Experimental|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
89045899|NCT05472909|Experimental|Standardized Relaxation Music|
89045900|NCT05472909|Active Comparator|Personal Choice of Music|
89045901|NCT05446870|Experimental|Pembrolizumab + Standard of Care (SOC) + MK-4830|Before surgery participants will receive pembrolizumab 200 mg, paclitaxel 175 mg/m^2, carboplatin Area Under the Curve (AUC) 5 to 6, (or docetaxel 75 mg/m^2), and MK-4830 800 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for 3 cycles. After surgery participants will receive pembrolizumab 200 mg, paclitaxel 175 mg/m^2, carboplatin AUC 5 to 6, (or docetaxel 75 mg/m^2), MK-4830 800 mg, and avastin (or biosimilar) by IV infusion on Day 1 of each 21-day cycle (Q3W) for 3 cycles.
89045902|NCT05446870|Active Comparator|Pembrolizumab + SOC|Before surgery participants will receive pembrolizumab 200 mg, paclitaxel 175 mg/m^2, carboplatin AUC 5 to 6 and (or docetaxel 75 mg/m^2) by IV infusion on Day 1 of each 21-day cycle (Q3W) for 3 cycles. After surgery participants will receive pembrolizumab 200 mg, paclitaxel 175 mg/m^2, carboplatin AUC 5 to 6, (or docetaxel 75 mg/m^2) and avastin (or biosimilar) by IV infusion on Day 1 of each 21-day cycle (Q3W) for 3 cycles.
89045903|NCT05442515|Experimental|1/Phase I Dose Escalation-with standard LD - CLOSED|CD19/CD22-CAR-transduced T cells at escalating dose + standard LD
89045904|NCT05442515|Experimental|1b/Phase 1 Dose Escalation - low disease burden|CD19/CD22-CAR-transduced T cells
89045905|NCT05442515|Experimental|2/Phase I Dose Escalation- with intensified LD - CLOSED|CD19/CD22-CAR-transduced T cells + standard LD
89045906|NCT05442515|Experimental|2b/Phase 1 Dose Escalation - high disease burden|CD19/CD22-CAR-transduced T cells
89652355|NCT01831401|Experimental|Y° Head Down & Standard Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & standard straight acetabular component introducer without alignment guide.
89652356|NCT01831401|Experimental|Y° Head Down & Modified 35° Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & modified 35°acetabular component introducer.
89652357|NCT01831401|Experimental|Y° Head Down & Inclinometer-assisted Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & inclinometer-assisted acetabular component introducer.
89652358|NCT05060874||single group|gripwise or jamar will be randomly assessed first
89652359|NCT05036928||HIV infection group|
89652360|NCT03218319|Experimental|All patients|
89652361|NCT01384877|Experimental|Lidocaine|Lidocaine
89652362|NCT01384877|Placebo Comparator|Placebo (D5W)|Placebo first as compared with lidocaine first
89652363|NCT00114517|Active Comparator|17B-estradiol|Oral 17B-estradiol 1 mg daily
89045907|NCT05442515|Experimental|3/Phase II Dose Expansion- with low disease burden|CD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD
89045908|NCT05442515|Experimental|4/Phase II Dose Expansion- with high disease burden|CD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD regimen #2
89045909|NCT05433662||Veterans|Veterans will be ages 65 and older, cognitively intact, and experiencing pandemic-related stress.
89045910|NCT05424380|Experimental|Part 1: Dose escalation|Part 1 will evaluate a dosing schedule for a total of 28 days in each cycle. The starting dose for Cycle 1 will be escalated in the next dose escalation cohort until MTD is reached.
89045911|NCT05424380|Experimental|Part 2: Dose expansion|Part 2 will evaluate efficacy after an induction phase. The induction phase consists of a treatment regimen at RP2D determined in Part 1.
89045912|NCT05424081|Experimental|EMBER|Self-help tool to increase weight management engagement
89045913|NCT05424081|Active Comparator|Control|List of treatments
89045914|NCT05420844|Other|Kintsugi|Enrolled participants who will be using the Kintsugi voice journaling phone application.
89045915|NCT05405426|Active Comparator|Indication-based red blood cell transfusion strategy|Red blood cell transfusion will occur if the center-specific hemoglobin/hematocrit threshold for transfusion is met AND at least one of the following conditions is present: a) moderate or severe bleeding; b) reduced tissue oxygen delivery, defined as serum lactate >5 mmol/L or 2 serum lactate levels > 3 mmol/L measured 2 hours apart; or c) hemoglobin < 8 g/dL or hematocrit < 25%, except for neonates (age =< 28 d) and children with single ventricle congenital heart disease (age < 1 y) RBC transfusion for hemoglobin < 10g/dL or hematocrit <30% is allowed.
89652364|NCT00114517|Placebo Comparator|Placebo|Matching oral 17B-estradiol placebo daily
89652365|NCT01831479|Experimental|Rosuvastatin and Olmesartan|A multiple-dose administration of rosuvastatin, a multiple-dose administration of olmesartan, and a multiple-dose administration of rosuvastatin and olmesartan, given orally with a washout period of 8 days between each administrations
89652366|NCT03836391|Experimental|Nudge Intervention|"Each of 7 intervention message options has specific decision rules (including weighed/not weighed and progress toward daily dietary and activity goals) that make a participant eligible to receive a specific intervention type at a specific time (decision points).~At each decision point (early morning, morning, midday, and evening), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability)."
89652367|NCT03099720|Experimental|intervention group|Participants are given ropivacaine (0.5%) at a total dose of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation as pre-emptive analgesia.
89652368|NCT03099720|Placebo Comparator|control group|Participants are given a placebo in the form of fluid injection of saline (0.9%) at total of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation
89652369|NCT04746391|Experimental|Solacea_60min|"blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
89652370|NCT04746391|Experimental|Solacea_120min|"blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
89652371|NCT04746391|Experimental|Solacea_240min|"blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
89652372|NCT04746391|Experimental|FX800_60min|"blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
89045916|NCT05405426|Other|Center-specific hemoglobin/hematocrit threshold-based red blood cell transfusion strategy|Red blood cell transfusion will occur according to each study center's standard of care strategy, typically based on a particular hemoglobin threshold or hematocrit threshold. When hemoglobin or hematocrit decrease to the threshold, red blood cell transfusion is administered.
89045917|NCT05393037|Experimental|V116|Participants will receive a single intramuscular (IM) dose of V116 on Day 1, a single IM dose of placebo for PPSV23 on Week 8, and a single IM dose of PCV15 between 10 to 18 months after V116.
89045918|NCT05393037|Active Comparator|PCV15 + PPSV23|Participants will receive a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.
89652373|NCT04746391|Experimental|FX800_120min|"blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
89652374|NCT04746391|Experimental|FX800_240min|"blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination~microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers"
89652375|NCT04027439|Active Comparator|Part A: RPL554|Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind
89652376|NCT04027439|Active Comparator|Part B: RPL554|Double-blind, placebo-controlled, complete block cross-over
89045919|NCT05384262|Active Comparator|Cohort 1: Part A1 - AZD0780 dose 1/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
89045920|NCT05384262|Active Comparator|Cohort 2: Part A1 - AZD0780 dose 2/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
89652377|NCT04766567|Experimental|Serosal myomectomy|Patients with singleton pregnancy, who had serosal myomectomy during cesarean section
89652378|NCT04766567|Experimental|Endometrial myomectomy|Patients with singleton pregnancy, who had endometrial myomectomy during cesarean section
89652379|NCT04766567|Placebo Comparator|Control group|Patients with singleton pregnancy, who did not have myomectomy during cesarean section
89652380|NCT03217773|Experimental|ESD|ESD is an endoscopic procedure that enables en bloc resection of large tumors in the gastrointestinal tract, irrespective of the size of the lesion. ESD uses an electrosurgical cutting device to purposely dissect the deeper layers of the submucosa to remove neoplastic mucosal lesions in a single piece.
89652381|NCT03217773|Active Comparator|TAMIS|TAMIS is a minimally invasive means of removing large rectal neoplastic lesions not accessible by conventional transanal excision. It is performed using the GelPOINT path transanal access platform and laparoscopic instruments.
89652382|NCT01839045||Breast Cancer|ACR BI-RAD Category 3 or 4 result
89652383|NCT01384019|Experimental|DP-TA|distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)
89652384|NCT01384019|Placebo Comparator|c-PCI|conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction
89045921|NCT05384262|Active Comparator|Cohort 3: Part A1 - AZD0780 dose 3/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
89652385|NCT01839123|Active Comparator|Non-Vacuum Socket|Prosthetic suction or pin socket
89652386|NCT01839123|Experimental|Vacuum Socket|Prosthetic LimbLogic vacuum socket
89652387|NCT01831557||Childrens' Milk Intake|The milk intake of children will be reconciled with body measurement index and blood samples will be taken for gene sequencing
89652388|NCT03025295|Experimental|Dexmedetomidine group|Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.
89652389|NCT03025295|Placebo Comparator|Saline group|Control group given equal volume of saline with the dexmedetomidine group.
89652390|NCT00033631|Active Comparator|70.2 Gy|70.2 Gy 3D-CRT/IMRT
89652391|NCT00033631|Experimental|79.2 Gy|79.2 Gy 3D-CRT/IMRT
89045922|NCT05384262|Active Comparator|Cohort 4: Part A1 - AZD0780 dose 4/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
89045923|NCT05384262|Active Comparator|Cohort 5: Part A1 - AZD0780 dose 5/placebo tablet|A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.
89652392|NCT03218007|Experimental|acute coronary syndrome|
89652393|NCT03025061||15 children with moderate asthma|Assessment of E-nose measurements: three E-nose measurements on 15 children with moderate asthma (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the outpatient clinic of Pediatric Allergology & Pulmonology (PAP) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (IBIM CNR).
89652394|NCT03025061||30 healthy children|"Assessment of E-nose measurements: three E-nose measurements on 30 healthy children (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the primary schools involved in the municipal project Educational Pathways (Palermo)."
89652395|NCT01471574|Experimental|Daclatsvir + Ribavirin + PEG-Interferon alfa-2a|
89652396|NCT01831713||CHF patients and Controls|CHF patients refer to Decompensated patients and Compensated patients
89652397|NCT03217929|Active Comparator|Active-taVNS|
89652398|NCT03217929|Sham Comparator|Sham-taVNS|
89652399|NCT01831869|Active Comparator|L-thyroxine|Oral administration, starting dose 25 or 50 micrograms once daily.
89652400|NCT01831869|No Intervention|blank|no intervention
89688612|NCT02808052|Experimental|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives a single 200-mg dose of Minocin (minocycline) for Injection except for the hemodialysis therapy/end stage renal disease cohort, which receives two 200-mg doses.
89652401|NCT01383707|Experimental|Bevacizumab + mFOLFOX-6|Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
89652402|NCT01839357|Experimental|Rivaroxaban|
89652403|NCT04369859||pregnant women with COVID-19|Pregnant women who have tested positive for COVID-19
89652404|NCT03837951||Uninjured hands|healthy participants without injuries to hands or wrists
89652405|NCT03837951||Injured hands|participants undergoing medical treatment for recent hand or wrist injury
89652406|NCT03306901|Experimental|Concurrent Chemoradiotherapy|"Patients receive 2 courses (every 3 weeks) of chemotherapy including cisplatin (45-60mg/m2) intravenously over 1 hour on day 1 and 5-fluorouracil (3,200 ~ 4,000mg/m2) intravenously for 4 to 5 days.~Patients receive a total of 45 Gy radiation therapy (5 days a week for 5 weeks)."
89652407|NCT03306901|Active Comparator|Esophagectomy|Patients receive surgical resection, including Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy.
89652408|NCT01839435|Experimental|outpatient patients|Outpatient surgery will be proposed to all patients
89652409|NCT01383317|Active Comparator|RIPC|A tourniquet on the thigh will be inflated to 300 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
89652410|NCT01383317|Sham Comparator|Sham RIPC|A tourniquet on the thigh will be inflated to 15 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
89652411|NCT01455428|Experimental|Lyrica (pregabalin)|
89652412|NCT01455428|Placebo Comparator|Placebo|
89652413|NCT01831947|Experimental|Ranibizumab fixed dose|Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.
89652414|NCT01831947|Experimental|Ranibizumab on demand|Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.
89652415|NCT01832025|Active Comparator|Internal|internal maxillary sinus floor elevation technique with simultaneous implant placement
89652416|NCT01832025|Active Comparator|External|external maxillary sinus floor elevation technique with simultaneous implant placement
89652417|NCT01383161|Active Comparator|Curcumin|Theracurmin (180mg/day)
89652418|NCT01383161|Placebo Comparator|Placebo|Sugar Pill
89652419|NCT00894699|Active Comparator|1|single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
89652420|NCT00894699|Placebo Comparator|2|single dose of sublingual Placebo NanoTab™
89652421|NCT03087019|Experimental|Pembrolizumab + Radiation|"Up to 5 metastatic lesions targeted with radiation~Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab~Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
89652422|NCT03087019|Experimental|Pembrolizumab|"Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
88993657|NCT00523159|Other|1|Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
88993658|NCT00523159|Other|2|No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
88993659|NCT00152217|Experimental|1|TS-1 (S-1)
88993660|NCT00152217|Other|2|Surgery alone
88993661|NCT04693897||Overactive bladder with Mirabegron|100 patients with overactive bladder syndrome, diagnosed according to 2002 ICS diagnosis will undergo 12 weeks of Mirabegron 50mg once daily use. Evaluation include questionnaire survey and urine beta-3 adrenoceptor concentration.
88993662|NCT04693897||Overactive bladder with Solifenacin|100 patients with overactive bladder syndrome, diagnosed according to 2002 ICS diagnosis will undergo 12 weeks of Solifenacin 5mg once daily use. Evaluation include questionnaire survey and urine beta-3 adrenoceptor concentration.
88993663|NCT04693897||Urinary tract infection|Urinary samples for beta-3 adrenoceptor concentration of 100 patients with urinary tract infection.
88993664|NCT04693897||Control|Urinary samples for beta-3 adrenoceptor concentration of 100 patients without lower urinary tract symptoms.
88993665|NCT00424242|Experimental|Escalating doses of Pemetrexed|Escalating doses of Pemetrexed beginning at 500 mg/m2
88993666|NCT04726553|Experimental|Anifrolumab plus Standard of Care|Anifrolumab will be added to Standard of Care Treatments for SLE
88993667|NCT04726553|Placebo Comparator|Standard of Care|Standard of Care Treatments for SLE
88993668|NCT02947945|Other|Open-Label|all subjects will receive the study medication- reslizumab.
88993669|NCT02948101|Experimental|Treatment (PD 0360324, cyclophosphamide)|Patients receive anti-CSF1 monoclonal antibody anti-CSF1 monoclonal antibody PD 0360324 IV over 30 minutes on days 1, 8, 15, and 22. Starting on day 43, patients receive cyclophosphamide PO QD. Courses with cyclophosphamide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88993670|NCT00167466|Experimental|A|4 week brushing with experimental Soladey-3 toothbrush followed by 4 week washout period followed by 4 week brushing with placebo Soladey-3 toothbrush
88993671|NCT00167466|Placebo Comparator|B|subjects to brush with Placebo Soladey-3 toothbrush for 4 weeks followed by a 4 week washout followed by 4 week brushing with experimental Soladey-3 toothbrush
88993672|NCT02952157|Sham Comparator|Control|Normal saline will be applied to the endotracheal tube.
88993673|NCT02952157|Active Comparator|Lidocaine|Lidocaine jelly will be applied to the endotracheal tube.
88993674|NCT00523276||HCWs|Who may/may not have contact with SARS patients
88993675|NCT00523276||Family/close contacts|No illness but household/close contact
88993676|NCT00523276||SARS subjects|Diagnosed with active disease
89652423|NCT05632289|Experimental|osteopathic treatment|
89652424|NCT05632289|Sham Comparator|sham of osteopathic treatment|
89688613|NCT01724957||Patients with coronary bifurcation lesions|Only one group will be studied. The patient will be a slef-reference.
89688614|NCT03402581||c-mac used for intubation|obese patients intubated with c-mac videolaryngoscope
89652425|NCT03217383|Experimental|MATRx plus test|All study participants will receive the same test protocol. All participants will complete the MATRx plus theragnostic test and receive a prediction of oral appliance outcome. All participants will then receive a custom oral appliance set to the predicted protrusive position or a sham position, and outcome home sleep tests will be performed with the custom oral appliance in place to determine if the test prediction was correct.
89652426|NCT01832103|Experimental|MK-7145|MK-7145 2 mg IR administered as a single oral dose.
89652427|NCT01839591|Experimental|Bronchial Thermoplasty|bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
89652428|NCT01382225|Experimental|Sodium Hyaluronate|Sodium Hyaluronate Ophthalmic Solution, 0.18%, 1-2 drops instilled in each eye 3-6 times a day for 14 days
89652429|NCT01382225|Placebo Comparator|Vehicle|Inactive ingredients, 1-2 drops instilled in each eye 3-6 times a day for 14 days
89652430|NCT03217617|Experimental|Single arm|Gene transfer to treat SCID-X1
89652431|NCT03217461|Experimental|Corneal epithelial autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted corneal epithelial autograft
89652432|NCT03217461|Active Comparator|Limbal autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted limbal autograft
89652433|NCT01839747|Experimental|Imaging|PET-MRI PET-CT
89652434|NCT01381679||All participants|Participants in whom LDL-C target levels have not been achieved and for whom ezetimibe therapy has been chosen.
89045924|NCT05384262|Active Comparator|Cohort 6: Part B - AZD0780 dose 6/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
89045925|NCT05384262|Active Comparator|Cohort 7: Part B - AZD0780 dose 7/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
89045926|NCT05384262|Active Comparator|Cohort 8: Part B - AZD0780 dose 8/placebo tablet|A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.
89045927|NCT05384262|Active Comparator|Cohort 9: Part B - AZD0780 dose 9/placebo tablet|A total of 6 subjects will receive single and multiple ascending doses of AZD0780 and 2 will receive placebo.
89045928|NCT05384262|Active Comparator|Cohort 10: Part B - AZD0780 dose 10/placebo tablet|A total of 6 subjects will receive single and multiple ascending doses of AZD0780 and 2 will receive placebo.
89045929|NCT05384262|Active Comparator|Cohort 11: Part A2 - AZD0780 dose 11/placebo tablet|A total of 5 subjects will receive single ascending doses of AZD0780 and placebo.
89652435|NCT01832337|Experimental|precondition|
89652436|NCT03217539|Experimental|Active Study Population|In the experimental arm, women aged 40-74 who were randomly selected to receive an invitation to undergo imaging with periodic single view mammography screening. This arm is referred to as the Active Study Population (ASP)
89652437|NCT03217539|No Intervention|Passive Study Population|In the no intervention arm, women aged 40-74 who were randomly selected to not receive an invitation to undergo periodic single view mammography screening received usual care. This arm is referred to as the Passive Study Population (PSP)
89652438|NCT05631665|Experimental|postmenopausal women|women with postmenopausal sexual function problems will be the study arm
89652439|NCT05631587|Experimental|Intervention condition (WExercise)|Participants will receive a written information sheet (i.e., PA guide, safety precautions, and goal) same as the control group. In addition, participants in the WExercise group will be provided with 10 weekly technology-based classes delivered in a mobile application aimed at promoting PA. Participants will be given individualised access to the app. The classes aim at developing reflective, regulatory, and reflexive processes of cancer survivors to engage in PA based on the M-PAC framework. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.
89688615|NCT03402581||mc-grath used for intubation|obese patients intubated with mc-grath videolaryngoscope
89045930|NCT05384262|Active Comparator|Cohort 12: Part B - AZD0780 dose 1/rosuvastatin dose 12|A total of 20 subjects will receive single dose of AZD0780 and rosuvastatin.
89045931|NCT05384262|Active Comparator|Cohort 13: Part B - placebo tablet/rosuvastatin dose 12|A total of 20 subjects will receive single dose of placebo and rosuvastatin.
89045932|NCT05384262|Active Comparator|Cohort 14: Part B - AZD0780 with placebo tablet/AZD0780 with rosuvastatin dose 12|A total of 20 subjects will receive AZD0780 in combination with rosuvastatin or 5 subjects will receive placebo in combination with rosuvastatin.
89045933|NCT05370079|Other|Control cohort|Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
89045934|NCT05367245|Experimental|Cal-Mag-Butyrate|Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.
89045935|NCT05367245|Placebo Comparator|Placebo for Cal-Mag-Butyrate|Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.
89045936|NCT05367076|Experimental|FitABCS exercise|Web-based community-led, 12-week exercise program
89045937|NCT05359783|Experimental|Sentinel node detection with 0.1mL SPIO|An intradermal injection of SPIO (MagTrace®), according to the pre-specified dose of 0.1mL, will be performed 7 days, up to the day of surgery. The injection should be in the skin over the tumour, or at the border of the areola
89045938|NCT05348863|Experimental|SPARK app|Access to the SPARK app which will provide support for a healthier diet and increased physical activity as well as daily monitoring of blood glucose levels.
89045939|NCT05348863|No Intervention|Control arm|Standard care i.e., the routine treatment program for GDM delivered by the care provider.
89045940|NCT05338697||Ischemic & Hemorrhagic stroke patients|557 ischemic stroke patients and 100 hemorrhagic stroke patients
89045941|NCT05331729|Experimental|Patients with idiopathic pulmonary fibrosis|
89045942|NCT05331729|Active Comparator|Healthy volunteers|
89045943|NCT05309733||Observational Cohort 1|All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
89045944|NCT05306834|Active Comparator|Minimal cSVD patient group|little or no white matter hyperintensities
89045945|NCT05306834|Active Comparator|Extensive cSVD patient group|moderate to severe white matter hyperintensities
89045946|NCT05302908|Experimental|Spanish-speaking Latinx communities|Individual in-depth interviews with Spanish-speaking Latinx participants
89652440|NCT05631587|Active Comparator|Control condition (Self-directed exercise)|Participants will receive a one-page written information sheet regarding the PA guidelines for cancer survivors and exercise safety precautions extracted from the website of the Centre for Health Protection of the HKSAR Government. Although mixed aerobic and resistance exercise are recommended, participants will be provided with a simple goal of increasing their aerobic exercise levels to 150 minutes of moderate aerobic activity or 75 minutes of vigorous aerobic exercise per week because resistance exercise requires instructions from trained personnel.
89652441|NCT01832415||Use of bevacizumab (Avastin ®) - First-line ovarian cancer|Patient receiving bevacizumab in ovarian cancer first line treatment
89652442|NCT05631431|Placebo Comparator|Placebo|
89652443|NCT05631431|Active Comparator|Treatment|
89652444|NCT01455194|Active Comparator|CIC 160|Two puffs of 40 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 160 mcg)
89652445|NCT01455194|Active Comparator|CIC 320|Two puffs of 80 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 320 mcg)
89652446|NCT01455194|Active Comparator|CIC 640|Two puffs of 160 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 640 mcg)
89652447|NCT03089281|Other|SmartDelay™ algorithm|Subjects programmed with AV Delay and pacing chamber determined by SmartDelay
89652448|NCT03089281|Other|Fixed AV Delay with BiV pacing|Subjects programmed with a Fixed AV Delay of 120ms with BiV pacing
89652449|NCT03216759|No Intervention|control group|Tourniquet would be tied to left upper limb of Patients who undergoing laparotomy for 30 minutes after the induction of anesthesia,but put no press on it. Other processes are consistent with conventional methods.
89652450|NCT03216759|Experimental|intervention|"After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning.~At the beginning of anesthesia induction, 3 μg / kg / h of dexmedetomidine was infused and adjusted to 0.3 ug / kg / h after 10 min of infusion until 30 minutes before the end of the procedure.~Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap."
89652451|NCT01839825|Experimental|QuietCare|QuieCare system installed
89652452|NCT01839825|No Intervention|control|no system installed
89652453|NCT01839903|Active Comparator|RIH EDIS|Data will be collected in two steps at the RIH site: step one will be care as usual. Step 2 will involve changes to the EDIS system
89045947|NCT05292846|Experimental|Uninterruped direct-acting oral anticoagulation|Uninterrupted direct-acting oral anticoagulation in patients undergoing trans-radial percutaneous coronary procedures
89045948|NCT05282342||Transplanted with low levels of physical activity (TPL)|
89045949|NCT05282342||Transplanted with moderate levels of physical activity (TPM)|
89045950|NCT05282342||Transplanted with high levels of physical activity (TPH)|
89045951|NCT05282342||Healthy sedentary individuals (S)|
89045952|NCT05270837|Experimental|Pegvaliase|
89652454|NCT01839903|Active Comparator|Care as usual|Care as usual in the ED will be tracked
89652455|NCT03570385|Experimental|Patient with Optic Neuritis|
89652456|NCT01832571|Experimental|Once daily Truvada®|One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
89652457|NCT01454726|Experimental|experimental group|receiving both Diaoshi Jifa therapy and the Western medical treatment.
89652458|NCT01454726|Other|control group|receiving the Western medical treatment alone.
89652459|NCT01361568|Experimental|CR845|Peripheral kappa opioid receptor agonist
89652460|NCT01361568|Placebo Comparator|Placebo|Matched Placebo
89652461|NCT03084367||iFR post angiographically successful PCI|
89652462|NCT04076696|Experimental|Scatter corrected s-DCT|The study scan, s-DCT and correction scan, will be performed within two weeks of the patient's clinical evaluations by chest CT and x-ray. The study scan may be done within 2 weeks prior or two weeks following standard of care imaging. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the standard of care (SOC) imaging and the s-DCT. All patients will have a breath held s-DCT scan in an anterior-posterior direction.
89045953|NCT05270837|Other|Drug: Diet Only|Participants will be managing their PKU with diet alone. Participants in the diet-only control arm will be required to maintain and adjust dietary and medical protein food intake through Week 72, initiating pegvaliase treatment beginning Week 73 and, from Weeks 73 through 215.
89652463|NCT01832649|Experimental|Exercise|Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
89652464|NCT01832649|Active Comparator|Health education|Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
89652465|NCT04399057||andrological patients|shear wave elastosonography of the corpora cavernosa was performed to all patients who went to our clinic for andrological problems. in addition, the International Index of Erectile Function short form (IIEF5) questionnaire and the Erectile Hardness Score (EHS) questionnaire were administered.
89045954|NCT05268315|Experimental|Brief Psychoeducational Intervention|Parents of children with cancer who complete the study participate in a brief, 1-session psychoeducational intervention.
89045955|NCT05237648|Experimental|Experimental Group|Participants will complete an online module with content focusing on patient self-rating of vocal quality within 24 hours of evaluation, approximately 1-2 weeks prior to their first therapy session, and within 24 hours after each therapy session;
89652466|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
89652467|NCT03216993|Experimental|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
89652468|NCT05368805|Experimental|Part A|On Day 1, a single oral dose of dabigatran etexilate 150 mg will be given under fasted conditions and serial PK samples will be collected as indicated on the schedule of events. On Day 5, subjects will receive a single oral dose of fruquintinib 5 mg at approximately 1 hour prior to administration of a single oral dose of dabigatran etexilate 150 mg under fasted conditions and serial PK samples will be collected
89652469|NCT05368805|Experimental|Part B|On Day 1, a single oral dose of rosuvastatin 10 mg will be given under fasted conditions and serial PK samples will be collected as indicated on the schedule of events. On Day 5, subjects will receive a single oral dose of rosuvastatin 10 mg with fruquintinib 5 mg under fasted conditions and serial PK samples will be collected
89652470|NCT01454570|Experimental|Powered Exoskeleton|persons with SCI trained to use a powered exoskeleton to ambulate overground
89652471|NCT01839981|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89652472|NCT03081156|Active Comparator|Glycopyrrolate/Formoterol Inhaler|Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
89652473|NCT03081156|Placebo Comparator|Placebo|Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
89652474|NCT02079311|Experimental|Active self-warming blanket|Active warming with BARRIER® EasyWarm active self-warming blanket during the perioperative phase
89652475|NCT02079311|Active Comparator|Forced air warming device|Active warming with forced air warming (FAW) during the intraoperative phase.
89652476|NCT01494350|Experimental|WR 279,396 topical cream|120 subjects will be enrolled to this open label study to receive WR 279,396 topical cream
89652477|NCT03217149|Experimental|heliox combined with mechanical ventilation (MV)|heliox combined with mechanical ventilation (MV) is given to infant with ARDS
89652478|NCT03217149|Active Comparator|mechanical ventilation|mechanical ventilation (MV) is given to infant with ARDS
89652479|NCT04407455||Children with cerebral palsy|Children who will be referred to pediatric dentistry above the age of 2 years.
89652480|NCT04407455||Children with typical development|Children who will be referred to pediatric dentistry above the age of 2 years.
89652481|NCT01725711|Experimental|Implant System|
89652482|NCT02135484|Experimental|Alpharadin|Participants treated with standard dosing of Alpharadin 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
89652483|NCT03281629|Active Comparator|Active TMS stimulation|Real active rTMS stimulation.
89652484|NCT03281629|Sham Comparator|Sham TMS stimulation|Sham repetitive TMS stimulation.
89652485|NCT01832805|Experimental|Theta burst stimulation|Specific developed sham coil.
89652486|NCT01725789|Experimental|Ferinject® Group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
89652487|NCT01725789|Placebo Comparator|Placebo Group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
89652488|NCT05630729|Other|My Kidney Guru Intervention|Youth Participants with CKD will complete the 9 My Kidney Guru modules over the 6-month intervention period, at a rate of approximately one module every 2-3 weeks. Parent participants will complete the parent module within the first t2 weeks of the intervention period, and to review the remaining youth modules by the end of the trial period. Participants will complete outcomes measures within 1 month prior to beginning the intervention. Software usage data will be gathered regarding fidelity and dosage of the My Kidney Guru intervention. Within 1 month of completing the intervention period, participants will complete the same set of outcomes assessments, along with an evaluation survey of the intervention. Once post-intervention data collection has been completed and the intervention period has ended, participants will participate in a 45 minute follow up Web-Ex focus group to provide feedback on their experiences with My Kidney Guru and collect additional suggestions for improvement.
89652489|NCT03271333||patients with systemic sclerosis|
89652490|NCT03837171|Active Comparator|Liberal strategy|Maintain a hemoglobin level > 9 g/dL during the first 48 hours of resuscitation of septic shock
89652491|NCT03837171|Experimental|Restrictive strategy|Maintain a hemoglobin level > 7 g/dL during the resuscitation of septic shock
89652492|NCT05630651|Experimental|ZS801|Single intravenous (i.v.) infusion of ZS801 Intervention: Gene Therapy / Gene Transfer
89652493|NCT03258385|Active Comparator|Vitamin B12-fortified UHT milk|Supplementation group (N=74) that will receive vitamin B12 fortified UHT milk daily
89652494|NCT03258385|Placebo Comparator|Plain UHT milk|Placebo group (N=74) that will receive plain UHT milk daily
89652495|NCT05068050|Experimental|Experimental group|This arm will be provided by horse-assisted therapy interventions.
89652496|NCT05068050|Active Comparator|Control group|This arm will be provided by the physical exercise interventions.
89045956|NCT05237648|Sham Comparator|Sham Control Group|Participants will complete an online module within 24 hours of evaluation, approximately 1-2 weeks prior to their first therapy session, and within 24 hours after each therapy session with content focusing on vocal hygiene.
89045957|NCT05237648|No Intervention|Control group|Participants will not complete an online module. The groups will be compared in terms of attendance, self-efficacy, and treatment outcome measures based on the data collected within the NYU Voice Center standard of care
89045958|NCT05232708|Experimental|Semaglutide B, 1.34 mg/mL followed by Semaglutide D, 1.0 mg/mL|
89045959|NCT05232708|Experimental|Semaglutide D, 1.0 mg/mL followed by Semaglutide B, 1.34 mg/mL|
89045960|NCT05230758|Experimental|Metformin|Oral metformin will be administered approximately 500mg/m2/day for 1 week and increased to 1000mg/m2/day for 15 weeks. Doses will be rounded to increments of half tablets (250mg, 500mg, 750mg and 1000mg).
89045961|NCT05230758|Placebo Comparator|Placebo|Oral placebo will be administered approximately 500mg/m2/day for 1 week and increased to 1000mg/m2/day for 15 weeks. Doses will be rounded to increments of half tablets (250mg, 500mg, 750mg and 1000mg).
89045962|NCT05226494|Experimental|Treatment (fb-PMT)|Daily subcutaneous injection of fb-PMT in four escalating cohorts to determine maximum tolerated dose, followed by treatment of up to 10 additional patients at maximum tolerated dose.
89045963|NCT05224531|Experimental|CS1 480 mg dose group|480 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
89652497|NCT03024593|Experimental|Searching condition|To simulate participants' natural behavior they are requested to search online for personally relevant health or illness information in their usual manner. By doing so their attentional focus lies on the searching process and the information they obtain.
89652498|NCT03024593|No Intervention|Waiting condition (i.e. non- searching, no distraction)|Participants are requested to do nothing and not to distract themselves by reading or using their smartphone for instance. By doing so, it is expected that their attentional focus lies on their induced worries and symptoms.
88993677|NCT02951728|Experimental|Decitabine plus R-CHOP|"Rituximab 375 mg/m2 IV d6; Cyclophosphamide 750mg/m2 IV d7; Doxorubicin 50mg/m2 IV d7; Vincristine 1.4 mg/m2 IV d7; Prednisone 60 mg/m2 PO d7-11;~Decitabine will be administered intravenously at dose levels as follow in Phase 1:~Dose level 1: Decitabine 10 mg/m2 days 1-5; Dose level 2: Decitabine 15 mg/m2 days 1-5; Dose level 3: Decitabine 20 mg/m2 days 1-5 and determine the maximum tolerated dose.~In phase 2, Decitabine will be administered intravenously at MTD."
88993678|NCT04726046|Experimental|Antibiotic treatment group|They were Antibiotic treatment group (AG, cefotetan 1g, 1 dose/prophylactic) before surgery.
88993679|NCT04726046|No Intervention|Non-antibiotic treatment group|They were Non-antibiotics treatment such as cefotetan 1g before surgery.
88993680|NCT00167505|Experimental|Risk Avoidance|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
88993681|NCT00167505|Experimental|Risk Reduction|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
88993682|NCT00523354|Experimental|1 (open-label)|prospective, open label, uncontrolled trial
88993683|NCT02276794|Experimental|Thrust manipulation (TM)|"The patients allocated to the TM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive a rotational TM technique. The treating therapist will have up to two attempts to perform the TM in each patient.~There is no need for cavitation in order to consider the TM successful; the occurence of cavitation, however, will be recorded.~A single treatment will be provided."
88993684|NCT02276794|Experimental|Non-thrust manipulation (NTM)|"The patients allocated to the NTM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive 30 oscilations of a grade III rotational NTM.~A single treatment will be provided"
88993685|NCT00523393|No Intervention|1|
88993686|NCT00523393|Experimental|2|
88993687|NCT00523393|Active Comparator|3|
88993688|NCT00523432|Experimental|A|Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
88993689|NCT00523432|Experimental|B|Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
88993690|NCT00523510|Experimental|Feasibility Study|HIV positive women [and a smaller number of HIV negative/unknown status (1 for every 3 infected women)] to avoid stigmatizing home-based counseling will be recruited at 1-2 postpartum and provided enhanced home-based infant feeding counseling by community health workers to exclusively breastfeed for 6 months. Mothers will also be told about the option to Flash-heat breastmilk during and after the transition from exclusive breastfeeding. Mothers who choose to Flash-heat will be provided continued home-based counseling and support. Feasibility data will be collected during the time mothers Flash-heat.
88993691|NCT00523510|Experimental|Pilot efficacy|We will collect infant health data to monitor and compare health outcomes among 3 groups of infants who had exclusive breast feeding (EBF) for the first months and then either: 1) fed Flash-heated breast milk and complementary foods (n=30), or 2) weaned to replacement foods and NO breast milk (n=15; per standard WHO recommendation for rapid cessation), or 3) continued feeding at the breast and providing other foods and/or fluids, i.e. mixed feeds (n=15; per WHO consensus that breastfeeding continue if replacement feeding is not AFASS94). We will collect infant growth and morbidity data. Infant health outcomes will be compared for the 3 groups noted above. These data will be collected primarily to pilot an efficacy trial.
88993692|NCT00512044|Active Comparator|A: general|general anesthesia: spinal and general
88993693|NCT00512044|Experimental|B: pudendal|local anesthesia: pudendal block
88993694|NCT00521950|Experimental|Intervention, TPMT genotyping|Pre-treatment TPMT genotyping to optimize initial thiopurine treatment dose. Intervention is based on the genotype.
88993695|NCT00521950|Active Comparator|control|Standard thiopurine treatment
88993696|NCT00523666|Active Comparator|1|
88993697|NCT00523666|Placebo Comparator|2|
88993698|NCT00167583|Active Comparator|A Cyclosporin A|Cyclosporin A
88993699|NCT00167583|Active Comparator|B Interferon alpha|Interferon-alpha2a
88993700|NCT00512200||Case|Patients aged 65 or older
88993701|NCT00512200||Control|Patients aged 20 to 40
88993702|NCT00512200||Control 2|Healthy volunteers aged 65 or older
88993703|NCT03943511|Active Comparator|Group 1|Oral Antibiotics
88993704|NCT03943511|Active Comparator|Group 2|Standard of Care
89652499|NCT01838031|No Intervention|the control group|The serum will be stored and the measurements will be obtained after the delivery
89652500|NCT01838031|Active Comparator|the thyroid screening group|The thyroid function and antibody will be measured during pregnancy. The subclinical hypothyroidism will be treated individually.
89652501|NCT05068362|Other|Implant|Use of Medpor implant in auricle reconstruction in microtia
89652502|NCT04005989|Placebo Comparator|PLACEBO GROUP|injection of saline solution
89652503|NCT04005989|Active Comparator|Low dose group|hASC injection (1x10e6 / kg body weight)
89652504|NCT04005989|Active Comparator|Intermediate Dose|injection of hASC (2x10e6 / kg of body weight)
89652505|NCT04005989|Active Comparator|High dose group|injection of hASC (4x10e6 / kg body weight)
89652506|NCT01725867|Experimental|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
89652507|NCT01725867|Active Comparator|Splint group|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
89652508|NCT03101904|Experimental|Nitrate then Placebo|"Participants will consume a daily a beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
89652509|NCT03101904|Placebo Comparator|Placebo then Nitrate|"Participants will consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
89045964|NCT05224531|Experimental|CS1 960 mg dose group|960 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
89652510|NCT03024515|Experimental|Standard Practice Arm|Standard Practice Arm with opioids titration of physicians' choice
89652511|NCT03024515|Experimental|Structured Tritration Arm|Structured titration method with predefined titration steps with the use of oxycodone immediate-release and oxycodone sustained-release preparations.
89652512|NCT01834911|Experimental|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
89652513|NCT03170947|Experimental|Custom insoles|Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. Custom insoles will make with direct adaptation technique (TAD) being of pvc resin.
89652514|NCT03170947|Active Comparator|Standardized insoles|Standardized insoles will be done by Ethylene-vinyl acetate (EVA) material.
89652515|NCT01725945|No Intervention|Usual Care|Usual Care
89652516|NCT01725945|Experimental|DASH Intervention|Dietary Approaches to Stop Hypertension dietary pattern. Usual care in combination with a DASH intervention consisting of 8 group and 3 individual sessions over 3 months, followed by 3 monthly phone consultations.
89652517|NCT04287829|Experimental|pembrolizumab and lenvatinib|"Patients will receive pembrolizumab 200mg/iv (fixed dose) every 3 weeks and lenvatinib 20mg QD in a three weekly cycle.~Treatment continues until disease progression by modified RECIST 1.1 for MPM, severe toxicity, serious intercurrent illness, patient request for discontinuation, need or use for any other anti-cancer agent other than protocol treatment, except for palliative radiotherapy, for a maximum period of 35 cycles"
89652518|NCT01953276||Serial Electrocardiogram Arm|All study participants will receive serial electrocardiograms.
89652519|NCT01726413|Experimental|Test Arm|GRC17356 for daily administration
89652520|NCT01726413|Placebo Comparator|Placebo|Matching placebo for daily administration
89652521|NCT05367869|Experimental|Intraoperative Spraying Methylene Blue In Thyroidectomy|
89652522|NCT03082651|Active Comparator|Constant training/Constant footwear|Group 1 - Runners will be assigned identical training sessions over a 7-day period and will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus). The weekly training volume will increase on a weekly basis in order to progressively increase training load in preparation for the half-marathon event.
89652523|NCT03082651|Experimental|Alternate training/Constant footwear|Group 2 - Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period. As with Group 1, weekly training volume will increase on a weekly basis. Runners in Group 2 will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
89652524|NCT03082651|Experimental|Constant training/Alternating footwear|Group 3 - Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
89652525|NCT03082651|Experimental|Alternating training/Alternating footwear|Group 4 - Runners will be assigned a variation of workouts throughout each 7-day period and will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak).
89652526|NCT01720017|Active Comparator|Inservice Training Only|Inservice training will include review of a product information handout and a video demonstration. Specific attention will be given to (1) describing each system component and its operation, (2) attaching the wireless camera head and coordinating channel selection with the monitor, (3) turning on the Airtraq Avant light and device preparation for use, (4) Airtraq Avant insertion into the patient's mouth and advancement into the hypopharynx (deep in the throat) to obtain a view of the vocal cords, (5) use of standard lift and rotation movements to optimize the vocal cord view, (6) tracheal tube advancement through the vocal cords tracheal intubation, (7) standard methods for confirmation of correct tracheal tube placement, (8) tracheal tube removal from the Airtraq Avant and the Airtraq Avant removal from the patient's mouth, and (9) disposal of the disposable blade and cleaning of the reusable optics insert.
89045965|NCT05224531|Experimental|CS1 1920 mg dose group|1920 mg of CS1, twice daily administration with 1/3 of the dose in the morning and 2/3 in the evening.
89045966|NCT05222828|Experimental|Mepivacaine arm|mepivacaine injection
89045967|NCT05212246|Experimental|5% Imiquimod Cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
89688616|NCT02808130||group H|"Group H: normolipidemic+ periodontally healthy individuals The healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
89652527|NCT01720017|Experimental|Inservice and Manikin Training|Study subjects in this group will receive the standard inservice training described above, as well as, preclinical manikin training on use of the Airtraq Avant and Wireless Monitor System in simulated difficult airway conditions (swollen tongue and cervical collar). During the preclinical manikin training, each subject will perform 10 intubations. Performance characteristics including attempts for successful Airtraq Avant insertion, glottic view obtained, ease of insertion, ease of tracheal intubation, time required for tracheal intubation, and attempts for successful tracheal intubation will be recorded for each intubation.
89652528|NCT05361161|Experimental|Transarterial Chemoembolization With Lipiodol for Initial Unresectable Gastric Cancer|
89652529|NCT03101202|Experimental|SSD Arm|In the SSD arm, the patients will be intubated with an endotracheal tube with suglottic suction drainage (SSD tube)
89652530|NCT03101202|No Intervention|Standard Arm|In the standard arm, the patients will be intubated with the standard endotracheal tube which does not have subglottic suction.
89652531|NCT01720095|Experimental|Niaspan|these are the first episode psychosis patients that are randomized to receive niaspan
89652532|NCT01720095|No Intervention|healthy control|this is the group of healthy controls for cognitive outcome measures
89652533|NCT01720095|No Intervention|first episode control group|first episode psychosis patients who are randomized to no intervention
89652534|NCT03082027||ultrasonography|diagnostic tool
89652535|NCT03082027||operative release|
89652536|NCT05067660|Active Comparator|Cohort A - Standard-of-care template-based salvage radiotherapy|Study participants in cohort A undergo template-based salvage radiotherapy according to current standard-of-care protocol. Dose fractionations include dose of 70/2 Gy in the prostatic bed, 50/2 Gy in the pelvic lymph node area and 45/1,8 Gy in the para-aortic lymph node. To the PSMA PET-CT positive lymph nodes, a boost dose will be considered depending on the anatomic site and will be delivered with a simultaneous integrated boost technique (SIB). The typical boost dose to PSMA PET-CT positive lymph nodes is 57,5/2,3 Gy, respecting normal tissue constraints. The dose to PSMA PET-CT positive areas in the prostatic bed is 74-78/2 Gy.
89652537|NCT05067660|Experimental|Cohort B - PSMA PET CT-targeted stereotactic ablative radiotherapy|Study participants in cohort B undergo stereotactic ablative radiotherapy, targeted only to PSMA PET-CT-positive areas judged to be suspicious of prostate cancer metastasis by nuclear medicine physician. Dose fractionations in the experimental arm vary from 24/8 Gy to 30/10 Gy in PSMA PET-CT positive lymph nodes in pelvic or para-aortic areas. PSMA PET-CT positive areas in the prostatic bed receive a dose of 35/7 Gy.
89652538|NCT01720329|Active Comparator|Probiotics|Participants randomized to probiotics will receive 2 capsules supplemented with 10 billion cfu of Lactobacillus rhamnosus GG on a daily basis for six months
89652539|NCT01720329|Placebo Comparator|Probiotic placebo|Participants randomized to placebo will receive 2 capsules of matching placebo on a daily basis for six months
89652540|NCT03139045|Active Comparator|Venous puncture using VVV at the beginning of the procedure|
89652541|NCT03139045|Active Comparator|Venous puncture without VVV|
89652542|NCT04859088|Experimental|Partial Enteral Nutrition|Patients allocated to Partial Enteral Nutrition study arm will be asked to replace 50% of their daily energy requirements with a proprietary formula (Modulen IBD, Nestle) for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
89652543|NCT04859088|No Intervention|Unrestricted diet|Patients allocated to unrestricted diet study arm will be asked to follow their normal diet for 6 weeks alongside standard care of treatment with adalimumab as induction therapy.
88993705|NCT02951923|Experimental|Bovine colostrum|8 weeks of Bovine colostrum power, 60g per day
88993706|NCT02951923|Active Comparator|Soy powder|8 weeks of Soy powder, 60g per day
88993707|NCT03922802|Experimental|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|"May receive up to 45 minutes of AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.~Intervention: Device: AIH prior to Noninvasive spinal stimulation during gait training"
88993708|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
88993709|NCT03922802|Sham Comparator|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|May receive up to 45 minutes of Sham AIH prior to up to 50 min of locomotion training with sham transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
88993710|NCT00172809|Active Comparator|1|Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks
88993711|NCT00172809|Active Comparator|2|Interferon alfa-2a (Roferon, Hoffmann-LaRoche) 3 MU tiw for 24 weeks
88993712|NCT04696120|Experimental|Study group: apixaban|apixaban 2.5mg or 5mg bid
88993713|NCT04696120|Placebo Comparator|Control group: placebo|placebo bid
88993714|NCT00523900|Experimental|Experimental|Malnourished adults who will be given a dietary supplement.
88993715|NCT00512356|Experimental|Investigational product group|"Anti-Adhesion Product was applied to the rectal stump and the incision line.~Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves."
88993716|NCT00512356|No Intervention|Control group|Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied.
88993717|NCT04694014||Emotional Intelligence Skills study among frontline HCW managing Covid19 in Busia Kenya|Researchers from Alupe University College will select study participants as follows 6 Clinical officers, 2 nurses, 1 nutritionist, 1 lab technician, 2 lab technologists, 7 members on the sub county surveillance Matayos, Teso north and Bunyala 2 from UHC office
88993718|NCT04693741|Other|"Autogenous iliac bone graft group A"|The autogenous iliac bone graft will be used to fill the alveolar defect.
88993719|NCT04693741|Other|"Xenograft with PRF group B"|Xenograft with PRF will be used to fill the alveolar defect.
89045968|NCT05212246|Placebo Comparator|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
89652544|NCT03836157|Experimental|Mirvetuximab and Bevacizumab|"Mirvetuximab Soravtansine 6mg/kg IV (adjusted ideal body weight), on day 1 of each 21 day cycle.~Bevacizumab 15 mg/kg, IV, on day 1 of each 21-day cycle."
89652545|NCT03080545|Experimental|Open Label Enstilar|open label
89045969|NCT05212090|Other|Pre-THA|Subjects will be receiving EOS imaging prior to Total Hip Arthoplasty
89652546|NCT03101124|Experimental|abdominoplasty moistening|Tranexamic Acid 25 mg/ml for wound surface moistening prior to wound closure
89652547|NCT03101124|Experimental|abdominoplasty bolus|Tranexamic Acid 5 mg/ml as bolus in wound cavity after wound closure
89652548|NCT03101124|Active Comparator|preoperative intravenous administration|Tranexamic Acid Injectable Solution administered before hip replacement surgery
89652549|NCT02985203|Experimental|Vinorelbine oral|Oral Navelbine plus Cisplatin followed by metronomic oral vinorelbine.
89652550|NCT02985203|No Intervention|Physician's choice|Observation or maintenance therapy other than orla navelbine.
89652551|NCT01832883||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
89652552|NCT01832883||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
89652553|NCT01832883||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
89652554|NCT04480164|Experimental|NDMC 40 mg/day|Oral administration of two NDMC 20mg capsules per day over 6 weeks
89652555|NCT04480164|Experimental|NDMC 60 mg/day|Oral administration of three NDMC 20mg capsules per day over 6 weeks
89652556|NCT04480164|Experimental|NDMC 120 mg/day|Oral administration of six NDMC 20mg capsules per day over 6 weeks
89652557|NCT04480164|Placebo Comparator|Placebo|Oral administration respectively, according to the experimental arm considered, of two, three or six placebo capsules per day over 6 weeks
89652558|NCT03187561|Experimental|Family Foundations (FF)|The original Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants assigned to this arm
89652559|NCT03187561|Experimental|Sleep-adapted Family Foundations (FF+)|A sleep-adapted Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants in this arm. The adaptation will be an emphasis on coparenting in relation to infant sleep concerns and activities.
89652560|NCT03187561|Other|Control|Participants in this arm will not receive either intervention.
89045970|NCT05212090|Other|Post-THA|Subjects will be receiving EOS imaging after Total Hip Arthroplasty
89045971|NCT05206500|Other|Symptomatic Patients with low Colony Count|Patients with positive urinalysis, symptomatic, and Urine Culture Colony Count <10,000 to be treated based on Next Generation Sequencing result.
89045972|NCT05192954|Experimental|Vessel sealing device|Vessel sealing device to be utilized for vaginal hysterectomy
89045973|NCT05192954|No Intervention|Conventional clamping and suturing method|Vaginal hysterectomy will be performed utilizing conventional Heaney clamps, scissors, and suturing material.
89045974|NCT05191680|Experimental|Apalutamide 6 months|Participants will receive apalutamide 240 mg (4 x 60 mg tablets) orally once a day for up to 6 months.
89652561|NCT05632835|Experimental|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries.
89652562|NCT05632835|Active Comparator|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
89652563|NCT01703520||Male Finasteride Users|Male finasteride users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
89652564|NCT01703520||Male Finasteride Non-users|Country-matched male finasteride non-users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
89652565|NCT01703520||Men with Breast Cancer|Breast cancer cases among men aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
89652566|NCT01703520||Men without Breast Cancer|Country- and age-matched controls: men without breast cancer aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
89652567|NCT05247619|Experimental|Intervention|Tislelizumab + Bevacizumab + Paclitaxel + Cisplatin/Carboplatin
89652568|NCT04020965|No Intervention|Control arm|This arm includes all households in villages randomized to the active control arm (double-sized) or passive control arm of the original trial. Village-level promoter visited households enrolled in the WASH Benefits Kenya study active control arm and strictly engaged in recording the child's MUAC and referring children identified as malnourished (MUAC<11.5 cm) to health clinics, for two years. These visits were also conducted in all active comparator arms. Households in active control and active comparator villages which were not enrolled in the original study did not receive such visits.
89213032|NCT04080089||Case group|Children over the age of 6 who came to the outpatient clinic of our hospital received the informed consent of the parents, and then included in the case group, conducted a self-made sleep questionnaire, established a file, and monitored the sleep on the Mofeh Time Sleep Apnea Monitor. The results were uploaded to the cloud system for analysis. 50 children with OSAHS were screened. Voluntary participation in the study; ability to complete all tests as well as magnetic resonance studies. Exclusion criteria: 1 mental retardation, generalized developmental disorders, severe physical and endocrine diseases, neurological diseases and other mental disorders; 2 visual and auditory diseases affecting the processing of cognitive information. 3 Psychiatric drugs were used in January.
89213033|NCT04080089||Control group|Children in the same age group of children with health checkups were screened for sleep and questionnaires without sleep. After receiving parental informed consent, 30 children were included in the control group. Exclusion criteria: 1 mental retardation, generalized developmental disorder, learning disabilities, conduct Disorders, severe physical and endocrine diseases, neurological diseases and other mental illnesses. 2 There are visual and auditory diseases that affect the processing of cognitive information.
89213034|NCT00999297|Placebo Comparator|Sugar pill (Placebo o mg/d)|0 mg/d sugar pill
89213035|NCT00999297|Active Comparator|Dihydrocapsiate|Drug 3 mg/d or 9 mg/d including Placebo
89213036|NCT00999297|Active Comparator|3 mg/d or 9 mg/d Dihydrocapsiate|Drug including Placebo
89213037|NCT02582801|Experimental|breast cancer|Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
89213038|NCT02582801|Active Comparator|benign breast lesions|Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
89213039|NCT03929705||Test Arm 1- T-SPOT.TB assay|T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
89213040|NCT03929705||Test Arm 2 -QuantiFERON-TB Gold Plus assay|QuantiFERON-TB Gold Plus, for each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
89213041|NCT02583815||Cancer Patients|This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.
89652569|NCT04020965|Experimental|Water Treatment|This arm includes all households in villages randomized in the original WASH Benefits trial to the water treatment arm, combined water treatment with handwashing and sanitation (WASH) arm, and combined WASH + nutrition arm. Village-level promoter visited households enrolled in the original trial to promote the interventions for approximately two years.
89213042|NCT05388695|Experimental|19+22 CART and 19+20 CART|Eligible patients will be treated with 19+22 CAR-T and 19+20 CAR-T.
89213043|NCT04078451|Experimental|the experimental group|"The experimental group operated by the left side of laparoscopic cholecystectomy preserving the main cystic artery.~The operation area of cystic artery dissection is moved from the traditional triangular area to the gallbladder neck plane, away from the hepatic duct and hepatic portal.Only the superficial and even more minute branches of the cystic artery were isolated and coagulated."
89652570|NCT01726491||Insulin resistance epigenetics|"This experiment will use the Infinium methylation assay to perform epigenome mapping and define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. We will test the hypotheses that~(1) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (2) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (3) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance."
89652571|NCT01726491||Single bout of exercise|"This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and~Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise."
89652572|NCT01726491||Eight weeks of exercise|"This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes,~There is altered methylation of genes involved in inflammation and cytoskeletal structure."
89652573|NCT05249803||Patients with COVID-19 pneumonia|These patients were admitted in ICU for management of Covid-19 pneumonia usual care was offered to all patients
89652574|NCT01726647||No product is tested|No intervention
89213044|NCT04078451|No Intervention|the control group|treated with conventional laparoscopic cholecystectomy cutting the cystic artery
89213045|NCT00583115|Experimental|Gleevec|Drug taken orally 260mg/M2/day once per day
89213046|NCT04079075|Experimental|Non-pharmacological intervention|"Non-pharmacological strategy, implemented in groups of 10 participants, over 10 consecutive months, based on five different interventions:~cognitive training, physical activity; nutrition education; adaption to memory loss; detection and correction of hearing impairment."
89213047|NCT05370443|Experimental|Life Skills intervention group|The participants in the intervention group will receive eight sessions of the online life skills educational program via the zoom platform for eight weeks. Each session will last for 1-hour. All the participants will receive a short reminder SMS for enrolling in the online session. The assessment for all students will be done at baseline, immediate and 3-months post-intervention.
89213048|NCT05370443|No Intervention|control group|Participants in the control group will receive no intervention during the study period. However, they will receive the same educational activities after finishing study. They will answer the same questionnaires at baseline, immediately following the intervention, and three months later.
89213049|NCT02582411||Group 1: 18-34 years|Patients in age group 18-34 years
89652575|NCT01833273|Experimental|PolyMVA|This arm will be taking 8 tsp/day of the study compound (PolyMVA) in addition to receiving normal care as determined by his/her neuro-oncologist.
89213050|NCT02582411||Group 2: 35-49 years|Patients in age group 35-49 years
89213051|NCT02582411||Group 3: 50-64 years|Patients in age group 50-64 years
89213052|NCT02582411||Group 4: 65-80 years|Patients in age group 65-80 years
89213053|NCT00532779|Experimental|NB16|Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy
89213054|NCT00532779|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy
89213055|NCT00532779|Placebo Comparator|Placebo|Placebo with ancillary therapy
89213056|NCT02583737|Active Comparator|group lyophilized bone allograft|sinus lifting with tissue bank lyophilized bone filling
89213057|NCT02583737|Active Comparator|group freeze bone allograft|sinus lifting with freeze bone bank filling
89213058|NCT04489355||CABG|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG)
89213059|NCT04489355||CABG with SVR|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR)
89213060|NCT04489355||CABG with mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with and mitral repair (MR)
89652576|NCT05247307|Experimental|Intervention|"Treatment in the intervention group:~Infusion of 300 cc of convalescent donor plasma from COVID 19, administered within more than 168 hours from the onset of symptoms Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment."
89652577|NCT05247307|Active Comparator|Control|"Treatment in the control group:~For the study to be blind, the infusion of non-convalescent donor plasma, obtained before the start of the epidemic, is required to guarantee the absence of anti-COVID antibodies in the plasma of the control group.~Treatments in both arms of the study All patients included in the study will receive the same standard treatment that is deemed appropriate at any time, understanding as standard treatment that established at any time by the guidelines established by the Department of Health, or by the Osakidetza Directorate, in each moment."
89652578|NCT00805584|Experimental|Arm 1|
89652579|NCT01833351|Experimental|Phase I, IV Vitamin C Healthy Normals|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
89652580|NCT01833351|Experimental|Phase 1 IV Vitamin C- Cancer Patients|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
89652581|NCT05067192||Parkinson's Disease|Patients with Parkinson's Disease. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned
89652582|NCT05067192||Dementia with Lewy Bodies|Patients with Dementia with Lewy Bodies. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
89652583|NCT05067192||Multiple System Atrophy|Patients with Multiple System Atrophy. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
89652584|NCT05067192||Corticobasal Syndrome|Patients with Corticobasal Syndrome. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
89652585|NCT05067192||Progressive Supranuclear Palsy|Patients with Progressive Supranuclear Palsy. Patients will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 10 patients will be scanned
89652586|NCT05067192||Healthy controls|Healthy contols. Contols will undergo [18F]ACI-3847 PET, [18F]DOPA PET and MRI. Up to 20 patients will be scanned
89652587|NCT04017767|Experimental|Moderate to Severe Obstructive Sleep Apnea (OSA)|Individuals with moderate to severe OSA defined as having an Apnea-hypopnea Index (AHI) that is greater than or equal to 15.
89652588|NCT04017767|Active Comparator|Without OSA|Individuals without OSA defined as having AHI less than 5.
89213061|NCT04489355||CABG with SVR and mitral repair|The patients with ischemic cardiomyopathy underwent coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)
89213062|NCT03926273||group 1|Epileptic participants group consisted of 40 adults (15 females and 25 males) clinically and electrophysiological were diagnosed according to the international league against epilepsy classification 2010.
89652589|NCT05066958|Experimental|boost anti-viral immunity after T-cell depleted HSCT|
89652590|NCT00218543|Experimental|Atomoxetine|Atomoxetine
89213063|NCT03926273||group 2|Control group consisted of 40 adults (16 females and 24 males) non - epileptic healthy subjects.
89213064|NCT04078763|Experimental|visual-auditory feedback|Patients included in this arm will follow the rehabilitation protocol with visual-auditory feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
89213065|NCT04078763|Experimental|visual feedback|Patients included in this arm will follow the rehabilitation protocol with visual feedback. Performance of the rehabilitation protocol will be assessed thanks to 3 tests : SPHERE protocol, French Matrix Test and SSQ15 questionnaire
89213066|NCT04001673|Active Comparator|Pharmacist's intervention|Evaluation of knowledge and adherence of patients treated by bDMARDs before and after the intervention of a pharmacist that will give information concerning bDMARDs management.
89213067|NCT04001673|No Intervention|Control|Evaluation of knowledge and adherence of patients treated by bDMARDs who did not receive pharmacist's intervention.
89213068|NCT00500266|Experimental|1|13-valent Pneumococcal Conjugate Vaccine
89213069|NCT00996411|Experimental|Salvinorin A|
89213070|NCT02583659||Combined chemotherapy|AGC patients treated with first-line combined chemotherapy
89213071|NCT00996567|Experimental|Cetuximab (Erbitux)|
89652591|NCT04477668|Experimental|Helmet group|Patients will be allocated to helmet non-invasive ventilation
89652592|NCT04477668|No Intervention|Control group|Patients will be allocated to standard of care
89652593|NCT00795522|Experimental|Arm 1|Desloratadine
89652594|NCT00910845|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
89652595|NCT00910845|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
89652596|NCT05366309|Active Comparator|Standard Care (Control) Group|Participants randomised to this group will receive usual care in terms of their education.
89045975|NCT05191680|Experimental|Apalutamide 3 months + Placebo 3 months|Participants will receive apalutamide 240mg (4 x 60 mg tablets) orally once a day for up to 3 months followed by placebo to match apalutamide (4 tablets) orally once a day for up to 3 months.
89045976|NCT05191680|Placebo Comparator|Placebo 6 months|Participants will receive placebo to match apalutamide (4 tablets) orally once a day for up to 6 months.
89045977|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Not Receiving Active Treatment|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
89045978|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Treatment Break for BTKi|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
89045979|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Treatment Naive|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
89045980|NCT05170399|Experimental|Chronic Lymphocytic Leukemia Treatment with BTKi|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
89045981|NCT05170399|Experimental|Follicular Lymphoma|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
89045982|NCT05170399|Experimental|Follicular Lymphoma Treatment Naive|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
89045983|NCT05170399|Experimental|Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
89045984|NCT05170399|Experimental|Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia - Treatment with Targeted Therapies|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
89045985|NCT05170399|Experimental|Participants diagnosed with Chronic Lymphocytic Leukemia (CLL)|Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
89045986|NCT05161507||Non-palpable breast cancer lesion|Patients with the non-palpable histologically confirmed breast cancer lesion that will undergo breast-conserving surgery and sentinel lymph node detection - the tumor lesion will be labeled with Magseed.
89045987|NCT05161507||Palpable breast cancer lesion|Patients with the palpable histologically confirmed breast cancer lesion that will undergo breast-conserving surgery and sentinel lymph node detection - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag.
89045988|NCT05161507||Axillary lymph node metastasis|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy.
89045989|NCT05155566||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in Latin America
89045990|NCT05149534|Experimental|Active TMS/WET|Active repetitive transcranial magnetic stimulation completed prior to written exposure therapy
89045991|NCT05149534|Sham Comparator|Sham TMS/WET|Sham repetitive transcranial magnetic stimulation completed prior to written exposure therapy
89045992|NCT05096403|Active Comparator|Pegcetacoplan|1080 mg, subcutaneus injection, twice weekly
89045993|NCT05096403|Placebo Comparator|Placebo|Sodium acetate, subcutaneus injection, twice weekly
89045994|NCT05091788|Experimental|Treatment Arm|All subjects will receive two coring treatments on the cheeks with the robotic coring device.
89045995|NCT05079256|Experimental|Laser therapy|595 nm Pulsed dye laser (PDL) therapy for psoriasis
89045996|NCT05070793|Other|Culturally adapted interpersonal psychotherapy|Individual psychotherapy intervention based on Brief Interpersonal Psychotherapy (IPT-B) with additional cultural adaptation for transgender and nonbinary individuals.
89045997|NCT05069974|Experimental|Linezolid (LZD) 1200|Patients will take film coated tables of LZD 600 mg every 12 hours during 10 days
89045998|NCT05069974|Active Comparator|Benzathine Penicillin G (BPG)|Administration of intramuscular BPG 2.4 MIU single dose during day 1
89045999|NCT05069974|Experimental|Linezolid (LZD) 600|Patients will take film coated tables of LZD 600 mg every 24 hours during 5 days
89046000|NCT05068414||Patients with atrial fibrillation|
89046001|NCT05065411|Experimental|Enobosarm Combination Group|"Enobosarm Combination Group will receive enobosarm 9 mg each day by mouth (QD), and abemaciclib will administered by mouth at a dose of 150 mg BID.~Stage 2 Subjects in the Enobosarm Combination Group will receive enobosarm 9 mg QD each day by mouth and abemaciclib 150 mg BID by mouth until disease progression is observed and confirmed by BICR."
89046002|NCT05065411|Active Comparator|Control Treatment Group|Control Treatment Group will receive a non-steroidal AI, a non-steroidal or steroidal (exemestane with or without everolimus), AI OR fulvestrant approved for the treatment of metastatic breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The decision of which comparator treatment will be used will be made prior to randomization.
89046003|NCT05055570||Hypoxemia group|oxygenation index (OI)≤200
89046004|NCT05055570||Non-hypoxemia group|oxygenation index (OI)>200
89046005|NCT05053997|Experimental|NAVIGATE intervention arm|Nurse navigation
89046006|NCT05053997|No Intervention|Navigate control arm|Standard treatment and care
89652597|NCT05366309|Experimental|Tailored Education Group|Participants randomised to this group will receive tailored education, which is additional to standard care.
89046008|NCT05026177|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 76 weeks
89046009|NCT05026177|Experimental|Simufilam 50 mg|Simufilam 50 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
89652598|NCT05243251|Active Comparator|Olanzapine|82 patients will receive olanzapine 5 mg daily at night for 4 weeks
89652599|NCT05243251|Placebo Comparator|Placebo|82 patients will receive placebo for 4 weeks
89652600|NCT04434612|Experimental|OXSIGHT smart glasses|Wearing OXSIGHT smart glasses
89652601|NCT03045679|Experimental|RYGB-group|Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
89652602|NCT03045679|Experimental|OAGB/MGB-group|Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
89652603|NCT01720641|No Intervention|Control|Standardized partner notification counseling
89652604|NCT01720641|Experimental|Internet Notification|Standardized partner notification counseling and referral to internet-based partner referral website.
89652605|NCT01720641|Experimental|Referral Card|Standardized partner notification counseling and provision of 5 printed partner referral cards.
89046010|NCT05026177|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
89652606|NCT01720641|Experimental|Internet and Referral Card|Standardized partner notification counseling and referral to internet-based partner referral website and provision of 5 printed partner referral cards.
89652607|NCT05008770||Older adults without sarcopenia|Healthy volunteers aged 65+ years who do not fulfill diagnostic criteria for sarcopenia, according to the revised European Working Group on Sarcopenia in Older People (EWGSOP2)
89652608|NCT02997475||Women with Bulimia Nervosa|
89652609|NCT02997475||Women Healthy Controls|
89652610|NCT01833429||Resistant Hypertension|The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
89652611|NCT05245123||Families of rare diseased children|Clinical study participants are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf and University Medical Centre Mannheim due to the rare disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
89652612|NCT05245123||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-17 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
89652613|NCT04376424|Experimental|Ultra Sound Guided Therapy Group|Hand carried ultrasound will be used in this group to measure IVCd, collapsibility along with internal jugular vein collapsibility. The results of the ultrasound will be unblinded to the treating team.
89652614|NCT04376424|No Intervention|Conventional Therapy Group|Conventional therapy will occur the use of hand carried ultrasound. The results will be blinded to the treating team. The managing team will analyze the data at the end of the study.
89652615|NCT01726881|Experimental|Fresh Spinal Cord Injury patients|Spinal Cord Injury patients that are currently admitted to the rehabilitation unit with three weeks or less since injury that will over go several tests and will fill out several questionnaires.
89046011|NCT05018299|Placebo Comparator|FB704A placebo|placebo
89046012|NCT05018299|Experimental|FB704A|Anti-IL6 antibody
89046013|NCT05017545|Experimental|Cohort 1 (N=5 Subjects)|"The two investigational agents used in this study are carfilzomib and belatacept.~Per protocol, Carfilzomib administered intravenously:~Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43).~Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99).~Per protocol, Belatacept:~-Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert."
89213072|NCT02583581|Experimental|Participants diagnosed with migraine|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv)
89213073|NCT02852655|Experimental|Pre-surgery MK-3475|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~Pembrolizumab (MK3475) pre-surgery at pre-determine dosage followed by Pembrolizumab at pre-determine dosage every 3 weeks post surgery.~MK-3475 will be administered intravenously"
89652616|NCT01726881|Experimental|Chronic Spinal Cord Injury patients|Spinal Cord Injury patients with one year or more since injury that will over go several tests and will fill out several questionnaires
89652617|NCT01726881|Active Comparator|Healthy volunteers|Healthy subjects that will over go several tests and will fill out several questionnaires
89046014|NCT05017545|Experimental|Cohort 2 (N=10 Subjects)|"The enrollment of ten additional subjects and dosing regimen is dependent on the results in Cohort 1.°~Per protocol, Carfilzomib administered intravenously:~Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43).~Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99).~Per protocol, Belatacept:~-Belatacept will be administered intravenously on days 28 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert.~° May be modified based on the safety and efficacy analysis of Cohort 1."
89046015|NCT05000645|No Intervention|Women, Infants, and Children (WIC)|Usual WIC counseling and food benefits for use in person at approved grocery stores.
89046016|NCT05000645|Experimental|WIC + grocery delivery|Usual WIC counseling and food benefits, as well as twice-monthly home deliveries of WIC-approved foods.
89046017|NCT05000645|Experimental|WIC + grocery delivery + unsweetened beverage delivery|Usual WIC counseling and food benefits as well as twice-monthly home deliveries of WIC-approved foods PLUS unsweetened beverages to replace their current sugar-sweetened beverages (SSB) intake.
89046018|NCT04993625|Experimental|Avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|
89046019|NCT04992728||Male Prostate Patients|Adult male patients with fair to good performance status and who (1) have undergone an MRI of the prostate for suspected or known prostate cancer and/or (2) are planning to undergo radical prostatectomy for prostate cancer.
89046020|NCT04989816|Experimental|T-DXd arm|T-DXd monotherapy
89046021|NCT04989699|Active Comparator|OTX-TKI|
89046022|NCT04989699|Active Comparator|Aflibercept|
89046023|NCT04987086|Experimental|PSMA PET Arm|The PSMA PET arm received PSMA PET and enhanced CT at the same time in the diagnosis of the patients with suspected renal cancer.
89046024|NCT04980300|Experimental|Expanded Intervention|Virtual consultation sessions with a physical therapist, focusing on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis.
89213074|NCT02852655|Active Comparator|No MK-3475 at Pre-Surgery|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~Pembrolizumab (MK-3475) at pre-determine dosage every 3 weeks post surgery.~MK-3475 will be administered intravenously"
89213075|NCT00500110|Experimental|Hormonal Ablation, Imatinib + Docetaxel|Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months
89213076|NCT02582333||Tenofovir|Chronic hepatitis B patients who receive tenofovir as their first anti-HBV therapy and are indicated for stopping tenofovir therapy
89213077|NCT02582333||Entecavir|Chronic hepatitis B patients who receive entecavir as their first anti-HBV therapy and are indicated for stopping entecavir therapy
89652618|NCT05244265|Experimental|Mindfulness-based stress reduction (MBSR)|The 9 session MBSR program following the manual (Kabat-Zinn, 1982).
89652619|NCT05244265|Active Comparator|Treatment as usual (TAU)|Participants take part in their treatment as usual in outpatient habilitation and other services.
89652620|NCT01833507|Active Comparator|self-exercise|Intervention will include a video(DVD) on exercise, and 2 self-help manuals on exercise and nutrition, in addition to a journal and pedometer.
89652621|NCT01833507|Placebo Comparator|usual care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics.
89652622|NCT00216671|Experimental|001|early initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
89652623|NCT00216671|Active Comparator|002|routine initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
89652624|NCT01833585|Experimental|peripheral blood mononuclear cells|peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia
89652625|NCT00783354|Active Comparator|Continuous Treatment|
89652626|NCT00783354|Experimental|PRN regimen|
89652627|NCT05240365|Experimental|SDF modified Hall technique|"When Hall technique is used an accurate size of PMC is placed without local anesthesia, caries removal, or tooth preparation.~SDF is applied directly to carious lesions to arrest caries, the technique is noninvasive and relatively painless that could be a good option for treating dental caries in children"
89652628|NCT05240365|Active Comparator|Conventional pulpotomy and stainless steel crown|Amputation of the coronal pulp and treatment of the remaining vital radicular portion with a long term clinically successful medicament. Then using an accurate size of stainless steel crown.
89652629|NCT01727037|Experimental|BIABI arm|Patients will undergo intrabullous autologous blood instillation
89213078|NCT05335551||Patients monitored with TruGraf/TRAC Liver testing|"Subjects in the biomarker arm will have TruGraf Liver and TRAC Liver testing at study enrollment (1-2 months post-liver transplant) and thereafter every month for 6 months. Subjects will also have Trugraf Liver and TRAC Liver testing at months 9 and 12 following transplantation (7-8 and 10-11 months postbaseline)~The TruGraf and TRAC Liver results will be used in the biomarker arm in conjunction with all other clinical parameters available to guide decisions of the Principal Investigator and Sub-Investigators related to immunosuppression management.~changes."
89213079|NCT05335551||Patients not monitored with TruGraf/TRAC Liver testing|Patients in control/ stamdard of care arm will have immusuppresion reduction based on the clinical judgement and management of the Principal Investigator and Sub-Investigators.
89213080|NCT04358159|Experimental|Ventralex|Repair with Ventralex patch in sublay position
89213081|NCT04358159|Active Comparator|Progrip|Repair with Progrip in Onlay position
89213082|NCT05304533|Experimental|Arm 1: MYK-224|
89213083|NCT05304533|Experimental|Arm 2: MYK-224 + Itraconazole|
89213084|NCT05304533|Experimental|Arm 3: MYK-224 + Verapamil|
89213085|NCT00534495|Experimental|Group 1|Loading dose of rilonacept (4.4mg/kg) at Week 0, followed by rilonacept 2.2 mg/kg/week for the remainder of the study
89213086|NCT00534495|Placebo Comparator|Group 2|Placebo for 4 weeks, followed by rilonacept loading dose (4.4mg/kg), followed by rilonacept 2.2 mg/kg/week for the remainder of the study
89213087|NCT04077827|Experimental|Total intravenous anesthesia|"The patients will recieve intravenous anesthesia (propofol-remifentanyl)~Recommended dosage:~Propofol: Induction dosage 1,5-2,5 mg/kg Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
89652630|NCT05245344||Patients with RRMS (untreated)|"Relapsing-remitting MS, as diagnosed by the revised 2010 McDonald Criteria;~EDSS score ≤ 5.5;~Age between 18 and 55 years (exclusive);~no disease modifying therapies for at least 3 months or treatment naïve;~no corticosteroid administration in the previous month;~disease duration <10 years;~Ability to provide written informed consent."
89652631|NCT05245344||Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD)|"Main inclusion criteria of NMOSD patients (Wingerchuk et al., 2015):~Positive test for Aquaporin 4 IgG;~Age between 18 and 55 years (exclusive);~no immunosuppressive therapies for at least 3 months or treatment naïve.~no corticosteroid administration in the previous month~disease duration <10 years~Ability to provide written informed consent"
89652632|NCT05245344||Healthy subjects (HD)|"Age between 18 and 55 years (exclusive), matched by gender, age and ethnicity towards the MS groups.~Ability to provide written informed consent."
89652633|NCT01833663|Experimental|Solifenacin Succinate Tablets and Estrogen capsules|Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks
89652634|NCT01833663|Active Comparator|Solifenacin Succinate Tablets|Solifenacin Succinate Tablets (5mg/d) for 12 weeks
89213088|NCT04077827|Experimental|volatile anesthesia|"The patients will recieve volatile anesthesia (desflurane-remifentanyl)~Recommended dosage:~Desflurane dosage 6-7 MAC Remifentanyl: Induction dosage 0,5-1μg/min The preservation dosage will depend from patients' body weight, body height and BMI"
89213089|NCT00999375|Experimental|Group A|
89213090|NCT00999375|Active Comparator|Group B|
89213091|NCT00996645|No Intervention|Feedback report only|This arm will receive performance feedback reports but no worksheet to facilitate goal-setting and action plans.
89213092|NCT00996645|Experimental|Goal-Setting Worksheet|This arm will receive a theory-informed worksheet to facilitate the development of goals and action plans in response to the performance feedback reports.
89213093|NCT00996723|Other|1|
89213094|NCT03925805||Chronic disease|Cardiovascular disease (including diabetes), mental disease, musculoskeletal disease
89213095|NCT00999453|Experimental|LDL-cholesterol 70 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
89213096|NCT00999453|Active Comparator|LDL-cholesterol 100 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
89213097|NCT01019122||Dexa Scan|Eligible patients from 2003 study will receive a follow-up Dexa scan.
89213098|NCT05332587|Experimental|Rituximab Treated|rituximab
89213099|NCT04078529|Experimental|Intervention group|This group will complete a 5 day falls prevention training programme, followed by a 12 week home exercise programme, then a repeat 5 day training intervention.
89213100|NCT04078529|Active Comparator|Comparison group[|This group will complete the home exercise programme only.
89213101|NCT01015690||unexplained infertility|patients with unexplained infertility
89213102|NCT01015690||healthy controls|women who wish to conceive, no more tha 3 previous cycles, age above 18
89213103|NCT01015690||references|lesbian women with a regular cycle without use of anticonception and not at risk of becoming pregnant
89213104|NCT00996879|Experimental|Midazolam + BMS-791325|
89652635|NCT01720875|Experimental|Vorinostat Velcade Dexamethasone (VVD)|"Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression.~Cycles 1-8 (21-day cycle)~Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11~Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12~Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle)~Vorinostat: 400mg PO on 1-4 and 15-18"
89652636|NCT04277143||critical ill patient with bloodstream infections|Severe patients with bloodstream infections often have sepsis / septic shock, acute kidney injury (AKI), hypoproteinemia, and renal replacement treatment.
89652637|NCT00750750|Active Comparator|1|MFNS once daily
89652638|NCT00750750|Experimental|2|MFNS twice daily
89652639|NCT00750750|Active Comparator|3|Amoxicillin
89652640|NCT00750750|Placebo Comparator|4|Placebo
89213105|NCT02581397|Experimental|Transpulmin suppository|"It is a rectal suppository that is manufactured by Aché S.A. and which is composed of camphor, eucalyptol, guaiacol and menthol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
89213106|NCT02581397|Experimental|Guaiacol suppository|"It is a rectal suppository that is manufactured by Aché S.A. and consists of guaiacol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
89213107|NCT02581397|Active Comparator|Transpulmin syrup|"It is a syrup which is manufactured by Aché S.A. and which is composed of guaifenesin.~Transpulmin syrup will be dispensed to 90 participants of this group in a bottle of 150ml plus a dosing cup.~The participant shall administer 7,5ml orally every 4 hours, The duration of treatment may be up to 07 days."
89213108|NCT02582177|Experimental|Candicort®/ Nizoral®|Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage. The cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Nizoral ® will be dispensed to the same participants. It´s a cream composed by ketoconazole 20mg/g that will be applied in the affected area once a day for 14 days. The total duration of treatment may be 28 (+1) days.
89652641|NCT04379661|Experimental|Online support group|Online weekly 1-hour moderated support group sessions for 12-weeks; participants complete surveys at baseline and 12-week follow-up
89652642|NCT04379661|No Intervention|Treatment as usual|Inactive control group of participants who complete surveys at baseline and 12-weeks later
89652643|NCT04397887|Experimental|Men with Azoospermia and varicocele|In this single arm study, TEX 101 is measured in the seminal fluid of all participants, and it will be used as a predictor for appearance of sperms in the ejaculate in 3 and 6 moths follow-up periods
89652644|NCT05245110|Experimental|experimental group|received a tele-exercise training program
89652645|NCT05245110|No Intervention|control group|usual care only
89652646|NCT01727115|Active Comparator|NUTRAMIGEN®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Nutramigen® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Nutramigen®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
89652647|NCT01727115|Experimental|ALTHERA®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Althera® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Althera®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
89652648|NCT05066802|Experimental|modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42~46h continuous infusion, every other week for 6 cycles (12 weeks).
89688617|NCT02808130||Group G|"Group G: normolipidemic + gingivitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
89652649|NCT05066568|Other|Sequence of interventions starting with tDCS as the first intervention|"Week 1 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.~Week 3 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.~Intervention time: 20 minutes~Week 4 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes.~Week 5 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.~Intervention time: 20 minutes"
89652650|NCT05066568|Other|Sequence of interventions starting with Hypnosis as the first intervention|"Week 1 Hypnotic analgesia suggestion Classic approach. The intervention starts with a induction with suggestions for the subject to focus her attention in a single stimuli, combined with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction.~Intervention time: 20 minutes~Week 2 Rest The subjects will be asked to remain seated and still for 20 minutes.~Week 3 Active tDCS left dorso-lateral prefrontal cortex. F3 anode F4 catode Area of electrodes: 35 cm2 Current intensity: 2mA Stimulation Time: 20min~Week 4 Sham tDCS + Hypnotic analgesia suggestion The sham tDCS will have the same areas of stimulation of the active tDCS, but the device will turn itself out after 30 seconds.~Intervention time: 20 minutes~Week 5 Active tDCS + Hypnotic analgesia suggestion Intervention Time: 20 minutes."
89652651|NCT04379427|Experimental|Optimization and control 1|The first study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
89652652|NCT04379427|Experimental|Optimization and control 2|The second study part/arm includes 12 patients and will be used for optimization and control of the measurement algorithms of the Sanmina biosensors.
89652653|NCT04379427|Other|Precision and accuracy|During the third study part with enrolment of 36 patients, the precision and accuracy of the final Sanmina biosensor algorithm will be demonstrated.
89652654|NCT05248633|Active Comparator|Radiotherapy|
89652655|NCT05248633|Experimental|Chemotherapy combined with radiotherapy|
89652656|NCT00216203|Experimental|Investigational Treatment|Pemetrexed + cetuximab for patients with recurrent non-small cell lung cancer.
89652657|NCT01727271|Active Comparator|Tenofovir Monotherapy|Tenofovir 300 mg tablet, orally (PO) once daily for 8 weeks, then Tenofovir 300 mg tablet, PO, once daily for an additional 96 weeks (total treatment duration 104 weeks)
89652658|NCT01727271|Experimental|PegIFN-2b/Tenofovir Sequential Therapy|Tenofovir 300 mg tablet, PO, once daily for 8 weeks, then PegIFN-2b, 1.5 mcg/kg subcutaneously (SC), once weekly, for 24 weeks, then Tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
89652659|NCT01727271|Experimental|Peg-IFN-2b + Tenofovir Combination Therapy|Tenofovir 300 mg tablet, PO once daily for 8 weeks, then pegIFN-2b, 1.5 mcg/kg SC once weekly and tenofovir 300 mg tablet, PO, once daily for 24 weeks, and then tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
89652660|NCT04474704|Experimental|Cheetah® non-invasive cardiac monitoring system|Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 24 hours postpartum.
89652661|NCT04474704|Other|Standard of care|24 hours of postpartum magnesium sulfate (current arbitrary standard of care)
89652662|NCT05246917|Experimental|Handsewn ileocolic anastomosis|"Randomised comparison of handsewn (end-to-end and the Kono-S) with the side-to-side stapled anastomosis.~to use a manual anastomosis technique avoiding stapled technique to verify if stapled anastomosis can cause ulcers at endoscopic follow up with systematic overscoring"
89652663|NCT05246917|No Intervention|Side to side stapled anastomosis|"Randomised comparison of handsewn (end-to-end and the Kono-S) with the side-to-side stapled anastomosis.~to use a manual anastomosis technique avoiding stapled technique to verify if stapled anastomosis can cause ulcers at endoscopic follow up with systematic overscoring"
89652664|NCT00653796|Experimental|Ezetimibe + Atorvastatin|
89652665|NCT00653796|Active Comparator|Atorvastatin|
89652666|NCT01833819|Other|Opiod-free group|Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
89652667|NCT01833819|Other|Opioid-based group|Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).
89046025|NCT04980300|Active Comparator|Brief Intervention|Web-based resources on knee osteoarthritis, including an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis.
89046026|NCT04965493|Experimental|Arm A (PVR)|Fixed duration pirtobrutinib in combination with venetoclax and rituximab
89046027|NCT04965493|Active Comparator|Arm B (VR)|Venetoclax with rituximab
89521727|NCT03414073|Sham Comparator|Group A Phase 3|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group A will use the conventional interdental brushing technique in the third phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
89046031|NCT04948749|Experimental|Drug-eluting stent implantation with aggressive medical treatment group|DES implantation (The Maurora ® Sirolimus Eluting Stent System) combined with aggressive medical treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 mg per day, or ticagrelor 90 mg twice per day for 6 months); management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
89046032|NCT04948749|Active Comparator|Standard medical treatment group|Standard medical treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 mg per day, or ticagrelor 90 mg twice per day for 3 months after enrolment), management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
89046033|NCT04927663|Experimental|Cohort A: 11C-YJH08 with PET/MRI or PET/CT|Patients receive approximately 20 millicurie (mCi) of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline.
89652668|NCT05244109|Experimental|NSAIDs|Patients responding to any class of NSAIDs and unlikely to initiate biotherapy
89652669|NCT05244109|Experimental|Anti-TNF antibody|Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-TNF treatment arm
89652670|NCT05244109|Experimental|Anti-IL17 antibody|Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-IL-17 treatment arm
89652671|NCT00651144|Experimental|Ezetimibe + Rosuvastatin|
89652672|NCT00651144|Active Comparator|Ezetimibe|
89652673|NCT00651144|Active Comparator|Rosuvastatin|
89652674|NCT00651144|Placebo Comparator|Placebo|
89652675|NCT01727349|Other|Type 2 diabetic subject|Subject with type 2 diabetes
89652676|NCT01727349|Other|healthy subject|Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
89652677|NCT04276285|Active Comparator|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
89652678|NCT04276285|Active Comparator|US TAP|Subcostal TAP block will be performed after surgery under ultrasound guidance
89652679|NCT04276285|No Intervention|No TAP|No TAP block will be performed
89652680|NCT04276519|Experimental|Experimental|Physiotherapeutic non-invasive position-induced opening of the intervertebral foramen and pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
89652681|NCT04276519|Active Comparator|Control group|Pharmacological treatment with steroid antiinflammatory drugs - dexamethasone, nonsteroid antiinflammatory drugs and pain killers - tramadol.
89652682|NCT05066256|Experimental|Fluid responsive test|Measure cardiac output, inferior vena cava (IVC) diameter variation and LV diastolic function (E/e') baseline Fluid challenge Measure cardiac output, IVC diameter variation and LV diastolic function (E/e') after fluid challenge
89652683|NCT01720953||Healthy control subjects|Matched healthy control subjects will be assessed at 6 month intervals to compare changes in DNA methylation, BDNF serum levels, salivary cortisol levels, and neuropsychological test performance. Healthy control subjects will within the 1-year study period also undergo continuous assessment for comparative changes in symptoms of dissociation, depression, and personality dysfunction.
89652684|NCT03100812|Experimental|Group A|
89652685|NCT03100812|Experimental|Group B|
89652686|NCT04378413|Experimental|The Effect of Aquatic Exercises on Pain, quality of life|Water-based exercise program was conducted in the second group of 15 patients in an indoor swimming pool. Temperature of mineral water was 36 °C. The program included warming up by walking forwards, sideways and backwards through the water in the pool; active range of motion of the joints of the lower extremities; stretching lower extremities; strengthening exercises for hips, knees, arms, elbows and wrists; and cooling down (slow walking, squatting and standing).
89652687|NCT04378413|Experimental|The Effect of Land Exercises on Pain, Quality of life|Land-based exercise program included abdominal and back strengthening exercises.
89652688|NCT01721031|Experimental|DPNB|Patients receive DPNB 30min before extubation at the end of operation.
89652689|NCT01721031|Active Comparator|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
89652690|NCT05066334|Experimental|Active Arm|"Two procedures:~Bone marrow harvesting from the posterior superior iliac crest region~Single injections of a dose of 15 million of autologous BM-MSC for each disc affected by IDD (up to 3 discs) via imaging control"
89652691|NCT05066334|Sham Comparator|Sham Procedure|"Two sham procedures:~Simulated bone marrow harvesting without insertion into the posterior iliac crest region~Simulated injection under only local anaesthesia without disc injection and without placebo injection."
89652692|NCT03218683|Experimental|Monotherapy AZD5991|Dose escalation - multiple dose levels
89652693|NCT03218683|Experimental|Monotherapy AZD5991 expansion|Dose expansion
89652694|NCT03218683|Experimental|AZD5991 + venetoclax|Dose escalation - multiple dose levels
89652695|NCT05066412|Experimental|Arm 1|Prophylactic CD45RA-depleted DLI
89652696|NCT01833975|Other|stem cell [ MNCs ]|transplantation of autologous stem cell [MNCs ]
89652697|NCT03182491||Anaphylaxis|
89652698|NCT03182491||Febrile transfusion reactions|
89652699|NCT03182491||Mild allergic reactions|
89046034|NCT04927663|Experimental|Cohort B: 11C-YJH08 with additional PET/MRI, PET/CT at progression|Patients receive approximately 20 mCi of 11C-YJH08 IV over 1-2 minutes and 10-60 minutes later, undergo either PET/MRI or PET/CT over 90 minutes at baseline and at time of disease progression.
89046035|NCT04908423|Experimental|Xeomin®|Participants will be injected via electromyographic guidance with a total of 200 units of Xeomin® into the pectoralis major, biceps brachii, brachioradialis, and latissimus dorsi muscles of the hemiparetic side using a standardized injection protocol (16). An additional 100 units of Xeomin® will be available at the discretion of the investigator for injection into additional affected upper extremity muscles
89046036|NCT04892017|Experimental|Dose Escalation (Part 1, Cohort A Monotherapy)|DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation may continue to the next planned dose cohort.
89652700|NCT03182491||Healthy controls|
89652701|NCT05065788||2020 Lockdown period|Patients who access to Ophthalmological emergency service during lockdown period in 2020
89652702|NCT05065788||2019|Patients who access to Ophthalmological emergency service in 2019 definite periods
89046037|NCT04892017|Experimental|Dose Escalation (Part 1, Cohort B Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.
89046038|NCT04892017|Experimental|Dose Escalation (Part 1, Cohort C Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with binimetinib.
89046039|NCT04892017|Experimental|Dose Escalation (Part 1, Cohort D Combination)|Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with sotorasib.
89046040|NCT04892017|Experimental|Expansion Cohort 1 (Part 2)|DCC-3116 tablets given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) (with a documented mutation in KRAS).
89046041|NCT04892017|Experimental|Expansion Cohort 2 (Part 2)|DCC-3116 tablets orally given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with non-small cell lung cancer (NSCLC) (with a documented mutation in KRAS, NRAS, NF1,or BRAF).
89046042|NCT04892017|Experimental|Expansion Cohort 3 (Part 2)|DCC-3116 tablets orally given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with colorectal cancer (CRC) (with a documented mutation in KRAS, NRAS, NF1, or BRAF).
89046043|NCT04892017|Experimental|Expansion Cohort 4 (Part 2)|DCC-3116 tablets orally given in combination with binimetinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with melanoma (with a documented mutation in NRAS).
89046044|NCT04892017|Experimental|Expansion Cohort 5 (Part 2)|DCC-3116 tablets orally given in combination with sotorasib in 28-day cycles to evaluate safety and preliminary efficacy of participants with NSCLC (with a documented mutation in KRAS G12C).
89652703|NCT01834053|Other|STEM CELL|Transfer of autologous Stem cell( MNCs) intrathecally
89652704|NCT05244720|Experimental|Intervention|"Baseline questionnaire filled out at recruitment. Invited to an examination of the liver, by fibroscan and blood samples, shortly after recruitment.~Follow-up by phone after 6 months."
89652705|NCT05244720|Other|Control|Baseline questionnaire filled out at recruitment. Follow-up by phone after 6 months. Invited to an optional examination of the liver, by fibroscan and blood samples, after 6 months.
89652706|NCT01727583|Active Comparator|Lipid 1|Meal intake
89652707|NCT01727583|Placebo Comparator|Lipid-free|Maltodextrine + proteins
89652708|NCT01727583|Active Comparator|Lipid 2|Meal intake
89652709|NCT01727583|Active Comparator|Lipid 3|Meal intake
89652710|NCT01727583|Active Comparator|Lipid 4|meal intake
89652711|NCT05244642|Experimental|Group A (Penpulimab)|Participants receive Penpulimab 200mg intravenously (IV) on Day 1, Q2W for 24 months.
89652712|NCT05244642|Active Comparator|Group B (Chemotherapy)|Participants receive investigator's choice of chemotherapy Q2W or Q3W for up to 4 or 6 cycles.
89046045|NCT04869943|Experimental|Enobosarm Treatment Group|Subjects in the Enobosarm Treatment Group will receive enobosarm 9mg each day by mouth until disease progression or an unacceptable adverse event is observed. The total duration of the study for a subject in the study from screening to follow-up visit is not standardized and will be different for each subject.
89046046|NCT04869943|Active Comparator|Control Treatment Group|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site. The decision of which comparator treatment will be used will be made prior to randomization. After radiographic progression, subjects randomized to the Control Treatment Group may be crossed over to receive enobosarm 9mg.
89652713|NCT01721421|Experimental|Extended Treatment time|Extended treatment time of 6 hours
89652714|NCT01721421|Active Comparator|standard treatment time|Standard Treatment time of 4 hours
89652715|NCT05244564|Experimental|3MDR delivered via Augmented Reality Head Mounted Display|All participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
89652716|NCT05244564|Active Comparator|3MDR delivered in the Computer Assisted Rehabilitation Environment (CAREN)|All participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
89652717|NCT01721499|Experimental|Mindfulness intervention|"The mindfulness intervention consists of weekly group format mindfulness instruction and skills development, weekly individual therapy sessions, and 6 nutritional sessions.~The control group receives 6 nutritional sessions only."
89652718|NCT01721499|Active Comparator|Nutrition Control Group|The control group receives 6 nutritional counseling sessions.
89652719|NCT04396951|No Intervention|Passive external overheating|"Passive external overheating in the environmental temperature control adjusted to thermal comfort.~Measure during 6 hours with indirect calorimetry"
89652720|NCT04396951|Active Comparator|Active external overheating with heating plate|Combination of passive and active external heating with heating plate Measure during 6 hours with indirect calorimetry
89652721|NCT04396951|Active Comparator|Active external overheating with air blanket|Combination of passive and active external heating with convective air blanket Measure during 6 hours with indirect calorimetry
89652722|NCT05244330||Partial vaccination|One dose of vaccine received at least 7 days prior to study enrollment
89652723|NCT05244330||Full vaccination|Two doses of COVID-19 vaccine received at least 7 days prior to study enrollment
89652724|NCT05244330||Unvaccinated|No dose of COVID-19 vaccine for at least 7 days prior to study enrollment
89652725|NCT00370890|Experimental|A|Adjuvant chemotherapy and then clinical follow-up and surveillance
89652726|NCT00370890|No Intervention|B|Clinical follow-up and surveillance only
89046047|NCT04852276||Control participants|Control participants will be healthy volunteers, and may include unaffected relatives of immunodeficient/dysregulated participants
89046048|NCT04852276||Patients with immunodeficiencies and immune dysregulations|Affected patients with evidence of a primary or secondary immune deficiency or dysregulation
89652727|NCT02669953||AMD patients previously teated with Lucentis|"Adults ≥ 50 years; Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS; Willingness and ability to comply with regular visits; Signed informed consent form;~The patient can take his medicine in the prescribed manner. The prescribed drugs do not constitute an exclusion criteria."
89652728|NCT02669953||treatment naive AMD patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
89652729|NCT02669953||DME patients previously teated with Lucentis|Adults ≥ 50 years; Patients who have been treated with ranibizumab due to DME for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
89652730|NCT02669953||treatment naive DME patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
89652731|NCT01727739|Active Comparator|PLLA bioscrew|poly-L-lactic acid bioscrew
89652732|NCT01727739|Active Comparator|PLLA+TCP bioscrew|poly-l-lactic acid with beta tricalcium phosphate bioscrew
89652733|NCT01721655|Active Comparator|Spironolactone|Oral spironolactone suspension dosed at 3 mg/kg/day will be administered once-daily to the patients assigned to the treatment arm.
89652734|NCT01721655|Placebo Comparator|Placebo suspension|An oral placebo suspension dosed at 3 mg/kg/day administered once-daily will be given to patients in the placebo arm.
89652735|NCT02619955||Rare iron overload with hepcidin deficiency|clinical, biological, and genetic analysis of rare iron overlaod phenotype (except C282Yhomozygisity), samples with DNA
89652736|NCT04380129|Experimental|Μusic therapy-conversation sessions|
89652737|NCT04380129|Active Comparator|Discussion sessions|
89652738|NCT00904995|Experimental|Group 1 - Oral|Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
89652739|NCT00904995|Experimental|Group 2 - IV + Oral|Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.
89652740|NCT05249725|Experimental|Irsogladine Maleate|
89652741|NCT05249725|Placebo Comparator|Hydrotalcite|
89652742|NCT01727817|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
89652743|NCT01727817|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
89652744|NCT05241535|Experimental|Sequence 1 (starting with MT-7117 or Placebo)|"Treatment A or B (a single oral dose of MT-7117 or Placebo), Treatment C (a single oral dose of moxifloxacin), then Treatment A or B (a single oral dose of placebo or MT-7117)."
89652745|NCT05241535|Experimental|Sequence 2 (starting with MT-7117 or Placebo)|Treatment A or B (a single oral dose of placebo or MT-7117), Treatment A or B (a single oral dose of MT-7117 or Placebo), then Treatment C (a single oral dose of moxifloxacin).
89652746|NCT05241535|Experimental|Sequence 3 (starting sequence with Moxifloxacin)|Treatment C (A single oral dose of moxifloxacin), Treatment A or B (a single oral dose of placebo or MT-7117), then Treatment A or B (a single oral dose of MT-7117 or Placebo).
89652747|NCT01721811|Experimental|Healthy|Healthy study participanats
89652748|NCT01721811|Experimental|Diabetes|Patients with diabetes
89652749|NCT01721889||Radiostereometric analysis - Intact fusion|Clinically fused per classical radiographic assessment (≤ 2 degrees angular motion and evidence of bone bridging)
89652750|NCT01721889||Radiostereometric analysis - Symptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis (not fused, ˃ 2 degrees angular motion or absence of bone bridge) and scheduled for surgical exploration
89046049|NCT04849728|Experimental|Lanifibranor (IVA 337) (800 mg/day)|2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --> once a day (quaque die, QD)
89652751|NCT01721889||Radiostereometric analysis - Asymptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis without scheduled surgical exploration.
89652752|NCT02488135|Experimental|Floseal Hemostatic Matrix|Patients will receive Floseal Hemostatic Matrix topically at the location of active bleeding. Floseal is a gel-like fibrin glue that is applied using a syringe and forms a hemostatic clot.
89652753|NCT02488135|Active Comparator|Traditional Nasal Packing|Patients will receive traditional nasal packing to try and abort bleeding. This includes either vaseline gauze or nasal merocels being inserted into the anterior nasal cavity using forceps. These expand upon contact with blood or liquid therefore creating a compression type hemostasis.
89652754|NCT01727973|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
89652755|NCT02644668|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive a placebo suspension twice daily for 8 weeks.
89652756|NCT02644668|Experimental|Reldesemtiv 150 mg twice daily|Patient randomized to this treatment arm will receive reldesemtiv suspension at a dose of 150 mg, twice daily for 8 weeks.
89652757|NCT02644668|Experimental|Reldesemtiv 450 mg twice daily|Patients randomized to this treatment arm will receive reldesemtiv suspension at a dose of 450 mg, twice daily for 8 weeks.
89652758|NCT05240833|Experimental|VExUS-Guided Arm|VExUS results will be available for the treating physician. Patients will be treated according to current clinical practice. The use of diuretic and diuretic dosage will depend on treating physician's criteria.
89652759|NCT00912795|Experimental|SMS Turkey|6-week smoking cessation program delivered via daily text messages
89046050|NCT04849728|Experimental|Lanifibranor (IVA 337) (1200 mg/day)|3 Lanifibranor tablets 400mg with food --> once a day (quaque die, QD)
89046051|NCT04849728|Placebo Comparator|Matching placebo|3 Placebo to match tablets with food --> once a day (quaque die, QD)
89652760|NCT00912795|No Intervention|Brochure control|7-page brochure that provided general information and tips on how to quit smoking
89652761|NCT01722123|No Intervention|DLST Only|Patients will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
89652762|NCT01722123|Experimental|Contemplate only|Patients will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
89213109|NCT02582177|Experimental|Baycuten N®/ Canesten®|Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage. he cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Canesten ® will be dispensed to the same participants. It´s a cream composed by clotrimazole 10mg that will be applied in the affected area once a day for 14 days.The total duration of treatment may be 28 (+1) days.
89213110|NCT00999531|Experimental|1|GS-9411 9.6 mg
89213111|NCT00999531|Experimental|2|GS-9411 4.8 mg
89213112|NCT00999531|Experimental|3|GS-9411 2.4 mg
89213113|NCT00999531|Placebo Comparator|4|Saline Placebo
89652763|NCT01722123|Experimental|Decide with advice|Patients will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, patients will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
89652764|NCT01722123|Experimental|Decide without advice|Patients will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
89652765|NCT00144924|Experimental|laparoscopic pyloromyotomy|
89652766|NCT00144924|Active Comparator|open pyloromyotomy|
89213114|NCT00996957|Experimental|ACE-041|Patients assigned to 1 of 9 possible dosing groups
89213115|NCT04099667|Experimental|Phase 2; Low Dose MYOBLOC|Low Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
89213116|NCT04099667|Experimental|Phase 2; High Dose MYOBLOC|High Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
89652767|NCT01834287|Experimental|Physical Activity Intervention|Motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
89652768|NCT01834287|Active Comparator|Wellness Control|Internet-based, Spanish language, Wellness Contact control intervention addressing relevant health topics other than Physical Activity.
89652769|NCT03100734||With RA|Participants with RA previously treated with Enbrel and transitioned to Benepali
89652770|NCT03100734||With axSpA|Participants with axSpA previously treated with Enbrel and transitioned to Benepali
89652771|NCT01834365|Experimental|Structured education & checklist|Formatted education and checklist every month for 3 months
89652772|NCT01834365|Active Comparator|Structured education|Formatted education every month for 3 months
89652773|NCT01834365|Active Comparator|Without Structured Education with checklist|No structured education with checklist
89652774|NCT05243706|No Intervention|Control group|30 patients will receive Vincristine 1.5 mg/m2 (maximum: 2 mg) or Vinblastine 6 mg/m2 according to treatment protocol.
89652775|NCT05243706|Experimental|Loratadine group|30 patients will receive One tablet 10 mg orally once daily starting with vincristine or vinblastine administration for three cycles
89652776|NCT05243706|Experimental|diosmin 450mg / hesperidin 50 mg group|30 patients will receive 50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet orally twice daily starting with vincristine or vinblastine administration for three cycles
89652777|NCT01722201|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
89652778|NCT01722201|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
89213117|NCT04099667|Placebo Comparator|Phase 2; Placebo|Volume-matched placebo is a single treatment
89652779|NCT01728129|Experimental|Concussed|Subjects who are diagnosed with a concussion by a clinician will be assessed with the MACE and DANA Rapid every 24 hours for up to 72 hours post-injury.
89652780|NCT01728129|Active Comparator|Non-concussed|Subjects will have been exposed to a potentially concussive event but be clinically evaluated and found not to have sustained a concussion. Control subjects from this arm will take both the MACE and DANA Rapid twice: once within 24 hours of potentially concussive event, and again on the day of return to duty.
89652781|NCT01722279||Bariatric surgery patients, at least 5 years post-surgery|Survey participants had bariatric surgery at the St. Vincent Bariatric Center of Excellence at least 5 years before completing survey.
89652782|NCT01834443|Experimental|GVS CL|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the left mastoid
89652783|NCT01834443|Experimental|GVS CR|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the right mastoid
89652784|NCT01834443|Sham Comparator|GVS Sham|Transmastoid galvanic stimulation set-up is applied, with only 30s of stimulation
89652785|NCT02644356|Experimental|Online CE/CME course|Participant in taking the three course modules and completing pre- and post-course data collection.
89652786|NCT01728285|Active Comparator|Electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) using an electronic compliance device (Memozax®)
89652787|NCT01728285|No Intervention|No electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) without any electronic compliance device (Memozax®)
89213118|NCT04099667|Experimental|Phase 3; MYOBLOC|MYOBLOC is a single treatment and will be compared to volume-matched placebo
89213119|NCT04099667|Placebo Comparator|Phase 3; Placebo|Volume-matched placebo is a single treatment
89213120|NCT00997191|Active Comparator|Laser Group|Focal / grid Laser photocoagulation in diabetic macular edema
89213121|NCT00997191|Experimental|Triamcinolone group|Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema
89213122|NCT00997191|Experimental|Bevacizumab group|Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema
89213123|NCT02581319|Other|Periodontal treatment|Both groups of patients (smokers and non-smokers) will receive periodontal treatment consisting of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects will be made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
89213124|NCT05315739|Active Comparator|Active treatment|Non-invasive transcutaneous vagus nerve stimulation applied by the gammaCore device (electroCore)
89046052|NCT04840823|Experimental|Enoxacin 200mg twice daily|Enoxacin 200mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 1 active 200mg enoxacin tablet and 2 placebo tablets per dose.
89046053|NCT04840823|Experimental|Enoxacin 400mg twice daily|Enoxacin 400mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 2 active 200mg enoxacin tablets and 1 placebo tablet per dose.
89046054|NCT04840823|Experimental|Enoxacin 600mg twice daily|Enoxacin 600mg twice daily (one dose in the morning and one dose in the evening) for 30 days, except day 1 and day 30 when only the morning dose will be taken. Participants will take 3 active 200mg enoxacin tablets per dose.
89046055|NCT04838743||IDegLira|Real-world adult population with type 2 diabetes mellitus in Japan.
89652788|NCT03100188|Experimental|modified PD|Patients with residual renal kt/v were placed in intervention group
89652789|NCT01722357|Experimental|Pedometer + Exercise Counseling|
89652790|NCT01722357|Experimental|Pedometer|
89652791|NCT01722357|No Intervention|Usual Care|"Self-help information provided on physical activity (WIN:Weight Control Network Active At Any Size provided by National Institute of Diabetes and Digestive and Kidney Diseases, 2006)."
89652792|NCT05243238|Active Comparator|Hesperidin group|
89652793|NCT05243238|Active Comparator|Diosmin|
89652794|NCT05243238|Active Comparator|Hesperidin and diosmin|
89652795|NCT05243238|No Intervention|control group|
89652796|NCT01722513|Experimental|Alprostadil, Control|Alprostadil interventions: Alprostadil 40 ug + 1cc/kg/hr normal salin 6 hour before and after angiography AND Control interventions:Normal salin 1cc/kg/hr before and after angiography
89652797|NCT03099330|Experimental|TQ-B3139|TQ-B3139 p.o. qd
89652798|NCT03099252||Enrolled|"Participating hospitals will offer the video to all parents on their MBU during the 6 month intervention period (using the preferred delivery methods of the hospital and the parents). The video will be available via multiple means to facilitate optimal parental exposure in diverse settings. This will ensure flexibility of the delivery of the intervention, based on preferences of the nominated nurse leaders and their HCP team, families and available resources.~All participating maternal/newborn centres will receive the following tools via the designated nurse unit leader of enrolled sites:~Parent-targeted BSweet2Babies video~Parent cards- Reminder for parents of video, with Quick Response (QR) code of the video~BSweet2Babies Poster-visual reminder for parents and HCP's on the enrolled units~Monthly support calls for the nursing leaders of the Mother Baby Units (MBU)~Bi-monthly community of practice teleconferences for the nursing leaders of the MBU"
89652799|NCT01728441|Experimental|Paclitaxel Eluting Stent|Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.
89652800|NCT01728441|Active Comparator|Paclitaxel Eluting Balloon|For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.
89652801|NCT03099408|Active Comparator|Metronidazole Oral|Metronidazole Oral
89652802|NCT03099408|Active Comparator|"Metronidazole and Lactobacillus"|"Metronidazole and Lactobacillus"
89652803|NCT01722591|Experimental|Cardiapex device|Use of the Cardiapex device in the context of transapical TAVI procedures
89652804|NCT01728519|Experimental|AllerT SC|AllerT subcutaneous injections
89046056|NCT04832932||80 years of age or older|Individuals 80-89, 90-99, 100 years of age and older who received COVID-19 vaccine
89046057|NCT04832932||60-79 years of age|Individuals 60-69 and 70-79 years of age who received COVID-19 vaccine
89046058|NCT04832932||40-59 years of age|Individuals in 40-49, 50-59 age range who received COVID-19 vaccine
89046059|NCT04832932||18-39 years of age|Individuals in 18-29, 30-39 age range who received COVID-19 vaccine
89046060|NCT04832932||MEBO/PATM|Individuals with present or past MEBO/PATM symptoms who received COVID-19 vaccine
89046061|NCT04832932||Chronic Disease|Individuals with self-reported chronic health conditions who received COVID-19 vaccine
89046062|NCT04832282|Other|Roux-en-Y gastric bypass patients with weight regain|The study population is Roux-en-Y gastric bypass (RYGB) patients with weight regain undergoing an endoscopy at Bellevue Hospital Center or Brigham and Women's Hospital.
89213125|NCT05315739|Sham Comparator|Sham treatment|Inactive sham vagus nerve stimulation applied by the gammaCore sham device (electroCore)
89213126|NCT00997269|Experimental|CoQ-10 supplementation|
89652805|NCT01728519|Placebo Comparator|Placebo SC|placebo subcutaneous injections
89652806|NCT01728519|Experimental|AllerT ID|AllerT intra-dermal injections
89652807|NCT01728519|Placebo Comparator|Placebo ID|placebo intra-dermal injections
89652808|NCT05240521|Other|ARM A: GA-AT0119 / Placebo|Cross-over Study
89652809|NCT05240521|Other|ARM B: Placebo / GA-AT0119|Cross-over Study
89652810|NCT04171518||Catalys Precision Laser System|Cataract Surgery with use of Catalys Precision Laser System
89652811|NCT00905151||HIV Positive|Across-sectional analysis of 200 HIV+ patients with varying levels of kidney function
89652812|NCT04378257|Experimental|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform. The sessions will be conducted in the Arabic or English languages.~Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~Acknowledging emotions and normalizing current stress~Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~Behavioral Activation Acceptance and Commitment Therapy (ACT)~Grounding, Breathing, Acceptance of emotions, and de-fusion"
89652813|NCT04378257|Active Comparator|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice.
89652814|NCT05000190|Experimental|250 mg citicoline|Opaque capsule
89652815|NCT05000190|Placebo Comparator|0 mg citicoline|Opaque capsule matched in appearance to the active capsule
89652816|NCT05240053|Active Comparator|group (1)|Group 1: included 25 patients who were subjected to enhance recovery program after laparoscopic colorectal surgery .
89652817|NCT05240053|No Intervention|group (2)|Group 2: included 25 patients who were subjected to traditional way
89652818|NCT01834521|Experimental|Web-based screening and tailored support|A personalized website (username/password) will become available to patients assigned to the intervention arm for 12 subsequent weeks. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive digital feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, (self)help options and possibilities for referral to professional care. Contact information of one of the investigators will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.
89652819|NCT01834521|No Intervention|Standard care|Patients assigned to standard convalescent care will receive the usual follow-up care delivered by their treating oncologists. Patients will be referred to psychosocial or allied care by their oncologist and/or oncology nurse if certain physical and/or psychosocial problems require more in-depth professional care
89652820|NCT05248477|No Intervention|usual practice|
89652821|NCT05248477|Experimental|Premex protocol|a new organization of care, based on the EXPRIM (EXtrem PRematurity Innovative Management) protocol, involving early, standardized, and multidisciplinary management of women hospitalized for a risk of extremely preterm birth and their children
89652822|NCT04984200||AB|
89652823|NCT04099381|Experimental|Group 1 Low HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or less HLA compatibility degree in A, B, DRB1 loci will be used.
89652824|NCT04099381|Experimental|Group 2 High HLA compatibility|ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or more HLA compatibility degree in A, B, DRB1 loci will be used.
89652825|NCT04099381|Other|Group 3 Control|Patients with standard therapy as a control group.
89652826|NCT00906165|Active Comparator|1- Immediately provisionalized|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will be immediately provisionalized upon placement, i.e. impressions will be taken directly after implant installation in order to fabricate screw-retained resin crowns within 48 hours after implant placement. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
89652827|NCT00906165|Active Comparator|2- Delayed Loading|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will not be immediately provisionalized, instead there will be delayed implant loading. i.e. the patient will receive a removable prosthesis if necessary and the impressions for the final restoration will be taken 12-14 weeks after implant installation. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
89652828|NCT04435002|Experimental|Intervention Group|For 9 different points acupressure technique applied to this group for 4 weeks
89652829|NCT04435002|No Intervention|Control Group|
89652830|NCT05064852||Surufatinib|Patients with BTC visited the site from 2021 to 2023 and received Surufatinib therapy.
89652831|NCT05240287|Active Comparator|Study group -adults with pes planus|"Individuals between the ages of 20-45~Individuals with bilateral pes planus according to the Navicular Drop Test and Foot Posture Index"
89652832|NCT05240287|Other|Control group -adults without pes planus (normal foot)|"Individuals between the ages of 20-45~Individuals without pes planus according to the Navicular Drop Test and Foot Posture Index"
89652833|NCT04434690|Experimental|Simultaneous|2 surgeons will perform simultaneous total knee arthroplasty in this group.
89652834|NCT04434690|Active Comparator|Single surgeon bilateral TKA group|One surgeon will perform sequentially tptal knee arthroplasty in this group
89652835|NCT00912873|Active Comparator|0.1% Ropivicaine|Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
89046063|NCT04830111|Experimental|heart rate variability biofeedback training group|The goal of heart rate variability biofeedback is to increase heart rate variability through paced breathing exercises, which have shown to be effective in reducing stress and anxiety in general adult populations.
89046064|NCT04830111|No Intervention|Care as usual|In this condition, all of this group take care by hospital routine and the questionnaires were completed over a period with similar intervals.
89046065|NCT04827979|Experimental|Cohort 1 (N=5 Subjects)|"Multiple intravenous infusions of daratumumab and belatacept over 10 weeks:~Daratumumab will be administered intravenously at a dose of 8 mg/kg weekly for 4 weeks, then every other week for 4 weeks (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.~Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, and 14). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit, and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%."
89046066|NCT04827979|Experimental|Cohort 2 (N=10 Subjects)|"The enrollment of ten additional subjects is dependent on the results in Cohort 1.~Multiple intravenous infusions of daratumumab and belatacept over 14 weeks:°~Daratumumab will be administered intravenously at a dose of 8 mg/kg for the first dose, then 16 mg/kg for subsequent given weekly for 3 weeks, then every 2 weeks for 2 doses (week 9 and week 11). The dose administered will be calculated based on the actual body weight of the subject at each visit.~Belatacept will be administered intravenously at a dose of 10 mg/kg every 2 weeks starting at week 8 (dosed at weeks 8, 10, 12, 14, 16 and 18). The total infusion dose of belatacept will be based on the actual body weight of the subject at the baseline visit and will not be modified during the course of therapy, unless there is a change in body weight of greater than 10%.~Was modified based on the safety and efficacy analysis of Cohort 1."
89046067|NCT04821375|Experimental|Bazedoxifene plus conjugated estrogens immediately|Immediate receipt of 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
89046068|NCT04821375|Other|Bazedoxifene plus conjugated estrogens wait list|After a 6-month waiting period, receipt of 6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
89652836|NCT00912873|Experimental|0.4% Ropivicaine|Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
89652837|NCT01494038|Experimental|Arm A (Immediate INH Treatment)|Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
89652838|NCT01494038|Experimental|Arm B (Deferred INH Treatment)|Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
89652839|NCT05059782|Active Comparator|Group A (drug treatment group)|Group A (drug treatment group) : Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
89652840|NCT05059782|Experimental|Group B (radiotherapy group)|IFRT, IMRT or SBRT is applied. Irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent.
89652841|NCT05059782|Experimental|Group C (radiotherapy + drug group)|Drug therapy is the same as group A; IFRT is the same as group B.
89652842|NCT03835611|Experimental|Intervention group|"Intervention Group: Participants in the intervention group will receive DT TT with GTP. GTP consists of standard treadmill nested with a pressure mapping system and an interactive computer game based sub-station in front of the treadmill. A miniature motion mouse with inbuilt sensors that enables real-time movements to be translated in computer sub-station by standard USB will be used. This miniature mouse will be secured to a helmet that participants will wear while walking on the treadmill to interact with computer sub-station. Participants will be expected to play commercial computer games while standing on compliant surface or walking on the treadmill. The motion mouse will help participants to control computer games hand free."
89652843|NCT03835611|Active Comparator|Control Group|Control group: Participants in the control group will undergo a mixture of current gait training programs available for people with Parkinson Disease. The protocol will be:
89652844|NCT05242081|Experimental|S-ketamine|
89652845|NCT05242081|Active Comparator|Sufentanil|
89652846|NCT03098940|Experimental|Chewing gum|Chewing gum with various doses of dronabinol
89652847|NCT03098940|Active Comparator|Capsule (Marinol)|Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
89652848|NCT03098784||Air France employees working near runways|"Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.~Intervention: Exposure to aircraft exhaust"
89652849|NCT03098784||Air France employees working inside|"Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.~Intervention: Non exposure to aircraft exhaust"
89652850|NCT03158779|Experimental|SBRT and chemotherapy|"Participants received 4 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered. A 3-weeks break from chemotherapy and restaging with thorax-abdominal CT scan to confirm the absence of distant metastases was required before SBRT delivery.~Before SBRT simulation, patients may will have implanted fiducial into the pancreatic tumor.~The SBRT schedule will be [6 x 9 Gy = 54 Gy] delivered in consecutive days."
89652851|NCT05059548||Male Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
89652852|NCT05059548||Female Group|Video-Assisted Thoracoscopic Surgery patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
89652853|NCT04409210|Experimental|Intervention Group|The intervention group will receive establishment of individual health records, cardiovascular risk assessment, popularization of medical knowledge, personalized reminders and routine treatment.
89652854|NCT04409210|Other|Control Group|The control group just receive routine treatment and routine management.
89652855|NCT03098316||POAG|Primary open angle glaucoma patients
89652856|NCT03098316||NTG|Normal/Low tension glaucoma patients
89652857|NCT03098316||Control|Patients with cataract and without glaucoma or other eye diseases
89652858|NCT03145441|Experimental|CytoSorb®|The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
89652859|NCT03145441|No Intervention|Control|No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
89652860|NCT05064228|Experimental|m-ReACT app condition|Participants will download the m-ReACT app on their mobile phones and will be asked to engage with the app for a period of 12 weeks.
89652861|NCT05064228|Active Comparator|Brief Advice|Participants will be given a one time brief informational session on the importance of engaging in substance-free activity while in AUD treatment.
89652862|NCT04412304||thrombose prophylaxis|The dose used to prevent thromboembolic complication in critically ill
89652863|NCT04412304||double thrombose prophylaxis|Double the dose used to prevent thromboembolic complication in critically ill
89652864|NCT04412304||full dose anticoagulant|Dose used to treat thromboembolic event
89652865|NCT05064072|Experimental|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
89652866|NCT05064072|Experimental|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube
89652867|NCT05064072|Active Comparator|Silk plaster|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube
89652868|NCT04276129|Experimental|post-surgical CHX mouth-rinses (treatment group - CHX)|periodontal surgery + post-surgical CHX mouth-rinses + buccal attached gingival (G) biopsies 24 hr after surgical procedure
89213127|NCT00997269|Placebo Comparator|CoQ-10 placebo supplementation|
89652869|NCT04276129|Other|NO post-surgical mouth-rinses treatment (non treatment group - NT)|periodontal surgery + buccal attached gingival (G) biopsies 24 hr after surgical procedure
89652870|NCT05063682|Experimental|Treatment|Patients receive EGFRvIII -CAR T cells intracerebroventricular over 15 minutes on day 1. Patients may receive additional cycles based on the persistence of the cells.
89213128|NCT02582099|Active Comparator|Gentamicin|Gentamicin nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
89046069|NCT04821141|Experimental|Bazedoxifene plus conjugated estrogens immediately|BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing immediately.
89046070|NCT04821141|Other|Bazedoxifene plus conjugated estrogens wait list|No intervention for initial 6 months (wait list), then BZA (20 mg) plus CE (0.45 mg) taken together once daily for 6 months, commencing 6 months after enrollment. Optional on the part of subject.
89652871|NCT00915603|Active Comparator|paclitaxel/bevacizumab/everolimus|Systemic Therapy
89652872|NCT00915603|Placebo Comparator|paclitaxel/bevacizumab/placebo|Systemic Therapy
89652873|NCT01922401|Experimental|inverse ratio ventilation|in one group change the I:E ratio during pneumoperitoneum 1:2-1:2-2:1
89652874|NCT05063526||Group B|"40 patients who are mechanically ventilated due to pulmonary disease at respiratory ICU had their diagnosis as follows: 21 (53%) had COPD, 8 (20%) had asthma, 5 (13%) had bronchiectasis, 5 (13%) had pneumonia and~1 (3%) had viral influenza H1N1. Out of group B patients, 11 patients (13.75%) had failed weaning, of which 6 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 3 patients were re-intubated and 2 patients died."
89652875|NCT05063526||Group A|40 patients on mechanical ventilation due to non-pulmonary disease at respiratory ICU had their diagnosis as follows: 24 (60%) had congestive heart failure, 4 (10%) had diabetes mellitus, 4 (10%) had sepsis other than pneumonia, 2 (5%) had epilepsy, 2 (5%) had embolic hemiplegia, and 4 (10%) had chronic renal failure. Out of group A patient, 9 patients (11.25%) had failed weaning of which 4 patients needed reintubation and 5 patients needed non-invasive positive ventilation of which 2 patients were reintubated and 3 patients died.
89046071|NCT04820790|Experimental|Experimental Group 1|The efficiency of the mobile app in the follow-up of patients with home oxygen will be evaluated during 6 months
89046072|NCT04820790|No Intervention|Intervention Group 2:|Regular monitoring of the home oxygen without mobile app during 6 months
89046073|NCT04815291|Experimental|Device|Receives SCOUT at biopsy
89046074|NCT04810091|Experimental|Arm A (telotristat ethyl, SSA)|Patients receive telotristat ethyl PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
89046075|NCT04810091|Active Comparator|Arm B (placebo, SSA)|Patients receive placebo PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.
89046076|NCT04801368|Experimental|Receiving Ropivacaine|Patients receiving Ropivacaine.
89046077|NCT04801368|Experimental|Receiving Liposomal Bupivacaine|Patients receiving Liposomal Bupivacaine.
89652876|NCT05063526||control group.|40 patients Chronic obstructive pulmonary disease (COPD) from Outpatient Clinic
89652877|NCT01929265|Experimental|Rituximab - Bendamustine (RB)|"1 arm: Rituximab - Bendamustine (RB)~1 arm for all patients"
89652878|NCT05063058|Experimental|Molecular guided therapy|
89046078|NCT04794894||Telerehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at home via telecommunication technologies.
89046079|NCT04794894||Clinic-based rehabilitation services|Physical therapy, occupational therapy, speech-language therapy, and/or counseling provided at a local facility.
89046080|NCT04792099|Experimental|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) with blended oxygen delivered by binasal prongs or nasal mask.
89652879|NCT01922479|Experimental|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
89652880|NCT01922479|Active Comparator|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
89046081|NCT04792099|Active Comparator|Nasal Cannula|Blended oxygen delivered by nasal cannula (NC).
89046082|NCT04782336|Other|Sample Collection - Symptomatic Patients|The patient will be completing or has completed a SOC Influenza A/B and/or COVID-19 and/or RSV test on the day of study
89046083|NCT04777435|Experimental|Patients with Thrombotic micro-angiopathy|
89046084|NCT04763746||Sub-protocol 1|"Blood pressure, oxygen saturation and heart rate measured from participants selected because of their blood pressure.~Within each study session, participants will have their blood pressure, oxygen saturation and heart rate measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
89046085|NCT04763746||Sub-protocol 2|"Respiratory rate and oxygen saturation measured from any participant.~Within each study session, participants will have their respiratory rate and oxygen saturation measured twice using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
89046086|NCT04763746||Sub-protocol 3|"Oxygen saturation measured from participants expected to have low oxygen saturation.~Within each study session, participants will have their oxygen saturation measured twice using standard-of-care equipment. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
89213129|NCT02582099|Placebo Comparator|Normal saline|Normal saline nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
89652881|NCT05063292|No Intervention|Control group|Patients covered with a 41 centigrade degrees double layered cotton cloth
89213130|NCT00997347|Experimental|64-70 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days
89652882|NCT05063292|Experimental|Prewarmed group|Patients receive active prewarming with an air forced blanket ( full body blanket) 30 minutes prior to the operation
89652883|NCT00906243|Experimental|CV9103|CV9103 will be applied intradermally on three (3) or five (5) time points. Treatment with CV9103 is administered over a period of either seven (7) or twenty-three (23) weeks.
89652884|NCT02390011||MRI|Day 1
89652885|NCT05063214||Ultrasound assessment|Muscle ultrasound evaluation
89652886|NCT03835299|No Intervention|Fear Control|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions then proceed through the normal blood donation process.
89652887|NCT03835299|Experimental|Fear Intervention|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions and view a brief presentation of coping strategies presented via a computer tablet. They will then proceed through the normal blood donation process.
89046087|NCT04763746||Sub-protocol 4|"Blood pressure, heart rate, respiratory rate and oxygen saturation measured from adults lacking capacity.~Within each study session, participants will have their blood pressure, heart rate, respiratory rate and oxygen saturation measured three times using standard-of-care equipment and methods. At the same time, video of the participant's face will be captured using the Data Collect app running on a tablet positioned opposite them."
89652888|NCT03835299|No Intervention|No Fear Control|Participants who report no blood donation-related fear will proceed through the normal blood donation process.
89652889|NCT01929421|Experimental|Gemcitabine/ s-1|
89652890|NCT01834599||anterior placenta|"Cerebral oximetry device used to obtain:~Saturation value of the placenta probe with no oxygen, saturation value of the placenta probe with oxygen, saturation value of the myometrium probe with no oxygen saturation value of the myometrium probe with oxygen saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen saturation value of the leg probe with no oxygen saturation value of the leg probe with oxygen Timing between the contractions measure by cardiotocography"
89652891|NCT04474002|Active Comparator|4L Klean Prep®|Drug: 59g polyethylene glycol, 5.685g Na sulphate, 1.685g Na bicarbonate, 1.465g NaCl, 0.7425g KCl and aspartame 0.0494g
89652892|NCT04474002|Experimental|1L Klean prep® and 2 sachets Picoprep®|Drug: 59g polyethylene glycol, 5.685g Na sulphate, 1.685g Na bicarbonate, 1.465g NaCl, 0.7425g KCl, aspartame 0.0494g, sodium picosulfate 0.01g, magnesium oxide 3.5g, citric acid 12.0g
89046088|NCT04757922||Intervention: bilateral salpingectomy|Premenopausal women between 30 and 45 years of age, who will undergo sterilization through Opportunistic Salpingectomy will be asked to participate in the STOPOVCAyoung study.
89046089|NCT04757922||Control: tubal ligation or no sterilization|The control group will consists of women who chose for sterilization by clips/tubal ligation supplemented by friend/acquaintances, around the same age, who are not planning to undergo sterilization.
89046090|NCT04747834|Active Comparator|Cohort 1|Subjects with mild to moderate cataracts (Grade 1 to 2) scheduled to undergo mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion.
89046091|NCT04747834|Active Comparator|Cohort 2|Subjects with moderate to dense cataracts (Grade 2+ to 3+) scheduled to undergo mechanical non-phacoemulsification lens extraction using low-energy segment removal with a micro-interventional irrigation/aspiration port (MICOR-304) to evacuate the lens prior to intraocular lens insertion..
89046092|NCT04742439|Sham Comparator|Sham stimulation|
89046093|NCT04742439|Experimental|Individualized stimulation|
89046094|NCT04742439|Experimental|2mA stimulation|
89046095|NCT04742439|Experimental|4mA stimulation|
89046096|NCT04729413|Experimental|Couples Counseling Intervention|Couples in the intervention group will receive two group health education sessions (one during pregnancy and one postpartum) covering information on pregnancy and postpartum health, as well as three couple counseling visits (one during pregnancy and two postpartum). The couples counseling sessions will provide (1) information on key relationship topics (communication, trust and respect, love and support); (2) relationship skills exercises (role playing); and (3) the opportunity to discuss health and relationship priorities/goals of the couple.
89046097|NCT04729413|Sham Comparator|Control|Couples assigned to the control group will receive two group health education sessions (one during pregnancy and one postpartum) covering information on pregnancy and postpartum health. Couples will also have the opportunity after the trial is complete to opt-in to receive a condensed one-session couples counseling visit (data not to be used for study purposes but offered for ethical reasons).
89046098|NCT04727944|Experimental|MEG and EEG recordings on Healthy volunteers|"All subjects can participate in experiment 1 and/or 2. All analyses are intra-subject (no analyses are between-subject).~Experiment 1 will test the functional role of beta bursts in naturalistic action preparation, using a combined anatomical MEG-MRI approach which will be conducted in 2 sessions.~Experiment 2 will study the relationship between beta bursts and naturalistic action preparation using EEG."
89046099|NCT04712851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 4 cycles (24 weeks).
89046100|NCT04702425|Experimental|VOB560-MIK665 - Part 1a|Part 1a - Patients with relapsed/refractory non-Hodgkin lymphoma and relapsed/refractory multiple myeloma administered VOB560 and MIK665 as an intravenous (IV) infusion.
89046101|NCT04702425|Experimental|VOB560-MIK665 - Part 1b|Part 1b - Patients with relapsed/refractory acute myeloid leukemia administered VOB560 and MIK665 as an intravenous (IV) infusion.
89046102|NCT04702425|Experimental|VOB560-MIK665 - Part 2a|Part 2a - Patients with relapsed/refractory multiple myeloma with at least 10 patients with 1q gain cytogenetic abnormality and 10 patients with high risk R/R MM as defined in (Sonneveld et al 2016) administered VOB560 and MIK665 as an intravenous (IV) infusion.
89652893|NCT01929499|Experimental|synchronous CIK group|"After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months.~For CapeOx regimen:~3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles.~For mFolfox6 regimen:~Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles."
89652894|NCT01929499|Experimental|sequence CIK group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later.
89652895|NCT01929499|No Intervention|control group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）.
89652896|NCT01722747|Experimental|Intervention Condition|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
89652897|NCT01722747|No Intervention|Delayed Intervention Control condition|Receives abbreviated 3-month delayed intervention after final data collection time point
89652898|NCT03744936|Experimental|DA4Afib|Developing a tool to use during the encounter
89652899|NCT01929577|Experimental|ASP015K Test Tablet - Fasting Conditions|ASP015K administered as a single tablet under fasting conditions.
89652900|NCT01929577|Experimental|ASP015K Reference Tablet - Fasting Conditions|ASP015K administered via multiple tablets under fasting conditions
89652901|NCT01929577|Experimental|ASP015K Test Tablet -Fed Conditions|ASP015K administered as a single tablet under fed conditions
89652902|NCT01722825|Experimental|LY2157299|80 up to 150 milligrams of LY2157299 administered orally, twice daily for 14 days, followed by 14 days with no study drug (2 weeks on/2 weeks off schedule) for at least two 28 day cycles. Participants receiving clinical benefit may continue receiving treatment until discontinuation criterion is met.
89652903|NCT01722903||Stage IV colorectal cancer|CTCs will be drawn during liver and/or lung metastasectomy for colorectal cancer
89652904|NCT01929655|Experimental|Radium-223 dichloride|
89652905|NCT01722981|Active Comparator|Direct laryngoscopy|Performing percutaneous tracheostomy as accepted in our institute: By placing the tube higher up near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
89652906|NCT01722981|Active Comparator|Real time sonography|"Percutaneous tracheostomy will be guided by real time sonography (with the visualization of the needle path) using acoustic shadows of the cricoid and the tracheal rings.~In both methods, in order to identify the anatomic location of the needle prick- after passing the guide wire, the front elevation will be verified by optical means, which will be drawn out immediately afterwards."
89652907|NCT01722981|Active Comparator|Bronchoscopy|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
89652908|NCT01834677||Healthy Human|
89652909|NCT01834677||Depressed Human|
89652910|NCT01834677||Depressed Human, Undergoing Electroconvulsive Therapy|Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
89652911|NCT01834677||Human Diagnosed with Parkinson's Disease|
89652912|NCT01922557||NICOM|
89652913|NCT04506931|Experimental|Short Message Service (SMS) survey|Participants will receive an SMS survey
89652914|NCT04506931|Experimental|Interactive Voice Response (IVR) survey|Participants will receive an IVR survey
89652915|NCT04506931|Experimental|Computer Assisted Telephone Interviews (CATI) survey|Participants will receive a CATI survey
89652916|NCT03836703|Active Comparator|Single Dose Daily Iron|single dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
89652917|NCT03836703|Experimental|Double dose Daily iron|Double dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
89046103|NCT04702425|Experimental|VOB560-MIK665 - Part 2b|Part 2b - Patients with relapsed/refractory non-Hodgkin lymphoma with at least 10 patients with double-hit (DH) lymphoma, based on the overall bad prognosis and limited therapeutic options for patients with DH NHL administered VOB560 and MIK665 as an intravenous (IV) infusion.
89046104|NCT04702425|Experimental|VOB560-MIK665 - Part 2c|Part 2c - Patients with relapsed/refractory acute myeloid leukemia venetoclax refractory or insensitive with at least 6 patients M5 as proposed by French-American-British (FAB) group, based on the observation that venetoclax resistance in AML M5 can be caused by up-regulation of MCL1 administered VOB560 and MIK665 as an intravenous (IV) infusion.
89046105|NCT04702425|Experimental|VOB560-MIK665 - Part 2d|Part 2d - Patients with relapsed/refractory acute myeloid leukemia venetoclax naive patients administered VOB560 and MIK665 as an intravenous (IV) infusion.
89046106|NCT04700124|Experimental|Arm A: Perioperative EV+ Pembrolizumab and RC + PLND|Participants receive 4 cycles (each cycle length = 21 days) of EV intravenous (IV) infusion plus pembrolizumab IV infusion preoperatively, followed by RC + PLND, followed by 5 cycles of adjuvant EV IV infusion plus 13 cycles of adjuvant pembrolizumab IV infusion postoperatively. The total treatment duration is up to approximately 1 year.
89652918|NCT02398825|Experimental|Ponatinib|
89652919|NCT02640612|Experimental|BI 695501|
89652920|NCT01723059|Other|Standard triple therapy|Gold standard for management of H pylori is amoxicillin 1 gm twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 10 days.
89652921|NCT01723059|Active Comparator|Sequential Therapy|Amoxicillin 1 gm twice daily and omeprazole 20 mg twice daily for 5 days followed by metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 5 days.
89652922|NCT04379193|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
89046107|NCT04700124|Active Comparator|Arm B: Standard of Care (SOC)-Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND|Participants receive 4 cycles (each cycle length = 21 days) of standard of care (SOC) chemotherapy (gemcitabine IV infusion plus cisplatin IV infusion) preoperatively, followed by RC + PLND. The total treatment duration is up to approximately 3 months.
89046108|NCT04698876|Experimental|Outpatient measurement of intraocular pressure|The intervention group measures its intraocular pressure itself in their home environment for 7 days at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m. with a self-tonometer (iCareHOME).
89046109|NCT04698876|Active Comparator|Stationary measurements of intraocular pressure|The intraocular pressure of the control group is measured by means of rebound tonometry or Goldmann applanation tonometry in a clinic for minimum 24 hours at 6 a.m., 8 a.m., 12 a.m., 4 p.m., 8 p.m. and 12 p.m.
89046110|NCT04681677|Experimental|Experimental: Intra-operative Radiation Therapy - IORT|Radiation: Intra-operative Radiation Therapy - IORT
89652923|NCT04379193|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
89652924|NCT04379349|Experimental|Active SMS|Weekly interactive SMS text messaging check-ins.
89046111|NCT04674813|Experimental|Administration of CC-95266|
89046112|NCT04662515||DOAC|Information about which type of DOAC and the dose that is prescribed to the patient will be collected.
89046113|NCT04662515||Warfarin|A PK-INR ≤3.0 retained whitin the last 24 hours have to be present for inclusion.
89652925|NCT04379349|Sham Comparator|Sham SMS|Weekly minimally interactive SMS text messages.
89652926|NCT05062512||Participants living with and without neurodegenerative diseases|No intervention
89652927|NCT01929967||Heterotaxy syndrome|Patients with a diagnosis of heterotaxy syndrome, as objectively defined by visceral heterotaxy (malrotation, interrupted inferior vena cava) with either documented polysplenia or asplenia by radiological imaging
89652928|NCT04379271|Experimental|IMU-838|twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC)
89652929|NCT04379271|Placebo Comparator|Placebo|twice-daily (BID) oral placebo (+ SoC)
89652930|NCT01723137||In pain|Patients who report pain greater than or equal to 3 out of 10 are eligible for this study.
89652931|NCT02395315||Well-controlled diabetic (WC)|well-controlled diabetic controls (HbA1c ≤ 7.0%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
89652932|NCT02395315||Poorly controlled diabetics (PC)|Poorly controlled diabetics (HbA1c >7.5% & <10%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
89652933|NCT03659604|Experimental|Experimental with tailored feedback|'SmartLife' with tailored feedback: School classes will receive the developed 'SmartLife' intervention with tailored feedback, that is based on data from a sensors that is integrated in a T-shirt.
89652934|NCT03659604|Active Comparator|Active control without tailored feedback|'SmartLife' without tailored feedback: School classes will receive the developed 'SmartLife' intervention without tailored feedback.
89652935|NCT03659604|Other|Passive control|School classes will not receive any intervention, thus no game.
89652936|NCT01728909|Experimental|Oxytocin|40 IU Oxytocin
89652937|NCT01728909|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
89652938|NCT01923727|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).
89652939|NCT05058066|Active Comparator|Control implant loaded at 6 weeks post-surgery|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
89652940|NCT05058066|Experimental|Test implant loaded at 6 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
89652941|NCT05058066|Experimental|Test implant loaded at 3 weeks post-surgery|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment.
89652942|NCT01723215|Active Comparator|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
89652943|NCT01723215|Active Comparator|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
89652944|NCT01723215|No Intervention|Control|Control: will not receive any intervention
89046125|NCT04626518|Experimental|Coformulation Pembrolizumab/Quavonlimab|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg). Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years).
89046126|NCT04626518|Experimental|Coformulation Favezelimab/Pembrolizumab|Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg). Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years).
89046127|NCT04626518|Experimental|Pembrolizumab + MK-4830|Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to ~2 years).
89046128|NCT04626518|Experimental|Pembrolizumab + Belzutifan|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Belzutifan will be administered orally once-daily (QD) until progressive disease or discontinuation.
89046129|NCT04626518|Experimental|Belzutifan + Lenvatinib|Participants will receive Belzutifan 120 mg PLUS lenvatinib 20 mg. Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
89046130|NCT04626518|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
89652945|NCT01723215|Placebo Comparator|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
89652946|NCT01922713|Placebo Comparator|white maize|white maize and a corn oil capsule
89652947|NCT01922713|Experimental|orange maize|orange maize and a corn oil capsule
89652948|NCT01922713|Active Comparator|vitamin A|white maize and a vitamin A capsule
89652949|NCT05061732|Experimental|RBCL|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, clarithromycin 0.5 g bid and levofloxacin 0.5 g qd for 14 days
89652950|NCT05061732|Experimental|RBLM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and levofloxacin 0.5 g bid for 14 days
89652951|NCT05061732|Experimental|RBCM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and clarithromycin 0.5 g bid for 14 days
89652952|NCT05061732|Experimental|RA|Rabeprazole 20 mg bid, and Amoxicillin 1.0 g tid for 14 days
89046131|NCT04598399|Experimental|MBRP program:|
89046132|NCT04598399|Active Comparator|Standard care|
89046133|NCT04570579||Observational cohort|"This is a prospective, nonrandomized study of patients undergoing bilateral cataract surgery with implantation of the spherical Vivity and/or Vivity toric IOL. Preoperative patient data such as age, sex, prior ocular history, medical history, and intraocular lens calculations/formulae used will be recorded. Uncorrected and best-corrected visual acuity will be measured at distance (4m), intermediate (60cm) and near (40cm). All 3 surveys will be administered prior to surgery (at baseline) and at 3 months postoperative, regarding spectacle independence, visual disturbances, and visual quality. A proper perioperative record will be maintained, documenting planned IOL implantation, actual IOL implant used, use of femtosecond laser, use of intraoperative aberrometry, and use of pupillary expansion devices. Patients will be examined 1 day (postoperative day 1), 1 week (postoperative week 1), 1 month (postoperative month 1) and 3 months (postoperative month 3) following surgery."
89046134|NCT04527926|Experimental|STEPuP Intervention|STEPuP interventions
89046135|NCT04527926|Active Comparator|Usual Care|Standard of Care
89046136|NCT04510506|Experimental|Randomized substudy: Artificial Pancreas Therapy|Participants will use a study assigned Tandem t:slim X2 with Control-IQ Technology.for two years.
89652953|NCT05061732|Experimental|RAB|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, and Amoxicillin 1.0 g tid for 14 days
89652954|NCT05061732|Experimental|RAM|Rabeprazole 20 mg bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
89046137|NCT04510506|No Intervention|Randomized substudy: Usual Care + CGM|Participant will use their usual diabetes care along with a study CGM.
89046138|NCT04510506|No Intervention|Triple Label Surveillance substudy (observational arm)|Participants will remain on own baseline diabetes management (e.g. automated insulin delivery system, non-AID pump, MDI)
89046139|NCT04506177||Permanent Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using permanent (polytetrafluoroethylene, Gore-Tex) suture for vaginal mesh attachment
89046140|NCT04506177||Delayed Absorbable Monofilament Sutures|Women who previously received (in the PACT Study Trial) minimally-invasive total hysterectomy and sacrocolpopexy (SCP) with a light-weight polypropylene mesh (Upsylon™ y-mesh) using delayed absorbable monofilament (polydioxanone, PDS) suture for vaginal mesh attachment
89046141|NCT04502862|Experimental|Dupilumab|2 x dupilumab injections as loading dose on Day 1, followed by 1 dupilumab maintenance dose injection every 2 weeks (Q2W) during 12 weeks
89046142|NCT04502862|Placebo Comparator|Placebo|2 x placebo injections on Day 1, then 1 placebo injection Q2W during 12 weeks
89046143|NCT04470921||Choice for Opportunistic Salpingectomy|Women who will undergo a gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved, can opt for an opportunistic salpingectomy.
89046144|NCT04467502|Experimental|CBT with VRET|
89046145|NCT04467502|Active Comparator|CBT with imaginal ET|
89046146|NCT04463368|Experimental|Arm A|Patients will be treated with IHP followed by 4 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
89046147|NCT04463368|Experimental|Arm B|Patients will be treated with 1 course of ipilimumab 3mg/kg and nivolumab 1mg/kg followed by IHP after 3 weeks and then another 3 courses of ipilimumab 3mg/kg and nivolumab 1mg/kg every third week followed by continued nivolumab 480mg q4w up to 1 year.
89046148|NCT04460053|Experimental|Neurofilament light protein measurement|Neurofilament light protein measurements in peripheral blood pre- peri- and postoperatively.
89652955|NCT05061732|Experimental|RBAM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g tid, and Amoxicillin 1.0 g tid for 14 days
89652956|NCT05061732|Experimental|RBAM4|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g tid for 14 days
89652957|NCT05061732|Experimental|RBDM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid and doxycycline 0.1 g bid for 14 days
89652958|NCT05061732|Active Comparator|RBTM|Rabeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and tetracycline 0.5 g qid for 14 days
89046149|NCT04454528|Active Comparator|Arm 1|Arm 1 will receive radiotherapy on day -14 and pembrolizumab on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
89046150|NCT04454528|Active Comparator|Arm 2|Arm 2 will receive pembrolizumab on day -14 and radiotherapy on day -7. Subjects in all arms will undergo surgery on day 0 and follow the same postoperative blood sampling and safety schedule.
89046151|NCT04454528|Other|Arm 4 (Historical Controls)|Arm 4 will not receive any study treatment. Subjects will undergo surgery on day 0 and follow a preoperative (Day 0) and postoperative blood (Day 30) and tissue (Day 0) sampling schedule.
89046152|NCT04421963|Experimental|Olaparib|Treatment
89652959|NCT01834833|No Intervention|Control|usual care without systematic cardiology evaluation between 1 and 2 weeks
89652960|NCT01834833|Experimental|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
89652961|NCT02391571|Experimental|Oxycodone/Naltrexone|Oxycodone/Naltrexone Capsules (over-encapsulated), on days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
89652962|NCT02391571|Active Comparator|Oxycodone|Oxycodone Tablets (Over-encapsulated), on Days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
89046153|NCT04398862||Children with Down syndrome and aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
89046154|NCT04398862||Children with Down syndrome without aspiration|Outcomes will be compared between two groups although no intervention is submitted, this is an observational study.
89046155|NCT04385485|Experimental|Active mobilisation|The patient see an occupational therapist 1-3 days after surgery. A splint is made to immobilise the wrist and work as a extension block for the MCP-joints. This splint has to be worn day and night for 4 weeks. Another splint that immobilise the distal interphalangeal (DIP) joint and the proximal interphalangeal (PIP) joints are worn whenever the patient is not exercising. During active exercise the patient follows a strict protocol with both active and passive training and increasing number of repetitions. The rehabilitation is proceeding for 3 months.
89046156|NCT04385485|Active Comparator|Passive mobilisation with place and hold|1-3 days after surgery the patient gets a new plaster that immobilise the wrist and work as an extension block for the MCP-joints. The occupational therapist attach rubberbands to the nails of all the fingers and the training is done passively with active hold according to a strict protocol. The training with rubberbands is done during 4 weeks. After that the rehabilitation is active. The rehabilitation is proceeding for 3 months.
89652963|NCT02391571|Other|Placebo Lead-In|Placebo Lead-In: Placebo Capsules (matching to Active and Experimental) on days 4-5, every 6 hours (at 09:00, 15:00, 21:00)
89652964|NCT01728987|Active Comparator|cholecalciferol|vitamin d (cholecalciferol) will be given as a capsule of 20.000 Iu twice a week
89046157|NCT04369131|Experimental|Intervention|All participants will receive intervention in four conditions: (a) no FES, (b) calves only FES, (c) quads and abdominals only FES, and (d) calves, quads, and abdominals FES. Session-by-session alternation among conditions will occur in a unique, predetermined, randomized order for each participant.
89046158|NCT04349501|Experimental|RSI-MRI|Participants will undergo RSI-MRI at three time points: before androgen deprivation therapy (ADT); after neoadjuvant ADT but before radiation therapy (RT); and after RT.
89046159|NCT04337021|Active Comparator|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving-related stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
89046160|NCT04337021|No Intervention|Usual Care|CGs in this arm will be contacted telephonically once by a CM. After a brief needs assessment, the CM will provide contact information for appropriate VA (e.g., local CSP clinicians) and non-VA community resources/services. CGs will be sent brochures for the national VA CSP. Information on both the program's website (which includes links to training, education, resources, and outreach programs for CGs) and the national CG hotline number will be included in the mailed packet. After this initial contact, CGs in this group will only be contacted again 4 and 9 months after baseline for administration of follow-up research assessments. CGs will be encouraged to seek medical, psychological, social support, and social services that are available to them through VAMCs or any other non-VA/community source. CGs in the SOS group will be offered similar information.
89046161|NCT04334954||Healthy Volunteers|Healthy Volunteers
89046162|NCT04330664|Experimental|Phase 1 Dose Exploration|Dose escalation of TNO155 to determine maximum tolerated dose of TNO155 in combination with MRTX849
89046163|NCT04330664|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with TNO155 to recommend Phase 2 regimens
89652965|NCT01728987|Placebo Comparator|placebo|the placebo capsules are looking identical to the vitamin d capsules and contain medium chain triglycerides and arachis oil
89652966|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.
89652967|NCT01927159|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.
89652968|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.
89652969|NCT01927159|Experimental|10 mcg ID93 + 5 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.
89652970|NCT01927159|Placebo Comparator|Saline|Three intramuscular injections of saline at Days 0, 28, and 112.
89652971|NCT01834989|Active Comparator|Insulin-like growth factor I|3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention
89652972|NCT01834989|Placebo Comparator|Placebo injections|3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period
89652973|NCT01835067|Sham Comparator|Control Group (A)|Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
89652974|NCT01835067|Experimental|C3F8 Only Group (B)|C3F8 given. Ranibizumab given as standard.
89652975|NCT01835067|Experimental|tPA and C3F8 Group (C)|Both C3F8 gas and tPA given. Ranibizumab given as standard.
89652976|NCT01835067|Experimental|tPA Only Group (D)|tPA given. Ranibizumab given as standard.
89652977|NCT03100422|Experimental|ARMin|Therapy with the arm therapy robot ARMin
89652978|NCT03100422|Active Comparator|Arm+ occupational therapy|a form of conventional occupational therapy that involves both arms
89652979|NCT00639769|Experimental|Therapeutic Intervention|
89652980|NCT05061342||Cancer Patients|Those with cancer.
89652981|NCT05061342||Normal (non cancer) controls|Those without cancer.
89652982|NCT01723293|No Intervention|Control|Sedentary pregnant women
89652983|NCT01723293|Experimental|Exercise group|
89652984|NCT01729065|No Intervention|Home Program|Participants perform home program only.
89652985|NCT01729065|Experimental|Physical Therapy Intervention|Physical therapy intervention provided for first 12 weeks following surgery.
89652986|NCT01922869|Experimental|COB mixture|One time ingestion of flavonoid mixture from chocolate (80 g), orange juice (500 ml)and blackberries (160 g), also known as the 'COB mixture' providing approximately 640 mg of flavan-3-ols, 390 mg of anthocyanins and 342 mg of flavanones respectively.
89652987|NCT05061264|Experimental|Active infection group|A cohort of 38 patients carrying an active infection (mesh sinus, exposed mesh or enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with PVDF mesh.
89652988|NCT05061264|Active Comparator|Clean control group|A cohort of 38 patients with ventral hernias, and submitted to clean ventral hernia repair with PVDF mesh.
89652989|NCT01723371|Experimental|Carvedilol|
89652990|NCT03139669|Experimental|HPV home testing kit|The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
89046164|NCT04330664|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis for evaluation of clinical activity to evaluate clinical activity of MRTX849 and TNO155 in combination
89046165|NCT04315181|Experimental|Oral opioid agonist|Participants will receive non-therapeutic experimental doses of active or placebo oral opioid agonist. Active opioid agonist/placebo will be administered once per session and will be administered orally.
89046166|NCT04315181|Experimental|Oral sedative|Participants will receive non-therapeutic experimental doses of active or placebo oral sedative. Active sedative/placebo will be administered once per session and will be administered orally.
89046167|NCT04315181|Experimental|Opioid agonist/sedative|Participants will receive non-therapeutic, experimental doses of active opioid agonist/placebo in combination with non-therapeutic, experimental doses of active sedative/placebo. Opioid/placebo and sedative/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid and sedative doses will be administered orally.
89046168|NCT04303169|Experimental|Pembrolizumab + Vibostolimab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
89652991|NCT01729143|Active Comparator|Black pepper|During the black pepper study day, subjects consumed 1.5g of black pepper (0.5g/meal) in 60.8g of vegetable juice. Black pepper was consumed was a meal on each occasion. 24-hour energy expenditure and substrate utilization will be measured.
89046169|NCT04303169|Experimental|Pembrolizumab + Gebasaxturev|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus gebasaxturev (V937) intratumorally (IT) at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
89046170|NCT04303169|Experimental|Pembrolizumab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
89213131|NCT00997347|No Intervention|57-63 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)
89652992|NCT01729143|Placebo Comparator|No pepper control|During the no pepper control study day, subjects consumed an identical menu without black pepper. 60.8g of vegetable juice (vehicle) was consumed at each of the three study meals. 24-hour energy expenditure and substrate utilization will be measured.
89652993|NCT05057598|Experimental|Intervention group on diet and lifestyles|The arm consists to provide survivors with evidence-based recommendations and to promote improved nutrition and physical activity through videos and lectures available on the website (theoretical lectures on preventive strategies, and practical videos on cooking techniques and specific physical exercises).
89652994|NCT00639457|Experimental|Pioglitazone|Pioglitazone (Actos; 30mg/day) for 16 weeks.
89652995|NCT00639457|Active Comparator|Pioglitazone + Exercise training|Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.
89652996|NCT05057286|Experimental|Subjects with gummy smile|The study procedure consisted of recruitment, pre&post-operative photography, gingivoplasty, BTX-A injection, recall visits, and data collecting.
89652997|NCT01729221||HCV infected patients treated by stem cell therap|Hepatitis C virus infected patients treated by stem cell therapy
89652998|NCT01729221||HCV infected patients treated by standared line of care|Hepatitis C virus infected patients treated by standared line of care
89652999|NCT05060796|Experimental|EGFR CAR-T|Group: 3 dose levels
89653000|NCT01723527|Experimental|Therapeutic Workplace|Participants assigned to this condition will receive the standard services and requirements for diversion as described for the usual care group, and will also be eligible to attend the three-phase Therapeutic Workplace (TW) intervention. All phases of this intervention include employment-based drug abstinence reinforcement contingencies. Under these contingencies, participants can work and earn wages or wage subsidies contingent upon drug abstinence as verified by urinalysis. Phase 1 of the TW intervention is expected to increase cocaine abstinence and to prepare participants for employment. Phase 2 of the TW intervention is expected to maintain abstinence while participants are employed in an onsite model workplace. Phase 3 is designed to increase employment in community jobs and to maintain abstinence while participants are employed in offsite community workplaces.
89653001|NCT01723527|Active Comparator|Diversion to treatment (Usual Care)|Participants in this condition will be offered the standard treatment services available in community methadone and buprenorphine programs, including medication (methadone or buprenorphine, respectively), counseling services, HIV testing, and case management. All services will be provided in the treatment clinics. There are a number of clinics within easy walking distance from the research site, and others throughout the city that are reachable by public transportation from the research site. In addition, all participants will receive referrals to the Re-Entry Center, a One-Stop Career Center tailored to the needs of offenders, at all intake and monthly assessments. As mentioned in detail above, participants will be required by the court to stay enrolled in treatment for 90 days. It is important to note that all diverted individuals will receive these services and requirements, independent of whether they agree to participate in the pilot study.
89653002|NCT01922947|Active Comparator|Motivational Interviewing w/Social Network Counseling|Motivational Interviewing integrated with Social Network Counseling, 20-minute session.
89653003|NCT01922947|Sham Comparator|Health Counseling|
89653004|NCT03100266|Experimental|probiotic|Lactobacillus rhamnosis GG
89653005|NCT03100266|Placebo Comparator|placebo|Inactive capsules
89653006|NCT01835301||DES|Patients who received a DES stent > 3 years ago.
89653007|NCT01835301||BMS|Patients who received BMS stents > 3 years ago.
89653008|NCT00639379|Experimental|senofilcon A|senofilcon A toric daily wear contact lenses
89653009|NCT00639379|Active Comparator|alphafilcon A|alphafilcon A toric daily wear contact lenses
89653010|NCT01729299|Placebo Comparator|saline|Saline: 0.9% saline solution
89653011|NCT01729299|Experimental|ghrelin and exendin (9-39)|Ghrelin+Ex-9: Combination of ghrelin and Ex-9,
89653012|NCT01729299|Experimental|Exendin (9-39)|Exendin (9-39) (25 µg/kg) bolus over 1 min followed by a continuous infusion of 2.5 µg/kg/min
88993720|NCT02951845|Experimental|Part 1: Treatment Sequence A1B1C1|Participants in Part 1 will only receive single dose of Treatment A1 oral Suspension (25 milligram [mg], Fasted) then Treatment B1 (Direct Compression Tablets, 5*5 mg Tablets, Fasted) followed by Treatment C1 (Direct Compression Tablets (5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993721|NCT02951845|Experimental|Part 1: Treatment Sequence B1C1A1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment C1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993722|NCT02951845|Experimental|Part 1: Treatment Sequence C1A1B1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment A1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993723|NCT02951845|Experimental|Part 1: Treatment Sequence A1C1B1|Participants in Part 1 will only receive single dose of Treatment A1 then Treatment C1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993724|NCT02951845|Experimental|Part 1: Treatment Sequence B1A1C1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment A1 followed by Treatment C1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993725|NCT02951845|Experimental|Part 1: Treatment Sequence C1B1A1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment B1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993726|NCT02951845|Experimental|Part 2: Treatment Sequence A2B2C2|Participants in Part 2 will only receive single dose of Treatment A2 oral Suspension (25 mg, Fasted) then Treatment B2 (Fluid Bed Granulation Tablets (5*5 mg Tablets, Fasted) followed by Treatment C2 (Fluid Bed Granulation Tablets, 5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
89213132|NCT00997581|Experimental|apremilast|Experimental treatment for acute gout
89213133|NCT00997581|Active Comparator|indomethacin|Medication currently used for the treatment of acute gout
89213134|NCT04001439|Other|Clinical trial|the study design is an open-label, single-arm propective clinical trial. In this proof-of-concept study we will assess feasibility safety and potential efficacy of an intervention of FMT in SZ subjects with MD.
88993727|NCT02951845|Experimental|Part 2: Treatment Sequence B2C2A2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment C2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993728|NCT02951845|Experimental|Part 2: Treatment Sequence C2A2B2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment A2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
89653013|NCT01729299|Experimental|ghrelin|synthetic human Acyl Ghrelin (0.28 μg/kg) bolus over 1 min followed by 2 μg/kg/h continuous infusion,
89653014|NCT05060952||PJI|Patients with septic arthroplasty failure
89653015|NCT05060952||Aseptic|Patients with aseptic causes of arthroplasty failure
89653016|NCT01723605|Experimental|insitu repair|insitu repair of the uterine incision during caeserean section
89653017|NCT01723605|Active Comparator|exteriorisation of the uretus|uterine closure during caeserian section with exteriorisation of the uterus
89653018|NCT05057208||Vaccinated|COVID Vaccinated
89653019|NCT05057208||Non-vaccinated|COVID Non-vaccinated
89653020|NCT01729377||Suicidal older persons and their families|Suicidal older persons and their families will be interviewed
89653021|NCT00639223|Active Comparator|Pravastatin|
89653022|NCT00639223|Experimental|Red yeast Rice|
89653023|NCT04434534|Experimental|Hipocaloric Diet with Açaí Juçara|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories, including 200g of Açaí Juçara (2 pulps).
89653024|NCT04434534|Active Comparator|Hipocaloric Diet|Individualized diet plans calculated for each participant, reducing 500-1000 daily calories.
89653025|NCT01723683|Experimental|MISTCPAP group|MISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP.
89213135|NCT05301153||Myasthenia Gravis cases|"Collection of Peripheral Blood Peripheral blood mononuclear cells (PBMCs) will be isolated from freshly drawn heparinized blood by ficoll density gradient centrifugation according to the manufacturer's protocol.~Real-Time Reverse Transcription -PCR (RT-PCR) Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39.~Autoantibodies detection:~Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA according to the manufacturer's protocol."
89213136|NCT05301153||Healthy Control|"Collection of Peripheral Blood Peripheral blood mononuclear cells (PBMCs) will be isolated from freshly drawn heparinized blood by ficoll density gradient centrifugation according to the manufacturer's protocol.~Real-Time Reverse Transcription -PCR (RT-PCR) Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39."
89653026|NCT01723683|Active Comparator|INSURE group|INSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP.
89653027|NCT03519984|Experimental|Arm A (sEPHB4-HSA, cytarabine)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and cytarabine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89653028|NCT03519984|Experimental|Arm B (sEPHB4-HSA, vincristine liposomal)|Participants receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, 15, and 22 and vincristine liposomal IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89653029|NCT01835457|Experimental|Concentration/meditation group|Subjects in this arm will be performing the concentration/meditation technique of Wim Hof (The Iceman) prior to, during and after intravenously injected 2 ng/kg Lipopolysaccharide
89653030|NCT01835457|Active Comparator|Control group|Subjects in this group will be intravenously injected with 2 ng/kg Lipopolysaccharide
89653031|NCT01729533|Active Comparator|ICSI|In this arm, patients will be provided with standard intracytoplasmic sperm injection (ICSI), in which sperm selection is performed under an overall magnification of x400.
89653032|NCT01729533|Experimental|IMSI|In this arm, patients will be provided with a modified intracytoplasmic sperm injection (ICSI) procedure, the IMSI, in which sperm selection is performed under an overall magnification of x6600.
89653033|NCT01835535|Experimental|Severe Resistant HTN|Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
89653034|NCT00638989|Experimental|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
89653035|NCT00638989|Experimental|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
89653036|NCT00638989|Experimental|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
89653037|NCT01723917|Experimental|PhytoSERM 50 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
89653038|NCT01723917|Experimental|PhytoSERM 100 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
89653039|NCT01723917|Placebo Comparator|Placebo tablet|Dietary supplement: placebo tablet to be taken once per day for 12 weeks
89653040|NCT01729611||Scleroderma|60 patients with scleroderma - 30 with and 30 without Pulmonary Arterial Hypertension
89653041|NCT01729611||Cirrhosis|60 patients with cirrhosis - 30 with and 30 without Pulmonary Arteria Hypertension
89653042|NCT05056194|Experimental|Valiloxybate|XW10172 Modified Release (MR) Granules for Oral Suspension
89653043|NCT05056194|Placebo Comparator|Placebo|Placebo Granules for Oral Suspension
89653044|NCT01923025|Experimental|RO5545965|
89653045|NCT01835613|Other|Tocilizumab|"Biomarkers Measures~At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
89653046|NCT04661761|Experimental|stimulated salivary flow rate|stimulated salivary flow rate determined in a crossover design: first using Paraffin Pellets from Aurosan GmbH; thereafter using Chewing wax from the Saliva-Check Buffer from GC Europe
89653047|NCT04379037|Experimental|Intervention Arm|Adults over 18 years of age hospitalized because of COVID-19 infection will be treated with transcutaneous auricular vagus nerve stimulation (taVNS).
89653048|NCT01729689|Experimental|Supportive care (cognitive behavioral therapy)|Participants undergo cognitive behavioral therapy over 1 hour once weekly for a total of 6 sessions. Sessions are tailored to patient and caregiver cognitions and approach and avoidance behaviors.
89653049|NCT05060406|Experimental|LY06006 60mg|"injection~Interventions:~Drug: LY06006 Injection； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
89653050|NCT05060406|Placebo Comparator|Placebo|"injection~Interventions:~Drug: Placebo； Dietary Supplement: Elemental Calcium； Dietary Supplement: Vitamin D"
89653051|NCT01723995|Experimental|low-level laser on nipples|Application of laser light from the device in direct contact with the nipple injury, equipment connected and set up at a dose of 5J/cm2 (Epoint = 0.2J/cm2) for both groups, three consecutive doses of 5J/cm2 (ETotal = 0.6J/cm2) along the entire length of the injury.
89653052|NCT01723995|Placebo Comparator|low-level laser off on nipples|Laser with modified standard operation - shutdown of InGaAIP semiconductor diode and installation of a visible red light emitting diode with optical power of 0mW (LED - Light Emitting Diode - maximum power with standard nozzle).
89653053|NCT01835691|Experimental|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
89653054|NCT01835691|Experimental|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
89653055|NCT03131635|Experimental|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
89653056|NCT03131635|No Intervention|Delayed Treatment Group (DTG)|
89653057|NCT01729767|Experimental|Acyclovir|Acyclovir 400 mg tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
89653058|NCT01729767|Placebo Comparator|Placebo|Placebo tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
89653059|NCT05055804|Experimental|ELG Device Comparison to Whole Blood Testing|Participant will place thumb in the ELG device for scan. Scan generally takes between 1-2 minutes. ELG then displays a readout of both a glucose and A1C reading on the screen of the ELG device.
89653060|NCT03243786|Active Comparator|"12-week Stay on Track intervention"|The study intervention includes three personal exercise training sessions, three dietary counseling sessions, use of a physical activity tracking device, and approximately three weekly text messaging
89653061|NCT03243786|Active Comparator|12-week self-guided control|The self guided group does not receive the study intervention, but is offered a Nutrition and wellness guide at the end of 6 months
89653062|NCT01724073|Experimental|Leafy vegetable-fish sauce|one meal per day, 6 days a week, with leafy vegetable-fish sauce + tô, a local cereal-based paste
89653063|NCT01724073|Experimental|Leafy vegetable-fish/liver sauce|one meal per day, 6 days a week, 5 days with leafy vegetable-fish sauce + tô, 1 day with leafy vegetable-liver sauce + tô
89653064|NCT01724073|Experimental|Misola|one meal per day, 6 days a week, with gruel prepared with the fortified Misola flour
89653065|NCT01724073|No Intervention|no test food|control group receiving no test food
89653066|NCT05055882||children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
89653067|NCT00913263|Experimental|2-Hydroxyflutamide|Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
89653068|NCT04378803|Experimental|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session. Then, 4 weeks of no-training interval followed by a testing session.
89653069|NCT04378803|Experimental|Wait-list control (WLC) group|Receives 4 weeks of no-training interval followed by a testing session. Then, 4 weeks of mindfulness training followed by a testing session.
89653070|NCT02940288|Experimental|Intervention|Participants will be randomized to receive bilateral auricular acupuncture for postoperative pain.
89653071|NCT02940288|Sham Comparator|Control|Participants will be randomized to receive bilateral sham acupuncture.
89653072|NCT04377867||LRBA deficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
89653073|NCT04377867||CTLA4 haploinsufficient patients on abatacept|These patients will prospectively followed and biological samples collected at baseline as well as periodically every 3 months under therapy. Abatacept will be provided on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to drug instructions provided by the drug company based on the weight of the patients.
89653074|NCT04377867||Control group|Age matched healthy control group will be used during the study to determine the reference values of the immunological assays.
89653075|NCT05046678||Control|Periodontally healthy, non-smoking
89653076|NCT05046678||Smokers with periodontally healthy|Periodontally healthy, smoking
89653077|NCT05046678||Non-smokers with gingivitis|Gingivitis, non-smoking
89653078|NCT05046678||Smokers with gingivitis|Gingivitis, smoking
89653079|NCT05046678||Non-smokers with periodontitis|Periodontitis, non-smoking
89653080|NCT05046678||Smokers with periodontitis|Periodontitis, smoking
89653081|NCT00637273|Experimental|1|
89653082|NCT00637273|Active Comparator|2|
89653083|NCT00637273|Active Comparator|3|
89653084|NCT04378725|No Intervention|Control School|"When a student is screened as a smoker. The student will only be receiving Brief Intervention Advice from the dentist.~Brief Intervention advice: delivered to all schoolchildren regardless of smoking status by the dentist. Brief information of dangers of smoking was embedded in the generic lecture of Dental Health Education given to the whole school in large group."
89653085|NCT04378725|Experimental|Intervention School|The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval.
89653086|NCT01724151||Healthy adults|Healthy adults, over 45 years old
89653087|NCT01724151||Mild cognitive impairment|subjects with mild cognitive impairment
89653088|NCT01724151||Alzheimer's disease|subjects with Alzheimer's disease
89653089|NCT05036382||Experimental Group|A group that receives an incentive message one month after the start of the experiment
89653090|NCT05036382||Control Group|A group that does not receive an incentive message (for equity, incentive messages will be sent in the last month of the experiment)
89653091|NCT01835847|Experimental|A single-arm study|
89653092|NCT05046210|Experimental|LHA group (EG)|"Behavioral: LHA intervention~Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day, whereas the participants in the EG also received 4 lessons from a LHA over 4 weeks."
89653093|NCT05046210|Placebo Comparator|Leaflet group (CG)|"Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.~The participants in the CG received oral exercise intervention and leaflets only."
89653094|NCT01835925||Tissue specmien|
89653095|NCT01726569|Experimental|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session and follow up counseling after operation 1 week and 6 weeks
89653096|NCT01726569|Other|traditional counseling|Subjects will be participate or not participate in pre-operative counseling and/or post-operative counseling with a rural hospital's doctor/nurse.
89653097|NCT05045742||Training|A subset of patients that are used to train the machine learning algorithm.
89653098|NCT05045742||Validation|"A subset of patients that are held back and used to validate the algorithm's accuracy."
89653099|NCT01923259|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
89653100|NCT01923259|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
89653101|NCT05055414|Experimental|UI030|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
89653102|NCT05055414|Placebo Comparator|Placebo|UI030 (Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days) or placebo for 2 weeks.
89653103|NCT01923337|Experimental|Treatment (irinotecan, alisertib)|Patients receive irinotecan hydrochloride IV over 30 minutes on days 1 and 8 and alisertib PO BID on days 1-3 and 8-10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89653104|NCT01836081|Experimental|fluid responsiveness|
89653105|NCT01724307|Active Comparator|Asthma positive to Methacholine Challenge Testing|Asthma diagnosis by positive Methacholine Challenge Testing
89653106|NCT01724307|Active Comparator|Asthma positive to Eucapnic voluntary hyperventilation testing|Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing
89653107|NCT03098160|Experimental|Evofosfamide plus Ipilimumab|Ipilimumab to be administered at same dose. Evofosfamide dose to be determined during duration of trial
89653108|NCT00988351|Active Comparator|PSG CPAP titration then CPAP treatment|Patients diagnosed with sleep apnea will have a continuous positive airway pressure (CPAP) titration with polysomnography (PSG) followed by continuous positive airway pressure (CPAP) Treatment
89653109|NCT00988351|Active Comparator|Auto-Adjusting Positive Airway Pressure|Following diagnosis of obstructive sleep apnea patients will be have auto-adjusting positive airway pressure treatment without a titration.
89653110|NCT05036694|Other|Ambulatory HIV positive patients|Ambulatory HIV positive patients with signs and symptoms of TB, and Ambulatory HIV positive patients with advanced disease and CD4 less than 200 cell.
89653111|NCT01724385|Experimental|intravitreal bevacizumab injection|intravitreal injection of bevacizumab 1.25 mg
89653112|NCT05036460|Active Comparator|Ultrasonography + direct visualization|To detect using ultrasonography assisted direct visualization.
89653113|NCT05036460|Experimental|Direct visualization|To detect using direct visualization.
89653114|NCT05055180||HFpEF with pulmonary hypertension|Invasively diagnosed HFpEF and pulmonary hypertension according to current guidelines
89653115|NCT05055180||HFpEF without pulmonary hypertension|Invasively diagnosed HFpEF without pulmonary hypertension according to current guidelines
89653116|NCT05055180||Patients without HFpEF|Patients without invasive evidence of HFpEF
89653117|NCT04377789|No Intervention|non-quercetin group|Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
89213137|NCT05183139|Experimental|Cohort A: Ixazomib 4 mg + Pomalidomide 4 mg + Dexamethasone 40 mg|Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with pomalidomide 4 mg, capsules, orally from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of pomalidomide or dexamethasone can start at that dose level in the study.
89653118|NCT04377789|Active Comparator|quercetin prophylaxis group|Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
89653119|NCT04377789|Active Comparator|quercetin treatment group|Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
89653120|NCT00988117|Experimental|Rivastigmine Patch 9.5 cm2|
89653121|NCT01728753|Placebo Comparator|Placebo|Placebo
89653122|NCT01728753|Experimental|T-705 A|Favipiravir regimen 1: 1200 mg 3x daily (TID) on Day 1, then 600 mg TID on Days 2-5
89653123|NCT01728753|Experimental|T-705 B|Favipiravir regimen 2: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
89653124|NCT01728753|Experimental|T-705 C|Favipiravir regimen 3: 1800 mg BID on Day 1, then 800 mg BID for Days 2-5
89653125|NCT05055102||Patient with WOVEX bifurcated prosthesis|"Patients who have undergone open abdominal aortic surgery between January 1st, 2013 and December 31, 2017 in Burgundy Dijon Hospital.~Patients who have been treated with a WOVEX bifurcated prosthesis (Wovex® Polyester Vascular Protheses)"
89653126|NCT01724619|Experimental|Healthy Volunteers|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
89653127|NCT01724619|Experimental|Prostate Cancer Patients|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
89653128|NCT05045508|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|
89653129|NCT05045508|Placebo Comparator|Placebo (vehicle) nasal spray|
89653130|NCT01724697|Active Comparator|conventional treatment|conventional treatment & antivrial treatment.
89653131|NCT01724697|Experimental|BMSC transplantation|conventional treatment & antiviral treatment & autologous bone marrow stem cell transplantation via hepatic artery
89653132|NCT05035914|Experimental|Experimental: anlotinib+mXELIRI|"Dose-escalation phase:~A: anlotinib 8 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~B: anlotinib 10 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~C: anlotinib 12 mg, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;~Dose-expansion phase:~anlotinib RP2D, po, qd, d1-14; iritecan 180-200mg/m2, iv, d1;capecitabine 800mg/m2, po, bid, d1-14; every 3 weeks as a cycle;"
89653133|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
89046171|NCT04303169|Experimental|Pembrolizumab + MK-4830|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus MK-4830 IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
89046172|NCT04303169|Experimental|Favezelimab + Pembrolizumab|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive MK-4280A (favezelimab and pembrolizumab administered as a co-formulation) IV at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
89046173|NCT04303169|Experimental|Pembrolizumab + all-trans retinoic acid (ATRA)|"Prior to tumor resection surgery, in the neoadjuvant phase, participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days. After surgery, in the adjuvant phase, participants will receive pembrolizumab IV at a specified dose on specified days.~Participants will receive treatments in the neoadjuvant and adjuvant phase for a total treatment duration of up to approximately 1 year."
89046176|NCT04268641|Experimental|Use of positioning equipment order 1|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
89046177|NCT04268641|Experimental|Use of positioning equipment order 2|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
89653134|NCT01836159|Experimental|iPad Intervention|Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
89653135|NCT03095820|Active Comparator|Supportive therapy|The control group received supportive therapy for 12 weeks. In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth. The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
89653136|NCT03095820|Experimental|Multidomain intervention|"As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program.~In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit."
89653137|NCT04379895|Active Comparator|Heated RF ablation|Patients with OA that will undergo heated RF of the genicular nerves
89653138|NCT04379895|Active Comparator|Pulsed RF ablation|Patients with OA that will undergo pulsed RF of the genicular nerves
89653139|NCT05054634||Experimental Group (EG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
89653140|NCT05054634||Control Group (CG)|Patients diagnosed with DTC, treated with thyroidectomy and candidates to RIT to be treated in Nuclear Medicine (NM) Service of Hospital Quirónsalud Torrevieja were considered to be included in the study. They were alternatively assigned to the EG or CG, according to their order of entry.
89653141|NCT00637195|Experimental|Cervarix™ & Engerix™ Group|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) (Months 0, 1 & 6) and 4 doses of Hepatitis B (Engerix™) vaccine (Months 0, 1, 2 & 12).
89653142|NCT00637195|Active Comparator|Engerix™ Group|Subjects received 4 doses of Hepatitis B (HBV) vaccine (Months 0, 1, 2 & 12).
89653143|NCT05045274|Active Comparator|dapagliflozin|(a) Dapagliflozin 10 mg once daily within 24 hours after PPCI for 3 month
89653144|NCT05045274|Placebo Comparator|conventional therapy|"Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
89653145|NCT01721733|Placebo Comparator|Placebo|Each patient will receive a volume of placebo based on weight
89653146|NCT01721733|Active Comparator|EPI-743 15 mg/kg|Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.
89653147|NCT01721733|Active Comparator|EPI-743 5 mg/kg|Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.
89653148|NCT00915759|Active Comparator|ProKera|
89653149|NCT00915759|Placebo Comparator|Bandage contact lens|
89653150|NCT03077425|Experimental|Intervention|An RCT will enroll 360 mothers (total) of children 4-6 month olds from New York City (n=3) and New Jersey (n=2) pediatric practices. Half (180) will be assigned to the Community Health Worker intervention comprised of: a) home visits with mothers/families (n=6 visits over one year) and follow up telephone support; b) patient navigation to make/keep timely dental visits (2x by 18 months).
89653151|NCT03077425|Placebo Comparator|Enhanced Usual Care (EUC)|"Community Health Workers (CHWs)- will deliver the EUC to all study participants at their 6 month well-child visit, which will occur just after their T0 Baseline Interview, just prior to randomization. EUC Components: 1) Pamphlet- CHWs will hand out and review deliver and review a pamphlet with basic ECC and Obesity prevention messages for parents of 6-18 month olds; and 2) Dental Referral List of dentists who will see 12 month olds, and who accept most insurance plans in the pediatric practices we are recruiting from.~Thus, the EUC will be delivered to n=180 families in the EUC Control and n=180 families in the Intervention group."
89653152|NCT05045118|Experimental|Intervention arm|Single-arm prospective, multiple assessment intervention study. Participants will receive a digital structured patient education material
89653153|NCT01720485|Experimental|Desloratadine + Prednisolone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the test medication(Desloratadine 5 mg + Prednisolone 20 mg) + 1 tablet of placebo control medication.~Afternoon: 1 tablet of placebo test medication + 1 tablet of placebo control medication.~Night: 1 tablet of placebo test medication + 1 tablet of placebo control medication."
89653154|NCT01720485|Active Comparator|Dexchlorpheniramine + Betamethasone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Afternoon: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Night: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication."
89653155|NCT03095664|Experimental|Intervention group|6 months after surgical treatment, women in the experimental group will attend a counseling program to promote healthy eating and physical activity.
89653156|NCT03095664|No Intervention|Control group|Control group will receive usual care (verbal nutritional counseling after surgical treatment, at discharge).
89653157|NCT01724775||CME surgery for colon cancer|
89653158|NCT01724775||non-CME surgery for colon cancer|
89653159|NCT01836315||Obese|Defined by a BMI >35 kg/M2
89653160|NCT01836315||Non-Obese|Defined by a BMI <35 kg/M2
88993729|NCT02951845|Experimental|Part 2: Treatment Sequence A2C2B2|Participants in Part 2 will only receive single dose of Treatment A2 then Treatment C2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993730|NCT02951845|Experimental|Part 2: Treatment Sequence B2A2C2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment A2 followed by Treatment C2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993731|NCT02951845|Experimental|Part 2: Treatment Sequence C2B2A2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment B2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
88993732|NCT00167622|Active Comparator|1|Physiotherapy, oxygen as needed
88993733|NCT00167622|Experimental|2|Mechanical ventilation
88993734|NCT00512395|Active Comparator|1|epidural analgesia
88993735|NCT00512395|No Intervention|2|traditional analgesia with opioids
88993736|NCT02276833|Experimental|Single patient group with qualifying OA|intra-articular space injection of SVF Single patient group with pre-operative and post-operative assessments
88993737|NCT00512434|Active Comparator|Control in arm fields|Standard treatment Intervention no'Osteosynthesis'
88993738|NCT00512434|Experimental|IMOCA|Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327
88993739|NCT00512473|Placebo Comparator|A|I.v. saline for 8 hours
88993740|NCT00512473|Experimental|GH|Growth hormone (0.5 mg s.c. at t = 0 hours)
88993741|NCT00512473|Experimental|Pegvisomant|Pegvisomant injection 30 mg 36 hours prior to the study
88993742|NCT00524095|No Intervention|1|standard of care
88993743|NCT00524095|Experimental|2|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
88993744|NCT00524095|Experimental|3|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
88993745|NCT00167700|Experimental|Probiotics|
88993746|NCT00167700|Experimental|Probiotics + Dietary counseling|
88993747|NCT00167700|Experimental|Dietary counseling + placebo|
88993748|NCT00167700|Experimental|Prebiotics|
88993749|NCT00167700|Placebo Comparator|Placebo|
88993750|NCT00167700|No Intervention|Control|
88993751|NCT00512551||Cervical cancer tumor biopsy + radiation therapy|Cervical cancer tumor biopsy + radiation therapy.
88993752|NCT00512590|Experimental|Experimental|
88993753|NCT00512629|Experimental|Omegaven|Omegaven is a fish based intravenous fat emulsion
88993754|NCT00512629|Active Comparator|Intralipid|
88993755|NCT00524212||IE confirmed IE rejected|Prospective, controlled, blinded study of clinical/TEE criteria of IE compare to clinical/blood test criteria of IE.
88993756|NCT00524212||IE confirmed IE rejected|
88993757|NCT00512668|Experimental|Treatment (hormone therapy, temsirolimus)|"Patients receive combined androgen ablation therapy comprising a luteinizing hormone-releasing hormone analogue (i.e., leuprolide acetate intramuscularly once monthly or goserelin subcutaneously every 3 months) and an oral anti-androgen drug (i.e., bicalutamide or nilutamide once daily or flutamide 3 times daily) on days 1-90.* Beginning on day 60 of hormonal therapy, patients receive temsirolimus IV over 30 minutes once weekly. Treatment with temsirolimus continues for up to 36 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive no more than 3 months of hormonal therapy, including therapy initiated within 2 months of study entry."
88993758|NCT00512746|Other|Surveillance|Screened arm
88993759|NCT00512746|Active Comparator|Control|Control arm
89653161|NCT00636961|Experimental|Sequence 1: Indacaterol 300μg followed by Placebo|In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
89653162|NCT00636961|Experimental|Sequence 2 : Placebo followed by Indacaterol 300μg|In period I, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
89653163|NCT01726725||hemifacial spasm, lateral spread, motor evoked potentials|EMG recordings from facial muscles of HFS patients during MVD surgery will be compared during total intravenous anesthesia (propofol), 0.5 MAC desflurane and 1.0 MAC desflurane
89653164|NCT05044728|Experimental|Neoadjuvant Chemotherapy Immunotherapy stage|Patients with locally advanced non-small cell lung cancer and locally advanced thoracic esophageal squamous cell carcinoma who met the entry and discharge criteria will be enrolled. After detecting the functional subsets of peripheral CD8-positive T cells, the group was randomly stratified 1:1, respectively. Group A received immunotherapy 24 hours after chemotherapy, and group B received chemotherapy 24 hours after immunotherapy.
89653165|NCT05054478|Experimental|Experimental Arm|"4 days of dexamethasone. According to local practice, one dose of doxorubicine (30 mg/m2 IV) or cyclophosphamide (750 mg/m2 IV) may also be added~Induction Treatment (4 months): Subject will receive 4 x 28 days cycles of Dara-VRD induction:~Daratumumab sc 1800 mg on D1 D8 D15 D22 for cycle1 & 2 and D1 D15 for cycle 3 & 4 Bortezomib sc 1.3 mg/m2 on D1 D4 D8 D11 for each cycle Lenalidomide po 25 mg on D1 to D21 for each cycle Dexamethasone po 20 mg on D1 D2 D8 D9 D15 D16 D22 D23 for each cycle~High dose melphalan 200mg/m2 as conditioning therapy and first ASCT~First consolidation : 2 cycles of Dara-VRd~Daratumumab 1800 mg s.c D1 D15~Bortezomib 1.3 mg/m2 s.c D1 D8 D15 D22~Lenalidomide 25 mg p.o from D1 to D21~Dexa 20 mg p.o D1 D8 D15 D22~High dose melphalan 200mg/m2 as conditioning therapy and second ASCT Second consolidation : 6 cycles of Dara-VRd (every 2 months for 2 years) Then maintenance: Lenalidomide every 28 days (25 mg from D1 to D21) for 1 year"
89653166|NCT01041807||All participants|Participants with hypertension treated with amlodipine/losartan(Cozaar XQ)
89653167|NCT01836393|Experimental|placebo and plai|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
88993760|NCT00512785|Experimental|E1|
88993761|NCT00512785|Experimental|E2|
88993762|NCT00512824|Placebo Comparator|1|
88993763|NCT00512824|Active Comparator|2|
88993764|NCT00512824|Active Comparator|3|
88993765|NCT00512824|Active Comparator|4|
88993766|NCT00512941||1|HBV: Carrier
88993767|NCT00512941||2|HBV: cure
88993768|NCT00512941||3|HBV: isolate anti-HBc
88993769|NCT00512941||4|HBV: vaccinated
88993770|NCT00512941||5|HCV: anti-HCV positive test
88993771|NCT00512941||6|HBV/HCV co-infection
88993772|NCT00512941||7|Susceptible individuals
88993773|NCT00525889|Experimental|Rapamycin/IL-2 combination therapy|IL-2 (Proleukin) was administered at 4.5 3 106 IU s.c., three times per week for 4 weeks for a total of 12 doses. Rapamycin (Rapamune or Sirolimus) was administered without a loading dose at 2 mg/day, with adjustments to maintain trough blood levels of 5-10 ng/mL for 3 months.
88993774|NCT00524446|No Intervention|ST-DI|Standard treatment - delayed intervention. Counselling on complementary feeding + Vitamin A (200,000 IU) every 6 months until 36 months + 1 kg maize / soy flour 2-weekly (71 g / day) between 18 and 30 months of age.
88993775|NCT00524446|Experimental|FSm|Fortified Spread (milk). Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
88993776|NCT00524446|Experimental|FSs|Counselling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
88993777|NCT00524446|Experimental|LP|Likuni Phala. Counseling + Vitamin A as for ST-DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
88993778|NCT03879122|Active Comparator|ADT + Docetaxel|ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL
88993779|NCT03879122|Experimental|ADT + Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB
88993780|NCT03879122|Experimental|ADT + Ipilimumab / Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB
88993781|NCT03868982|Experimental|NAVA group|Participent in this group will received NAVA for two days
88993782|NCT03868982|No Intervention|Control group|Participent in this group will received standard care
88993783|NCT02948023|No Intervention|Standard Surgical therapy|Includes the control group that fulfills the inclusion criteria
88993784|NCT02948023|Active Comparator|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
88993785|NCT02952079|Active Comparator|BlephEx treatment|Treatment with the BlephEx instrument (lid margin exfoliation)
88993786|NCT02952079|Active Comparator|MiBoFlo treatment|Treatment with the MiboFlo equipment (heat therapy to eyelids)
88993787|NCT02948218|Active Comparator|Shanghai Longhua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
88993788|NCT02948218|Active Comparator|Shanghai Guanghua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
88993789|NCT02948218|Active Comparator|Huadong hospital of Fudan University|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
88993790|NCT02948218|Active Comparator|Shanghai Yueyang Integrated hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
88993791|NCT02947906||Study group|Participants with multiple sclerosis who able to walk at least 30 meters independently.
88993792|NCT02947906||Control Group|Healthy participants
88993793|NCT02947711|Experimental|E2027 100 mg alone and in combination with diltiazem ER 300 mg|E2027 100 milligrams (mg) will be administered orally on Days 1 and 12. Diltiazem extended release (ER) 300 mg will be administered alone on Days 7 to 24; however, on the morning of Day 12 it will be coadministered with E2027 100 mg.
88993794|NCT02946736|Experimental|Supervisor Intervention|Supervisors in the intervention group will go through the FSSB/sleep leadership training and receive actigraphy feedback.
88993795|NCT02946736|Experimental|Employee Intervention|Employees in the intervention group will receive actigraphy feedback.
88993796|NCT03845348|Experimental|TD3|TD3, bi-daily x 4 weeks
88993797|NCT03845348|Experimental|TD7|TD7, bi-daily x 4 weeks
88993798|NCT03845348|Active Comparator|Ketoconazole 2%|Ketoconazole 2% shampoo bi-daily x 4 weeks
88993799|NCT04723563|Experimental|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: Four times per day Duration: until hospital discharge
88993800|NCT04723563|Placebo Comparator|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: Four times per day Duration: until hospital discharge
88993801|NCT00525967|Active Comparator|1|Methadone plus Placebo
88993802|NCT00525967|Experimental|2|Methadone plus Acetaminophen
88993803|NCT00524719|Active Comparator|Open, internal fixation volar plate|Open reduction and internal fixation (ORIF) with volar locked plate
88993804|NCT00524719|Active Comparator|Closed reduction with external fixator|Surgical procedure - Closed reduction and non-spanning external fixation (Ex-FIX)
88993805|NCT00524719|Active Comparator|Closed reduction percutaneous pinning|Surgical procedure - Closed reduction with percutaneous pinning (CRPP) and the application of a cast
88993806|NCT03817307|Experimental|USPIO enhanced-MRI|The contrast agent ferumoxtran-10 will be administered intravenously under constant medical supervision 24-36 hours before performing a T2* weighted MRI scan (prior to surgery).
88993807|NCT02947789||Postoperative mortality within 3 days|Group 1: Patients undergoing emergency surgery with postoperative mortality within 3 days Group 2: Patients undergoing emergency surgery without postoperative mortality within 3 days
88993808|NCT00167856|Experimental|1|Venlafaxine HCL (extended release)
88993809|NCT00167856|Active Comparator|2|Benztropine Mesylate
88993810|NCT04693273||Carpal Tunnel Release surgical patients|This is the group the investigators survey who are candidates for carpal tunnel release (CTR) surgery: patients should be 18 years or older, comprehend and read English, and patients who consent to do the survey.
88993811|NCT00524758|Experimental|Ologen in Trabeculectomy|Ologen in Trabeculectomy
88993812|NCT00524758|Active Comparator|MMC in Trabeculectomy|MMC in Trabeculectomy
88993813|NCT04693117|Experimental|Study Group|Participants were voluntarily participated by non-probability consecutive sampling. It was a one group study with a limitation of non-randomization. The interventional group had performed interval training for 12 weeks, 3 days/week (figure 1). They sedentary conferring to activity level (≥ 30-minute, 3 days/weeks, moderate-intensity physical activity). They were not participated in any interval training program before participating in the study from six months. Written consent was taken after demonstration of the purpose, procedure, and related pros and cons. They were instructed to participate regularly in interval training.
88993814|NCT02947477|Experimental|Treatment|The EMA intervention uses twice-a-day interactive questions for emotion tracking including type of emotion, intensity of emotion, trigger to emotion and response to emotion through an Iphone app designed for the study. The study users receive individualized feedback about their daily reporting of emotions, sleep and stress.The study tracking is for 14 days.
88993815|NCT02947477|No Intervention|Control|The control arm does nothing for 14 days and then receives the 14 day emotion tracking listed above.
88993816|NCT02946346|Experimental|Vaginal and blood sampling|
89653168|NCT04314648|Active Comparator|START|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid and alcohol use disorders, and to increase linkage to aftercare.~The components of the START intervention are as follows:~Triage~Engage, Assess, and Plan~Treat~Communicate and Coordinate~Follow up~Monitor"
89653169|NCT04314648|No Intervention|Usual Care|Usual care for people with alcohol or opioid use disorder.
89653170|NCT01724853|Other|Surgery|Preferred surgery
89653171|NCT01724853|Other|Conservative|Conservative treatment
89653172|NCT04472364|Experimental|HemoPill|All participants will receive the blood detection capsule HemoPill Acute ®.
89653173|NCT01724931|Placebo Comparator|Placebo|Placebo once weekly
89653174|NCT01724931|Experimental|3 mg LD-Aminopterin|3 mg LD-aminopterin once weekly
89653175|NCT01724931|Experimental|1 mg LD-aminopterin|1 mg LD-aminopterin once weekly
89653176|NCT05035446|Experimental|single-incision plus one-port laparoscopic surgery(SILS + 1)|It requires an auxiliary small incision and one more port to perform laparoscopic gastrectomy
89653177|NCT05035446|Other|conventional laparoscopic surgery(CLS)|It requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy
89653178|NCT00635089|Other|Open-Label Reslizumab|Open-label reslizumab intravenous (IV) infusion at an initial dose of 1 mg/kg monthly
89653179|NCT01725009|Experimental|Levetiracetam IV infusions in Japanese|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects
89653180|NCT01725009|Experimental|Levetiracetam IV infusions in Caucasian|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects
89653181|NCT05044494||study group|non-prompt surgery after acute type a aortic dissection occurred
89653182|NCT05044494||control group|prompt surgery after acute type a aortic dissection occurred
89653183|NCT01725087|Placebo Comparator|Matching Placebo|Twice daily oral administration of matching placebo for 14 weeks
89653184|NCT01725087|Experimental|Low Dose GRT6005|Once daily GRT6005 low dose oral administration for 12 weeks with a titration period of 2 weeks.
89653185|NCT01725087|Experimental|Medium Dose GRT6005|Once daily GRT6005 medium dose oral administration for 12 weeks with a titration period of 2 weeks.
89653186|NCT01725087|Experimental|High Dose GRT6005|Once daily GRT6005 high dose oral administration for 12 weeks with a titration period of 2 weeks.
88993817|NCT02946814|Active Comparator|essential oils|a single mouthwash with 20 ml of essential oils for 30 seconds.
88993818|NCT02946814|Experimental|essential oils without mouthwash|a single mouthwash with 20 ml of essential oils without alcohol for 30 seconds.
88993819|NCT02946814|Sham Comparator|sterile water|a single mouthwash with 20 ml of sterile water for 30 seconds.
88993820|NCT00524797|Active Comparator|Main|50 patients will receive Profonycia 5 gr/day PO for 7 days
88993821|NCT02946619|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
88993822|NCT02946619|Experimental|Self-regulation condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
88993823|NCT02946619|Experimental|Enhanced self-regulation condition|For the enhanced self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; during session two, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
89653187|NCT01725087|Active Comparator|Tapentadol|Twice daily oral administration of Tapentadol for 12 weeks with a titration period of 2 weeks.
89653188|NCT05035758|No Intervention|Control Goups|The control group (A) receives standard exercise therapy that is part of the rehabilitation at the center and no additional intervention
89653189|NCT05035758|Experimental|Transcendental Meditation|The intervention group (B) receives transcendental meditation sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
89653190|NCT05035758|Experimental|Yoga|The intervention group (C) receives yoga sessions (twice per day for 30 minutes) additionally to the standard rehabilitation therapy.
89653191|NCT05044260|Experimental|Direct Sinus elevation using SLA Kit|
89653192|NCT01923415||Group 1: SLE|>=10 participants with systemic lupus erythematosus (SLE)
89653193|NCT01923415||Group 2: DLE|>=10 participants with discoid lupus erythematosus (DLE)
89653194|NCT01923415||Group 3: SCLE|>=10 participants with subacute cutaneous lupus erythematosus (SCLE)
89653195|NCT01493414|Experimental|INC424|5 - 25 mg twice a day (BID)
89653196|NCT01923493|Active Comparator|no intervention waiting list|Patients in the no intervention waiting list group will not receive a study intervention.
89653197|NCT01923493|Experimental|tuina|tuina treatment
89653198|NCT05035524|Active Comparator|Sodium Bicarbonate|Adjuvant SB treatment Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group
89653199|NCT05035524|Placebo Comparator|Placebo|Placebo
89653200|NCT00634543|Experimental|Tramadol hydrochloride (HCl)/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3, 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
89046178|NCT04268641|Experimental|Use of positioning equipment order 3|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
89046179|NCT04268641|Experimental|Use of positioning equipment order 4|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
89046180|NCT04268641|Experimental|Use of positioning equipment order 5|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
89653201|NCT00634543|Active Comparator|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
89653202|NCT05054322|No Intervention|Standard Care|Participants will be monitored via video call twice a day without any specific drugs.
89653203|NCT05054322|Experimental|Fluticasone propionate with spacer|Fluticasone propionate 125 mcg with spacer, 4 puffs, twice a day, added to standard care
89653204|NCT03097770|Experimental|anti-CD19/20 CAR T cells|Patients receive anti-CD19/20-CAR retroviral vector-transduced autologous or donor-derived T cells on day 1 in the absence of disease progression or unacceptable toxicity.
89653205|NCT00985465|Experimental|Pn-Pn group|subjects from the Pn-Pn group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in the Malian centre of study NCT00678301, receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A
89653206|NCT00985465|Experimental|Zil-Pn group|subjects from the unprimed group of the NCT00678301 Malian study centre, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
89653207|NCT04409366|Active Comparator|Conventional Crown Lengthening; CCL|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days.
89653208|NCT04409366|Experimental|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan
89653209|NCT03097380|Experimental|AZD2115|
89653210|NCT03097380|Active Comparator|Spiriva (Tiotropium)|
89653211|NCT03097380|Experimental|[11C]AZ13754366|
89653212|NCT04275505|Active Comparator|treatment group|the participants were given 10 sessions of shortwave diathermy treatment and elbow splint and told to avoid symptom provoking activities
89653213|NCT04275505|Placebo Comparator|control group|the participants were given 10 sessions of placebo shortwave diathermy treatment (the device was not turned on), elbow splint and told to avoid symtpom provoking activities
89653214|NCT04396327|Active Comparator|Active Comparator: 2-Drug Combination|50 mg diphenhydramine and 0.5 mg lorazepam
89653215|NCT04396327|Experimental|Active Treatment: SM-1 3-Drug Combination|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
89653216|NCT03097458|Experimental|Counselling|short-term counselling for families
89653217|NCT03097458|No Intervention|Wait-list control group|Wait-list control group
89653218|NCT03097224|Experimental|Prehabilitation group|Tele-supervised prehabilitation
89653219|NCT03097224|No Intervention|Control group|Usual care
89653220|NCT03102775|Experimental|Comprehensive follow-up program|15 offices have been randomized to experimental group. Experimental group offices implement the HOLF model developed by the Labor and Welfare Administration
89653221|NCT03102775|Active Comparator|Local family projects|14 offices have been randomized to control group. these implement local family projects. These are developed based on local practice needs
89653222|NCT01049919|Experimental|Concentrated bone marrow aspirate (cBMA)|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
89653223|NCT01049919|Sham Comparator|Placebo control (sham)|Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb
89653224|NCT05043948||Coronary Artery Disease_collateral flow grade 2|
89653225|NCT05043948||Coronary Artery Disease_collateral flow grade 0|
89653226|NCT05043948||Peripheral Artery Disease_collateral flow grade 2|
89653227|NCT05043948||Peripheral Artery Disease_collateral flow grade 0|
89653228|NCT03102697||Obese individuals|Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
89046181|NCT04268641|Experimental|Use of positioning equipment order 6|One standardized course is performed 3 times by each patient : one with a standard wheelchair and the 2 other with one or two positioning equipment (Seat back or/and positioning cushion) Each arm differs from the previous by the order of use of the equipment.
89046182|NCT04242329|Experimental|PD1-inhibitor + surgery|Patients randomised to the interventional study arm, receiving both surgical metastasectomy and continued immunotherapy. Each patient case will be individually planned for surgery. Procedures will include, but will not be limited to, lung resections, liver resections, bowel resection, skin excisions and lymph node clearances. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
89046183|NCT04242329|Active Comparator|PD1-inhibitor|Patients randomized to control study arm, receiving continued immunotherapy only. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
89046184|NCT04239625|Experimental|ALK-001|
89046185|NCT04234360|Experimental|Eosinophil count > 2%; corticotherapy|Eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
89046186|NCT04234360|Experimental|Eosinophil count <= 2%; corticotherapy|Non-eosinophilic patients randomized to this arm will receive 5 days of corticotherapy.
89046187|NCT04234360|Placebo Comparator|Eosinophil count > 2%; placebo|Eosinophilic patients randomized to this arm will receive 5 days of placebo.
89653229|NCT05053542||With or without enema before operation|Patients who had received pre-operative bowel preparation(PBP) were identified using electronic medical records. Patients prescribed an enema solution (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before surgery were allocated to the PBP group. Patients who received no PBP were allocated to none PBP group.
89653230|NCT04759729|Experimental|PRO+D group|Participants will receive probiotic as well as vitamin D supplementation.
89653231|NCT04759729|Experimental|PL+D group|Participants will receive placebo instead of probiotics and vitamin D supplementation.
89653232|NCT05053698||Initial gas tamponade|Primary vitrectomy and fluid-air exchange with SF6 or C2F6 gas tamponade
89653233|NCT05053698||Initial silicone oil tamponade|Primary vitrectomy and fluid-air exchange with silicone oil tamponade
89653234|NCT05053698||Relapse treated with gas tamponade|Secondary vitrectomy and fluid-air exchange with SF6 or C2F6 or C3F8 gas tamponade
89653235|NCT05053698||Relapse treated with silicone oil tamponade|Secondary vitrectomy and fluid-air exchange with silicone oil tamponade
89653236|NCT05052840|Experimental|Muscle endurance training (MET)|
89653237|NCT05052840|Active Comparator|Conventional Treatment|
89653238|NCT04396561|Experimental|Paravertebral group (group P):|After induction of general anesthesia and stabilization of the patients, they were positioned in lateral decubitus position with the side to be blocked uppermost.
89653239|NCT04396561|Experimental|Control group (group C):|Patients underwent surgery under general anesthesia and received the perioperative routine protocol of analgesia (IV fentanyl 2 μcg/kg at induction and 1 gm of IV paracetamol).
89653240|NCT01923571||Normoglycemia|patients with intraoperative BGC in the 80-180 mg/dl range
89653241|NCT01923571||Hyperglycemia|patients with intraoperative BGC exceeding 180 mg/dl
89653242|NCT01049373|Experimental|Lymphdiaral Basistropfen (HDC)|HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
89653243|NCT01049373|Placebo Comparator|Placebo Solution|10 drops t.i.d. for 15 weeks
89653244|NCT00985231|Experimental|PureVision Multi-Focal contact lenses|
89653245|NCT00985231|Active Comparator|SofLens59 contact lens|
89653246|NCT05053386|Experimental|Idarubicin|10mg idarubicin is dissolved in 5ml water for injection, and 5~20ml lipiodol is used to prepare lipiodol emulsion.
89653247|NCT05053386|Active Comparator|Epirubicin|50mg epirubicin is dissolved in 5ml 5% glucose solution, and 5~20ml lipiodol is used to prepare lipiodol emulsion.
89653248|NCT01725243|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg IV, once following delivery.
89653249|NCT01725243|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg IV, once following delivery.
89653250|NCT01725243|Active Comparator|Carbetocin 40mcg|Carbetocin 40mcg IV, once following delivery.
89653251|NCT01725243|Active Comparator|Carbetocin 60mcg|Carbetocin 60mcg IV, once following delivery.
89653252|NCT01725243|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg IV, once following delivery.
89653253|NCT01725243|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg IV, once following delivery.
89653254|NCT01725243|Active Comparator|Carbetocin 120mcg|Carbetocin 120mcg IV, once following delivery.
89653255|NCT01725243|Active Comparator|Carbetocin 140mcg|Carbetocin 140mcg IV, once following delivery.
89653256|NCT05034666|Active Comparator|Before education|"Before alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.~This is before applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
89653257|NCT05034666|Active Comparator|After education|"After alarming the participant anaesthetists about the pressure values of their practice in inflating the ETT cuff.~This is after applying the intervention which is informing and educating the participant anaesthetists about the proper ETT cuff pressure."
89653258|NCT01725321||Narrow band imaging|Colonoscopy with new narrow band imaging
89653259|NCT05052450||Dementia with Alzheimer|Patients previously diagnosed with Alzheimer disease would be included
89653260|NCT05052450||Dementia with Lewy Body Dementia|Patients previously diagnosed with Lewy Body Dementia would be included
89653261|NCT05052450||Dementia with Fronto-Temporal Dementia|Patients previously diagnosed with Fronto-Temporal Dementia would be included
89653262|NCT05052450||Dementia with Vascular Disease|Patients previously diagnosed with Dementia with Vascular Disease would be included
89653263|NCT05052450||Dementia with Parkinson Disease|Patients previously diagnosed with Dementia with Parkinson Disease would be included
89653264|NCT01725399|Placebo Comparator|Water|Water will be given as the study subject's first oral intake after emergence from general anesthesia.
89046188|NCT04234360|Placebo Comparator|Eosinophil count <= 2%; placebo|Non-eosinophilic patients randomized to this arm will receive 5 days of placebo.
89046189|NCT04211961|Placebo Comparator|Control|Participants randomised to the placebo group will receive one 15-minute IV infusion of Saline at 4 visits.
89046190|NCT04211961|Active Comparator|Treatment|Participants randomised to the treatment group will receive one 15-minute IV infusion of Scopolamine at 4 visits.
89046191|NCT04206787||Patients with non-small cell lung cancer (NSCLC)|
89046192|NCT04206436||on CFTR|For patients on or near time of initiation CFTR modulator therapy
89046193|NCT04206436||Controls|controls will be patients not eligible for available treatment
89046194|NCT04201782||Cohort 1|Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T in a previous trial.
89046195|NCT04195477|Experimental|vDPP Full Study|Participants will take part in a 52 week study receiving the vDPP intervention.
89046196|NCT04190563|Experimental|Pain De-Catastrophizing|Brief behavioral education on how to modify the interpretation of pain.
89046197|NCT04190563|Placebo Comparator|Pain Education|Brief behavioral education on pain.
89046198|NCT04184284||Primary Study Cohort - Anti-IL5/IL5R naïve patients|Severe eosinophilic asthma patients who have never received anti-Interleukin-5 / anti-Interleukin-5-receptor (anti-IL-5/anti-IL-5R) biologic treatment for severe eosinophilic asthma, for whom the investigator had decided to initiate benralizumab biologic treatment.
89046199|NCT04184284||Secondary Study Cohort - Biologic experienced patients|Patients that previously received a biologic treatment for severe asthma (at least one dose).
89046200|NCT04165486|Experimental|Part 1: ION464|ION464 will be administered at multiple-ascending doses by IT injection at regular intervals over 12 weeks.
89046201|NCT04165486|Placebo Comparator|Part 1: Placebo|ION464-matching placebo will be administered by IT injection at regular intervals over 12 weeks.
89046202|NCT04165486|Experimental|Part 2: ION464|ION464 will be administered at the same doses as Part 1 by IT injection, at regular intervals, for 72 weeks.
89046203|NCT04165486|Placebo Comparator|Part 2: Placebo|ION464-matching placebo will be administered by IT injection, at regular intervals, for 72 weeks.
89046204|NCT04154683|Experimental|group using Cellvizio® optical biopsy|
89046205|NCT04145141||1/ Cohort 1|Subjects with a diagnosis or suspicion of PLC
89046206|NCT04137380|Experimental|Mirikizumab - Intravenous (IV)|Participants received a single dose of 300 milligram (mg), 600 mg and 1200 mg mirikizumab administered IV using a forearm vein infused over at least 30 minutes, 60 minutes and 2 hours.
89046207|NCT04137380|Placebo Comparator|Placebo - IV|Participants received a single dose of placebo administered IV using a forearm vein.
89046208|NCT04137380|Experimental|Mirikizumab - Subcutaneous (SC)|Participants received a single dose of 200 mg, 400 mg mirikizumab administered SC as 2 injections, 1 into the skinfold of each lower abdominal wall quadrant (left and right).
89046209|NCT04137380|Placebo Comparator|Placebo - SC|Participants received a single dose of placebo administered SC as 2 injections, 1 into the skinfold of each lower abdominal wall quadrant (left and right).
89046210|NCT04122690|Experimental|Partnered Dance Aerobic Exercise|Partnered Dance-Aerobic Exercise (PDAE) is an adapted form of Argentine tango, aka Adapted tango. Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
89653265|NCT01725399|Experimental|Apple Juice|Apple juice will be given as the study subject's first oral intake after emergence from general anesthesia.
89653266|NCT03096912|Experimental|Ribociclib|Oral, ribociclib 600 mg x 1 a day, 21 days on 7 days off
89653267|NCT01725477|Experimental|Dye& normal saline/ 20ml methylene blue +50 ml normal saline|first arm:20 ml methylene blue washing with50 ml normal saline
89046211|NCT04122690|Active Comparator|Walking Aerobic Exercise|Walking Aerobic Exercise (WAE) Participants in WAE will receive equivalent dose, volume, frequency, intensity and duration of exercise to the PDAE group. The investigators will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The investigators will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention.
89046212|NCT04076683|Experimental|Algorithm (arm A)|Frequency and volume for apherisis proposed by algorithm and validated by the physician
89046213|NCT04076683|No Intervention|Usual care (arm C)|Frequency and volume for apherisis only decided by the physician (usual care)
89046214|NCT04075825|Experimental|Darvadstrocel|Participants who received a single dose of darvadstrocel, 120 million cells, intralesionally or darvadstrocel matching placebo previously in the ADMIRE-CD II study will be observed for efficacy and safety. No drug administration in this study.
89046215|NCT04075292|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity
89653268|NCT01725477|Active Comparator|injection of 20ml metheylen blue|20 ml methylene blue injected without washing
89653269|NCT03096990||Use of apremilast in patients with active PsA|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
89653270|NCT01725555|Experimental|Fasted treatment|
89653271|NCT01725555|Experimental|Fed treatment|
89046216|NCT04075292|Active Comparator|Rituximab and Chlorambucil|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles
89046217|NCT04032587|Experimental|Non-treatment seeking subjects with Alcohol Use Disorder|AUD; mild vs. moderate to heavy
89046218|NCT04032587|Active Comparator|Healthy Controls|
89653272|NCT03409887|Experimental|Intraorifice Group|Intraorifice barrier of GIC.
89653273|NCT03409887|Experimental|Base Group|Base of GIC
89653274|NCT03409887|Active Comparator|Control Group|Direct composite restoration
89653275|NCT04377633|Sham Comparator|Pre-intervention|Anesthesia handover during surgery will be performed as usual, i.e., a verbal exchange of pertinent clinical information.
89653276|NCT04377633|Experimental|Post-intervention|Anesthesia handover during surgery will be performed according to a structured checklist.
89653277|NCT00917865|Experimental|FACBC Imaging|Dynamic FACBC PET of primary prostate carcinoma.
89653278|NCT01836627|Experimental|Treatment Hyperinsufflation Therapy|Treatment group will have 15 minute hyperinsufflation treatments twice a day for one year.
89653279|NCT01836627|No Intervention|Control|The control group will continue with their current daily care
89653280|NCT01836705|Experimental|Single-sequence|SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)
89653281|NCT01836861|Experimental|IPI-145 and [14C] IPI-145|
89653282|NCT01048671||Antiretroviral combination therapy including raltegravir|Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
89653283|NCT03836781|Active Comparator|ketorolac 3%|ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
89653284|NCT03836781|Other|chlorhexidine 2%|chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
89653285|NCT03409575|Other|5 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes.
89653286|NCT03409575|Other|10 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes.
89653287|NCT01360866|Experimental|OPC-34712 (Brexpiprazole) and Escitalopram|OPC-34712: Oral tablet; 0.5 to 3 mg/day Escitalopram: Oral tablet; 10 or 20 mg/day
89653288|NCT01360866|Experimental|OPC-34712 and Fluoxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Fluoxetine: Oral capsules; 20 or 40 mg/day
89653289|NCT01360866|Experimental|OPC-34712 and Paroxetine CR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Paroxetine CR: Oral controlled-release tablets; 37.5 or 50 mg/day
89653290|NCT01360866|Experimental|OPC-34712 and Sertraline|OPC-34712: Oral tablet; 0.5 to 3 mg/day Sertraline: Oral tablets; 100, 150, or 200 mg/day
89653291|NCT01360866|Experimental|OPC-34712 and Duloxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Duloxetine: Oral delayed-release capsules; 40 or 60 mg/day
89046219|NCT04024540|Experimental|isocaloric dietary restriction|Very low caloric diet 400 kcal/d for a week, 600 kcal/d for another week and 800 kcal/d for 2 weeks.
89046220|NCT04024540|Active Comparator|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
89046221|NCT04021537|Experimental|non-invasive nerve stimulation a|Electrical stimulation will be delivered to a location at the ear.
89046222|NCT04021537|Active Comparator|non-invasive nerve stimulation b|Electrical stimulation will be delivered to a location at the ear.
89046223|NCT04013152||clinical database|
89653292|NCT01360866|Experimental|OPC-34712 and Venlafaxine XR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Venlafaxine XR: Oral extended-release capsules; 75, 150, or 225 mg/day
89653293|NCT03409497|Active Comparator|Concord Grape Juice|Concord Grape Juice
89653294|NCT03409497|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
89653295|NCT03409497|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
89653296|NCT00985153|Experimental|1|ProQuad Lot 1
89653297|NCT00985153|Experimental|2|ProQuad Lot 2
89653298|NCT00985153|Experimental|3|ProQuad Lot 3
89653299|NCT00985153|Active Comparator|4|M-M-R II + Varivax
89653300|NCT03095430||ESPI Group|General Anesthesia using Entropy and Surgical Pleth Index Monitoring
89653301|NCT03095430||Control Group|General Anesthesia without Entropy and Surgical Pleth Index (Control Group)
89653302|NCT05051826|Experimental|1.Drag Umbrella 2. Hand Resistance 3.Resistance Suit|"In the water, a small umbrella is attached to the athlete to increase resistance.~In the water, increase resistance by increasing the area of the hand.~In the water, use swim shorts that increase resistance"
89653303|NCT05051826|Experimental|1 Resistance 2 Bands Swiss Ball 3 Medicine Ball 4 Pulley Pull|"On land, use a stretch rope to increase resistance.~On land, inflatable bouncy balls are used to increase strength.~On land, solid balls are used to increase strength.~On land, pulleys are used to increase resistance."
89653304|NCT01047345|Experimental|9vHPV Vaccine|Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
89653305|NCT01047345|Placebo Comparator|Placebo|Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
89653306|NCT03385759|Active Comparator|UKA|Medial unicompartmental knee arthroplasty
89653307|NCT03385759|Active Comparator|TKA|Total knee arthroplasty
89046224|NCT04000061||acute coronary syndrome (ACS)|Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed.
89046225|NCT04000061||acute heart failure (AHF)|Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed.
89046226|NCT03944941|Active Comparator|Arm I (Avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with avelumab failure will crossover to Arm II.
89653308|NCT05034588||Intensiv care patients after acute kidney injury|Patients with condition after intensive care stay and acute kidney injury and subsequent convalescence (without preexisting underlying cardiac disease or other disease with potential cardiac involvement).
89653309|NCT05034588||Intensiv care patients without kidney injury|Patients with condition after intensive care stay and subsequent convalescence (without kidney injury and preexisting underlying cardiac disease or other disease with potential cardiac involvement).
89653310|NCT05034120|Experimental|MB:Single arm|10 subjects will be enrolled in this arm. The subjects will take a single dose XZP-3621 tablet after a low-fat meal and perform excretion collection consistently.
89653311|NCT05034120|Experimental|FE:Arm A|Cycle1 Day1: fasting; Cycle2 Day10: High-fat meal; Cycle3 Day19: Low-fat meal
89653312|NCT05034120|Experimental|FE:Arm B|Cycle1 Day1: High-fat meal; Cycle2 Day10: Low-fat meal; Cycle3 Day19: fasting
89653313|NCT05034120|Experimental|FE:Arm C|Cycle1 Day1: Low-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: High-fat meal
89653314|NCT05034120|Experimental|FE:Arm D|Cycle1 Day1: fasting; Cycle2 Day10: Low-fat meal; Cycle3 Day19: High-fat meal
89653315|NCT05034120|Experimental|FE:Arm E|Cycle1 Day1: High-fat meal; Cycle2 Day10: fasting; Cycle3 Day19: Low-fat meal
89653316|NCT05034120|Experimental|FE:Arm F|Cycle1 Day1: Low-fat meal; Cycle2 Day10: High-fat meal; Cycle3 Day19:fasting
89653317|NCT03075943|Experimental|InSea2|2 capsules/day of InSea2 administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
89653318|NCT03075943|Placebo Comparator|Placebo|2 capsules/day of Placebo administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
89653319|NCT05051748|Active Comparator|In-office bleaching|40% hydrogen peroxide in-office bleaching (Opalescence™ boost™ PF 40%, Ultradent Products, Inc., South Jordan, UT, USA)
89653320|NCT05051748|Active Comparator|microabrasion|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste (Opalustre™, Ultradent Products, Inc., South Jordan, UT, USA).
89653321|NCT05051748|Active Comparator|Remineralization|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème (MI-Paste Plus®, GC America Inc., USA).
89653322|NCT05051748|Active Comparator|Microabrasion + In-office bleaching|teeth were treated with enamel microabrasion followed by in-office bleaching.
89653323|NCT05051748|Active Comparator|In-office bleaching + Remineralization|n-office bleaching was applied followed by MI-Paste Plus®
89653324|NCT05051748|Active Comparator|Microabrasion + Remineralization|microabrasion was applied followed by MI-Paste Plus®
89653325|NCT05051748|Active Comparator|Microabrasion + In-office bleaching + Remineralization|teeth were treated with microabrasion followed by in-office bleaching and lastly MI-Paste Plus®
89653326|NCT05051748|No Intervention|Control|no treatment (control).
89653327|NCT05051670|Experimental|SP group|patients group underwent gastrectomy using da vinci SP
89653328|NCT01046877|Experimental|Tympanostomy Tube placement|Tympanostomy Tube Delivery System (TTDS) used for placement of tympanostomy tubes in patients indicated for such treatment for chronic Otitis Media with Effusion (OME) or recurrent Acute Otitis Media(AOM).
89653329|NCT00984061|Experimental|colchicine alone|colchicine baseline pharmacokinetics
89653330|NCT00984061|Experimental|colchicine with clarithromycin|colchicine pharmacokinetics in presence of clarithromycin
89653331|NCT01837017|Experimental|Home-based Exercise|The home-based exercise group attends 4 exercise instructional sessions lead by a train exercise specialist. The exercise protocol focuses on improving balance, walking, lower limb and core muscle strength, and spasticity. The instructional session teaches participants a standardized series of exercises that focus on balance, muscle strength, and stretching. The exercises target lower limb & core muscle function. Once taught, participants will perform the exercises 3 times a week in their home as outlined in a manual. Subjects return in the first month and second month to ensure that exercises are being executed with correct form and appropriate intensity level. Compliance of at-home exercise will be assessed with diaries that participants complete every other week.
89653332|NCT01837017|No Intervention|Control|Wait-list control.
89653333|NCT04395235|Experimental|Targeted Surgical Therapy Plan|This study pointed out that 3D surgico-anatomical models lead to more precise anatomical understanding compared to CT images in terms of detail perception. The 3D models of vascular patterns proves to be the optimal design according to the experts' evaluation with its teaching effects on surgical residents. The demonstration of the hepatic source vascular anatomy and corresponding vascular patterns may provide practically useful guides in decision making related to vascular detail during living donor liver transplantation.Model CT's were measured in order to verify 1:1 modelling and the printing the process was carried out with 3D printers of Mass Portal Pharaoh xd 20 with Eryone PLA 3D printer flament (2.2LBS)/Spool, White). Measurements of the anatomical structures were compared between the original CT images, and the CT images of the 3D model. The morphometric values such as inter-arterial distances, inter-venous distances and the distance between artery and vein were noted.
89653334|NCT01046643|Active Comparator|Estrogen followed by Placebo|Estrogen treatment with Estradiol (E2) followed by Placebo.
89653335|NCT01046643|Active Comparator|Progesterone followed by Placebo|Progesterone (P10) treatment followed by Placebo.
89653336|NCT01046643|Active Comparator|Placebo followed by Estrogen|Placebo followed by Estrogen treatment with Estradiol (E2)
89653337|NCT01046643|Active Comparator|Placebo followed by Progesterone|Placebo followed by Progesterone (P10) treatment.
89653338|NCT03095196||T2DM, treated by multipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
89653339|NCT03095196||T2DM, treated by bipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
89653340|NCT03096756|Other|Part 1: Single Ascending Dose Escalation GC4702|Serially increase dose escalation of orally formulated GC4702 or placebo (6:2 ratio), preceded by single dose of active comparator, GC4419 IV.
89653341|NCT03096756|Experimental|Part 2: Food Effect Study|Following Part 1 dose find, single dose level of GC4702 administered under fasting for and fed condition.
89653342|NCT05043558|Experimental|beprostaglandin sodium|
89653343|NCT05043558|No Intervention|control group|
89653344|NCT00983905|Active Comparator|Theophylline alone|baseline theophylline kinetics
89653345|NCT00983905|Experimental|Theophylline with steady-state Colchicine|theophylline pharmacokinetics upon administration with colchicine at steady-state
89653346|NCT03409029|Experimental|MRI Scan|As part of the study patients will undergo 4 MRI scans during radiotherapy treatment. These will take place during the 1st, 2nd, 3rd and 4th week of treatment
89653347|NCT05043480|Experimental|PEMF arm|In this single-arm study, all participants will be assigned to the intervention arm.
89653348|NCT01046565|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
89653349|NCT01046565|Active Comparator|Differin® Lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face
89653350|NCT00983827|Experimental|Aquatic treadmill training|Aquatic treadmill training (ATT) is a pool-based treadmill training that combines the three concepts of unweighting the body, treadmill training, and the resistance effects of water into one modality.
89653351|NCT05051280|Experimental|CBCT guidance group|Left atrial appendage occlusion under cone-beam computed tomography fusion image guidance
89653352|NCT01837095|Experimental|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
89653353|NCT05050968|Experimental|Adapted Physical Activity Group|Patients will follow a 3-month physical activity program 3 times a week between V1 and V2. Then, between V2 and V3, no APA program will be offered to both groups.
89653354|NCT05050968|No Intervention|Control group|Patients will receive standard hospital management
89653355|NCT03408951||Interventions (recording)|Patients requiring Intracardiac defibrillator (ICD) implantation or Defibrillation Test (DFT) or Electrophysiology (EP) study with high probability of supra ventricular tachyarrhythmia.
89653356|NCT00983749|Experimental|Full-pressure ECP|"Patients in the Full-pressure ECP arm receive a 1-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner up to 300mmHg, while assessments are made."
89653357|NCT00983749|Sham Comparator|Sham-pressure ECP|A 1-hour treatment of ECP at an inactive pressure (75mmHg)
89653358|NCT05033496||Newborn infants|Newborn infants born in our medical center
89653359|NCT01046253|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
89653360|NCT01046253|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
89653361|NCT05050656|Active Comparator|Group D (duloxetine group)|Two hours before surgery, participants received oral duloxetine 60 mg tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
89653362|NCT05050656|Placebo Comparator|Group C (control group)|Two hours before surgery, participants received oral placebo tablets in the ward then transferred to OR to receive spinal anesthesia before surgery.
89653363|NCT00983515|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
89653364|NCT00983515|Experimental|Colchicine with Ritonavir|-colchicine pharmacokinetics in presence of steady-state ritonavir
89653365|NCT05050890||Breast cancer|Breast cancer patients who are currently receiving neoadjuvant therapy
89653366|NCT05050812|Experimental|Grounded|All participants will sleep on a grounding mat for at least six hours per 24-hour period.
89653367|NCT03069859|Experimental|TXA (1g)|For vaginal, TXA (1g) will be administered upon delivery of the anterior shoulder. For c-section, TXA (1g) will be administered when the obstetrician begins to cleanse the incision site
89653368|NCT03069859|Placebo Comparator|Placebo (0.9% saline)|For vaginal, placebo (0.9% saline) will be administered upon delivery of the anterior shoulder. For c-section, placebo (0.9% saline) will be administered when the obstetrician begins to cleanse the incision site
89653369|NCT05050734|Experimental|CBIT-E|For those randomized to CBIT-E, treatment will be administered according to the standard CBIT manual, which includes psychoeducation, functional assessment/interventions, habit reversal training, relaxation techniques, and a motivational reward program. However, there will be two modifications. CBIT-E will include additional in-session and out of session practice of exercises, called competing response. Treatment will include a screening visit, baseline assessment, 11 weeks (9 sessions) of CBIT-E, a post treatment assessment, and a three-month follow up assessment. Further, starting after session 3, there will be four 15-minute practice periods scheduled each week between sessions. During these practice periods, the child and therapist will meet over Microsoft Teams and the therapist will administer an enhanced reward task.
89653370|NCT05050734|No Intervention|Waitlist Control (WLC)|These participants will not receive treatment during the 11-week period. Instead, they will be placed on a waitlist to receive standard CBIT following the end of the study period. The final assessment will be approximately 11 weeks after baseline.
89653371|NCT01361178|No Intervention|Transplant patients who do not receive SQ IVIG|Patients participating in the observational arm of the study who do not need to receive IgG replacement.
89653372|NCT01361178|Active Comparator|Transplant patients who receive SQ IVIG|Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.
89653373|NCT03069547|Active Comparator|Quadriceps Exercise program|The Quadricepts Exercise (QE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
89653374|NCT03069547|Active Comparator|Hip Exercise program|The Hip Exercise (HE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
89653375|NCT05042622|Experimental|Cytokine adsorber patients on ECMO|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
89653376|NCT05042622|Experimental|Cytokine adsorber patients with sepsis|Cytokine adsorber filter will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
89653377|NCT05042622|Experimental|Extracorporeal hemoperfusion cartridge patients on ECMO|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients on ECMO)
89653378|NCT05042622|Experimental|Extracorporeal hemoperfusion cartridge patients with sepsis|Extracorporeal hemoperfusion cartridge will be installed into the (hemodialysis or cardiopulmonary bypass (CPB) (15 patients with sepsis)
89653379|NCT05042622|No Intervention|Control (subgroups)1|No filter will be installed into the ECMO in this study group (15 patients)
89653380|NCT05042622|No Intervention|Control (subgroups) 2|No filter will be installed into the patient with sepsis (15 patients)
89653381|NCT05042856|Experimental|PanOptix|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
89653382|NCT05033730|No Intervention|Standard care: Control (Group A)|Patients who are scheduled for elective surgical upper airway surgery will be given General Anesthesia by an anesthesiologist who is the principal investigator and the surgical procedures will be done by the same ENT surgeon. IV Induction of Anesthesia with Propofol Target controlled infusion (TCI), Remifentanil Target controlled infusion (TCI) and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed endotracheal tube after direct laryngoscopy. After intubation by a Suitable size Endotracheal tube, they will be mechanically ventilated using Volume Controlled Ventilation (VCV) with 40% Oxygen and minute ventilation adjusted to keep ETCO2 of 40 mmHg or less, and a PEEP of 5 cmH2O.
89653383|NCT05033730|Experimental|Intervention Group: (Group B)|General Anesthesia will be induced with IV Induction of Anesthesia by an anesthesiologist with Propofol (Target controlled infusion), Remifentanil (Target controlled infusion), and Rocuronium (0.5mg/Kg) for muscle relaxation. The airway will be secured with cuffed Tritube after direct laryngoscopy. They will be mechanically ventilated using Flow Controlled Ventilation (FCV) with 40% Oxygen, Flow rate:13L/Min., Peak Airway Pressure (15 cmH2O), and a PEEP of (5 cmH2O) to keep ETCO2 of 40 mmHg or less. The anesthesia will be maintained with Intravenous Infusion of Propofol, Remifentanil (TCI) to keep BIS 40-60.
89653384|NCT05050422|Placebo Comparator|Control|
89653385|NCT05050422|Active Comparator|Study|
89653386|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa simplex|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
89653387|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of junctional epidermolysis bullosa|"Female patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
89653388|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of epidermolysis bullosa dystrophic|"Female patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
89653389|NCT05033574||Prepubescent and pubertal girls with an established diagnosis of Kindler syndrome|Female patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
89653390|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa simplex|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
89653391|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of junctional epidermolysis bullosa|"Male patients aged 8 to 18 years with a diagnosis of junctional epidermolysis bullosa.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
89653392|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of epidermolysis bullosa dystrophic|"Male patients aged 8 to 18 years with a diagnosis of epidermolysis bullosa dystrophic.~Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned."
89653393|NCT05033574||Prepubescent and pubertal boys with an established diagnosis of Kindler epidermolysis bullosa|Male patients aged 8 to 18 years with a diagnosis of Kindler syndrome. Based on the results of diagnostic methods, further division of patients into prepubertal and pubertal periods of puberty is planned.
89653394|NCT03096678||LBBB without LV dysfunction|LVEDD>55mm or LVEF<55%
89653395|NCT03096678||LBBB with LV dysfunction|LVEDD<55mm and LVEF>55%
89653396|NCT03097926|Active Comparator|Standard BPD-DS|Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel
89653397|NCT03097926|Experimental|Long alimentary limb BPD-DS|BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel
89653398|NCT05033418|Experimental|IPRP + CBT-I|Interdisciplinary Pain Rehabilitation Program + Cognitive Behavioral Therapy for Insomnia (IPRP + CBT-I)
89653399|NCT05033418|Active Comparator|IPRP-UC|Interdisciplinary Pain Rehabilitation Program Usual Care (IPRP-UC)
89653400|NCT04434378|Placebo Comparator|Placebo|Patients undergoing laparoscopic inguinal hernia repair will randomized to one dose of placebo in the preoperative holding area 2 hours before surgery.
89653401|NCT04434378|Experimental|Interventional|Patients undergoing laparoscopic inguinal hernia repair will be randomized to one dose of 0.4 mg tamsulosin in the preoperative holding area 2 hours before surgery.
89653402|NCT00981799|Experimental|Nelarabine Dose Level 1|The study will begin at Dose Level 1 at 480 mg/m2 Nelarabine (75% of single agent maximum tolerated dose) and 330 mg/m2 Cyclophospamide and will escalate to the next Dose Level if the maximum tolerated dose (MTD) is not exceeded. The first 3 patients will be enrolled into Dose Level 1. If 0/3 experiences dose limiting toxicity (DLT) at a given dose level, then the dose is escalated to the next higher level and 3 more patients are enrolled. If 1/3 experiences DLT at current dose, the up to 3 more patients are accrued at the same dose level. If 2 or more DLTs are observed in a 3-patient or 6-patient cohort at a given dose level, then the MTD has been exceeded, dose escalation will be stopped, and up to 3 additional patients will be enrolled at the next lower dose level (unless 6 patients have already been treated at that prior dose). If the MTD is exceeded at Dose Level 0, the study will be closed.
89653403|NCT00981799|Experimental|Nelarabine Dose Level 2|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 330 mg/m2 Cyclophosphamide.
89653404|NCT00981799|Experimental|Nelarabine Dose Level 3|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 400 mg/m2 Cyclophosphamide
89653405|NCT00981799|Experimental|Nelarabine Dose Level 0|Patients in this arm will be administered Nelarabine 325 mg/m2 (50% of single agent MTD) and 330 mg/2 Cyclophosphamide. Patients will only enter this arm if the MTD at Dose Level 1 has been exceeded. If the MTD is exceeded at Dose Level 0, the study will be closed.
89653406|NCT03097692|Active Comparator|Ischemic preconditioing|50 patients ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
89653407|NCT03097692|Active Comparator|Pharmacologic preconditioing|by sevoflurane anesthesia
89653408|NCT05033106|Active Comparator|Eyes with IVI bevacizumab|0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye
89653409|NCT05033106|Active Comparator|Eyes with IVI ranibizumab|A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant
89653410|NCT03095040|Experimental|CM082 combined with everolimus|
89653411|NCT03095040|Experimental|CM082|
89653412|NCT03095040|Active Comparator|Everolimus|
89653413|NCT05049642|Experimental|Group 1|Patients will either be randomized to group 1 (instillation of 1 drop of C-NAC) or group 2 (no instillation of C-NAC) in a 1:1 fashion. Afterwards one drop of C-NAC will be instilled into the study eye of group 1. 1 hour after treatment VAS and the symptom questionnaire will be performed repeatedly in both groups. Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days. Patients assigned to group 1 will receive Lacrimera® for home treatment over the following 5 days. 1 drop of Lacrimera® is supposed to be installed into the eye 20 minutes prior to installation of the respective antibiotic eye drops or ointments.
89653414|NCT05049642|No Intervention|Group 2|Both groups will receive antibiotic ointment bandages and antibiotic eye drops for 5 days.
89653415|NCT00981175|Experimental|Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo|Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28
89653416|NCT00981175|Experimental|Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine|Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.
89653417|NCT05042154|No Intervention|Standard of Care Cohort for COPD|Standard care patients will receive routine clinical management as per their treating physicians based on the GOLD Criteria.
89653418|NCT05042154|Active Comparator|WatchPAT Cohort|Consented patients will undergo group randomization to either standard AECOPD care or to the WatchPAT One cohort (WPC). The WPC will undergo a single night of in-hospital sleep apnea testing from 2200 to 0600 using the WatchPAT One, a portable and disposable home sleep apnea testing device (Itamar Medical, Israel [WPAT]).
89653419|NCT03094962|Other|Motion capture, MR scan, CT scan|All volunteers will go through the same data collection process
89653420|NCT00981019||mortality*incidence*5-year survival*early stage|Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.
89653421|NCT05049486|No Intervention|MRI sequences and (DTI)|The aim of this study is to obtain finer details of tissues surrounding a lead in the pelvis using a combination of high resolution anatomical MRI sequences and diffusion tensor imaging (DTI). To do so, the patient will undergo a MRI scan (3 Tesla) of the pelvis using sequences including anatomical sequences and diffusion tensor imaging technique for construction of sacral nerve tractography prior to permanent SNS. This will be performed over an hour: first 30 minutes for anatomical sequences and the second 30 minutes for DTI sequencing.
89653422|NCT05049486|Active Comparator|CT scan|Three to 4 weeks after the procedure the patient will undergo a limited CT scan of the pelvis to visualise the position of the SNS lead. The scan will focus only on the sacrum, implanted lead, and rectum and will not be extended beyond this area. Imaging from this CT will be superimposed to the MRI imaging the patient had pre-operatively, and a computational simulation will be performed.
89653423|NCT01923883|Active Comparator|Negative-pressure syringe|EUS-FNA with negative-pressure suction with syringe
89653424|NCT01923883|Experimental|Capillary sampling with slow-pull|EUS-FNA with capillary sampling with stylet slow-pull technique
89653425|NCT05049408||Group OSCC|Patients with Oral Squamous Cell Carcinoma (OSCC)
89653426|NCT05049408||Group OPMD|Patients with oral potentially malignant disorders (OPMD)
89653427|NCT05049408||Group HC|Healthy Control
89653428|NCT01924039|Experimental|Brief Motivational Enhancement Therapy|
89653429|NCT01924039|Other|treatment as usual|
89653430|NCT05032404|Experimental|BNT103|All participants receive BNT103. BNT103 provides 10 sessions over approximately 10 weeks.
89653431|NCT05049564|Experimental|keyhole group|patient harbored aneurysm who was treated by microsurgical clipping via keyhole approach.
89653432|NCT05049564|Experimental|conventional group|patient harbored aneurysm who was treated by microsurgical clipping via conventional craniotomy.
89653433|NCT05049564|Experimental|endovascular group|patient harbored aneurysm who was treated by endovascular coiling via femoral approach.
89653434|NCT05049018|Active Comparator|Control Group|"Participants who participated in the control group received a traditional physical therapy program for two hours. It included two parts, each of them was for one hour and 15 minutes rest in between. The first part included: muscle strengthening and facilitation exercises, stretching exercises, and postural reactions exercises. The second part included: functional exercise for facilitation of arm-reaching and arm-hand skills, manipulative tasks (grasping and release activities), and daily living activities for the affected upper limb.~The traditional treatment program was applied for both groups by therapists, experienced in stroke rehabilitation. It was carried out three sessions per week for twelve successive weeks."
89653435|NCT05049018|Experimental|Experimental Group|"Participants in the experimental group received two hours treatment program that included three parts, the first and the second parts (similar to that were applied for participants in the control group). These two parts were applied for one hour followed by 15 minutes rest, then the third part was applied for one hour. The third part of the program was a one-hour virtual reality intervention program by using (ArmeoSpring) virtual reality equipment to simulate a range of upper limb tasks that facilitate arm activities, manipulative skills, and daily living tasks through using different interactive games and soft-wares.~The traditional treatment part of the program was applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program was applied by other experienced physiotherapists, who were well trained in using the (ArmeoSpring) System. All three parts of the program were carried out three sessions per week for twelve successive weeks."
89653436|NCT01924117|No Intervention|Linear Array HPV Genotyping assay|Women submitted to colposcopy with a suspicion of squamous intraepithelial lesion were programmed a clinical follow up to cervical swab in order to extract DNA and perform a Linear Array HPV Genotyping assay (Roche®, Mannheim, Germany).
89653437|NCT03096522|Active Comparator|Phenytoin 2% spray|Patients undergoing anal fistulotomy with postoperative topical phenytoin therapy
89653438|NCT03096522|Active Comparator|Anal fistulotomy|Patients undergoing anal fistulotomy without postoperative topical therapy
89046227|NCT03944941|Experimental|Arm II (Avelumab, cetuximab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8,15, and 22 and avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles for cetuximab and 24 cycles for avelumab in the absence of disease progression or unacceptable toxicity.
89046228|NCT03919929|Active Comparator|Diet Intervention|Weight loss with dietary intervention
89653439|NCT01045161|Experimental|1|Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
89653440|NCT01045161|Experimental|2|Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
89653441|NCT01045161|Placebo Comparator|3|Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks
89653442|NCT03096210|Other|Titanium-Prepared Platelet Rich Fibrin|After careful elevation of the schneiderian membrane without perforation,T-PRFs were only used in the test group.
89653443|NCT03096210|Other|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
89653444|NCT03095898|Experimental|True Acupuncture|
89653445|NCT03095898|Sham Comparator|Sham Acupuncture|
89653446|NCT03095898|No Intervention|Control Group|
89653447|NCT01924195|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89653448|NCT01924195|Placebo Comparator|Placebo Capsule|Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent
89653449|NCT05032482|Other|Investigational Treatment 1|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device.
89653450|NCT05032482|Other|Investigational Treatment 2|Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device.
89653451|NCT05032248|Experimental|tacrolimus|group I (Colchicine and topically applied Tacrolimus),
89653452|NCT05032248|Placebo Comparator|placebo|group II (Colchicine and topically applied Placebo),
89653453|NCT03408795|Other|JORS-LDG Group|Participants in JORS-LDG Group score the performance of procedure after LDG.
89653454|NCT00633217|Active Comparator|arm 1|
89653455|NCT00633217|Experimental|arm 2|
89046229|NCT03919929|Experimental|GLP-1 Intervention|Participants will take a daily oral tablet of semaglutide for 4 months.
89046230|NCT03900221||Pregnant women with multiple sclerosis or related neurological|Children born to women with multiple sclerosis or related neurological syndromes.
89653456|NCT01837173||Extracapsular LNI|Patients with positive lymph nodes that show extracapsular lymph node involvement
89653457|NCT01837173||Intracapsular LNI|Patients with positive lymph nodes that show NO extracapsular lymph node involvement
89653458|NCT01673490|Experimental|Combodart/Duodart|Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin
89653459|NCT00215657|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
89653460|NCT00215657|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
89653461|NCT00215657|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
89653462|NCT00215657|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
89653463|NCT00215657|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
89653464|NCT00215657|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
89653465|NCT00215657|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
89653466|NCT00215657|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
89653467|NCT00633061|Experimental|A-randomized to treatment|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
89653468|NCT00633061|No Intervention|B-randomized to close|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks
89046231|NCT03893916|Experimental|cohort|MEG - EEG HR
89046232|NCT03879395||Cohort|Patients with stage IV malignant melanoma with abdominal metastasis (M1c) that underwent abdominal surgery with metastasectomy during the study period.
89046233|NCT03872284||1|Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
89653469|NCT05041764||PCR positive|samples that are positive for the detection of SARS-CoV2. The SARS-CoV2 sequence of positive samples is provided, together with an indication about patient's neigborhood, corresponding to one of the 21 different spots which wastewater was analyzed
89653470|NCT05041764||PCR negative|samples that are p negative for the detection of SARS-CoV2. T
89653471|NCT02979743|Placebo Comparator|Occupational therapy group|The children worked with an occupational therapist for 4 hours a day for 5 days per week (totaling 40 hours) and initially concentrated on unilateral activities with the hemiplegic hand,and added bilateral activities during the second week.
89653472|NCT02979743|Active Comparator|Occupational therapy puls acupuncture and massage methods|The patients receive occupational therapy puls acupuncture and massage methods.
89653473|NCT05041686|Experimental|CADISS® System|
89688618|NCT02808130||Group CP|"Group CP: normolipidemic + generalized chronic periodontitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
89213138|NCT05183139|Experimental|Cohort B: Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg (3 mg for participants with moderate or severe hepatic impairment, severe renal impairment, or end-stage renal disease requiring dialysis), capsules, orally, on Days 1, 8, and 15, along with lenalidomide 25 mg capsules, orally, from Days 1 to 21 and dexamethasone 40 mg (20 mg if the participant is over 75 years of age), tablets, orally, on Days 1, 8, 15, and 22 of each 28-day cycle, for a maximum of 39 cycles or until disease progression or unacceptable toxicity leading to discontinuation of ixazomib or to a change in regimen. Participants who were taking modified doses of lenalidomide or dexamethasone can start at that dose level in the study.
89653474|NCT00632827|Experimental|Treatment Plan|(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5
89653475|NCT00214019|Placebo Comparator|Placebo Diskus|Placebo comparator
89653476|NCT00214019|Experimental|Salmeterol Diskus 50 mcg twice per day|Salmeterol Diskus 50 mcg twice per day
89653477|NCT00214019|Experimental|Placebo diskus, fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
89653478|NCT00214019|Experimental|Salmeterol, Fluticasone|Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day
89653479|NCT03097848|Experimental|Sorafenib+RFA group|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
89653480|NCT03097848|Active Comparator|RFA group|for eligible cases, RFA will be given only.
89653481|NCT01924351|Other|HER2-positive Breast Cancer with Brain Metastasis|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
89653482|NCT05047848|Experimental|chidamide + fulvestrant|
89653483|NCT00210119|Experimental|Imatinib mesylate|Imatinib mesylate 600 or 800 mg/day PO + zoledronate 4 mg IV over 15 min every 3 weeks for 6 months.
89653484|NCT03998033|Experimental|ET140202 T cells|ET140202 Receptor (+) T Cells
89653485|NCT01044459|Experimental|Aclidinium Bromide 200 µg|aclidinium bromide, inhaled, 52 weeks of treatment
89653486|NCT01044459|Experimental|Aclidinium Bromide 400 µg|aclidinium bromide, inhaled, 52 weeks of treatment
89653487|NCT05031858|Experimental|Vojta Therapy|Reflex turn first phase: Patient positioned supine with legs flexed 30º-45º. The pectoral area is stimulated for five minutes on each side x 2 consecutive times. Total 20 minutes per session.
89653488|NCT05031858|Active Comparator|Control Group|.Inspiratory techniques, mucociliary clearance techniques (expiratory). Use of inspiratory and expiratory incentives. Employment of mechanical assistants
89653489|NCT03997487|Experimental|Children examined|All children examined for clinical signs of trachoma will be invited to participate to have photos of conjunctivae taken with the TOFTEE smartphone app and a DSLR camera.
89653490|NCT05047614|Experimental|Study 1|Twelve patients in study group 1 receiving lumbar repositioning feedback training
89653491|NCT05047614|Experimental|Study 2|Twelve patients in study group 2 receiving transverses abdominis training
89653492|NCT05047614|Experimental|Study 3|Twelve patients in study group 3 receiving both lumbar repositioning feedback training and tranversus abdominis training
89653493|NCT05047614|Experimental|Control|Twelve patients in control group receiving conventional lumbar propriception physical therapy program .
89653494|NCT03763721|Experimental|iOCT optimized protocol (iOCT-p)|In the iOCT optimized protocol (iOCT-p) group, graft apposition will be assessed with special detail for graft orientation, interface fluid, and any peripheral folds as described by Xu et al. Potential tissue manipulations will be therefore based on the iOCT image. Apposition of the graft will be obtained using a complete filling of the anterior chamber with 20% sulphur hexafluoride (SF6) endotamponade for 1-2 minutes, whilst the OCT image is assessed and any graft manipulation can be performed if deemed necessary. After this period, the gas is partly exchanged for BSS (Balanced Salt Solution, Alcon) to achieve a bubble with a diameter of approximately the same size of the graft (i.e. 8.5mm)
89653495|NCT03763721|Active Comparator|current practice protocol (CP-p)|In the current practice protocol (CP-p), graft apposition will be obtained using a complete and pressurized (approx. 65mmHg) filling of the anterior chamber with 20% SF6, for 8 minutes. Tissue manipulations, such as corneal swiping, will be performed as deemed necessary by the surgeon, based on the en face view from the conventional microscope image. The intraocular pressure is normalized by exchanging the SF6 gas for BSS, to achieve a gas bubble approximately the size of the graft (i.e 8.5mm). Now, the graft apposition is assessed using iOCT, to ensure all trial patients eventually undergo advanced iOCT imaging. Should this iOCT image reveal improper graft adherence or any other irregularity, the surgeon will perform additional manipulations or interventions as deemed necessary
89653496|NCT05047458|Experimental|Cohort 1: 40 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
89653497|NCT05047458|Experimental|Cohort 2: 80 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
89653498|NCT05047458|Experimental|Cohort 3: 120 mg ALXN2050/Placebo|Participants randomized to receive ALXN2050 or placebo on Day 1.
89653499|NCT05041452||Noncirrhotic portal hypertension (NCPH)|Patients with non-cirrhotic portal hypertension (NCPH) with pre-sinusoidal (e.g., porto-sinusoidal vascular disease, portal vein obstruction, congenital hepatic fibrosis, biliary diseases,), sinusoidal (e.g., sinusoidal destruction in the setting of acute hepatic injury, inflammatory or toxic fibrosis, non-alcoholic steatohepatitis), or post-sinusoidal causes (Budd-Chiari syndrome, sinusoidal obstruction syndrome).
89653500|NCT05041452||Cirrhotic portal hypertension|Patients with cirrhosis and portal hypertension.
89213139|NCT03830567||Pharmacist prescription|
89213140|NCT03830567||Clinician prescription|
89213141|NCT00997659|Experimental|chromium picolinate|
89213142|NCT00997737|Experimental|DB, VI and FV|Breathing exercises
89213143|NCT05300919|Experimental|MBC for depressive and manic symptoms|"Measurement-based care (MBC) is a clinical strategy involving consistent assessment of clinical status and using those findings to drive clinical decision making. MBC involves clinic staff providing the measure to the patient at each visit which the patient completes and returns, staff enters results into the electronic medical record, clinician reviews current results and compares to past results, and discusses with the patient.~The experimental condition patients will receive MBC for manic and depressive symptoms."
89213144|NCT05300919|Active Comparator|MBC for depressive symptoms only|The active comparator arm patients will receive MBC for depressive symptoms.
89653501|NCT01837329|Experimental|Tetrathiomolybdate|"Dose Escalation - It is aimed at determining the maximum tolerated dose of TM in combination with carboplatin and pemetrexed.~Dose Expansion - The dose expansion portion of the study will begin after completion of the dose escalation phase."
89653502|NCT05041296||Chronic group|Chronic epilepsy with recurrent seizures
89653503|NCT05041296||Acute group|Epilepsy and short-term history of seizures
89213145|NCT03827213|Experimental|Single shot Interscalene Nerve Block|This group will receive an interscalene nerve block. This will be administered as a single 20mL injection consisting of a mixture of 10mL of Exparel and 10mL of 0.5% bupivacaine hydrochloride.
89213146|NCT03827213|Active Comparator|Indwelling Interscalene Catheter|"This group will receive an indwelling interscalene catheter placed posterior to C5-C6 nerve roots (between the shoulders) and administered 15 mL of 0.5% ropivacaine plain for the block with no superficial cervical block. The On-Q pump will be set at a rate of 4 mL/hr."
89213147|NCT00999999|Active Comparator|Standard|Standard dural closure
89213148|NCT00999999|Experimental|Experimental|Experimental dural closure, adding of Investigational Medicinal Product (IMP)
89213149|NCT00997815|Experimental|Botulinum toxin A|The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.
89213150|NCT00997815|Placebo Comparator|Placebo|Using normal saline
89213151|NCT04078139|Experimental|The MP/RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 40mg methylprednisolone, plus 10ml saline;
89653504|NCT05041296||Control group|Healthy participants
89653505|NCT03408561|Experimental|Health Services Research (message via Twitter)|Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
89653506|NCT05031312|Active Comparator|inferior oblique anterior nasal transposition|Group A for inferior oblique anterior nasal transposition 2mmx2mm posterior and nasal to inferior rectus insertion to control vertical deviation especially large angle vertical deviation and V pattern with more potent postoperative effect in unilateral and bilateral cases
89653507|NCT05031312|Active Comparator|inferior oblique myectomy|Group B for inferior oblique myectomy to control vertical deviation but not of large angle which lead to residual inferior oblique overaction
89653508|NCT03993041|Experimental|Cognitive-behavioral therapy (CBT)|Individuals in the CBT arm are expected to participate in a phone screen + baseline phase (one assessment) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
89653509|NCT03993041|Active Comparator|Waitlist Control|Individuals in the Waitlist Control arm are expected to participate in a phone screen + baseline phase (two assessments, 12 weeks apart) + 10-12 weeks of CBT intervention + post-intervention assessment + 6 week follow-up assessment.
89653510|NCT00980005|Experimental|Flulaval Group|"subjects received Flulaval™ vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Flulaval vaccine was administered intramuscularly into the non-dominant deltoid."
89653511|NCT00980005|Active Comparator|Fluzone Group|"subjects received Fluzone® Sanofi Pasteur's vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Fluzone vaccine was administered intramuscularly into the non-dominant deltoid."
89653512|NCT05040906|Experimental|H02+ Chemotherapy|Participants received six cycles of H02(375 mg/m2) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
89653513|NCT05040906|Active Comparator|Rituxan+Chemotherapy|Participants received six cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
89653514|NCT03590405|Experimental|uterus transplantation|uterus transplantation from living donor with the donor being close relative
89653515|NCT01044303|Experimental|Myfortic Escalation|Participants EC-MPS dose was escalated to a minimum daily dose of 1440mg or equivalent, with the maximum dose never exceeding the manufacturer's recommendations.
89213152|NCT04078139|Active Comparator|The RP group|Participates will receive peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10ml saline;
89213153|NCT01000077||Discarded Operating Room Tissue|The purpose of this research study is to use the discarded (tissue that would normally be thrown out) tissue from your surgery in order to obtain cells that can be grown in a laboratory to study how to use cells like these to fix sick and diseased organs. We will test if these cells can be used to build new and healthy tissues. This technique is called tissue engineering. In this study we will be comparing cells obtained from different individuals.
89653516|NCT05040828|Experimental|Early interventional treatment group|The patients in this group:oral drug therapy from onset of the low pollen stage (August 1st, 2020) to the end of the pollen stage (September 30, 2020). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
89653517|NCT05040828|Active Comparator|Post-onset treatment group|The patients in this group: oral drug therapy after the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020.). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
89653518|NCT05040828|Active Comparator|Control group|The patients in this group:Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
89653519|NCT04250363|Experimental|M5717|Participants will receive single ascending oral dose of M5717 powder in capsule after DVI of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
89653520|NCT04250363|Placebo Comparator|Placebo|Participants will receive placebo matched to M5717 after DIV of PfSPZ challenge on Day 1 (early liver stage) or on Day 4 (late liver stage).
89653521|NCT03408327|Experimental|Experimental group|"Wearable technology (fitness wristband & App)~4 times group activities (2 hr / each times)~LINE group interaction~Reminder and feedback form researcher"
89653522|NCT03408327|Active Comparator|Control group|"Wearable technology (fitness wristband + App)~Health promotion manual"
89653523|NCT05047380||coccycodinia group|A total of 54 patients diagnosed with coccycodinia
89653524|NCT03595475||Psychiatric RBD cases|"Presence of REM sleep without atonia;~At least one of the followings is present: i). Dream enactment behaviors, SRIs, potentially injurious or disruptive behaviors by history; ii). Abnormal REM sleep behaviors documented during v-PSG monitoring;~Absence of electroencephalogram (EEG) epileptiform activity during REM sleep unless RBD can be clearly distinguished from any concurrent REM sleep related seizure disorder;~The sleep disturbance is not better explained by other sleep disorder (e.g., obstructive sleep apnea, medical or neurological disorder, mental disorder, medication use, or substance use disorder)"
89653525|NCT03595475||Psychiatric control|"Age- and sex- matched with pRBD proband;~Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on REM sleep behavior disorder questionnaire (RBDQ-HK) and v-PSG; 5) Free of neurodegenerative diseases"
89653526|NCT03595475||Healthy control|"Age- and sex- matched with pRBD proband;~Without lifetime psychiatric disorder according to Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on RBDQ-HK and v-PSG;~Free of neurodegenerative diseases"
89653527|NCT03408249|Experimental|IBD patients|IBD patients performing IBDoc calprotectin test and ease-of-use questionnaires
89653528|NCT00983437|Experimental|Armodafinil|Armodafinil tablets 150 mg or 250 mg administered orally, once daily in the morning.
89653529|NCT05046756|Experimental|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
89653530|NCT05046756|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
89653531|NCT03594773|Experimental|Interpersonal Psychotherapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in IPT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
89046234|NCT03861897|Experimental|Intervention KRP-NI + KM|Realization of Non instrumental pleural chest physiotherapy and Mobilization physiotherapy sessions (KRP-NI)
89046235|NCT03861897|Active Comparator|Control KM|Realization of mobilization physiotherapy sessions (KM)
89046236|NCT03843008|Experimental|Melatonin Group|Participants will receive 3mg of melatonin at 18:00 (+/- one hour) each evening up to seven days or for the duration of his or her hospital stay.
89046237|NCT03843008|No Intervention|No Melatonin Group|Participants will receive no melatonin for the length of their hospital stay.
89046238|NCT03838536|Experimental|Whole egg powder|Participants are given whole egg powder which contains high levels of the nutrients choline, lutein, and docosahexaenoic acid.
89046239|NCT03838536|Placebo Comparator|Egg white powder|The participants are given an egg white powder that does not contain the target nutrients (choline, lutein, and docosahexaenoic acid).
89046240|NCT03833622|Experimental|Shared decision aid assessment|Patients will be selected to have a goals of care discussion with an emergency physician utilizing a pilot decision aid and will be asked for feedback to assist with refinement of the decision aid.
89046241|NCT03829475|Experimental|FMT + Bezlo|Patients in this arm will received an FMT via colonoscopy ( 250ml) as well as a single IV infusion of bezlotoxumab (10mg/kg) that will take place over 60 mins.
89046242|NCT03829475|Placebo Comparator|FMT + Placebo|Patients in this arm will receive a single FMT via colonoscopy (250ml) and a placebo (saline) infusion (250cc) over
89046243|NCT03824444|Experimental|Treatment|Implant and followup
89046244|NCT03819985|Experimental|Treatment (hypofractionated RT)|Patients receive hypofractionated radiation therapy in 15 daily fractions over 3 weeks in the absence of disease progression or unacceptable toxicity.
89046245|NCT03811886|Experimental|Phase I: Natalizumab|"Traditional 3+3 design escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed a maximum dose of 300mg~Phase II treatment to continue if the participant has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS as defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If the participant has progressive disease after 6 cycles, they will be removed from the study."
89046246|NCT03807401|Active Comparator|Classical prismatic adaptation|Classical prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
89046247|NCT03807401|Experimental|Virtual prismatic adaptation|virtual prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
89046248|NCT03807401|Experimental|Imaged prismatic adaptation|Imaged prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
89046249|NCT03797183||Premature Infants|Premature infants >1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection
89046250|NCT03797183||Chronic Respiratory Disease|Participants ages >1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease
89046251|NCT03797183||Neuromuscular Disease|Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy
89046252|NCT03797183||Healthy Controls|Age and height matched healthy controls
89046253|NCT03797183||V/Q Scan validation|Adults or children who are having or have recently had a V/Q scan
89046254|NCT03797183||Premature Infants (Longitudinal Cohort)|Premature infants ages 2 weeks to 1 year with diagnosed or suspected bronchopulmonary dysplasia
89046255|NCT03797183||Pulmonary Vein/Artery Stenosis|Children age 2 months to 18 years, who will be undergoing cardiac catheterization for pulmonary vein stenosis, pulmonary hypertension and/or pulmonary artery stenosis
89046256|NCT03777267|Experimental|Experimental: Active CR|For this single arm, open label, exploratory trial this will be the intervention arm using active CR.
89046257|NCT03744468|Experimental|Phase 1 Dose Escalation|Dose escalation of BGB-A425 in combination with Tislelizumab in participants with advanced solid tumors
89653532|NCT03594773|Experimental|Cognitive Behavioral Therapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in CBT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
89653533|NCT01837407|Other|Surgical flap|The flap includes the nerve for repair of the soft tissue and nerve defects
89653534|NCT05031390|Experimental|Physiotherapist-led training|Physiotherapy-led training of patients with FAIS
89653535|NCT03989219||lung nodules were found by CT scanning|Plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
89653536|NCT05026242|Experimental|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
89653537|NCT05026242|Active Comparator|Control|Participants will be provided with isocaloric snacks
89653538|NCT00988741|Experimental|ARQ 197|
89653539|NCT00988741|Placebo Comparator|placebo|
89653540|NCT03095586|Active Comparator|News with Spin|News items reporting results of RCTs with spin
89653541|NCT03095586|Experimental|News without spin|News items reporting results of RCTs without spin
89653542|NCT03989063|Experimental|Amputees (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
89653543|NCT03989063|Active Comparator|Amputees (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
89653544|NCT03989063|Experimental|Diabetes (External Focus)|Participants in this group will receive the external focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
89653545|NCT03989063|Active Comparator|Diabetes (Internal Focus)|Participants in this group will receive the internal focus instruction on where to direct their attention while training to perform the balance task. During training, the assigned instruction will be reinforced at the beginning and after every 5 practice trials.
89653546|NCT05031156|Active Comparator|non-splinting of OT Bridge system|Leaving the dental implants abutments solitary followed by denture pick up
89653547|NCT05031156|Experimental|splinting of OT Bridge|Splinting of implants abutments using titanium wire then followed by denture pick up
89653548|NCT03599609|Experimental|Treatment|Treatment: Simvastatin 40mg/day
89653549|NCT05040594|Experimental|Treatment A (right) B (left)|Subjects will receive PavéDerm J-Fill Soft Dermal Filler and Restylane® Lyft Lidocaine. One product will be randomized, per NLF.
89046258|NCT03744468|Experimental|Phase 2 Safety Lead-in|Dose escalation for Cohort A (LBL-007 + Tislelizumab) and Cohort B (BGB-A425 + LBL-007 + Tislelizumab) in participants with advanced solid tumors
89046259|NCT03744468|Experimental|Phase 2 Dose Expansion|Further explore the safety and clinical activity of BGB-A425 and LBL-007 in combination with Tislelizumab in participants with NSCLC, HNSCC and RCC
89046260|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose A|Participants of age group 12 to <18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
89046261|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose B|Participants of age group 12 to <18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.
89046262|NCT03725007|Experimental|Participants of age group 6 to <12 years receiving dose A|Participants of age group 6 to <12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
89046263|NCT03725007|Experimental|Participants of age group 2 to <6 years receiving dose A|Participants of age group 2 to <6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
89046264|NCT03725007|Experimental|Participants of age group 2 to <18 years receiving dose A|Participants of age group 2 to <18 years administered with upadacitinib dose A as described in the protocol.
89046265|NCT03685890|Experimental|ILP + Nivolumab|The day before planned ILP, the patient will receive one infusion of nivolumab 480mg
89046266|NCT03685890|Placebo Comparator|ILP + Placebo|The day before planned ILP, the patient will receive one infusion of placebo
89046267|NCT03670680|Experimental|Lina LibrataTM|Use of the Lina LibrataTM
89046268|NCT03632473||clinically isolated syndrome (CIS)|"Multiple sclerosis (MS) with a clinically isolated syndrome (CIS) within six months of first clinical event.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
89653550|NCT05040594|Experimental|Treatment B (right) A (left)|Subjects will receive Restylane® Lyft Lidocaine and PavéDerm J-Fill Soft Dermal Filler. One product will be randomized, per NLF.
89653551|NCT05025930|Experimental|endoscopic surgical instrument control system (SP1000: single- port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (SP1000)
89653552|NCT05025930|Active Comparator|Comparator: endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|Urological surgery procedures such as prostatectomy, and partial or radical nephrectomy will be performed using endoscopic surgical instrument control system (IS3000)
89653553|NCT03599375|Experimental|B-ALL treated with CD19 CART cell|The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.
89653554|NCT05025696|Experimental|Intervention|Blacksoap(R) applied whole body twice daily
89653555|NCT05025696|Placebo Comparator|Control|Johnson and Johnsons Baby Soap applied whole body twice daily
89653556|NCT03984461|Active Comparator|Group A - PRP plus Lipoaspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate). Total Volume varies by joint.
89653557|NCT03984461|Active Comparator|Group B - PRP plus Bone Marrow Aspirate|Equal proportions of PRP plus bone marrow aspirate. Total Volume varies by joint.
89653558|NCT03984461|Active Comparator|Group C - PRP plus Lipoaspirate plus Bone Marrow Aspirate|Equal proportions of PRP plus micronized adipose tissue (lipoaspirate) plus bone marrow aspirate. Total Volume varies by joint.
89653559|NCT03094728||Liver transplantation receipients|All patients underwent Living donor liver transplantation at Ain Shams center for organ transplantation (ASCOT) during the designed study period
89653560|NCT03599063|Experimental|Cohort 1|Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
89653561|NCT03599063|Experimental|Cohort 2|Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
89653562|NCT03599063|Experimental|Cohort 3|Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
89653563|NCT03599063|Experimental|Cohort 4|Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
89653564|NCT03599063|Experimental|Cohort 5|Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
89653565|NCT03599063|Experimental|Cohort 6|Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
89653566|NCT03599063|Experimental|Cohort 7|Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
89046269|NCT03632473||early relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting early disease course (RRMS) </= 10 years, Expanded Disability Status Scale (EDSS) </=3.5~EDSS:~1.0: No disability, minimal signs in 1 functional System (FS) 1.5: No disability, minimal signs in more than one FS 2.0: Minimal disability in one FS 2.5: Mild disability in one FS or minimal disability in two FS 3.0: Moderate disability in one FS, or mild disability in three or four FS. No impairment to Walking 3.5: Moderate disability in one FS and more than minimal disability in several others. No impairment to Walking.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
89213154|NCT01000077||Discarded Placenta|During a standard surgery or delivery of a baby unneeded tissue is usually discarded. We would like to explore the opportunity to grow the cells of these discarded tissues in the laboratory. The cells will be placed in special dishes and supplemented with a mixture of salts and nutrients that were designed to allow the cells to survive outside the body and grow. This procedure is called tissue culture of cells. We will attempt to isolate a population of cells from the tissue culture and study them in the laboratory.
89213155|NCT04077983|Experimental|combined therapy using nab-paclitaxel and gemcitabine chemo|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~Three weeks is a course of treatment with a total of 4 courses."
89213156|NCT00997971|Experimental|Modilac Rose 1|Infant formula with partially hydrolysed rice protein
89213157|NCT01003977||Xience V|Patients treated with a Xience V everolimus-eluting stent
89653567|NCT03599063|Experimental|Optional: Cohort 8|Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects
89653568|NCT05040516||Group 1|"The planned procedures include: medical interview, physical examination with basic anthropometric measurements (age, height, body weight); biochemical tests including blood selenium, selenoproteins, renalase and creatinine levels; total antioxidant status (TAS), 24-hour Holter electrocardiography, polysomnography and echocardiography.~A 10 ml of venous blood sample will be collected by venopuncture. Laboratory tests will be performed using commercially available standardized tests."
89653569|NCT01042977|Experimental|1|dapagliflozin 10 mg tablet
89653570|NCT01042977|Placebo Comparator|2|matching placebo tablet
89653571|NCT05040438|Experimental|Autologous NK cell infusion combined with HAIC|HAIC of 5-FU (500 mg/m2, Q4W) and cisplatin (15 mg/m2, Q4W) will be administered for up to 4 cycles to patients with locally advanced HCC. Subjects who achieved sustained SD or better based on the mRECIST criteria after 2nd cycle of HAIC will be enrolled to receive 1x10^9 cells VAX-NK/HCC infusion.
89653572|NCT03598751|Experimental|BCD-085|"Blinded period:~BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
89653573|NCT03598751|Placebo Comparator|Placebo|"Blinded period:~Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14~patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22~patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
89653574|NCT05030532|Experimental|EVERYbody Project: Expert facilitator version|"This gender inclusive, dissonance-based body image program was created from focus group feedback. Based on the Body Project, the program retains key dissonance activities while expanding the inclusivity focus (e.g., expanding the gender focus, exploring diversity within appearance ideals, critically discussing the impact of limited diversity representation in cultural appearance norms).~Around 10% of content from the previous trial was modified to form the current intervention. Changes focused on enhancing diversity-focused content. College students with body image content interest completed two days (16 hours) of training on the program manual, group management, and conducting inclusive conversations. Post training, students self-assessed their facilitation readiness and were evaluated by two trainers on facilitation expertise. Peer leaders with sufficient expertise were invited to facilitate EVERYbody Project groups."
89653575|NCT05030532|Active Comparator|Video + Expressive Writing group|"Video + expressive writing groups were facilitated by a peer leader following a detailed script. This intervention was designed as an active but low-dissonance comparison condition. Participants viewed two separate documentary movies related to gender and/or appearance-related pressures (one during each session): (1) The Illusionists, and (2) The Mask You Live In. Participants engaged in a brief (10 minute) reflective writing exercise after each film. In order to keep dissonance low, participants were told that their reflections would not be shared with anyone and they were not turned in.~Peer facilitators received brief (1 hour) training on the video group manual."
89653576|NCT03598673||Hypertensives to receiving Nevibolol|Patients to receive Nevibolol
89046270|NCT03632473||late relapsing-remitting late disease course (RRMS)|"MS with relapsing-remitting late disease course (late RRMS) of 5 to 15 years, EDSS: 2.0-5.5 inclusive~EDSS:~4.0: Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk without aid or rest for 500m 4.5: Significant disability but up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal assistance. Able to walk without aid or rest for 300m 5.0: Disability severe enough to impair full daily activities and ability to work a full day without special provisions. Able to walk without aid or rest for 200m 5.5: Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 100m.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
89046271|NCT03632473||primary progressive disease course (PPMS)|"MS with a primary progressive disease course (PPMS) up to 15 years, EDSS: 2.0-6.5 inclusive~EDSS:~6.0: Requires a walking aid - cane, crutch, etc. - to walk about 100m with or without resting 6.5: Requires two walking aids - pair of canes, crutches, etc. - to walk about 20m without resting.~Multimodal evoked potentials (mmEP) assessments will take place at baseline, month 12 (from baseline), month 24 (from baseline) and month 36 (from baseline)"
89653577|NCT03984149||FH pediatric patients|1000 clinically diagnosed FH pediatric patients (age <18 years) included in the LIPIGEN (Lipid TransPort Disorders italian Genetic Network) database
89653578|NCT03094572|No Intervention|visual motor tasks with dominant arm (1)|experimental arm for the first sub-study healthy volunteer
89653579|NCT03094572|No Intervention|control tasks with dominant arm|control arm for the first sub-study healthy volunteer
89653580|NCT03094572|No Intervention|visual motor tasks with non-dominant arm|control arm for the second sub-study healthy volunteer
89653581|NCT03094572|No Intervention|visual motor tasks on dominant arm, flexion movement|experimental arm for the third sub-study healthy volunteer
89653582|NCT03094572|No Intervention|visual motor tasks on dominant arm, extension movement|experimental arm for the third sub-study healthy volunteer
89653583|NCT03094572|Experimental|visual motor tasks|fourth sub-study with hemiplegic patient
89653584|NCT03094572|No Intervention|visual motor tasks with dominant arm (2)|experimental arm for the second sub-study healthy volunteer
89653585|NCT04766489|Experimental|Complete Deongestive Therapy|Patients will be given complete decongestive therapy for 5 days a week and for a mean of 20 sessions. Each session will be of approximately 2 hours and 15 minutes in duration, although short stretch bandaging will be left on for 23 hours a day.
89653586|NCT05039658|Experimental|Single agent treatment arm with IBI110|IBI110 administered at RP2D
89653587|NCT05039658|Experimental|Combination treatment arm with IBI10 and sintilimab|IBI110 and sintilimab administered at RP2D
89653588|NCT01837485|Experimental|Lactol|
89653589|NCT01837485|Placebo Comparator|Placebo|
89653590|NCT04177823|Experimental|Chinese participants with relapsed/refractory multiple myeloma|Participants will be administered belantamab mafodotin 2.5 mg/kg or 3.4 mg/kg as an intravenous infusion on Day 1 of each 21-day cycle over 30 minutes. Participants will be treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.
89653591|NCT05039580|Experimental|PD-1 monoclonal antibody group|PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age >=18 years, or age <18 years but weight >=40kg. While for patients age <18 years, the dose of PD-1 monoclonal antibody is 3mg/kg.
89653592|NCT05025306|No Intervention|control group|only atraumatic extractions were done, honey was not applied
89653593|NCT05025306|Experimental|experimental group|ziziphus honey was applied into the sockets after tooth extractions in experimental group
89213158|NCT03823469|Active Comparator|Intervention: Nutritional counseling + CCTP|Nutritional counseling + Culinary Coaching Telemedicine Program (CCTP)
89213159|NCT03823469|Active Comparator|Control: Nutritional counseling only|Two 30-minute nutritional counseling sessions
89213160|NCT04000191|Active Comparator|Usual monitored anesthesia care (MAC)|Monitored anesthesia care (MAC) administered by anesthesiology and injection of local anesthesia by the operating surgeon.
89653594|NCT03598517|Experimental|high dose chemoradiotherapy|all eligible patients receive image-guided intensity-modulated radiotherapy 60 Gy in 30 fractions over 6 weeks and concurrent weekly paclitaxel and cisplatin，followed by hyperfractionated intensity-modulated radiotherapy boost to residual metabolic disease concurrent with the same chemotherapy regimen, followed by adjuvant chemotherapy 6 weeks after completion of radiation therapy.
89653595|NCT05025228||Paracetamol IV|Patients with femur fracture that received an initial analgesic treatment with paracetamol intravenously (IV).
89653596|NCT05025228||Paracetamol OR|Patients with femur fracture that received an initial analgesic treatment with paracetamol orally (OR).
89653597|NCT03598283||Severely burned patients|In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
89653598|NCT05025072|Experimental|Test IMP|Hydroxycarbamide dispersible tablets (20 x 50 mg)
89653599|NCT05025072|Active Comparator|Reference IMP|Hydroxycarbamide film-coated tablet (1000 mg)
89653600|NCT03598205|Experimental|DIABEC plus intravitreal dexamethazone|Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment
89653601|NCT03598205|No Intervention|dexamethazone intravitreal injection|Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.
89653602|NCT03094650|Experimental|MindMotion PRO|The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
89653603|NCT04407299||1|180 patients diagnosed with autoimmune rheumatic disease. Patients are RA SLE Rhupus AS Behcet Sjogren Vasculitis FM Polymyalgia APA Sarcoidosis IBD Scleroderma DM PSA Mixed
89653604|NCT04407299||2|control group composed of 180 healthy individuals (matched for age and sex)
89653605|NCT05030064|Experimental|Intestinal flora capsule(FMT)|The group includes 27patients.They will receive 16 capsules of intestinal bacteria each time, once a week, 4 times in a row.Each capsule contains 200mg of fecal bacteria.
89653606|NCT05030064|Placebo Comparator|Placebo group|The group includes 27patients.They will receive 16 Placebo capsules each time, once a week, 4 times in a row.
89653607|NCT03598127||sepsis group|patients of sepsis group are diagnosed with sepsis according to International Pediatric Sepsis Consensus Conference:Definitions for sepsis and organ dysfunction in pediatrics.
89653608|NCT03598127||control group|A gender- and age- matched control group are recruited from among non-sepsis children from Pediatric Intensive Care Unit of West China Hospital.
89653609|NCT05024682|Experimental|conventional pulsed radiofrequency|
89653610|NCT05024682|Experimental|pulse dosed pulsed radiofrequency|
89653611|NCT03598049|Experimental|densah burs drilling group|implant osteotomy site drilling using the densah burs osseo densification drills
89653612|NCT03598049|Active Comparator|surgical burs drilling group|implant osteotomy site drilling using conventional surgical burs drilling
89653613|NCT05024604||study group|women receiving mini pills as a method of contraception with symptoms not diagnosed with us
89653614|NCT05024604||Control group|women attending to office hysteroscopy unit and not taking hormonal therapy
89653615|NCT03597971|Experimental|Part A: experimental|Subjects will receive HMPL004-6599 or matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, or reduced if deemed appropriate by the Safety Monitoring Committee (SMC).
89653616|NCT03597971|Placebo Comparator|Part A: placebo|Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
89653617|NCT05039502|Experimental|Retreatment system using in rotational motion|Previous root canal filling materials were removed with D1-D2-D3 retreatment files with using an endodontic motor in rotational motion
89653618|NCT05039502|Experimental|Retreatment system using in reciprocal motion|Previous root canal filling materials were removed with Reciproc 25 file with using an endodontic motor in reciprocal motion
89653619|NCT05039502|Experimental|Retreatment system using in additional rotational motion|Previous root canal filling materials were removed with XP-endo finisher r file with using an endodontic motor in rotational motion
89653620|NCT03597893|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
89653621|NCT03597893|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.
89653622|NCT05039034||Low-risk Group|Low-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but without chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
89653623|NCT05039034||Mediate-risk Group|Mediate-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but meanwhile suffer from chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
89653624|NCT05039034||High-risk Group|High-risk Group is defined as the population with ≥3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), or population with history of stroke or/and transient ischemic attack.
89213161|NCT04000191|Experimental|MAC and perianal ice|Monitored anesthesia care (MAC) administered by anesthesiology, application of ice to the perianal area after it is prepared with betadine, and injection of local anesthesia by the operating surgeon.
89213162|NCT03822845|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET/CT scan
89213163|NCT01000233|Active Comparator|Phytine (Phytate)|300 mg tid* 24 months
89213164|NCT01000233|Placebo Comparator|Placebo|
89213165|NCT04075955|Experimental|Study treatment group|Olanzapine in combination with ondansetron and dexamethasone
89653625|NCT03597737|Experimental|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor APP. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
89653626|NCT05024838||Spinal anesthesia|The investigators retrospectively collected the electronic medical record of patients receiving spinal anesthesia from July 1, 2018, to Dec 31, 2018. Patients less than 18 years old were excluded from this study.
89653627|NCT03597659||BioVU-Emerge EHR cohort|"A primary EHR population derived from the eMERGE Phase I & II Network (n=16,924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's (VUMC) BioVU resource (n=20,230).~BioVU is VUMC's de-identified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a de-identified EHR.~All subjects were born prior to 1990 and fell within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (SNVs) for the subset of subjects self-identified as White, non-Hispanic."
89653628|NCT05029908||TMD disorders|"75 patients with temporomandibular disorder (TMD) who will apply to the outpatient clinic of Istanbul Physical Therapy and Rehabilitation Training and Research Hospital will be included in our study. Ethics Committee approval was obtained from Bakırköy Sadi Konuk Training and Research Hospital before starting the study and a voluntary consent form will be signed by the patients before the evaluation.~In this cross-sectional study; 75 participants aged 18-65 years who has temporomandibular joint (TMJ) complaints for more than 3 months and has the cognitive ability to understand test instructions will be included. Patients with a history of previous TMJ operation, muscle, neurological or rheumatic disease that may affect TMJ, and a history of facial/cervical trauma or neoplasia will excluded from the study."
89653629|NCT01041573|Experimental|IC51 0.5 mL|Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28
89653630|NCT01041573|Experimental|IC51 0.25 mL|Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28
89653631|NCT01041573|Active Comparator|Havrix 720|Havrix®720 0.5 ml im. at day 0 and month 7
89653632|NCT01041573|Active Comparator|Prevnar|Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13
89653633|NCT05029440|Experimental|Electromagnetic and Exercise Group|Pulsed Electromagnetic Field (PEMF) PEMF was administered to the whole body using a 1.8×0.6m mat Exercise Program Exercise program to facilitate bone health
89653634|NCT05029440|Active Comparator|Laser and Exercise Group|Pulsed High Intensity Laser Therapy (HILT) HILT was administered to lumbar region and femoral head using Exercise Program Exercise program to facilitate bone health
89653635|NCT05029440|Active Comparator|Exercise Group|Exercise Program Exercise program to facilitate bone health
89653636|NCT03597191|Experimental|Spinal Stabilization Exercise Program|"Participants in the spinal stabilization exercise group will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) abdominal bracing, (b) quadruped, (c) prone plank, and (d) side plank exercises. Each exercise will be progressed and advanced in difficulty by increasing repetitions, hold times, and/or extremity movements.~The progression of exercises will be based on the participants' performance at each supervised physical therapy session based on pre-established criteria by Hicks et al. (2005)."
89653637|NCT03597191|Placebo Comparator|General Exercises Program|Participants in the general exercise group will perform a range of motion (ROM) and flexibility exercises of low back and lower extremities. Each participant will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) knee to chest, (b) lower trunk rotation, (c) prone press-ups, and (d) hamstring stretch exercises. These exercises will be progressed by increasing repetitions and pain-free ROM.
89653638|NCT03093558|Experimental|Intervention arm|Receive the ECA/Kardia for 30-day use.
89653639|NCT03093558|No Intervention|Usual care arm|Receive a journal for observation of adherence and symptoms.
89653640|NCT05024448|Active Comparator|Prednisone|Prednisone, 60mg/d, for 10 days
89653641|NCT05024448|Placebo Comparator|Placebo|
89653642|NCT00906789||Radiologists|Radiologists who have certification by the American Board of Radiology
89653643|NCT03596957|Active Comparator|Tolvaptan group|Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication
89653644|NCT03596957|No Intervention|Control group|No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group
89653645|NCT01837641|Experimental|LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg|0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
89213166|NCT04075955|Active Comparator|Standard treatment group|Aprepitant in combination with ondansetron and dexamethasone
89213167|NCT04076033|Experimental|ECF ESPIRAL|The volunteer is submitted to four-layer spiral functional compressive bandage, then performs Taylor's Jebsen manual function test with comprehensive functional bandage (ECF).
89213168|NCT04076033|Experimental|ECF OITO|The volunteer is submitted to functional compressive bandage in eight with four layers, then performs the Taylor Jebsen manual function test with the comprehensive functional bandage (ECF).
89213169|NCT00484198|Placebo Comparator|1|
89213170|NCT00484198|Experimental|2|Rivoglitazone 1.0 mg
89213171|NCT00484198|Experimental|3|Rivoglitazone 1.5 mg
89213172|NCT00484198|Active Comparator|4|Pioglitazone 45 mg
89213173|NCT04077905|Experimental|DEP regimen|pegylated liposomal doxorubicin, etoposide and methylprednisolone administered in 2 week cycles for 2 cycles
89213174|NCT04076501|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
89653646|NCT01837641|Experimental|LY3002813-Single then multiple 0.3 mg/kg|0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
89046272|NCT03613532|Experimental|Venetoclax|"This study has three periods: 1) Screening 2) Treatment with venetoclax + FluBu2 chemotherapy and transplantation and 3) Post-Transplant follow up.~Dose escalations begin in level I with dose cohorts and rules for escalation/de-escalation.~Part 1 dose escalation will occur using a 3+3 approach. Post-transplant period includes routine follow-up.~Venetoclax: 6-7 total doses based on level assigned~Busulfan: given 2x daily for 4 days~Fludarabine: given 1x daily for 4 days~Part 2 post-transplant period includes therapy with azacitidine and venetoclax. Dose escalation will occur using a 10+10 approach.~Venetoclax: 14 doses for 8-12 cycles based on level assigned~Azacitidine: 5 doses for 8-12 cycles based on level assigned~Part 3 post-transplant period includes therapy with oral decitabine/cedazuridine and venetoclax. Dose escalation will occur using a 10+10 approach.~Venetoclax: 14 doses for 8 cycles~Decitabine/cedazuridine: 3 doses for 8 cycles"
89046273|NCT03605927|Experimental|Combination Therapy|"BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT.~Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care."
89046274|NCT03595293|Experimental|Experimental Group for AUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When patients encounter the alcohol image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
89046275|NCT03595293|Sham Comparator|Sham Feedback Group for AUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When participants encounter the alcohol image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
89046276|NCT03595293|Experimental|Experimental Group for pOUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When patients encounter the pill image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
89046277|NCT03595293|Sham Comparator|Sham Feedback Group for pOUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When participants encounter the pill image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
89046278|NCT03531450|Experimental|Cognitive Behavioral Therapy|Patients in the cognitive behavioral therapy group will be asked to undergo a 8-week CBT trial. An online videoconferencing link will be used to deliver CBT virtual sessions that will be approximately 60 minutes in length. Each session will be conducted by a clinical psychology doctoral student, supervised by a licensed psychologist. Patients will also undergo careful phenotyping pre- and post intervention with brain MRI, AFT, and NDT.
89046279|NCT03504241|Experimental|MSCs 10^4 cells/kg+anti-rejection drugs|The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.
89046280|NCT03504241|Experimental|MSCs 10^5 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.
89213175|NCT04076501|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
89213176|NCT04077749|Experimental|Probiotic|
89653647|NCT01837641|Experimental|LY3002813-Single then multiple 1 mg/kg|1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
89653648|NCT01837641|Experimental|LY3002813-Single then multiple 3 mg/kg|3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
89653649|NCT01837641|Experimental|LY3002813-Single then multiple 10 mg/kg|10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
89653650|NCT01837641|Placebo Comparator|Placebo-Single then multiple|Placebo given once, then every 4 weeks for up to 16 weeks IV
89653651|NCT01837641|Experimental|LY3002813-SC|Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
89653652|NCT01837641|Experimental|LY3002813-IV|Up to 3mg/kg LY3002813 given once intravenously (IV)
89653653|NCT03596879|Experimental|dCBTI|Online access to the digital CBTI program Sleepio.
89653654|NCT03596879|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations.
89653655|NCT03408015|Experimental|Normal, asymptomatic non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
89653656|NCT03408015|Experimental|Dry eye subjects, non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
89653657|NCT03408015|Experimental|Contact lens wearers with discomfort|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
89653658|NCT03596567|Experimental|Normal Renal Function Group|Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
89653659|NCT03596567|Experimental|Moderate Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
89653660|NCT03596567|Experimental|Severe Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
89653661|NCT01041495|Experimental|cyclobenzaprine ER|
89653662|NCT01041495|Placebo Comparator|placebo|
89653663|NCT03596255||Patients|All public dental clinics in the region of Östergötland, Sweden, were asked to consecutively recruit adult patients returning for their annual examination
89653664|NCT03596255||Dental personnel|All public dental clinics in the region of Östergötland, Sweden were contacted and asked to participate in the study
89653665|NCT03407937|Other|Intervention|Receiving the conditioned pain modulation intervention during the first session and receiving the placebo and the hypnosis or meditation interventions during the second session.
89653666|NCT03596099|Experimental|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
89653667|NCT03596099|Placebo Comparator|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
89653668|NCT01041417|Experimental|GM-CSF|Subjects will receive GM-CSF 500μg (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
89653669|NCT01041417|Placebo Comparator|Placebo|Subjects will receive a saline injection (placebo) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
89653670|NCT03024359|Active Comparator|obese individuals|Individuals with BMI between 30 and 35 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and brain activity (18F-FDG PET/MRI; in a subsample of 5 obese individuals)will be collected.
89653671|NCT03024359|Active Comparator|normal weight individuals|Individuals with BMI between 18.5 and 24.99 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and and brain activity (18F-FDG PET/MRI; in a subsample of 10 normal weight individuals) will be collected.
89653672|NCT03595943|Experimental|Low glycemic index diet|Low glycemic index pulse-based diet (i.e. beans, peas, lentils, chickpeas)
89653673|NCT03595943|Active Comparator|Regular hospital diet|Moderate glycemic index diet based on hospital menus
89653674|NCT03595865|Experimental|residual primary open angle glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
89653675|NCT03595865|Experimental|residual primary angle-closure glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
89653676|NCT03595709|Experimental|combined tablet (EFV 400,TDF 300, 3TC 300)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
89653677|NCT03595631|Active Comparator|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
89653678|NCT03595631|Experimental|Physical Therapy plus neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
89653679|NCT03595397|Active Comparator|Group I|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
89653680|NCT03595397|Active Comparator|Group II|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg magnesium sulfate, followed by continuous infusion of 8 ml/hour of a mixture of 0.125% bupivacaine and 20% magnesium sulfate
89653681|NCT03595397|Active Comparator|Group III|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour
89653682|NCT03595319|Experimental|Young patients|Patients between 19 and 40 years-old
89653683|NCT03595319|Experimental|Elder patients|Older than 65
89653684|NCT01040871|Experimental|VR-CAP|VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.
89653685|NCT01040871|Active Comparator|R-CHOP|R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone
89653686|NCT03595007||Phase 1|
89653687|NCT03595007||Phase 2|
89653688|NCT03595007||Phase 3|
89653689|NCT03594929|Active Comparator|Active RIC|Active RIC using a manual BP cuff to inflate to 200mmHg.
89653690|NCT03594929|Sham Comparator|Sham Control|A sham control using a manual blood pressure cuff visually identical to that used in the RIC protocol will be placed on the upper arm and a simulated RIC protocol will be administered.
89653691|NCT01040169|Placebo Comparator|Nupro C Prophylaxis paste|Fluoride Free
89653692|NCT01040169|Experimental|ProClude Prophylaxis paste|Arginine
89653693|NCT04407065|Experimental|Double trigger|GnRH-agonist and HCG are used to trigger ovulation
89653694|NCT04407065|Active Comparator|HCG|HCG is used to trigger ovulation
89653695|NCT01044381|Experimental|Luliconazole Solution, 10%|
89653696|NCT03594695||Group G|Patients undergoing general anesthesia HSCRP and NLR measurement
89653697|NCT03594695||Group R|Patients undergoing spinal anesthesia HSCRP and NLR measurement
89653698|NCT03594617|Experimental|ICC-C|Intervention: Interaction Competencies with children - for Caregivers (ICC-C) 11 days with 8 hours of training for caregivers. Core training components include caregiver-child interactions, maltreatment prevention, effective discipline strategies, child-centered institutional care, identifying and supporting burdened children and implementation of the training materials into the daily working
89046281|NCT03501706|Experimental|Active Training (AT) Group|Participants will complete four computerized training programs to improve executive function (EF), including Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Words - Visual, Verbal Memory - Visual.
89653699|NCT03594617|No Intervention|Control institutions|The control institutions do not receive any intervention.
89653700|NCT03594539|No Intervention|Standard|Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
89653701|NCT03594539|Placebo Comparator|Intervention|Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
89653702|NCT01040637|Experimental|TD-1211 dose level 1|Ascending doses
89653703|NCT01040637|Experimental|TD-1211 dose level 2|Ascending doses
89653704|NCT01040637|Experimental|TD-1211 dose level 3|Ascending doses
89653705|NCT01040637|Experimental|TD-1211 dose level 4|Ascending doses
89653706|NCT01040637|Experimental|TD-1211 OIC dose level 1|Ascending doses
89653707|NCT01040637|Experimental|TD-1211 OIC dose level 2|Ascending doses
89653708|NCT01040637|Experimental|TD-1211 OIC dose level 3|Ascending doses
89653709|NCT01040637|Experimental|TD-1211 OIC dose level 4|Ascending doses
89653710|NCT01040637|Experimental|TD-1211 OIC dose level 5|Ascending doses
89653711|NCT01040637|Placebo Comparator|Placebo|Ascending doses
89653712|NCT03407781|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
89653713|NCT03594461|Experimental|2mg IAI q2w|2mg Intravitreal Aflibercept injection will be given every 2 weeks starting at baseline and then at weeks 2, 4, 6, 8, 10 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
89653714|NCT03594461|Experimental|2mg IAI q3w|2mg Intravitreal Aflibercept injection will be given every 3 weeks starting at baseline and then at weeks 3, 6, 9 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
89653715|NCT03594149|Experimental|antibacterial prophylaxis|Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine
89653716|NCT03594149|No Intervention|control|No levofloxacin will be given.
89653717|NCT03830073||Group I:|Seventy patients with pancreatitis
89653718|NCT03830073||Group II:|Thirty healthy controls
89653719|NCT03024125|Experimental|High protein diet (HP)|Diet with 1.2 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
89046282|NCT03501706|No Intervention|Control Training (CT) Group|Participants will complete the four computerized programs relating to executive function (EF), but will be provided with the answer (i.e., without memory requirements). That is, participants in the control condition will not be asked to engage their cognitive functions.
89046283|NCT03471247|Experimental|In-Bed Cycle Ergometer + Routine PT|Patients will receive 30 minutes of in-bed cycling once per day, 5 days per week, while they remain in the ICU, for up to a maximum of 28 days. They will also receive routine physiotherapy.
89046284|NCT03471247|Active Comparator|Routine PT|Patients will receive routine physiotherapy interventions per current institutional practice
89046285|NCT03467243|Experimental|CBSST|Veterans participate in 20 weekly group sessions using Cognitive Behavioral Social Skills Training model
89653720|NCT03024125|Placebo Comparator|Normal protein diet (NP)|Diet with 0.8 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
89653721|NCT04379583||Subjects|Female subjects providing DNA saliva sample
89653722|NCT03593837|Experimental|Experimental group|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
89653723|NCT03593837|Placebo Comparator|Placebo group|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
89653724|NCT00916539|Experimental|Cast that immobilizes the thumb|Cast that immobilizes the thumb
89046286|NCT03467243|Experimental|SST|Veterans participate in 20 weekly group sessions using Social Skills Training model
89046287|NCT03467243|Other|Treatment as usual|Veterans receive treatment as usual
89653725|NCT00916539|Active Comparator|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
89653726|NCT03593603||Nellcor™ Bedside Respiratory Monitoring System|Patients on the general care floor who are prescribed non-invasive respiratory monitoring via spot check vital signs at least every 4 hours
89653727|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin
89653728|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
89653729|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181
89653730|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181
89653731|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
89653732|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181
89653733|NCT03024203|Experimental|Executive Training|Executive Training (ET) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. ET will be delivered in both individual and group settings.
89653734|NCT03024203|Experimental|Perceptual Training|Perceptual Training (PT) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. PT will be delivered in both individual and group settings.
89653735|NCT03593369|Experimental|KLOX BioPhotonic System (single treatment)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
89653736|NCT03593369|Experimental|KLOX BioPhotonic System (consecutive treatments)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
89653737|NCT03593369|Active Comparator|Standard of Care|SOC only (5 patients)
89653738|NCT03407391||Picky eater|Identified as a very picky eater from parental questionnaire
89653739|NCT03407391||Not a picky eater|Identified as not a picky eater from parental questionnaire
89653740|NCT03407391||Somewhat picky eater|Identified as a somewhat picky eater from parental questionnaire
89653741|NCT03400917|Experimental|AV-GBM-1|Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
89653742|NCT03593135|Experimental|Intervention group|Intervention group taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatments continued (including tablet Tagipment 50mg/1000mg twice a day)(Metformin + Sitagliptin group). 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time was prescribed.
89653743|NCT03593135|Placebo Comparator|Comparison group|Control group also taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatment continued (including tablet Tagipmet 50mg/1000mg twice a day)( Metformin + Sitagliptin group). Flavor of apple cider vinegar used as placebo, mixed in 200ml plain water during meal at night time.
89653744|NCT01837875|No Intervention|Control|Mailed informational literature
89653745|NCT01837875|Active Comparator|Set Menu|Intervention: Enrollment in a local Chronic Disease Self-Management program (CDSMP) and monthly follow up calls to gauge progress and comfort
89653746|NCT01837875|Experimental|Intervention|Intervention: Each individualized intervention plan (IIP) will include 1-4 options, including a mail-delivered arthritis kit, addition and access to a listserv, participation in a support group, and enrollment in local self-management program(s).
89653747|NCT03592979|Experimental|Order A|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
89653748|NCT03592979|Experimental|Order B|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
89046288|NCT03454035|Experimental|Open-label, single arm Phase I|Ulixertinib added to palbociclib
89046289|NCT03376126||MI-ILP|
89046290|NCT03326596|Experimental|ProphylacticTranexamic Acid|Once consented, patients to receive 1000mg/10ml normal saline infusion of TXA with the delivery of the infant's anterior shoulder.
89046291|NCT03323905|Experimental|MR Guided High Intensity Focused Ultrasound|
89046292|NCT03320304||Vagal Nerve Simulation (VNS) Therapy|"The aim of this study is to include patients with difficult to treat depression from a global real world (standard of care) population who are referred for treatment with VNS Therapy."
89046293|NCT03318939|Experimental|Poziotinib|"Cohort 1: Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC (closed to enrollment)~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC (closed to enrollment)~Cohort 3: Treatment naïve patients with EGFR exon 20 insertion-mutant positive NSCLC (fully enrolled)~Cohort 4: Treatment naïve patients with HER2 exon 20 insertion mutant positive NSCLC~Cohort 5: Patients who meet the criteria for enrollment in Cohort 1 to 4, but the enrollment in the respective cohort has been closed~Cohort 6: Patients with acquired EGFR mutation who progressed while on treatment with first-line osimertinib~Cohort 7: Patients with EGFR or HER2 activating mutations"
89046294|NCT03310905|Experimental|Isolated Abdominal Wall Transplant|
89046295|NCT03310905|Experimental|Abdominal Wall with Solid Organ Transplant|
89046296|NCT03283085|Experimental|25 mg Ontamalimab|Participants will be receiving 25 milligram (mg) of ontamalimab solution for injection subcutaneously (SC) every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
89213177|NCT04077749|Placebo Comparator|Placebo|
89213178|NCT01015846|Experimental|Intervention|
89653749|NCT01837953|Other|Unguided Self-Help, No Further Treatment for 16 Weeks|All participants will first receive 10 weeks of unguided self-help (USH), followed by no further treatment for 16 weeks. Participants will be offered a follow up referral to the eating disorders program at The Ottawa Hospital after the 16 week no-treatment period.
89653750|NCT01837953|Experimental|Unguided Self-Help, GPIP|All participants will first receive 10 weeks of unguided self-help (USH). For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy condition, this second step will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy.
89653751|NCT03592901||BPA Patients|Participants that are receiving brachial plexus anesthesia for a previously planned shoulder surgery.
89213179|NCT01015846|Active Comparator|Core stability exercise|Traditional core stability exercise
89653752|NCT03830385|Experimental|Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or|
89653753|NCT03592823|No Intervention|control|receiving radiofrequency ablation and anticoagulant therapy
89653754|NCT03592823|Experimental|hydrochloroquine|receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)
89653755|NCT01838109|Experimental|ONS group|oral administration of Encover 2 package for day starting at the time of discharge (200ml/package x 2, total 400Kcal/day) total 87 patients
89653756|NCT01838109|No Intervention|Control group|no intervention total 87 patients
89653757|NCT03592667|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
89653758|NCT03592667|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
89653759|NCT03407235|Other|Laparoscopic Novices|"Four laparoscopic task will be undertaken on a computerized laparoscopic trainer and box trainer with eye patch.~Time to completion is recorded."
89653760|NCT04406909|Experimental|Training|Access to training at membership training facility
89653761|NCT04406909|No Intervention|No training|No access to training at membership training facility
89653762|NCT03409965|Experimental|Lutronic Systems Combination Treatment|Combination treatment of the face and/or neck using the Lutronic Infini System and Lutronic LaseMD System.
89653763|NCT03592511|Experimental|Intervention|WGPF-burger group
89653764|NCT03592511|Placebo Comparator|Control|Control-burger group
89653765|NCT03407001|Experimental|Screening (US, CEUS, Lumason)|Within 30 days of routine MRI, participants undergo non-contrast ultrasound of the abdomen. Participants then receive Lumason IV and undergo contrast-enhanced ultrasound of the abdomen over 1 hour in the absence of disease progression or unacceptable toxicity.
89653766|NCT03592043||MitraClip|All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada
89653767|NCT03406923|No Intervention|Usual care|Receive usual care only.
89653768|NCT03406923|Experimental|Health literacy-psychosocial support|Receive 6-week sessions of individual health literacy-psychosocial support in addition to usual care. The health literacy-psychosocial support intervention includes 45-minute face-to-face counseling at week 1 and week 6 as well as weekly phone calls (week 2 to week 5.)
89653769|NCT03406845|Experimental|Chair-side mindfulness intervention|Consists of individually conducted meditative practices, lasting 20 minutes/session, 3 times per week for 8 weeks. The interventions will be conducted during their dialysis sessions. The mindfulness meditation sessions include well-described meditations such as the body scan (being aware of bodily sensation), gentle arm movements, guided and silent breath meditations.
89653770|NCT03406845|Active Comparator|Health Enhancement Plan (HEP)|Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
89653771|NCT03406689|Active Comparator|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be administered 45' prior to the injection
89653772|NCT03406689|Active Comparator|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be administered 45' prior to the injection
89653773|NCT03406689|Placebo Comparator|Artificial tears|One drop of Artificial Tears will be administered 45' prior to the injection
89653774|NCT01838265||AS: Active Surveillance Alone|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
89653775|NCT01838265||MRI-AS: MRI+ Active Surveillance|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
89046297|NCT03283085|Experimental|75 mg Ontamalimab|Participants will be receiving 75 mg of ontamalimab solution for injection SC every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
89046298|NCT03266276|No Intervention|Treatment as Usual Control Group|Treatment as usual.
89653776|NCT03591653|Experimental|LXI-15028 50mg group|
89653777|NCT03591653|Placebo Comparator|Placebo group|
89046299|NCT03266276|Experimental|Intervention Group|Use of a standardized PSOPC pathway approach, prompted follow up with patients and documentation.
89653778|NCT01838343|No Intervention|No Ultrasound|Patients randomized to no ultrasound will get standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
89653779|NCT01838343|Experimental|Ultrasound|Patients randomized to ultrasound will get a goal-directed ultrasound performed by a critical care fellow along with standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
89046300|NCT03224767|Experimental|Treatment (vemurafenib, cobimetinib)|Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
89046301|NCT03202602||Telemedicine|Patients randomized to receive telemonitoring in combination with telephone calls after CPAP start.
89653780|NCT03591497|Experimental|Intervention Group|"Instrument to be used:~Software Neuro@home (semi immersive virtual reality system for neurological rehabilitation) was used. In each of the sessions, an avatar on screen that representing the patient was regulated by the patient to perform a virtual task that focused on the training of a specific body part.~Programme schedule:~Each session of virtual reality therapy lasted for thirty minutes. Day 0 included an orientation to the machine with five minutes of gaming. This was followed by virtual reality therapy for five days a week at the same time of the day for three consecutive weeks."
89653781|NCT03591497|No Intervention|Control Group|Virtual reality sessions were not provided.
89653782|NCT01838421||Children under 12 years of age|Children under 12 years of age who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12
89046302|NCT03202602||Standard care|Patients randomized to receive usual office visits after CPAP start.
89046303|NCT03198416|Experimental|Investigational Device|Consented participants who meet eligibility will have a drug induced sleep endoscopy (DISE) with the Solar GI High Resolution pharyngeal Manometry system.
89046304|NCT03181399|Experimental|Triheptanoin|This is a single arm study.
89046305|NCT03173950|Experimental|1/Experimental Therapy|Patients will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
89046306|NCT03142893|Experimental|Control Condition|"8 am - Saline Solution for Injection 10 am - Placebo oral capsule~1 pm - Saline Solution for Injection 4 pm - Placebo oral capsule & start hourly blood sampling 7 pm - Gonadorelin (GnRH) and Corticorelin (CRH) injections 9 pm - Saline Solution for Injection & last blood sample"
89046307|NCT03142893|Experimental|Hypothalamic Condition|"8 am - Ganirelix 10 am - Placebo oral capsule~1 pm - Dexamethasone injection 4 pm - Placebo oral capsule and start of hourly blood sampling 7 pm - GnRH and CRH injections 9 pm - Saline Solution for Injection and last sample of blood taken"
89046308|NCT03142893|Experimental|Pituitary Condition|"8am - Saline Solution for Injection 10am - Ketoconazole Pill~1pm - Saline Solution for Injection 4pm - Ketoconazole Pill & start of hourly blood sampling 7pm - GnRH and CRH 9pm - Hydrocortisone Injection & last blood sample"
89046309|NCT03142893|Experimental|Adrenal/Testis Condition|"10pm - Ganirelix Injection & Dexamethasone Pills (night before) 8am - start of hourly blood sampling 10am - Dexamethasone Pills 11am - last hourly blood sample taken 11:30am - start of blood sampling every 10 minutes~1pm - Recombinant Human Luteinizing Hormone (rhLH) Injection 3pm - rhLH Injection 5pm - rhLH Injection 5pm - Cosyntropin Injectable product 7pm - GnRH and CRH Injections 9pm - last blood sample taken"
89046310|NCT03094312|Experimental|Dynamic Spectral Imaging (ISD)|Evaluation of cognitive functions by ISD
89046311|NCT03073304|Active Comparator|Control|Erythrocyte based prime solution
89046312|NCT03073304|Experimental|Intervention|Crystalloid based prime solution
89046313|NCT02999022|Experimental|Lithium carbonate|Lithium carbonate 300mg capsule; once per day for 2 weeks.
89046314|NCT02999022|Placebo Comparator|Lactose placebo|Lactose placebo capsule; once per day for 2 weeks.
89046315|NCT02996955|Experimental|SoSup group|usual care will be provided and social support and treatment of illness perceptions and activity advice and wearing the activ8
89046316|NCT02996955|Active Comparator|C group|usual care will be provided and treatment of illness perceptions and activity advice and wearing the Activ8
89046317|NCT02927301|Experimental|Atezolizumab|Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.
89046320|NCT02892123|Experimental|ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy|
89213180|NCT04471246|Experimental|High Dose Cephalexin|The intervention is high-dose cephalexin (1000mg PO QID) for seven days
89653783|NCT03591419|Experimental|polymer clip|polymer clips will be used to ligate the appendicular stump. and time and ease of appliction and cost of clips will be calculated
89653784|NCT03591419|Active Comparator|endoloop|endoloops will be used to ligate the appendicular stump an time and ease of application and cost of loops will be calculated
89653785|NCT03406533|Experimental|Group F|Sedated with midazolam and fentanyl
89653786|NCT03406533|Experimental|Group DR|Sedated with midazolam, dexmedetomidine and remifentanil
89653787|NCT03406533|Experimental|Group DF|Sedated with midazolam, dexmedetomidine and fentanyl
89653788|NCT03406533|Experimental|Group PR|Sedated with midazolam, propofol and remifentanil
89653789|NCT03591341||nursing women|women who gave birth and are breast feeding their baby- melatonin level in pumped breast milk have been checked
89653790|NCT03406455||Primary TKA|A cohort of 25 patients undergoing primary TKA for osteoarthritis at our hospital will be enrolled into the study, which will receive IRB approval and be registered on ClinicalTrials.gov and RedCap. Patients will download the mobile application onto their personal smartphones (iOS) to record baseline activity and PROMs in the 2-4 weeks leading up to surgery. During the hospital admission, the knee sleeve will be fitted to the patient. The patient cohort will be followed for three months and four data points (both passive and active) will be extracted from the dashboard: PROMs, mean daily steps, ROM (particular attention to 2 weeks postoperatively), and home exercise plan (HEP) compliance.
89653791|NCT03591185|Experimental|Exercise group|Exercise group, including community-dwelling adults aged 50 years or over, will perform an initial evaluation, 24 intervention sessions with FallSensing clinical tool (2 or 3 sessions per week) and a final evaluation.
89653792|NCT04377399|Active Comparator|high dose|vitamin D (40,000 IU weekly) for 24 weeks
89653793|NCT04377399|Active Comparator|Low dose|vitamin D (5,000 IU weekly) for 24 weeks
89653794|NCT03023969|Active Comparator|group A|percutaneous ozone intradiscal injection group A receive 10 ml of ozone oxygen mixture 40 ug O3/ ml O2
89653795|NCT03023969|Active Comparator|group B|percutaneous ozone intradiscal injection group receive 10 ml of ozone oxygen mixture 30 ug O3/ ml O2.
89653796|NCT01838577||Case cohort|"Patients with proven EGFR mutation in exons 18-21 from tumor material. Patients with unknown or failed tumor EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR mutation will become eligible for the case cohort.~No known somatic KRAS, HER2, LKB1, BRAF, or PI3K, mutation or ALK gene rearrangement (or ALK3+ immunohistochemistry). If these mutations are known to be present the patient will be ineligible. However, patients will not be tested specifically for these mutations for this study and patients with unknown status are acceptable. If patients are subsequently tested after enrollment and found to harbor any of these mutations they will be considered ineligible and will be replaced.~No known Li Fraumeni, Li Fraumeni-like, or Peutz Jeghers syndrome family, or known germline carriers of mutant LKB1 or TP53. Patients will not have to be tested specifically for these syndromes to be eligible for this study."
89653797|NCT01838577||Control cohort|"Patients known to be somatic EGFR wild-type, i.e. no mutation detected in exons 18-21 from tumor material.~Patients with unknown or failed EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR wild-type will become eligible for the control cohort.~Never smoker (<100 cigarettes in lifetime) or ex-light smoker (stopped ≥1 year ago and smoked ≤10 pack-years)."
89046321|NCT02754323|Other|apparatus CODESNA|correlation between job stress measurement by the Maslach Burnout INVENTORY and KARASEK questionnaires and measurement of chronic stress by CODESNA tool
89046322|NCT02737878|Experimental|Aerobic Training and Resistance Training (A&RT)|The A&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
89046323|NCT02737878|Experimental|Aerobic Training (AT)|The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
89213181|NCT04471246|Active Comparator|Standard Dose Cephalexin|The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days
89653798|NCT03400995|Experimental|Intervention Arm|Each subject will receive a single oral administration of a solution containing 300 mg radiolabeled AK0529 in the fasted state.
89653799|NCT03590873|No Intervention|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
89653800|NCT03590873|Experimental|Restrictive group|"Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
89653801|NCT01673178|Placebo Comparator|Placebo Arm|
89653802|NCT01673178|Experimental|25 mg|
89653803|NCT01673178|Experimental|50 mg|
89653804|NCT01673178|Experimental|100 mg|
89653805|NCT01673178|Experimental|150 mg|
89653806|NCT03590795||Problem Sleepers|Those individuals that have self identified as having a unspecified sleep problem will take the sleep survey.
89653807|NCT02155335|Experimental|Prefilled Syringe→Smartject™ Device|Golimumab 50 mg supplied in a prefilled syringe administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied in the Smartject 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab).
89653808|NCT02155335|Experimental|Smartject™ Device→ Prefilled Syringe|Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
89653809|NCT03590717|Other|BCC-Only|Intervention: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
89653810|NCT03590717|Experimental|Small-voucher|Intervention: Households in the 'Small-voucher' arm receive a voucher (~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
89653811|NCT03590717|Experimental|Large-voucher|Intervention: Households in the 'Large-voucher' arm receive a larger voucher (~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
89653812|NCT03400839||Patients with ILD|"Patients with a medical diagnosis of interstitial lung disease.~Patients will be submitted to the assessment of:~Daily physical activity levels;~6-minute walk test;~Cardiopulmonary exercise testing;~Muscle Function;~Lung Function;~Body composition;~HRQoL - SGRQ-I;~HRQoL - SF36;~Anxiety and depression;~Symptoms - mMRC~Symptoms - UCSD/SOBQ;~Sleep quality;~Sleepiness;~Inflammatory markers and oxidative stress.~Functional performance tests"
89653813|NCT03400839||Control Group|"Age-matched peers without lung diseases.~Participants will be submitted to the assessment of:~Daily physical activity levels;~6-minute walk test;~Cardiopulmonary exercise testing;~Muscle Function;~Lung Function;~Body composition;~HRQoL - SF36;~Anxiety and depression;~Sleep quality;~Sleepiness;~Inflammatory markers and oxidative stress.~Functional performance tests"
89653814|NCT03590561|Experimental|High caloric diet|Participants will eat 1500 kcal more than their usual diet for five days.
89653815|NCT03590561|No Intervention|Control diet|Participants will eat regular diet.
89653816|NCT03406143|Experimental|CGF injection group|Concentrate Growth Factors(CGF) will be harvested through centrifugation afte intravenous blood collection. Venous blood was collected in tube and then centrifuged in Medifuge system（Thermo Scientific）. About 2ml liquid CGF can be harvested from 9ml venous blood. Patients will receive autologous CGF injection subdermally to expanded skin at the density of 0.02 ml/cm2.
89653817|NCT03406143|Sham Comparator|Control group|0.9% saline will be injected into expanded skin for control study. Patients will receive saline injection subdermally to expanded skin at the density of 0.02 ml/cm2.
89653818|NCT03406065|Experimental|Sodium bicarbonate supplementation|Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
89653819|NCT03406065|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (maltodextrin with NaCl) in a similar tablet form prepared by the same producer as NaHCO3 tablets.
89046324|NCT02737878|Experimental|Resistance Training (RT)|The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
89046325|NCT02737878|Active Comparator|Balance and Tone Program (CON)|The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
89046326|NCT02735109|Other|description|photographies and biopsy on normal area
89046327|NCT02720874|Experimental|Intervention Arm|In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
89046328|NCT02720874|Active Comparator|Control Arm|Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.
89046329|NCT02669394|Experimental|Resistance Training (RT)|"The RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
89213182|NCT01019200||Psoriasis|Individuals with a diagnosis of psoriasis as confirmed by the principle investigator will comprise the psoriasis or case group. Participants must meet inclusion and exclusion criteria as defined below. This group will consist of 100 individuals.
89653820|NCT03590093|Experimental|Periodontal Surgery with EMD|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect. Suture were placed to maintain wound stability.
89653821|NCT03590093|Active Comparator|Periodontal Surgery|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. Suture were placed to maintain wound stability.
89653822|NCT05024526|Experimental|edaravone dexborneol group|
89653823|NCT05024526|Active Comparator|edaravone group|
89653824|NCT03590015|Other|old letter of invitation|"Old invitation letter written by researchers/doctors in The coronary project sent to patients in order to recruit to an ongoing project"
89653825|NCT03590015|Other|New letter of invitation|New invitation Letter written with consideration of impaired language comprehension and has therefore been written in simple sentences with a sequential structure of basic information sent to patients in an ongoing project.
89653826|NCT03405987||ECV < median|
89653827|NCT03405987||ECV ≥ median|
89653828|NCT05024370||Multiparas, planned cesarean section|Multiparas having a planned cesarean section at the departement of Obstetrics and Gynecology in Herning Hospital. Uncomplicated pregnancy that makes early discharge possible.
89653829|NCT03597035|Experimental|Patiromer Add-On|Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
89653830|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 1)|Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects
89653831|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 2)|Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects
89653832|NCT03093714|Experimental|FDL 169 test formulation ( Dose Level 3)|Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects
89653833|NCT03093714|Placebo Comparator|Placebo|Multiple dose placebo as repeat doses in CF subjects
89046330|NCT02669394|Active Comparator|Stretching and Relaxation (CON)|"The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
89046331|NCT02659930|Experimental|1/Group I|Pomalidomide and liposomal doxorubicin given at escalating doses to patients with KS requiring systemic therapy
89046332|NCT02659930|Experimental|2/Group I; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS requiring systemic therapy
89046333|NCT02659930|Experimental|3/Group II|Pomalidomide with liposomal doxorubicin given at escalating doses in to patients with advanced KS or KS and concurrent KSHV-associated MCD or KICS requiring systemic therapy
89046334|NCT02659930|Experimental|4/Group II; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS or KS with concurrent KSHV-associated MCD or KICS requiring systemic therapy
89046335|NCT02653976|Experimental|SP-02L (darinaparsin for injection)|
89046336|NCT02611037|Experimental|Chemoperfusion + Questionnaire|"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m^2), methotrexate (100 mg/m^2) and gemcitabine (1000 mg/m^2).~Patients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.~Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire."
89046337|NCT02607202|Experimental|Arm A|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes. Treatment to be repeated Q21 days.
89046338|NCT02607202|Experimental|Arm B|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by carboplatin AUC 2 on Day 1 and 8 by IV administration over 60 minutes. Treatment to be repeated Q21 days.
89046339|NCT02573441|Experimental|Math + Liaison Service|To help with mathematics, participants will be assigned to a workbook based version of the JUMP Math program which will be completed at home with a parent. This intervention focuses on mental math skills. In addition all participants will receive the liaison service program.
89046340|NCT02573441|Experimental|Working Memory + Liaison Service|To help with working memory, participants will be assigned to Cogmed, a game-like computer exercise focusing on improving working memory. In addition all participants will receive the liaison service program.
89653834|NCT03400683|Active Comparator|misoprostol only group|given 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), in sublingual every four hours for a maximum of five doses
89653835|NCT03400683|Active Comparator|misoprostol with letrozole group|group received 15mg( letrozole2.5mg) on three successive day patient take doses of letrozole for daily oral three successive day at home by herself and forth day admitted to our hospital followed by sublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
89653836|NCT03400683|Active Comparator|misoprotol with Foley's catheter group|the transcervical 16F Foley's catheter with 30 ml balloon capacity (Euromed for Medical Industries, Cairo, Egypt, under license of Kanglite, USA), inserted under aseptic conditions withsublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
89653837|NCT01838889|Experimental|Culturally adapted psychological intervention (PHP)|Depressed Mothers randomized to experimental arm will undergo a 12 week group psychological intervention on the 'positive health programme'.
89653838|NCT01838889|No Intervention|Treatment as usual (TAU)|Depressed mothers randomized to TAU arm will receive treatment as usual.
89653839|NCT03094260|Experimental|High intensity light therapy|Treatment with light therapy in high intensity (10,000 lux)
89653840|NCT03094260|Placebo Comparator|Low intensity light therapy|Treatment with light therapy in low intensity (<500 lux)
89653841|NCT05037240|Active Comparator|Intervention Group|
89653842|NCT05037240|Placebo Comparator|Placebo|
89653843|NCT01838967|Experimental|C - V - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
89653844|NCT01838967|Experimental|V - C - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
89653845|NCT01838967|Experimental|V - C+V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
89653846|NCT01838967|Experimental|C+V - V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
89653847|NCT01838967|Experimental|C+V - C - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
89653848|NCT01838967|Experimental|C - C+V - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
89653849|NCT05037006|Experimental|Group I-30|Inhalational anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
89653850|NCT05037006|Experimental|Group I-50|Inhalational anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
89653851|NCT05037006|Experimental|Group I-70|Inhalational anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
89653852|NCT05037006|Experimental|Group V-30|Intravenous anesthesia and reversal with neostigmine 30 mcg/kg and atropine 15 mcg/kg
89653853|NCT05037006|Experimental|Group V-50|Intravenous anesthesia and reversal with neostigmine 50 mcg/kg and atropine 25 mcg/kg
89653854|NCT05037006|Experimental|Group V-70|Intravenous anesthesia and reversal with neostigmine 70 mcg/kg and atropine 35 mcg/kg
89653855|NCT03405909||Patients at risk for HCC|"Patients with any of the following conditions:~liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis~Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology"
89653856|NCT03093090|Active Comparator|Water First|20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
89653857|NCT03093090|Active Comparator|Milk First|Parmalat™ Whole Milk 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
89653858|NCT03093090|Active Comparator|Baby formula first|Similac Pro-Advance™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
89653859|NCT03093090|Active Comparator|Ensure Plus first|Ensure Plus™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
89653860|NCT03400293||Subjects living with HIV|Subjects living with HIV will be recruited via digital advertising. These subjects will participate in completing various PRO instruments and targeted questions.
89653861|NCT03093168|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma
89653862|NCT04377321||group 1 on cochicine|The first group patients received colchicine 0.5 twice daily for 6 months
89046341|NCT02573441|Other|Liaison Services|Participants in this group will only receive the liaison service program for 12 weeks before being assigned to one of the intervention groups.
89046342|NCT02560662|Experimental|Physical activity|Individual consultation with a physiotherapist in order to increase the participants existing level of physical activity by adding 30minutes of physical activity daily, preoperatively and 4 weeks postoperatively.
89046343|NCT02560662|No Intervention|Control|Participants randomized to the control group will not be advised to change their current level of physical activity.
89653863|NCT04377321||group 2 on glucophage 1 gm twice daily|second group received glucophage 1gm twice daily for 6 months
89653864|NCT04377321||group 3 control|the third group patients were on diet only for 6 months
89653865|NCT05028192||Rectal cancer after neoadjuvant treatment|Rectal cancer patients, ycTNM stage II, III, and IV (AJCC 8th), clinically stratified in the pre-cachectic or cachectic stage according to Fearon K et al. definition. That will be subject to curative intent resection or palliative surgery through any approach (open, laparoscopic, or robotic).
89653866|NCT05028192||Control group|Patients who will undergo programmed abdominal surgery through any approach type for no neoplastic or inflammatory disease.
89653867|NCT04377243|Experimental|V8 850 mg|Arm 1: Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of V8
89653868|NCT04377243|Placebo Comparator|Placebo 850 mg|Arm: 2 Individuals with chronic kidney failure having creatinine level twice higher than normal. They will receive once daily pill of placebo
89653869|NCT03090672|Experimental|tSVF + PRP Arm1|Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate
89653870|NCT03090672|Experimental|tSVF + PRP + cSVF Enrichment Arm 2|tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)
89653871|NCT03090672|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction
89653872|NCT03405831|Active Comparator|Ivabradine|Study participants in this arm will receive ivabradin 5 mg bid for a period of 12 weeks.
89653873|NCT03405831|Placebo Comparator|Placebo|Study participants in this arm will receive placebo bid for a period of 12 weeks.
89653874|NCT03094494||Double Carbapenem Group|Patients underwent Double carbapenem treatment
89653875|NCT03094494||Standard Treatment Group|Patients who were not treated with the double carbapenem
89653876|NCT05028036|Experimental|Personalized lifestyle intervention|The intervention consists of a personalized lifestyle treatment program to address specific lifestyle issues.
89046344|NCT02429479|Active Comparator|Standard ACP/Patient Alone|Patients (without their family caregiver) complete a standard living will form online.
89046345|NCT02429479|Experimental|Decision Aid/Patient Alone|Patients (without their family caregiver) complete Making Your Wishes Known, an online decision aid for advance care planning.
89213183|NCT01019200||Control|Individuals without psoriasis, but meeting inclusion and exclusion criteria, will be selected to be within the control group. For each patient with psoriasis within the psoriasis group, an age, sex, and BMI-matched control will be selected. The group will consist of 100 individuals.
89213184|NCT03797651|Active Comparator|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
89213185|NCT03797651|Experimental|Very-short DAPT within 1 month|Patient will stop aspirin after discharge (DAPT less than 1 months after PCI) (ticagrelor monotherapy). Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
89213186|NCT05062109|Experimental|Multimodal geriatric prehabilitation|
89213187|NCT00499486|Experimental|Sirolimus|Sirolimus 5mg. po QD continously (28 days=cycle)
89213188|NCT03794375|Active Comparator|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
89213189|NCT03794375|Experimental|Telehealth|"The patients will be discharged from the HCPA thyroid disease outpatient clinic, being instructed to seek the primary care level according to their place of residence to schedule a routine consultation in up to six months.~After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed."
89213190|NCT01019278|Experimental|Arm I|Patients undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy.
89213191|NCT02581241|Experimental|drug-induced long QT syndrome|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 due to drug-induced long QT syndrome and the associated torsades de pointes, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
89213192|NCT02581241|Active Comparator|control|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 and were treated with specific drugs (antibiotics) that potentially prolong the QT interval but they do not have drug-induced long QT syndrome, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
89213193|NCT01014520|Experimental|Gabapentin|Neurontin
89213194|NCT01014520|Experimental|Amitriptyline|Elavil
89213195|NCT04040699|Experimental|KN026 combined with KN046|"KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, leading to a dual HER2 signal blockade.~KN046 is a PD-L1 - CTLA-4 bispecific antibody."
89213196|NCT01015924|Active Comparator|Elastic Stable Intramedullary Nailing|Operative intervention with closed or open reduction and intramedullary stabilization of midshaft clavicle fractures
89213197|NCT01015924|Active Comparator|Plate osteosynthesis|Open reduction and plate fixation of midshaft clavicle fractures
89213198|NCT04267367|Experimental|Intervention|The intervention will include a dietitian-led nutrition education, counseling session and individual basis diet plan emphasis on glycemic control diet targeted to T2DM patients attending during the OPD visits in hospital.
89213199|NCT04267367|No Intervention|Usual care|The usual care arm will be only provided general education.
89213200|NCT04266574|Experimental|Near Infrared Spectroscopy (NIRS)|
89213201|NCT04266574|Active Comparator|Standard Care|
89213202|NCT01016002|Experimental|Intervention|
89213203|NCT01016080|Active Comparator|oral glutathione|glutathione, 500 mg, taken orally twice daily
89213204|NCT01016080|Placebo Comparator|placebo capsules|identical-appearing placebo capsules
89213205|NCT01019434|Other|Temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
89213206|NCT01019434|Experimental|Temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
89653877|NCT03409419||pre cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed before the treatment interventions.
89653878|NCT03409419||post cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed after the treatment interventions.
89213207|NCT01016158|Experimental|umbilical cord serum eyedrops|patients with recurrent corneal erosions were treated with 20% umbilical cord serum eye drops 3 to 4 times a day in addition to artificial tears
89213208|NCT04024631|Other|Phenotyping|"All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.~They will also undergo a whole body DXA (intervention) during the study day."
89213209|NCT00499252|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89213210|NCT00499174|No Intervention|Active Surveillance|Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression
89653879|NCT05018364||cases|measure serum erythropoietin level
89213211|NCT00499174|Active Comparator|Radical Intervention|Radical prostatectomy or radiotherapy based on patient and physician preference
89213212|NCT01019512|Active Comparator|Arm I|Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administerd), and nighttime bandaging with low stretch Comprilan bandages.
89213213|NCT01019512|Experimental|Arm II|Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening.
89213214|NCT01019512|Experimental|Arm III|Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening.
89213215|NCT01019590|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
89213216|NCT01019590|Active Comparator|2|Benicar HCT ® Tablets 40 mg/25 mg
89213217|NCT03775421|Experimental|Open-label treatment period|oral administration of 10 mg macitentan once daily
89213218|NCT01016314|Experimental|Aspen Spinous Process System|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
89213219|NCT01016314|Active Comparator|Pedicle Screw Fixation|Subjects randomized to the pedicle screw group will have the pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
89213220|NCT01014676|Active Comparator|Probiotic milk|
89213221|NCT01014676|Placebo Comparator|Standard milk|
89213222|NCT00532155|Experimental|Placebo/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
89653880|NCT05018364||controls|measure serum erythropoietin level
89653881|NCT04375371|Active Comparator|Obese patients who have received a bariatric surgery|Obese patients who have undergone a bariaric surgery as part of routine clinical management within the indication of this intervention.
89653882|NCT04375371|No Intervention|Obese patients without a bariatric surgery|Obese patients who have not undergone bariaric surgery.
89653883|NCT03090594|Other|Biopsy|Transbronchial biopsies with cryoprobe.
89653884|NCT03405597|Experimental|Healthy control|Commercial Hepatitis B vaccine
89653885|NCT03405597|Experimental|Chronic hepatitis B with vaccination|Commercial Hepatitis B vaccine
89653886|NCT03405597|Active Comparator|Chronic hepatitis B without vaccination|Standard treatment
89653887|NCT03593213|Experimental|Cariprazine 4.5 mg/day (Open-label Treatment Period)|Cariprazine 1.5 mg capsules orally once daily at Week 1, titrated to 3.0 mg capsules orally once daily at Week 2 and then titrated to 4.5 mg orally once daily from Week 3 through Week 18 in the Open-label Treatment Period.
89213223|NCT00532155|Placebo Comparator|Aflibercept/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
89653888|NCT03593213|Placebo Comparator|Placebo (Double-blind Treatment Period)|Cariprazine placebo-matching capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
89653889|NCT03593213|Experimental|Cariprazine 3.0 mg/day (Double-blind Treatment Period)|Cariprazine 3.0 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
89653890|NCT03593213|Experimental|Cariprazine 4.5 mg/day (Double-blind Treatment Period)|Cariprazine 4.5 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
89653891|NCT05023824|Experimental|alpha-blocker withdrawal|receives 5-ARI monotherapy
89213224|NCT01019668|Active Comparator|verteporfin PDT, half-dose|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
89213225|NCT01019668|Active Comparator|verteporfin PDT, half-fluence|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
89213226|NCT04076345||Bacterial group|Newborns or infants less dans 3 months old with fever and positive bacterial sample.
89213227|NCT04076345||Viral group|Newborns or infants less dans 3 months old with fever and positive viral sample.
89213228|NCT04076345||Negatives Microbiological samples|Newborns or infants less dans 3 months old with fever and negatives microbiological samples.
89653892|NCT05023824|Experimental|5-ARI withdrawal|receives alpha-blocker monotherapy
89653893|NCT05023824|Active Comparator|combination therapy|receives alpha-blocker and 5-ARI
89653894|NCT03834285||Cirrhosis in pregnancy|Cirrhotic patients with a confirmed pregnancy will be placed into Cohort 1.
89653895|NCT03834285||Pregnancy-associated liver diseases|Patients who develop Acute Fatty Liver of Pregnancy, HELLP Syndrome / Intrahepatic Cholestasis of pregnancy will be placed into Cohort 2.
89653896|NCT03833973||Runners|Long-distance runners, marathon runners, 5 km and 10 km runners, both female and male aged 20 - 40 years, participating in regular training and competitions.
89653897|NCT03833973||Soccer Players|High Level soccer players, both female and male aged 15-30, participating in all games
89653898|NCT05023902|Active Comparator|Pilates|The Pilates Mat exercise group followed an eight-week exercise program. The exercise protocol of this study was designed by the researchers (Table I). According to previous reports, 6 to 8 weeks of Pilates training has positive effects on physical and psychological health (Akbas, Unver, 2021; Bavli & Koybasi, 2016; Pourvaghar, Bahram, Sharif & Sayyah, 2014; Rogers & Gibson, 2009). As the program advanced, 20-cm diameter mini soft balls, Pilates rings, 65 cm diameter soft gymnastic balls, and rubber bands were used in this order as materials in Pilates exercises. After an initial warm-up exercises at a slow pace for 10 minutes, Pilates exercises with and without equipment were performed for 40 minutes. The exercises ended with a 10- minute recovery and stretching exercises for relaxation of all muscle groups
89653899|NCT05023902|Experimental|NIA Dance|NIA includes nine basic movement forms, 13 principles, and 52 basic moves. The nine movement forms were derived from martial arts, dance arts, and the healing arts of the Alexander Technique, Feldenkrais Method, and Yoga (Rosas & Rosas, 2004). The 13 principles specify areas related to fitness, personal growth, and lifestyle. Centered on the joy of movement, they focus on, for example, being sensitive to personal rhythms, making the correct movement choices, and experiencing positive changes in daily life. The moves of NIA are used to engage all body areas, improve fitness, and facilitate self-healing.
89653900|NCT03405519|Other|Radiotherapy planning|Radiotherapy planning using both CT and MRI scans
89653901|NCT05023746||Clinically diagnosed as non-small cell lung cancer samples|
89653902|NCT03405441|Experimental|Part 1 (Panel 1): JNJ-55375515 and placebo|Participants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
89653903|NCT03405441|Experimental|Part 1 (Panel 2): JNJ-55375515 and placebo|Participants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
89653904|NCT03405441|Experimental|Part 2: JNJ-55375515 and placebo|Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3.
89653905|NCT03595163|Experimental|Group S|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and maintained with 2.0-2.5vol% sevoflurane, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
89653906|NCT03595163|Active Comparator|Group P|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and continuous infusion of 7 to 8mg/kg/hour, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
89653907|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
89653908|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.1%)|
89653909|NCT03404115|Placebo Comparator|Vehicle Ophthalmic Solution|
89653910|NCT04434456||CGuard stenting (interventional)|CGuard implantation in the carotid artery with aneurysm requiring intervention
89653911|NCT04191317|Experimental|Pain Neuroscience Education and gradual exposure|"Education explaining the neurophysiological processes that lead to chronic pain, in order to change maladaptive belief towards disease, reconceptualising them and desensitizing the Central Nervous system.~On first session of gradual exposure the patients are challenged to create a hierarchically list with the functional activities they experience fear, and exposure begins with the one they have less. Both the therapist and participant will determine a specific group of exercises after the patient understands the benign nature of pain, and will be evaluated the maximal performance of the individual to perform each exercise separately."
89653912|NCT04191317|Active Comparator|Pilates and postural education|In the first session, basic Pilates principles will be taught and reinforced at the beginning of the follow up sessions, including: postural alignment (neutral spine position, shoulder blade and neck position) and core recruitment along with a controlled breathing. Each session will have a warm up, mobility, stability and strengthening exercises and a cool down period.
89653913|NCT05023590|Active Comparator|cryo ablation|cryo ablation of left atrium during mitral valve open chest intervention
89653914|NCT05023590|Active Comparator|radio frequency ablation|radio frequency ablation of left atrium during mitral valve open chest intervention
89046346|NCT02429479|Active Comparator|Standard ACP/Together|Patients and their family caregiver together complete a standard living will form online.
89046347|NCT02429479|Experimental|Decision Aid/Together|Patients and their family caregiver together complete Making Your Wishes Known, an online decision aid for advance care planning.
89046348|NCT02402660|Experimental|ALK-001|Daily, oral administration of one capsule. See details below.
89046349|NCT02402660|Placebo Comparator|Placebo|Daily, oral administration of one capsule. See details below.
89046350|NCT02347228|Experimental|OB318 capsule|
89046351|NCT02309840|No Intervention|control|Students received standard meals in a standard cafeteria environment
89046352|NCT02309840|Experimental|Chef|Students were exposed to chef-enhanced meals
89046353|NCT02309840|Experimental|choice architecture|"Students were exposed to modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
89213229|NCT01019746|Experimental|control propofol administration|
89213230|NCT01014754||NSF|Biopsy-proven diagnosis of NSF
89653915|NCT04199819|Other|HBsAg-negative recipients|Recipients who are HBsAg-negative will undergo a panel of test to detect HBV viral markers. In addition, real-time PCR will be used to determine the presence of intrahepatic HBV DNA and cccDNA on the explant histology. Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis. For those without evidence of OBI, that is, negative for all biomarkers, no antiviral prophylaxis will be given.
89653916|NCT05023668||Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy|Chinese moderate to severe atopic dermatitis patients not controlled by topical therapy
89653917|NCT00918723|Experimental|Treatment (induction and maintenance chemotherapy)|"INDUCTION THERAPY: Patients receive vorinostat PO once daily on days 1-5 and 8-12; cyclophosphamide IV over 30-60 minutes and fludarabine phosphate IV over 30-60 minutes on days 1-3; and rituximab IV on day 1, 2, 3, 4, or 5. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 3 months after the completion of induction therapy, patients receive vorinostat PO on days 1-14 and rituximab IV on day 1. Treatment repeats every 3 months for 2 years in the absence of disease progression or unacceptable toxicity."
89653918|NCT04193033|Experimental|FLOW intervention|Sites receive the FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
89653919|NCT04193033|No Intervention|Waitlist until Time 2|Arm 2: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 2.
89653920|NCT04193033|No Intervention|Waitlist until Time 3|Arm 3: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 3.
89653921|NCT04953390|Experimental|Experimental|All study participants wearing study devices and evaluating three different microphone settings in simulated noise environments in lab, and using study devices during home trial period.
89653922|NCT04198883|Experimental|Protheracytes|Single arm study : Stem cells injection called Protheracytes
89653923|NCT04950114|Experimental|200 mg Dose Cohort|Participants who received GFB-887 or placebo in GFB-887-201 will receive GFB-887 at a daily dose level of 200 mg regardless of original dose level.
89653924|NCT04192331|Experimental|2/3dose strategy|HER2 negative advanced breast cancer patient
89653925|NCT04192331|Active Comparator|3/4dose strategy|HER2 negative advanced breast cancer patient
89653926|NCT04766255|Active Comparator|Control Group|Implant placement and prosthetic rehabilitation of the missing tooth
89653927|NCT04766255|Experimental|SCTG group|Implant placement, soft tissue augumentation of Connective Tissue Graft (from the palate) (SCTG) at the implant site and prosthetic rehabilitation of the missing tooth.
89653928|NCT04766255|Experimental|CM group|Implant placement, soft tissue augumentation of porcine collagen matrix (CM) at the implant site and prosthetic rehabilitation of the missing tooth.
89653929|NCT04766255|Experimental|PADM group|Implant placement, soft tissue augumentation of Porcine acellular dermal matrix (PADM) at the implant site and prosthetic rehabilitation of the missing tooth.
89653930|NCT00919035|Experimental|Torisel|Single Agent Temsirolimus (Torisel®)
89653931|NCT04195217|Active Comparator|With art therapy|Art therapy as supportive care in 6 consecutive sessions of cancer treatments with or without additional supportive care
89653932|NCT04195217|No Intervention|Without art therapy|6 consecutive sessions of cancer treatments without art therapy with other supportive care added.
89653933|NCT04133064|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 10 or more cigarettes per day
89653934|NCT04376931|Experimental|Iscador®P as intravenous infusion|"Investigational therapy will be administered in six Dose Groups (DG):~10 mg, 20 mg, 40 mg, 90 mg, 140 mg and 200 mg Iscador®P. The initial dose group of the study is set to 40 mg Iscador®P. The two lower dose groups (20 or 10 mg) will only be used in case of intolerance at 40 mg Iscador®P. Once per week patients receive intravenous infusions of Iscador®P dissolved in 250 ml of sodium chloride solution (0.9 %). After the 4-week period of the MTD estimation phase each subject will immediately be included into a follow up observation in which he/she receives the last well tolerated dosage they had or the next lower dosage than the currently investigated DG in the running phase Ib study depending on the current estimate of the MTD at that time."
89653935|NCT04193345|Active Comparator|Early cord clamping|The umbilical cord will be clamped within 15 seconds from delivery of the baby
89653936|NCT04193345|Active Comparator|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds from delivery of the baby
89653937|NCT00919113|Experimental|8 weekly bladder instillations of Uracyst|20 mL Uracyst (2% sodium chondroitin sulfate) per instillation; 8 instillations over a 7-week period
89653938|NCT00919113|Placebo Comparator|8 weekly bladder instillations of inactive control|20 mL inactive control buffer (phosphate-buffered saline); 8 instillations over a 7-week period
89653939|NCT03092778|Experimental|Cryoablation Group|Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.
89653940|NCT03092622|Experimental|exercise training|Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions.
89653941|NCT04374981|Experimental|Celecoxib|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of celecoxib tablets (100mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
89653942|NCT04374981|Experimental|Montelukast|Twelve healthy male subjects participated in this arm under fasting condition. A randomized, open-label, 2-way crossover study design with 2-week washout period between treatments was used. Participants received a single oral dose of Montelukast tablets (10mg) after pre-treatment with 250ml of either pineapple juice or water (control) for four consecutive days before the beginning of the study.
89653943|NCT03092544|Active Comparator|RRMS on therapy|18 subjects with a diagnosis of Relapsing Remitting (RRMS) ages 18-55, that are scheduled to begin on dimethyl fumarate
89213231|NCT01014754||Kidney dysfunction plus gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have had a medical imaging procedure using GBCA in the 2 years prior to skin biopsy.
89213232|NCT01014754||Kidney dysfunction without gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have never been exposed to GBCA and have had skin biopsy.
89213233|NCT01014754||Normal kidney function with gadolinium exposure|Those with normal kidney function who have undergone a medical imaging procedure using Gd-based contrast agent (GBCA) in the 2 years prior to a skin biopsy.
89213234|NCT01014754||Normal kidneys without gadolinium exposure|Those with normal kidney function who have never been exposed to GBCA and have had a skin biopsy.
89213235|NCT01014754||Controls|Existing skin tissue from neonatal skin (<6 months) will be used as controls, as they presumably have never been exposed to gadolinium
89213236|NCT00205777|Active Comparator|A|
89213237|NCT00205777|Placebo Comparator|B|
89653944|NCT03092544|Active Comparator|SPMS on therapy|18 subjects with a diagnosis of Secondary Progressive (SPMS) ages 25-65 without clinical or MRI evidence of relapse in two years that are scheduled to begin on dimethyl fumarate
89653945|NCT03092544|No Intervention|SPMS not on therapy|18 subjects with a diagnosis of SPMS ages 25-65 without clinical or MRI evidence of relapse in two years, that are NOT scheduled to begin on dimethyl fumarate
89653946|NCT03092544|No Intervention|Normal Control 1|10 normal controls (younger cohort, mean age 38)
89653947|NCT03092544|No Intervention|Normal Control 2|10 normal controls (younger cohort, mean age 58)
89653948|NCT04375059|Active Comparator|Study group|3 months of interactive attention training programs, 2 times per week, 15 min per session, a total of 24 sessions, with conventional rehabilitation programs
89653949|NCT04375059|No Intervention|Control group|3 months of conventional rehabilitation programs without interactive attention training programs
89653950|NCT05017896||Normal Perfusion|
89653951|NCT05017896||Low Perfusion|
89653952|NCT04199975|Other|Orthoses|Only one single arm in this study
89653953|NCT03403803||Control Group|
89653954|NCT03403803||Optune Only|
89653955|NCT03403803||Optune and TMZ|
89653956|NCT04199585|Experimental|Cohort A: single-ascending oral dose|Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential
89653957|NCT04199585|Experimental|Cohort B: (fasting/fed conditions)|"Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.~B1: fed-fasting-fasting condition (spiked dosage)~B2: fasting-fed-fasting condition (spiked dosage)~B3: fasting-fasting-fed condition"
89653958|NCT03090516|Experimental|Arm A ：Donepezil|A：People are randomly divided into three groups according to the educational conditiono，gender and age.
89653959|NCT03090516|Experimental|Arm B ：Donepezil and Ginkgo biloba dispersible tablets|B：People are randomly divided into three groups according to the educational conditiono，gender and age.
89653960|NCT03090516|Experimental|Arm C：Ginkgo biloba dispersible tablets|C：People are randomly divided into three groups according to the educational conditiono，gender and age.
89653961|NCT04375215|Active Comparator|Selective caries removal to soft dentin (one step)|In selective caries removal to soft dentine, after caries excavation application of liner will be done on pulpal floor. Teeth will then be filled with composite resin material.
89213238|NCT03762395|Experimental|CXA-10|Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.
89213239|NCT03762395|Placebo Comparator|Matching Placebo|Administered orally, daily, and continuously for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Placebo will be dispensed at Visit 4.
89653962|NCT04375215|Active Comparator|Stepwise caries removal (two step)|The stepwise caries removal is a two step procedure. The first step is similar to selective caries removal to soft dentin group. In the second step, after 6 months lesion will be re-entered to remove remaining carious tissue till firm dentin is encountered. Once all the caries is removed from floor of cavity a liner followed by final restoration with composite will be performed.
89653963|NCT04199507||Autism|Assessment of physical activity level and physical fitness
89653964|NCT04199507||Healthy|Assessment of physical activity level and physical fitness
89653965|NCT04108884|Experimental|App Group|In the app group, if an episode of arrhythmia is detected with the app, the local investigator will contact the respective patient to schedule an appointment for a 14 day Holter ECG.
89653966|NCT04108884|Other|Standard Care Group|The control group will perform the same measurements as the intervention group, with the only difference that a cumulated Portable Document Format (PDF) report is provided after 6 months instead of the immediate feedback in the app group.
89653967|NCT04199039|Experimental|ET fixation with ET holder|ET fixation of the patients in the study group was performed with an ET holder when they arrived at the CVS ICU
89653968|NCT04199039|No Intervention|ET fixation with plaster|ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted.
89653969|NCT04375137||Severe COVID|patients with positive PCR or compatible CT admitted in ICU or intubated
89653970|NCT04375137||Non-severe COVID-19|patients with positive PCR or compatible CT admitted in ward without hypoxia
89653971|NCT04375137||Healthy Controls|Healthy controls with negative IgM/IgG for COVID-19
89653972|NCT04199429|Experimental|Experimental|"Each nurse applied the RBC model through the treatment Take 5 minutes (T5M), to parents allocated to the experimental group. This consisted in devoting some time (from 5 to 10 minutes) to improving the relationship with the parent. This treatment can be considered as the practical development of the core principles of the RBC model by the study team.~During the T5M the nurse applied the strategies of empathic communication and active listening, learned during the education and training phase. The treatment lasted from 5 to 10 minutes and was delivered once per day during the admission of the patient.~The T5M time was considered as additional or supplementary, but not substitutive, of the standard nursing time dedicated daily to patients and parents."
89213240|NCT01004055|Experimental|Procellera™ Wound Dressing|
89653973|NCT04199429|Active Comparator|Control|Standard nursing time dedicated daily to patients and parents.
89653974|NCT03090204|Other|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle during a sharp decline of right ventricle preload induced during a session of Intermittent hemodialysis.
89653975|NCT03405285|Experimental|Connected Catheter Feasibility Study|Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
89653976|NCT03092310|Experimental|Artificial Pancreas|The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
89653977|NCT03405207|Active Comparator|active drug receiving group|the drug is vitamin D3 50000 UNT oral capsule prescribing under Holick's protocol, which is every week for 8 weeks then every month for long life
89653978|NCT03405207|Placebo Comparator|placebo receiving group|the same as active comparator unless the drug is the identical placebo oral capsule
89653979|NCT04198493|Experimental|Continuous Positive Airway Pressure(CPAP)|"Patients with CPAP treatment. Titration will be performed by polysomnography CPAP to determine the optimal treatment pressure.~This group will also be instructed in sleep hygiene and dietary counseling~Intervention:~Device: CPAP Other: Conservative treatment for OSA"
89653980|NCT04198493|Active Comparator|CONSERVATIVE TREATMENT for OSA|Sleep hygiene and dietary counseling. Sleep hygiene (regular sleep schedule, physical exercise) and dietary counseling Intervention: Other: Conservative treatment for OSA
89653981|NCT03402009|Experimental|Experimental|independent meditation using web-based tools, apps, and EEG neurofeedback
89653982|NCT03402009|Active Comparator|Active Control|independent meditation using web-based tools and apps
89653983|NCT04198259|Active Comparator|interventional devascularization|Interventional devascularization includes BRTO and similar procedure. Several variations of the technique exist, such as balloon-occluded antegrade transvenous obliteration or occlusion of the collateral by the placement of a vascular plug or coils.
89653984|NCT04198259|Experimental|Transjugular intrahepatic portosystemic shunt|TIPS is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein.
89653985|NCT03404817|Active Comparator|Sequence 1|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fed condition Period 2: EMB-001 new formulation under fasted conditions Period 3: EMB-001 original formulation under fed conditions"
89653986|NCT03404817|Active Comparator|Sequence 2|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 original formulation under fed conditions Period 2: EMB-001 new formulation under fed conditions Period 3: EMB-001 new formulation under fasted conditions"
89653987|NCT03404817|Active Comparator|Sequence 3|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fasted conditions Period 2: EMB-001 original formulation under fed conditions Period 3: EMB-001 new formulation under fed conditions"
89653988|NCT04197947|Experimental|PD patient who have FoG|
89653989|NCT03404583|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform
89653990|NCT03404583|No Intervention|Usual Care|Evidence-based care
89653991|NCT04375293|Experimental|AERD|Patients suffering from AERD
89653992|NCT04375293|Sham Comparator|Healthy|Healthy Controls
89653993|NCT04375293|Active Comparator|CRSwNP|Patients suffering from CRS with nasal polyps
89653994|NCT04375293|Active Comparator|CRSsNP|Patients suffering from CRS without nasal polyps
89653995|NCT05023356||Contact vital signs monitoring|Routine monitors with cables
89653996|NCT05023356||Non-contact vital signs monitoring|Camera
89653997|NCT04197323|Experimental|Alprostadil liposomes for injection|
89653998|NCT04197323|Active Comparator|KAISHI for injection|
89653999|NCT04374825|Experimental|Acceptance and Commitment Therapy (ACT)|Weekly video conference groups led by a trained facilitator introducing key concepts of ACT
89654000|NCT04374825|Active Comparator|Cognitive Behavioral Stress Management (CBSM)|Weekly video conference groups led by a trained facilitator introducing key concepts of CBSM
89654001|NCT04374825|No Intervention|Usual care|Patients' usual health care as received over the duration of the pilot trial
89654002|NCT04197245|Experimental|group on treatment|saline injection has been given intradermal in atrophic scars of acne on face.
89654003|NCT03404427|Sham Comparator|Normal sleep night|The first endurance test is the endurance motor control test after a normal sleep night.
89654004|NCT03404427|Experimental|Sleepless night|The first endurance test is the endurance motor test after a sleepless night.
89654005|NCT04196855|Experimental|Intervention - Teriparatide Treatment|Teriparatide 20ug/day from confirmation of stress fracture for 16 weeks, with the potential to extend to 24 weeks if required.
89654006|NCT04196855|No Intervention|Control - Standard Care|Standard rehabilitation care with additional monitoring to assess healing.
89654007|NCT03023579|Experimental|The star excursion balance test|The star excursion balance test: simple test for dynamic balance
89654008|NCT05022888|Active Comparator|myofascial pain syndrome|Patients diagnosed with myofascial pain syndrome Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
89654009|NCT05022888|Active Comparator|Healthy volunteers|Healthy volunteers Tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle
89654010|NCT03090438|Active Comparator|Varicocele embolization before IVF|Participants will have catheterization and embolization of varicoceles six months before beginning IVF
89654011|NCT03090438|No Intervention|IVF without varicocele embolization|Participants will proceed from enrollment directly to IVF
89654012|NCT04196621|Active Comparator|High viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, high viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
89213241|NCT01004055|Active Comparator|ACTICOAT™|
89213242|NCT01004055|Active Comparator|Mepilex® Ag|
89654013|NCT04196621|Active Comparator|Low viscous artificial tears|First, a native measurement at the IOL Master will be performed. Following which, low viscous artificial tears are installed and the biometry will be repeated within 30 seconds, as well as after 2 and 5 minutes
89654014|NCT04196309|Experimental|Tinzaparin group|LMWH (tinzaparin) for 1 month (at body-weight-adjusted therapeutic dose)
89654015|NCT04196309|No Intervention|Control group|No intervention
89654016|NCT03090126||Alveolar hypoventilation|
89654017|NCT03090360|Placebo Comparator|Placebo comparator (Control)|Starter infant formula with a probiotic and without a prebiotic. Volumes of feed depend on age, weight and appetite.
89654018|NCT03090360|Experimental|Experimental Formula (Test)|Starter infant formula with a probiotic and prebiotic. Volumes of feed depend on age, weight and appetite.
89654019|NCT03090360|No Intervention|Breastfed reference group|Breastfed reference group
89654020|NCT04196465|Experimental|Neoadjuvant IMC-001|Neoadjuvant immune check point inhibitor of IMC-001 in participants with resectable and localized gastric cancer, esophageal cancer, and hepatocellular carcinoma
89654021|NCT05027412|Experimental|En Bloc TURBT with Collins Loop|"If the patient is randomized to the TURB group, it will be carried out with a Collins loop, with bipolar energy.~After randomization, demographic data (age, sex, exposure to tobacco, occupational risk), symptoms prior to randomization (micro or macrohematuria, LUTS) and laboratory data (urinary cytology, hemoglobin and serum creatinine) will be collected. Finally, the physical characteristics of the lesion will be noted in the cystoscopy immediately prior to the intervention: size, location (s) and appearance of the tumor. After the intervention, the type of procedure (TURB / TUB), the duration of the procedure from when the resector is inserted until the urinary catheter is placed, and complications according to the Clavien-Dindo scale will be recorded. In your first post-surgical check-up, the days of hospital stay and the time of bladder catheterization will be collected."
89654022|NCT05027412|Active Comparator|Conventional TURBT|The TURB will be carried out with bipolar current according to the traditional technique.
89654023|NCT03090048|Experimental|Vitamin A|retinyl palmitate USP
89654024|NCT03090048|Experimental|Azithromycin with Vitamin A|USP grade ingredients
89654025|NCT03090048|Active Comparator|Azithromycin|azithromycin monohydrate
89654026|NCT04195997|Experimental|bivalurudin|Bivalirudin will be given as a bolus of 0.75 mg/kg once transseptal puncture is successully performed with no pericardial effusion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
89654027|NCT04195997|Active Comparator|heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
89654028|NCT05027334|Experimental|Interventional arm|Participants will be asked to use a designed mobile app to monitor their blood sugar levels
89654029|NCT04195841|Experimental|Test group|Two horizontal incisions placed 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles.
89654030|NCT04195841|Experimental|Control group|Sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth
89654031|NCT05023122|Experimental|vitamin D3 + calcium|vitamin D3 (cholecalciferol) 800 IU QD and calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
89213243|NCT03748511||fatty liver disease 0-1F|20 patients with uncomplicated liver disease, with fibrosis stage 0-1F.
89213244|NCT03748511||fatty liver disease 2F|20 patients with liver disease, fibrosis stage 2F.
89213245|NCT03748511||fatty liver disease 3-4F|20 patients with advanced liver disease, fibrosis stage 3-4F.
89654032|NCT05023122|Active Comparator|calcium only|only calcium citrate 600 mg QD, given from postoperative day 1 and lasted for 3 months
89654033|NCT05022966||Older people|
89654034|NCT04195373|Experimental|TMV-018 + 5-FC|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC.
89654035|NCT04195373|Experimental|TMV-018 + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with an anti-PD-1 Inhibitor.
89654036|NCT04195373|Experimental|TMV-018 + 5-FC + anti-PD-1 inhibitor|Patients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC and an anti-PD-1 Inhibitor.
89654037|NCT05022576|Experimental|PSMA PET/CT guided biopsy arm|Ga-68 PSMA PET/CT imaging is now routinely done in patients with prostate cancer with biochemical recurrence, response evaluation and even in patients with clinical suspicion of prostate cancer. In the present study, we aim to plan robotic arm-assisted Ga-68 PSMA guided transgluteal prostatic biopsies.
89213246|NCT00483652|Placebo Comparator|Placebo|Placebo control
89213247|NCT00483652|Active Comparator|Fampridine-SR|10 mg b.i.d.
89213248|NCT04000425||ctDNA detection|The blood samples for ctDNA and other tumor markers (such as CEA, et al.) will be first collected within 7 days before surgery, and then be tested after radical gastrectomy in scheduled interval.
89213249|NCT03742791|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
89213250|NCT03742791|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
89213251|NCT04245683||Operative Group|Patients who select operative treatment and follow up after successful neoadjuvant treatment.
89654038|NCT04195295|Experimental|periosteal membrane and egg shell graft|Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material and periosteal pedicle as barrier membrane.
89213252|NCT04245683||Non-operative Group|Patients who select non-operative follow up after successful neoadjuvant treatment
89213253|NCT00998283|Experimental|Cohort 1|Administration of HM10460A 5μg/kg or Placebo
89213254|NCT00998283|Experimental|Cohort 2|Administration of HM10460A 15μg/kg or placebo
89213255|NCT00998283|Experimental|Cohort 3|Administration of HM10460A 45μg/kg or placebo
89213256|NCT00998283|Experimental|Cohort 4|Administration of HM10460A 135μg/kg or placebo
89213257|NCT00998283|Experimental|Cohort 5|Administration of HM10460A 350μg/kg or placebo
89213258|NCT01014832|Experimental|Uncontrolled diabetes|Uncontrolled diabetes
89213259|NCT03996473|Experimental|Phase 1: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
89213260|NCT03996473|Experimental|Phase 2 Cohort 1: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
89213261|NCT03996473|Active Comparator|Phase 2 Cohort 1: Pembrolizumab alone|Participants will receive pembrolizumab every 3 weeks
89654039|NCT04195295|Experimental|only egg shell graft|Only Egg shell derived nano hydroxyapatite (EnHA) as graft material.
89213262|NCT03996473|Experimental|Phase 2 Cohort 2: Radium-223+Pembrolizumab|Participants will receive radium-223 dichloride every 6 weeks in combination with pembrolizumab every 3 weeks
89213263|NCT01004133||Subjects 80 years of age or older without chronic diseases.|
89213264|NCT04075565|Active Comparator|Simulated altitude|The participants are exposed to simulated altitude in a normobaric situation.
89654040|NCT04195295|Active Comparator|open flap debridement|open flap debridement procedure only.
89654041|NCT05022732|Placebo Comparator|Control formula|Excipients and gum arabic in tablet
89213265|NCT04075565|Experimental|Terrestrial altitude|The participants are exposed to terrestrial altitude in a hypobaric situation.
89213266|NCT04075565|No Intervention|Control|the participants are exposed to a normoxic and normobaric environment.
89654042|NCT05022732|Active Comparator|Experimental formula|Polyglucosamine L112 (750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients)
89654043|NCT04194983|Experimental|Fish oils and dairy fats|
89213267|NCT01004211|Active Comparator|Standard transurethral resection|Patients will be submitted to standard white light transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer
89213268|NCT01004211|Experimental|Narrow band imaging transurethral resection|The system will be switched to narrow band imaging by simply pushing a button. Transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer will be performed; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer.
89213269|NCT02580461|Experimental|Immediate Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the immediate exercise group. The immediate exercise group will receive a 12 week center based structured exercise program followed by a 12 week maintenance of exercise program.
89213270|NCT02580461|No Intervention|Delayed Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the delayed exercise group. This will be a wait list control group and the participants will receive no active intervention for 12 weeks. The wait list control group will then be enrolled in the 12 week structured exercise intervention.
89213271|NCT01004289|Active Comparator|Control|Primary angioplasty and stenting without additional intervention.
89213272|NCT01004289|Experimental|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion.
89213273|NCT03745079||Group 1|"Participants' temperature measured at 3 places at the same time~Esophagus~Skin near to temporal artery~Skin near to carotid artery"
89213274|NCT01000545|Placebo Comparator|placebo gelcaps + best medical treatment|Patient will receive 4 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
89654044|NCT04194983|Placebo Comparator|Fish oils and plant fats|
89654045|NCT03092232|Experimental|Cohort 1_Active and Matching Placebo|
89654046|NCT03092232|Experimental|Cohort 2_Active and Matching Placebo|
89654047|NCT03092232|Experimental|Cohort 3_Active and Matching Placebo|
89654048|NCT05022420||Salivary gland biospy,|100 Salivary gland biospy use for the diagnosis of sjogern disease or other auto-immune disease.
89654049|NCT05022420||muscular biopsy,|muscular biospy use for the diagnosis of muscular auto-immune disease.
89654050|NCT05022420||neuro muscular biospy|neuro muscular biospy use for the diagnosis of vasculitis,muscular auto-immune disease or neuro-muscumar auto-immune disease
89654051|NCT05022420||temporal arteries biospy|temporal arteries biospy uses for the diagnosis of giant cell arteritis
89654052|NCT04194749|Experimental|Digital Media Therapy|The digital media based group will receive a modified post immobilization protocol. This will include giving the patients a Universal Serial Bus (USB) drive loaded with a 12 week physical therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health & Science University website.
89654053|NCT04194749|Active Comparator|Traditional Therapy|The traditional group will have clinic-based physical therapy protocol.
89213275|NCT01000545|Active Comparator|SLX 500LRU/day + best medical treatment|Patient will receive 1 SLX gelcap and 3 placebo gelcaps twice a day.Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
89213276|NCT01000545|Active Comparator|SLX 1000LRU/day + best medical treatment|Patient will receive 2 SLX gelcaps and 2 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
89654054|NCT04406753|Experimental|Manual Therapy + Exercise Group|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
89654055|NCT04406753|Active Comparator|Exercise Group|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
89654056|NCT05017350|Experimental|Radiofrequency ablation group|hemostasis using radiofrequency ablation for track bleeding
89654057|NCT04194905|Experimental|Levonorgestrel Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
89654058|NCT04194905|Active Comparator|Levonorgestrel Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg. The tablets will be taken with water and in a fasting condition.
89654059|NCT05017428|Experimental|Low Dose|The Low Dose arm provides subjects with supplementation with 5mg of spermidine (in the form of 5g of a 0.1% spermidine wheat germ extract), 500mg of nicotinamide, 400mg of palmitoylethanolamide, and 200mg of oleoylethanolamide.
89654060|NCT05017428|Experimental|Medium Dose|The Medium Dose arm provides subjects with supplementation with 10mg of spermidine (in the form of 10g of a 0.1% spermidine wheat germ extract), 750mg of nicotinamide, 800mg of palmitoylethanolamide, and 400mg of oleoylethanolamide.
89654061|NCT05017428|Experimental|High Dose|The Low Dose arm provides subjects with supplementation with 15mg of spermidine (in the form of 15g of a 0.1% spermidine wheat germ extract), 1000mg of nicotinamide, 1200mg of palmitoylethanolamide, and 600mg of oleoylethanolamide.
89654062|NCT05017428|Placebo Comparator|Placebo|In this arm the participants are given supplementation with a placebo control consisting of 15g of wheat flour.
89654063|NCT04196231|Active Comparator|FR insulin/GLP-1RA|Patients in this arm will receive one of these fixed ratio combo of insulin and GLP-1RAs, according to the current clinical practice and the drugs' data sheet: IDegLira or IGlarLixi
89654064|NCT04196231|Active Comparator|Insulin/SGLT-2i|Patients in this arm will receive the basal insulin used before the randomization and one of these SGLT-2i according to the current clinical practice and the drugs' data sheet: canagliflozin, dapagliflozin or empagliflozin.
89654065|NCT04196231|Active Comparator|Basal Bolus|Patients in this arm will receive a basal insulin (glargine, glargine-300 or degludec) at bed-time plus 3 injections of a short-acting insulin analogue (aspart, lispro or glulisine) before meals
89654066|NCT00013611|No Intervention|Antiretroviral therapy alone|
89654067|NCT00013611|Experimental|Proleukin plus antiretroviral therapy|
89654068|NCT04194515||YH1 group|
89654069|NCT04194515||Metformin group|
89654070|NCT04194593||Glioma|FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma)
89654071|NCT03404349|Experimental|Mindfulness for Adolescence Course|Participants will attend mindfulness classes to include deep breathing, yoga, listening to music and meditation.
89654072|NCT03094182|Experimental|iron group|Patients in the iron group are given Intravenous iron isomaltoside during operation.
89654073|NCT03094182|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
89654074|NCT04194281|Experimental|Action Observation Therapy [AOT]|
89654075|NCT04374591|Other|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
89654076|NCT04374591|Placebo Comparator|Control|placebo
89654077|NCT04193813||POAF|
89654078|NCT04193813||Non POAF|
89654079|NCT03889067|Experimental|Combination of Challenge Agents|"Wild-Type Quailes Strain Salmonella Typhi: Quailes Typhoid toxin knock out strain in a 1:1 ratio at a dose of 1-5 x 10^4CFU~All participants will receive the same intervention in a given group for challenge (dose reduction may occur for later participants depending on the results from the first six participants)"
89654080|NCT04192877||Experimental|30 healthy subjects from both genders, aged between 18 and 60 years will be screened for neurological deficits. If neurological examination will be negative markers for motion capture, analysis will be placed on the chest and shoulders and a rubber band, with 3 markers, will be placed on the forehead. The subjects will be invited to lay on a medical table and heart rate (HR) will be assessed at rest. The vagus nerve neurodynamic test (VN-NDT) will be performed by an expert and a novice, in a random order, and under ultrasound imaging (USI). Assessors will be blinded to their results. Heart rate (HR) of the subjects will be monitored and a pain drawaing tools will be used to describe and locate the symptoms induced during the test administration.
89654081|NCT04406675|Other|Patients Amyotrophic Lateral Sclerosis|
89654082|NCT04406675|Other|Control subjects|
89654083|NCT05022030|Experimental|Arm A|mCapOX (capecitabine+oxaliplatin) plus cetuximab
89213277|NCT01000545|Active Comparator|SLX 2000LRU/day + best medical treatment|Patient will receive 4 SLX gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
89213278|NCT03992729||Tildrakizumab-Exposed Cohort|Exposure to tildrakizumab for the treatment of an approved indication
89213279|NCT03992729||Disease-Matched Comparison Cohort|No exposure to tildrakizumab at any time in the current pregnancy
89213280|NCT00483574|Experimental|Group 1: Menactra® and Routine Pediatric Vaccines|Participants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate [PCV], and hepatitis A [HepA]) at age 12 months.
89213281|NCT00483574|Other|Group 2: Routine Pediatric Vaccines|Participants received routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate[PCV], and hepatitis A [HepA]) at age 12 months.
89654084|NCT05022030|Active Comparator|Arm B|mFOLFOX6 (fluorouracil+leucovorin+oxaliplatin) plus cetuximab
89654085|NCT03092388|Experimental|Study Group Basic|Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
89654086|NCT03092388|Experimental|Study Group Extended|"Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.~Additionally, during daytime a special test with random parts of the study group basic is performed:~A tilting table with hemodynamic monitoring is used to induce an artificial LFS by moving patients from vertical into horizontal position. Bodyfluid changes are monitored by mfBIA during this procedure."
89654087|NCT04192643|Experimental|TRANEXAMİC ACİD|. 1 gr tranexamic acid in 100 ml salin given in 15 minutes
89654088|NCT04192643|Placebo Comparator|NO TRANEXAMİC ACİD|100 ml salin solution
89654089|NCT05022108|Experimental|Antihistamine test|The forearm was sensitized at four points (A, B, C and D). Point A: positive control sensitized with a drop of histamine at a concentration of 10 mg / Ml. Point B: histamine was applied and immediately after, the alpha bisabolol gel with a concentration of 0.5%. Point C: histamine and gel with 2.5% alpha-bisabolol were applied. Point D was sensitized with a drop of histamine and 5.0% alpha-bisabolol gel. The test reading at each point occurred 15 minutes after the procedure.
89654090|NCT05021952|Experimental|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
89654091|NCT05021952|No Intervention|Education brochure|Control group is provided general education through the hospital brochure.
89654092|NCT00010257|Experimental|Paclitaxel plus Carboplatin|Paclitaxel 225 mg/m2 IV over 3 hours and Carboplatin AUC 6.0 IV over 30 minutes on day 1 of a 21-day cycle
89654093|NCT04192565|Experimental|Robotic Endoluminal Resection|Robotic resection of mucosal lesions of the colon and rectum
89654094|NCT05021874|Active Comparator|Physiotherapeutic procedures: magnetotherapy|Magnetotherapy is a pulsating, non-homogeneous magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) will be applied using an elliptical applicator with a beam width of approx. 5 cm. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
89654095|NCT05021874|Active Comparator|Physiotherapeutic procedures:magneto-led therapy|Magneto-led therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) and LED diodes with the wavelength of 860 nm were applied using an elliptic magnetic-light (IR) applicator with a diameter of 5 [cm] containing 47 infrared diodes. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
89654096|NCT05021874|Active Comparator|Physiotherapeutic procedures:magneto-laser therapy|Magneto-laser therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med & Life, Poland) and a low-energy laser with infrared wavelength of 808 [nm] (max. power 300 mW) was applied. The dose was set to increase from 3,0 J/cm2 to 5,0 J/cm2 and the total dose applied per each patient from this subgroup was 40 J/cm2. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
89654097|NCT05021874|Active Comparator|Physiotherapeutic procedures: manual therapy of soft tissues|Manual therapy of soft tissues will include: post-isometric relaxation of the masseter, cellular and tissue mobilization with Kibler fold, masseter trigger point therapy. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
89213282|NCT01000623|Experimental|Arm I|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
89213283|NCT01000623|Active Comparator|Arm II|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
89213284|NCT01000623|Active Comparator|Arm III|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
89213285|NCT01000623|Active Comparator|Arm IV|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
89213286|NCT00998361|Experimental|Stem Cell Transplant|All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation
89213287|NCT00483184|Placebo Comparator|1|(placebo)0 IU IFNa
89213288|NCT00483184|Experimental|2|(Veldona)500 IU IFNα bid
89213289|NCT00483184|Experimental|3|(Veldona)1000 IU IFNα bid
89213290|NCT00998439|Experimental|Paclitaxel coated balloon catheter|
89213291|NCT00998439|Active Comparator|uncoated balloon catheter (POBA)|
89654098|NCT04192721|Experimental|Cognitive Behavioral Therapy-Based Group Counseling|The CBT-based group counseling provided to the intervention group was carried out as a group intervention with structured sessions in which various techniques and methods of CBT, having mainly educational content, were applied, including an experiential interaction process. The counseling was performed in a total of six 60- to 90-minute sessions, comprising one session per week for four groups consisting of six to 10 members each.
89654099|NCT04192721|No Intervention|Control group|No counseling was given to the control group during the study.
89654100|NCT05022186|Experimental|Group receiving Cannabidiol|These patients will receive cannabidiol 5% without other medication for cognition and depression
89654101|NCT05022186|Experimental|Group receiving Homotaurine|These patients will receive Vivimind (homotaurine) without other medication for memory and depression
89654102|NCT05022186|No Intervention|Control group|These patients will not receive treatment
89654103|NCT04191941|Experimental|Novel CAR-T|Novel CAR-T cells will be administered intravenously
89654104|NCT02240043|Other|growth hormone secretion|The elderly had common morbidities peculiar to their age, such as systemic arterial hypertension, diabetes mellitus, Parkinson's disease, initial stages of senile dementia, and osteoporosis.
89654105|NCT05016648||PEARS patients|Patients who underwent the personalized external aortic root support procedure at the AMC. Cerebral monitoring measurements (NIRS, EEG, TCD and blood pressure) are used for the study.
89654106|NCT03404037||Group I|Fifty-five coronary artery disease patients without type 2 DM
89654107|NCT03404037||Group II|Fifty-five coronary artery disease patients with type 2 DM
89654108|NCT03093792|Placebo Comparator|Control|(no diet or exercise intervention)
89654109|NCT03093792|Experimental|American Heart Association|(AHA: 55% carbohydrate, 15% protein, 30% fat - diet plus exercise)
89654110|NCT03093792|Active Comparator|Curves Complete - I|(CC - I: 30% carbohydrate, 45% protein, 25% fat - diet plus exercise)
89654111|NCT03093792|Active Comparator|Curves Complete - II|(CC - II: 20% carbohydrate, 45% protein, 35% fat - diet plus exercise)
89654112|NCT04191473|Experimental|group P|
89654113|NCT04191473|Other|group C|
89654114|NCT03403959|Experimental|SAD|Persons with visual impairment and SAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry during symptomatic winter phase and asymptomatic summer phase. Winter assessment is followed by a 6 week light therapy protocol ending with assessment of depression severity and repeated pupillometry.
89654115|NCT03403959|No Intervention|non-SAD|Control participants with similar visual impairment but without SAD/sSAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry in winter and summer.
89654116|NCT04191629|Experimental|50K to 200K cells|
89654117|NCT04191629|Experimental|50K to 200K cells with endothelial brushing|
89654118|NCT04191629|Experimental|500K cells|
89654119|NCT04191629|Experimental|500K cells with endothelial brushing|
89654120|NCT05016492|Experimental|Digital game group|The digital game group received the standard 4-week course of rehabilitation but with an additional 30-min interactive digital game training session per week.
89654121|NCT05016492|Active Comparator|Standard rehab group|The standard rehab group received the standard 4-week course of rehabilitation delivered in one 30-min session per week.
89654122|NCT02240199|Experimental|Pregabalin/Lidocaine|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Infusion
89654123|NCT02240199|Active Comparator|Pregabalin Placebo/Lidocaine|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Infusion
89654124|NCT02240199|Active Comparator|Pregabalin/Lidocaine Placebo|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Placebo Infusion
89654125|NCT02240199|Placebo Comparator|Pregabalin Placebo/Lidocaine Placebo|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Placebo Infusion
89654126|NCT05016414|No Intervention|Control|4 days of strict bed rest
89654127|NCT05016414|Experimental|Lower body negative pressure|4 days of strict bed rest with nightly lower body negative pressure at -20mmHg
89654128|NCT04377477|Experimental|Lung low dose radiotherapy|Irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
89654129|NCT05016102|Other|Control condition|30 min to watching exercise-related video
89654130|NCT05016102|Other|Aerobic exercise condition|20 minutes of moderate-intensity exercise on treadmill
89654131|NCT05016102|Other|Resistance exercise condition|One set of 15 repetition 9 muscle exercises dumbbell squat with chair, dumbbell right/left foot lunge, sit-up, push-up, back muscle with superman, dumbbell right/left bicep curl, dumbbell calf raise.
89654132|NCT04190927|Experimental|Treatment|All patients will be symptomatic peri or post menopausal and will all be started on the same protocol. The Dosing schedule of topical estradiol and topical progesterone will be modified for each subject in the first three months to address individual symptoms. The dosing will be relatively unique to each patient. Patients will remain on their dosing schedule for the remainder of the three year study and will be assessed during at the end of the study for changes in mood, symptoms of menopause, breast health, BMD and thickness of uterine lining .
89654133|NCT00919191|Experimental|Two interventions in split-face model|"Once daily use in a split face model:~Tretinoin gel~Adapalene Benzoyl peroxide"
89654134|NCT05016336|Experimental|strategy-based cognitive training + social interaction|The experimental group received twelve 60 minutes sessions of strategy-based cognitive training. (i.e., training in mnemonic memory strategies). We chose to train multiple strategies instead of a single one in effort to reach larger training gains. each session began with engaging conversations between the researcher and participants. After each practice trial, participants were encouraged to share their ideas/stories/associations or visual images (mnemonic uses) in turn. All other participants were allowed to give feedback relating to what can be learned from each mnemonic use or give their own ideas on how they think it can be improved.
89654135|NCT05016336|Active Comparator|social interaction|The social interaction control group received the same number of group meetings but without the strategy training. Meetings content consisted of providing tools for making social connections, providing tools for interpersonal communication and raising the participant's sense of personal well-being through group contact.
89046354|NCT02309840|Experimental|Chef and choice architecture|"Students were exposed to both chef-enhanced meals and modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
89046355|NCT02162420|Experimental|Treatment Plan for Dyskeratosis Congenita|Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, and total body irradiation, followed by stem cell transplant for the treatment of dyskeratosis congenita.
89046356|NCT02162420|Experimental|Treatment for Severe Aplastic Anemia|Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
89654136|NCT05021406|Experimental|Carvedilol+ NUCs therapy|Patients randomized to Carvedilol combined with NUCs group during the previous 2-year treatment of RCT study; Patients showed the progression of esophageal varices in NUCs group during the 2-year treatment of RCT study. Based on nucleoside analogue (NUCs), carvedilol will be added to the patients. Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
89654137|NCT05021406|No Intervention|NUCs therapy|Continuing take single or combined nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
89654138|NCT03403881|Active Comparator|Physical activity promotion + TAU|"Physical activity promotion based on:~Pedometers use;~Weekly contact (telephone or face-to-face);~Contact based on a self-determination theory.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
89654139|NCT03403881|Placebo Comparator|Control|"Weekly calls with general health content.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
89654140|NCT04766177|Experimental|bumetanide group|Bumetanide a dose of 0.5 mg twice per day
89654141|NCT04766177|Placebo Comparator|Placebo|Placebo twice daily
89654142|NCT05021796||Nurses|"Including criteria: (1) registered nurses, (2) nurses undergoing a training for asthma telecounseling, (3) age 21 or more.~Excluding criteria: (1) nurses with previous training for asthma counseling, (2) nurses who do not take care of patients with asthma, (3) Pregnant women"
89654143|NCT04191083|Experimental|Motor Imagery|
89654144|NCT04191083|Experimental|Double Time Motor Imagery|
89654145|NCT04191083|Experimental|Action observation|
89654146|NCT04191083|Placebo Comparator|Placebo group|
89654147|NCT05021718|Experimental|Intervention group (IG)|A total of 35 patients in IG received different back and hip strengthening exercises five times a week for six weeks. They were also instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
89654148|NCT05021718|Active Comparator|Control group (CG)|The remaining 35 patients were allocated to CG. The patients in CG were treated with Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks, followed by hot moist compression for the next three weeks. Moreover, they were instructed to follow the ADLIs to perform different tasks at home and in workplaces during the intervention and at least 3 months after the intervention.
89654149|NCT04191239||PRVC|Preterm infants with need of mechanical ventilation will receive PRVC mode until extubation
89654150|NCT04191239||Bilevel VG|Preterm infants with need of mechanical ventilation will receive Bilevel VG mode until extubation
89654151|NCT04466280|Active Comparator|Control Group|Participants in this group use personal protective equipment in the face of patients with COVID-19
89654152|NCT04466280|Experimental|Intervention Group 1|In this group, participants will receive 200 mg of hydroxychloroquine tablets daily in addition to personal protective equipment.
89654153|NCT04466280|Experimental|Intervention Group 2|In this group, participants, while observing and using complete personal protective equipment, will apply a thin layer of Dentol gel to the vestibular area of the mouth daily, every 6 to 8 hours.
89654154|NCT04190771|Experimental|TAU + multicomponent treatment NAT-FM|NAT-FM is a multicomponent non-pharmacological program based on mindfulness ingredients, pain neuroscience education, and nature exposure. NAT-FM is conceived as an add-on therapy.
89654155|NCT04190771|Active Comparator|Treatment as Usual (TAU)|Standard Care. Although there is no treatment considered as the gold standard for fibromyalgia, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.
89654156|NCT05016180|Placebo Comparator|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
89654157|NCT05016180|Experimental|Ropivacaine|Before the induction of anesthesia, Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
89654158|NCT03023501|Experimental|Gabapentin|Gabapentin 1200mg capsule was administered orally 2 hours before surgery
89654159|NCT03023501|Placebo Comparator|Placebo|Placebo capsule was prepared by hospital pharmacy and was administered orally 2 hours before surgery.
89046357|NCT02040376|Experimental|Group A (Crossover Group 1)|Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.
89046358|NCT02040376|Experimental|Group B (Crossover Group 2)|Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.
89046359|NCT01944761|Experimental|Exercise Training|The 16 participants in this group will be quasi-randomized based on the order of recruitment to start the 12 week exercise intervention without delay (immediate condition).
89046360|NCT01944761|Experimental|Delayed Exercise Training|The 16 participants in this group will be quasi-randomized based on the order of recruitment to start the 12 week exercise intervention after a 12 week no exercise training period (delayed condition).
89213292|NCT01000779|Active Comparator|Endoscopic Variceal Ligation|endoscopic therapy to obliterate varices
89213293|NCT01000779|Active Comparator|Propranolol|drugs to decrease portal pressure
89654160|NCT03094104|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
89654161|NCT03094104|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
89654162|NCT04190459||LSG|laparoscopic sleeve gastrectomy
89654163|NCT04190459||LRYGB|laparoscopic Roux-en-Y gastric bypass
89654164|NCT05021016|Experimental|"Group 1: Vaccine"|150 volunteers who will be vaccinated with the EpiVacCorona vaccine with two doses spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89654165|NCT04190069|No Intervention|OPTIFAST only|Control group will consist of participants that have not undergone behavioral modifications with the Prescription for Wellness Program. These are participants that only go through the OPTIFAST Program.
89654166|NCT04190069|Experimental|UPMC PFW followed by OPTIFAST|The intervention group will consist of participants that have undergone behavioral modifications with the Prescription for Wellness Program. These are participants who undergo the Prescription for Wellness Program prior to the OPTIFAST Program.
89654167|NCT02155725|Experimental|Human Fibrinogen concentrate|2 vials (200ml) / 3g intravenous
89654168|NCT02155725|Placebo Comparator|Placebo|2 vials (200ml)
89654169|NCT03093948|Experimental|Remote Ischemic post-conditioning|
89654170|NCT03093948|No Intervention|standard of care|
89654171|NCT05009472|Experimental|Cleft Lip and Palate Patient|Cleft patient with transverse maxillary constriction and anteroposterior deficiency
89654172|NCT05015946|Experimental|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
89654173|NCT04193423|Experimental|A-Group: craniocervical and cervicothoracic extension training|
89654174|NCT04193423|Experimental|B-Group: craniocervical flexion training|
89654175|NCT04193423|Active Comparator|C-Group: control group|No intervention will be performed due to the fact that they will be still on the waiting list.
89654176|NCT05015790|Experimental|use of virtual reality Bliss Solution|in the experimental arm the patient will receive the usual practice associated with a virtual reality session (20 minutes renewable) in a world chosen with the patient beforehand
89654177|NCT05015790|No Intervention|current practice, without Bliss Solution|patient will receive the usual practice, local anesthesia
89654178|NCT05015322|Active Comparator|subacromial injection|ultrasound (US)-guided subacromial injection
89654179|NCT05015322|Active Comparator|acromioclavicular joint and subacromial injection|ultrasound (US)-guided acromioclavicular joint and subacromial injection
89654180|NCT05015322|Active Comparator|suprascapular nerve block|ultrasound (US)-guided suprascapular nerve block
89654181|NCT03087240|Experimental|Test|Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)
89654182|NCT03087240|Other|Control|Wait & Control Study Design: Dental Prophylaxis after 3 months (T2) only
89654183|NCT00919503|Experimental|Regimen A (PBSCT and BMT)|"CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
89654184|NCT00919503|Experimental|Regimen B (UBCT)|"CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD."
89654185|NCT03091998|Active Comparator|Study Drug (CD-NP)|Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
89654186|NCT03091998|Placebo Comparator|Placebo (saline)|Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running
89654187|NCT03957941|Experimental|FamilyLink Pumping|Pump three times while away from infant, while watching baby via FamilyLink.
89654188|NCT03957941|Active Comparator|Standard Pumping|Pump three times while away from infant, not watching baby via FamilyLink.
89654189|NCT05020704|Experimental|empagliflozin|empagliflozin 10mg once daily
89654190|NCT05020704|Placebo Comparator|Placebo|matched placebo
89654191|NCT05020548|Active Comparator|pressure 10|mask ventilation with peak inspiratory pressure of 10 cmH2O
89654192|NCT05020548|Active Comparator|pressure 15|mask ventilation with peak inspiratory pressure of 15 cmH2O
89654193|NCT05020548|Active Comparator|pressure 20|mask ventilation with peak inspiratory pressure of 20 cmH2O
89654194|NCT02979665||Ranibizumab Ophthalmic|DME consults requiring anti-VEGF treatment
89654195|NCT02979665||Control|DME consults not requiring anti-VEGF
89654196|NCT03092076|Experimental|Pharmacokinetics|The pharmacokinetics characteristic of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
89654197|NCT03092076|Experimental|Antiplatelet effects|The antiplatelet effects of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
89654198|NCT03092076|No Intervention|The impact of genotype|The recovery time of platelet function following the administration of ticagrelor is widely varied that genetic variants maybe an underlying factor.The impact of genotype on pharmacokinetic parameters and ADP of ticagrelor is compared among different genotypes.
89654199|NCT04374435|Experimental|MKTP with Surgical Blade|The investigator harvested skin from the donor site and skin from the recipient site using a surgical blade in the first arm of the study.
89654200|NCT04374435|Experimental|MKTP with Negative Pressure Instrument|Blister grafting technique with dissociation of the cells was performed in the second arm of the study.
89213294|NCT00998595|Experimental|Promotora|This group receives additional education and proactive follow-up by removing barriers to already existing services and reminders by a lay community health workers (Promotora)
89213295|NCT00998595|No Intervention|Standard of Care|These subjects receive the routine standard of postpartum care
89213296|NCT04075643|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug"
89213297|NCT04075643|Experimental|Group 2|"Period 1: Test drug~Period 2: Reference drug"
89213298|NCT01000857|Experimental|Open label treatment with 2-period crossover design|"Group 1: Paroxetine CR 25 mg/day for 14 days / Paroxetine IR 20 mg/day for 14 days.~Group 2: Paroxetine IR 20 mg/day for 14 days / Paroxetine CR 25 mg/day for 14 days.,~PK results will be compared between the Paroxetine CR treatment period and the Paroxetine IR treatment period."
89654201|NCT04374435|Experimental|Suction blister grafting without cell dissociation|In this arm, transplanting the blisters without dissociation of the cells will be conducted.
89654202|NCT04193501|Experimental|Experimental arms|Melatonin dose: 3mg/OD
89654203|NCT04193501|Placebo Comparator|Control arms|Placebo
89654204|NCT04374279|Active Comparator|Standard of care and bicalutamide|Randomized participants receive bicalutamide 150mg oral for 7 days, plus standard of care
89654205|NCT04374279|No Intervention|Standard of care only|Randomized participants receive standard of care only.
89654206|NCT03086694||group surgery|using medications to maintain low stable blood pressure
89654207|NCT02240433|Experimental|LY2157299 + Sorafenib|LY2157299 will be administered orally twice daily for 14 days, followed by 14 days with no study drug per 28-day cycle. Sorafenib will be administered orally twice daily for 28 days, in each cycle.
89654208|NCT05009550|Active Comparator|Erector spinae plane block group (ESP)|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group. Then standard sedation method is applied to all patients.
89654209|NCT05009550|Other|Control Group|This Group was received no intervention.Standard sedation method is applied to all patients.
89654210|NCT03403647|Experimental|Vitamin D deficient|Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
89654211|NCT03403647|No Intervention|No vitamin D deficiency|Regular and routine monitoring
89654212|NCT04193267|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
89654213|NCT02240511|Active Comparator|Resistance Exercise|"Resistance Exercise (RE) therapy was divided in four parts: stretching: arms, hands, wrists, legs, knees and ankles, each one for 10 - 20 seconds with resting intervals of 5 seconds (4 series), warming and flexion: the same muscle groups, making small circles forward and backward for 5 - 10 seconds with resting intervals of 5 seconds (4 series), resistance exercises: flexion, contractions and twisting of the same muscle groups worked in the two previous sections. In this part resistance was increased with the aid of dumbbells (500 g - 1500 g), barbells and bands, and patients performed the same exercises with 15 - 20 repetitions with resting intervals of 10 seconds. (4 series), relaxation: involved the same exercises as stretching to rest all muscle groups worked."
89654214|NCT02240511|Experimental|RE and BCAA Supplementation|"RE: Resistance Exercise Resistance Exercise therapy was the same as in the Active Comparator~Branched Chain Aminoacids Amino 2000 BCAA (PRONAT® laboratory) supplementation group received 180 packets of 5 grams (g)and ingested 10 g/day (5 g after breakfast and 5 g before RE)"
89654215|NCT04021199|Active Comparator|T1D Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
89654216|NCT04021199|Experimental|MODY Group|"Retrospective analysis of data from active and historical diabetic patients within diabetes care conventions of pediatric endocrinology services; screening of patients with atypical diabetes; use of tests used in clinical routine to allow referral to the genetic diagnosis of the condition.~Prospective analysis of the evolution of new diabetic patients followed in pediatric endocrinology services of diabetes care conventions; screening of patients with atypical diabetes; use of tests used in clinical routine to allow the genetic diagnosis of the condition.~Screening of patients with atypical diabetes: first evaluated according to the MODY probability calculator. In addition, other clinical criteria will be used to improve the sensitivity and specificity of pediatric monogenic diabetes screening."
89654217|NCT02240355|Experimental|Part 1|Up to 2 cohorts of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
89654218|NCT02240355|Experimental|Part 2|1 cohort of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
89654219|NCT02240355|Experimental|Part 3|1 cohort of patients, within each cohort patients will receive RO6885247 once daily for 12 weeks or 20 weeks
89654220|NCT03403335|Experimental|Mindfulness Based Practices for Health Care Professionals|
89654221|NCT03403335|No Intervention|Control Group|
89654222|NCT05014308|Experimental|piezocision group|piezocision surgical procedure was done according to Dibart's et al,
89654223|NCT05014308|Experimental|fiberotomy group|the fiberotomy procedure followed Edward's et al
89654224|NCT05014308|No Intervention|control group|no intervention
89654225|NCT04024475||A: Opportunistic screening & benign prostate syndrome (BPS)|Asymptomatic men offered screening (PSA testing) with prostate biopsy (A1). Or patients with lower urinary tract symptoms from benign prostatic hyperplasia undergoing: no treatment (A2), medical therapy (A3), or transurethral resection of the prostate (A4)
89654226|NCT04024475||B: Localized/locally advanced PCa with curative intent|B0: Patients under active surveillance (B0, closed group); B1: radical prostatectomy (RP) or RP followed by (adjuvant) external beam radiation; B2: external beam radiation therapy (EBRT) without androgen deprivation therapy (ADT); B3: external beam radiation therapy with ADT
89654227|NCT04024475||C: Biochemical relapse|Patients with PSA progression after RP with or without systemic therapy
89654228|NCT04024475||D: Metastatic PCa but hormone sensitive|Metastatic PCa without curative treatment but hormone sensitive disease, treated with ADT (medical or surgical), with or without additive treatments. Oligometastatic PCa.
89654229|NCT04024475||E: Metastatic castration resistant prostate cancer (mCRPC)|Metastatic castration resistant prostate cancer (mCRPC). Oligometastatic PCa.
89213299|NCT01004445|Experimental|Arm 1|
89213300|NCT01004445|Experimental|Arm 2|
89213301|NCT01004445|Placebo Comparator|Arm 3|
89213302|NCT02580695|Experimental|Umbilical-cord mesenchymal stromal cells|"Umbilical-cord mesenchymal stromal cells (UC-MSCs)~Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB~Arm 2a: single infusion group. UC-MSCs at 0 month~Arm 2b: double infusion group. UC-MSCs at 0 and 6 months"
89213303|NCT02580695|Active Comparator|Hyaluronic Acid (HA)|Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months
89213304|NCT04075019|Experimental|full intervention|students assigned to intervention classrooms in grades 1 through 4 and who remained in schools assigned to the intervention condition in grades 5 or 6
89213305|NCT04075019|Experimental|late intervention|students in intervention classrooms in grades 5 and 6 only
89213306|NCT04075019|Experimental|parent-training only|students whose parents were offered parent training only when their children were in grades 5 and 6 and no other intervention
89213307|NCT04075019|No Intervention|control|students in schools assigned to receive no intervention in grades 5 and 6 and who were not in intervention classrooms in grades 1 through 4
89213308|NCT03672929|No Intervention|Full cohort|Prospective non Controlled to Document long term performance of Allofit IT Shell in combination with the Longevity® Liner when used in primary total hip arthroplasty.
89654230|NCT03403179|Experimental|Receiving Psychosocial Intervention|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
89654231|NCT03403101|Experimental|SIRIOX regimen|5-FU and leucovorin in the FOLFIRINOX regimen were replaced with oral S-1, forming the SIRIOX regimen(S1 plus irinotecan and oxaliplatin)
89654232|NCT05014386|Active Comparator|Ahmed Glaucoma Valve Implantation|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
89654233|NCT05014386|Active Comparator|Ologen augmentation group|In addition to what is planned for the other Arm;, a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure.
89654234|NCT04374201||2 zirconia FDPs|11 patients received 2 zirconia fixed dental prostheses
89654235|NCT04374201||1 zirconia FDP|26 patients received 1 zirconia FDP
89654236|NCT00211757|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.
89654237|NCT00211757|Experimental|Divalproex Sodium|Subjects will receive the study drug, divalproex sodium.
89654238|NCT03091842|Experimental|Group I (CARE program)|Patients undergo supervised CARE program over 50 minutes comprising of warm up over 5 minutes, moderate to vigorous aerobic and resistance exercises over 40 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
89654239|NCT03091842|Experimental|Group II (TARE program)|Patients undergo supervised TARE program over 80 minutes comprising of warm up over 5 minutes, aerobic exercise over 15 minutes, resistance exercise over 55 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
89654240|NCT03091842|Active Comparator|Group III (home-based stretching program)|Patients undergo home-based stretching program comprising of one set of 3-4 static stretching exercises held for 30 seconds 3 days per week for 16 weeks. Patients receive instructional DVD and booklet of the flexibility exercises. Patients also complete a weekly activity log. After completion of the stretching program, patients may optionally undergo the CARE program as in group I.
89654241|NCT04374045||Patients with SARS-CoV-2|patients having a continuous recording of the heart rhythm during their hospitalization
89654242|NCT04960644|Experimental|MTX and corticosteroid|perimental: MTX and corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response MTX (5-6mg/m^2/day,Maximum dose 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
89654243|NCT04960644|Active Comparator|corticosteroid|perimental: corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then gradually reduce the dose according to patient's response
89654244|NCT02245113|Experimental|Test Fat P|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
89654245|NCT02245113|Experimental|Test Fat Q|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
89654246|NCT02245113|Experimental|Test Fat R|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
89654247|NCT04373967|Experimental|TQZ2451+metformin hydrochloride|TQZ2451 injection (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
89213309|NCT03672929|Other|Subgroup RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years and will only be conducted on 40 patients.
89213310|NCT02581553|Experimental|Sequence AB|Day 1: lesinurad/allopurinol FDC tablets (Treatment A); Day 8: lesinurad + allopurinol (Treatment B)
89654248|NCT04373967|Active Comparator|Victoza®+metformin hydrochloride|Victoza® (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)
88993824|NCT03660449|Experimental|Experiment|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
89213311|NCT02581553|Experimental|Sequence BA|Day 1: lesinurad + allopurinol (Treatment B); Day 8: lesinurad/allopurinol FDC tablets (Treatment A).
89654249|NCT03091530|Experimental|Sleeper Stretch THEN Balloon Blow|Sleeper Stretch CROSSOVER TO 90/90 Hip Lift with Balloon Blow Exercise
89654250|NCT03091530|Experimental|Balloon Blow THEN Sleeper Stretch|90/90 Hip Lift with Balloon Blow Exercise CROSSOVER TO Sleeper Stretch
89654251|NCT04026191|Other|Orthovisc-T|
89654252|NCT04373499|Experimental|Virtual Teach-to-Goal (V-TTG)|"The RA will show the patient how to use the tablet to access the education module and be available for questions about the technology / tablet but not about the content. Within the module, the child will:~answer questions about how to use the inhaler as part of a pre-video assessment.~watch a video about how to correctly use a Metered Dose Inhaler (MDI) and spacer.~answer questions on the tablet to assess how well they understand how to use the inhaler.~If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions."
89654253|NCT04373499|Active Comparator|Brief Intervention (BI)|The RA will give the patient a handout about inhaler technique and read the steps to the child.
89654254|NCT03091608||The individuals taking XLGB Granule|The overall individuals taking XLGB Granule with recommended dosage and achieving the inclusion criteria.
89654255|NCT03023267|Experimental|Interventional|Applying music therapy with kangaroo care to mothers and fathers during their NICU hospitalization
89654256|NCT03023267|Active Comparator|Control|Applying only Kangaroo care to mothers and fathers during their stay in the NICU
89654257|NCT02240979||Adults able to undergo cardiac MRI exam|Adults able to undergo cardiac MRI
89654258|NCT03091686|Experimental|Experimental Group (HAPA SB)|"Experimental (same outcome questionnaire but with informational slideshow focusing on sedentary behaviour and diabetes risk)~HAPA SB Intervention Slideshow"
89654259|NCT03091686|Active Comparator|Attention-Control Group (HAPA MVPA)|"Attention-Control (same outcome questionnaire but with slideshow focusing on benefits of moderate-vigorous physical activity)~HAPA MVPA Intervention Slideshow"
89654260|NCT03091686|No Intervention|Control Group|"Control (outcome questionnaire without any slideshow)~Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaire."
89654261|NCT03955757|Experimental|Boot Camp Translation|Intervention communities will undergo the Boot Camp Translation process.
89654262|NCT03955757|Active Comparator|Control|Control communities will behave as usual
89654263|NCT02241057|Experimental|Temperature|Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear
89654264|NCT02241057|Experimental|Adhesion|Evaluate the adhesion with and without the presence of a temperature probe
89654265|NCT05019768|Active Comparator|sCXL|Standard protocol of Dresden Riboflavin-VEPTGS solution applied every 2 mins during UV UVA fluence of 3mW/cm2 UVA Irradiation time 30 minutes
89654266|NCT05019768|Experimental|aCFXL|"Accelerated custom fast CXL protocol. The protocol has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin con-sumption rate and the corneal thickness at its thinnest point.~Riboflavin-VEPTGS solution: Epithelial lavage before UV UVA fluence of 1.8 ±0.9 mW/cm2 UVA Irradiation time 10 ± 1.5 minutes"
89654267|NCT00921687|Experimental|Multifactorial intervention|The multifactorial intervention will consist of a CKD lecture, the CKD reference card, academic detailing, and access to the CKD registry.
89654268|NCT00921687|Active Comparator|Education only|Providers in the education only arm will receive a CKD lecture and be given a CKD reference card.
89654269|NCT04022057|Active Comparator|Pre-GA|10 mL of 1% ropivacaine injection before the start of surgery and 10 ml of 5% dextrose injection at the end of surgery through both the popliteal and the saphenous catheter
89654270|NCT04022057|Sham Comparator|Post-GA|10 mL of 5% dextrose injection before the start of surgery and 10 ml of 1% ropivacaine injection at the end of surgery through both the popliteal and the saphenous catheter
89654271|NCT03091296||Men with testosterone deficiency|Screening testosterone concentration of less than 350 ng/dL
89654272|NCT03091296||Men without testosterone deficiency|Screening testosterone concentration of greater than 350 ng/dL
89654273|NCT04029701|Experimental|Research group|"Subjects who are recruited into this group are asked to take the Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.~P.S. Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
89654274|NCT04029701|Placebo Comparator|Control group|"Subjects who are recruited into this group are asked to take the placebo of Ruyizhenbao Pill on the basis of routine internal medicine and rehabilitation treatment.~P.S. Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row."
89654275|NCT03091218||The individuals taking RZZY Capsule|The overall individuals taking RZZY Capsule with recommended dosage and achieving the inclusion criteria.
89654276|NCT03402867|Experimental|Intervention|Deep dry needling applied on active myofascial trigger points in the shoulder and neck regions
89654277|NCT04029935|Experimental|Physical Fatigue Condition|
89654278|NCT04029935|Placebo Comparator|Control Condition|
89654279|NCT03091140||Group A|patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention
89654280|NCT03091140||Group B|patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.
89654281|NCT03091140||Group C|patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.
88993825|NCT02946307|Experimental|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter>2.00 mm） in small vessel cohort
89213312|NCT02581553|Experimental|Sequence CD|Day 1: lesinurad/allopurinol FDC tablets (Treatment C [fasted]); Day 8: lesinurad/allopurinol FDC tablets (Treatment D [fed]).
89654282|NCT03091140||Group D|healthy subjects. This group will be considered as control group.
89046361|NCT01850888|Experimental|131 I-MIBG Treatment Arm|Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
89046362|NCT01785316|Experimental|IHP|Isolated Hepatic Perfusion
89046363|NCT01785316|No Intervention|BAC|Best alternative care
89046364|NCT01776398||1.1 HEALTHY SUBJECTS|Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.
89046365|NCT01776398||1.2 SUBJECTS WITH LUNG DISEASE|Defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population)
89046366|NCT01776398||2. WCMC/NYPH CLINICAL PATIENTS|"Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit.~WCMC/NYPH clinical patients will not undergo any additional procedures listed in this protocol as part of this research study."
89046367|NCT01776398||3. PCNY CLINICAL PATIENTS|Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit. Clinical patients seen at the Pulmonary Consultants of New York will only undergo the nasal sample collection and may be asked to have a blood draw of about 2 teaspoons (9ml).
89046368|NCT01663142||Patients who receive surgical resection for intestinal in CD|
89654283|NCT03402711||Bleeding Risk in Chinese ACS II|1.This is an observational study，there is no intervention to be administered. 2.5500 ACS patients who meet the inclusion criteria for PCI treatment will be consecutively enrolled according to random number sampling.
89654284|NCT03091062|Experimental|Study Group|Study subjects will serve as their own control and all will receive treatment with two different Airway Clearance Systems- the Vest® Airway Clearance System and the Monarch™ System. Subjects will be randomized to which treatment is received first.
89654285|NCT04376463|Experimental|Mood state and aminoacids supplementation|The aim of this study was to analyse the isolated and combined effects of BCAA supplementation and exercise on physical frailty status and mood states in pre-frail institutionalized older women.
89654286|NCT04376463|Experimental|Physical Tests|Through the combination of bcaa supplementation and physical exercise is able to improve the functional capacity of the elderly, through the SPPB test battery, short performance physical battery.
89654287|NCT04376463|Experimental|Psychometrics evaluated|Through the combination of bcaa supplementation and physical exercise, it is able to improve moods and cognition of the elderly.
89654288|NCT04376463|Experimental|Fried Scale Phenotype|Primary outcomes include Physical Frailty evaluated according to Fried's Frailty Phenotype2): Shrinking assessed by self-report of unintentional weight loss of four kilograms or more in the last six months; Self-reported exhaustion evaluated by concordance of two questions (7 and 20) of the Center for Epidemiology-Depression (CES-D) scale; Weakness analyzed using the handgrip strength test; Slowness measured by the 4.6 meters walking test; levels of Physical Activity assessed by the (IPAQ).
89654289|NCT04029779|Experimental|Immediate implant placement coated with I-PRF|The test group received implants coated with injectable platelet-rich fibrin and also the sockets were injected with injectable- platelet rich fibrin
89654290|NCT04029779|No Intervention|immediate implant only|The control group received immediate dental implants only after extraction of the teeth without any local coating.
89654291|NCT04373187|Experimental|CC-93538, 180mg/mL|26 healthy subjects will receive one injection of 2mL, 180mg/mL CC-93538
89654292|NCT04373187|Experimental|CC-93538, 150mg/mL|26 healthy subjects will receive 2 injections of 1.2mL, 150mg/mL CC-93538
89654293|NCT02639052|Experimental|Botox|10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
89654294|NCT02639052|Placebo Comparator|Saline|Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
89654295|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Conservational|After ESWT therapy patients suffer from extreme pain will recieve only conservational therapy (26 patients)
89654296|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Local|After ESWT therapy patients suffer from extreme pain will receive local steroid injections
89654297|NCT04029389|Experimental|Recalcitrant Plantar Fasciitis/Tibial nerve|After ESWT therapy patients suffer from extreme pain will receive tibial nerve block
89046369|NCT01652092|Other|Arm A: Fully Myeloablative regimen|For use in patients with diseases including Wiskott-Aldrich syndrome, MHC Class II deficiency, hypomorphic SCID, etc. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, cyclophosphamide 50 mg/kg IV plus MESNA on days -9 through -6, busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2 and stem cell infusion on day 0.
89046370|NCT01652092|Other|Arm B: Reduced Toxicity Ablative Regimen|For use in patients with diseases including SCID, CGD, CHS and other CID. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6, fludarabine phosphate 40 mg/m^2 IV on days -5 through -2 and stem cell infusion on day 0.
89213313|NCT02581553|Experimental|Sequence DC|Day 1: lesinurad/allopurinol FDC tablets (Treatment D [fed]); Day 8: lesinurad/allopurinol FDC tablets (Treatment C [fasted]).
89654298|NCT00921843|Experimental|Methadone 0.1mg/kg|Methadone 0.1mg/kg
89654299|NCT00921843|Experimental|Methadone 0.2mg/kg|Methadone 0.2mg/kg
89654300|NCT00921843|Experimental|Methadone 0.3mg/kg|Methadone 0.3mg/kg
89654301|NCT00921843|Placebo Comparator|Control|No methadone
89654302|NCT04020653|Placebo Comparator|Placebo + ACT|Patients will receive placebo for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.
89654303|NCT04020653|Experimental|5 ALA/SFC+placebo+ACT BID|"5-ALA HCl 300 mg and SFC 236 mg will be administered BID for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3.~Patients will receive 5-ALA HCl+Placebo and SFC+Placebo at odd number of study medication dosing (Dose 1, 3, 5, 7, 9, 11, 13) and only 5-ALA HCl and SFC at even numbers of study medication dosing (Dose 2, 4, 6, 8, 10,12, 14)."
89046371|NCT01652092|Other|Arm C: Reduced Intensity Conditioning|For use in patients with diseases including HLH. Receives Alemtuzumab 0.2 mg/kg intravenously (IV) on days -14 through -10, fludarabine phosphate 30 mg/m^2 IV on days -8 through -4, melphalan 140 mg/m^2 IV on day -3 and stem cell infusion on day 0.
89046372|NCT01652092|Other|Arm D: No Preparative Regimen|For use in patients with complete SCID phenotype with no evidence of maternal engraftment or residual immune function who will be receiving their stem cell transplantation from a genotypically matched donor.
89046373|NCT01566695|Experimental|Oral Azacitidine|Arm 1: Oral azacitidine tablets 300 mg daily (QD) + best supportive care (BSC) on days 1 through 21 of each 28-day treatment cycle.
89046374|NCT01566695|Placebo Comparator|Placebo|Arm 2: Identically matching placebo tablets plus best supportive care on days 1 to 21 of each 28-day treatment cycle.
89046375|NCT01506141|Experimental|Idursulfase-IT|Idursulfase-IT will be administered once monthly and weekly IV infusions of Elaprase at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
89654304|NCT04020653|Experimental|5-ALA/SFC+placebo+ACT QD|5-ALA HCl 600 mg and SFC 472 mg will be administered QD in the morning or evening for Day 1 to Day 7 and ACT (as per package instruction) for Day 1 to Day 3. Patients will receive 5-ALA HCl and SFC at odd number of study medication dosing (Dose 1, 3, 5, 7) and placebo at even numbers of study medication dosing (Dose 2, 4, 6).
89654305|NCT03083730|Experimental|Atopic Dermatitis Cohort|"Narrow band UVB treatment (NB-UVB) NB-UVB light treatment 3x/week for 12 weeks (36 visits)~Healthy Control Cohort will be obtained to take baseline blood work as a reference value for baseline expression of blood markers."
89654306|NCT03022643|No Intervention|Pain Patients|40 Pain Patients will be screened for social and behavioral rhythms with no treatment involved. All patients will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
89654307|NCT03022643|No Intervention|Controls|40 Controls will be screened for social and behavioral rhythms with no treatment involved. All Controls will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
89654308|NCT03022643|Experimental|Treatment|10 patients from the original 40 will receive Interpersonal Social Rhythms Psychotherapy and Bright Light Device therapy to improve social and behavioral rhythms.
89654309|NCT04373109||Single-group study|Assessment of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
89654310|NCT05008458||children with febrile seizures|
89654311|NCT05008458||febrile children without seizures|
89654312|NCT05008458||healthy control children|
89654313|NCT02241135|Experimental|80 µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
89654314|NCT02241135|Experimental|160µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
89654315|NCT02241135|Experimental|80 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
89654316|NCT02241135|Experimental|160 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
89654317|NCT02241135|Experimental|320 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
89654318|NCT02241135|Experimental|640 µg CV7201 mRNA long|Vaccination by injection on days 0, 28.
89654319|NCT02241135|Experimental|200 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
89654320|NCT02241135|Experimental|400 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
89654321|NCT02080637|Active Comparator|Ambrisentan|Oral ambrisentan 2.5 - 5 mg, single dose, once daily
89654322|NCT02080637|Placebo Comparator|Placebo|Oral placebo 2.5 - 5 mg, single dose, once daily
89654323|NCT03090984|Active Comparator|PMMA (BKU)|"Patients included in the study will undergo 3 hemodialysis treatments. During the PMMA Arm, patient will be dialyzed using a BKU 1.6 (Toray) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.~During each study treatment, blood samples will be taken at specified time points (T0, T5, T15, T30, T90, T240) to assess overall coagulation activation (TAT, PF1+2, d-dimers), contact phase activation (kallikrein, fXIa, fXIIa), and activation of the extrinsic coagulation pathway (TF)."
89654324|NCT03090984|Active Comparator|PS (Phylter)|Patients included in the study will undergo 3 hemodialysis treatments. During the PS Arm, patient will be dialyzed using a Phylter 1.7 (Bellco) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
89654325|NCT03090984|Active Comparator|AN69ST (Evodial)|Patients included in the study will undergo 3 hemodialysis treatments. During the AN69ST Arm, patient will be dialyzed using a Evodial 1.6 (Gambro) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
89654326|NCT05008302|Experimental|To improve the coordination of the wrist and hand after stroke in three age groups.|The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
89654327|NCT05019690|Experimental|Apatinib Combined With Albumin-Bound Paclitaxel|Participants will receive apatinib combined with albumin-bound paclitaxel until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89654328|NCT04029467|Active Comparator|Precedex|participants will receive an ESP block with 20 ml Ropivacaine 0.375% in the induction room 20 minutes before their operation
89046376|NCT01451502|Experimental|Unlicensed Umbilical Cord Blood Infusion|"All patients will be registered in OnCore under this protocol as well as the specific treatment protocol.~Pre-infusion treatment using intravenous hydration, acetaminophen and diphenhydramine hydrochloride~Unlicensed Umbilical Cord Blood Infusion according to institutional guidelines.~Infusion of minimally manipulated unlicensed UCB units:~vital signs Monitoring during and after UCB infusion:~Management of infusion reactions~Post-transplant care and follow-up: will be done according to the disease specific treatment protocol and institutional guidelines."
89046377|NCT01373866|Experimental|Multimodal MRI-guided rTMS|
89213314|NCT02581553|Experimental|Sequence EF|Day 1: lesinurad/allopurinol 200/200 FDC tablets (Treatment E); Day 8: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2)
89213315|NCT02581553|Experimental|Sequence FE|Day 1: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2) (Treatment F); Day 8: lesinurad/allopurinol 200/200 FDC tablets (Treatment E).
89654329|NCT04029467|Experimental|Dexmedetomidine|participants will receive an ESP block with 20 ml Ropivacaine 0.375% + 0.5mcg/kg dexmedetomidine in the induction room 20 minutes before their operation
89654330|NCT02241213|Active Comparator|Active Transcranial Magnetic Stimulation TMS- r|Application of single stimulation pulses and regularly repeated ones, the frequency may be divided into high frequency EMT (> 1 Hz), low frequency (<1 Hz) This classification is based on physiological effects (stimulation or inhibition neuronal respectively). In this particular case, we will use low frequency <1 Hz with repetitive pulses.
89654331|NCT02241213|Placebo Comparator|Placebo Transcranial Magnetic Stimulation|Placebo coil that will simulate the sound of the pulses.
89654332|NCT05019300||COVID-19 patients discharged from critical care units|Adults over 18 years of age who have been hospitalized after COVID-19 diagnosis in the critical care units of Red Salud UC Christus who have been cognitively evaluated with Montreal Cognitive Assessment (MoCA) days prior to their discharge. All patients with a previous history of confirmed neurocognitive or psychotic disorders, prior to hospital admission, were excluded.
89654333|NCT04028999|Experimental|the EO31 shoulder sling|To develop and evaluate the effects of the EO31 shoulder sling for the prevention of pain, subluxation, spasticity, as well as effect on increasing functional use of the UL in activities of daily living.
89654334|NCT02241369|Experimental|Cohort I|3 mg of INO-3106 (D0); 6 mg of INO-3106 (Wk3); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk6); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk9);
89654335|NCT02241369|Experimental|Cohort II|6 mg of INO-3106 in combination with 1 mg of INO-9012, or at the MTD determined above at D0, Wk3, Wk6, Wk9
89654336|NCT05019456|Experimental|Vaccine|Participants who elect to receive the vaccine
89654337|NCT03402399|Other|Primary Myelofibrosis|Blood test
89654338|NCT03402399|Other|Secondary Myelofibrosis|Blood test
89654339|NCT05019378|Experimental|autologous SVF treatment|Three milliliter of cell suspension injection containing 1.0E8 SVF cells into the knee joint
89654340|NCT05019378|No Intervention|Placebo group|No treatment
89654341|NCT03402321|Active Comparator|control group|Gelatin Sponge Sheet is a heamostatic agent act as a mechanical barrier to protect the palatal donor site
89654342|NCT03402321|Experimental|intervention group|alvogyl in a paste form with analgesic action to protect the palatal donor site and help to relief pain
89654343|NCT04028453||Mother|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation questionnaire.
89654344|NCT05013606|Experimental|Active Treatment: Hydrogen water|Hydrogen pills mixed in a water glass that is ingested up to five time a day for 30 days.
89654345|NCT05013606|Placebo Comparator|Placebo: Inactive pill|Inactive pills mixed in a water glass that is ingested up to five time a day for 30 days.
89654346|NCT03402165|Experimental|Normal Alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
89654347|NCT03402165|Experimental|Mild elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
89654348|NCT03402165|Experimental|High elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
89213316|NCT04077203|Sham Comparator|Control|Those receiving no visual feedback because the handheld device monitor will be occluded with black tape (the control group).
89213317|NCT04077203|Experimental|Test|Those receiving the ability to visualize their glucose levels via the handheld device (the biofeedback group).
89213318|NCT03944915|Experimental|ARM 1|Induction Therapy
89213319|NCT03944915|Experimental|ARM 2|Radiation therapy with chemotherapy
89213320|NCT05674019|Experimental|Neurodevelopmental Group|The volunteer presents at least 2 of 12 neurodevelopmental crieria
89654349|NCT04020497|Experimental|Ensemble + SAU (Support as usual)|The five-session Ensemble program provided to informal caregivers targeted support + SAU
89654350|NCT04020497|Active Comparator|SAU (Support as usual)|SAU alone which was chosen as a control condition.
89654351|NCT05013684|Active Comparator|Older adults with BPPV|
89654352|NCT05013684|No Intervention|Older adults without BPPV|
89213321|NCT05674019|Active Comparator|Non-neurodevelopmental Group|The volunteer does not present any of the 12 neurodevelopmental crieria
89213322|NCT00482170|Experimental|1|Arm 1: Enbrel 50 mg Prefilled Syringe
89213323|NCT00482170|Active Comparator|2|Arm 2 Enbrel 50 mg Autoinjector
89654353|NCT02241447||Observation|the nurse identifies cases with severe AS and collects their data. Baseline data for each patient will be collected and a follow-up will be done after three months for each patient to determine his/her outcome and the treatment that was decided on
89654354|NCT02241447||Early information|in this arm, the physician referring a patient for echocardiography will be notified of a finding of severe aortic stenosis: the nurse brings cases with severe AS to the attention of the referring physician within a week (via phone, e-mail or letter) to make them aware of the diagnosis.
89654355|NCT04028219||Transgender patients|Gender dysphoric patients undergoing hormone treatment
89654356|NCT05013762|Active Comparator|Speed-biased complex motor skill training|"Participants will perform 400 complex movements per day over 4 days over a one-week period. The task requires participants to navigate their hand through a track projected on the surface of a table with a width of 5cm. Participants receive adaptive score based on their movement time. ."
89654357|NCT05013762|Other|Accuracy-biased complex motor skill training|The accuracy-biased group receives a dose equivalent intervention with a emphasize on accuracy. The width of the track projected on the table is narrower (less than 2cm) and the adaptive score received are based on their accuracy to say within the boundary of the track.
89654358|NCT03402087|Experimental|BMS-986165+Methotrexate+Leucovorin|Three treatments administered
89654359|NCT03082872|Experimental|Cemented K-wire Fixation|Fractures were transverse (n=32), short oblique or spiral (n=5), and comminuted (n=14) fractures.
89654360|NCT03082872|Experimental|Open Transfixion Pinning|Fractures were transverse (n=28), short oblique or spiral (n=4), and comminuted (n=15) fractures.
89046378|NCT01373866|Active Comparator|Conventional T3-P3 rTMS|
89046379|NCT01171872||Unaffected|Individuals who do not have IBD
89046380|NCT01171872||Affected|Individuals who have IBD
89046381|NCT01169207||Unaffected|Individuals who do not have IBD
89046382|NCT01169207||Affected|Individuals with IBD
89046383|NCT01081951|Experimental|1|"Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator.~Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid).~The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions."
89046384|NCT01081951|Active Comparator|2|paclitaxel iv and carboplatin iv
89046385|NCT00777582|Experimental|Treatment A|300mg bid (twice daily) tablet dose
89046386|NCT00777582|Experimental|Treatment B|400 mg twice daily (bid) capsule dose
89046387|NCT00777582|Experimental|Treatment C|400mg bid (twice daily) tablet dose
89046388|NCT00753974||biological specimen|Biological specimen is taken from cardiovascular procedures that would have been discarded
89046389|NCT00736385|Active Comparator|Metformin|Metformin XR (extended-release) 2000 mg daily
89046390|NCT00736385|Placebo Comparator|Placebo|Placebo capsule
89654361|NCT04020263|Experimental|Levosimendan|Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.
89654362|NCT04020263|Placebo Comparator|Placebo|Control group: Patients with cardiogenic shock treated with placebo for levosimendan in addition to the conventional strategy.
89654363|NCT00924885|Experimental|Thin Follicle Aspiration Needle|Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the RN needle that had an outer diameter of 0.9 mm (20 gauge) and inner diameter of 0.6 mm for the last 50 mm from the tip of the needle and an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg.
89654364|NCT00924885|Active Comparator|Standard Follicle Aspiration Needle|"Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the SN needle that had an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. or the SN with an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the whole length of the needle.~The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg."
89654365|NCT02241525||Prospective|Twenty patients will be enrolled and scanned with the RESEARCH procedures
89654366|NCT02241525||Retrospective|Patients with matching age and BMI will be selected from existing patients with a CLINICAL STANDARD of Care CTPA scan.
89654367|NCT05008068|Experimental|PRF alone|
89654368|NCT05008068|Active Comparator|PRF in addition to Simvastatin|
89654369|NCT04027985|Experimental|KT group|the patients will receive KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
89654370|NCT04027985|Sham Comparator|Control group|the patients will receive sham KT for 5 days a week, for three weeks. And a 30-minute hand functional training would also be provided once daily every day during the intervention.
89654371|NCT03079362||Children|Children who underwent selective dorsal rhizotomy (SDR) including intraoperative neuromonitoring (IOM)
89654372|NCT00925119|Experimental|Atenolol|Participants will receive atenolol for 8 weeks.
89654373|NCT04020809|Experimental|Atezolizumab|Atezolizumab will be administered as 1200 mg intravenously on Day 1 every 3 weeks for 2 cycles.
89654374|NCT03081078|Experimental|TAU w/ mobile app + volunteer support|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention, plus support from volunteers.
89654375|NCT03081078|Experimental|TAU w/ mobile app engagement|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention.
89654376|NCT03081078|No Intervention|Treatment as Usual (TAU)|Participants will be receiving usual medical treatment from the hospitals, and without the interventions (i.e., mobile app and/or volunteer support) introduced through this randomized control trial.
89654377|NCT04027751|Experimental|Tropisetron|Patients allocated to this arm will receive single dose of intravenous Tropisetron (5mg) before anesthesia induction.
89654378|NCT04027751|Placebo Comparator|Placebo|Patients allocated to this arm will receive an identical volume of saline solution before anesthesia induction.
89654379|NCT03090906|Experimental|Control group: SCTG from palate|Soft tissue augmentation palate
89654380|NCT03090906|Experimental|Test group: SCTG from tuberosity|Soft tissue augmentation tuberosity
89654381|NCT02241603|Experimental|Weight loss|Obese Veterans will aim to lose 5-10% body weight
89654382|NCT02241603|No Intervention|Baseline comparator|Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
89654383|NCT04027907||T2DM|
89654384|NCT04027907||healthy controls|
89654385|NCT05018988|Experimental|Oral vitamin D3 spray|10µg/day for 12 weeks (BetterYou ltd.)
89654386|NCT05018988|Placebo Comparator|Placebo Comparator|Xylitol (BetterYou ltd.)
89654387|NCT02241681|Other|Peptamen 1.5|500 mL of Peptamen 1.5
89654388|NCT03023345|Experimental|Microwave|Microwave trans rectal focal treatment
89654389|NCT03401775|Experimental|Group1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
89654390|NCT03401775|No Intervention|Group2|No intervention will be administered
89654391|NCT04406285|Active Comparator|Leukemia Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
89654392|NCT04406285|Experimental|Leukemia Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
89654393|NCT04406285|Active Comparator|Lymphoma Control Group|In this group the exercise program will be based on the standard protocol of physical therapy.
89654394|NCT04406285|Experimental|Lymphoma Experimental Group|In this group the exercise program will be based on a periodic resistance training program, with an autoregulated approach within a non-linear model, based on the individual's patient daily response.
89654395|NCT03090828|No Intervention|control|treatment as usual will be provided to patients
89654396|NCT03090828|Active Comparator|app-based therapeutic education|patients will have access to the app providing information of the disease as well as educational guidelines
89654397|NCT03090828|Experimental|enhanced app-based therapeutic education|patients will also have access to a chat room and discussion forum
89654398|NCT04377165|Active Comparator|Newsfeed|This will provide you with reliable accurate information on the pandemic.
89654399|NCT04377165|Experimental|Gamification|The gamification function will allow users to earn points for actions completed. The gamification function has links to resources for infection control, watching or completing tasks or playing games to earn points. Points can be viewed at a facility level, state level or national level.
89654400|NCT03832517|Active Comparator|Single intravenous doses of RC-01|Single escalating doses of RC-01 from 200 mg to 1600 mg
89654401|NCT03832517|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match RC-01
89654402|NCT03832517|Active Comparator|Multiple intravenous doses of RC-01|Two or three times daily escalating intravenous doses of RC-01 for 10 days. Doses to be determined
89654403|NCT03832517|Placebo Comparator|Multiple intravenous doses of placebo|Two or three times daily intravenous doses of placebo to match RC-01
89654404|NCT03079596|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic total gastrectomy, following the ERAS protocols
89654405|NCT03079596|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways
89654406|NCT04376697|Experimental|Active rTMS|Treatment will be delivered daily (weekdays) rTMS treatments, for up to 10 daily sessions and up to 75 sessions in total.
89654407|NCT02241759|Experimental|TA-8995|Single oral dose of 150mg TA-8995
89654408|NCT02241759|Experimental|Placebo|Single oral dose of placebo to TA-8995
89654409|NCT02241759|Active Comparator|Moxifloxacin|Single open-label oral dose of 400mg moxifloxacin
89654410|NCT03078894||Districts: Contaminated Water|Subjects in this group are from districts that have contaminated water sources.
89654411|NCT03078894||Districts: Uncontaminated Water|Subjects in this group are from districts that do not have contaminated water sources.
89654412|NCT04376775||Transplant patient|This study will involve all the transplant centres in France. The investigator will use patient-completed surveys for all participants. Wait Listed Transplant Candidates and Transplant Recipients (liver, kidney, pancreas, heart, lung) will be contacted by the all French transplant centres and patient's associations.
89654413|NCT04434144||Group A:|Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for 10days
89654414|NCT04434144||Group B|Hydroxychloroquine 400mg first day then 200mg BID for 9days + Azithromycin 500mg daily for 5Days.
89654415|NCT04026971|Experimental|Phone Application Supported Nutrition Education|Classic nutrition training and diet list is provided. Then notification was sent to obese patients for 3 months by phone application named 'MotiVe'
89654416|NCT04026971|Other|Classical Nutrition Education|Classic nutrition training and diet list is provided.
89654417|NCT03401697||HIV/HCV Co-infected|Patients with HIV/HCV co-infection
89654418|NCT03401697||Type 2 Diabetes|Patients with Type 2 Diabetes
89654419|NCT05007912||Orvil Group|Group that used the Orvil (circular stapler) for esophagojejunostomy
89654420|NCT05007912||Linear Group|Group that used the linear stapler for esophagojejunostomy
89654421|NCT04372719|Experimental|H3N2 10EXP5 TCID50/mL|A/Belgium/4217/2015 (H3N2) (SGS Code: SGS 421-7), Wild-type, influenza A (H3N2) human challenge strain
89654422|NCT04957914|Active Comparator|Insulin Glargine (Period 1)|Insulin glargine administered subcutaneously (SC).
89654423|NCT04957914|Experimental|LY3209590 (Period 2)|LY3209590 administered SC.
89654424|NCT04027127|Active Comparator|ACS GRUP|"Demographic characteristics, history, vital signs, laboratory findings, coronary angiography (CAG) and echocardiography (ECO) findings of the patients were recorded. Netrin-1 levels were studied with blood collected at the hospital and 6-8 hours after CAG. CAG results were evaluated by TIMI flow. The patients were divided into two groups with and without TIMI 3 flow and Netrin-1 levels were compared.~GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Ischemia) clinical risk assessments were performed and Netrin-1 values were compared."
89654425|NCT04027127|Active Comparator|plasebo grup|It consisted of those without any disease and netri-1 values at admission were compared with the uptake patient group.
89654426|NCT04027283|Active Comparator|Erythritol|18 volunteers receive 50g erythritol dissolved in 300mL tap water via a nasogastric tube
89654427|NCT04027283|Active Comparator|Erythritol + lactisole|18 volunteers receive 50g erythritol with lactisol (450ppm) dissolved in 300mL tap water via a nasogastric tube
89654428|NCT04027283|Active Comparator|D-allulose|18 volunteers receive 25g D-allulose dissolved in 300mL tap water via a nasogastric tube
89654429|NCT04027283|Active Comparator|D-allulose + lactisole|18 volunteers receive 25g D-allulose with lactisole (450ppm) dissolved in 300mL tap water via a nasogastric tube
88993826|NCT02946307|Active Comparator|small vessel cohort:Resolute DES|receiving the treatment with Resolute DES in small vessel cohort
89654430|NCT04027283|Placebo Comparator|Tap water|18 volunteers receive 300mL tap water via a nasogastric tube
89654431|NCT04027283|Placebo Comparator|Tap water + lactisole|18 volunteers receive 300mL tap water + lactisole (450ppm) via a nasogastric tube
89654432|NCT02241915|Active Comparator|Microbial Sealant|Integuseal (Kimberly Clark)
89654433|NCT02241915|Sham Comparator|Control|No microbial sealant
89654434|NCT00920439|Experimental|POLIORIX GROUP|Healthy male or female subjects between, and including, 18 and 24 months of age, received a single booster dose of Poliorix™ vaccine that was administrated into the upper right thigh by intramuscular injection (IM).
89654435|NCT03076632|Active Comparator|Non-disabled volunteers|"Volunteers without neurological injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
89654436|NCT03076632|Active Comparator|Spinal cord injury|"Volunteers with motor-incomplete cervical spinal cord injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
89046391|NCT00392327|Active Comparator|Arm A (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD five days a week for 6 weeks. Patients also receive vincristine sulfate IV over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim SC or IV beginning on day 4 and continuing until blood counts recover (at least 10 days).~Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity."
89046392|NCT00392327|Experimental|Arm B (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients receive vincristine sulfate and undergo radiation therapy as in Arm A. Patients also receive carboplatin IV over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm A."
89046393|NCT00392327|Experimental|Arm C (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm A. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive isotretinoin PO BID on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm A maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
89046394|NCT00392327|Experimental|Arm D (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm B. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm C. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive continuation therapy as in Arm C."
89046395|NCT00357565|Experimental|Double Unit UCB Transplantation|Patients that receive 2 units of umbilical cord blood transplantation (UCBT).
89046396|NCT00357565|Experimental|Single Unit UCB Transplantation|Patients that receive one unit of umbilical cord blood transplantation (only if 2 adequate size and matched units are not available).
89046397|NCT00352534|Experimental|Stratum I (very low-risk disease)|Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks.
89046398|NCT00352534|Experimental|Stratum II (standard-risk, stage I or II)|Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks.
89654437|NCT03076632|Active Comparator|Amyotrophic lateral sclerosis|"Volunteers with amyotrophic lateral sclerosis.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
89654438|NCT04028141||participants undergoing procedural sedation|"The study gathered observational data about participants who underwent procedural sedation according to the new standard protocol with ketofol in a 1 on 4 concentration.~The participant was observed for complications or cardiorespiratory interventions by the sedating physician until he was fully awake. Thirty minutes after the awakening, the participant was questioned for his remembrance and perception of the sedation and procedure. He was observed for complications until discharge"
89654439|NCT02241993||Type 1 diabetic|
89654440|NCT04027673|Experimental|Treatment|Participants in the treatment group complete interactive modules. They will be asked to complete one module per week, for a total of eight weeks.
89654441|NCT04027673|No Intervention|Control|Participants in the control group will have no active study requirements for the eight weeks following Survey Session 1.
89654442|NCT03401541|Experimental|Fat-Mal, calcifediol then calciferol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and then receive one capsule of calciferol for the second round.
89654443|NCT03401541|Experimental|Fat-Mal, calciferol then calcifediol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
89654444|NCT03401541|Experimental|Non Fat-Mal, calcifediol then calciferol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and thenreceive one capsule of calciferol for the second round.
89654445|NCT03401541|Experimental|Non Fat-Mal, calciferol then calcifediol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
89654446|NCT05012514|No Intervention|Control- Without intervention|The participants have the right side of the abdomen as a control without inversion
89654447|NCT05012514|Active Comparator|LLLT- With intervention|The participants received the LED PBMT treatment with associated red and infrared wavelengths sequentially on the left side of the abdomen
89654448|NCT04027205|Experimental|Physiotherapist-led exercise|Structured and progressive physiotherapist-led exercise programme. Reflective of current guidance for exercise programmes for people with rotator cuff disorders, an individualised programme developed in relation to the participant's specific goals will be prescribed by the physiotherapist and supported over approximately six contact sessions across a 12-week period.
89654449|NCT04027205|Active Comparator|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation.
89654450|NCT03079128|Experimental|Intervention|Weight Watchers Intervention
89654451|NCT04026815||60 - 65 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
89654452|NCT04026815||65 - 69 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
89654453|NCT04026815||70 - 74 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
89654454|NCT04026815||75 - 79 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
89654455|NCT04026815||80 - 84 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
89654456|NCT04026815||85 - 89 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
89654457|NCT04026815||≥90 years|Subjects were selected using a three stage stratified and proportional random sampling in seven equally size (n=850) age groups: 60-65, 65-69, 70-74, 75-79, 80-84, 85-89, 90+ years.
89654458|NCT03080220|Experimental|Astym|The Astym treatment (AT) is specifically used by medical professionals to treat musculoskeletal dysfunctions by stimulating the body's ability to break down adhesions and reabsorb dysfunctional tissue (scar tissue).6-16,19 The treatment induces collagen building, fibroblastic activity, and phagocytosis.17,18 Part of the treatment includes utilizing a series of instruments glided across the skin tissue, in a non-invasive manner, along the route of the underlying muscle fibers' direction. The treatment specifically spares healthy tissue and stimulates growth factors and cellular mediators that stimulate the repair of dysfunctional tissue in the body's internal mechanisms.17,18 Astym is an FDA approved device. Specifically, Astym is registered as having a device class as 1 and regulation number as 890.5660.
89654459|NCT03080220|Experimental|Stick|The Stick treatment (ST) utilizes an instrument to convert non-compliant muscle to compliant muscle by compressing the muscle. The individual spindles of The Stick create a stripping massage by applying progressively deeper strokes over the soft tissue.38 The Stick permits individuals to perform trigger point release on own person, allowing the muscle to become compliant to the wanted movement.
89654460|NCT03080220|Placebo Comparator|Massage|Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
89654461|NCT02242071|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
89654462|NCT04433754||patients with pancreatic injury|patients with higher amylase and lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
89654463|NCT04433754||patients without pancreatic injury|patients with normal amylase and lipase levels in the course of SARS-CoV-2 infection
89654464|NCT03953261|Experimental|Curcumin|
89654465|NCT03953261|Placebo Comparator|Placebo|
89654466|NCT02982603|Experimental|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761 .Qinggongshoutao bolus 70 pills every time (7g), 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
89654467|NCT02982603|Active Comparator|Ginkgo Biloba Extract 761|Ginkgo Biloba Extract 761 and placebo identified to Qinggongshoutao bolus.The subjects will take Ginkgo Biloba Extract 761 2 times per day, 2 pills per time(80mg) ,and identified to Qinggongshoutao bolus 70 pills every time, 2 times per day for 48 weeks.
89654468|NCT02982603|Placebo Comparator|Placebos|Placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761.Placebo identified to Qinggongshoutao bolus 70 pills every time, 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
89654469|NCT03952013||Study group|"All eligible patients included into one of the three existing cohorts studies of Hospices Civils de Lyon's hospitals: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE~LOOP-HF (Registry of Congestive Heart Failure, NCT03422991),~HIBISCUS-STEMI (Prospective cohort with a heart attack from ST segment elevation myocardium admitted to the centre coronary angiography room participating investigators, NCT03070496)~HIBISCUS-STROKE (Prospective cohort of Stroke patients, NCT03149705)"
89654470|NCT04433676||Patients with surgical procedures|Adult patients undergoing surgical procedures under general or regional anesthesia and with an admission to a recovery unit for the initial postoperative care.
89654471|NCT02242149|Placebo Comparator|Placebo|All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
89654472|NCT02242149|Experimental|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
89654473|NCT03022565|Experimental|Vorinostat|"Vorinostat:~400 mg orally, once daily for 15 days."
89654474|NCT03401463|Active Comparator|once a day|Cuff pressure checks once a day.
89654475|NCT03401463|Active Comparator|three times a day|Cuff pressure checks three times a day
89654476|NCT03079050|Experimental|1|34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
89654477|NCT04026269|Experimental|MOAP treatment|Chlormethine Hydrochloride Injection 10mg d1,8 iv Vindesine Sulfate for Injection 4mg d1,8 iv Doxorubicin Hydrochloride Injection 25mg/m2 d1,8 iv Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po 28 days/Cycle
89654478|NCT03834129|Experimental|(Dex group) intravenous infusion of dexmedetomidine|Pre-anesthetic and per-operative intravenous infusions of dexmedetomidine 1µg/kg in 250ml of sodium chloride 0.9%
89654479|NCT03834129|Placebo Comparator|(Control group) intravenous infusion of physiological serum|Pre-anesthetic and per-operative intravenous infusions of 250ml of sodium chloride 0.9%
89046399|NCT00352534|Experimental|Stratum III (standard-risk, stage III)|Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks.
89046400|NCT00071786||Group 1|All study participants fall into one group for this observational family study regardless of diagnosis.
89654480|NCT05001204|Experimental|68Ga-NOTA-RM26 PET/CT|Patients underwent whole-body PET/CT scans at 30-90 minutes after intravenous injection of 55.5-148 MBq (1.5-4 mCi) of 68Ga-NOTA-RM26.
89654481|NCT03022409|Experimental|AZD6738|AZD6738 (160 mg) tablet twice daily continuous dosing for a minimum of 9 days and a maximum of 21 days.
89654482|NCT03022409|Experimental|Olaparib|Olaparib (300 mg) tablets administered orally twice daily continuously for a minimum of 9 days and a maximum of 21 days.
89654483|NCT03833895|Experimental|Group 1 Elements|Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
89654484|NCT03833895|Experimental|Group 2 Elements|Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
89654485|NCT03833895|Placebo Comparator|Group 3 Elements|In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.
89654486|NCT03079908|Experimental|Da Vinci Skills Simulator®|Participants in this group will undergo robotic virtual reality surgical simulator training (Da Vinci Mimics) and will subsequently be evaluated on a dry lab laparoscopic box
89654487|NCT03079908|Active Comparator|LapSim®|Participants in this group will undergo laparoscopic virtual reality surgical simulator Training (LapSim) and will subsequently be evaluated on a dry lab laparoscopic box
89654488|NCT03079908|Placebo Comparator|Dry lab box laparoscopic training|Participants in this group will undergo dry lab box laparoscopic training only
89046401|NCT02910440|Experimental|DCL-101|
89046402|NCT02910440|Active Comparator|GoLytely|
89046403|NCT04676997|Experimental|Camrelizumab+Chemotherapy|Participants receive Camrelizumab d1,15 (Q2W) + nab-paclitaxel d1,8,15(QW 3/4) x 4 cycles, followed by Camrelizumab Q2W + epirubicin + cyclophosphamide Q2W x 4 cycles as neoadjuvant therapy prior to surgery
89046404|NCT01217047|Experimental|Group A|For 3 weeks, you will need to come to the ICSCI one (1) time per week during which you will perform FES cycling for 1 hour each.
89046405|NCT01217047|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
89046406|NCT01217047|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
89046407|NCT01217047|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
89046408|NCT00624403|Active Comparator|1|LMA ProSeal
89046409|NCT00624403|Experimental|2|I-Gel
89046410|NCT02910128|Experimental|School intervention|chiquichefs education innovation
89046411|NCT02910128|No Intervention|control school|A primary schools will function as control schools.
89654489|NCT02701751|Other|Exercise session|Subjects will exercise at a moderate intensity for 60 minutes. There are no different arms in this study.
89654490|NCT02242227|Experimental|Salmeterol xinafoate|25 μg Salmeterol inhalation powder administered via HandiHaler®
89654491|NCT02242227|Active Comparator|Serevent® Diskus®|50 μg Salmeterol (dry powder inhaler) administered via Diskus®
89654492|NCT02242227|Placebo Comparator|Placebo|
89654493|NCT03079206|Experimental|Hazelnut allergy|patients with positive case history of hazelnut allergy and a positive skin testing are undergoing a food challenge and blood sampling for basophile activation testing
89046412|NCT01968720|Experimental|CAT-2003 or Placebo|All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
89046413|NCT02910206|Experimental|etomidate|etomidate is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
89654494|NCT04366947|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
89654495|NCT04366947|Experimental|Experimental: IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
89654496|NCT05011968|Experimental|No Intervention: (control group)|The control group was assigned to crop lettuce without any biofortification but with the same characteristic of bioforticated lettuce (soil, water, harvesting time)
89654497|NCT05011968|Experimental|Experimental: intervention group|The intervention group was assigned to biofortificated Iodine crop lettuce.
89654498|NCT04366557|Experimental|Body posture correction|Subjects from study group had an education about pelvic floor and additional a six week body posture therapy.
89654499|NCT04366557|Other|Without correction of body posture|Subjects form control group had only an education about pelvic floor.
89654500|NCT05000892|Experimental|Sintilimab + Carboplatin + Nab-paclitaxel|"Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
89654501|NCT02982525|Experimental|No Mussels|The control group will continue to consume their normal habitual diet
89654502|NCT02982525|Experimental|One mussel portion|One 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption.
89654503|NCT02982525|Experimental|Two mussel portions|Two 75g portions of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
89654504|NCT02982525|Experimental|Three mussel portions|Three 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
89654505|NCT04372407|Experimental|Treatment Crossover Arm|All patients will receive a single dose of surufatinib on day 1 in period 1, and a both itraconazole and single dose of surufatinib in period 2
89654506|NCT05007600|Experimental|trial group|Participants in the experimental group received an 8-week intensive (Monday to Friday) online interactive course.
89654507|NCT05007600|No Intervention|Control group|Participants in the control group consumed 8 weeks of unidirectional online video and audio programs (such as from YouTube).
89654508|NCT02242383||Essential hypertension|
89654509|NCT03076086|Experimental|induced sputum procedure|Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
89654510|NCT02708381||Senior Adult Cancer Patients|Cancer patient population 70 years and older, eligible for screening.
89654511|NCT04366479|Experimental|intervention group|The study lasted for 5 weeks (1 month 7 days). During the research process, we monitor closely, especially the training schedule, implementation, and evaluation, directly and indirectly. Directly assisting participants to do endurance training activities, not directly monitoring via telephone or WhatsApp.
89654512|NCT05000112||Patients with mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is seen on surface of the vaginal mucosa, the patient is diagnosed with mesh exposure.
89654513|NCT05000112||Patients without mesh exposure|During the physical examination, a speculum was inserted into the vagina to observe the vaginal epithelium for mesh exposure. If the mesh is not seen on surface of the vaginal mucosa, bimanual examination will be performed to confirm no foreign body can be feeled on surface of the vaginal mucosa. Then the patient belong to this group.
89654514|NCT04025723|Active Comparator|Young|men aged between 18 to 30 years old
89654515|NCT04025723|Active Comparator|Middle-aged|men aged between 35 to 50 years old
89654516|NCT03079986|Experimental|Ignoring CL (group A)|Standard care irrespective of CL.
89654517|NCT03079986|Active Comparator|Dietary treatment (group B)|Dietary treatment with medium-chain triglyceride diet (MCT-diet) until resolution of CL.
89654518|NCT04366089|Active Comparator|Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
89654519|NCT04366089|Experimental|Oxygen-ozone and probiotic|"Oxygen-ozone therapy, probiotic supplementation plus standard of care~Oxygen-ozone therapy: systemic autohemotherapy (twice a day).~Probiotic supplementation: SivoMixx 200 billion (six sachets twice a day)."
89654520|NCT05011500|Experimental|Starting with closed mask|Patient 1-8, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using a closed mask. For the next 5 fractions these patients will receive radiotherapy using an open mask. For the 5 fractions after that these patients will receive radiotherapy using no mask. This schedule repeats for the rest of their treatment.
89654521|NCT05011500|Experimental|Starting with open mask|Patient 9-16, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using an open mask. For the next 5 fractions these patients will receive radiotherapy using no mask. For the 5 fractions after that these patients will receive radiotherapy using a closed mask. This schedule repeats for the rest of their treatment.
89654522|NCT05011500|Experimental|Starting with no mask|Patient 17-24, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using no mask. For the next 5 fractions these patients will receive radiotherapy using a closed mask. For the 5 fractions after that these patients will receive radiotherapy using an open mask. This schedule repeats for the rest of their treatment.
89654523|NCT02242461|Placebo Comparator|Rhodiola placebo capsules|starch
89654524|NCT02242461|Experimental|Rhodiola Crenulata|Rhodiola Crenulata
89654525|NCT05011110|Experimental|GraduSOX (left leg) & Sigvaris (right leg)|Half of participants will wear a GraduSOX compression stocking on their left leg whilst wearing a Sigvaris compression stocking on their right leg.
89654526|NCT05011110|Experimental|GraduSOX (right leg) & Sigvaris (left leg)|Half of participants will wear a GraduSOX compression stocking on their right leg whilst wearing a Sigvaris compression stocking on their left leg.
89654527|NCT03078738|Experimental|OMT-28-SAD|OMT-28-SAD, Single ascending dose levels 1 - 3 of OMT-28 (15, 30, 60 mg) Oral, healthy young male
89654528|NCT03078738|Experimental|OMT-28-MAD|Multiple ascending dose of dose levels 1 - 3 of OMT-28 over 14 days (4, 12, 36 mg) Oral, healthy young male
89654529|NCT03078738|Experimental|OMT-28- Food Effect|Single dose of OMT-28 (4 mg) Oral, healthy young male
89654530|NCT03078738|Experimental|OMT-28-Gender|Single dose of OMT-28 (4 mg) Oral, healthy non-child bearing potential female
89654531|NCT03078738|Placebo Comparator|Placebo-SAD|Single dose levels 1 - 3 of matching placebo, Oral, healthy young male
89654532|NCT03078738|Placebo Comparator|Placebo MAD|Multiple dose levels 1 - 3 of matching placebo over 14 days Oral, healthy young male
89654533|NCT03078738|Placebo Comparator|Placebo-Gender|Single dose of matching Placebo Oral, healthy non-child bearing potential female
89654534|NCT00929331|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years who received one dose of Fluviral® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
89654535|NCT00929331|Experimental|Fluviral Elderly Group|Subjects over 60 years of age who received one dose of Fluviral ® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
89654536|NCT03079830|Active Comparator|Ropivacaine continous infusion|Piritramid
89654537|NCT03079830|Sham Comparator|Saline continous|Piritramid
89654538|NCT04371939|Experimental|I (Romiplostim)|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
89654539|NCT04371939|Experimental|II (Eltrombopag)|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
89654540|NCT03079752|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
89654541|NCT03079752|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
89654542|NCT03079752|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
89654543|NCT03079752|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
89654544|NCT02242539|Experimental|Height measurement poster|
89654545|NCT02242539|Experimental|Community-based monitoring|
89654546|NCT02242539|No Intervention|Control|
89654547|NCT05011344|Experimental|Exposed hospital staff|"Hospital health care or non-health care staff willing to participate in the study:~Healthcare personnel (physician, nurse, caregiver) who have worked for a minimum of 2 weeks since March 1, 2020 in a care unit dedicated to the management of patients confirmed or suspected of COVID-19 infection, in the participating centers: intensive care units, emergency rooms, radiology, COVID-19 units;~Staff (physician, technician) who have worked for a minimum of 2 weeks since March 1, 2020 in the AP-HM laboratories handling samples from patients confirmed or suspected of having COVID-19 infection."
89654548|NCT05011344|Other|'Non-exposed' hospital workers|Hospital health care worker (physician, nurse, caregiver) willing to participate in the study who has not worked since March 1, 2020 in an intensive care unit or emergency department or other department dedicated to the management of patients confirmed or suspected of having COVID-19 infection.
89654549|NCT02242695|Experimental|Fluomizin vaginal tablets|Fluomizin vaginal tablets containing 10mg dequalinium chloride once daily for 6 days and one placebo vaginal tablet on day 7
89654550|NCT02242695|Active Comparator|Canesten vaginal tablets|Canesten vaginal tablets containing 100mg clotrimazole once daily for 7 days
89654551|NCT04999800|Experimental|Pembrolizumab combined with Anlotinib|Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week, combined with Pembrolizumab 200 mg iv on day 1, and every 21 days is a treatment cycle until the disease progresses or the toxicity cannot be tolerated
89654552|NCT04366011|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is a twelve-week therapeutic intervention based on the theory that maladaptive thoughts contribute to symptom development and maintenance of PD/A.
89654553|NCT04366011|Experimental|Capnometry Assisted Respiratory Training (CART)|Capnometry-assisted respiratory therapy is a five-week treatment based on the theory that hyperventilation causes or maintains panic disorder.
89654554|NCT02242851||Hypertensive patients|
89654555|NCT04999878|Experimental|treatment group|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
89654556|NCT02242929|Active Comparator|Standard surgical excision|"Standard surgical elliptical excision including a 3-mm clinically tumour-free margin according to the current local hospital arrangements."
89654557|NCT02242929|Experimental|Imiquimod 5% cream with prior curettage|Tumours will be partially debulked under local anaesthesia by removing all tumour tissue until normal dermis remains with a blunt curette. After curettage patients will receive an instruction sheet to apply imiquimod 5% cream once daily, 5 days a week, during 6 weeks, starting one week after the curettage procedure. Patients will be instructed to apply a thin layer to the tumour including 5-10mm of the surrounding skin at least 1 hour before going to bed at night. The lesion will not be covered (unless needed because of weeping or bleeding). Participants will be asked to wash their hands after applying the cream, and to wipe the cream off after 8 hours (in the morning).
89654558|NCT04365621|Other|ultra-high risk of psychosis patient|patient with ultra -high risk of psychosis will be enrolled to the study
89654559|NCT04458090|Experimental|Intervention|Receive hospice patient decision aid
89654560|NCT04458090|No Intervention|Control|Does not receive hospice decision aid
89654561|NCT04365543|Experimental|UP-C/A for Misophonia|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) are manualized treatments for treating emotional disorders in youth. We have modified the UP-C/A to meet the needs for youth with misophonia.
89654562|NCT04365543|Experimental|Psychoeducation and Relaxation Therapy|Psychoeducation and Relaxation Therapy (PRT) is a treatment that educates the child on misophonia and provides training in relaxation skills and tools for calming panic, anxiety and anger feelings.
89654563|NCT04457856|Experimental|TJ003234|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
89654564|NCT04457856|Placebo Comparator|Placebo|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) Mode of administration: The investigational drug is administered by intravenous infusion
89654565|NCT04371705|Experimental|ESPB group|31 patients Will undergo ultrasound guided ESP block with 40 ml bupivacaine 0.25% (20 ml on each side).
89654566|NCT04371705|Placebo Comparator|control group|31 patients anesthetized with the protocol followed by Minia University Hospital
89654567|NCT02243085||photoselective vaporization|
89654568|NCT05011032|Other|Control Group|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
89654569|NCT05011032|Experimental|Non-diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
89654570|NCT05011032|Experimental|Diabetic cardiac|The blood sample of 5ml was collected from the subjects via a sterile disposable 5ml syringe. The site for the blood collection was antecubital vein of the forearm, which was cleaned an alcoholic swab. The blood sample was shifted to assigned plain bottle container, where it was allowed to clot at room temperature. The serum sample was separated from the blood sample through a centrifugation process at a speed of 5000 revolutions per minute (rpm) for 15 minutes and stored frozen in another bottle container until the time for analysis
89654571|NCT02243163|Experimental|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
89654572|NCT05006898|Experimental|PBO Investigational drug|Pilocarpine, brimonidine, oxymetazoline combined with hyaluronic acid and bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.
89654573|NCT05006898|Active Comparator|Pilocarpine|Pilocarpine was instilled in the other oye.
89654574|NCT05006898|Active Comparator|Brimonidine|Brimonidine was instilled in the other eye.
89654575|NCT04463628||Questionnaire and/or interview|An online questionnaire to assess the quantitative aspect of the impact of lockdown on all areas of the cystic fibrosis patient's health, be it physical, mental or social (using quality of life assessment in particular and interviews in the human and social sciences).
89654576|NCT02243241|Experimental|HYD|
89654577|NCT02243241|Other|Moxifloxacin|Moxifloxacin is the positive control.
89654578|NCT02243241|Placebo Comparator|Placebo|Placebo for HYD and placebo for moxifloxacin
89654579|NCT04365309|No Intervention|the NCP standard treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment).
89654580|NCT04365309|Experimental|the NCP aspirin treatment group|According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment). Patients in the NCP aspirin group were given aspirin 100 mg/d orally after admission and aspirin for 14 days after discharge.
89654581|NCT05007210|Experimental|Prenatal massage therapy group|Prenatal massage therapy for prenatal attachment, physiological and psychological distress, maternal and fetal well-being.
89654582|NCT05007210|No Intervention|Control group|Pregnant women in the control group were interviewed twice (once a week for 30th and 34th week) by the same massaging midwife. No additional attempt was made except for filling out the forms and evaluating the biophysical profile by the obstetrician in these interviews. The massaging midwife's phone number was given to the pregnant women in both groups if they want to reach anytime. A phone number was set for the study, and this phone number was used by the massaging midwife. This service has been provided for pregnant women to reach her whenever they want.
89654583|NCT02243319|Experimental|Group 1|"A → B → C~A: HGP1201 for 9 days B: HGP0904 for 9 days C: HGP1201+ HGP0904 for 9 days"
89654584|NCT02243319|Experimental|Group 2|C → A → B
89654585|NCT02243319|Experimental|Group 3|B → C → A
89654586|NCT02243319|Experimental|Group 4|C → B → A
89654587|NCT02243319|Experimental|Group 5|B → A → C
89654588|NCT02243319|Experimental|Group 6|A → C → B
89654589|NCT05007054||Percutaneous coronary intervention|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months.
89654590|NCT05007054||Coronary artery bypass grafting|The left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. Te procedure was performed by surgeons experienced in onpump or of-pump surgery at the operator's discretion.
89654591|NCT05007054||Medical therapy|Patients with neither PCI nor CABG treatment were allocated to the MT alone group. For medical therapy, antiplatelet medication, statins, renin-angiotensin system blockade, β-blockers, and nitrate were used.
89654592|NCT02243553|Experimental|Treatment A|tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral
89654593|NCT02243553|Experimental|Treatment B|TPV capsule + RTV capsule + cocktail + digoxin injection
89654594|NCT02243553|Experimental|Treatment C|TPV solution + RTV capsule + cocktail + digoxin oral
89654595|NCT02243553|Experimental|Treatment D|TPV solution + RTV capsule + cocktail + digoxin injection
89654596|NCT03079518|Active Comparator|Patients with HFREF & CKD|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
89654597|NCT03079518|Active Comparator|Patients with HFREF|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
89654598|NCT00922233|Experimental|Levonorgestrel|0.75 mg of levonorgestrel within 24 hours of sex
89654599|NCT03079674||NICE patients|Non-disabling ischemic cerebrovascular events patients indicate patients with transient ischemic attack and minor stroke (National Institute of Health stroke scale, NIHSS≤3).
89654600|NCT04364919|Experimental|aerobic exercise intervention|The intervention group received a DVD with low-impact aerobic exercises developed by the researchers in collaboration with a qualified prenatal yoga teacher. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercise program requires twenty minutes to complete. Women were instructed to use the DVD 3 times a week for 3 months.
89654601|NCT04364919|No Intervention|control group|The control group received routine prenatal care only.
89654602|NCT04364685|Active Comparator|Normal Walking|The participants performed 30 minutes on levelled surface on the track and field ground. Participants performed moderate intensity walking, self paced.
89654603|NCT04364685|Experimental|Sand Walking|The participants performed supervised walking on sand on the 20 meters pathway containing soft sand.The walking on sand for 30 minutes.
89654604|NCT04371237|Experimental|Intermittent pneumatic compression|IPC sleeve device on leg
89654605|NCT04371237|Experimental|Heat therapy|Custom water-circulating garment on leg
89654606|NCT02243787|Experimental|COVA322|single i.v. infusion
89654607|NCT02243787|Placebo Comparator|Placebo|single i.v. infusion
89654608|NCT05010330||healthy control|healthy people
89654609|NCT05010330||lung cancer|patients diagnosed with lung cancer
89654610|NCT05010252|Experimental|Cycled Light|It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies over 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
89654611|NCT05010252|No Intervention|Dim light|no intervention
89654612|NCT04371159|Experimental|Velieve U.S.|Each participant will test their urine sample using the Velieve U.S. device
89654613|NCT05009940|Experimental|Gradusox then Sigvaris compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Gradusox compression stockings applied to both legs.~After a washout period, the second intervention received are Sigvaris compression stockings applied to both legs."
89654614|NCT05009940|Experimental|Sigvaris then Gradusox compression stockings|"This arm refers to the order of interventions received by the participant. The first intervention received by participants in this arm are Sigvaris compression stockings applied to both legs.~After a washout period, the second intervention received are Gradusox compression stockings applied to both legs."
89654615|NCT00922701|Experimental|Peritoneal Dialysis Solution|
89046414|NCT02910206|Experimental|propofol|propofol is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
89046415|NCT04675086|Experimental|Aralast NP + Antiviral Treatment + Standard of Care|"The investigational product is alpha1-proteinase inhibitor, administered as a loading dose of 120mg/kg/body weight intravenous infusion on the first day, and then 60mg/kg/BW intravenous infusion on Days 3, 5, 7 and 9. Booster infusion of 120 mg/kg/BWon Day 17.~The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes~Standard of Care treatments are at the investigator's discretion based on best practices."
89654616|NCT05006664|Experimental|Brentuximab Vedotin (Adcetris) in Combination with CHEP|Single arm, open label, Brentuximab Vedotin (Adcetris) in Combination with CHEP
89654617|NCT04346901|Other|Single Intervention|Before-and-After type of research
89654618|NCT02244021|Experimental|BRENTUXIMAB VEDOTIN|1 arm for all patients
89654619|NCT04994028|Active Comparator|Conventional treatment|Conventional treatment that include behavioral and life style modification and dyspnea prevention education
89654620|NCT04994028|Experimental|conventional treatment with volume Spirometry and deep breathing|Conventional treatment along with volume Spirometry and deep breathing exercise
89654621|NCT03075852||3D VRS Patients|Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)
89654622|NCT03075852||Standard operating microscope|Those who undergo surgery with the standard operating microscope
89654623|NCT02244099|Experimental|Controlled Substance|Consenting physicians who care for patients who have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months in Martha Morehouse General Internal Medicine Resident Continuity Clinic.
89654624|NCT03075930||Extended Electrocardiogram|Elective patients receiving an AF ablation receiving a extended ECG
89654625|NCT03075930||Body surface potential map|Elective patients receiving an AF ablation receiving a body surface potential map
89654626|NCT04370769||Women with Kidney Disease|Women with kidney disease
89654627|NCT02244177||normotension group|Until 11,March, 2015, 31 cases are collected.
89654628|NCT02244177||hypertension group without treatment|Until 11,March, 2015, 60 cases are collected.
89654629|NCT02244177||hypertension group with antihypertensive treatment|"(ACEI, beta-blocker, Ca blocker, Diuretics) prior to the surgery.~Until 11,March, 2015, 59 cases are collected."
89654630|NCT03075618||Acute Pancreatitis|Patients with Acute Pancreatitis.
89654631|NCT03075540|Other|YouTube Video|Participants will watch a 15-minute YouTube video. The video will provide information about hereditary breast and ovarian cancer and about the process of genetic counseling and testing.
89688619|NCT02808130||Group HH|"Group HH: hyperlipidemic + periodontally healthy individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
89654632|NCT03833739|Experimental|Upper Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the upper and lower arches.~starting treatment in the upper arch The upper ach was bonded for 28 patients and teeth alignment was started using round 0.014NiTi arch wire. The 0.014NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. Orthodontic treatment was continued in the upper arch with arch wire sequence of 0.014NiTi, 0.018NiTi, 0.016X0.022NiTi, 0.019X0.025NiTi, and 0.019X0.025stainless steel arch wires. The patients were followed up on a monthly basis until sufficient proclination of the upper incisors achieved to establish an overjet of at least 4 mm. After reaching the full working arch wire in lower arch (0.019 X 0.025stainless steel wire), lateral cephalogram and study models were taken."
89654633|NCT03833739|Experimental|Lower Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the lower arch and anterior bite plate in the upper arch.~The lower arch was bonded after taking the pretreatment records. At the same appointment an anterior bite plate in the upper arch was delivered to prevent shearing off the mandibular incisor brackets and help in correction of anterior deep bite .After lower arch alignment and leveling in the same arch wire sequence as the other group and 0.019 X 0.025stainless steel arch wire was reached, the anterior bite plate was removed and the upper arch was bonded. The same arch wire sequence was used in the upper arch as was used in the lower arch. When the full working arch wire (0.019 X 0.025stainless steel arch wire) was reached in the upper arch, study models and lateral cephalogram were taken."
89654634|NCT05006742|Active Comparator|CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
89654635|NCT05006742|Active Comparator|FB-CB study arm|Included patients are 1:1 randomized to receive either CB (CB study arm) or FB and CB within the same session (FB-CB study arm
89654636|NCT02245269|Experimental|TPV/r + Atorvastatin followed by TPV/r + antacid|Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV
89654637|NCT05006586||RVF|All patients having undergone repair for rectovaginal fistula
89654638|NCT04999722|Active Comparator|APP group|Participants with diabetes who had access to a mobile APP
89654639|NCT04999722|Placebo Comparator|Control Group|Diabetes participants who accepted the traditional management model
89046416|NCT04675086|Active Comparator|Antiviral Treatment + Standard of Care|"The Antiviral treatment is Remdesivir. For patients not requiring invasive mechanical ventilation and/or ECMO, the recommended total treatment duration is 5 days. If a patient does not demonstrate clinical improvement, treatment may be extended for up to 5 additional days for a total treatment duration of up to 10 days. Recommended dosage in adults and pediatric patients 12 years of age and older and weighing at least 40 kg: a single loading dose of Remdesivir 200 mg on Day 1 followed by once-daily maintenance doses of Remdesivir 100 mg from Day 2 infused over 30 to 120 minutes~Standard of Care treatments are at the investigator's discretion based on best practices."
89654640|NCT00923481|Experimental|Multi-kinase inhibitor Fostamatinib Disodium (R935788)|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
89654641|NCT04364139|Experimental|Lower BP goal and Ramipril|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Ramipril 2.5 to 10 mg/d
89654642|NCT04364139|Experimental|Usual BP goal and Ramipril|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and participants assigned to Receive Ramipril 2.5 to 10 mg/d
89654643|NCT04364139|Experimental|Lower BP goal and Amlodipine|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
89654644|NCT04364139|Experimental|Usual BP goal and Amlodipine|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Amlodipine 5 to 10 mg/d
89654645|NCT04364139|Experimental|Lower BP goal and Metoprolol|Participants assigned to Lower Blood Pressure Goal (MAP less than or equal to 92 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
89654646|NCT04364139|Experimental|Usual BP goal and Metoprolol|Participants assigned to usual Blood Pressure Goal (MAP of 102 to 107 mm Hg) and Participants assigned to Receive Metoprolol 50 to 200 mg/d
89654647|NCT00931359|Experimental|Treatment with DTS-G2 System|Subjects receive treatment with the DTS-G2 System (an energy-based medical device) in both axilla. Multiple treatment sessions may be used.
89654648|NCT00931359|Sham Comparator|Sham treatment|All elements of the treatment are given except that no energy is delivered. Multiple treatment sessions may be used.
89654649|NCT04370925|Active Comparator|Matched control|Patients undergo radical resection of primary colorectal cancer and receive standard adjuvant systemic chemotherapy
89654650|NCT04370925|Experimental|HIPEC|Patients undergo radical resection of colorectal cancer and HIPEC simultaneously or within 2 days after primary tumor resection. Followed by standard adjuvant systemic chemotherapy
89654651|NCT02244255|Experimental|FLOMAX®|
89654652|NCT02244255|Active Comparator|HYTRIN®|
89654653|NCT04363983|Active Comparator|Located/resected colorectal cancer|
89046417|NCT02909972|Experimental|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days
89046418|NCT02909972|Experimental|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
89046419|NCT04688138||ischemic stroke|Patients with ischemic stroke within 7 days of onset
89046420|NCT01961778|Active Comparator|Radio-Frequency Ablation|Patients in this arm will receive treatment with radio-frequency ablation.
89046421|NCT01961778|Active Comparator|Cryothearpy|Patients in this arm will receive treatment with cryotherapy.
89654654|NCT04363983|Active Comparator|Advanced colorectal cancer|
89654655|NCT04363983|Active Comparator|Located/resected pancreatic cancer|
89654656|NCT04363983|Active Comparator|Advanced pancreatic cancer|
89654657|NCT04363983|Active Comparator|Located/resected biliary tract cancer|
89654658|NCT04363983|Active Comparator|Advanced biliary tract cancer|
89654659|NCT04363983|Active Comparator|Located/resected gastroesophageal cancer|
89654660|NCT04363983|Active Comparator|Advanced gastroesophageal cancer|
88993827|NCT02946307|Other|very small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter:2.00 mm）in very small vessel cohort
88993828|NCT00524875|Experimental|1|Intravitreal bevacizumab injection 1-2 weeks before surgery
88993829|NCT00524875|Sham Comparator|2|Sham injection (needleless syringe pressed against conjunctiva)
88993830|NCT00524914|Experimental|1|Apomorphine
88993831|NCT00524914|Placebo Comparator|2|Placebo
88993832|NCT02957864|Experimental|Switch to tenofovir alafenamide|Switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide
88993833|NCT02957864|Active Comparator|Switch to abacavir|Switch from tenofovir disoproxil fumarate (TDF) to abacavir
88993834|NCT00524953|Experimental|I|10 patients after allogeneic BMT (non T-depleted).
88993835|NCT02946541|Experimental|evogliptin 5mg|evogliptin 5mg QD
88993836|NCT02946541|Placebo Comparator|placebo|Placebo QD
88993837|NCT00526201|Experimental|Exercise|Subjects will be randomized to exercise (12 week EnhanceFitness class) or a wait-list control group.
88993838|NCT00526201|Other|Control|Wait-list control group will receive intervention after 12-weeks.
89046422|NCT04687943||PELOID therapy|A total of 15 sessions of peloid therapy for 3 weeks, 5 days a week for 42 patients in the first group
89654661|NCT04363983|Active Comparator|Located/resected neuroendocrine cancer|
89654662|NCT04363983|Active Comparator|Advanced neuroendocrine cancer|
89654663|NCT04363827|Experimental|Group 1: Hydroxychloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1, followed by a weekly dose of Hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, covering a total of 1 month of treatment.
89654664|NCT04363827|No Intervention|Group 1: Observation|observation only
89654665|NCT04363827|Experimental|Group 2: Hydroxycloroquine|A loading dose Hydroxychloroquine 400 mg twice daily at day 1 followed by 200 mg twice daily for a total of at least 5-7 days according to clinical evolution.
89654666|NCT04363827|No Intervention|Group 2: Observation|Observation only
89654667|NCT02157909|Experimental|AOA Modified|Lotrafilcon B sphere modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
89654668|NCT02157909|Active Comparator|AOA|Lotrafilcon B sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
89654669|NCT00923949|Experimental|Pioglitazone|45 mg tablet daily by mouth for six weeks
89654670|NCT02244333||Patients with symptomatic BPS|
89654671|NCT04364061|Experimental|Women with overweight or obesity|
89654672|NCT04363749|Experimental|15 COVID positive patients|dyspnea rating to various dyspneic stimulus
89654673|NCT04363749|Active Comparator|15 healthy controls|dyspnea rating to various dyspneic stimulus
88993839|NCT00525109||1|Single family cohort
88993840|NCT03585452|Active Comparator|Group C|Patients with typical anesthetic regimen: premedication: 2 mg estazolam p.o. and 10 mg morphine s.c. - 1 hour before procedure. Preoxygenation and induction of anaesthesia: remifentanyl 1 µg/kg, etomidate 0.3 mg/kg, pancuronium 0.1 mg/kg and intubation. Maintenance of the anesthesia: remifentanyl 0.2-0.5 µg/kg/min and propofol 2-4 mg/kg/min infusions. Ventilation with Air/O2. Additionally: nitroglycerine infusion or phenylephrine 0.05-0.1 mg boluses will be used for normotension maintenance at demanding doses. Subsequently typical CABG procedure with normothermic CPB will be performed. Weaning from CPB will be performed with inotropic support (dobutamine) and vasodilator (nitroglycerine) administration - with patients dependent doses. Routine recovery after surgery.
89046423|NCT04687943||Kinesio tape|42 patients in group 2 will be given 2 sessions of muscle and fascia correction techniques per week, with kinesio tape application and cold application
89654674|NCT04376541||early extubation|the patients extubated in O.R or within 2 hours in the ICU
89654675|NCT04376541||late extubation|the patients extubated after 2 hours from O.R
89654676|NCT04363593|Other|prospective group COVID|New patients consulting for suspected or diagnosed COVID(+)
89654677|NCT04363593|Other|retrospective group COVID|Patients already diagnosed with COVID(+) or with a suspicion of unconfirmed COVID or at a date before the apparition of the COVID infection (April-March 2019)
89654678|NCT04363593|Other|Hospital staff|All hospital staff including those already diagnosed at COVID(+)
89654679|NCT04370223|Experimental|Ozone auto-hemotherapy plus standard treatment|Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days.
89654680|NCT04370223|No Intervention|Standard treatment alone|Standard treatment will be the one used in each hospital participating in the trial.
89654681|NCT02635776|Experimental|AR101 powder provided in capsules & sachets|Study product provided as peanut protein in pull-apart capsules or sachets
89654682|NCT02635776|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
89654683|NCT04376307|Experimental|minimal flow anesthesia|the patiennts who have thoracic sugery with one lung ventilaiton
89654684|NCT04370457|Experimental|Experimental arm|Administration of the MyPal ePRO system
89654685|NCT04370457|No Intervention|Standard care arm|No further intervention besides standard palliative care approach if needed
89654686|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine|Participants will receive momelotinib (MMB)+capecitabine at varying dose levels to determine the MTD for momelotinib (MMB) and capecitabine.
89654687|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine+oxaliplatin|Upon reaching the MTD for momelotinib (MMB) and capecitabine or if no MTD is reached, participants will receive momelotinib (MMB)+capecitabine at the MTD plus oxaliplatin at varying dose levels to determine the MTD of combination capecitabine, momelotinib (MMB), and oxaliplatin.
89654688|NCT04993794|Active Comparator|XueBiJing|XBJ (Composed of Carthamus tinctorius L., Paeonia Lactifora Pall, Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, etc. Tianjin Chase Sun Pharmaceutical Group, Tianjin, China, batch No. 1603231) 100ml Xuebijing injection every 12 h (q12h) for 60 min
89654689|NCT04993794|Placebo Comparator|Normal saline|0.9% saline every 12 h (q12h) for 60 min
89654690|NCT04363515|No Intervention|Usual Pre-Transplant Counseling Intervention|Subjects in the control arm will undergo usual pre-transplant counseling as per the standard of care.
89046424|NCT04687943||Exercise|42 patients in the third group will be given 3 sets of 10 repetitions home exercise programs for 3 weeks
89046425|NCT04674657||caspofungin|Adult critically ill patients on ECMO receiving caspofungin therapy
89046426|NCT04674657||posaconazole|Adult critically ill patients on ECMO receiving posaconazole therapy
89654691|NCT04363515|Experimental|Social Support Network Counseling Intervention|Subjects in the intervention arm will undergo an additional pretransplant counseling session along with members of their social support networks between 2-12 weeks after their initial transplant evaluation and counseling
89654692|NCT05006508|Experimental|Usage of tool|Participants get access to the tool and use it regularly
89654693|NCT05006508|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool and get no further follow-up. Their development of type 2 diabetes or development of HbA1c is tracked via clinical registries.
89654694|NCT02244567|Active Comparator|Metformin|Cidophage 850 mg twice daily for three months will be given to the patientwith PCOS.
89654695|NCT02244567|Active Comparator|Serum under-carboxylated osteocalcin|Serum uc-oc will be measured before and after 3 months of treatment with cidophage.
89654696|NCT02244567|Active Comparator|Placebo|Other group of patients with high serum UC-OC will be given a placebo.
89654697|NCT04999410|Experimental|Long-HITT|Long work bout durations (4 minutes) on cycle ergometers or home trainers
89654698|NCT04999410|Active Comparator|Medium HIIT-L|Medium duration work bouts (2 minutes) with intensity matched to the Long-HITT intensity
89654699|NCT04999410|Active Comparator|Medium HIIT-H|Medium duration work bouts (2 minutes) with intensity at 30% of the difference between Wmax and mean TT power outputs
89654700|NCT04999410|Active Comparator|Short HIIT|Short duration work bouts (30 seconds) with intensity at 50% of the difference between Wmax and mean TT power outputs
89654701|NCT02244645|Other|Passive modality control group|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
89654702|NCT02244645|Experimental|Yoga treatment group|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
89654703|NCT04993092|Experimental|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
89654704|NCT04993092|Active Comparator|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
89654705|NCT04376073|Experimental|Treatment group|"Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh <77 kg) po QD day1~21, Anlotinib 12mg po QD day1~14.~Starting dose of anlotinib changed to 10mg from 2020-11-13."
89654706|NCT05006274||Group 1-Traditional soft tissue balance|Patients in group 1 will receive traditional, manual soft-tissue balancing during surgery. For the purpose of the study, the balance will be quantitatively assessed at the end of the case, by means of surgeon-blinded VERASENSE measurements before and after cementation.
89046427|NCT04688060||fallers|stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure Patients who have fallen 1 or more times since stroke
89046428|NCT04688060||non-fallers|"stroke duration of 6 months or more follow 3-step commands, were able to walk 10m with no physical assistance with or without any assistive device, and scoring ≥3 on Functional Ambulation Category, and physically able to complete the testing procedure.~Patients who have not fallen 1 or more times since stroke"
89654707|NCT05006274||Group 2-Soft tissue balance using VERASENSE|For the patients in Group 2, intra-operative sensor feedback will be used in creating a quantitatively balanced knee (VERASENSE, OrthoSensor Inc.). Thereby, a quantitatively balanced knee is characterized by a mediolateral load differential below 15lbs at 10-45-90 degrees of flexion.
89654708|NCT02244723||Patients with suspected VAP|"Only one group is studied : mechanically-ventilated patients with suspected VAP in ICUs.~For each patient a lung ultrasound examination will be performed."
89654709|NCT04999176|Experimental|Rivaroxaban|Oral Rivaroxaban (10 mg once daily) for 30 days post-operative
89654710|NCT04999176|Active Comparator|Enoxaparin|Subcutaneous Enoxaparin (40 mg once daily) for 30 days post-operative
89654711|NCT04363203|Active Comparator|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg capsule in the AM and 200 mg in the PM on Days 2-5
89654712|NCT04363203|Active Comparator|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM followed by 250mg PO every day on days 2-5
89654713|NCT04363203|Placebo Comparator|Placebo|The pills packs for the 3 arms are identical.
89654714|NCT03073590|Experimental|Intervention with lunch|Intervention factory with hot lunch program A. Nutritionally enhanced lunch meal program B. Once weekly iron/folate supplement C. Behavior change communications program
89654715|NCT03073590|Active Comparator|Control with lunch|Control factory with lunch program A. Regular lunch meal program B. Behavior change communications program
89046429|NCT04674735|Experimental|APSLXR|
89046430|NCT00555594|Active Comparator|A|Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
89046431|NCT00555594|Active Comparator|B|Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.
89654716|NCT03073590|Experimental|Intervention without lunch|Intervention factory without lunch program A. Twice weekly provision of iron/folate supplements B. Enhanced behavior change communications program
89654717|NCT03073590|Active Comparator|Control without lunch|Control factory without lunch program A. Behavior change communications program
89654718|NCT04369833||continuous glucose monitoring group|all participants wearing a continuous glucose monitoring device
89654719|NCT03073356|Experimental|Control - Healthy test subjects|Age matched subjects without symptoms of heart failure or ischemic heart disease N=10
89654720|NCT03073356|Experimental|HFrEF - Heart failure patients investigated by PET|Patients with heart failure (HFrEF) N=12
89046432|NCT02910050|Experimental|bicalutamide+ Aromatase Inhibitor|ER(+)/AR(+)/HER2(+) metastatic breast cancer patients that previously treated by an aromatase inhibitor
89046433|NCT04674930|No Intervention|Control group|Pharmacological management
89654721|NCT03073356|Experimental|HFrEF - Right heart catheterization|Patients with heart failure (HFrEF) N=12
89654722|NCT03073356|Experimental|HFrEF - Right heart catheterization study 2|Dose finding study (increasing dosage of 3-OHB)
89046434|NCT04674930|Experimental|Exercise group|"Aerobic training: The target training zone was set at 40-60% of the peak heart rate, as determined in the baseline 6min walk test (6MWT), with a rating of 11-13 on the Borg rating of perceived Exertion scale.~Resistance Training: This training was prescribed at 70% of one repetition maximum (RM). Patients were instructed to train a variety of upper and lower body muscle groups (e.g., latissimus, deltoid, biceps, quadriceps, and gastrocnemius muscles), using Thera-band"
89654723|NCT02244801|Other|Cohort 1|"3 subjects treated with a target dose of 300 million darTreg with the possibility of expanding to 5 patients if safety signals should require additional patients be observed at the 300 million dose.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
89654724|NCT02244801|Other|Cohort 2|"The second cohort will comprise a minimum of 3 and up to 5 subjects treated at a target dose of 900 million darTreg, depending on how many patients were required to be treated in lower dose group.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
89046435|NCT02909933|Experimental|liraglutide|liraglutide 3 mg QD for 12 weeks
89654725|NCT03078660|Experimental|Smartphone Application|Participants will have access to a smartphone application that provides a healthy shopping list based on requirements, budget and discounts to improve dietary practices and weight
89654726|NCT03078660|Active Comparator|Traditional Nutritional Counseling|Participants will participant in a face-to-face counseling session with a registered dietitian.
89654727|NCT02244879|Placebo Comparator|placebo|In this arm, 64 patients will receive a tablet of placebo once/day for 6 months
89654728|NCT02244879|Experimental|resveratrol 40|In this arm, 64 patients will receive a tablet of 40mg resveratrol once/day for 6 months
89654729|NCT02244879|Experimental|resveratrol 500|In this arm, 64 patients will receive a tablet of 500 mg resveratrol once/day for 6 months
89654730|NCT04369521|Experimental|Intervention|low free sugar diet with nutrition and exercise recommendation
89654731|NCT04369521|No Intervention|control|regular diet with nutrition and exercise recommendation
89654732|NCT04363047||Healthy Volunteers|"These people will have already provided at least one sample as part of the National Repository Healthy Volunteer Study.~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
89654733|NCT04363047||Rheumatoid Arthritis|"These people will have already provided at least one sample as part of the BRAGGSS Study.~We aim to take blood samples from participants who have recovered from COVID-19 and compare them with blood samples we already have which were taken before the COVID-19 pandemic.~We will need to compare these samples to other samples, so we will also need to blood samples from people who have not had COVID-19 (who have either tested negative or never had any symptoms)."
89654734|NCT02245035||Low dairy intake|1 serving/day or less of dairy food characterized at enrollment using 24 hr dietary recall
89654735|NCT02245035||Moderate Dairy Intake|1-2 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
89654736|NCT02245035||Recommended Dairy Intake|Greater than 3 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
89654737|NCT04998630|Experimental|A (4Hz)|ESWT frequency 4Hz washout period: 1 week
89654738|NCT04998630|Experimental|B (8Hz)|ESWT frequency 8Hz washout period: 1 week
89654739|NCT04998552|Experimental|SBRT (Cyberknife)|5-10 Gy/fraction. Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
89654740|NCT04998552|Active Comparator|IMRT|1.2-3 Gy/fraction up to 40 fractions. 15 mins daily (M-F) for a total of 28 sessions (5.5 weeks).
89654741|NCT04376151|Experimental|Intervention|Participants will work through an Acceptance and Commitment Therapy informed self-help bibliotherapy over a period of eight weeks. The bibliotherapy is called 'Get Out of Your Life and Into your Mind' written by Steve. C. Hayes.
89654742|NCT02704403|Experimental|120 mg Elafibranor|Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
89046436|NCT02909933|Experimental|metformin and liraglutide|metformin 1000 mg BID and liraglutide 1.2 mg QD for 12 weeks
89046437|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 1 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 1 of aluminum adjuvant Day 28: Placebo
89046438|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant Day 28: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant
89046439|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant
89654743|NCT02704403|Placebo Comparator|Placebo|Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
89654744|NCT04998474|Experimental|FRAME-001 personalized vaccine|"Prospective, single arm, multi center, open-label, phase II clinical trial.~Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs."
89654745|NCT04362735||Study group|All patients using vedolizumab for Crohn's disease as first biologic agent (all patients naive to previous biological therapy)
89654746|NCT05005884|Active Comparator|oral phenolics intake|Prescription of oral phenolics 250 mg two times daily
89654747|NCT05005884|Placebo Comparator|placebo caplet intake|Prescription of oral phenolics 250 mg two times daily
89654748|NCT03075384||open reduction and internal fixation|A classic method was used to treat unilateral complicated zygomatic fractures without the assistance of computer-assisted navigation system
89654749|NCT04375995|Other|Asthma group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed to all asthmatic patients.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. Asthma control test (ACT) and asthma quality of life scale (AQLQ) will be applied. All patients will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for asthma.
89654750|NCT04375995|Other|Healthy control group|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
89654751|NCT04365231|Experimental|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
89654752|NCT04365231|Active Comparator|conventional management of patients|Regular management of patients
89654753|NCT03075306|No Intervention|usual care|usual care and materials on healthy weight
89654754|NCT03075306|Experimental|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
89654755|NCT03075228||Lean subjects|Lean is defined as having a BMI of 19-23 kg/m2, waist circumference <80 cm and fasting glucose levels <6.1 mmol/L.
89654756|NCT03075228||Obese subjects|Obese is defined as having a BMI of 30-35 kg/m2, waist circumference >88 cm and fasting glucose levels >=6.1 and <7.5 mmol/L
89654757|NCT04369287||IDH1-mutated AML|Patients affected with AML and carryng IDH1 mutations
89654758|NCT04369287||IDH2-mutated AML|Patients affected with AML and carryng IDH2 mutations
89654759|NCT04369287||IDH1/2 unmutated AML|Patients affected with AML without IDH1/2 mutations
89654760|NCT04370535|Placebo Comparator|Control group + cellulose (Group A)|healthy subjects (control group) receive placebo (cellulose) as powder
89654761|NCT04370535|Active Comparator|Control group + PMA-zeolite(Group B)|healthy subjects (control group) receive PMA-zeolite as powder
89654762|NCT04370535|Placebo Comparator|UCD-group + Cellulose (Group C)|subjects with uncontrolled Crohn disease (UCD group) receive placebo (cellulose) as powder
89654763|NCT04370535|Active Comparator|UCD-group + PMA-zeolite (Group D)|subjects with uncontrolled Crohn disease receive PMA-zeolite as powder
89654764|NCT04993014|Active Comparator|Cohort 1, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 positive CTCs at baseline
89654765|NCT04993014|Experimental|Cohort 1, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 positive CTCs at baseline
89654766|NCT04993014|Active Comparator|Cohort 2, Arm A - trastuzumab|Adjuvant trastuzumab for patients with HER2 negative/absent CTCs at baseline
89046440|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant
89046441|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 2 of aluminum adjuvant Day 28: Placebo
89046442|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Placebo
89046443|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen content with Dose 4 of aluminum adjuvant Day 28: Placebo
89046444|NCT01960686|Placebo Comparator|Placebo|Day 0: Placebo Day 28: Placebo
89654767|NCT04993014|Experimental|Cohort 2, Arm B - Trastuzumab + pertuzumab|Adjuvant trastuzumab + pertuzumab for patients with HER2 negative/absent CTCs at baseline
89654768|NCT05005494|Active Comparator|Magnesium sulfate IV|10 patients scheduled for thyroidectomy
89654769|NCT05005494|Placebo Comparator|Placebo|10 patients scheduled for thyroidectomy
89654770|NCT04362423||propofol+fNIRS|During data collection, only propofol is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
89654771|NCT04362423||sevoflurane+fNIRS|During data collection, only sevoflurane is used to maintain the anesthesia. Peripheral noxious stimuli produced from the neurophysiological monitoring (SSEP)
89654772|NCT04362423||neuro-stimulator+fNIRS|During data collection, we use neuro-stimulator to give the stimulation.
89654773|NCT03072966|Experimental|Distress screening group|Physical activities will be monitored by wearable device. Patient-reported outcomes including distress, depression, physical activities and quality of life are going to be collected by questionnaires based on smartphone application and paper. The algorithm of distress screening will be developed with the analysis of patterns of physical activities.
89654774|NCT04025645||PATIENTS WITH CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITH CHOLELITHIASIS
89654775|NCT04025645||PATIENTS WITHOUT CHOLELITHIASIS|COMMON BILE DUCT PRESSURES WERE MEASURED IN PATIENTS WITHOUT CHOLELITHIASIS
89654776|NCT04375839|Experimental|Main treatment group|Zirconia implants will be placed in a prosthetically guided position in horizontally deficient ridges in main treatment group.
89654777|NCT04375839|Active Comparator|Control group|Titanium implants will be placed in a prosthetically guided position in horizontally deficient ridges in control group.
89654778|NCT04025567|Experimental|1/Arm 1|Oral vancomycin
89654779|NCT03074994|Experimental|Peri-articular tranexamic acid injection|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue+Medial gutter area+Lateral gutter area)
89654780|NCT03074994|Experimental|Intraarticular tranexamic acid injection|TXA inject into intraaricular knee capsule after multimodal local anesthetic infiltration
89654781|NCT03074994|No Intervention|Control group|Don't receive any route of TXA
89654782|NCT04025177|Experimental|Neonates with an open PDA|Neonates born between 23 (0/7) and 26 (6/7) weeks gestational age with an open PDA, according to clinical protocol criteria, and no contraindication to the use of indomethacin.
89654783|NCT04992702|Experimental|Animated Video|The information in the ACL animated video (https://vimeo.com/281721823) was displayed as a story of a typical athlete who sustained an injury and how this could be prevented through evidence-based prevention strategies.
89654784|NCT04992702|Active Comparator|Web-based Article|The active control group received commonly accessed information from a WebMD web-based article on ACL injury prevention.
89654785|NCT04992702|Placebo Comparator|Placebo control|The placebo control group intervention received an educational video from the CDC about concussions that is comparable in duration to that of the ACL video (https://youtu.be/fSRWF44wgn8).
89654786|NCT04347057|Experimental|Arm 1|"Arm 1 (39 patients) included first the control period, followed by one-day wash-out, and then the intervention period.~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
89654787|NCT04347057|Experimental|Arm 2|"Arm 2 (39 patients) included first the intervention period, followed by one-day wash-out, and then the control period.~Procedures for control period included providing daily bed bathing with soap and water over three consecutive days, while intervention period included daily bed bathing with 2% CHG solution over three consecutive days."
89654788|NCT03078036||Observation|Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
89654789|NCT02709317|Active Comparator|Standard Care|In this arm, veterans receive the care that they would receive had they not enrolled in the research. No one will receive less than standard care.
89654790|NCT02709317|Experimental|Prevention Intervention|An adaptive monitoring intervention, delivered through text messages and brief telephone calls, that can provide extended prevention services for veterans engaging in risky alcohol use. After a veteran receives a BI for risky drinking, we will monitor alcohol use for 4 weeks. Veterans who reduce alcohol use to safe levels will be placed in a monitoring track, which consists of tailored text messages and brief monthly telephone contacts. Conversely, veterans who continue to use alcohol at hazardous levels will be placed in a track that provides tailored text messages and more frequent telephone calls. These calls provide further prevention/intervention services to help the veteran reduce alcohol use. These services address motivational issues and identify more effective ways to cope with stress and other factors that trigger unsafe alcohol use. Information on the veteran's progress is used to guide the content of subsequent text messages and prevention interventions.
89654791|NCT04357977||Covid +|Laboratory obtained Covid+ specimen results will be compared to saliva specimen
89046445|NCT02910245|Active Comparator|Mercaptopurine (Purinethol)|Mercaptopurine (Purinethol),1-1.5 mg/kg/day oral, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
89046446|NCT02910245|Placebo Comparator|Placebo|Placebo, 1-1.5 mg/kg/day, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
89046447|NCT04674891|Active Comparator|baseline physical therapy treatment|baseline physical therapy treatment ,Control group- Group A
89046448|NCT04674891|Experimental|Cervical Stabilization exercises|baseline physical therapy treatment along with Cervical Stabilization exercises- Experimental Group- Group B
89046449|NCT01185340|Experimental|LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the LY2216684 treatment arm.~For the first 2 weeks of the AT Phase, participants received a starting dose of 12 mg QD. Then, based on efficacy and tolerability, the dose could be increased to 18 mg QD over the next 6 weeks. Participants who had their dose increased to 18 mg QD could have had their dose decreased to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
89046450|NCT01185340|Placebo Comparator|Placebo + SSRI|"Placebo: Administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the placebo treatment arm.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
89046451|NCT01959282|Placebo Comparator|Placebo|Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32
89046452|NCT01959282|Experimental|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32
89654792|NCT04362033|Experimental|PLR group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:~In PLR arm, patients will be submitted to the PLR maneuver (patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grade) firstly, then PEEP increment maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
89046453|NCT01959282|Experimental|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32
89654793|NCT04362033|Experimental|PEEP group|"Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization:~In PEEP arm, patients will be submitted to the PEEP maneuver (consisted in increase the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position) firstly, then PLR maneuver. At the end, all patients will receive a bolus of 500mL of Lactate Ringer's"
89654794|NCT02985281|Active Comparator|Arm 1|"20 patients will be randomly assigned into arm 1; treated for fixed 24 duration with Gratisovir (Sofosbuvir) and Ribavirin. First intervention 'Sofosbuvir oral product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
89654795|NCT02985281|Active Comparator|Arm 2|"20 patients will be randomly assigned into arm 2; treated as response guided duration; patient who show very rapid virological (undetectable HCV RNA after 2 weeks) will be treated for 16 weeks duration and reset will complete the 24 weeks duration.~Intervention 'Sofosbuvir Oral Product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
89654796|NCT03072888|Experimental|TENS|TENS treatment will be apply with 30 minutes sessions seven times per day at the intensity between 9-15 milliamps (mA) which will be adjusted depending on the sensitivity of each individual patient.
89654797|NCT03072888|Sham Comparator|Control|Patients will receive 30 minutes sessions seven times per day of sham TENS therapy without the intensity impulse.
89654798|NCT00927849|Active Comparator|surgical group lateral sphincterotomy|underwent closed lateral internal sphincterotomy (LIS) under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
89654799|NCT00927849|Active Comparator|Glycerin trinitrate group|all were instructed to apply the Glycerin trinitrate group (GTN) ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
89654800|NCT00927849|Active Comparator|botulinum toxin injection|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
89654801|NCT03072810|Experimental|Positive mindfulness program|Participants will receive a 4 week online positive mindfulness program as described in previous sections.
89654802|NCT03072810|Other|Waitlist control|Participants will receive the same intervention as the intervention arm (positive mindfulness program) but will be required to wait 4 weeks before commencing.
89654803|NCT04149587||Brodalumab 210 mg Q2W|Participants will receive brodalumab 210 milligrams (mg) administered as 1 subcutaneous injection at Day 1 and at Weeks 1 and 2 followed by 210 mg every 2 weeks (Q2W) thereafter until Week 26.
89654804|NCT02985125|Experimental|Phase I - Dose Level 1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 250mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
89654805|NCT02985125|Experimental|Phase I - Dose Level 2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 300mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
89654806|NCT02985125|Experimental|Phase I - Dose Level -1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 200mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
89654807|NCT02985125|Experimental|Phase I - Dose Level -2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 150mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
89654808|NCT02985125|Experimental|Phase II - Dose|"Treatment cycles are 28 days long.~LEE011 (taken orally) - the recommended phase II dose Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
89654809|NCT03072420|Experimental|Group no manual work or activity|Subject with an office or student job.
89654810|NCT03072420|Sham Comparator|Group manual work|Subject working in a manual or predominantly manual.
89654811|NCT04025099|Experimental|Internal Cues|"Over 10 weeks, participants will be asked to participate in the following:~Classes (held in STAR Tower 419/420 IPE Space and Conference Room 413)~One ~60-minute Intuitive Eating class per week (total = 10 classes);~Two ~60-minute yoga classes per week (total = 20 classes);~Repeat one of the ~60-minute yoga classes each week on the participants' own, in a space participants feel comfortable, using a video recording (total = 10 classes).~Assessments (held in STAR tower)~Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
89046454|NCT01959282|Experimental|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32
89654812|NCT04025099|Active Comparator|External Cues|"Over the next 10 weeks, participants will be asked to participate in the following:~Classes (held in STAR Tower 419/420 IPE Space)~One ~60-minute Healthy Eating class per week (total = 10 classes);~Participants will be provided with a UD group fitness membership. Using this membership, participants will be asked to attend at least 2 cardio fitness classes per week and do an additional 30 minutes of heart-raising activity on participants' own (total = 3 exercise sessions/week).~Assessments (held in STAR tower)~Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
89046455|NCT01959282|Experimental|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32
89046456|NCT01216189||Preoperative radiotherapy|Women with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
89654813|NCT04025099|No Intervention|Assessment Only|"Over the next 10 weeks, participants will be asked to participate in the following:~a. Assessments (held in STAR tower)~•Three ~60-minute assessments* which will include:~Height & weight measurements (taken privately)~A questionnaire that asks about participants' relationship with their body and eating and activity behaviors~Collection of participants' heart rate overnight (on their own)~Collection of participants' saliva three times in one day (on their own)"
89654814|NCT04140929|Experimental|Intervention group|In the intervention group, a range of clinical parameters are recorded and the dentists prepares an individual oral hygiene and care recommendation, based on the Oral Health Tool Box. The Box is also used for instructing the dental assistants and the nursing staff for each patient individually. It is then determined when and how the dental assistants re-evaluates the oral hygiene and care process and reinstructs and remotivates the nursing staff. If the examination reveals a need for dental treatment (possibly requiring referral and transport), this will be communicated to the nursing staff. The dental assistant will further receive a training in communication, enabling them in reinstruction and remotivation. Dentists and dental assistants will further receive a training in geriatric dentistry by the State Commissioner of the German Society for Geriatric Dentistry.
89654815|NCT04140929|No Intervention|Control group|In the control group, the residents receive care as usual. This includes the recording of the same parameters are recorded as in intervention group, a standardized form is filled out and handed over to the nursing staff. As in the case of Intervention group, the nursing staff is informed in the event of a need for treatment. No further measures are applied.
89654816|NCT00936741|Experimental|Mifepristone|Mifepristone 300mg to 1200mg once daily
89654817|NCT04141631|Experimental|STOP Group|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~Hb < 13g/dL the day before surgery~Hb ≥ 7g/dL AND ScvO2 > 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb < 7g/dL independently of ScVO2 value"
89046457|NCT01216189||No preoperative radiotherapy|Women with rectal cancer treated with surgery alone (no RT).
89046458|NCT02909738||Volunteers|Healthy volunteers willing to pedal a bike for 30 minutes.
89046459|NCT04674696|Experimental|Experimental|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
89046460|NCT02909699||Dose 1|1,000mg of resveratrol per day (1 pill 3 times per day). This ancillary study will be observational without drug administration.
89046461|NCT02909699||Dose 2|1,500mg of resveratrol per day (1 pill 3 times per day)
89046462|NCT02909699||Placebo|Alike looking 1 pill 3 times per day
89046463|NCT01958853|Experimental|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
89046464|NCT01185301|Active Comparator|ADA + 2.5 mg MTX|2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
89046465|NCT01185301|Active Comparator|ADA + 5 mg MTX|5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
89046466|NCT01185301|Active Comparator|ADA + 10 mg MTX|10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
89046467|NCT01185301|Active Comparator|ADA + 20 mg MTX|MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
89046468|NCT02909855||Participants|Parents of children aged 2-4 who will receive the child flu vaccine from their general practitioner (GP)
89046469|NCT01957722|Experimental|NOVOCART 3D|Scaffold assisted autologous chondrocyte Implant
89046470|NCT01957722|Active Comparator|Microfracture|considered a typical treatment for articular cartilage repair
89046471|NCT02909660|Experimental|Support-seeking intervention|Cognitive-behavioural therapy intervention that guides participants to seek support rather than reassurance; participants' significant others are asked to provide support rather than reassurance.
89046472|NCT02909660|Active Comparator|Family accommodation reduction intervention|Cognitive-behavioural therapy intervention that guides participants' significant others to withhold reassurance when it is requested; participants are asked to refrain from seeking reassurance.
89046473|NCT02909894|Experimental|Prolonged Sitting|
89046474|NCT02909894|Active Comparator|Light intensity arm ergometry breaks|
89046475|NCT01955616|Active Comparator|RM-131|RM-131 100 µg by subcutaneous injection daily in the morning
89046476|NCT01955616|Placebo Comparator|Placebo|by subcutaneous injection daily in the morning
89046477|NCT02909621|Active Comparator|Group A|Group A: FLEXOFYTOL® high dosage
89046478|NCT02909621|Active Comparator|Group B|Group B: FLEXOFYTOL® low dosage
89046479|NCT02909621|Placebo Comparator|Group C|Group C: PLACEBO
89654818|NCT04141631|No Intervention|Control Group|"Only postoperative anemia will be managed:~RBC transfusion will be performed if Hb ≤ 8 g/dL (2017 EACTS/EACTA guidelines)~Iron sucrose administration if Hb > 8g/dL : 2 injections of 200 mg according to Height (+/- 70 Kg) in 250 mL of saline solution 0.9% over 1h30 into 48 h intervals without exceeding a total dose of 15mg/kg."
89046480|NCT04675008|Experimental|Study arm|Dacomitinib
89046481|NCT01954173|Experimental|3D conformal radiation therapy|Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
89046482|NCT01216072|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .
89046483|NCT01216072|Active Comparator|Multiple Sclerosis Disease Modifying Treatments (MS DMTs)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.
89654819|NCT04024865||Treated with domperidone|Women who received a prescription for domperidone during the six months following delivery.
89654820|NCT04024865||Unexposed group (reference)|Women with no prescription for domperidone during the six months following delivery.
89654821|NCT04997928||Group 1 (n=20; with mild symptoms)|"Group 1 (n=20; with mild symptoms)~Covid positive patients with mild symptoms who required to be hospitalized,~Symptomatic (fever, cough, weakness, joint pain, etc.) new patients who apply to the Covid clinic for the first time,~Patients with stable vital signs and/or SpO2 ≥92% in room air, no radiological signs of lung involvement or mild pneumonia,~Patients who have not been started on steroid therapy and who have not yet received anticoagulant therapy."
89654822|NCT04997928||Group 2 (n=20; with moderate symptoms)|"Group 2 (n=20; with moderate symptoms)~Patients who are positive for Covid 19 and admitted to the covid clinic for the first time;~Radiologically moderate pneumonia findings and/or SpO2=88-92% in room air,~Patients who have not been started antiviral, steroid, and anticoagulant treatment."
89654823|NCT04997928||Group 3 (n=20; with severe symptoms)|"Group 3 (n=20; with severe symptoms)~Patients who are currently hospitalized in the Covid clinic,~Patients with radiological findings of severe pneumonia or ARDS and/or high FiO2 requirement due to respiratory failure.~Patients of this group may have received antiviral, anticoagulant, and/or steroid and/or biologic agent treatment."
89654824|NCT04997928||Group 4 (n=20; Control group)|"Group 4 (n=20; Control group)~The control group will be composed of healthy adult individuals applying to adult allergy outpatient clinics on a voluntary basis.~Patients who have not been previously diagnosed with Covid-19 and have not vaccinated against Covid-19,~The control patients will be matched with the study groups according to age, gender, and BMI."
89654825|NCT04357743|Experimental|Chin supported Arm ergometry with pursed lip breathing|Chin supported along with Arm ergometry with pursed lip breathing
89654826|NCT04357743|Active Comparator|Arm ergometry with pursed lip breathing|Arm ergometry with pursed lip breathing
89654827|NCT02985047|Experimental|Brief Admission|Participants randomised to Brief admission (BA) will have the possibility of admitting themselves to hospital for a maximum duration of three consecutive days at a maximum frequency of three times per month. Apart from BA they have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
89654828|NCT02985047|No Intervention|Control|Participants randomized to Treatment as Usual will receive no intervention from the study protocol, except the baseline assessments and repeated assessments administered on the same schedule as described above for the treatment group. They will not be given the evaluation measures that are specific to the intervention. Participants have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
89654829|NCT04024319||Genicular Nerve Block|GNB will be performed on this group of patients undergoing TKR. The patient will be positioned in the supine position, with the extremity to operate slightly in external rotation. The anesthesiologist will be located ipsilateral to the knee to intervene; asepsis will be performed with 70% chlorhexidine, sterile gloves will be used and the ultrasound probe will be protected with a sterile cover. The ultrasound transducer will be placed in a long axis of the knee in the corresponding area to block according to anatomical repairs. 4 ml of 0,2% ropivacaine was administered in each GN.
89654830|NCT04024319||Local Infiltration Analgesia|Retrospectively, the data of the patients belonging to the control group (LIA) were collected through the electronic file in the SAPP program of the internal network of the Barcelona Clinic Hospital in chronological order until completing 35 cases. To include them in the control group, the patients had to meet the same criteria as those belonging to the intervention group (GNB), therefore, the surgery should have been performed under spinal anesthesia and subsequently followed with an oral analgesia schedule meeting criteria of fast track hospitalization. The same data were obtained as in the GNBG, demographic data (age, sex, weight, height, hematocrit, hemoglobin, ASA), duration of the surgery and ischemia time, PACU VAS, AM VAS, PM VAS and finally some data of the post-operative period (hematocrit, hemoglobin, transfusion, hospital stay)
89654831|NCT04024241||high dose of cytarabine|high dose of cytarabine
89654832|NCT04024241||HAM|medium dose of cytarabine and mitoxantrone
89654833|NCT03074916||DIP arthroplasty|
89654834|NCT03074916||DIP arthrodesis|
89654835|NCT04996992||Parkinson's disease|The cohort includes patients with Parkinson's disease who underwent MRgFUS pallidothalamic tractotomy (PTT).
89654836|NCT04023929||Term babies|Babies who are born at or after 37 gestational weeks.
89654837|NCT04023929||Preterm babies|Babies who are born between 32 and 36+6 gestational weeks.
89046484|NCT02909582|No Intervention|Pfannenstiel Incision|This curved incision is approximately 10-15 cm long and 2 cm above the pubic symphysis. If a pannus is present, the pannus should be retracted up (see diagram) to allow placement of the Pfannenstiel incision.
89046485|NCT02909582|Experimental|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
89046486|NCT01940991|Placebo Comparator|Dose B|Dose B: Placebo
89046487|NCT01940991|Experimental|Dose A|Dose A: Botulinum Toxin Type A
89046488|NCT02909465|Placebo Comparator|placebo|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections of distilled water (one 2 ml and the other 0.05 cc/kg) 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
89046489|NCT02909465|Experimental|midazolam|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. one will be 2 ml of distilled water and the other 0.05 mg/kg midazolam, 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
89654838|NCT04023929||Very preterm babies|Babies who are born before 32 gestational weeks.
89654839|NCT04996836|Experimental|BC diagnosis and Omics|"Participants will be offered:~Liquid biopsy of ctDNA and targeted NGS (BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, RAD50, RAD51C, RAD51D, NF1, EPCAM, SMARCA4, CDK12);~Whole-genome RRBS"
89654840|NCT04996836|No Intervention|BC diagnosis and standard of the care|Participants will not be offered targeted NGS or whole-genome RRBS but will receive their usual clinical care
89654841|NCT04023851||Adolescent patient|"Participant between the ages of 15-18~Participants who are taking antiepileptic drug for seizure control"
89654842|NCT04023851||Parents with epilepsy children|"Participants who have child with epilepsy (ages of 1-15)~Participants' child who are taking antiepileptic drug for seizure control"
89654843|NCT04996914|Experimental|TACE+SBRT.|If a patient is eligible to participate in the project according to the in- and exclusion criteria, the patient will assigned to 1-2 sessions of TACE followed by SBRT within one month from last TACE session .
89654844|NCT03023033|Experimental|Clinic group 1|Clinics using SMS health promotion and reminder messages (mhealth messaging)
89654845|NCT03023033|Experimental|Clinic group 2|Clinics using SMS health promotion and reminder messages + Clinics providing payment scaled to reflect typical transport costs to facility (transport payments)
89654846|NCT03023033|No Intervention|Clinic group 3|Services provided under the Ministry of Health standard care
89654847|NCT03074760||Contaminated acequias|
89654848|NCT03074760||Non-contaminated acequias|
89654849|NCT04145375|Experimental|Experimental: ZEN003694 in Combination with Enzalutamide|Patients who have completed participation in their original ZEN003694-002 protocol and have clinical benefit as determined by the investigator may continue to receive treatment with ZEN003694 in combination with enzalutamide
89654850|NCT03022955|Active Comparator|Dark chocolate: FDG-PET|100 g dark chocolate bar (70% cocoa solids (~500kcal, ~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
89654851|NCT03022955|Active Comparator|Dark chocolate: Physiological Measurement|150 g dark chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
89654852|NCT03022955|Placebo Comparator|White chocolate: FDG-PET|100 g white chocolate bar (0% cocoa solids (~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.
89654853|NCT03022955|Placebo Comparator|White chocolate: Physiological Measurement|150 g white chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
89654854|NCT03074838|Experimental|Transarterial aortic valve implantation|Patients that are treated by trans arterial valve implantation (TAVI)
89654855|NCT03074838|Active Comparator|Surgical aortic valve replacement|Patients that are treated by surgical aortic valve replacement (SAVR)
89654856|NCT04996290|Active Comparator|PENG + LFCN block|"The participants in this group received a combined regional technique just before surgery:~Pericapsular nerve group (PENG) block~Lateral femoral cutaneus nerve (LFCN) block"
89654857|NCT04996290|No Intervention|No regional anesthesia|Control group
89654858|NCT03022721||Patients with diabetes|"Patients with both type 1 and type 2 Diabetes will be enrolled, Independent of Diabetes Duration, therapy etc.~No interventions are planned."
89654859|NCT03022721||Pre-Diabetics|"Patients who have either imparied fasting Glucose or impaired Glucose tolerance in the oral Glucose tolerance test.~No interventions are planned."
89654860|NCT03022721||Healthy controls|"Study participants without Diabetes or Pre-diabetes in the oral Glucose tolerance test.~no interventions are planned."
89654861|NCT04023617|Experimental|Nivolumab + Docetaxel|"Nivolumab was administered at a dose of 300 mg on the first day of the 21-day cycle (every 3 weeks; q3w) when combined with docetaxel, and administered at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w) after stopping docetaxel treatment.~On the first day of each cycle (21 days), docetaxel 75 mg/m2 was infused by IV on Day 1 of each 21-day cycle for 4-6 cycles (judged by investigator)."
89654862|NCT04023617|Active Comparator|Nivolumab|Nivolumab was administered in the monotherapy group at a dose of 200 mg on the first day of each 14-day cycle (every 2 weeks; q2w).
89654863|NCT04023149|Experimental|experimental group|Patients will receive rhIL-2 solution oral gargle twice per day (2 million units of rhIL-2 dissolved in 5ml normal saline for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
89654864|NCT04023149|Placebo Comparator|control group|Patients will receive placebo solution oral gargle twice per day (5ml for each dose, garble for 3 minutes) and continue for 3 weeks. A standard dose of glucocorticoids (mucosal-dominant PV: prednisone 0.5 mg/kg/d, moderate mucocutaneous PV: prednisone 0.75 mg/kg/d) will be applied at the same time.
89654865|NCT04149431|Active Comparator|Derinat|nasal drops
89654866|NCT04149431|Placebo Comparator|Placebo|nasal drops
89654867|NCT04149275|Experimental|Cabozantinib + Nivolumab + Ipilimumab|All recurrent carcinosarcomas
89654868|NCT04148963|Experimental|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
89654869|NCT04148963|Placebo Comparator|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
89654870|NCT04022837|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
89654871|NCT04022837|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
89654872|NCT04022681||Non-specific liver disease|Patients who were categorised as having a non-specific liver disease in the original BALLETS study.
89654873|NCT04022759|Active Comparator|Treatment as Usual|Participants randomised to the 'treatment as usual' group will receive behavioural activation guided-self help intervention as routinely delivered in the service.
89654874|NCT04022759|Experimental|Treatment with Security Prime|Participants randomised to the experimental group will receive behavioural activation guided self-help intervention as is routinely delivered in the service with additional attachment security priming intervention.
89046490|NCT02909465|Experimental|haloperidol|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
89046491|NCT01184989|Other|Dabigatran etexilate|open label, once daily dose approved by EMEA and Health Canada
89046492|NCT02909192|Active Comparator|Bright light therapy|Participants will be treated twice daily with bright light therapy.
89654875|NCT03022331||Observational|
89654876|NCT03022175|Experimental|SPR741|"SPR741 is a novel chemical entity known as a potentiator that specifically interacts with the outer membrane of Gram-negative bacteria to increase the membrane's permeability. This increase in permeability allows Gram-positive antibiotics to enter and kill the cell.~SAD cohorts: Subjects will receive single doses of SPR741 over 60 minute IV infusion. Planned doses to be studied are 5, 15, 50, 100, 200, 400, 600 and 800 mg.~MAD cohorts: Subjects will receive SPR741 over 60 minute IV infusion three times a day (TID). Four dose groups will be studied. Doses will be determined by assessing SAD cohort data."
89654877|NCT03022175|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over 60 minutes.~MAD: Subjects will receive TID infusions of placebo over 60 minutes for 14 days"
89654878|NCT04022993|Active Comparator|Lantus® SoloStar®|Lantus® SoloStar® once a day, individually glucose-level based administered in stable doses, started before enrollement
89654879|NCT04022993|Experimental|Insulin RinGlar®|Insulin RinGlar® once a day, individually glucose-level based administered in stable doses, started before enrollement
89654880|NCT04148885|Experimental|nab-paclitaxel + Carboplatin|nab-paclitaxel at 260 mg/m^2 on days 1; Carboplatin AUG=5, d1, 21 days in one cycle, 3 cycles in total
89654881|NCT04022525||leflunomide responsive vs non-responsive|
89654882|NCT04022291|Experimental|Biocon Insulin 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
89654883|NCT04022291|Active Comparator|Humulin® 70/30|0.4 IU/kg Dose per administration, Subcutaneous Route of administration
89654884|NCT02636868|Experimental|Aerosolized lucinactant (low dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
89654885|NCT02636868|Experimental|Aerosolized lucinactant (high dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
89654886|NCT02636868|Active Comparator|nasal CPAP|nCPAP alone
89654887|NCT04022369|Experimental|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. Education program based on Empowerment model. Weekly motivational telephone interviews were conducted with the patients, and the home visits and telephone interviews were repeated when belived necessary. The purpose of the study were explained to all individuals involved in the study. Body movements, balance levels, exercise durations, and strengths of individuals before exercise program and after exercise program were evaluated. A booklet demonstrating the exercises was given to the patients to enhance their understanding, and they were allowed to ask questions about the exercise program during the training.
89654888|NCT04022369|No Intervention|Control Group|The patients in the control group continued their standard treatment and care. Data collection forms were applied to the patients in the control group at the first month and 12 weeks after discharge. After the study was completed, all patients in the control group were provided with home-based exercise training booklets.
89654889|NCT04021823||DBS patients|Patients with treatment resistant major depression participating in the FORESEE III study.
89654890|NCT04021823||Healthy controls|Age- and sex-matched healthy controls undergoing analyses of neurodegenerative markers (neurofilament light protein) in blood and metabolomic analyses in blood and urine.
89654891|NCT03074448|Active Comparator|Sodium Picosulfate solution (Picoprep)|On the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
89046493|NCT02909192|Active Comparator|Dim-Red light therapy|Participants will be treated twice daily with dim-red light therapy.
89046494|NCT04674423|Experimental|TAF Treatment|TAF treatment for 144 weeks and followed for 48 weeks after 144-week TAF treatment
89046495|NCT04674423|No Intervention|Observation arm|Observation for 144 weeks
89046496|NCT02909387|Experimental|Stratum A|This group will be the first to receive the Project UPLIFT intervention, a distance-delivered mindfulness-based cognitive therapy intervention. The intervention is conducted by phone for one hour once a week for 8 weeks.
89046497|NCT02909387|Active Comparator|Stratum B|This group will also receive the Project UPLIFT intervention at crossover, after a 10-week waiting period.
89046498|NCT00555828|Experimental|A1|5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
89046499|NCT00555828|Other|A2|5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
89046500|NCT00555828|Experimental|B1|5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
89654892|NCT03074448|Experimental|Aquanet bowel cleansing devices|For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
89654893|NCT03074604|Experimental|aortic no-touch OPCABG|aortic no-touch OPCABG
89654894|NCT03074604|Experimental|OPCABG with partial clamp applying carbon dioxide|OPCABG with partial clamp applying carbon dioxide
89654895|NCT03074604|Active Comparator|OPCABG with partial clamp|OPCABG with partial clamp
89654896|NCT04405895|Experimental|Breakfast Diet (3Mdiet)|The Breakfast Diet (3Mdiet) will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
89654897|NCT04405895|Active Comparator|Allday Diet (6Mdiet)|The Allday Diet (6Mdiet) will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% in each of the three snacks.
89654898|NCT04992000|Experimental|4-free app + PHN intervention|"The intervention group was received initial education, 4-free apps, and followed by PHN interventions.~Education, app, and PHN intervention"
89654899|NCT04992000|Experimental|4-free app alone|The apps alone group received the initial education and the 4-free Apps.
89654900|NCT04992000|No Intervention|education|Standard care group received just the initial education.
89654901|NCT04021979|Experimental|Enteral Nutritional+PEG|Enteral Nutritional Powder with low volume 1.5L PEG
89654902|NCT04021979|Placebo Comparator|Self-controlled diet+PEG|Self-controlled diet with normal amount of 2L PEG
89654903|NCT04991844|No Intervention|Control group|The control group did not receive any intervention, but met at three timepoints to complete study questionnaires and provide anthropometric measurements,
89654904|NCT04991844|Experimental|Intervention Group|This group received the study intervention protocol.
89654905|NCT04021433|Experimental|MDD|Treatment resistant patients will be treated with multiple doses of IM/SC ketamine [dose range 0.3-1.5mg/kg]
89654906|NCT04991610|Active Comparator|Adult male|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
89654907|NCT04991610|Active Comparator|Adult female|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
89654908|NCT04021745|Experimental|App-based mindful eating|The intervention will be delivered through a mindful eating smartphone application using the latest evidence-based mindful eating methods and behavior change theory.
89654909|NCT04991532||Dasatinib group|the CML patient treated with dasatinib
89654910|NCT04991532||Imatinib group|the CML patient treated with imatinib
89654911|NCT04147481|Experimental|Group Abdominal Nerve Block|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
89654912|NCT04147481|Placebo Comparator|Group control|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.9% saline.
89654913|NCT03072342|Active Comparator|Intensive Periodontal Treatment (IPT)|
89654914|NCT03072342|Placebo Comparator|Control Periodontal Treatment (CPT)|
89654915|NCT04148339||Patients|Patients with Elevated Cholesterol
89654916|NCT04148261|Active Comparator|Healthy Arm, CORT + EPI, then PLB + EPI|Healthy participant will receive cortisol pill and epinephrine infusion
89654917|NCT04148261|Active Comparator|Healthy Arm, PLB + EPI, then CORT + EPI|Healthy participant will receive placebo pill and epinephrine infusion
89654918|NCT04148261|Experimental|Depression Arm, CORT + EPI, then PLB + EPI|Depressed participant will receive cortisol pill and epinephrine infusion
89654919|NCT04148261|Experimental|Depression Arm, PLB + EPI, then CORT + EPI|Depressed participant will receive placebo pill and epinephrine infusion
89654920|NCT03072264|Experimental|Body in Mind Training (BMT)|This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
89654921|NCT03072264|Active Comparator|Medication|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
89654922|NCT03072264|Active Comparator|Quality of Life Group|This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.
89654923|NCT03072030|Experimental|Active Drug Group|1900 volunteers will be immunized with vaccine GamEvac-Combi They will receive product twice according to the following dosing regimen: on Day 1 (component A) and Day 21 of the study (component B) in the dose of 0.5 ml
89654924|NCT03072030|Placebo Comparator|Placebo Drug Group|100 volunteers will be immunized with placebo They will receive product twice according to the following dosing regimen: on Day 1 (placebo - component A) and Day 21 of the study (placebo- component B) in the dose of 0.5 ml
89654925|NCT04147091|Experimental|domestic nanohydroxyapatite gel ApaCare & Repair|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
89654926|NCT04147091|Experimental|in-office ozone therapy OzonyTron|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
89654927|NCT04147091|Experimental|both remineralizing gel and ozone therapy|6-months treatment, caries lesions were assessed on bitewing radiographs at baseline, after 1 year and after 2 years
89654928|NCT04991220|Experimental|preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
89654929|NCT04991064|Other|AB arm|participants allocated to this arm receive treatment A first, followed by treatment B.
89654930|NCT04991064|Other|BA arm|participants allocated to this arm receive treatment B first, followed by treatment A.
89654931|NCT04147169||Dying patients|Dying patients admitted to the Intensive Care Unit who are approaching end-of-life.
89654932|NCT03072108|Experimental|Bonolive|
89654933|NCT03072108|Placebo Comparator|Placebo|
89654934|NCT00928083|Experimental|Part A - 50 mg Single Dose|OZ439 Single doses of 50mg (capsules)
89046501|NCT00555828|Other|B2|3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
89654935|NCT00928083|Experimental|Part A - 100mg Single Dose|OZ439 Single doses of 100mg (capsules)
89654936|NCT00928083|Experimental|Part A - 200mg Single Dose|OZ439 Single doses of 200mg (capsules)
89654937|NCT00928083|Experimental|Part A - 400mg Single Dose|OZ439 Single doses of 400mg (capsules)
89654938|NCT00928083|Experimental|Part A - 400mg Single Dose + Food|OZ439 Single doses of 400mg (capsules) administered with food.
89654939|NCT00928083|Experimental|Part A - 400mg AD Single Dose|OZ439 Single doses of 400mg (aqueous dispersion)
89654940|NCT00928083|Experimental|Part A - 800mg Single Dose|OZ439 Single doses of 800mg (capsules)
89654941|NCT00928083|Experimental|Part A - 800mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
89654942|NCT00928083|Experimental|Part A - 1200mg Single Dose|OZ439 Single doses of 1200mg (capsules)
89654943|NCT00928083|Experimental|Part A - 1600mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
89654944|NCT00928083|Placebo Comparator|Part A - Placebo|Placebo control for Single rising Part A
89654945|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fed|Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
89654946|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fast|Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
89654947|NCT00928083|Experimental|Part C - 200mg AD Multiple Dose|200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
89654948|NCT00928083|Experimental|Part C - 400mg AD Multiple Dose|400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
89654949|NCT00928083|Experimental|Part C - 800mg AD Multiple Dose|800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
89654950|NCT00928083|Placebo Comparator|Part C - Placebo|Placebo control for Multiple rising Part C
89654951|NCT04996446|Experimental|Alpps plus Tislelizumab group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
89046502|NCT00555828|Experimental|C1|5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
89654952|NCT04996446|Active Comparator|Alpps group|Patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
89654953|NCT04405973||COVID-19 ARDS, vv-ECMO|All patients in the study centers with diagnosed COVID-19 infection (PCR proven) and treatment with vv-ECMO
89654954|NCT04147949|Experimental|AV-101|1440 mg of L-4-chlorokynurenine administered twice a day orally
89654955|NCT04147949|Placebo Comparator|Placebo|Matching capsules of placebo
89654956|NCT03078114|Experimental|Spinal Manipulation|Subjects with subacute low back pain. Subjects will receive 6 treatments of Spinal Manipulation (SM) over 2 consecutive weeks
89654957|NCT03078114|Placebo Comparator|Placebo Spinal Manipulation|Subjects with subacute low back pain. Subjects will be asked to visit the clinic for 6 times. The clinician will go through SM motions but the spine will not actually be manipulated.
89654958|NCT04146779|Experimental|Video and Written Yoga Instruction|Videos and written instructions on Hatha yoga will be provided
89654959|NCT04146779|Experimental|Video, Written Yoga Instruction Plus Guided Yoga Sessions|Videos and written instructions on Hatha yoga and instructor guided session on Hatha yoga will be provided
89654960|NCT00928395|Active Comparator|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
89654961|NCT03077880||thin soft tissue|full thickness thin mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
89046503|NCT00555828|Other|C2|2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
89046504|NCT02909426||Women aged 40-59|"Asymptomatic women aged 40-59 who participate in the National Cancer Screening Program in Korea and agreed with participating in this study will be the cohort.~The participants' digital mammography and ultrasonography will be interpreted combinedly by radiologists who perform the screening sonography and the participants' digital mammography will be interpreted independently by other radiologists who do not perform the screening sonography."
89046505|NCT00555867||1|Standard routine care for breast cancer
89654962|NCT03077880||thick soft tissue|full thickness thick mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
89654963|NCT04147637|Experimental|FSL-M|FreeStyle Libre + MiaoMiao Bluetooth adjunct with mobile application
89654964|NCT04147637|Active Comparator|FSL-A|FreeStyle Libre alone
89654965|NCT04995744|Other|Patients with closed Neer type 4 proximal humerus fractures|patients aged 50-75 years with closed Neer type 4 proximal humerus fractures
89654966|NCT04368741|Experimental|Experimental group|SANZ®KINGWILL
89654967|NCT04368741|Other|Control group|GLUCERNA SR®
89654968|NCT03674645|Experimental|MRI|MRI exam performed on 200 healthy volunteers
89654969|NCT04361721||Chronic migraine patients|Three monthly administration of erenumab 70 mg subcutaneously.
89654970|NCT04361643|Experimental|Experimental|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
89654971|NCT04361643|Placebo Comparator|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3, and 5.
89654972|NCT03074292|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
89654973|NCT03074292|Active Comparator|extensive phototherapy|neonates with unconjugated hyperbilirubinemia exposed to extensive phototherapy
89654974|NCT03074292|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
89654975|NCT04357665|Active Comparator|Lap TAPP Group|Patients treated by laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
89654976|NCT04357665|Active Comparator|Open PP Group|Patients treated by open preperitoneal single mesh repair fixated using sutures
89654977|NCT04357665|Active Comparator|Bilateral LICHT Group|Patients treated by standard bilateral Lichtenstein repair using 2 separate meshes fixed by sutures
89654978|NCT03071874|Experimental|AZD2014|"AZD2014 will be administered orally at a pre-determine dose~Twice daily for two consecutive days out of every seven days~Cycles will last 28 days"
89654979|NCT04406051|Active Comparator|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive colloid preloading (5 mL/kg)
89654980|NCT04406051|Active Comparator|norepinephrine infusion and crystalloid co-loading (NOR-CRYS)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive crystalloid co-loading (10 mL/kg)
89654981|NCT03077802|Experimental|Modified Seldinger technique, Experienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
89654982|NCT03077802|Active Comparator|Seldinger technique, Experienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
89654983|NCT03077802|Experimental|Modified Seldinger technique, Inexperienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
89654984|NCT03077802|Active Comparator|Seldinger technique, Inexperienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
89654985|NCT00938457|Experimental|Arm I|Patients undergo either percutaneous placement of metallic fiducial markers within the liver or respiratory-correlated cone-beam computed tomography for stereotactic targeting and planning. Patients then undergo single-fraction stereotactic body radiotherapy over approximately 1 hour within 1 week of the marker placement.
89654986|NCT03938207||Dry eye syndrome|Dry eye syndrome patients were extracted from Taiwan Biobank.
89654987|NCT03938207||Health subjects|Health subjects were extracted from Taiwan Biobank.
89654988|NCT03938207||Sjögren's syndrome|Sjogren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
89654989|NCT03938207||other inflammation disease|Other inflammation disease were extracted from Taiwan Biobank.
89654990|NCT04991298|Active Comparator|Group M|patients will be premedicated with the undiluted IV formulation of Midazolam
89654991|NCT04991298|Active Comparator|Group F|patients will be premedicated with the undiluted IV formulation of fentanyl citrate
89654992|NCT04361175|Experimental|letrozole group|letrozole group, Patients will receive 5 mg of letrozole oral tablets daily from day 2 of the cycle for 5 days for three successive cycles
89654993|NCT04361175|Experimental|Clomiphene Citrate group|Clomiphene Citrate group, Patients will receive 100 mg : Clomiphene Citrate daily starting on cycle day 2 for 5 days for three successive cycles
89654994|NCT03074526|Active Comparator|4mL amniotic fluid|Amniotic Fluid: 4mL dose of amniotic fluid
89654995|NCT03074526|Active Comparator|4mL2x amniotic fluid|Amniotic Fluid: 4mL 2x dose of amniotic fluid
89654996|NCT03074526|Placebo Comparator|4mL Saline Placebo|Normal Saline
89654997|NCT04146701||Acute heart failure|All consecutive patients admitted with acute heart failure to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
89654998|NCT04146701||STEMI|All consecutive patients admitted with STEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
89654999|NCT04146701||NSTEMI|All consecutive patients admitted with NSTEMI to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
89655000|NCT04146701||Ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
89655001|NCT04146701||Non-ischemic cardiomyopathy|All consecutive patients with an implantable cardioverter defibrillator (ICD) due to non-ischemic cardiomyopathy and LVEF <35% presenting for ICD check-up to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
89655002|NCT04146701||Sepsis|All consecutive patients admitted with sepsis or septic shock to University Medical Center Mannheim. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
89655003|NCT04146701||Healthy controls|Clinically inapparent group as controls. One venous blood withdraw will be performed. Demographic and clinical data will be documented.
89655004|NCT03077490||Single center vs. multicenter|Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
89655005|NCT04368819|Active Comparator|Allopurinol|Allopurinol 300mg P.O. once daily for four weeks followed by allopurinol 300mg P.O. twice daily for 12 weeks.
89655006|NCT04368819|Placebo Comparator|Placebo|Placebo pills indistinguishable from the active comparator given P.O. once daily for four weeks, followed by twice daily for 12 weeks.
89655007|NCT04146311|Active Comparator|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) is injected into the left infrapatellar fat pad.
89213324|NCT05228249|Experimental|Treatment (loncastuximab tesirine, BEAM chemotherapy)|"PART I (CONDITIONING): Patients receive loncastuximab tesirine IV on day -7, carmustine IV over 2 hours on day -7, etoposide IV over 1-2 hours BID days -6, -5, -4, and -3, cytarabine IV over 1 hour BID on days -6, -5, -4, and -3, and melphalan IV over 15-20 minutes on day -2. Patients undergo peripheral blood ASCT per standard practice on day 0.~PART II (MAINTENANCE): Beginning 30-90 days after ASCT, patients receive loncastuximab tesirine IV Q3V for up to 9 cycles in the absence of disease progression or unacceptable toxicity."
89213325|NCT02580383||Group none|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When both needles were positioned inadequately for a facet joint."
89213326|NCT02580383||Group partial|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~when one of the needles for a facet joint medial branch was placed inadequately."
89213327|NCT02580383||Group complete|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When all needles were placed adequately.'"
89213328|NCT02580227|Active Comparator|Tranexamic Acid|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
89213329|NCT02580227|Placebo Comparator|Placebo|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
89213330|NCT04076267||Patients with cancer|
89655008|NCT04146311|Placebo Comparator|Isotonic saline|A bolus injection (0.25 ml) of isotonic saline (0.9 %) is injected into the left infrapatellar fat pad.
89655009|NCT04146311|Experimental|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
89655010|NCT04368585|Experimental|TBPM-PI-HBr Alone (Period 1)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally alone.
89655011|NCT04368585|Experimental|TBPM-PI-HBr and Antacid (Period 2)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension will be coadministered with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr at Hour 0 on Day 1.
89655012|NCT04368585|Experimental|TBPM-PI-HBr and Omeprazole (Period 3)|40 mg (1 x 40 mg capsule) omeprazole administered QD at Hour -2 on Days 1 through 5, with 600 mg (2 x 300 mg tablets) TBPM-PI-HBr administered at Hour 0 on Day 5.
89655013|NCT03074058|Experimental|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
89655014|NCT03074058|Active Comparator|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY77-1931 chewable tablet in Period 1 and Fosrenol BAY 77-1931 ODT 500 mg in Period 2. The washout interval between period 1 and 2 will be at least 14 days.
89655015|NCT04357509|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
89655016|NCT03071796|Experimental|multivitamin supplement|liquid multivitamin supplement for 12 weeks
89655017|NCT03071796|Placebo Comparator|placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
89655018|NCT04361097|Experimental|Faecal microbiota transplant|This group will receive frozen capsules to be ingested orally constituted of TMF with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
89655019|NCT04361097|Placebo Comparator|Placebo|This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
89655020|NCT03077568|Experimental|My Stress Control|This group gets access to the web-based program for stress-management. They will, by their own, go through the automated program. Measurements are conducted before, after as well as 3 months after the intervention.
89655021|NCT03077568|No Intervention|Wait-list group|The wait-list grop will complete the same measures as the intervention group completes before and after the intervention with similar time spread. The wait-list group will then get access to the web-based program.
89655022|NCT04361331|Other|Toripalimab combined with lenvatinib|"Toripalimab: 240 mg, intravenous infusion, Q3W;~Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd;"
89655023|NCT04361331|Other|Lenvatinib combined with gemox|"Lenvatinib: 8mg (body weight <60kg) or 12mg (body weight ≥60kg), qd~Gemox chemotherapy D1: Oxaliplatin 85mg / m2, Gemcitabine 1g / m2 D8: Gemcitabine 1g / m2 Three weeks are a course, a total of 6-8 courses"
89655024|NCT04990830|Experimental|Inhalation Treatment|"Treatment: Inhaled Low molecular weight heparin + Standard COVID-19 treatment,~Inhaled Low molecular weight heparin (4000 IU given twice a day for 10 days)"
89655025|NCT04990830|Other|Control Group|Treatment: Standard COVID-19 treatment
89213331|NCT03883113|Experimental|MVA-NP+M1 & H3N2 Challenge Virus|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
89213332|NCT03883113|Placebo Comparator|Saline Placebo & H3N2 Challenge Virus|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
89213333|NCT04218695|Experimental|Treatment|1 gram intravenous ceftriaxone once daily for up to one week or until end of hospitalization
89213334|NCT04218695|Placebo Comparator|Placebo|Normal saline (50cc) once daily for up to one week or until end of hospitalization
89213335|NCT01000935|Active Comparator|Platelet Rich Plasma|The platelet concentrate extracted from patient's own blood (PRP) will be applied to the surgical site after completion of the repair.
89213336|NCT01000935|No Intervention|Surgical repair (standard-of-care)|Patients will have a rotator cuff repair without the PRP application.
89213337|NCT03967639||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
89213338|NCT03967639||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
89655026|NCT04361253|Experimental|Arm A|Two units of apheresis HT-CCP, collected from the same donor whenever possible, will be administered sequentially over no greater than a 24-hour period to participants randomized to Arm A. Each unit of HT-CCP will be approximately 250 mL, for a total transfused volume of approximately 500 mL.
89655027|NCT04361253|Placebo Comparator|Arm B|Two units of FFP or FP24 (each 200-275 mL, approximately 500 mL total) will be administered sequentially to participants randomized to Arm B. (FFP/FP24 unit volumes vary more than apheresis plasma units. Two FFP/FP24 units that are approximately 250 mL apiece will be provided.)
89655028|NCT03071718|Experimental|Med-D|Subjects will follow a Mediterranean diet for two months
89655029|NCT03071718|Active Comparator|Cont-D|Subjects will follow a control diet for two months
89655030|NCT04357431||study group|Health care providers include physicians, nurses, and health officers both medical and nursing subjects.
89655031|NCT04433598|Experimental|Nutrition Education Intervention|the participants the intervention group under went to Nutrition Education Intervention program were received the developed educational materials (pamphlets).
89655032|NCT04433598|No Intervention|Treatment as usual|the participants in the control group were received the usual medical care at their respective Center.The developed educational materials (pamphlets) were distributed at the end of the study.
89655033|NCT04146623|Placebo Comparator|Normal Saline Placebo|Saline (0.9%)
89655034|NCT04146623|Experimental|CodaVax-H1N1|Live-attenuated influenza vaccine
89655035|NCT03074214||STEMI patients receiving PCI|patients with STEMI receiving percutaneous coronary intervention
89046506|NCT00555867||2|Standard + Intervention arm: standard routine care for breast cancer and additional information material via post
89655036|NCT04361409|Experimental|Rituximab plus chemotherapy|"Drug:Rituximab~Drug:Cisplatin~Drug:Gemcitabine"
89046507|NCT02909309|Other|ALL INCLUDED PATIENTS|"A single arm for this study. All the patients benefit of both systems. The participants are their own control.~Non invasive sensors are used to monitor and record data of those two systems in a synchron way ( JAWAC / Capnoline + Spo2)."
89046508|NCT01932099|Experimental|Single arm feasibility study|Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
89046509|NCT00555945|Active Comparator|1|Gamma3 intramedullary nail
89046510|NCT00555945|Active Comparator|2|Sliding hip screw
89655037|NCT04368273|Experimental|treatment|PD-1 antibody combined CCRT for patients with local advanced cervical cancer.
89655038|NCT03022019|No Intervention|No ReNovaCell treatment|Lesion on the same patient that receives only standard therapy, no ReNovaCell treatment.
89655039|NCT03022019|Experimental|ReNovaCell treatment|Lesion on the same patient that receives the ReNovaCell treatment
89655040|NCT04995354|Experimental|EGF loaded Hydrogel (Gp I)|30 patients will receive EGF loaded Hydrogel (Intervention 1) to be applied three times a day for 1weeks.
89655041|NCT04995354|Active Comparator|Hydrogel alone ( Gp II)|30 patients will receive Hydrogel alone (Intervention 2) to be applied three times a day for 2 weeks.
89655042|NCT04995354|No Intervention|Control (Gp III)|30 patients will receive the standard of care treatment (Control) which includes benzydamine mouthwash, increased hydration, topical analgesics and antifungals.
89655043|NCT04357119|Active Comparator|CL measured from Treitz ligament|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 200 cm distal to the ligament of Treitz with the same stapler using a 60 mm blue cartridge
89655044|NCT04357119|Active Comparator|CL measured from ileocecal valve|A 14-16 cm long gastric tube is created using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A loop gastroenterostomy is then created with the small bowel about 300 cm proximal to the ileocecal valve with the same stapler using a 60 mm blue cartridge
89655045|NCT03906929|Experimental|Pediatric forearm fracture fixed by buried or exposed intamedullary implant|compare complication of buried or exposed intamedullary implant
89655046|NCT03077334||K-type|FDG uptake in pancreatic cancer is similar to that of kidney
89655047|NCT03077334||non K-type|FDG uptake in pancreatic cancer is lower than that of kidney
89655048|NCT04368351||Standard of care|Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), plus hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
89655049|NCT04368351||bacteriotherapy|Dietary Supplement: SivoMixx (200 billion) plus Azithromycin 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day), and hydroxychloroquine cp 200 mg, 1 cp x 2 / day.
89655050|NCT04146233|Other|Orange Juice without pulp|Drink orange juice without pulp and have gastric ultrasound performed 2 hours later
89655051|NCT04146233|Other|Orange juice with pulp|Drink orange juice with pulp and have gastric ultrasound performed 2 hours later
89655052|NCT03077100||Newborns with positive cultures|Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
89655053|NCT04360863||Youth smokers|Participants of Youth Quitline
89655054|NCT04148417|Experimental|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
89655055|NCT03071484|Experimental|Transcranial Direct Current Stimulation|After being randomly allocated, the experimental group will receive a 20 minutes of active 2-mA tDCS once a day on 10 consecutive weekdays.
89046511|NCT02909270|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
89046512|NCT02909270|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
89655056|NCT03071484|Placebo Comparator|Sham - tDCS|The control group will receive a sham stimulation, which chosen parameters consists in after 40 seconds of real stimulation (2 mA), only a small current pulse occurred every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
89655057|NCT04148729|Active Comparator|bupivacaine+lidocaine|15 ml bupivacaine+ 5 ml lidocaine will use for USG guided ESP block under general anaesthesia with Sevuflurane and remifentanil. This block will perform at the T10 level bilaterally after induction of anaesthesia at the prone position. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with VAS score. The rescue analgesic 0.4 mg/kg meperidine will be apply intravenously whenever the patient requested to the analgesic.
89655058|NCT04148729|Sham Comparator|saline|"In this group, the same volume saline will apply to the block region. The patients will receive Morphine 0.1 microgram/kg intravenously and diclofenac sodium 75 mg intramuscularly at the last 30th minute of surgery. Postoperative pain assessment will perform with VAS score.~The rescue analgesic 0.4 mg/kg meperidine will be apply intravenously whenever the patient requested to the analgesic."
89655059|NCT03077022||Femoracetabular impingent (FAI)|Subjects will be given a prescription for physical therapy specifically for Femoracetabular impingent (FAI). They will then be followed clinically per the investigator's normal routine and the gold standard.
89655060|NCT04144283|Experimental|NAP|The NAP group will undergo a post-learning 2-hour sleep opportunity in Experiment 1.
89655061|NCT04144283|Active Comparator|WAKE|The WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness in Experiment 1.
89655062|NCT03071562|Experimental|Yoga-mindfulness|Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
89655063|NCT03071562|No Intervention|Control|Participants in this group will not participate in an exercise program. They will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
89655064|NCT04360317|Experimental|Experimental group|
89655065|NCT03074136|Experimental|Photodinamic therapy|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
89655066|NCT03074136|Experimental|Diode laser|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that high power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA).
89655067|NCT03074136|Experimental|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius).
89655068|NCT04146155|Experimental|Liraglutide+standard-of-care treatment|Intervention: Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies.
89655069|NCT04146155|Active Comparator|standard-of-care treatment|standard-of-care treatment with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
89655070|NCT04367727|Experimental|5 minutes before 1|Light emitting diode applied 5 minutes before fatiguing task
89655071|NCT04367727|Placebo Comparator|5 minutes before 2|Light emitting diode applied 5 minutes before fatiguing task
89655072|NCT04367727|Experimental|1 hour before 1|Light emitting diode applied 1 hour before fatiguing task
89655073|NCT04367727|Placebo Comparator|1 hour before 2|Light emitting diode applied 1 hour before fatiguing task
89655074|NCT04367727|Experimental|5 hours before 1|Light emitting diode applied 5 hours before fatiguing task
89655075|NCT04367727|Placebo Comparator|5 hours before 2|Light emitting diode applied 5 hours before fatiguing task
89655076|NCT04145999|Experimental|PRP + PBM group|This group will receive both PRP application and photobiomodulation.
89655077|NCT04145999|Experimental|PRP + placebo PBM|This group will receive PRP application and placebo photobiomodulation.
89655078|NCT04145999|Experimental|PBM + placebo PRP|This group will receive placebo PRP application with a saline solution and active photobiomodulation.
89655079|NCT04357197|Experimental|Closed-loop|Closed-loop administration of norepinephrine in critically ill patients
89655080|NCT04990752||The ulinastatin group|In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. The recommended dosage of ulinastatin is 300,000 IU, q8h (Continuous administration for more than 5 days).
89655081|NCT04990752||The control group|In the control group, patients were treated with conventional treatment without ulinastatin.
89655082|NCT04142333|Other|GIA Access|All patients consented to this study will be given access to the GIA technology to share with their family members.
89655083|NCT02245191|Experimental|Ephedrine Group|Patients who will receive ephedrine after spinal anesthesia
89655084|NCT02245191|Experimental|Phenylephrine Group|Patients who will receive Phenylephrine after spinal anesthesia
89213339|NCT05674331|Active Comparator|socket seal group|After tooth extraction a soft tissue pounch is sutured above the extraction socket.
89655085|NCT02245191|Experimental|Metaraminol|Patients who will receive Metaraminol after spinal anesthesia
89655086|NCT03077178|Experimental|Prospective cohort|Geriatric assessment
89655087|NCT04367649|Experimental|Hall technique|
89655088|NCT04367649|Active Comparator|Atraumatic restorative treatment|
89655089|NCT04367649|Sham Comparator|Conventional restorative treatment|
89655090|NCT03076944|Active Comparator|Neural agent|UltraEZ. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
89655091|NCT03076944|Active Comparator|Obliterator agent|Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
89655092|NCT03076944|Active Comparator|Associative approach|UltraEZ and Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions. In each session, fistly the UltraEZ (neural agent) will be applied and after the Enamelast (obliterator agent.)
89655093|NCT05585567|Experimental|V-01/V-01-B5 group|One dose of V-01/V-01-B5
89655094|NCT05585567|Experimental|V-01-351/V-01-B5 group|One dose of V-01-351/V-01-B5
89655095|NCT05585567|Experimental|V-01 group|One dose of V-01
89655096|NCT03925181|Experimental|Intervention|Recovery counselling group.
89655097|NCT03925181|No Intervention|Waitlist control|Waitlist control group. Will receive intervention after arm one is complete.
89655098|NCT04356807|Experimental|Reflex Locomotion Therapy|during 15 minutes once a day five days a week
89655099|NCT04356807|Experimental|Passive Joint Mobilizations|during 15 minutes once a day five days a week
89655100|NCT04356807|Placebo Comparator|Massage|during 15 minutes once a day five days a week
89655101|NCT05004948|Active Comparator|Resistance exercise group|This group has conducted a resistance exercise program (50-60% of 1RM, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
89655102|NCT05004948|Active Comparator|Aerobic exercise program|This group has conducted an aerobic exercise program ( 50-70% maxHR, for 40-50 min) thrice weekly for consecutive twelve weeks plus metformin medication.
89655103|NCT05004948|No Intervention|Metformin group|This group received only metformin without any exercise intervention.
89655104|NCT04145921|Experimental|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
89655105|NCT04145921|Active Comparator|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
89655106|NCT04367493|Experimental|1. Group 55% cocoa intervention|55% cocoa intervention
89655107|NCT04367493|Experimental|2. Group White Chocolate|White chocolate
89655108|NCT04367493|No Intervention|3. Control Group|Control Group
89655109|NCT04360161|Experimental|Healthy participants|Swept-source optical coherence tomography A device testing TM/SC and Lens morphology
89655110|NCT04145687|Active Comparator|Metformin|
89655111|NCT04145687|Placebo Comparator|Placebo|
89046513|NCT00555984|Active Comparator|Total Intravenous anesthetic|Intravenous anesthetics (propofol + remifentanil) for maintenance of General Anesthesia
89046514|NCT00555984|Active Comparator|Volatile Anesthetic|Inhalational anesthetics (sevoflurane+remifentanil) for maintenance of General Anesthesia. Patients receive Sevoflurane as a volatile anesthetic and remifentanil as an IV agent for maintenance of general anesthesia.
89046515|NCT02909231||Foothills Medical Centre|Patients admitted to the Foothills Medical Centre trauma service (Calgary, AB) over four months.
89046516|NCT02909231||Vancouver General Hospital|Patients admitted to the Vancouver General Hospital trauma service (Vancouver, BC) over four months.
89046517|NCT01917825|Experimental|MDT-15|The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.
89046518|NCT01912560|Experimental|CAT-2003 or Placebo Dose 1|Daily for 28 days in patients with moderate hypertriglyceridemia
89655112|NCT02245347||Patients with expected MDR TB|
89655113|NCT04359615|Experimental|Favipiravir|
89655114|NCT04359615|Active Comparator|Control|
89655115|NCT03021785|Experimental|0.5mg|In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
89655116|NCT03021785|Experimental|1.0mg|In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
89046519|NCT01912560|Experimental|CAT-2003 or Placebo Dose 2|Daily for 28 days in patients with moderate hypertriglyceridemia
89655117|NCT03021785|Experimental|1.5mg|In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
89655118|NCT02635386|Experimental|Exenatide once weekly (EQW )|EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks
89655119|NCT02635386|Experimental|Dapagliflozin (DAPA)|DAPA-10 mg oral pill once daily in am for 24 weeks
89655120|NCT02635386|Experimental|EQW plus DAPA|EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks
89655121|NCT02635386|Experimental|Dapagliflozin plus Glucophage (MET ER)|Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks
89655122|NCT02635386|Active Comparator|Phentermine /Topiramate (PHEN/ TPM) ER|Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks
89655123|NCT00934635|Active Comparator|002|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours
89655124|NCT00934635|Active Comparator|003|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours
89655125|NCT00934635|Active Comparator|004|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours
89655126|NCT00934635|Active Comparator|005|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours
89655127|NCT00934635|Active Comparator|006|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours
89655128|NCT00934635|Active Comparator|007|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours
89655129|NCT00934635|Active Comparator|008|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours
89655130|NCT00934635|Other|009|PET Scan PET Scan
89655131|NCT00934635|Active Comparator|001|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours
89655132|NCT03924557|Active Comparator|Genotyping Intervention Supportive Care|For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results.
89655133|NCT03924557|No Intervention|Delayed Genotyping Intervention Supportive Care|For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice.
89655134|NCT04359537|Experimental|Arm 1|Hydroxychloroquine Sulphate will be administered at a dose of 400mg twice a day on day 1 followed by 400 mg once a week for a total of 12 weeks
89655135|NCT04359537|Experimental|Arm 2|Hydroxychloroquine Sulphate will be admoinistered at a dose of 400 mg on day 1 followed by 400mg once every 3 weeks for at total of 12 weeks
89655136|NCT04359537|Experimental|Arm 3|Hydroxychloroquine Sulphate will be administered at a dose of 200 mg on day 1 followed by 200 mg once every 3 weeks for a total of 12 weeks
89655137|NCT04359537|Placebo Comparator|Arm 4|Control group will recieve Placebo 200mg on day 1 followed by Placebo 200mg every three weeks for 12 weeks
89655138|NCT04356651|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
89655139|NCT04356651|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
89655140|NCT03922997|Experimental|Atezolizumab|Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
89655141|NCT04367259|Active Comparator|Single puncture arthrocentesis (SPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with single puncture arthrocentesis
89655142|NCT04367259|Active Comparator|Double puncture arthrocentesis (DPA) group|Patients presenting temporomandibular joint disc displacement without reduction (DDwoR) treated with double puncture arthrocentesis
89655143|NCT03073902||Observed group|The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.
89655144|NCT04367415||Normal uterine cavity on office hysteroscopy|If the uterine cavity is normal the patient will be allocated as group A.
89655145|NCT04367415||uterine cavity shown one or more polyps on office hysteroscopy|If there is one or more polyp(s) the patient will be allocated as group B. Localization and size estimation of the polyp(s) is mandatory.
89655146|NCT05004792|Active Comparator|Intervention|Access to DermLoop Learn IT platform
89655147|NCT05004792|No Intervention|Control group|No access to DermLoop Learn
89655148|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent will be placed (usually the standard of care)
89655149|NCT04145063|Active Comparator|uncomplicated ureteroscopic lithotripsy without US|Following uncomplicated uretroscopic lithotripsy no uretric stent will be placed
89655150|NCT04145063|No Intervention|uncomplicated ureteroscopic lithotripsy with DJ-US-string|Following uncomplicated uretroscopic lithotripsy, a double J uretric stent with an extraxtion string will be placed
89655151|NCT04355949|Experimental|Patients with premature ejaculation|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
89655152|NCT04355949|Experimental|Normal subjects|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
89655153|NCT03021239|Active Comparator|1) Echo Guided Testing -|This testing uses echocardiography to create images of the heart and make measurements while gradually increasing the heart pump speed. The final pump speed and medical treatment are determined using the echo measurements. This will take about 45 minutes.
89655154|NCT03021239|Active Comparator|2) Hemodynamic-Echo Ramp Testing -|This testing is performed during a right heart catheterization procedure which provides hemodynamic measurements (pressure and blood flow) in addition to the echocardiography measurements. With this method, more echo images and measurements are taken. The final pump speed and medical treatment adjustments are made using the hemodynamic measurements as well as the information from the echo. This test will take about 1 hour and 45 minutes.
89655155|NCT02982369|Experimental|Spinal Manipulation|"High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region and pain education.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
89655156|NCT02982369|Sham Comparator|Pain Education|"Pain education and a simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
89655157|NCT02982447|Active Comparator|Blue Laser Imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
89655158|NCT02982447|Experimental|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
89655159|NCT05580887||Patients with luminal A breast cancer|
89655160|NCT05580887||Patients with high risk luminal B breast cancer|
89655161|NCT05580887||Patients with high pancreatic cancer|
89655162|NCT00936351|Experimental|Arm 1|Mindfulness Meditation
89046520|NCT01912560|Experimental|CAT-2003 or Placebo Dose 3|Daily for 28 days in patients with moderate hypertriglyceridemia
89046521|NCT01912560|Experimental|CAT-2003 or Placebo Dose 4|Daily for 28 days in patients with hypercholesterolemia who are on a statin
89655163|NCT00936351|Active Comparator|Arm 2|Support Group that involves discussion of work-related issues in which participants are facilitated to assist each other with problem solving and offer support
89655164|NCT04994340||Children|From a cross-sectional perspective, children will fill out questionnaires related to their subjective physical activity levels (PAQ-C), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of children through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
89046522|NCT05312489||Upper extremity arterial trauma|Vascular traumatic injuries of the arterial system of the upper limbs.
89046523|NCT05312489||Lower extremity arterial trauma|Vascular traumatic injuries of the arterial system of the lower limbs.
89046524|NCT05312333||critically-ill childern|
89046525|NCT01910025|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
89046526|NCT03457337|Experimental|S-1 plus Gefitinib|"S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally, continuous administration of 14 days, rest for 7 days. BSA <1.25 m2, 80 mg / day; BSA 1.25 m2 to <1.5 m2, 100 mg / day; BSA 1.5 m2 or more, 120 mg / day. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject.~Gefitinib: 250mg, 1 day, orally, fasting or with the same service. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject."
89046527|NCT03457337|Active Comparator|Gefitinib|Gefitinib 250 mg/day oral daily
89655165|NCT04994340||Adolescents|From a cross-sectional perspective, adolescents will fill out questionnaires related to their subjective physical activity levels (PAQ-A), levels of sedentary activity (YLSBQ), and socio-economic status (Family Affluence Scale III) during school hours. Two sessions of physical education will be used to measure the health-related physical fitness of adolescents through the ALPHA-Fitness battery test. The sequence to administer this battery will be: 1. Weight and height (BMI); 2. Waist circumference; 3. Skin folds; 4. Hand grip strength, long jump with feet together, and 4x10 m shuttle run test (these tests could be carried out alternately or simultaneously since there will always be 2 or more evaluators); 5. 20 m Course Navette test.
89655166|NCT04144985|Active Comparator|Eyelid Speculum|Eyelid retraction was performed with an eyelid speculum.
89655167|NCT04144985|Experimental|Cotton Tipped Applicator|Eyelid retraction was performed with the cotton tipped applicator eyelid retraction technique.
89655168|NCT04144985|Experimental|Unimanual Eyelid Retraction|Eyelid retraction was performed with the unimanual eyelid retraction method.
89655169|NCT04359381|Experimental|kinesiotaping|by kinesiotaping during menstruation for 3 successive menstruation
89655170|NCT04359381|Experimental|pilate exercises|pilate exercises, 3 sessions per week for 3 months
89655171|NCT04994184||Perforated duodenal ulcer|MORBIDITY AND MORTALITY
89655172|NCT03904979|Experimental|Therapeutic Writing Prompts|Participants will be given writing prompts that discuss events that have been perceived as stressful in their lives and how they may or may not have cultivated resilience and coping strategies because of it.
89655173|NCT03904979|Placebo Comparator|General Writing Prompts|"Participants will be given writing prompts that discuss neutral topics unrelated to their life stress, resilience, or coping."
89655174|NCT03904979|No Intervention|No Writing|Participants will not be given writing prompts during their prenatal care. They will be given blank journals that will NOT contain any instructions or writing prompts.
89655175|NCT04359303|No Intervention|CONTROL|Base WHO recommended treatment.
89655176|NCT04359303|Experimental|TREATMENT|Base WHO recommended treatment + Systemic indirect endovenous ozone therapy
89655177|NCT04994262|Experimental|Intervention Group|"Patients in the intervention group will be given a lozenge with menthol at the 30th, 60th and 90th minutes after extubation and it will be explained that they should be dissolved in the mouth without swallowing, and the patients will be kept under observation during this time.~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded. These parameters will be evaluated just before the menthol lozenge application at the 30th, 60th and 90th minutes.~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded.~Second postoperative day: The comfort level of the patients will be evaluated using the General Comfort Scale Short Form."
89655178|NCT04994262|No Intervention|Control Group|"Patients in the control group will be followed up according to their routine clinical procedures. Since there is no procedure or intervention in the clinical procedures, only the patients will be followed up. Patients in the control group will be followed up with the same forms at the same time.~Thirty, 60, 90, and 120 minutes after extubation: Patients' thirst level and severity of nausea will be evaluated with the Visual Analogue Scale (VAS) and the presence of vomiting will be questioned. In addition, its physiological parameters will be recorded.~Sixty, 120, 180, and 240 minutes after extubation: The amount and types of analgesic and antiemetic usage of the patients will be recorded hourly.~Second day after surgery: The comfort level of the patients will be evaluated and recorded using the General Comfort Inventory Short Form."
89655179|NCT04144595||Low plasma glucose|This group will be formed by women with low plasma glucose: fasting plasma glucose (<10th percentile, <65 mg/dL), 1 or 2-hour low plasma glucose results after OGTT.
89046528|NCT04674540||Sedation and Analgesia Implementation Status Group|To investigate the implementation status of sedation and analgesia in ICU critical patients.
89046529|NCT04674501||Thoracic irradiation|A cohort of cancer patients who receive thoracic irradiation. Patients with any type of malignancy, such as lung cancer, breast cancer, esophageal cancer, or thymoma, are eligible as long as the patients undergo thoracic irradiation.
89046530|NCT03455010|No Intervention|Normal load|Healthy subjects walking for 30 minutes on a treadmill with normal body weight
89046531|NCT03455010|Experimental|Increased load|Healthy subjects walking for 30 minutes on a treadmill with 20% additional body weight
89046532|NCT03455010|Experimental|Reduced load|Healthy subjects walking for 30 minutes on a treadmill with 20% lower body weight
89213340|NCT05674331|Experimental|XSD+ socket seal group|After tooth extraction for the reconstruction of the buccal bony wall a xenograft membrane with a long absorption rate is fixed with titanium pins to the buccal side. A soft tissue pounch is sutured above the extraction socket.
89046533|NCT05311280|Experimental|high intensity interval training plus myotherapy|"Subjects were instructed to perform tongue slide, tongue force, tongue press, tongue reach, swallowing exercise, smiling exercise, jaw press exercise, chewing exercise, breathing exercise and buccinator exercise.These myofunctional exercise were performed 10 repetitions for a set, 2 sets in a treatment session depends on patient's condition. Between each session, subjects were allowed to rest at least 1 minutes.~Exercise training would be implemented in the form of high-intensity interval training and resistance exercise. High-intensity interval training intensity of the target heart rate (THR) was calculated as follows: THR = (HRmax - HRrest) × 80-90%Intensity + HRrest[26]. The HIIT program included four 3-min bouts at high-intensity (80-90%HRR), separated by 3-min of active recovery and total for 4 cycles of 24-min HIIT intervention. The HIIT exercise options were running on a treadmill."
89046534|NCT05311280|Active Comparator|home exercise training plus myotherapy|"Subjects were instructed to perform tongue slide, tongue force, tongue press, tongue reach, swallowing exercise, smiling exercise, jaw press exercise, chewing exercise, breathing exercise and buccinator exercise.These myofunctional exercise were performed 10 repetitions for a set, 2 sets in a treatment session depends on patient's condition.~Home exercise is composed of ambulation training outside or inside. Three phase including warm up, training phase, and cool down. The intensity of training phase is decided by rating of perceived exertion (RPE) range from 11~15. 2~5 training times a week will involved according to patients' preference."
89046535|NCT01908738|Experimental|paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)|first groups receive paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)
89046536|NCT01908738|Experimental|10%lidocaine spray and paracervical block with 0.9%NSS|the second groups receive 10%lidocaine spray and paracervical block with 0.9%NSS(placebo)
89046537|NCT01908738|Placebo Comparator|receive placebo both paracervical block and spray|the third groups receive placebo both paracervical block and spray
89046538|NCT04673838|Experimental|Lower Extremity Sensory Training + Bobath Therapy|Intervention Group will have Lower extremity sensory training and Bobath Therapy.
89655180|NCT04144595||Normal plasma glucose|This group will be formed by women with normal plasma glucose: fasting plasma glucose ( ≥10th percentile, ≥65 mg/dL but < 92 mg/dL), 1 or 2-hour normal glucose (< 180 mg/dL and 153 mg/dL, respectively) results after OGTT.
89655181|NCT03073746|Experimental|Health Search|Access to Health Knowledge Panels and Symptom Search Tool.
89655182|NCT03073746|Experimental|Standard Search|No access to Health Knowledge Panels and Symptom Search Tool, but access to prior version of Google search.
89655183|NCT03073746|No Intervention|No Search|No access to Health Knowledge Panels, Symptom Search Tool, prior version of Google search, or mobile device.
89655184|NCT04359225|Active Comparator|3D telemedicine|3D telemedicine system
89655185|NCT04359225|Placebo Comparator|2D telemedicine|2D telemedicine system (standard care)
89655186|NCT00939159|Experimental|LBH589|LBH589 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
89655187|NCT05004636|No Intervention|No_Mg|Ctrl Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will not receive Mg (the intervention) in the block; instead they will receive 0.3mL of sterile saline.
89655188|NCT05004636|Experimental|Mg|Treatment Group. Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Patients in this Arm (selected randomly) will receive 150 mg Mg (0.3 mL-the intervention) in the block.
89655189|NCT04765319||Vets|Veterans receiving care from the PTSD Clinical Team at the Salt Lake City VAMC. All participants are adults with a diagnosis of PTSD. This study plans on reviewing data collected as part of standard clinical practices. The study will have no impact on the treatment provided to the patient.
89655190|NCT04358679|Active Comparator|Conventional Treatment|Conventional Treatment: Deep breathing, Assisted coughing, Sustained stretching, Splinting, Bracing and Functional mobility
89655191|NCT04358679|Experimental|Upper Limb ergometer training|Conventional Treatment + Upper Limb (UL) ergo-meter exercise
89655192|NCT03073824|Experimental|vSculpt, model #VS1100|A novel intravaginal device for females
89655193|NCT04765631||Patients with Type 2 diabetes|Subjects from 3 cohorts (QUALYOR, OFELY, STRAMBO) presenting type 2 diabetes
89655194|NCT04765631||Control subjects without Type 2 diabetes|Controls patients from 3 cohorts (QUALYOR, OFELY, STRAMBO) without type 2 diabetes
89655195|NCT03073668|Experimental|Heart Failure Patients|After obtaining written informed consent, patients will undergo induction with general anesthesia as per clinical practice. The chest will be open but pericardium left intact. Cardiac hemodynamics will be measured using PA catheter already in place at rest, and then during conditions of increased cardiac preload, induced by passive leg elevation and saline bolus (300 ml administered over 1-2 minutes). The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure. The surgical team will then repeat hemodynamic assessments at rest and with acute volume loading (leg raise + saline) in exactly the same manner as with the pericardium intact.
89655196|NCT03833349|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
89655197|NCT03833349|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
89655198|NCT03833349|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
89046539|NCT04673838|Active Comparator|Bobath Therapy|Control Group will have only Bobath Therapy. Bobath approach will be applied for 4 weeks, 3 days a week and 12 sessions in total.
89046540|NCT05298293|Experimental|ONCOLAXY follow-up|patients will make a regular assessment of symptoms via an electronic questionnaire
89046541|NCT05298293|No Intervention|Standard follow-up|patients will have the standard follow-up
89046542|NCT01904409|Placebo Comparator|Placebo|Placebo tablets once daily.
89046543|NCT01904409|Experimental|Rifaximin SSD 40 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.
89655199|NCT04144439|No Intervention|Before treatment|no intervention
89655200|NCT04144439|Active Comparator|After treatment|GABA
89655201|NCT04358601|Experimental|All-polyethylene tibial components|Triathlon PS Knee System with all-polyethylene tibial components
89655202|NCT04358601|Active Comparator|Metal-backed modular components|Triathlon PS Knee System with metal-backed modular components
89655203|NCT04144361|Experimental|sleeve without plication|sleeve gastrectomy on bougie 36 without plication
89655204|NCT04144361|Active Comparator|sleeve with plication|sleeve gastrectomy on bougie 42 without plication
89655205|NCT04456218|Experimental|Biliary stone|Participants who meet the criteria of biliary stone enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
89655206|NCT04456218|Experimental|Biliary stricture|Participants who meet the criteria of biliary neoplasm enrollment and are willing to join in this study will be applied to the custom-made endoscope system for biliary disease diagnosis.
89655207|NCT04367181|Experimental|ELGA group|"*Less than 29 weeks Gestational Age (GA) preemies (100)~DCS monitoring will be performed for up to 72 hours starting within 2 days after birth. In a subgroup of infants, we will also perform additional measurements with aEEG and FDNIRS. At a second stage we will add Transcranial Doppler Ultrasound (TCD)"
89655208|NCT04144673|Experimental|Investigational Product|
89655209|NCT04144673|Placebo Comparator|Placebo|
89655210|NCT05004324|Experimental|Furestem-AD Inj.|"Investigational product name: FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL~baseline (0week) Experimental group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL).~After 12 weeks, Experimental group will receive placebo."
89655211|NCT05004324|Placebo Comparator|Placebo|"Placebo~baseline (0week) Placebo comparator group will receive placebo.~After 12 weeks, Placebo comparator group will receive Investigational product (FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL)."
89655212|NCT02984969||Slow transit constipation|subjects met the Rome III criteria for STC
89655213|NCT02984969||Healthy subjects|Healthy controls
89655214|NCT04355559||conventional oxygen therapy|Continuous use of current oxygen therapy
89655215|NCT04355559||high flow nasal cannula|change the oxygen therapy to high flow nasal cannula
89655216|NCT04355559||Noninvasive ventilation|change the oxygen therapy to noninvasive ventilation
89655217|NCT05004480|Experimental|Surgical Mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill while wearing surgical mask
89655218|NCT05004480|Experimental|Non mask Group|participants of both sexes who will perform controlled endurance exercise on treadmill without wearing surgical mask
89655219|NCT04358835|Experimental|Intubated patients with COVID-19 on a ketogenic diet only|4:1 ketogenic diet formula
89655220|NCT04144829|Active Comparator|HIFU|3 cycles of HIFU treatment in 6-week intervals
89655221|NCT04144829|Active Comparator|Fibrin|3 cycles of platelet-rich fibrin injection treatment in 6-week intervals
89655222|NCT04994574|Experimental|tiotropium/olodaterol|
89655223|NCT04143971|Placebo Comparator|Continiuous Low calorie diets|Low calorie diet with daily calorie restriction
89655224|NCT04143971|Active Comparator|Intermittent Fasting|Intermittent fasting every other day, in which daily calorie intake will be up to 30% of required calorie.
89655225|NCT05004558|Experimental|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
89655226|NCT04355637|No Intervention|Control|patients receiving standard of care to treat their pneumonia
89655227|NCT04355637|Experimental|Intervention|patients receiving standard of care to treat their pneumonia + inhaled budesonide
89655228|NCT05004168|Experimental|SPF evaluation|Healthy male or female subjects with Fitzpatrick Skin Type of II-IV were included in the SPF study
89655229|NCT04144205|Experimental|Fraction of inspired oxygen setting change|
89655230|NCT05580341|Experimental|Zerun HPV-9|Subjects receive 3 doses of Zerun HPV-9 vaccine
89655231|NCT05580341|Active Comparator|GARDASIL®9|Subjects receive 3 doses of GARDASIL®9
89655232|NCT04367337||Poland|Adults, general population, N = 400
89655233|NCT04367337||Australia|Adults, general population, N = 400
89655234|NCT04367337||Canada|Adults, general population, N = 400
89655235|NCT04367337||China|Adults, general population, N = 400
89655236|NCT04367337||France|Adults, general population, N = 400
89655237|NCT04367337||Gambia|Adults, general population, N = 400
89655238|NCT04367337||Germany|Adults, general population, N = 400
89655239|NCT04367337||Israel|Adults, general population, N = 400
89655240|NCT04367337||Italy|Adults, general population, N = 400
89655241|NCT04367337||Malaysia|Adults, general population, N = 400
89655242|NCT04367337||Portugal|Adults, general population, N = 400
89655243|NCT04367337||Romania|Adults, general population, N = 400
89655244|NCT04367337||Singapore|Adults, general population, N = 400
89655245|NCT04367337||Switzerland|Adults, general population, N = 400
89655246|NCT04143893||Cardiogenic shock with MCS|Patients with cardiogenic shock who underwent MCS
89655247|NCT04143893||Cardiogenic shock without MCS|Patients with cardiogenic shock who did not undergo MCS
89655248|NCT04355325|Active Comparator|Experimental|modified monolithic zirconia crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
89655249|NCT04355325|Placebo Comparator|control|metal ceramic crowns At the time of the second optical impression, implants will be randomly allocated to either the test group (modified monolithic zirconia crowns) or the control group (metal ceramic crowns), using a computer-generated randomization list.
89655250|NCT04989192|Other|CT scanner 1|Patients will undergo imaging on scanner 1.
89655251|NCT04989192|Other|CT scanner 2|Patients will undergo imaging on scanner 2.
89655252|NCT04989192|Other|CT scanner 3|Patients will undergo imaging on scanner 3.
89655253|NCT04144049|Experimental|MT921|1% or 1.5%, subcutaneously administered at most 50 injections per treatment.
89046544|NCT01904409|Experimental|Rifaximin SSD 80 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.
89046545|NCT01904409|Experimental|Rifaximin SSD 40 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.
89046546|NCT01904409|Experimental|Rifaximin SSD 80 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.
89655254|NCT04144049|Placebo Comparator|Placebo|Subcutaneously administered at most 50 injections per treatment.
89655255|NCT04367025|Active Comparator|SOX|SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy for 2-4 cycles, adjuvant chemotherapy for 2-4 cycles
89046547|NCT01904409|Experimental|Rifaximin SSD 80mgIR/80mgSER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.
89655256|NCT04367025|Experimental|Camrelizumab+ SOX|Camrelizumab:200mg,iv drip for 1h,d1,q3w SOX: Oxaliplatin+S-1 Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w; S-1:40~60mg Bid, d1~14, q3w; Neoadjuvant chemotherapy+ Camrelizumab for 2-4 cycles, adjuvant chemotherapy + Camrelizumab for 2-4 cycles.
89655257|NCT03076710||Opioids delivered through PCA|PCA devices used to deliver opioids
89655258|NCT03076710||EXPAREL® infiltration|EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
89655259|NCT05620485|Experimental|prenatally diagnosed CDC|All patients received laparoscopic-assisted CDC excision and hepaticojejunostomy.
89655260|NCT04143581|Experimental|IMP|
89655261|NCT03071172|Experimental|Recombinant Human Follitropin|Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
89655262|NCT03071172|Active Comparator|Gonal-F|Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
89655263|NCT02979509||Endoscopic ultrasound- (EUS) guided tissue sampling|All patients scheduled to undergo EUS with tissue sampling (TS) as medically indicated will be considered for the study. Patients in whom EUS-TS is considered as part of their standard medical care will be offered to participate in this study.
89655264|NCT02245425|Active Comparator|Supine Thoracic Spine Manipulation|Supine (lying face-up on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
89655265|NCT02245425|Active Comparator|Prone Thoracic Spine Manipulation|Prone (lying face down on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
89046548|NCT02277158|Experimental|Chemoradiotherapy|There are four dose levels and one arm only. Level 1: S-1, 50 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 2: S-1, 65 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 3: S-1, 80 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 4: S-1, 90 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks
89046549|NCT01902381|Experimental|Treatment (6, 8-bis(benzylthio) octanoic acid)|Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89046550|NCT04673916|Active Comparator|Clobetasol treatment|The clobetasol group was treated with clobetasol propionate 0.05%, while the anti-inflammatory group was treated with mouthwash. The drug used consisted of Clobetasol propionate 0.05%, Ethyl alcohol 96° (50%), Hydroxyethylcellulose (4%); Preserved water (just enough to 100%) that was topically applied [11]. This drug was produced as a galenic formulation. Clobetasol propionate twice a day (every 12 hours) to the lesions with a soft bristle brush and were advised not to drink or eat during the hour following application of the medication.
89655266|NCT04143815|Experimental|MBA-P01 30U|Experimental group, Dose: 30U
89655267|NCT04143815|Experimental|MBA-P01 20U|Experimental group, Dose: 20U
89655268|NCT04143815|Experimental|MBA-P01 10U|Experimental group, Dose: 10U
89655269|NCT04143815|Placebo Comparator|Placebo|Placebo group, Normal saline
89655270|NCT04987866|Experimental|group Vibration|The participants who were chose an opaque envelope containing yellow paper represented the vibration group (Group V). After 1 min of pre-treatment with the vibration device on the intravenous catheter trace, we manually injected 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunterand. Also asked the patients whether they had any discomfort. After the propofol injection, pain scores were observed during propofol injection and 20 seconds after the injection, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and after 20 seconds rocuronium injection.
89655271|NCT04987866|No Intervention|group Control|The participants who were chose an opaque envelope containing red paper represented the group control (Group C).Only propofol and rocuronium were given to these patients. propofol injection made manually 2-2,5 mg/kg, 1% propofol (Propofol 1%, Fresenius 20 ml flacon, Germany) over 15 s. Patients were observed during and after the injection of propofol for 20 seconds. Observer rated the pain responses according to a four-point scale which developed by McCrirrick and Hunter. During the injection of propofol, we also asked the patients whether they had any discomfort. After the propofol injection for 20 seconds, pain scores were observed, and hemodynamic records were taken. 0,6 mg/kg rocuronium (Esmeron® 50 mg.5ml-1 N.V. Organon, Oss, Holland) were injected over 10 seconds. The movement response to rocuronium injection pain was evaluated by the same observer on a four-point scale (FPS) during and 20 seconds after the rocuronium injection.
89655272|NCT04355403|Experimental|Hyalo Gyn gel|Vaginal application of Hyalo Gyn gel in prefilled applicators
89655273|NCT04355403|No Intervention|No treatment|No treatment application
89655274|NCT05003466|Experimental|candidate vaccine|
89655275|NCT05003466|Placebo Comparator|Placebo|
89655276|NCT04355247|Experimental|Single Arm|"Patients will be admitted to a regular room in the hospital (not ICU)~They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
89046551|NCT04673916|Active Comparator|Anti-inflammatory mouthwash|In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
89655277|NCT03903809|Experimental|HS-20039 Pegol-Sihematide|Pegol-Sihematide's starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 13 doses
89655278|NCT03903809|Active Comparator|ReHuman Erythropoietin Injection|ESPO(Recombinant Human Erythropoietin Injection) ESPO's starting dose was 6000 IU per week
89655279|NCT04987554|Experimental|AM3 supplementation group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
89655280|NCT04987554|Placebo Comparator|Control Group|2 capsules for 30 consecutive days, distributed in a single daily oral intake in the morning on an empty stomach.
89655281|NCT04358367|Active Comparator|Dexmedetomidine|spinal anesthesia and intravenous dexmedetomidine(1µg/kg)
89655282|NCT04358367|Placebo Comparator|Saline|spinal anesthesia and placebo (saline).
89655283|NCT04358523|Experimental|ASC18 (D1,D4-13）;RDV + SOF(D27,D30-39)|ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 1 and day 4 to 13. RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 27 and day 30 to 39.
89655284|NCT04358523|Experimental|RDV + SOF (D1,D4-13）;ASC18(D27,D30-39)|RDV one tablet (200mg / tablet) SOF one tablet (400mg/tablet)at a time, once per day, day 1 and day 4 to 13. ASC18 one tablet (200mg RDV+400mg SOF / tablet) at a time, once per day, day 27 and day 30 to 39.
89655285|NCT05583383|Experimental|Cohort 1|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (< <1.25 40 mg；; 1.25-1.5 50 mg； > >1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trazumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks
89655286|NCT05583383|Active Comparator|Cohort 2|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (< <1.25 40 mg；; 1.25-1.5 50 mg； > >1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle;
89655287|NCT03070158|Experimental|Attachment Promotion Intervention|Mothers will receive the intervention which includes an education session about newborn care, training in multisensory stimulation with the intervention ATVV and two domiciliary visits to follow up the mother and her premature infant.
89655288|NCT03070158|No Intervention|Usual Care|Mothers will continue to receive usual which consist in education session about newborn care in home.
89655289|NCT03070080|Active Comparator|restrictive group|restrictive fluid strategy, 6 ml/kg/hour of lactated Ringer, during intraoperative period
89655290|NCT03070080|Active Comparator|conservative group|conservative fluid strategy, 12 ml/kg/hour of lactated Ringer, during intraoperative period
89655291|NCT03903341|Other|idiopathic blepharospasm (BSP) de novo|bold signal in visual pathway
89655292|NCT03903341|Other|Healthy subjects|bold signal in visual pathway
89655293|NCT04354857||RT-PCR SARS-CoV-2 positive|
89655294|NCT04354857||RT-PCR SARS-CoV-2 negative|
89655295|NCT04143347||Community Hospitals - CH|Patients with head injury managed at Community Hospitals
89655296|NCT04143347||Level 1 Trauma Center - L1TC|Patients with head injury presenting to level 1 trauma center directly
89655297|NCT04143347||Transfer|Patients with head injury presenting at a community hospital but then getting transferred to the level 1 trauma center
89655298|NCT00939471|Other|Relieva™ Balloon Sinuplasty™ System|Balloon Dilation of sinus ostium
89655299|NCT04989114|No Intervention|standard care|In this arm, oxygen inhalation will be provided without positive end expiratory pressure
89655300|NCT04989114|Experimental|nasal continuous positive airway pressure|In this arm, positive end expiratory pressure will be provided by nasal continuous positive airway pressure
89655301|NCT03917303|Active Comparator|Adalimumab|Episodic adalimumab monotherapy as first line treatment for 6 months
89655302|NCT03917303|Active Comparator|Standard step-up care|Step-up care as first line treatment, starting with corticosteroids.
89655303|NCT04989036|Experimental|CALCIUM HYDROXIDE™|Non-setting Calcium hydroxide Pulpotomy capping agent. Deepak. Promotion Industrial Park, Bari Brahmana, Jammu - 181133 India form : powder and liquid. application : Calcium hydroxide was mixed with saline to a thick consistency immediately before use. The paste was carefully placed on the pulp stump surface 2-3 mm thick over a small sterile wet cotton with a small condenser, and the excess material was scraped off.
89655304|NCT04989036|Experimental|Biodentine ™|Biodentine ™ Pulpotomy capping agent. Calcium Silicate-Based Material.Septodent®, Saint-Maurdes-Fosses, France form: capsule and liquid. application: According to the instructions of manufacture, Biodentine ™powder and liquid were mixed to achieve a creamy consistency, by mixing a single-unit powder part and 5 drops of a single-unit liquid part for 30 seconds by mixing device . Final mixing and adjustment were done manually to obtain the desired consistency for each case
89655305|NCT04782609|Experimental|20 mg Icapamespib cohort|Icapamespib will be administered orally once daily for each 28-day cycle. The initial dose in this trial will be 20 mg
89655306|NCT04782609|Experimental|dose expansion cohort|dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D)
89655307|NCT03070860|Experimental|PXE Patient|positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
89046552|NCT01887366|Experimental|TV-1380 150 mg|
89046553|NCT01887366|Experimental|TV-1380 300 mg|
89046554|NCT01887366|Placebo Comparator|Placebo|
89046555|NCT04674072|Experimental|Intervention group|The intervention group will be instructed to include the reverse Nordic curl exercise into their warm up 15 to 20 mins before training session (3 times per week) during one season (6 months).
89046556|NCT04674072|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions
89046557|NCT04674150|Sham Comparator|Non-AR Group|Patients allocated to the control group will be able to interact with the iPad and visualize objects and decals in the walls but not able to initiate the AR technology. In other terms, patients in this group will be provided with the same iPad to the AR group patients with the only exception that the AR technology will be off and will only see objects through the device camera in normal reality.
89655308|NCT05583149|Experimental|ACALABRUTINIB and LISOCABTAGENE MARALEUCEL|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits, as tolerated for one year~Liso-cel~Acalabrutinib"
89213341|NCT05674331|Experimental|XSD+ ATB+socket seal group|After tooth extraction, the tooth will be grinded and after the sterilization procedure it will be filled back to the extraction socket. For the reconstruction of the buccal bony wall a xenograft membrane with a long absorption rate is fixed with titanium pins to the buccal side. A soft tissue pounch is sutured above the extraction socket.
89655309|NCT04366869|Active Comparator|control|traditional approach of removing denture at night
89655310|NCT04366869|Experimental|intervention 1|occlusal splint
89655311|NCT04366869|Experimental|intervention 2|Botox
89655312|NCT04989270||Patients undergoing Cesarean section|Group of patients undergoing Cesarean section between Jan'2015 to Dec'2019
89655313|NCT04366635|Experimental|Mineralised Plasmatic Matrix Group|Mineralized Plasmatic Matrix (MPM) is a product of mixing of two phases: the mineral phase and the plasma phase. After centrifugation, the white blood cells are recovered and mixed with the mineral phase of bone graft that can be autogenic, allogeneic bone, or a bone substitute like Xenogeneic Bone Synthetic. We will use Beta-tricalcium phosphate as a graft material. The result of this mixture is a homogeneous single component, which is compact and stable, containing the graft, the dense fibrin network, and the promoting healing. And then we are planning to place MPM material to extraction socket of impacted third molar tooth to improve periodontal healing at the distal aspect of second molar tooth. Additional after MPM places to extraction socket, Once the MPM has been placed, it will be covered with a Platelet Rich Fibrin (PRF) membrane and sutured as a primer.
89655314|NCT04366635|Experimental|Beta-tricalcium phosphate Group|Beta-tricalcium phosphate graft will place in the extraction socket and cover with a PRF membrane.
89655315|NCT04366635|Active Comparator|Control Group|In the control group, after removal of impacted third molar tooth no material will be placed on the extraction socket. Only the extraction socket was primarily closed with non-resorbable sutures.
89655316|NCT04346823|Experimental|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3 minutes. Then, parturients breath 1% of sevoflurane in mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min. Values of inspired (FI) and end-tidal (FET) concentrations of sevoflurane, oxygen and respiratory rate (RR) measured by end-tidal carbon dioxide (EtC02) were monitored continuously and recorded at 30 seconds intervals by a gas analyzer.~30 seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure. HR, FI and FET concentration of sevoflurane, Sp02 and EtC02 will be recorded at 30-s interval during ECV. Non-invasive BP will be recorded every one minute. Duration of ECV in addition to level of difficulty estimated by obstetrician will be recorded.~ECV considered successful when a cephalic presentation, confirmed by ultrasound scan, achieved."
89655317|NCT04346823|No Intervention|No sevoflurane|If the parturient is assigned to the control (nonintervention) group, the participants will not receive any medications neither tocolytics nor analgesics as the routine care in our hospital. However, the participants will be monitored throughout the procedure for vital signs and for pain scores as in the intervention group.
89655318|NCT05003232|No Intervention|Control group|
89655319|NCT05003232|Experimental|Optimal MAP group|
89655320|NCT05582837|Experimental|nortriptyline + topiramate|Nortriptyline (starting dose 7.5 mg) plus Topiramate (starting dose 10 mg) with appropriate dosage increase as necessary
89655321|NCT05582837|Active Comparator|hydrochlorothiazide + triamterene + placebo|hydrochlorothiazide (starting dose 25 mg) plus triamterene (starting dose 37.5 mg) with placebo being added in case of a dosage increase
89655322|NCT04986774|Experimental|Rescue Intracranial Stenting (RIS)|RIS in Acute Ischemic Stroke caused by intracranial large vessel occlusion
89655323|NCT01688388|Experimental|IORT Arm|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.
89655324|NCT04143113|No Intervention|Usual Care (n=20)|Control: general information about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
89655325|NCT04143113|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
89655326|NCT05003700|Experimental|HAIC(RALOX) plus Lenvatinib and Camrelizumab|Hepatic arterial infusion of oxaliplatin and raltitrexed every 3 weeks. Lenvatinib 8 mg once daily (QD) oral dosing. Camrelizumab 200mg intravenously every 3 weeks.
89655327|NCT02982291|Active Comparator|Standard|
89655328|NCT02982291|Experimental|Individualized|
89655329|NCT04143191|Active Comparator|Sorafenib|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. If any drug related adverse event occurred, the dosage will be reduced.
89655330|NCT04143191|Experimental|Sorafenib plus TACE|Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. TACE will be performed on the fourth day after randomization. If any drug related adverse event occurred, the dosage will be reduced.
89655331|NCT03916055|Experimental|Exposure and response prevention (ERP)|Therapist-guided and parent-guided internet-delivered exposure and response prevention (ERP)
89655332|NCT03916055|Active Comparator|Education on tics|Therapist-guided and parent-guided internet-delivered education on tics
89655333|NCT04896216|Experimental|Stigma Reduction Intervention|A Stigma Reduction Intervention curriculum will be developed using data generated from Stage 1 of the study.
89213342|NCT00998673|Experimental|Arm 1|
89213343|NCT00998673|Other|Arm 2|
89213344|NCT03967561|Experimental|Progressive aerobic training|Water-based aerobic training performed with progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
89655334|NCT04896216|No Intervention|Control|This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
89655335|NCT03647657|Experimental|Entresto second|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)
89046558|NCT04674150|Active Comparator|AR Group|Patients randomized to the AR group will be able to use the iPad and SpellBound app to initiate the AR experiences in the game.
89046559|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 1|ISIS-GCGRRx Dose Level 1
89655336|NCT03647657|Experimental|Entresto first|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)
89655337|NCT04895514|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of gamma-irradiated preserved corneal tissue
89655338|NCT04986384|Active Comparator|Active Treatment Group|Patients will be instructed to use the anti-pruritic spray for four weeks starting from the day which informed consent was signed in active treatment group. A follow-up visit will be on week 2 for a mid-term review.
89655339|NCT04986384|Active Comparator|Wait-list Control Group|Patients will be instructed to start the treatment after two weeks from the day which consent was signed and for a duration of two weeks in wait-list control group. A follow-up visit will be on week 2 for a mid-term review and for the dispense of treating material.
89655340|NCT04461288|Experimental|Pride Posts|This six month intervention will be conducted on the Facebook platform. Participants will receive regular social media posts tailored to the sexual and gender minority communities (LGBTQ+). Weekly live sessions with a tobacco expert will be available. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
89655341|NCT04461288|Experimental|Pride Posts Plus|This six month intervention will include all elements of the Pride Posts arm. In addition, the intervention will include gamification, gaming elements designed to encourage participation in the program and behavior change. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
89655342|NCT04461288|Active Comparator|Usual Care Condition|Participants in this arm will be provided with a referral to smokefree.gov, a federally-funded website which provides support and digital-based interventions to assist in smoking cessation activities. Participants will also have access to up to six months of nicotine replacement therapy (patch + gum/lozenge). Dosage will be based manufacturer's recommendations which are based on self-reported smoking behaviors.
89655343|NCT05582135|Active Comparator|group A|The parturients in group A were administered 2 mg morphine sulfate through the epidural catheter.
89655344|NCT05582135|Active Comparator|group B|The parturients in group B were administered 0.25mg/kg of esketamine.
89655345|NCT05582135|Active Comparator|group C|The parturients in group C were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate.
89655346|NCT05582135|Active Comparator|group D|The parturients in group D were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate.
89655347|NCT04142801|Experimental|MeMo group|MeMo group: experimental: regular use at home of the Memo web application In the Memo group patients were instructed on how to use the application, and allowed to train for 12 weeks. It was also explained that this training needed to be done regularly on a basis of 4 sessions of 30 minutes each per week.
89655348|NCT04142801|Placebo Comparator|Control group|Regular follow up at the memory center without cognitive training
89655349|NCT05003154|No Intervention|Conventional management group|Received conventional management based on Guidelines for GDM in China
89655350|NCT05003154|Experimental|Digitalized management group|Reveived conventional management and digitalized management
89655351|NCT03070626|Experimental|Interventional group|Carbohydrate-rich, dietary supplement: PreOp® 800ml day before surgery and PreOp® 400ml 2-4hours preoperative.
89655352|NCT03070626|No Intervention|Control group|Standard of care: Fasting from 24hours (midnight), night before surgery.
89655353|NCT04142099|Experimental|skin to skin contact 60 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.~Observe the time of newborn spent in suctioning the maternal nipple in 60 minutes of skin to skin contact.~No intervention or forced neonatal suction."
89655354|NCT04142099|Active Comparator|skin to skin contact 20 min group|"Newborns are exposed to maternal and child skin within five minutes of birth.~Observe the time of newborn spent in suctioning the maternal nipple in 20 minutes of skin to skin contact.~No intervention or forced neonatal suction."
89655355|NCT03070704||Insulin degludec /liraglutide|
89655356|NCT04141943|Experimental|VR|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality
89655357|NCT04141943|No Intervention|Printed document|The patients who are allocated to the Printed document arm will receive information about radiotherapy via printed document.
89655358|NCT03069768|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
89655359|NCT03069768|Active Comparator|Control|Smokers in this group will not be given the mSMART application.
89655360|NCT04141553|Active Comparator|Diltiazem IV push|In the standard IV push group, diltiazem will be administered at a dose of 0.25 mg/kg, to a max dose of 25 mg, over 2 minutes. At time 0, these participants will also receive 30 mg of immediate release oral diltiazem. After 15 minutes, if adequate rate control of <110 BPM has not been achieved, an additional dose 0.35 mg/kg to a max dose of 35 mg will be administered. In order to maintain the blind, the control group will also receive 50 mL of 0.9% NS IV over 20 minutes.
89046560|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 2|ISIS-GCGRRx Dose Level 2
89046561|NCT01885260|Placebo Comparator|Placebo|Placebo
89046562|NCT01876719|Experimental|0.5 mg AR08|0.5 mg AR08, QD for 7 weeks
89046563|NCT01876719|Experimental|1.0 mg AR08|1.0 mg AR08, QD for 7 weeks
89046564|NCT01876719|Experimental|2.0 mg AR08|2.0 mg AR08, QD for 7 weeks
89046565|NCT01876719|Placebo Comparator|Placebo|Placebo, QD for 7 weeks
89046566|NCT05285540|Experimental|Single Dose: DT-216|DT-216 will be administered once
89046567|NCT05285540|Experimental|Single Dose: DT-216 matching placebo|Placebo will be administered once
89046568|NCT04673799|Experimental|MV088|MV088 injection (60mg) by subcutaneous injection once on the first day
89655361|NCT04141553|Active Comparator|Diltiazem IV Slow Infusion|In the slow infusion group, 50 mg of diltiazem will be diluted in 50 mL of 0.9% NS and infused over 20 minutes. Similar the other group, these participants will also receive 30 mg of immediate release oral diltiazem. In order to maintain the blind, this slow infusion group will receive the equivalent volume of IV 0.9% NS over 2 minutes as a placebo.
89655362|NCT03069846|Experimental|Measurement using Spectra-Scope|Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
89046569|NCT04673799|Active Comparator|Prolia®|Prolia® injection (60mg) by subcutaneous injection once on the first day
89046570|NCT01873677|Placebo Comparator|Vehicle|Proper quantity twice a day
89046571|NCT01873677|Experimental|M518101|Proper quantity twice a day
89046572|NCT05236400|Experimental|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|After participating in a clinical trial and receiving unmanned electric airway aspiration, the efficacy and safety are checked on Day 3 and on Day 7 and Day 14 of the follow-up period.
89046573|NCT05236400|Active Comparator|Manual phlegm suction system|After participating in a clinical trial and applying manual airway aspiration, the efficacy and safety are checked on Day 3 and on Day 7 and Day 14 of the follow-up period.
89655363|NCT04141241|Experimental|Low Dose PH100: 800mg/day|"PH100 (Ecklonia cava Phlorotannin) 200mg/tablet~PH100 2 tablets (400mg) and Placebo 2 tablets BID during 12wks"
89655364|NCT04141241|Experimental|High Dose PH100: 1600mg/day|- PH100 4 tablets (800mg) BID during 12wks
89655365|NCT04141241|Placebo Comparator|Placebo|"Placebo 200mg/tablet~Placebo 4 tablets BID during 12wks"
89655366|NCT04456062|Experimental|Caring Contacts Group|
89655367|NCT04456062|No Intervention|Standard Treatment Group|
89655368|NCT04141397||POG patients|Patients enrolled in POG who initiated WGTA between July 2014 and December 2017
89655369|NCT04141397||Usual care controls|Matched controls who received usual care and were diagnosed with metastatic cancer prior to December 2017
89655370|NCT04986462||patients with bursal-side partial-thickness rotator cuff tears|Patients with bursal-side partial-thickness rotator cuff tears who underwent arthroscopic surgery and was followed up at Peking University Third Hospital.
89655371|NCT04141163|Experimental|Metformin|Subjects randomized to metformin will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
89655372|NCT04141163|Placebo Comparator|Placebo|Subjects randomized to placebo will start at 500mg once a day for 7 days and increase as is tolerated to 500mg twice a day for 7 days, then to 1000mg in the morning and 500mg at dinner for 7 days and then to the target dose of 1,000mg twice a day.
89655373|NCT00942825|Experimental|A CBP501 +Cisplatin + Pemetrexed|CBP501 25 mg/m2 + Cisplatin 75 mg/m2 + Pemetrexed 500mg/m2
89655374|NCT00942825|Active Comparator|B Cisplatin + Pemetrexed|Cisplatin + Pemetrexed
89655375|NCT04986306||clinical tumor stage 1-3 (cT1-3) and nodal stage 1 (cN1) breast cancer patients|Patients who will undergo neoadjuvant chemotherapy were asked to participate in this study. Informed consent will be given. Clip will be placed over the positive lymph node by surgeon which was proven by fine-needle aspiration cytology. After completion of neoadjuvant chemotherapy, surgery of the breast and the axilla was executed in the same session. Different surgeons performed the procedure.
89655376|NCT04544943|Experimental|Cohort 1|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The total body surface area (BSA) dosed will be either 9% or 27% BSA. Part A will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control, applied at 9% or 27% BSA.
89655377|NCT04544943|Placebo Comparator|Cohort 2|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The minimum % BSA dosed will be 3% BSA and the maximum will be 27% BSA for patients in Cohort 2. Part B will include both an active-control (lotion base + 0.1% gentamicin) and a placebo control.
89655378|NCT04544943|Experimental|Open-Label|Route of Administration: Topical; Dosage Form: Topical lotion. Product Name: BioLexa. The minimum % BSA dosed will be 3% BSA and the maximum will be 27% BSA for patients
89655379|NCT04140461|Experimental|Trial|Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks
89655380|NCT04140461|Active Comparator|Control|Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks
89655381|NCT04988100|Experimental|Patients who undergo Splenic artery ligation|If inclusion criteria are met, these group of patients will undergo splenic artery ligation .
89655382|NCT04988100|Active Comparator|No splenic artery ligation|If inclusion criteria are met, these group of patients will not undergo splenic artery ligation.
89655383|NCT03032757|Experimental|Resting leg of young males|
89655384|NCT03032757|Experimental|Exercising leg of young males|
89046574|NCT04673526|Experimental|Intersphincteric resection|After a laparoscopic TME (total mesorectal excision) is carried out down to the elevator ani plane and the anorectal junction, the intersphincteric plane is dissected, opening the space between puborectalis muscle and interior sphincter. Margin of resection is at least 1 cm below the lower margin of the tumor. Rectal excision is completed with transanal circumferential dissection and after specimen extraction through the anus, a colo-anal hand sewn anastomosis is fashioned.
89046575|NCT04673526|Active Comparator|Abdomen-perineal procedures|After identification of the elevator ani plane, the descendent colon is transected with a linear stapler and a terminal stoma is fashioned. Then, a circumferential incision is made around anal orifice and perineal dissection is performed circumferentially to the pelvic cavity. Perineal defect is repaired performing mono-lateral or bilateral inferior gluteal flap.
89046576|NCT01215955|Experimental|3 Day Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the past three days.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
89655385|NCT03032757|Experimental|Resting leg of elderly males|
89655386|NCT03032757|Experimental|Exercising leg of elderly males|
89655387|NCT04140617|Experimental|E-cigarette aerosol exposure in a room|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a 25 m3 room.
89655388|NCT04140617|Experimental|E-cigarette aerosol exposure in a car|Exposure to aerosol of electronic cigarette produced by experienced user (30 minutes of exposure) in a car.
89655389|NCT05002920||cleft patients received alveolar bone grafting|alveolar bone grafting was performed when the cleft patients were aged around 9 years old. CBCT was used to analyze the bone mineral density of grafted tissue.
89655390|NCT00947505|Active Comparator|HairMax LaserComb 2009, 7 Beam|Lower level laser phototherapy medical device with 7 laser beams
89655391|NCT00947505|Active Comparator|Control Device|Identical to the Active device, but with 7 LED's instead of lasers
89655392|NCT04140383||Group 1, patients aged 85 years and older|75 eyes of 75 patients (39 female, 36 male) Mean age: 86,8 ± 1,8 years
89655393|NCT04140383||Group 2, patients aged 65 and 85 years|77 eyes of 77 patients (34 female, 43 male) Mean age:73,3 ± 5,2 years
89655394|NCT03070314|Experimental|Echinaforce junior|Echinaforce is an ethanolic extract from Echinacea purpurea fresh plant and root. The product is registered in Switzerland for children from age 4 years on for Treatment and prevention of respiratory tract infections.
89655395|NCT03021629||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
89655396|NCT03021629||high myopia patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
89655397|NCT03021629||age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
89655398|NCT04988334|Active Comparator|FAST|12 weeks of FAST, 2/week 45 minute sessions with half hour per week of education, same group of men and women
89655399|NCT04988334|Placebo Comparator|wait control|12 weeks of usual activity prior to intervention, same group of men and women
89655400|NCT03021395|Experimental|MRD-positive|MRD-positive patients receive Decitabine regimen.
89655401|NCT03021395|No Intervention|MRD-negative|MRD-negative patients receive no intervention.
89655402|NCT00947661|Experimental|SPARC0912|Test drug
89655403|NCT00947661|Experimental|Reference0912|Reference drug
89655404|NCT03021317|Experimental|Treated Group|Open label, single arm treatment study using MRI and laboratory markers to assess efficacy of ACTHAR in MS patients who are undergoing relapses.
89655405|NCT04987632|Experimental|Letrozole combined with acupuncture and Du Meridian moxibustion group|Letrozole combined with acupuncture and Du Meridian moxibustion was taken from 3-5 days of menstrual period (spontaneous menstruation or progesterone withdrawal bleeding). The acupuncture treatment was 3 times / week, with an interval of 2-4 days, 12 times a week, 30 minutes each time; Du Meridian moxibustion is 20 minutes each time, once a week, four times a week. The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. If not pregnant, the subjects received letrozole for up to 4 cycles to induce ovulation with acupuncture plus Du Meridian moxibustion.
89655406|NCT04987632|Active Comparator|Letrozole group|Letrozole was taken 3-5 days after menstruation (spontaneous menstruation or progesterone withdrawal bleeding). The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. In the absence of pregnancy, subjects were treated with letrozole for up to four cycles.
89655407|NCT03032445|Experimental|Alcoholic beer|At least 6% alcohol content
89655408|NCT03032445|Placebo Comparator|Non alcoholic beer|Less than 0.5% alcohol content
89655409|NCT03069612|Experimental|rTMS Active Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains.
89655410|NCT03069612|Sham Comparator|rTMS Sham Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains with a sham coil.
89655411|NCT03032367|Other|Sequence 1|Bedaquiline 4 x 100mg administered in a whole tablet form, followed by bedaquiline 4 x 100mg administered in crushed form as a once only oral dose
89655412|NCT03032367|Other|Sequence 2|Bedaquiline 4x 100mg administered in crushed form, followed by bedaquiline 4 x 100mg administered in a whole tablet form, as a once only oral dose
89655413|NCT03032679||Single group of patients|Non interventional study. Observational with questionnaires
89655414|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - Low Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
89655415|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - High Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
89655416|NCT02634606|Placebo Comparator|Sugar Pill|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
89655417|NCT04355091|Experimental|Intervention Group|"The pregnant women in this group will be informed about the application of EFT with a written material.~The pregnant women who have undergone EFT will be interviewed a week or two after the application, and how they feel and whether the problem still disturbs him. If a new issue is reported, similar actions will be repeated for this new issue. The number of EFT sessions was decided based on the condition of the pregnant woman. After all EFT sessions are completed, a re-evaluation (post-test) of Edinburgh Postpartum Depression Scale, Stress Coping Scale and State-Trait Anxiety Inventory will be done.~The same participants will be asked to apply the other inventories and the postpartum interview form if she had birth three months and six months after the last application (follow-up). In the follow-up study performed three months after the last application, EFT will be applied to the pregnant women in need."
89046577|NCT01215955|Experimental|Daily Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the previous day.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
89655418|NCT04355091|No Intervention|control group|"The participants in this group will be talked about the problems they should have in routine midwifery care, the problems they encounter during pregnancy or postpartum period and the subjects they want to receive information.~If necessary, suggestions will be made for problems related to pregnancy, postpartum period or newborn care. Again, with these participants, after the depression risk determination (pre-test), after the interviews ended (post-test), three months and six months after the last application, Edinburgh Postpar All Depression Scale, Stressful Life Events List, Stress Coping Scale. If the pregnant woman has given birth, State-Trait Anxiety Inventory and postnatal interview form will be performed."
89655419|NCT03588923|Active Comparator|Cohort 1|SH229 (400 mg) or matching placebo, once daily
89655420|NCT03588923|Active Comparator|Cohort 2|SH229 (600 mg) or matching placebo, once daily
89655421|NCT03588923|Active Comparator|Cohort 3|SH229 (800 mg) or matching placebo, once daily
89655422|NCT05002686|Experimental|Sintilimab+ Albumin-Paclitaxel+Oxaliplatin +capecitabine+radiothrerapy+D2 Surgical Resection|
89655423|NCT03588689|No Intervention|Standard Treatment|Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
89655424|NCT03588689|Experimental|Continuous fascia iliaca block|"The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure.~The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter."
89655425|NCT04985526|Experimental|Polymorphic light eruption patients|PLE patients subjected to MED testing and photoprovocation
89655426|NCT04985526|Other|Healthy subjects|Normal healthy subjects
89655427|NCT03588611|Experimental|Low dose group with eGFR ≥60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
89655428|NCT03588611|Active Comparator|Standard dose group with eGFR ≥ 60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
89655429|NCT03588611|Active Comparator|Standard dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
89655430|NCT03588611|Experimental|Low dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
89655431|NCT04985292|Experimental|Probiotic|10^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
89655432|NCT04985292|Placebo Comparator|Placebo|Inactive substance packaged to be identical to active treatment
89655433|NCT03588533|Experimental|Herzuma-capecitabine/cisplatin(XP)|"Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle~ ) every 3 weeks~Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks~Cisplatin 60~100mg/m2 i.v. D1 every 3 weeks"
89655434|NCT03069456|Active Comparator|BIS group|Combined sigmoidal Emax models from the BIS data
89655435|NCT03069456|Experimental|ADMS group|Combined sigmoidal Emax models from the ADMS data
89655436|NCT00942903|Experimental|Compliant HME users|Laryngectomized patients who are currently compliant (24/7) users of a Provox HME
89655437|NCT02335229||Axium DRG Neurostimulator|All eligible subjects recruited and treated with the Axium Neurostimulator
89655438|NCT04478175|Other|Patients with advanced gastrointestinal (GI) cancers|"All patients will receive usual care including:~Chemotherapy at the investigator's choice,~Outpatient clinical visits according to the regular schedule,~Tumor evaluation based on tumor marker serum levels, as appropriate, and TAP-CT with intravenous contrast injection every 8 weeks.~Nutritional support will consist of:~A nutrition assessment by a dieticianat W4 and W8 (plus additional visits if required),~Nutritional intervention ± oral supplementation, enteral tube feeding, and/or parenteral nutrition).~Physical activity support will consist of:~A physical condition assessment by a APA profesional including physical tests (6-minute walking test, handgrip test, chair stand fitness test, get-up and go test, balance in single-leg and bipodal stance) at baseline, W4 and W8,~Personalized counselling for unsupervised home-based exercises"
89655439|NCT03588221|Other|Six-step hand hygiene technique with application time of 30|
89655440|NCT03588221|Other|Six-step hand hygiene technique with application time of 15|
89655441|NCT03588221|Other|Three-step hand hygiene technique with application time of 3|
89655442|NCT03588221|Other|Three-step hand hygiene technique with application time of 1|
89655443|NCT03068520|Other|PRIMARY BRAIN TUMOR (PBT)|patients with PBT (Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma), before treatment with radiation and chemotherapy.will be followed with PET MRI
89655444|NCT03068520|Other|METASTATIC BT TREATED BY SRS|"patients with lung or breast metastasis to brain treated by SRS in which at least one lesion showed deterioration by MR performed after treatment.~will be followed with PET MRI"
89655445|NCT03068520|Other|METASTATIC BT NOT TREATED BY SRS|"patients with lung or breast metastasis to brain where the SRS treatment was postponed for clinical reasons (getting mutation information for targeted treatment) the lesion size measures 5-40 mm.~will be followed with PET MRI"
89655446|NCT03588143|Active Comparator|Electrical stimulation with TENS|TENS with 100 Hz frequency, 65 microseconds pulse duration, in continuous pattern
89655447|NCT03588143|Experimental|Electrical stimulation with HVPS|HVPS with twin spiked monophasic current at 100 pps frequency, in continuous pattern
89046578|NCT01873404|Experimental|BG00010|Administered as an IV injection at various dose levels 3 times per week for 1 week
89046579|NCT01873404|Placebo Comparator|Placebo|Matched placebo IV injection 3 times per week for 1 week
89655448|NCT03588143|Placebo Comparator|Placebo electrical stimulation|same electrode placement with other interventions, using the same electrotherapy device, without activating the device except its time unit.
89655449|NCT00939705|Experimental|Torrent Topiramate|
89655450|NCT00939705|Active Comparator|Topamax|
89655451|NCT05002296|Active Comparator|traditional physical therapy program|
89655452|NCT05002296|Experimental|rotatory upper cervical manipulation to both sides|
89655453|NCT03588065|Experimental|attend education for TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
89655454|NCT03588065|Active Comparator|attend education for conference|"The intervention arm descriptionTHE CONFERENCE include face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing.~The face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing."
89655455|NCT03588065|Sham Comparator|attend for FMS|The FMS test was applied in two moments with three blind evaluators physiotherapists with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience in sport greater than 6 years in sports clubs in the region.
89655456|NCT04354779||AUVA HCW|health care workers in Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA)
89655457|NCT05001672|Experimental|TAF arm|"54 patients will be randomized into TAF arm*. TAF 25 mg QD will be initiated 7 days before bDMARDs, and continued for up to 144-weeks.~*for patients received rituximab (anti-CD20 monoclonal antibody) will be enrolled into TAF arm, and TAF 25 mg QD will be initiated 7 days before rituximab, and continued for up to 144-weeks. Max 20 rituximab patients will be recruited."
89655458|NCT05001672|Other|Observation arm|54 patients will be randomized into observation arm initially. These patients will be closely monitored their HBV status (including qHBsAg and HBV DNA) for 48 weeks. TAF 25 mg QD will be initiated for 144 weeks in the presence of HBV reactivation, or after 48 weeks of observation.
89655459|NCT03587909|Active Comparator|Phacoemulsification Cataract Surgery|Procedure / Surgery : Phacoemulsification Surgery
89655460|NCT03587909|Active Comparator|Femtosecond Cataract Surgery|Procedure / SUrgery - Femtosecond Laser Cataract surgery
89655461|NCT04354545||Group 1|Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks
89655462|NCT03587597|Experimental|socket shield technique|socket shield technique with immediate temporization
89655463|NCT03587597|Active Comparator|conventional immediate implant|conventional implant placement with immediate temporization
89655464|NCT03032133|Active Comparator|Regional pain control|Regional pain catheter
89655465|NCT03032133|Experimental|Local pain control|Local intraarticular pain catheter
89655466|NCT03587363|Experimental|Cohort 1: Normal Hepatic Function|Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
89655467|NCT03587363|Experimental|Cohort 2: Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
89655468|NCT03587363|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
89655469|NCT03587363|Experimental|Cohort 4: Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.
89655470|NCT03032211|Experimental|Treatment|Alfapump
89655471|NCT03587285|Experimental|Arm 1|metastatic hormone-sensitive prostate cancer (mHSPC):After diagnosis of mHSPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by hormonal therapy of maximal androgen blockade (LHRH-a + Anti-androgen).
89655472|NCT03587285|Experimental|Arm 2|metastatic castration-resistant prostate cancer (mCRPC):After diagnosis of mCRPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by goserelin acetate monthly. Abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily will be also administered continuously during the duration of the trial.
89655473|NCT04354389|Experimental|DAS181 b.i.d.+ standard local care for COVID-19|4.5 mg DAS181 b.i.d nebulized inhalation for 10 consecutive days + standard local care for COVID-19
89655474|NCT04354389|Placebo Comparator|Placebo+ standard local care for COVID-19|nebulized inhalation for 10 consecutive days + standard local care for COVID-19
89655475|NCT04354389|Experimental|DAS181 q.d.+ standard local care for COVID-19|4.5 mg placebo q.d. nebulized inhalation for 10 consecutive days + standard local care for COVID-19
89655476|NCT03587129|Experimental|apatinib|1 times a day, atapinib, 500 mg, is taken orally
89655477|NCT02245503||Benign prostatic hyperplasia|Patients with symptomatic BPH to whom ALNA was prescribed
89655478|NCT03587051|Experimental|Low glycemic index post-exercise diet|Lentil-based post-exercise meal
89655479|NCT03587051|Active Comparator|High glycemic index post-exercise diet|Instant potato, white bread, and egg white post-exercise meal
89655480|NCT04354311|Experimental|Experimental|"Anesthetic induction : total target-controlled intravenous anesthesia d was used with propofol and remifentanil. The effect site was then gradually increased to obtain a satisfaction depth of anesthesia. Assisted ventilation was then started by facemask ventilation (Sat O2>95% and expired CO2 fraction normal, tidal volume of 8 mL/kg, a respiratory rate of 12 cycles per minute, with an FiO2 100% with no positive end expiratory pressure.~After stabilisation period of 2 minutes and record of the patient's parameters, a standardized nociceptive stimulation was applied at the level of the ulnar nerve (PTC of 50 Hz at 70 mA). The variation of ANI score and hemodynamic parameters were collected during the 2 following minutes.~After stabilization of ANI, orotracheal intubation was attempted. Maximal variation of heart rate (HR), blood pressure and the occurrence of somatic manifestations (intense cough, movement, tears) were recorded."
89655481|NCT02159079|No Intervention|Usual Care|Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
89655482|NCT02159079|Experimental|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
89655483|NCT04406129|Experimental|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
89655484|NCT04406129|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 1, Day 7 (Week 1) and Day 14 (Week 2).
89655485|NCT03586817|Active Comparator|Palonosetrona|Palonosetron 75 mcg during the anesthesia
89655486|NCT03586817|Active Comparator|Fosaprepitant|Fosaprepitant 150 mg during the anesthesia
89655487|NCT04353999|Experimental|980 nm diode laser photocoagulation|980 nm diode laser was used to coagulate the blood over the bone graft particles and achieve a socket seal after socket grafting
89655488|NCT04353999|Active Comparator|Dense polytetrafluroethylene membrane|dPTFE membrane was used to seal the socket after grafting
89655489|NCT04335981|Experimental|FT-CC and Swallow Exercises|
89655490|NCT04335981|Active Comparator|Swallow Exercises|
89655491|NCT05620251||COVID-19 infection-naive adolescents with type 1 diabetes|
89655492|NCT05620251||COVID-19 infection-naive healthy controls|
89655493|NCT03586505|Experimental|Light exposure|"The keratitis eye of the patient is exposed to 6 lights with increasing intensity according to a constant speed.~The patients switch off the light when the discomfort is too elevated"
89655494|NCT03891173|Experimental|L-DOS47 in combination with cisplatin + vinorelbine|L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.
89655495|NCT03891173|Active Comparator|Cisplatin + vinorelbine alone|Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.
89655496|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1a)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
89655497|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1b)|Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen A. Rimiducid may be administered as indicated.
89655498|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Single Dose - Part 1c)|Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
89655499|NCT04249947|Experimental|P-PSMA-101 CAR-T cells (Multiple Dose - Part 1d)|Cyclic administration of ascending dose cohorts, given via intravenous infusions of CAR-T cells, following conditioning chemotherapy regimen B. Rimiducid may be administered as indicated.
89655500|NCT03586193||patients with HMF|Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group
89655501|NCT03586115||Patients with Hereditary telangectasia|In addition to all laboratory analyses and imaging studies required to evaluate the disease, hepatic elastometry and critical flicker frequency assessment will be performed.
89655502|NCT03031977|Experimental|visceral mobilization|Conventional physical therapy and visceral mobilization. The experimental group was also submitted to mobilization of the ascending colon, descending colon, sigmoid colon and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual.
89655503|NCT03031977|Sham Comparator|sham mobilization|Conventional physical therapy and sham mobilization. In the control group, sham mobilization was performed, which consisted of superficial contact with no pressure on the abdominal region corresponding to the loops of the large intestine.
89655504|NCT03586037|Experimental|Sequence 1|Period 1: AD-2011 10/20mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
89655505|NCT03586037|Experimental|Sequence 2|Period 1: AD-2011 10/20mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2012 80mg QD
89655506|NCT03586037|Experimental|Sequence 3|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
89655507|NCT03586037|Experimental|Sequence 4|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
89655508|NCT03586037|Experimental|Sequence 5|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2012 80mg QD
89655509|NCT03586037|Experimental|Sequence 6|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
89655510|NCT03585881|Experimental|window bracket positioning tray|
89655511|NCT03585881|No Intervention|conventional indirect boning tray|
89655512|NCT05620017|Experimental|A/0.8mg/kg|Drug：BAT8008 for Injection,0.8mg/kg
89655513|NCT05620017|Experimental|B/1.2mg/kg|Drug：BAT8008 for Injection,1.2mg/kg
89655514|NCT05620017|Experimental|C/2.4mg/kg|Drug：BAT8008 for Injection,2.4mg/kg
89213345|NCT03967561|Experimental|Non-progressive aerobic training|Water-based aerobic training performed without progression in the training variables. The intervention will be performed during 12 weeks, with 3 weekly sessions (of 50 minutes each), of walking/running in shallow pool.
89655515|NCT05620017|Experimental|D/3.6mg/kg|Drug：BAT8008 for Injection,3.6mg/kg
89655516|NCT05620017|Experimental|E/4.8mg/kg|Drug：BAT8008 for Injection,4.8mg/kg
89655517|NCT05620017|Experimental|F/6.0mg/kg|Drug：BAT8008 for Injection,6.0mg/kg
89655518|NCT05620017|Experimental|G/7.2mg/kg|Drug：BAT8008 for Injection,7.2mg/kg
89655519|NCT03888911|Experimental|High dose IQP-LU-104 (5120mg)|High dose treatment group
89655520|NCT03888911|Experimental|Low dose IQP-LU-104 (2560mg)|Low dose treatment group
89655521|NCT03888911|Placebo Comparator|Placebo|Placebo group
89655522|NCT03031509|Experimental|hAECs treatment|Human Amniotic Epithelial Cells of 50 million transplant to nonunion site after debridement surgery
89655523|NCT03031509|Sham Comparator|debridement surgery|debridement surgery
89655524|NCT03585803|Other|KMRC011 5μg or Placebo|Cohort 1
89655525|NCT03585803|Other|KMRC011 10μg or Placebo|Cohort 2
89655526|NCT03585803|Other|KMRC011 15μg or Placebo|Cohort 3
89655527|NCT03585803|Other|KMRC011 20μg or Placebo|Cohort 4
89655528|NCT03585803|Other|KMRC011 25μg or Placebo|Cohort 5
89655529|NCT03031743||rotavirus (Rotarix TM) vaccination|Infants who received rotavirus vaccination (Rotarix TM) at 6 and 10 weeks, 10 and 14 weeks or 6,10, and 14 weeks. This is a nested study and infants received the vaccination in the overarching study: The Immunogenicity of ROtavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine (clinicaltrials.gov: NCT01199874)
89655530|NCT03585725|Experimental|Ribavirin|Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.
89655531|NCT03585647||GA-group|Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
89655532|NCT03585647||RA-group|"Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.~A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine."
89655533|NCT03585647||IA-group|Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.
89213346|NCT01001013|Experimental|LC15-0444 200 mg|LC15-0444 200 mg
89655534|NCT03966027|Experimental|Hindfoot Offloading Braces / Immediate Weight-bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
89655535|NCT03966027|Placebo Comparator|No Hindfoot Offloading Braces / Delayed Weight-Bearing|Diabetic patients over 18 years of age who sustained an isolated (non-pilon) ankle fracture will undergo ORIF of the ankle fracture within 3 weeks of the event
89655536|NCT05619861|Experimental|CAR-T|Autologous CAR-T cells, intravenous infusion, infusion dose 0.1-3 × 106CAR-T cells/kg
89655537|NCT03585179|Experimental|Oral tranexamic acid|250 mg of tranexamic acid bid orally
89213347|NCT01001013|Experimental|Pioglitazone 30 mg|Pioglitazone 30 mg
89213348|NCT01001013|Experimental|LC15-0444 200 mg + pioglitazone 30 mg|LC15-0444 200 mg + pioglitazone 30 mg
89655538|NCT03585179|Experimental|Topical tranexamic acid|5% topical tranexamic acid bid
89655539|NCT03585179|Active Comparator|Topical hydroquinone|4% hydroquinone once daily at night
89655540|NCT03585101|Experimental|All participants|Intervention: Elbasvir/grazoprevir
89655541|NCT03585023||Spontaneous miscarriage|The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.
89655542|NCT03585023||Voluntary pregnancy interruption|The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.
89655543|NCT03584555|Active Comparator|120 μm group|The subjects underwent SMILE using 120 μm cap.
89655544|NCT03584555|Active Comparator|140 μm group|The subjects underwent SMILE using 140 μm cap.
89655545|NCT00944073|Experimental|Group 2: 30 mcg H1N1 Vaccine|300 subjects to receive 30 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
89655546|NCT00944073|Experimental|Group 1: 15 mcg H1N1 Vaccine|300 subjects to receive 15 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
89655547|NCT03584321||Participants with Coronary Artery Disease|Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
89655548|NCT03584243|Experimental|Patient with progressive keratoconus|"Patient with progressive keratoconus will be included after providing their consent.~The intervention administrated is a cross-linking with oxygen treatment"
89655549|NCT03584087|Placebo Comparator|TG 0 (0Hr)|TG0 will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly in place of Terlipressin therapy after EVL.
89655550|NCT03584087|Active Comparator|TG 2 (48Hr)|TG2 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 48 hours after EVL .
89046580|NCT05212220|Experimental|Intervention|The intervention group will first receive 5 times EMA per day for one week. The EMA will document participants smoking behaviors, smoking cues, smoking cravings, etc. The intervention group will receive 15-30 minutes of a nurse-led phone call, and 10-week instant messaging after completing the one-week EMA documentation.
89046581|NCT05212220|No Intervention|Control|The control group will first receive 5 times EMA per day for one week. The EMA will document participants smoking behaviors, smoking cues, smoking cravings, etc. No intervention will be provided to the control group after completing the one-week EMA documentation.
89655551|NCT03584087|Active Comparator|TG 5 (120Hr)|TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
89655552|NCT02245581|Active Comparator|SVV-guided fluid management|SVV : Stoke volume variation
89655553|NCT02245581|Active Comparator|CVP-guided fluid management|CVP : Central venous pressure
89046582|NCT04677270|Experimental|Traditional interface|Digital problem solving tool with a simple textbased graphical interface
89046583|NCT04677270|Experimental|Advanced interface|Digital problem solving tool with an advanced graphical interface and automatic functions
89046584|NCT02887105||Patients with cerebrovascular accident|
89046585|NCT01871415|Experimental|Aleglitazar + metformin|
89046586|NCT01871415|Active Comparator|Placebo + metformin|
89046587|NCT05189717|Experimental|Single Group|Firstly Dose Escalation and Dose Expansion of HRS-8080 monotherapy should be conducted. After RP2D and MTD of the HRS-8080 monotherapy were confirmed, Dose Escalation and Dose Extension of HRS-8080 in combination with other anti-cancer treatment would be completed, including SHR 6390, or Abemaciclib, or Everolimus.
89046588|NCT05182463|Experimental|Sequential Combination Group|Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks, followed by combination therapy with peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
89046589|NCT05182463|Experimental|Initial Combination Group|NAs combined with peginterferon are used for 12-24 weeks, followed by peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
89046590|NCT05182463|Experimental|Whole-course Combination Group|NAs combined with peginterferon are used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
89046591|NCT05182463|Experimental|Peginterferon Monotherapy Group|Peginterferon is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
89046592|NCT05182463|Experimental|NAs Monotherapy Group|NAs is used for a maximum course of 96 weeks. Follow-up period is 144 weeks.
89046593|NCT04673643|Experimental|taVNS|Transcutaneous Auricular Vagus Nerve Stimulation
89046594|NCT05125484|Experimental|Experimental Intervention group 1|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
89046595|NCT05125484|Experimental|Experimental interventional group II|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
89213349|NCT01004523||Single group|Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.
89213350|NCT00490282|Experimental|Image-Guided Adaptive Radiotherapy|Intensity Modulated Radiotherapy (IMRT) + Adaptive Radiotherapy (ART)
89213351|NCT00998751|Experimental|masitinib (AB1010)|oral masitinib 7.5 mg/kg/day
89213352|NCT02580929|Experimental|radiation|
89213353|NCT02580929|No Intervention|no radiation|
89655554|NCT03583853||patients|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)
89655555|NCT03583853||control|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction
89655556|NCT03583619|Experimental|APBI|Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.
89655557|NCT03583619|Active Comparator|WBI|Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.
89655558|NCT03583151|Active Comparator|Steroid injection|1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
89655559|NCT03583151|Experimental|Amniotic fluid injection|1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
89655560|NCT03582995|Active Comparator|Flap Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a flap technique
89655561|NCT03582995|Experimental|Tunnel Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a tunnel technique
89655562|NCT03582761|Experimental|320U /0.5ml in children|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
89046596|NCT04673097|Experimental|Group 1|
89046597|NCT04673097|Active Comparator|Group 2|
89046598|NCT04673097|Active Comparator|Group 3|
89046599|NCT05108129|Active Comparator|Group M-TAPA|In the operating room, all of the patients will receive standard monitoring. An anesthesiologist will perform anesthesia inductions. After tracheal intubation, a linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol.
89213354|NCT01016470|Placebo Comparator|B|Placebo
89655563|NCT02982057|Active Comparator|Bioresorbable vascular scaffold(BVS)+ OMT|"hypothesis: scaffolding a non culprit coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modification of plaque morphology.~Intervention:Device"
89655564|NCT02982057|Active Comparator|OMT|"Comparator with ONLY optimal medical treatment (OMT): the aim of the study is to compare the evolution of non culprit lesions after treatment by BVS versus Optimal Medical Therapy at 2 years follow- up.~Intervention: medical treatment"
89655565|NCT03582683|Experimental|CPSMP Intervention|Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
89655566|NCT03582683|Active Comparator|Wait-list Control Group|Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
89655567|NCT02981823|Experimental|hip replacement|The patients undergo total hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
89655568|NCT03582527||observation group|All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
89655569|NCT02980185||Laparoscopic primary cytoreduction|Patients in whom primary cytoreduction was performed using a laparoscopic approach
89655570|NCT02980185||Abdominal primary cytoreduction|Patients in whom primary cytoreduction was performed using an open abdominal approach
89655571|NCT03582059|Other|Patient group meeting inclusion criteria group 1|Patients meeting the inclusion criteria in the first 10 days of entering trial and are randomised to first intervention.
89655572|NCT03582059|Other|Patient group meeting inclusion criteria group 2|Patient group meeting inclusion criteria after 10 days and are allocated second intervention.
89655573|NCT03581747||Subjects with atopic dermatitis|
89655574|NCT03581747||Controls|
89655575|NCT03031353|Experimental|Misoprostol|After preparing for elective caesarean section, the pessary will be given containing the misoprostol medication 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
89655576|NCT03031353|Active Comparator|Placebo|After preparing for elective caesarean section, the pessary will be given containing placebo 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
89655577|NCT03581591|Experimental|Primary; open label|Injection of Burosumab every two to three weeks based on Serum Phosphorus level of subject. Initial dose to be 0.3 mg/kg. Subsequent dosing will be titrated up or down depending on Serum Phosphorus level for that time period.
89655578|NCT03711747||Post-traumatic Ankle OA|Post-traumatic ankle OA and requiring osteochondral allograft to tibia and/or talus in ankle
89655579|NCT05702957|Experimental|letrozole|Patients were given letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
89655580|NCT05702957|Active Comparator|Clomiphene citrate|Patients were given clomiphene citrate 50-150mg per day for 5 days started from 2nd day of the menses.
89655581|NCT05536401|Other|Optical Coherence Tomography (OCT)|
89655582|NCT04405505|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89655583|NCT04405505|Active Comparator|Paclitaxel for injection (albumin bound)|Paclitaxel for Injection (albumin bound) 100mg / m2 administered intravenously (IV) on Day 1, 8, 15 in 28-day cycle.
89655584|NCT03581435||gallbladder carcinoma patients|Cases will be the patients with newly-diagnosed gallbladder carcinoma.
89655585|NCT03581435||The controls|The controls will be matched （1：1）by sex，race and age which will be selected from the patients receiving cholecystectomy due to gallstones from the same hospital with the cases.
89655586|NCT03031041|Experimental|Short-axis hydrodissection|Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve
89655587|NCT03031041|Active Comparator|Long-axis hydrodissection|Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve
89655588|NCT01672866|Experimental|SIM 75 mg|During the Randomized Double-Blind Phase, participants will receive SIM 75 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
89655589|NCT01672866|Experimental|SIM 125 mg|During the Randomized Double-Blind Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
89655590|NCT01672866|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
89655591|NCT03581201||Oral contraception|Healthy females at childbearing age with oral contraception.
89655592|NCT03581201||No contraception|Healthy females without any contraception at all.
89655593|NCT03580811|Active Comparator|Dental Implant & ADMG|Dental implant placed with simultaneous grafting using one layer of ADMG
89655594|NCT03580811|Experimental|Dental implant & ADMG & BDX|Dental implant placed plus simultaneous grafting using ADMG with BDX
89655595|NCT03580733|Placebo Comparator|placebo|placebo
89655596|NCT03580733|Experimental|antifungal therapy|caspofungin
89655597|NCT03030963|Experimental|Equal-ratio ventilation(ERV) group|ventilator inspiration to expiration ratio will be set 1:1.
89655598|NCT03030963|Active Comparator|Control group|ventilator inspiration to expiration ratio will be set 1:2.
89655599|NCT04984746|Experimental|No Intervention: (control group)|No Intervention: (control group) The control group was assigned to lettuce without any biofortification but with the same characteristic of bioforticated lettuce(soil, water, harvesting time).
89655600|NCT04984746|Experimental|Experimental: intervention group|Experimental: intervention group To the intervention group was assigned the biofortificated Molibdenum lettuce and Iodine lettuce.
89655601|NCT04984824|No Intervention|No nap group|No nap opportunity will be given in this condition.
89655602|NCT04984824|Experimental|10 minute nap|Participants will be given a 10 minute nap.
89046600|NCT05108129|Experimental|Group OSTAP|In the second group, the patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol.
89046601|NCT01854294|Experimental|GM604 treated|8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
89046602|NCT01854294|Placebo Comparator|Placebo comparator|4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
89046603|NCT02277197|Experimental|Ficlatuzumab and Cetuximab|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every 2 weeks. Ficlatuzumab will be administered 30-60 minutes after the completion of the cetuximab infusion.~Cetuximab will be administered as an IV infusion once every 2 weeks. The first dose will be administered over 120 minutes (± 15 minutes). Subsequent doses may be infused over 60 minutes (± 15 minutes). The starting dose of cetuximab (dose tier 1) will be 500 mg/m2. Cetuximab will be administered prior to ficlatuzumab."
89046604|NCT00555087|Experimental|A= Nebido|It is and intervention study with 1 arm
89046605|NCT04673253|Active Comparator|Passive leg raise|group for passive leg raise
89046606|NCT04673253|Placebo Comparator|Control|
89046607|NCT05096897||IBD patients|
89046608|NCT05096897||Non-IBD patients (irritable bowel syndrome)|
89046609|NCT04673214|Experimental|Triple therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half tablet (250 mg) orally every 24 for 4 days, Ivermectin tablets of 200mcg which will be calculated according to your weight and dose, will be every 24 hours for 2 days and Rivaroxaban tablets of 10 mg will take 1 every 24 hours for 10 days
89046610|NCT04673214|Active Comparator|Double therapy|Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin 500 mg tablets will take 1 tablet single dose the first day and then half a tablet orally every 24 for 4 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days.
89655603|NCT04984824|Experimental|30 minute nap|Participants will be given a 30 minute nap.
89046611|NCT04672473|Experimental|Treatment|DAC combined with Ag-CTL
89655604|NCT04984824|Experimental|60 minute nap|Participants will be given a 60 minute nap.
89655605|NCT05702489|Experimental|ZX-7101A low dose group|40 mg, tablet, single oral administration when the subject screened successfully
89655606|NCT05702489|Experimental|ZX-7101A high dose group|80 mg, tablet, single oral adminitration when the subject screened successfully
89655607|NCT05702489|Placebo Comparator|Placebo control|Analog tablet with no active ingredient, single oral administration when the subject screened successfully
89655608|NCT04984434|Experimental|Experimental: Single Arm|
89655609|NCT05702411|Experimental|Protocol 1|Closed system aspiration with an expiratory pause of 10 seconds followed by hyper insufflation maneuver with the Air Stacking technique.
89655610|NCT05702411|Experimental|Protocol 2|Closed system aspiration with an expiratory pause of 10 seconds.
89655611|NCT05001438|Active Comparator|Hidro alone|The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
89655612|NCT05001438|Experimental|Hidro + MUA|"The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.~After the Hidrodilatation the patient is sedated and then a Movilization of the glenohumeral joint is performed."
89655613|NCT03430401|Experimental|Perceptual-based memory encoding|It will involve the use of visual imagery and the method of loci. To achieve this, each of the 15 daily tasks will be filmed and a short video created. In addition, each task will be broken down into 5-6 photographed steps based on activity analysis and task breakdown. The program will prompt the user to indicate in which room of the house the task would usually be completed. Once correct location is identified, the program will prompt the user to watch a chosen daily task video and then visualise themselves completing the task in their home environment.
89655614|NCT03430401|Experimental|Semantic-based memory encoding|It will incorporate association-based strategies to assist with recalling the steps of daily tasks. The steps of a given daily task will be provided and the user will be prompted to link the steps using a honeycomb concept, which makes use of the chunking method to encode the sequenced steps. Following this, the program will prompt the user to categorise the steps according to their association with given words cues. The word cues will represent time, places, objects, and people. The program will then take the user response and form a verbal and visual story according to the responses given. The program will help identify any problems in the sequencing and prompt the user to re-categorise if required.
89046612|NCT05040113|Experimental|CBP-307|Take CBP-307orally at 30 min ± 2 min after the start of high-fat breakfast intake
89046613|NCT01845987|Placebo Comparator|Placebo|
89046614|NCT01845987|Experimental|CNTO 1959|
89046615|NCT00556023|Experimental|CP-675,206 and gemcitabine|
89046616|NCT05011214|Active Comparator|group S|patients were anesthetized by face mask with 5 vol% sevoflurane with total 5 L/min-1 fresh gas flow. Anaesthesia was maintained by continuously using 3-4% sevoflurane.
89655615|NCT03430401|Active Comparator|Cognitive stimulation|Participants will complete an online cognitive exercise program, Lumosity (Sarkar, Scanlon, & Drescher, 2007). A study conducted by Hardy, Drescher, Sarkar, Kellett, and Scanlon (2011) indicated that participants who engaged in Lumosity showed greater improvements in memory in comparison to a non-intervention control group.
89046617|NCT05011214|Experimental|group E|patients received 0.5mg/kg IV esketamine at first, after surgical field disinfection, another 0.25mg/kg IV esketamine was administered. Then 1mg/kg propofol was administered every 5 minutes after intubation.
89655616|NCT03580265|Experimental|Six-sessions of laser acupuncture|Laser acupuncture was given three times a week for 2 weeks.
89046618|NCT00556062|Experimental|1: Lot 1|
89655617|NCT03580265|Sham Comparator|Six-sessions of sham laser acupuncture|Sham laser acupuncture was given three times a week for 2 weeks.
89655618|NCT03068286|Experimental|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
89655619|NCT03068286|Experimental|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
89655620|NCT03068286|Experimental|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
89655621|NCT03208023|Active Comparator|Standard intraoperative care- no interventions|Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
89655622|NCT03208023|Experimental|RESIPI|Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).
89655623|NCT05702099||Detorsion|The group in which only adnexal detorsion was performed during the operation (Because there is no ovarian mass)
89655624|NCT05702099||Detorsion+cystectomy|Women with an ovarian mass who underwent emergency surgery for torsion, who underwent both detorsion and cystectomy in the same session.
89655625|NCT04930380||Cases|"male and female aged 25 years or more~diagnosis of defined MS~written informed consent must be obtained before the enrolment."
89655626|NCT04930380||Controls|"male and female aged 25 years or more~written informed consent must be obtained before the enrolment no history of MS"
89655627|NCT03094143|Experimental|Group A: Early intervention|Patients will be referred immediately for aortic valve intervention.
89655628|NCT03094143|No Intervention|Group B: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the participant's clinical team (cardiologist and cardiac surgeon).
89655629|NCT03094143|No Intervention|Group C: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). Group C will appear identical to Group B
89655630|NCT03094143|No Intervention|Group D: No further study follow up|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). No further study follow up will take place but personal data will be retained for future data linkage.
89655631|NCT03030885|Experimental|131I-MIP-1095|"FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
89655632|NCT02982135|Other|group 1 direct bypass|direct bypass : patients recieve direct bypass treatment
89655633|NCT02982135|Other|group 2 indirect bypass|indirect bypass: patients recieve indirect bypass treatment
89655634|NCT03901781|Experimental|Cohort One|Three (3) subjects, ST266 200 µL administered by trans-cribriform intranasal device once a day for 14 days using alternating sides (nostrils) with a follow-up visit at seven (7) days following End of Treatment (EOT), a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
89655635|NCT03901781|Experimental|Cohort Two|Three (3) subjects, ST266 400 µL administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 14 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
89046619|NCT00556062|Experimental|2: Lot 2|
89046620|NCT00556062|Experimental|3: Lot 3|
89046621|NCT00556062|Active Comparator|4: control vaccine|
89046622|NCT04676841||Hemiarthroplasty|Hip fracture patients operated with hemiarthroplasty
89046623|NCT04949438|Experimental|Cohort 1: Participants with severe renal impairment|Participants with severe renal impairment will receive a single oral dose of AZD4831 on Day 1.
89046624|NCT04949438|Experimental|Cohort 2 :Healthy participants|Healthy participants will receive a single oral dose of AZD4831 on Day 1.
89046625|NCT04676763|Experimental|Substance P challenge in Part 1|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 1 will include a single challenge visit.
89046626|NCT04676763|Experimental|Substance P challenge in Part 2|Eligible participants will receive control challenge with saline and histamine, followed by challenge with ascending concentrations of Substance P. Part 2 will include two challenge visits.
89046627|NCT04944563|Experimental|Segmentectomy|Patients receive segmentectomy
89046628|NCT04944563|Active Comparator|Lobectomy|Patients receive lobectomy
89655636|NCT03901781|Experimental|Cohort Three|Three (3) subjects, 400 µL ST266 administered by trans-cribriform intranasal device bilaterally (200 µL/nostril) once a day for 28 days with a follow-up visit at seven (7) days following EOT, a follow-up call at one (1) month, and follow-up visits at three (3) months, six (6) months and 12 months following EOT.
89655637|NCT05701943|Experimental|Sprint Interval Training|The SIT consisted of a combination of aerobic, resistance, balance, and flexibility exercises. Exercise started with 5 min of warm-up followed by bouts of 5-10 min of exercise consisting of 5-20 s all-out sprints followed by 15-45 s of low cadence recovery (1:3-1:2 work-rest ratio). The duration of the sprints and active recovery were modified throughout the program. To ensure that participants exercised at the appropriate intensity, the OMNI scale 8-10 (Stanish & Aucoin, 2007) was applied during the home intervention, and an HR chest band (H10 Polar, Electro, Kempele, Finland) was used during the gym intervention.
89655638|NCT05701943|Active Comparator|Continuous Aerobic Exercise Training|CAET was based on a combination of aerobic, resistance, balance, and flexibility exercises. The exercise on the cycle ergometer started with 5-min of warm-up followed by 3 bouts of continuous cycling at a steady-state intensity. The duration of the bouts (5-10 min) and the intensity (55-85% HRR) were progressively increased throughout each phase. To ensure that the participants exercised at the appropriate intensity, the OMNI scale 4-6 (Stanish & Aucoin, 2007) was used during the home-based intervention, and an HR chest band (H10 Polar, Electro, Kempele, Finland) was worn during the gym-based intervention.
89655639|NCT03030729||Intermediate AMD|
89655640|NCT03030729||Advanced AMD|
89655641|NCT03030729||DR without macular edema|
89655642|NCT03030729||DR with macular edema|
89655643|NCT04450524|Experimental|Hypnosis|Hypnosis formed from hypnotic induction (an adapted version from Harvard Group Scale of Hypnotic Susceptibility) together with hypnotic suggestions about a future where they will control their eating behaviors by choosing the low-calorie food instead of dense calorie one.
89655644|NCT04450524|Experimental|Food Inhibition Training|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press or not a button when the pictures are framed in a bold frame (dense calorie food).
89655645|NCT04450524|Placebo Comparator|Control|Participants will perform an online computer go-no-go task. They will be shown pictures of dense and low-calorie food together with neutral pictures, followed by the instruction to press the button to indicate the position of the picture - left or right.
89655646|NCT00950235|Other|Usual Care|This arm will receive one additional nutrition counseling session that typically received in the health system. This arm will be compared to our intervention group
89655647|NCT00950235|Experimental|Weight Management Counseling|In-person and group session counseling
89655648|NCT03583931|Active Comparator|Operative VATS decortication|Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
89655649|NCT03583931|Active Comparator|Non-operative Fibrinolytic Therapy|Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.
88993841|NCT03585452|Experimental|Group D|Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
88993842|NCT00525226||1|Women who have experienced symptoms of depression or anxiety during pregnancy.
88993843|NCT02946502|Experimental|Handheld dynamometry (handgrip strength)|All included patients will have a blinded evaluation of handgrip strength before weaning process.
88993844|NCT02947828||T2D patients|600 type 2 diabetes (T2D) patients recruited from the DD2 cohort
88993845|NCT02947828||Gender- and age-matched healthy controls|100 healthy subjects
88993846|NCT02947867|Experimental|"aganirsen low-dose:"|43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily
88993847|NCT02947867|Experimental|"aganirsen high-dose"|86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)
88993848|NCT02947867|Placebo Comparator|aganirsen placebo (vehicle)|one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily
88993849|NCT02947672|Active Comparator|Intravenous dexamethasone|50 patients will receive intravenous dexamethasone
88993850|NCT02947672|Active Comparator|Intra peritoneal dexamethasone|50 patients will receive intraperitoneal dexamethasone
88993851|NCT02947555||DM+/AT+|Patients with type 2 diabetes mellitus and atherosclerotic event in history
88993852|NCT02947555||DM+/AT-|Patients with type 2 diabetes mellitus without atherosclerotic event in history
88993853|NCT02947555||DM-/AT+|Non-diabetic patients with atherosclerotic event in history
88993854|NCT02947555||DM-/AT-|Non-diabetic patients without atherosclerotic event in history
88993855|NCT02947360|Experimental|FOVUS|All eligible and consenting patients will receive a focused vascular ultrasound examination of the carotid arteries
88993856|NCT03539627||patients with hypertension, CAD and diabetes|Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
88993857|NCT02947399|Other|I-124 in thyroid hormone withdrawal|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
88993858|NCT02946268|Experimental|Volume of bolus|Ropivacaine 0.2% volume increased or decreased by 1ml based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient, the current patient will receive an increase in volume of bolus by 1ml. If pain is less than 5/10 in the previous patient the current patient will receive a decrease in volume by 1ml.
88993859|NCT02946268|Experimental|Rate of delivery of bolus|Ropivacaine 0.2% rate increased or decreased by 50ml/hr based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient at 30 minutes, the current patient will receive an increase in rate of bolus by 50ml/hr. If the pain is less than 5/10 the rate will be decreased by 50ml/hr.
89046629|NCT04672707|Experimental|Group A|Bromhexine Hydrochloride Tablet, 32 mg, 8 mg 4 tablets, three times a day, for 2 days
89046630|NCT04672707|Experimental|Group B|Bromhexine Hydrochloride Tablet, 48 mg, 8 mg 6 tablets, three times a day, continuous service within 2 days
89655650|NCT00951093||Patients assessed for GERD|Patients who had an open gastric bypass were assessed for GERD before and after surgery following the Montreal Consensus through a validated questionnaire in Portuguese language
89655651|NCT00951561|Experimental|Vipon|
89655652|NCT00951561|Active Comparator|Ibuprofen|
89655653|NCT03581279|Active Comparator|EM present|All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
89655654|NCT03581279|Active Comparator|No EM present|All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.
89655655|NCT03030651|Experimental|Breastfeeding Education and Support|Pregnant women in the intervention arm will receive breastfeeding education and support intervention for nine months starting in their third trimester
89655656|NCT03030651|No Intervention|Usual or routine care|Pregnant women in the intervention arm will continue to receive the usual/routine care.
89655657|NCT05585333|Experimental|Photobiomodulation Group|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
89655658|NCT05585333|No Intervention|Control Group|
89655659|NCT03031119|Placebo Comparator|Placebo|Tablets administered once or twice daily, with food, in Part A for 14 days.
89655660|NCT03031119|Experimental|PF-06835919|Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
89655661|NCT03031119|Experimental|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
89655662|NCT03030573|Other|Device: Round ligament and the bile duct|The investigators describe the safety and efficacy of the reconstruction of the bile duct with the Round ligament.
89655663|NCT03589625|Experimental|Solar Suitcase Installation First Group|Facilities will receive the installation of the Solar Suitcase shortly after baseline data collection.
89213355|NCT01016470|Experimental|A|VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor
89213356|NCT01004601|Active Comparator|low dose docetaxel|Low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)
89655664|NCT03589625|Experimental|Solar Suitcase Installation Second Group|Facilities will act as a comparator for experimental group 1 and then will receive the installation of the Solar Suitcase shortly after midline data collection.
89655665|NCT03588845|Other|Protocol Treatment|"If a score on the GSS is > 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.~Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment."
89655666|NCT03588845|Other|Standard of Care|Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.
89655667|NCT03581903|Experimental|H7N3 pLAIV + H7N9 pIIV|Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
89046631|NCT04672707|Experimental|Group C|Bromhexine Hydrochloride Tablet, 64 mg ,8 mg spec 8 tablets ,3 times daily ,2 days in succession)
89046632|NCT04672707|Experimental|Group D|Bromhexine Hydrochloride Tablets, 80 mg ,8 mg Standard preparation 10 tablets ,3 times a day ,2 day
89046633|NCT04932083|Placebo Comparator|Bupivacaine|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.5 ml sterile water.
89046634|NCT04932083|Experimental|Fentanyl|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.5 ml fentanyl (25µg).
89046635|NCT04932083|Experimental|Nalbuphine|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water.
89046636|NCT04932083|Experimental|Midazolam|patients will receive 2.5 ml of 0.5% hyperbaric bupivacaine (12.5 mg) plus 2mg of midazolam in 0.5 ml sterile water.
89046637|NCT00555126|Active Comparator|Warming with Forced Air|Forced Air Warming
89046638|NCT00555126|Experimental|Endovascular Warming|Warming with Endovascular Catheter
89046639|NCT04672785||Patients who underwent a posterior fossa craniectomy for a cerebellar hematoma|
89046640|NCT01825980|Experimental|BZF961|
89046641|NCT01825980|Placebo Comparator|Placebo|
89046642|NCT04672200|Experimental|Intervention arm|This group will receive the weekly group exercise which will be delivered online initially, and in the community clubs once they are allowed to reconvene according to government guidance. The duration of the intervention is 12 weeks.
89655668|NCT02783547|Experimental|SyB C-1101 and Azacytidine|
89655669|NCT04405427|Experimental|head acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the head
89655670|NCT04405427|Active Comparator|body acupoints acupuncture|Acupuncture treatment for 12 acupoints on both sides of the body
89655671|NCT02555007|Experimental|Oral Vinorelbine|
89655672|NCT04455438|Experimental|SBRT Level 1|The starting dose level will be SBRT 30 Gy in 5 fractions (level 1 or L1).
89655673|NCT04455438|Experimental|SBRT Level 2|If the starting dose is tolerated in the first 5 patients, the next dose will be SBRT 40 Gy in 5 fractions (level 2 or L2)
89655674|NCT04455438|Experimental|SBRT Level 3|If the second dose is tolerated in the next 5 patients, the next dose will be SBRT 50 Gy in 5 fractions (level 3 or L3)
89213357|NCT01004601|Active Comparator|Pemetrexed|Pemetrexed (500 mg/m2 every 3 weeks)
89213358|NCT00998829||Study population|The group comprises the entire study population
89655675|NCT03898037|Experimental|lifestyle intervention group|"Subjects will receive weight loss intervention under the guidance of a dietitian after assigned to lifestyle intervention group, including: restricted energy balanced diet, aerobic exercise, etc. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test oral glucose tolerance test (OGTT)/insulin resistance test(IRT)/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The pregnancy and perinatal outcomes after transfer were followed up."
89655676|NCT03898037|Experimental|metformin intervention group|"Subjects will be given metformin intervention with a starting dose of 0.5g bid after assigned to metformin intervention group, and the dose will be adjusted by doctors according to the insulin level and adverse events. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and the 4th week, the 8th week, the 12th week after grouping.~The aim is to adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will start to receive ovarian stimulation treatment in advance, Otherwise treatment starts after 3 months. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
89655677|NCT03898037|Experimental|lifestyle combined with metformin intervention group|"Subjects will receive weight loss intervention and metformin intervention after assigned to lifestyle combined with metformin intervention group. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight and adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
89655678|NCT03898037|No Intervention|routine clinical education group|Subjects will only accept clinical routine education after assigned to routine clinical education group. Subjects will measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and will start induced ovulation therapy after completing routine clinical examination. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.
89655679|NCT01770015|Experimental|ventilated patient|"all patients underwent the same diagnostic test . cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization.~HLA DR antigen, cytokines (IL 6 and 10), B-glucan. fungi and bacteria endotracheal aspiration"
89655680|NCT05701631||non-HIV patients hospitalized for suspected PCP|non-HIV patients hospitalized for suspected PCP
89655681|NCT02084745|Active Comparator|Simultaneous implantation|Simultaneous implantation of a glaucoma drainage device at the time of Boston keratoprosthesis type 1 surgery
89655682|NCT02084745|Active Comparator|Implantation at post-Kpro at 6 months|Implantation of a glaucoma drainage device 6 months after Boston keratoprosthesis type 1 surgery
89655683|NCT03583775||Patients with congenital heart disease|Patients with congenital heart disease who are greater than 40 kg and are referred for a clinically indicated 2D CMR exam with a gadolinium-based contrast agent.
89655684|NCT03169686|Experimental|Intervention Group|Participants in the intervention group will receive the 'WeChat WeQuit' program from the WeChat subscription account. The period for intervention was 14 weeks, including 2-week quiting preparation intervention and 12-week postquit intervention. The number of messages/pictures/audios received by participants will gradually decrease (will be intensively sent to them during 2-week prequit and 4-week postquit, and less intensively during 5-week to 12-week postquit), and follow-up questionnaires were sent only once a month in 14-28 weeks (week 16, 20, and 26 after the quit date). A WeChat group was created for answering questions from participants, and sharing the latest resources related to quitting smoking, and promoting communication between participants.
89655685|NCT03169686|No Intervention|Control Group|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 26 points.
89655686|NCT03068208|Experimental|MB-PDT|
89213359|NCT04205357|Other|Sulfasalazine in addition to stereotactic radiosurgery|"3 + 3 dose escalation The first cohort of 3-6 patients will receive 1.5 g Sulfasalazine daily for 3 days before single fraction stereotactic radiosurgery utilizing 12 Gy prescription dose to the tumor margin.~The second, third and fourth cohort will receive 3 days pretreatment with 3 g, 4.5 g and 6 g Sulfasalazine, respectively, before 12 Gy single fraction stereotactic radiosurgery."
89213360|NCT01004757|Active Comparator|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled, aerobic exercise
89213361|NCT01004757|Active Comparator|Low Fat diet|cross over design of three weeks Low Fat diet followed by two weeks LOGI diet always combined with heart rate controlled aerobic exercise
89213362|NCT02580773|Other|Prophylactic anticoagulation|
89213363|NCT02580773|Experimental|Curative anticoagulation|
89213364|NCT01008735||women with hodgkin lymphoma treated with chemotherapy|
89655687|NCT03068208|No Intervention|Control|
89655688|NCT03020225|Active Comparator|White cheese|Reference group- animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
89655689|NCT03020225|Experimental|Green peas|Plant food source: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
89655690|NCT03020225|Experimental|Mankai|Plant food source: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
89655691|NCT03067974|Experimental|Intranasal ketamine arm|10mg/kg intranasal ketamine administered one time
89655692|NCT03581513|Experimental|IMR<40 and defer PCI|Patients whose IMR<40 undergo stent implantation after an interval of 7±2 days.
89655693|NCT03581513|Active Comparator|IMR<40 and immediately PCI|Patients whose IMR<40 undergo immediately stent implantation.
89655694|NCT03581513|Experimental|IMR≥40 and defer PCI|Patients whose IMR≥40 undergo stent implantation after an interval of 7±2 days.
89655695|NCT03581513|Active Comparator|IMR≥40 and immediately PCI|Patients whose IMR≥40 undergo immediately stent implantation.
89655696|NCT03154151|Experimental|Online Cognitive-Behavioral Therapy|Through guided writing, Internet-based cognitive therapy aims to help WTC responders and survivors process any traumatic experiences they lived through during their WTC recovery work and exposure.
89655697|NCT03154151|Active Comparator|Online Supportive Therapy|Through guided writing, Internet-based supportive therapy aims to help WTC responders and survivors work through any life problems they might currently be experiencing.
89655698|NCT03582137|Experimental|CBD Cannabis extract oral solution|Cannabidiol (CBD) Cannabis extract oral solution
89655699|NCT03582137|Placebo Comparator|placebo|Placebo oral solution
89655700|NCT05635890|Experimental|Group I|received conventional vestibular rehabilitation along with the Cawthorne Cooksey exercise protocol
89655701|NCT05635890|Active Comparator|Group II|received conventional vestibular rehabilitation only
89655702|NCT05701553||Anti-PD-1/PD-L1 antibodies and S-adenosyl-methionine combination|"Drug: Anti-PD-1/PD-L1 Intravenous injection for at least 6 months~Drug: S-adenosyl-methionine Taken orally for at least 6 months"
89655703|NCT05635422|Experimental|isokinetism test in high level triathletes practicing an endurance sport|
89655704|NCT03159689|Experimental|Mixed Tree Nuts|a hypo caloric weight loss dietary plan with mixed tree nuts
89655705|NCT03159689|Active Comparator|Pretzels|a hypo caloric weight loss dietary plan with pretzels
89655706|NCT03035721|Experimental|Low protein formula group|Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
89655707|NCT03035721|Active Comparator|Standard protein formula group|Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
89655708|NCT03035721|No Intervention|Breastfeeding group|Breastfed full term healthy infants
89655709|NCT03589781|Experimental|Mikei Red Reishi Essence EX|There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).
89655710|NCT03589781|Placebo Comparator|Placebo|Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.
89655711|NCT03035799|Experimental|Paleolithic Diet|Paleolithic Diet
89655712|NCT03035799|Active Comparator|General Healthful Diet|General Healthful Diet
89655713|NCT03159533|Active Comparator|CHW Intervention|CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, & Smoking Session 5: Health Communication, Healthcare access & Review
89655714|NCT03159533|Placebo Comparator|Control Group|Wait-list
89655715|NCT04405193|Experimental|Treatment|2 capsules, each containing 600 mg N-acetylcysteine administered once daily every morning.
89655716|NCT04405193|Placebo Comparator|Placebo|2 capsules of matching placebo administered once daily every morning
89655717|NCT03589391|Experimental|Procedures with the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration. The device is used.
89655718|NCT03589391|No Intervention|Procedures without the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration
89655719|NCT05227833|Experimental|Vonoprazan|Vonoprazan (vonaspire 20 mg), tablets, one tablet per day before breakfast for 14 days starting from the day of band ligation.
89655720|NCT05227833|Active Comparator|Pantoprazole|Pantoprazole (Controloc 40 mg OR Antopral 40 mg OR Perloc 40 mg), tablets, one tablet per day before breakfast for 14 days, starting from the day of band ligation.
88993860|NCT02946268|Experimental|Interval between bolus|Ropivacaine 0.2% interval increased or decreased by 1 hour based on previous patient experience. If the previous patient received pain score of 2/10 at 2 hours then the current patient will have an interval of three hours. If the pain is greater than 2/10, the interval will be shortened by 1 hour.
89655721|NCT05227833|Placebo Comparator|Placebo|No acid suppressive medications will be described.
89655722|NCT03069534|Experimental|rhIL-2 Group|The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy. rhIL-2 (500，000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
89655723|NCT03069534|No Intervention|Control Group|The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
89655724|NCT03589313|Experimental|GLPG3067 single dose.|Single Dose of GLPG3067 film coated tablets.
89655725|NCT03068988|Experimental|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
89655726|NCT03068988|Placebo Comparator|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
89655727|NCT05083299||Anpl-one SR Tablet|Patients who prescribed Anpl-one SR Tablet
89655728|NCT03035175|Experimental|Video Laryngoscopy Group|Subjects enrolled in this arm received real-time guidance from a supervisor utilizing the screen of the video laryngoscope while the subjects performed direct neonatal intubations in the NICU.
89655729|NCT03035175|Active Comparator|Traditional Laryngoscopy Group|Subjects enrolled in this arm, received traditional guidance while they performed direct neonatal intubations in the NICU.
89655730|NCT03035253|Experimental|OMP-305B83 combined with FOLFIRI or FOLFOX|
89655731|NCT05701397|Experimental|Study group|Patients undergoing surgery for lumbar spinal stenosis. Patients will have a biopsy taken from the ligamentum flavum and test for the presence of amyloid. Patients with amyloid in the ligamentum flavum will be referred for a DPD scintigraphy.
89655732|NCT04405271|Experimental|FTC/TAF|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks.
89655733|NCT04405271|Placebo Comparator|Placebo|Identical tablets to the active experimental tablets with the same characteristics and packaging. A dose of 1 tablet per day will be administered for a total of 12 weeks
89655734|NCT03034941|Active Comparator|metformin group|Drug: metformin
89655735|NCT03034941|Active Comparator|COMBI group|Drug: liraglutide + metformin
89655736|NCT03034941|No Intervention|CONTROL group|control group of obese PCOS patients without therapy
89655737|NCT04775316||Patients with fragile skin|Patient aged 65 years and older presenting with fragile skin and require wound care of an acute wound (laceration or surgical wound). Siliconized sterile wound dressing will be applied for a treatment period of 7 days.
89655738|NCT03035019|Experimental|Lantern for primary care patients|All patients between the ages of 20-65 at specific primary care practices and score 5 or greater on the GAD7 questionnaire are offered the Lantern app to help with stress/anxiety.
89655739|NCT03020771|Active Comparator|5 mcg IM|
89655740|NCT03020771|Active Comparator|5 mcg SC|
89655741|NCT03020771|Placebo Comparator|5 mcg IM control|0.9% NaCl Solution
89046643|NCT04676685|Experimental|Part A, Cohort 1: E2730 20 Milligram (mg) or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 20 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
89046644|NCT04676685|Experimental|Part A, Cohort 2: E2730 40 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 40 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
89046645|NCT04676685|Experimental|Part A, Cohort 3: E2730 60 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 60 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
89046646|NCT04676685|Experimental|Part A, Cohort 4: E2730 80 mg or Placebo|Healthy Japanese and non-Japanese participants will receive E2730 80 mg or E2730-matched placebo, capsules, orally, once daily for 18 days under fasted conditions.
89046647|NCT04676685|Experimental|Part B, E2730 80 mg: Fasted + Fed|Participants will receive a single treatment of E2730 (80 mg capsule) in fasted condition on Day 1 treatment period 1 followed by E2730 80 mg capsule in fed condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
89046648|NCT04676685|Experimental|Part B, E2730 80 mg: Fed + Fasted|Participants will receive a single treatment of E2730 80 mg capsule in fed condition on Day 1 of treatment period 1 followed by E2730 80 mg capsule in fasted condition on Day 1 of treatment period 2. A washout period of at least 21 days will be maintained between the 2 treatments.
89046649|NCT04672317|Experimental|Neoadjuvant arm|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
89046650|NCT04791878|Experimental|Mesenchymal stem cells|allogeneic bone marrow derived mesenchymal stem cells
89655742|NCT03020771|Placebo Comparator|5 mcg SC control|0.9% NaCl Solution
89655743|NCT03020771|Active Comparator|10 mcg IM|
89655744|NCT03020771|Active Comparator|10 mcg SC|
89655745|NCT03030339||Group 1: High VA intake, recent VAS|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake
89655746|NCT03030339||Group 2: High VA intake|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
89655747|NCT03030339||Group 3: Low/adequate VA intake|Children who are not exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
89655748|NCT03020459|Experimental|peeling-reposition|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX), the intervention of peeling-reposition was used to peel and unfold the ILM. And the postoperative posture would be prone position in two weeks for all patients after the operation."
89655749|NCT03020459|Active Comparator|peeling|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system, the intervention of peeling was used to grasped ILM with end-gripping forceps. And the postoperative posture would be prone position in two weeks for all patients after the operation."
89655750|NCT03030027|Experimental|Connecting Through Caregiving|This arm focuses on perspective-taking reappraisal procedures.
89655751|NCT03030027|Other|Basic Skills Building|This arm focuses on skill building.
89655752|NCT05730426|Active Comparator|Group A|In addition to Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors), patients received deep dry needling on active trigger points in selected muscles (upper trapezius, levator scapulae, and sternocleidomastoid ), 3 sessions/week, for 4 weeks period.
89655753|NCT05730426|Active Comparator|Group B|In addition to Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors), patients received muscle energy technique (post isometric relaxation) in selected muscles (upper trapezius, levator scapulae, and sternocleidomastoid ), 3 sessions/week, for 4 weeks period.
89655754|NCT05730426|Placebo Comparator|Group C|Patients receive Transcutaneous Electrical Nerve Stimulation (TENS) (typical,100 Hz, 20 mins), Infrared (7 mins), and Exercises (Cervical Stability Exercises through activation of deep neck flexors) , 3 sessions/week, for 4 weeks period.
89655755|NCT04765397|Active Comparator|Group M|Patients are in this group with monopolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
89655756|NCT04765397|Active Comparator|Group B|Patients are in this group with bipolar technique according to the resectoscope technique used by the surgeon.Demographic data of the patients, mean arterial pressure (MAP), pulse minute number (NDS), peripheral oxygen saturation (SpO2), irrigation and intravenous fluid amounts, operation times, serum electrolytes (Na +, K +) and hemoglobin levels were analyzed and recorded.
89655757|NCT03030105|Placebo Comparator|A) P:P:P|Scopolamine placebo : BPN14770 placebo : Donepezil placebo
89655758|NCT03030105|Placebo Comparator|B) S:P:P|Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo
89655759|NCT03030105|Experimental|C) S:B:P|Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo
89655760|NCT03030105|Experimental|D) S:B:P|Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo
89655761|NCT03030105|Active Comparator|E) S:P:D|Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg
89655762|NCT03030105|Experimental|F) S:B:D|Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg
89655763|NCT03159221|Experimental|BFST for Teens with Type 2 Diabetes|Psychological intervention: Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
89655764|NCT03159221|No Intervention|Control group (Standard Care)|The participants assigned to the control group will receive their standard medical care for diabetes.
89655765|NCT05051865|Experimental|Camrelizumab Combined With SHR1020|Camrelizumab combined with SHR1020 for advanced melanoma.
89655766|NCT03589157|Experimental|Drug-coated balloon group|
89655767|NCT03589157|Active Comparator|second-generation drug-eluting stent group|
89655768|NCT03068052|Active Comparator|No incentive|Colon cancer risk assessment and direct access colonoscopy scheduling for those that are eligible.
89655769|NCT03068052|Experimental|Incentive|Loss-framed incentive to participate in risk assessment and additional unconditional pro-social incentive to complete colorectal cancer screening.
89655770|NCT02245659|Experimental|CPAP|
89655771|NCT02245659|Other|Nasal dilator strip|Control
89655772|NCT03158909|Experimental|Interventional|Patients in this group will receive eyemask and earplugs, for use during the night, and orientations about space and time, every night.
89655773|NCT03158909|Active Comparator|Orientation about space and time|This group will receive orientations about space and time olny, every night.
89655774|NCT03067896|Active Comparator|Group C|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
89655775|NCT03067896|Active Comparator|Group D|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .
89655776|NCT03067896|Active Comparator|Group M|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .
89655777|NCT03034707|Experimental|Biotin arm|biotin 10 mg/day for 7 days
89655778|NCT03589001||OSD|51 adolescents with Osgood Schlatter who participated in an activity modification intervention.
89655779|NCT03067740|Active Comparator|Bupivacaine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
89046651|NCT04672278|Experimental|Group A|
89655780|NCT03067740|Experimental|Bupivacaine-Dexmedetomidine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
89655781|NCT05634330|Experimental|treatment group|treatment group: core stabilization exercises used to improve balance
89655782|NCT05634330|No Intervention|control group|this group members have continued their normal lives
89655783|NCT03158519|Experimental|iMETX intervention|Individualized exercise recommendation
89655784|NCT05730114||OHCA/ECMO|Patient resuscitated from Out of Hospital Cardiac Arrest from acute coronary syndrome and on VA-ECMO.
89655785|NCT05730114||OHCA/nonECMO|Patient resuscitated from Out of Hospital Cardiac Arrest from acute coronary syndrome and without VA-ECMO.
89655786|NCT05730114||nonOHCA/nonECMO|Patient with acute coronary syndrome without Out of Hospital Cardiac Arrest from acute coronary syndrome and without VA-ECMO.
89655787|NCT03158675|Experimental|Fractional co2 laser&topical steroid|"participant will be compared with one side of the body to the ather side.~Intervention:~-Procedure: Fractional carbon dioxide laser.~-Drug: Topical corticosteroid.~-Radiation: Ultraviolet B narrow band."
89655788|NCT03034551|Experimental|Intervention Arm|Subjects in the treatment arm will be offered a $150 incentive to use the Wellth app each day to log one daily self-weighing and one medication check-in. If a sudden jump in weight is detected among any subjects receiving the Financial Incentive, Mobile Phone App, and Cellular Scale, a UMCPP physician or nurse will then call the patient to assess the patient's symptoms (i.e. increasing shortness of breath or decreases in exertional tolerance, medication and dietary adherence).
89655789|NCT03034551|No Intervention|Standard of Care (Control) Arm|Patients randomized to the standard of care arm will not receive the Wellth app or scale. They will have the usual discharge instructions as prescribed by their health care team.
89046652|NCT04672278|Experimental|Group B|
89046653|NCT04676568|Active Comparator|extravesical VVF repair|
89046654|NCT04676568|Active Comparator|Transvesical VVF repair|
89655790|NCT03158441||cases|The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
89655791|NCT03158441||control|same patients , dynamic scan
89655792|NCT00941889|Placebo Comparator|Placebo|Patients who are in the control group received a placebo of saline in the upper extremity at initial visit, 2 months and 6 months after enrollment.
89655793|NCT00941889|Active Comparator|Gardasil|The treatment group received a 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity at initial visit, and again at two months and six months after enrollment.
89655794|NCT03158363|Experimental|"LPS, 36 hour immobilization and fast"|"Interventions:~Test subjects undergo 48 hour exercise restriction and overnight fast.~Study day 1:~- LPS (1 ng/kg) will be administered. Test subjects will fast and bedrest for the rest of the study period.~Study day 2:~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies.~Study day 3:~- Blood sample."
89655795|NCT03158363|No Intervention|"Control"|"Test subjects undergo overnight fast. No exercise restrictions.~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies."
89655796|NCT03158207|Experimental|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask.. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
89655797|NCT03158207|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
89655798|NCT03034395|Other|Wide Local Excision 1cm|
89655799|NCT03034395|Other|Wide Local Excision 2cm|
89655800|NCT03069066|Experimental|BVS implantation in patients with ISR|BVS implantation in patients with ISR after scoring balloon pre-dilatation
89655801|NCT04904757|Other|CESM Pre and Post Survey|"Subject will be asked to complete a questionnaire that will ask you about your general attitude toward Contrast-Enhanced Spectral Mammography (CESM). Questions will include:~Thoughts regarding risk of breast cancer~Concerns regarding contrast procedures such as the CESM~Past mammogram/breast imaging experience"
89655802|NCT03157817||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of Chronic Obstructive Pulmonary Disease
89655803|NCT03157817||Healthy Volunteers|Volunteers without any respiratory condition or symptoms
89655804|NCT03067818|Experimental|Unaffected Hemisphere|"Application of Unaffected Transcranial Magnetic Stimulation to unaffected hemisphere site prior to physical practice"
89655805|NCT03067818|Experimental|Affected Hemisphere|"Application of Affected Transcranial Magnetic Stimulation to affected hemisphere site prior to physical practice"
89655806|NCT03067818|Active Comparator|Control Site|"Application of Control Transcranial Magnetic Stimulation to control site prior to practice"
89655807|NCT03034083||Couples Elevate Weekly Series|Participants in a couple relationship receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
89655808|NCT03034083||Foster Parents Elevate Weekend Intensive|Foster parent participants receive 8 hours of classes over a weekend in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
89655809|NCT03069222||Patient|SCI patients enrolled at Kessler Institute Rehabiliation
89655810|NCT03069222||Control|age and gender matched with patient enrolled
89655811|NCT03034239|Experimental|Insect protein group|Exercise + insect protein 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Insect protein supplementation (4g/kg) after each training + before sleep at training days, and once in the morning at non training days.
89655812|NCT03034239|Placebo Comparator|Placebo group|Exercise + isocaloric carbohydrate 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Carbohydrate supplementation (isocaloric to protein group) after each training + before sleep at training days, and once in the morning at non training days.
89655813|NCT03027843|Active Comparator|GH group|patients in group mini-dose GnRH-a long protocol combine with growth hormone
89655814|NCT03027843|No Intervention|control group|patients in group mini-dose GnRH-a long protocol without growth hormone
89655815|NCT03025997|Active Comparator|Active yoghurt|Yoghurt snack containing encapsulated lipid
89655816|NCT03025997|Placebo Comparator|Placebo yoghurt|"Yoghurt snack containing non-encapsulated lipid~+ empty encapsulation matrix"
89655817|NCT03027765||Egyptian children|"Population1:~Egyptian children with constructed space maintainers at Cairo University."
89655818|NCT03027765||Pediatric dentists|"Population2:~Pediatric dentists at Cairo University."
89655819|NCT03157739|Experimental|Evaluation of Optimized Prototype|Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
88993861|NCT00526357|Other|A|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists alone to treat their asthma
89655820|NCT03068832|Experimental|Personalized peptide vaccine and poly-ICLC|"The synthetic long peptide(s) and poly-ICLC will be given on Cycle 1 Day 1 when available.~Additional peptide vaccine doses will be administered again on Days 4, 8, 15, and 22 of the first cycle as a priming strategy. On all subsequent cycles, the peptide vaccine will be given on Day 1.~Peptide vaccine administration will continue until supply is exhausted or development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until supply is exhausted or intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression if remaining vaccine is available."
89655821|NCT03027375|Experimental|Qishen granules|The QSG treatment group will receive Qishen granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks; dosage based on the requirements of Pharmacopoeia of the People's Republic of China).
89655822|NCT03027375|Placebo Comparator|placebo granules|The placebo group will receive placebo granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks).
89655823|NCT03157661||Single group study|"The study population will involve patients presenting for elective surgery, who fulfil inclusion criteria, in all surgical disciplines with elective surgical slates in the main theatre complex, during the period of the study.~Inclusion Criteria:~Patients included in the study will be:~> 18 years of age~Non-cardiac patients~Non-obstetric patients~Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
89655824|NCT04861233||All Participants|Participants diagnosed with constipation who have been prescribed with lubiprostone for the first time in a real-world setting will be observed prospectively and followed up for 12 months after initiation of study medication. Treatment regimen, frequency of laboratory and clinical assessments will be determined by investigator in a routine clinical practice.
89655825|NCT03157427|Experimental|CRYOBEAUTY MAINS|Cryotherapy medical device designed to treat solar lentigo on the randomized hand.
89655826|NCT03157427|No Intervention|Control|The non randomized hand is not teated.
89655827|NCT03067662|Experimental|Supervised exercise intervention|Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (Heart Rate Reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (by increasing 2 min/week).
89655828|NCT03067662|No Intervention|Current standard of care|Women in the control group will receive standard physical exercise recommendations.
89655829|NCT02981901||Patient with ovarian epithelial cancer|Ovarian epithelial cancer diagnosed in 2012
89655830|NCT03157271|No Intervention|PFPS Treatment|This arm (group of patients) will receive typical/pragmatically designed treatment for patellofemoral pain syndrome.
89655831|NCT03157271|Experimental|PFPS Plus Dry Needling Treatment|This group will receive the same typical/pragmatically designed treatment for patellofemoral pain syndrome but with the addition of a dry needling intervention.
89655832|NCT03034161||Stage I Pressure Ulcer|Ten patients with a Stage I decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
89655833|NCT03034161||Stage II Pressure Ulcer|Ten patients with a Stage II decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
89655834|NCT03034161||Stage III Pressure Ulcer|Ten patients with a Stage III decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
89655835|NCT03034161||Stage IV Pressure Ulcer|Ten patients with a Stage IV decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
89655836|NCT03157349|Experimental|Experimental|The experimental group will receive the active product (Biofreeze) over the course of 1 week.
89655837|NCT03157349|Sham Comparator|Placebo|The placebo will use a product created to mimic the topical analgesic Biofreeze over the course of one week. All active ingredients have been removed.
89655838|NCT05729880||Older|16 older (>50y) will be recruited. MRI, MRS and Ultrasound will be measured in each participant in calf and thigh muscle, at the same location within a 1 hour time frame.
89655839|NCT05729880||Young|16 young (<40y) will be recruited. MRI, MRS and Ultrasound will be measured in each participant in calf and thigh muscle, at the same location within a 1 hour time frame.
89655840|NCT03034317|Active Comparator|NeuRx DPS|Subjects who have initiated noninvasive ventilation (NIV) and receive the NeuRx diaphragm pacing system (DPS).
89655841|NCT03034317|No Intervention|No DPS|Subjects who have initiated noninvasive ventilation (NIV) and do not receive the DPS device.
89655842|NCT04836117|Experimental|Informed|"Blood draw for SomaSignal Test and laboratory assessments at baseline, and 6 months (±30 days); SomaSignal Test results to be sent to investigators as available. Review and discussion of results with the participant from baseline and 6 months within 30 days (2-4 weeks to get SomaSignal results) after blood draw. Initiation of changes in medical management as soon as test results are known and discussed with patient.~Patients will have a blood draw performed at baseline and 6 months for lipid panel, hemoglobin A1C, CBC, and BMP."
89655843|NCT04836117|No Intervention|Uninformed|"Blood draw for SomaSignal Test at baseline and 6 months (+30 days). However, results will not be provided to clinician and participant until study conclusion. Patients contacted within 30 days (2-4 weeks) after baseline and 6-month visits to discuss treatment strategy (nothing, add/ remove medication, etc.) made at visit. Patients will have a blood draw performed at baseline and for lipid panel, hemoglobin A1C, CBC, and BMP~SomaSignal Test results to be sent to investigators AFTER study conclusion. Patients will be provided with SomaSignal Test results after the 6 month post-test timepoint."
89655844|NCT01670357|Experimental|DA-6034 Low dose|DA-6034 3%
89213365|NCT05032937|Experimental|ECMR|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.
89213366|NCT01008813|Experimental|adjuvanted A(H1N1)v influenza vaccine|Two injections at day 0 and day 21
89655845|NCT01670357|Experimental|DA-6034 High dose|DA-6034 5%
89655846|NCT01670357|Placebo Comparator|Placebo|DA-6034 Placebo
89655847|NCT03033537||Verapamil|Intracavernosal injection of Verapamil
89655848|NCT03033537||Phentolamine|Intracavernosal injection of Phentolamine to treat erectile dysfunction for a period of 2 wweks
89655849|NCT01670435||Group 1|
89655850|NCT05729802|Experimental|Group A: HoloSIM (intervention)|Training by Mixed Reality Simulation
88993862|NCT00526357|Other|B|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists and inhaled steroids to treat their asthma
88993863|NCT04693312|Experimental|Group I|scalene muscle level injection of depomedrol
88993864|NCT04693312|Experimental|Group II|Rheumboid muscle level injection of depomedrol
88993865|NCT04710381|Experimental|IMUNOR|Study subjects in this arm will receive IMUNOR preparation as prevention against COVID-19 disease.
88993866|NCT00525304|Experimental|1|Participants will receive a self-management program for chronic illness
88993867|NCT00525304|No Intervention|Usaual Care|Usual Care; no additional intervention
88993868|NCT04692571|Experimental|Study B: Limb-Absent Subject|"Ten unilateral transradial limb-absent subjects will each participate in one, half-day experimental session. Subjects will be seated and prepared in test apparatus seat (16 electrodes on the affected side, hand-wrist on the able side secured to load cells). Subjects will complete the 1-DoF and 2-DoF dynamic (force-varying) contractions (40-s duration, 0.75 Hz bandlimited, uniform random target). With 2 DoF contraction trials, hand Opn-Cls will always be one of the dimensions. The subject will then be released from the cuff and their able side not further involved in the experiment. The force feedback triangle cursor on the computer screen will be deleted such that only the target remains. Subjects will then repeat 1-DoF and 2-DoF trials in which the affected side attempts to produce hand-wrist effort that mimic movement of the target (with no feedback provided)."
89046655|NCT04676295|Experimental|PE intervention|A 12-month lifestyle intervention program to improve mothers and their children blood pressure and CVD risk profile.
89046656|NCT04676295|No Intervention|PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
89046657|NCT04676295|No Intervention|Non-PE control|The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.
89046658|NCT01655225|Experimental|Part A: LY3023414 Once Daily|LY3023414 administered orally once daily (QD) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
89655851|NCT05729802|Active Comparator|Group B: Mannequin (control)|Training by Mannequin Based Simulation
89655852|NCT03033615|Active Comparator|Chest CT|Conventional processing vs. PixelShine processing
89655853|NCT03033615|Active Comparator|Abdominal CT|Conventional processing vs. PixelShine processing
89655854|NCT01670513|Experimental|IDP-118 Low Strength|IDP-118 Low Strength
89655855|NCT01670513|Experimental|IDP-118 High Strength|IDP-118 High Strength
89655856|NCT03069144|Experimental|HAT1 topical solution|HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
89655857|NCT03069144|Active Comparator|Calcipotriol ointment (0.005%)|Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
89655858|NCT03017703|Experimental|Type 2 Diabetes|8 weeks of treatment with Aldosterone blocker Eplerenone
89655859|NCT03017703|Experimental|Healthy|8 weeks of treatment with Aldosterone blocker Eplerenone
89655860|NCT03159767|Experimental|Spinal Mobility Measurement: Rater A|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
89655861|NCT03159767|Experimental|Spinal Mobility Measurement: Rater B|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
89655862|NCT01670591|Experimental|PS - Prevention in School|Teachers learn to use the core program components (defining and teaching school rules and the handling of rule breakings, principles of positive behavior support)with help from external consultants during approximately 1.5 years.
89655863|NCT01670591|No Intervention|Business as usual|
89655864|NCT01670669|Active Comparator|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
89655865|NCT01670747||ARDS|Sedated and mechanically ventilated patients admitted to ICU
89655866|NCT04159272|Experimental|Mindfulness Training|The MT programme adheres to a standardized protocol developed from MBSR (Kabat-Zinn, 1990) and MBCT (Segal et al., 2012) manuals and is adjusted to an adolescent population. Adjustments are based on our ample experience with mindfulness and adolescents in different contexts. Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience. This accepting attitude changes the person's relationship with the experience, being a detached and non-reactive orientation. Participants learn to recognize entanglement with one's thoughts and emotions and there is an increased understanding of one's spontaneous reactions. If adolescents adopt these skills, their negative emotions and cognitions will no longer be reinforced, creating the opportunity to deal with problematic thoughts and feelings.
89655867|NCT04159272|No Intervention|Control|Participants follow their regular course curriculum.
89655868|NCT01670903||ARBs|Hypertensive patients treated with ARBs
89655869|NCT01670903||ACE inhibitors|Hypertensive patients treated with ACE inhibitors
89655870|NCT01670903||non ARB/ACE|Hypertensive patients treated with non ARBs or ACE inhibitors meds
89046659|NCT01655225|Experimental|Part A2: LY3023414 Twice Daily|LY3023414 administered orally twice daily (BID) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
89046660|NCT01655225|Experimental|Part B1 : LY3023414 + Midazolam|LY3023414 administered orally BID for two 21 day cycles to participants with advanced/metastatic cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose based on Part A. 0.2 milligrams (mg) midazolam administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
89046661|NCT01655225|Experimental|Part B2: LY3023414 + Fulvestrant|LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.
89213367|NCT01008813|Experimental|non-adjuvanted A(H1N1)v influenza vaccine|Two injection at day 0 and day 21
89655871|NCT00946023|Experimental|Transplant|Non-myeloablative allogeneic bone marrow transplant (BMT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD (graft vs host disease) prophylaxis. Rituximab will be given as post-transplant maintenance.
89655872|NCT01671137|Active Comparator|Lactobacillus Rhamnosus Strain GG|LGG (6 × 109 colony forming units)
89655873|NCT01671137|Placebo Comparator|Placebo|Placebo
89655874|NCT04410666|Experimental|GREEN TEA MOUTH WASH|an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C.
89655875|NCT04410666|Placebo Comparator|Placebo|distilled water, in sterile glass containers.
89655876|NCT03033849|Experimental|Blood glucose measurement|Every study subject shall test three out of the five devices. The testing order of the BGMS will be changed on each subject to minimize any order effects on measurement results.
89213368|NCT01004835||Migraine Disease|Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.
89213369|NCT03923309||Intended rectal preservation|When rectal preservation (non-operative management or local excision) was agreed by their surgeon.
89213370|NCT03923309||Unintended rectal preservation|When rectal preservation (non-operative management or local excision) was disagreed by their surgeon.
89213371|NCT01001481||001|
89046662|NCT01655225|Experimental|Part B3: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation.
89655877|NCT03066414||non-obese patients with genetic hemochromatosis|"PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
89655878|NCT01671527||Cervical Dystonia: DBS Subjects|Subjects who have undergone or plan to undergo DBS surgery for cervical dystonia
89655879|NCT01671527||Cervical Dystonia: Control Subjects|Subjects who DO NOT plan to undergo DBS surgery for cervical dystonia
89655880|NCT01671527||Healthy Controls|Healthy control subjects who do not have dystonia.
89655881|NCT03026361||oral lichen planus (OLP)|"Histopathologically confirmed samples of OLP underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OLP changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
89655882|NCT03026361||oral squamous cell carcinoma (OSCC)|"Histopathologically confirmed samples of OSCC underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OSCC changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
89655883|NCT03026361||healthy mucosa|"Archival samples of healthy oral mucosa underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of healthy mucosa taken during alveolotomy underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
89655884|NCT03017547|Experimental|IC14|IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.
89655885|NCT03017547|Placebo Comparator|Placebo|Placebo IV once daily on Study Day 1-4
89655886|NCT03066180|Experimental|Group 1|Single study treatment (Viveve SUI treatment) will be administered.
89655887|NCT03066180|Experimental|Group 2|Two study treatments (Viveve SUI treatments) will be administered approximately 6 weeks apart.
89655888|NCT01671761||young adults|19-24 years old
89655889|NCT01671761||adolescents|15-18 years old
89655890|NCT03017781||Study Group|Offspring (15-25 years old) of parents with Bipolar Disorder (BD) with at least mild impairment in psychosocial functioning were observed to evaluate the relationship of impairment in psychosocial functioning with the manifestation of mood symptoms over 24 months
89655891|NCT03017781||Control Group|A group of offspring of bipolar parents with no impairment in psychosocial functioning will be used for comparison.
89655892|NCT03067428|Active Comparator|Glucose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.
89655893|NCT03067428|Placebo Comparator|Fructose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.
89655894|NCT03025581|Active Comparator|Intervention group|Nipple stimulation.
89655895|NCT03025581|No Intervention|Control group|No intervention (expectant management only).
89655896|NCT03067038|Active Comparator|Single incision LC|Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
89655897|NCT03067038|Sham Comparator|Three port LC|Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars
89655898|NCT02981745|Experimental|CT-1530|
89655899|NCT01672229|Experimental|Dose-escalation|Bortezomib starting dose is 0.2 mg/m2 subcutaneously which will be given weekly with incremental increase of 0.2 mg/m2 every other week, if no improvement is seen, and no dose limiting toxicities are observed to the maximum dose of 1.6 mg/m2. Bortezomib will be administered in the outpatient clinic.
89655900|NCT03024411|Experimental|Music/video games|iPod (Music/video games)
89655901|NCT03024411|No Intervention|No intervention|No intervention
89655902|NCT01672307|Experimental|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
89655903|NCT01672307|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
89655904|NCT03067194|Active Comparator|Celecoxib 100mg|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
89655905|NCT03067194|Active Comparator|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
89655906|NCT03033381|Active Comparator|operated side testis|Operated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
89655907|NCT03033381|Sham Comparator|Contralateral testis|Nonoperated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
89655908|NCT05132387||Out-of-hospital cardiac arrest|Patients with out-of-hospital cardiac arrest which occured in the predefined area of the city of Wroclaw.
89655909|NCT03068676|Experimental|Space from depression|Space from Depression is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
89046663|NCT01655225|Experimental|Part B4: LY3023414 + pemetrexed/cisplatin|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 administered IV once every 21 days.
89655910|NCT03068676|Experimental|Space from Anxiety|Space from Anxiety is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
89655911|NCT01672385|Experimental|Intervention Group|Telemonitoring plus self-management support
89213372|NCT03999645|Active Comparator|Group E: Early LC (n=60)|Early laparoscopic cholecystectomy (within 72h from symptom onset)
89655912|NCT01672385|No Intervention|Usual Care Group|Usual Care
89655913|NCT03017469|Experimental|ARISE Intervention|Nurses who participate in the 1.5 day ARISE Intervention
89655914|NCT03017469|No Intervention|Control Group|Nurses who do not participate in the ARISE Intervention
89655915|NCT05068973|Experimental|Luciola|Bronchoscopic implantation of the fiducial marker NOVATECH® LUCIOLA™ EB prior to radiotherapy treatment.
89655916|NCT03068598|Experimental|sleep monitoring|The sleep tracker and a smartphone will be given to the patient after discharge. The patient will recieve a brief training on how to use the PulseOn watch or the Suunto Spartan Ultra watch. Patient will be proposed to monitor his sleep during the five nights following the discharge.
89655917|NCT05629494|Active Comparator|Repeat serum PSA test|Repeat PSA test at 6 (± 1) weeks, without any treatment
89655918|NCT05629494|Experimental|Treatment with NSAIDS|Treatment with NSAIDS (Ibuprofen 400 mg, 3 times per day or Naproxen 220 mg, twice per day for 10 days), then repeat PSA test at 6 (± 1) weeks
89655919|NCT01672619||children with craniosynostosis|children with craniosynostosis aged 6 months to 13
89655920|NCT04272281|Experimental|Share making tool decision|Patient recruited from general practitioner in this group will use a share making tool decision to adapt antibiotherapy
89655921|NCT04272281|Active Comparator|Standard recommandation|Patients recruited from general practitioner will receive the standard medical care
89655922|NCT01672697|Experimental|Physical & Behavioral Therapy Group|"Intervention Group: Randomized to Physical Therapy (PT)~2-week visit which includes: Demographic Data, Physical Exam, ehavioral Therapy (BT) handouts Functional questionnaires administered Physiologic measurements obtained~Follow-up Evaluation-6-week visit PT session #1 Functional questionnaires administered~Follow-up Evaluation-8-week visit PT session #2~Follow-up Evaluation-10-week visit PT session #3~Study Completion Visit-12-week visit Functional questionnaires administered PT session #4 Physiologic measurements Physical Exam~Long-term Follow-up-24-weeks Functional questionnaires administered by mail"
89655923|NCT01672697|No Intervention|Control Group|"Control Group:~Baseline Data obtained at 2-week visit Demographic Data General Physical Exam findings Functional questionnaires administered in person (FIQOL, FISI, SF-12, FSFI, UDI-6, IIQ-7) Physiologic measurements obtained (Vaginal EMG, Anal-rectal manometry)~Follow-up Evaluation at 6-week visit Functional questionnaires administered in person at patient's previously scheduled postpartum office visit with primary Ob/Gyn or by mail~Study Completion Visit at 12-week visit Functional questionnaires administered Physiologic measurements obtained Physical Exam findings~Long-term Follow-up at 24-weeks - Functional questionnaires administered by mail"
89655924|NCT00952653|Experimental|DVS SR|
89655925|NCT01672775|Experimental|Cohort 1 AGS-16C3F highest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
89655926|NCT01672775|Experimental|Cohort 0 AGS-16C3F higher dose|Renal Cell Carcinoma subjects with clear and non-clear histology
89655927|NCT01672775|Experimental|Cohort (-1) AGS-16C3F high dose|Renal Cell Carcinoma subjects with clear and non-clear histology
89655928|NCT01672775|Experimental|Cohort (-2) AGS-16C3F middle dose|Renal Cell Carcinoma subjects with clear and non-clear histology
89655929|NCT01672775|Experimental|Cohort (-3) AGS-16C3F low dose|Renal Cell Carcinoma subjects with clear and non-clear histology
89655930|NCT01672775|Experimental|Cohort (-4) AGS-16C3F lowest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
89655931|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Clear Cell Histology|Expansion Cohort
89213373|NCT03999645|Active Comparator|Group L: Late LC (n=60)|Late laparoscopic cholecystectomy (after 72h up to seven days from symptom onset)
89213374|NCT05195801||Group with local anesthesia|The group that did not apply general anesthesia
89655932|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Papillary Histology|Expansion Cohort
89655933|NCT01672931||BMI over 30|Women undergoing IVF with BMI over 30
89655934|NCT01672931||BMI 20-25|Women undergoing IVF treatments with BMI between 20-25
89655935|NCT01673087|Experimental|laboratory HPA probes|"All subjects will be studied with multiple probes of HPA axis function over the course of one to two months:~Metyrapone, oral, 750 mg, administered twice 3.5 hrs apart; Dexamethasone, oral, 1.5 mg administered once; oral, 0.25 mg administered once; Corticorelin ovine triflutate (CRH), intravenous, 100 mcg, administered once over 30 seconds; Cortrosyn (ACTH), intravenous, 250 mcg, administered once by bolus."
89655936|NCT01673243||Cancer|Parents of children with cancer will complete a questionnaire.
89655937|NCT01673243||Sickle cell disease|Parents of children with sickle cell disease will complete a questionnaire.
89655938|NCT01673243||Survivors|Parents of survivors of childhood cancer will complete a questionnaire.
89655939|NCT02299505|Experimental|ceritinib 450 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 450 mg (3×150 mg/capsule) administered in the morning immediately (within 30 minutes)following a low-fat meal.
89655940|NCT02299505|Experimental|ceritinib 600 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 600 mg (4×150 mg/capsule) administered in the morning immediately (within 30 minutes) following a low-fat meal.
89655941|NCT02299505|Active Comparator|ceritinib 750 mg on an empty stomach|Oral ceritinib QD (21 days/ cycle) at a dose of 750 mg (5×150 mg/capsule) administered in the morning on an empty stomach (i.e., fasted from food and drink except water)
89655942|NCT01673321|Experimental|Non-fat Yogurt-Plain flavored|Protein to carbohydrate ratio: 2.30
89655943|NCT01673321|Experimental|Skim milk|Protein to carbohydrate ratio: 0.69
89655944|NCT01673321|Experimental|Non-fat Yogurt with honey-Plain flavored|Protein to carbohydrate ratio: 1.24
89655945|NCT01673321|Experimental|Orange juice|Protein to carbohydrate ratio: 0.07
89655946|NCT01673321|Experimental|Non-fat Yogurt-Strawberry flavored|Protein to carbohydrate ratio: 0.79
89655947|NCT01673399|Active Comparator|Atosiban|Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.
89655948|NCT01673399|Placebo Comparator|placebo|Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours
89655949|NCT01673555|Experimental|GSK1278863 5mg|GSK1278863 5mg
89655950|NCT01673555|Experimental|GSK1278863 100mg|GSK1278863 100mg
89655951|NCT01673555|Placebo Comparator|Placebo|Placebo
89655952|NCT01673633||SSc|Sacroiliitis
89655953|NCT01673633||Rheumatoid arthritis|Sacroiliitis
89655954|NCT01673633||Healthy controls|Sacroiliitis
89655955|NCT01673711||Basic Science (deuterated phenanthrene tetraol)|Patients receive deuterated phenanthrene tetraol PO and collect urine for 6 hours after dosing.
89655956|NCT01673945|Active Comparator|EUS-FNA with the CLA-EUS|patients examined with the CLA-EUS
89655957|NCT01673945|Experimental|EUS-FNA With the FV-EUS|patients examined with the FV-EUS
89655958|NCT01674023||human vitreous, human blood serum, PCR|"human vitreous and blood serum sampling, PCR~1ml of human vitreous and 3ml of human blood serum of patients with various vitreoretinal diseases"
89655959|NCT01674101|Experimental|Physical Therapy|"The intervention group will receive PT 3 times per week for 60 minutes each session. The therapy sessions will include endurance, strengthening, and stretching exercises.~Exercise time and resistance will be progressed per individual's medical status and per participant's tolerance. All participants will be given a tailored home exercise program (HEP).~Participants will participate in PT 10 weeks prior to surgery and 10-12 weeks after surgery. Subjects will be seen by the physical therapist both when inpatient and outpatient. Patients will not be seen for PT if platelet count is less than 20,000mm3 and/or hemoglobin is less than 8g/dL."
89655960|NCT02235701|Experimental|aldoxorubicin|
89655961|NCT01674179||ACR diagnosis of Fibromyalgia|
89655962|NCT01674179||Patients without Fibromyalgia|
89655963|NCT01674257||Carotid Endarterectomy|Patients due to undergo carotid endarterectomy for symptomatic carotid artery stenosis will undergo an 18F-Fluoride PET/CT, an 18F-Flurodeoxyglucose PET/CT and a USPIO (ferumoxytol)-enhanced MRI scan (2 MRI scans).
89655964|NCT01674413|Placebo Comparator|Placebo/Step-Down|1 syringe of placebo SC q 2 weeks.
89655965|NCT01674413|Active Comparator|PRNLOAD Arm|160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38)
89655966|NCT01674413|Active Comparator|Maintenance Arm|Adalimumab 40 mg q 2 weeks.
89655967|NCT03156881|Experimental|Treatment group|"The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease.~This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series."
89655968|NCT03156881|No Intervention|Control Group|This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.
89655969|NCT03156725|Experimental|Ferrous Sulfate|The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.
89655970|NCT03156725|Experimental|Aspiron|The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.
89655971|NCT03156491||Recurrent miscarriage group|Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
89655972|NCT03156491||Control group|Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
89655973|NCT01674491|Experimental|4.5g/day black soy peptide|4.5 g/day, 8weeks
89213375|NCT05195801||Group with Sevoflurane|The Sevoflurane used for maintenance of general anesthesia
89213376|NCT05195801||Group with Propofol|The Propofol (IV) used for maintenance of general anesthesia
89655974|NCT01674491|Placebo Comparator|placebo|similar appearance to the black soy peptide tablet, 8 weeks
89655975|NCT03156413|Experimental|F&P Nasal Mask|Trial nasal pillows CPAP mask
89655976|NCT01674881|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|This group will receive MBCT for 8 consecutive weeks.
89655977|NCT01674881|Other|Waitlist control group|This group is a waitlist control group.
89655978|NCT00953121|Experimental|Cohort A-Grade IV No Failure|Recurrent GBM patients who have not previously failed bevacizumab, irinotecan, or carboplatin
89655979|NCT00953121|Experimental|Cohort B-Grade III No Failure|Recurrent Grade 3 malignant glioma patients who have not previously failed either bevacizumab, irinotecan or carboplatin
89655980|NCT00953121|Experimental|Cohort C-Failed Prior Therapy|Recurrent Grade IV GBM patients who have failed prior bevacizumab therapy, but not prior CPT-11 or carboplatin therapies
89655981|NCT03156647||idiopathic Parkinson disease|
89655982|NCT03156647||iatrogenic parkinsonian syndrome|
89655983|NCT03156647||healthy volunteers|
89213377|NCT01005069|Experimental|Treatment I|
89213378|NCT01005069|Experimental|Treatment II|
89213379|NCT01005069|Experimental|Treatment III|
89213380|NCT01005069|Experimental|Treatment IV|
89655984|NCT01674959|Experimental|concurrent chemoradiation|"• Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative current chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
89655985|NCT03017391|Active Comparator|algorithm 1 first metoclopramide|metoclopramide 10 mg tablets 3x daily orally and in those patients that cannot swallow tablets the medication will be substituted by suppositories 10 mg 3x daily rectally. In case of failure, granisetron patch 3.1mg/24 hours will be added to the treatment and a loading dose of 2 mg granisetron oral if the patient can swallow. In case of toxicity metoclopramide will be stopped. In case of failure of the combination (second step) or toxicity, an oral dose of dexamethasone 8 mg will be added daily.
89213381|NCT01005069|Placebo Comparator|Placebo|
89213382|NCT01009125|Experimental|$2 cash incentive|
89213383|NCT01009125|Experimental|$5 cash incentive|
89213384|NCT02580851|Other|Coronary angiography|Patients directly undergo diagnostic coronary angiography. A PCI is performed according to current guidelines in case of ≥70% stenosis in a coronary vessel with ≥2 mm diameter.
89655986|NCT03017391|Active Comparator|algorithm 2 first granisetron|"granisetron patch 3.1 mg/24 hours will be offered to the patient, and a loading dose of 2 mg granisetron oral if the patient can swallow In case of failure, metoclopramide 10 mg tablets 3x daily orally will be added and in those patients that cannot swallow tablets the oral medication will be substituted with rectal suppositories 10 mg. The granisetron patch will only be withdrawn from patients that suffer from clinically relevant toxicity. Metoclopramide will then be administered.~In the case of secondary failure or toxicity, dexamethasone 8 mg orally daily will be added."
89655987|NCT01675037||obstructive|obstructive hydrocephalus in children and adults with biological evaluation
89655988|NCT01675193|No Intervention|Current screening protocol|Eye screening at age 1-2, 3-4, 6-9, 14-24, 36, 45 and 54-60 months
89655989|NCT01675193|Other|Disinvestment protocol|No eye screening at 6-9 and 14-24 months
89655990|NCT00953199|Experimental|Lidocaine|Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
89655991|NCT00953199|Active Comparator|Normal Saline|The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
89655992|NCT01675349|Experimental|Chenopodium album allergen extract|Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
89655993|NCT03033147|Experimental|Amoxicillin/Clavulanate Potassium|Amoxicillin/Clavulanate Potassium 875 mg-125 mg orally 30 minutes before root canal treatment
89655994|NCT03033147|Placebo Comparator|Placebo|placebo 30 minutes before root canal treatment
89655995|NCT01675505||Patients|"Inclusion criteria:~Patients with first-diagnosed colon cancer. Age 18-60 y.o.~Exclusion criteria:~Metastatic colon cancer. Former psychiatric history. Substance use. Previous serious medical conditions."
89213385|NCT02580851|Other|Cardiac magnetic resonance imaging|Patients receive adenosine perfusion CMR for functional testing, first. The examination is conducted on a 3.0 Tesla whole-body scanner with a 32-channel phased-array cardiac receiver coil according to a well-established standard protocol [21-23]. In case reversible ischemia can be detected, subjects are sent to coronary angiography and PCI afterwards.
89213386|NCT01005147|Experimental|Tranexamic acid arm|
89213387|NCT01005147|Placebo Comparator|Control arm|Will receive a placebo in place of tranexamic acid treatment
89213388|NCT01009359|Experimental|Arm 1|
89213389|NCT01009359|Experimental|Arm 2|
89213390|NCT01009359|Experimental|Arm 3|
89213391|NCT01001871|Experimental|Vitamin/mineral fortificant with iron|
89213392|NCT01001871|Placebo Comparator|Vitamin/mineral fortificant without iron|
89655996|NCT01675583||Standard Care Group|Subjects who will undergo only standard wound care management.
89655997|NCT01675583||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
89655998|NCT00947271|Experimental|DVD 1 plus assessment 1|Participants will view educational DVD 1 and complete the first version of the study assessment.
89655999|NCT00947271|Experimental|DVD 1 plus assessment 2|Participants will view educational DVD 1 and complete the second version of the study assessment.
89656000|NCT00947271|Experimental|DVD 2 plus assessment 1|Participants will view educational DVD 2 and complete the first version of the study assessment.
89656001|NCT00947271|Experimental|DVD 2 plus assessment 2|Participants will view educational DVD 2 and complete the second version of the study assessment.
89656002|NCT03024099|Experimental|Hippotherapy once a week|Hippotherapy once a week;
89656003|NCT03024099|Experimental|Hippotherapy twice a week|hippotherapy twice a week
89656004|NCT03017157||Anterior Myocardial Infarction|Patients who have suffered anterior myocardial infarction in our hospital
89656005|NCT01675739|Active Comparator|No-SMS group|In No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy without SMS.
89656006|NCT01675739|Experimental|SMS group|Patients in SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled short message service(SMS)
89656007|NCT03032913||Pancreatic ductal adenocarcinoma patients|Patients with recent diagnosis of pancreatic ductal adenocarcinoma (PDAC) or with strong suspicion PDAC
89656008|NCT03032913||Non-cancer patients|Patients with no Cancer
89656009|NCT03016923|Experimental|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
89656010|NCT01675895|Experimental|Group Levobupivacaine lidocaine|Group Levobupivacaine lidocaine Spinal anesthesia with 1.5 ml hyperbaric levobupivacaine (6.75 mg) + 0.3 ml 2 % lidocaine
89656011|NCT01675895|Active Comparator|Group Control|Group Control levobupivacaine spinal anesthesia with levobupivacaine (6.75 mg) + saline
89656012|NCT03032991||Control|Children at 8 years old born from healthy pregnancies
89656013|NCT03032991||GDM|Children at 8 years old born from mothers with gestational diabetes during pregnancy
89656014|NCT04642937|Experimental|hP1A8|Up to 3 dose levels of hP1A8 will be tested with a Dose Level -1 in the event of toxicity. The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort.
89656015|NCT03023865|Experimental|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
89656016|NCT01675973|Experimental|Subjects with severe renal impairment|Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
89656017|NCT01675973|Experimental|Subjects with normal renal function|Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
89656018|NCT03017001|Experimental|CHO (carbohydrate) group|Patients received a 8h preoperative fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g) and no infusion of intraoperative w-3-PUFA
89656019|NCT03017001|Experimental|W-3 PUFA group|Patients received preoperative fast for solids but allowed to drink 200 mL of water until 2h before anesthesia, and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
89656020|NCT03017001|Experimental|CHO plus intravenous w3-PUFA group|Patients received a 8h fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g), and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
89656021|NCT03017001|No Intervention|Control|Patients received preoperative fast for solids for 8h but allowed to drink 200 mL of water until 2h before anesthesia; and no infusion of intraoperative intravenous w-3-PUFA
89656022|NCT01676051||Chloraprep|
89656023|NCT01676051||Duraprep|
89656024|NCT01676051||Betadine only|
89656025|NCT04764851|Other|Cohort 1|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Cocktail given on 2 separate days:~midazolam: 1 µg infused IV~caffeine: 200 mg oral tablet~omeprazole: two 20 mg oral tablets~dextromethorphan: 1.6mL (containing ~10 mg) oral solution"
89656026|NCT04764851|Other|Cohort 2|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Cocktail given on 3 separate days:~midazolam: 10 µg/mL given as 1mL oral solution.~dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution"
89656027|NCT04764851|Other|Cohort 3|"ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Cocktail given on 2 separate days:~- bupropion: 100mg oral tablet"
89656028|NCT00956085|Experimental|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
89656029|NCT01005459|Active Comparator|tetracaine 2mg|
89656030|NCT01005459|Active Comparator|Bupivacaine 2 mg|
89656031|NCT04764461|No Intervention|Control Group|The control group will continue with the standard practice of antenatal care using Mc Donald's rule for fundal heights measurements.
89656032|NCT04764461|Experimental|Intervention Group|Intervention group will follow the same antenatal visit plan as the control group with the use of customised GROW Charts for fundal height measurements.
89656033|NCT03016767|Experimental|oral stimulation|"All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care.~Infants of the experimental group, in addition, will be applied a manual oral stimulation protocol designed ad hoc for this study, which consists of 12 maneuvers performed by a physiotherapist."
89656034|NCT03016767|No Intervention|non oral stimulation|All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care. But this group will not be applied the oral stimulation protocol.
89656035|NCT01007643|Experimental|Wii Fit (TM) Interactive Video Game|Wii Fit (TM) Interactive Video Game
89656036|NCT01007643|Active Comparator|Traditional Home Exercise Program|Traditional Home Exercise Program
89656037|NCT03022305|Experimental|Group one - standard therapy|Standard physical therapy treatment for shoulder and hip malalignment will be administered for one week.
89656038|NCT03022305|Experimental|Group two - neuromuscular therapy|Experimental neuromuscular physical therapy treatment for shoulder and hip malalignment will be administered for one week. This therapy is exercised based.
89656039|NCT03022305|No Intervention|Group three - no treatment|No physical therapy treatment will be given to this group.
89656040|NCT01676207||1|CAD
89656041|NCT01676207||2|no CAD
89656042|NCT04747535|No Intervention|Control|Regular treatment
89656043|NCT04747535|Experimental|Auto CPAP|Auto CPAP, AirSense 10 AutoSet, ResMed Inc, max pressure 10 cm water, min pressure 5 cm water
89656044|NCT04747535|Other|CPAP since before|Patients with CPAP since before will all continue using CPAP. They will not attend the randomization process. They will be regarded as a separate group.
89656045|NCT04747223|Experimental|Retraining (RT) Group|The retraining group will receive a watch accelerometer to use for monitoring their step rate with instructions to increase their preferred step rate by 7.5% over the ten in-field training sessions.
89656046|NCT04747223|No Intervention|Control (CON) Group|The control group will receive the same device to monitor their pace but receive no instruction to change their preferred step rate over the ten in-field training sessions.
89656047|NCT00956631|Other|interlaminar decompression|Commercially available product (mild® Device Kit) used to perform interlaminar decompression
88993869|NCT04692571|Experimental|Study B: Able-bodied Subjects|Ten able-bodied subjects, the electrodes will be mounted on the dominant arm for the EMG-force and EMG-target tracking trials. In addition, the non-dominant arm will also be constrained and measured in a second load cell. This load cell will not be used for feedback during the experiment, but will compare (RMS error, off-line) the dominant vs. non-dominant forces. For EMG-target tracking, the dominant hand will remain in the wrist cuff (to prevent flailing during contractions), with the screen feedback disabled. These subjects will repeat the trials with the electrodes moved to the non-dominant side. EMG-force tracking will be repeated using mirrored contractions. The three training methods (EMG-force ipsilateral, EMG-force contralateral mirrored, EMG-target on the dominant side) will be contrasted to help understand the source of errors when training with limb-absent subjects.
88993870|NCT00526435|Experimental|Group WWE|Subjects will participate in a group-assisted 6 week WWE program.
88993871|NCT00526435|Experimental|Self-directed|Subjects will follow the self-directed WWE program.
89656048|NCT01676285|Active Comparator|Metoprolol succinate|Metoprolol succinate
89656049|NCT01676285|Placebo Comparator|Placebo|Placebo
89656050|NCT01676285|No Intervention|Follow up|Group without cirrhotic cardiomyopathy, only follow up without randomization.
89656051|NCT01676363|Experimental|Diflunisal|
89656052|NCT03022071|Experimental|Cognitive behavior therapy|The included patients will receive cognitive therapy for depression for 16 weeks and monthly booster sessions up to 28 weeks.
89656053|NCT03022071|Active Comparator|Psychodynamic psychotherapy|The included patients will receive time-limited psychodynamic psychotherapy for 28 weeks.
89656054|NCT01676441|Experimental|cellgram-spine|posterior cervical laminectomy and Mesenchymal stem cells tranplantation. After laminectomy, 1.6X10^7 and 3.2 X10^7 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively
89656055|NCT00956709|Active Comparator|Levobupivacaïne 0,5 %|
89656056|NCT00956709|Active Comparator|Ropivacaïne 0,5%|
89656057|NCT04545983|Active Comparator|ACD|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
89656058|NCT04545983|Experimental|ACDA|In the previously conducted RCT 27 adult patients with an indication for ACD because of a monoradicular syndrome, corresponding to the C5-C6 or C6-C7 level, with corresponding pathology on MRI, were included and randomized to undergo ACD or ACDA.
89656059|NCT00957333||case|ketamine + Cystitis
89656060|NCT01010763|Experimental|M2a Magnum|Total HIp Arthroplasty using with the M2a Magnum Large Metal Articulation is an ultra-high performance metal-on-metal articulation with a big ball (greater than or equal to 38mm) in acetabulums as small as 44mm.
89656061|NCT01010763|Active Comparator|M2a Taper|Total Hip Arthroplasty using with the M2a Taper Acetabular System consists of a titanium outer shell with cobalt chromium (Co-Cr-Mo) metallic liner, which articulates with with a cobalt chromium (Co-Cr-Mo) modular femoral head.
89656062|NCT02159547|Active Comparator|Dexketoprofen|50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
89656063|NCT02159547|Placebo Comparator|normal slaline|50 ml normal saline
89656064|NCT04353219|Experimental|research group|training program with compression stocking
89656065|NCT04353219|Active Comparator|control group|training program without compression stocking
89656066|NCT00958035|Experimental|LATISSE®|bimatoprost ophthalmic 0.03% solution
89656067|NCT00958035|Placebo Comparator|Placebo|vehicle sterile solution
89656068|NCT04465877|Experimental|JTT-662 5 mg|JTT-662 5 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
89656069|NCT04465877|Experimental|JTT-662 10 mg|JTT-662 10 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
89656070|NCT04465877|Experimental|JTT-662 20 mg|JTT-662 20 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
89656071|NCT04465877|Placebo Comparator|Placebo|Placebo orally once daily from Day -1 to Day 28
89656072|NCT01011075|Experimental|Imatinib mesylate + Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
89656073|NCT04453163|Experimental|RAAC program|"If the patient is under the RAAC group, he/she will then be received in consultation by a RAAC specialist nurse, between the anesthesia / radiology consultation and the intervention. This RAAC nurse will explain the procedure and show him/her an information video on vertebroplasty. Information about managing anxiety and pain will also be provided. In addition, the day after the patient leaves the clinic, the RAAC nurse will call him/her to inquire."
89656074|NCT04453163|Other|Standard management program|"If the patient is under the control group, he/she will be taken care of according to the standard protocol after a surgery in percutaneous vertebroplasty. The patient will not have a consultation with the specialized nurse."
89656075|NCT00958581|Placebo Comparator|Normal Saline|Patients infused with normal saline before and during the surgical procedure as a placebo.
89656076|NCT00958581|Experimental|Tranexamic acid|Patients receive TXA before and during the surgical case.
89656077|NCT00958581|Experimental|Epsilon Aminocaproic Acid|Patients will receive EACA before and during the surgical case.
89656078|NCT04451915|Experimental|Early management GDM group|defined as no intervention until GDM screening at 24-28 weeks' gestation. If there is a diagnosis of GDM at 24-28 according to the IADPSG criteria), intensive metabolic treatment until delivery
89656079|NCT04451915|Experimental|Late management GDM group|early management of GDM defined as intensive metabolic treatment (diet, physical activity self-blood glucose monitoring according and/or insulin therapy according to the French guidelines). This intensive treatment will begin after the randomization until delivery.
89656080|NCT01012089|Experimental|Daptomycin|Pediatric patients on hemodialysis or peritoneal dialysis with suspected or confirmed infection and who were receiving standard of care antibiotics were also eligible to receive a single dose of daptomycin 5mg/kg IV. Serial blood draws were obtained to assess daptomycin pharmacokinetics
89656081|NCT04289441|Active Comparator|probiotic treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day~Lactobacillus salivarius LS01 (DSM 22775): 10^9 CFU Bifidobacterium breve B632 (DSM 24706): 10^9 CFU Maltodextrin and silicon dioxide"
89656082|NCT04289441|Placebo Comparator|Placebo treatment|"For the first 8 weeks was administered 1 sachet in the morning and 1 in the evening, for the last 8 weeks was administered 1 sachet per day~Maltodextrin and silicon dioxide"
89656083|NCT00959985|No Intervention|Group 1A|Mild Lymphedema: Only required to meet with the lymphedema physical therapist
89656084|NCT00959985|Active Comparator|Group 1B|Mild Lymphedema: Fitted for compression sleeve
89656085|NCT00959985|Active Comparator|Group 2A|Moderate lymphedema: Fitted with a compression sleeve
89656086|NCT00959985|Active Comparator|Group 2B|Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage
89656087|NCT04267133|Experimental|All Participants|
89656088|NCT04265651|Experimental|Infigratinib 0.016 mg/kg|"Dose Escalation:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
89656089|NCT04265651|Experimental|Infigratinib 0.032 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
89656090|NCT04265651|Experimental|Infigratinib 0.064 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
89656091|NCT04265651|Experimental|Infigratinib 0.128 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.~Dose Expansion:~Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose."
89656092|NCT04265651|Experimental|Infigratinib 0.25 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
89656093|NCT04404647|Experimental|Intervention|Selected patients who choose to participate will undergo ablation of the target lesion using irreversible electroporation.
89656094|NCT04055753||Doxorubicin|
89656095|NCT04055753||Doxil|
89656096|NCT01676519||PCI|diabetic patients undergoing percutaneous coronary intervention
89656097|NCT03472157|Experimental|Bariatric surgery|"Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.~Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care."
89656098|NCT03472157|Active Comparator|Lifestyle therapy|The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
89656099|NCT02947607||Healthy control|Patients undergoing lower GI endoscopy without any colorectal adenoma or carcinoma.
89656100|NCT02947607||Adenoma|Patients undergoing lower GI endoscopy with presence of colorectal adenoma detected.
89656101|NCT02947607||Colorectal cancer|Patients diagnosed with colorectal cancer and referred to surgical carcinoma resection.
89656102|NCT04764383|Experimental|PK/PD Group|Participants in the Pharmacokinetic (PK)/pharmacodynamic (PD) Group will receive L-Histidine and Lodosyn daily for 7 consecutive days.
89656103|NCT04764383|Placebo Comparator|L-Histidine and Lodosyn followed by Placebo Group|Participants in this group will receive L-Histidine and Lodosyn daily for 2 consecutive weeks followed by Placebo for an additional 2 consecutive weeks with a 1-week wash-out period in between.
89656104|NCT04764383|Experimental|Placebo followed by L-Histidine and Lodosyn Group|Participants in this group will receive Placebo daily for 2 consecutive weeks followed by L-Histidine and Lodosyn for an additional 2 consecutive weeks with a 1 week wash out period in between.
89656105|NCT02081573|Experimental|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
89656106|NCT01780025||Mixed hearing loss|
89656107|NCT01012245||patients with glaucoma and ocular hypertension|
89656108|NCT03016611|Active Comparator|Chewing Ticagrelor|
89656109|NCT03016611|Experimental|Chewing Prasugrel|
89656110|NCT03020511|Other|Ancient wheat flours|"We prospectively will survey 30 nuns from the Congregazione delle Suore Collegine della Santa Famiglia, Palermo, Italy. The subjects will be recruited between January 2017 and June 2017 and will be examined before and after the diet period (30 days) with ancient grains, undergoing clinical evaluation and blood and feces samples collection. Ancient wheat flours will be administered in open label for 30 days"
89656111|NCT03020355|Experimental|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
89656112|NCT03020355|Active Comparator|not Placental Blood Drainage|In the control group, the clamped cord will not released.
89656113|NCT00961233|Experimental|inhaled/swallowed budesonide|
89656114|NCT00961233|Active Comparator|viscous/swallowed budesonide|
89656115|NCT00961311|Experimental|Trial Arm|All patients with systematic ischemic heart disease with stenotic lesions that are amenable to percutaneous treatment.
89656116|NCT00962871|Active Comparator|1|
89656117|NCT00962871|Experimental|2|
89656118|NCT00962871|Experimental|3|
89656119|NCT00962871|No Intervention|4|
89656120|NCT01014351|Experimental|Paclitaxel/Carboplatin/Everolimus|Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
89656121|NCT01014741|Experimental|Ibutilide arm|
89656122|NCT01014741|Placebo Comparator|Placebo arm|
89656123|NCT01015443|Experimental|Investigational Arm|Tecemotide (L-BLP25) + Single low dose cyclophosphamide + Best supportive care (BSC)
89656124|NCT01015443|Placebo Comparator|Control Arm|Saline + Placebo + Best supportive care (BSC)
89656125|NCT00962949|Experimental|Control|Healthy controls
89656126|NCT00962949|Experimental|Postural Tachycardia Syndrome|Patients with Postural Tachycardia Syndrome
89656127|NCT01244789|Active Comparator|Observation|postoperative observation only
89656128|NCT01244789|Experimental|Combination chemotherapy|postoperative 6 courses of 3 weekly iv carboplatin-paclitaxel combination chemotherapy
89656129|NCT00856895||Hispanic|
89656130|NCT00856895||Non-Hispanic|
89656131|NCT05687591||Patients indicated for LAAO with the Amplatzer Amulet|All subjects who are indicated for LAAO with the Amplatzer Amulet are eligible for the study.
89656132|NCT02081807||Dabigatran|
89656133|NCT02081807||Warfarin|
89656134|NCT02631876|Experimental|Mirvetuximab Soravtansine|Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee [BIRC]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
89656135|NCT02631876|Experimental|Investigator's Choice (IC) Chemotherapy|Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)
89656136|NCT04765163||physician group with assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group using assistive equipment
89656137|NCT04765163||Physician group without assistive equipment|The number of colonoscopy operations completed per unit time and the degree of fatigue in the physician group without assistive equipment
89656138|NCT03156179||Girls with type 1 diabetes|
89656139|NCT03156101|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/maximum dose: 1x10^6/kg / 1x10^7/kg administered to patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
89656140|NCT05729490|Experimental|Participants|
89656141|NCT03881891|Experimental|Follow-app intervention arm|This arm will comprise of patients who are prompted to complete the PROMIS pain intensity scale through text/Short Message Service(SMS) or email mobile device notifications at pre-defined time intervals on Days 1, 3, 5 and 7 post-operatively.
89656142|NCT03881891|No Intervention|Standard care arm|This arm will comprise of patients who receive the usual care.
89656143|NCT03067116||Subjects|Adult, healthy pregnant women undergoing Posturography Evaluation, Anthropometrics, Vitals and answering Health and daily activity questionnaires
89656144|NCT03156257||Self-reported healthy males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
89656145|NCT04436796|Experimental|Artificial Pancreas|Subjects will be provided the Interoperable Artificial Pancreas System (iAPS) which includes the iAPS phone platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This iAPS is designed to help control blood sugar in people living with type 1 diabetes.
89656146|NCT04436796|Active Comparator|Sensor Augmented Pump/Predictive Low Glucose Suspend|Subjects will continue use of home insulin pump with a study continuous glucose monitor (CGM) and study glucometer. Subject may use home pump in PLGS mode if this is supported and compatible with the study sensor.
89656147|NCT02081963|Experimental|Nebulized amikacin|Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.
89656148|NCT02081963|Other|Nebulized normal saline|Participants received nebulized normal saline BID for 14 days in combination with standard treatment.
89656149|NCT03155867|Active Comparator|Meal replacement A|
89656150|NCT03155867|Active Comparator|Meal replacement B|
89656151|NCT03155867|Active Comparator|Meal replacement C|
89656152|NCT03155867|Active Comparator|Meal replacement D|
89656153|NCT03155867|Active Comparator|Meal replacement E|
89656154|NCT03155867|Active Comparator|Meal replacement F|
89656155|NCT02082119|Experimental|High Grade Glioma|To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.
89656156|NCT04765085|Experimental|CBIT Group|Patients in this group would only receive the CBIT treatment.
89656157|NCT04765085|Experimental|Drug therapy Group|Patients in this group would only receive the drug therapy.
89656158|NCT02633046|Other|Acthar Gel|Acthar Gel, 1 mL (80 U) by subcutaneous injection (SC) 3x/week will be administered to all participants from Week 0 to 50. Tapering of dose to 1 mL SC 2x/week will be allowed for safety and/ tolerability issues. Once the dose is tapered to 1 mL SC 2x/week it must remain at this level. Participants unable to tolerate 1 mL SC 2x/week will be discontinued. All participants will have an End of Study/Early Termination Visit 4 weeks after discontinuing Investigational Medicinal Product (IMP).
89656159|NCT01676129|Experimental|Nocipoint Therapy|"Nocipoint therapy (NT) follows rules of TENS stimulation in each session, all within the general FDA guidelines of TENS uses. The key points of Nocipoint Therapy include the following:~The stimulation pads are located at the skin surface location of the nociceptors of the muscle/tissue in pain (i.e., Nocipoint)~The intensity is set to induce C-fiber response during the stimulation~The duration of stimulation (about 1.5-4 minutes for each tissue stimulation)~Stimulations for different tissues (muscles, ligaments) are sequenced such that later stimulations will not cause re-injury of previously treated tissues.~Patient are instructed not to use the newly recovered muscle/tissue too much for an estimated rest period depending on his/her age."
89046664|NCT01655225|Experimental|Part B5: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.
89046665|NCT01655225|Experimental|Part B6: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.
89656160|NCT01676129|Active Comparator|Physical Therapy|"Patients in this group will be treated with comprehensive physical therapy program including typical electrical stimulation using a standard transcutaneous electrical nerve stimulation (TENS) device, manual myofascial release and postural correction exercise.~The application of TENS will follow general physical therapy guidelines, especially for TMD. Manual myofacial release will be applied on orofacial muscles and neck muscles.~TENS will serve both as a part of the standard of care and as placebo, as the same TENS device is used in both arms."
89656161|NCT04765007|Experimental|Mindfulness group|This arm will be treated with a mindfulness-based stress reduction therapy.
89656162|NCT04765007|Other|Control group|This arm will be treated with a minimal intervention.
89656163|NCT01676597|Experimental|rifaximin and pentoxifylline|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
89656164|NCT01676597|Active Comparator|pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
89656165|NCT03155555||Experimental|Children aged 1-12 years undergoing major surgeries under general endotracheal anaesthesia with mechanical ventilation under neuromuscular blockade
89656166|NCT02837471|Experimental|Intervention group, PiezoRx device|Participants will use the PiezoRx pedometer at leisure for 12 weeks, and receive the standard care of the FrancoForme cardiac prevention and rehabilitation program.
89656167|NCT02837471|No Intervention|Control group, Standard care|Participants will receive the standard care of the FrancoForme Cardiovascular disease prevention and rehabilitation program.
89656168|NCT05540964||Single group|Study participants will be taken off antiretroviral therapy and blood samples will be collected during each clinic visit.
89656169|NCT03155789||Low Back Pain emanating from L4-5|"S TLIF at L4-5 (n=10)~MI TLIF at L4-5 (n=10)~XLIF at L4-5 (n=10)"
89656170|NCT03155789||Low Back Pain emanating from L5-S1|"S TLIF at L5-S1 (n=10)~MI TLIF at L5-S1 (n=10)~XLIF at L5-S1 (n=10)"
89656171|NCT03155789||Low Back Pain emanating from L4-5 and L5-S1|"S TLIF at L4-5 and L5-S1 (n=10)~MI TLIF at L4-5 and L5-S1 (n=10)~XLIF at L4-5 and L5-S1 (n=10)"
89656172|NCT04364802|No Intervention|Healthcare Workers - Control|Front-line healthcare workers (FLCHW) who are negative for COVID will receive standard PPE and a pre- and post-study test for COVID-19.
89046666|NCT01655225|Experimental|Part B7: LY3023414 + Abemaciclib + Letrozole|LY3023414 administered orally BID with abemaciclib administered orally BID and letrozole administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.
89046667|NCT00555165|Experimental|I|
89046668|NCT03457298|Experimental|Ossix Volumax|lateral bone augmentation using volume maintaining collagen scaffold (Ossix Volumax)
89046669|NCT03457298|Active Comparator|FDBA with collagen membrane|lateral bone augmentation using the current gold standard FDBA plus resorbable collagen membrane
89656173|NCT04364802|Experimental|Healthcare Workers - PVP-I|Front-line healthcare workers (FLCHW) who are negative for COVID-19 will receive standard PPE and a pre- and post-study test for COVID-19. Additionally, they will receive PVP-I spray and gargle.
89656174|NCT04364802|No Intervention|Inpatients - Control|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test.
89656175|NCT04364802|Experimental|Inpatients - PVP-I|Inpatients who have a 7+ day hospitalization or who are set to undergo a significant surgical procedure will receive standard care and a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays that will be applied shortly after admission or perioperatively.
89656176|NCT04364802|No Intervention|Community - Control|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test.
89656177|NCT04364802|Experimental|Community - PVP-I|Community participants who are negative for COVID-19 will receive a pre- and post-study COVID-19 test. Additionally, they will receive PVP-I gargle and nasal sprays.
89656178|NCT03155243||Participants receiving adalimumab (Humira®)|Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
89656179|NCT03155087||T2DM patients|Metformin dosages ranged from 500 to 2000 mg per day
89656180|NCT03155087||healthy subjects|the healthy subjects was not intervened
89656181|NCT05729100|Experimental|Oral carbohydrate-electrolyte solution|The intervention group who will receive 50 ml/kg of oral solution containing carbohydrate-electrolyte
89656182|NCT05729100|Sham Comparator|Standard clear fluid|The control group who will receive 50 ml/kg of clear fluid (i.e. water; which does not contain carbohydrate-electrolyte)
89656183|NCT00963105|Experimental|Lenalidomide 5 mg|"Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
89656184|NCT00963105|Experimental|Lenalidomide 10 mg|"Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
89656185|NCT00963105|Experimental|Lenalidomide 15 mg|"Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
89656186|NCT04879992|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
89046670|NCT04671888|Experimental|COPD patients|
89046671|NCT04722653|Experimental|NN0194-0499|Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo, Asian participants will only receive NNC0194-0499. There will be 3 cohorts with escalating dose levels. There should be at least 4 days between dose administration of the last participant in a dose level cohort and dose administration of the first participant in the following dose level cohort.
89046672|NCT04722653|Placebo Comparator|Placebo|Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo.
89046673|NCT01818921|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks.
89656187|NCT04879992|Experimental|rifabutin triple therapy|Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid
89656188|NCT03864965|Experimental|Intervention Group|Patients diagnosed with mild cognitive impairment, very mild dementia, or mild dementia, will receive the guided advance care planning conversations with the PI
89046674|NCT01818921|Experimental|1.2 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
89046675|NCT01818921|Experimental|1.8 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
89046676|NCT04700345|Experimental|Embolization|Middle meningeal artery(MMA) embolization
89046677|NCT04700345|Active Comparator|No embolization|Traditional treatment group
89046678|NCT01815450|Experimental|BLI1100|BLI1100 topical cream
89046679|NCT01815450|Experimental|BLI1100 - modified formulation|BLI1100 topical cream
89046680|NCT01815450|Placebo Comparator|Placebo|Topical cream
89046681|NCT01810575|Active Comparator|WC3036-11F/Alprostadil in Vehicle 2.5%|Treatment A
89656189|NCT03864965|No Intervention|Control Patients|Patients diagnosed with mild cognitive impairment, very mild dementia, or mild dementia, will not receive the guided advance care planning conversations with the PI
89656190|NCT05728710||Perforation|all patients with immediate or delayed perforation identified from the FECCO (NCT04592003)
89656191|NCT01016691|Experimental|High Dose Drug Device/ bimatoprost 0.03%|drug device containing 65 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
89656192|NCT01016691|Experimental|Low Dose Drug Device / bimatoprost 0.03%|drug device containing 45 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
89656193|NCT01016691|Other|Placebo Device / bimatoprost 0.03%|placebo drug device worn over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
89656194|NCT04181736|Experimental|Guanfacine Treatment Group|Participants will be prescribed tabs containing guanfacine immediate release (GIR) to be taken for 4 weeks and will be monitored by one of the study psychiatrists. Subjects randomized to GIR will start with 0.25mg GIR upon waking and increase by 0.25mg every other day with a goal dose of 2mg.
89046682|NCT01810575|Experimental|WC3036-12F/Alprostadil in Vehicle 0.5%|Treatment B
89046683|NCT01810575|Placebo Comparator|WC3036-13P/Vehicle Only 0.5%|Treatment C
89046684|NCT04671524|Experimental|pediatric patients diagnosed with rheumatic diseases.|"Exercise group; a combination of stretching, range of motion, and strengthening exercise.~The exercise program will take 8 weeks, 3 days per week, and 45 minutes."
89656195|NCT04181736|Placebo Comparator|Placebo Group|Participants will be prescribed tabs containing placebo to be taken for 4 weeks and will be monitored by one of thestudy psychiatrists. Subjects randomized placebo will be asked to follow the same pill regimen as subjects randomized to treatment.
89656196|NCT04404491|Active Comparator|PD-1 and Concurrent chemoradiotherapy|Camrelizumab: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
89656197|NCT04404491|Placebo Comparator|placebo and Concurrent chemoradiotherapy|placebo: 200mg,d1,15,29,43,57,I.V oxaliplatin：65mg/m2，d1，8，22, 29 capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total. radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
89656198|NCT04764071|Active Comparator|percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F. Pneumatic lithotripter is used for fragmentation and stone removal is accomplished with retrieval graspers through a rigid 22F nephroscope. An 18-24 F nephrostomy tube is placed at the end of the operation.
89046685|NCT04671524|No Intervention|healthy controls|The healthy control group will be examined and the outcomes will be compared with the experimental group.
89046686|NCT04671849|Experimental|adult patients_Dose 1|
89046687|NCT04671849|Experimental|adult patients_Dose 2|
89046688|NCT04671849|Experimental|adult patients_Dose 3|
89046689|NCT04671849|Experimental|adult patients_Dose 4|
89046690|NCT04671849|Experimental|adult patients_Dose 5|
89046691|NCT04671849|Experimental|adult patients_Dose 6|
89046692|NCT04671849|Experimental|adult patients_Dose 7|
89046693|NCT04671849|Experimental|adult patients_Dose 8|
89046694|NCT04664777||Group1|"Living liver donors who operated between 1 August and 15 november:~After anesthesia induction and surgical field sterilization, before surgical incision; blood sample will be taken, SpHb, PI and vital measurements (SpO2, Heart rate, NIBP, body temperature) will be recorded.~After the surgical procedure is over and before the patient is awakened from anesthesia; blood sample will be taken, SpHb, PI and vital measurements (SpO2, Heart rate, NIBP, body temperature) will be recorded."
89046695|NCT01785771|Experimental|ITCA 650|
89046696|NCT04664582|Experimental|Sentinel Lymph Node Biopsy|Lymphoscintigraphy will be ordered alongside usual pre-operative investigations. Intra-operatively, the excision of the primary tumor will be done with the aim of histologically clear margins and appropriate closure as per routine practice at the operating surgeon's discretion. The patients are injected with technicium 99 pre-operatively and a sentinel lymph node biopsy will be performed with a handheld gamma probe.
89046697|NCT04664582|No Intervention|Standard of Care|These patients will be treated with standard of care, which is wide local excision of the primary tumor without performance of sentinel lymph node biopsy, if not indicated.
89046698|NCT04671537|Experimental|Study group (preloading with crystalloid fluid - isotonic solution)|Preloading with crystalloid fluid (isotonic solution) at 10 ml/kg of ideal body weight
89046699|NCT04671537|No Intervention|Control group (not preloading)|no preloading
89656199|NCT04764071|Experimental|ultra-mini percutaneous nephrolithotomy|Patients are positioned in the lithotomy position and a 6 F ureteral catheter is placed and the bladder is drained with a 16F urethral Foley catheter. After ureteral catheterization, patients are placed in the prone position, and percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath. Then, a 9.5-F, rigid ureteroscope (KARL STORZ Medical Instruments) was introduced to the sheath. The renal stones were broken into pieces using holmium laser lithotripsy. Finally, the ureteroscope and sheath were removed and the tract site was packed for 2-3 min. then placement of double J stent will be done according to the decision of the operating surgeon for 3 to 4 weeks.
89656200|NCT03154853|No Intervention|normal foot|no intervention
89656201|NCT03154853|Experimental|functional flatfoot|Behavioral: short foot exercise
89656202|NCT04764149||PFll Group|Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/ m2) on day 1 and day 28, every 60 days. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
89656203|NCT04764149||Non-PFLL Group|Patients were treated with other platinum-based chemotherapy every 21 days including: PF regimen: 5-fluorouracil at a dose of 1,000 mg/m2 daily by continuous intravenous infusion on days 1-4 and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. GP regimen: gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1. TP regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1 and intravenous infusion of cisplatin at a dose of 75 mg/m2 on day 1. TPF regimen: paclitaxel intravenous infusion at a dose of 175 mg/m2 or docetaxel at a dose of 75 mg/m2 on day 1; cisplatin intravenous infusion at a dose of 75 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at a dose of 750 mg/m2 daily on days 1-5. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.
89656204|NCT03154931|Active Comparator|CBT-SG|This CBT-Supportive group will focus on the interaction here-and-now, realizing that the group acts as a secure place, driven by interactions among its participants and therapist and co-therapist. The main objective is to welcome and support the participation of all patients and stimulate the group's initiatives, encouraging interpersonal interactions and mutual aid. There will be no specific therapeutic intervention in relation to any PTSD related content.
89656205|NCT03154931|Experimental|CFT-G|This CFT-group will focus on activities using specific therapeutic strategies, to learn and training compassionate skills - psychoeducation and exercises developed for use in session and at home.They will learn What is compassion and shame? Steps to the training of compassion and how Building a compassionate image. Will use Thoughts Daily Record - self critical and self compassionate. Explanation of Formulation of Strategy Threats and Security, The Three Emotional regulation systems and PTSD formulation - based on shame and guilt. They will learn how to incorporate these skills to everyday situations. At the end, will write an Autobiography writing about this experience and share with the group.
89656206|NCT03066492|Active Comparator|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
89656207|NCT03066492|Experimental|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
89656208|NCT03154775|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
89656209|NCT04124640||treatment group|The study population will be women between 45 and 65 years old, both ages included, who present a decrease in sexual desire or arousal
89656210|NCT03155009|Experimental|Alectinib|600 mg orally twice daily (BID) for up to 2 years
89656211|NCT03066024||Children and adolescents|Children and adolescents for elective surgery
89656212|NCT05573568|Experimental|Group A - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (5 mg, followed by 20 mg) with a 2-hour dose interval (5 subjects).
89656213|NCT05573568|Experimental|Group B - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (7.5 mg, followed by 30 mg) with a 2-hour dose interval (5 subjects).
89656214|NCT05573568|Experimental|Group C - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (10 mg, followed by 40 mg) with a 2-hour dose interval (5 subjects).
89656215|NCT05573568|Experimental|Group D - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (12.5 mg, followed by 50 mg) with a 2-hour dose interval (5 subjects).
89656216|NCT05573568|Experimental|Group E - single ascending dose|Administration of up to 2 inhaled doses of DMT within a single day (15 mg, followed by 60 mg) with a 2-hour dose interval (5 subjects).
89046700|NCT04620356|Experimental|DryNites arm|"Participants in this arm use DryNites every night for 4 weeks (run-in period), an additional 4 weeks (intervention core trial period), and an optional additional 4 weeks (extension period). All participants in this arm also receive absorbent bad mats to use every night."
89046701|NCT04620356|No Intervention|No Pants arm|"Participants in this arm use DryNites every night for 4 weeks only during the initial run-in period. Thereafter, participants in this arm do not use DryNites during the 4 week intervention core trial period or the optional additional 4 weeks extension period. All participants in this arm also receive absorbent bad mats to use every night."
89046702|NCT01784874|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg) Serum Free
89046703|NCT01784874|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies
89656217|NCT03858491|Experimental|Cobicistat|Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).
89656218|NCT01672788|Experimental|Test 1|fixed dose combination tablet
89656219|NCT01672788|Active Comparator|Reference 1|empagliflozin tablets and metformin tablet
89656220|NCT01672788|Experimental|Test 2|fixed dose combination tablet
89656221|NCT01672788|Active Comparator|Reference 2|empagliflozin tablet and metformin tablet
89656222|NCT03154619|Active Comparator|TR987|This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
89656223|NCT03154619|Placebo Comparator|Placebo|This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
89656224|NCT03065946||Case series|Early wakening
89656225|NCT05610059|Other|Blood Pressure Technology System M|These participants will receive information about high blood pressure, medications and strategies that can be used to take medications and manage blood pressure. They will complete a mid-assessment at 3-months and a post-assessment at 6-months.
89656226|NCT05610059|Other|Blood Pressure Technology System E|These participants receive information about high blood pressure and medications. They will complete a mid-assessment at 3-months and a post-assessment at 6-months.
89656227|NCT03154541|Experimental|Non Cystic Fibrosis (CF) cohort|"The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. No prescription is necessary. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline."
89656228|NCT03154541|Experimental|Cystic Fibrosis (CF) cohort|The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
89656229|NCT02705963|Experimental|Oral Contraceptive / Trametinib|In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).
89656230|NCT04404413|Experimental|PARTICIPANTS|A single-group crossover design was used to compare the effects of 2x8 weeks of high-intensity interval training without (HIIT) or with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake) on body composition and performance. There were two weeks in the middle of both phases in which they did not carry out programmed activity, in order not to alter the experimental phase.
89656231|NCT03065868|Experimental|eradictaion|H. pylori eradication group
89656232|NCT03065868|No Intervention|non-eradication|H. pylori non-eradication group
89656233|NCT03885102|Experimental|Intervention|12 months intradialytic exercise intervention
89656234|NCT03885102|Active Comparator|Usual care|Usual care according to current guidelines
89656235|NCT05728398|Active Comparator|Music Intervention Group|Participants randomized to receive music intervention during interventional radiology procedure.
89656236|NCT05728398|Sham Comparator|No Music Comparator Group|Participants randomized to have no music played during interventional radiology procedure.
89656237|NCT03843437|Experimental|Tencel Therapeutic Garments|Children in this group will wear Tencel Therapeutic Garments
89656238|NCT03843437|Placebo Comparator|Cotton Therapeutic Garments|Children in this group will wear Cotton Therapeutic Garments
89656239|NCT03834857|Other|single|Implantation of Stentrode device
89656240|NCT02632110|Experimental|ALA 25 min 10 Milliwatts (mW)|ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
89656241|NCT02632110|Experimental|MN + ALA 25 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
89656242|NCT02632110|Experimental|ALA 25 min 20 mW|ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
89656243|NCT02632110|Experimental|MN + ALA 25 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
89656244|NCT02632110|Experimental|ALA 60 min 10 mW|ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
89656245|NCT02632110|Experimental|MN + ALA 60 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
89656246|NCT02632110|Experimental|ALA 60 min 20 mW|ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
89656247|NCT02632110|Experimental|MN + ALA 60 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
89656248|NCT02632110|Placebo Comparator|VEH|Vehicle (VEH) PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
89656249|NCT02632110|Placebo Comparator|MN + VEH|Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
89656250|NCT03830723|Other|Rekovelle (Follitropin delta)|All participants will receive a prescription for study medication Rekovelle (follitropin delta)
89656251|NCT05728320||Gastric bypass|Subjects submitted to gastric bypass
89656252|NCT05728320||Sleeve gastrectomy|Subjects submitted to sleeve gastrectomy
89656253|NCT05728320||Normal control subjects|Subjects not submitted to bariatric surgery with IMC < 25
89656254|NCT05728320||Obese control subjects|Subjects not submitted to bariatric surgery with IMC > 30
89656255|NCT04404179||CASE|59 COVID-19 POSITIVE PRISONERS WHO UNDERWENT TREATMENT AT THE COVID-19 CARE FACILITY AT CAMP JAIL.
89656256|NCT05504772||High-risk cancers|"One of the following two criteria must be met:~Confirmed or suspected high-risk malignancy defined as expected overall survival < 30% based on current literature for the specific cancer~Cancers for which standard therapy would result in unacceptable and severe morbidity (e.g., infantile fibrosarcoma where definitive surgery would require amputation of limb) Note: This does not include HR neuroblastoma at diagnosis as this group of patients have an overall survival ≥30% and belongs to Cohort 4A."
89656257|NCT05504772||Rare tumors|"At least one of the following three criteria must be met:~A rare tumor of uncertain prognosis due to rarity of disease~A rare tumor with no established treatment strategy~A cancer where routine histopathological examination has not been able to establish a diagnosis~Confirmed histiocytic disorder AND molecular profiling may facilitate diagnosis and/or treatment~Confirmed proliferative vascular or lymphatic malformation AND has failed conventional treatment, e.g., surgery or embolization, OR no appropriate treatment is available AND the disease is organ, limb or life threatening, or debilitating"
89656258|NCT05504772||Primary central nervous system (CNS) tumours|Patient is suspected or confirmed to have a primary CNS tumor, including low and high-grade tumors
89656259|NCT05504772||Neuroblastoma|Patient is suspected or confirmed to have neuroblastoma 4A: HR neuroblastoma at diagnosis 4B: Non-HR neuroblastoma
89656260|NCT05504772||Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL|Patient is confirmed by flow cytometry to have acute myeloid leukemia (AML) or other leukemias (Note: Verbal confirmation of flow cytometry result is adequate for enrolment)
89656261|NCT05504772||Acute lymphoblastic leukemia (ALL)|Patient is confirmed to have acute lymphoblastic leukemia by flow cytometry (Note: Verbal confirmation of flow cytometry result is adequate for enrolment)
88993872|NCT04692805|Experimental|EUS-guided treatment of varices|"Procedure: EUS-guided injection of coils with cyanoacrylate glue (CYA) and sclerosing agent.~First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with Coils plus CYA and sclerosing agent (Group A)."
88993873|NCT04692805|Experimental|EUS-guided partial splenic embolization + EUS-guided treatment of varices|"Procedure: EUS-guided partial splenic embolization + EUS-guided treatment of varices First CT scan will be ordered to determine the patient having esophageal and gastric varices and splenomegaly.~Complete blood count (CBC) will be ordered to confirm the deficiency of one or more blood cell lines.~A standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient considered as a candidate will be treated with coils plus CYA and sclerosing agent.~At the same procedure, a branch of splenic artery will be identified by EUS and implanted with coils plus CYA (Group B)."
88993874|NCT03432299|Experimental|RFA for PTMC|Group who will undergo RFA after diagnosis of PTC
88993875|NCT02946112||Shoulder pain|volleyball players with shoulder pain
88993876|NCT02946112||No shoulder pain|volleyball players without shoulder pain
88993877|NCT02946151|Experimental|Implantation|Implantation of a subcutaneous electrode and connection to the external logging device
88993878|NCT02946190|Experimental|Arm 1: Pertagen® aP + Td-pur®|BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0
88993879|NCT02946190|Active Comparator|Arm 2: Boostrix® dTpa|Licensed Tetanus-diphtheria (reduced dose)-acellular Pertussis vaccine (Boostrix® dTpa; GSK) given intramuscularly as a single dose on Day 0
88993880|NCT03346694|Active Comparator|Dressing 1: Standard Island Dressing|Standard dressing that is applied on most patients with a sternotomy wound incision immediately after cardiovascular surgery before leaving the operating room. Dressing will be removed 48 hours after surgery.
88993881|NCT03346694|Active Comparator|Dressing 2: Prevena negative pressure|Prevena negative pressure wound suction machine dressing applied to sternotomy wound incision immediately after cardiovascular surgery. Dressing will be in use for 7 days or removed sooner if participant is discharged before end of 7 day post-operative time period.
88993882|NCT03346694|Active Comparator|Dressing 3: Mepilex Border Post-Op Ag|Mepilex Border PostOp AG dressing impregnated with silver ions. Dressing will be in use for 7 days or removed earlier if patient is discharged before end of 7 days post0operative time period.
88993883|NCT02945761|Active Comparator|High concentration of sugar solution|Lavage group of high-concentration sugar solution (HCSS): disinfected the Skin outside wound with conventional PVP. HCSS refers to supersaturated sugar solution made of 50% high-concentration glucose and white sugar. Prior to wound irrigation, dry cotton balls are used to wipe the wound and internal lacuna, to clean some necrotic tissues out of the wound. HCSS is applied on the wound once a day, and whether the lavaging is stopped based on the amount of exudation from the wound.
88993884|NCT02945761|Active Comparator|conventional surgical dressing change|conventional surgical dressing change:separated suture, expanded the wound, placed drainage ribbon gauze and used hydrogen peroxide or(and) PVP to wash the wound; the decision-making power of these operators is determined by a doctor. After the doctor confirms granulation cleaning in the wound, the decision-making power of suture is also determined by a doctor.
88993885|NCT02945683|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 3 months
88993886|NCT02945683|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 3 months
88993887|NCT02947321|Experimental|RFA Group|A genicular nerve RFA will be performed prior to planned total knee arthroplasty.
88993888|NCT02947321|Sham Comparator|Control Group|A sham genicular nerve RFA will be performed prior to planned total knee arthroplasty.
88993889|NCT02947009|Experimental|Adolescent athletes with PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index"
89046704|NCT01784133|Active Comparator|omiganan mid dose|omiganan mid dose once daily application for 12 weeks
89656262|NCT05504772||Lymphomas|Patient is suspected or confirmed to have a lymphoma
89656263|NCT05504772||Sarcomas|Patient is suspected or confirmed to have a sarcoma Includes gastrointestinal stromal tumour (GIST), malignant peripheral nerve sheath tumour (MPNST), desmoplastic small round cell tumour (DSRCT)
89656264|NCT05504772||Renal tumors|Patient is suspected or confirmed to have a renal tumor Includes clear cell sarcoma of kidney
89656265|NCT05504772||Hepatic and biliary tree tumors|Patient is suspected or confirmed to have a liver or biliary tree tumor
89656266|NCT05504772||Thyroid and endocrine tumors|Patient is suspected or confirmed to have a thyroid or endocrine cancer
89656267|NCT05504772||Other tumors|Patient is suspected or confirmed to have a tumor which does not fit into any of the above
89656268|NCT05504772||Germline only|"One of the following two criteria must be met:~Patients whose submitted tumor sample could not yield sufficient DNA for any molecular analysis AND participants/parents have consented to return of germline findings.~Patients who do not have appropriate tumor sample to be submitted for molecular profiling may be considered for germline only analysis. Obtaining tumor samples wherever possible will be encouraged."
89656269|NCT03816917||topical treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: only topical/UV therapy (no systemic therapy)
89656270|NCT03816917||systemic treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy, but no biologicals. Topical therapy is permitted.
89656271|NCT03816917||biologics|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy with biologics. Other systemic and topical therapy is permitted.
89656272|NCT03065712|Experimental|FES PET/CT|"This is a single arm study that involves FES PET/CT.~Procedure: Computed Tomography~Drug: [F-18] fluoroestradiol: [F-18]FES~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
89656273|NCT03814109|Experimental|LENINGRADO|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet Leningrado association,1 tablet indapamide placebo, 1 tablet levamlodipine placebo, oral, once a day."
89656274|NCT03814109|Active Comparator|Indapamide|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet indapamide 1,5 mg, 1 tablet Leningrado association placebo, and 1 tablet levamlodipine placebo, oral, once a day."
89656275|NCT03814109|Active Comparator|Levamlodipine|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet levamlodipine 2.5/ 5 mg, 1 tablet indapamide placebo, and 1 tablet Leningrado association placebo, oral, once a day."
89656276|NCT05491746|Experimental|Eye4|This is the arm with the Eyedaptic Device
89656277|NCT05491746|Placebo Comparator|Baseline|This is the placebo arm with the best correction the subject has
89656278|NCT03809585||Iris Tumors|This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines.
89656279|NCT03809585||Healthy Controls|This group will consist of 50 adults age 18 and older who have healthy eyes.
89656280|NCT01016769|Experimental|Temsirolimus + Weekly Paclitaxel + Carboplatin|"In Part 1 (Phase I) of the study, the primary endpoint is to establish the phase II recommended dose for the combination of temsirolimus + weekly paclitaxel + carboplatinPart 1 (Phase I) features a standard 3 + 3 phase I dose escalation design. Up to 3 dose levels are planned in the Phase I portion of the study.~In Part 2 (Phase II) of the study, the primary endpoint is to determine the objective response rate (CR or PR) after two cycles (approximately 6 weeks) of treatment with the combination of temsirolimus + weekly paclitaxel + carboplatin as palliative therapy for recurrent or metastatic HNSCC. A two-stage design will be employed."
89656281|NCT03066882|Experimental|Study group I|Study group I (19 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
89656282|NCT03066882|Experimental|Study group II|Study group II (18 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
89656283|NCT05728164|Experimental|STUDY GROUP|"The group (35 students) will be divided into 7 small groups of (5 students in each group). In addition to routine training provided for the control group, the students of the intervention group will be provided with micro learning content following the educational topics of the course in the form of short videos of cinematic films reinforcing values of resilience, empathy, and positive emotions in dealing with others.~• Pre-simulation activities will also be developed that required watching a tutorial video on how to create a plan of care for such cases. Students also will be provided with background on cinematic simulation and a summary of the characters. Learners will be assigned to one of the films characters and introduced to the assessment tool they would utilize. A pre-briefing discussion on patient confidentiality, nursing role expectations, and developing a plan of care also preceded the activity."
89656284|NCT05728164|No Intervention|Cintrol group|They will receive usual training based on the educational objectives of routine methods of lectures, discussion.
89656285|NCT03019809|Experimental|Plerixafor/G-CSF for HSCT conditioning|Myeloablative conditioning regimen with Plerixafor and G-CSF as addition agents before stem cell transplantation in WAS patients.
89656286|NCT03066570|Experimental|Single case study|Single case study using Graded exposure.
89656287|NCT01676675|Experimental|7.5μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adolescents aged 12-17 years old on day 0, 21
89656288|NCT01676675|Experimental|15μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
89656289|NCT01676675|Experimental|30μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
89656290|NCT01676675|Experimental|7.5μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
89656291|NCT01676675|Experimental|15μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
88993890|NCT02947009|Active Comparator|Adolescent athletes at-risk for PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index."
88993891|NCT02947204|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge.
88993892|NCT02947204|Experimental|Intermittent oxygen monitoring|Oxygen saturation will be measured intermittently, every 4 hours, through the child's hospital stay until discharge.
88993893|NCT00526747||Epo-resistant|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
88993894|NCT00526747||Epo-responsive|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are requiring <100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
88993895|NCT03225755||Adults with growth hormone deficiency|12 subjects with GH deficiency, adult or childhood onset, and not currently on GH therapy will be studied. Subjects enrolled will be those planning GH therapy and beginning this therapy as part of their routine clinical care. Subjects will be 50% female and all subjects will be on 3 months of stable hormone replacements prior to testing.
88993896|NCT00525577|Experimental|1:A|Placebo
88993897|NCT00525577|Experimental|2:B|AGI-1067 75 mg
88993898|NCT00525577|Experimental|3:C|AGI-1067 150 mg
88993899|NCT03186755|Experimental|Hylo-Dual|Hyaluronic acid 0.05% & Ectoine 2.0% (Hylo-Dual) 1 drop in both eyes 3 times/day for 8 weeks
88993900|NCT03186755|Active Comparator|Patanol|Olopatadine hydrochloride ophthalmic solution 0.1% (Olopatadine) 1 drop in both eyes 2 times/day for 8 weeks
88993901|NCT00525616|Experimental|Rituximab|Treatment consists of two slow intravenous infusions of rituximab 1000mg to 15 days apart with local corticosteroid .
88993902|NCT00525655|Experimental|Multimedia Intervention|
88993903|NCT00173433||Culture-confirmed relapse of TB|Patients who have a recurrent episode of culture-confirmed TB after completion of treatment for the first episode of culture-confirmed TB
88993904|NCT00526864||Elderly patients|
88993905|NCT00526864||HIV infected patients|
88993906|NCT00526864||Immunosuppressed patients|
88993907|NCT00525694|Other|1|glucose tolerance test solution
88993908|NCT00525694|Other|2|Diet Coke
88993909|NCT00525694|Other|3.|Coke Zero
88993910|NCT00526903|Experimental|Fiber|Fiber added to diet for a total of 6 weeks.
88993911|NCT00526903|Placebo Comparator|Placebo|Placebo powder taken for a total of 6 weeks.
88993912|NCT00405470|Active Comparator|Medial Pivot|
88993913|NCT00405470|Active Comparator|Posterior Stabilized|
88993914|NCT00526942|No Intervention|I|No contact control (NCC)
88993915|NCT00526942|Experimental|II|Computerized, SAAGE-designed, visual memory-based cognitive training
88993916|NCT02947243|Active Comparator|Standard pharmacological treatment|Standard pharmacological treatment (including Morphine) according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
88993917|NCT02947243|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
88993918|NCT02947282|Active Comparator|Intervention|Educational Workshop
88993919|NCT02947282|No Intervention|Control|They will continue regular prenatal care as planned
88993920|NCT04693000|Experimental|Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|"An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.~Keratotic nodular size observation after 12 weeks"
88993921|NCT03177863|Experimental|Study cohort|"Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The intervention is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3"
88993922|NCT02946970|Placebo Comparator|Control|Intragastric infusion
88993923|NCT02946970|Experimental|Quinine hydrochloride|Intragastric infusion
88993924|NCT04692727|Active Comparator|Exercise grup|An exercise program that includes stretching, strengthening and balance exercises accompanied by physiotherapist in the clinic will be applied to all individuals participating in the study for 6 weeks, 2 times a week (12 sessions). Each session will take approximately 40 minutes and patients will be asked to repeat the exercises at least 2 sets a day at home when they are not in the clinic (other 5 days a week). The home program will be followed by the exercise daily form.
88993925|NCT04692727|Experimental|McConnell patellar taping grup|McConnell patellar taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group. The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
88993926|NCT04692727|Experimental|Femoral rotational taping grup|Femoral lateral rotation taping technique will be applied using a rigid tape in addition to the exercise program applied to the exercise group.The tape will remain in the body for a maximum of 48 hours and will be renewed by the same physiotherapist in each session.
88993927|NCT00526981|Experimental|Treatment|Prone position + all conventional treatment.
88993928|NCT00526981|No Intervention|Control|Conventional treatment
88993929|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort A|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
88993930|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort B|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
89656292|NCT01676675|Experimental|30μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
89656293|NCT01676675|Placebo Comparator|0/0.5ml in adolescents (12-17 years old)|0/0.5ml placebo in 30 adolescents aged 12-17 years old on day 0, 21
89656294|NCT01676675|Placebo Comparator|0/0.5ml in adults(18-60 years old)|0/0.5ml placebo in 30 adults aged 18-60 years old on day 0, 21
89656295|NCT03019731|Experimental|Children with Tourette syndrome|Eligible children, between ages 7-13 years, with the diagnosis of Tourette syndrome or chronic motor/vocal tic disorder will be recruited from the Tourette Syndrome Clinics at Johns Hopkins (Dr. Singer). The Johns Hopkins Center has been acclaimed a Center of Excellence by the Tourette Association of America. This center currently follows more than 1,000 tic patients and averages 4-6 new referrals and 4 follow up patients weekly. Children will be randomly assigned to either the Therapist-directed Behavioral Therapy group or the Home-based DVD therapy group.
89656296|NCT00964353|Active Comparator|Clinically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on clinical data algorithms
89656297|NCT00964353|Experimental|Pharmacogenetically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.
89656298|NCT05480826|Other|Patients|"Subject suffering from (according to DSM IV criteria)~bipolar disorder~unipolar depression~schizophrenia~autism spectrum disorder~Collection of hair follicle cells"
89656299|NCT05480826|Other|Relatives|"Relatives of enrolled patients suffering from psychiatric disorder.~test to detect psychiatric disorders~blood or saliva sampling for genomic DNA extraction~Collection of hair follicle cells"
89656300|NCT00964431|Experimental|Indomethacin Test (lower dose)|
89656301|NCT00964431|Experimental|Indomethacin Test (upper dose)|Single dose
89656302|NCT00964431|Active Comparator|Celecoxib 400 mg|
89656303|NCT00964431|Placebo Comparator|Placebo|
89656304|NCT04763525|Experimental|Intervention group Pythagorean Self-Awareness in patients with type 2 diabetes|N=21 patients with type 2 diabetes
89656305|NCT04763525|Experimental|Intervention group Pythagorean Self-Awareness for healthy individuals|N=27 healthy individuals
89656306|NCT00966849|Experimental|Conditional Cash Transfer|Vulnerable households in this arm will receive conditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
89656307|NCT00966849|Experimental|Unconditional Cash Transfer|Vulnerable households in this arm will receive unconditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
89656308|NCT00966849|Other|Control|Vulnerable households in this arm will not receive cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
89656309|NCT05475054||Open liver resection|Non-obese or obese patients that underwent an open liver resection for all indications
89656310|NCT05475054||Minimally invasive liver resection|Non-obese or obese patients that underwent a minimally invasive liver resection for all indications
89656311|NCT04763369|Experimental|Sub-tenon injection group|In total twenty five subjects will be treated by injecting UMSCs in sub-tenon space of eye.
89656312|NCT04763369|Experimental|Suprachoroidal injection group|A total of twenty five subjects will be treated by suprachoroidal injection of UMSCs.
89656313|NCT03019419|Experimental|Perampanel 4mg|Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks
89656314|NCT03019419|Experimental|Perampanel 8mg|Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks
89656315|NCT03019419|Placebo Comparator|Placebo|Once daily placebo for control for 48 weeks
89656316|NCT01017003|Experimental|1|0.6mg colchicine tablet
89656317|NCT01017003|Experimental|2|colchicine 0.6mg q12 hours for 10 days
89656318|NCT04956900|Experimental|Aurase wound gel X0|Cohort 1: Aurase wound gel x0 dose concentration
89656319|NCT04956900|Experimental|Aurase wound gel X1|Cohort 2: Aurase wound gel x1 dose concentration
89656320|NCT04956900|Experimental|Aurase wound gel X1.8|Cohort 3: Aurase wound gel X1.8 dose concentration
89656321|NCT04956900|Experimental|Aurase wound gel X5|Cohort 4: Aurase wound gel X5 dose concentration
89656322|NCT04956900|Experimental|Aurase wound gel X9|Cohort 5: Aurase wound gel X9 dose concentration
89656323|NCT03793907|Active Comparator|Cohort 2 (walking program)|Patients receive a Fitbit to track their physical activity, and complete an unsupervised walking program daily at home, increasing physical activity stepwise weekly, for 6 months.
89656324|NCT03793907|Experimental|Cohort 1 (strength training)|Patients receive a Fitbit to track their physical activity, and complete an in-person personalized and supervised full-body strength training program over 1 hour BID up to 52 sessions for 6 months.
89656325|NCT01017237|Active Comparator|Dex plus midazolam|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
89656326|NCT01017237|Active Comparator|Dex plus midazolam and ketamine|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.
89656327|NCT01390415||Losartan 50 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 50 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
89656328|NCT01390415||Losartan 100 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 100 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
89656329|NCT04442412|Experimental|Arm B (Experimental):|"Patients randomized to Arm B will receive a prephase with oral prednisone and a prephase therapy with VitD according to the below reported schedule followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.~Schedule for VitD supplementation: 25,000 U/day starting on day -6:~daily loading dose for 7 days if 25 VitD baseline level 20-40 ng/ml daily loading dose for 14 days if 25 VitD baseline level < 20 ng/ml followed by weekly maintenance supplementation of 25,000 U for the entire duration of immunochemotherapy (6 courses every 21 days - 18 weeks), regardless of the baseline level of 25 VitD."
89656330|NCT04442412|Other|Arm A (Standard arm)|"Patients randomized to Arm A will receive a prephase with oral prednisone followed by 6 courses of R-CHOP or R-miniCHOP every 21 days.~If patients randomized to arm A are already on VitD, they are allowed to continue receiving VitD supplementation at a dose that can be considered part of the standard of care and does not exceed the maximum standard VitD dose recommended for general adult and elderly population , up to 10,000 U/week VitD"
89656331|NCT01018095|Active Comparator|Single dose|Metronidazole 2 gm single dose
89656332|NCT01018095|Active Comparator|7 day dose|Metronidazole 500 mg dose x 7 days
89656333|NCT03788759|Experimental|Experimental group|25 subjects will be randomized to 100mg of alpha-lipoic acid.
89656334|NCT03788759|Placebo Comparator|Placebo group|25 subjects will be randomized to placebo.
89656335|NCT03785561||Exposed (intervention) group|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital.
89656336|NCT03785561||Unexposed (comparator) group|The unexposed group is defined as patients, diagnosed with a musculoskeletal disorder receiving standard clinical care at the outpatient osteoarthritis clinic at Bispebjerg and Frederiksberg Hospital. They are not currently enrolled in a health research study concerning their musculoskeletal disorder at Bispebjerg and Frederiksberg Hospital
89656337|NCT00967473|Experimental|Toric Intraocular Lens|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Models SN60T9/SN60T8
89656338|NCT03783533|Experimental|Adolescent Target Users of Behavioral Activation (BA) App|Adolescents with PHQ-9 scores between 5 and 12 (Mild Range) who do not report current suicidality (Pine et al., 1999) will be recruited from clinician target users' practice settings. The investigators will recruit new adolescents for each Aim to decrease bias in feedback and outcomes.
89656339|NCT05724342||rhTNK-tPA Thrombolysis|
89656340|NCT00967551|Active Comparator|Micronutrient Sprinkles without zinc|Micronutrient sprinkles without zinc
89656341|NCT00967551|Experimental|Micronutrient sprinkles with zinc|Micronutrient sprinkles with zinc gluconate
89656342|NCT01020591|Active Comparator|Osteopathic evaluation|osteopathic evaluation of motion and tissue mobility
89656343|NCT01020591|Experimental|Osteopathic evaluation with treatment|osteopathic evaluation of motion and tissue mobility followed by osteopathic manual therapy release of the tight or restricted tissues
89656344|NCT03778073|Experimental|Cohort A|Cosibelimab (TG-1501) single-agent
89656345|NCT03778073|Experimental|Cohort B|Cosibelimab + Ublituximab + Bendamustine combination
89656346|NCT03778073|Experimental|Cohort C|Cosibelimab + Ublituximab + Bendamustine combination
89656347|NCT00967941||Ancef|
89656348|NCT00967941||Vancomycin and Cefazolin|
89656349|NCT00967941||Daptomycin and Cefazolin|
89656350|NCT04403945||Group 1|healthy volunteers with normal fasting blood glucose and HbA1c, without hypertension, kidney diseases, or taking drugs that affects microcirculation
89656351|NCT04403945||Group 2|type 2 diabetic patients without microvascular complications like Diabetic nephropathy, diabetic retinopathy, diabetic foot or diabetic peripheral neuropathy
89656352|NCT04403945||Group 3|type 2 diabetic patients with diabetic nephropathy diagnosed by clinic or pathology.
89656353|NCT00968019||Presillion stent|Patients treated with the Presillion stent in up to two de novo coronary artery lesions
89656354|NCT01368185||All Participants|Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
89656355|NCT00969501|Experimental|EUFLEXXA|ACTIVE CONTROL
89656356|NCT03774407|Other|urogenital symptoms|To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
89656357|NCT03774407|Experimental|remyelination|To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
89656358|NCT05395845|Experimental|value of platlet rich plasma|
89656359|NCT02981667||Active men and women|Healthy, active men and women ages 18-45 yr completed 1 bout of high intensity interval training and moderate intensity continuous training in a randomized, crossover design.
89656360|NCT03064698||Normal second trimester Doppler|This group consists of women who had normal doppler ultrasound results at second trimester
89046705|NCT01784133|Active Comparator|omiganan high dose|omiganan high dose once daily application for 12 weeks
89656361|NCT03064698||Abnormal second trimester Doppler|This group consists of women who had abnormal doppler ultrasound results at second trimester
89656362|NCT00970203|Experimental|Cohort A|"3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
89656363|NCT00970203|Experimental|Cohort B|"3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
89656364|NCT00971295|Experimental|Treatment Sequence A|Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
89656365|NCT00971295|Experimental|Treatment Sequence B|Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
89656366|NCT03064464||CA-MRSA infection|None intervention
89656367|NCT03064464||HA-MRSA infection|None intervention
89656368|NCT03064464||CA-MSSA infection|None intervention
89656369|NCT00954681|Experimental|quetiapine treatment|Open label treatment with quetiapine
89656370|NCT05395611||Lung cancer|"Patients with primary non small cell lung cancer listed for tumor resection. EBP, plasma and lung tumor tissue will be collected for protein profiling.~Collection of EBP will be done at 2 time points before and after surgery. Collection of plasma will be done at 2 time points before and after surgery. Collection of lung/tumor tissue will be done at the time of surgery"
89656371|NCT05395611||Control|Patients without lung cancer matched according to age and smoking history (control cohort) Collection of EBP will be done at one time point. Collection of plasma will be done at one time point.
89656372|NCT05704452||Patient group|who diagnosed with dementia
89656373|NCT05704452||Control group|who diagnosed as healthy (don't have dementia)
89656374|NCT05395455|No Intervention|Periodontally Healthy|Systemically and periodontally healthy
89656375|NCT05395455|Active Comparator|Stage III Grade B Periodontitis|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
89656376|NCT05395455|Active Comparator|Stage III Grade C Periodontitis|The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
89656377|NCT03064620||Israel PCV13|Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
89656378|NCT03064620||East Jerusalem PCV13|Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
89656379|NCT03064620||Palestine PCV7 PCV10|Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.
89656380|NCT05395377|Active Comparator|Registered Dietitian/Nutritionist|
89656381|NCT05395377|Active Comparator|DPP Group Classes|
89656382|NCT05395377|Active Comparator|Weight Watchers, Reimagined|
89656383|NCT05395377|Active Comparator|Pharmacological Treatment|
89656384|NCT05395377|Active Comparator|Bariatric Surgery Evaluation|
89656385|NCT03064776|Experimental|m-RESIST Patients|"m-RESIST is a system designed to improve illness self-management and facilitate recovery in individuals with Treatment-resistant schizophrenia (TRS). The system will be used to~Continuously capture multidimensional behaviour as it occurs in real-time and in real-world environments, using continuous collection and analysis of sensor data.~Detect individual early warning signs, and trigger targeted interventions that may mitigate the severity of worsening or prevent their recurrence altogether, using the clinical decision support system (CDSS) and Recommender operation.~The m-RESIST will deliver both system initiated (i.e. pre-programmed) and patient-initiated (i.e. on-demand) real-time assessments, to the participants and in their own environment."
89656386|NCT03064776|Experimental|m-RESIST Caregivers|m-RESIST is a system designed to improve illness self-knowledge and facilitate the involvement of caregivers in treatment of individuals with treatment-resistant schizophrenia.
89656387|NCT02980263|Experimental|Kawasaki patients|
89656388|NCT00971841|Experimental|Paclitaxel|One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.
89656389|NCT03019263|Experimental|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
88993931|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort C|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
88993932|NCT00527020|Experimental|Part B: Subjects in 5 period crossover period|Eligible subjects (first 14 subjects) will be randomized to one of the following 14 sequences as a 5 period crossover with sequences; LMNOQ, MNOLQ, NOLMQ, OLMNQ, ONMLQ, NMLOQ, MLONQ, LONMQ, LNMOQ, NMOLQM MOLNQ, OLNMQ, OMNLQ and MNLOQ) (L= 80 milligrams GSK1018921 given in fasted state, M= 200 milligrams GSK1018921 given in fasted state, N= nicotine lozenge, O= placebo and Q= 80 milligrams GSK1018921 in fed state).
88993933|NCT00527020|Experimental|Part B: Subjects in 4 period crossover period|Eligible subjects (last 7 subjects) will be randomized to one of the following 7 sequences as a 4 period crossover with sequences; NLOM, LOMN, OLNM, LNMO, NMOL, MOLN, and MNLO.
88993934|NCT00407277|Experimental|1A|
88993935|NCT00407277|Placebo Comparator|1B|
89656390|NCT03019263|Active Comparator|Control|Nutritional counseling
89656391|NCT02246049|Experimental|FOLFOXIRI plus bevacizumab|"Induction therapy is followed by the maintenance therapy.~[Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~[Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks."
89656392|NCT05409768|Experimental|Short axis, out of plane approach|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein with a short axis out of the plane method
89656393|NCT05409768|Experimental|Short axis, anteroposterior in plane approach|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein with an anteroposterior short axis in-plane method
89656394|NCT05395143|Experimental|Atorvastatin and zinc|46 Hyperlipidemic patients are included in this arm who will receive Atorvastatin and Zinc. Zinc tablets of 30mg will be used once daily according to randomization along with Atorvastatin.
89656395|NCT05395143|Placebo Comparator|Atorvastatin and placebo|46 Hyperlipidemic patients are included in this arm who will receive Atorvastatin and placebo. Placebo tablets of 30mg will be used once daily according to randomization along with Atorvastatin.
89656396|NCT00972621|Experimental|Vitrax II|Investigational dispersive viscoelastic
89656397|NCT00972621|Active Comparator|Viscoat|Marketed control dispersive viscoelastic
89656398|NCT03018951||Tool Development Stage|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
88993936|NCT00407277|Experimental|2A|
89656399|NCT03018951||Pilot Test 1|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
89656400|NCT03018951||Pilot Test 2|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
89656401|NCT00954993|Experimental|Vaniprevir 600 mg - 300 mg|For each participant in period 1, 600 mg of Vaniprevir was taken twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg was taken on Day 4. Period 1 was followed by a minimum 30-day, up to approximately 140 day, washout interval. In period 2, 300 mg of Vaniprevir was taken twice daily by each participant on Days 1-3 and a single dose of Vaniprevir 300 mg was taken on Day 4.
89656402|NCT02159703|Experimental|Single Arm Phase 2|
89656403|NCT05394753|Experimental|Unified Protocol|8-session group-based intervention
89656404|NCT05394753|No Intervention|Wait-list control|Participants in the wait-list control group will receive the same program, two months after their counterparts in the experimental group completed the intervention.
89656405|NCT05394597|Experimental|Treatment group|Receives a dose of repellent on the lower portion of the leg that is exposed
89656406|NCT05394597|No Intervention|Control group|Does not receive a dose of repellent, but subject to similar exposure period
89656407|NCT02159859|Experimental|Ertapenem|Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session
89656408|NCT00974493|Active Comparator|Oral antibiotics|
88993937|NCT00527059|Experimental|1|patients with acute heart failure
88993938|NCT00527059|Active Comparator|2|standard therapy for heart failure
88993939|NCT04693078|Experimental|Intervention Arm|Consecutive patients undergoing screening or surveillance colonoscopy in whom a new polyp detection system based on deep learning will be used during the procedure.
88993940|NCT03156452|Experimental|Steroid & Mycophenolate mofetil 1st line|Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
89656409|NCT00974493|Active Comparator|Intravenous antibiotics|
89656410|NCT05366634|Experimental|Cohort 1|Single injection of MDK-703 (dose level 1) or matching placebo
89656411|NCT05366634|Experimental|Cohort 2|Single injection of MDK-703 (dose level 2) or matching placebo
89656412|NCT05366634|Experimental|Cohort 3|Single injection of MDK-703 (dose level 3) or matching placebo
89656413|NCT04445454|Experimental|MSC therapy for severe COVID-19 infection|After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.
89656414|NCT03018873|Experimental|long-term RIPC group|"routine treatment + interventions interventions: once preoperative RIPC and once RIPC/day after PCI for one year. Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention(PCI).~Once RIPC/day after PCI for one year:Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg."
89656415|NCT03018873|Active Comparator|preoperative RIPC group|routine treatment + Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention.
89656416|NCT03018873|No Intervention|control group|routine treatment, no RIPC
89656417|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|
89656418|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|
89656419|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|
89656420|NCT02083679|Experimental|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|
89656421|NCT01672710|Experimental|regimen of niacin, exercise, sauna,|4-5 week daily sauna, exercise and niacin with other supplements
89656422|NCT01672710|Other|waitlist|4 week waitlist with treatment as usual
89656423|NCT04763213||Invasive treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
89656424|NCT04763213||Medically treatment|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
88993941|NCT03156452|Active Comparator|Prednisolone (Steroid) alone 1st line|Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
88993942|NCT00525772|Active Comparator|1|ciclesonide 50 and 200ug
88993943|NCT00525772|Active Comparator|2|ciclesonide 100ug and 400ug
88993944|NCT00525811|Experimental|A|Interactive decision aid
88993945|NCT00525811|Active Comparator|B|Regular patient information
89656425|NCT03766763|Experimental|ARM A VENETOCLAX|VENETOCLAX
89656426|NCT03064386|Experimental|plate group|internal fixation with the plate
89656427|NCT03064386|Experimental|screw group|internal fixation with the screw
89656428|NCT03065478||Colon carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy."
89656429|NCT03065478||Mamma carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen."
89656430|NCT03065634|Experimental|Manualized RELIANCE intervention|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
89656431|NCT03065634|Active Comparator|Non-manualized socio-legal counseling|two socio-legal counseling sessions delivered by a social worker
89656432|NCT03761381||Early Dementia|This group will consist of adults with suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in one study visit.
89656433|NCT03761381||Dementia-Free Controls|This group will consist of adults without suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in one study visit.
89656434|NCT03065322||Women with PCOS|Women with confirmed diagnosis of PCOS, based on the Rotterdam Criteria. To assess risk of OSA: the risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed.
89656435|NCT03760601|No Intervention|Baseline phase ('A')|Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
89656436|NCT03760601|Experimental|Intervention phase ('B')|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task selfguided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
89656437|NCT03065010|Other|BCD-115 in dose escalation regimen|BCD-115 will be administered p.o. with intrapatient dose escalation in the population of patients with ER(+) HER2(-) advanced breast cancer in combination with a standard dose of endocrine therapy.
89656438|NCT03019341||Patients with enhanced CT scan|Patients undergo CT examination after the administration of non-ionic contrast media for clinical need.
89656439|NCT04790448|Experimental|VIC regimen|"Patients will receive VIC regimen every 2 weeks:~Cetuximab 500mg/m2 IV on Day 1; Irinotecan 180mg/m2 IV on Day 1 (If patient carries UGT*28 7/7 or UGT*6 A/A or UGT*28 6/7 and UGT*6 A/G variants, use Irinotecan IV 150mg/m2 instead); Vemurafenib PO BID on Days 1 to 14 (Dosage: 480mg; 720mg; 960mg, determined by the maximum tolerated dose (MTD) in Phase Ia trial)."
89656440|NCT03756389|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.
89656441|NCT03756389|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.
89656442|NCT03064230||Athletes agonists (Experimental Group)|"I) age between 14 and 40 years who met the definition of competitive sports athletes adopted by the Italian Ministry of Health II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy.~QoL questionnaire SF-12 and and a screening questionnaire were requested"
89656443|NCT03064230||women not agonists (Control Group)|"I) age between 14 and 40 years who did not met the definition of competitive sports athletes adopted by the Italian Ministry of Health; II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy. QoL questionnaire SF-12 and and a screening questionnaire were requested"
89656444|NCT03747809||Patients with CIEDs having Remote Monitoring|
89656445|NCT03747809||Patients with CIEDs having no Remote Monitoring|
89656446|NCT03743753|No Intervention|Control|The control group will receive the current standard educational information from the surgeon along with an information package.
89656447|NCT03743753|Experimental|Experimental|The experimental group will receive an additional educational session before their operation about what to expect during their reconstructive journey, in addition to the current standard educational information from the surgeon along with an information package.
89656448|NCT00976521|Experimental|Local infusion, thrombus aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
89656449|NCT00976521|Experimental|Local infusion, no aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
89656450|NCT00976521|Active Comparator|No local infusion, thrombus aspiration|No local infusion of abciximab, thrombus aspiration.
89656451|NCT00976521|Active Comparator|No local infusion, no aspiration|No local infusion abciximab and no thrombus aspiration
88993946|NCT00525850|Other|1|high saturated fat diet
88993947|NCT00525850|Other|2|low calorie low saturated fat low trans fat high fiber diet
88993948|NCT02945956|Placebo Comparator|Entecavir|Tablet with Entrcavir
88993949|NCT02945956|Experimental|Entecavir + Fuzheng Huayu|Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu
88993950|NCT04692610|Placebo Comparator|Group A|Postoperative Education Group received stoma education and stoma care after surgery beginning from the postoperative day-1. In the preoperative period they were informed about stoma and stoma sites were marked.
88993951|NCT04692610|Active Comparator|Group B|Pre- and Postoperative Education Group received stoma education both before surgery and on the postoperative day-1. They received stoma care postoperatively as usual. In the preoperative period they were also informed about stoma and stoma sites were marked.
88993952|NCT04692610|Experimental|Group C|Prehabilitation Group received the same protocol as Group B, however in addition they were prehabilitated with a water-filled stoma pouch (250 ml) 48 hours before surgery. These pouches were not removed until surgery, and EST nurse preoperatively taught the patients how to manage the stoma pouch with similar standards as the usual postoperative stoma-care.
88993953|NCT04692454|Experimental|the scalp and ear acupuncture|CHIAN HUEI ACUPUNCTURE NEEDLE
89656452|NCT05311332|Experimental|Anterior maxillary bone augmentation using computer guided autogenous cortical shell technique.|a patient-specific guide was used to harvest a chin cortical shell which was also prepared and positioned at the (anterior horizontally atrophied maxilla) recipient site using another patient-specific positioning guide.
89656453|NCT05311332|Active Comparator|Anterior maxilla bone augmentation using free hand autogenous cortical shell technique.|the horizontally atrophic anterior maxilla was augmented with a cortical shell technique the bone was harvested from the chin without a patient-specific guide.
89656454|NCT04410588|No Intervention|saline|saline for pain for nasal packing
89656455|NCT04410588|Active Comparator|levobupivacaine|levobupivacaine for pain of nasal packing
89656456|NCT04410588|Active Comparator|fentanyl +levobupivacaine|fentanyle with levobupivacaine for pain of nasal packing
89656457|NCT05394129||SurePath™|"The subjects are randomly assigned to SurePath™/Conventional test group at a ratio of 1:1.~In SurePath™ group, subjects who underwent SurePath™ liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
89656458|NCT05394129||Conventional|"The subjects are randomly assigned to SurePath™/Conventional test group at a ratio of 1:1.~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePath™ liquid cell test with the second obtained sample."
89656459|NCT05303220|Experimental|Part 1 Treatment A|
89656460|NCT05303220|Experimental|Part 1 Treatment B|
89656461|NCT05303220|Experimental|Part 1 Treatment C|
89656462|NCT05303220|Experimental|Part 1 Treatment D|
89656463|NCT05303220|Experimental|Part 2 Treatment A|
89656464|NCT05303220|Experimental|Part 2 Treatment B|
89656465|NCT05303220|Experimental|Part 2 Treatment C|
89656466|NCT05303220|Experimental|Part 3 Treatment A|
89656467|NCT05303220|Placebo Comparator|Part 3 Treatment B|
89656468|NCT04444830|No Intervention|Standard|"To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed a standard postoperative regimen of Acetaminophen 650 mg PO q 6-8 hours + Ibuprofen 600 mg PO q 6-8 hours + rescue narcotics (Oxycodone 5-10 mg PO q 4-6 hours or if allergic to Oxycodone, Norco 5-10mg/325mg PO q 4-6 hours) for breakthrough pain"
89213393|NCT02580071|Experimental|Sheng-Yu-Tang|"Treatment group will receive standard of care, as well as:~2-3 months post-HSCT, patients will be administered the herbal formula Sheng-Yu-Tang (聖愈湯), which they will receive for 6 months. The herbal formula will be provided from a GMP herbal company and will be given in granulated form."
89213394|NCT02580071|No Intervention|Control|Control group will receive standard of care
89656469|NCT04444830|Experimental|Sprix|To compare the total amount of opioid consumption, as measured by morphine mEq, consumed in patients immediately postoperative from minimally invasive female pelvic reconstructive surgery - they will be prescribed regimen of Sprix 30.5mg Intranasal q 6-8 hour up to 4 times daily + Acetaminophen 650 mg PO q 6- 8 hours + rescue narcotics (as above) for breakthrough pain during the day of surgery and the following 4 postoperative days.
89656470|NCT01273259|Experimental|200 mg /day arm|
89656471|NCT01273259|Experimental|25 mg/day arm|
89656472|NCT05273580||Patients|Eligible patients will be identified by the Nurse Practitioner Cancer & Palliative Care.
89656473|NCT05273580||Carers|The respective carers who are identified by the Nurse Practitioner Cancer & Palliative Care as eligible participants.
89656474|NCT03738917|Active Comparator|Dextromethorphan|Usual clinical practice + dextromethorphan (15 milligrams unit), one 15 mg-tablet t.i.d. up to a maximum of 14 days.
89656475|NCT03738917|Active Comparator|Ipratropium|Usual clinical practice + ipratropium bromide 20Micrograms Inhaler each puff), 2 puffs t.i.d. up to a maximum of 14 days.
89656476|NCT03738917|Active Comparator|Honey|Usual clinical practice + Honey 30 g (full tablespoon) t.i.d. up to a maximum of 14 days. Patients will be given two 750 milligram bottles of wildflower honey (the most frequent type of honey used in our country) and patients will be recommended to add the honey to a cup of lemon or thyme juice, milk herbal tea, yogurt, as a hot toddy, etc.
89656477|NCT03738917|Placebo Comparator|Usual clinical practice|Usual care.
89656478|NCT02984813|Experimental|GlaucoHealth|2 pills once daily in the morning for 3 months
89656479|NCT02984813|Experimental|GlaucoSelect|2 pills once daily in the morning for 3 months
89656480|NCT02984813|Placebo Comparator|Placebo|2 pills once daily in the morning for 3 months
89213395|NCT01005225||Solid tumors|Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
89656481|NCT00976599|Experimental|CP-690,550 + methotrexate|
89656482|NCT00976599|Placebo Comparator|Placebo + methotrexate|
88993954|NCT00527137|Active Comparator|rHuEPO|
88993955|NCT00527137|Experimental|darbepoetin alfa|
89656483|NCT02630472|Experimental|Quinine Sulfate|"Each study participant randomized into the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes. Patients will apply 3 mls of quinine sulfate to each nostril twice per day. Thus the patients will be exposed to a maximum of 12mls or 12.0 mg of quinine per day.~The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application to the subject. The application of the solution is exactly the same as if the study subject were to irrigate with regular saline as part of their daily regimen for chronic rhinosinusitis."
89656484|NCT02630472|Placebo Comparator|Placebo|"The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production.~Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes.~The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials."
89656485|NCT05264922|Active Comparator|Fibrin Glue|Single 4 milliliter (mL) injection of 0.9% normal saline and fibrin glue solution
89656486|NCT05264922|Experimental|SVF cells and Fibrin Glue|Nucleated adipose-derived cells loaded in a fibrin glue scaffold
89656487|NCT03727451|Experimental|PH-Pulmonary Fibrosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr~Part 2: Optional open label long term extension at the optimal dose as identified in Part 1"
89656488|NCT03727451|Experimental|PH-Sarcoidosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr~Part 2: Optional Open label long term extension at the optimal dose as identified in Part 1"
89656489|NCT00977769|Experimental|carbetocin 100 µg|Carbetocin injection, 100µg, single injection
89656490|NCT00977769|Active Comparator|oxytocin 5 u|Oxytocin 5U, injection, single injection
89656491|NCT00977769|Placebo Comparator|placebo (NaCl)|Saline single injection
89656492|NCT03725501|Experimental|Ranibizumab + ALS-L1023 600mg|"ALS-L1023 600 mg - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
89656493|NCT03725501|Experimental|Ranibizumab + ALS-L1023 1200mg|"ALS-L1023 1200 mg - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
89656494|NCT03725501|Placebo Comparator|Ranibizumab + Placebo|"Placebo - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
89656495|NCT04443426|Experimental|Single dose oral 3-hydroxybutyrate monoester|Cross-over study in 8 patients receiving single-dose oral 3-hydroxybutyrate monoester, 3-OHB salt and placebo.
89656496|NCT04443426|Experimental|Single dose oral 3-hydroxybutyrate Salt|
89656497|NCT04443426|Placebo Comparator|Single dose oral placebo|maltodextrin-based, isocaloric to ketone dosis.
89656498|NCT04353141||Pregnant patients with confirmed COVID-19 infection|
89656499|NCT04353141||Pregnant patients symptomatic for COVID-19|Symptomatic patients suspicious for COVID-19 infection (swab is taken on admission)
89656500|NCT04353141||Pregnant patients asymptomatic for COVID19|Patients asymptomatic for COVID19 with other feto-maternal diseases or who come for delivery or caesarean section
89656501|NCT04348565|Experimental|Diabetes Care Programme|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who receive the intervention (Diabetes Care Programme) in addition to usual medical care at the GP
89656502|NCT04348565|No Intervention|Standard Usual Care|People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who only receive the usual medical care at the GP
89656503|NCT04443192|Active Comparator|Part A Cohort 1 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 1
89656504|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874 - Single Dose|Single oral dose of placebo by mouth in the fasted state
89656505|NCT04443192|Active Comparator|Part A Cohort 2 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 2
89656506|NCT04443192|Active Comparator|Part A Cohort 3 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 3
89656507|NCT04443192|Active Comparator|Part A Cohort 4 - ZF874|Single oral dose of ZF874 by mouth in the fasted state. Dose Level 4
89656508|NCT04443192|Placebo Comparator|Part A - Placebo to ZF874 - Two Doses|Two doses of placebo (12 h apart) by mouth in the fasted state
89656509|NCT04443192|Active Comparator|Part A Cohort 5 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 5
89656510|NCT04443192|Active Comparator|Part A Cohort 6 - ZF874 - Two Doses|Two doses of ZF874 (12 h apart) by mouth in the fasted state. Dose Level 6
89656511|NCT04443192|Active Comparator|Part A Cohort 7 - ZF874 - Single Dose|Single oral dose of ZF874 by mouth after consuming a high-fat breakfast. Dose Level 3
89656512|NCT04443192|Active Comparator|Part B Cohort 1 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
89656513|NCT04443192|Placebo Comparator|Part B Cohort 1 - Placebo to ZF874|Two doses of placebo (12 h apart) by mouth daily for 28 days.
89656514|NCT04443192|Active Comparator|Part B Cohort 2 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
89656515|NCT04443192|Active Comparator|Part B Cohort 3 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
89656516|NCT04443192|Active Comparator|Part B Cohort 4 - ZF874|Two doses of ZF874 (12 h apart) by mouth daily for 28 days.
89656517|NCT03724487|Experimental|Coachman|The first study condition, A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement (COACHMAN) will be exposed to three Technology-based Interventions (TBI) accessible via smartphone and counseling from a local community nurse organization for hypertension self-management support.
89656518|NCT03724487|Experimental|Enhanced Usual Care|The second study condition, Enhanced Usual Care (EUC) will be exposed to routine and standard hypertension education materials and one session on self-monitoring blood pressure.
89656519|NCT00979017|Experimental|Avastin in combination with temozolomide and irinotecan|Avastin 10 mg/kg every 14 days. Temozolomide 200 mg/m2 daily x 5 days in a 28-day cycle. Irinotecan dose depends on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). EIAED 340 mg/m2 every other week and no EIAED 125 mg/m2 every other week. Irinotecan dose also depends on if the patient has the UGT 1A1 polymorphism (7/7). If so, they do not metabolize the irinotecan normally, so these patients will start out at a two dose level reduction. EIAED starting dose will be 275 mg/m2 and no EIAED starting dose will be 75 mg/ m2.
89656520|NCT03723005||Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
89656521|NCT03723005||Standard-of-Care Phototherapy|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
89656522|NCT01670526|Experimental|Rivastigmine|Rivastigmine transdermal patch
89656523|NCT01670526|Placebo Comparator|Placebo|Placebo
89656524|NCT03721913|Experimental|Intervention group|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
89656525|NCT03721913|No Intervention|Control group|The control group will not receive the intervention during the study.
89656526|NCT03018795|Active Comparator|Ozone Group|Decontamination of implant surfaces with saline irrigation and additional ozone therapy in combination with regenerative surgery
89656527|NCT03018795|Active Comparator|Control Group|Decontamination of implant surfaces with saline irrigation alone in combination with regenerative surgery
89656528|NCT05212038|Experimental|liopsoas plane block group|Arm Description: a iliopsoas plane block before surgery
89656529|NCT05212038|Sham Comparator|sham block group|sham block before surgery
89656530|NCT00945035|Active Comparator|A|Etoricoxib, 20% tablet
89656531|NCT00945035|Active Comparator|B|Etoricoxib, 30% tablet
89656532|NCT03018639||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
89656533|NCT04432740|Active Comparator|Below Arm Cast Group|All the patients were prepared in the supine position at the emergency department. For analgesia, we used the hematoma block technique with 3 cc of 2% prilocaine hydrochloride®. In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, the standard below arm cast was applied. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
89656534|NCT04432740|Active Comparator|Reverse Sugar Tong Group|In this group, after traction was applied using a finger-trap traction with a 4.5 kg weight for 5 minutes, sugar tong splint made of 12 layers of plaster was performed by one person. The reverse sugar tong splint succeeds as a classic sugar tong splint by stabilizing the volar and dorsal aspects of the wrist and forearm, maintaining the same degree of immobilization. The splint fold is located distally at the first web space of the hand, which does not immobilize the elbow. In all the groups, the wrist immobilization position was the same; pronated forearm, 15-20° wrist flexion, ulnar deviation, and care was taken not to immobilize the metacarpophalangeal joints. Patients were encouraged to actively move their fingers, ipsilateral shoulder, and elbow in all the groups. Both treatments lasted 5 or 6 weeks after at our clinic
89656535|NCT03720431|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
89656536|NCT05187156|Experimental|Intervention|Veterans will participate in a novel intervention to improve PTSD and social support
89656537|NCT05187156|Active Comparator|Treatment as usual|Veterans will participate in usual care in PCMHI
89656538|NCT05386953||Balanced group|Patients who received balanced crystalloids of lactated Ringer's solution or plasma solution during liver transplantation surgery
89656539|NCT05386953||Saline group|Patients who received only normal saline during liver transplantation surgery
89656540|NCT03719573|Experimental|Geriatric intervention|A comprehensive geriatric assessment and intervention, including exercise program.
89656541|NCT03719573|No Intervention|control.|Usual treatment and care.
89656542|NCT05176548||Group 1|Patients in whom Cardiac Amyloidosis is confirmed
89656543|NCT05176548||Group 2|Patients in whom Cardiac Amyloidosis is ruled out
89656544|NCT00979875|Experimental|Lispro+PH20, Lispro, Glulis+PH20, Glulis, Aspart+PH20, Aspart|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout.~Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart.~Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart.~Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart."
89656545|NCT03716531|Experimental|IORT|"IORT will be administered as determined to be best practice by the treating radiation oncologist,~Electron beam intraoperative radiation therapy will occur in a hybrid operating room with a portable linear accelerator"
89656546|NCT03714425|Active Comparator|High frequency device|Subjects will use high frequency Quell devices.
89656547|NCT03714425|Sham Comparator|Low frequency device|Subjects will use low frequency Quell devices.
89656548|NCT03710603|Active Comparator|Velcade Lenalidomide dexamethasone (VRd)|VRd: subjects will receive VRd for induction and consolidation, followed by lenalidomide (R) maintenance until disease progression or unacceptable toxicity.
89046706|NCT01784133|Placebo Comparator|Vehicle group|Vehicle once daily application for 12 weeks
89046707|NCT01784133|Active Comparator|omiganan low dose|omiganan low dose once daily application for 12 weeks
89046708|NCT04607252|Experimental|Metformin plus megestrol acetate|Metformin 1500mg per day plus megestrol acetate 160mg per day.
89046709|NCT04607252|Active Comparator|Megestrol acetate|Megestrol acetate 160mg per day.
89046710|NCT01782729|Experimental|Tacrolimus ointment (pediatric)|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
89521728|NCT03414073|Sham Comparator|Group B Phase 3|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group B will use the conventional finger flossing technique in the third phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
89656549|NCT03710603|Experimental|Daratumumab + VRd (D-VRd)|D-VRd: Subjects will receive D-VRd for induction and consolidation followed by daratumumab and lenalidomide maintenance until disease progression or unacceptable toxicity. Minimal residual disease (MRD)-negative subjects in Arm B will stop therapy with daratumumab after sustained MRD negativity for 12 months and after a minimum of 24 months of maintenance therapy. These subjects will continue lenalidomide maintenance therapy until disease progression or unacceptable toxicity. After stopping daratumumab therapy, subjects with sustained MRD negativity should restart therapy with daratumumab if there is a recurrence of MRD or a confirmed loss of Complete Response (CR) without International Myeloma Working Group (IMWG)-defined disease progression. After reinitiating daratumumab, the subject will continue daratumumab and lenalidomide therapy until disease progression or unacceptable toxicity.
89656550|NCT02630706|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
89656551|NCT02630706|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
89656552|NCT02630706|Placebo Comparator|Placebo|Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
89656553|NCT04763057|Experimental|indirect pulp treatment with NeoPUTTY MTA|
89656554|NCT04763057|Active Comparator|indirect pulp treatment with calcium hydroxide|
89656555|NCT03702179|Experimental|Durvalumab + Tremelimumab|"The treatment consisted of initial TUR of the tumor, with multiple random biopsies of normal-appearing bladder urothelium, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for a total of 3 doses.~Two weeks after the initiation of immunotherapy, normofractionated external-beam radiotherapy with high-energy photons will be started. Radiotherapy will be administered concurrently with immunotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder."
89656556|NCT03065166|Experimental|Raisin Treatment|3.2 ounces of dried Cabernet wine grapes.
89656557|NCT03065166|Other|Bagel Control|One 95g whole wheat bagel.
89656558|NCT03700931|Experimental|Eating recall condition|Participants receive a questionnaire asking them to write down what they ate the day before at breakfast, between breakfasts and lunch, at lunch, between lunch and dinner, at dinner, and after dinner, reporting for each episode the foods and drinks consumed, place, time of the day and people present (10).
89656559|NCT03700931|Active Comparator|Non-eating recall condition|Participants receive a questionnaire asking them to write down their school, homework (assignment), study, or work-related activities, two at morning, two at afternoon and two at night, of the day before reporting the name of each activity, place, time of the day and people present.
89656560|NCT03065088|Experimental|aLiFE|The aLiFE programme is developed for young older adults, where balance activities, strengthening activities, and specific recommendations for increasing physical activity, are embedded within everyday activities, so that the activities can be performed multiple times throughout the day. The programme is presented by an instructor by use of a paper based manual during a 6 month intervention period in participants homes.
89656561|NCT03065088|Experimental|eLiFE|The aLiFE programme is transferred to a mobile health system, called the eLiFE. The intervention is delivered on smartphones and smartwatches including inertial sensors well suited to monitor physical activity and movement quality in daily life. An instructor teaches the participants how to use the mobile health system during home visits and phone calls during the 6 month intervention period. A virtual instructor teaches the participants the eLiFE programme. Pictures and videos of the aLiFE activities are delivered by use of the system. Behavioural change strategies are also included in the system.
89656562|NCT03065088|Active Comparator|control|The control group follows the World Health Organization's recommendations of physical activity.
89656563|NCT01677143|Active Comparator|bupivacaine|Injection of 5 ml bupivacaine, 5mg/ml in each port site.
89656564|NCT01677143|Placebo Comparator|Placebo|Injection of 5 ml saline in each port site.
89656565|NCT03693365||Patients undergoing surgeries|"Patients undergoing surgery with general anesthesia and controlled mechanical ventilation with indication of invasive arterial blood pressure.~Classification ASA 2-4"
89656566|NCT03692663|Experimental|TABP EIC treatment group|Drug: TABP EIC Experimental Interventional Therapy
89656567|NCT02084069|Active Comparator|Treatment|Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
89656568|NCT02084069|Placebo Comparator|Control|Placebo
89656569|NCT03691961|Experimental|Medium dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥400 to 800 µg budesonide of budesonide/formoterol Symbicort Turbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
89656570|NCT03691961|Experimental|High dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥800 µg budesonide of budesonide/formoterol Symbicort TurbuhalerTurbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
89656571|NCT05117112|Experimental|10g of nutritional product|All subjects will ingest 10g of a commercially available nutritional supplement one time during a study visit.
89656572|NCT04438356|Experimental|M-health|After the acute myocardial infarction, patients will be randomly assigned to the intervention group. Give the intervention group mobile health care programs and given Garmin monitoring hands ring. In order to give patients clear walking goals and exercise intensity, the intervention group will use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
89656573|NCT04438356|Experimental|wait list control|wait list control for 3 months and then use the Mobile Health Medical Line app to remind patients of the walking frequency and time, and use Garmin monitoring bracelet to record the patient's daily walking steps. The Mobile Health Medical Line app content includes: 1. Encourage the walking exercise to perform 2. Give them knowledge about acute myocardial infarction 3. How to self-care themselves 4. How to release their anxiety?
89656574|NCT03682601|Placebo Comparator|Placebo|"15 postmenopausal women will apply a 1/2 inch strand of Placebo ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
89656575|NCT03682601|Active Comparator|5% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 5% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
89656576|NCT03682601|Active Comparator|10% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 10% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
89656577|NCT03681041||Pancreatic injury|Patient diagnosed with pancreatic trauma by surgery, computed tomography, Endoscopic retrograde cholangiopancreatography (ERCP) and Magnetic resonance cholangiopancreatography (MRCP) were included
89656578|NCT00981045|Experimental|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
89656579|NCT00981045|Active Comparator|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
89656580|NCT04432896|Experimental|New dietary protocol|Exclusion of food containing nickel (duration: 4 weeks) + gradual weekly reintroduction of food containing nickel (duration: 4 weeks) under the supervision of a trained dietician who monitors symptoms related to systemic nickel allergy syndrome.
89656581|NCT04432896|Active Comparator|Traditional dietary protocol|Exclusion of foods containing nickel without monitoring for symptoms related to systemic nickel allergy syndrome by a trained dietician.
89656582|NCT00981435|Experimental|Artificial Tears|Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
89656583|NCT00981435|Experimental|Non-steroidal anti-inflammatory|Topical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
89656584|NCT00981435|Experimental|Steroid|Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
89656585|NCT03063996|Other|Standard of Care (peripheral IV access)|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access.
89656586|NCT03063996|Active Comparator|Peripheral IJ access|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access and is randomized into the group that gets peripheral IJ access.
89656587|NCT00981669|Experimental|rotavirus vaccine|3 doses with 6 weeks interval
89656588|NCT00981669|Placebo Comparator|placebo|3 doses with 6 weeks interval
89656589|NCT03676673||ASD group|120 patients with clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
89656590|NCT03676673||Unaffected siblings of ASD|40 unaffected siblings of ASD probands
89656591|NCT03676673||TD group|40 healthy age/gender-matched TD controls according to age and neighborhood distribution of the ASD group after interviewed by the Chinese K-SADS-E-DSM-5
89656592|NCT03064308|No Intervention|Control|Participants will receive standard NHS care with no intervention.
89656593|NCT03064308|Other|Exercise|Participants will receive standard NHS care and complete the exercise programme, the intervention.
89656594|NCT00981825|Placebo Comparator|A|fluoride toothpaste control
89656595|NCT00981825|Active Comparator|B|triclosan/fluoride toothpaste
89656596|NCT00983307|Experimental|Erlotinib and radiotherapy|Patients will be treated with Erlotinib and hypofractionated radiotherapy.
89656597|NCT04762667|Experimental|Patients will undergo reverse shoulder arthroplasty with patient-specific instrumentation.|The patients underwent preoperative planning. A 3D model was made based on CT. The optimal position of the components of the endoprosthesis has been calculated. patient-specific instrumentation were created for each scapula and humerus using 3D modeling software. Individual guides use during operation for exact position of the components of the endoprosthesis.
89656598|NCT04762667|Other|Patients will undergo conventional reverse shoulder arthroplasty.|This group of patients was examined according to the standard method, Rg and CT of the shoulder joint were performed. According to the study, the sizes of the endoprosthesis were selected. Installation of the components of the endoprosthesis during the operation was carried out using standard (included in the set) guides. Orientation was performed according to the anatomical landmarks of the glenoid and the neck of the humerus, without taking into account the individual characteristics of the bones.
89656599|NCT05376735|Experimental|Purrble intervention + Single Session Intervention|"The Purrble intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~The Single Session Intervention has been co-produced with university students and clinical experts (Prof Jessica Schleider), combining the theories of emotion regulation with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~Initial guided reflection exercise~Short interactive psychoeducation~Personalised action plan~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
89656600|NCT05376735|No Intervention|Treatment as usual / Waiting list|Participants in the control group will be given a Purrble & access to the online SSI intervention before the academic term ends, after 4 week follow-up questionnaires are completed.
89656601|NCT04762745|Experimental|Phase I, Cohort 1|The combination of bendamustine, 60mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
89656602|NCT04762745|Experimental|Phase I, Cohort 2|The combination of bendamustine, 70mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
89656603|NCT04762745|Experimental|Phase I, Cohort 3|The combination of bendamustine, 80mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).
89656604|NCT04762745|Experimental|Phase II|The combination of MTD dosage of bendamustine with pomalidomide and dexamethasone will be administrated in an expanded relapsed or refractory multiple myeloma cohorts for 8 cycles, then under the combination of pomalidomide and dexamethasone as maintenance therapy until progression or intolerable toxicities.
89656605|NCT05373927||Study group 1|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication) or one leg in healthy volunteers (total 1 site)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
89656606|NCT05373927||Study group 2|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of the Musculus triceps surae of the affected leg in PAD patients in Fontaine stage II (intermittent claudication) or one leg in healthy volunteers (total 1 site)~Physical assessment: Pulse status / Color-Coded Duplex Sonography / Ankle-Brachial Index / 6-minute walk test (6MWT) / Continued heel raises for at least 30s"
89656607|NCT03673865|Experimental|Treatment Group|Patients undergo orbital reconstruction using pre-adjusted patient-specific orbital implants with office-based 3-dimensional printers (OB3DP)
89656608|NCT03673865|Active Comparator|Control Group|Patients undergo orbital reconstruction with non-patient-specific orbital implants (traditional approach, Control Group) which is a standard stock orbital plate
89656609|NCT03018561|Active Comparator|aged-gender matched healthy controls|Healthy subjects: with no MetS and no-documented coronary heart disease (CHD), both males and females, aged>18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living.
88993956|NCT02945839|Active Comparator|Acute Treatment+ED-initiated preventive medication +PMR|All subjects will be discharged on acute migraine therapy (naproxen, triptan) unless there is a contraindication and will also be started on topiramate (25mg/night) with a plan to increase the dose every week by 25 mg up to 100 mg/night. Subjects will receive medicine along with progressive muscle relaxation therapy
88993957|NCT02945839|Active Comparator|Enhanced Usual Care (EUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that they receive. All subjects will be asked to track headache frequency, intensity, and acute medication use on the APP.
89656610|NCT03018561|Experimental|patients with metabolic syndrome|Patients with MetS and no-documented CHD, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Metabolic syndrome (MetS) will be defined according to recent updated criteria (Alberti et al. 2005):presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l.
89656611|NCT03018561|Experimental|patients with coronary heart disease|CHD patients, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy).
89656612|NCT03018561|Experimental|patients with chronic heart failure|"Patients with documented stable chronic heart failure will be recruited if they show the following inclusion criteria:~≥18 years~Left ventricular ejection fraction (LVEF) <40% (measured within 6 months of their enrolment by a multigated acquisition Scan, echo or radiological ventriculography)~NYHA functional class I-III~Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).~Able to perform an symptom limited exercise test.~Capacity and willingness to sign the informed consent form."
89656613|NCT03018717|Other|Tele-monitoring Constant|To analyze the efficacy and cost-efficacy of incorporating tele-monitoring of bio-parameters into the shared comprehensive clinical care plan. Patients will receive in their home a kit consisting of a briefcase containing all equipment (scale, pulse-oximeter ... etc) and a logo access to devices (Tablet) through mobile communications m2m between patient and platform Management for Chronic Patients.
89656614|NCT03018717|Other|Standard clinical care|Standard clinical care plan shared between plan of attention to the patient with Pluri-pathological process and the care plan for patients with chronic diseases, based on a comprehensive clinical assistance shared between Primary Care and Hospital Care
89656615|NCT00983541|Experimental|All patients|All participants enrolled.
89656616|NCT03667703|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an equivalent volume (mL) of normal saline intravenously or Ora-plus orally based on weight and age.
89656617|NCT03667703|Active Comparator|Study Drug|Subjects randomized to study drug will receive famotidine, a histamine-2 receptor antagonist. Dosing will be weight based and age-dependent. Infants < 90 days old will receive either 0.5mg/kg intravenously daily or 0.5mg/kg orally twice a day of famotidine. Infants ≥ 90 days or older will receive 0.25mg/kg intravenously every 12 hours or 0.5mg/kg orally twice a day.
89656618|NCT00985257|Other|Subjects with diabetes|Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
89656619|NCT05208177|Experimental|SHR-1802 for injection combined with Camrelizumab for Injection and Famitinib Malate Capsules|
89656620|NCT03656705|Experimental|CCCR-NK92 cells immunotherapy|Preparation of CCCR-NK92 cells suspended in a saline and plasma solution.
89656621|NCT03018405|Experimental|Hematological tumors|The dose escalation arm for hematological tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort 10-11 (only in AML/MDS) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
89656622|NCT03018405|Experimental|Solid Tumors|The dose escalation arm for solid tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort cohort 8-9 ( only in CRC) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
89656623|NCT03018327||Case group|250 Renal Transplant Recipients; 125 women and 125 men
89656624|NCT03018327||Control group|250 healthy controls; 125 women and 125 men
89656625|NCT03740711|Experimental|Early LA venting|When detect B-line on serial lung ultrasound, we will perform early LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
89656626|NCT03740711|Active Comparator|Conventional LA venting|When detect refractory pulmonary congestion on chest radiograph or inadequate AV opening on serial echocardiography, we will perform LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
89656627|NCT03062904|Experimental|drug|
89656628|NCT03655067|Experimental|Intervention|The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
89656629|NCT03655067|No Intervention|Usual Care|Participants in the Usual Care group may undergo an evaluation with the Social Worker if the clinician determines that it is necessary. The participants in the Usual Care group will also receive motivational coaching with safety phone calls during weeks 1-6.
89656630|NCT00986583|Other|Statin use group|Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
89656631|NCT00986583|Other|non statin use|Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
89656632|NCT03649685|Active Comparator|Group1: rTMS(bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
89656633|NCT03649685|Experimental|Group2: rTMS(right DLPFC)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC once a day, 5 days/week, for 4 weeks.
89656634|NCT03649685|Experimental|Group3: rTMS(right DLPFC+bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC and bilateral SMA once a day, 5 days/week, for 4 weeks.
89656635|NCT03649685|Sham Comparator|Group4: shame rTMS|The sham rTMS will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
89656636|NCT05056974|Experimental|UB-421 + chidamide|UB-421 + chidamide combination therapy
89656637|NCT03643913|Active Comparator|Comparison group|"Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.~To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.~Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)"
89656638|NCT03643913|Experimental|Deep group|Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)
89656639|NCT04762511|Experimental|HSV lower dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV lower dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
89656640|NCT04762511|Placebo Comparator|Placebo Step 1 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
89656641|NCT04762511|Experimental|HSV low dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV low dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
89656642|NCT04762511|Placebo Comparator|Placebo Step 2 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
89656643|NCT04762511|Experimental|HSV medium dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV medium dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
89656644|NCT04762511|Placebo Comparator|Placebo Step 3 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
89656645|NCT04762511|Experimental|HSV high dose formulation Group|Healthy participants, 18 to 40 years of age, receive two doses of the HSV high dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
89656646|NCT04762511|Placebo Comparator|Placebo Step 4 Group|Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
89656647|NCT04762901|Experimental|Stage 1 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles, followed by AC IV every 21 days
89656648|NCT04762901|Experimental|Stage 1 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
89656649|NCT04762901|Experimental|Stage 1 Arm 3|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, 15, and 22 every 28 days
89656650|NCT04762901|Experimental|Stage 1 Arm 4|Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, and 15 every 21 days and carboplatin IV every 21 days
89656651|NCT04762901|Experimental|Stage 2 Arm 1|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles
89656652|NCT04762901|Experimental|Stage 2 Arm 2|Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
89656653|NCT00988143|Experimental|Study Group 1|Participants will receive the 2009-2010 Trivalent Influenza Vaccine (TIV) (Pediatric dose have no preservatives)
89656654|NCT00988143|Active Comparator|Study Group 2|Participants will receive the 2008-2009 Trivalent Influenza Vaccine (TIV)
89656655|NCT00988143|Active Comparator|Study Group 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV)
89656656|NCT03642119||iButton® Validation in Perimenopause|Women in the late phase of perimenopause (based on the STRAW+10 criteria).
89656657|NCT03063840|Experimental|Microwave ablation (MWA)|Microwave ablation (MWA)
89656658|NCT03018093|Experimental|C-CAR011|In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
89656659|NCT03018171|Experimental|SC|this arm will receive intrathecal clonidine addiction to sufentanil during combined spinal epidural analgesia for labor
88993958|NCT02957786|Experimental|Cytisine plus behavioural support|"12-week course of cytisine capsules (1.5mg), with a decreasing dosing regimen (9mg/day for days 1-3, 7.5mg/day for days 4-12, 6mg/day for days 13-16, 4.5mg/day for days 17-20, 3.0mg/day from days 21-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
89656660|NCT03018171|Active Comparator|S|this arm will receive intrathecal sufentanil during combined spinal epidural analgesia for labor
89656661|NCT02160873|Experimental|chocolate milk|In this arm, subjects receive chocolate milk
89656662|NCT02160873|Placebo Comparator|flavor-matched placebo|In this arm, subjects receive a flavor-matched placebo
89656663|NCT03636035|Experimental|Tregocel® supplementation|Tregocel® coated tablets (2/day) orally for 36 weeks
89656664|NCT03018483|Experimental|Variable PSV|
89656665|NCT03018483|Active Comparator|Conventional PSV|
89656666|NCT03018483|Active Comparator|Automated PSV|
89656667|NCT03018483|Active Comparator|NAVA|
89656668|NCT00989157|Experimental|Active drug|All subjects received drug. Single arm.
89656669|NCT03632525|Experimental|Intravenous iron|All participants will receive a single dose of intravenous ferric carboxymaltose
89656670|NCT04403477|No Intervention|Standard treatment|Standard supportive treatment (Oxygen, Enoxaparine, antibiotic, fluid, immune modulator (Steroid) and or antiviral (favipiravir or ramdesivir or lopinavir + ritonavir)
89656671|NCT04403477|Experimental|Standard treatment + 200 ml plasma|Standard supportive treatment + 200 ml apheretic convalescent plasma single transfusion
89656672|NCT04403477|Experimental|Standard treatment + 400 ml plasma|Standard supportive treatment + 400 ml apheretic convalescent plasma single transfusion
89656673|NCT03016455||DSA positive patients without cAMR|Presence of DSA w/o cAMR
89656674|NCT03016455||DSA positive patients with cAMR|Presence of DSA w/ cAMR
89656675|NCT03016455||Stable patients|No DSA No cAMR
89656676|NCT01677455|Experimental|HER2+ breast cancer|
89656677|NCT01677455|Experimental|Triple negative breast cancer|Closed to enrollment
89656678|NCT01677455|Experimental|ER/PR+ Refractory to Prior Hormonal Treatment|
89656679|NCT03628235||Early stage HDGECs|CAG length ≥ 40; DCL = 4, TFC ≥ 11
89656680|NCT03628235||Middle stage HDGECs|CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10
89656681|NCT03628235||Late stage HDGECs|CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6
89656682|NCT03628235||Companions of early stage HDGECs|
89656683|NCT03628235||Companions of middle stage HDGECs|
89656684|NCT03628235||Companions of late stage HDGECs|
89656685|NCT03628001|Other|A|ERCP with (Group A) ES before biliary SEMS placement
89656686|NCT03628001|Other|B|ERCP without (Group B) ES before biliary SEMS placement
89656687|NCT00990561|Active Comparator|Twice Daily Ultravate|Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
89656688|NCT00990561|Active Comparator|Once daily Ultravate|Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily
89656689|NCT03018015|Experimental|Ibuprofen 400 mg oral powder|oral fasted administration of 1 sachet of Ibuprofen 400 mg oral powder (Hermes Arzneimittel GmbH, Germany), containing 400 mg ibuprofen
89213396|NCT05673941|Experimental|Creative movement|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
89213397|NCT05673941|No Intervention|Control group|The control group receives standard medical care and gets access to the intervention in digital form after the study has ended.
89656690|NCT03018015|Active Comparator|Brufen 400 mg film-coated tablets|oral fasted administration of Brufen 400 mg film-coated tablets (Abbott Scandinavia AB, Sweden), containing 400 mg ibuprofen
89656691|NCT03018015|Active Comparator|Spalt forte 400 mg Weichkapseln|oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen
89656692|NCT03620045|Experimental|Acute moderate physical activity|Participants will walk at a moderate intensity for 20 minutes on a treadmill
89656693|NCT03620045|No Intervention|Sedentary activity|Participants will be permitted to read books and/or draw for 20 minutes
89656694|NCT03614195|Experimental|MCDTT|The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
89656695|NCT03614195|Active Comparator|MDTT|The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
89213398|NCT01001949|Experimental|Wheat Bran Extract|
89656696|NCT03614195|Active Comparator|CDTT|The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
89213399|NCT01001949|Placebo Comparator|placebo|
89213400|NCT01002027|Active Comparator|CBT-counselling with Nurse|CBT-counselling with Maternal Health Nurse, adjunctive to management by general medical practitioner
89656697|NCT03611465|Other|VT ablation group|patients presenting history of myocardial infarction and ventricular tachycardia undergoing a VT ablation
89656698|NCT03611465|Experimental|pre implantation group|patients presenting history of myocardial infarction but without history of ventricular tachycardia. Patients scheduled for a cardiac defibrillator implantation in primary prevention.
89656699|NCT03611465|Experimental|control group|patients without history of myocardial infarction and without history of ventricular tachycardia, undergoing an ablation in the left atrium for an atrial fibrillation or an accessory pathway ablation.
89656700|NCT03609593|Experimental|BR followed by venetoclax and rituximab|Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.
89656701|NCT00004547|Experimental|Peritoneal mesothelioma|Patients with peritoneal mesothelioma suffer with intractable ascites but have a very surface oriented tumor which usually does not invade into organs and cause organ dysfunction. The main source of symptoms and cause of death is intractable ascites.
89656702|NCT00004547|Experimental|Low grade mucinous adenocarcinoma|Low grade mucinous adenocarcinoma also includes low grade mucinous neoplasms of borderline malignant potential. Patients with low grade mucinous adenocarcinoma can have prolonged survival with debulking surgery alone. The majority of patients with truly malignant disease will die of complications from intraperitoneal progression of tumor within 2 to 5 years. The tumors are often surface oriented within the peritoneal cavity without metastases to other distant sites. The most common origin for this type of tumor is the appendix and ovary.
89656703|NCT00004547|Experimental|Adenocarcinoma of gastrointestinal origin|Adenocarcinoma of gastrointestinal origin also includes other than low grade mucinous. Aggressive gastrointestinal adenocarcinomas such as gastric, small bowel, and colon cancer , tend to be more invasive into tissues and can more readily metastasize to distant sites. The cause of death is usually directly related to intraperitoneal progression of tumor. It is a more difficult group of patients to treat with intraperitoneal therapy because of the aggressive and invasive nature of the tumors.
89656704|NCT00005669|Active Comparator|1 - Metformin HCL|Subjects receive metformin plus a weight loss program
89656705|NCT00005669|Placebo Comparator|2 - Placebo|Subjects receive placebo plus a weight loss program
89656706|NCT00954018||Cystic Fibrosis patient during outpatient clinic visit|
89656707|NCT00954018||Cystic Fibrosis patients during hospitalization|
89656708|NCT00954018||CF patients about to have sinus surgery and bronchoscopy|
89656709|NCT03605849|Experimental|Centanafadine|400 mg total daily dose
89656710|NCT03908346|Other|Decision Aid for Surrogate Decision Makers|In this pilot trial all participants will be presented with the decision aid and queried as to the feasibility, acceptability and knowledge translation that is gained by exposure to the decision aid
89656711|NCT03603977||Lpv/r+3TC|These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).
89656712|NCT02089997||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
89656713|NCT03908268|Active Comparator|CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Standard Children's Learning Center Program group.
89656714|NCT03908268|Experimental|FNI plus CLC Program|Half of the mother-child dyads who are enrolled in the study will be randomly assigned to the Family Nurture Intervention plus Standard CLC Program group.
89656715|NCT03603275||Patient/caregiver of Kovaltry or Jivi|Patients who are switching factor replacement products to Kovaltry or Jivi and patients who have switched factor replacement products to Kovaltry or Jivi previously
89656716|NCT03603275||Physician Group|Physicians participating in the study are associated with US hemophilia treatment centers that are affiliated with the ATHN hemophilia treatment center network
89656717|NCT01363661|Experimental|Molsidomine|Coruno (molsidomine 16 mg tablet; per os; once daily)
89656718|NCT01363661|Placebo Comparator|Placebo|Placebo (16 mg tablet; once a day)
89656719|NCT03154229|Active Comparator|Paper-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use paper-based decision support at the 5 hospitals designated.
89656720|NCT03154229|Active Comparator|Smartphone-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use smartphon-based decision support at the 5 hospitals designated.
89656721|NCT02628600|Experimental|Prior LAI + Multidrug Regimen|Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR.
89656722|NCT02628600|Experimental|Prior Multidrug Regimen Alone|Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR.
89656723|NCT00006101|Experimental|eflornithine|500mg/d for 12 months
89656724|NCT00006101|Placebo Comparator|Placebo|placebo for 12 months
89656725|NCT03153839|Experimental|Study group|74 infants who will practice with their parents a programme of aquatic physical activity in a swimming pool for one year. They will be evaluated before and after the programme.
89656726|NCT03153839|No Intervention|Control group|71 infants who will not practice the programme. They only will be evaluated.
89656727|NCT03063528|Experimental|Healthy Eating/Physical Activity (HEPA)|"The goals of the HEPA condition are to encourage healthy eating and physical activity behaviors for gaining a healthy amount of weight during pregnancy and to provide motivation and social support to help overcome challenges to eating healthier and becoming more physically active while pregnant.~12 weeks of group-based health behavior (nutrition/PA focused) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
89656728|NCT03063528|Experimental|Stress Reduction/Management (SRAM)|"The goals of the SRAM condition are to encourage stress reduction and management techniques as well as to provide motivation and social support to reduce stress levels during pregnancy.~12 weeks of group-based health behavior (stress reduction/management) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
89656729|NCT05570747|Experimental|In-House Usability Study Group|Human subjects will interact with two different CPAP interfaces including a traditional CPAP mask and the 2nd generation DreamPort-Eclipse. Subjects will be requested to put on each of the different CPAP interface options a total of three times for a total of 6 trials. The order of device tries will be randomized.
89656730|NCT01973634|Active Comparator|Minimal surgical margin 1 mm, conventional arm: seq boost|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost).
89656731|NCT01973634|Experimental|Minimal surgical margin of 1 mm, experimental arm with SIB|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
89656732|NCT01973634|Active Comparator|Minimal surgical margin <1 mm, conventional arm: seq boost|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
89656733|NCT01973634|Experimental|Minimal surgical margin < 1 mm, experimental arm with SIB.|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
89656734|NCT04432818|Experimental|Pack Health's digital life coaching (DLC)|Access to the DLC platform during a 16-week period encompassing pre-HCT conditioning chemotherapy, post-HCT recovery, and 100-day follow-up
89656735|NCT03063684|Experimental|Vaginal atrophy|"With decreasing estrogen levels occurring following menopause, changes of the vaginal mucosa appear: it becomes thin and pale and loses its elasticity. The blood supply decreases, normal secretion is reduced, the epithelial cells do not undergo the normal differentiation process, the bacterial population changes with loss of lactobacilli and pH increases. These changes are associated with morphological and histological changes, manifested, among other findings, by alterations in the collagen composition, loss of the trabecular organization of collagen and reduced amount of elastic fibers. Women with reduced vaginal estrogen content may report dryness, itching, discomfort, burning sensation during micturition, pain and dyspareunia. These changes are reversible: topical or systemic estrogen change the vaginal mucosa's characteristics and may also alleviate complaints arising from estrogen deficiency.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
89046711|NCT04671264|Experimental|VC group|"Vibrating capsule (VC) was proposed and applied for the patent by professor Liao Zhuan from Changhai Hospital, developed and manufactured by the Ankon Medical Technology Co., Ltd. The system consisted of a vibrating capsule and an external configuration device (ECD). It's 26.7 mm in length, 11.8 mm in diameter and 4.5 + 0.5 g in weight.~Each VC has its own semiconductor chip with serial number in order to be recognized and controlled by ECD. VC can be stopped by ECD or mobile-phone application. There was a bidirectional radio frequency communication signal between VC and ECD. In addition, an application (APP) named VCP can be connected to ECD through smart phone to select mode and debug specific parameters for VC. The capsule can be activated by ECD, and then the vibration mode can be controlled by a configurator or an smartphone application."
89656736|NCT03063684|Experimental|Lichen sclerosus|"Lichen sclerosus is a chronic cutaneous disease involving the vulvar and peri-anal skin. The involved skin becomes thin and white, with frequently present bruises or petechiae and anatomic changes.~Lichen sclerosus is thought to be an auto-immune disorder and its most frequent signs are itching, irritation or burning. The discoloration may involve the entire vulvar and peri-anal area (sometimes having the form of an 8 or a keyhole surrounding the vulva and anus) or appear as separated spots of various sizes occupying only part of the skin. At advanced stages of lichen sclerosus, scarring may appear, with loss of the labia minor and adhesions which may entirely cover the clitoris.~The treatment is of topical steroid. Lichen sclerosus is a chronic disorder, and even with good treatment, in a certain proportion of cases the skin does not return to its original appearance.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
89656737|NCT04224402|Other|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion
89656738|NCT00591318|Experimental|IV Ceftriaxone|IV Ceftriaxone 2 grams/day
89656739|NCT00591318|Placebo Comparator|IV Placebo|IV Placebo (Normal Saline)
89656740|NCT01360632|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
89656741|NCT01360632|Placebo Comparator|Phase A|Drug: Placebo + ADT
89656742|NCT00991029|Active Comparator|clopidogrel|Patients assigned to clopidogrel in addition to aspirin
89656743|NCT00991029|Placebo Comparator|placebo|Patients assigned to placebo in addition to aspirin
89656744|NCT03017859|Experimental|High flow nasal cannula treatment|Airvo 2 device will be used to administer high flow air during the night
89656745|NCT04835649|Experimental|Exercise group|The group that will receive task-oriented training via telerehabilitation
89656746|NCT04835649|Placebo Comparator|Control group|The control group only will be given a home program that includes walking and balance exercises
89656747|NCT04714437|Active Comparator|F-R/L-A1/A3/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5)
89656748|NCT04714437|Active Comparator|F-R/L-A1/A5/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3)
89656749|NCT04714437|Active Comparator|F-R/L-A3/A1/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5)
89656750|NCT04714437|Active Comparator|F-R/L-A3/A5/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1)
89656751|NCT04714437|Active Comparator|F-R/L-A5/A1/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3)
89656752|NCT04714437|Active Comparator|F-R/L-A5/A3/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1)
89656753|NCT02245971|Active Comparator|Whole precutting group|
89656754|NCT02245971|Active Comparator|Partial precutting group|
89656755|NCT00991809|Experimental|Alfentanil|Subjects received a series of acute alfentanil administrations each session (15 mcg/kg IM per session), with sessions spaced at 3-4 day intervals.
89656756|NCT00991809|Active Comparator|Diphenhydramine|Subjects received a series of acute diphenhydramine administrations each session (25 mg IM per session), with sessions spaced at 3-4 day intervals.
89046712|NCT04671264|Placebo Comparator|Control group|The Intervention of control group were similar to VC group except the capsule function. Sham capsule we used in control group which had no function of vibrating.
89046713|NCT04671303|Experimental|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
89046714|NCT01780428|Experimental|CL-108|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg)
89046715|NCT01780428|Active Comparator|Norco|Commercial product containing hydrocodone 7.5 mg. acetaminophen 325 mg
89046716|NCT01780428|Placebo Comparator|Placebo|CL-108 formulation without API
89656757|NCT02627274|Experimental|Part A: RO6874281 Monotherapy|Dose Escalation: RO6874281 will be administered as an intravenous (IV) infusion. The starting dose regimen of RO6874281 as a single agent will be 5 milligrams (mg) once weekly (QW). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
89656758|NCT02627274|Experimental|Part B: RO6874281 in Combination with Trastuzumab|Dose Escalation: RO6874281 will be administered as an IV infusion. RO6874281 will be administered QW for the first 4 administrations, then Q2W. The standard dose for trastuzumab will be a loading dose of 6 milligrams per kilogram (mg/kg) followed by a maintenance dose of 4 mg/kg from Cycle 2 in a Q2W regimen. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with trastuzumab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with trastuzumab for a maximum of 24 months.
89656759|NCT02627274|Experimental|Part C: RO6874281 in Combination with Cetuximab|"RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with cetuximab will be 5 mg QW for the first 4 administrations, then Q2W. Cetuximab will be administered Q2W at 500 milligrams per square meter (mg/m^2). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with cetuximab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with cetuximab for a maximum of 24 months.~Extension Phase: The MTD for RO6874281 was determined to be 10mg and therefore patients in the extension will be treated with 10mg RO6874281. Cetuximab and R06874281 will be administered weekly during induction phase (cycle 1 and cycle 2). Both IMPs will be administered Q2W starting in cycle 3."
89656760|NCT04982016|No Intervention|Control group|There is no treatment before anesthesia induction.
89656761|NCT04982016|Experimental|Crystal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV >16%, restore the head height to 45°, and 250ml carbonated Ringer's solution was infused (infusion time >10min).
89656762|NCT04982016|Experimental|Colloidal group|The fluid reactivity was determined by PLR test before anesthesia induction. The basic value was measured when maintain the head height at 45° for 2 min. and the liquid reactivity value was measured when both legs were raised 45° for 2 min. If △SV >16%, restore the head height to 45°, and 250ml colloidal fluid was infused (infusion time >10min).
89656763|NCT00992433|Experimental|Group 2, 30 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 30 mcg H1N1 vaccine on Day 0 and Day 21.
89656764|NCT00992433|Experimental|Group 1, 15 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 15 micrograms (mcg) H1N1 vaccine on Day 0 and Day 21.
89656765|NCT04190082||Group Control|Group who maintains deep sedation using the University of Michigan sedation scale (UMSS) score.
89656766|NCT04190082||Group BIS|Group who maintain deep sedation using Bispectral Index (BIS) score.
89656767|NCT00994929|Experimental|Neumega (Oprelveken, Interleukin 11)|Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
89656768|NCT04157400|Experimental|Epidural Spinal Cord Stimulation|Subjects with chronic pain that have been scheduled to receive spinal cord simulators for standard of care treatment.
89656769|NCT00929253|Active Comparator|Computer delivered CRA + CM + Suboxone|"In this arm, participants are administered Suboxone and therapy is delivered by a computer. Fluency training is provided. The participant then listens through headphones and reads the information on the screen. They progress through various modules that involve education regarding high risk situations for potential use drug and skills to deal with those situations. In addition, skills for dealing with anxiety and anger are also provided. Videos are displayed that have examples of real-left situations. HIV/AIDS education is also provided. The program is interactive with the participant being required to answer short questions at the end of each module and prompts for homework worksheets are provided. These participants receive vouchers for providing drug negative urine samples."
88993959|NCT02957786|Active Comparator|Varenicline plus behavioural support|"12-week course of Varenicline tablets (0.5mg/1mg), with an increasing dosing regimen (0.5mg/day for days 1-3, 1.0mg/day for days 4-7, 2.0mg/day for day 8-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also receive withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
88993960|NCT03109964|Active Comparator|Hemostasis with bipolar coagulation|Patients undergoing laparoscopic ovarian cystectomy with bipolar coagulation hemostasis.
88993961|NCT03109964|Experimental|Hemostasis with SURGIFLO|Patients undergoing laparoscopic ovarian cystectomy with SURGIFLO hemostasis.
88993962|NCT03083873|Experimental|Cohort 1|Treatment with LN-145, Generation 1 (Gen 1), non-cryopreserved TIL
88993963|NCT03083873|Experimental|Cohort 2|Treatment with LN-145 Generation 2 (Gen 2), cryopreserved TIL
88993964|NCT03083873|Experimental|Cohort 3|Treatment with LN-145 Generation 3 (Gen 3), cryopreserved TIL
88993965|NCT03083873|Experimental|Cohort 4|Treatment with LN-145-S1 cryopreserved TIL
88993966|NCT03083873|Experimental|Cohort 5|LN-145 cryopreserved/LN-145-S1 cryopreserved TIL re-treatment
88993967|NCT02484430|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are non-responders and in PR at the end of course 4 may receive sapanisertib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88993968|NCT00516412|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89656770|NCT00929253|Active Comparator|CM + Suboxone|In this arm of the study, the participants receive vouchers for providing a drug negative urine sample. These participants, however, do not have computer delivered therapy.
89656771|NCT04877418|Experimental|TeleCIMT group|"One month after baseline evaluations, patients will receive a 3-week program through TeleCIMT.~Task Oriented Repetitive Training~Use of the Affected Upper Extremity~Transfer Package"
89656772|NCT04981938||Lobectomy with angioplasty|81 patients who underwent lobectomy with pulmonary artery reconstruction during oncologic lung resection from January 2001 to December 2020
89656773|NCT04374903|Experimental|Study Arm A (HCQ & AZ)|Subjects will receive HCQ 600mg PO X 10 days and AZ PO 250mg DAILY X 10 days.
89656774|NCT04374903|Experimental|Study Arm B (HCQ+SIR)|Subjects will receive HCQ 600mg PO X 10 days and SIR 4mg PO X 1 day then 2mg PO DAILY X 9 days
89656775|NCT04234893||Drug-coated balloon|The Patients who treated with Bingo drug-coated balloon
89656776|NCT03062982|Experimental|Group A|Administration of 120mg in fed state in Dosing Period 1 followed by administration of 120mg in fasted state in Dosing Period 2
89656777|NCT03062982|Experimental|Group B|Administration of 120mg in fasted state in Dosing Period 1 followed by administration of 120mg in fed state in Dosing Period 2
89656778|NCT03062436|Experimental|Sustained molecular remission|Patients of CML who remain in sustained molecular remission at 12 months after Stopping the standard drug therapy
89656779|NCT00997113|Active Comparator|Propofol|propofol only for deep procedural sedation
89656780|NCT00997113|Active Comparator|Propofol/alfentanil|Propofol with alfentanil for deep procedural sedation
89656781|NCT04981314|Experimental|Treatment with echinacea|EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
88993969|NCT03058835|Experimental|PrEP with Truvada|All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP
88993970|NCT00516451|Experimental|1|
88993971|NCT00516490|Experimental|1|GnRH agonist administration
88993972|NCT00516490|Placebo Comparator|2|Sterile saline injection
88993973|NCT03043586||Treatment Pattern|The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. A phone script will be utilized to obtain verbal informed consent from subjects for this phase of the study. The questionnaire will collect current information on acromegaly treatment, morbidities and other relevant history. Subjects will provide verbal consent to participate in this questionnaire part of the study and review of their medical records by the PI and study staff.
88993974|NCT04695145|Experimental|Aerobic exercise in group|"The patients will participate in aerobic group exercise for 60 minutes three times a week for 12 weeks with continuous heart rate monitoring. The sessions will be held in a small gym under supervision of a personal trainer with special training in medical issues. The exercise will be monitored with continuous heart rate registration.~The group training session will begin with a warm-up to increase heart rate including balance tasks and dynamic stretching for 10-15 minutes. Every third session will be pure aerobic training, every third session will be strengthening exercises designed to also increase heart rate, and every third session will be a mixed session of both aerobic and strength exercises. All major muscle groups will be used at each session. Interval training with gradually increased intensity throughout the program will be applied."
88993975|NCT04695145|Active Comparator|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
88993976|NCT00516646|Active Comparator|1|ALT-711 200 mg bid
88993977|NCT00516646|Placebo Comparator|2|
88993978|NCT00516685|Experimental|Vaccine Group|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
88993979|NCT00516685|No Intervention|Control Group|Patients in this arm will only receive Best Supportive Care.
88993980|NCT03458689|Other|Left hemicolectomy without nerve blocks|Left hemicolectomy, laparoscopic technique Enteral and parenteral analgesics such as paracetamol and oksykodon
88993981|NCT03458689|Active Comparator|Left hemicolectomy with TAP block|Left hemicolectomy, laparoscopic technique TAP block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
89656782|NCT04981314|Placebo Comparator|Placebo|Hard caplets indistinguishable from EQUINÁCEA ARKOPHARMA, 2 caplets at breakfast, 2 caplets at lunch and 2 caplets at dinner with a glass of water, for 10 days.
89656783|NCT04090905||Unselected cohort|Consecutive adult patients who were referred for acute abdominal surgery. Patients underwent standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
89656784|NCT04090905||Subgroup with Holter monitoring|Consecutive adult patients who were referred for acute abdominal surgery in the time interval 7 AM to 11 PM. Holter monitoring was applied on top of standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
89656785|NCT04981704|Experimental|Part 1: Itraconazole/Poziotinib Drug-drug interaction (DDI)|On Day 1 of Treatment period 1, a single oral dose of 8 milligrams (mg) poziotinib will be administered. On Day 1 of Treatment Period 2, 200 mg itraconazole oral solution will be administered twice a day (BID) followed by 200 mg itraconazole oral solution once daily (QD) for 7 consecutive days (Day 2 to Day 8) with a single oral dose of 8 mg poziotinib coadministered on Day 4.
88993982|NCT03458689|Active Comparator|Left hemicolectomy with QL block|Left hemicolectomy, laparoscopic technique QL block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
88993983|NCT00527215|Experimental|darbepoetin alfa|
88993984|NCT00527254|No Intervention|Control group|
89656786|NCT04981704|Experimental|Part 2: Phenytoin/Poziotinib DDI|On Day 1 of Treatment period 1, a single oral dose of 16 mg poziotinib will be administered. In treatment period 2, an oral dose of 100 mg phenytoin will be administered three times daily (TID) for 17 consecutive days (Day 1 to Day 17) with a single oral dose of 16 mg poziotinib coadministered on Day 14.
89656787|NCT04981704|Experimental|Part 3: Paroxetine/Poziotinib DDI|On Day 1 of Treatment Period 1, a single oral dose of 8 mg poziotinib will be administered. On Day 1 and Day 2 of Treatment Period 2, an oral dose of 20 mg paroxetine will be administered BID followed by 20 mg paroxetine QD for 9 consecutive days (Day 3 to Day 11) with a single oral dose of 8 mg poziotinib coadministered on Day 7.
89656788|NCT02163837|Experimental|rifaximine|
89656789|NCT04974060|Experimental|Remifentanil intervention|After the satisfactory analgesia and sedation, remifentanil will continuously infuse an escalating dose in the sequence of 0.02, 0.04, 0.06, and 0.08 μg/kg/min, each dose infusion lasting at least 30 minutes.
89656790|NCT02246205|Experimental|DPC DN|Roux-en Y reconstruction after pancreaticoduodenectomy
89656791|NCT02246205|Active Comparator|DPC UN|Child reconstruction after pancreaticoduodenectomy
89656792|NCT01021761|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
89656793|NCT01021761|Active Comparator|Nevanac|Nevanac to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
89656794|NCT01021761|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.
89656795|NCT04973904|Experimental|PD-1+Paclitaxel+Cisplatin+Bevacizumab|"Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W)~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)~Cisplatin 50mg/m2 (Q3W)~Bevacizumab 7.5mg/kg IV every 3 weeks (Q3W)"
88993985|NCT00527254|Active Comparator|Telemedicine group|
88993986|NCT00527293|Experimental|MammoSite Brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
88993987|NCT00527293|Experimental|3-dimensional conformal radiotherapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
88993988|NCT04692142|Active Comparator|Passive online|Before L1, all students will be asked to complete a set of multiple-choice questions (MCQs), formative exam (i.e. pre-test). Following the test , the lecture will be delivered to the participants of PG using a passive online teaching format for 60 minutes (i.e., live-video streaming). After the lecture is completed, students will be asked to re-take the same pre-test exam and complete questionnaire regarding their experience with the teaching methods.
88993989|NCT04692142|Experimental|Flipped classroom|"Participants of FG will have an access to a recorded lecture. and they will be taught using an active teaching model known as flipped classroom model. In this model, participants will have 7 -day monitored remote access to the recorded L1. Similar to PG, completing the online pre-test formative exam will be preliminary requirement to access the published recorded L1.~At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately. After the lecture is completed, students will be asked to re-take the same pre-test of L1 and complete questionnaire regarding their experience with the teaching methods."
88993990|NCT00527371|Experimental|PVP|Photoselective vaporization of the prostate.
88993991|NCT00527371|Active Comparator|TURP|Transurethral resection of the prostate.
88993992|NCT02516540|No Intervention|Control|Study participants are instructed regarding a healthy diet according to the recommendations of the German Nutrition Society (DGE) and are informed about positive effects of physical activity on incidence and prognosis of breast cancer
88993993|NCT02516540|Experimental|Intervention|Structured exercise training plus mediterranean diet: Study participants receive a lifestyle intervention of 12 months duration (3 months intensive intervention plus 9 months maintenance using monthly contacts and meetings). The intervention comprises a structured intensified training based on the results of physical performance diagnostics and a nutrition program based on a mediterranean diet.
88993994|NCT02489422|Experimental|Group I (Yoga Skills Training)|Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.
88993995|NCT02489422|Active Comparator|Group II (Attention Control)|Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.
88993996|NCT02945644|Placebo Comparator|Placebo|pill filled with inert material
88993997|NCT02945644|Active Comparator|Trazodone 50mg|
88993998|NCT02945644|Active Comparator|Trazodone 100mg|
88993999|NCT02945488|Experimental|Exercise and dietary plan|Combination cardiovascular and resistance training and Mediterranean dietary plan
89656796|NCT03061422|Experimental|xylitol chewing gum|intervention
89656797|NCT03061422|Experimental|xylitol with bicarbonate chewing gum|intervention
89656798|NCT03061422|Active Comparator|Paraffin pellet|comparator
89656799|NCT01022073||Globus Pallidus interna Group|Cohort of subjects who received DBS-GPi as part of the CSP 468 intervention trial, and still have their device working and in place.
89656800|NCT01022073||Subthalamic Nucleus Group|Cohort of subjects who received DBS-STN as part of the CSP 468 intervention trial, and still have their device working and in place.
89656801|NCT04837482|Experimental|AGN-190584 Sequence 1|AGN-190584 Sequence 1 (Participants will receive AGN-190584 from Visit 2 through Visit 3 followed by Vehicle from Visit 4 through Visit 5).
89656802|NCT04837482|Experimental|AGN-190584 Sequence 2|AGN-190584 Sequence 2 (Participants will receive Vehicle from Visit 2 through Visit 3 followed by AGN-190584 from Visit 4 through Visit 5).
88994000|NCT02945488|Experimental|Exercise and no dietary plan|Combination cardiovascular and resistance training and participants regular diet (control diet)
88994001|NCT02945488|Experimental|Stretching and dietary plan|Flexibility training (control exercise) and Mediterranean dietary plan
88994002|NCT02945488|Active Comparator|Stretching and no dietary plan|Flexibility training (control exercise) and participants regular diet (control diet)
89656803|NCT00997425|Experimental|Door Cover/Floor Cover|Baseline One (14 days), First Intervention (14 days), Baseline Two (14 days), Second Intervention (14 days)
89656804|NCT04981080||Symptom of voiding dysfunction|Women with lower urinary tract symptoms including voiding symptoms but without cystocele who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
89656805|NCT04981080||No symptom of voiding dysfunction|Women with lower urinary tract symptoms but without cystocele or voiding symptoms who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed
89656806|NCT00998049|Experimental|Plerixafor|"Plerixafor 160mg/kg/dose by IV on days 5-8~Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8."
89656807|NCT00998205|Other|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micrograms/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micrograms/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate. If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
89656808|NCT04980924||Pulmonary Embolism without reccurence or complication|Pulmonary Embolism without reccurence or complication
89656809|NCT04980924||Pulmonary Embolism with reccurence or complication|Pulmonary Embolism with reccurence or complication, in particular occurrence of pulmonary hypertension.
89656810|NCT01022307||Group 1: no history of TBI|184 participants with no history of traumatic brain injury (TBI).
89656811|NCT01022307||Group 2: with a history of TBI|28 patients with a history of TBI. Most of these patients had suffered mild TBI.
89656812|NCT02626182|Experimental|Sildenafil|Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.
89656813|NCT02626182|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive placebo p.o. t.i.d for 1 week followed by 2 placebo tablets p.o. t.i.d. for 11 weeks.
89656814|NCT00998517|Active Comparator|Soy/peanut fortified spread|
89656815|NCT00998517|Experimental|Milk fortified corn/soy blend|
89656816|NCT00998517|Active Comparator|Supplementary Plumpy®|
89656817|NCT03062592|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
89656818|NCT03062592|Experimental|Non-hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of non-hydrolyzed pine nut oil
89656819|NCT03062592|Experimental|hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
89656820|NCT01023477|Experimental|Chloroquine Standard Dose (500mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week).
89656821|NCT01023477|Experimental|Chloroquine Low Dose (250mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week).
89656822|NCT04973592||Child with Blunt Abdominal Trauma|
89213401|NCT01002027|Active Comparator|CBT-Counselling by Psychologist|CBT-counselling with Psychologist, adjunctive to management by general medical practitioner
89213402|NCT01002027|No Intervention|Routine management|Ongoing management by general medical practitioner
89656823|NCT00999141|Experimental|FS VH S/D 4 s-apr|One side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
89656824|NCT00999141|No Intervention|Standard of Care (SoC)|Other side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
89656825|NCT04980768|Other|Root canal treatment|Root canal treatment will be provided to all the participants with the diagnosis of apical periodontitis.
89656826|NCT03062202|Experimental|Depression group|SilverCloud iCBT for depression.
89656827|NCT03062202|Experimental|Anxiety group|SilverCloud iCBT anxiety disorders.
89656828|NCT03062202|Experimental|Comorbid Depression and Anxiety group|SilverCloud iCBT for comorbid depression and anxiety.
89656829|NCT01023711|Other|Inactivated H1N1 Vaccine|Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine
89656830|NCT04428762|Experimental|I-Port use arm|
89656831|NCT04428762|No Intervention|Regular injection arm|
89656832|NCT04428216|Active Comparator|Group RIB = Rhomboid intercostal block group|In group RIB, RIB block will be performed with patients in the lateral decubitus position. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injected into the fascial plane.
89656833|NCT04428216|No Intervention|Group C = Control group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
89656834|NCT01001403|Experimental|nafamostat|The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
89656835|NCT01001403|Placebo Comparator|Control|The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
89656836|NCT01024335|Active Comparator|Naltrexone and placebo|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
89213403|NCT01005381|Experimental|Small Particle Size Calcium Carbonate|Subjects are given small particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
89213404|NCT01005381|Active Comparator|Large Particle Size Calcium Carbonate|Subjects are given a large particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
89213405|NCT01005381|Placebo Comparator|Calcium Placebo|Subjects are given two placebo tablets daily, which are identical to the large and small particle size calcium carbonate supplements.
89213406|NCT01005381|Active Comparator|No Vitamin D supplement|Subjects are given calcium carbonate supplement once daily (325 mg/d from supplement).
89213407|NCT01005381|Experimental|Vitamin D supplement|Subjects are given a calcium supplement once daily (325 mg/d from supplement) with 1000 IU/d vitamin D supplement.
89213408|NCT05080335|Active Comparator|TRANS-gender female instructor, with videos (TV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a TRANS-gender woman with extensive experience as an educator on transgender health
89656837|NCT01024335|Experimental|Naltrexone and dronabinol|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
89656838|NCT03841695|Experimental|Treatment Group|Experimental group received Robot Assisted Training (RMTC finger-hand robot (Mirror Hand)) and traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
89656839|NCT03841695|Active Comparator|Control Group|Control group received traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
89656840|NCT03787719|Experimental|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment (Monday and Friday or Tuesday and Saturday).
89656841|NCT03787719|No Intervention|Thrice per week dialysis|Standard thrice-weekly 4 hour dialysis treatment (Monday, Wednesday and Friday or Tuesday, Thursday and Staurday)
89656842|NCT01669902||Cohort|
89656843|NCT01024569|Experimental|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues.
89656844|NCT01024569|No Intervention|Comparison Wait-List Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
89656845|NCT01001559||Deplin + antidepressant|Deplin in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
89656846|NCT01001559||Antidepressant alone|SSRI or SNRI alone
89656847|NCT03061344|Experimental|liquid buccal mucosa graft|DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
89656848|NCT01003275|Active Comparator|Paricalcitol followed by placebo|Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks.
89656849|NCT01003275|Active Comparator|Placebo followed by paricalcitol|Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.
89656850|NCT01670292|Other|Experimental: HVLA-SM|Experimental High Velocity Low Amplitude Spinal Manipulation
89656851|NCT01025427|Experimental|Elite controller|Sixteen controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
89656852|NCT03624777|Experimental|Stroll Safe Program|
89656853|NCT03624777|Active Comparator|Outdoor Fall Prevention Brochure|
89656854|NCT03061266|Experimental|E-health education group|E-health education group will be received the shared care program using e-health education.
89656855|NCT03061266|Other|Routine care|Control group will be received the shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
89656856|NCT04352751|Experimental|Single Arm|"Intervention: Convalescent plasma (Frozen Solution for infusion) obtained from COVID-19 recovered patients.~The dosage depends upon the clinical situation and underlying disorder. Children: 15 ml/kg over 4-6 hours once in patients under 35 kg body weight. Adults: maximum 450 - 500 ml over 4-6 hours once in all adults patients."
89656857|NCT03494205|Experimental|Test group|"For the patients of the test-group Urtica comp gel is applied three times per day locally on the skin as soon as the patient senses itching, tingling and/or reddening. Otherwise the skincare is exactly as the control group in line with the departments general guidelines.~In case of marked worsening, e.g. epitheliolysis, the patient may receive Flammazine and Ialugen plus as rescue-care.~Rescue care: according to the departments therapeutic guidelines patients will receive Flammazine and/or Ialugen plus as clinically indicated at the discretion of the treating physician (usually in cases of marked worsening of the skin condition like e.g. epitheliolysis)."
89656858|NCT03494205|Active Comparator|Control group|"Control group receiving the institutional standard skin care Excipial-Hydrolotion - all other therapeutic interventions, assessments and rescue-care will be the same in both groups."
89656859|NCT04432116|Experimental|virtual reality 1|the subject is in a virtual room and is asked to emit a retrospective time duration judgement at the end of the session
89656860|NCT04432116|Experimental|virtual reality 2|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible while the background of the virtual environment is a starfield with standard speed vs. self-determined speed vs. static stars
89213409|NCT05080335|Active Comparator|CIS-gender female instructor, with videos (CV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a CIS-gender woman with extensive experience as an educator on transgender health
89213410|NCT05080335|Active Comparator|CIS-gender female, with NO videos (CN)|Didactic materials do NOT use short videos of transgender youth [until AFTER completion of the POST outcome measures]; lesson is led by a CIS-gender woman with extensive experience as an educator on transgender health
89213411|NCT05080335|No Intervention|No intervention control|Subjects randomized to this arm will complete the baseline assessment and the post assessment thirty days later, but just *before* receiving the intervention (TV).
89656861|NCT04432116|Experimental|virtual reality 3|the subject is in a virtual environment mimicking a space ship. The subject is asked to detect targets as fast as possible.Asynchronous distracters vs. synchronous distracters, vs no distracters are displayed while the subjects wait for the target
89213412|NCT01002183|No Intervention|single arm|Fos-clin/Arte
89656862|NCT04972422|Experimental|Single Agent Dose Escalation|Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
89656863|NCT02162433|Active Comparator|1. Awake extubation/dexmedetomidine|Awake extubation receiving dexmedetomidine.
89656864|NCT02162433|Placebo Comparator|2. Awake extubation/placebo|Awake extubation receiving placebo (normal saline).
89656865|NCT02162433|Active Comparator|3.Deep extubation/dexmedetomidine|Deep extubation receiving dexmedetomidine.
89656866|NCT02162433|Placebo Comparator|4. Deep extubation/placebo|Deep extubation receiving placebo (normal saline).
89656867|NCT01004991|Experimental|All patients|subjects will receive azacytidine dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose RCHOP
89656868|NCT03063060||total thyroidectomy|patients who underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels.
89656869|NCT03161847||OPMD Subjects|The study cohort consists of individuals with genetically confirmed OPMD who will be followed longitudinally using periodic standardized assessments of clinical status in an observational, non-interventional study.
89656870|NCT03161613||Cancer patients in Mexico|lung cancer, melanoma cancer, renal cancer, Squamous Cell Carcinoma of the Head and Neck, and chronic Hodgkin Lymphoma patients in Mexico who have failed at least one treatment before being treated with nivolumab
89656871|NCT03115047|Experimental|dexmedetomidine|"Unique dose of dexmedetomidine injection:~intravenous injection~0.35 mcg/kg~in two minutes~if shivering 5 minutes after delivery"
89656872|NCT03115047|Active Comparator|meperidine|"Unique dose of meperidine injection:~intravenous injection~0.35 mg/kg~in two minutes~if shivering 5 minutes after delivery"
89656873|NCT01026909|Experimental|Injection|Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
89656874|NCT01026909|No Intervention|Control|Patients will be enrolled in physical therapy
89656875|NCT03015519|Experimental|Albiglutide cohort 1: Part A|Approximately 12 eligible subjects, aged between 14 to 18 years, will receive a single dose of 30 mg albiglutide post-randomization.
89656876|NCT03015519|Placebo Comparator|Placebo cohort 1: Part A|Approximately 3 eligible subjects, aged between 14 to 18 years, will receive a single dose of matching placebo post-randomization.
89656877|NCT03015519|Experimental|Albiglutide cohort 2: Part A|Approximately 12 eligible subjects, aged between 10 to 14 years, will receive a single dose of 30 mg albiglutide post-randomization.
89656878|NCT03015519|Placebo Comparator|Placebo cohort 2: Part A|Approximately 3 eligible subjects, aged between 10 to 14 years, will receive a single dose of matching placebo post-randomization.
89656879|NCT03015519|Experimental|Albiglutide: Part B|Approximately 120 eligible subjects, aged between 10 to 18 years, will receive albiglutide 30 mg once weekly post-randomization.
89656880|NCT03015519|Placebo Comparator|Placebo: Part B|Approximately 60 eligible subjects, aged between 10 to 18 years, will receive matching placebo once weekly post-randomization.
89656881|NCT04973358|Experimental|BuccoTherm|buccotherm mouthwash
89213413|NCT05734209|Experimental|Virtual, then real meal|Participant first had two lunch sessions eating virtual food (meal), with a wash-out period of three days. Participants then had two lunch sessions eating real food (meal), with a wash-out period of three days.
89656882|NCT04973358|Placebo Comparator|Placebo|placebo mouthwash
89656883|NCT03015441|Other|Arm 1: Fermented milk product containing probiotics|
89656884|NCT03015441|Other|Arm 2: Milk-based non-fermented dairy product|
89656885|NCT01028937|Experimental|Hyperopia|The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.
89656886|NCT03015597|Experimental|Contingency Management: smoking|"Contingency Management: smoking~Participants receive rewards contingent on biochemical verification of tobacco smoking abstinence"
89656887|NCT03015597|Placebo Comparator|Contingency Management: attendance|"Contingency Management: attendance~Participants receive rewards contingent on attending the stop smoking clinic (independent of smoking status)"
89656888|NCT01030653|Experimental|Voriconazole low dose first then high dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)
89656889|NCT01030653|Experimental|Voriconazole high dose first then low dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)
89213414|NCT05734209|Experimental|Real, then virtual meal|Participant first had two lunch sessions eating real food (meal), with a wash-out period of three days. Participants then had two lunch sessions eating virtual food (meal), with a wash-out period of three days.
89213415|NCT05154279|Active Comparator|intramyometrial Terlipressin|intramyometrial injection of Terlipressin in women undergoing laparoscopic myomectomy procedure
89213416|NCT05154279|Active Comparator|intramyometrial carbitocin|intramyometrial injection of Carbetocin in women undergoing laparoscopic myomectomy procedure
89213417|NCT05154279|Placebo Comparator|intramyometrial saline|intramyometrial injection of saline in women undergoing laparoscopic myomectomy procedure
89213418|NCT01002261||Liver cirrhosis / healthy subjects|10 patients with liver cirrhosis and 10 sex and age-matched healthy subjects
89656890|NCT01031043|Experimental|Topical Bethanechol|patients will be given either 5 mg (first phase) or 10 mg (second phase) of bethanechol in 1 ml of solution containing an absorption enhancer. Administration will be performed by throat spray device
89046717|NCT04578392|Active Comparator|high ligation of ileocolic artery|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
89046718|NCT04578392|Active Comparator|mesenteric sparing for a primary ileocolic resection|Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
89046719|NCT04671420|Experimental|HLX01|
89046720|NCT04671420|Active Comparator|EU-sourced rituximab (Mabthera®)|
89046721|NCT04573556||Lemborexant|Participants with insomnia will initiate treatment with lemborexant 5 milligram (mg), tablet, orally as per the clinical judgment of the treating physician as part of routine clinical care. Dosage and administration of lemborexant tablet will be according to package insert and actual dosing and frequency will be decided by physician including dose escalation from initial dose of 5 mg up to 10 mg once daily. All participants will be observed prospectively for up to 24 weeks.
89046722|NCT04671108|Experimental|Test to Moist|1 week of Test DD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
89046723|NCT04671108|Active Comparator|Moist to Test|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test DD contact lenses.
89046724|NCT04573166|Experimental|CURB procedure|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation (CURB)
89656891|NCT02593071|Experimental|Treatment Group A|RSV-F Vaccine ( 0.5mL Injection)
89656892|NCT02593071|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
89656893|NCT02387385|Active Comparator|Intervention|Whole body cooling to 33 degrees C to 34 degrees C
89656894|NCT02387385|No Intervention|Standard of Care|Standard of care
89656895|NCT01050153|Active Comparator|Control (standard of care)|Dalteparin sodium 5000IU subcutaneously daily
89656896|NCT01050153|Experimental|TEG-guided thromboprophylaxis|Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm
89656897|NCT01050231|Experimental|Robotic group (Type I)|Type I Robotic Therapy (Functional activities first) Participants in this group will participate in functional/task-oriented multi-joint training with the BONES robot first, followed by individual joint training with the BONES robot. A one-week break was provided between interventions.
89656898|NCT01050231|Active Comparator|Robotic group (Type II)|Type II Robotic Therapy (Individual joints first) Participants in this group will participate in individual joint training with the BONES robot first, followed by functional/task-oriented multi-joint training with the BONES robot. A one-week break was provided between interventions.
89656899|NCT01032135|Active Comparator|1-MI-IOP Engaged|Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
89046725|NCT01779453|Experimental|ETC-1002|ETC-1002 treatment group, oral once daily
89046726|NCT01779453|Placebo Comparator|Placebo|Placebo treatment group, oral once daily
89046727|NCT04687982|Experimental|mDLI infusion|"The planned number of mDLI is 3.~Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
89046728|NCT04671147||Skull tong femoral traction|
89046729|NCT04671147||Cotrell longitudinal traction|
89046730|NCT04571723|Active Comparator|Established Diabetes Prevention Program|This arm will receive the established diabetes prevention program curriculum.
89046731|NCT04571723|Active Comparator|Health Mindset modified Diabetes Prevention Program|This arm will receive the modified curriculum with the added health mindset information.
89046732|NCT01776606|Active Comparator|Dose A|Dose A: Botulinum toxin type A
89046733|NCT01776606|Placebo Comparator|Dose B|Dose B: Placebo
89046734|NCT04670952|Experimental|Low Pressure Laparoscopic Cholecystectomy|"LPLC refers to Low Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 10mmHg."
89046735|NCT04670952|Other|Standard Pressure Laparoscopic Cholecystectomy|"This is taken as the control group. SPLC refers to Standard Pressure Laparoscopic Cholecystectomy. In this arm, the pneumoperitoneum pressure is set as 14 mmHg."
89046736|NCT01774578|Active Comparator|Arm 1: Docetaxel|"Arm 1: Docetaxel 75 mg/m^2 IV given every 3 weeks x 4 doses. If response or stable: Observe until disease progression.~First Progression: Gemcitabine 1250 mg/m^2/week for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity."
89046737|NCT01774578|Experimental|Arm 2a: HyperAcute®-Lung Immunotherapy (weekly)|"Arm 2a: 300 Million HAL cells given by intradermal injection weekly for 11 weeks and then every 2 months for 5 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
89046738|NCT01774578|Experimental|Arm 2b: HyperAcute®-Lung Immunotherapy (biweekly)|"Arm 2b: 300 Million HAL cells given by intradermal injection biweekly for 6 doses and then every month for 10 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
89046739|NCT01756482|Experimental|GS-5806|GS-5806, powder for oral solution
89046740|NCT01756482|Placebo Comparator|Sugar powder for oral solution in juice|Sugar powder for oral solution
89046741|NCT04543994|Experimental|Remestemcel-L (150 million cells)|"Targeted endoscopic delivery of remestemcel-L at a dose of 150 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)."
89213419|NCT01002261||Liver cirrhosis and healthy subjects|Patients with liver cirrhosis and healthy subjects
89656900|NCT01032135|Experimental|2-MI-IOP Non-Engaged|Randomized to treatment as usual, and do not attend.
89656901|NCT01032135|Active Comparator|3-MI-PC Engaged|Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
89656902|NCT01032135|Experimental|4-MI-PC Non-engaged|Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
89656903|NCT04358133|Experimental|Chlorhydrate de morphine|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
89656904|NCT04358133|Placebo Comparator|NaCl 0,9%|initial dose of 2 mg, followed by 1 mg every 3 minutes until a VAS-dyspnea <40 then relay subcut
89656905|NCT01032759|Active Comparator|Memantine|
89656906|NCT01032759|Placebo Comparator|Placebo|Placebo
89656907|NCT01032993|Active Comparator|Coenzyme Q10|600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
89656908|NCT01032993|Placebo Comparator|Placebo|Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
89656909|NCT03015285|Experimental|Anxiety Sensitivity Cognitive Therapy|Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.
89656910|NCT03015285|Active Comparator|Disorder specific Cognitive Therapy|Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.
88994003|NCT02945605|Experimental|Early Vestibular Rehabilitation|Participants in this group will receive a customized vestibular rehabilitation program designed and implemented by a vestibular physical therapist. The vestibular physical therapy must be initiated within 72 hours after randomization. Participants in this group will continue to receive standard of care treatment as directed by their physician.
88994004|NCT02945605|Active Comparator|Standard of Care|Participants in this group will receive standard care as directed by their physician.
88994005|NCT02945527|Active Comparator|Acetazolamide|750 mg acetazolamide p.o. divided in three dily doses, for 10 days
88994006|NCT02945527|Active Comparator|Dexamethasone|8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
88994007|NCT02945527|No Intervention|No additional anti-edema treatment|No additional treatment
88994008|NCT02945371|Experimental|IC Training|"The experimental arm (ARM1) is a person-centered inhibitory control training intervention, or PeCIC.~Between the baseline and endpoint sessions, participants come to our lab 12 times to participate in the training sessions. Each participant is randomly assigned to either the PeCIC training or an active control training. The training sessions will take place approx. every other day for 24 days.~Beginning 2-3 days after the baseline session, the experimental group (will come to our behavioral testing lab to receive the PeCIC training. At 11 sessions spaced one every other day, participants will complete one 8-min run of a modified stop-signal task. The cue on each trial (preceding the go signal arrow) will be an image of a personalized risk-cue (PRC) or a neural image."
88994009|NCT02945371|Active Comparator|Control Training|Participants in the active control group (ARM2) of the PeCIC intervention will come to the behavioral testing laboratory to complete an 8-min control task every other day for 12 sessions. This control task is identical to the PeCIC except the auditory stop cues are omitted. All other procedures, settings, and schedules are identical to those in the experimental group. The only difference between the groups is that the active control does not practice IC.
88994010|NCT02448095||CML ph+ patients|Chronic myeloid leukemia patients who are philadelphia positive
88994011|NCT03458650|Experimental|LXI-15028 50 mg|For 50 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
88994012|NCT03458650|Experimental|LXI-15028 100 mg|100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
88994013|NCT03458650|Experimental|LXI-15028 200 mg|200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
88994014|NCT00529477|Active Comparator|1|The Wright Nebulizer will be used to perform the methacholine challenge in arm 1.
88994015|NCT00529477|Active Comparator|2|The Pari LC nebulizer will be used to perform the methacholine challenge in arm 2.
88994016|NCT00529477|Active Comparator|3|The Pari Sinustar nebulizer will be used to perform the methacholine challenge in arm 3.
89656911|NCT01033227|No Intervention|No drug|No study drug administered
89656912|NCT01033227|Experimental|Sodium nitrite injection, USP|Administration if sodium nitrite injection, USP
89656913|NCT01033383|Placebo Comparator|3 placebo capsules|3 placebo capsules qd
89656914|NCT01033383|Experimental|1 cranberry capsule & 2 placebo capsules|1 active cranberry capsule and 2 placebo capsules qd
89656915|NCT01033383|Experimental|2 cranberry capsules & 1 placebo capsule|2 active cranberry capsules and 1 placebo capsules qd
89656916|NCT01033383|Experimental|3 cranberry capsules|3 active cranberry capsules qd
89656917|NCT01033773|Other|Diabetes education and medication management|All enrolled patients received the intervention. There was no comparative arm. The analysis was done as pre and post.
89656918|NCT02167815|Active Comparator|Standard care|standard care ( such as alginate, hydrofiber or other treatment)
89656919|NCT02167815|Experimental|Intervention ( Mepilex XT)|
89656920|NCT01053507|Active Comparator|Treximet|In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.
89656921|NCT01053507|Placebo Comparator|Placebo|In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.
89656922|NCT01053819|Experimental|Etanercept|open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
89656923|NCT01053897|Experimental|GBT009|
89656924|NCT01053897|Placebo Comparator|Placebo|
89656925|NCT01054209|No Intervention|A: standard care, no warming|Control arm. Full standard care. No mattress warming. May receive warmed fluids if standard practise for clinician
89656926|NCT01054209|Active Comparator|B: electric warming mattress|Warming with warming mattress
89656927|NCT01054911|Experimental|Sunitinib pill|Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.
89656928|NCT04184427|Active Comparator|Group I|6 mm height of power arm
89656929|NCT04184427|Experimental|Group II|3 mm height of power arm
89656930|NCT04184427|Experimental|Group III|9 mm height of power arm
89656931|NCT01055067|Experimental|Tivantinib (ARQ 197)|3 capsules of 120 mg each, administered twice a day (once in the morning and once in the evening - total daily dose of 720 mg) in continuous 4-week cycles
89656932|NCT01055223||Type 2 diabetes subjects|Type 2 diabetes subjects
88994017|NCT02444000|Experimental|experimental|Administration of 6 cycles of PCV chemotherapy PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
88994018|NCT02444000|Active Comparator|control|radiotherapy followed by 6 cycles of PCV chemotherapy given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
88994019|NCT00529594|Placebo Comparator|Control Group|Patients who received placebo
89656933|NCT02168361|Active Comparator|Standard|Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
89656934|NCT02168361|Experimental|Simeprevir + Sofosbuvir|(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
89656935|NCT01360554|Experimental|A|Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
89656936|NCT01360554|Active Comparator|B|Blinded active comparator (erlotinib) + blinded placebo PF-00299804
89656937|NCT01055769|Other|Group 1|Subjects will accept Linezolid OS 600 MG first, after 4 days wash-out, then will accept Linezolid tablet 600 MG.
89656938|NCT01055769|Other|Group 2|Subjects will accept Linezolid tablet 600 MG first, after 4 days wash-out, then will accept Linezolid OS 600 MG.
89656939|NCT03014973|Experimental|prostate cancer patients resistant to castration|
88994020|NCT00529594|Active Comparator|Treatment Group|Patients who received etoricoxib 120 mg
88994021|NCT00529672|Active Comparator|1|Surgery: crossectomy plus short stripping
88994022|NCT00529672|Active Comparator|2|ultrasound guided sclerotherapy with foam (3% polidocanol)
88994023|NCT00529672|Active Comparator|3|Endovenous laser therapy (940 nm, about 70 J/cm)
88994024|NCT00173862|Experimental|A|
88994025|NCT00529711|Experimental|Group 1|Hypertonic lactate
88994026|NCT00529711|Active Comparator|Group 2|Ringer's lactate
88994027|NCT00529750|Experimental|Irbesartan Group|150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
88994028|NCT00529750|Active Comparator|Atenolol Group|50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
88994029|NCT02387606|Experimental|Cohort 1|Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
88994030|NCT02387606|Experimental|Cohort 2|Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
88994031|NCT02387606|Experimental|Cohort 3|Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.
88994032|NCT00529867|Active Comparator|A|
88994033|NCT00529867|Active Comparator|B|
88994034|NCT02944708|Active Comparator|Conventional chemotherapy|Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.
88994035|NCT02944708|Experimental|Maintenance chemotherapy 1|Patients in this arm will receive 6 cycles of oral fluoropyrimidine monotherapy as maintenance therapy, in addition to 4-8 cycles of cisplatin-based standard chemotherapy.
88994036|NCT02944708|Experimental|Maintenance chemotherapy 2|Patients in this arm will receive oral fluoropyrimidine maintenance therapy until disease progression or intolerable toxicities, after 4-8 cycles of cisplatin-based standard chemotherapy.
89656940|NCT03014973|Experimental|patients naif of hormonal treatment|
89656941|NCT01057017|Experimental|intervention|"Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.~Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
89656942|NCT01059357|Experimental|Transoral Robotic Surgery (TORS)|Transoral Robotic Surgery (TORS) using the Da Vinci Robotic Surgical System
89656943|NCT03061110|Active Comparator|Usual Care|Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
89656944|NCT03061110|Experimental|Stromal Vascular Fraction|Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
88994037|NCT02376686|Experimental|Music intervention|Patient receives Music Intervention before going to sleep.
88994038|NCT02376686|No Intervention|treatment as usual|Patient receives Treatment as usual.
88994039|NCT02944630|Experimental|Experimental:|Receiving psychotherapy and medical treatment.
88994040|NCT02944630|No Intervention|Control|Awaiting group: Receiving medical treatment.
88994041|NCT00168480|Experimental|1|Botulinum Toxin Type A
88994042|NCT02944435|Experimental|CB-839 Capsules|A single dose of 3 x 200-mg capsules of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
89656945|NCT01360398|Other|Cohort|COPD male and female patients between 40 and 85 years of age, recruited among the patients of the Southampton General Hospital and referring practices.
89656946|NCT04972032|Experimental|Estrogen Intrauterine Stent System|An Intrauterine Stent System with estrogen will be introduced into the uterine cavity after TCRA(transcervical resection of adheison).
89656947|NCT04972032|Other|Foley balloon combined with self-cross-link sodium hyaluronate gel|Subjects will be given Foley balloon (manufacturer: Zhanjiang Star Enterprise Co., Ltd.) combined with self-cross-linked sodium hyaluronate gel (manufacturer: BioRegen Biomedical (Changzhou) Co., Ltd.) after TCRA surgery.
89656948|NCT03061968|Experimental|experimental group|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
89656949|NCT03061968|No Intervention|control group|The control group only receive routine care in sick baby room unite.
89656950|NCT03062046|Experimental|RF ablation|Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
89656951|NCT04433208|Experimental|Cohort 1 (PPI + probiotic)|Subjects in Cohort 1 will take a PPI and a probiotic orally once daily on Days 1-7. Subjects will mix the probiotic in an aqueous diluent supplied by the pharmacy and ingest between 1-2 hours after taking a PPI.
89656952|NCT04433208|Experimental|Cohort 2 (Complex oligosaccharide + PPI)|Subjects in Cohort 2 will take the complex oligosaccharide orally twice daily on Days 1-14. On Days 1-7, the first dose of the complex oligosaccharide will be taken between 1-2 hours after taking a PPI. On Days 8-14, subjects will not take a PPI prior to the complex oligosaccharide.
89656953|NCT04433208|Experimental|Cohort 3-6 (Complex oligosaccharide + PPI +probiotic)|Subjects in Cohort 3, 4, and 6 will take a complex oligosaccharide orally twice daily (doses will vary per cohort) on Days 1-14 in combination with a probiotic orally once daily on Days 1-7. Cohort 5 will undergo the same dosing regimen a second time on days 29-43
89656954|NCT04971330||Known HCV Ab Positive Patients|leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for positive samples.
89656955|NCT04971330||Hospitalized Patients|"leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for hospitalized patient.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
89656956|NCT04971330||Unselected Blood Donors|"Leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. les. For blood donors, Abbott PRISM HCV will be used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status."
89656957|NCT03062514|Experimental|Experimental|Subjects'Vagus Nerve stimulator is on always
89656958|NCT03062514|Sham Comparator|Control|Subjects'Vagus Nerve stimulator is off from enrollment to 3 month
88994043|NCT02944435|Active Comparator|CB-839 Tablets|A single dose of 3 x 200-mg tablets of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
88994044|NCT01708538|Active Comparator|Epithelium on|Epi not removed during CXL treatment
88994045|NCT01708538|Active Comparator|Epithelium off|Epi removed before CXL treatment
88994046|NCT02945449|Experimental|Dose I|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.
88994047|NCT00168519|Active Comparator|1|
88994048|NCT00144521|Experimental|1|
88994049|NCT00144521|Active Comparator|2|
88994050|NCT04692376|Experimental|MSCs group|MSCs group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously) weekly for 8 doses. Besides, glucocorticoids and cyclosporine (CsA) will be used for treatment concurrently.
88994051|NCT04692376|Active Comparator|Control group|Glucocorticoids and CsA will be used for treatment.
88994052|NCT00527527|Active Comparator|1|8 flexion distraction visits
88994053|NCT00527527|Active Comparator|2|12 flexion distraction visits
88994054|NCT00527527|Active Comparator|3|18 flexion distraction visits
88994055|NCT00527527|Placebo Comparator|4|8 placebo control visits
88994056|NCT00527683|Active Comparator|A|Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
88994057|NCT00527683|Placebo Comparator|B|Orange juice and administration identical to Arm A.
88994058|NCT00527761|Experimental|Temozolomide, Docetaxel + Cisplatin|
88994059|NCT00527800|Experimental|1|Treatment for episodes of uncomplicated malaria
88994060|NCT00527800|Active Comparator|2|Treatment for uncomplicated malaria
88994061|NCT00527800|Experimental|A|Prevention of malaria in HIV uninfected, exposed children
88994062|NCT00527800|No Intervention|B|Prevention of malaria in HIV uninfected, exposed children
88994063|NCT00168558|Active Comparator|1|Standard titre Edmonston-Zagreb measles vaccine at 4½ and 9 months of age
88994064|NCT00168558|Active Comparator|2|Standard titre Schwarz measles vaccine at 9 months of age
88994065|NCT00168558|Active Comparator|3|Standard titre Edmonston-Zagreb measles vaccine at 9 months of age
88994066|NCT00144599|Experimental|1|
88994067|NCT00144599|Placebo Comparator|2|
89046742|NCT04543994|Experimental|Remestemcel-L (300 million cells)|"Targeted endoscopic delivery of remestemcel-L at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial)."
89046743|NCT04543994|Placebo Comparator|Placebo|"Direct injection of normal saline into the submucosal layer of the colon wall.~If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.~If at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
89656959|NCT04979208||Acute myocardial infarction (AMI) cohort|Adult patients with recent acute myocardial infarction admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis all recent AMI patients less than 24 hours old diagnosed by emergency physicians on the basis of suggestive clinical symptoms and electrocardiogram (ECG) criteria, cared in the 30 emergency units and 19 mobil intensive care unit, with a coronary angiography or a percutaneous coronary intervention (PCI) realized in the 11 cathlabs in Aquitaine
89656960|NCT04979208||Stroke cohort|Adult patients with recent stroke admitted to an hospital in the French Aquitaine region between January 1st 2019 and August 31 2020 and included in the ongoing, permanent, multicenter, retrospective and nominative ObA2 and REANIM/ACIRA registries. Were included in the analysis recent ischemic or hemorragic stroke patients with brain imaging managed in one of the 14 participating hospitals in Aquitaine (7 stroke units and 7 primary care centers).
89656961|NCT04970940|Experimental|Sequence 1|"Period 1: Treatment A(AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days)~Wash-out for 7 days~Period 2: Treatment B(AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days)~Period 3: Treatment C(AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days)"
89656962|NCT02896608||Dravet syndrome - HCN1 channel mutation|early infantile epileptic encephalopathy with HCN1 channel mutation
89656963|NCT02896608||control with epilepsy|
89046744|NCT04519697|Experimental|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
89046745|NCT04519697|Placebo Comparator|Placebo|Direct injection of normal saline with a possible repeat injection at 3 months if not completely healed from the first injection. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula.
89046746|NCT04670601|Experimental|Flurbiprofen 8.75 mg|Flurbiprofen 8.75 mg lemon and honey flavour lozenge
89656964|NCT02896608||control without epilepsy|
89656965|NCT04978974|Experimental|Patients with type 2 Diabetes mellitus and Hypertension|patients with type 2 diabetes mellitus and hypertension were selected by using purposive sampling technique to apply stress management program
89046747|NCT04670601|Active Comparator|Strepfen 8.75 mg|Strepfen 8.75 mg lemon and honey lozenge
89046748|NCT04670913|Experimental|Camrelizumab plus Apatinib|Camrelizumab, 200mg, q3w, iv and Apatinib, 250mg, qd, po
89046749|NCT04419896||Retrospective|"Inclusion criteria for Retrospective Subjects:~Men and women 18 years or older;~Is or was a patient of a Participating Practice and was previously tested with Germline, Genomic, or other Biomarker Tests; and~For Germline Genetic Test patients, have a diagnosis of cancer or pathogenic or likely pathogenic (P/LP) result."
89046750|NCT04419896||Prospective|"Inclusion criteria for Prospective Subjects:~Men and women aged 18 years or older;~Presents consecutively to a Participating Practice and who has previously been screened and tested (i.e., is a new patient scheduled for a visit at a Participating Practice or is an existing patient who returns to a Participating Practice);~Receives or has received Germline, Genomic, or other Biomarker Testing, either through a prior healthcare provider or a Participating Practice; and~Consents to be a part of the Registry."
89046751|NCT04671069|Experimental|MGL-3196 100 mg tablet plus Clopidogrel 75 mg tablet|
89046752|NCT04670835||Case Group (unic)|"Group/Cohort Label :~Users of Emergency Call Centers Users of French territory 'Region Pays de la Loire'~Group/Cohort Description:~All Users calling through the five Emergency Medical Centers of the French Pays de la Loire region (5 areas of the region are : Loire-Atlantique, Maine-et-Loire, Mayenne, Sarthe, Vendée).~In each Emergency Medical Center, an advanced telephone system automatically keeps track of all inbound calls.~Average annual number of incoming calls for the 5 Emergency Medical Center of Pays de la Loire region is 1,6 million."
89046753|NCT04374539|Experimental|Plasma exchange|Plasma exchange with human serum albumin + Polyclonal immunoglobulin + standard medical treatment
89046754|NCT04374539|Active Comparator|Standar medical treatment|Standar medical treatment
89213420|NCT01002417|Placebo Comparator|Placebo|Both the phase 2b and phase 3 parts of the study have the placebo arm.
89656966|NCT04978896|Experimental|Intervention group: Stress-coping Program|Participants will complete an 8-day self-guided programme on stress-coping delivered via a mobile-phone application with daily exercises guided by cognitive-behavioural principles.
89656967|NCT04978896|Active Comparator|Control group|Participants will complete an 8-day self-guided programme on cooperation delivered via a mobile-phone application with daily exercises that differ to the intervention group in terms of content but are comparable in terms of duration.
89656968|NCT04978194|Experimental|Online group|"Online group: online university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included:~9- video capsules (one per week)~An exchange room on each video on a private discord group"
89656969|NCT04978194|Experimental|Hybrid group|"Hybrid group: hybrid university-based 9-weeks intervention to promote better management of emotions and learning. This intervention included: 10 lessons of 2 hours including~The viewing of the videos~A time of exchange between students, and with the teacher"
89656970|NCT04978194|No Intervention|Control group|Control group: No intervention, only two measurement times of 9 weeks apart. Nothing has changed.
89656971|NCT04970706||Healthy Volunteers|Volunteers were healthy people without ACL rupture
89656972|NCT04970706||Patients with ACL Rupture|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
89656973|NCT04152564|Active Comparator|levo-bupivacaine continuous epidural infusion [CEI])|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion. Proper placement of the catheter was verified through an aspiration test and a test dose (2 ml) of lidocaine 2%. At the end of surgery, a 14 ml bolus of L-bupivacaine 0.125 will be administered through the catheter and then a continuous rate of .1 ml/kg/h infusion of L-bupivacaine 0.125 will be delivered.
89656974|NCT04152564|Active Comparator|Levo-bupivacaine continuous preperitoneal infusion [CPI]),|At the end of surgery and after the closure of the peritoneal layer, the preperitoneal catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing. Thereafter, a 20 ml bolus of L-bupivacaine 0.25% will be administered through the catheter and then a continuous fixed-rate infusion of L-bupivacaine 0.25% will be delivered.
89656975|NCT04970784||Patients cared for by the adult sector|Patients admitted to emergencies, non-hospitalized and cared for by the adult sector of emergencies (classical emergencies)
89656976|NCT04970784||Patients cared for by the geriatric sector|Patients admitted to emergencies, non-hospitalized and cared for by the geriatric sector of emergencies
89656977|NCT04970628||Study group|Patients performed airway obstruction after anterior cervical operation
89656978|NCT04970628||Control group|Patients did not perform airway obstruction after anterior cervical operation
89656979|NCT04977960|No Intervention|Reference group|"Patients randomized to the Reference Group will receive the standard-of-care treatments, according to institutional procedures in force:~Dexamethasone i.v. 6 mg die for consecutive 5 days~Methylprednisolone i.v. 40 mg bid for consecutive 10 days~Low-molecular-weight-heparin i.v. at standardized dose of 70 UI/kg twice~Remdesivir i.v. 200 mg in bolus (1st day) then 100 mg die for 4 days; remdesivir will be used only in patients supported with low-flow nasal cannula oxygen or Venturi mask~Antibiotic therapy:~azithromycin: 500 mg/die per os for 5 days~ceftriaxone: 2 g i.v. die for 8 days"
89656980|NCT04977960|Experimental|Experimental Group|Patients randomized in the Experimental Group will receive canrenone as add-on therapy to standard-of-care treatments. Different starting doses of i.v. canrenone will be administrated in a single or double infusion per day, for 7 days, according to the serum concentration of potassium at randomization
89046755|NCT01753167|Experimental|MCMV5322A/MCMV3068A|Participants will receive a total of four doses of study drug administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57. MCMV5322A/MCMV3068A will be tested in this study at 10 milligrams per kilogram (mg/kg) of each component antibody. Thus, at each dose, 10 mg/kg of MCMV5322A and 10 mg/kg of MCMV3068A will be tested (20 mg/kg total).
89046756|NCT01753167|Placebo Comparator|Placebo|Participants will receive a total of four doses of placebo matched with MCMV5322A/MCMV3068A administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57.
89046757|NCT01741194|Experimental|AC-1204|Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed. Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.
89046758|NCT01741194|Placebo Comparator|Placebo|Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste. Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.
89046759|NCT04363346|Experimental|Dose Strategy 1|"Dose Strategy 1:~Day 1 - FT516 is given at 9x107 cells/dose (low)"
89656981|NCT02626026|Experimental|Cohort 1, Part A: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.
89046760|NCT04363346|Experimental|Dose Strategy 2|"Dose Strategy 2:~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid)"
89046761|NCT04363346|Experimental|Dose Strategy 3|"Dose Strategy 3:~Day 1 - FT516 is given at 9x107 cells/dose (low) + Day 4 - FT516 is given at 3x108 cells/dose (mid) + Day 7 - FT516 is given at 9x108 cells/dose (high)"
89046762|NCT04670718|Experimental|OCT probe|The examination of gastrointestinal tract resected specimen with the use of the OCT probe
89046763|NCT04332458|Other|Patients with stroke without exercise experience|Patients who are discharged from the hospital within one month after a minor stroke or TIA and are not offered physical rehabilitation afterwards
89046764|NCT04332458|Other|Patients with stroke with exercise experience|Patients with a minor stroke who have participated in an exercise study (HITPALS)
89046765|NCT01823016|Placebo Comparator|Placebo|
89656982|NCT02626026|Placebo Comparator|Cohort 1, Part A: Placebo|Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.
89046766|NCT01823016|Experimental|JNJ-38518168|
89046767|NCT04670211||Tooth-borne distractor|Maxillary distraction with the use of a tooth-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
89046768|NCT04670211||Bone-borne distractor|Maxillary distraction with the use of a bone-borne distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
89046769|NCT04670211||Hybrid distractor|Maxillary distraction with the use of a hybrid distractor following Surgically-assisted Rapid Palatal Expansion (SARPE) surgery.
89046770|NCT04322123|Experimental|Hydroxychloroquine|Hydroxychloroquine after randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 07 days.
89046771|NCT04322123|Experimental|Hydroxychloroquine + azithromycin|Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 07 days.
89046772|NCT04322123|No Intervention|Control|standard treatment protocol for 2019-nCoV infection.
89046773|NCT04670328||Covid-19 disease severity|Mild, moderate, severe and critical disease
89046774|NCT04670367|Placebo Comparator|Arm A: usual care|routine usual care
89046775|NCT04670367|Experimental|Arm B: walk|walk 30mins per day, 5 days per week.
89046776|NCT04670367|Experimental|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
89046777|NCT04670367|Experimental|Arm D: Baduanjin plus walk|walk 30mins then Baduanjin 12 mins per day, 5 days per week.
89046778|NCT04313348|Active Comparator|Control Arm|Study participants in this arm will receive no SMS reminders nor social supporter notifications.
89656983|NCT02626026|Experimental|Cohort 2, Part A: Tirabrutinib 10 mg BID|Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
89656984|NCT02626026|Placebo Comparator|Cohort 2, Part A: Placebo|Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
89656985|NCT02626026|Experimental|Part B: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally QD for 4 weeks.
89046779|NCT04313348|Experimental|Intervention Arm 1|"Participants will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery at their preferred time and day of the week will be sent to study participants. The content of the SMS reminders will be customized and determined by each individual at enrollment. If the participant has no preference, we will suggest This is your ANC visit reminder, encouraging you to attend. This technology is already integrated and running in Uganda via the Yo! Uganda Gateway."
89046780|NCT04313348|Experimental|Intervention Arm 2|"Participants will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information and SMS reminders same as those of scheduled SMS arm above + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for the study participant they are supporting for all the study follow-up period (also called the social support engagement arm). Social supporters will be able to personalize the SMS content at enrollment. They will be advised to assist study participants with any problems that may affect ANC attendance or facility delivery, but will not be given specific instructions on what to do."
89046781|NCT04670289|Experimental|Treatment|TenoMiR intralesional injection
89046782|NCT04670289|Placebo Comparator|Placebo|0.9% saline intralesional injection
89046783|NCT01741155|Experimental|Single Arm Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 IV followed by docetaxel 75 mg/m2 IV. Cycles will continue every 3 weeks until progression or intolerable toxicity.
89046784|NCT01741155|Experimental|Randomized Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m^2 of SPI-1620 intravenous (IV) followed by docetaxel 75 mg/m^2 IV administered in 3-week cycles until progression or intolerable toxicity.
89046785|NCT01741155|Active Comparator|Randomized Part: Docetaxel|Patients will receive 75 mg/m^2 docetaxel in 3-week cycles until progression or intolerable toxicity.
89046786|NCT04244630|Other|Antioxidants|Eligible patients will receive over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses.
89046787|NCT04670406|Experimental|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
89046788|NCT04239053||ESPB block group|Patients receiving ESPB will be enrolled to this group.
89046789|NCT04670250||newly diagnosed patients with ulcerative colitis|patients who are newly diagnosed to have ulcerative colitis who are above 18 years old,not pregnant and not known to have cancer colon
89046790|NCT00556179|Experimental|1|
89656986|NCT02626026|Placebo Comparator|Part B: Placebo|Placebo to match tirabrutinib capsules orally QD for 4 weeks.
89656987|NCT01059435|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of matching placebo administered by subcutaneous or intravenous injection.
89656988|NCT01059435|Experimental|Romosozumab|Participants were randomized to receive a single dose of romosozumab administered by subcutaneous or intravenous injection. The starting dose was 0.1 mg/kg, with sequential escalation up to 10 mg/kg.
89656989|NCT03016221|Experimental|Axanova hot gel|Intervention: Axanova hot gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
89656990|NCT03016221|No Intervention|Axanova hot gel control|No product application. The contralateral lumbar back side acts as a Axanova hot gel control.
89656991|NCT03016221|Experimental|Axanova activ gel|Intervention: Axanova activ gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
89656992|NCT03016221|No Intervention|Axanova activ gel control|No product application. The contralateral lumbar back side acts as a Axanova activ gel control.
89046791|NCT01718145|Experimental|Arm 1: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Naive cohort"
89046792|NCT01718145|Active Comparator|Arm 2: Telaprevir + pegIFNα-2b + Ribavirin|"Telaprevir 750 mg tablets by mouth three times daily, pegIFNα-2b 1.5 μg/kg solution by Subcutaneous weekly & Ribavirin 600- 1000 mg Capsules by mouth twice daily for 24 Weeks~- Naive cohort"
89046793|NCT01718145|Experimental|Arm 3: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Relapser cohort"
89046794|NCT04687748|Experimental|EMG BF Group|Pelvic floor muscle contraction will be performed via an S-EMGBF device; patients in the s-EMGBF group will receive visual and auditory feedback.
89046795|NCT04687748|Active Comparator|Control Group|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds.
89046796|NCT00556257|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications.
89046797|NCT00556257|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive select standard of care medications.
89046798|NCT04687787|Experimental|Group I|This group will receive Core Stability Exercises with Application of TENS
89046799|NCT04687787|Active Comparator|Group II|This group will receive Routinely prescribed Exercises with application of TENS
89046800|NCT01712451|Experimental|LIPO-102, Low|
89046801|NCT01712451|Experimental|LIPO-102, Mid|
89046802|NCT01712451|Experimental|LIPO-102, High|
89046803|NCT01712451|Experimental|LIPO-102; Placebo|
88994068|NCT02945293||Study Procedures|Study procedures include a screening visit, a study day visit, and a follow-up phone call. Oxycodone is administered on the study day.
88994069|NCT02945332|Experimental|Required supervised walking|Device: Fitbit Flexes
88994070|NCT02945332|Active Comparator|Non-required supervised walking|Device: Fitbit Flexes
88994071|NCT04692415|Active Comparator|degludec arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IDeg-100 In phase one they received IDeg-100 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IDeg-100 to IGlar-300 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
88994072|NCT04692415|Active Comparator|glargine arm|25 patients were discontinued their previous therapy and given metformin alone (2 g/day) for seven days. After seven days they were randomized to first receive IGlar-300 In phase one they received IGlar-300 and metformin for 12 weeks. Phase one was followed by a second wash-up period in which patients received metformin alone again for seven days. In phase two, which also lasted for 12 weeks, patients were switched from IGlar-300 to IDeg-100 (and metformin was continued). The initial dose of both insulins was 0.2 IU/kg.
88994073|NCT00527917|Experimental|Uracyst|Sodium chondroitin sulfate
88994074|NCT00527917|Placebo Comparator|Placebo|placebo
88994075|NCT02945176|Experimental|ARGOS-IO system|"The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.~Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation~Accessories: MESOGRAPH reading device, Implant Injector"
88994076|NCT02945215|Experimental|IBI301|
88994077|NCT02945215|Active Comparator|Rituximab|
88994078|NCT00531115|Experimental|1|
88994079|NCT00531193|Other|1|Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
88994080|NCT02943616|Experimental|Absorb BVS|Subjects receiving Absorb GT1 Bioresorbable Vascular Scaffold (BVS).
89656993|NCT03016221|Experimental|Perskindol Dolo Gel|Intervention: Perskindol Dolo Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
89656994|NCT03016221|No Intervention|Perskindol Dolo Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Dolo Gel control.
89656995|NCT03016221|Experimental|Perskindol Classic Gel|Intervention: Perskindol Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
89656996|NCT03016221|No Intervention|Perskindol Classic Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Classic Gel control.
89656997|NCT03016221|Experimental|Perskindol Cool Kühl-Gel|Intervention: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
89656998|NCT03016221|No Intervention|Perskindol Cool Kühl-Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Cool Kühl-Gel control.
89656999|NCT03016221|Experimental|Dolor-X Hot Gel|Intervention: Dolor-X Hot Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
89657000|NCT03016221|No Intervention|Dolor-X Hot Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Hot Gel control.
89657001|NCT03016221|Experimental|Dolor-X Classic Gel|Intervention: Dolor-X Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
89657002|NCT03016221|No Intervention|Dolor-X Classic Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Classic Gel control.
89657003|NCT03016221|Experimental|Dolor-X Cool Gel|Intervention: Dolor-X Cool Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
89657004|NCT03016221|No Intervention|Dolor-X Cool Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Cool Gel control.
89657005|NCT05593419||Immunotherapy Group|
89657006|NCT05593263|Experimental|Clear corneal incisions|the Steep meridian will be identified and marked, One clear corneal incision will be made on one side of the steep axis using 2.4mm keratome knife then enlarged to 4mm after completion of cataract surgery & other corneal 4mm incision is added to the other side of the steep axis
89657007|NCT05593263|Experimental|Limbal relaxing incision|Single or paired LRI will be performed on the steep axis prior to phaco-emulsification procedure using a 600 μm diamond guarded blade.
89657008|NCT01062009|No Intervention|Control group|No intervention
89657009|NCT01062009|Active Comparator|Low dose group|250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
89657010|NCT01062009|Active Comparator|Medium dose group|500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
89657011|NCT01062009|Active Comparator|High dose group|750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
89657012|NCT01062165|Experimental|Capsofungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
88994081|NCT00144755|Active Comparator|R-CHOP21|8 cycles of R-CHOP21
88994082|NCT00144755|Experimental|R-CHOP21, Darbepoetin alfa|8 cycles of R-CHOP21 + prophylactic darbepoetin alfa
88994083|NCT00144755|Experimental|R-CHOP14|8 cycles of R-CHOP14
88994084|NCT00144755|Experimental|R-CHOP14, Darbepoetin alfa|8 cycles of R-CHOP14 + prophylactic darbepoetin alfa
89657013|NCT03013725||The Homocysteine Study|Conducted in 1992-93, ca. 18000 participated.
89657014|NCT03013725||The Hordaland Health Study (HUSK)|Conducted in 1997-99, ca. 26000 participated.
89657015|NCT03015051|Experimental|High flow|High flow (2 L/kg/min) nasal cannula oxygen therapy
89657016|NCT03015051|Active Comparator|Low flow|Low flow (max 3 L/min) oxygen therapy
89657017|NCT04041843|Experimental|Abixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.
89657018|NCT03952767|Experimental|Digital Physical Measures and Survey Assessments|Digital physical measure data will be collected in clinic and at home and survey assessments will be collected
89657019|NCT05592873||Patients with locally advanced rectal adenocarcinoma|Patients with histollogically confirmed locally advanced rectal adenocarcinoma (clinical T3-T4N0M0 or T(any) N+M0) treated with neoadjuvant CRT followed by curtive intent elective surgery.
89657020|NCT01067781|Experimental|1|Two vaccination regimen with an LT patch (no swabbing)
89657021|NCT01067781|Experimental|2|Two vaccination regimen with an LT patch (with swabbing)
89657022|NCT01067781|Placebo Comparator|3|Two vaccination regimen with a placebo patch (no swabbing)
89657023|NCT01067781|Placebo Comparator|4|Two vaccination regimen with a placebo patch (with swabbing)
89657024|NCT01068873|Experimental|open label single arm|Drug: lopinavir/ritonavir plus maraviroc
89657025|NCT03015207|Experimental|NNC0194-0499|Injected s.c. /subcutaneously (under the skin)
89657026|NCT03015207|Placebo Comparator|Placebo|Injected s.c. /subcutaneously (under the skin)
89657027|NCT01069185|Experimental|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
89657028|NCT01069185|Other|Routine endotracheal suctioning|Endotracheal suctioning every two hours
89657029|NCT05592795||Patients with Gallbladder polyp or gallbladder adenomyosis|Patients with Gallbladder polyp or gallbladder adenomyosis In view of the difficulty in obtaining bile from normal people, our research team plans to select bile samples from patients undergoing laparoscopic cholecystectomy and patients with pathological diagnosis of gallbladder polyps or gallbladder adenomyosis as physiological bile of normal people.
89657030|NCT05592795||Patients with choledocholithiasis|Patients with choledocholithiasis The research group plans to select bile samples from patients with first episode choledocholithiasis, patients receiving ERCP treatment for the first time, and patients undergoing duodenal papillary incision during EST operation to study the biliary flora of patients with choledocholithiasis. Compared with the normal group, analyze whether there are differences, similarities and uniqueness between the groups, dynamically track changes in the structure of biliary flora before and after treatment, and whether there is specific flora related to the type of disease, and compared with the existing biliary microbiome database, to study whether there are new bacterial species.
89657031|NCT05592795||Patients with previous ERCP and/or EST operations and duodenal papilla incision during operation|Patients with previous ERCP and/or EST operations and duodenal papilla incision during operation Bile from patients who had undergone ERCP and EST duodenal papillary incision was collected, and the long-term impact of duodenal papillary incision on biliary microecology was discussed by comparing with that of normal patients.
89657032|NCT03014895|Placebo Comparator|Cohort 1: Placebo|Intravenous placebo infusion
89657033|NCT03014895|Experimental|Cohort 1: E3112|Intravenous E3112 infusion
89657034|NCT03014895|Placebo Comparator|Cohort 2: Placebo|Intravenous placebo infusion
89657035|NCT03014895|Experimental|Cohort 2: E3112|Intravenous E3112 infusion
89657036|NCT03014895|Placebo Comparator|Cohort 3: Placebo|Intravenous placebo infusion
89657037|NCT03014895|Experimental|Cohort 3: E3112|Intravenous E3112 infusion
89657038|NCT03014895|Placebo Comparator|Cohort 4: Placebo|Intravenous placebo infusion
89657039|NCT03014895|Experimental|Cohort 4: E3112|Intravenous E3112 infusion
89657040|NCT03014895|Placebo Comparator|Cohort 5: Placebo|Intravenous placebo infusion
88994085|NCT02943382|Experimental|Fingerprick Autologous Blood (FAB)|Assigned treatment with FAB
88994086|NCT00531310|Experimental|Matched Family Donor|Matched Family Donor
89657041|NCT03014895|Experimental|Cohort 5: E3112|Intravenous E3112 infusion
89657042|NCT01072617|Experimental|Safety of rTMS in schizophrenia patients|Participants will receive repetitive transcranial magnetic stimulation via MagPro x100 device to the vermis of cerebellum twice a day over 5 days
89657043|NCT01072773|Experimental|Bortez/Cyc/Dex|Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
89657044|NCT01074099|Active Comparator|Control|CABG only
89657045|NCT01074099|Experimental|BMAC enhanced CABG|Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
89657046|NCT03013647|Other|Actinic Keratosis|Twenty patients with multiple thin AK on the face will be treated with Daylight Photodynamic Therapy with methyl aminolevulinate Skin biopsies before and after treatment will be performed in an AK lesion and in a field cancerization area.
89657047|NCT01074177|Experimental|BIBW 2992|BIBW 2992 Taken orally once a day
88994087|NCT00531310|Experimental|Unrelated Donor|Unrelated Donor Transplant/ Cord Blood Transplant
88994088|NCT00528034|Experimental|Lymphoscintigraphy|
88994089|NCT02944864|Experimental|TQ-B3395|TQ-B3395 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89657048|NCT03014661||Single group study|Single Group study investigating retrospectively the Quality of life of patients with pollinosis under or after specific immunotherapy with Pollinex quattro
89657049|NCT01075347|Active Comparator|Autologous serum use|Patients treated with additional 20% autoserum after diabetic vitrectomy or penetrating keratoplasty
89657050|NCT01075347|Placebo Comparator|Non-autologous serum use|Patients treated with traditional medication(0.1% betamethasone, 0.3% gentamicin and 0.4% tropicamide eye drops application 4 times daily) after diabetic vitrectomy or penetrating keratoplasty
89657051|NCT01076049|Active Comparator|Standard of Care (SoC)|For subjects randomized to the control group, the preferred irrigation solution was chosen by the site's emergency department physician(s).
89657052|NCT01076049|Active Comparator|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
89657053|NCT01076283|Active Comparator|Baclofen|Baclofen 10 mg three times a day (t.i.d.) for 8-10 days
89657054|NCT01076283|Placebo Comparator|Cyproheptadine|Cyproheptadine 2 mg t.i.d. for 8-10 days
89657055|NCT05570487||N0A Group|patients with negative lymph nodes and resected lymph nodes less than 15
89657056|NCT05570487||N0B Group|patients with negative lymph nodes and resected lymph nodes no less than 15
89657057|NCT05570487||N+A Group|patients with positive lymph nodes and resected lymph nodes less than 15
89657058|NCT05570487||N+B Group|patients with positive lymph nodes and resected lymph nodes no less than 15
89657059|NCT01076985||Lopinavir/ritonavir group|All pregnant women in this noninterventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
89213421|NCT01002417|Active Comparator|MCS-2 15 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 15 mg/day is selected as the optimal dosage.
89213422|NCT01002417|Active Comparator|MCS-2 30 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 30 mg/day is selected as the optimal dosage.
89657060|NCT02176005|Active Comparator|Moxifloxacin|Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
89657061|NCT02176005|Experimental|moxifloxacin + DAV132|Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
89213423|NCT01002495|Experimental|Cohort 1|Eight endocardial injection for a total dose of 1mg VM202
89213424|NCT01002495|Experimental|Cohort 2|Eight endocardial injections for a total dose of 2mg VM202
89213425|NCT01002495|Experimental|Cohort 3|Twelve endocardial injections for a total dose of 3mg VM202
89213426|NCT01005771|Experimental|GF-001001-00 2%|
89213427|NCT01005771|Experimental|GF-001001-00 1%|
89213428|NCT01005771|Experimental|GF-001001-00 0.25%|
89213429|NCT01005771|Placebo Comparator|Placebo|
89213430|NCT01005849|Experimental|Protecflor|
89213431|NCT01005849|Placebo Comparator|Placebo|
89657062|NCT02176005|Experimental|DAV132|DAV132 oral, 7.5g x3/day for 7 days
89657063|NCT02176005|Placebo Comparator|Negative control|Negative control: 7.5g x3/day for 7 days
89657064|NCT02176083|Experimental|Intervention|Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness
89657065|NCT02176083|No Intervention|Control|Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness
89657066|NCT05539911|Active Comparator|group f|patient received 50 mic fentanyl as an adjuvant to the local anesthetic mixture applied during peribulbar block in the operative eye
89657067|NCT05539911|Placebo Comparator|group C|received the traditional mixture used
89213432|NCT01005927|Placebo Comparator|No Fructooligosaccharide|0 g fructooligosaccharide added to calcium-containing beverage
89213433|NCT01005927|Active Comparator|3 g Fructooligosaccharide|3 g fructooligosaccharide added to calcium-containing beverage
89213434|NCT03742713|Experimental|CPC634 (CriPec® docetaxel)|CPC634 (CriPec® docetaxel) administered intra-venously every 21 days at 60 mg/m2
89213435|NCT01002651|Experimental|Wheat Bran Extract (high dose)|
89213436|NCT01002651|Experimental|Wheat Bran Extract (low dose)|
89213437|NCT01002651|Placebo Comparator|placebo|
89213438|NCT05733429|Experimental|eye cervical re-education|patients will receive eye cervical re-education three times a week for four weeks
89213439|NCT05733429|Experimental|motor imagery therapy|patients will receive motor imagery therapy three times a week for four weeks
89213440|NCT05733429|Active Comparator|conventional physical therapy|patients will receive conventional physical therapy three times a week for four weeks
89213441|NCT01002807|Other|FDC of dapagliflozin/metformin XR|
89213442|NCT01002807|Other|FDC of dapagliflozin/reduced mass metformin XR|
89213443|NCT01002807|Other|dapagliflozin and Glucophage® XR|
89213444|NCT01006083||Low-risk patients, not on APAs|Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
89213445|NCT01006083||High-risk patients, not on APAs|Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
89213446|NCT01006083||APA for primary prevention|High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
89213447|NCT01006083||APA for secondary prevention|Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.
89213448|NCT01002963|Experimental|PF-04418948 30 mg|
89213449|NCT01002963|Experimental|PF-04418948 100 mg|
89213450|NCT01002963|Experimental|PF-04418948 300 mg|
89213451|NCT01002963|Experimental|PF-04418948 1000 mg|
89213452|NCT01002963|Experimental|PF-04418948 3000 mg|
89213453|NCT01002963|Experimental|PF-04418948 4500 mg|
89213454|NCT01002963|Experimental|PF-04418948 6000 mg|
89657068|NCT03589833|Placebo Comparator|MTX|Treated with oral methotrexate and two placebos.
89657069|NCT03589833|Placebo Comparator|Tripterygium Wilfordii|Treated with oral Tripterygium Wilfordii and two placebos.
89657070|NCT03589833|Active Comparator|Yisaipu + MTX|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
89657071|NCT03589833|Experimental|Yisaipu + Tripterygium Wilfordii|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
89657072|NCT01077921|Experimental|Propranolol|Drug arm
89657073|NCT01077921|Placebo Comparator|Sugar pill|Placebo arm
89657074|NCT01078233||Raltegravir Cohort|Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.
89657075|NCT01078233||Historical Cohort|Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.
89657076|NCT01078233||Concurrent Cohort|Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.
89046804|NCT01712451|Experimental|salmeterol xinafoate|
89046805|NCT00541268|Experimental|A - ICD implantation|Heart Failure nonischemic etiology treated by optimal medical treatment and receiving a prophylactic ICD
89046806|NCT00541268|Active Comparator|B - control|Heart Failure nonischemic etiology treated by optimal medical treatment
89046807|NCT01712217|Experimental|AT13387 and Crizotinib|Part A is a single-arm, Phase 1, open-label, dose-escalation design in patients with NSCLC who have already been receiving crizotinib 250 mg by mouth (PO) twice daily (BID) for at least 8 weeks and are still tolerating treatment at that dose. Patients will continue treatment with crizotinib + escalating doses of AT13387 IV weekly for 3 weeks in a 4-week cycle. Each cohort will consist of at least 6 patients until the maximum tolerated dose (MTD) is reached. An additional 12 patients will be treated at the MTD level of AT13387 in combination with crizotinib to confirm the safety profile of the combination at that dose level.
89046808|NCT01712217|Active Comparator|Crizotinib versus crizotinib + AT13387|Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the MTD established in Part A. Part B will enroll 128 patients with NSCLC who have been treated with crizotinib for at least 8 weeks and are still tolerating treatment without evidence of disease progression.
89046809|NCT01712217|Active Comparator|AT13387 or AT13387 + crizotinib|Part C is an open-label, randomized, Phase 2, Simon's 2-stage design of AT13387 administered alone once weekly for 3 weeks (QW×3) or in combination with crizotinib at the MTD established in Part A.
89046810|NCT04046237|No Intervention|Usual treatment - Control group|"The patient is referred to his treating dentist with a diagnosis report of his oral state including his periodontal status.~The usual care usually includes the extraction of non-preservable teeth, the dental prosthesis to replace them and at least one descaling session."
89057971|NCT02278757|Experimental|High protein diet (HPD)|HPD received a diet with higher protein content (1.34gr/kg body weight). HPD and LPD diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less than the resting metabolic rate (RMR). Meal replacements (drinks and bars), and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
89657077|NCT03014505|Experimental|FMT|Fecal Microbiota Transplantation via endoscope and/or cenema and the traditional treatments
89657078|NCT03014505|Active Comparator|The traditional treatments|
89657079|NCT01080261|Experimental|PROMUS Element|everolimus-eluting coronary stent
89657080|NCT03349905|Active Comparator|Fresh transfer|"Women randomized in the non experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~All of their embryo kept in prolonged culture~A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~Supernumerary blastocysts cryopreserved"
89657081|NCT03349905|Experimental|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
89657082|NCT04970238|Experimental|Levosimendan group|
89657083|NCT04970238|Placebo Comparator|placebo group|
89657084|NCT04970394||Intervention|"The principal investigator reviews the medical notes of all individuals they consult over a period of three years to check if they are non responders. If confirmed as non responder, they receive a three-step verbal intervention:~Your cervical cancer screening is now overdue.~The test is easy to perform and saves thousands of lives from cervical cancer every year.~Should we book an appointment for cervical screening now so that you make sure you have it done?~Those who are seen face-to-face receive a fourth intervention:~An appointment slip is given to the patient to hand to the receptionist. This includes the patient's name and the comment, book an appointment with practice nurse for cervical screening."
89657085|NCT04970394||Control|The control group receives standard unstructured reminders regarding their overdue status from any of the 6 other clinicians during appointments and / or reminder letters from the administration team.
89657086|NCT04970160||TSARP|Is a surgical procedure
89657087|NCT04970160||ASARP classic|Surgical procedure
89657088|NCT04970160||PSARP|Surgical procedure
89657089|NCT04970160||Modified ASARP|Surgical procedure
89657090|NCT04977570|Experimental|SYHA1805|subjects will be randomized to receive multiple ascending doses of SYHA1805 tablets.
89657091|NCT04977570|Placebo Comparator|Placebo|subjects will be randomized to receive the matching placebo tablets.
89657092|NCT04970316||HIPEC cohort|Patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases
89657093|NCT04970316||PE cohort|Patients undergoing pelvic exenteration (PE) for colorectal cancer with involvement of the urinary bladder
89657094|NCT04432350||Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
89657095|NCT04432350||Not Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were not treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
89657096|NCT03062670|Experimental|Retreat|A full day off-site training session
89657097|NCT03062670|No Intervention|Control|Care teams normal process
89657098|NCT02169453|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
89657099|NCT02169453|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
89657100|NCT02169453|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
89657101|NCT02169453|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods."
89657102|NCT02038998|Sham Comparator|Static group|Control group. They will receive the standard care provided by the protocols of the ictus unit. They will lay on the Exer-Rest® TL device but the acceleration will NOT be connected.
89657103|NCT02038998|Experimental|Single pGz intervention|In addition to the standard care established in the ictus unit, these patients will receive a single exposure to pGz on the Exer-Rest® TL, for 3 hours, during the first day of their stay in the hospital.
89657104|NCT02038998|Experimental|Multiple pGz interventions|In addition to the standard care, these patients will be exposed to 45 minutes of pGz, on the Exer-Rest® TL, every day during their first week in the Hospital.
89657105|NCT04969614||kidney transplant recipients|kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine
89657106|NCT04969458||participants|The study included individuals whose native language is Turkish, who are over the age of 18 and under the age 70, diagnosed with chronic low back pain, without Psychiatric disorder, Cognitive impairment, Dementia, or Alzheimer's and who want to participate in the study.
89657107|NCT04977258|Active Comparator|Control group|Only treadmill aerobic exercise with 60 min recovery in supine position.
89657108|NCT04977258|Experimental|Controlled hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water predetermined intake.
89657109|NCT04977258|Experimental|Ad Libitum hydration group|Treadmill aerobic exercise with 60 min recovery in supine position, with mineral water intake in an uncontrolled manner.
89657110|NCT04432194|No Intervention|Control group|The subjects in this group will receive the usual care, which includes the non-pharmacology recommendations by the European Society of Cardiologists 2006 (1) and COPD guides for treatment (6), both founded in the sodium and liquids restriction.
89657111|NCT04432194|Active Comparator|Pulmonary Rehabilitation Group|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months.
89657112|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus HMB (4g)|Patients in this group will receive pulmonary rehabilitation specified by rehabilitation doctors according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
89657113|NCT04432194|Experimental|Pulmonary Rehabilitation Group plus citrulline (3g)|Patients in this group will receive pulmonary rehabilitation specified by the doctor specialized in rehabilitation according to the needs and capacities of each individual, who will attend three times a week for three months. Furthermore, they will receive 4g of citrulline supplementation.
89657114|NCT04977492||observation group|People suffered from excessive lateral pressure syndrome with extracapsular release of lateral retinaculum.
89657115|NCT04977492||control group|People suffered from excessive lateral pressure syndrome with conservative treatment.
89657116|NCT04977102|Experimental|Intraocular caliper-assisted capsulotomy group|In intraocular caliper-assisted capsulotomy group, a modified intraocular caliper with standard calibration on the rinse needle was used to measure and locate the position of capsulorhexis with 5.3 mm diameter and the principle of pupillary margin in concentric circles. The surgeon could gently use the blunt needle in the front of the intraocular caliper to further make corresponding markers on the lens anterior capsule, and then carry out capsulotomy according to the marks.
89657117|NCT04977102|Active Comparator|Verion navigation system-assisted capsulotomy group|In the Verion-assisted capsulotomy group, Verion navigation system was applied to project a 5.3 mm capsulorhexis centered on the corneal vertex. According to the projected capsulorhexis, capsulotomy was performed.
89657118|NCT04968600|Experimental|Posterior-cruciate-ligament-retaining (CR)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
89657119|NCT04968600|Experimental|posterior-cruciate-ligament-stabilized (PS)|Posterior-cruciate-ligament-retaining (CR) technique of total knee arthroplasty
89657120|NCT01765296|Active Comparator|Celecoxib|Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
89657121|NCT01765296|Placebo Comparator|Placebo|Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
89657122|NCT01765296|Experimental|CG100649|CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)
89657123|NCT01081041|Experimental|Safety Lead-In (cetuximab manufactured by ImClone)|"Cycle 1:~Week 1 - Cetuximab 400 milligrams per square meter (mg/m^2) on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
89657124|NCT01081041|Experimental|Cetuximab manufactured by ImClone|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
89057972|NCT02278874||Multiple gestation high risk pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
89657125|NCT01081041|Experimental|Cetuximab manufactured by Boehringer Ingelheim|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
89657126|NCT03252951|Experimental|Eccentric Training|
89657127|NCT03252951|Experimental|Concentric Training|
89657128|NCT03252951|Experimental|Isometric Training|
89657129|NCT03252951|Active Comparator|Biofeedback|
89657130|NCT03227289||Stayed in NRDS|The neonates with NRDS are stayed in NRDS
89657131|NCT03227289||Converted to ARDS|The neonates with NRDS are converted to ARDS
89657132|NCT01083849||Paricalcitol|Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
89657133|NCT05451225|Experimental|Targeted Educational Campaign (TEC) for Correction Officers|The investigators will implement a Targeted Educational Campaign (TEC) within 3 jails. The TEC is designed to lead to referrals of detainees (previously not detected as having potential mental health concerns) to Correctional Health Services (CHS) by Correction Officers.
89657134|NCT02246517|Experimental|N2O&Oxygen|70% N2O & 30% Oxygen by Aspiration for 5 min
89657135|NCT02246517|Placebo Comparator|Oxygen|100% Oxygen by Aspiration for 5 min
89657136|NCT03022617|Experimental|Study Group|Open-label drug administration group. No comparator.
89657137|NCT01085331|Experimental|Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI|
89657138|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI|Planned, not performed
89657139|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI|Planned, not performed
89657140|NCT02171247|Active Comparator|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
89046811|NCT04046237|Experimental|Periodontal treatment - Intervention group|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit at M9.~Briefly, the intervention group includes initial therapy with information on oral hygiene techniques, scaling and surfacing of dental roots. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
89046812|NCT00555243|Experimental|1|Laparoscopic Simulation Education
89046813|NCT00555243|Placebo Comparator|2|
89046814|NCT04014764||Single group|"Documented hematologic malignancy in need of starting an active anti-cancer therapy.~This is a non-interventional study."
89046815|NCT04669821|Experimental|HSK3486|
89657141|NCT02171247|Active Comparator|Visipaque 320|Standard protocol is Visipaque 320.
89046816|NCT04669821|Active Comparator|Propofol|
89046817|NCT04670055|Experimental|Administration of BCMA Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89046818|NCT00532025|Experimental|1|Sorafenib treatment
89046819|NCT04669119|Experimental|Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and Centella Asiatica/Vitamins
89046820|NCT04669119|Experimental|Bromelain/Boswellia Serrata Casperome and placebo|Patients treated post-operatively for 30 days with Bromelain/Boswellia Serrata Casperome and placebo
89046821|NCT04669119|Placebo Comparator|Placebo|Patients treated post-operatively for 30 days with placebo
89046822|NCT04669080|Other|Cost navigation training intervention|
89046823|NCT03954080|Experimental|ISS|
89213455|NCT01003041||lifestyle counseling|in the future parents will be advised to expose their infants to phonetic sounds in order to develop their phonetic categories in the future
89657142|NCT05376969|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
89657143|NCT03016299||Osteoarthritis hip joint|specimen of head of femur will be used- after total hip arthroplasty (due to Degenerative Osteoarthritis hip joint )
89657144|NCT03016299||Non-Osteoarthritis hip joint|specimen of head of femur will be used- after Hip Hemiarthroplasty -Partial replacment (due to traumatic fracture)
89657145|NCT05339607|Experimental|Intervention|
89657146|NCT02089685|Experimental|Pembrolizumab + PegIFN-2b|Participants in Part 1A receive pembrolizumab intravenously (IV) 200 mg every three weeks (Q3W) + PEG-IFN at assigned dose subcutaneously (SC) once a week for up to ~2 years.
89657147|NCT02089685|Experimental|Pembrolizumab + IPI Q3W|Participants in Parts 1A and 1B receive pembrolizumab IV 200 mg Q3W for up to ~2 years + IPI IV 1 mg/kg Q3W for up to ~12 weeks.
89657148|NCT02089685|Experimental|Pembrolizumab + IPI Q6W|Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to ~2 years + IPI IV 50 mg every 6 weeks (Q6W) for up to ~24 weeks.
89657149|NCT02089685|Experimental|Pembrolizumab + IPI Q12W|Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to ~2 years + IPI IV 100 mg every 12 weeks (Q12W) for up to ~48 weeks.
89657150|NCT01088295|Experimental|Telmisartan|Telmisartan 40mg po daily for 24 weeks
89657151|NCT01089231|Placebo Comparator|Placebo - healthy subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
89657152|NCT01089231|Placebo Comparator|Placebo - hyperlipedemic subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
89657153|NCT01089231|Experimental|Fish oil - hyperlipidemic subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
89657154|NCT01089231|Experimental|Fish oil - healthy subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months.
89657155|NCT03013335|Experimental|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
89657156|NCT04730531|Experimental|Treatment Arm|Local infiltration with 0.25% bupivacaine and epinephrine
89657157|NCT04730531|Placebo Comparator|Control Arm|Placebo of equal volume injectable saline
89657158|NCT01092195|Active Comparator|Cohort 1|Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
89657159|NCT01092195|Active Comparator|Cohort 2|Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
89657160|NCT01092195|Active Comparator|Cohort 3|Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
89657161|NCT03153761|Experimental|CSD170201AA, CSD170201AB Use Group|Use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
89657162|NCT03153761|Experimental|CSD170201AB, CSD170201AA Use Group|Use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
89657163|NCT05569733||VSS|Patients with visual snow syndrome
89657164|NCT05569733||controls|healthy, screened age-matched controls
89657165|NCT05853562|No Intervention|T0-T1 period|It was a control period. Participants were asked to continue their routine activities for 4 weeks.
89657166|NCT05853562|Experimental|T1-T2 period (structured vestibular rehabilitation program)|A structured vestibular rehabilitation program was applied in 50-minute sessions under the supervision of a physiotherapist once a week and as a home exercise program 3 days a week over 4 weeks.
89657167|NCT05853562|Active Comparator|T2-T3 period|A structured vestibular rehabilitation program was applied in 50-minute sessions under the supervision of a physiotherapist once a week and as a home exercise program 3 days a week over 4 weeks. Afterwards, participants participated in the home program with telerehabilitation for 8 weeks.
89657168|NCT05853549|Experimental|optical surface monitoring system group|Every radiotherapy fraction from each patients with OSMS technology. Marks were placed on each patient's skin to align the room lasers for presetup, and the setup was completed with information from the OSMS. The deviation values of setup were obtained. The absolute values of setup error and error distribution of the standard laser-based setup and OSMS in the multi-directions were compared.
89657169|NCT05853536||Standard of Care|As recommended by treatment guidelines.
89657170|NCT05853536||Cardiovascular Intervention|"Examples include:~Cardiac surgery - Coronary artery bypass grafting (CABG), Repair and replacement of heart valve and other cardiovascular surgery including surgery on the thoracic aorta.~On-pump / off-pump / minimally invasive bypass.~Open / Transcatheter approach for valve replacement or repair.~Open versus minimally invasive valve repair/ replacement.~Procedural coronary revascularization Percutaneous Coronary Intervention.~Closure of the left atrial appendage."
89657171|NCT05853523|Experimental|Gas ozone group|Participant received 32 g/m3 of gas ozone for 30 second.
89657172|NCT05853523|Experimental|Diode laser group|Participant received an application of desensitized gel, fluoride and potassium nitrate gel , and a first step of an irradiation with diode laser for 20 second of interval, 808 wavelength, and power incrementation, from 0,2 till 0,6 W, not in contact. Then the second step of irradiation for 30 second in contact with dentine surface, 808 wavelength, and power incrementation, from 0,2 till 0,6 W. Then the surface was rinsed, and the irradiation applied for a third time again without the gel as the second step.
89657173|NCT05853471|Active Comparator|Alzheimer's disease|Patients diagnosed with Alzheimer's disease
89657174|NCT05853471|Active Comparator|Mild Cognitive Impairment|Patients diagnosed with Mild Cognitive Impairment
89657175|NCT05853471|Active Comparator|Parkinson's disease|Patients diagnosed with Parkinson's disease
89657176|NCT05853302||Laparoscopic TLA|Patients who underwent laparoscopic lateral transabdominal unilateral adrenalectomy
89657177|NCT05853302||Robotic TLA|Patients who underwent robotic lateral transabdominal unilateral adrenalectomy
89688620|NCT02808130||Group HG|"Group HG: hyperlipidemic + gingivitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
89046824|NCT04669353|Active Comparator|Platelet Rich Plasma|In the operating room before the start of each procedure, approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate. After closure of the fascia and prior to skin closure, PRP was directly applied to the subcutaneous tissue of the wound site by using a sterile syringe.
89046825|NCT04669353|No Intervention|control group|In the control group (group II), the patients did not receive topical treatment and the subcutaneous tissue was cleaned with normal saline before skin closure
89046826|NCT00532064||Ancillary-correlative (biospecimen collection)|Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
89213456|NCT01006161|Experimental|Low dose SCH 527123|
89213457|NCT01006161|Experimental|Medium dose SCH 527123|
89657178|NCT05853250|Experimental|Reiki/manual therapy|Reiki, a Japanese energy-based healing technique, is universal vital energy that flows throughout and encompasses all living forms (Rand, 1991). It is delivered by gentle hand placement either on/slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 min. and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (~ 3 minutes to each body part). Manual therapy (MT) includes light effleurage to head and feet (for 5 minutes; ~ 2.5 minutes to each body part) by the Reiki practitioner. MT techniques are defined as light circular stroking movements made with the hands. Reiki and MT will be delivered for 3 consecutive days beginning on the day after endotracheal tube removal. Reiki and MT will be delivered by 4 Reiki practitioners with training at a Level 2+. Reiki and manual therapy was delivered as one intervention. They are not two separate interventions.
89657179|NCT05853250|No Intervention|Usual care quiet time|All usual care provided pre and post-operative management will continue, uninterrupted; including the 20 minute rest period. The only non-usual care component will be placement of a sign on the door to discourage visitors and providers from entering the room and disturbing the rest period.
89657180|NCT05853237|Experimental|class IV group|start from day one surgery for 4 successive weeks, the goal in the phase I (1st 10 days after surgery) is decontamination, improve circulation, pain reduction &wound healing acceleration The goal of phase II (next10 days till complete healing) is improve osteo-integration, pain reduction & enhance superficial collagen production to decrease scarring. The parameters are: Power > 500 mW; fluence 20 joule/ cm2 with (980, 915, 810 nm) and 5 joules/ cm2 by 650 nm; mode (continuous); hand piece radius = 2.5 cm; spot size (Area) = 5 cm; application by scanning not spotting to avoid thermal effect and time of session is 5- 10 minutes
89657181|NCT05853237|Experimental|class IIIb|Use the same protocol as in HLLT with the same wave lengths but with low power Power = 200- 300 mW; fluence 20 joule/ cm2 with (980, 915, 810 nm) and 5 joules/ cm2 by 650 nm; mode (continuous); hand piece radius = 2.5 cm; spot size (Area) = 5 cm; application by spotting and time of session was 25- 30 minutes.
89657182|NCT05853237|Active Comparator|traditional wound care|According to the hospital protocol Irrigation of the wound by normal saline, betadine application, bivatracin spray and Change dressing daily to protect the wound from infection
89657183|NCT05853224|Experimental|Crosslinked Hyaluronic Acid (CLHA) Hydrogel with Lidocaine|Patients were treated, on one side of the face with crosslinked Hyaluronic Acid Hydrogel with 0.3% lidocaine hydrochloride.
89657184|NCT05853224|Experimental|Crosslinked Hyaluronic Acid (CLHA) Hydrogel without Lidocaine|Patients were treated, on the other side of the face with crosslinked Hyaluronic Acid Hydrogel without lidocaine hydrochloride.
89657185|NCT05853198|Other|PDAC patients|PDAC patients as described in the inclusion criteria
89657186|NCT05853172|Experimental|AK104 plus apatinib, paclitaxel and S-1|AK104 (10mg/kg, iv, Q3W) is combined with apatinib (250mg, po, qd), paclitaxel (non-peritoneal metastasis: 130mg/m2, iv, D1; peritoneal metastasis: 90mg/m2, iv, 40mg/m2, ip, D1) and S-1(60mg, po, bid, D1-D14) for up to 6 cycle for up to 6 cycles.
89657187|NCT05853263|Other|morphine|Standard care, continuous morphine IV.
89657188|NCT05853263|Active Comparator|paracetamol|intervention group, intermittent paracetamol IV
89657189|NCT05853146||pregnant women|Healthy women in their third trimester of pregnancy with one fetus
89657190|NCT05853107|Experimental|Implant AuTNA I|This is a single arm study where the status and performance of the implanted eye prior to the surgery serves as the comparator.
89657191|NCT05853016||Cohort A|Healthy adults
89657192|NCT05853016||Cohort B|Adults with stable chronic morbidities
89657193|NCT05852990|Experimental|Intervention diet|Astringent diet supplemented with one sachet containing 10 grams of glutamine plus 100 million Colony Forming Units (CFU) of Lactobacillus reueri every 12 hours, from baseline treatment up to 6 weeks or death.
89657194|NCT05852990|No Intervention|Standard diet|Astringent diet from baseline treatment up to 6 weeks or death.
89657195|NCT05852964||Control|Healthy 13 female 14 male subjects
89657196|NCT05852964||Transplantation Patients|10 female, 17 male subjects
89657197|NCT05852951||Menstrual patterns|Regular menstrual cycles and irregular menstrual cycles; irregular menstrual cycles are defined as having variation in menstrual cycles of greater than 2 days and less than 2 months
89657198|NCT05852912||elders combined with mild mental illness|elders combined with mild mental illness(120 subjects)
89657199|NCT05852912||elders combined without mild mental illness|elders combined without mild mental illness(120 subjects)
89657200|NCT05852847|Experimental|Low-dose baricitinib plus danazol|Oral baricitinib is given at a dose of 2 mg daily for 6 months. Danazol is given at a dose of 200 mg twice a day for 6 months. Treatment will be discontinued if very severe or life-threatening adverse events developed or at the patients' request.
89657201|NCT05852847|Active Comparator|Danazol|Danazol is given at a dose of 200 mg twice a day for 6 months. Treatment will be discontinued if very severe or life-threatening adverse events developed or at the patients' request.
89657202|NCT05852795|Experimental|Experimental group|VR-based and audio-based mindfulness experience. Partecipants watch VR scenario and receive a guided mindfulness practice.
89657203|NCT05852795|Other|Control Group|VR-based mindfulness experience. Participants watch VR scenario without experiencing voice guided mindfulness practice.
89657204|NCT05852782|Experimental|Light exposure broadband|Participants will be exposed to indoor levels of light that appear colorless for one hour
89657205|NCT05852782|Experimental|Light exposure long wavelength|Participants will be exposed to indoor levels of light that appear red for one hour
89657206|NCT05852782|Experimental|Light exposure short wavelength|Participants will be exposed to indoor levels of light that appear blue for one hour
89657207|NCT05852782|Experimental|Light exposure darkness|Participants will be exposed to darkness for one hour
89657208|NCT05852704|Active Comparator|Active arm|Treatment with dapagliflozin 10 mg once daily.
89057973|NCT02278913|Experimental|Basal Bolus (Glargine and Glulisine)|Basal bolus: with Insulin analogs (glargine and glulisine), 50% of total daily dose as glargine given before breakfast and 50% as glulisine insulin given in three equally divided doses before each meal.
89657209|NCT05852704|Placebo Comparator|Placebo arm|Treatment with matching placebo once daily.
89657210|NCT05852665|Experimental|Ultrasound-guided surgery|
89213458|NCT01006161|Experimental|High dose SCH 527123|
89213459|NCT01006161|Placebo Comparator|Placebo|
89213460|NCT05733195||Women with GDM|All basic information was collected in the first trimester, and all subjects underwent OGTT (75g glucose) at 24-28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG. At four time points during pregnancy (6-13 weeks, 24-28 weeks, 36-weeks before delivery, and 6 weeks after delivery), blood samples of 5ml were collected from each subject at each time point without increasing the number of blood samples. In the GDM group, blood samples were collected at the same time during routine visit 6 weeks after delivery. The relevant broad metabolomics and targeted vitamin profiles were also detected.
89213461|NCT05733195||Women with no-GDM|All basic information was collected in the first trimester, and all subjects underwent OGTT (75g glucose) at 24-28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG. At three time points during pregnancy (6-13 weeks, 24-28 weeks, 36-weeks before delivery), blood samples of 5ml were collected from each subject at each time point without increasing the number of blood samples. The relevant broad metabolomics and targeted vitamin profiles were also detected.
89657211|NCT05852652|Experimental|cryolipolysis and aerobic exercise|in this arm we combined between Three Max cool shaping Cryolipolysis device (ESM-8l00MO; EunSung global, Korea) was utilised. Vacuum controllable heads with cold temperatures ranging from (-10to 5)°C were adjusted according to each patient's tolerance, after careful patient sensation examination and vital sign evaluation before and after each session ,they got two sessions and walked from 30 to 60 minutes in nearby park.Two Cryolipolysis treatments totaling 45 minutes each were administered to each patient in the experimental group at the hypogastrium region, 5 cm below the umbilicus, using an anti-freezing membrane to prevent cold burn, in order to conduct the treatment
89657212|NCT05852639||Insulin|patients on insulin treatment for gestational diabetes
89657213|NCT05852639||Metformin|patients on metformin treatment for gestational diabetes
89657214|NCT05852626|Experimental|Intervention|Multimodal intervention in the primary care team that includes: redistribution of diabetes care between nurses and physicians, use of the individualized glycemic target calculator and implementation of minimum care recommendations
89657215|NCT05852626|Active Comparator|Control|Usual follow-up in Primary Health Care (no intervention in the teams)
89657216|NCT05852535||case report|
89657217|NCT05852496|Active Comparator|Vitamin D supplement|Vitamin D supplement intake for 6 months
89657218|NCT05852496|Placebo Comparator|Placebo group|Group with no vitamin D supplement treatment
89657219|NCT05852392|Experimental|Adapted PARENT Model|"PARENT is a team-based approach to care that utilizes a community health worker (called a coach) as part of the WCC team to provide comprehensive and family-centered preventive care services, address concerns related to family social needs, and decrease reliance on the clinician as the sole provider of preventive care services. The coach independently meets with the family at every early childhood well-child care visit to provide anticipatory guidance, social needs screening, developmental screening, and connection to needed community resources. All NCH-PCN practices will start in the control group, and then sequentially (by random assignment) move to become intervention. Practices will implement the adapted PARENT model for all well-visits, newborn through 15 months of age, and have a 9-month implementation exposure period to ensure that children ≤15 months of age at the practice have received the intervention; thereafter the practices maintain the intervention."
89657220|NCT05852392|No Intervention|Traditional Well-Child Care|Our comparator is traditional well-child care, which follows national preventive care guidelines including structured and standardized developmental and social needs screening, and is in widespread use. These are well-child care visits led by the primary care clinician without a community health worker. All NCH-PCN practices will start in the control group, and then sequentially (by random assignment) move to become intervention.
89657221|NCT05852366|Experimental|Group A (Experimental group): (n=25): Curcumin based Jasmate toothpaste preparation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Curcumin based Jasmate toothpaste onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 8 weeks for assessment of the efficacy
89657222|NCT05852366|Active Comparator|Group B (Positive Control): (n=25): Bioactive glass based BioMin F toothpaste preparation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Biomin F toothpaste (Bioactive glass with Calcium, Phosphate and Fluoride) onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 8 weeks for assessment of the efficacy
89657223|NCT05852366|Placebo Comparator|Group C (Negative Control): (n=25): Placebo toothpaste without any active desensitizing agent|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Placebo toothpaste without any active desensitizing agent onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 8 weeks for assessment of the efficacy
89657224|NCT05852301||HI-ART|People living with HIV with CD4+ T cells > 800 c/uL on ART initiation
89657225|NCT05852301||HI-ART control|People living with HIV with CD4+ T cells between 500-800 c/uL on ART initiation
89657226|NCT05852301||Hyper|People living with HIV with CD4+ T cells >800 c/μL on ART initiation, but increase to >1000c/μL within 48 months of ART initiation
89657227|NCT05852301||Hyper control|People living with HIV with CD4+ T cells <500 c/μL on ART initiation and reconstituted to 500-1000c/μL within 48 months of ART initiation
89213462|NCT05733117|Active Comparator|NanoVitD|Oral nano form of the calciferol
89213463|NCT05733117|Active Comparator|ConvVitD|Conventional oral calciferol
89657228|NCT05852288||Individuals with carpal tunnel syndrome|This study will follow a group of individuals with carpal tunnel syndrome (CTS) according to Bland's grading scale (grades 1-3) to assess the role of inflammation in CTS. Participants will undergo clinical and biochemical evaluations to assess inflammatory markers and CTS severity. The study will follow participants over time to determine the relationship between inflammation and CTS, which can inform the choice of transdermal drug administration.
89657229|NCT05852275|Experimental|Olive oil arm|Participants will include, in their usual diet, the daily intake of 30 mL of an olive oil rich in polyphenols (intervention group) for 100 days. At the beginning (day 1), in the middle (between days 50 and 60) and at the end of the intervention period (day 100), participants will be evaluated.
89657230|NCT05852236|Experimental|Control Group|The standard care of the clinic was applied to the control group.
89657231|NCT05852236|Experimental|Study Group|The pressure ulcer care package developed for this study was applied to the study group.
89657232|NCT05852210||Infrared CRPS Group|"This group includes people who have recently been diagnosed with CRPS type 1. Participants in the Infrared group will have their feet photographed using a:~FLIR T420 or T62101 camera with 320*240 resolution.~Each image will be captured at a perpendicular angle with a 1-inch gap on all four sides.~The patients' feet will be separated from the background using a Myler blanket.~The camera will be normalized to the temperate range of 15°C minimum and 40°C maximum.~Patients will complete questionnaires about the severity of their CRPS and their pain levels."
89657233|NCT05852197||Use a combination of anticoagulant or antiplatelet drugs ， group 1|
89657234|NCT05852197||Use a combination of anticoagulant or antiplatelet drugs， group 2|
89657235|NCT05852171|Experimental|Baricitinib|Baricitinib，2mg QD，oral use.
89657236|NCT05852119|Experimental|Hemodynamically stable patients with very low risk symptomatic acute pulmonary embolism (PE)|
89657237|NCT05852106|Experimental|Experimental|"Preoperative:Once the surgery date is set, appointments will be made with the surgeon for surgical simulation and with the family for education one week prior to surgery. The surgeon will be asked to complete the Surgical Simulation Evaluation Form-Part I. At the same time, another researcher will complete the family sociodemographic information form and PedsQL questions in the examination room. After completion of the pre-test and the surgical simulation, the families are given a 30-minute preoperative education with the Congenital Heart Disease Parent Education Booklet, together with a life-size 3D heart model obtained from their child's own heart, and drawings on paper where they are not understood.~Postoperative: After surgery, the patient will be followed until discharge, and only Part II of the Surgical Simulation Evaluation Form will be completed. On the 15th postoperative day, the Surgical Simulation Evaluation Form Part II and the PedsQL will be given again as a posttest."
89657238|NCT05852106|No Intervention|Control Group|"Preoperative:When the operation date is determined, one week before the operation, the patients included in the study's control group will be asked the Sociodemographic Information Form and Pediatric Quality of Life Inventory Family Module (PedQL) questions in the examination room. After the pretest, standardized education will be given to the families. The disease process will be explained to the patients with the same 'Congenital Heart Diseases Parent Education Booklet', and the disease process will be presented with the heart model used in standard medical faculty anatomy courses and the ununderstood parts will be detailed by drawing on paper. The remaining 15 minutes of the education will be conducted as a question and answer with the parents.~Postoperative:After the operation, the Surgical Simulation Evaluation Form Part II and PedsQL will be filled out again as post-tests for this group."
89657239|NCT05852093|Active Comparator|Drug: Celecoxib+Buprenorphine Transdermal Patch|
89657240|NCT05852093|Experimental|Drug: Celecoxib+Buprenorphine Transdermal Patch+Tizanidine|
89657241|NCT05852080|Experimental|intervention arm|Hospitals in the intervention arm will receive a multilevel system intervention based on information platform
89657242|NCT05852080|No Intervention|control arm|Hospitals in the control arm will receive no intervention
89657243|NCT05852067|Experimental|Active stimulation of M1|pcTBS was administered to the left M1 at 80% resting motor threshold (RMT), consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline.
89657244|NCT05852067|Sham Comparator|SHAM stimulation|The Sham stimulation was delivered using the same protocol, with the coil being orientated at 90° to the scalp so that the magnetic field would be delivered away from the scal
89657245|NCT05852028||selinexor-based regimens|This study is a real-world study to explore the safety and efficacy of selinexor-based therapy in patients with lymphoma. It is planned to enroll 250 patients with lymphoma, including 150 patients with diffuse large B-cell lymphoma and 100 patients with peripheral T and NK/T-cell lymphoma.
89657246|NCT05851989||Neurosurgical treatment|This cohort contains the patients with aneurysmal subarachnoid hemorrhage who received the neurosurgical clipping treatment.
89046827|NCT04669977|Experimental|Auxiliary|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. They are expected to finish the mulberry juice in 10 to 11 days. Measurements of clinical symptoms and blood sampling are conducted on day 1 of every other week for 5 weeks. If clinical measurements or blood extractions fail or miss, a substitute assessment or blood sample will be obtained on day 2 or day 3. The research period for these participants is 29 days (4 weeks). The checkpoints are arranged because patients with oxaliplatin treatment visit the clinic every two weeks, and patients with paclitaxel treatment visit the clinic every week. For patients having docetaxel therapy, the research period is 43 days (6 weeks) because docetaxel is administered every three weeks.
89046828|NCT04669977|No Intervention|Non-auxiliary|For the non-auxiliary group (control group), patients are informed of their allocation results and they will not consume mulberry juice during the research period but will receive the mulberry juice after the research period.
89046829|NCT04668807|Experimental|Connected Medical Device|"SMART ANGEL Intra-hospital System 's Connected Medical Device (DMC) measuring physiological parameters in the operating room"
89046830|NCT04668807|Active Comparator|Traditional system|Traditional wired transmission system between the sensor and the data processing device in the operating room
89046831|NCT03849248|Experimental|Intervention|This group of babies will have a maternal scented cloth placed under their heads
89657247|NCT05851989||Endovascular treatment|This cohort contains the patients with neurysmal subarachnoid hemorrhage who received the endovascular coiling treatment. Other endovascular treatments which will be included as well are flow diverter procedures, Woven EndoBridge (WEB) devices and stent assisted coiling.
89657248|NCT05851937|Experimental|Written language intervention|"Participants will receive 3 months of weekly written language intervention sessions via telepractice.~Participants will be assessed at three time points to monitor outcomes."
89657249|NCT05851937|No Intervention|Periodic language check-up|Participants will be assessed at three time points to monitor outcomes.
89657250|NCT05851885|Experimental|Experimental group|Physicians draft EGD reports with the assistance of the AI-based reporting system.
89657251|NCT05851885|No Intervention|Control group|Physicians use the conventional reporting system to draft EGD reports. At the same time, the AI-based reporting system will automatically generate a report of the EGD examination.
89657252|NCT05851846|Experimental|Intervention|Mind body intervention + Usual care: The intervention will be delivered virtually
89657253|NCT05851846|No Intervention|Control arm|The participants in the comparator group will be wait listed for the intervention
89657254|NCT05851833||Early MobilizatioN|
89657255|NCT05851833||conventional Mobilization|
89657256|NCT05851820||diabetic patients with COVID-19|patients hospitalized for COVID-19 and were diabetic
89657257|NCT05851820||Non-diabetic patients with COVID-19|patients hospitalized for COVID-19 and were not diabetic
89657258|NCT05851742|Active Comparator|Mfofascial release with electrical stimulation|TENS 50-280 HZ frequency and a pulse duration of 50 us for 10 minutes along with 10 minutes myofascial release.
89657259|NCT05851742|Experimental|Myofascial release without electrical stimulation|Release of trigger points
89657260|NCT05851729|Experimental|Kegal exercises with postural correction|
89657261|NCT05851729|Experimental|Kegal exercises without postural correction|
89657262|NCT05851703|Experimental|Manual therapy applications:|In lower cervical lateral flexion problems, pushing technique will be applied with instrument support from the articular pillar part of the superior vertebra on the side where the limitation is present
89657263|NCT05851703|Experimental|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) techniques will be applied to the second group.
89657264|NCT05851690|Active Comparator|Bilateral Parallel Elliptic Flap|Patients operated with the bilateral parallel elliptic flap technique.
89657265|NCT05851690|Active Comparator|Karydakis Flap|Patients operated with the karydakis flap technique.
89657266|NCT05851651|Experimental|Standard care plus an antenatal milk expression education|Participants will have one face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation and telephone follow-up weekly till delivery.
89657267|NCT05851651|No Intervention|Standard hospital antenatal care|Participants will receive standard care include prenatal breastfeeding education at gestation of 24-36 weeks same as intervention group. They will not discuss about antenatal milk expression, breastfeeding self-efficacy and the effects of breastfeeding on GDM women.
89657268|NCT05851638||Healthy term neonates|"Inclusion criteria for participant selection are:~Healthy infant on postnatal ward.~Full term (gestational age ≥37 weeks).~Anticipated stay in the hospital > 1 day.~Exclusion criteria for participant selection are:~Parent/guardian unable to/decline to participate in the study.~Baby admitted to the Neonatal Unit.~Presence of congenital cardiac anomalies (report of antenatal scans from patient electronic record chart)."
89657269|NCT05850910|Experimental|Supine practice group|The participant was asked to cross his arms in front of his body while lying on his back.
89657270|NCT05850910|Experimental|Prone application group|The participant positions their hands freely from the side of the treatment table in the prone position.
89657271|NCT05850897|Experimental|Massage Group|Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
89657272|NCT05850897|No Intervention|Control Group|Massage will not be applied to the control group; intervention scales will be applied by taking vital signs after waiting until the massage application in the group (20 minutes in total) and the rest period (30 minutes).
89657273|NCT05850728|Experimental|TLC-ART 101 Initial Dosage|"The arms will all receive the nanoparticle suspension of lopinavir, ritonavir, and tenofovir (TLC-ART 101). The arms are also called cohorts. The dose a participant receives will vary, depending upon the study results and the time of when they enroll in the study.~The initial dosage administered to 4 participants will contain:~lopinavir 15.6 mg, ritonavir 4.2 mg, and tenofovir 9.15 mg in 1.5mL of the formulation~If the initial dose is appropriate, an additional 8 participants will be enrolled in Arm 1, for a total study size of 12 participants."
89657274|NCT05850728|Experimental|TLC-ART 101 Dosage 2A|"In the scenario in which the dosage in Arm 1 produces insufficient pharmacokinetics (PK), the dosage will be increased 2 fold in Arm 2A and administered to 4 participants.~If Arm 2A shows ideal PK parameters, and additional 8 participants will be enrolled in this arm, for a total study size of 16 participants."
89657275|NCT05850728|Experimental|TLC-ART 101 Dosage 2B|"In the scenario in which the dosage in Arm 1 produces excessive drug levels, the dosage will be decreased by up to 2-5 fold (2-5x descending dose) and administered to 4 participants.~If Arm 2B shows ideal PK parameters, and additional 8 participants will be enrolled in this arm, for a total study size of 16 participants."
89657276|NCT05850728|Experimental|TLC-ART 101 Dosage 3A|"In the scenario in which the dosage in Arm 2A produces insufficient drug levels, the dosage may be further increased by 2-fold from Arm 2A dosage (4x total dosage increase) and administered to an additional 4 participants.~If Arm 3A shows ideal PK parameters, and additional 4 participants will be enrolled in this arm, for a total study size of 16 participants"
89657277|NCT05850728|Experimental|TLC-ART 101 Dosage 3B|"In the scenario in which the dosage in Arm 2B produces excessive drug levels, the dosage may be further decreased further by up to 2-5-fold from Arm 2B dosage (4-10x dose decrease) and administered to 4 participants.~If Arm 3B shows ideal PK parameters, and additional 4 participants will be enrolled in this arm, for a total study size of 16 participants"
89657278|NCT05845762||Response|1000mg i.v. per day
89657279|NCT05845762||Non-response|1000mg i.v. per day
89657280|NCT05837832|Experimental|Experimental group|Participants will consume the dietary supplement every morning for 4 weeks.
89657281|NCT05830396|Experimental|Ambroxol|Ambroxol 1800mg/day
89657282|NCT05830396|Placebo Comparator|Placebo|Placebo
89657283|NCT05827627|Other|Pelvic simulator group (PSG)|The trainer positioned the foetus in the pelvic simulator in frank breech presentation. Descent of the baby in the pelvic simulator was administered by a person independent of the study and the training.
89657284|NCT05827627|Experimental|Computer-based simulator group (CBSG)|The trainer positioned the foetus in the computer-based full-body childbirth simulator in frank breech presentation. The pregnancy simulator streamed audio to increase reality and the patient monitor displayed vital signs of the pregnant simulator and foetal heart rate.
89657285|NCT05821634|Experimental|Personalized intervention condition|This experimental condition will test a data-driven, person-specific intervention using CBT skills.
89657286|NCT05821634|Active Comparator|Therapeutic control condition|This control condition will provide an experimental comparison to test the process of personalization.
89657287|NCT05821634|Active Comparator|Tracking control condition|This second control condition will provide an experimental comparison to test the effects of health-related tracking and therapeutic contact.
89657288|NCT05812443|Experimental|Shabad Kriya Meditation|87 participants (intervention group) will be trained to perform Shabad Kriya meditation for 30 minutes, daily, before going to sleep, for 8 weeks
89657289|NCT05812443|Active Comparator|Relaxing reading|87 participants (control group) will perform relaxing reading for 30 minutes, daily, before going to sleep, for 8 weeks
89657290|NCT05810311|Active Comparator|Roxadustat|The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight <100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.
89657291|NCT05810311|Active Comparator|Darbepoietin alpha|The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.
89657292|NCT05809362||Atrial Fibrillation|Subjects with known diagnosis of atrial fibrillation (persistent or paroxysmal) documented in the medical record.
89046832|NCT03849248|No Intervention|Control|This group of babies will have a clean non- maternal scented cloth placed under their head
89046833|NCT04669392|Experimental|70% Ethanol|Using 70% Ethanol Alcohol as a root canal irrigating solution before obturating the lower primary second molar with Metapex
89657293|NCT05809362||No atrial fibrillation|Subjects with no known diagnosis of atrial fibrillation as documented in the medical record.
89657294|NCT05809297|Experimental|Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo® (MEDENCY)|According to the manufacturer's recommendations, the treatment will be carried out in consultation in 8 sessions by a specialised podiatrist.
89657295|NCT05809297|Active Comparator|Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer|The application of Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer will be performed at home by the patient once a day.
89657296|NCT05805423|Experimental|Bilateral superficial cervical plexus blocks + local wound infiltration|the bilateral superficial cervical plexus block will be performed with 10mL of 0.25% Bupivacaine injected bilaterally (total 20mL) at Erb's point in the lateral neck, which is located at the mid-point between the mastoid process and the posterior border of the clavicular head of the sternocleidomastoid muscle. The injection is just below the lateral border of the sternocleidomastoid muscle, which produces surface level anesthesia of the neck, targeting superficial nerves of the cervical plexus. Then 10mL of 0.25% Bupivacaine will be injected at the planned neck incision (local wound infiltration) on the anterior neck. These will be done intra-operative and only once
89657297|NCT05805423|Placebo Comparator|placebo + local wound infiltration|10mL of 0.25% bupivacaine injected at the planned neck incision (local wound infiltration), with 10mL of normal saline injected at bilateral Erb's point (total 20mL) (placebo at site of BSCPB). These will be done intra-operative and only once.
89657298|NCT05791942|No Intervention|Holdout Condition: No reminder|Eligible, randomized participants will receive no text message reminder.
89657299|NCT05791942|Experimental|Control Reminder|Eligible, randomized participants will receive a generic text message reminding them to close their outstanding health gap.
89657300|NCT05791942|Experimental|Anecdote-based Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings.
89657301|NCT05791942|Experimental|Call-to-action Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will prompt people to take care of the health gap right away before it slips their mind.
89657302|NCT05790850|No Intervention|Control|Usual preoperative care prior to radical cystectomy
89657303|NCT05790850|Experimental|Intervention|Preoperative pre-habilitation
89657304|NCT05790642||Participants with sinus rhythm|
89657305|NCT05790642||Participants with atrial fibrillation|
89657306|NCT05790642||Participants with extra systoles|
89657307|NCT05790642||Participants with heart failure with reduced ejection fraction|
89657308|NCT05790642||Participants with mildly reduced or preserved ejection fraction|
89046834|NCT04669392|No Intervention|Normal Saline|Irrigating the canals with Normal Saline before obturating the lower primary second molar with Metapex
89657309|NCT05784740|Experimental|Exercise Intervention|Patients will participate in a 12-week (36 sessions) precision exercise training intervention
89657310|NCT05784740|No Intervention|Attention Control|Patients will not receive exercise training but will be contacted 1x per week via phone to document self-reported physical activity and general wellbeing.
89657311|NCT05783414|Experimental|vCST + f2f carer support|vCST followed by in-person carer support programme
89657312|NCT05783414|Active Comparator|f2f CST + f2f carer support|In-person CST followed by in-person carer support programme
89657313|NCT05783414|Experimental|vCST + online carer support|vCST followed by online carer support programme
89657314|NCT05783414|Experimental|f2f CST + online carer support|In-person CST followed by online carer support programme
89657315|NCT05782634|Experimental|subjected to immediate cortical satellite implants with immediate loading|All patients involved in this study will be subjected to immediate cortical satellite implants with immediate loading
89657316|NCT05778708|Experimental|Tai-Chi intervention group|The standardized 16-form Yang-style Tai-Chi exercise set will be adopted.
89657317|NCT05778708|Experimental|Aerobic exercise intervention|The aerobic exercise class will be designed to cover both aerobic and resistance exercises.
89657318|NCT05778708|No Intervention|Self-management control group|Patients in this group will receive written information regarding the recommended levels of exercise (i.e., at least 150 min of moderate-intensity or 75 min of vigorous-intensity aerobic exercise every week) that they can perform at home (self-management) while continuing to receive their standard treatment. They will also be provided with a daily exercise log to record their exercise type, frequency, and intensity.
89657319|NCT05774444|Placebo Comparator|Vegetable oil + Carbohydrate|The vegetable oil will be a placebo control for the Krill oil (4g/day). The carbohydrate will be a placebo control for the Krill protein (20g)
89657320|NCT05774444|Experimental|Vegetable oil + Krill protein|The vegetable oil will be a placebo control for the Krill oil (4g/day). Krill protein will be our active intervention (20g)
89657321|NCT05774444|Experimental|Krill oil + Carbohydrate|The Krill oil will be the active supplement for the intervention (4g/day). The carbohydrate will be a placebo control for the Krill protein (20g)
89657322|NCT05774444|Experimental|Krill oil + Krill protein|Both the Krill oil (4g/day) and the Krill protein will be the active intervention supplements (20g)
89657323|NCT05773482|Experimental|Breathing and Attention Training (BAT)|Participants will be asked to do 20-minutes of focused breathing and attention training, involving focusing on taking deep breaths and becoming aware of the changing body sensations associated with breathing (mindfulness).
89657324|NCT05773482|Active Comparator|Controlled Deep Breathing|Participants will be asked to do 20-minutes of deep breathing and letting the body relax.
89657325|NCT05772689|Active Comparator|Usual Care|Standard of Care
89657326|NCT05772689|Experimental|Caregiving while Black|Caregivers of PLWD taking part in a fully self-paced asynchronous online caregiver education program.
89657327|NCT05765032|Experimental|SHR-A1921|A1：SHR-A1921+Adebrelimab A2：SHR-A1921+Carboplatin A3：SHR-A1921+Cisplatin A4：SHR-A1921+Bevacizumab A5：SHR-A1921+Adebrelimab+Carboplatin A6：SHR-A1921+Adebrelimab+Cisplatin B1：SHR-A1921+Adebrelimab B2：SHR-A1921+Adebrelimab+Carboplatin/Cisplatin
89657328|NCT05760846|Experimental|Bimanual Circuit version 1|Training on the REAplan® robot with a serious game based on proximal motor skill learning (bim-MSkL) with the bimanual version 1 of the Circuit task and training on the Dextrain Manipulandum with a serious game based on distal bim-MSkL
89657329|NCT05760846|Experimental|Bimanual Circuit version 2|Training on the REAplan® robot with a serious game based on motor skill learning (MSkL) with bimanual version 2 of the Circuit task and training on the Dextrain Manipulandum with a serious game based on distal bim-MSkL
89657330|NCT05760118||Diabetes Mellitus Patients|Patients diagnosed with diabetes mellitus.
89657331|NCT05756127||All eligible patients|Observational cohort using anonymized patient-level primary care data linked to secondary administrative data; CPRD-GOLD and CPRD-AURUM.
89657332|NCT05755646|Experimental|Ice Plant Intensive Cream plus Standard Care|This group receives a 30-minute nursing consultation on the standard treatment and on the use of the Ice Plant Intensive Cream for the prevention of hand-foot syndrome.
89657333|NCT05755646|Active Comparator|Standard Care|This group receives a 30-minute nursing consultation on the standard treatment for the prevention of hand-foot syndrome.
89657334|NCT05750316|Experimental|Freeze dried cowpea leaves mixed in jam|6g of freeze-dried cowpea leaves (equivalent to one portion of vegetables) mixed with apricot jam and spread on bread.
89657335|NCT05750316|Active Comparator|Jam with green food colour|Apricot jam mixed with green colouring and spread on bread
89657336|NCT05745987|Experimental|Smallpox vaccine|Participants will receive the Bavarian Nordic smallpox vaccine 0.5 ml single-dose
89657337|NCT05745987|Active Comparator|Typhoid vaccine|Participants will receive the TYPHIM Vi® typhoid vaccine 0.5 ml single-dose
89657338|NCT05745558|Experimental|Prehabilitation|A 3-to-6-week prehabilitation program consisting of training and nutritional, smoking cessation and psychosocial counselling.
89657339|NCT05736302||Individuals without movement limitations|Individuals who are not classified as impaired or functionally limited per results of physical function testing.
89657340|NCT05736302||Individuals with impaired movement|Individuals who are classified as impaired, but not functionally limited per results of physical function testing.
89657341|NCT05736302||Individuals with impaired movement who are functionally impaired|Individuals who are classified as impaired and functionally limited per results of physical function testing.
89657342|NCT05736198||Dexmedetomidine|Dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
89657343|NCT05736198||Placebo|Normal Saline, midazolam, and fentanyl (titrated to effect) to facilitate the intubation
89657344|NCT05735457|Experimental|Intervention Arm|"Participants will be shown a short, animated storytelling (SAS) video on dietary sodium and thereafter be asked to complete a questionnaire to assess knowledge on dietary sodium and behavioral expectation.~Two weeks later, participants will once again be asked to complete the knowledge and behavioral expectation questionnaire."
89657345|NCT05735457|No Intervention|Exposed Control Arm|"Participants will be asked to complete a questionnaire to assess knowledge on dietary sodium and behavioral expectation (the same questionnaire as in arm 1, however, without being exposed to the SAS video on dietary sodium before.~Two weeks later, participants will once again be asked to complete the knowledge and behavioral expectation questionnaire."
89657346|NCT05735457|Placebo Comparator|Attention Placebo Control Arm|"Participants will be shown a attention placebo control (APC) video, unrelated to the outcomes measured in this trial, before being asked to complete the knowledge and behavioral expectation questionnaire.~Two weeks later, participants will once again be asked to complete the knowledge and behavioral expectation questionnaire."
88994090|NCT02944942||Postoperative nausea and vomiting|Group 1: Patients undergoing general anesthesia with postoperative nausea and vomiting Group 2: Patients undergoing general anesthesia without postoperative nausea and vomiting
88994091|NCT02964000|Active Comparator|Low level 1 Watt|"The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
88994092|NCT02964000|Experimental|Phoenix Thera-Lase System 42|"The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
88994093|NCT02964000|Experimental|Phoenix Thera-Lase System 74|"The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
88994094|NCT00144872|Experimental|Subjects receiving lamotrigine|Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.
88994095|NCT02945020|Experimental|Dabigatran etexilate mesylate+Odalasvir+Simeprevir|All participants will receive study medications in a fixed sequential order as: a single dose of dabigatran etexilate mesylate 75 milligram (mg) on Days 1, 17 and 26; Odalasvir (ODV) 25 mg once daily from Day 4 to 28; Simeprevir (SMV) 75 mg once daily from Day 20 to 28. The study drugs will be taken orally.
88994096|NCT00528073|Experimental|A|Rifaximin-EIR tablet 1x400 mg + Placebo 2 tablets bid
88994097|NCT00528073|Experimental|B|Rifaximin-EIR tablet 2x400 mg + Placebo 1 tablet bid
88994098|NCT00528073|Experimental|C|Rifaximin-EIR tablet 3x400 mg bid
88994099|NCT00528073|Placebo Comparator|D|Placebo 3 tablets bid
88994100|NCT00407901||A, B|A: High functioning visually challenged (legally blind) B: Low-functioning visually challenged (legally blind)
88994101|NCT00528151|Placebo Comparator|2|"curcumin~placebo"
88994102|NCT00144911|Experimental|Arm 1|
88994103|NCT00528307|Active Comparator|1|First 3 months of biventricular pacing, second 3 months right ventricular apical pacing
88994104|NCT00528307|Active Comparator|2|First 3 months of right ventricular apical pacing, second 3 months biventricular pacing
88994105|NCT00528346|Active Comparator|1|Participants will see their own brain activation.
88994106|NCT00528346|Placebo Comparator|2|Participants will see simulated data that does not come from their own brains.
88994107|NCT00528463|Experimental|sciatic block|One arm, all patient studied received a block
88994108|NCT02945098|No Intervention|Control group|No intervention. Remained five minutes at rest.
88994109|NCT02945098|Placebo Comparator|Placebo group|Apply Kinesio Taping without tension.
88994110|NCT02945098|Experimental|KT group|Apply Kinesio Taping application with tension.
88994111|NCT02944786|Experimental|HOPE-model|Four person-centred health dialogue sessions that include pain/stress management and education about stress and pain.
88994112|NCT02944786|No Intervention|Control|Standard care
89657347|NCT05735457|No Intervention|Un-exposed Control Arm|"Participants will not view a video and will not be asked to complete the questionnaire.~Two weeks later, participants will once again be asked to complete the knowledge and behavioral expectation questionnaire."
88994113|NCT02944981|Experimental|Gabapentin|Patient receiving oral gabapentin 600 mg preoperatively
88994114|NCT02944981|Placebo Comparator|Placebo|Patient receiving oral placebo tablet preoperatively
88994115|NCT00144989|Active Comparator|1|Etoposide and cisplatin after chemoradiotherapy
88994116|NCT00144989|Experimental|2|Irinotecan and cisplatin after chemoradiotherapy
88994117|NCT04692025|Experimental|Group 1|ASC41 one tablet, on Day 1 before meal；ASC41 one tablet, on Day 15 after meal.
88994118|NCT04692025|Experimental|Group 2|ASC41 one tablet, on Day 1 after meal；ASC41 one tablet, on Day 15 before meal.
88994119|NCT00528502|Experimental|Saline|Saline misted into the air breathe during the surgery.
88994120|NCT00528502|Experimental|Lidocaine|Lidocaine misted into the air during the surgery.
88994121|NCT00528619|Experimental|A|
88994122|NCT00168714||Pregnant participants|Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy
88994123|NCT00528658|Experimental|1|
88994124|NCT00528658|Experimental|2|
88994125|NCT00528658|Experimental|3|
88994126|NCT04691674|Experimental|Study group|Endoscopic removal of pancreatic duct stent at 4 weeks following ERCP, unless spontaneously dislodged.
88994127|NCT04691674|Placebo Comparator|Control group|Endoscopic removal of pancreatic duct stent at 2 weeks following ERCP, unless spontaneously dislodged.
88994128|NCT00528814|Experimental|Two Step Hand-Hygiene|Hand washing plus hand sanitizer
88994129|NCT00528814|No Intervention|Usual Care Hand Hygiene|
88994130|NCT04691752||COPD patients|"Adults (men or women) aged more than 40 years old~Diagnostic code in Andalusian clinical records (Diraya) in accordance with ICD-9 (Diagnostic codes 496, 492.8, 494.0, 491.20, 493.2)~Current of former smokers of at least 10 pack- years~Patient with a minimum follow up of 1 year, who have been assisted in a scheduled primary care appointment at inclusion date."
88994131|NCT01580527|Active Comparator|total parenteral nutrition|
88994132|NCT01580527|Experimental|Early enteral nutrition|
88994133|NCT05647603||"group Parents of adolescents"|Parents of adolescents aged 12 to 18
88994134|NCT00168753|Experimental|1|
88994135|NCT00528892|Experimental|1|Switch current boosted-PI to raltegravir 400 mg BID.
88994136|NCT00528892|Active Comparator|2|Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
88994137|NCT04691401|No Intervention|Standard WL (white light) colonoscopy|all patients receive standard colonoscopy (with high definition- HD- endoscopes) with white light (WL) in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination.
88994138|NCT04691401|Experimental|Standard colonoscopy with assistance of Artificial Intelligence (CAD-EYE (Fujifilm Co, Tokyo, Japan)|all patients receive colonoscopy examinations (with HD endoscopes) equipped with an Ai system (CAD-EYE, Fujifilm Co, Tokyo, Japan) in both insertion and withdrawal phase). This system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.All polyps identified are removed and sent for histopathology examination.
88994139|NCT00531349|Active Comparator|A|General anesthesia and opioid analgesia for the treatment of pain after surgery.
88994140|NCT00531349|Active Comparator|B|Regional anesthesia and analgesia (epidural) combined with deep sedation or general anesthesia.
88994141|NCT00531466|Active Comparator|1|
89657348|NCT05729919|Experimental|Free gingival graft|Free gingival technique will be done
89657349|NCT05729503|Experimental|2% Lidocaine|1 cotton tip applicator, pre-soaked in 2% lidocaine, inserted into each nare, and left for 10 minutes
89657350|NCT05729503|Placebo Comparator|Placebo|1 cotton tip applicator, pre-soaked in saline, inserted into each nare, and left for 10 minutes
89657351|NCT05725876|Experimental|Ustekinumab naïve patients|
89657352|NCT05725876|Experimental|Ustekinumab treatment 12+ weeks|
89657353|NCT05720390|Active Comparator|Quinine only|In this arm, participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of control for L-leucine.
89657354|NCT05720390|Active Comparator|L-leucine only|In this arm, participants will receive a 10 ml intragastric bolus of control for quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-leucine.
89657355|NCT05720390|Active Comparator|Quinine + L-leucine|In this arm participants will receive a 10 ml intragastric bolus of 300 mg quinine followed 30 min later by 100 ml intragastric bolus of 5 g L-leucine.
89657356|NCT05720390|Placebo Comparator|Control|In this arm, participants will receive a 10 ml intragastric bolus of control solution followed 30 min later by 100 ml intragastric bolus of control solution.
89657357|NCT05718973|Experimental|Intervention Arm|"At Time 1, the Intervention Arm will view a short, animated storytelling video designed to promote psychological capital and, immediately thereafter, complete the CPC-12R, the GQ-6 as well as a single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
89657358|NCT05718973|No Intervention|Scale-Exposed Control Arm|"The Scale-Exposed Control Arm will watch no video content at Time 1, but will complete the CPC-12R, the GQ-6 as well as a single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
89657359|NCT05718973|Placebo Comparator|Attention Placebo Control Arm|"The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial, before completing the CPC-12R, the GQ-6 and the single-item validated happiness scale.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
89657360|NCT05718973|No Intervention|Un-exposed Control Arm|"The Un-exposed Control Arm will neither watch video content, nor complete the CPC-12R, the GQ-6 and the single-item validated happiness scale at Time 1.~Two weeks later, the participants will complete the CPC-12R, the GQ-6 and the single-item validated happiness scale."
89657361|NCT05718479|Experimental|Trauma Informed Prenatal Intervention (TPI)|The experimental arm consists of four weekly, individual (45-60 minute) sessions via Zoom with a research staff member facilitating motivational interviewing focused on behavior change and mindfulness awareness practice.
88994142|NCT00531466|Placebo Comparator|2|
89657362|NCT05718479|Active Comparator|Prenatal Education Topics|The active comparator arm consists of four weekly, individual (30-minute) sessions via Zoom with a research staff member delivering prenatal education topics consisting of lecture (power point slides) and video.
89657363|NCT05715112||Experimental group|A convenience sample of older adults (65 and older).
89657364|NCT05711641|Experimental|Lidocaine 10%|The patient is instructed to lie down in lateral decubitus, with the ear in study facing upwards and 10% lidocaine is applied to the external auditory canal, using an eyedropper, until its complete filling (approximate average of 2ml).
89657365|NCT05711641|Placebo Comparator|Placebo|The patient is instructed to lie down in lateral decubitus, with the ear in study facing upwards and distilled water is applied to the external auditory canal, using an eyedropper, until its complete filling (approximate average of 2ml).
89657366|NCT05709054|Experimental|Diaphragmatic excursion assessment with Ultrasonography|The time motion mode (M-mode) may be used to measure the diaphragm excursion in a curvilinear low-frequency transducer placed in the midclavicular line and angled in a cranial direction.
89657367|NCT05709054|Experimental|Chest wall expansion|The difference between the values obtained during deep inspiration and expiration will be determined by tape ruler (cm), high degrees represent better outcome, low degrees represent worse outcome.
88994143|NCT00531505||2a|Morbid Obese individuals undergoing bariatric surgery (i.e. Laparoscopic Banding, Gastric Bypass). These individuals are a subset population of the greater Longitudinal Assessment of Bariatric Surgery (LABS-1) study population. This subpopulation engaged in memory tests as well as tissue extraction.
89657368|NCT05709054|Experimental|Nijmegen Questionnaire|Screening tool used to detect patients with hyperventilation complaints and DB patterns. Scores>20 are used as the cut-score to identify DB in patients with various conditions. NQ values in healthy individuals range from 10 to 12 ± 7 and values do tend to decrease towards these levels after breathing retraining.
89657369|NCT05709054|Experimental|Asthma Control Test|The ACT evaluates how well asthma affects daily functioning, and overall asthma control self-assessment. The score ranges from 5 (poor control of asthma) to 25 (well control of asthma). An ACT score >19 indicates well-controlled asthma.
89657370|NCT05709054|Experimental|Sf-12v2 questionnaire|With one or two questions per domain, it evaluates the exact eight health dimensions as the SF-36v2: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Higher ratings indicate better physical and mental well-functioning, ranging from 0 to 100. It has been suggested that a cut-off of 50 or less be used to identify a physical condition, while a score of 42 or less may signify clinical depression
89657371|NCT05709054|Experimental|Borg scale|The Borg dyspnea scale is a simple, scoring system extensively used to evaluate symptoms of shortness of breath and provides valuable data. It begins with 0, where you have no breathing problems, and rises to 10, where you have the most respiratory distress. As a result, healthcare professionals need to give patients enough time to learn and make sure they comprehend before using it
88994144|NCT00405665|Experimental|1|
88994145|NCT00405665|Experimental|2|
88994146|NCT03458572|Experimental|Intervention|1.5mm Seirin Pyonex needle at LI11 point
88994147|NCT03458572|Sham Comparator|Control|0.3mm Seirin Pyonex needle at TB10 point
88994148|NCT00531700|Experimental|I|Exposure to both tailored/targeted health messages about influenza and also to reports about contextualized influenza risk
88994149|NCT00531700|Experimental|II|Exposure to tailored/targeted health messages
89657372|NCT05699369|Experimental|Intervention arm|A comprehensive package of digital health interventions to connect patients, patient champions and public health providers to improve the management of non-communicable diseases (NCDs) during the pandemic will be implemented, including 1) providing training to health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve NCD case management and linking with patient champions; and 3) employing telementoring platform to improve quality of care. Patient champions are experienced patients who can provide peer support.
89657373|NCT05699369|No Intervention|Control arm|Usual care, which is routine hypertension and diabetes diagnosis and treatment under the World Diabetes Foundation (WDF) project will be implemented. The WDF project provides initial Zoom-based training of NCD care to rural health center (RHC) staff, but no tele-mentorship is offered. Under the usual care, patients with hypertension or diabetes are required to visit RHCs every month to renew their medications and measure their blood pressure. No other interventional components will be implemented in the control arm.
89657374|NCT05699330|Experimental|Bilateral subgenual cingulate deep brain stimulation (SGC DBS)|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone. All patients will receive deep brain stimulation (DBS) targeting the subgenual cingulate (SGC) bilaterally. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
89657375|NCT05698810|Other|Healthy Volunteers|tests
89657376|NCT05698810|Other|Parkinson's Disease patients|tests
89657377|NCT05698810|Other|Para/tetraplegic Patients|tests
89657378|NCT05693467|Experimental|The dexamethasone palmitate emulsion(DXP) plus ropivacaine group|The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of dexamethasone palmitate emulsion(DXP) and ropivacaine.
89657379|NCT05693467|Active Comparator|The ropivacaine alone group|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone.
89657380|NCT05676567||Hip Arthroplasty|Patients undergoing total hip replacement, hip resurfacing or revision hip replacement
89657381|NCT05676567||Knee Arthroplasty|Patients undergoing total knee replacement, partial knee replacement or revision knee replacement
89657382|NCT05676567||Shoulder Arthroplasty|Patients undergoing total shoulder replacement, reverse shoulder replacement or partial shoulder replacement (hemiarthroplasty).
89657383|NCT05673096|Experimental|PACT + Management as usual|"PACT + management (MAU - see comparator intervention). PACT is a parent-mediated and video-aided intervention designed to improve socio-communicative functioning in children with ASD. The intervention is based on theory and research on pre-linguistic and early social interaction and language development. The programme focuses on changing the interaction in the parent-child dyad in order to enhance communication and language development and skills in children with ASD.~The overall focus of the intervention is to guide parents to provide a sensitive, highly adapted interaction context in which their own responses and language are matched to the child's communication competence and language comprehension. Parents learn to identify windows of opportunity to facilitate joint interactions, enhance emerging communication, elicit child intentionality and support language comprehension, thereby aiming to ameliorate abnormal developmental pathways."
89657384|NCT05673096|Active Comparator|Management as usual|"Enhanced management as usual (MAU). MAU is delivered by the regional Child and Adolescent Mental Health Center (CAMHS). All participants will have equal access to seek advice via a telephone hotline in the trial period (12 months).~Following the diagnosis of ASD, the parents will be offered psychoeducation as usual in the local CAMHS. A telephone hotline open to all participants will offer pedagogical advice and try to help the parents to collaborate and engage with their professional partners in the municipality. The parents will also be able to contact the CAMHS when needed. The hotline team will be able to consult with the responsible clinician at the CAMHS. The clinician should always be notified within the same day, if a parent describes acute worsening of the child's condition, risk of suicidality, or severe aggression. The responsible clinician will be able to refer the child to further assessment and treatment within the CAMHS without any significant delay."
89657385|NCT05658887|Placebo Comparator|Placebo|Preoperative tylenol, preoperative celecoxib, preoperative gabapentin placebo
89657386|NCT05658887|Experimental|Intervention|Preoperative tylenol, preoperative celecoxib, preoperative gabapentin
89657387|NCT05656638|Experimental|Brain-injured participants|Participants with post-stroke fluent or non-fluent chronic aphasia
89657388|NCT05655247|Experimental|Split-thickness non-advanced tunnel (Zabalegui et al. 1999)|
89657389|NCT05655247|Active Comparator|Full-thickness coronally-advanced tunnel (Aroca et al. 2010)|Modified Coronally Advanced Tunnel (MCAT)
89657390|NCT05654142|Active Comparator|Group A: Waitlist-Base Intervention|Participants in Group A will be in the waitlist control condition initially and transition to receive the base intervention at Week 12, which includes 12 GLB video sessions from Week 13-24 and digital messages from Week 25-52.
89657391|NCT05654142|Active Comparator|Group B: Waitlist-Augmented Intervention|Participants in Group B will be in the waitlist control condition initially and transition to receive the augmented intervention at Week 12, which includes 12 GLB video sessions plus one-on-one PST from Week 13-24 and digital messages plus group-based PST from Week 25-52. Trained coaches will deliver the PST via videoconference (preferred) or phone.
89657392|NCT05654142|Experimental|Group C: Base Intervention (Responders)|Participants in Group C will be the individuals initially randomized to receive the base intervention who achieve 3% weight loss or more by Week 6 after completing the first 6 GLB videos. They will continue the base intervention without re-randomization and complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
88994150|NCT00531700|Experimental|III|Exposure to reports about influenza related contextualized risk
88994151|NCT00531700|Active Comparator|IV|Comparison group exposed to community level health promotion messages not generated by the study
88994152|NCT02943538|Experimental|Telemedicine group|In this group, monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
88994153|NCT02943538|Experimental|Telephone support group|A telephone control of their state and evolution will be made through the nursing staff of the unit.
89657393|NCT05654142|Experimental|Group D: Base Intervention (Non-responders)|Participants in Group D will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to continue the base intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
89657394|NCT05654142|Experimental|Group E: Augmented Intervention (Non-responders)|Participants in Group E will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to receive the augmented intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. They will also work with a trained coach via videoconference (preferred) or phone to receive one-on-one PST from Week 7-24 and group-based PST from Week 25-52.
89657395|NCT05652972|Experimental|Ketogenic diet|40 women which will follow the ketogenic diet with 1700 kcal daily for 8 weeks
89657396|NCT05652972|Active Comparator|Control diet|40 women which will follow the standard diet with 1700 kcal daily for 8 weeks
89657397|NCT05652283|Experimental|experience group|Pamiparib 40 mg, BID, oral, 3 weeks as a cycle, 3 cycles Surufatinib 250 mg, QD, oral, 3 weeks as a cycle, 2 cycles
89657398|NCT05651230|Experimental|Rhamnan sulfate|The subjects will take rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.
89657399|NCT05651230|Placebo Comparator|Placebo|The subjects will take placebo (Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) orally three time daily at each meal time.
89657400|NCT05648604|Experimental|Mentored Community Gardening|This arm will consist of gardening at least once per week, meeting with a master gardener mentor bi-monthly, and attending a gardening informational workshop once monthly.
89657401|NCT05646550|Experimental|Dose Escalation Part|In the dose escalation part, up to 7 dose cohorts will be included depending on occurrence of dose-limiting toxicity (DLT). Each dose cohort has a predefined day 3 dose level (DL): cohort 1, 78µg; cohort 2, 110µg; cohort 3, 150µg; cohort 4, 210µg; cohort 5, 300µg; cohort 6, 400µg; cohort 7, 600µg. Each dose cohort will consist of at least three patients evaluable for DLT. Maximum tolerated dose (MTD) is defined on at least six patients
89657402|NCT05646550|Experimental|Dose Expansion Part|CC-1 is administered as a 3-hour short-term intravenous infusion started at the MTD dose level identified in the dose escalation part of the study or based on the discretion of the sponsors delegate and DSMB recommendation supported by preliminary safety and efficacy data to constitute a modified MTD, e.g. to be one or more dose levels lower than the MTD determined. Patients can be treated simultaneously during the dose expansion phase. Patients must be hospitalized during step dosing, i.e. from day 1-4 (last dosing on day 3) of the first cycle. Thereafter inpatient treatment (overnight stay) depends on the discretion of the investigator, an outpatient treatment is preferred.
89657403|NCT05645575|Experimental|Open-label TMS|
89657404|NCT05639361||Standard Condensed|"Will complete a traditional schedule of 10 exposures over a 2-week period followed by a one-month break period before the final assessment. Because this schedule of exposure has been used most frequently in repeated exposure studies, this group will serve as the reference group."
89657405|NCT05639361||Periodic|Will complete a schedule of 5 exposures over a 2-week period, followed by a 2-week break, and then another 5 exposures over an additional 2-week period.
89657406|NCT05639361||Extended|Will complete a schedule of 10 exposures over a continuous 6-week period of time (approximately one exposure every 3-5 days).
89657407|NCT05636202||Survival group|Patients who survived sepsis
89657408|NCT05636202||Death group|Patients who died of sepsis
89657409|NCT05632601|Experimental|Sex-Specific Risk HDP Subgroup Factor Group and Age-Matched Control Group|"Blood sample~Questionnaires~Arterial stiffness assessment~Transthoracic Echocardiogram~Coronary Computed Tomography Angiography (CTA)~Cardiac Positron Emission Tomography (PET)"
89657410|NCT05632601|No Intervention|Sex-Specific Risk factor group and Age-Matched Control Group|"Blood sample~Questionnaires~Arterial stiffness assessment"
89657411|NCT05629858|Experimental|6-hour Time restricted eating (TRE)|Ad libitum food intake from 1-7 pm every day Fasting from 7-1 pm every day (18-h fast)
89657412|NCT05629858|Experimental|Calorie restriction (CR)|25% energy restriction every day
89657413|NCT05629858|Experimental|Control|Usual diet
89657414|NCT05625178|Experimental|tVNS group|This will be a single-arm study where all study participants will receive transcutaneous vagus nerve stimulation (tVNS) at the cymba concha of the left ear for 60 minutes. The tVNS parameters will be a below-discomfort-threshold intensity with 25 Hz and a pulse width of 250 uS.
88994154|NCT02943538|Active Comparator|Control group|Conventional care provided in the unit to patients with IBD -high moderate complexity.
88994155|NCT00145184|Placebo Comparator|Placebo|Placebo
88994156|NCT00145184|Experimental|Multivitamins|Multivitamin supplement containing the following vitamins: B1, B2, Niacin, B6, Folate, B12, C, and E
88994157|NCT02944357|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, AGS-003-BLD)|"NEOADJUVANT PHASE: Patients receive gemcitabine hydrochloride IV on days 1 and 8, AGS-003-BLD ID on day 1, and cisplatin IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive AGS-003-BLD ID on day 1. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo cystectomy during course 8.~ADJUVANT PHASE: Patients continue AGS-003-BLD ID on day 1 of course 9. Treatment repeats every 12 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity."
88994158|NCT02944474|Experimental|Cohort 1 (200 mg)|Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
88994159|NCT02944474|Experimental|Cohort 2 (500 mg)|Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions
88994160|NCT02944474|Experimental|Cohort 3 (500 mg)|Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
88994161|NCT02944474|Experimental|Cohort 4 (1000 mg)|Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions
89657415|NCT05606419|Experimental|CDED + PEN|Crohn's Disease Exclusion Diet (CDED)+Partial Enteral Nutrition (PEN): Patients will follow the first phase diet (CDED+50%PEN) for 6 weeks and will continue with CDED phase 2 + 25%PEN for another 6 weeks. Total duration: 12 weeks.
89657416|NCT05606419|Active Comparator|Usual Nutritional Care + PEN|Partial Enteral Nutrition (PEN) + usual nutritional care: Patients will be given PEN plus the usual advice for a healthy dietary pattern. PEN will cover the 50% of total energy requirements for the first 6 weeks. During the second 6 weeks, PEN will cover the 25% of the total energy requirements.Total duration: 12 weeks
89046835|NCT04668963|Experimental|INTENSIVE MIRROR THERAPY|The intensive therapy group participants received 5 Mirror Therapy (+physiotherapy) sessions /week for 6 weeks, which makes a total of 30 sessions.
89046836|NCT04668963|Active Comparator|SPACED OVER TIME MIRROR THERAPY|The conventional therapy group received the same number of sessions but more spaced in time, consisting in 3 Mirror Therapy (+physiotherapy) sessions/week for 10 weeks.
89657417|NCT05606419|Active Comparator|CDED + Dairy|Crohn's Disease Exclusion Diet (CDED) + dairy products: Patients will follow the first phase diet CDED + 50% of their energy requirements covered by dairy products for 6 week and then will continue with the CDED phase 2 diet + 25% dairy products.
89657418|NCT05601713|Active Comparator|No cooling intervention (control)|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
89657419|NCT05601713|Experimental|Lower limb immersion|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
89657420|NCT05601713|Experimental|Lower limb immersion + neck cooling|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension.
89657421|NCT05596019|Experimental|neurodynamics specific exercise group|"The experimental group will perform a multimodal therapeutic physical exercise program. The components of balance, walking, cardiovascular endurance, strength and flexibility will be worked globally, in addition to including respiratory exercises.~Specific neurodynamic exercises oriented to the treatment of the main nerves of the brachial plexus will be included as part of the exercise sessions. The specific neurodynamic program will consist of the following exercises:~Opening of the cervical conjunction holes with cranio-cervical and cervical flexion movements, cervical lateroflexions and lateral vertebral sliding self-mobilizations.~Opening of the thoracic passages of the brachial plexus with stretching of the scalene muscles, opening of the costoclavicular space and stretching of the pectoralis minor muscles.~Specific exercises of neurodynamic sliding of the nerves of the upper limb: median, radial and ulnar nerves."
89657422|NCT05596019|Active Comparator|The nonspecific exercise group|The nonspecific exercise group performed balance, cardiovascular endurance, stability, upper and lower limb strength, flexibility, and breathing exercises.
89657423|NCT05589090|Experimental|Intervention group|Super Skills for Life intervention
89657424|NCT05589090|No Intervention|Wait-list group|Children in this group did not receive any phycological (public or private) intervention during the eight-week duration of the SSL program. They were informed that children in this group will receive the intervention once the follow-up visit is completed.
89657425|NCT05574686|Experimental|Telehealth Hypertension and Food Insecurity Intervention|Telehealth Hypertension and Food Insecurity Intervention Established clinical telehealth services will be provided to monitor and give behavioral and educational management advice to women with breast cancer to better control their hypertension. Resources for food insecurity will be provided to participants.
89657426|NCT05572255|Experimental|Treatment A (Reference)|An intact 200 mg cenobamate tablet administered orally.
89657427|NCT05572255|Experimental|Treatment B (Test 1)|A crushed 200 mg cenobamate tablet in suspension administrated orally.
89657428|NCT05572255|Experimental|Treatment C (Test 2)|A crushed 200 mg cenobamate tablet in suspension administered via an NG tube
89657429|NCT05571917|Experimental|ACT + MBRP Intervention|The ACT + MBRP group will follow a manualized clinical protocol. Treatment will include 12 weekly, virtual group-based sessions, each lasting 90 minutes. Group sizes will range from three to ten participants. All sessions will be audio recorded for fidelity. Over the course of the group meetings, participants identify areas of meaningful functioning that have been adversely impacted by pain, learn methods to enhance pain willingness in the service of these meaningful areas, and practice present-focused awareness skills. Group sessions include discussions of the impact of pain and distress avoidance, identifying alternatives to this avoidance and establishing plans for behavior change, demonstration and role-playing exercises, and homework assignments. Participants are provided with a treatment manual to help guide and inform practice outside of group sessions.
89657430|NCT05571917|Active Comparator|Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) condition will supplement standard practices within the study sites related to chronic pain and OUD education. Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with a list of chronic pain treatment resources, signs and management of opioid overdose including naloxone, and overdose prevention, and will encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms. In addition to receiving the brochure, EUC condition participants will meet with a therapist remotely for approximately 15 minutes for a descriptive overview of the brochure. In this session, the therapist will point out the resources in the brochure and read the helpful tips out loud to the participant. This session will be audio recorded for fidelity.
89046837|NCT04865627||independent walking with walking aid|the participant is able to walk with a walking aid and does not need further assistance.
89046838|NCT04865627||dependent walking with walking aid|the participant is able to walk with assistance and a walking aid
89046839|NCT04669626|Other|Group 2|Wound cleansing with NaCl (natrium chlorid) solution 0.9%
89046840|NCT04669626|Experimental|Group 1|Wound cleansing with Octenilin®
89046841|NCT04669470|Active Comparator|Group with adjustable IGB|
89657431|NCT05566483|Experimental|Exercise|
89657432|NCT05566483|No Intervention|Control|
89046842|NCT04669470|Active Comparator|Group with nin-adjustable IGB|
89046843|NCT04738760||Group 1|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with standard dose vitamin D in addition to standard COVID-19 management.
89046844|NCT04738760||Group 2|Moderate and severe patients who were infected with SARS-CoV-2 and who were already receiving treatment with high dose vitamin Din addition to standard COVID-19 management.
89657433|NCT05566379|Experimental|Mindfulness Intervention|All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center at UCLA. Participants will learn Mindful concepts and a variety of Mindfulness practices. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. MAPs classes meets weekly for two hours per week for six weeks. Participants are encouraged to complete some daily meditation practice starting at five minutes a day and working up to 20 minutes daily by the end of the course.
89657434|NCT05566327|No Intervention|Usual Care|Clinics in this arm will receive the usual information about low value preoperative testing. Staff at these hospitals may be aware of the Choosing Wisely Anaesthesia Guidelines for reducing unnecessary testing, the Ontario Anaesthesiology Toolkit to operationalize the Choosing Wisely guidelines.
89657435|NCT05566327|Active Comparator|Intervention Group|The intervention will focus on increasing accountability for preoperative test ordering to reduce the number of inappropriate tests ordered for patients having ambulatory surgeries. A multi-component approach will be used to address the accountability of who should order preoperative tests for patients undergoing ambulatory surgery.
89046845|NCT04669431|Experimental|Xbox kinect Training|X Box Games include Tennis Playing, Joy riding, Rally ball.
89046846|NCT04669431|Active Comparator|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living
89046847|NCT04668612|Active Comparator|Standard-bolus|Standard boluses for all meal
89046848|NCT04668612|Experimental|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m
89046849|NCT00533390|Experimental|EFAVIRENZ 800mg|Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
89046850|NCT00533390|Active Comparator|EFAVIRENZ 600mg|Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
89046851|NCT00556296|Experimental|1|
89046852|NCT00556296|Experimental|2|
89046853|NCT00556296|Experimental|3|
89046854|NCT00556296|Placebo Comparator|4|
89046855|NCT04709003||vaccinated|participants who received the Covid-19 vaccine
89046856|NCT04709003||unvaccinated|participants who didn't received the Covid-19 vaccine
89657436|NCT05550831|Experimental|Radiofrequency|"Radiofrequency procedure prior to the removal of morton's neuroma.~Radiofrequency Machine: Multilesion Generator 3 Channels TLG-10 STP.~Temperature: 80-85ºC~Time: 90 seconds~Active needle size: 1 cm~Number of Applications: 3~Impedance: less than 550~Ultrasound. General Electric Logic R7 with 12 Mgh probe."
89657437|NCT05547594|Experimental|Prehabilitation|Arm undergoing multimodal prehabilitation (physical activity, nutritional education and anxiety management) during the weeks leading up to surgery
89657438|NCT05547594|No Intervention|Standard of care|Arm receiving standard of care (no prehabilitation)
89657439|NCT05543759||Cases|Children aged 6-59 months of both sexes from households established permanently in the catchment area of the selected health posts or health centers, meeting the SAM or MAM acute malnutrition case definitions described below with no medical complications and disability, and whose caregiver has granted consent to participate.
89657440|NCT05543499||Monochorionic Pregnancy Group|Participants with complicated monochorionic pregnancies (MC) will be followed prospectively beginning at the time of the mother's evaluation for a complication related to monochorionic (MC) multiple pregnancies through delivery of the child and follow-up of the child to 12 months of life.
89657441|NCT05537818|Experimental|Group 1a Clinic Treatment|Randomized, active or sham in-clinic treatment during a migraine, followed by open-label treatments in the home environment.
89657442|NCT05537818|Other|Group 1b Clinic & Home Treatment|Open-label, active treatment for subjects treated in prior clinical trials for this device, followed by open-label treatments in the home environment.
89657443|NCT05537818|Experimental|Group 2 Home Treatment|Randomized active or sham for first home treatment followed by open-label treatments in the home environment.
89657444|NCT05531123|Experimental|Arm1(cCR=cT0, cTa)|
89657445|NCT05531123|Experimental|Arm2 (non-cCR)|
89657446|NCT05527236|Experimental|Breathing Exercise Group|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercise again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
89046857|NCT00556335|Experimental|manual aspiration|manual aspiration
89046858|NCT00556335|Active Comparator|conventional drainage|conventional drainage
89046859|NCT04668456|Placebo Comparator|Group C (control group)|Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
89046860|NCT04668456|Active Comparator|Group SD (subtenon dexmedetomiine)|Group SD ( subtenon dexmedetomidine): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ 0.5 μg/kg dexmedetomidine (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.
89046861|NCT04668456|Active Comparator|Group ID (iv dexmedetomidine)|Group ID (iv dexmedetomidine): received received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of 0.5 μg/kg dexmedetomidine over 10 min. before subtenon block.
89046862|NCT04668417|Active Comparator|Reminders with direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with a link enabling direct scheduling
89046863|NCT04668417|Active Comparator|Reminders with no direct scheduling link|Patient proxy receives a reminder/recall messages regarding second dose influenza vaccination via the patient portal with no direct scheduling link
89657447|NCT05527236|Experimental|Virtual Reality Group|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
89657448|NCT05527236|No Intervention|Control Group|"Descriptive information form was filled out at 36th week of pregnancy in a quiet pregnant outpatient clinic in the hospital. After participants were admitted to the delivery room of Gaziantep Cengiz Gökçek Obstetrics and Pediatrics Hospital at the 40th week of pregnancy, and taken to their beds, in labour observation form, the labour section and the birth evaluation section which is used to evaluate the second and third stages of labour were filled out. Then, VAS was applied when cervical dilatation was 4 cm (the beginning of the active phase). Birth satisfaction was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.~No application was made to pregnant women in this group, except for routine practices in the pregnant outpatient clinic at the hospital and in the delivery room."
89657449|NCT05526872|Experimental|Arm I (PReVenT intervention)|Participants receive usual care as well as a portal message reminder to schedule a SM and a callback link if they need assistance. Participants who have not or do not schedule their SM at the time of the first reminder receive a reminder text-message one week later with a link to receive assistance with scheduling.
89657450|NCT05526872|Active Comparator|Arm II (enhanced usual care)|Participants receive usual care as well as portal and text messages one week apart with educational materials about healthy eating.
89657451|NCT05523492|Experimental|Culturally Enhanced Wellbeing Course|For this study, the ICBT program, called the Wellbeing Course was culturally enhanced by simplifying language for individuals with limited command of English, acknowledging cultural differences and increase representation in imagery. Audiovisual components were included to provide a brief summary of each lesson. Furthermore, additional client stories were added to the intervention to diversify narratives and be more representative of the clients seeking this intervention.
89657452|NCT05516264|Other|Dog visits first|Participants receive the three dogs visits first and then, after a break, receive the three control visits
89657453|NCT05516264|Other|Control visits first|Participants receive the three control visits first and then, after a break, receive the three dog visits
89657454|NCT05514808|Active Comparator|Nutrition education intervention group|Each week, participants will learn about a topic related to nutrition, health and values-based ethics of clean sport. The intervention group will also receive information on dietary supplements, their benefits and their risks. Doping and body appreciation and their links to the use of dietary supplements will also be covered in this group. The duration of the intervention is 4 weeks; 1 module to be released every week.
89657455|NCT05514808|No Intervention|Control group|No intervention to be received during the 4-week period.
89046864|NCT04686968|Experimental|Greenhouse group|Patients underwent greenhouse technique：The high-strength suture was passed through the tendon using Mason-Allen method, and then Crimson duvet procedure was performed on the foot print area from the articular surface of the humeral head to the apex of the greater tubercle. Immediately after this procedure, a lateral row anchor was used.
89046865|NCT04686968|Active Comparator|Vent group|The three-line anchor suture method is the same as before, the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
89657456|NCT05513326|Experimental|Intervention Group|Intervention group will received education and a specific rehabilitation program (exercises).
89657457|NCT05513326|Other|Control Group|Control group will received education alone.
89657458|NCT05506878|Active Comparator|NSS-2 BRIDGE device|"This experimental arm involves the use of the NSS-2 BRIDGE device, which is a disposable device that stimulates the branches of cranial nerves and of the superficial cervical plexus innervating the ear. It will be placed on the subject immediately after surgery and worn for 5 days.~It is a percutaneous nerve field stimulator (PNFS) system, that can be used as an aid to reduce the symptoms of opioid withdrawal, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination."
89657459|NCT05506878|Sham Comparator|Placebo Bridge|"The sham group involves the use of 3 non-active points, or nonfunctional points. The sham device will be placed on the subject immediately post-operatively and worn for 5 days just like the active group."
89657460|NCT05503069|No Intervention|Group A - Control|The control group will receive standard of care, which include basic training by lactation educators.
89657461|NCT05503069|Experimental|Group B - Intervention|"Women in the intervention arm will receive standard of care, which includes basic training in breastfeeding by lactation educators, and the action items related to the intervention.~The intervention will include the following~Providing a breast milk pumping machine to the mother,~Facilitating training session to improve dietary literacy for lactating mothers,~Distribution of educational material describing the benefits of continuing breastfeeding infants up to 12 months of age to family members, employers, day care managers/caregivers."
89657462|NCT05483465|Experimental|NR|Treatment with oral NR (1g/day per os for 8 weeks)
89657463|NCT05483465|Placebo Comparator|Control|Visually identical placebo (daily, per os, for 8 weeks)
89657464|NCT05483023|Experimental|18F-fluorofuranylnorprogesterone PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
89657465|NCT05482724|Experimental|Intervention group|Super Skills for Life intervention group
89046866|NCT00556413|Experimental|ERBIRINOX|5FU + Irinotecan + Oxaliplatine + Cetuximab
89046867|NCT04687085|Placebo Comparator|Neutral Content|Participants will listen to a 10 minute neutral content recording just prior to epidural catheter placement.
89046868|NCT04687085|Experimental|Mindful Meditation|Participants will listen to a 10 minute mindful meditation recording just prior to epidural catheter placement.
89046869|NCT04668573|Experimental|Trunk exercise group|Participants received trunk exercise for 30 minutes per session, twice a week for 12 weeks.
89046870|NCT04668573|No Intervention|Control group|Participants remained their regular activities.
89046871|NCT04686695|Experimental|Transcutaneous Auricular Vagus Nerve Stimulation|
89046872|NCT04668690|Experimental|Experimental: Mitoxantrone Hydrochloride Liposome Injection|Patients with relapsed/refractory PTCL will receive Mitoxantrone Hydrochloride Liposome Injection every 28 days (a cycle) for a maximum of 8 cycles. The dose of Mitoxantrone Hydrochloride Liposome Injection is 20 mg/m2.
89046873|NCT04668690|Active Comparator|Active Comparator: Chidamide|Patients with relapsed/refractory PTCL will receive Chidamide 30 mg p.o., twice per week until disease progression.
89046874|NCT04668534|Experimental|Treatment group 1|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
89657466|NCT05482724|No Intervention|Wait-list group|Group without any intervention. Participants in the wait-list group received no phycological (public or private) intervention during the eight-week duration of the SSL program. They were informed that children in this group will receive the intervention once the follow-up visit is completed.
89657467|NCT05480319|Experimental|EDICARS|
89046875|NCT04668534|Experimental|Treatment group 2|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
89046876|NCT04668534|Active Comparator|Control group|"Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left earlobe. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)."
89046877|NCT04668495||Cangrelor Group|This is the study cohort that the blood sample will be obtained from. There are no interventions
89046878|NCT04658979|Experimental|Intervention group|
89046879|NCT04593992|Experimental|HTEMS|High-tone external muscle stimulation 5 times within a week for 12 weeks
89657468|NCT05480319|Active Comparator|Usual care|
89657469|NCT05477108|Experimental|Treatment A: BGF MDI HFO 160/7.2/4.8 μg ex-actuator with oral activated charcoal|Subjects will receive Test formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
89046880|NCT04593992|Placebo Comparator|Placebo|Placebo stimulation 5 times within a week for 12 weeks
89657470|NCT05477108|Experimental|Treatment B: BGF MDI HFA 160/7.2/4.8 μg ex-actuator with oral activated charcoal|Subjects will receive Reference formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
89657471|NCT05464979|Experimental|Esketamine intubation group|Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation. The Richmond Agitation Sedation Scale (RASS) was used to assess the sedation of patients every 1 hour and maintains a RASS score of -2 to 0.
89657472|NCT05464979|Placebo Comparator|Conventional intubation group|Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score. The RASS score was assessed every 1 h and maintained at -2 to 0.
89657473|NCT05462600||BMI>24.9 kg/m2|
89046881|NCT04668729|No Intervention|Control group|20 people will be included in the control group. 3 measurements will be taken one week apart in total. Measurements will consist of maximum isometric muscle strength, lumbar range of motion, balance performance, and pain intensity. And it will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD) and Modified Schober test, flamingo balance test, and visual analog scale.
89057974|NCT02278913|Active Comparator|Human Insulin|Human insulin: NPH and regular insulin: 2/3 of total daily dose as NPH and 1/3 as regular insulin. NPH insulin dose given as 2/3 in the morning before breakfast and 1/3 before dinner. Regular insulin given in three equally divided doses before each meal
89657474|NCT05462600||BMI 18-24.9 kg/m2|
89657475|NCT05457205|Experimental|Neuromodulation with 50 Hz and low intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 50 Hz and stimulation intensity of 0.45 x lowest motor threshold (reflex threshold in leg muscles).
89657476|NCT05457205|Experimental|Neuromodulation with 50 Hz and high intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 50 Hz and stimulation intensity of 0.90 x lowest motor threshold (reflex threshold in leg muscles).
89657477|NCT05457205|Experimental|Neuromodulation with 100 Hz and low intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 100 Hz and stimulation intensity of 0.45 x lowest motor threshold (reflex threshold in leg muscles).
89657478|NCT05457205|Experimental|Neuromodulation with 100 Hz and high intensity|Transcutaneous spinal stimulation for 30 min with a stimulation frequency of 100 Hz and stimulation intensity of 0.90 x lowest motor threshold (reflex threshold in leg muscles).
89657479|NCT05455268|Experimental|eHOPE|Participants in the intervention group will receive access to e-Hematological Oncology Parent Education (eHOPE) and usual care. Participants will need to complete 4 self-paced activities over a period of 8 weeks. Each activity will be released at 2-weekly intervals.
89657480|NCT05455268|Active Comparator|Usual care|Participants in the waitlist-control group will receive verbal explanations and caregiver education based on clinician's needs assessment in the course of their child's treatment process. At the end of 8-weeks, they will also receive access to eHOPE.
89657481|NCT05447338|Experimental|Specific joint mobilization post muscle inhibition on C1 and C2|Experimental technique alone, with its two variants. That applies a sliding of the articular surfaces of the atlas and axis after a muscular reflex inhibition (proprioceptive neuromuscular facilitation). Between 1 and 5 mobilizations will be carried out per variant of the technique. There will be 4 treatment sessions distributed over 2 weeks.
89657482|NCT05447338|Experimental|Specific joint mobilization post muscle inhibition on C1 and C2 + myofascial inductions|Experimental technique alone, with its two variants. That applies a sliding of the articular surfaces of the atlas and axis after a muscular reflex inhibition (proprioceptive neuromuscular facilitation). Between 1 and 5 mobilizations will be carried out per variant of the technique. Myofascial inductions will also be applied to the cranial and cervical fascia, as well as to the suboccipital, pectoral, angular scapula, sternocleidomastoid, trapezius, internal and external pterygoid, masseter and temporal muscles. There will be 4 treatment sessions distributed over 2 weeks.
89657483|NCT05447338|Active Comparator|Maitland C2 + SNAG C1|The Maitland technique will be applied, central postero-anterior passive joint mobilization in the C2 vertebra. As well as the sustained apophyseal slip technique (SNAG) in rotation on C1. The dosage is from 1 to 5 mobilizations per technique. There will be 4 treatment sessions distributed over 2 weeks.
89657484|NCT05442463||women|"Iohexol 5 ml IV push followed 10 ml IV flush of normal saline is administered to establish baseline GFR (glomerular filtration rate). FF (filtration fraction) is calculated as follows: GFR/RPF=FF. Captopril 25 mg is given orally.~Blood will be collected at specific time points, pulse wave velocity testing 3 times throughout morning, Holter monitor and bioelectrical impedance testing."
89657485|NCT05442463||men|"Iohexol 5 ml IV push followed 10 ml IV flush of normal saline is administered to establish baseline GFR (glomerular filtration rate). FF (filtration fraction) is calculated as follows: GFR/RPF=FF. Captopril 25 mg is given orally.~Blood will be collected at specific time points, pulse wave velocity testing 3 times throughout morning, Holter monitor and bioelectrical impedance testing."
89657486|NCT05440175|Experimental|Group A|The participants will be given Mirror therapy along with the electrical muscle stimulation and exercises.
89657487|NCT05440175|Experimental|Group B|The participants will be given constraint induced movement therapy (CIMT) along with exercises.
89657488|NCT05440175|Experimental|Group C|The participants will be given mirror therapy and exercises.
89657489|NCT05435989|Experimental|Normal-hearing listeners|
89657490|NCT05435222|Experimental|male-specific psychotherapeutic program (MSPP)|In this treatment group, eugonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting.
89657491|NCT05435222|Active Comparator|cognitive behavioral therapy (CBT)|In this treatment group, depressed men will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting.
89657492|NCT05435222|No Intervention|Waitlist|"The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP.~As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality."
89657493|NCT05435222|Experimental|male-specific psychotherapeutic program (MSPP) + testosterone treatment (TT)|In this treatment group, hypogonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
89657494|NCT05435222|Active Comparator|cognitive behavioral therapy (CBT) + testosterone treatment (TT)|In this treatment group, hypogonadal depressed men (blood testosterone ≤ 12.1 nmol/l) will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.
89657495|NCT05435222|No Intervention|Waitlist + testosterone treatment (TT)|"The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP. As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality.~Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection."
89657496|NCT05408338|Experimental|Low Added Sugar Meal|Participants will be provided a meal low in added sugars.
89657497|NCT05408338|Experimental|High Added Sugar Meal|Participants will be provided a meal high in added sugars.
89657498|NCT05402319|Experimental|Antibiotic monotherapy|Single antibiotic is given intravenously or orally (systemically).
89657499|NCT05402319|Experimental|Antibiotic combination therapy|At least two different antibiotics are given intravenously or orally.
89657500|NCT05402319|Experimental|Topical antibiotic therapy|Single antibiotic bladder irrigation.
89657501|NCT05400980|Experimental|Urocross implant group|The investigational products in this trial are the Urocross Expander Implant as delivered by the Urocross Expander System and the Urocross Retrieval Sheath used to retrieve the implant after 6 months following its implant.
89657502|NCT05400980|Sham Comparator|Sham-control group|The sham-control in this trial is cystoscopy only.
89657503|NCT05398289|Experimental|4-week duration of antibiotic therapy|
89657504|NCT05398289|Active Comparator|standard 6-week duration of antibiotic therapy|
89657505|NCT05392894|Active Comparator|Standard of care|The comparator arm is standard medical care for this patient population. Standard medical care may include all currently available non-trial therapies for SCD.
89657506|NCT05392894|Experimental|Haploidentical stem cell transplantation|Participants receiving Haploidentical Stem Cell Transplantation will receive the transplant conditioning regimen as per the standard transplant protocol. Stem cells from a haploidentical donor will be infused on Day 0 according to standard institutional practices. Bone marrow is the preferred stem cell source however peripheral blood may be used as an alternative where required due to donor reasons.
89657507|NCT05388565|Experimental|The DOVE in China Intervention Group|Our intervention consists of four major components: a) information about IPV and effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
89657508|NCT05388565|Placebo Comparator|The Control Group|The control group will be provided with a standard of care including usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV, and mental health resources).
89657509|NCT05387291|Experimental|Nursing Intervention|The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
89657510|NCT05387291|Other|Usual intervention|The control group will receive the usual intervention of the center.
89657511|NCT05383261||control|"patients will take medical treatment only~patients will receive medical treatment in addition to aerobic exercises"
89657512|NCT05382884|Experimental|Intervention|Fifty participants will be randomized to the intervention group, receiving immediate access to postpartumcare.ca for a period of 4 weeks. Intervention group participants may use postpartumcare.ca as often as desired for the duration of the 4-week intervention period. Following the 4-week intervention period and a 2-week follow-up period, intervention group participants will retain access to postpartumcare.ca.
89657513|NCT05382884|No Intervention|Waitlist Control|Fifty participants will be randomized to a waitlist control group, receiving treatment as usual (TAU) for a period of 4 weeks. Following the 4-week intervention period and a 2-week follow-up period, waitlist control participants will receive access to postpartumcare.ca.
89657514|NCT05377515||IC-8 IOL Group|Visual outcomes in patients previously contralaterally implanted with the IC-8 IOL will be evaluated.
89657515|NCT05377268|Experimental|LH Protocol|Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally and by written instruction to inject insulin in sites of subclinical lipohypertrophy.
89657516|NCT05377268|Active Comparator|Normal Protocol|"Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally and by written instruction to inject insulin in sites of normal subcutaneous tissue.~Outcomes measured will consist of mean glucose, glucose standard deviation around the mean value, percentage of time with glucose below 3 mmol/liter, and percentage of time spent with glicose above 10 mmol/liter. The device will be calibrated and placed by a trained research nurse. There will be a member of the rsearch team available 24 hours per day to answer subject questions."
89657517|NCT05374330|Experimental|Electroacupuncture|Acupuncture needles will be inserted into the body at standardized acupuncture points. Electrical current will then be applied using 2 channels of electrical current for a total of 4 points receiving electroacupuncture
89657518|NCT05374330|Sham Comparator|Sham acupuncture|Sham Acupuncture needles will be placed at standardized acupuncture points. Sham electrical current will then be applied using 2 channels / 4 points as in the electroacupuncture group. The electrical current will not be turned on.
89657519|NCT05374330|No Intervention|Waitlist|The wait list group will be required to complete questionnaires at 4 separate time points over the 12 week study period.
89657520|NCT05373329|Experimental|self-guided app use|Participants receive the self-guided app intervention immediately. All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
89657521|NCT05373329|No Intervention|waitlist control|Participants receive the self-guided intervention after an 8-week waiting period (waitlist control group). All participants will have a total of 8 weeks participating in the study, and will complete assessments every 2 weeks during that 8-week period.
89657522|NCT05371548|Experimental|Intervention (SAM app)|"Patients will receive training in and access to the SAM app at discharge. SAM uses prescribed and dispensed medication data to display a continuously updated drug list and provides patients and caregivers with tools to address barriers to adherence.~Drug information: Provides patient-friendly drug monographs. Interaction checker: Generates drug-drug interactions between the patient's medications and other OTC drugs.~Adherence alerts: Uses decision algorithms to alert users to adherence problems with the new regimen.~Side effect checker: Displays possible side effects for each medication and frequency of occurrence.~PIMs alerts: Alerts patients to potentially inappropriate medications in their list.~Pharmacist connect: Connects users with pharmacists through a secured messaging service.~Social connect: Allows users to share medication experiences. Caregiver connect: Allows patients to enroll caregivers who can use the app. Weekly medication schedule & pill reminders"
89688621|NCT02808130||group HCP|"Group HCP: hyperlipidemic + generalized chronic periodontitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
89046882|NCT04668729|Experimental|Chiropractic group|20 people will be included in the experimental group. Lumbal chiropractic HVLA (High Velocity, Low amplitude: HVLA) spinal manipulation and sacroiliac joint chiropractic HVLA manipulation will be applied 3 times in total with a weekly interval. The maximum isometric muscle strength before and immediately after the application, lumbar joint range of motion, balance performance, and pain intensity will be evaluated respectively by back dynamometer, hand finger-to-ground distance (HFGD), and Modified Schober test, flamingo balance test, and visual analog scale.
89213464|NCT01003119|Experimental|A CHESS|Those in the ACHESS arm will also be given a smart-phone with access to the ACHESS system (the intervention) for a full 12 months. The ACHESS intervention includes: 1) the Core CHESS system that has been tested in several diseases, 2) a proactive computer-based relapse prevention system, 3) data transfer from the phone to a computer accessible by the patient's counselor/care manager, and 4) systems for the patient to maintain contact with his/her Care Manager
89213465|NCT01003119|No Intervention|Usual Care|Those randomized into the Usual Care group will receive usual medical care.
89657523|NCT05371548|No Intervention|Control (usual care)|Patients will receive usual care at discharge. On study units, medication reconciliation is conducted for all patients. Patients have their community medication list obtained via fax from their community pharmacy. The list is validated by the unit pharmacist who then reconciles it with admission orders, and recommends changes as needed to the attending physician. At discharge, the community drug list is reconciled with medications administered in hospital and the discharge prescription is generated by the attending physician or resident, classifying each medication as new medication, dose modification, discontinued therapy, or continued community medication. The discharge prescription is provided to the patient. Patients fill their discharge prescription at their community pharmacy. If there are questions about changes to the community drug list, the pharmacist will ask the patient, and if not clear will contact the discharging physician.
89657524|NCT05368753|Experimental|thoracic epidural analgesia|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end), then ropivacaine will be injected in the TEA at the same time and infused during 24h. The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period
89657525|NCT05360719|Experimental|Group Tele-exercise Class|Volunteers will be asked to participate in the group online exercise class 2 times per week for 8 weeks. Each activity session will last about 60 minutes and will focus on mind-body practices, tailored to physical and emotional needs of individuals with SCI. Class will be taught by a physical therapist who is an experienced community exercise instructor. Class will be co-led by a person who is living with SCI (one of our community partners). Classes will take place over a secure virtual platform (Zoom). Before beginning and after completion of the program, participants will be asked to participate in small group interviews to share expectations and experiences of the study
89657526|NCT05360719|Other|Waitlist Control|The waitlist control group will complete all quantitative measures as a baseline (baseline-control) and will be instructed to continue their activities as usual, with measures obtained again at 8-weeks (post-control/pre-program). Following the initial 8-week baseline, each waitlist group will participate in pre-intervention semi-structured interview or small focus group with the post-control measures as pre-intervention assessment. They will join the tele-exercise intervention with all measures at 8-weeks (post-intervention) and with leisure time physical activity and quality of life assessed at 16-weeks following initiation of the program.
89657527|NCT05356611|Experimental|Engage Treatment|The study is a single-arm study. The single-arm will be implementation of the 9-week protocol of Engage in an older adult population with late-life depression and comorbid executive dysfunction and mild cognitive impairment.
89657528|NCT05354609|Experimental|MR-enterography|
89657529|NCT05352425|Experimental|MobiusHD|Each subject enrolled in the study will undergo implantation of the MobiusHD® device
89657530|NCT05350566|Experimental|Sprint interval training group (SIT group)|The model of sprint interval training (SIT) consists of six 30 s all-out cycling bouts on a cycle ergometer, with 4 min rests between tests.
89657531|NCT05350566|Experimental|Moderate intensity continuous training (MICT group)|The moderate intensity continuous training (MICT) consists of 1h cycling on a cycle ergometer at 50% of the maximal aerobic power output
89657532|NCT05350189||Gadavist Single-dose vial|Data will be collected from contrast-enhanced Magnetic Resonance Imaging (MRI) using Gadavist from a single-dose vial of 7.5 or 10 or 15 milliliters (mL).
89657533|NCT05350189||Gadavist IBP|Data will be collected from contrast-enhanced MRI using Gadavist from an IBP of either 30 or 65 milliliters (mL), and from Gadavist via a single-dose vial due to insufficient product remaining in an IBP during the IBP cohort.
89657534|NCT05345691|Experimental|Bmab 1000|
89657535|NCT05345691|Active Comparator|Prolia®:|
89657536|NCT05345600|Experimental|MILTA|The MILTA® uses photons which are emitted with low intensity in the visible and near infrared combining 5 physical principles to reduce pain
89657537|NCT05345600|Placebo Comparator|placebo|
89657538|NCT05336851||Viral infection|Viral infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree
89657539|NCT05336851||Bacterial infection|Bacterial infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
89657540|NCT05336851||Viral-Viral co-infection|Viral-viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
89657541|NCT05336851||Bacterial-Viral co-infection|Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
89213466|NCT01003197||complication group < III|
89213467|NCT01003197||complication group >= III|
89213468|NCT01006239||Biorepository|Patients undergoing surgical resection of a solid tumor.
88994162|NCT02944474|Placebo Comparator|Placebo cohorts 1 to 4|Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)
89657542|NCT05336851||Fungal-Mycobacterium co-infection|Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
89657543|NCT05336851||Infection of uncertain origin|Infection of uncertain origin subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
89657544|NCT05336851||Control Subjects|Control group subjects, if they agree, will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms (if applicable); and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if applicable); and c) 48 hours +/- 6 hours from symptom onset (if applicable).
89657545|NCT05319600|Experimental|Intervention|This arm will complete an intervention delivered remotely via an online website and online communication from the research team across the 12-week intervention period. This intervention has two parts, taking place simultaneously over the 12 weeks. First, participants will complete 8 web-delivered online behavior-change skills learning sessions which include reading and activities. Second, participants will be given daily and weekly personalized physical activity goals to meet, which will be tracked via their Garmin activity tracker and weekday text and if indicated video support. They have the opportunity to win money each week for meeting activity goals.
89657546|NCT05319600|No Intervention|Treatment as usual - Control|This arm will not complete an intervention. Participants will be instructed to wear a Garmin activity tracker but will be given no other specific instructions, other than to continue to follow their normal daily diabetes care plan.
89657547|NCT05317988|Experimental|Intervention group|Participants receive a step-by-step demonstration video of detailed reconstitution procedures and text-based vaccine product information
89657548|NCT05317988|Placebo Comparator|Control group|Participants receive a generic video of similar duration on basic facts of COVID-19 (unrelated to reconstitution procedures) and text-based product information
89657549|NCT05315401|Experimental|Probiotic 9 log CFU/day|The intervention consists of daily administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
89657550|NCT05315401|Placebo Comparator|Placebo|placebo contains primarily carrier and without probiotic. The placebo are identical in taste and appearance and appear as a light-yellow powder.
89657551|NCT05315401|Experimental|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week
89657552|NCT05313217|Experimental|neural tension testing|All participants in this arm will undergo four tests: KEA, SLR, Slump, and Extended Slump
89657553|NCT05309356|Active Comparator|Usual care (Control)|Routine COPD patient care.
89657554|NCT05309356|Experimental|ACCEPT Decision Intervention|Clinical prediction model (ACCEPT)-based treatment recommendations: The ACCEPT tool will display the predicted risk of exacerbations, and the corresponding treatment recommendations to the physicians. These recommendations will be provided in a non-mandatory 'directive' format where the physician can override the recommendation, but is required to provide a justification (pre-set choices and a free text).
88994163|NCT02944396|Experimental|Veliparib and nivolumab with platinum doublet chemotherapy|Veliparib and nivolumab in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
88994164|NCT02944396|Experimental|Veliparib with platinum doublet chemotherapy|Veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
88994165|NCT00529984|Experimental|Cohort 1|
88994166|NCT00529984|Experimental|Cohort 2|
88994167|NCT00529984|Experimental|Cohort 3|
88994168|NCT00529984|Experimental|Cohort 4|
88994169|NCT00529984|Experimental|Cohort 5|
88994170|NCT00530140|Experimental|A|All patients will receive the same vaccination schedule/formulation
88994171|NCT02944279||Peking University Third Hospital|
88994172|NCT02944279||Beijing Friendship Hospital|
88994173|NCT02944279||Beijing Shijitan Hospital|
88994174|NCT02944279||Beijing Xiyuan Hospital|
88994175|NCT02944279||China-Japan Friendship Hospital|
88994176|NCT02944552|Experimental|low dose group|Patients in the low dose group administrated bicyclol tablet 25mg orally, three times daily for 4-8 weeks.
88994177|NCT02944552|Experimental|high dose group|Patients in the high dose group administrated bicyclol tablet 50mg orally, three times daily for 4-8 weeks.
88994178|NCT02944552|Active Comparator|positive drug control group|Patients in the positive drug control group administrated polyene phosphatidylcholine capsule 456mg orally, three times daily for 4-8 weeks.
88994179|NCT00530179|Active Comparator|Arm A|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)~Assigned interventions: Drug: R-CHOP (Rituximab, Cyclophosphamide, Etoposide, Cisplatin, Mesna, G-CSF 6 - 21 DAY Cycles of R-CHOP"
88994180|NCT00530179|Active Comparator|Arm B|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.~Assigned Interventions: Procedure/Surgery: Autologous Blood Stem Transplantation 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION"
89046883|NCT00533585|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (Sorafenib) + Bevacizumab + Paclitaxel + Carboplatin
89046884|NCT04585100|Experimental|Bioequivalent test of FM101 oral solution and FM101 tablet|
89046885|NCT04585100|Experimental|Phase 2a|
89046886|NCT04668378|Experimental|Time restricted eating (TRE) - two month|partecipants underwent 2 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
89046887|NCT04668378|Active Comparator|Normal Diet (ND) - two month|partecipants underwent 2 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
89046888|NCT04668378|Experimental|Time restricted eating (TRE) - twelve month|partecipants underwent 12 months of a TRE protocol, during which they consumed 100% of the daily energy needs in an 8-hour time window: from 1:00 PM to 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
89046889|NCT04668378|Active Comparator|Normal Diet (ND) - twelve month|partecipants underwent 12 months of a regular diet schedule and consumed 100% of the daily energy needs in 3 meals between 8:00 AM and 8:00 PM. Body composition, muscle strength and blood parameters were measured before and after the diet intervention.
89046890|NCT04668222|Experimental|Deficiency of Qi and Yang (QYang-group)|Participants will receive Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
89657555|NCT05307120|Experimental|Intervention|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on Android smartphones that enables continuous monitoring of nutrition (via food diary), physical activity (via activity tracker Fitbit and self-reported activities) and blood glucose values (via Freestyle libre 2 sensors). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
89657556|NCT05306821|Experimental|Implementation of an electronic tool for risk stratification and thromboprophylaxis prescription|
89046891|NCT04668222|Placebo Comparator|Placebo control of invigorating Qi and Yang (PQYang-group)|The placebo is made of 5% Yu-Ping-Feng and Xiang-Sha-Liu-Jun formula (Chinese Medicine Formula)
89046892|NCT04668222|Experimental|Deficiency of Qi and Yin (QYin-group)|Participants will receive Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
89046893|NCT04668222|Placebo Comparator|Placebo control of invigorating Qi and Yin (PQYin-group)|The placebo is made of 5% Yu-Ping-Feng and Liu-Wei-Di-Huang formula (Chinese Medicine Formula)
89046894|NCT04659057|Active Comparator|Group L|Lidocaine group; 45 randomly assigned patients.
89046895|NCT04659057|Active Comparator|Group D|Demedetomidine group; 45 randomly assigned patients.
89046896|NCT04659057|Active Comparator|Group DL|Combined lidocaine and dexmedetomidine group. 45 randomly assigned patients.
89046897|NCT04659057|Placebo Comparator|Group C|Control group; 45 randomly assigned patients.
89046898|NCT04668261||Neurosurgical patients|"• Neurosurgical diseases with the potential to alter blood flow to the brain:~Cerebrovascular disease~Brain tumors~Normal Pressure Hydrocephalus"
89046899|NCT04668261||Healthy subjects|"Male and Female subjects >18 years of age~Written Informed Consent by the participant after information about the project. Foreign speaking healthy subjects should be accompanied by a person with sufficient German language proficiency to act as a translator"
89046900|NCT04658745|Experimental|iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS: iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
89046901|NCT04658745|Sham Comparator|Sham iTBS over the ipsilesional primary motor cortex plus mirror therapy|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere, but with a sham coil (i.e., sham iTBS). After the sham stimulation, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
89057975|NCT04846530||Approved products will be placed in small boluses (0.2 mL) intradermally|Subjects will be assigned to receive two products each from the RHA® line of products (RHA® 1, RHA® 2, RHA® 3, and RHA® 4).
89057976|NCT02278991||Lutonix Drug Coated Balloon|Paclitaxel coated balloon catheter
89657557|NCT05306821|Experimental|Implementation of educative sessions and pocket cards for thromboprophylaxis|
89657558|NCT05302687|Experimental|probiotic 9 log CFU/day|Intervention consists of daily administration of one sachet/day of probiotic for 12 weeks, where each sachet contains 9 log CFU of probiotic.
89657559|NCT05302687|Placebo Comparator|placebo|placebo contains primarily carrier and without probiotic. The placebo are identical in taste and appearance and appear as light-yellow powder.
89657560|NCT05295966|Experimental|Intervention Group|Subjects in the intervention group will perform 20 sessions of multisensory training
89657561|NCT05295966|Active Comparator|Control Group|Subjects in the Control Group will not perform 20 sessions of multisensory training and they will keep doing the current therapy
89657562|NCT05290103|Experimental|Game intervention|Participants in this arm will receive the game intervention including 15-30 minutes of digital health game playing at school and 2 weeks of free usage of the game during free time and a 30-minute debriefing session with a researcher.
89657563|NCT05290103|No Intervention|No intervention|The participants in this arm will receive no intervention.
89657564|NCT05288686|Experimental|SPIO arm|Superparamagnetic iron oxide guided sentinel lymph node mapping
89657565|NCT05288686|Active Comparator|Control arm|Conventional radioisotope and blue dye guided sentinel lymph node mapping
88994181|NCT02944318|Experimental|"The Movement Program"|The intervention program was structured according three main components: (1) training and activities in general curriculum and Physical Education classes; (2) active facilities in the school environment; (3) health education in school community.
88994182|NCT02944318|No Intervention|No intervention|"Schools in the control group will maintain a regular academic year with conventional activities. Thus schools have two weekly Physical Education classes which are organized by according to the perspective of their teachers. Besides that, the Program Saúde na Escola is also performed."
88994183|NCT02944201|Experimental|Carvedilol|Carvedilol will be started at 6.25 mg by mouth twice daily. Patients will take carvedilol for 28 days prior to prostatectomy. They will be seen every 7 days and adjustments in the dose will be considered at those visits.
88994184|NCT02944162|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.
88994185|NCT00168909|Experimental|1|alfacalcidol 1µg/d
88994186|NCT00168909|Placebo Comparator|2|placebo
88994187|NCT00531739|No Intervention|A|Colorectal Surgery without use of SurgiWrapTM
88994188|NCT00531739|Active Comparator|B|Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
88994189|NCT00531778||NYU OCEDP Population|
88994190|NCT00145379|Experimental|Metformin|
88994191|NCT00145379|Placebo Comparator|Placebo comparator|
88994192|NCT00530374|Active Comparator|1|Each child in this group will receive daily supplementation of Iron Sprinkles with a single sachet for 60 days
88994193|NCT00530374|Placebo Comparator|2|Each child in this group will receive daily supplementation of placebo Sprinkles with a single sachet for 60 days
88994194|NCT00530452|Experimental|A|2.0 mg (loading dose, Day 0) followed by 0.3 mg/day (Days 1-20)
88994195|NCT00530452|Experimental|B|4.0 mg (loading dose, Day 0) followed by 0.6 mg/day (Days 1-20)
88994196|NCT00530452|Experimental|C|8.0 mg (loading dose, Day 0) followed by 1.2 mg/day (Days 1-20)
88994197|NCT00530452|Placebo Comparator|D|Placebo (identical number of capsules to active drug groups) (Days 0-20)
88994198|NCT00530491|Active Comparator|1|conventional perioperative management for lung surgery
88994199|NCT00530491|Experimental|2|fast track management for lung surgery
88994200|NCT00530530|Experimental|1|Dose 1
88994201|NCT00530530|Experimental|2|Dose 2
88994202|NCT00530530|Experimental|3|Dose 3
88994203|NCT00530530|Placebo Comparator|4|
88994204|NCT00530413|Experimental|1|Phenobarbital - dose based by weight range
88994205|NCT00530413|Placebo Comparator|2|Placebo group
88994206|NCT00531856|Experimental|1|5.97 mg/L of carbon monoxide in 30% oxygen
88994207|NCT00531856|Placebo Comparator|2|Oxygen 30% in Nitrogen
88994208|NCT04691479|Experimental|PIMAGroup|"Educational and training program using motivational interview technical.~Stratification labels: to determine the personalized intervention plan are obtained from two types of variables: personal and modulation variables. For psychological variables the Perceived Competence Evaluation Questionnaire validated in Adherence to CPAP in OSA (CEPCA) is used. Drowsiness is obtained through the administration of the Epworth Somnolence Test, and the apnoea-hypopnea index is taken from the patient's clinical history.~Segmentation: With the psychological and clinical variables, in this first visit, predictive information is obtained on how the patient's adherence will be: high adherence, moderate adherence or low adherence.~Taking this information into account, the care plan will start considering how the patient is and their situation with respect to adherence. Depending on their evolution, the care plan is adapted. For patients with low adherence, telemonitoring is used."
88994209|NCT04691479|Experimental|Control|The patients followed the standard of care, which consists of starting therapy in the hospital, where the nurse performed training in the use of CPAP equipment, mask adjustment, and safety and maintenance instructions. For follow-up, the patient was always referred to the Hospital, with a frequency established by the Spanish Society of Pulmonology and Thoracic Surgery (Day 30, Day 90 and Day 180). The follow-up procedure consisted of reviewing the CPAP hour meter and resolving any incidents that may have arisen, with the necessary corrective actions (change of mask, positive reinforcement, and explanation of specific aspects).
88994210|NCT00174369|Experimental|PD0325901|15 mg BID
88994211|NCT00145535|Experimental|1|Titanium sapphire laser treatment
88994212|NCT00145535|Active Comparator|2|Argon laser treatment
88994213|NCT02943109|Experimental|High tech, high touch|Patient receives the full version of MyChart Bedside. Patient receives training/intervention from technology navigator
88994214|NCT02943109|Experimental|Low tech, high touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives training/intervention from technology navigator
88994215|NCT02943109|Experimental|High tech, low touch|Patient receives the full version of MyChart Bedside. Patient receives online training, only
88994216|NCT02943109|Experimental|Low tech, low touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives online training, only
88994217|NCT02942914|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
88994218|NCT02942914|Placebo Comparator|Placebo|Placebo (sterile saline) administered SC.
88994219|NCT02942914|Active Comparator|Insulin Glargine (Lantus)|Insulin Glargine administered SC.
88994220|NCT00145613|Other|1|
88994221|NCT02943187|Experimental|Nutrition and Cognitive Training|The intervention includes a physician-directed diet, exercise, and nutritional supplementation regimen, combined with a 60-hour, clinician-delivered cognitive training program created by LearningRx.
88994222|NCT00531973|Experimental|A|Liposomal doxorubicin
88994223|NCT00531973|Active Comparator|B|epirubicin
88994224|NCT02942992|No Intervention|Control|Usual Care Group
88994225|NCT02942992|Other|Intervention|Intervention Group
88994226|NCT05319769||Zero fluoroscopy|"Zero fluoroscopy Patients undergoing AF ablation using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography.~Reconstruction of a bipolar map of the right atrium with a mapping catheter. Then, the interatrial septum is reconstructed and the oval fossa is defined. Transseptal puncture is performed using the steerable introducer (which can be viewed on the EAM) through which, a transseptal needle is introduced. The introducer is positioned at the fossa ovalis. The transseptal needle is advanced to perform the puncture of the septum. After accessing the left atrium, the mapping catheter is introduced iusing the introducer, with which all the structures of the left atrium are mapped. In addition, with intracardiac echocardiography, it is possible to identify important structures such as the pulmonary veins and the esophagus. The pulmonary veins are isolated by means of a catheter."
88994227|NCT05319769||Traditional approach|"Traditional approach Patients who have undergone atrial fibrillation ablation procedure using the traditional approach.~The procedure is based on 3D reconstruction using intracardiac ultrasound first and then electroanatomical mapping of the left atrium through a transseptal approach guided by integration of fluoroscopy and intracardiac ultrasound. The transseptal puncture is performed using a transseptal needle which is brought into place using a long introducer with a dilator. The fluoroscopic support is essential as the introducer is not viewable with 3D mapping systems. After accessing the left atrium, through the previously used introducer, a mapping catheter is taken to the left atrium for electro-anatomical reconstruction. Subsequently, the antral pulmonary veins are isolated by means of an ablator catheter with irrigated tip."
88994228|NCT05319418|Experimental|Hypertensive Patients Monitored Daily|Physicians utilize DailyDoctor remote monitoring platform to virtually monitor daily BP of patients. Physicians use their independent medical judgement to recommend any clinical follow up or adjustment in medications/prescriptions for any patients whose daily reporting of BP triggers an alert based on physician-driven alert thresholds.
88994229|NCT05319340|Other|anticoagulants arm|The study embraces patients who are advised to take the anticoagulant therapy (as per the European Society of Cardiology Guidelines). The study evaluates the compliance with the anticoagulant therapy, safety and effectiveness, mortality
88994230|NCT05319301|Experimental|Patients with hypopituitarism|A single dose of melatonin administration
88994231|NCT05319301|Active Comparator|Healthy controls|A single dose of melatonin administration
88994232|NCT00169065|Active Comparator|Clozapine|Clozapine or olanzapine in treatment resistant schizophrenia
88994233|NCT00169065|Active Comparator|olanzapine|clozapine or olanzapine in treatment resistant schizophrenia
88994234|NCT02943031|Experimental|IPTP Group|The IPTP Group will receive the Individualized Precision Therapy Programs. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
88994235|NCT05319223||Patient management group|patient blood management group
88994236|NCT05319223||Control|control
88994237|NCT02942875|Experimental|Mirror therapy group|MT group subjects will attend training sessions of bilateral upper limb exercise daily in the presence of the mirror.
88994238|NCT02942875|Active Comparator|Control therapy group|Control group subjects will undergo the same training sessions of bilateral upper limb exercise daily without mirror.
89657566|NCT05284669|Experimental|Experimental e-learning|The experimental interactive intervention is based on international guidelines for the management of LBP and includes multiple interactions with the participant in a virtual environment. Metaphors and concrete clinical situations are presented to translate the knowledge (i.e. the management of low back pain from a biopsychosocial point of view) to clinical practice. Interactions consists of videos, open and closed questions and audio records.
89657567|NCT05284669|Other|Traditional e-learning|The traditional intervention consists of a traditional online lecture based on international guidelines for the management of LBP without any interaction. The focus is more fundamental (theoretical) without metaphors or clinical cases.
89657568|NCT05284344||patients with newly diagnosed type 2 diabetes|Newly diagnosed, drug-naïve, Chinese patients with type 2 diabetes.
89657569|NCT05284344||Non-diabetic control subjects|
89657570|NCT05283889|Experimental|Group 1 (GRFA)|After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
89657571|NCT05283889|Active Comparator|Group 2 (Sham)|The same procedure will be employed as per Group 1 - However, the sham procedure will involve no electrical signal applied to the participant.
89657572|NCT05282004|Experimental|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
89657573|NCT05267808||Obstructive sleep apnea patients eligible for DISE|Patients with obstructive sleep apnea (AHI>=5) will be included in the study. Subjects should be eligible for drug-induced sleep endoscopy as the next step in their clinical path.
89657574|NCT05250895|Experimental|Diagnostic (18F-fluoromisonidazole, PET, DCE MRI)|Patients receive 18F-fluoromisonidazole IV and undergo PET and DCE MRI within 30 days before beginning Y90 SIRT. Patients undergo Y90 SIRT per standard of care.
89657575|NCT05248581||All Participants|Potential subjects for this registry must have Stage IV colorectal cancer with liver metastases and be candidates for liver transplantation based on multidisciplinary discussion by the Liver transplantation team. Patients must demonstrate favorable tumor biology and no evidence of extra hepatic disease.
89657576|NCT05231811|Experimental|experimental group|During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated.
89657577|NCT05231811|No Intervention|control group|no intervention will be made in the control group
89657578|NCT05230823|Experimental|Intervention|The intervention consists of a traditional 12-week outpatient CR program with added weekly behavioural weight loss classes.
89657579|NCT05227976|Active Comparator|Theory only|Once weekly for 10 weeks
89213469|NCT01006317|No Intervention|Control|Financial coverage of MCH care within the local reimbursement system (CMS).
89657580|NCT05227976|Active Comparator|Theory and physical training|Once weekly for 10 weeks
88994239|NCT00145769|Active Comparator|Short Course Radiotherapy|Short Course (SC) pre-operative radiotherapy, followed by surgery and adjuvant chemotherapy
88994240|NCT00145769|Active Comparator|Long Course Radiotherapy|Long Course (LC) radiotherapy delivered with concurrent chemotherapy, followed by surgery and adjuvant chemotherapy
88994241|NCT00145769|Active Comparator|Surgery|Patients will receive initial surgery followed by post-operative management according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Adjuvant therapy for rectal cancer.
88994242|NCT02942953||Diaphragmatic Pacer|Patient that have been proposed to diaphragmatic pacer placement at our institution.
88994243|NCT02942680|Experimental|Experimental|acetylsalicylic acid started for 24 hours before surgery and determination of platelet function
88994244|NCT02942680|Other|Control|acetylsalicylic acid stayed for 5 days before surgery and determination of platelet function
88994245|NCT02942719||Shanghai First Maternity and Infant Hospital|
88994246|NCT02942719||Dalian Maternity and Child Health Hospital|
88994247|NCT02942719||Beijing Obstetrics and Gynecology Hospital|
88994248|NCT02942719||Shijiazhuang Obstetrics and Gynecology Hospital|
88994249|NCT02942719||The Children and Women's Healthcare of Laiwu City|
88994250|NCT02942719||Suzhou Municipal Hospital|
88994251|NCT02942719||Wenling Women's and Children's Hospital|
88994252|NCT02942719||First Affiliated Hospital of Kunming Medical University|
88994253|NCT02942719||Changsha Hospital for Maternal and Child Health Care|
89213470|NCT01006317|Experimental|Clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
88994254|NCT02942719||Xinxiang Maternity and Child Health Hospital|
88994255|NCT02942719||Yanshi People's Hospital|
88994256|NCT02942719||The Maternal and Child Health Hospital of Guangxi|
88994257|NCT02942719||Northwest Women and Children's Hospital|
88994258|NCT02942719||Suining Central Hospital|
88994259|NCT02942719||Inner Mongolia Maternity and Child Health Hospital|
88994260|NCT02942719||Fujian Province Maternity and Child Health Hospital|
88994261|NCT02942719||Qinghai Red Cross Hospital|
88994262|NCT02942719||Xinjiang Maternity and Child Health Hospital|
88994263|NCT02942719||Jiangmen Maternity and Child Health Care Hospital|
88994264|NCT02942719||Gansu Provincial Maternity and Child-care Hospital|
88994265|NCT00529048||T2DM|T2DM patients (WHO-criteria)
88994266|NCT00529048||CTRL|Healthy control subjects matched individually to the cases.
88994267|NCT00529165|Experimental|A|with injection-meal-interval,cross over after 3 month, than without injection-meal-interval for 3 month
89657581|NCT05227976|Active Comparator|Theory and mindfulness/medical yoga|Once weekly for 10 weeks
89657582|NCT05226585|Active Comparator|In-person CBTi|CBTi of variable treatment length will be administered by trained study staff in-person.
89657583|NCT05226585|Active Comparator|Telehealth CBTi|CBTi of variable treatment length will be administered by trained study staff via HIPAA-compliant tele-video conference.
89657584|NCT05226585|Active Comparator|Internet CBTi|Self-paced CBTi of variable treatment length will be administered via Sleep Healthy Using The Internet (SHUTi).
89657585|NCT05226585|No Intervention|Waitlist Control|Treatment will be postponed by 12 weeks.
89657586|NCT05225038|Active Comparator|Control Arm (Standard of Care)|Participants will receive the current standard preoperative education and counseling. Participants will receive information regarding exercise and nutrition from a member of the surgical team. Participants will meet with a behavioral medicine specialist for additional education regarding factors affecting postoperative stress and relaxation techniques. Participants who are actively smoking will be counseled regarding smoking cessation and offered a referral to smoking cessation resources.
89657587|NCT05225038|Experimental|Intervention Arm (Prehabilitation)|"Participants in the intervention arm will receive all of the standard of care, as listed above, as well as individualized exercise and nutritional prehabilitation regimens.~During the data analysis, participants will be subdivided into treatment groups, upfront surgical resection versus neoadjuvant chemotherapy, in order to determine whether length of prehabilitation affected outcomes and distinguish any possible effect of chemotherapy toxicity."
89657588|NCT05221242|Experimental|Patients with PLV|All patients will receive ceramic partial laminate veneers as treatment. As this is a split mouth design, one side of the mouth will receive partial laminate veneers bonded with a conventional light-curing resin cement and the other side of the mouth with a pre-heated resin composite.
89657589|NCT05219409|Active Comparator|Treatment group|Sitagliptin
89657590|NCT05219409|Placebo Comparator|Control group|Placebo
89657591|NCT05217901|Experimental|14C-labeled ASP0367|Participants will receive a single oral dose of [14C]ASP0367 solution under fasting conditions on day 1.
89657592|NCT05211115|Experimental|Split thickness flap + Volume stable collagen matrix|A split thickness flap will be raised with a micro-blade, keeping a flap thickness >0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 6mm thick volume stable collagen matrix will be stabilised at the inner aspect of the flap.
89657593|NCT05211115|Active Comparator|Full thickness flap + Volume stable collagen matrix|A full thickness flap will be raised with a periosteal elevator. The healing abutment will be connected to the implant, and a 10mm wide by 6-8mm high volume stable collagen matrix will be stabilised at the inner aspect of the flap.
89657594|NCT05211115|Active Comparator|Split thickness flap + Autogenous connective tissue|A split thickness flap will be raised with a micro-blade, keeping a flap thickness >0,5mm. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
89657595|NCT05211115|Active Comparator|Full thickness flap + Autogenous connective tissue|A full thickness flap will be raised with a periosteal elevator. The healing abutment will be connected to the implant, and a 10mm wide, 6-8mm high, 1,5mm thick autogenous sub epithelial connective tissue graft will be stabilised at the inner aspect of the flap.
89657596|NCT05209399|Active Comparator|Hip injection with prior local anesthesia|
89657597|NCT05209399|Active Comparator|Hip injection without prior local anesthesia|
89657598|NCT05208008||With service dog|Veterans living with a certified service dog
89657599|NCT05208008||Without service dog|Veterans living without a certified service dog
89657600|NCT05206292|Other|Patient cohort|There is only one patient arm. It corresponds to the cohort of included patients, all of whom had psychotic disorders with no known organic etiology.
89657601|NCT05203861|Experimental|Positive Affect Treatment|15 sessions of psychotherapy designed to augment reward anticipation, reward attainment, and reward learning.
88994268|NCT00529165|Experimental|B|without injection-meal-interval,cross over after 3 month, than with injection-meal-interval for 3 month
88994269|NCT02276911|Active Comparator|Intravenous (IV) ibuprofen|800mg IV ibuprofen before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
88994270|NCT02276911|Placebo Comparator|Intravenous (IV) normal saline|800mg normal saline before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
88994271|NCT00145847|Active Comparator|Naltrexone|Naltrexone 50 mg per day, directly administered as 100 mg on Mondays, 100 mg on Wednesdays and 150 mg on Fridays
88994272|NCT00145847|Placebo Comparator|Lactose pill|
88994273|NCT00169182|Experimental|TPF|Docetaxel, Cisplatine, 5-FU
88994274|NCT00169182|Active Comparator|PF|Cisplatine, 5-FU
88994275|NCT02944825|Active Comparator|Antibiotic|Patients randomized to the intervention arm will be provided a single oral dose of prophylactic oral antibiotic at the time of cystoscopic stent removal
88994276|NCT02944825|Active Comparator|No Antibiotic|Patients randomized to the non-intervention arm will not undergo prophylaxis at the time of cystoscopic stent removal
89657602|NCT05203861|Active Comparator|Negative Affect Treatment|15 sessions of psychotherapy designed to decrease threat avoidance, threat appraisal and arousal.
88994277|NCT02942797||NRS 2002 score ≥ 3|
88994278|NCT02942797||NRS 2002 score < 3|
88994279|NCT02942758|Experimental|low-dose AZA / ATRA / Pioglitazone|low-dose azacitidine (75 mg/d), ATRA, pioglitazone
88994280|NCT02942758|Active Comparator|standard-dose AZA|standard-dose azacitidine (75mg/m²/d)
88994281|NCT00145886|Experimental|rhPTH|Subjects will be treated rhPTH for 12 months
88994282|NCT02942563|Experimental|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
88994283|NCT02942446|Experimental|Headgear|Investigative Headgear with CPAP mask
88994284|NCT05318950|No Intervention|Control|No intervention
88994285|NCT05318950|Experimental|E-learning|E-learning: 8 lessons about nutrition and lifestyle
89657603|NCT05197777|Active Comparator|Group 1 : conservator physiotherapy|Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
89657604|NCT05197777|Experimental|Group 2- tDCS associated to functional activities|The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated to physical task from functional activity of daily life. Functional task for the assessment of pain with high-tech tools for the implementation an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. The dummy will be set at the height of the hands in a constrained position for the arms, i.e. with elbows flexed at 60 degrees. Elbow angles will be adjusted in a static position with a manual goniometer. The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes. The elbow will be in a prolonged constraint position, undergoing repetitive movements, for 30 consecutive minutes. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat
89657605|NCT05197244|Experimental|Culinary Medicine Intervention|Participants will attend a 2-hour hands-on cooking class in additional to usual care.
89657606|NCT05197244|No Intervention|Control|Participants will receive usual care.
89657607|NCT05196932||COVID Card|Enrolled patients will receive antibody testing using both: 1) point-of-care, semi-quantitative SARS-CoV-2 antibodies test, 2) SARS-CoV-2 central laboratory antibodies test
89657608|NCT05189756|Experimental|Verum|Patients will receive 2 encapsulated capsules containing aprepitant 80mg to be ingested with a sip of water 2 hours before surgery and 24 hours after surgery. Surgery will follow our hospital enhanced recovery after surgery (ERAS) standard (general anaesthesia using volatile anaesthetics, intravenous dexamethasone 8mg and ondansetron 4mg for PONV prophylaxis).
89657609|NCT05189756|Placebo Comparator|Placebo|Patients will receive similar looking encapsulated capsules containing only placebo to be ingested with a sip of water 2 hours before surgery and 24 hours after surgery. Surgical and anaesthetic procedures are identical to the verum arm.
89657610|NCT05181267|Experimental|Intermittent fasting|Three weeks of alternate-day fasting.
89657611|NCT05181267|No Intervention|Western diet|Three weeks of normal Western diet (no restrictions).
89657612|NCT05181150|Experimental|Meal test|
89657613|NCT05181150|Experimental|GIP, Glucose-dependent insulinotropic polypeptide|
89657614|NCT05181150|Experimental|GLP-2, Glucagon-like-peptide-2|
89657615|NCT05181150|Experimental|GIP + GLP-2|
89657616|NCT05181150|Placebo Comparator|Placebo (saline)|
89657617|NCT05178420|Experimental|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
89657618|NCT05178420|No Intervention|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
89657619|NCT05174637|Experimental|FDA018-ADC A mg/kg|Subjects will receive FDA018-ADC A mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
89657620|NCT05174637|Experimental|FDA018-ADC B mg/kg|Subjects will receive FDA018-ADC B mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
89657621|NCT05174637|Experimental|FDA018-ADC C mg/kg|Subjects will receive FDA018-ADC C mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
89657622|NCT05174637|Experimental|FDA018-ADC D mg/kg|Subjects will receive FDA018-ADC D mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
88994286|NCT05318950|Experimental|Diet A|MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids)
88994287|NCT05318950|Experimental|Diet B|MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
88994288|NCT00145925|Placebo Comparator|Blood pressure|Perindopril indapamide vs placebo
88994289|NCT00145925|Other|Glucose control|Standard versus intensive glucose control
88994290|NCT00169221|Active Comparator|postop chemoradio with cisplatin|postoperative chemoradiotherapy with cisplatin
88994291|NCT00169221|Experimental|postop chemoradio (cisplatin)+gefitinib|postoperative chemoradiotherapy with cisplatin + gefitinib
88994292|NCT00529360|Experimental|Part A|Part A will be the dose escalation phase to determine the MTD and/or safe/tolerated dose of clofarabine.
88994293|NCT00529360|Experimental|Part B|Part B will accrue patients to further define the event free, disease free and overall survival at the MTD or safe/tolerated dose of clofarabine.
88994294|NCT00174642|Experimental|1|Insulin Glargine + 3 bolus of Insulin Glulisine + Metformin
88994295|NCT00174642|Experimental|2|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin
88994296|NCT00174642|Experimental|3|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin + Insulin secretagogue
88994297|NCT05318014|Experimental|Intervention group|Regular nutrition education and supply one serving per day of 6% low protein formula.
88994298|NCT05318014|Placebo Comparator|Regular nutrition education|Regular nutrition education
88994299|NCT02942056|Experimental|Study Drug|Randomized to cinnamon cassia 750 mg TID for 6 months. Assess HbA1c and CV risk profile
88994300|NCT02942056|Placebo Comparator|Placebo|Randomized to placebo matching tablet TID for 6 months. Assess HbA1c and CV risk profile
88994301|NCT00169260|Experimental|1|Intervention
88994302|NCT00169260|Placebo Comparator|2|Control
89046902|NCT04658745|Sham Comparator|iTBS to the ipsilesional primary motor cortex plus sham mirror therapy|"iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. After the iTBS therapy, participants will practice the movements with the non-affected hand and try moving the affected arm at the same time, but with a covered mirror (e.g., sham mirror therapy).~In the sham mirror therapy condition, the mirror is covered by a cloth and the participant is instructed to move both arms while looking at a cross mark on the covered mirror and imaging the analogous movements of the affected arm. The movement practice will involve 5 table-top tasks (same as mirror therapy) and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes."
89046903|NCT00533741|Experimental|1c (10 mcg)|4 subjects randomized in a 1:3 fashion to receive a two dose regimen of placebo or vaccine with 10 mcg of antigen and no adjuvant.
89046904|NCT00533741|Experimental|2 (dose comparison stage)|54 subjects (9 per vaccine group) randomized 1:1:1:1:1:1 to receive vaccines containing, 2.5, 5.0, or 10.0 mcg of antigen without adjuvant, or 2.5 or 5.0 mcg of antigen with Alum, or placebo.
89046905|NCT00533741|Experimental|1a (2.5 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 2.5 mcg of antigen and no adjuvant, or 2.5 mcg of antigen and Alum adjuvant.
89046906|NCT00533741|Experimental|1b (5.0 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 5.0 mcg of antigen and no adjuvant, or 5.0 mcg of antigen and Alum adjuvant.
89046907|NCT04658511|Experimental|Participants|Patients diagnosed with cubital tunnel syndrome who are being scheduled for a primary endoscopic cubital tunnel release by the principle investigator will be recruited
89046908|NCT04668027|Experimental|chronic airway disease group|Before the test, patients with FEV1/FVC≥0.7 are divided into the provocation test group, patients with FEV1/FVC <0.7 are divided into the dilation test group.
89046909|NCT00533819|Experimental|1|
89046910|NCT00533819|No Intervention|2|would have routine physical activity
89046911|NCT04658589|Experimental|Laparoscopic distal gastrectomy|Laparoscopic distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
89046912|NCT04658589|Active Comparator|Open distal gastrectomy|Open distal gastrectomy after neoadjuvant chemotherapy for the treatment of locally advanced gastric cancer patients
89046913|NCT04545671||Patients already implanted with study lens|No intervention as patients are already implanted.
89046914|NCT04658394|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving RT or to a control group receiving treatment as usual. Participants in the intervention group will participate in two RT sessions per week for 13 weeks besides their treatment as usual. The sessions will be based on the Book of the Past and the Present and they will follow the same protocol in every participant institution.
89046915|NCT04658394|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
89046916|NCT04667988|Experimental|RA patients|newly diagnosed RA will started therapy with conventional synthetic DMARDs (including methotrexate)
89046917|NCT04667988|Experimental|control|JAK2 mutation assesment by PCR
89046918|NCT04536116|Experimental|MRI simulation|MRI simulation with a Virtual Reality headset
89046919|NCT04536116|No Intervention|Standard medical care|Standard medical care
89046920|NCT04668183||Pudendal Nerve Block|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
89046921|NCT04668183||Dorsal Penile Nerve Block|Ultrasound (US) guided dorsal penile nerve block with in plane technique was done. Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
89657623|NCT05174637|Experimental|FDA018-ADC E mg/kg|Subjects will receive FDA018-ADC E mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
89657624|NCT05174637|Experimental|FDA018-ADC F mg/kg|Subjects will receive FDA018-ADC F mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle (Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
89657625|NCT05174637|Experimental|FDA018-ADC G mg/kg|Subjects will receive FDA018-ADC G mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle (Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
89657626|NCT05172609|Experimental|Exposure Based Implementation Strategy (EBIS)|EBIS is informed by the latest science in exposure theory, borrowing heavily from brief exposure-based treatments that can be delivered in a single session. We anticipate that EBIS will occur in four phases that map on to standard exposure therapy practice for patients with anxiety disorders: psychoeducation, assessment, practice, and relapse prevention; however, the final version will depend on the outcomes of the preparatory phases of this study. Clinicians assigned to the EBIS arm will also receive all elements of IAU.
89657627|NCT05172609|Active Comparator|Implementation as Usual (IAU)|Gold-standard IAU for SSAIs typically comprises pre-implementation preparation, didactic training, knowledge tests, experiential role plays, ongoing expert consultation, and providing certification status to clinicians who attain established benchmarks. Pre-implementation preparation will include provision of materials. Didactic training will occur in two parts: (1) suicide screening and assessment, and (2) Safety Planning Intervention (SPI) use. Part one will consist of materials we previously developed based on community clinician feedback. Part two will follow established SPI guidelines, including didactic training about SPI rationale and evidence base and experiential practice. IAU also will include supports for electronic health record integration (e.g., previously developed templates). After training, clinicians will receive 8 weeks of expert consultation to discuss implementation barriers and receive more role play practice.
89657628|NCT05172544|Experimental|Low Dose Sentinel|3 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
89657629|NCT05172544|Experimental|Low Dose Expanded|7 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-002 YFV and 2 subject will receive placebo IM on Days 1 and 29.
89657630|NCT05172544|Experimental|High Dose Sentinel|3 subjects will receive 5 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
89657631|NCT05172544|Experimental|High Dose Expanded|7 subjects will receive 5 mcg intramuscularly (IM) of HydroVax-002 YFV and 1 subject will receive placebo IM on Days 1 and 29.
89657632|NCT05167097|Experimental|Deliberative Mindset|Participants receive a paper/pencil questionnaire that evokes a deliberative mindset. The questionnaire asks participants to deliberate upon the positive and negative short- and long-term consequences of acting vs. not acting toward a goal. This procedure is based on previous research on the mindset theory of action phases.
89657633|NCT05167097|Experimental|Implemental Mindset|Participants receive a paper/pencil questionnaire that evokes an implemental mindset. The questionnaire asks participants to plan the when, where, and how of taking five steps toward a goal. This procedure is based on previous research on the mindset theory of action phases.
89657634|NCT05167097|Experimental|Decisional Balance BI|Participants receive the ASSIST-linked Brief Intervention via an interview with a trained interventionist. The decisional balance element describes Steps 6-9 of the ten steps of the manual. They include probing for the positive and negative sides of alcohol consumption, weighing them against each other, focusing on the negative sides, and asking participants how concerned they are regarding the negative sides.
89657635|NCT05167097|Experimental|No Decisional Balance BI|Participants receive the ASSIST-linked Brief Intervention via an interview with a trained interventionist. This is the short-form of the ASSIST-linked Brief Intervention. It drops the decisional balance element that is described above.
89657636|NCT05167097|Other|Control Group|Participants perform a filler task in the control group, crossing out a specific letter in paragraphs of nonsense text.
89657637|NCT05166486|Experimental|Calisthenic exercise|The patients in the calisthenic exercise group will be given one-to-one hands-on calisthenic exercises by the research physiotherapist. They will be asked to do these exercises 3 times a week for 8 weeks. Patients will be followed up by asking whether they do their exercises or not. They will be asked to do the exercises twice a month for 8 weeks under the control of a physiotherapist. In this way, it will be ensured that the exercises are done correctly and that the patients do it completely.
89657638|NCT05166486|No Intervention|Control|Control
89657639|NCT05151159||FIGO group 1A1|20 subjects with tumor invasion depth up to 1 mm
89657640|NCT05151159||FIGO group 1A2|20 subjects with an invasion depth of 1 - 3 mm
89657641|NCT05151159||FIGO group 1B1|20 subjects with invasion depth up to 2 cm
89657642|NCT05151159||FIGO group 1B2|20 subjects with tumor invasion depth> 2 cm 20 subjects with tumor invasion depth> 2 cm
89657643|NCT05144529|Active Comparator|Ipilimumab/nivolumab|Subjects receive ipilimumab 1 mg/kg IV every 6 weeks and nivolumab 240 mg IV every 2 weeks.
89657644|NCT05144529|Experimental|ipilimumab/nivolumab/evolucumab|Subjects receive ipilimumab 1 mg/kg IV every 6 weeks and nivolumab 240 mg IV every 2 weeks plus evolocumab 140 mg SC every 2 weeks
89657645|NCT05140967|Experimental|High Intensity Interval Training (A)|Exercise training with intermittent bouts of high intensity
89657646|NCT05140967|Experimental|Moderate Intensity Continous Training (B)|Exercise training with constant workload
89657647|NCT05132920|Experimental|Experimental arm|3 x 8 mg (2 ml) dexamethasone daily for days 1-7 and 1 x 8 mg (2 ml) dexamethasone daily for days 8-21 in addition to aneurysm treatment and best medical intensive care of SAH patients
89657648|NCT05132920|Placebo Comparator|Control arm|3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21 in addition to aneurysm treatment and best medical intensive care of SAH patients
89046922|NCT04521998|Experimental|electroacupuncture|The needles remained in situ for 30 minutes, during which time the acupuncturist returned to stimulate the needles once to re-elicit the de qi sensation. Participants have 2 sessions per week, with total 5 weeks and 10 sessions. The body points included LI4, LI11, SP6 and ST36. The individual specific points protocol are as follows: GB20, TE5, SP10, GB34, LV3, ba xie, ba fen, Ashi). The acupuncture protocol consists of the body points and some of the individual specific points depending on subjects' condition.
89046923|NCT04521998|Experimental|Transcutaneous electrical nerve stimulation|The protocol consisted of first swabbing all points with alcohol, then pads of TENS were sticked on the proper location of acupoints included LI4, LI11, SP6 and ST36. Electrical output of one channel was administered to the surface of body via a combination of two pads. LI4 and LI11, ST36 and SP6 are combination of acupoints, respectively. Participants had 2 sessions per week, with total 5 weeks and 10 sessions. Each session lasted 30 minutes.
89046924|NCT04658706|Sham Comparator|Control|a physical activity prescription to be performed autonomously
89046925|NCT04658706|Experimental|Prehabilitation|They will receive a supervised exercise programat least 2 weeks before starting the conventional chemoradiotherapy treatment and concomitant
89046926|NCT04658706|Experimental|Rehabilitation|They will receive a supervised exercise programat 12 weeks after the first radiotherapy session, once standard treatment has finished
89657649|NCT05130931|Experimental|Multimodal Conservative Treatment|
89657650|NCT05130931|No Intervention|Standard healthcare.|
89657651|NCT05129150||assessment of cognitive functions|Assessment of cognitive disorders with an ultrasound examination performed in routine care during a day hospital.
89657652|NCT05129085|Experimental|Group ESI|Patients in group ESI will undergo epidural steroid injection.
89657653|NCT05129085|Active Comparator|Group EPRP|Patients in group EPRP will undergo epidural PRP injection.
89657654|NCT05119283|Experimental|Phtalox|Patients will undergo scaling and coronal-radicular smoothing and rinses with PHTALOX mouthwashes.
89657655|NCT05115032|Experimental|Vestibular retraining with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
89657656|NCT05115032|Active Comparator|At-home rehabilitation exercises|Daily rehabilitation exercises involving nodding and shaking of the head
89657657|NCT05109988|Experimental|Intervention|The intervention consists of four weekly 20-30 minutes telephone-administered counselling sessions on breastfeeding, delivered individually in the first month postpartum for mothers and fathers.
89657658|NCT05109988|No Intervention|Control|Standard postpartum care
89657659|NCT05107817|Experimental|Aquatic Exercise group|Participants will engage in a single session of training consisting of 120 repetitions of a ball throwing and catching task in water.
89657660|NCT05107817|Active Comparator|Land Exercise group|Participants will engage in a single session of training consisting of 120 repetitions of a ball throwing and catching task on dry land.
89657661|NCT05105867|Experimental|Anti-CD19 Universal CAR-T Cells injection|Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion .
89657662|NCT05099471|Experimental|Venetoclax / Rituximab|"Cycle 1 (28-days cycle) Stepwise dose escalation of Venetoclax in all patients with a target dose of 800 mg/d QD PO.~Day 1-7: Venetoclax 200 mg/d QD PO Day 8-14: Venetoclax 400 mg/d QD PO Day 15-28: Venetoclax 800 mg/d QD PO~Cycle 2-12:~Day 1: Rituximab 375 mg/m2 IV Day 1-28: Venetoclax 800 mg/d QD PO"
89657663|NCT05099471|Active Comparator|Dexamethasone / Rituximab / Cyclophosphamide|"Cycle 1-6:~Day 1: Dexamethasone 20 mg PO Day 1: Rituximab 375 mg/m2 IV Day 1-5: Cyclophosphamide 100 mg/m2 BID PO"
89657664|NCT05095090||Hospitalised Patients|Participants admitted to hospital with an acute respiratory condition including exacerbation of an underlying physician diagnosed chronic lung disease.
89657665|NCT05095090||Matched Controls|The study will include matched controls (non-hospitalised patients with stable chronic respiratory conditions or healthy volunteers) to compare the exploratory endpoints. The number of the matched controls will not exceed 25% of the main study recruitment.
89657666|NCT05094908|Active Comparator|Regime 1 (30 days)|Regimen 1: arnica tincture applied 3 times a day for 30 days (group 1). For both regimens, the participant applies the tincture in the morning, afternoon and evening, that is, three times a day.
89657667|NCT05094908|Active Comparator|Regime 2 (45 days)|Regimen 2 arnica tincture applied 3 times a day for 45 days (group 2). For both regimens, the participant applies the tincture in the morning, afternoon and evening, that is, three times a day.
89657668|NCT05092932||Normal Control Data|"Normal adults with no history of neuromusculoskeletal disease will be recruited for this study. Participants will be independent walkers (no walking aid needed) and will not have needed a walking aid for injury over the past 5 years.~Participants will walk 200 m under 4 randomized conditions: non-weightbearing ambulation using crutches, a walker, a wheeled knee walker, and unaided walking. An in-shoe sensor will measure stance limb plantar force, a stopwatch will time each walk, perceived exertion will be reported using the BORG CR-10 scale, and device preference will be identified."
89657669|NCT05088746||Non-surgical periodontal therapy|
89657670|NCT05087693|Experimental|Exercising in ozone following salbutamol inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling 200ug of salbutamol.
89657671|NCT05087693|Active Comparator|Exercising in filtered air following salbutamol inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered air after inhaling 200ug of salbutamol.
89657672|NCT05087693|Placebo Comparator|Exercising in ozone following placebo inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling placebo medication.
89657673|NCT05087693|Placebo Comparator|Exercising in filtered air following placebo inhalation|Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered after inhaling placebo medication.
89046927|NCT04520555|Experimental|Laryngeal mask airway group|Flexible laryngeal mask airway is inserted for general anesthesia
89046928|NCT04520555|Active Comparator|intubation group|Endotracheal intubation was performed for general anesthesia
89046929|NCT04658355|Active Comparator|Povidone-Iodine|Povidone-iodine to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
89046930|NCT04658355|Experimental|Chlorhexidine Gluconate|Chlorhexidine gluconate to be used as the cleansing solution in this arm of patients for surgical vaginal preparation.
89046931|NCT04498442|No Intervention|Yoga Practitioners|Yoga practitioners arm is the observational arm of the study, wherein participants who follow Isha school of yoga and have completed either of the three courses : Inner Engineering Online (IEO), Inner Engineering Completion (Shambhavi Mahamudra kriya) or Shakthi Chalana Kriya can be included in this group. The participant are advised to continue with their routine yoga practice with no change in the duration of practice or frequency of their practices. Participants of this group have expertise in yoga practice and have been practicing yoga for more than 6 weeks before study enrollment.
89046932|NCT04498442|Active Comparator|Control Yoga|"Control Yoga is the active comparator arm of the study. Participants who are randomly allocated to this group, practice Simha Kriya, a deep breathing exercise taught by the Isha School of yoga."
89046933|NCT04498442|Placebo Comparator|Control Idle|Control Idle is the active comparator arm of the study. Participants who are randomly allocated to this group, are advised to either read a book for 15 minutes each day or sit idle for 15 minutes. This is the true control group for the study
89046934|NCT04667598|Experimental|Experimental group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given modified Wenxin Tang granules, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
89046935|NCT04667598|Placebo Comparator|Control group|On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.
89657674|NCT05081583|Experimental|Study Arm 1: Baseline|Twenty type 2 diabetic subjects (10 men, 10 women) will be administered a single dose of midazolam (0.5 mg) intravenously via a peripherally inserted catheter in conjunction with their daily oral administration of metformin. Plasma and urine will be collected from 0-24 hours post-midazolam administration. Participants will take their metformin as prescribed for the entirety of the study with no interruption in pharmacotherapy.
89657675|NCT05081583|Experimental|Study Arm 2: Acute Goldenseal Exposure|For Arm 2, the same 20 subjects will be administered a single dose of goldenseal (3.3 g) orally 30 minutes prior to administration of midazolam (as described in Arm 1). Plasma and urine will be collected in a manner identical to that in Arm 1. With respect to midazolam administration, a washout period of 7 days will separate Arm 2 from Arm 1.
89657676|NCT05081583|Experimental|Study Arm 3: Chronic Goldenseal Exposure|For Arm 3, the same 20 subjects will be administered goldenseal (1.1 g) orally three times daily for 27 days. On the 28th day, participants will be administered the goldenseal three times daily, as well as the single dose of midazolam (as described in Arm 1). Plasma and urine will be collected in a manner identical to that in Arm 1. A designated washout period for midazolam will not be necessary to separate Arm 3 from Arm 2 since there will be 27 days of goldenseal administration prior to the midazolam administration.
89657677|NCT05081284|No Intervention|Control group|Immediate implant insertion in fresh-extraction site, will be performed. Peri-implant bone defect will be grafted with a deproteinized bovine bone mineral with 10% collagen and covered with a collagen matrix. After the surgical procedures, each implant will receive a healing abutment until prosthetic restorative procedures.
89657678|NCT05081284|Experimental|Test Group|Immediate implant insertion in fresh-extraction site, will be performed. Peri-implant bone defect will be grafted with a deproteinized bovine bone mineral with 10% collagen and covered with a collagen matrix, and then a volume-stable collagen matrix will be buccally inserted with a split-thickness flap preparation. Subsequently, the collagen matrix graft will be stabilized with a horizontal mattress suture to the buccal flap. After the surgical procedures, each implant will receive healing abutment connection until the prosthetic restorative procedures
89657679|NCT05077241|Experimental|Experimental group - inspiratory muscle training group with load|Experimental group: Inspiratory muscle training with POWERbreathe® (POWERbreathe®, HaB Ltd, Southam, UK) with 30% of Pimax. with weekly load increment of 10% of the Pimax value. initial. The sessions will consist of 30 repetitions, twice a day, one in the morning and one in the afternoon, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds in each maneuver, and will have the possibility to rest every 3 repetitions of the TMI, for 30 seconds, to avoid muscle fatigue or any other complication.
89657680|NCT05077241|Placebo Comparator|Control group - inspiratory muscle training group without load|Subjects will use a IMT POWERbreathe® (POWERbreathe®, HaB Ltd, Southam, UK) device without any load and will receive the same guidelines as experimental group (The sessions will consist of 30 repetitions, twice a day, one in the morning and one in the afternoon, 7 consecutive days a week, for 6 weeks. Individuals will be instructed to perform a rapid contraction of the inspiratory muscles and sustain it for 2 seconds in each maneuver, and will have the possibility to rest every 3 repetitions of the TMI, for 30 seconds, to avoid muscle fatigue or any other complication). At the end of the research, the control group will have the right to experimental treatment with the IMT protocol, if this is effective.
89657681|NCT05071105|Experimental|40Gy/5fx|The starting dose level will be 8Gy x 5 fractions, i.e., 40 Gy/5 nonconsecutive once-daily fractions.
89657682|NCT05071105|Experimental|42.5Gy/5fx|The intermediate dose level will be 8.5Gy x 5 fractions, i.e. 42.5Gy/5 nonconsecutive once-daily fractions.
89046936|NCT04667676|Experimental|TENS Therapy Group|patients received acupoint TENS
89046937|NCT04667676|Sham Comparator|Control group|patients received shame acupoint TENS
89046938|NCT04686539|Experimental|Recipients of CBD oil|Patients receiving Cannabidiol oil drops, administered sublingual, 3 times a day, while hospitalized. Dosing and administration frequency would be assessed bi-daily by the medical staff.
89046939|NCT04686539|Placebo Comparator|Recipients of Placebo|Patients receiving placebo oil, administered sublingual, 3 times a day, while hospitalized.
89046940|NCT00557544|Experimental|1|metoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
89046941|NCT00557544|Active Comparator|2|metoclopramide 0,15 mg/Kg + placebo per os
89046942|NCT00557544|Active Comparator|3|ketoprofen 1 mg/Kg and placebo in single dose
89046943|NCT04667871||Eyes for cataract surgery|Eyes for cataract surgery
89046944|NCT04667871||Eyes without cataract surgery|Eyes without cataract surgery
89046945|NCT04686578||Fibromyalgia group|Diagnosed as Fibromyalgia according to American College of Rheumatology Fibromyalgia 2018 classification criteria over 1 year, and disease activity was stabil with the same drug at least 3 months.
89046946|NCT04686578||Control Group|The participants who have no physicological or severe musculoskeletal, rheumatologic diseases.
89046947|NCT04667832||abnormal ABI|those patients with ankle brachial index ( ABI) less than 0.9
89046948|NCT04667832||normal ABI|Those patients with ankle brachial index more than 0.9
89046949|NCT04667910|Experimental|601 1.25mg|
89046950|NCT04667910|Experimental|Ranibizuman 0.5 mg|
89046951|NCT04404608||Asymptomatic or mild symptoms patients patients|Patients with no or mild symptoms and need no respiratory support.
89046952|NCT04404608||Severe symptoms patients|Patients who need admission to ICU because he needs oxygen by nasal canula and needs drugs whether azthromycin or remdesivir according to treatment protocol.
89046953|NCT04404608||Critically ill patients|Patients who need artificial ventilation because of many causes and may need plasma from convalescent patients
89657683|NCT05071105|Experimental|45Gy/5fx|The higher dose level will be 9Gy x 5 fractions, i.e. 45Gy/5 nonconsecutive once-daily fractions
89657684|NCT05070754|Experimental|Cold Atmospheric Plasma (CAP)|We are proposing a clinical trial of a floating electrode-dielectric barrier device (FE-DBD), a Cold Atmospheric Plasma (CAP) device for the treatment of Verrucae Vulgaris and Molluscum Contagiosum. While novel to the medical field, and especially to dermatology, there are already a number of publications regarding its use on human skin in adults and children. CAP devices utilize noble gases (such as helium) to deliver plasma state matter to the skin. As its name implies, the generated plasma stream is of near skin temperature and it exists on normal atmospheric pressure. During the generation of the plasma there is no electric contact with the patient. The treatment does not increase skin surface temperature and the used helium gas, the same as used for balloons, being a noble gas does not cause a chemical reaction with the skin. The flow of the gas is slow, thus there is no mechanical effect on the skin.
89657685|NCT05070754|Active Comparator|Cryotherapy|Current standard of care (SOC) for treating Verruca Vulgaris in Children is cryotherapy. Patients randomized to this arm of the study will receive SOC treatment for their identified condition.
89657686|NCT05070754|Active Comparator|Cantharidin|SOC for treatment of Molluscum Contagiosum is cantharidin. Patients randomized to this arm of the study will receive SOC treatment for their identified condition.
89657687|NCT05070143|Experimental|Brief education|"Participants will be randomly allocated to the Brief Education condition or one of the five treatment conditions (see below).~In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time."
89657688|NCT05070143|Experimental|Treatment condition|All participants will receive the Brief Education intervention described above. Then, participants will be randomly allocated to one of the following conditions for habit formation.
89657689|NCT05065684||rhBMP-2 and rhBMP-7|patients who have been treated with rhBMP-2 or rhBMP-7 for long bone non-union or acute fractures
89657690|NCT05065684||No-BMP|patients who have been treated with standart care, i.e. non-union resection and autologous bone graft
89657691|NCT05061511||Healthy gingival tissue|healthy patients with absence of gingivitis (full-mouth bleeding score <10%), no history of periodontal disease, having ≥20 teeth, and ≤1 tooth with interdental clinical attachment loss.
89657692|NCT05061511||Periodontitis patients|patients with stage III or IV periodontitis, which means that these patients would have deep periodontal lesions that extend at least to the mid portion of the roots and whose management is complicated by the presence of intrabony defects, furcation involvement, history of periodontal tooth loss and localized ridge defects.
89657693|NCT05061511||Peri-implantitis patients|patients affected by peri-implantitis, defined as radiographic evidence of bone loss ≥3 mm and probing pocket depth ≥6 mm around implants in conjunction with bleeding on probing; or defined as bleeding and/or suppuration on probing, increased probing pocket depth from a previous examination and loss of peri-implant bone.
89657694|NCT05052099|Experimental|mFOLFOX6 combined with Atezolizumab and Bevacizumab|"Patients will receive mFOLFOX6 combined with Atezolizumab 840 mg and Bevacizumab 10 mg/kg in 14-day cycles.~Treatment will be continued until disease progression, unacceptable toxicity or voluntary withdrawal."
89657695|NCT05040763|Experimental|COVID-19 Swab Collection|All participants will receive standard of care COVID-19 testing in addition to buccal swab COVID-19 testing
89657696|NCT05040321|Experimental|MIB-626|Subjects will either take MIB-626 or placebo tablet twice a day for 90 days. For those who receive MIB-626, we plan on giving subjects 1000mg of the drug, twice a day for 90 days. MIB-626 will be in two 500mg tablets.
89657697|NCT05040321|Placebo Comparator|Placebo Tablet|Subjects will be randomized to receive either the placebo or MIB-626 tablets twice a day orally.
89657698|NCT05037487|Placebo Comparator|Placebo|Smoked placebo cannabis
89657699|NCT05037487|Experimental|20 mg CBD|Smoked cannabis with CBD
89657700|NCT05037487|Experimental|20 mg CBD + 20 mg THC|Smoked cannabis with CBD and THC
89657701|NCT05037487|Experimental|20 mg THC|Smoked cannabis with THC
89657702|NCT05031650|Active Comparator|openCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with a T-piece resuscitator with 8 cm H2O pressure and 0.30 fiO2. The heart rate (HR) and preductal saturation (SpO2) will be evaluated every 30 seconds. Individually, the following steps will be done according to the situation:~If the HR > 120 / min and SpO2 not measured yet or be in the target range: The pressure will be continue as 8 cmH2O.~If the HR between 100-120 but SpO2 below the target range or not measured yet : First the pressure will be increased to 10 cm H2O; than fiO2 will be increased gradually if the patient will not respond to 10 cmH2O pressure. Pressure will be reduced to 8 cmH2O if the HR remains> 120 / min and oxygen requirement <0.30 for more than 60 seconds."
89657703|NCT05031650|Active Comparator|standardCPAP|"Immediately after birth, early nCPAP will be started with a nasal mask with T-piece resuscitator at 6 cmH2O pressure and 0.30 fiO2. HR and preductal saturation will be evaluated every 30 seconds. The following steps will be performed according to the situation:~If the HR > 120 / min and SpO2 be in the target range or not measurable yet: The pressure will be continue as 6 cmH2O.~If the HR between 100-120 but SpO2 below the target range or not measured yet : The pressure will increased up to 8 cm H2O. FiO2 will be increased gradually if the patient will not respond to 8 cmH2O pressure. Pressure will be reduced to 6 cmH2O if the HR remains> 120 / min and oxygen requirement <0.30 for more than 60 seconds."
89657704|NCT05030922|Experimental|Diet intervention|Follow up of both mother and offspring 20 years after allocation to an antiatherogenic diet during pregnancy.
89657705|NCT05030922|No Intervention|Control|Follow up of both mother and offspring 20 years after allocation to control group during pregnancy.
89657706|NCT05024903|Active Comparator|Control Group: (PWG 1.0)|Those randomized to PWG 1.0 would have already completed their serious illness medical planning. Further involvement in the trial will be solely for the purposes of the outcome data collection
89657707|NCT05024903|Active Comparator|Intervention group: PWG 2.0|Serious illness medical planning plus the novel e-health platform designed to help people more broadly think and plan ahead
89657708|NCT05022537|Experimental|Treatment (retrograde nephrostomy)|
89657709|NCT05022537|Active Comparator|Control Group ( antegrade nephrostomy)|
89657710|NCT05012826|Experimental|Osteopathic Manipulative Treatment (OMT)+ Physiotherapy (PT) Group|Participants in this group will receive OMT in addition to the same interventions of PT group for the same 2- month period. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
89657711|NCT05012826|Active Comparator|Physiotherapy Group (PT)|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 2 months. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council. the treatment provided will be registered on each participant's clinical notes and a summary of main interventions will be reported.
89657712|NCT05007743|Active Comparator|Stimulation of inner tragus|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
89657713|NCT05007743|Sham Comparator|Stimulation of ear lobe|Comparing autonomic hemodynamic functions and immune responses pre- and post-stimulation of the vagus nerve
89657714|NCT05004649|Experimental|Healthy participants|"Participants will be excluded prior to the experiment if their best-corrected visual acuity is worse than 20/40 in either eye or if they make any errors on the Ishihara plate test.~For enrolled participants, their threshold for horizontal position discrimination will be calculated based on their performance on the experimental task during their first session. Participants will be excluded after the conclusion of their first session if their horizontal position discrimination threshold in the control condition is higher than a maximum value of 0.6 degrees of visual angle, and participants excluded at this point will not participate in any further experimental sessions."
89657715|NCT05001074|Experimental|de novo cohort, extended release tacrolimus|de novo cohort, extended release tacrolimus
89657716|NCT05001074|Active Comparator|de novo cohort, immediate release tacrolimus|de novo cohort, immediate release tacrolimus
89657717|NCT05001074|Experimental|conversion cohort, extended release tacrolimus|conversion cohort, extended release tacrolimus
89657718|NCT05001074|Active Comparator|conversion cohort, immediate release tacrolimus|conversion cohort, immediate release tacrolimus
89657719|NCT04998942|Experimental|Experimental|
89657720|NCT04998942|Placebo Comparator|Placebo comparator|
89657721|NCT04986267||ACL Rupture|Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
89657722|NCT04985890|Experimental|UB-421 monotherapy|Subjects will receive 10 mg/kg UB-421 weekly infusion for 8 weeks.
89657723|NCT04985890|Experimental|UB-421 + chidamide combination therapy|Subjects will receive 10 mg/kg UB-421 weekly infusion and 10 mg chidamide twice a week administration for 8weeks.
89657724|NCT04983134|No Intervention|Standard Intervention(SI)|the HealthStreet Standard Intervention to include a CHW referral to an accessible and acceptable lung cancer screening site to include a financial counselor (if needed), tobacco cessation and quit resources (if still smoking) and, additionally, will watch the Genentech lung cancer screening video with the CHW;
89657725|NCT04983134|Experimental|Enhanced CHW Intervention|After 1:1 randomization, 30 women will additionally receive a 6-hour four week Enhanced CHW Intervention (E-CHW-I) modelled on successful peer-partnered interventions and informed by Stages of Change theory, which will add to the SI, calls and texts (if appropriate) to help problem solve and encourage screening receipt and transportation to the screening (if needed);
89657726|NCT04982757|Experimental|Depression - DMPFC target to (for non-responders) LPFC target|Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the DMPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
89657727|NCT04982757|Active Comparator|Depression - LPFC target to (for non-responders) DMPFC target|Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
89657728|NCT04982757|Experimental|OCD - DMPFC target to (for non-responders) LPFC target|Participants with OCD will receive a 5-day course of rTMS delivered to the DMPFC.Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
89657729|NCT04982757|Active Comparator|OCD - LPFC target to (for non-responders) DMPFC target|Participants with OCD will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
89657730|NCT04977037|Experimental|Active tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered at 2mA for 20 minutes
89657731|NCT04977037|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered at 2mA for 20 minutes
89657732|NCT04964388|Experimental|GLP-1 cohort|Participants on GLP-1 receptor agonists
89657733|NCT04964388|No Intervention|Non GLP-1 cohort|Participants not on GLP-1 receptor agonists
89657734|NCT04960592||SCS Responders|Patients who receive Spinal Cord Stimulation treatment and experience greater than 50% reduction in pain score following treatment.
89657735|NCT04960592||SCS Non Responders|Patients who receive Spinal Cord Stimulation treatment and do not experience greater than 50% reduction in pain score following treatment.
89657736|NCT04955717|Experimental|Testing and treatment|Participants will receive CT and NG testing and treatment (if necessary) at their first antenatal care visit and a visit during their third trimester. Women will also receive support for partner notification. All women will receive postnatal testing and treatment. Those who test positive at the postnatal visit will be offered infant testing.
89657737|NCT04955717|No Intervention|Standard of care|Participants will receive the standard of care for STI management, which is treatment based on signs and symptoms. Women will also receive support for partner notification. All women will receive postnatal testing and treatment. Those who test positive at the postnatal visit will be offered infant testing.
89657738|NCT04948606||Diroximel Fumarate (DRF)|Participants with a confirmed diagnosis of MS who are newly prescribed DRF in routine clinical practice and who satisfy the approved therapeutic indication for DRF will be enrolled.
89657739|NCT04946461||group 1; lisdex - dex|subjects are assigned to group 1 based on the type of medication prescribed by the practitioner. Subjects which started with lisdexamphetamine are assigned to group 1.
89657740|NCT04946461||group 2; dex - lisdex|subjects are assigned to group 2 based on the type of medication prescribed by the practitioner. Subjects which started with dexamphetamine are assigned to group 1.
89657741|NCT04925232|Experimental|One group|All participants will undergo 2 weeks (5 times each week) of repetitive TMS
89657742|NCT04917926|Experimental|Financial and social intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, social incentives and weekly feedback on performance for 6 months.
89657743|NCT04917926|No Intervention|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
89657744|NCT04917926|Experimental|Financial intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentives, and weekly feedback on performance for 6 months.
89657745|NCT04905823||Type 1 diabetes patients|Patients with type 1 diabetes
89657746|NCT04905823||Non-diabetic subjects|Subjects in whom diabetes has not been diagnosed
89657747|NCT04905823||Type 2 diabetes patients|Patients with type 2 diabetes
89657748|NCT04899115|Placebo Comparator|Placebo|
89657749|NCT04899115|Experimental|VE303|VE303 is a live biotherapeutic product comprising 8 nonpathogenic commensal strains of Clostridia.
89657750|NCT04891185|Experimental|Primary Debulking Surgery|
89657751|NCT04891185|Experimental|Interval Debulking Surgery|
89657752|NCT04888650||angiodema hereditary patients|Patient with HAE with or without C1 inhibitor deficiency will respond to an electronic questionnaire
89657753|NCT04868903|Active Comparator|Low Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 400 IU/day) for 9 continuous months.
89657754|NCT04868903|Active Comparator|Medium Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 4,000 IU/day) for 9 continuous months.
89657755|NCT04868903|Active Comparator|High Dose Vitamin D|Subjects in this arm will be randomized to receive low dose vitamin D therapy (oral, 10,000 IU/day) for 9 continuous months.
89657756|NCT04866979|Experimental|Combination of continuous TBS plus cognitive training (cTBS + CT)|Continuous mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
89657757|NCT04866979|Experimental|Combination of intermittent TBS plus cognitive training (iTBS + CT)|Intermittent mode of TBS applied in conjunction with cognitive training that will commence directly after the stimulation protocol has been completed.
89657758|NCT04866979|Experimental|Continuous TBS only (cTBS)|TBS in continuous mode application, only (without cognitive training).
89657759|NCT04866979|Experimental|Intermittent TBS only (iTBS)|TBS in intermittent mode application, only (without cognitive training).
89657760|NCT04866979|Active Comparator|Cognitive training only (with sham TBS) (CT).|"TBS Sham will be implemented using the same set-up as a true TBS protocol but with sham stimulation. Directly following sham stimulation (as in the true combination of stimulation + cognitive training protocols), patients will undergo 25 minutes of cognitive training."
89657761|NCT04864158|Experimental|RSA-group|Surgery
89657762|NCT04864158|Experimental|Exercise-group|Exercise
89657763|NCT04859530|Experimental|AVC test|
89657764|NCT04858295|Active Comparator|Texting Arm|"Participants will receive automated text message reminders to check their blood pressure (BP) at least three days per week (participants will choose which days and times to receive reminders). Participants will transmit BP readings with text message to the Way to Health server. If a BP reading is not received within 3 hours, another reminder will be sent. Automated text message feedback will be sent with a tailored message. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
89046954|NCT04668105|Experimental|High volume nordic hamstring exercise|High volume Nordic hamstring exercise
89046955|NCT04668105|Experimental|Low volume Nordic Hamstring exercise|Low volume Nordic Hamstring exercise
89046956|NCT04333043||Hearing Aids|Hearing Aids use
89046957|NCT04667286|Experimental|Oxygen and Prone Position (PP)|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96% plus PP for a minimum of 10 hrs a day
89657765|NCT04858295|Active Comparator|mHealth app Arm|"Participants randomized to the mHealth app (Omron Connect) arm will receive reminder messages to check their BP via push notifications from the Omron Connect app at least three times weekly. Upon receipt of the BP reading to the research platform from Omron Connect, participants will receive automatic tailored text message feedback similar to the texting arm. Participants will asked to set a daily step goal of at least 3,000 steps per day and transmit their step count information from their FitBit. Participants will be reminded once a day to sync their FitBit. Motivating messages will be sent weekly. After 4 weeks, and 8 weeks of the study, a usability survey will be sent. Weekly and daily feedback will be sent. At the conclusion of week 6, individuals will crossover and will continue for an additional 6 weeks using the opposite technology to communicate BP readings."
89657766|NCT04851301|Active Comparator|Naloxone|NARCAN® Naloxone Nasal Spray will be used to determine how the opioid tone shapes VR-induced hypoalgesia. Participants will be stratified for sex and then randomized to naloxone (The dose of naloxone will be 4 mg, so 0.1 mL of 40 mg/ml naloxone solution given intranasally) or saline (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
89657767|NCT04851301|Sham Comparator|Saline|Saline group, where participants will be given saline solution (4mg) via an identical spray device. Participants will be stratified for sex and then randomized to saline arm (The dose of saline will be (0.1 mL 0.9% sodium chloride intranasally), respectively. Investigators, staff, and participants will be blinded to the treatment options.
89657768|NCT04851301|Other|Natural History|Natural history group, where participants will not be given any drugs. Participants will be stratified for sex and then randomized to the Natural History group.
89657769|NCT04849091||iReadMore users|"Participants will be iReadMore users who completed a baseline reading test between XX/XX/XXXX and XX/XX/XXXX, and who performed at least 5 hours of reading training and a second (interval) reading test.~iReadMore users will self-register to participate in the study."
89657770|NCT04845074|Experimental|TSA-group|Surgery
89657771|NCT04845074|Experimental|Exercise-group|Exercise
89657772|NCT04831216|Experimental|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
89046958|NCT04667286|Active Comparator|Oxygen|Oxygen via a Venturi mask in order to keep an oxygen saturation between 92 and 96%
89657773|NCT04828447|Experimental|High Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet high in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
89657774|NCT04828447|Experimental|Low Olive Oil|There will be a total of 4 in-person clinic visits as well as 8 weekly remote cooking classes and individual sessions with a registered dietitian. Subject will first have a physical exam, have their blood (about 3 tablespoons) and urine collected, complete surveys, and talk about their eating style and meal planning. Subject will then follow a plant-based diet low in olive oil for 4 weeks before switching to the other type of diet for 4 weeks.
89657775|NCT04823273|Experimental|General improvement|"Using the expertise of the study personnel, electronic-health record system architects working for UCHealth, and incorporating feedback from the users who participated in the user-centered design sessions we made changes to the blood transfusion order-set as well as the prepare and transfuse orders. The intention of the changes to the interface are to be more intuitive for ordering clinicians."
89657776|NCT04823273|Experimental|In-line help text|In addition to general improvement changes, subjects exposed to the in-line help text arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. This text appears within the transfusion order but is non-interruptive as it does not require users to acknowledge the text nor does is require any additional keystrokes or clicks.
89046959|NCT04657965|Experimental|Administration of LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
89046960|NCT04658004|Experimental|Administration of NKG2D CAR T-cells|
89046961|NCT00534053|Experimental|1|400 patients will be given a mailed educational reminder 10 days after picking up their FOBT cards from the VA laboratory.
89046962|NCT00534053|No Intervention|2|400 patients will not receive a mailed educational reminder to return their FOBT cards after they have picked up the FOBT cards from the VA laboratory
89046963|NCT04658043|Experimental|ASD Intervention Group|Participants in the ASD intervention group will receive training to help children improve socioemotional functioning.
89046964|NCT04658043|No Intervention|Wait List Control Group|Participants in this group will be placed on the wait list and receive the ASD intervention training 2 months after the other groups
88994303|NCT05318911|Active Comparator|Supplement Group|"10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of novel yogurt drink per day for a period of 28 days.~Then, after a 2-week washout period in which the subjects do not take any yoghurt drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis."
88994304|NCT05318911|Placebo Comparator|Placebo Group|"10 participants will provide baseline blood samples after overnight fasting, on day 0 of the study. Following this they will initially consume 200 mL of placebo drink per day for a period of 28 days.~Then, after a 2-week washout period in which the subjects do not take any placebo drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis."
88994305|NCT05318833|Experimental|HRS7415|
88994306|NCT03458494|Experimental|Mediterranean Diet|during one week participants will receive food products common in the diet of Mediterranean populations
88994307|NCT03458494|Experimental|Low-fat diet|during one week participants will receive food products low in fat content
88994308|NCT02942602|Experimental|Atorvastatin 20 mg|lipid lowering treatment
88994309|NCT02942602|Experimental|Cholestyramine 8 g|lipid lowering treatment
88994310|NCT02942602|Experimental|Omega-3 (EPA+DHA) 2 g|lipid lowering treatment
88994311|NCT02942602|Experimental|Atorvastatin 5 mg + Ezetimibe 10 mg|lipid lowering treatment
88994312|NCT02942602|Active Comparator|Life style modification for management of dyslipidemia|
88994313|NCT00146081|Experimental|A|Family Program: Participants who have identified at least 1 family member or friend to enroll in SHARE with them, who are randomly assigned to program A, are invited to bring their enrolled family member or friend (co-participant) with them to the study intervention group sessions as their supportive team member.
88994314|NCT00146081|Active Comparator|B|Coach Program: Participants who identify 1 or 2 family members or friends to enroll in SHARE with them, who are randomly assigned to program B, are invited to attend the study intervention group sessions without their enrolled family or friend (co-participants). The co-participants receive the same written materials, but act as supportive team members outside of the group sessions only. They are invited to attend special field workshops and personal counseling sessions with their co-participants.
88994315|NCT00146081|Experimental|C|Team Program: Participants who do not identify 1 or 2 family or friend co-participants, and are randomly assigned to program C, are paired with other unrelated enrollees in their group sessions as supportive team members.
88994316|NCT00146081|Active Comparator|D|Individual Program: Participants who do not identify 1 or 2 family members or friends to enroll in SHARE with them, and are randomly assigned to program D, attend group sessions as individuals.
88994317|NCT02942524|Experimental|Supportive care (TEPID)|Patients complete the TEPID checklist of items during hospital stay.
88994318|NCT02942329|Experimental|apatinib and SHR-1210|Every patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effects.
88994319|NCT02958176|Experimental|HRV Biofeedback|At home HRV biofeedback using mobile device
88994320|NCT02958176|Experimental|HRV Biofeedback with Autogenic Training|At home HRV biofeedback using mobile device plus autogenic training recording
88994321|NCT02958176|No Intervention|Wait List|Wait list control
88994322|NCT02942641|Experimental|Indwelling urethral catheterization (Foley)|Foley catheter as the intervention.
88994323|NCT02942641|Experimental|Clean intermittent catheterization (CIC)|CIC as the intervention .
88994324|NCT05318716|Experimental|Reconstructive group|This group of patients would be undergoing fat grafting following implant-based reconstruction. We will be excluding patients that have had autologous based reconstruction, including regional and free flaps. This group will be analyzed based on volume (<200cc or 50% and >200cc or 50%) as well as subgroup analysis based on adjuvant chemo or radiation therapy.
88994325|NCT05318716|Experimental|Cosmetic augmentation group|This group of patients will be undergoing a primary or secondary augmentation for cosmesis. They will be included if this is a primary augmentation using fat grafting or a secondary augmentation with no history of fat grafting to the breasts.
89657777|NCT04823273|Experimental|Interruptive alert|In addition to general improvement changes, subjects exposed to the interruptive alert arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. In contrast to the in-line help text arm, this arm includes an interruptive alert that appears when the user selects the transfusion order. This alert offers users the option to remove the order which results in no-blood product ordered. Alternatively, users may continue to order blood and are asked to select the reason for proceeding with the intended order.
89657778|NCT04818333|Experimental|SHR-A1811|SHR-A1811 was administered intravenously every 3 weeks (Q3W) until discontinuation treatment
89657779|NCT04817449||Suspected Ovarian Cancer|Patients referred or self presenting to secondary care with signs or symptoms of ovarian cancer.
89657780|NCT04816305|Experimental|rTMSc + physiotherapy|A conventional high-frequency rTMS (rTMSc) will be applied over the lesioned hemisphere over the motor cortex. After rTMSc, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
89657781|NCT04816305|Experimental|rTMSp + physiotherapy|A personalized high or low-frequency rTMS (rTMSp) will be applied to the lesioned or non-lesioned hemisphere depending on cortical biomarkers assessment guide a personalized stimulation for each patient in this group. After rTMSp, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
89657782|NCT04816305|Sham Comparator|tDCS sham + physiotherapy|The sham protocol will be delivered to each patient of this arm imitating the exat sound of the equipment and structure of the experimental arms. After rTMS sham, patients will be submitted to 45 minutes of neurofunctional physiotherapy. Experimental sessions will be repeated five times per week for two weeks.
89657783|NCT04805593|Experimental|WaveLight EX500 excimer laser system|Laser-assisted in situ keratomileusis (LASIK) surgery using the WaveLight EX500 excimer laser system
89657784|NCT04801966|Experimental|Treatment|"All participants will have an individualised treatment plan. The possible treatments that can be prescribed are as follows, they may be given as a single agent or in combination~Trametinib 2 mg/day~Cobimetinib 60 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)~Binimetinib 45 mg/ twice a day~Alpelisib 300 mg/day~Vemurafenib 960 mg twice a day~Dabrafenib 150 mg twice a day~Encorafenib 450 mg/day~Palbociclib 125 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off)~Ribociclib 600 mg/day, on day 1-21 of each 28 day cycle (21 days on, 7 days off~Abemaciclib 150 mg twice a day~Olaparib 300 mg twice a day~Talazoparib 1 mg/day~Nivolumab 240 mg IV once every two weeks~Atezolizumab 1200 mg IV on day 1 of a 21 day cycle~Pembrolizumab 200 mg IV on day 1 of a 21 day cycle"
89657785|NCT04800263|Experimental|SHR-1905 Dose Level 1|SHR-1905 Dose level 1
89657786|NCT04800263|Experimental|SHR-1905 Dose Level 2|SHR-1905 Dose level 2
89657787|NCT04800263|Experimental|SHR-1905 Dose Level 3|SHR-1905 Dose level 3
89657788|NCT04800263|Experimental|SHR-1905 Dose Level 4|SHR-1905 Dose level 4
89657789|NCT04800263|Experimental|SHR-1905 Dose Level 5|SHR-1905 Dose level 5
89657790|NCT04797455|Experimental|PI+ Inpatient Treatment as Usual|"Standard inpatient treatment delivered in the context of an adolescent psychaitric inpatient unit plus an 4 session DBT-based parenting intervention PI)~Intervention: Behavioral: DBT-Based Parenting Intervention"
89657791|NCT04797455|Active Comparator|Inpatient Treatment alone|"No parenting intervention provided beyond what is part of the inpatient treatment as usual.~Intervention: Behavioral: Treatment as Usual"
89657792|NCT04789915|Active Comparator|Memantine + aripiprazole|"Tablet memantine or placebo will be initiated at 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. The tablets will be identical and be provided in 10mg tablets or 20 mg tablets. (12 weeks of treatment).~Tablet aripiprazole will be administered in doses starting at 5-10 mg/day. Doses will be increased slowly according to effect and side effects up to 30 mg/day."
89657793|NCT04789915|Placebo Comparator|Placebo + aripiprazole|"Coated placebo tablets will be provided to match memantine. Placebo equivalent of 10mg/day for 1 week, hereafter the dose will be increased to 20mg/day until end of trial. (12 weeks of treatment).~Tablet aripiprazole will be administered in doses starting at 5-10 mg/day. Doses will be increased slowly according to effect and side effects up to 30 mg/day."
89046965|NCT04657848|Experimental|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
89657794|NCT04786951|Experimental|Cognitive-behavioral therapy plus VR-based body exposure and Attentional Bias Modification Training.|In this group, five sessions of VRE will be added to the usual CBT, as in the other experimental group, but, in addition, at the beginning of each of the exposure sessions, the training aimed at reducing the attentional bias will be carried out. The training will be developed through the visual selection of geometric figures that fit approximately with specific parts of the body. Each of these figures can have different colors. Specifically, the patient must detect and identify the figures that will appear in different parts of the avatar's body. In half of the trials, the shape of the figure must be discriminated and in the remaining 50%, the discrimination will be based on color. Throughout the training, the geometric figures will appear on weight-related body parts in 45% of the trials, and in another 45% of the trials, it will appear on non-weight-related body parts. In the remaining trials (10%), the test will appear on one of three neutral stimuli located next to the avatar.
89657795|NCT04786951|Experimental|Cognitive-behavioral therapy for anorexia and VR-based body exposure:|Patients assigned to this group will receive the usual CBT from the clinical unit or the hospital where they are, and additionally, five sessions of VR-based body exposure intervention. In these weekly sessions patients will go through a body exposure intervention in which they will own a virtual avatar with their real measurements, that will progressively increase its BMI values throughout the following exposure sessions until a healthy BMI value is reached.
89657796|NCT04786951|Active Comparator|Cognitive behavioral therapy|Patients assigned to this group will receive the usual treatment from the center in which they are recruited for the study (CBT), and will have to complete the evaluations following the same schedule as the experimental group.
89657797|NCT04778852|Experimental|EksoGT|Device: EksoGT. EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
89657798|NCT04778852|Active Comparator|Functional kinematic training|Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
89657799|NCT04772911||Strata A: One-time OCT Measurements|The indication for Strata A is that some participants will elect not to undergo laser treatment, particularly if they have been extensively treated with laser previously, or have a light pink vascular stain that has been stable.
89657800|NCT04772911||Strata B: Serial OCT Measurements|Participants will have serial OCT measurements of their vascular stain performed prior to the start of standard of care laser treatment. OCT will be performed prior to each standard of care laser treatment if the participant has elected to have standard of care laser treatment as treatment of their vascular stain at the time of enrollment.
89657801|NCT04772911||Strata C: Laser SOC without OCT|Participants will have serial evaluation with standard of care laser treatment without use of OCT.
89657802|NCT04771299|Active Comparator|Cariprazine|1.5mg of Cariprazine added to their current treatment for 6 week period
89657803|NCT04771299|Placebo Comparator|Placebo|Matching placebo added to their current treatment for 6 week period.
89657804|NCT04770103|Experimental|Dynamic|Participants within the dynamic arm will receive either traditional balance training within ACSM guidelines or Dynamic Step training known as Perturbation based training (PBT). Outcome measures assessed will be Margin of Stability during dynamic step recovery when subjected to a forward loss of balance, along with static postural sway ( a measure of postural control not requiring a step recovery). Participants motivation, mental wellness, attitudes to exercise and fear of falling will be assessed prior to the intervention and 6 months following the intervention.
89046966|NCT04658121||Senior Living Facilities|Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
89046967|NCT04658121||Outpatient Healthcare Facilities|Adults attending outpatient healthcare in neighborhoods of selected research sites
89046968|NCT04658121||General Communities|Adults and children (>2 months of age) in neighborhoods of selected research sites
89046969|NCT04657614|Experimental|Neutral Alignment Group|A straight pylon with the ankle at neutral.
89046970|NCT04657614|Experimental|Anterior Alignment Group|An anteriorly displaced pylon with ankle dorsiflexion at 5 degrees.
89046971|NCT04657614|Experimental|Posterior Alignment Group|A posteriorly displaced pylon with 5 degrees of plantarflexion at the ankle.
89046972|NCT00534170|Experimental|A,F,T,K|Two arms are for intervention and two are for control or placebo
89657805|NCT04770103|Experimental|Static|Participants within the static arm will receive only traditional balance training within ACSM guidelines. The outcome measure within the static arm is limited to static postural sway. Participants motivation, mental wellness, attitudes to exercise and fear of falling will be assessed prior to the intervention and 6 months following the intervention.
89657806|NCT04757961|Experimental|Lifestories|Participants in this condition will be actively participating in the online intervention for 4 weeks.
89657807|NCT04757961|No Intervention|Waitlist Control Condition|Participant in the waitlist group will be asked to not use other self-help websites or books for four weeks, after which they will be given weekly access to LifeStories modules. All participants will be asked to continue their antidepressant treatment as usual as directed by their primary care provider.
89657808|NCT04745000||Pulmonary Hypertension Participants|Children with Primary Pediatric Pulmonary Arterial Hypertension
89657809|NCT04745000||Control Participants|Children with a healthy heart and lungs
89657810|NCT04720898|Experimental|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG once a week for 12 weeks.
89657811|NCT04720898|No Intervention|Control|The control group will receive its rehabilitation care.
89657812|NCT04716829|Experimental|LUNA-EMG|The experimental group will receive 30 minutes of training with the LUNA-EMG for 12 weeks.
89657813|NCT04716829|No Intervention|Control|The control group will receive its rehabilitation care.
89657814|NCT04715139||All Products listed in Descriptions|"ProStop~BioCompression Screw~TRIM-IT Drill Pin/TRIM-IT Spin Pin~Headless Compression Screw/Compression FT Screw~DynaNite Nitinol Staple~Beveled Headed FT Screw"
89657815|NCT04705246|Experimental|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
89657816|NCT04704063|Active Comparator|Active|Tocovid Suprabio 200mg
89657817|NCT04704063|Placebo Comparator|Placebo|Placebo
89657818|NCT04703036|Experimental|Active arm|The active supplements are glycine and N-acetylcysteine
89657819|NCT04703036|Placebo Comparator|Placebo arm|The placebo arm is alanine
89657820|NCT04678804|Experimental|Matrix Graft Group|patients treated with Porcine Derived Volume Stable Matrix
89657821|NCT04678804|Other|Autogenous ctg group|patients treated with autologous tissue
89657822|NCT04674384|Active Comparator|Intermittent Low Energy Diet (ILED)|
89657823|NCT04674384|Active Comparator|Continuous Low Energy Diet (CLED)|
89657824|NCT04666298|Experimental|300 mg inclisiran sodium|Subcutaneous injection
89657825|NCT04666298|Experimental|200 mg inclisiran sodium|Subcutaneous injection
89657826|NCT04666298|Experimental|100 mg inclisiran sodium|Subcutaneous injection
89657827|NCT04666298|Placebo Comparator|Placebo|Subcutaneous injection
89657828|NCT04665440|Other|Voice only then distraction|First intervention: mother's voice without tactile stimuli Second intervention: mother's voice with tactile stimuli
89657829|NCT04665440|Other|Distraction then voice only|First intervention: mother's voice with tactile stimuli Second intervention: mother's voice without tactile stimuli
89657830|NCT04664140|Experimental|QFR-based virtual PCI|"Before starting PCI, the operator must acquire QFR angiographic projections after nitroglycerin administration at 15 frames/second. Angiographic projections should be at least 25 apart, aiming for minimal vessel foreshortening and minimal vessel overlap. In agreement with previous studies, operators follow a table of recommended projection angles. Afterwards, online QFR analysis must be performed. The tool residual vessel QFR should be used to anticipate the result of stenting (virtual PCI) by placing the proximal (p) and distal (d) marker in order to obtain a post-PCI QFR ≥0.90. then, the operator has to implant one or more stents following the pre-PCI plan and utilizing the QFR and angio to place the stent(s) according to the virtual PCI plan. Post-dilation with non-compliant (NC) balloon is strongly suggested. Blinded QFR projections must be obtained after PCI."
89657831|NCT04664140|Active Comparator|Angiography-based PCI|Invasive coronary angiography and PCI are performed following best local practices. Post-dilation with a noncompliant balloon is strongly suggested. Blinded QFR projections must be obtained before and after PCI.
89657832|NCT04657900||All eligible patients|Observational cohort using anonymized patient-level primary care data linked to secondary administrative data; CPRD-GOLD and CPRD-AURUM.
89657833|NCT04648228|Experimental|ACT + MBRP|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP) group will follow a manualized clinical protocol. Treatment will include 12 weekly group-based sessions, each lasting 90 minutes. Group sizes will range from 3 to 8. ACT + MBRP will be delivered via the VA Video Connect telehealth platform.
89657834|NCT04648228|Active Comparator|Education Control (EC)|The EC group will follow a protocol that combines opioid education sessions and psychology-led pain education sessions that are offered as part of the interdisciplinary pain program. Specifically, education will include 12 group-based sessions, each lasting 60 to 90 minutes. Group sizes will range from 3 to 8. EC will be delivered via the VA Video Connect telehealth platform.
89657835|NCT04641039|Active Comparator|Anterior annulus removal|In these patients the anterior portion of the annulus fibrosus will be removed when inserting a complete lumbar disc prosthesis
89046973|NCT04244513|Experimental|HD-DBS|This group will be routinely activated after surgery and then stimulated for 6 months.
89046974|NCT04244513|Sham Comparator|HD-sham-DBS|This group of patients will be re-launched 3 months after surgery, continued stimulation for 3 months
89046975|NCT04657536|Experimental|TRF group|the group who treated with temperature controlled radiofrequency
89046976|NCT04657536|Active Comparator|Estriol group|the group who treated with promestriene vaginal soft capsules
89046977|NCT04236206|Experimental|SMS Recipients|• Mobile phone SMSs will be sent to the intervention group with the aim of improving medication adherence and knowledge about diabetes, its complications, diet and physical activity.
89046978|NCT04236206|No Intervention|Non-SMS Recipients|Control group with no intervention.
89046979|NCT04686617|No Intervention|No-force group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction on one side and the other side was used as the premolar tooth control group. Oral B HummingBird device (Procter&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks. At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
89046980|NCT04686617|Active Comparator|Force Group|The right and left side first premolar teeth were randomly assigned (split-mouth design) so that mechanical vibration was applied in the buccal direction to one side and the other side was used as the premolar tooth control group. As in no-force group, same device procedure was used for the application of vibration. Self-ligating Speed (Strite Industries, Cambridge, Ontario, Canada) tubes and brackets with 0.022×0.026 inch slots were bonded to the buccal surfaces of the right and left first molar teeth and first premolar teeth.150g of buccally directed forces, producing by a 0.017×0.025-in beta-titanium-molybdenum alloy (3M Unitek, Monrovia, Calif) cantilever spring, were applied to premolar teeth on both side.The force magnitude was measured with a strain gauge (Dentaurum). At the end of the 12th week, the first stage was completed and the first premolar teeth were extracted.
89046981|NCT04657419||Participant|Patient or health professional coming to the Bordeaux University Hospital screening center for COVID-19 screening
89046982|NCT04187768||Healthy Group|Healthy volunteers will donate a sample of blood to be used as controls
89046983|NCT04187768||NSCLC Group|Patients with advanced NSCLC will have blood collected prior to treatment and after completing 3 cycles of immune checkpoint therapy. . If a patient is noted to have progressive disease after 2 cycles of treatment, a sample will be collected after the 2nd cycle. If a patient is noted to have pseudoprogression (determined at the discretion of the treating physician), an additional sample may be collected after 3 cycles of therapy.
89046984|NCT00556569|Experimental|Intervention|2 Intervention schools are cluster randomized to receive CHAM JAM (previously known as the Moving Smart Program) in Year 1
89046985|NCT00556569|No Intervention|Wait-Listed Control|2 Wait-Listed Control Schools will receive CHAM JAM (previously known as the Moving Smart Program) in Year 2 of the study
89046986|NCT04184804|Experimental|Behavioral Intervention|School-based intervention
89046987|NCT04184804|No Intervention|Control|Control. No intervention (usual education). The school does not receive any material and gets the information that they are part of a study on eating habits of primary school children.
89046988|NCT00556608|Experimental|Sinovial|3 intra-articular injections of Sinovial®
89046989|NCT00556608|Active Comparator|Sinvisc|
89657836|NCT04641039|Active Comparator|Anterior annulus replacement|In these group of patients the anterior portion of the annulus fibrosus will be opened up in to flaps hinged lateraly and replaced once the complete lumbar disc prosthesis is inserted
89657837|NCT04636255|Experimental|Exercise training group|Patients in the experimental group, under clinic follow up will perform combined exercise training for 16 weeks
89657838|NCT04636255|Sham Comparator|Control Group|Patients will be only clinically followed up. They will not perform exercise training.
89657839|NCT04635176|Placebo Comparator|Sham iPACK block|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia+ sham iPACK block with 20 mL of normal saline.
89657840|NCT04635176|Active Comparator|Real IPACK block.|This groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia + real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
89657841|NCT04634136|Active Comparator|Active Substance: Full-spectrum Medical Canabis Product (HemPhar)|For research purposes the investigators will use a preparation in the form of drops, containing full-spectrum medical cannabis extract (HemPhar) with THC:CBD ratio 1:10, and other cannabinoids as well, provided by Pharmahemp, GMP-certified medical cannabis producer.
89657842|NCT04634136|Placebo Comparator|Placebo|For research purposes the investigators will use a placebo in the form of drops, containing oil only, provided by Pharmahemp, GMP-certified medical cannabis producer.
89657843|NCT04631939|Experimental|study intervention|"The intervention consists of a puzzle adventure game, in which players have to explore the fantasy world Macu'ta. The puzzles are based on Metacognitive Training for Psychosis (MCT), an intervention using playful, entertaining exercises to increase awareness of reasoning biases in patients and 'sow the seeds of doubt' through corrective ('aha!') experiences. The tasks will address reasoning biases associated with the emergence and maintenance of delusions."
89657844|NCT04631939|Sham Comparator|control intervention|The control intervention consists of a puzzles focused exclusively on dexterity and accuracy.
89657845|NCT04625907|Experimental|Phase 1b Dose finding: VHR induction - IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . For the phase 1b registration, starting dose of 20 mg/m2.~Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
89046990|NCT00534287|Active Comparator|MeroMono|Monotherapy with meropenem
89046991|NCT00534287|Active Comparator|MeroMoxi|Combination therapy with meropenem + moxifloxacin
89046992|NCT00556647||A|Fast-track diagnosis
89046993|NCT00556686||1|Individuals with a history of canker sores.
89046994|NCT00556686||2|Individuals with no history of canker sores.
89046995|NCT00534326|Active Comparator|1|Standard Reaming of femoral shaft fracture prior to intramedullary nailing
88994326|NCT02942212|Experimental|Project HALT II: In-Depth Interviews|"Participants complete a computerized questionnaire to assess demographics and smoking history.~Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program."
88994327|NCT02942212|Active Comparator|Project HALT II: Standard Treatment (ST)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants receive phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
88994328|NCT02942212|Experimental|Project HALT II: Tailored Treatment (HALT)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants scheduled to attend 5 individual, in-person smoking cessation treatment counseling sessions.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
88994329|NCT00169338|Experimental|deep brain stimulation|Paladin deep brain stimulation
88994330|NCT00169338|Placebo Comparator|sham deep brain stimulation|no stimulation
88994331|NCT02942251|Experimental|Clinical features and medication|A group patients with significant high risk of clinical features and medications.
88994332|NCT02942251|Experimental|Psycho-social|A group patients with significant high risk of psycho-social problems.
88994333|NCT02942251|Experimental|immunology|A group patients with significant high risk of immune disturbance.
88994334|NCT02942251|Experimental|Laboratory abnormality|A group patients with significant high risk of Laboratory abnormalities.
88994335|NCT02942251|Experimental|Comorbidity|A group patients with physical or mental disorders comorbidities.
88994336|NCT02942251|Experimental|Treatment as usual|Control group.
88994337|NCT00169377|Active Comparator|Group A|Deep brain stimulation on followed by off
88994338|NCT00169377|Sham Comparator|Group B|No stimulation, deep brain stimulation off followed by on
88994339|NCT00146159|Experimental|1|1st group: 12 mg Mitoxantrone/m²
88994340|NCT00146159|Experimental|2|2nd group: 9mg Mitoxantrone/m²
88994341|NCT00146159|Experimental|3|3rd group: 5mg Mitoxantrone/m²
88994342|NCT05318677||1|"Fifteen patients with spina bifida aged 8-12 years living in Denizli province were included in the study. The participants were informed about the research and read the voluntary consent form, and written consent was obtained from their families since the participants were children.~Children with literate, well cooperated, aged 8-12 years, and attending any primary school were included in the study. Children who had a second illness and could not be contacted were not included in the study. Non-dominant and dominant extremities of all cases were evaluated by the tests. It was recorded socio-demographic data were questioned. Sensory evaluation forms for upper extremities, Bruininks-Oseretsky motor proficiency, and ability tests were administered by a physiotherapist."
89657846|NCT04625907|Active Comparator|CT1A: VHR induction - IVADO|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1. Doxorubicin: 30 mg/m2 as an i.v infusion over 1 hour on days 1 and 2 on cycles 1-4"
89657847|NCT04625907|Experimental|CT1A: VHR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
89657848|NCT04625907|Active Comparator|CT1B: HR Induction IVA|"Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
89657849|NCT04625907|Experimental|CT1B: HR Induction IRIVA|"Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.~Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1."
89657850|NCT04625907|Experimental|RT1A: Preoperative Radiotherapy|To be given either 41.4 Gy or 50.4 Gy prior to surgery
89657851|NCT04625907|Active Comparator|RT1A: Post operative radiotherapy|To be given either 41.4 Gy or 50.4 Gy following surgery
89657852|NCT04625907|Experimental|RT1B: Radiotherapy for resectable disease: dose escalated|To receive 50.4 Gy
89657853|NCT04625907|Active Comparator|RT1B: Radiotherapy for resectable disease: standard dose|To receive 41.4 Gy
89657854|NCT04625907|Experimental|RT1C: Radiotherapy for unresectable disease: dose escalated|To receive 59.4 Gy
89657855|NCT04625907|Active Comparator|RT1C: Radiotherapy for unresectable disease: standard dose|To receive 50.4 Gy
89657856|NCT04625907|Experimental|RT2: Radiotherapy to primary tumour and involved lymph nodes|Radiotherapy to the primary tumour and involved regional lymph nodes only
89657857|NCT04625907|Experimental|RT2: Radiotherapy to all metastatic sites|Radiotherapy given to all metastatic sites
89657858|NCT04625907|Experimental|CT2A: VHR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. or 60 mg/m2 orally on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
89657859|NCT04625907|No Intervention|CT2A: Maintenance -Stop treatment|To stop treatment at the point of randomisation
89657860|NCT04625907|Experimental|CT2B: HR Maintenance - VC|Vinorelbine: 25 mg/m2 i.v. on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days
89657861|NCT04625907|No Intervention|CT2B: HR Maintenance - Stop Treatment|To stop treatment at the point of randomisation
89657862|NCT04625907|Active Comparator|CT3: Relpased Chemotherapy - VIRT|Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Temozolomide: 125 mg/m2 (Escalate to 150mg/m2/day in Cycle 2 if no toxicity > grade 3) as an oral tablets prior to vincristine and irinotecan on days 1-5
89657863|NCT04625907|Experimental|CT3: Relapsed Chemotherapy - VIRR|Vincristine: 1.5 mg/m2 As per local practice: recommended as a short infusion (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Regorafenib: Children between 6 and 24 months = 65 mg/m2, children less than 12 and/or less than 40kg dose = 82 mg/m2 Maximum 120 mg, Fixed dose of 120 mg for patients over 12 years of age AND ≥ 40 kg, as an oral tablets on days 8 to 21.
89657864|NCT04623580||Inguinal or femoral hernia repair|All consecutive inguinal or femoral hernia repair (primary or mesh)
89657865|NCT04620564||Patients|
89657866|NCT04620564||Relatives|
89657867|NCT04612166|Experimental|Intervention|Patients will receive a medication action plan approved by themselves and their primary care providers to reduce their medications. They will also receive check in calls and follow ups from study health coaches to monitor their progress. During health coaching sessions motivational interviewing techniques and patient empowerment strategies will be used by trained health coaches. Participants will also participate in assessments for the study (baseline and quarterly follow ups) and will complete up to 12 months of falls calendars.
89657868|NCT04612166|No Intervention|Control|Will participate in assessments for the study (baseline and quarterly follow ups) and will complete up to 12 months of falls calendars. No intervention will be given to this group, but standard practices of care delivered by the MercyOneSM Health Network.
89657869|NCT04608292|Active Comparator|Single-voxel MRS|MRS
89657870|NCT04608292|Active Comparator|Multi-voxel MRSI|MRSI
89657871|NCT04608292|Active Comparator|Magnetization Transfer Imaging|MTI
89657872|NCT04608292|Active Comparator|Single-voxel MRS + ClearMate(TM)|MRS+CM
89657873|NCT04608292|Active Comparator|Multi-voxel MRSI + ClearMate(TM)|MRSI+CM
89657874|NCT04608292|Active Comparator|Magnetization Transfer Imaging + ClearMate(TM)|MTI+CM
89657875|NCT04608292|Active Comparator|Single-voxel MRS + CM + Blood Sampling|MRS+CM+B
89657876|NCT04608292|Active Comparator|Multi-voxel MRSI + CM + Blood Sampling|MRSI+CM+B
89657877|NCT04608292|Active Comparator|Magnetization Transfer Imaging + CM + Blood Sampling|MTI+CM+B
89657878|NCT04605016|Experimental|Hydrophilic surface implants|
89657879|NCT04605016|Active Comparator|Hydrophobic surface implants|
89657880|NCT04598048||EMMACE 3|Participants who were recruited to the EMMACE 3 study and have agreed to contact for further research.
89657881|NCT04598022||vegan|subjects having a vegan nutrition pattern for at least the last 3 months
89657882|NCT04598022||vegetarian|subjects having a vegetarian nutrition pattern for at least the last 3 months
89657883|NCT04598022||omnivores|subjects having a omnivore nutrition pattern for at least the last 3 months
89657884|NCT04596592||Transgender|
89657885|NCT04596592||Cisgender|
89657886|NCT04596501|Experimental|Early postmenopausal women|Healthy sedentary early postmenopausal women
89657887|NCT04596501|Experimental|Late postmenopausal women|Healthy sedentary late postmenopausal women
89046996|NCT00534326|Active Comparator|2|Reamer/Irrigator/Aspirating of femoral shaft fracture prior to intramedullary nailing
89046997|NCT04686656|Active Comparator|nasal oxygen supplementation group|supplemental oxygen will be administered with nasal cannula
89046998|NCT04686656|Active Comparator|buccal oxygen supplementation group|supplemental oxygen will be administered with Ring-Adair-Elwyn (RAE) tube
89046999|NCT04168502|Experimental|Experimental arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~Maintenance with glasdegib 100 mg daily for one year or until toxicity/relapse"
89657888|NCT04591223|Experimental|TAU + six weekly sessions of competency-based module (CbM)|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider as well as a well-designed, one on one structural physical workout module to be offered by a licensed senior physical trainer in public sports ground or gymnasium.
89657889|NCT04591223|No Intervention|TAU|This group of participants will be receiving online social work (OSW) treatment as usual (TAU) from NGO service provider.
89657890|NCT04584372|Active Comparator|High-nitrate (HI-NI) intervention|The 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.
89657891|NCT04584372|Placebo Comparator|Low-nitrate (LO-NI) intervention|The placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.
89657892|NCT04581980|No Intervention|Control|This arm will receive no exercise
89657893|NCT04581980|Experimental|Moderate Intensity Exercise|This group will exercise on a cycle ergometer (Lode Bike) at moderate intensity. Moderate intensity will be defined by the lactate threshold. A heart rate monitor will be utilized at all times to record heart rate.
89657894|NCT04581980|Experimental|High Intensity Exercise|This group will exercise on a cycle ergometer (Lode Bike) at high intensity. High intensity will be defined by an by 75% of the difference between the lactate threshold and peak.
89657895|NCT04574713|Experimental|Candesartan 8 mg|
89657896|NCT04574713|Experimental|Candesartan 16 mg|
89657897|NCT04574713|Placebo Comparator|Control group|
89657898|NCT04570202|No Intervention|Usual Care|Subject from this group are screened positive for psychological distress but they will only receive standard of care.
89657899|NCT04570202|Experimental|Eye Movement Desensitization & Reprocessing Group|Subject from this group are screened positive for psychological distress. They will receive 12 sessions of Eye Movement Desensitization & Reprocessing therapy by a trained therapist over three months in addition to standard of care.
89657900|NCT04569877|Experimental|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution
89657901|NCT04569877|Placebo Comparator|Placebo nebuliser solution|Placebo nebuliser solution
89657902|NCT04558710||CGM|CGM users
89657903|NCT04558710||SMBG|Non-CGM users
89657904|NCT04550234|Experimental|Treatment 1|Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fasted state on Day 1.
89657905|NCT04550234|Experimental|Treatment 2|Subjects will receive verinurad/allopurinol FDC capsule in fasted state on Day 1.
89657906|NCT04550234|Experimental|Treatment 3|Subjects will receive verinurad/allopurinol FDC capsule in fed state on Day 1.
89657907|NCT04550234|Experimental|Treatment 4|Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fed state on Day 1.
89657908|NCT04550234|Experimental|Treatment 5|Subjects will receive verinurad prolonged release gelatin capsule in fasted state on Day 1.
89047000|NCT04168502|Active Comparator|Standard arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~clinical observation"
89047001|NCT04666896|Experimental|Evidence-based tailored care (group A)|Patients who were randomized to group A received a tailored exercise program, with exercises developed based on recent hEDS/HSD research data.
89657909|NCT04541797|Placebo Comparator|Control|Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
89657910|NCT04541797|Experimental|Intervention|Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
89657911|NCT04540666|Experimental|VR group|VR program will be displayed throughout the surgery.
89657912|NCT04540666|Placebo Comparator|Non-VR group|VR program will be turned off throughout the surgery.
89657913|NCT04530383|Experimental|Metformin dose regimen A|Participants with CFRD on elexacaftor/tezacaftor/ivacaftor who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study week 0 after undergoing study procedures through week 14. They will then undergo a two week washout period. For the second half of the study metformin will be resumed and, if tolerated, dose will be increased by 500mg on weeks 17 and 18 to a final dose of 1000 mg twice daily through end of study (week 30).
89657914|NCT04530383|Experimental|Metformin dose regimen B|Participants with CFRD on elexacaftor/tezacaftor/ivafactor who meet criteria and agree to participation in the study will be placed on metformin 500 mg twice daily on study week 0 after undergoing study procedures. If tolerated, dose will be increased by 500mg on weeks 1 and 2 to a final dose of 1000 mg twice daily through week 14.They will then undergo a two week washout period. For the second half of the study metformin will be resumed at a dose of 500 mg twice daily through the end of study (week 30).
89657915|NCT04524247|Experimental|PMEG FEVAR|The only arm of this study will be enrolled subjects who undergo physician modified endografting as a treatment of their thoracoabdominal aortic aneurysms or complex abdominal aortic aneurysms.
89657916|NCT04522765||Health|Healthy individuals with no known medical condition and taking no regular medication
89657917|NCT04522765||Acute kidney injury|Individuals with acute kidney injury as defined by KDIGO criteria
89657918|NCT04522765||Chronic kidney disease|Individuals with chronic kidney disease as defined by KDIGO criteria
89047002|NCT04666896|Active Comparator|Evidence-based standard care (group B)|This exercise program was composed in order to reflect evidence-based standard care, in a telerehabilitation format.
89047003|NCT04666935|Experimental|Intervention group|The intervention group will be instructed to include the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program as a warm up before training session (3 times per week) during one season (6 months).
89047004|NCT04666935|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
89047005|NCT00534443|Experimental|1|A total of 130 patients with peptic ulcer disease and /or chronic gastritis will be enrolled in the study after written informed consent. Patients will be prescribed oral treatment with rabeprazole or esomeprazole according to standard guidelines. Rabeprazole is administered 20mg twice daily and esomeprazole 10 mg once daily. Selection of rabeprazole or esomeprazole is at the discretion of the attending physicians. The drug is administered for four weeks in patients with duodenal ulcers, for eight weeks in patients with gastric ulcers and for four weeks in patients with chronic gastritis.
89047006|NCT04667091|Experimental|Experimental|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:~1. Positional Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
89047007|NCT04667091|Active Comparator|Comparator|"Following physiotherapy will be given to the participants in this group for 6 weeks, 2 times a week:~1. Myofascial Release Technique 2. Ultrasound 3. Cold Packs 4. Hip Strengthening Exercises 5. Knee Strengthening exercises"
89657919|NCT04522765||Small vessel vasculitis|Individuals with active small vessel vasculitis an diagnosed by a specialist physician
89657920|NCT04522765||Kidney transplant recipient|Individuals who have received a kidney transplant
89657921|NCT04522765||Kidney donor|Individuals who have donated a kidney for transplantation
89657922|NCT04518098|Experimental|Intervention group|Participants in the IG will receive the STABLE intervention, which entails orientation, and undertaking a remotely delivered resistance and balance training regimen 3 times weekly for 3 months
89657923|NCT04518098|No Intervention|Control group|Participants in the CG will not receive the intervention, and will be advised to carry out their usual daily activities.
89657924|NCT04513236|No Intervention|Control|No Airtime Incentive was given for completing the survey
89657925|NCT04513236|Experimental|Pre-survey incentive|0.1X incentive before the survey, 1X afterwards
89657926|NCT04513236|Experimental|Post-survey incentive|1X incentive after the survey
89657927|NCT04507555|Experimental|Intervention|
89047008|NCT00534482|Experimental|A, 1, I|Practice-level treatment group
89047009|NCT00534482|Active Comparator|A, 1, II|Practice-level comparison group
89047010|NCT00534482|Experimental|B, 1, I|Patient-level treatment group
89047011|NCT00534482|Active Comparator|B, 1, II|Patient-level comparison group
89047012|NCT04667052|Experimental|JNJ 64304500: Reference|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 reference formulation.
89047013|NCT04667052|Experimental|JNJ 64304500: Test|Participants (including individuals of Han Chinese background) will be randomized to receive a single subcutaneous dose of JNJ-64304500 test formulation.
89047014|NCT04136522|Active Comparator|conventional|The patients who included this group will undergo conventional pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD). We will identify and isolate superior mesenteric vein (SMV) before pancreatic resection. The surgeon will dissect tissue around superior mesenteric artery (SMA) and uncinate process of pancreas along the SMA.
89047015|NCT04136522|Experimental|total mesopancreas excision with arterial first approach|The patients who included this group will undergo PD or PPPD including total pancreatic mesopancreas excision and superior mesenteric artery approach. Before pancreatic transection, the surgeon will isolate superior mesenteric vein (SMV) and superior mesenteric artery (SMA). And the surgeon will dissect nerve plexus and lymph node around SMA. inferior pancreaticoduodenal artery (IPDA) and first jejunal artery will be identified and the surgeon will ligate according to surgical margin. Anastomosis will be performed as usual manners.
89047016|NCT04667130|Experimental|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Providing information about the possibilities of physiotherapy, Computer Kinesiology, psychotherapy, Motor progam activating therapy, aerobic exercise
89657928|NCT04507555|Active Comparator|Standard Care|
89657929|NCT04507555|No Intervention|Observational|
89657930|NCT04506112|Experimental|TranS-C + Usual Care|Participants in this group will receive TranS-C and will continue with care in cardiac rehabilitation as usual.
89657931|NCT04506112|No Intervention|Usual Care|Participants in this group will receive only usual care and thus will continue with care in cardiac rehabilitation as usual.
89657932|NCT04499170|Experimental|Muscle energy technique (G1)|Group Elderly (G1)
89657933|NCT04499170|Active Comparator|Muscle energy technique (G2)|Group of young people (G2)
89657934|NCT04497506|Experimental|Self-affirmation and Incremental theory of personality|1 hour Wise intervention (based on SA and ITP) consisting on several tasks to be completed online individually.
89657935|NCT04497506|Other|Standard preventive intervention|1 hour educational intervention (about stress management) consisting on several tasks to be completed online individually.
89657936|NCT04482920||Transgender males|Transgender males who are clinically ready to start testosterone
89657937|NCT04482920||Transgender females|Transgender females who are clinically ready to start estradiol
89657938|NCT04482894|Experimental|Palliative Care Intervention|Participants on this arm will see a palliative care specialist twice a week while they are in the hospital and about every other week when they are out of the hospital. If participants see their oncologist less often than every other week while they're out of the hospital, then visits with the palliative care specialist would be timed to occur on the same day as the oncologist visit. Participants will complete a questionnaire about once a month.
89657939|NCT04482894|No Intervention|Standard Clinical Care|Participants will see a palliative care specialist only if they have a referral from their oncologist according to standard clinical care. Participants on this arm will not be discouraged from requesting a consult.
89657940|NCT04472104|Active Comparator|MBCT-S|Mindfulness-Based Cognitive Therapy for sexuality (MBCT-S) which incorporates several empirically supported therapeutic approaches, integrating elements of education, mindfulness meditation skills, and sex therapy.
89657941|NCT04472104|Active Comparator|SexEd|Sexuality education on sexual desire, sexual distress, and sexual pain.
89657942|NCT04471805|Experimental|Eumenorrheic Women|"Participants will have the anode (active electrode) placed over the brain area that controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. tDCS is administered in the early follicular phase, late follicular phase, and mid-luteal phase of their menstrual cycle.~tDCS: Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the simulation time.~Sham: Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial but stays at 0 mA in the intervening time."
89657943|NCT04463849|Experimental|COVID-19 positive patients|Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal glucose and no previous history of diabetes or impaired fasting glucose or impaired tolerance glucose. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
89657944|NCT04463849|Other|Healthy volunteers|Healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance will be enrolled. Healthy volunteers will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
89657945|NCT04463849|Other|Type 2 diabetes patients|Patients with established Type 2 diabetes, not affects by COVID-19. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.
89657946|NCT04452032|Experimental|Single arm|"The first phase of the study will consist of an evaluation of the initial dental state of each subject based on stomatological examination, orthopantomogram, bitewing radiographs, evaluation of potential risks of caries and fractures. Dental decalcification, dental care and/or avulsion if necessary, and afterwards, a dental splint will be performed before the start of RT treatment.Based on our predictive model, every tooth which potentially will receive more than 40 Gy and for which long term survival is compromised will be avulsed at least 2 weeks before the start of RT.~After RT, the subject will have clinical follow-up with dental evaluation every 6 months for 36 months in order to identify possible dental events. At each consultation, a stomatological examination will be performed as well as bitewing radiographs. Orthopantomogram will be done once a year. Periapical X-rays will be performed if there is a dental complain or to refine a lesion visible on orthopantomogram."
89657947|NCT04436042|Experimental|MyHand Treatment|Participants will use the MyHand device during repetitive grasp and release tasks.
89657948|NCT04431245||Stop antiviral|HBeAg-negative non-cirrhotic CHB patients on long-term NA ≥3 years will be identified. Only those who have undetectable serum HBV DNA by the conventional assay (Cobas Taqman, Roche Diagnostics, Branchburg, NJ) which has a lower limit of detection (LLOD) of 10 IU/mL will be recruited. CHB patients were treated with potent oral NA (i.e. tenofovir or entecavir). All recruited patients will have written informed consent for participation of study. Patients with HCC, cirrhosis, history of liver transplantation, or on immunosuppressants, will be excluded.
89657949|NCT04421248|Experimental|Attention Deficit Hyperactivity Disorder (ADHD)|8 to 12 year old children diagnosed with ADHD. Randomized, blinded, single dose, placebo controlled, crossover trial.
89657950|NCT04421248|No Intervention|Typically developing controls (TDC)|Typically developing controls - 8 to 12 year old children
89657951|NCT04382807||Subjective, chronic tinnitus|Tinnitus patients who received internet-based psycho-educational counseling
89657952|NCT04368949|Experimental|Stepping-Up Group|Participants will attend one 2-hour virtual session (1-hour exercise and 1-hour SM) per week. Each class of 6-8 participants is supervised by a Physiotherapist (PT) and kinesiologist who will individually tailor the exercises for each participant.
89657953|NCT04368949|Active Comparator|TELE Group|The initial telephone session will be 20-30 minutes, with subsequent weekly calls will be approximately 10 minutes.
89657954|NCT04368949|Placebo Comparator|Chair-Based Yoga Group|Participants will attend two 1-hour virtual sessions per week to ensure this group is matched for attention to STEPPING-UP.
89657955|NCT04366388||Frail hospitalized old adults|Over than 65-years of age Admitted into Acute Unit Nonambulatory
89657956|NCT04357821|Experimental|Combination intervention arm|All volunteers will receive the combination intervention outlined above.
89657957|NCT04349475|Experimental|Omega 3 Supplementation|Supplementation of 4g of DHA/EPA daily
89657958|NCT04349475|Placebo Comparator|Safflower Oil Supplement|Supplementation of Safflower Oil daily
89657959|NCT04326465|Experimental|Fractional CO2 Laser Therapy at 10-15% Laser Density Coverage|Study participants with Peyronies Disease will be treated with a Fractional Carbon Dioxide Laser set at a 10-15% laser density. The patient will receive three laser therapy sessions over 12 weeks (one session every four weeks). Following each session, topical triamcinolone will be applied to the treated area.
89657960|NCT04323774|No Intervention|Aim 1-Part 1 Stakeholder Interview|"This arm will focus on finding the best format for the study intervention (called AYA-RISE) whether AYA-RISE is easy to use; and whether patients, family caregivers, and providers find AYA-RISE acceptable.~The research study procedures include:~Using and reviewing AYA-RISE~Participating in audio-recorded, 30-minute interviews"
89657961|NCT04323774|Experimental|Aim 1-Part 2|"This arm is a pilot study of the study intervention (called AYA-RISE).~The activities involved in this part of the study are:~Baseline Questionnaire~Using and reviewing AYA-RISE~Follow-up Questionnaire~Brief interviews to get feedback on AYA-RISE"
89657962|NCT04323774|Active Comparator|Aim 2-Genetic Counseling|"The names of the study activities involved in this study are:~Baseline Questionnaire~Follow-up Questionnaire~Medical record review~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
89657963|NCT04323774|Experimental|Aim 2- Genetic Counseling with AYA-RISE|"The names of the study activities involved in this study are:~Baseline Questionnaire~Follow-up Questionnaire~Medical record review~Using the study intervention, AYA-RISE~The study procedures will all take place on the day of the patient's regularly scheduled clinic visit. Participants will be in this research study for up to 1 year."
89657964|NCT04323774|No Intervention|Aim 3 Semi-structured interviews|Each site will conduct 30-minute interviews with patients, caregivers, and providers, and site principal investigators.
89657965|NCT04312165|Experimental|Duramesh Laparotomy Closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
89657966|NCT04312165|Active Comparator|Control group-Conventional suture closure|Patients undergoing a midline laparotomy for trauma or emergency surgery will be randomized to either #1 Duramesh suture or standard suture, which is a #1 slowly-absorbing PDS single strand or looped suture based on surgeon preference.
89657967|NCT04310904||ICU cardiac output (CO) assessment patients|all ICU patients intubated/ventilated with a central line and an arterial catheter who need trans esophageal echocardiography examination with a saline contrast test.
89657968|NCT04303689|Experimental|Colchicine|3 weeks of treatment with colchicine
89657969|NCT04303689|Placebo Comparator|Placebo|3 weeks of placebo-treatment
89657970|NCT04296097|Experimental|Deep Brain Stimulation (DBS) activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position ON
89657971|NCT04296097|Other|Deep Brain Stimulation (DBS) non-activated|Patients with severe permanent non-pulsatile tinnitus treated by Deep Brain Stimulation (DBS) in position OFF
89657972|NCT04269070|Active Comparator|Move, Stand|Usual behavior condition, followed by the standing condition, followed by the LPA condition.
89657973|NCT04269070|Active Comparator|Stand, Move|Usual behavior condition, followed by the LPA condition, followed by the standing condition.
89657974|NCT04264325||Malignant pleural effusions : diaphragmatic ultrasound measure|
89657975|NCT04263363|Experimental|CDS pathway|When the anesthesiologist completes the preoperative evaluation for a patient who is flagged as having either respiratory disease or OSA and will receive general anesthesia, the anesthesiologist will receive a pop-up window reminding them of the best practice guidelines for pulmonary management in high-risk patients. We anticipate that the pathway will suggest 1) use of sugammadex to reverse neuromuscular blockade if rocuronium was used 2) use of objective train of four monitoring throughout the case and to confirm reversal 3) use of a tidal volume of 6-8 cc/kg 4) use of at least 5 cmH2O of PEEP
89657976|NCT04249388||Decliners of Pulmonary Rehabilitation|No intervention, just observation
89657977|NCT04242524|Experimental|Circadian Clock Alignment - High BMI|Subjects will come to the Sleep Lab three nights before their bariatric surgery procedure for an intervention that will align their central circadian clock. The intervention includes eating meals and snacks at fixed times and having lights off at a specific time at night and lights on at a specific time in the morning.
89657978|NCT04242524|Active Comparator|Circadian Clock Control - High BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
89657979|NCT04242524|Active Comparator|Circadian Clock Control - Low BMI|Subjects will not come to the Sleep Lab and will live normally at home with no changes to their meal, sleep or wake times.
89657980|NCT04223089||Revascularization|This group will include patients whose cutaneous oxygen partial pressure (PO2) around the wound of interest measures less than 40 mmHg and therefore require revascularization.
89657981|NCT04223089||Medical Management|This group will include patients whose cutaneous PO2 around the wound of interest measures greater than 40 mmHg and will be managed conservatively in wound clinic
89657982|NCT04219813|Other|Patients affected with Non-celiac Gluten/Wheat Sensitivity|The researchers will deliver to each patient 10 kits for the analysis of the GIP and they will ask them to use them two times per week, for 5 weeks. Furthermore, the patients will test urine GIP in the event of symptoms/signs that they attribute to the accidental intake of gluten, within the same 5 weeks. Both gastrointestinal and extra-intestinal symptoms which the patients will attribute to the accidental intake of gluten, will be considered.
89657983|NCT04217278|Active Comparator|R1: Intermediate dose Cytarabine|First Randomisation (closed to recruitment) - control arm: Intermediate dose Cytarabine (1g/m^2 administered by intravenous infusion over 2 hours on days 1-5 inclusive)
89657984|NCT04217278|Experimental|R1: Vyxeos|First Randomisation (closed to recruitment) - experimental arm: Vyxeos (29mg/65mg/m^2 administered by intravenous infusion over 90 minutes on days 1 and 3)
89657985|NCT04217278|Active Comparator|R2: FB4|Second Randomisation - under 55 years - control arm: Fludarabine (40mg/m^2 days -7, -6, -5, and -4), Busulphan (3.2mg/kg days -7, -6, -5 and -4)
89657986|NCT04217278|Experimental|R2: TBF|Second Randomisation - under 55 years - experimental arm: Thiotepa (5mg/kg day -7 and -6), Busulphan (3.2mg/kg days -5, -4 and -3), Fludarabine (50mg/m^2 days -5, -4 and -3)
89657987|NCT04217278|Active Comparator|R3: FB2|Third Randomisation - 55 years and over (or under 55 with comorbidities) - control arm: Fludarabine (30mg/m^2 days -6, -5, -4, -3 and -2), Busulphan (3.2mg/kg days -6 and -5)
89657988|NCT04217278|Experimental|Mini-TBF|Third Randomisation - 55 years and over (or under 55 with comorbidities) - experimental arm: Thiotepa (5mg/kg day -6), Busulphan (3.2mg/kg days -5 and -4), Fludarabine (50mg/m^2 days -5, -4, and -3)
89657989|NCT04211714|Experimental|EXG34217|single autologous CD34+ cells contacted ex vivo with EXG-001
89657990|NCT04202809|Experimental|Chemo- and Radiochemotherapy + Durvalumab|
89657991|NCT04202809|No Intervention|Chemo- and Radiochemotherapy|
89657992|NCT04202211|Placebo Comparator|Placebo oral & enema|twice weekly x 8 weeks: 10 placebo oral capsules + placebo enema
89657993|NCT04202211|Active Comparator|LYO-FMT oral + placebo enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 placebo enema
89657994|NCT04202211|Active Comparator|LYO-FMT oral + LYO-FMT enema|twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 LYO-FMT enema
89657995|NCT04200625||Semaglutide|Patients using standard of care weekly GLP-1A analog Semaglutide
89657996|NCT04200625||Dulaglutide|Patients using standard of care weekly GLP-1A analog Dulaglutide
89657997|NCT04200625||Metformin|Patients using standard of care daily Metformin.
89657998|NCT04188301|Active Comparator|IVM + ALB|Single dose of oral IVM (150 µg/kg) plus ALB (400 mg)
89657999|NCT04188301|Experimental|IDA x 1 dose|Single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
89658000|NCT04188301|Experimental|IDA x 3 doses|Once daily for 3 days oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
89658001|NCT04187651|Experimental|PRP gel application|PRP application for perianal fistula
89658002|NCT04177953|Active Comparator|Carboplatin or Cisplatin and Pemetrexed|"Four cycles (q4w) platinum-based adjuvant chemotherapy i.v.:~carboplatin AUC5 or cisplatin 75 mg/m2~pemetrexed 500 mg/m2"
89658003|NCT04177953|Experimental|Carboplatin or Cisplatin and Pemetrexed + Nivolumab|"Four cycles (q4w) of a combination of platinum-based adjuvant chemotherapy and immunotherapy i.v.:~carboplatin AUC5 or cisplatin 75 mg/m2~pemetrexed 500 mg/m2~nivolumab 480 mg flat-dose.~Followed by up to 12 cycles (q4w) maintenance immunotherapy:~- nivolumab 480 mg flat-dose i.v."
89658004|NCT04154917|Experimental|Experimental|HOME will be delivered by a community-based OT, who will be involved in the hospital discharge planning, trained by the PI. The HOME intervention comprises 4 phases: Phase 1 (in hospital): The clinician will focus on building a rapport with the patient and family members. Information will be gathered about the participant's home environment and functional ability. Phase 2 (± 5 days prior to expected discharge): Clinician will conduct a pre-discharge home assessment with patient and family to evaluate the environment, identify potential problems, and suggest appropriate ways to address them. Phase 3 (<1 week after discharge): Post-discharge home assessment will be conducted to provide additional in-home training and follow up on any of the patient's unmet needs. Phase 4 (2-4 weeks post-discharge): Follow-up telephone calls will be made to provide ongoing support to participant and family and encourage self-problem solving and independence.
89658005|NCT04154917|No Intervention|Usual care|Usual care group will receive the customary discharge planning assessment by a different clinician (OT). During this assessment, according to usual care, information regarding the participants' ability to perform activities of daily living and regarding their home environment is gathered and used to plan for discharge. Usual care group will not receive an OT home assessment as this is not part of usual care. If the clinician identifies a potential need for assistive equipment and home modification needs, patients will be referred to community-based homecare services as is the current practice, and a home visit may be performed following discharge, typically after an lengthy wait (weeks, months) for service.
89658006|NCT04152109|Other|Without laying on of hands|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or do count math during 5 minutes, around 8 weeks.
89658007|NCT04152109|Sham Comparator|Laying on of hands with healing intent and without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, 8 weeks.
89658008|NCT04152109|Experimental|"Laying on of hands with healing intent and Spiritual connection by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the passistas who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
89658009|NCT04151160||Case Subjects|Infants with hemodynamically significant congenital heart disease.
89658010|NCT04151160||Control Subjects|Healthy infants with no heart disease or non-hemodynamically significant congenital heart disease.
89658011|NCT04151043|Other|Verbal suggestion|
89658012|NCT04151043|Other|No suggestion|
89658013|NCT04131738|Experimental|Baricitinib 2 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice~Baricitinib will be administered PO at a starting dose of 2 mg daily from Day -3 to Day 100~After Day 100, for patients already dose reduced to 2 mg daily, reduce baricitinib to 2 mg every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
89658014|NCT04131738|Experimental|Baricitinib 4 mg Dose Level|"On Day 0 the allograft will be infused per standard institutional practice~Baricitinib will be administered PO at a starting dose of 4 mg daily from Day -3 to Day 100~After Day 100, for patients at a dose of 4 mg daily, reduce baricitinib to 2 mg daily for one month, then every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue."
89658015|NCT04114448|Experimental|Therapeutic exercise|Patients will be trained to perform a therapeutic exercise intervention protocol. The program will be based on active physical activity including strength, balance an coordination exercises, among others. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
89658016|NCT04114448|Active Comparator|Usual care|Patients will be instructed to perform an usual care physical therapy intervention protocol. Participants in this group will be told to undergo gentle self-performed joint mobilization and stretching exercises. Each initial contact session will last approximately 1 hour. After baseline, participants will be instructed to undergo at least two sessions per week during 3 consecutive months.
89658017|NCT04106869|Active Comparator|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
89658018|NCT04106869|Placebo Comparator|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 ( 40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
89658019|NCT04100850|Experimental|Aquatic Exercises|Aquatic Exercises (AE) are water aerobics exercises and resistance exercises, classes will be supervised by a Physical Educator, in collective sessions of up to 30 people per class, twice a week, lasting 50 minutes, for two months.
89658020|NCT04100850|Active Comparator|Watsu|The Watsu (water shiatsu) will be applied by a physical therapist, in individual sessions, twice a week, lasting 50 minutes, for two months in a warn pool (± 34°C). Watsu in particular prescribes transition of movements, once they are instituted, the therapist can create and adapt according to the limitations and restrictions that are encountered.
89658021|NCT04100850|No Intervention|Control|The control group will not receive any of these treatments (aquatic exercises and Watsu).
89658022|NCT04085809|Experimental|Left Leg: AmLactin® Rapid Relief / Right Leg: No Treatment|AmLactin® Rapid Relief, BID application for 14 days on left leg and no treatment on right leg
89658023|NCT04085809|Experimental|Left Leg: No Treatment / Right Leg: AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days on right leg and no treatment on left leg
89658024|NCT04083430|Other|Vaccine|Yellow Fever Vaccine
89658025|NCT04082143|Experimental|Implant with prophylactic allograft|
89658026|NCT04082143|Active Comparator|Implant without prophylactic allograft|
89658027|NCT04078022|Experimental|Cohort 1: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
89658028|NCT04078022|Experimental|Cohort 2: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
89658029|NCT04078022|Experimental|Cohort 3: Shigella Vaccine or Placebo, Followed by Challenge|1:1 randomization to investigational Shigella vaccine or placebo (n=30). The majority of participants will then receive the Shigella challenge (n=22).
89658030|NCT04078022|Experimental|Cohort 4: Shigella Vaccine Only, No Challenge|All volunteers receive the investigational Shigella vaccine (n=12). No Shigella challenge.
89658031|NCT04063579|Experimental|Patients with heart failure with preserved ejection fraction|
89658032|NCT04063579|Experimental|Non-heart failure patients|
89658033|NCT04063579|Experimental|Normal Volunteers|
89658034|NCT04061512|Active Comparator|DRC Arm|The DRC arm (chemotherapy) is the control arm and consists of rituximab, cyclophosphamide and dexamethasone. It is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.
89658035|NCT04061512|Experimental|RI Arm|The RI arm (chemotherapy free) arm will be using the drug ibrutinib, which in combination with rituximab (RI) will be the experimental arm.
89658036|NCT04060823|Experimental|Easy Breathing|Easy Breathing will be implemented in participating clinics. Asthma-related sick visits will be monitored for changes.
89658037|NCT04055493|Experimental|Ribociclib plus ET|Ribociclib 600mg / day over 26 cycles + endocrine treatment of physician´s choice
89658038|NCT04055493|No Intervention|Standard-of-care chemotherapy|Standard-of-care chemotherapy according to the clinical guidelines, e.g., of the Breast Committee of the German Gynecological Oncology Group (AGO), and regional prescribing information depending on patient's needs for 16-24 weeks,
89658039|NCT04055155||Staff/Provider end-users|Testing usability of a technology-enabled behavioral intervention for depression among provider end-users in primary care.
89658040|NCT04055155||Patient participants|Testing acceptability, feasibility, and preliminary effectiveness of a technology-enabled behavioral intervention for depression among patients with depression in primary care.
89658041|NCT04055051||Hemophilia A and B Cases|No intervention. Only patients that have undergone a liver transplant per study eligibility are in this cohort.
89658042|NCT04055051||Hemophilia A and B Controls|No intervention. Comparable patients to those in Case cohort will be put in this cohort.
89658043|NCT04047784|Experimental|Critically Ill Patients|"Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
89658044|NCT04047784|Experimental|Patients undergoing standard of care clinical bronchoscopy|"Patients undergoing clinical bronchoscopy as a part of their standard of care.~The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS."
89658045|NCT04047784|No Intervention|Previously recorded patient media from standard of care clinical bronchoscopy with EBUS|"Patients who underwent a standard of care clinical bronchoscopy with EBUS previously.~Information and media including images and videos that were previously recorded for patients who underwent a standard of care clinical bronchoscopy with EBUS will be available to the study team."
89047017|NCT01215916|Experimental|Experimental: Pemetrexed followed by LY573636|Pemetrexed on Day 1 followed by LY573636 on Day 4
89047018|NCT01215916|Experimental|Experimental: LY573636 followed by Pemetrexed|LY573636 on Day 1, pemetrexed on Day 4
89047019|NCT01215916|Experimental|Experimental: LY573636 and Pemetrexed on Day 1|LY573636 and Pemetrexed on Day 1
89047020|NCT00534521|Active Comparator|Active Treatment Arm|Subjects will have their leg and foot draped to remain blinded to the test. They will be in a supine position with the knees abducted and flexed. The medial aspect of the lower extremity is palpated and a needle insertion site is identified. Between the posterior margin of the tibia and the soleus muscle, an acupuncture-like needle is inserted. An adhesive grounding pad is placed on the bottom of the foot just below the smallest toe. The needle and grounding pad are connected to the stimulator and the stimulation is increased as tolerated.
89047021|NCT00534521|Sham Comparator|Sham Arm|"Since subjects with the PTNS will feel foot stimulation, the sham was devised to mimic this feeling without the tibial nerve being stimulated. Again the leg and foot will be draped and out of view from the subject. The medial aspect of the lower extremity is palpated (Figure 4) and the tibial nerve site is identified approximately 5 cm cephalad from the medial malleolus. A Streitberger needle is used at the tibial nerve insertion site to simulate needle placement without puncturing the skin. The needle will be taped in place as in the PTNS procedure. The grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe."
89047022|NCT04666818||Self Monitoring Blood Glucose (SMBG)|Women used self-monitoring of blood glucose= Control group (CG)
89047023|NCT04666818||Flash Glucose Monitoring (FGM)|Women used flash glucose monitoring= FGM group (FG)
89047024|NCT00534560|Experimental|1|
89047025|NCT00534560|Experimental|2|
89047026|NCT00534560|Placebo Comparator|3|
89213471|NCT01006317|Experimental|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
89213472|NCT01006317|Experimental|Financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
89213473|NCT01006395|Active Comparator|zoledronic acid|intervention
89213474|NCT01006395|Placebo Comparator|Placebo|
89213475|NCT03999801|No Intervention|Main Observational Study|All subjects that previously received RGX-314 in a subretinal administration parent study are enrolled into this arm.
89658046|NCT04041479|Active Comparator|Standard of Care|FDA-cleared, standard-of-care iTBS repetitive Transcranial Magnetic Stimulation targeting the left dorsolateral prefrontal cortex (DLPFC), regardless of the depression subtype (biotype) determined by a magnetic resonance imaging (MRI) scan.
89658047|NCT04041479|Experimental|Targeted Side Arm|iTBS rTMS targeting the area of the brain (DLPFC or dorsomedial prefrontal cortex DMPFC)) that we hypothesize will be most effective for that subject's biotype (confirmation arm).
89213476|NCT03999801|Experimental|RGX-314 Fellow Eye Treatment Substudy|RGX-314 Fellow Eye Treatment
89213477|NCT05732805|Experimental|BCD-217 (nurulimab + prolgolimab)|BCD-217 followed by prolgolimab 1 mg/kg monotherapy.
89658048|NCT04041479|Active Comparator|Opposite Side Arm|iTBS rTMS targeting the opposite site (DLPFC or DMPFC) than the one we hypothesize will be most effective for that subject's biotype (disconfirmation arm).
89658049|NCT04172974|Experimental|Treatment for depression and anxiety|Treatment
89658050|NCT04172974|Other|Usual care|Usual Care
89658051|NCT04040062|Experimental|SCC|Subjects will be treated according to their frequency response pattern which may show one or more distinct frequencies of stimulation that generated increased SCC
89658052|NCT04033809|Active Comparator|Multigrain powder (S)|Oral high fiber multigrain supplements
89658053|NCT04033809|No Intervention|Standard care (C)|Standard care without oral high fiber multigrain supplements
89658054|NCT04031339||Patients diagnosed with thyroid cancer|Patients with histologically-confirmed diagnoses of papillary, follicular, Hürthle, poorly differentiated, anaplastic, or medullary thyroid cancer
89213478|NCT05732805|Active Comparator|BCD-100 (prolgolimab)|Prolgolimab monotherapy.
89213479|NCT00615056|Active Comparator|B|Bevacizumab (avastin)
89213480|NCT00615056|Experimental|C|AG-013736 (axitinib)
89213481|NCT00615056|Experimental|A|AG-013736 (axitinib)
89213482|NCT00615056|Active Comparator|D|bevacizumab (avastin)
89213483|NCT01003431|Experimental|1|RotaTeq™ + DTwP
89213484|NCT01003431|Active Comparator|2|Rotarix™ + DTwP
89213485|NCT01003431|Active Comparator|3|RotaTeq™ + DTaP
89213486|NCT01006473|Experimental|Exercise training group|Exercise training is performed in subgroups of 6 patients supervised by two physiotherapists. Exercise prescription consisted of a 15-min warm-up, walking up to 30 min, followed by a 15-min cooling-down. The exercise intensity during the first 2 weeks corresponds to 55% at 65% of the HR peak reached at the baseline exercise test. In posterior sessions, individual adjustments are performed with gradual increases in order to reach the adequate target HR training intensity, as determined by the Karvonen formula {(maximal HR - HR at rest) x 50 to 70% + HR at rest}. Exercise training is performed in the morning, three times a week (on alternate days) for a total of 12 weeks (36 sessions).
89213487|NCT01006473|No Intervention|Inactive control group|No intervention
89213488|NCT01006551|Experimental|Ziprasidone|
89213489|NCT00873626|Active Comparator|1|fluoroquinolones 5 days
89658055|NCT04019548|Experimental|Prophylactic PEG|Prophylactic PEG tube will be placed before the start of the study treatment (CRT). The enteral nutrition will start following the assessment by the clinical dietitian in order to complete the current oral consumption according to the estimated energy needs (on the basis of 30 to 35 kcal / kg adapted and 1.2 to 1.5 g / prot./ kg.BW) with an increase as needed during the treatment.
89658056|NCT04019548|Experimental|Reactive PEG|Reactive PEG tube will be placed and enteral nutrition initiated, during the study treatment period in case of decrease of oral intake less than 2/3 of estimated energy requirements (based on 30-35 kcal / adapted kg .BW and 1.2 - 1.5 g/prot./adapted kg. BW) for a period of or anticipated to be, greater than 7 days or weight loss ≥ 5% from pre-treatment baseline).
89658057|NCT04006925|Active Comparator|Sodium Oxybate (SXB) arm|Sodium Oxybate (SXB) will be dispensed to the participants.
89658058|NCT04006925|Placebo Comparator|Placebo (PBO) arm|Placebo will be dispensed to the participants.
89658059|NCT04004104|Active Comparator|Control - Upright Exercise|Participants will perform upright exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
89658060|NCT04004104|Experimental|Intervention - Supine Exercise|Participants will perform supine exercise on a cycle ergometer. The opposite test will be completed within 4 weeks.
89658061|NCT04002271|Active Comparator|Group SA|Patients in Group SA will undergo spinal anaesthesia.
89658062|NCT04002271|Active Comparator|Group GAS|Patients in Group GAS will undergo general inhalational anaesthesia using sevoflurane.
89658063|NCT04002271|Experimental|Group TIVA|Patients in Group TIVA will undergo general anaesthesia using propofol total intravenous anaesthesia.
89658064|NCT03995186|Experimental|Behavioural activation group|
89658065|NCT03995186|Active Comparator|Activity monitoring group|
89658066|NCT03995186|No Intervention|Waiting list control group|
89658067|NCT03986190|Experimental|Healthy Juntos Intervention Condition|Parent-adolescent dyads randomized to the Healthy Juntos intervention condition will access a program that includes didactic, behavioral, and positive parenting content from their smartphones for 8 weeks.
89658068|NCT03986190|No Intervention|Control Group|This group will receive a digital standard of care - a list of publicly available lifestyle apps and websites which they may access at their discretion.
89658069|NCT03985917|Experimental|Intervention Singing Group Program|Singing group intervention program that includes six components: (1) vocal warm-up exercises; (2) vocal technique; (3) rehearsal of repertoire; (4) break for socialization; (5) creation and presentation of a show; (6) assessment of participants performance (vocal tuning).
89213490|NCT00873626|Active Comparator|2|fluoroquinolones 10 days
89658070|NCT03985917|Active Comparator|Alternative Social and Leisure Activities|While the experimental group is participating in the intervention program, the control group will participate in the other activities proposed by the day care centers, which will be registered.
89658071|NCT03972592|Experimental|Topical sirolimus|The experimental group will consist in one area of the CMLM (almost half of it) that will receive 0.1% sirolimus preparation. This product will be applied 1/day on the randomly allocated area, by a nurse at home, during 12 weeks.
89658072|NCT03972592|Placebo Comparator|Vehicle|The control group will consist in the other half area of the CMLM, that will receive the same vehicle than the one used in the topical 0.1% sirolimus preparation. It will be applied 1/day in the corresponding area by a nurse, at home, during 12 weeks.
89658073|NCT03959462|Experimental|Real tDCS|20 min of 1 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
89658074|NCT03959462|Sham Comparator|Sham tDCS|30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the decision task.
89658075|NCT03937297|Experimental|Arm 1|Six Arts intervention
89658076|NCT03937297|Experimental|Arm 2|Cognitive Stimulation Therapy (CST)
88994343|NCT05318677||2|"20 healthy subjects as a control group aged 8-12 years living in Denizli province were included in the study. The participants were informed about the research and read the voluntary consent form, and written consent was obtained from their families since the participants were children.~Children with literate, well cooperated, aged 8-12 years, and attending any primary school were included in the study. Children who had a second illness and could not be contacted were not included in the study. Non-dominant and dominant extremities of all cases were evaluated by the tests. It was recorded socio-demographic data were questioned. Sensory evaluation forms for upper extremities, Bruininks-Oseretsky motor proficiency, and ability tests were administered by a physiotherapist."
89658077|NCT03937297|Active Comparator|Arm 3|Usual care (control group)
89658078|NCT03932786||Retrospective(biospecimens, vision assessment, questionnaires)|
88994344|NCT02276989|Experimental|Compliance Intervention|Subjects will receive acetazolamide, quinine and riboflavin as experimental compliance markers and will serve as their own controls.
89658079|NCT03932786||Prospective (biospecimens, vision assessment, questionnaires)|
89658080|NCT03929146|Experimental|Liposomal Bupivacaine|Patients in this group will receive a single intra-operative injection of liposomal bupivacaine near the surgical site (40 ml total: consisting of 20 ml 1.3% liposomal bupivacaine and 20 ml normal saline).
89658081|NCT03929146|Other|Interscalene Nerve Block|Patients in this group will receive a single pre-operative interscalene nerve block in the neck/shoulder consisting of 30 ml 0.5% ropivacaine.
88994345|NCT02941978|Experimental|Subject on Motivational Interview|"Motivational Interview - Baseline: At hospital discharge, patients assigned to the intervention group will be contacted in person by a study physician for an interactive session and will be given an educational leaflet. Both methods will aim to educate them about the risk for stroke and the importance of adherence to OAC medication. The leaflet will also provide some basic information on how to take OAC medication (doses, food interactions, skipping doses, etc.) and will describe the main clinical manifestations of side effects.~Motivational Interview - Follow-up: Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview at 1 week, 2 months, 6 months and 1 year after discharge. The delegated study personnel will assess whether an intervention is required and provide specific support tailored to the needs of the patient, aiming to improve adherence to OAC."
89658082|NCT03928704|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
89658083|NCT03928704|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
89658084|NCT03928457|Experimental|preterm neonate|
89658085|NCT03905239|Experimental|algorithm arm|Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.
89658086|NCT03905239|No Intervention|no algorithm arm|Patient management is based on clinical examination. Conservative management will be continued for 48 hours in the absence of signs of bowel ischemia (clinical and laboratory assessment other than procalcitonin, as procalcitonin will not be assayed in this arm). Gastrografin will not be used in this arm. Operative management (adhesiolysis or bowel resection) will be performed 48 hours after initiation of conservative management or in the case of absence of bowel function.
88994346|NCT02941978|Active Comparator|Subject Control|Patients assigned to the control group will receive usual treatment and will be contacted via telephone for a pre-specified interview at 1 year after discharge for outcome assessment.
88994347|NCT02941042|Experimental|NNC9204-1177|
88994348|NCT02941042|Placebo Comparator|Placebo|
88994349|NCT02941120||NOVOCART® Inject patients|Patients who where treated with NOVOCART® Inject autologous chondrocyte implantation in the knee joint.
88994350|NCT02963727|Experimental|Wharton Jelly mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose
89688622|NCT02677870|Other|Diet treatment|In part 1 of the study, patients will not receive any medication. Each patient will DIET treatment alone. They will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week. Based on these diaries, average weekly Phe intake and Phe tolerance will be calculated and recorded.
88994351|NCT02277067|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
89047027|NCT01184872|Experimental|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
89047028|NCT01184872|Active Comparator|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
89047029|NCT04666779||No access|Group not accessing chiropractic care
89047030|NCT04666779||Access to care|Group with access to care in a 6 months period. Differences in the degree of access, measured in ranges of numbers of visits, will be used as independent variable within this group.
89047031|NCT02887924|Active Comparator|group 1|SLI group In this group the preterm infants will receive sustained lung inflation (SLI) via short binasal prongs in the delivery room.
89047032|NCT02887924|Placebo Comparator|group 2|Preterm infants will be assisted in the delivery room without sustained lung inflation.
89658087|NCT03901924|Active Comparator|Volume Support Mode Mechanical Ventilation|Volume support mode ventilation is a spontaneous mode where a target goal volume is set on the ventilator. This ventilatory strategy is dependent on patients spontaneously breathing and triggering (or activating) the ventilator to support the breath. The ventilator adjusts the amount of pressure support to deliver with each breath (i.e. if the patient's tidal volume is greater than the set target volume, then the ventilator will decrease the amount of pressure support in the subsequent breath to try to achieve the goal volume and vice versa). The respiratory rate is not set in this mode of ventilation and is dependent on the patient. For patients randomized to this mode, the goal tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
89658088|NCT03901924|Active Comparator|Assist Control Mode Mechanical Ventilation|In assist control mode ventilation, the machine is programmed to deliver a set tidal volume and set respiratory rate. Patients can breathe over the set respiratory rate, but the volume of breath that they receive is fixed and delivered by the ventilator. For patients randomized to this mode, the tidal volume will be set at 6 cc/kg of ideal body weight (IBW).
89658089|NCT03901235|Experimental|Mesenchymal Stromal Cells|
89658090|NCT03898570||Patients undergoing vascular surgery procedures|Patients will report outcomes via their smartphone.
89658091|NCT03882320|Experimental|Sublingual Patient Controlled Analgesia (PCA)|Sufentanil Sublingual Patient Controlled Analgesia (PCA)
89658092|NCT03882320|Active Comparator|Intravenous Patient Controlled Analgesia (PCA)|Oxycodone Intravenous Patient Controlled Analgesia (PCA)
89658093|NCT03881150|Experimental|Hybrid Cardiac Rehabilitation|"This intervention is adapted from the Cardiac Rehabilitation Delivery Model for Low-Resource Settings proposed by the International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement. This program will be delivered by an exercise specialist (physiotherapist) and the principal purposes of the exercise sessions is to develop patient self-management related to the physical activity habit, and educate them how to monitor exercise intensity at home and in daily life. The program include 10 face-to-face exercise sessions and a transition to unsupervised phase using mobile technology.~Counseling is considered about physical activity, diet, smoking, and medication compliance."
89658094|NCT03881150|Active Comparator|Standard Cardiac Rehabilitation|The participants in the control group will receive the standard cardiac rehabilitation that is delivered in participating centers. These programs accounts with physicians, nurses, nutritionists and physiotherapists. The programs will be standardized in participating centers in accordance with currents guidelines (only 18-22 face-to-face exercise sessions). Differentially, this programs provide, group education sessions about physical activity, diet, smoking, and medication compliance (without counseling).
89658095|NCT03875872||Group propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
89658096|NCT03875872||Group inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
89658097|NCT03869567|Experimental|Cone beam CT|A cone beam CT wll be performed just after thrombectomy on patients with acute ischemic stroke
89658098|NCT03860376||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
89047033|NCT01215721|Experimental|Vesicare|Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
89658099|NCT03859908|Experimental|Iodine-Povacrylex Alcohol|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control
89658100|NCT03859908|Active Comparator|Chlorhexidine Alcohol|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control
89057977|NCT02216474|Sham Comparator|Sham transcranial direct current stimulation (frontal cortex)|Transcranial direct current stimulation will be ramped up over 60 seconds and then ramped down gradually to encourage blinding to condition.
89658101|NCT03840356||Postoperative|The study will evaluate orthopedic postoperative patients during the hospitalization.
89658102|NCT03833544|Experimental|Treatment Arm|Exercise training: Progressive resistance training of hip, knee, and ankle flexors.
89658103|NCT03810079|Active Comparator|Anodal tDCS High Vigilance|Patients will undergo continuous 20 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined high level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
89658104|NCT03810079|Active Comparator|Anodal tDCS Low Vigilance|Patients will undergo continuous 20 channels EEG and receive anodal tDCS (bilateral prefrontal stimulation) at a pre-determined low level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
89658105|NCT03810079|Sham Comparator|Anodal tDCS Random Vigilance|Patients will undergo continuous 20 channels EEG and receive tDCS (bilateral prefrontal stimulation) at a random level of EEG-derived spectral entropy during 20 minutes followed by a clinical assessment (Coma Recovery Scale-Revised)
89047034|NCT02886910|Experimental|Clinical observation|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. They will receive a limited evaluation (blood culture, complete blood count), and a clinical observation. Antibiotics will be started only if sepsis-related signs or symptoms are present.
89047035|NCT02886910|Active Comparator|Standard management|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. The will receive a limited evaluation (blood culture, complete blood count), a clinical observation and antibiotics at birth.
89047036|NCT02887027|Experimental|Exercise Group 1|Participants assigned to this group will complete a baseline period of 8 days and an Exercise4Mood Intervention period of 21 days.
89047037|NCT02887027|Experimental|Exercise Group 2|Participants assigned to this group will complete a baseline period of 11 days and an Exercise4Mood Intervention period of 18 days.
89047038|NCT02887027|Experimental|Exercise Group 3|Participants assigned to this group will complete a baseline period of 15 days and an Exercise4Mood Intervention period of 14 days.
89658106|NCT03797196|Active Comparator|group 1|standard tacrolimus with mycophenolate mofetil
89658107|NCT03797196|Experimental|group 2|low dose tacrolimus with everolimus
89658108|NCT03794739||Healthy subjects|"Healthy subjects without diabetes, no recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
89658109|NCT03794739||T1D individuals|"Type 1 diabetic individuals with at least 3-year of duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
89658110|NCT03794739||T2D individuals|"Type 2 diabetic individuals with at least 5-year duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
89658111|NCT03794739||AutoAb+ individuals|"Individuals at risk for type 1 diabetes, with one or more autoantibody detected. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
89658112|NCT03790956|Experimental|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
89658113|NCT04197765|Sham Comparator|Sham|All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
89658114|NCT04197765|Active Comparator|Active acTBS|"For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays."
89658115|NCT03790631||imipenem TDM|Adult patients receiving imipenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
89658116|NCT03790631||meropenem TDM|Adult patients receiving meropenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
89658117|NCT03790631||piperacillin TDM|Adult patients receiving piperacillin (with or without tazobactam) for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
89658118|NCT03790631||flucloxacillin TDM|Adult patients receiving flucloxacillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
89658119|NCT03790631||amoxicillin TDM|Adult patients receiving amoxicillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
89658120|NCT03790631||ceftazidime TDM|Adult patients receiving ceftazidime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
89658121|NCT03790631||cefepime TDM|Adult patients receiving cefepime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
89658122|NCT03775382|Placebo Comparator|Placebo|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
89658123|NCT03775382|Active Comparator|Ascorbic Acid|"Ascorbic acid will be measured into sterile syringes by the research nurse and infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline or lactated ringers followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
89658124|NCT03772431|Experimental|Male Informational|Male voice, informational introduction
89658125|NCT03772431|Experimental|Male Motivational|Male voice, motivational introduction
89658126|NCT03772431|Experimental|Female Informational|Female voice, informational introduction
89658127|NCT03772431|Experimental|Female Motivational|Female voice, motivational introduction
89658128|NCT03758573|Experimental|Inspiratory Muscle Training (IMT)|IMT by means of the Powerbreath equipment (Classic, London, UK), according to the following parameters: initial loading of 40% of MIP, 3 sets of 10 repetitions with interval of 1 minute between each sets, 7 days a week, 2 times a day , with the patients in the bed with the angulation of 45 °. The IMT load settings will be adjusted according to the values evaluated weekly. If there is need for addition of supplemental oxygen will be performed to perform the IMT.
89047039|NCT04113239||Diagnosed Type 2 Diabetes Mellitus|Patients with incident type 2 diabetes mellitus
89658129|NCT03758573|Active Comparator|Intensive Physiotherapy (IPT)|IPT will be to individualized and supervised intervention program consisting of any of the following procedures: passive, assisted, active or resisted mobilization, sedation and orthostasis depending on the functional level of the patient, as well as bronchial hygiene therapy and pulmonary expansion therapy.
89658130|NCT03754270|Active Comparator|Lifestyle advice|Patients receive instructions and advice on lifestyle according to current clinical practice.
89658131|NCT03754270|Experimental|Lifestyle advice and cervical collar|"Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it."
89658132|NCT03749863|Experimental|Serial PRP injections|This arm will receive experimental intervention of serial monthly platelet-rich plasma (PRP) injections to a unilateral vocal fold mucosa for a total of 4 injections.
89658133|NCT03749278|Experimental|ALMA Intervention Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention after baseline assessment.
89658134|NCT03749278|Active Comparator|ALMA Delayed Intervention Control Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention six months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
89658135|NCT03747432|Experimental|Propofol|Procedural sedation with propofol during the TAVR procedure (anticipated around 2 hours), dosage: 0,5-2,5 mg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
89658136|NCT03747432|Experimental|Dexmedetomidine|Procedural sedation with dexmedetomidine during the TAVR procedure (anticipated around 2 hours), dosage: bolus of 0,5 mcg/kg during 10 minutes, then continuous infusion of 0,2-1 mcg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
89658137|NCT03743792|Experimental|Active|Freeze-dried red raspberry powder (25 g) in active breakfast meal
89658138|NCT03743792|Placebo Comparator|Placebo|Placebo breakfast
89658139|NCT03732144|Experimental|Connect Staff-based PA intervention|Sites receiving the Connect physical activity intervention will involve three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum.
89658140|NCT03732144|Other|Connect Health Curriculum Control|Sites receiving the general health curriculum control will also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff.
89658141|NCT03726151|No Intervention|Usual Care|
89658142|NCT03726151|Experimental|Parent Reminders|
89658143|NCT03726151|Experimental|Multicomponent clinic-system strategies|
89658144|NCT03726151|Experimental|Combined Condition|
89658145|NCT03726047|No Intervention|Control|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately after and 24 hours later (without visual feedback).
89658146|NCT03726047|Experimental|Exercise|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately without visual feedback. This will be followed immediately by 5 minutes of high intensity exercise. Retention without visual feedback will them be tested again 24 hours later.
89658147|NCT03724019|Experimental|Group Q|20 milliliter of ketamine (0.5mg / kg ideal body weight) at induction of anesthesia.
89658148|NCT03724019|No Intervention|Group S|
89658149|NCT03697512|Experimental|Ibrutinib and Rituximab|"Induction PART A, from Day 1 to Day 56.~Patients will be treated with:~Ibrutinib 560 mg/day continuously up to Day 56;~Rituximab 375 mg/m2 intravenously at Day 1, and then subcutaneous (1400 mg, flat dose) at Day 8, 15 and 22 of cycle 1.~Induction PART B, from Day 57 to Day 196.~Patients will be treated with:~Ibrutinib 560 mg/day continuously up to Day 196;~Rituximab subcutaneous (1400 mg, flat dose) at Day 1 every 28 days for 4 cycles.~Maintenance PART C, from Day 197 to Day 730.~Patients will be treated with:~- Ibrutinib 560 mg/day continuously up to Day 730."
89658150|NCT03695900|Other|Targeting SpO2 at 93-95% followed by targeting at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
89658151|NCT03695900|Other|Targeting SpO2 at 90-92% followed by targeting at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours.
89047040|NCT04113239||Control|Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria
89658152|NCT03688061|Experimental|Group 1 (low dose/healthy volunteers)|5 healthy volunteers receiving 1 dose ChAd3-hliNSmut (5x10*9 vp) IM at week 0 and 1 dose of MVA-hliNSmut (5 X10*7 pfu) IM at week 8
89658153|NCT03688061|Experimental|Group 2 (higher dose/healthy volunteers)|10 healthy volunteers receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X 10*8 pfu) IM at week 8
89658154|NCT03688061|Experimental|Group 3 (higher dose/HCV cured volunteers)|10 DAA treated volunteers (previously HCV positive) receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X10*8 pfu) IM at week 8
89658155|NCT03683550|Experimental|SPEC/CT|SLNE with preoperative hybrid SPECT/CT
89047041|NCT04666506||VR as distraction during a medical procedure|Paediatric outpatients undergoing a medical procedure, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a distraction method during a potentially painful or scary procedure (e.g., vaccination, wound care, venipuncture,...).
89047042|NCT04666506||VR as relaxation method during a hospital stay|Paediatric inpatients, aged 4-16 years old in Belgian hospitals UZ Brussel and AZ Sint-Maarten, will use VR as a relaxation method during a potentially stressful hospital stay (e.g., patients with psychosomatic complaints, patients with eating disorders,...).
89047043|NCT04072211|Other|Vaccine arm|Engerix-B vaccine will be administered. This arm will include all those at risk of hepatitis B virus infection
89047044|NCT00534677|Active Comparator|A|
89658156|NCT03683550|Active Comparator|Standard|Standard SLNE (with planar preoperative lymphoscintigraphy)
89658157|NCT03675503|No Intervention|Control|No change in the standard of care.
89658158|NCT03675503|Experimental|Fall Prevention Decision Support|"Nursing assesses patient using the Assistive Device Checklist and provides assistive devices to patients, if appropriate.~Decision support aimed at preventing hospital falls and empowering nurses."
89658159|NCT03667651|Active Comparator|Twice daily use treatment with EpiCeram|They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.
89658160|NCT03667651|No Intervention|Standard skin care|Parents are to follow standard skin care practices
89658161|NCT03660618|Other|Clinic Subjects|cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.
89658162|NCT03649698|Experimental|Home-based training program|Home-based training program + protein placebo + omega-3 placebo
89658163|NCT03649698|Experimental|High-quality protein supplement|High-quality protein supplement + omega-3 placebo
89658164|NCT03649698|Experimental|2 Anabolic interventions|Home-based training program and high quality protein supplement
89658165|NCT03649698|Experimental|3 Anabolic interventions|Home-based training program, high-quality protein supplement and omega-3 fatty acids
89658166|NCT03649698|Placebo Comparator|Placebo protein powder and omega-3|Control group: protein placebo + omega-3 placebo
89658167|NCT03649633|Experimental|Steroids/Vitamin C group|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
89658168|NCT03649633|Placebo Comparator|Control group|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
89658169|NCT03629730|Experimental|High dose|Will receive the greatest duration of coordination intervention training.
89658170|NCT03629730|Experimental|Intermediate dose|Will receive a moderate duration of coordination intervention training.
89658171|NCT03629730|Experimental|Low dose|Will receive a short duration of coordination intervention training.
89658172|NCT03629730|Active Comparator|Active control|Will perform the same number and duration of physical exercises as the High Dose group, but while moving one body segment at a time.
89658173|NCT03621280|Experimental|Levoketoconazole|Levoketoconazole taken twice daily up to 1200 mg daily
89658174|NCT03620903|Experimental|Bortezomib-Rituximab-Ibrutinib|"Cycle 1:~Rituximab: 375 mg/m2 intravenously (i.v) day 1; Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15; Ibrutinib: 420 mg orally (p.o.) day 1-28;~Cycle 2-6 Rituximab: 1400 mg absolute SC day 1; Bortezomib:1.6 mg/ m2 SC day 1,8,15; Ibrutinib: 420 mg p.o. day 1-28;~Maintenance I (1 cycle = 56 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years); Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30);~Maintenance II (1 cycle = 84 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years);"
89658175|NCT03616990|Active Comparator|Usual Care (Control)|"Usual care. These individuals will receive linkages to community-based services only. These linkages will be made while in the Discharge Area of the Cook County Jail. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.~Receives: TASC Service Linkages - Discharge Area Only"
89658176|NCT03616990|Experimental|Supportive Release Center (Treatment)|"These individuals will receive SRC services: an overnight stay at the SRC, linkages to community-based services made at the SRC or in the discharge area of the CCJ if they choose not to visit the SRC facility, and access to an Advanced Practice Nurse. Individuals randomized on days Heartland Alliance Health recruits at SRC for non-SRC study are excluded from population.~Receives: TASC Service Linkages - Discharge Area Only -OR- SRC Overnight Stay, TASC Services Linkages - SRC Onsite, APN Appointment"
89658177|NCT03597061|Experimental|Healthy Start to Feeding Intervention|Participants and their parents will participate in a 3 session intervention targeting healthy introduction of complementary foods. Intervention sessions will occur when the infant is 4, 6, and 9 months of age.
89658178|NCT03597061|No Intervention|Control|Participants and their parents will complete pre- and post-treatment period study visits to assess study outcomes. They will receive no intervention.
89658179|NCT03588182|Experimental|Group VR|Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 - 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
89658180|NCT03588182|No Intervention|Group No VR|No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 - 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient - for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.
89658181|NCT03579498||Patient group|Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.
89658182|NCT03579498||Control group|The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.
89658183|NCT03555721||Oral examination followed by biopsy, CytID, and hpvID|Identification of oral lesions with oral examination with both incandescent light and fluorescent light (OralID), and subsequent testing of suspicious oral lesions with biopsy, CytID, and hpvID
89047045|NCT00534677|Active Comparator|B|
89658184|NCT03538405|Experimental|all participants|All participants received the same interventions, there were no subgroups interventions: supporting cushions and harmonic techniques
89047046|NCT00556764|Experimental|2 cohorts|"In this observational study 2 cohorts will participate. Cohort 1 will include people with Parkinson disease and Cohort 2 will include healthy volunteers.~A subset of twelve subjects (8 PD and 4 HC) will be enrolled in the [123I] IBVM and SPECT imaging portion of this study"
89047047|NCT00556803|Experimental|1|TACE after RFA within one month as an adjuvant therapy
89047048|NCT00556803|Active Comparator|2|RFA alone
89047049|NCT04018235||localized disease or locally advanced disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy"
89047050|NCT04018235||metastatic disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
89047051|NCT04018235||follow up disease|"Subgroups:~A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery"
89047052|NCT00556959|Experimental|1|CLONICEL High Dose
89047053|NCT00556959|Experimental|2|CLONICEL Low Dose
89047054|NCT00556959|Placebo Comparator|3|Placebo
89658185|NCT03510169|Experimental|NeoVest|Negative pressure ventilation using NeoVest
89658186|NCT03506282|No Intervention|No music|The participants will be required to run on a treadmill at 3 different speeds (6-8-10 km/h) with no music.
89658187|NCT03506282|Active Comparator|Traffic audio track|In addition to running on the treadmill, participants will be listening to an audio track resembling normal outdoor noise (70 dB) through earphones connected to a mobile phone.
89658188|NCT03506282|Experimental|Music at moderate volume|In addition to running on the treadmill, participants will be listening to music at a moderate volume (80 dB) through earphones connected to a mobile phone.
89658189|NCT03506282|Experimental|Music at moderate-to-high volume|In addition to running on the treadmill, participants will be listening to music at a moderate-to-high volume (85 dB) through earphones connected to a mobile phone.
89658190|NCT03504254||CSM|A total of 50 CM patients requiring surgical decompression will be recruited. The inclusion criteria are a clinical diagnosis of CM including the signs of corticospinal lesions together with the appropriate radiographic findings. Patients with acute spinal cord injuries, prior spinal intervention or claustrophobia will be excluded.
89658191|NCT03499756|Experimental|Couple-based interpersonal psychotherapy|The intervention consists of three weekly 2-hour antenatal sessions and two 30-minute telephone follow-up sessions delivered within four weeks postpartum.
89658192|NCT03499756|No Intervention|Control|The control group will receive the standard prenatal and postnatal care.
89658193|NCT03494959|Experimental|Treatment with Pentaglobin|Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days.
89658194|NCT03486860|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
89658195|NCT03486860|Other|Waitlist Control|Untreated comparison group during the study, received parent psychoeducation intervention after the active treatment group.
89658196|NCT03474471|Experimental|Group 1:PR-EBV treatment|Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment
89658197|NCT03474471|Experimental|Group 2: EBV treatment-PR|Follow a Pulmonary rehabilitation program AFTER the EBV treatment
89658198|NCT03474471|Active Comparator|Group 3: EBV treatment|Only EBV treatment
89658199|NCT03471117|Active Comparator|Pioglitazone|The subjects will be given 1 month supply of Pioglitazone pills. Pioglitazone is a class of anti-diabetic drugs called thiazolidinediones that are primarily used in the treatment of type 2 diabetes. The aim of the study is to determine if Pioglitazone also reduces ADMA and sympathetic nerve activity in CKD patients. This drug will be taken orally as a pill or capsule for one month. The dosage is 15 mg/day. This is on the lower dosage side for pioglitazone with the maximum dosage being 45mg/day. The research subjects are not responsible for the cost of the drug or for drug administration costs. The subjects will be verbally instructed to take 1 pill everyday by mouth, for 1 month. In addition, the pill bottle will be labeled with the same instructions.
89047055|NCT04008641||Parents after pediatric antenatal consultation|Survey after pediatric antenatal consultation, for both members of couple if possible
89047056|NCT00557037|Experimental|A|Patients with chemotherapy naïve androgen independent disease
89047057|NCT00557037|Experimental|B|Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent
89047058|NCT01184326|Experimental|Dose Level 0: Everolimus 5mg + Pazopanib 600 mg|Everolimus 5mg + Pazopanib 600 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
89047059|NCT01184326|Experimental|Dose Level -1: Everolimus 5mg + Pazopanib 400 mg|Everolimus 5mg + Pazopanib 400 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
89047060|NCT01184326|Experimental|All Phase I Dose Expansion Participants|All phase I dose expansion participants received Everolimus 5mg and Pazopanib at the maximum tolerated dose established in the dose finding part of the study.
89047061|NCT01184326|Experimental|All Phase I Participants|All phase I participants received Everolimus 5mg and Pazopanib according to the established dose escalation schedule or the maximum tolerated dose established in the dose finding part of the study.
89057978|NCT02216474|Experimental|Anodal transcranial DC stimulation (frontal cortex)|Anodal transcranial direct current stimulation to prefrontal cortex for approximately 15 minutes plus ramp up and down time
89057979|NCT02216513|Active Comparator|Desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days
89057980|NCT02216513|Placebo Comparator|placebo|normal saline IV for 4 hours for 5 consecutive days
89047062|NCT01215253|Active Comparator|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
89658200|NCT03471117|Placebo Comparator|Placebo|Placebo pills are made of avicel microcrystalline cellulose and magnesium stearate, which are inactive ingredients in the Pioglitazone pills. The placebo pills will be of similar color and appearance as the Pioglitazone pills
89658201|NCT03446326|Experimental|Stroke volume and cardiac output|"Pacing runs will occur at the following rates:~50 beats per minute (bpm)~60 bpm~70 bpm~80 bpm~90 bpm~100 bpm~110 bpm~120 bpm~130 bpm~The finger blood pressure cuff will be calibrated between pacing runs.~Following the final pacing run while supine, the patient will be given 10 minutes to rest prior to the upright portion of the study. They will then be strapped into the table (so they will not fall) and then they will be tilted up to >70 degrees (almost standing up). They will stand for ~10 minutes prior to commencing the next pacing trains."
89658202|NCT03438474|Active Comparator|Arm A standard surgical procedure|"Standard surgical procedure for endometrial cancer:~total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)"
89658203|NCT03438474|Experimental|Arm B systematic lymphadenectomy (LNE)|"In addition to standard procedures as defined for Arm A:~systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels"
89658204|NCT03436875||Healthy|Healthy people either with (FH+) or without (FH-) a family history of diabetes or Alzheimer's Disease.
89658205|NCT03436875||unhealthy|People type 2 diabetes or Alzheimer's Disease that have either: a family history of that disease (FH+) or no family history of T2D or Alzheimer's for two generations (FH-).
89658206|NCT03435939|Experimental|losartan|a daily dose of 50 mg losartan for 7 days (for tolerability). Then, the losartan dose will be increased to 100 mg daily for 12 weeks.
89658207|NCT03429868|Experimental|integrated PET/MRI|The participants receive an integrated 18F-FDG PET/MRI during tumor staging.
89658208|NCT03428737|Other|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
89658209|NCT03428737|Other|Nocturnal pressure support ventilation|Use of a pressure support level identical during the night to the pressure support level at the end of the day.
89658210|NCT03422393|Experimental|venetoclax with high-dose ibrutinib|venetoclax with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent ibrutinib.
89658211|NCT03377543|Experimental|Control Sleep/Non-Active Placebo or 81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
89658212|NCT03377543|Experimental|Sleep Restriction/81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
89658213|NCT03377543|Experimental|Sleep Restriction/Non-Active Placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
89658214|NCT03369600|Experimental|Healthy Controls|Women Supersonic Imagine Aixplorer SWE Ultrasound Imaging on two separate occasions.
89658215|NCT03369600|Experimental|FIB-Sx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to elective hysterectomy for treatment of symptomatic uterine fibroids.
89658216|NCT03369600|Experimental|FIB-Mx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to and at two points during elective medical therapy for treatment of symptomatic uterine fibroids.
89658217|NCT03366831|Active Comparator|15 minute version without questions|15 minute version of the TMW-Newborn intervention video without questions interspersed
89658218|NCT03366831|Active Comparator|15 minute version with questions|15 minute version of the TMW-Newborn intervention video with questions interspersed
89658219|NCT03366831|Active Comparator|7 minute version without questions|7 minute version of the TMW-Newborn intervention video without questions interspersed
89658220|NCT03366831|Active Comparator|7 minute version with questions|7 minute version of the TMW-Newborn intervention video with questions interspersed.
89658221|NCT03365908|Experimental|Adductor Canal Nerve Block|Participant will receive an adductor canal nerve block via 15 mL 0.5% ropivacaine injection prior to OR for ACL reconstruction. Participant will receive pre-op oral medications.
89658222|NCT03365908|No Intervention|No Nerve Block|Participant will receive pre-op oral medications but no nerve block prior to OR for ACL reconstruction.
89047063|NCT01215253|Placebo Comparator|Placebo|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
89047064|NCT03898115|Experimental|CHG Bathing Implementation|In a step-wedged design, ICUs and BMT units will be enrolled into a educational program to improve knowledge/compliance with daily CHG bathing
89658223|NCT03362047|Experimental|Riciguat Group|15 PAH patients will be administered Riciguat according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
89658224|NCT03362047|Experimental|Macitentan Group|15 PAH patients will be administered Macitentan according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
89047065|NCT03898115|No Intervention|Control|In a step-wedged design, ICUs and BMT units will be enrolled over a rolling 4 month time frame; when not enrolled, this data will serve as control data
89658225|NCT03360591|Experimental|Physiologically-guided strategy|"Patients randomized in this group will undergo stenting of coronary lesions showing FFR values ≤0.80 only.~Lesions showing positive FFR measurements (<0.80) must be treated with PCI, before or after TAVI.~Lesions showing clearly negative values (FFR >0.80) will not be treated with PCI before TAVI, and repeated FFR and iFR measurements after TAVI are strongly recommended.~Lesions showing borderline FFR measurements before TAVI (FFR 0.80-0.83), should be measured again (both FFR and iFR) after TAVI, and the decision of treating of deferring treatment in a given lesion will be based on the FFR value obtained after TAVI.~In all cases iFR values will be recorded for a post hoc analysis and for validation of the study endpoints according to iFR values."
89658226|NCT03360591|Other|Angiographically-guided strategy|Patients allocated in this group will undergo stenting of all coronary stenosis ≥50% as assessed by visual estimation in vessels ≥2.5mm. PCI can be performed before in a previous procedure, or after TAVI, but always within one month, ± 5 days of the valve implantation.PCI in the group randomized to the angio-guided procedure can be performed therefore, either before or after valve implantation, in the same or in different procedures. Implantation of second-generation drug eluting stents (DES) in all interventions is advised, but not mandatory, and the brand of the stent is left to the operators and center's choice.
89658227|NCT03337919|Experimental|Nivolumab|Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.
89658228|NCT03331718|No Intervention|Control|Pancreaticojejunostomy with duct-to-mucosa anastomosis is performed as usual.
89658229|NCT03331718|Active Comparator|PGA felt reinforcement|In addition to usual pancreaticojejunostomy, PGA felt is used in duplicate.
89658230|NCT03320473|Experimental|IC-8 IOL|IC-8 IOL implantation after removal of KAMRA ACI 7000 PDT inlay
89658231|NCT03281798|Experimental|Fetal Cystoscopy Group|Participants in this group will receive the fetal cystoscopy procedure around 16 weeks 0 days to 25 weeks and 6 days of gestation.
89658232|NCT03272919|Experimental|Arm 1: Investigational INF|Intraneural Facilitation (INF) treatment is an effective way to restore blood flow to damaged nerves as neuropathy is strongly impacted by reduced blood flow.
89658233|NCT03272919|Other|Arm 2: Standardized muscle stretching and strengthen|subjects will receive a standardized program of muscle stretching and strengthening exercise twice a week for six weeks under the supervision of treating physical therapist
89658234|NCT03236324|Placebo Comparator|TFP block with saline|Placebo bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with 40 mL saline, single shot
89658235|NCT03236324|Experimental|TFP block with local anesthetic|Experimental bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with local anesthesic of Bupivacaine-epinephrine [0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)], single shot
89658236|NCT03229967||Exploration Cohort|Up to 150 VLBW (very low birthweight) infants enrolled from the Regional One Health NICU (neonatal intensive care unit). Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines, will be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA (ribosomal ribonucleic acid) sequencing after conclusion of initial enrollment period. ITS (internal transcribed spacer) DNA may also be used to characterize fungal communities.
89658237|NCT03229967||Validation Cohort|Up to 10 VLBW infants enrolled from the Le Bonheur Children's Hospital NICU. Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines willl be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA sequencing after conclusion of initial enrollment period.
89658238|NCT03229967||Well Baby Cohort|40 Well Baby Infants have been enrolled and may be used for secondary analysis of microbial community composition of the meconium.
89658239|NCT03229850|Other|Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.
89658240|NCT03229850|Other|No Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.
89658241|NCT03229538|Experimental|Methylprednisolone Arm|IV Methylprednisolone
89658242|NCT03229538|Placebo Comparator|Placebo Arm|IV Isotonic Saline
89658243|NCT03195127|Experimental|multimodal physical therapy|Multimodal physical therapy sessions three times a week, for four weeks, lasting one hour. Consist of limb strengthening exercises, endurance training, and balance/coordination drills.
88994352|NCT02277067|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
88994353|NCT02940964|Experimental|COMSCPR first|Group A will proceed to perform one cycle (two minutes) of COMSCPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
88994354|NCT02940964|Active Comparator|Standard CPR first|Group A will proceed to perform one cycle (two minutes) of Standard CPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
88994355|NCT00174798|Placebo Comparator|Placebo|
88994356|NCT00174798|Experimental|SSR240600C|
88994357|NCT00174798|Active Comparator|Tolterodine|
88994358|NCT05200975|Other|Adequate renal function|Patients with adequate renal function (egfr>30ml/min) receiving a regular cefuroxime dose
88994359|NCT05200975|Other|Impaired renal function|Patients with impaired renal function (egfr<30ml/min) receiving a guideline recommended reduced dose
88994360|NCT00146315|Active Comparator|Control|Secondary prevention program for coronary heart disease
88994361|NCT00146315|Experimental|Supervised exercise|
88994362|NCT05187520|Active Comparator|Patient-controlled epidural analgesia (PCEA)|Patients assigned to PCEA group will receive epidural analgesia as the standard postoperative pain control strategy. After completion of cesarean section, a PCEA device will be connected to the epidural catheter to deliver mixture of local anesthetic (0.8 mg/ml) and fentanyl (2 mcg/ml) with preset continuous dose of 3-5 ml/h and a bolus dose of 3-4 ml.
89213491|NCT01003509|No Intervention|study, control|Control: Only modified shouldice repair performed Study: Modified Shouldice + Moloney repairs performed
89213492|NCT01003509|No Intervention|modified shouldice and double|one arm is only modified shouldice, other one is double
89213493|NCT00879242|Experimental|Deferasirox|30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.
89213494|NCT00868556||1 episodic migraine sufferers|
89213495|NCT00868556||2 chronic migraine sufferers|
89213496|NCT00868556||3 non migraine sufferers (controls)|
89213497|NCT05732493|Experimental|short-course radiotherapy and immunotherapy|A total of 60 patients will receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the surgery.
89658244|NCT03195127|No Intervention|Usual care|Subjects will receive the standard therapy program provided by University Specialty Hospital therapy services. To compliment the physical therapy regimen, an optimized nutritional program will be administered according accepted guidelines.
89658245|NCT03193242|Experimental|Intervention|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
89658246|NCT03193242|No Intervention|Control|"Electronic Asthma Management System: eAMS - Control~At control sites, eligible clinicians will be offered access to the web-based clinician-oriented asthma action plan (AAP) educational module produced by the Lung Association, copies of the Canadian Asthma Guidelines, and standard fillable paper-based AAPs (the eAMS will be offered after study end)."
89658247|NCT03186859|Active Comparator|Roux-en-Y Gastric Bypass (RYGB) surgery|
89658248|NCT03186859|Active Comparator|Sleeve Gastrectomy (SG) surgery|
89658249|NCT03184181|Experimental|EPTE® group|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis (EPTE®). Patient received EPTE® once week for four weeks associated with eccentric exercises device at home.
89658250|NCT03184181|Active Comparator|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
89658251|NCT03179800|Experimental|MobiusHD Implantation|MobiusHD Implantation
89658252|NCT03179800|Sham Comparator|Sham Implantation|Sham Implantation
89658253|NCT03170843|Experimental|O-Trac|The experimental group will use the plastic ring wound retractor for wound protection during the surgery.
89658254|NCT03170843|No Intervention|Surgical pad|The control group will use a conventional surgical pad for wound protection during the surgery.
89213498|NCT05732493|Active Comparator|chemotherapy|A total of 60 patients will receive 4 cycles of CAPOX chemotherapy ,then receive the surgery.
89213499|NCT00873704|Active Comparator|1|recieves supplemental oxygen postoperatively
89213500|NCT00873704|No Intervention|2|treated as usual without supplemental oxygen
89213501|NCT01003587|Experimental|District health information package|
89213502|NCT01003587|No Intervention|No Intervention|
89213503|NCT00868634|Active Comparator|A|Capecitabine / Bevacizumab
89213504|NCT00868634|Experimental|B|Capecitabine / Bevacizumab / Vinorelbine
89213505|NCT01003665||Intensive Care treatement|ASA status 3 or 4 patients with invasive blood pressure measurement on the intensive care unit
89213506|NCT00879320||1|Adults with ADHD
89213507|NCT00879320||2|Healthy adults without ADHD
89213508|NCT05232357|Experimental|Endoscopic nerve staining|Methylene blue (MB) solution was used as nerve staining agent. Routine endoscopic submucosal injection of MB solution for mucosal nerve staining was used to identify and evaluate the neural architecture and special morphology of normal gastrointestinal mucosa, adenoma and malignant lesions.
89213509|NCT04038944||Subjects with new onset atrial fibrillation|Subjects with new onset atrial fibrillation who may or may not require electrical cardioversion
89213510|NCT00879476|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
89213511|NCT00879476|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
89213512|NCT00873938||1-supervised|
89213513|NCT00873938||2 -unsupervised|
89658255|NCT03151200|Active Comparator|binocular treatment|Active treatment group will receive five days of one hour visual binocular training by playing a specifically designed falling blocks video game on a computer screen that will be individually calibrated for each person with red-green glasses with treatment effect.
89658256|NCT03151200|Sham Comparator|sham treatment|Sham treatment group will receive five days of one hour sham visual binocular training by playing a specially designed falling blocks video game on a computer screen with polarized glasses with no treatment effect.
89658257|NCT03148795|Experimental|Talazoparib|Talazoparib 1 mg daily
89658258|NCT03146845|Experimental|ALLEVYN Life Non-Bordered|Foam Dressing
89658259|NCT03146845|Other|Standard care|Standard care dressing
89658260|NCT03139981|Experimental|ASN002 40 mg|40 mg ASN002
89658261|NCT03139981|Experimental|ASN002 80 mg|80 mg ASN002
89658262|NCT03139981|Experimental|ASN002 20 mg|20 mg ASN002
89658263|NCT03139981|Experimental|ASN002 120 mg|120 mg ASN002
89658264|NCT03114917|Experimental|CARMS therapy + TAU|Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
89658265|NCT03114917|No Intervention|TAU|Participants allocated to treatment as usual (TAU) will receive their usual care and treatment from mental health services.
89658266|NCT03076268|Experimental|Treatment Group|The investigators will deliver the TMP Curriculum to 45 Treatment families. The TMP Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings. This curriculum is delivered in Spanish.
89658267|NCT03076268|No Intervention|Control Group|The investigators will deliver a Nutrition Curriculum to 45Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.This curriculum is delivered in Spanish.
89658268|NCT03070054|No Intervention|Control|non-LIA group prior to surgery
89658269|NCT03070054|Experimental|Treatment|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
89658270|NCT03040778|Experimental|Standard of Care + PENTO|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014) AND PENTO regimen consisting of 400mg pentoxifylline (PTX) and 400IU tocopherol twice-daily PO for a total of 800mg/day PTX and 800 IU/day tocopherol
89658271|NCT03040778|Placebo Comparator|Standard of Care|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014). Placebo drugs to be taken in the control group 2 pills BID.
89658272|NCT03003403|Experimental|Intervention Program|Balance Intervention Program: Participants randomly assigned to the 12-month digital health behavioral intervention will receive: tailored behavior change goals with interactive self-monitoring and feedback; network-connected scales to track their weight; skills training materials; and stepped coaching (via phone and/or text) from Registered Dieticians serving as health coaches within a local network of community health centers.
89658273|NCT03003403|No Intervention|Usual Care Program|Balance Usual Care Program: Participants randomly assigned to the Usual Care program will receive the standard primary care offered by their providers; health information/skills training materials to maintain a healthy weight; and automated (non-tailored) text messages with health information.
89658274|NCT03000803|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will consume the majority of their daily calories during breakfast.
88994363|NCT05187520|Experimental|Naldebain®|Patients assigned to Naldebain® group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance after completion of cesarean section.
88994364|NCT02940808|Other|Caffeine first, placebo second|"Caffeine consumption during session 1, placebo consumption during session 2 (after baseline session 0)."
88994365|NCT02940808|Other|Placebo first, caffeine second|"Placebo consumption during session 1, caffeine consumption during session 2 (after baseline session 0)."
88994366|NCT02940847|Active Comparator|blind technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. The blind technique consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
88994367|NCT02940847|Active Comparator|ultrasound-guided technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. In the ultrasound-guided technique, ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
88994368|NCT02941003|Experimental|OCT treatment|Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.
88994369|NCT02941003|Experimental|OCT free|Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.
88994370|NCT02963805|Experimental|High intensity physical activity (HIPA)|Participants attended high intensity vigorous activity after school clubs.
88994371|NCT02963805|Experimental|Fundamental movement skill (FMS)|Participants attended fundamental movement skill based after school clubs.
88994372|NCT02963805|Experimental|Physical activity signposting (PASS)|Participants attended educational physical activity signposting sessions during school hours.
88994373|NCT02963805|No Intervention|Control|Children in the control group received British Heart Foundation leaflets that included information on heart health (given to all groups). Children participated in their usual school curriculum including two hours of physical education and school sport per week, both within and beyond the curriculum.
88994374|NCT02941081|Experimental|IHAT|IHAT arm: novel iron supplement - 1 dose/day single IMP containing IHAT (iron hydroxide adipate tartrate) powder bioequivalent to 12.5 mg elemental iron (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to ferrous sulphate)
88994375|NCT02941081|Active Comparator|ferrous sulphate|Ferrous sulphate arm: clinical standard of oral iron supplementation - 1 dose/day single IMP containing ferrous sulphate (FeSO4 ) powder equivalent to 12.5 mg elemental iron
88994376|NCT02941081|Placebo Comparator|placebo|Placebo arm: 'no iron' arm - 1 dose/day containing saccharose powder
88994377|NCT02940613|Experimental|Visual feedback of symptom frequency|Participants in this arm receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
88994378|NCT02940613|No Intervention|No visual feedback of symptom frequency|Participants in this arm complete the symptom checklist as is typically done during treatment, but receive no visual feedback of their self-reported symptom frequency over the first 4 weeks of active treatment.
88994379|NCT04691440|Experimental|HBOT|Hyperbaric oxygen breathing at 2.4 atm.abs for 90 minutes. The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
88994380|NCT02940652||Paediatric patients undergoing MRI scanning|All paediatric patients undergoing elective MRI scanning of the brain and/or brain and cervical spine
89047066|NCT04666233|Experimental|Resuscitation with PPE for prevention of SARS-Cov-2 infection|
88994381|NCT00146471|Active Comparator|2|
88994382|NCT00146471|Placebo Comparator|1: Diazepam plus Placebo|
88994383|NCT04691245|Experimental|Intervention|Femoral access using 3D US
88994384|NCT04691245|Active Comparator|Control|Femoral access using 2D US
88994385|NCT04691713|Experimental|Targeting CD276 autologous chimeric antigen receptor T cells|
88994386|NCT04690933||Multicentric NAViRe cohort with biocollection|"The National Reference Center (CNR) for cytomegalovirus with the French Society for Medullary Transplantation and Cell Therapy (SFGM-TC) has set up a surveillance cohort of allografted patients (NAViRe cohort) receiving, as prevention or treatment, Anti-Cytomegalovirus (Anti-CMV) molecules, new or less recent, thus allowing the development of a new observatory evaluating in real life the potentials of these drugs in terms of efficacy, emergence of resistance, tolerance and morbidity and mortality associated with CMV infection.This work is useful to propose recommendations on management strategies, in particular for the most at-risk patients i.e. CMV-seropositive recipients and allows the emergence of an real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients."
88994387|NCT00174993|Experimental|Pioglitazone QD|
88994388|NCT00174993|Placebo Comparator|Placebo QD|
88994389|NCT04690894|Active Comparator|Erector spinae group|the child received ultrasound-guided erector spinae muscle block in a dose of 0.4mg/kg of 0.25%bupivacaine between the 10th transverse process and erector spinae muscle
88994390|NCT04690894|Active Comparator|caudal group|child received ultrasound-guided caudal block in a dose of 2.5mg/kg of bupivacaine 0.25%
88994391|NCT04690894|No Intervention|control|child didn't received any regional block
89658275|NCT03000803|Active Comparator|Late Total Caloric Intake|The Late Total Caloric Intake study group will consume the majority of their daily calories during dinner.
89658276|NCT02976961|Experimental|Intervention|Implantable cardioverter defibrillator implant + usual care + supportive care given via an e-health platform. The supportive care consists of information, dialogue with a nurse or psychologist, CBT-based psychological intervention online, quizzes to increase knowledge
89658277|NCT02976961|No Intervention|Usual care|Implantable cardioverter defibrillator implant + usual care
88994392|NCT04691830|Experimental|group IA|"Preschool cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
88994393|NCT04691830|Active Comparator|group IB|preschool control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the preschool age control group.
88994394|NCT04691830|Experimental|group IIA|"School age cases group who received the proposed prosody treatment program in addition to the traditional auditory and language rehabilitation therapy."
88994395|NCT04691830|Active Comparator|group IIB|School age control group who received the traditional auditory and language rehabilitation therapy without the prosody rehabilitation program. This was considered the school age control group.
88994396|NCT02940379|Experimental|Cohort 1|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days
88994397|NCT02940379|Experimental|Cohort 2|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 2 of Sotagliflozin plus cocktail) after 3 days
88994398|NCT02940535|Experimental|Low Dose GnRHa|Diphereline 0.375mg was administered in the early-luteal-phase. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the day 28.
88994399|NCT02940535|Active Comparator|GnRHa Ultra-short Protocol|Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.
88994400|NCT04690972||Hepato-bilio-pancreatic surgery|Patients whom hepato-bilio-pancreatic surgery is indicated as part of the care
89658278|NCT02975700|Experimental|PLX3397|"Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated~Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma."
88994401|NCT04690972||biopsy of the hepatic parenchyma|Patients whom a biopsy of the hepatic parenchyma, one or more hepatic nodules or a loco-regional treatment is indicated as part of the care
88994402|NCT04690972||Viral chronic infection|Patients with a viral chronic liver disease
88994403|NCT05157802|Experimental|Physical Activity Coaching|Participants will receive up to 5 individualized coaching sessions delivered via telehealth to facilitate and optimize exercise uptake. The therapist will facilitate discussion on specific and measurable goals, and will provide options for tracking their progress, such as written or web-based exercise logs or an activity monitor. The recommended exercises will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. Balance and strengthening exercises will also be recommended as appropriate.
88994404|NCT05146843|Experimental|Mitoquinone|MitoQ, 20 mg per day for three months
88994405|NCT05146843|Placebo Comparator|Placebo|Placebo, 20 mg per day for three months
88994406|NCT00175032|Experimental|Lansoprazole 30 mg QD + Naproxen 500 mg BID|(and added aspirin)
88994407|NCT00175032|Active Comparator|Celecoxib 200 mg QD|(and added aspirin)
88994408|NCT05139355|Experimental|Oat product 1|The test portion is based on 50 gram available carbohydrates with added vegetable oil A. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
88994409|NCT05139355|Experimental|Oat product 2|The test portion is based on 50 gram available carbohydrates with added vegetable oil B. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
88994410|NCT05139355|Experimental|Oat product 3|The test portion is based on 50 gram available carbohydrates with added vegetable oil C. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning.
88994411|NCT05139355|Placebo Comparator|Control Product|The test portion is based on 50 gram available carbohydrates without added vegetable oil.
88994412|NCT04691050|Other|OrthoMta (BioMTA)|OrthoMTA was applied in primary molars without successors
88994413|NCT00175071|Experimental|Comparison of cooking oils|Postmenopausal women (50-85 y) with LDL cholesterol 120 mg/dL.
88994414|NCT02940418|Active Comparator|Dose 1 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
88994415|NCT02940418|Active Comparator|Dose 10 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
88994416|NCT02940457|Experimental|Verum tDCS|prefrontal anodal stimulation
88994417|NCT02940457|Experimental|Sham tDCS|sham stimulation, same electrode positions
88994418|NCT00169533|Experimental|Arm 1|Lapatinib either 750, 1000, 1250 or 1500 mgs
88994419|NCT00530725|Active Comparator|chest drainage|This represents the best current standard of care although this is quite controversial
88994420|NCT00530725|Experimental|close observation|This is the novel approach that has some justification in the literature
88994421|NCT02944123|Other|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose and followed by 75 mg/day as maintenance dose.
88994422|NCT02944123|Experimental|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
89047067|NCT04666233|Active Comparator|Resuscitation without PPE for prevention of SARS-Cov-2 infection|
89047068|NCT01184053|Experimental|Trisenox treatment|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
89047069|NCT04206241||High-risk infants|"Mother answered yes to any of the following questions on a risk-screening tool:~Mother diagnosed with HIV in labor and delivery?~Mother start ART after 32 weeks' gestation?~Maternal viral load above 1000 copies/ml in the 3rd trimester?~Mother seroconvert during pregnancy?~Was the mother not adhering to ART during pregnancy?"
89047070|NCT04206241||Low-risk infants|Mothers did not answer affirmatively to any of the four screening questions
89047071|NCT03895814|Experimental|Multi-baseline Step Training|"Participants will be assessed before and after a 2-week baseline period, and again before and after a 2 week protective step training period. Participants will also be assessed 2 months later at a follow-up visit."
89047072|NCT01183975||Patients treated with SAGB by solicited teams|Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period.
89047073|NCT04666194|Active Comparator|Cold forceps|4-6mm polyps were removed with cold forceps
89047074|NCT04666194|Active Comparator|Cold snare|4-6mm polyps were removed with cold snare
89047075|NCT04666194|Active Comparator|Hot snare|4-6mm polyps were removed with hot snare
89658279|NCT02969785|Experimental|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
89047076|NCT03870698|Experimental|Laparoscopic group|The patients who underwent laparoscopic procedures for periampullary tumors
89047077|NCT03870698|No Intervention|Open group|The patients who underwent open procedures for periampullary tumors
89047078|NCT04666077|Experimental|Home-based MT through Supervised, Supported Singing (H3S)|Treatment arm 1
89047079|NCT04666077|Experimental|H3S and IMT|Treatment arm 2 received both Home-based Supervised, Supported Singing (H3S) and Individualized Music Therapy (IMT)
89047080|NCT04666077|Placebo Comparator|Attention Control (AtCon)|Comparison condition with comparable attention
89047081|NCT04666116|No Intervention|COVID-19 patients no dietary administration|Only medication agreed by the hospital committee
89047082|NCT04666116|Experimental|COVID-19 patients with dietary administration|Medication agreed by the hospital committee and nutritional supplement.
89047083|NCT03813875||TEE (transesophageal echocardiography)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~TEE group: the routine sedation medication for the procedure include midazolam (approximately 1~5mg per patient), alfentanil (200~1000mcg per patient) and propofol (small boluses of 10~20mg on demand, total dose usually below 100mg per patient depending on the overall examination timespan) all in intravenous boluses. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
89047084|NCT03813875||LMA (laryngeal mask airway)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~LMA group: routine induction medications include propofol (50~200mg per patient), fentanyl (50~150mcg per patient) and sevoflurane (machine setting at 1.5% to 3% according to clinical needs). Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
89047085|NCT01183858|Experimental|Erlotinib 150 mg|Erlotinib 150 mg single daily oral dose until disease progression.
89047086|NCT01183858|Experimental|Erlotinib 300 mg|Erlotinib 300 mg single daily oral dose until disease progression.
89658280|NCT02969785|Active Comparator|G2: back strengthening exercises|Back strengthening exercises. The Group 2 (G2) will perform therapy including strengthning of back muscles on a Roman chair machine for flexion and extension of trunk with load progression from training volume for endurance and strength gains.
89658281|NCT02959047|Experimental|Alirocumab|Alirocumab 150mg SQ every 2 weeks
89658282|NCT02959047|Placebo Comparator|Placebo|Matched placebo
89658283|NCT02923609|Experimental|SC Group|In Phase 1 of the study, all patients will be treated with optimization of medical therapy for 6 months. Thereafter, all patients will cros over to Phase 2 of the study, where they will receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 will last for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).
89047087|NCT04665882|Experimental|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
89047088|NCT04665882|No Intervention|Standard axillary lymph node dissection|Standard axillary lymph node dissection was performed with complete resection of Berg's levels I and II.
89047089|NCT04686344|Active Comparator|Hypertonic saline continuous infusion Group|will receive Hypertonic saline continuous infusion
89658284|NCT02895750|Experimental|normal to mild renal impairment|(12 subjects): eGFR ≥ 60 (normal renal function to mild renal impairment, CKD stages 1-2) METFORMIN
89658285|NCT02895750|Experimental|mild to moderate renal impairment|(12 subjects): eGFR 59-45 (mild to moderate renal impairment, CKD stage 3a) METFORMIN
89047090|NCT04686344|Active Comparator|Hypertonic saline intermittent boluses Group|will receive Hypertonic saline intermittent boluses for 48 hours
89047091|NCT05450536|Other|Autism College Students|Single subject design means subjects are their own control.
89047092|NCT05349136|Experimental|Synchronous telerehabilitation group|Synchronous telerehabilitation based-Action Observation Treatment and conventional physiotherapy
89047093|NCT05349136|Experimental|Asynchronous telerehabilitation group|Asynchronous telerehabilitation based-Action Observation Treatment and conventional physiotherapy
89047094|NCT05349136|No Intervention|Control group|Conventional physiotherapy
89047095|NCT04316416|Active Comparator|T7 Bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging T7 (7th thoracal vertebrae ) transverse process accompanied by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
89047096|NCT04316416|Active Comparator|T9 bilateral ESP block|Ultrasound-guided bilateral Erector spinae plane block will performe at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture by imaging transverse process T9 (9th thoracal vertebrae) by ultrasound. Postoperative routine analgesic protocol planned (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block). Standard pain follow-up and monitorization will be performed.
89658286|NCT02895750|Experimental|moderate to severe renal impairment|(12 subjects): eGFR 44-30 (moderate to severe renal impairment, CKD stage 3b) METFORMIN
89658287|NCT02895360|Experimental|Phase 1|Fixed 3+3 dose escalation of BAL101553 in patients with advanced solid tumors
89658288|NCT02895360|Experimental|Phase 2a|BAL101553 at MTD in patients with platinum-resistant/refractory ovarian cancer or recurrent glioblastoma
89658289|NCT02890784|Active Comparator|A. Standard arm|100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)
89658290|NCT02890784|Experimental|B. Study arm|100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)
89658291|NCT02880878|Experimental|Early Surgical Hematoma Evacuation|Subjects will receive early surgical hematoma evacuation using Minimally Invasive Parafascicular Surgery (MIPS).
89658292|NCT02880878|No Intervention|Medical Management|Subjects will receive standard of care medical management for ICH.
89658293|NCT02872753|Experimental|ACP GROUP|Patients will receive a single intra-op ACP injection following a procedure of arthroscopic partial meniscectomy (medial or lateral)
89658294|NCT02872753|Other|CONTROL GROUP|Patients will be treated by standard meniscectomy alone (medial or lateral)
89658295|NCT02863809|Experimental|Active Treatment Arm|De-epithelialized corneas cross-linked with riboflavin 0.1% and dextran 20% solution AND ultraviolet A light (UVA Light Source).
89658296|NCT02863809|Active Comparator|Control Treatment Arm|De-epithelialized corneas will be exposed to only riboflavin 0.1% with dextran 20% solution (NO ultraviolet A light).
89658297|NCT02832193||Study group|"POCD data of study patients of the following studies:~Phydelio - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 ReCosa - EA1/056/13 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 Pain-Long-EA2/041/17 PCI - EA2/024/18 PODSPA - EA4/138/18, PRÄP-GO -EA1/225/19, ANA-PRÄP-Go (EA1/266/20) Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
89658298|NCT02832193||Control group I|"POCD data of prospective control subjects/patients (ASA I+II+III) and POCD data of control subjects/patients of the following studies:~Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 Phydeliostudie - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 BioCog-Studie - EA2/092/14 REACT-Studie - EA2/091/15 PAINLONG-Studie - EA2/041/17 PCI - EA2/024/18 PODSPA - EA4/138/18, PRÄP-GO -EA1/225/19, ANA-PRÄP-Go (EA1/266/20) Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
89658299|NCT02823028|Active Comparator|NRT + Web Guide|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges)
89658300|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Coed|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a coed Tweet2Quit group
89658301|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Women|Experimental: NRT + Web Guide + Tweet2Quit-Women NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a women-only Tweet2Quit group
89658302|NCT02786394|Experimental|REACH Participant Course|This study will run twice a week over 6 weeks with 6 REACH sessions optional walking program sessions. The optional walking program will be run by SportMedBC and may consist of one or more educational sessions (e.g., nutrition). Each REACH session introduces new topics, strength and balance activities and home practices which progressively build on each other. We will ask participants to provide feedback after each session, and in two to three 30 minutes recorded interviews (in-person or over the telephone) at the end of the study.
89047097|NCT04316416|Placebo Comparator|Control group|Postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard pain follow-up and monitorization will be performed. No block will be performed in this group.
89047098|NCT05449522|Experimental|Treatment group|Experimental group will receive 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) theoretically to achieve sufficient level of vitamin D.
89047099|NCT05449522|Placebo Comparator|Control group|
89047100|NCT04665804|Experimental|Experimental Group A (Creatine Supplementation)|
89658303|NCT02775760|Experimental|Cardiovascular endurance|Participants will undergo cardiovascular endurance training. The trainer-supervised endurance training will involve walking on a treadmill at moderate intensity
89658304|NCT02775760|Active Comparator|Strength, balance, and flexibility|Participants will undergo Strength, balance, and flexibility training.
89047101|NCT04665804|Experimental|Experimental Group B (Glucosamine and Chondroitin sulfate Supplementation)|
89047102|NCT05434468|Experimental|Sustained neutral apophyseal glides group|Sustained neutral apophyseal glides will apply on this group.
89047103|NCT05434468|Experimental|Gong mobilization|mobilization technique
89047104|NCT04316455|Experimental|Integrative Yoga Therapy|Participants engaging in a 6-week chronic pain self-management program. Intervention: Integrative Yoga Therapy
89047105|NCT05431192|Experimental|Mindful Training + Enhanced Usual Care|Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks.
89658305|NCT02768363|Active Comparator|CAN-2409|Patients randomized to the active arm will receive two courses of aglatimagene besadenovec (CAN-2409) + valacyclovir
89047106|NCT05431192|Other|Enhanced Usual Care alone|Usual care.
89047107|NCT00534755|Other|Breast database|Database
89047108|NCT00534872|Experimental|SB649868|10 mg
89047109|NCT00534911|Experimental|Cognitive Behavioral Therapy|Primary & Secondary Control Enhancement Training (PASCET)
89658306|NCT02768363|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir
89658307|NCT02753530|Experimental|Arimoclomol|248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
89047110|NCT00534911|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy
89047111|NCT04665609|Experimental|Anlotinib and TQB2450 solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Oral anlotinib (12 mg/d) will be administered and its cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks. The treatment continues until disease progression or treatment intolerance. Anlotinib and TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
89047112|NCT04665609|Active Comparator|TQB2450 Solution|Microwave ablation will be performed according to patients' tumor number, size and liver function. Patients will be given 1200 mg TQB245 solution intravenously every 3 weeks.TQB2450 solution will be given after 2 weeks of microwave ablation procedure.
89047113|NCT04665492||SCI with CNP|People with subacute spinal cord injury and no chronic pain
89047114|NCT04665492||SCI no CNP|People with subacute spinal cord injury with central neuropathic pain
89047115|NCT04665492||Able bodied|Able bodied people with no chronic pain
89047116|NCT04665219|Active Comparator|Control group|Only receive a standard message.
89047117|NCT04665219|Experimental|Test group|Receive HBM-based messages.
89047118|NCT04665102||No pathology|
89658308|NCT02753530|Placebo Comparator|Placebo|248 mg matching placebo 3 times daily
89047119|NCT04665102||Pathology|
89047120|NCT04665141||Standard of care|Patients with severe asthma being treated with non-biological standard therapies, mainly systemic corticosteroids.
89047121|NCT04665141||Biological therapies|Patients with severe asthma being treated with omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab.
89047122|NCT04665063|Experimental|Auto CAR-T|Patients will be treated with Auto CAR-T cells
89047123|NCT04664712|Active Comparator|shock wave|
89047124|NCT04664712|Active Comparator|shock wave and tendon supplement|
89047125|NCT04664439|Experimental|CT-FFR|The CCTA images of the patients in this group will be analyzed and the FFR values of the lesions will be measured using the indicated software. ICA will be determined according to the value of CTFFR.
89047126|NCT04664439|No Intervention|direct ICA|The patients will be submitted to undergoing ICA procedure according to the decision of the investigators.
89047127|NCT04664595|Sham Comparator|Group SP|The Supreme™ group
89047128|NCT04664595|Active Comparator|Group PS|The ProSeal™ group
89658309|NCT02748434|Other|Lipohypertrophy|Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.
89658310|NCT02748434|Other|Normal Subcutaneous Tissue|Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.
89658311|NCT02729805|Placebo Comparator|Saline|A syringe of 50 ml 0.9% normal saline will be prepared as placebo for infusion and a syringe of 10ml 0.9% normal saline for bolus injection.
89658312|NCT02729805|Active Comparator|Ketamine 0.5mg/kg|A bolus injection of intravenous ketamine at a dose of 0.5mg/kg during anaesthetic induction before skin incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation.
89658313|NCT02729805|Experimental|Ketamine 0.75mg/kg|A bolus injection of intravenous ketamine at a dose of 0.75mg/kg during anaesthetic induction before skin incision followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation.
89658314|NCT02635685|Experimental|Intervention group|Intervention with Clinical Decision Support tool installed on units.
89047129|NCT04664595|Active Comparator|Group IG|The I-gel™ group
89047130|NCT04664595|Active Comparator|Group LT|The Laryngeal Tube Suction IITM group
89047131|NCT04665024|Active Comparator|Group 1|"G1 included patients undergoing planned surgery who performed chest physiotherapy at home in two weeks period before the surgical operation pre and postoperative chest physiotherapy was performed in G1.~The chest physiotherapy included the following steps~Snipping through the nose several times, then breathe out through the mouth~Taking a deep breath through the nose, hold the air in, push it down in the stomach, than back to the chest, and in the end breath out through the mouth~Put both hands on the shoulders. Lift the elbows to the sides and take a deep breath through the nose, then lower them, breathe out through the mouth. This procedure was done for the other side as well.~Put both hands on your hips. Lift your right arm to the side, turn backwards with it and take a deep breath through the nose, then turn back, put your hand back to the hip and breathe out through the mouth.This procedure was done for the other side as well"
89057981|NCT04534998|Experimental|Robotic-assisted partial nephrectomy|Partial nephrectomy will be performed using a robotic-assisted laparoscopic approach.
89057982|NCT04534998|Active Comparator|Open partial nephrectomy|Partial nephrectomy will be performed using an open retroperitoneal approach.
89057983|NCT02218775|Experimental|LY2456302|LY2456302 dosed orally at 10 mg daily for 2 weeks in healthy volunteers
89057984|NCT02216552|Experimental|Resveratrol|Intervention: Resveratrol Oral supplementation of resveratrol (ResVida) 75 mg twice daily (with breakfast and dinner) for a total daily dose of 150 mg for the duration of 30 days.
89057985|NCT02216552|Placebo Comparator|Placebo|Intervention: Placebo Control Oral supplementation of placebo twice daily (with breakfast and dinner) for a total duration of 30 days.
89658315|NCT02635685|No Intervention|Control group|Control group without intervention with Clinical Decision Support tool installed on units.
89658316|NCT02531295|Experimental|Kansui 1g per day x 1 day|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
89658317|NCT02531295|Experimental|Kansui 1g per day x 2 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
89658318|NCT02531295|Experimental|Kansui 1g per day x 3 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
89658319|NCT02521311|Experimental|Clemastine|Participants will receive clemastine until 3 months and then will be off treatment until 9 month time point.
89658320|NCT02521311|Placebo Comparator|Placebo|Participants will receive placebo until 3 months and then will be off treatment until 9 month time point.
89658321|NCT02437045|Active Comparator|Meropenem|Meropenem 1g every 8 hrs IV to day 4
89658322|NCT02437045|Experimental|Piperacillin-tazobactam combination product|Piperacillin tazobactam 4.5g every 6 hrs IV to day 4
89658323|NCT02389595||HIV positive subjects|This group will provide a blood sample.
89658324|NCT02389595||Non-infected control subjects|This group consist of de-identified blood samples from a commercial source.
89658325|NCT02385916|Experimental|EstroSense®/MD|3 capsules per day during the study period
89658326|NCT02385916|Placebo Comparator|Placebo|3 capsules per day during the study period
89658327|NCT02380716|Experimental|GORE® Ascending Stent Graft|Treatment with the GORE® Ascending Stent Graft
89658328|NCT02371265|Experimental|Adherence and retention intervention|Implementation of adherence and retention package
89658329|NCT02371265|No Intervention|Control|Clusters continue without intervention package
89658330|NCT02308826|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
89658331|NCT02308826|Active Comparator|Cool Little Kids|A 6-week parent psychoeducation group administered over an 8-week period.
89658332|NCT02308527|Active Comparator|Temozolomide|Temozolomide Days 1-5 every 4 weeks
89658333|NCT02308527|Experimental|Bevacizumab + Temozolomide|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
89658334|NCT02308527|Experimental|Irinotecan + Temozolomide|Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
89658335|NCT02308527|Experimental|Bevacizumab + Irinotecan + Temozolomide|Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
89658336|NCT02308527|Experimental|Temozolomide + Topotecan|Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
89658337|NCT02308527|Experimental|Bevacizumab + Temozolomide + Topotecan|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
89658338|NCT02308527|Experimental|Dinutuximab beta + Temozolomide|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks
89658339|NCT02308527|Experimental|Dinutuximab beta + Temozolomide + Topotecan|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
89658340|NCT02308527|Other|Dinutuximab beta + Topotecan + Cyclophosphamide|Dinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
89658341|NCT02289079|Experimental|liposomal bupivacaine TAP|these patients receive a subcostal TAP with liposomal bupivacaine
89658342|NCT02289079|Active Comparator|bupivacaine TAP|These patients receive a subcostal TAP with bupivacaine
89658343|NCT02287480|Experimental|VSV-ZEBOV lower dose|"One intramuscular (deltoid) injection of a lower dose (10^7 plaque-forming units) of VSV-ZEBOV.~Study amendment (01.2015) : One intramuscular (deltoid) injection of a markedly lower dose (3x 10^5 plaque-forming units) of VSV-ZEBOV"
89658344|NCT02287480|Experimental|VSV-ZEBOV higher dose|"One intramuscular (deltoid) injection of a higher dose (5 x 10^7 pfu) of VSV-ZEBOV.~Study amendment (01.2015) : interrupted"
89658345|NCT02287480|Placebo Comparator|Placebo|One intramuscular (deltoid) injection of normal saline (0.5 ml)
89658346|NCT02234245|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
89658347|NCT02234245|Experimental|Remote monitoring of pacemakers|"Telemedicine System:~Patients have not to go to the hospital to be monitorized"
89658348|NCT02131753|Other|Cladribine s.c. injection, HCL treatment|Cladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 - 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment
89658349|NCT02085499|Other|NIMV followed by S-NIMV|During the study infants assigned to this arm will undergo a 2-hour period of non-synchronized NIMV followed by a 2-hour period of Synchronized-NIMV.
89658350|NCT02085499|Other|S-NIMV followed by NIMV|During the study infants assigned to this arm will undergo a 2-hour period of synchronized NIMV followed by a 2-hour period of non-synchronized NIMV.
89658351|NCT02058706|Experimental|Arm A (enzalutamide and LHRH analogue therapy)|Patients receive enzalutamide orally PO QD and undergo orchiectomy or receive LHRH analogue therapy (leuprolide acetate, goserelin acetate, or any other FDA approved preparation). Treatment continues in the absence of disease progression or unacceptable toxicity.
89658352|NCT02058706|Active Comparator|Arm B (bicalutamide and LHRH analogue therapy)|Patients receive bicalutamide PO QD and undergo orchiectomy or receive LHRH analogue therapy as in Arm A. Treatment continues in the absence of disease progression or unacceptable toxicity.
89658353|NCT01932801|No Intervention|Assessment-only|Assessment-only control condition
89658354|NCT01932801|Active Comparator|HRC|Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
89658355|NCT01932801|Experimental|XR-NTX+HRC|3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
89658356|NCT01932801|Placebo Comparator|Placebo+HRC|3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period
89658357|NCT01762579|Active Comparator|wheat flour|wheat flour is administered blindly versus placebo for 15 days
89658358|NCT01762579|Placebo Comparator|Xylose|placebo will be administered blindly versus wheat flour for 15 days
89658359|NCT01758991|Active Comparator|real tDCS|"patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing.~tDCS will be applied during swallowing therapy, during 20 minutes"
89658360|NCT01758991|Placebo Comparator|sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
89658361|NCT01705548|Experimental|Hypofractionated Radiosurgery|"HR (Hypofractionated Radiosurgery) delivered in 5 fractions, with a minimum of 2 and a maximum of 3 fractions being delivered per week, to patients with brain metastases or resection cavity greater than 3 cm and less than 6 cm.~Dose escalation will proceed according to the Escalation with Overdose Control (EWOC) method with a planned total enrollment of 24 patients, in 8 patient cohorts with 3 patients per cohort. A 4 month observation period will occur for each completed cohort prior to dose escalation, with a goal timeline for trial completion of 4 years from first patient enrollment."
89658362|NCT01686191||Cardiac transplant recipients|
89658363|NCT01657604|Experimental|Nilotinib+IFN|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with Peginterferon α2b at a starting target dose of 30μg/week.
89658364|NCT01657604|Active Comparator|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily.
89658365|NCT01644110|Experimental|ruxolitinib/pomalidomide|"Cohort 1 (Patient 1 - Patient 41): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.~Cohort 2 (Patient 42 - Patient 90): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be started at 0.5 mg once daily up to 2 mg once daily."
89658366|NCT01593423|Experimental|Homestead Food Production plus small pond aquaculture|
89658367|NCT01593423|Active Comparator|plant-based Homestead Food Production|
89658368|NCT01593423|Sham Comparator|Control|
89658369|NCT01478542|Active Comparator|Favourable Prognosis F-A - Recruitment completed|Induction therapy with 4 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHOP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
89658370|NCT01478542|Experimental|Favourable F-B - Arm Closed|Induction therapy with 4 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,4 mg/sqm (max. 2mg absolute), Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHLIP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.
88994423|NCT02944123|Experimental|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
88994424|NCT02944045|Placebo Comparator|Placebo|Saline serum, same volume as in the Experimental arm.
88994425|NCT02944045|Experimental|Steroids|"Methylprednisolone intra veinous~Day 1 to 5 : 30mg twice per day~Day 6 to 10 : 30mg per day~Day 11 to 21 : 20mg per day"
88994426|NCT02944084|Experimental|Rice bran extract|2 g of unprocessed rice bran extract
88994427|NCT02944084|Experimental|Porridge in water|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm water
88994428|NCT02944084|Experimental|Porridge in milk|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm milk (3.8% fat)
88994429|NCT02943889|Experimental|Mesenchymal stem cell transplantation|This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.
88994430|NCT02943889|No Intervention|Control group|This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them.
88994431|NCT02943694|Experimental|TaTME with CS-Compact (GelPoint Path)|Based on newly-designed devices tailored for transanal TME, CS-Compact, GelPoint and Octoport are employed for the clinical applications.
88994432|NCT02943850|Experimental|Stem cell implantation|Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
88994433|NCT02943967|Active Comparator|CXL + PRK group|"Corneal cross-linking surgery is perfomed in one eye : deepithelization of the cornea and instillation of 0,1% riboflavin (ophthalmos - Brazil) for 30 minutes and UVA for irradiated for 30 minutes with ultraviolet-A of 365nm light with an irradiance of 3 mW/cm2 using Xlink (Opto - São Carlos) Photorefractive keratotomy will be perfomed in the same eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
88994434|NCT02943967|Active Comparator|PRK group|"Photorefractive keratotomy will be perfomed in the fellow eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
88994435|NCT00530881|Placebo Comparator|4|
88994436|NCT00530881|Placebo Comparator|3 active, 1 placebo|
89658371|NCT01478542|Active Comparator|Less Favourable LF-A - Recruitment completed|Induction therapy with 6 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHOP-14 an interim restaging will be performed.
89658372|NCT01478542|Experimental|Less Favourable LF-B - Recruitment completed|Induction therapy with 6 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,67 mg/sqm [uncapped], , Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHLIP-14 an interim restaging will be performed. Recruitment completed.
89658373|NCT01478542|Experimental|Less Favourable LF-C - Recruitment completed|Induction therapy with 6 cycles of CHOP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) combined with an optimized Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHOP-14 an interim restaging will be performed. Recruitment completed.
89658374|NCT01478542|Experimental|Less Favourable LF-D - Recruitment completed|Induction therapy with 6 cycles of CHLIP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, 1,67 mg/sqm [uncapped], , Predniso[lo]ne 100mg/d d1-5) combined with an optimised Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHLIP-14 an interim restaging will be performed. Recruitment completed.
89658375|NCT01406678|Active Comparator|RIPC|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 and 10 Minutes after aortic unclamping during reperfusion of the myocardium.
89658376|NCT01406678|Placebo Comparator|Control|Control group: Coronary artery bypass surgery without remote ischemic preconditioning protocol
89658377|NCT01397929|Experimental|Drug: BAL101553 at MTD|
89658378|NCT01397929|Experimental|Drug: BAL101553 at 50% of MTD|
89057986|NCT01198756|Experimental|GSK2282512A 1 Group|Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89057987|NCT01198756|Active Comparator|Victoria strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89213514|NCT04925102||GMFCS level I|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level I will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
88815719|NCT01089062|Other|Treatment B, then Treatment C, then Treatment A|"The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
88994437|NCT00175149|Active Comparator|1|Given alfacalcidiol. Dose adjusted after PTH level
88994438|NCT00175149|No Intervention|2|The untreated arm
88994439|NCT00530998||1|Group #1 NOTES Appendectomy - Transvaginal approach
88994440|NCT00530998||2|Group #2 NOTES Cholecystectomy - Transvaginal approach
88994441|NCT02943772|Experimental|Local hypothermia|Local application of a brick cooled to -20(celsius)
88994442|NCT02943772|Sham Comparator|Control|Local application of a brick in room temperature
88994443|NCT02943811||MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy with the use of a uterine manipulator
88994444|NCT02943811||NO MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy without the use of a uterine manipulator
88994445|NCT02943655|Active Comparator|combined oral contraceptives|oral second generation pills one tablet daily
88994446|NCT02943655|Active Comparator|medroxyprogesterone acetate|oral 5 mg daily
88994447|NCT02943655|Active Comparator|non-steroidal anti-inflammatory|oral 500 mg mefenamic acid three times per day
88994448|NCT00175188|Active Comparator|Cemented PIP implant|Avanta PIP
88994449|NCT00175188|Active Comparator|Uncemented PIP implant|Avanta PIP
88994450|NCT00175227|Experimental|Intervention|Saline hydration + mannitol + furosemide
88994451|NCT00175227|Placebo Comparator|Controls|Saline hydration without mannitol or furosemide
88994452|NCT02940262|Experimental|Treatment (68Ga-PSMA-11)|Patients receive gallium Ga 68-labeled PSMA-11 IV. Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.
88994453|NCT00146900|Experimental|Prolonged Exposure (CBT)|Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy
88994454|NCT00146900|Active Comparator|Cognitive Therapy|Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.
88994455|NCT00146900|Experimental|SSRI (escitalopram)|Twenty milligrams daily of escitalopram (blinded capsules)
88994456|NCT00146900|Placebo Comparator|Placebo|Two concealed placebo pills resembling 10mg escitalopram tablets
88994457|NCT00146900|No Intervention|Waiting List|Twelve weeks of waiting list no intervention group
89658379|NCT01250938|Experimental|ESI - Community Outreach|All families receive the same Early Social Intervention - Community Outreach (ESI-CO) treatment for 3 months in addition to 6 months of community resource support.
89047132|NCT04665024|Active Comparator|Group 2|"G2 included patients who patients undergoing planned surgery but did not perform preoperative chest physiotherapy at home.only postoperative chest physiotherapy made in G2.~The patient was seen on the first day after surgery in the intensive care unit and was asked if he had performed breathing exercises at home before surgery and then re-evaluation of both groups with respect to respiratory functions and oxygen saturation values from the first day until the seventh after surgery. Also, a daily chest physical therapy program was introduced in accordance with the hospital's policy until the patient's discharge.~Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy mentioned above but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days.~The exercises were repeated 10 times and performed 3-4 times per day."
89047133|NCT01215175|Active Comparator|Prevnar™ - Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
89047134|NCT01215175|Experimental|V114 Adjuvanted -Toddler Cohort|Healthy toddler (12-15 months of age) participants who had completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
89658380|NCT01062984|Active Comparator|Continuous Venovenous Hemofiltration|
89658381|NCT01062984|Active Comparator|Continuous Venovenouos Hemodialysis|
89658382|NCT00991640|No Intervention|Control|No intervention
89658383|NCT00991640|Experimental|Preceptorships|Preceptorships with e-learning
89658384|NCT00707265|Experimental|Investigational|Open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System.
89658385|NCT00707265|Active Comparator|Control|The bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.
89658386|NCT00695214|Other|1|OSA Patients considering surgical treatment
89658387|NCT00691756|Experimental|1|Cold blood renal perfusion
89658388|NCT00691756|Active Comparator|2|Cold crystalloid renal perfusion
89658389|NCT00678327|Active Comparator|Arm I|Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89658390|NCT00678327|Active Comparator|Arm II|Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89658391|NCT00678327|Experimental|BEACOPP-14 chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89658392|NCT00678327|Experimental|BEACOPP-escalated chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89658393|NCT00642876|Active Comparator|Control|The Control cohort are patients that receive the fusion treatment.
89658394|NCT00642876|Experimental|Investigational|The Investigational cohort are the study patients that received the PRESTIGE® Cervical Disc.
89658395|NCT00602667|Experimental|Low-Risk Patients|"Patients with GTR/M0 medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.~Note: Accrual to the low-risk medulloblastoma cohort is closed as of 12/2/2015. Accrual to the low-risk high grade glioma remains open."
89658396|NCT00602667|Experimental|High-Risk Patients|Patients with CNS metastatic disease will receive induction chemotherapy and high-risk therapy.
89658397|NCT00602667|Experimental|Intermediate-Risk Therapy|Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
89658398|NCT00594789|Experimental|1 (physician-only)|Physician(s) connected with a fracture that meets study inclusion criteria.
89658399|NCT00594789|Experimental|2 (physician/patient)|Physician(s) and patient connected with a fracture that meets study inclusion criteria.
89047135|NCT01215175|Experimental|V114 Nonadjuvanted-Toddler Cohort|Healthy toddlers (12-15 months of age) participants who completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of non-adjuvanted V114 on Day 1.
89047136|NCT01215175|Active Comparator|Prevnar™- Toddler Cohort|Healthy toddlers (12-15 months of age) participants who had previously completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
89047137|NCT01215175|Experimental|V114 Adjuvanted -Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
89047138|NCT04664283|Experimental|DCB group by OCT guided|
89047139|NCT04664283|Active Comparator|DES group by OCT guided|
89047140|NCT03580148|Active Comparator|Cortisone|Patients randomized to this arm will receive one (1) ultrasound guided injection of 80mg Depo Medrol cortisone in the glenohumeral joint of the affected shoulder. Procedure time of approximately 10 minutes
89047141|NCT03580148|Active Comparator|Bone Marrow Aspirate|Patients randomized to this arm will receive one (1) ultrasound injection of bone marrow aspirate, harvested from the posterior superior iliac spine, and injected into the glenohumeral joint of the affected shoulder. Procedure time of approximately 45 minutes
89658400|NCT00594789|No Intervention|Control|Usual care.
88994458|NCT02940145|Experimental|intervention 1|"The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums.The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise.~Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise"
88994459|NCT02940145|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
88994460|NCT02940067|Experimental|MedEx|This group will receive nutritional supplementation (based on components of the MEDiterranean diet) and supervised EXercise training for four weeks - hence the trial name, MedEx.
88994461|NCT02940067|No Intervention|Standard Care|This group will follow current standard preoperative care before scheduled pancreatic resection.
89658401|NCT00492999|Experimental|Group 1|Patients receive hepatic arterial infusion (HAI) therapy comprising floxuridine and dexamethasone continuously on days 1-14. Patients also receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 30 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89658402|NCT00492999|Experimental|Group 2|Patients receive HAI therapy as in group 1. Patients also receive irinotecan hydrochloride IV over 30 minutes and leucovorin calcium IV over 30 minutes on days 1 and 15 and fluorouracil IV continuously over 48 hours on days 1, 2, 15, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88994462|NCT00169650||1|Registry and database of subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction
88994463|NCT02940028|Experimental|Expressive writing intervention|The intervention group will participate in a brief expressive writing intervention.
88994464|NCT02940028|Other|Control writing intervention|The control group will receive a control writing condition (fact based writing).
88994465|NCT02939482|Active Comparator|Group 1: 40 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 0.5 min
88994466|NCT02939482|Experimental|Group 2: 20 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 1 min
88994467|NCT00405782|Active Comparator|Immediate Exercise Group|Exercise Intervention begins immediately
88994468|NCT00405782|Active Comparator|Delayed Exercise Group|Exercise intervention delayed by 16 weeks
88994469|NCT02939521|Experimental|Surgery|Consists of a dorsal flattening of of the bone at the distal phalanx, with a frontal lifting of the distal skin of the toe
88994470|NCT02939443|Other|cross-sectional study|
88994471|NCT02939248|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
88994472|NCT02939248|Active Comparator|Crushed ticagrelor, morphine,naloxone|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
88994473|NCT02939053||Single-arm|All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.
88994474|NCT00169689|Sham Comparator|rTMS|sham coil system versus verum rTMS stimulation
88994475|NCT02938975|Placebo Comparator|Placebo|placebo group receiving untreated army combat uniform and placebo lotion. Assigned interventions: Placebo lotion - a liposome lotion with no DEET Army combat uniform - army combat uniform with no permethrin
88994476|NCT02938975|Active Comparator|Combo|"Combined intervention group of receiving Permethrin treated uniform 0.52% w/w and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) One application of Lipo DEET protects for up to 12 hours. DEET is a broad spectrum insect repellent that has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft Permethrin is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings."
88994477|NCT02938975|Active Comparator|Permethrin|"permethrin intervention group receiving Permethrin treated uniform 0.52% w/w and placebo lotion.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft~Placebo lotion: liposome lotion with no DEET"
88994478|NCT02938975|Active Comparator|DEET|"DEET intervention group receiving untreated army combat uniform and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) Army combat uniform with no permethrin"
88994479|NCT02939092|Experimental|Pomegranate peel extract|Pomegranate is antimicrobial, anti inflammatory and antioxidant
88994480|NCT02939092|Active Comparator|Chlorhexidine|Chlorhexidine mouthwash is antiplaque treatment and effective against gingivitis
88994481|NCT02938936|Experimental|Scheduling Intervention|Pre-natal visit scheduling
88994482|NCT02938936|No Intervention|Control|
88994483|NCT00147056|Experimental|ExAblate transcranial system|MR Guided Focused Ultrasound
88994484|NCT02938897|Experimental|Telenutrition Intervention|Participants receive diet-related educational materials and self-monitoring tools PLUS registered dietitian nutritionist support.
88994485|NCT02938897|Active Comparator|Enhanced Usual Care Control|Participants receive diet-related educational materials and self-monitoring tools.
89658403|NCT00413439|Experimental|Low dose isavuconazole intravenous solution|
88994486|NCT02938819|Experimental|Experimental group|Patients in the experimental group received a Goal-oriented upper limb intervention.
88994487|NCT02938819|Active Comparator|Control group|Patients in the control group received a standard upper limb intervention
88994488|NCT02938741|Experimental|r-ATG Immunosuppressive agents|"Rabbit Anti-human Thymoglobulin (r-ATG 2.5 mg/kg×4 days) were extra used in the treatment group.~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
88994489|NCT02938741|Placebo Comparator|placebo|"Rabbit Anti-human Thymoglobulin (r-ATG) were not used as intervention in the treatment group.~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
89658404|NCT00413439|Experimental|High dose isavuconazole intravenous solution or oral capsules|
89658405|NCT00323466|Experimental|IMRT|
89658406|NCT00177918||lung transplant patients|
89658407|NCT00112931|Active Comparator|Watch and Wait|Watch and Wait - no treatment
89658408|NCT00112931|Experimental|Arm C Rituximab 4 and Rixuximab Maintenance|4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks
89658409|NCT00110110|Experimental|CEV Chemo + Cyclosporine & Focal Therapy|Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.
89658410|NCT05307003||Quetiapine|"Patients diagnosed with delirium who received quetiapine for treatment.~Start study medication at 25 mg daily PO ; may increase to BID (twice a day) or TID (three times a day) if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE (adverse effects) likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
89658411|NCT05307003||Trazodone|"Patients diagnosed with delirium who received trazodone for treatment.~Start study medication at 25 mg daily PO ; may increase to BID or TID if RASS>=2 or rescue medication must be given; thereafter, if med is TID, dose can be increased by increment of 50 mg q12 hr if RASS>=2 and/or >1 dose of rescue medication is given within 24 hours [max dose 200 mg/day]~dose can be reduced/discontinued per discretion of ICU attending if delirium improving, patient experiences AE likely related to study drug, after 14 days of treatment, or patient is discharged from ICU~dose should be held if RASS is -3 to -5/comatose/unresponsive or sudden acute change in mental status"
89658412|NCT03153917|Experimental|melatonin and cortisol sampling|14 healthy volunteer nurses working on 12 hours night/day schedules in the Sleep Medicine Center of Lyon.
88994490|NCT00407589|Experimental|BOL-303224-A|Systemic exposure of BOL-303224-A following single and multiple topical doses
88994491|NCT02938858||ATRA-chimio|according to usual practice center
88994492|NCT02938858||ATRA-ATO|according to usual practice center
88994493|NCT00147095||HEALTHY NON-SMOKER|Healthy non-smoker participants
88994494|NCT00147095||HEALTHY SMOKER|Healthy smoker participants
88994495|NCT00147095||COPD and smoking|Smoking participants with COPD
88994496|NCT02938546|Active Comparator|before therapy|18F-FDG PET/CT performed before therapy
88994497|NCT02938546|Experimental|3 days after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed 3 days after chemotherapy and targeted therapy
88994498|NCT02938546|Experimental|longer time after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed before the third cycle chemotherapy and the 7th week targeted therapy
88994499|NCT00175344|Experimental|A|Arm A: Self-administered massage of the postoperative scar after breast cancer surgery.
88994500|NCT00147134|Active Comparator|1|Procedure/Surgery: open colectomy
88994501|NCT00147134|Experimental|2|Procedure/Surgery: laparoscopic colectomy
88994502|NCT04891393|Experimental|Caffeine|Single-dose, orally ingested, instant coffee.
88994503|NCT04891393|Placebo Comparator|Inactive Placebo|Single-dose, orally ingested, instant decaffeinated coffee (equal weight to intervention dose).
88994504|NCT03458065||S-ICD|
88994505|NCT03458065||T-ICD|
88994506|NCT02938663||Questionnaires and measurements|assessment of physical activity, dietary intake, psychosocial factors, weight status
89658413|NCT03153995|Experimental|sub-periosteal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-periosteal positions using the tunnel technique.
89658414|NCT03153995|Active Comparator|periosteal releasing incision|periosteal releasing incision will be performed for Eight patients during ridge augmentation surgery .
89658415|NCT03154073|Experimental|Moderate Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of moderate intensity exercise per week. Exercise will be supervised by trained staff.
89658416|NCT03154073|Experimental|Vigorous Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of vigorous intensity exercise per week. Exercise will be supervised by trained staff.
89658417|NCT02294409|Experimental|Cognitive-behavioral therapy (CBT)|Manualized group cognitive-behavioral therapy for social anxiety in first episode psychosis
88994507|NCT02938702||Active surveillance|Group with active surveillance of their PTC
88994508|NCT02938702||Surgery|Group who underwent surgery after diagnosis of PTC
88994509|NCT02938780|Placebo Comparator|Control|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
88994510|NCT02938780|Experimental|Intervention|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message.
88994511|NCT04690543|Active Comparator|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
88994512|NCT04690543|Experimental|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
88994513|NCT00175383|Experimental|Leuprolide preparations|One versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program
88994514|NCT02938468|Active Comparator|Surgery|Patients in this arm will receive any form if surgical intervention (i.e. bedside burrhole craniostomy, 2 burrhole washout, craniotomy, endoscopy etc.) for treatment of their chronic subdural hematoma
88994515|NCT02938468|Experimental|Dexamethasone|Patients in this arm will receive Dexamethasone over a 21day period for treatment of their chronic subdural hematoma
88994516|NCT02938507|Experimental|Formulation 1 solabegron|Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
89213515|NCT04925102||GMFCS level II|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level II will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
89658418|NCT02294409|Active Comparator|Computer assisted Cognitive Remediation therapy (CACRT)|Group computer assisted cognitive remediation therapy
89658419|NCT03013413|Experimental|Diagnostic (elastography imaging using the Aixplorer system)|Patients undergo ultrasound-based elastography imaging using the Aixplorer system followed by standard of care ultrasound-guided prostate biopsy over approximately 25 minutes.
89658420|NCT02088905|Experimental|Parent Child Interaction Therapy|Families will either receive Parent Child Interaction Therapy or be placed on a wait-list control group
89658421|NCT02088905|No Intervention|Wait list control|Families will wait 18 weeks for treatment, serving as controls.
89658422|NCT03014115|Active Comparator|combination ARA+ DHA|combination 0.76% ARA+ 0.4% DHA in infant formula per day
89658423|NCT03014115|Experimental|DHA|0% ARA +0.4% DHA in infant formula per day
89658424|NCT02088047|Experimental|Profoveate|The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment. Steel pellets (1.2 mm) will be placed strategically on ears following instructions on how to use the ProFoveate™ pellets. Parents will be provided with a Patient Diary Sheet and will be instructed to perform and document daily checks for placement of the pellets. Parents will be given a one month supply of stainless steel pellets at the initial study visit. Child participants will wear the stainless steel ProFoveate™ pellets for four weeks.
89658425|NCT02088047|No Intervention|NonProFoveate|Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
89658426|NCT05186727|Active Comparator|Researcher-Group|Education delivered in a group session by a member of the research team
89658427|NCT05186727|Active Comparator|Research-One on One|Education delivered telephonically one-on-one by a member of the research team
89658428|NCT05186727|Active Comparator|Patient Ambassador-Group|Education delivered in a group session by a Patient Ambassador (a peer mentor)
89658429|NCT05186727|Active Comparator|Patient Ambassador- One on One|Education delivered telephonically one-on-one by a Patient Ambassador (peer mentor)
89658430|NCT05433935||Prospective IPMN cohort|Multi-omics analysis of 5000 prospectively collected samples.
89658431|NCT01096875|Active Comparator|Atorvastatin|Hydroxymethylglutaryl-CoA Reductase Inhibitors
89658432|NCT01096875|Placebo Comparator|Placebo|Atorvastatin like pill
89658433|NCT03581045||ALL Survivors|Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
89658434|NCT03581045||Control Group|Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
89658435|NCT03153605|Experimental|SATISI_7|
89658436|NCT01097343|Active Comparator|75 mg clopidogrel|
89658437|NCT01097343|Active Comparator|150 mg clopidogrel|
89658438|NCT02246751|Experimental|Single subject design case series|Targeted Training for trunk control, 5-6 days a week for 9 months, minimum of 20 minutes per day.
89658439|NCT03153293|Experimental|rAAV2-ND4|A Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
89658440|NCT05347745|Other|Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit|The therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx (US) instrument for the detection of seven somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE), colorectal cancer (CRC) tissue
89658441|NCT04352829|Experimental|EXPERİMENTAL GROUP|1st day, patients were asked to use an MDI sample that didn't contain an active agent. At the same time, they filled the MDI Skill Evaluation Form, obtaining 'the scores of the 1st measurement'. Next, MDI use was explained through the video twice. After each video and explanation, the patients were asked to use the same MDI sample for 10 min. Simultaneously, the skills were marked by the researcher through observation on the form, obtaining 'the scores of the 2nd measurement'. 2nd day, they were again asked to use the MDI. While using the MDI, the form was marked and 'the scores of the 3rd measurement' were found. Later, a video session was held as on the 1st day, the video was watched twice, and after each repetition, were requested to use the MDI again. While they were using the MDI, the skills were simultaneously marked on the form and 'the scores of the 4th measurement were determined. 3rd day, all steps were repeated.
89658442|NCT04352829|No Intervention|CONTROL GROUP|20 patients were recruited to the control group. The controls received a routine training on MDI from their clinic nurses including verbal explanation of MDI use. The controls received training about MDI use in line with ethical principles and watched the video once after the 5th measurement. After the study, participants who wished to watch the training video again were provided internet links.
89658443|NCT01677533|Active Comparator|PM-Data|Team will receive data only.
89658444|NCT01677533|Experimental|PM-Support|Team will receive data and panel management support
88994517|NCT02938507|Experimental|Formulation 2 solabegron|Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
88994518|NCT02938429|Other|Participants with Fontan circulation|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
89047142|NCT04664517|Active Comparator|FIN (Flexible intramedullary nail)|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
89658445|NCT01677533|Experimental|PM-Education|Team will receive data, panel management support, and educational interventions.
89658446|NCT04729127|No Intervention|Treatment as usual|The families keep receiving their treatment as usual
89047143|NCT04664517|Active Comparator|Long arm cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
89047144|NCT04664517|Other|Patient Choice FIN|Fracture reduction and fixation using flexible intramedullary nails. Nails size is 0.4 times the smallest diameter of the medullary canal of radius or ulna measured in radiographs.
89047145|NCT04664517|Other|Patient Choice cast|Fractures are reduced under general anesthesia within 3 days from injury and a synthetic circular above elbow cast in neutral pro-supination is applied for six weeks.
89658447|NCT04729127|Active Comparator|ImPACT at a dose of 1 hour/week|ImPACT at a dose of 1 hour/week over 6 months
89658448|NCT04729127|Active Comparator|ImPACT at 4 hours/week|ImPACT at 4 hours/week over 6 months.
89658449|NCT03580187|Other|morphine +|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success.~morphine (+) group: good response to morphine in nebulization after 30 min if VAS > than 4 we conclude to morhine (-)"
89658450|NCT02086565|Experimental|Portal training and home visits|Portal training and home visits from a community health worker to promote care coordination and use of the patient portal
89658451|NCT02086565|Active Comparator|portal training|Participants are assured internet access and taught to use the patient portal
89658452|NCT02085941|Experimental|MRI guided cryoablation +/- biopsy|Intraoperative MRI guidance for cryoablation of tumor using 17G Galil cryoprobe with concurrent biopsy with 18G Temno core biopsy needle if biopsy not previously performed
89658453|NCT02085941|Experimental|PET-CT guided cryoablation +/- biopsy|Intraoperative PET-CT guidance for cryoablation of tumor using 17G Galil cryoprobe with concurrent biopsy with 18G Temno core biopsy needle if biopsy not previously performed
89658454|NCT02085785|Experimental|Coached|Participants randomized to the coached arm will receive the same educational and self-monitoring materials as the self-directed group. In addition, participants in the coached arm will receive 11 calls from a health coach and a single visit to their home by an exercise specialist.
89658455|NCT02085785|Active Comparator|Self-directed|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group, but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
89658456|NCT02085785|Other|Screened|Individuals who were contacted to inform them about the study or who contacted study personnel to express an interest in participating. This group is presented in order to present statistics on feasibility regarding recruitment
89658457|NCT01098747|Experimental|Treatment A|
89658458|NCT01098747|Active Comparator|Treatment B|
89658459|NCT01098747|Active Comparator|Treatment C|
89658460|NCT01098747|Placebo Comparator|Treatment D|
89658461|NCT02085161|Placebo Comparator|placebo|patient will receive placebo once daily, 2 puffs in the morning
89658462|NCT02085161|Experimental|tiotropium + olodaterol high dose with BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
89658463|NCT02085161|Active Comparator|tiotropium|patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
89658464|NCT02085161|Experimental|tiotropium + olodaterol with exercise training and BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
89658465|NCT01034553|Experimental|Arm I|Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11.
89658466|NCT01035333|Experimental|orlistat 60mg|Patients assigned to treatment group for up to 6 months of therapy.
89658467|NCT03579017||Patients with ALS|Patients with ALS will be tested by two independent testers with the ECAS-N at 4 months (baseline) and 8 months (follow-up), and the MoCA at 4 months (baseline) by one tester
89658468|NCT03579017||Healthy controls|Persons with no cognitive impairment will be tested with the ECAS-N once, by one tester
89658469|NCT03579017||Controls with dementia|Persons with cognitive impairment due to other disorders will be tested with the ECAS-N once, by one tester
89658470|NCT05073549|Experimental|Collaborative antimicrobial stewardship group|Collaborative antimicrobial stewardship intervention will be implemented in NICUs of this group.
89658471|NCT03577301|Active Comparator|Clinic-based Delivery|Participants will receive the intervention in person following HIV counseling and testing. The intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
89658472|NCT03577301|Active Comparator|Remote Delivery|Participants will receive the intervention by remote delivery following HIV counseling and testing. Just as the clinic-based participants, he intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
89658473|NCT03577301|Active Comparator|Multi-modal Delivery|A 4 session MI intervention. Session 1 is always delivered in person immediately after baseline. Session 2-4 can be delivered in person or remotely based upon youth preference. This arm is open to enrollment as of 11/15/2019.
89658474|NCT03577301|No Intervention|Treatment as Usual|Treatment as usual control = individual HIV testing with referrals and link age to care as provided by the sites under routine circumstances. This arm is open to enrollment as of 11/15/2019.
89658475|NCT03013179||Black/African American Women and their 3-5 year old children|
89658476|NCT03152981|Active Comparator|Desflurane group|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure
89047146|NCT01215097|Experimental|Linagliptin|once a day
89047147|NCT01215097|Placebo Comparator|placebo|once a day
89047148|NCT04664322||NIV/HFNC|patients receiving non-invasive ventilation than high flow nasal canulae oxygen therapy
89047149|NCT04664322||HFNC/NIV|patients receiving high flow nasal canulae oxygen therapy than non-invasive ventilation
88994519|NCT02938429|Other|Age and gender matched controlled|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
88994520|NCT00407667|Experimental|1|patients receive 20 min of anodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
88994521|NCT00407667|Experimental|2|patients receive 20 min of cathodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
88994522|NCT00407667|Sham Comparator|3|patients receive 20 min of sham transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
88994523|NCT02938312|Active Comparator|Weight Loss Only|24- month weight loss program (year 1: weekly in-person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
88994524|NCT02938312|Experimental|Weight Loss Plus|"Same intervention as Weight Loss Only but includes community-wide interventions to increase access to healthy affordable food and opportunities for safe and convenient physical activity"
88994525|NCT02938351|Experimental|collaborative care|To test the efficacy of a collaborative care intervention with patients treated with dialysis to reduce depression, pain, fatigue, and improve quality of life
89658477|NCT03152981|Active Comparator|Propofol group|In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
89658478|NCT04762355|Experimental|Dose 1|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
89658479|NCT04762355|Experimental|Dose 2|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
89658480|NCT04762355|Experimental|Dose 3|Subjects were randomized in a 3:1 ratio to receive one dose regimen of either active treatment or placebo (vehicle). Advancement of the study from the once daily (QD) dosing regimen to the twice daily (BID) dosing regimen, and dose escalation to the next dose regimen
89658481|NCT03153059||group 1|a large number of defecation group (≥ 2-3 times/day) - 20 subjects
89658482|NCT03153059||group 2|normal defecation group (1 time/day or 1 time/2 days) - 20 subjects
89658483|NCT03153059||group 3|a small number of defecation group (≤ 2 times/week) - 20 subjects
89658484|NCT03572387|Experimental|(5-AZA) + (ATRA) combination|Combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group after one month of Lupron, group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
89658485|NCT03572387|Active Comparator|Lupron only|No treatment after one month of Lupron
89213516|NCT04925102||GMFCS level III|Goal specific treatment protocol with respect to the problem enlisted in GMFCS level III will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
89658486|NCT04728971|Experimental|Micafungin Preventing Group|
89658487|NCT04728971|Active Comparator|Others Preventing Group|
89658488|NCT04185155|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
89658489|NCT04185155|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
89658490|NCT03152747||A|"Group A with pre-operative complete posterior vitreous detachment Group A will be invited for one follow-up visit (two months post-operatively) followed up by telephone interviews at one, two, three and five years after surgery to determine occurrence of pseudophakic retinal detachment.~Examinations: Best corrected Visual Acuity (BCVA) , SD-OCT (spectral domain optical coherence tomography), Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
89658491|NCT03152747||B|"Group B with no/partial PVD~Group B will be invited for follow-up examinations at two months, six months and one year after surgery to document occurrence of PVD (if a PVD is present at one of the follow-ups, no more visits are necessary). Two, three and five years after surgery, all patients from group B will be interviewed by telephone, as in group A, to document the occurrence of pseudophakic retinal detachment.~Examinations: BCVA, SD-OCT, Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
89658492|NCT03568643|Experimental|Azithromycin|children in this arm will receive one dose of azithromycin
88994526|NCT02938195|Experimental|experimental arm|PF regimen (cis-platinum of 25 mg/m2/d, d1-3; 5-fluorouracil of 500mg/m2/d, d1-4) every 4 weeks for 2 cycles concurrently with three-dimensional radiation therapy or intensity-modulated radiotherapy followed by surgery 4-8weeks after neoadjuvant therapy in a standard manner.
89658493|NCT03568643|Active Comparator|Amoxicillin|Children in this arm will receive a 7 day course of amoxicillin (standard of care)
89658494|NCT01100931|Experimental|YM155 in Solid Tumors|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days."
88994527|NCT04773106|Other|Single-arm longterm Follow up ARGOS-SC Sensor Pressure system|The ARGOS-SC sensor was already implanted in a previous study as ARGOS-SC01.
88994528|NCT03457870|Experimental|Intermittent Energy Restriction|Dietary intervention: Intermittent energy restriction
88994529|NCT03457870|Experimental|Chewing|Mastication intervention: chewing
89213517|NCT04925102||GMFCS level IV|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level IV will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
89213518|NCT04925102||GMFCS level V|Goal specific treatment protocol with respect to the problem enlisted in gross motor function measure (GMFCS) level V will be provided to the spastic cerebral palsy children in the sets of 15-30 repetitions. The protocol will be performed in 30-40 minute sessions thrice a week.
89213519|NCT00879554|Experimental|1|
89213520|NCT00879632||1|TREATMENT AS USUAL
89213521|NCT00879632||2|CONTROLS
89658495|NCT01101867|Experimental|Aspart flexible dose|aspart dose determined based upon carbohydrate intake.
89658496|NCT01101867|Active Comparator|Aspart fixed dose|fixed meal dose of aspart (based upon weight or total daily insulin dose)
89213522|NCT00868946|Experimental|Treatment with IND Ribavirin|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with IND Virazole (Ribavirin) for 7 days with multiple dosing regime based on weight and dosage day.
89213523|NCT00874016|Active Comparator|Airtraq|Intubation with the use of the Airtraq
89658497|NCT01039467|Active Comparator|Managed Ventricular Pacing|Managed Ventricular Pacing group: programmed on
89658498|NCT01039467|Active Comparator|Search AV+|Search AV+: programmed on
89658499|NCT01102413|Experimental|Monofer|Injections or infusions
89658500|NCT01102413|Active Comparator|Iron Sulphate|Oral intake
89658501|NCT01103271|Experimental|Open-label Placebo Immediate Treatment|Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.
89213524|NCT00874016|Active Comparator|Direct Laryngoscopy|Intubation using direct laryngoscopy
89213525|NCT00482014|Experimental|A: Pemetrexed + Carboplatin|Pemetrexed + Carboplatin
89213526|NCT00482014|Experimental|B: Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
89213527|NCT00879788|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
89658502|NCT01103271|Placebo Comparator|Open-label Placebo Waitlist Treatment|Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.
89658503|NCT01103505|Other|ForeseeHome AMD Monitoring Device|Participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device in addition to standard care
89658504|NCT01103505|No Intervention|Standard care alone (control) arm|Standard care instruction per clinic routine for home vision monitoring to detect progression of AMD and routine eye exams
89213528|NCT00879788|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
89213529|NCT03595553|Experimental|ridinilazole|ridinilazole 200mg bid
89213530|NCT03595553|Active Comparator|vancomycin|vancomycin 125 mg qid
89658505|NCT01103973|Placebo Comparator|Control (Spa Certificate)|For every three months in the study control subjects received $50 spa gift certificates.
89658506|NCT01103973|Experimental|Mind/Body Program|Ten week group mind/body program. Skills include relaxation training, cognitive strategies, and lifestyle modifications.
89658507|NCT01104207|Experimental|Arm 1|Half of the study participants will receive 2000 pulses of 1 Hz active rTMS daily on 10 consecutive work days.
89658508|NCT01104207|Sham Comparator|Arm 2|Half of the study participants will receive 2000 pulses of 1 Hz placebo rTMS daily on 10 consecutive work days.
89658509|NCT01104285||Standard care|Treatment of pleural effusion with diuresis
89658510|NCT01104285||Chest tube|Treatment of pleural effusion with diuresis and chest tube
88994530|NCT03457870|Experimental|Chewing + Intermittent Energy Restriction|Dietary and mastication intervention: Intermittent energy restriction and chewing
89213531|NCT00874172|Active Comparator|2|Combination of acetaminophen, morphine
89213532|NCT00874172|Experimental|1|Combination of acetaminophen, nitrous oxide, nefopam, morphine
89213533|NCT04119154|Experimental|Standard diagnosis and CEM platform|Participants will receive standard diagnostic approach and assessment by CEM platform
89213534|NCT00614822|Other|one arm for study|Carboplatin, Pemetrexed and Bevacizumab are given day 1 every 3 weeks for 6 cycles and will be continued if patient tolerates treatments and has stable disease. The Bevacizumab will be continued every 3 weeks for 1 year if the patient tolerates treatment and has stable disease.
89213535|NCT04861298|Active Comparator|Standard of care (SOC)|This arm will receive the standard of care (SOC) for COVID-19 as per the hospital guidelines.
89213536|NCT04861298|Experimental|Quercetin|This arm will receive standard of care + oral Quercetin for two weeks
89213537|NCT00869102|Experimental|GLP-1|
89213538|NCT03582917|Experimental|Alphacalscidol|0,5mg tablet by mouth, one each day for one year
89213539|NCT03582917|No Intervention|No treatment|
89213540|NCT05226728|Experimental|pharmacokinetic-guided pembrolizumab cohort|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression.
89213541|NCT00869180|Experimental|Diclofenac Sodium Patch|
89213542|NCT00869180|Placebo Comparator|Topical Placebo Patch|
89213543|NCT00874328|Experimental|study arm|Irinotecan /IV D1 Cisplatin 60mg/m2 iv D1 S-1 bid, P.o. D1 ~ 14 q 3 weeks until maximum 6 cycles
89213544|NCT00879866|Experimental|1|
89658511|NCT04973709||Delirium with dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
89213545|NCT00879944||Psoriasis|Children ages 5-17 years old with moderate or severe plaque type psoriasis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
89213546|NCT00879944||Atopic Dermatitis Controls|Children ages 5 to 17 years old with moderate to severe atopic dermatitis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
89658512|NCT04973709||Dementia without Delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
89658513|NCT04973709||Delirium without Dementia|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
89658514|NCT04973709||No dementia, No delirium|Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.
89658515|NCT04948515||group 1 patients with severe covid 19 respiratory infections|Patients with severe covid 19 admitted to ICU, blood samples will be collected for testing different genotypes and serum level of IL 17
89658516|NCT04948515||group 2 patients with non severe covid 19 respiratory infections|Patients with nonsevere covid 19 admitted to the internal ward, blood samples will be collected for testing different genotypes and serum level of IL 17
89658517|NCT03014349||primary open-angle glaucoma and/or glaucoma suspects|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
89658518|NCT03013959||Resting control group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are observed as control group
89658519|NCT03013959||Resting test group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are treated with pranoprofen and observed as test group
89658520|NCT03013959||Active control group|The active control group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are observed as control group
89658521|NCT03013959||Active test group|The active test group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are treated with pranoprofen and observed as test group
89658522|NCT02246595|Active Comparator|CaCP29|dose escalating i.v. administration of CaCP29 (verum)
89658523|NCT02246595|Placebo Comparator|Placebo|dose escalation mimicing i.v. placebo treatment:
89658524|NCT01106859|Active Comparator|zopiclone|Zopiclone is taken at bedtime 9 hours before driving. The middle-of-the-night medication is a placebo matching zolpidem tartrate sublingual tablet.
89658525|NCT01106859|Experimental|zolpidem 3 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 3 hours prior to driving.
89658526|NCT01106859|Experimental|zolpidem 4 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 4 hours prior to driving.
89658527|NCT01106859|Placebo Comparator|Placebo|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is a placebo matching zolpidem tartrate sublingual tablet.
88815720|NCT01089062|Other|Treatment C, then Treatment A, then Treatment B|"The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
89658528|NCT03013803|Experimental|Nutricomp Drink Plus Fibre|Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)
89658529|NCT03016143|Active Comparator|Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
89658530|NCT03016143|Active Comparator|Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
89658531|NCT03016143|Experimental|Group #3 (Vaccine VAXIGRIP)|50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP
89658532|NCT03016143|Experimental|Group #4 (Vaccine VAXIGRIP)|50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP
89658533|NCT01042509|Experimental|Alemtuzumab and rituximab|Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.
89658534|NCT02179047||stable angina, biomarker|patients with stable angina who received coronary angiography.
89658535|NCT02179047||placebo|healthy subject
89658536|NCT02179671|Experimental|Gefitinib with a Seq. Switch to a MEDI4736|Gefitinib once daily followed by MEDI4736
89658537|NCT02179671|Experimental|AZD9291 with a Seq. Switch to a MEDI4736|AZD9291 once daily followed by MEDI4736
89658538|NCT02179671|Experimental|Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736|Selumetinib twice daily + docetaxel, followed by MEDI4736
89658539|NCT02179671|Experimental|Tremelimumab with a Seq. Switch to a MEDI4736|Tremelimumab every 4 weeks followed by MEDI4736
89658540|NCT02322333|Active Comparator|MLD10|Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
88994531|NCT03457870|No Intervention|Control|No intervention: Control
88994532|NCT02938273|Experimental|Bioimmunoradiotherapy|Concurrent Radiation therapy (i.e. 5 times a week, 7 weeks, total dose 70 Gy) with cetuximab (loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7) and Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months (wk 8,10, 12, 14, 16, 18, 20, 22, 24, 26.
88994533|NCT02941939|Active Comparator|Ambient pressure arm|High intensity training will be completed while the subjects are breathing normal air.
88994534|NCT02941939|Experimental|Hyperoxic-hyperbaric arm|The high intensity training program will be carried out in a hyperbaric chamber.
88994535|NCT02941861||recurrence rate of HCC after surgery|There were 33 for Hepatocellular carcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
89047150|NCT04318795|Experimental|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
89047151|NCT04318795|Experimental|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
89047152|NCT03527576|Active Comparator|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
89047153|NCT03527576|Placebo Comparator|Placebo|Intravenous injection of NaCl 0,9% before the surgery.
89658541|NCT02322333|Placebo Comparator|Placebo|Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
89658542|NCT01110135|Experimental|Treatment (chemotherapy and colony-stimulating factor)|"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until > 5 x 10^6 CD34+/kg has been collected.~."
89658543|NCT03015987|Experimental|diode laser activated irrigation|Laser-activated irrigation (LAI) has been introduced as a powerful method enhancing irrigant action; The laser radiation produces transient cavitation in the liquid through optical breakdown by strong absorption of the laser energy. The high-power diode laser has been tested in several areas of dentistry such as bleaching, depigmentation and gingivectomy, with promising results in dentinal disinfection. The diode laser has proved to be a resource worth testing, because of the it's properties and its low cost and availability in comparison to most lasers used in endodontics.
89658544|NCT03015987|Active Comparator|ultrasonic activated irrigation|"ultrasonics have been developed to improve the penetration and effectiveness of irrigation in peripheral areas of the root canal space. The efficiency of sonic and ultrasonic devices is based on the creation of hydrodynamic phenomenon in well-shaped canals filled with an irrigant.~Such active root canal irrigation has been shown to facilitate the disruption of biofilms and make the cell membrane of bacteria more permeable to NaOCl."
89658545|NCT01043133|Experimental|Intervention group|
89658546|NCT01043133|No Intervention|Control Group|
89658547|NCT01043523||Group 1|
89658548|NCT01112241|Experimental|albuterol-tiotropium|At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide [Spiriva®] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).
89658549|NCT03013881|Experimental|UB-921 2 mg/kg (Main-study)|Intravenous infusion
89658550|NCT03013881|Experimental|UB-921 6 mg/kg (Main-study)|Intravenous infusion
89658551|NCT03013881|Experimental|UB-921 8 mg/kg (Main-study)|Intravenous infusion
89658552|NCT03013881|Experimental|UB-921 6 mg/kg (Sub-study)|Intravenous infusion
89658553|NCT03013881|Active Comparator|Herceptin 6 mg/kg (Sub-study)|Intravenous infusion
89658554|NCT02174913|Active Comparator|bispectral index/TCI propofol/fentanyl|Bispectral index guides the target controlled infusion of propofol by keeping BIS 40-60 throughout operation. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
89658555|NCT02174913|Placebo Comparator|clinical signs/TCI propofol/fentanyl|Clinical signs (heart rate, blood pressure and movement) guide target controlled infusion(TCI) of propofol. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
89658556|NCT01112865|Other|Mark VII/Current pen|Subject will use Mark VII pen for 2 months followed by Current pen for 2 months
89658557|NCT01112865|Other|Current pen/Mark VII|Subject will use current Genotropin pen for 2 months followed by Mark VII pen for 2 months
88994536|NCT02941861||recurrence rate of CCA after surgery|There were 34 patients underwent liver resection for Cholangiocarcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
89658558|NCT01113723|Other|CMAC Device|CMAC Intubating device time to achieve successful tracheal intubation.
89658559|NCT01113723|Active Comparator|Fiberoptic bronchoscope|Fiberoptic bronchoscope Intubating device time to achieve successful tracheal intubation.
89658560|NCT01114503|Experimental|Part A|Up to 4 cohorts of 5 patients receive dose rising treatments of otelixizumab
89658561|NCT01114503|Experimental|Part B - Otelixizumab|Parallel dosing group in Part B receive otelixizumab over 8 days at a dose decided upon results from Part A
89658562|NCT01114503|Active Comparator|Part B - Methylprednisolone|Parallel dosing group in Part B of weekly doses of methylprednisolone for 12 weeks
89658563|NCT03015831|Active Comparator|Colchicine|Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge
89658564|NCT03015831|Placebo Comparator|Placebo Oral Tablet|Identical tablet (placebo) administered in a similar way as that in the active comparator arm
89658565|NCT03015909|Other|Eutropin pen inj.|
89658566|NCT01044537|Placebo Comparator|Placebo|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.
89658567|NCT01044537|Experimental|PF-04937319|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319
89658568|NCT01114581|Active Comparator|Guaifenesin|Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
89658569|NCT01114581|Placebo Comparator|Placebo|Given as 2 tablets
89658570|NCT01114893|Active Comparator|TRAVATAN|TRAVATAN 0.004% once daily
89658571|NCT01114893|Placebo Comparator|Travoprost Vehicle|Travoprost Vehicle
89658572|NCT01114893|Experimental|Travoprost Group A|Travoprost Group A
89658573|NCT01114893|Experimental|Travoprost Group B|Travoprost Group B
89658574|NCT01114893|Experimental|Travoprost Group C|Travoprost Group C
89658575|NCT01114971|Active Comparator|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or Heart Rate (HR) > 80 bpm)"
89658576|NCT01114971|Experimental|Labetalol|"Labetalol 5 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
89658577|NCT01114971|Experimental|Esmolol|"Esmolol 10 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
89658578|NCT01044693|Placebo Comparator|Placebo capsule|Placebo capsule
88994537|NCT00169767||A|Comparison study between KTP and HoLAP procedures for BPH
88994538|NCT02941588||non-cardiac surgery after DES|The patients who underwent non-cardiac surgery after percutaneous coronary intervention with drug-eluting stent
88994539|NCT02941744|Experimental|IpNiv|low fixed dose ipilimumab plus low fixed dose nivolumab
89658579|NCT01044693|Experimental|Nebivolol 5 mg|Nebivolol 5 mg capsule
89658580|NCT01044693|Active Comparator|Metoprolol tartrate 50 mg|Metoprolol tartrate 50 mg single oral dose
88994540|NCT02941822|Experimental|Arm 1|"Each patient will self-administer the study drug, ambroxol (60 mg per tablet) at 5 intra-dose escalations (DE) over the duration of 6 months that will be taken three times a day, see below:~Day 1-7, 60 mg~Day 8-14, 120 mg~Day 15-21, 180 mg~Day 22-28, 300 mg~Day 29-186, 420 mg"
88994541|NCT02941471|Experimental|Interferential Stimulation|Medical Device: Interferential stimulation. Stimulation parameters: 4 KHz of carrier stimulation, beat frequency between 80-160Hz, amplitude upto 33mA. Delivered via two 100mm x 50mm adhesive pads placed on the anterior abdominal wall
88994542|NCT02941471|Active Comparator|Standard electrical stimulation|Medical Device: Standard electrical stimulation. Parameters set to provide continuous electrical stimulation at a pulse width of 210µs and a frequency of 14Hz and an amplitude upto 33mA.
88994543|NCT02941510|Experimental|Budesonide|Will participate in all study activities but will receive budesonide.
88994544|NCT02941510|Placebo Comparator|Placebo|Will participate in all study activities but will receive placebo.
89658581|NCT01044693|Active Comparator|Sildenafil 25 mg|Sildenafil 25 mg single oral dose
89658582|NCT01115517|Experimental|Bevacizumab|
89658583|NCT01115517|Active Comparator|Mitomycin C|
89658584|NCT04723953|Experimental|Acute myocardial infarction patient group|
89658585|NCT03015675|Experimental|Ascorbic Acid with mFOLFOX6 group|"Ascorbic Acid with mFOLFOX6 Ascorbic Acid (20g/day, D1-3) every 2 weeks~mFOLOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
89658586|NCT03015675|Active Comparator|mFOLFOX6 group|"mFOLOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
89658587|NCT01044771|Other|change from tenofovir to raltegravir|"Single arm study:~Tenofovir containing nucleoside backbone changed over to raltegravir in all patients"
89658588|NCT01115673|Experimental|ACE-1000|1000 mg Acetaminophen Caplet
89658589|NCT01115673|Active Comparator|ACE-650|650 mg Acetaminophen Caplet
89658590|NCT01115673|Placebo Comparator|ACE-0|0 mg Acetaminophen Caplet
89658591|NCT04353063|No Intervention|control group|"The patients in the control group will not receive any walking exercise education until the 4-week intervention ends. They will then receive the same education material (How walking is beneficial to your health) and will be told about the benefits of walking."
89658592|NCT04353063|Experimental|experimental group|"Participants in the experimental group will also be educated on the general use of the ActiGraph through verbal and written information and will be asked to wear the ActiGraph during week 0 for 3 consecutive days. The collected physical activity parameters will be the baseline data.Afterward, participants in the experimental group will be educated with the educational materials How walking is beneficial to muscle mass and your health. And then the ActiGraph will be collected by the research assistant in order to analyze the physical activity parameters, including time spent walking and walking steps. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4."
89658593|NCT03013023|Placebo Comparator|Routine care|Control group
89658594|NCT03013023|Active Comparator|Behavioral-support interventions (BS)|NNS, FT, positional support, and oral sucrose feeding will be provided while infants are undergoing painful procedures
89658595|NCT03013023|Active Comparator|Parent-infant transaction program (PITP)|The PITP will be a six-session, one-on-one teaching intervention beginning on day 22 after birth, with four sessions at bedside, and two home-visit sessions within the first month after discharge.
89658596|NCT03013023|Active Comparator|BS+PITP|Behavioral-support interventions + Parent-infant transaction program
89658597|NCT01116921|Active Comparator|nCPAP Control Group|Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
89658598|NCT01116921|Experimental|LMA Group|Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.
89658599|NCT01117311|Experimental|VNB off first, then VNB on|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).
89658600|NCT01117311|Experimental|VNB on first, then VNB off|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).
89658601|NCT04634019|No Intervention|Control arm|Providers in control facilities will not receive any additional training or knowledge assessments.
89658602|NCT04634019|Experimental|Financial incentive arm|Providers in treatment facilities will be visited once a quarter for a knowledge assessment using vignettes. Facilities performing well in this assessment will receive a quarterly bonus payment, which will be distributed among providers.
89658603|NCT01118091|Active Comparator|Arm 1-Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
89658604|NCT01118091|Experimental|Arm 2 - Adoptive cell therapy|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x10^8) and the administration of high-dose aldesleukin.
89658605|NCT01045551|Experimental|Apremilast 20 mg (twice per day)|All subjects will receive Apremilast 20mg taken orally twice per day.
89658606|NCT01047189|Experimental|1|Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
89658607|NCT01047189|Active Comparator|2|Generic clindamycin 1% gel plus tretinoin 0.025% cream
89658608|NCT01048593|Experimental|Dose 1|114ug
89658609|NCT01048593|Experimental|Dose 2|513ug
89658610|NCT01048593|Experimental|Dose 3|684ug
89658611|NCT01118715|Experimental|Compression glove|Patients in this group have a compression glove incorporated into their splint for 2 weeks post-op, and wear a glove underneath their cast for 3 weeks. The patient then wears the glove at night after cast removal.
89658612|NCT01118715|No Intervention|Control|Patients in this group undergo standard recovery procedures. This includes a splint worn for 2 weeks post-op, followed by a short arm cast worn for the next 3 weeks.
89658613|NCT03012945|Experimental|Combined epidural-general anesthesia|Patients assigned to this group (experimental group) receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
89658614|NCT03012945|Active Comparator|General anesthesia|Patients assigned to this group (control group) receive general anesthesia and postoperative patient-controlled intravenous analgesia.
89658615|NCT01120197|Experimental|Exercise group|"Exercise group with intervention~Subjects in the intervention group must participate in a training course consisted of 24 sessions over 3 months. The exercises include aerobic, stretching, balance and functional training, i.e. circuit exercises focus been on: the prevention of falls and fractures, improving balance and coordination, improving posture, and informing subjects about risk factors for falls and for osteoporosis and fractures. A 3-hour session of information and supervision will be hold for the intervention group by the same physiotherapist who leads the training sessions. The focus is on body awareness and ergonomic advice in specific, daily-life situations (e.g. lifting/carrying, resting positions)."
89658616|NCT01120197|Other|Control Group|"Control group with no intervention~Subjects in the control group are asked to maintain their current lifestyle. No restrictions are placed on their exercise activities. The control group is followed for the same duration as the intervention group."
89658617|NCT01048905|Experimental|Treatment: L-glutamine|Patients will receive an 8-week course of oral L-glutamine 10 grams TID
89658618|NCT04352283|No Intervention|palpation|Usual method to determinate needle puncture site
89658619|NCT04352283|Experimental|Ultrasound|Ultrasound preprocedural exam used to determinate needle puncture site
89658620|NCT03010449|Experimental|Intra-bronchial valve and blood|Bronchoscopic lung volume reduction using intra-bronchial valves combined with autologous blood instillation.
89658621|NCT01121211|Active Comparator|Testosterone|Testosterone x 24 weeks
89658622|NCT01121211|Placebo Comparator|Placebo|Placebo x 24 weeks
89658623|NCT01162551|Experimental|Sirolimus and Methotrexate|"Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days"
89658624|NCT01163097|Experimental|Palifermin 40 µg/kg and heparin IV infusion|Treatment A: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections and continuous heparin IV infusion
89047154|NCT04664010|Experimental|moderate COVID-19 group|patients with moderate COVID-19 receiving western medicine treatment
89047155|NCT04664010|Experimental|severe COVID-19 group|patients with severe COVID-19 receiving western medicine treatment
89658625|NCT01163097|Experimental|Palifermin 40 µg/kg|Treatment B: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections
89658626|NCT01163097|No Intervention|Control group without any treatment|Treatment C: control group without any treatment administered.
89658627|NCT03010371|Experimental|Positive Psychotherapy|A group of breast cancer survivors are randomly allocated to the presential version of the positive psychotherapy
89658628|NCT03010371|Experimental|Positive Online Psychotherapy|A group of breast cancer survivors are randomly allocated to the online version of the positive psychotherapy
89658629|NCT03010371|Experimental|Cognitive Behavioral Therapy|A group of breast cancer survivors are randomly allocated to the presential cognitive behavioral therapy (Cognitive Behavioral Stress Management, CBSM)
89658630|NCT01163643|Experimental|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension
89658631|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension
89658632|NCT01163643|Placebo Comparator|Vehicle|Vehicle twice daily (BID)
89658633|NCT01163643|Experimental|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension
89658634|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension in the morning|2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)
89658635|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension PM|Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.
89658636|NCT01122849|Experimental|Prototype Nasal Dilator|Prototype Nasal Dilator
89658637|NCT01122849|Active Comparator|Marketed Nasal Strip|Marketed Nasal Strip
89658638|NCT01122849|Placebo Comparator|Placebo Nasal Strip|Placebo
89658639|NCT03013101|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
89658640|NCT03088137|Experimental|Primapur (Follitropin alfa)|
89658641|NCT03088137|Active Comparator|Gonal-f (Follitropin alfa)|
89658642|NCT01163955|Other|Sitting in a chair|Sitting in a chair with back support and feet flat on the ground
89658643|NCT01163955|Other|Sitting on the Floor|Sitting on the floor without back support, crossed leg style
89658644|NCT02951481||Systematic evaluation by an ID expert.|Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
89658645|NCT02951481||Retrospective historic cohort.|Patients diagnosed with CDI during 2015 in the University Hospital 12 de Octubre in which a systematic intervention was not done.
89658646|NCT01124955|Active Comparator|Intervention Group|Patients receive 5 sessions of real acupuncture. The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.
89658647|NCT01124955|Placebo Comparator|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
89658648|NCT01165047|Experimental|Nitric Oxide|80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM
89658649|NCT01165983|Placebo Comparator|Placebo|
89658650|NCT01165983|Experimental|Aliskiren|
89658651|NCT05308173||Surgical Aortic Valve Replacement|Surgically replaced aortic valve. Patients with planned concomitant bypass grafting other valvular interventions, arrhythmia ablation, or left atrial appendage occlusion were excluded. Any tissue or mechanical valve implantation in an aortic position with sternotomy or minimal access was included.
88994545|NCT05037877|Active Comparator|Intervention group|HUM supplement - 1 capsule per day
89658652|NCT05308173||Transcutaneous Aortic Valve Implantation|Transfemoral aortic valve implantation. Patients with a planned concomitant percutaneous coronary intervention were excluded
89658653|NCT05307861|Active Comparator|Pancreatic duct stenting with plastic stent|Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
89658654|NCT05307861|Active Comparator|Pancreatic duct stenting with Biodegradable Stent|Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
89658655|NCT01166139|Experimental|Nilotinib 400 mg twice daily|
89658656|NCT01166997|Experimental|Ultrasound accelerated thrombolysis|Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose <20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
88994546|NCT05037877|Placebo Comparator|Placebo group|Placebo supplement - 1 capsule per day
88994547|NCT02940184|Experimental|Enteral fructose with DPP-4 inhibition|"Enteral fructose + DPP-4 inhibition (sitagliptin)~After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals."
88994548|NCT02940184|Experimental|Enteral fructose without DPP-4 inhibition|Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
88994549|NCT03458377|Experimental|Telephone call group|The patient receives the colonoscopy information from the primary care center on the day of the request for the test and a 20 minute educational telephone call 7 days before de procedure.
88994550|NCT03458377|No Intervention|Non-telephone call group|The patient only receives the colonoscopy information from the primary care center on the day of the request for the test.
89658657|NCT01166997|Active Comparator|Intravenous unfractionated heparin|Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
89658658|NCT03010215|Other|Minimally Invasive Surgery (MIS)|Patients with plantar chronic diabetic foot ulcers will be treated by Distal Metatarsal Minimally invasive Osteotomy (DMMO).
89658659|NCT02674503|Experimental|Intensive|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
89047156|NCT04664010|Experimental|moderate COVID-19 with traditional Chinese medicine group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
89047157|NCT04664010|Experimental|moderate COVID-19 with combination therapy group|patients with moderate COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
89658660|NCT02674503|Placebo Comparator|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
89658661|NCT05307471||neuropathic pain|This study will be proposed to patients undergoing thoracotomy or thoracoscopy for partial or total lung resection in the service of Thoracic Surgery of Centre Jean Perrin (Prof. M. Filaire), the objective is to recruit 120 patients (for 100 evaluable patients) over a period of 18 months of inclusion
89658662|NCT01170117|Placebo Comparator|Placebo|Control group receiving placebo
89658663|NCT01170117|Experimental|Olanzapine|Group receiving olanzapine
89658664|NCT02577861|Experimental|Holoclar|Treatment with Holoclar (medicinal product), including biopsy, graft production and implantation of the graft containing stem cell
89658665|NCT02246907|No Intervention|Control Group|The control group will receive standard of care which includes recreational therapy and standard encouragement.
89658666|NCT02246907|Other|Exercise|Participants in this arm will receive standard of care plus exercise for the duration of their inpatient stay for induction chemotherapy.
89658667|NCT02324439|Experimental|Omega Nutrition cold-milled flaxseeds|All subjects will receive a 20g daily dose of cold-milled flaxseeds for 24 months.
89658668|NCT05306847|Experimental|Experimental arm|"Sintilimab will be given intravenously at a dose of 200mg every 21 days. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.~Tumor evaluation will be conducted after treatment of the tested regimen every 2 cycles. Subsequent treatment will be determined based on the evaluation results: If the patients are not suitable for radical surgery, but the result of efficacy evaluation is CR, PR, or SD, they can continue to receive the tested regimen. If the patients are still not suitable for radical surgery after 6 cycles of the tested regimen, the standard first-line or immunotherapy after chemoradiotherapy or radiotherapy will be given. If patients are eligible for radical surgery, surgery will be performed within 4 weeks after completion of the last tested regimen."
89658669|NCT05306769||Group 1|"HIV positive~≥18 years old~Currently registered to receive care under Harrison Wing (and thus potential candidates for Harrison Wing clinical studies)~Has ≥ 1 demographic identified to be underrepresented as specified in 'trial statistics'~Able and willing to provide written or witnessed informed consent to participate"
89658670|NCT05306769||Group 2|"HIV positive~≥18 years old~Currently registered to receive care under Harrison Wing~Currently participating in any clinical study in which Harrison Wing is the/ a participating centre1~Able and willing to provide written or witnessed informed consent to participate"
89658671|NCT05306691|Experimental|Bio-smart Light Cured Protective Shield with bioactive S-PRG filler technology (PRG Barrier Coat)|Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas
89658672|NCT05306691|Active Comparator|5% NaF varnish (Proflourid Varnish VOCO America Inc.).|The gold standard remineralizing agent recommended by the guidelines
89658673|NCT01172067|Experimental|Quickopt Group|the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
89658674|NCT01172067|Active Comparator|Echocardiography group|the Echo Group patients will be optimized by Echo.
89658675|NCT01172145|Placebo Comparator|Cholinesterase inhibitor only|
89658676|NCT01172145|Experimental|Cholinesterase Plus Modafinil|
89658677|NCT01173159|Experimental|Omegaven|Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require Total Parenteral Nutrition or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.
89658678|NCT02981355|Active Comparator|Microfracture treatment|Microfracture surgery of the femoral condyle
89658679|NCT02981355|Experimental|BST-CarGel plus microfracture treatment|BST-CarGel combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following an arthroscopic microfracture surgery.
89658680|NCT01175031|Experimental|REMstar Auto with A-Flex|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be measured with REMstar Auto with A-Flex.
89658681|NCT01175031|Other|Manually Scored Polysomnography (PSG)|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be Manually Scored Polysomnography (PSG).
89047158|NCT04664010|Experimental|severe COVID-19 with traditional Chinese medicine group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose
89658682|NCT01175343|Experimental|Treatment (RO4929097)|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected."
89658683|NCT01176435|Active Comparator|0.76 mg/kg L-DOPA|Solution taken orally three times a day.
89658684|NCT01176435|Active Comparator|0.51 mg/kg L-DOPA|Solution taken orally three times a day.
89658685|NCT01176435|Placebo Comparator|Placebo|Solution taken orally three times a day.
89658686|NCT00597441|Experimental|I|Thymic tissue from third party donor
89047159|NCT04664010|Experimental|severe COVID-19 with combination therapy group|patients with severe COVID-19 receiving western medicine treatment + traditional Chinese medicine + intravenous administration of 5% glucose containing high-dose vitamin C
89658687|NCT01176591|Experimental|Placebo Session 1, Aprepitant Session 2|Participants receive placebo in session 1 and Aprepitant in session 2 of a psychological stressor presentation and receive placebo in session 1 and Aprepitant in session 2 of a physiological stressor presentation. Participants take Aprepitant (80 mg) or placebo tablets for 7 days prior to each session.
89658688|NCT01176591|Placebo Comparator|Placebo Session 1, Placebo Session 2|Participants receive placebo in session 1 and placebo in session 2 of a psychological stressor presentation and receive placebo in session 1 and placebo in session 2 of a physiological stressor presentation. Participants take placebo tablets for 7 days prior to each session. The placebo group is used for analysis purposes in order to control for any order effects found in the Experimental group.
89658689|NCT03012555||Sickle Cell Disease and Vitamin D deficiency|
89658690|NCT01176981|Experimental|HDMTX|This is a single arm study. All subjects enrolled in the study will be in this arm.
89658691|NCT01126593|Placebo Comparator|Placebo group|The placebo group will receive the same subacromial infusion catheter as the study group.However, the reservoir will be filled with 200cc of 0.9% normal saline.
89658692|NCT01126593|No Intervention|Control group|The control group patients will receive no continuous infusion catheter.
89658693|NCT01126593|Experimental|Study Group|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The infusion rate will be 4cc per hour.
89658694|NCT01181349||P07535 study participants with a TOF ratio <0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio <0.9 at PACU arrival.
89658695|NCT01181349||P07535 study participants with a TOF ratio ≥0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio ≥0.9 at PACU arrival.
89658696|NCT01126671|Active Comparator|Low Dose Vitamin D|Subjects are randomized to take 200 IU vitamin D3 daily in this arm.
89658697|NCT01126671|Active Comparator|High Dose Vitamin D|Subjects are randomized to take 1000 IU vitamin D3 daily in this arm.
89658698|NCT05213715||1/Children with diparetic cerebral palsy|1/Children with diparetic cerebral palsy
89658699|NCT05213715||2/Children with hemiparetic cerebral palsy|2/Children with hemiparetic cerebral palsy
89658700|NCT05213715||3/healty peer aged children|3/healty peer aged children
89658701|NCT05196243||Study Group|Study on the genomic and molecular pathological characteristics of gastrointestinal mucosal lesions
89658702|NCT05196243||Control Group|Study on the genomic and molecular pathological characteristics of normal gastrointestinal mucosa
89658703|NCT01182675|Experimental|T-cell Graft Permissive SCID|"Patients with SCID with:~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only"
89047160|NCT04664127||Combination therapy (Kagocel + Valacyclovir: n=25)|Therapy according to routine practice (including Kagocel). Groups will be splitted during the final data analysis.
89047161|NCT04664127||Monotherapy by Valacyclovir (n=20)|Therapy according to routine practice. Groups will be splitted during the final data analysis.
89047162|NCT04664049||NRICM101|Subjects who confirmed, suspected or prevented infected of COVID 19 disease and received dietary supplement NRICM101
89047163|NCT00535028|Experimental|A|AER 001 s.c. once daily for 28 days
89047164|NCT00535028|Placebo Comparator|P|placebo s.c. once daily for 28 days
89047165|NCT04664088|Experimental|Acupuncture group|Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions).
89047166|NCT04664088|Active Comparator|Medication group|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks.
89047167|NCT00535067||Breast Cancer Survivors|
89047168|NCT00557115|No Intervention|Usual Care|Usual Care (UC): usual follow up care post acute COPD exacerbation
89047169|NCT00557115|Experimental|EPR|Early pulmonary rehabilitation (EPR): pulmonary rehabilitation commenced within 1-week of hospital discharge from an acute COPD exacerbation
89658704|NCT01182675|Experimental|T-cell Graft Resistant SCID|Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab
89658705|NCT01129245|No Intervention|Control cycle|Control menstrual cycle
89658706|NCT01129245|Experimental|Pre-LH surge celecoxib administration|Pre-LH surge dosing of celecoxib
89658707|NCT01129245|Experimental|Post-LH surge celecoxib administration|Post-LH surge dosing of celecoxib
89658708|NCT01183533|Experimental|off label rt-PA used|off label rt-PA used on all subject enrolled within 3 hours of waking with stroke symptoms at the standard of care dose.
89658709|NCT01183689|No Intervention|Control Group|"Self-Guided Behavior Changes. This group will be used to determine average rate of weight gain over 3 years with little intervention. Participants randomized to this group will receive one face-to-face session that will provide general education of self-weighing and information about both the small and large changes approach. Participants will also be provided with quarterly newsletters describing study events and very limited information on health eating."
89658710|NCT01183689|Experimental|Small behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate small changes (e.g., modify diet by approximately 100 kcal, decrease portion sizes or change types of food, increase activity by 2000 steps/day).
89658711|NCT01183689|Experimental|Large behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate large changes (e.g., modify diet to 1200-1500 or 1500-1800 kcal/day with < 30% fat, increase exercise to 250 minutes/week of moderate intensity activity).
89658712|NCT01183923|Experimental|Broccoli Sprouts, then Alfalfa Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by alfalfa sprouts after washout.
89658713|NCT01183923|Experimental|Alfalfa Sprouts, then Broccoli Sprouts|Alfalfa Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by broccoli sprouts after washout.
89658714|NCT01187355|Experimental|Alcon MPDS|MPDS used for 30 days as specified in protocol for contact lens care.
89658715|NCT01187355|Active Comparator|renu fresh MPS|MPS used for 30 days as indicated for contact lens care.
89658716|NCT03011853||Non-invasive only|Non-invasive ventilation as first and only respiratory support
89658717|NCT03011853||Invasive|Invasive ventilation with intubation as first respiratory support
89658718|NCT03011853||NIV+Inv|Non-invasive ventilation as first respiratory support followed by invasive ventilation with intubation
89658719|NCT01134081|Experimental|CelTx™|Living bilayered cell therapy product
89658720|NCT01134081|Active Comparator|Free Gingival Grafts|Harvested tissue from palate
89658721|NCT01187511|Active Comparator|GSK561679|GSK561679 was given orally, once a day in the evening, for 21 days, at a dose of 350mg, administered as four tablets consisting of 3 x 100mg tablets plus 1 x 50mg tablet.
89658722|NCT01187511|Placebo Comparator|Placebo|Placebo was given orally, once a day in the evening, for 21 days, in the form of four tablets that matched those of GSK561679
89658723|NCT01188369|Experimental|levosimendan|infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation
89658724|NCT01188369|Placebo Comparator|Placebo|Identical placebo
89658725|NCT01188447|Experimental|Eligible low-risk trauma patients|Paramedics will use the Canadian C-Spine Rule to evaluate low-risk trauma patients meeting the study inclusion criteria in order to determine the need for spinal immobilization for transport to the hospital.
89658726|NCT01134549|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous injection.
89658727|NCT01134549|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide intravenous injection; the starting dose was 0.5 mg.
89658728|NCT01188603|Experimental|flibanserin|flibanserin 100 mg dose every evening
88994551|NCT03458143||ketamine 150 ng/ml|The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.
89658729|NCT01189617|Experimental|Formula PD-F-7619|At least twice per week for one week, massage about a dime-sized amount of the PD-F-7619 personal lubricant product to the application site as directed.
89658730|NCT01135095|Experimental|low-dose imaging|low dose versus standard dose imaging
88994552|NCT03458143||ketamine 200 ng/ml|The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.
88994553|NCT00147485|Experimental|1|
88994554|NCT02939911||Paediatric patients after NMBA administration|Paediatric patients undergoing surgery with neuromuscular blockade
88994555|NCT02941354|Experimental|Turoctocog alfa|
88994556|NCT02941432|Other|Black tea|Black tea compress treatment
88994557|NCT05301946||Stroke patients|The created-ICF Core Set for Stroke including activitiy, participation, and environmental factors was used show the meaningfulness of the clinical outcome measurements. The correlation of the created-ICF Core Set for Stroke's items and the outcome measurements were analyzed through Spearman or Pearson correlation analysis.
89658731|NCT01135329|Experimental|Transplant|Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.
89658732|NCT03012009|Active Comparator|Full ablative CO2 laser + MAL PDT|The treatment starts with a full ablative CO2 laser pretreatment under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with a LED lamp. This treatment is repeated after 14 days.
89658733|NCT03012009|Active Comparator|Fractional ablative CO2 laser+ MAL PDT|The treatment starts with a fractional ablative CO2 laser ablation under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with LED lamp. This treatment is repeated after 14 days.
88994558|NCT02941393|Active Comparator|Intrauterine pressure catheter|Intrauterine pressure catheter is used during labor to follow up the contractions
88994559|NCT02941393|Active Comparator|External tocodynamometry|External tocodynamometry is used during labor to follow up the contractions
88994560|NCT02941198|Active Comparator|Gynefix|The GyneFix® 200 IUD(frameless iud) is only 2 cm long. Its small surface area is 1/3 of that of the conventional T-shaped IUDs such as TCu380A
89658734|NCT01190085|Active Comparator|Ghrelin (1 microg/kg)|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
89658735|NCT01190085|Active Comparator|Ghrelin (3 microg/kg)|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
89658736|NCT01190085|Placebo Comparator|Saline Solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
89047170|NCT00535106|Active Comparator|Standard resusc|Patients in this arm will be treated with standard resuscitation efforts, including the delivery of an immediate defibrillatory shock for all patients presenting in VF.
89047171|NCT00535106|Experimental|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
89047172|NCT00535106|Active Comparator|Delayed defib|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation. Data is being collected on this population as well, thereby providing a cohort population for comparative purposes.
89658737|NCT02082977|Experimental|Part 1:GSK2816126 50 mg twice-weekly|Eligible subjects will receive GSK2816126 with a starting dose of 50 milligrams (mg) twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658738|NCT02082977|Experimental|Part 1:GSK2816126 100 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658739|NCT02082977|Experimental|Part 1:GSK2816126 200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658740|NCT02082977|Experimental|Part 1:GSK2816126 400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658741|NCT02082977|Experimental|Part 1:GSK2816126 800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658742|NCT02082977|Experimental|Part 1:GSK2816126 1200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658743|NCT02082977|Experimental|Part 1:GSK2816126 1800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658744|NCT02082977|Experimental|Part 1:GSK2816126 2400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658745|NCT02082977|Experimental|Part 1:GSK2816126 3000 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
89658746|NCT02082977|Experimental|Part 2: All subjects|Subjects with Germinal Center B-cell-like Diffuse Large B-cell Lymphoma (GCB-DLBCL)-mutant and wild type, Transformed Follicular Lymphoma (TFL)-mutant and wild type as well as with multiple myeloma (MM) will be enrolled in Part 2 of the study. Subjects enrolled in Part 2 will receive recommended Phase II dose (RP2D).
89658747|NCT04403555|Experimental|Ivermectin|Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
89658748|NCT04403555|No Intervention|Standard of care|Standard of care treatment
89658749|NCT03565835|Experimental|Abiraterone and Prednisone without a GnRH Analogue|Abiraterone (1000 mg daily) with Prednisone (5 mg) with Discontinuation of GnRH Analogue Injection
89658750|NCT03557099|Experimental|Hetrombopag Olamine|Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.
89658751|NCT01624259|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
89658752|NCT01624259|Active Comparator|Liraglutide|"Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
89658753|NCT02081417|Other|Peer led|"Number sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)"
89658754|NCT02081417|Other|Clinician led|"Number intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion)."
89658755|NCT02081183|Experimental|MMF, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received mycophenolate mofetil (MMF), 1 g/day, PO, twice daily (BID) for 2 weeks; 1.5 g/day, PO, three times daily (TID) for the next 2 weeks; 2 g/day, PO, BID for the remainder of the Maintenance Phase. Participants also received prednisone, as in the Induction Phase."
89658756|NCT02081183|Active Comparator|Maintenance Cyclophosphamide, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 - 1 g/m^2, IV, pulse once per month. Participants also received prednisone, 1 mg/kg/day), PO; the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received cyclophosphamide, 0.5-1 g/m^2, IV, pulse once every 3 months. Participants also received prednisone, as in the Induction Phase."
89658757|NCT03556631|Experimental|probiotics group|live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
89658758|NCT03556631|Placebo Comparator|placebo group|placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
89658759|NCT05347433||Tube baby pregnancy group|18-24-week pregnant women with in vitro fertilization
89658760|NCT05347433||Spontaneous pregnancy group|18-24-week pregnant women with spontaneous
88994561|NCT02941198|Active Comparator|Cu T380a|conventional T-shaped IUDs (TCu380A)which has a frame will be placed into the uterus after placental extraction
88994562|NCT00407979||People with Atopic Dermatitis|
88994563|NCT00407979||People with Psoriasis|
88994564|NCT00407979||Generally healthy people|
88994565|NCT00407979||People with Atopic Dermatitis and Eczema Herpeticum|
88994566|NCT02941159|Active Comparator|SF2000SD|The test product is a Sondashi Formula Spray dried extract (SF2000SD). It is derived from spray drying with water the Sondashi Formula (SF2000), which is a mixture of mixture of 4 plants. SF2000SD is packaged into capsules of 500mg and six capsules are taken twice, daily for 42 days. This drug has anti-HIV properties but in this study we are just looking at safety issues.
89047173|NCT04663854|Experimental|Trehalose|Trehalose Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks.
88994567|NCT02941159|Placebo Comparator|Placebo|The placebo arm is composed of capsule containing 500mg of inactive ingredient (Microcrystalline Cellulose PH102 -240mg; Starch - 10mg; Magnesium Stearate -10mg; and Maltodextrin Unidry 20 - 240mg).
88994568|NCT05273671|Experimental|nalbuphine|0.1 mg/kg nalbuphine diluted in 10 ml I.V 10 minutes before the end of surgery
88994569|NCT05273671|Experimental|dexmedetomedine|receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
88994570|NCT05273671|Placebo Comparator|saline|receive a saline solution 10 min before the end of surgery
88994571|NCT05229484|Experimental|Intervention Group: an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
88994572|NCT05229484|No Intervention|Control group|The control group is the Treatment as Usual (TAU).
88994573|NCT02931409|Experimental|Optimal PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a decremental PEEP titration procedure directed by static pulmonary compliance (Cstat). During PEEP titration procedure PEEP will be decreased from 14 cmH2O by 2 cmH2O every 4 minutes, until a final PEEP of 6 cmH2O. Optimal PEEP is considered as a PEEP value resulting the highest possible Cstat measured by ventilator. After PEEP titration procedure a lung protective mechanical ventilation will be performed using optimal PEEP and low tidal volumes (6 mL/Kg IBW).
88994574|NCT02931409|Active Comparator|Standard PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a standard lung protective mechanical ventilation using a PEEP value of 6 cmH2O and low tidal volumes (6 mL/Kg).
88994575|NCT02931526||Group CRRT|Patients who need to treat with tigecycline for bacterial infection, have renal insufficiency and have to treat with CRRT
88994576|NCT02931526||Group non-CRRT|Patients who need to treat with tigecycline for bacterial infection, have normal renal function in ICU and have no need to treat with CRRT
88994577|NCT00169845|Experimental|Alpha-Tocopherol and Beta-Carotene|Patients received a daily supplementation of alpha-tocopherol (one capsule of 400 IU dl-alpha-tocopherol) and beta-carotene (one capsule of 30 mg) for 3 years after the end of radiation therapy. Due to ethical concerns, the beta-carotene supplementation was stopped during the trial (after the randomization of 156 patients). See details in JNCI, 2005: 97 (7), 481-8.
88994578|NCT00169845|Placebo Comparator|Placebo|Patients received two capsules of placebos per day during 3 years. When the beta-carotene was stopped, they received only one capsule.
89047174|NCT04663854|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks.
89658761|NCT02080871|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
89658762|NCT02080481|Experimental|Infiniti Plus needle guidance system|ultrasound guidance with the InfinitiPlus (TM) needle guidance system
89658763|NCT02080481|Other|conventional block needle|ultrasound guidance with a conventional block needle
89658764|NCT02080403|Experimental|Treatment|Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip®) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months.
89658765|NCT02080403|No Intervention|Control|Mechanical Subgingival Debridement at Baseline and 3 months.
89658766|NCT02080091||Chronic DME|Patients with vision impairment associated with chronic diabetic macular edema (DME)
89658767|NCT03550469|Experimental|Computer-assisted Oxygen Weaning|A computer with an adaptive model algorithm will guide oxygen weaning.
89658768|NCT03550469|No Intervention|Manual Oxygen Weaning|Oxygen weaning will be done by staff manually.
89658769|NCT03547349|Active Comparator|Group 1|These study patients will receive a study information/authorization sheet about the study prior to surgery during their pre-operative clinic visit. This subgroup will be provided postoperatively with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer. Subjects in this group will receive current standard of care with routine surgical and RN encouragement to use the spirometer. The tablet will monitor and record spirometer device utilization.
89658770|NCT03547349|Active Comparator|Group 2|These study patients will be consented by members of the research team prior to surgery at their pre-operative clinic visit. The patient will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer, and will set a spirometry goal while collecting usage and pulmonary function data. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
89658771|NCT03547349|Experimental|Group 3|These study patients will be consented by a member of the research team prior to surgery at their pre-operative clinic visit. The patients will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with both intensive education reinforcement and the Jamboxx Respiratory Therapy Device that also includes multiple gaming programs. The games are meant to encourage incentive spirometry and are programmed to progress in accordance with the patient's personal increasing capacity. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
89658772|NCT02079077|Other|Acetylsalicylic Acid (ASA)|ASA 81 mg. p.o. daily for two months
89658773|NCT02079077|Other|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.
89658774|NCT03547271|Experimental|Group 1|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and measles, mumps, and rubella [MMR] vaccine) at 2, 4 and 12 to 18 months of age
89658775|NCT03547271|Active Comparator|Group 2|Licensed meningococcal vaccine (Nimenrix®), 3 doses, co-administered with routine vaccines (10-valent pneumococcal vaccine, DTaP-IPV- HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
89658776|NCT03547271|Experimental|Group 3|MenACYW conjugate vaccine, 3 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4 and 12 to 18 months of age
89658777|NCT03547271|Experimental|Group 4|MenACYW conjugate vaccine, 4 doses, co-administered with routine vaccines (13-valent pneumococcal vaccine, DTaP-IPV-HB-Hib vaccine, and MMR vaccine) at 2, 4, and 12 to 18 months of age and administered alone at 6 months of age
89658778|NCT03536117|Experimental|MTBVAC Group 1|MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
89658779|NCT03536117|Experimental|MTBVAC Group 2|MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
89658780|NCT03536117|Experimental|MTBVAC Group 3|MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
89658781|NCT03536117|Active Comparator|BCG Group 4|BCG control 2.5 x 10E+05 CFU/0.05 mL
89658782|NCT01191255|Active Comparator|Active Control|PhosLo (calcium acetate) Renvela (sevelamer carbonate)
89658783|NCT01191255|Placebo Comparator|Placebo|Placebo
89658784|NCT01191255|Experimental|KRX-0502 (Ferric Citrate)|ferric citrate
89658785|NCT02078219|Experimental|RDEA3170 1|RDEA3170 5mg followed by RDEA3170 7.5mg
89658786|NCT02078219|Experimental|RDEA3170 2|RDEA3170 10mg followed by RDEA3170 12.5mg
89658787|NCT02078219|Experimental|RDEA3170 3|RDEA3170 12.5mg followed by RDEA3170 15mg
89658788|NCT02078219|Placebo Comparator|RDEA3170 4|RDEA3170 Placebo
89658789|NCT02078219|Other|Allopurinol|Allopurinol 200mg
89658790|NCT03536039|Experimental|NGR-hTNF + R-CHOP|Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course
89658791|NCT02075255|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
89658792|NCT02075255|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
89658793|NCT02075255|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks
89688623|NCT02677870|Active Comparator|Standard dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin dihydrochloride (Kuvan) or high-dose saproterin dihydrochloride (Kuvan)  groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Standard-dose saproterin dihydrochloride will be 20mg/kg (rounded up to the nearest 100mg) provided in the form of 100mg tablets. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
89658794|NCT03532217|Experimental|PROSTVAC/Ipilimumab/Nivolumab/Neoantigen DNA vaccine|"Within 60 days after the last chemo, patients will start a priming dose of PROSTVAC-V, and subsequent doses of PROSTVAC- F (weeks 0, 2, 5, 8, 11, 14, and 17). During Treatment A phase, subjects should receive nivolumab intravenously on Day 1 of each cycle every 3 weeks for 6 doses. Ipilimumab on Day 1 of each cycle every 3 weeks for 2 doses.~Patients will then receive a neoantigen DNA vaccine with continuous nivolumab treatment. The vaccine will be administered starting approximately week 21 by intramuscular injection for a total of 6 treatments every 28 days +/-7 days. Each DNA vaccination will be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device. Patients will receive nivolumab at 480 mg every 28 days concurrently with neoantigen DNA vaccine. This is Treatment B. In the event the DNA vaccine production is delayed, patients will receive single agent nivolumab every 4 weeks beginning week 21 until the vaccine is ready"
89658795|NCT03529487|Experimental|Oxymetazoline applied intra analy|
89658796|NCT03527147|Experimental|AZD9150 + Acalabrutinib|AZD9150 given in combination with acalabrutinib
89658797|NCT03527147|Experimental|AZD6738 + Acalabrutinib|AZD6738 in combination with acalabrutinib
89658798|NCT03527147|Experimental|Hu5F9-G4 + rituximab + Acalabrutinib|Hu5F9-G4/rituximab in combination with acalabrutinib
89658799|NCT03527147|Experimental|AZD5153 + Acalabrutinib|AZD5153 in combination with acalabrutinib
89658800|NCT03525743||Patients undergoing intubation|Adhesive gel pads will be placed on patient to measure continuous cardiac output and to calculate stroke volume variation. Other physiologic data will be analyzed in real time using the NICOM (Non invasive cardiac output monitor) device.
89658801|NCT01677611|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial.Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of either resveratrol.The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia. Subjects were instructed to abstain from foods with high resveratrol content during the entire duration of the trial.
89658802|NCT01677611|Placebo Comparator|Placebo|All subjects underwent a 2-week run-in period during which placebo was administered. The placebo was manufactured so that it was not distinguishable by color, form, or taste from the active drug. Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of matching placebo and instructed to abstain from foods with high resveratrol content during the entire duration of the trial. The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
89658803|NCT01191333|Experimental|Active rTMS|Those receiving experimental treatment will receive 20 to 30 sessions of rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
89658804|NCT01191333|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 to 30 sessions of sham rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
89658805|NCT04402931|Other|Transcatheter Valve-in-Valve Intervention|Transcatheter Valve-in-Valve Intervention
89658806|NCT04402931|Other|Redo Surgery|Surgical Mitral valve replacement
89658807|NCT01191411|Active Comparator|Mailed invitations for FIT test kits|"Fecal Immunochemical Tests (FIT) kits from Polymedco Incorporated are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer using a Polymedco home FIT kit. Mailed invitation to complete a free one sample home FIT kit. Automated and live phone call reminders to promote screening completion, plus usual medical care.~Patients with abnormal FIT results are navigated to complete a diagnostic colonoscopy."
89658808|NCT01191411|Active Comparator|Mailed invitations for a colonoscopy|"Invitation to schedule a colonoscopy are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer with colonoscopy. Mailed invitation to complete one free colonoscopy. Automated and live phone reminders to promote screening completion, plus usual medical care.~Patients with abnormal polyps or adenomas will follow standard clinical protocol after their procedure."
89658809|NCT01191411|Active Comparator|Visit Based Care|"No invitation to complete colorectal cancer screening.~Intervention: Usual medical care. Patients will continue to see their regular physician, and follow their physician's regular standard of care."
89658810|NCT03707873|Experimental|In-person education|Education will be given on a regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
89658811|NCT03707873|Experimental|Online education|Education will be given on a regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
89658812|NCT03707873|No Intervention|Standard Care|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
89658813|NCT01191723|Other|Treatment A, then Treatment B, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
89658814|NCT01191723|Other|Treatment A, then Treatment C, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
89658815|NCT01191723|Other|Treatment B, then Treatment A, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
89658816|NCT01191723|Other|Treatment B, then Treatment C, then Treatment A|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
89658817|NCT01191723|Other|Treatment C, then Treatment A, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
89658818|NCT01191723|Other|Treatment C, then Treatment B, then Treatment A|"There was 48 hour wash-out between treatment visits.~Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
89658819|NCT01678469|Other|blood sample|
89658820|NCT01193049|Experimental|Prednisone, then Placebo|Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
89658821|NCT01193049|Experimental|Placebo, then Prednisone|Placebo in the first crossover treatment period and prednisone in the second crossover treatment period
89658822|NCT01679951|Placebo Comparator|Placebo|
89658823|NCT01679951|Experimental|JNJ-38518168 (3 mg/d)|
89658824|NCT01679951|Experimental|JNJ-38518168 (10 mg/d)|
89658825|NCT01679951|Experimental|JNJ-38518168 (30 mg/d)|
89658826|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 12.5 mcg|1 dose of 0.5 mL containing 12.5 mcg of Vi-CRM
89658827|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 5 mcg|1 dose of 0.5 mL containing 5 mcg of Vi-CRM
89658828|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 1.25 mcg|1 dose of 0.5 mL containing 1.25 mcg of Vi-CRM
89658829|NCT01193907|Active Comparator|Typherix|1 dose of 0.5 mL containing 25 mcg of Vi-polysaccharide
89658830|NCT01194297|Experimental|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
89658831|NCT01194297|Active Comparator|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
89658832|NCT03510845|Experimental|Repairable ACL tear|Patients whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
89658833|NCT03510845|Other|Irreparable ACL tear|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
89658834|NCT05347277||OCB positive|The pattern of oligoclonal bands in CSF is reviewed by pathologist and their findings are noted as negative for the presence of CSF OCB
89047175|NCT04664244|Experimental|All eligible patients|All eligible patients enrolled
89047176|NCT04663815|Other|AB arm|Animal-assisted activity intervention on 2nd day of hospitalization, control intervention on the 4th day of hospitalization.
89658835|NCT05347277||OCB negative|The pattern of oligoclonal bands in CSF is reviewed by pathologist and their findings are noted as positive for the presence of CSF OCB
89658836|NCT01194453|Experimental|Group A|
89658837|NCT01194453|Active Comparator|Group B|
89658838|NCT01673789|Experimental|Stem Cell Educator|The collected lymphocytes are transferred into the device for exposure to CB-SCs, and other blood components are automatically returned to the patient. The Stem Cell Educator functions as part of a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with CB-SCs in vitro, and returns the educated lymphocytes to the patient's circulation. CB-SCs tightly attached to interior surfaces in the device, and only the CB-SC-educated autologous lymphocytes are returned to the subjects. The Stem Cell Educator therapy requires only two venipunctures with minimal pain, and does not introduce stem cells or reagents into patients.
89047177|NCT04663815|Other|BA arm|Control intervention on 2nd day of hospitalization, animal-assisted activity intervention on the 4th day of hospitalization.
89047178|NCT04663581|Experimental|Left Sided Colonoscopy|Left Sided starting position in colonoscopy
89047179|NCT04663581|Active Comparator|Right sided Colonoscopy|Right Sided starting position in colonoscopy
89047180|NCT04663698|Experimental|Healthy|Lung-healthy subjects, randomized lung function testing
89047181|NCT04663698|Experimental|Patient 1|COPD patients, randomized lung function testing
89047182|NCT04663698|Experimental|Patient 2|COPD patients, randomized lung function testing
89047183|NCT04663698|Experimental|Patient 3|COPD patients, randomized lung function testing
89047184|NCT04663698|Experimental|Patient 4|COPD patients, randomized lung function testing
89047185|NCT04663425||Sleeve gastrectomy operation|Outcome of patients that underwent sleeve gastrectomy with BMI greater than 60.
89047186|NCT04663425||Gastric bypass operation|Outcome of patients that underwent gastric bypass with BMI greater than 60.
89047187|NCT04663425||Gastric Band operation|Outcome of patients that underwent gastric banding with BMI greater than 60.
89047188|NCT04663659||diabetic group|Patients over the age of 18 with diabetes mellitus in intensive care unit
89047189|NCT04663659||non-diabetic group|Patients over the age of 18 without diabetes mellitus in intensive care unit
89047190|NCT04663971||Crohn's disease|Patients with Crohn's disease.
89047191|NCT04663971||Ulcerative colitis|Patients with Ulcerative colitis
89047192|NCT04663542|Experimental|0-week immobilization|0-week brace immobilization after the surgery will be conducted.
89047193|NCT04663542|Experimental|2-week immobilization|2-week brace immobilization after the surgery will be conducted.
89047194|NCT04663542|Other|4-week immobilization|4-week brace immobilization after the surgery will be conducted.
89047195|NCT04663542|Other|6-week immobilization|6-week brace immobilization after the surgery will be conducted.
89047196|NCT04663269|Other|Control|Standard Care Protocol - peritubal block standard local analgesic administration in the form of a peritubal block
89658839|NCT01195467|Experimental|All Subjects Truvada/Raltegravir|All Subjects will receive the same intervention, Truvada/Raltegravir
89658840|NCT03501797|Experimental|Early singing intervention (AB)|Participants receive a 16 weeks of singing-based rehabilitation and standard care (SC) followed by 16 weeks of SC only.
89658841|NCT03501797|Experimental|Late singing intervention (BA)|Participants receive a 16 weeks of SC only followed by 16 weeks of singing intervention and SC.
89658842|NCT01195701||Anorgasmia (cases)|Women with difficulty or inability to reach sexual climax will be the cases in this study.
89658843|NCT01195701||Normal orgasmic function|Women who report that they usually or always achieve sexual climax will be the controls in this study.
89658844|NCT02407613|Experimental|MR-HIFU ablation|Ten patients undergo MR-HIFU ablation with the Sonalleve MR-HIFU Breast Tumor Therapy System (Profound Medical). According to a treat-and-resect protocol, these patients also undergo standard therapy consisting of breast cancer surgery 1 to 2 weeks after MR-HIFU treatment (+/- radiotherapy).
89658845|NCT02403869||Group 1|MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease
89658846|NCT03500939|Experimental|Normobaric hyperoxygenation + standard of care|Normobaric hyperoxygenation (NBHO), i.e. inhalation of 100% oxygen at high flow (≥ 40 L/min) via a sealed non-rebreather face-mask with reservoir, or in case of intubation/ventilation for (study-independent) TBY, ventilation with an inspiratory oxygen fraction (FiO2) of 1.0. NBHO is started within 3 hours of stroke symptom onset (witnessed or last seen well) and within 20 minutes after end of baseline brain imaging and applied until the end of TBY procedure (defined by removal of guide catheter from sheath) or, in case TBY is not attempted, 4 hours after start of study treatment.
89658847|NCT03500939|Active Comparator|standard of care alone|standard of care alone; oxygen supplementation if SpO2 ≤ 94% at 2 to 4 L/min via nasal cannula according to guidelines of the European Stroke Organisation (ESO), or in case of TBY-related intubation/ventilation, ventilation with an initial FiO2 of 0.3 to be gradually increased if SpO2 ≤ 94%.
89047197|NCT04663269|Experimental|ANES Block|Patients randomized to the erector spinae block (Group 2) will have the block placed in the preoperative area by the anesthesia team. 0-4 mg midazolam and/or 0-100 mcg of fentanyl may be provided prior to and in order to place the block itself. The local anesthetic will diffuse to involve the dorsal and ventral rami of the spinal nerves, achieving a sensory block of the affected area. The erector spinae block analgesic will be administered by the anesthesia team. The analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone.
89047198|NCT03465020||ITP patients|On active treatment
89047199|NCT04686500|Other|Deep Inspiration Breath-hold (DIBH) Respiratory Motion|DIBH qualified patient will experience one high-resolution CT scan as SOC and additional 3 low resolution/lower dose CT scans to further investigate inter-DIBH patient surface and tumor position stability and repeatability
89047200|NCT03303339|Experimental|Phase 1b: Onvansertib + low-dose cytarabine|Onvansertib, administered in escalating doses orally Day 1 through Day 5 every 28 days (1 cycle) in combination with cytarabine, which will be administered in all cohorts as 20 mg/m^2 subcutaneously, once daily on Day 1 through Day 10 every 28 days (1 cycle). Onvansertib administration, in combination with cytarabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days. Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
89047201|NCT03303339|Experimental|Phase 1b: Onvansertib + decitabine|Onvansertib will be administered in escalating doses orally, Day 1 through Day 5 every 28 days (1 cycle) in combination with decitabine, administered consistently in all cohorts as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle). Onvansertib administration, in combination with decitabine, will be initiated at a starting dose of 12 mg/m^2 orally, daily for 5 days (Day 1 through Day 5). Onvansertib dose will be escalated in successive cohorts until the recommended phase 2 dose is achieved.
89047202|NCT03303339|Experimental|Phase 2: Onvansertib + decitabine|Onvansertib recommended phase 2 dose, orally Day 1 through Day 5 every 28 days (1 cycle) and decitabine, administered consistently as 20 mg/m^2 intravenously over 1 hour on Day 1 through Day 5 every 28 days (1 cycle), with treatment modifications or delays based on return of hematopoietic function to baseline or Grade ≤1 toxicity for optimal subject management.
89047203|NCT04686461|Experimental|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment dose- twice daily for 12 weeks
89658848|NCT02402699||Unresectable, recurrent or metastatic melanoma patients|All adult unresectable, recurrent, or metastatic melanoma patients with HBV or HCV treated with at least 1 dose of ipilimumab therapy in Taiwan
89658849|NCT03494621|No Intervention|Control group|Participants randomly assigned to the control group will have three prenatal contacts at the same gestational ages as the intervention participants. These contacts will include collection of covariate data, review of locally available educational materials on pregnancy/infant care led by trained study staff, and assessment of the overall session quality and acceptability. The educational materials provided during these sessions are drawn from materials currently available at local health care facilities
89658850|NCT03494621|Experimental|Protecting Babies While They Sleep|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. The protocol for the focus groups and interviews has been reviewed by the Tribal Institutional Review Board. The focus groups were conducted in Rapid City and a western Tribal reservation with pregnant adult women and pregnant, parenting, or other interested adolescent women; fathers (adult men); and elder women. Two focus groups were held for each category of individuals. Additional qualitative data was collected via key informant interviews with individuals vested and experienced in maternal and child health.
89658851|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
89658852|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
89658853|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
89047204|NCT03422471|Experimental|Hypoglycemia|Participants are exposed to two 90 minute episodes of hypoglycemia (50 mg/dl) through a hyperinsulinemic hypoglycemic clamp. Baroreflex sensitivity will be assessed before, during, and 16 hours after the hypoglycemia.
89047205|NCT03299946|Experimental|Arm 1|
89047206|NCT03399929||TBI + Rehabilitation|Traumatic Brain Injury patients that received post acute rehabilitation
89047207|NCT03399929||TBI + No Rehabilitation|Traumatic Brain Injury patients that did not receive post acute rehabilitation
89658854|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
89658855|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
89658856|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
89658857|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
89658858|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
89658859|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
89658860|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
89658861|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
89658862|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
89658863|NCT01195779|Experimental|GSK2321138A vaccine Group|Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).
89658864|NCT01195779|Active Comparator|Fluarix Group|Subjects received 2 doses of Fluarix Vaccine.
89658865|NCT02405585|Experimental|mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"SOC mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 93-100 Disease evaluated: Progressive disease = salvage therapy off study. Day 93-100 Disease evaluated: Stable disease or better = SBRT + HAPa on days 1 and 15 of radiotherapy Post SBRT: surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for 6 cycles.~Post adjuvant therapy: 6 monthly immunizations with HAPa"
89658866|NCT05347121||difficult airway|
89658867|NCT01196793||febrile children, age 3 m to 5 y|
89658868|NCT03491345|Experimental|avelumab|
89658869|NCT01677689|Placebo Comparator|Control Group|Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal
89658870|NCT01677689|Experimental|Study Group|Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
89658871|NCT01138917|Experimental|all participants|All participants will receive both ReCell and split-thickness skin graft
89658872|NCT02400671|Experimental|Two-way SMS|Participants will receive weekly push SMS messaging with a questions and have the ability to text back to the study nurse
89658873|NCT02400671|Experimental|One-Way SMS|Participants will receive weekly push SMS messaging
89658874|NCT02400671|No Intervention|Control|Participants will receive standard of care (no intervention)
89658875|NCT01677845|Experimental|Radiation Therapy|Radiation Therapy
89658876|NCT00089843|Active Comparator|2|Placebo Actonel (risedronate) and active testosterone patch
89658877|NCT00089843|Active Comparator|3|Active Actonel (risedronate) and active testosterone patch
89047208|NCT03399929||CVA + Rehabilitation|Stroke patients that received post acute rehabilitation
89047209|NCT03399929||CVA + No Rehabilitation|Stroke patients that did not received post acute rehabilitation
89047210|NCT00535379|Experimental|1|
89047211|NCT00535418|Experimental|Letrozole|
89658878|NCT00089843|Active Comparator|4|Active Actonel (risedronate) and placebo testosterone
89658879|NCT00089843|Placebo Comparator|1|Placebo testosterone patch and placebo Actonel (risedronate)
89658880|NCT01677923|No Intervention|Control without Metformin|Conventional management of obesity including basic instructions on diet and physical activity
89658881|NCT01677923|Experimental|Control with Metformin|Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment
89658882|NCT01677923|Experimental|Intervention with Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.
89658883|NCT01677923|No Intervention|Intervention without Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian
89688624|NCT02677870|Experimental|High dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin or high-dose saproterin groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Goal high-dose saproterin dihydrochloride dosing will be 40mg/kg (rounded up to the nearest 500mg), provided in the form of pre-packaged 500mg packets of powder. Labeled dosing on these packets will be covered by the investigational drug pharmacy and unidentifiable to patients. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
89047212|NCT03288948|Active Comparator|Standard Contrast Increment|
89047213|NCT03288948|Experimental|Reduced Contrast Increment|
89047214|NCT03288948|Experimental|No Contrast Increment|
89057988|NCT01198756|Active Comparator|Yamagata strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89047215|NCT03307382|Experimental|SpyGlass DS Cholangioscopy|ERCP with cholangiogram will be performed to assess the common bile duct (CBD) and intrahepatic ducts (IHD) for presence of a stricture. Once a biliary stricture is confirmed on cholangiogram during ERCP, SpyGlass DS Cholangioscopy would be performed. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy. Endoscopic stenting will be performed in standard fashion for biliary drainage to relieve the obstructive jaundice.
89047216|NCT04679064|Active Comparator|Phisician's choice of standard chemotherapy|"Chemotherapy at physician's choice between Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 Gemcitabine 1000 mg/mq d 1,8,15 q 28 Topotecan 1.25 mg/mq day 1-5 q 21~+/- Bevacizumab at defined scehedule"
89047217|NCT04679064|Experimental|Niraparib+Dostarlimab|Dostarlimab 500 mg q 3W for the fist 4 cycles, 1000 mg q 6W thereafter + Niraparib 300 mg or 200 mg if platelet count <150,000 /μL and/or body weight <77kg QD po q 28
89047218|NCT01183780|Experimental|FOLFIRI + Ramucirumab|
89047219|NCT01183780|Placebo Comparator|FOLFIRI + Placebo|
89047220|NCT04662957|Experimental|Probiotic preparation|Multi-strain probiotic mixture. The daily dose was five billion (2 capsules/day).
89047221|NCT04662957|Placebo Comparator|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture (2 capsules/day).
89047222|NCT00535457|Experimental|1|"Children will watch tricks (magic) before anesthesia induction"
89047223|NCT04679103|Experimental|Eculisumab (JSC GENERIUM, Russia)|Eculizumab
89047224|NCT04663191||Full VATS|
89047225|NCT04663191||VATS with conversion|
89047226|NCT04663191||Thoracotomy upfront|
89658884|NCT00089297|Experimental|Cetuximab/Paclitaxel/Carboplatin|"Induction: Cetuximab (C225) 400 mg/m2 at wk 1 then 250 mg/m2 for 5 weeks. Paclitaxel (P) 90 mg/m2 IV and carboplatin (C) AUC = 2 IV were given weekly.~Restaging biopsy of primary site scheduled at wk 7. Concurrent chemoradiation: Radiation therapy at 200cGy/d/5 wks for a total of 50Gy and C225 at 250 mg/m2/wk. P following C225 at 30 mg/m2/wk and C following P at AUC = 1/week. Patients with a negative biopsy continued concurrent therapy to complete radiation (68-72Gy).~Restaging biopsy of primary site: Patients with positive biopsy at wk 7 or patients without a clinical complete response at the primary site after induction therapy had re-biopsy at wk 14. If the biopsy was negative, the patients continued concurrent therapy to complete radiation (68-72 Gy). If positive, resection of the primary site was done.~Additional concurrent chemoradiation: C225 at 250mg/m2/wk IV followed by P 30mg/m2/wk IV followed by C AUC = 1/wk and RT for 3 wks."
89047227|NCT00535574|Placebo Comparator|Bexarotene (Targretin LGD1069)|
89047228|NCT00535574|Active Comparator|placebo|
89047229|NCT04678830|Placebo Comparator|Placebo|
89047230|NCT04678830|Experimental|700mg Leronlimab|
89047231|NCT01183468|Experimental|Part 1a(Aralast NP)-Subjects Aged 16-35 Yrs|Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by intravenous (IV) infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
89047232|NCT01183468|Experimental|Part 1a (Aralast NP)-Subjects 8-15 Yrs|Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
89047233|NCT01183468|Experimental|Part 1b (Aralast NP)--Subjects Aged 18-35 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
89658885|NCT03483077|Placebo Comparator|Placebo matching BI 730460|Placebo tablet(s) matching BI 730460 tablet(s) administered orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
89658886|NCT03483077|Experimental|2 milligram (mg) - BI 730460|A single dose of 2 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
89047234|NCT01183468|Experimental|Part 1b (Aralast NP)-Subjects 8-17 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
89047235|NCT03245021|Other|Open-Label|Opdivo - Single-arm open label study
89658887|NCT03483077|Experimental|8 mg - BI 730460|A single dose of 8 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
89658888|NCT03483077|Experimental|25 mg - BI 730460|A single dose of 25 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
89658889|NCT03483077|Experimental|50 mg - BI 730460|A single dose of 50 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
89658890|NCT03483077|Experimental|100 mg - BI 730460|A single dose of 100 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
89047236|NCT04678791|Experimental|Nimotuzumab+ chemoradiotherapy|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy.
89047237|NCT04678791|Active Comparator|Chemoradiotherapy|Patients receive cisplatin and undergo external-beam radiation and brachytherapy
89047238|NCT01183390|Experimental|Investigational Test Product|Anastrozole 1 mg Tablets
89047239|NCT01183390|Active Comparator|Reference Listed Drug|Arimidex® 1 mg Tablets
89658891|NCT03483077|Experimental|200 mg - BI 730460|A single dose of 200 mg BI 730460 administered as film-coated tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) - Single rising dose (SRD) part.
88994579|NCT02931487|Experimental|Attentional Bias Modification|ABM dot-probe task with image stimuli (faces) of three valences: positive (happy), neutral, or negative (angry and fearful). In the ABM condition, probes were located behind positive stimuli in 87 % of the trials (valid trials), as opposed to 13% with probes located behind the more negative stimuli (invalid trials). Consequently, participants should implicitly learn to deploy their attention toward positive stimuli, and in this way develop a more positive AB when completing the task.
88994580|NCT02931487|Sham Comparator|Sham comparator|Sham condition without modification of attentional bias. These trials are identical in structure to the ABM trials with the exception that target probes replaced negative and positive images with equal frequency.
89047240|NCT02887807|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
88994581|NCT00147797||Pravastatin group|Patients in the pravastatin group were consecutively recruited in four department of infectious diseases if they fulfilled the following criteria : (1) HIV-infected treated with HAART for > 12 months 2) with dyslipidemia, defined as fasting serum LDL cholesterol > 160 mg/dL before initiation of pravastatin, (3) treated with pravastatin > 12 months and one more coronary risk factor.
88994582|NCT00147797||COotrol group|The patients in the control group were selected consecutively in the same departments among 1) HIV-infected patients treated with HAART > 12 months 2) fasting serum LDL cholesterol > 160 mg/dL 3) without lipid-lowering drugs and one more coronary risk factor. Cases and control patients were matched for age, gender and tobacco consumption.
88994583|NCT02931370||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
88994584|NCT02931331||Observational|Patients undergoing standard of care (PET stress testing followed by mechanical revascularization) are undergoing an additional PET stress test to determine the impact of revascularization.
88994585|NCT04597684|Active Comparator|Treatment/Intervention|Total Knee Arthroplasty (TKA) with cementless knees
88994586|NCT04597684|Active Comparator|Control|Total Knee Arthroplasty (TKA) with cemented knees
88994587|NCT00147836|Active Comparator|CSII|Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
88994588|NCT00147836|Active Comparator|MDI|Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
88994589|NCT00147836|Active Comparator|OHA|In oral hpoglycemic agents group, the patients with 20 kg/m2<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization
88994590|NCT02931292||Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
88994591|NCT02931136|Active Comparator|treatment group|Huperzine A treatment.
88994592|NCT02931136|Placebo Comparator|Placebo group|The placebo in 52 weeks.
88994593|NCT02931175|Experimental|Group 1|Mandatory twice a week (Mondays and Thursdays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
88994594|NCT02931175|Experimental|Group 2|Mandatory thrice a week (Mondays, Wednesdays, and Fridays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
88994595|NCT04690036|Experimental|one group|All patients encountered EBV reactivation after allo-HCT could be enrolled in this study, there was only one group of treatment.
89658892|NCT01678001|Active Comparator|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
89658893|NCT01678001|Placebo Comparator|Placebo|Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
89658894|NCT00088907|Active Comparator|Arm I (docetaxel and placebo)|Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
88994596|NCT02931214|Experimental|GMI-1359|Dose escalation
88994597|NCT02931214|Experimental|Placebo|Dose escalation
88994598|NCT02931019|Experimental|neck flexion first|"With specific head posture, intubation is done under flexible fiberoscopy guide.~In this arm, at the position with neck flexion, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck extension, And the laryngeal view is gotten in the same way."
89658895|NCT00088907|Experimental|Arm II (docetaxel and gefitinib)|"Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.~ZD1839 (Iressa, gefitinib) will be given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.~In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression."
89658896|NCT00088829|Experimental|Paclitaxel|Paclitaxel given before surgery
89658897|NCT00088595|Experimental|Pasireotide|
89658898|NCT03480893|Experimental|Small size interarcuair decompression|Patients will undergo small size interarcuair decompression
89658899|NCT03480893|Active Comparator|Laminectomy|Patients will undergo laminectomy
89658900|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (500 mg/day)|Encapsulated Calcium
89658901|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1000 mg/day)|Encapsulated Calcium
89658902|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1500 mg/day)|Encapsulated Calcium
89658903|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (500 mg/day)|Non-capsulated Calcium
89658904|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1000 mg/day)|Non-capsulated Calcium
89658905|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1500 mg/day)|Non-capsulated Calcium
89658906|NCT00088205|Experimental|A|
89658907|NCT01678235|Experimental|GLU_ASP|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin glulisine~Second day: insulin aspart"
89658908|NCT01678235|Experimental|ASP_GLU|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin aspart~Second day: insulin glulisine"
88994599|NCT02931019|Experimental|neck extension first|In this arm, at the position with neck extension, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck flexion, And the laryngeal view is gotten in the same way.
88994600|NCT00147914|Active Comparator|1|cefdinir
88994601|NCT00147914|Active Comparator|2|amoxicillin/clavulanate
88994602|NCT02930746|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
88994603|NCT02930863|Active Comparator|Control Non-Automated Group|Participants assigned to this group will receive the standard of care procedures for the monitoring and treatment of hypoxemia. Complete brief post-PACU stay survey.
88994604|NCT02930863|Experimental|Automated Prompt Group|Participants assigned to this group will utilize the automated verbal prompts to enable their ability to improve their current condition by following generated commands. Complete a questionnaire focused around their experience with the pulse oximetry software and its effects on the patient's satisfaction and experience.
88994605|NCT02930785|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
88994606|NCT02930551|Active Comparator|Lidocaine|Lidocaine 2 ml injection with 2% Adrenaline
88994607|NCT02930551|Placebo Comparator|Isotonic Saline|Isotonic Saline 2 ml Injection
88994608|NCT02930356|Experimental|NSPT-Test group|NSPT was done after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
88994609|NCT02930356|Experimental|Scaling and root planing-Control group|Scaling and root planing was done after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
88994610|NCT02930707|Active Comparator|Magnesium group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg), on each side of the abdominal wall.
89213547|NCT00879944||Healthy Controls|"Children 5-17 years of age who are healthy and seen in dermatology clinic for a non-systemic skin condition.~Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm"
89658909|NCT01678625||Acceleromyography group|Train-of-four ratio calculation (TOF-Watch-SX-Bluestar enterprise)
89658910|NCT01678625||Electromyography group|Train-of-four ratio calculation (T4-EMG)
89658911|NCT04402853||COVID 19 Patients|hospitalized patients with COVID 19
89658912|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg)|
89658913|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg)|
89658914|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg)|
89658915|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg)|
89658916|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg)|
89658917|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg)|
89658918|NCT01138995|Active Comparator|Ankle-foot orthosis (AFO) Control Group|"The Control Group will walk with the a usual ankle-foot orthosis (AFO) for 30 weeks."
89658919|NCT01138995|Experimental|Ness L300 Treatment Group|The Original Treatment Group will walk with the Ness L300 for 30 weeks.
89658920|NCT01197495|Experimental|Treatment|Juvederm(R) Ultra XC Injectable Gel
89658921|NCT01197495|Experimental|Control|No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.
89658922|NCT01197573|Active Comparator|Standard DCD liver transplant|Standard method of liver transplant utilizing a DCD organ
89658923|NCT01197573|Active Comparator|rTPA Treatment Liver Transplant|Ex-vivo treatment of liver donated after cardiac death (DCD) with rTPA
89658924|NCT01197573|Active Comparator|Standard DCD kidney transplant|Standard method of kidney transplant utilizing a DCD organ
89658925|NCT01197573|Active Comparator|rTPA Treatment Kidney Transplant|Ex-vivo treatment of kidney donated after cardiac death (DCD) with rTPA
89658926|NCT03010059|Experimental|Panel 1: Treatment ABC|Participants will receive 240 milligram (mg) JNJ-64041575 as 6.0 milliliter (mL) of a 40-milligram per milliliter (mg/mL) current oral suspension formulation (reference 1) under fasted conditions (Treatment A) in period 1, then 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 1) under fasted conditions (Treatment B) in period 2 followed by 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 2) under fed conditions (Treatment C) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658927|NCT03010059|Experimental|Panel 1: Treatment BCA|Participants will receive Treatment B (test 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658928|NCT03010059|Experimental|Panel 1: Treatment CAB|Participants will receive Treatment C (test 2) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658929|NCT03010059|Experimental|Panel 1: Treatment ACB|Participants will receive Treatment A (reference 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658930|NCT03010059|Experimental|Panel 1: Treatment BAC|Participants will receive Treatment B (test 1) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment C (test 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658931|NCT03010059|Experimental|Panel 1: Treatment CBA|Participants will receive Treatment C (test 2) in period 1, then Treatment B (test 1) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658932|NCT03010059|Experimental|Panel 2: Treatment DEF|Participants will receive JNJ-64041575 as 1 tablet of the 250-mg current oral tablet formulation (reference 2) under fasted conditions (Treatment D) in period 1, then 1 tablet of the 250-mg new concept oral tablet formulation (test 3) under fasted conditions (Treatment E) in period 2 followed by 1 tablet of the 250-mg new concept oral tablet formulation (test 4) under fed conditions (Treatment F) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658933|NCT03010059|Experimental|Panel 2: Treatment EFD|Participants will receive Treatment E (test 3) in period 1, then Treatment F (test 4) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658934|NCT03010059|Experimental|Panel 2: Treatment FDE|Participants will receive Treatment F (test 4) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment E (test 3) then in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658935|NCT03010059|Experimental|Panel 2: Treatment DFE|Participants will receive Treatment D (reference 2) in period 1, then Treatment F (test 4) in period 2 followed by Treatment E (test 3) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89213548|NCT00874406|Experimental|1|transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
89658936|NCT03010059|Experimental|Panel 2: Treatment EDF|Participants will receive Treatment E (test 3) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment F (test 4) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658937|NCT03010059|Experimental|Panel 2: Treatment FED|Participants will receive Treatment F (test 4) in period 1, then Treatment E (test 3) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
89658938|NCT03011931|Experimental|Simvastatin|Simvastatin tablet, 20 mg, one time by mouth
89658939|NCT01201629|Sham Comparator|t DC stimulation|Sham transcranial direct current stimulation tDCS induces slight short-lasting tingling with onset of the stimulation. These sensations usually fade away in seconds. Sham interventions are essential to blind the subject and the assessor in order to obtain unbiased assessment of intervention effects
89658940|NCT01201629|Experimental|tDC stimulation|Actual DC stimulation
89658941|NCT02185131|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
89658942|NCT02185131|Active Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
89658943|NCT00085709|Experimental|Post-consolidation GO|Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
89658944|NCT00085709|Other|Post-consolidation observation|Patients receive no additional therapy. Patients are observed at days 30 and 60 after randomization.
89658945|NCT00085709|Active Comparator|Induction 7+3|Standard induction regimen of 7 days of Ara-C (cytosine arabinoside) and 3 days of daunomycin
89658946|NCT00085709|Active Comparator|Induction 7+3+GO|Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C and 3 days of daunomycin
89658947|NCT01201863|Experimental|Low T Intervention - Androgel Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Androgel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
89658948|NCT01201863|Placebo Comparator|Low T Intervention - Placebo Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Placebo gel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
89658949|NCT01201863|No Intervention|Normal T|A subset of men with TBI meeting study criteria with normal T at screening were assessed at all data collection time points to provide a control group. Thirty-eight men obtained normal T levels at screening of which 24 were followed.
89658950|NCT01202253||Anidulafungin|
89658951|NCT01202565||Adalimumab|Participants with moderate to severe plaque psoriasis received adalimumab (Humira®) therapy according to the local product label and prescription/reimbursement guidelines.
89658952|NCT01678703|Active Comparator|Laminaria group|Patients in this group will have cervical preparation with laminaria MedGyn Products, Inc. USA overnight the day before the abortion
89658953|NCT01678703|Active Comparator|Misoprostol group|Patients in this group will have cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
89658954|NCT00085631|Experimental|Arm I|Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of chemoradiotherapy and hyperthermia, patients underwent brachytherapy to the cervix for 2-3 days.
89658955|NCT00085631|Active Comparator|Arm II|Patients received cisplatin and undergo external beam radiation therapy (and brachytherapy) as in arm I.
89658956|NCT01141491|Experimental|Arm A|Vaccine plus OPT-821
89658957|NCT01141491|Active Comparator|Arm B - OPT-821 immunologic adjuvant|Patients will be given 10 injections of OPT-821 alone as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
89658958|NCT00084929|Experimental|CT Colonography|CT colonography conducted during the same assessment as colonoscopy.
89658959|NCT01141569|Experimental|Treatment (RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89658960|NCT01678781||One patient group|Patients suffering from irritable bowel syndrome
89658961|NCT01141647|Experimental|24-Month Supported Employment|Evidence-Based Supported Employment Vocational Rehabilitation or Other Vocational Services
89658962|NCT01202643|Experimental|G-CSF|G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
89658963|NCT01202643|Placebo Comparator|Saline|Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
89658964|NCT01679015||Dry Eyes, Eye Allergies|Patients with ocular allergies and those with dry eyes.
89658965|NCT01141725|Experimental|Treatment (combination chemotherapy)|Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89658966|NCT01202721|Experimental|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg.
89658967|NCT01202721|Experimental|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg
89658968|NCT00084617|Experimental|Treatment (oxaliplatin, irinotecan, capecitabine)|Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on days 1, 8, 15, and 22 and oral capecitabine twice daily on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89658969|NCT01203189|Active Comparator|Shampoo Group|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
89658970|NCT01203189|Active Comparator|Foam group|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
89658971|NCT01203189|Active Comparator|Cross Over Group|apply ketoconazole 2% foam to scalp twice daily for four weeks. Subjects in the Shampoo group will be able to cross over into the Foam group if the TDSS score does not improve by 60% at the end of the four week treatment period using shampoo.
89658972|NCT01204203|Experimental|Zometa|Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.
89658973|NCT01679249||Hemodialysis patients|Stable prevalent patients on 3-times-per-week hemodialysis
89658974|NCT01679327|Experimental|Bevacizumab plus chemotherapy（XELOX or FOLFOX）|Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1 5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2 CIV 48h;repeated in 14 days)
89658975|NCT01206387|Experimental|active product|Desoximetasone Spray 0.25%
89658976|NCT01206387|Placebo Comparator|placebo comparator|vehicle
89658977|NCT03012087|Experimental|Intervention Group|MyHealthyChoices
89658978|NCT03012087|Placebo Comparator|Control Group|Health Risk Assessment
89658979|NCT01679483|Experimental|FloSeal group|This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
89658980|NCT01679483|No Intervention|No FloSeal group|All surgical procedures of control group is the same with study group except that Floseal is not applicated in control group.
89658981|NCT01679561|Experimental|intralipids|Two hundreds patients (group1) with abnormal NK activity results (NKa)will receive intralipids 20% i.v. (9 mg/mL total blood volume -corresponds to 2 mL of intralipids 20% diluted in 250 mL saline; or 18 mg/mL - corresponds to 4 mL of intralipids 20% diluted in 250 mL saline) infusions and their NKa will be tested periodically. The determination of NK cell function will be performed by flow cytometry using K562 cells as targets,then follow up of the patients by the Doppler of endometrial blood follow at the time of luteal phase,and the clinical pregnancy rate.Group(2)of 180 patients will receive placebo.
89658982|NCT01679639|Experimental|Aleglitazar|
89658983|NCT01679717|Active Comparator|Early mobilisation after CMC1-surgery|Mobilisation at two weeks after operation. The participants will wear a soft splint for six weeks.
89658984|NCT01679717|Other|Conservative treatment after CMC1-surgery|Current standard procedure: Mobilisation at six weeks after operation. The participants will wear a rigid splint for six weeks.
89658985|NCT01679795|Experimental|Tibolone|patientes will use tibolone 2,5mg/day during 30 days
89658986|NCT01679795|Placebo Comparator|Placebo use|Patients will use placebo for 30 days
89658987|NCT03470285|Other|Patients with small solid renal tumor|In addition to the actual workflow for a patient presenting a renal tumor, patients will undergo an additional Multiparametric MR imaging (mpMRI).
89658988|NCT01207401|Experimental|Paracervical Block|
89658989|NCT01207401|No Intervention|No Paracervical Block|
89658990|NCT01679873|Placebo Comparator|Control group|Assess abstract not reporting funding sources or conflicts of interest
89658991|NCT01679873|Experimental|Funding sources|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources only.
89658992|NCT01679873|Experimental|Funding sources/Conflicts of Interests|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources and conflicts of interest
89658993|NCT04761731|Experimental|ADVAGRAF®|One arm: Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
89658994|NCT03088475|Experimental|Experimental Group|A six-month nurse-led smartphone-based self-management programme (i.e. NSSMP) will be provided to the participants in the experimental group.
89658995|NCT03088475|Active Comparator|Control Group|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
89658996|NCT03088163|Experimental|DWI-MRI|
89658997|NCT03087929||Treatment Arm|Patients who had previously undergone high dose therapy with stem cell support followed by consolidation with Rituximab and alpha-interferon as part of the trial Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon. The patients in this arm have consented to long-term follow up.
89658998|NCT03088007||IME attending ID children|Children with mild to moderate Intellectual Deficiency attending school at IME (Instituts Médico-Educatifs, which are special schools mandated to accommodate children and young people with Intellectual Disability at any level of disability).
89658999|NCT03088007||ULIS attending ID children|Children with mild to moderate Intellectual Deficiency attending school at ULIS (Unités Localisées pour l'Inclusion Scolaire, which enables disabled children to attend regular schools)
89659000|NCT03088085|Experimental|Self-mobilization|Use of foam roller to mobilize thoracic spine and ribs every night before going to bed
89659001|NCT03088085|Active Comparator|Sleep Education|Education on sleep hygiene with tips for improving sleep.
89659002|NCT04746599|Experimental|Patients with critic limb ischemia|"Patient enrolled from emergency room or outpatient population undergo pre-operatory tests including blood test, thoracic radiography, electrocardiogram, cardiologic visit, TcPO2 measurement and Doppler ultrasonography. During surgery the terminal branches of the patient's leg arteries are mapped and under local anesthesia multiple injections (1 mL each) of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries. Furthermore, a total amount of 0.5-1 ml of the autologous adipose tissue-derived cell (ATDC) fraction is injected 1 cm near to ischaemic lesions.~After the surgical procedure, the patient will be followed for 6 months, during which he will undergo outpatient visits at 7 and 21 days; then at 1, 3 and 6 months. At each visit, the patient will be assessed for the amount of pain, the transcutaneous oximetry value, measurement of the ABI index, arterial ultrasound Doppler lower limbs."
89659003|NCT03087539|Experimental|Clotinab (Abciximab)|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
89659004|NCT03087539|Placebo Comparator|Placebo|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
89659005|NCT03087305||1|All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer
89659006|NCT03087461|Experimental|Intervention Group|"The intervention group will receive a multi-component KT intervention. This will include exercise and self-management components.~The exercise intervention will involve a moderate intensity aerobic exercise program, using recumbent bikes, delivered within the cancer institution. Participants will take part in the 30-minute sessions 8 times. The intervention will be supervised by a physiotherapist (PT) educated in cancer rehabilitation.~The SM component will include educational modules created by a PT. Participants will view these 30 minute modules prior to each exercise intervention, over the same 8 sessions."
89047241|NCT02887807|Placebo Comparator|Control|Single intravenous bolus of placebo (2.5 mg/kg) at the onset of resuscitation
89047242|NCT04663035|Experimental|Ablation Plus Tislelizumab|Patients in this arm will receive ablation followed by tislelizumab, which will be started within 3-7 days after ablation until disease progression or intolerable toxicity, for 12 months.
89047243|NCT04663035|Active Comparator|Ablation Alone|Patients in this group will receive ablation therapy and then enter the follow-up phase.
89047244|NCT04662762|Experimental|nursing intervention group|An educational interview by trained nurses was performed at three months in patients allocated to the intervention group. The visit was carried out at the hospital. Family and caregivers were also asked to attend this visit for instruction. For patients unable to move, the nursing team went to their home to perform the intervention, or it was conducted by phone. The duration of this interview was approximately 40 minutes and was focused on some measures and recommendations to improve or maintain adherence. Then, there is a reminder call at 6 months.
89047245|NCT04662762|No Intervention|Usual care group|The patient is followed up and regular visits
89047246|NCT03191942|Experimental|Modified ortho-k lenses|Participants wearing ortho-k lens with a modified BOZD of 5mm
89047247|NCT03191942|Active Comparator|Ortho-k lenses|Participants wearing ortho-k lens with a standardized BOZD of 6mm
89047248|NCT04662606|No Intervention|Fasting-group|
89047249|NCT04662606|Experimental|Fed-group|
89659007|NCT03087461|No Intervention|Usual Care|Control group receiving usual care (no exercise or self-management education within the institution).
89659008|NCT03087149|Experimental|monitored group|The monitored group will received monitored vit D supplementation
89659009|NCT03087149|Active Comparator|standard group|The standard group will receive standard vit D supplementation
89659010|NCT03087383||Prospective Cohort|In adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm, investigator will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
89659011|NCT03087383||Retrospective Cohort|In previous study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm (NCT02700126, 4-2015-1195), investigator enrolled patients and collected data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions.
89659012|NCT03086681|Experimental|concurrent chemoradiotherapy + endostar|4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
89659013|NCT03086681|Active Comparator|concurrent chemoradiotherapy|5 cycles of DDP concurrent with radiotherapy
89659014|NCT03086759|Experimental|Platelet rich plasm group|
89659015|NCT03086759|Active Comparator|Triamcinolone Hexacetonide group|
89659016|NCT03086759|Placebo Comparator|Isotonic Saline Solution group|
89659017|NCT03086525||Musculoskeletal pain|Participants Healthy male and female students, students of the University of Málaga, will be recruited. . The inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the University of Málaga.
89659018|NCT03086291|Experimental|simvastatin|One arm Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days Cohort 1: 7.5 mg/kg bid for 7 days 14 days off Cohort 2: 10 mg/kg bid for 7 days 14 days off Cohort 3: ( ) mg/kg bid for 7 days 14 days off (to be determined based on PK data of cohort 1 and 2) Q 3 weeks
89659019|NCT03086915||Patients with neuromuscular block|Neuromuscular blocking agent administrated during surgery to the paediatric patient
89659020|NCT03085901|Active Comparator|Precizon toric intraocular lens|Cataract surgery and implantation of Precizon toric intraocular lens
89659021|NCT03085901|Active Comparator|Tecnis toric intraocular lens|Cataract surgery and implantation of Tecnis toric intraocular lens
89047250|NCT03058952|Experimental|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
89047251|NCT03058952|Active Comparator|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
89047252|NCT04662528|Placebo Comparator|Placebo|
89047253|NCT04662528|Experimental|MAT9001 (omega-3-pentaenoic acid)|
89213549|NCT00874406|Active Comparator|2|Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
89659022|NCT03085745|Experimental|Transcranial Magnetic Stimulation (TMS)|15 patients suffering from a writer's cramp, aged 20-80 who are currently treated with botulinum toxin will receive single pulse TMS
89659023|NCT03085511|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
89659024|NCT03085511|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
89659025|NCT03085355|Active Comparator|Exercises and PNE|Individuals with neck pain will receive a exercises program and pain neuroscience education. Participants will receive treatments during 4 weeks, 1 treatment per week
89659026|NCT03085355|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and pain neuroscience education and the participants will receive treatments during 4 weeks, 1 treatment per week associated with Osteopathic Manipulative Treatment (OMT)
89659027|NCT03085199|Other|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, laparoscopic reinforcement suture commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
89659028|NCT03084887|Experimental|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
89659029|NCT03084887|No Intervention|controlled group|no intervention until secondary hospital
89659030|NCT01209195|Experimental|MM-121 + Paclitaxel|Escalating doses of MM-121 given IV QW in combination with paclitaxel at standard dose of 80 mg/m2 IV QW
89659031|NCT03084809|Experimental|Cytokine-induced killer cells + FOLFOX4|"Cytokine-induced killer cells + FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.The treatment is given for 4-6 cycles, every 3 weeks.~Collected cytokine-induced killer cells (CIK) cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days."
89659032|NCT03084809|Experimental|FOLFOX4|"FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks."
89659033|NCT01144143|Experimental|Infliximab|
89659034|NCT01144143|Placebo Comparator|Salt Water|
89659035|NCT01144143|Active Comparator|Methylprednisolone acetate|
89659036|NCT03084575|Active Comparator|Thermal Radiofrequency group|"Group 1 RF group: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy."
89659037|NCT03084575|Active Comparator|phenol group|"Group 2 phenol group: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin."
89659038|NCT03084653||Survey|Close-ended survey questions were formed and will be sent to general surgeons by e-mail containing the web address of the survey.
89659039|NCT02984891||Treatment|Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be used in patients with coronary artery disease.
89659040|NCT01212471|Experimental|Bromfenac Ophthalmic Solution A|Bromfenac ophthalmic solution A
89659041|NCT01212471|Experimental|Bromfenac Ophthalmic Solution B|Bromfenac ophthalmic solution B
89659042|NCT01212471|Placebo Comparator|Placebo Comparator|Placebo Comparator
89659043|NCT03084497|Experimental|Group receiving Infant Massage|The subjects of this group will receive a total of 5 sessions of Infat Massage.
89659044|NCT03084497|No Intervention|Group without intervention|The subjects of this group won´t receive any intervention.
89659045|NCT03084341|Active Comparator|NMEE Group|Neuromuscular Electrical Elongation
89659046|NCT03084341|Active Comparator|PNF Group|Proprioceptive Neuromuscular Facilitation stretching
89659047|NCT03084341|No Intervention|Control Group|No intervention
89659048|NCT03084419|Experimental|Abatacept in patients with RA-ILD|Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.
89659049|NCT03084107|Experimental|Questionnaire|technology acceptance model (TAM) questionnaire
89659050|NCT03084263|Experimental|AORIF of Ankle Fractures|Arthroscopic Assisted Open Reduction Internal Fixation of ankle fracture.
89659051|NCT03084263|Active Comparator|ORIF of Ankle Fractures|Open Reduction Internal Fixation of ankle fracture.
89659052|NCT03084029|Experimental|male participants - oxytocin nasal spray|male participants - receiving a single dose of 40 IU intranasal oxytocin
89659053|NCT03084029|Experimental|female participants - oxytocin nasal spray|female participants - receiving a single dose of 40 IU intranasal oxytocin
89659054|NCT03084029|Placebo Comparator|male participants - placebo nasal spray|male participants - receiving a single dose of 40 IU intranasal placebo
89659055|NCT03084029|Placebo Comparator|female participants - placebo nasal spray|female participants - receiving a single dose of 40 IU intranasal placebo
89659056|NCT03405545|Experimental|HIIT|This group of subjects will perform High Intensity Interval training 3x/week for 12 weeks
89659057|NCT03083717||Patients with compensated heart failure|
89659058|NCT03083717||Patients with decompensated heart failure|
89659059|NCT03083717||Healthy subjects|
89659060|NCT04278053|Experimental|Nitrosigine supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Nitrosigine (1.5 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
89659061|NCT04278053|Experimental|Citrulline-Malate supplementation|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, Citrulline-Malate (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
89659062|NCT04278053|Placebo Comparator|Placebo|Ultrasound is a non-invasive way of determining the diameter of arteries. A total of 10 measurements will be taken of the brachial artery. After the initial 10 measurements (~3-5 minutes), flow-mediated dilation (FMD) was performed. Flow mediated dilation was performed with a Hokanson rapid cuff inflator. The cuff (blood pressure cuff) was position on the forearm (just above the wrist) and was inflated to 250-300mmHg for a period of 5 minutes to restrict blood flow. After the 5-minute inflation period, the cuff was deflated and vessel diameter was re-assessed (10 additional trails). Following the initial FMD assessment, dextrose (8 g) was provided in an 8 ounce solution with a cherry flavoring to mask taste. After consumption, participants remained in ESRC for 60 minutes to allow for digestion of the substance. Following the 60-minute absorption period, FMD was re-assessed.
89659063|NCT03083327|Active Comparator|Standard Care|The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided.
89659064|NCT03083327|Active Comparator|Early supplemental parenteral nutrition|"Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.~The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake."
89659065|NCT03083171|Placebo Comparator|Placebo|
89659066|NCT03083171|Active Comparator|Adrecizumab 0.5 mg/kg|A single intravenous dose of 0.5 mg/kg Adrecizumab given over a 1 hour period.
89659067|NCT03083171|Active Comparator|Adrecizumab 2.0 mg/kg|A single intravenous dose of 2.0 mg/kg Adrecizumab given over a 1 hour period.
89659068|NCT03083171|Active Comparator|Adrecizumab 8.0 mg/kg|A single intravenous dose of 8.0 mg/kg Adrecizumab given over a 1 hour period.
89659069|NCT03083015|Experimental|Revascularization|Blood clot initiation and grey MTA ( Mineral Tri-oxide Aggregate) cervically compacted.
89659070|NCT03083015|Active Comparator|Apexfication|Apexification using grey MTA apically compacted without mechanical preparation.
89659071|NCT03082937|Experimental|3 mg [14C]-A4250 capsule|
89659072|NCT03082859|Experimental|Reduced-exertion high-intensity interval training|Cycling Exercise. 2 x 20-sec sprints.
89659073|NCT03082859|Experimental|High Intensity Interval Training (HIT)|Cycling Exercise. 10 x 1 min at approx 85% peak power output (Wmax)
89659074|NCT03082859|Experimental|Moderate Intensity Continuous Exercise|Cycling exercise. 30 min at 50% peak power output (Wmax)
89659075|NCT03082859|No Intervention|Sedentary (no exercise)|No exercise. Rest.
89659076|NCT05346107|Experimental|PldCHP---Nab-PHP|he patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
89659077|NCT03082781|Experimental|Study group I|Study group I (57 participants) received the NCD with exercise (NCDsport).This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
89659078|NCT03082781|Experimental|Study group II|Study group II (54 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
89659079|NCT03400631|Experimental|Dextrose 0. Aspiration 1 week.|Dextrose injection given at time 0, at 1 week aspiration only, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
89659080|NCT03400631|Experimental|Aspiration 0. Dextrose 1 week.|Aspiration only at time 0. Dextrose injection given at 1 week, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
89659081|NCT03082703|Experimental|Text Messaging|
89659082|NCT03082703|No Intervention|Control|
89659083|NCT03082547||Headache Groub|Headache patients with myofascial trigger points.
89659084|NCT03082547||Healthy Groub|No headache or other diseases can cause headaches of healthy people.
89659085|NCT03082235|Experimental|Cohort 1: 10 mg E6742|Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.
89659086|NCT03082235|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
89659087|NCT03082235|Experimental|Cohort 2: 25 mg E6742|Participants will receive 25 mg E6742 as a single oral dose in the fasted state.
89659088|NCT03082235|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
89659089|NCT03082235|Experimental|Cohort 3: 50 mg E6742|Participants will receive 50 mg E6742 as a single oral dose in the fasted state.
89659090|NCT03082235|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
89659091|NCT03082235|Experimental|Cohort 4: 100 mg E6742|Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.
89659092|NCT03082235|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.
89659093|NCT03082235|Experimental|Cohort 5: 200 mg E6742|Participants will receive 200 mg E6742 as a single oral dose in the fasted state.
89057989|NCT01198756|Experimental|GSK2282512A 2 Group|Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants <12 months of age.
89659094|NCT03082235|Placebo Comparator|Cohort 5: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
89659095|NCT03082235|Experimental|Cohort 6: 400 mg E6742|Participants will receive 400 mg E6742 as a single oral dose in the fasted state.
89047254|NCT02830997||Conventional guidance|The conventional guidance will undergo TKA surgery with use of the Investigator's usual precision guided technique based on conventional instrumentation (mechanical and simple computer-assisted guidance techniques). For participants of the conventional guidance arm, the Investigator will employ the established technique he currently employs for all routine TKA procedures and would employ if the patient were not a participant in the study.
89047255|NCT02830997||Stereotactic guidance|The stereotactic guidance group will undergo their TKA surgery with use of a stereotactic guidance system.
89047256|NCT03098706|Other|NT normothermia|After information for donation and research has been explained, organ donors in the normothermia (NT) group will either be maintained to spontaneously reach a body temperature of 36,5 °C-37,5°, until transfer to the operating room.
89659096|NCT03082235|Placebo Comparator|Cohort 6: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
89659097|NCT03082235|Experimental|Cohort 7: 800 mg E6742|Participants will receive 800 mg E6742 as a single oral dose in the fasted state.
89659098|NCT03082235|Placebo Comparator|Cohort 7: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
89659099|NCT03082157|Experimental|Mighty Men Intervention|Mighty Men weight-loss intervention including health education and exercise during small group sessions
89659100|NCT03082157|No Intervention|Comparison|Exercise-only small group sessions
89659101|NCT03082001|Active Comparator|24% Sucrose|"The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~24% sucrose was prepared by mixing 2.4gm of sucrose in 10ml distilled water."
89659102|NCT03082001|Experimental|12% Sucrose|"The enrolled infants were administered 0.2 ml of 12% sucrose 2 min prior to procedure.~These solution were prepared under all sterile precautions by the laboratory staff unrelated to the study. 12%sucrose was prepared by mixing 1.2 gm of sucrose in 10 ml of distilled water. here were two study groups A & B. The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~Out of these solutions 1ml was measured by 1 ml syringe and packed and covered with serially numbered opaque sealed envelopes. At the initiation of venepuncture 2 min prior to procedure 0.2 ml of solution marked with patient serial no was administered by a pre-filled syringe to the patient on the anterior aspect of the tongue avoiding spillage, by the personnel carrying out the procedure. The above mentioned personnel was blinded to the contents of the solution."
89659103|NCT00083915|Active Comparator|Auto Transplant w/ High Dose Melphalan|Autologous transplant with High Dose Melphalan alone
89659104|NCT00083915|Active Comparator|Auto Transplant w/ Melphalan + DT Pace|Melphalan plus Dexamethasone, Thalidomide, CisPlatinum, Adriamycin, Cyclophosphamide, and Etoposide
89659105|NCT03081533|Experimental|Circle Dance Program (CircleCare)|Caregivers (n=20) allocated to the experimental group will participate in 12-week CircleCare twice a week (24 sessions), for 60 min each session. The planning and conduction of the intervention will be the responsibility of the researcher, a Fitness Professional with training in Circle Dance, called focalizer.
89659106|NCT03081533|No Intervention|Control group|Caregivers (n=20) of this group will not receive the intervention, participating only in the assessment protocol. They will be instructed not to initiate any regular exercise program during the study period. At the end of the study, the same CircleCare applied to the experimental group will be offered to the interested of the control group.
89659107|NCT03081611|Experimental|Ram cannula|NIPPV VIA Ram cannula
89659108|NCT03081611|Active Comparator|Short nasal prongs|NIPPV VIA short nasal prongs
89659109|NCT03081455||Women meeting guidelines for genetic testing|Women who present for an OB/GYN office visit (new patient visit, well woman visit, or problem visit) and who meet guidelines for genetic diagnostic testing will provide a blood or saliva sample for genetic diagnostic testing and complete a satisfaction survey.
89659110|NCT03081299||Total Knee Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
89659111|NCT03081299||Total Hip Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
89659112|NCT03081299||Mastectomy|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
89659113|NCT03081299||Thoracic Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
89659114|NCT03081299||Major Abdominal Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
89659115|NCT03081299||Spinal Fusion|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
89659116|NCT04401839|Active Comparator|Control group|153 patients received Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
89659117|NCT04401839|Active Comparator|Study group|156 patients received Oxytocin 10 IU I.V shot at the time of delivery of the of the anterior shoulder of the baby according to the WHO recommendation .Then oxytocin is stopped and cervical traction (Amr maneuver )is applied.
89659118|NCT03080987|Experimental|Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.
88994611|NCT02930707|Placebo Comparator|control group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
89659119|NCT03080987|Experimental|Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
89659120|NCT03080987|Experimental|Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
89659121|NCT03080987|Experimental|Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
89659122|NCT03080987|Experimental|Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
89659123|NCT03080987|Experimental|Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.
89659124|NCT04761185|Experimental|HIPEC using Raltitrexed|
89659125|NCT03080909|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The encapsulated nutrients will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. test products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
89659126|NCT03080909|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The placebo products will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. placebo products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
89659127|NCT01144455|Active Comparator|Gemcitabine|Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle
89659128|NCT01144455|Experimental|240 mg/m2 TH-302 + Gemcitabine|"TH-302: 240 mg/m2 administered IV over 30 minutes Day 1, 8, and 15 of each 28-day cycle~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
89659129|NCT01144455|Experimental|340 mg/m2 TH-302 + Gemcitabine|"TH-302: 340 mg/m2 of TH-302 be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
89659130|NCT03080675|Experimental|Experimental|Nutritional blend of ingrédients including vitamins and fish oil
89659131|NCT03080675|Placebo Comparator|Control comparator:|control product does not contain any of the active ingredients and is matched for carbohydrate content to the active intervention.
89659132|NCT04401527|Active Comparator|Sodium Nitrite|Hope Pharmaceuticals' Sodium Nitrite Injection administered by continuous intravenous infusion.
89659133|NCT04401527|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP (normal saline) administered by continuous intravenous infusion.
89659134|NCT04401683|Experimental|Digital Rehabilitation|Standard medical treatment + Fully remote rehabilitation program with a digital therapist
89659135|NCT04401683|Active Comparator|Conventional Rehabilitation|Standard medical treatment + Home-based rehabilitation program
89659136|NCT03080363|Active Comparator|Quadratus Lumborum Block|Ultrasound guided Quadratus Lumborum Block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
89659137|NCT03080363|No Intervention|Group Control|No intervention
89659138|NCT03080597|Experimental|Smartphone app condition|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart."
89659139|NCT01212627|Experimental|Ridaforolimus|Ridaforolimus: 20mg Daily, 5 days each week, on a 28 day cycle until progression
89659140|NCT03080519|Experimental|Endovascular Therapy|Renal artery revascularization
89659141|NCT03392753|Active Comparator|Mechanochemical ablation (MOCA)|Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
89659142|NCT03392753|Active Comparator|Cyanoacrylate adhesive (CAE)|Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
89659143|NCT01145001|Active Comparator|Active Nicotine Patch and Contingency Management|Subjects in this group will receive Contingency Management and active nicotine patch
89659144|NCT01145001|Active Comparator|Nicotine Patch with no Contingency Management|Subjects in this group will receive active nicotine patch without contingency management for abstinence
89659145|NCT01145001|Placebo Comparator|Placebo patch and Contingency Management|Subjects in this group will receive a placebo transdermal patch and contingency management
89659146|NCT01145001|Placebo Comparator|Placebo Patch and no Contingency Management|Subjects in this group will receive a placebo patch and will not receive contingency management
89659147|NCT03080207|Experimental|Platelets / Platelet Enriched Plasma Regard (PRP) Method|
88994612|NCT00148031|Experimental|1|On-site (MMT Clinic) HCV evaluation and treatment
88994613|NCT00148031|Active Comparator|2|Off-site (GI Clinic) HCV evaluation and treatment
88994614|NCT02930473|Experimental|Psychotherapeutic Intervention(s) for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s) for anxiety (plus psychopharmaceuticals)."
88994615|NCT02930473|Active Comparator|Treatment-as-Usual for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will receive treatment as usual for anxiety (psychopharmaceuticals)."
89659148|NCT03080207|Experimental|Complex Decongestive Physiotherapy|
89659149|NCT03080207|Experimental|Low Level Laser|
89659150|NCT03011463|Active Comparator|trospium intravenous|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o.
89659151|NCT03011463|Active Comparator|trospium oral|Oral administration of 30 mg trospium chloride with 240 ml tap water
89659152|NCT03011463|Active Comparator|trospium intravenous with ranitidine|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 300 mg ranitidine with 240 ml tap water
89659153|NCT03011463|Active Comparator|trospium intravenous with clarithromycin|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 500 mg clarithromycin with 240 ml tap water
89659154|NCT03011463|Active Comparator|trospium oral with ranitidine|Oral administration of 30 mg trospium chloride together with 300 mg ranitidine with 240 ml tap water
89659155|NCT03011463|Active Comparator|trospium oral with clarithromycin|Oral administration of 30 mg trospium chloride together with 500 mg clarithromycin with 240 ml tap water
89659156|NCT03085589||Amulet adaptation and validation|The Amulet development team will develop and configure applications assessing: steps/distance; strength; activity type; gait speed; and real-time, self-monitored activity feedback. Objective measures will be validated with the Amulet from 60 participants ensuring usability and feasibility. Each participant will be asked to come into the clinic for one afternoon for about 2-3 hours.
89659157|NCT03152825||Viable myocardium Group|"At least ONE of the following:~Late gadolinium enhancement <75%.~Improvement in segmental function ≥1 grade during low dose dobutamine"
89659158|NCT03152825||Non-viable myocardium group|"At least ONE of the following:~Late gadolinium enhancement ≥75%.~No improvement in segmental function during low dose dobutamine"
89659159|NCT03152825||Inducible ischaemia group|"At least ONE of the following:~perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine~new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine"
89659160|NCT03152825||Non-inducible ischaemia group|"None of conditions qualifying for the Inducible ischemia group"
89659161|NCT03152435|Experimental|anti-tumor response of CART-EGFR|
89659162|NCT05345873|Experimental|SCTV01E Group|one dose of SCTV01E, intramuscular
89659163|NCT05345873|Active Comparator|mRNA-1273|one dose of mRNA-1273, intramuscular
89659164|NCT03150017|Experimental|Online programme|SPIRE The programme consists of six modules over six weeks and is based on cognitive behavioural principles. It comprises psychology sessions using cognitive techniques to identify unhelpful and unrealistic thoughts and beliefs related to pain and to challenge and change them and weekly relaxation audios and a home exercise session. Goal setting by participants is used encouraged throughout the programme to aid the implementation of learned CBT techniques into daily life. Educational sessions are delivered across a range of topics including mechanisms of pain after SCI, explanations of the pain gate control theory and how CBT strategies employed can impact on the perception of pain, discussion of medication use, stress management and pacing strategies for activities of daily living.
89659165|NCT03150017|No Intervention|Usual Care|Continue to manage pain using usual care.
89659166|NCT05342051|Experimental|balneotherapy group|balneotherapy plus usual care
89659167|NCT05342051|No Intervention|control group|usual care
89659168|NCT01214109|Experimental|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
89659169|NCT01214109|Active Comparator|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
89659170|NCT01145391|No Intervention|Control|Patients receive usual care.
89659171|NCT01145391|Active Comparator|Intervention|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
89659172|NCT03150407|Active Comparator|VR101 Device|Subjects assigned to use randomly-assigned VR101 devices. Each device is to be used for 7 consecutive days, then replaced with a fresh device. Four each VR101 devices will be used. These will be investigated in a cross-over design that will also include consecutive use of 4 Shams, each for 7 days.
89659173|NCT03150407|Sham Comparator|Sham Control Ring|Subjects assigned to use randomly-assigned Sham rings. Each Sham is to be used for 7 consecutive days, then replaced with a fresh sham. Four each Shams will be used. These will be investigated in a cross-over design that will also include consecutive use of 4 VR101 Devices, each for 7 days.
89659174|NCT03150407|Other|Long-term Safety Evaluation|13-week investigation of the safety of the use of VR101 Devices
89659175|NCT01145547|Active Comparator|low glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low Glycemic Index.
89659176|NCT01145547|Active Comparator|high glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a high Glycemic Index.
89659177|NCT01214811|Other|Mepilex Border Ag|Non comparative study with one active arm - Mepilex Border Ag
89659178|NCT03153371||Early-onset Alzheimer's disease|This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
89659179|NCT03153371||Alzheimer's disease|This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)
89659180|NCT03153371||Controls|Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.
89659181|NCT05688605|Experimental|MRG003+HX008|"MRG003 will be administrated via intravenous infusion at 1.5, 2.0 mg/kg (MTD=2.5 mg/kg) once on Day 1 of every 3 weeks (21-day cycle).~HX008 will be administrated via intravenous infusion at 3 mg/kg once on Day 1 of every 3 weeks (21-day cycle)."
89659182|NCT01215123||Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
89659183|NCT05688449|Active Comparator|Epidural analgesia|Eeg monitoring will be implemented with Sedline monitor(Masimo Irvine CA) 5 minutes before epidural catheter insertion, 30 minutes after epidural catheter insertion, during surgery and 5 minutes after extubation.
89659184|NCT05688449|Placebo Comparator|placebo|Eeg monitoring will be implemented with Sedline monitor (Masimo Irvine CA) 5 minutes before epidural catheter insertion, 30 minutes after epidural catheter insertion, during surgery and 5 minutes after extubation.
89659185|NCT01215279|Experimental|AZD2423|AZD2423 Oral Treatment for 28 days
89659186|NCT01215279|Placebo Comparator|Placebo|Oral treatment for 28 days
89659187|NCT03158597||AMI|
89659188|NCT03158597||Control|
89659189|NCT04401137|Placebo Comparator|Placebo|
89659190|NCT04401137|Experimental|QDX 25|
89659191|NCT04401137|Experimental|QDX 50|
89659192|NCT04401137|Experimental|QDX 100|
89659193|NCT04401137|Experimental|QDX 200|
89659194|NCT01670123|Experimental|Mobile Phone Condition|This arm will involve daily self-monitoring with an electronic mobile device with responses to survey questions about mood status. Mood status reports are linked with personalized coping strategies.
89659195|NCT01670123|Placebo Comparator|Paper-and-pencil condition|This arm will complete a paper-and-pencil mood chart on a daily basis
89659196|NCT02189889|Active Comparator|EPO and Feraheme|Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
89659197|NCT02189889|No Intervention|Control|The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.
89659198|NCT03388385|Placebo Comparator|Placebo|Intervention: 250 mL Sodium Chloride 0.9% Intravenous Solution, representing control infusion, over 30 minutes.
89659199|NCT03388385|Active Comparator|Ferric carboxymaltose|Intervention: 1000 mg Ferinject in 250 mL 0.9%NaCl, representing medication in study infusion, over 30 minutes.
89659200|NCT01148745|Other|ferumoxytol|FDA approved drug
89659201|NCT04401215|Other|Technology Augmented Treatment group|Intervention Group
89659202|NCT04401215|No Intervention|Control group|After the baseline visit the control arm participants will receive no additional follow-up beyond usual care until the 30 days' end. Surveys at the end of 30 days.
89659203|NCT02190045|Experimental|Wii-Fit program|Wii-Fit exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
89659204|NCT02190045|Placebo Comparator|Cognitive remediation program|Cognitive remediation exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
89659205|NCT04348487|Other|Standard procedure|For the conventional TIVAPS with cephalic vein approach, incision was made either in the midline of infraclivular or supraclavicular. Cathether was introduced to the central and then connected to the laterally implanted port in the deltopectoral region. The experience in the local center experienced several pitfalls with this method such as pneumothorax, pinch-off syndrome, compression of the catheter by the clavicle, kinking of the catheter, and loss of patencty.
89659206|NCT04761029|Active Comparator|grup R|Unilateral Rhomboid intercostal and subserratus block + intravenous patient-controlled analgesia
89659207|NCT04761029|Placebo Comparator|Group P|intravenous patient-controlled analgesia
89047257|NCT03098706|Experimental|HT mild hypothermia|The intervention will take place after information for donation and research has been explained . Organ donors in the intervention group will either be actively warmed or allowed to reach a body temperature of 34 °C-35°C, until transfer to the operating room.
89047258|NCT02802488|Experimental|D-dimers|This arm encompasses patients between 18 and 80 years old and diagnosed with atrial fibrillation.
89047259|NCT04662333|Active Comparator|Crestal sinus lift|Implant site preparation with detachment of Schneiderian membrane and subsequent implant placement. The corresponding healing abutment is made up of PEEK (poly-ether-ether-ketone)
89047260|NCT04662333|Experimental|Crestal sinus lift with adjunctive xenograft|Implant site preparation with detachment of Schneiderian membrane. After that, collagen membrane plus xenogenic bone substitute will be placed into the site before implant placement. The corresponding healing abutment is made up of titanium.
89047261|NCT05300672|Experimental|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
89047262|NCT05300672|No Intervention|No fibrinogen infusion|No fibrinogen infusion
89047263|NCT03098589||Patients with T-cell leukemia lymphoma treated with Revlimid|Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
89213550|NCT04840628|Experimental|neural respiratory drive|neural respiratory drive assessed by EMGdi recorded from a multipair esophageal electrode
89213551|NCT00880178||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
89213552|NCT00880178||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
89659208|NCT03384875|Experimental|CytoSorb Device|Standard of care plus treatment with CytoSorb device installed on the Cardiopulmonary bypass (CPB) machine
89659209|NCT03384875|Placebo Comparator|Control|Standard of care
89659210|NCT05688137|Active Comparator|DRAINAGE GROUP (D)|This patients will take the abdominal drainage.
89659211|NCT05688137|No Intervention|NON DRAINAGE GROUP (ND)|This patients will not take the abdominal drainage.
89659212|NCT05687981|Active Comparator|Patients will receive 10 ml of 0.5% bupivacaine|A 2mg dexamethasone will be added
89659213|NCT05687981|Active Comparator|Patients will receive 10 ml of 0.25% bupivacaine|A 2mg dexamethasone will be added
89659214|NCT05687747|Experimental|68Gallium-FAPI-46 PET/MRI|Patients receiving Ga68-FAPI-46 will be injected at a dose of 4mCi +/- 2mCi (0.05mCi/kg). Whole body PET scans will be acquired 45mins post injection from head to mid thighs
89659215|NCT05687669|Experimental|Group GTN|Glyceryl trinitrates (GTN) is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure
89659216|NCT05687669|Experimental|Group Phentolamine|Phentolamine is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure
89659217|NCT05687513|Experimental|treatment group|
89659218|NCT05687513|Placebo Comparator|control group|
89659219|NCT05687435|Experimental|Changyanning group|Changyanning tablet: Each tablet weighs 0.42g and is taken orally, 4 tablets once and 3 times a day.The course of treatment was 8 weeks.
89659220|NCT05687435|Placebo Comparator|Placebo group|Changyanning tablet placebo: Each tablet weighs 0.42g and is taken orally, 4 tablets once and 3 times a day.The course of treatment was 8 weeks.
89659221|NCT05687201||APOE-E4 (ε2/ε4,ε3/ε4,ε4/ε4) group|All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.In addition, all patients received more comprehensive measures to prevent deep vein thrombosis (DVT), control blood pressure and glucose, nutritional support, and prevent other complications.
89659222|NCT05687201||APOEε3(ε3/ε3) group|All the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.In addition, all patients received more comprehensive measures to prevent deep vein thrombosis (DVT), control blood pressure and glucose, nutritional support, and prevent other complications.
89659223|NCT05687045|Experimental|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
89659224|NCT05687045|Active Comparator|Standard Treatment|If peripheral oxygen saturation will be < 95%, conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
89659225|NCT05686889|Experimental|Success|Symptomatic improvement present
89659226|NCT05686889|Experimental|Failure|Symptomatic improvement absent
89659227|NCT04400825|Experimental|Dry needling|Dry needling of 3 active MTrPs at most.
89659228|NCT04400825|Active Comparator|Stretching|Stretching of the main hip flexors (rectus femoris, iliopsoas and tensor fasciae latae)
89659229|NCT05686811|Active Comparator|Myofascial release therapy|This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
89659230|NCT05686811|Experimental|post isometric relaxation technique|This group will receive routine physical therapy with post isometric relaxation technique.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
89659231|NCT04400747|Experimental|weekly treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 50,000 IU of vitamin D weekly for 8 weeks.
89659232|NCT04400747|Experimental|daily treatment group|Twenty patients with spinal cord injury with serum 25 (OH) D3 level less than 20 ng / ml will receive 6,000 IU of vitamin D daily for 8 weeks.
89659233|NCT04400747|No Intervention|control group|20 patients with high calcium (Ca) values in blood tests, patients with kidney and urinary stones, as well as patients who refuse to use vitamin D supplements will be included in the control group
89659234|NCT03372707|Experimental|Intervention Arm|Patients randomized to the intervention arm will have the results of the Cuff Leak Test (CLT) (whether failed or passed) communicated to the treating physician; the treating physician will decide whether to proceed with extubation or not based on the CLT results. It is at the discretion of the treating physician to provide corticosteroids (4-5 mg of intravenous dexamethasone every six hours for up to 24 hours, with the last dose given one hour preceding extubation) and/or delay extubation by 24 hours should the patient fail the CLT.
89659235|NCT03372707|No Intervention|Control Arm|In the control arm of this trial; the treating physicians and healthcare workers will be blinded to the results of the Cuff Leak Test (CLT); therefore, the Respiratory Therapist (RT) will proceed with extubation without delay or administering systemic steroid, regardless to the CLT results.
89659236|NCT05686655||diabetes children|
89659237|NCT03372161|Experimental|SP-102|SP-102
89047264|NCT05298137|No Intervention|IV Cannulation Without Passive Leg Raise|"Patients will be randomized to either the passive leg raise (PLR) group or standard care (control group). In both groups baseline measurements of a peripheral vein diameter using ultrasound will be undertaken at the level of the left antecubital fossa with and without a proximally placed venous tourniquet.~Those in the control group will then have a peripheral IV (PIV) placed in the ipsilateral arm as the baseline measurements, the number of attempts to successful PIV placement will be recorded. A repeat diameter assessment of the previously assessed vein, number of PIV attempts, and time to successful IV cannulation (measured as the time from skin puncture to successful IV cannulation) will be recorded."
89659238|NCT03372161|Placebo Comparator|Placebo|Placebo
89659239|NCT05686577||learning database group|The results of blood cultures and the clinical elements of the patients in the first sample (1600 patients) will constitute the learning database. A supervised learning will be performed on these data in order to select a set of clinical elements allowing to define a predictive score of positive blood cultures
89659240|NCT05686577||validation database group|The score will be validated on the remaining sample (800 patients), independent of the first sample. Both samples will be constituted by randomization.
89659241|NCT02190747|Experimental|Palovarotene dose level 1 (Cohort 1)|Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.
89659242|NCT02190747|Experimental|Palovarotene dose level 2 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.
89659243|NCT02190747|Experimental|Palovarotene dose level 3 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.
89659244|NCT02190747|Placebo Comparator|Sugar pill|The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.
89659245|NCT04279457|Active Comparator|Standardized Hydration protocol|These cases will follow Charleston Area Medical Centers standard Hydration protocol
89659246|NCT04279457|Active Comparator|Hydration + Device|These cases will follow Charleston Area Medical Centers standard hydration protocol plus use the DyeVert Plus System
89659247|NCT03370991|Experimental|Blueberry|22 g/day freeze-dried blueberry powder for 12 weeks
89659248|NCT03370991|Placebo Comparator|Control|22 g/day placebo powder for 12 weeks
89659249|NCT05686343||Treated|
89659250|NCT05686343||Untreated|
89659251|NCT02190903|Active Comparator|General endotracheal anesthesia|Standard care general endotracheal anesthesia
89659252|NCT02190903|Active Comparator|Regional (spinal) anesthesia|Standard care spinal anesthesia
89659253|NCT02246985|Experimental|Plain bread with plain mayonnaise|Control meal. The bread and mayonnaise in this meal does not have vegetable powders incorporated into them, hence this meal does not contain carotenoids
89659254|NCT02246985|Experimental|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids
89659255|NCT02246985|Experimental|Vegetable bread with plain mayonnaise|A vegetable powder (carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids.
89047265|NCT05298137|Experimental|IV Cannulation With Passive Leg Raise|"Patients will be randomized to either the passive leg raise (PLR) group or standard care (control group). In both groups baseline measurements of a peripheral vein diameter using ultrasound will be undertaken at the level of the left antecubital fossa with and without a proximally placed venous tourniquet.~Those in the passive leg raise (PLR) group will have their legs elevated to 45 degrees until successful peripheral IV (PIV) placement. A repeat diameter assessment of the previously assessed vein, number of PIV attempts, and time to successful IV cannulation (measured as the time from skin puncture to successful IV cannulation) will be recorded."
89047266|NCT04662177|Experimental|Group 1: Co-administration of dexmedetomidine and propofol with electrophysiological studies|The group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by continuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression.
89659256|NCT02246985|Experimental|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
89659257|NCT01149759|Experimental|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks.
89659258|NCT05686187|Experimental|AR's platform for gender empowerment|The experimental group's intervention consists of a course that embraces AR's platform for gender empowerment. The intervention course will require 50-60 minutes for preliminary planning, and participants in the experimental group can design at least three course modules to suit their learning needs.
89659259|NCT05686187|No Intervention|control group|The control group will adopt the classroom narration method.
89659260|NCT01216761|Active Comparator|CHG then PI then IT|"Skin antisepsis prior to any peripheral blood culture collection on Floor A was performed with CHG for 3 months, followed by PI for 3 months, followed by IT for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT"
89659261|NCT01216761|Active Comparator|IT then CHG then PI|"Skin antisepsis prior to any peripheral blood culture collection on Floor B was performed with iodine tincture for 3 months, followed by Chlorhexidine gluconate for 3 months, followed by povidone iodine for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI"
89659262|NCT01216761|Active Comparator|PI then IT then CHG|"Skin antisepsis prior to any peripheral blood culture collection on Floor C was performed with povidone iodine for 3 months, followed by iodine tincture for 3 months, followed by chlorhexidine gluconate for 3 months. Each 3 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG"
89659263|NCT04279379|Experimental|treatment arm|Sintilimab,200mg,ivdrip,day1 Decitabine 10mg d1-5, ivdrip, repeated every 3 weeks.
89047267|NCT04662177|No Intervention|Group 2: Standard anaesthesia with propofol and electrophysiological studies|The group 2 receive standard anaesthesia management.
89047268|NCT05292560|Experimental|Positive psychology app|
89659264|NCT01150461|Experimental|losartan|Losartan 50 mg b.i.d.
89047269|NCT05292560|Other|Waiting list|
89047270|NCT02971098|Experimental|Reduced activity|participants will undergo a reduced physical activity period (75% step reduction) for two weeks.
89047271|NCT05259449|No Intervention|Control (CG+INACT)|Participants who do not receive neither nutritional education nor exercise program. They will be instructed to maintain their normal life habits with respect to physical activity and diet.
89047272|NCT05259449|Active Comparator|Moderate-intensity continuous training (CG+MICT)|Participants who do not receive nutritional education but are enrolled in a moderate-intensity continuous training exercise program.
89659265|NCT01150461|Placebo Comparator|placebo|Placebo b.i.d.
89659266|NCT05685641|Experimental|Intervention group|All enrolled patients will be included in this arm of the study, patients will be administered all rapid diagnostic tests as part of their diagnostic work-up (this will constitute the main intervention of the study)
89659267|NCT01218399|Active Comparator|Budesonide|"Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm."
89688625|NCT02809846|Active Comparator|Quell Device|Quell is a class II medical device with FDA 510(k) clearance for the symptomatic relief and management of chronic intractable pain, without a prescription. It operates by using an electrical stimulator to activate peripheral sensory nerves and trigger analgesia.
89047273|NCT05259449|Active Comparator|High-intensity interval training (CG+HIIT)|Participants who do not receive nutritional education but are enrolled in a high-intensity interval training exercise program.
89047274|NCT05259449|Active Comparator|Nutritional Education (EDU+INACT)|Participants who receive nutritional education but not an exercise program.
89659268|NCT01218399|Placebo Comparator|Placebo Comparator: Budesonide|"Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm."
89659269|NCT05685563||sweep rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
89659270|NCT05685563||scull rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
89659271|NCT05685563||control non-rowers|Each subject was assessed using DIERS formetic 4D and DIERS pedoscan devices. Additionally, participants in each group were assessed by FAIR test, Cluster of Laslett, trigger point palpation of the m. piriformis and Visual analogue scale.
89659272|NCT05480657|Experimental|Single Arm AT-1501|Single-arm, open-label trial
89659273|NCT01219881|Active Comparator|Desflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane.
89659274|NCT01219881|Active Comparator|Sevoflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane.
89659275|NCT05443139|Experimental|Interactive intervention|The participants will receive a self-applied intervention composed by 10 sessions following a multi component structure. The participants assigned to this condition will count with interactive resources such as Videos, Online Forum and Exercises embedded on the platform.
89659276|NCT05443139|Experimental|non-interactive intervention|Self-administered treatment with 10 sessions will be provided through care manuals in PDF format within the same web platform. Participants in this group will receive a manual within the platform with the same content of the sessions as the experimental group but in PDF format.
88994616|NCT02930434|Active Comparator|Standard daily vitamin D3|Cholecalciferol 600 IU daily during one year or exit from Antarctica.
88994617|NCT02930434|Active Comparator|Higher weekly vitamin D3|Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica.
88994618|NCT02930512||patients with idiopathic Parkinson's disease|
88994619|NCT02930395||professional rugby players|
89659277|NCT05443139|No Intervention|Waiting List group|The control condition consists of a 30-day waiting list, in which participants will not be able to access the interventions. After the waiting process, they will be given access to either the interactive intervention or the non-interactive intervention.
89659278|NCT03011619|Active Comparator|Control Condition|usual standard of care during an inpatient psychiatric hospitalization; medication management, group therapy, and individual therapy.
89659279|NCT03011619|Experimental|CBT Condition|If a patient is randomly assigned to the enhanced CBT group, they will participate in manualized CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
89659280|NCT05428787|Active Comparator|Cardiac Resynchronization Therapy + AV node ablation|The active comparator group will be treated with CRT followed by an Atrioventricular Node Ablation.
89659281|NCT05428787|Experimental|Left Bundle Branch Area Pacing + AV node ablation|The experimental group will be treated with LBBAP followed by an Atrioventricular Node Ablation.
89659282|NCT03310853|Experimental|Probiotic|Combination of two probiotic strains in one capsule
89659283|NCT03310853|Placebo Comparator|Placebo|Non active ingredients in a capsule
89659284|NCT01220739|Sham Comparator|IV tPA + Sham Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
88994620|NCT02930317|Experimental|Pharmacokinetic parameters|Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
88994621|NCT02930317|Experimental|On-demand treatment|On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years. In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.
88994622|NCT02929966|Placebo Comparator|standard respiratory care|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy"
88994623|NCT02929966|Experimental|standard respiratory care PLUS a palliative care program|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy PLUS a palliative care program that includes paid to assessing physical and psychosocial symptoms"
88994624|NCT04438135|Active Comparator|active test|
88994625|NCT04438135|Placebo Comparator|placebo test|
88994626|NCT02930239|Experimental|Gait rehabilitation|Will perform 2 weeks of gait rehabilitation using the anti gravity treadmill. Intervention will start 2 weeks post-surgery. This rehabilitation will be performed simultaneously as the patient receives the standardized rehabilitation at Linkoping University Hospital.
88994627|NCT02930239|Active Comparator|Control group|Will only receive the standardized rehabilitation at Linkoping University Hospital.
88994628|NCT04438018||No DD or DS|No diabetes distress or depressive symptoms reported (CES-D < 22, PAID < 40)
88994629|NCT04438018||DD without DS|Diabetes distress but no depressive symptoms reported (CES-D < 22, PAID ≥ 40)
88994630|NCT04438018||DS without DD|Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID < 40)
89659285|NCT01220739|Active Comparator|IV tPA +Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
89659286|NCT01220973|Experimental|Atorvastatin and Celecoxib|
89659287|NCT05375747|Experimental|Remimazolam based total intravenous anesthesia|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.
89659288|NCT05375747|Active Comparator|Propofol based total intravenous anesthesia|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
89659289|NCT05354687|No Intervention|Control Group|No intervention will be given to participants. Students will be given pre-test and post-tests.
89659290|NCT05354687|Experimental|Small-group Teaching Group|Participants will be given training on the evaluation of pressure injuries with small-group teaching techniques.
89659291|NCT05354687|Experimental|Self-directed Learning Group|Participants will be given training on the evaluation of pressure injuries with self-directed learning technique.
89659292|NCT01221207|Active Comparator|Device - Total Contact Cast (TCC)|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
89659293|NCT01221207|Active Comparator|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
89659294|NCT01221207|Active Comparator|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
89659295|NCT04348097|Experimental|activator trigger point therapy|"The Activator adjusting instrument used had force settings ranging from 1 to 6~. For this study a force setting of 3 was used."
89659296|NCT04348097|Active Comparator|Trigger point dry needling|First, a tight band was held between the index finger and the thumb of the non-dominant hand and the needle (0.25-40 mm - Shen Long) was perpendicularly inserted into the muscle with the dominant hand.
89659297|NCT04347863|Experimental|Experimental group|Group swallowing disorder diet preparation program
89659298|NCT04347863|No Intervention|Control group|No Intervention
89659299|NCT03296813|Active Comparator|Torsemide|Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
89659300|NCT03296813|Active Comparator|Furosemide|"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:~1 mg oral torsemide = 2-4 mg oral furosemide~1 mg oral or intravenous bumetanide = 40 mg oral furosemide"
89659301|NCT01221441|Experimental|TissueGene-C|TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
89659302|NCT01221441|Placebo Comparator|Placebo Control|Normal Saline injection
89659303|NCT03009903||P. acne subjects|14-50 year of age, P. acne diagnosed subjects
89659304|NCT03009903||None P. acne subjects|14-50 year of age, none P. acne diagnosed subjects
89659305|NCT01153503|Active Comparator|Ketorolac 30 mg, IV + TAP block|"Ketorolac 30 mg, IV + Bilateral ultrasound-guided TAP blocks at the end of the surgery~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
89659306|NCT01153503|Active Comparator|TAP block|"Intraoperative (at the end of surgery): Bilateral ultrasound-guided TAP block at the end of the surgery~First 24-h Postoperative: IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
89659307|NCT01153503|No Intervention|Ketorolac 30 mg|"Intraoperative (at the end of surgery): Ketorolac 30 mg, IV at the end of the surgery.~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h +IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
89659308|NCT01222299|Experimental|Arm 1 - Low Dose|bepotastine besilate nasal product - low dose
89659309|NCT01222299|Experimental|Arm 2 - Medium Dose|bepotastine besilate nasal product - medium dose
89659310|NCT01222299|Experimental|Arm 3 - High Dose|bepotastine besilate nasal product - high dose
89659311|NCT01222299|Placebo Comparator|Arm 4 - Placebo|placebo comparator nasal product
89659312|NCT03286283|Experimental|J-Plasma|Each study subject will receive one procedure with J-Plasma at enrollment.
89659313|NCT04400279|Experimental|Yoga Exercise group|Using the Down Dog app, this group will be given access to an at-home personalized yoga practice, unique every time the participants complete it. Asked to complete yoga practice 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
89659314|NCT04400279|Experimental|High Intensity Interval Training group|Using the Down Dog app, this group will be given access to at-home bodyweight high intensity interval training (HIIT) workouts. Asked to complete these HIIT workouts 4 times per week for 6 weeks. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
89659315|NCT04400279|Experimental|Combination Yoga & HIIT group|Using the Down Dog app, this group will be given access to both the unique yoga practice and bodyweight HIIT workouts. Asked to complete 2 yoga and 2 HIIT workouts per week. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. The second 6 weeks of the study, participants will have continued access to the Down Dog app and a final wellbeing and health survey will be administered at the end of the second 6 weeks.
89659316|NCT04400279|No Intervention|Control group|This group will be maintaining their pre-study activity levels for the first 6 weeks of the study. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. Then the participants will be given access to all the Down Dog apps (both yoga and HIIT included) to use as the participants please for the following 6 weeks. A final wellbeing and health survey at the end of the second 6 weeks will be administered.
89659317|NCT04400045|Experimental|intervention/treatment|Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Cyclophosphamide 40mg/kg (days -3, -2) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Stem cell infusion - day 0
89659318|NCT01222689|Experimental|Treatment (erlotinib hydrochloride, selumetinib)|Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89659319|NCT05289635|Experimental|test group|vertical mattress suture
89659320|NCT05289635|Other|control group|horizontal mattress suture
89047275|NCT05259449|Experimental|Nutritional Education Moderate-intensity continuous training (EDU+MICT)|Participants who receive nutritional education and are enrolled in a moderate-intensity continuous training exercise program.
89047276|NCT05259449|Experimental|Nutritional Education High-intensity interval training (EDU+HIIT)|Participants who receive nutritional education and are enrolled in a high-intensity interval training exercise program.
89047277|NCT04661943|Experimental|Arm A|Chidamide Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
89047278|NCT05252000|Experimental|mechanical debridement and adjunctive aPDT|
89047279|NCT05252000|Active Comparator|mechanical debridement and sham aPDT|
89047280|NCT00557154|Experimental|1|Ultrasound used to visualize peripheral venous anatomy. This guides subsequent attempts at venipuncture.
89047281|NCT00557154|Active Comparator|2|Routine venipuncture using standard methods.
89659321|NCT05288933|Active Comparator|Group (A) conventional physical therapy|20 participants will receive conventional physical therapy.TENS, the frequency of the current is 100 Hz and the duty cycle is 250 microseconds, three times per week for 4 weeks. Ultrasound waves, frequency 1 MHz with intensity 1 W/cm2, a pulsed mode for 5 minutes, three times per week for 4 weeks, passive stretching, and isometric exercises three times per week for 4 weeks.
89659322|NCT05288933|Experimental|Group (B )IASTM and conventional physical therapy|20 participants will receive Instrument-Assisted Soft Tissue Mobilization (IASTM) and conventional physical therapy, the M2T blade will be used to find the exact areas of restriction in the upper trapezius. Then the M2T blade will be used, at an angle of 45 and using treatment planes 1, 2, and 3, to apply slow strokes along with the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. This procedure will be repeated twice a week for four weeks
89659323|NCT05288933|Experimental|Group (C) HPPT US and conventional physical therapy|20 participants will receive High Power Pain Threshold Ultrasound (HPPT US) and conventional physical therapy. For the HPPT US, ultrasound waves will be applied to trigger points of the upper trapezius in continuous mode, and the power of ultrasound will first increase to the threshold pain level at intensity (1.5-2 W/cm) according to the patient for 4-5 seconds with the probe placed directly on the trigger point and held motionlessly and then reduced to one-half of that intensity for15 seconds with the probe placed directly on the trigger point and move in a circular motion and repeat this three times. This procedure will be repeated twice a week for two weeks
89659324|NCT05286593|Other|Normal volunteers|Normal participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
89659325|NCT05286593|Other|Clinical patients|Clinical patients participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
89659326|NCT05286593|Other|Infarcts|Infarct participants will receive serial doses of Rb-82 administered as either a bolus (B) (gold standard) or slow infusion (SI). Under resting conditions, they will receive 3 weight based doses. The first two doses are randomly assigned B and SI. The third dose is either B or SI. Under stress conditions, they will receive 2 weight based doses that are randomly assigned B and SI.
89659327|NCT01153581|Experimental|Ganirelix acetate|Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
89659328|NCT01153581|Experimental|17β-Oestradiol, E2|The same women added 17β-Oestradiol, E2; 0.2 mg day-1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
89659329|NCT01153581|Experimental|Progesterone|The same women added progesterone (P4, 200 mg day-1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
89659330|NCT04278599|Experimental|Test group|The patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
89659331|NCT04278599|Placebo Comparator|Control group|The patients will be administered Placebo tablets for 6 weeks from the baseline. Topical corticosteroid paste will be prescribed according to the intensity of the lesion.
89659332|NCT05277623|Active Comparator|mannitol group|
89047282|NCT05237414|Experimental|Binge Drinkers with Combined Intervention (active CT + active tDCS)|Subjects will perform a variation of the TNTA task (Anderson & Green, 2001; López-Caneda et al., 2019) to enhance the suppression of alcohol-related memories. The Learning phase will be composed of 2 blocks of 12-image pairs (as there is no a baseline block), and in the TNT phase, all the stimuli to be inhibited will be alcohol-related images. After the Learning Phase, active neuromodulation will be performed using tDCS. Twenty minutes of 2 mA direct current will be applied on the scalp using a saline-soaked pair of 35 cm2 surface sponge electrodes, through an Eldith DC Stimulator Plus (Neuroconn, Germany). To stimulate the right DLPFC, the anodal electrode will be placed over F4 according to the 10-20 international system for EEG electrode placement. The cathode electrode will be over the contralateral supraorbital area. The current fade in for 15 seconds, is constant at 2 mA for 20 minutes, and then fade out for 15 seconds.
89047283|NCT05237414|Experimental|Binge Drinkers with Cognitive Intervention (active CT + sham tDCS)|Subjects perform the variation of the TNTA task for active CT. After the Learning Phase, sham neuromodulation is performed using the same montage of the active tDCS. However, the electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds. There is no current for the rest of the time.
89659333|NCT05277623|Placebo Comparator|control group|
89659334|NCT01223469|Experimental|Atrial Fibrillation|
89659335|NCT01223469|Experimental|Right-sided Supraventricular Tachycardia|
89659336|NCT01223703|Active Comparator|n-3 PUFAs|
89659337|NCT01223703|Placebo Comparator|Placebo|
89659338|NCT01224015|Other|onabotulinumtoxinA 24U|24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
89659339|NCT01224015|Placebo Comparator|placebo (normal saline)|Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
89659340|NCT01224015|Experimental|onabotulinumtoxinA 44U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
89659341|NCT01225029|No Intervention|Standard Fluids|Term neonates receive total fluids of 60 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
89659342|NCT01225029|Experimental|Restricted Fluids|Term neonates receive total fluids of 40 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 60 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved
89659343|NCT04760327|Experimental|Electrochemotherapy of gynecological cancers|
89659344|NCT05235581|Experimental|BCAD's arm|The 4 interventions are in the BCAD's order.
89659345|NCT05235581|Experimental|BACD's arm|The 4 interventions are in the BACD's order.
89659346|NCT05235581|Experimental|CABD's arm|The 4 interventions are in the CABD's order.
89659347|NCT05235581|Experimental|ACBD's arm|The 4 interventions are in the ACBD's order.
89659348|NCT01225263|Experimental|Simvastatin and vitamin D|Participants in this arm will receive simvastatin + vitamin D.
89659349|NCT01225263|Placebo Comparator|"Placebo Sugar Pill"|"Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a sugar pill."
89659350|NCT05217173|Experimental|Intervention group|"Rehabilitation service that will be provided remotely through information and communication technologies. It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks.~The content of the rehabilitation program will consist of e modules: 1) Information module on the disease and self-care, 2) Exercise module (Stretching, strengthening and proprioception)."
89659351|NCT05217173|No Intervention|Control group|Care service that is carried out by the Family Physician. The medical care that the patient with an ankle sprain will carry out with the Family Physician of the assigned office; Medical care will consist of the approach that the Doctor considers appropriate for the patient. The follow-up and time of disability will be the responsibility of the Physician in question
89659352|NCT01154751|Other|Device SUPERA Stent|SUPERA Interwoven Self-Expanding Nitinol Stent System
89659353|NCT05179265|Placebo Comparator|Control group|0.45 g/bottle，50 mL
89659354|NCT05179265|Experimental|test group|10 g/bottle (20%, 50 mL)
89659355|NCT01226979|Experimental|HDRBT (High Dose Rectal Brachytherapy)|Radiation: High-dose endorectal brachytherapy The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer. A daily dose of 6.5 Gy over four consecutive days
89659356|NCT04278287|Experimental|Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy|Chemoradiotherapy arm receives intensity-modulated radiation therapy, volume modulated arc therapy or tomotherapy concurrently with albumin-bound paclitaxel and cisplatin (weekly intravenous infusion in 5-6 weeks).
89659357|NCT05162027|Active Comparator|Erenumab-aooe|"Erenumab-aooe 70 mg/ml. Subcutaneous injection. Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other Name: Aimovig®"
89659358|NCT05162027|Placebo Comparator|Placebo|"Placebo. Subcutaneous injection.Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other name: Placebo"
89659359|NCT05141435|Active Comparator|NCPAP|
89659360|NCT05141435|Active Comparator|NHFOV|
89659361|NCT04278443||Low dose rate brachytherapy|20 patients receiving low dose rate brachytherapy
89659362|NCT04278443||High dose rate brachytherapy|20 patients receiving high dose rate brachytherapy.
89659363|NCT01154985|Placebo Comparator|Placebo|3x placebo capsules TID
89659364|NCT01154985|Experimental|EPA-E 1800 mg/day|2x EPA-E 300 mg capsules + 1placebo capsule TID
89659365|NCT01154985|Experimental|EPA-E 2700 mg/day|3x EPA-E 300 mg capsules TID
88994631|NCT04438018||DD and DS|Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
88994632|NCT02930161|Experimental|Runihol 2 tablets x 2 times a day|Intake of 1 tablet of Runihol and 1 placebo tablet orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
88994633|NCT02930161|Experimental|Runihol 1 tablet x 3 times a day|Intake of Runihol, 2 tablets orally, with drinking 100 ml of water, 30 minutes before meals, 2 times a day (morning and evening) for 84 days (12 weeks), and 2 placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals, 1 time a day (afternoon) for 84 days (12 weeks).
88994634|NCT02930161|Placebo Comparator|Placebo|Two placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
88994635|NCT00170001|Placebo Comparator|Sugar pill|
88994636|NCT00170001|Active Comparator|Active Comparator|
88994637|NCT02930200|Active Comparator|Treatment as Usual|Behavioral: Treatment as Usual (TAU) is the Tobacco Treatment Research Program (TTRP) which offers all components of an intensive tobacco treatment intervention including: 1) initial assessment of willingness to participate, 2) the use of multiple types of clinicians, 3) at least 4 treatment sessions, in an individual- or group-counseling format, that are greater than 10 minutes in duration, 4) counseling that includes problem-solving, skills training, and social support components, and 5) and the opportunity to use effective medications to aid in tobacco cessation.
88994638|NCT02930200|Active Comparator|NCI QuitGuide|Behavioral: The National Cancer Institute's (NCI's) QuitGuide app is a free smartphone app that is available through the Smokefree.gov website. Participants can track cravings, smoking triggers, and motivations for quitting. Participants who are randomly assigned to the QuitGuide app group will receive a smartphone that is preloaded with the QuitGuide app and a quit date scheduled for 1 week after the baseline visit.
89659366|NCT03278717|Experimental|Olaparib and Cediranib|"Patients will receive oral olaparib 300mg BD and oral cediranib 20mg OD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
89659367|NCT03278717|Active Comparator|Olaparib|"Patients will receive oral olaparib 300mg BD.~Patients will attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse."
89659368|NCT01227057|Experimental|Arm 1: Cognitive Rehabilitation|Cognitive rehabilitation and exposure therapy for hoarding
89659369|NCT01227057|Active Comparator|Arm 2: Case Management|Case management
89659370|NCT01227681|Experimental|high dose G-CSF|high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
89659371|NCT01227681|Active Comparator|low dose G-CSF|low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
89659372|NCT01227681|Placebo Comparator|placebo|Sodium Chloride (NaCl) 0.9 %
89659373|NCT01227993|Experimental|Finasteride|Participants are treated with 5 mg oral finasteride daily when they have clinically significant subretinal fluid accumulation, defined as any subretinal fluid in the macula with a volume of at least 0.1 microliter and causing visual change such as reduced acuity, metamorphopsia, or microperimetry deficits.
89659374|NCT01155999|Experimental|T1225|
89659375|NCT01155999|Active Comparator|Tobramycin|
89659376|NCT03275597|Experimental|SBRT followed by Durvalumab+Tremelimumab|"Therapeutic Interventions Stereotactic Body Radiotherapy (SBRT) to all sites of disease between 30 and 50 Gy in five fractions administered over two weeks.~Investigational Product(s), Dose, and Mode of Administration: to begin 7 days (+/- 3 days) after radiation Durvalumab 1500 mg via infusion Q4W (equivalent to 20 mg/kg Q4W) until disease progression in patients > 30 kg Tremelimumab 300 mg via infusion (equivalent to 4 mg/kg) in one dose in patients >30 kg Weight-based dosing should be utilized for patients ≤30 kg; durvalumab 20 mg/kg Q4W and tremelimumab 4 mg/kg"
88994639|NCT02930200|Experimental|Smart-T|"Behavioral: The Smart-Treatment (Smart-T) phone based smoking cessation intervention has multiple components (e.g., an on-demand Quit Tips function, an on-demand Medications function/button that offers information about nicotine replacement therapy (NRT), button available 24/7 that offers general smoking cessation advice, daily treatment messages, and an algorithm that uses participant's EMA responses to assess risk of lapse and automatically push relevant messages to help them avoid smoking)."
88994640|NCT02929732|Experimental|Willis-Ekbom disease patients (CASE)|
88994641|NCT02929732|Experimental|Healthy volunteers (CONTROL)|
88994642|NCT04426201|Experimental|CYT107 Treatment|Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
88994643|NCT04426201|Placebo Comparator|Saline control|Intramuscular (IM) placebo (normal saline) at the same frequency
88994644|NCT00170079|Experimental|Step care vs. regular care|Participants were randomized either to (1) Step care intervention, where smokers who failed to quit or who relapsed received increasingly intensive smoking cessation interventions; vs. (2) Regular care, where smokers who failed to quit or who relapsed received repeated intervention.
88994645|NCT02929771|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the Samsung GearVR with head mounted display (HMD), controller, and headphones. They will situated in front of the nurse and beside/on the lap of the parent, or they may be lying supine. The VR intervention will use auditory and visual stimuli (simulating the peaceful underwater environment) to distract the child before, during, and after the SCP needle insertion. Children will be allowed to 'try-out' the VR system before the SCP access to familiarize themselves with the equipment. The entire study will be videotaped.
88994646|NCT02929771|Active Comparator|Control Group|In addition to usual care, participants in the control group will be seated with their parent and in front of the nurse, according to preference. Children will watch an age appropriate video selected by an oncology-affiliated child life specialist on an iPad, while wearing the same headphones used in the experimental condition. The RA will hold the iPad and positioned within a meter of the child so that the child can still see the iPad without the RA interfering in the clinical procedure. The entire study will be videotaped.
89659377|NCT05087069|Experimental|BV100|BV100 intravenous infusion
89659378|NCT05087069|Placebo Comparator|Placebo|Saline intravenous infusion
89659379|NCT01228149|Active Comparator|Diamox/DexaEDO|Patients receive Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy. 7 days preoperatively DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally. Patient will undergo trabeculectomy.
89659380|NCT01228149|Experimental|Cosopt S|Patients receive Cosopt S (dorzolamide/timolol) eye drops starting 28 days before trabeculectomy.
89659381|NCT01228929|Experimental|Normal|Subjects with no clinical diagnosis or symptoms of dry eye.
89659382|NCT01228929|Experimental|Aqueous Deficiency Dry Eye (ADDE)|Subjects with low tear volume measured by Schirmer's test less than 10 mm.
88994647|NCT02929615|Experimental|Treatment group|
89659383|NCT01228929|Experimental|Meibomian Gland Dysfunction (MGD)|Subjects having mild to moderate Meibomian Gland Dysfunction by slit lamp evaluation.
89659384|NCT03274193|Experimental|Yoga|The yoga group will engage in the yoga training program which is 60 minutes per session, 2 times per week for 12 weeks.
89659385|NCT03274193|No Intervention|Control|The control group will be asked not to participate in any exercise program during the course of the study.
88994648|NCT02929537||Western medicine|Patients in this group only choose conventional medicine treatment based on the classes of medications recommended by 2015 GOLD for COPD.
88994649|NCT02929537||Traditional Chinese Medicine|Patients in this group only choose conventional medicine treatment based on the Chinese Treatment Guidelines for COPD.
88994650|NCT02929537||Integrative Medicine|Patients in this group choose western medicine and Traditional Chinese Medicine.
88994651|NCT04395703||Maternity staff|Interviews with maternity staff working within a maternity unit including midwifery managers and infant feeding lead staff members.
89659386|NCT02192307|Experimental|potassium oxalate gel|Professional application
89659387|NCT02192307|Active Comparator|Potassium oxalate liquid|Professional application
89659388|NCT04991831||Post Exablate Neuro Thalamotomy for Tremor Associated with Tremor Dominant Parkinson's Disease|This is a post Exablate Neuro Thalamotomy registry. No intervention is performed under this registry protocol.
89659389|NCT04989413|Active Comparator|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|Cannabidiol + Cannabigerol + Tetrahydrocannabinol in the maximum dosage of 133/66/4mg, divided in 2 doses of 66.5/33/2mg a day for 12 weeks. Each drop contain CBD/CBG/THC 1.66/0.8/0.05 mg, and medication will be titrated up as follow: day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drrops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day
89659390|NCT04989413|Placebo Comparator|Placebo|"Placebo capsules will be titrated up as follow:~day 1 to day 3 - 10 drops twice a day day 4 to day 6 - 20 drops twice a day day 7 to day 9 - 30 drops twice a day from day 10 to the end of the study 40 drops twice a day"
89659391|NCT05071157||anorexia nervosa|girls between 12 and 18 years old with behavioral eating disorder characterized by a drastic reduction in intakes resulting in weight loss and a BMI ≤ 17.5 kg / m2. Anorexia can be restrictive pure or associated with bulimia
89659392|NCT05071157||obesity|girls between 12 and 18 years old with a BMI projecting ≥ 30 kg / m2 at the age of 18 (IOTF C30).
89659393|NCT05071157||normal weight|girls between 12 and 18 years old without BMI abnormality, without eating disorders, without serious medical pathology
89659394|NCT02192541|Experimental|Ganetespib and Ziv-Aflibercept|Ganetespib was administered intravenously, over 1 hour, weekly, on days 1, 8, and 15 of each 28-day cycle. Ziv-aflibercept was administered intravenously, over 1 hour, every 2 weeks, on days 1 and 15 of each 28-day cycle. Ganetespib was started at a dose level of 100 mg/m^2 + ziv-aflibercept at 3 mg/kg or 4 mg/kg.
89659395|NCT01156701||Cohort1: Prophylaxis with untreated index|"Individuals are eligible to be included in the prophylaxis with untreated index cohort if they are at least 5 years old and have at least 6 months of continuous enrollment, and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family identifier code has had a medical visit (outpatient, inpatient or emergency room (ER) visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
89659396|NCT01156701||Cohort2: Prophylaxis with treated index|"Individuals are eligible to be included in the prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
89659397|NCT01156701||Cohort3: No prophylaxis with untreated index|"Individuals are eligible to be included in the no prophylaxis with untreated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
89659398|NCT01156701||Cohort4: No prophylaxis with treated index|"Individuals are eligible to be included in the no prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza(HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received zanamivir (Relenza) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza"
89659399|NCT01230021|Experimental|recombinant factor XIII|
89659400|NCT06222580|Experimental|Treatment (SNDX-5613 and gilteritinib)|Patients receive SNDX-5613 PO BID and gilteritinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration, and blood sample collection throughout the study.
89659401|NCT06222567|Experimental|Pumping individual|Clinical indication for pumping
89659402|NCT06222541|Experimental|"Nudge Web-Based Supermarket"|"Participants will be asked to simulate one grocery shopping trip in a web-based supermarket and to select three unique beverages for their household that their child would drink.~Participants randomized to the nudge web-based supermarket will view beverages in descending order of healthfulness (i.e., the healthiest beverages will appear at the top of the screen), view a store landing page promoting the healthiest beverages with a health message, and be offered healthier swaps for sugary drinks at point-of-selection (i.e., immediately after selecting an item to be added to their shopping cart)."
89688626|NCT02809846|Sham Comparator|Sham Quell Device|Identical to Active Comparator, but provides sub-therapeutic electronic stimulation.
88994652|NCT04395703||Neonatal unit staff|Staff working within a local maternity unit.
88994653|NCT00148304||Group 1|
88994654|NCT02929693|Experimental|combination|YYJD plus gefitinib
88994655|NCT02929693|Placebo Comparator|controll|placebo plus gefitinib
88994656|NCT02929654|Active Comparator|Control|Subject continue to use their own Blood Glucose Monitoring System ( BGMS) for 12 weeks.
88994657|NCT02929654|Experimental|OneTouch Verio®|Subjects use LifeScan provided BGMS (OneTouch Verio®) for 12 weeks
88994658|NCT02929654|Experimental|Intervention 02|Subjects use LifeScan provided BGMS (OneTouch Verio® Flex ) for 12 weeks.
89659403|NCT06222541|No Intervention|Standard Web-Based Supermarket|"Participants will be asked to simulate one grocery shopping trip in a web-based supermarket and to select three unique beverages for their household that their child would drink.~Participants randomized to the standard web-based supermarket will not receive any nudges related to health."
89659404|NCT06222476|Experimental|Patients treat with Dorzagliatin|Dorzagliatin will be initiated and maintained at 75mg twice a day until the completion of the study. Meanwhile, all patients will also continue on regimen of metformin 500mg three times a day throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs.
89659405|NCT06222476|Active Comparator|Patients treat with Gliclazide|Gliclazide will be initiated and maintained at 30mg once a day until the completion of the study. Meanwhile, all patients will also continue on regimen of metformin 500mg three times a day throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs.
89659406|NCT06222450|Active Comparator|Standard VRT|The gaze stabilization, habituation and balance/gait HEP will be delivered using standard paper handouts
89659407|NCT06222450|Experimental|Digital VRT|The gaze stabilization, habituation and balance/gait HEP will be delivered using a digital home program using the Health in Motion platform
89659408|NCT06222424|Other|Patients at MCMC who had a prescription sent by an EMP between November 1, 2021 and June 30, 2023|Evaluation of utility will involve describing all EMP-written prescriptions pursuant to resolution of prescription issues realized after discharge.
89659409|NCT06222385|Experimental|Sleep Opportunity-Sleep Deprivation|Participant randomized to overnight sleep period with a morning wake period on first visit of cross-over study.
89659410|NCT06222385|Experimental|Sleep Deprivation-Sleep Opportunity|Participant randomized to overnight sleep deprivation period with a morning recovery sleep period on first visit of cross-over study.
89659411|NCT06222372|Experimental|Single dose rifampin (SDR)|To household contacts of newly diagnosed leprosy patients SDR is provided as follows: 600 mg rifampicin for adults weighing 35 kg and over, 450 mg for adults weighing less than 35 kg and for children older than 9 years, and 300 mg for children aged 5 to 9 years.
89659412|NCT06222372|Experimental|Single double dose rifampin (SDDR)|To household contacts of newly diagnosed leprosy patients SDDR is provided as follows: 1200 mg rifampicin for adults weighing 35 kg and over, 900 mg for adults weighing less than 35 kg and for children older than 9 years, and 600 mg for children aged 5 to 9 years.
89659413|NCT06222333|Experimental|Respiratory physiotherapy group|In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour
89659414|NCT06222333|Active Comparator|Routine treatment group|Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
89659415|NCT06222320|Experimental|Kinesiotaping group|Kinesiotaping will be applied to patients in this group in addition to painkillers.
89659416|NCT06222320|Active Comparator|Routine treatment group|Patients in this group will be administered painkillers routinely in the hospital.
89659417|NCT06222307|Experimental|Game-Based Exercises|The participants will engage in game-based exercise training twice a week for a total of 6 weeks. Each session will last for 45 minutes, and to ensure participants' sustained engagement, the activities will vary weekly. Here's an outline of the weekly activities:
89659418|NCT06222307|No Intervention|Control|No intervention will be applied to the control group
89659419|NCT06222294|Experimental|Remimazolam Tosilate for Injection|
89659420|NCT06222294|Active Comparator|Propofol Medium and Long Chain Fat Emulsion Injection|
89659421|NCT06222268|Placebo Comparator|Placebo (PBO) only|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
89659422|NCT06222268|Experimental|Cannabidiol (CBD) only|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
89659423|NCT06222268|Experimental|Delta-9-tetrahydrocannabinol (THC) only|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
89659424|NCT06222268|Experimental|THC:CBD 1:1|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
89659425|NCT06222268|Experimental|THC:CBD 1:10|In a double-blind, placebo and active-controlled, between-subjects design, the investigators will administer drugs using a vaporizer containing THC (2.5mg), CBD (2.5mg,25mg) or PBO (0mg THC/CBD). Drug is administered immediately prior to exposure therapy sessions 3-6. 75 participants will be randomly assigned to each treatment arm. All participants will receive prolonged exposure therapy.
89659426|NCT06222255|No Intervention|Loperamide group|The group only takes loperamide in the evening.
89659427|NCT06222255|Experimental|Loperamide + Transanal irirgation group|The group takes Loperamide in the evening and undergoes Transanal irrigation before bedtime.
89659428|NCT06222242|Experimental|mychoiceTM intervention|Single arm study - all participants receive mychoiceTM
89659429|NCT06222229|Experimental|No-bandaging group|Only general measures will be recommended without the use of external support devices.
89659430|NCT06222229|Active Comparator|Bandaging group|functional bandage for 5 days and general measure.
89688627|NCT00945061|Experimental|Intraoperative radiation therapy|Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.
89659431|NCT06222216|Experimental|Intervention Group (Chilled Needle):|Before subcutaneous injection, 26G sterile disposable needles will be kept in the cooling compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.
89659432|NCT06222216|Active Comparator|Control Group:|SC injection will be administered to the control group in accordance with the clinical routine. No different procedure will be applied. Injection will be performed with a needle at room temperature without any instrument or procedure in accordance with the SC injection protocol. After the injection, the patient's pain assessment will be made and marked on the SCI, and ecchymosis assessment will be made after 24, 48 and 72 hours.
89659433|NCT06222177||GERD group|Patients with AET>6% at pH-study
89659434|NCT06222177||Non GERD group|Patients with AET<6% at pH-study
89659435|NCT06222151|Experimental|A|Participates in intervention 1 and 2
89659436|NCT06222151|Other|B|Participates in intervention 1, control in intervention 2
89659437|NCT06222151|Other|C|Participates in intervention 2, control in intervention 1
89659438|NCT06222151|Active Comparator|D|Control in both intervention 1 and 2
89659439|NCT06222125|Experimental|Arm 1|10 mg/kg intravenously, every 2 weeks, till tumor progression or intolerance.
89659440|NCT06222125|Experimental|Arm 2|20 mg/kg intravenously, every 2 weeks, till tumor progression or intolerance.
89659441|NCT06222073||Postmenopausal + Hot Flush (P+HF)|Postmenopausal women who regularly experience hot flushes.
89659442|NCT06222073||Postmenopausal + Hot Flush (P-HF)|Postmenopausal women who do not experience hot flushes.
89659443|NCT06222073||Premenopausal|Premenopausal women who experience regular menstruation.
89659444|NCT06222047|Experimental|Breast milk|Breast Milk Intervention: Wrapping was applied to the baby as a standard approach. 2 minutes before the insertion of the oragastric catheter, 2 ml of breast milk was given to the babys mouth with a syringe. After the baby was given breast milk, video recording started. The steps for inserting an orogastric catheter were followed, and the baby was monitored in an incubator during the application, with pulse and saturation monitored.
89659445|NCT06222047|Experimental|Dextrose|Dextrose Intervention: The baby will receive wrapping as standard treatment. The orogastric catheter is visible to the brim with 2 ml of 20% dextrose syringe 2 minutes before the insertion chamber (Bueno et al., 2013). After the baby is given dextrose, the video recording will start. The steps of the orogastric tube insertion procedure will be followed. The baby will be in an incubator during the application, with pulse and saturation monitored.
89659446|NCT06222047|No Intervention|Control group|The control group: Baby will be wrapped as standard treatment. Video recording will start 2 minutes before the baby is inserted into the orogastric catheter. The steps of the orogastric tube insertion procedure will be followed. The baby will be in an incubator during the application, with pulse and saturation monitored. No additional intervention will be applied to the baby.
89659447|NCT06222034|Experimental|Filgotinib Dose A|Dose A of filgotinib mini-tablet for participants with bodyweight (BW) 15-<25 kg
89659448|NCT06222034|Experimental|Filgotinib Dose B|Dose B of filgotinib tablet for participants with BW ≥25-<60 kg
89659449|NCT06222034|Experimental|Filgotinib Dose C|Dose C of filgotinib tablet for participants with BW ≥60 kg
89659450|NCT06222021|Other|Genetic analysis of polymorphisms of membrane receptors involved in lactate transport|Before the start of surgery, after arterial line cannulation, a blood sample will be collected in an ethylenediaminetetraacetic acid (EDTA) test tube for genetic analysis of polymorphisms of membrane receptors involved in lactate transport including transporter family monocarboxylates 1 (MTC1), transporter family monocarboxylates 4 (MTC4) and Gi-coupled protein receptor 81 (GPR81).
89659451|NCT06221995||Ulcerative Colitis patients undergoing proctocolectomy|Measurement of resting energy expenditure among patients with Ulcerative Colitis about to undergo proctocolectomy with ileoanal j-pouch anastomosis
89659452|NCT06221982||Patients undergoing TIPS procedure|Patients undergoing TIPS procedure due to portal hypertension-related complications
89659453|NCT06221891||case group|This group contains the patients with chronic kidney disease.
89659454|NCT06221891||control group|This group contains the healthy adults.
89047284|NCT05237414|Sham Comparator|Binge Drinkers with Control Intervention (sham CT + sham tDCS)|"Subjects will perform a variation of the TNTA task, where the Learning phase also have only two blocks of 12-image pairs. However, in this case the TNT phase is replaced by a Forced-Choice Reaction Time (FCRT) task, during which the participants only must categorize alcoholic and non-alcoholic images answering to the question What type of beverage was there in the image? (answer: Alcoholic drink or Non-alcoholic drink); thus, they do not have to inhibit the memories related to the alcoholic images. During this phase, sham neuromodulation will be performed using the same montage of the active tDCS. The electric current fade in during 15 seconds until reaching 2 mA, then is constant at 2 mA for 15 seconds and fade out for 15 seconds, while a sham memory inhibition CT is performed."
89047285|NCT05237414|No Intervention|Non/Low-Drinkers|No intervention.
89047286|NCT05226299|Experimental|Experimental: Supra-threshold capsaicin|Arm: Experimental: Supra-threshold capsaicin Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
89047287|NCT05226299|Placebo Comparator|Arm: Placebo Comparator: Saline|Participants will be exposed repeatedly to aerosolized saline through a nebulizer during treatment.
89047288|NCT02797119|Experimental|tranexamic acid 1 g (TA1)|"To measure the efficacy of a standard 1g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section.~To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration"
88994659|NCT04689841|Experimental|Vojta Therapy|In Vojta therapy, the therapist selectively presses certain areas of the body, with the patient lying prone, - supine or - lateral. These types of stimuli, in humans of any age, provoke automatically and without their own initiative, that is, without the active voluntary collaboration of the person
88994660|NCT04689841|Placebo Comparator|Control Group|In the control group, a placebo intervention is administered, similar to an experimental intervention
88994661|NCT02929888|Experimental|Lysine Acetilsalicilate (LA)|Loading dose (LD) of intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
88994662|NCT02929888|Active Comparator|Aspirin|Loading dose (LD) of oral aspirin 300mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
88994663|NCT04689763|Experimental|Lifestyle Redesign Training|The participants will receive a total of 12 training sessions, and each session will contain 120 minutes of training.
88994664|NCT04689412||Cases|Children spontaneously treated with nasal resveratrol at the beginning of each upper airways infection
88994665|NCT04689412||Controls|Children spontaneously treated with nasal lavage at the beginning of each upper airways infection
88994666|NCT04689451||Perclose ProGlide|Perclose ProGlide group: use Perclose ProGlide to suture the artery
89659455|NCT06221878||Laparoscopic Group|Individuals with a body mass index of ≥ 30 kg/m2 underwent laparoscopic surgery for primary stage I-III colorectal adenocarcinoma.
89659456|NCT06221878||Open Group|Individuals with a body mass index of ≥ 30 kg/m2 underwent open surgery for primary stage I-III colorectal adenocarcinoma.
88994667|NCT04689451||Surgical Arterial Repair|Surgical Arterial Repair group : suture the artery by surgery
88994668|NCT02929459|Experimental|Riboflavin Dose 1|100 mg Riboflavin (one capsule) per day for 2 weeks
88994669|NCT02929459|Experimental|Riboflavin Dose 2|50 mg Riboflavin (one capsule) per day for 2 weeks
89659457|NCT06221826|Active Comparator|Mexidol and standart treatment|
89659458|NCT06221826|No Intervention|Standart treatment|
89659459|NCT06221787|Placebo Comparator|1565 nm non-ablative fractional laser combined with normal saline|The treatment parameters were adjusted according to each patient's age, skin color, surface area of affected skin, location of melasma, and skin type.After the scanning, infusing with normal saline in the entire face.
89659460|NCT06221787|Experimental|microneedles combined with hUCMSC-Exos|The hUCMSC-Exos were applied while rolling a microneedle roller in the entire face.
89659461|NCT06221787|Experimental|1565 nm non-ablative fractional laser combined with hUCMSC-Exos|The treatment parameters were adjusted according to each patient's age, skin color, surface area of affected skin, location of melasma, and skin type.After the scanning, infusing with hUCMSC-Exos in the entire face.
89659462|NCT06221787|Experimental|PBASM combined with hUCMSC-Exos|4-5 levels of intensity were used, rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face.
89659463|NCT06221774|Experimental|Phase Ib: dose optimization phase|"Approximately 12 participants will be enrolled and randomized 1:1 into two different dosage groups:~Dose Group A (N=6): TT-00420 tablets 10mg QD + Toripalimab 240mg Q3W.~Dose Group B (N=6): TT-00420 tablets 8mg QD + Toripalimab 240mg Q3W."
89659464|NCT06221774|Experimental|Phase II|"Based on the safety and efficacy data from Phase Ib, further cohorts will enroll participants with specific tumor types at the optimal dose of TT-00420 tablets:~Cohort 1 (N=10): Metastatic or unresectable advanced renal clear cell carcinoma (RCC).~Cohort 2 (N=10): Metastatic or unresectable advanced urothelial carcinoma (UC).~Cohort 3 (N=10): Metastatic castration-resistant prostate cancer (mCRPC)."
89659465|NCT06221761|Experimental|Non antibiotic group|Not using antibiotics within 72 hours after burns
89659466|NCT06221761|Active Comparator|antibiotic group|Using antibiotics within 72 hours after burns
89659467|NCT06221748|Experimental|Disitamab Vedotin + Cadonilimab|Disitamab Vedotin With Cadonilimab
89659468|NCT06221748|Experimental|Disitamab Vedotin|Disitamab Vedotin arm
89659469|NCT06221748|Experimental|Paclitaxel|Paclitaxel Arm
89659470|NCT06221722||Refractory constipation: fluoxetine sensitive|"Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.~After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with effective treatment of constipation symptoms."
89659471|NCT06221722||Refractory constipation: fluoxetine insensitive|"Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.~After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with ineffective treatment of constipation symptoms."
89659472|NCT06221722||Non-refractory constipation|Functional constipation patients maintained at least 3 months of continuous regular therapy with effective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
89659473|NCT06221722||Health Control|Volunteers without symptoms of constipation
89659474|NCT06221709|Active Comparator|Control Group|This group will be submitted to an intraarticular infiltration of corticosteroid + anesthetic.
89659475|NCT06221709|Experimental|CRF group|This group will be submitted to radiofrequency for sensitive hip branches from the Femoral and Obturator nerves followed by an intraarticular infiltration of corticosteroid + anesthetic similar to the control group.
89659476|NCT06221670|Experimental|Toripalimab adjuvant therapy group|Patients must be enrolled within 8 weeks of complete surgical excision and receive Toripalimab at a dose of 240 mg intravenously (IV) once every 3 weeks for a planned duration of 1 years.
89659477|NCT06221657|Experimental|TAF group|
89659478|NCT06221657|Active Comparator|TDF group|
89659479|NCT06221631||Group 1: Healthy Controls|Healthy individuals with a predefined healthy lifestyle (s. inclusion/exclusion criteria), without any progressive disease or any neurological disorder (aside from primary headaches)
89659480|NCT06221631||Group 2: Patients with Multiple Sclerosis|Patients with MS with a similar healthy lifestyle (s. inclusion/exclusion criteria), who are able to walk without more than one-sided walking aid (max. EDSS of 6 points), no relapse activity in the last 6 months, without any other progressive disease or other neurological disorder (aside from primary headaches)
89047289|NCT02797119|Experimental|tranexamic acid 0.5 g (TA1/2)|To measure the efficacy of a low 0,5g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
89047290|NCT02797119|Placebo Comparator|Saline Solution (TA0)|To measure the evolution of blood loss without TA in ongoing hemorrhagic cesarean section To correlate this clinical evolution with fibrinolysis.
89659481|NCT06221618||Coronary heart disease cohort|CCTA required for coronary heart disease cohort
89659482|NCT06221618||Stroke cohort|Cranial MRA required for stroke cohort
89659483|NCT06221618||Normal control group|Healthy elderly without coronary heart disease and stroke (≥ 60 years old)
89659484|NCT06221605|Experimental|Probiotic group|15B CFU/sachet/day, before meals; Compound Probiotics (Bifidobacterium animalis subsp. animalis BLa80、Bifidobacterium longum subsp. longum BL21、Lacticaseibacillus rhamnosus LRa05) Storage: store in a cool, dry place without sun exposure.
89659485|NCT06221605|Placebo Comparator|placebo|Maltodextrin, 1 sachet/day, before meals; Storage: store in a cool, dry place without sun exposure.
89659486|NCT06221592|Experimental|Full axis multi-point defocus spectacle lenses|
89659487|NCT06221592|Experimental|Innovative micro defocus spectacle lenses|
89659488|NCT06221592|Experimental|Circular multi-point optical micro transparent defocus spectacle lenses|
89659489|NCT06221592|Placebo Comparator|High non spherical micro transparent defocus spectacle lenses|
89659490|NCT06221579|Experimental|Interview|Conducting interviews with MCI patients to identify their needs and preferences related to the intervention to be developed
89659491|NCT06221553|Experimental|Locoregional delivery of B7H3/IL-7Ra CAR T cell in DIPG|"Patients with DIPG for whom CAR T cells will be delivered into the ventricular system~Interventions:~Biological: Autologous B7H3-specific chimeric antigen receptor (CAR) T cell with additional of IL-7Ra signaling domain Dose level: 1x10e7 CAR T cell, 3x10e7 CAR T cell, 10x10e7 CAR T cell"
89659492|NCT06221540|Experimental|Received written patient information leaflet|
89659493|NCT06221540|No Intervention|Routine education at first clinic appointment|Active Comparator
89659494|NCT06221527|Active Comparator|conventional group|fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border.
89659495|NCT06221527|Active Comparator|study group|"placement of hyaluronic acid will be carried over gel foam and placed between fractured segments before plate fixation.~fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border."
89659496|NCT06221514|Other|Core Group|"Each session will begin with a 5-10-minute core dynamic warm-up exercise.~The participants then will perform approximately 30 minutes of core exercises using therapy resistance bands. All players will rest for a few seconds between the exercises. The core exercises will include: bicycle crunches with the band placed around the feet, standing knee tucks with the band placed around the feet (without shoulder rotations and while applying posterior pelvic tilts), flutter kicks with the band placed above the ankles, leg raises with knees flexed and no resistance band, and posterior pelvic tilts from a supine position with hold.~Lastly, the training session will end with a 5-10-minute cool-down."
89659497|NCT06221514|Other|Shoulder Group|"Each session will begin with a 5-10-minute shoulder dynamic warm-up exercise.~The participants then will perform approximately 30 minutes of shoulder exercises using therapy resistance bands. All players will rest for a few seconds between the exercises. The shoulder exercises will include: internal and external rotations with the elbow flexed and band wrapped around an object of appropriate height, shoulder abduction to 90˚ with band placed under feet for fixation, shoulder flexion to 90˚ with band placed under feet for fixation, and seated rowing with band held in hands while being placed around the feet were all performed in a sitting position to avoid activation of core muscles.~Lastly, the training session will end with a 5-10-minute cool-down."
89659498|NCT06221449|Placebo Comparator|Group (I) Control group:(31 patients)|Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg Ideal body weight - fixed fio2 0.5% - fixed POSITIVE end expiratory pressure 6 cm. water - fixed respiratory rate10-14 Respiratory rate /min)
89659499|NCT06221449|Active Comparator|Group (II) Sustained inflation group (SI): (31 patients)|Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 centimetreswater, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg Ideal bogy weight - fixed fio2 0.5% - fixed positive end expiratory pressure 6 cmH2O - fixed respiratory rate 10-14 per minute.
89659500|NCT06221449|Active Comparator|Group (III) Stepwise PEEP increasing: (31 patients)|Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in Positive end expiratory pressure 2 centimetres water every 5 respiratory cycle with maximum 10-12 centimetres water guided by hemodynamics & airway pressure not exceeding 40 centimetres water With these parameters (fixed Tidal Volume 6-8ml/Kg Ideal body weight - fixed fio2 0.5% -fixed respiratory rate10-14 .
89659501|NCT06221436|Experimental|Mental Imagery|The Mental Imaging group will receive olfactory mental imagery technique and vagus breathing therapy for 1 hour in the morning and evening on the 1st, 2nd, 3rd and 4th days after surgery. In addition, the standard care (breathing exercises with Triflo, early walking, frequent position changes in bed) and treatment plan, which are the standard protocol of the Cardiovascular Surgery Service, will be continued by the clinic nurse and physician.
89659502|NCT06221436|No Intervention|Control|The control group was given no intervention other than standard care (breathing exercise with Triflo, early ambulation, frequent position changes in bed) and treatment, which is the standard protocol of the Cardiovascular Surgery Service, by the clinic nurse and physician on the 1st, 2nd, 3rd and 4th days after surgery. Will not be implemented.
89047291|NCT02797119|No Intervention|NH|To measure the reference fibrinolytic activity in non-hemorrhagic cesarean section
89047292|NCT05173259|Active Comparator|F-R/L-G05/G15/G25 or G25/G15/G05-L/R-F Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
89659503|NCT06221423||Fru plus TAS-102|mCRC patients receiveing Fruquintinib combined with TAS-102 in third- or late- line
89659504|NCT06221410|No Intervention|Control Group|The control group will only receive traditional teaching methods (PowerPoint).
89659505|NCT06221410|Experimental|Funny Scenario-Based Group|"The Funny Scenario-Based approach is an educational approach where humor is integrated with scenario-based learning. Using this teaching strategy, comedic elements are incorporated into realistic or hypothetical scenarios to engage students and make learning more fun.~In such scenarios, students may encounter a wide range of characters, situations, and challenges designed to entertain and engage students with different types of medical terms. It is common to incorporate humor into the educational process, helping to maintain educational relevance while appealing to the student's sense of enjoyment."
89659506|NCT06221410|Experimental|Mind-mapping Group|"The term Mind-mapping Group refers to a collaborative educational setting in which students use mind-mapping as an instructional strategy. A mind map is a visual thinking tool that involves diagramming tasks, words, concepts, or items that are related to and arranged around a central concept."
89659507|NCT06221371|Experimental|IVT with rhTNK-tPA+EVT|"rhTNK-tPA 0.25mg/kg: 1-2 vials (1.0×107 IU/16 mg per vial) Each vial of rhTNK-tPA is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. The total amount of drug will be calculated according to the subject's actual body weight and the required drug volume will be measured. The maximum dose should not exceed 25mg. rhTNK-tPA should be given as a single, intravenous bolus (drug administered over 5-10 seconds).~Endovascular treatment (EVT) should be performed as soon as possible after rhTNK-tPA administration."
89659508|NCT06221371|Active Comparator|Direct EVT|During the study period, NMPA-approved stents are permitted. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.
89659509|NCT06221345|Experimental|HPG/HA group|Systane HYDRATION®
89659510|NCT06221345|Active Comparator|CMC/HA group|Optive Fusion®
89659511|NCT06221280|Active Comparator|Group E|Patients who underwent erector spinae plane block
89659512|NCT06221280|Active Comparator|Group T|Patients who underwent transversus abdominis plane block
89659513|NCT06221254|Experimental|Intervention- COBMINDEX application|The intervention in this arm is to learn during the first 3 months, cognitive, behavioral and mindfulness based stress reduction with daily exercise using a research dedicated application. Than, additional 9 months of practicing daily only with the application.
89659514|NCT06221254|Active Comparator|Control- COBMINDEX with Human therapist|The intervention in this arm is to learn during the first 3 months, cognitive, behavioral and mindfulness based stress reduction with daily exercise with human therapist, and than practicing daily only with the application.
89659515|NCT06221241|Experimental|JMKX000623|JMKX000623 for 12 weeks
89659516|NCT06221241|Active Comparator|Pregabalin|Pregabalin for 12 weeks
89659517|NCT06221241|Placebo Comparator|Placebo|placebo for 12 weeks
89659518|NCT06221228|No Intervention|Conventional Training (CT):|Usual care in the clinical practice: Pre-dialysis training class
89659519|NCT06221228|Experimental|Audio-visual assisted Flipped Classroom pre-dialysis training|The audio-visual assisted Flipped Classroom (FC) CAPD Training Programme is a one-week individual intervention, which consists of five sessions (8-hours each). Pre-class audio-visual tutorials will be provided for self-study prior to F2F sessions. Six instructional videos, each dedicated to a specific procedure, are accessible for preview and repeated viewing as needed. Such flexibility allows the patients to revise at their own preferred time and pace. The four videos are (1) CAPD preparation and hand washing, (2) CAPD bag exchange procedure (Ultrabag or Balance systems), (3) Trouble shooting, and (4) Addressing contamination, (5) Detecting peritonitis, and (6) Exit site care. Participants will be asked to take note of any issues or difficulties they encounter while watching the video. A CAPD education booklet will be prepared and distributed to the patients at the beginning of the F2F training session. Take-home exercises will allow participants to revise the materials covered.
89659520|NCT06221215||Traumatic brain injury Group|The levels of related hormones (growth hormone, pituitary prolactin, ACTH, cortisol, FSH, thyroid hormone, etc.) were measured in patients with traumatic brain injury on the 1st, 7th and 14th day.
89659521|NCT06221215||Spontaneous cerebral hemorrhage roup|The levels of related hormones (growth hormone, pituitary prolactin, ACTH, cortisol, FSH, thyroid hormone, etc.) were measured in patients with spontaneous craniocerebral injury on the 1st, 7th and 14th day.
89659522|NCT06221202|Experimental|Stories in the Moment Dance Intervention|12 weeks online dance program - 1hour/week for 12 weeks
89659523|NCT06221163||Young transgender|"Transgender patients consulting the Reproductive Medicine Department for a request related to the preservation of their fertility or hormone therapy, as well as parents/family members present at the time of the appointment.~The ceiling is 20 interviews and 80 hours."
89659524|NCT06221150|Experimental|SAPB group|
89659525|NCT06221150|No Intervention|control|
89659526|NCT06221124|Experimental|BEL-Participant|First, we will measure the size of the finger of the participant and select appropriate size of Belun Ring device and the participant will be instructed to wear it on a finger in addition to regular PSG set up on the night of sleep study. Simultaneous recording of Belun Ring data {pulse oximeter, pulse rate and actigraphy} and standard PSG will be performed for one night.
89659527|NCT06221098|Active Comparator|congenital esotropia|will be defined as that type of esotropia with an onset prior to 6 months of age & characterized by a large stable angle
89659528|NCT06221098|Active Comparator|accommodative esotropia|Fully accommodative esotropia will be defined as an esotropia which is controlled for distance and near with full hypermetropic correction. Partially accommodative esotropia will be defined as a reduction in the angle of esotropia of 10 dioptres or more for distance or near, using the full hypermetropic correctionAccommodative esotropia with convergence excess occurs when the near angle exceeded the distance angle by 15 dioptres or more when fixating an accommodative target, using the full hypermetropic correction.
89659529|NCT06221098|Active Comparator|non-accommodative esotropia|neither congenital nor accommodative esotropia
89659530|NCT06221072|Experimental|Group 1-JMT103|Participants will receive JMT103 and zoledronic acid placebo.
89659531|NCT06221072|Experimental|Group 2-zoledronic acid|Participants will receive zoledronic acid and JMT103 placebo.
89659532|NCT06221059|Experimental|HRS-1780 dose 1|
89659533|NCT06221059|Experimental|HRS-1780 dose 2|
89047293|NCT05173259|Active Comparator|F-R/L-G05/G25/G15 or G15/G25/G05-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G25-G15-G15-G25-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G25-G15-G15-G25-G05). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
89659534|NCT06221059|Active Comparator|Henagliflozin Proline|
89659535|NCT06221059|Placebo Comparator|Placebo|
89659536|NCT06221033|Experimental|manual hyperinflation group|this group will receive manual hyper inflation technique as a treatment modality
89659537|NCT06221033|Experimental|diaphragmatic proprioceptive neuromuscular facilitation group|this group will receive diaphragmatic proprioceptive neuromuscular facilitation technique
89659538|NCT06221033|Other|control group|this group will receive the traditional physiotherapy techniques ( percussion , shaking , breathing ex )
89659539|NCT06221020||Patients with ERAS|"In the experimental group (Patients with ERAS), participants will undergo an assessment of the Enhanced Recovery After Surgery (ERAS) consensus items.~The experimental group will complete all the items on the ERAS forms as far as possible. All groups will undergo our routine preoperative evaluation for pituitary tumor surgery, such as cardiopulmonary function, hormone testing, vision and visual field examination, etc. The care during hospitalization and surgery will be the same as previously for patients with pituitary tumors, and the post-discharge outpatient follow-up will also be the same as for patients who have undergone pituitary tumor surgery."
89659540|NCT06221020||Patients with Regular|"In the control group (Patients with Regular), participants will only complete the routine items as before.~All groups will undergo our routine preoperative evaluation for pituitary tumor surgery, such as cardiopulmonary function, hormone testing, vision and visual field examination, etc. The care during hospitalization and surgery will be the same as previously for patients with pituitary tumors, and the post-discharge outpatient follow-up will also be the same as for patients who have undergone pituitary tumor surgery."
89659541|NCT06220994||Chronic limb-threatening ischemia|Resting pain for at least 2 weeks with at least one hemodynamic index: ABI<0.4,AP<50mmHg, TP or TCPO2<30mmHg. Tissue defects (ulceration or gangrene) persisted for at least 2 weeks with at least one significant PAD objective evidence: ABI<0.8, AP<100mmHg, TP or TCPO2<60mmHg.
89659542|NCT06220994||health control|sex - and age-matched healthy people (without history of atherosclerotic plaque, coronary heart disease or stroke).
89659543|NCT06220929|Sham Comparator|Control group|Patients were randomly divided into intervention and control groups, with both groups receiving standard treatment and care for sepsis (decided by the attending physician). On this basis, the following treatments were administered: Control group (n=20): intravenous saline drip/oral placebo tablets.
89659544|NCT06220929|Experimental|Intervention group|Patients were randomly divided into intervention and control groups, with both groups receiving standard treatment and care for sepsis (decided by the attending physician). On this basis, the following treatments were administered: Intervention group (n=20): intravenous drip of ceftriaxone sodium 1g per dose, twice daily (continuously for 14 days), mecobalamin injection 1mg per dose, once daily (on days 1, 2, 3, 5, 7, 9, 11, 13), with a half-hour interval between medications. From day 15 to 28, take mecobalamin tablets orally, 1mg per dose, three times a day.
89659545|NCT06220890|Experimental|Class IV lesion with 2 mm bevel (BV)|All the enamel margins will be beveled at a 45-degree angle of the width of approximately 2 mm, enamel selectively etched, bonding of tooth using universal adhesive will be done and restored with nano-filled composite.
89659546|NCT06220890|Experimental|Class IV lesion with 2mm stair-step chamfer (SSC)|Enamel margins facially will be prepared 2mm deep in stair-step chamfer form, enamel selectively etched, and bonding of tooth using universal adhesive will be done and restored with nano-filled composite.
89659547|NCT06220877|Active Comparator|Group I|patients were treated using Buccal Pad of Fat for management of OAC.
89659548|NCT06220877|Active Comparator|Group II|patients were treated using A-PRF technique for management of OAC.
89659549|NCT06220877|Active Comparator|Group III|patients were treated with Fibrin Glue for management of OAC.
89659550|NCT06220877|Active Comparator|Group IV|oxidized regenerated cellulose plug have been used for management of OAC.
89659551|NCT06220851||COPD|COPD patients aged 40 years or older with a postbronchodilator ratio of forced expiratory volume at one second (FEV1) to forced vital capacity (FVC) <0.7.
89659552|NCT06220838|Experimental|SC-101|
89659553|NCT06220812|Experimental|study group A|20 children will receive designed physical therapy program in addition to low level laser
89659554|NCT06220812|Experimental|study group B|20 children will receive designed physical therapy program in addition to pulsed electromagnetic field .
89659555|NCT06220799||The Study group (GI)|The Study group (GI) will include twenty five patients with chronic cervical radiculopathy with forward head posture (FHP) (CVA=less than 49° ).
89659556|NCT06220799||The Control group (GII)|The Control group (GII) will include twenty five patients with chronic cervical radiculopathy without forward head posture (FHP)( CVA = more than 49).
89659557|NCT06220786|Active Comparator|Low-level laser therapy|Laser pen with low-level laser therapy.
89659558|NCT06220786|Sham Comparator|Sham no low-level laser therapy|Identical laser pen without the low-level laser production.
89659559|NCT06220721|Experimental|REPAIR ARM|Intensive postpartum BP control with Nifedipine ER initiation at SBP≥140 mmHg or DBP≥90 mmHg and maintaining BP at <140/90 mmHg during the first 6 weeks postpartum
89659560|NCT06220721|Active Comparator|CONTROL ARM|A group of usual care with Nifedipine ER initiation at SBP≥150 mmHg or DBP≥100 mmHg and maintaining BP at <150/100 mmHg during the first 6 weeks postpartum.
89659561|NCT06220708|Experimental|The intervention group|The intervention group underwent dance movement therapy.
89659562|NCT06220708|Other|The control group|The control group received yoga training.
89688628|NCT00945061|Experimental|Intracavitary balloon brachytherapy|Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.
89659563|NCT06220695|Experimental|Mediterranean Diet Group|"The Mediterranean diet includes high amounts of olive oil, olives, fruits, vegetables, whole grains, legumes, nuts, a high intake of fish, moderate consumption of eggs, poultry, and dairy, and low consumption of red meat and products. The targeted macronutrient distribution is 40% of total energy from carbohydrates, approximately 20% from protein, and 40% from fats. The share of saturated fats in total energy will not exceed 10%. Participants will be provided with written resources, brochures explaining the Mediterranean diet, and information about the Mediterranean diet pyramid. A weekly menu will be planned for all participants, along with cooking tips.~Participants in this group will receive a weekly food support package for 12 weeks, including essential elements of the Mediterranean diet such as olive oil, fish, nuts, and legumes."
89659564|NCT06220695|Active Comparator|Low Fat Diet Group|"The type of diet to be followed in this group is based on the recommendations of the American Heart Association, the American Diabetes Association guidelines, and the Specific Nutrition Guide for Turkey. The targeted macronutrient distribution will be 50% of total energy from carbohydrates, approximately 20% from protein, and less than 30% from fats. The share of saturated fats in total energy will not exceed 10%. Participants will be provided with information notes and brochures explaining the low-fat diet. A weekly menu will be planned for all participants, and cooking tips will be provided.~Participants in this group will receive a weekly food support package for 12 weeks, including low-fat dairy products, whole grains, and legumes, which are the essential elements of a low-fat diet."
89659565|NCT06220656|Experimental|Immediate biopsy (usual care)|"The aim of biopsy is to sample the thyroid nodule so that it can be tested for cancer. A biopsy is done with a small needle in an office. If the biopsy result shows the nodule is unlikely to be cancer, the next step is check-ups every 6 months to a year for two years followed by additional checkups that occur less frequently.~If the biopsy result shows the nodule may be cancerous, usual treatment is surgery to remove part or all of the thyroid gland. Afterwards, regular check-ups and ultrasounds follow. Surgery may be outpatient or overnight stay. Recovery takes a couple weeks or more. Time in the hospital and recovering depends on the type of operation and any side-effects."
89659566|NCT06220656|Experimental|Active monitoring, proceeding to biopsy if needed|"The aim of Active Monitoring is to monitor the thyroid nodule closely. An ultrasound and a check-up with a clinician are done every six months for two years, then less often after that.~If no changes in the nodule or new abnormal lymph nodes are seen, Active Monitoring continues and surgery and its side-effects are avoided. If changes in the nodule are seen on ultrasound, they are explained at the visit. The doctor may recommend that continued Active Monitoring or recommend a biopsy to investigate the changes. The biopsy result may suggest Active Monitoring can be continued, or may indicate surgery should be done, as described above."
89659567|NCT06220643|Active Comparator|Echoguide steroid injection without exercise (only education)|received 40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%) injected into the inflamed subacromial bursa with ultrasound guidance
89659568|NCT06220643|Experimental|Echoguide steroid injection with exercise|experimental group received 40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%) injected into the inflamed subacromial bursa with ultrasound guidance, and a 12-week elastic band progressive resistance exercise
89659569|NCT06220630||Chinese|About 1,200 Chinese male breast cancer cases are anticipated to collected retrospectively. The clinicopathological characteristics, treatment and survival information are retrospectively collected.
89659570|NCT06220617||Case arm|Prospective enrollment of participants confirmed with colorectal adenocarcinoma or advanced adenoma
89659571|NCT06220617||Control arm|Prospective enrollment of healthy participants who have general risk or high risk of colorectal cancer
89659572|NCT06220591|Active Comparator|Superior trunk group|"The patient will undergo selective supraclavicular nerve block, then will undergo block of superior trunk The fifth & sixth cervical nerve roots of the brachial plexus on the side of the affected clavicle."
89659573|NCT06220591|Active Comparator|Clavipectoral fascial plane group|The patient will undergo selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block on the lateral and medial ends of the affected clavicle.
89659574|NCT06220578||candidates seeking corneal refractive surgery|Persons from both sexes between 18 and 45 years seeking corneal refractive surgery
89659575|NCT06220565|Experimental|"Products for graded exercise interventions Graded Exercise"|Through digital means, patients are able to execute a personalized exercise program based on their rehabilitation plan and incorporate digital assessment methods to receive real-time feedback and recommendations for adjustments. By providing a personalized rehabilitation program and regular telecare, the aim is to focus on the patient's rehabilitation needs in a holistic manner.
89659576|NCT06220565|Placebo Comparator|Education group|Educational Manual on Exercise Rehabilitation for Patients with Osteoarthritis of the Knee
89659577|NCT06220552|Experimental|Low-dose Radiotherapy Combined With Sintilimab and Temozolomide|
89659578|NCT06220539|Experimental|Casting and Supervised Rehabilitation|Patients in the intervention group will undergo non-weightbearing immobilization for 8 weeks in phase one: 4 in a circular cast with non-weightbearing followed by 4 weeks toe-tip weightbearing (10-20% of body weight) in a walking boot during daytime and a removable cast at night. In phase 2, a supervised rehabilitation will be performed till week 16 after which phase 3 will start at week 16-18
89659579|NCT06220539|No Intervention|Standard Care|Patients in the control group will undergo the standard care. Standard care (''skill-full'' neglect) is described as adjustment of activities within the boundaries of pain. They can perform all activities wanted, except for painful activities. Patients and caretakers will be advised on the amount of activities by specialized orthopedic surgeons and periodical evaluation, and adjustment, will take place at the regular follow-up moments which is the same as in the intervention group. In this group, no supervised training or rehabilitation will be performed.
89659580|NCT06220526|Other|Menghini-type needle|the standard needle type
89659581|NCT06220526|Active Comparator|Franseen-type needles|the active comparator arm
89688629|NCT02924350|Experimental|Test dentifrice containing stannous fluoride|All the participants in the test arm applied test dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using test dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
89659582|NCT06220513|Active Comparator|Group A (ESP) block group|the first group (ESP) will be placed in the lateral decubitus position. The ultrasound probe will be placed in longitudinal orientation at the level of the T7 spinous process and then moved the probe 3 cm laterally from the midline. The ultrasound landmarks, which included the T7 transverse process and the overlying erector spinae muscle, will be identified. Under complete aseptic conditions, an 80-mm 21-gauge block needle will be inserted in plane at an angle of 30-40° in cranial-to-caudal direction until the tip contacted the T7 transverse process. After hydro-dissection with 3 mL of isotonic saline solution confirmed the correct needle tip position, 30 mL of 0.25% bupivacaine and dexamethasone 4mg will be injected deep to the erector spinae muscle. The same procedure will be repeated with 30 mL of 0.25% bupivacaine solution and dexamethasone 4mg on the contralateral side.
89659583|NCT06220513|Active Comparator|Group B TAP block group|patients who will receive TAP block. A high-frequency ultrasound probe placed transversely, approximately midway between the iliac crest and costal margin shows the three muscle layers of the abdominal wall. A regional block needle can then be inserted anteriorly and slightly away from the probe and carefully advanced until it reaches the transversus plane. In this 'in-plane' technique. The needle and its tip are visualised throughout the procedure, as it enters the transversus plane after piercing the fascial layer below the internal oblique muscle. The needle will be directed toward the transversus abdominis fascia and injected 30 mL of 0.25% bupivacaine and dexamethasone 4mg between the rectus abdominis and transversus abdominis muscles. The same procedure will be repeated with 30 mL of 0.25% bupivacaine solution and dexamethasone 4mg on the contralateral side.
89659584|NCT06220487|Experimental|ABC protocol|Adult patients with Ph-positive ALL eligble for this study will begin treatment with ABC protocol, as (A) olverembAtinib, (B) Blinatumomab and (C) Chidamide after pre-treatment with glucocorticoid, including induction and consolidation therapy for one year, and subsequent maintenance therapy for three years.
89659585|NCT06220474|Experimental|Radiofrequency treatment (RF), followed by meibomian gland expression (MGX)|Before treatment, a thermage return pad will be applied to subject's skin to help prevent electrical burns. The return pad is a rubber, non-active electrode that creates a return path for radiofrequency energy back to the thermage comfort pulse technology (CPT) system. The upper and lower lid of both eyes are marked with skin marking paper (Thermage ® Skin Marking Paper TK-3.00). Coupling fluid is then applied to the external surface of the upper and lower lids of both eyes. All subjects then receive 225 applications to each eye over the upper and lower eyelids. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.
89659586|NCT06220474|Sham Comparator|Sham treatment, followed by meibomian gland expression (MGX)|The training mode is used in the Thermage FLX, which simulates treatment without dissipation of radiofrequency energy. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.
89659587|NCT06220409|Experimental|Dance|The patients persuading dance classes two times a wek for 3 months .
89659588|NCT06220409|No Intervention|Passive|The patients engage in no structured or self-induced physical exercise or activity (sedentary individuals)
89659589|NCT06220409|No Intervention|Healthy subjects|The subjects engage in sports recreationally
89659590|NCT06220110|Experimental|Experimental group|Probiotic intake containing 10 billions of Colony Forming Units of Lactobacillus plantarum (1 capsule per day)
89659591|NCT06220110|Placebo Comparator|Placebo group|Placebo intake. Placebo capsules will contain dextrose (1 capsule per day)
89659592|NCT06219681|Experimental|Active neurofeedback|Receiving feedback signals from the repetitive negative thinking (RNT)-related brain functional connectivity
89659593|NCT06219681|Sham Comparator|Sham neurofeedback|Receiving artificially generated feedback signals.
89659594|NCT06218693|Experimental|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
89659595|NCT06218693|Active Comparator|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness within the catchment area of the study. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
89659596|NCT06218628|Experimental|Dose Level -1|0.25 mg (PO, QD) Talazoparib (Days 1-7) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
89659597|NCT06218628|Experimental|Dose Level 1|0.25 mg (PO, QD) Talazoparib (Days 1-14) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
89659598|NCT06218628|Experimental|Dose Level 2|0.5 mg (PO, QD) Talazoparib (Days 1-14) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
89659599|NCT06218628|Experimental|Dose Level 3|0.75 mg (PO, QD) Talazoparib (Days 1-14) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
89659600|NCT06218628|Experimental|Dose Level 4|1 mg (PO, QD) Talazoparib (Days 1-14) 200 mg (PO, BID) Pacritinib (Day 1-28, Lead in dosing of Pacritinib day -7 for the first cycle of treatment)
89659601|NCT06218030|Experimental|L-methylfolate arm|Oral administration of L-methylfolate 15 mg per day for 8 weeks.
89659602|NCT06217731|Active Comparator|Group1 laser + clonazepam|Group 1 (n=20) were treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril ( clonazepam) 0.25mg once every 24 hours for a month.
89659603|NCT06217731|Sham Comparator|group2 Laser Sham|Group 2 (n=19) were treated with the same laser once a week for a month, but with the tip deactivated
89659604|NCT06217731|Experimental|group3 laser|Group 3 (n=21) were treated with the Helbo® laser once a week for a month.
89659605|NCT06217731|Experimental|group4 clonazepam|Group 4 (n=18) were treated with Rivotril 0.25mg once a day for a month.
89659606|NCT06217575|Active Comparator|Visual Attention Training|Visual attention training is at the core of well-known training programs such as useful field of view (UFOV) training. The adapted nature of the computerized training approach affords individual differences in performance at the training outset while evaluating gains using specified performance criteria. Training parameters (duration of stimulus presentation for processing speed) are adjusted based on accuracy.
89659607|NCT06217575|Experimental|Alpha Neurofeedback training|Electroencephalogram (EEG) based neurofeedback (NFB) is a method in which brain activity is modulated via self-induced increases or decreases in the power of selected EEG frequency bands. The subject's control over his or her EEG activity is mediated with visual feedback. We will employ alpha neurofeedback training to examine how this conditioning paradigm may improve visual attention.
89213553|NCT04038866|Experimental|DUAL-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait with a dual-task program with secondary cognitive and upper limb motor tasks.~In this group, the training of the tasks (walking and cognitive or motor) was performed separately and then they were trained at the same time under a progression system. Cognitive/motor secondary tasks were different from those used in the assessment of gait.~Each training session consisted of three parts: the initial warm-up, dual-training, and back-to-calm."
89659608|NCT06216795||kidney transplant group|
89659609|NCT06216769|Active Comparator|non-interrupted group|Anticoagulation is continued regardless of atrial fibrillation recurrence.
89659610|NCT06216769|Experimental|PIP anticoagulation group|Anticoagulation continuation will be determined based on the rhythm monitored by ILR. If atrial fibrillation persists more than 6 hours a day, anticoagulation should be started at that point on and continued for four weeks. Anticoagulation can be prescribed even in case of less-than-6-hour cumulative atrial fibrillation burden if the investigator decides that the anticoagulation is necessary.
89659611|NCT06216626|Experimental|Prebiotic fibre|The treatment group will consume 10g per day of a diverse prebiotic fibre supplement. Supplements are powdered and unflavoured, and given to the participants in 300g packets lasting for 30 days. A 10g scoop is included in each packet and participants are advised to consume one level scoop at any time of the day. Participants are provided with examples on how to consume the supplement (e.g., breakfast cereal, coffee, tea, water).
89659612|NCT06216626|Active Comparator|Control|Participants are provided with standard of care (dietary advice). Recommendations for diet and lifestyle advice are provided by a UK-registered GP, and follow the Heart UK's Healthy Eating Guidelines. These recommendations emphasise a Mediterranean diet, rich in fruit, vegetables, and healthy fats (omega-3 fatty acids), while reducing refined sugar, salt, processed foods, and alcohol intake. The Mediterranean diet is considered a gold-standard for participants with MetS and poor mental health.
89659613|NCT06216561|Experimental|CRS-HIPEC + LSTA1|Experimental Arm
89659614|NCT06216561|Active Comparator|CRS-HIPEC alone|Control Arm
89659615|NCT06215781|Experimental|Fully digital workflow|Patients of this group are subjected to entire digital workflow, from the digital planning to the delivery of definitive zirconia fixed dental prosthesis
89659616|NCT06215781|Experimental|Combined digital-conventional workflows|"Patients of this group were subjected to every digital steps as the fully digital workflow arm, except for the impression that includes analog material (silicones)."
89659617|NCT06215781|Active Comparator|Fully conventional workflow|Patients of this group follow the entire analog protocol. All the procedures exclude digital involvement.
89659618|NCT06214936|Other|Oocytes allocated to the benchtop incubator|Half of the mature oocytes and subsequent embryos will be cultured in the benchtop incubator
89659619|NCT06214936|Other|Oocytes allocated to the box incubator|Half of the mature oocytes and subsequent embryos will be cultured in the box incubator
89659620|NCT06214611|Other|Adaptive Radiotherapy|Adaptive Radiation Therapy
89659621|NCT06214611|Active Comparator|Standard Treatment Arm, IGRT|Standard Treatment Arm, IGRT
89659622|NCT06213597|Experimental|repetitive transcranial magnetic stimulation group|Randomization was performed by a staff member of our hospital, who was not involved in the implementation or evaluation of the trial, and who randomly assigned subjects to either the rTMS group or the sham rTMS group in a 1:1 ratio through the use of an electronic random sequence generator. Opaque, sealed envelopes were used to mask the randomization tables.
89659623|NCT06213597|Sham Comparator|sham repetitive transcranial magnetic stimulation|Randomization was performed by a staff member of our hospital, who was not involved in the implementation or evaluation of the trial, and who randomly assigned subjects to either the rTMS group or the sham rTMS group in a 1:1 ratio through the use of an electronic random sequence generator. Opaque, sealed envelopes were used to mask the randomization tables.
89659624|NCT06212674|Experimental|A|80 patients
89659625|NCT06212674|Experimental|B|80 patients
89659626|NCT06212674|Active Comparator|C|80 patients
89659627|NCT06211959|Experimental|Classical Approach Bias Modification|The 3 arms will follow a similar procedure, except that they will receive 3 different experimental interventions, dependly on their conditions.
89659628|NCT06211959|Experimental|Approach Bias Modification with Implementation Intentions|The 3 arms will follow a similar procedure, except that they will receive 3 different experimental interventions, dependly on their conditions.
89659629|NCT06211959|Placebo Comparator|Sham-training|The 3 arms will follow a similar procedure, except that they will receive 3 different experimental interventions, dependly on their conditions.
89659630|NCT06209619|Experimental|Treatment (rituximab, CC-99282)|Patients receive rituximab IV on day 1 of each cycle and CC-99282 PO QD on days 1-14 of each cycle. Treatment repeats every 28 days for up to 6 cycles of rituximab and up to 24 cycles of CC-99282 in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and collection of blood samples throughout the trial. Patients may undergo biopsy at screening.
89659631|NCT06209541|Experimental|Unified Protocol, support by a specific therapist|The participants receive eight weeks of ICBT, based on the treatment manual Unified Protocol by David Barlow and colleagues (2013), with weekly support by a specific therapist that follow the individual participant through all treatment weeks. During the eight weeks, the participant will receive in total eight treatment modules.
89688630|NCT02924350|Active Comparator|Control dentifrice containing sodium monofluorophosphate|All the participants in the control arm applied control dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using control dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
89659632|NCT06209541|Experimental|Unified Protocol, support by a team|The participants receive eight weeks of ICBT, based on the treatment manual Unified Protocol by David Barlow and colleagues (2013), with weekly support by a team of therapists. This arm implies that the participant will get support from different therapists each week. During the eight weeks, the participant will receive in total eight treatment modules.
89659633|NCT06209541|Experimental|Individually tailored treatment, support by a specific therapist|The participants receive ICBT in an individually tailored format, where they get to select which modules they want to be included in their specific treatment. The participants are recommended to select eight modules (out of 25) and work with one modules each week, but this is only recommendations. In their treatment, weekly support by a specific therapist that follow the individual participant through all treatment weeks is included.
89659634|NCT06209541|Experimental|Individually tailored treatment, support by team|The participants receive ICBT in an individually tailored format, where they get to select which modules they want to be included in their specific treatment. The participants are recommended to select eight modules (out of 25) and work with one modules each week, but this is only recommendations. In their treatment, weekly support by a team of therapists is included. This arm implies that the participant will get support from different therapists each week.
89659635|NCT06209437||Inhalation Anesthesia Group|After induction, anesthesia will be provided with sevoflurane (2.0 mac) and intravenous remifentanil infusion (0.05-0.2 mcg/kg/min). Depth of anesthesia will be evaluated with Bispectral Index (BIS).
89659636|NCT06209437||Total Intravenous Anesthesia Group|After induction, anesthesia will be provided with intravenous propofol infusion (50-150 mcg/kg/min) and intravenous remifentanil infusion (0.05-0.2 mcg/kg/min). Depth of anesthesia will be evaluated with Bispectral Index (BIS).
89659637|NCT06208930|Experimental|FMT group|
89659638|NCT06205199|Experimental|Hydromorphone group|Hydromorphone 50 micrograms combined with ropivacaine 15 mg was injected into the subarachnoid space
89659639|NCT06205199|No Intervention|Control group|Ropivacaine 15 mg was injected into the subarachnoid space
89659640|NCT06203717|Experimental|Alpha-Stim AID cranial electrotherapy stimulation|Four-week course of noninvasive cranial electrotherapy stimulation.
89659641|NCT06202196|Experimental|Experimental group|"Patients of the experimental group will have therapeutic patient education sessions that include one Recognizing and Managing the Risks of Epilepsy workshop."
89659642|NCT06202196|Other|"Control group Usual management"|"Patients of the control group will have the usual therapeutic patient education sessions."
89659643|NCT06201429|Experimental|Mechanical Tissue Resuscitation (MTR™)|
89659644|NCT06201078|Experimental|Salvage SBRT for locally recurrent prostate cancer after radiotherapy|SBRT: 5 x 6.75 Gy (every other day) to the total dose of 33.75 Gy
89659645|NCT06200311|Experimental|AF ablation|These patients will undergo Pulmonary vein isolation (PVI) (only)
89659646|NCT06200311|Active Comparator|Pharmacological rhythm management|These patients will take rate control medication. If this therapy fails, pharmacological rhythm control and AF ablation are 2nd and 3rd line options respectively within this arm,
89659647|NCT06195215|Experimental|peer counselling|"Does not have any cognitive, affective and verbal problems that prevent communication~It is planned to include nursing students with an Image Scale for Nursing Profession score of 143 and lower.~The peer counselling process related to nursing image was applied to this group by 1 senior nursing student for 1 hour a week for 7 weeks. Before and immediately after the 7-week period, the nursing image scale is applied."
89659648|NCT06195215|No Intervention|Control|"Does not have any cognitive, affective and verbal problems that prevent communication~It is planned to include nursing students with an Image Scale for Nursing Profession score of 143 and lower.~No peer counselling process is applied to this group. Seven weeks after the first data collection, the final data are collected for the second time using the nursing image scale."
89659649|NCT06188949|Active Comparator|Dolichos biflorus (Horsegram) seed extract|1 capsule twice a day (Before breakfast & dinner)
89659650|NCT06188949|Active Comparator|Carica papaya leaves extract|1 capsule twice a day (Before breakfast & dinner)
89659651|NCT06188949|Placebo Comparator|Placebo (MCC)|1 capsule twice a day (Before breakfast & dinner)
89659652|NCT06184477||prolonged hospitalization after tonsillectomy|Prolonged hospitalization refers to prolonged discharge time and readmission.
89659653|NCT06184477||normal hospitalization time|normal hospitalization time for pediatric patients accepted as 1 night stay.
89659654|NCT06178900|Experimental|Assisted by the AI-Gatekeeper software group|After a baseline examination (chest X-ray, electrocardiogram, echocardiogram, clinical risk factors and blood test), the AI-Gatekeeper software will be used to guide clinical care.
89659655|NCT06178900|No Intervention|Usual care group|The usual care group will be managed based on established guidelines.
89659656|NCT06175221|Experimental|Treatment - Investigational Product|"Product Name: Tumor lysate, particle only (TLPO) vaccine~Dosage Form: Intradermal Injection~Unit Dose: 1x10^8 autologous tumor lysate-loaded, yeast cell wall particles~Route of Administration: Intradermal; primary vaccine series at 0, 1, 2 months followed by boosters at 6, 9, and 12 months~Physical Description: 250 uL clear liquid vials~Manufacturer: Elios Therapeutics, LLC"
89659657|NCT06174441|Active Comparator|Test group 1 (CPMSM)|Investigational product 1: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg.
89659658|NCT06174441|Active Comparator|Test group 2 (HC+)|"Investigational product 2: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg.~Intervention: Dietary Supplement: Placebo Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients)."
89659659|NCT06174441|Placebo Comparator|Placebo group|placebo product without any of the active ingredients, daily dose 25 mL: no active ingredients.
89659660|NCT06172608|Experimental|Intervention Group (I)|Intervention group (I) will be receiving a psychoeducational intervention along with routine care they are getting in the hospital
89659661|NCT06172608|No Intervention|Control group (C)|Comparison usual care and Leaflet of the information. At the end of the trial these also get the video and educational sessions as intervention group.
89659662|NCT06170489|Experimental|JS004 plus Toripalimab|JS004 200mg plus Toripalimab 240mg IV on day 1 of each cycle, every 3 weeks for up to 2 years
89659663|NCT06170489|Active Comparator|Investigator-Selected Chemotherapy|Bendamustine or gemcitabine
89659664|NCT06163521|Experimental|Education|
89659665|NCT06160128||Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Feb 2022|"This cohort study assessed outpatient Veterans with risk factors for severe COVID-19 who tested positive for SARS-CoV-2 during January and February 2022.~The purpose is to describe factors associated with receipt of outpatient COVID-19 pharmacotherapies in the Veterans Affairs (VA) health care system."
89659666|NCT06160128||Nonhospitalized Veterans in VHA at risk for SARS-CoV-2 Jan-Jul 2022|"Three retrospective target trial emulation studies comparing matched cohorts of nirmatrelvir-ritonavir versus no treatment, molnupiravir versus no treatment, and nirmatrelvir- ritonavir versus molnupiravir.~The purpose is to measure the effectiveness of nirmatrelvir-ritonavir and molnupiravir for outpatient treatment of COVID-19."
89659667|NCT06160128||Outpatient Veterans who tested positive for SARS-CoV-2 from Jan 2022 through Jan 2023|"This cohort study evaluated nonhospitalized Veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases.~The purpose is to analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA)."
89659668|NCT06160128||Outpatient Veterans with risk factors for severe COVID-19 & tested positive during Jan-Jul 2022|"Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment.~The purpose is to measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing Post COVID conditions."
89659669|NCT06152224|Experimental|8 week use of Leva|
89659670|NCT06152224|Active Comparator|16 week use of Leva|
89659671|NCT06149195||positive|positive imaging, referring to the tracer absented in the left myocardium whether diffuse or localized on 18F-FMBG cardiac imaging.
89659672|NCT06138522||Adolescents|Participants in consultations specialising in the treatment of psychotrauma at the Maison de Solenn
89659673|NCT06138522||Parents|Participants in consultations specialising in the treatment of psychotrauma at the Maison de Solenn
89659674|NCT06138522||Professionals|Participants in consultations specialising in the treatment of psychotrauma at the Maison de Solenn
89659675|NCT06133829|Experimental|Intervention Group|Demographic and baseline measures will be obtained from the participants electronically. The participant will receive at least 1 prenatal home visit and at least 1 postpartum home visit. During the visits, the home visitor will review the screening assessments that were completed at baseline, identify health and social needs (including but not limited to referrals to substance use treatment providers, domestic violence hotline/shelters, mental health providers, applications for public assistance, and basic needs provision),work with the client to prioritize their needs, assist with applications and connections to community resources, support the participant in communicating with medical and social service providers, and provide education to help the participant advocate for their health, think ahead for after delivery (prenatal), and understand infant health and safety. At 2 months postpartum, both intervention and control groups will receive a post- survey through REDCap.
89659676|NCT06133829|No Intervention|Control Group|Demographic and baseline measures will be obtained from the participants electronically through REDCap surveys. The participants will receive standard care from the obstetric clinic. At approximately 2 months postpartum, both intervention and control groups will receive a post- survey through REDCap.
89659677|NCT06127316|No Intervention|NoCDO|Participants will complete study activities without a CDO
89688631|NCT00374062|Experimental|I|relaxation tape 1
88994670|NCT02929459|Placebo Comparator|Placebo|100 mg starch plus 0,5% silica (one capsule) per day for 2 weeks
88994671|NCT02929576|Experimental|Double-blind enzalutamide with paclitaxel|
88994672|NCT02929576|Placebo Comparator|Double-blind placebo with paclitaxel|
88994673|NCT02929576|Experimental|Open-label enzalutamide monotherapy followed by paclitaxel|At the time of disease progression, enzalutamide treatment will be discontinued and paclitaxel will be administered if considered to be an appropriate treatment by the treating physician until second disease progression.
88994674|NCT02929420|Experimental|Xiaoru Sanjie capsules|a new recipe of traditional chinese medicine； Xiaoru Sanjie capsules,three pills every time,three time a day,PO, last three months.
88994675|NCT02929420|Placebo Comparator|Xiao Yao pills|"a kind of traditional chinese medicine that is efficient and safe to treat hyperplasia of mammary glands.~Xiaoyao pills,three pills every time,three time a day,PO,last three months."
88994676|NCT00175812|Experimental|ATRA plus valproic acid plus theophyllin|ATRA for 14 days, continuous treatment with valproic acid and theophyllin
88994677|NCT02929342|Experimental|Pitolisant|Pitolisant, oral single dose administration, from Day1 to Day7.
88994678|NCT02929342|Experimental|[14C]-Pitolisant|[14C]-Pitolisant, oral single dose administration at Day8.
88994679|NCT02929381|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus)
88994680|NCT02929381|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
88994681|NCT00148538|Active Comparator|1|resistance exercise
88994682|NCT00148538|Active Comparator|2|Aerobic and Resistance exercise
88994683|NCT03457597|Experimental|Period 1|Period 1 (Study Days 1 to 4): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 1. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 2
88994684|NCT03457597|Experimental|Period 2|Period 2 (Study Days 5 to 13): Relacorilant will be given daily from Day 5 to Day 13.
88994685|NCT03457597|Experimental|Period 3|Period 3 (Study Days 14 to 17): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 14. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 15. Relacorilant will be given daily from Day 14 to Day 17.
88994686|NCT02929147|Experimental|Morphine 1 mg|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
88994687|NCT02929147|Experimental|Morphine 0.5|In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours
89659678|NCT06127316|Experimental|0cm Distraction|Participants will complete study activities while wearing a CDO with 0cm of heel distraction height
89659679|NCT06127316|Experimental|1cm Distraction|Participants will complete study activities while wearing a CDO with 1cm of heel distraction height
89659680|NCT06127316|Experimental|2cm Distraction|Participants will complete study activities while wearing a CDO with 2cm of heel distraction height
89659681|NCT06125769|Experimental|Study population|"Candidates will be evaluated by the Multidisciplinary Group after routine radiological studies (CT, MRI, PET-MRI/CT).~Patients will receive 6 months of standard of care chemotherapy and undergo PET-MRI with FDG to exclude the presence of extrahepatic disease.~Following completion of therapy, patients will undergo radiological restaging. If the disease is resectable, the patient will be considered for curative-intent surgical resection; if not, the patients will be evaluated by the Center's Multidisciplinary Transplantation Group. Patients will continue chemotherapy until a compatible liver becomes available. If there are no further contraindications, exploratory laparotomy and surgical nodal staging of the tumor will be performed at the time of transplantation. If there are no signs of extrahepatic disease, transplantation will be conducted according to institutional protocols."
89659682|NCT06124898|Experimental|"Moderate drinking technologies with lower tech facilitation"|"Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with lower tech facilitation."
89659683|NCT06124898|Experimental|"Moderate drinking technologies with higher tech facilitation"|"Brief motivational-interviewing-based counseling followed by use of three moderate drinking technologies (breath alcohol device and app, blood alcohol content estimator app and self-texting procedure) with higher tech facilitation"
89659684|NCT06124898|Active Comparator|Attention control condition|To be determined attention control condition, which will involve either non-personalized information about alcohol or feedback regarding another health behavior with minimal relationship to alcohol use, followed by related technology use.
89659685|NCT06121596|Experimental|Breathing Exercise with 40 Percent of the Spontaneous Breathing Frequency (A)|Participants are instructed (via visual pacer) to reduce their breathing frequency to 40 percent of their spontaneous breathing frequency for a period of five minutes. In advance, participants are instructed (via pre-recorded video) to breathe nasally (if possible) and abdominally, with a prolonged exhalation (inspiration-to-expiration ratio is 1-to-2 - also instructed via visual pacer) during the breathing exercise.
89659686|NCT06121596|Experimental|Breathing Exercise with 60 Percent of the Spontaneous Breathing Frequency (B)|Participants are instructed (via visual pacer) to reduce their breathing frequency to 60 percent of their spontaneous breathing frequency for a period of five minutes. In advance, participants are instructed (via pre-recorded video) to breathe nasally (if possible) and abdominally, with a prolonged exhalation (inspiration-to-expiration ratio is 1-to-2 - also instructed via visual pacer) during the breathing exercise.
89659687|NCT06121596|Experimental|Breathing Exercise with 80 Percent of the Spontaneous Breathing Frequency (C)|Participants are instructed (via visual pacer) to reduce their breathing frequency to 80 percent of their spontaneous breathing frequency for a period of five minutes. In advance, participants are instructed (via pre-recorded video) to breathe nasally (if possible) and abdominally, with a prolonged exhalation (inspiration-to-expiration ratio is 1-to-2 - also instructed via visual pacer) during the breathing exercise.
89659688|NCT06116669|Experimental|Pre-treatment group|Participants assigned to this group will receive 100 mg oral iron daily on study days 1-56.
89659689|NCT06116669|Experimental|Simultaneous treatment group|Participants assigned to this group will receive placebo daily on study days 1-28 and 100 mg oral iron daily on study days 29-56.
89659690|NCT06116669|Placebo Comparator|Control group|Participants assigned to this group will receive placebo daily on study days 1-56.
89659691|NCT06115135|Experimental|open-label|"This is a Phase 2, multicenter, open-label study evaluating the safety and efficacy of venetoclax in combination with isatuximab and dexamethasone among RRMM patients who show the t(11;14) marker and currently show PD and have received at least 3 prior lines of therapy for multiple myeloma. All subjects in Dose Level 0 will receive 1) venetoclax, PO, at 400 mg every day (QD) on Days 1-28 of a 28-day cycle, 2) dexamethasone 40 mg IV, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle where day 8 and 22 doses may be administered PO; and 3) isatuximab 10mg/kg, IV, on Days 1, 8, 15, and 22 of the first 28-day cycle, and then Days 1 and 15 during subsequent 28-day cycles.~The primary safety analysis will focus on determining the DLTs for the study regimen, and occurrence of AEs throughout the study."
89659692|NCT06100952|Experimental|Active Treatment|Epithelium-on corneal cross-linking
88994688|NCT02929147|Active Comparator|Dexketoprofen & Placebo|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
88994689|NCT02929264|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
88994690|NCT02929264|Placebo Comparator|Placebo|Placebo, capsules, single dose
88994691|NCT02929264|No Intervention|Control|No Intervention
88994692|NCT02929186|Experimental|Opt-In|Opt-In Outreach
89659693|NCT06100952|Placebo Comparator|Control Treatment|Placebo and sham for epithelium-on corneal cross-linking
89659694|NCT06100939|Experimental|Active Treatment|Epithelium-on corneal cross-linking
89659695|NCT06100939|Placebo Comparator|Control Treatment|Placebo and sham for epithelium-on corneal cross-linking
89688632|NCT00374062|Experimental|II|relaxation tape 2
89688633|NCT00374062|Placebo Comparator|III|relaxation tape 3
88994693|NCT02929186|Experimental|Opt-Out|Opt-Out Outreach
88994694|NCT00175890|Placebo Comparator|Placebo|Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
88994695|NCT00175890|Experimental|Levetiractem|10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
88994696|NCT02929030||NANO Plus SES|All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.
89659696|NCT06098547|Experimental|Study population|"Candidates will be evaluated by theMultidisciplinary Group after routine radiological studies (CT, MRI, PET-MR/CT).~Patients will receive 6 months of standard of care chemotherapy and undergo PET-MR with FDG to exclude the presence of extrahepatic disease.~Following completion of therapy, patients will undergo radiological restaging. If the disease is resectable, the patient will be considered for curative-intent surgical resection; if not, the patients will be evaluated by the Center's Multidisciplinary Transplantation Group.~Patients will continue chemotherapy until a compatible liver becomes available. If there are no further contraindications, exploratory laparotomy and surgical nodal staging of the tumor will be performed at the time of transplantation. If there are no signs of extrahepatic disease, transplantation will be conducted according to institutional protocols."
89659697|NCT06090110|Active Comparator|Intervention|transcutaneous auricular vagal nerve stimulation, for 8 weeks at least one hour a day
89659698|NCT06090110|Placebo Comparator|placebo|sham stimulation with a non-conducting electrode, for 8 weeks at least one hour a day
89659699|NCT06089265|Experimental|HFI patients|HFI participants will receive PF-06835919 for 9 days. Dosage; once daily 300 mg PF-06835919 in the form of 3 tablets, oral.
89659700|NCT06089265|No Intervention|Healthy controls|Healthy controls will receive no intervention, but a single fructose tolerance test.
89659701|NCT06089070|No Intervention|Control|Participants will not have access to view the data from the CGM sensor during the screening period, nor during the main part of the study.
89659702|NCT06089070|Experimental|Intervention|Participants will wear the CGM sensor and have access to the data during the main part of the study.
89659703|NCT06088342||study subjects|In this study, participants will participate in the study after reading and approving the informed consent form. Volunteers participating in the study will first fill out the demographic information form. Then, the volunteers will be administered the Tampa Kinesiophobia Scale, Timed Up and Go Test, Trunk Impairment Scale, and Tinetti Fall Effectiveness Scale. This study is a correlation study. Individuals' Tampa Kinesiophobia Scale results will be analyzed and interpreted with other scale results.
89659704|NCT06075316|Other|ePRO monitoring|Thoracic surgery patients will be enrolled in ePRO monitoring using web-based or telephone surveys.
89659705|NCT06067347||Massachusetts General Hospital, Boston, USA|Participating investigators at various institutions will perform weekly review of their new patients with PTCL (newly diagnosed or relapsed/refractory) on the outpatient and inpatient clinical services with their clinical research teams to identify potential subjects for enrollment based on the above inclusion/exclusion criteria. Expected enrollment is anticipated to be up to 30 patients per site per year.
89659706|NCT06065657|Experimental|Ketogenic diet|Eat a ketogenic diet for 3 days
89659707|NCT06065657|Placebo Comparator|Control Diet|Eat a control diet for 3 days
89659708|NCT06065657|Experimental|Ketone supplement|Eat a control diet for 3 days with a ketone supplement drink
89659709|NCT06065657|Experimental|Alcohol Intervention|Alcohol lab, participants will receive ethanol drinks that are dose-adjusted for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
89659710|NCT06064253|Other|intervention group|health education program explaining the nature of the condition(KOA causes, pathological changes, and natural course of the disease), we explained the recommendations for the treatment of KOA, teaching the patient a home exercise program of 5 exercises (targeting knee extensor and hip muscle ), selection of a physiotherapy program suitable to the patient clinical condition, recommendations to increase daily physical activity ( e.g. brisk walking) with joint protection measures along with a weight reduction regimen proposed in overweight and obese patients and prescribing a suitable pharmacological treatment to the patients
89659711|NCT06064253|No Intervention|control group|were assigned the traditional approach for KOA management, they were told their diagnosis if they were not already familiar with it, received the treatment for KOA according to ACR guidelines, they were offered physical therapy modalities if their condition required but they were not given the health education program or the other interventional steps.
89659712|NCT06062329|Experimental|Symphony Thrombectomy system|Mechanical thrombectomy using the Symphony Thrombectomy system for the treatment of acute pulmonary embolism.
89659713|NCT06058195||Group QLB (quadratus lumborum plane block)|"Group QLB (quadratus lumborum plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.~- Plane block applications will be applied only once in the preoperative period"
89659714|NCT06058195||Group TAPB (transverse abdominis plane block)|Group TAPB (transverse abdominis plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
89659715|NCT06058195||Group IVA (Intravenous analgesia)|Group IVA (Intravenous analgesia): These patients will be administered 1000 mg paracetamol intravenously in the preoperative waiting room in the operating room approximately 20-30 minutes before induction of anaesthesia. No block procedure will be performed. Patients will not be given any analgesic medication before awakening from anaesthesia.
89659716|NCT06055790|Experimental|18F-Fluciclovine (Axumin) PET/CT|Patients with recently diagnosed brain metastatic lesion(s) will be recruited based on MRI with or without histological confirmation, per standard of care. All patients will undergo an 18F-fluciclovine head PET/CT scan prior to treatment for brain metastatic lesions, post treatment, and 3 years post treatment.
89659717|NCT06046690|Experimental|MV Modification Group|Participant in this group will be applied inspiratory muscle training with trigger system modification in addition to conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization, twice a day until the day of extubation.
89659718|NCT06046690|Experimental|External Device Group|Participant in this group will be applied inspiratory muscle training with Inspiratory Muscle Training (IMT) device in addition to conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization, twice a day until the day of extubation.
89659719|NCT06041607|Experimental|Shared meditation|"Shared meditation: mixed groups of patients, carers and third parties"
89659720|NCT06041607|Active Comparator|"Meditation patients"|groups of patients only
89659721|NCT06039995|Experimental|(Adjuvant Oral Care) Intervention Group|This group represents the intervention arm of the study. Patients in this arm receive a combination of interventions, including Chlorhexidine mouthwash, toothbrushing, and the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This group is the focus of the study's investigation to determine the effectiveness of adjuvant oral care in reducing the incidence of Ventilator-Associated Pneumonia (VAP) and improving patient outcomes.
89659722|NCT06039995|Active Comparator|(Traditional Oral Care) Control Group|This group represents the control arm of the study. Patients in this arm receive traditional oral care, which involves the use of 0.2% Chlorhexidine mouthwash only.
89659723|NCT06035094|Experimental|High Intensity Interval Training (HIIT) exercise group,|Participants will be asked to exercise independently 4 days/week for 10 weeks, following a high intensity interval training (HIIT) protocol.
89659724|NCT06035094|Experimental|Moderate Intensity Training (MIT) exercise group|Participants will be asked to exercise independently 4 days/week for 10 weeks, following a moderate intensity training (MIT) protocol.
89659725|NCT06035094|Active Comparator|Control exercise group|Participants will be advised to follow the American Heart Association (AHA) guidelines on exercise.
89659726|NCT06027268|Experimental|Trilaciclib, Pembrolizumab, Gemcitabine, and Carboplatin|Trilaciclib is an agent that helps protect the bone marrow from the side effects of chemotherapy. It is given as an intravenous (IV) infusion over 30 minutes prior to gemcitabine and carboplatin. Gemcitabine is given IV over 30 minutes. Carboplatin is given over 30 minutes. Trilaciclib, gemcitabine and carboplatin are given on Days 1 and 8 every 21 days. Pembrolizumab is given IV over 30 minutes on Day 1 every 21 days.
89659727|NCT06021925||Blood donors tested for anti-HLA Antibody|Blood donors tested for anti-HLA Antibody between 2010 and 2020 as part of TRALI prevention program.
89659728|NCT06017258|Experimental|Dose Level 1|Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
89659729|NCT06017258|Experimental|Dose Level 2|Participants with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
89659730|NCT06000722||Healthcare practitioners|Participants who are trained healthcare practitioners involved in the care of patients with current or previous diabetic foot ulcer disease
89659731|NCT05997550|Active Comparator|Pursed Lip Breathing Exercise Group|During the first interview, the training and demonstration of pursed lip breathing exercise is performed by the thesis student in a single session. After this information session, the pursed lip breathing exercise taught from the patients; They are asked to do it in their own homes, 3 days a week on Monday, Wednesday and Friday, for about 30 minutes each session, for a total of eight weeks. In addition, one day a week (on a day determined by the patient, Monday, Wednesday or Friday), the thesis student makes a video call to the patient on WhatsApp, and the practice of pursed lip breathing exercise is performed during the video call.
89659732|NCT05997550|Active Comparator|Laughter Therapy Group|During the first interview, laughter therapy training and demonstration is carried out by the thesis student in a single session. After this information session, the laughter therapy taught from the patients; They are asked to do this in their own homes, 3 days a week on Monday, Wednesday and Friday, 30 minutes each session, for a total of eight weeks. . In addition, once a week (on a day determined by the patient, Monday, Wednesday or Friday), the thesis student makes a video call to the patient on WhatsApp, and laughter therapy is practiced during the video call.
89659733|NCT05997550|Placebo Comparator|Control Group|"Attention-match training is given to the patients in the control group. During the first interview, attention matching training is carried out by the thesis student for one time, about Lung structure and functioning, lasting approximately 20 minutes. In addition, a brochure about lung structure and functioning is given to patients. The patients in the control group are not subjected to any other interventions throughout the study."
89659734|NCT05996835|Experimental|TIN816 Dose A|Administered as a one time intravenous dose
89659735|NCT05996835|Experimental|TIN816 Dose B|Administered as a one time intravenous dose
89659736|NCT05996835|Experimental|TIN816 Dose C|Administered as a one time intravenous dose
89659737|NCT05996835|Placebo Comparator|Placebo|0.9% sterile saline administered as a one time intravenous dose
89659738|NCT05994664|Experimental|Intervention|Group of up to 20 patients will be randomly allocated into an experimental group at a 1:1 ratio intervention to controls. The experimental group will receive all of the preliminary outcome screening with the additional 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
89659739|NCT05994664|Placebo Comparator|Control|Group of up to 20 patients will be randomly allocated into a control group at a 1:1 ratio for intervention to controls. The control group will receive all of the preliminary outcome screening and will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
89659740|NCT05991414|Experimental|Pharmacist care in conjunction with home blood pressure monitoring|Patients will have BP assessed at baseline in the pharmacy by the pharmacist, and they will receive a home blood pressure monitor in addition to education and counselling provided by the pharmacist. Patients will measure their BP at home for seven days every four weeks and input their results into a data management system called REDCap that is accessible by the pharmacist. The pharmacist will follow up with the patient every 4 weeks to review their readings and at 24-weeks the patient will come into the pharmacy for a final follow-up and BP readings. The pharmacist will fax BP readings as well as suggestions for therapy modification to the patient's prescribing clinician. Patients will then have their care returned to their prescribing clinician with no pharmacist specific interventions outside of usual pharmacy care activities and have a single follow-up at month-12 with the pharmacist reviewing home BP monitor use and reporting of data to prescribing clinician.
89659741|NCT05991414|Active Comparator|Usual pharmacist care|Patients will have BP assessed at baseline, 12-, and 24-weeks in the pharmacy by the pharmacist. Patients will not receive a home blood pressure monitor. Pharmacist will provide them usual care, education and counselling on BP management. Pharmacists will fax BP readings to the patient's prescribing clinician but will not provide any suggestions for therapy modification. After 24-weeks patients will be offered a home blood pressure monitor with education on its use. They will then be offered to crossover to the intervention group for the next 6-months or have their care returned to their prescribing clinician with no pharmacist specific interventions outside of usual pharmacy care activities and have a single follow-up at month-12 with the pharmacist reviewing home BP monitor use and reporting of data to prescribing clinician.
89659742|NCT05989347|Experimental|Dapagliflozin|All participants (with insulin resistance and Estrogen Receptor (ER)+HER2-negative or ER/Progesterone receptor (PR)/HER2-negative breast cancer) will receive current standard of care neoadjuvant chemotherapy as determined by the treating physician, plus dapagliflozin 10 mg orally taken daily throughout chemotherapy treatment.
89659743|NCT05987813|Experimental|FGID|Patients with a FGID
89659744|NCT05987813|Experimental|Non-FGID|Patients without a FGID
89047294|NCT05173259|Active Comparator|F-R/L-G15/G05/G25 or G25/G05/G15-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G05-G15-G25-G25-G15-G05).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G05-G25-G25-G05-G15). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
89047295|NCT05173259|Active Comparator|F-R/L-G15/G25/G05 or G05/G25/G15-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G25-G05-G05-G25-G15).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G15-G25-G05-G05-G25-G15). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
89659745|NCT05987137||Households|Interviews conducted with the parent or guardian of a child or children under age 13.
89659746|NCT05987137||Home-based providers|Interviews conducted with individuals who provide care in a home-based setting to children under age 13 who are not their own for five or more hours a week.
89659747|NCT05987137||Center-based Providers|Interviews conducted with directors of early care and educations programs that provide care to children not yet in kindergarten.
89659748|NCT05987137||Workforce (Classroom Staff)|Interviews conducted with classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
89659749|NCT05985343|Other|Neostigmine/Glycopyrrolate|Patients assigned to the control arm receive the standardized reversal neostigmine dose with on-label dosing (0.03-0.07mg/kg) and a fixed ratio of glycopyrrolate
89659750|NCT05985343|Other|Sugammadex|Patients randomized to the experimental arm will receive an IV dose of sugammadex according to the package insert of 2 mg/kg for ≥ 2 twitches, 4 mg/kg for 1-2 post-tetanic twitches
89047296|NCT05173259|Active Comparator|F-R/L-G25/G05/G15 or G15/G05/G25-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G05-G15-G15-G05-G25).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G05-G15-G15-G05-G25). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
89659751|NCT05983809|Experimental|Experimental Group (HO, Hunova-Observation)|Patients in the HO group will undergo a specific rehabilitation treatment for balance disorders using the robotic platform Hunova® Movendo Technology srl, Genova, IT), for 4 weeks, 3 times a week for 45 minutes each. In particular, the technological rehabilitation carried out with the platform will have as main objective the improvement of balance, both in sitting and standing position, and static and dynamic exercises, dual-task exercises and exercises to improve trunk control will be proposed. Afterwards, patients will undergo 4 weeks of observation without rehabilitation treatment.
89659752|NCT05983809|Active Comparator|Control Group (OH, Observation-Hunova)|Patients in the OH group will undergo 4 weeks of observation without rehabilitation treatment, followed by specific rehabilitation treatment for balance disorders using the robotic platform Hunova® Movendo Technology srl, Genova, IT), for 4 weeks, 3 times a week for 45 minutes each. In particular, the technological rehabilitation carried out with the platform will have as main objective the improvement of balance, both in sitting and standing position, and static and dynamic exercises, dual-task exercises and exercises to improve trunk control will be proposed.
89659753|NCT05977179|Experimental|Dietary intervention to mitigate Post-Acute COVID-19 Syndrome|During the intervention, participants will receive an individual dietary plan from a Registered Dietitian (RD) that emphasizes nutrients with high anti-inflammatory activity, which can be obtained from various foods and supplements (e.g., vitamin D, omega-3, and quality protein). Additionally, participants will actively participate in weekly dietary sessions that cover topics from 'What's On Your Plate?', specifically tailored to address the nutrition recommendations for older adults in the Dietary Guidelines for Americans 2020-2025.
89659754|NCT05977179|Other|Attention Control|Participants in the control group will receive an equal amount of social attention, in terms of both dose and duration, comparable to that provided in the intervention group. Topics covered during these sessions will focus on healthy aging, including oral health, hearing loss, eyesight, and ensuring a safe environment by addressing issues such as gas leaks, fire hazards, and fall prevention. No dietary information will be included in these discussions.
89659755|NCT05973032||MRD positive and MRD negative groups|"MRD postive: NGS-MRD>=0.01% at the end of induction or >=0.0001% at the end of consoidation.~MRD negative: NGS-MRD<0.01% at the end of induction or <0.0001% at the end of consoidation."
89659756|NCT05968833|Experimental|iParent2Parent Program|
89659757|NCT05968833|No Intervention|Standard of Care Waitlist Control Group|
89659758|NCT05968807|Experimental|iParent2Parent Program|
89659759|NCT05968807|No Intervention|Standard of Care Waitlist Control Group|
89659760|NCT05968300|Experimental|INFORMED-Living Well|INFORMED-Living Well consists of two components: 1) LHW outreach support providing responsive education and support; and 2) a 6-week automated SMS text messaging. The LHW educational outreach component includes 2 small group educational sessions with 2-8 participants. Participants will also receive a weekly SMS Text or instant message on managing emotional wellness within and beyond the context of the COVID-19 pandemic over 6 weeks. In addition, participants will receive as-needed messages on updates of COVID-19 or other situations that may introduce new worries and tragic culturally-based traumatic events.
89659761|NCT05968300|Active Comparator|Text Messaging Only|Participants will have a 6-week SMS text messaging program identical to that received by the INFORMED-Living Well participants.
89659762|NCT05967572|Experimental|Experiment 1 (Rainstick)|The experimental group will start playing music 3 minutes before the start of the process. The examination begins with the insertion of the speculum into the eye. The duration of the examination depends on the visibility of the vascularity in the retina and the examination will end with the removal of the speculum from the eye. The rain bar will continue to play during the ROP inspection. The rain stick will be played 25cm away from the baby.
89659763|NCT05967572|Experimental|Experiment 2 (Music-The Happiest Baby)|"During the ROP examination, Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, is a group of babies who are listened to. The experimental group will start playing music 3 minutes before the start of the process. The examination begins with the insertion of the speculum into the eye. The duration of the examination depends on the visibility of the vascularity in the retina and the examination will end with the removal of the speculum from the eye. Music will continue to play during the ROP exam. The voice recorder that will play The Happiest Baby will be placed 25 cm away from the baby. In the study, the music volume will be set as 45-50 decibels."
89659764|NCT05967572|No Intervention|Control|It is the group of infants who receive routine care during the ROP examination. In the control group, a routine ROP procedure will be performed without any music before, during and after the ROP examination.
89659765|NCT05963659|Experimental|Group N|
89047297|NCT05173259|Active Comparator|F-R/L-G25/G15/G05 or G05/G15/G25-F-L/R Sequence|"First, 2 freestyle masticatory assays (F). Second, 2 only-right (R) and 2 only-left (L) masticatory assays in the following order (R-L-L-R). Third, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G15-G05-G05-G15-G25).~Or~First, 6 masticatory assays changing in 5% (G05), 15% (G15) or 25% (G25) in the following order (G25-G15-G05-G05-G15-G25). Second, 2 only-left (L) and 2 only-right (R) masticatory assays in the following order (L-R-R-L). Third, 2 freestyle masticatory assays (F)."
89047298|NCT02741544||Patients with newly-diagnosed multiple myeloma (NDMM)|Patients with newly-diagnosed multiple myeloma (NDMM) who are treated with Revlimid Capsules (Revlimid)
89047299|NCT00557388|Experimental|1|Young men 18-30 years, BMI < 27 kg/m2
89047300|NCT00557388|Experimental|2|Young men 18-30 years, BMI < 27 kg/m2
89047301|NCT00557388|Experimental|3|Old men 70-85 years, BMI < 27 kg/m2
89047302|NCT00557388|Experimental|4|Old men 70-85 years, BMI < 27 kg/m2
89047303|NCT00557388|Experimental|5|Old men 70-85 years, BMI < 27 kg/m2
89047304|NCT00557388|Experimental|6|Old men 70-85 years, BMI < 27 kg/m2
89047305|NCT00557388|Experimental|7|Old men 70-85 years, BMI < 27 kg/m2
89047306|NCT00557388|Experimental|8|Old men 70-85 years, BMI < 27 kg/m2
89047307|NCT00557388|Experimental|9|Old men 70-85 years, BMI < 27 kg/m2
89047308|NCT00557388|Experimental|10|Old men 70-85 years, BMI < 27 kg/m2
89047309|NCT05161208|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
89047310|NCT05161208|Placebo Comparator|Placebo (vehicle) nasal spray|Intranasal delivery of placebo vehicle nasal spray twice daily (BID)
89047311|NCT00538070|Placebo Comparator|Placebo|You will receive two grams of placebo per day. You will take two 500 mg placebo capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
89047312|NCT00538070|Experimental|Sarcosine|You will receive two grams of sarcosine per day. You will take two 500 mg capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
89047313|NCT04662021|Experimental|Exercise group|
89047314|NCT04662021|Experimental|Cognitive therapy group|
89047315|NCT04661904|Experimental|cTBS group|Patients randomly assigned to cTBS group will receive 12 sessions cTBS for total four days after surgery.
89047316|NCT04661904|Sham Comparator|sham group|Patients randomly assigned to sham group will receive 12 sessions sham stimulation for total four days after surgery.
89047317|NCT04661865|Other|Control group|Routine care only They will receive routine antenatal care that included iron supplementation with follow up of hemoglobin level
89047318|NCT04661865|Experimental|Intervention group|They will receive the Heath Information Package Program (HIP program)
89047319|NCT04661553|Experimental|Group1: patients with a low risk of premature birth|Asymptomatic patient receiving usual follow-up in the maternity ward.
89047320|NCT04661553|Experimental|Group2: patients with a high risk of premature birth|Symptomatic patients with cervical changes objectified by endovaginal ultrasound of the cervix with length <20mm. Asymptomatic patients with a history of premature delivery or late miscarriage and cervical changes objectified by endovaginal ultrasound of the cervix with length <20mm.
89047321|NCT05134025|Experimental|SMART A1|A full dose of meal-time insulin with announced exercise immediately prior to commencement
89047322|NCT05134025|Experimental|SMART A2|a 25% dose reduction in meal-time insulin with exercise announcement 90-minutes prior to commencement
89047323|NCT05134025|Experimental|SMART A3|a 25% dose reduction in meal-time insulin with exercise announcement 45-minutes prior to commencement
89213554|NCT04038866|Active Comparator|SINGLE-TASK|"Patients with Parkinson's disease who carry out the rehabilitation gait without a dual-task program (physical and walking exercises without additional load of cognitive or upper limb motor tasks).~Each training session consisted of three parts: initial warm-up, physical exercise in single-task condition, and back-to-calm.~The objectives and walking exercises were the same as those performed in the experimental group."
89213555|NCT00529659|Experimental|MK-0773|MK-0773
89659766|NCT05963659|Placebo Comparator|Group P|
89659767|NCT05963516|Active Comparator|Real-time Guidance|The LIVEBORN app will provide audio-visual guidance to the birth attendant during a resuscitation based on the data inputted by an observer as well as heart rate data from NeoBeat (if used).
89659768|NCT05963516|Active Comparator|Debriefing|The LIVEBORN app will support birth attendants in debriefing following a resuscitation based on the data inputted by an observer as well as heart rate data from NeoBeat (if used).
89659769|NCT05955261|Experimental|Low Risk|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Cytabrine, Danunorubicin Hydrochloride, Gemtuzumab Ozogamicin, Etoposide, Mitoxantrone Hydrochloride, Gilteritinib"
89659770|NCT05955261|Experimental|Intermediate Risk|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Cytabrine, Danunorubicin Hydrochloride, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Etoposide, Idarubin Hydrochloride, Mitoxantrone Hydrochloride, Gilteritinib"
89659771|NCT05955261|Experimental|High Risk|"All eligible patients receive intervention according to the Detailed Description section with the following:~Venetoclax, Azacitidine, Cytabrine, Danunorubicin Hydrochloride, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Etoposide, Idarubin Hydrochloride, Gilteritinib"
89659772|NCT05954585|Active Comparator|Treatment as usual|Emergency department treatment as usual
89659773|NCT05954585|Experimental|Family Navigator|Follow provision provided by a Family Navigator for the length of the treatment or until youth attends community-based mental health care
89659774|NCT05950035|Experimental|Immediate Intervention|Will begin treatment within 2 weeks of randomization.
89659775|NCT05950035|Active Comparator|Delayed Intervention|Will be scheduled to begin treatment within 4-6 weeks of randomization.
89659776|NCT05948956|Experimental|Ketone Ester Beverage & Exercise|Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Juvenescence Cognitive Switch ™ and electrolyte solution diluted in water, before each of 5 1-hour sessions of aerobic exercise.
89659777|NCT05948956|Placebo Comparator|Electrolyte Beverage & Exercise|Participants will consume placebo electrolyte (EL) beverage, consisting of an electrolyte solution diluted in water, before each of 5 1-hour sessions of aerobic exercise
89659778|NCT05935605||LHD with no PH|Subjects with Left Heart Disease (LHD) and no Pulmonary Hypertension (PH; mean pulmonary artery (PA) pressure ≤20 mmHg) that are already referred for invasive hemodynamic assessment by right heart catheterization for clinical reasons will undergo transthoracic echocardiography and lung ultrasound.
89659779|NCT05935605||LHD with isolated PVH|Subjects with Left Heart Disease (LHD) and isolated Pulmonary Venous Hypertension (PVH; mean PA pressure>20 mmHg and PVR<3 WU) that are already referred for invasive hemodynamic assessment by right heart catheterization for clinical reasons will undergo transthoracic echocardiography and lung ultrasound.
89659780|NCT05935605||LHD with vasoactive PVD|Subjects with Left Heart Disease (LHD) and vasoactive Pulmonary Vascular Disease (PVD; mean PA pressure>20 mmHg and PVR≥3 WU with ≥20% reduction in PVR with inhaled nitric oxide) that are already referred for invasive hemodynamic assessment by right heart catheterization for clinical reasons will undergo transthoracic echocardiography and lung ultrasound.
89659781|NCT05935605||LHD with fixed PVD|Subjects with Left Heart Disease (LHD) and fixed Pulmonary Vascular Disease (PVD; mean PA pressure>20 mmHg, PVR≥3 WU, and PVR reduction of <20% with inhaled nitric oxide) that are already referred for invasive hemodynamic assessment by right heart catheterization for clinical reasons will undergo transthoracic echocardiography and lung ultrasound.
89047324|NCT04661670|Active Comparator|occlusal stabilization splints equilibrated by articulating paper|In this group the final occlusal correction will be performed with the patient in supine position using 20 um thick articulating paper and articulating foil 8 um thick. The patient will be asked to tap 3 times on the articulating paper and occlusal correction will be done using carbide laboratory bur and rubber cone till uniform contact on all teeth is achieved in centric relation which is illustrated on the splint by a series of uniformly appearing articulating paper dots. Then the patient will be asked to make protrusive and right and left excursions to ensure smooth anterior guidance and posterior disocclusion.
89213556|NCT00529659|Placebo Comparator|Placebo|Placebo
89659782|NCT05935475|Active Comparator|group A|75 children and adolescent will insert dialysis catheter using the anatomical landmark technique
89659783|NCT05935475|Active Comparator|group B|75 children and adolescent will insert dialysis catheter using the ECG guided technique
89659784|NCT05926570|Experimental|35 children and adolescents with end stage renal disease on regular hemodialysis|All children will receive cinacalcet in a dose of 30 mg/day taken with food for 3 months
89659785|NCT05919537|Experimental|Arm A|Participants with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring NRG1 gene fusions
89659786|NCT05919537|Experimental|Arm B|Participants with non-small cell lung cancer (NSCLC) harboring NRG1 gene fusions
89659787|NCT05919537|Experimental|Arm C|Participants with other solid tumors harboring NRG1 gene fusions
89659788|NCT05919537|Experimental|Arm D|Participants with solid tumors harboring selected HER3 extracellular mutations
89659789|NCT05908045||Physical Therapists|"Physical Therapists currently working in a clinical setting.~Group Participants (Inclusion/Exclusion Criteria)~Inclusion Criteria:~Must be a licensed Physical Therapist~Must be actively be involved in clinical practice~Must have ≥ 5 years of experience practicing in a clinical setting as a Physical Therapist~Exclusion Criteria:~(1) Did not provide informed consent~The survey will be disseminated across the American Physical Therapy Association (APTA) email lists. Further potential candidates may be identified through existing professional networks, clinical settings, and social medial/internet-based searching."
89659790|NCT05907044|Active Comparator|RQ3013|C-3013B-202211005, Alpha/Beta, mRNA 30μg dose
89659791|NCT05907044|Experimental|RQ3025|INDA-3025TB-20221002, Alpha/Beta + Omicron BA.2/4/5, mRNA 30μg dose
89659792|NCT05907044|Experimental|RQ3027|IND-3027TB-202304001, Alpha/Beta + Omicron XBB.1.5, mRNA 30μg dose
89659793|NCT05898139||Assisting (caregiver) / aided (patient with Parkinsonian syndrome) dyad|The dyad will be filmed during a meal had during a hospitalization, and an interview with the sick person and his caregiver will be carried out independently. Between 15 days and a month after the first visit, excerpts from the film will be presented and commented by the dyad according to the technique of self-confrontation
89659794|NCT05889780|Active Comparator|Pantry only|Referrals to onsite food pantry or emergency food boxes from partner pantry if onsite pantry is not open by 2024.
89659795|NCT05889780|Experimental|Nutritious, no-prep meals|Participants will receive up to 12 nutritious no-prep meals per month (three meals per week) for three-months.
89659796|NCT05889780|Experimental|Vouchers|Participants will receive $75 vouchers each month for three-months.
89659797|NCT05877729|Active Comparator|Standard of Care Arm|The Standard of Care (SOC) arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression) . At each assessment, the investigators will review participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, researchers will also do monthly check-ins to improve retention and check contact information.
89659798|NCT05877729|Experimental|Intervention Arm: Video-Counseling+app|The video-counseling+app arm will receive 12 brief weekly counseling sessions (given over 16 weeks) with a social worker, along with access to the WYZ app to use based on their needs. After 16 weeks, participants receive another assessment and based on VL, those in the video-counseling+app arm will be categorized as intervention responders or non-responders (responder= virologically suppressed; non-responder= virologically unsuppressed. Responders in video-counseling+app arm will continue to use the app only. Non-responders in the intervention arm will continue with intensified video-counseling+app for 16 more weeks.
89659799|NCT05874193|Experimental|Treatment every 6 weeks|Treatment every 6 weeks
89659800|NCT05860933|Experimental|LY3537982 + Itraconazole (Part 1)|LY3537982 administered orally alone followed by LY3537982 administered in combination with itraconazole orally.
89659801|NCT05860933|Experimental|LY3537982 + Carbamazepine (Part 2)|LY3537982 administered orally alone followed by LY3537982 administered in combination with carbamazepine orally.
89659802|NCT05846620||Women|
89659803|NCT05846620||Men|
89659804|NCT05840939|Experimental|pranayama|At the beginning, each patient in this group was shown one-on-one by the researcher and taught by applying them together, taking into account the application steps, how to practice pranayama. In the next step, the patients were asked to do this application themselves. Sleep quality, pain and fatigue levels of the patients were determined after 6 weeks.
89659805|NCT05840939|Experimental|diaphragm breathing exercise group|At the beginning, the patients in this group were shown how to do the diaphragm breathing exercise and how to do the diaphragm breathing exercise, taking into account the application steps, each patient was shown individually by the researcher and taught by applying them together. In the next step, the patients were asked to do this application themselves. Sleep quality, pain and fatigue levels of the patients were determined after 6 weeks.
89659806|NCT05840939|No Intervention|control group|It is the group where no application has been made.
89659807|NCT05838885|Experimental|YPEG-GH low dose group|
89659808|NCT05838885|Experimental|YPEG-GH high dose group|
89659809|NCT05838885|Active Comparator|rhGH low dose group|
89659810|NCT05838885|Active Comparator|rhGH high dose group|
89213557|NCT03842306||Study Cohort|Patients undergoing rapid sequence intubation in the emergency department for which end tidal oxygen was monitored.
89659811|NCT05819788||FFP|Patients undergoing CPB receiving FFP
89659812|NCT05819788||no FFP|Patients undergoing CPB not receiving FFP
89659813|NCT05819346|Experimental|Digital lifestyle intervention|Self-management mobile application covering physical activity, nutrition, and breathing/relaxation
89213558|NCT05726565||LNNB-S >=10|As one of the core components of multidisciplinary CR, psychiatrist and psychologist consultation was delivered to all patients. Cognitive function was assessed with the Luria-Nebraska Neuropsychological Battery-Screening test (LNNB-S) Chinese version by an experienced psychologist. The evaluation would be completed during admission. The initial LNNB was condensed to fifteen items for the screen test by Golden. LNNB-S Chinese version focuses on 3 domains, including number calculation, cognitive function, and rhythm control. In our participants' cohort, investigators choose LNNB-S >=10 as a cutoff point. That is, participants may have cognitive impairment when their LNNB-S >=10.
89659814|NCT05819346|No Intervention|Control|Usual care (study participation does not interfere with or change any other planned treatments)
89659815|NCT05809323|Experimental|Exercise Intervention Group|Group of up to 50 patients will randomly allocated into an experimental group at a 4:1 ratio intervention to controls. The experimental group will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
89659816|NCT05809323|Other|Control Group|Control group will be randomly allocated at a 4:1 ratio, intervention to controls.. The control group will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) and will be instructed to continue with baseline physical activities. They will be asked to return for a reassessment of all baseline procedures (cardiovascular, musculoskeletal, and psychological screening).
89659817|NCT05804669|Experimental|Multiple Ascending Doses|Sequential, open-label, 10-day fixed-dose cohorts.
89659818|NCT05767073|Experimental|Intervention|Lifestyle intervention
89659819|NCT05757167|Experimental|HS-RDT screening/AL treatment|Pregnant women will be screened with a malaria HS-RDT and, if positive, treated with artemether-lumefantrine
89659820|NCT05757167|No Intervention|Usual antenatal care|Pregnant women will receive usual antenatal care
89659821|NCT05754775|Experimental|Low-calorie diet|Korean low-calorie diet for type 2 diabetes
89659822|NCT05752097||Renal inflammatory or fibrotic disease|[18F]AIF-NOTA-FAPI-04 (4.81MBq/Kg) will be injected intravenously according to the patient's body weight. PET/CT examination will be performed 50-60 minutes after the injection of radiotracer. The patients will undergo renal puncture biopsy one day after PET/CT examination.
89659823|NCT05748834|Experimental|Tucatinib Experimental Treatment Arm|Participants will receive tucatinib 300mg by mouth twice daily continuously in combination with Doxil 40mg/m2 given intravenously on day 1 of each cycle. Cycles will be 28 days. Up to 36 participants will be enrolled in this Phase 2 study.
89659824|NCT05746429|Experimental|Arm I (mobile CBT + active tDCS)|Participants receive mobile CBT and undergo active tDCS to the dorsolateral prefrontal cortex (DLPFC) over 20 minutes twice a week for 6 weeks.
89047325|NCT04661670|Active Comparator|occlusal stabilization splints equilibrated by T-scan|"In this group the same adjustment sequence will be done using T Scan III (software version 8.0) computerized occlusal analysis, a new patient file will be opened, the patient's biological data will be entered, and the T Scan dental arch size is customized to fit the patients arch anatomy. The patient will be asked to clench to record occlusal force and areas that needs adjustment will be grinded using the paper marks as the guideline and carbide laboratory bur till bilateral force balance achieved and the center of force (COF) icon sits close to the midline.~Mandibular excursions are then adjusted in a similar fashion. Contacts rather than anterior and canine guidance will be eliminated till achieving anterior guidance and posterior disocclusion in time less than 0.5 seconds."
89047326|NCT02470884|Experimental|FAST|Subjects treated with the Boston Scientific Fully Absorbable Scaffold
89047327|NCT05114174|No Intervention|Usual care group|Pregnant women enrolled in the prenatal control program who receive routine medical care.
89047328|NCT05114174|Experimental|mami-educ group|Pregnant women enrolled in the prenatal care program who receive routine medical care and nutritional messages mom-educ.
89047329|NCT04661826|Experimental|Oncofid-P-B|Oncofid-P-B will be administered once a week for 6 weeks in the first treatment phase and once a month for 6 months followed by other 6 months in the second maintenance phase
89047330|NCT05110391||NOA_Treated|Hypogonadal patients with non-obstructive azoospermia who received gonadotropin therapy before sperm retrieval
89047331|NCT05110391||NOA_Untreated|Hypogonadal patients with non-obstructive azoospermia who did not receive gonadotropin therapy before sperm retrieval
89659825|NCT05746429|Sham Comparator|Arm II (mobile CBT + sham tDCS)|Participants receive mobile CBT and undergo sham tDCS to the DLPFC over 20 minutes twice a week for 6 weeks.
89659826|NCT05746429|Experimental|Interview|Participants attend virtual meetings and virtual focus groups during the cultural adaptation phase. Feedback is collected and analyzed to develop the finalized adaptation.
89659827|NCT05742984|Experimental|25 mg Linaprazan Glurate QD|25 mg ( one 25 mg oral tablet) Linaprazan Glurate QD for 14 days
89659828|NCT05742984|Experimental|50 mg Linaprazan Glurate QD|50 mg (two 25 mg oral tablets) Linaprazan Glurate QD for 14 days
89659829|NCT05742984|Experimental|75 mg Linaprazan Glurate QD|75 mg ( three 25 mg oral tablet) Linaprazan Glurate QD for 14 days
89659830|NCT05742984|Experimental|25 mg Linaprazan Glurate BID|25 mg ( one 25mg oral tablet) Linaprazan Glurate BID for 14 days
89659831|NCT05742984|Experimental|50 mg Linaprazan Glurate BID|50 mg ( two 25 mg oral tablets) Linaprazan Glurate BID for 14 days
89659832|NCT05742984|Experimental|75 mg Linaprazan Glurate BID|75 mg ( three 25 mg oral tablet) Linaprazan Glurate BID for 14 days
89659833|NCT05741333|Experimental|Solo+ Tympanostomy Tube Device (Solo+ TTD)|The Solo+ TTD is a disposable surgical tool designed to deliver a tympanostomy tube into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure.
89659834|NCT05733910|Experimental|carbon ion radiotherapy|simultaneous integrated boost with carbon ion radiotherapy
89659835|NCT05730257|Experimental|Robot-assisted Kidney Transplantation (RAKT)|"Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels.~Participants will be managed according to the standard protocol for renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality. The anaestethic protocol will be tailored to suit robot-assisted surgery"
89659836|NCT05730257|Active Comparator|Open Kidney Transplantation (OKT)|"Participants will undergo standard work-up prior to transplantation according to the KDIGO guidelines, in addition, participation in the study will require a non-contrast CT of the abdomen to exclude severe calcification of the iliac vessels.~Participants will be managed according to the standard protocol for anaesthesia and renal transplantation at Rigshospitalet and will follow standard pre-, peri- and post-operative care aside from operating modality."
89047332|NCT00538187|Experimental|Treatment (obatoclax mesylate, bortezomib)|Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
89047333|NCT04661709|Experimental|Wen Xin granule|Patients are given Wen Xin granule by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
89047334|NCT04661709|Placebo Comparator|WXG placebo|Patients are given Wen Xin granule placebo by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.
89047335|NCT02466867|Experimental|Naftin® Cream, 2% (younger pediatric cohort)|Subject aged 2 years to 5 years, 11 months with tinea corporis
89047336|NCT02466867|Experimental|Naftin® Cream, 2% (older pediatric cohort)|Subject aged 6 years to 11 years, 11 months with tinea corporis
89047337|NCT02462850|Experimental|CL-108|CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
89047338|NCT00538265|Active Comparator|A|tacrolimus + steroids
89047339|NCT00538265|Experimental|B|ATG+ tacrolimus without steroids in maintenance therapy
89047340|NCT00538265|Experimental|C|ATG+ Mycophenolate Mofetil + tacrolimus a reduced dosage without steroids in maintenance therapy
89659837|NCT05723575|Experimental|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
89659838|NCT05718921|Experimental|Part A, Active dose A and Low body surface area|The intervention is YR001 Dose A on low body surface area, low dose YR001 for single topical administration
89659839|NCT05718921|Experimental|Part A, Active dose A and Middle body surface area|The intervention is YR001 Dose A on middle body surface area, low dose for single topical administration
89659840|NCT05718921|Experimental|Part A, Active dose A and High body surface area|The intervention is YR001 Dose A on high body surface area, low dose for single topical administration
89659841|NCT05718921|Experimental|Part A, Active dose B and Low body surface area|The intervention is YR001 Dose B on low body surface area, high dose YR001 for single topical administration
89659842|NCT05718921|Experimental|Part A, Active dose B and Middle body surface area|The intervention is YR001 Dose B on middle body surface area, high dose YR001 for single topical administration
89659843|NCT05718921|Experimental|Part A, Active dose B and High body surface area|The intervention is YR001 Dose B on high body surface area, high dose YR001 for single topical administration
89659844|NCT05718921|Placebo Comparator|Part A, Placebo and Low body surface area|The intervention is Placebo on low body surface area, Placebo for single topical administration
89659845|NCT05718921|Placebo Comparator|Part A, Placebo and Middle body surface area|The intervention is Placebo on middle body surface area, Placebo for single topical administration
89659846|NCT05718921|Placebo Comparator|Part A, Placebo and High body surface area|The intervention is Placebo on high body surface area, Placebo for single topical administration
89659847|NCT05718921|Experimental|Part B, Active dose A and High body surface area|The intervention is YR001 Dose A on high body surface area twice daily, low dose YR001 for multiple topical administration
89659848|NCT05718921|Experimental|Part B, Active dose B and High body surface area|The intervention is YR001 Dose B on high body surface area twice daily, high dose YR001 for multiple topical administration
89659849|NCT05718921|Placebo Comparator|Part B, Placebo and High body surface area|The intervention is Placebo on high body surface area twice daily, Placebo for multiple topical administration
89659850|NCT05716334||Rituximab originator recipients|Patients aged ≥18 with a diagnosis of GPA or MPA treated with rituximab (RTX) originator for induction and/or maintenance.
89659851|NCT05716334||Rituximab biosimilar recipients|Patients aged ≥18 with a diagnosis of GPA or MPA treated with RTX biosimilars (e.g. Ruxience, Truxima, Riximyo, etc) for induction and/or maintenance.
89659852|NCT05710679|Experimental|Interventional|
89659853|NCT05706064||COVID-19 Infection|
89659854|NCT05703516||Capmatinib|Participants will be treated with capmatinib as per locally approved label
89659855|NCT05698316||Age related macular degeneration|Collection of both retrospective and prospective data collection in 3 visits.
89659856|NCT05696119|Experimental|I-PROTECT|I-PROTECT includes physical and psychological injury prevention information and training (i.e., the intervention) and tailored support to implement it specifically developed for Swedish community youth handball.
89659857|NCT05696119|Active Comparator|Control group|"Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material."
89659858|NCT05693246|Experimental|Glycopyrrolate|
89659859|NCT05693246|Placebo Comparator|Control|
89659860|NCT05673057|Experimental|Dose escalation|
89659861|NCT05673057|Experimental|Dose expansion|
89659862|NCT05667974|Experimental|PIKA Rabies|Receive 1 of the 3 lots of PIKA rabies vaccine via IM administration that 2-2-1 schedule with a double-dose injection on Day 0 and 3 and a single-dose injection on Day 7
89659863|NCT05667974|Active Comparator|Control|Receive ChiroRab via IM administration that the classic Essen 5-dose regimen 1-1-1-1-1 schedule on Days 0, 3, 7, 14 and 28
89659864|NCT05651607|Experimental|Cannabidiol (Epidyolex)|
89659865|NCT05639322|Active Comparator|Ketamine only|
89659866|NCT05639322|Active Comparator|Psychotherapy only|
89659867|NCT05639322|Experimental|Ketamine + Psychotherapy|
89659868|NCT05631353|Active Comparator|Group I: Patients will be treated by Carriere Motion Appliance using passive lingual arch .|Conventional mandibular anchorage During the first month, 1/4-inch heavy elastics will be used. In the following months, 3/16-inch heavy elastics will be used. The patients will be instructed to wear the elastics 24 hours per day, except during mealtimes, and to change them daily
89659869|NCT05631353|Active Comparator|Group II: Patients will be treated by Carriere Motion Appliance using direct mini-screw.|TADs mandibular anchorage. During the first month, 1/4-inch heavy elastics will be used. In the following months, 3/16-inch heavy elastics will be used. The patients will be instructed to wear the elastics 24 hours per day, except during mealtimes, and to change them daily
89659870|NCT05617820|Experimental|Estradiol vaginal inserts, 4 mcg|Estradiol vaginal inserts, 4 mcg. Insert vaginally once daily for 14 days.
89659871|NCT05617820|Active Comparator|IMVEXXY® (estradiol vaginal inserts) 4 mcg|IMVEXXY® (estradiol vaginal inserts) 4 mcg. Insert vaginally once for 14 days.
89659872|NCT05617820|Placebo Comparator|Placebo vaginal inserts|Placebo vaginal inserts. Insert vaginally once for 14 days.
89659873|NCT05616182||LARS ligament and bone prosthesis replacement was performed|To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
89659874|NCT05607056|Experimental|Probiotic|During the antibiotic dosing (from 5 to 10 days): 2 capsules once a day 2 hours before or 2 hours after antibiotic administration. 14 days following completion of antibiotic dosing: 1 capsule a day.
89659875|NCT05607056|Placebo Comparator|Placebo|During the antibiotic dosing (from 5 to 10 days): 2 capsules once a day 2 hours before or 2 hours after antibiotic administration. 14 days following completion of antibiotic dosing: 1 capsule a day.
89047341|NCT02462811|Experimental|CL-108|CL-108 hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
89659876|NCT05593445|Experimental|Ruxolitinib cream|Ruxolitinib 1.5% cream BID for 12 weeks followed by ruxolitinb 1.5% cream BID (or QD) for 12-weeks in an open-label extension.
89659877|NCT05593445|Placebo Comparator|Vehicle Cream|Vehicle cream BID for 12 weeks followed by ruxolitinb 1.5% cream BID (or QD) for 12-weeks in an open-label extension.
89659878|NCT05590585|Experimental|dupilumab|Adolescents and adults will receive 1 of 2 dose regimens based on age and body weight
89659879|NCT05583422|Experimental|Cases|This arm will be compiled of prospectively recruited cases for confirmatory testing based on their suspected genotype per Michigan Genomics Initiative and patients who have been retrospectively identified as any patient who had clinical genotype testing and had a variant that was their clinician used to guide the chemotherapy treatment. Prospective patients will undergo confirmatory genetic testing by a CLIA lab and those results will be provided to the patients clinical team at that time.
89659880|NCT05583422|No Intervention|Controls|This arm will be compiled of all retrospective patients where genetic information was not known prior to receiving treatment.
89047342|NCT02462811|Active Comparator|Active Comparator: Norco|Commercial product containing hydrocodone 7.5 mg, acetaminophen 325 mg
89047343|NCT02462811|Placebo Comparator|Placebo|CL-108 formulation without API
89047344|NCT00538382|Experimental|Case|Cases are defined as parasitemic pregnant women during the second trimester (22-26 weeks gestation) and the third trimester (32-36 weeks gestation).
89047345|NCT00538382|Active Comparator|Non-pregnant Control|Non-pregnant controls are defined as parasitemic non-pregnant women recruited from the same community as the cases.
89047346|NCT00538382|Active Comparator|Internal Control|Internal controls are defined as the same women(cases)at three months postpartum.
89047347|NCT00538421|Active Comparator|1|
89047348|NCT00538421|Active Comparator|2|
89047349|NCT04661475|Experimental|Dexmedetomidine adjunctive to ECT arm|
89047350|NCT04661475|Placebo Comparator|Normal Saline adjunctive to ECT arm|
89659881|NCT05579158|Experimental|Mobile application-supported both calorie restriction and time-restricted eating (mCR/TRE)|This arm receives wearable device and mobile application-supported nutritional counseling for four months. The nutritional counseling consists of both calorie restriction (500kcal below estimated energy requirement) and time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day).
89659882|NCT05579158|Active Comparator|Mobile application-supported calorie restriction (mCR)|This arm receives wearable device and mobile application-supported nutritional counseling for four months. The nutritional counseling consists of only calorie restriction (500kcal below estimated energy requirement).
89659883|NCT05579158|No Intervention|Calorie restriction (CR)|Standard of care. This arm receives a brief counseling of calorie restriction.
89659884|NCT05576077|Experimental|Breast Cancer|Patients with locally advanced or metastatic breast cancer that has failed or is intolerant to standard of care therapies. Includes, HER2+, HER 2-, TNBC.
89659885|NCT05576077|Experimental|Colorectal carcinoma|Patients with advanced, metastatic colorectal adenocarcinoma who have failed or are intolerant to at least one line of therapy that included either irinotecan or oxaliplatin.
89659886|NCT05576077|Experimental|Uveal Melanoma|Patients with advanced, metastatic uveal melanoma.
89659887|NCT05576077|Experimental|Cutaneous Melanoma|Patients with cutaneous melanoma who have experienced disease progression following a PD-1 or PD-L1 inhibitor.
89659888|NCT05576077|Experimental|Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer who have experienced disease progression following platinum containing chemotherapy and/or PD-1 or PD-L1 inhibitor.
89659889|NCT05576077|Experimental|Head and Neck Squamous Cell Carcinoma|"Patients with head and neck squamous cell carcinoma who have received no prior therapy for metastatic disease~Patients with head and neck squamous cell carcinoma who are PD-1/PD-L1 inhibitor naïve at the time of TIL harvest and will be treated with TBio-4101 at the time of progression, inadequate response or intolerance to the PD-1/PD-L1 inhibitor-based standard of care regimen given on study."
89659890|NCT05576025|Experimental|Period 1: Shivering intensity 1|During Arm 1 of the study participants will undergo the first cold exposure at either mild or moderate shivering intensity (depending on the randomisation).
89659891|NCT05576025|Experimental|Period 2: Shivering intensity 2|During Arm 2 of the study participants will undergo the second cold exposure at the alternative shivering intensity.
89659892|NCT05573035|Experimental|Experimental LYL845|Epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy
89659893|NCT05567016|Experimental|Active Case Detection using molecular testing (ACDm)|"Per standard of care, children will receive passive case detection (PCD) using rapid diagnostic test (RDT) if they present with fever.~Children will receive malaria active case detection (ACD) using RDT and qPCR (quantitative polymerase chain reaction) three times yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive."
89659894|NCT05567016|Experimental|Passive Case Detection using molecular testing (PCDm)|"Children who present with fever will receive PCD using RDT and qPCR with treatment using AL if RDT or qPCR positive.~Per standard of care, children will not receive malaria ACD."
89659895|NCT05567016|Active Comparator|Standard passive case detection (PCD)|"Per standard of care, children will receive PCD using RDT.~Per standard of care, children will not receive malaria ACD."
89659896|NCT05565482|Experimental|Standard Transition Services + Work Chat|This arm will receive services as usual plus the Work Chat intervention over a series of a few weeks. We estimate approximately 15-18 hours of training will occur.
89659897|NCT05565482|No Intervention|Standard Transition Services|This arm will receive services as usual.
89659898|NCT05554198|Experimental|Pilot Intervention|pre/post-test, mixed method study design with quantitative data collection at baseline and post-intervention and qualitative data collection once at post-intervention. Participants will have access to the Attend Behavior program for a full year, but intervention usage monitoring and study outcomes will be assessed until post-intervention (12-weeks post-baseline).
89659899|NCT05530044|Experimental|vaccine|Promotes COVID-19 vaccine uptake
89047351|NCT00554268|Experimental|PBI-05204|PBI-05204 starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle.
89047352|NCT00538499|Other|Fentanyl citrate|
89047353|NCT00538499|Experimental|bupivcaine hydrochloride|
89047354|NCT00538499|Other|videothoracoscopy|
89047355|NCT00554307||Indo|Infants that are treated with indomethacin
89047356|NCT00554307||Neo|Infants treated with neoprofen
89047357|NCT00554307||Control|Infants without PDA
89047358|NCT00538538|Active Comparator|A|Does not receive Gas bubble
89047359|NCT00538538|Active Comparator|B|Does receive gas bubble
89047360|NCT00554346|Active Comparator|1|Etoricoxib 90mg
89047361|NCT00554346|Placebo Comparator|2|placebo
89047362|NCT04661046|Experimental|TCM Syndrome Types|Traditional Chinese Medicine
89047363|NCT00538655|Experimental|modafinil|
89047364|NCT04661319|Experimental|video editing training group|"- inclusion criteria~trainees in general surgery~No experience of laparoscopic cholecystectomy~Less than 5 experiences of laparoscopic surgery~Uncomplicated symptomatic gallstone disease~The experimental group received video editing training"
89047365|NCT04661319|Experimental|traditional training group|"- inclusion criteria~trainees in general surgery~No experience of laparoscopic cholecystectomy~Less than 5 experiences of laparoscopic surgery~Uncomplicated symptomatic gallstone disease~The control group received tradtional training"
89659900|NCT05530044|Active Comparator|climate change|Promotes climate change activism
89659901|NCT05528978||Inner Engineering Intervention|The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.
89659902|NCT05523362|No Intervention|Blinded|During Phase 1 (10 days), the patient wears the Dexcom G6 Pro CGM in blinded mode and is unaware and unable to access the data. The patient performs standard care, self-monitoring with twice daily glucose checks using standard finger-sticks and a glucometer device. During this phase, the medical providers are also blinded to the CGM data and continue standard care without any specific intervention.
89659903|NCT05523362|Experimental|Unblinded|During Phase 2 (3 months), the patient wears the Dexcom G6 Personal CGM in un-blinded mode and the medical providers have access to the data via Clarity and/or direct download via the transmitter. CGM data are collected continuously in each phase and at the end of each phase.
89659904|NCT05506449|Active Comparator|Control Arm|Subjects randomized to the Control Arm will be treated based on recommendations for cardiogenic shock in the contemporary AHA/ACC/SCAI and ESC Practice Guidelines for STEMI and Heart Failure Management and local standard of care.
89659905|NCT05506449|Experimental|Treatment Arm|Subjects randomized to the Treatment Arm will receive hemodynamic support using an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI).
89659906|NCT05506423||CycloPen Cyclodialysis System in conjunction with cataract surgery|Ophthalmic surgical intervention with the CycloPen Cyclodialysis System in conjunction with cataract surgery
89659907|NCT05506423||CycloPen Cyclodialysis System in standalone surgery|Ophthalmic surgical intervention with the CycloPen Cyclodialysis System
89659908|NCT05483309|Experimental|Diagnostic Treatment Regimen 1|Patients will receive a chest x-ray and their sputum sample will be analysed using the FilmArray Pneumonia Panel.
89659909|NCT05483309|No Intervention|Diagnostic Treatment Regimen 2|Patients will receive a chest x-ray and their sputum sample will not be analysed using the FilmArray Pneumonia Panel.
89659910|NCT05483309|Experimental|Diagnostic Treatment Regimen 3|Patients will receive a CT scan and their sputum sample will be analysed using the FilmArray Pneumonia Panel.
89659911|NCT05483309|Experimental|Diagnostic Treatment Regimen 4|Patients will receive a CT scan and their sputum sample will not be analysed using the FilmArray Pneumonia Panel.
89659912|NCT05478525|Experimental|0.5 g GLY-200|
89659913|NCT05478525|Experimental|1.0 g GLY-200|
89659914|NCT05478525|Experimental|2.0 g GLY-200|
89659915|NCT05478525|Placebo Comparator|Placebo for 0.5 g GLY-200 arm|
89659916|NCT05478525|Placebo Comparator|Placebo for 1.0 g GLY-200 arm|
89659917|NCT05478525|Placebo Comparator|Placebo for 2.0 GLY-200 arm|
88994697|NCT02929225|Experimental|Bifid Triple Viable Capsules|BIFICO(Shanghai Sine Pharmaceutical Laboratories Co.Ltd,S10950032), A biological preparation composed of triple viable microbe(Live combined Bifidobacterium, Lactobacillus and enterococcus capsules)
88994698|NCT02929225|Placebo Comparator|placebo|placebo is also manufactured by Sine Pharmaceutical Laboratories,but only contains starch.And placebo is the same as probiotics in appearance,odor,flavor and color.
88994699|NCT00148616|Active Comparator|Memantine plus Risperidone|24 weeks memantine add on treatment to risperidone
88994700|NCT00148616|Placebo Comparator|Placebo plus Risperidone|24 weeks placebo add on treatment to risperidone
88994701|NCT02928835|Experimental|Dynasplint group|The experimental group received standardized physical therapy intervention and used the knee flexion Dynasplint orthosis six hours daily during one month, starting at day seven after total knee arthroplasty surgery.
88994702|NCT02928835|No Intervention|Control group|Control group received standardized physical therapy intervention.
88994703|NCT00175929|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day
88994704|NCT00175929|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
88994705|NCT00175929|Experimental|Brivaracetam 150 mg/day|Brivaracetam 150 mg/day, 75 mg administered twice a day
88994706|NCT02928796||Trainees|Registrar Cardiologists
88994707|NCT02928796||Trainers|Consultant Cardiologists
88994708|NCT02928874|Experimental|Caloric compensation|Twenty-five minutes before breakfast, participants will be asked to consume in full one of two oatmeal preloads that will vary in ED. The order of preload conditions will be randomized across groups of children participating in the visits.
88994709|NCT02928874|Experimental|Eating in the absence of hunger (EAH)|During both study visits, children's EAH will be assessed after lunch and again after dinner. The order of presenting the low and high ED snacks will be counterbalanced across meals.
88994710|NCT02928913||Sedentary|Predominantly engage in sedentary behaviours
88994711|NCT02928913||Non-sedentary|Predominantly engage in non-sedentary behaviours
88994712|NCT02928679|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
88994713|NCT02928679|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
88994714|NCT02928640|Experimental|ClariCore System|ClairCore System study designed for data collection to build the prostrate tissue classification algorithm.
88994715|NCT02928445|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
88994716|NCT02928445|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
88994717|NCT02928562|No Intervention|Control|TKA patients without exercise intervention
88994718|NCT02928562|Experimental|Exercise|TKA patients with exercise intervention ( cyclic exercise, aerobic exercise and resistant training exercise )
88994719|NCT02928601|Experimental|Ondansetron|
89213559|NCT05726565||LNNB-S <10|As one of the core components of multidisciplinary CR, psychiatrist and psychologist consultation was delivered to all patients. Cognitive function was assessed with the Luria-Nebraska Neuropsychological Battery-Screening test (LNNB-S) Chinese version by an experienced psychologist. The evaluation would be completed during admission. The initial LNNB was condensed to fifteen items for the screen test by Golden. LNNB-S Chinese version focuses on 3 domains, including number calculation, cognitive function, and rhythm control. In our participants' cohort, investigators choose LNNB-S >=10 as a cutoff point. That is, participants may have cognitive impairment when their LNNB-S >=10.
89213560|NCT04076969|Experimental|Integrated Educational Session|The anemic pregnant women in the study group received an integrated health education in one session. The educational session was steered as 40-minutes session in a personalized manner. The educational session content included; disease specific information, effect of anemia on maternal and neonatal outcome, management possibilities, the effectiveness, benefits and disadvantages of treatment options, identify diet rich with iron, false dietary habits prevent iron absorption and the balanced diet and meals.
89659918|NCT05475262|Experimental|Night A active white noise|Patients receiving active level of white noise on night A
89213561|NCT04076969|Other|Routine follow up|Routine follow up
89213562|NCT04077125||Cirrhosis no MHE|Patients with liver cirrhosis without signs of minimal hepatic encephalopathy
89213563|NCT04077125||Cirrhosis MHE|Patients with liver cirrhosis with minimal hepatic encephalopathy
89213564|NCT04077125||Controls|Healhty subjects
89213565|NCT05707689|Experimental|Gaming|Gaming intervention with entertainment video games will be run in small groups (6-10 players) closely monitored by trained gaming facilitators. Pre-scheduled gaming sessions, about 60 minutes each, will be run twice a week over 10 weeks (totally 20 hours).
89659919|NCT05475262|Sham Comparator|Night B inactive white noise|"Patients will receive a lower Level of white noise on night B. Termed inactive, because do not expect the level to have a noticeable change in sound level changes, and thus sleep."
89659920|NCT05459584|Experimental|Experimental: Technological Group|Technological group (TG) patients will undergo robotic treatment for the improvement balance through the robotic platform (Hunova® Movendo Technology srl, Genova, IT), 3 times per week for 45 minutes each, in addition to the conventional treatment (total 180 minutes per day). In particular, the technological rehabilitation performed employing a footboard will be mostly aimed at improving the balance both in sitting and standing position, and will be proposed static and dynamic exercises, exercises dual-task exercises, and exercises to improve trunk control.
89659921|NCT05459584|No Intervention|No Intervention: Control Group|Congrol Group (CG) patients will undergo conventional rehabilitation treatment only, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive neuromuscular facilitation, etc.).
89659922|NCT05458908|Experimental|Cranial non-contrast syngo DynaCT Sine Spin scan|There is only one arm as all patients undergo the same intervention. Subjects with clinical features/symptoms of a stroke (hemorrhagic and non-hemorrhagic stroke patients) will be enrolled. All patients will undergo first a non-contrast MDCT scan and then a non-contrast syngo DynaCT Sine Spin head scan within a maximum timespan of 4 hours between both scans. Only patients in which no invasive procedure in between is planned can be enrolled.
89659923|NCT05442827|Experimental|Treatment group A: SHR7280 tablets|
89659924|NCT05442827|Experimental|Treatment group B:SHR7280 tablets|
89659925|NCT05442827|Placebo Comparator|Treatment group C:Intervention: Drug: PlaceboSHR7280 tablets blank preparation|
89659926|NCT05436015|Experimental|Intervention Group|In addition to usual standard care during childbirth in hospital, the intervention group will receive a virtual nature-based intervention
89659927|NCT05436015|No Intervention|Control Group|The control group receives the usual standard care during childbirth in hospital
89659928|NCT05422508|Experimental|MG1111(BARICELA) arm|0.5ml, single dose, subcutaneous injection
89659929|NCT05422508|Active Comparator|VARIVAX arm|0.5ml, single dose, subcutaneous injection
89659930|NCT05422508|Active Comparator|Suduvax arm|0.5ml, single dose, subcutaneous injection
89659931|NCT05415449||No groups|"Identify eligible patients--Informed Consent--Provide education and two protective wearable device--Demographic data (electronic health record)--Interview parent on device--Every month complete 30-day satisfaction survey for a total of three data collection period-Discharge from study.~Nurse data collection scheme: Study participants hospitalized at time of enrollment in study or anytime during the study period. Nurse of patients using device will complete satisfaction survey."
89213566|NCT05707689|No Intervention|Treatment as usual (TAU)|Participants will join usual practices as planned in community services. No specific activities will be organized to them by the research team.
89213567|NCT05172401|Experimental|Active Treatment - Oxulumis® - Triesence®|"The Oxulumis® device will be used for the administration of Triesence® (Triamcinolone acetonide) via suprachoroidal microcatheterization~Interventions:~Device: Oxulumis® suprachoroidal microcatheterization device~Drug: Triesence® (Triamcinolone acetonide)"
89213568|NCT01006785|Experimental|Treatment I|DLBS1425 150 mg three times daily
89213569|NCT01006785|Experimental|Treatment II|DLBS1425 300 mg three times daily
89213570|NCT00143455|Experimental|B|
89213571|NCT00143455|Experimental|A|
89659932|NCT05394116|Experimental|High dose Garetosmab|Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)
89659933|NCT05394116|Experimental|Low dose Garetosmab|Garetosmab is administered by IV administration Q4W
89659934|NCT05394116|Experimental|Placebo|Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W.
89659935|NCT05387239|Experimental|Experimental/treatment arm|
89659936|NCT05387239|Placebo Comparator|Placebo|
89659937|NCT05381974|Experimental|Psilocybin|25mg of Psilocybin
89659938|NCT05379959|Experimental|Experimental: Placebo Then MDMA Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive 125 mg MDMA. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
89659939|NCT05379959|Experimental|Experimental: MDMA Then Placebo Then Methampetamine|Participants first receive 125 mg of MDMA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
89659940|NCT05379959|Experimental|Experimental: Methampetamine Then Placebo Then MDMA|Participants first receive 20 mg of MA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 125 mg of MDMA.
89659941|NCT05372484|Experimental|Multi-Modal Optical Imaging|Multi-modal imaging (mobile colposcopy and high resolution imaging) of study participants will be performed during the colposcopy examination. Cervical biopsies will be performed using biopsy forceps per standard protocols.
89659942|NCT05362890|Experimental|Patients with obstructive sleep apnea|Patients with OSAS who have been previously examined by a neurologist for sleep disorders, have undergone polysomnography, and have been diagnosed with moderate severe obstructive sleep apnea according to the AHI index
89659943|NCT05362890|No Intervention|Control Group|The control group will consist of subjects in whom specific questionnaires excluded the existence of obstructive sleep apnea.
89659944|NCT05354947|Experimental|30 minute, dual site stimulation|Ultrasound Deliveryfor 30 minutes total: 15 minutes on the liver target site and 15 minutes on the intestinal target site.
89659945|NCT05354947|Experimental|60 minute, dual site stimulation|Ultrasound Delivery for 60 minutes total: 30 minutes on the liver target site and 30 minutes on the intestinal target site.
89659946|NCT05350176|Experimental|Experimental group|Probiotic intake containing 10 billions of Colony Forming Units of Lactobacillus plantarum (1 capsule per day)
89659947|NCT05350176|Placebo Comparator|Placebo group|Placebo intake. Placebo capsules will contain dextrose (1 capsule per day)
89659948|NCT05344625|Experimental|Ketamine Assisted Psychotherapy|3 KAP sessions lasting approximately 3 hours using less than or equal to 60mg or 1mg/kg of intramuscular Ketalar as the facilitating chemical. KAP sessions will be supplemented with integration sessions occurring the following day and 1 month after the final KAP session.
89659949|NCT05331144|Experimental|Intensive Treatment (IT)|Lowering SBP < 120 mmHG
89659950|NCT05331144|Active Comparator|Usual Care (UC)|Participants will follow their PCP's recommendations for BP control
89659951|NCT05331131|Experimental|Ketamine Mouthwash|"Enrolled patients with histologically confirmed squamous cell carcinoma of the head and neck undergoing definitive radiation therapy to 70Gy with concurrent cisplatin chemotherapy who develop grade 3+ toxicity will be prescribed ketamine mouthwash at a strength of 20mg/5mL in NovaFilm suspension with OraSweet flavoring agent via swish and spit route of administration. They will take the investigational drug four times daily."
89659952|NCT05326451|Experimental|active tDCS|
89659953|NCT05324384|Experimental|Low dose of sirolimus|The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 6 months. Then, The plasma trough concentration of sirolimus is maintained within the range of 5-8 ng/ml by adjusting sirolimus dose, for 6 months.
89659954|NCT05324384|Active Comparator|Regular dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.
89659955|NCT05302089|Experimental|One-time physiotherapy instruction|One-time physiotherapy instruction and no usual rehabilitation care
89659956|NCT05302089|Active Comparator|Usual rehabilitation care|One-time physiotherapy instruction and usual rehabilitation care
89659957|NCT05293249|Experimental|Cohort A1 - 1x 0.5 mg|Participants (n=3) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, for a total dose of 0.5 mg of each plasmid.
89659958|NCT05293249|Experimental|Cohort A2 - 1x 1 mg|Participants (n=3) will be administered 1 mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, for a total dose of 1 mg of each plasmid.
89659959|NCT05293249|Experimental|Cohort B - 2x 0.5 mg|Participants (n=6) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 1 mg of each plasmid.
89659960|NCT05293249|Experimental|Cohort C - 2x 1 mg|Participants (n=6) will be administered 1mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 2 mg of each plasmid.
89659961|NCT05293249|Experimental|Cohort D - 2x 0.25 mg|Participants (n=6) will be administered 1 mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 2 mg of each plasmid.
89659962|NCT05293249|Experimental|Cohort E - 2x 2 mg|Participants (n=5) will be administered 2 mg of dMAb AZD5396 and 2 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 4 mg of each plasmid.
89659963|NCT05293249|Experimental|Cohort F - 2x 0.5 mg|Participants (n=5) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0070 parameter on D0 and D3, for a total dose of 1 mg of each plasmid.
89659964|NCT05293249|Experimental|Cohort G - 4x 0.5 mg|Participants (n=5) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, D3, D28 and D31, for a total dose of 2 mg of each plasmid.
89659965|NCT05293249|Experimental|Cohort H - 2x 1 mg|Participants (n=5) will be administered 1 mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3 more than 52 weeks after prior administration, for a total dose of 2 mg of each plasmid.
89688634|NCT02469220|Experimental|Low FODMAP diet|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement low in FODMAPS are administered in a blinded fashion.
88994720|NCT02928601|Active Comparator|Saline|
89213572|NCT05166551|Experimental|Experimental Group|"Acupressure will be applied to the infants in this group by the researcher in accordance with the technique for 1 minute on the GB31 acupuncture point on the leg where the vaccine will be administered.The considerations before, during and after acupressure application are as follows:~The hands will be washed to warm them up to body temperature.~The acupressure will be applied using the thumb to the GB31 acupuncture point for 1 minute before the vaccine is administered to the infants in the experimental group.~Pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
89659966|NCT05279898|Experimental|Multimodal General Anesthesia (MMGA Bundle) - EEG Guided|"Routine anesthetic induction~Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.2% ropivacaine on both sides of the sternum after anesthetic induction but before surgical incision (total of 40mL)~Ketamine (0.1 to 0.2 mg.kg/hr)~Remifentanil (0.05-0.4 mcg/kg/min)~Dexmedetomidine (0.2-0.5 mcg/kg/hr)~Rocuronium intermittent bolus (TOF)~Propofol infusion (15 to 200 mcg/kg/min)~Postop~Standard pain management protocol~IV Acetaminophen~IV Hydromorphone/fentanyl boluses as needed per current practice for rescue analgesia~Other oral pain medications as per standard of care (Oxycodone, etc)~Dexmedetomidine infusion (0.4-1.4 mcg/kg/hr) - EEG Guided; Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion~PIFB on postoperative day 1 (provided they are extubated/getting ready to be extubated)(for intervention group)~Lidocaine patches"
89659967|NCT05279898|No Intervention|Standard of Care/Control|"EEG monitoring will be blinded, and not guide anesthesiologists. Patients will receive standard/routine anesthesia practice intraoperatively.~Postoperative Propofol infusion (15 to 200 mcg/kg/min) ± Sevoflurane~Standard pain management protocol~IV Acetaminophen (1 gram) x 4 doses at 6 hour intervals starting from 1 hr after ICU arrival~IV Hydromorphone/fentanyl boluses as needed per current practice for rescue analgesia~Other oral pain medications as per standard of care (Oxycodone, etc)~Dexmedetomidine infusion (0.4-1.4 mcg/kg/hr) - EEG Guided; Infusion continued till extubation~Propofol infusion may be added/used for sedation based on the treating physician's discretion~Lidocaine patches~Parasternal block (PIFB or Transversus Thoracic Plane Block) on Postoperative day 0 - currently incorporated into standard pain management after surgery based on physician discretion"
89659968|NCT05265013|Other|ASP-1929 Photoimmunotherapy Combined With Pembrolizumab|"Patients will receive the approved label dose of pembrolizumab, which is administered every 3 weeks on days 1 and 22 of each treatment cycle.~On Day 8 of each cycle, patients will receive ASP-1929 followed by illumination at accessible tumor sites using the investigational PIT690 Laser System on Day 9.~Each treatment cycle, which is driven by ASP-1929 PIT frequency of administration, will last 42 days. Patients will be treated with ASP-1929 PIT and pembrolizumab for up to 12 months with a maximum of 8 treatment cycles."
89659969|NCT05254184|Experimental|Patients With NSCLC|All participants will receive the intervention.
89659970|NCT05239624|Experimental|enfortumab vedotin in combination with pembrolizumab|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles. Patients can proceed to surgery prior to completion of cycle 6 at the discretion of the investigator and urologist if toxicities prevent completion of 6 cycles of treatment. Enfortumab vedotin will be capped at a maximum dose of 125 mg for each infusion (for patients who weigh > 100 kg). Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles. After completion of 3 cycles patients with have imaging assessment, and patients with progression of disease as measured by distant metastases will be removed from the study. At completion of cycle 6, patients will have repeat imaging assessment and proceed to cystectomy within 4-8 weeks. Following cystectomy, patients will resume pembrolizumab monotherapy on day 1 of each 21-day cycle for an additional 11 doses (Cycles 7-17), to complete 1 year of pembrolizumab therapy.
89659971|NCT05223231|Experimental|LBL-019|singal -arm
89659972|NCT05209412|Experimental|Drug-coated balloon|Lepu Paclitaxel coated balloon will be used
89659973|NCT05209412|Active Comparator|Drug-eluting stent|Resolute Integrity Zotarolimus eluting stents will be used
89659974|NCT05208905|Experimental|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
89659975|NCT05208502||BIS|All inclusions will receive the general anesthesia with BIS monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the EEG monitor signal. As the surgery ends, this researcher will record the time started from the end of the surgery to extubation, as well as the emergence quality when the patient was evaluated.
89659976|NCT05208502||DSA|All inclusions will receive the general anesthesia with SedLine monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the DSA monitor signal. As the surgery ends, this researcher will record the time started from the end of the surgery to extubation, as well as the emergence quality when the patient was evaluated.
89659977|NCT05205954|Experimental|Hepatology Hospital at Home|Patients with cirrhosis presenting with symptomatic ascites receive their care in the home.
89659978|NCT05205954|No Intervention|Usual Hepatology Care|Patients with cirrhosis presenting with symptomatic ascites receive their care in the hospital, as usual.
89659979|NCT05199740||mtDNA mutation carriers|Carriers of a pathogenic mtDNA mutation
89659980|NCT05183126|Active Comparator|Normal SMA (>7310 mm^2)|Standard paclitaxel infusion time.
89659981|NCT05183126|Experimental|Low SMA (5120 - 7310 mm^2) and Sarcopenic SMA (<5120 mm^2)|Adjusted paclitaxel infusion time during only one dose; standard paclitaxel infusion time for all other doses.
89659982|NCT05173831|Experimental|Two MDMA-assisted Therapy Sessions|Two Experimental MDMA-assisted Therapy Sessions, and four Integrative Sessions following each Experimental Sessions.
89659983|NCT05158205|Experimental|Yoga postures or slow, deep breathing|
89659984|NCT05158205|Sham Comparator|Control|
89659985|NCT05155176||Individuals with Alcohol Use Disorder|Participants who meet the criteria for Alcohol Use Disorder will complete six weeks of smartphone monitoring. During this monitoring period, they will also complete two three-consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
89688635|NCT02469220|Active Comparator|Standardized FODMAP|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement with FODMAPS are administered in a blinded fashion.
89659986|NCT05155176||Social drinkers|Participants who have a past year history of alcohol use and do not meet the criteria for Alcohol Use Disorder will complete two weeks of smartphone monitoring. During this monitoring period, they will also complete three consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
89659987|NCT05147402|Active Comparator|Fasted Treatments with 100 mg of MDMA|Following an overnight fast of at least 10 hours, participants will be administered 100 mg MDMA (equivalent to 120 mg MDMA HCl) with 240 mL of water. No food should be allowed for at least 4 hours post-dose.
89659988|NCT05147402|Active Comparator|Fed Treatments with 100 mg of MDMA|A high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal will be used as a test meal for food-effect evaluation. Following an overnight fast of at least 10 hours, participants will start the recommended meal 30 minutes prior to administration of the drug product. Participants will eat this entire meal in 30 minutes or less. 100 mg MDMA (equivalent to 120 mg MDMA HCl) will be administered 30 minutes after start of the meal with 240 mL of water.
89659989|NCT05137054|Experimental|Cohort 1: Linvoseltamab + Daratumumab|Linvoseltamab + Daratumumab
89659990|NCT05137054|Experimental|Cohort 2: Linvolseltamab + Carfilzomib|Linvoseltamab + Carfilzomib
89659991|NCT05137054|Experimental|Cohort 3: Linvoseltamab + Lenalidomide|Linvoseltamab + Lenalidomide
89659992|NCT05137054|Experimental|Cohort 4: Linvoseltamab + Bortezomib|Linvoseltamab + Bortezomib
89659993|NCT05137054|Experimental|Cohort 5: Linvoseltamab + Pomalidomide|Linvoseltamab + Pomalidomide
89659994|NCT05137054|Experimental|Cohort 6: Linvoseltamab + Isatuximab|Linvoseltamab + Isatuximab
89659995|NCT05137054|Experimental|Cohort 7: Linvoseltamab + Fianlimab|Linvoseltamab + Fianlimab
89659996|NCT05137054|Experimental|Cohort 8: Linvoseltamab + Cemiplimab|Linvoseltamab + Cemiplimab
89659997|NCT05137054|Experimental|Cohort 9: Linvoseltamab + Nirogacestat|Linvoseltamab + Nirogacestat
89659998|NCT05131373|Experimental|Experimental 1|C. acnes vaccine in adjuvanted formulation will be administered in double-blind fashion in 3 single increasing doses given i.m.
89659999|NCT05131373|Placebo Comparator|Placebo 1|Placebo in adjuvanted formulation will be administered in double-blind fashion in single i.m. injections
89660000|NCT05125471|Experimental|Investigational Drug|Cobimetinib will be administered at a maximal dose of 60 mg daily for 21 days on, then 7 days off, in a 28-Day treatment cycle for 12 cycles (approximately 12 months). Cobimetinib should be taken once daily at approximately the same time each day, and no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal. Cobimetinib tablets should never be chewed, cut, or crushed. Therapy may continue for up to 12 cycles provided the subject meets the criteria for starting subsequent cycles and does not meet any of the criteria for cobimetinib discontinuation. At least 7 days off cobimetinib (within +7 days) is required prior to starting a new treatment cycle.
89660001|NCT05122624|Experimental|Score intervention arm|The PredicTB score will be implemented in this arm.
89660002|NCT05122624|No Intervention|Control arm|The standard of care will be conducted in this arm.
89660003|NCT05120180|Experimental|Branches Sparing|The patients in this arm will undergo axillary lymph node dissection with preserved axillary vein branches
89660004|NCT05120180|Active Comparator|None Branches Sparing|The patients in this arm will undergo axillary lymph node dissection without preserved axillary vein branches
89660005|NCT05107011|Experimental|Evaluation of LBL-015 Phase I/II study in patients with advanced malignancies|Drug: LBL-015 for Injection The test drugLBL-003will be preset with 5 escalation dose levels: dose A , dose B, dose C ,dose D and dose E, administered twice a week.
89660006|NCT05105438|Active Comparator|Consecutive Day Dosing|100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.
89660007|NCT05105438|Experimental|Alternate Day Dosing|100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
89660008|NCT05066282||Participants with past PTSD who received IMP in the main study|
89660009|NCT05058924|Active Comparator|Prophylactic Low Molecular Weight Heparin (LMWH)|Prophylactic LMWH for 6 weeks postpartum
89660010|NCT05058924|Experimental|Prophylactic Low Molecular Weight Heparin (LMWH) + Low Dose Aspirin|Prophylactic LMWH for 3 weeks followed by low dose Aspirin for 3 weeks.
89660011|NCT05054803|Experimental|WJ-MSC (XCEL-UMC-BETA)|Pre-filled syringe with 4 ± 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.
89660012|NCT05054803|Placebo Comparator|Placebo|Pre-filled syringe with 4 ± 1 mL containing a balanced saline solution supplemented with human albumin
89660013|NCT05053321|Experimental|Valbenazine|All participants will be treated with Valbenazine for 7 weeks.
89660014|NCT05049512|Experimental|Multi-nut OIT|Participants will have a personalised combination of two nuts they are allergic to for their multi-nut OIT (a. peanut, b. almond, c. cashew, d. hazelnut, e. walnut). In the escalation visit, participants will receive 5 increasing doses of personalised multi-nut OIT in clinic at 20-minute intervals: 1 mg, 3 mg, 6 mg, 12 mg, 24 mg total nut protein, 12 mg/nut. The build-up phase will consist of daily home doses of multi-nut OIT and clinic visits every 2 weeks for up-dosing, up to a maintenance dose of 600 mg total protein, 300 mg/nut, over 3-8 months. In the maintenance phase, participants will continue to take their multi-nut OIT dose of 600 mg total protein each day at home for the remainder of the 18 months, with visits to the clinic every 3 months.
89660015|NCT05049512|No Intervention|Standard Care|Strict avoidance of the 2 study nuts the participants are allergic to over 18 months - a. peanut, b. almond, c. cashew, d. hazelnut, e. walnut, as per standard care instructions for children with allergies in Australia.
89688636|NCT02469220|No Intervention|Control|Watchful waiting. No diets or food supplements are administered
89688637|NCT00945139|Experimental|Single Arm: Doxil and Avastin|Patients receive both agents, doxil and Avastin.
89047366|NCT02436096|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
89047367|NCT02436096|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
89047368|NCT00538772||Biomarker|
89047369|NCT02435121|Experimental|SAR125844|Given intravenously weekly at the dose of 570 mg/m^2 for at least 18 weeks
89047370|NCT00538811|Experimental|1|Interferon alpha, ribavirin, interferon gamma
89047371|NCT00538811|Active Comparator|2|Interferon alpha, ribavirin, amantadine
89660016|NCT05029726|Experimental|Investigational|Patients will undergo regional ESPB with bupivacaine plus clonidine in the holding area of the OR immediately prior to surgery. 30mL of 0.25% bupivacaine/1:200,000 epinephrine/50mcg clonidine will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
89660017|NCT05029726|Placebo Comparator|Control|Patients will receive a placebo injection of normal saline via the same ESPB technique. 30ml of normal saline will be administered bilaterally (total 60ml) to the lumbar paraspinal erector spine plane using ultrasound-guidance.
89660018|NCT05019612||single-group/one cohort|Women with endometriosis, having the clinical indication for laparoscopic endometriosis excision
89660019|NCT05017129|Experimental|Inmates Care modules|This is a within-subjects, pre-post design with a single intervention. The intervention is a 6 module computer-based learning program for training peer caregivers in end-of-life care.
89660020|NCT05015426|Experimental|Dose Level -1|"Dose Level -1 may be used as a de-escalation dose level due to Dose Limiting Toxicities (DLTs) from Dose Level 1~Participants will receive 1.0 x 106 cells/kg (0.75-1.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion"
89660021|NCT05015426|Experimental|Dose Level 1|Participants will receive 5.0 x 106 cells/kg (3.75-6.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
89660022|NCT05015426|Experimental|Dose Level 2|Participants will receive 2.5 x 107 cells/kg (1.875-3.125 x 107 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
89660023|NCT05015426|Experimental|Dose Level 3|Participants will receive 1.0 x 108 cells/kg (0.75-1.25 x 108 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion
89660024|NCT05015426|Experimental|Treatment at Maximum Tolerated Dose|Participants will receive Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells at the dose determined to be the Maximum Tolerated Dose, administered as a single infusion
89660025|NCT05006573|Experimental|Benralizumab|Benralizumab will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
89660026|NCT05006573|Placebo Comparator|Placebo|Matching placebo solution will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
89660027|NCT05005390|Experimental|TTIP ventilation, then mask ventilation|Subjects will first be ventilated with the TTIP technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1). Subjects will then be ventilated with mask ventilation (Step 2). In Step 1, if ventilation fails with the TTIP technique for all of the first three consecutive breaths, the subject will be crossed over to the mask ventilation. If ventilation fails again with all the first three consecutive breaths after crossover, the study will be terminated. The routine care is resumed including tracheal intubation or laryngeal mask airway (LMA) insertion.
89660028|NCT05005390|Active Comparator|Mask ventilation, then TTIP ventilation|Subjects will first be ventilated with the mask technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1). Subjects will then be ventilated with TTIP technique (Step 2). In Step 1, if ventilation fails for all of the first three consecutive breaths, the subject will be crossed over to the TTIP ventilation. If ventilation fails again with all the first three consecutive breaths after crossover, the study will be terminated. The routine care is resumed including tracheal intubation or LMA insertion.
89660029|NCT05003076|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
89660030|NCT05003076|Experimental|Methamphetamine Then Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
89660031|NCT05001009|Active Comparator|No then high patient engagement|"First stage: No patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training.~Second stage (non-responders only): High patient engagement and high intensity clinician training."
89660032|NCT05001009|Active Comparator|No then low patient engagement|"First stage: No patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training.~Second stage (non-responders only): Low intensity patient engagement and high intensity clinician training."
89660033|NCT05001009|Active Comparator|Low then high patient engagement|"First stage: Low intensity patient engagement. Low intensity clinician training.~Second stage (responders only): No patient engagement and high intensity clinician training.~Second stage (non-responders only): High patient engagement and high intensity clinician training."
89660034|NCT05001009|Active Comparator|Low then low patient engagement|"First stage: Low patient engagement. Low intensity clinician training. Second stage (responders only): No patient engagement and high intensity clinician training.~Second stage (non-responders only): Low intensity patient engagement and high intensity clinician training."
89660035|NCT04995653|Experimental|Cohort 1 - Open Label Study|Vancomycin & SER-155
89660036|NCT04995653|Experimental|Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study|Vancomycin & SER-155 OR Vancomycin placebo & SER-155 placebo
89660037|NCT04968938|Experimental|MDMA-assisted therapy|Two sessions of MDMA-assisted therapy with flexible dose of MDMA from 80 mg initial dose and optional supplemental dose half that of initial dose 1.5 to 2 hours later
89660038|NCT04964544|Other|Open Label, Single Arm Technology-Assisted Cholesterol Trial|Open Label Single Arm study in All-comers population who self-report having concern about high cholesterol or heart health
89660039|NCT04957368|Experimental|Nitrous Oxide + saline solution|
89660040|NCT04957368|Active Comparator|Oxygen + Midazolam|
89660041|NCT04952506|Experimental|R-T1-T2|"Period 1: Reference~Period 2: Test 1~Period 3: Test 2"
89660042|NCT04952506|Experimental|T2-R-T1|"Period 1: Test 2~Period 2: Reference~Period 3: Test 1"
89660043|NCT04952506|Experimental|T1-T2-R|"Period 1: Test 1~Period 2: Test 2~Period 3: Reference"
89660044|NCT04952506|Experimental|T2-T1-R|"Period 1: Test 2~Period 2: Test 1~Period 3: Reference"
89660045|NCT04952506|Experimental|T1-R-T2|"Period 1: Test 1~Period 2: Reference~Period 3: Test 2"
89660046|NCT04952506|Experimental|R-T2-T1|"Period 1: Reference~Period 2: Test 2~Period 3: Test 1"
89660047|NCT04945369|Experimental|Children born prematurely included in the EPIPOD protocol and now in the peripubertal period|"At inclusion in the INFANTPOD study :~Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~Assessment of body composition by a commercialized device called BOP-POD and by impedancemetry~Assessment of pulse wave by a commercialized device called popmetre~Questionnaires for analysis of eating behaviour~Assessment of physical activity by a commercialized device called accelerometer and by questionnaire."
89660048|NCT04939571||Preterm born infants treated for ROP|
89660049|NCT04917809|Experimental|Participants with FGFR3-mutant or -fusion noninvasive bladder tumors|25 participants with FGFR3-mutant or -fusion noninvasive bladder tumors will be accrued.
89660050|NCT04916730|Placebo Comparator|Standard of Care (SOC)|Participants will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
89660051|NCT04916730|Experimental|TRE + SOC|Participants in this arm will receive standard of care nutritional behavioral counseling and will implement a daily, self-selected, 10-hour window within which they must consume all calories. They will also be required to log their caloric intake through the use of a smartphone app
89660052|NCT04906265|Active Comparator|Intervention|The intervention comprises of standard rehabilitation and continuous measures of body positions and movements 24 hour a day with an IMU. Standard rehabilitation comprises of home-visits by a PT, where an individualized rehabilitation plan is outlined together with the patient. The plan includes individually tailored functional exercises. The plan also includes individually tailored walking exercises, indoor and outdoor when possible. At each home visit, the PT provides feedback to the participant based on the data from the IMU, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed).
89660053|NCT04906265|Active Comparator|Control|Standard rehabilitation alone
89660054|NCT04884763|Active Comparator|Arm A|Arm A: erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
89660055|NCT04884763|Placebo Comparator|Arm B|Arm B: placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
89660056|NCT04880967||Standard Group|"Cohort of n=20 intensive care unit patients from the ages of 18 years will be collected.~Participants of this cohort will not use the ICU Feel Better App."
89660057|NCT04880967||Experimental Group|Cohort of n=20 intensive care unit patients from the ages of 18 years will be collected. Participants of this cohort will have the opportunity to use the ICU Feel Better App every day from the second day after admission to the ICU until the day of discharge from ICU.
89660058|NCT04876040|Experimental|PCI+Impella plus SSO2|Patients who present with STEMI-CS will undergo treatment with Impella, followed by PCI. Subjects are then immediately treated post-procedure with an infusion of SSO2 Therapy for a duration of 60 minutes.
89660059|NCT04876040|Active Comparator|PCI+Impella|Patients who present with STEMI-CS will undergo treatment with Impella, followed by PCI. Subjects are then immediately treated with Standard of Care.
89660060|NCT04866810|Experimental|1|Intervention
89660061|NCT04866810|Other|2|Control- Standard diet and Exercise
89660062|NCT04857281|Experimental|nVNS device|Candidates who, after the screening period are eligible to receive the nVNS device.
89660063|NCT04831684|Placebo Comparator|Group A|
89660064|NCT04831684|Experimental|Group B|
89660065|NCT04824105|Experimental|Neurostimulation Group|"On one study day, participants will complete experimental tasks during functional magnetic resonance imaging. On two other study days, participants will complete tasks before and after receiving repetitive transcranial magnetic stimulation (rTMS). All participants will receive rTMS to ventromedial prefrontal cortex on one study day, and to pre-supplementary motor area on another study day.~Two stimulation procedures will be used, one for ventromedial prefrontal cortex and one for pre-supplementary motor area. For both targets, 3 sessions of 600 pulses at 110% of resting motor threshold will be presented over 30 minutes. For ventromedial cortex, a session will involve intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. For pre-supplementary motor area, a session will involve continuous theta burst presented in 3-pulse bursts with 15 pulses/ sec."
89660066|NCT04808427|Experimental|1/Arm 1|Ultrasound ablation of focal prostate cancer
89660067|NCT04787744|Active Comparator|Standard Systemic Therapy (SST)|All Veterans will receive SST (if De novo, Veterans will receive prostate-directed radiation).
89660068|NCT04787744|Experimental|SST + PET-directed local therapy|In addition to SST, all Veterans will receive PET-directed local therapy to all metastases using surgery or radiation. If De novo, Veterans will also receive prostate-directed radiation or radical prostatectomy to treat the prostate/prostate bed. The best course of treatment will be determined using shared decision-making between the physician and Veteran.
89660069|NCT04784143|Active Comparator|Two sessions of MDMA-assisted therapy|Two experimental sessions of MDMA-assisted therapy
89660070|NCT04784143|Active Comparator|Three sessions of MDMA-assisted therapy|Three experimental sessions of MDMA-assisted therapy
89660071|NCT04775173|Experimental|Low dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 5-8 ng/ml by adjusting sirolimus dose, for 1 year.
89660072|NCT04775173|Active Comparator|Regular dose of sirolimus|Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.
89660073|NCT04767984|Experimental|Arm I (atorvastatin, biospecimen collection)|Patients receive atorvastatin PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.
89660074|NCT04767984|Placebo Comparator|Arm II (placebo, biospecimen collection)|Patients receive placebo PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.
89660075|NCT04755790|No Intervention|No Prosthesis|Baseline outcome measurements will be performed without a prosthesis
89660076|NCT04755790|Experimental|Prosthesis|Outcome measurements will be performed after the subject has been fit with a prosthesis at 3 different points in time: immediately post-fitting, ~30 days post-fitting, and ~60 days post-fitting
89660077|NCT04744818|Active Comparator|Immediate iron treatment|Iron and multivitamin syrup
89660078|NCT04744818|Placebo Comparator|Delayed iron treatment|Multivitamin syrup
89660079|NCT04733885|Experimental|Electrical Stimulation group|ES and lifestyle advice have been applied ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
89660080|NCT04733885|Sham Comparator|Sham Electric Stimulation group|Sham ES and lifestyle advice have been applied Sham ES application will be done 3 days a week for 8 weeks, 20 minutes. An informative brochure with lifestyle advice will be provided for both groups.
89660081|NCT04732117|Experimental|Secukinumab Arm|Secukinumab 150 mg PFS s.c.
89660082|NCT04732117|Placebo Comparator|Placebo Arm|Placebo 150mg PFS s.c.
89660083|NCT04726969|Experimental|Arm A: moxidectin and albendazole|Combination therapy of moxidectin (8 mg, i.e. 4 tablets of 2 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89660084|NCT04726969|Placebo Comparator|Arm B: albendazole|Placebo (for moxidectin, 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89660085|NCT04726969|Experimental|Arm C: ivermectin and albendazole|Combination therapy of ivermectin (Stromectol®, 200 µg/kg using tablets of 3 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0
89660086|NCT04717349||Family Members of PAG patients|Clinical evaluation of family members that would provide clinical information related to the diagnosis of a proband in future research.
89660087|NCT04717349||PAG patient|Pediatric and adolescent patients with gynecologic conditions.
89660088|NCT04714359|Experimental|MDMA-assisted therapy|Three open-label sessions of MDMA-assisted therapy with flexible dose of MDMA (80 or 120 mg) and optional supplemental dose of (40 or 60 mg), 1.5 to 2 hours later
89660089|NCT04707391|Experimental|ABCWY Group|All participants in this group receive 2 doses of the MenABCWY vaccine on Day 1 and Day 181 (0,6-month schedule) and 1 dose of placebo on Day 211.
89660090|NCT04707391|Active Comparator|ACWY Group|All participants in this group receive 1 dose of MenACWY vaccine on Day 1 and 2 doses of MenB vaccine on Day 181 and Day 211.
89660091|NCT04703868|Experimental|YPI-011 10/500mg|Part A: 1 tablet administered before the breakfast during 7 days
89660092|NCT04703868|Experimental|YPI-011 20/500mg|Part B: 1 tablet administered before the breakfast during 7 days
89660093|NCT04699630|Experimental|Part A|Participants will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 every 3 weeks. All participants will undergo pre-treatment biopsies. (An archival tissue sample taken within two months of treatment should be provided if it is not medically feasible to provide a pre-treatment biopsy). Up to 60 participants will be enrolled into this arm.
89660094|NCT04699630|Experimental|Part B|Participants will receive 5.6 mg/kg U3-1402 intravenously on day 1 every 3 weeks. Part B will enroll 20 participants with metastatic hormone-receptor positive (HR+) HER2-negative cancer and 20 participants with metastatic triple-negative breast cancer (mTNBC), regardless of HER3 expression.
89660095|NCT04699630|Experimental|Part Z|Participants will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 every 3 weeks. Part Z will enroll an additional 21 participants with HER2+ MBC.
89660096|NCT04646785|Experimental|Mindfulness-based cognitive therapy (MBCT) added to treatment as usual|Patients in the MBCT arm will in addition to their treatment as usual be invited to participate in MBCT.
89660097|NCT04646785|Active Comparator|Treatment as usual (TAU)|Patients in this arm will receive treatment as usual.
89660098|NCT04639414|Experimental|Combined treatment with Empagliflozin and Semaglutide|Combined treatment with Empagliflozin, film-coated tablet, 10mg once daily and Semaglutide, colourless solution in pre-filled pen, 1mg once weekly
89660099|NCT04639414|Experimental|Empagliflozin monotherapy|Empagliflozin, film-coated tablet, 10mg once daily and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
89660100|NCT04639414|Placebo Comparator|Placebo|Placebo matching Empagliflozin (film-coated tablet, once daily) and Placebo matching Semaglutide (colourless solution in pre-filled pen, once weekly)
89660101|NCT04613596|Experimental|Phase 2 Cohort 1a: PD-L1 TPS <1%|Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab
89660102|NCT04613596|Experimental|Phase 2 Cohort 1b: PD-L1 TPS <1%|Cohort 1b: Adagrasib BID monotherapy
89660103|NCT04613596|Experimental|Phase 2 Cohort 2: PD-L1 TPS ≥1%|Cohort 2: Adagrasib BID in combination with pembrolizumab
89660104|NCT04613596|Experimental|Phase 3 Cohort 3 Investigational Arm|Adagrasib BID in combination with pembrolizumab
89660105|NCT04613596|Active Comparator|Phase 3 Cohort 4 Comparator Arm|Pembrolizumab
89660106|NCT04607837|Experimental|Etrasimod 2 mg|
89660107|NCT04607837|Placebo Comparator|Placebo|
89660108|NCT04593888|No Intervention|No intervention|The group will be followed without any intervention, with regular visits at the research clinic.
89660109|NCT04593888|Experimental|Gluten reduced diet|"Subjects will follow a diet that does not exceed a daily intake of 3 gram gluten.~The group will be followed with regular visits at the research clinic."
89660110|NCT04592653|Experimental|Cohort 1: Tumor Microenvironment (TME) Nemvaleukin and Pembrolizumab|Nemvaleukin will be administered via Intravenous (IV) infusion given daily for 5 consecutive days followed by an off-treatment period. Starting on Cycle 3, Day 1 of each cycle, Pembrolizumab will be administered via IV infusion followed by IV infusion of nemvaleukin
89660111|NCT04592653|Experimental|Cohort 2 Part A: Less Frequent IV Dosing Nemvaleukin|
89660112|NCT04592653|Experimental|Cohort 2 Part B: Less Frequent IV Dosing Nemvaleukin and Pembrolizumab|
89660113|NCT04585503|Experimental|Central nervous system monitoring|Each 20 patients will be implanted with subdural or intra cortical electrodes
89660114|NCT04544410|Experimental|Tildacerfont Group|Tildacerfont administered daily via oral tablet for 24 weeks at dose level 1; followed by open label tildacerfont for 52 weeks
89660115|NCT04544410|Placebo Comparator|Placebo|Placebo administered daily via oral tablet for 24 weeks; followed by open label tildacerfont for 52 weeks
89660116|NCT04541628|Experimental|SIG-001|B-Domain Deleted Human Factor VIII (BDD-hFVIII) Producing Spheres
89660117|NCT04513171|Experimental|Y-shape pegylated somatropin low dose|
89660118|NCT04513171|Experimental|Y-shape pegylated somatropin middle dose|
89660119|NCT04513171|Experimental|Y-shape pegylated somatropin high dose|
89660120|NCT04513171|Active Comparator|Norditropin-1|
89660121|NCT04513171|Experimental|Y-shape pegylated somatropin optimal dose|
89660122|NCT04513171|Active Comparator|Norditropin-2|
89660123|NCT04505722|Experimental|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S at a dose level of 5*10^10 virus particles (vp) as single dose vaccine on Day 1. At Year 1 (booster visit), participants who previously received any coronavirus disease-2019 (COVID-19) vaccination (as primary regimen or additional dose) will be offered a single booster dose of Ad26.COV2.S at the 5*10^10 vp dose level.
89660124|NCT04505722|Experimental|Placebo|Participants will receive IM injection of placebo on Day 1. At Month 6/unblinding visit, post Emergency Use Authorization (EUA), conditional licensure, or approval for the single dose regimen, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S vaccine IM at a dose level of 5*10^10 vp. At Year 1 (booster visit), participants who previously received any COVID-19 vaccination (as primary regimen or additional dose) will be offered a single booster dose of Ad26.COV2.S at the 5*10^10 vp dose level.
89660125|NCT04500301|Experimental|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
89660126|NCT04491942|Experimental|Arm I (cisplatin, elimusertib)|Patients receive cisplatin IV over 1-2 hours on day 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89660127|NCT04491942|Experimental|Arm II (cisplatin, gemcitabine, elimusertib)|Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89660128|NCT04488601|Experimental|Rapamycin 5|Rapamycin 5 mg/week
89660129|NCT04488601|Experimental|Rapamycin 10|Rapamycin 10 mg/week
89660130|NCT04488601|Placebo Comparator|Placebo 1|Placebo once per week
89660131|NCT04465760|Experimental|Supportive Care (xisomab 3G3)|Patients receive xisomab 3G3 IV or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT.
89047372|NCT04660773|Active Comparator|NB UVB phototherapy|(20 patients) will receive NB UVB phototherapy 3 sessions per week for 2 months.
89660132|NCT04463251|Experimental|RPH-104 80 mg|subjects received subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of placebo on different administration sites
89660133|NCT04463251|Experimental|RPH-104 160 mg|subjects received subcutaneous single injection of 2 mL (80 mg) of RPH-104 and 2 mL of (80 mg) of RPH-104 on different administration sites
89660134|NCT04463251|Placebo Comparator|Placebo|subjects received subcutaneous single injection of 2 mL of placebo and 2 mL of placebo on different administration sites
89660135|NCT04463212||Patient|Diagnosis of probable SVCR evoked, faced with a single or repeated episode of unusual thunderclap or rapidly progressive headache, and demonstration of diffuse vasospasms via sectional imaging (angiography, angio-MRI or cerebral arteriography) or an increase in transcranial doppler speeds
89660136|NCT04463212||Subject control|Subject without SVCR (current and history)
89660137|NCT04454684|Experimental|AN-R: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
89660138|NCT04454684|Experimental|BED: MDMA-assisted Psychotherapy|Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg MDMA followed by a supplemental half-dose of 40 mg MDMA 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of MDMA followed by a supplemental half-dose of 40 or 80 mg MDMA, respectively, 1.5 to 2 hours later, unless contraindicated.
89660139|NCT04454684|Experimental|Caregivers: Psychotherapy|Psychotherapy alone
89660140|NCT04450069|Experimental|Dose Escalation|CLBR001 + SWI019 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD)
89660141|NCT04437069|No Intervention|Standard Care (Control)|Participants will receive standard care and will not view either the Decision Aid or the Values Clarification Exercise
89660142|NCT04437069|Experimental|Decision Aid|Participants view the Decision Aid only
89660143|NCT04437069|Experimental|Decision Aid & Values Clarification Exercise|Participants view both the Decision Aid and the Values Clarification Exercise
89660144|NCT04408430|Experimental|Transseptal ViMAC|110 MAC patients treated with transseptal Valve-in-MAC.
89660145|NCT04408430|No Intervention|Registry of untreated patients|100 MAC patients not eligible for transseptal ViMAC, treated with conservative management including medications.
89660146|NCT04402138|Experimental|Acalabrutinib|Acalabrutinib will be self-administered orally for up to approximately 2 years post-BMT.
89688638|NCT02812342|Experimental|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
89047373|NCT04660773|Active Comparator|pregabalin|20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.
89047374|NCT02413827|Experimental|Phase l: varlilumab and ipilimumab|
89047375|NCT02413827|Experimental|Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC.|
89047376|NCT00538928|Experimental|1|Intervention: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
89047377|NCT00538928|Active Comparator|2|no device: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
89047378|NCT00538967|No Intervention|1|
89047379|NCT00538967|Active Comparator|2|doxycycline 50 mg/day
89047380|NCT00538967|Active Comparator|3|doxycycline 100 mg
89047381|NCT00538967|Active Comparator|4|doxycycline 300 mg
89047382|NCT04660851|Experimental|Coached|10 weeks of diet coaching
89047383|NCT04660851|No Intervention|Not-coached|No coaching provided
89660147|NCT04400695|Experimental|RC48-ADC|RC48-ADC common name：Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form：Lyophilized powder injection specification：60 mg / piece Medication plan：Every 2 weeks Expiration date：18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.
89660148|NCT04400695|Active Comparator|Physician's Choice|"Physician's Choice:~HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.~Physician's choice from the following options:~Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets"
89660149|NCT04335539|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg of cefiderocol and participants ≥34 kg will receive 2000 mg.
89660150|NCT04335539|Experimental|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered via IV every 8 hours on Day 1 and continuing for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg of cefiderocol and participants ≥34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
89660151|NCT04307355|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
89660152|NCT04307355|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
89660153|NCT04300790|Experimental|CohortA: Normoglycemic patients|"Alpelisib plus metformin and Endocrine Therapy (fulvestrant or Letrozole or Exemestane): During the first cycle, patients will receive Endocrine Therapy and metformin at least one-week prior alpelisib administration (D8).~Alpelisib (BYL719) 300 mg PO (two tablets of 150 mg once a day) on a continuous dosing schedule starting on Cycle 1.~Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.~Endocrine Therapy:~Fulvestrant 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles) or Letrozole 2,5 mg, once daily, orally or Exemestane 25 mg once daily, orally."
89660154|NCT04300790|Experimental|CohortB: Pre-diabetic patients|"Alpelisib plus metformin and Endocrine Therapy (fulvestrant or Letrozole or Exemestane): During the first cycle, patients will receive Endocrine Therapy and metformin at least one-week prior alpelisib administration (D8). Alpelisib (BYL719) 300 mg PO (two tablets of 150 mg once a day) on a continuous dosing schedule starting on Cycle 1.~Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.~Endocrine Therapy:~Fulvestrant 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles) or Letrozole 2,5 mg, once daily, orally or Exemestane 25 mg once daily, orally."
89660155|NCT04300790|Experimental|CohortC: Insulin naïve type 2 diabetic mellitus patients|"Alpelisib plus metformin plus vildagliptin and Endocrine Therapy (fulvestrant or Letrozole or Exemestane or Tamoxifen): During the first cycle, patients will receive Endocrine Therapy, metformin and vildagliptin at least two-weeks prior alpelisib administration (D15).Alpelisib (BYL719) 300 mg PO (two tablets of 150 mg once a day) on a continuous dosing schedule starting on Cycle 1.~Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.~Endocrine Therapy:~Fulvestrant 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles) or Letrozole 2,5 mg, once daily, orally or Exemestane 25 mg once daily, orally or Tamoxifen 20 mg once daily, orally."
89660156|NCT04257500|Experimental|Contraceptive Ring|Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing), which releases 120 mcg of etonogestrel and 15 mcg of ethinyl estradiol daily.
89660157|NCT04254913|Experimental|MT-1186|Patients receive the edaravone oral suspension.
89660158|NCT04247646|Active Comparator|Melatonin|Melatonin 5 mg sublingual nightly x 29 nights, starting on post-operative day 0.
89660159|NCT04247646|Placebo Comparator|Placebo|Placebo troche, sublingual nightly x 29 nights, starting on post-operative day 0.
89660160|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E7 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E7 Inf.U.
89660161|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E8 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E8 Inf.U.
89660162|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E9 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E9 Inf.U.
89660163|NCT04246671|Experimental|Stage 1 dose escalation: TAEK-VAC-HerBy (1x10E10 Inf.U)|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level 1x10E10 Inf.U.
89660164|NCT04246671|Experimental|Stage 2: Chordoma Cancer Cohort|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose level defined in stage 1.
89660165|NCT04246671|Experimental|Stage 2: HER2-positive Breast Cancer Cohort (Trastuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of trastuzumab, every three weeks with three administrations in total at the dose defined in stage 1.
89660166|NCT04246671|Experimental|Stage 2: HER2-positive Breast Cancer Cohort (Trastuzumab + Pertuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to patients who are on stable dose of trastuzumab and pertuzumab. TAEK-VAC-HerBy will be administered every three weeks with three administrations in total at the dose defined in stage 1.
89660167|NCT04246671|Experimental|Stage 2: HER2-positive Gastric/GEJ cancer cohort (Trastuzumab + TAEK-VAC-HerBy)|TAEK-VAC-HerBy will be administered intravenously to HER2-positive gastric/GEJ cancer patients who are on stable dose of trastuzumab. TAEK-VAC-HerBy will be administered every three weeks with
89660168|NCT04234399||Group|All patients receiving SOC imaging and Axumin PET scans.
89660169|NCT04225442|Other|Fatty meal|To study how a fatty meal modifies the physiological chronobiome in young and old, an isocaloric controlled liquid high fat meal (ICLHFM) will be consumed within 5 min. The ICLHFM contains an equivalent to 35% of the estimated total daily energy requirements (TDE), 60% of kcal delivered from fat while 13% come from protein and 27 % from carbohydrate.
89660170|NCT04221139|Experimental|Healthy young adults|Healthy young adults will play four virtual reality games: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
89660171|NCT04215991|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously (IV) on Day 1, in addition to standard of care. Participants weighing less than 34 kilograms (kg) will receive 60 milligrams (mg)/kg cefiderocol and participants ≥34 kg will receive 2000 mg.
89660172|NCT04215991|Experimental|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered via IV every 8 hours for an expected 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
89660173|NCT04215991|Active Comparator|Multiple Dose Phase: Standard of Care Alone|Participants will receive standard of care treatment according to local standards.
89047384|NCT00539045||A|The study population will consist of patients who are admitted to The New York Presbyterian Hospital-Weill Medical College of Cornell University (NYP-WMC) with ST elevation myocardial infarctions (STEMI). STEMI will be established based on standard clinical and ECG criteria.
89047385|NCT02410356|Experimental|TV-1106|TV-1106 to be injected once weekly.
89047386|NCT02410356|Active Comparator|dGH|dGH to be given as daily injections.
89660174|NCT04176575|Experimental|Acupuncture|"Eligible participants:~have advanced stage cancer and associated pain~will receive up to 12 acupuncture sessions~will attend sessions at UPMC's Center for Integrative Medicine~will complete study assessments at each visit~will complete a follow-up 4 to 6 weeks after their last acupuncture visit. Total study involvement will range from 16 to 18 weeks."
89047387|NCT00539084|Experimental|1|Intradermal injection of Lidocaine followed by a painful stimulus (venipuncture)
89047388|NCT00539084|Placebo Comparator|2|Intradermal injection of placebo followed by a painful stimulus (venipuncture)
89047389|NCT04660734|Experimental|3D printing group|"Group 1 (G1) consisted of 20 patients who underwent preoperative molding of the osteosynthesis plate on a 3D printed model of the pelvis. A preoperative scan of the healthy hemi-pelvis was used to create the 3D-printed model for patients in G1 according to the following three-step methodology: 1) A scanographic acquisition of images was performed using a multi-strip scanner in thin sections. These images were recorded as digital images in the standard medical format of digital imaging and communications ; 2) A digital, 3D model of the pelvis in the stereolithography format was created to digitally treat the 2D images. The individualization of the healthy hemi-pelvis, to which a mirror effect was applied allowed for the creation of a symmetrical 3D image, as hemi-pelvises are globally symmetrical. 3) A 3D printer was used to create a physical, 3D-printed model of the affected hemi-pelvis using polylactic acid."
89047390|NCT04660734|Experimental|conventional technique group|Group 2 (G2 or control group) included 23 patients who underwent surgery using the conventional technique.The patients in the control group (G2) underwent surgery following the conventional procedure based on radiographic and CT images with 3D reconstructions.
89047391|NCT00539123|Experimental|NCB|Participants receive Physician Management (PM) and non-contingent provision of take-home doses of buprenorphine-naloxone (NCB).
89660175|NCT04176224|Experimental|MT-1186|Patients receive the edaravone oral suspension.
89660176|NCT04176081|Active Comparator|Group 1: Radiation Therapy Only|Participants randomized to Group 1 will receive radiation therapy only.
89660177|NCT04176081|Experimental|Group 2: Radiation Therapy + darolutamide + degarelix|Participants randomized to Group 2 will receive radiation therapy only + darolutamide + degarelix.
89660178|NCT04166487|Experimental|Pembrolizumab Cycles 1-2|"For the first two cycles, Pembrolizumab will be administered at a predetermined dose every 3 weeks.~InVision plasma draw will take place at Cycle 1 Day 1 and Cycle 2 Day 1, with return of results to the treating oncologist prior to Cycle 3 Day 1.~At Cycle 3, patients will be re-registered per the inclusion criteria into 3 arms;~PEMBROLIZUMAB Alone~PEMBROLIZUMAB + Doublet Chemotherapy"
89660179|NCT04166487|Experimental|Pembrolizumab Alone, Cycle 3+|"- Following imaging assessment at Cycle 3, participants will continue pembrolizumab alone if the following responses are observed:~Response of Partial Response/Complete Response~Response of Stable Disease with plasma response~Response of Progressive Disease without worsening cancer symptoms AND plasma response"
89660180|NCT04166487|Experimental|Pembrolizumab + Doublet Chemotherapy, Cycles 3+|"Following imaging assessment at Cycle 3, participants will receive pembrolizumab in combination with platinum doublet chemotherapy if they have a response of stable disease without plasma response, OR no plasma response and response of progressive disease without worsening cancer systems. Platinum doublet should be histology-appropriate and will be given on-label, per treating oncologist.~PEMBROLIZUMAB~Chemotherapy multiple agents systemic~PEMETREXED~CARBOPLATIN~PACLITAXEL"
89660181|NCT04165941|Experimental|DRI cell therapy|The only arm will receive the DRI modified gamma delta T cells following standard therapy with radiation and temozolomide chemotherapy concurrent.
89660182|NCT04160091|Experimental|FX006 32mg in Glenohumeral OA Population|Single intra-articular (IA) injection
89660183|NCT04160091|Placebo Comparator|Normal Saline in Glenohumeral OA Population|Single intra-articular (IA) injection
89660184|NCT04160091|Experimental|FX006 32mg in Adhesive Capsulitis Population|Single intra-articular (IA) injection
89660185|NCT04160091|Placebo Comparator|Normal Saline in Adhesive Capsulitis Population|Single intra-articular (IA) injection
89660186|NCT04145895|Other|Physician-directed Postoperative Activity Restriction|Postoperative activity restrictions prescribed by physician.
89660187|NCT04145895|Other|Self-directed Postoperative Activity Restriction|Postoperative activity restrictions self-determined (parent/guardian and/or patient).
89660188|NCT04141774|Active Comparator|Passive FES|Subjects randomized to this control group will be asked to participate in a passive FES intervention or non-EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, and functional electric stimulation (FES) treatment.
89688639|NCT02254642|Experimental|Ischemic preconditioning arm|Patients will have the ischemic preconditioning protocol 1 hour before the aortic clamping.
89047392|NCT00539123|Experimental|ACB|Participants receive Physician Management (PM) and abstinence-contingent provision of take-home doses of buprenorphine-naloxone (ACB).
89047393|NCT02385201|Experimental|Senza|Subjects with chronic, intractable pain of the upper limbs and/or neck will be implanted with a Senza Spinal Cord Stimulation (SCS) system designed to deliver electrical stimulation to the spinal cord.
89047394|NCT00539318||GI Cancer|
89660189|NCT04141774|Experimental|Active FES|Subjects randomized to this experimental group will be asked to complete the active FES intervention which include EEG guided muscle stimulation. Participation will include behavioral assessments, functional magnetic resonance imaging, functional electric stimulation (FES) treatment, and EEG.
89660190|NCT04113018|Experimental|1|Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
89660191|NCT04093167|Active Comparator|Pembrolizumab alone|
89660192|NCT04093167|Experimental|Pembrolizumab + standard platinum-based chemotherapy|
89660193|NCT04092179|Experimental|Venetoclax and Enadisenib|"Enasidenib and venetoclax will be taken by mouth (orally), once a day, every day, continuously.~Every 28-day period will be called a cycle. Participants will start venetoclax alone on Cycle 1 Day 1 and continue the study drug alone until Day 15. On Day 15, participants will take enasidenib and venetoclax together and will continue to take the combination of study drugs until intolerable side effects or disease worsening."
89660194|NCT04077437|Experimental|Experimental: MDMA-assisted psychotherapy|Administration of 80 to 120 mg MDMA in combination with psychotherapy, followed by a supplemental half-dose of 40 or 60 mg MDMA offered 1.5 to 2 hrs after the initial dose, respectively.
89660195|NCT04077437|Placebo Comparator|Placebo Comparator: Placebo|Administration of inactive placebo in combination with psychotherapy.
89660196|NCT04073433|Experimental|MDMA-assisted therapy|One session of MDMA-assisted therapy with a dose of MDMA 120 mg and optional supplemental dose of 60 mg 1.5 to 2 hours later
89660197|NCT04070209|Experimental|Darolutamide (BAY1841788)+ SBRT|"CRPC subjects will receive LHRH agonist in combination with the new generation of hormonal therapy Darolutamide (300mg).~Subjects who progress on LHRH + Darolutamide and develop oligometastases will receive SBRT"
89660198|NCT04068948|Active Comparator|Midazolam, Hydroxyzine, Meperidine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, Hydroxyzine 1.0mg/kg, and Meperidine 1.5mg/kg prior to their dental procedure.
89660199|NCT04068948|Experimental|Midazolam, Hydroxyzine|Participants assigned to this group will receive a regimen of Midazolam 0.5mg/kg, and Hydroxyzine 1.0mg/kg prior to their dental procedure.
89660200|NCT04065074|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
89660201|NCT04056962|Experimental|patients treated with Tacrolimus ointment|
89660202|NCT04050345||Part B TRACC Colon|Patients with diagnosis of large bowel cancer (in the colon) and no evidence of metastatic disease
89660203|NCT04050345||Part B TRACC Rectal|Patients who have a diagnosis of large bowel cancer (in the Rectum) and no evidence of metastatic disease
89660204|NCT04050345||Part C TRACC- Standard of Care Adjuvant Chemotherapy|Randomised to Arm A: Standard of Care Arm (Patients with fully resected high risk stage II or stage III colon or Rectal cancer with no evidence of metastatic disease. Patients with locally advanced rectal cancer who have previously undergone chemoradiotherapy are also eligible to enrol.
89660205|NCT04050345||Part C-ct DNA Guided Arm|"Patients with fully resected high risk stage II or stage III colon or rectal cancer with no evidence of metastatic disease. Patients with locally advanced rectal cancer who have previously undergone chemoradiotherapy are also eligible to enrol.~De-escalation of adjuvant chemotherapy in patients who have a post-operative ctDNA negative result"
89660206|NCT04025216|Experimental|Dose Escalation Arm1: Solid Tumors|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
89660207|NCT04025216|Experimental|Dose Escalation Arm 2: Multiple Myeloma|Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
89660208|NCT04021121|Experimental|High Dose RIF with LZD|Arm 1 participants will receive high dose oral RIF (35mg/kg/day) and LZD 1200 mg daily for the first 4 weeks of therapy, along with standard doses of Isoniazid (INH), Pyrazinamide (PZA), and Ethambutol (EMB). After 4 weeks, LZD will be discontinued and high dose RIF will return to standard dose for the remainder of treatment.
89660209|NCT04021121|Experimental|Standard dose RIF with LZD|Arm 2 participants will receive standard dose RIF, INH, PZA, and EMB along with LZD 1200 mg daily. After 4 weeks, LZD will be discontinued.
89660210|NCT04021121|Experimental|High Dose RIF|Arm 3 participants will receive high dose oral RIF (35mg/kg/day) for the first 4 weeks of therapy, along with standard doses of INH, PZA, and EMB. After 4 weeks, high dose RIF will return to standard dose for the remainder of treatment.
89660211|NCT04021121|Active Comparator|Standard Dose RIF|Arm 4 participants will receive standard doses of RIF, INH, PZA, and EMB.
89047395|NCT02382510|Experimental|TRN-157|
89047396|NCT02382510|Placebo Comparator|Placebo|
89660212|NCT04018261|Experimental|Activated T-Lymphocytes|Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.
89660213|NCT03972930|Experimental|Hypofractionated Radiotherapy for Soft Tissue Sarcoma|Participants will be treated with 3-8 fractions, with the maximum prescribed dose to the Planning Tumor Volume (PTV) volume being 60 Gy delivered over a period of at most 8 weeks.
89660214|NCT03969680|Experimental|BMSCs plus PRP group|Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
89688640|NCT02254642|Other|Control patients|Usual surgery assigned to control patients
89047397|NCT02382510|Active Comparator|Tiotropium|
89047398|NCT00539357|Experimental|1|All patients self-administered stimulation for 60 consecutive minutes each day. Participants self-administered the treatment for a period of 6 weeks, 7 days a week between the hours of 15:00 and 19:00. Assessments took place every 2 weeks during the treatment period.
89047399|NCT04660695||Group 1|Patients included will undergo an EUS-guided gastroenterostomy with a 15x10mm or a 20x10mm lumen apposing metal Stent (Axios, Boston Scientific, Mass).
89660215|NCT03969680|Active Comparator|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
89660216|NCT03969563|Experimental|MBSR|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
89660217|NCT03969563|Active Comparator|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
89660218|NCT03961802|Experimental|systematic early rehabilitation|systematic early rehabilitation
89660219|NCT03961802|No Intervention|without systematic rehabilitation|without systematic rehabilitation
89660220|NCT03950739|Experimental|Tyvaso to TreT|Each subject will receive a corresponding dose of TreT for 3 weeks during the Treatment Phase based on the subject's current stable Tyvaso dose.
89660221|NCT03945318|Experimental|Part 1: BION-1301|Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.
89660222|NCT03945318|Placebo Comparator|Part 1: Placebo|Participants will receive a single dose of placebo administered by IV infusion.
89660223|NCT03945318|Experimental|Part 2: BION-1301|Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.
89660224|NCT03945318|Placebo Comparator|Part 2: Placebo|Participants will receive placebo by IV infusion.
89660225|NCT03945318|Experimental|Part 3: BION-1301|Two cohorts of participants will receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2) at 600mg/biweekly.
89660226|NCT03945318|Experimental|Part 4 Retreatment: BION-1301|Eligible participants from Part 3 may enroll in Part 4 due to disease progression or by choice for optional retreatment and receive SC injection at 600mg/biweekly.
89660227|NCT03937128|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
89660228|NCT03937128|Active Comparator|Services as Usual|Study participants will be receiving their Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
89660229|NCT03880461|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve GWG within the range recommended by the Institute of Medicine. The lifestyle intervention will be delivered through 1 telephone counseling session with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and weekly e-mails of core lifestyle intervention sessions. Personalized text messages and 1:1 telephone coaching sessions will be given to those who are not meeting the GWG guidelines.
89047400|NCT03456986|Experimental|PATH neurotraining (treatment)|Subject looks at computer screen to determine whether bars in fish-shaped window move left or right relative to background bars. The subject reports which way center pattern moves by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
89047401|NCT03456986|Active Comparator|Orientation Discrimination (control)|Subject looks at computer screen to determine whether bars in center circular window are tilted left or right relative to vertically oriented background bars. The subject reports which way center pattern is tilted by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes orientation of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern colored or black and white, and by increasing pattern's complexity level. This Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
89047402|NCT02376465|Experimental|BLI4600 Regimen 1|Oral bowel preparation for colonoscopy
89047403|NCT02376465|Experimental|BLI4600 Regimen 2|Oral bowel preparation for colonoscopy
89047404|NCT02376465|Active Comparator|PEG based below preparation|Oral bowel preparation for colonoscopy
89047405|NCT00539435|Active Comparator|1|Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
89047406|NCT04660578|Experimental|Single Group|A.Chohan continuous squeezing suture (ACCSS); An Obstetrical procedure using half circle 40mm round body polyglactin 910 suture #1 (Vicryl plus by Ethicon®), for controlling hemorrhage from the lower uterine segment, in patients with placenta previa / accreta for the prevention of hysterectomy at cesarean section.
89047407|NCT00539474|Active Comparator|1|Wireguided localisation
89047408|NCT00539474|Experimental|2|Radioguided occult lesion localisation
89047409|NCT04660266|Other|all cohort|
89047410|NCT04660461|Experimental|1. Randomized placebo-controlled, parallel-group study, crossover-design|
89047411|NCT04660461|Experimental|2. Randomized placebo-controlled, parallel-group study, crossover-design|
89660230|NCT03880461|No Intervention|Usual Care - Control|Usual Medical Care
89660231|NCT03874338||Colchicine|
89660232|NCT03874338||Placebo|
89660233|NCT03869216|Experimental|Intervention|Patients in the intervention will receive the educational intervention
89660234|NCT03869216|No Intervention|Usual Care|Patients in the control arm will receive usual care
89660235|NCT03862430|Experimental|NanO2TM|NanO2TM infusion in conjunction with Radiation Treatment and temozolomide
89660236|NCT03862430|Placebo Comparator|Placebo|Placebo Saline infusion in conjunction with Radiation Treatment and temozolomide
89660237|NCT03851133||All Participants|Blood samples, tumor samples and data will be collected from all participants as applicable.
89660238|NCT03793010|Experimental|FX006|FX006 32mg
89660239|NCT03793010|Placebo Comparator|Normal Saline|Normal Saline
89660240|NCT03790358|Placebo Comparator|Placebo|Placebo
89660241|NCT03790358|Experimental|low dose MDMA|6.5ug dose of serotonin agonist
89660242|NCT03790358|Experimental|medium dose|13ug dose of serotonin agonist
89660243|NCT03790358|Experimental|high dose|26ug dose of serotonin agonist
89660244|NCT03767517|Experimental|Active Intervention|Usual Care + Tele-consult Intervention
89660245|NCT03767517|Active Comparator|Usual Care|Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
89660246|NCT03761511|Active Comparator|Treatment arm|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
89660247|NCT03761511|Placebo Comparator|Placebo arm|Matching Placebo (capsules) once daily
89660248|NCT03728257|Experimental|LTGO-Home Based Exercise|The lung transplant recipient will receive LTGO- Home Based Exercise, a behavioral exercise intervention that consists of in-home exercise training integrated with behavioral coaching using tele-rehabilitation.
89660249|NCT03728257|Active Comparator|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
89660250|NCT03727880|Experimental|Arm A - Pembrolizumab and Defactinib|
89660251|NCT03727880|Experimental|Arm B - Pembrolizumab|
89660252|NCT03617536|Experimental|CR845 0.25 mg Oral Tablet|Oral CR845 0.25 mg to be taken orally once daily for 12 weeks
89660253|NCT03617536|Experimental|CR845 0.5 mg Oral Tablet|Oral CR845 0.5 mg to be taken orally once daily for 12 weeks
89660254|NCT03617536|Experimental|CR845 1 mg Oral Tablet|Oral CR845 1 mg to be taken orally once daily for 12 weeks
89660255|NCT03617536|Placebo Comparator|Placebo Oral Tablet|Oral Placebo to be taken orally once daily
89660256|NCT03615534|Placebo Comparator|Placebo|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
89660257|NCT03615534|Active Comparator|Fenofibrate Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
89660258|NCT03615534|Active Comparator|WMER Niacin Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
89660259|NCT03615534|Active Comparator|Combination Therapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
89660260|NCT03610750|Active Comparator|Specialty Care|Psychiatric medications and evidence-based psychotherapies to be provided at a specialty mental clinic facilitated by psychiatric technicians, the mental health specialty workforce already in place in Mozambique.
89660261|NCT03610750|Experimental|Integrated Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers.
89660262|NCT03610750|Experimental|Community Clinic Stepped Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers and community health workers, respectively.
89660263|NCT03609047|Experimental|experimental palbociclib arm|Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.
89660264|NCT03609047|Active Comparator|control chemotherapy arm|"Adjuvant chemotherapy:~4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w~Followed by standard adjuvant endocrine therapy for a duration of at least 5 years."
89660265|NCT03606538|Experimental|Moderate hepatic impairment|Eight participants with moderate hepatic impairment receive a single dose of 80 mg MDMA.
89660266|NCT03606538|Experimental|Normal hepatic function|Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg MDMA.
89660267|NCT03599661||Fertilit-e|Participants review Fertilit-e content, undergo interviews about issues of content, functionality, and ease of use, and complete questionnaires over 45-60 minutes.
89660268|NCT03599622|Experimental|BMS-986165 Dose 1|
89660269|NCT03599622|Experimental|BMS-986165 Dose 2|
89660270|NCT03599622|Placebo Comparator|Placebo|
89660271|NCT03584516|Experimental|Part 1 : Dose determination of itacitinib|itacitinib administered in combination with corticosteroids.
89660272|NCT03584516|Experimental|Part 1 : Dose expansion of itacitinib|itacitinib administered in combination with corticosteroids or corticosteroids alone.
89660273|NCT03584516|Placebo Comparator|Part 2 : itacitinib recommended dose from part 1|itacitinib or placebo administered in combination with corticosteroids
89660274|NCT03579251|Other|Pilot test|12 weeks of behavioral intervention (Black Men's Care), including an in-person session and two-way SMS, with a three-month follow-up period post-intervention.
89660275|NCT03539575|Other|Synthetic Psychoactive Cannabinoid Users|Synthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer [11-C]OMAR.
89660276|NCT03537014|Experimental|MDMA-assisted therapy|Administration of 80 or 120 mg MDMA (with a supplemental dose offered 1.5 to 2 hours later of 40 or 60 mg MDMA respectively) in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart.
89660277|NCT03537014|Placebo Comparator|Placebo with therapy|Administration of inactive placebo in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart
89660278|NCT03529942|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
89660279|NCT03485287|Experimental|MDMA-assisted therapy|Three sessions of MDMA-assisted therapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
89660280|NCT03476369|Experimental|Fentanyl and Crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
89660281|NCT03476369|Active Comparator|Fentanyl and Non-crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
89660282|NCT03442413|Experimental|2-[18F]-FA PET/CT|Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight
89660283|NCT03432949|No Intervention|Standard of Care Radium-223|Radium-223 treatment will be administered as per standard of care.
89660284|NCT03432949|Experimental|Radium-223 with oral Dexamethasone 0.5 mg|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
89660285|NCT03423160||Autism|Right-handed children, ages 8.0-12.9, diagnosed with high-functioning ASD (and no co-morbid conditions, excluding anxiety disorders)
89660286|NCT03423160||Control|Right-handed children, ages 8.0-12.9, with no neurological or psychiatric diagnoses, currently or by history
89660287|NCT03392324|Experimental|PRIMA|Implantation of PRIMA device
89660288|NCT03382262|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
89660289|NCT03382262|Active Comparator|TAcs 40 mg|Single intra-articular (IA) injection of TAcs 40 mg
89660290|NCT03381274|Experimental|Oleclumab Dose 1 + Osimertinib Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab (MEDI9447) Dose 1 every 2 weeks (Q2W) and oral osimertinib Dose 1 once daily (QD).
89660291|NCT03381274|Experimental|Oleclumab Dose 2 + Osimertinib Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 2 Q2W and oral osimertinib Dose 1 QD. In Part 2 (dose-expansion), participants (including participants dosed at the RP2D in Part 1) will receive IV oleclumab Dose 2 Q2W and oral osimertinib Dose 1 QD until documentation of disease progression, intolerable toxicity, or development of other reason for treatment discontinuation, whichever occurs first.
89660292|NCT03381274|Experimental|Oleclumab Dose 1 + AZD4635 Dose 1|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 1 Q2W and oral AZD4635 Dose 1 QD.
89660293|NCT03381274|Experimental|Oleclumab Dose 1 + AZD4635 Dose 2|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 1 Q2W and oral AZD4635 Dose 2 QD.
89660294|NCT03381274|Experimental|Oleclumab Dose 2 + AZD4635 Dose 2|In Part 1 (dose-escalation), participants will receive intravenous oleclumab Dose 2 Q2W and oral AZD4635 Dose 2 QD.
89660295|NCT03378076|Experimental|FX006 32 mg|Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
89660296|NCT03378076|Active Comparator|TAcs 40 mg|Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
89660297|NCT03365375|Active Comparator|Usual Care Referral|Subjects will be referred for primary care provider (PCP) follow up and/or to psychiatry for further management and treatment of elevated anxiety levels according to standard of care.
89660298|NCT03365375|Experimental|MBSR Referral|Referral to a local mindfulness-based stress reduction course in addition to referral to their PCP.
89660299|NCT03341403|Active Comparator|Synbiotic group|"severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive Probiotical ®/Bactecal® (3 pills a day, content: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill) during 3 months."
89660300|NCT03341403|Placebo Comparator|Placebo group|severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive a placebo (3 pills a day) during 3 months.
89660301|NCT03323944|Experimental|Cohort 1: huCART-meso cells via intravenous infusion (IV).|Subjects will receive a single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells on day 0 via intravenous infusion.
89660302|NCT03323944|Experimental|Cohort -1: low dose huCART-meso cells via intravenous infusion|In the event that 2 DLTs occur among subjects enrolled in Cohort 1, then enrollment in Cohort 1 will be stopped and the dose will be de-escalated by 10-fold to 1-3x10^6 cells/m^2. Subjects will receive a single dose of 1-3x10^6 cells/m^2 lentiviral transduced huCART-meso cells on day 0.
89660303|NCT03323944|Experimental|Cohort 2 - huCART meso cells via intraperitoneal infusion (IP)|Permanently closed
89660304|NCT03323944|Experimental|Cohort 3 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)|Permanently closed
89660305|NCT03323944|Experimental|Cohort 4 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)|Subjects will receive a single dose of of 1-3x10^7 cells/m^2 lentiviral transduced huCART-meso cells on day 0 following a minimum 1 week washout from standard care chemotherapy. This initial intrahepatic infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart.
89047412|NCT04685330||Adult patients undergoing an ultrasound-guided procedure|Adult patients undergoing an ultrasound-guided procedure, such as paracentesis, thoracentesis, or biopsy
89047413|NCT00554424|Active Comparator|LA|Intravaginal and pre-peritoneal injection of 1% lignocaine into each side of the upper vagina under ultrasound guidance immediately prior to ultrasound guided transvaginal oocyte retrieval
89047414|NCT00554424|Placebo Comparator|P|Intravaginal saline placebo injection into each side of upper vagina under ultrasound guidance immediately prior to transvaginal oocyte retrieval
89047415|NCT00539708|Experimental|NIV|Non-invasive ventilation
89047416|NCT00539708|Active Comparator|Control|Oxygen therapy
89660306|NCT03297281|Experimental|S1: maintenance|Maintenance of OAC in surgery of BPH by PVP.
89660307|NCT03297281|Active Comparator|S2 : discontinuation|Discontinuation of OAC in surgery of BPH by PVP.
89660308|NCT03291470|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
89660309|NCT03291470|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
89660310|NCT03282123|Experimental|MDMA-assisted therapy|Three sessions of MDMA-assisted therapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
89047417|NCT04660305|Experimental|AT278|Single subcutaneous injection 0.3U/kg
89047418|NCT04660305|Active Comparator|NovoRapid|Single subcutaneous injection 0.3U/kg
89047419|NCT00554502|Active Comparator|A|
89047420|NCT00554502|Active Comparator|B|
89660311|NCT03278340|Experimental|Sun Safe Workplaces - Technology (SSW-T)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via a range of technology systems including web-enabled visits with senior managers, online training of outdoor workers, and online access to collateral materials (e.g., brochures, posters, tip cards).
89660312|NCT03278340|Active Comparator|Sun Safe Workplaces - In Person (SSW-IP)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via personal visits with senior managers and in person training of outdoor workers by research staff over two years. Collateral materials (e.g., brochures, posters, tip cards) will be provided to worksites.
89660313|NCT03268603|Experimental|Mesenchymal Stromal Cells|Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10^7 or increased to 1 x 10^8, based on Dose Modification Rules.
89660314|NCT03224546|No Intervention|Control Group|This group will receive payment for providing urine samples throughout the trial.
89660315|NCT03224546|Experimental|Low Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
89660316|NCT03224546|Experimental|High Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
89660317|NCT03197194|Experimental|A : Alteplase|Intravenous injection of Alteplase and one tablet of placebo
89660318|NCT03197194|Active Comparator|B : Acetylsalicylic Acid|one tablet of Acetylsalicylic Acid and one dose of IV placebo
89660319|NCT03181763|Experimental|MDMA|Participants receive 100 mg MDMA
89660320|NCT03181763|Placebo Comparator|Placebo|Participants receive inactive placebo
89660321|NCT03099356|Experimental|Cyclophosphamide and Sirolimus|Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
89660322|NCT03089957|Experimental|Ulinastatin group|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
89660323|NCT03089957|Placebo Comparator|Control group|Control group will be in usual care without any intervention.
89660324|NCT03081429||Perioperative covert stroke|
89660325|NCT03081429||Postoperative cognitive dysfunction|
89660326|NCT03054298|Active Comparator|Cohort 1|Single dose of 1-3x10^7 huCARTmeso cells/m^2
89660327|NCT03054298|Active Comparator|Cohort 2|Cyclophosphamide 1 gram/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 huCARTmeso cells/m^2
89660328|NCT03054298|Active Comparator|Cohort 3|PERMANENTLY CLOSED
89660329|NCT03054298|Active Comparator|Cohort 4|PERMANENTLY CLOSED
89660330|NCT03054298|Active Comparator|Cohort 5|Single dose of 1-3x10^7 huCART-meso cells/m^2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen.
89047421|NCT00554541||Normal Body-Mass|BMI Index: 18.5-24.9 Ankle Brachial Index Venous physiologic study
89047422|NCT00554541||Obese Body-Mass|BMI Index: 30.0-39.9 Ankle Brachial Index Venous physiologic study
89047423|NCT00554541||Morbidly Obese Body-Mass|BMI Index: ≥ 40 Ankle Brachial Index Venous physiologic study
89660331|NCT03054298|Active Comparator|Cohort 6|Cyclophosphamide 1 gram/m^2 administered 2-4 days prior to dose of 1-3x10^7 huCART-meso cells/m^2 via IV infusion on Day 0. This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells.
89660332|NCT03054298|Active Comparator|Cohort 7|Cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day given over 3 days by IV infusion followed by a single dose of 1-3x10^7 huCART-meso cells/m^2 via intraperitoneal (i.p.) administration. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells.
89660333|NCT03046446|Experimental|FX006 32 mg|Single intra-articular injection
89660334|NCT03029403|Experimental|Dose Escalation|Patients with epithelial ovarian, fallopian tube or primary peritoneal cancer.
89660335|NCT03029403|Experimental|Dose Expansion - Cohort A|Patients with platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
89660336|NCT03029403|Experimental|Dose Expansion - Cohort B|Patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
89660337|NCT03029403|Experimental|Dose Expansion - Cohort C|Patients with recurrent advanced epithelial ovarian, fallopian tube and primary peritoneal patients with uncommon tumor histologies, including clear cell, mucinous and low grade serous or low grade endometrioid ovarian subtypes.
89660338|NCT02986230|Experimental|CP-CDS|The CP-CDS group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services.
89660339|NCT02986230|Experimental|CP-CDS + SDMT|The CP-CDS + SDMT group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services. The CP-CDS + SDMT arm also provides shared decision making tools to patient and provider at the time of the visit.
89660340|NCT02986230|No Intervention|Usual Care|The usual care group will have no access to the CP-CDS, or the CP-CDS + SDMT.
89660341|NCT02954562||Anxiety|"Participants enrolled in study A randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness (NCT02427568) who meet further inclusion criteria for fMRI scan"
89660342|NCT02945059|Experimental|1|Patients will undergo reversible PVE before major hepatic resection.
89660343|NCT02925234|Experimental|Panitumumab|Panitumumab for patients with a molecular tumor profile that can potentially be targeted by Panitumumab.
89660344|NCT02925234|Experimental|Olaparib|Olaparib for patients with a molecular tumor profile that can potentially be targeted by Olaparib.
89660345|NCT02925234|Experimental|Dabrafenib|Dabrafenib for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib.
89660346|NCT02925234|Experimental|Nilotinib|Nilotinib for patients with a molecular tumor profile that can potentially be targeted by nilotinib.
89660347|NCT02925234|Experimental|Trametinib|Trametinib for patients with a molecular tumor profile that can potentially be targeted by trametinib.
89660348|NCT02925234|Experimental|Erlotinib|Erlotinib for patients with a molecular tumor profile that can potentially be targeted by erlotinib.
89660349|NCT02925234|Experimental|Trastuzumab & Pertuzumab (combination)|Trastuzumab and Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab and Pertuzumab.
89660350|NCT02925234|Experimental|Vemurafenib & Cobimetinib (combination)|Vemurafenib and Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib and Cobimetinib.
89660351|NCT02925234|Experimental|Vismodegib|Vismodegib for patients with a molecular tumor profile that can potentially be targeted by vismodegib.
89047424|NCT00540020|Experimental|Cognitive-Didactic|Developed by Sohlberg & Mateer to target four cognitive domains often impaired by TBI: attention, memory, executive functions, and pragmatic communication. Subjects practiced progressively more difficult paper-and-pencil or computerized cognitive tasks in 1:1 cognitive therapy sessions (1.5-2.5 hours daily).
89047425|NCT00540020|Experimental|Functional-Experiential|The works of Giles and Clark-Wilson and Hartley guided the basic concepts and treatment of the functional-experiential arm (Functional). The objective of the functional protocol was to use real life performance situations and common tasks to remediate or compensate for functional deficits after brain injury. Functional protocol treatment interventions (1.5-2.5 hours daily) typically occurred in group settings and natural environments (hospital recreation areas, group rooms, simulated home environments in the dining room, community outings, etc.).
89047426|NCT00554580|Active Comparator|A|Usual care of pulmonary acute oedema
89047427|NCT00554580|Experimental|B|CPAP + usual care of pulmonary acute oedema
89047428|NCT02359227|Experimental|Cenderitide|Cenderitide will be administered as four, 48-hour, continuous, subcutaneous infusion rates of 0.5, 1.0, 2.0 and 3.0 ng/kg/min totaling up to eight sequential days of dosing.
89047429|NCT00540098|Experimental|1|Paroxetine + aerobic exercise
89047430|NCT00540098|Active Comparator|2|Paroxetine + relaxation
89047431|NCT00540098|Active Comparator|3|Placebo + aerobic exercise
89047432|NCT00540098|Placebo Comparator|4|Placebo + relaxation
89047433|NCT00540137|Active Comparator|NRTIs plus NNRTI arm|nevirapine 400 mg once daily (after 12 weeks induction)with a nucleoside backbone
89047434|NCT00540137|Active Comparator|NRTIs plus PI arm|atazanavir 300 mg once daily, ritonavir 100 mg once daily with a nucleoside backbone
89047435|NCT04660110|Active Comparator|Intervention arm|A single dose/round of IPT with DP (40mg/320mg tabs, Fosun Pharmaceuticals)
89047436|NCT04660110|No Intervention|Standard of care|Health information, no study drugs
89047437|NCT00540176|Experimental|Cohort A|Recurrent disease with previous surgery, radiation therapy and/or chemotherapy
89047438|NCT00540176|Experimental|Cohort B|Newly diagnosed disease with no previous therapy
89047439|NCT02341560|Active Comparator|single dose or multiple dose|QPI-1007 Injection - 1.5 mg
89047440|NCT02341560|Active Comparator|single or multiple dose|QPI-1007 Injection - 3.0 mg
89047441|NCT02341560|Sham Comparator|Sham|Sham injection procedure
89047442|NCT00540215|Active Comparator|1|450 nmol GLP-2 SC
89047443|NCT00540215|Placebo Comparator|2|1 ml isotonic saline SC
89047444|NCT00540254|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
89047445|NCT00540254|Active Comparator|Arm 2|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
89047446|NCT00540332|Placebo Comparator|Placebo|"Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
89047447|NCT00540332|Experimental|Palifermin|"Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
89047448|NCT02336685|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase in addition to opioids as standard of care.
89047449|NCT02336685|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase in addition to opioids as standard of care.
89047450|NCT02336685|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase in addition to opioids as standard of care.
89047451|NCT00540410|Experimental|1|
89047452|NCT00540410|Active Comparator|2|
89660352|NCT02925234|Experimental|Regorafenib|Regorafenib for patients with a molecular tumor profile that can potentially be targeted by regorafenib.
89660353|NCT02925234|Experimental|Nivolumab|Nivolumab for patients with a molecular tumor profile that can potentially be targeted by nivolumab.
89660354|NCT02925234|Experimental|Afatinib|Afatinib for patients with a molecular tumor profile that can potentially be targeted by Afatinib.
89660355|NCT02925234|Experimental|Dabrafenib & trametinib (combination)|Dabrafenib and trametinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib and trametinib.
89660356|NCT02925234|Experimental|Ribociclib|Ribociclib for patients with a molecular tumor profile that can potentially be targeted by Ribociclib.
89660357|NCT02925234|Experimental|Lenvatinib|Lenvatinib for patients with a molecular tumor profile that can potentially be targeted by Lenvatinib.
89660358|NCT02925234|Experimental|Pembrolizumab|Pembrolizumab for patients with a molecular tumor profile that can potentially be targeted by Pembrolizumab.
89660359|NCT02925234|Experimental|Durvalumab|Durvalumab for patients with a molecular tumor profile that can potentially be targeted by Durvalumab.
89660360|NCT02925234|Experimental|Rucaparib|Rucaparib for patients with a molecular tumor profile that can potentially be targeted by Rucaparib.
89660361|NCT02925234|Experimental|Axitinib|Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
89660362|NCT02925234|Experimental|Palbociclib|Palbociclib for patients with a molecular tumor profile that can potentially be targeted by Palbociclib.
89660363|NCT02925234|Experimental|Crizotinib|Crizotinib for patients with a molecular tumor profile that can potentially be targeted by Crizotinib.
89660364|NCT02925234|Experimental|Sunitinib|Sunitinib for patients with a molecular tumor profile that can potentially be targeted by Sunitinib.
89660365|NCT02925234|Experimental|Cabozantinib|Cabozantinib for patients with a molecular tumor profile that can potentially be targeted by Cabozantinib.
89660366|NCT02925234|Experimental|Abemaciclib|Abemaciclib for patients with a molecular tumor profile that can potentially be targeted by Abemaciclib.
89047453|NCT04659837|Active Comparator|Inhibitory Control Training|Active Inhibitory Control Training vs. Sham Inhibitory Control Training
89047454|NCT04659837|Other|Gameification|Gameified elements added vs. No gameified elements added
89660367|NCT02925234|Experimental|Alectinib|Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
89660368|NCT02925234|Experimental|Atezolizumab/bevacizumab|Atezolizumab and bevacizumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab and bevacizumab.
89660369|NCT02925234|Experimental|Ipilimumab/nivolumab|Ipilimumab and nivolumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Ipilimumab and nivolumab.
89660370|NCT02925234|Experimental|Entrectinib|Entrectinib for patients with a molecular tumor profile that can potentially be targeted by entrectinib.
89660371|NCT02925234|Experimental|Talazoparib|Talazoparib for patients with a molecular tumor profile that can potentially be targeted by talazoparib.
89047455|NCT00540527|Experimental|1|local intraarterial recombinant tissue plasminogen activator
89047456|NCT00540527|Active Comparator|2|intravenous (IV) rt-PA
89047457|NCT04659720|Active Comparator|summers' osteotome technique for closed sinus lift|Implant stability will be evaluated after closed sinus lift using summer's osteotome technique in posterior edentulous maxilla
89047458|NCT04659720|Active Comparator|Patient satisfaction evaluation after closed sinus lifting using summers' osteotome technique|"Will be assessed numerically using a patient satisfaction chart .~Time of assessment: immediately after surgery"
89047459|NCT00540605|Experimental|1|4g tenofovir 1% gel applied vaginally 2 hours prior to expected time of cesarean delivery
89047460|NCT04659915|Experimental|Metformin + Prednison|"During one of the study periods, subjects receive Metformin 500 mg tablets p.o. for seven days (starting with a dose of 500 mg /d, then the dose will be increased by 500 mg the next days until 2000 mg /d is achieved).~Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days."
89047461|NCT04659915|Placebo Comparator|Placebo + Prednison|During the other study period, subjects receive the same dose of placebo tablets p.o instead of metformin. Subjects also receive Prednisone 20 mg 1.5x/d tablets p.o. for seven days.
89047462|NCT00557427|Experimental|A|hypericum 250mg tablets twice daily for 8 weeks
89047463|NCT00557427|Active Comparator|B|fluoxetine 20mg - 40mg daily for 8 weeks
89047464|NCT00540800|Active Comparator|A|Three-weekly chemotherapy
89047465|NCT00540800|Experimental|B|Weekly chemotherapy
89047466|NCT00540917|Experimental|cooling spray|cooling spray during laser treatment
89047467|NCT04659876||Grup S (Survivors)|Survivors in ICU follow-up
89047468|NCT04659876||Grup NS (Nonsurvivors)|Patients who died in ICU follow-up
89047469|NCT04678596|Active Comparator|EonAligner|Patients in the EonAligner group were given a single thickness and hardness aligner and were asked to use the same it for 3 weeks.
89047470|NCT04678596|Active Comparator|Clearfix|In the Clearfix group, the patients were given three different thickness and hardness aligner and they were asked to use each aligner for one week from soft to hard.
89047471|NCT04678323|Active Comparator|Phentermine Plus Lifestyle Therapy|Participants in this arm will receive 15 mg p.o.q.day of phentermine plus lifestyle therapy for 52 weeks.
89047472|NCT04678323|Placebo Comparator|Placebo Plus Lifestyle Therapy|Participants in this arm will receive a matching placebo plus lifestyle therapy for 52 weeks.
89047473|NCT04678011||Personalized surveillance and intervention protocol|
89047474|NCT04659447|Experimental|Platelet-Rich Plasma|Four semitendinosus tendons and gracilis tendons are prepared. 4 ml platelet-rich plasma is completely absorbed by a gelatin sponge and fixed in the center of the four tendons. 4-0 absorbable line is used for fixation.Then we use conventional surgical techniques to reconstruct the ACL.
89047475|NCT04659447|No Intervention|control group|We performed conventional surgical techniques to reconstruction without using platelet-rich plasma.
89660372|NCT02925234|Experimental|dacomitinib|Dacomitinib for patients with a molecular tumor profile that can potentially be targeted by dacomitinib.
89660373|NCT02925234|Experimental|Lorlatinib|Lorlatinib for patients with a molecular tumor profile that can potentially be targeted by lorlatinib.
89660374|NCT02925234|Experimental|Erdafitinib|Erdafitinib for patients with a molecular tumor profile that can potentially be targeted by erdafitinib.
89660375|NCT02925234|Experimental|Alpelisib|Alpelisib for patients with a molecular tumor profile that can potentially be targeted by alpelisib.
89660376|NCT02925234|Experimental|Niraparib|Niraparib for patients with a molecular tumor profile that can potentially be targeted by niraparib.
89660377|NCT02925234|Experimental|Pemigatinib|Pemigatinib for patients with a molecular tumor profile that can potentially be targeted by pemigatinib.
89660378|NCT02925234|Experimental|Selpercatinib|Selpercatinib for patients with a molecular tumor profile that can potentially be targeted by selpercatinib.
89660379|NCT02925234|Experimental|Tepotinib|Tepotinib for patients with a molecular tumor profile that can potentially be targeted by tepotinib.
89660380|NCT02917993|Experimental|Itacitinib + osimertinib|
89047476|NCT04659525|Experimental|Evolocumab + Ezetimibe|Patients in this arm will receive subcutaneous evolocumab 140 mg every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
89047477|NCT04659525|Placebo Comparator|Placebo + Ezetimibe|Patients in this arm will receive subcutaneous placebo every two weeks plus ezetimibe 10 mg per os daily for 24 weeks
89047478|NCT03456908|Experimental|myeloma before MV-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with myeloma before MV-NIS treatment, and at Day 8-9 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 8 scan. Patients will be selected from subjects electing to participate in IRB 06-005263 at Mayo Clinic: Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma,"
89047479|NCT03456908|Experimental|endometrial cancer before VSV-hINF-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with endometrial cancer before VSV-hINF-NIS treatment, and at Day 3-5 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 3-5 scan. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Metastatic and/or Incurable Endometrial and Epithelial Ovarian Cancer, IRB 15-007000"
89047480|NCT02333643|Experimental|CLS003|Topical digoxin/furosemide
89047481|NCT02333643|Experimental|Digoxin topical formulation|
89047482|NCT02333643|Experimental|Furosemide topical formulation|
89047483|NCT02333643|Placebo Comparator|Vehicle topical formulation|
89047484|NCT03456869|Experimental|PSI group|The patient specific implant (PSI) is used to completed the genioplasty.
89047485|NCT04659330|Other|Intervention group|All patients underwent intervention
89660381|NCT02912078|Experimental|Pocket-warmed epidural medication|This arm will consist of pocket-warmed epidural medications to be administered per standard protocol to patients randomized to this group; this group is the pocket-warming group.
89047486|NCT00541424||PET/CT Scanning|Patients that have newly diagnosed mantle cell lymphoma will first undergo CT colonography (CT or CTC) and PET followed by conventional colonoscopy.
89047487|NCT02330445|Experimental|Part A|Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
89047488|NCT02330445|Experimental|Part B|Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
89047489|NCT04659486|Experimental|Exercise training|A 12 weeks parallel-group randomized controlled trial will be performed, in which covid-19 survivors adolescents will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength and aerobic exercises
89047490|NCT04659486|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
89047491|NCT02324985|Active Comparator|Active Arm|S-Ibuprofen Topical Gel 5%
89660382|NCT02912078|Active Comparator|Room-temperature epidural medication|This arm will consist of room-temperature epidural medications to be administered per standard protocol to patients randomized to this group. This group has no experimental intervention; standard of care labor epidural.
89660383|NCT02876172|Experimental|MDMA and CBCT|Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted therapy.
89047492|NCT02324985|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
89047493|NCT02314299|Experimental|Low Dose Regimen|MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
89047494|NCT02314299|Experimental|High Dose Regimen|MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
89047495|NCT04659681|Active Comparator|PVI Guided Fluid Therapy|Patients will receive PVI guided fluids during surgery PVI to be maintained below 12% if PVI >12 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 Lung zones in both lungs to measure total number of B-lines.
89047496|NCT04659681|Active Comparator|CVP Guided Fluid Therapy|Patients will receive Standard CVP Guided Fluids , CVP maintained between 10-16 cms H20 , if CVP< 10 then colloid bolus 200ml will be given. Lung Ultrasonography will be performed post-intubation as baseline and at the end of surgery before extubation in 4 zones in both lungs to measure total number of B-lines.
89047497|NCT00541619||A|hypertensives with proteinuria
89047498|NCT04659642|Active Comparator|dexmedetomidine group (group A)|will receive Dexmedetomidine 1ug/kg body weight IV diluted to 100ml normal saline (NS) over 15 minutes.
89047499|NCT04659642|Active Comparator|Fentanyl group (group B)|will receive Fentanyl 1 ug/kg body weight IV diluted to 100 ml normal saline (NS) over 15 minutes.
89660384|NCT02861898|Experimental|Intra-arterial Cetuximab after BBBD|Mannitol 20% 12.5ml over two minutes for Blood Brain Barrier (BBB) disruption followed by CTX administered intra-arterially for three doses at a dose of 250mg/m2
89660385|NCT02799095|Experimental|ALKS 4230|
89660386|NCT02799095|Experimental|ALKS 4230 + pembrolizumab|
89688641|NCT03871465|Experimental|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
89047500|NCT04659642|Active Comparator|Both Dexmedetomidine and fentanyl group (group C)|will receive both Dexmedetomidine 1ug/kg body weight mixed with fentanyl 1ug/kg in 100 ml normal saline (NS) over 15 minutes.
89660387|NCT02791581|Experimental|Breast Cancer Patients|"Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment."
89660388|NCT02791581|Experimental|Non-Cancer Controls|"Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities."
89660389|NCT02762370|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
89660390|NCT02762370|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release Formulation
89660391|NCT02751580|Experimental|Health services research (telehealth)|Patients undergo their first post-treatment visit as a virtual telehealth visit using the JeffConnect application downloaded onto their electronic device.
89660392|NCT02734069||Sarcopenic|Patients with sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
89047501|NCT00541736|Experimental|Patients|GTN-infusion
89047502|NCT00541736|Active Comparator|Controls|GTN-infusion
89047503|NCT02306811|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 every 4 weeks (Q4W) for 96 weeks
89047504|NCT02306811|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 every 4 weeks (Q4W) for 96 weeks
89047505|NCT02306811|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 every 4 weeks (Q4W) for 96 weeks
89047506|NCT02306811|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 every 4 weeks (Q4W) for 96 weeks
89047507|NCT00541814|Active Comparator|1|CNI [Cyclosporine] minimisation Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to target blood level of 50-100 ng/ml.
89047508|NCT00541814|Experimental|2|CNI [Cyclosporine] withdrawal Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to the point of withdrawal.
89047509|NCT04659564|Other|Breast-cancer related lymphedema (BCRL)|
89047510|NCT00541853|Active Comparator|A|ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.
89047511|NCT00541853|Experimental|B|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.
89047512|NCT00541853|Active Comparator|C|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.
89660393|NCT02734069||Non Sarcopenic|Patients without sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
89660394|NCT02717611|Experimental|ACP-196 (acalabrutinib)|ACP-196 (acalabrutinib) 100 mg to be administered orally (PO) twice a day BID
89660395|NCT02648997|Experimental|Cohort 1 (original cohort): Nivolumab Monotherapy|Nivolumab monotherapy (240 mg every 2 weeks)
89660396|NCT02648997|Experimental|Cohort 2: Nivolumab in Combination with Ipilimumab|"External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy)~Followed by 4 cycles of Nivolumab (3 mg/kg every 3 weeks) + Ipilimumab (1 mg/kg every 3 weeks)~Followed by Nivolumab monotherapy (480 mg every 4 weeks)."
89660397|NCT02577926|Experimental|Ruxolitinib|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.
89047513|NCT02301234|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib 100 mg orally (by mouth) twice daily for up to 16 weeks.
89047514|NCT02301234|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
89047515|NCT02301234|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
89047516|NCT00541892|Experimental|1|Medium with no human serum albumine added
89047517|NCT00541892|Active Comparator|2|Conventional medium
89047518|NCT00542048|Experimental|1|
89047519|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
89047520|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
89047521|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
89047522|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
89660398|NCT02577926|Active Comparator|Best available therapy (BAT)|BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.
89660399|NCT02518945|Placebo Comparator|Placebo|"12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo"
89660400|NCT02518945|Active Comparator|Active drugs|"12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug"
89660401|NCT02513394|Experimental|Arm A|Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.
89660402|NCT02513394|Other|Arm B|Standard adjuvant endocrine therapy for a duration of at least 5 years.
89660403|NCT02495701||Patients|Patients having Hip arthroscopic surgery
89047523|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
89047524|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
89047525|NCT01214668|Experimental|LY573636 + Liposomal Doxorubicin|
89047526|NCT00542126|Active Comparator|1|GnRH analog administration following embryo transfer
89047527|NCT00542126|No Intervention|2|
89047528|NCT02886832|Experimental|Prostate Health formulation|Prostate Health formulation
89660404|NCT02492074|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
89660405|NCT02492074|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
89660406|NCT02492074|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each)
89660407|NCT02492074|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
89047529|NCT02293941|Experimental|JKB-122 5mg|5mg, oral, once daily
89047530|NCT02293941|Experimental|JKB-122 15 mg|15mg, oral, once daily
89047531|NCT02293941|Experimental|JKB-122 35 mg|35mg, oral, once daily
89047532|NCT02293941|Placebo Comparator|placebo|comparable capsule, oral, once daily
89047533|NCT02289846|Placebo Comparator|Placebo BID|Placebo once in the morning and once in the evening.
89047534|NCT02289846|Experimental|IW-9179 QD AM + Placebo QD PM|IW-9179 once in the morning and placebo once in the evening.
89047535|NCT02289846|Experimental|Placebo QD AM + IW-9179 QD PM|Placebo once in the morning and IW-9179 once in the evening.
89047536|NCT02289846|Experimental|IW-9179 BID|IW-9179 once in the morning and once in the evening
89660408|NCT02468583|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
89660409|NCT02468583|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release formulation
89660410|NCT02427568|Placebo Comparator|Placebo with therapy|Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose.
89660411|NCT02427568|Active Comparator|MDMA-assisted therapy (125 mg)|125 mg 3,4-methylenedioxymethamphetamine (MDMA) administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg MDMA.
89660412|NCT02310399|Experimental|Pre-lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years
89660413|NCT02310399|Experimental|Post-Lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children < 21 years of age
89660414|NCT02284113|Experimental|Treatment|Treatment with focused cold therapy.
89660415|NCT02284113|Sham Comparator|Sham|Sham treatment with focused cold therapy device
89660416|NCT02151084|Experimental|Arm A (Continuous Dosing)|"Run-In: Selumetinib, orally, BID for 7 days (Day -7 to Day -1)~On treatment: Selumetinib, orally, BID from Day 1-21 of every 28 day cycle. Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
89660417|NCT02151084|Experimental|Arm B (Sequential Dosing)|"Run-In: Selumetinib, orally, BID for 5 days (Day -7 to Day -3) with 2 days washout~On treatment: Selumetinib, orally, BID from Day 1-5 and 8-19 of every 28 day cycle.~Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
89660418|NCT02151084|Experimental|Arm C (Standard Care)|Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.
89660419|NCT02116972|Experimental|FX006 16 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
89660420|NCT02116972|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
89047537|NCT00542204|Experimental|Online disease management|The PAMFOnline-mediated Personalized Health Care Program, which couples a multidisciplinary diabetes care management team with an EHR-integrated Online Disease Management (ODM) system.
89047538|NCT00542204|No Intervention|Usual care|Usual medical care. No access to the PHCP electronic system and self-management tools supporting this care management.
89047539|NCT04648800|No Intervention|Group I|with positive RT23 test reading, not randomised and not vaccinated against tuberculosis
89047540|NCT04648800|Active Comparator|Group II|with negative RT23 test reading, receiving BCG-10 Vaccine
89047541|NCT04648800|Placebo Comparator|Group III|with negative RT23 test reading, receiving placebo
89047542|NCT00542243|Active Comparator|Finasteride|"The recommended dosage of PROSCAR© is one 5 mg tablet daily with or without food. If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual.~PROSCAR© 5 mg tablets are blue, apple-shaped; film coated with the code MSD 72 on one side and PROSCAR on the other. They will be provided in bottles of 35 tablets."
89047543|NCT00542243|Placebo Comparator|Placebo|Patient will receive a placebo comparator each day for 6 months.
89047544|NCT02286804|Experimental|Ultherapy treatment|Subjects receiving Ultherapy treatment to up to 4 spider veins
89660421|NCT02116972|Placebo Comparator|Placebo|Normal Saline Single 5 mL intra-articular (IA) injection
89660422|NCT02102802||Full dose MDMA|Participants will receive 125 mg MDMA possibly followed 1.5 to 2 h later by 62.5 mg MDMA
89660423|NCT02009449|Experimental|Part A: Dose Escalation Cohort 1|Pegilodecakin (1 ug/kg) - Daily subcutaneous (SC) injections of pegilodecakin for up to 22 months
89660424|NCT02009449|Experimental|Part A: Dose Escalation Cohort 2|Pegilodecakin (2.5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
89660425|NCT02009449|Experimental|Part A: Dose Escalation Cohort 3|Pegilodecakin (5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
89660426|NCT02009449|Experimental|Part A: Dose Escalation Cohort 4|Pegilodecakin (10 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
89660427|NCT02009449|Experimental|Part A: Dose Escalation Cohort 5|Pegilodecakin (20 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
89660428|NCT02009449|Experimental|Part A: Dose Escalation Cohort 6|Pegilodecakin (40 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
89660429|NCT02009449|Experimental|Part A: Dose Expansion Cohort 1|at least 15 RCC participants will be dosed with pegilodecakin for up to 22 months
89660430|NCT02009449|Experimental|Part B: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
89660431|NCT02009449|Experimental|Part B: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
89660432|NCT02009449|Experimental|Part B: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
89660433|NCT02009449|Experimental|Part B: Dose Expansion Cohort|"Daily SC injection with pegilodecakin with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
89660434|NCT02009449|Experimental|Part C: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
89660435|NCT02009449|Experimental|Part C: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
89660436|NCT02009449|Experimental|Part C: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
89660437|NCT02009449|Experimental|Part C: Dose Expansion Cohort 1|"Daily SC injection with pegilodecakin with FOLFOX4 Every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
89660438|NCT02009449|Experimental|Part D: Dose Escalation Cohort 1|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Gemcitabine and nab-paclitaxel on Days 1, 8, 15 of each cycle (28 days = 1 cycle).~Nab-paclitaxel 125 mg/m2 IV over 30 minutes followed by~• Gemcitabine 1000 mg/m2 IV."
89660439|NCT02009449|Experimental|Part E: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with capecitabine BID daily for 14 days of each cycle (21 days= 1 cycle).~• Capecitabine 1000 mg/m2 po BID"
89660440|NCT02009449|Experimental|Part F: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with paclitaxel on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
89660441|NCT02009449|Experimental|Part G: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pazopanib orally given daily for 14 days of each cycle (21 days= 1 cycle)~• Pazopanib 800 mg po QD"
89660442|NCT02009449|Experimental|Part H: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
89660443|NCT02009449|Experimental|Part I: Dose Escalation Cohort 1|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with nivolumab on Day 1 of each cycle (14 days= 1 cycle).~• Nivolumab 3 mg/kg IV over 60 min"
89660444|NCT02009449|Experimental|Part H: Dose Escalation Cohort 2|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
89660445|NCT02009449|Experimental|Part H: Dose Escalation Cohort 3|"Pegilodecakin (40 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
89660446|NCT02009449|Experimental|Part J: Dose Escalation Cohort 1|Pegilodecakin (10 ug/kg) daily subcutaneous injections with gemcitabine and carbolplatin on Days 1,8 of each cycle (21 days=1 cycle) until disease progression gemcitabine 1000mg/m2 IV over 30 minutes followed by carboplatin AUC2 over 60 minutes
89660447|NCT02008396|Placebo Comparator|Inactive Placebo with Therapy|Subjects will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
89660448|NCT02008396|Experimental|MDMA-assisted therapy|Participants will receive 75 to 125 mg during two sessions of MDMA-assisted therapy lasting approximately 7 hours; first session dose lower than second session dose.
89660449|NCT01964859|Experimental|autologous skin fibroblasts|we are comparing 3 injection sites in the same individual
89660450|NCT01904136|Experimental|Treatment (NK cells, allogeneic stem cell transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and NK cells IV over 30 minutes on day -2 or -1.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and receive NK cells IV over 30 minutes on day -2 or -1.~TRANSPLANT: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO TID beginning on day 5 for approximately 6-7 months.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28-90."
89660451|NCT01894633|Experimental|Chloroquine, radiosensitizer|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the CLQ plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days.
89660452|NCT01894633|Placebo Comparator|Placebo|30 Gy of whole-brain radiotherapy in 10 daily fractions and an oral matching placebo for 28 days
89660453|NCT01891045|No Intervention|Control|Patients merely monitored on background variables to function as a baseline of comparison
89660454|NCT01891045|Active Comparator|Prediction|Patients randomized to this condition completes the OQ-45.2 weekly, but the reports are withheld from therapists and patients.
89660455|NCT01891045|Experimental|Intervention|Patients and therapists uses the feedback-system as intended, with real-time feedback to the therapist and full use of the suggested interventions
89660456|NCT01864096|Experimental|Metformin|Metformin 850 mg, twice daily for 36 months
89660457|NCT01864096|Placebo Comparator|Placebo|Placebo tablets, 2teice daily for 36 months
89660458|NCT01863901|Experimental|Treatment with the Cryo-Touch III Device|
89660459|NCT01856049|Other|Umbilical Cord Blood Collection|Umbilical Cord Blood is drawn from the umbilical cord of newborn babies diagnosed with Hypoplastic Left Heart Syndrome, before placental detachment. Cord blood is packaged in a Credo Cube, and sent at a temperate state to the manufacturer immediately after draw. At least 65 mL of cord blood is needed to produce a stem cell product during manufacturing. Once processed, the patient's autologous cord blood stem cells will be frozen for their potential future use in a clinical trial.
89660460|NCT01828099|Experimental|Ceritinib|Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.
89660461|NCT01828099|Active Comparator|Chemotherapy|Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg/m2 iv + Cisplatin 75 mg/m2 or Pemetrexed 500 mg/m2 iv + Carboplatin AUC 5-6 iv followed by Pemetrexed 500 mg/m2 every 21 days followed by Pemetrexed maintenance in non-progressors, etc (other usual rule to stop treatment).
89660462|NCT01793610|Active Comparator|Comparator-dose (40 mg) MDMA and Psychotherapy|Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.
89660463|NCT01793610|Experimental|Active Dose 2 (100 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.
89660464|NCT01793610|Experimental|Active Dose 1 (125 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.
89660465|NCT01788839||women with breast cancer|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with breast cancer. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Breast cancer patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
89660466|NCT01788839||women with lymphoma|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Lymphoma patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
89660467|NCT01769222|Experimental|Ipilimumab 25 mg (Phase 1)|Participants receive ipilimumab intratumorally on Day 1
89660468|NCT01769222|Experimental|Ipilimumab 25 mg and radiation therapy (Phase 2)|Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions
89660469|NCT01753765|Experimental|Treatment|Study treatment with Cryo-Touch III device at Day 0.
89660470|NCT01689740|Experimental|Lead in: 125 mg MDMA (Open Label)|Participants receive open-label MDMA with an initial dose of 125 mg, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
89660471|NCT01689740|Placebo Comparator|Active placebo dose MDMA (25 mg)|Participants receive initial dose of 25 mg MDMA, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
89660472|NCT01689740|Experimental|Full dose MDMA (125 mg)|Participants receive initial dose of 125 mg MDMA, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
89660473|NCT01681745|Experimental|Cryo-Touch Treatment|Initial treatment with Cryo-Touch III and three optional re-treatments (up to 4 treatments) performed 68 days to 1 day prior to abdominoplasty.
89660474|NCT01605318|Experimental|Phase1: Dose-escalation Phase: Labetuzumab Govitecan (LG) Once Weekly Dosing|Participants will receive 8, 12 and 16 mg/dose of LG once weekly dosing until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to up to 8 cycles, with a contingency to examine intermediate dose levels of 10 or 14 mg/kg, or if necessary to a lower dose level of 6 mg/kg.
89660475|NCT01605318|Experimental|Phase1: Dose-escalation Phase: LG Twice Weekly Dosing|Participants will receive 6 and 9 mg/kg per dose twice weekly dose of LG until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to up to 8 cycles. A lower dose level of 4 mg/kg may be added if > 1 out of 3 or 2 out of 6 participants are unable to tolerate all 4 doses without dose delay or reduction.
89660476|NCT01605318|Experimental|Phase 2: Dose-expansion Phase: LG Once or Twice Weekly Dosing|Participants will receive selected doses of LG once or twice weekly until unacceptable toxicity, progressive disease or death whichever occurs first, for each 21-day cycle for up to 8 cycles.
89660477|NCT01458327|Experimental|MDMA-assisted therapy|One experimental session of MDMA-assisted therapy
89660478|NCT01404754|Placebo Comparator|Lactose (Inactive Placebo)|Participant receives inactive placebo during day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
89660479|NCT01404754|Active Comparator|3,4-methylenedioxymethamphetamine|Participant receives 120 mg MDMA possibly followed by 40 mg MDMA during a day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
89660480|NCT01386710|Experimental|Arm 2|Drug: Bevacizumab and Carboplatin
89660481|NCT01386710|Experimental|Arm 1|Drug: Bevacizumab and Carboplatin
89660482|NCT01320085|Experimental|BRAFV600 mutant, 45mg bid MEK162|BRAFV600 mutant, 45mg bid MEK162
89660483|NCT01320085|Experimental|NRAS mutant, 45mg bid MEK162|NRAS mutant, 45mg bid MEK162
89660484|NCT01320085|Experimental|BRAFV600 mutant, 60mg bid MEK162|BRAFV600 mutant, 60mg bid MEK162
89660485|NCT01291914|Experimental|FX005|
89660486|NCT01291914|Placebo Comparator|Placebo 1 (Carrier)|
89660487|NCT01291914|Placebo Comparator|Placebo 2 (Diluent)|
89660488|NCT01269853|Experimental|Arm 2|
89660489|NCT01269853|Experimental|Arm 1|
89660490|NCT01211405|Active Comparator|Low dose MDMA|Participants will receive 30 mg MDMA during each of two blinded experimental sessions.
89660491|NCT01211405|Active Comparator|Medium dose MDMA|Participants will receive 75 mg MDMA on each of two blinded experimental sessions
89660492|NCT01211405|Experimental|Full dose MDMA|Participants will receive 125 mg MDMA during each of two blinded experimental sessions, followed by a third open label session.
89660493|NCT01207492|Experimental|Nilotinib|Nilotinib 200 mg taken as 400 mg twice daily, continuously
89660494|NCT01167140|Experimental|Cryo-Touch II|
89660495|NCT01083966|Experimental|Avastin|IA Avastin
89660496|NCT00503438||Salto Talaris Ankle|This is an Implant Registry of the approved Salto Talaris Ankle replacement device
89660497|NCT00402298|Experimental|Full dose (125 mg) MDMA-assisted therapy|Participants will receive an initial dose of 125 mg MDMA followed 2.5 hours later by a supplemental dose of 62.5 mg MDMA during the course of two day-long therapy sessions.
89660498|NCT00402298|Active Comparator|Active Comparator (25 mg) MDMA-assisted therapy|Participants will receive an initial dose of 25 mg MDMA followed 2.5 hours later by a supplemental dose of 12.5 mg MDMA during the course of two day-long therapy sessions.
89660499|NCT03266081|Experimental|0.75% bupivacaine|
89660500|NCT04933565|Experimental|ORG-129|Single ascending dose (up to 4 cohorts), Multiple ascending dose (up to 4 cohorts), Food interaction cohort, Multiple dose PK/PD cohort
89660501|NCT04933565|Placebo Comparator|Placebo|Single ascending dose (up to 4 cohorts), Multiple ascending dose (up to 4 cohorts), Food interaction cohort, Multiple dose PK/PD cohort
89660502|NCT04926311||Developmental Language Disorder patients|
89660503|NCT03010995|Active Comparator|18 mg nicotine|E-cigarette with 18 mg nicotine
89660504|NCT03010995|Active Comparator|9 mg nicotine|E-cigarette with 9 mg nicotine
89660505|NCT03010995|Placebo Comparator|0 mg nicotine|E-cigarette with 0 mg nicotine
89660506|NCT01158573||Healthy non-asthmatic obese adults|Healthy non-asthmatic obese adults
89660507|NCT01158573||Healthy non-asthmatic non-obese adults|Healthy non-asthmatic non-obese adults
89660508|NCT01158573||Asthmatic obese adults|Asthmatic obese adults
89660509|NCT01158573||Asthmatic non-obese adults|Asthmatic non-obese adults
89660510|NCT02984579||All Subjects|"All strains in Phase 1 and all Sputum samples in Phase 2 were tested with Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2, and YD REBA MTB-MDR diagnostic tests.~Investigators and Operators were blinded to all other results for a sample upon data entry."
89660511|NCT04278365|Experimental|AMP-A|Participants will complete 11, 90-minute sessions of positive affect training. The positive affect training will be conducted in an individual setting. Positive affect training directly targets reward and positive valence processing and has been shown by previous research to enhance positive affect (and decrease negative affect).
89660512|NCT01230177||Etanercept (genetical recombination)|Among the patients with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy), the patients who will have changed regimen from 10 mg twice a week administration to 25 mg once a week administration.
89660513|NCT02984657||2012 patients|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
89660514|NCT02984657||2015 patients|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
89660515|NCT01158651|Experimental|RAD001 (Everolimus) Active Therapy|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
89660516|NCT03263507|Experimental|Donidalorsen|Ascending single and multiple doses of Donidalorsen administered subcutaneously
89660517|NCT03263507|Placebo Comparator|Placebo (sterile saline 0.9%)|Calculated volume to match active comparator
89660518|NCT04852679|Other|lanreotide Autogel 120 mg|Subjects will be treated with lanreotide Autogel® 120mg, every 28 days (+/- 3 days).
89660519|NCT03262103|Experimental|Cohort 1|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
89660520|NCT03262103|Experimental|Cohort 2|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
89660521|NCT03262103|Experimental|Cohort 3|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
89660522|NCT03262103|Experimental|Cohort 4|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
89660523|NCT04779593|Experimental|experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin."
89660524|NCT04779593|Active Comparator|control group|"Patients treated with bloodletting according to current guidelines ferritin alone"
89660525|NCT04775225|Active Comparator|Hip denervation group|This group will receive Lidocaine 2% block of the femoral and obturator genicular branches.
89660526|NCT04775225|Placebo Comparator|control group|this group will receive saline injection subcutaneously at the same places.
89660527|NCT04775225|Active Comparator|Steroid|This group with receiving an intra-articular injection of 80mg triamcinolone
89660528|NCT04746443||STUDENTS|COLLEGE STUDENTS WITH POSITIVE COVID-19 TEST
89660529|NCT04723277|Experimental|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
89660530|NCT04723277|Active Comparator|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
89660531|NCT04723277|Experimental|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
89660532|NCT04723277|Active Comparator|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|EUC (control arm)
89660533|NCT04723277|Experimental|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
89660534|NCT04723277|Active Comparator|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
89660535|NCT04719143|Active Comparator|CBT-I|
89660536|NCT04719143|No Intervention|Waitlist Control|
89660537|NCT04717895|Experimental|1st Situation|Subjects included will be identified with an even selection number will begin the virtual reality session by viewing a rocking environment followed by a translation environment
89660538|NCT04717895|Active Comparator|2nd Situation|Subjects included will be identified with an odd selection number will start the virtual reality session by viewing a translation environment followed by a rocking environment
89660539|NCT04685915|Experimental|Addition of copanlisib to either ibrutinib or acalabrutinib|"During the 28-day study treatment cycles, participants will:~Continue to take ibrutinib (daily) or acalabrutinib (twice a day) at a predetermined dose for as long as there are no serious side effects and disease progression~Receive intravenous infusion of copanlisib at a predetermined dose days 1, 8 and 15 for cycles 1-6."
89660540|NCT03255785|Experimental|G1 plus G3 with phaco|Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra
89660541|NCT04399187|Experimental|scaling and root planing, Sodium hypochlorite gel application|Periodontal pockets > 5 mm in patients of test group were treated by scaling and root planing and Sodium hypochlorite gel application
89660542|NCT04399187|Placebo Comparator|scaling and root planing alone|scaling and root planing alone was performed
89660543|NCT04277897|Experimental|Drug SAD Cohorts|Hepenofovir Fumarate Tablets Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily in one single administration.
89660544|NCT04277897|Placebo Comparator|Placebo SAD Cohorts|Matching placebo, orally, once daily in one single administration.
89660545|NCT04277897|Experimental|Drug MAD Group|Hepenofovir Fumarate Tablets Dose 3 orally, once daily for 7 days.
89660546|NCT04277897|Placebo Comparator|Placebo MAD Group|Matching placebo, orally, once daily for 7 days.
89660547|NCT04277897|Experimental|Food-influnced Group|Hepenofovir Fumarate Tablets Dose 4 orally, once daily in one single administration in fast condition,cross-over 7 days later in fed condition.
89660548|NCT04655495|Experimental|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
89660549|NCT04655495|Active Comparator|Balanced gluten free diet|Balanced gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients.
89660550|NCT03239561|Experimental|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
89660551|NCT03239249|Experimental|Intervention group: IKO-model (20 schools)|Schools randomized to experimental group will implement the IKO-drop-out prevention intervention. Each county have a project leader responsible for following up the implementation. The model is described in a manual, that schools should follow.
89660552|NCT03239249|Active Comparator|Treatment as usual (22 schools)|Schools randomized to control group will work as previously with their drop-out prevention. This include various activities, but they are not systematic as in the IKO-model.
89660553|NCT04746365|Experimental|ivermectin|ivermectin was given as a total daily dose of 36 mg on days 0, 3, 6. The daily dose was divided into 3 equal doses of 12 mg (2 tablets) every 8 hours
89660554|NCT04746365|Experimental|hydroxychloroquine|hydroxychloroquine was given as 200 mg (one tablet) every 12 hours for 5 days
89660555|NCT04746365|Placebo Comparator|Placebo|Unlabelled standard treatment according to the clinical condition of patients
89660556|NCT04399577|Experimental|Wart Patients|Patient receive 0.1 mL of diluted preparation of candida solution at 2 weeks interval for the maximum of 5 sessions
89660557|NCT03237455|Experimental|study group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
89660558|NCT03237455|Active Comparator|control group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
89660559|NCT03237299||Cases|Cases: children with loco-regional complications of pharyngitis
89660560|NCT03237299||Controls|Controls: children with pharyngitis but without infectious complications
89660561|NCT04399343|Experimental|Dexmedetomidine group|Continuously intravenous infusion of dexmedetomidine hydrochloride at a rate of 0.1 μg/kg/hour (0.025 ml/kg/hour) started immediately after enrollment until 08:00 AM on the postoperative day one.
89660562|NCT04399343|Placebo Comparator|Normal saline group|Continuously intravenous infusion of normal saline at a rate of 0.025 ml/kg/hour started immediately after enrollment until 08:00 AM on the postoperative day one.
89660563|NCT03233633|Other|Single treatment arm|marijuana adjuvant treatment group utilizing scheduled opioid therapy in inpatient hospice hospital setting
89660564|NCT03233555|Active Comparator|Arm I (brochure)|Participants receive National Cancer Institute's Facing Forward brochure.
89660565|NCT03233555|Experimental|Arm II (EXCELS website)|Participants have untimed access to the EXCELS mobile web application.
89660566|NCT03233555|Experimental|Arm III (Healthcare coaching call)|Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
89660567|NCT03233555|Experimental|Arm IV (EXCELS website, health coaching calls)|Participants have access to EXCELS as in Arm II. Participants also receive 4 calls as in Arm III.
89660568|NCT04277429||Normal cardiac function|Normal cardiac function
89660569|NCT04277429||Heart failure with reduced ejection fraction|Heart failure with reduced ejection fraction
89660570|NCT04277429||Heart failure with preserved ejection fraction|Heart failure with preserved ejection fraction
89660571|NCT04347707|Experimental|BRIDGE Clinical Group|This group of mother-child dyads will have mothers who have been screened for and met diagnostic criteria for depression. Mothers in this group will participate in the 20-week group therapy and parent skills training intervention.
89660572|NCT04347707|No Intervention|Baseline Comparison Group|This group of mother-child dyads will not meet diagnostic criteria for depression and will serve as a comparison group for baseline measures. Dyads will be matched to the BRIDGE clinical group based on household income and child age.
89660573|NCT01230801|Experimental|BMN 701|IV infusion
89660574|NCT02984345|Active Comparator|Mycoprotein beverage|
89660575|NCT02984345|Placebo Comparator|Milk protein beverage|
89660576|NCT01232205|Active Comparator|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
89660577|NCT01232205|Placebo Comparator|Control|
89660578|NCT04584125|Experimental|Ex vivo cross linking of donor corneal tissue|Treatment Arm: The donor corneal tissue used in the PK or DALK procedures will previously undergo ex vivo crosslinking.
89660579|NCT04584125|Sham Comparator|Non-cross-linked donor corneal tissue for keratoplasty|Control Arm: The donor corneal tissue used in the PK or DALK procedures will not previously undergo ex vivo crosslinking.
89660580|NCT03011229|Active Comparator|Pro Core|Subject is randomized to ProCore standard needle.
89660581|NCT03011229|Experimental|Medtronic Shark Core|Subject is randomized to Medtronic Sharkcore needle
89660582|NCT04348409|Experimental|nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
89660583|NCT04348409|Placebo Comparator|Placebo|Patients will receive placebo BID for 7 days
89660584|NCT01158885|Experimental|Single Arm|"A maximum of two courses of the following regimen will be administered.~Clofarabine: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.~Cytarabine intravenous: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.~Methotrexate: to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age.~Intrathecal (IT) cytarabine: is optional for acute myelogenous leukemia (AML) patients."
89660585|NCT03368183|Experimental|SCAMP arm|The SCAMP is a clinical decision support tool. See Mendu et al. CJASN 2017.
89660586|NCT03368183|Active Comparator|"Control arm SHAM SCAMP"|The control arm will be a form that asks questions about indications for renal replacement therapy but does not provide suggestions about when to initiate renal replacement therapy, as is being done in the active SCAMP arm. The goal of the control group is to test whether the SCAMP clinical decision support influences provider practice patterns and improves care.
89660587|NCT01232829|Experimental|Treatment (RO4929097)|"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies."
89660588|NCT04574063|No Intervention|Breast cancer risk leaflet only|
89660589|NCT04574063|No Intervention|Breast cancer risk leaflet PLUS SNPs|
89660590|NCT04574063|Experimental|Lifestyle website only|
89213573|NCT05166551|Placebo Comparator|Placebo Group|"Pressure will be applied by the researcher on a placebo point at least 2 cun above the GB31 acupuncture point, on the leg to be vaccinated, for 1 minute. The considerations before, during and after pressure are as follows:~The hands will be washed to warm them up to body temperature.~For the infants in the placebo group, pressure will be applied using the thumb for 1 minute to a placebo point that does not coincide with any acupuncture point at least 2 cun above the acupuncture point before the vaccine is administered.~Pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
89213574|NCT05166551|No Intervention|Control Group|"The considerations before, during and after are as follows:~Without any intervention, the infants in this group pain scoring will be performed using the FLACC scale by the parents, the observing nurse, and the researcher after the vaccination procedure. In addition, the HR and SPO2 level of the infants before, during and after the procedure will be evaluated and recorded by the researcher.The crying time of infants will also be recorded."
89213575|NCT01006863|Active Comparator|Ephedrine 0.15 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1.5 mg/kg of ephedrine
89213576|NCT01006863|Active Comparator|Ephedrine 0.1 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1 mg/kg of ephedrine
89213577|NCT01006863|Active Comparator|Ephedrine 0.07 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 0.7 mg/kg of ephedrine
89660591|NCT04574063|Experimental|Lifestyle website PLUS SNPs|
89660592|NCT04574063|Experimental|Lifestyle website PLUS group coaching|
89660593|NCT04574063|Experimental|Lifestyle website PLUS group coaching PLUS SNPs|
89660594|NCT01233921|Experimental|Arm I (palifermin)|Patients receive palifermin IV on days 1-3 in the absence of unacceptable toxicity.
89660595|NCT01233921|Active Comparator|Arm II (no palifermin)|Patients do not receive palifermin.
89660596|NCT04566341||Feasibility of OCT TCE in identifying signs of PD|Participants that fulfill our Inclusion/Exclusion criteria will be asked to swallow our Capsule Imaging device.
89660597|NCT03226301|Experimental|Ibrutinib until progression/relapse|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRDpositive patients (PB and BM) will continue on Ibrutinib maintenance (non-randomized group) until progression/relapse"
89660598|NCT03226301|Experimental|Arm A|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm A: Ibrutinib until progression/relapse (Continuous ibrutinib treatment until toxicity or progression)"
89660599|NCT03226301|Experimental|Arm B|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm B: Observation until event.~Patients randomized to Arm B will get reinitiation of therapy during the observation period in case of:~progression according to IWCLL criteria or~MRD≥10-3 (PB) and at least one month later MRD ≥10-2 (PB).~Treatment reinitiation will consist of ibrutinib and venetoclax (with ramp up of venetoclax from cycle 1) for 12 cycles"
89660600|NCT01236105|Experimental|6 mg LY2624803 Alone Morning Dosing|Participants received 6 milligrams (mg) LY2624803 alone orally (po) at approximately 0800 hours following an overnight fast.
89660601|NCT01236105|Experimental|6 mg LY2624803 Morning Dosing + Activated Charcoal|Participants received 6 mg LY2624803 po at approximately 0800 hours following an overnight fast, followed 1 hour later by a single po dose of 1 gram per kilogram (g/kg) body weight of activated charcoal, mixed with caffeine-free diet cola.
89660602|NCT01236105|Experimental|6 mg LY2624803 Alone Evening Dosing|Participants received 6 mg LY2624803 alone po at approximately 2200 hours following a 4-hour fast.
89660603|NCT04348253|Active Comparator|Berger|Bergers capsulodesis
89660604|NCT04348253|Active Comparator|3LT|Three ligament tenodesis
89660605|NCT04534283|Experimental|Abemaciclib + LY3214996|Subjects will receive Abemaciclib 150 mg orally twice daily with LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
89213578|NCT01006863|Placebo Comparator|Placebo|received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution
89660606|NCT01159743||Efavirenz|HIV-infected patients on initial antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
89213579|NCT01006863|Active Comparator|Phenylephrine|received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/kg of phenylephrine
89213580|NCT05688189|Experimental|37 degree centigrade|The 37°C arm implies the setting of the temperature immediately at 37°C.
89213581|NCT05688189|Experimental|34-37 degree centigrade|The 34-37°C arm implies the setting of the temperature at 34°C and after 15 minutes at 37°C.
89213582|NCT05688189|Experimental|31-34-37 degree centigrade|The 31-34-37°C arm implies setting the temperature initially at 31°C, after 15 minutes at 34°C and after another 15 minutes at 37°C.
89660607|NCT01159743||Lopinavir / Ritonavir|HIV-infected patients on initial antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
89660608|NCT05683847||Adults with epilepsy|User controlled epilepsy follow-up by means of digital patient reported outcome measures (PROM).
89660609|NCT03364517|Experimental|Experimental group SPIA|The regulator will be asked to systematically use the tool Predictor score of the imminence of a childbirth (SPIA). This tool is used to evaluate the means to be sent following a call for imminent delivery outside the hospital.
89660610|NCT03364517|No Intervention|Control group|The classic care will be made according to the usual practices of the doctor and the center.
89660611|NCT04533347|Active Comparator|Tafenoquine|Tafenoquine two 100 mg oral tablets 1x/day on Days 1,2,3 and 10
89660612|NCT04533347|Placebo Comparator|Placebo|Placebo two tablets 1x/day on Days 1,2,3 and 10
89660613|NCT04488263||Cohort 1|Subjects with confirmed/suspected NENs.
89660614|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Melanoma|"Patients with metastatic melanoma Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
89660615|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Renal Cell|"Patients with metastatic renal cancer Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
89660616|NCT04398875|Experimental|ASC|Traditional manual acupuncture with standard care (ASC) will be provided. Subjects in the ASC group will receive 9 sessions of acupuncture and standard care for 3 weeks. A semi-standardized acupuncture treatment protocol (combined fixed acupoints with additional acupoints by symptom differentiation) will be employed. The fixed acupuncture points including, Guanyuan (CV4), Xuanzhong(GB39), Sanyinjiao (SP6), Yinlingquan (SP9), Zusanli (ST36), Yingtang (EX-HN3), Baihui (GV20), and Qihai (CV6) will be used in every session.
89660617|NCT04398875|Sham Comparator|SSC|Sham acupuncture plus standard care (SSC) will be provided. Subjects in the SSC group will receive 9 sessions of sham acupuncture and standard care for 3 weeks. The Streitberger sham acupuncture will be employed. The selection of acupoints is the same as ASC.
89660618|NCT04398875|Placebo Comparator|SC|Standard care alone (SC) will be provided. Subjects in the SC group will standard care for 3 weeks.
89660619|NCT05680025|No Intervention|Control|Participants in the control group will be invited to attend two workshops, where they will be given and have explained a guide to physical activity and one for diet for patients with hypertension. In addition to pharmacological treatment, this is the information given as part of conventional treatment patients with hypertension receive from health care personnel.
89660620|NCT05680025|Experimental|Physical exercise intervention|Promoting physical exercise. The intervention group will have access to training videos through social networks and infographics.
89660621|NCT01237041|Experimental|Niacin First|Subjects receive niacin 500mg hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive placebo hourly for 4 hours on day 2 at (7:30am, 8:30am, 9:30am, and 10:30am).
89660622|NCT01237041|Experimental|Placebo First|Subjects receive placebo hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive niacin hourly for 4 hours on day 2 (at 7:30am, 8:30am, 9:30am, and 10:30am).
89660623|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 250mg|Subjects received Niacin 250 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
89660624|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 500mg|Subjects received Niacin 500 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
89660625|NCT01237041|Experimental|Dose-Establishing Study 2 Niacin 500mg|Subjects received Niacin 500 mg hourly for 4 doses (administered at 7:30am, 8:30am, 9:30am, and 10:30am).
89660626|NCT04279145|Experimental|pulmonary hypertension group 1|each patient will be submitted to : swan-ganze catheterization detailed echocardiography blood sample for biomarkers (troponin, uric acid and micro RNA)
89660627|NCT03010605|Active Comparator|Standard of care physical therapy|Patients will receive 2 weeks of in-home physical therapy consisting of 3 sessions per week followed by 4 weeks of outpatient physical therapy three times weekly.
89660628|NCT03010605|Active Comparator|MED Device|Patients will perform 10 repetitions with the MED device 3 times daily at 8am, 2pm, and 8pm and will transmit the 10th measurement of each time point to the clinicians office.
89660629|NCT04278911||Participates|This is an observational study
89660630|NCT01237197|Experimental|Exenatide, then Open-Label Exenatide|Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
89660631|NCT01237197|Placebo Comparator|Placebo, then Open Label Exenatide|Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.
89660632|NCT05673395|Experimental|EARW group|This group drink electrolyzed alkaline reduced water (EARW, pH 9.5) 10 mL/kg body weight in 10 min after exercise.
89660633|NCT05673395|Sham Comparator|PW group|PW is purified water generated from sham device, and PW group drink 10 mL/kg body weight in 10 min after exercise.
89660634|NCT01237353|Experimental|betaine hydrochloride and rabeprazole|
89660635|NCT04277585|Experimental|OASIS Clients|Clients of the OASIS Program who live at least 45 minutes away from an Early Psychosis Coordinated Specialty Care Program and are willing to engage in some of their services through telehealth.
89660636|NCT01237821|Active Comparator|BenzaClin|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
89660637|NCT01237821|Active Comparator|effaclar|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
89660638|NCT03362489|Other|IVF / IVF-ICSI|In Vitro Fertilization / In Vitro Fertilization - Intracytoplasmic Sperm Injection (ICSI)
89660639|NCT03362489|Other|IUI|Intrauterine insemination
89660640|NCT01241565|Experimental|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|Single arm study, all patients will receive the study device.
89660641|NCT05664581|Experimental|Rapid Acoustic Pulse (RAP)|Participants will receive 3 separate RAP cellulite treatments sessions.
89660642|NCT03010761|Experimental|medication pills 1: escitalopram 10mg|10mg once daily, 8 weeks
89660643|NCT03010761|Experimental|medication pills 2: moclobemide 150mg|150mg once daily, 8 weeks
89660644|NCT03010761|Experimental|medication pills 3: Placebo - Cap|placebo once daily, 8 weeks
89660645|NCT04400669|Experimental|Mechanical Bowel Preparation|Patients will have only clear liquids after a normal breakfast and lunch on the day before surgery and subsequently fasten for 7-9 hours prior to surgery. Patients will ingest first dose of 45 ml oral sodium phosphate (NaP) enema (BT ORAL SOLUSYON 45 ML®, Yenisehir Lab. Tic. San. Ltd. Sti, Turkey) at 4 p.m. and a second dose at 8 p.m. in the evening before the scheduled surgery.
89660646|NCT04400669|Active Comparator|Low fibre diet|Patients will be given detailed instructions about the pre-operative diet (total daily Fibre intake inferior to 10 g) to be used for 3 days prior to surgery.
89660647|NCT04400669|Active Comparator|MBP plus low fibre diet|This group will receive both mechanical bowel preparation and 3-days low fibre diet.
89660648|NCT04400669|No Intervention|Control|Control subjects will receive no instructions about the pre-operative diet (free diet).
89660649|NCT04746755|Experimental|Experimental: Lower back pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced lower back pain; the subjects selection was corroborated by a physiotherapist.
89660650|NCT04746755|Experimental|Experimental: Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the heels of their feet; the subjects selection was corroborated by a physiotherapist.
89660651|NCT04746755|Experimental|Experimental: Knee to Heel pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced Knee to Heel pain; the subjects selection was corroborated by a physiotherapist.
89660652|NCT04746755|Experimental|Experimental: Arch pain associated with musculoskeletal stress|Subjects eligible for the study self selected the insole for the pain in-accordance with the pain that they were experiencing due to musculoskeletal stress. Subjects within this arm of the study experienced pain in the arch of their feet; the subjects selection was corroborated by a physiotherapist.
89660653|NCT01161225|Experimental|peer-led asthma self-managment program|
89660654|NCT01161225|Active Comparator|Adult-led asthma self-management program|
89660655|NCT03010839|Active Comparator|Modified Remote Ischemic Preconditioning(mRIPC)|modified RIPC was induced at 24 h, 12 h and 1 h before surgery to reinforce the protective effects of RIPC. The single RIPC protocol was induced by three cycles of upper-limb ischemia, a standard blood-pressure cuff was placed on the ringt upper arm, then inflated the cuff to 200 mm Hg for 5 minutes, followed by 5 min of cuff deflation.
89660656|NCT03010839|Placebo Comparator|Control|Control group without remote ischemic preconditioning
89660657|NCT04389827||Incident & Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
89660658|NCT01243593|Experimental|Treatment Group|
89660659|NCT01243593|Active Comparator|Control Group|
89660660|NCT04383431|Experimental|Standard CXL|Standard epithelium-off CXL, 30 minutes soaking time with riboflavin, 30 minutes UVA corneal irradiation continuous mode.
89660661|NCT04383431|Experimental|Accelerated CXL|Accelerated epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation continuous mode.
89660662|NCT01161771||Patients with cataract and corneal astigmatism|Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)
89660663|NCT05649839|Active Comparator|conventional garment|
89660664|NCT05649839|Experimental|prototype garment|
89660665|NCT04362761|Experimental|ELX/TEZ/IVA|"Part A: Participants received elexacaftor (ELX) 200 milligram (mg) once daily (qd)/tezacaftor (TEZ)100 mg qd/ivacaftor (IVA)150 mg every 12 hours (q12h) in the treatment period for 48 weeks.~Part B: Participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period up to 86 weeks."
89660666|NCT01162005|Experimental|Tacrolimus|Tacrobell
89660667|NCT05639309||Case (hemodynamically significant patent ductus arteriosus)|Hemodynamically significant patent ductus arteriosus (hsPDA) diagnosed by echocardiographic criteria including pulsatile left-to-right shunt through patent ductus arteriosus, enlarged left atrium and/or left ventricle, increased left pulmonary artery velocity, absent or reversed end-diastolic flow of anterior cerebral artery and/or renal artery
89660668|NCT05639309||Control (no hemodynamically significant patent ductus arteriosus)|no hsPDA based on the same echocardiographic criteria described for the Case group
89660669|NCT01244451|Experimental|Bendofa|Bendamustine + Ofatumumab
89660670|NCT04398953|Experimental|TQ-B3525 tablet|TQ-B3525 tablet administered orally.
89660671|NCT03009591|Experimental|Expermiental group|All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
89660672|NCT03009591|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
89660673|NCT01244529|Other|galy A Plus/ galy A / seno A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
89660674|NCT01244529|Other|galy A Plus / seno A / galy A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
89660675|NCT01244529|Other|galy A / galy A Plus / seno A|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
89213583|NCT03967093|Experimental|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with relapsed solid tumors, including malignant brain tumors, will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level (3.2 mg/kg) is reached.
89213584|NCT03967093|Experimental|Part 2: Ependymoma Patients|Cohort of patients with recurrent ependymoma will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
89660676|NCT01244529|Other|galy A / seno A / galy A Plus|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
89660677|NCT01244529|Other|seno A / galy A / glay A Plus|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
89660678|NCT01244529|Other|seno A / galy A Plus / galy A|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A -subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
89660679|NCT01162317|Active Comparator|Arm 1: sham acupuncture|sham acupuncture
89660680|NCT01162317|Experimental|Arm 2: acupuncture|acupuncture
89660681|NCT01245699|No Intervention|Before RTAVF and post-event debriefing|Before scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
89660682|NCT01245699|Active Comparator|After RTAVF and post-event debriefing|After scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
89660683|NCT05629871|Experimental|Single arm|Alzheimer
89660684|NCT03220529|Active Comparator|Normal healthy subjects|Healthy subjects with normal appearing corneas respecting all the general inclusion/exclusion criteria. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
89660685|NCT03220529|Active Comparator|Keratoconus subjects|Subjects classified as patients with mild, moderate, or advanced keratoconus. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
89660686|NCT03220529|Active Comparator|Subjects diagnosed with PMD|Subjects with Pellucid marginal corneal degeneration (PMD). Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
89660687|NCT03220529|Active Comparator|Patients before and after LASK surgery|Healthy subjects who are scheduled to undergo LASIK surgery. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
89660688|NCT03220529|Active Comparator|Patients with keratoconus before and after CXL|Subjects who are scheduled to undergo collagen crosslinking treatment. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
89660689|NCT04333667|Experimental|Intervention group|The intervention group will get an 8-week mindfulness-based internet intervention.
89660690|NCT04333667|No Intervention|Control group|The waiting list will get no intervention while the intervention group is getting the intervention. The waiting list has the possibility to get an intervention after the intervention group finishes it.
89660691|NCT01246401|Active Comparator|Extended-Release Naltrexone|Participants will receive intramuscular (IM) injections of Naltrexone once monthly for 6 months, the first injection being prior release
89660692|NCT01246401|Placebo Comparator|Placebo|Participants will receive IM injections of Placebo once monthly for 6 months, the first injection being prior release
89660693|NCT05628545|Experimental|GDKM-100 injection|"In this trial, the patients will receive multiple high-activity γδ T cell immunotherapies.The trial is divided into two parts: Part 1 is a multiple-dose escalation trial consisting of 3 dose groups (2×10^8 cells/person, 5×10^8 cells/person, 10×10^8 cells/person at 1-3 infusion, 4-6 infusion and 7-9 infusion), with 9 patients planned to be enrolled. Part 2 is a single dose trial in which doctor and the PI evaluates whether to give the rest patients to receive the 10×10^8 cells/person infusions based on available safety data.~The check indexes are CT scan，intestinal flora detection and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89660694|NCT01281501|Active Comparator|Conventional|Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline
89660695|NCT01281501|Experimental|Pantoprazole|Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole
89660696|NCT03353831|Placebo Comparator|Arm A: Chemotherapy + Bevacizumab + Placebo|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Placebos q14
89660697|NCT03353831|Experimental|Arm B: Chemotherapy + Bevacizumab + Atezolizumab|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Atezolizumab 840 mg q14
89660698|NCT01246479|Other|No treatment|subjects will be followed up on immunity (analysis of blood samples) and safety
89660699|NCT01246713|Placebo Comparator|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
89660700|NCT01246713|Active Comparator|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
89660701|NCT01246791|Experimental|NPC-01|Single oral administration of NPC-01
89213585|NCT03967093|Experimental|Part 2: Brain Tumor Patients|Cohort of patients with recurrent malignant brain tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
89660702|NCT04319081||Uncontrolled patients with hypercholesterolemia|Patients that meet criteria inclusions and they have just started to take Alirocumab or Evolocumab
89660703|NCT05345639|Experimental|TTP group (= Transversus Thoracic Plane block = Deep PIP = Deep parasternal intercostal plane block)|At the end of the surgery, realisation of a bilateral transverse thoracic block. (20ml of Naropeine 0.2%, each side) Followed by standard analgesic treatment.
89660704|NCT05345639|Experimental|PSB group (=ParaSternal Block = Superficial PIP = Superficial parasternal intercostal plane block)|"At the end of the surgery, realisation of a bilateral parasternal block (20ml of Naropeine 0.2%, each side).~Followed by standard analgesic treatment."
89660705|NCT05345639|Sham Comparator|Control group|Standard analgesic treatment alone (without LRA) .
89660706|NCT04399109|Active Comparator|TCC-COVID mHealth solution|TCC-COVID is an app-based model of care which includes a smartphone app and a pulse oximeter that measures oxygen saturation, pulse rate and collects symptoms, connected to a back-end clinical database with inbuilt data analytics.
89660707|NCT04399109|No Intervention|Control|Propensity matched and synthetic control groups will be utilised from another local health district not participating in the ReCOVER study. The control group will not be actively recruited at the same time as the intervention. The control group will be matched via data linkage at the completion of the trial. However, it is not a historical control, as the control standard of care treatment will be provided simultaneously as our intervention
89660708|NCT01247571|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89660709|NCT04303325|Placebo Comparator|Control|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
89660710|NCT04303325|Active Comparator|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine.
89660711|NCT03009747||sphincter-preserving surgery|Patients meet the inclusion criteria will be enrolled into this observing group
89660712|NCT03630263|Experimental|Raw Corn Starch|Vehicle (apple sauce) will be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
89660713|NCT03630263|Placebo Comparator|No Raw Corn Starch|Vehicle (apple sauce) will not be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
89660714|NCT04228679|Experimental|Erbium laser treatment|Women with vaginal looseness and sexual dysfunction treated with real laser.
89660715|NCT04228679|Sham Comparator|Sham laser treatment|Women with vaginal looseness and sexual dysfunction treated with sham laser.
89660716|NCT04277195||NUH Adjuvant Breast Cancer Cohort: Historical|This is a series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (1986-1999; n=1650). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
89660717|NCT04277195||NUH Adjuvant Breast Cancer Cohort: New|A series of breast cancer patients treated with adjuvant therapy, who were identified and samples selected for inclusion in the Nottingham Tenovus Breast research project by Prof Ian Ellis's research group (2000-2006; n=2000). The clinical dataset for this cohort of breast cancer patients has been collected in a master clinical database by the team supporting Professor Ian Ellis. The study research team will work with a pseudo-anonymised copy of this dataset.
89660718|NCT04277195||NUH Neoadjuvant Breast Cancer Cohort|For many years clinical data on this cohort of breast cancer patients has been collected in a master clinical database by the clinical team supporting Dr Chan (1996-2021; n=900 patients). This has been used for internal audits and reviews of clinical practice. The study research team will work with a pseudo-anonymised copy of this dataset.
89660719|NCT04277195||NUH Oncotype DX tested Adjuvant Breast Cancer Cohort|A list of patients tested with Oncotype DX as part of their standard treatment pathway (2015-2021; n=200) will be collected and will form the basis of a master clinical database for this cohort. The database will be managed and populated by the clinical team supporting Dr Chan. The study research team will work with a pseudo-anonymised copy of this dataset.
89660720|NCT04277039|Experimental|OMT+CT|It consists of 8 sessions of osteopathic treatment and two 20-min sessions of cognitive training per week per 2 months
89660721|NCT04277039|Active Comparator|osteopathic treatment|It consists of 8 sessions of osteopathic treatment throughout the 2-month study period
89660722|NCT04277039|Other|usual care|patients will continue the routine care as established by international guidelines
89660723|NCT04276961|Experimental|Acupuncture plus usual care|Acupuncture will be given on the basis of usual care. A total of 12 sessions of acupuncture will be given over a period of 4 weeks.
89660724|NCT04276961|Sham Comparator|Sham acupuncture plus usual care|Sham acupuncture refers to acupuncture at sham points. Sham acupuncture will be given on the basis of usual care. A total of 12 sessions of sham acupuncture will be given over a period of 4 weeks.
89660725|NCT04759859||Carotid Endarterectomy (CEA)|70 participants undergoing CEA
89660726|NCT04759859||Other Peripheral Vascular Surgery|30 participants undergoing other peripheral vascular surgical procedures
89660727|NCT04746209|Experimental|Alpha/beta T-cell and B-cell Depleted, Myeloablative HCT|Patients who are MRD Negative by Flow cytometry but are MRD Positive by High Throughput Sequencing, will receive a myeloablative conditioning regimen which includes total body irradiation (TBI) followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
89660728|NCT04746209|Experimental|Alpha/beta T-cell and B-cell Depleted, Reduced Intensity HCT|Patients who are MRD Negative by Flow cytometry and are MRD Negative by High Throughput Sequencing, will receive a reduced intensity conditioning regimen followed by an alpha/beta T-cell and B-cell depleted transplant. They will also receive a 28 day continuous infusion of blinatumomab starting on Day 100 post-transplant in the absence of significant ongoing GVHD.
89660729|NCT04168931|Experimental|Interventional|Use of trastuzumab combination chemotherapy in patients with relapsed or metastatic gastric cancer with expression HER2 negative in the tumor tissue but positive in CTC.
89660730|NCT04160663|Experimental|Subjects with atrial fibrillation|Subjects with atrial fibrillation that have been clinically scheduled for an electrical cardioversion procedure will have carotid ultrasound testing done before and after the procedure
89660731|NCT04133987|Experimental|Tetravalent live attenuated dengue vaccine admixture TV005|Tetravalent live attenuated dengue vaccine admixture TV005
89660732|NCT04133987|Placebo Comparator|placebo|Plasma-Lyte A
89660733|NCT04098029|Experimental|Group 1 Low HLA compatibility|The patients in the first group will receive two CBU of low-level HLA matched infusions within a 6-month interval. The low-level match is 3 or less HLA compatibility degree by A, B, DRB1 loci.
89213586|NCT03967093|Experimental|Part 2: DIPG Patients|Cohort of patients with recurrent diffuse intrinsic pontine glioma (DIPG) will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
89213587|NCT03967093|Experimental|Part 2: Other Solid Tumor Patients|Cohort of patients with relapsed non-central nervous system (CNS) solid tumors will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at 3.2 mg/kg if the MAD is not reached.
89213588|NCT01006941|Experimental|Trichuris suis ova|
89213589|NCT03534167|Experimental|TODAY! App and Coaching|RCT participants will be randomized into a 10-week intervention condition during which they will receive the CBT modules through the TODAY! app. In addition to the mobile app, participants will receive coaching from the study Coach who is trained in Motivational Interviewing principles. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks.
89213590|NCT03534167|No Intervention|Referrals|RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
89213591|NCT02531347|Experimental|Telemedical blood pressure monitoring|Telemedical home blood pressure measurements for three days every second week. The average of all measures excluding day one is electronically transmitted to the General Practitioners. Following communication primarily by email or telephone.
89660734|NCT04098029|Experimental|Group 2 High HLA compatibility|The patients in the second group will receive two CBU of high-level HLA matched infusions within a 6-month interval. The high-level match is 4 or more HLA compatibility degree by A, B, DRB1 loci.
89213592|NCT02531347|Active Comparator|Conventional blood pressure monitoring|Conventional blood pressure monitoring
89213593|NCT04075175|Experimental|S315 human monoclonal antibody|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo (0.9% Sodium Chloride)) with escalation of a fixed dose of S315
89213594|NCT04075175|Placebo Comparator|0.9% sodium chloride (NaCl)|5 cohorts of 8 subjects each randomized 6:2 (S315:Placebo(0.9% Sodium Chloride)) with escalation of a fixed dose of S315
89660735|NCT04098029|Other|Standard therapy|Patients with standard therapy as a control group
89213595|NCT05550051|Active Comparator|lignocaine nebulization before awake nasal fiberoptic intubation|Patients will have lignocaine nebulization by using 3 ml of lignocaine 2%, with O2 flow rate 10 l/min to deliver 60 mg lignocaine, of which about 25% is absorbed, and patients were encouraged to inhale deeply to facilitate further delivery of the anesthetic in their airway. After finishing the nebulization setting the patient will be asked about facial, nasal, and oral numbness if no numbness, the patient will have another nebulization setting.
89521729|NCT03414073|Active Comparator|Group C Phase 3|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the knotted floss technique in the third phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
89521730|NCT04637971|Experimental|Coaching|The present intervention is a structured, group-based coaching program that is facilitating an active process of change through the identification of achievable personal goals, the formulation of action plans, the provision of constructive feedback, and progressive monitoring of goal attainment.
89521731|NCT04637971|Active Comparator|Self-help tips plus telephone support|Self-help tips including stress coping methods. Our project staff will contact the subject to encourage her to make use of the tips we sent her.
89521732|NCT03425929|Active Comparator|Oxytocin (6 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure and three days after the second trauma movie exposure (24 IU per day)
89521733|NCT03425929|Active Comparator|Oxytocin (3 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure (24 IU per day) and placebo nasal spray for three days after the second trauma movie exposure
89521734|NCT03425929|Placebo Comparator|Placebo|Placebo nasal spray for six days
89521735|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment B|Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) [with different particle size distribution (PSD) as compared to Treatment A, D, C and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
89521736|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment D|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment D containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and E) on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
89521737|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment A|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment A containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment B, C, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
89521738|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment C|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment C containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
89521739|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment E|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment E containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and D] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
89213596|NCT05550051|Active Comparator|Upper airway block before awake nasal fiberoptic intubation|"Upper airway block by using about lignocaine 2%, the block will be performed by:~Bilateral superior laryngeal nerve block and will be performed by slight neck extension to identify the hyoid bone. Insert the needle laterally aiming at the greater cornu, and after hitting the bone, it will slide inferiorly, and 2 mL of 2% lignocaine will be injected blocking both the internal and the external branches of the superior laryngeal nerve.~Trans tracheal instillation for recurrent laryngeal nerve block and will be performed by extending the neck to identify the midline and palpate the cricoid cartilage. The cricothyroid membrane lies above the cricoid cartilage. A needle will be inserted in the cricothyroid membrane while aspirating and once air bubbles appears, 5ml of 4% lignocaine will be injected resulting in cough and dispersing of the LA, blocking the nerve."
89213597|NCT03967015|Experimental|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will receive MUAC training and nutritional education at enrollment. A short message service (SMS) message will be sent at 7 days following enrollment asking them to measure and send their child's MUAC. Weekly SMS messages asking for the child's MUAC measurement will be sent every 7 days until the last study visit at 180 days following enrollment.
89213598|NCT03967015|No Intervention|Standard of care (SOC)|Participants randomized to the standard of care (SOC) arm will receive the same MUAC training and nutritional education as mothers in the MAMMS arm. To accurately simulate community malnutrition outreach programs, no SMS message will be sent to participants in this arm.
89213599|NCT05012007|No Intervention|Control arm: No Reminder|Usual care
89213600|NCT05012007|Experimental|Automated phone reminder|Standard reminder via phone (audiocare)
89213601|NCT05012007|Experimental|Text reminder|Standard reminder via text (VEText)
89213602|NCT03741439|Experimental|Treatment arm|Receives real treatment according to manufactures instructions. 6 sessions of low intensity shockwave treatment with an electromagnetic emitter.
89213603|NCT03741439|Sham Comparator|Sham Arm|Receives sham treatment with same applicator, same sound, same time and number of shocks. But no real energy is delivered.
89213604|NCT03529955|Experimental|Dermatomyositis patients with refractory cutaneous disease|Patients with dermatomyositis and refractory skin disease on steroids and one steroid-sparing agent.
89660736|NCT04080635|Experimental|Standard of care - brodalumab|Patients will continue to receive brodalumab according to standard care dosing regimen, i.e. loading dose first (210mg), once a week for 2 weeks (210mg), then a regular dose regimen (210mg) every 2 weeks.
89660737|NCT03211949|Experimental|axillary block with infiltration MCAN|With the performance of the axillary blok, 2 ml of scandicaine will be placed around the medial cutaneous ante brachial nerve (MACN)
89660738|NCT01285635|Active Comparator|Docetaxel Alone|
89660739|NCT01285635|Experimental|Pulse Dose AT-101 Arm|
89660740|NCT01285635|Experimental|Metronomic AT-101 Arm|
89660741|NCT01285713|Experimental|5% Dextrose (D5) in Normal Saline (NS)|10cc/kg D5NS, followed by 30cc/kg NS
89660742|NCT01285713|Active Comparator|Normal Saline (NS)|10cc/kg NS, followed by 30cc/kg NS
89660743|NCT01285791||patients undergoing laparoscopic adjustable gastric banding|morbid obese patients undergoing laparoscopic adjustable gastric banding will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased.
89660744|NCT01285791||patients undergoing laparoscopic sleeve gastrectomy|morbid obese patients undergoing laparoscopic sleeve gastrectomy will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
89660745|NCT01285791||patients undergoing laparoscopic gastric bypass|morbid obese patients undergoing laparoscopic gastric bypass will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
89660746|NCT01286259|Experimental|Intervention Arm|
89660747|NCT01286493|Experimental|Rabies vaccines on day 0 and 3|Cell culture Rabies vaccines on day 0 and 3
89660748|NCT01286805|Experimental|Lumbar Plexus Blockade + CSE|The study group will receive a lumbar plexus blockade with 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine, followed by a combined spinal-epidural.
89660749|NCT01286805|Placebo Comparator|Control Group|The control group will receive only a combined spinal-epidural.
89660750|NCT04019561|Experimental|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
89660751|NCT04019561|Placebo Comparator|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
89660752|NCT04019561|Experimental|MEDI0382 low dose|MEDI0382 low dose administered subcutaneoously
89660753|NCT04019561|Placebo Comparator|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
89660754|NCT01288521|Experimental|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
89660755|NCT01288521|Experimental|Tacrolimus alone, Then Tacrolimus + Ketoconazole|The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.
89660756|NCT01288833|Experimental|Close focus HD NBI Colonoscopy System|Use of close focus to make optical diagnosis
89660757|NCT01288833|No Intervention|Current HD NBI Colonoscopy System|Use of standard focus for optical diagnosis
89660758|NCT00632749|Experimental|Schedule A|BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10
89660759|NCT00632749|Experimental|Schedule B|BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10
89660760|NCT01289067|Other|Satraplatin, Single Arm|
89660761|NCT03616223|Experimental|FX-322 Low Dose|Cohort of 8. Single intratympanic injection
89660762|NCT03616223|Experimental|FX-322 High Dose|Cohort of 8. Single intratympanic injection
89660763|NCT03616223|Placebo Comparator|Placebo-Low Dose|Cohort of 4. Single intratympanic injection
89660764|NCT03616223|Placebo Comparator|Placebo-High Dose|Cohort of 4. Single intratympanic injection
89660765|NCT00632359|Experimental|Lenalidomide|Lenalidomide 10 mg daily given for 12 months.
89660766|NCT03990311|Experimental|Intervention|The experimental arm receives 2 months of sodium restricted prepared meals plus dietary counseling followed by 3 months of counseling alone.
89660767|NCT03990311|Placebo Comparator|Control|The control arm receives 5 months of usual care followed by 2 months of receipt of sodium restricted prepared meals.
89047545|NCT00542282||1, 2, 3|known moderate to severe COPD, known moderate or severe Asthma, suspected obstructive moderate to severe airways disease
89521740|NCT02521051|Experimental|Alectinib and Bevacizumab.|"Phase 1~Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Alectinib, orally, twice a day, per cycle~Bevacizumab, iv, once per cycle~Phase II In the phase II portion of this study, the investigators will evaluate the combination of alectinib plus bevacizumab in ALK-positive patients with untreated or progressive, asymptomatic brain metastases. Eligible participants will receive alectinib plus bevacizumab at the recommended phase II doses determined in the phase I portion of the study."
89521741|NCT03413917||Control group|patients who are admitted for repeat cesarean delivery with bilateral tubal ligation who do not develop uterine atony
89521742|NCT03413917||Study group|Patients who develop uterine atony either during cesarean delivery or who require surgical management of atony after delivery
89521743|NCT01239797|Active Comparator|Lenalidomide + Dexamethasone|
89521744|NCT01239797|Experimental|Lenalidomide + Dexamethasone +Elotuzumab|
89521745|NCT03418519|Experimental|CIMT group|"Two-hour mCIMT per day for 15 days (dosage = 30 hours)~24-hour restraint for 3 weeks"
89521746|NCT03418519|No Intervention|Control group|no CIMT
89521747|NCT01092143|Experimental|BI 671800 (low dose)|Patients receive BI 671800 (low dose) capsules twice daily
89521748|NCT01092143|Active Comparator|Fluticasone propionate|Patients inhale from Fluticasone propionate metered dose inhaler (MDI) twice daily
89521749|NCT01092143|Placebo Comparator|Placebo|Patients receive placebo capsules twice daily
89521750|NCT01092143|Experimental|BI 671800 (medium dose)|Patients receive BI 671800 (medium dose) capsules twice daily
89521751|NCT01092143|Experimental|BI 671800 (high dose)|Patients receive BI 671800 (high dose) capsules twice daily
89521752|NCT03421457|Experimental|Lateral suspension|"Uterus-preserving Laparoscopic lateral suspension with mesh technique will be performed in this arm."
89521753|NCT03421457|Experimental|Sacrocervicopexy|"Uterus-preserving Laparoscopic sacrocervicopexy with mesh technique will be performed in this arm."
89521754|NCT02377466|Experimental|Retosiban|Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.
89521755|NCT02377466|Placebo Comparator|Placebo|The placebo control will be a normal saline (0.9% sodium chloride [NaCl]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.
89521756|NCT03418363|Active Comparator|DHEA Oral Capsule|Subjects will take 100mg DHEA (dehydroepiandrosterone) daily
89521757|NCT03418363|Placebo Comparator|Placebo Oral Capsule|
89521758|NCT03421301|Experimental|1. Dietary portfolio (DP)|the dietary portfolio was given daily in the breakfast and dinner for 2.5 months
89521759|NCT03421301|Placebo Comparator|2. placebo (P)|the placebo (P) was based was given daily in the breakfast and dinner for 2.5 months
89521760|NCT03421223||Case|Individuals diagnosed with chronic pain
89521761|NCT03421223||Control|Individuals without chronic pain
89521762|NCT00816491|Active Comparator|A|Conventional white light colonoscopy
89521763|NCT00816491|Experimental|B|Chromoendoscopy
89521764|NCT03416387|Other|OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION|
89521765|NCT00950989|Placebo Comparator|Placebo|Placebo on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
89521766|NCT00950989|Experimental|Brodalumab 70 mg|70 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
89521767|NCT00950989|Experimental|Brodalumab 140 mg|140 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexateand folic acid supplementation (at least 5 mg per week).
89521768|NCT00950989|Placebo Comparator|Brodalumab 210 mg|210 mg brodalumab on day 1 and weeks 1, 2, 4, 6, 8, and 10 for a total of 7 doses plus a stable weekly dose of methotrexate and folic acid supplementation (at least 5 mg per week).
89521769|NCT03420911|Active Comparator|dexketoprofen trometamol group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg
89521770|NCT03420911|Active Comparator|dexketoprofen trometamol plus midazolam group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg and the midazolam dose was 1 mg.
89521771|NCT03416231|Experimental|apatinib plus docetaxel|apatinib combine with docetaxel， 4~6 cycles
89521772|NCT03420755|Experimental|MB 1-on-1 Only|Mothers and Babies 1-on-1. MB 1-on-1 -12-session intervention Each MB session lasts 15-20 minutes and is delivered as part of a regularly scheduled home visit (English or Spanish).
89521773|NCT03420755|Experimental|MB 1-on-1 Plus TEXT|Mothers and Babies Plus Text. MB 1-on-1 along with text enhancements both in English and Spanish.
89521774|NCT03420677|Active Comparator|Application of tones|During non-rapid eye movement (NREM) sleep short tones will be played
89521775|NCT03420677|Sham Comparator|No application of tones|During NREM sleep no short tones will be played
89521776|NCT03420599||health control|healthy controls are all from normal volunteers
89521777|NCT03420599||splenectomy|Traumatic patients after total splenectomy
89521778|NCT03420443|Experimental|Oat bran|45 g oat bran
89521779|NCT03420443|Experimental|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
89521780|NCT03420443|Other|No oral supplementation|No oral supplementation.
89521781|NCT03415997|Active Comparator|Total Body Weight|
89521782|NCT03415997|Active Comparator|Lean Body Weight|
89521783|NCT03420365|Experimental|Type of intervention|A single bout of aerobic exercise, or a single bout of balance and coordination exercise, or reading a magazine
89213605|NCT00142909|Experimental|Drug: Lofexidine|"Lofexidine: Study medication~Participants will receive daily lofexidine and the dosing will be initiated at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject."
89213606|NCT00142909|Placebo Comparator|Drug: Placebo|"Placebo pill.~Participants will receive daily placebo and will follow the same scheduled delivery as those in the intervention for 12 weeks."
89213607|NCT03885245|Experimental|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
89213608|NCT03885245|Placebo Comparator|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
89213609|NCT01007019|Experimental|YH4808 30mg|"1.Single dose~2.12 volunteers were administered YH4808 30mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89660768|NCT03972917||ulipristal acetate based therapy|Fertile women under ulipristal acetate treatment
89660769|NCT03954899|Experimental|MCI+ Melatonin 5mg|MCI+ individuals receiving 5mg of melatonin-OTC for a period of 9 months
89660770|NCT03954899|Placebo Comparator|MCI+ placebo|MCI+ individuals receiving placebo for a period of 9 months
89660771|NCT03954899|Experimental|MCI- Melatonin 5mg|MCI- individuals receiving 5mg of melatonin-OTC for a period of 9 months
89660772|NCT03954899|Placebo Comparator|MCI- placebo|MCI- individuals receiving placebo for a period of 9 months
89660773|NCT03934307|Experimental|Part A: SAD: ALN-AGT01|Participants will be administered a single dose of ALN-AGT01.
89213610|NCT01007019|Experimental|YH4808 50mg|"1.Single dose~2.12 volunteers were administered YH4808 50mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89213611|NCT01007019|Experimental|YH4808 100mg|"1.Single dose~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89213612|NCT01007019|Experimental|YH4808 200mg|"1.Single dose~2.12 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89521784|NCT03415919||IBD patients|Patients suffering from IBD scheduled to have a biopsy by colonoscopy.
89521785|NCT03415919||CRC patients|Patients suffering from CRC scheduled to have a biopsy by colonoscopy, or surgical resection of colon.
89521786|NCT03415919||Control patients|Patients who are scheduled to have a colonoscopy for routine screening to serve as a control population.
89521787|NCT03415841|Experimental|mHealth|"50 patients who are randomized to the intervention group (mHealth remote monitoring devices) will be enabled with remote monitoring devices (Blood Pressure and wearable vital signs monitor, Biovotion) and Kardia mobile application, for home-based rehabilitation program followed by review in the outpatient Cardiology clinics."
89521788|NCT03415841|No Intervention|Control|The control group (50 patients) will just be monitored at fixed intervals in the outpatient Cardiology clinics
89521789|NCT03415763|No Intervention|Observation|Observation for patients with pathological complete response or yp stage I(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil)
89521790|NCT03415763|Experimental|5-fluorouracil|Capecitabine for patients with pathological complete response or yp stage I Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil )
89521791|NCT03415763|Experimental|5-fluorouracil alone|5-fluorouracil alone for patients with yp stage II or III Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
89521792|NCT03415763|Experimental|mFOLFOX6 or CAPOX|Oxaliplatin combined with 5-fluorouracil for patients with yp stage II or III mFOLFOX6 (leucovorin 400 mg/m2 as a 2-hour infusion, and the concurrent administration of oxaliplatin 85 mg/m2 as a 2-hour infusion, followed by a bolus of 5-FU 400 mg/m2 within 15 min and 46-hour infusion of 5-FU 2400 mg/m2 on day 1 every 2 weeks), three cycles or CAPOX (oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1, followed by capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks), three cycles( According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
89521793|NCT03415529||4500 patients with ARDS|This is a secondary analysis of data from the LUNG SAFE database to determine the impact of alterations in arterial carbon dioxide tensions in patients with ARDS.
89521794|NCT03415451|Experimental|Fiberscope-Guided Nasogastric tube|Fiberscope-Guided Nasogastric tube insertion
89521795|NCT03420287|Experimental|MPM prepared from allogenic bone graft|All patients in this group will receive MPM prepared from allogenic bone graft
89521796|NCT03420287|Active Comparator|Autogenous bone graft group|All patients in this group will receive autogenous bone graft only
89521797|NCT03415373|Experimental|Intervention arm|Each subject will undergo ID administration by Microneedle Adapter (Model UAR-2S) and hypodermic needle + syringe of 100 μL injectable saline into 3 different regions: the inner forearm, the deltoid and the thigh, at three (3) study visits. A total of 4 injections (2 x 50 μL saline and 2 x 100 μL saline) will be administered to each study participant in the injection sites (2 injections per inner forearm/deltoid/thigh and 2 injection per device).
89660774|NCT03934307|Placebo Comparator|Part A: SAD: ALN-AGT01-Matching Placebo|Participants will be administered a single dose of ALN-AGT01-matching placebo.
89660775|NCT03934307|Experimental|Part B: SD: ALN-AGT01|Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
89660776|NCT03934307|Placebo Comparator|Part B: SD: ALN-AGT01-Matching Placebo|Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
89660777|NCT03934307|Experimental|Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo|Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
89660778|NCT03934307|Active Comparator|Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan|Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
89660779|NCT03934307|Experimental|Part E: Open Label: ALN-AGT01 + Irbesartan|Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.
89660780|NCT03924635|Active Comparator|SYMBICORT as maintenance and reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 twice a day (BID) for maintenance and as needed (PRN) for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance and PRN for relief.
89660781|NCT03924635|Active Comparator|SYMBICORT as maintenance, salbutamol as reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief.
89660782|NCT04398641||Nerve and vessel sparing segmental resection (NVSSR)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of nerve and vessel sparing segmental resection (NVSSR)
89660783|NCT04398641||Transanal disc excision (TADE)|Women undergoing surgery for deep endometriosis of the lower rectum using the surgical technique of transanal disc excision (TADE)
89660784|NCT04398251|Experimental|Uric acid drug control group|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week
89660785|NCT04398251|Active Comparator|Non-drug control group|They are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly.
89660786|NCT00632203|Experimental|Temozolomide treatment|Subjects will receive temozolomide at a dose of 75 mg/m^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
89660787|NCT00632203|No Intervention|Observation|Observation
89660788|NCT04398173||Group A (previous negative biopsy)|Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI
89660789|NCT04398173||Group B (biopsy naive)|Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI
89660790|NCT04398095|Experimental|Radiotherapy with hyperthermia in resectable sarcomas|12x 3 Gy (4 fractions per week) + hyperthermia (6x) + surgery
89660791|NCT04398095|Experimental|Radiotherapy with hyperthermia in non-resectable sarcomas|12x 3 Gy with simultaneous integrated boost 3.5 Gy (4 fractions per week) + hyperthermia (6x)
89660792|NCT01289457|Experimental|Clofarabine + Idarubicin + Cytarabine|Phase I: Clofarabine Starting dose 15 mg/m2 by vein for 5 days (days 1-5) + Idarubicin 10 mg/m2 by vein on day 1-3 + Cytarabine 1 g/m2 by vein on day 1-5.
89660793|NCT01289457|Experimental|Group 1 CIA|Phase II, Group 1 CIA (Clofarabine + Idarubicin + Cytarabine): Clofarabine Maximum Tolerated Dose (MTD) based on Phase I by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
89660794|NCT01289457|Experimental|Group 2 FLAI|Phase II, Group 2 FLAI (Fludarabine + Idarubicin + Cytarabine): Fludarabine 30 mg/m2 by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
89660795|NCT03830333|Experimental|Ceftolozane/Tazobactam + Metronidazole|Participants receive ceftolozane/tazobactam 1500 mg (ceftolozane 1000 mg + tazobactam 500 mg) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days (per protocol, ceftolozane/tazobactam may be adjusted to 500 mg/250 mg if creatinine clearance [CrCL] is 30 to ≤50 mL/min)
89660796|NCT03830333|Active Comparator|Meropenem + Placebo|Participants receive meropenem 1000 mg plus saline administered as an IV infusion every 8 hours for 4 to 14 days (per protocol, meropenem may be adjusted to every 12 hours if CrCL was 30 to ≤50 mL/min).
89660797|NCT01248741|Experimental|HDR prostate brachytherapy|An array of 17 gauge steel needles, 20 cm in length, is inserted under Ultrasound (US) guidance into the prostate and advanced to the base of the prostate. A template is used to maintain spacing and parallelism and the needles are individually locked into the template once positioned. A continuously acquired set of US images is obtained for treatment planning purposes. Each needle is connected to a Varisource afterloader and treatment is delivered using a 10 Curie Iridium-192 source. The needles are then removed.
89660798|NCT03818165|Experimental|CAR2 Anti-CEA CAR-T cell|3 doses of CAR2 Anti-CEA CAR-T cells for each cycle; up to 3 additional cycles received per investigator discretion
89660799|NCT01251315|Placebo Comparator|Placebo low dose|Placebo for low dose group given as a single dose.
89660800|NCT01251315|Active Comparator|N Acetyl cysteine, 600mg (low dose)|N-Acetyl Cysteine (NAC)600 mg (low dose) given as a single dose.
89660801|NCT01251315|Active Comparator|Proimmune 200(FT061452)|Proimmune 200(FT061452) low dose group 3000 mg given as a single dose.
89660802|NCT01251315|Placebo Comparator|Placebo high dose|Placebo given to high dose group given as a single dose.
89660803|NCT01251315|Active Comparator|N Acetyly cysteine, 1200mg (high dose)|N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
89660804|NCT01251315|Active Comparator|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
89660805|NCT01290237|Experimental|Vancomycin loading dose|Intervention: administer intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
89660806|NCT01290237|Active Comparator|Control|No intervention. Administer intravenous vancomycin 20 mg/kg/dose every 8 hours as per hospital guideline.
89660807|NCT01251393|Experimental|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
89660808|NCT01251393|Placebo Comparator|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
89660809|NCT01253343||inpatient high aggression|
89660810|NCT01253343||inpatient low aggression|
89660811|NCT00631969|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
89660812|NCT00631969|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
89660813|NCT03539861|Other|Hemodialysis|"The treatment arm (all participants are in this arm) is done in two phases that are described below:~Treatment 1 will be standard hemodialysis (no device).~Treatment 2 will be hemodialysis with the study device. Of importance, this 5 hour session is planned to ensure adequate solute clearance but with only 4 hour high ultrafiltration to achieve the patients dry weight."
89660814|NCT01290627||Knee Prosthesis LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
89660815|NCT01290627||Knee Prosthesis Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
89660816|NCT01290627||Control|Subjects with normal knees
89660817|NCT03469193|Active Comparator|internal PUC implanted with mechanical ancillary|
89660818|NCT03469193|Experimental|Internal PUC implanted with robotic assistance|
89660819|NCT01924585||Frail patient|Patients will be stratified into groups frail and non-frail based on pre-operative frailty and disability.
89660820|NCT01255137|Experimental|Adrenal Cortex Neoplasms|Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.
89660821|NCT01255449|Experimental|albuterol|Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.
89660822|NCT00631657|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
89660823|NCT00631657|Placebo Comparator|Placebo|Participants receive placebo tablets, administered once a day for 6 months
89660824|NCT03170141|Experimental|Antigen-specific IgT cells|Patients will receive non-myeloablative chemotherapy consisting of fludarabine and/or cyclophosphamide, followed by intravenous infusion of autologous IgT cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of IgT cells. The tested IgT cell dosage ranges from 0.5×10^5 /kg to 2.5×10^7 /kg
89660825|NCT01257087|Experimental|Intensive glycaemic control|Intensive glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
89660826|NCT01257087|Active Comparator|Conservative glycaemic control|Conservative glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
89660827|NCT01259427|Experimental|Arm 1: Ending Self Stigma|Ending Self Stigma (ESS): Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
89660828|NCT01259427|Active Comparator|Arm 2: Health and Wellness Group|Health and Wellness Group: The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
89660829|NCT02984501|Experimental|Single Arm|Patients treated with induction chemotherapy with gemcitabine and oxaliplatin; for patients without disease progression as detected through restaging exams, chemotherapy was followed by radiochemotherapy which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
89660830|NCT02947997||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
89660831|NCT00631189|Active Comparator|1|Rosuvastatin and Pravastatin
89660832|NCT00631189|Active Comparator|2|Rosuvastatin and Atorvastatin
89660833|NCT03831919|Experimental|SYNC III accommodative support lenses|Wear spectacles with SYNC III accommodative support lenses (add +0.75)
89660834|NCT03831919|Placebo Comparator|control|Wear single vision spectacles (no add)
89047546|NCT02286765|Active Comparator|Group A|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
89047547|NCT02286765|Active Comparator|Group B|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
89047548|NCT00542360|Experimental|Social marketing program|Behavioral: Social marketing program to motivate exercise class participation
89660835|NCT00630877|Experimental|NER/ASA|
89660836|NCT00630877|Experimental|NER/ASA Placebo|
89660837|NCT00630877|Experimental|NER Placebo/ASA Placebo|
89047549|NCT00542360|No Intervention|Control|Control: No intervention
89047550|NCT02283957|Experimental|2 mL injection of 200 µg of CNTX-4975|Single dose, 2 mL
89660838|NCT04557163|Experimental|Subjects receiving TS-142 and itraconazole|Eligible subjects will receive a single dose of 5 mg TS-142 on Day 1. Subjects will also receive twice-a-day of 200 mg itraconazole on Day 3 and an once-daily single dose of 200 mg itraconazole from Day 4 to Day 7 and single dose of 1 mg TS-142 on Day 6.
89660839|NCT02915783|Experimental|lenvatinib 18 mg/day and everolimus 5 mg/day|Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).
89660840|NCT02745821|Experimental|Coronary physiology|Non-target and target vessels of patients with diabetes mellitus referred for PCI will be assessed for FFR, CFR and IMR. Intravenous adenosine at 140 micrograms/kg/min will be used to induce maximal hyperemia.
89660841|NCT02736149|Experimental|ubenimex|"ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment."
89660842|NCT03177473||CervicalStim PEMF group|all subjects will receive active CervicalStim bone growth stimulator
89660843|NCT03176303||Pulsed Electromagnetic Field|one group all of whom will be treated with the PEMF device
89660844|NCT02307149|Experimental|CAVATAK and ipilimumab|CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg
89660845|NCT04397705|Experimental|Ambulatory monitoring|Participants will be asked to wear the sensors (heart rate, respiratory rate, temperature, and pulse oximetry) for three weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care.
89660846|NCT02198183||Near-infrared spectroscopy|Casmed Fore-Sight Elite and Non-invasive Cardiac Output Monitor (NICOM)
89660847|NCT02102165|Experimental|metastatic lesion biopsy|biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
89660848|NCT02023073||Healthy volunteers|
89660849|NCT04397783|No Intervention|Cruciate incision|the classic cruciate incision in the colostomy construction
89660850|NCT04397783|Experimental|longitudinal incision|longitudinal incision with two proline sutures
89660851|NCT04397315|Active Comparator|Complete Pulpotomy|In case of complete pulpotomy procedure the exposed pulp tissue will be amputated using sterile bur in high speed hand piece to the level of canal orifices.
89660852|NCT04397315|Active Comparator|Partial Pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece to a depth of 2-3 mm.
89660853|NCT04397393||non-camel milk consumption|non-camel milk consumption over life time
89660854|NCT04397393||camel milk consumption|camel milk consumption at least once during lifetime, with 2 subgroups of camel milk consumption: once, twice, three times; as well as regularly (daily, once per week, once per month, once per year).
89660855|NCT03172403|Experimental|Patients with digestive cancer requiring resection surgery|"Patients with cancer of digestive system requiring resection surgery will be included. They will have measure of height and weight, blood samples, skeletal muscle force, skeletal muscle index and muscle biopsy.~V1: Inclusion will be effectuated at the time of anaesthetic consultation V2: The day before and day of resection surgery about 1 month after V3: Follow-up at 1 month V4: Follow-up at 3 months V6: Follow-up at 6 months"
89660856|NCT01176461|Experimental|A1 - Phase I Dose Escalation|Cohorts 1 through 5. Each treatment cycle is comprised of 6 doses of BMS-936558 and 6 peptide vaccines administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
89047551|NCT02283957|Experimental|2 mL injection of 600 µg of CNTX-4975|Single dose, 2 mL
89047552|NCT02283957|Placebo Comparator|2 mL injection of placebo|Single dose, 2 mL
89047553|NCT02283957|Experimental|2 mL injection of 25 µg of CNTX-4975|Single dose, 2 mL
89047554|NCT04648995|Other|High energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
89047555|NCT04648995|Other|Low energy|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
89047556|NCT00542399|Experimental|1|once a day
89047557|NCT00542399|Experimental|2|twice a day
89047558|NCT04648722||Left-side hemithyroidectomy|Patients who received a hemithyroidectomy of the left thyroid lobe since 1994
89047559|NCT04648722||Right-side hemithyroidectomy|Patients who received a hemithyroidectomy of the right thyroid lobe since 1994
89047560|NCT00542516|Experimental|HES 130/04|Pre-expansion with HES
89047561|NCT00542516|Active Comparator|Ringer's lactate|Pre-expansion with Ringer's lactate
89047562|NCT03456830|Experimental|ALLN-177|ALLN-177 3,750 units per capsule
89047563|NCT03456830|Placebo Comparator|Placebo|Placebo capsule
89660857|NCT01176461|Active Comparator|A2 - BMS-936558 Without Peptide Vaccine|Cohort 6. Each treatment cycle is comprised of 6 doses of BMS-936558 administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
89660858|NCT04397471||Healthy Volunteer|A one time only 30-80 mL sample of bone marrow will be collected from both posterior superior iliac crests.
89660859|NCT00630331|Experimental|CCI|Subjects received one dose of cell culture-derived influenza vaccine.
89660860|NCT00630331|Experimental|IVV|Subjects received one dose of the trivalent egg-derived influenza vaccine.
89660861|NCT00630331|Placebo Comparator|Placebo|Subjects received one dose of phosphate buffered solution (PBS).
89660862|NCT04557865|Experimental|Participants receving 18F-PMPBB3 (APN-1607) PET imaging|Single arm, open label
89213613|NCT01007019|Experimental|YH4808 400mg|"1.Single dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89660863|NCT04555291|Experimental|Drug Ropivacaïne 2 mg/ml|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
89660864|NCT04555291|Placebo Comparator|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
89660865|NCT01924897|Experimental|Exercise Training Arm|"Patients randomised to exercise training will be offered three sessions of aerobic interval exercise per week over the subsequent 4 weeks prior to their procedure. Each session will comprise 6 x 5 min repetitions at 60-80% peak VO2, with 2.5 min rest intervals. The aim will be to quickly progress patients to exercise intensities that correspond to and exceed the individual AT. Heart rate, clinical signs, blood pressure and perceived exertion will be recorded regularly throughout exercise.~Repeat CPET testing will then take place 4 weeks from the baseline test in the exercise laboratory (on the day prior to surgery) to determine changes (if any) in AT, VO2, VE/VCO2."
89660866|NCT01924897|No Intervention|No Exercise Training Arm|The patients in the non-exercise arm of the study will not undergo any exercise intervention but will be CPET tested in the exercise laboratory at the same time points as the exercise arm patients.
89660867|NCT04275739|Experimental|Experimental: Episodic Future Thinking|
89660868|NCT04275739|Active Comparator|Control: Vivid Memory Task|
89660869|NCT00638755|Experimental|1|The following treatment sequence: A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo)
89047564|NCT02265393|Active Comparator|OTO-104|12 mg OTO-104 (dexamethasone)
89047565|NCT02265393|Placebo Comparator|Placebo|OTO-104 vehicle
89660870|NCT00638755|Experimental|2|The following treatment sequence: B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide)
89660871|NCT00638755|Experimental|3|The following treatment sequence: C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide)
89660872|NCT00638755|Experimental|4|The following treatment sequence: D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide)
89660873|NCT04550065|Experimental|Intervention arm|Digital game
89660874|NCT02984449|Experimental|Pre+postoperative Cardiac rehabilitation|receive a cardiac rehabilitation program consisting of three phases. 1) A preoperative optimization phase (3x p/wk, 4-6 weeks, before surgery), 2) a postoperative in-patient phase (15 to 18 days in rehabilitation center, weekend at home) and, 3) an outpatient patient clinical rehabilitation phase (2x p/wk, 4 weeks). During each phase, patients will visit a physical therapist (group sessions of inspiratory muscle training (IMT), strength training, aerobic cycling and breath, cough and relaxation sessions), a dietician and a psychologist to optimize general health and receive advice on lifestyle, anxiety and stress management. Two additional components are coaching to stop smoking
89660875|NCT02984449|Active Comparator|Postoperative Cardiac rehabilitation|Patients who are randomized to the POST group receive an out-patient cardiac rehabilitation program after surgery. In general, this program starts three to six weeks after discharge (phase ǀǀ) and patients always start with an exercise program, which is supervised by a physical therapist for about six weeks (twice a week). On indication support of psychological and/or dietary consult is added.
89660876|NCT04275427|Experimental|study laser group|laser therapy on knee for 2 weeks
89660877|NCT04275427|No Intervention|control group|no intervention
89660878|NCT04275349||Exposure group(continuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital or at hospital)
89660879|NCT04275349||Exposure group(uncontinuously)|xingnaojing injection will be intravenously administered within 24 hours of symptom onset for once (on prehospital ambulance )
89660880|NCT04275349||Completely unexposed group|xingnaojing injection will not be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital)
89660881|NCT04275349||Incompletely unexposed group|xingnaojing injection will not be intravenously administered on ambulance but administered more than 24 hours of symptom onset at hospital
89660882|NCT04275115|Experimental|Foliglurax|Foliglurax, iv midazolam and cocktail of CYP450 probe substrates
89047566|NCT00542555|Placebo Comparator|Placebo bid|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
89047567|NCT00542555|Experimental|Naproxcinod 375 mg bid|
89047568|NCT00542555|Active Comparator|Naproxen 500 mg bid|
89047569|NCT00542555|Experimental|Naproxcinod 750 mg bid|
89047570|NCT04648488|Experimental|Early mobilisation|Patients will start unloaded exercise treatment 3 days after surgery. They will remove the plaster 5 times every day to perform range of motion exercises.
89047571|NCT04648488|Active Comparator|Standard treatment|Patients will have a plaster 3 weeks after surgery and after that start with exercise treatment.
89047572|NCT04685018||HC|Mentally and medically healthy adults between 18 and 60 years, free from any current or previous medical or psychiatric condition.
89047573|NCT04685018||OCD|Adults between 18 and 60 years, with a diagnosis of Obsessive-Compulsive Disorder and medication-free or with stable medication regimen for at least 3 weeks prior to the study.
89047574|NCT02260674|Experimental|Treatment Group 1|Participants will self-administer JNJ-54861911, two tablets of 5 milligram (mg) each for a total of 10 mg, orally, once daily, from Day 1 until Month 6.
89047575|NCT02260674|Experimental|Treatment Group 2|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6.
89047576|NCT02260674|Placebo Comparator|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6.
89047577|NCT04679025||Diabetes with postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who had postoperative hyperglycemia (point of care test > 10.0 mmol/L).
89047578|NCT04679025||Diabetes without postoperative hyperglycemia|Patients with known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who did not have postoperative hyperglycemia (point of care test > 10.0 mmol/L).
89047579|NCT04679025||No diabetes with postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who had postoperative hyperglycemia (point of care test > 10.0 mmol/L).
89660883|NCT04275193|Experimental|Zishenqing|The original treatment and Zishenqing 1Co by mouth,twice a day for 12 weeks
89660884|NCT04275193|Placebo Comparator|Placebo|The original treatment and Zishenqing simulator 1Co by mouth,twice a day for 12 weeks
89660885|NCT00633997|Experimental|1|Healthy volunteers
89660886|NCT00633997|Experimental|2|Type II diabetics
89047580|NCT04679025||No diabetes and no postoperative hyperglycemia|Patients without known diabetes (Discharge Abstract Database or hemoglobin A1c > 6.5%) who did not have postoperative hyperglycemia (point of care test > 10.0 mmol/L).
89660887|NCT04274959|Active Comparator|ceramic onlay with shoulder preparation design.|posterior ceramic onlay restoration with shoulder design with 1 mm shoulder thickness
89660888|NCT04274959|Experimental|ceramic onlay with butt joint preparation design|posterior ceramic onlay with butt joint preparation design with flat occlusal reduction with inclined surface
89660889|NCT04559347|Experimental|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine for erector spinae block as local anesthetic
89047581|NCT04678128|Active Comparator|Dance4Healing control group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will not have a dance buddy.
89660890|NCT04559347|Active Comparator|Continuous catheter infusion ropivacaine|Ropivacaine (0.5% bolus followed by 0.2% infusion) using a continuous catheter for erector spinae plane block as local anesthetic
89660891|NCT01925053|Placebo Comparator|Ref meal|"The reference meal (REF) is based on WHO dietary guidelines for protein, fat and carbohydrate. It comprises everyday modern ingredients such as white rice."
89047582|NCT04678128|Experimental|Dance4Healing Buddy Group|Participants will monitor their heart rate for 8 weeks (pre-intervention period), then engage in weekly live zoom dance sessions on digital Dance4Healing platform for 8 consecutive weeks (intervention period), then may elect to continue with monitoring for an additional 12 weeks (3-month post-intervention period for long-term results). During the intervention period, this group will have a dance buddy.
89660892|NCT01925053|Active Comparator|PAL meal|Palaeolithic meal (PAL) is based on WHO dietary guidelines for protein, fat and carbohydrate but only uses ingredients that would have been available in Palaeolithic times (e.g. no cereals or dairy).
89660893|NCT00631111|Experimental|1|
89660894|NCT00631111|Active Comparator|2|
89047583|NCT00542906|Other|1|healthy volunteers
89047584|NCT04678674|Experimental|bone defect surgery|augmentation on insufficient alveolar ridges with autologous teeth will be performed (wisdom tooth or periodontally compromised tooth)
89047585|NCT00542945|Experimental|A|Heart Failure nonischemic ethiology
89047586|NCT00542945|Active Comparator|B|
89660895|NCT00631111|Active Comparator|3|
89660896|NCT00631111|Placebo Comparator|4|
89660897|NCT00630799|Experimental|1|leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)
89660898|NCT04558723|Experimental|ICD group|Patients receiving OMT and ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) if indicated.
89047587|NCT04677933|Experimental|Arm A|Patients will receive 5 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
89047588|NCT04677933|Experimental|Arm B|Patients will receive 10 µg OLP-1002 BIW for 15 days (Day 1, 4, 8, 11 and 15). Mode of Administration: Subcutaneous injection
89660899|NCT04558723|No Intervention|Optimal HF care group|Patients receiving OMT and CRT pacemaker (CRT-P) implantation without a defibrillator if indicated. Patients without CRT indication will receive an ICM for detection of malignant VAs.
89660900|NCT01925287|Active Comparator|Native curcumin powder|500 mg curcumin as native powder
89660901|NCT01925287|Experimental|Micronized curcumin powder|500 mg curcumin as micronized powder
89660902|NCT01925287|Experimental|Curcumin micelles|500 mg curcumin incorporated into liquid micelles
89047589|NCT04677933|Experimental|Arm C|Patients will receive Diluent placebo BIW for 15 days (Day 1, 4, 8, 11 and 15) Mode of Administration: Subcutaneous injection
89047590|NCT00542984|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
89047591|NCT00542984|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
89047592|NCT02257983|Active Comparator|EPI-743|EPI-743 400 mg P.O. TID
89047593|NCT02257983|Placebo Comparator|Placebo|Sesame Oil, NF in sealed gelatin capsules to match the test product
89047594|NCT00543023|Experimental|A|teriparatide 20 micrograms/day subcutaneous
89047595|NCT00543023|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
89047596|NCT04648917|Experimental|Arm A|In Arm A: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval (weight >50kg, 200mg per time, weight < or =50kg, 100mg per time)
89047597|NCT04648917|Placebo Comparator|Arm B|In Arm B: 40 patients will receive the placebo tablets: 100-200mg, tid, po, 2 weeks treated then 1 week black interval.
89047598|NCT00543218|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
89047599|NCT00543218|Active Comparator|B|
89047600|NCT00543257||Parents|Parents of children with ADHD will be recruited from the greater Boston community. We are interested in enrollment of parents with a range of educational and technical backgrounds, and specifically will look to enroll parents who may not have much computer experience.
89047601|NCT02252835|Experimental|Arhalofenate with febuxostat (PK cohort)|
89047602|NCT02252835|Experimental|Arhalofenate with febuxostat (non-PK cohort)|
89047603|NCT03456752|Experimental|Dexamethasone|Dexamethasone 8mg intravenously prior to anesthesia induction
89047604|NCT03456752|Placebo Comparator|Control|Normal Saline 1.6ml intravenously prior to anesthesia induction
89047605|NCT02227290|Experimental|Naftin Cream, 2%|Once Daily
89047606|NCT02227290|Placebo Comparator|Placebo Cream|Once Daily
89047607|NCT03456713|Experimental|Part A: 250 mg LY3074828 (Reference)|250 mg LY3074828 administered subcutaneous (SC) as solution formulation in two prefilled syringes targeting a 5- to 10-second injection time for each injection on day 1.
89213614|NCT01007019|Experimental|YH4808 100mg(repeat doses)|"1.Repeat doses~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89213615|NCT01007019|Experimental|YH4808 200mg(repeat doses)|"1.Repeat doses~2.16 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:6:2)"
89660903|NCT01924273|Other|Port Wine Stain Birthmarks|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
89660904|NCT04558801|Experimental|Mobile application-based lifestyle change program|"This arm receives the mobile application-based lifestyle change program at baseline. The mobile application-based lifestyle change program consists of twice a week content for the first 6 months, continuing with less frequent content for the following 6 months. The follow-up period is 6 months. Weight is measured and blood samples (lipids, glucose and metabolic syndrome measures) are collected at 0, 6, 12, and 18 months.~The mobile application-based counselling contains aspects of cognitive behavior therapy and persuasive system design and consists of twice a week reminders, tasks, self-monitoring, and reflection."
89660905|NCT04558801|Active Comparator|"The waiting-list control"|"The waiting-list control arm will receive mobile application-based lifestyle change program after 6 months, following same principles as Mobile application-based lifestyle change program-arm, excluding follow-up period (6 months of waiting list, 6 months of more intense and 6 months of less intense application use)."
89660906|NCT04828343|Experimental|Cohort 1 <50 kg|Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
89660907|NCT04828343|Experimental|Cohort 2 <50 kg|Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
89660908|NCT04828343|Experimental|Cohort 3 >=50 kg|Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
89660909|NCT04828343|Experimental|Cohort 4 >=50 kg|Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
89660910|NCT02337517|Experimental|Supportive care (vismodegib)|Patients receive vismodegib PO daily, every other day, every three days, or twice weekly for 6-12 months in the absence of disease progression or unacceptable toxicity.
89660911|NCT04276649||Caltrate+Mesalazine|Patients in this group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months.
89660912|NCT04276649||Mesalazine|Patients in this group were received with Mesalazine 4g/d orally at least 12 months.
89660913|NCT01920139|Other|Breast cancer and Axillary Adenopathy|Women with breast cancer with abnormal appearing ipsilateral axillary nodes undergoing fine needle aspiration and core biopsy of a lymph node.
89660914|NCT04558489|Experimental|IPR + GMI|Participants receiving IPR + GMI will complete a 30-minute on-line intervention via qualtrics that covers the following topics: (1) Educate youth and caregiver that thoughts and emotions are not fixed but are malleable and subject to change; (2) provide youth and families with a brief intervention that instills hopefulness through an action plan for managing internalizing symptoms; (3) assist with developing system of support to access during times of distress; and (4) educate the caregiver on the importance of these interventions.
89660915|NCT03167099|Experimental|Full Weight Bearing|Participants assigned to full weight bearing after fixation of distal femur fracture.
89660916|NCT03167099|No Intervention|Partial Weight Bearing|Participants assigned to partial weight bearing, standard of care, after fixation of distal femur fracture.
89660917|NCT04553419|Experimental|Cephalexin|Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.
89660918|NCT04553419|Placebo Comparator|Placebo|The placebo will be available in both capsule and suspension format. Doses will be administered 3 times a day for 2 weeks
89213616|NCT01007019|Experimental|YH4808 400mg(repeat doses)|"1.Repeat dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89660919|NCT03082313|Experimental|Movement intervention|The intervention promotes movement experience from 3 months to sitting onset in infants at risk for developmental delay (AR). The goal of the intervention is to increase amount and type of infant leg movement experience above 1200 movements per hour of awake time.
89660920|NCT04420819|Experimental|IPC-LOP|this group will carry out the baseline assessments, perform the ischemic preconditioning using exactly the limb occlusion pressure , then perform post-IPC assessments and start the excentric exercise, and the post-exercise assessments will take place immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
89660921|NCT04420819|Experimental|IPC-40%|this group will carry out baseline assessments, perform IPC using 40% more occlusion than LOP, then perform assessments after IPC protocol and start EE, and post exercise assessments will take place immediately after the end of EE and will be repeated in 24h, 48h, 72h and 96h.
89660922|NCT04420819|Placebo Comparator|IPC-10mmHg:|this group will perform baseline assessments, perform occlusion-perfusion intervention with 10 mmHg restriction characterizing the placebo, then perform post-IPC assessments and initiate EE, and post-exercise assessments will take place immediately after completion of EE and if will repeat in 24h, 48h, 72h and 96h.
89660923|NCT04420819|No Intervention|CONTR|this group will carry out the baseline assessments, immediately after starting the EE, and the post-exercise assessments will happen immediately after the end of the EE and will be repeated in 24h, 48h, 72h and 96h.
89660924|NCT01920217||normal control|
89213617|NCT01007019|Experimental|YH4808 600mg|"1.Single dose~2.12 volunteers were administered YH4808 600mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89213618|NCT01007019|Experimental|YH4808 800mg|"1.Single dose~2.12 volunteers were administered YH4808 800mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
89213619|NCT01007019|Placebo Comparator|Placebo|
89213620|NCT01007019|Active Comparator|Esomeprazole 40mg|
89213621|NCT05673863|Experimental|Psychological resilience training program|Children in the intervention group participated in a psychological resilience program organized as a group activity.
89213622|NCT05673863|No Intervention|control group|Children in the control group did not receive any intervention. There was also no intervention for the family members accompanying the children.
89213623|NCT02579993|Experimental|Stem Cell Transplantation|Cultivated Limbal Stem Cell Transplantation
89660925|NCT01920217||Sepsis group|
89660926|NCT04346407|Experimental|Dronabinol|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
89660927|NCT04346407|Placebo Comparator|Placebo|Capsule with placebo daily starting with pre-op cocktail and continued twice daily for three days after surgery
89213624|NCT04075097|Experimental|Aerobic exercise|44 minutes of moderate intensity walking on a treadmill.
89213625|NCT04075097|Experimental|Yoga|44 minutes of Iyengar yoga.
89660928|NCT04397549|Active Comparator|Block group|Cervical Erector Spinae Plane Block administered group
89660929|NCT04397549|Sham Comparator|Control group|Control group
89660930|NCT03085121|Experimental|Male Extramedullary|In this group, patients are male and femoral extramedullary resection would be used.
89660931|NCT03085121|Experimental|Female Extramedullary|In this group, patients are female and femoral extramedullary resection would be used.
89660932|NCT03085121|Active Comparator|Male Intramedullary|In this group, patients are male and femoral Intramedullary resection would be used.
89660933|NCT03085121|Active Comparator|Female Intramedullary|In this group, patients are female and femoral Intramedullary resection would be used.
89660934|NCT01920295|Experimental|Cryoballoon ablation|Cryoballoon ablation
89660935|NCT01920295|Active Comparator|Cryoballoon after medical therapy|Cryoballoon ablation
89660936|NCT01920295|Experimental|Cryoballoon as first-line therapy|Cryoballoon ablation
89660937|NCT01920295|Active Comparator|Cryoballoon after failed drug therapy|Cryoballoon ablation
89660938|NCT03161873||avaOnly|Participants will measure with Ava bracelet and determine ovulation with a home (luteinizing hormone) LH urine test
89660939|NCT03161873||avaSaliva|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone.
89660940|NCT03161873||avaSalivaUS|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone. Moreover ultrasound will be used to observe the day at which the ovum is released.
89660941|NCT03161873||avaBBT|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition, participants will measure their basal body temperature (BBT) daily.
89660942|NCT04551001|Experimental|Cold forcep|Cold forcep polypectomy performed for polyps <=3mm.
89660943|NCT04551001|Experimental|Cold snare|Cold forcep polypectomy performed for polyps <=3mm.
89660944|NCT03080441|Experimental|Phase 1 Group 1|pressure stockings worn during dialysis treatment
89660945|NCT03080441|Experimental|Phase 1 Group 2|Midodrine before dialysis treatment
89660946|NCT03080441|Experimental|Phase 1 Group 3|pressure stocking and Midodrine
89660947|NCT03092635|Experimental|OPC|During weeks 1- 12, subjects will take one OPC tablet in the morning and in the evening, about 12 hours apart.
89660948|NCT03085433|Experimental|Microfluidic sperm sorting|Couples undergoing in vitro fertilization randomized to microfluidic sperm sorting will have raw semen sorted by the microfluidics chip prior to fertilization with IVF/ICSI.
89660949|NCT03085433|Active Comparator|Conventional sperm preparation|Couples undergoing in vitro fertilization randomized to conventional methods for sperm processing will undergo separation of semen by density gradient centrifugation prior to IVF/ICSI.
89213626|NCT01007175|Experimental|Cohort 1|
89660950|NCT01925443|Experimental|low level laser therapy|individuals will be subject to the application of low level laser therapy, but this group will have three subdivisions related to dose in joules that will be administered to the individual, and J 4, J 6, 8 J. To be administered in the quadriceps muscle.
89660951|NCT01925443|No Intervention|Control Group|will consist of individuals diagnosed with diabetes mellitus non-insulin-dependent, however, will not perform low level laser therapy, participate only in the evaluations
89660952|NCT01925443|Experimental|Placebo group|individuals will be subject to the application of low level laser therapy but with a dose of 0 Joules.
89660953|NCT03568175|Experimental|JR-141 2.0 mg/kg/week|
89660954|NCT01920373|Active Comparator|Group A (corticosteroid injection group)|Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint
89660955|NCT01920373|Experimental|Group B (platelet rich plasma injection)|Group B will receive a 2 ml intra-articular injection of a platelet rich plasma preparation per affected joint
89660956|NCT01920451|Experimental|Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) consists of an an individually-tailored sleep prescription intended to consolidate fragmented sleep; guidance on changing learned associations that are harmful to sleep using stimulus control theory; education on standard sleep hygiene and to correct unrealistic sleep expectations; and the identification and restructuring of maladaptive thoughts and beliefs about sleep.
89660957|NCT01920451|No Intervention|Wait List|Study participants who are randomized to the wait-list condition will not receive the intervention as part of this study protocol. They will, however, be offered the opportunity to receive CBTI at the end of their participation in this study. Wait-list participants will not be restricted in terms of additional therapies/treatments which they may seek for their sleep complaint.
89660958|NCT05244395|Experimental|Duchenne Muscular Dystrophy Gait Assessment Scale|The DMD-GAS was developed using the two-round Delphi method. After a detailed literature review, the items of scale were compiled. The DMD-GAS was designed to consist of 10 items and each item scored as 0,1,2. The DMD-GAS was presented to the expert group (10 physical therapists), who had experience in the management of patients with DMD. According to the scale items, it is classified as 2: no compensation, 1: minimal compensation, and 0: excessive compensation for the relevant body part.
89213627|NCT01007175|Experimental|Cohort 2|
89213628|NCT01007175|Experimental|Cohort 3|
89213629|NCT01007175|Experimental|Cohort 4|
89213630|NCT01007175|Experimental|Cohort 5|
89213631|NCT04076189|Experimental|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
89660959|NCT01925521|Experimental|Part1 : OPS-2071|Single dose, OPS-2071 30,60,120,240,300,600,900,1200mg/day
89660960|NCT01925521|Placebo Comparator|Part1 : Placebo of OPS-2071|Single dose, Placebo
89660961|NCT01925521|Experimental|Part2 : OPS-2071|Multiple dose
89660962|NCT01925521|Placebo Comparator|Part2 : Placebo of OPS-2071|Multiple doses, Placebo
89660963|NCT01920529|Experimental|aerobic exercise|The study will consist of two groups: Group Comparison (GC) will be submitted to two evaluations at the beginning of a week and end of 6 weeks, without receiving any kind of physical training intervention. Group Training (GT) will undergo two assessments at the beginning of the end of the 1st and 6th week, however will be submitted to aerobic training for six weeks. Supervised aerobic training will be held three times a week for six weeks,treadmill in four consecutive steps each (05 minutes stretching, 05 minutes heating, 20 training minutes (1 st and 2 nd week) and 30 minutes (3 rd to 6 weeks) and cool down 05 minutes). The exercise intensity will be maintained through a desired percentage of heart rate for training (x%) from 70% to 80%, obtaining then the optimal heart rate training.
89660964|NCT01920529|Placebo Comparator|control|Investigators evaluated the distance walked during the 6-minute walk test and recorded variables such as heart rate, respiratory frequency, pulse oxygen saturation and a scale of perceived exertion (Borg) in the moments before and after the test. There was only evaluation without intervention.
89660965|NCT05248529|Experimental|Intervention group|Within 12-24 hours before the surgery, the demonstrative education was given based on 'Hip Replacement Adaptation Booklet' and 'Knee Replacement Adaptation Booklet' to the patients in the intervention group.
89660966|NCT05248529|No Intervention|Control gorup|Routine preoperative preparation training was performed to the patients in the control group.
89660967|NCT05248373|Experimental|rAd26 single administration|
89660968|NCT05248373|Experimental|rAd5 single administration|
89660969|NCT05248373|Experimental|prime-boost regimen with rAd26 followed rAd5 administration|
89660970|NCT05248373|Placebo Comparator|placebo|
89660971|NCT01920607|Active Comparator|NMS|Implantation under general of local anesthesia of sacral nerve stimulation system (Interstim Therapy)
89660972|NCT01920607|Experimental|SAM|Implantation under general anesthesia of magnetic anal sphincter (Fenix)
89660973|NCT01920685|Experimental|Immediate therapy|6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered for a period of 8 weeks immediately after randomisation.
89660974|NCT01920685|Other|Delayed intervention|Therapy will be delayed until 12 weeks following randomisation, and then 6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered over a period of 8 weeks.
89660975|NCT03831607|Experimental|KHK7791|Patients start at KHK7791 30 mg BID and can down titrate weekly to 20, 15, 10, and 5 mg BID, sequentially based on a GI tolerability question.
89660976|NCT01920841|Experimental|Left (A), Right (B)|Cream A applied to left thigh and Cream B to right thigh
89660977|NCT01920841|Experimental|Left (B) Right (A)|Cream B applied to left thigh and Cream A to right thigh
89660978|NCT03373981|Experimental|intervention|rTMS
89660979|NCT04759495|Experimental|rtCGM|Patients with use of the DEXCOM G5 or G6 system (real time continuous glucose monitoring).
89660980|NCT04759495|Experimental|FGM|Patients with use of the FreeStyle Libre Flash system (flash glucose monitoring).
89660981|NCT05245019|Experimental|cardamom group|the pH of saliva will be checked first then they r required to chew cardamom nd after 15 minutes again pH will be checked
89213632|NCT04076189|Active Comparator|No endotracheal suctioning|Procedure includes: Initiation of positive pressure ventilation without endotracheal suctioning
89660982|NCT05245019|Experimental|fennel group|the pH of saliva will be checked first then they r required to chew fennel and after 15 minutes again pH will be checked
89660983|NCT01925755||Group 1|
89660984|NCT01925833|Experimental|Both insertion and withdrawal|
89660985|NCT01925833|Active Comparator|Only withdrawal|
89660986|NCT04397081||Control Group|Control group was defined as healthy patients between the ages of 30-65 without allergic complaints.Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.
89660987|NCT04397081||Study group|"Study group was defined as patients between the ages of 30-65 with allergic complaints complaints (sneezing, itching,runy nose, respiratory distress) were diagnosed atopic disease (allergic asthma, allergic rhinitis, allergic conjunctivitis, chronic urticaria and atopic dermatitis) by same clinician in Immunology and Allergy Department. Patients' height, weight, demographic features (age, marital status, income level), obstetric histories (gravida, parity, mode of delivery), contraception methods and smoking status were noted.~Subgroup atopic disease diagnoses, duration of illness, treatments regimes and treatment time of the patients in the study group were also questioned and recorded."
89660988|NCT01920919|Experimental|Dexamethasone 1 mg|Dexamethasone 1 mg per day, for 180 days
89660989|NCT01920919|Placebo Comparator|Placebo|Placebo tablet, for 180 days
89660990|NCT04787237|Experimental|Vestibulart socket therapy and immediate implants|A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted . A flexible cortical membrane shield that is made of cortical bone of heterologous origin was introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a membrane tack or a micro screw to the alveolar bone apical to the base of the socket . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
89660991|NCT04787237|Active Comparator|Buser's technique and early implant placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks was followed. Then an open flap implant surgery using a triangular flap design was cut. Implant was then placed under the crest of the palatal bone. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone conditioned medium (BCM) added to bioss bone granules to activate it.
89660992|NCT04760171||Group 1|Patients diagnosed with medullary thyroid cancer (MTC) who are undergoing standard surgical treatment for their disease. This will be either hemithyroidectomy or total thyroidectomy. Patients with laryngeal amyloidosis (LA) who are undergoing standard surgical treatment of this disease. This will be microlaryngoscopy & biopsy/debulking
89660993|NCT01920997||No drug intervention|The objective of this study is to investigate the expression of NEI network and urine metabolomics of healthy women with normal menstrual cycles.
89660994|NCT04396769|Experimental|FLOW-PA|Participants received the physical activity component of FLOW five days a week during participants' 45-minute long physical education (PE) class period for six months. Intervention activities were designed to promote moderate-vigorous physical activity through circuit-based stations with both aerobic and strength exercises. Trained research staff partnered with PE teachers to facilitate lessons and undergraduate college students were trained to complete activities with participants.
89660995|NCT04396769|Active Comparator|PE class as usual|Participants had PE class as usual 5 days a week for 45 minutes.
89660996|NCT02984137|Experimental|idiopathic RBD group|A group of patients diagnosed as idiopathic RBD that is confirmed by polysomnography. Interventions as testing, evaluation, samplings at baseline, then repeat at 2 years and 4 years of prospective follow-up. thereafter only clinical observations until Lewy body disease is diagnosed.
89660997|NCT02984137|Active Comparator|incident PD group|A group of patients who are newly diagnosed as Parkinson's disease, and never been treated with prolonged history of probable RBD. Interventions as testing, evaluation, sampling at baseline and then evaluations only at 3 year follow-up after anti-parkinsonian treatment.
89660998|NCT02984137|Placebo Comparator|Control|Control group includes elderly controls without neurodegerative diseases examined by neurologists. Interventions as testing, evaluation, sampling at baseline only.
89660999|NCT01921075||Volunteers|young (age<30), healthy, lean (BMI<25) volunteers
89661000|NCT05241587|Experimental|The chewing gum group|"Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010). Therefore, this group of patients was allowed to chew xylitol gum for 10 minutes, five times a day for six weeks."
89661001|NCT05241587|Experimental|The mouth spray group|The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request.
89661002|NCT05241509|Experimental|Group I (test)|included twenty patients treated with SRP and intrapocket application of 2% lemongrass oil gel.
89661003|NCT05241509|Placebo Comparator|Group II (control)|included twenty treated with SRP and intrapocket application of placebo gel.
89661004|NCT01921153|Experimental|Short Intervention|All participants will be measured for (1) baseline, (2) two-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
89661005|NCT01921153|Experimental|Long Intervention|All participants will be measured for (1) baseline, (2) four-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
89661006|NCT05241431|Active Comparator|Intervention group|10 mg (oral) SGLT-2 inhibitor once daily
89661007|NCT05241431|Placebo Comparator|Control group|Placebo tablet encapsulated as the active treatment.
89661008|NCT01921231|Experimental|Hyperbaric prilocaine 1%|Solution for injection. Intradural use. In order to obtain Prilocaine 1% we charge a syringe with 2 mL Prilocaine 2%, and we add 1 mL Saline solution (0.9%) and 1 mL Glucose solution (33%). Administer 3 mL of syringe contains in two minutes.
89661009|NCT01921231|Active Comparator|Hyperbaric Bupivacaine 0.5%|Solution for injection. Intradural use. Charge a syringe with 1 mL of Bupivacaine (0.5%) and administer it in a minute.
89661010|NCT05241119|Experimental|SLNB Group|undergo fluorescence SLNB
89661011|NCT05241119|Experimental|pALND Group|undergo low axillary lymph node dissection with ICBN as the boundary
89661012|NCT05241119|Experimental|ALND Group|undergo ALND
89661013|NCT01921309|Experimental|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head and ceramic acetabular cup liner
89661014|NCT01921309|Active Comparator|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head and polyethylene acetabular cup liner
89661015|NCT05241041|Experimental|[1st year]Auricular Acupressure Experimental Group 1|auricular acupressure
89661016|NCT05241041|No Intervention|[1st year]Control Group 1|education material
89661017|NCT05241041|No Intervention|[1st year]Normal Group|Non-gamblers
89661018|NCT05241041|Experimental|[2nd&3rd year]Auricular Acupressure Experimental Group 2|auricular acupressure + group counseling
89661019|NCT05241041|Placebo Comparator|[2nd&3rd year]Placebo Group|placebo acupressure + group counseling
89661020|NCT05241041|No Intervention|[2nd&3rd year]Control Group 2|education material
89661021|NCT05240963|Experimental|PEEK implant|Temporal PEEK implant to prevent temporal hollowing after temporalis muscle transfer
89661022|NCT05240885||Controls|"Study subjects that are eligible based on inclusion/exclusion criteria~Screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~Study day(s): may include combinations of stable tracer infusions and with blood draws, cognitive and muscle performance testing"
89661023|NCT03056833|Experimental|Ribociclib|Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
89661024|NCT05240495|Experimental|Internet-based Cognitive-behavioural therapy group (n=61)|TThe generic iCBT program was based on contemporary CBT techniques adapted for stress-related disorders, and recovery from work training inspired by Hahn et al. [2011]. The iCBT consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week. In the first module (introduction), the participants received information about the outline of the program, stress physiology and defined individual treatment goals. During the second week participants were introduced to different recovery techniques and applied relaxation. The third and fourth week contained exercises related to behavioral activation, work-home balance, and values-based action skills. Between weeks five and ten, participants were able to choose between different exposure-based exercises. In addition, participants with insomnia could choose to focus on sleep management.
89688642|NCT03871465|Experimental|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
89661025|NCT05240495|Experimental|Internet-based Work-focused Cognitive-behavioural therapy group (n=61)|The internet-based and work-focused cognitive-behavioral therapy (W-iCBT) consisted of the generic treatment for stress-related disorders (iCBT), plus components focusing on work and return-to-work. These sections were integrated and represented in each of the ten modules. Work-focused CBT is built on the same conceptual framework as regular CBT. For example, CBT principles are used to change the appraisal of work stressors, change the dysfunctional behaviour, or increase health promoting behaviours. The CBT principal, exposure, is given special attention. Gradual exposure can help individuals develop more effective coping skills when dealing with work-related stressors (e.g., assertiveness) and stimulate gradual return to the work setting for individuals on a long-term sick leave [27].
89661026|NCT05240495|No Intervention|Wait-list control group (n=60)|Wait-list control group received equal and parallell assessment and eligibility procedure as the two experimental konditions. Wait-list control group gained access to iCBT/W-iCBT program after the six months follow-up.
89661027|NCT01921465||multiparas having a planned cesarean section|elective cesarean section
89661028|NCT05240261|Other|ESRAD on regular haemodialysis|30 ESRD Patients with sleep < 6 hours on regular haemodialysis . Before and after taking medications for 3 month.
89661029|NCT05240261|Other|CKD patients (predialydsis)|30 CKD Patients (predialysis) with sleep < 6 hours . Before and after taking medications for 3 month.
89661030|NCT01921543|Experimental|CI/BNST stimulation on|
89661031|NCT01921543|Experimental|CI/BNST vs stimulation off|randomized, double blind, 1 week crossover
89661032|NCT01921543|Experimental|ITP stimulation on|
89661033|NCT01921543|Experimental|CI/BNST vs ITP vs stimulation off|randomized, double blind, two month crossover
89661034|NCT05240105||Departments for Psychosomatic Medicine at University Clinics|no study interventions, observational group
89661035|NCT05240105||Clinics specialized in Psychosomatic Medicine|no study interventions, observational group
89661036|NCT05240105||Departments for Psychosomatic Medicine at general hospitals|no study interventions, observational group
89661037|NCT05240105||Departments for Psychosomatic Medicine at psychiatric hospitals|no study interventions, observational group
89661038|NCT05241977||Anterior suprasscapular nerve block|A single researcher will perform the nerve blocks of all participants.
89661039|NCT01921621|No Intervention|Group A|Control: Group of Orthopedic Residents who receive arthroscopic surgery training at the Orthopedic Learning Center during a standard week-end Resident Arthroscopic Training Course
89661040|NCT01921621|Active Comparator|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
89661041|NCT01921621|Experimental|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
89661042|NCT05602051|Experimental|Virtual reality+Mindfulness|Intervention method combining virtual reality technology and mindfulness therapy, twice a week, lasting for 7 weeks
89661043|NCT05602051|No Intervention|Mindfulness|Intervention method of mindfulness therapy, twice a week, lasting for 7 weeks
89661044|NCT01926223|Experimental|Home visiting Group|
89661045|NCT01926223|No Intervention|Control Group|
89661046|NCT03152669||Chronic obstructive pulmonary disease|Subjects with COPD who were randomised to treatment in the original SLS
89661047|NCT03152669||Asthma|Subjects with asthma who were randomised to treatment in the original SLS.
89661048|NCT01926301||Hemodialysis|Patients with severe sepsis or septic shock with acute renal failure and requirement of continuous veno-venous hemodialysis
89661049|NCT01926301||No hemodialysis|Patients with severe sepsis or septic shock without acute renal failure and no requirement of continuous veno-venous hemodialysis
89661050|NCT03148457|Experimental|Early treatment|Early treatment of patients with ischaemic stroke related to atrial fibrillation (AF) with direct oral anticoagulations (DOACs).
89661051|NCT03148457|Other|Late treatment|Treatment with direct oral anticoagulations (DOACs) according the current standard practice in patients with acute ischemic stroke related to atrial fibrillation (AF).
89661052|NCT01921699|Other|irrelevant|
89661053|NCT01921777|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
89661054|NCT01921777|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
89661055|NCT05601739||Lumbar degenerative disc disease|The case group was made of 50 patients, 24 women (48%) and 26 men (52%) with several clinical symptoms suggestive of LDD and the condition confirmed by MRI.
89661056|NCT05601739||Healthy|The control group was made of 44 healthy volunteers.
89661057|NCT05244551|Experimental|ABSK061|Dose escalation of oral ABSK061 will be guided by the Bayesian optimal interval (BOIN) design based on safety data collected until a maximum tolerated dose (MTD) or maximum administered dose (MAD) has been identified. During the dose escalation part of the study, patients will receive a single dose of ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in the subsequent cycles. If the actual elimination half-life of ABSK061 is greatly exceeding that predicted, a run-in period with a single-dose and a longer drug-free observation period could be performed in subsequent patients after the Investigator and Sponsor have discussed and agreed.
89661058|NCT01921855|Experimental|BAY Factor VII (6.5 µg/kg) / Placebo|n = 4, randomized 3:1; 6.5 µg/kg BAY 86-6150 (B0189):Placebo
89661059|NCT01921855|Experimental|BAY Factor VII (20 µg/kg) / Placebo|n = 4, randomized 3:1; 20 µg/kg BAY 86-6150 (B0189):Placebo
89661060|NCT01921855|Experimental|BAY Factor VII (50 µg/kg) / Placebo|n = 4, randomized 3:1; 50 µg/kg BAY 86-6150 (B0189):Placebo
89661061|NCT01921855|Experimental|BAY Factor VII (90 µg/kg) / Placebo|n = 4, randomized 3:1; 90 µg/kg BAY 86-6150 (B0189):Placebo
89661062|NCT01926379|Experimental|Combination Intervention Package (CIP)|Patients who enrolled in HIV care at a CIP site on or after January 1, 2013 and initiate Isoniazid Prevention Therapy (IPT) on or after study initiation on July 1, 2013 will receive the combination intervention components that is a part of the Combination Intervention Package (CIP).
89661063|NCT01926379|Other|Standard Of Care (IPT alone)|Patients are screened for tuberculosis (TB) at enrollment in HIV care at a HIV clinic and during each routine clinic visit using a simple symptom questionnaire. Eligible patients will receive the standard of care intervention, Isoniazid Prevention Therapy (IPT), per national guidelines. After IPT initiation, patients return to the HIV clinic monthly for monitoring of side effects, TB symptoms, self-reported 30-day adherence, and to receive a 30-day supply of isoniazid. If adherence problems are noted at any time, the nurse counsels the patient, and if the patient still wants to take IPT, it is continued.
89661064|NCT05601505|No Intervention|Traditional neoadjuvant chemoradiotherapy group|"Eligible patients randomized into arm A will receive traditional neoadjuvant chemoradiotherapy, including long-course radiotherapy with a total number of 45-50.4Gy in 25-28 fractions, and with concurrent 3 times of oral capecitabine, the strategies of capecitabine are:~During radiotherapy: capecitabine 1650mg/m2/d, orally administered twice a day, d1-d14, every 3 weeks as a course; During the non-radiotherapy period: capecitabine 2000mg/m2/d, orally administered twice daily, d1-d14, every 3 weeks as a course"
89661065|NCT05601505|Experimental|ctDNA-guided neoadjuvant treatment group|"After sequencing tumor tissue, those with MSI-H/TMB-H or POLD/POLE2 mutation willed be arranged to receive immune therapy following NCRT，Terelizumab，200mg.~The others are arranged to randomly receive TNT (VAF>0.4%) or NCRT (VAF<0.4%) according to VAF value by the level of ctDNA.~TNT： Long course radiotherapy combined with 2 courses of single-agent capecitabine chemotherapy → 6 courses of CapeOX (Capecitabine 2000mg/m2/ day, twice orally, d1-14; Oxaliplatin 100-130mg/m2, intravenous infusion, d1; Every 3 weeks for a course of treatment.) chemotherapy was performed 2 to 3 weeks after the end of chemotherapy."
89661066|NCT05601427|Active Comparator|Anesthesiologist-Performed Adductor Canal Block (aACB)|Patients will get a pre-operative adductor canal block performed by an anesthesiologist.
89661067|NCT05601427|Experimental|Surgeon-Performed Adductor Canal Block (sACB)|Patients will get an intra-operative adductor canal block performed by the surgeon
89661068|NCT05240027|Other|Middle, High and College students within the Dallas-Fort Worth area that may Vape|The program will be going to middle school, high school, and college campuses in the Dallas-Fort Worth (DFW) area to speak with students about vaping. The program will be implemented by community outreach, as the students will be presented with information about vaping and the resources necessary to prevent or stop vaping.
89661069|NCT04396015|Placebo Comparator|medium chain triglyceride (MCT) vs placebo|MCT or placebo (olive oil) for 4 months. Crossover at 4 months
89661070|NCT04396015|Other|open label extension|6 months of MCT oil.
89661071|NCT04396301|Active Comparator|Fydrane group|Fydrane is injected intracamerally at the beginning of cataract surgery after the first incision, at a dose of 0.2 ml of solution, in only one injection. Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE). No preoperative topical eye drops are used.
89661072|NCT04396301|No Intervention|Reference group:|not injected with intracameral Fydrane. Pupillary dilatation in this group is achieved using preoperative topical eye drops: cyclopentolate hydrochloride 1% and tropicamide 1 % one drop every 15 min for 1 hour preoperatively.
89661073|NCT02984059||IBD w/abdominal pain|"Patients with IBD with abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for both genomic DNA and calprotectin, and stool analyzed for microbiome. If no blood is drawn then a buccal swab done for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
89661074|NCT02984059||IBD w/out abdominal pain|"Patients with IBD and no abdominal pain. Colonoscopy done for standard of care, extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
89661075|NCT02984059||Colonoscopy other reasons no abd pain|Patients who have a colonoscopy for other reasons, rectal bleeding or polyp surveillance, no abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
89661076|NCT02397629||Patients Undergoing Prostate Biopsy|Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
89661077|NCT05601349|Other|Usual Implementation of the Clinical Practice Guideline|In this group, all participants (cluster) have access to the clinical practice guideline that has been sent to the office responsible for implementing the guideline in the hospital. Due to the characteristics of the intervention in the control group it does not work as a placebo or a sham intervention.
89661078|NCT05601349|Active Comparator|Tele-education strategy|Tele-educational program consisting of a virtual course with recommendations from the CPG of lower limb amputees, with three modules: Perioperative, rehabilitation and prostheses
89661079|NCT05604755|Experimental|HQP1351 prophylactic therapy|HQP1351 prophylactic therapy after allo-hct on days 30 to 60
89661080|NCT01921933|Experimental|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
89661081|NCT02984371|Experimental|Group 1|Coronary artery bypass grafting + epicardial ganglionated plexi ablation
89661082|NCT02984371|Active Comparator|Group 2|Coronary artery bypass grafting
89047608|NCT03456713|Experimental|Part A: 250 mg LY3074828 (Test 1)|250 mg LY3074828 administered SC as solution formulation in a prefilled syringe targeting a 5- to 15-second injection time on day 1.
89661083|NCT01926613|Active Comparator|Supported Employment Only|Supported employment is an evidence based practice designed to help people with serious mental illness obtain competitive work. This vocational model adheres to the principles of zero inclusion, rapid job search, no prevocational training, attention to client preferences and integration with clinical services.
89661084|NCT01926613|Experimental|Thinking Skills for Work|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
89661085|NCT03110965|Experimental|Experimental arm|Patients will have an X-ray before beginning to do one or two yoga poses daily for 4 - 10 months. After that period, they will have a second X-ray.
89661086|NCT01926691||Acute First-ever Stroke|Patients over 50 years and without pre-stroke dementia, displaying an ischemic first-ever stroke or transient ischemic attack (TIA), onset within the last 72 hours, Israeli residents.
89661087|NCT03351647||Group Ustekinumab|Patients presenting an active crohn's disease (HBI score ≥ 4) with an indication of treatment by ustekinumab because of failure or unacceptable side effects of previous treatments, and who have already been treated by at least one anti TNF The patients must be 18 years old or older.
89661088|NCT05601193|Experimental|PRP group|Experimental: autologous PRP Bilateral ovaries autologous PRP injection under transvaginal ultrasound guidance. 3ml on each ovary.Once a month. two consecutive injections
89661089|NCT05601193|No Intervention|Control group|No intervention
89661090|NCT01922167|Experimental|Leucine|2.5 g doses of leucine isolate three times per day (7.5 g total) of leucine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
89661091|NCT01922167|Placebo Comparator|Alanine|2.5 g doses of alanine isolate three times per day (7.5 g total) of alanine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
89661092|NCT04347421|Experimental|Krill oil group|This group takes Krill oil for 12 weeks
89661093|NCT04347421|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
89661094|NCT02392637|Experimental|Treatment (nab-paclitaxel, cisplatin, gemcitabine)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89661095|NCT01922245|Experimental|anodal tDCS|Soterix 1x1 device: anodal tDCS administered to the left hemisphere
89661096|NCT05593289|Experimental|Telerehabilitation group|Participants assigned to the telerehabilitation program will complete a 3 month intervention consisting of 5 weekly sessions of 30 minutes of pre-recorded video, with a frequency of 2-3 times a day.
89661097|NCT05593289|No Intervention|Control group|The usual care group will be instructed to follow their physicians' orders during the 3-month intervention period. Baseline measurements will be made for each group, at 2 weeks, 6 weeks and 3rd month.
89661098|NCT05600959||Lymphoma group|Patients with histopathologically confirmed lymphoma who did not receive systemic chemotherapy before enrollment.
89661099|NCT05600959||Lymphoma-associated HLH group|Patients with histopathologically confirmed lymphoma who meet HLH-04 diagnostic criteria, and did not receive systemic chemotherapy before enrollment.
89661100|NCT05600881||ADHD|This study will recruit people aged 14-17 with ADHD who are 'Assigned Female At Birth' (AFAB). This is to include cisgender women alongside those who may not identify with womanhood such as those who are non-binary but AFAB or transgender men who have not undergone hormonal/medical transition.
89661101|NCT01926769|Experimental|FOLFOX6+Metformin/FOFIRI+Metformin|
89661102|NCT04394143|Experimental|AD128|The study specific intervention includes per oral administration of two capsules of AD128, once daily, just before lights out, for 7 days.
89661103|NCT04394143|Placebo Comparator|placebo|Two placebo capsules (Mannitol) will be administered for the control intervention once daily, just before light outs, for one week.
89661104|NCT00639509|Experimental|Treatment (monoclonal antibody therapy)|Patients receive anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
89661105|NCT01926847|Experimental|Riociguat+Placebo|Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo
89661106|NCT01926847|Experimental|Placebo+Riociguat|Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521
89661107|NCT05586815|Active Comparator|Colistin plus Placebo|Colistin alone, 150 mg every 8 hours intravenously or according to renal function, plus Placebo
89661108|NCT05586815|Experimental|Colistin plus Minocycline|Colistin, 150 mg every 8 hours intravenously or according to renal function, plus Minocycline, 200 mg every 12 hours orally
89661109|NCT05607901|Active Comparator|Tacrolimus Group|50 patients will be treated with a thin layer of 0.03% topical tacrolimus ointment on the affected areas twice daily for 4 months.
89661110|NCT05607901|Active Comparator|Hydrocortisone Group|50 patients will be treated with a thin layer of 1% hydrocortisone cream on the affected areas twice daily for 4 months.
89047609|NCT03456713|Experimental|Part B: 250 mg LY3074828 (Test 2 and Test 3)|"Test 2: 250 mg LY3074828 administered subcutaneous (SC) as solution formulation in an auto-injector at slow speed targeting an approximately 13-second injection time on day 1.~Test 3: 250 mg LY3074828 administered subcutaneous (SC) as solution formulation in an auto-injector at fast speed targeting an approximately 5-second injection time on day 2."
89661111|NCT05586503|Experimental|ECG-gated CTA|For study's purposes, patients will undergo ECG-gated CTA scans instead of CTA scans at pre-operative planning, prior to discharge, 30 days, 6 months, 12 months in order to assess the stent stability and durability as well as the seal of the stent graft during the cardiac cycle and over time. An additional ECG-gated CTA scan may optionally be performed at 24 months if the device fixation and conformability continue up to the 12 months scan.
89661112|NCT03133325|Other|All subjects|Treatment with both GP0045 and Restylane Lyft Lidocaine
89047610|NCT03456713|Experimental|Part B: 125 mg LY3074828 (Test 4 and Test 5)|"Test 4: 125 mg LY3074828 administered SC as solution formulation in an auto-injector at slow speed targeting an approximately 7-second injection time on day 1.~Test 5: 125 mg LY3074828 administered SC as solution formulation in an auto-injector at fast speed targeting an approximately 4.5-second injection time on day 2."
89661113|NCT04759573|Experimental|Early Vocal Contact|"The EVC will take place in the hospital room while infants are in their individual incubators or open cribs. In the intervention group, mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.~Early Vocal Contact will be performed by mothers three times a week for 2 weeks, more than one hour after afternoon feeding. It will begin when the newborns are in an active sleep state, in calm awake state or in active awake state, but not in deep sleep or crying. Preterm infants will be enrolled from 25+0 to 32+6 weeks of GA, following the established inclusion criteria."
89661114|NCT04759573|Active Comparator|Behavioral observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
89661115|NCT05607745|Active Comparator|FMT|Fecal transplantation is given 2:1 compared to placebo transplantation via gastroscopy as a fluid of 100-150ml. Similar healthy diet counseling is given to all participants in both FMT and placebo group.
89661116|NCT05607745|Placebo Comparator|Placebo|Placebo is brown-colored water and given the same way than fecal transplantation fluid. All study subjects receive similar dietary advice based on healthy diet. Similar healthy diet counseling is given to all participants in both FMT and placebo group.
89661117|NCT05607667|Experimental|Experimental: Treatment|Device: J-Valve® valve delivery system， Transvascularized biological aortic valve system
89661118|NCT00638963|Experimental|Temozolomide|
89661119|NCT00638963|No Intervention|Observational|
89661120|NCT01926925||1|Overweight Hispanic children/adolescents
89661121|NCT01926925||2|Lean Hispanic children/adolescents
89661122|NCT05604625|Active Comparator|Group A|12 patients will receive Van-Beek activator and a headgear
89661123|NCT05604625|Active Comparator|Group B|12 patients will receive Andresen activator
89661124|NCT05607589|Experimental|DWP213388|"Each cohort, healthy subjects will be administered DWP213388 (6 subjects per each cohort) SAD Cohort 1: DWP213388 x mg QD Cohort 2: DWP213388 x mg QD Cohort 3: DWP213388 x mg QD Cohort 4: DWP213388 x mg QD Cohort 5: DWP213388 x mg QD~MAD Cohort 6: DWP213388 x mg QD Cohort 7: DWP213388 x mg QD Cohort 8: DWP213388 x mg QD Cohort 9: DWP213388 x mg QD"
89661125|NCT05607589|Placebo Comparator|Placebo|"Each cohort, healthy subjects will be administered placebo (2 subjects per each cohort) SAD Cohort 1: Placebo QD Cohort 2: Placebo QD Cohort 3: Placebo QD Cohort 4: Placebo QD Cohort 5: Placebo QD~MAD Cohort 6: Placebo QD Cohort 7: Placebo QD Cohort 8: Placebo QD Cohort 9: Placebo QD"
89661126|NCT04278677|Active Comparator|Melatonin supplementation|5mg melatonin tablets to be taken for 6 weeks
89661127|NCT04278677|No Intervention|No supplementation|
89661128|NCT00638027|Experimental|1|Memantine 10 mg bid
89661129|NCT00638027|Placebo Comparator|2|Placebo
89661130|NCT03548519|Experimental|Attention Training|OCAT-only: An attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
89661131|NCT03548519|Active Comparator|Active placebo training|OCAT-sham: An active placebo training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. The training task is an undirected Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
89661132|NCT03548519|Experimental|PSE and Attention Training|OCAT-combo: An online PSE session prior to an attention training, consisting of 10 sessions of ±12 minutes each (during an intervention period of two weeks), will be administered. Content of the PSE will focus on how adaptive functions of automatic and controlled processes may become maladaptive when used inappropriately or excessively. The training task is a positively directed Scrambled Sentences Test (SST) with mouse-gaze contingent feedback.
89661133|NCT01927081|Active Comparator|discussion group|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain
89661134|NCT01927081|Active Comparator|discussion group + exercise|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain and learn gentle exercise and breathing techniques
89661135|NCT03342911|Experimental|Treatment (nivolumab, paclitaxel, carboplatin)|Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89661136|NCT05604079|Experimental|Electrolarynx|In this single arm study, all participants will receive training in the Electrolarynx
89661137|NCT05603767|Experimental|RMT+ VR|The patient selects a video with the Oculus Quest headset and music to be played live.
89047611|NCT04648137|Experimental|Patients with central diabetes insipidus|
89047612|NCT04648137|Experimental|Healthy volunteers|
89047613|NCT03456674|Experimental|LaseMD System|Subjects will receive LaseMD System treatment(s) for treatment of melasma.
89661138|NCT05603767|No Intervention|Control|No intervention
89661139|NCT01927315|Experimental|Fenofibrate|Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks
89661140|NCT01927315|Placebo Comparator|Placebo|Placebo oral tablets daily for 12 weeks
89661141|NCT01927393|Experimental|Arm I (PCPI)|Patients undergo a comprehensive physical, psychological, social, and spiritual palliative care assessment. Patients also receive a workbook that covers physical and psychological well-being and social and spiritual well-being, delivered over 2 educational sessions.
89661142|NCT01927393|Active Comparator|Arm II (standard care plus attention control)|Patients receive standard care plus attention comprising two telephone contacts.
89661143|NCT00636155|Experimental|all patients|EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)
89661144|NCT05603689|Active Comparator|Normal diet|no limitations on food consumption.
89661145|NCT05603689|Experimental|Isocaloric ketogenic diet|We defined ICKD as a daily CHOs ingestion < 30 to 50 g.d-1, without any limitation in fat consumption.
89661146|NCT05553977||Consecutive patients for outpatient colonoscopy|The researchers will offer to participate in the study to patients scheduled for a colonoscopy who meet all the inclusion criteria and none of the exclusion criteria
89661147|NCT03030859|Experimental|Group I (Usual Care)|Patients receive monthly automated system telephone call for 12 months.
89661148|NCT03030859|Experimental|Group II (Usual Care plus LEF-SCP)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients also review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed.
89661149|NCT03030859|Experimental|Group III (Usual Care plus LEF-SCP plus Follow-Up)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed. Patients also meet with the study lymphedema therapist over 1 hour at 3, 6, and 9 months.
89661150|NCT00634907|Experimental|Pharmacogenetic-based warfarin dosing|"Pharmacogenetic-based warfarin dosing: Warfarin dosing based on formula that incorporates genetic testing results.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
89661151|NCT00634907|Active Comparator|Standard of care (control)|"Control or usual care warfarin dosing~NOTE: Standard of care (usual care) for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
89661152|NCT05600335||ERAS group|
89661153|NCT05600335||Conventional group|
89661154|NCT05603221||Endovascular Group|Patients who had successful endovascular revascularization
89661155|NCT05602909|Experimental|Guided biaxial distraction|
89661156|NCT04759261|Other|Study group|
89047614|NCT04648332|Experimental|Group 1|Patients in group 1 underwent catheterization of the lumbar plexus from the posterior access on admission to the hospital and began analgesia with bupivacaine 0.125% 6-8 ml / h. Intraoperative anaesthesia was provided with a bupivacaine bolus of 0.5% 200 mg in a lumbar catheter and a sciatic nerve block with 1.5% 450 mg of lidocaine. Postoperative analgesia was provided by an elongated lumbar plexus block with bupivacaine 0.125% 6-8 ml / h.
89047615|NCT04648332|No Intervention|Group 2|Patients in group 2 underwent intraoperative spinal anaesthesia at the level of L3-L4 with hyperbaric bupivacaine at a dose of 10-15 mg.
89047616|NCT04648332|No Intervention|Group 3|Group 3 patients underwent general inhalation anaesthesia with sevoflurane with a constant infusion of fentanyl for analgesia.
89047617|NCT03456596||Institution|Community cancer centers implementing ENABLE
89661157|NCT01927705|Experimental|Treatment|"FURESTEM-AD Inj. 1. 2.5 x 10^7 stem cells after registration.~FURESTEM-AD Inj. 2. 5.0 x 10^7 stem cells after registration."
89661158|NCT04124497|Experimental|Daratumumab Pomalidomide dexamethasone|"Therapy consists in cycles of the DPd combination as follows:~Pomalidomide 4 mg once daily on days 1-21;~Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22;~Daratumumab 16 mg/kg intravenously at following schedule:~cycle 1 and 2: days 1, 8, 15, and 22~cycle 3 through 6: days 1, and 15~from cycle 7 until disease progression: day 1."
89661159|NCT03831373|Experimental|Upper-limb-focused resistance training|
89661160|NCT03831373|Experimental|Lower-limb-focused resistance training|Lower-limb-focused resistance training with elastic bands.
89661161|NCT03831373|Active Comparator|Stretching exercise|Stretching exercise program in a sitting position.
89661162|NCT04394611||Fetal Growth Restriction (FGR)|FGR will be defined as an estimated fetal weight (grams) less than the 10th percentile for gestational age. Hadlock I formula will be used to calculating estimated fetal weight percentiles
89661163|NCT04394611||Control|healthy pregnancies will be selected for the control group.
89661164|NCT04127851|Experimental|Sodium Hyaluronate 0.15% mono-therapy|HA 0.15% group was treated with HA 0.15% six times daily for 12 weeks
89661165|NCT04127851|Active Comparator|Cyclosporin 0.05% + carboxymethylcellulose (CMC) 0.5% (standard therapy)|CsA 0.05% + CMC 0.5% group was treated with CsA 0.05% two times daily and CMC 0.5% two ~ six times daily for 12 weeks.
89047618|NCT04647981||Xpert® Bladder Test|A urine sample is collected before cystoscopy.
89047619|NCT03456557|Experimental|Computed tomography.|
89047620|NCT04648566|Placebo Comparator|IIU control group|
89047621|NCT04648566|Active Comparator|IIU PBMC group|
89047622|NCT04648566|Placebo Comparator|FIV control group|
89047623|NCT04648566|Active Comparator|FIV PBMC group|
89047624|NCT04648566|Active Comparator|RIF group|
89047625|NCT05078411|Other|Patients without a history of tooth loss due to periodontitis (NTLP)|
89047626|NCT05078411|Other|Patients with a history of tooth loss due to periodontitis (TLP)|
89047627|NCT04648176|Active Comparator|HoLEP|Conventional laser
89047628|NCT04648176|Experimental|m-HoLEP|Moses technology
89047629|NCT00543335|Experimental|Sorafenib + Radiation Therapy|Sorafenib starting dose 200 mg orally daily + 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
89047630|NCT02223039|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
89047631|NCT02223039|Experimental|AbGn-168H High Dose|Subject to receive high dose of AbGn-168H intravenously
89047632|NCT02223039|Placebo Comparator|Placebo|Subject to receive placebo intravenously
89047633|NCT00543413|Experimental|1|Arm 1: Drug 250 mg
89047634|NCT00543413|Experimental|2|Arm 2: Drug 500 mg
89047635|NCT00543413|Active Comparator|3|Arm 3: Active Comparator
89047636|NCT00543413|Placebo Comparator|4|Arm 4: Pbo Comparator
89047637|NCT00554658|Active Comparator|A|Patients will be taken quetiapine for the treatment of first episode schizophrenia.
89047638|NCT00543452|Active Comparator|oxygen|4 liters of oxygen a minute
89661166|NCT04127851|Other|HA 0.15% + CsA 0.05% (combination therapy)|HA 0.15% + CsA 0.05% group was treated with HA 0.15% six times daily and CsA 0.05% twice daily for 12 weeks.
89661167|NCT06255106||Group 1|Group 1, consisting of individuals treated with a cast
89661168|NCT06255106||Group 2|Group 2, comprising those who underwent surgical intervention (Open reduction volar plate fixation.
89661169|NCT06255080|Experimental|Intervention group|This group practiced the proficiency-based program on the LAPSIM(R) simulator using the new 2019-version of the software
89661170|NCT06255080|No Intervention|Control Group|This group practiced the proficiency-based program on the LAPSIM(R) simulator using the original (and evidence based) 2016-version of the software
89661171|NCT06255067|Experimental|Minocycline hydrochloride with noisome as carrier|"Group I ( Minocycline hydrochloride with noisome carrier)~15 patients will receive the drug ( Minocycline hydrochloride with noisome carrier gel) at intervals 1,3,7&14 days"
89661172|NCT06255067|Active Comparator|Minocycline hydrochoride only|"Group II (Minocycline hydrochloride only)~15 patients will receive the drug (Minocycline hydrochloride only gel) at intervals 1,3,7&14 days"
89661173|NCT06255054||Non-Users|People who do not use cannabis.
89661174|NCT06255054||Daily Flower Users|People who use cannabis flower daily.
89661175|NCT06255054||Daily Concentrate Users|People who use cannabis concentrate products daily.
89661176|NCT06255054||Occasional Flower Users|People who use cannabis flower at least once a month and no more than three times per week.
89661177|NCT06255028|Experimental|Part 1: Dose Escalation Phase|"Lymphodepleting chemotherapy (LDC) will be followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental human recombinant interleukin 2 (IL-2).~After completion of Cycle 1, CNTY-101 (without preceding LDC), administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2."
89661178|NCT06255028|Experimental|Part 2: Dose Expansion Phase|Treatment using the recommended phase 2 regimen (RP2R) confirmed during Part 1 of the study.
89661179|NCT06255015|Active Comparator|Breastfeeding toolkit card|"50% of participants will be allocated to the intervention group, and receive a breastfeeding toolkit card at the 24 week appointment.~The Breastfeeding toolkit provides advice on circumventing common breastfeeding problems and contact details for breastfeeding support services."
89661180|NCT06255015|No Intervention|No planning card|50% of women will receive routine antenatal care only.
89661181|NCT06255002||Patients|Patients giving birth in the Cochin Port Royal and Necker Enfants Malades (APHP) maternity units and cared for severe postpartum haemorrhage defined as bleeding greater than 1000 ml within 24 hours of postpartum, regardless of the route of delivery (vaginal delivery and cesarean section).
89661182|NCT06254963|Experimental|Sand jump training|Participants will conduct 6 weeks (twice weekly) supplemental jump training on a sand surface (within their warm ups) in addition to their regular training.
89661183|NCT06254963|Active Comparator|Land jump training|Participants will conduct 6 weeks (twice weekly) supplemental jump training on a land surface (within their warm ups) in addition to their regular training.
89661184|NCT06254937|Experimental|enterprise group|"The research will be conducted as a randomized controlled trial with a pretest-posttest design.~Intervention Group: Participants in the intervention group will be given group training based on the contents of the booklet created by the researcher in line with the literature. Training will be given to participants face to face for 40 minutes, once a week for five weeks. Each training session will include two topics in Reproductive Life Plan Based Training Booklet.~Control Group: A pre-test will be applied to the control group. Reproductive Life Plan Based Training Booklet will be given after the final test.~Post Intervention Phase After the pre-test is applied to the participants in both groups, the data collection form will be applied again 8 weeks later and the post-test phase of the research will be completed. Participants in the control group will be given Reproductive Life Plan Based Training Booklet."
89661185|NCT06254937|No Intervention|control group|"Control Group: A pre-test will be applied to the control group. After the final test, the Reproductive Life Plan Based Training Booklet will be given.~Post Intervention Phase Following the application of the pre-test to the participants in both groups, the data collection form will be applied again 8 weeks later and the post-test phase of the research will be completed. Participants in the control group will be given the Reproductive Life Plan Based Training Booklet after the post-test."
89661186|NCT06254833|No Intervention|regular dose ICG|
89661187|NCT06254833|Active Comparator|micro dose icg|
89661188|NCT06254820|Experimental|Part A Dose Arm 1|Medium dose, expected to be approximately 10^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
89661189|NCT06254820|Experimental|Part A Dose Arm 2|Dose Arm 2: High dose, expected to be approximately 10^7 TCID50/ mL (titer may be adjusted based on stock titer)
89661190|NCT06254820|Experimental|Part B Dose Extension:|Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR
89661191|NCT06254820|Experimental|Part B Dose Arm 3|Addition of a 3rd dose, TBD depending on outcome of Part A
89661192|NCT06254794|Experimental|Blood flow restriction group|The study group will undergo normal Achilles tendon rupture reconstruction rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
89047639|NCT00543452|Placebo Comparator|air|4 liters of room air
89047640|NCT04647942||Meniscectomy|Patients who underwent a meniscectomy
89047641|NCT00554697||1|
89047642|NCT00554697||2|
89047643|NCT00554736|Experimental|1|In the first phase, subjects with a history of grass pollinosis, with positive skin tests to grass, will be studied out of season and will be randomized to active treatment for 4 months.
89047644|NCT00543608|Experimental|1|Dose 1 iclaprim
89047645|NCT00543608|Experimental|2|Dose 2 iclaprim
89047646|NCT00543608|Active Comparator|3|vancomycin
89047647|NCT00554775|Experimental|erlotinib hydrochloride|WBRT plus Tarceva (OSI-774, erlotinib) PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
89047648|NCT00554775|Placebo Comparator|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride arm
89047649|NCT00543647|Experimental|1|
89213633|NCT03508739|Experimental|ARM 1: randomization order AB|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
89661193|NCT06254794|Other|Standard of Care (control) group|The control group will undergo the normal Achilles tendon rupture reconstruction rehab protocol as determined by Drs. Varner and McCulloch.
89661194|NCT06254781|Experimental|Luspatercept in metastatic AGCT of the ovary|Luspatercept, 1.0 mg/kg, subcutaneously, every three weeks
89661195|NCT06254768|Experimental|Unblinded|They will wear the device and have access to their data- UNBLINDED ARM
89661196|NCT06254768|Experimental|Blinded|They will wear the device but will not have access to their data- BLINDED ARM
89213634|NCT03508739|Experimental|ARM 2: randomization order BA|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
89213635|NCT03882437|Experimental|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single intravenous (IV) infusion. Subjects will receive one of three dose levels depending on the cohort.
89213636|NCT00205699|Active Comparator|aripiprazole|Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.
89213637|NCT00205699|Active Comparator|olanzapine|Participants in this group will be randomized to flexibly-dosed treatment with olanzapine.
89213638|NCT00205699|Active Comparator|risperidone|Participants in this group will be randomized to flexibly-dosed treatment with risperidone.
89213639|NCT03503513|Experimental|Gentamicin sulfate|Participants initiate Gentamicin instillations every night for a period of 6 months. After baseline and consented they are instructed on how to do the instillations through a catheter, once they receive the drug and aid equipment (i.e. syringes) to do installations. Remaining drug is to be disposed after each use. Participants use their own catheters.
89213640|NCT03882801|Experimental|Sequence 1: Placebo -> Gefapixant|In Period 1, participants receive a single oral dose of placebo matching gefapixant (MK-7264) every night at bedtime (QHS), for 7 days. In Period 2, participants receive a single oral dose of gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
89661197|NCT06254755|Experimental|suction aspiration group|suction aspiration group is based on a large bore catheter for thrombus removal under negative pressure of pump or manual syringe.
89661198|NCT06254755|Active Comparator|combination group|combination group is based on a stent retrieval with a large bore catheter for thrombus removal under negative pressure of pump or manual syringe.
89661199|NCT06254742|Experimental|Treatment group A|first cycle: Auto-HHPG-19K Injection second cycle: HHPG-19K Injection
89661200|NCT06254742|Experimental|Treatment group B|first cycle: HHPG-19K Injection second cycle: Auto-HHPG-19K Injection
89661201|NCT06254729||training group|The training group is used to train the model.
89661202|NCT06254729||validation group|The validation group is used to evaluate model performance.
89661203|NCT06254716||Disc resection of rectal endometriosis|Patients who underwent disc resection and anastomosis for rectal endometriosis involving the full thickness of the rectum reaching the mucosa or submucosa during preoperative evaluation or intraoperative exploration, and who were diagnosed pathologically.
89661204|NCT06254716||Segmental resection of rectal endometriosis|Patients who underwent segmental resection and anastomosis for rectal endometriosis involving the full thickness of the rectum reaching the mucosa or submucosa during preoperative evaluation or intraoperative exploration, and who were diagnosed pathologically.
89661205|NCT06254703||Patients receiving CKRT|"Adults (≥ 18 years of age)~Admitted to ICU~Plan to initiate CKRT by clinician's judgement"
89661206|NCT06254690|Experimental|Pyrotinib dose escalation group|Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd)
89661207|NCT06254690|Active Comparator|Pyrotinib dose normal group|Pyrotinib: 400mg per week, by mouth(po),once a day(qd)
89661208|NCT06254664|Experimental|Tiotropium 18 µg inhalation powder, hard capsule once daily (QD)|"Interventions:~Drug: Tiotropium 18 µg inhalation powder, hard capsule~Device: Zephir inhaler"
89661209|NCT06254651|Experimental|High resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's xiphoid process in a neonatal manikin.
89661210|NCT06254651|Active Comparator|Low resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's superior anterior iliac spines in a neonatal manikin.
89661211|NCT06254638|Experimental|Multicomponent school-based intervention|"The multicomponent intervention will be composed of:~Physically Active Learning: consists of incorporating physical activity (usually of moderate-vigorous intensity) into the educational content taught in non-physical education academic classes.~Active breaks: consists of short breaks during non-physical education academic classes that include moderate to vigorous intensity physical activity.~Active Recess: consists of promoting PA during school breaks. To this end, three strategies will be developed: i) modification of the environment; ii) loose equipment; iii) structured recess. The modification of the environment will consist of providing students with a greater number of spaces for them to be active during recess. Access to sports equipment consists of providing sports equipment to encourage PA practice during recess. Structured recess includes the organization of sports competitions and teacher-led activities."
89661212|NCT06254638|No Intervention|Control Group|The control group will receive the usual academic classes without any methodological modification during the intervention period.
89661213|NCT06254625|Experimental|Fecal microbiome transplantation|25-30 capsules are ingested with apple juice or coca cola light, and the patient is observed for 30-60 minutes before they are allowed to go home. The capsules are to be ingested within 4 hours of thawing. Each transplant, comprising 25-30 capsules, contain 50 g of feces originating from one donor.
89661214|NCT06254625|Placebo Comparator|Placebo|The placebo group receives 25-30 placebo capsules.
89661215|NCT06254599|Experimental|SY-3505|SY-3505, single agent, 600 mg oral capsules, QD, continuously
89661216|NCT06254599|Active Comparator|Crizotinib|Crizotinib, single agent, 250 mg oral capsules, BID, continuously
89661217|NCT06254586|Experimental|Aerobic exercise|This group received a single session of low-intensity cycling for 20 minutes.
89661218|NCT06254586|Active Comparator|Resisted exercises|This group received four sets of 15 repetitions of knee extension, hamstring curls, and standing calf raises (20-40% 1RM) with a 30 sec to 1 minute rest period between sets.
89661219|NCT06254560|Experimental|rituximab group|Rituximab combined with cyclosporine
89661220|NCT06254547|Experimental|Motivational messages and leaderboard|This group will receive daily reminders/motivational messages. They will be able to view their personal score and will be ranked on a daily updated leaderboard.
89661221|NCT06254547|Experimental|Only motivational messages|This group will receive daily reminders/motivational messages. They will be able to view their personal score, but they will not be ranked on a leaderboard.
89661222|NCT06254547|No Intervention|Control|This group will be able to view their personal score, but will not be ranked on a leaderboard or receive daily reminders/motivational messages.
89661223|NCT06254521|Experimental|neoadjuvant Tislelizumab combined with chemotherapy|"Patients with locally advanced rectal cancer who met the inclusion criteria received two or four cycles of Tislelizumab combined Capecitabine and Oxaliplatin regimen chemotherapy and were evaluated by enhanced CT and MRI\TRUS. Then, these patients will receive curative surgery for rectal cancer.~Interventions:~Drug: Oxaliplatin Drug: Capecitabine Drug: Tislelizumab Procedure: curative surgery for rectal cancer"
89661224|NCT06254495|Experimental|SGN-35C|SGN-35C Monotherapy
89661225|NCT06254469|Other|Part A - Lead in|Part A plans to enroll 50 participants (approximately 20 participants with mild cognitive impairment [MCI] due to suspected CTE, 20 participants with MCI due to suspected AD, and 10 age-matched healthy volunteers, whose age is within 3 years of any participants with MCI due to suspected CTE or AD in Part A).
89661226|NCT06254469|Experimental|Part B - AD|Part B plans to enroll 90 participants with MCI due to suspected AD for primary accuracy assessments of F-18 FNT-PET imaging.
89661227|NCT06254469|Experimental|Part B - CTE|Part B plans to enroll 90 participants with MCI due to suspected CTE from concussive and percussive injuries in approximately 1:1 ratio for primary accuracy assessments of F-18 FNT-PET imaging.
89661228|NCT06254456|Experimental|Prone patients|
89661229|NCT06254443|Other|Oral PEG group|Following the administration protocol recommended by the Chinese expert consensus for PEG, a 3 L PEG regimen is employed. The regimen involves segmented intake, with 1 L taken 10-12 hours before the intestinal examination and an additional 2 L taken 4-6 hours before the examination on the day of the procedure.
89661230|NCT06254443|Other|Enema group|Enema is administered using either normal saline or 1% soapy water for cleansing until the effluent is clear of fecal debris, or until a total volume of 3000 ml of enema solution has been administered. The enema should be initiated 4-6 hours before colonoscopy, with the dosage and frequency of incremental enemas determined based on the patient's tolerance. The final enema administration should be completed no later than 10 minutes before the scheduled colonoscopy.
89661231|NCT06254417|Active Comparator|NON VENTILATED GROUP|
89661232|NCT06254417|Active Comparator|VENTILATED GROUP|
89661233|NCT06254404|Active Comparator|Low dose of Protamine|
89661234|NCT06254404|Experimental|Normal dose of protamine|
89661235|NCT06254391|Other|Very low-dose aspirin first|"Patients will receive ASA 30mg per day (in the morning) for 14 days, followed by ASA 75mg per day (in the morning) for the next 14 days.~All the participants will receive standard maintenance dose of ticagrelor 90mg twice a day as part of the DAPT therapy. All the participants will receive the loading dose of ASA 300mg before the PCI procedure."
89661236|NCT06254391|Other|Standard low-dose aspirin first|"Patients will receive ASA 75mg per day (in the morning) for 14 days, followed by ASA 30mg per day (in the morning) for the next 14 days.~All the participants will receive standard maintenance dose of ticagrelor 90mg twice a day as part of the DAPT therapy. All the participants will receive the loading dose of ASA 300mg before the PCI procedure."
89661237|NCT06254378|Active Comparator|Sinus lifting without graft (control )|Patients will receive sinus lifting with immediate implant placement without graft placement.
89661238|NCT06254378|Experimental|Sinus lifting with graft (intervention)|Patients will receive sinus lifting with immediate implant and allograft placement.
89661239|NCT06254326|Experimental|Adoptive Cellular Therapy|All participants will receive 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment), a single i.v. infusion of ex vivo expanded tumor-reactive T cells, and a i.v. single infusion of autologous HSCs.
89661240|NCT06254313||Influenza-related ARDS group|Person with influenza virus infection proven by a positive polymerase chain reaction test for the influenza ARDS group. Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
89047650|NCT00543647|Placebo Comparator|2|
89047651|NCT04647669|Placebo Comparator|Local Standard of Care|Local Standard of Care
89047652|NCT04647669|Active Comparator|Remdesivir|Remdesivir (daily infusion for 10 days)
89047653|NCT04647669|Active Comparator|Acalabrutinib|Acalabrutinib (orally twice daily for 10 days)
89047654|NCT04647669|Active Comparator|Interferon|Interferon β1a(daily injection for 6 days).
89047655|NCT00543686|Active Comparator|1|Montelukast
89047656|NCT00543686|Active Comparator|2|Fluticasone
89047657|NCT04647864||Group 1|Edwards Sapien 3 and Edwards Sapien 3 Ultra
89213641|NCT03882801|Experimental|Sequence 2: Gefapixant -> Placebo|In Period 1, participants receive a single oral dose of gefapixant (MK-7264) QHS for 7 days. In Period 2, participants receive a single oral dose of placebo matching gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
89661241|NCT06254313||Bacterial-related ARDS group|A person with a proven bacterial infection (105 colony-forming units/mL for tracheal aspirates and more than 104 colony-forming units/mL for BAL). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample.
89661242|NCT06254313||Extra-pulmonary (digestive inflammation) ARDS group|"Person presenting with acute pancreatitis according to the 2013 international recommendations (typical pain, lipasemia above 3 times normal and/or abnormality on imaging).~Or Person presenting with acute bacterial peritonitis based on a clinical diagnosis and bacteria isolated on peritoneal samples (RFE SFAR 2018). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample."
89661243|NCT06254300|Experimental|Intervention Group|The intervention group will participate in a supervised online exercise prehabilitation program that will extend throughout the chemotherapy until one week before the scheduled surgery. The exercise program will consist of three sessions per week, each lasting 60 minutes. The design of the prehabilitation program is based on exercise prescription recommendations for cancer survivors and will be tailored to each patient's initial functional capacity. The exercise sessions will be conducted at home through an online platform, enabling real-time interaction among groups of patients.
89661244|NCT06254300|No Intervention|Control Group|Participants from the control group will be offered optimal medical care, which includes general advice about healthy lifestyle including regular physical activity participation according to the current guidelines.
89661245|NCT06254287|Experimental|Avatrombopag group|The Avatrombopag group was given Avatrombopag: 40 mg/ time, once a day, orally, for 3 months
89661246|NCT06254287|Other|Avatrombopag +rhTPO group|Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.
89661247|NCT06254274|Experimental|RAY1225 (cohort 1)|Participants received dose1 or dose2 RAY1225 administered subcutaneously (SC) once two week for 24 weeks.
89661248|NCT06254274|Placebo Comparator|Placebo (cohort 1)|Participants received Placebo administered SC once two weeks for 24 weeks.
89661249|NCT06254274|Experimental|RAY1225 (cohort 2)|Escalating doses of RAY1225 administered subcutaneously (SC) once two week
89661250|NCT06254274|Placebo Comparator|Placebo (cohort 2)|Participants received Placebo administered SC once two week
89661251|NCT06254248|Experimental|Atezo-Beva combination|first-line Atezo-Beva combination in LT patients with advanced HCC in association with a standardized immunosuppressive treatment to prevent the risk of acute cellular rejection
89661252|NCT06254235|Experimental|Test|
89661253|NCT06254235|Active Comparator|Reference|
89661254|NCT06254209|Placebo Comparator|Placebo|Maltodextrin
89661255|NCT06254209|Experimental|Verum1|Combination of clove (Syzygium aromaticum) and immortelle (Helichrysum italicum) extracts
89661256|NCT06254209|Experimental|Verum2|Olive fruit extract (Olea europaea)
89661257|NCT06254209|Experimental|Verum3|Hibiscus flower extract (Hibiscus sabdariffa)
89661258|NCT06254196|No Intervention|Control group: current clinical practice|
89661259|NCT06254196|Experimental|Experimental group: Telenursing nursing intervention|
89661260|NCT06254183|Active Comparator|Gabapentin|"30 patients will represent the treatment group and will receive a single oral dose of Gabapentin 1200 mg 1 hr before the surgery.~Blood and urine samples will be collected before the surgery, then 24 hrs postoperatively."
89661261|NCT06254183|Placebo Comparator|Placebo|"30 patients will represent the treatment group and will receive a single oral dose of Placebo 1 hr before the surgery.~Blood and urine samples will be collected before the surgery, then 24 hrs postoperatively."
89661262|NCT06254170|Experimental|Euterpe Edulis suplementation|Male, aged between 19 and 30 years and practicing physical exercises regularly for at least 3 months will receive the Euterpe Edulis juice for 10 days.
89661263|NCT06254170|Placebo Comparator|Placebo|Male, aged between 19 and 30 years and practicing physical exercises regularly for at least 3 months will receive the placebo product for 10 days.
89661264|NCT06254118|Experimental|group 2 polyunsaturated fatty acids|"intervention: systemic administration of 1000 mg polyunsaturated fatty acids. to be taken once daily with meals for 12 months~patients treated by scaling and root planing and oral systemic administration of Omega-3 fatty acids a soft gelatinous capsule containing 1000 mg polyunsaturated fatty acids (PUFAs)"
89661265|NCT06254118|Sham Comparator|group 1 control|control group, patients treated by scaling and root planing and an oral soft gelatinous capsule containing olive oil to be taken once daily with meals for 12 months
89661266|NCT06254092|Experimental|tourniquet|The investigators use tourniquets to bind the cervical for intervention groups to block venous return to the lower uterine segments to reduce the inflow of amniotic fluid into the uterus.
89661267|NCT06254079|Experimental|Intervention group|A video containing information about the operating room environment and intraoperative care will be watched. The patients who watch the video will be questioned again about the points they do not understand, the issues they are curious about about the perioperative period, and the information they want to learn, and this information will be given verbally by the researchers.
89661268|NCT06254079|No Intervention|Control Group|Patients in this group will not be shown any videos and will continue to receive care according to their clinical routine.They will be asked to answer the questions in the patient introduction form the day before the surgical intervention. The surgical anxiety scale will be filled in when patients come from the ward to the preoperative waiting room on the day of surgery. Finally, patients will be asked to answer the questions on VAS and Quality of Recovery-15 (QoR-15) in the patient room at the 24th hour after surgery.
89661269|NCT06254066|Experimental|Adebrelimab+Fluzoparib|
89661270|NCT06254040|Placebo Comparator|Control Group|Volunteers will take 1 dissolving powder pack with maltodextrin daily for 6 months.
89661271|NCT06254040|Experimental|Experimental Group|Volunteers will take 1 dissolving powder pack with the mixture of extracts and DHA daily for 6 months.
89661272|NCT06254027|Experimental|Forte|"Device:~One application per day for 9 months."
89661273|NCT06254027|Experimental|Active Cover Light|"Device:~One application per day for 9 months."
89213642|NCT01073917|Other|Spontaneous Breathing|Patients will be breathing spontaneously during anesthesia
89661274|NCT06254027|Active Comparator|Loceryl 5%|Drug: Loceryl 5% One application per week for 3 months
89661275|NCT06253988|Active Comparator|Group probiotic|received conventional periodontal treatment combined with topically applied probiotic
89661276|NCT06253988|Placebo Comparator|Group placebo|received conventional periodontal treatment only.
89661277|NCT06253975|Experimental|AT-EV group|
89661278|NCT06253975|Placebo Comparator|HA group|
89661279|NCT06253962||carotid atherosclerosis|
89047658|NCT04647864||Group 2|Medtronic Corevalve Evolut R and Medtronic Corevalve Evolut PRO
89661280|NCT06253962||without carotid atherosclerosis|
89047659|NCT04647864||Group 3|Boston Scientific Acurate neo and Boston Scientific Acurate neo2
89047660|NCT04647864||Group 4|St. Jude Medical Portico
89661281|NCT06253949|Active Comparator|high tie ligation of inferior mesenteric artery|Group A patients of elective operable colorectal cancer : high tie group
89661282|NCT06253949|Active Comparator|low tie ligation of inferior mesenteric artery|Group B patients of elective operable colorectal cancer : low tie group
89661283|NCT06253858|Experimental|Catheter placement with Solopass system|The Solopass US system will be used during catheter placement procedure to guide the placement of the catheter.
89661284|NCT06253832||conservative surgery|resective-constructive surgery: the excision of the placenta and its attachment site on the myometrium. Subsequently, uterine reconstruction is undertaken.
89661285|NCT06253832||hysterectomy 1|Standard hysterectomy is performed
89661286|NCT06253832||hysterectomy 2|Standard hysterectomy is performed
89661287|NCT06253819||geriatrics individuals with metabolic syndrome|
89661288|NCT06253819||geriatrics individuals without metabolic syndrome|
89661289|NCT06253806|Active Comparator|Experimental: Stellate Ganglion Block|The ultrasound guided stellate ganglion blocks will be performed at the initial visit by a board-certified anesthesiologist and pain management specialist with extensive experience performing these blocks. Laterality of the stellate ganglion blocks will be randomized between the left and right sides of the neck.
89661290|NCT06253806|Placebo Comparator|Placebo: Sham Injection|The ultrasound guided placebo sham injections will be performed at the initial visit by a board-certified anesthesiologist and pain management specialist with extensive experience performing these injections. Laterality of the placebo sham injections will be randomized between the left and right sides of the neck.
89661291|NCT06253780||Cohort 1|Adult patients (age > 18 years old) admitted to the NSICU at UT Southwestern Medical Center with a neurological, neurosurgical, or neurovascular diagnosis are eligible receiving Intravenous vasoactive medication infusing at the time of consent.
89661292|NCT06253767|Experimental|Treatment Group (TG)|They are composed of 29 participants. After endodontic treatment, they will receive PBM for molars with 808nm application (AsGaAl), infrared, equipment with a power of 100 mW, and an exit beam area of 1 cm² perpendicular in contact with the mucosa at the level of the root apices at two vestibular points and one complementary palatal point, with 3J of energy per point (30s per point), totaling 9J of total delivered energy and 90 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 9J/cm² overall. To premolars the parameters will be 808nm application (AsGaAl), infrared, Laser Duo® equipment with a power of 100 mW and an exit beam area of 1cm² perpendicular in contact with the mucosa at the level of the root apices at one vestibular point and one complementary palatal point, with 3J of energy per point (30s per point), totaling 6J of total delivered energy and 60 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 6J/cm² overall
89661293|NCT06253767|Sham Comparator|Control Group (CG)|They are composed of 29 participants. After endodontic treatment, they will receive a simulation of the PBM session with all individual preparation involved, such as individual protection with goggles, and the sounds of the equipment (Laser Duo®, MMOptics, São Carlos, SP) will be recorded and played at the time of the session, but the equipment will not be activated.
89047661|NCT00543842|Experimental|Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy|Bevacizumab 5 mg/kg intravenous (IV) every 2 weeks for 3 Doses (Weeks 1, 3, 5). Erlotinib starting dose 50 mg orally daily Weeks 1-3. Capecitabine starting dose 650 mg/m^2 orally twice daily Monday-Friday for 6 Weeks. Radiation Therapy 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments. At least 8 weeks after radiation therapy, surgical removal of rectal tumor.
89047662|NCT00543881|Experimental|1|Interventional group
89047663|NCT00543881|Active Comparator|2|Usual care group
89047664|NCT04638855|Experimental|Medicurtain®|Treat Medicurtain 5ml prefilled syringe after hysteroscopy surgery
89047665|NCT04638855|Sham Comparator|Placebo|No device after hysteroscopy surgery
89047666|NCT04638738||Pre-implementation|Pre-implementation of digital alerting sensor systems
89047667|NCT04638738||Post-implementation|Implementation of digital alerting sensor systems
89047668|NCT00543959|Experimental|Part1 - Arm 1|Part1: Arm 1: drug
89047669|NCT00543959|Placebo Comparator|Part1 - Arm 2|Part1 - Arm 2: Pbo comparator
89047670|NCT00543959|Placebo Comparator|Part 2 - Arm 1|Part 2 - Arm 1: Pbo
89047671|NCT00543959|Experimental|Part 2 - Arm 2|Part 2- Arm 2: drug 5mg
89047672|NCT00543959|Experimental|Part 2 - Arm 3|Part 2 - Arm 3: drug 15mg
89047673|NCT00543959|Experimental|Part 2 - Arm 4|Part 2 - Arm 4: drug 30mg
89047674|NCT00543959|Active Comparator|Part 2 - Arm 5|Part 2 - Arm 5: active comparator
89213643|NCT01073917|Other|Pressure controlled ventilation|Patients in the PPV group will be ventilated by pressure control (tidal volume 8-10 ml/kg, frequency 10-14, I:E 1:1, no PEEP, target CO2 4.5 kPa).
89661294|NCT06253754||Postdural puncture headache after lumbar puncture|Group of patients with aged 20-40 years undergoing planned neurological work-up including a lumbar puncture (LP). The group will include 40 subjects with and 40 subjects without PDPH.
89661295|NCT06253754||Postdural puncture headache after accidental dural puncture|Group of parturients with EDA. The group will include 40 subjects with accidental dural puncture (ADP) with PDPH and 40 subjects without ADP and PDPH.
89661296|NCT06253741|Active Comparator|PARAVERTEBRAL BLOCK|After induction of general anesthesia and endotracheal intubation in the operating room, following the positioning of the patient for surgery, ultrasound-guided paravertebral block (PVB) will be routinely performed in our clinic using 0.25% bupivacaine solution at a dose of 0.5 ml/kg.
89661297|NCT06253741|Active Comparator|RHOMBOID INTERCOSTAL AND SUBSERRATUS PLANE BLOCK|After induction of general anesthesia and endotracheal intubation in the operating room, following the positioning of the patient for surgery, rhomboid intercostal block with sub-serratus plane block (RISS) will be routinely performed in our clinic using 0.25% bupivacaine solution at a dose of 0.5 ml/kg under ultrasound guidance.
89661298|NCT06253741|Placebo Comparator|PLACEBO|The group without any peripheral block application will be included
89661299|NCT06253728|Experimental|Meal 1|Meal with plant protein and fiber in an intact structure
89661300|NCT06253728|Experimental|Meal 2|Meal with plant protein and fiber, where the cell structure is broken
89661301|NCT06253728|Placebo Comparator|Meal 3|Low protein and low fiber cereal
89661302|NCT06253728|Experimental|Meal 4|High protein and low carbohydrate bread with animal proteins
89661303|NCT06253728|Experimental|Meal 5|High protein and low carbohydrate bread with plant protein
89661304|NCT06253715|Active Comparator|Regimen 1: Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Ethambutol (E)|8 weeks of daily HRZ(E) followed by either 16 or 24 weeks of daily HR, per local standard of care
89661305|NCT06253715|Experimental|Regimen 2: Isoniazid (H), Rifapentine (P), Pyrazinamide (Z), Moxifloxacin (M)|8 weeks of daily HPZM
89661306|NCT06253702|Experimental|Placebo First: Hormone Suppression|Participants drug (placebo vs Indo) are randomized prior to first set of MRI visits, while experiencing hormone suppression.
89661307|NCT06253702|Experimental|Indo First: Hormone Suppression|Participants drug (placebo vs Indo) are randomized prior to first set of MRI visits, while experiencing hormone suppression.
89661308|NCT06253702|Experimental|Placebo First: Hormone Add-Back|Participants drug (placebo vs Indo) are randomized prior to second set of MRI visits, while experiencing hormone add-back.
89661309|NCT06253702|Experimental|Indo First: Hormone Add-Back|Participants drug (placebo vs Indo) are randomized prior to second set of MRI visits, while experiencing hormone add-back.
89661310|NCT06253689|Experimental|Defecation Posture Modification Device|
89661311|NCT06253689|No Intervention|Control|
89661312|NCT06253676|Active Comparator|Standard Delivery of Problem Management Plus (PM+)|"For an eligible, consenting mother participant randomized to the comparator arm, our team will not provide her with active passive sensing technology. As such, no passive sensing data regarding maternal activity and health will be transmitted to or made available to trained, non-specialist providers (i.e., 'PM+ helpers').~Following enrollment, the mother participant will undergo the five intervention sessions with an assigned PM+ helper in an in-person capacity. In particular, the helper will only deliver the intervention as originally manualized; in other words, s/he will not integrate key findings/interpretations of the aforementioned passive sensing data into delivery."
89661313|NCT06253676|Experimental|StandStrong Platform-Informed Delivery of Problem Management Plus (PM+)|"For an eligible, consenting mother participant randomized to the experimental arm, our team will provide her a smart phone (with EBM application) and her infant with a GPS beacon. Collectively, these passive sensors will non-invasively collect data regarding maternal activity and health (e.g., heart rate, step count, proximity to infant, etc.) from her and the infant. Upon acquisition of said data, we will transmit it to a data analysis engine based in a machine-learning approach and then visualize it within an application (i.e., 'dashboard') available to trained, non-specialist providers (i.e., 'PM+ helpers').~Following enrollment, the mother participant will undergo the five intervention sessions with an assigned PM+ helper in an in-person capacity. In particular, the helper will integrate key findings/interpretations of the aforementioned passive sensing data into delivery of a given session with respect to an adapted fidelity checklist."
89661314|NCT06253650|Experimental|Experimental|treatment with T-DXd (6.4 mg/kg intravenous every 3 weeks) plus capecitabine (1000 mg/sqm BID orally on days 1-14 every 3 weeks) or 5-fluorouracil (600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks) as per Investigator's choice for 6 cycles.
89661315|NCT06253650|Active Comparator|Control|treatment with post-operative FLOT for 4 cycles as per standard of care and using the doses previously adopted in the last cycle of the preoperative phase, i.e. 5-fluorouracil (2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks), leucovorin (200 mg/m2 intravenous infusion on day 1 every 2 weeks), oxaliplatin 85 mg/m2 (intravenous infusion on day 1 every 2 weeks) and docetaxel (50 mg/m2 intravenous infusion on day 1 every 2 weeks).
89661316|NCT06253637|Experimental|Very high risk T-ALL patients treated with daratumumab and the national treatment program|"After a steroid/cyclophosphamide pre-treatment phase, patients will be treated according to the national treatmetn program - as per the previous GIMEMA LAL1913 - plus daratumumab as follows:~In the first cycle, C1, daratumumab (subcutaneous) 1800 mg will be administered on days 1, 8, 15 and 22~In the second cycle, C2, daratumumab 1800 mg will be administered on days 1, 8, 15~In the subsequent cycles C3-C8 daratumumab 1800 mg will be administered on day 1~in addition to chemotherapy according to the national treatment program~Induction/consolidation cycles are administered at 28 (C1-2) and 21(C2-8) day intervals. Dose reductions are required in patients > 55y~All patients are eligible for allo-SCT after C3. All patients unable to undergo an allo-SCT are eligible for an auto-SCT after C8, If unable to undergo an auto-SCT, these patients are eligible to maintenance at the end of the consolidation program."
89661317|NCT06253598|Experimental|intervention arm|
89661318|NCT06253585|Experimental|EHR Alert|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to the intervention arm.
89661319|NCT06253585|Active Comparator|Standard of Care|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care.
89661320|NCT06253533|Experimental|Low-dose Group|Clinically stable HIV-infected patients under ART treatment will receive 1 mg/dose ICVAX or Placebo at 4:1 ratio. ICVAX and Placebo will be administered via intramuscular injection followed by electroporation at 0, 4th, 8th, 12th, and 36th week.
89661321|NCT06253533|Experimental|Medium-dose Group|Clinically stable HIV-infected patients under ART treatment will receive 2 mg/dose ICVAX or Placebo at 4:1 ratio. ICVAX and Placebo will be administered via intramuscular injection followed by electroporation at 0, 4th, 8th, 12th, and 36th week.
89661322|NCT06253533|Experimental|High-dose Group|Clinically stable HIV-infected patients under ART treatment will receive 4 mg/dose ICVAX or Placebo at 4:1 ratio. ICVAX and Placebo will be administered via intramuscular injection followed by electroporation at 0, 4th, 8th, 12th, and 36th week.
89661323|NCT06253481||Group I: patients diagnosed with various types of ASCVD|Group I: Patients diagnosed with various types of ASCVD (> 50% stenosis caused by atherosclerotic plaque) of various vascular beds (coronary vessels, carotid arteries, mesenteric arteries, lower extremities, and kidneys) (case; n=6500).
89661324|NCT06253481||Group II: patients with no clinically significant ASCVD (control, n=3500)|Group II: patients with no ultrasound/ angiography findings of ASCVD (control, n=3500)
89661325|NCT06253468|Experimental|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
89661326|NCT06253468|Experimental|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA) 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
89661327|NCT06253468|Experimental|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score > 5
89661328|NCT06253455|Experimental|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
89661329|NCT06253455|Experimental|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
89661330|NCT06253455|Experimental|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score > 5
89661331|NCT06253429|Active Comparator|Interventional arm|"including pediatric patients with diabetic nephropathy receiving oral alpha-lipoic acid daily.~The capsule of ALA ( Thiotex 300 mg capsule) contains 300 mg of thioctic acid, manufactured bt Marcyrl Pharmaceutical Industries - Egypt.) The patient will receive 1 capsule twice daily for 3 months. Patients' compliance to therapy will be checked by counting pills.~oral angiotensin-converting enzyme inhibitors (ACE-Is) captopril 25 mg tablet provided their blood pressure will be maintained within normal range for age"
89661332|NCT06253429|Placebo Comparator|Control Arm|including pediatric patients with diabetic nephropathy receiving placebo that is similar in appearance to the oral alpha-lipoic acid (Thiotex 300 mg capsule) and oral angiotensin-converting enzyme inhibitors (ACE-Is)(Captopril 25 mg tablet) provided their blood pressure will be maintained within normal range for age
89661333|NCT06253390|Active Comparator|D-MCT group|
89661334|NCT06253390|Other|DPN group|
89661335|NCT06253377||Study cohort|Patients with Acute Kidney Injury and Renal Replacement Therapy indication, following local clinical patterns, who were treated with Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris™
89661336|NCT06253338|Experimental|Interventional Arm|
89661337|NCT06253325||Patients presenting to the Emergency Department with suspected sepsis|Patients who present with potential sepsis. This is characterised by their illness suspected to be from an infection and significantly unwell defined by one of two scoring systems, either the National Early Warning Score or quick Sequential Organ Failure Assessment
89661338|NCT06253299||Group L|Just before the vascular access is opened, a 4x5 cm sized marble stone will be applied to the carotid in the left lateral neck region (2-3 cm above the clavicle, on the sternocleidomastoid muscle (SKM)) for 30 seconds, and then the vascular access will be opened
89661339|NCT06253299||Group R|Just before the vascular access is opened, a 4x5 cm cold marble stone will be held on the carotid in the right lateral neck area (2-3 cm above the clavicle, on the sternocleidomastoid muscle (SKM)) for 30 seconds (sec), and then the vascular access will be opened.
89661340|NCT06253286|Active Comparator|part-time wear|Patients will be instructed to wear the aligner for 16 hours per day, then the aligner going to be changed to the next step according to its numerical order in the software
89661341|NCT06253286|Active Comparator|Full-time wear|Patients will be instructed to wear the aligner for 22 hours per day, then the aligner going to be changed to the next step according to its numerical order in the software
89661342|NCT06253247|Experimental|Patients with necrotic mandibular premolars will be treated with NanoChitosan impregnated Ca(OH)2|25-45 years old patients with necrotic single rooted mandibular premolars with single canal will be treated with NanoChitosan impregnated Calcium Hydroxide as an intracanal medicament for 7 days
89661343|NCT06253247|Active Comparator|Patients with necrotic mandibular premolars will be treated with Calcium Hydroxide|25-45 years old patients with necrotic single rooted mandibular premolars with single canal will be treated with calcium hydroxide as an intracanal medicament for 7 days
89661344|NCT06253208||laparoscopic block|laparoscopic transversus abdominis plane block
89661345|NCT06253208||ultrasound guided block|ultrasound guided transversus abdominis plane block
89661346|NCT06253195|Experimental|Phase 1a: Dose Escalation|Sequential cohorts of increasing dose levels of BGB-43395 will be evaluated as monotherapy and in combination with either fulvestrant or letrozole.
89661347|NCT06253195|Experimental|Phase 1b: Dose Expansion|The recommended dose for expansion (RDFE) for BGB-43395 in combination with fulvestrant from Phase 1a will be evaluated in HR+ breast cancer and selected tumor cohorts.
89661348|NCT06253182|Experimental|Self-Guided PEPP Intervention workbook|Following completion of the virtual consent/baseline visit and the virtual education visit, dyads will work through content of self-guided workbook. Every two weeks, participants will receive a check-in email and/or text message from study staff to assess their adherence and respond to questions or concerns.
89661349|NCT06253182|Active Comparator|Self-Guided PEPP Education Workbook|Following completion of the virtual consent/baseline visit and the virtual education visit, dyads will work through content of self-guided workbook. Every two weeks, participants will receive a check-in email and/or text message from study staff to assess their adherence and respond to questions or concerns.
89661350|NCT06253169||Not participating in screening|All women over 30 years of age who are not participating in screening or have not had a screening visit in less than 5 years.
89661351|NCT06253169||Participating in the screening|All women over 30 years of age who regularly participate in screening but have not had an HPV test in the last 3 years.
89661352|NCT06253130|Experimental|Cohort 1|IMP1734 monotherapy; oral tablet(s) daily (except for the single-dose period). The maximum trial duration is 3 years after the last participant's first treatment in the trial.
89661353|NCT06253117|Placebo Comparator|Placebo|Placebo
89661354|NCT06253117|Experimental|Pirfenidone|Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day Total duration of experimental or placebo drug treatment 6 months
89047675|NCT04638972||Tactile Sense Method|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
89047676|NCT04638972||Radiographic Method (digital periapical radiography)|In clinical practice, tactile sense and conventional radiography have been the methods of choice for determination of working length for a long time. However, these two methods have some limitations in determining working length. While the accuracy rate in tactile sense changes with experience, radiographic examination in children is usually hard due to poor cooperation or the unsuitable sensor size for child's small mouth [7]. Also, these techniques may yield inaccurate information especially in cases with root resorption
89047677|NCT04638972||Ipex® EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
89047678|NCT04638972||Propex® pixi EAL|Electronic apex locaters (EALs), which are based on electrical principles instead of visual determinants, have been used more frequently in primary teeth.
89047679|NCT00543998||Optical Measurement transillumination|Optical Measurement of sinus
89047680|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and PFC|
89047681|NCT04638777|Active Comparator|Real rTMS stimulation over M1 and sham rTMS over PFC|
89047682|NCT04638777|Sham Comparator|Sham rTMS over M1 and PFC|
89047683|NCT00544037||Group 1|
89047684|NCT04647357|Experimental|SHR-1316|
89047685|NCT04638582|Experimental|Neoadjuvant pembrolizumab + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles.~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
89047686|NCT04638582|Experimental|Neoadjuvant pembrolizumab and chemotherapy + adjuvant pembrolizumab +/- adjuvant chemotherapy|"Neoadjuvant: Participants receive pembrolizumab [200 mg, intravenous (IV)] every 3 weeks for 3 cycles in combination with standard of care histology-specific chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 3 cycles.~Adjuvant: Participants receive pembrolizumab [400 mg IV] every 6 weeks for 6 cycles, and may receive histology-specific adjuvant chemotherapy [consisting of carboplatin AUC 6 and paclitaxel 200 mg/m2, or carboplatin AUC 5 and paclitaxel 500 mg/m2] every 3 weeks for 4 cycles, if indicated."
89047687|NCT00544232|Experimental|epirubicin, paclitaxel and CMF +/- darbepoetin|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
89047688|NCT00544232|Experimental|EC followed by paclitaxel +/- darbepoetin|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
89047689|NCT04647318|Experimental|Compassion focused imagery, relaxation imagery and control task|Participants engage in three tasks (compassion focused imagery, relaxation imagery and control task), three or four times every three days.
89047690|NCT01191268|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
89047691|NCT01191268|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
89047692|NCT01191268|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
89047693|NCT04647552||hydrocortisone|The patients with septic shock who required a noradrenaline infusion rate above 0.5µg/kg
89047694|NCT04647552||control|The patients with septic shock who needed a noradrenaline infusion rate of up to 0.5µg/kg/min to maintain MAP>65 mmHg
89047695|NCT04647279||Normal control group|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
89047696|NCT04647279||Osteopenia|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
89661355|NCT06253078|Experimental|65-69 years old|The initial dose of ciprofol was 0.4mg/ in this group.
89661356|NCT06253078|Experimental|70-74 years old|The initial dose of ciprofol was 0.4mg/ in this group.
89661357|NCT06253078|Experimental|75-79 years old|The initial dose of ciprofol was 0.3mg/ in this group.
89661358|NCT06253078|Experimental|80-84 years old|The initial dose of ciprofol was 0.3mg/ in this group.
89661359|NCT06253078|Experimental|Older than 85 years (include 85 years old)|The initial dose of ciprofol was 0.2mg/ in this group.
89661360|NCT06253065||Patients undergoing PLND|Patients (will) undergo radical prostatectomy and pelvic lymph node dissection
89661361|NCT06253052|No Intervention|Usual care|Fasting instructions as given by anaesthesiologist according to national guidelines (6 h solid meal and thick liquids, 2 h clear fluids).
89661362|NCT06253052|Active Comparator|Instructed guideline adherence|Patients should not involuntarily fast fluids for longer than 2 h.
89661363|NCT06253052|Experimental|Experimental intervention|Patients should not involuntarily fast fluids for longer than 30 min.
89661364|NCT06253039|Experimental|Normobaric hypoxia (RSH)|The RSH group will perform training sessions in a normobaric hypoxic chamber at a simulated altitude of 3000 meters (FiO2 14.5%)
89661365|NCT06253039|Experimental|Hypoventilation (RSH-VHL)|RSH-VHL group will be asked to exhale down to functional residual capacity just before each repetition and then hold their breath until the end of the sprint
89661366|NCT06253039|Active Comparator|Normoxia (RSN)|The control group will perform the training sessions in normoxia (FIO2, 20.9%)
89661367|NCT06253026||Air mission personnel|Military crew that goes to air search and rescue missions in groups of five
89661368|NCT06253026||Control|Ground military personnel
89661369|NCT06253013|Experimental|Full study intervention|"In addition to the standard of care at the institutions which includes virtual pulmonary rehabilitation, remote clinical monitoring and integrated care, patients will have the option to use the following interventions:~FitBit wearable device with continuous monitoring for oxygen saturation and respiratory rate for 90 days~Hyfe cough monitoring smartwatch with continuous monitoring for 90 days~Home spirometer used once daily for 90 days~Audio recordings on a tablet once daily for 90 days"
89661370|NCT06253000|Active Comparator|Cryoablation|Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.
89661371|NCT06253000|Active Comparator|Radiofrequency ablation|"Radiofrequency ablation of pulmonary veins according to the box isolation type using a non-fluoroscopic navigation system."
89661372|NCT06252987|Sham Comparator|common group|routine training
89661373|NCT06252987|Experimental|tDCS group|tDCS
89661374|NCT06252987|Experimental|rTMS group|rTMS
89661375|NCT06252987|Experimental|Combination group|tDCS-rTMS
89661376|NCT06252961|Experimental|Levamisole 3 days|Participants randomized in this arm will receive 3 days of levamisole 2.5mg/kg, followed by 2 days of placebo
89661377|NCT06252961|Experimental|Levamisole 5 days|Participants randomized in this arm will receive a 5-day course of levamisole 2.5mg/kg
89661378|NCT06252961|Placebo Comparator|Placebo|Participants randomized in this arm will receive 5 days of placebo
89661379|NCT06252935|Experimental|FormaAid group|Patients with intrabony defects are randomly assigned to receive either FormaAid collagen membrane or Geistlich Bio-Gide (control)before the GTR. And then treated with GTR surgery, the surgical procedure involves a full-thickness flap, the affected area is cleaned, and the damaged or diseased tissue may be removed. The allograft will be then placed into the defect and the collagen membrane is then trimmed and adapted over the defect. After all the treatment is done, 5-0 nylon suture will be used for the flap closure.
89661380|NCT06252935|Active Comparator|Bio-Gide group|Patients with intrabony defects are randomly assigned to receive either FormaAid collagen membrane or Geistlich Bio-Gide (control)before the GTR. And then treated with GTR surgery, the surgical procedure involves a full-thickness flap, the affected area is cleaned, and the damaged or diseased tissue may be removed. The allograft will be then placed into the defect and the collagen membrane is then trimmed and adapted over the defect. After all the treatment is done, 5-0 nylon suture will be used for the flap closure.
89661381|NCT06252909|Experimental|Interpersonal Psychotherapy for Couples|
89661382|NCT06252909|Active Comparator|Interpersonal Psychotherapy (Individual)|
89661383|NCT06252896|Experimental|IASTM Group|Individuals were positioned on the stretcher so that the area to be applied was exposed. ADYDM to be applied to ensure comfortable movement of the instrument on the tissue before application baby oil was applied to cover the area. In order to increase the effectiveness of the application suggestions were made to the person to relax. Application ADYDM for each muscle group tool (Figure 3.4) for 5 minutes. The occurrence of allergic reactions on the skin the test was terminated.
89661384|NCT06252896|Placebo Comparator|Control Group|The control group was kept for 30 minutes without ADYDM application and then muscle strength assessment, flexibility assessment, agility assessment, balance assessment and finally aerobic capacity assessment were performed respectively.
89661385|NCT06252870|Experimental|(CLO)-BALTIMORE|BALTIMORE conditioning regime for LYMPHOID HEMOPATHY CLO-BALTIMORE conditioning regime for MYELOID HEMOPATHY
89661386|NCT06252870|Active Comparator|TBF|Conditioning regimen for LYMPHOID AND MYELOID HEMOPATHY
89661387|NCT06252831|Experimental|Healthy volunteers|1 sachet (1 g) take 2 times a day with an interval of 12 hours. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis. The total duration of each subject's participation in the clinical trial is no more than 21±1 days.
89661388|NCT06252805||SPOCCAT|Severe Chronic Obstructive Pulmonary Disease patients in Catalonia
89661389|NCT06252792||daratumumab, pomalidomide, and dexamethasone (Dara-PD)|the first relapse of patients who received daratumumab, pomalidomide, and dexamethasone (Dara-PD) treatment
89661390|NCT06252792||other regimens in the same period (including Dara-KPD, VPd, KPd, IPd, Pd)|the first relapse of patients who received other regimens in the same period (including Dara-KPD, VPd, KPd, IPd, Pd) treatment
89661391|NCT06252779|Experimental|Plasma stimulation therapy group|
89661392|NCT06252779|Placebo Comparator|False stimulation treatment group|
89661393|NCT06252740||control group|Baseball players without a history of low back pain
89661394|NCT06252740||experimental group|Baseball players with a history of low back pain
89661395|NCT06252727|Experimental|Aminolevulinic acid (5-ALA)|20 mg/kg body weight of 5-ALA orally at 3-4 hours prior to surgical resection. 5-ALA fluorescence will be used to evaluate the resected tumor per gross margins and identifying further areas of fluorescing tissues beyond the gross tumor margins.
89047697|NCT04647279||Osteoporosis|Diagnostic Test: Quantitative MRI imaging IR-UTE, UTE-MT, Maigc, Ideal IQ, DTI, and IVIM
89047698|NCT00544310|Experimental|1|Post surgery adhesion prevention treatment
89047699|NCT01191190|Experimental|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered.~Each patient may receive 3 cycles of treatment in the absence of progressive disease or significant toxicity."
89047700|NCT00559806|Experimental|1|9 healthy elderly males
89047701|NCT00559806|Experimental|2|11 healthy young males
89047702|NCT00544583|Active Comparator|A|Interrupted closure with Vicryl equivalent sutures (USP 2, 45 cm)
89047703|NCT00544583|Experimental|B|Continuous closure with PDS II equivalent sutures (USP 1, 150 cm loops)
89047704|NCT00544700|Active Comparator|Arm A: Bevacizumab monotherapy|Bevacizumab maintenance monotherapy
89047705|NCT00544700|Other|Arm B: No maintenance|No antitumor treatment until progression
89047706|NCT00544739||1|323 women with established coronary artery disease before 55 year of age
89661396|NCT06252688|Other|Participants|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are patients with an eating disorder."
89661397|NCT06252675|Experimental|Treatment (obinutuzumab, glofitamab, pirtobrutinib)|Participants receive obinutuzumab IV on days 1 and 2 of cycle 1 for a total of 2 doses. Participants receive glofitamab IV on days 8 and 15 of cycle 1 and day 1 of remaining cycles. Cycles repeat every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Participants receive pirtobrutinib PO once a day (QD) on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo FDG-PET/CT at screening, after every 4 cycles through cycle 13 and then after every 6 cycles. Participants will undergo a bone marrow biopsy and aspiration at cycle 13 and blood sample collection throughout study and a tissue biopsy at relapse or progression.
89661398|NCT06252662|Active Comparator|Liposomal bupivacaine and bupivacaine plain erector spinae plane block|Erector spinae plane block performed on the surgical side (left, right or bilateral) as appropriate based on planned surgical consent. Utilizing ultrasound to see the fascial layers and guide the needle placement under direct visualization. Block will include 1.33% liposomal bupivacaine 10ml plus 0.25% bupivacaine plain 20 ml per side of the block.
89661399|NCT06252662|Experimental|Bupivacaine plain with dexmedetomidine|Erector spinae plane block performed on the surgical side (left, right or bilateral) as appropriate based on planned surgical consent. Utilizing ultrasound to see the fascial layers and guide the needle placement under direct visualization. Block will include 0.25% bupivacaine plain 30 ml plus dexmedetomidine 0.5 mcg/kg per side of the block.
89047707|NCT00544739||2|347 clinically healthy, age matched women selected from the National Health Survey WOBASZ study with negative history of CVD or negative exertional chest pain.
89047708|NCT05824676|Experimental|Depuy Synthes LCP Patella Plating System|This group will have 18 randomly selected participants, who will receive the Depuy Synthes LCP Patella Plating System for patella fracture.
89047709|NCT05824676|Other|Control/Conventional Fixation|This group will have 18 randomly selected participants, who will receive the conventional treatment for patella fracture.
89047710|NCT05824663|Experimental|HBM1020|HBM1020 is a recombinant fully human anti-B7H7 monoclonal antibody
89047711|NCT05824624|Experimental|study group|Animal-supported application will be made to the children in the study group.
89047712|NCT05824624|Experimental|control group|Routine care will be given to the children in the control group.
89047713|NCT05824585|Experimental|DZD8586|
89047714|NCT05824520|Experimental|CT-derived FFR guided-ITS group|CT-derived FFR≤0.8; ITS plus OMT
89047715|NCT05824520|Active Comparator|Medical therapy group|CT-derived FFR≤0.8; OMT alone
89047716|NCT05824481|Experimental|Cadonilimab + Lenvatinib|"Safety run-in stage. A dose de-escalation schedule is used in this phase. Dose Level 1: cadonilimab 10 mg/kg administered intravenously on day 1 and lenvatinib 16 mg administered orally once daily on a 21-day treatment cycle. If ≥2/6 patients experience a DLT, we will de-escalate to Dose Level 2: cadonilimab 10 mg/kg administered intravenously on day 1 and lenvatinib 12 mg administered orally once daily on a 21-day treatment cycle. Approximately 3-12 patients will be enrolled in the safety run-in phase.~Expansion stage. The expansion stage will begin once the RP2D of lenvatinib have been determined in the safety run-in phase in order to assess antitumor activity of cadonilimab and lenvatinib combination. In expansion stage, cadonilimab 10 mg/kg and lenvatinib PR2D will be administered."
89047717|NCT05824468|Experimental|Zimberelimab + Lenvatinib|"Safety run-in phase A dose de-escalation schedule is used in this phase. Dose Level 1: zimberelimab 240 mg administered intravenously on day 1 and lenvatinib 16 mg administered orally once daily on a 21-day treatment cycle. If ≥2/6 patients experience a DLT, we will de-escalate to Dose Level 2: zimberelimab 240 mg administered intravenously on day 1 and lenvatinib 12 mg administered orally once daily on a 21-day treatment cycle. Approximately 3-12 patients will be enrolled in the safety run-in phase.~Expansion phase The expansion stage will begin once the RP2D of lenvatinib have been determined in the safety run-in phase in order to assess antitumor activity of zimberelimab and lenvatinib combination. In expansion stage, zimberelimab 240 mg administered intravenously and lenvatinib PR2D will be administered."
89047718|NCT05824455|Experimental|JS109 combination with irinotecan|
89047721|NCT05824390|Experimental|Group A ( ACEi and / or ARB + rituximab group )|Patients in the experimental group were treated with the maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and / or angiotensin II receptor blocker ( ARB ) combined with rituximab. The specific usage and dosage are as follows : On the basis of the use of ACEI and / or ARB, rituximab was used on D1 and D31 days, 1 g each time, intravenous drip, twice in total. Add 1 g rituximab at 6 months. All patients who received rituximab were given oral acetaminophen ( 1g ), diphenhydramine hydrochloride ( 50mg ) and intravenous methylprednisolone ( 40mg ) 30-60min before the beginning of infusion. ACEI and / or ARB were given daily maximum tolerable dose according to individual factors of subjects.
89047722|NCT05824390|No Intervention|Group B ( ACEi and / or ARB )|According to the individual factors of the subjects, the maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and / or angiotensin II receptor blocker ( ARB ) were used daily.
89047723|NCT05824312||TKI group|patients with LATC receiving Tyrosine kinase inhibitor drugs.
89047724|NCT05824312||Controlled group|patients with LATC receiving other treatment.
89047725|NCT05824286|Experimental|HbA1c prediction model group|HbA1c was predicted every month based on self-monitoring blood glucose for patients in HbA1c prediction model group. Study physicians adjusted patients' hypoglycemic therapy based on self-monitoring blood glucose records/glycated albumin and predicted HbA1c every month.
89047726|NCT05824286|No Intervention|Conventional treatment group|Study physicians adjusted patients' hypoglycemic therapy based on self-monitoring blood glucose records/glycated albumin, without predicted HbA1c.
89047727|NCT05824260||patients with complications|
89047728|NCT05824260||patients without complication|
89047729|NCT05824221|Experimental|Active rTMS (15 Hz)|Active stimulation of LDLPFC (15 Hz; 100% of RMT; 40 trains with 60 stimuli per train; inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
89213644|NCT01073917|Other|Pressure Support Ventilation|The patients in the PSV group will breathing spontaneously on the ventilator with assistance by inspiratory support pressure. The support pressure will be adjusted to achieve a tidal volume of 8-10 ml/kg.
89213645|NCT01582399|Experimental|Arm A: ASKP1240 intravenous (IV) infusion|
89213646|NCT01582399|Experimental|Arm B: ASKP1240 subcutaneous (SC)|
89213647|NCT03880227|Experimental|Anodal followed by sham stimulation tDCS to rTPJ|cross-over design - active stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the rTPJ followed by behavioral testing.
89213648|NCT03880227|Active Comparator|Anodal followed by sham stimulation tDCS to dmPFC|cross-over design - active stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the dmPFC followed by behavioral testing.
89213649|NCT03880227|Experimental|Sham followed by anodal stimulation tDCS to rTPJ|cross-over design - sham stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week delay, active stimulation tDCS to the rTPJ followed by behavioral testing.
89213650|NCT03880227|Active Comparator|Sham followed by anodal stimulation tDCS to dmPFC|cross-over design - sham stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week delay, active stimulation tDCS to the dmPFC followed by behavioral testing.
89213651|NCT04000113|Experimental|laser acupuncture treatment|Subjects accept low-dose near-infrared laser acupuncture (10mWx10) treatment for 5 minutes in each trial.
89661400|NCT06252649|Experimental|Arm A: Sotorasib + Panitumumab + FOLFIRI|Sotorasib was taken daily (QD) as an oral tablet. Panitumumab and FOLFIRI were received every 2 weeks (Q2W) via intravenous infusion (IV).
89661401|NCT06252649|Active Comparator|Arm B: FOLFIRI with or Without Bevacizumab-awwb|Participants received FOLFIRI Q2W with or without bevacizumab-awwb.
89661402|NCT06252571|Experimental|Active therapy|Active therapy combining evening melatonin + morning active light over 6 weeks
89661403|NCT06252571|Placebo Comparator|Placebo therapy|placebo therapy combining evening melatonin placebo + morning placebo light over 6 weeks.
89661404|NCT06252493||Crohn Disease|Patients with confirmed/suspected Crohn's disease scheduled for operative management/surgical intervention
89661405|NCT06252324|Experimental|submerged implant placement with healing abtument|"the implant was placed flush to the bone crest after anaesthesia and with no flap elevation.~A healing screw was positioned to have a transmucosal healing. the healing was removed after 3 months and cement restoration technique was performed in all cases."
89661406|NCT06252324|Other|Tissue level implant placement cover screw|"the implant was placed above the bone crest after anaesthesia and with no flap elevation.~A cover screw was positioned to have a tissue level healing. the screw was removed after 3 months and cement restoration technique was performed in all cases."
89661407|NCT06252155|No Intervention|Control|No intervention will be made to the control group.
89661408|NCT06252155|Experimental|Music Group|Mothers will listen to music for 30 minutes every day for 2 postpartum days. The type of music to be used in this study will be Turkish music . Turkish music will be preferred in the study because it is a part of the culture in which the study will be conducted. This type of music was preferred because it evokes feelings of happiness, laughter, joy, power, courage and heroism in the human soul. In deciding the type of music listened to in the study, expert opinion was taken from a faculty member teaching music therapy at a state university. During the music session, the mother will take a comfortable position on the sofa or bed. She will also be asked to close her eyes and imagine where she wants to be. She will also be asked to breathe slowly and deeply to regulate her breathing.
89661409|NCT06251882|Experimental|D5W group|The patients received one session of ultrasound-guided 10ml D5W injection around the lateral femoral cutaneous nerve as it exited the pelvis.
89661410|NCT06251674|Experimental|long-axis group|The patients in the long-axis group received one session of ultrasound-guided long-axis needle release of transverse carpal ligament.
89661411|NCT06251674|Active Comparator|short-axis group|The patients in the short-axis group received one session of ultrasound-guided short-axis needle release of transverse carpal ligament.
89661412|NCT06251375|Experimental|Dexmedetomidine Intervention|"Patients randomized to the experimental arm will receive dexmedetomidine. The study medication will be reconstituted by mixing 4 vials (8 ml) into a 100 ml bag of normal saline or 5% dextrose, this is the preferred dilution, or 2 vials (4ml) into 50 ml syringe to an equivalent concentration of 8 mcg/ml of dexmedetomidine. The constituted infusion is stable at room temperature for up to 24 hours.~The recommended starting infusion rate is equivalent to 1 µg/kg/h of dexmedetomidine, without loading or bolus. This will be titrated to an equivalent dexmedetomidine dose of 0 to 1.0 µg/kg/h according to study algorithm to maintain target sedation of Richmond Agitation-Sedation Scale (RASS) score of -1 to +1."
89661413|NCT06251375|Placebo Comparator|Control Intervention|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. The placebo is a matching vial containing 2 mL sterile normal saline.
89213652|NCT04000113|Sham Comparator|Sham laser acupuncture treatment|Subjects accept the sham (blank) laser acupuncture treatment for 5 minutes in each trial.
89213653|NCT03999567|Experimental|Pen and Paper vs. Mobile Digit Symbol Substitution Test|This validation study will assess the convergent validity of the mobile DSST application with the pencil version of the DSST. Correlations between performance on app-based version of the DSST and paper-based version of DSST will be measured.
89213654|NCT02580149|Active Comparator|Ticagrelor|Loading dose of 180 mg on day one, followed by a regular intake (90 mg twice daily) for 14 days
89213655|NCT02580149|Active Comparator|Clopidogrel|Loading dose of 600 mg on day one, followed by a regular intake (75 mg once daily) for 14 days
89213656|NCT04996017|Experimental|Arm A|atezolizumab 1200mg every 21 days
89213657|NCT04996017|Placebo Comparator|Arm B|Placebo will be supplied by the sponsor and will be identical in appearance to atezolizumab and will comprise the same excipients but without atezolizumab every 21 days
89213658|NCT03483935|Experimental|Microwave energy treatment|The microwave treatment will be delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for this indication, will be used to deliver the microwave treatment. The microwave dose will be between 2 Watt and 4 Watt. The treatment will consist of 3, 2 to 3 second bursts delivered to the same lesion with 5-20 seconds between bursts.
89213659|NCT03483935|No Intervention|Control|No treatment will be given.
89213660|NCT00530439|Experimental|Lifestyle intervention|physical activity, dietetic counselling
89661414|NCT06251336|Experimental|Uroial Plus Arm|UroialTM Plus sachets one sachet daily at night before going to bed after urinating for 30 days
89661415|NCT06251336|Placebo Comparator|Placebo Arm|one placebo sachet daily at night before going to bed after urinating for 30 days
89047730|NCT05824221|Sham Comparator|Sham rTMS|A pre-programmed software set sham stimulation by a staff member that will not be involved in data collection and analysis. The sham condition will match the number of pulses delivered during the 15Hz session and will use the same coil placement but the intensity of stimulation will be set a 3% of the RMT so to ensure that the participant will feel similar scalp sensations experienced by participants receiving active rTMS, but brain tissue will not be stimulated. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
89047731|NCT05824221|No Intervention|Healthy Control|Subject without diagnosis of Cocaine Use Disorder or other major psychiatric disorder.
89047732|NCT05824156|Experimental|5 mg/kg CM-101|Subcutaneous injection CM-101 every 2 weeks
89047733|NCT05824156|Placebo Comparator|Placebo|Subcutaneous Injection Placebo every 2 weeks
89047734|NCT05824117|Experimental|Intervention Group (TAU+SEE)|The experimental intervention is treatment as usual (TAU) for adolescents and young adults with early psychosis in the respective recruitment centers for 12 months plus Supported Employment and Education following the Individual Placement and Support model.
89047735|NCT05824117|No Intervention|Control Group (TAU)|The control condition is treatment as usual (TAU) for adolescents and young adults with early psychosis in the respective recruitment centers for 12 months (including medical review, pharmacological treatment, and psychosocial support: group programs and social counseling to external government-funded vocational programs).
89661416|NCT06251206|Experimental|ADL/Postoperative Instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated by ORIF and postoperative care. Participants in the experimental group will also receive a handout on ADL participation and postoperative care with a QR code to the video.
89661417|NCT06251206|Active Comparator|Postoperative Instruction|Participants in the control group will watch a video instructing them on postoperative care. Participants in the control group will receive a handout on postoperative care with a QR code to the video.
89661418|NCT06250959|Experimental|Reduced-dose Chemotherapy Followed by Blinatumomab|Reduced-dose Chemotherapy(including 1 dose of Idarubicin 8 mg/m2, 1 dose of Vincristine 1.4 mg/m2[max 2mg], and 7 days of Dexamethasone 9 mg/m2/d) followed by 2 weeks of Blinatumomab (9 ug/d d8-14, 28 ug/d d15-21) immediately. If not achieved CR/CRi, Blinatumomab 28 ug for another 14 days should be continued.
89047736|NCT05824091|Experimental|MK-7762 (TBD09)|In Part 1 of the trial (SAD/FE), up to five sequential cohorts will be enrolled to evaluate up to five escalating single doses of MK-7762; 8 participants in each cohort will be randomized (3:1) to receive MK-7762 or placebo. A sixth cohort will evaluate the effect of food on PK of single doses of MK-7762 utilizing an open-label, two-period design in 8 participants.
89047737|NCT05824091|Placebo Comparator|Placebo|Participants will receive placebos matched to MK-7762 (TBD09).
89047738|NCT05823935|Active Comparator|Bakay purse string group|Bakay purse string will be used to close the vaginal cuff after total laparoscopic hysterectomy for benign lesions.
89047739|NCT05823935|Active Comparator|Cuff closure via vaginal route group|Vaginal cuff closure via vaginal route with continuous locked suturing will be used to close the vaginal cuff after total laparoscopic hysterectomy for benign lesions.
89047740|NCT05823883|Experimental|Sequence A|Period 1: Empagliflozin and Metformin Period 2: DW6014
89047741|NCT05823883|Experimental|Sequence B|Period 1: DW6014 Period 2: Empagliflozin and Metformin
89047742|NCT05823870|Experimental|Sequence A|Period 1: Empagliflozin and Metformin Period 2: DW6014
89661419|NCT06250959|Active Comparator|hyperCVAD|CTX 300mg/m2 q12h D1-3 VCR 1.4mg/m2 (max 2mg) D4,D11 DNR 50mg/m2, D4 DEX 40mg/d D1-4, D11-14
89661420|NCT06250751|Experimental|Behavioral exercise training (BET) to introduce behavioral skills for adopting an exercise program|Single-arm, ORBIT-prospective, multicenter, nonblinded clinical trial, feasibility pilot. The BET intervention will be delivered and refined over 12 weeks. The protocol aim is to enroll men from the same representative groups of underserved men in groups of 5-10, to foster social support and group cohesion.
89661421|NCT06250543|Other|AbobotulinumtoxinA and lidocaine|"The bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter.~30 minutes afterwards patients received 300 units of AbobotulinumtoxinA using rigid cystoscopy. Normal saline was used to dilute the vial to 20 ml. A total of 20 evenly distributed intradetrusor injections, 1 ml per site, were performed, 2 of them included the trigone area."
89661422|NCT06250543|Other|AbobotulinumtoxinA and placebo|"The bladder was instilled with 40 ml of 0.9% NaCl solution using a 16Fr urethral Foley catheter.~30 minutes afterwards patients received 300 units of AbobotulinumtoxinA using rigid cystoscopy. Normal saline was used to dilute the vial to 20 ml. A total of 20 evenly distributed intradetrusor injections, 1 ml per site, were performed, 2 of them included the trigone area."
89661423|NCT06250543|Other|IncobotulinumtoxinA and lidocaine|"The bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter.~30 minutes afterwards patients received 100 units of IncobotulinumtoxinA using rigid cystoscopy. Normal saline was used to dilute the vial to 20 ml. A total of 20 evenly distributed intradetrusor injections, 1 ml per site, were performed, 2 of them included the trigone area."
89661424|NCT06250543|Other|IncobotulinumtoxinA and placebo|"The bladder was instilled with 40 ml of 0.9% NaCl solution using a 16Fr urethral Foley catheter.~30 minutes afterwards patients received 100 units of IncobotulinumtoxinA. using rigid cystoscopy. Normal saline was used to dilute the vial to 20 ml. A total of 20 evenly distributed intradetrusor injections, 1 ml per site, were performed, 2 of them included the trigone area."
89661425|NCT06250296||Intervention group|All patients admitted to the ward implementing the foreseen intervention as to February 2024 (pilot phase)
89661426|NCT06250296||Control group|All patients admitted to the two wards implementing the foreseen intervention after the initial pilot phase
89661427|NCT06250257|Active Comparator|Control group|This group of study participants are expected to receive Guideline-directed medical therapy (GDMT).
89661428|NCT06250257|Experimental|Treatment group|This group of study participants are expected to receive Guideline-directed medical therapy (GDMT) plus the study drug (Bromocriptine).
89661429|NCT06250127|Active Comparator|Group 1 (Conventional facemask)|Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion.
89661430|NCT06250127|Experimental|Group 2 (Modified 3D printed facemask)|Modified facemask appliances will be used for growing patients who have Cl. III malocclusion.
89661431|NCT06249581|Experimental|Arm A: fasting|AUX-001 40mg QD
89213661|NCT00530439|No Intervention|Control|
89213662|NCT01007409|Active Comparator|Group B|Period 1: fed control → Period 2: fasted control
89213663|NCT01007409|Active Comparator|Group A|Period 1: fasted control → Period 2: fed control
89213664|NCT04994223|Experimental|Group A(combined anticoagulation plus antithrombotic therapy group)|group A patients would be receiving rivaroxaban and aspirin as experimental group to see the efficacy of rivaroxaban in peripheral arterial disease.
89213665|NCT04994223|Active Comparator|Group B( antithrombotic therapy alone group)|group B patients would be those receiving traditional antithrombotic therapy as usually given n Peripheral Arterial Disease.
89213666|NCT04962633|Experimental|Probiotic Pasta Group|Subjects in the Probiotic Pasta group will consume 80 g per day of a probiotic pasta for 4 weeks
89661432|NCT06249581|Experimental|Arm B: fed|AUX-001 40mg QD
89661433|NCT06249347|Experimental|PROMISED|"Guided by a circular mapping catheter, all patients initially underwent wide-area circumferential pulmonary vein isolation (CPVI) using radiofrequency ablation catheter. If sinus rhythm was restored after performing the CPVI ablation, the ablation procedure would be stopped. If AF persisted, patients underwent linear ablation (roof linear ablation+anterior septal linear ablation+mitral isthmus linear ablation) using radiofrequency ablation catheter. Then, guided by left atrial appendage (LAA) angiography, the operators selected an appropriately sized left atrial appendage occlusion device according to the LAA size and morphology.~Interventions:~Procedure: CPVI+ roof linear ablation + anterior septal linear ablation + mitral isthmus linear ablation + Left atrial appendage closure (LAAC)"
89661434|NCT06249347|Active Comparator|CPVI and LAAC|"Guided by a circular mapping catheter, all patients initially underwent wide-area CPVI using radiofrequency ablation catheter. Then, guided by LAA angiography, the operators selected an appropriately sized left atrial appendage occlusion device according to the LAA size and morphology.~Interventions:~Procedure: CPVI and LAAC"
89661435|NCT06249230||Pregnancy success|Patients followed up with a live intrauterine pregnancy beyond 32 weeks were judged as pregnancy success.
89661436|NCT06249230||Pregnancy loss|Patients with histologically confirmed spontaneous abortion by ultrasound or curettage before 28 weeks of gestation, including biochemical pregnancies and embryonic arrests, were judged as pregnancy loss
89661437|NCT06248983||Participants|Observational study, therefore no intervention that is administered.
89661438|NCT06248463||Woman with hypertension risk related to gestation|SBP readings above 130 mmHg in office or the presence of a risk factor for eclampsia: (hypertensive disease in previous pregnancy, chronic hypertension, chronic renal disease, diabetes mellitus, or autoimmune disease) or any two moderate-risk factors (nulliparity, age ≥40 years, BMI ≥35 kg/m2, family history of PE, or interpregnancy interval >10 years)
89661439|NCT06247930|Experimental|Vitamin D3 + Mental Health Education|"Vitamin D3: 2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.~Mental Health Education: consists of providing a brochure with information about mental health problems and a set of educational mental health videos regarding depression."
89661440|NCT06247930|Placebo Comparator|Vitamin D3 placebo + Mental Health Education|Vitamin D3 placebo (i.e., soybean oil). Mental Health Education: consists of providing a brochure with information about mental health problems and a set of educational mental health videos regarding depression.
89661441|NCT06247670|Experimental|Single Ascending Dose Part|Adult healthy volunteers in 4 cohorts of 12 will receive CMP-CPS-001 or placebo. Four dose levels will be evaluated.
89661442|NCT06247670|Experimental|Multiple Ascending Dose Part|Adult healthy volunteers in 4 cohorts of 12 will receive 3 monthly doses of either CMP-CPS-001 or placebo. Four dose levels will be evaluated.
89661443|NCT06245876||Cases Cohort|Subjects age 50-80 years old, with smoking history of at least 20 pack years with either (a) a high suspicion for lung cancer, who are planned to undergo biopsy or surgery to establish a definitive diagnosis after enrollment; or (b) confirmed primary lung cancer diagnosis, treatment naïve subjects.
89661444|NCT06245876||USPSTF At Risk - Control Cohort|Healthy subjects aged 50-80 years old with smoking history of at least 20 pack years.
89661445|NCT06245876||Healthy Control Cohort|Healthy subjects aged 20-80 years old which are non-smokers or with smoking history of less than 20 pack years.
89661446|NCT06244758|Active Comparator|Treatment|Renal hemodynamic parameters and oxidative stress will be obtained and the patient will be given finerenone orally
89213667|NCT04962633|Active Comparator|Control Pasta Group|Control Pasta Subjects in the Control Pasta group will consume 80 g per day of conventional pasta for 4 weeks.
89213668|NCT01007565|Experimental|periarticular injection, pain level|
89213669|NCT00497146|Experimental|Paricalcitol|Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
89213670|NCT00497146|Placebo Comparator|Placebo|Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
89213671|NCT01016548|Experimental|Two doses of vaccine|Second dose is given 21 days after the initial dose. The same dose and route of administration are used.
89661447|NCT06244758|Placebo Comparator|Placebo|Renal hemodynamic parameters and oxidative stress will be obtained and the patient will be given placebo orally
89688643|NCT03871465|Experimental|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
89213672|NCT01016548|Active Comparator|One dose of vaccine|Given at baseline only.
89213673|NCT01019824|Experimental|Low Dose|160 mg dose
89213674|NCT01019824|Experimental|High Dose|320 mg dose
89213675|NCT01019824|Placebo Comparator|Placebo|Placebo Comparator
89213676|NCT01016626|Experimental|CKD-4101 tablet|
89661448|NCT06237036||patients diagnosed with any of the specified chronic dermatological conditions|"The study encompasses patients diagnosed with any of the specified chronic dermatological conditions that meet the inclusion criteria. These patients are attended at the Dermatology Department of the Hospital Universitario de Torrejón.~Treatment Patients participating in this study did not receive any specific treatment as part of the research protocol.~Concomitant Medication/Treatment Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study.~Follow-Up Duration The follow-up period extended for seven months. Throughout this duration, patients underwent a minimum of two follow-up visits, which could be conducted either remotely or in-person, as per the study&amp;#39;s protocol."
89661449|NCT06232733|Experimental|Immediate Intervention|Access to HELP e-intervention from 0 to 6 months with kinesiology support.
89661450|NCT06232733|Active Comparator|Delayed Intervention|Access to HELP e-intervention from 6 to 12 months with kinesiology support.
89661451|NCT06232655|Experimental|Cladribine plus Venetoclax|Subjects will receive cladribine at a dose of 5mg/m2 daily via intravenous infusion on days 1 through 5 of a 28 day cycle. Concomitantly, venetoclax will be administered orally at a dose of 100mg on day 1, 200mg on day 2, and 400mg daily on days 3 through 28.
89661452|NCT06232655|Experimental|Alternating Aza/Ven and Clad/Ven|Alternating 28-day consolidation cycles of Aza/Ven (even cycles) and Clad/Ven (odd cycles), while those who do not respond will come off the study.
89661453|NCT06230952||axial spondyloarthritis patients|patients diagnosed with axial spondyloarthritis
89661454|NCT06230523|Experimental|LY3841136 Dose 1|Participants will receive LY3841136 subcutaneously (SC).
89661455|NCT06230523|Experimental|LY3841136 Dose 2|Participants will receive LY3841136 SC.
89661456|NCT06230523|Experimental|LY3841136 Dose 3|Participants will receive LY3841136 SC.
89661457|NCT06230523|Experimental|LY3841136 Dose 4|Participants will receive LY3841136 SC.
89213677|NCT01016626|Active Comparator|Mycophenolate Mofetil capsule|
89661458|NCT06230523|Experimental|LY3841136 Dose 5|Participants will receive LY3841136 SC.
89661459|NCT06230523|Placebo Comparator|Placebo|Participants will receive LY3841136 matching placebo.
89661460|NCT06229964|Active Comparator|SSNB + IACI|"Patients randomized to this arm will receive a SSNB (40-mg methylprednisolone acetate and 5-mL Ropivacaine 2mg/ml) than a IACI (40-mg methylprednisolone acetate and 1-mL Ropivacaine 2mg/ml).~Rehabilitation/physiotherapy is considered standard of care."
89661461|NCT06229964|Placebo Comparator|Sham SSNB + IACI|"Patients randomized to this arm will receive a SSNB (5-mL Linisol 10mg/ml) than a IACI (80-mg methylprednisolone acetate and 1-mL Ropivacaine 2mg/ml)~Rehabilitation/physiotherapy is considered standard of care."
89661462|NCT06229158||Patients' group|Patients diagnosed with advanced solid or hematological cancers, whether or not undergoing specific treatment for the ongoing oncological condition and having a cancer diagnosis for more than 3 months (baseline diagnosis consultation).
88994721|NCT02928484|Active Comparator|Test product|The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar.
89661463|NCT06229158||Partners' of life group|Partners' of life group of patients' diagnosed with advanced solid or hematological cancers, whether or not undergoing specific treatment for the ongoing oncological condition and having a cancer diagnosis for more than 3 months (baseline diagnosis consultation).
89661464|NCT06228586|Experimental|MenACYW conjugate vaccine|MenACYW conjugate vaccine single injection on Day 01
89661465|NCT06224335||sportwoman with high intensity of physical activity with stress urinary incontinence|High-intensity of regular physical activity at least three days per week, 90 minutes per day, for more than two years.
88994722|NCT02928484|Placebo Comparator|Placebo product|The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.
88994723|NCT02928523|Experimental|Autologous Fecal Microbiota Transplantation|Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.
88994724|NCT02928367||Pneumonia patients|rectal swab (4x) divided over two time points (day 0 and day 28) nasopharyngeal swab (2x) divided over two time points (day 0 and day 28) blood draw (90ml) divided over two time points (day 0 and day 28)
88994725|NCT02928367||Healthy subjects|rectal swab (2x) nasopharyngeal swab (2x) blood draw (70ml)
88994726|NCT02928328|Experimental|GABA oral solution|This study will test if oral administration of GABA containing solutions will reduce the pain and sensitivity induced by application of capsaicin to the tongue of healthy human subjects.
88994727|NCT02928328|Experimental|Intramuscular GABA|This study will test the hypothesis that intramuscular injection of GABA alone will not be painful, but will reduce muscle pain sensitivity in healthy human subjects.
88994728|NCT02928328|Experimental|Pain modulation|This study will test the hypothesis that intramuscular injection of GABA with glutamate will decrease the intensity of glutamate-evoked muscle pain in healthy human subjects.
88994729|NCT02928250|Active Comparator|Carnosine oral daily|Intervention group included pediatric patients with diabetic nephropathy receiving oral carnosine daily.
89661466|NCT06224335||sportwoman with high intensity of physical activity without stress urinary incontinence|High-intensity of regular physical activity at least three days per week, 90 minutes per day, for more than two years.
89661467|NCT06223672|Experimental|Walnuts|consumption of walnuts every day
89661468|NCT06223672|Experimental|White chocolate-style bar|consumption of a white chocolate-style bar every day
89047743|NCT05823870|Experimental|Sequence B|Period 1: DW6014 Period 2: Empagliflozin and Metformin
89047744|NCT05823792||Patients aged 3-36 months with suspected ileocolic intussusception|Patients aged 3-36 months with suspected ileocolic intussusception
89047745|NCT05823766||Telephone Assessment Battery|TRACK-TBI participants may complete up to three annual telephone calls to assess outcome status and screen for PTE. These assessments will determine eligibility for the in-person study visit.
89213678|NCT01016704|No Intervention|Control|
89213679|NCT01016704|Experimental|Incentive|
89213680|NCT00489970|Experimental|Boostrix Group|Subjects received in the primary study (NCT00346073) a single dose of Boostrix vaccine [Tdap](GSK776423) intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a second dose of Boostrix vaccine [Tdap](GSK776423).
89213681|NCT00489970|Active Comparator|Adacel Group|Subjects received in the primary study (NCT00346073) a single dose of Adacel vaccine intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a dose of Boostrix vaccine [Tdap](GSK776423).
89213682|NCT00489970|Active Comparator|Control group|Subjects received the first dose of Boostrix vaccine [Tdap](GSK776423) in this study at Year 9.
89213683|NCT01020058|Active Comparator|Lichtenstein in local anesthesia (LLA)|Patient operated in local anesthesia, with an anterior mesh repair according to Lichtenstein
89213684|NCT01020058|Active Comparator|TEP|Patient receives a totally extraperitoneal laparoscopic repair
89661469|NCT06210048||Mild Primary Dysmenorrhoea|Consists of participants with mild dysmenorrhea according to VAS score
89661470|NCT06210048||Moderate Primary Dysmenorrhoea|Consists of participants with moderate dysmenorrhea according to VAS score
89661471|NCT06210048||Severe Primary Dysmenorrhoea|Consists of participants with severe dysmenorrhea according to VAS score
89661472|NCT06180460|Experimental|Managing Cancer and Living Meaningfully (CALM)|CALM optimally consists of six individual sessions of 45 to 60 minutes, delivered over a three- to six-month period. CALM sessions address four broad and interrelated domains found to be important and relevant in this population: (1) symptom management and communication with healthcare providers, (2) changes in personal relationships, (3) sense of meaning and purpose, and (4) the future, hope and mortality.
89661473|NCT06180460|Placebo Comparator|Treatment as Usual (TAU)|Treatment as usual (TAU) for managing distress in brain cancer involves being provided a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.
89661474|NCT06179069|Experimental|Dose Escalation|Dose Escalation
89661475|NCT06179069|Experimental|Dose Expansion: Arm 1|Dose level 1 established from escalation
89661476|NCT06179069|Experimental|Dose Expansion: Arm 2|Dose level 2 established from escalation
89661477|NCT06177613|Experimental|With blank culture|
89661478|NCT06177613|Sham Comparator|Without blank culture|
89661479|NCT06175091|Active Comparator|control group|Usual management, i.e. alarm management left to the discretion of the nurse caring for the patient.
89661480|NCT06175091|Experimental|intervention group|restrictive alarm strategy
89213685|NCT02798471|Experimental|Edoxaban|"Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.~Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period."
89213686|NCT02798471|Experimental|Standard of Care|Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.
89213687|NCT03443765||Patients with Pityriasis alba|
89661481|NCT06168240|Experimental|group A|will receive Manual lymphatic drainage plus Traditional physical therapy program that will include LASER, cold packs, manual mobilization, and exercise program. Training will applied 3 days a week, for a total of 4 weeks.
89661482|NCT06168240|Active Comparator|group B|will receive Traditional physical therapy program only that will include LASER, cold packs, manual mobilization, and exercise program. Training will applied 3 days a week, for a total of 4 weeks.
89661483|NCT06167330|Experimental|Progressive rehabilitation program|The progressive rehabilitation program is a multicomponent intervention, including pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy.
89661484|NCT06167330|Experimental|Stimulation devices|The treatment program includes Transcutaneous Electrical Nerve Stimulation and Cranial Electrical Stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol.
89661485|NCT06164262||Individuals with CSVD|This does not entail the application of interventions.
89661486|NCT06155292|Placebo Comparator|Arm 1: Standard Communication Arm|"Quarterly email communication:~Quarterly standard communication via email providing a link to physicians to check their PCCE program performance over the prior quarter, and a link to access the PCCE dashboard. The email will also include a link to resources. Starting with the email communication in February 2024, there will be a reminder email sent two weeks after the first email with the same content.~Quarterly survey:~Quarterly standard communication via survey with questions about physician attitudes and beliefs."
89661487|NCT06155292|Experimental|Arm 2: Personalized Report Card|"Quarterly email communication:~Quarterly personalized communication via email providing individualized performance metrics to physicians for the PCCE program from the prior quarter. All the links in the Arm 1 emails will be included in Arm 2 emails. Starting with the email communication in February 2024, there will be a reminder email sent two weeks after the first email with the same content.~Quarterly survey:~Quarterly standard communication via survey with the same questions about physician attitudes and beliefs as in Arm 1."
89688644|NCT02125864|Experimental|Aflibercept|There is only one arm. Plasma VEGF is investigated in the same patient before and after intravitreal Aflibercept injection.
89688645|NCT02814448|Active Comparator|CO2 standard cryotherapy- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
89213688|NCT03443765||Healthy participants (control group)|
89213689|NCT03441893|Active Comparator|Patients with ulcerative colitis|Patients with ulcerative colitis in this group will take nitazoxanide per os
89213690|NCT03441893|No Intervention|Participants (control group)|only parasitological diagnostics will be performed in this group to compare the prevalence of some representatives of the microbiota
89213691|NCT03441893|Active Comparator|UC patients (cohort 1)|Patients with ulcerative colitis in this group will take standart therapy (mesalazin)
89213692|NCT03441893|Placebo Comparator|UC patients (cohort 2)|Patients with ulcerative colitis in this group will take placebo tabletes
89213693|NCT03441893|Active Comparator|UC patients (cohort 3)|Patients with ulcerative colitis in this group will take combination standart therapy with nitazoxanide
89213694|NCT00489736|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg
89661488|NCT06155292|Experimental|Arm 3: Personalized Report Card + Bottom-Up Framing|"Quarterly email communication as in Arm 2. Bottom-up intervention: The quarterly email communication will also describe the ways in which the PCCE program and its features were informed by physician feedback and recommendations.~Quarterly survey: The quarterly survey will include information about the ways in which the PCCE program and its features were informed by physician feedback and recommendations. Physicians will respond to the same questions about physician attitudes and beliefs as in Arms 1 and 2."
89661489|NCT06150651|Experimental|CAR T-cell therapy|Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide, followed by the infusion of 1x10^6 cells/kg CD-19 CAR-T cells.
89661490|NCT06149559|Experimental|rozanolixizumab|Study participants will receive pre-defined doses of rozanolixizumab for 6 weeks.
89661491|NCT06147856|Experimental|mRNA-3210|Participants will receive single dose of mRNA-3210 by intravenous (IV) infusion every 3 weeks (Q3W), every 2 weeks (Q2W), or every 1 week (Q1W) for up to 12 doses.
89661492|NCT06143852|No Intervention|Control|Participants will not receive an intervention. They will receive instructions to use their social media use as usual.
89661493|NCT06143852|Experimental|Mindfulness|"Approximately 12-minute mindfulness-style meditations will be completed daily for one week through the Calm platform. Participants can listen to the exercise on the web-enabled version of Calm, or through the smartphone app. The course is entitled 7 Days of Gratitude and centers around noticing and appreciating things in daily life."
89661494|NCT06143852|Experimental|Social Media Reduction + Exercise|Participants will reduce their social media use by at least 30 minutes daily for one week. Simultaneously, participants will exercise at least 30 minutes daily. Participants are given examples of common exercises (walking, yoga, strength training, etc.), but they are allowed to choose any type, although they are dissuaded from activities with high potential for injury.
89661495|NCT06142747||Control|Healthy Controls. Super-Resolution Ultrasound Imaging of Erythrocytes (SURE) of both Achilles and Patellar Tendons.
89661496|NCT06142747||Tendinopathy Achilles|Patients with Achilles Tendinopathy. Super-Resolution Ultrasound Imaging of Erythrocytes (SURE) of Achilles Tendons.
89661497|NCT06142747||Tendinopathy Patellar|Patients with Patellar Tendinopathy. Super-Resolution Ultrasound Imaging of Erythrocytes (SURE) of Patellar Tendons.
89661498|NCT06140927|Experimental|Ketamine|"All subjects will be in a single arm. Patients will serve as their own control.~Patients will receive general anesthesia in the usual fashion for the indicated procedures. This anesthetic will be standardized between patients. All patients participating in the study will have neuromonitoring as part of their spine surgery as standard care. Baseline motor-evoked potential data will then be collected. Then study drug Ketamine will be administered as following:~Step 1: 0.1 mg/kg bolus over 30 sec followed by infusion of 3mcg/kg/min (0.18 mg/kg/hr)~Step 2: 0.3 mg/kg bolus over 30 sec followed by infusion of 15mcg/kg/min (0.9mg/kg/hr)~Step 3: 0.85 mg/kg bolus over 30 sec followed by infusion at 50mcg/kg/min (3mg/kg/hr)~Motor Evoked Potentials will be collected for 5 times at minutes 2, 4, 6, 8, 10 after drug step."
89661499|NCT06140303|Experimental|SkinTE|SkinTE plus standard care
89661500|NCT06140303|Other|Control|Standard care alone
89213695|NCT00489736|Active Comparator|Amiodarone 600mg/200mg od|over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets
89661501|NCT06134648|Experimental|Sentinel Cohort: RSV/hMPV Group 0 (Dose L)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
89661502|NCT06134648|Experimental|Sentinel Cohort: RSV/hMPV Group 1 (Dose A)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
88994730|NCT02928250|Placebo Comparator|Second arm received placebo oral daily|Placebo group or control patients received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
88994731|NCT02928211|Experimental|Experimental|All subjects will receive the ointment and have scans with the Sapphire II device
88994732|NCT02927977|Active Comparator|Control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
88994733|NCT02927977|Experimental|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks. Participants will receive 4-6 treatments during 4 weeks.
88994734|NCT02928016|Experimental|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
88994735|NCT02928016|Experimental|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
89213696|NCT00617084|Active Comparator|1. Resolute|Medtronic Endeavor Resolute
89213697|NCT00617084|Active Comparator|2. XIENCE V|Abbott Xience V
89661503|NCT06134648|Experimental|Sentinel Cohort: RSV/hMPV Group 2 (Dose B)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
89661504|NCT06134648|Placebo Comparator|Sentinel Cohort: Placebo-Group 3|Participants will be randomized to receive a single IM injection of placebo
89661505|NCT06134648|Experimental|Main Cohort: RSV/hMPV Group 1 (Dose A)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
89661506|NCT06134648|Experimental|Main Cohort: RSV/hMPV Group 2 (Dose B)|Participants will be randomized to receive a single IM injection of RSV/hMPV vaccine candidate
89661507|NCT06134648|Placebo Comparator|Main Cohort: Placebo-Group 3|Participants will be randomized to receive a single IM injection of placebo
89661508|NCT06134648|Experimental|Booster Cohort-RSV/hMPV|Participants will be randomized to receive a determined dose of single IM injection of RSV/hMPV vaccine candidate from a subset of Main cohort
89661509|NCT06134648|Placebo Comparator|Booster Cohort-Placebo|Participants will be randomized to receive of single IM injection of placebo from a subset of Main cohort
89661510|NCT06127888||Unit of headache and neurological pain of the Hospital Vall d'Hebron (VHIR) - Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89661511|NCT06127888||Unit of headaches and neuralgias of the Hospital de Sant Pau - Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89661512|NCT06127888||Unit of headache of the Hospital Sant Joan de Déu - Althaia - Manresa|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89661513|NCT06127888||Unit of headache of the Hospital Universitari Arnau de Vilanova - Lleida|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89661514|NCT06127888||Group of work on headaches of the Hospital Clínic de Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89213698|NCT02758847|Other|Critical Limb Ischemia (CLI) and Tissue Loss|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Patients with CLI will receive either Angiogram, Medtronic DCB (paclitaxel)/stent or Angiogram, Bard DCB (paclitaxel)/stent
89213699|NCT01016860|Experimental|OSI-906 and/or irinotecan|Dose Escalation Phase: Treatment for Cycle 1 will commence on Day -3 of a 21-day cycle (3 weeks) when a single dose OSI-906 is given with full pharmacokinetics(PK) sampling at predetermined time points. Irinotecan will be administered intravenously over 90 minutes on Day 1 and Day 8 with full PK sampling on Day 1. The institution of oral dosing of OSI-906 2-4, 8-10, 15-17 (for cycle 1 only) will be given followed by full PK sampling of both drugs on Day 8. Pre-dose samples of OSI-906 will be drawn on Cycle 1 Days 8, 10, 15, 17 and Cycle 2 Days 1, 8, 10, 15 and 17. For Cycle 2 and thereafter, both drugs will be administered starting on Day 1.
89661515|NCT06127888||Headache Unit of Hospital de Bellvitge - Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89661516|NCT06127888||Headache Unit of Hospital del Mar - Barcelona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89661517|NCT06127888||Headache Unit of Hospital de Germans Tries i Pujol - Can Ruti - Badalona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89661518|NCT06127888||Headache Unit of Hospital Josep Trueta - Girona|Neurologists, nurses, pharmacists, health managers, physiotherapists, and other healthcare professionals related to the headache unit.
89661519|NCT06120985|Active Comparator|Treatment|Households randomized to the treatment group will be provided countertop pitcher water filters
89661520|NCT06120985|No Intervention|Control|Households randomized to the control group will be provided water filters at the completion of the study
89661521|NCT06107803|Experimental|Treatment Phase 1|Roluperidone 64 mg monotherapy administered as an oral dose daily for 7 days on Days 1-7.
89661522|NCT06107803|Experimental|Treatment Phase 2|Roluperidone 64 mg oral and olanzapine 10 mg oral administered at the same time daily for 10 days on Days 8-17.
89661523|NCT06106633|Experimental|Intervention Arm|Patient will undergo UFE using PEDD
89661524|NCT06105047|Experimental|Patients with Alzheimer disease|Patients will perform experimental task in four conditions : control, mime, emotion, dual
89661525|NCT06099327||Postoperative after cardiac surgery|Patients after cardiac surgery will participate in the trial during their postoperative stay on the cardiothoracic ward.
89661526|NCT06095375|Experimental|Cohort A (Adjuvant/Maintenance Phase)|
89661527|NCT06095375|Experimental|Cohort B (Concomitant Phase)|
89661528|NCT06084728||Pregnant women|30 pregnant women.
89661529|NCT06084728||Non-pregnant women|30 non pregnant women as control group
89661530|NCT06077526|Experimental|Experimental - P.E.A.K. Rx|Group A intervention, P.E.A.K. Rx, will be supervised and directed by healthcare clinicians, known as Pain Coaches. P.E.A.K. Rx will involve 2 meetings per week of pain education + physical activity.
89661531|NCT06077526|Active Comparator|Control - Usual Care|Group B will receive the community hospital's usual care.
89661532|NCT06073704|Experimental|Antimicrobial Photodynamic therapy adjunct to scaling and root planing|Treatment of scaling and root planing followed by antimicrobial photodynamic therapy with methylene blue (100 micrograms/ml) and red laser
89661533|NCT06073704|Active Comparator|Control|Treatment of scaling and root planing.
89661534|NCT06069856|Experimental|MMS with 60 mg of iron first, then IFA with 60 mg of iron|Women will receive the first regimen (MMS with 60 mg of iron) for 2 months and then crossover on to the second regimen (IFA with 60 mg of iron) for 2 months
89661535|NCT06069856|Experimental|IFA with 60 mg of iron first, then MMS with 60 mg of iron|Women will receive the first regimen (IFA with 60 mg of iron) for 2 months and then crossover on to the second regimen (MMS with 60 mg of iron) for 2 months
89661536|NCT06060379|Experimental|Intervention gruop|Partecipant will participate in playful encounters
89661537|NCT06060379|No Intervention|Control group|Subjects will not partecipate in the games
89661538|NCT06051110|Other|Usual care|Patients who receive usual care by EMS protocols
89661539|NCT06051110|Other|point-of-care troponin|Patients in who risk-stratification was performed by the use of a point-of-care troponin in the EMS setting
89661540|NCT06051110|Other|Combined risk scores|Patients in who risk-stratification was performed by the use of a combined risk score in the EMS setting
89661541|NCT06043427|Active Comparator|Paclitaxel and Ramucriumab|
89661542|NCT06043427|Experimental|Zanidatamab + Paclitaxel and Ramucirumab|
89688646|NCT02814448|Active Comparator|CO2 standard cryotherapy- single freeze|Single freeze treatment consists of one five-minute freeze
89047746|NCT05823766||Comprehensive Assessment Battery (CAB)|Participants who demonstrate decision-making capacity will be asked to complete the Comprehensive Assessment Battery (CAB). The CAB in-person is comprised of measures of cognition (i.e. attention, memory, information processing speed, executive functions), mood (i.e., depression, anxiety), social participation, subjective well-being, post-traumatic stress, interviews, global functional status measures, and a COVID-19 questionnaire.
89047747|NCT05823766||Abbreviated Assessment Battery (AAB)|Participants who do not have decision-making capacity will be asked to complete a modified assessment battery, called the Abbreviated Assessment Battery (AAB). The AAB in-person assessment will administer the Speech Intelligibility, GOAT, and CAP and/or CRS-R to study participants.
89047748|NCT05823766||TED Friend Controls|Participants enrolled in the TBI Endpoints Development (TED) cohort from 2017-2019 who did not experience a TBI prior to affiliated enrollment in TRACK-TBI will be asked to complete an assessment battery.
89661543|NCT06036524|Experimental|Multi-modal imaging of myofascial pain|Participants with and without myofascial-related pain disease will receive multi-modal, multi-parametric, multi-scale imaging, including magnetic resonance imaging, surface electromyography, and fiber-optic imaging and sensing.
89661544|NCT06030349||Standard|In addition to data from clinical assessment, sleep studies and non-invasive ventilator downloads recorded as part of standard care participants will undergo questionnaire assessment of behaviour, quality of life and barriers to tolerating treatment. Participants aged 3 years and above will receive the Child Sleep Habits Questionnaire, Obstructive Sleep Apnoea-18 questionnaire and Adherence Barriers to CPAP (Continuous Positive Airway Pressure) Questionnaire. Participants aged 6 months to 3 years will receive the Brief Infant Sleep Questionnaire, Infant Toddler Quality of Life - Short Form 47, Obstructive Sleep Apnoea -18 Caregiver Concern Domain and a modified version of the Adherence Barriers to CPAP Questionnaire.
89661545|NCT06030349||Advanced|In addition to all elements of the standard testing group, a sub-group of up to 20 participants will be invited to take part in 45-60 minute semi-structured interviews exploring expectations, experiences and barriers encountered.
89661546|NCT06027554|Placebo Comparator|Placebo capsule|Gelatin capsules
89661547|NCT06027554|Experimental|MitoQ capsule|Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 20 mg taken every day for 12 weeks.
89661548|NCT06016686|Experimental|VNS|participants with surgically implanted VNS electrodes to treat drug-resistant epilepsy
89661549|NCT06016686|Experimental|non-VNS participants|participants without implanted VNS devices
89661550|NCT06016504|Experimental|Arm 1 (AVCT)|Patients participate in an adaptive virtual consultation on trial.
89661551|NCT06016504|Active Comparator|Arm 2 (non-AVCT)|Patients participate in a non-adaptive virtual consultation on trial.
89661552|NCT06016504|Active Comparator|Arm 3 (information-only)|Patients receive information-only on trial.
89661553|NCT06007911|Experimental|Cladribine-Low Dose Cytarabine Backbone Dose Level -1|Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
89661554|NCT06007911|Experimental|Cladribine-Low Dose Cytarabine Backbone Dose Level 0|This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
89661555|NCT06007911|Experimental|Cladribine-Low Dose Cytarabine Backbone Dose Level 1|This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
89661556|NCT06007911|Experimental|Cladribine-Low Dose Cytarabine Backbone Dose Level 2|This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
89661557|NCT06007911|Experimental|Cladribine-Low Dose Cytarabine Backbone Dose Maximum Tolerated Dose (MTD)|The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a dose-limiting toxicity.
89661558|NCT06007911|Experimental|CLAG-M Backbone Level -1|Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
89661559|NCT06007911|Experimental|CLAG-M Backbone Level 0|This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and granulocyte colony-stimulating factor (G-CSF).
89661560|NCT06007911|Experimental|CLAG-M Backbone Level 1|This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
89661561|NCT06007911|Experimental|CLAG-M Backbone Level 2|This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
89661562|NCT06007911|Experimental|CLAG-M Backbone Maximum Tolerated Dose|The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a dose-limiting toxicity.
89661563|NCT06003127|Experimental|Transcranial Magnetic Stimulation (TMS) Arm|This arm will undergo TMS during the study.
89661564|NCT06003127|No Intervention|Non-Transcranial Magnetic Stimulation (TMS) Arm|This arm will not undergo TMS during the study.
89661565|NCT06002880|Experimental|Post/Core-Total Etch|Endodontic posts and/or cores-Total etch
89661566|NCT06002880|Experimental|Ceramic-Total Etch|Glass-ceramics-Total etch
89661567|NCT06002880|Experimental|Metal/Zi-Total Etch|Metal-Zi-Total etch
89661568|NCT06002880|Experimental|Composite-Total Etch|Composite-Total etch
89047749|NCT05823740|Other|Single Arm|Children with malignant diseases, receiving anti-cancer treatment and completed study interventions.
89047750|NCT05823714|Experimental|VEN+AZA+Modified BUCY|
89661569|NCT06002880|Experimental|Post/Core-Self Etch|Endodontic posts and/or cores-Self etch
89661570|NCT06002880|Experimental|Ceramic-Self Etch|Glass-ceramics-Self etch
89661571|NCT06002880|Experimental|Metal/Zi-Self Etch|Metal-Zi-Self etch
89661572|NCT06002880|Experimental|Composite-Self Etch|Composite-Self etch
89661573|NCT05999968|Experimental|Abemaciclib + Darolutamide|Abemaciclib plus (+) darolutamide. Participants who have not undergone bilateral orchiectomy are required to continue background androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) agonist/antagonist throughout the study.
89661574|NCT05992831|Sham Comparator|Dose Step 1 - 0 Active Accelerated iTBS Sessions|Participant will receive 10 sessions of accelerated iTBS on each of 6 treatment days, including 0/10 active sessions and 10/10 sham sessions per day for a total of 0 active sessions
89661575|NCT05992831|Experimental|Dose Step 2 - 12 Active Accelerated iTBS Sessions|Participant will receive 10 sessions of accelerated iTBS on each of 6 treatment days, including 2/10 active sessions and 8/10 sham sessions per day for a total of 12 active sessions (7,200 active pulses).
89661576|NCT05992831|Experimental|Dose Step 3 - 24 Active Accelerated iTBS Sessions|Participant will receive 4/10 active sessions and 6/10 sham sessions per day for a total of 24 active sessions (14,400 active pulses).
89661577|NCT05992831|Experimental|Dose Step 4 - 36 Active Accelerated iTBS Sessions|Participant will receive 6/10 active sessions and 4/10 sham sessions per day for a total of 36 active sessions (21,600 active pulses).
89047751|NCT05823701|Experimental|Chidamide, Azacitidine Combined With GM(CAGM) Regimen|R/R DLBCL patients were treated with 2 cycles of CAGM regimen including chidamide, azacitidine, obinutuzumab and liposomal mitoxantrone followed by imaging examination. Patients achieved CR/PR were exposed to ASCT/CAR-T therapy or additional 4 cycles of CAGM regimen in patients ineligible for ASCT/CAR-T therapy; whereas, patients with SD/PD were withdrawn from this study.
89047752|NCT05823649|Experimental|Early feeding/intervention group|The postoperative patients will be intervened after one to two hours from the entry of the patients to the postoperative ward.
89661578|NCT05992831|Experimental|Dose Step 5 - 48 Active Accelerated iTBS Sessions|Participant will receive 8/10 active sessions and 2/10 sham sessions per day for a total of 48 active sessions (28,800 active pulses).
89661579|NCT05992831|Experimental|Dose Step 6 - 60 Active Accelerated iTBS Sessions|Participant will receive 10/10 active sessions and 0/10 sham sessions per day for a total of 60 active sessions (36,000 active pulses).
89661580|NCT05990816||Arthroplasty Patients|Only one group that consist patients who underwent primary total joint arthroplasty
89661581|NCT05988814|Experimental|FOLFIRINOX treatment|"Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression."
89661582|NCT05981573||Visit Day 1|AIM 1 : Determine if an RMM can assess the status of taking a prescribed dose of methadone. To complete this aim, the peak and trough concentrations of a witnessed methadone dose will be assessed in ISF collected through the surface of the skin using existing ISF extraction methods and assessed outside the body via differential pulse voltammetry (DPV). We hypothesize that the peak and trough blood samples will correlate with the level of methadone in collected ISF.
89661583|NCT05981573||Visit Day 2|AIM 2 : Determine if an RMM can continuously assess the status of taking a prescribed dose of methadone over time. To complete this aim, the pharmacokinetic profile of a witnessed methadone dose will be assessed in ISF continuously from the surface of the skin using the RMM for up to 6 hours. We hypothesize that a clinician can recognize a dose taken from the continuous and real-time RMM measurements made in live ISF.
89661584|NCT05981300||Ages 8-25 with delayed gastric emptying|Participants aged 8-25 with delayed gastric emptying of solids based on gastric emptying scintigraphy
89661585|NCT05981300||Ages 8-25 with normal gastric emptying|Participants aged 8-25 with normal gastric emptying of solids based on gastric emptying scintigraphy
89661586|NCT05977621||Intact anatomy|Patients with intact anatomy (uterus and cervix)
89661587|NCT05977621||Post-hysterectomy|Post-hysterectomy patients (vaginal cuff) who are planned to receive brachytherapy
89661588|NCT05972629|Experimental|SAR444836|Participants will receive a single dose of SAR444836 on Day 1
89661589|NCT05972330|Experimental|VRx MyBiotics Oral Lozenges|Participants will receive a 30 day supply of their personalized oral biotic lozenges.
89661590|NCT05968703|Experimental|Vertical Nuclear Trajectory|Participants will receive combined STN + NBM DBS. The lead placed within the NBM will use a vertical trajectory targeting the nucleus itself.
89661591|NCT05968703|Experimental|Lateral NBM Bundle Trajectory|Participants will receive combined STN + NBM DBS. The lead placed within the NBM will use a lateral trajectory targeting the lateral efferent bundle from the NBM
89661592|NCT05965609|Other|CBTI|Cognitive Behavioral Therapy for Insomnia
89661593|NCT05965609|Other|MRTI|Multicomponent Relaxation Therapy for Insomnia
89661594|NCT05957432|Active Comparator|Group 1 , Black seed oil group|45 patients will receive they will receive 1800 mg (4 soft gelatin capsules of 450 mg) black seed oil (2 capsules twice daily 30 min after the meal) for 6 weeks plus vonoprazan-based triple therapy ( conventional therapy ) consists of vonoprazan 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily for 14 days
89661595|NCT05957432|Active Comparator|Group 2 , control group|This group consists of 45 patients, who will receive vonoprazan-based triple therapy(conventional therapy ) consists of vonoprazan 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily for 14 days
89661596|NCT05953480|Experimental|Redasemtide Dose A|Redasemtide will be administered as an intravenous (IV) infusion once daily for 5 consecutive days during hospitalization.
89661597|NCT05953480|Experimental|Redasemtide Dose B|Redasemtide will be administered as an IV infusion once daily for 5 consecutive days during hospitalization.
89661598|NCT05953480|Placebo Comparator|Placebo|Placebo will be administered in an amount equivalent to redasemtide, as an IV infusion, once daily for 5 consecutive days during hospitalization.
89688647|NCT02814448|Active Comparator|CryoPen- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
89047753|NCT05823649|Active Comparator|Delayed feeding/control group|The postoperative patients will be fed delayed as traditionally practiced for long time as per the hospital's protocol that breaks the postoperative fasting only after four to six hours of the surgery according to the patient condition. The guideline of the hospital recommends the patients to drink black tea as first postoperative feeding and then facilitated by the semi-solid diet, especially mushy rice which is generally cooked by mixture of rice, vegetables and pulses with salt and a lot of water.
89688648|NCT02814448|Active Comparator|CryoPen- single freeze|Single freeze treatment consists of one five-minute freeze
89047754|NCT05823636||uninvestigated dyspepsia|Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.
89047755|NCT05823610||study group|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
89047756|NCT05823597|Experimental|Sugar Intensive Treatment|The Sugar-Intensive Intervention touched on exercise, sleep, and other aspects of healthy diet, but focused primarily on added sugar reduction. Beyond defining added sugar, the sugar-intensive intervention also included: information on how sugar is metabolized; description of health risks associated with excessive added sugar; opportunities to rehearse women's and men's recommended daily maxima; a game guessing the sugar content of various foods and beverages; information on proportion of undergraduates at their university who report being motivated to reduce their sugar intake; training in finding added-sugar information in nutritional labels; and concrete suggestions for replacing high-sugar foods and beverages with healthy options, and managing tempting situations.
89047757|NCT05823597|Active Comparator|General Health Control|The General Health Intervention presentation covered Healthy People 2030 goals regarding physical activity (aerobic exercise, strength training), healthy eating (fruit, vegetable, and whole grain consumption; decreasing consumption of saturated fats and added sugar), and sleep (minimum of 7 hours per night), as well as healthy stress management/emotion regulation. The health benefits/risks associated with each goal were described, along with suggested strategies for achieving each goal. This version of the intervention also included a definition of added sugar and information about the recommended daily added-sugar maxima for women and men, but served mainly as an active control condition for testing the effects of the target intervention of interest.
89047758|NCT05823519||SINGLE Arm|Observational, Multicenter, Prospective, single arm registry study with consecutive, eligible patient enrollment at each site. Subjects will be followed procedurally to discharge, and as per institutional standard of care thereafter through to 3 years (total follow-up commitment), with follow up including Computed tomography angiography (CTA) study and Case Report Form data at 1 month, 6 months, 1 years, 2 years and 3 years, closing at this time the study primary endpoint.
89047759|NCT05823493|Experimental|the experimental group|
89047760|NCT05823493|Active Comparator|the control group|
89047761|NCT05823428|Active Comparator|Rotator cuff debridement + acromioplasty|Group A was formed by performing rotator cuff debridement + acromioplasty in 18 patients.
89661599|NCT05940350|Experimental|Intervention group|A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10.
89661600|NCT05940350|No Intervention|Control group|"The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months"
89661601|NCT05933772|Experimental|Lens A, Then Lens B|Participants will wear Lens A for one month and then crossover to Lens B for one month.
89661602|NCT05933772|Experimental|Lens B, Then Lens A|Participants will wear Lens B for one month and then crossover to Lens A for one month.
89661603|NCT05932641|Experimental|Cohort 1 - AZD3152 300 mg IM direct anterolateral thigh injection|
89661604|NCT05932641|Placebo Comparator|Cohort 1 - Placebo IM direct anterolateral thigh injection|
89661605|NCT05932641|Experimental|Cohort 2 - AZD3152 600 mg IM direct anterolateral thigh injection|
89661606|NCT05932641|Placebo Comparator|Cohort 2 - Placebo direct anterolateral thigh injection|
89661607|NCT05932641|Experimental|Cohort 3 - AZD3152 1200 mg IV administration|
89661608|NCT05932641|Placebo Comparator|Cohort 3 - Placebo IV administration|
89661609|NCT05931393|Experimental|Cohort 1: Cabozantinib Dose Escalation|cabozantinib 80mg PO daily
89661610|NCT05931393|Experimental|Cohort 2: cabozantinib + nivolumab|cabozantinib 40mg PO daily + nivolumab 480 mg IV every 4 weeks (q4w)
89661611|NCT05931276|Active Comparator|Metoprolol Succinate|"Depending on baseline type and dose of beta blocker:~25 mg once daily (12.5 mg once daily if > NYHA class II)~50 mg (or 25 mg) once daily~100 mg (or 50 mg) once daily~200 mg (or 100 mg titrated to 200 mg) once daily"
89661612|NCT05931276|Active Comparator|Carvedilol|"Depending on baseline type and dose of beta blocker:~3.125 mg twice daily~6.25 mg twice daily~12.5 mg twice daily~25 mg twice daily (may titrate to 5 0mg twice daily if > 85 kg)"
89661613|NCT05918705||ONSD / ETD Ratio Correlation With Prognosis of Sepsis Associated Encephalopathy|"Data on in-hospital mortality will be recorded for all patients.~Clinical diagnosis of brain death will be also recorded for all patients.~Morbidity will be assessed both on ICU discharge and 3 months following ICU discharge with the Modified Rankin Scale (mRS), where patients will be assessed at the 3-month follow-up by telephone or face-to-face interviews with the patients or relatives.~According to neurologic outcome on ICU discharge and 3 months following ICU discharge, the included patients will be classified into two groups;~Good Neurologic Outcome (GNO); mRS 0 - 2.~Poor Neurologic Outcome (PNO); mRS 3 - 6."
89661614|NCT05914805|Experimental|Clascoterone Part 1 and Part 2|Subjects treated for 12 months with Clascoterone 5% solution (both in double-blind Part 1 and in the single-blind Part 2 of the study).
89661615|NCT05914805|Other|Clascoterone Part 1 + Vehicle Part 2|Subjects treated for the first 6 months Part 1 in double-blind with Clascoterone 5% solution followed by 6 months Part 2 in the single-blind label with Vehicle.
89661616|NCT05914805|Other|Vehicle Part 1 + Clascoterone Part 2|Subjects treated for the first 6 months Part 1 in double-blind with Vehicle followed by 6 months Part 2 in the single-blind label with Clascoterone 5% solution.
89661617|NCT05914805|Placebo Comparator|Vehicle Part 1 and Part 2|Subjects treated for 12 months with Vehicle (both in double-blind Part 1 and in the single-blind Part 2 of the study).
89661618|NCT05913765|Active Comparator|Intervention|an air cleaner with HEPA and carbon filter installed
89661619|NCT05913765|Placebo Comparator|Placebo|an air cleaner with the primary filter removed
89661620|NCT05911828|Active Comparator|ZY19489 + Ferroquine (FQ)|"A single daily dose 600 mg ZY19489 + 600 mg FQ, or 900 mg ZY19489 + 900 mg FQ are selected as the doses to be evaluated in Cohort 1 and 2, respectively. A daily dose of 600 mg ZY19489 + 600 mg FQ will be administered daily for 2 days in Cohort 3.~ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h."
89661621|NCT05911828|Placebo Comparator|Placebo|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
89047762|NCT05823428|Active Comparator|Augmentation with subacromial bursa + acromioplasty|Group B was formed by performing augmentation with subacromial bursa + acromioplasty in 22 patients.
89661622|NCT05910450|Experimental|Clascoterone Part 1 and Part 2|Subjects treated for 12 months with Clascoterone 5% solution (both in double-blind Part 1 and in the single-blind Part 2 of the study)
89661623|NCT05910450|Other|Clascoterone Part 1 + Vehicle Part 2|Subjects treated for the first 6 months Part 1 in double-blind with Clascoterone 5% solution followed by 6 months Part 2 in the single-blind label with Vehicle
89661624|NCT05910450|Other|Vehicle Part 1 + Clascoterone Part 2|Subjects treated for the first 6 months Part 1 in double-blind with Vehicle followed by 6 months Part 2 in the single-blind label with Clascoterone 5% solution.
89661625|NCT05910450|Placebo Comparator|Vehicle Part 1 and Part 2|Subjects treated for 12 months with Vehicle (both in double-blind Part 1 and in the single-blind Part 2 of the study)
89661626|NCT05898464|Experimental|HIV #1|CD4+ T cell count <300 cells/µL
89661627|NCT05898464|Active Comparator|HIV #2|CD4+ T cell count≥300 cells/µL
89661628|NCT05898464|Active Comparator|non-HIV|Healthy adult
89661629|NCT05897281|Experimental|Exercise Group|In addition to routine training, the experimental group will be done a progressive resistance band exercise program (SHOOT) created for shooters, 3 days a week for 8 weeks, accompanied by a physiotherapist.
89661630|NCT05897281|Other|Control Group|The control group will continue their routine training.
89661631|NCT05872204|Experimental|Abemaciclib and letrozole|Participants received abemaciclib 150 mg tablet orally twice daily and letrozole tablet 2.5 mg orally once daily until disease progression, unacceptable adverse event(s) or death.
89661632|NCT05855811|Experimental|Dostarlimab|4 intravenous injections maximum of dostarlimab, 500mg, every 3 weeks
89661633|NCT05855811|No Intervention|No treatment|
89661634|NCT05854966|Experimental|Treatment - CPI-613 with Metformin|"Induction therapy with CPI-613 and Metformin (ideally 2 hours prior to start of CPI-613 infusions on days 1-5) for two cycles of treatment.~Maintenance therapy with CPI-613 and Metformin (ideally 2 hours prior to start of CPI-613 infusions on days 1-5) until progression, intolerable toxicity of withdrawal of consent."
89661635|NCT05849038|Experimental|Baricitinib|Participants will be randomized to receive 10 weeks of treatment with baricitinib.
89661636|NCT05849038|Placebo Comparator|Placebo|Participants will be randomized to receive 10 weeks of treatment with placebo.
89661637|NCT05848453|Experimental|Cohort 1|1 mg/mL (0.1%) BAC6027 formulation; placebo
89661638|NCT05848453|Experimental|Cohort 2|5 mg/mL (0.5%) BAC6027 formulation; placebo
89661639|NCT05848453|Experimental|Cohort 3|10 mg/mL (1.0%) BAC6027 formulation; placebo
89661640|NCT05844644|Experimental|GOLO for Life® Plan (G4LP) and Release Supplement|Participants will be instructed to use the resources provided and follow the G4LP for the duration of the study period. Participants will also take one capsule of Release three times a day, to be taken at the beginning of or during each meal, starting on Day 1. If a dose is missed before or during a meal, participants are instructed to take the dose as soon as they remember after the meal. Participants will be advised not to exceed three capsules daily.
89661641|NCT05844631|Experimental|Golo for Life® Plan(G4LP) and Release Supplement|Participants will be instructed to use the resources provided and follow the G4LP for the duration of the study period. Participants will also take one capsule of Release three times a day, to be taken at the beginning of or during each meal, starting on Day 1. If a dose is missed before or during a meal, participants are instructed to take the dose as soon as they remember after the meal. Participants will be advised not to exceed three capsules daily.
89661642|NCT05836883|Placebo Comparator|Cohort 1: Placebo|Local injection 15 mL of normal saline on Day 0
89661643|NCT05836883|Placebo Comparator|Cohort 2: Placebo|Local injection 30 mL of normal saline on Day 0
89661644|NCT05836883|Placebo Comparator|Cohort 3: Placebo|Local injection 30 mL of normal saline on Day 0 and Month 3
89661645|NCT05836883|Experimental|Cohort 1: Treatment|Local injection of 15 mL of ExoFlo on Day 0
89661646|NCT05836883|Experimental|Cohort 2: Treatment|Local injection of 30 mL of ExoFlo on Day 0
89661647|NCT05836883|Experimental|Cohort 3: Treatment|Local injection of 30 mL of ExoFlo on Day 0 and Month 3
89661648|NCT05829434|Experimental|Magrolimab + intensive chemotherapy (7+3)|"Patients will receive magrolimab in combination with 7+3"
89661649|NCT05829434|Experimental|Magrolimab + intensive chemotherapy (CPX-351)|Patients will receive magrolimab in combination with CPX-351
89661650|NCT05808257|Experimental|Thulium Fibre Laser (TFL)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Thulium fibre laser (TFL)
89661651|NCT05808257|Experimental|Holmium:Yttrium-Aluminum-Garnet (Ho:YAG)|Patients who are randomized to undergo ureteroscopic laser lithotripsy with the Holmium:Yttrium-Aluminum-Garnet (Ho:YAG) laser
89661652|NCT05807386|Experimental|Exercise Intervention|Participants will undertake a 12 week, online delivered, home-based exercise programme.
89661653|NCT05807386|No Intervention|Waitlist Control|Participants assigned to the waitlist control will adhere to their usual routine.
89661654|NCT05791227|Active Comparator|Sonographer Annotation|Currently, sonographer technicians provide preliminary interpretations prior to validation and overreading by cardiologists. This staggered, stepwise evaluation allows for the introduction of AI decision support with minimal impact on patient care. Physicians are already used to adjusting the preliminary report given the variable training of sonographers and on the lookout for changes, variation, or adjustments that need to be made.
89661655|NCT05791227|Experimental|Artificial Intelligence Annotation|A novel AI algorithm developed to assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd). The AI will provide preliminary assessments for cardiologist evaluation.
89661656|NCT05776823|Experimental|Pharmacist Narcan Training|Pharmacist-led intervention
89661657|NCT05776823|Active Comparator|Substance Use Counselor Narcan Training|Non-clinician intervention
89661658|NCT05776823|Experimental|Brief Intervention and Referral to Treatment (BIRT)|BIRT intervention
89661659|NCT05776823|Active Comparator|Standard Medication Counseling (SMC)|SMC intervention
89688649|NCT02814448|Experimental|Thermocoagulator|Single heat application at 100 ºC for 40 seconds
89047763|NCT05823415|Experimental|Laterally closed tunnel technique with CTG|
89047764|NCT05823415|Active Comparator|Coronally advanced flap with CTG|
89047765|NCT05823389|Experimental|Flapless Emdogain (FEMD) group|Re-instrumentation with flapless emdogain application
89047766|NCT05823389|Active Comparator|Placebo group|Re-instrumentation without flapless emdogain application
89047767|NCT05823350|Experimental|Experimental group|"The relatives of the patients were shown the video before the colonoscopy. The video consisted of visual and verbal content about colonoscopy, and the benefits and application steps of abdominal massage in pain management after the procedure.~After the procedure, the relatives of the patients in the experimental group were asked to apply abdominal massage to their patients. During the massage application, when necessary, guidance was given to the patient's relatives about the application of the massage. In this supine position, patient's abdomen was massaged with circular movements and different techniques in the direction of the colon."
89047768|NCT05823350|No Intervention|Control Group|After the procedure, the patients who were taken to their beds were asked to evaluate their pain and distension levels after the colonoscopy. The vital signs of the patients who received standard care were monitored after the procedure and were followed up for possible complications.
89047769|NCT05823324|Experimental|Therapeutic play|The therapeutic play method with the teddy bear during PIVC was applied in this group
89661660|NCT05776056|Other|N-of-1 crossover study enrollment: start with placebo|All participants spend time receiving both active study drug (methylphenidate) and placebo (sham study drug), in randomized order, across 4 treatment blocks separated by 1 week washout periods (where no study drug is given).
89661661|NCT05776056|Other|N-of-1 crossover study enrollment: start with methylphenidate|All participants spend time receiving both active study drug (methylphenidate) and placebo (sham study drug), in randomized order, across 4 treatment blocks separated by 1 week washout periods (where no study drug is given).
89661662|NCT05772845|Other|Daily Users of ENDS|Participants who use nicotine-containing ENDS daily or near-daily but who do NOT smoke combustible cigarettes daily or near-daily.
89661663|NCT05772845|Other|Daily Users of Combustible Cigarettes|Participants who smoke combustible cigarettes daily or near-daily but do NOT use nicotine-containing ENDS daily or near-daily.
89661664|NCT05772845|Other|Daily Dual Users of ENDS and Combustible Cigarettes|Participants who both use nicotine-containing ENDS and combustible cigarettes daily or near-daily
89661665|NCT05766332||Observational (clinical evaluation, record review)|Patients undergo a clinical evaluation consisting of a six-minute walk test, hand grip strength test, and gait speed test on study. Patients' medical records are also reviewed for a year on study.
89661666|NCT05764707|Experimental|Intravenous Acetaminophen|Intravenous acetaminophen (1000mg) will be administered within 30 minutes of skin closure.
89661667|NCT05764707|Placebo Comparator|Intravenous Placebo|Intravenous normal saline will be administered within 30 minutes of skin closure.
89661668|NCT05764122|Experimental|Part 1: BIIB131 Low Dose|Participants will receive a single low dose of BIIB131 as an IV bolus followed by continuous IV infusion on Day 1. Based on the dose selection results from Part 1, participants may receive a single active dose of BIIB131 in Part 2.
89661669|NCT05764122|Experimental|Part 1: BIIB131 Medium Dose|Participants will receive a single medium dose of BIIB131 as an IV bolus followed by continuous IV infusion on Day 1. Based on the dose selection results from Part 1, participants may receive a single active dose of BIIB131 in Part 2.
89661670|NCT05764122|Experimental|Part 1: BIIB131 High Dose|Participants will receive a single high dose of BIIB131 as an IV bolus followed by continuous IV infusion on Day 1. Based on the dose selection results from Part 1, participants may receive a single active dose of BIIB131 in Part 2.
89661671|NCT05764122|Placebo Comparator|Part 1 and Part 2: Placebo|Participants will receive a single dose of BIIB131-matching placebo in Part 1 and Part 2, as an IV bolus followed by continuous IV infusion on Day 1.
89661672|NCT05761184||Steatosis grade 2-3|Subjects with Prader-Willi syndrome and with steatosis grade 2-3
89661673|NCT05761184||Steatosis grade 0-1|Subjects with Prader-Willi syndrome and with steatosis grade 0-1
89661674|NCT05742776||Patient Group|CTS Patients
89661675|NCT05742776||Control Group|Healthy Individuals
89661676|NCT05740241||Healthy participants aged more than 65 years old|Participation in 8 physical activity sessions, lasting 45 minutes, at the rate of 2 sessions per week
89661677|NCT05730491|Experimental|Social Learning and Cognitive Behavioral Therapy (SLCBT)|
89661678|NCT05730491|Placebo Comparator|Attention Education Control|
89661679|NCT05720325|Active Comparator|Adaptive Phenotypes randomized to study drug|This group will be comprised of the Adaptive-A and Adaptive-B subgroup and will consist of the adaptive phenotype participants identified during the initial HDM ACC challenge, administered the study drug.
89661680|NCT05720325|Experimental|Maladaptive Phenotypes randomized to study drug|This group will be comprised of the Maladaptive-A and Maladaptive-B subgroup and will consist of the maladaptive phenotype participants identified during the initial HDM ACC challenge administered the study drug.
89661681|NCT05720325|Placebo Comparator|Adaptive Phenotype randomized to placebo|This group will be comprised of the Adaptive-A and Adaptive-B subgroup and will consist of the adaptive phenotype participants identified during the initial HDM ACC challenge, administered the placebo.
89661682|NCT05720325|Placebo Comparator|Maladaptive Phenotype randomized to placebo|This group will be comprised of the Maladaptive-A and Maladaptive-B subgroup and will consist of the maladaptive phenotype participants identified during the initial HDM ACC challenge administered the placebo.
89661683|NCT05704985|Experimental|DK210 (EGFR) Monotherapy (Dose escalation and expansion)|DK210 (EGFR) will be administered as monotherapy three times per week via subcutaneous (SC) administration. Dose will be escalated from 0.025 mg/kg to 0.3 mg/kg or until unacceptable toxicity, disease progression, or withdrawal of consent. An expansion cohort at the optimal dose will be enrolled in parallel with the combination arms.
89661684|NCT05704985|Experimental|DK210 (EGFR) + chemotherapy|In patients with good tolerance of first line systemic therapy, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with second-line intravenous (IV) chemotherapy until unacceptable toxicity, disease progression, or withdrawal of consent
89661685|NCT05704985|Experimental|DK210 (EGFR) + radiation|In patients with need of palliative radiation, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with short course radiation therapy (10 fractions or less) until unacceptable toxicity, disease progression, or withdrawal of consent
89661686|NCT05704985|Experimental|DK210 (EGFR) + immunotherapy|In patients with good tolerance of first line immunotherapy, DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with intravenous (IV) immune checkpoint blockers until unacceptable toxicity, disease progression, or withdrawal of consent
89661687|NCT05695313|Placebo Comparator|Placebo|Standard chemotherapy PACLITAXEL + placebo dietary supplement
89661688|NCT05695313|Experimental|OnLife®|Standard chemotherapy + OnLife® dietary supplement
89661689|NCT05693571|Experimental|Valera Pilot Study|All participants in the open-label pilot study will be provided with the Valera smart phone application and online care manager dashboard
89661690|NCT05687240|Active Comparator|Qigong/Tai Chi Intervention|Meditative movement practice based on qigong and tai chi, delivered via video link
89661691|NCT05687240|Experimental|Qigong/Tai Chi (QTC) + Heart Rate Variability (HRVB) Intervention|Meditative movement practice based on qigong and tai chi, delivered via video link with the addition of a brief practice with a the feedback on heart rate variability from an Inner Balance app.
89661692|NCT05686993|Experimental|Cinnarizine and nifedipine|Drug 1 for 2 weeks, 2 weeks of washout, then Drug 2 for 2 weeks Drug 1 and 2, in no specified order, Cinnarizine 30 mg oral TDS and Nifedipine 60 mg oral daily
89661693|NCT05675917|Experimental|MacuTest website|"The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet)."
89661694|NCT05672823|Experimental|Minimally invasive, upper extremity|Radial artery for pigtail catheter and pacing over the Left Ventricular (LV) stiff wire OR radial artery for pigtail catheter and brachial vein for temporary pacemaker when not pacing over the LV stiff wire.
89661695|NCT05672823|Active Comparator|Lower extremity|Femoral artery for pigtail catheter and pacing over the LV stiff wire OR femoral artery for pigtail catheter and femoral vein for temporary pacemaker when not pacing over the LV stiff wire.
89661696|NCT05670639|Other|Pilot|
89661697|NCT05667649|Experimental|RB-ADSC low dose|Participants will receive one dose of 2x10^6 RB-ADSC infused in the previously implanted Ommaya reservoir
89661698|NCT05667649|Experimental|RB-ADSC medium dose|Participants will receive one dose of 5x10^6 RB-ADSC infused in the previously implanted Ommaya reservoir
89661699|NCT05667649|Experimental|RB-ADSC high dose|Participants will receive one dose of 10x10^6 RB-ADSC infused in the previously implanted Ommaya reservoir
89661700|NCT05665179|Experimental|Treatment|Receives tutorial for free online legal resolution at treatment center
89661701|NCT05665179|No Intervention|Control|The control group is not provided the experimental intervention.
89661702|NCT05664893|Experimental|Principal arm|registration phase : 3 cycles of 600mg per day of ribociclib Treatment phase : 3 cycles of dose de-escalation of ribociclib (600 or 400 or 200mg per day) Maintenance phase : 600mg per day of ribociclib until 24months of total treatment
89661703|NCT05664594|Experimental|Perceptual Discrimination Training|Training will involve Gabor patch and other visual stimuli discrimination exercises that focus on improving signal-to-noise resolution and attentional control with minimal working memory/cognitive control effects. On each training trial, participants are required to distinguish a target stimulus among a set of distractor stimuli. The similarity between target and distractors increases in level of difficulty based on an adaptive perceptual processing staircase function. Consecutive correct responses lead to increased modulation of the distractors to be more similar to the target, while 1 incorrect response drops the user to an easier level. Difficulty is adapted to maintain an 80% correct response rate. Each session will consist of 4 exercises requiring ~45 minutes. with 40 trials for each exercise.
89661704|NCT05664594|Experimental|Visual Cognitive Control Training|"Training will involve maintaining accurate representations of cognitive context (the rule) in working memory during response selection. On each training trial, participants must observe stimuli, and hold the correct response context on-line in order to select the correct response from among the stimuli. Training is adaptive using a staircase function, such that two consecutive correct responses increases either the speed of stimuli presentation or the working memory load via an increased number of stimuli that are presented; one incorrect response reduces the cognitive load. Each session will consist of 45 exercises requiring ~45 minutes."
89047770|NCT05823324|No Intervention|Control|The standard procedure of the clinic was applied in the control group. The routine invasive procedure of the clinic, the mothers accompany their children and are involved in the procedure
89047771|NCT05823285|Experimental|QLS31903|0.01μg/kg-2.16 μg/kg QLS31903 for injection
89047772|NCT05823246|Experimental|QLF31907|single arm with QLF31907
89047773|NCT05823194|Other|Fertility spared gynecologic cancer diagnosed women|Participants recruited from a tertiary care hospital, and women diagnosed with gynecological malignancies (e.g. cervical, ovarian, endometrial cancer) who underwent fertility-sparing surgery between 2010 and 2022.
89047774|NCT05823181||Early laparoscopic exploration of common bile duct|Early laparoscopic exploration of common bile duct after failure of extraction of common bile duct stones by ERCP
89047775|NCT05823181||Late laparoscopic exploration of common bile duct|late laparoscopic exploration of common bile duct after failure of extraction of common bile duct stones by ERCP
89047776|NCT05823168||patients with seizures|patients with traumatic brain injury
89047777|NCT05823168||patients without seizures|patients with traumatic brain injury
89047778|NCT05823155|Experimental|Detailed penicillin allergy evaluation during pre-operative care|This group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Patients with negative result in skin test and oral provocation test will have their prior labelled penicillin allergy removed from electronic health record, and an additional entry documenting the negative allergy evaluation will be added. A letter signed by an infectious disease specialist documenting the allergy evaluation results will also be given to patients.
89661705|NCT05664009|Experimental|Redsenol-1 Plus|Participants will be instructed to take two (2) capsules, three (3) times a day in the morning, at noon and in the evening (before going to bed), for a total of 6 capsules a day, with food for 12 weeks. If a dose is missed participants are instructed to take the missed dose as soon as possible.
89661706|NCT05664009|Placebo Comparator|Placebo|Participants will be instructed to take two (2) capsules, three (3) times a day in the morning, at noon and in the evening (before going to bed), for a total of 6 capsules a day, with food for 12 weeks. If a dose is missed participants are instructed to take the missed dose as soon as possible.
89661707|NCT05651243|Experimental|Ketone Ester|Oral ketone ester supplement
89661708|NCT05651243|Placebo Comparator|Placebo|Taste and viscosity matched placebo
89661709|NCT05642442|Placebo Comparator|Placebo|Participants who will receive a matching placebo during the Dose Titration, Optimization Period, and Maintenance Period.
89661710|NCT05642442|Experimental|Sulvecaltamide|Participants who will receive an optimal dose of suvecaltamide during the Dose Titration, Optimization Period, and Maintenance Period.
89661711|NCT05641961|Experimental|Survivorship Mobile Application|Participants are seen in the survivorship clinic and receive education about potential late effects and the survivorship application on study. Participants enrolled in this study will be asked to complete two self-administered questionnaires at 4 time points. Questionnaires will be designed and made available electronically, to be completed on the participant's personal mobile device (e.g., mobile phone).
89661712|NCT05641324|Experimental|ANV419 single agent, dose 1, Q2W|
89661713|NCT05641324|Experimental|ANV419 single agent, dose 2, Q2W|
89661714|NCT05641324|Experimental|ANV419 Q2W + Lenalidomide plus low-dose dexamethasone|
89661715|NCT05641324|Experimental|ANV419 Q2W + Daratumumab|
89661716|NCT05627687|Placebo Comparator|Music Listening Control|Music listening control (MLC) will consist of listening to selected music tracks of choice using either the Pandora or Spotify app (with coaching to download app and play, and log listening time in diary), specifically choosing a neutral channel, Coffeehouse Playlist. For both interventions, FCG will be asked to practice/listen 10-minutes at a time with their AD patient (sharing as much or as little as is possible/preferred) for at least 4-5 days/week, and asked to complete diary/checklists to show times practicing/listening.
89661717|NCT05627687|Active Comparator|Heart Rate Variability Biofeedback|"Participants will receive coaching in a practice that is guided using an Inner Balance app with a device that senses pulse and provides feedback to help achieve a rhythm of heart rate variability called resonant frequency, or coherence. They will be guided first in slowed heart-focused breathing and positively-focused emotions and then will connect to the app to receives visual feedback to achieve a favorable HRV."
89661718|NCT05626049|Active Comparator|Usual Medical Care|This group will consist of patients who contact clinics that have been randomized to usual medical care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
89661719|NCT05626049|Experimental|Primary Spine Provider Model|This group will consist of patients who contact clinics that have been randomized to the primary spine provider (PSP) model (intervention clinics). Patients seeking care at intervention clinics will be given the option of seeing either a DC or a PT as their first contact clinician for an initial trial of PSP care.
89661720|NCT05609942|Experimental|Monotherapy|Participants with AdvSM (ASM, SM-AHN, or MCL) will receive BLU-263 monotherapy.
89661721|NCT05609942|Experimental|Combination therapy|Participants with high risk and very high risk systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) of non-MC lineage will receive BLU-263 in combination with azacitidine.
89661722|NCT05607576|Experimental|Uncovered|Dexcom G6 CGM will be uncovered during standard of care radiologic procedures.
89661723|NCT05600439|Experimental|Experimental GP|CareME Program. Group attachment-based intervention program developed for improving relational abilities in professional caregivers working in Youth Residential Care (YRC) settings.
89661724|NCT05600439|No Intervention|Control GP|The control group had no intervention assigned.
89661725|NCT05594368|Experimental|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|
89661726|NCT05587127|Experimental|Cognitive Behavioral Therapy|Subjects will receive cognitive behavioral therapy for functional dyspepsia with avoidant restrictive food intake disorder.
89661727|NCT05587127|No Intervention|Usual Care|In the usual care condition, participants will be allowed to continue with treatment they are already receiving at the time of randomization, and we will collect detailed data on the nature of these interventions. Participants will be allowed to pursue non study treatments in this condition.
89661728|NCT05578872|Experimental|ANV419 single agent, dose 1, Q2W|
89661729|NCT05578872|Experimental|ANV419 single agent, dose 2, Q2W|
89661730|NCT05578872|Other|ANV419 + Pembrolizumab, Q3W|
89661731|NCT05578872|Other|ANV419 + Ipilimumab, Q3W|
89661732|NCT05572944||Never smoker with lung cancer high risk assessment|High risk: above the median of the initial risk model from retrospective study
89661733|NCT05572944||Never smoker with lung cancer low risk assessment|Low risk: below the median of the initial risk model from retrospective study
89661734|NCT05568667|Experimental|Risk sub-group|"st sub-grouup : Low risk to develop a CRC~nd sub-group : Moderate risk to develop a CRC~rd sub-group : High risk to develop a CRC"
89661735|NCT05563766|Experimental|Itraconazole|Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
89661736|NCT05559619|Active Comparator|Drug treatment group|34 postmenopausal women who only received oral calcium and vitamin D3 supplement (Calcium D3F® (Arab Company for Pharmaceutical& medicinal plants (MEPACO-MEDIFOOD, EGPYT). Each tablet contains 1000 mg of natural calcium carbonate, 1000 IU vitamin D3 (0.025 mg) and 0.25 mg Sodium Fluoride. They received 1 tablet once daily for 12 weeks
89661737|NCT05559619|Active Comparator|Drug treatment + laser acupuncture group|34 postmenopausal women who received laser acupuncture therapy in addition to the same calcium and vitamin D3 supplement for 12 weeks.
89661738|NCT05554692|Experimental|Enrolled Participants - Older adults with cochlear implants|Individuals who already use at least one cochlear implant.
89661739|NCT05554692|Other|Enrolled Participants - Adults with typical hearing|Control group to provide baseline or comparison data
89661740|NCT05551299|Experimental|Photodynamic therapy (PDT)|The index procedure in all patients at baseline includes stenting, using an endoscopic retrograde cholangio-pancreatography (ERCP) procedure. The Intervention is at least one PDT at baseline according to the clinical routine of the trial site.
89661741|NCT05551299|Experimental|Radiofrequency ablation (RFA)|The index procedure in all patients at baseline includes stenting, using an endoscopic retrograde cholangio-pancreatography (ERCP) procedure. The Intervention is at least one RFA at baseline according to the clinical routine of the trial site.
89661742|NCT05547464|Experimental|BNT164a1|Escalating dose levels
89661743|NCT05547464|Experimental|BNT164b1|Escalating dose levels
89661744|NCT05547464|Placebo Comparator|Placebo|Isotonic NaCl solution (0.9%)
89661745|NCT05541003|Experimental|Experimental Arm|All participants will receive NBT-NM108 prepared as muffin (each contains 30 g of the product) for 4 weeks. The dosage will be 2 muffins a day. This dosage of NBT-NM108 will provide 24 g/day of dietary fibers.
89661746|NCT05527145|Active Comparator|surgery|Oper or minimally invasive surgery
89661747|NCT05527145|Active Comparator|percutaneous|percutaneous non-surgical insertion of interspinous device
89661748|NCT05524935|Experimental|Pembrolizumab and Olaparib|Participants will be given 200 mg Pembrolizumab IV every 21 days + will take 300 mg Olaparib by mouth twice daily days 1-21 of each 21 day cycle. Treatment will continue until progression, unacceptable toxicity, or for a maximum of 35 treatment cycles
89661749|NCT05514548|Experimental|INV 202 10 mg|INV-202 10 mg Arm
89661750|NCT05514548|Experimental|INV-202 25 mg|INV-202 25 mg Arm
89661751|NCT05514548|Placebo Comparator|Placebo|Placebo Arm
89661752|NCT05496556|Other|All patients included in the study|Patient with stage IV non-small cell bronchopulmonary carcinoma receiving first-line treatment and received LFQP questionnaire
89661753|NCT05495555||High IOP setting|Cataract removal with high IOP setting
89661754|NCT05495555||Low IOP setting|Cataract removal with low IOP setting
89661755|NCT05482243|No Intervention|Habitual lifestyle period|"All participants will be encouraged to keep their diet and physical activity similar to before the study period. Subjects will be asked to record their food intake and wear an Actical physical activity monitor for 3 days throughout the habitual lifestyle period (2 week days and 1 weekend day).~All participants will be asked to ingest 20 mL deuterated water and take a saliva sample daily"
89661756|NCT05482243|Experimental|Exercise training period|"All participants will be encouraged to keep their diet and physical activity similar to before the study period. Subjects will be asked to record their food intake and wear an Actical physical activity monitor for 3 days throughout the exercise training period (2 week days and 1 weekend day).~Participants will be asked to ingest 20 mL deuterated water and take a saliva sample daily~Participants will visit the University three times with 2-day intervals (e.g. Monday-Wednesday-Friday) for an exercise training session as described in 5.6.~Following the training sessions, participants will be provided with a protein supplement as described in 5.7.~Before and after ingestion of the protein supplement, participants will be asked to fill in a gastrointestinal tolerance and palatability survey."
89047779|NCT05823155|No Intervention|Standard pre-operative care|This group will receive standard perioperative care. The choice of antibiotics during the perioperative period will be decided by surgical team.
89661757|NCT05475743|Experimental|Pain Informed Movement program|
89661758|NCT05475743|Active Comparator|Standard medical care and leaflet education|
89661759|NCT05464836|Experimental|CB-103+Venetoclax|Control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients.
89661760|NCT05462717|Experimental|RMC-6291|Dose Escalation and Dose Expansion
89661761|NCT05454150|Experimental|TAVI with balloon-expandable valve (Sapien 3/Ultra, Edwards Lifesciences©)|
89661762|NCT05454150|Active Comparator|TAVI with self-expanding valve (Evolut R/Pro, Medtronic©)|
89661763|NCT05432453||Women with constipation|"Bowel functional markers (defecation frequency, defecation time, and stool density) and constipation-related quality of life of women with constipation will be evaluated with the Constipation Severity Scale, Constipation Quality of Life Scale, 7-day bowel diary, and Bristol Stool Scale.~Sacroiliac joint dysfunctions of women with constipation will be evaluated by standing forward bending test, sitting forward bending test, compression test, posterior friction test and Patrick-Faber test."
89661764|NCT05432453||Women without constipation (Control)|"Bowel functional markers (defecation frequency, defecation time, and stool density) and constipation-related quality of life of women without constipation will be evaluated with the Constipation Severity Scale, Constipation Quality of Life Scale, 7-day bowel diary, and Bristol Stool Scale.~Sacroiliac joint dysfunctions of women without constipation will be evaluated by standing forward bending test, sitting forward bending test, compression test, posterior friction test and Patrick-Faber test."
89661765|NCT05427422||Recovery|We would use recovery rate defined as difference between Fugl-meyer scores in the end of follow-up(eF) and in the enrollment (sF) normalized by sf to indicate the recovery Level of a patients, i.e., (eF-sF)/sF. A previously reported recovery rate, i.e., proportional recovery((eF-sF)/sF=0.7) was chosen as a standard of recovery. Hierarchial cluster method would be used to divide patients into Recovery and Non-recovery group. The Recovery group indicates that patients showed proportional Recovery determined by hierarchial cluster.
89661766|NCT05427422||Non-Recovery|The Non-Recovery group indicates that patients fail to show proportional recovery.
89661767|NCT05427422||Healthy Control|Age/sex matched healthy subjects enrolled to compare with group of patients.
89688650|NCT00931489|Active Comparator|Wet AMD Patients Responders|Dilated eye exam once a month for 7 months; visual acuity and OCT once a month for 7 months; Lucentis(R)/ranibizumab injection once each month for the Baseline and Month 1-3 visits, then as needed at Month 4 and 5; 3 Tbls. blood draw at Baseline, Month 3 and Month 6 visits.
89688651|NCT00931489|No Intervention|Normal Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
89047780|NCT05823103|Active Comparator|Hysteroscopic Metroplasty using ESHRE ASRM Classification|
89047781|NCT05823103|Active Comparator|Hysteroscopic Metroplasty using Shawki Septum Scoring System|
89047782|NCT05823051|Experimental|VASIDS-TP and Counseling Practice|Video-Assisted Sudden Infant Death Syndrome Prevention Training Program (VASIDS-TP) and Counseling Practice
89047783|NCT05823051|No Intervention|Routine Care|"The control group will receive routine care in the obstetric ward. A pre-test will be conducted using the Google Survey form. Personal Information Form, Sudden Infant Death Syndrome Knowledge Level Assessment Form (Pre-Test) and General Self-Efficacy Scale will be completed at this stage.~The mothers in the control group will receive the training included in clinical routine care. The mothers in this group will not receive any planned structured training by the researchers during the study. The mothers in the control group will be administered the Sudden Infant Death Syndrome Knowledge Level Assessment Data Form and the General Self-Efficacy Scale with the Google survey that will be sent to their phones 1 month after the pre-test application. After the completion of the study, the control group will receive the same intervention (VASIDS-TP) as the intervention group."
89047784|NCT05822999|Experimental|WELT-IP|Eligible subjects were able to access WELT-IP (an investigational digital therapeutic) on a mobile device (iOS and Android) as scheduled to receive CBT-I.
89047785|NCT05822999|Sham Comparator|Sham|Eligible subjects were able to access a sham app downloaded on a mobile device (iOS and Android) which included sleep diary and general content regarding sleep.
89047786|NCT05822973|Active Comparator|would closure using absorbable sutures|patients randomized into the absorbable suture group will have their incisions closed with 3.0 monocryl sutures
89047787|NCT05822973|Active Comparator|would closure using non-absorbable sutures|Patients randomized into the nonabsorbable suture group will have their incisions closed with either a 3.0 nylon suture
89047788|NCT05822947|Experimental|Active manual therapy|Active manual therapy intervention involved mobilization of the lumbar paraspinal musculature. With participants laying prone on a chiropractic table, the intervention provider administered hand-reinforced circumferential movements to six focal areas, using continuous ischemic compression strokes, and adjusting the pressure to participants' tolerability.
89047789|NCT05822947|Sham Comparator|Control manual therapy|Control MT intervention included light touch to six distal, broad areas of the thoracic region, with a synchronized breathing exercise.
89047790|NCT05822908|Experimental|Cohort 1|A dose of 10 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
89661768|NCT05420857|Experimental|Hip Biofeedback|Training: Participants will complete three training bouts in a session. For these training bouts, participants will be instructed to walk around the perimeter of the 9m x 15m laboratory while wearing the custom gait biofeedback device and visual display glasses. The training bouts will each be 6 minutes in duration with a 5-minute break in between bouts. The biofeedback will be intermittent, with one minute on and one minute off, in order for the individual to not become dependent on the feedback and to promote motor learning. Participants will be told that the device measures the angle their paretic leg is at, and as they move their leg, the line on the screen will move. They will be shown as they move their leg farther back, the line moves up, closer to the target. Participants will not be given specific feedback on what walking strategies to use to increase hip extension angle. If the participant surpasses the target hip extension angle, the target will blink green.
89661769|NCT05417958|Experimental|Extremely Thick - Mildly Thick - Extremely Thick - Mildly Thick|Participants will receive 4 weeks Extremely Thick, 4 weeks Mildly Thick, 4 weeks Extremely Thick and 4 weeks Mildly Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
89661770|NCT05417958|Experimental|Extremely Thick - Mildly Thick - Mildly Thick - Extremely Thick|Participants will receive 4 weeks Extremely Thick, 4 weeks Mildly Thick, 4 weeks Mildly Thick and 4 weeks Extremely Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
89661771|NCT05417958|Experimental|Mildly Thick - Extremely Thick - Extremely Thick - Mildly Thick|Participants will receive 4 weeks Mildly Thick, 4 weeks Extremely Thick, 4 weeks Extremely Thick and 4 weeks Mildly Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
89661772|NCT05417958|Experimental|Mildly Thick - Extremely Thick - Mildly Thick - Extremely Thick|Participants will receive 4 weeks Mildly Thick, 4 weeks Extremely Thick, 4 weeks Mildly Thick and 4 weeks Extremely Thick blenderized tube feeds. The volume, caloric density and frequency will be matched to pre-study feeding regimen.
89661773|NCT05408065|Experimental|Cingal|A single infiltration of Cingal, 4 mL, 88 of mg hyaluronic acid and 18 mg of triamcinolone hexacetonide
89661774|NCT05408065|Active Comparator|Cortisone|A single infiltration of cortisone, 40mg of triamcinolone and 4mL of bupivacaine 0.25%
89661775|NCT05399355|Active Comparator|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
89661776|NCT05399355|Sham Comparator|Sham Treatment|Application of 7-30 days of a nonfunctional sham device.
89661777|NCT05398666|Sham Comparator|White LED|Participants will be asked to use white LEDs for 1-2 hours/day in a dark room in their home.
89661778|NCT05398666|Experimental|Green LED|Participants will be asked to use green LEDs for 1-2 hours/day in a dark room in their home.
89661779|NCT05383209|Experimental|EYP-1901 2060 ug|EYP-1901 2060 ug; single injection
89661780|NCT05383209|Experimental|EYP-1901 3090 ug|EYP-1901 3090 ug; single injection
89047791|NCT05822908|Experimental|Cohort 2|A dose of 20 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
89047792|NCT05822908|Experimental|Cohort 3|A dose of 40 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
89047793|NCT05822908|Experimental|Cohort 4|A dose of 70 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
89047794|NCT05822908|Experimental|Cohort 5|A dose of 100 mg of the trial IMP VO659 will be administered intrathecally four times on Day 1, Day 29, Day 57 and Day 85 within the planned dosing blocks. The total duration of trial participation for each participant is up to approximately 42 weeks, consisting of a screening period of up to 6 weeks, a 13-week dosing period and a 23-week post-dosing period.
89047795|NCT05822882||Patients with epidural anesthesia|Patients following Abdominoplasty with postoperative epidural anesthesia via pain catheter
89047796|NCT05822882||Patients without epidural anesthesia|Patients following Abdominoplasty without postoperative epidural anesthesia
89047797|NCT05822804|Experimental|experimental group|Vascular Closure Device (Tonbridge)
89047798|NCT05822804|Active Comparator|control group|EXOSEAL Vascular Closure Device (Codis Corporation)
89661781|NCT05383209|Sham Comparator|Sham IVT|Sham IVT; single injection
89661782|NCT05378464|Experimental|T-Cell therapy dose level 1|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell 0.5.0-2.5 x 10^8, IL-7 and Expanded HER2 specific CD4+ Th1 cell 0.5.0-2.5 x 10^8.
89661783|NCT05378464|Experimental|T-Cell therapy dose level 2|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .25-1.2 x 10^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .25-1.2 x 10^9.
89661784|NCT05378464|Experimental|T-Cell therapy dose level 3|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10^9.
89661785|NCT05378464|Experimental|T Cell therapy dose expansion|Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines. After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with CD4 treated t-cells at the maximum tolerated dose determined.
89661786|NCT05377177|Experimental|Bilateral aTBS|Patients will receive Bilateral accelerated theta-burst stimulation bilaterally for 5 consecutive days, with a total of 10 hours a day. treatment will be 10min with 50min of breaks in between the 10 sessions.
89661787|NCT05377177|Active Comparator|Unilateral aiTBS|Patients will receive unilateral accelerated theta-burst stimulation to the left side for 5 consecutive days, with a total of 10 hours a day. treatment will be 10min with 50min of breaks in between the 10 sessions. There will be a right DLPFC sham component to this treatment arm for all treatment sessions.
89661788|NCT05356013|Placebo Comparator|Placebo|All subjects who are randomized to Placebo will receive an identical placebo pill to the experimental drug starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. After study conclusion (week 8), the dose will be discontinued.
89661789|NCT05356013|Experimental|Caplyta|All subjects who are randomized to Caplyta will receive 42mg/day starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. Dosage changes and reductions will not be permitted. After study conclusion (week 8), the dose will be discontinued.
89661790|NCT05354141|Placebo Comparator|Placebo|Normal saline 100 mL
89661791|NCT05354141|Experimental|Experimental Dose|Normal saline 85 mL and ExoFlo 15 mL
89661792|NCT05348954|Experimental|Sexual dysfunction of women|Sexual dysfunction of women
89661793|NCT05348954|Experimental|Quality of sexual life|Quality of sexual life
89661794|NCT05347693|Experimental|Sodium Zirconium Cyclosilicate (SZC)|Participants discharged with SZC, as per local label, to manage HK until the end of the outpatient phase
89661795|NCT05347693|Active Comparator|Local standard of care (SoC)|Participants discharged with SoC, as per local practice, to manage HK until the end of study.
89661796|NCT05341115|Experimental|Leuprorelin Acetate Depot 3M 11.25 mg|Participants with CPP having body weight ≥20 kg will receive the recommended dose of leuprorelin acetate depot 11.25 mg subcutaneous administration (SC) every 12 weeks based on the standard of 30～180ug/kg/4weeks for the 24-week Treatment Period. It is not recommended to exceed the dose above 180 μg/kg.
89661797|NCT05339490|Experimental|Progenitor Biological Bandages|"Donor Site Wound (DSW) is created with a dermatome. PBB are placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days.~Dressing's changes are performed at Day 5 ± 1 and Day 10 ± 1."
89661798|NCT05339490|Active Comparator|Jelonet|"Donor Site Wound is created with a dermatome. Jelonet® are placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days.~Dressing's changes are performed at Day 5 ± 1 and Day 10 ± 1."
89661799|NCT05339126|Active Comparator|Condition A|high-frequency short bursts (HFSB: 100 Hz, 160 µs pulse width, 200 msec burst)
89661800|NCT05339126|Active Comparator|Condition B|low-frequency long bursts (LFLB: 5 Hz, 160 µs pulse width, 5 sec burst)
89661801|NCT05327829|Sham Comparator|Sham|No stimulation
89661802|NCT05327829|Active Comparator|Stimulation|Stimulation
89047799|NCT05822778|Experimental|Formaderm(FD) group|Formaderm was randomly administered either side of subjects' facial areas once. The injection volume was limited to 2c.c.
89047800|NCT05822778|Active Comparator|control group|"As a self-controlled study, Q-MED RESTYLANE would be administered on the other side after injected Formaderm. The injection volume was limited to 2c.c."
89047801|NCT05822739|Experimental|Arm of BBM-P002|single-arm
89047802|NCT05822726|Experimental|The combination of PSMA-PET/MR and p2PSA|
89047803|NCT05822726|Active Comparator|The combination of mpMRI and p2PSA|
89047804|NCT05822713|Experimental|Experimental|Amisulpride at 5mg was given by slow iv administration during1 to 2 min at induction of anesthesia
89047805|NCT05822713|Placebo Comparator|Placebo|Placebo was given by slow iv administration during1 to 2 min at induction of anesthesia
89047806|NCT05822700|Experimental|K-wire|k wire transfixing hip
89047807|NCT05822687|Experimental|Education|Participants will complete an educational digital module and no skills-based digital modules.
89047808|NCT05822687|Experimental|Education + Reappraisal|Participants will complete an educational digital module and a skills-based digital module that teaches reappraisal coping.
89047809|NCT05822687|Experimental|Education + Distraction|Participants will complete an educational digital module and a skills-based digital module that teaches distraction coping.
89047810|NCT05822687|Experimental|Education + Relaxation|Participants will complete an educational digital module and a skills-based digital module that teaches relaxation coping.
89661803|NCT05327062|Experimental|CRT implantation guided by XSpline|The sample size estimation was based on two recent studies including CRT patients with similar clinical and demographic characteristics as in this study: the SMART-MSP and the SMART CRT. The SMART-MSP is a prospective, observational study that enrolled 584 CRT recipients at 52 US sites. In a typical modern CRT population, 75% of patients had a reduction of the end-systolic volume ≥ 15% at 6-month follow-up. The SMART-CRT study enrolled 699 CRT patients randomized to a treatment arm and a control group. At 6-months follow-up, a reduction of LVESV ≥15% was achieved for 67.7% of the patients in the control group and for 74.8% of those in the treatment arm. Therefore, it is assumed that in a modern CRT population at least 70% of the patients will have a reduction of the LVESV ≥15% of the baseline value at 6-months after CRT implantation. To demonstrate that this proportion of patients can be equally achieved with the approach tested in this study at least 150 patients need to be included.
89661804|NCT05320731|Active Comparator|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
89661805|NCT05320731|Active Comparator|Atomization with lidocaine|Our simple atomization device, a modification of the McKenzie technique, will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
89661806|NCT05311592|Experimental|In Person|Participants will receive all services in person, including participating in the initial intake process, and attending all workshops.
89661807|NCT05311592|Experimental|Virtual (Zoom)|Participants will complete their intake process in person, but will complete all workshops virtually through Zoom.
89661808|NCT05310071|Experimental|Aducanumab|Participants will receive aducanumab, up to 10 milligrams per kilograms (mg/kg), monthly (once every four weeks), administered as intravenous (IV) infusion.
89661809|NCT05310071|Placebo Comparator|Placebo|Participants will receive placebo, monthly (once every four weeks), administered as IV infusion.
89661810|NCT05307809|Experimental|Psoriasis|
89661811|NCT05307809|Experimental|Psoriatic arthritis|
89661812|NCT05307809|Active Comparator|Controls|
89661813|NCT05291975|Active Comparator|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device.
89047811|NCT05822687|Experimental|Education + Reappraisal + Distraction|Participants will complete an educational digital module and two skills-based digital modules, one that teaches reappraisal coping and one that teaches distraction coping.
89047812|NCT05822687|Experimental|Education + Reappraisal + Relaxation|Participants will complete an educational digital module and two skills-based digital modules, one that teaches reappraisal coping and one that teaches relaxation coping.
89661814|NCT05291975|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light.
89047813|NCT05822687|Experimental|Education + Distraction + Relaxation|Participants will complete an educational digital module and two skills-based digital modules, one that teaches distraction coping and one that teaches relaxation coping.
89047814|NCT05822687|Experimental|Education + Reappraisal + Distraction + Relaxation|Participants will complete an educational digital module and three skills-based digital modules, one that teaches reappraisal coping, one that teaches distraction coping, and one that teaches relaxation coping.
89047815|NCT05822674||Sitagliptin/metformin|Patients with T2D treated with sitagliptin/metformin (50/500mg) once daily for 10 weeks
89047816|NCT05822674||Empagliflozin/metformin|Patients with T2D treated with empagliflozin/metformin (10/500mg) once daily for 10 weeks
89047817|NCT05822661|Experimental|Black Seed Oil|900 mg (as two separate soft gels) twice daily for 8 weeks
89047818|NCT05822661|Placebo Comparator|Placebo|matched placebo capsules
89661815|NCT05275881|Experimental|Virtual Reality headset Group|30 patients will be included in the virtual reality arm
89661816|NCT05275881|Active Comparator|Control group with usual practices|30 patients will be included the usual practices
89661817|NCT05271578|Experimental|Smokers|Conventional tobacco cigarette smokers
89661818|NCT05271578|Experimental|Vapers|Electronic cigarette vapers
89661819|NCT05245513|Experimental|Recovery Community Center Linkage (RCCL)|The RCCL arm will involve a brief (~20 minutes) meeting with a recovery coach (i.e. linkage manager), in which the recovery coach will inform the participant of recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (i.e. peer facilitator). The linkage manager will also provide the participant with a list of recovery support service resources.
89661820|NCT05245513|Active Comparator|Control Condition (CC)|The CC arm will involve a time-matched meeting with a recovery coach (i.e. linkage manager), in which the recovery coach will broadly inform the participant of recovery support services, including recovery community centers, and provide them with a list of recovery support service resources.
89047819|NCT05822622||HFpEF(heart failure with preserved ejection fraction)|chronic heart failure with echocardiographic finding of LVEF (left ventricular ejection fraction) equal or more than 50% , diagnostic test :Abdominal ultrasound and transient elastography for detecting non alcoholic fatty liver disease .
89661821|NCT05245071|Experimental|Tusamitamab ravtansine|Tusamitamab ravtansine dose will be administered on Day 1 via IV infusion and repeated once every 2 weeks. The duration of 1 cycle will be 14 days (1 administration of tusamitamab ravtansine per cycle).
89661822|NCT05243485||Cohort 1 (reference group)|500 patients will be included as an observatory control group and as a reference group to the second cohort. The PreHEART score is calculated without further consequences for triage in the ambulance and are transferred to the ED of the nearest hospital for standard care.
89661823|NCT05243485||Cohort 2 (intervention group)|500 patients will be included in the interventional cohort. The calculated PreHEART score has consequences for triage in the ambulance. If the PreHEART score is ≥ 5, the patient is classified as a high-risk patient for having NSTE-ACS. These patients are immediately transferred to the ED of the nearest PCI center for further diagnostic examination and to rule out other life-threatening pathologies. When the PreHEART score is ≤ 4, the patient is classified as a low-risk patient for having NSTE-ACS and is transferred to the ED of the nearest hospital without PCI facilities (non-PCI center) for further diagnostic work-up
89661824|NCT05242510|Experimental|Patching|
89661825|NCT05242510|Experimental|Prism Adaptation|
89661826|NCT05239143|Experimental|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)|"Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen 1.~Rimiducid may be administered as indicated."
89661827|NCT05239143|Experimental|P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)|"Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen 1.~Rimiducid may be administered as indicated."
89661828|NCT05239143|Experimental|P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)|"Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen 2.~Rimiducid may be administered as indicated."
89661829|NCT05239143|Experimental|P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)|"Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following conditioning chemotherapy regimen 2.~Rimiducid may be administered as indicated."
89661830|NCT05237934||Cohort 1|Participants with confirmed/suspected NENs including ACC
89661831|NCT05216029|Experimental|Group I (oncology dashboard)|Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.
89661832|NCT05216029|Experimental|Group II (standard of care)|Patients receive standard of care.
89661833|NCT05215561||Cosentyx|Cosentyx for Subcutaneous Injection
89661834|NCT05214183|Experimental|Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma|
89661835|NCT05213195|Experimental|NKG2D CAR-NK|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation
89661836|NCT05212064|Sham Comparator|Nasal cannula group|Heated and humidified oxygen of 6 L/minute was supplied via an HFNC
89661837|NCT05212064|Experimental|High-flow nasal cannula (HFNC)|Heated and humidified oxygen of 40 L/minute was supplied via an HFNC
89661838|NCT05199467|Experimental|Health Coaching|Receipt of up to 12 sessions of health coaching, plus printed materials providing information on VA benefits
89661839|NCT05199467|Active Comparator|VA Benefits Information|Receipt of printed materials providing information on VA benefits
89661840|NCT05193396|Placebo Comparator|Placebo|Placebo tablets
89661841|NCT05193396|Active Comparator|Hydrocortisone|hydrocortisone tablets
89661842|NCT05187429|Experimental|Dose escalation phase (Cohort A)|Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: 0.1, 0.3 or 1.0 mg/kg Duration: Single dose administered on Study Day 7
89661843|NCT05187429|Experimental|Randomization phase (Cohort B)|Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: determined from Cohort 1 Duration: single dose administered on Day 0 (baseline)
89661844|NCT05187429|Placebo Comparator|Randomization phase comparator (Cohort B)|Comparator: saline Dose form: infusion Dose route: intravenous Duration: single dose administered on Day 0 (baseline)
89661845|NCT05182671||Children diagnosed with bowel and bladder dysfunction|Children who are between the ages of 5-12 and diagnosed with bladder- bowel dysfunction by pediatric urologist.
89661846|NCT05180773|Active Comparator|Bromocriptine Treatment Arm|100 Women in the Treatment Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of bromocriptine administered orally as 2.5 mg twice daily for 2 weeks then 2.5mg once daily for 6 weeks. Women not on clinical anticoagulation will also receive prophylactic anticoagulation with rivaroxaban 10 mg once daily for 8 weeks while on bromocriptine.
89661847|NCT05180773|Placebo Comparator|Placebo Arm|100 Women in the Placebo Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of a placebo administered orally twice daily for 2 weeks then once daily for 6 weeks. Women not on clinical anticoagulation will not receive rivaroxaban but will instead receive a second placebo for 8 weeks.
89661848|NCT05180773|Other|Breastfeeding Observational Cohort|Up to 50 women meeting all other criteria but excluded from REBIRTH due to an intent to continue to breastfeed will be enrolled in an observational cohort. They will receive guideline directed medical therapy with no additional interventions and will have the same follow up and assessment of myocardial recovery by echocardiogram at 6 and 12 months post entry as women in the randomized trial.
89661849|NCT05176366|Experimental|15ml at Day 0, 2, 4, 30 ml at Week 2, Week 6, and every 4 weeks after to week 46|IV administration of 15 mL study agent at Day 0, Day 2, Day 4 and 30 mL at Week 2, Week 6 and every 4 weeks thereafter to week 46 (total # doses = 15).
89688652|NCT00931489|Active Comparator|Wet AMD Patients Acute Non-responders|Participants in this Group will have not responded to 4 prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. Dilated eye exam at Month 4; visual acuity and OCT at Months 4-6; injection of anti-VEGF treatment as needed at Months 4 and 5; 3 Tbls. blood draw at Month 4
89688653|NCT00931489|No Intervention|Dry AMD Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
89688654|NCT00931489|Active Comparator|Wet AMD Patients Chronic Non-responderes|Participants in this Group will have not responded to 4 or more prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. One visit at Month 4: Dilated eye exam with visual acuity and OCT; injection of anti-VEGF as needed; 3 Tbls. blood drawn
89661850|NCT05158270|Active Comparator|Ultrasound Guided Erector Spinae Plane Block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
89661851|NCT05158270|Active Comparator|Ultrasound Guided Anterior Quadratus Lumborum Block|"Patient will be placed in lateral decubitus position. Under complete aseptic precautions, curved US probe will be placed in midaxillary line immediately above the iliac crest to identify anterior abdominal wall muscles. Probe will be then moved dorsally until visualization of transversus abdominis muscle becoming aponeurotic, then visualization of shamrock sign with psoas major muscle anteriorly, erector spinae muscle posteriorly and quadratus lumborum (QL) muscle adherent to the apex of L4 transverse process. After LA infiltration, a 20 gauge spinal needle will be inserted in-plane from posterior to anterior, and needle tip will be advanced through QL muscle, penetrating the ventral proper fascia of QL muscle. Target site for injection will be fascial plane between QL and psoas major muscles. 1 mL saline will be injected to confirm correct needle-tip position, followed by injection of 20 - 30 mL of 0.25% bupivacaine. Procedure will be performed bilaterally."
89661852|NCT05158270|Other|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Morphine, as 3 mg IV bolus at each dose, will be given when VAS equals or above 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
89661853|NCT05151666|Experimental|Hemodialysis Patients|
89661854|NCT05143372|Active Comparator|SaO2 (oxygen status)|Measurment 4 times per day, ABA (acid-bases analyses)
89661855|NCT05143372|Active Comparator|PaO2/FiO2 (respiratory index)|Measurment 4 times per day, ABA (acid-bases analyses)
89661856|NCT05130983|Experimental|15ml at Day 0, 2, 4, 30 ml at Week 2, Week 6, and every 4 weeks after to week 46|IV administration of 15 mL study agent at Day 0, Day 2, Day 4 and 30 mL at Week 2, Week 6 and every 4 weeks thereafter to week 46 (total # doses = 15).
89661857|NCT05128162|Experimental|Open Label Oral Psilocybin|This is an open-label study, and participants who meet the inclusion and exclusion criteria will be eligible and invited to enroll. Enrolled participants are planned to receive 2 doses of psilocybin: a 15 mg dose followed 2 weeks later by a 25 mg dose. The total planned duration of the study for an individual participant from screening to last follow-up is approximately 8 months.
89661858|NCT05127122|Placebo Comparator|Placebo Saline|Saline
89661859|NCT05127122|Experimental|10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
89661860|NCT05127122|Experimental|15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
89661861|NCT05116761|Placebo Comparator|Treatment Arm 1|Normal Saline 100 mL
89661862|NCT05116761|Experimental|Treatment Arm 2|Normal saline 85 mL and ExoFlo 15 mL, which is 10.5 x 10^8 EV
89661863|NCT05060549|Experimental|Cariprazine 1.5 mg|Participants will receive 1.5 mg daily of cariprazine (Vraylar) for six weeks
89661864|NCT05060549|Experimental|Cariprazine 3 mg|Participants will receive 3 mg daily of cariprazine (Vraylar) for six weeks
89661865|NCT05033041|Active Comparator|Group 1 Study Drug Metoclopramide|Intravenous administration of 10 mg metoclopramide
89661866|NCT05033041|Placebo Comparator|Group 2 Study Drug Placebo|Intravenous administration of sterile normal saline
89661867|NCT05029102|Experimental|TAS-102 and Anlotinib|TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
89661868|NCT05028933|Experimental|EPCAM CAR-T|"The first stage: single dose escalation The classic 3+3 dose escalation test. The starting dose refers to the results of the previous test of subsequent subjects. In this study, 3 increasing dose levels were set up, with 3 to 6 cases per dose.~The first dose group is 3×10^5/kg, allowing 10% dose error.~The second dose group is 1×10^6/kg, allowing 10% dose error.~The third dose group is 3×10^6/kg, allowing 10% dose error. Each dose group must complete the DLT observation before entering the next dose group; when the first subject in the same dose group has no DLT observed for at least 14 days after cell infusion, the subsequent subjects can receive cell infusion.~The second stage: combined radiofrequency/microwave ablation for the treatment of advanced digestive system malignant tumors with liver metastases"
89661869|NCT05023486|Experimental|NP-G2-044 Monotherapy - Capsule/Tablet|NP-G2-044 capsule/tablet PO QD for each 28-day cycle
89661870|NCT05023486|Experimental|NP-G2-044 Combination Therapy With Anti-PD-1 Therapy|NP-G2-044 capsules PO QD for each 28-day cycle, Anti-PD-1 Therapy per standard of care, at a dose and frequency in accordance with the package insert
89661871|NCT05022927|Experimental|Dose escalation part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to determine the MTD by evaluating DLTs of in patients with locally advanced or metastatic HCC.
89661872|NCT05022927|Experimental|Expansion part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent To evaluate the anti-tumor effect.
89661873|NCT05022927|Experimental|Concomitant use part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab and to determine the MTD.
89661874|NCT05022927|Experimental|Biomarker part|Patients will receive ERY974 in combination with atezolizumab and bevacizumab after administering ERY974 as a single agent and to evaluate the biomarkers.
89661875|NCT05022927|Experimental|Mono dose escalation part|Patients will receive ERY974 as a single agent and to determine the MTD by evaluating DLTs of in patients with locally advanced or metastatic HCC.
89661876|NCT05022446||Observational (survey)|Participants complete survey over 5-10 minutes.
89047820|NCT05822622||NAFLD(non alcoholic fatty liver disease)|ultrasound and transient elastographic finding of fatty liver disease, diagnostic test :echocardiography to determine heart failure with preserved ejection fraction .
89047821|NCT05820425||Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS|Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS, using PERCEPT device (Medtronic)
89047822|NCT05820360|Experimental|People with Serious Mental Illness|The target groups are adult (18 to 65 years) and elderly (over 65 years) patients with a Serious Mental Illness. Inclusion criteria: presence of SMI and behavioral problems, willingness and ability to participate in this research.
89047823|NCT05819294|Experimental|Standard thoracentesis followed by pre-aspiration fluid agitation|Participants will undergo the standard thoracentesis followed by the experimental pre-aspiration fluid agitation technique
89047824|NCT05819008||Patients with neurological disorders or injuries and Healthy Controls|
89047825|NCT05817474|Experimental|Group T|Group T: received lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed;
89661877|NCT05021224|Other|Engagement strategy groups|We anticipate that approximately 25 patients will receive an engagement strategy (~5 patients per strategy; only 1 strategy per patient). The exact strategies will be developed during the course of this R21 and cannot yet be specified. This is a non-control, pilot feasibility trial.
89661878|NCT05021185|Experimental|Interactive Mobile Doctor (iMD) Intervention|Participants will receive up to a total of 3 iMD sessions prior to their completion of radiation therapy; each session will take about 10-15 minutes and includes: 1) computerized assessments that will be delivered on the screen via text with accompanying audio and participants will respond directly on the tablet 2) tailored videos that deliver messages specific to patient's responses to selected assessment questions and 3) a summary printout
89661879|NCT05021185|No Intervention|Control Group|Participants will complete questionnaires and receive a handout containing tobacco cessation resources.
89661880|NCT05020145||Immunocompromised|Vaccinated Subject with 1 or >1 immunocompromising conditions.
89661881|NCT05020145||Non-Immunocompromised|Vaccinated subjects without evidence of immunocompromising condition.
89661882|NCT05020145||Total Population (immunocompromised and non)|Vaccinated Subjects with or without 1 or >1 immunocompromising conditions.
89661883|NCT05017662|Other|Data collection|
89661884|NCT04998201|Experimental|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
89661885|NCT04998201|Placebo Comparator|Placebo|calculated volume to match active treatment by sc injection
89661886|NCT04966247||Patients with Aortic Arch Pathology|Patients undergoing aortic arch surgery for aortic arch pathologies, such as aortic aneurysm and aortic dissection.
89661887|NCT04946201||With Extractions|Patients in this group will undergo dental extractions.
89661888|NCT04946201||Without Extractions|Patients in this group will not undergo dental extractions.
89661889|NCT04933513||preoperative Parkinson' disease|pre DBS parkinson's disease patients responding to the DBS-PS scale preoperatively
89661890|NCT04915898|Active Comparator|Oral Care Hygiene Intervention Group|Providing oral care kits designed to facilitate adherence to brushing teeth after meals and before sleep. Providing continuous education and feedback on performance to team members on the interventional units. Encouraging patients to brush their teeth and use the kits or own materials if desired.
89661891|NCT04915898|No Intervention|Control group - standard of care oral care on units|These units will perform their 'usual' or standard of care for oral hygiene practices without use of the oral care kits, no encouragement to perform outside of usual care
89047826|NCT05817474|Placebo Comparator|Group N|Group N (Control group): received 4 ml of normal saline in each tonsillar bed.
89047827|NCT05815251||Sphereplast group|Patients with osteoporotic vertebral compression fractures identified as candidates for kyphoplasty treatment with porous trabecular titanium microspheres
89047828|NCT05812560|Experimental|Intervetion|The intervention of the experimental group: application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
89047829|NCT05812560|No Intervention|Control|In the control group, each midwife will apply postural changes according to their usual practice. Differences with the experimental group: the choice of postural changes according to the stage of labor, its cadence and posture during the expulsive.
89047830|NCT05812170|Experimental|Educational online session about PF|Participants will attend an 90-minutes educational online session.
89047831|NCT05812170|No Intervention|Control|Despite the fact that all athletes will be invited to participate in the study, those who did not attend the educational session will be considered as control group. These participants will not receive any educational session or information about PF prior to be evaluated.
89661892|NCT04915170|Experimental|High intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 10 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
89661893|NCT04915170|Experimental|Low intensity group|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 10 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
89047834|NCT05808179|Experimental|Light + Cognitive Behavioral Therapy (CBT)|1 hour of light flashes (typical wake time - 75 min → typical wake time - 15 min) and cognitive behavioral therapy
89047835|NCT05808179|Active Comparator|Sham light + CBT|1 hour of sham light flashes (one flash) and cognitive behavioral therapy
89047836|NCT05805150|Experimental|Control Contact Lens, Then Test Contact Lens|Participants will wear control contact lenses for one week and then crossover to test contact lenses for one week.
89047837|NCT05805150|Experimental|Test Contact Lens, Then Control Contact Lens|Participants will wear test contact lenses for one week and then crossover to control contact lenses for one week.
89047838|NCT05805137|Experimental|Study subject with venous ulcer|The subjects will be monitored using the WoundWatch wound management system two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
89661894|NCT04907305||Feed-forward PRO|Participants in this group will participate in monthly learning collaborative webinars. Feed-forward of patient reported outcomes (PRO) data collected from the main study (NCT04735406) will be used.
89661895|NCT04907305||Control Group (Usual Care)|Participants in the control group will receive usual care practices during the clinical encounters.
89661896|NCT04900597|Experimental|Elecare - Nourish - Real Foods Blends|Elecare for first bolus, Nourish for second bolus, Real Foods Blends for third bolus
89661897|NCT04900597|Experimental|Nourish - Real Foods Blends - Elecare|Nourish for first bolus, Real Foods Blends for second bolus, Elecare for first bolus
89661898|NCT04900597|Experimental|Real Foods Blends - Elecare - Nourish|Real Foods Blends for first bolus, Elecare for second bolus, Nourish for third bolus
89661899|NCT04884971|Experimental|Microbiota Treatment Arm|Participants will receive the encapsulated microbiota intervention daily for seven days and will be subsequently monitored for six months.
89661900|NCT04881838|Experimental|High risk group|"Stage I, unresected; Stage I with B syndrome~Stage II~Stage III~Stage IV without CNS involvement"
89661901|NCT04875624||Hypoglycemic neonates|Preterm or small for gestational age neonates at risk for hypoglycemia who were found to be hypoglycemic during the screening for hypoglycemia
89661902|NCT04875624||Normoglycemic neonates|Preterm or small for gestational age neonates who were found to be normoglycemic during the screening for hypoglycemia
89661903|NCT04874493||Observational (questionnaire)|Patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.
89661904|NCT04871100|Experimental|UP-A|Cognitive behavior therapy using the Unified Protocol for Emotional Disorders with supplemental skills-based alcohol modules.
89661905|NCT04871100|Active Comparator|Problem Solving therapy|Skills based approach for managing negative moods and stress.
89661906|NCT04863118|Experimental|Strength training protocol performed in shallow water and dry land|Parkinson Disease and healthy individuals
89661907|NCT04863118|Experimental|High-intensity training protocol performed in shallow and deep water|Parkinson Disease and healthy individuals
89661908|NCT04862676|Experimental|Experimental Arm:single|Repeated treatments with hyperbaric oxygen on Days 0, +1 and +2 of high-dose therapy melphalan and autologous transplants.
89661909|NCT04849767||Transgender people living with HIV|Transgender person Living with HIV Followed in clinical service
89661910|NCT04846855|Experimental|Ropivacaine 35%|Local Anesthesia with Ropivacaine
89047839|NCT05780567|Experimental|TQB3616 capsules combined with endocrine|"The dose of TQB3616 capsules is 180mg, taken orally when fasting, once a day for 28 consecutive days as one treatment cycle.~The dose of Letrozole is 2.5mg, taken orally, once a day for 28 consecutive days as one treatment cycle.~The dose of Anastrozole is 1mg, taken orally, once a day for 28 consecutive days as one treatment cycle.~The dose of Tamoxifen is 10mg, taken orally, twice a day for 28 consecutive days as one treatment cycle."
89047840|NCT05780567|Placebo Comparator|placebo combined with endocrine|"The dose of placebo is 180mg, taken orally when fasting, once a day for 28 consecutive days as one treatment cycle.~The dose of Letrozole is 2.5mg, taken orally, once a day for 28 consecutive days as one treatment cycle.~The dose of Anastrozole is 1mg, taken orally, once a day for 28 consecutive days as one treatment cycle.~The dose of Tamoxifen is 10mg, taken orally, twice a day for 28 consecutive days as one treatment cycle."
89047841|NCT05751629|Experimental|Cohort A (Dostarlimab + Bevacizumab + Niraparib)|
89047842|NCT05744271|Experimental|FES+VFBT|Functional electrical stimulation combined with visual feedback balance training
89047843|NCT05736640|Active Comparator|Denosumab|
89047844|NCT05736640|Placebo Comparator|Placebo|
89047845|NCT05734014|Experimental|Intervention Group|The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
89047846|NCT05728294|Active Comparator|Femoral nerve block|Femoral nerve block performed under ultrasound guidance with ropivacaine 0.5%, 20mL
89047847|NCT05728294|Experimental|Sciatic nerve block|Sciatic nerve block performed under ultrasound guidance with ropivacaine 0.5%, 20mL
89661911|NCT04844528|Experimental|Treatment: all patients|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
89661912|NCT04844528|Placebo Comparator|Arm 2: Placebo|Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies.
89661913|NCT04839146|Experimental|Group 1: 6 microgram ABNCoV2 with/without MF59 adjuvant|In Group 1 (n=6), subjects will receive 6 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
89688655|NCT04363333||High Probability of OSA|Based on a sleep questionnaire
89688656|NCT04363333||Low Probability of OSA|Based on a sleep questionnaire
89047848|NCT05725577|Other|Care via the telemedicine system|Intervention
89047849|NCT05725577|Other|Standard care|Control
89047850|NCT05704829|Experimental|T-DXd: HER2+ and low-intermediate risk for recurrence|12 weeks T-DXd i.v. in neoadjuvant treatment; pCR dependent T-DXd for 1 year in total in postneoadjuvant treatment
89661914|NCT04839146|Experimental|Group 2: 12 microgram ABNCoV2 with/without MF59 adjuvant|In Group 2 (n=6), subjects will receive 12 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
89661915|NCT04839146|Experimental|Group 3: 25 microgram ABNCoV2 with/without MF59 adjuvant|In Group 3 (n=6), subjects will receive 25 μg ABNCoV2 intramuscularly, half of whom (n=3) will receive the non-adjuvanted vaccine formulation and the other half (n=3) will receive the MF59-adjuvanted vaccine formulation. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
89661916|NCT04839146|Experimental|Group 4: 50 microgram ABNCoV2 with/without MF59 adjuvant|In Group 4 (n=6), subjects will receive 50 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
89661917|NCT04839146|Experimental|Group 5: 70 microgram ABNCoV2 with/without MF59 adjuvant|In Group 5 (n=6), subjects will receive 70 μg non-adjuvanted or MF59-adjuvanted ABNCoV2 intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
89661918|NCT04839146|Experimental|Group 6: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 6 (n=6) will receive the next lower dosage of the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
89661919|NCT04839146|Experimental|Group 7: t.b.d. microgram ABNCoV2 with/without MF59 adjuvant|The subjects in Group 7 (n=6) will receive the highest non-adjuvanted or MF59-adjuvanted ABNCoV2 dose achieved intramuscularly. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination.
89661920|NCT04832373|Other|Humanoid Robot|
89047851|NCT05704829|Experimental|T-DXd: HER2+ and intermediate-high risk for recurrence|18 weeks T-DXd i.v. in neoadjuvant treatment; pCR dependent T-DXd for 1 year in total in postneoadjuvant treatment
89047852|NCT05704829|Other|Control: HER2+ and low-intermediate risk for recurrence|Standard-of-Care-Treatment: 12 weeks PAC+T+P (standard-of-care) in neoadjuvant treatment; pCR dependent SOC chemotherapy +T+/-P or SOC T+/-P for 1 year in total in postneoadjuvant treatment
89047853|NCT05704829|Other|Control: HER2+ and intermediate-high risk for recurrence|Standard-of-Care-Treatment: 18 weeks PAC/DOC+Carbo+T+P (standard-of-care) in neoadjuvant treatment; pCR dependent SOC chemotherapy +T+/-P or SOC T+/-P for 1 year in total in postneoadjuvant treatment
89047854|NCT05676840|Other|conventional niti arch wire group|all participants in this group will be placed conventional 014 niti lower archwire.
89047855|NCT05676840|Other|super elastic niti archwire group|all participants will be given super elastic 014 lower NiTi archwire.
89047856|NCT05676840|Other|thermal niti archwire group|all participants will be given thermal lower 014 niti archwire.
89047857|NCT05657366|Experimental|low and medium risk（a-FRS）lavage|alternative pancreatic fistula risk score system，a-FRS Low risk group (0~5%), medium risk group (>5%~20%), lavage
89047858|NCT05657366|No Intervention|low and medium risk（a-FRS） no lavage|alternative pancreatic fistula risk score system，a-FRS Low risk group (0~5%), medium risk group (>5%~20%), no lavage
89047859|NCT05657366|Experimental|high risk（a-FRS）lavage|alternative pancreatic fistula risk score system，a-FRS high risk group (>20%) lavage
89047860|NCT05657366|No Intervention|high risk（a-FRS）no lavage|alternative pancreatic fistula risk score system，a-FRS high risk group (>20%) no lavage
89047861|NCT05638347|Experimental|HRS-7085 tablets Cohort 1|Part 1- HRS-7085 tablets
89047862|NCT05638347|Experimental|HRS-7085 tablets Cohort 6|Part 1- HRS-7085 tablets
89047863|NCT05636748||Ischaemic Stroke|
89047864|NCT05633017||Pulmonary Rehab Patients|Patients who attend respiratory therapy at John Muir Pulmonary Rehab facility
89047865|NCT05633017||Control|Healthy adults, 18+
89047866|NCT05628142|Other|CATAMARAN SI Joint Fusion System|Subjects previously treated with the CATAMARAN Fixation Device
89047867|NCT05609474||Users (adolescents or young adults)|1430 users (adolescents and young adults) with addiction problems and consulting CJC for the first time
89047868|NCT05609474||Caregivers|715 caregivers
89047869|NCT05609474||Consultations Jeunes Consommateurs CJCs|"Initial survey (month 0) of participating CJCs: assessment of the structural characteristics of the CJCs (type of CJC (hospital, association), urban/rural area, number of users, number of consultations per month, type of workers...)~- Telephone interview at the 6th and 12th month: assessment of variables related to the user's pathway (referral to a specialized medical or social service…)"
89047870|NCT05591586|Active Comparator|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 5 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be <15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
89047871|NCT05591586|Experimental|Mobile video interpreting access (mVI)|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
89661921|NCT04820764|Experimental|CardioMech Mitral Valve Repair System (MVRS)|
89661922|NCT04810871|Experimental|Treatment (surgery)|Patients undergo surgery as indicated clinically when applicable.
89661923|NCT04791865|Active Comparator|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
89661924|NCT04791865|Experimental|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
89661925|NCT04791839|Experimental|Cohort A: Zimberelimab + Domvanalimab + Etrumadenant|"Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.~Cohort A participants are those that have PD-L1 1-49%"
89661926|NCT04791839|Experimental|Cohort B: Zimberelimab + Domvanalimab + Etrumadenant|"Patients will be treated on 21-day cycles with 360 mg zimberelimab intravenously on Day 1, 15 mg/kg domvanalimab intravenously on Day 1, and 150 mg etrumadenant orally daily on Days 1 to 21.~Cohort B participants are those that have PD-L1 ≥ 50%."
89661927|NCT04786847|Experimental|Single administration of 177Lu-DOTA-TLX591|Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart. This therapy will be administered with the current standard of care treatment regimens.
89661928|NCT04746872||Alinity m HR HPV|The Alinity m HR HPV IUO assay is a qualitative in vitro test that amplifies and detects HR HPV DNA in cervical cells collected in liquid media. The assay can differentiate between HPV 16, HPV 18, HPV 45 and non-HPV 16/18/45 genotypes [(31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68)].
89661929|NCT04740814|Experimental|Certolizumab pegol|Subjects in this arm will receive doses of certolizumab pegol for the treatment of Rheumatoid Arthritis, in accordance with the US label.
89661930|NCT04735406||Multiple Sclerosis (MS)|Data from the participants with diagnosed MS treated and untreated will be part of this study. Medical records of participants will be used to collect demographics and data pertaining to Multiple Sclerosis (MS) management.
89661931|NCT04730011|Experimental|Treatment Group|Patients are treated based on the Cognitive Behavioral Psychotherapy. This includes individual and group sessions over one week.
89661932|NCT04723498|Other|Patients|male and female patients, handled on an ambulatory basis in Psychiatric University Clinics, Department of Child and Adolescent Psychiatrythe ages from 8 - 18 years during the study
89661933|NCT04717375|Experimental|SAR444881 Dose Escalation (Sub-Part 1A)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 will be administered intravenously (IV), every 2 weeks (Q2W)."
89661934|NCT04717375|Experimental|SAR444881 in Combination with Pembrolizumab Dose Escalation (Sub-Part 1B)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and pembrolizumab will be administered intravenously (IV), every 3 weeks (Q3W)."
89661935|NCT04717375|Experimental|SAR444881 in Combination with Cetuximab Dose Escalation (Sub-Part 1C)|"Standard 3 + 3 dose escalation design with enrollment of at least 3 participants per dose level cohort. SAR444881 and cetuximab will be administered intravenously (IV), every 2 weeks (Q2W)."
89661936|NCT04717375|Experimental|SAR444881 Dose Optimization (Sub-Part 2A)|SAR444881 Dose Optimization in combination with pembrolizumab/carboplatin/pemetrexed, pembrolizumab, or cetuximab. The indication for the combination cohorts will be non-squamous non-small cell lung cancer (NSCLC), gastric cancer or gastro-esophageal junction adenocarcinoma (GC/GEJ), colorectal carcinoma (CRC) any RAS. Enrollment will start after the recommended dose(s) of SAR444881 have been determined based on data from Sub-Parts 1A, 1B, and 1C.
89661937|NCT04717375|Experimental|SAR444881 Dose Expansion (Sub-Part 2B)|The indication for this monotherapy cohort is cholangiocarcinoma. Enrollment will be opened based on emerging data from the dose-escalation phase and combination optimization data.
89661938|NCT04714944|Placebo Comparator|Placebo|isocaloric placebo
89047872|NCT05587920||Non-hormonal contraceptive users|Women not using any form of hormonal contraceptive.
89047873|NCT05587920||Combined oral contraceptive pill users|Women using the oral combined oral contraceptive pill.
89047874|NCT05587920||Hormonal IUS|Women using the hormonal intrauterine system contraceptive.
89047875|NCT05587920||Hormonal implant|Women using the hormonal contraceptive implant contraceptive.
89047876|NCT05587920||Hormonal injection|Women using the hormonal injection contraceptive.
89047877|NCT05564221|Experimental|YH35324|"There will be 4 dose groups of YH35324, escalating from low to high doses in a stepwise manner: 0.75 (Q2W), 3 (Q4W), 6 (Q4W), 6 (Q8W) mg/kg (Cohort 1 → Cohort 2, Cohort 2 → Cohorts 3 and 4).~YH35324 and placebo will be administered in a double-blinded manner."
89047878|NCT05564221|Placebo Comparator|Placebo|"There will be 4 dose groups of YH35324, escalating from low to high doses in a stepwise manner: 0.75 (Q2W), 3 (Q4W), 6 (Q4W), 6 (Q8W) mg/kg (Cohort 1 → Cohort 2, Cohort 2 → Cohorts 3 and 4).~YH35324 and placebo will be administered in a double-blinded manner."
89047879|NCT05564221|Active Comparator|Omalizumab|For Cohort 3, omalizumab 300 mg will be administered in an open-label manner.
89661939|NCT04714944|Experimental|whole fiber product|15 g for 2 weeks, followed by 30 g for 10 weeks
89661940|NCT04706741|Experimental|Izokibep and maintenance corticosteroid dose|Izokibep+ Prednisolon/Prednisone
89661941|NCT04706481||Healthy Control|Healthy subjects who have provided consent for specimen collection
89661942|NCT04706481||Cancer or Other Diseases|Diseased subjects who have provided consent for specimen collection
89661943|NCT04695626||Greenhouse Group|The patients in this group will be underwent Greenhouse tec to repair tendon tears.
89661944|NCT04695626||Traditional Single Row Group|The patients in this group will be underwent traditional single row repair to repair tendon tears.
89661945|NCT04691648||Xospata|Patients who receive Xospata® 40 mg tablet in routine clinical practice according to the drug label approved at the time of marketing authorization.
89047880|NCT05557357|Experimental|EA Group|Subjects assigned to EA group will receive EA treatment twice weekly for 5 weeks.
89047881|NCT05557357|Experimental|EAWN Group|Subjects assigned to EAWN group will receive EAWN treatment twice weekly for 5 weeks.
89661946|NCT04690595|Experimental|BAFFR-CAR T cells|B-cell activating factor receptor-Chimeric antigen receptor T cells
89661947|NCT04677946|Experimental|Healthy Cookie Group|All participants in the study
89661948|NCT04677920|Experimental|Healthy Cookie Group|All participants in the study
89661949|NCT04669899|Experimental|Stage 1, Dose Escalation: JTX-8064 monotherapy dose escalation|Dose Escalation, Stage 1 JTX-8064 Monotherapy. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies
89661950|NCT04669899|Experimental|Stage 2, Dose Escalation: JTX-8064 in combination with pimivalimab|Dose Escalation, Stage 2: JTX-8064 in combination with pimivalimab. Cohorts will enroll subjects with histologically or cytologically confirmed advanced/metastatic extracranial solid tumor malignancies
89661951|NCT04669899|Experimental|Stage 3 Expansion: JTX-8064 monotherapy (Ovarian)|Cohort will enroll subjects with advanced/metastatic PD-1/PD-L1 (PD-(L)1)-naïve, platinum-resistant ovarian cancer
89661952|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (ccRCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced clear cell renal cell carcinoma (ccRCC)
89661953|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (TNBC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1i-experienced triple negative breast cancer (TNBC)
89661954|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (HNSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, PD-L1+ head and neck squamous cell carcinoma (HNSCC)
89661955|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (Ovarian)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve, platinum resistant ovarian cancer
89661956|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (NSCLC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced non-small cell lung cancer (NSCLC)
89661957|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (cSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-experienced cutaneous squamous cell carcinoma (cSCC)
89661958|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (UPS & LPS)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with advanced/metastatic PD-(L)1-naïve undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS)
89661959|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (PD-(L)1i-experienced HNSCC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with PD-(L)1i-experienced HNSCC
89661960|NCT04669899|Experimental|Stage 4, Expansion: JTX-8064 in combination with pimivalimab (BTC)|JTX-8064 in combination with pimivalimab. Cohort will enroll subjects with biliary tract cancer (BTC), including intra-and extra-hepatic biliary duct cancer and cancer of the gallbladder. All subjects must have progressed on or after gemcitabine/cisplatin (Gem/Cis) in the metastatic setting, must have PD-(L)1 inhibitor resistance.
89661961|NCT04667481|Experimental|Arm I (aerobic exercise)|Patients participate in AE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and RE sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
89661962|NCT04667481|Experimental|Arm II (resistance exercise)|Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
89661963|NCT04667481|Experimental|Control Group (digital exercise interventions)|After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
89661964|NCT04661215||Symptoms of gastroparesis|Participants with symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0 (18/45 x 5)
89661965|NCT04661215||Control participants|Participants undergoing endoscopy for evaluation but without gastroparesis symptoms or gastroesophageal reflux symptoms. Score 1.0 or less (≤ 1 ) on the GCSI of Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) questionnaire
89661966|NCT04660201|Experimental|Group 1|AV7909 liquid formulation will be administered 0.5mL intramuscularly in a 2-dose schedule, 2 weeks apart (on Day 1 and Day 15). N=20
89661967|NCT04660201|Active Comparator|Group 2|AV7909 lyophilized formulation will be administered 0.5mL intramuscularly in a 2-dose schedule, 2 weeks apart (on Day 1 and Day 15). N=20
89661968|NCT04657146||Patients with suspected newly-diagnosed Glioblastoma (GBM)|Patients, ≥18 years of age, with newly diagnosed GBM, World Health Organization (WHO) Grade IV, undergoing gross total resection (defined as >90% of contrast enhancing volume removed on post-operative MRI) and collection of blood, bone marrow, and tumor.
89661969|NCT04657068|Experimental|Part A1|Part A1 will evaluate intermittent and continuous dosing of ART0380 monotherapy. Treatment will be given in 21-day cycles. Up to 50 participants will participate in this dose-escalation arm.
89661970|NCT04657068|Experimental|Part A2|Part A2 will evaluate intermittent dosing of ART0380 in combination with gemcitabine in 21-day cycles. Up to 21 participants will participate in this dose escalation arm.
89661971|NCT04657068|Experimental|Part A3|Part A3 will evaluate intermittent dosing of ART0380 in combination with irinotecan in 21-day cycles. Up to approximately 12 participants will participate in this dose escalation arm.
89661972|NCT04657068|Experimental|Part B1|"In Part B1, up to 3 cohorts making up to a total of approximately 90 participants with solid cancers with alterations in the ATM (ataxia-telangiectasia mutated) gene likely to predict for loss of ATM protein will be treated with either~ART0380 monotherapy Or~ART0380 in combination with irinotecan Or~ART0380 in combination with gemcitabine"
89688657|NCT02816710|Experimental|IVC Preoperative group|Conbercept injection before vitrectomy
89688658|NCT02816710|Experimental|IVC Postoperative group|Conbercept injection at the end of vitrectomy
89688659|NCT02816710|Experimental|IVC Pre- and Post-operative group|First conbercept injection before vitrectomy and second at the end of operation.
89688660|NCT04363411|Experimental|drug use|
89688661|NCT01929928||Surgical Patients|
89661973|NCT04657068|Experimental|Part B2|In Part B2, up to 110 participants with high grade serous ovarian, primary peritoneal, or fallopian tube carcinoma will be randomized (open label) 1:1 to either ART0380 in combination with gemcitabine or gemcitabine alone.
89661974|NCT04657068|Experimental|Part B3|Part B3: Patients with persistent or recurrent endometrial cancer (EC) will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle..
89661975|NCT04657068|Experimental|Part B4|Patients with advanced or metastatic solid tumors will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle.
89661976|NCT04634175|Experimental|Mind-body group|The mind-body group will practice mind-body intervention.
89661977|NCT04634175|Active Comparator|Sham group|The sham group will practice sham intervention.
89661978|NCT04629677||Cohort A (questionnaire, medical record review)|Patients complete a QoL questionnaire at 2-4 weeks and then 6-8 weeks after portal vein stenting procedure. Patients' medical records are also reviewed.
89661979|NCT04629677||Cohort B (medical record review)|Patients' medical records are reviewed retrospectively.
89661980|NCT04608045|Experimental|CPX-POM, 900 mg/m2 by 20 minute IV infusion|
89661981|NCT04605913|Experimental|Modified GCN+TTF treatment|The trial will compose of 2 parts with a total of 40 subjects. The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1. If 6 patients tolerate the dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).
89661982|NCT04593927||Mayzent|Patients administered Mayzent by prescription
89661983|NCT04593251|Experimental|CALY-002|
89047882|NCT05557357|Other|Waitlist Control Group|Subjects assigned to waitlist control group will not receive treatment during the 10-week waiting period after baseline assessment.
89047883|NCT05556564||No group|
89047884|NCT05550896||Mild to moderate AS|Patients with mild to moderate AS by echocardiography
89047885|NCT05550896||Controls|Age and sex match controls with no AS by echocardiography
89047886|NCT05540886|No Intervention|Control|Standard practices are expected at hospitals before the education intervention is deployed
89047887|NCT05540886|Experimental|Intervention|"The main intervention - the training of trainers/champions (ToT) will be delivered to selected facility cleaning champions from three or four hospitals within a certain month. Four sets of ToT are expected to happen during the study period."
89047888|NCT05517460|Experimental|experimental group I(auricular acupressure and usual care)|Experimental group I receives 8 weeks of auricular acupressure first, then interventions are stopped for two month as residual effect wash-out period. And after that Experimental group I receives 8 weeks of routine health care of constipation.
89047889|NCT05517460|Experimental|experimental group II(usual care and auricular acupressure)|Experimental group II receives 8 weeks of routine health care of constipation first, then interventions are stopped for two month as residual effect wash-out period. And after that Experimental group II receives 8 weeks of auricular acupressure .
89047890|NCT05511792|Experimental|TAVR with down sizing strategy|"Balloon sizing will be used during procedural. Pre-dilation with balloon size just below the annular size. 20mm for annular size of 20-23mm. 23mm for annular size 23-26mm.~Waist sign with less than mild contrast regurgitation: Evolut PRO Valve one size smaller than manufacturer recommendation and Target implant depth 0-3mm.~No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: Evolut PRO annular sizing (per manufacturer recommendation) with implant depth 0-3mm."
89047891|NCT05511792|Active Comparator|TAVR with standard sizing strategy|"Pre-dilation with balloon size just below the annular size. 20mm for annular size of 20-23mm. 23mm for annular size 23-26mm.~The prosthesis size of Evolut PRO will be chosen based on manufacturer recommendation. The target implant depth will be 0-3mm."
89047892|NCT05501561|Experimental|IIV-A Investigational|
89047893|NCT05501561|Experimental|aIIV-B Investigational|
89047894|NCT05501561|Experimental|aIIV-C Investigational|
89047895|NCT05501561|Active Comparator|Licensed IIV|
89047896|NCT05489081|Experimental|Implementation Resource Package Group|Teachers in this group will receive an implementation support package and receive support in using it within their classroom management practice. Also within the intervention group (experimental), will be students nested in the classrooms of the teachers that are assigned to the intervention group.
89047897|NCT05489081|No Intervention|Control Group|Within the control group (no intervention), teachers in this group will not receive the implementation support package nor extra support during the study period. They will continue to receive implementation support as usual. Also within the control group (no intervention) will be students nested in the classrooms of the teachers that are assigned to the control group.
89047898|NCT05468996|Active Comparator|young-old group|a group of patients who are 60 to 74 years old
89661984|NCT04593251|Placebo Comparator|Placebo|
89661985|NCT04571736|Active Comparator|access to the internet information platform|usual preoperative information and access to the internet information platform
89661986|NCT04571736|No Intervention|usual preoperative information|medical information delivered to the patient before any surgery
89661987|NCT04570020||Clinically-Selected Scleral Lens|The clinically-selected lens is based on slit lamp assessment. This lens will be compared against an OCT-selected lens.
89661988|NCT04570020||OCT-Selected Scleral Lens|The OCT-selected lens is based on OCT measurements. This lens will be compared against a clinically-selected lens.
89661989|NCT04569903|Experimental|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
89661990|NCT04567771|Experimental|Treatment (radiation therapy, questionnaires)|Patients undergo standard of care proton or intensity modulated radiation therapy. Patients also complete quality of life questionnaires and adverse event assessments over 10-15 minutes each at baseline, at the end of radiation therapy, and at 1 month, 1 year, and 3 years post-radiation therapy.
89661991|NCT04562623||Cohort A : High grade serous ovarian carcinoma|
89661992|NCT04562623||Cohort B :Breast carcinoma SBR grade II or III|Breast carcinoma SBR grade II or III superior to 3 cm
89661993|NCT04562623||Cohort C : Extended Breast carcinoma In situ|Extended Breast carcinoma In situ associated with invasive nodule carcinoma macroscopically visible and eligible to mastectomy
89661994|NCT04537624||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
89661995|NCT04530890|Experimental|One arm only|Only one arm with blood samples
89661996|NCT04525131|Experimental|CPX-POM|IV over 20 minutes once per day
89661997|NCT04461600|Experimental|AL101|The study included a lead-in cohort with 6 subjects at 6mg AL101 weekly. 13 additional patients were treated with 4mg AL101 weekly.
89661998|NCT04460807|Experimental|Exemestane|"Standard chemotherapy: paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.~+~Exemestane: single oral tablet of 25 mg/day until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
89661999|NCT04460807|Placebo Comparator|Placebo|"Standard chemotherapy : paclitaxel 175 mg/m2 + carboplatin AUC 5, on day 1 every 21 days ± bevacizumab 15mg/kg, on day 1 every 21 days. Chemotherapy will be administered for 6 cycles; Bevacizumab will be administered as up to a maximum of 22 cycles. Patients unfit for standard treatment can receive a weekly schedule of treatment or monotherapy with carboplatin alone. Neoadjuvant chemotherapy is allowed in patients unfit for primary elective surgery.~+~Placebo: single oral tablet until disease progression, unacceptable toxicity or physician/patient decision to withdraw, whichever comes first."
89662000|NCT04454463||Adult patients with NAFLD|1500 patients 18 years and older at the time of enrollment.
89662001|NCT04454463||Pediatric patients with NAFLD|750 patients 2 years or older and up to 17 years old at the time of enrollment.
89662002|NCT04419805|Experimental|Single Palatal TAD|Single Palatal TAD for orthodontic molar intrusion
89662003|NCT04419805|Experimental|Two buccal TADs|Two buccal TADs for orthodontic molar intrusion
89047899|NCT05468996|Active Comparator|old-old group|a group of patients who are equal or older than 75 years
89047900|NCT05468996|Active Comparator|young adult group|a group of patients who are 20-59 years old
89047901|NCT05431179|Experimental|Oral Ibrutinib|Open Label Ibrutinib Monotherapy Phase (16 weeks)
89047902|NCT05431179|Experimental|Arm A: IV Infusion of Ziloveramab and Oral Ibrutinib|Randomized, Double-Blind Treatment Phase
89047903|NCT05431179|Placebo Comparator|Arm B: IV Infusion of Placebo and Oral Ibrutinib|Randomized, Double-Blind Treatment Phase
89047904|NCT05410301|Experimental|Patients: sBE device applied during sleep, in combination with Lomustine and Bevacizumab|The sBE device is to be used 8 hours a day by the patients, during sleep, for 8 weeks, while also receiving standard chemotherapy Lomustine and Bevacizumab
89047905|NCT05410301|Experimental|Partners of Patients (who sleep in same bed): sBE|Up to 12 associated unaffected partners may agree to sleep within the investigational sBE device congruent with the period of exposure of their rGBM partner (8 weeks + possible extension)
89047906|NCT05409989|Other|Flow Re-Direction Endoluminal Device X|FRED™ X™ device
89047907|NCT05400434|Experimental|Randomized Standard-PCIT group|Participants enrolled in the randomized portion of the study and randomized to receive only Standard PCIT for a maximum of 18 weeks.
89047908|NCT05400434|Experimental|Randomized PCIT plus Natural Helper group|Participants enrolled in the randomized portion of the study and randomized to receive PCIT plus Natural Helper for a maximum of 18 weeks.
89047909|NCT05400434|Experimental|Opt-out Only Standard PCIT group|Participants enrolled in the non-randomized portion of the study and opted in to receive only Standard PCIT for a maximum of 18 weeks.
89047910|NCT05400434|Experimental|Opt-in PCIT plus Natural Helper group|Participants enrolled in the non-randomized portion of the study and opted in to receive PCIT plus Natural Helper for a maximum of 18 weeks.
89047911|NCT05390450|Experimental|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block.
89047912|NCT05390450|Experimental|Ultrasound-Guided Fascia Iliaca block|Patients in this group will receive Fascia Iliaca block.
89047913|NCT05387694|Experimental|Knee prosthesis group|
89047914|NCT05377411|Experimental|Optimized tDCS + Cognitive Training|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of up to 4.0mA direct current through two biocarbon rubber electrodes covered with at least 5mm-thick conductive electrode paste buffer, and placed over the optimized locations based on the international 10-20 system by using a combination of 10-20 EEG cap measurement and a stereotactic neuronavigation system. Stereotactic neuronavigation will be used as needed and may not be used on all participants.
89047915|NCT05377411|Sham Comparator|Sham tDCS + Cognitive Training|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of up to 4 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
89662004|NCT04416984|Experimental|ALLO-501A, ALLO-647|
89662005|NCT04398459|Experimental|iBRIAN|
89662006|NCT04394871||ALS4 Patients|Patients with ALS4 inherited defect in the senataxin (SETX) gene.
89662007|NCT04394871||Disease Control Participants|Disease control participants with mutation in other genes which alter RNA processing (e.g., RNASEH1+2 and loss of function SETX mutations in patients with ataxia and oculomotor apraxia type 2[AOA2]).
89662008|NCT04394871||Related, Unaffected Healthy Controls|Unrelated, unaffected healthy relatives of the ALS4 and disease control groups enrolled as controls.
89662009|NCT04394871||Unrelated, Healthy Controls|Unrelated, healthy volunteers who are age and sex matched to the affected ALS4 and disease control participants.
89662010|NCT04390646|Active Comparator|Pulsatile GnRH pump treatment|
89662011|NCT04390646|Placebo Comparator|Pulsatile placebo pump treatment|
89662012|NCT04373434|Experimental|Healthy Homes/Healthy Families (HH/HF) Intervention|Participants randomized to the HH/HF study intervention will work with a coach through phone calls and text messages for 12 weeks to set goals targeting home-based environmental determinants of dietary behaviors.
89662013|NCT04373434|Active Comparator|Control|Participants in the control condition will receive two mailings which focus on the same dietary outcomes as the HH/HF intervention but without the home environment emphasis.
89662014|NCT04349267|Experimental|BMS-986315|
89662015|NCT04349267|Experimental|BMS-986315 + nivolumab|
89662016|NCT04349267|Experimental|BMS-986315 + cetuximab|
89047916|NCT05375877|Other|Digital eHealth platform with connected mobile 1-lead ECGs + Standard of Care|"Patients will be fitted with a 1-channel ECG monitor after inclusion in the study and discharged to post ablation care. Here, ECGs are recorded regularly until the occurrence of an arrhythmic event. After the occurrence of an event, a discussion with the investigator will be performed. Interim medical contacts will be limited to the agreed-upon follow-up appointments for the long-term ECGs and other appointments routinely scheduled in the patient's care according to the Standard of Care.~long-term ECGs at defined time points"
89047917|NCT05366439|Experimental|AT-752|AT-752 administered orally for 14 days
89047918|NCT05366439|Placebo Comparator|Placebo|Matching placebo administered orally for 14 days
89047919|NCT05365230|Active Comparator|On-demand personalized follow-up care|On-demand personalized follow-up care (on-demand access to a Wellness Beyond Cancer Program (WBCP) nurse and an annual follow-up by telephone with WBCP nurse following the patient's annual mammogram). Both groups of participants will have yearly mammograms (current standard of care) organized by their healthcare provider.
89047920|NCT05365230|Active Comparator|Guideline-based follow-up care|Guideline-based follow-up care (i.e. current standard of care). Both groups will have yearly mammograms (current standard of care) organized by their healthcare provider.
89047921|NCT05339893|Sham Comparator|Affected Limb|"Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.~Within subject. Sham controlled. Double blind, the patient will not know whether they are receiving taVNS, all patients feel a ramp up current but only the active group will receive timed stimulation bursts during the robotic protocol that engages the affected limb. '"
89047922|NCT05339893|No Intervention|Unaffected limb|Patients will engage the robot first with their unaffected limb. This practice will ensure understanding and serve to activate the hemisphere ipsilateral to the impaired limb. Patients are likely to perform this activity quickly, there will not be any taVNS during this part of the procedure.
89047923|NCT05330793|Other|: Oral probiotic lozenges + placebo toothpaste (toothpaste without ADP-1)|1 active oral probiotic with placebo toothpaste
89047924|NCT05330793|Active Comparator|Oral probiotic lozenges + toothpaste with ADP-1|Oral probiotic and ADP1 toothpaste
89047925|NCT05330793|Placebo Comparator|Placebo lozenges (lozenges without oral probiotics) + placebo toothpaste (toothpaste without ADP-1)|Placebo without oral probiotics or ADP1 toothpaste
89047926|NCT05306977|Other|Pilot arm|Aims 1 and 2 of this project will be tested using a within-subjects design where anxiety patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right IPS.
89047927|NCT05297578|Experimental|Group 1|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
89047928|NCT05297578|Experimental|Group 2|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
89047929|NCT05297578|Experimental|Group 3|Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.
89047930|NCT05297578|Active Comparator|Group 4|Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
89047931|NCT05267496|Other|Conventional rehabilitation|Patients will receive conventional pulmonary rehabilitation
89662017|NCT04294160|Experimental|Dabrafenib + LTT462 backbone arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
89662018|NCT04294160|Experimental|Dabrafenib + LTT462 + trametinib triplet arm 1|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
89662019|NCT04294160|Experimental|Dabrafenib + LTT462 + LXH254 triplet arm 2|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
89662020|NCT04294160|Experimental|Dabrafenib + LTT462 + TNO155 triplet arm 3|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
89662021|NCT04294160|Experimental|Dabrafenib + LTT462 + spartalizumab triplet arm 4|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
89662022|NCT04294160|Experimental|Dabrafenib + trametinib + TNO155 triplet arm 5|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
89662023|NCT04294160|Experimental|Dabrafenib + LTT462 + Tislelizumab triplet arm 6|dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
89662024|NCT04287816|Experimental|Zero hard-boiled egg at 0 h|No eggs will be consumed on the test day. Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
89662025|NCT04287816|Experimental|One hard-boiled egg at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.
89662026|NCT04287816|Experimental|Two hard-boiled eggs at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
89662027|NCT04287816|Experimental|Three hard-boiled eggs at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
89662028|NCT04287816|Experimental|One hard-boiled egg at 3 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by 1 hard-boiled egg 3 hours after spinach consumption.
89662029|NCT04287816|Experimental|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by 1 egg 3 hours after spinach consumption.
89662030|NCT04286321|Experimental|Zero hard-boiled egg|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
89662031|NCT04286321|Experimental|Two egg whites|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two egg whites (0 g fat) prior to the 72-h pharmacokinetics trial.
89662032|NCT04286321|Experimental|Two hard-boiled eggs|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two whole eggs (9.6 g fat) prior to the 72-h pharmacokinetics trial.
89662033|NCT04286321|Experimental|Vegetable oil|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with vegetable oil (9.6 g fat) prior to the 72-h pharmacokinetics trial.
89662034|NCT04282148|Experimental|ABT NG DES 48 EECSS|Participants will receive ABT NG DES 48 EECSS device
89662035|NCT04242342|Experimental|Experimental arm|Patient with a localized primary tumor (hepatocellular carcinoma or cholangiocarcinoma) or a secondary hepatic localization of a solid carcinoma, with one to three hepatic lesions accessible to a treatment by stereotactic radiotherapy.
89662036|NCT04241666||normal renal function|individuals with renal clearance >89 ml/min/1.73m²
89662037|NCT04241666||mild renal insufficiency|individuals with renal clearance 60-89 ml/min/1.73m²
89662038|NCT04241666||moderate renal insufficiency|individuals with renal clearance 30-59 ml/min/1.73m²
89662039|NCT04229901|Experimental|HepaStem|Patients in the HepaStem arm will receive 2 infusions of HepaStem (i.v) at 1.0 million of cells/kg of total body weight (7 day interval)
89662040|NCT04229901|Placebo Comparator|Placebo|Patients in the placebo arm will receive 2 infusions of placebo (i.v) (7 day interval)
89662041|NCT04216953|Experimental|Atezolizumab + Cobimetinib|"Atezolimumab :~Adult Patient and patients ≥12 years-old with a BW ≥60kg: 840mg, Q2W~Pediatric Patient including patients ≥12 years-old with a BW <60kg: 15mg/kg, Q2W with a maximum of 840mg.~Cobimetinib :~Pediatric patients ≥ 12 and a BW < 60kg:1mg/kg. Pediatric patients ≥ 12 and with a BW ≥ 60kg: 60mg/d.~Adult Patients: 60mg/d D1 to D21 over a 28-day cycle."
89662042|NCT04209348|Experimental|Physical Activity Intervention|The behavioral physical activity (PA) intervention focuses on walking, or stepping in place when it is not possible to walk (e.g., stormy weather). The primary goal of the PA intervention is to achieve at least 30 minutes per day of walking/stepping in place. The secondary goal is to use a PA tracker (e.g., the Fitbit Charge 3 provided by the intervention) to log and review walking/stepping, and to accumulate at least 3,000 steps during their 30 minutes of walking/stepping each day.
89662043|NCT04209348|Active Comparator|Wellness Education|The Wellness Education intervention will deliver information on mom and baby wellness that is unrelated to physical activity, diet, metabolism, or weight (e.g., immunizations during pregnancy and encouragement to immunize the baby on schedule, postpartum contraceptive options and developing a contraceptive plan, infant car seats & safety checks).
89662044|NCT04171141|Experimental|Dose Escalation|Single Agent Dose Escalation
89662045|NCT04171141|Experimental|Dose Finding Anti-PD-1 Combination|Part 1B PF-07062119 plus anti-PD-1
89662046|NCT04171141|Experimental|Dose Finding anti-VEGF Combination|Part 1B PF-07062119 plus anti-VEGF
89662047|NCT04171141|Experimental|Dose Expansion Arm A|PF-07062119 as a Single Agent in CRC
89662048|NCT04171141|Experimental|Dose Expansion Arm B|PF-07062119 in Combination with anti-PD-1 in CRC
89662049|NCT04171141|Experimental|Dose Expansion Arm C|PF-07062119 in Combination with anti-VEGF in CRC
89047932|NCT05267496|Experimental|AEROBIKA|Patients will receive conventional pulmonary rehabilitation in addition to an oscillating positive expiratory pressure device
89047933|NCT05260944|Experimental|Group A|Group A. Thirty patients will receive a two supervised session using Acapella three sets for 10 repetitions two times daily from first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, Percussion and vibration).
89047934|NCT05260944|Experimental|Group B|Thirty patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days(André L.et al., 2016), in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration).
89662050|NCT04171141|Experimental|Dose Expansion Arm D|PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
89662051|NCT04169022|Experimental|AML patients at diagnosis|AML patients at diagnosis (except AML3)
89662052|NCT04169022|Experimental|AML patients at relapse|AML patients at relapse after chemotherapy, targeted therapy or allograft
89662053|NCT04163432|Experimental|Arm A: Chemo-Immuno|ArmA receives chemotherapy on D1 and immunotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
89047935|NCT05260944|Active Comparator|Group C|Thirty patients will receive only routine physical Therapy program.
89047936|NCT05260112|Experimental|ERICA|ERICA is a smartphone-based educational program that teaches women newly diagnosed with interstitial cystitis evidence-based strategies to self-manage their symptoms at home. The program is designed to bridge the interval/gap between initial visit where they are diagnosed with interstitial cystitis and follow up visit. Participants received video learning modules via a secure and HIPAA-compliant text messaging system.
89662054|NCT04163432|Experimental|Arm B: Immuno-Chemo|ArmB receives immunotherapy on D1 and chemotherapy on D8 of a 28-day cycle for the first 2cycles. After the first 2cycles, patients on Arm A and Arm B will be administered chemotherapy and immunotherapy on D1 of a 21day cycle for cycles 3 and 4. After 4cycles of chemo-immunotherapy, patients receive maintenance therapy with durvalumab and pemetrexed until treatment discontinuation. Maintenance therapy is administered on D1 of a 21day cycle.
89662055|NCT04144023|Experimental|Treatment (multi-epitope HER2 peptide vaccine H2NVAC, GM-CSF)|Prior to standard of care surgery, patients treated at dose levels 1 and 2 receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1 of each cycle. Treatment repeats every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients treated at dose level 3 receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on days 1, 4, 8, and 15 for 1 cycle. Patients also undergo ECHO and collection of blood samples throughout the trial and may undergo biopsy on trial.
89662056|NCT04141644|Experimental|Treatment: all patients|Patients entering trial should be on stable dose of osi for ≥4 weeks. Patients will self-administer osi by mouth regardless of food once daily. Doses should be taken at about the same time every day (±6hrs) and recorded on the patient dosing diary. Doses missed outside of the dosing window should not be made up but patients should be instructed to take their next dose at their regularly scheduled time. Ipi will be administered at the assigned dose level every 21 days (±3days) for a max of 4 doses. Ipi must be infused using a volumetric pump over 90min (±10min) through an IV line. Upon completion of the ipilimumab regimen, patients will continue osimertinib daily until disease progression, initiation of new anti-cancer therapy, or death by any cause.
89662057|NCT04106856|Experimental|Treatment (losartan, hypofractionated radiation therapy)|Beginning on day 1, patients receive losartan potassium PO QD. Beginning day 14, patients also undergo hypofractionated radiation therapy over 15 fractions 5 days a week for up to 3 weeks. Patients continue to receive losartan potassium PO QD during radiation therapy and for 28 days after completion of radiation therapy. Patients may begin additional anti-cancer therapy per investigator discretion after the last dose of HRT. Losartan can be given concurrently with additional therapy and Losartan dosing can continue until 28 days after last dose of HRT, regardless of when additional therapy is started.
89662058|NCT04103983|Active Comparator|Sensory Retraining Interactive Device|The interactive device is a sensory retraining device. A pad consisting of twelve equally spaced electrodes is placed over the residual limb. This pad is connected to a handheld device which delivers an electrical current to the electrodes. The type of electrical current is similar to a TENS device. The device stimulates the skin via one of the electrodes, with either a single, or a rapid burst of pulse(s). The device touch screen then presents the questions, Which electrode (location) was stimulated? Was a single continuous or a rapid burst of pulses given (stimulation type)? The user responds via the screen and is told if they are correct. If correct, a new stimulus is delivered (different location and type) and the process repeated. If incorrect, the user is informed of the correct response, the same stimulation (location and type) is repeated once before moving onto to a new stimulus.
89662059|NCT04103983|Placebo Comparator|Placebo Sensory Retraining Interactive Device|The placebo device is visually identical to the active device
89662060|NCT04103983|Active Comparator|Sensory Retraining Non-Interactive Device|The non-interactive device is physically visually identical to the interactive device. This device delivers the stimulation using microcurrents that the participants may or may not feel. There is no interaction required with this device i.e. there is no Q&A element, feedback nor response dependent progression.
89662061|NCT04103983|Placebo Comparator|Placebo Sensory Retraining Non-Interactive Device|The placebo device is visually identical to the active device
89662062|NCT04088864|Experimental|R/R B-ALL|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.~Lymphodepletion:~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2~Cyclophosphamide 900 mg/m2 per day IV on day -2~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
89662063|NCT04088864|Experimental|Lymphoma|"Subjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0.~Lymphodepletion:~Fludarabine 25 mg/m2 per day IV for days 4, 3, -2~Cyclophosphamide 900 mg/m2 per day IV on day -2~Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%))."
89662064|NCT04087772|Active Comparator|Mental Health-Enhanced PBIS|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
89662065|NCT04087772|Experimental|Mental Health-Enhanced PBIS + RED|PBIS-MH+RED involves the components of PBIS-MH integrated with racial/ethnic discrimination interventions (RED) to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
89662066|NCT04070443|Experimental|Induction phase with Ponatinib followed by Imatinib|"Ponatinib (Iclusig®) : Tyrosine Kinase Inhibitor (BCR-ABL); oral (tablets) : 30mg/day during 6 months (induction phase); Takeda & Incyte Biosciences.~Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months (then, depending of MR4.5)"
89662067|NCT04066244|Other|Cohort 1|Dose 1 of BLZ945
89662068|NCT04066244|Other|Cohort 2|Dose 2 of BLZ945
89662069|NCT04066244|Other|Cohort 3|Dose 3 of BLZ945
89662070|NCT04066244|Other|Cohort 4|Dose 4 of BLZ945
89662071|NCT04066244|Other|Cohort 5 Arm #1|Dose 4, Regimen 1 of BLZ945
89662072|NCT04066244|Other|Cohort 5 Arm #2|Dose 4, Regimen 2 of BLZ945
89662073|NCT04066244|Other|Cohort 5 Arm #1 extended treatment period|Dose 4, Regimen 1 of BLZ945
89047937|NCT05256836|Experimental|tablet group|A total of 36 sessions per week for 12 weeks of cognitive training program using a tablet computer are performed.
89047938|NCT05256836|No Intervention|control group|Subjects assigned to the control group did not receive any separate cognitive training for 12 weeks.
89213700|NCT04075877|Experimental|FOCUS|"Participants will complete a baseline survey battery and learn about The Hero's Journey. Starting at hospital discharge for 10 days, they will do the following: 1) identify which stage of The Hero's Journey they are experiencing; 2) take a picture of something good and write a caption describing the picture and provide advice; and 3) take a picture of something difficult or challenging during the day and write a caption for the photo and provide advice.~Daily text messages will remind participants to take the photographs, write the advice captions, upload both to the server, as well as to take a very brief daily survey. At the conclusion of day 10, participants will be asked to review their photos and captions and provide final advice in the form of a letter to other adolescents with SCD or cancer. Finally, they will complete a post-intervention battery."
89662074|NCT04066244|Other|Cohort 5 Arm #2 extended treatment period|Dose 4, Regimen 2 of BLZ945
89662075|NCT04058795|Experimental|Cancer Distress Coach (CaDC)|Participants in this group will get the mHealth CaDC app, which will give them tools based on cognitive behavioral therapy principles to manage their stress.
89662076|NCT04058795|Experimental|CaDC and mCoaching|Participants in this group will get both the CaDC app and weekly clinician support.
89662077|NCT04058795|Experimental|mCBT|Participants in this group will get 8-sessions with a therapist to receive cognitive behavioral therapy (CBT).
89047939|NCT05217004|Experimental|Dementia Talk|Participants in this group will be asked to use the mobile app Dementia Talk over a 2-week period.
89047940|NCT05217004|Experimental|CLEAR Dementia Care|Participants in this group will be asked to use the mobile app CLEAR Dementia Care over a 2-week period.
89047941|NCT05217004|No Intervention|Waitlist Control Group|Participants in this group will not use any of the apps.
89047942|NCT05206487|Experimental|Polydextrose|Patients will receive PDX 15 days prior and for a 6 month periods after TIPS.
89047943|NCT05203497|Experimental|The tested injected doses of 99mTc-ZHER2:41071 500 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose.~Subjects withdrawn from the study for any reason will be replaced."
89047944|NCT05203497|Experimental|The tested injected doses of 99mTc-ZHER2:41071 1000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose.~Subjects withdrawn from the study for any reason will be replaced."
89047945|NCT05181709|Placebo Comparator|Cohort 1: Placebo / Sodium Chloride|Participants in Cohort 1 will receive placebo given IN+IM in combination. Placebo administration will be given in an ambulatory setting. IN administration will be immediately followed by IM administration. Participants will be monitored by the research staff for 1-hour after administration. Participants will be permitted to receive any additional federally authorized or approved vaccines 56 days after receiving placebo.
89662078|NCT04058795|No Intervention|Control|Participants in this group can use mental health services commonly available to all cancer patients at their local medical facility but will not receive access to the CaDC app.
89662079|NCT03995966|Active Comparator|Subtype 2 Automatically Maintained SIB|
89662080|NCT03995966|Active Comparator|Subtype 3 Automatically Maintained SIB|
89662081|NCT03993132||Patients with type 2 diabetes|
89662082|NCT03987217|Experimental|Group I (resistance training)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minute each for 12 weeks.
89662083|NCT03987217|Experimental|Group II (resistance training, creatine supplementation)|Patients complete POWER resistance training program sessions twice weekly over 30-60 minutes each for 12 weeks and receive creatine monohydrate supplementation given orally 4 times daily during week 1, and then QD (once per day) during weeks 2-12.
89662084|NCT03976908|Experimental|ON-OFF|Patients receive the same baseline, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
89662085|NCT03976908|Experimental|OFF-ON|Patients receive the same baseline, a 6 week period of stimulation OFF (masked for both patient and investigator), one week of washout, a 6 week period of stimulation ON (masked for both patient and investigator), one week of washout, a 6 month follow-up period of open-label stimulation ON.
89662086|NCT03954535|Experimental|Intervention|9 sessions and website with entertainment features and resources
89662087|NCT03954535|Placebo Comparator|Control|website with entertainment features and resources
89662088|NCT03947619|Experimental|Experimental|"Subjects randomized to the experimental arm will have their heart unloaded for 30 minutes on the Impella CP® device prior to PCI.~Each site is required to have one roll-in per arm to test the study protocol before beginning enrollment."
89662089|NCT03947619|No Intervention|Control|"Primary PCI. Each site is required to have one roll-in per arm to test the study protocol before beginning enrollment."
89662090|NCT03928093|Experimental|Pregabalin followed by placebo|The study has a crossover design. Participants in this arm will receive pregabalin during the first study treatment period for ten weeks and placebo during their second ten-week treatment period . The dose will depend on the participant's weight and phase of treatment period. Each treatment period consists of 4 weeks of escalating dose until the desired maximum , 4 weeks of active treatment and 2 weeks of titrating down.
89662091|NCT03928093|Experimental|Placebo followed by Pregabalin|Participants will receive placebo during the first treatment period of the study(10 weeks) followed by 10 weeks of pregabalin treatment . The dose will depend on the participant's weight and phase of the treatment period . Each treatment period consists of 3 phases: 4 weeks of escalating dose until the desired maximum, 4 weeks of active treatment and 2 weeks of titrating down.
89662092|NCT03922932||Group A: PDR|This group will consist of 30 subjects with active proliferative diabetic retinopathy (PDR) and 30 subjects with treated PDR.
89662093|NCT03922932||Group B: NPDR|This group will consist of 60 subjects with severe non-proliferative diabetic retinopathy (NPDR), 60 subjects with moderate NPDR, and 60 subjects with mild NPDR.
89662094|NCT03922932||Group ME: Macular Edema|This group is a sub-set of 25 subjects from either Group A or B who have macular edema requiring treatment.
89662095|NCT03922932||Group C: DM without Retinopathy|This group will consist of 60 subjects with diabetes mellitus (DM) who do not have retinopathy.
89662096|NCT03922932||Group D: Healthy Controls|This group will consist of 50 subjects with healthy eyes who do not have diabetes.
88994736|NCT02928016|Experimental|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
89213701|NCT04075877|No Intervention|Control|"In a 30-min visit (in person or virtual) with adolescents during hospitalizations, we will have participants complete a baseline survey battery.~Daily text messages will remind participants to take a very brief daily survey. At the conclusion of day 10, participants will complete a post-intervention battery."
89213702|NCT00874484|Experimental|1|
89213703|NCT00874484|Placebo Comparator|2|
89213704|NCT00869492|Other|A|instructed nadifloxacine 1% cream twice dailly, and placebo for benzoyl peroxide 5% solution once dailly
89662097|NCT03900949|Experimental|Treatment (gemtuzumab ozogamicin, cytarabine, daunorubicin)|INDUCTION THERAPY: Cytarabine intravenously (IV) on days 1-7, daunorubicin IV on days 1-3 and midostaurin 50 mg orally (PO) twice daily (BID) on days 8-21. Gemtuzumab ozogamicin IV may be given either on days 1, or days 1 and 4 or days 1, 4 and 7. RE-INDUCTION THERAPY: Between days 14 and 21 of Induction Therapy, patients may receive a single 28-day cycle of cytarabine and daunorubicin with or without midostaurin per the treating physician. Patients may also undergo allogeneic stem cell transplantation (SCT) or receive consolidation therapy. CONSOLIDATION THERAPY: PATIENTS < 60 YEARS: high dose cytarabine (HiDAC) IV on days 1, 3, and 5 and gemtuzumab ozogamicin IV on day 1 of cycle 1 and midostaurin 50 mg PO BID on days 8-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. PATIENTS >= 60 YEARS: Same as above except cytarabine (MiDAC) IV on days 1, 3, and 5.
89662098|NCT03899467|Experimental|Arm 1: 400 mg /day of GT0918|"Group 1: Post enzalutamide failure~Group 2: Post abiraterone failure"
89662099|NCT03899467|Experimental|Arm 2: 500 mg/day of GT0918|"Group 1: Post enzalutamide failure~Group 2: Post abiraterone failure"
89662100|NCT03895827|Active Comparator|Passive Referral Control|Participants will be given information on recently expanded and publicly-funded MAT treatment in their community.
89662101|NCT03895827|Experimental|Recovery Initiation and Management after Overdose (RIMO)|Participants assigned to the RIMO arm will meet with Linkage Managers (LM), who will use motivational interviewing (MI) techniques to: 1) identify the need for treatment and barriers to going, 2) discuss with patients the benefits of their decision to go to treatment, including activities they might enjoy as well as things they do not like about their alcohol/substance use, 3) provide personalized feedback to participants about the status of their condition based on responses to the assessment instruments, 4) help participants resolve ambivalence about their use and move them toward a commitment to change by accessing additional care, 5) address existing barriers to treatment (e.g., childcare, transportation), 6) schedule a treatment appointment, and 7) facilitate medication assisted treatment re-entry and engagement.
89662102|NCT03878199|Experimental|Treatment (CPX-351, ruxolitinib, allogeneic SCT)|See Detailed Description.
89662103|NCT03839459|Experimental|Denosumab|
89662104|NCT03818685|Experimental|Nivolumab + Ipilimumab|Nivolumab (360 mg IV, every 3 weeks) for 8 doses and Ipilimumab (1 mg/kg, IV, every 6 weeks or every 2 doses of Nivolumab in case of dose delays) for 4 doses.
89662105|NCT03818685|Active Comparator|Capecitabine|Capecitabine (1000 mg/m2 twice a day, Bis In Die), 14 days on / 7 days off for 8 cycles.
89662106|NCT03811834|Experimental|Mobocertinib 160 mg and [14C]-Mobocertinib 50 mcg + [14C]-Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once under fasted state, followed by [14C]-mobocertinib 50 mcg (approximately 2 microcurie [mcCi]), infusion, intravenously, once on Day 1 of Period 1, further followed by a washout period of 9 days, followed by [14C]-mobocertinib 160 mg (approximately 100 mcCi), solution, orally, once under fasted state on Day 1 of Period 2.
89662107|NCT03786692|Experimental|Arm A|Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab
89662108|NCT03786692|Active Comparator|Arm B|Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab
88994737|NCT02928016|Experimental|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
88994738|NCT02928016|Experimental|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
88994739|NCT02928016|Experimental|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
89213705|NCT00869492|Other|B|instructed nadifloxacine 1% cream twice dailly, and active benzoyl peroxide 5% solution once dailly
89213706|NCT00489424|Experimental|Acetaminophen|2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
89213707|NCT00489424|Experimental|Fluvastatin|2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
88994740|NCT02927899|Experimental|Prevention (dietary intervention, survey)|Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption, and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
88994741|NCT00148694|Experimental|Intervention single arm|Cisplatin 75mg/m2 q21 days x 4 pre-surgery
88994742|NCT02927704||case (Aggressive periodontitis)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
88994743|NCT02927704||control (Periodontally healthy subjects)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
88994744|NCT02927782|Active Comparator|Bed Rest|48 hours of strict bed rest after incidental durotomy during lumbar spinal surgery
88994745|NCT02927782|Experimental|Early Mobilization|Immediate Mobilization after incidental durotomy during lumbar spinal surgery
88994746|NCT02927665||Study Subjects|Eligible subjects receiving ReShape Integrated Dual Balloon System treatment in a commercial clinical setting
89662109|NCT03786081|Experimental|A: Tisotumab Vedotin + bevacizumab|Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients
89662110|NCT03786081|Experimental|B: Tisotumab vedotin + pembrolizumab|Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
88994747|NCT03457480|Experimental|Prevention (text messages, computer messages)|"PHASE I: Participants attend focus group over 2 hours.~PHASE II: Participants receive 2 text messages per day for 30 days at baseline and after 3 months.~PHASE III: Participants read 64 computer messages with or without images over 30 minutes and have their facial expressions assessed."
88994748|NCT02927743|Active Comparator|evidence-based online feedback|During three months GPs will receive weekly feedback about evidence-based management of respiratory tract infections. In order to control that they read the material, there is a questionnaire, they have to fill in every week
88994749|NCT02927743|No Intervention|control|GPs will register data without receiving online feed-back
88994750|NCT02927626|Experimental|Yang Yin Fu Zheng therapy|
88994751|NCT02927626|Placebo Comparator|Routine medical care|
89662111|NCT03786081|Experimental|C: Tisotumab vedotin + carboplatin|Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients
89662112|NCT03786081|Experimental|D: Tisotumab vedotin + carboplatin|Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients
89662113|NCT03786081|Experimental|E: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients
88994752|NCT00176046|Experimental|viscum album pini|immediate start of treatment with Iscador P s.c.
88994753|NCT00176046|Active Comparator|waiting group|identical treatment with Iscador P s.c. after waiting period of 3 months
88994754|NCT02927587|Experimental|The induction Cet of propofol 1|The induction Cet of propofol was targeted at 1 ug/ml.
88994755|NCT02927587|Other|The induction Cet of propofol 2|The induction Cet of propofol was targeted at 2 ug/ml.
88994756|NCT02927353|Experimental|DMB-3113|adalimumab biosimilar
88994757|NCT02927353|Active Comparator|adalimumab|adalimumab
88994758|NCT00176085||healthy|healthy volunteers
89213708|NCT00489424|Placebo Comparator|Placebo|2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
89662114|NCT03786081|Experimental|F: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
89662115|NCT03786081|Experimental|G: Tisotumab vedotin monotherapy|Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.
89662116|NCT03786081|Experimental|H: Tisotumab vedotin + pembrolizumab + carboplatin +/- bevacizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab and carboplatin with or without bevacizumab once every three weeks in previously untreated patients
89662117|NCT03777722|Experimental|Aim 1: Active Intervention then Placebo|Tailored Lighting intervention (TLI). The active TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The active lighting intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the placebo control intervention for 8 weeks.
89662118|NCT03777722|Experimental|Aim 1: Placebo Intervention then Active|The placebo lighting intervention is designed to have no effect on the circadian system. The control intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the active tailored lighting intervention for 8 weeks.
88994759|NCT02927314|Placebo Comparator|Placebo|Placebo tablets orally q12h
88994760|NCT02927314|Active Comparator|CF102 12.5mg|CF102 tablets orally q12h
88994761|NCT02927314|Active Comparator|CF102 25mg|CF102 tablets orally q12h
88994762|NCT00148889|Sham Comparator|2|Sham-stimulation
88994763|NCT00148889|Active Comparator|1|Active GPI-DBS
88994764|NCT02927275|Experimental|Standing Modality|Performance on computerized cognitive tests while standing at a desk. Experimental: Standing Modality
88994765|NCT02927275|Experimental|Biking Modality|Performance on computerized cognitive tests while biking at user's preferred speed on stationary bicycle. Experimental: Biking Modality
88994766|NCT02927275|Experimental|Walking Modality|Performance on computerized cognitive tests while walking at 1mph. Experimental: Walking Modality
89662119|NCT03752398|Experimental|XmAb®23104 Monotherapy|XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles
89662120|NCT03752398|Experimental|XmAb®23104 Combination Therapy with Ipilimumab|XmAb®23104 administered by IV on Days 1 and 15 of each 28-day cycle x 2 cycles + Yervoy® (ipilimumab)
89662121|NCT03713970|Experimental|Celtra duo press|Celtra duo press ingot 20g for three laminate veneers
89662122|NCT03713970|Active Comparator|IPS e.max press|IPS e.max press ingot 20g for three laminate veneers
89662123|NCT03680820||Ages 5-9, gastroparesis|Participants 5-9 years of age at screening with documented gastroparesis (delayed gastric emptying)
89662124|NCT03680820||Ages 5-9, gastroparesis-like syndrome|Participants 5-9 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
89662125|NCT03680820||Ages 10-17, gastroparesis|Participants 10-17 years of age at screening with documented gastroparesis (delayed gastric emptying)
89662126|NCT03680820||Ages 10-17, gastroparesis-like syndrome|Participants 10-17 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
89662127|NCT03648372|Experimental|Phase 1, Dose Escalation Cohort: TAK-981|TAK-981, intravenously, administered as 60 minute-infusion, once on Days 1, 4, 8, and 11 in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study. If clinical safety, pharmacokinetics, and pharmacodynamics are supportive, the dosing schedule may be modified to evaluate a less intensive administration of TAK-981 on Day 1, or Days 1 and 8, or Day 1, Day 8, and Day 15 in 21-day cycles in participants with advanced or metastatic solid tumors or lymphomas. Dose levels will be escalated based on the Bayesian logistic regression modeling (BLRM). The dose escalation phase will determine the RP2D of TAK-981.
89662128|NCT03648372|Experimental|Phase 2, Cohort A: Nonsquamous NSCLC|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with nonsquamous non-small cell lung cancer (NSCLC).
89662129|NCT03648372|Experimental|Phase 2, Cohort B: Cervical Cancer|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with cervical cancer.
89662130|NCT03648372|Experimental|Phase 2, Cohort C: MSS-CRC|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with microsatellite-stable colorectal cancer (MSS-CRC).
89662131|NCT03648372|Experimental|Phase 2, Cohort D: r/r DLBCL after CAR T-cells therapy|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after prior chimeric antigen receptor (CAR) T-cells therapy.
89662132|NCT03648372|Experimental|Phase 2, Cohort E: r/r DLBCL without prior cellular therapy|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory DLBCL that have not received prior cellular therapy.
89662133|NCT03648372|Experimental|Phase 2, Cohort F: r/r Follicular Lymphoma|TAK-981 intravenously administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory follicular lymphoma (FL).
89662134|NCT03632135|Active Comparator|Physician Choice treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the Physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Carboplatin;~Irinotecan;~Etoposide;~BCNU;~CCNU;~Temozolomide;~Procarbazine;~Vincristine;~Imatinib;~Procarbazine, CCNU, Vincristine;~Carboplatin, Irinotecan;~Carboplatin, Etoposide;~Temozolomide, Etoposide;~Temozolomide, Imatinib. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
89662135|NCT03632135|Experimental|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Carboplatin;~Irinotecan;~Etoposide;~BCNU;~CCNU;~Temozolomide;~Procarbazine;~Vincristine;~Imatinib;~Procarbazine, CCNU, Vincristine;~Carboplatin, Irinotecan;~Carboplatin, Etoposide;~Temozolomide, Etoposide;~Temozolomide, Imatinib.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
89662136|NCT03624543|Experimental|Cohort 1: TNBC|N=9 to 24 patients
89662137|NCT03624543|Experimental|Cohort 2: PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
88994767|NCT02927275|Other|Seated Modality|Performance on computerized cognitive tests while sitting. No Intervention: Seated Modality
88994768|NCT00176124|No Intervention|1|storage and transfusion of autologous whole blood without leukocyte depletion : Control group
88994769|NCT00176124|Experimental|2|storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
88994770|NCT02927470|Experimental|Working memory task|Simple visual stimuli (e.g., dots, colors, lines) will be presented on a computer monitor. The positions of the stimuli must be attended and remembered and decisions about the stimuli and/or their locations must be made. Memory will be probed with a button press or an eye movement towards the remembered locations.
88994771|NCT02927197|Experimental|LearningRx Cognitive Training|The intervention is a 60-hour one-on-one cognitive training program
88994772|NCT02927197|No Intervention|Waitlist Control|The treatment-as-usual control group will begin the intervention when the experimental arm has completed the intervention.
88994773|NCT02927002|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the 30-minute stimulation period
88994774|NCT02927002|Sham Comparator|Noninvasive brain: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of 30-minute stimulation period.
88994775|NCT02927119||Non-users|Pregnant women who had not taken dietary iodine supplement before and during pregnancy.
88994776|NCT02927119||Users|Pregnant women who had taken dietary iodine supplement before and/or during pregnancy.
88994777|NCT02927041||OR-Trauma|Patients presenting with hemodynamic instability with expected intubation greater than 24 hours. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
89047946|NCT05181709|Active Comparator|Cohort 2: NDV-HXP-S low dose IN|Participants in Cohort 2 (low, IN) will receive a single administration of a low dose of NDV-HXP-S at 3.3x108 Egg-Infectious Dose50 (EID50). Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
89047947|NCT05181709|Active Comparator|Cohort 3: NDV-HXP-S low dose IM|Participants in Cohort 3 (low, IM) will receive a single administration of a low dose of NDV-HXP-S at 3.3x108 Egg-Infectious Dose50 (EID50). Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
89047948|NCT05181709|Active Comparator|Cohort 4: NDV-HXP-S low dose IN+IM in combination|Participants in Cohort 4 (low, IN+IM) will receive low doses of NDV-HXP-S at 3.3x108 EID50. Participants will be given NDV-HXP-S in an ambulatory setting where IN and IM doses will be given in succession. Participants will be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
89047949|NCT05181709|Active Comparator|Cohort 5: NDV-HXP-S high dose IN|Participants in Cohort 5 (high, IN) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 5 if Cohort 2 (low dose IN) did not have any SAEs that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
89047950|NCT05181709|Active Comparator|Cohort 6: NDV-HXP-S high dose IM|Participants in Cohort 6 (high, IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 6 if Cohort 3 (low dose IM) did not have any SAEs that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
89047951|NCT05181709|Active Comparator|Cohort 7: NDV-HXP-S high dose IN+IM in combination|Participants in Cohort 7 (high, IN+IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will only enroll into Cohort 7 if Cohort 4 did not have an SAE that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collection and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
89047952|NCT05166460|Experimental|Surgery utilizing the Kidney Skinn cooling device|All patients in Part A, and those randomized to the Kidney Skinn arm in Part B, will receive transplant surgery in the traditional fashion with the exception that the renal allograft will be placed in the cooling device at the initiation of the vascular anastomosis. Cold saline irrigation flowing through the device will be used to maintain renal hypothermia for the duration for the vascular anastomosis. After the vascular clamps are released, the device will be removed.
89047953|NCT05166460|No Intervention|Standard transplant surgery practice|Standard transplant surgery per site practice
89047954|NCT05110495|Experimental|Xentuzumab|All patients will be allocated to receive Xentuzumab
89047955|NCT05108883|No Intervention|standard care arm|decision whether a patient will be hospitalized or be treated as out-patient is based on routine clinical assessment and usual protocols
89047956|NCT05108883|Experimental|MR-proADM guided arm|decision whether a patient will be hospitalized or be treated as out-patient is based on routine clinical assessment, usual protocols and MR-proADM levels
89047957|NCT05094011|Experimental|Single Arm Study|Autologous MitoCell Transplantation in Subjects with Idiopathic Parkinson's Disease
89047958|NCT05086276|Active Comparator|FX-322|FX-322, 1 dose
89047959|NCT05086276|Placebo Comparator|Placebo|Placebo, 1 dose
89047960|NCT05065294|Experimental|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately three weeks apart, with preparation sessions before and integration sessions after.
89662138|NCT03624543|Experimental|Cohort 3: Not PTEN-null, ER+ and/or PR+, HER2-|N=9 to 24 patients
89662139|NCT03609866|Active Comparator|control|will be performed metatarsophalangeal joint passive mobilization
89047963|NCT05016375||T2DM|Individuals with T2DM.
89047964|NCT04990609|Experimental|Neoadjuvant chemotherapy (NAC) plus Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA)|
89047965|NCT04968899|Experimental|Experimental group|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21
89047966|NCT04968899|Active Comparator|Control|IVIg (1g/kg D1-D2) plus prednisone (1 mg/kg/day x 21 days (3 weeks))
89047967|NCT04965818|Experimental|Futibitanib in combination with binimetinib|"Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease.~Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC"
89662140|NCT03609866|Experimental|experimental|rapid thoracic compression technique will be applied
89662141|NCT03599206|Experimental|Ozone|
89662142|NCT03599206|Placebo Comparator|Filtered Air|
89662143|NCT03587805|Experimental|Tralokinumab, all subjects|"Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~From Week 2 up to Week 266*: SC injection of tralokinumab maintenance dose.~*The length of treatment for each subject will depend on when they enter the trial, and on which parent trial and country they come from."
89662144|NCT03567577|Experimental|Solnatide 5mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered
89662145|NCT03567577|Experimental|Solnatide 60mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered
89662146|NCT03567577|Experimental|Solnatide 125mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered
89047968|NCT04963205|Experimental|Adjustable bed backrest|Sleeping in elevated body position (>30 degrees from supine position) for 4 weeks is a requirement for the intervention group. Patients can define their own most comfortable position during the night.
89047969|NCT04963205|Active Comparator|Usual bed|"Sleeping in a standard bed and flat (<30 degrees from supine position) position for 4 weeks. Patients can define their own most comfortable position during the night."
89047970|NCT04957693|Experimental|treatment arm|vegan diet and lifestyle change
89047971|NCT04941105|Experimental|PCSK9 inhibitor (evolocumab)|140 mg of evolocumab as a single subcutaneous injection and standard of care accordance to the latest recommendations
89047972|NCT04941105|Placebo Comparator|Usual Care|1 ml of 0,9% saline solution as a single subcutaneous injection. Patients will be treated in accordance to the latest recommendations on caring for patients infected with SARS-CoV-2.
89662147|NCT03567577|Placebo Comparator|Placebo|0,9% saline solution
89662148|NCT03539614|Experimental|Open label, blinded discontinuation, prazosin, placebo|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this first arm, participants will spend 4 weeks on active treatment (prazosin), followed by 4 weeks on placebo."
89047973|NCT04925687|Experimental|Intravitreal autologous CD34+ cells|Intravitreal injection of autologous CD34+ cells harvested from bone marrow under GMP conditions
89047974|NCT04922632|Experimental|Transcendental Medication (TM)|Transcendental Meditation (TM): a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
89047975|NCT04922632|Experimental|Experience Resolution Methodology (ERM)|Experience Resolution Methodology (ERM): is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
89047976|NCT04922632|Experimental|TM+ERM|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM): an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
89662149|NCT03539614|Experimental|Open label, blinded discontinuation, placebo, prazosin|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this second arm, participants will spend 4 weeks on placebo, followed by 4 weeks on active treatment (prazosin)."
89662150|NCT03538899|Experimental|Gene therapy (AProArt)|Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells. The CliniMACS® CD34 Reagent System sorter device will be used to select CD34 cells. Patients will be conditioned with low dose busulfan prior to transplant.
89662151|NCT03535350|Experimental|Unmethylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation over 6 weeks. Patients will undergo a 4-week break and then Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
89662152|NCT03535350|Experimental|Methylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks. Patients will undergo a 4-week break and patients will then receive daily ibrutinib and adjuvant Temozolomide for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. The temozolomide will continue until disease progression, intolerable toxicity, or death or maximum of 6 cycles. Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
89662153|NCT03518567|Experimental|High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose [6% THC])
89662154|NCT03495388||Major Inpatient Surgeries|Children ages 8-17.9 undergoing pectus excavatum or idiopathic scoliosis spinal fusion at Riley Hospital for Children, who have consented to participate in an observational clinical study as approved by the IU IRB, protocol #1707525204.
89662155|NCT03467360|Experimental|One experimental arm|non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer
89662156|NCT03384537|Experimental|Listerine total care zero|Listerine total care zero
89662157|NCT03384537|Active Comparator|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
89047977|NCT04922632|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU): is the existing Duke Health & Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
89662158|NCT03380143|Experimental|Wellscapes Intervention|The wellness landscape intervention (Wellscapes) will establish a multi-level system infrastructure (Community Hub, Organization Wellness Teams, Activity Setting/Leaders) and provide training and support for population health quality improvement cycle processes targeting two evidence-based practices (EBPs): (1) stacking time segments of PA episodes within an organization's daily routine, and (2) improving the quality of PA episodes (% time in PA).
89662159|NCT03380143|Active Comparator|Standard Practice|The standard collective impact public health practice intervention will establish a multi-level system infrastructure and provide training on community development.
89662160|NCT03365609|Experimental|T-group|T-group(triple therapy)
89662161|NCT03365609|Experimental|S-group|S-group( sequential therapy)
89662162|NCT03365609|Experimental|B-group|B-group( bismuth quadruple therapy )
89662163|NCT03365609|Experimental|C-group|C-group( concomitant therapy)
89688662|NCT04363255|Experimental|Maintenance group|After 4-6 cycles of EP/EC chemotherapy regiment, maintenance therapy with toripalimab and anlotinib was followed and continued until disease progression.
89688663|NCT02818114|Experimental|PEET|Peer support interventions as an adjunct to prolonged exposure
89662164|NCT03348761|Experimental|rTMS Group|"Phase I: A Magstim Super-Rapid device with a 70-mm figure-of-eight double air film coil (Magstim Ltd, UK) and Brainsight neuronavigation (Rogue Resolutions Ltd, Canada) are used. Stimulation parameters: 10 Hz, 120% resting motor threshold, 30 trains of 5 seconds with 25 seconds rest, 3000 pulses per day delivered 5 days per week (total: 60000 pulses).~Phase II: MagVita X100 (FDA approved device) will be used to deliver intermittent theta burst stimulation (iTBS) to left DLPFC, comprising of 18 cycles of 10 bursts. Each burst is triplet of pulses discharged at 50 hz and the burst frequency is 5Hz. Between two cycles of bursts is 8-second inter-train rest. The device output is set at 120% above the resting motor threshold"
89662165|NCT03344848|Experimental|Single Arm|Implanted with the Orion Visual Cortical Prosthesis System
89662166|NCT03337646|Other|Lisdexamphetamine|All participants will receive Lisdexamfetamine Dimesylate (LDX) at an optimized dose based on protocol
89662167|NCT03326245|Active Comparator|1:Oral MP- IV PL|Oral Methylphenidate /IV Placebo
89662168|NCT03326245|Active Comparator|2 Oral PL/IV MP|Oral Placebo/IV Methylphenidate
89662169|NCT03326245|Placebo Comparator|3: Oral PL/IV PL|Oral Placebo/IV Placebo
89662170|NCT03304418|Experimental|Radium Ra 223 dichloride and radiation, all patients|
89662171|NCT03265808|Experimental|allogeneic human mesenchymal stem cells (allo-hMSCs)|Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
89662172|NCT03265808|Placebo Comparator|Placebo|Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
89662173|NCT03259035|Experimental|chemotherapy (FOLFOX or CAPOX) followed by tumour excision|
89662174|NCT03251079|Experimental|Continuous Glucose Monitoring Device|Senseonics continuous glucose monitoring system
89662175|NCT03250832|Experimental|Part 1a: TSR-033 monotherapy dose escalation|Part 1a will evaluate TSR-033 at ascending doses (20 milligrams [mg], 80 mg and 240 mg) every 2 weeks. Cohorts will be enrolled sequentially and will initially follow a 3+3 design at a starting dose of 20 mg.
89662176|NCT03250832|Experimental|Part 1b: TSR-033 monotherapy PK/PDy characterization|Part 1b will evaluate the PK profile and assess PDy data from blood and tumor tissue samples following TSR-033 treatment. The participants will begin treatment with TSR-033 on Day 1 followed by 28 days observation for collection of blood sampling for PK/PDy. Participants will receive their second dose of TSR-033 on Day 29 and every 14 days thereafter.
89662177|NCT03250832|Experimental|Part 1c: TSR-033+dostarlimab combination dose escalation|Participants will be administered ascending doses of TSR-033 in combination with dostarlimab 500 mg every 3 weeks. Planned dose levels of TSR-033 include 80 and 240 mg.
89662178|NCT03250832|Experimental|Part 2 Cohort A: TSR-033+dostarlimab combination|Part 2 Cohort A will evaluate the preliminary activity of TSR-033 in combination with dostarlimab in anti-PD-1 naive participants with third and fourth line MSS-CRC. TSR-033 will be administered every 2 weeks and dostarlimab every 6 weeks.
89662179|NCT03250832|Experimental|Part 2 Cohort B1: TSR-033+dostarlimab with mFOLFOX6|Part 2 Cohort B1 will evaluate the preliminary activity of TSR-033 administered every 2 weeks (Q2W) in combination with dostarlimab administered every 6 weeks (Q6W) along with mFOLFOX6 and bevacizumab (standard of care [SOC]) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFIRI, with or without biologics.
89662180|NCT03250832|Experimental|Part 2 Cohort B2: TSR-033+dostarlimab with FOLFIRI|Part 2 Cohort B2 will evaluate the preliminary activity of TSR-033 in combination with FOLFIRI and bevacizumab (SOC) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFOX, with or without biologics.
89662181|NCT03217422|Experimental|Arm 1|VAY736 Dose 1
89662182|NCT03217422|Experimental|Arm 2|VAY736 Dose 2
89662183|NCT03217422|Experimental|Arm 3|VAY736 Dose 3
89662184|NCT03217422|Placebo Comparator|Arm 4|Placebo
88994778|NCT02927041||OR-Cardiovascular|Requiring non-isolated cardiac surgery for repair of thoracic aortic aneurysm. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
88994779|NCT00170235|Experimental|1|Prehabilitation (exercises pre surgery)
89662185|NCT03199612|Active Comparator|Sildenafil|Baseline blood samples and study measurements will be acquired. Then 20 mg of the study drug will be administered. Then BP will be recorded every 30 minutes for two hours. If BP is stable (drop is < 5 mmHg after 2 hours and patient is asymptomatic), patient will proceed to take 20 mg of the study drug every 8 hours. The patient will return to clinic on day 8 and 20 mg of the study drug will be administered. After 2 hours blood samples and study measurements will be collected and the patient will resume 20 mg of the study for the next two doses. The patient will return for a third clinic visit on the next day and if BP is in the acceptable range, 40 mg of the study drug will be administered. If BP remains stable for 2 hours, then the patient will continue taking 40 mg every 8 hours. The patient will return to clinic on day 15 for a final study visit and will be given the last 40 mg dose of the study drug and after 2 hours blood samples and study measurements will be taken.
89662186|NCT03199612|Placebo Comparator|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation and aggregation in comparison to sildenafil.
89662187|NCT03174275|Experimental|Low Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive adjuvant durvalumab (750 mg) once every two weeks x 3 cycles"
89688664|NCT02930824|Experimental|Adult Genotype guided treatment|For adults randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
89688665|NCT02930824|No Intervention|Adult Conventional treatment|For adults randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
88994780|NCT00170235|Active Comparator|2|Usual care as provided by the institution
88994781|NCT02926885|Active Comparator|CONVENTIONAL LIVER RETRACTOR DEVICE|USE OF CONVENTIONAL LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
89662188|NCT03174275|Experimental|Medium Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive ipsilateral involved field radiation concurrent with weekly cisplatin 30mg/m2. Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
89662189|NCT03174275|Experimental|High Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- All patients will be treated with intensity modulation radiation therapy (IMRT) concurrent with weekly cisplatin 30mg/m2 or other standard of care chemoradiotherapy regimen.Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
89662190|NCT03173092|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 39 cycles until PD or unacceptable toxicity, whichever occurs first for up to 3 years.
89662191|NCT03170414||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
89662192|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA"|"Part 1 Tolerability with AZA - Low Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive low-risk intensifications I & II without azacitidine.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide,dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone., ITMHA."
89662193|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA"|"Part 1 Tolerability with DAC - Low Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive low-risk Intensifications I & II without decitabine.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA."
89662194|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | AZA+AE+Sor | AZA+MA+Sor"|"Part 2 Dose Expansion with AZA - Low Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and low- risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
89662195|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | DAC+AE+Sor|DAC+MA+Sor"|"Part 2 Dose Expansion with DAC - Low Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and low-risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA."
89662196|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with AZA - Intermediate Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive intermediate risk Intensifications I, II & III without azacitidine.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA,"
89662197|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida | AE | MA | Asp+AraC"|"Part 1 Tolerability with DAC - Intermediate Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive intermediate-risk Intensifications I, II & III without decitabine.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA."
89662198|NCT03164057|Experimental|"AZA| +ADE | +FLAG+Ida+Sor| +AE+Sor| +MA+Sor| +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - Intermediate-Risk~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and intermediate-risk Intensification I, II, and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
88994782|NCT02926885|Experimental|FLEXIBLE LIVER RETRACTOR DEVICE|USE OF THE FLEXIBLE LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
88994783|NCT02926963|Experimental|Chronic Granulomatous Disease|Sample collection were performed from patients with chronic granulomatous disease linked to X or due to Autosomal Recessive (AR) forms AR220, AR470 and AR670.
88994784|NCT02926807||Atopic Dermatis Subjects|30 subjects with atopic dermatitis
88994785|NCT02926807||Healthy Volunteers|30 subjects without AD that matches for sex, age (± 2 years) and coronary artery disease risk factor with the AD subjects will be included as control case
88994786|NCT00170274|No Intervention|Control Arm|Algorithms for prevention and termination of AF not activated
88994787|NCT00170274|Active Comparator|Prevention and Therapy Algorithms on|Activation of preventive and therapeutic algorithms
88994788|NCT02926846|Experimental|Lavage arm|Intravenous vancomycin & gentamicin with adjunctive lavage
88994789|NCT02926846|Active Comparator|Standard treatment arm|Intraperitoneal vancomycin & gentamicin
88994790|NCT02926612||HCT recipients ages ≤21 years|HCT recipients ages ≤21 years for whom lower respiratory secretions are being collected for direct patient care.
88994791|NCT02926534||Smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
88994792|NCT02926534||Ex-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) with a minimum of 10 pack-year smoking history who stopped smoking cigarettes between 1 and 5 years ago
89213709|NCT05325359||Multiple sclerosis|. Inclusion criteria for volunteers; Individuals with relapsing-remitting type MS, who are between 18-65, EDSS scores between 1 ≤ and ≤ 5.5, individuals who score 24 and above in Mini Mental State Examination and who can walk a minimum of 20 m independently will be included. In addition, exclusion criteria for volunteers; Severe spasticity of the lower extremities (Ashworth score 3 or 4), having an acute MS attack or a history of an attack in the last 1 month, having an orthopedic or systemic problem that would prevent participation in the tests, having another neuromuscular disorder other than MS, visual involvement or diplopia, and is that he has a cardio-pulmonary problem that will prevent him from participating in the tests.
89213710|NCT00869570|Experimental|Arm A: Sorafenib & Capecitabine & RT|"Sorafenib: day 1 to 33 (5 weeks, including Saturday and Sunday) every 24 hours, immediately or within two hours after RT according to the dose escalation table during phase I, and the recommended dose during phase IIa. The intake stops at the last day of RT. On nonradiotherapy days (e.g. Saturday, Sunday), the tablets have to be taken at the same time as during the week.~Capecitabine: day 1 to 33 (5 weeks, including Saturday and Sunday) according to dose escalation table during phase I, and at the recommended dose during phase IIa. The intake stops in the evening of the last day of RT.~External beam RT: Monday through Friday for 5 weeks starting on day 1 (daily fraction 1.8 Gy, final dose 45 Gy) each day at the same time (e.g. 11:00 a.m. daily).~Surgery: 6 weeks (± 1 week) after radiochemotherapy (RCT) has been completed"
89213711|NCT00880412|Experimental|EHT 0202 40 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
89662199|NCT03164057|Experimental|"DAC|+ADE | +FLAG+Ida+Sor | +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - Intermediate-Risk~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and intermediate-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
89662200|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG-Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA - High Risk (no donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I & II and high-risk intensifications I, II & III without azacitidine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
89662201|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | AE | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (no donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I, II & III without decitabine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA."
89662202|NCT03164057|Experimental|"AZA | + ADE | +FLAG+Ida+Sor| +AE+Sor | +MA+Sor | +Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (no donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
89662203|NCT03164057|Experimental|"DAC |+ADE |+FLAG+Ida+Sor |+AE+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (no donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA."
89662204|NCT03164057|Experimental|"AZA+ADE | AZA+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with AZA- High Risk (with donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I Induction II and high-risk Intensifications I or high risk intensification III without azacitidine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: azacitidine cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
89662205|NCT03164057|Experimental|"DAC+ADE | DAC+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor"|"Part 1 Tolerability with DAC - High Risk (with donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I or high risk intensification III without decitabine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
89662206|NCT03164057|Experimental|"DAC |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with DAC - High Risk (with donor)~Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy.~Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant"
89688666|NCT02930824|Experimental|Pediatric Genotype guided treatment|For children randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
89688667|NCT02930824|No Intervention|Pediatric Conventional treatment|For children randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
89662207|NCT03164057|Experimental|"AZA |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor"|"Part 2 Dose Expansion with AZA - High Risk (with donor)~Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensification I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy.~Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant."
89662208|NCT03129269|Experimental|neuroimaging amyloid diagnosis by MRI and PET scan|"There is only one arm. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease. MRI and PET Scan.~Visits at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation.~At 6 and 18 months in consultation by a Geriatrician and research assistant for a medical check.~one PET-Scan in the 2 months following inclusion for amyloid measurements and one MRI, depending on the clinical relevance~A blood sample for biobank at visit 2 and at visit 5.~Extension study (CogFrail-Plus): additional 2 years follow-up of the COGFRAIL study participants, following the initial 2 years period of the study:~2 Visits at at 36 and 48 months for a full neuropsychological, functional and physical evaluation~At 30 and 42 months in consultation by a Geriatrician and research assistant for a medical check~A blood sample at 36 and 48 months."
89662209|NCT03081910|Experimental|Autologous CD5.CAR/28zeta CAR T cells (Group A)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
89662210|NCT03081910|Experimental|Allogeneic CD5.CAR/28zeta CAR T cells (Group B)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
89662211|NCT03076008||MPFL Reconstruction|Subjects undergoing MPFL Reconstruction
89662212|NCT03061201|Experimental|Sequential dose escalation|SB-525 (PF-07055480) is administered as a single infusion
89662213|NCT03023124|Experimental|Trabectedin|trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles
89662214|NCT03023124|Experimental|Adriamycin and Dacarbazine|Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles
89662215|NCT02987686|Experimental|Topical Infliximab|Additionally to standard treatment, patients with all inclusive criteria and none exclusive criteria will be included in the therapeutic group and will receive topical infliximab QID for 4 weeks.
89662216|NCT02987686|No Intervention|Observational group|Patients with all inclusive criteria and one exclusive criteria will receive the standard treatment, without topical infliximab.
89662217|NCT02959086||1|Patients were diagnosed since January 2002.
89662218|NCT02866474|Other|- Puteaux or Paris for elderly persons|
89662219|NCT02866474|Other|-Two EHPAD in Lyon for elderly persons living|
89662220|NCT02845882|Other|Low risk group|Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
89662221|NCT02845882|Other|Intermediate risk group|Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
89662222|NCT02845882|Other|High risk group|Failure to qualify a PR, or >5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
89662223|NCT02817464|Experimental|TV-46046 - 1|
89662224|NCT02817464|Experimental|TV-46046 - 2|
89662225|NCT02752165|Experimental|TEAM-ED Intervention Group|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
88994793|NCT02926534||Never-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are current non-smokers and with no history of smoking (control group)
88994794|NCT02926495|Active Comparator|Treatment (ON)|
88994795|NCT02926495|Sham Comparator|Control (OFF)|
89662226|NCT02752165|Active Comparator|Enhanced Usual Care|Report of symptoms to primary care physician
89662227|NCT02671890|Experimental|Cohort I (gemcitabine hydrochloride and disulfiram)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and disulfiram PO on days 1-28 or days 1-35.
89662228|NCT02671890|Experimental|Cohort II (chemotherapy and disulfiram)|Patients receive chemotherapy at the discretion of the treating oncologist and disulfiram PO on days 1-28 or days 1-35.
89662229|NCT02667730|Placebo Comparator|Physiotherapy only|This group will receive non-pharmacological advice and physiotherapy only
88994796|NCT00170313|Experimental|Conducted AF-Response Algorithm (CAFR) On|"CAFR: On~Level medium~Max. Rate: 110ppm VSR: Off"
88994797|NCT00170313|Active Comparator|Conducted AF-Response Algorithm (CAFR) Off|CAFR: Off VSR: Off
89213712|NCT00880412|Experimental|EHT 0202 80 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
89213713|NCT00880412|Placebo Comparator|placebo bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
89213714|NCT01020136|Experimental|Sequence 1 (BABA)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
89213715|NCT01020136|Experimental|Sequence 2 (ABAB)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B-> A -> B
89662230|NCT02667730|Experimental|Acetaminophen + physiotherapy|This group will receive acetaminophen 500mg 4 times daily for 7 days in addition to standardized physiotherapy
89662231|NCT02667730|Experimental|Naproxen + physiotherapy|This group will receive naproxen 500mg twice daily for 7 days in addition to standardized physiotherapy
89662232|NCT02667730|Experimental|Celecoxib + physiotherapy|This group will receive celecoxib 100mg twice daily for 7 days in addition to standardized physiotherapy
89662233|NCT02537418|Experimental|durvalumab ± tremelimumab|"durvalumab; Day 1 every 3 weeks or 4 weeks~tremelimumab; every 3-6 weeks for a total of 1-6 doses"
89662234|NCT02511522|Active Comparator|Best Supportive Care|Patients will be randomized 1:1 to receive best supportive care alone
89662235|NCT02511522|Experimental|Best Supportive Care + RT 8 Gy/1|Patients will be randomized 1:1 to receive best supportive care plus radiation therapy (8 Gy in 1 fraction),
89662236|NCT02481466|Experimental|Portfolio diet and structured exercise|Participants will receive advice on a therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and be instructed on a standardized physical activity/exercise component supervised by kinesiologists.
89662237|NCT02481466|Active Comparator|DASH-like diet and structured exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and a be instructed on the Laval exercise program-a standardized physical activity/exercise component supervised by trained kinesiologists (exercise physiologists).
89662238|NCT02481466|Experimental|Portfolio diet and routine exercise|Participants will receive advice that will conform to the current therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
89662239|NCT02481466|Active Comparator|DASH-like diet and routine exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
89662240|NCT02422641|Experimental|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
89662241|NCT02405676|Other|Risk group 1|Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);
89662242|NCT02405676|Other|Risk group2|Not or incompletely resected stage I/II disease and LDH <2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;
89662243|NCT02405676|Other|Risk group3|Stage III with high LDH < 4 times NL, or Stage I,II with LDH >=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.
89662244|NCT02405676|Other|Risk group4|Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.
89662245|NCT02358031|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months.
89662246|NCT02358031|Experimental|Pembrolizumab + Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months; plus cisplatin 100 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
89662247|NCT02358031|Active Comparator|Cetuximab + Chemotherapy (Control)|Participants receive cetuximab on Day 1 at a dose of 400 mg/m^2 IV, and then 250 mg/m^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity; plus cisplatin 100 mg/m^2 IV or carboplatin AUC 5 IV (Investigator's choice) on Day 1 of each 3-week cycle (6 cycle maximum for platinum-based therapy); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
89662248|NCT02353819|Experimental|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy (SABR)
89662249|NCT02253030||Newly-diagnosed, untreated wet AMD|This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
89662250|NCT02253030||"Wet AMD undergoing as-needed treatment"|This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
89662251|NCT02253030||High-risk eyes|This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.
89662252|NCT02253030||"Wet AMD undergoing a treat and extend strategy"|"This group will be adults with wet AMD undergoing treatment under the treat and extend strategy. (The treat and extend strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals."
89662253|NCT02231775|Experimental|Treatment (dabrafenib, trametinib, surgery)|Patients receive dabrafenib PO BID and trametinib PO QD for 8 weeks. After completion of 8 weeks of dabrafenib and trametinib, patients undergo surgery. Approximately 1 week after surgery, patients receive dabrafenib PO BID and trametinib PO QD for 44 additional weeks in the absence of disease progression or unacceptable toxicity.
89662254|NCT02037919|Experimental|Immediate Nexplanon Insertion|An etonogestrel rod will be placed within 15 minutes following the abortion procedure.
89662255|NCT02037919|Active Comparator|Post-op Nexplanon Insertion|"Participants in the delayed placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure. Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment. At this time an etonogestrel rod will be placed in her arm using standard procedure."
89662256|NCT02026128||Active Uveitis|Physician-confirmed diagnosis of uveitis of any origin.
89662257|NCT01998464||Retinal Vasculitis Group|Up to 35 patients diagnosed with retinal vasculitis will be considered and evaluated for enrollment in this study.
89662258|NCT01992575||Retinal Vein Occlusion Group|Up to 35 patients diagnosed with retinal vein occlusions will be considered and evaluated for enrollment in this study.
89662259|NCT01953640||Ancillary-correlative (gene expression with CYP-17 inhibition)|Laboratory Biomarker Analysis: Tissue, blood, and urine samples are collected at baseline and after 12-14 weeks of treatment and assessed for circulating tumor cells, genome-wide SNP, and exome sequencing. Subjects will also receive a Quality-of-Life Assessment.
89662260|NCT01949662|Experimental|Lorazepam + Haloperidol|Participants given a single dose of lorazepam 3 mg by vein, in addition to a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
89047978|NCT04922138|Experimental|Arm A|Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day .
89047979|NCT04922138|No Intervention|Arm B|Observation
89047980|NCT04906590|Experimental|Study Drug|All participants will receive PI-2620.
89047981|NCT04873102|Experimental|Danazol in Treatment of Cytopenias|AGENT: Danazol 600mg, Oral, Daily for 24 months
89047982|NCT04871516|Experimental|Treatment (radiation therapy boost, WBI)|Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
89047983|NCT04870710|Experimental|cathodal transcranial direct current stimulation (tDCS)|Two, twenty minute sessions of cathodal tDCS to the bilateral extrastriate visual cortex for 5 days (10 total sessions).
89047984|NCT04870710|Experimental|Anodal transcranial alternating current stimulation (tACS)|Two, twenty minute sessions of anodal tACS delta phase aligned for 5 days (10 total sessions).
89047985|NCT04860375|Experimental|Multidisciplinary, holistic and patient-centered care|Based on the outcome from the assessment and disease phenotype, personalized care plans will be prepared and given to the patients, including dietary program, adjusted exercise program, psychological counselling, treatment of comorbidities etc. Patients will come for planned follow-up visits, according to the protocol (total 5 visits).
89047986|NCT04860375|Active Comparator|Standard care|The control group will be recruited from the Swedish Airway Register at the end of the study. Selection will be based on propensity score matching to the intervention group.
89047987|NCT04860141|Experimental|Gabapentin group|The patient in this group will take gabapentin 600mg PO 2 hours prior to his or her surgery.
89047988|NCT04860141|Placebo Comparator|Placebo group|The patient in this group will take a placebo that looks like gabapentin PO 2 hours prior to his or her surgery.
89047989|NCT04858802|Experimental|PROPEL Contour Sinus Implant|Following successful in-office bilateral balloon dilation, placement of PROPEL Contour Sinus Implant in the randomized side.
89047990|NCT04858802|Active Comparator|Balloon Sinus Dilation Alone|Following successful in-office bilateral balloon dilation, placement of no implant on the contralateral side.
89047991|NCT04857697|Experimental|Supportive care (biospecimen collection, probiotic)|Patients undergo collection of blood samples at baseline and time of surgery, and collection of stool samples at baseline and after completion of probiotic regimen. Patients receive probiotics PO once on day 1, and then BID or TID for 2-4 weeks before standard of care surgery. Patients also undergo collection of tissue samples during standard of care surgery.
89047992|NCT04834128|Experimental|γδ T cells (IMP, TCB008)|Patients will receive an infusion of γδ T cells (IMP, TCB008) following informed consent after admission to hospital for SARS-CoV-2 infection (COVID-19).
89047993|NCT04829656||Clinical Cohort|Enrolled via the 5 participating clinics at LBDA Research Centers of Excellence.
89047994|NCT04829656||Virtual Cohort|Enrolled via the LBDA.
89047995|NCT04823156|Experimental|Calcium Supplementation|1000 mg of calcium carbonate one hour before exercise
89047996|NCT04823156|No Intervention|No Calcium Supplementation|No calcium supplementation
89047997|NCT04816825|Experimental|Exergaming|The combination of 1) game-console based exercise programs, 2) specifically designed by professional physiotherapists with focus on subjects with a chronic lung disease and 3) weekly distant monitoring with close supervision by a physiotherapist. Individually prescribed exercise program based on tests of patient's physical fitness.
89047998|NCT04816825|Active Comparator|Standard rehabilitation|Standard rehabilitation at the COPD-Center. This includes recommendations about physical activity according to the general guidelines, however, individualized after each subject's physical fitness level.
89047999|NCT04815850||Patients on haemodialysis|Patients receiving haemodialysis
89048000|NCT04815850||Healthy controls|Participants with no chronic kidney disease or history of immunosuppression
89048001|NCT04813653|Experimental|cyclosporine in combination with carfilzomib and dexamethasone|cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed multiple myeloma refractory to carfilzomib with high expression of the PPIA gene in myeloma cells
89662261|NCT01949662|Active Comparator|Placebo + Haloperidol|Participants receive placebo, preservative free 0.9% normal saline, by vein plus a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
89662262|NCT01915498|Experimental|enasidenib|enasidenib administered orally. Multiple doses will be administered to determine the RP2D.
89662263|NCT01897961|Other|Patients whose renal disease of origin is a GEM|Patients whose renal disease of origin is a GEM
89662264|NCT01897961|Other|Transplanted Patients of origin is a GEM having done it again|Transplanted Patients of origin is a GEM having done it again
89662265|NCT01897961|Other|Transplanted patients, and having developed a GEM of novo|Transplanted patients, and having developed a GEM of novo
89662266|NCT01889238|Experimental|Enzalutamide|160 mg administered as four 40 mg soft gelatin capsules orally once daily
89662267|NCT01872260|Experimental|LEE011 + letrozole Arm 1|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day
89662268|NCT01872260|Experimental|BYL719 + letrozole Arm 2|BYL719 - daily (dose escalating) letrozole - 2.5 mg/day
89662269|NCT01872260|Experimental|LEE011 + BYL719 + letrozole Arm 3|LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day
89662270|NCT01872260|Experimental|LEE011+ BYL719+letrozole Arm 4|LEE011-daily (dose escalating), BYL719 -daily (dose escalating), letrozole 2.5 mg/day
89662271|NCT01674816|Active Comparator|Repeated Measurements of Knee Alignment and Kinematics|Patients in the Repeated Measurements Arm will have the kinematic measurement protocol repeated twice before and twice after the surgical procedure; the procedure itself will be performed with the traditional technique, i.e without guidance by the system.
89662272|NCT01674816|Active Comparator|Computer Guidance of Surgical Actions|Patients in the Computer Guidance of Surgical Actions Arm will have the kinematic measurement protocol performed only once before and once after the surgical procedure; the procedure itself will be performed with guidance by the system.
89048002|NCT04803747|Active Comparator|Tranexamic acid (TXAl Arm|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
89048003|NCT04803747|Placebo Comparator|Placebo Arm|Placebo 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
89048004|NCT04790474|Experimental|ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment|Prospective study of ixazomib-pomalidomide-dexamethasone as second or third-line combination treatment for patients with relapsed and refractory multiple myeloma (RRMM) previously treated with daratumumab, lenalidomide and bortezomib
89048005|NCT04789161||double kissing crush stenting|patients with true bifurcation lesion undergoing double kissing crush stenting
89048006|NCT04789161||double kissing culotte stenting|patients with true bifurcation lesion undergoing double kissing culotte stenting
89048007|NCT04787055|Experimental|Receiver in the canal hearing instrument 3 month|Group of subjects who will get the receiver in the canal hearing instrument and wear for period of three months.
89048008|NCT04787055|Experimental|Receiver in the canal hearing instrument 6 month|Group of subjects who will get the receiver in the canal hearing instrument and wear for period of six months.
89048009|NCT04777617||WU/Barnes cohort|SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
89048010|NCT04777617||UT Southwestern cohort|SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
89048011|NCT04767529|Experimental|EFX 28 mg|
89048012|NCT04767529|Experimental|EFX 50 mg|
89048013|NCT04767529|Placebo Comparator|Placebo|
89048014|NCT04743570|Placebo Comparator|Placebo treatment|Placebo consisting of Ringer's lactate in matched volume to active drug is added to 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.
89048015|NCT04743570|Active Comparator|Methylnaltrexone treatment|0.15 mg/kg methylnaltrexone will be dissolved in 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.
89048016|NCT04736030|Experimental|Conmigo PA Intervention|12-week program (90 minutes/week)
89048017|NCT04736030|No Intervention|Delayed Abbreviated Intervention|No intervention during experimental phase; participants in control group receive abridged program after the final measurement point (wait list control).
89662273|NCT01536275|No Intervention|Early parenteral nutrition|Parenteral nutrition supplements insufficient enteral nutrition from admission to ICU according to the current standard of care per center
89662274|NCT01536275|Experimental|Late parenteral nutrition|Parenteral nutrition will be withheld during the first 7 days of ICU stay
89662275|NCT01512589|Experimental|Proton Beam Therapy (PBT)|"Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy (or at RBE (Relative Biologic Equivalence for PBT)) to be delivered to the periphery of the planning target volume (PTV)."
89662276|NCT01512589|Active Comparator|Intensity Modulated Radiation Therapy (IMRT)|Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy to be delivered to the periphery of the planning target volume (PTV).
89662277|NCT01430351|Experimental|Arm 1 (temozolomide)|Patients receive temozolomide PO QD on days 1-5.
89213716|NCT03412643|Experimental|Arm 1|"Celcuity CELx HSF Test on tumor material obtained from research core biopsy to select patients with abnormal HER2 signaling tumors~Doxorubicin + cyclophosphamide followed by Weekly Paclitaxel +Trastuzumab+Pertuzumab"
89213717|NCT00614744|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
89213718|NCT00614744|Active Comparator|Normothermia|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
89213719|NCT01017094|Experimental|dry dressing|local application
89213720|NCT04074239|Experimental|Video triage|The sick child will be triaged on video by the operator.
89213721|NCT04074239|No Intervention|Telephone triage|The sick child will be triaged solely on telephone by the operator.
89213722|NCT01020214|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
89213723|NCT01020214|Active Comparator|2|Benicar HCT® Tablets 40 mg/25 mg
89213724|NCT02733029|Experimental|Sonazoid contrast|The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.
89213725|NCT02733029|No Intervention|Medical Review|Ultrasound imaging will be taken from a group of subjects recruited for stage 2. These will be obtained through medical record review from subjects with successful renal transplant at BWH and no transplant rejection.
89213726|NCT02578433|Experimental|Mindful Self Compassion|Participants will receive a shortened form (6 weeks) of mindful self compassion meditation, once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
89213727|NCT02578433|Other|Progressive Muscle Relaxation|Participants will receive progressive muscle relaxation once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
89213728|NCT04919993|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Group intervention; topics include psychoeducation about sleep, sleep restriction, stimulus control, relaxation strategies, and cognitive restructuring.
89213729|NCT00565812|Active Comparator|200 mg|High dose active comparator
89213730|NCT00565812|Active Comparator|50 mg|Low dose active comparator
89213731|NCT00565812|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
89213732|NCT03974334|Experimental|OWL-Hypertension 8 Wk Trial|Two groups of thirteen participants will use the Our Whole Lives - Hypertension eHealth online tool for 8 weeks each, with baseline, midline, and follow-up data collected to determine any change due to the intervention.
89213733|NCT03970824|Experimental|CT-P17|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
89213734|NCT03970824|Active Comparator|US-licensed Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
89213735|NCT03970824|Active Comparator|EU-approved Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
89213736|NCT00933972|Experimental|1 (normal)|
89213737|NCT00933972|Experimental|2 (mild)|
89213738|NCT00933972|Experimental|3 (moderate)|
89213739|NCT00933972|Experimental|4 (severe)|
89213740|NCT00564486|Placebo Comparator|IV Placebo 100 ml|IV Placebo 100 ml dosed every every 6 hours for 24 hours (4 doses total).
89213741|NCT00564486|Placebo Comparator|IV Placebo 65 ml|IV Placebo 65 ml dosed every every 4 hours for 24 hours (6 doses total).
89662278|NCT01430351|Experimental|Arm 2 (temozolomide, memantine hydrochloride)|Patients receive temozolomide PO as in Arm 1 and memantine hydrochloride PO BID.
89662279|NCT01430351|Experimental|Arm 3 (temozolomide, mefloquine)|Patients receive temozolomide PO as in Arm 1 and 30 mg mefloquine PO QD on days 1-3 of week 1 and then days 2, 4, and 6 every other week.
89662280|NCT01430351|Experimental|Arm 4 (temozolomide, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1 and metformin hydrochloride PO BID.
89662281|NCT01430351|Experimental|Arm 5 (temozolomide, memantine hydrochloride, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and mefloquine PO QD as in Arm 3.
89662282|NCT01430351|Experimental|Arm 6 (temozolomide, memantine hydrochloride, metformin)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and metformin hydrochloride PO BID as in Arm 4.
89662283|NCT01430351|Experimental|Arm 7 (temozolomide, mefloquine, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1, mefloquine PO QD as in Arm 3, and metformin hydrochloride PO BID as in Arm 4.
89662284|NCT01430351|Experimental|Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, metformin hydrochloride PO BID as in Arm 4, and mefloquine PO QD as in Arm 3.
89662285|NCT01302769|Experimental|battlefield auricular acupuncture|battlefield auricular acupuncture
89662286|NCT01302769|No Intervention|placebo|
89662287|NCT01243931|Experimental|Surgery|OCT is assisting in surgery guidance.
89662288|NCT00930332|Active Comparator|Arm A: Methadone|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
89662289|NCT00930332|Active Comparator|Arm B: Methadone|"Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
89662290|NCT00848289||Participants with Bladder Cancer|Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.
89662291|NCT00749515|Experimental|Single Arm|All patients received the same interventions of deferoxamine challenge, deferasirox dose with pharmacokinetic monitoring and HIDA scan. Then we compared responses between patients who were known to be slow responders to deferasirox and those who were known to be rapid responders (chelated well).
89662292|NCT00512122|Experimental|EN only|Withholding PN during the first week of ICU stay
89662293|NCT00512122|Active Comparator|EN plus early PN|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E Parenteral nutrition targeted at covering calculated needs together with the enteral nutrition intake that is achieved
89213742|NCT00564486|Experimental|IV Acetaminophen 1 gm|IV Acetaminophen 1 gm dosed every every 6 hours for 24 hours (4 doses total).
89213743|NCT00564486|Experimental|IV Acetaminophen 650 mg|IV Acetaminophen 650 mg dosed every every 4 hours for 24 hours (6 doses total).
89048018|NCT04718025|Experimental|Low-dose ticagrelor with aspirin (LDTA)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, and will receive the following antiplatelet therapy:~ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;~ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until 12 months after ACS."
89048019|NCT04718025|Experimental|Low-dose ticagrelor with placebo (LDTP)|"Patients with ACS in this arm will be subject to reduction of ticagrelor maintenance dose from 2x90mg to 2x60mg after the first month post-ACS, followed by discontinuation of aspirin after 3 months post-ACS, and will receive the following antiplatelet therapy:~ticagrelor 2x90mg + aspirin 1x100mg during the first 30 days after ACS;~ticagrelor 2x60mg + aspirin 1x100mg starting from day 31 until day 90 after ACS;~ticagrelor 2x60mg + placebo starting from day 91 until 12 months after ACS."
89048020|NCT04718025|Active Comparator|Standard-dose ticagrelor with aspirin (SDTA)|Patients with ACS in this arm will receive standard dual antiplatelet therapy including ticagrelor 2x90mg + aspirin 1x100mg during the whole 12 months after ACS.
89048021|NCT04711148|Placebo Comparator|placebo|"The Core Part：Participants receive placebo~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
89048022|NCT04711148|Experimental|orelabrutinib(low dose)|"The Core Part：Participants receive low dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
89048023|NCT04711148|Experimental|orelabrutinib(medium dose)|"The Core Part ：Participants receive medium dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
89048024|NCT04711148|Experimental|orelabrutinib (high dose)|"The Core Part：Participants receive high dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
89048025|NCT04666948|Active Comparator|Standard of Care Vancomycin treatment|Vancomycin standard-of-care dosing and therapeutic drug monitoring, according to institutional guidelines during 30 day study period
89048026|NCT04666948|Experimental|vancomycin model-informed precision dosing|Area Under the Concentration (AUC)-time curve/MIC-based model-informed precision dosing of vancomycin using a CE labelled dosing calculator during 30 day study period
89048027|NCT04660526|Experimental|Intervention (Enhanced Standard of Care)|Mass community CPR/AED training, optimize 911 medical dispatch, improve first responder performance
89048028|NCT04660526|No Intervention|Control (Standard of Care)|Usual care, continuing standard quality improvement effort
89048029|NCT04630080|Experimental|Scalp Cooling|
89048030|NCT04609176|Experimental|Camrelizumab+Apatinib+SOX|Participants who have not received any previous therapy for their disease will receive Camrelizumab and Apatinib in combination with Oxaliplatin and S-1. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
89048031|NCT04609176|Experimental|Camrelizumab+Apatinib|Participants who have received at least one prior therapy for their advanced disease will receive Camrelizumab and Apatinib. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
89048032|NCT04562090|Experimental|Mirabegron 25 mg|Participants received single oral dose of Mirabegron 25 milligrams (mg) tablet once daily, at the same time after a meal for a duration of 12 weeks. Dose escalation to 50 mg was permitted at Visit 3 (Week 4) or Visit 4 (Week 8) at the discretion of investigator.
89048033|NCT04562090|Experimental|Mirabegron 50 mg|Participants received single oral dose of Mirabegron 50 mg tablet once daily, at the same time after a meal for a duration of 12 weeks.
89048034|NCT04560920|Experimental|Experimental|This group will contribute PGD and it will be available in the study visit.
89048035|NCT04560920|No Intervention|Control|This group will contribute PGD but it will not be available during a study visit, it will be available to the provider in a subsequent visit.
89048036|NCT04560647||Psoriasis|Subjects diagnosed with psoriasis.
89048037|NCT04560647||Control|Subjects who do not have psoriasis.
89048038|NCT04557189|Experimental|Ondansetron 4 mg IV|Participants received prophylaxis with ondansetron 4 mg, intravenously (IV) immediately before induction and TAK-951 placebo subcutaneously (SC) approximately 30 to 45 minutes before the end of surgery (wound closure).
89048039|NCT04557189|Experimental|TAK-951 4 mg SC|Participants received prophylaxis with ondansetron placebo IV immediately before induction and TAK 951 4 mg, SC, approximately 30 to 45 minutes before the end of surgery (wound closure).
89048040|NCT04556461|Experimental|Tralokinumab|Tralokinumab 600mg loading dose s.c., followed by 300mg every other week.
89048041|NCT05306197|Experimental|Gaze-Contingent Feedback Training (toward threat)|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the soldier will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracker, the participant will be instructed to view matrices of faces as he chooses, as described above in the assessment task. The music chosen by the participant will play only when he is looking at threatening faces and it will stop when he looks at neutral faces. Thus, a change in viewing patterns is expected by implementing operant conditioning principles.
89213744|NCT00481078|Experimental|Arm I (vorinostat, paclitaxel, carboplatin)|Patients receive oral vorinostat (SAHA) at 400 mg once daily on days 1-14 and paclitaxel IV 200 mg/m2 over 3 hours and carboplatin IV dosed to achieve an area under the concentration versus time curve of 6 mg/mLXmin over 30 minutes on day 3.
89213745|NCT00481078|Active Comparator|Arm II (placebo, paclitaxel, carboplatin)|Patients receive an oral placebo once daily on days 1-14 and paclitaxel and carboplatin as in arm l.
89213746|NCT00934206|Experimental|Training|One month of endurance training (running / walking at 60 % heart rate reserve for 45 min 4 times per week)
89213747|NCT00934284|Active Comparator|Injection only|Participants receive a therapeutic selective nerve root block and advice to return to normal activity as tolerated.
89213748|NCT00934284|Experimental|Injection plus physical therapy|Participants are referred to physical therapy within one week of receiving a therapeutic selective nerve root block. Physical therapy consists of end-range movements in a directional preference and/or mechanical traction to reduce radicular symptoms.
89213749|NCT00938808|Active Comparator|One per day, Formula diet|The Cambridge Programme. Formula diet One-daily
89662294|NCT00365157|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 1-2 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89662295|NCT00099437|Experimental|1|Fulvestrant 500 mg
89662296|NCT00099437|Experimental|2|Fulvestrant 250 mg
89662297|NCT04394533|Experimental|Prilocaine (Intervention) Group|Subarachnoid block (SAB) with 40 mg (2 ml) of hyperbaric 20 mg/ml prilocaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
89662298|NCT04394533|Active Comparator|Bupivacaine (Control) Group|Subarachnoid block (SAB) with 10 mg (2 ml) of hyperbaric 5 mg/ml bupivacaine and 15 mcg (0.3 ml) fentanyl (50 mcg/ml)
89662299|NCT01928017||Hematooncology patients|No intervention
89662300|NCT04275583|Experimental|TQB3602 capsule|TQB3602 capsule administered orally on day 1, 8, 15 in 28-day cycle.
89662301|NCT04124653|Experimental|PF-06842874/Placebo|Single dose administration of PF-06842874 or placebo
89662302|NCT04124653|Experimental|Relative Bioavailability|Determination of relative bioavailability of modified-release formulation relative to immediate-release formulation
89662303|NCT04127695|Experimental|ABBV-0805 Dose 1 or Placebo|Participants will receive ABBV-0805 Dose 1 or Placebo.
89662304|NCT04127695|Experimental|ABBV-0805 Dose 2 or Placebo|Participants will receive ABBV-0805 Dose 2 or Placebo.
89662305|NCT04127695|Experimental|ABBV-0805 Dose 3 or Placebo|Participants will receive ABBV-0805 Dose 3 or Placebo.
89662306|NCT04127695|Experimental|ABBV-0805 Dose 4 or Placebo|Participants will receive ABBV-0805 Dose 4 or Placebo. Note: This dosing group may be added after a review of data from dosing groups 1-3.
89662307|NCT05602831||operable treatment group|"After enrollment, patients will receive standard treatment and conventional follow-up strategy.~Peripheral blood samples will be collected before treatment and at different time points after starting treatment.~Baseline surgical tissue will be also obtained."
89662308|NCT05602831||radical chemoradiotherapy group|"After enrollment, patients will receive standard treatment and conventional follow-up strategy.~Peripheral blood samples will be collected before treatment and at different time points after starting treatment.~Baseline puncture tissue will be also obtained before radical chemoradiotherapy."
89662309|NCT01928095||Carotid Endocardectomy Patients|Subsequent analyses will be performed on the basis of the pathological grading provided by UK Pathology (e.g do readouts of the Dicer pathway correlate with pathological plaque characteristics).
89662310|NCT04393831|Active Comparator|Retzius sparing|Using the Retzius technique, the surgeon will remove the prostate in a way that preserves a portion of the nerves and tissue structures that are typically removed during the conventional technique.
89662311|NCT04393831|No Intervention|Conventional (non-Retzius) nerve sparing|A non-Retzius nerve sparing technique will be performed, according to surgeon's preference--nerve sparing during radical prostatectomy is performed with significant variation and there is an absence of universally agreed upon steps or techniques.
89662312|NCT04394455|Experimental|Brief cognitive behavioral therapy|Medical staff (medical doctors and residents) who will receive brief cognitive behavioral therapy through telepsychiatry.
89213750|NCT00938808|Experimental|Repeated formula diet|Dietary instruction (low-energy diet) 3x5 weeks per year
89662313|NCT04394455|Active Comparator|Crisis intervention therapy|Medical staff (medical doctors and residents) who will receive 3 sessions of crisis intervention therapy through telepsychiatry.
89662314|NCT04394065||uEXPLORER total-body PET/CT|Newly diagnosed NPC patients will undergo a one-hour total-body dynamic PET/CT examination and subsequently followed by a conventional PET/CT scan within 30 minutes
89662315|NCT01928173|Active Comparator|Abbreviated cognitive behavioral therapy|Arm 1 is a multi-component package including sleep hygiene, stimulus control, cognitive therapy, and passive relaxation.
89662316|NCT01928173|Active Comparator|Sleep education/sleep hygiene|Arm 2 consists of education about sleep and fatigue as well as sleep hygiene recommendations (e.g., avoiding nicotine and caffeine late in the day).
89662317|NCT05604469||Group A (liver faluire patients with pruritus)|Patients with hepatic illness (autoimmune liver diseases, chronic viral hepatitis, and drug-induced liver injury)
89662318|NCT05604469||Group B (liver faluire patients without pruritus)|Patients with hepatic illness (autoimmune liver diseases, chronic viral hepatitis, and drug-induced liver injury)
89662319|NCT05604469||Group C (renal faluire patients with pruritus)|
89662320|NCT05604469||Group D (renal faluire patients without pruritus)|
89213751|NCT00480532|Experimental|Doxycycline 100bid x5 days|
89213752|NCT00480532|Placebo Comparator|placebo bid x 5 days|
89213753|NCT00480532|Experimental|Subantimicrobial doxycycline daily|
89213754|NCT00480532|Placebo Comparator|placebo daily|
89662321|NCT03423277|Experimental|Easy Stretch Toolkit|All participants will be using one or more of devices for 60 minutes 2 times per day for the duration of the 8 week trial. Prescriptive instructions for specific intraoral placements will be given based on the participant's deficit areas.
89662322|NCT04125823|Experimental|Video game-based physical activity training|
89662323|NCT04125823|Active Comparator|Conventional physiotherapy program|
89662324|NCT05602441|Experimental|VALID - diabetes supportive clubs|VALID - diabetes supportive clubs
89213755|NCT04013880|Experimental|Treatment (ASTX727, FT-2102)|Patients receive CDA inhibitor E7727/decitabine combination agent ASTX727 PO QD on days 1-5 and IDH-1 inhibitor FT-2102 PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89213756|NCT01017328||surgery with general anesthesia|
89213757|NCT00939432||Gender|male/female
89213758|NCT00939432||Age|18-100 years
89213759|NCT00939432||Educational level|primary school, secondary school, university
89213760|NCT00934518|Experimental|Radiation and Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
89213761|NCT00496366|Experimental|Capecitabine (Xeloda) + Lapatinib (Tykerb)|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Lapatinib will be taken daily continuously for 21 days (Days 1- 21)."
89213762|NCT00934674|Experimental|1|Commercial Tablet manufactured by Excella
89213763|NCT00934674|Experimental|2|Clinical Tablet manufactured by Wyeth Montreal
89213764|NCT00934752|Experimental|Lutonix Catheter|
89662325|NCT01928251|Experimental|Informed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days at 3-month follow-up and pass the 3-month biochemical validation (Exhaled carbon monoxide level < 4 ppm, saliva cotinine level < 10 ng/ml) (Group A-Q). Participants will be informed about the incentives through telephone follow-up at 1 week and 1 month. Those who have not quitted at 3 months (Group A-N) or those self-reported quitters who refuse to participate in biochemical validation will be informed again that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
89662326|NCT01928251|Experimental|Uninformed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days and pass the 3-month biochemical validation (Group B-Q), but they will not be informed about the incentive at the 1-week and 1-month follow-up. Those who have not quitted at 3 months (Group B-N) or those self-reported quitters who refuse to participate in the biochemical validation will be informed that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
89662327|NCT01928251|No Intervention|Uninformed late monetary incentive|Incentives for the self-reported and biochemically-validated abstinence at 6-month follow-up will be given after the 6-month biomedical validation. They would not be informed about the incentive at the 1-week, 1-month and 3-month follow-up. Group C also has two subgroups, those who have quitted at 3 months (Group C-Q) and those who have not (Group C-N).
89662328|NCT04120597|Experimental|Therapy group|
89662329|NCT04120597|Placebo Comparator|Control group|
89662330|NCT04129879|Experimental|1|all patients treated by conventional bare eye technique and then the use of methylene blue contrast technique to visualize endometriotic lesions perioperatively
89662331|NCT05602129|Experimental|HSK36273 Continuous infusion|Drug:HSK36273 Administration mode:Continuous infusion
89662332|NCT05602129|Experimental|HSK36273 Bolus+Continuous infusion|Drug:HSK36273 Administration mode:Bolus+Continuous infusion
89662333|NCT05602129|Active Comparator|Heparin sodium|Drug:Heparin sodium Administration mode:Bolus+Continuous infusion
89662334|NCT04393987|Experimental|Arms|Treatment Compliance Training The treatment compliance training consists of five sessions in total and was given individually. Each session of the treatment compliance training given once a week took 45 minutes on average.
89662335|NCT04393987|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
89662336|NCT05609851||experimental group|A physical performance test will be applied to the group and Questionnaires related to occupation will be made to individuals.
89662337|NCT03025165|Experimental|Community Adherence Clubs|ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker to a club meeting of 20-25 HIV+ patients every three months, with two clinic visits every year for clinical review and laboratory monitoring
89662338|NCT03025165|Experimental|Home-Based ART Delivery|Individuals receive ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker at their household every three months, with two clinic visits every year for clinical review and laboratory monitoring
89662339|NCT03025165|Other|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
89662340|NCT01928563|Experimental|Dapoxetine|Dapoxetine is administered
89662341|NCT01928563|Experimental|Udenafil|Udenafil is administered
89662342|NCT01928563|Experimental|Udenafil and Dapoxetine|Udenafil and Dapoxetine are co-administered
89662343|NCT02315755||Study cohort|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have signed the informed consent document.
89213765|NCT01020292|Experimental|NFV and Concurrent ChemoRads|
89213766|NCT01017406|Experimental|Plantar fascia stretching exercise|Patient perform plantar fascia stretching 3 times per day
89213767|NCT04014426|Other|Exposed|Healthcare workers participating at two PIPAC
89213768|NCT04014426|Other|Non-exposed|Healthy volunteers unexposed to chemotherapy
89213769|NCT01020370||Alemtuzumab Group|
89213770|NCT01020370||Interferon Beta-1a SC Group|
89213771|NCT03117582||Patients with C.diff infection|Patients with C.diff infection not responding to antibiotics who are now scheduled for the FMT procedure for routine care of their condition.
89213772|NCT00488644|Experimental|Levothyroxine + Liothyronine|Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks
89213773|NCT00934830|Active Comparator|Antibiotic|
89213774|NCT00934830|Experimental|Therapeutic ultrasound|
89213775|NCT00934908|Placebo Comparator|1|"Non-active sugar pill"
89213776|NCT00934908|Active Comparator|2|Green Tea Capsules
89213777|NCT02575404|Experimental|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
89213778|NCT02575404|Experimental|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
89213779|NCT02575404|Experimental|8 mg/kg GR-MD-02|8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
89662344|NCT01928641||Discrepancy in stroke onset|Patients with discrepancy in stroke symptom onset based on the diagnosis of the first neurologist who evaluated the patient at emergency room and the next day after admission
89662345|NCT05609617|Experimental|Face and neck injection|"NCTF135HA intradermal injection on face and neck. 3 injections spaced out by two weeks; injection points are spaced every 1-1.5 cm with a quantity of 0.05 ml on each point.~Application of Hydra Filler cream twice daily on the face and neck."
89662346|NCT05609617|Experimental|Face and upper chest/décolleté injection|"NCTF135HA intradermal injection on face and décolleté. 3 injections spaced out by two weeks; injection points are spaced every 1-1.5 cm with a quantity of 0.05 ml on each point.~Application of Hydra Filler cream twice daily on the face and décolleté."
89662347|NCT05609617|Active Comparator|Face and neck controle|Application of Hydra Filler cream twice daily on the face and neck.
89662348|NCT05609617|Active Comparator|Face and upper chest/décolleté controle|Application of Hydra Filler cream twice daily on the face and décolleté.
89662349|NCT04129255|Other|OCTREOTIDE LONG-ACTING RELEASE (OCT LAR)|OCT LAR is already registered By FDA for USA, by EMA for Europe and , also, by AIFA for Italy.
89213780|NCT02575404|Experimental|4 mg/kg GR-MD-02 17 Cycles Maximum|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment up to a maximum of 17 cycles.
89662350|NCT04129489|Experimental|Sintetic Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally twice a day
89662351|NCT04129567|Experimental|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
89662352|NCT04129567|Experimental|Dry air|Delivering dry air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
89662353|NCT04129567|Placebo Comparator|Humidified air|Delivering humidified air at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
89662354|NCT04129567|Active Comparator|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose and noting the change in primary and secondary outcome variables at 2 hours and 24 hours.
89662355|NCT04128787|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A (AG-881 Formulation 1, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 1) followed by Treatment B (AG-881 Formulation 2, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 2) followed by Treatment C (AG-881 Formulation 2, 50 mg, tablet, orally, under fed condition once on Day 1 of Period 3) followed by Treatment D (omeprazole 40 mg capsule, orally, once daily on Days 1 to 4 and AG-881 Formulation 2, 50 mg, tablet, orally, under fasted condition, once on Day 4 of Period 4). Each period will be separated by a Washout Period of 21 days.
89662356|NCT04128787|Experimental|Treatment Sequence BCAD|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 then Treatment A in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
89662357|NCT04128787|Experimental|Treatment Sequence CABD|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 then Treatment B in Period 3 followed by Treatment D in Period 4. Each period will be separated by a Washout Period of 21 days.
89662358|NCT04129099|Experimental|CAR-T treatment group|The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.
89662359|NCT05609227|Experimental|mobile application|Participants will get a mobile application containing information about information about all stages of stem cell transplantation process (pre, during and post).
89662360|NCT05609227|No Intervention|Control|Participants will receive routine care.
89662361|NCT04129021|Experimental|High-resolution retinal imaging through adaptive optics|High-resolution retinal imaging through adaptive optics, full field OCT and holographic systems
89662362|NCT05609149||T3 Rectal cancer|Patients with T3 rectal cancer who underwent curative surgery.
89662363|NCT04394377|Other|Group 1|"The routine full anticoagulation strategy will be applied for 30 days. In this strategy, full anticoagulation therapy will be maintained for all patients randomized to group 1 and, depending on the patient's clinical condition, there will be 2 possible routes of administration (oral or parenteral):~Oral: Rivaroxaban 20 mg 1 x daily (adjust the dose to 15 mg 1x daily if ClCr between 30 and 49ml/min and/or concomitant use of azithromycin);~Parenteral: Enoxaparin 1 mg/kg every 12 hours subcutaneously or Unfractionated heparin (preferable option for patients progressing with disseminated intravascular coagulation)."
89662364|NCT04394377|Other|Group 2|Patients in this group will receive the usual standard management and currently have no indication of full anticoagulation. Venous thromboembolism (VTE) prophylaxis should be used in group 2 (usual standard of care) as recommended by guidelines.
89662365|NCT02984293|Active Comparator|Atorvastatin|The participants will receive atorvastatin (80 mg) orally once daily for 28 days.
89662366|NCT02984293|Placebo Comparator|Placebo|The participants will receive matched placebo orally once daily for 28 days.
89662367|NCT04128163|Experimental|QL1206|"QL1206 injection (60mg:1ml) by subcutaneous injectionevery 6 month for two times.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
89662368|NCT04128163|Placebo Comparator|Placebo|"placebo injection (1ml) by subcutaneous injectionevery 6 month for two times.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
89662369|NCT01929187|Active Comparator|Phytonail|Phytonail is a mixture of herbal active ingredients including tea tree oil, lavender oil and Australian blue cypress (ABC) oil with BioEqual carrier system.
89662370|NCT01929187|Active Comparator|amorolfine 5% nail lacquer|5% amorolfine
89662371|NCT00634751|Experimental|Phase I: 200mg Sorafenib+2DOC|"Cohort 1: 200mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
89662372|NCT00634751|Experimental|Phase I: 400mg Sorafenib BID+2DOC|"Cohort 2: 400mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
89213781|NCT00564018|Experimental|Detemir|24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
89213782|NCT00564018|Experimental|Glargine|24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
89213783|NCT00564018|Experimental|NPH|24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.
89213784|NCT04013724|Experimental|Intervention group|"The behavioral group intervention consisted of 6 sessions over 12 weeks and were led by 2 trained facilitators, followed by monthly group meetings from weeks 14 to 26. This program was adapted from the Royal Australian College of General Practitioners' Supporting Smoking Cessation Guide for Health Professionals17 and the World Health Organization's Strengthening Health Systems for Treating Tobacco Dependence in Primary Care training package.18~The topics that were explored during the group sessions include:~Introduction to the Program and Reasons to Quit~Benefits of Quitting and Understanding Why We Smoke and Ways of Quitting~Withdrawal Symptoms and Social Support~Dealing with Stress and Anxiety and Coping with Depression~Assertiveness Training and Anger Management~Tobacco-Free Lifestyle and Dealing with High Risk Situations"
89213785|NCT04013724|No Intervention|Control|The control group was provided questionnaires to fill at the end of Weeks 4, 12, and 26. During the rest of the study, they continued receiving usual care, including clinical care at CSAT.
89213786|NCT04013412|Experimental|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
89213787|NCT04013412|No Intervention|Control|Ad libitum diet for four days immediately before surgery
88994798|NCT02926378|Experimental|Acupuncture Intervention|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
88994799|NCT02926183|Experimental|Gemcitabine plus nab-paclitaxel|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
88994800|NCT02926456||Cohort 1|HIV-1-infected patients being in stable ritonavir-boosted Antiretroviral (ARV) treatment with Protease Inhibitors (PIs) (either darunavir 800 milligram [mg] each day -based or not) since at least twelve months and virologically suppressed (HIV-RNA less than [<]50 copies/milliliters) since at least six months.
88994801|NCT02926339|Experimental|Teens Against Tobacco Use presentation|Students in the intervention group will receive anti-tobacco presentations from Teens Against Tobacco Use Members
88994802|NCT02926339|No Intervention|Control|Students in this group will receive a control presentation from their physical education teachers on a topic unrelated to tobacco.
88994803|NCT02926105|Experimental|T&E Home-based exercise programme|Individually tailored home-based test and exercise programme
88994804|NCT02926105|Experimental|Otago|Individually tailored exercise programme
88994805|NCT02926105|Active Comparator|Helsana booklet|Helsana recommendations and exercises
89213788|NCT00935298|Experimental|T|"The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation.After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*3 and *1/*1 ,expressors; CYP3A5*3/*3 nonexpressor）.~The objective is to determine the initial dosage Range of tacrolimus in Chinese renal transplantation patients by genotyping of the cytochrome P450 3A5"
89213789|NCT04014192|Experimental|Dapagliflozin Group|10mg/d for one week
89662373|NCT00634751|Experimental|Phase II: Pancreatic Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
89662374|NCT00634751|Experimental|Phase II: Biliary Tract Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
89662375|NCT04128085|Experimental|TQB3804|TQB3804 tablet administered orally , once daily in 28-day cycle.
89662376|NCT04127773||NEX group|oro gastric tube placement using NEX insertion length predictor
89662377|NCT04127773||NEMU group|oro gastric tube placement using NEMU insertion length predictor
89662378|NCT04348175|Experimental|Mild impairment|
89662379|NCT04348175|Experimental|Moderate impairment|
89662380|NCT04348175|Experimental|Severe impairment|
89662381|NCT04348175|Experimental|Normal (control)|
89213790|NCT04014192|Experimental|Empagliflozin Group|10mg/d for one week
89662382|NCT04127929|Active Comparator|Glass carbomer|
89662383|NCT04127929|Active Comparator|Tokuyama Estelite Posterior|
89662384|NCT04127617|Experimental|Osteopathic Manipulative Treatment|the treatment group will receive 5 osteopathic manipulative treatment. The treatment will last 45 - 60 minutes with the following frequency: the subjects will receive 3 OMT on a weekly basis, the two following twice weekly. The osteopathic treatment protocol will therefore last 7 weeks. Each individual patient will be taken in charge by two operators during the entire duration of the study.
89662385|NCT04127617|Active Comparator|Nursing Care|The conventional treatment consists in educational nursing care.
89662386|NCT04396067|Active Comparator|Aerosolized 13 cis retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
89662387|NCT04396067|Active Comparator|All trans retinoic acid|COVID 19 infected patients will receive one dose daily of Aerosolized All trans retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled All trans retinoic acid therapy for 14 days
89662388|NCT04396067|Placebo Comparator|Placebo Comparator|4 Placebo tablets twice daily by mouth for 2 weeks
89662389|NCT04124419|Experimental|Treatment Arm|Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.
89662390|NCT05608447|Active Comparator|FMT capsules|FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on Day 0 (randomization), Day 1, Day 2, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49.
89213791|NCT04014192|Experimental|Canagliflozin Group|100mg/d for one week
89662391|NCT05608447|Placebo Comparator|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on Day 0 (randomization), Day 1, Day 2, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49.
89662392|NCT05608213|Experimental|Len-I|
89662393|NCT05608213|Active Comparator|Len|
89662394|NCT04127461|Active Comparator|Open vessel harvesting|Arm 1 is the conventional procedure
89662395|NCT04127461|Experimental|Medtronic endoscope|Arm 2 - is the minimally invasive procedure
89662396|NCT04274647|Experimental|Device and Control|"NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose. 0.2ml"
89662397|NCT04124107|Experimental|Prostate biopsy with 68Ga-PSMA PET/MRI|Both targeted biopsy and 12-core systematic biopsy with positive 68Ga-PSMA PET/MRI
89662398|NCT03020017|Experimental|Treatment (NU-0129)|Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.
89662399|NCT03015259|Experimental|Treatment 1|Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
89662400|NCT03015259|Active Comparator|Treatment 2|Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
89662401|NCT03015259|Placebo Comparator|Treatment 3|Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
89662402|NCT03236545|Experimental|No to Low Endogenous Estrogen|PMW and young women (YW) will receive medical study clearance after a detailed physical examination. YW will self-administer subcutaneous injections of the gonadotropin-releasing hormone (GnRH) antagonist, ganirelix acetate (Antagon, 0.25 mg/day in 0.5 ml of normal saline, Organon, Inc., West Orange, New Jersey,) daily to suppress endogenous ovarian hormone production (16, 17, 18). This will begin following a separate medical screening at Reproductive Associates of Delaware 48 hours prior to initiating the hormone intervention to rule out other contraindications prior to beginning the treatment. YW will begin using the antagonist on days 26-28 of their menstrual cycle, and continue daily for 10-12 days. The experimental protocol will be conducted in YW after 3-4 days of using the GnRH antagonist. PMW will complete the experimental protocol prior to use of the 17β-estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch).
89662403|NCT03236545|Experimental|Estrogen Add-Back|Estradiol (E2, 0.1 mg/day patch, Vivelle dot; estradiol patch) will be administered for 7 days to both young and PMW. Young women will use the E2 over the last 7 days of Antagon administration.
89662404|NCT03014791||Healthy Volunteers|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~Acetylcholine: 7.5μg/min, 15μg/min and 30μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
89662405|NCT03014791||Hypertensive Patients (Case-control)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~Acetylcholine: 7.5μg/min, 15μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
89662406|NCT03014791||Hypertensive Patients (Cross-sectional)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Forearm blood flow Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Recruited from community-based cohort studies - CLEAREST and ACCT~Equal recruitment across the following parameters:~Age: 3 groups <30, 30-60, >60 years~Gender~BMI: 3 groups <25, 25-30, >30 Kg/m2"
89662407|NCT04126993|Experimental|Camrelizumab+ Apatinib test group|Camrelizumab intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
89662408|NCT04126993|Active Comparator|Apatinib single drug control group|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
89662409|NCT05604781||Symfony & Synergy IOL combination|
89662410|NCT05604313|Experimental|Ergonomic chinrest used with low shoulder rest (EC)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC)
89662411|NCT05604313|No Intervention|Do-as-usual|On the test day (crossover study), participants will play with the usual preferred chin and shoulder rest.
89662412|NCT04123483|Experimental|EnBrace HR for Acute Treatment of PMS and MRMD|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 weeks. Participants are currently experiencing clinically significant MRMD symptoms, defined as a ≥ 30% increase in the total Daily Record of Severity of Problems Scale (DRSP) score from the mid-follicular phase (average of DRSP scores for days 6-10) to the late-luteal phase (average of DRSP scores for last 5 days prior to menstrual bleeding).
89662413|NCT04127305||VA ECMO|Patients will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
89662414|NCT04127305||VA EMCO + RRT|Patients with RRT will be included at the beginning of VA ECMO therapy within 24-48h after start of an antiinfective therapy
89662415|NCT04127305||VV ECMO|Patients will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
89213792|NCT04014192|No Intervention|Normal Glucose Tolerance Group|
89662416|NCT04127305||VV ECMO + RRT|Patients with RRT will be included at the beginning of VV ECMO therapy within 24-48h after start of an antiinfective therapy
89662417|NCT04127305||Control|Patients will be included within 24-48h after start of an antiinfective therapy
89662418|NCT04274803|Experimental|Intralipid group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily. In addition intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
89662419|NCT04274803|Active Comparator|Standard care group|the patients will receive the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
89662420|NCT04127149|Experimental|Group with ultrasound|The first group consists of nine general practitioners having received a brief training on the use of ultrasound scanners in general practice. The general practitioner includes all adult patients who are consulting for one of the 8 medical conditions studied and perform an ultrasound scan. Two weeks later, he/she calls each patient to collect the necessary data.
89662421|NCT04127149|No Intervention|Group without ultrasound|The second group consists of nine general practitioners. Each physician includes all adult patients who are consulting for one of the 8 medical conditions studied and performs a standard consultation. Two weeks later, he/she calls each patient to collect the necessary data.
89662422|NCT03828175|Other|cop variables|non invasive cop vsriables correlation to basic monitoring variables during prone position spinal anesthesia intervention pcnl operation at basic ,1hour and 2hours .
89048042|NCT05306197|Active Comparator|Active Comparator: RT-Based Attention Bias Modification (toward threat)|"A dot-probe task of 160 trials. Trials begins with a fixation cross (+), on which the participant is asked to focus (500ms). Then two face stimuli (one angry one neutral) are presented above and below the fixation cross (500ms). After the stimuli disappear, a target probe (right- or left-pointing arrowhead) appears in place of one of the face stimuli. The participant is asked to indicate which target probe was presented using a predetermined key. The target probe will remain on the screen until response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the threat location (angry face). Thus, over multiple trials, learning is expected to occurs such that the threatening face predicts the location of the target probe, thereby achieving the desired change in attention pattern."
89048043|NCT05306197|Placebo Comparator|Non-Contingent Feedback Training|This condition is also based on the eye-tracking task (see Experimental Arm) with a fundamental change - The music chosen by the soldier will play continuously without any reinforcement for looking at threat or neutral faces.
89048044|NCT04530838|Experimental|20-valent pneumococcal conjugate vaccine (subcutaneous)|20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
89048045|NCT04530838|Active Comparator|13-valent pneumococcal conjugate vaccine (subcutaneous)|13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
89662423|NCT04126759|Experimental|Protocol 1|The subjects enrolled in this protocol will dedicate 33 days of home-based measurement and two days for in-clinic measurements. For reference measurements, subjects will be equipped with a BG-meter (Contour Next One, Ascenia). Optical measurements are collected with the IMD. Each day of measurements consists of four sessions each comprising two capillary blood glucose measurement with a BG-meter and two IMD measurements. IMD measurements will be performed using the thenar of the right hand of the subject.
89662424|NCT02315989|Other|safety|proton therapy
89048046|NCT04530838|Experimental|20-valent pneumococcal conjugate vaccine (intramuscular)|20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)
89662425|NCT04392973|Experimental|Intervention|Combination therapy Favipiravir (10 days) + Hydroxychloroquine(5 days)
89662426|NCT04392973|No Intervention|Control|Standard of Care Treatment for COVID-19 Infection
89662427|NCT03827863||ARDS WITH ACP|"Diagnostic criteria for ARDS ARDS defined as within 1 week of a known clinical insult or new or worsening respiratory symptoms. ARDS was classified as mild (200 mmHg < PaO2/FIO2≤300 mmHg), moderate (100 mmHg < PaO2/FIO2≤200 mmHg) and severe (PaO2/FIO2≤100 mmHg) according to the value of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2 ratio value is considered only with a CPAP or PEEP value of at least 5 cmH2O.~Ultrasound diagnostic criteria for ACP The specific diagnostic parameters are as follows: TR>2.8m/s; RVEDA/LVEDA>0.6 or Right ventricle/left ventricle basal diameter ratio>1.0 or systolic D sign; IVC >2cm with decreased inspiratory collapse; Pulmonary Regurgitation Velocity >2.2m/s."
89662428|NCT03827863||ARDS WITHOUT ACP|Diagnosis as ARDS but no ultrasound evidence of ACP.
89662429|NCT00634049|Experimental|Isavuconazole|Administration of isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days followed by daily administration of isavuconazole (IV) or oral
89048047|NCT04474054|Experimental|FARAPULSE Ablation System Plus|Ablation using the FARAPULSE Ablation System Plus
89048048|NCT04424901|Placebo Comparator|Standard Care|"Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.~Data collection ends on day 9."
89048049|NCT04424901|Experimental|Standard Care with Dipyridamole|"For this arm, Dipyridamole 100 mg, tid is given for 7 days. Hospitalized patients meeting screen criteria receive standard Hospital care from which clinical event and lab data are collected.~Day 3,6 & 9 research samples will be used for obtaining immunological profiles as well as metabolomic profiling and whole genome sequencing for discovery of new biomarkers/ genomic regions that confer increased susceptibility to infection and DIP treatment efficacy or safety. Other samples will be obtained for microbiome and viral analyses.~Data collection ends on day 9."
89662430|NCT03828097|Experimental|Experimental supplement|Participants in this arm will receive two capsules per day containing a total of 1 mg boron, 600 mcg folate, 8 mg iron, 50 mg magnesium, 320 mg omega-3 (DHA+EPA), 8 mcg vitamin B12, 50 mcg vitamin D3, and 7 mg vitamin E
89662431|NCT03828097|Placebo Comparator|Placebo|Participants in this arm will receive two capsules per day containing safflower oil
89213793|NCT00935376|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
89213794|NCT00935376|Experimental|Mindfulness Meditation Program|Mindfulness Meditation Program (MMP) is based on Mindfulness-Based Stress Reduction (MBSR), which teaches participants mindfulness skills such as meditation and yoga. Mindfulness may be defined as paying attention in a particular way, on purpose, in the present moment, and nonjudgmentally. The goal of MBSR is to provide participants with experiential tools and mindfulness practices to assist them to become more mindful of themselves, others and their external environment. The techniques are easy to learn and teach individuals to be aware of the present moment, with an open mind in which they can perceive their thoughts, physical sensations, and emotions nonjudgmentally.
89662432|NCT03827785|Experimental|rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 30 days.
89662433|NCT03827785|Sham Comparator|sham rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.
89662434|NCT04123249|Experimental|Group Propofol|In the Group P, propofol 4-6 mg/kg/h and remifentanil 0.2μg/kg/min were infused by intravenous pump separately for assisted sedation and assisted analgesia.
89662435|NCT04123249|Experimental|Group Sevoflurane|sevoflurane (concentration: 2%-3%, mixed with 50% air and 50% oxygen to keep the minimum alveolar concentration (MAC) at 1.0-1.1) was inhaled to maintain assisted sedation, and remifentanil 0.2 μg/kg/min was infused by intravenous pump for assisted analgesia.
89662436|NCT03336203|Active Comparator|Hyperurecemia with gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
89662437|NCT03336203|Active Comparator|Hyperurecemia without gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
89662438|NCT03128593|Experimental|Experimental: JR-141|
89662439|NCT03831737|Experimental|Group 1: In-Person|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will participate in in-person physical therapist-led instructional sessions three times per week. Each stretch will be performed twice, one on the left and one on the right. The therapist will describe what to do and briefly demonstrate each stretch. Stretches will be held for 45-60 seconds with therapist instructions and modification as needed based on subject technique."
89662440|NCT03831737|Experimental|Group 2: Video|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will complete sessions three times per week, led by a physical therapist and viewed remotely via pre-recorded video using a smartphone application."
89662441|NCT04125901|Experimental|Pain Neuroscience Education and Exercise|Participants will received an 8-week intervention consisting of exercise and pain neuroscience education. Pain neuroscience education will be conducted in line with international guidelines and will address the following topics: pain neurophysiology, nociception and nociceptive pathways, inhibition and spinal cord stimulation, peripheral and central sensitization, nervous system plasticity and the impact of variables such as stress, anxiety, sleep and exercise on pain behavior. Exercise will be performed in accordance with international guidelines for chronic NP. Motor control, endurance and strengthening exercises will be performed for the neck and scapulo-thoracic region.
89662442|NCT04125901|Other|Exercise|Participants will received an 8-week intervention consisting of exercise. The exercise performed in this group will be the same as in the intervention group and will follow the same international guidelines for chronic NP.
89662443|NCT04125979|Experimental|Preservation of pulmonary vagus nerve|Preservation of pulmonary branches of vagus nerve in minimally invasive surgery for lung cancer
89662444|NCT04125979|Experimental|No pulmonary vagus nerve preservation|In minimally invasive surgery for lung cancer, the pulmonary branches of vagus nerve were severed
89662445|NCT03129581|Active Comparator|Time Restricted|This group will receive dietary counseling.
89662446|NCT03129581|No Intervention|Time Unrestricted|This group will not receive dietary counseling.
89662447|NCT04393675|Active Comparator|LT5001|Administered twice daily (maximum 6 g per time, morning and evening respectively)
89662448|NCT04393675|Placebo Comparator|Placebo|Administered twice daily (maximum 6 g per time, morning and evening respectively)
89213795|NCT00935376|Active Comparator|Sleep Education Program|The Sleep Education Program (SEP) will serve as the control intervention in which participants will receive classes informing them how to change their habits to improve their sleep, and what to do if they have concerns about their sleep quality.
89213796|NCT00935610|Active Comparator|Immunocal|20g of Immunocal
89213797|NCT00935610|Placebo Comparator|Casein|20g of Casein
89662449|NCT04274413|Experimental|Interventional Arm|All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
89662450|NCT04274257|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
89662451|NCT04274257|Experimental|Double-Blind Rituximab|Participants will receive double-blind rituximab from baseline until week 24. Participants may then receive open-label rituximab from weeks 24 to 48.
89662452|NCT03128957|Experimental|Varying cerebral oxygenation with varying ventilation|Compare oxygenation under conditions of varying ventilation strategy. Low end tidal CO2/Low inspired oxygen vs High end tidal CO2/high inspired oxygen
89662453|NCT02983669|Experimental|Thyme|Zataria multiflora Boiss powder capsule 350 mg twice daily for 3 months
89662454|NCT02983669|Placebo Comparator|Placebo|Wheat powder capsule 350 mg twice daily for 3 months
89662455|NCT03827551|Experimental|Parkinson's Patients|
89662456|NCT03831815||Grupo C: cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
89662457|NCT03831815||Grupo R: rocuronium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
89662458|NCT04123171||The Three Villages Cohort|Individuals aged 60 years or more identified by means of door-to-door surveys, living in Atahualpa, El Tambo, and Prosperidad. Individuals will be interviewed with validated field instruments, and there will be invited for the practice of complementary exams to recognize markers of aterosclerosis and cerebral small vessel disease.
89662459|NCT04122937||Ovarian cancer|Patients affected by ovarian cancer will be stratified according to BRCA1 and BRCA2 mutational status.
89662460|NCT04122937||Colon cancer|Patients affected by colon cancer will be similarly stratified according to BRAF and KRAS mutational status and to the presence of low-grade or high-grade microsatellite instability (MSI).
89662461|NCT03234985||acute myeloid leukemia patients|Patients over 18 years with acute myeloid leukemia
89662462|NCT00632099|Placebo Comparator|Placebo|matched placebo
89662463|NCT00632099|Experimental|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day)
89662464|NCT04393519||Prospective|Prospective cohort that received TIPS from 05/12/2020 onwards
89662465|NCT00632021|No Intervention|1|Patients will receive usual care at hospital discharge, which generally includes physician reconciliation of medications and a nurse-provided explanation of how to take medications at the time of discharge.
89662466|NCT00632021|Experimental|2|Participants will receive pharmacist-led medication reconciliation, pharmacist counseling prior to discharge, a follow-up telephone call 1-4 days after discharge, and additional telephone support as needed.
89662467|NCT03827629|Experimental|Cohort 1: Treatment Sequence A-B-C|Participants received Treatment A on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
89662468|NCT03827629|Experimental|Cohort 2: Treatment Sequence B-C-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
89662469|NCT03827629|Experimental|Cohort 3: Treatment Sequence C-A-B|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
88994806|NCT02925832|Experimental|Group B|Deep Topical Fornix Nerve block anesthesia using bupivacaine and proparacaine
88994807|NCT02925832|Experimental|Group R|Deep Topical Fornix Nerve block anesthesia using ropivacaine and proparacaine
88994808|NCT02925988|Other|EEG monitoring|Neonates will receive their aEEG monitoring as soon as the indication for monitoring is established, and cEEG electrodes will be applied in parallel, as soon as an EEG technician is available, which should usually be within less than 16 hours, in many cases within 1-4 hours.
88994809|NCT02925910|Other|softwheels at second round|Begining with regular wheelchair for 2 days and then changing for shock absorbing wheelchair for 2 days
88994810|NCT02925910|Other|softwheels at first round|starting with Shock absorbing wheelchair for 2 days and then changing for regular wheelchair for 2 days
88994811|NCT00170469|Experimental|1|Low dose rPA vaccine
88994812|NCT00170469|Experimental|2|High dose rPA vaccine
88994813|NCT00170469|Active Comparator|3|Active vaccine control
88994814|NCT02925715|Experimental|supraclavicular|ultrasound guided central venous cannulation done by supraclavicular approach
88994815|NCT02925715|Experimental|infraclavicular|ultrasound guided central venous cannulation done by infraclavicular approach
88994816|NCT02925676|Experimental|hyposafe H02|All subjects included are assigned to hyposafe H02-testing
88994817|NCT02928289|Active Comparator|VISCO360 ab interno canaloplasty surgery|Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
88994818|NCT02928289|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects randomized to this arm will undergo the SLT procedure.
89048050|NCT04415060|Experimental|Inhaled - volatile anesthetic|The ICU patient will be randomized to either Isoflurane or Sevoflurane, whichever is available at the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
89662470|NCT03827629|Experimental|Cohort 4: Treatment Sequence A-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
89662471|NCT03827629|Experimental|Cohort 5: Treatment Sequence C-B-A|Participants received Treatment C on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
89662472|NCT03827629|Experimental|Cohort 6: Treatment Sequence B-A-C|Participants received Treatment B on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
89662473|NCT04125511|Experimental|68Ga-FAPI, PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
89662474|NCT02960347|Experimental|Active tDCS|open label active tDCS treatment
89662475|NCT00631475|Experimental|1|"For patients who were administered bosentan during BUILD 3 (NCT00391443):~Same dose will continue~For patients who were administered placebo during BUILD 3 (NCT00391443):~Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg"
89662476|NCT03827239|No Intervention|Control|No intervention. Study participants will be seated during the entire sedentary 3-hour time period and wheeled to phlebotomy (and exercise) stations when required. During the sedentary period, participants will eat the food according to the study protocol and be seated at desks and allowed to read and use computers.
89662477|NCT03827239|Experimental|Intervention|Will disrupt their sedentary time with 3 minute exercise sessions every 30 minutes
89662478|NCT04392739|Other|TPOXX|TPOXX 600 mg BID x 7 days
89662479|NCT04122547|Active Comparator|Roflumilast|Roflumilast 500 microgram one tab oral per day
89662480|NCT04122547|Placebo Comparator|Placebo|One tablet oral per day
89662481|NCT04109911|Experimental|Fermented oyster extract group|This group takes fermented oyster extract for 12 weeks
89662482|NCT04109911|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
89662483|NCT04393597|Experimental|Group 1|Subjects take DWJ1458 on a fasted condition, and after wash-out period, take DWJ1458 with a high-fat diet.
89662484|NCT04393597|Experimental|Group 2|Subjects take DWJ1458 with a high-fat diet, and after wash-out period, take DWJ1458 on a fasted condition.
89662485|NCT04122781|Experimental|with novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation and novel K-wire fixation devices
89662486|NCT04122781|Active Comparator|without novel K-wire fixation devices|Patients with supracondylar humeral fractures treated by percutaneous K-wire fixation
89662487|NCT02957227||1|cohort 1: Older adults with memory impairment
89662488|NCT02957227||2|cohort 2: Age matched healthy controls
89662489|NCT03827083||Spinal anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
89662490|NCT03827083||General anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
89662491|NCT03827161|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
89662492|NCT03827161|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
89662493|NCT03826537|Other|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin. Subjects to receive single dose of test material such that each subject receives 1.8 mcg/kg body weight of tutin.
89662494|NCT04121923|Experimental|Participant|All patients scheduled for attended overnight in-lab polysomnography (PSG) will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device with the results of the PSG on the same patient. There will be no separate arm to test a different device.
89662495|NCT04125433|Experimental|Medicaid Emergency Department High Utilizers|"This Arm will include the following individuals~Up to 400 Adults age 18 to 65~New York State Medicaid Managed Care Members~Have utilized emergency department services 6 or more times in a 12-month period~Have been assigned to the Pilot Project by their Medicaid Managed Care Plan"
89662496|NCT04125199|Experimental|experimental group|
89662497|NCT04125199|Placebo Comparator|control group|
89662498|NCT03826615|Experimental|Gabapentin|Gabapentin premedication group
89662499|NCT03826615|No Intervention|No medication|Control group
89662500|NCT04124887|Active Comparator|Sodium fluoride|Duraphat Varnish containing 5% Sodium fluoride
89662501|NCT04124887|Experimental|Tricalcium phosphate|Clinpro™ White Varnish containing 5% NaF with TCP
89662502|NCT04124887|Experimental|Xylitol-coated calcium and phosphate|Embrace ™ Varnish containing 5% NaF with CXP
89662503|NCT04124887|Experimental|Casein phosphopeptide amorphous calcium phosphate|MI Varnish containing 5% NaF with CPP-ACP
89662504|NCT04121767|Experimental|Edoxaban group|patients prescribed edoxaban after thoracoscopic ablation during window period to prevent stroke
89662505|NCT04121767|Active Comparator|Warfarin group|patients prescribed warfarin after thoracoscopic ablation during window period to prevent stroke
89662506|NCT04121689|Experimental|Milk Protein Concentrate|Seven young men (age: 22±1 y) will undergo repeated blood and biopsy sampling during primed continuous L-[ring-2H5]phenylalanine and L-[1-13C]leucine tracer infusions, and ingested 38 g of L-[1-13C]phenylalanine- and L-[1-13C]leucine-labeled milk protein concentrate
89662507|NCT04274569|Active Comparator|Sodium fluoride (NaF)|Group 1: Quarterly application of a 5% NaF varnish (Duraphat® Varnish, Colgate-Palmolive Ltd, (UK) Ltd., Guildford, Surrey, UK)
89662508|NCT04274569|Experimental|NaF plus tricalcium phosphate (TCP )|Group 2: Quarterly application of 5% NaF-TCP (ClinproTM White Varnish; 3M ESPE, St Paul, MN, USA)
89662509|NCT04274569|Experimental|NaF plus CPP-ACP|Group 3: Quarterly application of a 5% NaF plus casein phosphopeptide-stabilized amorphous calcium phosphate complexes (CPP-ACP) (MI Varnish TM; GC corporation, Itabashi-Ku, Tokyo, Japan)
89662510|NCT03830827|Experimental|MBRP+vortioxetine intervention|"Participants who allocate to the experimental group will receive 8-week 10-20mg/day vortioxetine combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~10-20mg/day vortioxetine will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
89662511|NCT03830827|Experimental|MBRP intervention|"Participants who allocate to the control group will receive 8-week 1-2#/day placebo combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~1-2#/day placebo will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
89662512|NCT04124731|Experimental|Sintilimab plus anlotinib|Sintilimab and anlotinib combination therapy
89662513|NCT04124731|Active Comparator|Control|Standard platinum-based chemotherapy
89662514|NCT03822481|Experimental|Experimental|Participants in this arm were given the MCD. The MCD is a mindful eating intervention aimed at facilitating weight loss and cultivating a present centred awareness. The MCD consists of ten questions that an individual must consider while eating. Participants were required to consider the questions while eating (no writing required). Participants were asked to use the MCD at their three main meals (breakfast, lunch, dinner). The
89662515|NCT03822481|No Intervention|Control|Participants in this arm were required to eat as normal and were not given the MCD until the study was complete.
89048051|NCT04415060|No Intervention|Standard Care|The ICU patient will be randomized to standard of care, which is any IV sedation supplied by the hospital. Dosage will be modified as per health care team guidance for the best treatment of the participant.
89048052|NCT04415060|No Intervention|Non-randomized|In this arm, ICU patients who cannot be randomized will receive inhaled or IV sedation as per available in their unit. This is done to try to obtain the maximum amount of information available from the patients present to our ICUs.
89048053|NCT04410445|Experimental|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Arm A: Participants will receive bempegaldesleukin (NKTR-214) IV in combination with nivolumab every 3 weeks.
89662516|NCT03826381||Study 1: DM2 + normal kidney function|"Number of patients: 54~Patients in this group are diagnosed with Diabetes type 2. Kidney function: eGFR is > 60, absence of clinical proteinuria.~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions and the same as in the other group.~The patients are examined once."
89662517|NCT03826381||Study 1: DM2 + CKD stage 3-5|"Number of patients: 54~Patients in this group are all diagnosed with diabetes type 2. Furthermore, the patients have chronic kidney disease stage 3-5 (eGFR <60).~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions are the same as in the other group.~The patients are examined once."
89662518|NCT03822403|Active Comparator|EQUIA|EQUIA Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
89662519|NCT03822403|Active Comparator|Gradia Direct Posterior|Gradia Direct Posterior The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
89662520|NCT04758559|Placebo Comparator|Usual care|Patients receive usual care concerning dietary advice.
89662521|NCT04758559|Experimental|myfood24|Patients receive myfood24 a new online app to support tracking of food and nutrient intakes, and allows patients and healthcare professionals to communicate, seeing results of intakes to promote healthy dietary behaviour changes.
89662522|NCT04758559|Experimental|myfood24 + diet optimisation|Personalised feedback. Patients use myfood24 with an additional feature of new technology providing guidance of how to optimise their diets against targets, using information they provide about current intakes.
89662523|NCT03822247|Experimental|Multidisciplinary Recovery Program|"Two cohorts of patients will randomly be placed in either experimental od no intervention group.~Patients undergoing Multidisciplinary Recovery After Surgery Program will gain better preparation for early mobilization after surgery, nutritional support, individually modified analgesia and psychological support during inpatient treatment. Program includes preoperative, intraoperative and postoperative multidisciplinary comprehensive interventions."
89662524|NCT03822247|No Intervention|Conventional Perioperative Care|Patients undergoing conventional care
89662525|NCT02924701||PBC patients|Patients diagnosed with primary biliary cholangitis
89662526|NCT03825913|Active Comparator|Exercise Intervention|"Subjects in the exercise group will participate in a 3-month exercise program at the University of Miami UHealth Fitness and Wellness Center. Participants will complete two exercise sessions a week, each 45-60 minutes long and on a one-on-one basis.~In addition to two site visits, the participants will receive a tailored daily home-based walking plan. The participants will use physical activity trackers (Fitbit®), with an ultimate goal of achieving 10,000 steps by the end of the intervention.~Participants in the exercise intervention will complete 24 sessions."
89662527|NCT03825913|Sham Comparator|Wellness Intervention|For 3 months, the wellness education group will not be offered any form of supervised exercise program or receive any specific instructions on physical activity as part of the study. The participants in this group will attend educational sessions about different wellness topics, such as nutrition, sleep, weight management, mindfulness, and the overall benefits of increased physical activity. The wellness visits will be held two times per month, and similar to the exercise sessions of the intervention arm, they will be 45-60 minutes long and on a one-on-one basis. Participants in the wellness education group will complete 6 sessions.
89662528|NCT03098485|Experimental|Levofloxacin|1 750mg tab of levofloxacin by mouth for 5 days
89662529|NCT03098485|Experimental|Azithromycin|1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
89662530|NCT03098485|Experimental|Cefpodoxime|200mg tab by mouth twice per day for 5 days
89662531|NCT03098485|Experimental|Azithromycin and cefpodoxime|"Azithromycin: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)~Cefpodoxime: 200mg tab by mouth twice per day for 5 days"
89048054|NCT04410445|Active Comparator|Nivolumab|Arm B: Participants will receive nivolumab IV alone every 4 weeks.
89048055|NCT04365764||Exposed to the treatment|Exposure variable will be studied treatment
89048056|NCT04365764||Not exposer to the treatment (control group)|
89048057|NCT04342494|Experimental|Enhanced Feedback + Standard Feedback|Participants will receive enhanced feedback from the MyDataHelps study app in addition to standard feedback from the activity tracker.
89048058|NCT04342494|Experimental|Headspace app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
89048059|NCT04342494|Experimental|Headspace app + Enhanced Feedback + Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback activity tracker.
89048060|NCT04342494|Experimental|SilverCloud app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
89662532|NCT04121533|Placebo Comparator|Placebo|Matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
89213798|NCT04013646|Experimental|UCB infusion and EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
89213799|NCT04013646|Experimental|UCB infusion and placebo EPO injection group|Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.
89662533|NCT04121533|Experimental|Vitamin D|Vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements taken daily for 84 days (12 weeks).
89662534|NCT04121533|Experimental|Vitamin D, glucosamine sulfate, and omega-3 fatty acids|Vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids). Supplements taken daily for 84 days (12 weeks).
89662535|NCT03822169|Experimental|Choline added as a phospholipid|A shake with phospholipid-bound choline (and bound DHA),
89662536|NCT03822169|Active Comparator|Choline added as a salt|control shake with choline added as a salt and added DHA.
89662537|NCT04121143|Active Comparator|Treatment group A|SHR-1314 low dose short intervals of subcutaneous injection
89213800|NCT04013646|Placebo Comparator|Placebo UCB infusion and placebo EPO injection group|Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
89213801|NCT03381287|Experimental|HTD1801 250 mg BID|Subjects received 500 mg/day HTD1801
89213802|NCT03381287|Experimental|HTD1801 500 mg BID|Subjects received 1000 mg/day HTD1801
89213803|NCT03381287|Experimental|HTD1801 1000 mg BID|Subjects received 2000 mg/day HTD1801
89662538|NCT04121143|Active Comparator|Treatment group B|SHR-1314 high dose long intervals of subcutaneous injection
89662539|NCT04121143|Active Comparator|Treatment group C|SHR-1314 high dose short intervals of subcutaneous injection
89662540|NCT04121143|Placebo Comparator|Placebo group|Placebo was subcutaneously injected into the 16 weeks turnover SHR-1314 subcutaneous injection
89662541|NCT03825601|Other|Patients with multiple sclerosis|The multiple sclerosis group (n=30) will be subdivided in two subgroups: 15 patients with a relapsing remmitting MS (RRMS), and 15 patients with a primary progressive MS (PPMS).
89662542|NCT03825601|Other|healthy subjects|15 healthy subjects will be included. Among them 7 to 8 subjects will be matched for age and gender with the RRMS subgroup, and 7 to 8 will be matched for age and gender with the PPMS subgroup.
89662543|NCT03817801|Experimental|non-slip element (NSE) predilation|In the NSE predilation group, NSE predilation will be performed for all lesions preparation before drug-coated balloon (DCB) treatment.
89662544|NCT03817801|Active Comparator|non-compliant (NC) balloon predilation|In the NC balloon predilation group, NC balloon predilation will be performed for all lesions preparation before DCB treatment.
89662545|NCT04273789|Experimental|far infrared reflecting sleepwear|Sleepwear (shorts + tshirt) with far infrared reflecting ceramic print produced by Dagsmejan AG (Zurich, Switzerland)
89662546|NCT04273789|Placebo Comparator|Placebo sleepwear|Sleepwear (shorts + tshirt)
89213804|NCT03381287|Placebo Comparator|Placebo|
89213805|NCT04074473|Placebo Comparator|Propranolol alone|TPropranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
89213806|NCT04074473|Active Comparator|Esophageal variceal ligation alone|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
89213807|NCT04074473|Experimental|Esophageal variceal ligation(DC inderal after EV eradication)|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
89213808|NCT04074473|No Intervention|Propranolol(Keep BB after EV eradication)|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
89213809|NCT03093480|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants were to receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 48 Weeks in ITI Period. Participants who met the criteria for immune tolerance induction (ITI) success entered the tapering period and received rFVIIIFc at a dose adjusted according to Investigator judgment based on the FVIII activity levels and with the aim of tapering the rFVIIIFc dose to reach a prophylactic dosing regimen within 16 weeks (4 months). Follow-Up was for 32 weeks under an adjusted prophylactic regimen according to Investigator judgment.
89662547|NCT03069079|Experimental|Non surgical Periodontal therapy|"All children will be offered an oral hygiene and tooth scaling and polishing session. For children affected by periodontal disease, subgingival debridement will also be performed according to needs, with the aim to disrupt the subgingival biofilm responsible for the onset and progression of the periodontal pathology. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. In addition, when required, nitrous oxide sedation (NOS) could be used before treatment.~Caries will be treated as necessary (shared care with the general dental practitioners / community dental services). Children with mucosal lesions requiring treatment will be given a letter for their GDP suggesting referral to a collaborating expert in Oral Medicine (Prof. Stephen Porter)."
89662548|NCT03825211|Experimental|Continuous suture|All parts of the perineal lesion (vaginal mucosa , perineal muscle and skin) be sutured with the same suture thread. A single suture for perineal lesion
89662549|NCT03825211|Active Comparator|Discontinuous suture|Interrupted suture technique: vaginal mucosa, perineal muscle and skin are sutured with separate and different threads, that is, the vaginal mucosa is sutured with a thread, then independently the perineal muscle is sutured with another type of thread and finally the skin is also sutured independently with another different thread. Three independent sutures for each of the parts that form a single perineal lesion
89662550|NCT03821701|Experimental|Newly diagnosed HFrEF ARNI|Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
89662551|NCT03821701|Active Comparator|Newly diagnosed HFrEF ACEI/ARB|Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
89662552|NCT03821701|Experimental|Prior diagnosed HFrEF ARNI|Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
89662553|NCT03821701|Active Comparator|Prior diagnosed HFrEF ACEI/ARB|Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
89662554|NCT03825445|Experimental|GnRHa trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial; Ferring Pharm Co, Switzerland) for ovulation trigger.
89662555|NCT03825445|Experimental|hCG trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive hCG (Pregnyl 5000IU; Organon Pharm Co, Nertheland) for ovulation trigger.
89662556|NCT03064867|Experimental|V+RICE|"Venetoclax given in combination with R-ICE chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide)~Phase I part of this study is a 3 + 3 design, with 3 dose levels, a minimum of 6 participants (maximum of 18) will be required to identify the recommended phase 2 dose (RP2D).~Phase II involvs two stages: In stage I, a total of 16 participants will be accrued. If there are 7 or fewer complete responses (CR), the study will be stopped. Otherwise, an additional 30 participants will be accrued in stage II.~The maximum number of treatment cycles with V+RICE is three. Participants who achieve complete remission at the interim response assessment after 2 cycles may omit cycle 3 in order to proceed to subsequent consolidation therapy with autologous stem cell transplant (AHSCT).~Participants will proceeed to other treatment including RICE, other chemotherapy, peripheral blood stemm cell collection, and ASCT per institutional guidelines."
89662557|NCT03821779|Experimental|Group 1: Go-no-go phase|"The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners.~Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery).~Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study."
89662558|NCT03821779|Experimental|Group 2.1|"In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~real exposure: oral presentation to a panel of examiners~virtual reality : oral presentation to virtual examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
89662559|NCT03821779|Experimental|Group 2.2|"In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~virtual reality : oral presentation to virtual examiners~real exposure: oral presentation to a panel of examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
89662560|NCT03824899|Experimental|CRT group|Patients With Advanced Rectal Cancer receiving CPT-11-based CRT and blood concentration check
89662561|NCT02983435|Experimental|G1 - Thrust manipulation|G1 - Thrust manipulation is an osteopathic technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
89048061|NCT04342494|Experimental|SilverCloud app +Enhanced Feedback +Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback from the activity tracker.
89048062|NCT04340921||1. COVID-19+ (n=120)|"COVID-19 positive without evidence of myocardial injury (n=120). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection.~Exclusion criteria: No biochemical evidence of acute myocardial injury (serum troponin>99th centile within previous 48-hour period)."
89048063|NCT04340921||2. COVID-19+ Myocardial injury+ (n=20)|"COVID-19 positive with myocarditis (n=20). Inclusion criteria: All adult (age≥18 but <100 years of age) inpatients with confirmed COVID-19 infection and clinically suspected or confirmed myocarditis including evidence of acute myocardial injury (troponin >99th centile within the previous 48-hour period) at the time of recruitment.~Exclusion criteria: significant chronic kidney disease (eGFR ≤30 or dialysis-dependent) or septic shock at the time of initial assessment. We will also exclude patients with a diagnosis of chronic heart muscle disease and those with known significant chronic or acute obstructive coronary disease."
89048064|NCT04340921||3. COVID-19+ Complication+ (estimated 10-25%)|Inclusion criteria: Participants form Groups 1 and 2 in whom a prespecified complication ocurs will be included in a derived Group3.
89048065|NCT04314817||Patients treated for Covid-19|
89048066|NCT04312269|Experimental|All phase TMR|TMR during every stage of sleep
89048067|NCT04312269|Experimental|Slow-wave sleep (SWS) only TMR|TMR during slow-wave sleep only
89048068|NCT04312269|Experimental|Reduced frequency TMR|TMR during only subset of sessions
89048069|NCT04312269|Sham Comparator|Sham TMR|Patients receive no TMR
89048070|NCT04307030||0 ~ 18 years old children|Children During Outpatient or Hospitalization
89662562|NCT02983435|Active Comparator|G2 - Muscle Energy|G2 - Muscle Energy is a manual therapy technique based in muscular contraction and stretching. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
89662563|NCT03820921||PATIENTS WITH PANCREATIC CANCER|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNB for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNB will be further verified during a clinical follow-up of at least 6 months.~Immunochemistry will be performed on the EUS-FNB specimens to determine PD-L1 expression and MMR status"
89662564|NCT03824743||Lactate Ringer|Patients managed with Ringer Lactate
89662565|NCT03824743||Plasma-Lyte|Patients managed with Plasma-Lyte
89662566|NCT03824665|Active Comparator|Nalbuphine Group|Nalbuphine Group (Nalbuphine) 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 4mg nalbuphine
89662567|NCT03824665|Active Comparator|Fentanyl Group|Fentanyl Group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 20 μg fentanyl
89662568|NCT03824665|Active Comparator|Control group|Control group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml normal saline
89662569|NCT04120831|Experimental|Rituximab + Abatacept + MTX|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
89662570|NCT04120831|Active Comparator|Rituximab + MTX (standard of care)|all participants receive Rituximab. Study subjects will be randomized into one of two treatment arms (Abatacept+MTX vs MTX) following a 1:1 randomization at Visit 3, at the day of the 2nd Rituximab Infusion.
89662571|NCT00631163|Experimental|Deferasirox|Participants received initial dose of 20 milligrams per kilogram (mg/kg) Deferasirox tablets was administered orally once daily (OD) based on the Participants body weight. The dose of Deferasirox was adjusted to either 10 mg/kg or 30 mg/kg based on the volumes of blood transfusions being administered.
89662572|NCT03820609|Experimental|Digital Intervention|Make a Change is a universal sexual assault (SA) prevention program that aligns with best-practices in prevention, utilizes the theory and strategies of serious games for health, and addresses risk and protective factors for SA across the social ecology of individual, peer and community factors that foster SA. This novel digital application also leverages theories of behavior change within serious games for health, and integrates successful practices in videogame design to promote engagement, learning and skill-building.
89662573|NCT04120675|Experimental|Experimental group|"Experimental Group 20 patients on Early Harvest Extra Virgin Olive Oil Aluminum bottle with 500 ml of early harvest extra virgin olive oil (3 tablespoons per day).~Dietary Supplement: Early Harvest Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
89662574|NCT04120675|Active Comparator|Control group|10 patients will not receive treatment with Extra Virgin Olive Oil
89662575|NCT03824431||patients with endoscopic microerosions|"==Patients with typical symptoms of Gastroesophageal Reflux Disease(GERD):~1- High resolution definition with NBI endoscopic findings of mucosal microerosions in distal esophagus .~."
89662576|NCT03824431||patients without microerosions|2- High resolution definition with NBI endoscopic without findings of mucosal microerosions in distal esophagus .
89662577|NCT04120441|Experimental|Group mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
89688668|NCT00931879|Placebo Comparator|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
88994819|NCT04689607|Experimental|Mulligan Traction Straight Leg Raise (TSLR)|This technique involves sustained traction applied to the limb. Patient actively does the SLR and both the therapist and the patient note the range. Therapist now grasp patient lower leg proximal to the ankle joint and raise it off the bed to a position just short of the painful range. Therapist flexes his knees and holds the clasped leg to his (therapist's) chest. When the therapist extends his knees this will effectively apply a longitudinal traction to the leg provided the bed is low enough and the therapist is tall enough. Sustain this traction and undertake a straight leg raise as far as it will go provided there is no pain.When pain free SLR with traction is given for three times.
88999215|NCT03004404|Experimental|SRD part-Dose group 8-9: BI 730357 tablet(s) 400 mg Fed|"The same participants conformed the Dose group (DG) 8 and DG 9. DG 8: Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (8x50mg) together with about 240 milliliter (mL) of water, 30 minutes (min) prior dose administration the participants consumed a standard continental breakfast.~DG 9: Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (8x50mg) together with about 240 milliliter (mL) of water, 30 minutes (min) prior dose administration the participants consumed a standard high fat breakfast.~Both treatment periods were separated by a wash-out phase of at least 14 days between drug administration of DG 8 and DG 9. One authorized employee of the trial site was witness of the administration of the trial medication."
89048071|NCT04294563|Experimental|Immediate Intervention Group|Participants will complete baseline measures and begin daily supplementation of peanut protein powder (72g/day) 7 days prior to total knee arthroplasty until 6 weeks after surgery.
89048072|NCT04294563|Active Comparator|Wait-llist Control Group|Participants will complete baseline measures 7 days prior to total knee arthroplasty and will receive a 7 week supply after completion of 12 week post-surgery visit.
89662578|NCT04120441|No Intervention|Routine care/control|Study participants randomized to control will receive information about community resources. Youth study participants will be interviewed about the youth's thoughts and behaviors and the youth's medical and school records will be reviewed. Parents will also be interviewed to ask questions about the program. The study will last for 12 months and youth/parents will be interviewed at the time of enrollment and 4-6 months later.
89662579|NCT03820453|Experimental|Active group|One tablet per day in the morning through oral administration of a dietary supplement containing Tribulus terrestris as the main active ingredient. During three months with the possibility to extend for another three months.
89662580|NCT03820453|Placebo Comparator|Control group|One tablet per day in the morning through oral administration of Placebo. During three months.
89662581|NCT04120519|Experimental|TCD|thalidomide 100mg qn cyclophosphamide 300mg/m2 d1,8,15 dexamethasone 40mg d1,8,15,22
89662582|NCT00631007|Experimental|INT131 besylate 0.5 mg|INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
89662583|NCT00631007|Experimental|INT131 besylate 1 mg|INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
88994820|NCT04689607|Active Comparator|Post Isometric Relaxation technique (PIR):|The patient is placed in the supine position with the non-affected leg lying flat on the table. The knee of the affected leg is gently placed in extension, and the affected hip is then flexed. The calf of the patient is then placed on the shoulder of the practitioner The practitioner stands on the side of the affected leg. The hands of the practitioner are then placed over the upper leg, just proximal to the knee. The hip of the affected leg is then passively flexed until resistance is felt. The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance. The practitioner resists hip extension to create an isometric contraction and then, after appropriate time and breathing instructions. The patient is instructed to relax and the practitioner gently flexes the hip until the next barrier is reached. After a period of relaxation, the technique will be repeated three to four times.
88994821|NCT04689217|Experimental|Group F|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml fentanyl (25 μg)
88994822|NCT04689217|Experimental|Group N|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.8 mg nalbuphine hydrochloride
88994823|NCT04689217|Placebo Comparator|Group C|will receive intrathecal injection of 0.5% hyperbaric bupivacaine plus 0.5 ml normal saline
88994824|NCT00149162|Active Comparator|1|Patients treated by Proleukin
89662584|NCT00631007|Experimental|INT131 besylate 2 mg|INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
89662585|NCT00631007|Experimental|INT131 besylate 3 mg|INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
88994825|NCT00149162|No Intervention|2|Without Proleukin
88994826|NCT02925637|Experimental|FACoT group|treatment group will receive FACoT, that include one to one 10 treatment sessions. the treatment sessions will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
88994827|NCT02925637|No Intervention|control group|control group receiving standard care - cognitive and functional assesment
88994828|NCT00170547|Experimental|Group 3|382 subjects will receive one 3 mcg dose of Fluzone intradermally using the Mantoux technique on Day 0,
88994829|NCT00170547|Experimental|Group 4|382 subjects will receive one 15 mcg dose Fluzone vaccine intramuscularly (IM) on Day 0,
88994830|NCT00170547|Experimental|Group 1|382 subjects will receive one 6 mcg dose of Trivalent inactivated influenza vaccine (TIV) intradermally (ID) with the BD ID System on Day 0,
88994831|NCT00170547|Experimental|Group 2|382 subjects will receive one 9 mcg dose of TIV intradermally (ID) with the BD ID System on Day 0,
88994832|NCT02925559|Experimental|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
88994833|NCT02925559|Active Comparator|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
88994834|NCT02925325|Experimental|Music Therapy|Music therapy 8 weekly sessions
88994835|NCT02925325|Active Comparator|Usual Treatment|It is the usual medical treatment.
88994836|NCT02925286|Experimental|Intervention group|Five organizations will get the intervention during fall/winter 2016.
89662586|NCT00631007|Active Comparator|pioglitazone HCl 45 mg|pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
89662587|NCT00631007|Placebo Comparator|placebo|placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl
88994837|NCT02925286|No Intervention|Wait-list group|Five organizations will be on the waitlist for 12 months and then get the intervention.
88994838|NCT02925247|Other|patient with atrial fibrillation|
89662588|NCT04392115|Experimental|Exercise Group|"The home-based exercise program called the PREPARE program.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
89662589|NCT04392115|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
89662590|NCT03820297|Other|Anti-Stigma Group|Complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.
89662591|NCT03824353|Experimental|Social Intelligence Training|The social intelligence training is delivered online to individuals in midlife (ages 40 and older). This is the sole active treatment condition within this RCT.
88994839|NCT02925481|Experimental|Low dose Yoga|12 week online yoga for 60 minutes per week
88994840|NCT02925481|Experimental|Moderate dose Yoga|12 week online yoga for 150 minutes per week
88994841|NCT02925481|Active Comparator|Stretch and toning|12 week online stretching, toning exercises for 60 minutes per week
89662592|NCT03824353|Placebo Comparator|Attention Control|The attention control condition, known as The Healthy Living program provides information about different aspects of health.
89662593|NCT04120207|Experimental|Home-based Pilates|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
88994842|NCT02925442|Experimental|Standard Thermal radiofrequency ablation|Patients randomized to t-RFA will receive standard genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
88994843|NCT02925442|Experimental|Cooled radiofrequency ablation|Patients randomized to C-RFA will receive cooled genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
88994844|NCT02925442|Sham Comparator|Control:Placebo Sham|Patients randomized to control will receive simulated genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty and receive the industry standard of care for unilateral knee arthroplasty pain management.
88994845|NCT02925598|Experimental|I-gel LMA|I-gel LMA insertion: I-gel insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
88994846|NCT02925598|Experimental|AuraGain LMA|AuraGain insertion:AuraGain LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
88994847|NCT02925598|Experimental|Endotracheal tube (ETT)|Endotracheal tube insertion: Endotracheal tube (ETT) insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
88994848|NCT00170664|Experimental|Paclitaxel, Carboplatin|
88994849|NCT02917954|No Intervention|ePRO Control (3 or 6 months)|Control participants will complete surveys at baseline, 3 months, and/or 6 months. Surveys will capture patient demographics, their assessment of quality-of-life, chronic disease management, and primary care experience. A part from completing these surveys, no change to routine care will be seen.
88994850|NCT02917954|Experimental|ePRO intervention (12 or 9 months)|"During the ePRO Tool intervention participants will complete surveys at every 3 months intervals starting month at 4 or month 7, for study duration. Surveys capture patient demographics, assessment of quality-of-life, chronic disease management, primary care experience, and Electronic Patient Reported Outcome (ePRO) Mobile Application tool usability.~Participants will also meet with their provider to setup and monitor a health goal to track during the study via the ePRO application. During the study, participants will meet with their primary care providers 4-5 times to discuss their health goal monitoring. Post-study participants will discuss their experience using the ePRO app in an interview or focus group setting."
88994851|NCT02917837|Active Comparator|Usual QCNL report group|Physicians receive the usual Quality of Care Newfoundland and Labrador utilization report: This reports ranks the physician on a figure of their peers according to the total number of tests ordered in a one-year period.
88994852|NCT02917837|Experimental|Usual QCNL report plus detailing.|This group receives the usual QCNL report described above. Shortly after the reports are sent, this group will be contacted at least three times to attempt to arrange a single in-person detailing session.
88994853|NCT02917837|Experimental|New utilization report|This group will receive a new type of report that shows individual physician ordering per 100 patients compared to the mean of all physicians, adjusted for patient complexity (age, sex, comorbidity, education, income, rurality).
88994854|NCT02917837|Experimental|New utilization report plus detailing|New type of report plus detailing as described above.
88994855|NCT04689022|Other|Group І received general anesthesia (n=53)|"The sedation with constant rate infusion of 1% propofol, 1-4mg/kg/h, guided by Bispectral analysis (60-70 - for regional anesthesia and 40-60 - for the general one). 0.005% fentanyl analgesia was injected, 3-10 mkg/kg or 0.05-0.2 mkg/kg/min during induction; and 2-10 mkg/kg/h for maintaining analgesia, by periodic bolus injection 25-100 mkg or by permanent infusion.~The postoperative pain management of the I group patients was provided according to the local clinical protocol: paracetamol+/-non-steroid anti-inflammatory drugs +/-opioids.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
88994856|NCT04689022|Other|Group II received regional anesthesia: peripheral block was performed (n=73)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
89048073|NCT04284969|No Intervention|Control arm|Patients treated according current practice of the inclusion center. If interventions are implemented locally (geriatric assessment, nutrition, physical activity) they may be proposed to the patient.
89048074|NCT04284969|Experimental|Intervention arm : PROADAPT program|Patients benefiting from the PROADAPT (interventional arm) program.
89048075|NCT04256538||Crohn's Disease Group|Patients are diagnosed as Crohn's disease and have no history of colectomy.
89048076|NCT04256538||Ulcerative Colitis Group|Patients are diagnosed as ulcerative colitis and have no history of colectomy.
89048077|NCT04256538||Healthy Control Group|Individuals that have no past medical history.
89048078|NCT04242953|Experimental|SCO-120|
89048079|NCT04242953|Placebo Comparator|Matching Placebo|
89662594|NCT04120207|Other|Delayed-Start Control|Participants randomized to Delayed-start will be instructed to maintain their pre-intervention physical activity levels during the trial and will be contacted by the lead researcher by email or telephone to ensure timely completion of the on-line outcome assessments at biweekly intervals. Following the 8-week intervention, Delayed start participants will be provided with the Pilates DVD for their own use, but no data will be collected. For both groups, participants who experience a relapse will be immediately withdrawn from the study, which will be recorded by the lead researcher.
89662595|NCT00630539|Placebo Comparator|Subjects on placebo|Subjects will self-administer 1 placebo tablet daily (in the morning with food) for 12 weeks
89662596|NCT00630539|Experimental|Subjects on ospemifene 5 mg/day|Subjects will self-administer 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks
89662597|NCT00630539|Experimental|Subjects on ospemifene 15 mg/day|Subjects will self-administer 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks
89662598|NCT00630539|Experimental|Subjects on ospemifene 30 mg/day|Subjects will self-administer 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks
89662599|NCT04392271|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 24 hours later.
89662600|NCT04120051|Experimental|Fermented canola-seaweed supplement|Ingredients: Canola meal, seaweed, wheat, glucose, Vitamin D and lactic acid bacteria
89662601|NCT04120051|Placebo Comparator|Placebo|Ingredients: Rye flour, water, iodized salt, brown sugar
89662602|NCT02195349|Experimental|Healthy Subjects (no DTH)|One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
89662603|NCT02195349|Experimental|Healthy Subjects (DTH)|Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
89662604|NCT02195349|Experimental|Subjects with Psoriasis|Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
89662605|NCT04120129|Experimental|TMS treatment|participants receive TMS treatment
89662606|NCT04120129|Sham Comparator|sham TMS|participants receive control TMS treatment
89662607|NCT04120129|No Intervention|non intervention|control group
89662608|NCT00630305|Other|Session A|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session A only contains senofilcon A toric and alphafilcon A toric lenses.
89662609|NCT00630305|Other|Session B|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session B only contains senofilcon A toric and alphafilcon A toric lenses.
89662610|NCT00630305|Other|Session C|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session C only contains senofilcon A toric and lotrafilcon B toric lenses.
89662611|NCT00630305|Other|Session D|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session D only contains senofilcon A toric and lotrafilcon B toric lenses.
89662612|NCT04758793|Other|patients without liver disease,|taking blood samples and biopsy of muscular wall
89662613|NCT04758793|Other|patient with chronic liver disease without cirrhosis,|taking blood samples and biopsy of muscular wall
89662614|NCT04758793|Other|patients with compensated cirrhosis,|taking blood samples and biopsy of muscular wall
89662615|NCT04758793|Other|patient with severe cirrhosis|taking blood samples and biopsy of muscular wall
89662616|NCT00634829|Experimental|T|Armstrong Albuterol HFA Inhalation Aerosol
89662617|NCT00634829|Active Comparator|R|2 inhalations Proventil-HFA Albuterol Sulfate, 108 mcg, prior to exercise
89662618|NCT00634829|Placebo Comparator|P|Placebo-HFA
89048080|NCT04226898|Experimental|Synbiotic Supplement|The active synbiotic supplement consists of a stick/packet containing 4 strains of probiotic microorganisms: Lactobacillus acidophilus, LA-5® (material number 501082 FD LAK KGPharma); Lactobacillis paracasei subsp. paracasei, L. CASEI 431® (material number 684301 FD L. casei 431 HA Granulate); Lactobacillus rhamnosus, LGG® (material number 699817 FD LGG HA-W-IF); and Bifidobacterium animalis subsp. lactis, BB-12® (material number 699813 FD BB-12 HA-W-IF). In addition, the stick/sachet contains 5 g inulin. The product is a powder which participants will be asked to take with liquid or food. In this arm, the participant will take 1 powder stick of the synbiotic supplement once a day for 12 weeks after a 2-week placebo run-in.
89048081|NCT04226898|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the synbiotic supplement. In this arm, the participant will take 1 powder stick of the placebo daily for 12 weeks after a 2 week placebo run-in.
89662619|NCT00634517|Experimental|T|Armstrong Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
89662620|NCT00634517|Active Comparator|R|Proventil-HFA, Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
89662621|NCT04395911|Other|SCD|Cytopheretic device
89662622|NCT01920035|Experimental|Local cooling/hypothermia|These patients will have the UroCool device inserted prior to RARP to induce localized cooling/hypothermia of the pelvic region prior to and during RARP surgery.
89662623|NCT01920035|No Intervention|Control Group: RARP without hypothermia|These patients will receive standard of care only for RARP surgery. They will not receive the UroCool investigational device.
89662624|NCT03824197|Other|EVOO-phenol high|Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet
89662625|NCT03824197|Other|OO-phenol low|Olive oil with low phenolic content that will be added to daily diet
89662626|NCT01920113|Experimental|DR group|In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex®, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started.
89662627|NCT01920113|Active Comparator|PR group|In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan).
88994857|NCT04689022|Other|Group III received regional anesthesia with sedation (n=92)|"The regional anesthesia was guided by ultrasound (apparatus Mindray DP-30 with linear array probe 5-10 MHz). A needle was inserted near the nerve roots and 20-30 ml of 0.5% bupivacaine was injected.~The postoperative pain management - repeated peripheral block or prolonged regional anesthesia with 0.25% bupivacaine solution.~The PTSD progress and treatment effectiveness were estimated using the Mississippi Scale for Combat-Related PTSD, anesthesia risks - the American Society of Anesthesiologists classification, pain intensity - the visual analogue scale, neuropathic pain component - the Douleur Neuropathique 4 questions."
88994858|NCT02917681|Experimental|MSC injection|Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.
88994859|NCT02917486||ECMO piperacillin|patients in intensive care treated with ECMO with antiinfective therapy : piperacillin
88994860|NCT02917486||without ECMO piperacillin|patients in intensive care without ECMO with antiinfective therapy : piperacillin
88994861|NCT03315403||Patients with CAP|"Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
88994862|NCT03315403||Related controls|"Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
88994863|NCT03315403||Unrelated controls|"Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
88994864|NCT03315403||Patients with stable COPD|"Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
88994865|NCT03315403||Patients with exacerbation of COPD|"Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
88994866|NCT00149318||Patients with Fabry disease|
88994867|NCT02917525|Experimental|Vitamin K2|22 patients will receive 360ug Vitamin K2 daily during 18 months.
88994868|NCT02917525|Placebo Comparator|Placebo|22 patients will receive placebo during 18 months.
88994869|NCT03457441|Other|Near visual acuity +1.0 and +0.7 logMAR|Subjects with near visual acuity between +1.0 and +0.7 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
88994870|NCT03457441|Other|Near visual acuity +0.6 and +0.3 logMAR|Subjects with near visual acuity between +0.6 and +0.3 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
88994871|NCT03457441|Other|Near visual acuity +0.2 and +0.0 logMAR|Subjects with near visual acuity between +0.2 and +0.0 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
88994872|NCT02917330|Experimental|Strength and stretching intervention|Treatment as usual + a strength and stretching intervention together with a physiotherapist
88994873|NCT02917330|No Intervention|Control group|Treatment as usual
88994874|NCT00149357||1, 2 ,3|Group 1 Women with unprovoked VTE and No Known Thrombophilia Group 2 Women who are investigated for VTE and are negative (Control) Group 3 Women with unprovoked VTE who have Thrombophilia
88994875|NCT02917369||Normal lung tissue|Normal lung tissue from LCLC patients
88994876|NCT02917369||LCLC tissues|LCLC tissues from LCLC patients
88994877|NCT02917369||Metastasis tissues|Metastasis tissues from LCLC patients
88994878|NCT02917408||Primary biliary cholangitis during January 2001 to July 2016|
88994879|NCT02917252|Active Comparator|Intervention|Subjects drink 3-hydroxybuturate
88994880|NCT02917252|Placebo Comparator|Placebo|Subjects drink saline
88994881|NCT02917291|Experimental|FAB117-HC (Ph 1)|Patients with acute traumatic spinal cord injury grading AIS A (8 patients)
88994882|NCT02917291|Other|Control group (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
89662628|NCT03823807|Experimental|SH-1028|QD,Oral
89662629|NCT01920191|Experimental|IMA 950 and Poly ICLC|
89662630|NCT03823963|Other|Standard care|pressure ulcer prevention standard care
89662631|NCT03823963|Experimental|standard care + Mepilex® Border|pressure ulcer prevention standard care + Mepilex® Border applied on sacrum
89662632|NCT01920269|Active Comparator|Transurethral resection alone|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra-ie, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
89662633|NCT01920269|Active Comparator|Intravesical passive diffusion mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin treatments. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
89688669|NCT00931879|Active Comparator|omega-3-ethyl esters 4g|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
89688670|NCT02930980|Experimental|Investigational Software|Investigational Software loaded on Micra device
88994883|NCT02917291|Experimental|FAB117-HC (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
88994884|NCT02917174|Experimental|mobile management|use mobile management to improve asthma control
88994885|NCT02917174|Other|Traditional management|use Traditional management to improve asthma control
88994886|NCT02917018|Active Comparator|Dexmedetomidine 1|patients will receive dexmedetomidine 1 mic/kg
88994887|NCT02917018|Active Comparator|Dexmedetomidine 0.75|patients will receive dexmedetomidine 0.75 mic/kg
88994888|NCT02917018|Active Comparator|Dexmedetomidine 0.5|patients will receive dexmedetomidine 0.5 mic/kg
88994889|NCT02917135||Angel® Catheter|All consecutive, hospitalized patients in whom the Angel® Catheter is placed, or there has been an attempt to place, at selected Registry sites.
88994890|NCT02917057||Exenatide once weekly initiators|Type 2 diabetes patients who initiated exenatide once weekly treatment during the index period
88994891|NCT02917057||Basal Insulin initiator cohort|Type 2 diabetes patients who initiated basal insulin treatment in the index period
88994892|NCT02916940|Experimental|Diprophos|Patients having had a sprain of the long fingers, within 2 weeks of consultation. This group will receive a single injection of corticoids.
88994893|NCT02916940|No Intervention|Control group|Patients having had a sprain of the long fingers (Eaton classification type I and II), within 2 weeks of consultation. This group will receive the standard of care treatment, without injection of corticoids.
88994894|NCT00149513|Experimental|1|Targeted nurse case management
88994895|NCT00149513|Active Comparator|2|Usual Care
88994896|NCT02916901|Experimental|CKD-519 200mg|CKD-519 tab(formulation II) 200mg (100mg X 2tabs)
88994897|NCT02916901|Placebo Comparator|Placebo|placebo
88994898|NCT02916784||Sit-to-stand: Pass|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'pass' if the subjects could safely rise from the chair without using their arms and with no more than contact guarding assist.
88994899|NCT02916784||Sit-to-stand: Fail|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'fail' if the subjects could not rise from the chair without using their arms and/or with more than contact guarding assist.
88994900|NCT02916355|Experimental|Normal BMI|Healthy young men, normal BMI (BMI >18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
88994901|NCT02916355|Experimental|Overweight|Healthy young men (BMI >30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
88994902|NCT00149552|Active Comparator|Zinc gluconate|Zinc supplementation
88994903|NCT00149552|Placebo Comparator|Placebo|Placebo
88994904|NCT02916589|Placebo Comparator|Baseline|The subjects will start with one week eating their normal diet.
88994905|NCT02916589|Active Comparator|Igelosa Diet|After one week the subjects will be provided the Igelosa Diet.
88994906|NCT02916628|Experimental|Group 1|auricular acupressure + group counseling
88994907|NCT02916628|Placebo Comparator|Group 2|placebo acupressure + group counseling
88994908|NCT02916628|No Intervention|Group 3|self-help smoking cessation
88994909|NCT02916628|No Intervention|Group 4|Non-smokers
88994910|NCT00163722|Active Comparator|Standard diagnostic strategy of culture and histology|The standard-diagnostic strategy was designed to be consistent with the 2002 guidelines for antimicrobial use in neutropenic patients with cancer. When an invasive fungal infection was suspected (e.g. persistent fevers) cultures of blood, urine, sputum (if available) and faeces (if clinically indicated), and HRCT scans of chest were performed. Bronchoscopy and biopsies were performed according to institutional protocols. Empiric antifungal therapy was recommended whilst undergoing these investigations and was continued, de-escalated to prophylaxis, or changed to treatment of invasive aspergillosis or other IFD according to test results.
88994911|NCT00163722|Experimental|Aspergillus galactomannan and PCR directed|Results of once to twice weekly testing with Aspergillus galactomannan and PCR directed the timing of CT scan performance and whether antifungal therapy was given
88994912|NCT02916667|Active Comparator|CNdiet|CNdiet includes chrono nutritional dietary guidelines
88994913|NCT02916667|Placebo Comparator|GDMdiet|GDMdiet includes regular GDM diet
88994914|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++|Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
89662634|NCT01920269|Active Comparator|Intravesical electromotive mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
89662635|NCT03823729|Experimental|Elosan Cabin|Treatment with Elosan cabin
89662636|NCT03823729|No Intervention|No Treatment|Continuation of taking pain medication as prescribed before study start.
89662637|NCT01920347||Neurological Pupil index|The NPi will be measured during treatment
89662638|NCT03823495|Experimental|Experimental group|12-week PAP (one 1-hour session per week). Each session includes 20-minute exercise, 30-minute interactive pain management education, practices on non-drug management techniques, and portfolio entry for activities of the day.
89662639|NCT03823495|No Intervention|Control group|The control group will receive the usual care and a pain management pamphlet distributed by nursing home staff
89662640|NCT01920425|Other|Hand-written diary first|Participants in this group will use the hand-written diary for the first two week and switch to Kinesia HomeView and the electronic diary for the second two weeks.
89662641|NCT01920425|Other|Kinesia HomeView first|Participants in this group will use Kinesia HomeView and the electronic diary for the first two week and switch to the hand-written diary for the second two weeks.
89662642|NCT02957929|Experimental|Cohort 1a, Period A|single intravenous dose, crossover
89662643|NCT02957929|Experimental|Cohort 1a, Period B|single oral dose, crossover
89662644|NCT02957929|Experimental|Cohort 1a, Period C|single oral dose
88994915|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++|Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
88994916|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+|Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
88994917|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：healthy volunteers|Patients in this group who are healthy volunteer.
88994918|NCT02915965|Experimental|DCX and surgery|docetaxol 60mg/m2 iv d1 and cisplatin 30mg/m2 iv d1-2 and capecitabine 850mg/m2 bid po d1-14 repeated every 21 days for 4-6 cycles, followed by surgery of Ivor Lewis Esophagectomy
88994919|NCT02916238|Experimental|Measurement Based Care|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
88994920|NCT02916238|Active Comparator|Enhanced Usual Care|Depression symptoms monitored at 3 month interval; results from PHQ-9 available to ART clinic physicians.
89662645|NCT02957929|Experimental|Cohort 1a, Period D|single oral dose, crossover
89662646|NCT02957929|Experimental|Cohort 1b, Period E|Single oral dose under fasted conditions, crossover
88994921|NCT02916082||Prolonged pregnancy|Pregnancies with 41 weeks or more of gestation determined by a reliable last menstrual period or early fetal ultrasound.
88994922|NCT00163761|Active Comparator|Commence VGF treatment|Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle
88994923|NCT00163761|Active Comparator|Commence F-GIV treatment|Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle
89662647|NCT02957929|Experimental|Cohort 1b, Period F|Single oral dose under fed conditions, crossover
89662648|NCT02957929|Experimental|Cohort 2|Multiple oral doses
88994924|NCT02916043||Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery with cardiopulmonary bypass
88994925|NCT02916160|Experimental|SACUBITRIL - VALSARTAN|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
88994926|NCT00149786|Experimental|1|Those adolescents receiving family based therapy
88994927|NCT00149786|Active Comparator|2|Those adolescents receiving individual therapy
88994928|NCT02916121|Experimental|folic acid 5 mg/cap|folic acid 5 mg/d and vitamin B12 500 ug/d
88994929|NCT02916121|Placebo Comparator|placebo|placebo
88994930|NCT02916199|Experimental|Needle knife fistulotomy|"Device: Needle knife fistulotomy Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
89048082|NCT04225312|Experimental|Personalized extended interval dosing|Patients will be receiving a personalized dosing schedule from 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
89662649|NCT02957929|Experimental|Cohort 3|Multiple oral doses
89662650|NCT02957929|Experimental|Cohort 4|Multiple oral doses in presence of CYP probe substrates
89662651|NCT01920503||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
89662652|NCT04352049|Active Comparator|3TV group|Patients were randomly assigned to receive either three minutes tidal volume (3TV) with a fresh gas flow (FGF 100% O2) via facemask of 5 L/min
89662653|NCT04352049|Active Comparator|8DB group|Or eight vital capacity breaths for 1 minute with FGF of 10 L/min
89662654|NCT01920581||volunteers|
89662655|NCT03821389|Experimental|NIOD Frequencer of 40Hz|40 Hz of NIOD will be applied and then 60Hz will be used 3 hours later. 60 Hz of NIOD will be applied and then 40Hz will be used 3 hours later for the rest of the patients. The investigators will analyze the difference in average effects between 40Hz and 60Hz.
89662656|NCT03821389|Active Comparator|NIOD Frequencer of 60Hz|
89662657|NCT01920659|Experimental|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
89662658|NCT01920659|Experimental|REHIT|6 weeks of HIT, 3 times a week (20sec)
89662659|NCT01920659|No Intervention|control|control
89662660|NCT01262547|Experimental|Dermabrasion-Micrografting|Dermabrasion-Micrografting
89662661|NCT01262547|Active Comparator|Dermabrasion alone|Dermabrasion alone
89662662|NCT01262547|No Intervention|Control|Control
89662663|NCT02983201|Active Comparator|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
89662664|NCT02983201|Experimental|thumbtack needle+filiform needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
89662665|NCT03831893|Sham Comparator|Control|A food product similar to the test products but without nopal
89662666|NCT03831893|Experimental|Nopal food product 1|Food product with Nopal
89662667|NCT03831893|Experimental|Nopal food product 2|Food product with Nopal
89662668|NCT01920815||Beta blocker therapy|Cohort will consist of those actively taking any beta blocker medication. Observation only.
89662669|NCT01920815||ARB therapy|Cohort will consist of those actively taking any angiotensin receptor blocker medication. Observation only.
89662670|NCT01920815||No therapy|Cohort will consist of those not taking either beta blocker nor angiotensin receptor blocker. Observation only.
89662671|NCT01293825|Experimental|Medication Adherence Bipolar Disorder|There was only one group in this study. All participants received the study drug Ziprasidone.
89662672|NCT04392349|Other|NORMAL|Normal group includes eyes with healthy cornea.
89662673|NCT04392349|Other|IRREGULAR|Irregular goup includes eyes with irregular astigmatism or corneal scarring.
89662674|NCT01920971|Active Comparator|inferared therapy|hot pack therapy combined active infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
89662675|NCT01920971|Placebo Comparator|placebo infrared therapy|hot pack therapy combined placebo infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
89662676|NCT03009513|Experimental|single arm|
88994931|NCT02916199|Active Comparator|conventional cannulation|"Device: conventional canulation catheter Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
89662677|NCT04129333|Experimental|Hypnosis group|A hypnosis group with standard care during the invasive procedure according to the usual practice of the care team and setting up a hypnotic accompaniment by an nurse trained beforehand and dedicated throughout the gesture. The hypnosis session will end at the same time as the invasive procedure.
89662678|NCT04129333|Placebo Comparator|Control group|A control group with standard care during the invasive procedure according to the usual practice of the care team.
89662679|NCT02983591|Experimental|Misoprostol|Rectal misoprostol
89662680|NCT02983591|Experimental|Oxytocin|intravenous oxytocin
89662681|NCT03829891|Experimental|Beinaglutide|"Beinaglutide for 8 weeks,~Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
89662682|NCT03829891|Active Comparator|glargine|"Glargine for 8 weeks,~Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
89662683|NCT01263717|Experimental|Tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
89662684|NCT01263717|Placebo Comparator|Placebo (inactive injection)|Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase
89662685|NCT04120753|Experimental|Treatment 1|OLOMAX 20/5/5mg
89662686|NCT04120753|Experimental|Treatment 2|OLOMAX 20/5/10mg
89662687|NCT04120753|Active Comparator|Treatment 3|Olmesartan 20 mg/Amlodipine 5 mg
89662688|NCT01921361|Active Comparator|Intravenous|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
89048083|NCT04225312|Other|Standard interval dosing|Patients who prefer to stay on standard interval dosing.
89662689|NCT01921361|Active Comparator|Intrathecal|Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
89662690|NCT01921361|Placebo Comparator|Control|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).
89662691|NCT03826459|Active Comparator|Locked Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & locking technique. The second layer will be performed based on surgeon preference.
89662692|NCT03826459|Experimental|Non-Locking Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.
89662693|NCT01265667|Experimental|CF101 2 mg|CF101 2mg oral tablets
89662694|NCT01265667|Placebo Comparator|Placebo|Placebo oral tablets
89662695|NCT01921439|Active Comparator|Feedback|Participants in this group will receive individualized feedback based on their stage of change. Feedback will include health effects of smoking, money spent per month and per year on cigarettes, time spent smoking compared with time spent doing other daily tasks, and how the participant compares to past study participants in average number of cigarettes per day used and level of addiction.
89662696|NCT01921439|No Intervention|No Feedback- Treatment as Usual (TAU)|Participants will take the computer based survey, but will only receive a number to the Oklahoma Tobacco Helpline (Treatment-as-usual condition) instead of feedback.
89662697|NCT01921595|Experimental|Valanced salt colloid group|
89662698|NCT01921595|Active Comparator|Valanced salt crystalloid group|
89662699|NCT01921673|Experimental|Dovitinib plus docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
89662700|NCT01921907|Experimental|Active|topical treatment
89662701|NCT01921907|Placebo Comparator|Placebo|topical treatment
89662702|NCT01921985|Active Comparator|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
89662703|NCT01921985|Placebo Comparator|NaCl|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
89662704|NCT01922063|Experimental|Physiotherapy Intervention|20 treatment sessions of a comprehensive physiotherapy program, 12 weeks' duration, with custom tailored instructions by the supervising physician; physicians discussed the course of therapy with the physiotherapist 1x/week. Patients had been treated by physiotherapist according to written prescriptions. Duration of treatment 30 min/ session. Patients were encouraged to practice regular home exercise.
89662705|NCT01922063|Sham Comparator|Sham neck massage|"received twenty sessions sham neck massage of 30 minutes' duration each with the patients lying in supine position on a massage bed and the head of the patient resting on the therapist's knees"
89662706|NCT01922063|No Intervention|No therapy|"no further therapy, patients were asked to wait and see for the first three months after operation, and no particular treatment was planned"
89662707|NCT02943733|Experimental|TAS-102 and TMZ|"Part 1: dose-escalation phase to determine MTD of TAS-102 in combination with Temozolomide (TMZ). Treatment cycles are 28 days, with TAS-102 administered orally twice daily days 1-5 and 8-12, and TMZ administered orally days 8-12. No treatment medications administered days 13-28 of each cycle. Growth factor support is required during Part 1 and should be dosed per institutional standards.~Part 2: expansion phase to evaluate preliminary efficacy of MTD. Subjects treated with the recommended phase 2 drug doses determined in part 1. Treatment will continue for up to 13 cycles (approx. 12 months). Growth factor support is allowed during Part 2 and should be dosed per institutional standards."
89662708|NCT01922141|Experimental|Aliskiren monotherapy|Aliskiren 150 mg, once a day, force titrated to Aliskiren 300 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
89048084|NCT04225312|Other|Historic cohort|Historic cohort of natalizumab treated patients on standard interval dosing.
89048085|NCT04209205|Experimental|AIN457 6 mg/kg - 3 mg/kg i.v.|AIN457 6 mg/kg i.v. infusion at baseline, followed by AIN457 3 mg/kg i.v. infusion every 4 weeks starting at Week 4 through Week 48 (exposure through Week 52).
89662709|NCT01922141|Experimental|Aliskiren dual therapy|Aliskiren 150 mg plus amlodipine 5 mg, once a day, force titrated to Aliskiren 300 mg plus amlodipine 5 mg after 8 weeks in 50% of patients. Optional titration of amlodipine 5 mg to 10 mg and optional addition/titration of hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
89662710|NCT01922141|Active Comparator|Ramipril monotherapy|Ramipril 5 mg, once a day, force titrated to Ramipril 10 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
89662711|NCT02856295|Active Comparator|clexane according to weight group|clexane dose adjusted for woman's weight according to: weight < 90 kg - 40mg, 91-130kg - 60 mg, 131-170kg - 80mg, >170kg-100mg.
89048086|NCT04209205|Placebo Comparator|Placebo|Matching placebo from baseline to Week 16 and switch to AIN457 3mg/kg i.v. infusion every 4 weeks through Week 48 (exposure through Week 52).
89662712|NCT02856295|Active Comparator|clexane mg per kg|clexane dose of 1mg/kg up to 120 mg
89662713|NCT01922297|Experimental|Day Treatment MDFT-HIV|Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
89048087|NCT04193787|Experimental|EPIC-P|Participants will enroll in a bio-behavioral intervention aimed at preventing HIV transmission in people who inject drugs.
89048088|NCT04193046|Other|Participants with PH and non-PH|Blood samples will be collected for biomarker analysis from new (incident) and existing (prevalent) participants who undergo right heart catheterization (RHC). Participants will be categorized into non-PH or PH based on the results of the RHC and those who are found to have PH will be further classified into the different groups of PH. A transthoracic echocardiography (TTE) will be performed if not done previously.
89048089|NCT04158908||Oncolo-GIST Arm: Caregivers|Caregiver stakeholders were bereaved family members of a patient who had died from solid tumor cancer in the past year. Stakeholders reviewed an initial version of the Oncolo-GIST manual to provide feedback and refine the manual for Phase 2.
89048090|NCT04158908||Oncolo-GIST Arm: Clinicians|Clinician stakeholders were physicians, nurses, nurse practitioners, and social workers with expertise in treating advanced cancer patients. Stakeholders reviewed an initial version of the Oncolo-GIST manual to provide feedback and refine the manual for Phase 2.
89048091|NCT04157595|Experimental|Participating Couples|Reproductive Genetic Carrier Screening
89048092|NCT04129086|Experimental|Ketamine plus Usual care|
89662714|NCT01922297|Other|Day Treatment SAU|The DT-Services as Usual (SAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions. It is an adolescent substance abuse treatment and services consistent with those recommended for juvenile justice-involved drug abusing youth (Cooper & Bartlett 1998; National Institute of Justice, 2001).
89662715|NCT01266447|Experimental|Treatment (veliparib, topotecan hydrochloride, filgrastim)|Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89662716|NCT02849977||Cohort 1|If the subject has a history of hyperphagia, early onset obesity and/or clinical characteristics known to be related to mutations in the MC4R pathway and related to obesity (1.4 times 95th percentile in children).
89662717|NCT02849977||Cohort 2|If the subject has exponentially high BMI (≥50 to 59), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.5 - 1.6 times 95th percentile in children).
89662718|NCT02849977||Cohort 3|If the subject has exponentially high BMI (≥60), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.6 times 95th percentile in children).
89662719|NCT02849977||Cohort 4|If the subject has had or is undergoing bariatric surgery, who represents a refractory population of severely obese individuals whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.4 times 95th percentile in children and adolescents aged 12 and older).
89662720|NCT03831581|Experimental|Erector Spinae Plane Block|Patients with chest pain or upper abdomen underwent Erector Spinae Plane Block guided by ultrasound, bupivacaine 0.5% 20 ml was administered in the interfascial plane between the transverse process of T5 and the erector muscles of the spine, 60 minutes after dermatomes distribution was evaluated with pinprick and cold.
89662721|NCT01922375|Experimental|Naftopidil dose 2|PO administration
89662722|NCT01922375|Placebo Comparator|Placebo|PO administration
89662723|NCT01922375|Experimental|Naftopidil dose 1|PO administration
89662724|NCT01922453|Experimental|Music and Sound|Music and Sound applied to maternal abdomen through a special device for pregnant women.
89662725|NCT01922453|No Intervention|no music and sound|
89662726|NCT03828721|Active Comparator|Control - screen time reduction|Families assigned to the control arm in each age category will receive customary ROR, including the provision of an age-appropriate children's book, and reading-related developmental surveillance and anticipatory guidance. In addition, control families will receive a new children's book reinforcing AAP screen-based media recommendations.
89662727|NCT03828721|Experimental|Rx for Success Smartphone Application|"Families in the intervention arm in both age categories will receive enhanced ROR involving the provision of the Rx for Success (RS) application at the baseline visit (6 months old and 18 months old, respectively). No additional intervention will take place, other than push notifications and other content such as demonstration videos built into the RS application."
89662728|NCT01922531||Mild Traumatic Brain Injury|These were patients who presented to the ER within 6 hours of a witnessed head injury. Patients were also eligible if the patient had a self-reported head injury with evidence of head trauma.
89662729|NCT01922531||Orthopedic Injury|Patients were eligible as an orthopedic injured control who presented to the ER within 6 hours of an isolated extremity trauma that radiography and an Abbreviated Injury Scale (AIS) of less than or equal to 3.
89662730|NCT03823339||Patients with type 2 diabetes (T2DM)|Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®
89662731|NCT01267227|Active Comparator|High Dose|Pterostilbene 125 mg twice daily
89662732|NCT01267227|Active Comparator|Low Dose|Pterostilbene 50 mg twice daily
89662733|NCT01267227|Active Comparator|Low Dose Combination|Pterostilbene 50 mg/Grape Extract 100 mg twice daily
89662734|NCT01267227|Placebo Comparator|Placebo|Matching placebo twice daily
89662735|NCT01922609||Normal cerebrovascular reserve|Patients without preprocedural TCD signs of impaired cerebrovascular reserve
89662736|NCT01922609||Impaired cerebrovascular reserve|Patients with preprocedural TCD signs of impaired cerebrovascular reserve
89048093|NCT04129086|Active Comparator|Usual care|
89048094|NCT04117685||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
89048095|NCT04117685||Arm II: Prior treatment at center|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
89048096|NCT04117685||Arm III: Prior treatment at outside center|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
89048097|NCT04103632|Experimental|Young recreational athletes (12-18 years)|"Young recreational athletes (12-18 years) of different sport disciplines:~Indoor sports~Outdoor sports~Swimming~Winter sports"
89048098|NCT04040764|Experimental|Uncemented Tritanium Knee Replacement|30 participants will be randomly allocated to receive an uncemented Tritanium total knee replacement.
89048099|NCT04040764|Active Comparator|Cemented Triathlon Knee Replacement|30 participants will be randomly allocated to receive standard Triathlon cemented total knee replacements.
89662737|NCT01267929|Experimental|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months. The mirror neurons stimulation based VCD program that contained four volumes. The first volume includes activities activities for improving balance in sitting position. The second volume includes activities of sitting to standing. The third volume includes activities for improving balance in standing position. The last one includes activities of sideway walking. The running time of each volume is 30 minutes. The children had been practicing for two weeks per volume. Their parents were trained for practicing their children by VCD program at home and were asked to complete daily record of children's activities. The children were scheduled to meet a pediatric physical therapist once a week to monitor possible side effects.
89662738|NCT01267929|Active Comparator|The conventional physical therapy|The children receive manual physical therapy regularly at the hospital once a week for first two months and twice a month for last four months. The conventional physical therapy technique in this study derive from the manual technique including the Bobath concept, stretching exercise and functional training for 30-45 minutes at a time.
89662739|NCT01922687|Experimental|Amlodipine Plus Atorvastatin (Caduet)|amlodipine plus atorvastatin in a single tablet (Caduet, Pfizer, USA) was given once daily
89662740|NCT01922687|Active Comparator|Amlodipine (Norvasc)|amlodipine(Norvasc, Pfizer, USA) given once daily
89662741|NCT01268553|Experimental|Active treatment|This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.
89662742|NCT03009435|Experimental|prophylactic manual rotation|"Only obstetricians will participate in the study. Manual rotation is performed at full dilatation.The technique employed will be at the discretion of the operator performing the procedure :~Tarnier and Chantreuil technique~or SOGC technique"
89662743|NCT03009435|No Intervention|expectative management|Expectative management . No manual rotation
89662744|NCT01922999|Active Comparator|Placebo controlled|comparison of placebo controlled to 1mg melatonin or 3mg melatonin
89662745|NCT01922999|Active Comparator|Melatonin|comparison of melatonin 1mg or melatonin 3mg
89662746|NCT01268943|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
89662747|NCT01268943|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
89662748|NCT01268943|Experimental|1400mg|capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
89662749|NCT01268943|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
89662750|NCT01923077|Placebo Comparator|Conventional|Conventional treatment with simvastatin
89662751|NCT01923077|Active Comparator|Rosuvastatin|loading dose of rosuvastatin 80 mg at randomization followed by 40 mg daily in 12 month.
89662752|NCT01923155|Active Comparator|Nurse endoscopists|Colonoscopy performed by nurse endoscopists supervised by senior medical endoscopists
89662753|NCT01923155|Active Comparator|Medical endoscopists|Colonoscopy performed by senior medical endoscopists
89662754|NCT01923233|Experimental|Treatment|Intradermal AlloStim(TM) (1ml) on day 0 and 3 in same location Intradermal AlloStim(TM) (1ml) on day 7 and day 10 in same location Radiofrequency ablation on day 14 followed by intralesional AlloStim (3ml) Intralesional AlloStim(TM)(3ml) on day 17 in same ablated lesion Intravenous AlloStim(TM)(5ml) on days 21, 49 and 78
89662755|NCT01269801|Active Comparator|Botox Cosmetic|onabotulinumtoxinA for injection
89662756|NCT01269801|Active Comparator|JUVÉDERM|JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
89662757|NCT05509907|Experimental|healthy adolescents within 12-18 years old|Adolescents aged 12-18 years who continue secondary education, do not have any chronic diseases or disabilities and volunteer to participate in the study will be included. Within the scope of the project, participants' demographic data, health parameters, physical fitness, functional capacity, fatigue level, exercise behavior, system availability and satisfaction will be evaluated. All evaluations, training on the use of smart watches and mobile and web-based physical activity tracking applications will be carried out at the school where the adolescents receive education.
89662758|NCT05509907|Experimental|Adolescents aged 12-18 years with chronic rheumatic disease|Children with rheumatic disease who were diagnosed with chronic rheumatic disease, diagnosed at least 6 months ago, whose medical treatment was stable, and who volunteered to participate in the study will be included. Within the scope of the project, participants' demographic data, health parameters, physical fitness, functional capacity, fatigue level, exercise behavior, system availability and satisfaction will be evaluated. All assessments and training on smartwatches and mobile and web-based physical activity tracking applications will be held at Department of Pediatric Rheumatology, Istanbul Faculty of Medicine, Istanbul University.
89662759|NCT05507255|Active Comparator|Relaxation training|Females will receive relaxation training, in the form of deep breathing, 3 days per week, for 8 weeks.
89662760|NCT05507255|Experimental|The same relaxation training plus an aerobic exercise program|Females will receive the same relaxation training, in addition to 30 minutes of a moderate aerobic exercise program on a treadmill, 3 days per week, for 8 weeks.
89662761|NCT01297335|Experimental|Intrathecal Clonidine|Subject will receive one time Clonidine injection via lower lumber interspace. Clonidine (Duraclon), 100 μg/ml, 1.5 ml will be diluted to 2 ml with preservative free saline, and total of 150 μg will be delivered. Supine and sitting blood pressures and heart rate will be measured at 10 minute intervals until 60 minutes after clonidine administration, then at 15 minutes for next 3 hours.
89662762|NCT05498129|Active Comparator|No school meal|
89662763|NCT05498129|Experimental|School meal|
89662764|NCT05498129|Experimental|School meal plus micronutrient powder|
89662765|NCT01270659|Experimental|Low-FBT|Subject will receive FBT and placebo at a low dose
89662766|NCT01270659|Experimental|High-FBT|Subject will receive the high dose regimen of FBT and a high dose placebo
89662767|NCT01270659|Active Comparator|Low control|"Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl placebo"
89662768|NCT01270659|Active Comparator|High control|"Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl placebo"
89662769|NCT03328715|Active Comparator|study group|only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
89662770|NCT03328715|Sham Comparator|controll group|only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
89662771|NCT05486117|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for 8 days
89662772|NCT01929239|Experimental|Anti PSMA Designer T Cells|Open Label, subjects receive anti PSMA designer T cells, plus IL2, low or moderate dose.
89662773|NCT01929629|Placebo Comparator|Placebo fasting|Single or multiple dosing placebo
89662774|NCT01929629|Experimental|Active fed condition|AZD0914 given as single dose
89662775|NCT01271907|Experimental|Cohort 0|Drosophila generated CTL + SQ IL-2 Drug: 1 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) (CTL-05), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
89662776|NCT01271907|Experimental|Cohort 1|2 Experimental Lymphodepleting regimen +Cells+Low dose IL-2 Drug: 2 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
89662777|NCT01271907|Experimental|Cohort 2|1 Experimental Lymphodepleting regimen +Cells Drug: 3 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells
89662778|NCT01929785||Pre and Post Transplant|Research blood samples will be drawn pre-transplant, and at monthly post transplant visits at times corresponding to post-transplant, standard of care ImmKnowo and AlloMap clinical testing. A minimum of 12 visits per patient is expected
89662779|NCT01929785||One year post transplant|The second group will include heart transplant recipients at one year post transplant who consent to participate in the study. Research blood samples will be drawn at quarterly post transplant visits (standard of care in Year 2 post transplant) corresponding to ImmunKnow and AlloMap testing. A minimum of 4 visits per patient is expected.
89662780|NCT01929941|Experimental|Group 1 INCB047986|
89662781|NCT01929941|Experimental|Group 2 Experimental: INCB047986, gemcitabine, nab-paclitaxel|
89662782|NCT01299285|Experimental|LY3009104|Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
89662783|NCT01922843|Experimental|DP001|DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
89662784|NCT01922843|Placebo Comparator|Placebo|Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
89662785|NCT01300065|Experimental|Experimental- Soflens|Bausch & Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.
89662786|NCT01300065|Active Comparator|Marketed - Soflens|Bausch & Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.
89662787|NCT01273857|Sham Comparator|Control|Subjects will undergo standard staged-procedures without cell infusion
89662788|NCT01273857|Experimental|Cell infusion|Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
89048100|NCT04013295|Experimental|Prize-linked savings intervention|Participants in the intervention group will be assisted with opening bank accounts at the partner bank and will be eligible for monetary rewards linked to the amount they save in these project accounts. During the intervention period, information about participants' savings activities will be shared with the study team at regular intervals by the bank. Winners will learn of their prize via text message and will have their prize money deposited into their accounts. Respondents who did not win the lottery will also receive a text message, which will remind them to save.
89048101|NCT04013295|No Intervention|Control|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
89048102|NCT04006665||Lung Ultrasonography prior to docking Robotic arms|Base line Lung ultrasonography will be performed in three basal zones for Right and Left lung -Post intubation and prior to docking robotic arms .
89048103|NCT04006665||Lung Ultrasonography after removal of robotic arms|Lung Ultrasonography will be performed to assess degree of atelectasis after removal of robotic arms and before extubation in three basal zones for Right and Left lung .
89048104|NCT04000555|Experimental|Study drug|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
89662789|NCT01276197|Experimental|Arm 1: Story-Telling DVD|Participant will receive a DVD with informational and story-telling components
89662790|NCT01276197|Active Comparator|Arm 2: Non-Storytelling DVD|Participant will receive an informational DVD
89662791|NCT01302483|Experimental|Kovacaine Nasal Spray|3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril
89662792|NCT01302483|Active Comparator|Lidocaine Injection|.5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine
89662793|NCT04769583|Active Comparator|concomitant quadruple therapy (QC)|PPI (esomeprazole: 40 mg x 2 per day) with the amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day) for 14 days
89662794|NCT04769583|Placebo Comparator|triple therapy (TT)|PPI (esomeprazole: 40 mg x 2 per day) with amoxicillin (1 g x 2 per day) and clarithromycin (500 mg x 2 per day) AND PLACEBO for 14 days.
89662795|NCT01304277|Experimental|Replagal® (0.2 mg/kg, IV, EOW)|"Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0)~Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF"
89662796|NCT01279317|Experimental|vinegar co-ingestion|25 ml vinegar is added to glucose containing beverage
89662797|NCT01279317|Placebo Comparator|Placebo co-ingestion|25 ml vinegar is substituted by 25 ml water
89662798|NCT01304589|Experimental|Milnacipran|This was an 18-week, open-label, flexible-dose exploratory trial where eligible patients were treated with 200 mg/day of milnacipran (or the maximum tolerated dose) for a total of 12 weeks. The study design involved 3 phases: screening and baseline assessment, dose escalation and stable-dose phase. All women received 12 weeks of stable dose treatment after a 6-week dose-escalation period for a total of 18 weeks of drug exposure.
89662799|NCT01280409|Placebo Comparator|Placebo|Compounded placebo
89662800|NCT01280409|Experimental|Metformin|Compounded metformin as the intervention
89662801|NCT01926197|Active Comparator|Modified FOLFIRINOX|Modified FOLFIRINOX (mFFX), a chemotherapeutic treatment regimen of 5FU, leucovorin, irinotecan, and oxaliplatin.
89662802|NCT01926197|Experimental|Modified FOLFIRINOX plus Stereotactic Body Radiotherapy|Modified FOLFIRINOX (mFFX), a chemotherapeutic treatment regimen of 5FU, leucovorin, irinotecan, and oxaliplatin, in combination with stereotactic body radiotherapy (SBRT)
89662803|NCT01925573|Other|Optune+RT+Bevacuzimab|"Part 1:~Bevacizumab every 2 weeks plus Optune daily for 4 week cycles.~Part 2:~RT will begin post 3 round of Bevacizumab (hypofractionated radiotherapy: 30 Gy in 5 fractions or 35 Gy in 10 fractions) per physician choice.~Part 3:~Adjuvant Bevacizumab and Optune"
89213810|NCT00616928|Experimental|Influenza A (H5N1) 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89213811|NCT00616928|Placebo Comparator|Placebo 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89213812|NCT00616928|Experimental|Influenza A (H5N1) >64Y Group|Subjects aged > 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89213813|NCT00616928|Placebo Comparator|Placebo >64Y Group|Subjects aged > 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89213814|NCT00616928|Experimental|Influenza A (H5N1) Group|Pooled group of subjects aged >18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89213815|NCT00616928|Placebo Comparator|Placebo Group|Pooled group of subjects aged >18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89213816|NCT00616928|Experimental|Influenza A (H5N1) 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89662804|NCT01923545|Experimental|DA-3031 3.6mg|PEG-G-CSF
89662805|NCT01923545|Experimental|DA-3031 6mg|PEG-G-CSF
89662806|NCT01923545|Active Comparator|Leucostim®|G-CSF
89662807|NCT01925027|Experimental|NANO+ DES|The Nano+ Polymer-free Sirolimus-Eluting Coronary Stent System is device/drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing rapamycin, the active ingredient, adhered to 316L stainless bare stent scaffold with submicron micropores, and is approved by State Food and Drug Administration of China in 2011(No. 3460037).
89662808|NCT01925261|Placebo Comparator|TPX-100 Cohort 1|Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
89662809|NCT01925261|Placebo Comparator|TPX-100 Cohort 2|Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee
89662810|NCT01925261|Placebo Comparator|TPX-100 Cohort 3|Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee
89662811|NCT01925261|Placebo Comparator|TPX-100 Cohort 4|Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
89662812|NCT01925261|Placebo Comparator|Part B|Part B will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
89662813|NCT01305213|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89662814|NCT01305213|Experimental|Arm II (bevacizumab, fosbretabulin tromethamine)|Patients receive bevacizumab IV over 30-90 minutes and fosbretabulin tromethamine IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89662815|NCT00989963|Experimental|Maximum Tolerated Dose (MTD)|Patients in the MTD treatment group will dose escalate weekly by 60µg b.i.d. until they reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion, further attempts at dose escalation may be made.
89662816|NCT00989963|Experimental|Low Fixed Dose|The low dose group will receive 60µg twice a day(b.i.d.)
89662817|NCT00989963|Experimental|High Fixed Dose|Patients in the high dose group will dose escalate weekly by 60µg twice a day (b.i.d.) until they reach the fixed dose of 240µg b.i.d. Once patients in these treatment groups have reached their assigned maximum dose of active drug,
88994932|NCT03266302|Experimental|Interventional group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
89662818|NCT03079739||fractional flow reserve group|consecutive patients undergoing coronary artery angiography for established or suspected ischemic heart disease and receiving in at least one lesion FFR assessment
89662819|NCT01337739|Placebo Comparator|Placebo Comparator|Continuous infusion of placebo during operative procedure
89662820|NCT01337739|Active Comparator|Active Comparator|Administration of Dexmedetomidine
89662821|NCT01339299|Experimental|recombinant luteinizing hormone|150 IU r-LH, recombinant luteinising hormone, from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14)
89662822|NCT01339299|Active Comparator|recombinant human chorionic gonadotrofin|25 IU of r-hCG from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14 )
89662823|NCT01307007|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
89662824|NCT01307007|Active Comparator|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
89662825|NCT00989573|Placebo Comparator|Placebo|oral administration of placebo once-daily for 8weeks
89662826|NCT00989573|Experimental|OPC-6535 25 mg|oral administration of OPC-6535 25 mg once-daily for 8 weeks
89662827|NCT00989573|Experimental|OPC-6535 50 mg|oral administration of OPC-6535 50mg once-daily for 8 weeks
89662828|NCT02197455|Experimental|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
89662829|NCT03078803|Experimental|Fecal microbiota transplant|Transfer of healthy human gut bacteria
89662830|NCT03078803|Placebo Comparator|Placebo|Water
89662831|NCT03101501|Experimental|MMC for fibrosis prevention|no intervention is required after procedure is performed
89662832|NCT01923623|Experimental|Block|Popliteal and saphenous Block with Ropivacaine
89662833|NCT01923623|Placebo Comparator|NaCl|
88994933|NCT03266302|No Intervention|Control group|Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
89662834|NCT01923779||TG002 Subjects|Subjects previously randomised in study TG002
89662835|NCT01923857|Experimental|Healthy Volunteers|Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m^2.
88994934|NCT03254212|Experimental|Oxygen therapy|Fixed nightime oxygen therapy throughout the protocol duration
88994935|NCT02915848||PC+S group|PC+S group gets Medtronic, Activa PC+S DBS device,
88994936|NCT04688632|Active Comparator|Group 1a|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin <Dose A>
89048105|NCT04000555|Placebo Comparator|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
89048106|NCT03994822|Experimental|pRESET Thrombectomy Device|Mechanical Thrombectomy using the pRESET Thrombectomy Device
89048107|NCT03994822|Active Comparator|Solitaire Revascularization Device|Mechanical Thrombectomy using the Solitaire Revascularization Device
89048108|NCT03994393|Active Comparator|Cohort 1|Participants with no evidence of T790M
89048109|NCT03994393|Active Comparator|Cohort 2|Participants with evidence of T790M
89048110|NCT03991624|Other|Alzheimer's patients (lack of executive functions)|
89048111|NCT03991624|Other|control (lack of executive functions)|
89048112|NCT03991624|Other|Alzheimer's patients (lack of working memory)|
89048113|NCT03991624|Other|control (lack of working memory)|
89048114|NCT03991624|Other|Alzheimer's patients (lack of episodic memory)|
89048115|NCT03991624|Other|control (lack of episodic memory)|
89048116|NCT03970733|Experimental|VLA15 with Alum lower dose|Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued
89048117|NCT03970733|Experimental|VLA15 with Alum higher dose|Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo
89662836|NCT01923857|Experimental|Mild Renal Impairment|Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 50-80 mL/min).
89662837|NCT01923857|Experimental|Moderate Renal Impairment|Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 30-50 mL/min).
89662838|NCT01923857|Experimental|Severe renal impairment|
89662839|NCT03495167|Experimental|SyB C-1101|
89662840|NCT03100253|Experimental|"Switching strategy"|Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
89662841|NCT03100253|Active Comparator|"Cycling strategy"|"Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR~Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept."
89662842|NCT01924091|Experimental|Dapivirine Gel|"As outlined above, multiple gel formulations of dapivirine have been developed for vaginal use.~Three formulations, Dapivirine Gel-001 (Gel-001), Dapivirine Gel-002 (Gel-002), and Dapivirine Gel 4750 (Gel 4750) are no longer in development. Dapivirine Gel 4789, which has been tested in one clinical trial (IPM012), and Dapivirine Gel 4759 were recently evaluated in clinical trials, IPM 014A and IPM 020. This trial will use Dapivirine Gel 4759."
89662843|NCT01924091|Experimental|Dapivirine Film|Dapivirine film is formulated in a polyvinyl alcohol (PVA) based vaginal film containing hydroxypropyl methyl cellulose (HPMC) E5 (5 cp), polyethylene glycol 8000 (PEG), propylene glycol, and glycerin. PVA constituted 55.1% (w/w) of the film. The target loading dose for the film is 1.25 mg dapivirine per film based on phase I studies using dapivirine gels at concentrations of 0.01%, 0.02% and 0.05%30-33. The quantity of gel administered in these studies was 2.5 mL. Consequently the administered dose corresponds to 0.25, 0.5 and 1.25 mg dapivirine, respectively.
89662844|NCT03485729|Experimental|Biopsy-mandated|
89662845|NCT03485729|Experimental|Biopsy-optional|
89662846|NCT03485729|Experimental|Dosing twice per week on two consecutive days|
89662847|NCT01924325|Active Comparator|Dual-antiplatelet Therapy|Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with placebo apixaban twice daily
89662848|NCT01924325|Experimental|Apixaban 2.5mg|Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
89662849|NCT01924325|Experimental|Apixaban 5mg|Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
89662850|NCT01924403|Experimental|Staple Closure|Staple closure will be one technique employed to close the wound in primary total knee arthroplasty.
89662851|NCT01924403|Experimental|Running Subcuticular Closure|Running subcuticular closure will be one technique employed to close the wound in primary total knee arthroplasty.
89662852|NCT01924403|Experimental|Vertical Mattress Closure|Vertical mattress closure will be one technique employed to close the wound in primary total knee arthroplasty.
89662853|NCT01924481|Experimental|low theobromine & low caffeine|Drink 1
89662854|NCT01924481|Experimental|low theobromine & high caffeine|Drink 2
89662855|NCT01924481|Experimental|high theobromine & low caffeine|Drink 3
89662856|NCT01924481|Active Comparator|no theobromine & high caffeine|Drink 4
89662857|NCT01924637|Experimental|FIASP|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
89662858|NCT01924637|Active Comparator|NovoRapid®|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
89213817|NCT00616928|Placebo Comparator|Placebo 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89662859|NCT01924715||ISTDP|Patients provided Intensive Short term Dynamic Psychotherapy
89662860|NCT01924715||Control Group|Patients referred for ISTDP but never seen for any reason
89662861|NCT01924793|Experimental|Formulation of DAS181-F02 Dry Powder in Bulk|"The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.~Dry Powder Inhaled Dose:~Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction."
89662862|NCT01924793|Experimental|Nebulized Formulation Inhaled Dose|"Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual.~Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual."
89662863|NCT04275947||Training|
89662864|NCT04275947||Validation|
89662865|NCT01925105|Experimental|Optimization of treatment|Optimization of treatment of diseases and symptoms
89662866|NCT01925105|Placebo Comparator|Control|Treatment as usual
89662867|NCT01925495|Experimental|healthy adults|Experiment 1 -- variation of ear-canal pressure; Experiment 2 -- varied middle-ear gas compositions; Experiment 3 -- variation of middle-ear pressure
89662868|NCT01925729|Experimental|ragweed|ragweed -- 1000PNU intranasal spray
89662869|NCT01925729|Experimental|histamine|5 mg intranasal spray
89662870|NCT01925729|Experimental|pseudoephedrine|pseudoephedrine -- 60 mg orally
89662871|NCT01925729|Experimental|oxymetazoline|oxymetazoline 0.05% solution intranasal spray
89662872|NCT01925885|Active Comparator|PVI Ablation|Standard of care arm-pulmonary vein isolation (PVI)-involving moving the ablation catheter from point to point in a continuous line to surround the the orifices of the pulmonary veins in order to eliminate electrical conduction between the veins and left atrium.
89662873|NCT01925885|Experimental|FIRM Ablation|FIRM ablation for paroxysmal atrial fibrillation at sites of rotors or focal impulse formation as designated by using the mapping algorithm of RhythmView
89662874|NCT01925963||Normal cohort|Normal, healthy adults without history of brain injury
89662875|NCT01926275|Experimental|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
89662876|NCT01926275|Active Comparator|NPPV|noninvasive positive pressure ventilation
89662877|NCT01926275|Active Comparator|IMT|inspiratory muscle training
89662878|NCT01926275|Placebo Comparator|LTOT|Long time oxygen therapy
89662879|NCT01926353||Vantris|Patient who categorized as who underwent endoscopic correction procedure, were patients who under general anesthesia performed by a single experienced surgeon using a 10Fr Storz® cystoscope with PPC (Vantris®) subureteral or intraureteral injection, or a combination of both techniques, depending on the anatomy of the ureteral meatus and VUR grade.
89662880|NCT01926353||Cohen reimplantation|Patient underwent surgical management were all had ureteral re-implatation with Cohen technique done by single experienced pediatric urologist.
89662881|NCT01926353||Continuous Antibiotic Prophylaxis|Group of patient treated with conservative management were children treated with culture guided antibiotics and maintained on 1st or 2nd generation cephalosporin as continuous antibiotic prophylaxis until time of 1 year follow-up.
89662882|NCT01926431|Experimental|Exercise|60 minutes of high intensity treadmill running
89662883|NCT01926431|Experimental|Rest|60 minutes of seated rest (control trial)
89662884|NCT01926587|Experimental|Oral rigosertib plus azacitidine|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle. Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
89662885|NCT04275635||Children with myopia|A total of 3,000 children from Zhongshan Ophthalmic Center is required to undergo ophthalmic examinations and complete questionnaires at baseline and 1yr after wearing Ortho-K.
89662886|NCT01922765|Experimental|AOC group|AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
89662887|NCT01922765|Experimental|AOM group|AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
89662888|NCT01922765|Experimental|Sequential group|Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
89048118|NCT03970733|Placebo Comparator|Placebo|Main Study Phase: placebo - Booster Phase: arm discontinued
89048119|NCT03961438|Active Comparator|Group A|HIV-uninfected participants
89662889|NCT01922765|Experimental|concomitant group|concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
89662890|NCT01925651|Other|Standard Risk - No bolus|No Bolus
89662891|NCT01925651|Other|Standard Risk - Alternate Bolus|Alternate 5mm Bolus
89662892|NCT01925651|Other|High Risk - Alternate Bolus|Alternate 5mm Bolus
89662893|NCT01925651|Other|High Risk - Continuous bolus|Continuous 5mm bolus
89662894|NCT01926665|Experimental|Carfilzomib|Carfilzomib given in four doses, days 1, 2, 15 and 16, every 28 days for 6 months starting within 6 months post ASCT. Doses given in an escalated phase 1 design, starting at 20/20 mg/m2, later increased to 20/27 mg/m2, 20/36 mg/m2 and 20/45 mg/m2. CFZ dose based on actual body surface area at baseline (cycle 1). Patients with a body surface area (BSA) greater than 2.2 m2 receive dose based upon a 2.2 m2 BSA. Adjustments are not made if weight gains or losses are less than or equal to 20% from baseline. Dexamethasone 4 mg by vein or mouth prior to each CFZ dose in cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, then it should be restarted and administered prior to subsequent doses for reactions.
89662895|NCT01926743|Experimental|NIR with ICG group|
89662896|NCT01926821|Experimental|sonifilan|Group who get sonifilan
89662897|NCT01926821|No Intervention|control|No Sonifilan administered
89048120|NCT03961438|Active Comparator|Group B|HIV-uninfected participants
89048121|NCT03921411|Experimental|Nemolizumab|Nemolizumab
89048122|NCT03906851|Experimental|Activity and diet|"Multi-component, holistic model with a) physical activity, b) nutrition, and c) psychosocial work.~A: physical activity will be provided as a pedagogical tool in subjects Mathematics, Norwegian and English B: Focus on school meals and menus in school cafeteria C: Psychosocial work with focus on the associations between physical activity, nutrition and psychosocial health. Collaboration between schools and school health services"
89048123|NCT03906851|No Intervention|Control|Schools are required to perform teaching activities, school meals and school cafeteria menus as usual
89048124|NCT03855475|Experimental|Aerobic exercise|Exercise training
89048125|NCT03855475|Active Comparator|Stretching|Control
89048126|NCT03798639|Experimental|Arm I (nivolumab, radiation therapy)|Patients receive nivolumab IV over 30 minutes at week 0. Treatments repeat every 4 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients also receive radiation therapy on Monday-Friday or 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
89048127|NCT03798639|Active Comparator|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes at week 0. Treatments repeat every 2 weeks for nivolumab and 6 weeks for ipilimumab for up to 1 year in the absence of disease progression or unacceptable toxicity.
89048128|NCT03774901|Experimental|avelumab maintenance|Avelumab will be administered at a dose of 10 mg/kg every 2 weeks with appropriate supportive care
89048129|NCT03762018|Active Comparator|Bevacizumab plus chemotherapy|Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
89048130|NCT03762018|Experimental|Atezolizumab plus bevacizumab plus chemotherapy|Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
89048131|NCT03750825|Experimental|Vapers|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
89048132|NCT03750825|No Intervention|Smokers|Smokers will continue to smoke.
89048133|NCT03750825|No Intervention|Nonsmokers non-vapers|Control nonsmokers non-vapers will continue to refrain from smoking or vaping.
89662898|NCT01926899|Experimental|Bortezomib administration|0.7 milligrams per meter squared given on Day 0 and Day +3
89662899|NCT01927133||FIBROFRANCE Project|
89662900|NCT01927289|Active Comparator|Proximal Brachial Plexus block|15 mls of 1.5% Mepivacaine injected in the supraclavicular approach and 15 mls of saline injected in the distal forarm nerve blocks
89662901|NCT01927289|Active Comparator|Distal Forearm block|15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
89662902|NCT03430661|Experimental|Part A: Group 1|Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
89662903|NCT03430661|Experimental|Part A: Group 2|Clopidogrel will be administered 12 h after ACT-246475 or placebo
89662904|NCT03430661|Experimental|Part A: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied
89662905|NCT03430661|Experimental|Part B: Group 1|Prasugrel will be administered 12 h after ACT-246475 or placebo
89662906|NCT03430661|Experimental|Part B: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
89662907|NCT03430661|Experimental|Part B: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
89662908|NCT03430661|Experimental|Part C: Group 1|Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
89662909|NCT03430661|Experimental|Part C: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
89662910|NCT03430661|Experimental|Part C: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
89662911|NCT01927523|No Intervention|Control group|These youth will not receive the non-academic cognitive behavioral programming nor the intensive academic mathematics tutoring.
89662912|NCT01927523|Experimental|BAM Group Therapy & Match Math Tutoring|These youth will receive both the non-academic cognitive behavioral programming and the intensive academic mathematics tutoring.
89662913|NCT01927523|Experimental|BAM Group Therapy|These youth will receive the non-academic cognitive behavioral programming.
89662914|NCT01927523|Experimental|Match Math Tutoring|These youth will receive the intensive academic mathematics tutoring.
89662915|NCT01927835|Experimental|Group 1A: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
89662916|NCT01927835|Experimental|Group 1B: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
89662917|NCT01927835|Experimental|Group 2A: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
89662918|NCT01927835|Experimental|Group 2B: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
89662919|NCT01927835|Placebo Comparator|Group 3A: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
89662920|NCT01927835|Placebo Comparator|Group 3B: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
89662921|NCT01927913|Experimental|SPD602|
89662922|NCT01927913|Active Comparator|Deferasirox|
89662923|NCT01927991|Experimental|iCBT with therapeutic support|Participants work with the online self-help and receive additional therapeutic support on demand
89662924|NCT01927991|Active Comparator|iCBT without therapeutic support|Participants work with the online self-help on their own and do not receive additional therapeutic support
89662925|NCT01928147|Experimental|PPI-383 single dose escalation in healthy volunteers|There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.
89048134|NCT03728582|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be verb naming therapy in a sentence context. This will be followed by sham tDCS plus speech-language therapy after a 2 month washout period.
89048135|NCT03728582|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. Language therapy will be verb naming therapy in a sentence context. This will be followed by active tDCS plus speech-language therapy after a 2 month washout period.
89048136|NCT03614234|Experimental|Experimental open label|Pegunigalsidase alfa
89048137|NCT03593395|Active Comparator|Program Structured Education Based Transition Program|Program Structured Education Based Transition Program [STE]
89048138|NCT03593395|Experimental|Structured Education Based Transition Program + Peer Mentoring|Structured Education Based Transition Program [STE] + Peer Mentoring [PM]
89048139|NCT03579680|Experimental|ADT ORDER CHECK ATTESTATION (OR)|"Experimental: ADT ORDER CHECK ATTESTATION (OR) Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior. Study staff will place a health factor structured data element in the EMR of patients whose clinic visits study staff have confirmed to be targets for ADT de-implementation. This health factor combined with a low PSA level will trigger the ADT Order Check Attestation Intervention (Or) when the provider places an order for ADT."
89048140|NCT03579680|Experimental|PROVIDER SCRIPT (SC)|"Experimental: PROVIDER SCRIPT (SC) The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior. Study staff will enter a pre-populated CPRS EMR progress note 1 business day prior to a target clinic visit. The note includes talking points for the provider to help with a discussion. It can be edited and cosigned by the provider, giving a quick and simple way to document the discussion. The progress note template asks providers to indicate whether patient prefers to continue or discontinue low-value ADT. Appropriate documentation of the decision will be tracked for fidelity. We will also have a patient handout entitled: Living well with prostate cancer: Is hormone therapy still right for you? as a patient engagement and information resource."
89048141|NCT03566017|Experimental|Experimental open label|pegunigalsidase alfa
89048142|NCT03555279|Experimental|Probation Staff (PS) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm intervention is delivered by Probation Staff working at the intervention site. Dosage is 8 2-hour sessions delivered over two weeks.
89048143|NCT03555279|Experimental|Youth Representative (YR) Facilitator|The PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm intervention is delivered by young adults who were formally in the juvenile justice system. Dosage is 8 2-hour sessions delivered over two weeks.
89662926|NCT01928147|Experimental|PPI-383 multiple doses in healthy volunteers|Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens
89662927|NCT01928147|Experimental|PPI-383 multiple dose escalation in HCV Subjects|Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients
89662928|NCT03085979|Experimental|Burch|Burch Colposuspension
89662929|NCT03085979|Experimental|Trans Obturator Tape|Trans Obturator Tape sling
89662930|NCT03085979|Experimental|Tension free vaginal tape|Tension free vaginal tape sling
89662931|NCT04759469|Experimental|High-intensity interval training (HIIT)|A high-intensity interval training program for 3 days/week (day after day) for 12 weeks on atreadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program intensity.
89662932|NCT04759469|Active Comparator|Moderate intensity interval training (MIIT)|A moderate intensity interval training program for 3 days/week (alternate days) on a treadmill (Biodex RTM500, Biodex Inc., New York), with a gradual increase in the program.
89662933|NCT01928459|Experimental|Metastatic breast cancer|Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.
89662934|NCT01928459|Experimental|Solid tumor arm 1|Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.
89662935|NCT01928459|Experimental|Solid tumor arm 2|Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3
89662936|NCT01928459|Experimental|Dose escalation|To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.
89662937|NCT01928537|Experimental|rigosertib sodium|Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles.
89662938|NCT01307397|Experimental|Vemurafenib|Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
89662939|NCT01929161|Experimental|Oxytocin|Oxytocin intranasal spray, 6 intranasal sufflations which deliver a total of 24 international units of oxytocin
89662940|NCT01929161|Placebo Comparator|Placebo (for oxytocin)|Intranasal spray with all equivalent ingredients except oxytocin
89662941|NCT01929161|Experimental|Lovingkindness Meditation|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
89662942|NCT01929161|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
89662943|NCT03373877|Experimental|Dose 1: PU-H71 225 mg/m2 + ruxolitinib|Cohort 1
89662944|NCT03373877|Experimental|Dose 2: PU-H71 300 mg/m2 + ruxolitinib|Cohort 2
89662945|NCT03373877|Experimental|Dose 3: PU-H71 400 mg/m2 + ruxolitinib|Cohort 3
89662946|NCT03373877|Experimental|Dose 4: PU-H71 600 mg/m2 + ruxolitinib|Cohort 4
89662947|NCT04552535||Second line (2L) afatinib|Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
89662948|NCT04552535||Second line (2L) chemotherapy|Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
89662949|NCT02197767|Experimental|rituximab|rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
89662950|NCT02199717||Boys with Hemophilia|Accelerometer use for 1 week.
89662951|NCT01342029|Experimental|Ranolazine|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
88994937|NCT04688632|Active Comparator|Group 1b|Day 1: Single dose of Moxifloxacin <Dose A>; Day 1 - Day 15: Single daily dose of Ampreloxetine Placebo; Day 15: Single dose of Moxifloxacin Placebo
88994938|NCT04688632|Experimental|Group 2 - Treatment|Day 1: Single dose of Moxifloxacin Placebo; Day 1 - Day 7: Single daily dose of Ampreloxetine <Dose A>; Day 8 - Day 14: Single daily dose of Ampreloxetine <Dose B>; Day 15: Single dose of Moxifloxacin Placebo; Day 15: Single dose of Ampreloxetine Placebo;
88994939|NCT05786690||Group 1|17 patients with MIC prosthesis,
88994940|NCT05786690||Group 2|17 patients with non-MIC prosthesis,
88994941|NCT05786677|Experimental|Patients with fibromyalgia and depression (1)|Patients in this group will receive physiotherapy protocol and medications.
88994942|NCT05786677|Active Comparator|Patients with fibromyalgia and depression (2)|Patients in this group will receive medications only.
89662952|NCT01342029|Placebo Comparator|Placebo|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
89662953|NCT05601557||hyperbilirubinemia|Gilbert syndrome Crigler-Najjar syndrome Dubin-Johnson syndrome Rotor syndrome PFIC BIRC
89662954|NCT05601557||Wilson disease|Leipzig score system was used for diagnosis, and the total score ≥4 points could be confirmed. The total score of 3 is suspected diagnosis, which requires further examination. A total score of 2 or less is not considered for diagnosis.
89213818|NCT00616928|Experimental|Influenza A (H5N1) >60Y Group|Subjects aged >60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89662955|NCT05601557||Hemochromatosis|① clinical manifestations of extensive skin pigmentation, bronzing; Decline to disappearance of sexual function; Mild hepatosplenomegaly, may appear jaundice; The heart is enlarged; Pain and swelling mainly in metacarpophalangeal joints; Decreased glucose tolerance and increased blood glucose; ② Serum iron was significantly increased, serum transferrin was normal or decreased, transferrin saturation was significantly increased, often more than 62%, serum ferritin was significantly increased, often more than 500ug/L; (3)/HJV/HAMP TFR2 / SLC40A1 HFE gene mutation.
89662956|NCT05601557||Glycogen accumulation disease|According to different types, there may be the following manifestations, which need specific analysis. ① Clinical manifestations of abdominal distension, fasting hypoglycemia and other symptoms; ② Laboratory examination showed metabolic acidosis, hyperlactic acidemia, hyperuricemia and hyperlipidemia; ③ Abdominal CT showed enlarged liver volume; ④ Serum glucosidase activity decreased; (5) the GAA/G6PC/SLC374A/AGL/PYG/PHK gene mutations.
89662957|NCT05601557||Other types of inherited metabolic liver disease|
89662958|NCT01342107|Experimental|FID 114675A|Contact lens soaked overnight in an investigational multi-purpose disinfecting solution randomly assigned to one eye, with contact lens removed directly from the blister pack assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
89662959|NCT01342107|Active Comparator|Blister Pack|Contact lens removed directly from the blister pack randomly assigned to one eye, with contact lens soaked overnight in an investigational multi-purpose disinfecting solution assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
89662960|NCT05601479|Experimental|Acetyl-L-carnitine group(ALC group)|At the beginning of the first chemotherapy of the oxaliplatin regimen, acetyl-L-carnitine 500mg will be given orally three times daily for 24 weeks.
89662961|NCT05601479|No Intervention|Blank Control group|No drugs for the prevention and treatment of peripheral neuropathy will be given.
89662962|NCT01343667|Other|GFRS EPD|Carotid artery stenting with Gore Flow Reversal System embolic protection device
89662963|NCT01343667|Other|GEF EPD|Carotid artery stenting with Gore Embolic Filter embolic protection device
89662964|NCT05601401|Experimental|Study arm|Patients receive RC48-ADC.
89662965|NCT04275245|Experimental|Meplazumab|10mg Meplazumab by intravenous infusion, every day for 2 days
89662966|NCT01346085|Experimental|CNI-free single-group|
89662967|NCT05608031||bariatric surgery|A cross-sectional study was conducted among patients that underwent bariatric surgery (laparoscopic sleeve gastrectomy). Sleep quality was assessed using the Pittsburgh sleep quality index (PSQI) scale preoperatively and at the 6th postoperative month.
89662968|NCT05607797|Experimental|Patients with gout|Patients aged 18-70 with gout diagnosis in their medical record or claiming to have gout according to ACR/EULAR (American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria.
89662969|NCT05607797|Experimental|Patients with CKD|"Patients aged 18-70, in dialysis or with CKD clinically diagnosed on the basis of markers of kidney damage or decreased kidney function.~Patients will be recruited in dialysis centers of Wé and Maré and during the monthly nephrology consultations in medical centers."
89662970|NCT05607797|Placebo Comparator|Control group|Persons aged 30-80 without gout or CKD. The recruitment will be done among people visiting the medical centers of Lifou and Maré for administrative or vaccination reasons.
89662971|NCT04394897||TIVA|TIVA either with remifentanil and propofol infusions separately
89662972|NCT04394897||MIXTIVA 2/1000|MIXTIVA infusion that had remifentanil/propofol proportion 2/1000
89662973|NCT04394897||MIXTIVA 3/1000|MIXTIVA infusion that had remifentanil/propofol proportion 3/1000
89662974|NCT05607641|Other|Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets|
89662975|NCT05607641|Active Comparator|Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets|
89662976|NCT05607641|Experimental|Neospastil, solution for injection then Neospastil, film-coated tablets|
89213819|NCT00616928|Placebo Comparator|Placebo >60Y Group|Subjects aged > 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
89213820|NCT00939042|Active Comparator|1|PCI plus BNNC Therapy after acute myocardial infarction
89213821|NCT00939042|Active Comparator|2|Percutaneous Coronary Intervention after acute myocardial infarction
89662977|NCT05607485|Other|Crowd workers|"Crowd workers watched 10 (oiut 45 possible) random videos and assessed with a standard assessment tool.~All participants were blinded to the identity and skill level of the surgeon"
88994943|NCT05786677|Experimental|Patients with depression only (1)|Patients in this group will receive physiotherapy protocol and medications.
89662978|NCT05607329|Experimental|Secondary cytoreduction followed by chemotherapy|
89662979|NCT05607329|Active Comparator|chemotherapy alone|
89662980|NCT05606861|Experimental|Intervention group|Mindfulness Based Intervention in pediatric nurses components was applied to this group.
89662981|NCT05606861|No Intervention|Control group|No procedure was conducted the control group.
89662982|NCT05603507|Experimental|inspiratory muscle training group|received both inspiratory muscle training and pulmonary rehabilitation
89662983|NCT05603507|Sham Comparator|pulmonary rehabilitation group|received only pulmonary rehabilitation and sham inspiratory muscle training
89662984|NCT05603039|Experimental|QL1706(5mg/kg)|QL1706(5mg/kg) Combined with Bevacizumab
89662985|NCT05603039|Experimental|QL1604|QL1604 Combined with Bevacizumab
89662986|NCT05603039|Experimental|QL1706(7.5mg/kg)|QL1706(7.5mg/kg) Combined with Bevacizumab
89662987|NCT03359213|Experimental|JR-141 1.0 mg/kg/week|
89662988|NCT03359213|Experimental|JR-141 2.0 mg/kg/week|
89662989|NCT03359213|Experimental|JR-141 4.0 mg/kg/week|
89662990|NCT04394741|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
89213822|NCT02578511|Experimental|Ixazomib (MLN9708) in combination with standard POMP/D|"Patients who are receiving maintenance therapy with the POMP/D (Methotrexate, 6-Mercaptopurine, Vincristine, Prednisone/Dexamethasone) will be enrolled. Each cycle will be 28 days. The patients will receive IV vincristine, dexamethasone or prednisone, methotrexate and 6 - Mercaptopurine. Ixazomib will be administered on days 1, 8 and 15.~Both prednisone and dexamethasone are acceptable drugs in maintenance therapy. For example, in the HyperCVAD regimen or the CALGB 8811 prednisone is used. Patients will continue the same maintenance regimen they are receiving and ixazomib will be added to that."
89213823|NCT00935688|Experimental|Rapid diagnostic tests|malaria diagnosis by rapid diagnostic test
89213824|NCT00935688|No Intervention|Clinic Microscopy|malaria diagnosed with field light-microscopy
89213825|NCT00935688|No Intervention|Clinical Diagnosis|Malaria diagnosed on the basis of clinical symptoms alone (i.e. not laboratory diagnosis)
89662991|NCT04394741|Sham Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
89662992|NCT04394507||Fontan Patients|Fontan patients operated at the two centres between 1991 and 2014.
89662993|NCT04394507||Control Group|Age, gender and weight matched healthy controls.
89662994|NCT04394195||patients with COVID-19 infection|patients with COVID-19 infection
89662995|NCT05602415|Experimental|Surgery + Dose Reduced Radiotherapy + Anlotinib|"Surgery would be performed to resect soft tissue sarcoma with as wide margin as possible. Important vessels and nerves should be preserved.~Postoperative radiotherapy would be performed. Postoperative intensity-modulated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction).~Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles)."
89662996|NCT05602337||Immunocompetent BCC Subjects|BCC-predominant group
89662997|NCT05602337||Immunocompetent SCC Subjects|SCC-predominant group
89213826|NCT02578355||Coronary CT Angiography (CCTA)|Patients included in the OPeRA Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
89213827|NCT00869648|Active Comparator|Neutralposition|Head placed in neutral position
89213828|NCT00869648|Active Comparator|Extension|Head placed in extension
89213829|NCT00869648|Active Comparator|Anaesthesiologist's position|Head placed in position deemed optimal by an anaesthesiologist
89213830|NCT00563784|Experimental|Erlotinib + Paclitaxel + Carboplatin|Oral Erlotinib 150 mg daily + Paclitaxel 45 mg/m^2 by vein weekly + Carboplatin 2 AUC by vein weekly and Radiation Therapy 63 GY/35 fractions for 7 weeks cycles
89213831|NCT00869882|Experimental|1|Posterolateral fusion with instrumentation combined to transforaminal lumbar interbody fusion
89213832|NCT00869882|Active Comparator|2|Posterolateral fusion with instrumentation
89213833|NCT03291509|Active Comparator|In-person Group|Participants randomized to this group will have a health educator to their house for in-person meetings. Participants will use paper forms to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
89213834|NCT03291509|Experimental|Computer Group|Participants randomized to this group will use an iPad to talk to the health educator via video conference meetings. Participants will use the iPad to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
89662998|NCT05602337||Immunocompetent MM Subjects|Melanoma group
89662999|NCT05602337||Control|age, sex and Fitzpatrick phototype match
89663000|NCT05602337||Solid Organ Transplantation Recipient - SC|At least 5 skin cancers and at least 5 years post-transplant
89663001|NCT05602337||Solid Organ Transplantation Recipient|No more than 1 skin cancer and at least 5 years post-transplant
89663002|NCT03046121|Experimental|Fam-FFC|The intervention consists of :Component 1- Environmental and Policy Assessments; Component II- Education of Nursing Staff; Component III-Ongoing Training/Motivation of Nursing Staff. The Fam-FFC Nurse will work with the champions to mentor and motivate nursing staff to provide: (a) role modeling Fam-FFC, reinforcing performance of Fam-FFC, and brainstorming about ways to overcome challenges; (b) highlighting staff role models; Component IV Implementation of the FamPath Pathway which includes: (a) information on the admitting condition, diagnostics, treatment;(b) family/patient education; (c) transitional hand-off to post-acute providers; and (d) post-acute follow-up to provide ongoing education and modification of the function-focused care plan.
88994944|NCT05786677|Active Comparator|Patients with depression only (2)|Patients in this group will receive medications only.
89213835|NCT00203047|Active Comparator|GA + Placebo|Glatiramer acetate (GA) 10mg as a subcutaneous injection daily, plus a placebo to mimic prednisone given daily.
89213836|NCT00203047|Experimental|GA + Prednisone|Glatiramer acetate (GA) 20mg daily as a subcutaneous injection, plus 1250 mg of prednisone daily.
89213837|NCT00870038|Experimental|1|Paclitaxel eluting balloon (Elutax) + Genous stent
89213838|NCT00870038|Experimental|2|Uncoated balloon + Genous stent
89213839|NCT00870038|Active Comparator|3|Drug eluting stent (Taxus stent)
89663003|NCT03046121|No Intervention|Attention Control (Fam- FFC Ed-only)|Education of the nursing staff in participating hospital units (exactly as offered in treatment sites), and education of family caregivers about hospital orientation and reinforcement of discharge teaching (medications/treatments, medical follow-up).
89663004|NCT02984033||Head and Neck patients|Patients affected by squamous cell carcinoma of head and neck (oral cavity, larynx, pharynx and hypopharynx) with no metastasis
89663005|NCT04200053|Experimental|Reflexology massage|Reflexology massage
89663006|NCT04200053|Experimental|Reflexology massage and passive music|Reflexology massage and passive music
89663007|NCT04200053|No Intervention|Control|Control
89663008|NCT05609201||Cases|36 participants with a multidisciplinary team diagnosis of IPF or non-IPF fibrotic-ILD
89663009|NCT05609201||Healthy Control|5 Age, sex and ethnicity matched controls
89213840|NCT04074551|Experimental|Experimental|HCP1701
89213841|NCT04074551|Active Comparator|Active Comparator 1|HGP0904, HGP0608
89663010|NCT04161599|Experimental|Oral + Parenteral prophylaxis + Mechanical Bowel Preparation|"Drug: Extra dosage - cefuroxime (750mg) I.V~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.~Drug: Sodium picosulfate, magnesium oxide, citric acid anhydrous 15.08 g oral An oral laxative for bowel cleansing (2 doses) the day before surgery.~Drug: Metronidazole 1 g Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
89663011|NCT04161599|Active Comparator|Oral + Parenteral prophylaxis|"Drug: Extra dosage - cefuroxime (750mg) I.V In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc~Procedure: Colonic Surgery Both groups undergo colonic surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)~Drug: Cefuroxime 750mg oral An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.~Drug: Metronidazole 250mg oral An oral antibiotic pattern of metronidazole (250mg / 8h, 3 doses) the day before surgery.~Drug: Metronidazole 1 gr Intravenous An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.~Drug: Cefuroxime 1,5 g Intravenous An intravenous antibiotic pattern of cefuroxime 1,5 g during anesthetic induction."
89663012|NCT04759235||neoadjuvant chemoradiotherapy of local advanced ESCC|All the patients receive paclitaxel/cisplatin chemotherapy and concurrent radiotherapy. Each patient receives radiation of 41.4 Gy / 23 fractions complied by intensity modulated radiotherapy or volumetric modulated arc therapy. Patients without disease progression after nCRT will be scheduled for surgery and patients with disease progression (PD) will continue to receive chemoradiation or additional treatments. Surgery will be performed 6 to 8 weeks after completion of chemoradiotherapy.
89663013|NCT04394273||Long- Term Exercise Group|They will exercise one an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).In this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
89663014|NCT04394273||Short-Term Exercise Group|They will exercise half an hour, two days a week, from the 16th week of pregnancy to the 32nd week (16 weeks).n this session, clinical pilates exercises are used as the basic exercise model and this exercise model is applied as a mixed exercise model in the form of posture and body mechanics training, lower-upper extremity strength training, pelvic floor muscle training and breathing exercises. Exercises can be started from the mat level and advanced in a modified manner with theraband and pilates ball.
89663015|NCT04394273||Home Program|Pregnant women who choose the home program group are told to continue their home program until the 32nd week, which includes posture and body mechanics training, increase their physical activity levels and be as active as possible and take daily walks.
89663016|NCT05608967||G_PREHapp|Experimental group will follow a prehabilitation programme through the PREHapp platform
89663017|NCT05608967||G_Control|Control group will follow a prehabilitation programme according to usual practice
89663018|NCT05608811|Experimental|Social Skills Training-intervention group|"Intervention group: Adolescents in the training group were given 8 sessions of Social Skills Training. At the end of the training, the final evaluation was made. Initial and final assessments were made face-to-face. The training was held via Zoom."
89663019|NCT05608811|Active Comparator|One Session General Social Skills-control group|The control group was informed about general social skills in one session. When the training given to the intervention group was completed, the final evaluation was made. Initial and final assessments were made face-to-face.
89663020|NCT05601167|Experimental|JTBC00201 (nirmatrelvir/ritonavir, Skayvira)|Group 1 (n=132) received the study drug nirmatrelvir/ritonavir, tablets 300/100 mg, 2 times a day with 12 ±2 hours interval for 5 days in the setting of pathogenetic and symptomatic therapy provided by Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 validated of the time of the study
89663021|NCT05601167|Active Comparator|Standard of care|Group 2 (n=132) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of COVID-19 validated of the time of the study
89663022|NCT04126213|Experimental|RSV MAT 60 Group-Mother|Maternal subjects randomized to RSV MAT 60 Group received a single dose of RSV MAT (60 µg) vaccine at Day 1, and were followed up until the study end.
89663023|NCT04126213|Experimental|RSV MAT 120 Group-Mother|Maternal subjects randomized to RSV MAT 120 group received a single dose of RSV MAT (120 µg) vaccine at Day 1, and were followed up until the study end.
89663024|NCT04126213|Placebo Comparator|Control Group-Mother|Maternal subjects randomized to the Control Group received a single dose of Placebo at Day 1, and were followed up until the study end.
88994946|NCT05786651|Experimental|Within-Subjects Attentional Information|Within-Subjects, all participants receive all interventions
88994947|NCT05786495|Experimental|Short treatment|Antibiotic treatment will be stopped at the time of allocation to the intervention group
88994948|NCT05786495|Active Comparator|Prolonged treatment|Antibiotic treatment will be continued until the resolution of neutropenia (ANC > 0.5x109/L)
88994949|NCT05786430|Experimental|experimental arm|
89213842|NCT04074551|Active Comparator|Active Comparator 2|HGP0608, HCP1306
89213843|NCT00870116|Other|1 - SBRT using cyberknife|SBRT using cyberknife: treatment = 2x15 Gy during 2 weeks
89213844|NCT00870116|Other|2 - SBRT using linear accelerator|SBRT using linear accelerator: treatment = 2x15 Gy during 2 weeks
89213845|NCT00870116|Other|3 - Conformational radiotherapy|Conformational radiotherapy: treatment = 5x2 Gy during 7 weeks
89213846|NCT01075867||Control group|Before ELIPS implementation 12 months follow-up
89213847|NCT01075867||Treatment group|After ELIPS implementation 12 months follow-up
89663025|NCT04126213|No Intervention|RSV MAT 60 Group-Infant|This group consisted of infants born to mothers (from RSV MAT 60 Group-Mother) who received a single dose of RSV MAT (60 µg) vaccine during pregnancy.
89663026|NCT04126213|No Intervention|RSV MAT 120 Group-Infant|This group consisted of infants born to mothers (from RSV MAT 120 Group-Mother) who received a single dose of RSV MAT (120 µg) vaccine during pregnancy.
89663027|NCT04126213|No Intervention|Control Group-Infant|This group consisted of infants born to mothers (from Control Group-Mother) who received a single dose of placebo during pregnancy.
89663028|NCT05609747|Experimental|TYPE 2 DIABETIC PATIENTS|NON SURGICAL ROOT CANAL TREATMENT
89663029|NCT05609747|Experimental|HEALTHY CONTROL GROUP PATIENTS|NON SURGICAL ROOT CANAL TREATMENT
89663030|NCT02983955|Other|SCI with Tetraplegia|
89663031|NCT05605613|Experimental|PD-1 Antibody in Addition to Bronchial Arterial Chemoembolization|Treated with BACE and PD-1 antibody as induction therapy during which BACE was performed on the first day and PD-1 antibody was given 3-5 days later, then PD-1 antibody was administered at 200mg Q3W as maintenance therapy.
89663032|NCT05605613|Active Comparator|Bronchial Arterial Chemoembolization|Bronchial artery chemoembolization (BACE) is a technique of drug delivery and embolization performed via injecting anti-tumor drugs with drug carriers and implanting the embolization agents into the tumor feeding artery
89663033|NCT04393883|Experimental|Standard maintenance programme group|pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
89663034|NCT04393883|Experimental|Improvement maintenance programme group,|pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
89663035|NCT04128319|Experimental|T-Guard Treatment|Patients will receive T-Guard for treatment of steroid-refractory acute GVHD.
89663036|NCT04129957||Patients who underwent placement of dental implants|The study only includes one cohort. That is the patients who underwent placement of dental implants at baseline.
89663037|NCT04273633|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant shoulder
89663038|NCT04273633|Placebo Comparator|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the dominant shoulder
89663039|NCT02983903|Experimental|Single intervention arm - transbronchial biopsy|Patients enrolled in this single arm study will have lung nodules biopsied by traditional forceps followed by transbronchial cryobiopsy
89663040|NCT05603975|Active Comparator|EsKetamine Group|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change.~Esketamine Hydrochloride Injection 2ml：50mg"
89663041|NCT05603975|Placebo Comparator|Control Group|
89663042|NCT04122859|Active Comparator|Zip Skin Closure Device|The device is a class IIa device as per Annex II of the MDD 93/42EEC, as amended by Directive 2007/47/EEC. A CE-mark was affixed in 2014. The Zip device adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives. A combination of acrylic and hydrocolloid adhesives is used to provide a skin-friendly environment while providing the necessary tack to maintain skin adhesion during a maximum wear time of 14 days. In addition to the pressure-sensitive adhesives, the device's closure and force distribution components are made up of polyurethane monofilm, polyethylene tape, polyester and nylon.
89663043|NCT04122859|Active Comparator|Standard of Care Sutures|Conventional sutures used for laceration repair
89663044|NCT05603663|Experimental|Intervention arm|Young (25-44 years) overweight adults with high (top 20%) CVD PRS. The participants will be informed about their high PRS at the start of the study, calculated the overall CVD risk, and provided counseling and treatment of hypertension and/or high cholesterol if appropriate.
89663045|NCT05603663|No Intervention|Control group #1|Young (25-44 years) overweight adults with high (top 20%) CVD PRS. The participants will be informed about the overall CVD risk and provided counseling and treatment of hypertension and/or high cholesterol if appropriate. The participants will be informed about their high PRS only at the end of the study.
89663046|NCT05603663|No Intervention|Control group #2|Young (25-44 years) overweight adults with low (bottom 20%) CVD PRS. The participants will be informed about the overall CVD risk and provided counseling and treatment of hypertension and/or high cholesterol if appropriate. The participants will be informed about their low PRS only at the end of the study.
89663047|NCT03823183|Experimental|Multi-domain training|Group that receives cognitive training and physical training
88994950|NCT05786391|Experimental|Flat position with no Insufflation|
89663048|NCT03823183|Experimental|Cognitive training|Group that receives cognitive training and physical control activity
89663049|NCT03823183|Experimental|Physical activity|Group that receives control cognitive activity and physical training
88994951|NCT05786391|Experimental|Trendelenburg position and Insufflation|insufflation to 15 mm Hg
88994952|NCT05786391|Experimental|Flat position and Insufflation|
88994953|NCT05786391|Experimental|Trendelenburg position with no Insufflation|
89663050|NCT03823183|Active Comparator|Active control|Group that receives cognitive control activity and physical control activity
89663051|NCT05606783|Experimental|Home blood pressure monitoring|"Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily~Patients will be scheduled for a one-hour in-person appointment for the initial study visit where informed consent will be obtained, and for the final study visit"
89663052|NCT04121377|Experimental|Resistance exercise program|Early resistance exercise sessions and home program
89663053|NCT05603117|Experimental|Intervention|Participants received a behavioral intervention, CISBAR, via zoom sessions.
89663054|NCT04273399|Experimental|Crohn's Disease|Twelve week jumping based exercise intervention
89663055|NCT04273399|Active Comparator|Controls|Age and sex matched controls will undertake the same twelve week intervention for active comparison between groups
89663056|NCT05608577||Retrospective|Up to 1,750,000 patient admissions (up to 10 years of admissions) from one National Health Service Trust (Hospital group)
89663057|NCT05608577||Prospective Hospital Cohort|Up to 87, 500 will be screened by the digital platform to identify those who may have bled during the recruitment period, of which at least 40 will be approached for their consent to retain their blood samples (collected as part of routine care).
89663058|NCT04129775|Experimental|OTO-413|
89663059|NCT04129775|Placebo Comparator|Placebo|
89663060|NCT04120363|Placebo Comparator|Placebo|single intramuscular injection of 750 mg sesame oil solution on Day 8
89663061|NCT04120363|Experimental|Testosterone|single intramuscular injection of 750 mg testosterone undecanoate on Day 8
89663062|NCT01450033|No Intervention|Control group|Standard of care
89663063|NCT01450033|Experimental|Mentoring group|Subjects in this group will participate in the following intervention activities: medical record review; questionnaires including the Hollingshead Socioeconomic Status Survey, modified Medication Adherence Module, Peds QL Transplant Module, Medical Outcomes Study Social Support Scale, and self-efficacy scale; in-person meetings with mentor; e-communication with mentor (i.e. texts, Facebook, phone calls, etc); and collection of pharmacy refill data and clinical data.
89663064|NCT04393961|Other|Past Positive COVID-19 confirmed|Invited participants who Radish Health has completed a positive COVID-19 test who have recovered from all symptoms for more than 14 days.
89663065|NCT04393961|Other|Physician Diagnosed: Not Tested|Individuals who self report that a medical professional has told them they likely have COVID-19 (and have since recovered), but did not get a confirmatory test.
89663066|NCT04393961|Other|Self-Diagnosed Not Tested|Participant suspects they contracted (and have since recovered) from COVID-19, but they do not have a medical diagnosis or confirmatory test.
89663067|NCT04393961|Other|Likely Exposed, No Symptoms. Not Tested|Participant suspects that they've been exposed to COVID-19, but have not shown symptoms and wonder if they have antibodies so they may return to some normalcy.
89663068|NCT04125745|Experimental|CXA-10|Oral CXA-10 300 mg once daily for 12 weeks
89663069|NCT04393805||MED-Cohort|Patients hospitalized for SARS-COVID-2 infection in a medical ward
89663070|NCT04393805||ICU-Cohort|Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit
89663071|NCT04394039|Experimental|public sp exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
89663072|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method A|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method A
89213848|NCT02608385|Experimental|Dose Escalation Cohort|Patients will be enrolled to receive specific doses of radiation (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects. Enrollment will continue until best safe dose of SBRT is determined for each organ type.
89048144|NCT03548467|Experimental|VB10.NEO intervention|Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing to patients within the selected tumor types.
89213849|NCT02608385|Experimental|Large Volume Tumors Cohort|Patients with large tumors will be enrolled and their tumors will be partially treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
89213850|NCT02608385|Experimental|Oligometastatic Cohort|Patients with few tumors (4 or less) will be enrolled and their tumors treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
89213851|NCT00142519|Active Comparator|1|methadone
89663073|NCT04126057|Experimental|DOT Spectacle Lenses using Manufacturing Method B|Single vision, impact-resistant spectacles using SightGlass Vision DOT spectacle lenses, manufacturing method B
89663074|NCT04122755|Experimental|Cohort1|Subjects receive a single subcutaneous injection of 1-fold ALA-1000 dose (first in human dose).
89663075|NCT04122755|Experimental|Cohort2|Subjects receive a single subcutaneous injection of 2-fold ALA-1000 dose
89663076|NCT04122755|Experimental|Cohort3|Subjects receive a single subcutaneous injection of 4.7-fold ALA-1000 dose
89663077|NCT04122755|Experimental|Cohort4|Subjects receive a single subcutaneous injection of 9.4-fold ALA-1000 dose
89663078|NCT04122755|Experimental|Cohort5|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose
89663079|NCT04122755|Experimental|Cohort6|Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose after 7 days of buprenorphine sublingual film dosing
89663080|NCT04129853|Experimental|Crossover|Performing a sit to stand with the Cyberlegs Xleg and comparing with their current prosthesis.
89213852|NCT00142519|Experimental|2|methadone and morphine
89663081|NCT04129853|Experimental|Case study|Comparing the cyberlegs xleg with other devices.
89663082|NCT03026387|Other|Neuropsychological battery tests|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are suicide attempters without psychotic features"
89663083|NCT04129697|Active Comparator|Dexamethasone|
89663084|NCT04129697|Active Comparator|Methylprednisolone|
89663085|NCT04129463|Active Comparator|SST with Iris incarceration|infants that underwent SST with iris incarceration procedure
89663086|NCT04129463|Active Comparator|Conventional trabeculotomy|infants that underwent Conventional trabeculotomy
89663087|NCT04129307|Experimental|Motor Imagery|
89663088|NCT04129307|Experimental|Double time Motor imagery|
89663089|NCT04129307|Active Comparator|Action observation|
89663090|NCT04129541|Active Comparator|SDD|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
89663091|NCT04129541|Active Comparator|OH|Patients will receive routine care during their admission for surgery. A standard voiding trial will be performed in the PACU for all patients. Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
89663092|NCT04128917|Experimental|Tegoprazan 50 mg|Tegoprazan 50 mg Triple Therapy
89663093|NCT04128917|Experimental|Tegoprazan 100 mg|Tegoprazan 100 mg Triple Therapy
89663094|NCT04128917|Active Comparator|RAPAE01|RAPAE01 Triple Therapy
89663095|NCT04128449|Experimental|docosahexaenoic acid|1,66 grams/24 hours (5 dragees)
89663096|NCT04128449|Placebo Comparator|Placebo|sunflower oil (5 dragees)
89663097|NCT02337959|Experimental|Predicate & Invest.-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
89663098|NCT02337959|Experimental|Predicate & Invest.-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
89663099|NCT02337959|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
89663100|NCT04393727|Experimental|Intervention|Patients in the intervention group will receive 200 cc of convalescent plasma
89663101|NCT04393727|No Intervention|Control|Patients will continue to receive standard therapy
89663102|NCT04127513|Experimental|12% AMMONIUM LACTATE|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 12% ammonium lactate. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
89663103|NCT04127513|Active Comparator|10% UREA|Matching paired subject was conducted on 40 residents. Test subject received two different randomized moisturizing creams to be applied on two separate locations on the lower limbs twice a day for 4 weeks. One of the moisturising cream contained active ingredient 10% urea. The evaluation of specified symptom sum score (SRRC), skin capacitance (SCap), transepidermal water loss (TEWL), and side effects were measured at baseline, week-2 and week-4 after therapy, and week-5 one week after therapy cessation.
89663104|NCT03295643|Other|Mobile smoking cessation program|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
89663105|NCT05794074|Experimental|lutéine|10 mg/d lutéine
89663106|NCT05794074|Experimental|zeaxanthine|10 mg/d zéaxanthine
89663107|NCT05794074|Experimental|lutéine and zeaxanthine|10 mg/d lutéine + 2 mg/d zéaxanthine
89663108|NCT05794074|Placebo Comparator|placebo|same excipient used in the other arms with a carmine red dye
89663109|NCT05794061||Patients|Patients with brain disorders
89663110|NCT05794061||Healthy controls|Neurologically Healthy Controls
88994954|NCT05786352|Experimental|ERAS|"ERAS Protocol~Preoperative:~Clear carbohydrate ( pulp free juice) drink 4 hours before cesarean. Water drinking is allowed until 4 hours before cesarean.~Prophylactic antibiotics 1 hour before cesarean ( Cephazole 2 g iv)~Intraoperative:~Hypothermia prevention (warming devices)~Pneuomatic compression stockings~Skin preparation with clorhexidine-alcohol~Vaginal preparation with povidone-iodine solution~Postoperative:~Regular diet within 2 hours after cesarean~Sugar-free gum chewing at postoperative 3rd, 5th and 7th hours, for 20 minutes~Tight control of capillary blood glucose~Mobilization at postoperative 4th hour.~Urinary catheter removal at postoperative 4th hour~Pneuomatic compression stockings~Prevention of nausea and vomiting with routine use of Metoclopramide.~Routine analgesia with Diclofenac sodium suppository application and oral Paracetamole."
88994955|NCT05786352|No Intervention|SOC (Standard of Care)|"Preoperative:~Fasting until 6 hours before cesarean.~Prophylactic antibiotics post-delivery during cesarean per institutional protocol ( Cephazole 2 g iv)~Intraoperative:~Pneuomatic compression stockings as needed~Skin preparation with povidone-iodine solution~Postoperative:~Water intake at 4th hour after cesarean, traditional delayed feeding until return of intestinal function (bowel sounds or flatus)~Capillary glucose control~Mobilization at postoperative 6th hour.~Urinary catheter removal at postoperative 6th hour~Pneuomatic compression stockings as needed.~Analgesia with Diclofenac sodium intramuscular and oral Paracetamole as needed."
88994956|NCT05786339|Experimental|Reference formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Sanofi Clir SNC
88994957|NCT05786339|Experimental|Test formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Shenzhen Haibin Pharmaceutical Co., Ltd.
88994958|NCT05786313|Active Comparator|Centerpiece titanium plate|All surgical operations were performed by the same group of senior spine surgeons. The range of open door decompression involved C3 ~ C7. For convenient operation and more accurate statistics, the right side of the door axis and the left side of the door seam were selected for all operations. Centerpiece titanium plates were used for intraoperative fixation.
88999216|NCT03004404|Experimental|SRD part-Dose group 10: BI 730357 tablet(s) 800 mg Fed|Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (16x50mg) together with about 240 milliliter (mL) of water, 30 minutes (min) prior dose administration the participants consumed a standard high fat breakfast. One authorized employee of the trial site was witness of the administration of the trial medication.
89213853|NCT03714776|Placebo Comparator|Placebo|Placebo matching solution injected subcutaneously (SC) once weekly for up to 6 weeks and an additional loading dose on Day 3.
89663111|NCT05794009|Experimental|Immersive Virtual Reality Exercise (IVRE)|VR exercise training for at least three times a week for 12 consecutive weeks (a total of 36 sessions) guided by the e-therapist: The tailored VR-based exercise program involves aerobic and resistance exercises, and VR games.
89663112|NCT05794009|Active Comparator|Home Exercise|Individuals randomized to the control group will attend a briefing session prior to the start of the program to complete demographic data collection and physical assessment. They will be given an exercise booklet and guided through a set of home-based exercises (identical training to the intervention group except for VR games) in the briefing session. Stepping exercises will be implemented as a substitution of cycling as an aerobic exercise training at home.
89663113|NCT05793983||Patients with acute or chronic liver disease|"Presence of chronic liver disease, or cirrhosis due to any aetiology (latter based upon a histopathological diagnosis or compatible laboratory data and radiological findings)~Acute alcoholic hepatitis~Acute liver failure due to any aetiology~Acute-on-chronic liver failure"
89663114|NCT05793983||Patients undergoing diagnostic or therapeutic abdominal paracentesis|Patients with acute or chronic liver disease of any aetiology undergoing clinically-indicated paracentesis for ascites
89663115|NCT05793983||Patients undergoing broncho-alveolar lavage|"Intubated patients with liver disease in intensive care~Undergoing a bronchoscopy or a non-directed broncho-alveolar lavage as part of their routine clinical care"
89663116|NCT05793983||Patients with acute or chronic liver disease undergoing liver biopsy|
89663117|NCT05793983||Patients with undergoing transjugular intrahepatic shunt (TIPSS) placement|
89663118|NCT05793983||Patients with acute or chronic liver disease undergoing orthoptic liver transplantation|
89663119|NCT05793983||Patients undergoing surgical liver resection or hepatectomy for liver-related diseases|
89663120|NCT05793983||Patients with ascites without chronic liver disease|"Absence of cirrhosis based on clinical, radiological or histopathological features, including patients with non-cirrhotic portal hypertension, cardiac ascites (ascites due to heart failure) or patients with chronic kidney disease undergoing continuous ambulatory peritoneal dialysis (CAPD)~Presence of clinically significant ascites~Undergoing diagnostic or therapeutic paracentesis"
89663121|NCT05793983||Patients with sepsis without acute or chronic liver disease|
89048145|NCT03548467|Experimental|VB10.NEO in combination with bempegaldesleukin (NKTR-214)|Bempegaldesleukin (NKTR-214) will be given in combination with VB10.NEO in up to 10 patients with SCCHN. Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing. Bempegaldesleukin (NKTR-214) will be given after at least 4 doses of VB10.NEO.
89048146|NCT03525990|Active Comparator|Intervention Arm|Quality of life questionnaires (electronic patient reported outcomes) to be filled out by the patients at every visit. Quality of life data is fully available for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
89048147|NCT03525990|Placebo Comparator|Control Arm|Quality of life questionnaires (electronic patient reported outcomes) only to filled out by the patients at baseline, after three months and after six months. Quality of life data is hidden for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
89048148|NCT03490669|Experimental|Dose Escalation|Multiple dose levels of MSC-1 treatment once every 3 weeks
89048149|NCT03490669|Experimental|Dose Expansion|MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks
89048150|NCT03456882|Active Comparator|RNS60|RNS60 for injection, i.e. in the IV bags, is produced using 0.9% Sodium Chloride for injection. RNS60 for inhalation, i.e. in the syringes, is produced using 0.9% Sodium Chloride for irrigation. Syringes and IV bags are to remain refrigerated at 2 to 8°C (36 to 46°F) when not in use. RNS60 meets its stability specification for 12 months.
89048151|NCT03456882|Placebo Comparator|NORMAL SALINE|"Normal saline (NS) for injection, i.e. in the IV bags, is packaged 0.9% Sodium Chloride for injection. NS for inhalation, i.e. in the syringes, is packaged 0.9% Sodium Chloride for irrigation. NS does not require refrigerated storage for use. However, for blinding purposes refrigeration is required before distributing to subjects. NS meets stability specifications for 24 months.~RNS60 has been tested in three Phase I safety studies, NCT01264783, NCT01057498, and NCT01511302 in the USA, and a Phase IIa (NCT02422121) study in UK without any safety concern. Two other Investigator initiated Phase IIa trials are currently ongoing, one in Mass General Hospital (NCT02525471), and one in the University of Zurich (with University of Innsbruck as a second site)."
89048152|NCT03416179|Experimental|Arm A (Intensive Study)|Glasdegib + '7+3' Induction(s)
89048153|NCT03416179|Placebo Comparator|Arm B (Intensive Study)|Placebo + '7+3' Induction(s)
89048154|NCT03416179|Experimental|Arm A (Non-intensive study)|Glasdegib + azacitidine
89048155|NCT03416179|Placebo Comparator|Arm B (Non-intensive study)|Placebo + azacitidine
89048156|NCT03408964||Group 0 (set-up)|Patients with known diagnosis of CSPC (Group 0a) and CRPC (Group 0b) irrespective of the PC treatment (not first diagnosis)
89048157|NCT03408964||Group 1a (control)|Patients who underwent biopsies for suspected Prostate Cancer (PC), with a negative result for invasive cancer
89048158|NCT03408964||Group 1|Patients with a first diagnosis of localized biopsy-proven PC, untreated, planned to undergo radical surgery and / or radical radiotherapy
89048159|NCT03408964||Group 2|Patients with a diagnosis of locally advanced unresectable, recurrent or metastatic PC planned to receive first-line hormono therapy
89663122|NCT05793983||Patients with haemochromatosis who undergo regular venesection|
89663123|NCT05793983||Healthy subjects|
89663124|NCT05793892|Experimental|Arm A|The order of administration of the test drug in both treatment areas in Arm A is the first, followed by the use of the control drug.
89663125|NCT05793892|Active Comparator|Arm B|The order of administration in both treatment areas in Arm B was the use of the control drug first, followed by the investigational drug.
89048160|NCT03408964||Group 3|Patients with recurrent/progressive/metastatic CRPC planned to receive chemotherapy
89048161|NCT03406767|Experimental|GLA:D Canada Program|GROUP 1: GLA:DTM CANADA GROUP (STANDARDIZED EXERCISE PROGRAM)
89048162|NCT03406767|Experimental|JointEffort Program|GROUP 2: JOINTEFFORT GROUP (INDIVIDUALIZED EXERCISE PROGRAM)
89048163|NCT03372902||normal mammograms (BI-RADS 1 or 2)|
89048164|NCT03372902||suspicious lesion group (BI-RADS 4)|
89048165|NCT03361215||Atopic dermatitis|Patients with dermatologist-diagnosed atopic dermatitis, psoriasis or autoimmune skin disease.
89663126|NCT05793814|Experimental|Experimental: Limosilactobacillus Supplement|Capsules containing Probiotic taken daily for 6 month
89663127|NCT05793814|Placebo Comparator|Placebo|Capsules containing Microcrystalline cellulose, magnesium stearate taken Daily for 6 month
89663128|NCT05793788|Experimental|Arm 1: Specific|Eligible, randomized participant will receive a brief, specific SMS message informing patients that they should obtain screenings and tests they are due for.
89663129|NCT05793788|Experimental|Arm 2: General|Eligible, randomized participant will receive a brief, generic SMS message informing patients that they have a health gap to be closed.
89663130|NCT05793788|Experimental|Arm 3: Intention-oriented; General|Eligible, randomized participant will receive an intention-oriented, generic SMS message informing patients that they have a health gap to be closed and highlighting the importance of doing so.
89663131|NCT05793788|Experimental|Arm 4: Action-oriented; General|Eligible, randomized participant will receive an action-oriented, generic SMS-message informing patients that they have a health gap to be closed and prompting them to act soon before they forget.
89048166|NCT03361215||Controls|Healthy volunteers with no history of atopic, autoimmune or chronic inflammatory disease.
89048167|NCT03349528|Experimental|Probiotic Supplement|The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
89048168|NCT03349528|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
89663132|NCT05793749|Experimental|Prophylactic lymphedema treatment|"Prophylactic lymphedema treatment：The lymphedema prophylaxis treatment consists of four parts:manual lymphatic drainage, skin care, functional exercise, and wearing lymphedema preventive compression stockings.~The prophylactic lymphedema treatment group receives lymphedema prophylaxis twice a week for a total of 10 sessions, each requiring an interval of at least 48 hours but no more than 2 weeks."
89663133|NCT05793749|No Intervention|Standard of care|Standard of care，includeIn knowledge education and telephone follow-up were routinely conducted.
89663134|NCT05793710|Experimental|the principle of laughter plus Qigong|"The basic method of  LQP  is the principle of laughter plus Qigong, combined with the sound of laughter, stretching the body, thereby activating the parasympathetic nerve, so that the body can automatically relax, and at the same time guide the individual to face their own emotions when facing pressure, and transform emotions into positive energy or relieve negative emotions through practice, so as to achieve the energy balance of body, mind and spirit."
89663135|NCT05793710|No Intervention|their current lifestyle for a 12-week|After baseline testing, participants in the waitlist control group (CON) were asked to maintain their current lifestyle for a 12-week. Participants in the CON group will then undergo a 12-week fully supervised intervention.
89663136|NCT05793671|Active Comparator|immediate stenting in heavy thrombus STEMI burden patients|This group - heavy thrombus burden STEMI patients with thrombolysis in myocardial infarction ( TIMI ) 2-3 flow - will receive loading dose of GPIIbIIIa inhibitor intracoronary followed by immediate stenting .
89663137|NCT05793671|Active Comparator|Deferred stenting in heavy thrombus burden STEMI patients .|This group - heavy thrombus burden STEMI patients with TIMI 2-3 flow - will receive loading dose of GPIIbIIIa inhibitor intracoronary followed by GPIIbIIIa inhibitor infusion and LMWH administration for 48 -72 hours followed by stenting .
89663138|NCT05793658|Active Comparator|Sedation with standard capnography|37 patient Sedation using midazolam + propofol for colonoscopy
89663139|NCT05793658|Active Comparator|Sedation with modified capnography|37 patients in Sedation using midazolam + fentanyl + propofol for colonoscopy
89663140|NCT05793606|Active Comparator|Deltoid repaired|
89663141|NCT05793606|No Intervention|non-deltoid repaired|
89663142|NCT05793554||Rectal tumour without prior evidence of cancer|"400 patients with a known rectal tumour that has not demonstrated evidence of cancer to date - may be benign or indeterminate on biopsy or without biopsy performed to date.~Patients in this cohort will undergo examination under anaesthesia as is standard of care. During this examination the pattern of fluorescence seen in NIR camera within the tumour will be observed following administration of ICG (dose 0.25mg/kg) and recorded. Following this, patients will continue with standard of care at the discretion of their surgeon.~The operative video will be uploaded to a secure cloud based system and annotated by the surgeon where further mathematical analysis will be carried out for the purposes of tissue classification."
89663143|NCT05793554||Rectal tumour previously confirmed as cancerous|"200 patients with a rectal tumour that has proven previously to contain cancer. Both patients who have and have not undergone neoadjuvant therapy are suitable for inclusion in this group.~Patients in this group will undergo the same processes as the patients in cohort 1."
89663144|NCT05793528||Those who had lumbar radicular pain|Patients with lumbar radicular pain identified by inclusion and exclusion criteria
89663145|NCT05793515||FB_001|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663146|NCT05793515||FB_002|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663147|NCT05793515||FB_003|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89048169|NCT03338764|Experimental|Experimental (SM-1)|Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
89048170|NCT03338764|Placebo Comparator|Placebo|Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.
89048171|NCT03313544|Experimental|NIVOLUMAB PATIENTS|
89048172|NCT03309579|Experimental|Liberal RBC Transfusion Strategy|Hemoglobin value of ≤100g/L
89048173|NCT03309579|Active Comparator|Restrictive RBC Transfusion Strategy|Hemoglobin value of ≤80g/L
89048174|NCT03251859|Active Comparator|Standard ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.
89048175|NCT03251859|Experimental|Reduced ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.
89663148|NCT05793515||FB_004|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663149|NCT05793515||FB_005|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89048176|NCT03156660|Experimental|Weight gain prevention (Group 1)|Small Changes weight stability intervention
89048177|NCT03156660|Experimental|Weight loss intervention (Group 2)|Look AHEAD weight loss intervention
89048178|NCT03156660|Active Comparator|Self-guided intervention (Group 3)|Self-guided weight management with the EatingWell Diet book
89663150|NCT05793515||FB_006|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663151|NCT05793515||FB_007|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663152|NCT05793515||FB_008|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663153|NCT05793515||FB_009|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663154|NCT05793515||FB_0010|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663155|NCT05793515||FB_0011|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663156|NCT05793515||FB_0012|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663157|NCT05793515||FB_0013|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663158|NCT05793515||FB_0014|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663159|NCT05793515||FB_0015|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663160|NCT05793515||FB_0016|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663161|NCT05793515||FB_0017|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663162|NCT05793515||FB_0018|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663163|NCT05793515||FB_0019|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663164|NCT05793515||FB_0020|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663165|NCT05793515||FB_0021|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663166|NCT05793515||FB_0022|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663167|NCT05793515||FB_0023|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663168|NCT05793515||FB_0024|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663169|NCT05793515||FB_0025|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663170|NCT05793515||FB_0026|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663171|NCT05793515||FB_0027|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663172|NCT05793515||FB_0028|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663173|NCT05793515||FB_0029|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663174|NCT05793515||FB_0030|Proband affected by IRD and affected and/or unaffected relatives without molecular diagnosis.
89663175|NCT05793502||LBBP|
89663176|NCT05793502||CRT|
89663177|NCT05793424||Patients with cerebral small vessel disease ( cSVD)|
89663178|NCT05793424||Control patients|
89663179|NCT05793398||Endomyocardial biopsy-positive Cardiac sarcoidosis|
89213854|NCT03714776|Experimental|ISIS 757456 80 mg|ISIS 757456 80 mg injected SC once weekly for up to 6 weeks and an additional loading dose of 80 mg on Day 3.
89663180|NCT05793398||Endomyocardial biopsy-negative non ischemic cardiomyopathy|
89663181|NCT05793359||Modified monthly regimen|Treatment with 3 pulses of 3 infusions of 500 mg methylprednisolone on 3 consecutive months with intramuscular administration of 125 mg methylprednisolone per week between the pulses. Additional low dose peroral treatment after completion of the pulses.
89663182|NCT05793359||Weekly regimen|Treatment with 6 infusions of 500 mg methylprednisolone during the first 6 weeks, followed by 6 infusions of 250 mg methylprednisolone during the next 6 weeks.
89663183|NCT05793346||Dataset 1: National Registry of Rare Kidney Diseases|This dataset is the: National Registry of Rare Kidney Diseases from the UK Renal Registry, this is a UK-wide, linked dataset. This cohort includes any woman who has previously had a previous diagnosis of kidney disease in the UK with maternity records and who has consented to participate.
89663184|NCT05793346||Dataset 2: Kent Integrated Data|Maternal and laboratory data from East and West Kent in the UK.
89663185|NCT05793346||Dataset 3: Stockholm Creatinine Measurement|An observational dataset with laboratory data from individuals in Stockholm (Sweden)
89663186|NCT05793346||Dataset 4: Ontario Renal Network Pregnancy Cohort|A population-based cohort of women in Ontario who had an obstetric delivery with outpatient laboratory data.
89663187|NCT05793346||Dataset 5: Combined cohort of three obstetric studies within the UK|A combined cohort derived from three obstetric studies within the UK.
89663188|NCT05793294||Birth cohort|All infants age 0 - 14 days will be recruited and followed until 24 months of age
89663189|NCT05793268|Experimental|Finite Therapy|Discontinuation of nucleos(t)ide analog (Nuc) therapy
89663190|NCT05793268|Active Comparator|Continuous Therapy|Continuation of oral Nuc monotherapy using entecavir (0.5mg/tab, once per day), tenofovir disoproxil fumarate (300mg/tab, once per day), or tenofovir alafenamide (25mg/tab, once per day) for 3 years
89663191|NCT05793229||improving frailty|Class 1
89663192|NCT05793229||maintaining frailty|Class 2
89663193|NCT05793229||deteriorating frailty|Class 3
89663194|NCT05793216|Experimental|Classroom interventions|Students within five classrooms will engage in prescribed vestibular activities embedded within learning curricula to determine the impact of the intervention on learning outcomes, particularly memory, sequencing, attention, and ordinance related outcomes.
89663195|NCT05793190||Healthy Control|Total number of 20 Healthy Control participants Included in the study
89663196|NCT05793190||Alcoholic hepatitis|Total number of 30 Alcoholic hepatitis patients included in the study
89663197|NCT05793190||Alcoholic cirrhosis|Total number of 30 alcoholic cirrhosis patients included in the study
89663198|NCT05793190||Acute-on-Chronic Liver Failure|Total number of 15 alcoholic acute-on-chronic liver failure patients included in the study
89663199|NCT05793190||Alcoholic Hepatocellular carcinoma|Total number of 25 Alcoholic Hepatocellular carcinoma patients included in the study
89663200|NCT05793177|Experimental|Intervention|
89663201|NCT05793177|No Intervention|Control|
89663202|NCT05793164||Patients with postoperative folliculitis|Patients presented folliculitis in surgical-area lesions after hair transplantation within 9-month follow up.
89663203|NCT05793164||patients without postoperative folliculitis|Patients didn't present folliculitis in surgical-area lesions after hair transplantation within 9-month follow up.
89663204|NCT05793086||active trigger point group|Individuals with active trigger points in trapezius
89663205|NCT05793086||latent trigger point group|Individuals with trigger points in trapezius without spontaneous pain
89663206|NCT05793086||healthy trapezius muscle|Individuals without trigger points.
89663207|NCT05793073||Pre-intervention group|
89663208|NCT05793073||Post-intervention group|
89663209|NCT05793034|Other|Biological biomarker assessment|FFPE tumor tissue will be processed with a number of molecular biology techniques
89663210|NCT05793021|Other|Single arm|
89663211|NCT05792995|Experimental|Immunomonotherapy plus Chemotherapy plus Anti-angiogenesis Therapy|Any first-line treatment that includes immunotherapy.
89663212|NCT05792995|Experimental|Chemotherapy plus Immunomonotherapy|Any first-line treatment that includes immunotherapy.
89663213|NCT05792995|Experimental|Immunomonotherapy plus Anti-angiogenesis Therapy|Any first-line treatment that includes immunotherapy.
89663214|NCT05792995|Experimental|Immunomonotherapy|Any first-line treatment that includes immunotherapy.
89663215|NCT05792982||Fasting Adult Males|A questionnaire was administered in order to determine individuals' general characteristics, nutrition habits, and smoking and alcohol habits. Anthropometric measurements, 24 hours dietary recall and physical activities were recorded and blood samples were taken four times in following periods; before Ramadan, first week of Ramadan, third week of Ramadan and two weeks after Ramadan.
89663216|NCT05792969||Stroke patients with USN and their caregivers|
89663217|NCT05792969||Stroke patients without USN and their caregivers|
89663218|NCT05792878||Interferon treatment group|Patients with chronic hepatitis B who received antiviral treatment with Interferon at the Second Department of Hepatology, Beijing Ditan Hospital Affiliated to Capital Medical University from February 2022 to December 2023 were enrolled.
89663219|NCT05792878||nucleoside analogues treatment group|Patients with chronic hepatitis B who received antiviral treatment with nucleoside analogues at the Second Department of Hepatology, Beijing Ditan Hospital Affiliated to Capital Medical University from February 2022 to December 2023 were enrolled
89663220|NCT05792865||Paxlovid（Within 5 days after the diagnosis of COVID-19）|According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID is within 5 days.
89663221|NCT05792865||Paxlovid （More than 5 days after the diagnosis of COVID-19）|According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID exceeds 5 days.
88994959|NCT05786313|Experimental|3D printed arch titanium plate|Before surgery, according to the imaging results, according to the effective imaging indicators screened in the early stage and the calculated door opening Angle formula, the door opening Angle of the patient's posterior cervical vertebra and the size of the fitted arch titanium plate were designed by mimics 10.0 software, and the titanium plate was printed using 3D printing technology. During the operation, the developed laminae opener was used to accurately control the door opening Angle and appropriate size titanium plate was installed for internal fixation. The standardized laminae door opening guide was used to complete the preparation of the door shaft side and door opening side of the lamina
88994960|NCT05786248|Other|Impedancemtry|measurement of fluid shift by impedancemetry, recording by polysomnography, measurement of neck, calf and ankle perimeters, at different times: 0 min (T0), 30min (T30), 90min (T90), and the next day on waking
88994961|NCT05786170|Experimental|magnetic resonance imaging|DW-MRI after ischemic stroke
88994962|NCT05786092|Experimental|treatment|
89663222|NCT05792865||No paxlovid used|Patients have never used Paxlovid after being diagnosed with COVID-19, whether before or after hospitalization.
89663223|NCT05792852|Experimental|ENGAGE|ENGAGE uses social learning, guided problem-solving and applied skill training to promote social participation among people with disabilities within the context of the COVID-19 pandemic. This is a group intervention using a self-management framework.
88994963|NCT05786092|No Intervention|control|
88994964|NCT05786053|Active Comparator|v pattern exotropia|v pattern exotropia patients with associated inferior oblique overreaction
88994965|NCT05786053|Active Comparator|Pattern esotropia|v pattern esotropia patients with inferior oblique overreaction
88994966|NCT05786001||Unhealthy group|Individuals with CLTI
88994967|NCT05786001||Age control group|Healthy individuals over the age of 50
89213855|NCT00573170|Other|TPB|TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)
89663224|NCT05792839|Active Comparator|Concomitant abdominoplasty with ventral hernia repair .|We do abdominoplasty with concomitant repair of the hernial defect and abdominal wall muscles in the same setting.
88994968|NCT05786001||Healthy group|Healthy and young individuals
88994969|NCT05785988||Patients with migraine treated with a second anti-CGRP|Patients with migraine treated with a second anti-CGRP monoclonal antibody as per responsible physician criteria in routine clinical practice.
88994970|NCT05785923|Experimental|Echo Arm|Chest pain patients identified by their treating physician as being low-risk chest pain will undergo a point-of-care echocardiogram performed by a trained emergency medicine attending or resident prior to discharge from the emergency department. The physician of record will review this ultrasound and it will be documented whether the findings on the ultrasound changed the physician of record's disposition decision for the patient or the follow up instructions or medications.
89213856|NCT00573170|Other|TBP|TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)
89213857|NCT00573170|Other|BTP|BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)
89663225|NCT05792839|Active Comparator|Ventral Hernioplasty|We do hernioplasty with mesh placement for a surgical treatment for ventral hernia.
89663226|NCT05792826|Experimental|BSZY Cream group|receiving BSZY Cream twice a day,in the morning and evening, for a period of four weeks.
89663227|NCT05792826|Placebo Comparator|emulsion matrix group|receiving the emulsion base twice a day, in the morning and evening, for a period of four weeks.
89663228|NCT05792761|Experimental|treatment-naïve children with hepatitis B|
89663229|NCT05792761|Experimental|previously treated children with hepatitis B|
89663230|NCT05792761|Experimental|chronic HBV carrying children with normal ALT|
89663231|NCT05792748|Active Comparator|ZOE group|Pulp hemostasis achieved by a dry cotton pellet applied on the pulp, then the chamber was filled with reinforced zinc oxide eugenol (ZOE) directly over the pulp.
89663232|NCT05792748|Active Comparator|FS group|Pulp hemostasis achieved by a wet cotton pellet impregnated with ferric sulphate (FS) applied on the pulp, then the chamber was filled with (ZOE) directly over the pulp.
89663233|NCT05792735|Experimental|Cadonilimab group|Cadonilimab is administrated with 6mg/kg and repeated every 2 weeks.
89663234|NCT05792709|Experimental|Oral Motor Therapy|These are exercises designed to increase the range of movement in tongue, lips, and jaw, which helped in speech and/or swallow functioning. It is important to move the designated area as far as can in each direction until feel the muscles stretch. Stop if feel any pain, and mention it to speech therapist or doctor. Practice these exercises, once through, 10 times a day.
89663235|NCT05792709|Other|Traditional Therapy|weeks traditional Speech Therapy was provided. Pre-language skills (vocalizations) manual sign languages, gestures, picture communication boards, voice output communication devices were used. Playing and talking, using pictures, books, objects, or ongoing events to help language development. Use of repetition exercises to build speech and language skills.
89663236|NCT05792683|Active Comparator|Early lumbar drain|30 in this group
89663237|NCT05792683|Other|conservative treatment|30 in this group
89663238|NCT05792657|Experimental|HIGH dosage in-person exercise coaching|One in-person exercise session with an exercise professional/weekly. A total of 20 hours of in-person coaching during the 20 weeks of intervention.
89663239|NCT05792657|Experimental|MEDIUM dosage in-person exercise coaching|Two in-person exercise session with an exercise professional/monthly, and 15 minutes web-based behavioral support on the non-supervised weeks.A total of 10 hours in-person coaching during the 20 weeks intervention.
89663240|NCT05792657|Experimental|LOW dosage in-person exercise coaching|One in-person exercise session with the exercise professional/monthly, and 15 minutes web-based behavioral support on the non-supervised weeks.Total of five hours of in-person coaching during the 20 weeks intervention.
89663241|NCT05792657|No Intervention|CONTROL|"Will be asked to continuing with normal life, and will receive regular follow-up care from their GP. This group will be giving the Norwegian Directorate of Health's recommendations for physical activity and nutrition, and will have access to the ABEL-app in order to register physical activity and exercise, but will not be provided any coaching during the 20 weeks."
89663242|NCT05792644|Experimental|Experimental|Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
89663243|NCT05792592||Uncontrolled Severe asthmatics|Uncontrolled Severe asthmatics
89663244|NCT05792579|Active Comparator|early closure of stoma|Detection complications of early closure of stoma in pateints with colorectal injures
89663245|NCT05792579|Active Comparator|late closure of stoma|Detection complications of late closure of stoma.
89663246|NCT05792527|No Intervention|control group|this group will include 23 patients which will receive the traditional therapy of RA for 3 months.
89663247|NCT05792527|Active Comparator|L-carnitine group|this group will include 23 patients which will receive 500mg L-carnitine two times daily after meal plus the traditional therapy of RA for 3 months.
89663248|NCT05792488|Other|Standard of care|
89663249|NCT05792488|Experimental|Lifestyle coach|
89663250|NCT05792488|Experimental|App|
89663251|NCT05792462|Experimental|Baricitinib|Baricitinib will be taken orally with a dose of 2mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
89663252|NCT05792449|Active Comparator|Standard Program|The current standard program for early intervention treatment is in-clinic therapy based on the Foundational Skills Curriculum (FSC): a framework for early intervention developed from outcomes of an Autism research project conducted in the UK. This framework provides a clear and systematic approach to understanding the child's functioning in 3 core areas of development (across 141 items): Play, Social Interaction, and Communication. Children and their parents will receive the standard program which consists of 16 clinic-based intervention sessions of 60 minutes each, separated into 3 intervention blocks, with breaks in between so that parents will have opportunities to practise at home.
89663253|NCT05792449|Experimental|Telerehab Program|The telerehab program will provide parent coaching through video conferencing using the FSC. The telerehabilitation program commences with 2 clinic-based intervention sessions of 60 minutes each followed by 16 video conferencing-based sessions of 45 minutes each. For clinic-based sessions, an additional 15 minutes is allocated to allow parent-child dyads to transit into and out of the therapist's room.
89663254|NCT05792410|Experimental|SHR-A1811 combined with Dalpiciclib Isethionate Tablets|
89663255|NCT05792410|Experimental|SHR-A1811 combined with Fulvestrant|
89663256|NCT05792410|Experimental|SHR-A1811 combined with Bevacizumab injection|
89213858|NCT00573170|Other|BPT|BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)
89213859|NCT00573170|Other|PTB|placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)
89213860|NCT00573170|Other|PBT|placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)
89663257|NCT05792397|Experimental|treatment group|The arm contains patients with acute pulmonary embolism who undergoing interventional therapy with transcatheter pulmonary embolectomy system which named 'TwiFlow-Thrombectomy Catheter System'
89663258|NCT05792384|Experimental|transbronchial cryobiopsy|transbronchial cryobiopsy with a 1.1 mm flexible cryoprobe
89663259|NCT05792384|Active Comparator|transbronchial lung biopsy|transbronchial lung biopsy with biopsy forceps
89663260|NCT05792371|Experimental|with induced membrane|operation of stage I and II
89663261|NCT05792371|Experimental|without induced membrane|only stage II
89663262|NCT05792280|Experimental|AI-assisted group|Subjects will undergo EUS examination with the assistance of AI system.
89663263|NCT05792280|No Intervention|non-assisted group|Subjects will undergo EUS examination without the assistance of AI system
89663264|NCT05792267|Experimental|AI-assisted group|Subjects will undergo EUS examination with the assistance of artificial intelligence(AI) system.
89663265|NCT05792267|No Intervention|Non-assisted group|Subjects will undergo EUS examination without the assistance of artificial intelligence(AI) system.
89663266|NCT05792254|Experimental|Huaier granule|Huaier granule is supplied as 20-g granule. Huaier granule will be administered as 20 g orally tid x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. In the absence of intolerable toxicity, a patient may continue to receive treatment with Huaier granule until disease progression, or until 24 months have elapsed.
89663267|NCT05792202|Experimental|Study group|double raw repair for full tear rotator cuff combined microfracture procedure
89663268|NCT05792202|Placebo Comparator|Control group|double raw repair for full tear rotator cuff
89663269|NCT05792176|Experimental|Musical Training Intervention|Participants randomized to this arm receive a 12-week intervention to teach them how to play the ukulele. The ukulele is a very manageable instrument to learn and requires less hand dexterity than other stringed instruments. Each week participants will follow the musical training intervention (MTI) protocol that provides instruction on how to tune, hold, and strum the ukulele and play basic chords. To practice the chords, they will also learn popular songs (e.g., Chain of Fools, Three Little Birds, Happy Birthday, Don't Worry Be Happy, and Stand by Me). Participants will be instructed to follow each session outlined weekly and asked to practice the instrument for at least 30 minutes, 5 days a week. They will be given a paper and digital version of the MTI protocol. A member of our research team will call the participants weekly to answer any questions about the MTI protocol.
89663270|NCT05792176|Active Comparator|Music Listening|Participants randomized to this arm will be asked to listen to their preferred music for at least 30 minutes, 5 days a week. A member of our research team will call them every week to answer any questions they have about the ML protocol. They will be asked to record their experience in a practice log.
89663271|NCT05792124|Experimental|ESP BLOCK|
89663272|NCT05792124|Active Comparator|RLB BLOCK|
89663273|NCT05792111|Experimental|Group C|Group C; caudal epidural steroid injection (10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space).
89663274|NCT05792111|Active Comparator|Group CT|Group CT; trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
89663275|NCT05789953||Development of the machine learning model|Perioperative clinical routine data are going to be assessed as per standard. Postoperatively, a standardized lung sonography is going to be performed in the recovery room. Patients will then be visited on the ward on postoperative day 1, 3 and 7 for clinical examination to detect postoperative pulmonary complications according to the criteria elaborated by the StEP- collaboration.
89663276|NCT05789836|Experimental|Study Group|This research was planned as a single group pretest-posttest quasi-experimental.
89663277|NCT05789771||patients with HR+/HER2- ABC/MBC who received abemaciclib based therapy for their ABC/MBC.|
89663278|NCT05789732|Placebo Comparator|Placebo group|Patients in this group will receive placebo treatment once daily.
89663279|NCT05789732|Experimental|Silodosin group|Patients will receive Silodosin 8 mg once daily.
89663280|NCT05789732|Experimental|Tadalafil group|Patients will receive Tadalafil 5 mg once daily.
89663281|NCT05789732|Experimental|Silodosin and Tadalafil|Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
89663282|NCT05789693|Experimental|Intervention|"Physical activity changes expected~Description:~Develop four sessions in the Tutorial Action Plan of the school~Connect several subjects aligned with the messages from the tutory~Physical education teachers provide some insights about healty behaviours"
89663283|NCT05789693|No Intervention|No intervention|"No Physical activity changes expected~Descrption:~- No intervention"
89663284|NCT05789511||Medically refractory Non-transplanted gastroparesis|"Etiology of gastroparesis deemed on clinical grounds to NOT be secondary to lung transplantation process ( diabetes, post-surgery, idiopathic, neuromuscular etc.)~Gastroparesis defined as > 10% radiotracer remains in the stomach after 4 hour gastric scintigraphy study.~Medically refractory is defined as lack of clinical response to trial of diet and lifestyle modifications such as small frequent low fat and low fiber meals and trial or contraindications to prokinetic medications for the treatment of gastroparesis~Case Cohort: Assessment of HR-EGG comparing controls (non lung transplant induced gastroparesis) vs lung transplant induced gastroparesis~Investigators will further categorize patients into sub- groups based on HR-EGG phenotypes:, such as High Frequency, Low Frequency, High Amplitude, Low Amplitude, Continuous Symptoms, Sensorimotor Symptoms, Mixed Symptoms and Normal on Day."
88994971|NCT05785923|No Intervention|Usual Care|Chest pain patients identified by their treating physician as being low-risk chest pain will receive the usual care for their condition.
88994972|NCT05785910|Experimental|Normal subjects|
88994973|NCT05785663||I|Subjects received Lysine hydrochloride 26 g ± 5% Arginine hydrochlordie 26 g ± 5% Amifostine trihydrate 0.65 g ± 5%
88994974|NCT05785663||II|Subjects received Lysine hydrochloride 39 g ± 5% Arginine hydrochlordie 39 g ± 5% Amifostine trihydrate 0.98 g ± 5%
88994975|NCT05785663||III|Subjects received Lysine hydrochloride 52 g ± 5% Arginine hydrochlordie 52 g ± 5% Amifostine trihydrate 1.3 ± 5%
88994976|NCT05785663||IV|Subjects received Lysine hydrochloride 60 g ± 5% Arginine hydrochlordie 60 g ± 5% Amifostine trihydrate 1.5 ± 5%
88994977|NCT05785572|Experimental|Radiofrequency group|Patient group that undergoes Radiofrequency of supraescapular nerve before shoulder arthroplasty surgery
88994978|NCT05785572|Active Comparator|Interscalenic braquial plexus block group|Interscalenic braquial plexus block done at the moment of the surgery.
88994979|NCT05785559|Experimental|Scarred uterus|Patients who have already undergone one or more cesarean section(s) during a previous pregnancy and for whom a cesarean section is indicated on a scheduled or emergency basis.
88994980|NCT05785559|Experimental|Scar dehiscence surgery|Patients who have already undergone one or more caesarean section(s) and for whom the surgical management of a dehiscence of a caesarean section scar is indicated outside of pregnancy.
88994981|NCT05785559|Experimental|Healthy uterus|"Patients with no history of caesarean section, pregnant with an indication for caesarean section: patients who have never had a caesarean section during a previous pregnancy or who are pregnant with their first pregnancy and for whom a caesarean section is indicated scheduled or urgently"
89663285|NCT05789511||Medically refractory Post Lung transplant gastroparesis|"Etiology of gastroparesis deemed on clinical grounds to be secondary to lung transplantation process.~Gastroparesis defined as > 10% radiotracer remains in the stomach after 4 hour gastric scintigraphy study.~Medically refractory is defined as lack of clinical response to trial of diet and lifestyle modifications such as small frequent low fat and low fiber meals and trial or contraindications to prokinetic medications for the treatment of gastroparesis~Case Cohort: Assessment of HR-EGG comparing controls (non lung transplant induced gastroparesis) vs lung transplant induced gastroparesis~Investigators will further categorize patients into sub- groups based on HR-EGG phenotypes:, such as High Frequency, Low Frequency, High Amplitude, Low Amplitude, Continuous Symptoms, Sensorimotor Symptoms, Mixed Symptoms and Normal on Day."
88994982|NCT05785520|Other|ST500 single-dose gel|The treatment is performed twice weekly for 6 weeks.
88994983|NCT05785494|Experimental|Intervention|Access to web-site
88994984|NCT05785494|No Intervention|Control|Standard care
89663286|NCT05789290||Test group|This group will receive a 30-minute cryocompression treatment to one knee using a Hilotherm device, which is set to circulate water through the cuff at a maintained temperature of 10℃. The Hilotherm device will be administered according to the manufacturer's guidelines and each participant will undergo this treatment once.
89663287|NCT05789121||Healthy subjects|30 healthy subject aged between 18 and 40.
88994985|NCT05785481||Patients with early diagnosis (within 6 hours of life) of mild HIE|
88994986|NCT05785416|Experimental|PNF- CR Group|The participants in the group were given PNF contract- relax stretching using the standard protocol. One trial had two isometric contractions each followed by five seconds muscle stretch and there was a total of four trials. Total of 12 sessions in 4 weeks (3sessions/week).
88994987|NCT05785416|Experimental|Static Stretching Group|"The participants in the group were given sustained stretching for a period of 80s at a stretch.~Total of 12 sessions in 4 weeks (3sessions/week)."
88994988|NCT05785416|No Intervention|Control Group|No intervention was given in this group
88994989|NCT05785312|Experimental|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The standard Face to Face Eye Movement Desensitization & Reprocessing Therapy will be applied by a trained clinical psychologist through in person face to face sessions.
88994990|NCT05785312|Active Comparator|Online Eye Movement Desensitization & Reprocessing Therapy|The Online Eye Movement Desensitization & Reprocessing Therapy will be applied by a trained clinical psychologist through computer system by connecting through internet. For this purpose the online EMDR therapy application software will be installed
88994991|NCT05785273||Dexmedetomidine|Patient undergoing general anesthesia receving initial administration of dexmedetomidine loading dose of 0.5-1 μg/kg (ADJUSTED weight) over 15 minutes. After intubation maintenance of general anesthesia is administrated with desflurane or sevoflurane (MAC 0.6 - 1, according to Bispectral Index (BIS) or Patient State Index (Psi)), dexmedetomidine (0.2- 0.4 μg/kg/h (Lean Body Weight)) with constant infusion rate unless hypotension or bradycardia not responsive to standard treatments (filling, atropine, ephedrine, ethylephrine) occurred, and remifentanil (0.02 - 0.2 μg/kg/min (LBW)) based on clinical and instrumental assessment (Heart Rate, Blood Pressure, BIS or Psi).
88994992|NCT05785273||No Dexmedetomidine|Patients in this group receive an eventual premedication with benzodiazepines according to anaesthesiologist assessment and patient condition. After intubation general anesthesia is administrated with inhaled (desflurane or sevoflurane; MAC 0.6 - 1) or intravenous (propofol) anesthetics (according to BIS or Psi) and remifentanil (0.02 - 0.2 μg/kg/min (LBW) based on clinical and instrumental assessment (HR, BP, BIS or Psi)).
89663288|NCT05785728|Experimental|DB-1202 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 1 on Day 1 of each cycle Q3W
89663289|NCT05785728|Experimental|DB-1202 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 2 on Day 1 of each cycle Q3W
89663290|NCT05785728|Experimental|DB-1202 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 3 on Day 1 of each cycle Q3W
89663291|NCT05785728|Experimental|DB-1202 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 4 on Day 1 of each cycle Q3W
89663292|NCT05785728|Experimental|DB-1202 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 5 on Day 1 of each cycle Q3W
89663293|NCT05785728|Experimental|DB-1202 Dose Level 6|Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 6 on Day 1 of each cycle Q3W
89663294|NCT05785728|Experimental|DB-1202 Dose Expansion 1|Enrolled Subjects with locally advanced or metastatic primary thyroid cancers with pathology of epithelial tumors that originated from thyroid follicular cells will be enrolled regardless of PD-L1 expression will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
89663295|NCT05785728|Experimental|DB-1202 Dose Expansion 2|Enrolled Subjects in selected solid malignant tumors can be added will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
89663296|NCT05785728|Experimental|DB-1202 Dose Expansion 3|Enrolled Subjects in selected solid malignant tumors can be added will receive initial dose of DB-1202 Q3W under a 21-day Treatment Cycle with RP2D.
89663297|NCT05785221|Placebo Comparator|Healthy Comparators|They will receive general lifestyle and nutritional education.
89663298|NCT05785221|Experimental|Overweight/Obese Group|They will receive personalized nutritional and lifestyle weight reduction intervention including dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians.
89663299|NCT05783037|Experimental|New Organic Infant Formula|New organic infant formula for healthy term infants
89663300|NCT05783037|Active Comparator|Commercial Organic Infant Formula|Commercially available organic infant formula for healthy term infants
89663301|NCT05783037|No Intervention|Breastfed Reference Group|Breastmilk
89048179|NCT03118349|Experimental|Escalation Cohorts|MVT-5873 blocking dose and MVT-1075 dose escalation; Initial to maximum tolerated dose
89048180|NCT03118349|Experimental|Expansion Cohort - no subjects enrolled|MVT-5873 blocking dose and MVT-1075 Maximum tolerated dose
89048181|NCT03053115|Experimental|CASES|treatment with levothyroxine and liothyronine
89048182|NCT03053115|Active Comparator|CONTROLS|treatment with levothyroxine and placebo
88994993|NCT05785260||Group 1|All patients are assessed. The neuropsychologist assessed global cognitive status and disposition to Mindfulness. Engineered bands for multi-parameter heart rate monitoring were delivered.From the time of delivery, for 9 consecutive days the patient received a reminder via WhatsApp at the most convenient time slot. At this point, he would wear the supplied chest strap by wetting it appropriately so that it adhered perfectly to the skin. The heart rate App was accessed via Bluetooth and recorded the basal heart rate for about 10 minutes.Then the Mindfulness session was carried out. At the end of 9 days, the completed input tests plus the heart rate measurement were sent on day 10, except for the Mindfulness session, which was not scheduled. After two weeks, the measurement was repeated with the same procedure.
88994994|NCT05785260||Group 2|Patients in this group met the inclusion criteria and did not take any measurements. They underwent only the neuropsychological evaluation
88994995|NCT05785234|Experimental|Sufentanil-remimazolam group|The sufentanil-remimazolam group receives total intravenous anesthesia with sufentanil-remimazolam.
88994996|NCT05785234|Active Comparator|Remifentanil-remimazolam group|The remifentanil-remimazolam group receives total intravenous anesthesia with remifentanil-remimazolam.
88994997|NCT05785208|Experimental|ARM A: TP53 wilde-type|Participants will receive osimertinib 80 mg once daily until disease progression or unacceptable toxicity.
88994998|NCT05785208|Experimental|ARM B: TP53 mutant|Participants will receive osimertinib 80 mg once daily until disease progression or unacceptable toxicity.
88994999|NCT05785156||acute stroke patients|
88995000|NCT05785156||cognitive neurodegenerative disorders|cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), FrontoTemporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)
88995001|NCT05785117|Experimental|Vagus nerve stimulation group|Vagus nerve stimulation group
88995002|NCT05785117|Experimental|Circuit weight training group Group|Circuit weight training group Group
88995003|NCT05785052||Renal-mass patients|Patients diagnosed with a first episode of renal mass attending the urology department.
88995004|NCT05785052||Control subjects|Patients affected by urological functional diseases or living kidney donor.
88995005|NCT05785026|Experimental|WP 1a|Menthol inhalation during resistive loaded breathing trials in healthy participants.
88995006|NCT05785026|Placebo Comparator|WP 1b|Strawberry scent during resistive loaded breathing trials in healthy participants.
88995007|NCT05785026|Experimental|WP 2a|Menthol inhalation during cycle exercise in healthy participants.
88995008|NCT05785026|Placebo Comparator|WP 2b|Strawberry scent during cycle exercise in healthy participants.
88995009|NCT05785026|Experimental|WP 3a|Menthol inhalation during resting breathing in dyspneic COPD participants.
88995010|NCT05785026|Placebo Comparator|WP 3b|Strawberry scent during resting breathing in dyspneic COPD participants.
88995011|NCT05785026|No Intervention|WP 3c|Resting breathing in dyspneic COPD participants.
88995012|NCT05785026|Experimental|WP 4a|Menthol inhalation during cycle exercise in COPD participants.
88995013|NCT05785026|Placebo Comparator|WP 4b|Strawberry scent during cycle exercise in COPD participants.
88995014|NCT05785000|Experimental|Aerobe graded physical exercise intervention and usual care|Physical exercise program. The experimental programme is an add-on to usual care and consists of an aerobe graded exercise program performed twice a week for 12 weeks. Usual care includes all public treatments that each patient is assigned to at entry to REPCon. The provision of officially available treatments follow the Danish Health Care Act.
88995015|NCT05785000|Placebo Comparator|Usual care|No physical exercise program in a patient control group with PCS. This group continues with usual care, but all clinical test, interviews and MRI protocol are the same.
88995016|NCT05784987|Experimental|R-MINE+X|"R-MINE: Rituximab, Isophosphamide, Mitoxantrone hydrochloride liposome, Etoposide~X: Orelabrutinib, Chidamide, Penpulimab, Lenalidomide"
88995017|NCT05784974|Experimental|Cadonilimab|Participants receive two cycles of Cadonilimab as neoadjuvant therapy prior to surgery; followed by surgery; followed by standard adjuvant chemotherapy +/- adjuvant Cadonilimab for 6 months.
88995018|NCT05784909|Experimental|patients diagnosed with bladder outlet obstruction due to BPH|all symptomatic patients with BPH with failure medical management or prefer minimal invasive procedure from the start.
88995019|NCT05784831|Experimental|Regular Intervention Group|Group using the app delivering reappraisal training for 21 consecutive days.
88995020|NCT05784831|Experimental|Burst Intervention Group|Group using the app delivering reappraisal training for 7 consecutive days, then having 7 days break and again using the app 7 consecutive days.
88995021|NCT05784831|Active Comparator|Active Control Group|Group using the ecological momentary assessment app for 21 consecutive days.
88995022|NCT05784818|Experimental|Intervention + No Booster|This arm will have n=67 participants. The Up To Me behavioral intervention will be administered via 2-hour sessions over three consecutive weeks. During these sessions, participants will complete worksheets from the Up To Me workbook.
88995023|NCT05784818|Experimental|Intervention + Booster|This arm will have n=67 participants. The Up To Me behavioral intervention will be administered via 2-hour sessions over three consecutive weeks. During these sessions, participants will complete worksheets from the Up To Me workbook. Additionally, participants randomized to this arm will complete an additional session 4 weeks after the third session of the intervention.
88995024|NCT05784818|No Intervention|Waitlist Control|"This arm will have n=67 participants. Those randomized to this arm will be engaged in treatment as usual, participating in the same services and activities that they were engaged with prior to recruitment into the study."
88995025|NCT05784649|Other|control group|The interventions of the control group will receive the routine health education proposed by relevant experts in China which are chosen by the Chinese Medical Association.
88995026|NCT05784649|Experimental|intervention group|The interventions of the intervention group will include routine health education. And then the participants will have individual counsel about health-promoting behaviors with a midwife and a doctor. The counseling will be based on the procedure of the health promotion model.
89048183|NCT03049969|Experimental|Cognitive Remediation|For the 20 cognitive remediation sessions, eligible participants will receive 20 minutes of active tDCS stimulation (up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while they complete the cognitive training tasks. Once the participant has completed his/her 20 sessions a pre/post treatment assessment measures will be completed.
89048184|NCT03003026|Experimental|Novel task-specific program|Intervention arm - see detailed intervention group description below
89048185|NCT03003026|Active Comparator|Parent-led home-based program|Comparison arm - see detailed comparison group description below
89663302|NCT05778656|Experimental|Mediterranean diet without red and/or processed meat|They will receive motivation and behavioral support through a study specific website which will be accessed after randomization. The research team will give participants further information on the use of this website. One of the features of the website will allow participants to collect and self-monitor their dietary intakes using 24h dietary recalls. Participants will be instructed to fill in as many recalls as possible throughout the study, with a minimum of 2 recalls at baseline and 2 recalls at follow up. Other features of the website include specific indications to eliminate red and processed meat in the context of a healthy Mediterranean dietary pattern, considering the key elements proposed in the dietary guidelines to improve cardiovascular health. The website will also provide them general information about the Mediterranean diet, as well as recipes, tips, and alternatives to replace meat when cooking at home or eating out. The rest of the clinical care will be as usual.
89663303|NCT05778656|No Intervention|General advice based on the Mediterranean diet|The control group will be guided to use the same website although they will only have access to a restricted version of it, with the dietary recall feature plus general information about the Mediterranean diet. They will not receive specific recommendations to reduce red and processed meat or any other support or advice. Participants will be instructed to fill in as many 24h dietary recalls as possible throughout the study, with a minimum of 2 recalls at baseline and 2 recalls at follow up. The rest of the clinical care will be as usual.
89663304|NCT05764889|Experimental|Experimental group|Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.
89663305|NCT05764889|Other|Control group|Patients in the control group were wrapped with traditional gauze after operation.
89663306|NCT05762770|No Intervention|standard ICSI|Only spermatozoa with a moving tail but no forward motion will be selected for use in ICSI.
89663307|NCT05762770|Experimental|PICSI (intervention)|Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
89663308|NCT05762341|Experimental|EXPERIMENT GROUP|BOTH GROUPS WILL RECEIVE PRESSURE INJURY PREVENTION TRAINING. ONLY EXPERIMENTAL GROUP WILL USE THE MOBILE LEARNING TOOL
89663309|NCT05762341|Experimental|CONTROL GROUP|BOTH GROUPS WILL RECEIVE PRESSURE INJURY PREVENTION TRAINING. ONLY EXPERIMENTAL GROUP WILL USE THE MOBILE LEARNING TOOL
89663310|NCT05761080|Experimental|Experimental branch|"Patients will be included in the study during the anesthetic surgery evaluation.~The patient will be randomized at the time of informed consent to know the postoperative guideline to be used.~Randomization of patients on postoperative day 3.~If patient belong to the Fast Track group:~Application of discharge criteria in the experimental branch at 72 hours post-surgery, and administration of oral antibiotic therapy: Amoxicillin - clavulanic acid, dose: 100mg/Kg/day every 8 hours for a total of 5 days.~There will be a follow-up at 5, 7 and 30 days after discharge. In addition, there will be a face-to-face visit 2 weeks after the intervention."
89663311|NCT05761080|Active Comparator|Control branch|"Patients will be included in the study during the anesthetic surgery evaluation.~The patient will be randomized at the time of informed consent to know the postoperative guideline to be used.~Randomization of patients on postoperative day 3.~If patient belongs to the control group:~Application of discharge criteria in control branch 5 days postoperative, according to current clinic guidelines. Administration of Amoxicillin - clavulanic acid, dose: 100mg/Kg/day every 8 hours, intravenous during 5 days~There will be a follow-up at 5, 7 and 30 days after discharge. In addition, there will be a face-to-face visit 2 weeks after the intervention."
89663312|NCT05755555|Experimental|Diabetes specialist|Message with a note from a diabetes specialist
89663313|NCT05755555|Experimental|Someone like you|"Message with a note from a person like you"
89663314|NCT05755555|Experimental|Vitality doctor|Message with a note from the Vitality doctor
89663315|NCT05753514|Experimental|ESWT|Effect of ESWT in alleviating pain
89663316|NCT05752240|Experimental|Active stimulation|Ten sessions of cathodic transcranial direct current stimulation over primary motor cortex
89663317|NCT05752240|Sham Comparator|Sham stimulation|Ten sessions of sham stimulation over primary motor cortex
89663318|NCT05743855|Placebo Comparator|Placebo|Participants consume 1 serving of Placebo daily and attend weekly chiropractor sessions for 12 weeks.
89663319|NCT05743855|Experimental|Treatment Group|Participants consume 1 serving of the Nutrional supplement daily and attend weekly chiropractor sessions for 12 weeks.
89663320|NCT05743764|Experimental|HU007|"Cyclosporine 0.02%, trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
89663321|NCT05743764|Active Comparator|Restasis|"Cyclosporine 0.05%~1 drop b.i.d at 12hr interval for 12 weeks"
89663322|NCT05743764|Active Comparator|Moisview|"trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
89048186|NCT02932332|Active Comparator|High-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (HFOx) is followed by 3 different breathing therapies of Low-flow oxygen (LFOx), High-flow air (HFAir), and Low-flow air (LFAir) with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
89048187|NCT02932332|Active Comparator|Low-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, HFAir, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
89213861|NCT03967171|Experimental|before uterine incision oxytocin group|IV infusion of 20 IU of oxytocin started before uterine incision
89048188|NCT02932332|Sham Comparator|High-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, LFOx, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
89048189|NCT02932332|Sham Comparator|Low-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow air (LFAir) is followed by 3 different breathing therapies of HFOx, LFOx, and HFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
89048190|NCT02918409|Active Comparator|Standard colistin arm|Subjects initially receive IV colistin 2.5 mg/kg/d divided into three times daily (TID) dosing. Subjects receiving colistin will undergo a 2 day up-titration of dose to an ultimate dose of 4-5 mg/kg/day, for a total treatment of 14 days. The drug is infused over 30 minutes on a TID dosing schedule.
89048191|NCT02918409|Active Comparator|Modified colistin arm|Subjects receiving IV colistin undergo a 2 day up-titration to a maximum dose of 5 mg/kg/day, divided into twice daily (BID) dosing, for a total treatment of 14 days. The drug is infused over 30 minutes BID. Steady state plasma concentrations on day 3 of therapy (on 2nd- 3rd dose once at goal dosing) will be measured; specifically, colistin peak (30 minutes after infusion), midpoint (6 hour) and trough (30 minutes prior to next infusion).
89663323|NCT05743075|Experimental|Ensifentrine|"Eligible subjects will be randomly assigned in a 5:3 ratio to receive either Ensifentrine or placebo. Doses and methods of administration are as follows:~Ensifentrine (RPL554) 3 mg BID or placebo BID will be administered by aerosol inhalation for 24 weeks; each nebulization time wil be approximately 5 minutes."
89663324|NCT05743075|Placebo Comparator|Placebo|"Eligible subjects will be randomly assigned in a 5:3 ratio to receive either Ensifentrine or placebo. Doses and methods of administration are as follows:~Ensifentrine (RPL554) 3 mg BID or placebo BID will be administered by aerosol inhalation for 24 weeks; each nebulization time wil be approximately 5 minutes."
89663325|NCT05741515|Experimental|VBP Intervention Group|Children coded as abnormal on functional tests (FT) (n=12) will participate in an 8-week 5X/week home-based VBT program. At the initial visit (T0), the PI will instruct the participants (caregiver and child) in the program and provide all materials. The exercises will be led by the caregiver, with weekly in person checks by the PI to progress and provide coaching. The child/caregiver will complete a daily log to report activities and level of enjoyment. VBT will be done 5 days/week and will include 4 key categories of exercises, each lasting 5 minutes (20 minutes total of exercise per day). The 4 categories, explained below, include: 1) Times 1 (X1) Viewing, 2) Gaze Shifting, 3) Static Balance, 4) Dynamic Balance. The proposed VBT home program will include 10 minutes of gaze stabilization exercises, and 10 minutes of balance training.
89663326|NCT05741515|Sham Comparator|Sham Intervention|"Sham Intervention (not to be compared to intervention - for feasibility only):~Aim 1 is to establish the feasibility of a control intervention to be used in future studies. Therefore, 3 participants who score above the set criterion for the Functional Tests (FT) (i.e., they do not need VBT) will participate in an 8-week sham intervention. At T0, the PI will instruct the participants to do the sham intervention, led by the caregiver with weekly checks to control for attention bias. The sham intervention will be done for 20 minutes per day and will consist of 10 minutes of focused reading a book of the child's choice and 10 minutes of active play. The child and caregiver will complete a daily activity log documenting the activity and level of enjoyment."
89663327|NCT05737186|Experimental|Intervention group|
89663328|NCT05737186|No Intervention|Control group|
89663329|NCT05700669|Experimental|Dose Escalation|Three dose levels of AsiDNA delivered intravenously weekly in combination with Olaparib
89663330|NCT05700669|Experimental|Dose Expansion: Recurrent Epithelial Ovarian Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
89663331|NCT05700669|Experimental|Dose Expansion: Metastatic Castration-resistant Prostate Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
89663332|NCT05700669|Experimental|Dose Expansion: Recurrent Breast Cancer Cohort|Recommended Phase 2 dose of AsiDNA delivered intravenously weekly in combination with Olaparib
89663333|NCT05692375|Experimental|Experimental|The experimental group will be inveted to use the game. Two weeks were defined as the time to use the game. The use of the game can be seen by the coded digital record on its digital platform .
89663334|NCT05692375|No Intervention|Control|The control group neither used nor had access to the game.
89663335|NCT05667272||Pancreatic fistula group|no intervention(s)
89663336|NCT05667272||non-pancreatic fistula group|no intervention(s)
89663337|NCT05718960|Placebo Comparator|Reassurance-alone|
89663338|NCT05718960|Active Comparator|Traditional Dietary Advice|
89663339|NCT05665569|Active Comparator|Routine Care|Women will undergo routine pelvic physical therapy for birth-related pelvic floor disorders as determined by their physical therapist who is also the Principal Investigator.
89048192|NCT02918409|Active Comparator|Standard tobramycin arm|Subjects receive IV tobramycin 8-10 mg/kg/day with once daily dosing for 14 days. Peaks and troughs are drawn with the second dose of tobramycin, and the drug is infused over 30 minutes
89213862|NCT03967171|Active Comparator|after clamping the umbilical cord oxytocin group|IV infusion of 20 IU of oxytocin started immediately after clamping the umbilical cord
89213863|NCT03971383|Experimental|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
89663340|NCT05665569|Experimental|Flourish HEC|"In addition to routine physical therapy, women will use a 3-component vaginal hygiene system, Flourish HEC (HEC = hydroxyethylcellulose to differentiate this system from a prior Flourish system based in aloe) plus a personal lubricant called BioNude."
89663341|NCT05660057|Experimental|Newly designed computer monitor|Participants will read a short story and then watch moving images for 30 minutes or until any of their persisting concussion symptoms arise. The number and severity of symptoms will be assessed by completing SCAT -III pre- and post-study tasks.
89663342|NCT05660057|Sham Comparator|Standard computer monitor|Same participants will read a short story and watch moving images for 30 minutes or until any of their persisting concussion symptoms arise on the standard computer screen.The number and severity of symptoms will be assessed by completing SCAT -III pre- and post-study tasks.
89663343|NCT05652660|Experimental|Rosuvastatin with/without ARV-471|Rosuvastatin administered as a single dose in Period 1 and Period 2. ARV-471 administered as a single dose in Period 2.
89663344|NCT05645562|Experimental|Intervention group|Intervention group will receive a pain neuroscience education program (once time per month, during 4 months). This program will include information about biological, psychological and perceptual aspects of pain in the sport context.
89663345|NCT05645562|Active Comparator|Control group|The control group will receive a self-care education program (once time per month, during 4 months). This program will include information about health habits in the sport.
89663346|NCT05643742|Experimental|CTX112|Administered by IV infusion following lymphodepleting chemotherapy.
89663347|NCT05637307|Experimental|sentinel node procedure|Participants will indergo the standard treatment for their disease ( i.e. brachytherapy) but a sentinel node procedure will be added to their treatment
89663348|NCT05624632||Cognitively unimpaired|Cognitively unimpaired participants from BBRC-sponsored studies
89663349|NCT05613868|Experimental|Active, TPN-101|100 mg/day to 400mg/ study investigational drug TPN-101 once daily for 48 weeks followed by 12 weeks of follow-up period.
89663350|NCT05600140|Experimental|Group A) early training group|T0 = baseline measurement T1 = posttest (within two weeks after training) T2 = follow up measurement (6 months after training)
89663351|NCT05600140|Experimental|Group B) late training group|T0 = baseline measurement T1 = test-retest reliability and natural development (over period 1 1/2-2 months after T0) T2 = posttest (within two weeks after training)
89663352|NCT05588505|Experimental|Cognitive Behavioral Therapy delivered in a group format|Participating students will be assessed before and after the 12-week group Cognitive-Behavioral intervention to ascertain their response to the treatment.
89663353|NCT05571709|Active Comparator|Aged individuals who perform exercise training|Aged individuals will perform an acute bout of resistance trainig (30 minutes). This training is focused on the lower limbs.
89663354|NCT05571709|Sham Comparator|Aged individuals who stay sedentary|Aged individuals will remain seated for 30 minutes.
89663355|NCT05529134|Experimental|PTW-002 10 mg/g gel|PTW-002 poloxamer hydrogel for topical administration (cutaneous use), 10 mg/g gel
89663356|NCT05529134|Placebo Comparator|Placebo|Matching placebo poloxamer hydrogel for topical administration (cutaneous use)
89663357|NCT05516238|Experimental|Video group|Case management through video format
89663358|NCT05516238|Active Comparator|In-person|Case management through in person format
89663359|NCT05489471||Adult Chest Radiographs|All chest X-rays for patients over 16 years from either a GP referral or performed in the Emergency department (ED) of the acute hospital, which includes Accident and Emergency attendances and in-patient studies.
89663360|NCT05488886|Experimental|A: Whole Aronia Berry Powder|
89663361|NCT05488886|Experimental|B: Aronia Berry Extract|
89663362|NCT05488886|Experimental|C: Phospholipid-Polyphenol|
89663363|NCT05488886|Experimental|D: Low-Polyphenol Control|
89663364|NCT05477290||Transverse incision|At the level of the A1 pulley, a transverse incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release
89663365|NCT05477290||Oblique incision|At the level of the A1 pulley, a oblique incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
89663366|NCT05477290||Vertical incision|At the level of the A1 pulley, a vertical incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
89663367|NCT05456932|Experimental|Intravenous iron|Intravenous iron therapy
89663368|NCT05456932|Experimental|Ferric maltol|Treatment with oral ferric maltol
89663369|NCT05456932|Experimental|Ferrous fumarate|Treatment with oral ferrous fumarate
89663370|NCT05447780|Experimental|General anesthesia|induction: propofol 1.5-2.5 mg\kg IV bolus and fentanyl 1-2 mcg\kg maintenance anesthesia: sevoflurane, doses of the inhalation agent according to bispectral index (BIS) monitor ( target BIS level 40-60) and fentanyl 1-5 mcg\kg\h.
88995027|NCT05784636|Experimental|Non-invasive BiPAP ventilation treatment group|Patients were first treated with HFNC on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40 L/min, maintaining SpO2>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge
89213864|NCT03971383|Placebo Comparator|Placebo|3 tablets one time, 3 times a day(tid)
89213865|NCT01077349|Experimental|high volume hemofiltration|
89663371|NCT05447780|Experimental|Combined anesthesia: general anesthesia and Erector spinae plane block (ESP block)|"induction: propofol 1.5-2.5 mg\kg IV bolus and fentanyl 1-2 mcg\kg ESP- block with US control with single shot of local anesthetic ( bupivacaine 0.375% or 0.25% 20-30 ml) is performed after induction.~maintenance anesthesia: sevoflurane, doses of the inhalation agent according to BIS monitor ( target BIS level 40-60) and fentanyl 0.5-1.5 mcg\kg\h."
89663372|NCT05447780|Experimental|Combined anesthesia: General anesthesia and Thoraco-lumbar interfacial plane block (TLIP block)|"induction: propofol 1.5-2.5 mg\kg IV bolus and fentanyl 1-2 mcg\kg TLIP- block with US control with single shot of local anesthetic ( bupivacaine 0.25% 15 ml or mixed bupivacaine 0.25% 7.5 ml and lidocaine 2% 7.5 ml) is performed after induction.~maintenance anesthesia: sevoflurane, doses of the inhalation agent according to BIS monitor ( target BIS level 40-60) and fentanyl 0.5-1.5 mcg\kg\h."
89213866|NCT01077349|Active Comparator|standard care|
89663373|NCT05441319||Chronic ankle instability group|After completing the evaluation form containing the demographic and clinical characteristics of all participants at their first visit, the Cumberland Ankle Instability Questionnaire (CAIT) scale will be completed and athletes with a CAIT score ≤ 25 will be assigned to the Chronic Ankle Instability Group;
89663374|NCT05441319||Control group|Athletes with a score > 25 in the Cumberland Ankle Instability Questionnaire (CAIT) will be included in the Control Group.
89663375|NCT05437289|Experimental|300 mg AZD7442 IM|Administration of a single dose of 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) sequentially by intramuscular (IM) injection.
89663376|NCT05437289|Placebo Comparator|300mg placebo IM|Administration of placebo with dose match to AZD7442 in the same cohort sequentially by intramuscular (IM) injection.
89663377|NCT05437289|Experimental|600 mg AZD7442 IM|Administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) sequentially by intramuscular (IM) injection.
89663378|NCT05437289|Placebo Comparator|600mg placebo IM|Administration of placebo with dose match to AZD7442 in the same cohort sequentially by intramuscular (IM) injection.
89663379|NCT05437289|Experimental|300 mg AZD7442 IV|co-administration of a single dose of 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) by intravenous (IV) infusion.
89663380|NCT05437289|Placebo Comparator|300mg placebo IV|co-administration of a single dose of placebo in equivalent volume by intravenous (IV) infusion.
89663381|NCT05437289|Experimental|600 mg AZD7442 IV|co-administration of a single dose of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by intravenous (IV) infusion.
89663382|NCT05437289|Placebo Comparator|600mg placebo IV|co-administration of a single dose of placebo in equivalent volume by intravenous (IV) infusion.
89663383|NCT05389930|Experimental|THC-dominant cannabis dose|367 mg of cannabis plant material with 9.53% THC and 0.09% CBD and 217 mg of placebo cannabis plant material will be mixed and smoked in a handheld pipe
89663384|NCT05389930|Experimental|CBD-dominant cannabis dose|367 mg of cannabis plant material with 11.27% CBD and 0.35% THC and 217 mg of placebo cannabis plant material will be mixed and smoked in a handheld pipe
89663385|NCT05389930|Placebo Comparator|Placebo|584 mg of cannabis plant material will be smoked in a handheld pipe
89663386|NCT05389930|Experimental|Alcohol priming dose|Alcohol: 0.3 g/kg. Alcohol priming drink is designed to raise blood alcohol levels to 0.03 g/dl and be consumed in 5 minutes. The drink is mixed using 80-proof liquor and juice. Participants are randomized to receive either the experimental alcohol priming dose or alcohol placebo.
89663387|NCT05389930|Placebo Comparator|Alcohol placebo dose|Placebo beverage contains only juice and a negligible trace of alcohol for masking. The weight and sex-adjusted volume of alcohol and non-alcohol containing beverages will be equal. Participants are randomized to receive either the experimental alcohol priming dose or alcohol placebo.
89663388|NCT05383404||mild dehydration|(3-5)% according to change in body weight.
89663389|NCT05383404||moderate dehydration|(6-9)% according to change in body weight.
89663390|NCT05383404||severe dehydration|(6-9)% according to change in body weight.
89663391|NCT05382546|Experimental|NTM-001 Treatment Arm|NTM-001 loading dose of 12.5 mg administered over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mg/h for 24h, by a pre-programmed infusion pump.
89663392|NCT05378321|Other|ACS risk gropu|Group of patients with an acute-cardiovascular syndrome.
89663393|NCT05356000|Other|Subjects who will follow low-oxalate diet followed by visit to research clinic|30 stone-forming participants will be recruited to this study.
89663394|NCT05351905|Experimental|CBD oil|Participants will receive CBD (cannabidiol) oil for a total duration of 12 weeks.
89663395|NCT05351905|Experimental|CBD+THC oil|Participants will receive CBD (cannabidiol) oil in combination with THC (delta-9-tetrahydrocannabinol) for a total duration of 12 weeks.
89663396|NCT05351905|Placebo Comparator|Placebo oil|Participants will receive matching placebo oil for a total duration of 12 weeks.
89663397|NCT05351671|Experimental|Arm A|RLS-0071 lower dose group
89663398|NCT05351671|Experimental|Arm B|RLS-0071 higher dose group
89663399|NCT05351671|Placebo Comparator|Arm C|Placebo group
89663400|NCT05320211|Experimental|3D-printed hand orthoses|
89663401|NCT05278351|Experimental|A|Tislelizumab 200mg, D1, D15, intravenous drip, Q4W and Cetuximab 500mg/m2, D1, D15, intravenous drip, Q4W and Irinotecan 180mg/m2, D1, D15, intravenous drip, Q4W
89663402|NCT05278351|Active Comparator|B|Fruquinitinib 5mg QD D1-21, oral, Q4W or Regorafenib 160mg QD D1-21 oral, Q4W or Trifluridine Tipiracil Tablets 35mg/m2 BID D1-D5, D8-D12 oral, Q4W
89663403|NCT05267028||AD-TAR|AD subjects who take part to Facial Emotion Recognition rehabilitation (TAR)
89663404|NCT05267028||AD-Cognitive Stimulation|AD subjects who take part to cognitive stimulation session (12 sessions during 4 weeks)
89663405|NCT05263700|Experimental|68Ga-FAPI-PET/CT|Patients receive 68Ga-FAPI IV then undergo PET/CT.
89663406|NCT05258097||Boys|Child sex based on parent report on a screening questionnaire
89663407|NCT05258097||Girls|Child sex based on parent report on a screening questionnaire
89663408|NCT05257447|Experimental|Baclofen 20mg tablet|Single oral dose of baclofen, 20 mg
89663409|NCT05257447|Experimental|Chlorzoxazone 500mg tablet|Single oral dose of chlorzoxazone, 500 mg
89663410|NCT05257447|Experimental|Baclofen 20 mg tablet and chlorzoxazone 500 mg tablet|Concurrent doses of baclofen, 20 mg, and chlorzoxazone, 500 mg
89663411|NCT05253911||Cohort 1|150 patients receiving tucatinib/trastuzumab/capecitabine (=study treatment) in 1st or 2nd palliative therapy line.
89663412|NCT05253911||Cohort 2|150 patients receiving tucatinib/trastuzumab/capecitabine (=study treatment) in 3rd or 4th palliative therapy line.
89663413|NCT05251545|Active Comparator|High power - short duration|Pulmonary vein isolation with high power settings of 45 Watts
89663414|NCT05251545|Active Comparator|Standard energy|Pulmonary vein isolation with standard power settings (30 Watts)
89663415|NCT05241353|Active Comparator|Standard Self-Monitoring Group|Standard behavioral treatment with a standard (full-frequency) self-monitoring prescription.
89663416|NCT05241353|Experimental|Reduced-Frequency Group|Standard behavioral treatment with a reduced-frequency self-monitoring prescription.
89663417|NCT05232812|Experimental|Administration of 3-[11C]-OHB|All participants will first be injected with 200 MBq 3-[11C]-OHB followed by an oral ingestion of 100 MBq 3-[11C]-OHB.
89663418|NCT05211154|Experimental|Diclofenac Potassium (soluble)|50 mg diclofenac potassium taken orally once
89663419|NCT05211154|Active Comparator|Rimegepant|75 mg rimegepant taken orally once
89663420|NCT05204199||Group A|Patients without a urological or gastrointestinal malignancy undergoing non-oncological bladder surgery or transurethral resection of the prostate (TUR-P)
89663421|NCT05204199||Group B|Low Risk NMIBC (primary, solitary, Ta / low grad < 3cm, no carcinoma in situ (CIS))
89663422|NCT05204199||Group C|NMIBC patients, BCG candidates, assessed as intermediate (between the category of low- and high risk) or high risk (T1 or high grade or CIS or multiple, recurrent and large (> 3 cm) Ta/ low grade tumours).
89048193|NCT02901574|Active Comparator|tDCS plus computerized naming therapy|Anodal or cathodal tDCS, 2 milliamps (mA) plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks.The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 20 minutes. Language therapy will be a computer delivered naming +picture matching task.
89663423|NCT05203640|Experimental|All participants|All participants will be in a single arm that undergoes two separate interventions. These interventions will include a high repetition, low resistance protocol, and a moderate repetition, moderate intensity protocol.
89663424|NCT05187637||Intervention|Patients on the waiting list for liver transplantation with haemoglobin less than 11.5g/dL and transferrin saturation index less than 40% with ferritin less than 800mcg/L, which are considered iron deficiency susceptible to respond to intravenous iron administration.
89663425|NCT05187637||Control|Patients on the waiting list for liver transplantation in the same period of the intervention cohort, with haemoglobin less than 11.5g/dL and transferrin saturation index more than 40%, which are considered of non susceptibles for iron supplement alone.
89663426|NCT05162391|Other|Contingency management|All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
89213867|NCT03966937|Experimental|Dry needling|The experimental group will receive dry needling over trigger points of Quadriceps muscles along with therapeutic exercises.
89663427|NCT05151809||PBC population residing in Italy|"All PBC patients living in Italy and aged at least 18 years can be included in the database. According to well-established criteria, PBC is diagnosed in subjects who fulfill two of the three of following criteria:~elevated alkaline phosphatase and /or GGT;~positive anti-mitochondrial autoantibodies (titer ≥ 1:40) or PBC-specific antinuclear antibodies (gp-210 and sp100);~characteristic histological features of florid bile ducts lesions and granulomatous lesion."
89663428|NCT05131568|Experimental|Thermal insulation system|"experimental: layered thermal insulation system~The system was applied in the upper body to the entrance of the operating room and remained until the exit of the same room.~The test included the evaluation of temperature, tremors and the visual perception of thermal comfort in 6 moments (T1 - reference temperature - at the entrance of the anesthetic induction room, T2 - at the entrance to the operating room, T3, T4 and T5 - fifteen , thirty and forty-five minutes after the start of surgery, and T6 - leaving the operating room)"
89663429|NCT05131568|No Intervention|Forced air active warming|Control: the same procedures as in the experiment group, were carried out in the control group, except for the intervention.
89663430|NCT05128344|Experimental|AMZ002|
89663431|NCT05128344|Active Comparator|Vigabatrin|
89663432|NCT05124470|Experimental|musical training sessions|24 musical training sessions over the 6 months + 3 months of follow-up post cognitive remediation.
89663433|NCT05099497|Experimental|Intervention group: Practice facilitation and additional support|Ontario Health will send out letters to physicians in the intervention group that will explain to them that they have a large group of eligible and unvaccinated patients and that an initiative is planned to support them in reaching out to those patients, with an embedded evaluation. It will ask them to reach out to the research team to plan a time to access the supports to gather more information, or to opt-out from the evaluation. Specifically, physicians will receive invitations to receive practice facilitation via mail letter and fax, followed by up to five weekly phone calls from a team member at Ontario Health.
89663434|NCT05099497|No Intervention|Control group- No intervention|We choose to include a control group as we do not have the resources to deliver the intervention to the entire physician group. Cluster randomization by primary practice address will limit contamination.
89663435|NCT05082428||Patients treated with Tofacitinib|Patients treated with tofacitinib for ulcerative colitis in Finland.
89663436|NCT05074082||Flap reconstruction|Patients who had a flap formation as part of a multi-visceral extended resection for advanced pelvic (rectal, urological, gynaecological, sarcomatous origin) malignancy
89663437|NCT05071833|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no peppermint content.
89663438|NCT05071833|Experimental|Peppermint oil|50 uL of peppermint oil, which will be diluted with 100 mL of water - taken twice per day.
89663439|NCT05054595|Active Comparator|Standard Pain Psychoeducation|
89663440|NCT05054595|Active Comparator|Audio-Recorded Mindfulness-Based Intervention|
89663441|NCT05054595|Experimental|Nurse-Led Mindfulness-Based Intervention|
89663442|NCT05038891||Digital Cervical Assessment performed first|A digital cervical exam will be performed by an experienced senior obstetrics and gynecology resident, using index finger and middle finger to measure the dilation and thickness of the cervix. This is the gold standard measurement utilized to assess the labor course. In this group, the digital cervical exam is done first, followed by a participant-performed ultrasound imaging assessment of the cervix.
89663443|NCT05038891||Ultrasound Assessment performed first|Ultrasound imaging will be first taught by an experienced RN, then self-performed by the participant in the presence of junior obstetrics and gynecology resident and the RN. The junior resident will ensure the ultrasound device is functioning properly and the images are saved. In this group, the participant-performed imaging assessment is done first, followed by a digital cervical exam performed by an experienced senior obstetrics and gynecology resident.
89663444|NCT05038384||Observational (survey)|Participants complete a survey over 20 minutes.
89663445|NCT05038293|Experimental|Automated mouthpiece-based toothbrush|Under observation of study staff, participants assigned to the automated mouthpiece-based toothbrush will insert a properly fitted mouthpiece and use the automated device directly over the sink.
89663446|NCT05038293|Active Comparator|Manual toothbrush|Under observation of study staff, participants assigned to the manual toothbrush will be timed brushing their teeth directly over the sink using a pre-dispensed quantity of toothpaste on bristles dampened with water.
89663447|NCT04999124|Other|Type 2 Diabetes Mellitus patients|
89663448|NCT04962100|Experimental|Study population|Male patients and donors who provide a sample of fresh ejaculated semen will be the population of this study, as well as female patients undergoing artificial insemination with their partner's semen or frozen donor semen.
89663449|NCT04942600|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|1 session (3,000 pulses) of high-frequency (10Hz) repetitive stimulation applied over the right temporal parietal junction (TPJ) gyrus in individuals with Functional Neurological Disorder using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
89663450|NCT04916860|Experimental|CD7 CAR-T|
89663451|NCT04897607|Active Comparator|Treatment Plan Option 1 (Standard Care)|Standard smoking cessation counseling will be offered + participant choice of nicotine patches or varenicline. Participants are also free to decline either medication.
89663452|NCT04897607|Experimental|Treatment Plan Option 2 (Precision Pharmacotherapy)|Standard smoking cessation counseling will be offered + a recommendation to take either the nicotine patch or varenicline based on the results of the NMR test. Regardless of the recommendation, it would still remain the participant's choice to be prescribed either nicotine patches or varenicline. Participants are also free to decline either medication.
89663453|NCT04871490|Other|Study Group|All eligible participants.
89663454|NCT04868526|Experimental|Control-Dietary Intervention|Control condition first, then the Dietary intervention. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
89663455|NCT04868526|Experimental|Dietary intervention-Control|Dietary intervention first, then the Control condition. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage but will be made public once enrollment closes.
89663456|NCT04847284|Experimental|Single arms|To determine the efficiency and safety of IORT with low-energy photons to the cavity after resection of brain metastases
89663457|NCT04818671|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
89663458|NCT04766216|Experimental|Warfarin Patient Self-Management|Patients managing decisions relating to warfarin dose and next INR test based on the results of current INR test
89663459|NCT04766216|Active Comparator|Historical Control|Patients managed by anticoagulation providers prior to transitioning to warfarin patient self-management
89048194|NCT02901574|Sham Comparator|Sham plus computerized naming therapy|Sham tDCS plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks. Current will be administered in the in a ramp like fashion for 15-30 seconds but then the current is gradually decreased and drop to 0 mA. Language therapy will be a computer delivered naming +picture matching task.
89048195|NCT02868450|Experimental|Patients with HLA-DQB1 06 and/or HLA-DRB 13|
89048196|NCT02868411|Experimental|Patients admitted for traveller's fever|
89048197|NCT02868346|Experimental|Patients admitted for sexually transmitted infection|
89048198|NCT02866565|Experimental|Diabetic foot ulcer|
89048199|NCT02866201|Experimental|Patient suffering from traveler's diarrhoea|Patient suffering form traveler's diarrhoea during a stay (up to 3 months) outside metropolitan France
89048200|NCT02861768|Experimental|diagnosis of M.tuberculosis infection|
89048201|NCT02859792|Placebo Comparator|Placebo|
89048202|NCT02859792|Experimental|Experimental|
89663460|NCT04763655|Other|Treatment as usual|
89663461|NCT04753164|Experimental|100 mg twice daily (b.i.d.) ACT-539313|
89663462|NCT04753164|Placebo Comparator|Placebo|
89663463|NCT04733898|Experimental|Social games|Participants in the social games group will be given access to an app with games that are either adaptations of well-known games or newly developed games, all designed to be played with just text messages and photos. A game is essentially a chat group with the people you invited to play that specific game with. Participants can play with their own network of family and friends, as well as other people in the same condition.
89663464|NCT04733898|Active Comparator|Non-personal games|Participants in the active control group will be given access to an app that offers 'non-personal games'. The portal will contain a subset of the social games, which have been adapted for non-personal play. This means that all aspects that make the games personal are removed and discouraged. The games that remain can still be played with others (family/friends and others in the same condition), but are designed not to elicit personal interaction. Participants are asked to play the games at least twice a week, but may play as often as they like.
89663465|NCT04733898|No Intervention|Passive control|The passive control group will be given access to an app that contains no games. Similar to the other groups, the portal is used to complete the questionnaires. Use of other games, (gaming) apps or social media platforms is allowed in this group, as in the other groups. The only restriction they will not have access to the games offered in the social games and active control groups.
89663466|NCT04729101|Experimental|Treatment A (vonoprazan)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.~Vonoprazan will be administered via 20 mg oral tablet once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
89048203|NCT02858687|Experimental|Patients with clinical diagnosis of tonsillitis|
89048204|NCT02858661|Experimental|Patients diagnosed with clinical meningitis|Patients admitted in emergency rooms for clinical meningitis, for which a nasopharyngeal swab will be performed in order to confirm the etiological diagnosis of meningitis
89048205|NCT02858609|Experimental|Patients with Diarrhoea|Patients admitted in emergency room with Diarrhoea
89048206|NCT02851771|Experimental|Pneumonia Patients|Patient admitted at hospital with pneumonia, who need a microbiological diagnosis
89048207|NCT02846753|Experimental|Implantation of Venus P-Valve™|Implantation of the Venus P-Valve™ in the pulmonic position in patients with native outflow tracts; trans catheter heart valve replacement.
89048208|NCT02842333|Experimental|Additional biological samples|"Blood samples will be realized at inclusion and 6 months after inclusion (optional).~Peripheral Blood Mononuclear Cells (PBMC) will be collected."
89048209|NCT02828085|Other|Infective Pericarditis|In patient prescribed with a pericardite kit for an etiological diagnosis of a pericardial syndrome, an additional nasal swab will be performed in order to perform a specific diagnosis with PCR technique.
89048210|NCT02827175|Experimental|fevers of the travelers|
89048211|NCT02822807|Other|Q fever without valvular disease|Q fever without valvular disease
89663467|NCT04729101|Active Comparator|Treatment B (lansoprazole)|"Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.~Lansoprazole will be administered via 30 mg oral capsule once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days."
89663468|NCT04720846|Active Comparator|Control|Patients will receive standard-of-care physical therapy.
89663469|NCT04720846|Experimental|Matrix-Based PT|Patients will receive matrix-based physical therapy, in addition to standard-of-care physical therapy.
89663470|NCT04719013|Experimental|treatment|Treatment areas include face, under chin (submental)
89663471|NCT04670081|Placebo Comparator|Nicotinamide|1st dose: 100 mg Nicotinamide (Vitamin B3) - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
89663472|NCT04670081|Experimental|Psilocybin (low-dose)|1st dose: 5 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin
89663473|NCT04670081|Experimental|Psilocybin (high-dose)|"1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 5 mg Psilocybin~1st dose: 25 mg Psilocybin - 2nd dose (after 6 weeks/after assessment of the primary endpoint): 25 mg Psilocybin"
89663474|NCT05267379||PEP patients|Patients who develop PEP
89663475|NCT05267379||Control cohort|Patients who do not develop PEP
89663476|NCT04666571|Experimental|Personalised (TOKA)|"During HTO surgery, the personalised plate will be inserted below the knee.~The investigational device and comparator are two types of metal plate used to fix the bone in place during a high tibial osteotomy (HTO)."
89663477|NCT04666571|Active Comparator|Standard (Tomofix or ActivMotion)|During HTO surgery, the standard plate will be inserted below the knee.
89663478|NCT04651660|Experimental|Manual Insertion|The surgeon will follow a classical surgical procedure for the cochlear implantation, i.e. mastoidectomy to access the temporal bone, posterior tympanotomy to access the cochlea and round window (RW) approach for the CI electrode array insertion. Before opening the RW, the eCochG recording electrode is placed on the cochlear promontory, and placed not to obstruct the surgery. The probe is thus maintained during the whole MANUAL insertion (by the surgeon).
89663479|NCT04651660|Experimental|Robotic insertion|The surgeon will follow a classical surgical procedure for the cochlear implantation, i.e. mastoidectomy to access the temporal bone, posterior tympanotomy to access the cochlea and round window (RW) approach for the CI electrode array insertion. Before opening the RW, the eCochG recording electrode is placed on the cochlear promontory, and placed not to obstruct the surgery. The probe is thus maintained during the whole ROBOTIC insertion.
89663480|NCT04648280|Experimental|Fostemsavir|Fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
89663481|NCT04647487|Experimental|LY3484356 Dose Level 1|Administered orally.
89663482|NCT04647487|Experimental|LY3484356 Dose Level 2|Administered orally.
89663483|NCT04647487|Experimental|LY3484356 Dose Level 3|Administered orally.
89663484|NCT04630535||Obstructive Sleep Apnea|Pacient with OSA (AHI≥5) undergoing aorto-bifemoral bypass
89663485|NCT04630535||Without Obstructive Sleep Apnea|Patinets without OSA undergoing aorto-bifemoral bypass
89663486|NCT04601961|Active Comparator|SEVO Group|Patients in SEVO group will be anaesthetized by inhalational anaesthesia using sevoflurane.
89663487|NCT04601961|Experimental|TIVA group|The patients in TIVA group will be anaesthetized using total intravenous propofol.
89663488|NCT04523909||Thoracic aortic surgery patients|
89663489|NCT04513314|Active Comparator|Standard of Care Only Group|Patients maintained with mechanical ventilation will be treated with standard of care after cessation of paralytic agents.
89663490|NCT04513314|Active Comparator|Treatment Arm Group|Patients maintained with mechanical ventilation will be treated with standard of care, plus Valproate on Days 1-7 after cessation of paralytic agents, and then augmented by the addition of Quetiapine beginning Days 3-7 if there are no improvement in RASS score.
89663491|NCT04488185|Experimental|Secukinumab 300mg|Randomized in a 2:1 ratio to secukinumab or placebo
89663492|NCT04488185|Placebo Comparator|Placebo|Randomized in a 2:1 ratio to secukinumab or placebo
89663493|NCT04485182||First|Patients receiving Transcutaneous Electrical Nerve Stimulation + underwater massage + spine gymnastics +
89663494|NCT04485182||controll group|Patients receiving Transcutaneous Electrical Nerve Stimulation + spine gymnastics
89663495|NCT04481373|Experimental|THRIVE|Acceptance and Commitment Therapy plus Education about HIV A master's level mental health professional will provide the 4-5 hour intervention for out-of-care PWH during a hospitalization. There are two important components to the intervention: Acceptance and Commitment Therapy (ACT) content, targeting avoidance with acceptance-based coping and active engagement in values-based living, and HIV education.
89663496|NCT04481373|Other|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
89663497|NCT04469868|Experimental|No opioids prescriptions at discharge|Patients will receive non-opioid analgesia, mostly over the counter, medications such as acetaminophen or ibuprofen. Opioids may be prescribed if the patients experience break through pain and call the office.
89663498|NCT04456400||Derivation cohort|"The derivation sub-cohort will be used to derive optimum reconstruction algorithm parameters of MSOT images.~Primary objective of the derivation cohort is to derive Multispectral Optoacoustic Tomography (MSOT) thresholds maximizing receiver operating characteristic (ROC) to distinguish endoscopic remission from active disease.~As secondary objective, performance of the Multispectral Optoacoustic Tomography (MSOT) device will be analyzed."
89663499|NCT04456400||Validation cohort|Objective of the validation cohort is to confirm the performance of Multispectral Optoacoustic Tomography (MSOT) using prescribed thresholds from the derivation cohort.
89048212|NCT02822807|Other|Q fever with valvular disease|Q fever with valvular disease
89663500|NCT04451187|Experimental|Treatment Sequence CADB|Participants will receive placebo once daily (OD) at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment C) in Period 1 followed by Dose 1 of seltorexant tablets and placebo OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment A) in Period 2 followed by Dose 2 of seltorexant tablets OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment D) in Period 3 followed by zopiclone on Day 1 and Day 8 and placebo from Day 2 to Day 7 OD at bedtime (Treatment B) in Period 4. There will be a washout period of 5 to 21 days between each period.
89663501|NCT04451187|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A in Period 1 followed by Treatment B in Period 2 followed by Treatment C in Period 3 followed by Treatment D in Period 4. There will be a washout period of 5 to 21 days between each period.
89663502|NCT04451187|Experimental|Treatment Sequence BDAC|Participants will receive Treatment B in Period 1 followed by Treatment D in Period 2 followed by Treatment A in Period 3 followed by Treatment C in Period 4. There will be a washout period of 5 to 21 days between each period.
89663503|NCT04451187|Experimental|Treatment Sequence DCBA|Participants will receive Treatment D in Period 1 followed by Treatment C in Period 2 followed by Treatment B in Period 3 followed by Treatment A in Period 4. There will be a washout period of 5 to 21 days between each period.
89663504|NCT04379414|Experimental|Newly Diagnosed Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~Surveys will be sent once every 6 months for the first 3 years, then annually.~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
89663505|NCT04379414|Experimental|Newly Diagnosed Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~Surveys will be sent once every 6 months for the first 3 years, then annually.~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
89688671|NCT03001258||PO (program organizers)|"PO (program organizers): Employed by Brac as field level organizers. A two day presbyopia screening training were provided.~A total of eight POs organized eye camps in two sub districts. POs were responsible for identifying the presbyopia patients through screening and SS assisted in organizing and mobilizing the community people for the eye camps, and glass sale (on the spot). Four camps were organized per day for five days by four POs in each sub-district. Thus a total of 40 eye camps were held in two sub districts by eight POs."
88995028|NCT05784636|Experimental|HFNC treatment group|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC until discharge.
88995029|NCT05784610|Active Comparator|TOF/PTC|Non-automated neuromuscular blockade monitoring (TOF/PTC). As the NMB monitoring is depending on anesthesiologist usual practice and so only TOF measure is systematic, it is necessary to include a blind anesthesiologist measurement with the ATP mode in order to compare with data obtained during Time 2.
88995030|NCT05784610|Experimental|ATP|Automated neuromuscular blockade monitoring (ATP). TOF and PTC stimulations are regularly performed, and PTC is systematically performed if TOF = 0/4. If PTC = 10/10, a TOF stimulation is automatically performed.
88995031|NCT05784584||Infants infected through breast-feeding and perinatally|Infants infected through breast-feeding and perinatally diagnosed with HIV ≤90 days of age and starting ART ≤90 days after diagnosis. For these patients clinical data and blood for viral load, immunology and serology will be collected in the 11 visits.
88995032|NCT05784558||UroLift System|Therapy to be treatment with the UroLift System.
88995033|NCT05784558||Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
88995034|NCT05784558||Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
88995035|NCT05784519|Experimental|experimental group|The MSCs eye drops was administered to enrolled patients with 5×10^5 /50μl in each eye, twice a day for 2 weeks.
88995036|NCT05784506|Experimental|Macronutrients loading test for healthy group|A total of 30 subjects with normal metabolic status underwent three successive food tolerance tests (glucose, protein and fat) at one-week intervals.
88995037|NCT05784506|Experimental|Mixed meal tolerance test (MMTT) for healthy group|A total of 40 subjects with normal weight and plasma glucose levels underwent MMTT.
88995038|NCT05784506|Experimental|Mixed meal tolerance test (MMTT) for overweight subjects with normal plasma glucose|A total of 40 overweight subjects without a history of diabetes underwent MMTT.
88995039|NCT05784506|Experimental|Mixed meal tolerance test (MMTT) for obese subjects with abnormal plasma glucose|A total of 40 obese subjects without a history of diabetes underwent MMTT.
88995040|NCT05784493|Experimental|Washing by heated saline group|
88995041|NCT05784493|Active Comparator|Washing by normal room temperature saline group|
88995042|NCT05784467|Other|English|Participants in the English arm will receive the eMPrISe intervention materials in English.
88995043|NCT05784467|Other|Spanish|Participants in the English arm will receive the eMPrISe intervention materials in Spanish.
89663506|NCT04379414|Experimental|Metastatic Automatic Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~Surveys will be sent once every 6 months for the first 3 years, then annually.~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
89663507|NCT04379414|Experimental|Metastatic Trigger Symptom Information|"Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant.~Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal.~YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month.~Surveys will be sent once every 6 months for the first 3 years, then annually.~Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank."
89663508|NCT04363697|Experimental|Dapagliflozin|Dapagliflozin 10 mg administered orally once daily for 2 months
89663509|NCT04363697|Placebo Comparator|Placebo|Matching placebo administered orally once daily for 2 months
89663510|NCT04358575|Experimental|All-polyethylene tibial components|Triathlon CS Knee System with all-polyethylene tibial components
89663511|NCT04358575|Active Comparator|Metal-backed modular components|Triathlon CS Knee System with metal-backed modular components
89663512|NCT04351750|Experimental|high-intensity group|The participants will receive high-intensity general exercise and pelvic floor muscle training in high-intensity group. The intensity of aerobic exercise is 60 ~ 89% of heart rate reserve (HRR) or oxygen uptake reserve (VO2R), which is equivalent to the vigorous intensity exercise proposed in the American College of Sports Medicine (ACSM). The intensity of resistance exercise is 60~80% of 1 repetition maximum (RM), which is equivalent to the moderate-to-vigorous intensity exercise proposed in ACSM. After finishing the general exercise, participants will receive pelvic floor muscle training.
89663513|NCT04351750|Experimental|low-intensity group|The participants will receive low-intensity general exercise and pelvic floor muscle training in low-intensity group. The intensity of aerobic exercise is 40~59% of HRR or VO2R, which is equivalent to the moderate intensity exercise proposed in ACSM. The intensity of resistance exercise is 40~50% of 1RM, which is equivalent to the very light-to-light intensity exercise proposed in ACSM. After finishing the general exercise, participants will receive pelvic floor muscle training.
89663514|NCT04351750|Active Comparator|control group|The participants will only receive pelvic floor muscle training in control group.
89663515|NCT04311320|Experimental|Low-Resource Oxygen Blender|This is a single-arm study. All participants will receive respiratory support using the investigational device.
89663516|NCT04304378|Active Comparator|Stabilization Techniques (ST)|"Participants randomized into ST will receive 6 weekly 1-hour sessions of Stabilization Techniques from a Khmer-speaking mental health professional. Sessions provide an opportunity to improve emotion regulation and provide coping skills for managing symptoms of PTSD.~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
89688672|NCT03001258||USS (Upgraded Shashthya Shebika)|"USS (Upgraded Shashthya Shebika): A new caddre of community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, 20 USSs were assigned in two upazillas to run the two camp-day i.e. screening patients and selling glasses during the total 40 eye camps."
88995044|NCT05783700||DIABETIC|"PERFORMANCE OF BIOIMPEDANCIOMETRY WITH DETERMINATION OF:~Daily calorie intake~Body fat mass and percentage~Segmental body fat percentage~Resting Heart Rate~Lean Mass~Risk of sarcopenia~Proteins~Extra Cellular Water~Intracellular Water~Phase Angle~Visceral fat~Muscle mass~Segmental muscle mass~Muscle quality score~Total body water (%)~Metabolic age"
88995045|NCT05782699|Experimental|patch monitoring|
88995046|NCT05782699|Active Comparator|standard BP monitoring|
88995047|NCT05782660|Experimental|Treatment Group|Participants in the treatment group received up to $400 per month.
88995048|NCT05782660|Active Comparator|Control Group|Participants in the control group did not receive monthly cash benefits.
88995049|NCT05781802||Adult mechanically ventilated patients with ARDS|Adult mechanically ventilated patients with ARDS (see inclusion/exclusion criteria)
88995050|NCT05781776|Experimental|Otago exercise program group|Participants performed Otago exercise program and core muscle strengthening exercises for eight weeks (thrice a week).
88995051|NCT05781776|Active Comparator|Gaze stability exercises group|Participants performed Gaze stability exercises and core muscle strengthening exercises for eight weeks (thrice a week).
88995052|NCT05781672|Experimental|Anthra2|"Patient will have an echocardiography with speckle tracking analysis 5 years after the end of their participation to SpeckleAnthra study (NCT02893787)"
88995053|NCT05781672|Active Comparator|Control|Cardiac ultrasound analysis with speckle tracking of age- and sex-matched healthy patients in the Anthra2 group
89048213|NCT02822807|Other|Q fever infective endocarditis|Q fever infective endocarditis
89663517|NCT04304378|Experimental|Stabilization Techniques with Behavioral Activation (ST+BA)|"Participants randomized into ST+BA will receive 3 weekly 1-hour sessions of ST and 3 weekly 1-hour sessions of BA from a Khmer-speaking mental health professional. Sessions include stabilization techniques and behavioral skills that aim to establish and maintain routines, reduce avoidance, and manage negative emotions.~Participants will complete a follow-up assessment 2 months after randomization in which PTSD symptoms will be re-assessed using the PTSD Checklist (PCL-5) for the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). Those who exhibit a 50% reduction in PTSD symptoms from baseline and no longer meet criteria for PTSD will be designated as responders and will receive no further treatment. Participants who continue to display clinically meaningful elevations in PTSD symptoms (i.e., non-responders) will receive EMDR, which is the standard of care for trauma treatment in Cambodia. EMDR sessions will be delivered by a Khmer-speaking mental health professional."
89663518|NCT04300478|Other|Sedentary Control/REx|Subjects will complete the Sedentary control testing sessions, have a 7-14 day washout period, and then complete the REx
89663519|NCT04300478|Other|REx/Sedentary Control|Subjects will complete the REx testing sessions, have a 7-14 day washout period, and then complete the Sedentary control
89663520|NCT04282629|Experimental|Milrinone|"milrinone group benefiting from an identical treatment to the standard care group and in addition, administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely."
89663521|NCT04282629|Placebo Comparator|Standard Care|The standard care group will follow the recommended management of SAHa and will receive a placebo (intravenous glucose 5%) from Day 4 to Day 14. In case of suspicion of vasospasm and after ineffective effect of medical measures (euvolemia and increase in mean arterial pressure), an endovascular treatment will be possible. The occurrence of vasospasm will be monitored closely with clinical examination and cerebral tissue oxygen pressure (PtiO2). From D4 to D14, general and biological data, clinical examination will be collected daily. Intensive care unit complications (neurologic, pulmonary, cardiac and septic complications) will be collected. At 1 month, the volume of DCI lesions will be measured on CT scan. Neurologic prognosis, quality of life and mortality will be studied at 1 month, 3 month, 6 month and 1 year. Adverse events will be monitored closely.
89663522|NCT04275492|Experimental|Fasting group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects were given 1 tablet of test preparation (T) orally and 240mL warm water on an empty stomach, and the other 15 subjects were given 1 tablet of reference preparation (R, Siforl®) orally and 240mL warm water on an empty stomach.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
88995054|NCT05781568||Control Group|"The control group will be composed of patients who will be candidates for HCC surveillance, i.e. those with liver cirrhosis or chronic hepatitis of any aetiology without HCC seen at our institution.~Included in this group are:~Patients newly enrolled and who will be tested for α-FP, α-FP-L3%, and DCP as part of their regular follow-up;~Patients who had previously given consent for the storage of a serum sample in the Biobank and who had authorized the dosage of α-FP, α-FP-L3% and DCP."
88995055|NCT05781568||Case Group|"The case group will be composed of patients with newly diagnosed HCC in the context of cirrhosis or any other aetiology during the same study period. This group will include:~Patients newly enrolled and who will be tested for α-FP, α-FP-L3%, and DCP as part of their regular follow-up;~Patients who had previously given consent for the storage of a serum sample in the Biobank and who had authorized the dosage of α-FP, α-FP-L3% and DCP at the time of tumor diagnosis."
88995056|NCT05781516|Placebo Comparator|Prednisolone monotherapy|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
88995057|NCT05781516|Experimental|Prednisolone plus Baricitinib|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months. Oral Baricitinib 2mg daily for 12 months.
88995058|NCT05780437|Experimental|AZD7442 plus SOC|"AZD7442 600 mg solution (separate vials containing 300 mg each of AZD88995 and AZD1061); administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
88995059|NCT05780437|Placebo Comparator|Placebo plus SOC|"Placebo administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
88995060|NCT05780333|Other|tap block|"Tap block is one of the frequently used field blocks for analgesia management of abdominal surgery.~At the end of surgery and general anesthesia, transversus abdominis fascial plane will be detected with using lineer usg probe. With in-plane tecnique after placement of the needle in the transversus abdominis fascial plane, and careful aspiration to exclude vascular puncture, a test dose of 1 mL will be injected to determine resistance to flow, and confirm needle tip placement within the fascial plane. After this, 20 ml local anaestetic mixture will be injected through the needle. The TAP block will be then performed on the opposite side using an identical technique."
88995061|NCT05780333|Active Comparator|esp block|"The effectiveness of esp block is also evaluated in abdominal surgery after spinal surgery, thoracic and cardiovascular surgery.~At the end of surgery and general anesthesia, in the lateral decubitus position, the linear probe will be placed approximately 3 cm lateral to the T10 spinous process, in the parasagittal plane. With the in-plane technique, when the block needle rests on the transverse process (approximately 3cm in depth), the erector spina plan will be confirmed with a 0.5-1 mL 0.9% NaCl test dose. 20 ml of local anesthetic mixture will be applied to the confirmed area. The procedure will be applied bilaterally."
88995062|NCT05779839|Experimental|Algorithmically Matched|Individuals that identify as a current and/or former caregiver for a person with dementia will be matched to other caregivers using an algorithm that matches a caregiver to another caregiver based on specific preferences each caregiver identifies in a questionnaire.
89663523|NCT04275492|Experimental|Feeding group|Subjects were randomly assigned to one of two sequential groups (t-r group, r-t group) in a 1:1 ratio.In the first cycle, 15 subjects took 1 tablet of the test preparation (T) orally and 240mL warm water about 30min after the high-fat meal, and another 15 subjects took 1 tablet of the reference preparation (R, Siforl®) orally and 240mL warm water about 30min after the high-fat meal.Cross-administration at 7±1 days.The authorized drug dispenser assigned the study drug to each phase of the study according to a randomized protocol.
89048214|NCT02822807|Other|Other Coxiella burnetii infections (including pregnant women)|Other Coxiella burnetii infections (including pregnant women)
89663524|NCT04265105|Active Comparator|standard of care|Short acting beta agonist or inhaled corticosteroids
89663525|NCT04265105|Experimental|fluticasone-vilanterol|LABA-ICS A combination of Long acting beta agonist and inhaled corticosteroid
89663526|NCT04262167|Experimental|Low Dose LSCs (cohort 1) n = 4 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 100 million Lung Spheroid Stem Cell (LSC) infusion.
89663527|NCT04262167|No Intervention|Usual Care (Cohort 1) n = 2 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
89663528|NCT04262167|Experimental|High Dose LSCs (Cohort 2) n = 12 planned|4-8 weeks following transbronchial biopsy, participants in this arm will receive 200 million LSC infusion.
89663529|NCT04262167|No Intervention|Usual Care (Cohort 2) n = 6 planned|Patients will receive standard of care with no biopsy and no infusion. Placebo will not be used.
89663530|NCT04246229|Experimental|transcutaneous bilirubinometry|in this arm the bilirubin level to monitor the effect of phototherapy will be measured through transcutaneous mbiirubinometry
89663531|NCT04246229|Active Comparator|serum bilirubin|In this arm the bilirubin level to monitor the effect of phototherapy wil be measured through measurements of serum bilirubin obtained through blood draws
89663532|NCT04240457|Experimental|Pulsed, accelerated|18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.
89663533|NCT04240457|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination.
89663534|NCT04238299||Main study cohort|Patients with CKD recruited from specialist nephrology clinics
89663535|NCT04154111|Experimental|Real TBS to the mPFC|Thirty sessions of real Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
89663536|NCT04154111|Sham Comparator|Sham TBS to the mPFC|Thirty sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
89663537|NCT04154111|Experimental|Real TBS to the dlPFC|Thirty sessions of real Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
89663538|NCT04154111|Sham Comparator|Sham TBS to the dlPFC|Thirty sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
89663539|NCT04116515|Active Comparator|Care Only|A third of the participants will have standard clinical care only.
89663540|NCT04116515|Experimental|Care + AVG|A third of the participants will have the same standard clinical care plus an Xbox and active games.
89663541|NCT04116515|Experimental|Care + AVG + Narratives|A third of the participants will have the same standard clinical care, an Xbox and active games, plus the stories delivered to their Xbox consoles.
89213868|NCT03966937|Active Comparator|Control|The control group will only receive standardized therapeutic exercises for Patellofemoral pain syndrome.
89663542|NCT04084444|Experimental|T8 tablet 0.5mg|Oral T8 tablet with HARRT, 0.5mg, once daily for 48 week
89663543|NCT04084444|Experimental|T8 tablet 1mg|Oral T8 tablet with HARRT, 1mg, once daily for 48 week
89663544|NCT04084444|Placebo Comparator|Placebo|Oral Placebo with HARRT, once daily for 48 week
89663545|NCT04080791|Experimental|Experimental Group- Virtual Reality (VR) Treatment|The participants in the experimental group will complete the educational/training session on how to use the VR equipment and programs (30 minutes). The following day, participants will begin the VR intervention attending a daily 30-minute sessions for 8 days or until a discharge date has been set, whichever comes first.
89663546|NCT04080791|Active Comparator|Standard of care group|The control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol. Prior to discharge, control group participants will meet with a licensed clinical therapist to complete the cognitive and physical assessments for the posttest evaluation.
89663547|NCT04067778|Experimental|Intervention Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
89663548|NCT04067778|Other|Control Group|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.
89663549|NCT04065360|Experimental|Cognitive behavioural family intervention|
89663550|NCT04065360|Active Comparator|Usual group psychoeducation|
89663551|NCT04063618|Experimental|Osteopathic Manipulative Therapy (OMT) Treatment Group|Initial concussion treatment will involve OMT in addition to standard of care treatment. The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles and joints are moved using techniques that include stretching, gentle pressure, and resistance.
89663552|NCT04063618|Active Comparator|Standard of care concussion treatment group|Standard of care concussion treatment without OMT
89663553|NCT04031833|Experimental|Phase 1a single ascending dose study|Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose.
89663554|NCT04031833|Experimental|Phase 1b multiple day dosing|9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days.
89663555|NCT04031833|Experimental|Phase 2 safety and tolerability|Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB.
89663556|NCT04024514|Experimental|Low dose|Low CT contrast media dose
89213869|NCT00880646|Experimental|1|
89213870|NCT00880646|Placebo Comparator|2|
89663557|NCT04024514|Active Comparator|Standard dose|Standard CT contrast media dose
89663558|NCT03984929|Experimental|Localized Information Resource Intervention|
89663559|NCT03984929|Active Comparator|Generic Information Resource Intervention|
89663560|NCT03982602|Experimental|Subjects on Ketogenic diet|Treatment with KD will consist of 4:1 [fat]: [protein + carbohydrate] weight ratio. KD will be started as soon as the patient is ready for alimentation (while they are in neurocritical care unit). The rate of feeds will be calculated by trained dietician on service. Ketogenic diet will be continued during the entire length of ICU stay. Supplementation with vitamins, calcium and phosphorus will be done.
89663561|NCT03968198|Experimental|ASC (Adipose-derived Stem/Stroma Cells)|Patients administrated with autologous ASC in their ischemic inferiors limbs
89663562|NCT03911908|Active Comparator|ERC guided CPR (intervention/NIRS group)|CPR protocol according to current ERC guidelines (2015)
89663563|NCT03911908|No Intervention|ERC-based CPR (control group)|modified CPR protocol based on current ERC guidelines (2015), extended by evaluation of NIRS readings and interventions to optimize CPR quality
89663564|NCT03908307|Experimental|Study Eye|OZURDEX implant 700 μg
89663565|NCT03908177|Experimental|Study Group (SG)|Receive new zirconia implant: Straumann® PURE 2-piece Ceramic Implant (tissue level), ZLA
89663566|NCT03908177|Active Comparator|Control Group (CG)|Receive standard titanium implant: Straumann® Bone Level Implant, Titanium, SLA
89663567|NCT03877939||Non-pregnant patients|Patients with β-hCG test < 10 UI/L.
89663568|NCT03877939||Patients with viable pregnancy|Patients with β-hCG test > 10 UI/L whose pregnancy is confirmed between gestational weeks 6 and 8.
89663569|NCT03877939||Patients with biochemical pregnancy|Patients with β-hCG test > 10 UI/L and without sac observed.
89663570|NCT03877939||Patients with ectopic pregnancy|Patients with β-hCG test > 10 UI/L whose sac is implantated outside the uterine cavity.
89663571|NCT03877939||Patients with clinical miscarriage|Patients with β-hCG test > 10 UI/L whose sac is implanted inside the uterine cavity, but non-viable pregnancy is confirmed before gestational week 8.
89663572|NCT03876171|Experimental|CIFFTA|Family Therapy, Individual Therapy, and Psycho-educational Modules
89663573|NCT03876171|Active Comparator|Standard of Care|The Diversion Programs used by the Juvenile Services Department in Miami-Dade.
89663574|NCT03847038|Experimental|Intervention|Multimodal lifestyle-interventional. Participants are disclosed their 5-year dementia risk estimate
89663575|NCT03830983||Stroke of likely cardioembolic cause or undetected mechanism|Lesions in at least one territory on MRI & absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% in arteries supplying the ischemic area(s) & absence of severe small vessel disease including micro-bleeds on Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% & absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings.
89663576|NCT03830983||Atherosclerotic stroke|Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% leading to the infarcted territory & absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% and presence of severe small vessel disease possibly including micro bleeds.
89663577|NCT03830983||Controls|Age and sex matched healthy controls with no history of stroke or AF.
89663578|NCT03815435|Experimental|Controlled hypotension|Controlled hypotension will be administered according to the clarity of the surgical field evaluated according to the Boezaart scale (1995).
89663579|NCT03800654|Other|Mindful Action for Pain (MAP) Development|In the first arm, MAP will be fully developed.
89663580|NCT03800654|Active Comparator|MAP vs. CBT-CP|In the second arm, MAP will be compared to CBT-CP to establish feasibility of a larger, future trial.
89663581|NCT03754699|Experimental|Patients with a therapeutic educational intervention|Arm 1 : Interventional group: A therapeutic educational intervention is performed following pre-anesthesia assessment
89663582|NCT03754699|Active Comparator|Patients without therapeutic educational intervention|Arm 2 : Control group: standard information on pain is performed following pre anesthesia assessment
89663583|NCT04569968|Experimental|Expiratory muscle training group|Daily expiratory muscle training for four weeks will be applied.
89663584|NCT04569968|No Intervention|Control group|Nothing will be applied except for the hospital conventional physiotherapy program.
89663585|NCT03737357|Experimental|SLActive® implant|
88995063|NCT05779839|Active Comparator|Randomly Matched|Individuals that identify as a current and/or former caregiver for a person with dementia will be randomly matched to other caregivers not based on the preferences they identified in a questionnaire.
89663586|NCT03737357|Active Comparator|SLA® implant|
89663587|NCT03723564|Experimental|Amnioinfusion|Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks.
89663588|NCT03688789|Experimental|Hydrocortisone supplementation|
89663589|NCT03684590|Active Comparator|Standard opioid administration|Intraoperative opioid will be administered by guiding standard practice
89663590|NCT03684590|Experimental|ANI-guided opioid administration|Intraoperative opioid will be administered based on the analgesia nociceptive index (ANI)
89663591|NCT03673618|Experimental|PROMOTIR soluble corn fiber|Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
89663592|NCT03673618|Placebo Comparator|Malodextrin|Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
89688673|NCT03001258||SS (Shashthya Shebika)|"SS: Community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, the SS, undertook the screening of potential presbyopia cases. A total of 27 SS organized 25 eye camps in eight days in two upazilas."
89688674|NCT00945295|Active Comparator|Cohort #1|Cohort 1 will receive BoNT-A plus rehabilitation therapy for the duration of the study (for up to 2 injections of BoNT-A).
89688675|NCT00945295|Active Comparator|Cohort #2|Cohort 2 will receive BoNT-A alone
89688676|NCT03772873||MIPE|Patients undergoing minimally invasive pilonidal excision with trephination.
89688677|NCT03772873||Other|Patients undergoing a different procedure for pilonidal disease.
89663593|NCT03664583|Experimental|Intervention Group|Patients randomly assigned to the intervention group will be offered the ACHRU-Community Partnership Program (CPP) intervention in addition to usual primary care services offered by their local diabetes education centre or primary care setting. The CPP is a 6-month self-management intervention consisting of six core components: 1) home or virtual visits (up to 3) supported by phone calls by either a Registered Nurse (RN) or Registered Dietician (RD); 2) wellness sessions (up to 6, one per month) provided to patients and their caregivers at the location of the community partner or virtually; 3) monthly team case conferences with the provider team; 4) caregiver support; 5) collaboration with the primary care interprofessional team and other specialists; 6) nurse-led care coordination/system navigation.
89663594|NCT03664583|No Intervention|Control Group|Those who are randomly assigned to the control group will continue to be offered usual primary care services through their local diabetes education centre or primary care setting. The services that comprise usual diabetes care vary across the provinces e.g., length and focus of educational sessions, whether classes are strongly recommended versus optional (e.g., foot care, cardiac health, eating and exercise interventions), home visits, access to on-site professionals (e.g., endocrinologist, dietitian, physiotherapist, exercise specialist, pharmacist), connections with support services and community resources, and type of follow-up services available. Details of usual care provided at each site will be recorded.
88995064|NCT05779293|Experimental|non-invasive auricular vagus nerve stimulation|non-invasive auricular vagus nerve stimulation + Neuromuscular Electrical Stimulation (NMES) exercise under the supervision of a physiotherapist
88995065|NCT05779293|Active Comparator|Conventional physical therapy|NMES exercise under the supervision of a physiotherapist
88995066|NCT05778266|Active Comparator|L-Cit + HIIT|adolescents will be supplemented with 6 g/day of L-citrulline and 3 sessions per week of HIIT for 12 weeks
88995067|NCT05778266|Active Comparator|L-Cit|adolescents will be supplemented with 6 g/day of L-citrulline but without do exercise for 12 weeks
88995068|NCT05778266|Placebo Comparator|Placebo + HIIT|adolescents will be supplemented with 6 g/day of Carboxymethyl cellulose and 3 sessions per week of HIIT for 12 weeks
88995069|NCT05775029||Study group 1|Short term compliance group
88995070|NCT05775029||Study group 2|Long term compliance group
88995071|NCT05774405|Experimental|Experimental|All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Estradiol patch (Climara 7.8 mg patch/week, Bayer, Germany) for 14 days.
88995072|NCT05774405|Placebo Comparator|Placebo|All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Hydrogel patch (Adhesive Hydrogel patch/week, Rebul Pharmacy, Turkey) for 14 days.
88995073|NCT05768776||HoLEP patients without MOSESTM 2.0 effect (open label)|control retrospective open label
88995074|NCT05768776||HoLEP patients with MOSESTM 2.0 effect (open label)|prospective open label
88995075|NCT05764941||Observational Group|Patients receive initetamab combined with pyrotinib and vinorelbine after trastuzumab progression.
88995076|NCT05761782||University of California, Davis Comprehensive Cancer Center's Catchment Area Population|Behavioral Intervention: Education and Training on Cancer Prevention and Education
88995077|NCT05754658||Breast Cancer|Female patients
88995078|NCT05754658||Prostate Cancer|Male patients
88995079|NCT05750017|Experimental|Cohort1: Low dose sentinel group|Three subjects will be first enrolled into low dose sentinel group in open-label, prior to initiation of dosing in each dose level main group.
88995080|NCT05750017|Experimental|Cohort2: High dose sentinel group|After reviewing the safety through 7 days after the first dose of LZ901, if no safety signals occur, another 3 subjects will be enrolled into high dose sentinel group in open-label.
88995081|NCT05750017|Placebo Comparator|Cohort3: Low dose main group|If also no safety signals occur through 7 days after the first dose of LZ901 in high dose sentinel group, 30 subjects will be randomized in a 2:1 ratio to receive two doses of LZ901 or placebo in a double-blind fashion in low dose main group.
88995082|NCT05750017|Placebo Comparator|Cohort4: High dose main group|Subjects will be enrolled in high dose main group also after the safety review through 7 days after the first dose of LZ901 or placebo in low dose main group.
88995083|NCT05745675||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
88995084|NCT05745662||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
88995085|NCT05730153|Active Comparator|group 1|
88995086|NCT05730153|Sham Comparator|group 2|
88995087|NCT05700734|Experimental|Panel A: MK-8510 at dose level 1|Single oral dose of MK-8510 administered at dose level 1 (≤1800 mg) following a 10-hour fast. Dose level 1 shall not exceed 1800 mg.
88995088|NCT05700734|Experimental|Panel B: MK-8510 at dose level 2|Single oral dose of MK-8510 administered at dose level 2 (≤2200 mg) following a 10-hour fast. Dose level 2 shall not exceed 2200 mg.
88995089|NCT05700734|Experimental|Panel C: MK-8510 at dose level 3|Single oral dose of MK-8510 administered at dose level 3 (≤2200 mg) following a 10-hour fast. Dose level 3 shall not exceed 2200 mg.
88995090|NCT05700734|Experimental|Panel D: MK-8510 at dose level 4|Single oral dose of MK-8510 administered at dose level 4 (≤2200 mg) following a 10-hour fast. Dose level 4 shall not exceed 2200 mg.
88995091|NCT05686226|Experimental|E7 TCR-T cells|Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin.
88995092|NCT05685082|Experimental|Standardized patient group|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
88995093|NCT05685082|Experimental|Manikin-based group|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
88995094|NCT05667506|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
88995095|NCT05656313|Experimental|Narrow reference beamformer|
88995096|NCT05656313|Active Comparator|Novel beamformer approach|
89663595|NCT03659188|Experimental|Cortico-alveolar perforations|Patients will undergo orthodontic treatment plus cortico-alveolar perforations.
89663596|NCT03659188|Experimental|Traditional Corticotomy|Patients will undergo orthodontic treatment plus an acceleration procedure employing traditional corticotomy.
89663597|NCT03659188|No Intervention|Control|Patients will undergo orthodontic treatment in which canine retraction will be accomplished using the standard sliding mechanism without any acceleration procedures.
89663598|NCT03593720||Hypospadias|Patients with hypospadias
89663599|NCT03593720||Control|Patients without hypospadias
89048215|NCT02820623|Experimental|Self-report|Therapists randomized to this condition will complete a brief self-report measure, the Therapy Process Observational Coding System for Child Psychotherapy Strategies Scale-Self Report version (TPOCS-SR) for each of the recorded clinical encounters with enrolled youth. The TPOCS-SR will be a self-report version of the Therapy Process Observational Coding System for Child Psychotherapy-Strategies Scale (TPOCS-S) and will be created in collaboration with the instrument developer (McLeod). In this condition, the investigators will (a) provide an operational definition for each item on the TPOCS-SR (e.g., cognitive education: teaches client the cognitive model (e.g., thoughts influence behavior)/identifies how the cognitive model applies to a specific aspects of the client's life), and (b) provide therapists with a 30-minute training session that includes sample vignettes of particular behaviors and information about how those vignettes should be rated.
89048216|NCT02820623|Experimental|Chart Stimulated Recall|"Therapists randomized to this condition will be asked to bring the charts of three enrolled youth to the chart-stimulated recall interview. A trained interviewer will ask the therapists how well they recall the encounter (rating of memory quality) followed by an open-ended question (Talk me through your last session with your client. Tell me what you did.). While the therapists are speaking, the interviewer will note any elements that represent a prescribed CBT strategy. The interviewer will go through a list of cognitive-behavioral strategies based upon the TPOCS-S and probe to determine if the therapists completed any of the strategies. Follow-up questions will be used to explore to what degree an element was used and how skillfully and responsively the strategies were used."
89048217|NCT02820623|Experimental|Behavioral Rehearsal|"Therapists randomized to this condition will be asked to engage in role-plays demonstrating the CBT strategies used with the three enrolled youth. The investigators will provide therapists with a list of the TPOCS-S CBT strategies and ask them to identify the CBT strategies used in their recorded encounter. The investigators will randomly select one of the strategies they report for each role-play. The investigators will then tell them, Please role-play how you used this strategy in session with your client, with the trained actor in front of you. Later, an independent rater will rate therapists' adherence and skill based on established scoring criteria."
89048218|NCT02819232|Other|Patient with a prescription of a microbiologic diagnostic of|Patient with a prescription of a microbiologic diagnostic of keratitis
89048219|NCT02819206|Other|Uveitis|Patient with a prescription of a microbiologic diagnostic of uveitis
89048220|NCT02819128|Other|Homeless people|Populations of homeless households in Marseille.
89048221|NCT02816307|Experimental|Infective endocarditis|
89048222|NCT02774005|Experimental|Raxone|
89048223|NCT02747849|Placebo Comparator|Hand neuromodulation|The stimulation characteristics for this arm include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for finger twitching - or the intensity that the subject feels comfortable with. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
89048224|NCT02747849|Active Comparator|Foot Neuromodulation|The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will be asked to wear socks on their foot to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
89048225|NCT02700828|Active Comparator|Hydrocortisone|Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland
89048226|NCT02700828|Placebo Comparator|Placebo|Isotonic sodium chloride is an aqueous solution of 0.9 percent sodium chloride which is isotonic with the blood and tissue fluid
89048227|NCT02695771|Experimental|Mitomycin C|Mitomycin C 40 mg in 40 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
89663600|NCT03541616||Enrolled Patients|
89663601|NCT03508752|Experimental|Radiation|Stereotactic Radiosurgery
89663602|NCT03506867|Active Comparator|Usual care arm|We will provide the participants in this arm with pamphlets and knowledge about available services in the city through partner agencies. The life skills, training, and work arm will be offered to the usual care arm participants after the first six months of study enrollment.
89663603|NCT03506867|Active Comparator|Life skills, training, and work arm|Participants will receive life-skills workshops, training, education resources and access to small-paid or volunteering positions.
89663604|NCT03492775|Active Comparator|Arm A:Obinutuzumab single agent|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
89663605|NCT03492775|Active Comparator|Arm B:Obinutuzumab plus Bendamustine|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
89663606|NCT03429166|Experimental|STAIR stands for Skills Training in Affective and Interpersonal Regulation|STAIR stands for Skills Training in Affective and Interpersonal Regulation a non-trauma-focused treatment
89663607|NCT03429166|Active Comparator|Present Centered Therapy|PCT , a non-trauma-focused treatment
89213871|NCT00880724|No Intervention|Medical management|
89213872|NCT03967327|Active Comparator|MOR SR|"This arm includes MOR SR and placebo for BUP TDS, detailed information is as below:~Treatment dosage form dosage frequency duration MOR SR Tablet 10,30,60mg q12h 8 weeks~Placebo for Patch -- every 3-4 days 8 weeks BUP TDS"
89213873|NCT03967327|Experimental|BUP TDS|"This arm includes BUP TDS and placebo for MOR SR, detailed information is as below:~Treatment dosage form dosage frequency duration Placebo for Tablet -- q12h 8 weeks MOR SR~BUP TDS Patch 20/30/40mg every 3-4 days 8 weeks"
89213874|NCT01075945|Experimental|Dihydroartemisinin- piperaquine|orally tablets
89213875|NCT01075945|Active Comparator|artemether- lumefantrine|oral tablets
89213876|NCT00882752||Ulcerative colitius|The method used to identify the microbes in the sample was chosen because it had the potential to provide more exhaustive identification of the bacteria present in the sample as compared to culturing methodology.
89213877|NCT00874562|Active Comparator|Steroid Only|Corticosteroid Alone
89213878|NCT00874562|Active Comparator|Steroid plus Rapamycin|Corticosteroid plus Rapamycin
89213879|NCT00874640||Group 1|
89663608|NCT03385304|Experimental|10% povidone-iodine (1% free iodine) in purified water|The povidone-iodine solution will contain 10% povidone-iodine (1% free iodine) in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions for use (e.g., technique of application, duration of application, drying time, drying techniques, replacement of draping, etc.).
89663609|NCT03385304|Experimental|4% chlorhexidine gluconate (CHG) in purified water|The CHG solution will contain 4% CHG in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions (e.g., technique of application, duration of application, drying time, replacement of draping, etc.).
89663610|NCT03348722||Active surveillance|Newly diagnosed low risk prostate cancer patients managed according to an active surveillance program
89663611|NCT03348722||Radical prostatectomy|Newly diagnosed low risk prostate cancer patients undergoing radical prostatectomy
89663612|NCT03348722||Radiotherapy|Newly diagnosed low risk prostate cancer patients undergoing radiotherapy (external or brachitherapy)
89663613|NCT03348722||Other radical treatment|Newly diagnosed low risk prostate cancer patients undergoing other radical treatments (HIFU, cryotherapy, others)
89663614|NCT03325608|Experimental|POISED Care|Dyads randomized to the POISED Care intervention will work with the POISED care management team - consisting of specially-trained nurses functioning as care managers (CMs) and para-professionals in the role of care manager assistants (CMAs) - to create an individualized care plan through the lens of cognitive impairment with an emphasis on coordinating care with the patient's primary care provider (PCP) and achieving relevance with the goals and capacity of the family care-giver and care-recipient.
89663615|NCT03325608|No Intervention|Usual Care|Participants will receive referrals to services at the time of enrollment.
89663616|NCT03285568||Palbociclib|women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib
89663617|NCT03228719|Active Comparator|Control Group|Standardized Outpatient Physical Therapy after TKR
89663618|NCT03228719|Experimental|Intervention Group|Standardized Outpatient Physical Therapy after TKR with a Physical Activity Intervention
89663619|NCT03194477|Experimental|Mobile-enhanced Engagement Intervention|Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18-months.
89213880|NCT00882830|Experimental|EMS group|
89663620|NCT03194477|No Intervention|Control - SOC Case Management|Standard of care (SOC) case management.
89663621|NCT03183141|Experimental|SER-109|Received oral dose of SER-109
89663622|NCT03165331|Other|Intervention group|The intervention group will go through the intervention programme (Ung Face IT) after T1 and randomisation. Programme takes 7 weeks to complete + Treatment as usual (local health care services). Questionnaires after the 7 weeks (T2) and after three months (T3) and 6 months (T4).
89663623|NCT03165331|Other|Control group|Treatment as usual for three months after T1 and randomisation, with local health care support if needed. Questionnaires at T2 and T3 before participants are given access to the intervention (Ung Face IT) after three months. Questionnaire at T4 (post-intervention).
89663624|NCT04277325|Experimental|Intervention|Couples will receive 19-21 free sessions of Emotionally-Focused Therapy.
89213881|NCT00882830|No Intervention|control group|
89213882|NCT00874718|Active Comparator|Action group|
89213883|NCT00874718|Other|Control group|Non-specific educational program for general health.
89213884|NCT00201643|Active Comparator|1 Test group|Receive 2nd Course = Study drug (betamethasone or dexamethasone)
89213885|NCT00201643|Placebo Comparator|2 - Control|Placebo group = received placebo course
89213886|NCT03798314|Experimental|Treatment (nivolumab and pomalidomide)|Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.
89213887|NCT00882986||1|Men with high fitness (above VO2max of 60)
89213888|NCT00882986||2|Men with average fitness (below VO2max of 50)
89213889|NCT01077427|Active Comparator|Gemcitabine + Capecitabine|
89213890|NCT01077427|Experimental|Gemcitabine + Cisplatin + regional hyperthermia|
89213891|NCT05204654|Experimental|In-office fabricated appliance|A customized in-office fabricated appliance using the printed digital model of the subject will be used for AP correction. AP correction will be completed following CMA protocol (see model description)
89213892|NCT05204654|Active Comparator|Carriere Motion Appliance|The appropriate length appliance will be placed as directed in the CMA handbook on the maxillary first molar and canine. AP correction will be completed following CMA protocol (see model description)
89213893|NCT00883064|Experimental|1|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
89213894|NCT00883064|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
89213895|NCT01077505|Experimental|albiglutide|albiglutide 50mg weekly
89213896|NCT00883142||Group 1|
89213897|NCT01073995|Active Comparator|Kenalog and Sensorcaine|"The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information:~Intervention:~Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc"
89213898|NCT01073995|Placebo Comparator|Saline|Saline injections will be used to mimic the Steroid dose
89213899|NCT01074073|Other|Lithium/Lurasidone|Schizophrenia Patients
89213900|NCT00883220|Experimental|Self-management of urinary catheter|Intervention: Self-management group--teaching behavioral approaches(awareness, self-monitoring, and self-management) to prevent or minimize urinary catheter complications.
89213901|NCT00883220|No Intervention|Usual care 2|Usual care for urinary catheter. Home care and/or clinic care is the usual care for people with long-term urinary catheters.
89213902|NCT01076101||Sisters who have a diagnosis of SLE|Sisters who have a diagnosis of SLE
89213903|NCT01076101||Unaffected Sisters|Sisters of SLE patients who do not have a diagnosis of SLE
89213904|NCT01076257|Experimental|Constraint-induced Movement Therapy|
89213905|NCT01076257|Other|Transditional rehabilitation|
89213906|NCT01076413|Experimental|skill-based exercise|2 times per week for 12 weeks. warm-up, stretching, strengthening, and skill-based exercises. Pre-gait and gait activities including stepping patterns and walking patterns and treadmill training at various walking speeds
89663625|NCT04277325|No Intervention|Waitlist|Couples will receive no intervention during the trial. After the trial is ended, they will be invited to participate in a weekend intervention meeting.
89663626|NCT03117816|Experimental|investigational arm A|There will be an overlapping treatment with AOP2014 and TKI for one month. After one month, the TKI therapy will be stopped and patient will receive only AOP2014 treatment for the next 14 months.
89663627|NCT03117816|Other|surveillance arm B|"This is an open-label study with a surveillance group as comparator arm. Similar as in the arm A, patient will discontinue TKI therapy one month after randomization. From then on patient will receive no further CML treatment."
89663628|NCT03038802|Active Comparator|Standard vaccine|Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
89663629|NCT03038802|Experimental|Experimental therapeutic vaccine|Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
89663630|NCT02957539|No Intervention|No Reward|At enrollment, participants randomized to usual care will be given the MOVE! workbook that serves both as an information resource on diet and exercise, a resource for tools to achieve weight loss goals, and a log of participants' goals, motivations, and outcomes. Each participant will be given a chart with a personalized target weight for a loss of 1lb. per week for 16 weeks. Participants will be given a digital scale or wireless scale and counseled to weigh themselves daily. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
89663631|NCT02957539|Experimental|Financial Reward Arm|Same as usual care, plus financial rewards that are earned in two ways: an assured and random. For the assured reward, they will receive compensation at the end of each month that they are at or below their target weight on the last day of that period. For the random portion, each week that a participant is at or below their target weight, the patient is entered in random drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning.Over the 17-32 week period, Veterans in this group will receive token rewards for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters his/her weight into the portal, he will have a 1-in-8 chance to earn the token reward, such as a t-shirt or movie tickets. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
89663632|NCT02957539|Experimental|Non-financial Reward Arm|Procedures for the non-financial rewards arm is identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each week a random drawing will be for 20 points, each monthly weigh in is worth 5 points. Veterans will be given non-financial rewards associated with the number of points they earn.
89663633|NCT02938793|Experimental|Single Arm|Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 300mg intravenously as a single dose on cycle 1 day 1 only.
89213907|NCT01076413|Active Comparator|aerobic exercise training|warm-up, strengthening and aerobic conditioning (treadmill walking)
89213908|NCT05204264|Experimental|Acceptance and Commitment Therapy (ACT)|Intervention based on Acceptance and Commitment Therapy that promotes the acceptance and defusion of unwanted internal experiences and commitment to values of the personal life project.
89213909|NCT05204264|Experimental|Mindfulness-based Emotional Regulation (MER)|Intervention inspired in the Mindfulness-Based Stress Reduction program that fosters the development of a behavioral pattern made up of conscious responses in order to decrease reactivity to stressors.
88995097|NCT05649852|Other|Chemotherapy|Adjuvant chemotherapy treatment
89213910|NCT04017884|Experimental|Remin Pro Forte.|intervention
89213911|NCT04017884|Active Comparator|Remin pro.|comparator
89213912|NCT00880880|Experimental|pre-visit e-PAQ-PF|Participants assigned to fill out the e-PAQ-PF prior to their clinic visit. Participants will arrive early to clinic appointment and fill out e-PAQ-PF. Results will be given to clinician and participant. After their visit they will complete the post visit questionnaire.
89213913|NCT00880880|No Intervention|post-visit e-PAQ-PF|Participants assigned to complete the e-PAQ-PF after their clinic visit. Pre-visit participants will sign consent form - but otherwise will receive no study interventions. Post-visit they will fill out e-PAQ-PF and post visit questionnaire.
89213914|NCT00880958|Experimental|1|
89213915|NCT00880958|Placebo Comparator|2|
89213916|NCT04489628|Active Comparator|Vitamin D|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
89663634|NCT02935400||Asymptomatic|Group 1 will have had no symptoms of porphyria in the past year.
89663635|NCT02935400||Symptomatic and treated with hemin|Group 2 will have a history of symptoms within the past year.
89663636|NCT02837094|Experimental|Safety of C19A3 GNP (general safety and induction of hypersensitivity).|To assess general safety different parameters were taken into account: A physical examination at screening and 0, 4, 8 and 14 weeks, a review of AEs at all visits and blood tests at screening, weeks 4, 9, 14 & 20 for full blood count; urea, electrolytes and creatinine; liver function tests; (prothrombin time, total bilirubin, total protein, albumin, AST (SGOT), SGPT (ALT), alkaline phosphatase; thyroid stimulating hormone; immunoglobulins (G, A, M); calcium; magnesium, phosphate, lipid profile (total cholesterol, LDL, HDL, triglyceride), urinalysis for pH blood, protein, urine beta-2-microglobulin and albumin/creatinine ratio at screening and visits 1, 2, 4, 5 and 6 and urine for cystatin-c was tested at visits 1, 4, 5 & 6, a urine pregnancy test in females only, at all trial visits. Subjects were observed for systemic hypersensitivity to C19-A3 GNP during the immediate period after peptide injection.
89663637|NCT02836925|Experimental|Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir|The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated
89663638|NCT02782091|Experimental|Schizophrenia Patient|
89663639|NCT02782091|Experimental|Control Subject|
89663640|NCT02728037|Experimental|Magnesium-Based Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
89663641|NCT02728037|Active Comparator|Lidocaine-Only Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
89663642|NCT02728037|No Intervention|Wait-Listed Patients|This arm is a non-randomized, no-treatment arm consisting of women who are on the waiting list for the chronic pain clinic.
89663643|NCT02690077|Active Comparator|Method 1 by Preference 1|Delivery through the Family-Centered Cesarean for patients with known Family-Centered preference.
89663644|NCT02690077|Active Comparator|Method 1 by Preference 2|Delivery through the Family-Centered Cesarean for patients with known Traditional Cesarean preference.
89663645|NCT02690077|Active Comparator|Method 2 by Preference 1|Delivery through the Traditional Cesarean for patients with known Family-Centered preference.
89048228|NCT02695771|Active Comparator|Gemcitabine|Gemcitabine 2 grams in 100 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
89048229|NCT02695771|No Intervention|No intervention|Patients randomized to this arm will receive no intervention intravesicular immediately following TURBT one time.
89048230|NCT02658032|Other|Standard Care/No Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the non bio feedback arm.
89048231|NCT02658032|Other|Standard Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the bio feedback arm.
89048232|NCT02658032|Other|Personalized Care/ No Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the non bio feedback arm.
89048233|NCT02658032|Experimental|Personalized Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the bio feedback arm.
89048234|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Trans thoraciq cardiac ultrasonography wil be perforfomed for pregnant women having a spinal or spinal-epidural anesthesia for elective caesarean section. All patients are more 18 years old and more 37 weeks pregnancy
89213917|NCT04489628|Placebo Comparator|Placebo|Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
89663646|NCT02690077|Active Comparator|Method 2 by Preference 2|Delivery through the Traditional Cesarean for patients with known Traditional Cesarean preference.
89663647|NCT02662777||Eso-SPONGE® vacuum treatment|leakage after esophagectomy and gastrectomy, perforation of the esophagus
89663648|NCT02546440|Experimental|treatment arm|patients are treated with dimethylfumarate over 24 weeks. Dosage will be escalated weekly from 30 mg/d to 720 mg/d over 9 weeks. The dose escalation scheme is the same as approved for psoriasis treatment in Germany
89663649|NCT02525614|Active Comparator|Triathlon Standard Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
89213918|NCT00130039|Experimental|cilostazol|cilostazol 100mg bid plus placebo of clopidogrel
89213919|NCT00130039|Active Comparator|Clopidogrel|clopidogrel 75mg qd and matching placebo of cilostazol
89663650|NCT02525614|Active Comparator|Triathlon Short Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
89663651|NCT02525601|Active Comparator|Triathlon CR cemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented Peri-Apatite (PA) knee fixation and migration properties versus the cemented version.
89663652|NCT02525601|Active Comparator|Triathlon CR uncemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented PA knee fixation and migration properties versus the cemented version.
89663653|NCT02485730||Adult children of AD patient|Cognitively healthy adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol) from 45 to 64 years old.
89663654|NCT02442375|Active Comparator|standard dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
89663655|NCT02442375|Experimental|FDG-PET guided gradient dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
89048235|NCT02462460||Patients with BRCA mutation|The purpose of this study is to optimize rapid pancreatic and ovarian MR screening protocols using T1, T2 and DW imaging sequences in BRCA mutation carriers. Each screening MR protocol is considered optimized if we reach 5 consecutive patients with technically adequate image quality. We will enroll up to 60 patients to perform the MR screening protocol, if the initial MR sequence parameters do not yield technically adequate MR images in a single patient, we will stop and modify our imaging protocol. We will continue to modify the technique until we reach 5 consecutive patients with technically adequate MR images for both on all imaging sequences. Thus, it is possible we will optimize different imaging sequences at different time points in our study. We plan to enroll at least 5 patients, and up to 60 patients with BRCA mutation who undergo breast MRI for this study. Participants will receive a copy of the questionnaire on the day of their Breast MRI.
89048236|NCT02339701|Other|IMRT|Patients will receive 38 fractions of radiation, each fraction size will be 2Gy. The total dose will be 78Gy to PTV 1. Whereas the total dose will be 70Gy over 38 fractions to PTV 2. The treatment will be delivered 5 fractions per week consecutively except public holiday, and the total duration of treatment will be 7.5 to 8 weeks.
89048237|NCT02339701|Other|SBRT|Patients will receive 5 fractions of radiation; each fraction size will be 7.25Gy. The total dose will be 36.25 Gy to PTV1. Whereas the total dose will be 32.5Gy over 5 fractions to PTV2. The 5 treatments will be scheduled to be delivered twice aweek over approximately 15-17 days. A minimum of 72 hours and a maximum of 96 hoursshould separate each treatment. No more than 2 fractions will be delivered per week. The total duration of treatment will be no shorter than 15 days and no longer than 17 days.
89048238|NCT02209142|Experimental|pan-genomic screen|A pan-genomic screen by blood prelevement and psychometric data collection will be set-up on a subset of MDE and control samples to identify mRNA candidates for a transcriptional signature of MDE,
89048239|NCT02209142|Sham Comparator|control|a pan genomic screening by blood prelevement and psychometric data collection wil be performed on healthy subject
89048240|NCT02200276|Other|Influenza Immunization|Influenza immunization in adults over age 75
89048241|NCT02190305|Experimental|Diagnostic: Multiplo HBc/HIV/HCV + Reveal HBsAg|Subjects tested with investigational devices and approved comparator assay algorithms for HIV and hepatitis B and C.
89663656|NCT02180412|Experimental|Panhematin|Panhematin plus glucose
89663657|NCT02180412|Placebo Comparator|Placebo|Placebo (saline) plus glucose
89663658|NCT02081768|Experimental|90yttrium colloid|90 Yttrium colloid will be inserted into the cystic cavity. Based on clinical expertise, the treating neurosurgeon will determine the appropriate surgical procedure for each patient on an individual basis which will be reflected in the surgical consent the patient is presented and signs.
89663659|NCT01991925||quality of life, quality of care|hereditary haemochromatosis patients
89048242|NCT02167711|Experimental|SIRT|
89048243|NCT01975428|Other|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
89048244|NCT01975428|Active Comparator|DM Pgm + device|"Disease management (DM) program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
89048245|NCT01941641|Experimental|neoadjuvant FOLFOXIRI|
89048246|NCT01792934|Active Comparator|XELOX or FOLFOX regimen|XELOX or FOLFOX regimen
89048247|NCT01792934|Experimental|XELOX or FOLFOX regimen and maximal tumor debulking|XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT).
89048248|NCT01751438|Experimental|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST). Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
89213920|NCT00875030|Experimental|1.0|
89213921|NCT00875030|Active Comparator|2.0|
89663660|NCT01617382||Registry|Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
89663661|NCT00545077|Active Comparator|Arm A: Endocrine Therapy (ET)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
89663662|NCT00545077|Experimental|Arm B: ET with Bevacizumab (ET-B)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
89663663|NCT00251433|Experimental|Phase I|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
89663664|NCT00130533|Experimental|Xeloda (capecitabine)|1000 mgrs/m2 twice a day, tablets, 8 cycles
89663665|NCT00130533|No Intervention|Observation|Observation. No intervention.
89663666|NCT00129935|Active Comparator|Arm A: EC-T|Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
89663667|NCT00129935|Experimental|Arm B: ET-X|Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
89663668|NCT04128059|Experimental|phase 1, component 1|component 1 of vaccine
89663669|NCT04128059|Experimental|phase 1, half dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in half dose
89663670|NCT04128059|Experimental|phase 1, full dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in full dose
89663671|NCT04128059|Experimental|phase 2, selected dose|prime-boost vaccination with component 1 and component 2 with an interval of 21 days in selected dose
89663672|NCT04128059|Placebo Comparator|phase 2, placebo|vaccination with placebo with an interval of 21 days
89663673|NCT04127669|Experimental|Arm A|Active substance treatment with OSU6162. Starting dose for all patients in the OSU6162 treatment group is 15 mg BID. The dose is taken orally as one circular coated tablet of 15 mg together with a light meal in the morning and one tablet around lunch unless otherwise agreed upon. In order to aim at optimal dosing of OSU6162, some flexibility is allowed. The investigators are able to modify the dose for individual patients based on how well the treatment is tolerated and how well the patients respond to it. In the case where there is no clear response, the dose can be increased to maximally 30 mg BID (intermediate dosage is allowed) after 4 weeks of treatment; it is also possible to decrease the dose to a lower level (even below 15 mg BID) if a higher dose is not tolerated and/or there is a perceived weakened therapeutic effect with the higher dose. All dose changes will be performed while retaining the blind.
89663674|NCT04127669|Placebo Comparator|Arm B|Placebo treatment. Starting dose for all patients in the placebo group is one circular coated tablet (with identical appearance to active treatment tablets 15 mg) taken BID, according to the same schedule as active treatment. The dose may be increased or decreased in the same manner as for active treatment.
89663675|NCT04127591||myocardial infarction group|Patients admitted with the diagnosis of myocardial infarction.
89663676|NCT04127591||Blank control group|Patients admitted without the diagnosis of myocardial infarction.
89663677|NCT02760667|Experimental|Induction Therapy with 3 cycles|Cisplatin 75mg/m2 IV and Taxotere 75mg/m2 every 3 weeks for 3 cycles (Induction Chemotherapy) followed by surgical treatment
89663678|NCT04127357|Other|A - Control|Brushing with 1450 ppm fluoride toothpaste.
89663679|NCT04127357|Experimental|B - Test|Resin sealing (FluroShield, Dentsply, Brazil).
89663680|NCT03823261|Experimental|CBT|
89663681|NCT04127435||High-Dose-Rate 192Ir Brachytherapy|"All patients underwent computed tomography (CT) 3-5 days before surgery. The collimation is 2.5 mm and CT Planning System.~Delineation of the gross tumor volume (GTV) and adjacent organs at risk (OARs);~Determination of the needle tract of the implanted insertion direction, distribution, and depth. Then calculation of the dose distribution of the target volume and OARs.~Depending on B-TPS data, we establish a digital model for the individual template.~Local anesthesia or intraspinal anesthesia was induced in all patients. The three-dimensional printing noncoplanar templates (3D-PNCT) was placed on the surface of the treatment area of the patient. The 3D-PNCT was aligned accurately with the outer-contour features. Through the guide hole of the 3D-PNCT, we inserted to pre-planned depths.~Delineation of the GTV and design planning .~Connect the source tube and 192Ir high dose rate interorganizational brinotherapy~At the end pressed to stop bleeding."
89663682|NCT04142021||patients with 3-vessel disease with or without left main|Patients with 3-vessel disease with or without left main involvement referred to CABG treatment based on coronary angiography.
89663683|NCT03023657|Experimental|Severe brain-damaged patient in coma awakening|For each patient, video sessions of the face will be performed during a waking period, until the spontaneous macro-EFE (Emotional Facial Expression) reappears. The video sessions will be done without stimulation or with visual, auditory or tactile stimulation. The sessions will be daily for 7 days then weekly for a maximum duration of 4 weeks.
89663684|NCT02706145|Experimental|Intervention Group (West Louisville)|This group will be exposed to the social norming campaign via traditional, mass, and social media over the three-year intervention period.
89213922|NCT00883298|Experimental|Open Label|temozolomide plus bevacizumab administered as open label single arm treatment
89663685|NCT02706145|No Intervention|Control Group (East Nashville)|This group will serve as the control group, and measures of social norms and attitudes toward violence will be compared between this group and the intervention group.
89663686|NCT03823105|Experimental|Nocturnal Recording|Recording of photoplethysmographic pulse wave and accelerometry with two devices (OHR Tracker, PulseWatch) in parallel to the standard polysomnography
89213923|NCT03969277|Experimental|Graded Motor Imagery|Each subject in the Graded Motor Imagery group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, and home exercises.
89663687|NCT02578446|Experimental|Uncemented Triathlon Tritanium CR|Primary total knee replacement with Uncemented Triathlon Tritanium CR Total Knee System
89663688|NCT02578446|Active Comparator|Cemented Triathlon CR|Primary total knee replacement with Cemented Triathlon CR Total Knee System
89663689|NCT01450111|Experimental|Lacosamide 50 mg group|Lacosamide 50 mg tablet, once a day per os (po)
89663690|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 50 mg|Placebo matched with lacosamide 50 mg tablet, po
89663691|NCT01450111|Experimental|Lacosamide 100 mg group|Lacosamide 100 mg tablet, po
89663692|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 100 mg|Placebo matched with lacosamide 100 mg tablet, po
89663693|NCT01450111|Experimental|Lacosamide 200 mg group|Lacosamide 200 mg tablet, po
89663694|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 200 mg|Placebo matched with lacosamide 200 mg tablet, po
89663695|NCT02697253|Experimental|Successful drug|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
89663696|NCT02697253|Experimental|Unsuccessful drug|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered Sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
89663697|NCT02697253|Placebo Comparator|Success placebo|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
89663698|NCT02697253|Placebo Comparator|Unsuccess placebo|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
89663699|NCT02660905|Experimental|Active Treatment|E/C/F/TAF Ledipasvir-Sofosbuvir/TAF
89663700|NCT03822715|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
89663701|NCT03829735|Experimental|Children and their mothers|Human biological samples from children aged 9 to 12 months and their mothers. Capillary and venous blood samples.
89663702|NCT01450345|Experimental|Pregabalin Group|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
89663703|NCT04392895||Patients with locally advanced cervical cancer|Patients with locally advanced cervical cancer, who had undergone a PAL
89663704|NCT02928757|Experimental|Intervention Group|In addition to standard medical care, participants will be enrolled to be seen as soon as possible in a complex care clinic as part of the CCKO initiative.
89663705|NCT02928757|No Intervention|Wait-list Group|The control group will receive usual care, but will be wait-listed for 1 year to be seen in a complex care clinic as part of the CCKO initiative.
89663706|NCT01450423|Experimental|Physical activity|
89663707|NCT01450423|No Intervention|Control|
89663708|NCT02926729|Experimental|Experimental|Standard lumpectomy followed by nonlinear microscopy imaging of excised surgical margins. If invasive cancer or DCIS at or close to the margin is detected, additional excision may be performed.
89663709|NCT02926729|Active Comparator|Control|Standard lumpectomy without nonlinear microscopy imaging.
89663710|NCT03822559|Experimental|DE-111A eye drops|
89663711|NCT03822559|Active Comparator|0.0015% tafluprost eye drops|
89663712|NCT02979691|Active Comparator|SIB-IMRT|SIB-IMRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday).
89663713|NCT02979691|Experimental|S1 based SIB-IMRT|S1 based SIB-IMRT receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday) followed by four cycles of S-1 (40-60mg, orally twice daily, d1-14, every 3 weeks) as an adjuvant chemotherapy.
89663714|NCT02979457|No Intervention|no awareness of Degree of Worry|Call handler is not made aware of caller's DOW on computer screen
89663715|NCT02979457|Experimental|awareness of Degree of Worry|Call handler is made aware of caller's DOW on computer screen alongside patient information as address etc.
89663716|NCT04391725|Experimental|Periapical surgery with guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and the defect is filled with mixture of iPRF and type 1 collagen granules before flap closure.
89663717|NCT04391725|Active Comparator|Periapical surgery without any guided tissue regeneration|Patients with through and through periapical lesion will undergo periapical surgery and flap closure done.
89663718|NCT01647828|Experimental|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel
89663719|NCT01647828|Experimental|Gemcitabine and Nab-Paclitaxel plus Placebo|Gemcitabine and Nab-Paclitaxel plus Placebo
89663720|NCT01450501||Patients with vascular chronic Q-fever|All patients with chronic Q-fever and an aneurysm or vascular reconstruction
89663721|NCT03825367|Other|Open label design|Nivolumab and 5-azacytidine,
89663722|NCT04273321|Experimental|MP group|
89663723|NCT04273321|No Intervention|Con group|
89663724|NCT01243476|Experimental|lenalidomide|Experimental treatment branch with Lenalidomide 5 mg/day (oral use)
89663725|NCT01243476|Placebo Comparator|placebo|Placebo branch (oral use)
89663726|NCT01450579|Placebo Comparator|Placebo|Saline
89663727|NCT01450579|Experimental|Dose -1|ASP7373
89663728|NCT01450579|Experimental|Dose -2|ASP7373
89663729|NCT01450579|Experimental|Dose -3|ASP7373
89663730|NCT01450657||Chronic Kidney Failure 3/4|
89663731|NCT01453933|Active Comparator|Raltegravir|At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).
89663732|NCT01453933|No Intervention|Lopinavir/ritonavir|Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)
89663733|NCT04976400|Experimental|test group|Semi-individualized total knee arthroplasty
89663734|NCT04976400|Active Comparator|Control group|Zimmer standard prosthesis total knee replacement
89663735|NCT04976478||observation group|All patients will be treated with Nimotuzumab combined with radiotherapy.
89663736|NCT01454011|Active Comparator|Testosterone 250mg injection,|
89663737|NCT01454011|Active Comparator|Testosterone transdermal application|
89663738|NCT01146756|Experimental|AZD6244 & Thoracic Radiotherapy|AZD6244 in combination with thoracic radiotherapy (RT)- the aim is to determine the recommended phase II dose (RP2D).
89663739|NCT03060018|Experimental|All included patients|All included patients will undergo the intervention of transcutaneous sensor placement
89663740|NCT01450969||Interventional Radiologists|All operators are Interventional Radiologists and co-investigators. Prior to start of the study, all operators are asked to provide written informed consent to participate in the study.
89663741|NCT02978677|Experimental|Grade II tumors (macroscopic)|Radiotherapy 68 Gy(RBE)
89663742|NCT02978677|Experimental|Grade III tumors (macroscopic)|Radiotherapy 72 Gy(RBE)
89663743|NCT02978677|Active Comparator|Grade II/III tumors (completely resected)|Radiotherapy 60 Gy(RBE)
89663744|NCT04975854|Experimental|Virtual Reality Exposure|Participants complete three 30-40-minute sessions of exposure administered via a virtual reality headset. The exposure involve exposure to various heights and height cues in the virtual city environment. Experimental group also attends 20-minute online information session (prerecorded video).
89663745|NCT04975854|Other|Control|Control group attends a single 20-minute information session (prerecorded video) about general principles of exposure therapy and anxiety before the start of the study, but receives no exposure-based intervention.
89663746|NCT01454245|Experimental|001|"JNJ-39439335 Part 1:Type=1 unit=mg number=25 form=capsule route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.,JNJ-39439335 Part 2:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods."
89663747|NCT04975932||Study group: TACE+ICIs|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); ICIs: atezolizumab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab or other ICIs
89663748|NCT04975932||Control group: TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
89663749|NCT01454323|Experimental|Intervention|Dose of bone marrow mononuclear cells: 5-7 x 108 total cells
89663750|NCT04968444|Active Comparator|one to one traditional physiotherapy|For clarity, 1-1 physiotherapy takes the form of a private consultation between patient and therapist. A discussion of symptoms is had and an individual physical examination is undertaken to explore what is mechanically causing their pain and what can be offered to help. This is also when the initial outcome scores are taken. Treatments are then offered which can take the form of exercise therapy, massage, and manual therapy. Symptoms are regularly monitored for effectiveness of treatment and adjusted accordingly. The number of sessions that forms their treatment is variable depending on response to treatment and how they are coping. At the final session the end outcome scores will be taken.
89663751|NCT04968444|Active Comparator|BOOST workshop group|The BOOST workshop is a novel approach whereby participants are invited to a 2.5 hour interactive session. Subjective discussion at the start is had about how people are affected and impacted by their back pain, and outcome scores are completed. Then during the 2.5 hours there is a delivery of information and a practical exercise component to better inform the participants on how to manage their back pain and understand it better. Following this on 3 separate occasions, 1 month apart further top up information is sent to ensure they remember exercises and advice on practical management if a flare up occurs or they are struggling to fit activity in to day to day routines. Finally, at 3 months, there participants are invited back to complete the outcomes scores but also to discuss any concerns they are having and be given any advice to support them continuing with managing with any ongoing symptoms.
89663752|NCT04967898|Experimental|bowen technique|group 1 will be treated with the Bowen technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up.
89663753|NCT04967898|Active Comparator|sustained stretching|group 1 will be treated with the sustained stretching technique and heating pad. this technique will be given to asymptomatic females. 22 subjects will be taken this treatment. treatment will be given thrice a week for 3 weeks. the subjects will come after 1 month for follow-up
89663754|NCT03826069|Active Comparator|Conventional Simulation Curriculum|Four, one-hour small-group sessions on the theory of colonoscopy including pathology, anatomy, and therapeutic technique. Following each session, a multiple choice test on topics covered will be administered. In addition, this group will be given a total of six hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (5 hours). During the high-fidelity simulation, endoscopic procedures will be performed with instructor support. The difficulty of the therapeutic intervention (polypectomy) will rise after each successfully completed module. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
89688678|NCT03634813|Experimental|High Blood Pressure Monitoring and Counseling|"Enrolled patients will be fitted with a HBPM device and instructed in its use. Patients will be asked to return the HBPM device on the morning of surgery. At the same time they receive the HBPM device, they will also be provided with the National Institutes of Health (NIH) booklet called Your guide on lowering blood pressure, which has several guidelines regarding diet, exercise and lifestyle changes that can be implemented to improve blood pressure control."
89213924|NCT03969277|Active Comparator|Standard Rehabilitation|Each subject in the Standard Rehabilitation group will receive a treatment protocol consisting of stretching and strengthening exercises, cold therapy, and home exercises.
89663755|NCT03826069|Experimental|Augmented Reality Group|This group will receive the same 4 hours of small group teaching and 6-hours of hands-on simulator training. The intervention is the augmented reality-based curriculum: (1) a brief explanation of the principles of AR and how it will be used during the VR simulations and (2) performance of the therapeutic procedure (polypectomy) as demonstrated by the real-time AR platform. Specific videos corresponding to the therapeutic intervention and pathology (e.g pedunculated vs non-pedunculated polyp) will be available every time a polypectomy is required. Each new module will come with increased technical challenges and will require adjustment to previously used technique by the learner. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
89663756|NCT04964154|No Intervention|BRAVE Non-Intervention|Survey participants in the BRAVE non-intervention arm will not have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
89663757|NCT04964154|Active Comparator|BRAVE Intervention|Survey participants in the BRAVE intervention arm will have received information (e.g., informational pamplets, flyers, townhalls) about COVID-19 testing and vaccination from the BRAVE project.
89663758|NCT01454479|Experimental|Lapatinib (Tykerb) Plus Ixabepilone|
89663759|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 12W|"Patients without cirrhosis and previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks."
89663760|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 12W|"Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks."
89663761|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 24W|"Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks."
89663762|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 24W|Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
89663763|NCT02911831|Experimental|Tranexamic Acid: Abdominal Hysterectomy|"Agent/Device: Tranexamic acid. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 1g in solution to be given intravenously, within 1 hour prior to procedure"
89663764|NCT02911831|Placebo Comparator|Sodium chloride (placebo): Abdominal Hysterectomy|"Agent/Device: 0.9% sodium chloride solution. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 100ml to be given intravenously, within 1 hour prior to procedure"
89663765|NCT04967976|Experimental|Breast Reconstruction with breast mesh|The tissue expander-implant reconstruction with TiLoop Bra mesh.
89663766|NCT04967976|Active Comparator|Breast Reconstruction without breast mesh|The tissue expander-implant reconstruction without TiLoop Bra mesh. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
89213925|NCT04038788|Active Comparator|Active tRNS|In active tRNS condition, random noise was delivered by a battery-operated device (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), with 2 mA amplitude, offset at 1 mA, frequency 100-640 Hz, for 20 min with 15 s ramp-in/ramp-out. The combined impedance of all electrodes was kept below 15 kΩ, as measured by NeuroConn DC stimulator Plus device, using electrolyte gel. The anode was placed over International 10-10 electrode position AF3 (a point midway between F3 and Fp1), with cathodes (reference electrodes) at AF4, F2, F6 and FC4. Stimulation was applied at an intensity of 2 milliampere (mA) for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active stimulation group were maintained on their antipsychotic medications throughout the study period.
89213926|NCT04038788|Sham Comparator|Sham treatment|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham group were maintained on their antipsychotic medications throughout the study period.
89663767|NCT01454557|Experimental|Acquired Brain Injury|auditory stimuli for ABI group
89663768|NCT01454557|Experimental|Controls|Auditory stimuli for control group
89663769|NCT03061734|Experimental|Naltrexone and Acetaminophen|Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
89663770|NCT03061734|Experimental|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
89663771|NCT03061734|Active Comparator|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
89663772|NCT03061734|Active Comparator|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
89213927|NCT00881114|Experimental|Cetuximab|patients with 2 or fewer genetic variants will receive cetuximab
89213928|NCT00881114|Experimental|Cisplatin|Subjects with 3 to 8 genetic variants will receive cisplatin
89663773|NCT03061734|Placebo Comparator|Placebo Capsules|Patient take two capsule containing placebo together for a qualifying migraine
89663774|NCT03829969|Experimental|Toripalimab|Toripalimab combine with paclitaxel and cisplatin
89663775|NCT03829969|Placebo Comparator|placebo|Placebo combine with paclitaxel and cisplatin
89663776|NCT01451125|Experimental|Treated|
89663777|NCT03061656|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (high-dose 131I-MIBG, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
89663778|NCT01454713||Veritas|Breast reconstruction with Veritas
89663779|NCT04964232|Experimental|Temperature monitoring group|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
89663780|NCT03059784|Experimental|intervention|APP-based multifaceted management, including sending education material, everyday medication reminder, giving risk factor control support, clinical support to patients after PCI through APP.
89663781|NCT03059784|No Intervention|control|usual care without APP
89663782|NCT02906761|Experimental|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
89663783|NCT02906761|Placebo Comparator|Placebo|Placebo (2 tablets) twice daily for 6 months
89663784|NCT04975542|Experimental|Treatment Group|
89663785|NCT04975542|Sham Comparator|Sham Group|
89663786|NCT04975386|Active Comparator|spinal anesthesia|
89048249|NCT01751438|Experimental|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy (BST) in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice. Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
89048250|NCT01669915|Active Comparator|ACTIVE Vitamin D + ACTIVE Omega-3 Fatty Acids|ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
89048251|NCT01669915|Active Comparator|ACTIVE Vitamin D + PLACEBO Omega-3 Fatty Acids|ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day
89663787|NCT04975386|Active Comparator|lumbar plexus+sacral plexus block|
89663788|NCT03829813|Experimental|Patients|Music therapy sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour. Music therapy includes a variety of techniques used to target mood, pain, socialisation, expressive speech, attention/cognitive or sensorimotor functional goals.
89048252|NCT01669915|Active Comparator|PLACEBO Vitamin D + ACTIVE Omega-3 Fatty Acids|PLACEBO Vitamin D, one capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
89048253|NCT01669915|Placebo Comparator|PLACEBO Vitamin D + PLACEBO Omega-3 Fatty Acids|PLACEBO Vitamin D, one capsule/day; PLACEBO Omega-3 Fatty Acids, one capsule/day
89048254|NCT01653223|No Intervention|control|untreated
89048255|NCT01653223|Experimental|short statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 7 days postoperatively.
89663789|NCT03829813|Experimental|Family|Family participation in music therapy treatment sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour.
89663790|NCT03829813|Experimental|Administration and Staff|Staff/Administration are not participants in music therapy, but rather have observed sessions, or worked as co-treating clinicians with music therapists for patient participants.
89048256|NCT01653223|Experimental|long statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 6 months postoperatively.
89048257|NCT01549587|Active Comparator|Regular Oral Hygiene|toothpaste, toothbrush and dental floss
89048258|NCT01549587|Experimental|Advanced Oral Hygiene plus counseling|toothpaste, toothbrush, mouth rinse and dental floss plus specialized education
89048259|NCT01047540|Experimental|Dose regimen 1|
89048260|NCT01047540|Experimental|Dose regimen 2|
89663791|NCT03060954|Experimental|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
89663792|NCT03060954|Other|FineVision ®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
89663793|NCT01451359|Experimental|endobronchial valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
89663794|NCT04393051|Experimental|BAR group|"Patients who will be assigned (after a computerized randomization) to the BAR group will. receive baricitinib as adjunctive therapy.~Baricitinib will be administered at 4 mg daily via oral route for 14 days as add-on therapy or 2 mg daily via oral route (eGFR between 30 and 60 ml/min and for patients with age >75 years old) for 14 days as add-on therapy"
88995098|NCT05643079||metal/Bio-Tenodesis group|"medializing calcaneal osteotomy, debridement of the tibialis posterior tendon, and/or transfer of the flexor digitorum longus (FDL) tendon with the following screws:~Metal-/Bio-Tenodesis screw (Arthrex, Naples, Florida, USA)~Metal-Screw:~ø 6,7 mm length: 40-60 mm~Bio-Tenodesis screw:~ø 4,00 mm, length: 10 mm ø 4,75 mm, length: 15 mm ø 5,50 mm, length: 15 mm"
89663795|NCT04393051|No Intervention|Control group|Patients in the control group will continue to receive standard therapy.
89663796|NCT04964310||APAP_DILI|"（①/②）+③+④：~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU/L ④ liver impairment is caused by acetaminophen：Russel U-Calf Causality Assessment Method(RUCAM) causality score>6"
89663797|NCT04964310||APAP_NO-DILI（NDILI）|"（①/②）not（③/④）：~① history of acetaminophen exposure ② abnormal acetaminophen concentration in blood or urine：≥150µg/mL after 4 hour ，≥4.5µg/mL at anytime，measurable ≥24 hours③ liver impairment：ALT or AST ≥ 1000 IU/L④ liver impairment is caused by acetaminophen：RUCAM causality score>6"
89663798|NCT01455025|Experimental|Plerixafor granulocyte-colony stimulating factor|4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.
89663799|NCT03060564|Experimental|AC repair with tendon graft|acromioclavicular repair with tendon graft.
89663800|NCT03060564|Active Comparator|AC repair with no tendon graft|acromioclavicular repair without tendon graft/no intervention
89663801|NCT03468205||Main Cohort|Main cohort of patients meeting all of the eligibility criteria enrolled through newspaper adds, flyers and via non personal recruitment.
89663802|NCT03468205||Subgroup|Smaller group of patients, meeting eligibility criteria for the main study, enrolled through clinical visits. These patients will be followed more closely and also be recorded in a logbook in order for later review. Some of the participants in this group will be interviewed in a semi-qualitative interview about their experiences of breathlessness.
89663803|NCT01451593|Experimental|phenytoin|active arm of trial 1:1 allocation active versus placebo
89663804|NCT01451593|Placebo Comparator|placebo|1:1 allocation active versus placebo
89663805|NCT01455103|Experimental|Arm 1: BMS-936559 (1mg/kg)|
89663806|NCT01455103|Experimental|Arm 2: BMS-936559 (3mg/kg)|
89663807|NCT01455103|Experimental|Arm 3: BMS-936559 (10mg/kg)|
89663808|NCT04975074|Experimental|Anemia Correction Group|Continue to take the current medication orally at the current dose
89663809|NCT04975074|Experimental|Anemia uncorrected group|Continue to take the current medication orally at the current dose
89663810|NCT04391647||HPV vaccinated group|"Women (18-25 years old) whom are previously fully vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.~No intervention/drug to be administered."
89663811|NCT04391647||HPV unvaccinated group|"Women (18-25 years old) whom are not previously vaccinated with the bivalent (Cervarix), quadrivalent (Gardasil) or nonavalent (Gardasil) prophylactic HPV vaccine.~No intervention/drug to be administered."
89663812|NCT04974918|Experimental|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of Lip defects|participants will be chosen according to liable age and information will be given about complications
89663813|NCT04963998|Experimental|Copper oxide dressings|Treatment of diabetic ulcers that were in a stagnated stage with copper oxide containing wound dressings
89663814|NCT04963608||non-interventional study|Her2 positive ABC patients who have received Inetetamab in the metastatic setting.
89663815|NCT04974450|Experimental|Trigona Honey|The intervention will be given by oral route in a form of liquid of 70-gram trigona honey once daily for 8 weeks
89663816|NCT04974450|Active Comparator|Control|The intervention will be given by oral route in a form of liquid of 70-gram artificial honey once daily for 8 weeks
89213929|NCT00875186||multiple-exercise group (ME)|participants exercised 2 times weekly for 1 hour (aerobic endurance training)
89663817|NCT01451905|Active Comparator|Psoriasis|
89663818|NCT01451905|Placebo Comparator|Placebo|
89663819|NCT04974606|Experimental|Coffeeberry 100 mg beverage|Appearance-matched to the other beverages
89663820|NCT04974606|Experimental|Coffeeberry 300 mg beverage|Appearance-matched to the other beverages
89663821|NCT04974606|Placebo Comparator|Placebo beverage|Appearance-matched to the other beverages
89663822|NCT04974606|Active Comparator|Caffeine 75 mg beverage|Appearance-matched to the other beverages
89663823|NCT02973061||GH treated patients|All participants family member and teacher will fill questionnaires regarding signs of ateention deficit prior to GH treatment and after 6 and 12 months
89663824|NCT02973061||Healthy control|All participants family member and teacher will fill questionnaires regarding signs of atention deficit at baseline and after 6 and 12 months
89663825|NCT04967586||Preclinical medical students|
89663826|NCT04967586||Clinical medical students|
89663827|NCT01455649|Experimental|Everolimus|
89663828|NCT01455649|Active Comparator|calcineurin inhibitor|
89048261|NCT01047540|Experimental|Dose regimen 3|
89663829|NCT04392817|Experimental|the participating group in the intervention|patient complaining of seppch rerrors due t ovelopharyngeal insufficiency and underwent the intervention
89663830|NCT04974294|Active Comparator|PPV23|
89663831|NCT04974294|Active Comparator|PCV13|
89663832|NCT04974294|Placebo Comparator|Saline placebo|
89663833|NCT01452061||ASD|Participants with autism spectrum disorder.
89663834|NCT01452061||ADHD/DD|Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
89663835|NCT01452061||Siblings|Siblings without a developmental or psychiatric disorder.
89663836|NCT01452061||Control|Unrelated individuals without a developmental or psychiatric disorder.
89048262|NCT01047540|Experimental|Dose regimen 4|
89048263|NCT01047540|Placebo Comparator|Placebo|
89048264|NCT00521222|Active Comparator|Arg/Arg genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Arg/Arg genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
89663837|NCT01455727|Experimental|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
89663838|NCT01455727|Active Comparator|Usual care|Patients received usual care directed by their physician.
89663839|NCT04974372||HT group|Patients have echocardiography examination before and after heart transplantation.
89663840|NCT04974372||Control group|healthy volunteers who had no history of hypertension, diabetes mellitus, renal failure or other organic diseases based on physical examinations, biochemical tests, electrocardiogram, echocardiography were enrolled as control group
89663841|NCT01452139|Experimental|At-Risk Genetics Arm: Prasugrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with prasugrel 10mg daily for 1 month.
89663842|NCT01452139|Active Comparator|At-Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with clopidogrel 150mg daily for 1 week followed by 75mg daily.
89663843|NCT01452139|Active Comparator|Low Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients with no at-risk genetic variants with clopidogrel 75mg daily.
89663844|NCT03061578||NDE|"Non Dry Eye (NDE) group will be used as control for DES diagnosis.~Subjects in the non-dry eye criteria must meet all of the following criteria:~Have a Schirmer's Test (without anesthesia) of ≥10mm/5min in both eyes~OSDI questionnaire score <13.~Fluorescein TBUT > 7 s in both eyes.~CFS of 0 in all areas in both eyes.~The NDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
89663845|NCT03061578||ADDE|"Aqueous Deficiency Dry Eye (ADDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe ADDE group, subjects must meet a predefined medical condition (Rheumatoid Arthritis, Dermatomyositis, Lupus or Sjögren's syndrome) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The ADDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
89663846|NCT03061578||LDDE|"Lipid Deficiency Dry Eye (LDDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe LDDE group, subjects must have moderate to severe Meibomian Gland Dysfunction (MGD score of 3-6) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The LDDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
89663847|NCT04852458|Experimental|Intravenous hydrocortisone|
89663848|NCT04852458|No Intervention|Observational|Participants will complete assessments/surveys only.
89663849|NCT01455883|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
89663850|NCT01455883|Active Comparator|glimepiride|glimepiride up-titrated to 8 mg/day over first 13 weeks
89663851|NCT04967040|Active Comparator|group 1 : medial plantar artery flap|
89663852|NCT04967040|Active Comparator|group 2 : distally based sural artery flap|
89663853|NCT01452217|Experimental|Secretin|
89663854|NCT04966650|Experimental|Intervention group|For the intervention group, participants will receive a 5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT). The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms. At the 2nd month, participants will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given a booster intervention. At 6th months, subjects will be assessed their depression symptoms and the level of physical activity changes via questionnaire.
89663855|NCT04966650|No Intervention|Control Group|A wellbeing leaflet from CHP will be provided to each participant. At the 2nd month, subjects will be assessed their depression symptoms via questionnaire, followed up their progress of physical activity changes and given another wellbeing leaflets. At 6th months, subjects will be assessed their depression symptoms the level of physical activity changes via questionnaire.
89663856|NCT01452295|Experimental|AOCH patients|Patients with acute on chronic hepatitis
89663857|NCT01452295|Experimental|AAH patients|Patients with acute alcoholic hepatitis
89663858|NCT04966962||Bladder cancer|Patients who diagnosis with incident or recurrent bladder cancer
89663859|NCT04966962||benign disease of urinary system|Patients who clinically diagnosis with benign disease of the urinary system, such as urinary calculi and benign prostatic hyperplasia.
89663860|NCT04966728||suspected tear of the anterior superior labrum of the hip|One group consisted of patients with suspected tear of the anterior superior labrum of the hip.
89048265|NCT00521222|Active Comparator|Gly/Gly genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Gly/Gly genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
89048266|NCT00521222|Experimental|Arg/Arg genotype on Fluticasone HFA|Asthma patients with the Arg/Arg genotype who are randomized to fluticasone (Flovent HFA) alone.
89048267|NCT00521222|Experimental|Gly/Gly genotype on Fluticasone HFA|Asthma patients with the Gly/Gly genotype who are randomized to fluticasone (Flovent HFA) alone.
89048268|NCT04647201||Control|Non-sepsis and non-GI adults
89048269|NCT04647201||Sepsis patients without GI|Patients who meet the criteria of sepsis3.0 with AGI grade I or less
89048270|NCT04647201||Sepsis patients with GI|Patients who meet the criteria of sepsis3.0 with AGI grade II or above
89048271|NCT00544856|Experimental|1|cognitive intervention
89048272|NCT00544856|Placebo Comparator|2|
89663861|NCT04966728||non-hip joint diseases|For non-hip joint reasons, come to the ultrasound department of our hospital to diagnose patients at the same time, and exclude other past and current hip diseases
89663862|NCT04966572|Experimental|Presurgical vacuum formed nasoalveolar molding aligners group|In this group, all patients will receive 1-2 VF-NAM aligners incorporated with palatal screw in addition to taping from day 1 for 4-6 Months with follow-up every 3 weeks
89663863|NCT04966572|Experimental|conventional Grayson acrylic formed nasoalveolar molding appliances group|This group will receive conventional Grayson acrylic formed nasoalveolar molding appliances without taping except some cases, with follow up every week for activation.
89048273|NCT00560001|Experimental|A|Those subjects that receive an MD.2 Medication Dispenser
89048274|NCT00560001|No Intervention|B|Control subjects that do not receive an MD.2 Medication Dispenser, but continue to take their medications utilizing standard care, such as pill boxes, etc.
89048275|NCT04647045|Active Comparator|IBS-C group|77 constipation-predominant IBS were given three bottles of 125 ml cultured milk drink daily for 30 days
89048276|NCT04647045|Other|Non-IBS group|88 non-IBS subjects (healthy individuals) were given similar probiotics for 30 days.
89048277|NCT00544934|Experimental|250 mg|
89048278|NCT00544934|Experimental|500 mg|
89048279|NCT00544934|Experimental|750 mg|
89048280|NCT00544934|Placebo Comparator|Placebo|
89048281|NCT04647123||Hopeless teeth|The teeth that can not be treated periodontally and who are desperate for extraction will be included in this group.
89048282|NCT04647123||Periodontitis|Teeth diagnosed with periodontitis will be included in this group.
89048283|NCT04647123||Gingivitis|Teeth diagnosed with gingivitis will be included in this group.
89048284|NCT04647123||Healthy|Teeth diagnosed with helthy will be included in this group.
89048285|NCT00545090|Experimental|1|
89048286|NCT00545207|Experimental|1|
89048287|NCT00545207|Placebo Comparator|2|
89048288|NCT04647006|Other|Conventional Thyroidectomy|Conventional Thyroidectomy
89048289|NCT04647006|Active Comparator|Transoral endoscopic thyroidectomy vestibular approach|Transoral endoscopic thyroidectomy vestibular approach
89663864|NCT04966884|Experimental|A single-arm open-label pilot observational study|Patients were received a glucocorticoids (0.8mg-1mg/kg/day) and a combination with tofacitinib (at a dose of 5 mg twice daily).
89663865|NCT04962906|Active Comparator|Gam-COVID-Vac / Gam-COVID-Vac|
89048290|NCT04638504||11-14 weeks of normal pregnancy.|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
89048291|NCT04638504||11-14 week obese pregnant|11-14. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, Visceral adipose tissue measurement (armellini method), and maternal uterine artery dopes will be examined ultrasonographically.
89048292|NCT04638504||24-28 week normal pregnant|24-28. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery, and maternal uterine artery dopes will be examined ultrasonographically.
89048293|NCT04638504||24w-28w obese normal pregnant|24w-28w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
89048294|NCT04638504||37w -40w normal pregant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
89048295|NCT04638504||37-40 w obese normal pregnant|37w-40 w. Measurement of brachial artery flow dilatation in the arm during pregnancy weeks, fetal umbilical artery and maternal uterine artery dopes will be examined ultrasonographically
89048296|NCT04684784|Experimental|Deep Dry Needling|Intervention-Dry Needling: Deep Dry Needing into the latent trigger point of the upper trapezius muscle
89048297|NCT04684784|Placebo Comparator|Sham Dry Needling|Control-Dry Needling: Sham Dry Needling into the latent trigger point of the upper trapezius muscle
89048298|NCT00545246|Experimental|aflibercept + docetaxel|
89663866|NCT04962906|Active Comparator|Gam-COVID-Vac / ChAdOx1 nCoV-19|
89663867|NCT04962906|Active Comparator|Gam-COVID-Vac / BBIBP-CorV|
89663868|NCT04966806|Other|Percentage of Coma and SA to Total ocular HOA|
89663869|NCT04966260|Experimental|Standardized Virtual Reality|Participants in the standard virtual reality (VR) group will choose from the general library of VR experiences. Participants will be asked to select an experience they desire but have never experienced in person. The session will be facilitated by the therapeutic recreation staff on the unit.
89663870|NCT04966260|Experimental|Personalized Virtual Reality|There are two types of personalized VR: 1) Family/friends provide personalized content (e.g., life stories, photos, videos) that will be used during the VR session. Family/friends of participants in the personalized VR group will have the opportunity to upload custom photos, videos, life stories or capture their own 360° footage of family events using a GoPro camera that will be loaned to them for the study. This content will be uploaded to a cloud-based portal. 2) If the family/friends of those in the personalized VR arm are unavailable/unable/unwilling to provide personalized content the participant will select a video from the VR library of an experience that is personally memorable to them, such as their childhood hometown, a favourite vacation destination. The session will be facilitated by the therapeutic recreation staff on the unit.
89663871|NCT04966260|Active Comparator|Two-Dimensional Video|Participants in the active comparator group will choose a two-dimensional video such as a mountain view, ocean view or safari. Participants will view the two-dimensional video on an iPad and the session will be facilitated by the therapeutic recreation staff on the unit.
89663872|NCT03829267|Experimental|eFIT Behavioral Intervention|Intervention: Participants randomized to the eFIT condition will join a 1-hour peer group meeting online each week, called eFIT intervention. They will learn about accountability partners, and use the group as an accountability partner to state and attain physical fitness goals.
89663873|NCT03829267|Active Comparator|eJournal Behavioral Intervention|Intervention: Participants in the eJournal condition will spend 1-hour online each week engaged in an active journaling activity, called eJournal Intervention. They will also receive the same psychoeducational materials online as the eFIT participants are presented in group.
89663874|NCT04954560|Active Comparator|losartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
89663875|NCT04954560|Active Comparator|eprosartan|Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
89663876|NCT04954482||The experimental group|The included specimens were used to establish a new posterior fork reconstruction procedure.
89663877|NCT04954482||The validation group|The included specimens were used to validate the new posterior fork reconstruction procedure.
89663878|NCT04962828|Experimental|Collaboration group|This group of children will have targets and vocabulary that has been designed collaboratively and then the therapist and teacher both reinforce the vocabulary during the week
89663879|NCT04962828|Active Comparator|Non-collaborative group|This group of children will have targets and vocabulary that has been designed collaboratively but they will only be practiced with the therapist during the week
89048299|NCT04638114|Experimental|CAM lesion|Mini-Open DAA Hip Arthroscopy
89048300|NCT04638114|Other|PINCER impingement|Mini-Open DAA Hip Arthroscopy
89048301|NCT00545285|Active Comparator|1|Total hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
89663880|NCT01456117|Experimental|Pioglitazone (Dose 1) QD|
89663881|NCT01456117|Experimental|Pioglitazone (Dose 2) QD|
89663882|NCT01456117|Experimental|Pioglitazone (Dose 3) QD|
89663883|NCT01456117|Placebo Comparator|Placebo QD|
89048302|NCT00545285|Active Comparator|2|Total hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell
89048303|NCT00545285|Active Comparator|3|Total hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell
89048304|NCT00545285|Active Comparator|4|Total hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell
89663884|NCT04962984|Experimental|THAL +|patients with beta thalassemia major, requiring blood transfusion regimen. Additional blood sampling will be performed before and immediately after transfusion (21 millilters and 24 millilters respectively), on the occasion of 3 programed transfusions (consecutive or not).
89663885|NCT04962984|Sham Comparator|THAL -|Patients with beta thalassemia trait, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
89663886|NCT04962984|Sham Comparator|Healthy volunteers|healthy subjects, matched with THAL + for age and gender. An unique blood sampling of 24 millilters will be performed.
89663887|NCT03829345|Experimental|Olaparaib|Olaparib will be given 300mg bd for a 28 day cycle.
89663888|NCT04962750|Experimental|laser therapy|
89663889|NCT04962750|Sham Comparator|Control|
89048305|NCT04637997|Other|Study group 1|Wearing of compression stockings class I between Investigation day 28 to 56. Wearing of compression stockings class II between Investigation day 56 to 84.
89048306|NCT04637997|Other|Study group 2|Wearing of compression stockings class II between Investigation day 28 to 56. Wearing of compression stockings class I between Investigation day 56 to 84.
89663890|NCT03829189|Active Comparator|inulin|
89663891|NCT03829189|Placebo Comparator|maltodextrin|
89663892|NCT03538093|Experimental|Local Stabilization Exercise|Experimental: Local Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as local stabilizers of the core (Transversus Abdominis and Multifidus).
89663893|NCT03538093|Experimental|Global Stabilization Exercise|Experimental: Global Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as global stabilizers of the core (Erector Spinae, Quadratus Lumborum, Abdominal External Oblique, Abdominal Internal Oblique and Rectus Abdominis).
89663894|NCT03538093|Experimental|Mixed Stabilization Exercise|Experimental: Mixed Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of both local and global core stabilizer muscles.
89663895|NCT01456273|Placebo Comparator|A2- Medical consultation + placebo|Traditional medical interview + placebo
89663896|NCT01456273|Active Comparator|B1 - Therapeutic Encounter / Omeprazol|
89663897|NCT01456273|Placebo Comparator|B2 - Therapeutic Encounter / Placebo|
89663898|NCT01456273|Active Comparator|A1- Medical consultation + omeprazole|Traditional medical interview + omeprazole
89663899|NCT04966026||COPD combined with CAP inpatients|(1) CAP meets the diagnostic criteria published in our 2016 CAP diagnosis and treatment guidelines; CPOPD and AECOPD meet the diagnostic criteria published in our 2013 COPD diagnosis and treatment guidelines; (2) age ≧ 18 years. Exclusion criteria: (1) age <18 years; (2) pregnancy; (3) positive human immunodeficiency virus (HIV) antibody; (4) suspected or confirmed tuberculosis or fungal infection of the lung.
89663900|NCT00989261|Experimental|Cohort 1; ≥60 years of age|"Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission <12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
89663901|NCT00989261|Experimental|Cohort 2; ≥18 years of age|"Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
89663902|NCT04966494|Experimental|BOSB Group|This group consumed a common beans and oats snack bar (BOSB) for 8 weeks.
89663903|NCT04966494|No Intervention|Control Group|This group corresponded to hypertriglyceridemic women who does not consume BOSB
89663904|NCT01456351|Experimental|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
88995099|NCT05643079||human, allogeneic cortical bone screw (Shark Screw®)|"medializing calcaneal osteotomy, debridement of the tibialis posterior tendon, and/or transfer of the flexor digitorum longus (FDL) tendon with the following screws:~Shark Screw® (Surgebright-GmbH, 4040 Lichtenberg, Austria)~Versions used:~Shark Screw® diver ø: 5,0 mm, length: 35 mm Shark Screw® diver ø: 5,0 mm, length: 45 mm Shark Screw® tendon ø: 5,0 mm, length: 15 mm"
89663905|NCT01456351|Active Comparator|Fludarabine plus Rituximab|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
88995100|NCT05634577|Experimental|Lead-in Phase|Participants will first have a Lead-in Phase in which participants receive only mitotane. This will be 4 weeks long in most participants. Participants will then begin receiving pembrolizumab.
89048307|NCT03456440||hepatitis C child pugh's class A|patients are examined with MRI
89048308|NCT03456440||normal individuals|controls cases are examined with MRI
89663906|NCT04954170||RCT patients|Patients suffering from rotator cuff injury
89663907|NCT04962282||group 1|Follow-up by telephone for researching compliance of patients receiving exercise prescriptions
89663908|NCT03828877|No Intervention|Group C|Arm: Group C control group. Non-acupuncture group. Gruop C will be Control group.
89663909|NCT03828877|Active Comparator|Group A|Arm: Group A, group of acupuncture Akupunktur will be done with Pres Needle (0.22x1.5 mm) Blood will be taken for the measurement of IL 17 and IL 23 from Group A (Acupuncture) patients 24 hours prior to endovenous ablation procedure. Then, with press needle (0.22x1.5) LU 9 (Taiyuan), LU7 (Lieque), SP 6 (Sanyinjiao) , ST 36 (Zusanli), LI 4 (Hegu) and LIV 3 (Taichong) points will be applied acupuncture.On the 3rd day, patients will be called for control. Blood will also be taken from the blood to measure IL 17, IL 23 values.
89663910|NCT04954404|Experimental|Transcatheter mitral valve repair/replacement|
89663911|NCT03829033|Active Comparator|Radiotherapy delivered with photons|
89663912|NCT03829033|Experimental|Radiotherapy delivered with protons|
89663913|NCT04954092|Experimental|1/10 of full adult dose|
89663914|NCT04954092|Experimental|1/5 of full adult dose|
89663915|NCT04954092|Experimental|Selected dose for second stage of the trial|
89663916|NCT04954092|Placebo Comparator|Placebo for second stage of the trial|
89663917|NCT03013673||HIV|HIV infected individuals residing in VL-endemic areas in Northern Ethiopia
89663918|NCT04965948|Experimental|Active group|Snack enriched with camelina sativa oil
89663919|NCT04965948|Placebo Comparator|Placebo group|Snack no enriched with camelina sativa oil
89663920|NCT01452685|Placebo Comparator|Placebo|
89663921|NCT01452685|Experimental|TAK-385 10 mg QD|
89663922|NCT01452685|Experimental|TAK-385 20 mg QD|
89663923|NCT01452685|Experimental|TAK-385 40 mg QD|
89663924|NCT01452685|Other|Leuplin|
89663925|NCT03059706|Experimental|RegenoGel-OSP™|
89663926|NCT03059706|Placebo Comparator|Placebo|
89663927|NCT04347785||Neurologic deficit|All consecutive patients from a tertiary referral center who underwent CEA for carotid artery stenosis who presented alterations in the neurologic examination after ICA clamping during CEA area selected
89663928|NCT04347785||control|The control patients are submitted to the same procedure but with no neurologic alterations, are consecutively selected. a 1 to 1 ratio is used
89663929|NCT04279925|Experimental|Locally-made Miniplate and screw|Locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia.
89663930|NCT04279925|Active Comparator|Imported Miniplate and screw|Biomet® miniplate 1.5 and screw 1.5 produced by Biomet, included in the Lorenz® Plating System Midface.
89663931|NCT01456429|Experimental|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
89663932|NCT03828565|Active Comparator|ScvO2 group|ScvO2 and Pulse Pressure Variation (PPV) : every 30 min (%) ScvO2 Evolution in case of corrective maneuver (%) PPV evolution in case of filling test (%)
89663933|NCT03828565|No Intervention|Control group|End-systolic Volume (ESV) : every 30 min (mL) ESV evolution in case of filling test (%)
89663934|NCT04953936|Experimental|HMB|The participants will receive oral HMB-enriched nutritional supplements (65 g once daily)
89663935|NCT04953936|Placebo Comparator|Placebo|The participants will receive a placebo (maltodextrin 65 g once daily) with the same package as the intervention.
89663936|NCT01452763|Experimental|TAK-438 10 mg QD|
89663937|NCT01452763|Experimental|TAK-438 20 mg QD|
89663938|NCT01452763|Active Comparator|Lansoprazole 15 mg QD|
89663939|NCT04127279|Experimental|Enriched Cream|The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.
89663940|NCT04127279|Active Comparator|Placebo Cream|Cream devoid of essential oils, self-administered
89663941|NCT04954014|Experimental|BEVACIZUMAB|Patients will receive best available treatment (BAT) for COVID-19 plus single dose bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
88995101|NCT05633628|Experimental|Periodic CGM- Intervention group|The participants in the intervention group will be provided with FreeStyle Libre (Abbott Diabetes Care). Participants wear the sensor and check their glucose level for a period of 28 days (14 days X 2) during week 0-4 and week 10-13.Patient's measurement data from the FreeStyle Libre system will be transferred to the OneTwo Analytics (DDA) analysis tool for an automated analysis and this Insight report will be presented to the participants at visit week 4 (digital) and at visit week 16 (clinical). The diabetes nurse and the patient reviews and discuss trends, patterns, and challenges to support the person's self-management care of their type 2 diabetes. This approach is intended to facilitate communication and patient participation and create the conditions for shared informed decisions and health planning.
88995102|NCT05633628|No Intervention|Self-monitoring of blood glucose, SMBG and usual care - Control Group|The participants in the control group perform SMBG testing as usual including fasting, pre- or post-prandial measurements. They also receive usual care which comprises consultation with physician diabetes specialist or diabetes nurse depending on individual health care needs.
88995103|NCT05632471|Experimental|web-based training for parents in the intervention group|"Parents were given I know digital games training with 10 videos from the website."
89663942|NCT04954014|Active Comparator|BEST AVAILABLE TREATMENT|Patients will receive best available treatment for COVID-19.
89663943|NCT03059628|Experimental|Personalized Normative Feedback group|A personalized normative feedback using a tablet application will be performed after the BTI at ED. The application installed on the patient's smartphone will automatically repeat the PNF, using a local algorithm, once a month over a 6-months period after discharge, and once every two months in the following 6-month period. It will be also possible to perform the PNF on the server website.
89663944|NCT03059628|Other|Control group|The control group will not receive further counseling or information after the baseline BTI at ED. The application installed in this group will be only used for the evaluation questionnaire at 6 and 12 months
89663945|NCT04431882|Experimental|optic nerve sheath fenestration|Leukemic patients mainly those suffering from acute lymphoblastic leukemia.
89663946|NCT05587075|Active Comparator|Control group|The control group was treated with filiform needle.
89663947|NCT05587075|Experimental|Observation group|The observation group was treated with long round needle.
89663948|NCT00988559|Experimental|PMED Delivery - groups 1 and 2|Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
89663949|NCT00988559|Experimental|IM injections - groups 5 and 6|Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
89663950|NCT00988559|Experimental|Intralesional delivery - group 3 and 4|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
89663951|NCT00988559|Experimental|Intralesional delivery + imiquimod - group 7|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
89663952|NCT04962516||Test group|
89663953|NCT04962516||Control group|
89663954|NCT04126967|Other|allo-PBSCT patients with no NGS text|
89663955|NCT01452841|Experimental|Grapefruit Consumption|
89663956|NCT01452841|Active Comparator|Control|
89663957|NCT04962438||Tumor patients using anti-VEGF drugs|
89663958|NCT04127045||IMN-Group|Patients treated with intramedullary nailing
89663959|NCT04127045||HA-Group|Patients treated with Hemiarthroplasty
89663960|NCT04961736||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
89663961|NCT04961736||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
89663962|NCT00988169|Experimental|oral erlotinib and pulsed doses of oral AT-101|This will be an open-label, single institution, phase II trial. The study will assess the efficacy of the combination of the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and the novel pan-Bcl-2 inhibitor, AT-101, in treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations A planned pause of 21 days will be performed after enrollment of the 10th and 20th patient to assess for excessive toxicity.
89663963|NCT04953624||CNAQ≤28|ALS patients with CNAQ ≤ 28
89663964|NCT04953624||CNAQ>28|ALS patients with CNAQ > 28
89663965|NCT02967133|Active Comparator|Arm A|Nivolumab q 14 days until disease progression/toxicity
89663966|NCT02967133|Active Comparator|Arm B|"Nivolumab every 21 days until disease progression~Nab-paclitaxel every 21 days"
89663967|NCT04961892||surgical treatment|Patients with CAI undergoing surgical treatment
89663968|NCT04961892||conservative treatment|Patients with CAI undergoing conservative treatment
89663969|NCT04961970|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin
89663970|NCT04961970|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and cisplatin
89663971|NCT02621749|Active Comparator|CRRT group|the CRRT group receives continuous renal replacement therapy for acute kidney injury
89663972|NCT02621749|Active Comparator|IRRT group|the IRRT group receives intermittent renal replacement therapy after termination of CRRT.
89663973|NCT04953546||ACL group|According to the previous clinical diagnosis, volunteers who has suffered the ACL injury.
89663974|NCT03523897|Active Comparator|Robot Assisted Total Knee Replacement|In addition to expert judgment and hand-eye coordination, the surgeon also relies on a robot in making cuts within the pre-determined diseased areas of the joints and placing the implants. This is made possible by uploading 3-dimensional (3D) images of the knee joints into the robot prior to surgery. The robot uses these 3D images to guide the surgeon during the procedure. The 3D images are obtained from a computerized tomography (CT) scan that combines a series of X-ray images taken from different angles to create cross-sectional images of the bones.
89663975|NCT03523897|Active Comparator|Traditional Total Knee Replacement|The traditional method where the surgeon employs mechanical guides, expert judgment, and natural hand-eye coordination in making the necessary cuts to prepare the bone for the implant as well as in placing the implant.
89663976|NCT04961424||Symptomatic spinal epidural hematoma Group|Patients who performed thoracic decompression surgery and developed neurological deficit after surgery due to the symptomatic spinal epidural hematoma were enrolled into case group.
89663977|NCT04961424||Control group|hose who did not develop the symptomatic spinal epidural hematoma, underwent the same procedures of similar complexity at the same section of thoracic spine in the same period (the same year or the following year) were randomly selected from the pool of patients.
89663978|NCT01456663|Experimental|AFQ056|
89663979|NCT04953468||ANXA2 high expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level ≥6 points were identified as the ANXA2 high expression group
89213930|NCT00875186||Low-exercise group (LE)|participants exercises 1 time weekly for 1 hour (aerobic endurance training)
89663980|NCT04953468||ANXA2 low expression in glioma|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In glioma tissues, samples with expression level <6 points were identified as the ANXA2 low expression group
89663981|NCT04953468||ANXA2 high expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level ≥2 were regarded as the ANXA2 high expression group
88995104|NCT05632471|Other|parents in the control group|No intervention was applied to the parents in the control group.
88995105|NCT05626296||Phlegm-heat syndrome in ischemic stroke|"Phlegm-heat syndrome: the score of Phlegm-dampness syndrome ≥10 with the score of Internal fire syndrome ≥10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke"
88995106|NCT05626296||Non-phlegm-heat syndrome in ischemic stroke|"Non-phlegm-heat syndrome: the score of Phlegm-dampness syndrome <10 with the score of Internal fire syndrome <10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke"
88995107|NCT05626296||Healthy subjects|
88995108|NCT05621564||early breast cancer|no requirements for therapy
88995109|NCT05621564||advanced breast cancer|no requirements for therapy
88995110|NCT05619952|Experimental|White Button Mushroom|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) + 14 grams white button mushroom powder, and a Wegmans Food Market Brand Big Hawaiian bun
89663982|NCT04953468||ANXA2 low expression in PTBE|We plan to grade the dyeing intensity of ANXA2 as follows: level 0 for non-stained, level 1 for lighter colored, level 3 for dark brown, and level 2 for those between the latter two.We planned to divide the staining proportion into 5 grades: grade 0 for those without staining, grade 1 for those with staining proportion < 10%, grade 2 for those with staining proportion ≥10% and < 50%, grade 3 for those with staining proportion ≥50% and < 80%, and grade 4 for those with staining proportion ≥ 80%.Finally, staining intensity grading × staining proportion grading = expression level was calculated In PTBE, samples with expression level <2 were regarded as the ANXA2 low expression group
89663983|NCT01452997|Active Comparator|Ibuprofen Gel|Ibuprofen 5% gel
89663984|NCT01452997|Placebo Comparator|Ibuprofen placebo|K-Y jelly
89663985|NCT01452997|Active Comparator|Eumovate|0.05% w/w clobetasone butyrate
89663986|NCT01452997|Placebo Comparator|Cream Placebo|Aqueous Cream B.P.
89663987|NCT01311687|Experimental|Pomalidomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
89663988|NCT01311687|Active Comparator|High-Dose Dexamethasone|Participants received 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day treatment cycle until disease progression.
89663989|NCT00988091|Placebo Comparator|IA-SA|Each participant received a single intra-articular (IA) injection of buffered saline (SA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they could receive a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and be followed for an additional 26 weeks.
89663990|NCT00988091|Experimental|IA-BioHA|Each participant received a single intra-articular (IA) injection of 1.2% sodium hyaluronate (BioHA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they received a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and were followed for an additional 26 weeks.
89663991|NCT01456741|Experimental|1-EBNA with ROSE|
89663992|NCT01456741|Experimental|1-EBNA without ROSE|
89663993|NCT04965324||Anaesthesia Depth BIS 35|BIS 35
89663994|NCT04965324||Anaesthesia Depth BIS 50|BIS 50
89663995|NCT02965729|Active Comparator|No Pedometer|Participants only participated in the family-based weight management intervention. Participants were not given a pedometer or step goals.
89663996|NCT02965729|Active Comparator|Pedometer Only|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. No step goals were provided.
89663997|NCT02965729|Active Comparator|Pedometer Plus Step Goals|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
89663998|NCT04964856|Experimental|ERAS exercise in perioperative period.|The patients take ERAS exercise from hospitalization to 30 days after operation.
89048309|NCT03456401|Other|Sorafenib or Sunitinib|Sorafenib will be administered at 400 mg bid daily Sunitinib will be administered at 50 mg die orally (4 week on/2 weeks off)
89663999|NCT04964856|Sham Comparator|No ERAS exercise in perioperative period.|The patients do not take ERAS exercise in perioperative period.
89664000|NCT03060252||The overall individuals taking ZGGJ Pill|The overall individuals taking ZGGJ Pill with recommended dosage and achieving the inclusion criteria.
89664001|NCT03060408||Open|Patients underwent open distal pancreatectomy
89664002|NCT03060408||Laparoscopic|Patients underwent laparoscopic distal pancreatectomy
89664003|NCT04961268|Active Comparator|Tramadol 50|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 50 mg in opaque yellow size 000 capsules."
89664004|NCT04961268|Active Comparator|Tramadol 100|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 100 mg in opaque yellow size 000 capsules."
89664005|NCT04961268|Active Comparator|Ibuprofen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg in opaque yellow size 000 capsules."
89664006|NCT04961268|Active Comparator|Ibuprofen/acetaminophen|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg/acetaminophen 1000 mg in opaque yellow size 000 capsules."
89664007|NCT04961268|Placebo Comparator|Placebo|"Before the inferior alveolar nerve block injection by 60 minutes, the patient received Placebo in opaque yellow size 000 capsules."
89664008|NCT03828643||Cases|Cases received secukinumab at the dose 300 mg every 4 weeks from the beginning.
89664009|NCT03828643||Controls|Controls received secukinumab at the dose 300 mg with loading dose at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
89664010|NCT03828409|Active Comparator|Short stitch|short stitch used as one arm
89664011|NCT03828409|Active Comparator|Long stitch|Long stitch as conventional mass-closure technique
89664012|NCT01456819|Experimental|Mononuclear and mesenchymal stem cells|Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells
89664013|NCT01456819|Active Comparator|Mononuclear cells only|Autologous bone marrow-derived mononuclear cells
89664014|NCT01346397||cyclosporine group|cyclosporine group - after alemtuzumab induction cyclosporine was administered
89664015|NCT01346397||tacrolimus group|tacrolimus group - after alemtuzumab induction tacrolimus was administered
89664016|NCT03058302|Experimental|Full CETA|Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
89048310|NCT04638192|Experimental|subject-specific tACS|Constant current (1mA) will be applied for 20min at subject-specific stimulation frequency and latency
89664017|NCT03058302|Experimental|Brief CETA|Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
89664018|NCT03058302|No Intervention|Wait-Control|Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.
89664019|NCT01453231|No Intervention|Control|No surgery
89664020|NCT01453231|Experimental|thighplasty|
89664021|NCT01347255|Experimental|LEO 90100 cutaneous spray ointment|LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).
89664022|NCT01347255|Active Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone|Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)
89664023|NCT01347255|Placebo Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle|LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.
89664024|NCT01347255|Active Comparator|Daivobet® Ointment|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
89664025|NCT01453309|Active Comparator|Cell Saver|Patients will have the use of a cell-saver during surgery
89664026|NCT01453309|Placebo Comparator|No Cell saver|Patient will not have cell saver available during surgery.
89664027|NCT04961346|Experimental|Ultrapro®|Participants received incisional hernia repair with an Ultrapro mesh in a sublay technique.
89664028|NCT04961346|Experimental|Premilene®|Participants received incisional hernia repair with a Premilene mesh in a sublay technique.
89664029|NCT01453465||Ancillary-Correlative (gene expression profile, miRNA profile)|Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
89664030|NCT03009123||Erectile dysfunction group|Group contains men with physician-diagnosed erectile dysfunction
89048311|NCT04638192|Experimental|standard tACS|Constant current (1mA) will be applied for 20min at 20Hz with a fixed 25ms latency
89048312|NCT04638192|Sham Comparator|Sham tACS|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect
89048313|NCT03456362|Active Comparator|Cerebellar iTBS|Intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
89048314|NCT03456362|Sham Comparator|Sham iTBS|Sham intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
89048315|NCT04646538|Experimental|X3 group|
89664031|NCT03009123||General population men without ED|Men 50 years and older having no ED and pre-existing prostate cancer
89664032|NCT03009123||Symptomatic BPH group without ED|Men 50 years old older with symptomatic prostatic hypertrophy but with no ED nor pre-existing prostate cancer
89048316|NCT03456323|Experimental|Palliative Care Consultation|After enrollment the palliative care consultation team will meet with the patient-surrogate pair one or more times to (1) assess symptoms, (2) provide supportive counseling, (3) make symptom treatment recommendations to the primary team of physicians, and (4) will address goals of care.
89048317|NCT03456323|Placebo Comparator|Usual Care|Patient-surrogate pairs randomized to usual care will continue to receive care by their primary physicians without having a palliative care consultation intervention offered.
89048318|NCT04638270|Experimental|anti-CD19 FasT CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.~3×10^5 /KG 6×10^5 /KG 1×10^6/KG"
89048319|NCT00545480|Experimental|1|
89664033|NCT01456975|Experimental|Valsalva|Reimplantation procedure using Valsalva prosthesis
89664034|NCT04961502|Experimental|Elderly person|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
89664035|NCT04961502|Active Comparator|Younger adults (priority caregivers)|Three blood sample: the first carried out before the anti-COVID-19 vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
89664036|NCT04960800|Experimental|Intervention group|The participants in the intervention group will participate in a 12- week specific exercise programme led by an experienced women's health physiotherapist. These groups will take place at a private physiotherapy clinic twice a week. In addition, the participants will carry out a self-managed exercise program twice weekly for the same 12-week period. They will be provided with an exercise diary so that adherence to the intervention can be registered and monitored. This exercise diary will be sent to the participants once a week as an electronic questionnaire; this will ensure that the information recorded is standardized and that the research assistant can aid the participants to register their activity and encourage the participants to adhere to the intervention.
89048320|NCT00545480|Active Comparator|2|
89048321|NCT00545519|Experimental|Dose Level 1|Thymoglobulin 2.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
89048322|NCT00545519|Experimental|Dose Level 2|Thymoglobulin 3.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
89048323|NCT00545519|Experimental|Dose Level 3|Thymoglobulin 4.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
89048324|NCT04637685|Active Comparator|Standard pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 70mmHg
89048325|NCT04637685|Active Comparator|Low or physiological pressure|Infusion pressures during phacoemulsification surgeon using the Alcon active sentry system with the Centurion - 30mmHg
89213931|NCT04687436||Foley catheter group|mechanical cervical ripening
89213932|NCT04687436||Double-balloon group|mechanical cervical ripening
89048326|NCT00545558|Experimental|1|Participants will receive ART consisting of efavirenz and the co-formulation of emtricitabine and tenofovir disoproxil fumarate. If participants are unable to tolerate the treatment, a different regimen will be prescribed.
89048327|NCT04638426|Experimental|Treatment A|HL237 tab. 200mg/day
89048328|NCT04638426|Experimental|Treatment B|HL237 tab. 400mg/day
89048329|NCT04638426|Experimental|Treatment C|HL237 tab. 800mg/day
89048330|NCT04638426|Placebo Comparator|Placebo|Placebo of HL237 tab.
89048331|NCT04646577|Active Comparator|Active|
89048332|NCT04646577|Sham Comparator|Sham|
89048333|NCT04646421||Motivational intervention - clients reached|Gamblers successfully reached with the motivational telephone intervention.
89048334|NCT04646421||Control group: clients not reached for the motivational intervention|Clients aimed to be reached for the same intervention, but who were not reached and therefore were not exposed to the intervention.
89048335|NCT04646421||Prospective intervention group|Clients subject to the prospective study part (target N 200), who are successfully reached by the intervention from November, 2020, and who provide informed consent to the web survey study. Studied as a cohort without control group, but with the pre-intervention situation as their own control condition.
89048336|NCT04684667|Other|Propranolol Therapy|This arm will involve patients with infantile hemangiomas who will be admitted at the Assiut University Children Hospital between January 2021 and December 2021.
89048337|NCT04637919|Experimental|IN-B001 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89048338|NCT04637919|Experimental|IN-B001 CVA16 B dose|Inactivated CVA16 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89048339|NCT04637919|Experimental|IN-B001 Bivalent C dose|Inactivated EV71/CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89048340|NCT00545675|Experimental|1|Abilify(aripiprazole) + Depakote(divalproate)
89048341|NCT00545675|Placebo Comparator|2|Divalproate + Placebo
89048342|NCT00545831|Experimental|A|Use of taurolidine in prevention of bloodstream infection related to central venous access
89048343|NCT00545831|Placebo Comparator|B|Use of Physiologic Serum to compare to arm A
89048344|NCT04637958||pain|THA
89048345|NCT04637958||no pain|THA
89048346|NCT00545870|Experimental|A|Bevacizumab treatment
89048347|NCT00545870|Active Comparator|B|Ranibizumab treatment
89048348|NCT04637451|Experimental|Gingival Unit Graft|For test group, gingival recessions were treated with gingival unit graft.
89048349|NCT04637451|Other|Connective Tissue Graft|For Control group, gingival recessions were treated with connective tissue graft.
89048350|NCT00545909|Experimental|1|
89048351|NCT00545909|Active Comparator|2|
89048352|NCT04637568||Maxillary Deficiency|59 CT scans of patients with maxillary deficiency requiring Le Fort osteotomy
89048353|NCT04637568||Control|61 CT scans of healthy patients
89048354|NCT04637412|Experimental|Control label|"Participant will see a QR code and footnote saying, Scan the QR code for more menu information. The label will be applied to all menu items displayed."
89048355|NCT04637412|Experimental|Icon plus text added sugars label|Participant will see a label containing an icon plus text label with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 18 variations of icons and text in this arm.
89048356|NCT04637412|Experimental|Icon only added sugars label|Participant will see a label containing an icon only with an explanatory footnote. The label will be applied to items high in added sugars (exceeding half the daily value). Participants will randomly view one of 6 variations of icons in this arm.
89048357|NCT05050292|Experimental|Experimental Group|"Activities are designed to target specific cognitive skills (attention, perception, inhibition).~An internal algorithm of the cognitive stimulation platform will adjust the activities' difficulty depending on the participant's performance, always demanding a maximum cognitive effort."
89048358|NCT05050292|Active Comparator|Control Group|"Painting and artistic activities not designed to target specific cognitive skills.~The internal algorithm will be deactivated, so the cognitive stimulation activities will be of constant difficulty throughout the intervention."
89048359|NCT04646304|Other|Objective Feedback (Motion Capture)|Participants in the objective feedback group will receive a report that compares their performance in Set 1 to that of the staff surgeons' using the target interval as a reference. Participants receiving objective feedback will then complete Sets 2 and 3 knowing what factors to improve upon.
89048360|NCT04646304|No Intervention|No Feedback|Participants receiving no feedback will complete all sets with no intervention.
89048361|NCT04645914|No Intervention|No smokers|Healthy subjects who do not consume any nicotine products
89048362|NCT04645914|Experimental|Smokers/Vapers|Healthy subjects who consume nicotine products
89048363|NCT04684433||Surgical intervention|Patients who had a surgical procedure since the start of the lockdown in Belgium due to the COVID19 pandemic (16 of March 2020 to the 12 of April 2020.
89048364|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using Inferior pedicle|Wise pattern reduction mammaplasty using Inferior pedicle
89048365|NCT04646070|Active Comparator|Wise pattern reduction mammaplasty using superomedial pedicle|
89048366|NCT00545987|Active Comparator|intramuscular injection|administration of an HIV-1 vaccine by conventional intramuscular injection
89048367|NCT00545987|Experimental|TriGrid Delivery System|electroporation-mediated intramuscular delivery using the TriGridTM device by Ichor Medical Systems, Inc.
89048368|NCT04637646||children with MPS|
89048369|NCT00546026|Active Comparator|Active group|Receive assessment of placental function
89048370|NCT00546065|Other|ablation of Barretts with concomitant esomeprazole therapy|comparison of recurrence-free survival
89048371|NCT00546065|No Intervention|non ablation|non ablation only surveillance
89048372|NCT00558324|Experimental|I|Corneal flaps were created with mechanical microkeratome (Hansatome 160μm (Chiron Vision Corp, Claremont, Calif)
89213933|NCT04687436||Cook cervical ripening balloon|mechanical cervical ripening
89048373|NCT00558324|Experimental|II|Corneal flaps were created with mechanical microkeratome K3000 130μm ( BD Ophthalmic Systems, Waltham, Mass) .
89048374|NCT00558324|Experimental|III|Corneal flaps were created with microkeratome femtoseconds laser (Intralase Corp, Irvine, Calif.)
89048375|NCT00546143|Experimental|1|Omalizumab 900 mg
89048376|NCT00546143|Experimental|2|Omalizumab 1050 mg
89048377|NCT00546143|Experimental|3|Omalizumab 1200 mg
89048378|NCT04645992|Active Comparator|study group|study group will receive only one session of yoga eye exercise for 20 minutes followed by transcutaneous electrical nerve stimulation by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
89048379|NCT04645992|Sham Comparator|control group|control group will be treated with the same protocol as the study group but with the unit of transcutaneous electrical nerve stimulation is off .
89048380|NCT00546221|Experimental|Psychosocial support|Comprising 22 participants engaging in the experimental exercise programme, exercising with psychosocial support.
89048381|NCT00546221|Active Comparator|Prescribed exercise|Comprising 21 participants engaging in a programme of typical prescribed exercise.
89048382|NCT05037383|Other|Study group|Each participant will be part of the same group, since the study is focusing on the motion and viewing of the operating staff. There are no patient records collected.
89048383|NCT00560079|Experimental|1|Lithium 900mg/day plus allopurinol 600mg/day
89048384|NCT00560079|Active Comparator|2|
89048385|NCT00560079|Placebo Comparator|3|
89048386|NCT04646265|Experimental|periodontal treatment|non-surgical root debridement
89048387|NCT00560157|Active Comparator|I|Sondalis HP
89048388|NCT00560157|Experimental|II|Crucial
89048389|NCT00558402|Experimental|1|Meditation class, 90min/week for 8 weeks, with home assignments, adapted from MBCT program
89048390|NCT00558402|Active Comparator|2|Education
89048391|NCT00558402|Active Comparator|3|Respite care only, 90 mins per week for 8 weeks
89664037|NCT04960800|No Intervention|Control group|The control group will not participate in any exercise intervention. The participants in the control group will be explained the importance of a control group in RCTs and will be recommended to continue with their normal activity levels. They will however, be recommended to follow national guidelines for general exercise during pregnancy and will receive information about these guidelines (15).
89664038|NCT04392661||Laparoscopic Sleeve Gastrectomy (group I)|111 morbid obese females underwent LSG (group I). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
89664039|NCT04392661||Laparoscopic Roux-en-Y Gastric Bypass (group II)|86 morbid obese females underwent LRYGB (group II). After 5 years follow up, the following were looked at: percentage excess weight loss (%EWL), comorbidity improvement or resolution, postoperative complications or mortality, fertility outcomes and breast feeding.
89664040|NCT04953234|Experimental|NovoTTF-100L|Patients receive TTFields using the NovoTTF-100L System together with COVID-19 best standard of care
89664041|NCT04952454|Active Comparator|External DCR|Patients treated with External DCR for functional epiphora
89664042|NCT04952454|Active Comparator|Endonasal DCR|Patients treated with Endonasal DCR for functional epiphora
89664043|NCT04952454|Active Comparator|Transcanalicular DCR|Patients treated with Transcanalicular DCR for functional epiphora
89664044|NCT04392427|Active Comparator|INTERVENTION|"*Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :"
89664045|NCT04392427|No Intervention|CONTROL|"B) Control group: will not receive nothing~Data collection will include: sociodemographic data, clinical history, results of follow up (daily or according to clinical situation )~Follow-up: to record any side effects of drugs, swab will be taken for PCR"
89664046|NCT04960878|Placebo Comparator|Placebo|1.5 g maltodextrin in a sachet once daily for 8 weeks.
89664047|NCT04960878|Experimental|Synbiotic|1.5 g synbiotics supplement of Lactobacillus rhamnosus HN001 (1.5×10^11 CFU) , Bifidobacterium lactis HN019 (7.5×10^10 CFU), and 500mg fructooligosaccharides in a sachet once daily for 8 weeks.
89664048|NCT01453543|Experimental|Deep transverse friction massage|Massage technique will be used.
89664049|NCT04432038||General population of adults from about 30 countries|Data will be collected in general population of adults from about 30 countries. Questionnaires contain also questions about the occurrence of chronic illnesses, being a professional athlete, etc. to control all such aspects.
89664050|NCT04432038||General population of adults from Poland|
89664051|NCT04432038||General population of adults from Germany|
89664052|NCT04432038||General population of adults from China|
89664053|NCT04432038||General population of adults from Vietnam|
89664054|NCT04432038||General population of adults from Spain|
89664055|NCT04432038||General population of adults from Brazil|
89664056|NCT04432038||General population of adults from Croatia|
89664057|NCT04432038||General population of adults from Ethiopia|
89664058|NCT04432038||General population of adults from France|
89048392|NCT04637607|Experimental|Ear-Acupressure Group|The subjects will receive true auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive sham auricular acupoints stimulation.
89048393|NCT04637607|Sham Comparator|Sham-Acupressure Group|The subjects will receive sham auricular acupoints stimulation with the attachment of Vaccaria seeds during the first round of play. After finishing the first round, the subjects will receive true auricular acupoints stimulation. (Crossover)
89048394|NCT00558441|Experimental|1|
89048395|NCT00558480|Active Comparator|1|Vitamin A
89048396|NCT00558480|Placebo Comparator|2|Vitamin A placebo
89213934|NCT00475852|Experimental|001|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
89664059|NCT04432038||General population of adults from Indonesia|
89664060|NCT04432038||General population of adults from Iran|
89664061|NCT04432038||General population of adults from Sri Lanka|
89664062|NCT04432038||General population of adults from USA|
89664063|NCT04432038||General population of adults from Italy|
89213935|NCT00475852|Placebo Comparator|002|Placebo matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
89664064|NCT04432038||General population of adults from South Africa|
89664065|NCT04432038||General population of adults from Portugal|
89664066|NCT04432038||General population of adults from Norway|
89664067|NCT04432038||General population of adults from Lithuania|
89664068|NCT04432038||General population of adults from Romania|
89664069|NCT04432038||General population of adults from Pakistan|
89664070|NCT04432038||General population of adults from Ukraine|
89664071|NCT04432038||General population of adults from India|
89664072|NCT04432038||General population of adults from Japan|
89664073|NCT04432038||General population of adults from Russia|
89664074|NCT04432038||General population of adults from Bangladesh|
89664075|NCT04432038||General population of adults from Nigeria|
89664076|NCT04432038||General population of adults from Egypt|
89664077|NCT03057990|Experimental|Pyrimethamine Treatment (Intra-patient)|50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
89664078|NCT01453621|Experimental|Clinical decision support (post-intervention phase)|Clinicians will receive computerized clinical decision support regarding the risk of clinically important traumatic brain injury (TBI) based on the prediction rules
89664079|NCT01453621|No Intervention|Standard care (pre-intervention phase)|Prior to implementation of the computerized clinical decision support, we will collect data to determine the baseline rate of CT use for children with minor blunt head trauma at very low risk of clinically-important traumatic brain injuries.
89664080|NCT01457365||subjects|it is a cross-sectional research and there is only one group.
89664081|NCT04944264|Active Comparator|Immediate start|Behavioral: Stress Management and Resiliency Training (SMART) program
89664082|NCT04944264|Active Comparator|Delayed start|Wait time control
89664083|NCT01312233|Active Comparator|Medical Care|Conventional medical care alone
89664084|NCT01312233|Active Comparator|Dual Care|Unlinked co-occurrence of conventional medical care and chiropractic care
89664085|NCT01312233|Active Comparator|Shared Care|Co-management of medical care and chiropractic care
89664086|NCT04944342||Individuals who have had COVID-19.|Individuals who have had COVID-19 and who treated by a standart medical treatment at home.
89664087|NCT04944342||Individuals who have not a COVID-19 illness history.|Individuals who have not a COVID-19 illness history.
89664088|NCT01455337|Active Comparator|prednisolone|
89664089|NCT01455337|Experimental|pentoxifylline|
89664090|NCT01347333|Other|liver metastases|Oligometastases (1-3) with aggregate tumor diameter < 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
89213936|NCT00875264|Experimental|1|At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days.
89213937|NCT01017484|Experimental|DASH|The Dietary Approaches to Stop Hypertension Dietary pattern.
89213938|NCT01017484|Experimental|Control|The typical American diet as estimated from the NHANES survey.
89213939|NCT00141271|Active Comparator|20-40mg BID arm|
89213940|NCT00141271|Active Comparator|60-80mg bid arm|
89213941|NCT00141271|Placebo Comparator|Placebo|
89664091|NCT01347333|Other|Primary Liver Tumors|Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
89664092|NCT03059316|Active Comparator|nitroglycerin group|this group will receive nitroglycerin infusion for controlled hypotension.0.5-5ug/kg/min to keep MAP 55-65mmhg then Massimo device will be attached to the patients when MAP reached the desired level
89664093|NCT03059316|Active Comparator|labetalol group|this group will receive labetalol infusion fo controlled hypotension 0.4-3mg/kg/hr to keep MAP 55-65mmhg.then Massimo device will be attached to the patients when MAP reached the desired level
89664094|NCT01890499|Experimental|Low residue diet arm|"Two arm randomized controlled trial. First arm is the Clear feeds on postoperative day one arm.~The second arm (interventional arm) is the Low Residue diet on postoperative day one arm."
89664095|NCT01890499|Active Comparator|Clear feeds arm|Standard of care is to start clear feeds on postoperative day one for elective colorectal surgery patients.
89664096|NCT04951830||control group|NORMAL TMJ
89664097|NCT04951830||Study group|patients with TMJ internal derangement
89664098|NCT01455571|Experimental|HM781-36B|Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...
89664099|NCT01312389|Experimental|Phase 2: Arm A|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions.
89664100|NCT01312389|Experimental|Phase 2: Arm B|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions, administered in combination with intravenous Ampligen.
89664101|NCT01312389|Experimental|Phase 1|3 patients will be enrolled receiving the vaccine (tumor lysate/Montanide) plus Ampligen using a 3+3 approach. If no DLTs in the first three subjects, we will move to phase II; if one 1/3 subject develops DLTs, we will enroll 3 additional subjects; if 2/6 subjects develop DLTs, we will discontinue the study. Following completion of run---in phase I (3 or 6 subjects), we will transition to Phase 2.
89664102|NCT01457599||Marking Liver|
89664103|NCT02816983||SBRT for oligometastatic prostate cancer|
89664104|NCT01350453|Experimental|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
89664105|NCT01350453|Active Comparator|Standard Care|Participants received their usual care which included home exercises
89664106|NCT03009279||The MS group|Patients with metabolic syndrome(MS).
89664107|NCT03009279||The non-MS group|Patients without metabolic syndrome(MS).
89664108|NCT03009357||thyrotoxicosis|patients with newly detected or recurrent thyrotoxicosis
89664109|NCT03009357||control|euthyroid, healthy adults
89664110|NCT04159038|Experimental|Immediate Intervention Group|Parents in the immediate intervention arm sign a study consent that is integrated into the WIC Referral Form. They also complete a brief demographic survey. No consent is necessary in the delayed intervention arm as only aggregate information will be reported to the study team by EI/ECSE. EI/ECSE referrals are tracked from clinics in both arms for 6 months in ecWeb. At the end of the data collection period, the study team will meet to refine the intervention based on the experience with the immediate intervention group. Qualitative Interviews will take place with WIC staff, parents who indicate interest, EI/ECSE staff, and primary care providers during and after the post-intervention data collection period.
89664111|NCT04159038|Other|Delayed Intervention Group|6 months after the immediate intervention group receives their training, the delayed intervention group will receive the training. Prior to implementation of the training in the delayed intervention group, the study team will meet with the Stakeholder Advisory Board. It will review interim results and consider the efficacy of the intervention as a whole. Based on actual use patterns and stakeholder feedback, the investigators will make improvements to the intervention prior to implementing it in the delayed intervention group.
89664112|NCT01351077|Experimental|CHICA DevScreen Module|This arm will get the CHICA Developmental Screening Module
89664113|NCT01351077|No Intervention|CHICA DevScreen Control|This arm will get CHICA without the developmental screening module
89664114|NCT04951908||control group|NORMAL TMJ
89664115|NCT04951908||Study group|Patients with TMJ internal derangement
89664116|NCT03059550||cardiac rehabilitation|Patients reffered to cardiac Rehabilitation after an acute coronary syndrome
89664117|NCT03059550||Whole French population post-ACS|The whole French population who presented an acute coronary syndrome (ACS) in the years 2013 and 2014.
89664118|NCT03058380||Stated-Preferences Evaluation Group|A stated-preferences evaluation instrument will be provided to participants with knee pain in the Stated-Preferences Evaluation Group. The instrument will measure patient preferences for total knee replacement versus unicompartmental knee replacement.
89664119|NCT01352637|Placebo Comparator|Placebo + Prolonged Imaginal Exposure|Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment
89664120|NCT01352637|Placebo Comparator|Placebo + VR exposure|Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
89664121|NCT01352637|Active Comparator|DCS + Prolonged Imaginal Exposure|Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment
89664122|NCT01352637|Active Comparator|DCS+VR exposure|Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment
89664123|NCT03058536|Active Comparator|Progesterone|400 mg micronized vaginal progesterone daily from randomization to 36 weeks
89664124|NCT03058536|Active Comparator|Arabin Pessary and Progesterone|"Arabin Pessary and Natural Micronized Progesterone~400 mg micronized vaginal progesterone daily from randomization to 36 weeks~The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone."
89664125|NCT03058536|Active Comparator|Arabin Pessary|The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
89664126|NCT03058536|No Intervention|No intervention|Expectant management
89664127|NCT01890655|Experimental|MT-1303-Low|MT-1303-Low Dose
89664128|NCT01890655|Experimental|MT-1303-Middle|MT-1303-Middle Dose
89664129|NCT01890655|Experimental|MT-1303-High|MT-1303-High Dose
89664130|NCT01314417|Experimental|Methotrexate|400 μg/100 μL injection
89664131|NCT01457911|Experimental|AMARYL M (Glimepiride and Metformin hydrochloride combination)|AMARYL M at a dosage regimen from 1 tablet to 6 tablets, once during a meal or twice during a meal
89664132|NCT01457911|Active Comparator|AMARYL (Glimepiride)|AMARYL at a dosage regimen from 1 mg to 6 mg, once during a meal or twice during a meal
89664133|NCT03058458|Experimental|SAD PIN201104 in Healthy Volunteers (HV)|PIN201104 or placebo IV administration, single dose, 10 dose cohorts
89664134|NCT03058458|Experimental|Repeat dose PIN201104 in HV|PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort
89664135|NCT03058458|Experimental|Single dose PIN201104 in asthma patients|PIN201104 or placebo IV administration, single dose, 2 cohorts
89664136|NCT03058458|Experimental|Single SC dose in HV|PIN201104 or placebo SC administration, single dose, 1 cohort
89048397|NCT04637100|Experimental|Experimental|The patient will utilize their personal mobile or tablet device to play a pre-selected set of problem-solving games for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
89048398|NCT04637100|Active Comparator|Control|The patient will utilize their personal mobile or tablet device to watch a pre-selected set of stroke-related educational videos for a goal of 1 hour daily for the duration of their inpatient rehabilitation stay (approximately 3 weeks).
89048399|NCT00546611|Active Comparator|1|Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.
89048400|NCT04637490|Experimental|patellar resurfacing|patellar resurfacing in TKA
89048401|NCT04637490|No Intervention|non-resurfacing|non-resurfacing TKA
89048402|NCT04645875|Experimental|Sit regimen|Participants will be instructed to restrict walking and standing to ≤1 h/day each (total ≤2 h/day ) and the remainder of the waking day will be seated apart from visiting the toilet.
89213942|NCT01017562||condition of joint implant|
89213943|NCT01017640|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID in the absence of disease progression or unacceptable toxicity.
89664137|NCT04943718|Experimental|personalized vaccine|patients with recurrent malignant gliomas enrolled into this arm will receive the personalized vaccine through sub-cutaneous.
89664138|NCT02983123||1 hour-troponin|1-hour troponin collected of all recruited patients in addition to the daily routine with serial troponins collected at 0- and 4/6 hours.
89664139|NCT04960410||Low air pollution|
89664140|NCT04960410||High air pollution|
89664141|NCT01314963|Experimental|Intraoperative handheld Gamma Camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC)
89664142|NCT01314963|Active Comparator|Gamma probes (GP)|Standard of care intraoperative gamma probes (GP) currently in use.
89664143|NCT01890733|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridment, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
89664144|NCT01890733|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridment, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
89664145|NCT04943640|Experimental|kinesio taping|"The patient was advised to clean the skin with alcohol and shave the hairy areas. The standing patient was asked to take off high heels if he/she was wearing them.~The paravertebral technique was used with 5 cm x 5 m kinesio tape material. While the patient was standing in an upright position, two longitudinal pieces were cut by taking the tape and slightly rolling its corners. The patient was asked to lean forward. The lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. The patient was asked to do a slight rotation to the left, and while in this position, the tape was attached to T11-T12 without stretching at all. Kinesio tape was attached to the opposite side of the vertebrae with the same procedure."
89664146|NCT04943640|Experimental|rigid taping|The patient was asked to lean forward, and 5 cm x 5 m rigid tape material was used in the right paravertebral region. When bonding the tape, first, the lower end of the tape was attached 7 cm below the sacroiliac joint at the level of the paravertebral muscles and the patient was bent forward. Then, the patient was asked to do a slight rotation to the left, and while in this position, the hypoallergenic tape (beta fix) was applied with no tension [23]. Then, rigid tape was applied upward onto the paravertebral muscles. The left paravertebral region was taped with the same procedure as the right paravertebral region .
89664147|NCT04943640|Placebo Comparator|placebo taping groups|"Placebo taping was applied to patients in this group using betafix, an elastic stabilization tape, as material. A straight line of betafix was applied to the non-painful scapular inferior alignment of the spine, right and left, while the patient was standing upright.~Treatment with taping was administered to all groups every 2 days by the same physiotherapist ."
89664148|NCT01890811|Experimental|Boost High Protein|Boost high protein with added spirulina
89664149|NCT01353495|Experimental|APM Graft (BIOTAPE XMTM|graft applied to wound q 3 weeks for 12 weeks
89664150|NCT01353495|Active Comparator|standard wound care|Wound debridement and gels and foams applied to wound weekly for 12 weeks.
89664151|NCT04951674|Experimental|DIET|Participants will receive four individual, approximately 30-minute long dietary education sessions. The participants will receive detailed instructions (including meal plans, information on high fiber foods and serving sizes) on how to consume at least 30 grams of fiber per day.
89664152|NCT04951674|Placebo Comparator|CONTROL|No diet education. Group will spend same amount of time with study dietitian, but discussion is limited to review of current eating habits and minimal input on eating habits with referencing the standard food pyramid.
89664153|NCT02893423|Active Comparator|Group 1 - 0.5% Ropivacaine|Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin
89664154|NCT02893423|Active Comparator|Group 2 - 0.25% Ropivacaine|Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin
89664155|NCT02893423|No Intervention|Group 3 - No Tap Block|Patients will not receive a TAP BLOCK
89664156|NCT05586919|Active Comparator|Direct Puncture Repair / Ethanol|
89664157|NCT05586919|Active Comparator|Direct Puncture Repair / Polidocanol|
89664158|NCT01354197||All ICU admission patients|All ICU admission to surgical intensive care unit at cohort time
89664159|NCT04951440|Experimental|Intervention group|"Intervention group: 30min intravenous point. Infusion of 1400 mg of tetranitrone was given to bed I with a dose of 100ml, twice a day, with an interval of 12 hours, and continued administration for 7 days, that is, a total of about 14 times.~version"
88995111|NCT05619952|Experimental|Shiitake Mushroom|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) + 14 grams Shiitake mushroom powder, and a Wegmans Food Market Brand Big Hawaiian bun
88995112|NCT05619952|No Intervention|Control|368.5 grams of irradiated ground beef patty (80/20 lean mass to fat ratio) and a Wegmans Food Market Brand Big Hawaiian bun.
88995113|NCT05617183|Experimental|CT-P47 Auto-injector|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
88995114|NCT05617183|Active Comparator|CT-P47 Pre-filled Syringe|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
88995115|NCT05616260|Experimental|Acetazolamide, then Placebo, then optional open-label CPAP-therapy|"Subjects will start with a 2-week ACETAZOLAMIDE regimen~Day 1-13: Acetazolamide 500mg at bedtime at home~Day 14: Acetazolamide 500mg at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 2-week PLACEBO regimen:~Day 1-13: Placebo (matching Acetazolamide 500mg) at bedtime at home~Day 14: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory~After a wash-out period, subjects may then undergo an OPTIONAL, OPEN-LABEL 2-week CPAP regimen:~- Day 1-14: CPAP will be used at home during sleep"
88995116|NCT05616260|Experimental|Placebo, then Acetazolamide, then optional open-label CPAP-therapy|"Subjects will start with a 2-week PLACEBO regimen~Day 1-13: Placebo (matching Acetazolamide 500mg) at bedtime at home~Day 14: Placebo (matching Acetazolamide 500mg) at bedtime in the sleep laboratory~After a wash-out period, subjects will then cross-over to a 2-week ACETAZOLAMIDE regimen:~Day 1-13: Acetazolamide 500mg at bedtime at home~Day 14: Acetazolamide 500mg at bedtime in the sleep laboratory~After a wash-out period, subjects may then undergo an OPTIONAL, OPEN-LABEL 2-week CPAP regimen:~- Day 1-14: CPAP will be used at home during sleep"
88995117|NCT05615753|Experimental|Acupuncture group|Participants will receive 2 acupuncture treatments each week for 5 weeks, for a total of 10 treatments. Each acupuncture treatment will take 30 minutes.
88995118|NCT05615753|No Intervention|Usual care group|Participants will continue to receive their usual care.
88995119|NCT05611034|Experimental|IVLP in single lung|
88995120|NCT05592509|Active Comparator|Supplement|This arm will take dietary supplement
88995121|NCT05592509|Placebo Comparator|Placebo|Placebo will take the placebo
88995122|NCT05582213|Other|classic group (CL group)|20 patients will be enrolled to induction with sevofloran as inhalational anesthetics
89664160|NCT04951440|Placebo Comparator|Placebo group|Placebo group: 30 minutes to earn pulse, I, 1, and dripping Yunmi gave 100mL placebo (sodium chloride injection). It is administered twice a day for 1 to 2 hours, and the pattern is transferred to about 7 people, that is, about 14 times in total.
89664161|NCT01890889|Active Comparator|Ad-Chol-Pre|A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
89664162|NCT01890889|Active Comparator|Half-dose Ad-Chol-Pre|A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
89664163|NCT01890889|Placebo Comparator|Capsule containing inactive component of defatted egg yolk|Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
89664164|NCT04951752||Hemicolectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
89664165|NCT04951752||Hemicolectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
89664166|NCT04951752||Nephrectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
89664167|NCT04951752||Nephrectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
89664168|NCT04951752||Percutaneous nephrolithotomy, Active treatment|1x30mL 0.75% Ropivacaine administered by way of transmuscular quadratus lumborum block
89664169|NCT04951752||Percutaneous nephrolithotomy, Placebo treatment|1x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
89664170|NCT04951752||Hysterectomy, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
89664171|NCT04951752||Hysterectomy, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
89664172|NCT04951752||Elective Caesarean section, Active treatment|2x30mL 0.375% Ropivacaine administered by way of transmuscular quadratus lumborum block
89664173|NCT04951752||Elective Caesarean section, Placebo treatment|2x30mL isotonic saline administered by way of transmuscular quadratus lumborum block
89664174|NCT01455493|Experimental|A|
89664175|NCT04960098||patient underwent hip and knee arthroplasty|Patients with hip and knee osteoarthritis underwent hip and knee arthroplasty included in inclusion criteria.
89664176|NCT01315665|Experimental|Healthy volunteers|100 grams of raw broccoli sprouts once daily for 5 consecutive days
89664177|NCT01315665|Experimental|Subjects with cystic fibrosis|100 grams of raw broccoli sprouts once daily for 5 consecutive days
89664178|NCT04943016|Experimental|CD19 Chimeric Antigen Receptor (CAR) T Cells|The dose is escalated in standard 3 +3 design with a starting dose of 1x10^6 cell/kilogram and maximum treatment dose of 5 x 10^6 cell/kilogram. The minimum number of 9 subjects would occur if no dose-limiting toxicities are observed in the 3 dose escalation cohorts. The maximum sample size of 18 subjects would be enrolled in 3 dose escalation cohorts (six in each cohort) for meeting dose-limiting toxicities request. In addition, we hypothesize that we will be able to successfully manufacture CAR T cells to meet the established release criteria at a minimum target dose of 1 X 106 +-30% cells/kilogram in this patient population using the Miltenyi CliniMACS Prodigy® closed transduction system.
89664179|NCT01454089|Experimental|OGX-427 600 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (600 mg)
89664180|NCT01454089|Experimental|OGX-427 1000 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (1000 mg)
89664181|NCT01454089|Active Comparator|Placebo|Standard chemotherapy (gemcitabine and cisplatin) in combination with placebo
89664182|NCT04960020||ACL injuries with e-scooter trauma|
89664183|NCT04942548|Experimental|HFpEF|Patients diagnosed with obesity related heart failure with preserved ejection fraction(HFpEF)
89664184|NCT04942548|Experimental|PH-HFpEF|Patients diagnosed with obesity related pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF)
89664185|NCT01356147|Sham Comparator|Sham placebo|No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
89664186|NCT01356147|Active Comparator|Dornase alfa|Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
89664187|NCT01457989||retigabine/ezogabine|retigabine/ezogabine; dose range up to 1200 mg/day
89664188|NCT04959942|Experimental|scapular stabilization exercise|the subjects will receive scapular stabilization exercise + postural correction exercise and advice three times per week for 10 weeks
89664189|NCT04959942|Experimental|postural correction exercise|the subjects will receive postural correction exercise and advice three times per week for 10 weeks
89664190|NCT04959942|Active Comparator|advice|the subjects will receive advice three times per week for 10 weeks
89664191|NCT01458067|Experimental|Part 1|GSK2636771 single dose and then daily dosing after approximately 1 week
89664192|NCT01458067|Experimental|Part 2|GSK2636771 single dose and then daily dosing starting on Day 4
89664193|NCT01458067|Experimental|Part 3|GSK2636771 daily dosing
89664194|NCT01458223|Active Comparator|Control|24 hours post-operative antibiotics
89664195|NCT01458223|Experimental|experimental|72 hours of post-operative antibiotics
89664196|NCT04959786|Experimental|INTERVENTION ARM|
89664197|NCT04959786|No Intervention|standard of care|
89664198|NCT01452451|Placebo Comparator|Placebo|Placebo
89664199|NCT01452451|Active Comparator|HM11260C|HM11260C
89664200|NCT03057912|Experimental|TALEN|TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.
89664201|NCT03057912|Experimental|CRISPR/Cas9|CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.
89664202|NCT03057912|No Intervention|Control group|Observation
89213944|NCT01017640|Experimental|Arm II (veliparib and mitomycin C)|Patients receive veliparib PO BID on days 1-7, 1-14, or 1-21. Patients also receive mitomycin C IV over 10-20 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89213945|NCT00614120|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg + metformin + glimepiride placebo
89213946|NCT00614120|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg + metformin + glimepiride placebo
89213947|NCT00614120|Experimental|Lira 1.8 + Met|Liraglutide + metformin + glimepiride placebo
89213948|NCT00614120|Experimental|Glim + Met|Glimepiride 4.0 mg + metformin + liraglutide placebo
89213949|NCT00496054|Experimental|RotaTeq™ Vaccine (V260)|Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.
89213950|NCT00881192|No Intervention|Control|No preoperative IABP; if needed, postoperative IABP placement
89213951|NCT00881192|Active Comparator|IABP|Preoperative IABP placement
88995123|NCT05582213|Other|Group ketamine:|This group includes (20) patients will receive ketamine 2 mg/kg intravenous for induction of sedation and unconsciousness
88995124|NCT05579080||NIV group|group that performed only non-invasive ventilation
88995125|NCT05579080||HFNC group|group that performed only oxygen therapy by high flow nasal cannula
88995126|NCT05579080||NIV and HFNC group|group that used non-invasive ventilation and oxygen therapy by high flow nasal cannula
88995127|NCT05579080||conventional oxygen therapy group|group that used only conventional oxygen therapy low-flow oxygen therapy.
88995128|NCT05550922|Experimental|Healthcare transition based education|The content of the education program and interviews include: the importance of transition readiness from pediatric to adult care; asthma, asthma management, asthma support groups and literature; asthma self-management skills (making appointments, taking medications regularly, knowing the risks and what to do during an asthma attack, visiting doctors alone, getting a prescription, communicating with health care professionals); filling out medical forms; insurance; decision making, autonomy, career plans; characteristics of adolescence; pediatrics and adult care differences; transition planning; discussions on case studies; knowledge and skills related to adult pulmonology service procedures; interview with pediatric and adult pulmonologists.
88995129|NCT05550922|No Intervention|No Intervention|Control: Not all control group participants will receive health care transition-based training. The control group will receive standard outpatient clinic asthma treatment during this process.
88995130|NCT05550597|Experimental|Group F|The intrathecal additive Fentanyl with hyperbaric bupivacaine
88995131|NCT05550597|Experimental|Group FT|The intrathecal additive of fentanyl with hyperbaric bupivacaine along with Ultrasound-guided TAP block
88995132|NCT05550597|Experimental|Group T|Hyperbaric bupivacaine along with Ultrasound-guided TAP block without the intrathecal addition of fentanyl
88995133|NCT05548140|Experimental|NOVEL MOTORIZED SPIRAL ENTEROSCOPY|This arm involves performance of spiral enteroscopy using a specialized enteroscope under general anaesthesia in patients who fulfill the inclusion criteria.
88995134|NCT05548140|Active Comparator|SINGLE BALLOON ENTEROSCOPY|This arm involves performance of single balloon enteroscopy using a specialized single balloon enteroscope in patients who fulfill inclusion criteria.
88995135|NCT05537662|Experimental|Subjects using Neuromodulation Therapy (SCS or DRG)|Patients will trial standard of care neuromodulation therapy (SCS or DRG), and if successful will proceed to a permanent implant.
89213952|NCT00495820|Experimental|Arm 1|Methylphenidate
89213953|NCT00495820|Placebo Comparator|Arm 2|Placebo
89213954|NCT00883376||1|OSAS patients
89664203|NCT04942782|Experimental|lumbopelvic stabilization exercises|the patients will receive trunk stabilization exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
89664204|NCT04942782|Experimental|Pilates exercises|the patients will receive trunk pilates exercise +strengthening exercises for the abdominal, back, and hip muscles three times/ week for three months
89664205|NCT04942782|Active Comparator|conventional therapy|the patients will receive trunk stabilization exercise three times/ week for three months
89664206|NCT04272229|Active Comparator|Control Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
89664207|NCT04272229|Experimental|Migrain Group|Cognitive tests will be performed to check if cognition is impaired in patients with migraine compared to healthy control. An R-R ECG recording will be recorded to evaluate the heart rate variability and then the sympathetic nervous system activation. Concentration and attention will be recorded with the MindWave headset during all cognitive tests.
89664208|NCT04951128|Experimental|Tranexamic acid arm|Eyelid(s) that received tranexamic acid in the local anesthetic
89664209|NCT04951128|Active Comparator|Control|Eyelid(s) that receive local anesthetic without tranexamic acid
89664210|NCT01458301|Placebo Comparator|Placebo|
89664211|NCT01458301|Experimental|TAK-385 10 mg QD|
89664212|NCT01458301|Experimental|TAK-385 20 mg QD|
89664213|NCT01458301|Experimental|TAK-385 40 mg QD|
89664214|NCT01458301|Other|Leuplin|
89664215|NCT04959630|Other|Group A|Group A received first five patient cases and 3D models via DI and another five cases in the VR environment
89664216|NCT04959630|Other|Group B|Group B received first five patient cases and 3D models via VR and another five cases in the DI.
89664217|NCT04960488|Experimental|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
89664218|NCT04960488|Active Comparator|carotid endarterectomy|carotid endarterectomy
89664219|NCT03059238|Experimental|Celecoxib group|Celecoxib 200mg oral capsule, 200 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
89664220|NCT03059238|Experimental|Parecoxib group|Parecoxib sodium , 40 mg, dissolved in 3 mL 0.9% sodium chloride intravenously one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
89664221|NCT03059238|Experimental|Oxycodone group|Controlled-release oxycodone, 10 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
89213955|NCT00883376||2|no OSAS patients
89213956|NCT04387240|Experimental|intervention group|this group will receive the Artemisinin / Artesunate 100mg once daily for 5 days
89664222|NCT04950738|Experimental|Acupuncture with press tack needle group (Acu)|Patients in acupuncture group will receive traditional Chinese acupuncture using Press Tack Needle (PYONEX 0.20 x l.5mm made by Seirin Corporation). The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), LI 4 (He Gu), SP 3 (Tai Bai,) ST 44 (Nei ting), LIV 3 (Tai Chong). The treatment will use bilateral acupuncture Interventions will be given on day 1, 3, and 5 after patient's enrolment.
89664223|NCT04950738|Placebo Comparator|Placebo group press tack placebo (Con)|Patients randomized to the control group will receive a press lack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to the acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), LU 9 (Tai yuan), L1 4 (He Gu), SP 3; (Tat Bai), ST 44 (Ne1 tmg), LIV 3 (Tat Chong). Interventions will be given on days 1, 3, and 5 after the patient's enrolment.
89664224|NCT04272307||Acute Severe Ulcerative Colitis group|
89213957|NCT04387240|Placebo Comparator|placibo|this group will receive a placebo of the same shape and picture of the study drug
89213958|NCT05203328|Experimental|High flow nasal cannula oxygen|High flow nasal cannula oxygen will be provided during the procedure using a Vapotherm device
89213959|NCT05203328|Active Comparator|Regular nasal cannula|Regular nasal cannula oxygen will be provided during the procedure
89664225|NCT04272307||Non-severe Ulcerative Colitis group|
89664226|NCT04942392|Experimental|digital dance for PD|
89664227|NCT04942314||Complete remission off therapy|"no clinical activity and serological activity~stop taking corticosteroid and immunosuppressive drugs~antimalarials allowed"
89664228|NCT04942314||Complete remission on therapy|"no clinical activity and serological activity~corticosteroid≤5 mg/day and immunosuppressive drugs allowed~antimalarials allowed"
89664229|NCT04942314||Clinical remission off therapy|"no clinical activity but serological activity allowed~stop taking corticosteroid and immunosuppressive drugs~antimalarials allowed"
89664230|NCT04942314||Clinical remission on therapy|"no clinical activity but serological activity allowed~corticosteroid≤5 mg/day and immunosuppressive drugs allowed~antimalarials allowed"
89664231|NCT04942314||Low disease activity state|(1) SLEDAI-2K ≤4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever), and no haemolytic anaemia or gastrointestinal active involvement; (2) no new lupus disease activity compared with the previous assessment; (3) a PGA ≤1; (4) a current predni- sone (or equivalent) dose ≤7.5mg/day; and (5) well-tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.
89664232|NCT04942314||Not in LDAS or Remission|At the end of follow-up, the disease state of SLE children was not in LDAS or any remissions defined above.
89664233|NCT04942314||Never in LDAS|During the follow-up, the disease state was never get LDAS.
89664234|NCT04843345||Reduced Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen positive for reduced salivary flow
89213960|NCT00495586|Placebo Comparator|Placebo|Placebo pills t.i.d. for 8 days
89213961|NCT00495586|Active Comparator|Amoxycillin and clavulanic acid|Amoxycillin and clavulanate t.i.d. for 8 days
89213962|NCT00881270|Experimental|Dermacyd infantile (Lactic Acid)|treatment duration 21 consecutive days
89213963|NCT00881348|Experimental|Dermacyd infantile (Lactic Acid)|5 weeks treatment
89664235|NCT04843345||Normal Salivary Flow Patients|Patients with lung disease matching inclusion criteria who screen negative for reduced salivary flow
89664236|NCT03059160|Experimental|open label|
89664237|NCT01891201||Not exposed to oxytocin|Mother-child dyads in which Oxt had not been administered during the birth process
89664238|NCT04950348|Experimental|3D printed personalized TKA prosthesis|Patients in the experimental group received 3D printed personalized TKA prosthesis treatment
89664239|NCT04950348|Active Comparator|Zimmer NexGen TKA prostheses|Patients in the active comparator group received Zimmer NexGen TKA prostheses treatment
89664240|NCT03059082|Other|Continued Interaction|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months.They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject. The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is continued throughout the study.~Note: The first 10 subjects will not be randomized and will be assigned to this Arm. The purpose of this is to ensure the fidelity of the intervention. The remaining 60 subjects will be randomized equally among the three Arms. Data from the first 10 subjects will not be considered for the outcome measures."
89664241|NCT03059082|Other|Single interaction|This group will undergo one interaction with the Recovery Navigator prior to the hospital discharge. They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject.The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is conducted once.
89664242|NCT03059082|Other|Control|This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
89664243|NCT04942002|Placebo Comparator|Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution
89664244|NCT04942002|Experimental|Standard treatment + intervention|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + retrobulbar injection of 2 cc (40 mg/mL) to methylprednisolone acetate
89664245|NCT01458457|Active Comparator|Usual care|
89664246|NCT01458457|Active Comparator|Usual Care + Complementary Medicine|
89664247|NCT01458691|Active Comparator|Steroid group|Triamcinolone injection group
89664248|NCT01458691|Experimental|PRP group|Allogeneic PRP injection group
89664249|NCT01891435|Active Comparator|oral paracetamol|patients in this arm will receive 1000mg of oral paracetamol
89664250|NCT01891435|Active Comparator|Intravenous paracetamol|patients in this arm will receive 1000 mg of intravenous paracetamol
89664251|NCT01891435|Active Comparator|Intramuscular Diclofenac|patients in this arm will receive 75 mg of intramuscular diclofenac sodium
89664252|NCT01458769|Active Comparator|Part A1|"Part A1 will evaluate two single ascending doses of the single agent C-10276 (an ATV isotopolog), and a dose of Reyataz.~C-10276 200 mg -> C-10276 400 mg -> Reyataz 400 mg~C-10276 200 mg -> Reyataz 400 mg -> C-10276 400 mg"
89664253|NCT01458769|Active Comparator|Part A2|"Part A2 will evaluate the single agent C-10276, co-administration of CTP-518 and C-10276, and a dose of Reyataz.~C-10276 300 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)-> C-10276 400 mg~C-10276 300 mg -> C-10276 400 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)"
89664254|NCT01458769|Active Comparator|Part B Group 1|"Group B1 will evaluate single doses of an ATV isotopolog, C-10297.~C-10297 200 mg"
89664255|NCT01458769|Active Comparator|Part B Group 2|"Group B2 will evaluate single doses of an ATV isotopolog, C-10299.~C-10299 200 mg"
89664256|NCT01458769|Active Comparator|Part B Group 3|"Group B3 will evaluate two single ascending doses of isotopologs C-10297 and 400 mg dose of Reyataz in a 3-way crossover design.~C-10297 400 mg -> Reyataz 400 mg -> C-10297 600 mg"
89664257|NCT01458769|Active Comparator|Part B Group 4|"Group B4 will evaluate two single ascending doses of isotopolog C-10299 and a 400 mg dose of Reyataz in a 3-way crossover design.~C-10299 400 mg -> Reyataz 400 mg -> C-10299 600 mg"
89664258|NCT01458769|Active Comparator|Part B Group 5|"Group B5 will evaluate a single dose of C-10276 and a 400 and 600 mg dose of Reyataz in a 3-way crossover design.~C-10276 600 mg -> Reyataz 400 mg -> Reyataz 600 mg"
89664259|NCT04959318|Experimental|Treatment group or counseling group|The treatment group will receive a counseling intervention addressing metabolic syndrome (comprised of abdominal adiposity, high blood pressure, high cholesterol, elevated fasting glucose, and elevated triglyceride level) and low vitamin D. This group will undergo baseline body composition measurements, phlebotomy, and an introduction to the digital app for recording diet and activity.
89664260|NCT04959318|Active Comparator|Control group or comparison group|Subjects randomized to the control group will undergo baseline body composition measurements, phlebotomy, and an introduction to the app for recording diet and activity. They will receive a packet of evidence-based pamphlets addressing Service-specific approaches to healthy eating and physical activity (e.g. Performance Triad). There will be no formal recurring interaction with an RD for those randomized to this control group.
89664261|NCT02520427|Experimental|Group 1: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)|
89664262|NCT02520427|Experimental|Group 2: Minimal Residual Disease Positive (MRD+) AML|
89664263|NCT02520427|Experimental|Group 3: Myelodysplastic syndrome (MDS)|
89664264|NCT02520427|Experimental|Group 4: R/R AML with alternative pretreatment|
89664265|NCT02520427|Experimental|Group 5: R/R AML with alternative dose schedule|
89664266|NCT04941612|Experimental|Activa IM-Nail|Activa IM-Nail
89664267|NCT01458847|Experimental|Cohort I: 2% cis-UCA solution (50 ml)|
89664268|NCT01458847|Experimental|Cohort II: 4% cis-UCA solution (50 ml)|
89664269|NCT01458847|Experimental|Cohort III: 6% cis-UCA solution (50 ml)|
89664270|NCT04959084|Experimental|Acupuncture|Acupuncture group A , consisting of 20 women will be received laser acupuncture therapy and pelvic floor training every other day for 30 min , 3 times per week for 12 sessions
89664271|NCT04959084|No Intervention|Medical|Medical group B, consisting of 20 women will be maintained their ordinary medical treatment
89664272|NCT04958928||Persistent AF Group|
89664273|NCT04941690||Men seen for preconception physicals|Ready to conceive, i.e. not having contraception and not having children for less than 1 year
89664274|NCT04941690||Men seen for infertility|Couples who have not used contraception and have not had children for more than 1 year
89213964|NCT00613730|Experimental|Gemcitabine + panitumumab|Panitumumab 6 mg/kg was administered intravenously (IV) before gemcitabine on Day 1 of Weeks 1, 3, 5, and 7, and then every 2 weeks (day 1 and 15) of each subsequent 4-week chemotherapy cycle. Gemcitabine 1000 mg/m^2 was administered IV once weekly (on Day 1) for 7 weeks, followed by a 1-week rest period. In subsequent cycles, gemcitabine was given once weekly (on Day 1) for 3 consecutive weeks followed by 1 week of rest. Panitumumab and gemcitabine treatment continued until disease progression, unacceptable adverse events, death, or study withdrawal occurred.
89213965|NCT05200754|Experimental|Convalescent/Vaccine-boosted Plasma|Infusion of plasma on day 1 and 2 (238 - 337 ml anti-SARS-Cov-2 CP/PVP each)
89213966|NCT05200754|No Intervention|Standard of Care|No intervention - standard therapy
89213967|NCT00881426|Experimental|1|Cefprozil 500 mg Tablets (Sandoz GmbH)
89213968|NCT00881426|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
89213969|NCT00883532|Experimental|budesonide|The treatment group will receive surfactant and budesonide.
89213970|NCT00883532|Placebo Comparator|surfactant and air|The placebo group will receive surfactant and air as control.
89213971|NCT00875498|Active Comparator|active iTBS|iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day
89664275|NCT04941690||Men who visited the clinic for their wives' miscarriage|Couples whose wives were previously pregnant but terminated the pregnancy due to fetal abortion, spontaneous abortion, biochemical pregnancy, fetal malformation or ectopic pregnancy
89664276|NCT02883673|Experimental|Intervention|Jada System for Postpartum Hemorrhage will be administered to subjects who are diagnosed with postpartum hemorrhage.
89664277|NCT01891513||ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 4 mg/day which will be titrated to 8 mg/day.
89664278|NCT01891513||Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
89664279|NCT01891513||Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
89664280|NCT04950036||Normal control group-Grade 0|Arthroscopic examination of the hip was normal, and the labrum was intact without injury or tear.
89664281|NCT04950036||Ligament injury -Grade 1|Arthroscopic examination of the hip showed labrum degeneration or injury, but no local or complete tear.
89664282|NCT04950036||Ligament tear-Grade 2|Arthroscopy of the hip revealed partial or complete loss of labrum.
89664283|NCT03058926||Chronic Pancreatitis|
89664284|NCT03058926||Diabetes|
89664285|NCT03058926||Pancreatic Cancer|
89664286|NCT04958616||Patients sensitive to HDM|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled.Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive [9]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
89664287|NCT04958616||Patients not sensitive to HDM allergy.|Classification of asthma according to disease severity. Patient maintained on step 2 treatments are often classified as having mild asthma. Those receive step 3-4 as moderate asthma and those prescribed step 4-5 as having moderate to severe asthma. Assessment level of asthma control Based on asthma control score according to GINA guideline defined as controlled, partially controlled and well controlled .Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive [9]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation).
89664288|NCT01891591||obese female subjects|16 obese female subjects with BMI > 40 kg/m2 on a waiting list for bariatric surgery
89664289|NCT04843423|Experimental|Cariprazine treatment|
89213972|NCT00875498|Placebo Comparator|sham iTBS|iTBS placebo (placebo coil)with same parameters than active
89213973|NCT00883766|Active Comparator|Long agonist protocol|
89213974|NCT00883766|Experimental|Antagonist protocol|
89213975|NCT04262258|Experimental|Blueberry Enriched Diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
89213976|NCT00881582|Experimental|Pegylated interferon alfa-2a plus ribavarin|Pegylated interferon alfa-2a plus ribavarin for 48 weeks
89213977|NCT00875654|No Intervention|1|Control group without intervention nor placebo
89664290|NCT01891825|Active Comparator|Pecutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
89664291|NCT01891825|Active Comparator|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
89664292|NCT04940988||See alert|The intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly assigned to receive the intervention, which is implementation of the RTPB tool.
89664293|NCT04940988||Do not see alert|The non intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly selected to not receive the intervention.
89213978|NCT00875654|Experimental|2|First dose of stem cells
89213979|NCT00875654|Experimental|3|Second dose of stem cells
89213980|NCT00881738|Experimental|1|Clarithromycin 250 mg Tablets (Geneva, USA)
89213981|NCT00881738|Active Comparator|2|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
89213982|NCT00613106|Experimental|HZT-501|HZT-501: ibuprofen 800mg/famotidine 26.6mg
89213983|NCT00613106|Active Comparator|Ibuprofen|Ibuprofen 800mg
89213984|NCT00883844|Experimental|1|Continuation of any Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
89664294|NCT02439853|Experimental|Check-In group|Subjects in the Check-In group will undergo three check-in sessions with the speech therapist. These sessions will happen remotely, via video-chat, and will last less than an hour. They will occur at 3-, 4-, and 5-months from the subject's enrollment date.
89664295|NCT02439853|No Intervention|Control Arm|Subjects in the Control arm will not undergo three check-in sessions with the speech therapist.
89664296|NCT01458925|Other|P1 capsule and screening Cscopy|"Male and female patients older than 40 and younger than 75 years old who volunteer for the experiment and qualify with the inclusion / Exclusion criteria.~The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study"
89213985|NCT00883844|Active Comparator|2|Continuation of Nucleos(t)ide analogue mono-therapy
89213986|NCT00875732|Experimental|1|Biventricular Pacing
89213987|NCT00875732|Active Comparator|2|Right Ventricular Pacing
89664297|NCT01459003|Experimental|experimental|
89664298|NCT01459003|No Intervention|control|
89664299|NCT01459081|Experimental|Zanamivir|
89664300|NCT01459081|Placebo Comparator|Placebo|
89664301|NCT03058068|Experimental|Safety Run-In: Treatment 1 Allo-hMSCs|Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.
89664302|NCT03058068|Experimental|Safety Run-In: Treatment 2 Allo-hMSCs|2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.
89664303|NCT03058068|Experimental|Randomized: Cohort 1 Allo-hMSCs|Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.
89664304|NCT03058068|Experimental|Randomized: Cohort 2 Allo-hMSCs|Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.
89664305|NCT03058068|Placebo Comparator|Randomized: Cohort 3 Allo-hMSCs|Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject.
89664306|NCT04849663|Experimental|study group|Use of free fat graft to cover exposed root
89664307|NCT04849663|Active Comparator|control group|use of sub epithelial connective tissue graft to cover exposed root
89664308|NCT04421196|No Intervention|Standard multimodal analgesic pathway with opioids|"This is the control group, who will receive the current standard multimodal analgesic regimen, which includes opioids following total hip arthroplasty at Johns Hopkins Bayview Hospital.~The current standard multimodal analgesic regimen utilizes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Opioid (fentanyl) & Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: 0.25 % bupivacaine with epinephrine and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Oxycodone 5-10 mg PO, IV opioids (Morphine, hydromorphone), Acetaminophen 1000 mg PO q6hr"
89664309|NCT04421196|Experimental|Modified multimodal analgesic pathway without opioids|"This is the experimental group, who will receive a modified multimodal analgesic regimen, which excludes the use of any opioids.~The modified multimodal analgesic regimen utilizes the following medications:~includes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: Liposomal bupivacaine, 0.25 % bupivacaine with epinephrine, Betamethasone sodium phosphate, betamethasone acetate and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Ketamine IV, Ketorolac 15 mg PO, Acetaminophen 1000 mg PO q6hr"
89664310|NCT04949334|Experimental|Dofin Breathing Strength Builder|Usual post stroke care and respiratory muscle training
89664311|NCT04949334|No Intervention|Usual post stroke care|Usual post stroke care
89664312|NCT04389931|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and two tablets containing lactose once a day for 90 days immediately after the scaling and root planning.
89213988|NCT00881816|Experimental|Liposomal paclitaxel plus capecitabine|
89213989|NCT03712904|Experimental|A. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
89213990|NCT03712904|Experimental|B. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
89213991|NCT00875888|Experimental|HCO|High cut-off filters HCO1100
89213992|NCT00875888|Active Comparator|control|conventional high-flux filters
89213993|NCT00881972|Experimental|exercise|
89213994|NCT04038554||Acute Pancreatitis|Patients older than 18 years old diagnosed of acute pancreatitis according to Atlanta 2012.
89213995|NCT04038554||Healthy Control|Healthy people with a proximity relationship with case patients and similar age (+/- 5 years).
89213996|NCT00875966|Experimental|1|Azithromycin for oral suspension 200mg/5mL
89213997|NCT00875966|Active Comparator|2|Zithromax (azithromycin for oral suspension) 200mg/5mL
89213998|NCT04142294|Experimental|4 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 4 g/day.
89213999|NCT04142294|Experimental|8 g / day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 8 g/day
89214000|NCT04142294|Experimental|12 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 12 g/day
89664313|NCT04389931|Experimental|Periodontal treatment, Omega 3|Periodontal treatment (scaling and root planning) and two tablets containing 1g of Omega 3 once a day for 90 days immediately after the scaling and root planning.
89664314|NCT04949178||Critically ill cirrhotics with septic shock and AKI undergoing CRRT|Consecutive critically ill cirrhotics with septic shock and AKI who give written informed consent will be included in this prospective study
89664315|NCT01892059|Experimental|Segmental artery clamping|Patients with Renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of segmental renal artery clamping will performed.
89664316|NCT01892059|Active Comparator|Main renal artery clamping|Patients with renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of traditional main renal artery clamping will be performed.
89664317|NCT04940754|Other|Stabilzation of Fracture|Arthrodesis nail used for stabilzation of a fracture, single patient
89664318|NCT01892137|Other|Open label active|
89664319|NCT04940910|Experimental|Black rice bran extract group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 1 g/day)
89664320|NCT04940910|Placebo Comparator|Placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.52 g/day, Black rice bran extract 0 g/day)
89664321|NCT01459315|Experimental|GSK1349572|
89664322|NCT04940520|Active Comparator|Control group|Group A: control group, drug recommended by the Brazilian Society of Dermatology
89664323|NCT04940520|Active Comparator|Alpha-bisabolol and laser|Group B: alpha bisabolol-based product associated with low-level laser therapy
89664324|NCT04940520|Active Comparator|Alpha bisabolol|Group C: alpha bisabolol based product
89664325|NCT04948788|Experimental|SHR1459 + YY-20394 (Stage 1)|
89664326|NCT04948788|Experimental|SHR1459 + YY-20394 (Stage 2)|
89664327|NCT04948788|Experimental|GemOx (Stage 2)|
89664328|NCT04958148|Experimental|High sodium|Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 4,300 mg/d sodium for 4 weeks.
89664329|NCT04958148|Placebo Comparator|Placebo|Subjects will be counseled to consume a diet with 2,300 mg/d sodium and will supplement with taking placebo pills for 4 weeks.
89664330|NCT04948242||Consecutive critically ill patients admitted to ICU with severe SARS-CoV-2 infection|Consecutive adult patients (> 16 years) with laboratory confirmed SARS-CoV-2 infection, detected by RT-PCR positive test of nasopharyngeal, oropharyngeal , swab or invasive respiratory samples according to the WHO recommendations. The follow-up of patients was to ICU discharge or death whichever occurred first. No interventions will be made. Only anonymized demographic data, clinical data, laboratory data and ventilatory support data will be collected. There is no standardized pharmacological treatment protocol. Only basic data are collected about the different treatments administered by the attending physician.
89664331|NCT04948086||TT MTHFR genotype|
89664332|NCT04948086||Non-TT (i.e. CC/CT) MTHFR genotype|
89664333|NCT04948320||Temporomandibular Disorder Group|
89664334|NCT04948320||Control Group|
89664335|NCT04940442|Experimental|Active choice|FIT or colonoscopy
89214001|NCT04142294|Experimental|16 g /day histidine|subjects ingest encapsulated high quality histidine for four continuous weeks at 16 g/day. The 16 g /day dose will be administered if no adverse effects are observed for doses 4-12 g/day
89664336|NCT04940442|Experimental|Sequential choice|FIT offered first, then colonoscopy offered to those still unscreened
89664337|NCT02865811|Experimental|Pembrolizumab in Combination With PLD|"A safety lead in with 6 patients will be studied prior the start of the treatment.~If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced.~If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD)~Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV~Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage"
89664338|NCT04957446|Experimental|Group 1|Subjects will receive 3 treatments of 1mL Poly-L-Lactic Acid (Sculptra Aesthetic)
89664339|NCT04957446|Placebo Comparator|Group 2|Subjects will receive 3 treatments of 1mL Saline solution.
89664340|NCT04939896||Compliance with rehabilitation|The patients' compliance with rehabilitation was followed up at 2, 6, 8, 12 and 24 weeks after onset, respectively
89664341|NCT01892215|Experimental|Cephalad-caudad|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
89664342|NCT01892215|Experimental|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
89664343|NCT03058224|Experimental|IGN-ES001|Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder
89664344|NCT03058224|Placebo Comparator|Placebo|Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder
89664345|NCT04957680|Experimental|computer-based cognitive behavioral therapy|
89664346|NCT04957680|Active Comparator|online stress management program|
89664347|NCT04957680|No Intervention|waitlist|
89664348|NCT01459471|Experimental|bleeding, leak, operative time|
89664349|NCT04948008|Experimental|Treatment group 1|The subjects received IBI306 150 mg Q2W subcutaneously injected into the abdomen each time for 12 weeks;
89664350|NCT04948008|Experimental|Treatment group 2|The subjects received IBI306 300 mg Q4W subcutaneously injected into the abdomen each time for 12 weeks;
89664351|NCT01459549|No Intervention|Control Group|Just clear the stone without choledochojejunostomy
89664352|NCT01459549|Experimental|Experimental Group|Clear the stone combined with Roux-en-y choledochojejunostomy
89664353|NCT04939974|Active Comparator|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
89664354|NCT04939974|Placebo Comparator|placebo|Placebo packet same in colour, smell and constituent to that of placebo one packet daily for 24 weeks
89664355|NCT01892449|Experimental|prolonged I:E ratio (1:1) group|
89664356|NCT01892449|Active Comparator|conventional I:E ratio (1:2) group|
89664357|NCT04957212|Experimental|TCHP regimen (trastuzumab, pertuzumab® (CinnaGen Co.), carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; pertuzumab® (CinnaGen Co.) is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
89664358|NCT04957212|Active Comparator|TCHP regimen (trastuzumab, Perjeta®, carboplatin, and docetaxel)|Study drugs are administered intravenously on a 3-weekly schedule and given consecutively on the same day in the following sequence: trastuzumab, followed by pertuzumab, carboplatin, and docetaxel. Trastuzumab is given at an initial dose of 8 mg/kg, followed by 6 mg/kg; Perjeta® is given at an initial dose of 840 mg, followed by 420 mg. Carboplatin is administered at a dose of AUC6 (area under the plasma concentration-time curve) and docetaxel is given at 75 mg/m2.
89664359|NCT02473315|Experimental|cryotherapy|
89664360|NCT02473315|Placebo Comparator|light cryotherapy|
89664361|NCT04939194|Experimental|Fast Track Protocol|the 22 items of ERAS (Early Recovery After Surgery) society
89664362|NCT04939194|No Intervention|Conventional perioperative care program|standard perioperative care
89664363|NCT04390789|Experimental|single visit retreatment|nonsurgical root canal retreatment will be carried out in single visit.
89664364|NCT04390789|Active Comparator|multi visit retreatment|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
89664365|NCT04947774||prophylactic cranial irradiation group|The extensive-stage SCLC patients will receive prophylactic cranial irradiation after standard first-line chemotherapy combined with immunotherapy, until disease progression or death.
89664366|NCT04947774||Observation group|Patients with extensive-stage SCLC do not receive preventive craniocerebral irradiation after standard first-line chemotherapy combined with immunotherapy until the disease progresses or death.
89664367|NCT01892605|Experimental|music listening, no music|The clinical application and mechanism of music therapy The clinical application and mechanism of music therapy (Mozart's effect) on epilepsy (Mozart's effect) on epilepsy
89664368|NCT04948164|Experimental|Test group|
89664369|NCT04948164|Placebo Comparator|Control group|
89664370|NCT04390711||Healthy subjects|We included 40 age- and gender-matched healthy subjects to serve as the control group, who had normal blood pressure, serum fasting glucose, lipid profile, and renal function.
89664371|NCT04390711||T2DM with CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. All patients were tested by angiography, with CAD diagnosed if luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
89664372|NCT04390711||T2DM without CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association.T2DM without CAD was diagnosed if no luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
89048403|NCT04645875|Experimental|SitLess regimen|Participants will be instructed to substitute a minimum of 5h/day of sitting with ≥2 h of light-intensity physical activity and ≥3 h of standing. Participants will be advised to rise from the seated position for 2-5 min every 30 min to engage in standing /light-intensity physical activities to interrupt their sitting.
89664373|NCT04947696||1|Patients undergoing a Whipples procedure for pancreatic cancer
89664374|NCT04957056||Study object|A young patient hospitalized in the Department of Neurosurgery of the Third Hospital of Beijing University of Medicine underwent CT examination of cervical vertebrae. The patient had no cervical bony deformity, no cervical degeneration, and no history of trauma
89664375|NCT02808871|Experimental|Pirfenidone|Pirfenidone 2403 mg/d for 52 weeks
89664376|NCT02808871|Placebo Comparator|Placebo|Placebo for 52 weeks
89664377|NCT04947228|Experimental|intervention group|in addition to the usual therapy, the patients were given access to the trackPAD app
89664378|NCT04947228|No Intervention|control group|patients in this group were treated as usual in the clinic without additional interventions.
89664379|NCT04413162|Other|measurement before and after capsular distention|
89664380|NCT04947306||All subjects|"Adult patients >18 years of age, who are scheduled to undergo any elective procedure under general anesthesia at our Institution in which the administration of rocuronium for neuromuscular blockade is anticipated.~All participants will be monitored with both TOF Watch and Tetragraph neuromuscular monitors."
89048404|NCT00546650|Experimental|A|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
89048405|NCT00546650|Active Comparator|B|Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.
89048406|NCT00546650|Active Comparator|C|Sumatriptan succinate (Imitrex®) injection: 6 mg subcutaneously (SQ).
89048407|NCT00546650|Active Comparator|D|Sumatriptan (Imitrex®) nasal spray: 20 mg (one spray) intranasal (IN) into one nostril.
89664381|NCT01892683||Propofol|This study will investigate patients that undergo routine anesthesia for elective surgical procedure at the hospital of the University of Munich(Klinikum der Universität München. Patients will receive intravenous anesthesia with propofol.
89664382|NCT04412070||Patient with Non-Muscle invasive Bladder Cancer|Patients in this group will be enrolled before the start of their treatment with BCG. This will start within 4 weeks after the transurethral bladder resection, in accordance with the guidelines
89664383|NCT04412070||Patient with Muscle Invasive Bladder Cancer|Patients in this group will be enrolled in the study before surgical treatment by radical cystectomy
89664384|NCT01459627|Active Comparator|6 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be discontinued after randomisation.
89664385|NCT01459627|Active Comparator|12 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be continued till 12 months after enrollment in the study
89664386|NCT02467621|Experimental|Proton pump inhibitor (PPI)|Pantoprazole 40 mg
89664387|NCT02467621|Placebo Comparator|Normal saline|Saline (0.9%)
89214002|NCT00141037|Active Comparator|Steroid-Based Immunosuppression|Subjects will receive prednisone immunosuppression (10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40kg and 1.5 mg/kg/day in subjects weighing >40 kg) and proceed with a prednisone taper according to the trial's protocol.
89664388|NCT04946838|Experimental|TENS|TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.
89664389|NCT04946838|Sham Comparator|Sham-TENS|Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.
89664390|NCT04946682|Experimental|Group of mNGS|
89664391|NCT04946682|Experimental|Group of PCR|
89664392|NCT01316211|Active Comparator|coflex™|Implantation of coflex™ device in assigned patients
89664393|NCT01316211|Active Comparator|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant.
89664394|NCT04431492||coronary artery bypass|
89664395|NCT04431492||thoracic surgery|
89664396|NCT01459861|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
89664397|NCT01459861|Active Comparator|Femoral with Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa.
89664398|NCT03057756||TB-MR patients|Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z
89664399|NCT01892761||TCL/MMF Group|
89664400|NCT01892761||CyA/MMF Group|
89664401|NCT03057522|Experimental|Intervention Group|This group will undergo home exercise program designed to increase their running cadence.
89664402|NCT03057522|No Intervention|Control Group|This group will not receive any intervention.
89664403|NCT04351971|Experimental|Intervention Group|The dorsal sliding technique C0-C1 will be applied to this group.
89664404|NCT04351971|Sham Comparator|Placebo group|A placebo dorsal mobilization technique will be applied
89664405|NCT01459939|Placebo Comparator|Placebo|Daily treatment with placebo
89664406|NCT01459939|Active Comparator|Rose-hip powder|Daily treatment with Rose-hip powder
89664407|NCT04937946|Experimental|Fentanyl|Fentanyl will be given within 24 hours from the initiation of mechanical ventilation at an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
89664408|NCT04937946|No Intervention|Placebo|Will receive continuous infusion of IV fluid up to 5 days or until the end of mechanical ventilation (if interrupted before 5 days ).
89664409|NCT05160987|Experimental|Remimazolam Group|The patients are administered with sedation of remimazolam and analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drug before enrollment, patient would be administered with a bolus of remimazolam with 0.1-0.3mg/kg intravenously in 1 minute for the first time. And maintenance dose is 0.25-0.1mg/kg/h, meanwhile the dose of remimazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
89664410|NCT05160987|Placebo Comparator|Midazolam Group|The patients are administered with sedation of midazolam analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drugs before enrollment, patients would be administered with a bolus of midazolam with 0.01-0.05mg/kg intravenously in 1 minute for the first time. And the maintenance dose is 0.02-0.1mg/kg/h, meanwhile the dose of midazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
89214003|NCT00141037|Experimental|Steroid-Free Immunosuppression|Subjects will receive extended daclizumab induction until the sixth month post-transplant (2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11 and months 4, 5, and 6).
89214004|NCT04612946|Experimental|Intervention Arm|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit and asked for permission to be referred (name and phone number) to the LCS navigator at Penn Medicine to schedule a telemedicine visit. Patients will also be given the option to directly contact the LCS navigator.
89214005|NCT04612946|Active Comparator|Control Arm|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their primary care providers.
89664411|NCT01892995|Experimental|Ketamine|active arm
89664412|NCT01892995|Sham Comparator|Diphenhydramine|sham arm
89664413|NCT01892995|Placebo Comparator|Saline|placebo
89664414|NCT04938102|No Intervention|Abnormal DI - Control|Patients' whose distensibility index is measured <2.8 will receive no intervention.
89664415|NCT04938102|Active Comparator|Abnormal DI - Botox|Patients' whose distensibility index is measured <2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
89664416|NCT04938102|No Intervention|Normal DI - Control|Patients' whose distensibility index is measured >2.8 will receive no intervention.
89664417|NCT04938102|Active Comparator|Normal DI - Botox|Patients' whose distensibility index is measured >2.8 will be injected with 100 units of botulinum toxin in the lower esophageal sphincter (25 units in each quadrant).
89664418|NCT04946448|Experimental|FIT group|Patients treated with biological treatment and the FIT diet
89664419|NCT04946448|No Intervention|Control group|Patients treated with biological treatment and the standard diet
89664420|NCT04946604|Other|Ashtangayoga|Participants attanded eight yoga sessions, one hour long.
89664421|NCT01893073|Active Comparator|Mindful walking|A weekly 60 minutes walking group exercise program consisting of a combination of walking and mindfulness over 8 weeks.
89664422|NCT01893073|No Intervention|Waiting group|
89664423|NCT04946760|Sham Comparator|Sham Protocol|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention. To provide a sham for the OMT-WB protocol, subjects will lie supine with the physician's hands under the occiput, palms toward the table, so that the subject's head rests on the dorsal aspect of the physician's hands. The time used in the sham procedures will be approximately 20-25 minutes.
89214006|NCT04602884|Experimental|COVID-19 Positive patients|subjects who were found COVID-19 Positive according to swab test.
89214007|NCT04602884|Other|Healthy subjects|subjects who were found COVID-19 Negative according to swab test.
89214008|NCT00140413|Experimental|Treatment Group 1: Receiving GH Treatment|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with growth deceleration were assigned to the GH treatment group in accordance with standard of care. Subjects with normal growth were randomized to treatment or to control (no intervention). The intervention was Nutropin AQ. The starting dose was calculated as 0.3 mg/kg/wk and subsequently modified based on observed length/height velocity and serum IGF-I levels.
89214009|NCT00140413|No Intervention|Treatment Group 2: Control|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with normal growth were randomized to treatment or to control. The control group received no intervention; however, control subjects were switched (crossed over) to the GH replacement group if, during the course of the study, they met criteria for growth deceleration.
89214010|NCT04039178|Active Comparator|Treatment group|Real BQ treatment, 40 treatments including 20 minutes of device guided functional motor tasks.
89214011|NCT04039178|Sham Comparator|Control group|Sham BQ treatment, (zero intensity) 40 treatments including 20 minutes of device guided functional motor tasks.
89214012|NCT04038398|Other|FiO2 : 100% - 50% - 21%|see above
89214013|NCT04038398|Other|FiO2: 21% - 50% - 100%|see above
89214014|NCT01582555|Experimental|saline irrigation|a control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation;
89214015|NCT01582555|Experimental|intervention arm (group B),|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
89214016|NCT00882128||1|
89664424|NCT04946760|Experimental|Whole-Body Protocol|"The whole-body protocol will include all the techniques in the OMT-ND protocol, but will also include techniques focused on the expected cranial dysfunctions [Rivera-Martinez 2002]. The OMT-WB protocol will last approximately 25-30 minutes.~The techniques will include:~Evaluation for strain pattern(s)~Occipitolatlantal decompression~Sphenobasilar synchondrosis decompression~Occipitomastoid suture V-spread~Temporal bone balancing~Venous sinus drainage technique"
89664425|NCT04946760|Experimental|Neck-down protocol|"The neck-down protocol takes into consideration previous relevant studies [Lopez 2011, Wells 1999]. OMT will be used bilaterally on the following areas with one or more techniques, including myofascial release, articulatory, muscle energy, and balanced ligamentous tension. The OMT-ND protocol will last approximately 15-20 minutes.~Cervical spine~Thoracic spine~Lumbar spine~Shoulder girdle~Sacroiliac joint~Innominates~Leg muscles (including psoas, piriformis, hamstring, adductors)~Ankles"
89664426|NCT02181075|Experimental|Part I|"All participants in Part I received:~Pre-LTLD Biopsy of Target Liver Tumour ThermoDox® (LTLD) Post-LTLD Biopsy of Target Liver Tumour Focused Ultrasound of Target Liver Tumour Thermometry of Target Tumour Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour~Part I of the study was designed to identify optimal focused ultrasound (FUS) exposure parameters for a range of tumour locations within the liver, using real-time thermometry data from an implanted thermometry device (a thermistor or thermocouple). Plasma and biopsy samples of the target liver tumour were taken pre-LTLD, post-LTLD and post-LTLD+FUS."
89664427|NCT02181075|Experimental|Part II|"All participants in Part II received:~ThermoDox® (LTLD) Focused Ultrasound of Target Liver Tumour Post-LTLD Biopsy of Target Liver Tumour~Following a minimum of 5 Part I cases, and subject to Trial Management Group approval, Part II of the study was opened to run in parallel to Part I. Part II did not require implantation of a thermometry device, and instead used predictions from Part I data to set the FUS parameters. Targeted drug delivery in Part II thus proceeded completely non-invasively, and this part of the study was designed to more closely reflect how the therapy might be implemented in routine clinical practice. Plasma samples were taken pre-LTLD, post-LTLD and post-LTLD+FUS. Biopsy samples of the target liver tumour were taken only post-LTLD+FUS."
89664428|NCT02802475||acquired chronic, focal, epilepsy|patients ≥18 years of age, with acquired chronic epilepsy of unknown origin
89214017|NCT03741361||Anxiety and Depression|Female patients scheduled for hysteroscopic surgery under propofol-based intravenous anesthesia will be recruited in this prospective cohort study.
89214018|NCT00884000|Active Comparator|1|
89214019|NCT00884000|Experimental|2|
89214020|NCT00884078|Experimental|1|C-MAPS (Culturally adapted manualized problem solving training) will be a brief problem focused therapy comprising of 8 sessions within three months after a self-harm episode. We will have two engagement sessions before the actual therapy. The adapted therapy/training will be delivered by therapists/trained counselors in the patient's home/GP practice depending upon patient's choice. Sessions will be offered weekly in the first month and than fortnightly and will last 50 minutes.
89214021|NCT00884078|No Intervention|2 Control group|"Patients who will be randomized to the treatment as usual arm will receive routine care. In most cases this consists of an assessment by a casualty doctor or a junior psychiatrist in the emergency department, on the basis of which about one third patients are referred for follow up as a psychiatry outpatient, a small number are referred to addiction services, and the remainder are advised to consult their own general practitioner (Kapur 1998) this is particularly so in case of Asian females (Cooper et al, 2006). No patients are routinely referred to psychotherapy or psychology services. Participants will receive an initial assessment along with treatment as usual (TAU) as ascertained by the general practitioner or mental health professional any type of treatment apart from C-MAPS will be permitted. We will record the degree of patient adherence to standard care."
89214022|NCT00885716|Experimental|communication skills training|group training in shared decision making.
89664429|NCT02802475||new onset epilepsy|patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis
89214023|NCT00885716|Active Comparator|cognitive training|standard group training of cognitive skills (Konzentrationstraining)
89214024|NCT02543684|Experimental|ready to eat mixed meal 1|
89214025|NCT02543684|Experimental|ready to eat mixed meal 2|
89214026|NCT02543684|Experimental|ready to eat mixed meal 3|
89214027|NCT02543684|Experimental|oral glucose load|
89214028|NCT02543762||Inflammatory Bowel Disease|"Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis and Crohn disease.~Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and typically extends in a proximal and continuous fashion to involve other portions of the colon.~Crohn disease is characterized by transmural inflammation and by skip lesions. The transmural inflammatory nature of Crohn disease may lead to fibrosis and strictures, and to obstructive clinical presentations that are not typically seen in ulcerative colitis. More commonly, the transmural inflammation results in sinus tracts, giving rise to microperforations and fistulae.~Crohn disease may involve the entire gastrointestinal tract from mouth to perianal área patients with long-standing inflammatory bowel disease are prone to the development of colorectal cancer"
89214029|NCT00923312|Experimental|CV9201|CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells.
89214030|NCT04038710||Patients with severe disease|Patients that are eligible to enroll in Vertex's triple combination therapy through the expanded access program.
89214031|NCT00882596|Experimental|1|Contura accelerated partial breast irradiation. Following a lumpectomy, a Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial breast irradiation begins.
89214032|NCT00882674|Experimental|1|
89214033|NCT00888524|Experimental|General Practice (GP) in Physio plus Deep water running|A supplementation of Deep Water running exercises of 20 minutes in high intensity around aerobic thresholds estimated in individual land and water test
89214034|NCT00888524|Experimental|General Practice in Physio|A procedure of evidence-based physiotherapy is usual care in pragmatic trial
89214035|NCT04038242|Experimental|Resilience promotion program|Subjects in the intervention group will participate in an eight-session resilience promotion program.
89214036|NCT04038242|No Intervention|Treatment as usual|Treatment as usual for subjects in the control group.
89521798|NCT03415295||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
89521799|NCT03415295||Healthy pregnant control|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls.
89521800|NCT00593567|Experimental|A|Daily topical gentamicin sponge and standard daily wound care
89214037|NCT00885794|Experimental|0.5 mg Ranibizumab|3 intravitreal injections of 0.5 mg Ranibizumab every 5 weeks
89214038|NCT00885794|Experimental|1.0 mg of Ranibizumab|3 intravitreal injections of 1.0mg Ranibizumab every 5 weeks
89214039|NCT00888602|Experimental|MM1 - Meal|3.4g psyllium served with a meal
89521801|NCT00593567|Active Comparator|B|Daily oral levofloxacin 750 mg and standard daily wound care
89521802|NCT03415217|Other|Neighbourhood Team Development|Neighbourhood Team Development consisted of a 30-month standardised training and implementation plan to promote inter-professional team collaboration and enhanced resident centeredness.
89521803|NCT03109613|Experimental|Positive end-expiratory pressure (PEEP) level changes|Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.
89521804|NCT03420131||FFR-iFR-QFR group|
89521805|NCT03420053|Experimental|Group 1 HIV- vaccine recipients|"Group 1: n=6, HIV negative vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either normal saline placebo (NS) or PfSPZ Vaccine.~Efficacy will be assessed by controlled human malaria infection (CHMI) at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
89521806|NCT03420053|Placebo Comparator|Group 1 HIV- NS controls|"Group 1: n=3, HIV negative NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
89521807|NCT03420053|Experimental|Group 2a HIV+ vaccine sentinels|Group 2a: n=3, HIV positive vaccine recipients will receive 4.5x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days.
89521808|NCT03420053|Experimental|Group 2b HIV+ vaccine recipients|"Group 2b: n=6, HIV positive vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
89521809|NCT03420053|Placebo Comparator|Group 2b HIV+ placebo controls|"Group 2b: n=3, HIV positive NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
89521810|NCT03419975|Experimental|TJO-002|
89521811|NCT03419975|Active Comparator|latanoprost|
89521812|NCT03109535|Active Comparator|Fitbit-only Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks.
89521813|NCT03109535|Experimental|Fitbit + MapTrek Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks. Participants also received access to an mHealth game called MapTrek for 10 weeks. MapTrek places users in weekly walking races and sends automated text messages to participants on a daily basis. Messages include a link to the online game as well as motivational messages designed to increase physical activity.
89521814|NCT03419663||gastric cancer|
89521815|NCT03414671||historical control|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 11/30/2015-11/30/2017 (historical control, pre-standardized defined CSCPE
89214040|NCT00888602|Experimental|MM2 - Meal|6.8 g psyllium served with a meal
89214041|NCT00888602|Experimental|MM2 (no Meal)|6.8 g psyllium consumed with no meal
89214042|NCT00888602|Sham Comparator|Meal Only|meal only
89214043|NCT02543450|Experimental|Cardiovascular/task-oriented training|8 cardiovascular exercises at moderate intensity, interrupted by 1-minute active breaks of task-oriented exercises.
89214044|NCT02543450|Active Comparator|Upper limb strength training program|Nine 5-minute station circuit session. Patients work 2+2 minutes in each exercise, with a 30-second rest between the 2-minute periods and between stations.
89214045|NCT00885872|Experimental|Treat|At visit 2 each eligible subject will be allocated to rosuvastatin. Subjects who reach the criteria at visit 3, dosage of rosuvastatin will be titrated. The subjects will be encouraged to take the study drug at the same time each day for 104 weeks.
89214046|NCT00888758|Experimental|1|
89214047|NCT00888758|Active Comparator|2|
89214048|NCT02542436||Cohort 1: bevacizumab|Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.
89664430|NCT04956588|Experimental|experimental group|
89664431|NCT04956588|Active Comparator|control group|
89664432|NCT01359735|Active Comparator|HP802-247|allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly
89664433|NCT01359735|Active Comparator|Bacitracin Ointment|bacitracin antibiotic ointment
89664434|NCT04945980|Experimental|Low-MUFA ground beef|Participants consumed ground beef low in monounsaturated fatty acids.
89664435|NCT04945980|Experimental|High-MUFA ground beef|Participants consumed ground beef high in monounsaturated fatty acids.
89664436|NCT02872987||B-ALL/NHL|
89664437|NCT02872987||ALL/ Lymphoblastic Lymphoma (LBL)|
89664438|NCT04955886|Experimental|Recurrent or Metastatic Nasopharyngeal Carcinoma.|Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma were given Surufatinib Combined With Toripalimab.
89664439|NCT01361217|Experimental|Fluoxetine DDI|Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
89664440|NCT04271839|Experimental|Fluticasone/formoterol k-haler (medium strength)|In this arm, uncontrolled patients who arrive at the consultation with their fixed combination of ICs (Inhaled CorticosteroidS) / LABA (Long-Acting Beta2-Agonist) (medium strength) will change their treatment to Fluticasone / formoterol k-haler (medium strength)
89664441|NCT04271839|Active Comparator|Standard of Care (SoC)|In this arm, uncontrolled patients arriving at the consultation with their fixed combination of ICs / LABA (medium strength) will change their treatment to the same fixed combination of ICs / LABA (high strength)
89664442|NCT04945902|Active Comparator|Asynchronous Group|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
89664443|NCT04945902|Experimental|Synchronous Group|If you are assigned to the synchronous intervention group, you will be required to complete the asynchronous interventions on Brightspace AND attend a weekly one-hour support group. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connections and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
89664444|NCT04945902|No Intervention|Waitlist|If you are assigned to the wait-list group, you will not have access to the asynchronous or synchronous interventions during the course of this study. After this study is completed, you will have access to the asynchronous intervention on Brightspace.
89664445|NCT04945668|Other|Pericapsular nerve group block|combined ultrasound and fluoroscopy-guided technique for pericapsular nerve group block
89664446|NCT05083143||COVID-19 Testicular Cancer|Patients diagnosed with testicular cancer in the COVID-19 period
89664447|NCT05083143||PreCOVID-19 Testicular Cancer|Patients diagnosed with testicular cancer before the COVID-19 period
89664448|NCT04945434|Experimental|S53P4 BAG intervention group|Patients recruited and enrolled in study for treatment with S53P4 BAG
89664449|NCT01319799||Surgical aortic valve replacement|Single observational study. Count of microembolic signals during open heart surgery and measurement of properative vs postoperative levels of markers in cerebrospinal fluid of neuronal damge.
89664450|NCT04408560|Active Comparator|Groupe A with homéopathic treatment|Conventional treatment : paracetamol (drug analgesic class1) + Homeopathic drug : Rhus toxicodendron 9 CH et Ruta graveolens 5 CH
89214049|NCT02542436||Cohort 2: no bevacizumab|Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.
89664451|NCT04408560|Sham Comparator|Groupe B without homeopathic treatment|Conventional treatment : paracetamol (drug analgesic class1)
89664452|NCT04937244|Experimental|Patients with new or recurrent malignant gliomas|
89664453|NCT04272853||Athletes|440 subjects will be recruited (see calculation of the sample size for details): all subjects will be athletes, professional or non-professional, belonging to any sporting discipline, members of one of the sports federations of the Lombardy region, officially recognized by CONI (National Committee of Italian Olympic Team).
89664454|NCT04936698||Hyperthyroidism|Elevated fT4, low TSH
89664455|NCT04936698||Hypothyroidism|Elevated TSH, low fT4
89664456|NCT04936698||Euthyroid|Normal TSH/fT4 level
89664457|NCT04844905|Experimental|Ivermectin Mass Drug Administration|Ivermectin and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
89664458|NCT04844905|Placebo Comparator|Placebo Mass Drug Administration|Placebo and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
89664459|NCT04418856|Experimental|Experimental light: Breast cancer surgery and chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
89664460|NCT04418856|Active Comparator|Comparison Light:Breast cancer surgery and chemotherapy|Exposed to comparison systematic light exposure for 30 minutes each morning from the time of breast cancer surgery until the end of the chemotherapy treatment
89664461|NCT04418856|Experimental|Experimental light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
89664462|NCT04418856|Active Comparator|Comparison light: Breast cancer surgery and no chemotherapy|Exposed to experimental systematic light exposure for 30 minutes each morning for four weeks starting at the time of breast cancer surgery
89664463|NCT04418856|No Intervention|Healthy control group|The healthy control group and the breast cancer patients undergo the same assessments (questionnaires, neuropsychological assessments and actigraphy) at the same time points
89664464|NCT01454635|Other|Sertraline, Treatment response|dosage, frequency and duration
89664465|NCT01893151|Experimental|Iguratimod|Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
89664466|NCT01893151|Placebo Comparator|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week;Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week
89664467|NCT04955496||ERAS Group|Patients were treated by enhanced recovery after surgery
89664468|NCT04955496||Control Group|Patients were not treated by enhanced recovery after surgery
89664469|NCT02196831|Experimental|Tesamorelin|tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
89664470|NCT02196831|Placebo Comparator|Placebo|placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
89664471|NCT04944966|Experimental|Group 1|"• Experimental: Group 1a: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 400mg once a day to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1b: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 600mg once a day to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1c: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis~• Experimental: Group 1d: n=3, Healthy male participants will receive Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days to test its safety and tolerability.~Interventions:~o Drugs: Maytenus senegalensis"
89664472|NCT04944966|Experimental|Group 2a|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Maytenus senegalensis.~Patients will be treated with Maytenus senegalensis administered orally at an estimated dose of 800mg for 8 hourly for 4 days.~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection~Interventions:~o Drugs: Maytenus senegalensis"
89664473|NCT04944966|Active Comparator|Group 2b|"Group 2a: n=52, Adults aged 18 to 45 years diagnosed with natural acquired uncomplicated malaria will be treated with Artemether-lumefantrine Patients will be treated with Artemether 20mg/lumefantrine 120mg administered orally by a six-dose regimen over 3 days.~Curative efficacy will be assessed by measure the portion of patients with Early Treatment Failure (ETF), Asexual parasite clearance time (PCT) and adequate Clinical and Parasitological Response (ACPR) for treatment at 28 days and 56 days after PCR correction of reinfection (ACPR 28 and 56 after PCR correction of reinfection~Interventions:~o Drugs: Artemether 20mg/lumefantrine 120mg"
89664474|NCT04758169|Experimental|Enhanced Homestead Food Production|Participant in this arm will receive the Helen Keller's EHFP model which involves homestead food production, nutrition and WASH education and gender transformative sessions (intervention group). Participants will also receive interventions related to parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH and basic life-skill trainings.
89664475|NCT04758169|Experimental|Control|Participants in this arm will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings. This particular arm will not receive any homestead food production intervention over the course of the implementation.
89664476|NCT04936152|Active Comparator|mime therapy using tablet PC mirror application|these individuals will receive mime therapy using tablet PC mirror application
89664477|NCT04936152|Experimental|the control intervention including the mime therapy|these individuals will receive the control intervention including the mime therapy).
89048408|NCT00546650|Experimental|E|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
89048409|NCT00546689||1 , 2|those with HIV
89048410|NCT04637373|Experimental|the group|Women aged 18-40 years who admit to the gynecology emergency department at our institution with early miscarriage up to 12 weeks and 6 days of gestation, and choose surgical evacuation over medical treatment, are having Hysteroscopy assisted suction curettage as detailed previously. retained products of conception found at the end of the procedure, and intrauterine adhesions found on follow up are compared to the data in the literature.
89048411|NCT00546767|Experimental|Mail and Live Phone|
89048412|NCT00546767|Experimental|IVR|
89048413|NCT00546767|Experimental|Computer Kiosk|
89048414|NCT00546767|Active Comparator|Traditional|
89214050|NCT00888836|Active Comparator|GBP|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo gastric bypass
89214051|NCT00888836|Active Comparator|BPD 2|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo bilio-pancreatic diversion
89214052|NCT00888836|Active Comparator|Med Ter3|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 yearsundergo medical therapy
89214053|NCT00888992|No Intervention|Group A|Receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls.
89214054|NCT00888992|Experimental|Group B|
89214055|NCT00888992|Experimental|Group C|
89214056|NCT00889070||1|Stage 1 (Pilot Study) All infants enrolled in the pilot stage and completing baseline screening will be evaluated as the analyzable set.
89214057|NCT04038320||HCV infected patients|All HCV infected confirmed by HCV RNA,
89214058|NCT00563706|Experimental|1|
89214059|NCT00563706|Active Comparator|2|4mg/day
89214060|NCT00563706|Placebo Comparator|3|matching placebo
89214061|NCT02543606|Experimental|Esomelone|powder for injection/ infusion Esomeprazole 40mg
89214062|NCT02543606|Active Comparator|Nexium|powder for injection/ infusion Esomeprazole 40mg
89214063|NCT04038632|Experimental|District Hospital focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be implemented at the DH level. PHCs in this district, will only conduct systematic TB screening.
89214064|NCT04038632|Experimental|Primary Health Center focused decentralization strategy|In this strategy, the patient care level innovative childhood TB diagnostic approach will be done at the PHC.
89214065|NCT00935844|Experimental|TAK-901 Arm|
89214066|NCT02543372|Experimental|Behavioral Couples Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. Both the gamblers and the CSOs receive 10 modules each.
89214067|NCT02543372|Active Comparator|Cognitive Behavioral Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. The gamblers receive 10 modules, but the CSOs do not receive any modules.
89214068|NCT00939588|Experimental|Aliskiren and Valsartan|
89214069|NCT00939588|Active Comparator|Telmisartan and Ramipril|
89214070|NCT02543138|Experimental|Closed thoracostomy|Closed thoracostomy using the new trocar by novice
89214071|NCT00935922|Placebo Comparator|Soybean oil bar|A nutrition bar enriched with soybean oil
89664478|NCT04955106|Other|Sample for reliability|Reliability and validity of SEM Scanner : intra rater, inter rater and inter novice/trained 8(2 trained rater, 2 novice rater, each one performed twice)measured will be performed on each patient.
89664479|NCT02678299|Experimental|Treatment|
88995136|NCT05535842|Experimental|Intervention|Participants in the intervention group will use GLOW the conversational agent/app for 6 months in addition to their usual diabetes care offered by their attending doctor or endocrinologist.
89214072|NCT00935922|Experimental|Flaxseed bar with low lignans|A nutrition bar enriched with flaxseed oil
89214073|NCT00935922|Experimental|Flaxseed bars with high lignans|A nutrition bar enriched with flaxseed oil and high lignans
89214074|NCT00884468||1|Patients with PsA that fulfill the eligibility criteria of the study
89214075|NCT00936000|Active Comparator|protandim therapy for 7 days|
89214076|NCT00936000|Placebo Comparator|placebo arm|Individuals will receive a placebo equivalent in two equally divided doses for seven days
89214077|NCT00885950||Colorectal liver metastases|Patients with colorectal liver metastases undergoing partial hepatic resection who were preoperatively treated with either neoadjuvant chemotherapy or not and/or anticoagulants or not
89214078|NCT00889148|Experimental|Gabapentin|600mg of gabapentin will be given orally two hours preoperatively and 200mg for 3 times a day after surgery for three days.
89214079|NCT00889148|Placebo Comparator|Placebo|
89214080|NCT00936156|Experimental|Chemotherapy|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
89214081|NCT00129961|Experimental|1|Conversion to a sirolimus-based regimen
89214082|NCT00129961|Active Comparator|2|Continuation of a CNI-based regimen
89214083|NCT00528567|Experimental|Bevacizumab and Chemotherapy|Participants randomized to receive bevacizumab in combination with chemotherapy as prescribed.
89214084|NCT00528567|Active Comparator|Chemotherapy|Participants randomized to receive standard adjuvant chemotherapy as prescribed.
89214085|NCT00936234|Active Comparator|Vildagliptin|starting with vildagliptin for 30 days followed by placebo for 30 days
89214086|NCT00936234|Placebo Comparator|Placebo|starting with placebo for 30 days followed by vildagliptin for 30 days
89214087|NCT00886028|Experimental|Liposomal doxorubicin|Thirty patients with MPM who received liposomal doxorubicin 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
89214088|NCT00936312||Females with Hemophilia|Females with severe or moderate Hemophilia A or B
89214089|NCT00936312||Control group|Male subjects with severe Hemophilia A or B and female subjects with mild (20-60%) Hemophilia A or B.
89214090|NCT00889304||A|HTO cohort
89214091|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (3.75ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 3.75ug given by IM injection to the upper deltoid.
89214092|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (7.5ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 7.5ug given by IM injection to the upper deltoid.
89214093|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (25ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 25ug given by IM injection to the upper deltoid.
89214094|NCT00936468|Experimental|Fluzone® vaccine alone|One vaccination on Day 0 with Fluzone vaccine at 45 ug given by IM injection in the upper deltoid.
89214095|NCT02543216|Experimental|CC genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
89214096|NCT02543216|Experimental|TT genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
89664480|NCT04955262|Experimental|Part 1 Initial Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214, 3 injections of 89Zr-Df-IAB22M2C, and 6 PET/CT scans. Starting with Cycle 2, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. Once the PET/CT imaging data from Part 1 have been reviewed, Part 2 will open for enrollment.
89664481|NCT04955262|Experimental|Part 2 Expansion Cohort to Evaluate the Biodistribution of CD8 Cells|During Cycle 1, patients will receive single-agent NKTR-214 or nivolumab, 2 injections of 89Zr-Df-IAB22M2C, and 3 PET/CT scans. In Cycle 2 and beyond, patients will receive NKTR-214 in combination with nivolumab q3w for the remainder of the study. During Cycle 2, patients will receive 1 injection of 89Zr-Df-IAB22M2C and 1 PET/CT scan.
89664482|NCT04944732||Patients with Creutzfeldt Jakob disease|Patients with Creutzfeldt Jakob disease
89664483|NCT04944498|Experimental|Intervention Group|Patients who received surgery with modified tarsorrhaphy technique
89664484|NCT04944498|Active Comparator|Control group|Patients who received surgery with gold weight implant technique
89664485|NCT04758013|Experimental|Laparoscopic gastric surgery with Epidural injection|Patients with laparoscopic gastric surgery who received epidural injection through an thoracic epidural catheter.
89664486|NCT04758013|Experimental|Laparoscopic gastric surgery without Epidural injection|Patients with laparoscopic gastric surgery who don't received epidural injection through an thoracic epidural catheter.
89664487|NCT04758013|No Intervention|Open gastric surgery|Patients with open gastric surgery.
89664488|NCT04955418|Active Comparator|Epi-no Group|The study group was evaluated before the intervention (between 30 and 32 weeks) and 6 months after delivery.From the 34th week onwards, they performed 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device. The pregnant woman was placed in the supine position and EPI-NO® was inserted into vaginal canal. After the introduction of the deflated tube, it was minimally inflated until the perception in the vaginal canal. The first 5 minutes were for perception of the pelvic floor with 10 contractions and relaxation of the perineum in order to maintain muscle strength. After 15 minutes for stretching the perineum, the device was gradually inflated and always respecting the pregnant woman's tolerance. After a total of 20 minutes, the pregnant woman was asked to relax the pelvic floor in order for the inflated device to gently exit her vaginal cavity. The perimeter was measured using a tape measure in its largest diameter.
89664489|NCT04955418|Placebo Comparator|Control Group|The control group was evaluated only once, six month after delivery.
89664490|NCT04954950||sports injuries|Patients were classified according to self-reported years of participation in skiing and snowboarding: beginner (first season), medium (1-5 years), advanced (5-10 years) and expert (≥10 years). Date of injury was divided into weekdays and weekends/ holidays according to the Chinese government holiday arrangement.
89664491|NCT01363479|Experimental|Oral palonosteron plus dexamethasone|Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
89664492|NCT01363479|Active Comparator|I.V. palonosetron plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
89664493|NCT04431570|Experimental|rTMS over M1 region|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is M1 region.
89214097|NCT00939666|Experimental|Wait&see or TEM with intensive follow-up|All patients will be included in this arm
89214098|NCT00936546|Experimental|Rituximab|
89214099|NCT00889460|Placebo Comparator|1|Placebo group
89214100|NCT00889460|Experimental|2|rBet v 1 tablets
89214101|NCT00936624|Experimental|SOTB07 100mg|
89214102|NCT00936624|Experimental|SOTB07 200mg|
89214103|NCT00936624|Placebo Comparator|Placebo|
89214104|NCT00936624|Active Comparator|Montelukast 10mg|
89214105|NCT00889538|Placebo Comparator|Placebo|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
89664494|NCT04431570|Experimental|rTMS over supplementary motor area (SMA)|The stimulus intensity was set to 100% of the resting motor threshold. Ten sessions of rTMS were delivered over 2 weeks, one session per day for 5 consecutive days per week. Each session consisted of 10 trains of 100 pulses at 10Hz with an inter-train interval of 40 seconds. In this group, the target of rTMS is SMA region.
89664495|NCT04431570|Sham Comparator|sham stimulation|
89664496|NCT04933656|Experimental|50g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
89664497|NCT04933656|Experimental|90g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
89664498|NCT04933656|Experimental|130g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
89664499|NCT04933656|Experimental|170g added sugar|Crossover design and each participant receives all 4 experimental arms/doses in random order
89048415|NCT04645758|Active Comparator|Dry Needling Group or (DN)|Dry needling for 5 mins on the flexor group of muscles of dominant forearm.
89664500|NCT01893385|Experimental|vitamin D|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
89664501|NCT01893385|Other|INTANZA 15|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
89664502|NCT04935996|Experimental|Pleuropulmonary echography|
89664503|NCT05076357|Experimental|Only diet group|Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein) during 8 weeks. Follow up with a registered dietitian.
89664504|NCT05076357|Experimental|Only cold exposure group|No dietary intervention. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during 90 min.
89664505|NCT05076357|Experimental|Combined diet + cold exposure group|Dietary energy prescription at -30% of Energy requirements (50% carbohydrate; 30% fat; 20% protein). Follow up with a registered dietitian. Visit at laboratory every 2nd day during the 8-week intervention to undergo the cold exposure as follows: 2 weeks of exposure at 18 degrees, 2 weeks of exposure at 14 degrees and 4 weeks of 10 degrees of exposure during during 90 min.
89664506|NCT04935918|Experimental|Study Arm 1|Children with bladder exstrophy or isolated epispadias
89664507|NCT04955028||intraoperative massive hemorrhage|blood loss of ≥200 mL with or without artery embolization (UAE) or local CSP resection by laparoscopy or laparotomy as additional interventions.
89664508|NCT04955028||the non-massive hemorrhage group|blood loss of <200 mL
89664509|NCT04933110||Multiple Sclerosis|Individuals with early-stage multiple sclerosis
89664510|NCT04933110||Healthy Volunteers|Healthy volunteers of similar age and sex as individuals with multiple sclerosis
89664511|NCT02181231|Experimental|venlafaxine plus buprenorphine|Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
89664512|NCT02181231|Placebo Comparator|venlafaxine XR plus placebo|Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
89664513|NCT04954716|Experimental|Deep Neck Flexor Massage|INTERVENTIONAL GROUP(DEEP Neck FLEXOR MASSAGE)
89664514|NCT04954716|Active Comparator|Post-Isometric Relaxation Technique|CONTROL GROUP (POST-ISOMETRIC RELAXATION TECHNIQUE)
89664515|NCT01364259|Placebo Comparator|Placebo|Placebo and SRS
89664516|NCT01364259|Experimental|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
89664517|NCT04932642|Experimental|High-intensity interval training plus resistance training (HIIT+RT)|The HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points. Second, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of as many repetitions as possible in 60 seconds, followed by 60 to 120 seconds of passive recovery.
89048416|NCT04645758|Active Comparator|Extra corporeal Shockwave therapy Group or (ESWT)|Delivering of Shock wave pulses of 1250 at the energy intensity of 0.58 mj/mm2 on the flexor group of muscles of dominant forearm
89048417|NCT00546806|Experimental|1|"AVIVA Soft Tissue Injury Care Model"
89048418|NCT00546806|Experimental|2|Pre-approved Framework Guideline for Grade I and II Whiplash Associated Disorders (PAF)
89048419|NCT00546806|Active Comparator|3|Physician-based Education and Activation
89048420|NCT04637178|Experimental|Resistance training added to endurance training|Participants (elite cyclists) will conduct heavy-load resistance training twice a week in addition to their habitual endurance training for ten weeks
89048421|NCT04637178|Other|Endurance training|Participants (elite cyclists) will conduct habitual endurance training-only for ten weeks
89048422|NCT04637022||3D laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 3D laparoscopic camera
89048423|NCT04637022||4k laparoscopy arm|Patients submitted to vaginal cuff closure after total laparoscopic hysterectomy using a 4k laparoscopic camera
89048424|NCT00560196||1|Patients with panic anxiety disorder without pain
89048425|NCT00560196||2|Patients with depression without pain
89048426|NCT00560196||3|Healthy controls
89048427|NCT04645563||Whatsapp Group|"This group includes 54 patients who have consulted via whatsapp. The ID physician will be consulted for all the subjects once laboratory results and CT reports were complete. All the consultations were performed with the same smartphone, and every Whatsapp consultation held since the very beginning of the pandemic was evaluated.~In this type of consultation, Thorax CT images of the patient were turned into a video of approximately 30-35 seconds, and during this video recording, the patient's clinical condition and laboratory results were also transferred to the ID physician. The ID physician, on the other hand, will state his/her admission-discharge decision via Whatsapp as hospitalization or discharge. Eventually the consultation result will be recorded in the patient's folder. The moment the video was sent will be recorded as the beginning of the patient's consultation period and response time to whatsapp video will be saved as consultation response time."
89214106|NCT00889538|Active Comparator|Glutathione|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
89214107|NCT00889538|Active Comparator|Glutathione, Vit C and NAC|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
89664518|NCT04932642|Experimental|Resistance training plus High-intensity interval training (RT+HIIT)|Firstly, in the RT section, three to out of four RT exercises were included (according to the planning week), targeting the following different muscle groups: (1) forearm, (2) knee flexors and extensors, (3) trunk, (4) chest, (5) shoulder elevators, (6) horizontal shoulder flexors, (7) extensors, and finally (8) plantar flexors. These exercises were performed in three 3 sets of 60 seconds, followed by 60 to 120 seconds of passive recovery, as previously reported. Secondly, in the HIIT+RT group, the HIIT section consisted of 60 seconds of maximum intensity exercise using a magnetic resistance static bicycle (OxfordTM Fitness, model BE-2701, Chile), followed by 60-120 seconds of passive recovery over the bicycle totally off. This was repeated four to seven times according to the weekly schedule. The intensity of the exercise was measured on the Borg scale of 1 to 10 of perceived exertion and the participants worked at a level of between 6 to 9 points.
89664519|NCT05014737||Patients with low risk of PONV|
89664520|NCT05014737||Patients with high risk of PONV|
89664521|NCT01321437|Experimental|Axitinib|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 14-21 days after completion of treatment. Beginning 28-56 days after surgery, patients receive axitinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
89664522|NCT02623218|Experimental|TBI-ACUP|This group will receive the standard of care plus acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
89664523|NCT02623218|Sham Comparator|TBI-SHAM|This group will receive the standard of care plus sham acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
89664524|NCT02623218|Active Comparator|C-ACUP|This group of participants without TBI will receive one acupuncture treatment and serve as a healthy control group.
89664525|NCT02623218|Sham Comparator|C-SHAM|This group of participants will receive one sham acupuncture treatment and serve as a healthy sham comparator group.
89664526|NCT02623218|Active Comparator|C-EX|This group of participants without TBI will receive one acupuncture treatment following 30-60 minutes of aerobic exercise, and serve as a healthy control group.
89664527|NCT04935294|Experimental|Group 1: Matched Control Group Of Healthy Participants|Participants received a single 200-milligram (mg) treatment on Day 1.
89664528|NCT04935294|Experimental|Group 2: Severe RI And Not On Dialysis|Participants received a single 200-mg treatment on Day 1.
89664529|NCT04956822||ALS|Amyotrophic lateral sclerosis group
89664530|NCT04956822||CMT|peroneal muscular dystrophy group
89664531|NCT04956822||KD|Kennedy's disease group
89664532|NCT04956822||Control|Healthy control group
89664533|NCT01365585||Sildenafil ≥20mg three times daily|Subjects receiving sildenafil ≥20mg three times daily for the treatment of PAH
89664534|NCT04922580||Hospitalization group|Newborns of ICP mothers require hospitalization after birth
89664535|NCT04922580||without Hospitalization group|Newborns of ICP mothers don't require hospitalization after birth
89664536|NCT04407390|Placebo Comparator|Control|Patients receiving placebo.
89664537|NCT04407390|Experimental|NR|Patients receiving nicotinamide riboside (NR-E)
89664538|NCT02181387|Active Comparator|acetaminophen|1000 mg every 6 hours during labor up to maximum 3 doses
89664539|NCT02181387|Placebo Comparator|placebo|placebo capsule identical to the acetaminophen capsule will be administered every 6 hours to a maximum of 4 doses
89664540|NCT04932876||ESKD - HD|End Stage Kidney Disease on Long Term Dialysis
89664541|NCT04932876||KTR|Kidney Transplant Recipient
89664542|NCT04351347|Experimental|Ivermectin|Ivermectin alone in larger doses
89214108|NCT04012476|Experimental|ICG|Patients undergoing total thyroidectomy with visualization of the parathyroid glands under infrared light after intraoperative intravenous injection of 5 mg of indocyanine green
89214109|NCT00138151|Experimental|Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b|"Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle~Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle~Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days"
89664543|NCT04351347|No Intervention|Standard treatment|Standard of care treatment
89664544|NCT04391101|Experimental|Intervention group|Administration of two units of fresh frozen plasma (between 400 and 500 ml) obtained from convalescent patients from infection by SARS-CoV-2. Convalescent plasma is defined as the plasma of patients who had PCR confirmed SARS-CoV-2 infection, who have recovered clinically, and who have positive antibodies against SARS-CoV-2.
89664545|NCT04391101|No Intervention|Control group|Subjects assigned to the control group will receive support treatment in the intensive care unit based on institutional management guidelines. The use of antiviral, antimalarial or anti-inflammatory drugs is allowed in both groups according to the ICU protocols.
89664546|NCT04932564|Experimental|Leflunomide Arm|Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children. This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
89664547|NCT03012867|Active Comparator|fat-based|Patients receive a fat-based enteral nutrition formula, which is routinely used as standard care in our ICU
89664548|NCT03012867|Active Comparator|glucose-based|Patients receive a glucose-based enteral nutrition formula, which is routinely used as standard care in our ICU
89664549|NCT04932720|Experimental|experimental group|Experimental group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
89664550|NCT04932720|No Intervention|control group|Also the control group consisted of children aged 8-18 years, who did not have a different disease accompanying the oncological disease.
89214110|NCT02543060|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
89214111|NCT02543060|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
89664551|NCT04898673|Experimental|CP1110 Sound Processor|
89664552|NCT04898673|Active Comparator|CP1000 Sound Processor.|
89214112|NCT04012788|Active Comparator|probiotic arm|inulin, 15 g Lactobacillus rhamnosus (LGG®) Lactobacillus acidophilus (LA-5®) Lactobacillus paracasei (L. casei 431®) Bifidobacterium lactis (BB-12®), Total cell counts 150 billion/day
89214113|NCT04012788|Placebo Comparator|placebo arm|placebo powder, 15 g
89214114|NCT00138073|Experimental|Web-based waveform interpretation guide|The arm has access to the Web-based waveform interpretation guide.
89214115|NCT04038164|Experimental|Dog-Assisted Therapy (DAT) and pharmacological treatment|The DAT program comprised 12 manualized sessions and included two phases: 1) individual intervention (6 sessions) and 2) group activity (6 sessions). Patients participated in weekly sessions for about 3 months. Each session lasted 45 minutes. The groups were formed by 3-4 patients. Sessions included the participation of two certified therapy dogs, two technicians specialized in DAT and a psychologist. Participants in this group were visited by their psychiatrist in order to monitor their adherence to medications.
89214116|NCT04038164|Active Comparator|Treatment as usual (TAU, pharmacological treatment)|Participants received their usual treatment. They were visited by their psychiatrist in order to monitor their adherence and continuation on medications as prescribed. Inclusion and exclusion criteria were the same as for the experimental group. Participants in the TAU group did not receive DAT sessions.
89214117|NCT04013490|Placebo Comparator|Placebo capsule|Subject receive the Placebo product for 4 weeks.
89214118|NCT04013490|Active Comparator|Cassava dietary fiber capsule 1.5 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 1.5 g/day for 4 weeks.
89214119|NCT04013490|Active Comparator|Cassava dietary fiber capsule 3 g/day|Subjects receive Cassava dietary fiber capsule at the dose of 3 g/day for 4 weeks.
89214120|NCT04037306|Active Comparator|Rapid Feedback|Participants received daily feedback on both fiber intake and stool butyrate measurements.
89214121|NCT04037306|Active Comparator|Delayed Feedback|Participants received daily feedback on fiber intake and one-time feedback on stool butyrate measurements at the end of the study period.
89214122|NCT02581631|Experimental|Nivolumab+Brentuximab Vedotin|Nivolumab+Brentuximab Vedotin dose as specified
89214123|NCT00939744||EAU2|Women who will have a c-section at the CHUS
89664553|NCT04932330||ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score < 48 out of a maximal score of 60 when discharged.
89664554|NCT04932330||no ICU-acquired weakness group|Patients receiving extracorporeal membrane oxygenation support who had a Medical Research Council (MRC) sum score ≥ 48 out of a maximal score of 60 when discharged.
89664555|NCT03008967||Total Knee and Hip Arthroplasty|Rehabilitation, observational. Identification of risk factors for poor response to rehabilitation programs after TJR and use these to identify patients who are most susceptible to poor outcomes
89664556|NCT04921566|Other|Sequence TR|13 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89664557|NCT04921566|Other|Sequence RT|13 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Toradiur® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Torasemide (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89664558|NCT02655601|Experimental|Radiation Therapy, TMZ and BMX-001|Patients will receive standard of care radiation therapy plus temozolomide (TMZ). BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks. A total of 80 subjects will receive BMX-001 in this phase.
89664559|NCT02655601|Active Comparator|Radiation Therapy and TMZ|In this arm, one-half of the study subjects will not receive BMX-001 but will undergo all components of standard therapy (radiation therapy plus temozolomide [TMZ]). A total of 80 subjects will be in this study arm.
89664560|NCT04821531|Experimental|PT Pal|Experimental Arm-PT PAL Participants randomized into this arm will receive exercise instructions via Pt_PAL. PT PAL is a mobile health technology used to facilitate communications between Care teams and patients, by allowing the team to send web-based exercise routines, surveys and educational materials. The PT Pal app captures patient activity adherence and reports
89664561|NCT04821531|Active Comparator|Exercise Manual|Control Arm- Exercise Manual Participants randomized into this arm will use the exercise manual to obtain their exercise instructions
89664562|NCT02622828|Other|Behavioural|Participant-identified community based activity
89664563|NCT02652247|Experimental|ventilated trauma patients with pneumonia|ventilated trauma patients with pneumonia
89664564|NCT02652247|Experimental|ventilated trauma patients without pneumonia|ventilated trauma patients without pneumonia
89214124|NCT00884546|Experimental|Arm 1|BMS-833923 (Starting dose is a loading dose of 60 mg for 7 days with a 30 mg daily dose thereafter)
89214125|NCT00884546|Active Comparator|Arm 2|"BMS-833923 (MTD or below)~Lenalidomide (at or below the recommended prescribing dose)~Dexamethasone (40 mg)"
89214126|NCT00884546|Active Comparator|Arm 3|"BMS-833923 (MTD or below)~Bortezomib (at or below the recommended prescribing dose)"
89214127|NCT04970277|Experimental|drinking water group|Patients in this group drink colorless water after capsule ingestion.
89214128|NCT04970277|Other|control group|Patients in this group don't drink colorless water after capsule ingestion.
89214129|NCT05444049|Experimental|Treatment|The NEURESCUE device will be used as an adjunct to ACLS.
89214130|NCT00886106|Experimental|1|Remifentanil
89214131|NCT00886106|Active Comparator|2|Midazolam
89214132|NCT00939978|Active Comparator|Venoferrum|
89214133|NCT00939978|Placebo Comparator|saline|
89214134|NCT04012320||Pamidronate therapy|
89214135|NCT04012320||Zoledronate therapy|
89214136|NCT05278910|Placebo Comparator|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour.
89214137|NCT05278910|Experimental|Fish oil + Roasted wheat flour|Assign fish oil capsule and roasted wheat flour.
89214138|NCT05278910|Experimental|Soybean oil + Vegetable and fruit extracts|Assign soybean oil capsule and Vegetable and fruit extracts.
89214139|NCT05278910|Experimental|Fish oil + Vegetable and fruit extracts|Assign fish oil capsule and Vegetable and fruit extracts.
89214140|NCT00940212|Experimental|A|AZD2423
89214141|NCT00940212|Experimental|B|Placebo
89214142|NCT00529035|Experimental|Interleukin-2|"Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)"
89214143|NCT04421664|Experimental|Treatment|Participants in this arm will receive the study drug, hydroxychloroquine.
89214144|NCT04421664|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
89214145|NCT02578043|Experimental|Clindamycin and BPO Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% applied to the face once daily for 84 days.
89214146|NCT02578043|Active Comparator|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) applied to the face once daily for 84 days.
89214147|NCT02578043|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied to the face once daily for 84 days.
89214148|NCT04037384|Active Comparator|Eye Yoga group|Eye yoga exercises
89214149|NCT04037384|Placebo Comparator|Reading Group|Passive reading
89214150|NCT03919643||SLE patients with nephritis|No intervention. Peripheral blood and urine samples will be obtained
89214151|NCT03919643||SLE patients with without nephritis|No intervention. Peripheral blood and urine samples will be obtained
89214152|NCT03919643||Healthy controls (blood donors)|No intervention. Peripheral blood and urine samples will be obtained
89214153|NCT00940056|Experimental|Endoscopic ablation of atrial fibrillation|
89214154|NCT00940056|Active Comparator|Rate control|
89214155|NCT00889850|Active Comparator|1|Oral fasted administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
89214156|NCT00889850|Active Comparator|2|Oral fasted administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
89214157|NCT00889850|Active Comparator|3|Oral fed administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
89214158|NCT00889850|Active Comparator|4|Oral fed administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
89214159|NCT04074317|Experimental|PRAM9 to Regular Insulin to Regular Insulin+pramlintide|Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin (Humulin®) to Regular Insulin+pramlintide (Symlin® pen) as separate SC injections
89214160|NCT04074317|Experimental|Regular Insulin to Regular Insulin+pramlintide to PRAM9|Regular Insulin (Humulin®) to Regular Insulin+pamlintide (Symlin® pen) as separate SC injections to PRAM9
89214161|NCT04074317|Experimental|Regular Insulin+pramlintide to PRAM9 to Regular Insulin|Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin
89521816|NCT03414671||Standardized|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 6/1/2018 - 12/31/20 (the group following implementation of the standardized defined CSCPE)
89521817|NCT03414593|Experimental|preoperative blocked leg: group preB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml Before surgical incision
89521818|NCT03414593|Active Comparator|postoperative blocked leg: group postB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml After surgical incision
89521819|NCT03414281|Experimental|TMQLB group 1|0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
89521820|NCT03414281|Experimental|TMQLB group 2|0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
89521821|NCT03414281|Active Comparator|TPVB group|0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.
89521822|NCT03419507|Active Comparator|Macintosh group|After separating participants into two groups, doctors that drawed envelop number 1 will be asked to intubate with laryngoscope by using No. 3 Macintosh laryngoscope
89521823|NCT03419507|Active Comparator|Endotracheal tube introducer group|After separating participants into two groups, doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by using the adult size endotracheal tube introducer with using No. 3 Macintosh laryngoscope.
89521824|NCT02411084|Experimental|BEGEDINA® (Begelomab)|BEGEDINA® (Begelomab) (murine monoclonal antibody against CD26). Dose is 2.7 mg/m2/day i.v. infusion for 5 consecutive days (Study Days 1, 2, 3, 4, 5) and then single dose on each of Study Days 10, 14, 17, 21, 24 and 28, for a total of 11 doses. BEGEDINA® is supplied as 1 mg/mL concentrate for solution for infusion in vials of 6 mL (5.4 mg of active substance) for reconstitution. The total volume to be administered should be further diluted in 100 mL of 0.9% sodium chloride solution for injection prior to administration. The infusion lasts 60 minutes. Subjects are eligible for a single treatment for flare after study Day 28
89521825|NCT02411084|Active Comparator|Conventional Second-line Treatment|Subjects in the conventional treatment arm will receive a second line treatment, which is to be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center. Currently no treatments for this life-threatening disease have been approved in either the USA or Europe. The recommendations of the American Society for Blood and Marrow Transplantation (ASBMT) confirm that no treatment for acute steroid-refractory GvHD can be considered gold standard in terms of TRM or survival as results remain unsatisfactory and this approach has been agreed by the FDA and the EMA.
89521826|NCT03413839|Experimental|PSSE Group|Individuals will receive at least 6 sessions of physiotherapeutic scoliosis specific exercises (PSSE) (Schroth) physical therapy. Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
89521827|NCT03413839|Other|Conventional PT Group|Individuals will receive at least 6 sessions of conventional physical therapy (PT). Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
89664565|NCT02652247|Experimental|ventilated surgical ICU patients with pneumonia|ventilated surgical ICU patients with pneumonia
89664566|NCT02652247|Experimental|ventilated surgical ICU patients without pneumonia|ventilated surgical ICU patients without pneumonia
89664567|NCT01322607|Other|Arm 1: High-Intensity Program|High-intensity treadmill-based exercise
89664568|NCT01322607|Other|Arm 2: Low-Intensity Program|Low-intensity lifestyle intervention (group exercise)
89664569|NCT05586841|Experimental|Dalpiciclib + Chidamide|Dalpiciclib will be administered in a dose of 100 mg/d or 125 mg/d. Chidamide shall be designed in a dose of 25 mg/BIW or 20 mg/BIW
89664570|NCT04431336||younger aortic dissection or aneurysm patients|this is an observation cohort study about younger aortic dissection or aneurysm patients without intervention.
89664571|NCT01365819|Placebo Comparator|Sugar pill|Placebo
89664572|NCT01365819|Experimental|Varenicline|Varenicline (Chantix (R))
89664573|NCT04932174|Experimental|High-intensity Interval Training|Group 2: the included 15 subjects will participate in High intensity Interval training exercise running on treadmill for 12 weeks, 3 times / week.
89664574|NCT04932174|Active Comparator|Low-intensity Continuous Training|Group 1: the included 15 subjects will participate in low intensity continuous exercise on treadmill for 12 weeks, 3 times / week
89664575|NCT01893463||Patients which received the iTClamp as treatment|Use of the iTClamp50 will be determined by the EMS and ER physicians. Patients who have received treatment will be tracked from pre-hospital to patient discharge (chart review). EMS care providers and physicians will answer a survey about their experience with the iTClamp50.
89664576|NCT04932408|Experimental|Hip Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed around the hip region.~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.~Cool down. Post intervention- Semi-structured Interview schedule"
89664577|NCT04932408|Experimental|Chest Region|"Pre selected exercises (8) will be performed by the participant using an elastic resistance band anchored from ground level and placed the chest region (using velcro on a chest harness/training vest).~Warm up: 5-10 mins~Exercises:~Forward step, forward tandem steps, forward tandem hold, Upper body rotation, side steps. backward step, backward tandem walk, backward tandem hold.~Cool down. Post intervention- Semi-structured Interview schedule"
89664578|NCT02635555|Experimental|Adjusted Spinal Dose|"Patients in this group receive height and weight adjusted dose for spinal anesthesia.During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
89664579|NCT02635555|Active Comparator|Standard Spinal Dose|"Patients in this group receive a fixed standard dose for spinal anesthesia. During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
89664580|NCT01322841|Active Comparator|CHICA Diagnosis Module|This arm had the CHICA screening module turned on
89664581|NCT01322841|Placebo Comparator|CHICA Placebo|This arm had CHICA but no additional module
89048428|NCT04645563||Bedside Consultation Group|"This group includes 90 patients who have consulted bedside. The patients that has problems which are concerning multiple consultation will be excluded.~The ED physician wrote a consultation note over the hospital information system by specifying the patient's clinical status, history and laboratory parameters. A physician will be consulted for all the eligible subjects after their laboratory results and CT reports were complete. The ID physician examined the subjects at the bedside within 30 minutes (the legal response time in Turkey) of seeing the consultation request. Consultation response time will be saved as time between entering consultation information through the system to completion of the consultation note Although the consultant ID physicians will be informed via Whatsapp, they held the consultation at the bedside for the subjects they deemed appropriate."
89048429|NCT00558597||1|30 patients with stable graft function
89048430|NCT00558597||2|30 patients with acute rejection after lung transplantation
89048431|NCT04637217||Control|
89048432|NCT04637217||Diabetes mellitus without Diabetic Retinopathy|
89048433|NCT04637217||Diabetes mellitus with Diabetic Retinopathy|
89048434|NCT04637061||REC4T study patients|Rectal adenocarcinoma or polyp with indication for resection and primary colo-rectal mechanical anastomosis using a circular stapler with/or without protective ostomy undergoing upfront surgery and patients undergoing neoadjuvant therapy followed by surgery (see Inclusion/Exclusion Criteria)
89048435|NCT00558675|Experimental|1|Single intravenous infusion of AlloStim
89664582|NCT04931940|Active Comparator|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
89664583|NCT04931940|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
89048436|NCT00558675|Experimental|2|Intravenous AlloStim infusion on day 1 and day 7
89048437|NCT00558675|Experimental|3|Intravenous AlloStim infusion on day 1, day 7 and day 14
89048438|NCT00558675|Experimental|4|Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21
89048439|NCT04637139|Experimental|Group 1|VBR 300 mg solution containing 2 µCi [14C]VBR
89048440|NCT00547001|Active Comparator|1|Group A will be tapered over 4 weeks, starting at baseline (week 0). Subjects in this group will take one tablet of ET daily (effective dose, 0.75 mg) for week 1, then one 0.50 mg tablet daily for week 2, then one 0.25 mg tablet daily for week 3, and finally one 0.125 mg tablet daily for week 4.
89048441|NCT00547001|Placebo Comparator|2|Group B will be administered placebo. These tablets will appear identical to those administered to subjects in Group A, but the tablets will contain no estrogen. Subjects in this group will be instructed to take one pill every day for the 4 weeks. Thus, while patients will, in effect, be stopped abruptly from their therapy, there is still the potential of a placebo effect.
89048442|NCT00547001|No Intervention|3|"Group C will have their therapy discontinued acutely at baseline (week 0); i.e., these subjects will not take any tablets after the 8-week stabilization phase ends. While we recognize that this group will not be blinded to the regimen they are receiving, we feel that group C will be important to include in light of the consistent decrease in vasomotor symptoms experienced by women taking placebo. Because women taking placebo have approximately a 35% decrease in vasomotor symptoms, it will be important to compare our taper regimen to the real life scenario of stopping medication abruptly."
89664584|NCT04673019|Experimental|Immediate Intervention|"The immediate intervention group will receive the intervention at the time of consent (baseline) and will be enrolled in the intervention for a total of 6 months:~Months 1- 3 (Approximately Day 1-Day 90)~Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).~Use of Nurse AMIE while receiving intervention phone calls from a study facilitator. We are interested in learning whether the phone calls are necessary or if the Nurse AMIE platform can stand alone and see the same effect.~Months 4-6 (Approximately Day 91-180) o Participant will continue to use Nurse AMIE, but without phone calls from study facilitator"
89664585|NCT04673019|Other|Delayed Intervention|"The delayed intervention group will receive the intervention 3 months after consent (3 months of no intervention followed by with 3 months of intervention, for a total of 6 months); the participant will follow the pattern listed below:~Months 1- 3 Approximately (Day 1-Day 90)~o No use of Nurse AMIE~Months 4-6 (Approximately Day 91-180)~Participant will receive the Echo Show, a pedometer (to track their steps) and an exercise band (to complete the exercise interventions).~Use of Nurse AMIE while receiving intervention phone calls from a study facilitator"
89664586|NCT04931784|Active Comparator|Nitrate Group|with administration of intra-coronary nitrate before percutaneous coronary intervention
89664587|NCT04931784|Placebo Comparator|Control Group|without administration of intra-coronary nitrate before percutaneous coronary intervention
89664588|NCT04352361|Experimental|TVB-2640 tablets|
89664589|NCT04352361|Placebo Comparator|placebo|
89664590|NCT04934202||Patients from the 1st epidemic wave|"One year after their discharge from the initial hospitalization, patients who presented symptoms during the evaluation in COMEBAC 1st wave in summer 2020 will benefit from a telephone assessment on the same schedule as that detailed above. If symptoms persist, they will be called to the day hospital for an assessment similar to the one detailed above."
89664591|NCT04934202||Patients from the 2nd epidemic wave|"As during the evaluation carried out during the 1st wave, the detection of persistent symptoms will be done in two stages:~During a teleconsultation, to which all eligible patients will be invited, systematically looking for general, neurological, cognitive and respiratory symptoms~During a hospitalization in an outpatient clinic to which all survivors who have stayed in an intensive care unit (ICU) will be invited and, among patients who have not stayed in an ICU, those who have residual symptoms detected during the teleconsultation."
89664592|NCT01893541|Active Comparator|EBL PLUS PROPRANOLOL|The EBL procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices were obliterated. The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
89048443|NCT05034107|Experimental|Persons with dementia|Persons who have been diagnosed with dementia by their physicians and in nursing homes. Persons with dementia who have at least one symptom of BPSD and willing to participate in this study. These participants will be exposed to diffused Ylang-Ylang aromatherapy.
89048444|NCT04645485|Experimental|Experimental arm|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).
89048445|NCT05030792|Experimental|ART VR 3 times/week|ART VR practice for 30 minutes, at home, 3 times per week
89048446|NCT05030792|Experimental|ART VR 4 times/week|ART VR practice for 30 minutes, at home, 4 times per week
89048447|NCT04636866||Gastric ulcer|
89048448|NCT04636866||Duodenal ulcer|
89048449|NCT05016674|Experimental|Laser-assisted liposuction|Laser-Assisted Liposuction with the LipoLife system.
89214162|NCT04074317|Experimental|PRAM9 to Regular Insulin+pramlintide to Regular Insulin|Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Regular Insulin
89214163|NCT04074317|Experimental|Regular Insulin to PRAM9 to Regular Insulin+pramlintide|Regular Insulin (Humulin®) to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin+pramlintide (Symlin® pen) as separate SC injections to Regular Insulin
89214164|NCT04074317|Experimental|Regular Insulin+pramlintide to Regular Insulin to PRAM9|Regular Insulin (Humulin®)+pramlintide (Symlin® pen) as separate SC injections to Xeris pramlintide + insulin co-formulation (PRAM9) to Regular Insulin to Xeris pramlintide + insulin co-formulation (PRAM9)
89214165|NCT00941148|Active Comparator|Insulin glargine|Insulin glargine, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
89048450|NCT04645641|Active Comparator|CGM Users|Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.
89048451|NCT04636476|Other|Modified Nesbit technique followed by dorsal dartos flap|Modified Nesbit technique to correct penile curvature followed by dorsal dartos flap to correct penile torsion
89048452|NCT04645407|Experimental|FZHY Group|conventional therapy plus Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time.)
89048453|NCT04645407|No Intervention|Control Group|conventional therapy
89048454|NCT00547040||A|incident renal transplant patients
89214166|NCT00941148|Active Comparator|NPH Insulin|NPH Insulin, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
89214167|NCT00941148|Active Comparator|Insulin detemir|Insulin detemir, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
89214168|NCT02541500|Experimental|Minocycline|Patients in this arm will receive oral minocycline
89521828|NCT01602315|Experimental|Phase Ib: A-BYL719 FC whole tab+cetux|Oral film-coated tablets without swallowing dysfunction.
89521829|NCT01602315|Experimental|Phase II: 2-Cetuximab|Cetuximab in patients naive to cetuximab (phase ll)
89521830|NCT01602315|Experimental|Phase Ib: B-BYL719 FC drink sus+cetux|Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
89521831|NCT01602315|Experimental|Phase II: 3-BYL719 + Cetuximab|BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
89664593|NCT01893541|Active Comparator|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
89664594|NCT03012711|Experimental|Training|Neuromuscular exercise training group will complete a 5 week NME training program
89048455|NCT04645056|Experimental|Intervention group|"a. Intervention Group: Neck stretching and movement~The patient starts the stretching exercises the morning after surgery with instructions from a trained professional at the department. The patient is informed that the stretching exercises will not affect the surgical wound. The patient is instructed in performing five repetitions of each of the following nine exercises three times each day in four weeks:~Relax shoulders and neck sufficiently~Look down - Stretching and movement~Look to each side - movement~Lower the head to each side - stretching~Lower the head diagonally to each side - stretching~Small nod movements~Lift the shoulders - movement~Roll the shoulders - movement~Lift the arms - movement~The first stretching session is observed by the instructor who gives feedback and correct the exercises, if necessary. Furthermore, the patient is given a training brochure."
89048456|NCT04645056|No Intervention|Control group|b. Control group The patients in the control group are not instructed in any intervention but are answering completely similar questionnaires as the intervention group.
89048457|NCT04684316|No Intervention|Care-as-usual: all consult physician|All employees at risk are invited to attend screening. Upon arrival, several biometrics are measured (weight, length, Body Mass Index, blood pressure), along with spirometries, a vision test, and a blood and urine test. The OP then investigates the general health status and systems of the employee, which includes an anamnesis with questions about new health burdens or changes in occupational risks, follow-up questions on previous complaints, medical advice, referral to a healthcare provider, or booking another appointment with an occupational health specialist. After the PHS, a (employee-unique) link to an online questionnaire is sent by email to gather information on final (health, health care use, absenteeism and presenteeism) and intermediary (health literacy, help-seeking behaviour) outcomes.
89664595|NCT03012711|No Intervention|Control|Control group will have 5 weeks with no intervention prior to being re-tested
89664596|NCT02849899|Active Comparator|Vildagliptin|Group 1 will be treated with Vildagliptin 50 or 100 mg/day for 2 months, then 25 or 50 mg/d for 1 month depending on their creatinine assay.
89664597|NCT02849899|Placebo Comparator|Placebo|Group 2 will be treated with placebo according to the same dosage.
89664598|NCT04934280|Other|2D transvaginal ultrasonography|
89664599|NCT04931706||N-Sleve patients|Patient that were selected for surgery
89664600|NCT01369875|Experimental|Standard Young TIL|"Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
89664601|NCT01369875|Experimental|ECCE Young TIL|"Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
89664602|NCT04931004|Experimental|0.075% Cetylpyridinium Chloride|
89664603|NCT04931004|Experimental|1.5% Hydrogen peroxide|
89664604|NCT04931004|Experimental|Chlorhexidine gluconate|
89664605|NCT04931004|Placebo Comparator|Water rinse|Control for impact on viral load changes from mechanical rinsing
89664606|NCT02763319|Experimental|Tafasitamab and bendamustine|Tafasitamab and bendamustine
89664607|NCT02763319|Active Comparator|Rituximab and bendamustine|Rituximab and bendamustine
89664608|NCT04921020||Normal participants|
89664609|NCT04921020||Patients with blepharoptosis|
89664610|NCT04921020||Patients with blepharospasm|
89664611|NCT04921020||Patients with dry eye disease|
89664612|NCT04921020||Patients with Graves' disease|
89664613|NCT04933578||Children|"The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children.~The children's preferences for the appearance of dentists were determined in the second part.~Routine dental examinations of children with a dental mirror and artificial light were completed by an experienced pediatric dentist according to the World Health Organization (WHO) guidelines and criteria."
89664614|NCT04933578||Parents|"The questionnaire including demographic information (age, sex, and medical and dental history) was applied to the parents.~In the second section, the MDAS was administered to parents, differently from children.~The parents' preferences for the appearance of dentists were determined in the second part."
89664615|NCT04841473|Active Comparator|Standard Concussion Education|Participants will receive standard concussion education materials (online training) focused on concussion prevention in youth sport.
89664616|NCT04841473|Experimental|TRAIN Concussion Education|After receiving the standard concussion education materials (online training), participants will receive an additional module, the TRAIN concussion education module.
89664617|NCT04930926||INFECTION DISEASE PATIENTS WITH PNEUMONIA OR SARHS COVID19|NO SPECIFIC INTERVENTION
89664618|NCT01323153|Experimental|Dalcetrapib|
89664619|NCT01323153|Placebo Comparator|Placebo|
89664620|NCT04920786|Experimental|TB006 70 mg - 5000 mg IV|TB006 infused intravenously over 1 hour
89664621|NCT04920786|Placebo Comparator|Placebo|0.9% normal saline infused intravenously over 1 hour
89664622|NCT04912986|Placebo Comparator|routine treatment|Review the collection of patient-related clinical data, collation of clinical data and outcome indicators
89664623|NCT04912986|Experimental|Experimental group|The intervention was implemented in accordance with the Early Lung Rehabilitation Training Programme for Adult Double Lung Transplant Patients
89664624|NCT01323777|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
89664625|NCT02846389|Experimental|Moderate Exercise|Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week).
89664626|NCT02846389|No Intervention|Control Group|No exercise
89664627|NCT01323855|Experimental|Part 1: Severe Renal Impairment|Participants with severe CRI, defined as creatinine clearance of <30 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
89664628|NCT01323855|Experimental|Part 2: Moderate Renal Impairment|Participants with moderate CRI defined as creatinine clearance of ≥30 and <50 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
89664629|NCT01323855|Experimental|Part 2: Mild Renal Impairment|Participants with mild CRI, defined as creatinine clearance of ≥50 and ≤80 mL/min/1.73m^2, were treated with a single tablet of 5 mg preladenant, administered orally
89664630|NCT01323855|Experimental|Part 1: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
89664631|NCT01323855|Experimental|Part 2: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
89664632|NCT02602327|Experimental|Tas-102 and radioembolization|Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
89664633|NCT04930848|Experimental|Intervention Arm|Euphorbia hirta
89664634|NCT04930848|Placebo Comparator|Placebo Arm|Terminalia arjuna and Terminalia bellerica
89664635|NCT02594371|Experimental|Oraxol (paclitaxel + HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
89664636|NCT02594371|Active Comparator|IV paclitaxel|IV paclitaxel - supplied as Taxol or generic
89664637|NCT02197065|Experimental|Atorvastatin|Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
89664638|NCT02197065|Placebo Comparator|Sugar pill|Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
89664639|NCT02591719|Experimental|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS with language task: Perilesional Broca's area
89664640|NCT02591719|Sham Comparator|MagPro magnetic stimulator (sham)|Most activated area from fNIRS with language task: Perilesional Broca's area
89664641|NCT02591719|Active Comparator|MagPro magnetic stimulator (LF rTMS)|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
89664642|NCT01375491|Experimental|Doxycycline|Participants with DM2 receiving doxycycline 100mg BID
89664643|NCT01375491|Placebo Comparator|Placebo|Pills prepared identical to doxycycline.
89664644|NCT02591251|Active Comparator|The povidone-iodine group|The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery
89664645|NCT02591251|Active Comparator|Normal saline group|The patients will be subjected to normal saline solution (Sod. Chloride 0.9%, Nile) for vaginal cleaning before the laparoscopic surgery.
89664646|NCT01325181|Active Comparator|Low-fluence PDT with Verteporfin|Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered
89664647|NCT01325181|Active Comparator|Ranibizumab|Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered
89664648|NCT02751853|Experimental|HFPEF|Patient with heart failure with preserved ejection fraction (HFPEF)
89664649|NCT02751853|Experimental|HFREF|Patient with heart failure with reduced ejection fraction (HFREF)
89664650|NCT02751853|Active Comparator|No HFPEF/HFREF|Patient without heart failure with preserved ejection fraction (HFPEF) or heart failure with reduced ejection fraction (HFREF)
89664651|NCT04345107|Experimental|SY-009-1mg/d-1|0.5mg BID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-1mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
89664652|NCT04345107|Experimental|SY-009-1mg/d-2|1mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8.Start at the same time as the SY-009-1mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，2mg/d.
89664653|NCT04345107|Experimental|SY-009-2mg/d-1|1mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-2 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
89664654|NCT04345107|Experimental|SY-009-2mg/d-2|2mg QD.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. Start at the same time as the SY-009-2mg/d-1 group. At the end of the two groups, the researchers will decide whether to move on to the next stage，4mg/d.
89664655|NCT04345107|Experimental|SY-009-4mg/d|2mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. If the test and safety assessment of 4mg daily dose group (2mg bid) are completed and the dose termination standard is not met, the test will be terminated; if the safety assessment during or after the test reaches the dose termination standard, the study of 3mg daily dose group (1.5mg bid) will be carried out, and then the test will be terminated.
89664656|NCT04345107|Experimental|SY-009-3mg/d|1.5mg BID.The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
89214169|NCT04073849|Active Comparator|Cohort A|EPOGEN® (epoetin alfa) Study Drug Epoetin Alfa (EPOGEN®) 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
89214170|NCT04073849|Sham Comparator|Cohort B|Saline 40 IU / kg dose during boosting phase, delivered s.c.; 8 injections 900 IU dose during microdosing, delivered i.v.; 6 injections
89214171|NCT05280210|Experimental|Neoadjuvant therapy based on PTC drug screening|Patients will receive neoadjuvant therapy based on PTC drug screening. The regimen is complied with NCCN and CSCO guidelines. PD-1 inhibitor will be used if effective in drug screening.
89214172|NCT05280210|No Intervention|Neoadjuvant therapy based on clinical experience|Patients will receive neoadjuvant therapy based on clinical experience. The regimen is complied with NCCN and CSCO guidelines.
89214173|NCT05221203|Experimental|Training|Participants in this arm will perform seven bodyweight training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
89214174|NCT05221203|No Intervention|Control|Participants in this arm will receive no intervention.
89214175|NCT03263429|Experimental|Panitumumab/Irinotecan/CB-839|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28, panitumumab IV over 60-90 minutes on days 1 and 15, and irinotecan hydrochloride IV over 90 minutes on day 1 and 15 (Phase I only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89214176|NCT00941226||Cerebral Palsy|Those kids who have cerebral palsy and are helped by carers
89214177|NCT00609674|Experimental|fluticasone furoate nasal spray|
89214178|NCT00609674|Placebo Comparator|Placebo|
89214179|NCT00940134|Placebo Comparator|placebo|Study participants will receive a 3 hour IV infusion of saline while fasting.
89664657|NCT04345107|Placebo Comparator|SY-009 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
89664658|NCT04912752|Other|Case-Control|Copy number variation
89664659|NCT04912752|Experimental|Case-Control 1|Gene expression
89664660|NCT03057444|Experimental|Intervention group|"The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.~Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention."
89664661|NCT02588443|Experimental|Arm1|Arm I provides one dose of RO70097890 as a single agent in the neoadjuvant setting. Patients will recover from any toxicities and will then have their disease surgically resected. After recovery from surgery patients will proceed to adjuvant therapy which will include nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle. Four cycles of adjuvant therapy will be given. All medications are administered intravenously.
89664662|NCT02588443|Experimental|Arm2|Arm II provides one dose of RO7009789 two days after one dose of nab-paclitaxel and one dose of gemcitabine prior to surgery. Nab-paclitaxel and gemcitabine are given on day 1. RO7009789 will be given on day 3. Patients will recover from any toxicities and will then have their disease surgically resected. Patients will receive four cycles of these same medications in an adjuvant fashion after recovering from surgical resection. A cycle will consist of nab-paclitaxel (125mg/m²), gemcitabine (1000mg/m²) given on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle.
89664663|NCT03055962|Experimental|E2609 50 mg|Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.
89214180|NCT00940134|Experimental|PYY3-36 + GLP-1|Study participants will receive a 3 hour IV infusion of (GLP-1 + PYY3-36) while fasting.
89214181|NCT00940134|Active Comparator|GLP-1|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
89214182|NCT00940134|Active Comparator|PYY3-36|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
89214183|NCT00941382|Experimental|Sibutramin-Metformin|Sibutramine-metformin therapy in a single tablet
89214184|NCT00941382|Active Comparator|Sibutramine|Sibutramine monotherapy
89664664|NCT03055962|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 days.
89664665|NCT04352595|Experimental|1% Hemay808|
89664666|NCT04352595|Experimental|3% Hemay808|
89664667|NCT04352595|Experimental|7% Hemay808|
89664668|NCT04352595|Placebo Comparator|vehicle|
89664669|NCT02744287|Experimental|Arm 1: Phase 1 Dose Escalation|Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.
89664670|NCT02744287|Experimental|Arm 2: Phase 2 Dose Expansion|Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.
89214185|NCT00941382|Active Comparator|Metformin|Metformin monotherapy
89214186|NCT00137839|Experimental|Erlotinib|Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.
89214187|NCT02542982|Experimental|Active treatment|Group of patients on active treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by 20 minutes of 2 mA anodal tDCS over the ipsilesional motor cortex.
89214188|NCT02542982|Sham Comparator|Sham comparator|Group of patients on sham treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by sham tDCS over the ipsilesional motor cortex.
89214189|NCT00941460|Experimental|one week on one week off|One week on temozolomide is followed by a week without temozolomide.
89214190|NCT00941460|Experimental|three weeks on, one week off|Temozolomide is given over 3 weeks, followed by a week without temozolomide.
89214191|NCT02542904|Active Comparator|LME|the anastomosis was performed as stapled side-to-side with local excision of the mesenteric tissue adjacent to the diseased bowel
89214192|NCT02542904|Active Comparator|EME|the anastomosis was performed as a stapled side-to-side anastomosis with extensive excision of mesenteric tissue.
89664671|NCT04920240|Placebo Comparator|routine group|"In accordance with the intensive care unit hospital infection prevention and control norms requirements"
89664672|NCT04920240|Experimental|Experimental group|Implement a multi-center unified ICU high-frequency contact surface standardized cleaning and disinfection mode
89214193|NCT04013178|Experimental|Accentuated eccentric loading + electromyostimulation|This group will undertake a supervised 12-week intervention involving accentuated eccentric loading and electromyostimulation of the knee extensors, dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
89664673|NCT04930224||Proliferative Diabetic retinopathy|40 patients with proliferative diabetic retinopathy
89214194|NCT04013178|Active Comparator|Traditional resistance training|This group with undertake a supervised 12-week intervention involving volume matched dynamic resistance training of the knee extensors, and dynamic resistance training of lower limb antagonist and synergist muscles and upper limb dynamic resistance training.
89214195|NCT00886184|Experimental|1|Induction of pre hospital early hypothermia in patients having a cardiac .
89214196|NCT00886184|Active Comparator|2|Induction of hypothermia only at hospital arrival.
89214197|NCT00884624||A|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
89214198|NCT02542670||Cancer colon with no distant metastasis|Genetic: Whole genome Sequencing
89214199|NCT02542670||Cancer colon with distant metastases|Genetic: Whole genome Sequencing
89214200|NCT02542670||control group|Genetic: Whole genome Sequencing
89214201|NCT00890318|Other|1|Healthy volunteers, receiving daily dose of 80 mg ABT-072 or placebo, QD for 10 days; and on Study Day 11 receiving a single dose of 80 mg ABT-072 or placebo + 400 mg ketoconazole
89214202|NCT00890318|Other|2|Healthy volunteers, receiving 160 mg ABT-072 or placebo, QD for 10 days.
89214203|NCT00890318|Other|3|Healthy volunteers, receiving 320 mg ABT-072 or placebo, QD for 10 days.
89664674|NCT04930224||Non-Proliferative Diabetic retinopathy|40 patients with non-proliferative diabetic retinopathy
89664675|NCT04930224||Healthy individuals|40 healthy persons
89664676|NCT05024305|Experimental|Dose Escalation Cohort|Four dose levels of TWP-102 injection will be tested by BOIN study design.
89664677|NCT05024305|Experimental|Dose Expansion Cohort|Once the effective doses have been determined, two expansion cohorts will be opened to evaluate the efficacy and safety in one or two tumors.
89664678|NCT03057210|No Intervention|S1 (Basal)|The behavior of the variables of functional and clinical outcome will be analyzed under no stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
89664679|NCT03057210|Experimental|S2 (Massage)|The behavior of the variables of functional and clinical outcome will be analyzed under stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
89214204|NCT00563316|Experimental|Panitumumab + Irinotecan|Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.
89214205|NCT04037774|Active Comparator|dex 5microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 5micrograms of dexmedetomidine.
89214206|NCT04037774|Active Comparator|dex 10microgram|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of 10micrograms of dexmedetomidine.
89214207|NCT04037774|Placebo Comparator|placebo|this group of patients is given total 2ml solution intrathecally, 1ml of 5mg local anesthetic i.e 0.5% hyperbaric bupivacaine and 1ml of placebo.
89214208|NCT00890474|Experimental|Moxibustion|
89214209|NCT00890474|No Intervention|Control|
89214210|NCT01529736|Experimental|High torque insertion|High torque insertion
89214211|NCT01529736|Active Comparator|Low torque insertion|Low torque insertion
89214212|NCT02542748|Experimental|norepinephrine|norepinephrine is injected after spinal anesthesia
89214213|NCT02542748|Other|ephedrine|ephedrine is injected after spinal anesthesia
89214214|NCT00941616|Experimental|PK|Includes subjects participating in the pharmacokinetic component of the study.
89664680|NCT03057210|Experimental|S3 (Exercise)|The behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exercise protocol is performed. In this stage the volunteers will first perform the protocol for exhaustion, and in specific moments the blood lactate and clinical data will be collected, and 2h after the beginning of the exercise protocol, the functional tests will be performed.
89664681|NCT03057210|Experimental|S4 (Exercise + Immediate Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed from the exercise protocol, followed by massage. Firstly the volunteers will carry out the protocol for exhaustion and the massage application will be done immediately after the end of the exercise. Blood lactate and clinical data will be collected at specific times during this stage. After 2h of the beginning of the stress protocol, the functional tests will be performed.
89688679|NCT03634813|Active Comparator|Usual Care|The usual care group will receive brief counseling after the PAT visit which will review their blood pressure readings taken at the clinic and how they compare with the American Heart Association (AHA) blood pressure guidelines. They will be offered the suggestion that they should follow up with their primary care doctor 2-4 weeks after their surgical episode is completed, or at their earliest convenience.
89214215|NCT00941616|Experimental|Prophylaxis|Includes subjects receiving 12 months of prophylactic therapy.
89214216|NCT00941616|Experimental|On-demand|Includes subjects receiving 12 months of on-demand treatment.
89214217|NCT00941616|Experimental|Cross-over to prophylaxis|"Includes subjects completing 12 months of on-demand treatment (the On-demand arm) who cross-over to prophylactic therapy for an additional 12-month period."
89214218|NCT04037540|Experimental|Operational approach|The patients enrolled in this arm underwent surgical treatment of the Jones fracture.
89214219|NCT04037540|Experimental|Conservative approach|The patients enrolled in this arm were treated conservatively, using fixation of the injured extremity.
89214220|NCT00941694|Experimental|Self-Management Intervention|Will receive 6 asthma self-management group or individual session over a 7 week period
89214221|NCT00941694|Placebo Comparator|Control|Group will receive 3 phone calls not related to asthma self management over a 7 week period
89214222|NCT02542592|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
89214223|NCT02542592|Placebo Comparator|Placebo|Preoperative single dose of isotonic Sodium Chloride
89664682|NCT03057210|Experimental|• S5 (Exercise + Active Recovery + Delayed Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exhaustion protocol and the application of the massage after 1h of passive recovery. Firstly the volunteers will perform the protocol for exercise, followed by a passive recovery of 1h and then the massage application. The functional tests will be performed 2 hours after the stress protocol begins. Again, blood lactate collection and clinical data will occur at specific times.
89664683|NCT04912440||MSE-ERCP|Group of patients, that received motorized spiral enteroscopy assisted ERCP in altered anatomy at the single study center
89664684|NCT01375569|Experimental|TRC105 in Liver Cancer|TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
89664685|NCT04919850|Active Comparator|Intervention group|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
89664686|NCT04919850|Placebo Comparator|Placebo group|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
89664687|NCT02734615|Experimental|Arm A|Patients will get LSZ102 single agent during dose escalation.
89664688|NCT02734615|Experimental|Arm B|Patients will get LSZ102 in combination with LEE011 during dose escalation.
89664689|NCT02734615|Experimental|Arm C|Patients will get LSZ102 in combination with BYL719 during dose escalation.
89664690|NCT02734615|Experimental|Arm 1|Patients will get LSZ102 single agent during dose expansion
89664691|NCT02734615|Experimental|Arm 2|Patients will get LSZ102 + LEE011 (LEE011 intermittent regimen) during dose expansion
89664692|NCT02734615|Experimental|Arm 3|Patients will get LSZ102 + LEE011 (LEE011 continuous regimen) during dose expansion
89664693|NCT02734615|Experimental|Arm 4|Patient will get LSZ102 in combination with BYL719 during dose expansion
89664694|NCT04912362|Experimental|YAG iridotomy+CLASS|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
89664695|NCT04912362|No Intervention|CLASS|CO2 Laser-Assisted Sclerectomy Surgery only
89664696|NCT03056820|Active Comparator|A - 25° head-up position|Participants will be positioned at 25° angle for procedure.
89664697|NCT03056820|Active Comparator|B - 55° head-up position|Participants will be positioned at 55° angle for procedure.
89664698|NCT02582359|Experimental|MLN9708|"Phase I dose escalation study of MLN9708 with induction chemotherapy~MLN9708 -oral on predetermined days per cycle~Cytarabine, continuous infusion for predetermined duration and dosage~Daunorubicin short IV infusion or rapid injection for predetermined~Phase I dose escalation study of MLN9708 with consolidation chemotherapy after establishment of MTD with induction"
89664699|NCT04919694|Experimental|combination of orbital compression and strabismus surgery|orbital compression and strabismus surgery are performed at the same time
89664700|NCT04919694|Active Comparator|perform strabismus surgery after orbital compression|Firstly, perform orbital compression, after about 3 to 6 months ,strabismus surgery is done.
89664701|NCT04912284||General population|Questionnaire administered to adult population
89664702|NCT04912284||Health care workers|Questionnaire administered to adult health care workers
89664703|NCT05021809|No Intervention|Group A|control group will not receive any intracanal medication
89664704|NCT05021809|Active Comparator|Group B|Calcium hydroxide intracanal medication without iodoform (Metapaste )
89664705|NCT05021809|Active Comparator|Group C|Calcium hydroxide intracanal medication with iodoform (Metapex)
89664706|NCT04930146|Experimental|Intervention group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8~Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.~Evaluating the meridian energy by M.E.A.D"
89664707|NCT04930146|No Intervention|Control group (Severe)|"A patient's Glasgow Coma Score (GCS) between 5-8~Conventional treatment.~Evaluating the meridian energy by M.E.A.D"
89688680|NCT04354363|Active Comparator|PRP|women who will receive PRP before ICSI
89688681|NCT04354363|No Intervention|No PRP|women who willnot receive PRP before ICSI
89048458|NCT04684316|Experimental|Intervention: Electronic survey with selective consultations|In the intervention group, all employees at risk receive a (employee-unique) link to an online health screening questionnaire by email. Dependent upon their answers, 20% of the employees (i.e. the 20% of the employees that mostly need contact with the OP) are referred to the occupational physician for a discussion of the results. The OP then gives medical advice, refers to a healthcare provider (e.g. general practitioner or specialist), or books a (follow-up) appointment with an occupational health specialist (OP, occupational nurse, etc.).
89048459|NCT04636788|Other|pancreatic cancer group|"pancreatic cancer, anticipated participants: 68~other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34"
89048460|NCT04636749|Active Comparator|Erbium laser|Treatment with Erbium laser
89048461|NCT04636749|Sham Comparator|Sham laser|Treatment with sham laser
89048462|NCT00547352|Active Comparator|1|sildenafil treatment for at least 10 weeks prior to a 1 week wash out
89048463|NCT00547352|Active Comparator|2|Tadalafil treatment for 8 weeks following the 1 week washout period.
89048464|NCT04645095|Active Comparator|Conventional TENS|Frequency:80 Hz, duration:100 μs
89048465|NCT04645095|Active Comparator|Burst TENS|Frequency:100 Hz, fr mod: 0, 200 µs, 2 Bps Hz
89048466|NCT04645095|Active Comparator|Modulated TENS|Frequency:80 Hz, fr mod: 50%, Amplitude mode: 40%, duration: 200 µs
89048467|NCT00547391|No Intervention|1|patients on waiting list for a minimum of 5 months. These patients receive no prophylactic intervention for their recurrent pharyngitis episodes.
89048468|NCT00547391|Active Comparator|2|Tonsillectomy as soon as possible after randomization (within 2-3 weeks).
89048469|NCT04636827|Experimental|group 1 (sIPV+DTaP+HepA)|150 subjects; simultaneously administration of sIPV+DTaP+HepA as booster immunization at the age of 18 months old, 0.5 ml each, respectively
89048470|NCT04636827|Active Comparator|group 2 (sIPV)|150 subjects; vaccination of 0.5 ml sIPV as booster immunization at the age of 18 months old
89664708|NCT04930146|Experimental|Intervention group (Moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13~Conventional treatment and bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.~Evaluating the meridian energy by M.E.A.D"
89664709|NCT04930146|No Intervention|Control group (moderate)|"A patient's Glasgow Coma Score (GCS) between 9-13~Conventional treatment.~Evaluating the meridian energy by M.E.A.D"
89664710|NCT02730715||Thymoglobulin|blood specimen collection
89664711|NCT02730715||Basiliximab|blood specimen collection
89664712|NCT04919616|Experimental|Single-arm|
89664713|NCT04125693|Experimental|Cancer patients|Patients from completed Bayer clinical trials, who received rogaratinib as monotherapy or combination therapy for the treatment of cancer.
89664714|NCT04063995|Experimental|Excitatory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment with 10 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in the stimulation. Stimulation is planned for a total of 15 minutes and a total of 1500 beats in the form of a 5 seconds 10 Hz stimulation followed by a 25 seconds interval.
88995137|NCT05535842|No Intervention|Control|The control group will continue with their usual care, i.e., scheduled consultations with their diabetes team at TTSH and any consultations with healthcare professionals and diabetes education support received either during the consultations or during dedicated times if there are any. They will not be asked to use GLOW during the trial.
89048471|NCT04636827|Active Comparator|group 3 (DTaP)|150 subjects; vaccination of 0.5 ml DTaP as booster immunization at the age of 18 months old
89048472|NCT04636827|Active Comparator|group 4 (HepA)|150 subjects; vaccination of 0.5 ml HepA as booster immunization at the age of 18 months old
89048473|NCT04636515|Experimental|Single Arm|
89048474|NCT04636593|Experimental|Induction group|If the lung V20 of initial radiation plan is equal to or more than 28%, then the patient will receive 2 months almonertinib before concurrent thoracic radiotherapy
89048475|NCT04636593|Experimental|Concurrent group|If the lung V20 of initial radiation plan is less than 28%, then the patient will receive concurrent thoracic radiotherapy with almonertinib.
89048476|NCT02277275|Placebo Comparator|Standard protein diet with placebo|Subjects will be provided with standard protein diet for four months and corn starch pills(Placebo) for 6 months
89048477|NCT02277275|Experimental|Standard protein diet with BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months, standard protein diet will be provided for four months
89048478|NCT02277275|Placebo Comparator|High protein diet with placebo|Subjects will be provided with high protein diet for four months and corn starch pills(Placebo) for 6 months
89048479|NCT00547508|Placebo Comparator|1|Placebo
89048480|NCT00547508|Placebo Comparator|2|Placebo
89048481|NCT00547508|Active Comparator|3|tadalafil
89048482|NCT00547508|Active Comparator|4|tadalafil
89048483|NCT00547508|Active Comparator|5|tadalafil
89048484|NCT00547508|Active Comparator|6|tadalafil
89048485|NCT00560274|Experimental|1|
89048486|NCT00547547|Experimental|Treatment (high-selenium therapy and chemotherapy)|
89048487|NCT00547625|Placebo Comparator|1|Placebo run in followed by 5 mg treatment phase 1 and then 20 mg treatment phase 2 which both include a placebo control.
89048488|NCT00547625|Active Comparator|2|Treatment phase 1 includes 5 mg tadalafil 6 weeks then treatment phase 2 which includes 20 mg tadalafil for 6 weeks.
89048489|NCT04645368||Longidaze|80 subjects Longidaze® (bovhyaluronidase azoxymer), lyophilisate for solution for injection
89048490|NCT04645368||Dynamic control|80 subjects Patients not receiving active therapy
89048491|NCT00547664|Experimental|A|
89048492|NCT00547664|Placebo Comparator|B|
89048493|NCT04644939|Experimental|Interventional group|Patients will receive bowel preparation instructions in a conventional way in addition to a telephone call for education purposes one day prior to procedure
89048494|NCT04644939|Placebo Comparator|Conventional group|Patients will receive bowel preparation instructions in a conventional way
89048495|NCT00560430|Active Comparator|T1|Telmisartan 80 mg/d
89048496|NCT00560430|Active Comparator|T2|Telmisartan 160 mg/d
89048497|NCT00560430|Placebo Comparator|P|placebo
89048498|NCT04644588||Children being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and hand function using postural zone software to assess scapular alignment and pediatric arm function test toassess upper limb function .
89048499|NCT00547820|Experimental|A|with application of urinary sensor
89048500|NCT00547820|Placebo Comparator|B|without use of urinary sensor
89048501|NCT00560469||1|Men and Women over age 40 who are obese (BMI>30) and insulin-resistant.
89048502|NCT00560469||2|Men and women over age 40 who are obese (BMI>30) and insulin-sensitive.
89048503|NCT00560547|Experimental|1|
89048504|NCT04644510||Lung ultrasonography group|Patient which benefited from a Lung ultrasonography during the medical consultation
89048505|NCT00547937|Sham Comparator|Sham-CPAP|The sham CPAP device consisted of a conventional CPAP device, in which the area of the exhalation port was amplified, thereby nearly cancelling nasal pressure; an orifice resistor was connected between the tubing and the CPAP unit that loads the blower with the same airflow resistance as in effective CPAP
89048506|NCT00547937|Active Comparator|CPAP|
89048507|NCT04644900|Active Comparator|the Mouthwash group|Patients in the mouthwash group received 15 ml of honeysuckle antibacterial mouthwash and vomited it out after 2 minutes
89048508|NCT04644900|Active Comparator|the gum group|patients in group gum chewed one piece of herbal sugar-free gum for 2 minutes and then spat it out.
89048509|NCT00548015|Active Comparator|State of the Art strategy|education, reminders, performance feedback,
89048510|NCT00548015|Experimental|extended strategy|state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
89214224|NCT03178487|Experimental|Upadacitinib 15 mg|Participants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2.
89214225|NCT03178487|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
89214226|NCT02542826|Experimental|Pulmonary Rehabilitation|
89521832|NCT01602315|Experimental|Phase II: 1-BYL719 + Cetuximab|BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
89521833|NCT01602315|Experimental|Phase Ib: C-BYL719 DT+cetux|Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
89521834|NCT01602315|Experimental|Phase II: Cross over|patients received BYL719 at RP2D in combination with cetuximab.
89521835|NCT02537197|Experimental|Treatment Group|Regular Naltrexone dosing (approximately 12 weeks): Initially, participants will be given seven 25mg oral naltrexone (ReVia, Generic Health, or similar) half tablets at intake (days 1-7). The Full dosing regimen will begin if no toxicity issues are present and consists of fourteen 50mg tablets (two per day; 100mg). If required, dosages can be stepped up or down. If adverse symptoms persist (or if gambling symptoms escalates), the participant will be removed from the study and given alternative treatments. Participants will receive the following week's medication at each Calgary Opioid Dependence Program visit. Pill counts will be made at each visit. Physicians will monitor the progress of participants from intake and adjust dosages up or down to control gambling behaviour.
89521836|NCT03418207|Other|TTMB for patients|give trans-perineal template-guided mapping biopsy for participants suspected prostate cancer
89521837|NCT03413605|Experimental|a multilevel CBPR intervention|The intervention will be delivered in group-based education workshop format. The education session is a curriculum-based group education; each group will be having about 15-20 participants. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics.(a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion. This session is to increase knowledge, change cultural beliefs and attitudes on risks of CRC and benefits of screening by using interactive discussion approaches, visual aids, motivation video and print materials.
89521838|NCT03413605|No Intervention|control group|the standard CDC's Clinical Preventive Services Guidelines for adults 50+ (CPS) will be provided to control groups.
89521839|NCT03413527|Experimental|rTMS Treatment|
89521840|NCT03127345|Experimental|Omegaven|15 infants with esophageal atresia undergoing surgical repair will receive Omegaven 1 g/kg/day IV infused over 8-24 hours for 28 days
89521841|NCT03127345|Active Comparator|Intralipid|15 infants with esophageal atresia undergoing surgical repair will receive the standard of care lipid formulation (Intralipid) as per hospital protocol for 28 days
89521842|NCT05117541||Observational (interview, biospecimen collection)|Patients participate in interviews over 20-40 minutes and undergo collection of hair samples at baseline and 18-24 months. Patients' medical records are also reviewed.
89521843|NCT05112159|Experimental|IPG1094 100mg|Four subjects in this cohort will receive a single dose of IPG1094 100 mg qd and two subjects will receive a single dose of placebo 100mg qd orally. Sentinel subjects (i.e. 1 subject will be dosed with IPG1094 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
89521844|NCT05112159|Experimental|IPG1094 300mg|Six subjects in this cohort will receive a single dose of IPG1094 300 mg qd and two subjects will receive a single dose of placebo 300mg qd orally.
89521845|NCT05112159|Experimental|IPG1094 600mg|Six subjects in this cohort will receive a single dose of IPG1094 600 mg qd and two subjects will receive a single dose of placebo 600mg qd orally.
89521846|NCT05112159|Experimental|IPG1094 900mg|Six subjects in this cohort will receive a single dose of IPG1094 900 mg qd and two subjects will receive a single dose of placebo 900mg qd orally.
89521847|NCT05112159|Experimental|IPG1094 1200mg|Six subjects in this cohort will receive a single dose of IPG1094 1200 mg qd and two subjects will receive a single dose of placebo 1200 mg qd orally.
89521848|NCT05112159|Experimental|IPG1094 1500mg|Six subjects in this cohort will receive a single dose of IPG1094 1500 mg qd and two subjects will receive a single dose of placebo 1500mg qd orally.
89521849|NCT03413371|Experimental|0,5 % bupivacaine with of 2% lidocaine|in group BL patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
89521850|NCT03413371|Experimental|0,5 % bupivacaine|in group B patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
89521851|NCT03413371|Experimental|1 % ropivacaine with of 2% lidocaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
89521852|NCT03413371|Experimental|1 % ropivacaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (5 ml)
89521853|NCT03413371|Experimental|paracetamol|in P group patients will receive preemptive analgesia using 1 gram of paracetamol before induction of general anaesthesia
89521854|NCT03425851|Experimental|Intervention Group|Receive 600 diapers.
89521855|NCT03425851|Active Comparator|Control Group|Receive resources of diaper banks as requested.
89521856|NCT03425773|Experimental|BVAC-B|BVAC-B IV injection at 0, 4, 8, 12nd weeks.
89521857|NCT03992001|Experimental|Sequence A-B|Patients in this arm will receive blood component A for 6 months and blood component B for the next 6 months
89521858|NCT03992001|Experimental|Sequence B-A|Patients in this arm will receive blood component B for 6 months and blood component A for the next 6 months
89521859|NCT03417973||complex regional pain syndrome|Chronic regional pain of lower limb(s) patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
89521860|NCT03417973||Chronic pelvic pain|Chronic pelvic or urological pain patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
89048511|NCT04636125|Other|Revision Total Shoulder Arthroplasty|Routine cultures are taken at the time of surgery. All patients are seen by an Infectious Disease Specialist and placed on 2 weeks oral doxycycline 100 mg (or alternative based on allergy or sensitivity) pending culture results.
89048512|NCT04636242|Experimental|Group 1: Phototherapy Group|patient will be instructed to apply 5-aminolevulinic acid HCL topical solution to their shoulder prior to their surgery. 16 minutes before skin incision a blue light will be applied to the area of the shoulder where the 5-ALA was administered
89048513|NCT04636242|Active Comparator|Group 2: Control Group|patient will undergo standard of care surgery
89048514|NCT00548054|Experimental|Vaccine Group for Vibriocidal Assay|Killed whole cell cholera vaccine bled at day 42 for vibriocidal assay
89048515|NCT00548054|Experimental|Vaccine Group for EPI Assay|Killed whole cell cholera vaccine bled at day 56 for EPI immunogenicity testing
89048516|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal Assay|Placebo bled at day 42 for vibriocidal assay
89048517|NCT00548054|Placebo Comparator|Placebo Group for EPI Assay|Placebo bled at day 56 for EPI immunogenicity testing
89048518|NCT00548054|Experimental|Vaccine Group for Vibriocidal and Measles Assay|Killed whole cell cholera vaccine bled at day 14 and 28 for measles immunogenicity testing
89048519|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal and Measles Assay|Placebo bled at day 14 and 28 for measles immunogenicity testing
89048520|NCT04644432|Experimental|A - for patients with a DNA mutation that match a targeted treatment|"Listed below are the possible study drugs and dosages:~Erlotinib 150 mg once a day for 4 weeks.~Osimertinib 80 mg once a day for 4 weeks.~Alectinib 600 mg twice a day for 4 weeks~Dabrafenib 150 mg twice a day combined with Trametinib 2 mg once a day for 4 weeks~Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week~Olaparib 400 mg twice a day for 4 weeks~Pembrolizumab iv infusion 2 mg/kg every 3rd week~Cabozantinib 60 mg once a day for 4 weeks~Crizotinib 250 mg twice a day for 4 weeks~Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week~Imatinib 400 mg once a day for 4 weeks~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
89048521|NCT04644432|Experimental|B - for patients with an angiogen profile|"Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule).~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
89048522|NCT04644432|Experimental|C - for patients with an immune profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
89521861|NCT02344004|No Intervention|Multi-drug Regimen|Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America [ATS/IDSA] Guidelines)
89521862|NCT02344004|Experimental|LAI + Multi-drug Regimen|"Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)~LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes"
89521863|NCT03417817|Other|Healthy subjects|Bravo wireless pH monitoring over 96 hours
89521864|NCT03677115|Experimental|dexmedetomidine group|a combination of ropivacaine and dexmedetomidine
89521865|NCT05116449||Patient seeking supportive care|
89521866|NCT05116449||Patient without any supportive care|
89521867|NCT03413293||Nosocomial infected cirrhotic patients|
89521868|NCT05116371||Group 1: Same day initiation option|1) ENG implant with initiation of concurrent COC use for bleeding control at time of insertion
89521869|NCT05116371||Group 2: Delayed initiation option|"2) ENG implant alone with option for delayed initiation of COC if bleeding concerns develop"
89521870|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
89521871|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Chloraprep|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
89521872|NCT03417661|Experimental|Chloraprep vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
89521873|NCT03008811|Active Comparator|Cryoballoon|Pulmonary vein isolation with cryoballoon catheter.
89521874|NCT03008811|Active Comparator|Radiofrequency|Pulmonary vein isolation with radiofrequency ablation catheter.
89521875|NCT03425695|Experimental|Test group|"Free Gingival Graft (FGG) + Low Level Laser Therapy (LLLT) + Clinical Examination~The test group received LLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) at the FGG sites with a wavelength of 810 nm and output power of 0.1 W, for 60 s, with an energy density of 6 J/cm2 in the continuous wave mode (spot size:0.5 cm). The laser beam was directed perpendicularly toward the tissue in the noncontact mode. The laser was irradiated at the recipient sites immediately after surgery and 1, 3, 7, and 14 days later."
89521876|NCT03425695|Placebo Comparator|Control group|"Free Gingival Graft (FGG)+Placebo Low Level Laser Therapy (PLLLT) + Clinical Examination~The control group received PLLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) same as test group without pushing the start button"
89521877|NCT05171413||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
89521878|NCT05171413||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
89521879|NCT04436211||TKA (mechanical alignment)|
89521880|NCT04436211||TKA (kinematic alignment)|
89521881|NCT03414749|Experimental|Lower Extremity First (LEF)|The treatment was a non-specific long-axis distraction to the ankle, knee, and hip provided was at the discretion of the clinic doctor (over 25 years experience).
89214227|NCT04430036|Experimental|Safety Run-In|The safety run-in of the study will first enroll three patients who will begin treatment with cisplatin and gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. These first 3 patients will be assessed for DLTs and there will be a pause in enrollment until all three complete the DLT period. If there are no DLTs in the first 3 patients, we will proceed to further accrual to stage I of phase II. If there is 1 DLT in the initial 3 patients, we will enroll 3 additional patients to the safety run-in. If > 2 DLTs are experienced in the initial 3 patients, the study will be terminated.
89664715|NCT04063995|Experimental|Inhibitory repetitive transcranial magnetic stimulation group|One session of repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency will be applied to the contralesional dorsal premotor cortex. Application will be performed with Neurosoft-Neuro MS / D device. 90% of the motor threshold will be used in the stimulation. Stimulation is planned for a total of 25 minutes and a total of 1500 beats in the form of 1 Hz stimulation.
89664716|NCT04063995|Sham Comparator|Sham repetitive transcranial magnetic stimulation group|Single session of sham application for a total of 25 minutes. Sham application will be performed by holding the probe of the device vertically to the vertex. The device will be operated at the lowest operating power of 1 to produce the same stimulation sounds like the active application. The device operating at this power is not likely to give any stimulation due to the probe being held upright.
89664717|NCT04919460|Other|clinical observation combined with pathological biopsy|Clinical observation (including inspection and palpation) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
89664718|NCT04919460|Experimental|Clinical observation, in vivo staining combined with pathological biopsy|Clinical observation (including inspection and palpation), in vivo staining (reagent: toluidine blue) combined with pathological biopsy. That is, inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
89664719|NCT04930068|Experimental|ultra-sound|ultrasonic cavitation applied on abdominal region for 30 minutes, 2 times per week for 6 weeks.
89664720|NCT04930068|Experimental|aerobic exercise|aerobic exercises through treadmill (60-70% of VO2 max.) for 30 minutes, 2 times per week for 6 weeks
89664721|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells + gemcitabine/nab paclitaxel|"Patients in the anti-CEA CAR-T Cells plus gemcitabine/nab paclitaxel arm will have achieved at least stable disease during the Bridging Therapy Period with gemcitabine/nab paclitaxel, and will receive the CAR-T cells in Cycles 1 and 3 and the gemcitabine/nab paclitaxel regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
89664722|NCT04037241|Experimental|2nd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|"Patients in the anti-CEA CAR-T Cells plus and nanolipsomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will have achieved at least stable disease during the Bridging Therapy Period with NLIR + FU/FA, and will receive the CAR-T cells in Cycles 1 and 3 and the NLIR/FU/FA regimen they received during the Bridging Therapy Period in Cycle 2 and Cycles ≥ 4 of the Treatment Period. Treatment will continue until the development of disease progression."
89664723|NCT04037241|Active Comparator|2nd Line: Gemcitabine /nab paclitaxel Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving gemcitabine plus nab paclitaxel will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
89664724|NCT04037241|Active Comparator|2nd Line: NLIR + FU/FA Alone|Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving nanoliposomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
89664725|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus NLIR+FU/FA|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Nanoliposomal irinotecan plus fluorouracil/leucovorin chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nab paclitaxel plus gemcitabine during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
89664726|NCT04037241|Experimental|3rd Line: Anti-CEA CAR-T Cells Plus Capecitabine|Patients randomized to the anti-CEA CAR-T Cells plus chemotherapy treatment arm who developed disease progression during the Bridging Therapy Period will receive the CAR-T cells in Cycles 1 and 3. Capecitabine chemotherapy will be administered in Cycle 2 and Cycles ≥ 4 of the Treatment Period to patients who progressed on nanoliposomal irinotecan fluorouracil/leucovorin during the Bridging Therapy Period. Treatment will continue until the development of disease progression.
89664727|NCT04037241|Active Comparator|3rd Line: NLIR+FU/FA Alone|Patients randomized to the chemotherapy alone treatment arm who developed disease progression during the Bridging Therapy Period while receiving nab paclitaxel plus gemcitabine will be treated with nanoliposomal irinotecan plus fluorouracil/leucovorin during the Treatment Period.
89664728|NCT04037241|Active Comparator|3rd Line: Capecitabine Alone|Patients that developed disease progression during the Bridging Therapy Period while receiving nanoliposomal irinotecan plus 5-FU/leucovorin will be treated with capecitabine during the Treatment Period.
89664729|NCT04912128||Anlotinib group|Patients in Anlotinib group took Anlotinib 1 week before the MRI-based simulation，12mg/d QD，day1~14, 21d/cycle. All patients received SBRT for brain metastases.
89664730|NCT04912128||SBRT group|Patients in SBRT group took no anti-angiogenic drugs. All patients received SBRT for brain metastases.
88995138|NCT05522855|Experimental|Intervention Version- EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion.
89214228|NCT04430036|Experimental|Phase II, Stage 1|In the first stage of phase II of this study, 17 patients will be enrolled. Patients will begin treatment with cisplatin and gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. They will be evaluated with each cycle of therapy, with radiographic restaging assessment after 2 cycles of therapy and prior to the third cycle of treatment. If no disease progression is identified, patients will receive a third and fourth cycle of therapy. Following this neoadjuvant regimen, they will proceed to planned surgery following preoperative clearance within 10 weeks of the last dose of neoadjuvant therapy.
89214229|NCT04430036|Experimental|Phase II, Stage 2|If criteria are met to continue to the second stage of the Phase II portion of the study, 19 more patients will be enrolled for a total of 36 evaluable patients. Patients will be treated and endpoints evaluated.
89214230|NCT00528957|Experimental|Tenofovir DF|
89214231|NCT00528957|Active Comparator|stavudine or zidovudine|
89214232|NCT00890630|Active Comparator|Oxytocin|Induction of Labour with Oxytocin Alone
89214233|NCT00890630|Experimental|Intracervical Catheter|Insertion of an Intracervical Balloon Catheter plus administration of oxytocin for labour induction.
89214234|NCT00890708|No Intervention|non-TDM of voriconazole|conventional dose
89214235|NCT00890708|Experimental|TDM of voriconazole|
89214236|NCT00890786|Experimental|HGG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the intervention section.
89214237|NCT00890786|Experimental|DIPG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the interventions section.
89214238|NCT00560508|Experimental|Pramipexole Extended Release|patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID
89521882|NCT03414749|Experimental|Upper Extremity First (UEF)|The treatment was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
89521883|NCT01328093|Experimental|LY2140023|Double Blind Phase: 40 milligrams (mg) administered orally, given twice daily for 24 weeks. Dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg. Open Label Phase: 40 mg administered orally, given twice daily for an additional 28 weeks.
89521884|NCT01328093|Active Comparator|Aripiprazole|Double Blind Phase: 15 mg administered orally, given once daily for 24 weeks. Dose can be adjusted to a minimum of 10 mg or a maximum of 30 mg. Open Label Phase: LY2140023, 40 mg administered orally, given twice daily for an additional 28 weeks.
89521885|NCT03417427|Active Comparator|Decitabine and Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive decitabine (15mg/m2 d1-5) combined with high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
89521886|NCT03417427|Placebo Comparator|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
89521887|NCT04262505|Experimental|Mediterranean Diet Group (Group A)|The intervention is based on components of the traditional Mediterranean diet which is primarily a plant based diet and emphasises intakes of vegetables, whole grains and fruit with the main added fat being extra virgin olive oil.The diet will be modified and tailored to cultured preferences by the registered dietitian. Participants will be informed of their diet allocation group during the baseline teleconsultation and will commence the diet the following day or as soon as is feasible for 12 weeks. Participants will be provided with resources specifically designed to explain the components of the Mediterranean diet and how it will be followed.
89521888|NCT04262505|Experimental|Healthy Eating Group (Group B)|Participants assigned to the Healthy Eating group will be advised to adhere to the current healthy eating guidelines and will be provided with resources to inform them of these guidelines and sample meal plans that are readily available on the Healthy Ireland website.
89521889|NCT05089305|Experimental|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications for the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07.
89521890|NCT04448275|Experimental|study group|received conventional selected exercise program and in addition to Neurodynamics Nerve flossing for femoral nerve
89521891|NCT04448275|Experimental|control group|received conventional selected exercise program in form of: Ultrasound therapy The flexibility exercises for iliopsoas & quadriceps in heamophilic patient The iliopsoas & quadriceps muscles strength exercise
89521892|NCT05059197|Experimental|AP collagen peptide|Each subject takes one active bottle per day for 12 weeks. Each bottle contains AP collagen 1000 mg
89521893|NCT05059197|Placebo Comparator|Placebo|Each subject takes one active bottle per day for 12 weeks.
89521894|NCT03425617|Experimental|Tiotropium + Olodaterol first|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 3 followed by PLACEBO via Respimat® single dose in Visit 4
89521895|NCT03425617|Experimental|PLACEBO FIRST|Placebo via Respimat® single dose in Visit 3 followed bytiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 4
89521896|NCT04448353||Development / training|Selected by stratified partitioning
89521897|NCT04448353||Sequestered / test|Selected by stratified partitioning
89521898|NCT03419429|Experimental|Simvastatin/Occlusive membrane|open flap procedure, 1.2%simvastatin gel applied and covering the defect with resorbable collagen occlusive membrane .
89521899|NCT03419429|Experimental|Simvastatin/perforated membrane|open flap procedure, 1.2% simvastatin gel and covering the defect with resorbable collagen modified perforated membrane.
89521900|NCT03419429|Experimental|EDTA/Simvastatin/Occlusive membrane|open flap procedure, 24% EDTA root surface etching,1.2% simvastatin gel and then coverage of the defect with occlusive membrane.
89048523|NCT04644432|Experimental|D - for patients that have neither mutations nor an immune- or angiogen profile|"Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.~If the patient can fit in several arms, arm A or the arm closest to arm A is chosen."
89048524|NCT04644354||Group A - Advanced Preterm Labor (aPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions 4 or more in 20 minutes and cervical dilatation at 2 cm and above
89048525|NCT04644354||Group B - Threatened Preterm Labor (tPL)|Singleton pregnant women with spontaneous preterm labor at their 23-36 weeks: regular contractions less then 4 in 20 minutes and cervical dilatation less then 2 cm
89048526|NCT00548366|Experimental|1|4 gram sodium diet
89048527|NCT00548366|Active Comparator|2|2 gram sodium diet
89048528|NCT04644081|Experimental|LTP+CaCBT|The LTP+CaCBT intervention will consist of a total of 12 (social distancing) group training sessions (60-90 minutes) and will deliver two sessions on a weekly basis for six weeks.
89048529|NCT04644081|Active Comparator|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of counselling services).
89048530|NCT00548444|Experimental|Group 1|Volunteers will receive a single dose of MVA85A followed by regular blood tests to measure the resulting cellular immune response.
89048531|NCT00548444|Experimental|Group 2|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
89048532|NCT00548444|Experimental|Group 3|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
89048533|NCT04636359|Experimental|Long term course of migraine patient without aura|Patients in this group have the history of migraine without aura more than 5 years.
89048534|NCT04636359|Experimental|Short term course of migraine patient without aura|Patients in this group have the history of migraine without aura equal or less than 5 years.
89048535|NCT00548483|Active Comparator|1|dexamethasone 5mg was administered every 6 hour for 1 day
89048536|NCT00548483|Active Comparator|2|dexamethasone 10mg was administered every 6 hour for 1 day
89048537|NCT04635813||Group 1 - COVID group|Patients that underwent surgery during COVID-19 pandemic
89048538|NCT04635813||Group 2 - control group|Patients that underwent surgery during 2019
89048539|NCT00548522||1|Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
89048540|NCT00548522||2|Pregnant women (34-38 wks gestation) with Type 1 diabetes
89048541|NCT00548522||3|Post partum women with Type 1 diabetes
89048542|NCT00548522||4|Non pregnant women with Type 1 diabetes
89048543|NCT04635852|Experimental|Fentanyl|Fentanyl buccal tablet Dosage: 100µg - 600 µg Fentanyl (to be determined by titration) Administration: buccal administration (tablet)
89048544|NCT04635852|Active Comparator|Immediate release morphine|Immediate release morphine, solution Dosage: Start with a minimum of 5mg (to be determined by titration)
89048545|NCT00548600|Experimental|1|Iridium implant plus external beam irradiation
89048546|NCT00548600|Active Comparator|2|Standard external beam irradiation alone
89214239|NCT00560508|Active Comparator|Pramipexole Immediate Release|patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID
89214240|NCT05127759|Experimental|HLX208|Participants receive HLX208 450mg bid po
89214241|NCT00890864|Active Comparator|1|Women aged 47-49 invited for breast screening
89214242|NCT00890864|Active Comparator|2|Women aged 71-73 invited for breast screening
89214243|NCT00890942|Experimental|naloxone|
89214244|NCT00890942|Placebo Comparator|normal saline|
89214245|NCT04037852|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
89214246|NCT04037852|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
89214247|NCT04037852|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
89214248|NCT00941850|Experimental|Triple site CRT|These patients will continue to receive CRT via existing device but will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced
89214249|NCT00941850|No Intervention|Optimised medical and device therapy|These patients will receive optimised medical and device therapy.
89664731|NCT01327677|Active Comparator|Pro re nata (PRN) fentanyl|A nurse can give the patient up to 3 doses of fentanyl intravenously (through a vein) each hour whenever a patient indicates that he or she is in pain.
89664732|NCT01327677|Active Comparator|Intravenous Patient-controlled Analgesia (IVPCA) fentanyl|Fentanyl will be given with a Patient Controlled Analgesia (PCA) pump.
89664733|NCT03055728||Group 1 / Study Group|Subjects presenting with signs or symptoms of acute pharyngitis, with a history of culture-proven GAS infection and subsequent 10-day antibiotic treatment within the preceding 28 days. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
89664734|NCT03055728||Group 2 / Control Group|Subjects presenting with signs or symptoms of acute pharyngitis, without a recent history of GAS infection. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
89664735|NCT03054480|Experimental|Fractional Micro-Needle Radiofrequency|each patient will be treated with FMR DeAge®, applicator device at 4-week intervals for 2 sessions of treatment. This applicator consists of rows of 36 (6x6 needles) insulated microneedles that form an array of positively and negatively charged electrodes. The microneedles will deliver bipolar radiofrequency energy in a fractional manner that extends from 3.0 mm below the surface of the skin. All subjects will be prepared by local anesthesia to induce numbness at the axilla prior to treatment. The targeted axillary side will be treated with a total of 4 passes.
89664736|NCT03054480|Active Comparator|Botulinum toxin type A|50 units of Botulinum toxin type A will be intradermal injected over axillary area. The protocol by using 1-2 units per 1 injection area with the coverage of 1x1 cm2 will be treated.
89664737|NCT03054558||patients with recurrent unexplained pregnancy loss|Patients with history of two or more recurrent pregnancy loss (RPL) and no history of living babies who had performed all investigations for recurrent miscarriage (RM) including : laboratory investigation ,trans vaginal ultrasound (TVS) ,autoimmune work up and hystroscopy and all results were free
89664738|NCT03054558||Healthy fertile patients|Healthy fertile patients with no history of previous miscarriage and have at least one uncomplicated pregnancy with no pelvic pathology
89664739|NCT02621034|Experimental|Control|K-file hand instrumentation
89664740|NCT02621034|Experimental|Reciproc|rotary reciprocating protocol
89664741|NCT02621034|Experimental|One shape|one shape continuous rotation protocol
89664742|NCT04911738|Experimental|Plane A for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane A, which corresponds to the following order: verticality perception (Baseline, effect during the intervention, post-effect), then active vertical body orientation (Baseline, effect during the intervention). The intervention is an immersion in a virtual static and tilted environnement (18°).~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
89664743|NCT04911738|Experimental|Plane B for the cross-over (Immersion in a virtual tilted room)|"Half of participants will perform the experiment according the plane B, which corresponds to the following order: active vertical body orientation (Baseline, effect during the intervention), then verticality perception (Baseline, effect during the intervention, post-effect). The intervention is an immersion in a virtual static and tilted environnement (18°).~During the intervention, participants will be immersed in a virtual tilted room for 15 minutes (after 5 minutes of pre -installation adjustments), then verticality perception or active body orientation assessments are performed while the participant is still virtually immersed (approximately 25 minutes). Participants will be immersed in a tilted virtual room for 45 minutes each day."
89664744|NCT02572453|Experimental|ALK+ ALCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
89214250|NCT04938986|Experimental|IMMUNOSCORE®|
89214251|NCT00942006|Active Comparator|LNB-doxycycline|
89214252|NCT00942006|Active Comparator|LNB-ceftriaxone|
89214253|NCT00886418|Active Comparator|1|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. A muscle relaxant is used to facilitate tracheal intubation; its administration is continued throughout anesthesia.
89214254|NCT00886418|Experimental|2|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. No muscle relaxant is used and a placebo is infused throughout anesthesia.
89214255|NCT00942240|Experimental|ACU-4429 tablet|
89214256|NCT00942240|Placebo Comparator|matching placebo tablet|
89664745|NCT02572453|Experimental|Relapsed MCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
89664746|NCT02572453|Experimental|BCL6+ DLBCL|Patients receive 160-mg/m2 onalespib by IV over 1 hour on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Patients will continue on treatment indefinitely as long as they are responding and tolerating treatment.
89664747|NCT04929990|Experimental|Inpiratory and expiratory muscle training|The initial intensity of training was set on 30% of the MIP and MEP for inspiratory and expiratory muscle training, respectively. The intensity was adjusted to add 5% of resistance each week
89664748|NCT04929990|Active Comparator|Inspiratory muscle training|The initial resistance of the breathing trainer was also set on 30% of MIP, and the following adjustments were also in accordance to the protocol of the experimental group
89664749|NCT02567539|Experimental|Recurrent high grade glioma|IMRT with or without radiosensitive therapy
89664750|NCT04929444|Active Comparator|Training group|The professionals of the primary care teams that are in Intervention group would receive the training at the beginning of the study
89664751|NCT04929444|No Intervention|Common Practice|The professionals of the primary care teams that are in Control group will be offered the training after the conclusion of the study
89664752|NCT04918914|Other|Intervention|
89664753|NCT04911504||Questionnaire survey group|All nurses were recruited from 3 tertiary hospitals in central China from 3rd October, 2019 to 15th December, 2019. A total of 992 clinical nurses from different nursing departments were recruited through convenience sampling. Data were collected using General information questionnaire, the Professional Quality of Life Scale, the Connor-Davidson Resilience Scale and General Perceived Self-Efficacy Scale.
89664754|NCT01327989||Solitaire™ FR device|Eligible subjects treated with the Solitaire™ FR device.
89214257|NCT02542124|Experimental|NM-IL-12 and TSEBT|TSEBT and subcutaneous doses of NM-IL-12
89214258|NCT00942318|Experimental|PPE|PPE : CSII +/- Metformin.
89214259|NCT00942318|Active Comparator|injections|INJ: basal/bolus MDI +/- Metformin
89214260|NCT04037618|Experimental|[14C]-EYP001a|[14C]-EYP001a dose A containing 100 μCi radioactivity
89214261|NCT00942396|Experimental|mammography|Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography
89664755|NCT04911114|Experimental|Intervention Arm|This is a single arm pilot study of group base exercise
89664756|NCT03054402|Experimental|Dose escalation/BAY1834845|Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day
89214262|NCT00891098|Active Comparator|Imaginal exposure|
89214263|NCT00891098|Experimental|Imagery rescripting|
89214264|NCT00944580|Experimental|Vaccine Intervention|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
89214265|NCT05280054|Experimental|AV-101|AV-101 360 mg oral capsules single dose
89214266|NCT05280054|Experimental|AV-101 + Probenecid|AV-101 360 mg oral capsules + 1000 mg Probenecid
89664757|NCT03054402|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo in the morning of the PK profile day
89664758|NCT04929366|Experimental|End-stage kidney patients treated in the dialysis unit group 1|
89664759|NCT04929366|Experimental|End-stage kidney patients treated in the dialysis unit group 2|
89664760|NCT01328379|Active Comparator|Dalfampridine-ER 5mg|5mg, twice daily
89664761|NCT01328379|Active Comparator|Dalfampridine-ER 10mg|10mg, twice daily
89214267|NCT00891254|Active Comparator|1. Intraperitoneal repair|Patients with incisional hernia, 5 cm in diameter or with an area of 25 cm2, submitted to elective surgery
89664762|NCT01328379|Placebo Comparator|Placebo|placebo, twice daily
89664763|NCT05026489||G6PD Deficiency|In the laboratory of the First Affiliated Hospital of Xi 'an Jiaotong University, tetrazolazole-blue quantitative method will be used to detect G6PD. According to the normal range of the tetrazole-blue quantitative method (6.8-20.5NBT), adults with G6PD activity < 6.8NBT were positive, and G6PD deficiency is confirmed.
89214268|NCT00891254|Active Comparator|2. On-Lay repair|Patients with incisional hernia, with a diameter of 5 cm or an area of 25 cm2, submitted to elective surgery
89214269|NCT00942474|Experimental|Research Arm|Facilitate nerve stimulation lead placement with the nerve access tool
89214270|NCT03999099|Placebo Comparator|Placebo|
89214271|NCT03999099|Experimental|Suvorexant 10mg|Suvorexant 10mg oral dose
89214272|NCT03999099|Experimental|Suvorexant 20mg|Suvorexant 20mg oral dose
89214273|NCT03962790|Experimental|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
89214274|NCT03962790|Experimental|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
89664764|NCT05026489||Normal|The G6PD activity ranged from 6.8 to 20.5 NBT and the G6PD activity is normal.
89664765|NCT02556385|Experimental|High frequency rTMS|Most activated area from fNIRS with language task: Perileisional Broca's area
89664766|NCT02556385|Active Comparator|Low Frequency rTMS|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
89664767|NCT05586763|Active Comparator|Metoclopramid|IM Metoclopramid 10mg
89664768|NCT05586763|Active Comparator|Promethazine|IM Promethazine 25mg
89664769|NCT05586763|Active Comparator|prochloraperazine|IM prochloraperazine 12.5mg
89664770|NCT01328769|Active Comparator|Febuxostat|Investigational
89664771|NCT01328769|Placebo Comparator|Placebo|Placebo
89688682|NCT03490825|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
89214275|NCT05323695|Other|Depression Screening Intervention|All eligible participants will be screened using the Patient Health Questionnaire-2 (PHQ-2) for depression. If screened positive, participants will be further screened with Patient Health Questionnaire-9 (PHQ-9).
89664772|NCT02717143||Acute myocarditis|"Patients with a clinical picture suggestive of acute myocarditis: increase of troponin above the threshold defined by the pathological laboratory, associated with at least one of the three following criteria:~prolonged chest pain > 10 minutes,~recent infectious context <7 days~young subject and / or absence of cardiovascular risk factors and / or absence of significant coronary lesion~Patients will be included after completion of MRI confirm the diagnosis. They will be followed for 3 years, every year, by the doctor who included them in the study.~This is an observational study that does not affect the management of patients."
89664773|NCT02552641|Experimental|Test 1|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily
89664774|NCT02552641|Experimental|Test 2|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily
89664775|NCT02552641|Experimental|Test 3|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses
89664776|NCT01378221||Group 1|cardiac surgery patients age 65 years and less
89664777|NCT01378221||Group 2|cardiac surgery patients aged 75 years and over
89664778|NCT02552563|No Intervention|Usual Care|Standard care received by veterans in the Corporal Michael J. Crescenz VA Medical Center
89664779|NCT02552563|Active Comparator|Dementia Care Management|CG education, continuous support, communication and coping skills training, and veteran monitoring, via CG report, of medication, symptoms, and service needs.
89664780|NCT02620020|Experimental|Fasinumab 6 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
89214276|NCT04013022||Young|Healthy young subjects (age 18 - 30 )
89214277|NCT04013022||Old Sedentary|Healthy and sedentary old subjects (age 65 - 75)
89664781|NCT02620020|Experimental|Fasinumab 9 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
89664782|NCT02620020|Experimental|Fasinumab 9 mg IV Q8W and Placebo SC Q4W|Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
89664783|NCT02620020|Experimental|Placebo SC Q4W and Placebo IV Q8W|Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.
89664784|NCT02549989|Experimental|LY3023414|This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.
89664785|NCT01378299|Experimental|Arm 1: Testosterone Cypionate|All patients who qualify for the study will receive testosterone cypionate
89664786|NCT04929522|Active Comparator|IANB/inferior alveolar nerve block|patients will be given standard IANB with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
89214278|NCT04013022||Old Endurance Trained|Healthy old subjects ( age 65 - 75) who participated in endurance sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
89214279|NCT04013022||Old Strength Trained|Healthy old subjects ( age 65 - 75) who participated in resistance training/sports for ≥30 years, ≥5 hours per week and ≥4 sessions per week
89214280|NCT01007799|Placebo Comparator|Placebo|Placebo pills to take for 12 weeks
89664787|NCT04929522|Active Comparator|IANB+IO|patients will be given standard IANB plus an intra-osseous with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
89664788|NCT04929522|Active Comparator|IANB+PDL|patients will be given standard IANB plus a PDL injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
89664789|NCT04929522|Active Comparator|IANB+BI|patients will be given standard IANB plus a BI injection with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain).
89664790|NCT02549833|Experimental|Vaccines before and after surgery|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery), every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine), and two booster vaccines (Weeks A32 and A48).
89664791|NCT02549833|Active Comparator|Vaccines after surgery only|GBM6-AD lysate protein 1 mg and poly-ICLC 1.4 mg administered as one formulation every 3 weeks after standard-of-care surgery to remove the WHO grade II glioma only (Weeks A1, A4, A7, A10, A13, A16; defining Week A1 as the first post-surgery vaccine) and two booster vaccines (Weeks A32 and A48). Patients will not receive vaccines before surgery.
89664792|NCT02549131|Active Comparator|Suture|Randomizing to Suture closure of Cesarean Section wound. In woman meeting inclusion criteria and not meeting exclusion criteria.
89664793|NCT02549131|Active Comparator|Staples|"Women in this Arm will be assigned to Standard Surgical Staples closure of Cesarean section.~Women will have met inclusion criteria and not meet exclusion criteria and willing to consent to study. Intervention is the randomization to either Arm. Both are standard of care at this facility."
89664794|NCT04911192|No Intervention|systemic thrombolysis group|patients without any contraindications for systemic fibrinolytic therapy will be treated with traditional systemic thrombolysis (intravenous administration of streptokinase).
89214281|NCT01007799|Active Comparator|Vitamin D|Vitamin D supplement for 12 weeks
89214282|NCT01007877|No Intervention|No break|
89214283|NCT01007877|Placebo Comparator|Placebo Energy Drink|During a 15 minute break, subjects consume a placebo energy drink
89214284|NCT01007877|Experimental|Red Bull Energy Drink|during a 15 minute break, subjects consume Red Bull Energy Drink
89214285|NCT01007955||Severely Obese|Severely obese individuals scheduled to undergo gastric bypass surgery
89214286|NCT00609518|Active Comparator|Standard Vitamin and Steroid Schedule + Pemetrexed|Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.
89214287|NCT00609518|Experimental|Simplified Vitamin and Steroid Schedule + Pemetrexed|Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.
89214288|NCT01008033|Experimental|IDP-108|
89214289|NCT01008033|Placebo Comparator|Vehicle|
89214290|NCT01008111|Active Comparator|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
89214291|NCT01008111|Placebo Comparator|Dermabond-Placebo Comparator|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
89664795|NCT04911192|Active Comparator|mechanical fragmentation group|patients will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy.
89214292|NCT00884780||Pediatric Pain|Children between the ages of 8 and 17 experiencing pain.
89214293|NCT00884858|Experimental|Maraviroc|Subjects in this group will add Maraviroc to their current HAART.
89664796|NCT04911192|Active Comparator|In Situ thrombolysis group|patients will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC(Swan-Ganz pulmonary artery catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
89664797|NCT02542969|Other|Treatment|Simvastatin followed by Rosuvastatin then MGL-3196 daily followed by separate co-administration of Simvastatin and Rosuvastatin
89664798|NCT04910802|Experimental|HPV-vaccination|Women ages 22-26 will be offered concomitant vaccination (1 dose of Gardasil9) and HPV screening. A second dose of Gardasil9 will be administered 3 years later.
89214294|NCT00884858|No Intervention|2|Subjects in this group will continue their current HAART without adding Maraviroc.
89214295|NCT05272293|Experimental|expanded haploidentical NK cell immunotherapy|After a cycle of chemotherapy a patient receive three intravenous infusions of expanded haploidentical NK cells.
89214296|NCT00891332|Experimental|1|S-1 plus LV
89214297|NCT02541344|Active Comparator|Dose 1 of IQP-VV-102|Total 4 tablets (2 tablets with active ingredients and 2 placebo tablets) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
89664799|NCT04918680||EcoFit® Total Hip System with implacross® E Polyethylene|Subjects who meet the indications for use for the EcoFit® Total Hip System with implacross® E Polyethylene and are candidates for a primary hip replacement.
89664800|NCT04918446|Experimental|T-POSE|Technology based brief educational intervention for hospitalized patients that will be discharged with an opioid prescription.
89664801|NCT04918446|Other|Usual Care|Standard discharge instructions provided.
89664802|NCT02539303|Experimental|Intervention|Infusion of Yamani-15/5 chemical solution.
89664803|NCT02716441||Radio-opaque Tissue Markers|Patients undergoing rotator cuff repair with implantation of radio-opaque tissue markers
89664804|NCT04910490||Patients received stereotaxic aspiration|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
89664805|NCT04910490||Patients received conservative therapy|No new/additional patients will be enrolled within this project. Only retrospective data will be collected on survival time and life quality
89214298|NCT02541344|Active Comparator|Dose 2 of IQP-VV-102|Total 4 tablets (4 tablets with active ingredients) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
89214299|NCT02541344|Placebo Comparator|Placebo|Total 4 placebo tablets, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
89214300|NCT00609362|Active Comparator|Rosiglitazone|25 women age 60 to 75 years receiving rosiglitazone 8 mg/day
89214301|NCT00609362|Placebo Comparator|Placebo|25 women 60 to 75 years of age receiving placebo once a day for 14 weeks
89214302|NCT02541266||Group 1|Patients currently recruited to studies with imaging at The Marsden
89214303|NCT02541266||Group 2|Patients who have previously participated in studies with imaging at The Marsden
89214304|NCT02541266||Group 3|Patients attending for scans as part of their clinical pathway
89214305|NCT00884936||Group 1|Young age: 20 to 30 years old
89214306|NCT00884936||Group 2|Middle Age: 38 to 48 years old (pre-menopausal only)
89214307|NCT00884936||Group 3|Elderly Age: 60 to 75 years old (Post-menopausal only)
89214308|NCT05278832|Experimental|QLS31905|QLS31905 injection
89214309|NCT00886574|Active Comparator|Aspirin|Aspirin 100 mg once a day
89664806|NCT04910646|Experimental|orange peel fermentation|
89664807|NCT04910646|Placebo Comparator|placebo|
89664808|NCT02715271||Retrospective cohort|Tuberculosis patients submitted to therapeutical surgery during the last 2-5 years.
89664809|NCT02715271||Prospective cohort|Tuberculosis patients prospectively submitted to therapeutical surgery.
89664810|NCT04928976||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89664811|NCT04928976||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89664812|NCT04928976||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89664813|NCT04928976||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89664814|NCT03055572|Experimental|Olfactory Training with Essential Oils|Participants assigned to this group will do olfactory training using essential oils, while continuing the medical therapy prescribed by their provider.
89664815|NCT03055572|Active Comparator|Olfactory Training with Pure Fragrance Oils|Participants assigned to this group will do olfactory training using pure fragrance oils, while continuing the medical therapy prescribed by their provider.
89664816|NCT03055572|No Intervention|Control Group|The control group will continue the medical therapy prescribed by their provider.
89664817|NCT02535169|Experimental|Health Education and Coaching|1. To evaluate whether a health education and coaching strategy in overweight and obese adolescents (≥85th percentile) with high risk for type 2 diabetes is superior to usual care (single nutrition consultation) for weight management, clinical health outcomes (measures of glucose tolerance), lifestyle behavior outcomes (diet and physical activity) and outcomes of importance to patients such as satisfaction with the health care team, treatment goals, and psychosocial functioning.
89664818|NCT02535169|Placebo Comparator|Usual Care|1. Dietary consult only
89664819|NCT02526043|Experimental|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by laparoscopic surgery
89664820|NCT02526043|Experimental|Open hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by open surgery
89664821|NCT03054168|Experimental|Old Testosterone trained|"8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)~Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection"
89664822|NCT03054168|Placebo Comparator|Old Placebo trained|8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
89664823|NCT03054168|Experimental|Young Zoladex trained|"8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)~Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician."
89664824|NCT03054168|Placebo Comparator|Young placebo trained|8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
89664825|NCT03054246|Other|Healthy volunteers|Seventy-five healthy volunteers with no oral/dental problems with Angle I occlusion relationship and without any missing teeth will be included in the study. Evaluation of chewing side preference and laterality will be performed.
89664826|NCT02710279|Other|Depressive patients|Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone
89664827|NCT04918368||Pregnant women between 18-45 years old, being in second and third trimester of a singleton pregnancy|
89664828|NCT03054012||CAS group|computer-assisted surgery group
89664829|NCT02522845|Active Comparator|Compression|Patients randomised to this group will be asked to wear Class II compression stockings for 1 week
89664830|NCT02522845|No Intervention|No Compression|Patients randomised to this group will not be provided with any compression
89214310|NCT00886574|Active Comparator|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
89664831|NCT04928274|Other|ball retained mandibular over denture|each patient in this group received 3 implant installed in mandible and 3 ball attachments for retention of over denture
89664832|NCT04928274|Other|locator retained mandibular over denture|
89664833|NCT04928274|Other|telescopic retained mandibular over denture|
89664834|NCT04927728|Experimental|Audio MP|Participants of the audio mental practice (MP) group will complete MP via audio-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
89664835|NCT04927728|Experimental|Video MP|Participants of the video mental practice (MP) group will complete MP via video-guided multisensory cues of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each audio recording consists of 20 repetitions of the task.
89664836|NCT04927728|Experimental|Repetitive-Task Practice|Participants of the repetitive-task practice group will complete repetitive practice of one of four tasks: (1) wiping a table (2) picking up a cup (3) brushing hair and/or (4) turning the page of a book. The assigned motor task is based upon the functional abilities of the patient. MP will be performed followed by physical practice of the same task with a research therapist 3x/week and independent MP 2 days/week. Each participant completed at least 20 repetitions of the task.
89664837|NCT04927728|Active Comparator|Traditional Therapy|The control group received traditional occupational therapy stroke rehabilitation.
89664838|NCT04918056||beta thalassemia patients|
89664839|NCT01893697||Healthy Participants|HRCT scan in a specific postural position
89664840|NCT05586295|Placebo Comparator|Placebo|
89664841|NCT05586295|Experimental|EX plus|
89664842|NCT03056976|Experimental|Single-implant mandibular overdenture|A single midline implant and an O'ring/ball attachment to retain a mandibular overdenture
89664843|NCT03056976|Experimental|Two-implant mandibular overdenture|Two implants in the canine region and two O'ring/ball attachments to retain a mandibular overdenture
89664844|NCT03056976|Experimental|Fixed mandibular denture|A fixed four-implant mandibular denture
89214311|NCT00891488||Fit|
89048547|NCT04635618|Experimental|Intervention I: Cognitive Behavioral Brief-Telepsychotherapy|Four sessions of cognitive-behavioral therapy (CBT) conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content and content related to CBT technique.
89048548|NCT04635618|Experimental|Intervention II: Brief Interpersonal Telepsychotherapy|Four sessions of interpersonal therapy (IPT) conducted by video call by a psychologist, accompanied by the sending of 2 to 3 minute videos with psychoeducational content and content related to the ITP technique.
89048549|NCT04635618|Active Comparator|Active Comparator: Telepsychoeducation group|One single session of psychoeducation conducted through a video call by a psychologist, accompanied by sending videos of 2 to 3 minutes with psychoeducational content for 4 weeks.
89048550|NCT04684355|No Intervention|Standard-of-care group|Participants in this group received their colonoscopic and pathological diagnosis simultaneously at next clinical visit, which arranged in 1 to 2 weeks later.
89048551|NCT04684355|Experimental|Intervention group|Participants in this group received their colonoscopic diagnosis right after they awake from general anesthesia, and then received pathological diagnosis at next clinical visit, which arranged in 1 to 2 weeks later.
89048552|NCT00548639|Experimental|Statin Choice|Statin Choice Decision Aid The provider will introduce the patient to the choice of statins using the decision aid. The patient may make a choice then or defer this choice; in all cases, the patient goes home with the Statin Choice decision aid and pamphlet.
89048553|NCT00548639|Sham Comparator|Usual Care|Control Pamphlet the provider meets with the patient to discuss treatment options in the usual fashion.
89048554|NCT04635696|Experimental|Ethyl Chloride|Ethyl Chloride topical anesthetic mist will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
89048555|NCT04635696|Placebo Comparator|Tissue culture grade water|Tissue culture grade water (Nature's Tears Eyemist) will be sprayed on the area of adhesive during dressing change for patients with negative pressure wound therapy
89048556|NCT04644120|Experimental|Part A: Group 1: ABBV-47D11 Dose A|Participants will receive ABBV-47D11 Dose A on Day 1.
89048557|NCT04644120|Placebo Comparator|Part A: Group 1: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
89048558|NCT04644120|Experimental|Part A: Group 2: ABBV-47D11 Dose B|Participants will receive ABBV-47D11 Dose B on Day 1.
89048559|NCT04644120|Placebo Comparator|Part A: Group 2: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
89048560|NCT04644120|Experimental|Part A: Group 3: ABBV-47D11 Dose C|Participants will receive ABBV-47D11 Dose C on Day 1.
89048561|NCT04644120|Placebo Comparator|Part A: Group 3: Placebo for ABBV-47D11|Participants will receive placebo for ABBV-47D11 on Day 1.
89048562|NCT04644120|Experimental|Part B: Group 1: ABBV-2B04 Dose A|Participants will receive ABBV-2B04 Dose A on Day 1.
89048563|NCT04644120|Experimental|Part B: Group 1: ABBV-2B04 Dose A + ABBV-47D11|Participants will receive ABBV-2B04 Dose A in combination with ABBV-47D11 on Day 1.
89048564|NCT04644120|Placebo Comparator|Part B: Group 1: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
89048565|NCT04644120|Experimental|Part B: Group 2: ABBV-2B04 Dose B|Participants will receive ABBV-2B04 Dose B on Day 1.
89048566|NCT04644120|Experimental|Part B: Group 2: ABBV-2B04 Dose B + ABBV-47D11|Participants will receive ABBV-2B04 Dose B in combination with ABBV-47D11 on Day 1.
89048567|NCT04644120|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive Placebo for ABBV-2B04 followed by Placebo for ABBV-47D11 on Day 1.
89048568|NCT04942145|Active Comparator|Virtual Reality Group|With virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
89048569|NCT04942145|Experimental|Control Grooup|Without virtual reality. In order to relate the following variables with the effectiveness in reducing dental anxiety.MDAS TEST (Modified Dental Anxiety Scale) FIS TEST (Facial Imagen Scale) Revised Neo Personality Test (NEO-FFI) Brief Cope Inventory, (coping strategies)
89048570|NCT04643964|Experimental|Entrée: Cognitive Skills|
89048571|NCT04643964|Experimental|Entrée: Behavioral Skills|
89048572|NCT04643964|Experimental|Entrée: Interpersonal Skills|
89048573|NCT04643964|Experimental|Sampler Skills|
89048574|NCT04643964|No Intervention|Control|Participants are not given videos to watch until their involvement in the study ends.
89048575|NCT00548678|Experimental|A|intravenous diclofenac sodium
89048576|NCT00548678|Active Comparator|B|intravenous ketorolac
89048577|NCT00548678|Active Comparator|C|oral diclofenac (Cataflam)
89048578|NCT00548678|Active Comparator|D|oral aspirin
89048579|NCT00548951|Active Comparator|1|Subject receives Snoezelen sessions once per week.
89048580|NCT00548951|Active Comparator|2|Subject receives Snoezelen sessions three times per week.
89048581|NCT00548951|Other|3|Subject receives no sessions per week.
89048582|NCT04635501|Experimental|ABS 5.6.7|Patients whose access site will be closed with the AbsorbaSeal 5.6.7 Vascular Closure Device
89048583|NCT04684199|Active Comparator|Melatonin|"Melatonin~All participants will receive a 5 mg. dose of melatonin before bed for a period of two weeks during study period."
89048584|NCT04684199|Placebo Comparator|Placebo|"Placebo~All participants will receive a placebo comparative in substance, color, and flavor, before bed for two weeks during the study."
89048585|NCT04635267||patients with ARDS|
89048586|NCT00548990|Experimental|1|a 10-month moderate aerobic exercise training program
89048587|NCT00548990|Placebo Comparator|2|flexibility/balance control group
89048588|NCT00560586|Experimental|Budesonide|Budesonide for 6 weeks followed by crossover to placebo
89048589|NCT00560586|Placebo Comparator|Placebo|Placebo for 6 weeks followed by crossover to treatment.
89664845|NCT04431180|Experimental|SMS with safty ensurance|SMS content in this group will be about what blood services will do to ensure the safety of blood donors'life saving donation during 2019-nCoV epidemic.
89664846|NCT04431180|Experimental|SMS with saving life call-1|SMS content in this group will be about calling the blood donors to a life saving donation.
89664847|NCT04431180|Experimental|SMS with saving life call-2|SMS content in this group will be about calling the blood donors to a life saving donation.
89664848|NCT04431180|Placebo Comparator|SMS with blood donor day greeting|SMS content in this group will be about SMS with blood donor day greeting.
89664849|NCT05020405|Experimental|ARS with GBR and SMV|alveolar ridge splitting in combination with the use of GBR with SMV with immediate implant placement
89664850|NCT05020405|Active Comparator|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without SMV with immediate implant placement
89664851|NCT04909944|Experimental|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation and ventilation
89664852|NCT04909944|Experimental|laryngeal tube suction disposable supraglottic insertion for oxygenation|laryngeal tube suction disposable insertion for oxygenation and ventilation
89664853|NCT04917978||beta thalassemia patients|
89664854|NCT04909632|Experimental|To establish metabolite pattern and biomarkers of tongue fur in DM|
89664855|NCT04909866|Experimental|TACE+Lenvatinib+Camrelizumab|
89664856|NCT04909476||Severe COVID pneumonia with ET|Severe COVID 19 pneumonia undergoing endotracheal intubation
89664857|NCT03054090|Other|Quality Improvement support|A blended support strategy will include practice facilitation, expert consultation, collaborative learning events, an online support center, and data feedback and benchmarking.
89664858|NCT04757779|Experimental|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach. Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle). On Day1 and Day8, subjects are required to inject irinotecan(65mg/m2) or docetaxel(60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
89664859|NCT03053934|Active Comparator|Traditional in-person|Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
89664860|NCT03053934|Experimental|Online counselling|Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)
89664861|NCT04757467|Active Comparator|Standard physiotherapy neuro-rehabilitation|Control Group: Patients included in the control group will receive standard physiotherapy neurorehabilitation protocols.
89664862|NCT04757467|Experimental|Repetition-CIMT|In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr
89664863|NCT04757467|Experimental|Hour-CIMT|The task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours.
89664864|NCT03053856|Experimental|Pembrolizumab arm|Adjuvant Pembrolizumab
89664865|NCT04757623|No Intervention|Group B : conventional primary closure|allileostomies are reversed with conventional method
89664866|NCT04757623|Experimental|Group A: Purse string closure|the ileostomy reversal circular incision used with stitches of continuous and non-absorbable. The wound of skin was closed by using (Proline No. 1) that leaving 0.5 cm defect on middle in the skin.
89664867|NCT05029219|Experimental|Virtual reality group|To become proficient in lumbar transforaminal epidural blocks, participants receive additional training using virtual reality programs after audiovisual education.
89664868|NCT05029219|Active Comparator|Self study group|In order to become proficient in lumbar transforaminal epidural block, participants have self-study time using books and videos after audiovisual education.
89664869|NCT03056742|Experimental|Stem cells|Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care
89664870|NCT03056586|Experimental|1. study group|"100 patients who agree to participate in the study, will be operate according to our protocol for pelvic organ prolapse. At the end of the operation a vaginal pessary will be inserted and suture to the vaginal walls for a 4 week period.~Follow-up will be after 3, 6, and 12 month period."
89664871|NCT03056586|No Intervention|2. control|100 Women who will refuse to participate in the study, will agree to be follow-up by our team for 3, 6, and 12 month post operative.
89664872|NCT02390323|Experimental|Lumbar Sympathetic Block|Patients receiving a Lumbar Sympathetic Block as treatment for lower extremity pain. Skin conductance algesimeter will be used to measure sympathetic activity.
89048590|NCT00549029||1,2|Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
89664873|NCT03056664|Experimental|MSC-1|Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
89664874|NCT03056664|Experimental|MSC-2|Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
89664875|NCT03056664|Experimental|Ctrl|Patient in this arm will receive routine surgery and local NS injection
89664876|NCT03056508|Experimental|Exercise plus Nutrition|6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
89664877|NCT03056508|Active Comparator|Exercise|Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.
89664878|NCT04927026|Experimental|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|Solution-focused brief therapy (SFBT) involving psychoeducation and structured life review therapy, as well as mindfulness-based training
89664879|NCT04927026|No Intervention|Control|No intervention
89664880|NCT04917666|Experimental|Treatment|Participants joined a 8-session horticultural therapy group program (60 minutes per session) over 8 weeks.
89664881|NCT04917666|Other|Comparison|Participants joined 4 sessions of individual, parallel, and table-top activities of their own interest, e.g. reading, drawing, coloring.
89664882|NCT02489695|Experimental|axitinib + pembrolizumab|axitinib 10mg twice a day
89214312|NCT00891488||Unfit|
89214313|NCT00886652|Experimental|Exercise|"The patients of the Exercise group were submitted to a four-month physiotherapy protocol, with three weekly sessions of 60 minutes each, accompanied by a physiotherapist, and consisting of warm-up, aerobic exercise on an electric treadmill, and then winding down and relaxation.~Each patient in this group was therefore submitted to an average of 48 sessions of exercises, always carried out at the same physiotherapy center."
89214314|NCT00886652|No Intervention|2|The patients of the control group were not submitted to any type of physical exercises. Like the patients submitted to the protocol, they were evaluated at the beginning, and again after four months.
89214315|NCT00885014|Experimental|CBT|Telephone cognitive-behavioral therapy
89214316|NCT00885014|Active Comparator|TAU|Treatment as usual through the Employees Assistance Program
89521901|NCT03419429|Experimental|EDTA/Simvastatin/perforated membrane|open flap procedure, 24% EDTA root surface etching, 1.2% simvastatin gel and then coverage of the defect with modified perforated membrane.
89521902|NCT04448041||Ghana|
89521903|NCT04448041||India|
89521904|NCT04448041||Philippines|
89521905|NCT04448041||Zambia|
89521906|NCT02654145|Experimental|Omalizumab switch to mepolizumab 100mg SC every 4 weeks|Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in period for a minimum of one week and a up to 4 weeks. Subjects will remain on their current maintenance therapy throughout the run-in period, including omalizumab. At Visit 2 (week 0) subjects will discontinue omalizumab treatment and will be switched to receiving mepolizumab 100 mg SC every 4 weeks for 28 weeks. Except for omalizumab, subjects will remain on their current maintenance therapy throughout the open-label treatment period. Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
89521907|NCT03414203|Active Comparator|active tDCS|Active tDCS for 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
89521908|NCT03414203|Experimental|active tDCS with interval|Active tDCS for 15 minutes, interval of 20 minutes and more 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
89521909|NCT03414203|Sham Comparator|sham tDCS|Sham tDCS for 15 minutes for 10 days over 2 weeks. The stimulation is non-active. Placement: anode - left DLPFC; cathode - right supraorbital region
89521910|NCT04447885|Experimental|Experimental blanket|This blanket is the weight being tested which cannot be disclosed without unblinding participants.
89521911|NCT04447885|Active Comparator|Control blanket|This blanket is the control weight which cannot be disclosed without unblinding participants.
89521912|NCT03413215|No Intervention|Standard Care|Patients randomized to the standard care group will receive usual care, which consists of clinic visits 4 monthly for review of BP, HbA1c and other investigations, and titration of medications;counseling with the diabetes nurse educator (DNE), and provision of educational materials on diabetes.
89521913|NCT03413215|Experimental|Intensive|Patient randomized to the intensive group will receive additional counselling and education by the DNE, medical social worker (MSW) on self-care and coping strategies for diabetes, and see the renal pharmacist for more intensive titration of antihypertensive medication between doctor visits. They will also be loaned blood pressure monitors and glucometers with test strips to perform self-monitoring at home in between outpatient visits. Smartphone and online technologies will be utilized to improve remote monitoring, education and self-care.
89521914|NCT05122455|Experimental|ASA baseline|Patients in chronic use of ASA
89521915|NCT05122455|Experimental|ASA + Edoxaban|During this intervention phase, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days.
89521916|NCT05122455|Experimental|Clopidogrel|Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA).
89521917|NCT05122455|Experimental|Clopidogrel + Edoxaban|Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days
89521918|NCT05122455|Experimental|Edoxaban|Finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered.
89521919|NCT03413137|Active Comparator|Arm A|A Transperineal mpMRI-US Fusion prostate biopsy followed by a Transrectal mpMRI-US Fusion prostate biopsy
89521920|NCT03413137|Active Comparator|Arm B|A Transrectal mpMRI-US Fusion prostate biopsy followed by a Transperineal mpMRI-US Fusion prostate biopsy
89521921|NCT03413059|Active Comparator|morphine sulfate group|patients in this arm will receive : morphine dose 0.1mg /kg with 9 ml of 0.25 % bupivacaine with through epidural catheter on admission Then continuous epidural infusion of bupivacaine (0.1 mg.kg-1.h) 1st 72 hours
89521922|NCT03413059|Active Comparator|triamcinolone acetonide group|patients in this arm will receive will receive a mixture of 9 ml of 0.125 % bupivacaine with 80mg of triamcinolone ( 10 ml total volume) through epidural catheter on admission
89521923|NCT05120817|No Intervention|Control Group|Participants do not undergo any intervention. Pre-and post data collection only.
89521924|NCT05120817|Experimental|Personal|Participants are exposed to the message about the personal benefits (and costs) of vaccination which refers to their own safety, their freedoms, their worries about the well-being of their significant others.
89521925|NCT05120817|Experimental|Social|Participants are exposed to the message about the social benefits (and costs) of vaccination which refers to public safety, the well-being of others in their community, the vulnerable groups, etc.
89521926|NCT05120817|Experimental|Personal + Social|Participants are exposed to the message about both personal and social benefits (and costs) of vaccination. The message alludes to personal safety as well as public safety and the strain on the healthcare system associated with the uncontrollable spread of the virus.
89521927|NCT05170087||Breast malignancies|Those diagnosed with breast malignancies
89521928|NCT05170087||Head and Neck malignancies|Those diagnosed with head and neck malignancies
89521929|NCT05170087||Brain malignancies|Those diagnosed with brain malignancies
89521930|NCT05170087||Gynecological malignancies|Those diagnosed with gynecological malignancies
89521931|NCT05122377||GnRHa 3-month|Patients using GnRHa 3-month depot
89521932|NCT05122377||GnRHa 1-month|Patients using GnRHa 1-month depot
89664883|NCT03053778|Experimental|Intervention|Early follow-up after discharge
89664884|NCT04917198|Experimental|median sternotomy|median sternotomy in penetrating cardiac trauma and hemodynamically unstable patients, does it affect morbidity and mortality.
89664885|NCT03053388|Experimental|Group 1 - Nitric Oxide treatment|• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
89664886|NCT03053388|Active Comparator|Group 2 - Control treatment|• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
89664887|NCT02487745|Active Comparator|IPS Only|IPS Only participants will receive the Individual Placement and Support (IPS) supported employment.
89664888|NCT02487745|Experimental|IPS Plus Wage Supplement|IPS Plus Abstinence-Contingent Wage Supplement participants will receive the Individual Placement and Support (IPS) supported employment intervention and abstinence-contingent wage supplements.
89664889|NCT03053544|Experimental|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
89664890|NCT02384083|Experimental|Filanesib, pomalidomide and dexamethasone|28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22
89664891|NCT04926480|Experimental|low flow Anesthesia group|Antioxidant parameters are measured in the low flow anesthesia group.
89664892|NCT04926480|Active Comparator|high flow Anesthesia gruop|Antioxidant parameters are measured in the high flow anesthesia group.
89664893|NCT04917276||Training Group|The training cohort that used to built the response prediction model
89664894|NCT04917276||Validation Group|The validation cohort that used to validate the response prediction model
89664895|NCT04917432|Active Comparator|IVUS guided CTO revascularization|To assess the effects of IVUS usage in CTO revascularization compared to conventional non-IVUS guided CTO-PCI as regard technical success and procedural success, MACE within 6 months.
89664896|NCT04917432|Active Comparator|Non-IVUS guided CTO revascularization|To compare this conventional non-IVUS guided CTO-PCI arm with the other IVUS guided arm as regard technical success and procedural success, MACE within 6 months.
89664897|NCT02380573|Experimental|Healthy Aging MB|Methylene Blue (USP grade, 282mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
89664898|NCT02380573|Placebo Comparator|Healthy Aging Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
89664899|NCT02380573|Experimental|Mild Cognitive Impairment (MCI) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
89664900|NCT02380573|Placebo Comparator|Mild Cognitive Impairment (MCI) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
89664901|NCT02380573|Experimental|Mild Alzheimer's Disease (AD) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
89664902|NCT02380573|Placebo Comparator|Mild Alzheimer's Disease (AD) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
89664903|NCT02380573|Experimental|Healthy Middle Age MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
89664904|NCT02380573|Placebo Comparator|Healthy Middle Age Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
89664905|NCT04917510|Active Comparator|Control|Will not receive erector spinae block. Will be administered 30 mL of 0.5% Marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
89664906|NCT04917510|Experimental|Study|Will receive an erector spinae block prior to surgery using 30-45 mL of 0.25 bupivacaine w/ epinephrine and 5 mL of dexmedetomidine. Will be administered 30 mL of 0.5% marcaine w/ epinephrine as a local block at the surgical site at the conclusion of the procedure.
88995139|NCT05522855|Active Comparator|Control Version- EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server like the Intervention version, but no mental workload or brain energy data will be displayed.
89664907|NCT04926870|Experimental|PACS group|PACS administration during teaching
89664908|NCT04926870|Active Comparator|Traditional group|Traditional teaching without PACS
89664909|NCT02378701||Quality of Life in Myelodysplasia Scale (QUALMS-1)|Participants complete the Quality of Life in Myelodysplasia Scale (QUALMS-1) and the Anemia Subset of FACT (FACT-An), instrument twice: at the start of treatment, and after four cycles or discontinuation of treatment, whichever comes first.
89664910|NCT04917354||hepatic lesion|
89664911|NCT04926402|No Intervention|Standard of care|The control group received standard routine care
89664912|NCT04926402|Experimental|Kangaroo care education program|The experimental group received a maternal kangaroo care education program
89664913|NCT04916808||Ductal Carcinoma In Situ (DCIS)|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
89664914|NCT02463877|Experimental|Minimally-Invasive Procedure|single-arm study of laparoscopic cytoreduction and HIPEC
89664915|NCT03053154||Experimental group1|15 stroke patients with right side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
88995140|NCT05495269|Experimental|QLS-101, 2.0%|Qlaris' investigational product, QLS-101, 2.0% concentration, ocular administration (eye drop), given once daily in the morning to both eyes
89048591|NCT04644198|Active Comparator|Convalescent Plasma Treatment|Convalescent Plasma
89664916|NCT03053154||Experimental group2|15 stroke patients with left side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
89664917|NCT03053154||Control group|15 Normal subjects without any diseases or dysfunctions , their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
89048592|NCT04644198|No Intervention|Control|Standard of care
89048593|NCT04643730|Experimental|Reflexology Group|Foot Reflexology was applied to the babies before heel lancing
89048594|NCT04643730|Experimental|Acupressure Group|Acupressure was applied to the babies before heel lancing
89048595|NCT04643730|Active Comparator|Control Group|No pre-application was made to the babies in the control group as a routine procedure
89048596|NCT00549107|Experimental|1|
89664918|NCT02461537|Active Comparator|RIST(remission induction)|high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)
89664919|NCT02461537|Experimental|DISC (disease control)|low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2
89664920|NCT03055104||severe malnutrition|Patients with severe malnutrition (BMI<13 kg/m2), admitted to Peking University Third Hospital from JAN 2008 are involved in this study. After admission, a multidisciplinary team, consisting of specialists in the field of intensive care, pharmacy, psychology, and physical therapy assessed all patients. Management and treatment of these patients are in accordance with guideline for the management of severe malnutrition in PUTH.
89664921|NCT03055182|Experimental|Low back pain patients|Subjects included in physical rehabilitation program.
89664922|NCT03055182|No Intervention|Control subjects|No intervention administered
89664923|NCT04272541|Active Comparator|Psychoeducation program|The intervention program consists of psychopharmacology (standard intervention in mental health services) + individual psychoeducation (individual treatment including learning of Healthy Lifestyle). This program is implemented for three months, allocated in several sessions.
89664924|NCT04272541|Active Comparator|Habitual intervention|Intervention program consists of psychopharmacology (standard intervention in mental health services). This program is implemented for three months.
89664925|NCT04909398|Experimental|Dynamic pupillometry sessions|"It is planned to include 60 participants divided into different groups:~15 healthy subjects, called controls.~15 patients with retinitis pigmentosa.~15 patients with Leber's hereditary optic neuropathy.~15 patients with Stargardt's disease."
89664926|NCT05021263|Experimental|Magnesium Group|The magnesium group (Mg) will receive a bolus of 50 mg/kg of IV magnesium prior to incision and an infusion of 15 mg/kg/hr, with no preoperative oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
89664927|NCT05021263|Placebo Comparator|Control Group|The control group (Ct) will receive saline solution and no IV magnesium or oral pregabalin. All groups will receive preoperative oral acetaminophen, preoperative NSAIDs, subcutaneous heparin, intraoperative TAP block, intraoperative dexamethasone, ondansetron, transdermal scopolamine patch, and postoperative care as per the current ERAS protocol.
89664928|NCT04916964|Experimental|Test & Exercise home-based program (T&E)|Eight home-based physiotherapy sessions will occur in two months, once a week
89664929|NCT05028673|Experimental|Lu AG06466 Capsule, Fasted State|Participants will receive 1 capsule of Lu AG06466 in a fasted state.
89664930|NCT05028673|Experimental|Lu AG06466 Tablet, Fasted State|Participants will receive 1 tablet of Lu AG06466 in a fasted state.
89664931|NCT05028673|Experimental|Lu AG06466 Tablet, Fed State|Participants will receive 1 tablet of Lu AG06466 in a fed state (high-fat meal).
89048597|NCT00549107|Active Comparator|2|
89048598|NCT04635306|Experimental|Low Nitrogen GEBT test meal|GEBT test meal containing low %N content (below 7%)
89048599|NCT04643496||Patients requiring ileocolic resection for Crohn disease.|All consecutive patients requiring an ileocolic resection for Crohn disease, between January 2010 and March 2020 at the Digestive Surgery Units of CHU Montpellier.
89048600|NCT04643847|Experimental|Stereotactic radiosurgery with Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions
89048601|NCT00549341|Active Comparator|1|
89048602|NCT00549341|Placebo Comparator|2|
89048603|NCT00549380|Experimental|1|
89664932|NCT05028673|Experimental|Lu AG06466 Tablet + Antacid, Fasted State|Participants will receive 1 tablet of Lu AG06466 dosed in combination with antacid in a fasted state.
89664933|NCT04925310||RSV Bronchiolitis Group|hospitalized children with confirmed RSV infection between the first month of life and second year of life
89664934|NCT01893931|Placebo Comparator|Satisfaction Survey|Within 1-3 days after ED discharge, patients will be called by a nurse to complete a brief satisfaction survey.
89664935|NCT01893931|Active Comparator|ED Discharge and Medication Call|Within 1-3 days after ED discharge, patients will receive a follow up phone call from a nurse to review discharge instructions, review medication instructions, and provide any necessary patient navigation.
89664936|NCT04909164||Immunotherapy group|Patients receiving reimbursed immunotherapy as a second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy)
89664937|NCT04909164||Cytotoxic chemotherapy group|Patients receiving reimbursed cytotoxic chemotherapy as second-line therapy after failure of platinum-based chemotherapy
89048604|NCT00549419|Experimental|1|In the Treatment group, the traditional vital signs and APCO are made continuously available for fluid and catecholamine optimization and clinical decision making.
89048605|NCT00549419|Active Comparator|2|
89048606|NCT04635540|Experimental|Interventional Arm|The Interventional Arm will receive the educational brochure and complete the study tasks and questionnaires.
89048607|NCT04635150|Experimental|Post-intervention parents and staff|An educational intervention for the multidisciplinary staff of a neonatal intensive care unit.
89048608|NCT03456050|Experimental|FRC group|This group will receive FRC exercise.
89048609|NCT03456050|Experimental|Conventional treatment|This group will receive conventional exercise.
89214317|NCT00611858|Experimental|Cetuximab, 5-FU and Radiation|"Cetuximab: Participants first receive cetuximab at the initial dose of 400 mg/m2 intravenously (IV) administered over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Cetuximab is given as single agent during the first 3 weeks on study and then in combination with 5-FU and radiation.~Radiation: Radiation therapy given as standard of care is initiated after the 3rd dose of cetuximab with a total dose of 50.4 Gray (Gy) in 28 fractions over approximately 5.5 weeks.~5-FU: Participants receive 5-Fluorouracil (5-FU) continuous infusion through central venous access at 225 mg/m2/day given 7 days a week starting day 1 of radiation (no later than 3 days) and lasting the duration of radiation therapy.~Duration of neoadjuvant therapy is estimated to be 9 weeks. Surgery follows at week 13-17. Sigmoidoscopy is performed for biopsy prior to the 1st dose and after 3rd dose of cetuximab before the initiation of radiation and/or 5-FU."
89214318|NCT00137449|Experimental|A|
89214319|NCT00886730|Experimental|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
89664938|NCT02368405|Active Comparator|Control|Control group will receive standard of care
89664939|NCT02368405|Experimental|Treatment|"Participants in the treatment group will receive six interactive nutrition lectures over the course of three weeks. The treatment program is titled Eat Smart, Live Better"
89664940|NCT04916574|Active Comparator|BioBlock® concentration 0.2 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
89664941|NCT04916574|Active Comparator|BioBlock® concentration 0.1 mg/mL|BioBlock®: Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum
89664942|NCT02460445|Experimental|Intervention|Premenopausal women with functional hyperandrogenism under combined oral contraceptive pill qd as usual clinical practice who will undergo a scheduled standard phlebotomy every 3 months from month 3 to 12 of follow-up.
89664943|NCT02460445|Active Comparator|Control|Premenopausal women with functional hyperandrogenism under standard combined oral contraceptive pill qd as usual clinical practice.
89664944|NCT04908540|Active Comparator|MARPE/ Conventional (Control) (Group A)|patients will open the appliance in its conventional way; 2 quarter turn (0.2 mm) in the morning, and 2 quarter turn in the evening until overcorrection achieved.
89664945|NCT04908540|Experimental|MARPE/ ALT-RAMEC (Group B)|Patients will open 2 quarter turn (0.2mm) in the morning, and 2 in the evening in the first week, then alternate with closing 2 quarter turn in the morning and 2 in the evening in the second week. And then continuing opening and closing till end with opening in the 7th week and continue opening until overcorrection achieved.
89664946|NCT04908618|Active Comparator|digital impression with normal abutment for dental implant|digital impression using a ready-made abutment for dental implant
89664947|NCT04908618|Experimental|digital impression with scan abutment for dental implant|digital impression with scan body abutment for dental implant
89664948|NCT04908618|Experimental|open tray conventional dental implant impression|Digitized open tray dental implant impression
89664949|NCT04908618|Experimental|closed tray impression for dental implant|Digitized closed tray dental implant impression
89664950|NCT04908696||TLM treatment for LC and PHC patients with early stage|TLM group: Laryngeal carcinoma (LC) (supraglottic type and glottic type) and hypopharyngeal carcinoma (HPC) (pyriform sinus and posterior pharyngeal wall) patients with T1 and T2 stages can be treated with transoral laser microsurgery (CO2 laser resection) for proper indications (NCCN 2020).
89664951|NCT04908696||OPL treatment for LC and PHC patients with T1, T2, and T3 stages|OPL group: Open partial laryngectomy with laryngeal function preservation is performed for patients with laryngeal carcinoma (LC) (supraglottic type, glottic type, and subglottic type) and hypopharyngeal carcinoma (PHC) (pyriform sinus, postcricoid, and posterior pharyngeal wall) with proper indications (NCCN 2020).
89664952|NCT04908696||R treatment for LC and PHC patients with early stage|R group: radiotherapy is treated for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications (NCCN 2020).
89664953|NCT04908696||TORS treatment for LC and PHC patients with early stage|TORS group: transoral robotic surgery is performed for proper laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with early stage with proper indications.
89664954|NCT04908696||SPA treatment for LC and PHC patients with advanced stage|SPA group: surgical treatment (S) ± postoperative adjuvant (PA) therapy is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
89664955|NCT04908696||CCR treatment for LC and PHC patients with advanced stage|CCR group: concurrent chemoradiotherapy (CCR) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
89664956|NCT04908696||ARC treatment for LC and PHC patients with advanced stage|ARC group: neoadjuvant therapy (A) + radiotherapy/chemoradiotherapy (RC) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
89664957|NCT04908696||ASRC treatment for LC and PHC patients with advanced stage|ASRC group: neoadjuvant therapy (A) + surgery (S) + radiotherapy (R) or chemoradiotherapy (C) is performed for laryngeal carcinoma (LC) and hypopharyngeal carcinoma (PHC) patients with advanced stage with proper indications (NCCN 2020).
89664958|NCT02449837||Head and Neck Cancer|Patient with locally advanced head and neck cancer but no distant metastasis scheduled to receive radiotherapy to the head and neck region with or without chemotherapy/targeted therapy (palliative or curative intent).
89664959|NCT02449837||Cervical Cancer|Patients with locally advanced cervical cancer without distant metastasis scheduled for radiotherapy to the pelvic region with or without chemotherapy/targeted therapy (palliative or curative intent).
89664960|NCT02449837||Non-Small Cell Lung Cancer|Patients with stage I to III non-small cell lung cancer, without distant metastasis, scheduled to receive stereotactic body radiotherapy for early stage lung disease and/or external beam radiotherapy for locally advanced lung disease, with or without concurrent/sequential chemotherapy and/or targeted therapy (curative intent).
89664961|NCT02449837||Rectal Cancer|Patients with locally advanced rectal cancer (no distant metastasis) scheduled to receive neoadjuvant chemoradiotherapy (curative intent).
89664962|NCT02449837||Metastatic Prostate Cancer|Patients with metastatic prostate cancer scheduled for palliative radiotherapy, or biochemically recurrent prostate cancer following radical prostatectomy scheduled for salvage prostatic fossa radiotherapy, with or without androgen deprivation, or with high risk prostate cancer.
89664963|NCT02449837||Oligometastatic Disease|Patients with oligometastatic cancer, defined as any solid malignancy with< 5 measurable sites of metastatic disease, limited to a maximum of 3 anatomic organ systems, excluding the primary tumor and regional lymph nodes. At least 1 site of metastatic disease, but as many as all 5 sites, in addition to the primary tumor and regional lymph nodes, is amenable to local ablative therapy with external beam radiation, stereotactic cranial radiosurgery or stereotactic body radiotherapy. Treatment will be guided by multi-disciplinary evaluation and may also include surgery, chemotherapy or target agents at the discretion of the primary oncologists. Patients may present with oligometastatic disease or have oligometastatic disease recurrence after definitive therapy for localized disease.
89664964|NCT02449837||Immunotherapy|Melanoma or metastatic NSCLC scheduled to receive ipilimumab, nivolumab, and/or pembrolizumab.
89664965|NCT02449837||Head and Neck Induction chemotherapy|Locally advanced head and neck cancer (HNSCC) scheduled to receive induction chemotherapy followed by radiotherapy.
89664966|NCT02449837||Metastatic Breast Cancer|Patients scheduled to receive any treatment, including radiation therapy, and/or systemic/hormonal therapy
89664967|NCT02449837||Endometrial Cancer|Patients with stage III endometrial cancer, being treated with adjuvant radiation
89664968|NCT03053232|Experimental|Purse string suture device|Use of purse string suture device to close gastrointestinal perforation.
89664969|NCT03053232|Active Comparator|Endoclips|Use of endoclips to close gastrointestinal perforation.
89664970|NCT02363647|Experimental|Tumor Genomic Analysis|Personalized Therapy Plan Patients with Metastatic Medullary or Colon Cancer being treated with the Personalized Treatment Plan developed during the different tumor genomic analysis study.
89664971|NCT04924686||Crohn's disease|The fecal and plasma were collected
89664972|NCT04924686||Ulcerative colitis|The fecal and plasma were collected
89664973|NCT04924686||Diabetes mellitus, type 2|The fecal and plasma were collected
89664974|NCT04924686||Atherosclerotic cardiovascular disease|The fecal and plasma were collected
89664975|NCT04924686||Colorectal cancer|The fecal and plasma were collected
89664976|NCT04924530|Sham Comparator|Maltodextrin|Glucose polymer; a common sugar substitute
89664977|NCT04924530|Active Comparator|Sucrose|Fructose-glucose disaccharide
89664978|NCT04924530|Experimental|Lactose|Galactose-glucose disaccharide
89664979|NCT02358967|Placebo Comparator|Placebo|Standard renal care + 300 mg placebo daily for 1 year
89664980|NCT02358967|Active Comparator|Treatment|Standard renal care + 300 mg TRF daily for 1 year
89664981|NCT03052998|Active Comparator|Ivermectin|Ivermectin and anti-epileptic treatment
89664982|NCT03052998|No Intervention|no treatment|only anti-epileptic treatment
89664983|NCT05586061|Experimental|RC48 Plus Tislelizumab and S-1(RCTS)|Disitamab Vedotin: 2.5mg/kg, ivdrip, d1, (every 3 weeks) Q3W； Tislelizumab: 200mg, ivdrip, d1, (every 3 weeks) Q3W； S-1: 40-60mg(according to patients' body surface area), po, bid, d1-14 and discontinued for 7 days in each cycle; until progressive disease (PD) or intolerable toxicity
89664984|NCT04916184|Active Comparator|aerobic exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
89664985|NCT04916184|Active Comparator|Combined exercise|effects on diastolic dysfunction in patients with stable chronic heart failure
89664986|NCT02354131|Experimental|Niraparib monotherapy|Niraparib mono therapy until progression
89664987|NCT02354131|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until progression
89664988|NCT03053076|Placebo Comparator|Placebo1|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
89664989|NCT03053076|Experimental|CBMNC|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
89688683|NCT03490825|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
88995141|NCT05494229|Experimental|Utilizing autologous whole blood for the full thickness macular hole|It is an interventional study by performing pars-plana vitrectomy
88995142|NCT05474638|Other|Controlateral and simultaneous comparison of neuromuscular transmission monitors|Controlateral and simultaneous comparison of responses from acceleromyography- and mechanomyography-based neuromuscular transmission monitors in the same patients.
88995143|NCT05468112|Experimental|Sky Meditation and Mindfulness Intervention|In person meditation classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions. An additional 7 online sessions will be delivered to participants in successive days after the initial in-person intervention. Participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. To support participants stabilization of the practices, optional daily guided practice will be offered online at a determined convenient time for all participants to allow full participation. The breathing techniques will be taught by certified instructors.
88995144|NCT05451953|Experimental|Apneic Oxygenation|
88995145|NCT05451953|Active Comparator|Standard of Care|
88995146|NCT05435443|Experimental|the PowerBreathe and PEP Therosold tools group|
88995147|NCT05435443|Active Comparator|perform diaphragmatic breathing, series of abdominal crunches and expiratory exercises group.|
88995148|NCT05425719|Experimental|eGFR ≥ 70 mL/min/1.73 m^2|Participants with eGFR ≥ 70 mL/min/1.73 m^2 will receive one 130 mg dose of MB-102 and a transdermal sensor placed on their chest. Blood samples and fluorescent measurements will be collected over 12 hours.
88995149|NCT05425719|Experimental|eGFR < 70 mL/min/1.73 m^2|Participants with eGFR < 70 mL/min/1.73 m^2 will receive one 130 mg dose of MB-102 and a transdermal sensor placed on their chest. Blood samples and fluorescent measurements will be collected over 24 hours.
88995150|NCT05423496|Active Comparator|Steroid Control Arm|133 patient undergoing KidneyCare Surveillance with Immune optimization at clinician discretion
89664990|NCT01894009|Active Comparator|Foot manipulation|"Asymmetry of the feet was treated by thrusting of the cuboid bone and the subtalar joint was treated with gapping thrust. Mobilisation of the distal tibia-fibula was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given with morning exercises. Four types of exercises were recommended: 1) Foot training with pro-and supination of the feet from dorsal to plantar flexion. 2)Caterpillar walk. 3) Training the take off of the great toes along a normal walking line and 4) Mobility of lateral malleoli and the talo-crural joint by dorsal flexion of feet while bending the knees."
89664991|NCT01894009|Sham Comparator|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones with the patient in the supine position on a psoas pillow. Further, light pressure on the Achilles tendon, with the patient standing against a wall with the feet 40 cm off the wall with bent knees on order to simulate the tibio-fibular mobilisation. Home exercises in the mornings to be repeated 8 times.
89664992|NCT04916262||TSH < 30uIU/mL group|Clinical information was collected from patients with TSH < 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
89664993|NCT04916262||TSH ≥ 30uIU/mL group|Clinical information was collected from patients with TSH ≥ 30UIU /mL on the 14th day of thyroxine withdrawal before 131I treatment，including TCM syndrome elements, general information ,medical history and biochemical examination during hospitalization.
89664994|NCT03052686||Childbirth with uterine rupture|No intervention. Follow-up of women with uterine rupture at the childbirth.
89664995|NCT02352337|Active Comparator|FOLFIRINOX|Every two weeks (maximum of 12 cycles) : Oxaliplatin 85 mg / m2 Day1 in 2 hours - then Irinotecan 180 mg / m2 Day1 in 90 minutes - Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion) - 5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours
89664996|NCT02352337|Experimental|FOLFIRINOX + LV5FU2 in maintenance|"Folfirinox during 4 months followed by LV5FU2 maintenance until progression:~Folfirinox (as described in arm FOLFIRINOX) LV5FU2 : Folinic acid 400 mg/m² (200 mg/m² if Elvorine), in perfusion over 2 hours the 5FU 400 mg/m² in bolus over 10 mn followed by 5FU 2400 mg/m² in perfusion over 46 hours."
89664997|NCT02352337|Experimental|FIRGEM|"Alternance of 2 months of FOLFIRI.3 with 2 months of GEMCITABINE:~Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours 5FU continue 2000 mg/m² over 46 heures then irinotécan at 90 mg/m² (1h) at day 3 when 5U perfusion is over~Gemcitabine: 1000 mg/m² in perfusion over 30 mn at day 1,8,15,29,36 and 43 over (1 injection per week during 3 weeks followed with 7 days of rest )"
89664998|NCT04431102|Experimental|PILATES METHOD|"It was intended the Pilates program were low supervision and easily realizable by all patients, which implied flexibility in the schedule. In this sense the sessions of Pilates was adjusted to these assumptions and the Pilates monitor offered several schedules on diferent days of the week.~The pregnant women assigned to the intervention group were supervised by the midwifery of reference and trained by a Pilates monitor who explained the training program. The women received eight sessions of Pilates, given with a frequency of two classes per week and one hour of duration during a period of four weeks. The exercises for each session were determined beforehand. In addition, the participants maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.~The therapeutic control were carried out by telephone call and clinical history review between the eighth and tenth day postpartum."
89664999|NCT04431102|No Intervention|MATERNAL EDUCATION|"The control group maintained the usual monitoring of pregnancy valued by the reference average, attending the sessions of the maternal education program of their health center.~Therapeutic control was carried out by phone call and review of the clinical history between the eighth and tenth day postpartum."
89665000|NCT02349217|Experimental|Mindfulness Based Stress Reduction Intervention (MBRE)|"Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
89665001|NCT02349217|Active Comparator|Standard of Care|"Participants receive self-help materials that have been previously developed by MD Anderson's Office of Public Education, the American Cancer Society, and the National Cancer Institute.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
88995151|NCT05423496|Experimental|Steroid Immuno-optimization Arm|267 patient undergoing KidneyCare Surveillance with protocolized AlloSure-guided immuno-optimization of steroids/CNI
88995152|NCT05423496|Active Comparator|Tacrolimus and mycophenolate mofetil (MMF) Control Arm|133 patient undergoing KidneyCare Surveillance with Immune optimization at clinician discretion
88995153|NCT05423496|Experimental|MMF Immuno-optimization Arm|267 patient undergoing KidneyCare Surveillance with protocolized AlloSure-guided immuno-optimization of MMF/CNI
88995154|NCT05401318||Primary resectable colon and rectal cancer|Patients with primary resectable, localized colon and rectal cancer eligible for blood and tissue sampling for organoid development.
88995155|NCT05366686|Experimental|Frailty and Quality of Life in Patients With Heart Failure|Patients in this group will receive a 12 week exercise program including: (1) one 40-60 minute individual consultation (teaching exercise which contain walking and resistance exercise by using elastic bands and elastic balls); (2) provided exercise booklet, exercise log, exercise video; (3) Nutritional consultation; (4) telephone follow-up once per week for 12 weeks
88995156|NCT05366686|No Intervention|Frailty and Quality of Life|Patients in this group maintain their daily life activities, and there is no intervention given.
88995157|NCT05355935|Experimental|Part 1: Treatment Dose 1|Participants (in a 3:1 ratio) will receive a single oral dose of brensocatib Dose 1 or placebo, once on Day 1.
89665002|NCT02827201|Experimental|nab-paclitaxel + gemcitabine/FOLFIRI.3|"Alternance of :~2 months with nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m², 30 min in IV, 3 injections follow by 1 week free)~follow by 2 months with FOLFIRI.3 (irinotecan: 90 mg/m² at D1, acid folinic 400 mg/m², 5Fu continus: 2000 mg/m² IV 46 hours, and irinotecan at D3, 90 mg/m²) This alternance continus until progression"
89665003|NCT02827201|Active Comparator|nab-paclitaxel + gemcitabine|nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m² - 30 min in IV) 3 injections follow by 1 week free, until progression
89665004|NCT04430868|Experimental|LRP group|The participants in LRP group receive lifestyle redesign program plus treatment as usual. The LRP intervention consisted of one 90-minute session each week for 10 weeks
89665005|NCT04430868|No Intervention|TAU group|The participants in TAU group received usual treatment at the same time as LRP group.
89665006|NCT04907994||Older patients and/or with chronic diseases|Retrospective cohort study of exposed/unexposed individuals in the national health data system (SNDS). The study population is composed of individuals aged 70 years or older and patients with a chronic disease. Exposure to containment is defined as the period between 17 March 2020 (beginning of week 12, start of containment) and 10 May 2020 (end of week 19, end of containment). The end of monitoring is set at 12 months after the start of the containment, on 17 March 2021. The unexposed group consists of random samples of comparable individuals (aged 70 years or older and/or chronically ill) for the two years prior to the outbreak (2015 and 2016). The second study period (May 10, 2020 to March 17, 2021) may be subdivided depending on the evolution of the health crisis and the governmental measures adopted. Measurement of the outcome measures and comparison between exposed and unexposed will be carried out at the end of each of the two periods.
89665007|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 12.5 mg|
89665008|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 25 mg|
89665009|NCT01378377|Experimental|Pimasertib 75 mg+Temsirolimus 25 mg|
89665010|NCT04924218|Active Comparator|rigid cystoscopy|Group undergoing endoscopic urethral procedure with rigid cystoscopy after radical prostatectomy
89665011|NCT04924218|Active Comparator|flexible cystoscopy|Group undergoing endoscopic urethral procedure with flexible cystoscopy after radical prostatectomy
89665012|NCT04924218|Active Comparator|semi-rigid ureterorenoscopy|Group undergoing endoscopic urethral procedure with semi-rigid ureterorenoscopy after radical prostatectomy
89665013|NCT04346719|Experimental|10 kHz stimulation|"Transcutaneous application of high frequency electrical current at 10 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
89665014|NCT04346719|Experimental|20 kHz stimulation|"Transcutaneous application of high frequency electrical current at 20 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
89665015|NCT04346719|Sham Comparator|Sham stimulation|Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
88995158|NCT05355935|Experimental|Part 1: Treatment Dose 2|Participants (in a 3:1 ratio) will receive a single oral dose of brensocatib Dose 2 or placebo, once on Day 1.
88995159|NCT05355935|Experimental|Part 2|Participants will be randomized to 1 of 4 treatment sequences (ABCD, BDAC, CADB, DCBA).
88995160|NCT05350397|Experimental|Acupressure group|The patients in the intervention group were informed about what acupressure was and why it was applied. An acupressure wristband was correctly worn on both wrists to provide patients with adequate pressure on the HT7 point for 5 minutes
88995161|NCT05350397|Placebo Comparator|Placebo Group|Patients in the placebo group were informed about what acupressure was and why it was applied. In order not to apply pressure to the Shenmen (HT7) pressure point in the patients in this group, the acupressure wristband was placed on both wrists in an inverted and loose manner and the wristband was worn for 5 minutes, the procedure was completed.
88995162|NCT05350397|No Intervention|Control group|No procedure was applied to the patients in the control group. The patients received routine treatment and care.
88995163|NCT05334017|Active Comparator|Xylometazoline|Xylometazoline 0,1% as nasal solution given immediately prior to nasal intubation
88995164|NCT05334017|Active Comparator|Cocaine|Cocaine 4% as nasal solution given immediately prior to nasal intubation
88995165|NCT05330104|Experimental|mEMA Arm|In this arm, participants will be using a mobile survey system to track the emergence of Chemotherapy-Induced Peripheral Neuropathy symptoms and fall risk over the course of the participant's chemotherapy.
88995166|NCT05326971|Experimental|Tenofovir disoproxil TDF|Participants who have used TDF as part of their stable antiretroviral regimen for at least past six months.
88995167|NCT05326971|Active Comparator|Tenofovir alafenamide (TAF)|Participants who have used TAF as part of their stable antiretroviral regimen for at least past six months.
88995168|NCT05307822|Experimental|Cohort 1: Menthol with HTP device (20020064)|Subjects will self-assign to one of three menthol flavor variants of non-combusted cigarette products based on their self-reported flavor usage history.
88995169|NCT05307822|Experimental|Cohort 2: Non-Menthol with HTP device (20020064)|Subjects will self-assign to a non-menthol flavor variant of a non-combusted cigarette product based on their self-reported flavor usage history.
88995170|NCT05302700|Experimental|Early Parental Sensitivity Intervention Program|The protocol will last five to seven days for preterm infant mothers.
88995171|NCT05302700|No Intervention|Control group|The control group received general routine nursing guidance.
88995172|NCT05292339|Active Comparator|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Participants will receive the triamcinolone injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
88995173|NCT05292339|Active Comparator|Ketorolac injection to the shoulder, elbow, wrist, or hand|Participants will receive the Ketoralac injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
88995174|NCT05291650|Active Comparator|glucocorticoid injection into infrapatellar fat pad|
88995175|NCT05291650|Placebo Comparator|placebo injection into infrapatellar fat pad|
88995176|NCT05285059||Patients|8- to 14-years-old children with epilepsy
88995177|NCT05285059||Control|8- to 14-years-old children without neurological, psychiatric, or developmental impairments
89214320|NCT00886730|Experimental|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
89214321|NCT00886730|Experimental|Physicians endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
89214322|NCT00886808|Experimental|1|110 microgram dose of iCo-007 Intravitreal Injection
89214323|NCT00886808|Experimental|2|350microgram dose of iCo-007 Intravitreal Injection
89214324|NCT00886808|Experimental|3|700microgram dose of iCo-007 Intravitreal Injection
89214325|NCT00886808|Experimental|4|1,000microgram dose of iCo-007 Intravitreal Injection
89214326|NCT00891644||1|HIV positive adolescents who never initiated care within 6 months of receipt of HIV positive results.
89214327|NCT00891644||2|HIV positive adolescents who initiated care, but did not follow up with care within 12 months of the initial care visit. Also included in this group are those who initiated and followed-up with care, but have dropped out of care for 12 or more months.
89214328|NCT00891644||3|HIV positive adolescents who initiated care and maintained care. These youth are currently in care.
89214329|NCT00886886|Other|Reboxetine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
89665016|NCT04924296|Experimental|Treatment group A|
89665017|NCT04924296|Placebo Comparator|Treatment group B|
89665018|NCT03056430|Experimental|Training Group 1|Slackline training
89665019|NCT03056430|Experimental|Training Group 2|Slackline training
89665020|NCT04924452|Experimental|Er:YAG laser therapy|Er:YAG laser will be used for enamel conditioning of the occlusal surfaces of the permanent molars before sealant application as well as the standardized caries treatment.
89665021|NCT04924452|Active Comparator|Conventional therapy|Conventional rotary instruments will be used for caries treatment.
89665022|NCT04915794|Experimental|Simulation based education|Simulation is a technique that creates a situation or environment that allows people to experience the representation of a real event, practice, learn, evaluate, test, or gain an understanding of systems or human actions
89665023|NCT04915794|No Intervention|Traditional education|Necessary procedures explained theoretically
89665024|NCT01379625|Active Comparator|Medium Chain Triglyceride (MCT)|Subjects randomized to consume 20% of energy from MCT
89665025|NCT01379625|Experimental|Triheptanoin|Subject randomized to consume 20% of energy from triheptanoin.
89665026|NCT04908150|Experimental|Core Group|The Core Group carried out core stability exercises. Their training consisted of the following exercises: bridge, Klapp, front plank and lateral plank
89665027|NCT04908150|Active Comparator|Abdominal Group|The Abdominal Group performed traditional exercises: trunk flexion or abdominal crunch, trunk extensions, lower abdominals with hip lifts and crunch with crossed legs
89665028|NCT04907604|Other|First intervention group|Clusters 1 and 2 (group 1) will start the intervention at month 1, immediately after completing the baseline assessment. After 7 weeks of using the app and having access to the EMPOWER website (with material related to the anti-stigma campaign and recommendations for employees to deal with psychosocial risk factors), they will answer a post-treatment assessment protocol through the app.
89665029|NCT04907604|Other|Second intervention group|Clusters 3 and 4 (group 2) that serve as control group of cluster 1 and 2 (group 1), will also complete the assessment at T1. Clusters 3 and 4 (group 2) will start the intervention in step 2, after completing the second assessment.
89665030|NCT04907604|Other|Third intervention group|Clusters 5 and 6 (group 3), that serve as control group of group 1 and 2, will also complete the assessment at T2. Clusters 5 and 6 (group 3) will start the intervention in step 3. All clusters will answer a total of five assessments
89665031|NCT01380639|Experimental|Rehabilitation with vibration training|
89665032|NCT01380639|No Intervention|Rehabilitation without vibration training|
89665033|NCT04915716||healthy pregnant woman|healthy pregnant woman
89665034|NCT04915716||pregnant women with GDM|pregnant women with gestational diabetes mellitus
89665035|NCT04915638|Experimental|Intervention group|Schoolchildren received enriched cookies containing a multiple micronutrients formula. Enriched cookies (20g) with a daily dose of 0.33g of organic mix formula were given in the morning during 4-weeks. The formulation is an industrial secret of UNAM.
89665036|NCT01382901|Experimental|Intravenous (IV) Iron|
89665037|NCT01382901|Placebo Comparator|Placebo|
89665038|NCT04907760|Experimental|With a personalized care program|The strategy implemented is a personalized care pathway that includes participant follow-up by a nurse for 5 years with contact every 4 months for the first year, then every 6 months
89665039|NCT04907760|No Intervention|Without a personalized care program|The comparison strategy does not include any specific management. The patient will not receive individualized management with the nurse coordinator.
89665040|NCT03784209||lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
89665041|NCT03740841|Other|LUNII|The interactive story teller LUNII is delivered to the child the day before surgery, during the usual pre-operative medical visit.
89665042|NCT03740841|No Intervention|Without LUNII|Usual pre-operative visit.
89665043|NCT04907448|Experimental|IsoK-ST group|Participants in this group received the usual physical rehabilitation program in addition to an IsoK-ST program.
89665044|NCT04907448|Active Comparator|Control group|Participants in this group received the usual physical rehabilitation program only.
89665045|NCT04907838|Experimental|Type 2 diabetics|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
89665046|NCT04907838|Experimental|Healthy controls|BQ123 (25 nmol/min), BQ788 (25 nmol/min)
89665047|NCT04923204||Bipolar depression pharmacogenetics|Patients 18 years and older, with a diagnosis of bipolar disorder with an index episode of depression with or without associated psychotic symptoms (according to the Diagnostic Manual of Mental Disorder 4th Edition Text Revision, DSM-IV-TR), who attended the Bipolar Disorder Program of the Psychiatry Service of the Hospital Clínic de Barcelona (Spain).
89665048|NCT04923438|Experimental|telerehabilitation|The exercises will be applied twice a week for a total of 12 weeks, and each program will last roughly 30 minutes.
89665049|NCT04923438|Active Comparator|control|The same exercise program will be prepared and given as a printout and they will be asked to do their exercises at home. This group will also be included in the study as a control group.
89665050|NCT04915326||Retrospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The first step will be a retrospective and exploratory analysis of FFPE slides retrieved from the pathology archives testing a panel of molecular marker exploring the immune reaction to the cancer (i.e. antigen presenting cells and T lymphocytes activation).
89665051|NCT04915326||Prospective|T1 and T2 rectal carcinoma operated on will be included in the study group. The second step will be a prospective and validating analysis. Tissue samples will be obtained from normal rectal mucosa adjacent to the cancer at the time of the trans anal or trans abdominal resection. In patients with early rectal cancer, the combination of immunological markers on healthy rectal mucosa adjacent to the cancer obtained in the part 1a of the study will be validated to identify the patients that will have not any nodal metastasis.
89665052|NCT03056274|Active Comparator|Metformin arm|Metformin
89665053|NCT03056274|Active Comparator|Ursodeoxycholic acid|Ursodeoxycholic acid
89048610|NCT04643691|Experimental|losartan / spironolactone|Losartan 50 mg and Spironolactone 25 mg pillules oral use
89048611|NCT04643691|No Intervention|usual care|Usual care of COVID-19 infection in intensive care
89048612|NCT03456011|Other|BFA with Eufflexa injections|"BFA treatment before Sodium Hyaluronate injections.~Intervention: BFA"
89048613|NCT03456011|No Intervention|Anesthetic with Eufflexa injections|"Receiving Standard of care determined by their provider~No interventions"
89048614|NCT03455972|Experimental|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (on d0) and anti-BCMA CAR T cells as split-dose (40% on d1 and 60% on d2)
89048615|NCT03455933|Experimental|Shockwave Light Pain Group|Sham Comparator. It will received a light intensity shockwave in the lateral epicondyle regulated until reach a 3/10 in the Visual Analog Scale (VAS) scale.
89048616|NCT03455933|Experimental|Shockwave Moderate Pain Group|Experimental Intervention. It will received a moderate intensity shockwave in the lateral epicondyle regulated until reach a 6/10 in the Visual Analog Scale (VAS) scale.
89048617|NCT03455933|Other|Cold Pressure Group|Control Group. The cold pressure test will be apply to this group. The investigators will use a container with an outer part filled with ice and an inner part filled with water, both separated by a screen that prevents direct contact between the ice and the hand. The water will be regularly stirred to maintain the temperature near to 0.7ºC.
89048618|NCT04634994|Experimental|[F-18]SDM-8 tracer|Subjects will be administered standardized questionnaires for cognitive testing/other co-morbidities. They will undergo PET Scan and 3T Brain MRI. For PET Scan, an intra-arterial catheter will be inserted into the radial artery for [F-18]SDM-8 metabolite blood sampling by a trained anesthesiologist. Allen's test will be performed prior to insertion of the intra-arterial catheter. If arterial line can't be established to obtain metabolite samples, a venous line will be placed. In addition, an intravenous (IV) catheter will be inserted into the radial antecubital or other arm or hand vein for injection of tracer. Radiopharmaceutical will be injected as a bolus (approximately 5mCi for [F-18]SDM-8 followed by 5 mL of saline). The PET session will last up to 120 min. A head support apparatus will be used to minimize head motion. Brain PET data acquisition will begin at the moment of radiotracer injection. For MRI, several pulse sequences will be performed, no IV contrast will be used.
89048619|NCT04635033||Intervention|2 hours of reduced FiO2 (11-15%) in the inspired air, 2-3x/week, 3 months
89048620|NCT00549497|Other|GW870086X|
89048621|NCT00549536|No Intervention|2|
89048622|NCT00549536|Active Comparator|1|Patients on calcium supplementation
89048623|NCT04643613|Experimental|PCNF|Totally 42 cancer patients with poor nutritional status under nasogastric (NG) tube feeding was recruited and administered with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks (84 days).
89665054|NCT03056118|Experimental|6-month dual anti-platelet therapy|maintain dual anti-platelet agents for 6 months
89665055|NCT03056118|Active Comparator|12-month dual anti-platelet therapy|maintain dual anti-platelet agents for 12 months
89665056|NCT03056118|Active Comparator|Zotarolimus eluting stent arm|implant with zotarolimus eluting stent (Resolute Integrity)
89665057|NCT03056118|Active Comparator|Biolimus eluting stent arm|implant with biolimus eluting stent (Biomatrix)
89665058|NCT04922892|Experimental|Total Parathyroidectomy Alone|Total Parathyroidectomy Alone , without autotransplantation
89665059|NCT04922892|Active Comparator|Total Parathyroidectomy With Autotransplantation|Total Parathyroidectomy With Autotransplantation
89665060|NCT01330953|Placebo Comparator|Placebo|Single intravenous placebo dose.
89665061|NCT01330953|Experimental|30 mg LY2928057 (Cohort 1)|Day 1: single 30-milligram (mg) LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 30-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 30-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 30 mg LY2928057.
89665062|NCT01330953|Experimental|100 mg LY2928057 (Cohort 2)|Day 1: single 100-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 100-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 100-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 100 mg LY2928057.
89665063|NCT01330953|Experimental|300 mg LY2928057 (Cohort 3)|Day 1: single 300-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 300-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 300-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 300 mg LY2928057.
89665064|NCT01330953|Experimental|1000 mg LY2928057 (Cohort 4)|Day 1: single 1000-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 1000-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 1000-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 1000 mg LY2928057.
89665065|NCT04922970|Experimental|Strength training|"In this arm participants will go through the Strength training intervention."
89665066|NCT01332123|Experimental|Alignment perturbations|The following modifications will be applied to the prostheses: increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
89665067|NCT00987935|Experimental|Nintedanib (BIBF 1120)|Phase I dose escalation and phase II using dose determined in phase I
89665068|NCT00987935|Active Comparator|Sorafenib|Twice daily dosing in phase II
89665069|NCT04351503||SARSCoV-infected patients (cases)|
89665070|NCT04351503||non-SARS-CoV-2 infected patients (control)|non-SARS-CoV-2 infected patients with or without other respiratory viruses (control).
89665071|NCT01597050|Active Comparator|Drug: R932333|R333 6% (60 mg/g), bid
89665072|NCT01597050|Placebo Comparator|Placebo|Placebo, bid
89665073|NCT01383213|Experimental|CPAP (group A)|group A will be treated with CPAP using a helmet, initial PEEP of 10 cmH20 and an FiO2 set in order to maintain SpO2 ≥92%
89665074|NCT01383213|Active Comparator|oxygen therapy (group B)|group B (standard treatment) will be treated with oxygen therapy by Venturi mask with an FiO2 set in order to maintain SpO2 ≥92%.
89665075|NCT04922814|No Intervention|Control group(group A)|Only sedation for mechanically ventilated COVID patients
89665076|NCT04922814|Experimental|Muscle relaxant group(group B)|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
89665077|NCT00987623|Experimental|nelfilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
89665078|NCT00987623|Active Comparator|narafilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
89665079|NCT04914624|Placebo Comparator|Regular ACBT training|Including quitting smoking, ACBT training, cough practicing.
89665080|NCT04914624|Experimental|Positive expiratory pressure therapy|Use acpella®PEP therapeutic system and regular nursing care.
89665081|NCT04914624|Experimental|External diaphragm pacemaker|Patients are trained to use external diaphragm pacemaker and receive regular nursing care.
89665082|NCT00987467|Experimental|Cyclosporine 0.05% ophthalmic|cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control
89665083|NCT05874427|Experimental|Multimedia informed consent|Multimedia informed consent with videos to explain transforaminal epidural steroid injection
89665084|NCT05874427|Active Comparator|Standard informed consent|A standard consent form to describe the procedure previously used.
89665085|NCT05874388|Experimental|open-label, comparative study|"The study will involve two groups: a group of adolescents and adults symptomatic with FA with a confirmed molecular diagnosis, followed in the genetics department of the Necker Hospital, and a control group comprising subjects free of any motor or cognitive impairment, recruited from healthy relatives of patients (siblings, cousins, spouses).~The study will take place in a single session, during a health care consultation, during which the previously selected patients will take the tests included in the battery on a computer dedicated for the study. The total duration of the test is 45 minutes. No further visits will be necessary.~The validation of the results obtained will be determined by the correlation indices between the cognitive test scores used and the demographic variables and disease parameters considered, in particular the number of GAA triplet repeats in the allele of the FXN gene that contains the fewest repeats."
89048624|NCT00549575|Experimental|A|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories). Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
89214330|NCT04036760||Standard of Care transitional care coordination|
89214331|NCT04036760||Research transitional care coordination|
89665086|NCT05874349||Cohort 1: Crohn's disease|Patients with CD diagnosed according to the criteria of the ECCO guidelines. For the histological and lymphocyte subpopulation analysis of duodenal samples, all patients with CD who required an endoscopic examination during the disease have been prospectively included. All the recorded variables were registered at the moment of the endoscopy.
89665087|NCT05874349||Cohort 2: Control groups|Two groups are included: 1) Disease control: Patients with celiac disease diagnosed according to the Catassi and Fasano criteria and 2) Healthy control subjects. For the histological and lymphocyte subpopulation analysis of duodenal samples, patients with celiac disease were prospectively included to undergone gastroscopy, before starting gluten-free diet. Control subjects were patients referred for upper endoscopy due to digestive symptoms that have normal appearing mucosa both at endoscopic and histological assessment (Marsh 0, <25 intraepithelial lymphocytes). Serological markers of celiac disease were negative and they have no signs of inflammatory bowel diseases.
89665088|NCT05874336|Experimental|Single dose administration of Aramchol in Part 1 and Part 2|6 subjects received Aramchol in Part 1 and Part 2 of the study
89665089|NCT05874310|Experimental|Low dose FT-002|Intraocular injection of a single low dose of FT-002
89665090|NCT05874310|Experimental|Intermediate dose FT-002|Intraocular injection of a single Intermediate dose of FT-002
89048625|NCT00549575|Placebo Comparator|B|After double blind randomization, patients received a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
89048626|NCT00549614|Experimental|1|
89048627|NCT00549614|Placebo Comparator|2|
89048628|NCT00558987|Experimental|1|
88815721|NCT01089062|Other|Treatment C, then Treatment B, then Treatment A|"The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
89048629|NCT00558987|Sham Comparator|2|
89048630|NCT00560664|Experimental|1|Autologous chondrocytes transplantation
89665091|NCT05874310|Experimental|High dose FT-002|Intraocular injection of a single High dose of FT-002
89665092|NCT05874232|Experimental|Heartfulness Group|Participants were asked to practice relaxation tools for 15 minutes a day using the calendar and HeartBot app, and participate in once a weekly webinar for 30 minutes during the four weeks. The GAD, SWLS, and UCLA Loneliness scale was recorded prior to the start of the study, at the end of the program at Week 4, and after the duration of 4 weeks at Week 8. The score was reviewed to see the changes in anxiety, satisfaction with life, and loneliness scale.
89665093|NCT05874232|No Intervention|Control Group|The control group had no change in their daily routines.
89665094|NCT05874180|Experimental|Sequence A|Period 1: Linagliptin and Metformin / Period 2: DW6013
89665095|NCT05874180|Experimental|Sequence B|Period 1: DW6013 / Period 2: Linagliptin and Metformin
89665096|NCT05874167|Experimental|Sequence A|Period 1: Linagliptin and Metformin / Period 2: DW6013
89665097|NCT05874167|Experimental|Sequence B|Period 1: DW6013 / Period 2: Linagliptin and Metformin
89665098|NCT05874128|Experimental|Medical Device (Software)|ONLY FOR CLINICAL TRIALS
89665099|NCT05874102|Active Comparator|Sidelying, then Upright|Positioning in sidelying on radiology table for assessment, then will be positioned upright in tumbleform. Same bottle and liquid viscosities will be assessed in both positions.
89665100|NCT05874102|Active Comparator|Upright, then Sidelying|Positioned upright in tumbleform, then will be positioned sidelying on radiology table for assessment. Same bottle and liquid viscosities will be assessed in both positions.
89665101|NCT05874089|Active Comparator|VSL#3®|VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 28 days
89665102|NCT05874089|Placebo Comparator|Placebo|Placebo sachets, two sachets per day for 28 days
89665103|NCT05874076|Active Comparator|Covid-19 group|This group underwent physiotherapy consisting of mobilization, normal range of motion, and a respiratory exercise program.
89665104|NCT05874076|Experimental|Mutation group|This group underwent physiotherapy consisting of mobilization, normal range of motion, and a respiratory exercise program.
89665105|NCT05874024||Placement 6 hours|double balloon catheter placement for 6 hours
89665106|NCT05874024||Placement 12 hours|double balloon catheter placement for 12 hours
89665107|NCT05874011||Patients|Patients with right stroke consecutively recruited according to inclusion and non-inclusion criteria
89665108|NCT05874011||Healthy volunteers|Healthy volunteers with no known history of stroke
89665109|NCT05873998||Adults anesthetized patients undergoing mediastinoscopy|Determination of the lung's closing pressure by pressure-CO2 and volume-CO2 curves using a slow pressure-volume curve after anesthesia induction. Later on, a standard lung recruitment maneuver followed by a positive end-expiratory pressure trial was done to detect the lung's closing pressure.
89665110|NCT05873985|Experimental|Dynamic tape on experimental group|As a result of randomization, dynamic tape was applied to 25 people with a special technique.
89665111|NCT05873985|Placebo Comparator|Sham tape on placebo group|As a result of randomization, dynamic tape was applied to 26people with a sham technique.
89665112|NCT05873972|Active Comparator|ARM A|Chemotherapy regimens are determined based on the clinical experience of specialists
89665113|NCT05873972|Experimental|ARM B|Chemotherapy regimens are determined based on the multimodal deep learning signature
89665114|NCT05873907|Experimental|AMG 592: Dose 1|Administered as a single dose subcutaneous (SC) injection.
89665115|NCT05873907|Experimental|AMG 592: Dose 2|Administered as a single dose SC injection.
89665116|NCT05873907|Experimental|AMG 592: Dose 3|Administered as a single dose SC injection.
89665117|NCT05873907|Experimental|AMG 592: Dose 4|Administered as a single dose SC injection.
89665118|NCT05873907|Experimental|AMG 592: Dose 5|Administered as a single dose SC injection.
89665119|NCT05873907|Experimental|AMG 592: Dose 6|Administered as a single dose SC injection.
89665120|NCT05873907|Experimental|AMG 592: Dose 7|Administered as a single dose SC injection.
88815722|NCT01109108||Children <2 years of age|Children <2 years of age with and without respiratory tract infection
89048631|NCT00560664|Active Comparator|2|Mosaicoplasty
89048632|NCT00549692|Experimental|Omacor|
89048633|NCT00549692|Placebo Comparator|Placebo Omacor|
89665121|NCT05873907|Experimental|AMG 592: Dose 8|Administered as a single dose SC injection.
89048634|NCT00560742|Active Comparator|Control|
89048635|NCT00560742|Experimental|Intramuscular|
89048636|NCT00560742|Experimental|Intracoronary|
89048637|NCT00560781|Active Comparator|1|Pregnenolone
89048638|NCT00560781|Placebo Comparator|2|Placebo
89665122|NCT05873907|Placebo Comparator|Placebo|Administered as SC injection.
89665123|NCT05873803|Experimental|Experimental: GR1802|GR1802 injection 300mg every two weeks for 16-week treatment
89665124|NCT05873803|Placebo Comparator|Placebo Comparator: Placebo|Placebo every two weeks for 16-week treatment
89665125|NCT05873790||Serplulimab and chemotherapy|Participants receive 6 cycles of first-line Serplulimab plus chemotherapy, And MRD testing was performed before treatment, after 2 cycles of treatment, after 6 cycles of treatment, 6 months after the end of chemotherapy, and 1 year after the end of chemotherapy.
89665126|NCT05873764|Experimental|200 mg RV521/78 µCi [ 14C]-RV521|200 mg RV521/78 µCi [ 14C]-RV521
89665127|NCT05873738||Group 1|Relapse
89665128|NCT05873738||Group 2|Smoking cessation
89665129|NCT05873673|Active Comparator|coenzyme group|
89665130|NCT05873673|Placebo Comparator|control group|
89665131|NCT05873634||HFpEF|Participants with HFpEF
89665132|NCT05873634||Non-HFpEF|Participants without HFpEF
89665133|NCT05873621|Experimental|ICG-guided lymphadenectomy|Patients will intraoperatively receive a transanal local administration of ICG. During laparoscopic total mesorectal excision, ICG-fluorescent lymph nodes beyond the mesorectum will be separately excised and sent for pathology
89665134|NCT05873543|Experimental|smartphone-assisted hybrid cardiac rehabilitation (SHCR)|Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months.
89665135|NCT05873543|No Intervention|Usual care|Participants receive usual care including general education and exercise suggestion.
89665136|NCT05873530|Experimental|Time|Morning or evening
89665137|NCT05873530|Experimental|Treatment|Grape or Placebo
89665138|NCT05873517|Experimental|Immediate NET+|Receives NET+ immediately
89665139|NCT05873517|Active Comparator|Waitlist NET+|Receives NET+ after waitlist
89665140|NCT05873426|Experimental|[14C]ZSP1273|
89665141|NCT05873400||1|Myocardial Infarction patients who responded to aldosterone antagonist and didn't develope heart failure
89665142|NCT05873400||2|Myocardial Infarction patients who didn't respond to aldosterone antagonist and developed heart failure
89665143|NCT05873400||3|Control group who didn't receive aldosterone antagonist
89665144|NCT05873296|Experimental|Health Education|Group of women being treated for breast cancer
89665145|NCT05873296|No Intervention|usual care|Group of women who will remain in usual care
89665146|NCT05873270||control group|
89665147|NCT05873270||Intervention group|
89665148|NCT05873127|Experimental|web-based guided self-help CBT-E|After randomization, 8-10 patients were assigned to self-help CBT-E group each time.
89665149|NCT05873127|Experimental|online group CBT-E|After randomization, 8-10 patients were assigned to online CBT-E group each time.
89665150|NCT05873127|No Intervention|waiting group|After randomization, 8-10 patients were assigned to the waiting list each time, and they would be allocated to web-based guided self-help CBT-E or online group CBT-E randomly after a 12-week waiting period.
89665151|NCT05873114|Experimental|Muscle Energy Technique (MET)|
89665152|NCT05873114|Other|Mobilization|
89665153|NCT05873101|Other|Mobilization With Movement (MWM)|
89665154|NCT05873101|Experimental|Kelternborn Treatment Technique|
89665155|NCT05873088|Other|Isometric|
89665156|NCT05873088|Experimental|Isotonic Exercise|
89665157|NCT05873049|Experimental|Fluorescence-guided|"Patients who used MolecuLight to achieve high-quality de-colonization during reconstruction surgery with artificial dermis or split-thickness skin graft"
89665158|NCT05873049|No Intervention|Control|"Patients who did not use MolecuLight to achieve high-quality de-colonization during reconstruction surgery with artificial dermis or split-thickness skin graft"
89665159|NCT05873036|Other|Aerobic Training|
89665160|NCT05873036|Experimental|Progressive Resistance Training|
89665161|NCT05873023|Experimental|Intervention|"The intervention group chew one unscented gum provided by the study for 12 weeks. The participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side.~After chewing gum, they perform masticatory muscle stretching and tongue exercises. After they finish chewing the gum, he or she reports completion by posting a proof photo in the KakaoTalk chat room."
89665162|NCT05873023|No Intervention|Control|The control group does not participate in chewing gum.
89665163|NCT05873010|Experimental|Manual Compression and Stretching|
89665164|NCT05872997|Experimental|Mobilization With Movement|Mobilization With Movement
89665165|NCT05872984|Experimental|Intervention arm: adjustment of dry weight based on absolute blood volume measurement|Dry weight will be adjusted at the start of the intervention period in all subjects in the intervention group with a normalized blood volume below 65 ml/kg, regardless the occurrence of intradialytic hypotension associated adverse events during the baseline period. Dry weight will be adjusted once with 0,5kg.
89665166|NCT05872984|No Intervention|Control arm: standard care|standard care provided by the clinician, no intervention.
89665167|NCT05872971|Experimental|Dry Needling|The technique will be used by a physiotherapist experienced in orthopedic conditions and with specific training in DN.
89665168|NCT05872971|Active Comparator|Lasertherapy|The application of the Laser will be performed by a physiotherapist specialized in traumato-orthopedics.
89665169|NCT05872906|Experimental|Acupuncture|All subjects will receive acupuncture at LI11, ST36, SP10, SP9, SP6, ST34, BL39, KI10, LIV8, LI10, HT3, SI8, LI4, PC6, HT7, GB34, GB40, KI3, BL2, GB20, LIV3, BL62, KI6, BI57, ST40, KI7 and be recorded with simultaneous ultrasound imaging, external video, and required to fill out sensation sheets. Pulse diagnosis will be taken after de qi is achieved.
89665170|NCT05872880||TPExtreme induced chemotherapy was followed by modified radical surgery and radiotherapy|"The effect was evaluated at three weeks after 2 cycles of TPExtreme(albumin-paclitaxel+cisplatin+cetuximab) induction chemotherapy according to the RECIST 1.1 guideline, lesion reduction by at least 50% can be included in our study. Patients choose modified radical surgery based on the tumor invasion scope after induction chemotherapy.~In this group, the incisal margin was located 1~1.5cm outside the boundary of the residual tumor lesion after induced chemotherapy. At the same time, improved radical neck dissection was performed on both sides of the affected neck. Postoperative conventional radiotherapy(or chemoradiotherapy) was performed within 4 to 6 weeks after surgery."
89665171|NCT05872880||TPExtreme induced chemotherapy was followed by radical surgery and radiotherapy|"The effect was evaluated at three weeks after 2 cycles of TPExtreme(albumin-paclitaxel+cisplatin+cetuximab) induction chemotherapy according to the RECIST 1.1 guideline, lesion reduction by at least 50% can be included in our study. Patients choose radical surgery based on the tumor invasion scope before induction chemotherapy.~In this group, the incisal margin was located 1~1.5cm outside the boundary of the tumor lesion before induced chemotherapy. At the same time, radical neck dissection was performed on both sides of the affected neck. Postoperative conventional radiotherapy(or chemoradiotherapy) was performed within 4 to 6 weeks after surgery."
89665172|NCT05872841|Experimental|Recombinant human adenovirus type 5 combined with TACE|"Recombinant human adenovirus type 5: The recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment. The recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with saline before administration.~TACE: Chemotherapeutic drugs were specifically oxaliplatin 85 mg/m2, calcium folinic acid 400 mg/m2, 5-fluorouracil 1200 mg/m2, and then superfluid iodinated oil bolus was given according to the intraoperative imaging tumor blood supply."
89665173|NCT05872776|Active Comparator|RR2 wearable home-care: active device|Real stimulation with RR2 neuromodulation device
89048639|NCT00549731||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study."
89665174|NCT05872776|Sham Comparator|RR2 wearable home-care: sham control device|Mock sham stimulation with RR2 neuromodulation device
89665175|NCT05872750|Experimental|Active arm|The intervention group will receive repetitive transcranial magnetic stimulation at the left dorsolateral prefrontal cortex and pre-supplementary motor area
89665176|NCT05872750|Sham Comparator|Sham arm|the control group will receive sham stimulation
89665177|NCT05872724|Experimental|Arm A|Eligible subjects were assigned to high-risk or medium-risk groups based on Peter's criteria and Sedlis criteria. Patients with a high-risk classification or MRDc0 (+) status received a treatment consisting of conventional pelvic concurrent chemoradiotherapy, adjuvant chemotherapy, four courses of immunotherapy, continued immunotherapy with MRDIn(+), and follow-up monitoring with MRDIn(-)
89665178|NCT05872724|Experimental|Arm B|Patients deemed intermediate risk and with MRDc0 (-) status received concurrent chemoradiotherapy in the small pelvic target volume, four courses of immunotherapy, continued immunotherapy with MRDIn(+), and follow-up monitoring with MRDIn(-)
89665179|NCT05872711|Experimental|Low carbohydrate diet|The LCD will provide 50-80g of carbohydrate per day with no caloric restriction. The planned macronutrient compositions (percentages of the total calories) of the diet were: 15-20% carbohydrate (<80 g/day), 33% protein and 58% total fat.
89665180|NCT05872711|Active Comparator|Mediterranean diet|The MED group was prescribed a moderate-fat MED, rich in vegetables and low in red meat, with poultry and fish preferred to beef and lamb. The primary sources of added fat were 30 to 45 g of olive oil and a handful of nuts (five to seven nuts <20g) per day. The planned macronutrient compositions of the diet were 40-50% carbohydrate, 25% protein and 35% total fat. The diet is based on the recommendations of Willett and Skerrett
89665181|NCT05872698|Active Comparator|Carvedilol|Oral Carvedilol 6.25 mg to 12.5 mg OD/ or 6.25mg BD (maximum dose 12.5mg)
89665182|NCT05872698|Placebo Comparator|Placebo|Oral tablet (1 or 2 tablets)
88815723|NCT01109108||Children 2<5 years of age|Children 2<5 years of age with and without respiratory tract infection
88815724|NCT02412618|Active Comparator|Mifepristone|Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once
89048640|NCT00549731||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
89048641|NCT00559026|Active Comparator|1|
89048642|NCT00559026|Experimental|2|
89048643|NCT00549809|Active Comparator|IMV, SIMV|
89048644|NCT00559065||Benzene Cohort|Benzene exposed and unexposed workers.
89048645|NCT00549887||Rapid acting to short acting|Patients on rapid-acting analog insulins who switch to short-acting human insulin
89048646|NCT00549887||Short acting to rapid acting|Patients on short-acting human insulins who switch to rapid-acting analog insulin
89048647|NCT00549926|Active Comparator|1|
89048648|NCT00549926|Active Comparator|2|
89048649|NCT00549926|Active Comparator|3|
89048650|NCT00549926|Active Comparator|4|
89048651|NCT04634448|Other|Interval appendectomy|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
89048652|NCT04634448|Other|Follow-up MRI|For all patients presenting with a periappendicular abscess, an interval appendectomy is planned at 2 to 3 months after initial conservative treatment, which is considered mandatory for all patients over 35 years of age. If a patient is under 35 and asymptomatic and does not want to undergo surgery, a follow-up MRI at 1 year will be performed.
89048653|NCT00550004|Active Comparator|Arm 1|RP101 and Gemcitabine
89048654|NCT00550004|Placebo Comparator|Arm 2|Placebo and Gemcitabine
89048655|NCT04634721|Active Comparator|Laparoscopic TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
89048656|NCT04634721|Active Comparator|Ultrasaund TAP block|injecting bupivacaine in transversus abdominis plane to block the somatic nerves
89048657|NCT04634721|No Intervention|no TAP block|no TAP block would be done
89048658|NCT04643262||Intraoperative morbidity and mortality|Intraoperative complications (i.e. splenectomy, bleeding, positive leak test if performed) and type treatment are collected and recorded.
89048659|NCT04643262||peri-operative morbidity and mortality (<30 days)|Perioperative complications (<30 days) considered are mortality, morbidity (i.e. leak, bleeding, occlusion, pneumonia, vascular complications, portal pulmonary-splenic embolism) and type treatment.
89048660|NCT04643262||Post-operative morbidity and mortality (>30 days)|Postoperative complications (>30 days) considered are morbidity, mortality (i.e. leak, embolism, Incisional trocar hernia, other) and type treatment
89048661|NCT04634565|Experimental|PF-06651600|PF-06651600 200 milligrams(mg) once daily for 10 days
89048662|NCT00550121|Experimental|1|
89048663|NCT00550121|Placebo Comparator|2|
89048664|NCT04643028|Other|Home exercise|The exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
89048665|NCT04643028|Other|Mulligan mobilization|Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions. Sixty seconds of rest will be given between sets.
89048666|NCT04643028|Other|Cervical stabilization|In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
89048667|NCT00550160|Active Comparator|1|The Home Management of Malaria (HMM) is a strategy aimed at improving access to prompt and effective antimalarial treatment of all fevers in children under 5 years. Community Drug Distributors (CDD) have been trained and equipped for this task.
89048668|NCT00550160|Experimental|2|An Intermittent Preventive Treatment (IPTc) schedule for asymptomatic pre-school children during high malaria transmission seasons alongside an ongoing Home Management of Malaria programme
89048669|NCT00550199|Experimental|LBH589 and Gemcitabine|Phase I dose escalation study
89048670|NCT04643301|Experimental|Adding Liraglutide to current treatment program|Adding 3,0mg of Liraglutide to the current treatment program of low-responders 3 months after bariatric surgery.
89048671|NCT00550355|Experimental|1|
89048672|NCT00550355|Experimental|2|
89048673|NCT00550355|Experimental|3|
89048674|NCT00550355|Placebo Comparator|4|
89048675|NCT04634292||Children with cerebral palsy 7-9 years|21 children
89048676|NCT04634292||Children with cerebral palsy 10-12 years|21 children
89665183|NCT05872672|Active Comparator|Sleep Program|
89665184|NCT05872672|Other|Waitlist|
89214332|NCT04036916|Experimental|Virtual Reality Training (Experimental)|Participants will receive multi-modal sensorimotor training interventions, including activities training the vestibular system, oculomotor control and visual perception, neuromotor control and strengthening of the cervical spine, postural control/ balance exercises, and exercises integrating the use of multiple types of sensory information for controlled motor output, including speed and accuracy. Novel headset virtual reality (VR) games/activities; compliant balance surfaces; resistance bands/weight; and biofeedback devices will be utilized to deliver the training intervention. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 12 sessions over 6 weeks.
89665185|NCT05872659|Placebo Comparator|Control group|Participants will receive continuous antiviral therapy and saline placebo (iv, 100 mL) treatment on Day 0，Day30，Day60 and followed up for 48 weeks.
89665186|NCT05872659|Experimental|Treatment group|Participants will receive continuous antiviral therapy and Mesenchymal stem cells (1*10^6/kg subject weight, iv, 100 mL) treatment on Day 0，Day30，Day60 and followed up for 48 weeks.
89665187|NCT05872646|Experimental|patient group|parkınson patient group
89665188|NCT05872646|Other|healthy group|age-gender matched healthy group
89214333|NCT04036916|No Intervention|No Virtual Reality Training (Control)|True control.
89214334|NCT00891800|Experimental|1|All patients will be treated with SIR-Sphere therapy.
89665189|NCT05872633|Experimental|Online self-management intervention (and care-as-usual)|At the start of the treatment, a face-to-face introductory meeting takes place between the participant and a psychologist, for acquaintance and to formulate goals for the treatment. Subsequently, a tailored self-management intervention, based on cognitive-behavioral therapeutic methods will be offered via an online program. Treatment will be conducted by a therapist who is specifically trained in the tailored cognitive-behavioral protocol. After finishing the online program, patients will be approached by their treating psychologist for two booster sessions via telephone. In these booster sessions it will be evaluated how the patient further attained his/her pre-set goals for the intervention. Strategies to strengthen the achieved results will be discussed. The booster sessions will take place 1 month and 2,5 months after finishing the online program.
89665190|NCT05872633|Other|Care-as-usual|Care-as-usual encompasses a consultation with the rheumatologist and a 1,5-hour consultation with a clinical nurse or occupational therapist of the Leiden University Medical Center. During this consultation, patients receive information on the nature of osteoarthritis, the prognosis, and available treatment modalities, and education on chronic pain, joint protection, healthy life style, and assistive devices.
89665191|NCT05872594||study group|"all participants older than 18 years who agreed to participate (i.e., who clicked on the button agree after reading informed consent form) with no regard to sex, race, education, family status"
89214335|NCT00886964|Active Comparator|1|HBV ID
89214336|NCT00886964|Active Comparator|2|HBV IM
89665192|NCT05872568|Experimental|Imitation EC-MPS(Ruiyirong)|
89665193|NCT05872568|Active Comparator|Original EC-MPS（myfortic）|
89665194|NCT05872529|No Intervention|BEFORE|The incidence of the POD and PND will determine before the education which consists processed EEG monitoring and SBI approach
89665195|NCT05872529|Active Comparator|AFTER|The incidence of the POD and PND will determine after the education which consists processed EEG monitoring and SBI approach
89665196|NCT05872516|Experimental|Software diagnosis|Software diagnosis with gold standard of 3 doctors' consensus.
89665197|NCT05872464|Experimental|Artificial saliva containing cumin and ginger extract|Artificial saliva containing cumin and ginger extract in spray bottle
89665198|NCT05872464|Placebo Comparator|Placebo|Placebo containing composition close to the test group without cumin and ginger extract in spray bottle
89665199|NCT05872373|Experimental|Intervention Group|Cases are the community people in the study area where interventions will be provided to measure the outcome of the study.
89665200|NCT05872334|Experimental|Monofix|In patients who underwent laparoscopic colorectal cancer surgery, the fascial closure of the midline incision was performed using a running suture type with Monofix, one of the barbed sutures.
89665201|NCT05872334|No Intervention|Control group|In patients who underwent laparoscopic colorectal cancer surgery, the fascial closure of the midline incision was performed using an interrupted suture type with PDS-II, one of the monofilament sutures.
89665202|NCT05872217|Placebo Comparator|control group|"• This group will receive conventional UE therapeutic program for 60 minutes each session including:~Exercises based on neurodevelopment technique .~Gentle manual stretching~Weight-bearing exercises for 10minutes for UE from prone lying, side sitting and quadriped position .~Strengthening exercises for 10 minutes for muscles of UE as push-up from prone lying position, quadriped position, 3 point exercise, walk on hand, climbing, hanging on a bar, squeeze stress balls, cutting usescissors to strengthen hand .~Goal directed training for 10 minutes the child will practice specific tasks that are needed for everyday life and which they find a challenge like (3 daily tasks as cleaning mirror, dressing and undressing, using pen and ruler to draw shapes, brushing teeth .~Fine motor activities as reach, grasp, carry and release activities."
89665203|NCT05872217|Experimental|study group|Children in this group will receive the same conventional UE therapeutic program as control group for 60 minutes in addition to virtual reality session using VRapeutic software gaming technology, Archeeko module (figure 3) for 30 min/3 sessions/week for 8 weeks
89214337|NCT00887042|Experimental|Fludarabine|
89214338|NCT00892112|Active Comparator|intravenous immunoglobulins|IV, 40 ml/kg over 4 days
89214339|NCT00892112|Placebo Comparator|plasma volume expander Albuman|IV, 40 ml/kg over 4 days
89665204|NCT05872178|Placebo Comparator|Omegia® Softgel -A|Take Omegia® Softgel -A once a day for 12 weeks
89665205|NCT05872178|Experimental|Omegia® Softgel -B|Take Omegia® Softgel-B once a day for 12 weeks
89665206|NCT05872165|Experimental|Experimental group|this group of 20 subjects will receive the ozonated media phonophoresis plus conventional physical therapy program 3 times weekly for 4 weeks.
89665207|NCT05872165|Other|Control group|this group of 20 subjects will receive only conventional physical therapy program 3 times weekly for 4 weeks.
89665208|NCT05872152|No Intervention|Standard care|Standard care are defined by routine procedures implemented in each center to prevent and control the diffusion of MDR-E bacteria in ICUs. In the first period of the study, the frequency of cross transmission will be assessed by sequencing the first ESBL-E isolate in each carrier patients (first isolate of a given species)
89665209|NCT05872152|Experimental|Transmission of FTIR results|In second phase of the study, the result of FTIR typing of recovered ESBL-E isolates will be weekly transmitted to participating centers.
89665210|NCT05872139|Placebo Comparator|Placebo|Gelatin capsules
89665211|NCT05872139|Experimental|MitoQ|Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 80 mg were taken once.
89665212|NCT05872126|Other|VATS surgical pleurodesis|Patients in whom we use VATS-surgical pleurodesis for malignant pleural effusion.
89665213|NCT05872126|Other|Tube drainage|Patients in whom we use tube drainage for malignant pleural effusion.
89665214|NCT05872113|Placebo Comparator|Placebo|The subjects who were on a placebo were put on the cream two times per day for 4 weeks. The questionnaire for testing the effects progressed when before using the cream, after 2 weeks, and after 4 weeks.
89665215|NCT05872113|Experimental|Experiment|The subjects who were on experimental were put on the cream two times per day for 4 weeks. The questionnaire for testing the effects progressed when before using the cream, after 2 weeks, and after 4 weeks.
89665216|NCT05872087|Active Comparator|Dexmedetomidine|will receive nebulized Dexmedetomidine 3 µg/kg
89665217|NCT05872087|Active Comparator|Midazolam|will receive nebulized Midazolam 0.3 mg/kg
89665218|NCT05872074|No Intervention|Conventional balloon|patients Who will undergo conventional provisional stenting using standard technique with plain balloon angioplasty wire both branches, MV and SB, with two coronary guide wires. Main branch pre-dilation Side branch pre-dilation using ordinary balloon for the side branch) Main vessel stenting Proximal optimization technique (POT) of the main vessel stent
89665219|NCT05872074|Experimental|Drug coated balloon|"patients Who will undergo provisional stenting using Drug coated balloon (paclitaxel-coated balloon (PCB)) wire both branches, main vessel and side branch, with two coronary guide wires.~Main branch pre-dilation Side branch pre-dilation using Drug coated balloon (paclitaxel-coated balloon for the side branch Main vessel stenting Proximal optimization technique (POT) of the main vessel stent"
89665220|NCT05872048|Experimental|periodontal distractor with interseptal bone cuts|
89665221|NCT05872048|Experimental|periodontal distractor without interseptal bone cuts|
89665222|NCT05871619|Experimental|Remin Pro with laser application|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye (0.05ml) to 1 mg of the assigned remineralizing agents. The diode laser was irradiated immediately with Average power of 1 W, Exposure time of 10 s, diode 810 nm, continuous and non-contact mode, and Irradiation speed of 1mm/ sec.
89665223|NCT05871619|Experimental|Remin pro without laser application|Used a pea-sized amount with a brush and allowed it to remain on the teeth for at least three minutes as it was recommended by the manufacturer. Instructed the patient to avoid rinsing, eating, and drinking for 30 minutes
89665224|NCT05871619|Experimental|Xpur remin with laser application|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye (0.05ml) to 1 mg of the assigned remineralizing agents. The diode laser was irradiated immediately with Average power of 1 W, Exposure time of 10 s, diode 810 nm, continuous and non-contact mode, and Irradiation speed of 1mm/ sec.
89665225|NCT05871619|Experimental|Xpur remin without laser application|used a thin film of toothpaste on a micro brush and then applied it on the tooth surface for three minutes 2- Do not eat, drink or rinse for 30 minutes
89665226|NCT05871619|Experimental|fluoride varinsh with laser application|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye (0.05ml) to 1 mg of the assigned remineralizing agents. The diode laser was irradiated immediately with Average power of 1 W, Exposure time of 10 s, diode 810 nm, continuous and non-contact mode, and Irradiation speed of 1mm/ sec.
89665227|NCT05871619|Experimental|fluoride varnish without laser application|Used brush applicator to uniformly apply fluoride Varnish, covering the surface to be treated as a thin film.Instructed patient to avoid hard food, alcohol, brushing or flossing for the next 4
89665228|NCT05871567||group 1 or MSS|colorectal cancers (CRCs) with stable microsatellite
89665229|NCT05871567||group 2 or MSI|colorectal cancers (CRCs) with unstable microsatellite
89665230|NCT05869513|Placebo Comparator|Vegetable oil + Resistance exercise|4g/day vegetable oil and home based resistance exercise for 16 weeks
89665231|NCT05869513|Active Comparator|Krill oil + Resistance exercise|4g/day krill oil and home based resistance exercise for 16 weeks
89665232|NCT05869357|Experimental|cream containing 2.5% sericin and 2%turmeric|cream containing 2.5% sericin and 2%turmeric
88815725|NCT02412618|Placebo Comparator|Placebo|Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once
89048677|NCT04634292||Healthy children 7-9 years|21 children
89048678|NCT04634292||Healthy children 10-12 years|21 children
89048679|NCT00559143|Active Comparator|1|DDD(R)-RV pacing
89048680|NCT00559143|Experimental|2|DDD(R)- BIV pacing
89048681|NCT00550472|Experimental|Probiotic|intervention
89048682|NCT04634370|Experimental|Intervention|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
89048683|NCT00550511|Other|Ultrasound|Surgeon-performed ultrasound as intervention, as a complement to clinical investigation and standardized laboratory testing.
89048684|NCT00550511|No Intervention|Control|Control group examined with clinical examination including standardized laboratory tests.
89048685|NCT04642989|Sham Comparator|Healthy Control + Sham Treatment|Healthy participants who received the sham treatment
89048686|NCT04642989|Active Comparator|Healthy Control + Facial Effleurage|Healthy participants who received the Facial Effleurage treatment
89048687|NCT04642989|Active Comparator|Acute Rhinosinusitis + Antibiotics|Sick participants who received the recommended antibiotics
89048688|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment|Sick participants who received the sham treatment
89048689|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage|Sick participants who received the Facial Effleurage treatment
89665233|NCT05869357|Experimental|cream containing 5%sericin and 2%turmeric|cream containing 5% sericin and 2%turmeric
89665234|NCT05869357|Experimental|cream containing 10%sericin and 2%turmeric|cream containing 10% sericin and 2%turmeric
89214340|NCT00887120|Active Comparator|1|Lopinavir/ritonavir standard dose + zidovudine and lamivudine
89214341|NCT00887120|Active Comparator|2|Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine
89665235|NCT05869357|Experimental|cream base|cream base without sericin and tumeric
89665236|NCT05869305|Experimental|whey protein isolate group|Whey protein isolate is contained in the sachet.
89665237|NCT05869305|Experimental|isolated soy protein group|Isolated soy protein, pea protein isolate, and brown rice protein are contained in the sachet.
89665238|NCT05869305|Experimental|placebo group|Base powder without proteins is contained in the sachet
89665239|NCT05869188|Active Comparator|Pateints with Moderate Acne|20 patients affected by Acne and More than half of the face is involved. Many papules and pustules, many open or closed comedones. One nodule may be present.
89665240|NCT05869188|Active Comparator|Pateints with Severe Acne|20 patients affected by Acne and Entire face is involved, covered with many papules and pustules, open or closed comedones and rare nodules
89665241|NCT05869188|Active Comparator|control|20 Health participants
89665242|NCT05868239|Experimental|Aerosol Box|The team will complete the resuscitation scenario with an Aerosol box placed.
89665243|NCT05868239|No Intervention|No Aerosol Box|The team will complete the resuscitation scenario without an Aerosol box placed.
89665244|NCT05868174|Experimental|89Zr-TLX250, 177Lu-TLX250 and Peposertib|"Diagnostic test: A single IV administration of 37 Megabecquerel (+/- 10%) 89Zr-DFO-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan~Treatment test: A single IV administration that could be 1887 - 2516 or 3145 Megabecquerel (+/- 10%) 177Lu-DOTA-girentuximab,containing a mass dose of 10 mg of girentuximab, on Day 1 of each 84-day cycle and p.o. administration of that could be 100-150 or 200 mg Peposertib BID on days 4-21 of each 84-day cycle."
89665245|NCT05862389||Anorexia nervosa|Patients with anorexia nervosa.
89665246|NCT05862389||Bulimia nervosa|Patients with bulimia nervosa.
89665247|NCT05862389||Healthy control|The healthy control group
89665248|NCT05850767|Experimental|Sleep deprivation|Participants will stay fully awake for 24 hours.
89665249|NCT05850767|No Intervention|Normal sleep|Participant will sleep a normal night sleep.
89665250|NCT05849740|Experimental|Treatment arm|Daratumumab and corticosteroid treatment
89665251|NCT05842551|Experimental|Experimental|Patients will receive anodic tEs combined with prismatic lenses for two weeks
89048690|NCT04642989|Sham Comparator|Acute Rhinosinusitis + Sham Treatment + Antibiotics|Sick participants who received the recommended antibiotics and the sham treatment
89048691|NCT04642989|Experimental|Acute Rhinosinusitis + Facial Effleurage + Antibiotics|Sick participants who received the recommended antibiotics and the Facial Effleurage treatment
89048692|NCT04634058|Experimental|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 antibody combined with CTLA-4 antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
89048693|NCT00550628||resection of a non-sarcomatous primary colon neoplasm|The surgically removed colon will undergo ex-vivo imaging after examination in pathology. A PET scanner will be used to acquire a scan of the whole specimen.
89048694|NCT04634214||COVID 19 positive patients without diabetes|COVID 19 positive patients without diabetes
89048695|NCT04634214||COVID 19 positive patients with diabetes|COVID 19 positive patients with diabetes
89048696|NCT00560820|Experimental|Deferasirox|30 mg/kg/day
89048697|NCT00550706||1Pediatric Dept A|Children's files from this department will be analysed once weekly and medication prescription data will be registered
89048698|NCT00550706||2 Pediatric Dept B|Children's files from this department will be analysed once weekly and medication prescription data will be registered
89048699|NCT04633941||Post Bariatric Surgery|Post Bariatric Surgery more than 6 month. Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
89048700|NCT04633941||Medical Weight Management|Obesity (BMI 30 kg/m2 and above), English literate and having mental capacity to make their own decisions. Patients were excluded if they had undergone bariatric surgery ≤ 6 months ago, have active eating disorders, are pregnant or had given birth ≤ 6 months ago. Patients who were admitted to hospital or tested positive for COVID-19 were excluded too. Patients who had symptoms of active severe psychological and psychiatric conditions like psychosis, self-harm, suicide, hallucinations were also excluded
89048701|NCT00550823|Experimental|A,1|
89048702|NCT04633785||wrist BP|
89048703|NCT04633746||sepsis with AKI|Patients admitted with the diagnosis of sepsis associated with elevation of renal function tests
89048704|NCT04633746||Sepsis without AKI|Patients admitted with the diagnosis of sepsis with no elevation of renal function tests
89214342|NCT00892190|Experimental|dasatinib (SPRYCEL) and all trans retinoic acid (VESANOID)|"Dasatinib DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours~ATRA 22.5mg/m2 every 12 hours"
89665252|NCT05842551|Sham Comparator|Control|Patients will receive sham tEs combined with prismatic lenses for two weeks
89665253|NCT05828927|Other|Caregiver of subject with cancer|Adults who identify as a primary unpaid caregiver for a rural-dwelling adult with cancer.
89665254|NCT05828927|No Intervention|Subject with Cancer|Subjects is with cancer and receive care from caregivers.
89665255|NCT05827328||Patients eligible for lung surgery or mediastinal surgery|Patients with or without SARS-CoV-2 infection eligible for lung surgery or mediastinal surgery
89665256|NCT05817448||control group|40 pregnant women with normal placentation having no pregnancy related disorders according to the physical examination and laboratory findings.
89665257|NCT05817448||placenta previa group|"40 pregnant women that will be diagnosed according to the ultrasound diagnostic criteria.~Then according to the histopathological examination, placenta previa group will be subdivided into 2 groups, placenta previa with MAP and placenta previa without MAP"
89665258|NCT05809388|Experimental|Experimental Group (EG)|The EG will perform a standard Parent Training program. This PT will be supplemented with virtual reality sessions. Each pair of parents will perform a total of 12 treatment sessions fortnightly.
89214343|NCT00887276|Active Comparator|Moxifloxacin|
89214344|NCT00887276|Active Comparator|Ampicillin; Amoxicillin|
89665259|NCT05809388|Active Comparator|Control Group (CG)|The CG will perform a standard Parent Training program plus two follow up sessions. Each pair of parents will perform a total of 12 treatment sessions fortnightly.
89665260|NCT05797467|Experimental|Combining targeted therapy group|Adjuvant chemotherapy with targeted therapy
89665261|NCT05797467|Sham Comparator|Single adjuvant chemotherapy group|Adjuvant chemotherapy alone
89665262|NCT05796973|Experimental|Guided physical exercise arm|20 patients from each type of cancer (altogether 80) are randomized to a 3 months guided physical exercise arm. At the beginning of the intervention the patients' physical condition and body composition are measured. After that an exercise program begins. All subjects participate in physical exercise program twice a week for three months. At the end of the intervention, the physical condition and body composition are measured again. During the follow-up after the intervention the patients are advised to exercise regularly. Physical condition and body composition are measured again after 6 months. Exercise activity is asked during each follow-up visit.
89665263|NCT05796973|Experimental|Atorvastatin arm|20 patients from each type of cancer (altogether 80) are randomized to a 3 months guided physical exercise + atorvastatin (40 mg QD) arm. At the beginning of the intervention the patients' physical condition and body composition are measured. After that an exercise program begins. All subjects participate in physical exercise program twice a week for three months. At the end of the intervention, the physical condition and body composition are measured again. During the follow-up after the intervention the patients are advised to exercise regularly. Physical condition and body composition are measured again after 6 months. Exercise activity is asked during each follow-up visit.
89665264|NCT05796973|Active Comparator|Non-guided physical exercise arm|20 patients from each type of cancer (altogether 80) are randomized to a non-guided physical exercise arm. The patients' physical condition and body composition are measured at baseline. The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own. The physical condition and body composition of this group is also measured at three months and six months after baseline to detect changes. After that the patients are given advise to exercise regularly and this is asked during each follow-up visit.
89665265|NCT05748847|Active Comparator|Pocket ICRS|Patients in this group are planned to undergo KeraRing implantation through a femtosecond laser-assisted corneal pocket creation for the management of their central keratoconus.
89665266|NCT05748847|Active Comparator|Tunnel ICRS|Patients in this group are planned to undergo KeraRing implantation through a femtosecond laser-assisted corneal tunnel creation for the management of their central keratoconus.
89665267|NCT05733741|Experimental|Preservative-free topical anesthetics group|Patients in this group had the standard post-PRK treatment regimen in addition to the prescription of preservative-free topical anesthetics for pain control following single-step transepithelial PRK surgery in one eye.
89665268|NCT05733741|Placebo Comparator|Preservative-free artificial tears group|Patients in this group had the standard post-PRK treatment regimen in addition to the prescription of preservative-free artificial tears as a placebo following single-step transepithelial PRK surgery in the other eye.
89665269|NCT05723237|Experimental|Experiment|The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
89665270|NCT05723237|No Intervention|Control Group|No application will be made to the control group (n=60).
89665271|NCT05708976|Experimental|Active Whole-body Hyperthermia (Active Treatment)|Participants receive 8 cognitive behavioral therapy (CBT) sessions and 4 bi-weekly whole-body hyperthermia (WBH) sessions that raise core body temperature to 38.5 C. Each active WBH session (including preparation and post-session activities) is up to approximately 3.5 hours, and each CBT session is approximately 50 minutes.
89665272|NCT05708976|Placebo Comparator|Sham Whole-body Hyperthermia (Sham Treatment)|Participants receive 8 cognitive behavioral therapy (CBT) sessions and 4 bi-weekly sham whole-body hyperthermia (WBH) sessions, which minimally raise body temperature. Each sham WBH session (including preparation and post-session activities) is up to approximately 3.5 hours, and each CBT session is approximately 50 minutes.
89665273|NCT05689463|Experimental|Patient with prurit|
89665274|NCT05673577|Experimental|Camrelizumab+cetuximab+chemotherapy|"Camrelizumab: 200mg vgtt q3w, 3 weeks as a cycle; Cetuximab first dose 400mg/m2, vgtt, following by 250 mg/m2 after first dose, qw, 3 weeks as a cycle; albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles; cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles;~Then, in maintenance therapy, Camrelizumab: 200mg vgtt q2w; Cetuximab 500mg/m2, vgtt q2w until intolerable toxicity or disease progression"
89665275|NCT05669573|Experimental|Early feeding group|Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories. Observe closely until 24h, and then continue to fasting until the next ESWL/ERCP or change the diet to the general diet according to the actual clinical needs.
89665276|NCT05669573|Active Comparator|Standard fasting group|Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period. After 24 hours, according to the actual clinical needs, continue to fast until the next ESWL/ERCP operation, or change the diet to a general diet.
89048705|NCT04633629||Patients with acute heart failure|Patients hospitalized for acute heart failure in medical department.
89048706|NCT00550979||1|Black women with history of pregnancy/ies complicated by gestational diabetes mellitus
89048707|NCT00550979||2|Black women with history of normal, uncomplicated pregnancy/ies
89048708|NCT00550979||3|White women with a history of pregnancy/ies complicated by gestational diabetes.
89665277|NCT05667857|No Intervention|Non-intervention group|These participants will a undergo a neurocognitive and psychosocial assessment at baseline, and in follow-up after 6 months and 1 year thereafter. The aim of this group is to measure the extent of psychosocial and cognitive difficulties and health-related quality of life.
89665278|NCT05667857|Experimental|Integrative neurocognitive remediation therapy|The experimental group will undergo profound neuropsychological and psychological assessment before starting the integrative neurocognitive remediation therapy, in addition to the assessment already done at baseline. This group will repeat the testing after completion of the integrative neurocognitive remediation therapy, and 6 months thereafter.
89665279|NCT05665998|Experimental|ARC-BSI Cervical Rehabilitation|Implantation of a neuroprosthetics system composed of an electrocorticography acquisition system (WIMAGINE) and a cervical epidural electrical spinal cord stimulation system (ARC-IM) to restore voluntary arm movements in participants with SCI.
89665280|NCT05628961|Experimental|Cohort 1: 100 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
89665281|NCT05628961|Experimental|Cohort 2: 200 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
89665282|NCT05628961|Experimental|Cohort 3: 500 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
89665283|NCT05628961|Experimental|Cohort 4: 1200 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
89665284|NCT05628961|Experimental|Cohort 5: 2500 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
89665285|NCT05628961|Experimental|Cohort 6: 5000 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
89665286|NCT05628961|Experimental|Cohort 7: 7500 mg|Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.
89665287|NCT05620160|Experimental|RAY1216|Participants received 400mg RAY1216 tablet orally three times daily for 5 days.
89665288|NCT05620160|Placebo Comparator|Placebo|Participants received 400mg placebo orally three times daily for 5 days.
89665289|NCT05588180|Active Comparator|Group (P)|Group (P) PPV guided group
89665290|NCT05588180|Active Comparator|Group (F)|Group (F) FVD/FAD ratio guided
89665291|NCT05576103||Primary brain tumour patients receiving RT|Primary brain tumor patients are screened at time of consultation for this observational study, and the study population is diverse across sex/gender, and racial/ethnic groups.
89665292|NCT05566678|Active Comparator|Cigarette|Smokers who self-selected to continue smoking cigarettes.
89665293|NCT05566678|Active Comparator|Tobacco Heating System|Smokers who self-selected to switch to THS use.
89665294|NCT05566678|Active Comparator|Smoking Abstinence|Smokers who self-selected to abstain from smoking.
89665295|NCT05555979||Chronic Lymphocytic Leukemia (CLL) Participants|Participants treated with venetoclax+rituximab or bruton's tyrosine kinase inhibitors in accordance with approved local label.
89665296|NCT05533164|Experimental|Rituximab|1000mg rituximab intravenously once
89665297|NCT05533164|Placebo Comparator|Placebo|0mg rituximab (placebo) intravenously once
89665298|NCT05533125|Experimental|Rituximab|1000mg rituximab intravenously once
89665299|NCT05533125|Placebo Comparator|Placebo|0mg rituximab (placebo) intravenously once
89665300|NCT05502692||Cohort 1|ADVANCE patient cohort, who have been on the TLD state programme for more than one year
89665301|NCT05502692||Cohort 2|Existing cohorts of patients initiating TLE (and subsequently switched to TEE) more than 9 years ago and who have since transitioned to TLD within the state programme for more than one year.
89665302|NCT05479656|Experimental|Training program|8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
89665303|NCT05464550|Experimental|Eye tracking|Utilisation of a eye tracker on a screen.
89665304|NCT05460364|Experimental|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 1: A-B-C"
89665305|NCT05460364|Experimental|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 2: A-C-B"
89665306|NCT05460364|Experimental|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 3: B-A-C"
89665307|NCT05460364|Experimental|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 4: B-C-A"
89665308|NCT05460364|Experimental|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 5: C-A-B"
89665309|NCT05460364|Experimental|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 6: C-B-A"
89665310|NCT05430022|Experimental|Autism-adapted Group Cognitive Behavioral Therapy|Autistic adolescents (11-17 years old; middle and high school) with depression will participate in a 12-week group intervention, autism-adapted Cognitive Behavioral Therapy, to increase perception and understanding of self and to decrease the severity of depressive symptoms.
89665311|NCT05428176|Experimental|Arm I (high intensity e-Health program)|Patients and parents receive the high intensity eHealth intervention through the interactive website and via videoconferencing for 30-50 minutes once every 3 to 4 weeks for up to 5 sessions over 6 months. Patients and parents also receive usual care. After 6 months, parents attend booster sessions at months 7, 9, and 11.
89665312|NCT05428176|Active Comparator|Arm II (usual care)|Patients and parents receive usual care.
89665313|NCT05407584|Experimental|Cohort 1(1-3 prior line of chemotherapy)|Oregovomab and PLD is synergistic in PARPi-resistant recurrent ovarian cancer.
89665314|NCT05407584|Experimental|Cohort2 (>3prior line of chemotherapy)|Oregovomab and Paclitaxel show synergistic in PARPi-resistant recurrent ovarian cancer.
89665315|NCT05397418|Experimental|Intervention group|Supervised exercise program week 1-12, unsupervised exercise week 13-24.
89665316|NCT05397418|Sham Comparator|Control group|Maintain habitual activity week 1-12, unsupervised exercise week 13-24.
89665317|NCT05396547|Experimental|Treated|Treatment with Ledinbio device
89665318|NCT05377450|Active Comparator|Cemented Engage Partial Knee|Engage partial knee implanted with bone cement for fixation.
89665319|NCT05377450|Active Comparator|Cementless Engage Partial Knee|Engage partial knee implanted with cementless fixation.
89665320|NCT05330936|Active Comparator|Group A|Steroid combination ointment in the treatment of chronic Plaque Psoriasis
89665321|NCT05330936|Active Comparator|Group B|Cyanocobalamin in Avocado Oil cream in the treatment of chronic Plaque
89665322|NCT05316558|Experimental|Body Confident Coaching|Participants in the intervention condition will take part in an online program consisting of five modules over two weeks.
89665323|NCT05316558|No Intervention|Waitlist control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
89665324|NCT05307965|Active Comparator|Standalone Percutaneous Coronary Intervention|Participants will have standard of care treatment. They will undergo PCI with devices and techniques driven by clinical decision making at the patient level and institutional level, and carried out in accordance with the Oxford University Hospitals NHS Foundation Trust department guidelines.
89665325|NCT05307965|Active Comparator|Percutaneous Coronary Intervention and Thrombus Aspiration|Participants will have standard of care treatment with manual thrombectomy catheter and PCI. They will undergo PCI with devices and techniques driven by clinical decision making at the patient level and institutional level, and carried out in accordance with the Oxford University Hospitals NHS Foundation Trust department guidelines.
89665326|NCT05307965|Experimental|Percutaneous Coronary Intervention and Retriever Thrombectomy|Participants randomised to the stent-retriever thrombectomy arm of the RETRIEVE AMI trial will undergo stent-retriever thrombectomy with the SolitaireTM X Revascularisation Device.
89665327|NCT05294588|Experimental|Experimental arm|"All participants receive two immunizations prior to the bacterial challenge phase and two immunizations after the challenge phase. Individuals assigned to the experimental arm receive the recommended two doses of BEXSERO™ prior to bacterial challenge and control vaccines (FLULAVAL™ and TDVAX™) in the post-challenge vaccination phase.~For bacterial challenge, all participants receive a suspension containing 10^6 colony-forming units of N. gonorrhoeae strain FA1090 delivered to the anterior urethra. Participants receive 100% effective antibiotic treatment for N. gonorrhoeae strain FA1090 infection when (1) requested by the participant regardless of signs, symptoms or positive cultures, (2) urethral discharge is observed by the examining clinician or reported by the participant, or (3) 10 days afterurethral inoculation with bacterial product, regardless of infection status."
89665328|NCT05294588|Other|Control arm|"All participants receive two immunizations prior to the bacterial challenge phase and two immunizations after the challenge phase. Individuals assigned to the control arm receive control vaccines that have no relevance to N. gonorrhoeae infection (FLULAVAL™ and TDVAX™) prior to bacterial challenge and then receive two doses of BEXSERO™ in the post-challenge vaccination phase.~For bacterial challenge, all participants receive a suspension containing 10^6 colony-forming units of N. gonorrhoeae strain FA1090 delivered to the anterior urethra. Participants receive 100% effective antibiotic treatment for N. gonorrhoeae strain FA1090 infection when (1) requested by the participant regardless of signs, symptoms or positive cultures, (2) urethral discharge is observed by the examining clinician or reported by the participant, or (3) 10 days afterurethral inoculation with bacterial product, regardless of infection status."
89665329|NCT05287841|Experimental|Batten graft, plus septoplasty and inferior turbinate reduction|In the intervention arm, a portion of the quadrangular cartilage of the nasal septum is also removed, but will be refashioned and re-implanted into the patient as an autologous batten graft. This will be performed together with standard septoplasty and turbinate reduction.
89665330|NCT05287841|Active Comparator|Septoplasty and inferior turbinate reduction alone|In the control arm, a portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty and turbinate reduction.
89665331|NCT05284721|Active Comparator|Care Coordination Phase III|Family member participants randomized to the active control will receive two brief psychoeducation sessions, two brief check ins across one month and linked to appropriate services.
89665332|NCT05284721|Experimental|Family Peer Navigator model Psychosis Phase III|Family member participants randomized to the Family Peer Navigator condition will participate in two sessions for introduction/assessment, four individual psychoeducation sessions, and six brief check ins delivered by Family Peer Navigators.
89665333|NCT05268640|Experimental|Double-level cerclage|double-level cervical cerclage placement with one suture above the other approximately 1 cm higher. Suture will be placed analogous to McDonald technique
89665334|NCT05268640|Active Comparator|Single-level cerclage|single-level cervical cerclage of McDonald technique
89665335|NCT05235685|Active Comparator|Patients with COPD|Patients with COPD will only exercise under medical air (for between-group comparison: COPD vs COPD-HF)
89214345|NCT00528879|Placebo Comparator|Placebo + Metformin|Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
89214346|NCT00528879|Experimental|Dapagliflozin, 2.5 mg + Metformin|Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
89214347|NCT00528879|Experimental|Dapagliflozin, 5 mg + Metformin|Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
88995180|NCT05266950|Experimental|CI-135 CAR-T|chimeric antigen receptor T cell treatment
88995181|NCT05266027|Experimental|Experimental Group|Nalbuphine Sebacate (Naldebain) intramuscular injection
88995182|NCT05266027|Placebo Comparator|Placebo Group|Placebo medication intramuscular injection
88995183|NCT05258669|Active Comparator|BBV152|BBV152
88995184|NCT05258669|Placebo Comparator|Placebo|0.9% normal saline
88995185|NCT05248867|Experimental|AGN-151586|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
89665336|NCT05235685|Experimental|Patients with COPD-HF overlap|Patients with COPD-HF overlap will first exercise under medical air (for between-group comparison: COPD vs COPD-HF); Patients with COPD-HF overlap will then exercise under interventions (randomized order: non-invasive ventilation + medical air; non-invasive ventilation + hyperoxia, for within-group comparison: medical air vs intervention trials)
89665337|NCT05235438|Experimental|IMM27M|IMM27M 0.1, 0.3, 1.0, 2.0, 3.0 mg/kg
89665338|NCT05231343|Experimental|Dual mini-fragment plating|
89665339|NCT05231343|Active Comparator|Single precontoured plating|
89665340|NCT05211648|Experimental|Patients with Aktiia bracelet|This is a prospective open-label single arm study. Study participants will wear the Aktiia bracelet for 6 months and will continue in parallel the procedures of the Remote Hypertension Program.
89665341|NCT05197712|Experimental|25 μg Baiya SARS-CoV-2 Vax 2|Experimental: 25 μg Baiya SARS-CoV-2 Vax 2, Adult Participants 2 doses of Baiya SARS-CoV-2 Vax 2 (25 μg), each on Day 1 and Day 22 for adult participants (18 - 64 years old)
89665342|NCT05197712|Experimental|50 μg Baiya SARS-CoV-2 Vax 2|Experimental: 50 μg Baiya SARS-CoV-2 Vax 2, Adult Participants 2 doses of Baiya SARS-CoV-2 Vax 2 (50 μg), each on Day 1 and Day 22 for adult participants (18 - 64 years old)
89665343|NCT05189691|Experimental|behavior change and walking exercise|A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale, Short Form 36 (SF-36) scales and continuously recorded step counts will be evaluated at week 0, 4 and at the end of week 12.
89665344|NCT05189691|No Intervention|behavior change|A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) scales will be evaluated at week 0, 4 and at the end of week 12.
88995186|NCT05248867|Placebo Comparator|Placebo|Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
89665345|NCT05170139|Experimental|Caffeine|Dietary Supplement: Caffeine supplementation Participants will ingest caffeine in liquid form (3mg/kg) with carbohydrates.
89665346|NCT05170139|Placebo Comparator|Control condition|Participants will ingest a drink of carbohydrates without caffeine
89665347|NCT05155501|Active Comparator|Robot-assisted radical prostatectomy (RP)|The conventional robotic-assisted radical prostatectomy is the gold standard approach to prostate cancer surgery.
89665348|NCT05155501|Experimental|Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)|A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate. These structures are disrupted and removed during conventional radical prostatectomy.
89665349|NCT05143931|Active Comparator|WW Only|WW is commercially-available weight management program focusing on diet, physical activity and mindset skills.
88995187|NCT05245266|Other|Analysis of blood samples from healthy pregnant women|Analysis of blood samples from healthy pregnant women. A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.
88995188|NCT05236465|Experimental|A 3-day course|The course consists of teaching in basic psychology, stress physiology and practice of a specific technique with self-instructions and visualization in a group setting by non-health personnel
88995189|NCT05236465|Active Comparator|Waiting list|Treatment as usual (TAU)
88995190|NCT05228886|Active Comparator|Call + Resources|Participants receive standard care typically provided to 211 callers, including ad hoc follow-up.
88995191|NCT05228886|Experimental|Call + Resources + Scheduled Follow-Up|Participants receive standard care typically provided to 211 callers plus scheduled follow-up calls according to the Scheduled Follow-Up intervention description.
88995192|NCT05228886|Experimental|Call + Resources + SINCERE|Participants receive standard care typically provided to 211 callers plus scheduled follow-up calls according to the SINCERE intervention description (scheduled follow up with active collaborative goal setting).
88995193|NCT05201508|Active Comparator|Sutures only|Traditional suture closure of hiatal defect
88995194|NCT05201508|Experimental|Polyglactin mesh|In addition to traditional sutures, key hole polyglactin mesh for hiatal defect closure.
88995195|NCT05200624|Active Comparator|Active laser|Application of the active 2RT sub threshold laser
88995196|NCT05200624|Sham Comparator|Sham laser|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant)
88995197|NCT05172726|Experimental|Open Label|
88995198|NCT05168046|Experimental|Parkinson Mindfullness Based Stress Reduction|Patients who have an assessment before and after a mindfulness based stress reduction intervention for 6 months
88995199|NCT05168046|No Intervention|Parkinson controls|Patients who have an assessment before and after 6 monthswithout intervention
88995200|NCT05159466||Kidney transplant recipients|Up to 25 HIV-positive participants requiring kidney organ transplantation
88995201|NCT05159466||Kidney living donors|Up to 5 HIV-positive living donors will be enrolled.
88995202|NCT05157867|Experimental|Amylase trypsin inhibitors (ATIs), then placebo|Test day 1: intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (bread wheat), dissolved in physiological saline. After a wash-out period of 4-6 weeks, test day 2: intraduodenal administration of placebo (physiological saline).
88995203|NCT05157867|Experimental|Placebo, then Amylase trypsin inhibitors|Test day 1: intraduodenal administration of placebo (physiological saline). After a wash-out period of 4-6 weeks, test day 2: intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (bread wheat), dissolved in physiological saline.
89665350|NCT05143931|Experimental|WW + Home modification and grocery delivery (AVOID)|WW + modification of home food environment + online grocery shopping and delivery
89665351|NCT05143931|Experimental|WW + Inhibitory control training (RESIST)|WW + daily gamified inhibitory control training
89665352|NCT05143931|Experimental|WW + Home food modification and grocery delivery (AVOID) + Inhibitory control training (RESIST)|WW + modification of home food environment + online grocery shopping and delivery + daily gamified inhibitory control training
89665353|NCT05140811|Experimental|Relapse/Refractory AML|"IMM01 and Azacitidine in Relapse/Refractory AML~Interventions:~Drug: IMM01 Drug: Azacitidine"
89665354|NCT05140811|Experimental|Relapsed or Refractory MDS|"IMM01 and Azacitidine in Relapse/Refractory MDS~Interventions:~Drug: IMM01 Drug: Azacitidine"
89665355|NCT05140811|Experimental|Treatment naive AML|"IMM01 and Azacitidine in treatment naive AML~Interventions:~Drug: IMM01 Drug: Azacitidine"
89665356|NCT05140811|Experimental|Treatment naive MDS and naive CMML|"IMM01 and Azacitidine in treatment naive MDS and naive CMML~Interventions:~Drug: IMM01 Drug: Azacitidine"
89665357|NCT05107947|Experimental|Intervention biocentric light environment|In all study rooms, a biocentric lighting environment will be able to be created by activating a special lighting system. In these rooms, light will change dynamically both in spectral distribution and intensity during the day. During the day, color temperature and intensity are high (1000 lux and up to 6500 K) to decrease both intensity and color temperature during the evening.
89665358|NCT05107947|No Intervention|Control standard light environment|Standard static light environment.
89665359|NCT05102903|Other|A(RT)|"Reference drug BR1016B 1 tablet is administered once in fasted state. After having a break of 7 days or more, study drug BR1016A 1 tablet is administered once in fasted state."
89665360|NCT05102903|Other|B(TR)|"Study drug BR1016A 1 tablet is administered once in fasted state. After having a break of 7 days or more, reference drug BR1016B 1 tablet is administered once in fasted state."
89665361|NCT05102266|Experimental|A(RT)|"Reference drug BR1016D 1 tablet is administered once in fasted state. After having a break of 7 days or more, study drug BR1016C 1 tablet is administered once in fasted state."
89665362|NCT05102266|Experimental|B(TR)|"Study drug BR1016C 1 tablet is administered once in fasted state. After having a break of 7 days or more, reference drug BR1016D 1 tablet is administered once in fasted state."
89665363|NCT05098743|Experimental|Participants using the medication adherence mobile application.|Participants in this arm will use the Medisafe app to receive medication reminders for thirty days.
89665364|NCT05098743|Active Comparator|Participants using a printed copy of their medication list.|Participants in this arm will use a printed out copy of their medication list for thirty days.
89665365|NCT05098249|Experimental|Verum|
89665366|NCT05098249|Placebo Comparator|Placebo|
89665367|NCT05061056|Experimental|Russian current 10%|Subjects will receive a interventions (Russian Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
89665368|NCT05061056|Experimental|Russian current 20%|Subjects will receive a interventions (Russian Current at 20% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
89665369|NCT05061056|Experimental|Aussie current 10%|Subjects will receive a interventions (Aussie Current at 10% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
89665370|NCT05061056|Experimental|Aussie current 20%|Subjects will receive a interventions (Aussie Current at 20% duty cycle). Evoked torque, muscle fatigue, sensory discomfort, and peripheral oxygen extraction will be evaluated.
89665371|NCT05053022|Experimental|Microneedling with Skinpen Precision System|"Skinpen precision system will be used in accordance with the instructions in the IFU on the treatment area. A numbing cream will be applied at least 20-30 minutes before the Skinpen Precision system treatment is done. The affected areas will be treated at depths of up to 2.50mm. Treatment depth will be recorded for each treatment at every visit.~Subjects will be dispensed with the Blue Lizard sunscreen and trained on proper use."
89665372|NCT05046184|No Intervention|Healthy Controls|Healthy controls will undergo clinician assessments and fMRI to compare to MDD group.
89665373|NCT05046184|Active Comparator|MDD - Ketamine|Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four ketamine infusions.
89665374|NCT05046184|Placebo Comparator|MDD - Midazolam|Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four midazolam infusions.
89048709|NCT00550979||4|White women with a history of normal, uncomplicated pregnancy/ies.
89665375|NCT05020028|Experimental|CBD Group|The first cohort will take two 25mg cannabidiol (total dose: 50mg) Orally Disintegrating Tablets (CBD ODT) three times daily for a maximum dose of 150mg per day.
89665376|NCT05020028|Placebo Comparator|Placebo Group|Cohort 2 will receive the same instructions, but with the placebo Orally Disintegrating Tablets (ODT) instead.
89665377|NCT05003583|Experimental|Experimental Condition|Speaking while viewing images with negative and neutral valence
89665378|NCT04990440|Experimental|Part A: Bermekimab Dose 1|Participants will receive bermekimab Dose 1 or placebo as an intravenous (IV) infusion weekly from Week 0 to Week 15.
89665379|NCT04990440|Experimental|Part B: Bermekimab Dose 2|Participants will receive bermekimab Dose 2 or placebo as an IV infusion weekly from Week 0 to Week 15.
89665380|NCT04990440|Experimental|Part C: Bermekimab Dose 3|Participants will receive bermekimab or placebo at a higher or lower dose (not less than [<] Dose 1) than Part B, but with a maximum dose of Dose 3 IV weekly based on pharmacokinetic (PK), pharmacodynamic (PD), efficacy, and safety analysis.
89665381|NCT04980560||VAC cohort|Subjects who will take COVID-19 vaccines
89665382|NCT04980560||CON cohort|Subjects who are COVID-19 survivors
89665383|NCT04976868||Pimecrolimus Cream 1% - Elidel®|Elidel® as prescribed within routine clinical practice
89665384|NCT04963946|Experimental|watch and monitor|After 18 months of acalabrutinib treatment, patients will stop acalabrutinib treatment for watch and monitor until month 60. If progression disease, patients will be re-treated with ACA at the last received dose after central reviewing of treatment criteria.
89665385|NCT04963946|Active Comparator|Acalabrutinib|After 18 months of acalabrutinib treatment, patients will continue acalabrutinib treatment until month 60. If progression disease or unacceptable toxicity, patients will receive next line therapy at the discretion of their physicians and according to iwCLL 2018 criteria
89665386|NCT04948528||Case group:|All suspected upper tract urothelial carcinoma participants will be assigned to case group.
89665387|NCT04948528||Control group|All suspected upper tract urothelial benign participants such as ureteral/renal calculi, ureteral stricture, upper urinary tract polyps, pyelonephritis, urinary tuberculosis will be assigned to control group.
89665388|NCT04944654|Experimental|Assigned intervention|Biktarvy OD for 96 weeks
89688684|NCT03490825|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
89688685|NCT03490825|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
89688686|NCT04363099||outpatients COVID 19 positive|
89688687|NCT04354207||Atopic dermatitis|
89048710|NCT04643223|Active Comparator|Kinesio tape with tension|The intervention group will receive the elastic bandage - kinesio tape with tension between seventy to ninety percent on the selected hypertrophic scar. The application of kinesio tape follows a protocol, which involves the cleaning of the selected scar with liquid soap, drying, alcohol application for sebum removal, scar measurement and marking of the therapeutic zone and anchors. Following the application of the kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the Vancouver assessments and collections of scarring material for the histopathology will be carried out, in the time intervals corresponding to the beginning of the study intervention / entry (time 0), 45 days and 90 days after being eligible, to agree to participate in the study study and intervention.
89048711|NCT04643223|Sham Comparator|Kinesio tape without tension|The controlled sham group will receive the application of kinesio tape without tension will follow the same protocol above, including the three moments of evaluation, beginning of the intervention (time 0), 45 days and 90 days, after the beginning of the intervention.
89048712|NCT00551018|Experimental|Vicriviroc + Reyataz + ritonavir|vicriviroc 30 mg tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
89048713|NCT00551018|Active Comparator|Truvada® + Reyataz + ritonavir|Truvada® 200/300 combination tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
89048714|NCT00551096|Experimental|Gemcitabine, capecitabine and ZD6474|"Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.~Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off .~ZD6474 administered orally at 300 mg/day once daily. One cycle will consist of 28 days."
89048715|NCT04642872|Experimental|infant cimt|
89048716|NCT04642872|Active Comparator|Infant BIT|
89048717|NCT04642872|Active Comparator|Infant CIMT/BIT|
89048718|NCT04642872|Active Comparator|Conventional Therapy|
89048719|NCT00551252|Experimental|I|
89048720|NCT04642716|Other|Salivary free amino acids profile observation|Saliva samples of periodontitis patients and healthy controls were collected. The AA analysis of the saliva was performed by LC-MS/MS by using the Thermo Scientific TSQ Quantum Access MAX (Thermo Scientific, Schaumburg, IL, USA) .
89048721|NCT00551330|Experimental|1|Vicriviroc 30 mg QD
89048722|NCT00551330|Placebo Comparator|2|Placebo
89048723|NCT00551408||A|20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization able to walk >50 m during a standardized 6-min walk test.
89048724|NCT04892966|Experimental|TXI (TXI group)|Arm undergoing normal colonoscopy with TXI light
89048725|NCT04892966|Active Comparator|WLI (White Light Imaging Group)|Arm undergoing normal colonoscopy with standard white light
89048726|NCT04642521||Iron deficiency anaemia|Preoperatively, participants who are iron deficient with or without anaemia will receive intravenous iron (Monofer) as per ProPBM protocol.
89048727|NCT04642521||No iron deficiency anaemia|Patient in this group will not be given intravenous iron.
89048728|NCT00551486||1|Patients with thyroid incidentaloma underwent ultrasound-guided fine needle aspiration biopsy
89048729|NCT04642248|Active Comparator|Non-intervention|This group will have the analysis and their data will be used to determine risk factors for developing running injuries.
89048730|NCT04642248|Experimental|Intervention|This group will get a personalized program based off of 3D and movement analysis results to judge the ability to reduce musculoskeletal injuries.
89048731|NCT03455894|Experimental|Smart carpet|
89048732|NCT04642482|Experimental|Synbiotic|"A fine powder to be taken orally consists of~Viable cell 1,0 x 10^9 Colony Forming Unit of :~Lactobacillus plantarum 8,55 mg~Streptococcus thermophilus 8,55 mg~Bifidobacterium bifidum 2,55 mg~Fructooligosaccharide 480 mg~Additional components : isomalt, xylitol"
89048733|NCT04642482|Active Comparator|Placebo|A powder of 5 gram maltodextrin is given as active comparator, taken orally.
89048734|NCT03455777|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
89048735|NCT04642209||Aggregometry|surgical timing will be guided by the results obtained by aggregometry
89048736|NCT01167374|Experimental|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
89048737|NCT04642560||Usual practice|Any child hospitalized in Pediatric or Neonatal ICU and receiving systemic (intravascular, intramuscular or oral) antibiotic treatment for an episode of suspected or proven community-acquired or nosocomial bacterial infection
89048738|NCT01125761|Experimental|dexamethasone 0.5 mg and 1.0 mg clemastine cream|
89048739|NCT01125761|Active Comparator|dexamethasone 0,5 mg cream|
89048740|NCT04642326|Experimental|Test Group: experimental - UVC Therapy applied|Test: Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy
89048741|NCT04642326|No Intervention|Control Group|Control: Antiviral + Antimalarial + Antibiotic Treatment
89665389|NCT04934956|Experimental|Intervention: Split-belt walking; Multiple transitions between split-belt and tied-belt walking|"Split-belt walking will be used in all experiments and consists of a time period during which the legs move at different speeds (0.5 m/s vs. 1 m/s). The investigators select those speeds since the investigators have observed in our preliminary data and published study (Sombric et al. 2017) that older individuals adapted at these speeds exhibit large deficits at motor switching when transitioning to overground walking. This large reference signal will facilitate the detection of a change in motor switching (Aim 2) following the Intervention.~This second intervention consists of multiple short adaptation blocks (i.e., 6 blocks of 200 strides each) interleaved with short de-adaptation blocks (i.e., 5 blocks of 200 strides of tied-belt walking each). It was designed based on several studies showing improvements in adaptation rate in young adults with a similar protocol (Malone et al. 2011; Day et al. 2018; Leech et al. 2018)."
89665390|NCT04886232|Experimental|VP1 Lido US - NC|Injection to the left cheek via needle and to the right cheek via canula
89665391|NCT04886232|Experimental|VP1 Lido US - CN|Injection to the left cheek via canula and to the right cheek via needle
89665392|NCT04886232|Active Comparator|Restylane Lyft Lidocaine - NC|Injection to the left cheek via needle and to the right cheek via canula
89665393|NCT04886232|Active Comparator|Restylane Lyft Lidocaine - CN|Injection to the left cheek via canula and to the right cheek via needle
89665394|NCT04885712|Experimental|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg Pioglitazone 30mg placebo
89665395|NCT04885712|Experimental|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 30mg Pioglitazone 15mg placebo
89665396|NCT04885712|Active Comparator|Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo|Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg placebo Pioglitazone 30mg placebo
89665397|NCT04883684|Experimental|Patients(Care givers)|"400 patients(caregivers) are enrolled and use the personal health wallet service (Personal Health Records service).~They fill out questionnaire to evaluate the service~Some of them are invited for an in-depth interview."
89665398|NCT04858152|Experimental|Experimental Arm: Transplantation of hair follicles to non-hair bearing areas affected by vitiligo|Punch biopsies will be used to extract hair follicles from area on participant's body that is not affected by vitiligo and has hair growth. The follicles will then be transplanted into an area of the body affected by vitiligo that is hairless.
89665399|NCT04843046|Active Comparator|CBT + pioglitazone|Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a pioglitazone (45 mg) capsule every day during weeks 1-12.
89665400|NCT04843046|Placebo Comparator|CBT + placebo|Cognitive Behavioral Therapy will be administered twice weekly during weeks 1-4 and once weekly during weeks 5-12 and augmented with a placebo capsule every day during weeks 1-12.
89665401|NCT04829747|Experimental|Atogepant|Participants will receive fixed dose of Atogepant once daily for 12 weeks.
89665402|NCT04794530|Active Comparator|cocoa flavanols|
89665403|NCT04794530|Placebo Comparator|placebo|
89665404|NCT04789499|Experimental|Theophylline|400mg theophylline capsule diluted in 240 mL isotonic nasal saline lavage twice daily for six weeks.
89665405|NCT04789499|Placebo Comparator|Placebo|500mg lactose capsule diluted in 240 mL isotonic nasal saline lavage twice daily for six weeks.
89665406|NCT04788862|Experimental|Group 1: High prior P. falciparum exposure|6 participants with high previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
89665407|NCT04788862|Experimental|Group 2: Low prior P. falciparum exposure|6 participants with no or low previous malaria exposure will be infected via IV administration of Plasmodium falciparum-infected human erythrocytes (planned dose of 1000 iRBCs) of the chloroquine-susceptible 3D7 strain.
89665408|NCT04771897|Experimental|Part 1 Dose Escalation: Safety and Tolerance|Sequential cohorts of patients with newly diagnosed DIPG or DMG will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose (MAD), the highest planned dose level is reached and radiation therapy.
89665409|NCT04771897|Experimental|Part 2 BXQ-350 Tumor and Plasma Concentrations|Newly diagnosed DIPG or DMG patients undergoing neurosurgical biopsy prior to receiving radiation therapy will receive BXQ-350 at the MTD established in Part 1, or the highest planned dose level, and radiation therapy. Excised tumor tissue and plasma samples will be evaluated for SapC levels and pharmacodynamic effects.
89665410|NCT04697823|Active Comparator|study group|Patients receiving an embryo transfer in hyaluronan-enriched transfer medium
89665411|NCT04697823|No Intervention|control group|Patients receiving an embryo transfer in conventional culture medium
89665412|NCT04697407|Experimental|MS Patients|Patients with MS at any stage and for any type of MS : MS at the onset of the disease, Clinically isolated syndrome (CIS), Relapsing-remitting MS (RRMS), Primary progressive MS (PPMS), Secondary progressive MS (SPMS)
89665413|NCT04697407|Active Comparator|non MS Patients|Patients with a neurological and immunological disease except MS.
89048742|NCT04642092|Experimental|PsicAP protocol|The treatment of the experimental group will be according to the PsicAP protocol: seven sessions of a psychological treatment based on transdiagnostic approaches, collaborative interventions, group-sessions, and evidence-based psychological techniques derived from cognitive behavioral therapy.
89665414|NCT04697407|Active Comparator|Healthy volunteers|
89665415|NCT04688359|Experimental|Intervention group|Those receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
89665416|NCT04688359|No Intervention|Control group|Those not receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
89665417|NCT04657016|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
89665418|NCT04657016|Placebo Comparator|Placebo|Administered SC
89665419|NCT04638036|Experimental|NIR endoscopy and surgery with cetuximab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, cetuximab-IRDye800CW will be administered to a total of 15 patients with proven locally advanced rectal cancer
89688688|NCT04354207||Asthma|
89665420|NCT04633343|Experimental|Small Volume Breath Group|Small volume breath and fast breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation
89665421|NCT04633343|Experimental|Large Volume Breath Group|Large volume breath and slow breathing rate for 5 minutes when the patient is in the Operating room and on mechanical ventilation.
89665422|NCT04593758|Experimental|CPI-613 + Hydroxychloroquine|dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.
89665423|NCT04577677|Experimental|optimization of control anesthetic condition|
89665424|NCT04577677|Experimental|understanding tDCS effect on motor learning|
89665425|NCT04577677|Experimental|understanding tDCS effects on cortical excitability|
89665426|NCT04577677|Experimental|optimizing peripheral nerve stimulation protocols|
89665427|NCT04577677|Experimental|Effect peripheral nerve stimulation on motor learning|
89665428|NCT04565418|Experimental|Exercise training|12 week high-intensity interval training (3 sessions per week): Before and after exercise, subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws and indirect calorimetry.
89665429|NCT04552366|Experimental|Group A: Intramuscular administration|24 subjects. 5E10 VP of Ad5-nCoV on Day 0 and on Day 56.
89665430|NCT04552366|Experimental|Group B: Mixed administration|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0 and a mucosal administration of 2E10 VP on Day 28.
89665431|NCT04552366|Experimental|Group C: Mucosal administration, high dose|24 subjects. A mucosal administration of 2E10 VP of Ad5-nCoV on Day 0 and Day 28.
89665432|NCT04552366|Experimental|Group D: Mucosal administration, low dose|24 subjects. A mucosal administration of 1E10 VP of Ad5-nCoV on day 0 and Day 28.
89665433|NCT04552366|Active Comparator|Group E: Intramuscular administration, one dose|24 subjects. An intramuscular administration of 5E10 VP of Ad5-nCoV on day 0.
89665434|NCT04552366|Experimental|Group F: Intramuscular administration, two doses|24 subjects. Two intramuscular administrations of 5E10 VP of Ad5-nCoV at left and right arms on day 0.
89665435|NCT04532749|Experimental|Seltorexant|Participants will receive Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
89665436|NCT04532749|Placebo Comparator|Placebo|Participants will receive matching placebo tablets orally once daily from Day 1 to Day 42 (until the end of Week 6).
89665437|NCT04462185||Prospective Cohort|This is a prospectively enrolling cohort study and 3000 patients (1500 GGO and 1500 solid / semi solid nodules) with radiologic diagnosis of indeterminate pulmonary nodule (5-30 mm) will be recruited. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, a genomic and transcriptomic landscape analysis, at each visit.
89665438|NCT04455633|Experimental|LX9211 low dose|LX9211, once daily
89665439|NCT04455633|Experimental|LX9211 high dose|LX9211, once daily
89665440|NCT04455633|Placebo Comparator|Placebo|Placebo, once daily
89665441|NCT04432727|Experimental|ACTIVE FT-CC|Text message reminders will be sent if subject does not use the device for 2 consecutive days.
89048743|NCT04642092|Active Comparator|Conventional treatment|The control group will have seven sessions based on the typical psychological services that currently are offered in the Dominican Primary Care Units.
89048744|NCT04641780||Rexulti Tablets|Target is 300 patients in the Philippines diagnosed with Schizophrenia and Major Depressive Disorder
89048745|NCT04641624||Premature ovarian insufficiency (POI)|"POI is a clinical syndrome defined by loss of ovarian activity before the age of 40 years. POI is characterized by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotrophins and low estradiol.~The study population will be consisted of 45 women with POI as study group."
89048746|NCT04641624||Control group|45 patients with normal healthy women as control group.
89048747|NCT05431127|Other|High Dose Inspiratory Muscle Training|Inspiratory Muscle Training 3 times a week over 26 weeks
89048748|NCT04641546|Experimental|Occupation-Based Intervention + Therapeutic Exercise Intervention Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of 30 minutes therapeutic exercise followed by 30 minutes of occupation-based intervention.
89048749|NCT04641546|Experimental|Therapeutic Exercise Control Group|Sixty-minute occupational therapy sessions were completed two times a week for six weeks consisting of therapeutic exercise only.
89048750|NCT05427656|Experimental|185 MBq [18F] TRACK|Each participant will receive a single scan with 185 MBq [18F] TRACK
89665442|NCT04432727|Experimental|PASSIVE FT-CC|Text message reminders will not be sent to subjects.
89665443|NCT04416360|Experimental|Interview by psychologists|Children and adolescent interview Parents interview Referring caregiver interview
89665444|NCT04416308|Other|Seroprevalence survey|NG Test + short self-questionnaire (except validation survey and detailed survey)
89665445|NCT04416308|Other|Validation test of the NG test survey|Blood test + NG test + detailed self-questionnaire
89665446|NCT04416308|Other|Detailed Survey|NG test + self-questionnaire complementary to the short questionnaire
89665447|NCT04416308|Other|Prevalence monitoring (2 population samples)|"Participants having presented a certain or probable COVID: acts of the validation test survey, + follow-up questionnaire,+ blood test + NG test, on D30 and D90~Others Participants : drawn by lot: acts of the seroprevalence survey, + follow-up questionnaire + NG test, on D90"
89665448|NCT04341389|Active Comparator|Arm 1|1×10^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
89665449|NCT04341389|Active Comparator|Arm 2|5×10^10vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
89665450|NCT04341389|Placebo Comparator|Arm 3|Placebo administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0
89665451|NCT04314245||Urothelial carcinoma group|Subjects who diagnosed with incident or recurrent urothelial carcinoma (including bladder/ureter/renal pelvis) by surgical pathology.
89665452|NCT04314245||interference group|Subjects who diagnosed with incident or recurrent bladder cancer other than urothelial carcinoma (including bladder squamous cell carcinoma/bladder adenocarcinoma/other bladder-related cancers/prostate cancer/rectal cancer) by surgical pathology.
89665453|NCT04314245||Control group|Subjects who clinically diagnosed with benign disease of the urinary system, such as Urinary calculi, urinary tract infection (except urinary tuberculosis), benign prostatic hyperplasia, glandular cystitis.
89665454|NCT04314245||Healthy volunteers group|Volunteers who have a normal routine urine test / ultrasound examination of the urinary system and do not carry suspected tumors of other organs.
89665455|NCT04307641|Experimental|Intervention|Pharmacists who received in the intervention.
89665456|NCT04307641|No Intervention|Control|Pharmacists who did not received in the intervention.
89665457|NCT04264156|Experimental|Lucinactant (160 mg/kg) + nCPAP|Lucinactant for inhalation, 160 mg total phospholipids (TPL)/kg Delivered as an aerosol once, with up to 3 repeats of 80 mg/kg allowed within 36 hours of birth
89665458|NCT04264156|Sham Comparator|nCPAP Only|nCPAP Only as sham comparator. Bubble nCPAP is standard of care. Treatment time behind barrier to match active treatment delivery time
89665459|NCT04258423|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
89214348|NCT00528879|Experimental|Dapagliflozin, 10 mg + Metformin|Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
89665460|NCT04258423|Experimental|Study Arm|Everolimus as maintenance immunosuppression
89665461|NCT04228978|Experimental|Weight loss + exercise (WL+EX)|Weight loss + home based walking exercise (WL+EX)
89665462|NCT04228978|Active Comparator|Exercise alone (EX)|Home based walking exercise (EX)
89214349|NCT00608894|Experimental|LCP-Tacro|LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
89214350|NCT00608894|Active Comparator|Azathioprine|Azathioprine tablets(50mg)+ prednisone tablets(5mg)
89214351|NCT00892268|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.
89665463|NCT04211987|Active Comparator|Fast track care protocol|patients treated using fast track care protocol
89665464|NCT04211987|Active Comparator|Standard care protocol|patients treated using standard care protocol
89665465|NCT04200729|Experimental|Irrigation with PVI|
89665466|NCT04200729|Active Comparator|Usual care|
89665467|NCT04200677|Experimental|MCN1|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
89665468|NCT04200677|Experimental|BCN05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve
89665469|NCT04200677|Experimental|BCN1|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
89665470|NCT04200677|Experimental|BCN2|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve
89665471|NCT04200677|Experimental|MCM1|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
89665472|NCT04200677|Experimental|BCM05|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly
89665473|NCT04200677|Experimental|BCM1|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly
89665474|NCT04200677|Experimental|BCM2|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly
89665475|NCT04200677|Experimental|BC25|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly
89665476|NCT04190433|Active Comparator|Group I (carvedilol, lisinopril)|Patients receive carvedilol orally (PO) and lisinopril orally (PO), up-titrated to maximum tolerated doses as per standard clinical practice for 6 months.
89665477|NCT04190433|Experimental|Group II (pravastatin, spironolactone)|Patients receive standard clinical practice therapy as in Group I. Patients also receive pravastatin PO and spironolactone PO for 6 months.
89665478|NCT04178967|Placebo Comparator|Placebo|"Induction Period (Baseline-Week 16):~Two subcutaneous (SC) injections of Placebo as a loading dose at Baseline and Week 2 followed by a single injection every 2 weeks (Q2W) from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~Two placebo SC injections as loading dose on Week 16 and Week 18. One placebo SC injection Q2W until Week 50."
89665479|NCT04178967|Experimental|Lebrikizumab Q2W|"Induction Period (Baseline-Week 16):~500 milligram (mg) Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 visits followed by a single 250 mg Lebrikizumab injection Q2W from Week 4 until Week 14.~Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and Week 18.~One 250 mg Lebrikizumab SC injection Q2W until Week 50."
89665480|NCT04178967|Experimental|Lebrikizumab Q4W|"Maintenance Period (Week 16-Week 52):~One 250 mg Lebrikizumab SC injection and one placebo SC injection as maintenance loading dose on Week 16 and two placebo SC injections on Week 18.~One 250 mg Lebrikizumab SC injection Every 4 weeks (Q4W) on Weeks 20, 24, 28, 32, 36, 40, 44, and 48.~One placebo SC injection Q4W on Weeks 22, 26, 30, 34, 38, 42, 46, and 50."
89665481|NCT04178967|Experimental|Escape Arm (Lebrikizumab Q2W)|"Maintenance Period (Week 16-Week 52):~Participants who require topical or systemic rescue treatment for atopic dermatitis during the Induction Period, or are non-responders at Week 16, will be eligible for treatment in an Escape Arm where participants will receive open-label lebrikizumab Q2W from Week 16 through Week 52. In addition, participants who do not maintain an acceptable response during the Maintenance Period (have an EASI score <50% of baseline), will be eligible for the Escape Arm."
89214352|NCT00892268|Active Comparator|Arm II|Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.
89665482|NCT04163900|Experimental|A - NUC-1031 and cisplatin|725 mg/m^2 NUC-1031 administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
89665483|NCT04163900|Active Comparator|B - gemcitabine and cisplatin|1000 mg/m^2 gemcitabine administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle
89665484|NCT04161495|Experimental|Arm A: Prophylaxis|Participants who were on a prophylaxis treatment with a FVIII product prior to study EFC16293 including participants who rolled over from study OBS16221, received BIVV001 50 international units per kilogram (IU/kg) intravenous (IV) injection once-weekly (QW) for 52 weeks in the current study. Study OBS16221 participants with 6 months historical data on prophylaxis treatment with a marketed FVIII product prior to enrollment were analyzed as a subgroup (named as: Arm A: Historical Prophylaxis [OBS16221]) in the outcome measure analysis.
89688689|NCT04354207||Healthy individuals|
89048751|NCT04641585|Experimental|Patients affected by Brugada Syndrome 1|Patients with spontaneous or drug-induced Brugada Syndrome 1
89048752|NCT04641585|Active Comparator|Controls|Patients with no condition associated with spontaneous or drug-induced Brugada Syndrome 1
89048753|NCT00559221|No Intervention|1|
89048754|NCT05408312|Experimental|Experimental group 1|
89048755|NCT05408312|Experimental|Experimental group 2|
89048756|NCT05408312|Experimental|Experimental group 3|
89665485|NCT04161495|Experimental|Arm B: On-Demand Then Prophylaxis|Participants who were on an on-demand treatment regimen with a FVIII product prior to study EFC16293, including participants who rolled over from study OBS16221, received BIVV001 50 IU/kg IV injection as an on-demand treatment (as needed for the treatment of bleeding episodes) from Week 1 to Week 26 in current study. At Week 26, participants in Arm B were switched to prophylaxis treatment, and received BIVV001 50 IU/kg, IV injection QW until Week 52.
89665486|NCT04146038|Experimental|Treatment (salsalate, decitabine, azacitidine, venetoclax)|"CYCLE 1: Patients receive salsalate PO BID until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.~CYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89665487|NCT04114955|Active Comparator|Intervention|Intervention condition comprised of two components designed to address intersectional stigma: 1) a group-level, peer-led intervention and 2) an individual-level peer navigation program to increase uptake of HIV testing and PrEP.
89665488|NCT04114955|Other|Wait-list control|Control participants will receive the intervention after a one-year waiting period.
89665489|NCT04109885|Experimental|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
89048757|NCT05408312|Placebo Comparator|placebo group|
89048758|NCT04641468|Other|Mediana 010 or 001 left main bifurcation lesion|DCB alone combined with retracted DES implantation if necessary (d-p-d strategy)
89048759|NCT04683497|Experimental|CE-IOUS|Patients with pancreatic cancer undergoing surgery with the performance of CE-IOUS
89048760|NCT04641117|Experimental|Exercise|Six months of power training
89048761|NCT04641390||Casos|altered vaginal microbiome resistant to drug treatment
89048762|NCT04641390||Controles|Altered vaginal microbiome not resistant to drug treatment
89048763|NCT04641390||semen donors|The semen donors included in the present work will be men between 18 and 35 years old who are included in the donation program of Instituto Bernabeu after having passed a series of physical, psychological, analytical, genetic and serological evaluations and are considered suitable for donation as established by Royal Decree-Law 9/2014. Likewise, donors are subjected to a series of seminal quality evaluations and seminal freeze-thaw tests in order to guarantee their fertile potential. In this way, the donors who are part of the Instituto Bernabeu donation program also comply with current legal regulations with a strict evaluation to be considered the gold standard of potentially fertile semen. In addition, it will be necessary for them to provide a signed informed consent accepting their participation in the study.
89048764|NCT00553085||Anx group|
89665490|NCT04109885|Active Comparator|Standard treatment|Intravenous administration of prochlorperazine and diphenhydramine.
89665491|NCT04108000|Experimental|SPIRIT-Dementia|Patients and their surrogates randomized to this study arm will receive the SPIRIT-dementia intervention.
89665492|NCT04108000|Active Comparator|Usual Care|Patients and surrogates randomized to this study arm will receive the standard information about advance directives that is provided at the time of diagnosis.
89665493|NCT04093973||MAC subjects|Outpatients with moderate to severe mitral annular calcification on echocardiogram who are able to perform supine bicycle exercise.
89665494|NCT04093973||Controls|Sex matched individuals who are within 5 years of age of the paired MAC subject and who have the same left ventricular wall thickness as measured by echocardiography.
89665495|NCT04087668|Other|Monitored Anesthesia Care|Patients in this arm will undergo an ERCP using monitored anesthesia care (MAC) with propofol based deep sedation.
89665496|NCT04087668|Other|General Anesthesia|Patients in this arm will receive standard general anesthesia with neuromuscular blockade.
89665497|NCT04087668|Other|General Anesthesia Without Neuromuscular Blockade|Patients in this arm will receive nasotracheal intubation without neuromuscular blockade.
89665498|NCT04087564|Experimental|music intervention|Healthy volunteers, and patients diagnosed with HIV or fibromyalgia will complete 4 rounds of QST testing; baseline + 3 music conditions to determine effect of music on pain sensitivity.
89665499|NCT04026906|Experimental|Skin Glue|Patients in the intervention group will receive standard peripheral intravenous catheter (PIVC) securement (with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape). In addition they will receive a drop of cyanoacrylate glue (Dermabond® topical skin adhesive) at both the PIVC insertion site and under the hub of the catheter.
89665500|NCT04026906|Placebo Comparator|Standard Care|Patients in the control group will receive standard PIVC placement with cloth-bordered transparent polyurethane dressing (Tegaderm® I.V. Advanced) and tape.
89665501|NCT04014270|Experimental|Self modulated functional electrical stimulation (SM-FES)|Patients will receive self-modulated functional electrical stimulation SM-FES
89665502|NCT04014270|Active Comparator|Standard care (SC)|Patients will receive standard care, dose matched to the experimental group therapy
89048765|NCT00553085||ADHD group|
89048766|NCT00553085||Nonanx/nonadhd group|
89048767|NCT05358080|Experimental|Entelon Tab. 50mg|
89048768|NCT05358080|Placebo Comparator|Placebo|
89048769|NCT00559338|Active Comparator|1|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
89048770|NCT00559338|Placebo Comparator|2|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
89048771|NCT05352737||Pri-Meta|patients with breast cancer metastasis at first diagnosis
89665503|NCT04012099|Experimental|BMT101|BMT101 injection (treatment)
89665504|NCT04012099|No Intervention|control|Un-treated control
89665505|NCT04006873|Active Comparator|Tezacaftor/Ivacaftor in combination with Ivacaftor|"A film-coated tablet containing 100mg tezacaftor and 150mg ivacaftor will be taken in the morning.~A film-coated tablet containing 150mg ivacaftor will be taken in the evening.~Participants will take these tablets for 28 days.~All tablets are licensed for use in the EU."
89665506|NCT04006873|Placebo Comparator|Placebo|A visually matched placebo to the active drugs will be taken in the morning and in the evening for 28 days.
89665507|NCT03984019|Other|A|Radiotherapy; SBRT Additional cardiac diagnostics
89665508|NCT03975478|Active Comparator|Gastric bypass|Bariatric surgery by gastric bypass (GB)
89665509|NCT03975478|Experimental|Sleeve gastrectomy|Bariatric surgery by sleeve gastrectomy (SG)
89665510|NCT03945266|Experimental|Intervention group|Participants receive the allocated intervention to help manage gestational weight gain that includes education on weight regulation, healthy eating, physical activity, and goal setting.
89665511|NCT03945266|Active Comparator|Control group|Participants do not receive the allocated intervention but self-monitor their behaviors, complete study tasks and receive prenatal care as normal.
89665512|NCT03942419|Experimental|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser
89665513|NCT03942419|Experimental|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser
89665514|NCT03942419|Placebo Comparator|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser
89665515|NCT03929432|Active Comparator|Active tDCS (with Speech-Language Treatment)|tDCS Stimulation Dose: 1.5 mA for 20-mins
89665516|NCT03929432|Sham Comparator|Sham tDCS (with Speech-Language Treatment)|No tDCS stimulation
89665517|NCT03916484|Experimental|AQ HIV Medication Adherence app-delivered intervention|AQ: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). The participant may or may not stay solely on AQ throughout the study.
89665518|NCT03916484|Experimental|AQ HIV Medication Adherence app-delivered intervention + NSC|AQ+NSC: At minimum, intended app usage (dose) is for participant to complete a set of activities (record medication taking, complete a challenge, complete a forum post) one time per day (frequency) for 6 months (duration). NSC sessions are scheduled approximately every other week (frequency) and last approximately 30 minutes per session (dose). The participant may or may not stay on AQ+NSC throughout the study.
89665519|NCT03916484|Experimental|AQ followed by AQ+NSC|At 3 months, those who were initially randomized to AQ who meet protocol defined definition for intervention non-responsiveness, are reassigned to AQ+NSC to complete months 4 - 6 of the trial.
89665520|NCT03916484|Experimental|AQ+NSC followed by AQ|At 3 months, those who were initially randomized to AQ+NSC who meet protocol defined definition for intervention responsiveness, may get re-randomized to AQ alone to complete months 4 - 6 of the trial.
89665521|NCT03905772|Experimental|Voluntary exercise|The participants will perform 36 voluntary contractions of 20% of maximal voluntary isometrical contraction, 3 times per week for 8 weeks.
89665522|NCT03905772|Experimental|Wide pulse responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.~This group will classified in responder in the acute fase."
89665523|NCT03905772|Experimental|Wide pulse non responder group|"The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.~This group will classified in non responder in the acute fase."
89665524|NCT03905772|Experimental|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
89665525|NCT03898297||Healthy control|60 psychiatrically-healthy subjects will be enrolled as controls may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
89665526|NCT03898297||MDD|30 subjects with major depressive disorder (MDD) may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
89665527|NCT03898297||Bipolar|30 subjects with bipolar disorder may participate in MRI or fMRI, [1H]MRS and/or [13C]MRS, [18F]FPEB and/or [11C]APP311 PET scans, cognitive testing
89665528|NCT03839732||Vascular Calcification Group|Patients with prevalent vascular calcifications will be analysed to verify the intra- and inter-observer reliability of the score of abdominal aorta calcifications
89665529|NCT03820310|Experimental|Experimental group|traditional therapy plus autologous Tcm cellular immunotherapy.
89665530|NCT03820310|No Intervention|control group|traditional therapy alone, such as radiotherapy or chemotherapy.
89665531|NCT03780673|Experimental|Simvastatin 20 mg + Rifaximin 400 mg|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 months
89665532|NCT03780673|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin|Placebo of simvastatin and placebo of rifaximin orally for 12 months
89665533|NCT03769311|Experimental|Pre-Operative Cetuximab Therapy|Two weekly doses of pre-operative cetuximab during the interval between diagnostic HNSCC biopsy and surgery (~14 days), ensuring that no delay in standard of care (SOC) will occur. For dose #1, participants will receive cetuximab 400 mg/m2 via intravenous infusion over 2 hours (maximum infusion rate 10 mg/min) as per the standard of care loading regimen for cetuximab monotherapy. For dose #2, participants will receive cetuximab 250 mg/m2 via intravenous infusion over 1 hour (maximum infusion rate 10 mg/min) as per the standard of care dosing regimen for cetuximab monotherapy.
89665534|NCT03767335|Experimental|MEN1611|MEN1611 + Trastuzumab +/- Fulvestrant
89665535|NCT03745430|Experimental|Ramucirumab+Nab-paclitaxel+Gemcitabine|Nab-paclitaxel and Gemcitabine will be administered on days 1, 8 and 15 every 4 weeks for a maximum of 8 cycles.
89665536|NCT03738566|Active Comparator|Standard Clinical Care Endoscopic Dilation Group|Following standard clinical care consisting of serial endoscopic dilation to achieve an esophageal diameter of at least 10 mm, subjects will undergo repeat upper endoscopy with dilation as needed if their dysphagia relapses which is the current standard of care. A relapse will be considered if a patient developed solid food dysphagia at least once a week.
89048772|NCT05352737||Sec-Meta|patients with early breast cancer developed distant metastasis within 5 years
89048773|NCT05352737||Non-Meta|patients with early breast cancer did not develop distant metastasis within 5 years
89048774|NCT05352737||older|patients with breast cancer older than 70 years old with G8 screening
89665537|NCT03738566|Active Comparator|Esophageal Self-Dilation Therapy (ESDT) Group|Following standard clinical care consisting of serial endoscopic dilation to achieve an esophageal diameter of at least 10 mm, subjects are instructed to perform esophageal self-dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months.
89048775|NCT05352737||pCR|patients with breast cancer reached pCR after neoadjuvant chemotherapy
89665538|NCT03738566|Other|Observational Study Group|Subjects undergo either esophageal self-dilation therapy or continued standard of clinical care base on shared decision making with their esophageal provider.
89665539|NCT03738566|Experimental|Standard Clinical Care Endoscopic Dilation, Then ESDT|Subjects that received standard of clinical care endoscopic dilation who required two endoscopic dilations within 3 months of randomization were considered to have failed standard care and offered cross-over to the self-dilation therapy.
89048776|NCT05352737||non-pCR|patients with breast cancer did not reach pCR after neoadjuvant chemotherapy
89665540|NCT03702816|Experimental|Alzheimer's Disease|"Alzheimer's Disease~GE180 PET Scan"
89665541|NCT03702816|Experimental|Parkinson's Disease|"Parkinson's Disease~GE180 PET Scan"
89665542|NCT03702816|Experimental|Control|"Control Group~GE180 PET Scan"
89665543|NCT03702816|Experimental|Mild Cognitive Impairment|"Mild Cognitive Impairment~GE180 PET Scan"
89665544|NCT03673189|Experimental|Healthy volunteers|Sensors assigned for 3 weeks
89665545|NCT03673189|Experimental|Patients with arythmic disease or peripheral vascular disease|Sensors assigned for 3 weeks
89665546|NCT03671785|Experimental|Active group treated with healthy fecal microbiota|
89665547|NCT03671785|Experimental|Placebo group|
89665548|NCT03666455|Experimental|Acceptance and Commitment Therapy|The intervention consists of eight individual (one-on-one) acceptance and commitment therapy sessions approximately one week apart over a 12-week period.
89665549|NCT03651986||Prospective Cohort|This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.
89665550|NCT03651882|Active Comparator|Oxytocin|
89048777|NCT04641429|Experimental|Qigong|Participants in the experimental group receive Qigong exercise training.
89048778|NCT04641429|Active Comparator|stretching|Participants in the control group receive stretching exercise training.
89048779|NCT04640883|Experimental|Sprints during low-intensity cycling|
89048780|NCT04640883|Active Comparator|Low-intensity cycling|
89048781|NCT04640649|Experimental|Prediction Algorithm|Patients in the test arm will have a screening visit, then will come for two follow-up visits, at 3 months (if the algorithm determines high-risk of conversion within 3 months) and 6 months.
89048782|NCT04640649|No Intervention|Control|Patients in the control arm will have a screening visit, then will come for one follow-up visit, at 6 months (standard care) only.
89048783|NCT05340335|Experimental|Remimazolam|A loading dose of remimazolam is administered for sedation
89048784|NCT04640805|No Intervention|Control group (standard fortification)|Pasteurized Donor Human Milk (PDHM) will be fortified as per unit protocols, at 1 packet of Human Milk Fortifier (Similac) to every 25ml PDHM at a feed volume of 80ml/kg/day
89048785|NCT04640805|Experimental|Intervention group (modified targeted fortification)|Pasteurized Donor Human Milk (PDHM) will be analyzed using the Miris Human Milk Analyzer, and PDHM with a fat content of 3.8g/dL or higher will be selected. Additional protein will be added using liquid protein fortifier (Similac) at 1ml to every 25ml PDHM to give an additional 0.67g/dL protein.
89048786|NCT04640844|Experimental|patients hospitalized|for surgery of the aorta and / or arteries of the lower limbs.
89048787|NCT04640610||Adenoidectomy / tonsillectomy|Children and adults, without SARS-CoV-2 infection, in whom an adenoidectomy and/or tonsillectomy is performed for their care in the centers of the study.
89665551|NCT03651882|Active Comparator|Carbetocin|
89665552|NCT03636932|Active Comparator|N-acetylcysteine (NAC) group|
89665553|NCT03636932|Placebo Comparator|Placebo group|
89665554|NCT03533751|Placebo Comparator|Placebo|Participants received matching placebo to etokimab, administered subcutaneously (SC) every 4 weeks (Q4W) for up to 16 weeks.
89665555|NCT03533751|Experimental|Etokimab 20 mg SC Q4W|Participants received etokimab 20 milligrams (mg) administered SC Q4W for up to 16 weeks.
89665556|NCT03533751|Experimental|Etokimab 300 mg load + 150 mg SC Q8W|Participants received a 300 mg loading dose of etokimab on Day 1 then 150 mg etokimab administered SC every 8 weeks (Q8W) for up to 16 weeks. At Weeks 4 and 12 participants received placebo.
89665557|NCT03533751|Experimental|Etokimab 300 mg load + 150 mg SC Q4W|Participants received a 300 mg loading dose of etokimab on Day 1 then 150 mg etokimab administered SC Q4W for up to 16 weeks.
89665558|NCT03533751|Experimental|Etokimab 600 mg load + 300 mg SC Q4W|Participants received a 600 mg loading dose of etokimab on Day 1 then 300 mg etokimab administered SC Q4W for up to 16 weeks.
89665559|NCT03520933||Embryos undergoing PGT-A / niPGT-A|Embryos from IVF patients between 20 and 44 years of age, undergoing PGT-A for any medical indication, with own oocytes or ovum donation cycles and with single embryo transfer (SET)
89665560|NCT05910541|Experimental|Intervention|Patients will receive standard care plus daily sessions of 30-minute mindful breathing for four consecutive days
89665561|NCT05910541|Sham Comparator|Control|Patients will only receive standard care.
89665562|NCT05910515|No Intervention|Control|Regular debriefing
89665563|NCT05910515|Experimental|Intervention|Structured debriefing in non-technical skills
89665564|NCT05910424|Experimental|Adults with Autism Spectrum Disorder|"Adults with autism spectrum disorder~Aged between 18 and 60 years old~Dental cares and follow-up in Nancy hospital"
89665565|NCT05910385|Active Comparator|laparoscopic|
89665566|NCT05910385|Experimental|vnotes|
89665567|NCT05910372||Fibromyalgia Patients|Patients with primary fibromyalgia diagnosis. May include other chronic pain comorbidities, but the pain associated with those diseases should be less severe than the pain caused by fibromyalgia.
89048788|NCT04640181|Active Comparator|Adaptive Dosing: Enoxaparin|"Low 40mg subcutaneous (SQ) daily, or~Intermediate 40mg SQ q12 hours, or~Therapeutic 1mg/kg SQ q12 hours"
89665568|NCT05910372||Healthy Controls|Volunteers with no clinical history of chronic pain, musculoskeletal or articular disorders.
89665569|NCT05910359|Experimental|Persistent Occiput Posterior Position|transabdominal and transperineal ultrasound by expert sonographers
89048789|NCT04640181|Active Comparator|Adaptive Dosing: Rivaroxaban|"Low 10mg po daily~Intermediate 10mg po daily~Therapeutic 20mg po daily"
89665570|NCT05910359|Active Comparator|Anterior Occiput Position at delivery|transabdominal and transperineal ultrasound by expert sonographers
89665571|NCT05910320|Experimental|Wearable Vital Signs Monitoring Device|
89665572|NCT05910151||reference group A|healthy newborns aged 1-7 days
89665573|NCT05910151||reference group B|healthy children aged 8 days - 7 years
89665574|NCT05910151||reference group C|healthy children aged 8 - 18 years
89665575|NCT05910151||selective group A|children aged 1 day - 7 days suspected with IEM
89665576|NCT05910151||Selective group B|children aged 8 days - 7 years suspected with IEM
89665577|NCT05910151||Selective group C|children aged 8-18 years suspected with IEM
89665578|NCT05910125|Experimental|DAPT group|Receiving dual antiplatelet therapy immediately after randomization (Oral aspirin 100mg+clopidogrel 300mg, Day 1). Participants who show no evidence of intracranial hemorrhage on skull CT 24 hours after randomization will receive oral aspirin 100mg/d (Day 2-90) and clopidogrel 75mg/d (Day 2-21), while those with intracranial hemorrhage on skull CT will not receive any antiplatelet drugs.
89665579|NCT05910125|Active Comparator|IVT group|Receiving intravenous thrombolysis immediately after randomization (Intravenous alteplase, 0.9mg/kg, a maximum dosage of 90mg). Participants who show no evidence of intracranial hemorrhage on skull CT 24 hours after randomization will receive oral aspirin 100mg/d (Day 2-90), while those with intracranial hemorrhage on skull CT will not receive any antiplatelet drugs.
89665580|NCT05910112||Undergoing pleural intervention|Any patient undergoing a pleural procedure (eg thoracocentesis, chest drain, indwelling pleural catheter, pleural biopsies, medical thoracoscopy)
89665581|NCT05910086||patients having an accidental dural puncture during the installation of an epidural anesthesia|"patients having an accidental dural puncture during the installation of an epidural anesthesia will be included.~Analysis datas of medical record."
89048790|NCT04640103||adjuvant therapy|Patients who received immunotherapy in adjuvant treatment stage only
89048791|NCT04640103||neoadjuvant therapy|Patients who received immunotherapy in neoadjuvant treatment stage and achieved R0 resection
89048792|NCT00559455|Experimental|1|
89048793|NCT00559494|Experimental|Minocycline|
89048794|NCT00559494|Placebo Comparator|Placebo|
89048795|NCT00559494|Experimental|SCPP augmentation|
89214353|NCT00892346|Experimental|Single ASCT with Thalidomide maintenance|"Single ASCT followed by Thalidomide maintenance:~patients recieved 4-6 cycles of standard VAD chemotherapy or Thalidomide/dexamethasone as induction therapy~CTX+G-SCF mobilization to collecetd PBSC~Patiens recieved Mel 200 as conditioning followed by Thalidomide 100mg maintenance"
89048796|NCT00559494|Sham Comparator|SCPP control|
89048797|NCT03455621|Placebo Comparator|Pea-size amount of non-F dentifrice|Non-fluoride dentifrice (0 ppm F); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
89048798|NCT03455621|Experimental|0.025 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.025 g
89048799|NCT03455621|Experimental|0.05 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.05 g
89048800|NCT03455621|Experimental|0.1 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.1 g
89048801|NCT03455621|Active Comparator|Pea-size amount of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
89048802|NCT00559533|Experimental|1|
89665582|NCT05910060||before protocol|patients between 5 and 18 years of age consulting the paediatric emergency department for ankle trauma, before protocol implementation.
89665583|NCT05910060||after protocol|patients between 5 and 18 years of age consulting the paediatric emergency department for ankle trauma, after the implementation of the protocol
89665584|NCT05910034|Experimental|Trilaciclib+Envafolimab+Docetaxel|Trilaciclib:240mg/m2 IV d1,within 4h before chemotherapy; Envafolimab:300mg SC d1,Q3W; Docetaxel:75mg/m2 IV d1, Q3W
89665585|NCT05910034|Experimental|Envafolimab+Docetaxel|Envafolimab:300mg SC d1,Q3W; Docetaxel:75mg/m2 IV d1, Q3W
89665586|NCT05910034|Experimental|Docetaxel|Docetaxel: 75mg/m2 IV d1, Q3W
89665587|NCT05909982|Experimental|Ischemic post-conditioning group|Mechanical thrombectomy combined with ischemic post-conditioning
89665588|NCT05909956|Experimental|KT Group|This group will receive Abdominal KT tape (From initial 4 h to 72 h of menstruation). General physio session will also be given to this group.
89665589|NCT05909956|Sham Comparator|ST Group|This group will receive Abdominal KT tape (without strech) from initial 4 h to 72 h of menstruation. General physio session will also be given to this group.
89665590|NCT05909956|Other|CT Group|this group will receive General physical therapy session including Hot pack (3-5min) and General body stretching(stretching of neck & upper trapezius, arm & shoulder girdle, triceps brachii, teres major & minor, quadriceps muscle iliopsoas muscle, adductors muscle, hamstrings muscle) 30-45 sec each, for 7-10 min, (0-4 week) ,45-60sec each, for 10-15 min(4-8week), 15-20 min(8-12week) will be repeated 2 times/day.
89665591|NCT05909943|Experimental|Ruxolitinib|Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
89214354|NCT00892424|Experimental|Sorafenib + RT|
89521933|NCT03425461|Experimental|Arm A (anti-SEMA4D VX15/2503, nivolumab)|ARM A: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 30 minutes every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
89521934|NCT03425461|Experimental|Arm B (anti-SEMA4D VX15/2503, ipilimumab)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 30 minutes every 21 days for courses 1-4, then receive anti-SEMA4D monoclonal antibody VX15/2503 every 28 days for subsequent courses for up to 12 months in the absence of disease progression or unacceptable toxicity.
89521935|NCT05122299|Other|Negative control group|
89521936|NCT05122299|Active Comparator|Positive control group|
89521937|NCT05122299|Experimental|Study group|
89521938|NCT03425383||Test group|Subjects having periapical disease diagnosed clinically and radiographically and free from any other systemic illness. FMD and c-IMT will be determined by ultrasound
89521939|NCT03425383||Control group|Healthy subject. FMD and c-IMT will be determined by ultrasound
89521940|NCT04865601||CRC|Patient affected by any sporadic colorectal cancer
89521941|NCT04865601||FAP|Patients affected by familial adenomatous polyposis coli
89521942|NCT04865601||HNPCC|Patient affected by hereditary non polyposis colorectal cancer
89521943|NCT04865601||Lynch|patient affected by lynch syndrome
89521944|NCT04865601||others|Patients affected by ulcerative colitis, chron disease, diverticulitis and other colon diseases, which represent the control
89521945|NCT03412903||Control group|First observational period: Standard care without an advising pharmacist, 140 patients
89521946|NCT03412903||Implementation group|Second observational period: Standard care with an advising pharmacist, 140 patients
89521947|NCT03412903||Learning success group|Second observational period: Standard care without an advising pharmacist, 30 patients
89521948|NCT04796727||OHCA|300 OHCA admitted directly to the cathlab and alive at discharge during a 2 years period of enrolement.
89521949|NCT02520973|Experimental|Universal screening|All HIV + pregnant women will be asked to give a sputum sample for TB prior to TB symptom screen
89521950|NCT02520973|Active Comparator|Symptom- directed screening|Only symptomatic HIV+ pregnant women will be asked to give a sputum sample for TB
89521951|NCT03411187|Active Comparator|foot-control exhaust group|The foot-control exhaust group used of the Pressure adjustable foot-control method by the way of adjustable Pressure to intermittent exhaust
89521952|NCT03411187|Placebo Comparator|direct exhaust group|direct exhaust group exhaust through the Trocar hole.and without use of the Pressure adjustable foot-control method
89521953|NCT04616079|Experimental|IV Cohort 1|Single intravenous (IV) dose 1 of REGN6490 or matching placebo
89521954|NCT04616079|Experimental|IV Cohort 2|Single IV dose 2 of REGN6490 or matching placebo
89521955|NCT04616079|Experimental|IV Cohort 3|Single IV dose 3 of REGN6490 or matching placebo
89521956|NCT04616079|Experimental|IV Cohort 4|Single IV dose 4 of REGN6490 or matching placebo
89521957|NCT04616079|Experimental|IV Cohort 5|Single IV dose 5 of REGN6490 or matching placebo
89521958|NCT04616079|Experimental|SC Cohort 1|Single subcutaneous (SC) dose 1 of REGN6490 or matching placebo
89521959|NCT04616079|Experimental|SC Cohort 2|Single SC dose 2 of REGN6490 or matching placebo
89521960|NCT04616079|Experimental|SC Cohort 3|Single SC dose 2 of REGN6490 or matching placebo
89521961|NCT03411109||Opioid Only Intrathecal|
89521962|NCT03411109||Opioid + Local Anesthetic Intrathecal|
89521963|NCT05121987|Active Comparator|Erector spinae plane block|
89521964|NCT05121987|Active Comparator|Continuous wound infusion|
89521965|NCT03425227|Experimental|study group / control group|"The subjects belonging to the study group carried out three sessions per week over a 6-week period. Each session involved 20 minutes of activity divided into three parts.~The subjects belonging to the control group continued to lead their daily lives in the course of which they had no physical activity scheduled."
89521966|NCT03425149|Experimental|Treatment Group I|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7
89521967|NCT03425149|Experimental|Treatment Group II|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28
89521968|NCT03425149|Experimental|Treatment Group III|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7
89521969|NCT03425149|Experimental|Treatment Group IV|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28
89521970|NCT03425149|Placebo Comparator|Treatment Group V|0.5 ml Placebo on Day 0, 7 and 28
89521971|NCT05119725||Patients with atrial fibrillation|Patients with previous diagnosis of atrial fibrillation
89521972|NCT05119725||Non-AF patients with high stroke risk|Non-AF patients with high stroke risk
89521973|NCT03412825|Experimental|Nutrition Supplementation|
89521974|NCT03412825|No Intervention|Control|
89521975|NCT01111565|Experimental|Phase B: Single-blind Prospective Treatment Phase|Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the Week 1 (end of Week 1) based upon tolerability profile, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
89521976|NCT01111565|Experimental|Phase B+: Single-blind Phase B Responders|Participants with response (≥50% reduction in depressive symptom severity in HAM-D17 Total Score; or a HAM-D17 Total Score of <14 at Week 8 or a Clinical Global Impression of Improvement (CGI-I) Score of <3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B, for an additional 6 weeks (Up to Week 14), in Phase B+.
89521977|NCT01111565|Experimental|Phase C: Aripiprazole/Escitalopram Combination|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally for 6 weeks (Up to Week 14), in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.
89665592|NCT05909891|Experimental|Experimental Group|"Patient selection will be made according to the planned randomization after examining the inclusion and exclusion criteria.~Introductory Form, Morisky Scale and Fatigue Scale will be applied to the individuals in the experimental group included in the study. The same forms will be applied to the patients included in the control group. Individuals in the control group will be followed up by the hospital routinely.~In addition to the routine follow-ups for the patients in the experimental group, the training material created by the researchers will be individually presented as an average of 35-40 minutes, and a session will be given in the form of mutual question and answer. After the training, a sample booklet, which is the training material, will be given to the patient as a reminder.~Adaptation and fatigue tests will be re-applied at the first control of the patients after the training."
89665593|NCT05909891|No Intervention|Control Group|
89665594|NCT05909852|Experimental|Treatment A: ABP 501-HCF|Participants will be administered a single SC dose of ABP 501-HCF on Day 1.
89665595|NCT05909852|Experimental|Treatment B: ABP 501-LCF|Participants will be administered a single SC dose of ABP 501-LCF on Day 1.
89665596|NCT05909826|Experimental|Weekly carfilzomib-oral cyclophosphamide-dexamethasone|Weekly carfilzomib-oral cyclophosphamide-dexamethasone
89665597|NCT05909813|Experimental|Individualized Piano Instruction (IPI)|Participants will receive six weeks of individualized piano instruction and two weeks follow-up for a total of eight weeks.
89665598|NCT05909787|Experimental|Auto-questionnaire MCH (Montreal Children's Hospital)|Auto-questionnaire MCH (Montreal Children's Hospital)
89665599|NCT05909774|Experimental|Exoskeleton second|"This group first perform tests without Atalante exoskeleton and secondly with Atalante exoskeleton. A second randomization is performed inside each group, with half of the patients first performing walk test with the Continuous walk and then with the Push & Swing walk, and the other half doing the opposite."
89665600|NCT05909774|Active Comparator|Exoskeleton first|"This group first perform tests with Atalante exoskeleton and secondly without Atalante exoskeleton. A second randomization is performed inside each group, with half of the patients first performing walk test with the Continuous walk and then with the Push & Swing walk, and the other half doing the opposite."
89665601|NCT05909748|Experimental|GEMINUS Transcatheter Aortic Valve Implantation system|Clinical follow up for all patients will be performed at 30 days, 6 months, 1, 2, 3, 4 and 5 years post-implantation
89665602|NCT05909670|Experimental|Phase 1 intervention|Families will receive text and telephone support for child behavior and parenting stress issues.
89665603|NCT05909631|Placebo Comparator|250 ml of a placebo|250 ml of a placebo
89665604|NCT05909631|Experimental|beetroot juice (BJ)|250 ml of concentrated beetroot juice
89665605|NCT05909631|Experimental|Mediterranean diet with beet juice (BJ+MeD)|Mediterranean diet with beet juice (BJ+MeD)
89665606|NCT05909631|Experimental|Mediterranean diet alone (MeD)|Mediterranean diet alone (MeD)
89665607|NCT05909579|Experimental|3 month PelvicSense(R) program|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
89665608|NCT05909540||Goel A Type Basilar Invagination|1) ADI>3mm in adults, or ADI>5mm in child.
89665609|NCT05909540||Goel B Type Basilar Invagination|"ADI<3mm in adults, or ADI<5mm in child.~The stabilization in atlantoaxial could can be found.~The tip of odontoid can exceed the Chamberlian's line， but not exceed the Wackenheim's line and Mcrae's line."
89665610|NCT05909475|Placebo Comparator|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
89665611|NCT05909475|Experimental|GKEX|GKEX group. Probiotic capsules contain 10 billion CFU (colony forming units) of GKEX, , 2 caps daily use.
89665612|NCT05909462|Experimental|suprascapular verve block|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine
88995204|NCT05145023||Development of the CARD-SARC (n=20)|"Interviews: 6-20 participants (depending of data saturation) will be recruited using a convenience sampling strategy.~Field-testing: 20 participants using a convenience/consecutive sampling strategy."
89521978|NCT01111565|Experimental|Phase C: Escitalopram Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B for 6 weeks (Up to Week 14), in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
89665613|NCT05909462|Experimental|intraarticular shoulder injection|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine
89665614|NCT05909449|Experimental|research group|provide primary care services to individuals with physical disabilities
89665615|NCT05909436|Experimental|Dose escalation and expansion of GLS-012 monotherapy and combination with GLS-010|
89665616|NCT05909423|Experimental|Treatment arm|Intratumoral flu vaccine treatment Systemic single dose pembrolizumab treatment
89665617|NCT05909410||Patients with Lynch syndrome|Certain genetic diagnosis o fLynch syndrome
89665618|NCT05909410||Healthy patients of reproductive age|
89665619|NCT05909358|Experimental|Candidate vaccine 1|One injection of cAd3 will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
89665620|NCT05909358|Experimental|Candidate vaccine 2|One injection of chAdOx1 will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
89665621|NCT05909358|Experimental|Candidate vaccine 3|One injection of rVSV-SUDV will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
89665622|NCT05909358|Placebo Comparator|Control|One injection of placebo will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
89665623|NCT05909345||Knee Osteoarthritis|
89665624|NCT05909345||Nonspecific Low Back Pain|
89665625|NCT05909319||ACLF|
89665626|NCT05909293|Experimental|Venclexta|"During the consolidation phase, which occurs within 2 months after the completion of consolidation therapy, the BCL-2 inhibitor maintenance treatment will consist of 12 cycles, with each cycle lasting 28 days.~The specific regimen for the Venclexta is as follows:~Venclexta: 400mg/day, orally, from day 1 to day 14 of each cycle."
89665627|NCT05909254|Experimental|Palatally impacted canine exposure using a surgical template|
89665628|NCT05909254|Experimental|Palatally impacted canine exposure using the conventional free-hand method|
89665629|NCT05909215|Active Comparator|Dexmedetomidine 0.5|Dexmedetomidine 0.5 μ/kg diluted in 20 mL normal saline through a syringe pump over 10 minutes followed by general anesthesia.
89665630|NCT05909215|Active Comparator|Dexmedetomidine 0.75|Dexmedetomidine 0.75 μ/kg diluted in 20 mL normal saline through a syringe pump over 10 minutes followed by general anesthesia.
89665631|NCT05909215|Placebo Comparator|Placebo|20 mL of normal saline as an infusion through a syringe pump over 10 minutes followed by induction of general anesthesia.
89665632|NCT05909189|Experimental|ADRD dyads|This is a single-arm study enrolling 60 ADRD community-based dyads.
89665633|NCT05909163||Pakinson's disease without cognitive impairment|"Age 50-90 years~Diagnosis of idiopathic Parkinson's disease (UK Brain Bank criteria) made by a movement disorders specialist~Under the care of a movement disorders specialist for a minimum of 1-year duration~Native monolingual English speaker~Hoehn & Yahr score between 1.5 and 4~Grade 10 education, or higher~Sufficient vision and hearing (aided or unaided) for all experiment tasks~Montreal Cognitive Assessment (or MoCA-converted MMSE score) greater than or equal to 25~No subjective complaints of cognitive difficulty or word finding issues"
89665634|NCT05909163||Pakinson's disease with cognitive impairment|"Age 50-90 years~Diagnosis of idiopathic Parkinson's disease (UK Brain Bank criteria) made by a movement disorders specialist~Under the care of a movement disorders specialist for a minimum of 1-year duration~Native monolingual English speaker~Hoehn & Yahr score between 1.5 and 4~Grade 10 education, or higher~Sufficient vision and hearing (aided or unaided) for all experiment tasks~Montreal Cognitive Assessment (or MoCA-converted MMSE score) greater than or equal to 17~Subjective complaints of cognitive difficulty or word finding issues, without significant impact on activities of daily living"
89665635|NCT05909124||healthy weight people (18.5≤BMI<25)|18.5≤BMI<25
89665636|NCT05909124||obese people (BMI≥30)|BMI≥30
89665637|NCT05909111|Experimental|MRI assessment during radiation therapy course|Patients perform on MRI every week during the 5-weeks treatment
89665638|NCT05909072|Active Comparator|right side of the face|microneedling with tranexamic acid alone on the right side of the face
89665639|NCT05909072|Active Comparator|Left side of the face|microneedling with tranexamic acid combined with hyaluronic acid on the left side
89665640|NCT05908981|Active Comparator|The effects of sandalwood oils on anxiety levels of pediatric|first group sandalwood aromatherapy
89665641|NCT05908981|Active Comparator|The effects of Lavender oils on anxiety levels of pediatric|second group lavender oil
89665642|NCT05908968|Experimental|Drinking ELO water|Drinking 1.5 litres of ELO water daily
89665643|NCT05908942||RF group|32 patients with knee osteoarthritis to undergo radiofrequency treatment of genicular nerves
89665644|NCT05908942||Phenol group|32 patients with knee osteoarthritis to undergo phenol treatment of genicular nerves
89665645|NCT05908929|Experimental|patients treated with SRP and insertion of PRF|
89665646|NCT05908929|Active Comparator|patients treated with SRP|
89665647|NCT05908916|Experimental|Therapeutic arm|AtezoBev with combined radiotherapy
89665648|NCT05908903|Experimental|Experimental Group|Take drinks with active ingredients such as poria and GABA. Drink half an hour before bedtime, 10ml/bag/day, daily.
89665649|NCT05908903|Placebo Comparator|Control product group|Take a control drink that does not contain GABA and poria. Drink half an hour before bedtime, 10ml/bag/day, daily.
89665650|NCT05908890|Experimental|Experimental Denture Adhesive|
89665651|NCT05908890|Active Comparator|Marketed Denture Adhesive|
89521979|NCT01111565|Experimental|Phase C: Aripiprazole Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily for 6 weeks (Up to Week 14), in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any visit, based upon tolerability.
89521980|NCT03412669|Experimental|Counselling|Supporting Addiction Affected Families Effectively is a contextually adapted version of the 5-Step Method, a psychosocial intervention based on the principles of the Stress-Strain-Coping-Support model. The intervention is manualised, and is delivered by lay counsellors over 5 sessions at a weekly basis. The 5 steps (covered in the 5 steps) include: 1) Exploring stresses and strains, 2) Providing relevant information, 3) Exploring and discussing coping behaviours, 4) Exploring and enhancing social support, and 5) Exploring additional needs, and further sources of help. The intervention is delivered in settings based on convenience of the participant: which might be a place outside the home (e.g. field office, neighbour's home), or the participant's home.
89665652|NCT05908877||Overweight and Obese Children|Children diagnosed as overweight or obese, defined by the Centers for Disease Control and Prevention (CDC) as a BMI between the 85th and 95th percentile, or above the 95th percentile for the same age and sex, respectively.
89665653|NCT05908864||IV Magnesium Sulfate|
89665654|NCT05908864||Inhaled Magnesium Sulfate|
89665655|NCT05908864||Control group|
89665656|NCT05908851|No Intervention|Regional Brachial Plexus Blockade|Ultrasound guided brachial plexus blocade with 10 ml of 0.5% ropivacaine using a high frequency linear array transducer.
89665657|NCT05908851|Experimental|Local Infiltration Anesthesia|High volume local infiltration anesthesia with 100 mL of 0.9% normal saline (57ml), 0.5% ropivacaine (40 ml), 10 mg morphine (10 mg/ml), 0.1 mg of epinephrine (0.1 mg/ml), and 30 mg of ketorolac (30 mg/ml) divided equally into a 20 ml five-zone field infiltration into the suprascapular notch/posterior capsule (suprascapular and axillary nerves), coracobrachialis muscle, anterior deltoid muscle, superior pectoralis major muscle, and skin incision at the conclusion of the procedure by the treating surgeon.
89665658|NCT05908838|Active Comparator|combination chemotherapy with Modified Banxia Xiexin Decoction|146 patients with gastric cancer were randomly divided into a treatment group of 73 cases and a control group of 73 cases. The treatment group received combination chemotherapy with Modified Banxia Xiexin Decoction
89665659|NCT05908838|Placebo Comparator|combination chemotherapy with Placebo granules|The control group received combination chemotherapy with Placebo granules.
89665660|NCT05908721|Experimental|CM310|Subcutaneous injection
89665661|NCT05908682||Study Cohort|Subjects who have been treated with Brexafemme (Ibrexafungerp) at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving the last dose of Brexafemme.
89665662|NCT05908643|Experimental|Treatment with pTTL|"A single dose of pTTL will be administered after pre-conditioning chemotherapy with Fludarabine (30 mg/m(2) body surface area) x 3 and Cyclophosphamide (300 mg/m(2) body surface area) x 3 on days -7 to -5. pTTL will usually be infused on day 1 (5 days after last chemotherapy) with the option of administering it on day -3 if judged preferable based on the T cell expansion kinetics during pTTL production. pTTL is administered as a fresh product directly after production.~Dose escalation will be applied. Cohort 1 (1 patient): 1 million (with an accepted range of down to -5%) viable cells per kg body weight~Cohort 2 (3 patients): 2.5 million (down to -5%) viable cells per kg body weight~Cohort 3 (3 patients): 5 million (down to -5%) viable cells per kg body weight~Cohort 4 (remaining patients): up to 1 billion viable cells"
89665663|NCT05908617|No Intervention|Paper Discharge Instruction|Patient will be given paper discharge instructions
89665664|NCT05908617|Experimental|Video Discharge Instructions|Patient will be given Video discharge instructions
89665665|NCT05908604|Active Comparator|Intervention group|In the IG, home care professionals load medications inside the robot, and it enabled older home care clients to carry out medication management by themselves.
89665666|NCT05908604|Sham Comparator|Control group|In the CG, home care professionals manually dispensed medications to doset and administrating medications during their home visits.
89665667|NCT05907317|Experimental|Cerebral oximetry + usual care|
89665668|NCT05907317|Other|Usual care|The control group will receive mechanical ventilation without access to cerebral oximetry and the SafeBoosC treatment guideline. If the newborn is cared for outside the neonatal unit at any time, e.g. during surgery, cerebral oximetry may or may not be used, as decided by the responsible physician there
89665669|NCT05907278|Experimental|Intervention|The ACE Program is a culturally inclusive, 4-H after school club where youth meet once a week for 12 weeks virtually. They also receive groceries to make a meal 1 day a week.
89665670|NCT05906108|Experimental|Intervention group|WeChat-based self-initiated learning, personalized and interactive behavioural support
89665671|NCT05906108|Active Comparator|Control group|General health information
89665672|NCT05904600|Experimental|Respiratory muscle training|Respiratory muscle training with the Orygen-Dual Valve (Forumed S.L. ESP) and an initial load of 30% of their maximum inspiratory and expiratory pressures.
89665673|NCT05904600|Sham Comparator|Control group|Simulated training with the Orygen-Dual Valve (Forumed S.L. ESP), without load.
89665674|NCT05904587|No Intervention|open mouth debonding|debonding of the bracket is done while the mouth of the patient is open and without any support to the teeth during the debonding procedure
88995205|NCT05145023||Validation of the CARD-SARC (n=100)|The CS-specialist centres (Barts Health NHS Trust and Royal Papworth Hospital NHS Foundation Trust) have a cohort of 60-70 potential candidates in each site. The estimated sample size for the Pilot-testing is 100 study participants, considering previous sarcoidosis studies including PROMs, with less than 10% population declining participation or failing to complete their questionnaires.
88995206|NCT05131581|No Intervention|Group 1|Standard care for cervical screening test (CST) at the midwifery clinic (control group)
88995207|NCT05131581|Experimental|Group 2|Standard care for CST at the youth clinic (intervention group 1)
88995208|NCT05131581|Experimental|Group 3|Standard care for CST at the youth clinic with extra time allotted (intervention group 2)
88995209|NCT05131581|Experimental|Group 4|Standard care for CST at the youth clinic with extra time allotted and the RLP-information (intervention group 3)
88995210|NCT05131386|Experimental|Multicohort trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas|"Premedication~4 mg oral dexamethasone 24h and 12h before trabectedin administration, 20 mg IV dexamethasone 30 minutes before treatment. Ondansetron or analogue will also be given prior to trabectedin.~Medication~Trabectedin at 1.5 mg/m2 24-h IV CI along with radiation therapy (30 Gy, 3 Gy/day for 10 days for non-extremity location and 45 Gy, 1.8 Gy/day for 25 days for extremity location of target lesion(s)), starting within 1 hour after the first trabectedin infusion withdrawal (day 2)) will be given every 3 weeks up to progression or intolerance."
88995211|NCT05129332|Experimental|Vaginal Dilator Intervention|Patients assigned to the vaginal dilator group will be provided the device, vaginal moisturizer, an adherence calendar, and standardized verbal and written instructions from a trained health professional to apply the moisturizer and use the dilator for 15 minutes daily. Standard medical grade vaginal dilators and pure Vitamin E oil will be provided for each study participant. They have the option of purchasing a dilator and/or moisturizer of a similar nature if they choose to.
88995212|NCT05129332|Other|Control (Vaginal Moisturizer Only)|Patients assigned to vaginal moisturizer alone will receive pure Vitamin E oil and similar standardized instructions on daily use and an adherence calendar. They will apply a dime-sized amount of Vitamin E oil every day. They have the option of purchasing their own moisturizer if they choose to.
88995213|NCT05118282|Experimental|Combined coping skills + asthma management arm|The combined coping skills + asthma management arm is a family-based coping skills + asthma management intervention that is bilingual and culturally relevant for Latino families. This program is manualized with video-guided and interactive content to improve coping with stress and asthma management behaviors for both children and their parents. Coping strategies taught include primary and secondary control coping. Asthma management content is interactive and culturally tailored.
88995214|NCT05118282|Active Comparator|Standard asthma management arm|The standard asthma management (AM) arm is an asthma management intervention covering standard asthma self-management content (e.g., symptom recognition, self-monitoring). AM is manualized and is matched in length, time, and number of sessions to the experimental arm.
88995215|NCT05111262|Active Comparator|As needed inhaled corticosteroid and long-acting beta-agonist|Symptom-driven ICS/LABA treatment strategy
88995216|NCT05111262|No Intervention|Standard therapy: maintenance inhaled corticosteroid and as needed short-acting beta-agonist|Continue maintenance ICS and SABA therapy
88995217|NCT05098431|Experimental|Experimental Arm|Receive Quadriceps MEPs during procedure
89665675|NCT05904587|Experimental|biting on soft elastomeric wafer|debonding of the bracket is done while the patient is biting on the preshaped soft elastomeric wafer (cut into a horseshoe shape) during the debonding procedure
89665676|NCT05904587|Experimental|biting on cotton roll|debonding of the bracket is done while the patient is biting on a cotton roll during the debonding procedure
89665677|NCT05904587|Experimental|biting on the mouthpiece of vibrational device|debonding of the bracket is done while the patient is biting on the mouthpiece of the vibrational device (SureSmile® VPro™) delivering vibrations to the dentition during the debonding procedure
89665678|NCT05904574||A|The patients who underwent tru-cut biopsy with the coaxial technique and applied an autologous blood patch.
89665679|NCT05904574||B|The patients whose true-cut biopsy with coaxial technique was taken and autologous blood patch was not applied.
89665680|NCT05904535||All patients|Cerebrospinal fluid will be collected from all study subjects and analyzed with sequencing techniques, Optotracing, and REDOX. All methods will compared with CSF bacterial cultures which is the current golden standard.
89665681|NCT05904457|Experimental|1|
89665682|NCT05904444|Experimental|daily training|Patients underwent microperimetric training on everyday
89665683|NCT05904444|Experimental|alternately training|Patients underwent microperimetric training on every other day
89665684|NCT05904366|Other|Patients|Participants will undergo an MRI with MR Spectroscopy (MRS) and MR Elastography (MRE) measurements
89665685|NCT05904366|Other|Healthy controls|Participants will undergo an MRI with MR Spectroscopy (MRS) and MR Elastography (MRE) measurements
89665686|NCT05904340|Experimental|Test Group|The percutaneous nerve discharger (model GM350PP) of APEX low-frequency therapeutic device is used for transcutaneous electrical nerve stimulation of acupoints. The approved number of medical equipment license for this product is: Department of Health Medical Device No. 006696, and the use mode of intervention measures is P5 Disperse -Dense Modulation mode (discharge frequency 2Hz/wave width 260μs/duration 3sec and discharge frequency 100 Hz/wavewidth 140μs/continuation 3sec alternately, maximum discharge volume 80mA), stimulate Neiguan (PC6), Hegu (LI4), Sanyinjiao (SP6) and Taichong (LR3) points, twice a day, 30 minutes each time, for 4 weeks, the intensity is divided into 10-25 mA for hands and 25-40 mA for feet, depending on personal tolerance Adjust flexibly within the interval, and evaluate the severity of neuropathy symptoms of the test every week.
89665687|NCT05904340|No Intervention|Control Group|4 weeks of usual care, including prescribe vitamin B6 or B12 and massage therapy. Assessing the severity of neuropathy symptoms every week.
89665688|NCT05904301||Systemic autoimmune and autoinflammatory diseases|
89665689|NCT05904275|Experimental|Group RD|Group RD - caudal epidural injection with 0.25% ropivacaine 20 ml containing dexamethasone 8 mg (0.5% Ropivacaine 10 ml + 8 mg/2 ml Dexamethasone + 8 ml NS)
89665690|NCT05904275|Experimental|Group R|Group R- caudal epidural injection with 0.25% ropivacaine 20 ml
89665691|NCT05904249|Experimental|Internet Based Synchronized Telerehabilitation Group (Group 1)|The treatments of the participants who meet the inclusion criteria in the study will be conducted remotely via instant video communication. The Specialist Physiotherapist will apply the necessary exercises, verbal guidance or repetition of the movements shown, according to the patient's condition, synchronized via instant video and audio calls (Whatsapp or Zoom).
89665692|NCT05904249|Experimental|Face-to-Face Rehabilitation Group (Group 2)|The treatments of the participants that meet the inclusion criteria of the study will be administered by Specialist Physiotherapist. The progress of the patients will be regularly followed up on a weekly basis, and treatments will be applied in accordance with the program in rehabilitation.
89665693|NCT05904197|Other|School age children with nephrotic syndrome and their Caregivers|"Children with NS will be expected to have higher knowledge scores about nephrotic syndrome post-intervention than pre-intervention.~Children with NS will be expected to have higher scores in healthcare-related practices including higher medication adherence post-intervention than pre-intervention.~Children with NS will be expected to have lower psychosocial problems post-intervention than pre-intervention.~Caregivers of children with NS will be expected to have higher knowledge scores about nephrotic syndrome post-intervention than pre-intervention.~Caregivers of children with NS will be expected to have higher scores in health care-related practices post-intervention than pre-intervention."
89665694|NCT05904184|Active Comparator|Epoxy resin-based sealers (ERS)|After root canal preparation, canal obturation was performed with Epoxy resin-based sealers (ERS)
89665695|NCT05904184|Active Comparator|calcium silicate-based sealers (CSS)|After root canal preparation, canal obturation was performed with Calcium silicate-based sealers (CSS)
89665696|NCT05904158|Experimental|PRF Group|Patients in this group, received PRF application during the standard ACL reconstruction surgery
88995218|NCT05091242|Experimental|Clonidine|Participants receive Clonidine solution for injection, 3 microg/kg, administered intravenously once over 2 minutes approximately 20 minutes before end of procedure. Injection is administered from a dilated solution of Clonidine 15 microg/mL (ie., 0.2 mL/kg).
88995219|NCT05091242|Placebo Comparator|Placebo|Participants receive Sodium Chloride isotonic (9mg/mL) solution for injection administered intravenously once over 2 minutes approximately 20 minutes before end of procedure. Dosage is administered according to weight: 0.2 mL/kg.
88995220|NCT05085535|Active Comparator|Exercise|to which the treatment of therapeutic exercise and pain education will be applied,
89665697|NCT05904158|Active Comparator|Control Group|Patients in this group received a standard ACL reconstruction surgery without any other intervention.
89665698|NCT05904119|Active Comparator|Control group|Lomustine alone
89665699|NCT05904119|Experimental|Experimental group|Lomustine plus reirradiation
89665700|NCT05904067|Experimental|Recipient of COVID-19 Convalescent Plasma (CCP) Transfusion|Transfusion of COVID-19 convalescent plasma to participants The experimental group (CCP group): 200 ml of CCP at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.
89665701|NCT05904067|No Intervention|Recipient without COVID-19 Convalescent Plasma (CCP) Transfusion|Control group (supportive therapy): patients were routinely given oral ursodeoxycholic acid for +14 days after transplantation.
89665702|NCT05904015|Experimental|Hypofractionated radiotherapy group|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin: Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 45Gy at a 95% PTV dose, with a single split dose of 3Gy, once a day, 5 times a week, for a total of 15 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
89665703|NCT05904015|Experimental|Conventional Radiotherapy|Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin:Cisplatin:75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 60Gy at a 95% PTV dose, with a single split dose of 2Gy, once per day, 5 times per week, for a total of 30 times Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable.
89665704|NCT05904002|Experimental|pulmicort inhaler|Group (A) consists of 30 patients. They will receive their inhaled glucocorticoids (pulmicort inhaler) on needs.
89665705|NCT05904002|Experimental|incentive spirometer|Group (B) consists of 30 patients. They will receive the same medical treatment and incentive spirometer program 3 days per week for six weeks.
89665706|NCT05903963|Active Comparator|Midazolam group|
89665707|NCT05903963|Active Comparator|dexmedetomidine group|
89665708|NCT05903937|Experimental|Autologous tumor infiltrating lymphocytes (TIL)|
89665709|NCT05903898|Experimental|Patients enrolled to a primary stroke center with access to AI-software image processing tool|Patients enrolled to a primary stroke center with access to AI-software image processing tool to aid the radiologist in LVO and MeVO detection.
89665710|NCT05903898|No Intervention|Patients enrolled to a primary stroke center without access to AI-software image processing tool|Patients enrolled to a primary stroke center without access to AI-software image processing tool to aid the radiologist in LVO and MeVO detection (standard care).
89665711|NCT05903872|Experimental|aromatherapy massage group|For three days, twice a day (15 minutes each), aromatherapy massage was applied with a mixture of lavender, fennel and frankincense essential oils in almond oil as a carrier oil.
89665712|NCT05903872|Active Comparator|back massage group|For three days, twice a day (15 minutes each), back massage was applied using only 1 tablespoon of almond oil (a carrier oil) in order to evaluate the effect of essential oils.
89665713|NCT05903846|Experimental|Oketani massage group|According to the Ministry of Health, the follow-up period for mothers after cesarean section in Turkey is 48 hours. After the mothers in the massage group were taken to the service, oketani massage was applied three times a day for an average of 15-20 minutes, starting before breastfeeding. Massage was applied to the Oketani massage group by a midwife working in the clinic. Before the mothers were discharged, the breast fullness and breastfeeding status of the mothers were evaluated using the breast engorgement assessment scale and the LATCH breastfeeding diagnostic scale.
89665714|NCT05903846|No Intervention|Control group|No intervention was made in the control group and routine follow-up of mothers and babies will be performed after cesarean section. No intervention was made regarding the breastfeeding process of the mothers, other than the breastfeeding counseling given by the breastfeeding consultant according to the hospital protocol. Before the mothers were discharged, the breast fullness and breastfeeding status of the mothers were evaluated using the breast fengorgement assessment scale and the LATCH breastfeeding diagnostic scale.
89665715|NCT05903833|Experimental|Treatment allocation|Administration of pembrolizumab 400 mg Q6W in combination with lenvatinib 20 mg QD
89665716|NCT05903755|Experimental|speed dependent treadmill training on moderate speed|speed dependent treadmill training on moderate speed along with strengthening, stretching and range of motion exercises.
89665717|NCT05903755|Active Comparator|speed dependent treadmill training on slow speed|Speed dependent treadmill training on slow speed along with physiotherapy.
89665718|NCT05903742||Hepatitis delta cohort|hepatitis delta patients aged ≥18 years
89665719|NCT05903716||Severe acne vulgaris|40 female patients aged 14-20 years, who were diagnosed with severe to moderate acne bulgaris and will be treated with isotretinoin.
89665720|NCT05903716||Healthy control|40 female patients aged 14-20 years
88995221|NCT05085535|Experimental|Manual Therapy|to which the same treatment as the control group will be applied, adding manual therapy sessions based on musculoskeletal rhythmic mobilizations.
89665721|NCT05903703|Experimental|Canagliflozin and Gemcitabine|
89665722|NCT05903703|Active Comparator|standard cisplatin|
89665723|NCT05903690|Experimental|RAG-17|Doses of RAG-17 will range from a minimum of 60 mg to the maximum tolerated dose (MTD). Dosing once every two weeks, starting from 60 mg, with dose escalation. After reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months.
89665724|NCT05903677||Adults undergoing cardiac surgery without preoperative renal affection|Detect the preoperative magnesium levels in adults undergoing cardiac surgery without preoperative renal affection and follow up if they developed postoperative acute kidney injury or not.
89665725|NCT05903638|No Intervention|Control|
88995222|NCT05077865|Experimental|Cohort 1 - Active|6 subjects, randomized to receive 150mg MYMD1 (Isomyosamine), administered as one 150mg capsule on Day 1.
89665726|NCT05903638|Experimental|Virtual Mindfulness-Based Stress Reduction (MBSR) program|
89665727|NCT05903599|Experimental|Group A|anodal Transcranial direct current stimulation with saline soaked sponges will be used on electrodes, for 20 mins in addition to the 60 mins of conventional treatment.
89665728|NCT05903599|Sham Comparator|Group B|A sham stimulation will be given. It will be comprised 20 min of sham TDCS followed by 60 mins of conventional treatment for postural stability in sub-acute stroke
89665729|NCT05903495|Experimental|DBS-ON|Titration will be based on stimulation parameters used in previous studies examining the role of DBS of the NAc in the treatment o OCD and depression as well as the parameters utilized in the initial pilot study conducted by the team.
89665730|NCT05903495|Sham Comparator|DBS-OFF|"For participants randomized to the DBS-OFF condition, titration sessions will be conducted identically to the DBS-ON arm, the only difference is that no stimulation is delivered and therefore, no actual adjustments made"
89665731|NCT05903456|Experimental|TACE +lenvatinib+Icaritin soft capsules|Trial drug Lenvatinib, 8mg (2 tablets for patients weighing less than 60kg), or 12mg (3 tablets for patients weighing more than 60kg), once daily. Icariin Soft Capsules 1200 mg/d (6 tablets in two doses) should be swallowed with warm water within 30 minutes after meal. Take lenvatinib and Icaritin soft capsules 3 to 5 days after TACE. Until the disease progresses or the patient becomes intolerant.
89665732|NCT05903443||BD group|All cases met the (brain death) BD clinical evaluation criteria, which were as follows: the cause of coma was known; exclusion of reversible coma; deep coma, Glasgow coma scale (GCS) = 2T; absence of five brain stem reflexes (pupillary light reflex, corneal reflex, oculocephalogyric reflex, oculovestibular reflex, and cough reflex); and no spontaneous respiration. Furthermore, according to whether the apnea test (AT) data were missing (implemented or completed), the patients were divided into the BD1 group (no AT missing group) and BD2 group (AT missing group).
89665733|NCT05903443||non-BD group|All cases were from BDQCHs and fulfilled the criteria for coma (GCS of 3-5 points), but did not meet the clinical criteria for BD, such as retaining the brainstem reflex or having spontaneous respiration. For coma cases, all assessment items, specifications of technical operations, assessment steps, and evaluators were conducted in accordance with the requirements for BDD. Cases with coma were then submitted to the BQCC/NHC quality control system.
89665734|NCT05903404||Target Population|The target population includes individuals diagnosed with PCOS by a healthcare provider, self-diagnosed with PCOS, or who are exhibiting PCOS Symptoms and willing to sign the consent.
89665735|NCT05903404||Control Population|The control population includes people born biologically female who have not been diagnosed with PCOS and who also do not have symptoms of PCOS.
89665736|NCT05903365||Patient with Fanconi disease|
89665737|NCT05903326||traditional treatment group|patients receiving bilateral myringotomy tube placement with the use of midazolam and intraoperative ketorolac
89665738|NCT05903326||New standard of care|patients receiving bilateral myringotomy tube placement with the use of dexmedetomidine alone
89665739|NCT05903248||Amateur American Football Team|
89665740|NCT05903222||Posterior Pericardiotomy|All patients who were randomized to receive posterior pericardiotomy (intervention) in the original PALACS trial.
89665741|NCT05903222||No Posterior Pericardiotomy (control)|All patients who were randomized to receive no intervention/no posterior pericardiotomy in the original PALACS trial
89665742|NCT05903144|Experimental|Study group|they received manual diaphragm release with conventional breathing exercises and prone positioning in addition to their prescribed medications.
89665743|NCT05903144|Active Comparator|Control group|they received conventional breathing exercises and prone positioning alone in addition to their prescribed medications.
89665744|NCT05903079|Placebo Comparator|Respondres placebo effect|"Braço: Comparador de placebo: responde ao efeito placebo Intervenção: 'Estimulação Transcraniana por Corrente Contínua - tDCS~Os pacientes receberão tratamento de estimulação tDCS córtex pré-frontal dorso lateral De acordo com o sistema 10-20 EEG, o ânodo será colocado no F3 esquerdo e o cátodo no F4 contralateral.~A estimulação placebo utiliza uma corrente de 2 miliamperes durante os primeiros minutos, nos 10 min e nos 19 minutos."
89665745|NCT05903079|Active Comparator|No Respondres placebo effect|"Braço: Comparador de placebo: responde ao efeito placebo Intervenção: 'Estimulação Transcraniana por Corrente Contínua - tDCS~Os pacientes receberão tratamento de estimulação tDCS córtex pré-frontal dorso lateral De acordo com o sistema 10-20 EEG, o ânodo será colocado no F3 esquerdo e o cátodo no F4 contralateral.~A estimulação placebo utiliza uma corrente de 2 miliamperes durante os primeiros minutos, nos 10 min e nos 19 minutos"
88995223|NCT05077865|Placebo Comparator|Cohort 1 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as one capsule matching the 150mg MYMD1 capsule in appearance.
88995224|NCT05077865|Experimental|Cohort 2 - Active|6 subjects, randomized to receive 300mg MYMD1 (Isomyosamine), administered as two 150mg capsules on Day 1.
88995225|NCT05077865|Placebo Comparator|Cohort 2 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as two capsules matching the 150mg MYMD1 capsules in appearance.
88995226|NCT05077865|Experimental|Cohort 3 - Active|6 subjects, randomized to receive 450mg MYMD1 (Isomyosamine), administered as three 150mg capsules on Day 1.
88995227|NCT05077865|Placebo Comparator|Cohort 3 - Placebo|2 subjects, randomized to receive placebo, administered on Day 1, as three capsules matching the 150mg MYMD1 capsules in appearance.
88995228|NCT05077865|Experimental|Cohort 4 - Active|6 subjects, randomized to receive 600mg MYMD1 (Isomyosamine), administered as four 150mg capsules each on Days 1, 2, 3, 4, and 5.
88995229|NCT05077865|Placebo Comparator|Cohort 4 - Placebo|2 subjects, randomized to receive placebo, administered on Days 1, 2, 3, 4, and 5 as four capsules each, matching the 150mg MYMD1 capsules in appearance.
88995230|NCT05060497||Covid patients|Participants who were treated in hospital with laboratory diagnosed Covid-19 requiring high flow oxygen, non invasive ventilation or intubation and have now recovered. They will be recruited 5-7 months post discharge from their local hospital Trust
88995231|NCT05060497||Healthy control volunteers|Participants who are otherwise healthy, who have not had Covid-19 infection and are age, gender, BMI and ethnicity matched to patients
88995232|NCT05052138|Experimental|Tactile massage|Tactile massage 1 will receivetwo 15-min tactile massages (hand massage) per week for 4 weeks
88995233|NCT05052138|No Intervention|comparison group|The comparison group will receive regular care and activities.
88995234|NCT05045976|Experimental|Experimental group|The experimental group will receive the web-based interactive self-management support intervention.
88995235|NCT05045976|No Intervention|Control group|The control group will receive usual care and regular patients education.
88995236|NCT05032859|Experimental|tapinarof cream|tapinarof cream, 1%, applied topically once daily
89665746|NCT05902975|Experimental|Fiber reinforced composite space maintainer|12 children received fiber reinforced composite (FRC) space maintainer without silver nanoparticle.
88995237|NCT05032859|Placebo Comparator|vehicle cream|vehicle cream, applied topically once daily
88995238|NCT05027516|Active Comparator|Rocephine®|ceftriaxone 1g + lidocaine 35mg; intramuscular injection
88995239|NCT05027516|Active Comparator|Rocephine® + Azithromycin|ceftriaxone 1g + lidocaine 35mg intramuscular injection + azithromycin 2g orally
88995241|NCT04975789|No Intervention|Usual Care Control|Standard of Care
89665747|NCT05902975|Experimental|Fiber reinforced space maintainer with silver nano particles|12 children received fiber reinforced composite (FRC) space maintainers modified with silver nanoparticles.
89665748|NCT05902936|Experimental|Control group|After control of bleeding in teeth allocated to the control group i-PRF is to be injected first. The i-PRF will be injected into the root canal to a level 3 mm below the cementoenamel junction (CEJ) then a layer of premixed bioceramic putty is to be added for coronal sealing.
89665749|NCT05902936|Active Comparator|Intervention group|After control of bleeding in teeth allocated to the intervention group, i-PRF is to be mixed with Nano bioactive glass (Nano-BAG) powder to a putty consistency and injected into the root canal to a level 3 mm below the cementoenamel junction (CEJ), then a layer of premixed bioceramic putty is to be added for coronal sealing.
89665750|NCT05902923|Other|intervention|All patients in the study will undergo same procedure. The implanted devices can be one of more of the study devices.
89665751|NCT05902871|Experimental|DSLT|Device study assessing safety and effectiveness of DSLT in Chinese Han participants
89665752|NCT05902858|Active Comparator|Control Group|Conventional intubation with hyperangulated videolaryngoscope
89665753|NCT05902858|Experimental|Provu TM video stylet + hyperangulated videolaryngoscope|Intubation ProVu TM video stylet combined with hyperangulated videolaryngoscope
89665754|NCT05902858|Experimental|Provu TM video stylet + Macintosh laryngoscope|Intubation ProVu TM video stylet combined with standard Macintosh laryngoscope
89665755|NCT05902845|Experimental|RD13-02 cell infusion|drugs use generic name : RD13-02 CAR-T cell injection; dosage form : Cell injection dosage : 2×10^8 CAR+ T cells frequency : Once
89665756|NCT05902832|Experimental|Experimental group - Autistic children|"60 7-10-years-old autistic children, from special education classes integrated in regular schools.~this group will receive EmotiPlay's intervention in the curriculum."
89665757|NCT05902832|No Intervention|Control group- Autistic children|"60 7-10-years-old autistic children, from special education classes integrated in regular schools.~this group will be wait-listed and receive treatment as usual."
89665758|NCT05902832|No Intervention|Control group-Neurotypical|30 6-10-years-old children, from regular education match in cognitive and linguistic abilities.
89665759|NCT05902793|Experimental|Investigational device: V.A.C. VERAFLO™ Dressing Kit|NPWT consists in applying topical sub-atmospheric pressure to a wound that is covered with V.A.C. VERAFLO™ Dressing, sealed with drape and connected by a tube to a suction pump and drainage collection system. Instillation and dwell of a topical wound solution allows thorough coverage of the wound bed, thereby cleansing the wound. The topical wound solution that is allowed to dwell over the wound bed also has the potential to dilute and solubilize infectious materials, devitalized tissue and slough. Soaking the dressing with solution prior to removal, thus promoting granulation tissue formation.
89665760|NCT05902793|Active Comparator|Dressing Name: Negative pressure wound drainage material|Nowadays, there is no approved dressing with solution instillation namely the NPWTi-d therapy in China market. So, a NPWT therapy will be selected in the trial. A Negative pressure wound drainage material manufactured by Guangdong Shuangling Pharmaceutical Co., Ltd. is selected as the control group treatment device, which can apply the NPWT therapy with wall suction. This control device is widely used in clinical institutions in China to deliver NPWT.
89665761|NCT05902728|Experimental|HLX208 in the fast state|HLX208 900mg in the fast state
89665762|NCT05902728|Experimental|HLX208 in the fed state|HLX208 900mg in the fed state
89665763|NCT05902728|Experimental|HLX208 + Itraconazole group|HLX208 + Itraconazole group
89665764|NCT05902728|Experimental|HLX208 + rifampicin group|HLX208 + rifampicin group
89665765|NCT05902702|Experimental|Nebulized isotonic saline|5 ml of isotonic saline is administered through a nebulizer with a flow of 10 l oxygen/min
89665766|NCT05902702|Experimental|Nasal irrigation with isotonic saline|0.5-2 ml isotonic saline in each nostril administered as nasal drops
89665767|NCT05902702|No Intervention|No treatment with saline|These children will not receive any treatment with isotonic saline, but superficial suctioning of nasal secretions as needed (as part of standard care).
89665768|NCT05902676||no anticholinergic burden|Patients with a score of 0 were considered to have not used anticholinergic medications. Short-term use of medications, daily dosages of medications, and topical, ophthalmic, otologic, or inhalation medications were excluded from scoring.
89665769|NCT05902676||anticholinergic burden|Patients with a score of 1 or higher were considered to have used anticholinergic medication. Short-term use of medications, daily dosages of medications, and topical, ophthalmic, otologic, or inhalation medications were excluded from scoring.
89665770|NCT05902650||Group 1|diabetic patients with no diabetic retinopathy
89665771|NCT05902650||Group 2|diabetic patients with mild nonproliferative diabetic retinopathy
89665772|NCT05902650||Group 3|diabetic patients with moderate and severe nonproliferative diabetic retinopathy
89665773|NCT05902650||Group 4|diabetic patients with proliferative diabetic retinopathy
89665774|NCT05902637|Active Comparator|Prostate Mapping Used|Those patients' Multiparametric Prostate Magnetic Resonance (MPMR) imaging's have been assessed by a genitourinary radiologist to guide the surgeon who performs cognitive prostate biopsy
89665775|NCT05902637|Sham Comparator|Prostate Mapping not Used|Those patients' Multiparametric Prostate Magnetic Resonance (MPMR) imaging's have not been assessed by a genitourinary radiologist to guide the surgeon who performs cognitive prostate biopsy. Surgeon assesses the Multiparametric Prostate Magnetic Resonance (MPMR) imaging's by him/herself
89665776|NCT05902598|Experimental|VSA001 25 mg|VSA001 25 mg every 3 months
89665777|NCT05902598|Placebo Comparator|VSA001 25 mg matching placebo|VSA001 25 mg matching placebo，every 3 months
89665778|NCT05902598|Experimental|VSA001 50 mg|VSA001 50 mg every 3 months
89665779|NCT05902598|Placebo Comparator|VSA001 50 mg matching placebo|VSA001 50 mg matching placebo，every 3 months
89665780|NCT05902585|No Intervention|Usual care|In this arm, the analysis will be done in the usual way (for example, distracting with questions).
89665781|NCT05902585|Active Comparator|Virtual reality|In this arm, the analysis will be done while the children use virtual reality.
89665782|NCT05902572||HIV treatment survey participants|HIV treatment patients eligible to be enrolled in the patient survey
89665783|NCT05902572||Provider survey participants|HIV treatment providers eligible to be enrolled in the provider survey
88995242|NCT04975789|Experimental|InfoViz Intervention|Pain information visualization (InfoViz) tool, Trained interpreters will use the InfoViz tool twice, before and during the clinical encounter
88995243|NCT04957953||Pregnant Women Vaccinated against Covid-19|Woman over 18 years of age who has received at least one Covid-19 vaccine during her pregnancy, regardless of the trimester of pregnancy.
88995244|NCT04947124|Experimental|1% QLS-101|dosed once a day for 14 days as either first or second dosing period per randomization
88995245|NCT04947124|Experimental|2% QLS-101|dosed once a day for 14 as either first or second dosing period per randomization
89214355|NCT02541032|Active Comparator|Intensive Dental Treatment|Patients will undergo up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm. All patients will be reexamined at 3, 6 and 9 months for safety checks. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention.
89521981|NCT03412669|Active Comparator|Enhanced Usual Care|In the study setting, usual care for affected family members is no care at all, as detection rates of stress/strain in affected family members are extremely low. Hence, Enhanced Usual Care for the control group consists of a minimal intervention, namely a leaflet. The leaflet focuses on the burden that affected family members experience in relation to a relative who drinks alcohol, and on various informal and formal sources of support that are available in the local community.
89521982|NCT04564365||with beta-blocker|
89521983|NCT04564365||without beta-blocker|
88995246|NCT04938908|Experimental|Ophthalmic probiotic|1 active drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
88995247|NCT04938908|Placebo Comparator|Placebo|1 placebo drop in each eye/ 5 hours plus oral placebo capsule, for 4 weeks
88995248|NCT04938908|Experimental|Opthalmic Probiotic + Oral Probiotic|1 active drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
88995249|NCT04938908|Experimental|Oral Probiotic|1 placebo drop in each eye/ 5 hours plus oral probiotic capsule, for 4 weeks
89521984|NCT04448665||patients with suspected infection|The hospitalized patients in whom, based on clinical signs and symptoms, an infection is suspected, and an administration of antimicrobial agents as empiric therapy is necessary.
89521985|NCT02520895||large B lymphoma cells (group 1)|30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings
89521986|NCT02520895||indolent B-cell lymphomas (group 2)|30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
89521987|NCT02520895||indolent B-cell lymphomas (group 3)|20 Patients with indolent B-cell lymphomas with lymphocytosis (> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
89521988|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 4)|20 patients with LLC never treated before and will receive an immunochemotherapy treatment (fludarabine +/- endoxan +/- rituximab or alemtuzumab)- patients will have blood samplings
89521989|NCT02520895||T-cell lymphoma (group 5)|10 Patients with T-cell lymphoma in 1st line therapy and will receive a combination of chemotherapy- patients will have blood samplings
89521990|NCT02520895||follicular lymphoma (group 6)|6 patients with follicular lymphoma in first line or relapsed and will receive a single immunotherapy treatment (rituximab)- patients will have blood samplings
89521991|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 7)|6 patients with LLC never treated and will receive a combination of rituximab, fludarabine, endoxan- patients will have blood samplings
89521992|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 8)|6 patients with LLC stage A followed for a period of 18 months without treatment- patients will have blood samplings
89521993|NCT02521025|Experimental|Intermittent feeding|Intermittent feeding pattern throughout the bedrest period, with 4 boluses per day
89521994|NCT02521025|Experimental|Continuous feeding|Continuous feeding pattern throughout the bedrest period, with 4 boluses per day, without breaks in food supply.
89521995|NCT02520583|Experimental|MICROBAC|Bacterial cultures
89521996|NCT02520583|Placebo Comparator|Placebo|Maltodextrin
89521997|NCT04170933|Experimental|Magnetic recanalization|The subjects in this group will be treated by magnetic recanalization
89521998|NCT05121207|Other|Dry skin condition|2. The second arm will consist of 50 patients with benign dry skin conditions (eczema, psoriasis, skin grafts, scars etc.) and will compare the water content of their skin before and after application of a propriety emollients in common usage (e.g. E45®, Aveeno®, Doublebase®). This will add to the existing dataset that has been recorded from healthy non-patient volunteers (unpublished data, University of Warwick). This may help to guide patient-specific emollient selection in the future.
89521999|NCT05121207|Other|Skin cancer|1. One arm will consist of 100 patients with known or suspected skin cancer (skin cancer defined as: incompletely excised BCC with histologically proven radial margin involvement; biopsy proven BCC, or pigmented lesions suspicious of malignant melanoma). Images will be taken in the clinic prior to planned skin surgery and later compared to the formal histology results after the primary (melanoma) or residual (BCC) tumour has been removed.
89522000|NCT03412513|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
89522001|NCT03412513|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
89522002|NCT03419351|Other|Main group|Main study group including all individuals that underwent the study procedures
89522003|NCT05119491||cases ultra sound and spirometry|observation by ultra sound and spirometry for cases
89522004|NCT05119491||heathy subjects ultra sound and spirometry|observation ultra sound and spirometry for control heathy subjects
89522005|NCT04797091||Patients with SARS-CoV-2-infection|Patients with evidence of SARS-CoV-2-infection
89665784|NCT05902572||Time and motion observation participants|HIV treatment providers eligible to be enrolled in the time and motion observation study
89665785|NCT05902572||HIV testing survey participants|Individuals presenting for HIV testing eligible to be enrolled in the HIV testing survey
89665786|NCT05902507||Breast Cancer Participants|Participants will receive both MRI and CT simulation scans.
89665787|NCT05902481|Experimental|Intervention Group|"Introductory Information Form, Antenatal Breastfeeding Self-Efficacy Scale will be applied as a pre-test after obtaining informed consent from the pregnant women who are between the 6th and 7th weeks of age.~After the pre-test is applied, pregnant women will be given breastfeeding counseling based on mixed reality technology."
89665788|NCT05902481|No Intervention|Control Group|"Introductory Information Form, Antenatal Breastfeeding Self-Efficacy Scale will be applied as a pre-test after obtaining informed consent from the pregnant women in the third trimester who agreed to participate in our study and met the inclusion criteria.~After the pre-test is applied, standard breastfeeding counseling will be given to pregnant women with Power Point technique."
89665789|NCT05902468|No Intervention|Group 1|44 diabetic patients receiving dual treatment with metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin)
89665790|NCT05902468|Active Comparator|Group 2|44 diabetic patients who will receive ursodeoxycholic acid 500 mg orally twice daily in addition to dual treatment with metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin)
89665791|NCT05902429|Experimental|Cladribine tablets|
89665792|NCT05902416||RIC regimen,Elderly,Haplo-HSCT,PFS,OS,TRM|
89665793|NCT05902403||Elevated Initial Mean Airway Pressure|Patients recieving invasive mechanical ventilation with mean airway pressure no less than 10 centimeter of water within the first 24 hours on ICU admission.
89665794|NCT05902390|Experimental|hydrogel spacer|The Subjects randomized to the treatment group underwent placement of hydrogel spacer.
89665795|NCT05902390|No Intervention|Control|The Subjects randomized to the control group did not receive injection of the hydrogel spacer.
89665796|NCT05902377|Experimental|68Ga-NY104 PET/CT|Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
89665797|NCT05901623||Case|Infants with THoP
89665798|NCT05901623||Control|Healthy infants
89665799|NCT05901428|Experimental|TCb arm|Chemotherapy: Intensive intravenous dose of docetaxel (75 mg/m2) + intravenous (IV) carboplatin [area under the curve (AUC) =5-6] repeated administration of Q3W for a total of 6 doses
89665800|NCT05901428|Active Comparator|EC-T arm|Chemotherapy: Intensive intravenous dose of epirubicin (80-90 mg/m2) + IV cyclophosphamide (600 mg/m2) repeated administration of Q3W for a total of 4 doses, followed by (IV) docetaxel (80 mg/m2) (Q3W) for 4 doses
89665801|NCT05900960|Experimental|Warm tea|50 degrees celsius hot tea.
89665802|NCT05900960|Active Comparator|Cool tea|10 degrees celsius cool tea
89665803|NCT05902442|Experimental|3DxSPLINT|
89665804|NCT05900778|Experimental|HABIT-ILE|Hand and arm bimanuel intensive therapy including lowers extremities
89665805|NCT05900778|Active Comparator|Conventional intervention|Conventional physical and occupational therapy
89665806|NCT05900596||pH < 3|Patients one or two fetal blood sampling
89665807|NCT05900596||pH > 3|Patients with three or more fetal blood sampling
89665808|NCT05900375|Experimental|Intervention Arm - Receipt of PtDA|Parents in the intervention arm will receive a paper decision aid prior to meeting with their health care professional about their child's treatment options for UPJO.
89665809|NCT05900375|No Intervention|Control - Usual Care|Parents in the control arm will not receive a paper decision aid and instead will just receive usual care about their child's treatment options for UPJO.
89665810|NCT05899972|Experimental|Experimental: Experimental group|The protocol is initiated by the suboccipital inhibition technique, with an average duration of three minutes. Afterwards, the frontal lift and parietal lift techniques were performed, which lasted an average of five minutes, being two and a half minutes for each one. Finally, the IV ventricle technique was performed, with an average duration of three minutes.
89665811|NCT05899972|Placebo Comparator|Control group|For the control group the placebo technique will be applied for 6 minutes.
89665812|NCT05899036|Experimental|Treatment Arm|Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove the thrombus in the neuro-vasculature using the RapidPulseTM Aspiration System.
89665813|NCT05897892|Experimental|Treatment Group|Treatment group received 50 g mangrove sword bean food bar each day during 15 days.
89665814|NCT05897892|Placebo Comparator|Control Group|Control group received 50 g sword bean food bar per day during 15 days.
89665815|NCT05896215|Experimental|Low dose group|Topical administration of low dose of KPN2002
89665816|NCT05896215|Experimental|Middle dose group|Topical administration of middle dose of KPN2002
89665817|NCT05896215|Experimental|High dose group|Topical administration of high dose of KPN2002
88995250|NCT04923841|No Intervention|Control|Subjects in control will receive single vision spectacle lenses and a placebo desk lamp
89665818|NCT05896215|Placebo Comparator|Placebo group|Topical administration of placebo
89665819|NCT05895643|Experimental|semaglutide|Wegovy once-weekly s.c.titrated to a maximum dose of 2.4 mg
89665820|NCT05895643|Placebo Comparator|placebo|Saline s.c. once-weekly
89665821|NCT05895383|Experimental|Self-adjusted nitrous oxide (SANO)|All patients will receive nitrous oxide at concentrations of minimal sedation (0-50%) throughout vasectomy.
89665822|NCT05894174|Experimental|Intervention Group|"The intervention group refers to the group that will the Food Hunter board game intervention developed by the researchers to enable children to recognize healthy and unhealthy foods; to learn what vitamins and minerals are necessary for children in the growth and development period, their effects on our health and in which foods they are found."
89665823|NCT05894174|No Intervention|Control Group|The control group refers to the group that will not receive any nutrition education intervention.
89665824|NCT05894096|Experimental|Cold Athmospheric Plasma Jet+Alginate patch|Leg Venous Ulcers will be treated in all patients belonging to the experimental arm using the PlasmAction Med cold plasma generator at atmospheric air pressure and alginate (Melgisorb Ag®) will be used after the plasma has been applied.
89665825|NCT05894096|Active Comparator|Alginate patch|For patients included in the control arm, alginate (Melgisorb Ag®) will be used as a cure for ulcers, size 10 X 10 cm and 5x5 (3 units), whose replacements will also be carried out twice a week.
89665826|NCT05892549||COVID|
89665827|NCT05892549||Other respiratory diseases|
89665828|NCT05892549||Healthy|
89665829|NCT05889936|Experimental|Treatment with the Lev-intervention|Screening of health-related habits using Lev-s + a three step/session intervention including the standard Lev protocol. Typically given over 10-20 weeks.
89665830|NCT05889819|Experimental|Treatment group|Intervention group received almond orange potato cookies during 4 weeks.
89665831|NCT05889819|Placebo Comparator|Control group|Control group received orange potato cookies during 4 weeks.
89665832|NCT05889481||Retrospective cohort|Patients diagnosed with uveal melanoma undergoing histological and cytogenetic analysis. The cases will be identified from patients referred to the Ocular Oncology Unit and they finished the follow-up
89665833|NCT05889481||Prospective cohort|Patients diagnosed with uveal melanoma undergoing histological and cytogenetic analysis. The cases will be identified from patients referred to the Ocular Oncology and they still have to complete the follow-up
89665834|NCT05887791|Experimental|Collagen hydrolysate dose 1|Source: porcine; standardized to 10 g provided as single dose. Orally applied in flavoured water.
89665835|NCT05887791|Experimental|Collagen hydrolysate dose 2|Source: porcine; standardized to 5 g provided as single dose. Orally applied in flavoured water.
89665836|NCT05887791|Placebo Comparator|Placebo|Flavoured water
89665837|NCT05884996|Experimental|PNF training|kabat training with elastic bands for 8 weeks 2 times a week before swimming training. 3 series of 10-15 repetitions will be performed
89665838|NCT05884996|No Intervention|Control group|swimming training 2 times a week
89665839|NCT05884736||DCC Donors|Standard criteria DCC donors will be undergoing the A-NRP perfusion process to recondition organs prior to procurement. Multimodal neuromonitors will be placed on the donor prior to withdrawal of life support and readings will be recorded during the withdrawal process and for the duration of the A-NRP perfusion process. The neuromonitoring team will be looking for evidence of brain blood flow or activity.
89665840|NCT05882097|Experimental|Treatment arm receiving the Transform program|"Transform: Participants will receive ICM's Transform program.~In the treatment arm, the full 15-session Transform program will be delivered once a week for 15 consecutive weeks in a venue located within the community. In each session, there will be 90 minutes lessons on livelihood and health delivered by trained ICM staff. Separately, a voluntary values lesson will be delivered by the host community leader."
89665841|NCT05882097|No Intervention|Control arm receiving no Transform program|Control: Participants will not receive any intervention during the study period.
89665842|NCT05880615||opioid reduced anesthesia with parasternal catheters inserted before sternotomy|Patients with opioid reduced anesthesia with parasternal catheters inserted before sternotomy will be included.
89665843|NCT05880615||Opioid Anesthesia (OA)|Patients with Opioid Anesthesia (OA) will be included.
89665844|NCT05880420|Experimental|Arm 1 - home group|
89665845|NCT05880420|Active Comparator|Arm 2 - outpatient calibration|
89665846|NCT05880043|Experimental|GIC-102|"On day -5, -4, and -3, patients receive cyclophosphamide 300 mg/m² and fludarabine 30mg/m² every 2 cycles~On day 0, patients receive GIC-102 3 times at intervals of 1 week, and 28 days is defined as 1 cycle"
88995251|NCT04923841|Experimental|BLT monotherapy|Subjects in BLT monotherapy group will receive a high intensity light box for bright light therapy and single vision spectacle lenses
88995252|NCT04923841|Experimental|BLT and DIMS|Subjects in BLT and DIMS group will receive a high intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
88995253|NCT04923841|Experimental|BLT and atropine|Subjects in BLT and atropine group will receive a high intensity light box for bright light therapy, single vision spectacle lens, and atropine 0.01% eye drop (twice a day)
88995254|NCT04923841|Experimental|Atropine monotherapy|Subjects in atropine group will receive atropine 0.01% eye drop (twice a day) and single vision spectacle lenses
88995255|NCT04906642|Active Comparator|Standard of Care|"Each of the following procedures will be conducted according to general or local site Standard of Care (SoC):~Medication administration at surgery~Surgical irrigation and wound debridement~Surgical fracture preparation/fixation~Surgical closure"
88995256|NCT04906642|Experimental|Standard of Care plus Next Science|In addition to the SoC, the blinded product will be applied in place of saline irrigation as the wound is closed (after bone fracture preparation/fixation), depending on the randomization.
88995257|NCT04898127|Experimental|Rapid test and concert|Participants in this arm will be offered access to a concert, after a negative rapid test.
88995258|NCT04898127|No Intervention|Control|Participants in this are will not be offered access to a concert during the study period.
88995259|NCT04888832|No Intervention|Control Group|No change to work requirements or recertification period
88995260|NCT04888832|Active Comparator|Intervention Group 1|Standard 6-month recertification period, additional 6-month work requirement exemption
88995261|NCT04888832|Active Comparator|Intervention Group 2|Standard 6-month recertification period, additional 12-month work requirement exemption
88995262|NCT04888832|Active Comparator|Intervention Group 3|Standard 6-month recertification period, additional 12-month work requirement exemption
88995263|NCT04888832|Active Comparator|Intervention Group 4|12-month recertification period (6-month extension), additional 6-month work requirement exemption
88995264|NCT04880629|Experimental|Sleep rectriction|Participants in METWI2 undergo both a baseline (unrestricted) sleep and sleep restriction condition. On the morning following each condition, participants complete an oral glucose tolerance test to measure changes in glucose and insulin following ingestion of a glucose load.
88995265|NCT04875338|Active Comparator|saline injection|2ml %0.9 NACI(Saline )injection to effected lateral epicondyle
88995266|NCT04875338|Active Comparator|platet riched plasma injection|2 ml prp )injection to effected lateral epicondyle
88995267|NCT04875338|Active Comparator|betametazon injection|2 ml betametazon )injection to effected lateral epicondyle
88995268|NCT04869098|Experimental|Whey protein preload condition|Participants will consume 30 g whey protein isolate powder (dissolved in water) 1-1.5 hr prior to their main evening meal every day for 12 days.
89665847|NCT05877534|Experimental|Intervention|A 16 week period of exercise, supervised by a physiotherapist once a week. The exercise should be individually tailored from a programme based on a previous feasibility study. The program consist of exercises both to improve endurance and muscle strength. Progression and adjustments of time and position will be performed during the intervention period based any symptoms the participant exhibits. Progression should be halted if the participant experience PEM or other symptoms within >24hours after last exercise. The participants will also recieve standard care during the intervention period. Standard care includes (but not restricted to) information about POTS and lifestyle changes that may effect the symptoms, advice about fluid intake and nutrition, compression garments, pharmacological interventions etc.
89665848|NCT05877534|No Intervention|Control|Standard care during 16 weeks. Standard care includes (but not restricted to) information about POTS and lifestyle changes that may effect the symptoms, advice about fluid intake and nutrition, compression garments, pharmacological interventions etc.
89665849|NCT05869864|Experimental|Intervention|Half of the participants in the pilot will receive the experimental behavioral intervention.
89665850|NCT05869864|No Intervention|Control|Half of the participants in the pilot will receive nothing, and serve as the control.
89665851|NCT05861570|Experimental|hydrodilatation with steroid|patient received ultrasound-guided 3cc NS + 40mg triamcinolone + 4cc xylocaine
89665852|NCT05861570|Active Comparator|hydrodilatation with hyaluronic acid and steroid|patient received ultrasound-guided 3cc hyaluronic acid + 40mg triamcinolone + 4cc xylocaine
89665853|NCT05857163|Experimental|Test Group|Rifasutenizol capsules, 400 mg, BID, taken orally within half an hour after breakfast and dinner Rabeprazole sodium enteric-coated tablets, 20 mg, BID, taken orally within half an hour before breakfast and dinner Amoxicillin capsules, 1 g, BID, taken orally within half an hour after breakfast and dinner Clarithromycin placebo tablets, BID, taken orally within half an hour after breakfast and dinner Bismuth potassium citrate placebo capsules, BID, taken orally within half an hour before breakfast and dinner
89665854|NCT05857163|Active Comparator|Control Group|Amoxicillin capsules, 1 g, BID, taken orally within half an hour after breakfast and dinner Clarithromycin tablets, 500 mg, BID, taken orally within half an hour after breakfast and dinner Rabeprazole sodium enteric-coated tablets, 20 mg, BID, taken orally within half an hour before breakfast and dinner Bismuth potassium citrate capsules, 240 mg, BID, taken orally within half an hour before breakfast and dinner Rifasutenizol placebo capsules, BID, taken orally within half an hour after breakfast and dinner
89665855|NCT05853848|Active Comparator|Standard postcard|Patients in this arm will receive a postcard with words and an image, typical of outreach in prior years, encouraging them to schedule their annual mammograms.
89665856|NCT05853848|Experimental|Formal letter|Patients in this arm will receive a letter from the Geisinger Health Plan (on Geisinger letterhead) noting that they're overdue for a mammogram and encouraging them to schedule.
89665857|NCT05853848|Experimental|Auto-dialer|Patients in this arm will receive a call from an auto-dialer with a message noting that they're overdue for a mammogram and encouraging them to schedule.
89665858|NCT05853848|Experimental|Live call|Patients in this arm will receive a call from a Geisinger Health Plan representative noting that they're overdue for a mammogram and encouraging them to schedule (and helping them schedule if they are interested).
89665859|NCT05852886|Experimental|Toothbrush|Use of experimental toothbrush for 28 days.
89665860|NCT05847920|Experimental|SHR-2010 Injection|
89665861|NCT05847920|Placebo Comparator|Placebo|
89665862|NCT05843864|Experimental|Standard Physical Therapy and Photobiomodulation Therapy|61 Participants will be randomized to this group and will receive Photobiomodulation Therapy (PBMT) in addition to standard physical therapy.
89665863|NCT05843864|Sham Comparator|Standard Physical Therapy and Sham Photobiomodulation Therapy|61 Participants will be randomized to this group and will receive sham Photobiomodulation Therapy (PBMT) in addition to standard physical therapy.
89665864|NCT05839301|Experimental|Experimental Group1|Single subcutaneous injection of the investigational vaccine (0.5ml)
89665865|NCT05839301|Experimental|Experimental Group2|Single subcutaneous injection of the investigational vaccine (0.5ml)
89665866|NCT05839301|Experimental|Experimental Group3|Single subcutaneous injection of the investigational vaccine (0.5ml)
89665867|NCT05836909|Experimental|Swisse Plus cholesterol capsules|(the main components are red yeast rice, phytosterol esters and lycopene)，the capsule is orally taken twice a day,two,tablets at a time 12 weeks
89665868|NCT05836909|Placebo Comparator|placebo contral|The placebo is an excipient and the colos, flavor, shape and weight are same with the Swisse plus cholesterol capsule
89665869|NCT05834907|Experimental|Circle of Security Parenting (COS-P)|These participants will receive the Circle of Security Parenting (COS-P) intervention, an attachment-based, manualized, 8-session (90 minutes/session), home visiting intervention.
89665870|NCT05834907|Active Comparator|Little Talks|These participants will receive the Little Talks intervention, a manualized, 8-session (90 minutes/session) early literacy home visiting intervention.
89665871|NCT05831592|Other|Diagnostic accuracy of muscle ultrasound in undernutrition|All included patients will undergo an muscle ultrasound assessment in undernutrition
88995269|NCT04869098|Placebo Comparator|Placebo condition|Participants will consume an energy-matched mixed-nutrient placebo drink 1-1.5 hr prior to their main evening meal every day for 12 days,
88995270|NCT04861792|No Intervention|Usual Care|Patients seen before the intervention launch date.
88995271|NCT04861792|Experimental|Quality Improvement Intervention|Patients seen after the intervention launch date.
88995272|NCT04855006|Experimental|Vaginal Microbiome Transplant|Women are given the vaginal microbiome transplant at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
88995273|NCT04855006|Placebo Comparator|Vaginal Microbiome Transplant Placebo|Women are given the vaginal microbiome transplant placebo at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
89665872|NCT05821556|Active Comparator|Standard|Nab-paclitaxel 125 mg/m2 followed by gemcitabine 1000 mg/m2 on days 1, 8, and 15 (AG); or nab-paclitaxel 150 mg/m2, followed by gemcitabine 800 mg/m2, followed by cisplatin 30 mg/m2 on days 1 and 15, and oral capecitabine 1250 mg/m2 on days 1-28 (PAXG).
89665873|NCT05821556|Experimental|Experimental|Chemotherapy (AG or PAXG) + simvastatin oral daily at a fixed dosage of 20 mg in combination with increasing doses of valproic acid administered oral daily from day -7 with an intra-patient titration for a final target serum level of 50-100µg/ml.
89522006|NCT04797091||Control group|Controls will be identified retrospectively at the same hospitals that based on matching of demographics, underlying diseases and duration of hospitalization.
89522007|NCT03413969|Experimental|Behavioral Intervention|The study subjects will be recruited for approximately six weeks prior to the projected start date. The participants will attend the two-day weekend retreat. Follow-up assessments will be administered three months and six months after the retreat. The investigators will analyze the data and complete the study one month after the final assessment is administered.
89522008|NCT04482699|Experimental|Single agent RAPA-501 cells (dose level 1)|Dose level 1 is 40 x 10^6
89522009|NCT04482699|Experimental|Single agent RAPA-501 cells (dose level 2)|Dose level 2 is 160 x 10^6
89522010|NCT04482699|Active Comparator|RAPA-501 cells|RAPA-501 cells at either dose level 1 or dose level 2 (whichever has been deemed safe during phase 1)
89522011|NCT04482699|Placebo Comparator|Placebo-control Cohort|Placebo
89522012|NCT03410719|Experimental|<55 (Low-GI group)|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals:Low-GI - pasta, barley, parboiled rice, legumes.
89522013|NCT03410719|Experimental|>70 (Hi-GI group).|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals: Hi-GI - rice, potato,
89522014|NCT04457817||CRI Monitoring/Management|These patients are COVID-19 positive; ages > 18 and < 70 years old; require > 2 liters of oxygen by nasal cannula to maintain SpO2 > 90%; are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service). Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces AKI and/or need for CRRT; and 4) improves clinical outcomes.
89522015|NCT03412357|Experimental|pleurectomy/decortication|
89522016|NCT03412357|Experimental|indwelling pleural catheter|
89522017|NCT03419117|Experimental|Treatment|Patients in the experimental arm will receive an ESP block prior to induction of general anesthetic for their thoracoscopic wedge resection
89522018|NCT03419117|Placebo Comparator|Placebo|Patients allocated to the placebo-control arm will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block.
89522019|NCT04370379|Experimental|low dose of IBI302|
89522020|NCT04370379|Experimental|high dose of IBI302|
89522021|NCT04370379|Active Comparator|2mg aflibercept|
89522022|NCT03413891|Placebo Comparator|Control Group|10mL water as mouthwash with white cherry flavor in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
89522023|NCT03413891|Experimental|Tranexamic Acid Group|10mL tranexamic acid mouthwash 10% in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
89522024|NCT03410641||Diet and antismoking advice|Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
89522025|NCT03410641||Control|No intervention
89522026|NCT03419039|Experimental|Anthocyanins|Medox. 2 capsules x 2 daily, 320 mg daily.
89522027|NCT03419039|Placebo Comparator|Placebo|2 identically appearing placebo capsules daily
89522028|NCT03126955||HELPS Syndrome unable to lateralize contractions|Each patient will have the following 3 diagnostic pre-operative tests: i) MRI (CISS sequence), ii) video laryngoscopy, and iii) sequential Botox injections in their throat (left side and then 3 months later on the right side).
89522029|NCT03425071||Healthy volunteers|"Healthy volunteers - subjects without exposure to tacrolimus. Blood samples from these subjects will be used in in vitro experiments."
89522030|NCT03425071||kidney transplant (KTx) months 1-2|"Kidney transplant recipients recruited during the months 1 to 2 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to high blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
89522031|NCT03425071||KTx months 4-5|"Kidney transplant recipients recruited during the months 4 to 5 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to standard blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
89522032|NCT03127397|No Intervention|Standard of Care|
89522033|NCT03127397|Experimental|Praise Message|Receives up to two praise message phone calls after each completed ART appointment.
89522034|NCT03413657|Other|Fluid responders|Patient's identified to have a significant increase in their cardiac output following a fluid bolus.
89522035|NCT03413657|Other|Fluid non-responders|Patient's identified to NOT have a significant increase in their cardiac output following a fluid bolus.
89522036|NCT03317613|Experimental|Capsaicin|Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..
89522037|NCT03410563||Healthy participants|
89522038|NCT03311763|Active Comparator|Counseling alone|Group 1: physical activity assessment, brief counseling session + physical activity wearable
89522039|NCT03311763|Experimental|Group exercise|Group 2: Group 1 intervention components + referral to a free, community-based, EIM practitioner led group exercise program (two, 1 hour classes/week for 8 weeks).
89522040|NCT03126877|Experimental|Optimized Ocular Surface|For patients enrolled into the treatment group for preoperative optimization of the ocular surface, utilize the LipiFlow® vectored thermal pulsating eyepieces (Activators) to gently apply heat and massage, thus evacuating the Meibomian glands. Omega-3 vitamin supplements should also be provided, initiated and dosed according to standard clinical practice, to maximize ocular surface health.
89522041|NCT03126877|Active Comparator|Non-Optimized Ocular Surface|Patients enrolled into the non-treatment group will not be optimized preoperatively for ocular surface health. No LipiFlow® Activators and no Omega-3 vitamin supplements will be provided, initiated, nor dosed.
89522042|NCT03412201|Active Comparator|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
89522043|NCT03412201|Experimental|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
89522044|NCT02343458|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
89522045|NCT02343458|Experimental|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
89522046|NCT02343458|Experimental|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
89522047|NCT02343458|Placebo Comparator|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
89522048|NCT02964377|Experimental|Cohort 1|8-weeks open-label (+)- Epicatechin at 25mg/day twice per day,
89522049|NCT02964377|Experimental|Cohort 2|8-weeks open-label (+)- Epicatechin at 25mg/day three times per day
89522050|NCT02964377|Experimental|Cohort 3|8-weeks open-label (+)- Epicatechin at 75mg/day at two times per day
89522051|NCT03126045|Active Comparator|Standard needle|Patients perform a spinal punction according to the usual practice, with a standard needle.
89522052|NCT03126045|Experimental|Atraumatic needle|Patients perform a spinal punction according to the usual practice, with an atraumatic needle.
89522053|NCT03424837|Experimental|Intervention Arm: SoC (standard of care) and ASCENT|Health care per institutional standard plus ASCENT via the TrueNTH website.
89522054|NCT03424837|No Intervention|Control Arm: SoC and TrueNRH|Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise & diet, and lived experiences modules.
89522055|NCT05230407||Women after Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES)|Study population will include all women after hysterectomy or adnexal surgery by vNOTE technique
89522056|NCT03424759|Experimental|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
89522057|NCT02839811|Experimental|immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
89522058|NCT05230329||Completemesocolic excision by laparoscopy for right sided cancer|
89522059|NCT05230329||Completemesocolic excision by robot for right sided cancer|
89522060|NCT05230329||Standard right hemi colectomy excision by laparoscopy for right sided cancer|
89522061|NCT03127813|Experimental|Treated glaucoma|POAG patients established on treatment
89522062|NCT03127813|Experimental|Untreated|Newly diagnosed treatment naïve POAG patients
89522063|NCT03127813|Active Comparator|Control|Control subjects without glaucoma
89522064|NCT03413579|Experimental|Nimotuzumab|"Injection of 200 mg of Nimotuzumab (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.~The objective of the present study is to assess the overall survival of patients after administration of Nimotuzumab hR3 monoclonal antibodies (combined with a chemotherapy) in the treatment of patients with cervix epithelial tumors as first-line treatment.~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
89522065|NCT03413579|Placebo Comparator|Placebo|"Injection of the Placebo in the same procedures (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
89522066|NCT04824807|Experimental|Clinical Pilates Group|Individuals in the this group will receive 24 sessions of Clinical Pilates training 3 times a week for 8 weeks. During the training, individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
89522067|NCT04824807|Experimental|Yoga Group|Individuals in the this group will be given 24 hours of yoga training 3 times a week for 8 weeks. During the training, individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
89522068|NCT04824807|Other|Control Group|Individuals in the this group will not receive any treatment. Individuals will be asked to wear compression stockings during the 8 weeks. An educational booklet will be given to the each group.
89522069|NCT03410485|Active Comparator|Control (C Group )|Intervention for intraoperative analgesic administration will be based on heart rate and blood pressure variations. Intervention for intraoperative hypnotice/desflurane administration will based on keeping the MAC at 0.8.
89522070|NCT03410485|Experimental|Monitoring (M Group )|Intervention for intraoperative analgesic administration will be based on the NOL index (to keep it below 25). Intervention for the desflurane administration will be based on the BIS index (to keep it between 40-60).
89048803|NCT05286632|Experimental|KidneYou APP|"In patients randomized in Group A (intervention group) the NP program will be administered by means of App KidneYou. Each patient will select the assigned daily menu or the proposed alternatives, following instructions reported for breakfast, mid-morning snack, lunch, afternoon snack, and dinner.~Patients randomized to Group A (intervention group) will be administered the PA program by means of App KidneYou. Each patient will follow the assigned exercise program (i.e., recommended type of PA, minutes of exercise/day, number of days/week, level of intensity).~Only patients randomized to Group A (KidneYou users) will be invited by the investigator to follow stress-reducing activities. This difference between the two groups is based on the nature of the mindfulness program, consisting solely of multimedia contents."
89522071|NCT04814745|Active Comparator|morphine|morphine 150 mcg will be administered intrathecally before surgery by using a 25 Gauge with acre spinal needle
89522072|NCT04814745|Active Comparator|tramadol|tramadol 400 mg will be administered by using an elastomeric pump for 24 hours after surgery
89522073|NCT04814745|Active Comparator|ropivacaine|at the end of surgery transversus abdominis plane block will be performed bilaterally and ropivacaine 80 mg will be used
89522074|NCT03412123|Experimental|gLiFE pilot group|
89522075|NCT03413345||subjects without a history of cardiac disease|
89522076|NCT03413345||subjects with a history of cardiac disease|
89522077|NCT03410329|Experimental|High weekly training frequency|three sessions a week of resistance training
89522078|NCT03410329|Experimental|Low weekly training frequency|one workouts per week
89522079|NCT04757103||Above S3|Lesion located above the third sacral vertebra
89522080|NCT04757103||Below S3|Lesion located below the third sacral vertebra
89522081|NCT04448093|Experimental|Treatment group|Treated group (53) that answered quality of life questionnaires before, after and with 45 days of treatment.
89522082|NCT04448093|No Intervention|Group control|Untreated group (68) that answered quality of life questionnaires before, after and with 45 days of treatment.
89522083|NCT04640571|Experimental|placebo, then metformin, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
89522084|NCT04640571|Experimental|metformin, then polysorbate 80, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
89522085|NCT04640571|Experimental|polysorbate 80, then placebo, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
89522086|NCT04640571|Experimental|polysorbate 80, then metformin, then placebo|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
89522087|NCT04640571|Experimental|placebo, then polysorbate 80, then metformin|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
89522088|NCT04640571|Experimental|metformin, then placebo, then polysorbate 80|Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
89522089|NCT02801825|Experimental|Axillary artery.|Cannulation of the axillary artery.
89522090|NCT02801825|Experimental|Femoral artery.|Cannulation of the femoral artery.
89522091|NCT04593147|Experimental|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with Sn-2 Palmitate, Alpha Lactalbumin and Lactoferrin to better mimic human milk.
89522092|NCT04593147|Active Comparator|Brand|A commercially available Infant Formula, for healthy term infants 0 to 2 months of age (Enfamil TM, Milk-Based Powder with Iron).
89522093|NCT04448405||Patients followed by the CRIAVS|Patients followed by the CRIAVS (resource center for workers working with authors of sexual violence) in CHU Motpellier from June to October 2020
89522094|NCT04431141|Experimental|Teneligliptin|
89522095|NCT04431141|Experimental|Empagliflozin|
89522096|NCT04431141|Experimental|Teneligliptin and Empagliflozin|
89522097|NCT03418883|Experimental|Mirror therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A mirror (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The reflective surface is oriented so that the participant could easily see the mirror image of his/her sound arm. Patient practises his/her sound arm with exercises, ranging from the simple elbow flexion-extension to complex tasks.
89522098|NCT03418883|Sham Comparator|Sham therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A box (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The opaque surface replaces the mirror reflecting surface. Patient practises his/her sound arm with exercises,ranging from the simple elbow flexion-extension to complex tasks.
89522099|NCT05229627||healthy control|healthy controls, screened by K-SADS-PL
89522100|NCT05229627||MPH induced Remission|patients show remission after 8-12 weeks of treatment with MPH
89522101|NCT05229627||non responder to MPH|patients don't show remission after 8-12 weeks of treatment with MPH
89522102|NCT05229627||ATX induced remission|patients show remission after 8-12 weeks of treatment with ATX
89522103|NCT05229627||non responder to ATX|patients don't show remission after 8-12 weeks of treatment with ATX
89522104|NCT03413267|Experimental|Custard|The food matrix ingested (once by each volunteer) is a custard containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
89522105|NCT03413267|Experimental|Flan|The food matrix ingested (once by each volunteer) is a flan containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
89522106|NCT03413267|Experimental|Sponge cake|The food matrix ingested (once by each volunteer) is a sponge cake containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
89522107|NCT03413267|Experimental|Biscuit|The food matrix ingested (once by each volunteer) is biscuits containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
89665874|NCT05820477|Experimental|FAMS-T1D|"Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support person will receive text messages that are tailored to the goal set by the person with type 1 diabetes.~All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes."
89665875|NCT05820477|Placebo Comparator|Digital resources for diabetes|Persons with type 1 diabetes will receive text messages as to how to access their HbA1c results and digital materials related to self-care behaviors for their diabetes. All support persons will receive digital materials about type 1 diabetes and how to provide helpful support to the person with diabetes.
89665876|NCT05817773|Experimental|breastfeeding cradle|After the control group was given breastfeeding education and the baby was breastfed, the questionnaire and breastfeeding self-efficacy scale were applied at the 6th hour postoperatively. The experimental group was given breastfeeding education and the baby was placed in a nursing cradle and the baby was breastfed. Then, the questionnaire and breastfeeding self-efficacy scale were applied at the 6th hour postoperatively.
89665877|NCT05814575|Active Comparator|Comparator|Standardized non-diagnostic fetal ultrasound protocol without interactive intervention to control for time and attention.
89665878|NCT05814575|Experimental|NEXUS Intervention|Standardized non-diagnostic fetal ultrasound with motivational interviewing techniques, focused on maternal and fetal strengths.
89665879|NCT05808374|Experimental|Part 1|Single Dose Incremental (SAD) Trial - Healthy Persons：HRS-5635 vs. Placebo
89665880|NCT05808374|Experimental|Part 2a|Multiple Dose Increase (MAD) Study - Patients Receiving Consolidation Therapy：HRS-5635 vs. Placebo
89665881|NCT05808374|Experimental|Part 2b|Patients not receiving consolidation treatment：HRS-5635 vs. Placebo
89665882|NCT05808335|Placebo Comparator|Placebo to hzVSF-v13|Placebo to match hzVSF-v13 + oral antiviral agent
89665883|NCT05808335|Experimental|hzVSF-v13 50mg|hzVSF-v13 50 mg/dose + oral antiviral agent
89665884|NCT05808335|Experimental|hzVSF-v13 200mg|hzVSF-v13 200 mg/dose + oral antiviral agent
89665885|NCT05808335|Experimental|hzVSF-v13 800mg|hzVSF-v13 800 mg/dose + oral antiviral agent
89665886|NCT05806658|Experimental|Intervention group|Eligible participants will be randomly assigned to receive usual care with the four-week visual arts-based intervention.
89665887|NCT05806658|No Intervention|Control group|Eligible participants will be randomly assigned to receive usual stroke care.
89665888|NCT05776303|Experimental|Good Bowls + App Nudges, followed by Good Bowls alone|Participants in this arm will be exposed to Good Bowls + App Nudges throughout the first four months followed by four months of Good Bowls alone.
89665889|NCT05776303|Active Comparator|Good Bowls, followed by Good Bowls + App Nudges|Participants in this arm will be exposed to Good Bowls alone throughout the first four months followed by four months of Good Bowls + App Nudges.
89665890|NCT05767359|Experimental|Safety Run-In|"Participants will be enrolled into each of the 2 safety run-in phases in a standard 3 + 3 design.~- Participants will undergo study procedures as outlined:~Apheresis for collection of peripheral blood mononuclear cells (PBMC) will occur on-site~Stem cell collection on-site post-apheresis per standard care.~Administration of Cyclophosphamide and fludarabine in pre-determined doses 1 x daily for 3 consecutive days.~Hospitalization to receive Cilta-cel in per-determined dose per protocol 1 x daily for 3 consecutive days and will remain in the hospital for 2 weeks post cilta-cell infusion.~Follow-up for 3 years post-treatment and up to 15 years."
89665891|NCT05767359|Experimental|Cilta-Cel Dose Expansion Cohort|"Expansion cohort of 14 participants will be enrolled after safety run-in phases, and participants will undergo study procedures as outlined:~Apheresis for collection of peripheral blood mononuclear cells (PBMC) will occur on-site~Stem cell collection on-site post-apheresis per standard care.~Administration of Cyclophosphamide and fludarabine in pre-determined doses 1 x daily for 3 consecutive days.~Hospitalization to receive Cilta-cel in per-determined dose per protocol 1 x daily for 3 consecutive days and will remain in the hospital for 2 weeks post cilta-cell infusion.~Follow-up for 3 years post-treatment and up to 15 years."
89665892|NCT05762835|Experimental|Intervention (Virtual Family-Centered Rounds [FCR])|"Virtual FCR-arm parents/guardians (referred to as parents hereafter) will have the option use have the option to use telehealth for virtual rounds. Parents can participate in virtual FCR as much, or as little, as they choose. Parents also will have the option to attend FCR in person or to not attend FCR."
89665893|NCT05762835|No Intervention|Control (Usual Care)|Usual care-arm parents will receive usual care. Usual care-arm parents will have the option to attend FCR in person or to not attend FCR.
89665894|NCT05760001|Experimental|Intervention Arm|"At the individual level, participants in the intervention arm will receive place-based and financial well-being interventions.~These will include, at the individual level:~Tax preparation~Access to public benefits~Financial counseling and microgrants~At the neighborhood level:~Abandoned house remediation~Trash cleanup~Vacant lot greening~Tree planting"
89665895|NCT05760001|No Intervention|Control Arm|Participants in the control arm will not receive any of the listed interventions
89665896|NCT05757830|Experimental|Exoskeleton-assisted arm|Each subject will perform 3 experimental conditions with and without the exoskeleton to assess the impact of exoskeleton assisted walking on metabolic consumption and cardiorespiratory effort compared to conventional overground walking training without an exoskeleton
89665897|NCT05757583||Patients with asthma, obesity and metabolic dysfunction|"Otherwise healthy asthmatic subjects with:~Body Mass Index (BMI) ≥ 30; and~Metabolic dysfunction evidenced by at least one of the following:~high plasma IL-6 (> 3.0 pg/mL)~insulin resistance (HOMA-IR > 3 mass units)"
89665898|NCT05757583||Patients with asthma, obesity and no metabolic dysfunction|"Otherwise healthy asthmatic subjects with:~Body Mass Index (BMI) ≥ 30; and~No evidence of metabolic dysfunction"
89665899|NCT05757583||Patients with severe asthma and mucus plugs|"Otherwise healthy asthmatic subjects:~Requiring treatment with high dose inhaled corticosteroids plus a second controller, systemic corticosteroid, or biologic therapy; and~Evidence of mucus plugs as defined by a mucus plug score ≥ 4"
89665900|NCT05757583||Patients with severe asthma and no mucus plugs|"Otherwise healthy asthmatic subjects:~Requiring treatment with high dose inhaled corticosteroids plus a second controller, systemic corticosteroid, or biologic therapy; and~No evidence of mucus plugs as defined by a mucus plug score < 4"
89048804|NCT05286632|No Intervention|Standard of care control group|"In patients randomized in Group B (control group) the NP program will be administered by means of a paper diary containing the entire range of daily menu and related alternatives needed to terminate the 3-month study period.~Patients randomized to Group B (control group) will be administered the PA program by means of a paper diary containing the entire range of exercises needed to terminate the 3-month study period.~The stress reduction program is not a standard of care currently used within the treatment strategy of CKD patients, neither through face-to-face visits with a specialist, nor through multimedia content.~Patients provided with paper diary and randomized in Group B (KidneYou non-users) represent the population followed by the current standard of care and will not be provided with any multimedia content in the context of their participation in the present study."
89048805|NCT05250167||CKD patients stage 2|
89048806|NCT05250167||CKD patients stage 3a|
89048807|NCT05250167||CKD patients stage 3b|
89048808|NCT05250167||CKD patients stage 4|
89048809|NCT05250167||Controls without CKD|
89048810|NCT00559572|Experimental|1|Exercise information group
89665901|NCT05749640|Active Comparator|"Palodent® plus sectional matrix system Control group"|
89665902|NCT05749640|Experimental|"PerForm™ Experimental"|
89665903|NCT05749640|Experimental|"Trimax™ Experimental"|
89665904|NCT05749640|Experimental|"Contact Pro™ Experimental"|
89665905|NCT05745441|Experimental|Early Dinner First|Participants will be served dinner and a stable isotope of oral [2H31] palmitate to measure fat oxidation, at an early dinner time (before DLMO). This arm will then cross-over to Late Dinner as the second metabolic visit.
89665906|NCT05745441|Experimental|Late Dinner First|Participants will be served dinner and a stable isotope of oral [2H31] palmitate to measure fat oxidation, at a late dinner time (after DLMO). This arm will then cross-over to Early Dinner as the second metabolic visit.
89665907|NCT05736666|Experimental|Training Group|The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side.
89665908|NCT05736666|Active Comparator|Education Group|This group will receive educational materials related to fall prevention in older adults.
89665909|NCT05733286|Active Comparator|Suvorexant Arm|
89665910|NCT05733286|Placebo Comparator|Placebo Arm|
89665911|NCT05711719|Experimental|Vericiguat|Initial 2.5 mg/day for two weeks, then 5 mg/day for two weeks, and then 10 mg/day for two weeks. Systolic blood pressure will be measured before and following each titration The participant will receive the final titration dose for a total of six weeks.. The drug is administered as an oral tablet once daily.
89665912|NCT05711719|Placebo Comparator|Placebo|A placebo tablet will be administered orally once daily.
89665913|NCT05709405|Experimental|Reading Intervention|"The reading material is made based on the research of Professor Janice Light and Professor David McNaughton at Penn State University. The reading material Lesing for alle (Reading for all) contains all the principles, strategies, and methods that form the basis of Accessible Literacy Learning (ALL). The intervention is conducted by trained teachers, in a place known to the students. The material contains: tasks in sound blending, letter-sound correspondence, phoneme- segmentation, sight words, single-word decoding, and shared reading.~Due to the multiple single baseline design, each participant will be regarded as being in the control condition, and then will be randonly assigned to four different baselines starting the intervention individually after the 2nd, 3rd, 4th, and 5th month."
88815726|NCT01040858|Experimental|Cognitive Strategies Training|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study). Cognitive Strategies training consisted of interactive didactic presentations, in-class discussions, and activities that introduced participants to a variety of cognitive strategies and external aids.
89048811|NCT00559572|Active Comparator|2|General health information group
89048812|NCT00559611|Experimental|Endobronchial Ultrasound vs. Mediastinoscopy|"Endobronchial Ultrasound - A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.~Mediastinoscopy - Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS."
89048813|NCT03454698|Other|Contol|"Usual care for patients in the CG is defined as follows: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the wound expert according to the hospital's own standards. This standard corresponds to the one from the EWMA."
89048814|NCT05186675|Experimental|Superselective adrenal arterial embolization|For patients with bilateral idiopathic hyperaldosteronism confirmed by adrenal venous sampling, Superselective adrenal arterial embolization（SAAE）shall be given according to the patient's wishes. The blood pressure, plasma aldosterone and potassium levels, and adverse events were assessed after SAAE. The primary endpoint was the change in home blood pressure at one months, compared with baseline.
89048815|NCT04639908||barriers|find out what are the barriers
89048816|NCT04639908||facilitators|find out what are the facilitators
89048817|NCT04640064||Patient with type 1 diabetes|Children younger than 17 years with a diagnosis of type 1 diabetes prior to 2018 will be included.
89048818|NCT04639791||Severe asthma patients|on step 4& 5 of GINA treatment
89665914|NCT05698628|Experimental|Preemptive distal perfusion group|Distal perfusion catheterization will be done within 1 hour after VA-ECMO application.
89665915|NCT05698628|Active Comparator|Conventional distal perfusion group|The conventional group will undergo distal perfusion catheterization at the time of limb ischemia sign.
89665916|NCT05696067|Experimental|Group 0a|Single dose of 7.2 lg EID50 of H3N2 vaccine component
89665917|NCT05696067|Experimental|Group 0b|Single dose of 7.5 lg EID50 of H1N1pdm09 vaccine component
89665918|NCT05696067|Experimental|Group 0c|Single dose of 8.0 lg EID50 of H3N2 vaccine component
89665919|NCT05696067|Experimental|Group 0d|Single dose of 8.3 lg EID50 of H1N1pdm09 vaccine component
89665920|NCT05696067|Experimental|Group 1a|Low dose vaccine, two components received three weeks apart
89665921|NCT05696067|Experimental|Group 1b|High dose vaccine, two components received three weeks apart
89665922|NCT05696067|Placebo Comparator|Group 1c|Placebo, two doses received three weeks apart
89214356|NCT02541032|Active Comparator|Standard Dental Treatment|Patients will undergo supragingival mechanical scaling and polishing. They will be informed of the presence and severity of their periodontal disease and will be advised to be seen by their dentist if their condition requires immediate attention. If they have no dental provider they will be referred for care. All patients will be reexamined at 3, 6 and 9 months for safety checks. Among the group the periodontal condition will be monitored to assure there is no progression of disease. If any site demonstrates an increase in periodontal pockets >3mm, they will receive site-directed scaling and root planing. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention. At the completion of the study, the control treatment patients will be offered to receive the same dental care as provided to the intensive treatment group as needed.
89214357|NCT00557856|Experimental|1|
89665923|NCT05696067|Experimental|Group 2a|High dose vaccine, two components received three weeks apart
89665924|NCT05696067|Placebo Comparator|Group 2b|Placebo, two doses received three weeks apart
89665925|NCT05690789||People / Person Living with Obesity (PLwO)|From online, general population consumer panels
89665926|NCT05690789||Health Care Professionals (HCPs)|HCPs treating people who have obesity
89665927|NCT05690789||Employers|Single-selection response from defined list
89665928|NCT05689567|Experimental|DEFOG group|Subjescts will wear DEFOG glasses(peripheral focus-out glasses).
89665929|NCT05689567|No Intervention|Control group|Subjects in the control group will just be observed.
89665930|NCT05671484|Active Comparator|Transversalis Fascial Plane Block Group|Patients will receive ultrasound-guided transversalis fascial plane block
89665931|NCT05671484|Active Comparator|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block
89665932|NCT05671419|Experimental|Mindful Self-Compassion|Mindful Self-Compassion (MSC) is a weekly class given for 8 weeks. The individual classes last about 2 hours each. The class is provided in a group setting.
89665933|NCT05671419|No Intervention|Treatment as Usual (TAU)|The TAU arm will not receive the additional treatment from the study. Subjects will receive psychiatric treatment from their usual providers.
89665934|NCT05669950|Experimental|Lu AG13909|Participants in Part A will receive multiple intravenous (IV) doses of Lu AG13909 per a prespecified dosing schedule. After data from Part A has shown that a pharmacologically relevant dose level is safe and tolerable, participants in Part B will then receive multiple IV doses of Lu AG13909 per a prespecified dosing schedule.
89665935|NCT05669625|Experimental|Experimental Group|Single subcutaneous injection of the investigational vaccine (0.5 ml)
89665936|NCT05669625|Placebo Comparator|Placebo Group|Single subcutaneous injection of the investigational placebo (0.5 ml)
89665937|NCT05669534|Active Comparator|Condition 1|Standard CHRP Intervention Components
89665938|NCT05669534|Experimental|Condition 2|Standard CHRP Intervention Components and Information Processing Components
89665939|NCT05669534|Experimental|Condition 3|Standard CHRP Intervention Components and Memory Components
89665940|NCT05669534|Experimental|Condition 4|Standard CHRP Intervention Components, Information Processing Components, and Memory Components
89665941|NCT05669534|Experimental|Condition 5|Standard CHRP Intervention Components, Executive Functioning Components
89665942|NCT05669534|Experimental|Condition 6|Standard CHRP Intervention Components, Information Processing Components, and Executive Functioning Components
89665943|NCT05669534|Experimental|Condition 7|Standard CHRP Intervention Components, Memory Components, and Executive Functioning Components
89665944|NCT05669534|Experimental|Condition 8|Standard CHRP Intervention Components, Information Processing Components, Memory Components, and Executive Functioning Components
89214358|NCT00892502|Active Comparator|1|Bismuth tablets
89214359|NCT00892502|Placebo Comparator|2|Placebo tablets, containing no active substance
89214360|NCT01008189|Active Comparator|Self study comparison group|Caregivers and children and adolescents each received three books about coping with grief after the death of a loved one and a syllabus to guide reading
89214361|NCT01008189|Experimental|Family Bereavement Program|12- session group for caregivers and bereaved children and adolescents plus 2 individual sessions
89665945|NCT05669534|Experimental|Condition 9|Standard CHRP Intervention Components and Attention Components
89665946|NCT05669534|Experimental|Condition 10|Standard CHRP Intervention Components, Information Processing Components, and Attention Components
89665947|NCT05669534|Experimental|Condition 11|Standard CHRP Intervention Components, Memory Components, and Attention Components
89665948|NCT05669534|Experimental|Condition 12|Standard CHRP Intervention Components, Information Processing Components, Memory Components, and Attention Components
89665949|NCT05669534|Experimental|Condition 13|Standard CHRP Intervention Components, Executive Functioning Components, and Attention Components
89665950|NCT05669534|Experimental|Condition 14|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, and Information Processing Components
89214362|NCT00885404|Other|Intravenous fluids|
89214363|NCT00191113|No Intervention|Control|Control arm; untreated with Humatrope. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
89665951|NCT05669534|Experimental|Condition 15|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, and Information Processing Components
89665952|NCT05669534|Experimental|Condition 16|Standard CHRP Intervention Components, Executive Functioning Components, Attention Components, Information Processing Components, and Memory Components
89665953|NCT05664022|Experimental|Global postural reeducation approach|The patient will receive 15 sessions of the Global Postural Re-education approach performed 2times/week for 1 hour including patient education. Each treatment will be individualized for every patient and for his/her pain-related limitation. Each session includes only 2-3 postures to increase the standardization of treatment.
89665954|NCT05664022|Active Comparator|Conventional treatment|The patient will receive the conventional treatment in form of exercise program of(abdominal and pelvic floor strengthening)and (stretching exercise of back and hip flexor muscles)to improve pain and function in chronic low back pain patients.
89048819|NCT04639557|Experimental|Virtual Intervention|Mothers in this group will participate in 16, once per week, scheduled 2-hour virtual group therapy sessions through Zoom for Healthcare. These sessions will include both visual media (e.g., presentations, recorded examples of skills), and discussions. A technician will be present in the virtual group therapy session to manage the technical component. These sessions will be supplemented with a 1-hour drop-in session moderated by a facilitator each week in which participants will be able to clarify topics for that week, discuss the material in more depth, and/or connect with other participants to share about the skill practice.
89048820|NCT04639557|Experimental|Therapy Intervention Pre-recorded|Mothers in this group will have access to short pre-recorded videos of the presentations with facilitator commentary (i.e., 10-12 minutes) with additional video material as warranted each week (e.g., recorded examples of skill practice) for a maximum of 30-minutes of material per week. This arm will also have a 1-hour drop-in session each week with a group facilitator to moderate homework check-ins and discussion of the material.
89048821|NCT05165693|Experimental|Experimental Formula|One 296 mL serving of study product
89048822|NCT05165693|Active Comparator|Test Meal|48 g Instant oatmeal
89048823|NCT04639362|Experimental|Intensification|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
89048824|NCT04639362|Experimental|Observation|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
89048825|NCT04683536||control group|Patients underwent TUR-BT under spinal anesthesia
89665955|NCT05663411|Experimental|Treatment group A: SHR6508|
89665956|NCT05663411|Experimental|Treatment group B: SHR6508|
89665957|NCT05663411|Active Comparator|Treatment group C: Cinacalcet|
89665958|NCT05660551|No Intervention|Control Group|
89665959|NCT05660551|Experimental|Demonstration group|
89665960|NCT05660551|Experimental|Telesimulation Group|
89665961|NCT05660551|Experimental|Kahoot Game Group|
89665962|NCT05653479|Experimental|Treatment Group 1|Single subcutaneous injection of a dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
89665963|NCT05653479|Experimental|Treatment Group 2|Single subcutaneous injection of a dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
89665964|NCT05653479|Experimental|Treatment Group 3|Single subcutaneous injection of a dose of UPB-101 (formerly ASP7266) in 8 Japanese participants
89665965|NCT05653479|Experimental|Treatment Group 4|Single subcutaneous injection of a dose of UPB-101 (formerly ASP7266) in 8 Non-Japanese Non-East Asian participants
89665966|NCT05651152|Experimental|JZP441|Participants who will be randomized to receive an oral dose of JZP441.
89665967|NCT05651152|Placebo Comparator|Placebo|Participants who will be randomized to receive an oral dose of placebo.
89665968|NCT05647733|Experimental|Restrictive group: Low splanchnic blood volume Restrictive fluid management strategy|The intervention group is targeted at lowering splanchnic blood volume using a phlebotomy and restricting fluid infusion, individualized to the physiological needs of this population and the distinct LT surgical phases. The strategy will first consist of performing a phlebotomy without fluid replacement at the start of surgery.We will combine it with fluid restriction to prevent excessive fluid administration and its effect on splanchnic blood volume and blood loss, combined with the effect of the phlebotomy, as well as to limit fluid overload, as previously reported. Fluid will be administered to compensate blood loss and treat severe hemodynamic instability.The phlebotomy will be transfused back at the beginning of the reperfusion phase where fluid management will be based on a goal-directed therapy (GDT) using either PPV or SV, as in the control group.
89665969|NCT05647733|Active Comparator|Liberal group: Optimized cardiac output liberal fluid management strategy|The control group will receive a liberal intraoperative fluid management strategy optimizing cardiac output throughout the surgery. It will consist of administering 250 mL fluid boluses until SV stops to increase by more than 10% or until PPV is below 12%, a dynamic indicator of fluid responsiveness validated in many surgical populations, including ESLD patients undergoing a LT.This strategy is informed by data from recent clinical trials on benefits of GDT in major surgery, data on strategies used in major surgery, liver resection or LT and our survey on current practice.
89665970|NCT05634876|Experimental|Treatment First - MSA|"Includes participants with MSA only.~Patients in the treatment-first arm will receive active treatment at weeks 1, 5, 13, 25, 37, 49, 73, and 97; and placebo doses at weeks 17, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
89665971|NCT05634876|Experimental|Delayed Start - MSA|"Includes participants with MSA only~Patients in the delayed-start arm will receive placebo injections at weeks 1, 5, 73, and 97; and active treatment at weeks 13, 17, 25, 37, 49, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
89665972|NCT05634876|Experimental|Treatment First - PD|"Includes participants with PD only.~Patients in the treatment-first arm will receive active treatment at weeks 1, 5, 13, 25, 37, 49, 73, and 97; and placebo doses at weeks 17, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
89665973|NCT05634876|Experimental|Delayed Start - PD|"Includes participants with PD only.~Patients in the delayed-start arm will receive placebo injections at weeks 1, 5, 73, and 97; and active treatment at weeks 13, 17, 25, 37, 49, 61, 85, and 109. Participants will be followed up for 24 weeks after their last dose.~All participants will receive three priming doses of UB-312 300 µg, followed by 5 booster doses of UB-312 300 µg. To keep the blind, both treatment arms will receive active treatment and placebo injections for a total of 12 injections (8 active treatment injections + 4 placebo injections)."
89665974|NCT05634785|Experimental|ATLCAR.CD30|Single Group Assignment: Subjects with Nonseminomatous Germ Cell Tumors who meet eligibility criteria for cellular therapy.
89665975|NCT05628532|Experimental|Use of the DBLG1 system|After a 14-day baseline period during which the patient will use a Dexcom G6 Continuous Glucose Monitoring (CGM) and his current therapy (multiple daily injection or open-loop pump), the patient will start a 42-day treatment period with the DBLG1 system followed by an optional 42-day extension period.
89665976|NCT05626686|Experimental|CLINY reusable catheter 28 days|The investigation is designed as an open-labelled, single-arm investigation, in which the reuse CLINY catheter will be compared to single use catheters at baseline.
89665977|NCT05618340|Experimental|Single group target value method|This trial is a prospective, multicenter, single-group target value method study. All subjects are treated uniformly with the pulse ablation system provided in this protocol for paroxysmal AF, and the test results for the main indicators are statistically compared with the target values, a widely accepted standard in professional medicine, and the test results are considered to be attained if the one-sided 95% confidence interval for the test results is not lower than the target values.
89665978|NCT05616572|Experimental|Caregiver|After consent, the study visit will occur. The study visit will consist of a brief set of demographic questions and a pre-game play knowledge assessment and anxiety assessment, followed by completion of the OncoWhiz game. Immediately after utilizing OncoWhiz, the participant will complete a knowledge assessment and anxiety assessment, in addition to a satisfaction survey.
89665979|NCT05603299|No Intervention|Control Group|The Control group treats their simulated patients using standard practice and have no introduction to the new test.
89665980|NCT05603299|Experimental|Intervention Group 1 - Test Results Given|Receiving educational materials describing the clinical validation and use cases of a predefined Dawn™ test and is given specific Dawn™ test results in Round 2 of CPV administration, whether they order the test or not.
89665981|NCT05603299|Experimental|Intervention Group 2 - Test Results Optional|Receiving educational materials describing the clinical validation and use cases of a predefined Dawn™ test and is given specific Dawn™ test results in Round 2 of CPV administration, only if they choose to order the test.
89665982|NCT05602116|Experimental|1 x 1000000 C2C_ASCs/kg body weight|Trial participant 1 - 5 will be treated with 1 x 1000000 C2C_ASCs/kg body weight
89665983|NCT05602116|Experimental|2 x 1000000 C2C_ASCs/kg body weight|Trial participant 6 - 10 will be treated with 2 x 1000000 C2C_ASCs/kg body weight
88995274|NCT04855006|Experimental|Vaginal Microbiome Donors|Women allocated in the donor group will donate their vaginal secretion, which will be processed and analyzed throughy before it is used as a transplant. In total, the donors will each provide approximately 10 donations of vaginal secretion.
88995275|NCT04838808|Active Comparator|Rivaroxaban|Rivaroxaban 2.5mg oral twice daily for 90-days
88995276|NCT04838808|Placebo Comparator|Placebo|Oral placebo tablet twice daily for 90-days
88995277|NCT04834726|Active Comparator|1: Usual Care|Patients will receive a phone call to schedule their appointment from an Access Center representative. Access Center representatives will make up to 3 attempts to schedule an appointment with the patient. Patients randomized to this arm will not receive any text messaging.
88995278|NCT04834726|Experimental|2A: Call Back + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
88995279|NCT04834726|Experimental|2B: Call Back + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
88995280|NCT04834726|Experimental|2C: Call Back + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
88995281|NCT04834726|Experimental|2D: Call Back + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-outWill include a prompt to agree to scheduling. The access center will call these patients back to schedule, calling up to 3 times.
88995282|NCT04834726|Experimental|3A: In-Bound Call + Standard Msg|The message describes that the patient is eligible for the COVID vaccine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
88995283|NCT04834726|Experimental|3B: In-Bound Call + Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
88995284|NCT04834726|Experimental|3C: In-Bound Call + Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
88995285|NCT04834726|Experimental|3D: In-Bound Call + Opt-Out Framing|The message will highlight that a vaccine is reserved for the patient, implying that they need to opt-out. Will include a prompt to agree to scheduling, which will be followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
88995286|NCT04781842|Experimental|Boxing Club Group|Participation in a weekly boxing program designed for people with Parkinson Disease
89214364|NCT00191113|Experimental|Humatrope|Humatrope (0.05 mg/kg/dose) by subcutaneous injection 6 times per week. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
89214365|NCT00608582|Experimental|Real rTMS|These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
89665984|NCT05600231|Experimental|Treatment Group: Brush Only|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
89665985|NCT05600231|Experimental|Treatment Group: Brush / Rinse (LISTERINE COOL MINT Antiseptic Mouthwash)|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste once daily for 1 timed minute during the week under supervision and rinse with 20 milliliters (mL) of LISTERINE COOL MINT Antiseptic Mouthwash for 30 seconds. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
89665986|NCT05600231|Experimental|Treatment Group: Brush / Rinse LISTERINE COOL MINT ZERO Alcohol Mouthwash)|Participants will brush their teeth using a marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste once daily for 1 timed minute during the week under supervision and rinse with 20 mL of LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 seconds. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over weekends and holidays for 12 weeks. First product use will occur at the site under supervision.
89665987|NCT05600231|Experimental|Treatment Group: Brush / Floss|Participants will brush their teeth using marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute and floss with Reach Unflavored Waxed Dental Floss under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening. Over weekends and holidays, participants will brush and floss once daily. Only brushing will be performed a second time in the evening for 12 weeks. First product use will occur at the site under supervision.
89665988|NCT05600231|Experimental|Treatment Group: Brush / Floss / Rinse (LISTERINE COOL MINT ZERO Alcohol Mouthwash)|Participants will brush their teeth using marketed soft bristled toothbrush and Colgate Cavity Protection Toothpaste for 1 timed minute, floss with Reach Unflavored Waxed Dental Floss and rinse with LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 seconds under virtual supervision once daily during the week. At home, participants will brush and rinse a second time unsupervised daily in the evening. Over weekends and holidays, participants will brush, floss and rinse once daily. Only brushing and rinsing will be performed a second time in the evening for 12 weeks. First product use will occur at the site under supervision.
89665989|NCT05600231|No Intervention|Healthy Reference Group|Healthy participants will enroll in this reference group and will not receive any study product nor will they receive a prophylaxis as part of their participation in this study. The healthy reference group will be used as a comparator group for microbiome.
89665990|NCT05600049|Experimental|Condition 1 : prototypes from (815-v1 001) to (815-v1 050) every day|Application on the brown spots of the face and/or hands for the prototypes (815-v1 001) to (815-v1 050) at D0, D1, D2, D3, D4 and D5.
89665991|NCT05600049|Experimental|Condition 2 : prototypes from (815-v1 051) to (815-v1 100) every week|Application on the brown spots of the face and/or hands for the prototypes (815-v1 051) to (815-v1 100) at D0, D7, D14, D21, D28 and D35.
89665992|NCT05600049|Experimental|Conditions 3 : prototypes from (815-v1 101) to (815-v1 150) every two weeks|Application on the brown spots of the face and/or hands for the prototypes (815-v1 101) to (815-v1 150) at D0, D14, D28, D42, D56 and D70.
89665993|NCT05600049|Experimental|Condition 4 : prototypes from (815-v1 151) to (815-v1 200) every two weeks|Application on the brown spots of the face and/or hands for the prototypes (815-v1 151) to (815-v1 200) at D0, D14, D28, D42, D56 and D70.
89665994|NCT05581784|Experimental|Pain neuroscience education.|This consists of generating elements from neurobiology and neurophysiology for the understanding of pain from the development of metaphors.
89665995|NCT05581784|Other|Conventional treatment or Usual Care|Pharmacological treatment and indications estimated by a specialist in palliative care and pain.
89665996|NCT05581472|Active Comparator|Online Acceptance and Commitment Therapy Intervention + Phone Coaching|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls: one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. The intervention includes 8 modules: Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Each module ends with a practice assignment which participants are asked to engage in over the next week.~During the phone coaching calls, the clinical student will be able to help troubleshoot any technical difficulties being experienced, as well as clarify any questions about the material being taught in the intervention."
89214366|NCT00608582|Sham Comparator|Sham rTMS|Patients receive a series of 10 Sham Transcranial Magnetic Stimulation, Repetitive (rTMS) treatments, followed by a series of 10 Real rTMS treatments. Sham rTMS treatments are identical to the Real rTMS treatments, however, no magnetic pulse is released. There is pre-testing, and post-testing at 2 months after the last Sham rTMS treatment.
89214367|NCT03965052|Experimental|PRO-179|Dosage: 1 drop every 24 hours, at night, in both eyes.
89214368|NCT03965052|Active Comparator|Travatan®|Dosage: 1 drop every 24 hours, at night, in both eyes.
89214369|NCT05265117||HIPEC|HIPEC is given after primary debulking surgery or interval debulking.
89214370|NCT05265117||CONTROL|No HIPEC
89665997|NCT05581472|Active Comparator|Online Acceptance and Commitment Therapy Intervention without phone coaching|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls: one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. The intervention includes 8 modules: Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Each module ends with a practice assignment which participants are asked to engage in over the next week."
89665998|NCT05581472|No Intervention|Waitlist Control|Participants in this arm of the study will complete the same sleep diaries and questionnaires at the same time points as the intervention group, but will not be administered the intervention modules and will not receive any phone coaching. When they have completed the 1-month follow-up they will be offered the intervention.
89665999|NCT05580380|Active Comparator|Limited Patient-Clinician Relationship Group|
89666000|NCT05580380|Experimental|Enhanced Patient-Clinician Relationship Group|
89666001|NCT05574777|Other|Gastric mucosal ablation|Participants receive submucosal injection followed by ablation of gastric mucosa using Hybrid argonplasma coagulation (HAPC).
89666002|NCT05565170|Active Comparator|Structured ICT-assisted multimodal lifestyle intervention|Participants assigned to this study arm follow an intensive structured, digitally supported multimodal lifestyle intervention programme (combination of individual and group-based in-person consultations/sessions and digital activities in the LETHE mobile phone App). Intervention duration is 2 years.
89666003|NCT05565170|Sham Comparator|Self-guided multimodal lifestyle intervention|Participants assigned to this study arm receive regular health advice in connection with the study visits (and through a simplified version of the LETHE mobile phone App), and are recommended and encouraged to independently implement healthy lifestyle changes that are suitable and fit in with their daily routine. Intervention duration is 2 years.
89666004|NCT05563402|Experimental|Treatment arm|"Therefore, the investigators propose an, open, non-randomized study. This study protocol includes 12 one-hour RAGT training sessions for 4 weeks, three times a week, under the supervision of a qualified rehabilitation team.~Informed consent will be obtained from patients before inclusion in the study, which will be carried out in accordance with the Declaration of Helsinki.~With the aim of describing Usability as the main objective, and Safety as a secondary objective and functional changes at the level of balance, walking speed and quality of life."
89666005|NCT05563337|Experimental|Denervation treatment|
89666006|NCT05563337|Sham Comparator|Control|
89666007|NCT05561621||Patients with relapsing MS|
89666008|NCT05561621||Healthy controls|
89666009|NCT05551260|Experimental|People with ASD|30 people with ASD without IDD
89666010|NCT05551260|Active Comparator|Neurotypicals|30 neurotypicals
89666011|NCT05543369|Experimental|Cohort 1 : Healthy Japanese Participants|Participants will receive Elafibranor 80 mg once daily on Day 1 to Day 18.
89666012|NCT05543369|Experimental|Cohort 2: Healthy Non-Asian Participants|Participants will receive Elafibranor 80 mg once daily on Day 1 to Day 18.
89666013|NCT05537857|Experimental|High dietary salt|High salt diet will be tested in random order by all participants.
89666014|NCT05537857|Experimental|Low Dietary salt|Low salt diet will be tested in random order by all participants.
89666015|NCT05530512|Experimental|Anti-inflammatory EA (AI-EA)|Anti-inflammatory electroacupuncture therapy
89048826|NCT04683536||Study group|Patients underwent TUR-BT under spinal anesthesia combined with ultrasound guided obturator nerve blockade
89048827|NCT04639401|Experimental|persons with Multiple Sclerosis|
89048828|NCT04639401|Placebo Comparator|Healthy controls|
89048829|NCT04683419|Experimental|Patients with pleural effusion of Undetermined etiology|Patients with undiagnosed exudative pleural effusion will undergo modified pleural cryobiopsies and conventional pleural forceps biopsies in the same settings
89048830|NCT04639284||Combinational therapy|Participants who receive systemic treatment with an anti-angiogenic agent, including sorafenib, lenvatinib, apatinib, and bevacizumab, in combination with an anti-PD-1/PD-L1 antibody, including pembrolizumab, nivolumab, sintilimab, toripalimab, camrelizumab, tislelizumab, and atezolizumab.
89048831|NCT05103800|No Intervention|control group|Babies in the control group will not listen to any sound during the invasive procedures, the procedure will be recorded with a camera, and at the end of the study, the camera images will be watched by two experts in the field and the pain and comfort scale will be filled.
89048832|NCT05103800|Experimental|Experimental group|During the invasive interventions, the white noise prepared by the researcher for the babies in the experimental group will be started to be listened to 5 minutes before the start of the intervention and will be listened to for 5 more minutes during and after the intervention. At the same time, the procedure will be recorded with a camera. At the end of the study, the camera images will be watched by two experts in the field. comfort scale will be filled.
89048833|NCT00559689||1|receive once-daily administration of inhaled glucocorticosteroids at bedtime
89048834|NCT00559689||2|receive twice-daily administration of inhaled glucocorticosteroids
89048835|NCT05089214|Experimental|Intra oral clinical examination|
89048836|NCT04639440||Obese or overweight patients|
89048837|NCT04639440||Patients without overweight|
89048838|NCT00561249|Experimental|1|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo.
89048839|NCT00561249|No Intervention|2|No intervention
89048840|NCT05076656|Experimental|Probiotics arm|Individuals who receive a probiotics pill daily: Lactobacillus fermentum D3 (PCT/EP 2012058214)
89048841|NCT05076656|Experimental|FMT arm|Individuals who receive a FMT in the form of pills with fecal material from a healthy donor.
89048842|NCT05076656|Placebo Comparator|Control arm|Individuals who receive a probiotics pill daily of placebo (milk powder)
89048843|NCT00561288|Experimental|1|2000 mg acetaminophen per day
89048844|NCT00561288|Placebo Comparator|2|2000 mg cornstarch per day
89048845|NCT00561327||A|Patients chronically treated with drug losartan
89048846|NCT00561327||B|Patients not chronically treated with losartan
89048847|NCT00561366|Placebo Comparator|1|
89048848|NCT00561366|Experimental|2|
89214371|NCT03964974|Experimental|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|
89214372|NCT03964974|Placebo Comparator|Sleep Hygiene Education (SHE)|
89214373|NCT00892658|Experimental|Sorafenib + RT|
89214374|NCT00892736|Experimental|Treatment (veliparib)|"Patients receive veliparib PO BID* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive veliparib once on day 1 of course 1 for pharmacokinetic and pharmacodynamic studies."
89214375|NCT03966235|Experimental|Melatonin group|drug: melatonin tablets (Sigma-Aldrich Co. LLC, St. Louis, MO, USA); the frequency:3mg melatonin tablet was taken daily; duration: study treatment was maintained for 6 months.
89666016|NCT05530512|Experimental|Sympathoinhibitory EA (SI-EA)|sympatho-inhibitory electroacupuncture therapy
89666017|NCT05530512|Experimental|Combined EA (cEA)|combination of SI-EA and AI-EA
89666018|NCT05530512|Experimental|Control EA (Sham-EA)|Sham electroacupuncture
89666019|NCT05522946|Experimental|Parent and child without disability|Parent and child will play the game on the iPad using the sensors provided.
89666020|NCT05522946|Experimental|Parent and adolescent with mild to moderate cognitive or physical disability|Parent and adolescent will play the game on the iPad using the sensors provided.
89666021|NCT05522946|Experimental|Parent and adolescent with moderate to severe cognitive and/or physical disability|Parent and adolescent will play the game on the iPad using the sensors provided.
89666022|NCT05510895|Experimental|neoadjuvant and adjuvant triplet combination of encorafenib, binimetinib and cetuximab|"Neoadjuvant treatment with encorafenib, binimetinib and cetuximab for up to 8 weeks (4 biweekly cycles). In Week 10-12 surgery of the tumor followed by central determination of tumor regression grade (TRG).~TRG0-1: insufficient response to neoadjuvant triplet. Standard chemotherapy with fluoropyrimidines and oxaliplatin should be applied. TRG2-4: 4-8 weeks after surgery adjuvant treatment with encorafenib, binimetinib and cetuximab continues for up to 16 Weeks (8 biweekly cycles)."
89666023|NCT05505136||MAPS Study Patients with Medication Change Reported|No intervention will be administered. This is a retrospective study of the patients who participating in the MAPS Protocol 90D0234 completed in 2021. Patients who had a medication change reported in that study are the focus of this study MAPS II 90D0255.
89666024|NCT05493254|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
89666025|NCT05493254|Active Comparator|Treatment as usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
89666026|NCT05491707|Experimental|Music|Patients in the intervention group will receive music after the ASA monitors are applied. The music will be played at a self-selected volume, on Pro Bass Swagger Series Aux disposable earphones and will be played for the duration of the surgical procedure. The music will be played from an iPhone which will be placed in a plastic bag for infection control purposes. These patients will receive standard anaesthetic care.
89666027|NCT05491707|No Intervention|Control|The control group will not receive music. These patients will receive standard anaesthetic care.
89666028|NCT05489731|Experimental|Dose escalation phase-Dose group 1 VIC-1911 Tablets with Osimertinib Mesylate Tablets|Advanced NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation negative or who experienced third-generation EGFR-TKI failure and a subsequent platinum-based doublet chemotherapy failure
89666029|NCT05489731|Experimental|Dose escalation stage - Dose group 2 VIC-1911 Tablets with Osimertinib Mesylate Tablets|Advanced NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation negative or who experienced third-generation EGFR-TKI failure and a subsequent platinum-based doublet chemotherapy failure
89666030|NCT05489731|Experimental|Dose expansion phase VIC-1911 Tablets with Osimertinib Mesylate Tablets|Cohort 1: NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation positive; Cohort 2: NSCLC patients who experienced third-generation EGFR-TKI failure
89666031|NCT05478473|Experimental|Chidamide combined with Toripalimab|
89666032|NCT05478291|Experimental|Vitamin D supplementation|"Appropriate diet and physical activity counselling~Supplementation with Vitamin D and oral Calcium- Doses of cholecalciferol (commercial name, Calcirol) 60,000 international units (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer.~After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated. If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 international units per day will be given as a maintenance dose."
89666033|NCT05473299|Experimental|aXess graft|
89666034|NCT05467293|Active Comparator|0.3% YP-P10 Ophthalmic Solution|
89666035|NCT05467293|Active Comparator|1% YP-P10 Ophthalmic Solution|
89666036|NCT05467293|Placebo Comparator|YP-P10 Placebo Ophthalmic Solution (vehicle)|
89214376|NCT03966235|Placebo Comparator|Control group|drug: placebo tablet; the frequency: placebo tablet was taken daily; duration: study treatment was maintained for 6 months.
89214377|NCT00892814|Experimental|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
89214378|NCT00892814|Active Comparator|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
89214379|NCT03966469||Support Person Present|Participants who bring a support person with them to their preoperative appointment.
89214380|NCT03966469||Patient Present Only|Participants who present by themselves to their preoperative appointment.
89214381|NCT01077661||Patients administrated Nebivolol|There is only one group. This group includes patients administrated Nebivolol
89214382|NCT00606320|Experimental|Aripiprazole|
89214383|NCT03966079|Experimental|Intervention arm|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
89048849|NCT00561405|Experimental|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner.
89048850|NCT00561405|Active Comparator|Body weight supported treadmill training|Body Weight Supported Treadmill Training. Participants walk on a treadmill while partially supported with an overhead harness system. Mass repetition of the normal gait cycle is encouraged through the support of the harness, the movement of the treadmill, and the assistance of one or two trainers to position limbs and trunk.
89048851|NCT00561444||Quality of Life Study|Prostate cancer patients
89048852|NCT05043974|Experimental|Dry immersion|5 days of dry-immersion.
89666037|NCT05463367|Experimental|Chronic Back Pain with Opioid Use|"Subjects of this arms will be on a previously prescribed, short term acting opioid. Previous to each of the three imaging visits, subjects will be instructed to withhold from taking their regular morning opioid dose. Subjects will be randomized into a group that determines the sequence of which they will receive the study drugs. The three sequences are as follows:~treatment dose #1: 25mg carbidopa/ 100mg levodopa + 500mg naproxen, treatment dose #2: subjects prescribed, short acting opioid;~treatment dose #1: placebo, treatment dose #2: subjects prescribed, short acting opioid; or~treatment #1: subjects prescribed, short acting opioid, treatment dose #2: placebo."
89666038|NCT05463367|Experimental|Chronic Back Pain with Opioid Misuse Disorder|"Subjects of this arms will be on a previously prescribed, short term acting opioid. Previous to each of the three imaging visits, subjects will be instructed to withhold from taking their regular morning opioid dose. Subjects will be randomized into a group that determines the sequence of which they will receive the study drugs. The three sequences are as follows:~treatment dose #1: 25mg carbidopa/ 100mg levodopa + 500mg naproxen, treatment dose #2: subjects prescribed, short acting opioid;~treatment dose #1: placebo, treatment dose #2: subjects prescribed, short acting opioid; or~treatment #1: subjects prescribed, short acting opioid, treatment dose #2: placebo."
89666039|NCT05448950|Experimental|VIG Continued Access|"Patients referred for AVG implant should be screened for study eligibility. A member of the Research Team will evaluate the patient for eligibility. If all initial inclusion criteria are met and no exclusion criteria are present, a member of the Research Team should inform the patient about the study's purpose and should obtain written informed consent.~Final enrollment eligibility is determined at the time of surgery, after the physician has confirmed the final inclusion criterion is met. Enrolled subjects will be assigned a unique study subject identification number."
89666040|NCT05444933||Sequencing post-cabozantinib|Participants treated by cabozantinib and who received another systemic therapy post-cabozantinib.
89666041|NCT05444933||Long responders|Participants treated by cabozantinib and who had a disease controlled (CR, PR or SDi during > 12 months after cabozantinib initiation with or without additional local treatment).
89666042|NCT05444933||Non-responders|Participants treated by cabozantinib and who had a progressive disease less than 3 months after cabozantinib treatment initiation.
89666043|NCT05444933||Cabozantinib & rechallenge|Participants treated by cabozantinib who received systemic therapy and/or had prolonged treatment-free interval (≥ 12 weeks) between two cabozantinib treatment periods. Participants with at least one cabozantinib rechallenge could be included in this subgroup.
89666044|NCT05444933||Cabozantinib & therapeutic schedules|Participants treated by cabozantinib and who needed 1/ a dose increase following disease progression and/or a prior reduction, Or 2/ had any dose reduction/dose interruption of cabozantinib (schedule adaptation).
89666045|NCT05444933||Cabozantinib & local treatment|Participants treated by cabozantinib and who needed concomitant local treatment (LT) by surgery or radiotherapy
89666046|NCT05444933||Cabozantinib & elderly patients|Participants treated by cabozantinib and aged ≥ 75 years
89666047|NCT05441748|Experimental|Intervention treatment|Intervention treatment will contain walnuts and be consumed everyday for 3 weeks.
89666048|NCT05441748|Experimental|Intervention treatment oil|Intervention treatment will contain walnut oil in foods and be consumed everyday for 3 weeks.
89666049|NCT05441748|Placebo Comparator|Control treatment|Intervention treatment will contain corn oil in foods and be consumed everyday for 3 weeks.
89666050|NCT05439733||Exposed group|Women with a history of cesarean section and with a base-line attempt after planned cesarean section (TVBAC).
89666051|NCT05439733||Non-exposed group|Women with a history of cesarean section and scheduled cesarean section after cesarean section (CPAC).
89666052|NCT05423418|Active Comparator|A244/B.63521 + 200 μg of ALFQ adjuvant|Arm 1: An injection containing 300 μg A244 plus 300 μg B.63521 with 200 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
89048853|NCT00561483||Observation|Patients admitted to the hospital with decompensated heart failure
89048854|NCT05041088|Experimental|Experimental Group (ALL participants)|This group will be taking plamalogen supplement (ProdromeNeuro) and be followed through the study with neuropsychological testing, serology, and follow up MRI data. They will be administered 2mL per day for 6 months
89048855|NCT00561522|Experimental|Intervention treatment|Capecitabine
89048856|NCT00561522|No Intervention|No intervention treatment|No other preventive treatment
89048857|NCT05009264||OMT Group|This group will receive OMT muscle energy as treatment for myofascial pain syndrome
89048858|NCT05009264||Injection Group|This group will receive lidocaine injections for myofascial pain syndrome
89048859|NCT03454659||high (0.8 )|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients are undergoing supratentorial craniotomy surgeons.
89048860|NCT03454659||low (0,4) fiO2|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients undergoing supratentorial craniotomy surgeons.
89048861|NCT03454620|Experimental|GC1118 combination with irinotecan|GC1118 weekly(3mg or 4mg) + irinotecan 180mg/m2 biweekly dosing
89048862|NCT03454620|Experimental|GC1118 combination with FOLFIRI|GC1118 weekly(3mg or 4mg) + FOLFIRI biweekly dosing
89048863|NCT04628559|Active Comparator|Dexmedetomine|Patients recieving Dexmedetomidine.
89048864|NCT04628559|Active Comparator|Ketamine|Patients recieving Ketamine.
88995287|NCT04781842|No Intervention|Control group|No changes to regular physical activity during the study period
88995288|NCT04770363|Experimental|Bihemispheric Stimulation Group|The first group tDCS bihemispheric stimulation consisted of 20 minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex M1 (C3 and C4 of the international 10 -20 EEG electrode system).
88995289|NCT04770363|Experimental|Unihemispheric Stimulation Group|The second group unilateral stimulation, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone.
88995290|NCT04770363|Sham Comparator|Sham Group|The third sham group, the anode placed over the ipsilesional motor cortex M1 (C3 or C4 of the international 10 -20 EEG electrode system) and the cathode over contralesional supraorbital bone, but delivering no current.
88995291|NCT04762251|Experimental|Time-restricted eating (TRE)|The TRE group will be instructed to follow TRE (9 h/day) every day for 12 months with no other dietary instructions or advice provided. The TRE group will attend the same consult schedule as the CP group, but consultations will focus on timing of dietary intake and strategies to promote adherence. No dietary guidance regarding quantity or quality will be provided. Participants will be able to self-select the precise 9-h schedule that will best suit their lifestyles, with the caveat that the latest time of eating will be set at 7:00 pm. Outside of the elected eating window, participants will be allowed to consume water and black coffee and/or tea.
88995292|NCT04762251|Active Comparator|Current Best Practice (CP)|This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. No specific advice will be provided regarding time of day to start and finish eating and/or drinking (since this information is not outlined in current practice guidelines).
88995293|NCT04732949|Active Comparator|SNG001|SNG001 via inhalation using Ultra device, once a day for 14 days
89214384|NCT02540486|Experimental|LTHome web tool|The long-acting insulin glargine titration web tool (LTHome) will provide insulin glargine titration suggestions based on user inputted blood glucose readings.
89666053|NCT05423418|Active Comparator|A244/B.63521 + 100 μg of ALFQ adjuvant|Arm 2: An injection containing 300 μg A244 plus 300 μg B.63521 with 100 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
89666054|NCT05423418|Active Comparator|A244/B.63521 + 50 μg of ALFQ adjuvant|Arm 3: An injection containing 300 μg of A244 plus 300 μg B.63521 with 50 μg of ALFQ adjuvant will be administered as an IM injection into the deltoid muscle at visits 1, 3, and 5 (corresponding to Day 1, Day 29, and Day 57).
89666055|NCT05416424|Experimental|Study group|Healthy patients aged 18-50 who have a uterus, identify as female and have come to the outpatient Center for Women's Health (CWH) for management of bleeding, pelvic pain and fibroids. They will be offered enrollment post-surgery or procedure and will be followed longitudinally for 12 months.
89666056|NCT05390853|Experimental|Active tDCS (A)|"Two daily tDCS sessions for 5 days a week, for 2 consecutive weeks, are carried out, simultaneously with the usual rehabilitation physiotherapy of the upper limbs.~Patients will receive the usual rehabilitation physiotherapy of the upper limbs at least in the 4 weeks before and in the 4 weeks after the tDCS treatment period too."
89666057|NCT05390853|Placebo Comparator|Sham tDCS (S)|"Two daily tDCS sessions for 5 days a week, for 2 consecutive weeks, are carried out, simultaneously with the usual rehabilitation physiotherapy of the upper limbs.~Patients will receive the usual rehabilitation physiotherapy of the upper limbs at least in the 4 weeks before and in the 4 weeks after the tDCS treatment period too."
89666058|NCT05382871|Experimental|1: BIBP Inactivated COVID-19 vaccine (Omicron)|subjects will be blinded and receive two doses of BIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine
89666059|NCT05382871|Experimental|2: WIBP Inactivated COVID-19 vaccine (Omicron)|subjects will be blinded and receive two doses of WIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine
89666060|NCT05382871|Experimental|3：BIBP Inactivated COVID-19 vaccine (Omicron)|subjects will be blinded and receive two doses of BIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine
89666061|NCT05382871|Experimental|4: WIBP Inactivated COVID-19 vaccine (Omicron)|subjects will be blinded and receive two doses of WIBP Inactivated COVID-19 vaccine (Omicron) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine
89666062|NCT05382871|Active Comparator|5：Inactivated COVID-19 Vaccine (prototype)|subjects will be blinded and receive two doses of Inactivated COVID-19 Vaccine (prototype) with 28 days apart more than 3 months after 2 or 3 doses of inactivated COVID-19 vaccine
89666063|NCT05382871|Active Comparator|6：Inactivated COVID-19 Vaccine (prototype)|subjects will be blinded and receive two doses of Inactivated COVID-19 Vaccine (prototype) with 28 days apart more than 3 months after 2 or 3 doses of COVID-19 mRNA vaccine
89666064|NCT05377086|Experimental|schroth group|This arm was planned as the exercise group which includes Schroth 3-Dimensional scoliosis exercise.
89666065|NCT05377086|Experimental|conventional group|This arm was planned as the exercise group which includes conventional scoliosis exercise.
89666066|NCT05375617||Acute lymphoblastic leukemia cohort|
89666067|NCT05375617||Brain tumor cohort|
89666068|NCT05374954|Experimental|A1：one dose, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
89666069|NCT05374954|Active Comparator|A2：one dose, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
89666070|NCT05374954|Experimental|A3：one dose, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
89214385|NCT02540486|Active Comparator|Enhanced Usual Therapy (EUT)|The Enhanced Usual Therapy arm will receive insulin glargine titration instructions that are the usual therapy provided by the physician/HCP, in addition to diabetes education.
89214386|NCT03966859|Placebo Comparator|Placebo|Participants will receive lactose placebo tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
89666071|NCT05374954|Active Comparator|A4：one dose, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
89666072|NCT05374954|Experimental|B1：one dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
89666073|NCT05374954|Active Comparator|B2：one dose, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
89214387|NCT03966859|Experimental|Atorvastatin|Participants will receive 20mg atorvastatin tablets, encapsulated in opaque capsules, and will be asked to take one capsule daily for seven days at night-time, by mouth
89666074|NCT05374954|Experimental|B3：one dose, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
89666075|NCT05374954|Active Comparator|B4：one dose, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive one dose from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
89666076|NCT05374954|Experimental|C1：two doses, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
89666077|NCT05374954|Active Comparator|C2：two doses, 18-59 years old, from 3 months to 6 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
89666078|NCT05374954|Experimental|C3：two doses, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
89666079|NCT05374954|Active Comparator|C4：two doses, 18-59 years old, from 6 months to 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
89048865|NCT04628559|Placebo Comparator|Placebo|Patients recieving Saline.
89048866|NCT04683341|Experimental|Arm A - initial TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and HBV NUC treatment naïve or experienced (except prior TAF) will receive initial treatment (Arm A) with TAF 25 mg/day.
89048867|NCT04683341|Experimental|Arm B - switch to TAF treatment group|cirrhotic or non-cirrhotic CHB patients with hepatic decompensation and currently under HBV NUC treatment (except TAF) with HBV DNA < 20 IU/mL within 6 months prior screening will switch (Arm B) to TAF 25 mg/day
89048868|NCT04683302|Active Comparator|control|conventional 2D guided internal jugular vein catheterization
89048869|NCT04683302|Experimental|intervention|3D biplanar guided internal jugular vein catheterization
89048870|NCT04683263|Active Comparator|Intervention|Fisiocrem®, a topical cream composed of the natural ingredients Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
89048871|NCT04683263|Placebo Comparator|Placebo|topical cream with similar characteristics and aspect, without active ingredients.
89666080|NCT05374954|Experimental|C5：two doses, 18-59 years old, more than 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 2 doses of inactivated COVID-19 vaccine
89666081|NCT05374954|Active Comparator|C6：two doses, 18-59 years old, more than 12 months after 2 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 2 doses of inactivated COVID-19 vaccine
89666082|NCT05374954|Experimental|D1：two doses, 60 years old and above, from 3 months to 6 months after 2 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
89666083|NCT05374954|Active Comparator|D2：two doses, 60 years old and above, from 3 months to 6 months after 2 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 2 doses of inactivated COVID-19 vaccine
89666084|NCT05374954|Experimental|D3：two doses, 60 years old and above, from 6 months to 12 months after 2 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
89666085|NCT05374954|Active Comparator|D4：two doses, 60 years old and above, from 6 months to 12 months after 2 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 2 doses of inactivated COVID-19 vaccine
89666086|NCT05374954|Experimental|E1：two doses, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
89666087|NCT05374954|Active Comparator|E2：two doses, 18-59 years old, from 3 months to 6 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
89666088|NCT05374954|Experimental|E3：two doses, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
89666089|NCT05374954|Active Comparator|E4：two doses, 18-59 years old, from 6 months to 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
89666090|NCT05374954|Experimental|E5：two doses, 18-59 years old, more than 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 3 doses of inactivated COVID-19 vaccine
89666091|NCT05374954|Active Comparator|E6：two doses, 18-59 years old, more than 12 months after 3 doses of vaccination|subjects aged 18-59 years old will be blinded and receive two doses of vaccine with 28 days apart more than 12 months after 3 doses of inactivated COVID-19 vaccine
89666092|NCT05374954|Experimental|F1：two doses, 60 years old and above, from 3 months to 6 months after 3 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
89666093|NCT05374954|Active Comparator|F2：two doses, 60 years old and above, from 3 months to 6 months after 3 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 3 months to 6 months after 3 doses of inactivated COVID-19 vaccine
89666094|NCT05374954|Experimental|F3：two doses, 60 years old and above, from 6 months to 12 months after 3 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
89666095|NCT05374954|Active Comparator|F4：two doses, 60 years old and above, from 6 months to 12 months after 3 doses of vaccination|subjects aged 60 years old and above will be blinded and receive two doses of vaccine with 28 days apart from 6 months to 12 months after 3 doses of inactivated COVID-19 vaccine
89048872|NCT04628676|Experimental|TXA group|tranexamic acid added to irrigation solution
89048873|NCT04628676|Experimental|EPN group|epinephrine added to irrigation solution
89048874|NCT00561561|Experimental|1|Subjects with schizophrenia
89048875|NCT00561561|Active Comparator|2|Health controls
89048876|NCT00561561|Active Comparator|3|Family members of subjects with schizophrenia
89048877|NCT00561561|Active Comparator|4|Family members of healthy controls
89048878|NCT01214629|Experimental|LY2523355|
89048879|NCT01214629|Experimental|LY2523355 + pegfilgrastim|
89666096|NCT05374720|Experimental|Salpingectomy for Extra-Uterine Pregnancy|patients with salpingectomy for Ectopic Pregnancy
89666097|NCT05374720|Sham Comparator|hysterectomies|patients with hysterectomy for prolapsus, adenomyosis or myomectomy
88995294|NCT04732949|Placebo Comparator|Placebo|Placebo via inhalation using Ultra device, once a day for 14 days
89666098|NCT05365724|Experimental|subjects aged 18-59 years old|
89666099|NCT05365724|Experimental|subjects aged 60 years old and above|
89666100|NCT05363007|Experimental|Upfront SI|Upfront nanoliposomal irinotecan + 5-FU/leucovorin plus SI
89666101|NCT05363007|Experimental|Add-on SI|Add-on SI following limited progression to nanoliposomal irinotecan + 5-FU/leucovorin
89666102|NCT05351606|Experimental|Brief Intervention|Participants will receive one time tobacco use cessation counseling and quitline number.
89666103|NCT05351606|Experimental|Intensive Intervention|Participants will receive intensive behavioral counseling spread over 12 sessions, Nicotine Replacement Therapy and Bupropion, and the quitline number.
89666104|NCT05350618||Asymptomatic controls|A single transperineal ultrasound assessment session will be conducted by two independent physiotherapists with an expertise in pelvic floor rehabilitation
89666105|NCT05350618||Women with provoked vestibulodynia|A single transperineal ultrasound assessment session will be conducted by one physiotherapist with an expertise in pelvic floor rehabilitation
89666106|NCT05346159||turner syndrome group|
89666107|NCT05346159||control group|
89666108|NCT05343052||Student Athlete|Student-athlete rostered on the varsity football team of participating institutions between 5/1/2022-6/30/2025 (study period)
89666109|NCT05329090|Experimental|experimental group|Experimental therapeutic strategy based on the use of rituximab in combination with glucocorticoids
89666110|NCT05329090|Placebo Comparator|control group|Control therapeutic strategy based on glucocorticoids plus placebo
89666111|NCT05328154|Other|Bisphosphonates (zoledronic acid, Aclasta® 5 mg) alone|Bisphosphonates are considered as the gold standard of treatment for osteoporosis. Zoledronic acid, Aclasta® 5 mg will be administered intravenously according to standard management criteria in order to obtain an homogeneous population.
89666112|NCT05328154|Active Comparator|bisphosphonates (zoledronic acid, Aclasta® 5 mg) associated with magnesium (MAG 2®, 100 mg)|In addition to bisphosphonates, patients in this group will take a 3-month treatment of magnesium (magnesium carbonate, MAG 2® 100 mg), 2 tablets of 100 mg/day, during the 3 months preceding the 1-year visit.
89666113|NCT05324059|Experimental|Group A: Pregabalin/Tramadol|Fixed dose combination tablet of 75 mg Pregabalin and 50 mg of Tramadol, orally, every 12 hours.
89666114|NCT05324059|Active Comparator|Group B: Pregabalin|Monotherapy with 75 mg of Pregabalin, orally, every 12 hours.
89666115|NCT05323292||Leukoplakia due to hyperkeratosis with dysplasia|Biopsy-confirmed diagnosis of hyperkeratosis with dysplasia.
89666116|NCT05323292||Leukoplakia due to hyperkeratosis with no dysplasia|Biopsy-confirmed diagnosis of hyperkeratosis with no dysplasia.
89666117|NCT05323292||Control group|Laryngoscopy showing no evidence of vocal fold mucosal disease.
89666118|NCT05303636|Experimental|Cohort 1 (adolescents aged 14-17) Hormonal Treatment Arm|Subjects in the USA will choose to use the LF111 tablets or drospirenone (DRSP) 3.5 mg chewable tablets; 1/3 of subjects in the USA should receive DRSP 3.5 mg chewable tablets. Only LF111 will be available to subjects in Europe.
89666119|NCT05303636|No Intervention|Cohort 1 (adolescents aged 14-17) Non-Hormonal Contraceptive Arm|Subjects in this group will not receive any investigational product. They will be free to use a non-hormonal contraceptive method of their choice. Non-hormonal contraceptive methods include barrier contraceptive methods (condoms, female condoms, cervical caps, diaphragms, and contraceptive sponges), double barrier methods, non-hormonal IUD (e.g., copper IUD), surgical female sterilization, vasectomized partner, spermicides, and sexual abstinence.
89666120|NCT05303636|Experimental|Cohort 2 (adults aged 18-45) Hormonal Treatment Arm|Subjects in the USA will choose to use the LF111 tablets or drospirenone (DRSP) 3.5 mg chewable tablets; 1/3 of subjects in the USA should receive DRSP 3.5 mg chewable tablets. Only LF111 will be available to subjects in Europe.
89666121|NCT05303636|No Intervention|Cohort 2 (adults aged 18-45) Non-Hormonal Contraceptive Method Arm|Subjects in this group will not receive any investigational product. They will be free to use a non-hormonal contraceptive method of their choice. Non-hormonal contraceptive methods include barrier contraceptive methods (condoms, female condoms, cervical caps, diaphragms, and contraceptive sponges), double barrier methods, non-hormonal IUD (e.g., copper IUD), surgical female sterilization, vasectomized partner, spermicides, and sexual abstinence.
88995295|NCT04685239|Active Comparator|Unipolar cup|Patients randomized to receive a conventional unipolar acetabular cup
88995296|NCT04685239|Active Comparator|dual mobility cup|Patients randomized to receive a double mobility acetabular cup
88995297|NCT04684147|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
88995298|NCT04637776||Patients with Heart Failure|Patients with heart failure who were discharged within the past month after hospitalization for any reason.
88995299|NCT04625504|Experimental|Mindfulness Based Intervention (MBI)|Patients Active Intervention group
88995300|NCT04625504|No Intervention|Wait-list Control (WL)|Patients Control receiving no treatment
88995301|NCT04625504|No Intervention|Healthy Control (HC)|Healthy Control receiving no treatment
89666122|NCT05290870||Subjects implanted with hydrophilic acrylic IOLs|Subjects were implanted with a HydroSmart IOL (FEMTIS, LENTIS or VISIOTIS)
89666123|NCT05290870||Subjects implanted with hydrophobic acrylic IOLs|Subjects were implanted with an ACUNEX IOL
89666124|NCT05287828||Indicators validation - Group A|"This group is composed with the contrasted pre-op CT scan of the 40 patients recruited.~The classification criterion is contrasted CT scan."
89666125|NCT05287828||Indicators validation - Group B|"This group is composed with the non-contrasted CT scan of the 40 patients recruted.~This group is composed with pre-op non-contrasted CT scans to validate the possibility to use the device on the first scan realised on patient, when there is a suspicion of a disease. The classification criterion is non-contrasted CT scan."
89666126|NCT05287828||Indicators validation - Group C|"This group is composed with the post-op contrasted CT scan of the 35 pathological patients listed above (25 AAA, 5 TAA, 5 JAA).~This last group is composed with post-op CT scans. These scans are realised in a purpose of follow-up. The classification criterion is post-op CT scan of patient with a AAA, TAA or JAA."
89666127|NCT05287828||Indicators validation - Group D|"This group is composed with the post-op non-contrasted CT scan of the 35 pathological patients above (25 AAA, 5 TAA, 5JAA).~To decrease risks for patients, practicians are doing more non-contrasted CT scan. Moreover, they still need the indicators to realize the follow-up of the patient after its surgery. This group is to evaluate the possibility for the software to analysis this type of scan. The classification criterion is post-op non-contrasted CT scan of patient with a AAA, TAA or JAA."
89666128|NCT05287828||Stent migration group|25 patients are added to the 25 patients treated with EVAR (25 AAA) recruted in part 1 in order to have more significative results.
89666129|NCT05274425||Enerzair 150/50/80 μg|Enerzair inhalation capsule (indacaterol acetate/glycopyrronium bromide/mometasone furoate; 150/50/80 μg) via Breezhaler
89666130|NCT05274425||Enerzair 150/50/160 μg|Enerzair inhalation capsule (indacaterol acetate/glycopyrronium bromide/mometasone furoate; 150/50/160 μg) via Breezhaler,
89666131|NCT05268666|Experimental|JBI-802|10 mg JBI-802 once daily as the starting dose with 4 days on/3 days off cycle
89666132|NCT05254041|Other|Mentrual Cup Removal|Menstrual Cup Removal.
89666133|NCT05251402|Active Comparator|Group A - Patinet Education|If you are assigned to this group, you will receive education on asthma and health from an ALOHA health coach.
89666134|NCT05251402|Active Comparator|Group B - Patient Education with Nutrition Counseling|If you are assigned to this group, you will receive the same patient education on asthma and health as Group A. In addition, you will receive nutrition counseling from your health coach who is a registered dietitian.
89666135|NCT05242900||At-risk for lymphedema|Participants at-risk for leg lymphedema
89666136|NCT05242900||With lymphedema|Participants with leg lymphedema
89666137|NCT05242900||With lymphedema undergoing complete decongestive therapy (CDT)|Participants with leg lymphedema undergoing routine complete decongestive therapy (CDT)
89666138|NCT05242887||Older adults hospitalized in acute geriatric units|Response to a questionnaire
89666139|NCT05240560|Experimental|BP1.3656|1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day
89666140|NCT05240560|Placebo Comparator|Placebo|1 tablet of matching placebo per day
89666141|NCT05235425|Active Comparator|Standard NDPP|12-month long, calorie-restricted NDPP
89666142|NCT05235425|Experimental|Very low-carbohydrate diet (VLCD)|VLCD is an adaptation of the standard NDPP curriculum, which preserves all features with the exception of altered dietary advice.
89666143|NCT05226429|Experimental|UNAIR Inactivated COVID-19 Vaccine 3 microgram|
89666144|NCT05226429|Experimental|UNAIR Inactivated COVID-19 Vaccine 5 microgram|
89666145|NCT05226429|Active Comparator|CoronaVac Biofarma COVID-19 Vaccine|
89666146|NCT05224245|Experimental|Single arm: ACURATE Prime XL Transfemoral Aortic Valve System|Subjects who provide written informed consent, meet all eligibility criteria, and are approved by the Case Review Committee (CRC) will be implanted with ACURATE Prime XL Transfemoral Aortic Valve using iSLEEVE, ACURATE Prime XL Delivery System and ACURATE Prime XL Loading kit
89666147|NCT05213468|Experimental|Self management app as add on to standard care|PainDrainerTM App as add on to standard treatment at the physiotherapy program at the clinic PainDrainer software application: PainDrainerTM app (version 1.1.19c). ' The PainDrainer app is an investigational device, intended as a digital aid for the self-management of chronic pain for use by adults without supervision by healthcare professionals in a home setting.
89666148|NCT05213468|No Intervention|Standard of care|Treatment as usual, standard treatment of care at the physiotherapy program at the clinic
89666149|NCT05212012|Experimental|D,L-methadonehydrochloride + mFOLFOX6|"Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)~Treatment with mFOLFOX6 every two weeks; will be administered:~Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1) LV at a dose of 400 mg/m² iv over two hours (day 1) 5-FU at a dose of 2400 mg/m² iv over 46 hours (day 1-3)"
89666150|NCT05202470|Experimental|Telehealth Education (TE)|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
89666151|NCT05202470|Active Comparator|Conventional Education (CE)|Paper-based education forms will be given to the patients in the first group. Face-to-face conventional diabetes education will be carried out.
89666152|NCT05198804|Experimental|ZN-c3 and Niraparib|ZN-c3 in combination with Niraparib
89666153|NCT05197439|Active Comparator|DEX group|Dexmedetomidine will be given at the beginning of the second step of DBS and last for 48 hours by electronic pump.
89666154|NCT05197439|Placebo Comparator|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively and postoperatively the same duration just like the DEX group would do.
89666155|NCT05195489|Experimental|Active Intervention|Family members participate in Connectors by phone and receive a packet of resources
89666156|NCT05195489|No Intervention|Comparison|Family members receive a pack of resources
89048880|NCT04628325|Experimental|high dose furosemide plus HSS|Patients treated high dose furosemide plus HSS
89666157|NCT05169060|Experimental|Fish oil capsules|Subjects will be randomized for the treatment of fish oil capsules. Subjects will take daily supplements of two or four fish oil capsules per day, 2 and 4 g respectively. Treatment will continue for 16 weeks. Fish oil capsules are enriched in omega-3 polyunsaturated fatty acids.
89048881|NCT04628325|Active Comparator|high dose furosemide alone|Patients treated high dose furosemide alone
89048882|NCT04318600|Experimental|human amniotic mesenchymal stem cell treatment group|
89048883|NCT04318600|No Intervention|blank control group|
89214388|NCT00528411|Active Comparator|1|Aspirin + Placebo
89214389|NCT00528411|Active Comparator|2|Aspirin + clopidogrel
89214390|NCT00528411|Experimental|3|Aspirin + Ticagrelor
89214391|NCT00895544|Experimental|1|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose B of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
89214392|NCT00895544|Experimental|2|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
89214393|NCT00136357|Experimental|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
89214394|NCT00136357|No Intervention|Delayed Intervention|Comparison group not receiving intervention until after the initial intervention was completed.
89666158|NCT05169060|Experimental|Fish oil and Salsalate|Salsalate is a non-steroid anti-inflammatory drug. Subjects taking 2 or 4g of fish oil capsules will be randomized to take in addition 1.5 or 3.0 g of salsalate per day. The combined treatment of fish oil and salsalate will continue for 8 weeks.
89666159|NCT05153408|Experimental|Part 1A: BLU-701 as monotherapy|Phase 1 dose escalation of BLU-701 as monotherapy at various dose levels
89666160|NCT05153408|Experimental|Part 1B: BLU-701 with osimertinib|BLU-701 in combination with osimertinib 40 mg or 80 mg tablets for oral administration
89666161|NCT05153408|Experimental|Part 1C: BLU-701 with platinum-based chemotherapy|"BLU-701 in combination with platinum-based chemotherapy (carboplatin and pemetrexed):~Carboplatin - IV infusion dosed to target AUC of 5-6 mg/mL min q3w~Pemetrexed - IV infusion dosed to 500 mg/m2 q3w"
89666162|NCT05153408|Experimental|Part 2A: BLU-701 as monotherapy|Phase 2 expansion group for BLU-701 as monotherapy at a dose determined during Part 1A in patients harboring the EGFR C797X resistance mutation
89666163|NCT05140044|Active Comparator|Home - Paper Intervention|Older adults who are given a 4-week paper-based balance intervention program. Performed 3days/week for 30min/day over the course of a 4-week period using printed materials with text instruction and images.
89666164|NCT05140044|Experimental|Home - Smartphone Intervention|Older adults who are given a 4-week home-based balance exercise program. Performed 3days/week for 30min/day over the course of a 4-week period using participants' smartphones.
89666165|NCT05131035|Experimental|Single Arm intervention|All participants will complete 40 hours of Cognitive Remediation with a mid-point assessment (20 hours/5 weeks) to determine the level of training needed to impact processing speed.
89666166|NCT05118230||Inclisiran Cohort|patients treated with inclisiran in certain special territories in China
89666167|NCT05118230||SoC Historical Cohort|patients treated with standard of care (SoC) in routine clinical practice from EMR database
89666168|NCT05101993|Experimental|AtriClip group|
89666169|NCT05100628|Experimental|Dose-Escalation Cohort 1: NOX66 800 mg + Doxorubicin|
89666170|NCT05100628|Experimental|Dose-Escalation Cohort 2: NOX66 1200 mg + Doxorubicin|
89666171|NCT05100628|Experimental|Dose-Escalation Cohort 3: NOX66 1800 mg + Doxorubicin|
89666172|NCT05100628|Experimental|Dose-Expansion Cohort: NOX66 + Doxorubicin|
89214395|NCT00895700|Experimental|Web-based behavioral intervention|
89214396|NCT00895700|No Intervention|Usual care|
89214397|NCT00129649|No Intervention|control group|This group received usual care and did not receive a telephone reminder
89214398|NCT00129649|Active Comparator|telephone reminder group|This group received a telephone reminder for their clinic appointment
89214399|NCT00895778|Experimental|NMB|muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
89214400|NCT00895778|Placebo Comparator|no NMB|no muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
89214401|NCT00895856||Old-aged people|
89214402|NCT00896246|Active Comparator|Klean-Prep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
89214403|NCT00896246|Experimental|Moviprep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
89214404|NCT00187135|Active Comparator|1|Fentanyl-1mcg/kg in 3 ml of Normal Saline
89214405|NCT00187135|Active Comparator|2|Fentanyl - 0.5 mcg/kg in 3 ml normal saline
89214406|NCT00187135|Placebo Comparator|3|normal saline
89214407|NCT00896324|Active Comparator|Cognitive Rehabilitation (Breast Cancer(BC) with chemotherapy)|Cognitive rehabilitation is a very low-risk method of treatment for cognitive deficits that involves restoring impaired function and/or training the individual to compensate for the area of deficit. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
89214408|NCT00896324|Active Comparator|Active Neurofeedback (BC pre-chemotherapy)|"In active Neurofeedback session subjects will be trained to increase brain activation in regions associated with executive function (EF) function deficits (as determined by neuroimaging measures) by viewing their own brain activation in real-time. The dose will be 2-3 sessions, each lasting approximately 30 minutes."
89666173|NCT05096494|Experimental|SP-103|One SP-103 transdermal system is worn 12 hours per day for 28 days on the lower back.
89666174|NCT05096494|Placebo Comparator|Placebo|One placebo transdermal system is worn for 12 hours per day for 28 days on the lower back
89214409|NCT00896324|Sham Comparator|Neurofeedback placebo (Sham) (BC pre-chemotherapy)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
89214410|NCT00528021|Active Comparator|1|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 2.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
89214411|NCT00528021|Active Comparator|2|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 10% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
89666175|NCT05091970|Experimental|In-Person|Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI) delivered face-to-face.
89666176|NCT05091970|Experimental|Telehealth|Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI) delivered via telehealth.
89666177|NCT05091619|Experimental|A1|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
89666178|NCT05091619|Active Comparator|A2|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
89666179|NCT05091619|Active Comparator|A3|subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
89666180|NCT05091619|Experimental|B1|subjects aged 2 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
89666181|NCT05091619|Active Comparator|B2|subjects aged 2 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old
89666182|NCT05091619|Experimental|B3|subjects aged 2 months receive 3 doses of vaccines with a interval of 2 months for primary immunization, and a booster dose at 18 month old
89048884|NCT04657497|Experimental|FOY-305 group|Camostat Mesilate tablets 600 mg will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
89048885|NCT04657497|Placebo Comparator|Placebo group|Placebo tablets will be orally administered 4 times daily, before breakfast, before lunch, before evening meal, and at bedtime. The treatment period is up to 14 days.
89048886|NCT01214434|Experimental|Promiseb Topical Cream|
89048887|NCT01214434|Sham Comparator|Bland emollient|
89048888|NCT04318639|Experimental|Donepazil+CRT|Donepazil+CRT
89048889|NCT04628403|No Intervention|control|
89048890|NCT04628403|Experimental|shock waves|
89048891|NCT04628403|Experimental|massage|
89048892|NCT04628403|Experimental|lasertherapy|
89666183|NCT05091619|Experimental|C1|subjects aged 3 months receive 3 doses of lot-1 vaccines with a interval of 30 days for primary immunization
89666184|NCT05091619|Experimental|C2|subjects aged 3 months receive 3 doses of lot-2 vaccines with a interval of 30 days for primary immunization
89666185|NCT05091619|Experimental|C3|subjects aged 3 months receive 3 doses of lot-3 vaccines with a interval of 30 days for primary immunization
89666186|NCT05089370|Experimental|Oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Mucosal Melanoma|
89666187|NCT05084911|Experimental|Test|Pyramax tablet
89666188|NCT05084911|Placebo Comparator|Control|Placebo tablet
89666189|NCT05081388|Experimental|REGN14256 + imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1 Phase 3: (Open label) (≥12 and <18 Years)
89666190|NCT05081388|Experimental|REGN14256|Phase 1, Phase 2: Randomized 1:1:1:1:1
89048893|NCT04656834||Hand incision closure type 1|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: buried monocryl sutures and skin glue
89048894|NCT04656834||Hand incision closure type 2|The participating surgeon closes the hand surgical incision via the standard method based on personal preference: simple nylon sutures
89048895|NCT01214239|Experimental|Linagliptin|once a day
89048896|NCT01214239|Placebo Comparator|Placebo|once a day
89048897|NCT04628520|Sham Comparator|Maintenance|Oral hygiene instruction and periodontal maintenance
89048898|NCT04628520|Active Comparator|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
89048899|NCT04628520|Active Comparator|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
89048900|NCT01214200|Experimental|High Intensity Non Invasive Pos.Pressure|The High Intensity Non-invasive Pos.Pressure trial is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation (HINPPV) for 90 days. Participants will receive HINPPV via bilevel positive airway pressure (BiPAP Synchrony) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O (centimeters of water); or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
89048901|NCT04967534|Experimental|WB-EMS|
89048902|NCT04967534|Sham Comparator|social contact control group|
89048903|NCT01214044|Experimental|Study Drug|Subjects will have a total of 12 visits to Oregon Clinical & Translational Research Institute at Oregon Health & Science University over the 14-16 weeks of study. Subjects will first undergo an initial screening visit to determine eligibility. Subjects who meet criteria and agree to participate will then stop taking their current antidepressant medication (if applicable), during which time the study doctor and staff will conduct weekly mood assessments to ensure safety. Subjects will then have a study initiation/materials visit followed by 9 visits during treatment with placebo or escitalopram. A final post-study follow-up safety visit will be scheduled at the end of treatment.
89048904|NCT04628286|Placebo Comparator|Sham Laser|Placebo laser application in plantar fascia
89666191|NCT05081388|Experimental|Imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1
89666192|NCT05081388|Experimental|casirivimab + imdevimab|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1
89666193|NCT05081388|Experimental|Placebo|Phase 1, Phase 2: Randomized 1:1:1:1:1 Phase 3: (≥18 Years): Randomized 1:1:1
89666194|NCT05072457|Experimental|Experimental|All participants in the study fit with Phonak Audeo P hearing aids and compatible Phonak Roger receivers.
89666195|NCT05033158|Other|Cancer patients|Level of antibodies against SARS-CoV-2 will be measured in these patients
89666196|NCT05024981|Active Comparator|Classic reeducation|
89666197|NCT05024981|Experimental|Classic reeducation + videographic feedback|
89666198|NCT05021653||Men who have sex with men (MSM)|Chinese men who have sex with men living with HIV infection and attending the service of HIV specialist service in Hong Kong
89214412|NCT00528021|Active Comparator|3|Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 12.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair.
89214413|NCT00528021|Placebo Comparator|4|
89666199|NCT05021653||non-MSM|Chinese heterosexual men and women living with HIV infection and attending the service of HIV specialist service in Hong Kong
89666200|NCT05018000|Active Comparator|Arm 1: Enhanced usual care|Participants in this arm will receive their usual care plus a Financial Resource Sheet. The financial resource sheet lists and describes existing organization and community resources available to KP members.
89666201|NCT05018000|Experimental|Arm 2: Brief financial navigation intervention|Participants in this arm will receive their usual care, and the Financial Resource Sheet described in Arm 1, plus one (1) cycle of financial navigation (total cycles: 1; total length: 6 months). In each intervention cycle participants will get at least one (1) phone call with a CAFÉ Financial Navigator, the navigator will talk with participants to identify financial questions or concerns. The navigator will create a personalized plan for each participant. Participants can request extra support from the navigator for up to 6 months.
89666202|NCT05018000|Experimental|Arm 3: Extended financial navigation intervention|Participants in this arm will receive their usual care, a Financial Resource Sheet and the brief intervention described in Arm 2 (i.e., one (1) cycle of financial navigation). Plus, they will receive two (2) additional cycles of financial navigation (total cycles: 3; total length: 6 months).
89666203|NCT05017246|Active Comparator|Epidural bupivacaine with hydromorphone patient-controlled anesthesia (EPCA)|"Standard of care at Washington University School of Medicine/Barnes-Jewish Hospital~Day of surgery: preoperative tylenol, gabapentin, celebrex, and epidural dosing per standard protocol.~Intraoperative: dexamethasone and epidural bupivacaine~Day of surgery postoperative: hydromorphone PCA, toradol, ibuprofen, tylenol, epidural bupivacaine~Postoperative: hydromorphone PCA, ibuprofen, oxycodone"
89666204|NCT05017246|Experimental|Intrathecal morphine with intraoperative lidocaine infusion|"Day or surgery: tylenol, gabapentin, celebrex, and preoperative intrathecal morphine one time injection (150mcg)~Intraoperative: dexamethasone and lidocaine infusion 1 mg/kg ideal body weight~Day of surgery postoperative: toradol, ibuprofen, tylenol~Postoperative: ibuprofen, oxycodone, and hydromorphone prn"
89666205|NCT05007041|Active Comparator|Recombinant Zoster Vaccine (RZV) and Quadrivalent adjuvanted influenza vaccine|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the quadrivalent adjuvanted influenza vaccine (FLUAD® Quadrivalent) simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
89666206|NCT05007041|Active Comparator|Recombinant Zoster Vaccine (RZV) and high-dose quadrivalent influenza vaccine|In this study arm, subjects will receive Dose 1 of RZV (SHINGRIX®) and Dose 1 of the (Fluzone® HD Quadrivalent) influenza vaccine simultaneously during Visit 1 and Dose 2 of RZV (SHINGRIX®) during Visit 6.
89666207|NCT04995900|Experimental|Intervention|Intervention period with active Heart Matters education delivered
89666208|NCT04995900|No Intervention|Control|Control period with no Heart Matters education delivered.
89666209|NCT04992195||Vaccination Group|Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and received COVID-19 vaccination (SinoVac or BioNTech).
89666210|NCT04992195||Control Group|Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and have not received any COVID-19 vaccines nor clinically/serologically evident SARS-CoV-2 infection.
89666211|NCT04987788|Experimental|Motívate group|Participants will engage with an app on an iPad, smartphone or computer.
89666212|NCT04987788|Active Comparator|Control Group|Participant receive a link to watch a general health information video.
89666213|NCT04983888|Experimental|Primary Focal Segmental Glomerulosclerosis (FSGS)|Subjects with immunosuppression-dependent or immunosuppression/treatment-resistant primary FSGS or contraindication/patient refusal to take high dose corticosteroids, will receive obinutuzumab 1 gram on day 1 and 1 gram on day 15, given intravenously and then an identical course at 6 months.
89666214|NCT04971408|Other|control|passive heat stress x1 visit then no intervention for 8 weeks. participants continue regular exercise habits as usual.
89666215|NCT04971408|Experimental|Passive heat stress|After arm 1, passive heat stress 3x/week x8 weeks.
89666216|NCT04963751|Active Comparator|pre-operative counseling with their caregiver|Patients will be asked to attend a standard-of-care pre-operative teaching session with their parent.
89666217|NCT04963751|Placebo Comparator|caregiver-only counseling.|Parents-only will attend a standard-of-care pre-operative teaching session.
89666218|NCT04917523|Experimental|Aged 3-6 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
89666219|NCT04917523|Experimental|Aged 7-12 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
89666220|NCT04917523|Experimental|Aged 13-17 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
89214414|NCT00896402|Active Comparator|Chlorhexidine|skin antisepsis with chlorhexidine
89666221|NCT04917523|Active Comparator|Aged ≥18 years old|300 subjects receive 2 dose according to the immunization schedule of D0, D21 (+7 Days). A booster dose might be introduced.
89666222|NCT04907929|Experimental|post-implantation care|
89666223|NCT04896112|Experimental|Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg|Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles
89666224|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg|LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles
89666225|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg|LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles
89666226|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg|LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles
89666227|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 150 mg|LNK01002 150 mg BID, followed by a 3-day observation period then 150 mg BID in 28-day treatment cycles
89666228|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 200 mg|LNK01002 200 mg BID, followed by a 3-day observation period then 200 mg BID in 28-day treatment cycles
89666229|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 260 mg|LNK01002 260 mg BID, followed by a 3-day observation period then 260 mg BID in 28-day treatment cycles
89666230|NCT04896112|Experimental|Patients with Acute Myeloid Leukemia With Mutant FLT3|LNK01002 at the RP2D dose in 28-day treatment cycles
89666231|NCT04896112|Experimental|Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3|LNK01002 at the RP2D dose in 28-day treatment cycles
89666232|NCT04896112|Experimental|Patients with Primary or Secondary Myelofibrosis,PV|LNK01002 at the RP2D dose in 28-day treatment cycles
89666233|NCT04891575|Active Comparator|Active Control Arm|An index participant with 2 or more risk factors for cardiovascular disease or type 2 diabetes who is randomized to this arm will attend 8 weekly educational sessions focused on self-management of risk factors and engagement in healthy behaviors for risk reduction. The index participant will attend the sessions as an individual and will receive standard individual-focused lifestyle modification education.
89666234|NCT04891575|Experimental|Family Dyad Arm|An index participant with 2 or more risk factors for cardiovascular disease or type 2 diabetes and a co-participating family member will together attend 8 weekly educational sessions focused on self-management of risk factors and engagement in healthy behaviors for risk reduction. The dyadic intervention sessions also incorporate family-focused throughout each session to encourage dyadic support.
89666235|NCT04886960|Experimental|Amniotic Fluid Injection|Amniotic Fluid Injection, 3ml, one time dose.
89666236|NCT04886960|Active Comparator|Standard of Care Steroid Injection|Corticosteroids, 3ml, one time dose.
89666237|NCT04883255|Experimental|HIV-positive subjects|Adult human subjects seropositive for HIV-1
89666238|NCT04883255|Active Comparator|Healthy Comparison Volunteers|Adult human subjects without HIV
89666239|NCT04882696|No Intervention|usual care with bare feet|patients will be treated barefoot during their stay
89666240|NCT04882696|Experimental|specific care with anti-slip socks|Patients in this group will wear non-slip socks
89666241|NCT04880850|Experimental|insulin icodec + insulin aspart|Participants will get once weekly injections in combination with 2-4 times daily injections of insulin aspart
89666242|NCT04880850|Active Comparator|Insulin glargine + insulin aspart|Participants will get once daily injections in combination with 2-4 times daily injections of insulin aspart
89666243|NCT04880330|Experimental|Experimental: Cryo-Auriculotherapy|Patients benefit from 1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
89666244|NCT04880330|Sham Comparator|Sham Comparator: Control group|Patients benefit from 1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points..
89666245|NCT04869280||Cohort-1: Pregnant Women Exposed to Prucalopride Prior to Enrollment|Pregnant women diagnosed with chronic idiopathic constipation (CIC) or irritable bowel syndrome-constipation (IBS-C) who have been exposed to prucalopride during pregnancy and prior to enrollment will be observed.
89666246|NCT04869280||Cohort-2: Pregnant Women Not Exposed to Prucalopride|Pregnant women diagnosed with CIC or IBS-C who have not been exposed to prucalopride will be observed.
89666247|NCT04868838|Experimental|Daratumumab|Subjects diagnosed with lupus nephritis will receive Daratumumab once weekly for 8 weeks and then once every 2 weeks for 8 additional does (+/- 4 days). Subjects will be followed for a total of 24 months (18 months after the last daratumumab administration).
89666248|NCT04863638|Experimental|A1 aged ≥ 71|300 subjects age ≥ 71 （A1）receive 3 doses of vaccine
89666249|NCT04863638|Experimental|A2 aged ≥ 71|200 subjects age ≥ 71 （A2）receive 3 doses of vaccine
89666250|NCT04863638|Experimental|A3 aged ≥ 71|200 subjects age ≥ 71 (A3) receive 3 doses of vaccine
89666251|NCT04863638|Experimental|B1 aged 60-70|300 subjects age 60-70 (B1) receive 3 doses of vaccine
89666252|NCT04863638|Experimental|B2 aged 60-70|200 subjects age 60-70 (B2) receive 3 doses of vaccine
89666253|NCT04863638|Experimental|B3 aged 60-70|200 subjects age 60-70 (B3) receive 3 doses of vaccine
89666254|NCT04863638|Experimental|C1 aged 18-59|300 subjects age 18-59 (C1) receive 3 doses of vaccine
89048905|NCT04628286|Experimental|Experimental group Myofascial Induction|Myofascial Induction technique application in plantar fascia
89666255|NCT04863638|Experimental|C2 aged 18-59|200 subjects age 18-59 (C2) receive 3 doses of vaccine
89666256|NCT04863638|Experimental|C3 aged 18-59|200 subjects age 18-59 (C3) receive 3 doses of vaccine
89666257|NCT04863638|Experimental|C4 aged 18-59|300 subjects age 18-59 (C4) receive 2 doses of vaccine
89666258|NCT04863638|Experimental|D1 aged 9-17|300 subjects age 9-17 (D1) receive 3 doses of vaccine
89666259|NCT04863638|Experimental|D2 aged 9-17|200 subjects age 9-17 (D2) receive 3 doses of vaccine
89666260|NCT04863638|Experimental|D3 aged 9-17|200 subjects age 9-17 （D3）receive 3 doses of vaccine
89666261|NCT04863638|Experimental|D4 aged 9-17|300 subjects age 9-17 （D4）receive 2 doses of vaccine
89666262|NCT04863638|Experimental|E1 aged 3-8|300 subjects age 3-8 （E1） receive 3 doses of vaccine
89666263|NCT04863638|Experimental|E2 aged 3-8|200 subjects age 3-8 （E2）receive 3 doses of vaccine
89666264|NCT04863638|Experimental|E3 aged 3-8|200 subjects age 3-8 （E3）receive 3 doses of vaccine
89666265|NCT04863638|Experimental|E4 aged 3-8|300 subjects age 3-8 （E4）receive 2 doses of vaccine
89666266|NCT04856917|Experimental|Imsidolimab 400/200 mg|Participants received imsidolimab 400 milligrams (mg) by subcutaneous (SC) injection on Day 1, followed by 200 mg on Days 29 and 57.
89214415|NCT00896402|Active Comparator|Povidone-iodine|skin antisepsis with povidone-iodine
89214416|NCT00560352|Experimental|Dasatinib + Bortezomib + Dexamethasone|Phase I dose escalation study
89048906|NCT01213966|Experimental|800 mg OZ439 po single dose|800 mg OZ439 po single dose
89048907|NCT01213966|Experimental|400 mg OZ439 p.o. single dose|400 mg OZ439 p.o. single dose
89048908|NCT01213966|Experimental|200mg OZ439 p.o. single dose|200mg OZ439 p.o. single dose
89048909|NCT01213966|Experimental|1200 mg OZ439 po single dose|1200 mg OZ439 po single dose
89048910|NCT04628598|Experimental|Home visiting pregnant women|The pregnant women in the experimental group will be given education and care with home visits.
89048911|NCT04628598|No Intervention|Control Group|Home visits will not be made to the control group, only the primary care antenatal care will be followed.
89048912|NCT01213264||Spontaneous NMB reversal|Participants whose reversal from NMB is spontaneous (no reversal agent used)
89048913|NCT01213264||NMB reversal with sugammadex|Participants who are administered sugammadex for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
89048914|NCT01213264||NMB reversal with other agents|Participants who are administered any other agent (other than sugammadex) for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
89048915|NCT04628247|Experimental|Study group|They will receive the same traditional physical therapy exercise program in addition to gait training on spring gravity bar for one hour
89048916|NCT04628637||Control Group|"Inclusion Criterias are consisted of; Not to have known acute, subacute or chronic disease history, Not to suffer from any infection in the last fortnight, Not to be on a particular medication, Presenting to the ED with reasons other than infectious complaints, and Giving their written consent to participate in the study.~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease"
89048917|NCT04628637||Covid-19 (-) Pneumonia Group|Inclusion Criterias are consisted of; Presenting to the Covid-19 outpatient policlinic of the ED with pneumonia symptoms To have CT imagings were not compatible with Covid-19 pneumonia in accordance with the Radiological Society of North America Expert Consensus (RSNAEC) criteria To have nasopharyngeal swab samples taken in the ED were negative for PCR, and To give their informed consent to participate in the study. Exclusion Criteria The exclusion criteria consisted of diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative
89666267|NCT04856917|Experimental|Imsidolimab 200/100 mg|Participants received imsidolimab 200 mg by SC injection on Day 1, followed by 100 mg on Days 29 and 57.
89666268|NCT04856917|Placebo Comparator|Placebo|Participants received imsidolimab matching placebo by SC injection on Days 1, 29, and 57.
89666269|NCT04855617||Patients Receiving Multiple Sclerosis care|Patients currently receiving ocrelizumab or initiating ocrelizumab per their MS treating physician.
89666270|NCT04853108||Remote Monitoring of COVID-19|Patients with COVID-19 who completed acute clinical monitoring of at least 30 days from symptom onset or positive COVID-19 test.
89666271|NCT04846933||HGSOC patients treated with Neoadjuvant chemotherapy (NACT)|"Diagnostic laparoscopy followed with 3-4 cycles of platinum-taxane NACT and interval debulking surgery (IDS). Treatment response is monitored with FDG PET/CT. IDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines).~Digital H&E slides and WGS, RNAseq are obtained from performed surgeries including relapse operations/ascites drainages. Patients are followed with longitudinal ctDNA sampling."
89666272|NCT04846933||HGSOC patients treated with primary debulking surgery (PDS)|PDS is followed by standard adjuvant therapy (ESGO/ESMO + local guidelines). Digital H&E slides and WGS, RNAseq obtained from PDS and possible relapse operations/ascites drainages when performed. Patients are followed with longitudinal ctDNA sampling.
89666273|NCT04846309|Experimental|Treatment: all patients|
89666274|NCT04838522||All Study Participants|Participants with chronic idiopathic constipation who are treated with prucalopride 2 milligrams (mg) oral tablets which was initiated prior to enrollment, and are breastfeeding their infant at the time of enrollment and sample collection will be observed prospectively.
89214417|NCT00892892|Experimental|Arm 1|Rilmenidine as a sympatholytic agent for three months
89666275|NCT04832412|Experimental|BrainPhyt Low dose|2 capsules of 275mg BrainPhyt for 24 weeks
89666276|NCT04832412|Placebo Comparator|Placebo|2 capsules of 275mg Maltodextrin
89666277|NCT04819373|Experimental|BDB001|BDB001 will be administered intravenously as monotherapy in subjects with histologically-confirmed unresectable or metastatic solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment either as monotherapy or in combination with other therapies.
89666278|NCT04809714|Active Comparator|Routine Post-operative Physical Therapy|The control group will undergo routine post-op and undergo a modified version of the graduated therapy protocol.
89666279|NCT04809714|Experimental|Routine Physical Therapy + Blood Flow Restriction and Neuromuscular Electrical Stimulation (NMES)|The intervention group will start with a Delfi tourniquet system cuff set on a limb occlusion pressure (LOP) of 60-100%. The intervention group will also use a neuromuscular electrical stimulation device at therapeutic level in addition to BFR.
89666280|NCT04790786|Experimental|Lilly Bamlanivimab|The Lilly monoclonal antibody bamlanivimab will be administered according to FDA EUA guidelines. Dosing is 700 mg intravenously times one within 10 days of COVID-19 symptom onset.
89666281|NCT04790786|Experimental|Regeneron Casirivimab + Imdevimab|The Regeneron monoclonal antibody cocktail Casirivimab + Imdevimab will be administered according to FDA EUA guidelines. Dosing is 1200 mg of each drug (2400 mg total) administered intravenously times one within 10 days of COVID-19 symptom onset.
89666282|NCT04790786|Experimental|Lilly Bamlanivimab + Etesevimab|The Lilly monoclonal antibody cocktail of bamlanivimab + etesevimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 10 days of COVID-19 symptom onset.
89666283|NCT04790786|Experimental|Sotrovimab|The monoclonal antibody of sotrovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
89214418|NCT00892892|Active Comparator|Arm 2|Nitrendipine as a non-sympatholytic agent for three months
89666284|NCT04790786|Experimental|Bebtelovimab|The monoclonal antibody of bebtelovimab will be administered according to FDA EUA guidelines. Dosing is given intravenously times one within 7 days of COVID-19 symptom onset.
89666285|NCT04788316|Experimental|Intervention|A computerized brief intervention (CBI) followed by six months of personalized text messaging
89666286|NCT04788316|No Intervention|Control|Treatment as usual
89666287|NCT04785950||Women with IUS|Women aged 18 to 35 years from Spain who chose to use any low-dose LNG-IUS marketed in Spain for the first time during routine clinical practice
89666288|NCT04751162||Phase I|Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones for tracking PA, SQ and symptoms for 3 weeks The ECOG-PS will be assessed by clinician at both, baseline and subsequent visit after the 3 weeks.
89666289|NCT04751162||Phase II|"Participants will be equipped with both devices (wearable and mobile application) for further monitoring during the following 9 weeks. Study participants will undergo scheduled visits according to local standard practice. The study will progress to Phase II just in case any of the following conditions are met at the end of Phase I:~The average time of use of the wearable device is equal or over 96 hours/week/participant, OR~The average SUS score is equal or above 68, OR~The average adherence to the app is equal or above 80%, measured as the rate of submitted ePROMs through the app."
89666290|NCT04750889||RFID tags localization|
89666291|NCT04750889||Wire localization|
89666292|NCT04750330||Severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the Intensive Care Unit (ICU) during hospitalisation
89666293|NCT04750330||Non-severe COVID-19|Patients, diagnosed with COVID-19, who were admitted to the hospital but NOT to the Intensive Care Unit (ICU) during hospitalisation
89666294|NCT04750330||Minor COVID-19|Patients, diagnosed with COVID-19, who were NOT admitted to the hospital and could recover at home
89666295|NCT04748744||Patients undergoing colorectal surgery|
89666296|NCT04744922|Experimental|Auraptene and Naringenin Arm|One capsule a day for 9 months
89666297|NCT04744922|Placebo Comparator|Control Arm|One capsule a day for 9 months
89666298|NCT04726059|Sham Comparator|ABT+SHAM|The SHAM is low-intensity, ineffective stimulation delivered at the same anatomical location as TSCS.
89666299|NCT04726059|Experimental|ABT+TSCS|Therapeutic TSCS will be delivered during ABT using an isolated bipolar constant current stimulator. Continuous TSCS applied over the T11-T12 spinous processes at 5-40 Hz has been shown to induce stepping movements in participants with their legs in a gravity-independent position.
89666300|NCT04724252|Active Comparator|Gabapentin Treatment|Given at a dose of 10mg/kg (max 600mg) perioperatively (immediately prior to surgery) followed by 3mg/kg/dose TID with first dose to be given starting at 8 hours post perioperative dose.
89666301|NCT04724252|Placebo Comparator|Control Group|Given placebo which coincides with the active treatment group
89214419|NCT04037696|Experimental|Experimental group|The experimental group will receive individual face-to-face brief MI (about 5 minutes) on a health-related lifestyle practice. The experimental group will then receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up.
89666302|NCT04703504|Experimental|multi-intervention|"Automatic creation of discharge prescription (personalized checklist of possible therapeutic optimizations generated from clinical data entered into the platform. This checklist will comply with the recommendations on altered left ventricular ejection fraction from European Society of Cardiology 2016.~Automatic creation of documents for patient:~Reminder letter to make an appointment with his general practitioner (at 7 days) and cardiologist (1 month) and to report the prescribed blood test.~Drug prescription.~Prescription for blood tests (5 days and 25 days before seeing the general practitioner and cardiologist).~Therapeutic education documents~Patients will receive numerous messages (SMS / e-mail) in order to 1 / not forget their medical appointments, 2 / not to forget to make and bring back their blood test for the consultation, 3 / to perfect the therapeutic education advice provided previously"
89666303|NCT04703504|No Intervention|Control|Discharge prescription according to the investigator's habits.
89666304|NCT04698954|Experimental|AIMS intervention group|A nurse-delivered behavioural intervention focussing on medication adherence, physical activity, and symptom management integrated in routine clinical care. AIMS-CHF incorporates nurse-counselling and feedback from electronic monitoring of medication use (using MEMS-buttons) and physical activity (using pedometers).
89666305|NCT04698954|Active Comparator|Treatment-as-usual group|Participants in the control group will receive treatment as usual. They will visit the out patient clinic each 3 or 6 months for 30 minutes.
89666306|NCT04675242|Experimental|NCX 4251|NCX 4251 Ophthalmic Suspension
89666307|NCT04675242|Placebo Comparator|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension
89666308|NCT04670068|Experimental|CAR.B7-H3 T cell product|Up to 12 patients will receive three weekly CAR.B7-H3 T cell product infusions at the same dose. To determine the recommended phase 2 dose (RP2D), a modified 3+3 dose escalation design will be used to evaluate two dose levels: Dose Level 1 (7.5x10^7 cells/infusion), Dose Level 2 (2x10^8 cells/infusion). If this dose is not tolerated, then a lower dose of 3.75 × 10^6 cells/infusion will be explored. Up to 3 dose levels of CAR.B7-H3 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 9 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and cyclophosphamide.
89666309|NCT04658667|Experimental|Full dose IHV01 and A244|Participants will receive a full dose of IHV01 (approximately 300μg) and A244 (approximately 300μg).
89666310|NCT04658667|Experimental|Fractional dose IHV01 and A244|Participants will receive a fractional dose of IHV01 (approximately 60μg) and A244 (approximately 60μg).
89666311|NCT04658667|Experimental|Full dose IHV01 and A244 + ALFQ|Participants will receive a full dose of IHV01 (approximately 300μg) and A244 (approximately 300μg) plus ALFQ (approximately 0.5mL).
89666312|NCT04658667|Experimental|Fractional dose IHV01 and A244 + ALFQ|Participants will receive a fractional dose of IHV01 (approximately 60μg) and A244 (approximately 60μg) plus ALFQ (approximately 0.5mL).
89666313|NCT04658667|Placebo Comparator|Placebo|Normal saline will serve as a placebo for the trial. All placebo injection volumes will match the study vaccine injection volumes for the group in which a participant has been randomized.
89666314|NCT04640415|No Intervention|No alarms|Patients will be connected to monitoring equipment, registering vital sign data, but data will be blinded to clinical staff.
89666315|NCT04640415|Active Comparator|Active alarms|Patients will be connected to monitoring equipment, registering data, and data will be available to clinical staff, including alarms for vital sign deterioration.
89666316|NCT04618289|Experimental|Vitamin D Group|The vitamin D3-fortified fruit juice supplement that will be used is vitamin D3 cholecalciferol (4000 IU, 100 mcg, Fiatec Biosystem Sdn Bhd, Selangor, Malaysia).
89666317|NCT04618289|Placebo Comparator|Placebo Group|The matching placebo will be also custom-produced and will be produced in the same manner, without the active ingredients by the same company. The placebo produced will match with vitamin D3 in terms of appearance, size, colour and taste to achieve the double-blind design.
89666318|NCT04617795|Experimental|Basal-Bolus (Group A)|"2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~4 weeks Omnipod 5 system use in Automated Mode with simplified bolus~6-month optional extension using Automated Mode"
89666319|NCT04617795|Experimental|Basal (Group B)|"2 weeks standard therapy - using basal injection only and Dexcom G6 Continuous Glucose Monitor (CGM), followed by:~2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 Continuous Glucose Monitor (CGM) - with fixed basal rate, no bolus, followed by:~4 weeks Omnipod 5 system use in Automated Mode with optional bolus, followed by:~If % time in range 70-180 mg/dL during Automated Mode is ≤50%, 4 weeks Omnipod 5 system use in Automated Mode with simplified bolus, OR~If % time in range 70-180 mg/dL during Automated Mode is >50%, 4 weeks Omnipod 5 system use in Automated Mode with optional bolus~6-month optional extension using Automated Mode"
89666320|NCT04615247|Experimental|Yoga Program|The study yoga intervention is designed to provide instruction and practice in selected yoga postures and techniques chosen by an expert panel for their potential to improve pelvic pain in women.
89666321|NCT04615247|Active Comparator|Physical Conditioning Program|A low-impact, muscle stretching and strengthening program.
89666322|NCT04611906||Stroke patient|Patients who have acute cerebral ischemic symptoms attributed by cSVD can be recruited into this study. Eligible patients will be screened by Neurologists based on the inclusion and exclusion criteria. The time window for recruitment of the patient is 4 weeks from the qualifying stroke.
89048918|NCT04628637||Covid-19 Infection Group|"This cohort included the patients InculUsion Criteria Presenting Whose CT imagings were normal in accordance with the RSNAEC criteria and whose PCR tests were positive To have Covid-19 PCR tests were positive as a result of contact tracing, Presenting to the ED for further examination.~The exclusion criteria consisted of; Diagnosis of kidney and liver failure, Acute pulmonary embolism Chronic inflammatory disease history (rheumatological disease, autoimmune disease) Pregnancy Presence of any cancer diagnosis Chronic obstructive pulmonary disease Asthma disease History of cerebrovascular disease To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative."
89666323|NCT04588441|Experimental|Adenosine|Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer
89666324|NCT04585178|Experimental|Biobeat patch|Patients will be asked to keep Biobeat patch during 72 hours after their surgery.
89666325|NCT04578015|Active Comparator|Metronidazole 500 mg|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
89666326|NCT04578015|Placebo Comparator|Placebo|Participants in this arm will receive placebo
89666327|NCT04575428|Experimental|Splanchnic nerve block|
89666328|NCT04572243|Experimental|Lorcaserin (Core Study and Open-label Extension Phase)|Participants will be randomized to receive lorcaserin administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to less than (<) 20, 20 to <40, and greater than or equal to (>=) 40 kilogram (kg) will be 5, 10, and 20 milligram per day (mg/day) respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
89666329|NCT04572243|Placebo Comparator|Placebo (Core Study) + Lorcaserin (Open-label Extension Phase)|Participants will be randomized to receive lorcaserin matching placebo administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to <20, 20 to <40, and >=40 kg will be 5, 10, and 20 mg/day respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
89666330|NCT04571008|Placebo Comparator|Placebo|At least 16 weeks of placebo.
89666331|NCT04571008|Experimental|NMN supplementation|At least 16 weeks of NMN.
89666332|NCT04558541|Experimental|Sensitivity to phonological rules: Children|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern; Arm 3: Family Resemblance/Prototype Pattern
89666333|NCT04558541|Experimental|Sensitivity to semantic category cues: Children|Arm 1.Referential cue during OR learning.
89666334|NCT04552132|Experimental|GentleWave|Patients randomly assigned to the GentleWave group will receive irrigation and activation of irrigants with the GentleWave device (multisonic energy) by Sonendo.
89666335|NCT04552132|Active Comparator|EndoActivator|Patients randomly assigned to the EndoActivator group will receive irrigation via a side-vented needle and activation using the EndoActivator (sonic energy) by Dentsply Sirona.
89666336|NCT04547699|Placebo Comparator|HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein,
89666337|NCT04547699|Experimental|CYK+ high HSA|A single step culture medium (SSCM; Global, Life Global)+5mg/ml (10% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma),and 5ng/mL LIF (SRP9001 Sigma).
89666338|NCT04547699|Active Comparator|CYK+low HSA|A single step culture medium (SSCM; Global, Life Global) +2mg/ml (5% Vol/Vol) life global protein, supplemented with 2ng/mL GM-CSF (G5035 Sigma), 5ng/mL HB-EGF (E4643 Sigma), and 5ng/mL LIF (SRP9001 Sigma).
89666339|NCT04516369|Experimental|Voretigene neparvovec|1.5 E11 vg (0.3 mL subretinal injection in each eye, 6-18 days apart)
89666340|NCT04510207|Experimental|Investigational Vaccine 1|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP according to the immunization schedule of D0 & D21.
89666341|NCT04510207|Experimental|Investigational Vaccine 2|Participants will receive 2 doses of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP according to the immunization schedule of D0 & D21.
89666342|NCT04510207|Placebo Comparator|Placebo|Participants will receive 2 doses of Placebo according to the immunization schedule of D0 & D21.
89666343|NCT04510207|Experimental|Investigational Vaccine 1b|Participants will receive a booster dose of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by WIBP after 3 months following two doses of immunization.
89666344|NCT04510207|Experimental|Investigational Vaccine 2b|Participants will receive a booster dose of the inactivated SARS-CoV-2 vaccine (Vero cell) manufactured by BIBP after 3 months following two doses of immunization.
89666345|NCT04510207|Placebo Comparator|Placebo-b|Participants will receive a booster dose of Placebo after 3 months following two doses of immunization.
89666346|NCT04471168|Experimental|Cryo-Auriculotherapy|Patients benefit from 3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
89666347|NCT04471168|Sham Comparator|Control group|Patients benefit from 3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
89666348|NCT04462861|Experimental|CVAD securement device|Patients with a pre-existing CVAD who will trial the new securement dressing
89666349|NCT04450238||Study Group|"All participants are inpatients at the clinic Stillachhaus in Germany. They are receiving treatment for a variety of psychological disoders, mostly depressive disoders."
89666350|NCT04445519|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily to both eyes (initial phase of trial)
89666351|NCT04445519|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes (initial phase of trial)
89666352|NCT04445519|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes (initial phase of trial)
89666353|NCT04445519|Experimental|NCX 470 0.1% (remainder of trial)|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes (chosen dose of NCX 470 to continue in remainder of trial)
89666354|NCT04445519|Active Comparator|Latanoprost 0.005% (remainder of trial)|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes (active comparator for remainder of trial)
89666355|NCT04440943|Experimental|CDX-527|"Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance.~Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase."
89666356|NCT04421456|Experimental|GWP42003-P 300 mg|GWP42003-P 300 milligrams (mg) per day
89666357|NCT04421456|Placebo Comparator|Placebo|Matching placebo
89666358|NCT04421456|Experimental|GWP42003-P 1000 mg|GWP42003-P 1000 mg per day
89666359|NCT04402242|Sham Comparator|"SCS Group"|"Receiving anesthesia according to routine standard care, with the use of the hidden NOL (used to compare the data at the end of anesthesia with those of the classic BIS - without monitoring of the anesthesia by the NOL (without adjustment of treatments ))"
89666360|NCT04402242|Experimental|NOL Group|Receiving anesthesia monitored by the NOL
89048919|NCT04628208||Negative for COVID-19|Subject determined to be negative for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
89666361|NCT04401943|Experimental|Fatigue intervention|the Fatigue intervention is a 6 week intervention delivered using video teleconferencing
89666362|NCT04399044|No Intervention|Group 1: No flap|Participants will undergo the scheduled vascular surgery procedure without involvement of the plastic surgery team and use of muscle flaps for graft coverage.
89666363|NCT04399044|Experimental|Group 2: Prophylactic muscle flap|Participants will undergo the scheduled vascular surgery procedure and then a muscle flap will be used to cover the vascular graft by a plastic surgeon in the same setting.
89666364|NCT04392804||0.1 ml 4% articaine|single dose of 0.1 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
89666365|NCT04392804||0.2 ml 4% articaine|single dose of 0.2 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
89666366|NCT04392804||0.3 ml 4% articaine|single dose of 0.3 ml 4% articaine with 1:100,000 epinephrine delivered by computer-controlled local delivery system (Anaject), in purpose for scaling and root planing
89666367|NCT04382677|Experimental|Promoting First Relationships|The PFR program designed for birth families being reunited after foster care placement consists of a manualized 12-session intervention delivered in the home by trained providers.
89666368|NCT04382677|Other|Resource & Referral|The service consists of a needs assessment conducted by phone, followed by a personalized resource packet and referrals, and 3 monthly check-in phone calls.
89666369|NCT04341363|Experimental|Microneedling|Participants with androgenic alopecia will receive microneedling with a tattoo machine.
89666370|NCT04324853||S. haematobium positive|Pregnant women infected with Schistosoma hematobium alone
89666371|NCT04324853||geohelminths positive|pregnant women infected with geohelminths alone
89666372|NCT04324853||Helminth negative|Pregnant women free of anyn helminths infection
89666373|NCT04279249|Active Comparator|HEPA Filtration|
89666374|NCT04279249|Sham Comparator|Sham HEPA Filtration|
89666375|NCT04277962|Experimental|Patients having vaginal delivery|EBL will be estimated visually vs quantitatively at time of vaginal delivery.
89666376|NCT04268303|Experimental|120 Micrograms|Sublingual film containing 120 Micrograms dexmedetomidine
89666377|NCT04268303|Experimental|180 Micrograms|Sublingual film containing 180 Micrograms dexmedetomidine
89666378|NCT04268303|Placebo Comparator|Placebo|Sublingual placebo film
89666379|NCT04267497|Experimental|Nebulized Amphotericin B|Amphotericin B.
89666380|NCT04267497|Placebo Comparator|Nebulized Placebo|Sterile water for injection.
89666381|NCT04266730|Experimental|PANDA-VAC combined with pembrolizumab|The final primary therapeutic neoantigen vaccine product will comprise 6 peptides at a dose of 300 μg per peptide and Poly-ICLC at a dose of 500 μg formulated in an aqueous solution containing <5% DMSO in isotonic dextrose for a total volume of 750 μL. The vaccine will be administered subcutaneously via 3 equal volume (250 μL) injections, one in an arm and one in each leg. The product will be administered on the following schedule: Days 1 and 4 of Week 1, Day 1 of Week 2, Day 1 of Week 3, Day 1 of Week 4, Day 1 of Week 11, and Day 1 of Week 21.
89666382|NCT04263831|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be two dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~Cohort 1: 1.0x10^6 IU/m^2/day. Cohort 2: 1.25x10^6 IU/m^2/day."
89666383|NCT04249687|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Mode of administration: intramuscular injection
89048920|NCT04628208||Positive for COVID-19|Subject determined to be positive for COVID-19 by the standard of care nasopharyngeal swab-based SARS-CoV-2 RT-PCR test.
89666384|NCT04249687|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
89666385|NCT04249583|Experimental|Treatment|QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
89666386|NCT04249583|Placebo Comparator|Placebo|A buffered solution; Mode of administration: intramuscular injection
89666387|NCT04230447||sepsis associated encephalopathy (SAE)|This study is an observational study without drug and other interventions The SAE was defined as the Glasgow Coma Scale (GCS) score of less than 15
89666388|NCT04230447||Non-SAE|This study is an observational study without drug and other interventions Non-SAE group GCS = 15
89666389|NCT04230447||Control|This study is an observational study without drug and other interventions The control group was the emergency department patients with acute disease strikes, including heart attack, infraction, and healthy control.
89666390|NCT04225260|Experimental|QM1114-DP in the LCL and the GL areas|"The investigational product (QM1114-DP) is a BoNT Type A.~At each treatment a total dose of QM1114-DP will be administered in the glabella and lateral canthal lines."
89666391|NCT04222478|Experimental|Real Auriculotherapy|"Patients benefit from 3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
89048921|NCT04656912||Acute CO poisoning|A diagnosis of CO poisoning was made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
89666392|NCT04222478|Sham Comparator|Sham Auriculotherapy|Patients are treated according to the same scheme as the experimental group but with semi-permanent needles positioned on non-specific points.
89666393|NCT04221516|Experimental|Camrelizumab|Camrelizumab 200mg every 21 days for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
89666394|NCT04205227|Experimental|ENB003 150 ug + Pembrolizumab|150 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
89666395|NCT04205227|Experimental|ENB003 300 ug + Pembrolizumab|300 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
89666396|NCT04205227|Experimental|ENB003 500 ug + Pembrolizumab|500 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
89666397|NCT04205227|Experimental|ENB003 750 ug + Pembrolizumab|750 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
89666398|NCT04205227|Experimental|ENB003 1000 ug + Pembrolizumab|1000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg)
89666399|NCT04205227|Experimental|ENB003 2000 ug + Pembrolizumab|2000 ug ENB003 will be administered in combination with a fixed dose of pembrolizumab (200mg). In this treatment arm, ENB003 will be administered during each 21 day cycle, as opposed to every other cycle in early arms
89666400|NCT04205227|Experimental|ENB003 RP2D from dose escalation + Pembrolizumab|The recommended phase 2 dose (RP2D) of ENB003 will be selected from the dose escalation portion of the study and administered in combination with a fixed dose of pembrolizumab (200mg)
89666401|NCT04200157||1|"Group assigned to the following answer combination:~2 sessions~4 sessions"
89666402|NCT04200157||2|"Group assigned to the following answer combination:~2 sessions~4 sessions~7 sessions"
89666403|NCT04200157||3|"Group assigned to the following answer combination:~2 sessions~7 sessions"
89666404|NCT04200157||4|"Group assigned to the following answer combination:~2 sessions~7 sessions~10 sessions"
89666405|NCT04200157||5|"Group assigned to the following answer combination:~2 sessions (30 minutes)~4 sessions (60 minutes)"
89666406|NCT04200157||6|"Group assigned to the following answer combination:~2 sessions (30 minutes)~4 sessions (60 minutes)~7 sessions (105 minutes)"
89666407|NCT04200157||7|"Group assigned to the following answer combination:~2 sessions (30 minutes)~7 sessions (105 minutes)"
89666408|NCT04200157||8|"Group assigned to the following answer combination:~2 sessions (30 minutes)~7 sessions (105 minutes)~10 sessions (150 minutes)"
89666409|NCT04200157||9|"Group assigned to the following answer combination:~2 sessions (30 minutes) - 10% chance of quitting~4 sessions (60 minutes) - 30% chance of quitting"
89666410|NCT04200157||10|"Group assigned to the following answer combination:~2 sessions (30 minutes) - 10% chance of quitting~4 sessions (60 minutes) - 30% chance of quitting~7 sessions (105 minutes) - 30% chance of quitting"
89666411|NCT04200157||11|"Group assigned to the following answer combination:~2 sessions (30 minutes) - 10% chance of quitting~7 sessions (105 minutes) - 30% chance of quitting"
89666412|NCT04200157||12|"Group assigned to the following answer combination:~2 sessions (30 minutes) - 10% chance of quitting~7 sessions (105 minutes) - 30% chance of quitting~10 sessions (150 minutes) - 30% chance of quitting"
89666413|NCT04165161|Other|superior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation without positive tele-expiratory pressure
89666414|NCT04165161|Other|superior with 10 cmH2O positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the superior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
89666415|NCT04165161|Other|inferior without positive tele-expiratory pressure|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation without positive tele-expiratory pressure
89214420|NCT04037696|Other|Control group|The control group will be given general brief advice and receive a self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
89214421|NCT00944736|Active Comparator|VSL#3|
89214422|NCT00944736|Placebo Comparator|Placebo|
89666416|NCT04165161|Other|inferior with 10 cmH2O positive tele-expiratory pressur|Diagnostic Test: Contrast injection in the inferior vena cava territory + controlled ventilation with 10 cmH2O positive tele-expiratory pressure
89666417|NCT04163653||Fontan Group|Fontan patients operated at the two centres between 1991 and 2014.
89214423|NCT00887900|Experimental|1|Submitted to deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
89214424|NCT00887900|Active Comparator|2|Submitted to regular penetrating keratoplasty
89214425|NCT00944814|Experimental|LNS with zinc|LNS containing 10 mg zinc per 20 g dose of LNS
89666418|NCT04163653||Healthy Control Group|Age, gender and weight matched healthy controls.
89666419|NCT04151615||Patients|Treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic transplantation
89666420|NCT04150263|Other|Traditional IOL repositioning|Intraocular lens (IOL) ab externo scleral suture fixation
89666421|NCT04150263|Other|Modification of traditional IOL repositioning|Modified intraocular lens (IOL) ab externo scleral suture fixation
89666422|NCT04149821|Experimental|Cohort A Post BTKi Therapy|Patients who progress after a BTKi containing regimen
89666423|NCT04149821|Experimental|Cohort B Post BCL-2 Therapy|"Patients who progress after BCL-2 containing regimens~Patients who progress on a regimen containing both a BTKi and a BCL-2 inhibitor"
89666424|NCT04123158||WHITE|If no Green Card criteria is fulfilled (Negative Green Criteria), the patient will receive an annual telephone follow up for 2 years.
89214426|NCT00944814|Placebo Comparator|LNS without zinc|LNS containing no zinc
89214427|NCT00527787|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
89214428|NCT00527787|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
89214429|NCT00893048|Experimental|Prednisone|Use of prednisone to decrease LOS and overall treatment time of cellulitis
89214430|NCT00893048|Experimental|Placebo|
89048922|NCT04657107|Placebo Comparator|Saline group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous normal saline before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
89048923|NCT04657107|Experimental|K1 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.2mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
89048924|NCT04657107|Experimental|K2 group|"Parturients were subsequently placed in a supine position with a left lateral tilt (15 ̊). Combined spinal-epidural anesthesia method (CSE) was performed at the L2-L3 or L3-L4 lumbar vertebral interspace, with 10～13mg 0.5% ropivacaine by a needle-through-needle technique. When adequate anesthesia to the T6 dermatome was achieved (Sensory and motor assessments were performed at 1 min intervals using pinprick testing and the modified Bromage score). Parturients received 10ml intravenous 0.3mg/kg before surgery, If the anesthesia is inadequate, another 5ml 0.5% ropivacaine was given. Morphine hydrochloride 1 mg in saline 10 mL was injected by several times into the epidural space at the end of the operation. After the surgery, their PCA protocol consisted of 150 ug sufentanil and 24ml atropisetron diluted into 150 ml (2ml of basal infusion, a bolus of 0.5ml on demand, lock-out interval of 10 min, last for 48 h postoperatively);"
89666425|NCT04123158||GREEN|"Patients will be assessed by a Green Card to check the eventual presence of at least one of the following clinical and/or ultrasound characteristics.~If one or more Green Card criteria is present (Positive Green Criteria), a dedicated clinical and ultrasound paper form will be fulfilled in order to check the presence of the criteria described in the Orange Card~In case of negative Orange Criteria (no Orange Card criteria, or only one Orange Card criteria, or only Orange clinical criteria) the patient will be scheduled for longitudinal follow up at 6, 12 and 24 months. At each follow-up visit, a transvaginal ultrasound examination will be performed (using the MYLUNAR Paper Form) and the patient will be re-evaluated according to the Orange Card. In case of positive Orange Criteria the patient will be triaged to MRI and surgery. Eventual treatment for the myometrial lesion during the study period will be recorded and the outcome of these patients will be described separately."
89666426|NCT04123158||ORANGE|- If at least two Orange Card criteria (including at least one ultrasound parameter) are present (Positive Orange Criteria), the patient will be examined by means of Magnetic Resonance (MRI) within 30 days and triaged to surgery (to be performed within 60 days since the enrollment in the study). A dedicated MRI paper form will be fulfilled Histology of the target myometrial lesion will be considered as the gold standard parameter.
89666427|NCT04118894||Foot and Ankle Devices|The study subjects included are those treated with one or more approved or cleared Wright Medical products included in this study.
89666428|NCT04117074|Experimental|Arm 1: Thoracic Epidural Analgesia with bupivicaine|Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter [mL] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
89666429|NCT04117074|Experimental|Arm 2: Surgical Site Infiltration with Liposomal Bupivacaine|Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
89666430|NCT04094675|Experimental|Treatment arm|"There will be a clinic visit and colonoscopy at study entrance with standard of care sampling and assessment of polyps, including resection of concerning polyps. The investigators will also collect data on well-being via the SF-36 health survey (a validated questionnaire to help monitor this aspect given anecdotal patient-level reports of improvement while on therapy).~Study subjects will then begin sirolimus 2 mg by mouth daily for 1 year.~Laboratories will be checked at 4 days after initiation, at 2 weeks after initiation, then every 4 weeks for 3 months, then every 3 months to complete the year of therapy~Participants will have a clinic visit at 3, 6 and 9 months and include well-being assessment with the SF-36 health survey.~Participants will have a clinic visit with well-being assessment and perform colonoscopy at study closure at 12 months. The investigators will perform standard of care sampling and assessment of polyps, including resection of concerning polyps."
89666431|NCT04092452|Experimental|Cohort 1|PF-06650833
89666432|NCT04092452|Experimental|Cohort 2|PF-6700841
89666433|NCT04092452|Experimental|Cohort 3|PF-06826647
89666434|NCT04092452|Placebo Comparator|Cohort placebo|placebo
89688690|NCT04362787||High pressure _ low pressure non-invasive ventilation|"In the high-pressure NIV,52 patients will undergo pressure-limited NPPV at a higher IPAP level. IPAP is initially set at 20 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (up to 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 15 mL/kg of IBW.~2- EPAP for patients with COPD will be started at EPAP 5 and will be increased till 7 and for the patients with hypoventilation syndrome will be increased up to EPAP 8.~3-Respiratory rate 10-12 b/min."
89048925|NCT04657029|Experimental|Treadmill condition|The intervention condition consisted of a single session of moderate-high intensity aerobic exercise (65% of heart rate reserve) for 30 minutes walking on a standard treadmill. The single treadmill session included a progressive increase in intensity to reach the target heart rate (approx. 5 mins) as well as a cooling down period (approx. 5 mins). The warm-up and cool-down were included as part of the total 30 minutes of walking exercise. Target heart rates were calculated using the Karvonen method [25] with levels adjusted for those taking heart rate lowering medications (i.e. beta blockers), following methods previously published in post stroke populations [26, 27]. Participants were asked to self-rate their intensity of exercise every 10 minutes verbally using BORG's 6-20 scale rating of perceived exertion [28]. Participants were instructed to walk at a pace that resulted in a rating between 11 (fairly light) and 14 (somewhat hard) on the scale.
89666435|NCT04070053|Experimental|TheraPPP Pathway|"We will perform a before and after study to evaluate the feasibility and acceptability of the HRF and ARDS Pathway during its pilot implementation.~All mechanically ventilated patients will enter the pathway during the one month implementation and one year post-implementation periods.~To assess Pathway feasibility we will collect patient data for approximately two years and one month: one year immediately prior to implementation, one month during, and one year following implementation.~To assess acceptability of the pathway we will conduct a survey to clinicians who used the Pathway."
89666436|NCT04050514|Experimental|H-MAD, hinge system according to Herbst|"Patients with snoring and OSAS. Therapy with MAD type H-MAD with lateral hinges according to Herbst.~Bite elevation 2 mm interocclusal distance with a lower jaw advancement of 5 mm"
89666437|NCT04050514|Active Comparator|F-MAD, SomnoDent Fusion|Patients with snoring and OSAS,Fusion MAD with sliding side wings (F-MAD). Bite elevation 5 mm interocclusal distance with a lower jaw advancement of 5 mm
89666438|NCT04030325|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
89666439|NCT04030325|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
89666440|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
89666441|NCT04030325|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during the high risk drinking event celebration(s).
89666442|NCT04030325|No Intervention|Assessment Only Control|Participants complete baseline survey, longitudinal follow up assessments, and pre- and post- event surveys.
89666443|NCT04029116|Experimental|Ibrexafungerp|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Ibrexafungerp 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
89666444|NCT04029116|Placebo Comparator|Placebo|Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Placebo BID (one day) every 4 weeks for a total of 6 dosing days
89666445|NCT04025489|Experimental|Vitamin D and Placebo|Doses of cholecalciferol (commercial name, Calcirol) 60,000IU (sachets, dissolved in half glass milk) once per week for eight weeks to intervention group and placebo (Lactose Granules) to the placebo group according to the random numbers generated by the computer.
89666446|NCT04017975|No Intervention|Non-imaging cohort|There will be no intervention for the non-imaging group. Subjects will receive standard of care for cardiac surgery.
89666447|NCT04017975|Experimental|Imaging cohort|Up to 5mL of 1:1000 dilute fluorescite will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes. The system will be used to assist the investigator with the operative course.
89666448|NCT03998839||Intervention|Children tested will live within an area targeted for community IPTp distribution for pregnant women.
89666449|NCT03998839||Control|Children tested will live within an area NOT targeted for C-IPTp, but will live in an area nearby.
89666450|NCT03987009|Experimental|Without RAMP and without video|Sniffing position and a standard Macintosh laryngoscope
89666451|NCT03987009|Experimental|With RAMP and with video|Ramped position and a McGrath Mac videolaryngoscope
89666452|NCT03987009|Experimental|Without RAMP and with video|Sniffing position and a McGrath Mac videolaryngoscope
89666453|NCT03987009|Experimental|With RAMP and without video|Ramped position and a standard Macintosh laryngoscope
89666454|NCT03972943|Active Comparator|Cohort I (observation)|Patients not diagnosed with OSA undergo observation for 6 months.
89666455|NCT03972943|Experimental|Cohort II: (CPAP treatment)|Patients diagnosed with OSA and prescribed a CPAP machine for treatment receive continuous treatment with CPAP for 6 months.
89666456|NCT03944057|Experimental|ATG-010 + Dexamethasone|Open-label ATG-010 80mg plus Dexamethasone 20 mg
89666457|NCT03943264|Experimental|0.3 mg/kg XPro1595|0.3 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
89666458|NCT03943264|Experimental|0.6 mg/kg XPro1595|0.6 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
89666459|NCT03943264|Experimental|1.0 mg/kg XPro1595|1.0 mg/kg of XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
89666460|NCT03926026|Experimental|NCX 4251 QD|NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days
89666461|NCT03926026|Placebo Comparator|Placebo QD|Placebo once daily for 14 days
89666462|NCT03926026|Experimental|NCX 4251 BID|NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days
89666463|NCT03926026|Placebo Comparator|Placebo BID|Placebo twice daily for 14 days
89688691|NCT04354051|Experimental|Sodium nitrite|
89048926|NCT04657029|Other|Control condition|The control condition involved an equivalent time period (30 minutes) of seated resting where participants were provided with an education session about the impact and effects of stroke by the same research assistant.
89048927|NCT04657185||Before OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place but without OR PathTrac feedback optimization.
89048928|NCT04657185||After OR PathTrac Feedback|Patients undergoing surgery with an evidence-based, multifaceted, perioperative infection control program in place AND OR PathTrac feedback optimization.
89048929|NCT04656483|Experimental|Telemedicine Video Feedback Arm|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
89048930|NCT04656483|Active Comparator|Psychoeducational booklet arm|Mothers assigned to condition B will receive an informative booklet addressing the same themes discussed in the experimental intervention (i.e., responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant or specific parenting challenges.
89048931|NCT00561717|Experimental|Arm 1|
89048932|NCT00561717|Active Comparator|Arm 2|
89048933|NCT00561717|Active Comparator|Arm 3|
89048934|NCT00561717|Placebo Comparator|Arm 4|
89666464|NCT03924739|Experimental|Intervention group|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model.
89666465|NCT03924739|No Intervention|Control group|The control group will receive the conventional care provided by the study hospital.
89666466|NCT03917082|Experimental|standard of care endocrine therapy for two years|Standard of care adjuvant endocrine therapy for two years. for postmenopausal women, initial therapy will be aromatase inhibitor unless contraindicated, in which case tamoxifen may be used. For premenopausal and perimenopausal women, initial therapy will be tamoxifen unless contraindicated, in which case an lutenizing hormone releasing hormone (LHRH) agonist with / without aromatase inhibitor may be used.
89666467|NCT03910010|Experimental|Experimental: placebos|Fibromyalgia participants will enter in an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
89666468|NCT03910010|No Intervention|Waitlist|Fibromyalgia participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar or on REDCap.
89666469|NCT03910010|No Intervention|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
89666470|NCT03869710|Experimental|Dry-Needling|Ultrasound-Guided Dry-Needling Therapy focused on the active and latent myofascial trigger points.
89666471|NCT03865771|Experimental|EPILEPSY GROUP|"Patients with typical BECTS (benign group) or atypical BECTS or ECSWS (severe group)~Medical visit~Neuropsychological testing~Neuropsychological procedure~Video EEG and polysomnography (standard of care procedure): 2h wake and whole night~Sleep diary"
89048935|NCT04901351|Experimental|Patients chronically infected with HPV|The study will be offered to patients with chronic HPV infection as part of an annual consultation scheduled in the gynecology care package.
89048936|NCT00561756|Experimental|Vaccine Therapy|This single arm, open-label, phase I clinical trial of xenogeneic CD20 DNA vaccination is designed to evaluate its safety in patients with B cell lymphoma. The study is a dose escalation study at three test doses, 0.5 mg, 2 mg and 4 mg of purified plasmid DNA per injection. There will be an initial cohort of three patients receiving a pre-level 1 dose of 0.1 mg/vaccination before proceeding to the three test doses.
89048937|NCT04860401|Experimental|precision and accuracy study|precision and accuracy of Oxyprem are studied
89048938|NCT04656444||phone call to emergency department|
89048939|NCT04827485|Active Comparator|Gluteal squeeze|Patients behind pressed together during part of the colonoscopy (The technicians arms will be covered with a towel to mask the provider of any pressure being applied)
89048940|NCT04827485|Sham Comparator|Non-squeeze|When the doctor asks for gluteal pressure, a technician will not administer the pressure but their arms will be covered with a towel and the doctor will not know if the pressure is being administered or not.
89048941|NCT04656756|Experimental|Experimental Group|The mothers in the experimental group (60) were administered.
89048942|NCT04656756|No Intervention|Control Group|The mothers in the control group (60) were given the routine care.
89048943|NCT04683107|Experimental|Eccentric protocol|
89048944|NCT04683107|Experimental|Isometric protocol|
89048945|NCT04683146|Active Comparator|Hand antisepsis with propanolol-1 60%|Effectiveness of pre-surgical hand washing in reducing bacterial load using propranolol- 1 60% as control.
89048946|NCT04683146|Active Comparator|Hand antisepsis with solution of alcohol, chlorhexidine digluconate and potassium sorbate|Effectiveness of pre-surgical hand washing in reducing bacterial load using a solution of alcohol, chlorhexidine digluconate and potassium sorbate
89048947|NCT04627935||COPD patients|Patients with a diagnosis of COPD aged over 60 years
89048948|NCT04800302|Experimental|Continuous QLB group|U/S-guided continous QLB III
89048949|NCT04800302|Active Comparator|Single dose QLB group|U/S-guided single dose QLB III
89048950|NCT04800302|Active Comparator|Morphine group|IV Morphine
89048951|NCT04795037|Experimental|CU06-1004 for SAD|"Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts~6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
89666472|NCT03865771|Other|CONTROL GROUP|"Patients hospitalized for non neurologic illness (diabetes, nephropathy, chronic intestinal disease)~Medical visit~Neuropsychological testing~Neuropsychological procedure~Video EEG and polysomnography : 2h wake and whole night~Sleep diary"
89666473|NCT03855020||observational cohort|Patients enrolled in this observational cohort would have regular blood taking for EBV DNA examination at baseline, after every cycle of chemotherapy, every week during radiotherapy, and 1-3 months after chemo-radiotherapy until EBV DNA becomes undetectable for at least two times.
89666474|NCT03819816|Experimental|DEA-App|The intervention (DEA) group will receive the newly developed app.
89666475|NCT03819816|Other|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
89666476|NCT03811405|Experimental|Patients with Essential Tremor|Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time. The DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation. The following random conditions will be applied: (1) Home Settings; (2) VIN Biphasic; (3) Stimulator Off. A 30-minute washout period will be applied between each of the random conditions. Therefore, each patient will serve as their own control.
89666477|NCT03809247||Pancreatic cancer|such as Pancreatic ductal adenocarcinoma, Pancreatic acinar adenocarcinoma, and so on.
89666478|NCT03809247||Other pancreatic diseases|such as chronic pancreatitis, Intraductal papillary mucinous neoplasm (IPMN); Solid pseudopapillary tumors (SPT); Serous cystic neoplasm (SCN); Pancreatic neuroendocrine neoplasm (P-NN); Mucinous cystic neoplasm (MCN) and so on.
89666479|NCT03771001|Other|Convenience sample participants|In this feasibility study all participants will receive the intervention.
89666480|NCT03761121|Experimental|Primary Testing Group|"This scan is in the same imaging session as the participant's scheduled clinical MRI and is no longer 15 minutes~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
89666481|NCT03761121|Experimental|Software Testing Group|"Participants will receive hour research-only scan~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
89666482|NCT03759223|Experimental|E-PST|Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training.
89666483|NCT03759223|Active Comparator|Control|Healthy Living Messages (Control) arm. Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care.
89666484|NCT03739996|Experimental|CAB LA + VRC07-523LS|"Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.~Step 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.~VRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.~Step 3: SOC oral ART regimen for approximately 48 weeks."
89666485|NCT03734029|Experimental|Trastuzumab deruxtecan|HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a
89048952|NCT04795037|Placebo Comparator|Placebo for SAD|"Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts~2 of out 8 subjects per cohort will be randomized to receive placebo"
89048953|NCT04795037|Experimental|CU06-1004 for MAD|"Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts~6 of out 8 subjects per cohort will be randomized to receive CU06-1004"
89048954|NCT04795037|Placebo Comparator|Placebo for MAD|"Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts~2 of out 8 subjects per cohort will be randomized to receive placebo"
89666486|NCT03734029|Active Comparator|Physician's Choice|"HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:~Capecitabine~Eribulin~Gemcitabine~Paclitaxel~Nab-paclitaxel"
89666487|NCT03729570|Experimental|ePrEP|Participants will receive the ePrEP home care system for telemedicine PrEP, permitting initiation and persistence in PrEP care. The ePrEP home care system consists of: a smartphone application (app) for video-based telemedicine PrEP consultations with a clinician; secure messaging; a system to track shipments to & from participants; and behavioral risk surveys that are complemented by home specimen kits. Self-collected specimens will be mailed to laboratories for routine, guideline-based testing for PrEP care. Home specimen collection will be used to determine the primary study outcome of tenofovir-diphosphate levels.
89666488|NCT03729570|No Intervention|Standard of care|Participants will be referred to a publicly available website that geolocates the nearest PrEP provider. They will receive standard of care, defined as what a member of the general public would be able to access for PrEP services. Home specimen self-collection will be used to determine the primary study outcome of tenofovir-diphosphate levels. Additional research assessments will include quarterly surveys.
89666489|NCT03727685|No Intervention|Usual care|Patients admitted to the hospital will not receive information about Our Care Wishes.
89666490|NCT03727685|Active Comparator|Intervention: Our Care Wishes|Patients admitted to the hospital during the intervention phase will receive information from registration representatives regarding Our Care Wishes.
89666491|NCT03724032|Active Comparator|TMD Patients Active Group: Active Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).
89048955|NCT04785482||Parents of infants with single ventricle heart disease|All participants
89048956|NCT04711304|Experimental|Wharton's Jelly|Intraarticular injection of Wharton's Jelly
89048957|NCT04711304|Active Comparator|Hyaluronic Acid|Intraarticular injection of Hyaluronic Acid
89048958|NCT04711304|Placebo Comparator|Saline|Intraarticular injection of Saline
89048959|NCT04710719|Active Comparator|TAC only|Participants will be treated with adjuvant intralesional TAC 40mg/mL 7-10 days post-op and then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
89048960|NCT04710719|Active Comparator|TAC + 5FU|Participants will be treated with adjuvant intralesional TAC and 5FU at a dose of 0.1mg TAC for every 0.9mg 5FU 7-10 days post-op then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
89048961|NCT04675853||Participants with PD|
89048962|NCT04675853||Care Partners of PD participants|
89048963|NCT04649372|Other|EndoVE endosCopic Treatment for Oesophageal and Gastric canceR|The patient will be placed under General Anaesthetic or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes. The patient will then be transferred to the step-down ward to monitor for any adverse events before being discharged. There will be a telephone follow up after 2 days, 7 days, 4 weeks and 8 weeks. The patient will be requested to attend the clinic for a 12-week follow up for clinical review.
89666492|NCT03724032|Sham Comparator|TMD Patients Sham Group: Sham Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).
89666493|NCT03724032|No Intervention|Healthy Control Group|"20 Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).~Healthy volunteer data (n </= 10) may be used from a prior study (NIDCR-R56-DE022637 project [IRBMED #HUM00080911; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
89666494|NCT03705962|Experimental|Antibiotic|Subjects will be injected locally at the wound cavity (i.e. fracture site, surrounding soft tissue which include muscle, and subcutaneous space) with 80mg/40mL of tobramycin after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
89666495|NCT03705962|Placebo Comparator|Normal Saline|Subjects will be injected locally with 40 mL 0.9% NS after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
89666496|NCT03693183|Experimental|Ketorolac/HPMC|"Drug: Ketorolac/HPMC Ophthalmic Solution~1 drop administered in each eye 4 times per day for 2 days"
89666497|NCT03693183|Active Comparator|HPMC|"Drug: 0.80% Hydroxypropyl Methylcellulose(HMPC) Ophthalmic Solution~1 Drop administered in each eye 4 times per day for 2 days"
89666498|NCT03693183|Placebo Comparator|Vehicle|"Drug: Vehicle Ophthalmic Solution~1 drop administered in each eye 4 times a day for 2 days"
89666499|NCT03672318|Experimental|CAR138 T cells|The first 3 subjects enrolled in the study will receive 5x10^6 CAR138 T-cells/m^2 via infusion. The number of cells for the infusion will be increased to 1x10^7 CAR138 T-cells/m^2 and then, 2.5x10^7 CAR138 T-cells/m^2, 5x10^7 CAR138 T-cells/m^2, 1x10^8 CAR138 T-cells/m^2 and 2x10^8 CAR138 T-cells/m^2 in subsequent cohorts of 3 subjects provided no dose limiting toxicities (DLTs) are observed within 4 weeks of the cell infusion. Cohort enrollment will be staggered, requiring each subject to complete at least 2 weeks of safety monitoring following CAR138 T-cell infusion at the designated dose level for the cohort before another subject is allowed to enroll in the cohort.
89666500|NCT03657797|Experimental|NCX 470 0.021%|NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks
89666501|NCT03657797|Experimental|NCX 470 0.042%|NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks
89666502|NCT03657797|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks
89666503|NCT03657797|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks
89666504|NCT03654014|Experimental|SofPulse active|SofPulse active group. Patients who will be treated with the SofPulse activated on their heads for up to seven days in intensive care or as long as they are in the unit The PEMF device is kept on throughout and provides a 15 min pulsed treatment every hour.
89666505|NCT03654014|Placebo Comparator|SofPulse inactive|SofPulse inactive. The SofPulse will be placed on the patient's head but not activated for as long as they are in intensive care.
89666506|NCT03654014|Sham Comparator|Normal pressure hydrocephalus|CSF and serum samples from 15 normal pressure hydrocephalus patients will be used to compare CSF and serum biomarker levels in the 30 TBI patients.
89666507|NCT03618199|Experimental|Efficacy of vibrating system on healthy volunteers|
89666508|NCT03618199|Experimental|Efficacy of vibrating system on vestibular patients|
89666509|NCT03613870|Active Comparator|PermeaDerm|Participants receive PermeaDerm dressing for wound treatment until wounds have healed completely
89666510|NCT03613870|Active Comparator|Mepilex Ag|Participants receive Mepilex Ag dressing for wound treatment until wounds have healed completely
89666511|NCT03595358|Experimental|Arm|"Ellume Home Flu Test and ellume.lab Flu A+B Test~Upper respiratory tract samples from participants will be tested with:~Ellume Home Flu Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and viral culture."
89666512|NCT03551938|No Intervention|Control|Receive only the standard HIV Counseling, Testing, and Referral or Couples HIV Testing and Counseling (CHTC) Session.
89048964|NCT04683185|Experimental|Cohort 2: E6742 200 mg or Placebo|Participants will receive E6742 200 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
89048965|NCT04683185|Experimental|Cohort 3: E6742 400 mg or Placebo|Participants will receive E6742 400 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
89048966|NCT04683185|Experimental|Cohort 1: E6742 100 milligram (mg) or Placebo|Participants will receive E6742 100 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.
89048967|NCT04656405|Experimental|Online real-time CPR training program|Online real-time quality measurement and feedback video-based CPR training will be provided to participants
89048968|NCT04656405|Active Comparator|Online real-time CPR training without quality measurement program|Online real-time feedback video-based CPR training without quality measurement will be provided to participants
89666513|NCT03551938|Experimental|Intervention|Receive one 45-minute Relationship skills session for YMSM individuals and couples (the intervention) as an addition to the standard HIV Counseling, Testing, and Referral (CTR) or Couples HIV Testing and Counseling (CHTC) Session.
89666514|NCT03546361|Experimental|Treatment (Ad-CCL21-DC vaccine, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by autologous dendritic cell-adenovirus CCL21 vaccine by CT-guided or bronchoscopic IT injection on days 0, 21, and 42. Patients then receive pembrolizumab every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
89048969|NCT04656405|Placebo Comparator|Conventional CPR training program|Conventional CPR training will be provided to participants
89048970|NCT04656288|Experimental|Formula A under fasted conditions - Part 1|
89048971|NCT04656288|Experimental|Formula B under fasted conditions - Part 1|
89048972|NCT04656288|Experimental|Formula B under fasted conditions - Part 2|
89666515|NCT03525600|Experimental|APL-2 15mg 0.1 mL monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
89666516|NCT03525600|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
89666517|NCT03525600|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure for 24 months
89666518|NCT03525600|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
89666519|NCT03506334|Experimental|Pediatric Scoliosis Patients|Tether group
89666520|NCT03506334|Active Comparator|Pediatric Scoliosis Control Patients|Fusion (control) group
89666521|NCT03478098|Experimental|10 Roux-en-Y Gastric Bypass patients|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
89666522|NCT03478098|Experimental|10 control subjects|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
89666523|NCT03473574|Experimental|Arm A|Durvalumab in combination with Tremelimumab (Regimen 1) and Gemcitabine
89666524|NCT03473574|Experimental|Arm B|Durvalumab in combination with Tremelimumab (Regimen 1), Gemcitabine and Cisplatin
89666525|NCT03473574|Other|Arm C|Gemcitabine in combination with Cisplatin
89666526|NCT03473574|Experimental|Arm D|Durvalumab in combination with Tremelimumab (Regimen 2), Gemcitabine and Cisplatin
89666527|NCT03473574|Experimental|Arm E|Durvalumab in combination with Gemcitabine and Cisplatin
89666528|NCT03472040|Experimental|BCX7353 150 mg once daily|
89048973|NCT04656288|Experimental|Formula C under fasted conditions - Part 2|
89048974|NCT04656288|Experimental|Formula D under fasted conditions - Part 2|
89048975|NCT04656288|Experimental|Formula B under fed conditions - Part 2|
89048976|NCT04592276|Experimental|PS128|Each PS128 capsule contained 3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg .
89048977|NCT04592276|Placebo Comparator|placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
89048978|NCT04627779|Experimental|Male Group|
89048979|NCT04627779|Active Comparator|Female Group|
89048980|NCT04656327||Non interventional group|Community-dwelling elders dependent for care
89048981|NCT04627584|Active Comparator|MW33 injection-1200mg|
89048982|NCT04627584|Active Comparator|MW33 injection-2400mg|
89048983|NCT04627584|Placebo Comparator|Placebo|
89048984|NCT04537598|Active Comparator|patient controlled analgesia|30 patients will receive only postoperative IV PCA alone for postoperative analgesia.
89048985|NCT04537598|Active Comparator|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia.
89048986|NCT04627467|Experimental|Chloroquine 150mg base|Volunteers received chloroquine tablets orally at days 0, 15, 30, 45, 60 and 75.
89048987|NCT04656093|Experimental|Intervention|"Intervention group - Cognitive Restructuring, Motivational Interviewing, and Multi-Medication Adherence.~The pilot intervention is comprised of three educational sessions for individual study patients, conducted by interventionist with a master's degree in psychology with cognitive behavioral therapy training. The topics addressed in the sessions are as follows:~Review of COPD medication inhaler technique, psychoeducation on maladaptive beliefs and emotional response."
89048988|NCT04656093|Active Comparator|Control|Control group - Supportive counseling for comorbidity management
89666529|NCT03428126|Experimental|Durvalumab + Trametinib|"Participants take Trametinib tablets by mouth every day. Trametinib taken alone for the first 7 days of the study then participants begin receiving it in combination with Durvalumab.~Participants receive Durvalumab by vein every 4 weeks.~Each cycle is 28 days."
89666530|NCT03416530|Experimental|ONC201 in relapsed/refractory H3 K27M glioma|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.
89666531|NCT03416530|Experimental|ONC201 in newly diagnosed DIPG|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
89666532|NCT03416530|Experimental|Midline Glioma Biopsy|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.
89666533|NCT03416530|Experimental|H3 K27M CSF Biopsy|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory), have completed at least one line of prior therapy, must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF), and must be scheduled to undergo sedated MRIs.
89666534|NCT03416530|Experimental|Liquid ONC201 in relapsed/refractory H3 K27M glioma|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.
89666535|NCT03416530|Experimental|Dose Expansion Cohort in relapsed/refractory H3 K27M glioma|Pediatric patients with previously-treated, histologically confirmed high-grade glioma with a known H3 K27M mutation, evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.
89666536|NCT03416530|Experimental|ONC201 given on two consecutive days of each week|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.
89666537|NCT03360656|Experimental|Transnasal Thermal Regulating Device|Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours
89666538|NCT03345810|Active Comparator|Control Arm A|Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3 Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2 D1,D8) Q3W
89666539|NCT03345810|Experimental|Experimental Arm B|"Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3~Induction:Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2) D1,D8; Q3W [2 cyc] followed by durvalumab (1125 mg; Q3W) [ 2 cyc] Maintenance:durvalumab (1500 mg) Q4W"
89666540|NCT03345810|Experimental|Experimental Arm C|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3~Induction: Vinorelbine (30 mg/m2; D1+D8) Q3W [ 2 cyc] or Gemcitabine (1000 mg/m2; D1+D8) Q3W [ 2 cyc] followed by durvalumab (1125 mg) Q3W [2 cyc] Maintenance:durvalumab (1500 mg; Q4W)"
89666541|NCT03345810|Active Comparator|Control Arm D|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3~Vinorelbine (30 mg/m2; D1+D8) Q3W or Gemcitabine (1000 mg/m2; D1+D8) Q3W"
89666542|NCT03323385|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
89666543|NCT03323385|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
89666544|NCT03295396|Experimental|Arm A|ONC201 in relapsed H3 K27M glioma
89666545|NCT03295396|Experimental|Arm B|"ONC201 in relapsed H3 K27M glioma, excluding:~Primary malignant lesion located in the pons or spinal cord.~Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).~Prior bevacizumab treatment of >4 doses of >7.5 mg/Kg~Tumors with known 1p/19q co-deletion."
89666546|NCT03254355|Experimental|Multimodal physiotherapy|12 weeks of weekly multimodal physiotherapy treatments
89666547|NCT03254355|No Intervention|Waiting-list control group|12 weeks of weekly full-body relaxation massage
89666548|NCT03215719|Experimental|HPV-Positive Oropharyngeal Carcinoma (OPSCC)|Standard radiation therapy + cisplatinum
89666549|NCT03197467|Experimental|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
89666550|NCT03161483|Experimental|CC-220 0.45 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
89666551|NCT03161483|Experimental|C-220 0.3 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
89666552|NCT03161483|Experimental|CC-220 0.15 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
89666553|NCT03161483|Placebo Comparator|Placebo|Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)
89666554|NCT03136302||Subthalamic Nucleus (STN)|Patients with Parkinson's disease
89666555|NCT03136302||Globus Pallidus (Gpi)|Patients with Dystonia
89666556|NCT03136302||Ventral intermediate nucleus of the thalamus (VIM)|Patients with Tremor
89666557|NCT03135886|Experimental|HIV Testing Practice Coaching Intervention Group|The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.
89666558|NCT03135886|Experimental|HIV and HCV Testing Practice Coaching Intervention Group|The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.
89666559|NCT03135886|Other|Information Control Group|The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.
89666560|NCT03132636|Experimental|Group 1- metastatic BCC|Administration of cemiplimab in accordance with protocol dosing regimen
89666561|NCT03132636|Experimental|Group 2 - unresectable locally advanced BCC|Administration of cemiplimab in accordance with protocol dosing regimen
89666562|NCT03059485|Experimental|DC/AML Vaccine|- Patients will be vaccinated with DC/AML Fusion Vaccine
89666563|NCT03059485|Experimental|Observation|- Patients will be monitored with routine labs and bone marrow biopsies
89666564|NCT03047993|Experimental|Treatment (glutaminase inhibitor CB-839, azacitidine)|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7.
89666565|NCT03044587|Experimental|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
89048989|NCT04531631|Other|Group 1|receive a single oral dose of dorzagliatin 75mg tablet on visit 2 and receive one placebo tablet on visit 3
89666566|NCT03044587|Other|Arm Cisplatin + Gemcitabine (Arm B, standard of care)|Cisplatin, Gemcitabine Cycle q3w
89666567|NCT03023202||PMMTB|"This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.~All standard of care functions will be performed by standard procedures."
89666568|NCT03008434|Experimental|Yoga Group|Yoga twice a week for 8 weeks focusing on balance and pain.
89666569|NCT02977585|Active Comparator|group 1|high level support
89666570|NCT02977585|No Intervention|group 0|low level support
89666571|NCT02947620|Active Comparator|Metformin/Atorvastatin|Metformin/Atorvastatin, QD
89666572|NCT02947620|Placebo Comparator|Metformin|Metformin, QD
89666573|NCT02947620|Placebo Comparator|Atorvastatin|Atorvastatin, QD
89666574|NCT02906202|Experimental|LentiGlobin BB305 Drug Product|Participants aged less than or equal to (<=) 50 years received a single intravenous (IV) infusion of LentiGlobin BB305 Drug Product at a dose of greater than or equal to (>=) 5.0*10^6 CD34 plus (+) cells per kilogram (cells/kg) following myeloablative conditioning with busulfan (termed the Transplant population).
89666575|NCT02869789|Experimental|Nivolumab in combination with Ipilimumab|Specified dose on specified days
89666576|NCT02863445|Active Comparator|LNG-ECx1|Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
89666577|NCT02863445|Experimental|LNG-ECx2|Levonorgestrel 3mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
89666578|NCT02760485|Experimental|itacitinib + ibrutinib|
89666579|NCT02661282|Experimental|Arm I (temozolomide, CMV-specific T cells, surgery)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer IV over 1-5 minutes on day 22. Patients undergo surgery on day 30 of cycle 1. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-21. Treatment repeats every 42 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89666580|NCT02661282|Active Comparator|Arm II (temozolomide, CMV-specific T cells)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer intravenously IV over 1-5 minutes on day 22. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89666581|NCT02659527|Active Comparator|standardized needle biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.~According to the randomization, the standardized 12 core TRUS (TransRectal UltraSound)-guided biopsy is performed without knowledge of imaging findings by the urologist. If the biopsy is negative patients will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
89666582|NCT02659527|Experimental|image-guided biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.~Patients will have a standardized 12 core TRUS-guided biopsy without knowledge of imaging findings by the urologist. Patients randomized in this arm will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
89666583|NCT02634333|Sham Comparator|Observation (Prompt Sham)|Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
89048990|NCT04531631|Other|Group 2|receive a single oral dose of one placebo tablet on visit 2 and receive dorzagliatin 75mg tablet on visit 3
89048991|NCT04529447||Patient satisfaction survey|Jaseng Hospital of Korean medicine conducted a pen and paper survey on patient satisfaction with regard to its COVID-19 response in inpatients hospitalized and outpatients visiting during March 23-25, 2020.
89048992|NCT04627623||Screened arm|"6000 peoples (3x2000) in all ages randomly selected from the general population of three towns (Katowice, Sosnowiec, Gliwice).~From all invited is collected a venous blood samples (5ml) to assay IgM and IgG antibodies."
89048993|NCT04627740|Experimental|CART treatment|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
89048994|NCT04656366||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
89048995|NCT04656366||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
89048996|NCT04525469|Experimental|Narrative Exposure Therapy|NET is a fully-manualized evidence-based treatment for PTSD. Participants will receive 6 weekly 60-minute individual sessions of NET.
89048997|NCT04627155|Experimental|7mg dose group|
89048998|NCT04627155|Experimental|14mg dose group|
89048999|NCT04656249|Experimental|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing <60 kg and 12mg/d to those ≥60 kg.
89049000|NCT04472312||Cirrhotic patients undergoing a liver transplantation|The investigators aim to conduct a prospective observational, non-interventional study including all cirrhotic patients undergoing a liver transplantation with a planned use of vasopressin during the surgery.
89049001|NCT04627350||LDCT|Single arm - all patients undergo low-dose CT (LDCT) examination of lungs
89049002|NCT04655859||severe early childhood caries|
89049003|NCT04655859||healthy children|
89049004|NCT04655898|Experimental|Administration of [14C]CC-90001|A single oral dose of [14C]CC-90001, containing approximately 100 μCi of radioactivity, will be administered on Day1 under fasted conditions.
89666584|NCT02634333|Experimental|Prompt aflibercept|Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
89666585|NCT02622997|Experimental|Flocked swab 1|Cervico-vaginal self-sample taken with first flocked swab followed by cervico-vaginal self-sample taken with a second flocked swab and finally cervico-vaginal self-sample taken with a HerSwab device
89666586|NCT02612532|Experimental|LuCID|"Standardised exhaled volatile organic compound collection by ReCIVA breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)"
89666587|NCT02515630|Experimental|Momelotinib|MMB for 24 weeks (± 7 days)
89666588|NCT02494167|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for AML or MDS
89666589|NCT02494167|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for AML or MDS
89666590|NCT02450331|Experimental|Atezolizumab|Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
89666591|NCT02450331|No Intervention|Observation|Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
89666592|NCT02391025|Experimental|Gallium-68 citrate, PET|Participants will receive a single scan obtained on a single day, followed by optional tumor biopsy within 6 weeks of scan. There will be optional follow up gallium-68 citrate PET scan to assess response to treatment received outside this study that will be completed within 12 weeks of baseline scan.
89666593|NCT02377245||Juvenile Inflammatory Rheumatism|Juvenile Inflammatory Rheumatism patients
89666594|NCT02371681|Experimental|1|TB drugs
89666595|NCT02335944|Experimental|Phase IB part- NSCLC with EGFR activating mutations|NSCLC participants who have previously documented EGFR mutation and progressed on EGFR TKI treatment. Participants were treated at a starting dose of 50 mg once a day for EGF816 and 200 mg twice a day for INC280 in fasted state
89666596|NCT02335944|Experimental|Phase II- Group 1 (EGFRmut, any T790M, any MET, 2/4L antineoplastic, EGFR TKI resistant)|NSCLC participants with previously documented activating EGFR mutation, with any T790M and MET dysregulation status, who received one to three lines of systemic antineoplastic therapy prior to study entry including one line maximum of first or second generation EGFR TKI and who progressed on this EGFR TKI treatment line. Participants were treated at the RP2D of INC280 and EGF816 in fasted state
89666597|NCT02335944|Experimental|Phase II- Group 2 (EGFRmut, de novo T790M, any MET, 1/3L antineoplastic, EGFR TKI naïve)|NSCLC participants harboring T790M mutation in de novo setting, irrespective of the activating mutation status who are treatment naïve or received maximum 2 lines of systemic antineoplastic therapy prior to study entry, but no therapy known to inhibit EGFR. Participants were treated at the RP2D of INC280 and EGF816 in fasted state
89666598|NCT02335944|Experimental|Phase II- Group 3 (EGFRmut, T790M negative, any MET, 1L antineoplastic)|NSCLC participants with previously documented EGFR activating mutation, T790M negative, and any MET status who never received any prior line of systemic antineoplastic systemic therapy prior to study entry. Participants were treated at the RP2D of INC280 and EGF816 in fasted state
89666599|NCT02335944|Experimental|Phase II- Group 4 (EGFRmut, any T790M, any MET, 1L (treatment naïve) 2-3L antineoplastic)|NSCLC participants with previously documented EGFR activating mutations and any T790M and MET status who were treatment naïve or failed maximum 2 prior lines of any systemic antineoplastic therapy for advanced disease. Participants were treated at the RP2D of INC280 and EGF816 in fed state
89666600|NCT02335944|Experimental|Phase II- Group 5 (EGFRmut, T790M-, MET GCN≥5, 2L, EGFR TKI resistant)|NSCLC participants with previously documented EGFR activating mutation, T790M negative, acquired MET amplification who have progressed on one prior line of therapy for advanced/metastatic NSCLC disease. Participants were to start with INC280 monotherapy (twice a day) and would have had the opportunity to continue to combination of EGF816 (once a day) and INC280 (twice a day) based on radiological disease progression evaluation by investigator's assessment per RECIST 1.1
89666601|NCT02315378|Other|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
89666602|NCT02315378|Other|TAU|Treatment as Usual
89666603|NCT02299518|Experimental|Cohort A (mitoxantrone, etoposide, cytarabine, selinexor)|Patients receive mitoxantrone hydrochloride IV, etoposide IV, and cytarabine IV QD on days 1-6 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment continues for 1 course (28 days). Further treatment is based on disease response. Patients achieving CR/CRi are evaluated for stem cell transplant; patients who do not proceed to transplant may receive selinexor as monotherapy in the absence of disease progression or unacceptable toxicity.
89688692|NCT04362943||Complete sample|"Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 in the Perpetuo Socorro Hospital of Albacete (Spain)"
89688693|NCT04362943||Baricitinib|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Baricitinib.
89049005|NCT04627194||Mild and asymptomatic COVID-19 patients|Symptomatic patients meeting the World Health Organization (WHO) case definition for COVID-19 without evidence of viral pneumonia or hypoxia, who have a laboratory-confirmed SARS-CoV-2 infection, or asymptomatic patients with a laboratory-confirmed SARS-CoV-2 infection at the time of hospitalization.
89049006|NCT04627194||Moderate severity COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition for moderate COVID-19 disease severity [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, but no signs of severe pneumonia] at the time of hospitalization.
89214431|NCT00940368|Experimental|Ginger arm|"The patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day"
89666604|NCT02299518|Experimental|Cohort B (etoposide, selinexor)|Patients receive etoposide PO QD on days 1-5 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment may repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving response after 4 courses discontinue treatment; patients achieving response may receive up to 4 courses of maintenance therapy every 8 weeks. Patients may then continue selinexor as monotherapy at the discretion of the principal investigator.
89666605|NCT02214550|No Intervention|D+COS-no OC|Ten participants in the Dysmenorrhea + COS group will not receive an OC intervention. Monthly questionnaires will be completed for 1 yr. QST will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
89666606|NCT02214550|Active Comparator|D+COS-cyclic microgestin 1/20|26 participants in the Dysmenorrhea + COS group will receive cyclic OC. Monthly questionnaires will be completed for 1 yr. QST will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
89666607|NCT02214550|Active Comparator|D+COS-continuous microgestin 1/20|26 participants in the Dysmenorrhea + COS group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. QST will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
89666608|NCT02214550|Active Comparator|PBS-continuous microgestin 1/20|26 participants in the Painful Bladder Syndrome group will receive continuous OC. Monthly questionnaires will be completed for 1 yr. QST will be repeated at 6 months and 12 months. A yearly follow-up questionnaire will be completed for 5 years.
89666609|NCT02214550|No Intervention|No Intervention: Pain Discovery Aim|"255 Reproductive-age women (18-45) will be identified and divided into 5 groups~Healthy Controls Chronic Pain (Positive Controls) Dysmenorrhea (D) Dysmenorrhea with Cross Organ Sensitization (D+COS) Painful bladder syndrome (PBS)/interstitial cystitis (IC) After a screening, dysmenorrhea with COS and PBS participants will be compared with controls. Daily Diaries will be completed for 1-3 months. During the luteal phase of the participants' menstrual cycle or a predetermined time, participants will complete aim #1 testing consisting of a battery of questionnaires, bladder sensitivity testing, quantitative sensory testing (QST), a blood draw and EEG testing. All participants will also complete a yearly follow-up questionnaire for 5 years."
89666610|NCT02200445|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be three dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~Cohort 1: 0.3x10^6 IU/m^2/day.~Cohort 2: 1.0x10^6 IU/m^2/day.~Cohort 3: 1.5x10^6 IU/m^2/day.~Up to 6 subjects will be recruited to each dose cohort.~Once the maximum effective dose has been identified, a further 10 subjects will receive IL-2 at the maximum effective dose."
89666611|NCT02058693|Placebo Comparator|Group 1(A): Placebo/MSA|"Phase I (3 weeks) placebo adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine controlled release (CR) 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlafaxine extended release (XR) 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT (as in Phase I)."
89666612|NCT02058693|Active Comparator|Group 2(B): MSA/MSA|"Phase I (3 weeks) mixed salts amphetamine adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine controlled release (CR) 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlafaxine extended release (XR) 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT (as in Phase I)."
89688694|NCT04362943||Anakinra|Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020 and receiving Anakinra.
89688695|NCT03317899|Experimental|Group I (auto HSCT tbo-filgrastim)|Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.
89688696|NCT03317899|Experimental|Group II (auto HSCT)|Patients undergo auto Hematopoietic Cell Transplantation (HSCT).
89049007|NCT04627194||Severe-to-critical COVID-19 patients|Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation [including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) < 90% on room air] or for critical COVID-19 disease presentation [including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium] at the time of hospitalization.
89049008|NCT04627194||COVID-19 survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who survived.
89049009|NCT04627194||COVID-19 non-survivors|Patients diagnosed with a laboratory-confirmed COVID-19, who did not survive.
89049010|NCT04682756||CNN model|Electronic health information of NSTEMI and UA patients in two chest pain centers from 2017 to 2019 was collected，After manual labeling, the characteristics of patient admission records were selected, and through the construction of one-dimensional convolution (CNN) model. Taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
89049011|NCT04682756||XG boost|Through the construction of XG boost model,taking the multi-fold cross-validation and ROC-AUC curve as the measurement index, 75% of the data are modeled and 25% of the data are used to verify the effect of the model.
89049012|NCT04682795|Experimental|Needle-free injector group|To evaluate the efficacy and safety of the needle-free injector in T2DM
89049013|NCT04682795|Active Comparator|Insulin pen group|To evaluate the efficacy and safety of the insulin pen in T2DM
89049014|NCT04627116|Experimental|Tecarfarin 10mg|
89049015|NCT04627116|Experimental|Tecarfarin 20mg|
89049016|NCT04627116|Experimental|Tecarfarin 30mg|
89049017|NCT04627116|Experimental|Tecarfarin 40mg|
89049018|NCT04655742|Experimental|single arm, treatment group|Subjects in the treatment group will be implanted with the VitaFlow™ Transcatheter Aortic Valve System
89666613|NCT02056873|Experimental|Deep Brain Stimulation (DBS)|"Subjects' DBS surgical intervention requires implantation of a DBS system: two CM thalamic leads (one in each brain hemisphere), two ECOG strip leads (one in each brain hemisphere), and two neurostimulators implanted in the chest.~The ECOG strip lead is implanted into the brain to provide an interface through which stimulation can be delivered or activity of the brain can be monitored by the device, or observed by a clinician using a programmer.~Neurostimulator and leads system includes a programmer, which includes a wand and telemetry interface, and a patient remote control to check battery status and whether the device is on or off. The programmer is used to set up the device, including setup of stimulation and recording, as well as to retrieve data for subsequent review."
89666614|NCT02047513|Experimental|perioperative nab-paclitaxel/gemcitabine|neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
89666615|NCT02047513|Experimental|adjuvant nab-paclitaxel/gemcitabine|Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death
89666616|NCT02043392|Experimental|Magnamosis|Create an intestinal anastomosis using the Magnamosis Magnetic Compression Anastomosis (Magnamosis) device to re-establish intestinal continuity that would otherwise be performed using sutures or stapling devices
89666617|NCT02039856|Experimental|EBQI-Supported WH-PACT Implementation|Evidence-based Quality Improvement (EBQI) is a structured research-clinical partnership approach to facilitating implementation of new care models, including multilevel stakeholder engagement, quality improvement (QI) education/training, technical support, formative feedback, external practice facilitation, and national policy guidance.
89666618|NCT02039856|Active Comparator|Routine WH-PACT Implementation|National policy guidance
89666619|NCT01991873|Experimental|Maintenance Chemotherapy + Panitumumab|"Maintenance therapy:~Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
89666620|NCT01991873|Experimental|Maintenance Chemotherapy w/o Panitumumab|"Maintenance therapy:~Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
89666621|NCT01843556|Experimental|E2022 Tape Formulation|
89666622|NCT01796392|Experimental|EBV and Optimal Medical Management|This study arm will undergo EBV treatment along with optimal medical management, including smoking cessation program, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
89666623|NCT01796392|Other|Optimal Medical Management|This study arm will receive maximal medical management, including smoking cessation program support if necessary, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
89666624|NCT01718197||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
89666625|NCT01718197||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids (ICS) for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to ICS, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis, or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past"
89666626|NCT01718197||Healthy Controls|Those without asthma or other chronic lung disease.
89666627|NCT01618136|Experimental|E7449|
89666628|NCT01618136|Active Comparator|E7449 plus TMZ|
89666629|NCT01618136|Active Comparator|E7449 plus carboplatin and paclitaxel|
89666630|NCT01577836||Robotic assistance, Nîmes|The patients in this group will undergo robot-assisted radial prostatectomy at the University Hospital of Nîmes.
89666631|NCT01577836||Laparotomy, Marseilles|The patients in this group will undergo radical prostatectomy via traditional laparotomy at the University Hospital Marseillles.
89666632|NCT01571635|Experimental|Sotatercept dose level 0.1mg/kg|Experimental 0.1 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
89666633|NCT01571635|Experimental|Sotatercept dose level 0.3mg/ kg|Experimental 0.3 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
89666634|NCT01571635|Experimental|Sotatercept dose level 0.5mg/kg|Experimental 0.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
89666635|NCT01571635|Experimental|Sotatercept dose level 0.75mg/kg|Experimental 0.75 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
89666636|NCT01571635|Experimental|Sotatercept dose level 1.0mg/kg|Experimental 1.0 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
89666637|NCT01571635|Experimental|Sotatercept dose level 1.5mg/kg|Experimental 1.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
89666638|NCT01539031|Experimental|10 mg group|
89666639|NCT01539031|Active Comparator|23 mg group|
89666640|NCT01484678||Age Matched Controls|"Age matched non-affected (non-DMD) boys * This arm is full~Age matched non-affected men, matched for men with Becker MD *Recruiting"
89666641|NCT01484678||Boys/Men with DMD|This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old. *Recruiting
89666642|NCT01484678||Adults with Becker MD|This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 18-62 years old. * Recruiting
89666643|NCT01385163|No Intervention|Control - VSLA|the wait control sample for the economic intervention
89688697|NCT04353505|Experimental|Intra-Arterial Delivery of Ketorolac and Dexamethasone|
89666644|NCT01385163|Other|Control - Mental Health|treatment as usual based on standard psychosocial services in the area
89666645|NCT01385163|Experimental|Voluntary Savings/Loans Assoc|
89666646|NCT01385163|Experimental|Cognitive Processing Therapy|
89666647|NCT01328171|Experimental|A (FOLFOXIRI + Panitumumab)|FOLFOXIRI + Panitumumab
89666648|NCT01328171|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
89666649|NCT01288963||IL-2 subjects|Subjects receiving IL-2 for advanced melanoma
89666650|NCT01269190|Experimental|Diagnostic (widefield multispectral imaging and HRME)|Patients undergo evaluation of oral cavity using a widefield multispectral imaging device and a high-resolution optical system (HRME) at baseline, after induction of general anesthesia, and prior to surgery.
89666651|NCT01248715|Experimental|Oseltamirvir|These patients will receive early oseltamivir plus current, standard empiric antibacterial therapy.
89666652|NCT01248715|No Intervention|Standard of care|These patients will be treated with the current, standard care, including currently recommended antibiotics or antiviral therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP and ACIP antiviral use guidelines for hospitalized patients with confirmed of suspect influenza, per clinician discretion. In addition these patients with have a NP swab collected for influenza PCR testing and clinical information will be extracted from the medical record.
89666653|NCT01096602|Experimental|Group 1|DC AML Fusion Vaccine
89666654|NCT01015625|Other|A: Surgical Therapy|Local therapy consists of lumpectomy or mastectomy with or without radiotherapy (according to center tumor board decision) with a resection free margin of at least 1 mm or more demonstrated on paraffin embedded histological sections. Intraoperative frozen sections are allowed but not definitive for margin assessment. Sentinel node biopsy may be performed and has always to be followed by axillary dissection of level I and II (axillary surgery level I and II is mandatory).
89666655|NCT01015625|Other|B: Surgery on Demand|In Arm B (no local therapy) it may be necessary to perform local therapy on demand (surgery, radiotherapy). Reasons may be uncontrolled bleeding or infected exulcerations with a septic component and no treatment benefit from conservative therapy. This will be considered as protocol deviation. However, the patient's follow up is recorded and data are available for analyses as intention to treat.
89666656|NCT00963040|Experimental|Syntocinon® TI-004 protocol|Treated group
89666657|NCT00963040|Placebo Comparator|Sterile water TI-004 protocol|Placebo group
89666658|NCT00963040|Experimental|Syntocinon® TI-005 protocol|
89666659|NCT00963040|Placebo Comparator|Sterile water TI-005 protocol|
89666660|NCT00941109|Experimental|1|
89666661|NCT00941109|Experimental|2|
89666662|NCT00941109|Experimental|3|
89666663|NCT00941109|Experimental|4|
89049019|NCT04395482||covid-19 pneumonia related patients|The study aims to collect the highest number possible of lung CT scan images performed in patients with COVID-19, in order to obtain a large sample size that will allow us to characterize the extent of lung injury, the presence of specific patterns of lung alteration, and their potential association with the outcome of patients - in view of assisting the medical staff in better understanding the grade of the severity impairment in these patients which might be potentially candidates to more intensive therapeutic strategies.
89049020|NCT04627233|Placebo Comparator|No intervention:control group|
89049021|NCT04627233|Experimental|Experimental:Intervention group|
89049022|NCT04655664|Experimental|Treatment Group|Men and women aged 18-60 years, not currently experiencing chronic pain, kidney problems, liver problems, or other hormone disorders
89666664|NCT00932139|Experimental|Electro-acupuncture control|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the Electro-acupuncture control treatment."
89666665|NCT00932139|Experimental|Electro-acupuncture test|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the active Electro-acupuncture treatment."
89666666|NCT00908050|Placebo Comparator|Placebo|Placebo arm
89666667|NCT00908050|Active Comparator|botulinum toxin type A|Active arm
89666668|NCT00828581|Experimental|Lorcaserin|
89666669|NCT00812214|Experimental|Eszopiclone (Lunesta) 3mg|Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. They were treated for 6 weeks with 3mg eszopiclone, followed by a 2-week runout period. Participants came in for five visits: a screening visit, a randomization visit, a compliance visit, an end-treatment visit, and an exit/early termination visit.
89666670|NCT00812214|Placebo Comparator|Placebo|Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. They were treated for 6 weeks with placebo, followed by a 2-week runout period. Participants came in for five visits: a screening visit, a randomization visit, a compliance visit, an end-treatment visit, and an exit/early termination visit.
89666671|NCT00445172|Experimental|1|
89666672|NCT00444613|Experimental|E0302 25 mg|
89666673|NCT00444613|Experimental|E0302 50 mg|
89666674|NCT00444613|Placebo Comparator|3|
89666675|NCT00301379||1|Patients with unresectable cholangiocarcinoma.
89666676|NCT00217425|Experimental|Treatment (A-CHOP followed by MA)|Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 [max. 2 mg]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
89666677|NCT00060567|Other|1|Active combination of E7070 and irinotecan.
89666678|NCT00060567|Other|2|Active combination of E7070 and irinotecan.
89666679|NCT00060567|Other|3|Active combination of E7070 and irinotecan.
89666680|NCT00002981|Experimental|PET Scan|Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.
89666681|NCT03452917|Placebo Comparator|Placebo|2 ml of normal saline (n=500)
89666682|NCT03452917|Experimental|sodium nitrite|45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.
89666683|NCT03452865|Experimental|Esomeprazole|Patients randomized to Esomeprazole Group will receive a bolus of 160 mg of esomeprazole (diluted in 100 ml of 0.9% sodium chloride for intravenous use and administered over 60 minutes) and an intravenous infusion of 12 mg/hr (diluted in 0.9% sodium chloride at a concentration of 8 mg/ml will be injected at a rate of 1.5 ml/hr) for 72 hours .
89666684|NCT03452865|Placebo Comparator|Placebo|Patients randomized to Placebo Group will receive a bolus of 100 ml of 0.9% sodium chloride for intravenous use administered over 60 minutes with no active principle and an intravenous infusion of 0.9% sodium chloride at a rate of 1.5 ml/hr with no active principle for 72 hours .
89666685|NCT03446001|Experimental|TRx0237 16 mg/day|
89666686|NCT03446001|Placebo Comparator|Placebo|
89666687|NCT03446001|Experimental|TRx0237 8 mg/day|
89666688|NCT03365804|Experimental|3D Printed Brace|This group will receive 3D printed brace
89666689|NCT03365804|No Intervention|Traditional Brace|This group will receive the traditional brace
89666690|NCT03333252|Experimental|Intervention Condition|Exposing caregivers to caregiving-related information and care recipients to cognitive training tasks
89666691|NCT03333252|Placebo Comparator|Control Condition|Exposing caregivers to Nutrition and Health promotional material. The care recipients are exposed to plain words games from computer.
89666692|NCT03332355|Experimental|PAC-1 in combination with temozolomide|Temozolomide (PO) will be dosed at 150 mg (adjusted for body size area [m2]) daily for 5 days starting on day 8 at cycle 1, and then for each successive cycle. In Component 2, the first PAC-1 dose will be 1 dose level lower than the PAC-1 MTD established in Component 1, and the maximum dose will not exceed 450 mg. PAC-1 will be taken in the morning on days 1-21 in each 28-day cycle.
89666693|NCT03208231|Experimental|VRC01 (Arm 1)|Infants received VRC01 subcutaneous injections (40 mg/kg) at Weeks 0, 2, 6, and 10.
89666694|NCT03208231|Active Comparator|No-VRC01 (Arm 2)|Infants did not receive VRC01.
89666695|NCT03198000|Experimental|Formula # 13418-148|
89666696|NCT03198000|Experimental|Formula # 13418-158|
89666697|NCT03198000|Active Comparator|Control Formula # PF004390|
89666698|NCT03102242|Experimental|Treatment|"Induction immunotherapy: atezolizumab 1200 mg IV q 21 days x 4 cycles. Restaging after cycle 2 and cycle 4 induction: patients with progression of disease (PD) at the post-cycle 2 assessment will stop atezolizumab and go immediately to chemoradiotherapy if still stage III and eligible for curative intent therapy.~Chemoradiotherapy: carboplatin AUC = 2 + paclitaxel 50 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 60 Gy given in 2 Gy fractions daily M-F x 30 fractions~Consolidation chemotherapy: Carboplatin AUC = 6 + paclitaxel 200 mg/m2 IV q 21 days x 2 cycles beginning 3-5 weeks after completion of radiation.~Adjuvant immunotherapy: atezolizumab 1200 mg IV q 21 days to complete one year of therapy (from start of induction)."
89666699|NCT03097328|Experimental|TAK-228|"TAK-228 will be taken orally on a weekly basis for 4 weeks per cycle~Dosage will be determined by the study team"
89666700|NCT03090776|Other|unenriched|all eligible women for partial or total mastectomy intervention will be ketamine or placebo saline
89666701|NCT03090776|Other|enriched for PPMP risk|women at high risk for persistent pain after partial or total mastectomy intervention will be ketamine or placebo saline
89666702|NCT03033602|Experimental|Written exposure therapy|5 sessions of imaginal exposure therapy.
89666703|NCT03033602|Active Comparator|CPT, cognitive only|12 sessions of cognitive therapy.
89666704|NCT03030625|Other|IGRT/VMAT focal therapy boost to DIL|Localized prostate cancer (PCa) of intermediate and high risk according to NCCN criteria
89666705|NCT03022656|Active Comparator|Monitor Only|A brace monitor will be embedded inside the brace to monitor compliance.
89049023|NCT04655664|Active Comparator|Regularly Group|Subjects who consumed vitamin D supplements regularly, were pregnant, or were breastfeeding.
89666706|NCT03022656|Active Comparator|Active Brace System|An active brace device will be embedded inside the brace to dynamically control interface pressure and monitor compliance.
89049024|NCT04365179|Experimental|NEROFE|"Dose Level - Nerofe Dose~-1 - 6mg/m2~- 12 mg/m2~- 24 mg/m2~- 48 mg/m2~- 96 mg/m2~- 150mg/m2"
89049025|NCT04355546||COPD patients|Trimbow 87/5/9 pMDI for COPD prescribed according to licensed indication
89666707|NCT03022552||MINOCA|Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).
89666708|NCT03022552||MI-CAD|Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).
89666709|NCT03022552||CATH-NOCA|Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization
89666710|NCT03014401|Experimental|Stem Cells|Fat pad harvest with stem cell transplantation and standard arthroscopic debridement.
89666711|NCT03014401|Active Comparator|Placebo|Standard arthroscopic debridement with fat pad harvest WITHOUT stem cell transplantation
89666712|NCT02994784|Experimental|Evomela|Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation
89666713|NCT02990195|Other|Double enterostomy|
89666714|NCT02966847|Experimental|CBCT Acquisition|The anesthesia and surgery will take place in the usual way. The intervention consists in the CBCT acquisition after the initiation of single-lung ventilation, after the introduction of trocars.
89666715|NCT02919280||No treatment|This is an observational study. No intervention / treatment involved.
89666716|NCT02905357||MINOCA|OCT and CMR imaging
89049026|NCT04627272|Experimental|AutoDX and Gold Standard|A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera
89049027|NCT04655781|Experimental|N-T group|ILM was peeled off from nasal retina to temporal retina.
89049028|NCT04655781|Experimental|T-N group|ILM was peeled off from temporal retina to nasal retina
89049029|NCT04626999|Active Comparator|Synovial fluid COMP|Knee joint fluid is aspirated for ELISA COMP examination
89049030|NCT04626999|Active Comparator|MRI T2 Mapping|Affected knee is subjected to an MRI T2 mapping examination to see the condition of cartilage
89049031|NCT04626999|Active Comparator|Instability Examination|Lachmant Test, Pivot shift test and Rolimeter Measurement
89666717|NCT02905357||MI-CAD|Screen failures with MI found to have obstructive CAD. Limited data collection for comparison to MINOCA cohort.
89666718|NCT02884440|Experimental|TAP block ropivacaine|Bilateral ultrasound guided with 15 ml ropivacaine 5mg/ml on each side under general anesthesia at the end of the intervention
89214432|NCT00940368|Placebo Comparator|Placebo arm|"Patients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day"
89214433|NCT00608426|No Intervention|Usual Care|Group who can elect to receive reactive (usual) care for smoking cessation.
89214434|NCT00608426|Experimental|Proactive Care|Group who will be proactively offered smoking cessation care with their choice of smoking cessation services (telephone care or in-person care).
89214435|NCT00557076|Experimental|Familiar Auditory Sensory Training|FAST is a standardized passive auditory stimulation protocol. The patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. The FAST protocol is provided on compact discs (CDs), using portable players and noise cancelling headphones, while patients were awake (ie, eyes open). Speakers were used for one patient not tolerating his headphones. The CDs were identical according to track duration, labeling, and administration procedures.
89522108|NCT01976169|Experimental|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
89522109|NCT03413111|Experimental|Modified double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, a tiny cut of opening, with the length of 5mm, was performed with the sphincterotome. Then the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, needle knife (NK) precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
89666719|NCT02884440|Placebo Comparator|TAP block placebo|Bilateral ultrasound guided with 15 ml saline on each side under general anesthesia at the end of the intervention
89214436|NCT00557076|Sham Comparator|Sham Auditory Sensory Training|Placebo protocol is silence. Patients receive sham protocols for 10 minutes 4 times per day, with at least 2 hours in between, for 6 weeks.
89214437|NCT00943020|Active Comparator|Nutricia PreOp + Lipid|Nutricia PreOp + Lipid
89688698|NCT03005899|Experimental|SyB P-1501 group|One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is activated. 40 µg fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours or maximum of 80 doses. Each system will inactivate at 80 doses or 24 hours, whichever occurs first.
89049032|NCT04626960||Patient|OAB patients
89049033|NCT04626960||Control|Healthy
89049034|NCT04655040|Experimental|Caffeine and Ritlecitinib|"In Period 1 Day 1, participants will be dosed with a single oral administration of caffeine 100 milligram (mg) tablet.~In Period 2 Day 1 to Day 7, participants will be dosed with a single oral administration of ritlecitinib 200 milligram (mg) tablet. On Day 8, participants will be dosed with caffeine 100 milligram (mg) tablet within 5 minutes after administration of a 200 milligram (mg) dose of ritlecitinib on the morning of Day 8. Dosing with oral 200 milligram (mg) ritlecitinib QD will continue until Day 9."
89049035|NCT02906735||Study group|Patients with knee surgery undergo plantar foot pressure measurement pre- and postoperatively
89049036|NCT04626765|Experimental|volunteer|The child's parents or legal guardians voluntarily signed the informed consent form, and the child himself/herself met the enter criteria for the diagnosis of patients with acute B-lymphoblastic leukemia (B-ALL) expressing specific target antigens
89049037|NCT02906969|Experimental|Colonoscopy educational Video|Brief educational video of colonoscopy to determine comprehension and quality of bowel preparation.
89049038|NCT02906969|Placebo Comparator|Control|Non-colonoscopy video as a control.
89214438|NCT00943020|Active Comparator|Nutrica PreOP + Glutamine|Nutrica PreOP + Glutamine
89214439|NCT00943020|Experimental|Nutricia PreOP|Nutricia PreOP: carbohydrate only drink
89214440|NCT04017728|Active Comparator|Conventional Percutaneous Vertebroplasty|The cement is injected after the successful puncture.
89214441|NCT04017728|Experimental|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied to destroy the metastatic lesion before coment injection.
89214442|NCT00896558|Experimental|Cohort A|A single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
89214443|NCT00896558|Experimental|Cohort B|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
89214444|NCT00896558|Experimental|Cohort C|Subjects in the probe cohort will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12. All subjects will receive a single dose of midazolam alone on Day -1, and co-administered with the morning dose of GSK1322322/placebo on Day 1 and Day 12.
89666720|NCT02851303|Active Comparator|Morphine|"Dose given q 3 - 4 hrs with feeds; do not exceed 4 hrs between doses Morphine (0.04mg/0.1ml)~Score Dose For Initiation 0-8 0 None 9-12 0.04 mg/dose 13-16 0.08 mg/dose 17-20 0.12 mg/dose 21-24 0.16 mg/dose 25 or above 0.20mg/dose~Morphine Maintenance/Escalation~Maintain dose if score 0-8~Increase dose by 0.02 if score is 9-12 (rescore before dosing) • Increase dose by 0.04 if score 13-16~Increase score by 0.06 if score 17-20~Weaning Instructions:~Maintain on dose 48 hrs before starting weaning~Wean 0.02 mg morphine every day for a score is 0-8 • Defer wean for score 9-12~Re-escalation~If neonate scores 9-12 re-score as described for initiation,~If second score is in 9-12 increase morphine 0.01 mg q3-4 hrs • If 2 consecutive scores 13-16, increase 0.02 mg q3-4 hrs~If 2 consecutive scores in 17-20, increase 0.04 mg q3-4 hrs etc"
89666721|NCT02851303|Active Comparator|Methadone|Step 1: 0.7 mgs/Kg/24 hrs. divided by into six doses (q 4 hrs) is starting dose Step 2: Decrease dose by half, which is 50% of starting dose, EVERY 4 hours. Step 3: Same dose which is 50% of starting dose EVERY 6 hours. Step 4: Same dose which is 50% of starting dose EVERY 8 hours. Step 5: Same dose which is 50% of starting dose EVERY 12 hours. Step 6: Decrease dose by half, which is 25% of starting dose EVERY 12 hours. Step 7: Same dose which is 25% of starting dose q 24 hours
89666722|NCT02837705||carriers of a mutation in the Prion gene|Carriers of a mutation in the Prion gene who are either symptomatic or pre-symptomatic and who do either know or not know their mutation status.
89666723|NCT02837705||family members of carriers of a mutation in the Prion gene|Relatives of confirmed PrP mutation carriers who carry two wild type alleles.
89049039|NCT02906891|Experimental|Usual Care Patients on MDI or CSII|Usual Care Patients on MDI or CSII Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
89049040|NCT04627077||SIC drug therapy patients|Patients with a cancer diagnosis currently being treated at SIC clinic
89049041|NCT04655274||RayOne Trifocal intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of RayOne Trifocal (Rayner IOL, Ltd.) intraocular lenses
89049042|NCT04655274||AcrySof IQ PanOptix intraocular lenses|Eyes of patients undergoing cataract surgery with implantation of AcrySof IQ PanOptix (Alcon Laboratories, Inc.) intraocular lenses
89049043|NCT04626648|No Intervention|Surgery without intraoperative pause|Surgical procedure without pause
89049044|NCT04626648|Experimental|Surgery with intraoperative pause|Three-minute long intraoperative pause, including a sugar-containing drink
89049045|NCT02906618|Experimental|LY3039478 - Oral|LY3039478 given once, orally
89049046|NCT02906618|Experimental|13C 15N 2H-LY3039478 - IV|13C 15N 2H-LY3039478 given once, IV
89049047|NCT04626726|Experimental|Volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with acute B lymphocytic leukemia expressing specific target antigens
89049048|NCT04655235||patients with schizophrenia|200 patients with a DSM 5- diagnosis of schizophrenia
89666724|NCT02814084|Active Comparator|Bilateral Internal Mammary Artery grafts|Standard care wound dressings used as part of coronary artery bypass graft operation
89666725|NCT02814084|Experimental|Prevena|Prevena dressing used as part of coronary artery bypass graft operation.
89666726|NCT02775500||Apremilast-Exposed Cohort|Women who have been exposed to apremilast in pregnancy for an approved indication in the first trimester of pregnancy for any length of time from the date of conception.
89666727|NCT02775500||Diseased Comparison Cohort|Women with an approved disease who have not been exposed to apremilast at any time in pregnancy.
89666728|NCT02775500||Healthy Comparison Cohort|Healthy women who have no diagnosis of an approved indication or other chronic illness, have not taken apremilast in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
89666729|NCT02775500||Apremilast-Exposed Registry Group|Women who have been exposed to apremilast in pregnancy, for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
89666730|NCT02732392|Experimental|lymphadenectomy|
89214445|NCT00896558|Experimental|Cohort D|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
89214446|NCT00896558|Experimental|Cohort E|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
89049049|NCT04655235||healthy relatives of patients with schizophrenia|200 healthy relatives of the patients with schizophrenia
89049050|NCT04655235||healthy control subjects|healthy control subjects without relatives with mental disorders
89049051|NCT04654962||patients receiving preoperative analgesic management with anesthetic block|This cohort includes all patients that received preoperative anesthetic block for hip fracture surgery as main analgesic management during the study period.
89049052|NCT04654962||patients receiving conventional preoperative analgesic management|This cohort includes all patients that received conventional preoperative analgesic management (oral, intravenous or intramuscular medication) for hip fracture surgery as main analgesic management during the study period.
89049053|NCT04654884|Active Comparator|Group 1|The participants in group 1 will receive AA as an adjunctive therapy to TaU (i.e. individual counseling therapy, psycho therapy, pharmacological therapy) during 8 weeks.
89214447|NCT00943176|Placebo Comparator|Sugar Pill|
89214448|NCT00943176|Experimental|Modafinil|
89214449|NCT00896636||Luteal|Pre-menopausal women who undergo rFNA procedure during the luteal phase of their menstrual cycle.
89049054|NCT04654884|No Intervention|Group 2|Group 2, the control group, will receive TaU and will, just like goup 1, have a follow-up after 8 weeks.
89049055|NCT02906501||Group I (n=15)|Male children and adolescents diagnosed with ADHD not treated with risperidone or any other antipsychotic treatment.
89666731|NCT02727335||patients ALK + who received crizotinib|patients with ALK rearrangement who started treatment with crizotinib (250 mg twice a day) between the 18/11/2010 and the 31/12/2013 (will include patients from the ATU programs and patients treated after the marketing of crizotinib)
89666732|NCT02617446|Placebo Comparator|Placebo|IV infusion of placebo for 24 hours
89666733|NCT02617446|Experimental|Istaroxime 0.5 µg/kg/min|The istaroxime treatment dosed at 0.5 µg/kg/min via IV infusion for 24 hours
89666734|NCT02617446|Experimental|Istaroxime 1.0 µg/kg/min|The istaroxime treatment dosed at 1.0 µg/kg/min via IV infusion for 24 hours
89666735|NCT02559466|Experimental|Patients stimulated with a H-TMS (deep)|20 sessions navigated with Deep Transcranial Magnetic Stimulation
89666736|NCT02559466|Other|Patients stimulated with a conventional TMS|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
89666737|NCT02558101|Active Comparator|Control invitation materials|Invitation materials and strategy mimicking those of existing UK screening programmes for other cancer types
89666738|NCT02558101|Experimental|Intervention invitation materials|A targeted, stepped and low information burden invitation strategy and materials, specifically designed to improve uptake by reducing barriers to participation among smokers from socioeconomically deprived backgrounds.
89666739|NCT02549170|Experimental|Epoch 1: HYQVIA/HyQvia|Participants received HYQVIA/HyQvia (rHuPH20) 80 U/g IG, following by SC injection of immunoglobulin (IGI) 10% at the same monthly equivalent IG dose as the individual participant's pre-randomized IG dose when administered every 2, 3, or 4 weeks for 30.28 weeks or until relapse.
89666740|NCT02549170|Placebo Comparator|Epoch 1: Placebo with rHuPH20|Participants received rHuPH20 80 U/I0 mL placebo solution, followed by SC placebo infusion at matching infusion volume as the participant's pre-randomization monthly equivalent IG dose when administered every 2, 3, or 4 weeks for 31.54 weeks or until relapse.
89666741|NCT02549170|Experimental|Epoch 2: E1: Placebo Relapse - E2: GGL/KIOVIG|Participants who were enrolled to receive placebo with rHuPH20 and achieved chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) relapse during Epoch 1 received the induction dose of GGL/KIOVIG 2 g/kg bi-weekly (BW), followed by IV infusion at the same monthly equivalent dose as the participant's pre-randomization IGIV dosing regimen when administered every 3 weeks for 25.63 weeks or until relapse.
89666742|NCT02549170|Experimental|Epoch 2: E1: HYQVIA Relapse - E2: GGL/KIOVIG|Participants who were enrolled to receive HYQVIA/HyQvia (rHuPH20) and achieved CIDP relapse during Epoch 1 received the induction dose of GGL/KIOVIG 2 g/kg BW, followed by IV infusion at the same monthly equivalent dose as the participant's pre-randomization IGIV dosing regimen when administered every 3 weeks for 28.67 weeks or until relapse.
89666743|NCT02549170|Experimental|Epoch 2: E1: Placebo Relapse - E2: GAMMUNEX-C|Participants who were enrolled to receive placebo with rHuPH20 and achieved CIDP relapse during Epoch 1 received the induction dose of GAMMUNEX-C 2 g/kg BW, followed by IV infusion at the same monthly equivalent dose as the participant's pre-randomization IGIV dosing regimen when administered every 3 weeks for 24.33 weeks or until relapse.
89666744|NCT02538822|Experimental|thoracic ascending aorta (ATA)|the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing
89666745|NCT02528032|Other|Echocardiographic evaluation|Echocardiographic evaluation of heart function with new processing tools
89666746|NCT02492529|Other|Healthy volunteers|"60 old healthy volunteers (aged 25-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure"
89666747|NCT02492529|Experimental|Patients with early Alzheimer disease|"20 patients (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure~A cranial MRI"
89666748|NCT02492529|Experimental|Old healthy volunteers|"20 healthy volunteers (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure~A cranial MRI"
89666749|NCT02470273||Dermatology patients|Patients with a suspicious skin lesion indicated for biopsy
89666750|NCT02470247|Experimental|Remote ischemic preconditioning|"Remote Ischemic Preconditioning (RIPC) is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
89666751|NCT02470247|Sham Comparator|SHAM remote ischemic preconditioning|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
89688699|NCT03005899|Placebo Comparator|SyB P-1501 placebo group|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
89049056|NCT02906501||Group II (n=15)|Male children and adolescents diagnosed with ADHD intended to start risperidone or any other antipsychotic treatment due to behavioral problems.
89049057|NCT02906501||Group III (n=15)|Male children and adolescents diagnosed with ADHD treated with risperidone or any other antipsychotic treatment due to behavioral problems.
89049058|NCT02906540|Experimental|Transpubic symphysis reset therapy group|Transpubic symphysis reset therapy will be conducted once a day for 7 consecutive days.
89049059|NCT02906540|Experimental|Physiotherapy group|Physiotherapy and a sham reset treatment will be performed once a day for 7 consecutive days.
89049060|NCT02906423||Allina health patients|
89049061|NCT02906462|Other|Usual Practices|Usual Practices
89049062|NCT02906462|Other|Early consideration of vulnerability|Strategy promoting early consideration of patients' vulnerability
89049063|NCT04654494||Chron's disease patients with colorectal cancer|This group of patients with Chron's disease have been diagnosed with colorectal cancer and treated surgically
89666752|NCT02435472|Experimental|Arm A: Exercise|Arm A will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test (CPET) performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing. Archival biopsy tissue samples from before and after the intervention will also be requested.
89666753|NCT02435472|No Intervention|Arm B: Usual Care|"Arm B will receive print material with physical activity guidance which includes general physical activity information (e.g., Moving through Cancer - A Guide to Exercise for Cancer Survivors) at baseline, but no specific exercise program or goals. At the conclusion of the 16 weeks, subjects in this group will be provided with a heart rate monitor, an individualized aerobic exercise program based on their cardiorespiratory fitness test results, and opportunity to consult with study exercise physiologist (one-time)."
89666754|NCT02435472|Active Comparator|Arm C: Exploratory|Arm C is a non-randomized control group of men without cancer, which will receive all baseline and 16 week follow-up assessments (except tissue procurement) will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing.
89666755|NCT02435472|Active Comparator|Observational Non-Randomized Group|There is also a non-randomized observational component to the study where biospecimens and survey data will be collected and one CPET will be administered. Individuals who will be enrolled to this group include those who do not meet all eligibility criteria for the RCT, or those who do not wish to be in a RCT, but are interested to participate in some lifestyle research.
89666756|NCT02410902|Experimental|CM-AT|Active substance in single unit dose powder
89666757|NCT02410902|Placebo Comparator|Placebo|Placebo powder of inactive substance
89666758|NCT02384122|Active Comparator|Octreotide|Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
89666759|NCT02384122|No Intervention|Standard of care|Patients receive standard of care without a placebo.
89049064|NCT02906345|No Intervention|Control Group|Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment
89049065|NCT02906345|Active Comparator|TPE-Filtration Group|Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment
89049066|NCT02906345|Active Comparator|TPE-Centrifugation|Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment
89049067|NCT04654572|Experimental|burned group|burned patients
89049068|NCT04654572|Experimental|control group|sedentary people
89049069|NCT02906306|Experimental|Individual Occupational therapy|In Individual Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT).
89049070|NCT02906306|Experimental|Group Occupational therapy|In group Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT) and psychosocial skills training.
89049071|NCT04626531|Experimental|Intervention Group|After the pre-tests (Self-Care Activities, Self-Efficacy, Quality of Life) , the patients were given web based education and containing information and recommendations on self-management strategies for three months.
89049072|NCT04626531|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
89666760|NCT02305771|Other|Healthy volunteers|"20 healthy volunteers will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Electroencephalography~MRI"
89666761|NCT02304874|Other|Phlebotomy|Phlebotomies will be performed every 14 days at the Clinical Investigation Unit (CIU) until the value of ferritin level is below 50 µg/mL and/or the value of hemoglobin level is below 12 g/dL.
89666762|NCT02212483|Experimental|Intervention group|"After randomisation and agreement of the patient and the family, the  intervention group  will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months."
89666763|NCT02212483|Active Comparator|Control group|"The  control group  is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.~This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed."
89666764|NCT02212483|Other|Non intervention group|"The  non intervention  group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study."
89049073|NCT02906384|No Intervention|routine PCI|PTV:25Gy/10F. Radiation technique: VMAT.
89049074|NCT02906384|Experimental|HA-PCI|"PTV 25Gy/10F. Hippocampus avoidance: decrease the dose to HAZ as the following criteria: Dmin<9Gy Dmax<16Gy.~Radiation technique: VMAT."
89049075|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fed condition|Single dose of 30 mg ferric maltol capsule in a fed condition
89049076|NCT04626414|Active Comparator|30 mg ferric maltol capsule in a fasted condition|Single dose of 30 mg ferric maltol capsule in a fasted condition
89049077|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fed condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition
89049078|NCT04626414|Experimental|30 mg (5 ml) ferric maltol suspension in a fasted condition|Single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition
89666765|NCT02131909|Experimental|mirror therapy|5 sessions mirror therapy 15 minutes per week for 5 weeks
89049079|NCT02906267|Other|Manual-controlled|Patient in the manual ventilation group will receive facemask ventilation to get a tidal volume of 8-10ml/kg with a respiratory rate of 15/min. The pop-off valve will be set to 20 cm H2O.
89666766|NCT02131909|Placebo Comparator|bimanual rehabilitation exercises|5 sessions control therapy 15 minutes per week for 5 weeks
89666767|NCT02125110|Experimental|study group (cohort PELAGIE)|100 children included in the cohort PELAGIE
89666768|NCT02125110|Experimental|pilot group (no cohort PELAGIE)|10 children not included in the PELAGIE cohort to optimise MRI
89049080|NCT02906267|Other|Volume-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Tidal volume will be set to 8-10 ml/min.
89049081|NCT02906267|Other|Pressure-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Pressure will be adjusted to obtain a tidal volume of 8-10 ml/min.
89666769|NCT02103361||Stelara (ustekinumab) exposed|Stelara (ustekinumab)-exposed pregnant women (this group is now closed to recruitment)
89666770|NCT02103361||Tremfya (guselkumab) exposed|Tremfya (guselkumab-exposed pregnant women
89666771|NCT02101736|Experimental|Experimental Agent XL184 (Cabozantinib)|"Cohort A (≥ 16 years - closed to accrual): Starting cabozantinib of 40 mg daily by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 60 mg based on dose tolerability. Subjects who do not tolerate 40 mg will dose reduce to 20 mg. Doses will be capped at 60 mg.~Cohort B (3 - 15 years). The starting cabozantinib dose is 30 mg/m2/day by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 40 mg/m2/day based on dose tolerability. Subjects who do not tolerate 30 mg/m2/day will dose reduce to 23 mg/m2/day. Doses will be capped at 60 mg/day max daily dose~Each cohort will enroll up to 24 evaluable subjects with a target minimum of 17 evaluable subjects per cohort."
89666772|NCT02090140|Experimental|ADSC Application|Patients undergo an arthroscopic surgical procedure, ADSC application, followed by physical therapy.
89666773|NCT02090140|Active Comparator|Microfracture Arm|Patients undergo an arthroscopic surgical procedure, microfracture, followed by physical therapy.
89666774|NCT02088593|Experimental|DAWN simulation|Simulated Dawn Light box
89666775|NCT02088593|Active Comparator|Sleep hygiene instructions read aloud|Standard sleep hygiene instructions were read aloud.
89666776|NCT02063464||Cohort 1|Subjects w/ovarian, primary peritoneal or fallopian tube ca who are not currently on therapy and are screening for trials, being seen in consultation, or presenting for enrollment on a trial.
89666777|NCT02061488|Active Comparator|open-loop night|
89666778|NCT02061488|Experimental|closed-loop night|
89666779|NCT02041169|Experimental|Subsequent walking performance|Subsequent walking performance
89666780|NCT01985919||Bone marrow aspirate/biopsy and blood specimens|Collection of blood and bone marrow specimens for research purposes and increase the successful acquisition of correlative bone marrow samples to improve translational research in bone marrow diseases
89666781|NCT01918397|Active Comparator|Dose 1|Levofloxacin 11mg/kg daily + Optimized Background Regimen (OBR)
89049082|NCT04654611|Other|Treatment group|The intervention will be preservative free tafluprost 0.0015% topical ophthalmic solution given once daily for the study duration.
89049083|NCT02906228|Experimental|GSM 900 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
89049084|NCT02906228|Experimental|TETRA 385 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
89049085|NCT02906228|Experimental|Sham Exposure|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
89049086|NCT04654416||Steroids|Dexamethasone 6mg intravenous OD for seven to ten days
89049087|NCT04654416||Colchicine|Patients treated with colchicine at a dose of 0.5 mg every 12 hours for 7 to 14 days.
89049088|NCT02906150|Experimental|Thymalfasin (Thymosin alpha 1, Ta1)|Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
89049089|NCT02906150|Active Comparator|SoC (chemotherapy and platinum agent)|Arm B: 70 patients (control group) will receive SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
89049090|NCT04626453|Experimental|sedentary older adults with Type 2 Diabetes|Sedentary older adults with Type 2 Diabetes as the intervention group will do a 2-month home exercise.
89049091|NCT04626453|No Intervention|Active older adults with Type 2 Diabetes|Active older adults with Type 2 Diabetes will not do exercise.
89049092|NCT04626453|No Intervention|Healthy older adults|Healthy older adults will not do exercise.
89049093|NCT00561990|Active Comparator|Nimotuzumab|Nimotuzumab
89049094|NCT00561990|Placebo Comparator|Placebo|Placebo
89666782|NCT01918397|Experimental|Dose 2|Levofloxacin 14mg/kg daily + Optimized Background Regimen (OBR)
89666783|NCT01918397|Experimental|Dose 3|Levofloxacin 17mg/kg daily + Optimized Background Regimen (OBR)
89666784|NCT01918397|Experimental|Dose 4|Levofloxacin 20mg/kg daily + Optimized Background Regimen (OBR)
89666785|NCT01901770|Experimental|Arm I-HPV vaccine education|"The educational intervention is that parents and providers receive materials about HPV by mail including HPV/ cervical cancer videos and brochures, fact sheets, HPV/cervical cancer resource lists. Clinics receive posters, brochures, tabletop/reminder cards, resource lists, newsletters, and invitation to be vaccinated letters for parents."
89666786|NCT01901770|Active Comparator|Arm II- Flu vaccine education|The educational intervention is that parents and providers receive materials about Flu by mail including Flu brochures, fact sheets, Flu resource lists. Clinics receive posters and brochures.
89049095|NCT02906072|Experimental|Low fat plant-based diet|Low fat plant-based diet with conventional meals and supplemented with plant-based meal replacements and participants attend the lectures on health effects of a low fat plant-based diet.
89049096|NCT02906072|Other|Control group|Control participants attend the lectures on health effects of a low fat plant-based diet.
89049097|NCT04654728|Active Comparator|ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using ePTFE vascular grafts
89666787|NCT01883024|Other|Type 1 diabetes|
89666788|NCT01877070||early stage prostate patients & their partners/close allies|
89666789|NCT01843036|Experimental|Durham Connects Eligible|From January 1, 2014 - June 30, 2014, all odd-birth-date residential births in Durham County, North Carolina will be randomly assigned to receive the Durham Connects nurse home visiting program.
89666790|NCT01843036|No Intervention|Control|From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
89666791|NCT01825499||Very low birth weight infants|Infants 401 to 1500 g or 22 to 29 weeks gestational age admitted to Vermont Oxford Network member centers within 28 days of birth
89666792|NCT01797224||Cohort 1 - Exposed Cohort|Pregnant women with a current diagnosis of an approved indication who have used Cimzia (certolizumab pegol) in the first trimester of pregnancy for any length of time from the date of conception.
89666793|NCT01797224||Cohort 2 - Diseased Comparison Cohort|Pregnant women with a current diagnosis of a Cimzia approved indication who have not used Cimzia (certolizumab pegol) during the current pregnancy.
89666794|NCT01797224||Cohort 3 - Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used Cimzia (certolizumab pegol) at any time in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
89666795|NCT01797224||Group 4 -Cimzia Registry, Not Qualified for the Cohort Study|Women who have used Cimzia (certolizumab pegol) for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
89666796|NCT01743703|Other|whole body MRI|diagnostic whole body MRI, and skeletal imaging following guidelines (whole body radiographic and scintigraphic screening)
89666797|NCT01738516|Other|epileptic patients|Electroencephalography
89666798|NCT01738516|Other|Healthy Volunteers|Electroencephalography and additional experimental tasks
89666799|NCT01708408||community|
89666800|NCT01613638|Other|Congenital malformations|"All livebirths, fetal deaths with gestational age (GA) ≥22 weeks and terminations of pregnancy (at any gestational age) after prenatal diagnosis of malformation.~born from mothers living in Brittany at delivery~with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth~or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one)"
89666801|NCT01613638|Other|control|2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case.
89666802|NCT01611116|Placebo Comparator|sodium chloride solution 0.9%|
89666803|NCT01611116|Experimental|temsirolimus|
89666804|NCT01576315|Experimental|itraconazole|"itraconazole 10 mg/mL oral solution~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
89666805|NCT01576315|Experimental|voriconazole|"voriconazole 40 mg/mL oral suspension :~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
89666806|NCT01543113|Other|melanoma|melanoma
89049098|NCT04654728|Other|Dacron graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
89049099|NCT02906111|Active Comparator|Study Group on estriol vaginal gel|Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
89049100|NCT02906111|Active Comparator|Control group, no estriol treatment|Procedure: vaginal surgery
89049101|NCT00562029|Experimental|DJB patient|Patient has undergone a duodeno-jejunal bypass
89049102|NCT02905916|Experimental|PEG-rhG-CSF|
89049103|NCT04626492||F0|Normal control group
89049104|NCT04626492||F1|Grade 1 of liver fibrosis
89049105|NCT04626492||F2|Grade 2 of liver fibrosis
89666807|NCT01514656|Active Comparator|Video Self-Instruction (VSI) kit|Individuals will learn CPR using American Heart Association's Video Self-Instruction kit. Main data points being collected at various increments over 12 months are: 1) CPR quality at 6 to 12 months 2) Comfort Level using the skills they learned
89666808|NCT01514656|Experimental|Video-only|Individuals will learn CPR skills using a Video training method. Main data points being collected at various increments over 12 months are: 1) CPR Skills at 6 to 12 months 2) Comfort Level with using CPR
89666809|NCT01514656|Active Comparator|Recruitment with Volunteers|Volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
89666810|NCT01514656|Active Comparator|Recruitment with Nurses|Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
89666811|NCT01514656|Active Comparator|Prompting to practice skills|Individuals will be prompted every two months and encouraged to practice the skills that they learned. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
89666812|NCT01514656|Active Comparator|No prompting to practice skills|Individuals will not be prompted to practice skills. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
89666813|NCT01465854||LCINS|Never smokers with newly diagnosed lung cancer
89666814|NCT01388387|Experimental|Tacrolimus pharmacokinetics|
89666815|NCT01282593|Other|CD9 expression level|Impact of CD9 expression level on motility assays
89666816|NCT01282554|Experimental|stimulated group|stimulated group
89666817|NCT01282554|No Intervention|control group|Control group : non stimulated group.
89666818|NCT01039090|Active Comparator|Per os dopaminergic treatment|
89666819|NCT01039090|Experimental|Continuous Apomorphine infusion|
89666820|NCT00925691|Active Comparator|APICAL|implantation at the apex
89666821|NCT00925691|Experimental|SEPTAL|implantation at the interventricular septum
89666822|NCT00819637|Experimental|Arformoterol 3 doses|
89666823|NCT00819637|Experimental|Arformoterol 1 dose, placebo 2 doses|
89666824|NCT00819637|Active Comparator|Levalbuterol 3 doses|
89666825|NCT00682812|Active Comparator|1|125 womens with normal cervix
89666826|NCT00682812|Other|2|105 womens with an intraepithelial lesion
89666827|NCT00682812|Other|3|105 womens with a cancer of the cervix
89666828|NCT00593060|Experimental|Temsirolimus Combined With Cetuximab|
89666829|NCT00401336|Experimental|Magnetic Resonance Imaging|New magnetic resonance imaging multiecho gradient-echo sequence
89666830|NCT00287105|Other|Good risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
89666831|NCT00287105|Other|Poor risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
89666832|NCT03670251|Other|Blood sampling|blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots
89666833|NCT01332357||Fluticasone propionate/salmeterol combination ED MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
89666834|NCT01332357||Fluticasone propionate/salmeterol combination OP MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician
89666835|NCT04914936|Experimental|Part 1: ACP-196 and Calcium carbonate|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and a single oral dose of calcium carbonate 1 g tablet coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 2.
89666836|NCT04914936|Experimental|Part 2: ACP-196 and Omeprazole|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of omeprazole 40 mg capsules once daily (QD) for 5 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 5 of Period 2.
89666837|NCT04914936|Experimental|Part 3: ACP-196 and Rifampin|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 and oral dose of rifampin 600 mg capsule QD for 9 consecutive days coadministered with a single oral dose of ACP-196 100 mg capsule on Day 1 and Day 9 of Period 2.
89666838|NCT04759391|Experimental|Exercise group|Lifestyle recommendations as well as digital pelvic floor muscle training to the exercise group
89666839|NCT04759391|Active Comparator|Control group|Lifestyle recommendations will be given to the control group
89666840|NCT03054948|Experimental|SMOFLipid|Patients in this arm with be randomized to SMOFlipid as their lipid emulsion
89666841|NCT03054948|Active Comparator|Standard therapy|Patients in this arm will be continue with their current lipid emulsion
89666842|NCT00986921|Experimental|mifepristone|women in the mifepristone are would take mifepristone 200 mg for cervical preparation the day before their procedure, and not have dilators inserted. In this group, the sstandard procedure of osmotic dilator insertion is NOT performed.
89666843|NCT00986921|Active Comparator|Osmotic dilator insertion|Women assigned to this arm would have the standard procedure for cervical preparation, which is insertion of osmotic dilators the day before the abortion procedure
89666844|NCT04914468||TMVR|Patients undergoing Transcatheter Mitral Valce Replacement (TMVR)
89666845|NCT04914468||TEER|Patients undergoing mitral Transcatheter Edge-to-Edge Repair (TEER) after screening for TMVR
89666846|NCT04914468||Surgery|Patients undergoing mitral valve surgery (repair or replacement) after screening for TMVR
89666847|NCT04914468||Medical therapy|Patients undergoing medical therapy after screening for TMVR
89049106|NCT04626492||F3|Grade 3 of liver fibrosis
89666848|NCT04906356||Study group|Single group observational study
89666849|NCT01596972|Experimental|Serum quantitative urine pregnancy test|uterine evacuation follow-up consisting of an at-home, self-administered SQ-UPT and standardized pregnancy symptom questionnaire in 1 week
89666850|NCT01596972|No Intervention|serum hCG|follow-up consisting of a 1 week return visit and serum hCG plus standardized pregnancy symptom questionnaire
89666851|NCT04914156|Experimental|Personalised, genetic-based advice for sport performance|This group will receive personalised nutrition advice for sports performance based on their genetic test results and tailored to their current dietary intake.
89666852|NCT04914156|Active Comparator|Personalised nutrition advice for sport performance based on population-based evidence|This group will receive personalised nutrition advice on key nutrients relating to sports performance based on current best practice, population-based sport nutrition guidelines. These will be tailored to their current dietary intake
89666853|NCT04903938||Criminal-Antisocial Personality Disorder|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
89049107|NCT04626492||F4|Hepatic cirrhosis
89049108|NCT02905994|Experimental|Volasertib with chemotherapy|"Patients enrolled on this trial will receive induction chemotherapy with 7+3~Cytarabine continuous infusion days 1-7~Idarubicin IV bolus on days 1, 2, and 3.~Patients will receive Volasertib as an intravenous infusion over approximately 1 hour, according to dosing level, on day 8~Patients will receive Standard Anti Fungal and Standard Antibiotic during induction~A bone marrow biopsy will be performed according to standard practice on day 14"
89049109|NCT04626336||Patients who undergo a cystectomy|Patients who undergo a cystectomy for cancer or not, since 2010 to 2020
89049110|NCT02905955|Other|Prevena|
89049111|NCT04654767||COPD-PH group|Patients with confirmed COPD and pulmonary hypertension
89049112|NCT04654767||IPF-PH|Patients with confirmed pulmonary fibrosis and pulmonary hypertension
89049113|NCT04654767||Control group|Control group without diagnosed COPD, IPF, or pulmonary hypertension
88995302|NCT04610658|Experimental|Phase 1 Dose Level 1: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 1: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 1.5 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 1 every 3 weeks.
88995303|NCT04610658|Experimental|Phase 1 Dose Level 2: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 2: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 2.6 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 2 every 3 weeks.
88995304|NCT04610658|Experimental|Phase 1 Dose Level 3: Nivolumab and Ipilimumab plus Lurbinectedin|Participants will be treated at dose level 3: nivolumab 1mg/kg, ipilimumab 3mg/kg plus 3.2 mg/m^2 lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at dose level 3 every 3 weeks.
88995305|NCT04610658|Experimental|Phase 2: Treatment at Maximum Tolerated Dose|Participants will be treated with nivolumab 1mg/kg, ipilimumab 3mg/kg plus maximum tolerated dose of lurbinectedin. Participants will receive nivolumab, ipilimumab and Lurbinectedin every 3 weeks for 4 cycles. After 4 treatment cycles, ipilimumab will be discontinued and participants will continue treatment with a flat dose of 360 mg nivolumab and Lurbinectedin at MTD every 3 weeks.
88995306|NCT04593264|Active Comparator|Traditional Supervised Prehabilitation with a Physical Therapist|
88995307|NCT04593264|Experimental|Self-guided Home-based Prehabilitation|
88995308|NCT04538066|Active Comparator|Bryostatin 1|20ug Bryostatin will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
88995309|NCT04538066|Placebo Comparator|Placebo|Placebo will be administered over 45 minutes IV. The course of treatment will include 7 doses over the first 12 weeks, followed by a second identical treatment period beginning 30 days after completion of the first treatment period.
88995310|NCT04532918|Experimental|Verinurad + allopurinol|The subjects will receive single oral dose of verinurad 7.5 mg and allopurinol 300 mg under fasted condition.
88995311|NCT04532918|Experimental|Verinurad + allopurinol + cyclosporine|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and cyclosporine 600 mg under fasted condition.
88995312|NCT04532918|Experimental|Verinurad + allopurinol + rifampicin|The subjects will receive single oral dose of verinurad 7.5 mg, allopurinol 300 mg and rifampicin 600 mg under fasted condition.
88995313|NCT04519502||Randomly Selected Delivery Dates 2019|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2019.
88995314|NCT04519502||Randomly Selected Delivery Dates 2020|Women who deliver at one of the MFMU Network hospitals on randomly selected days between March 1 and December 31, 2020
88995315|NCT04519502||Confirmed COVID-19 Infections|Women with confirmed COVID-19 infection between March 1, 2020 and December 31, 2020 and who delivered on or before December 31, 2020.
88995316|NCT04511247|Experimental|MagicTouch PTA sirolimus drug coated balloon (DCB)|MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
88995317|NCT04511247|Active Comparator|Placebo balloon angioplasty|Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
88995318|NCT04487860|Experimental|AS012 dose regimen I|Oral
88995319|NCT04487860|Experimental|AS012 dose regimen II|Oral
88995320|NCT04487860|Experimental|AS012 dose regimen III|Oral
88995321|NCT04487860|Experimental|AS012 dose regimen IV|Oral
88995322|NCT04487860|Placebo Comparator|Placebo|Oral
88995323|NCT04456101||Control group|healthy individuals without COVID-19
88995324|NCT04456101||Severe/Critical COVID-19 rehabilitation group|①Individuals recovering from Severe/Critical COVID-19
88995325|NCT04456101||mild/moderate COVID-19 rehabilitation group|Individuals recovering from mild/moderate COVID-19
88995326|NCT04456101||asymptomatic COVID-19 rehabilitation group|Asymptomatic COVID-19 individuals with laboratory test for SRARS-COV2 turning negative
88995327|NCT04423913|Experimental|Patients undergoing transarterial embolization of the prostate|Three patients will undergo transarterial embolization of the prostate using unloaded beads.
88995328|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 2.5 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 2.5 mg of doxorubicin.
88995329|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 5.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 5.0 mg of doxorubicin.
88995330|NCT04423913|Experimental|Transarterial prostatic chemoembolization, 10.0 mg doxorubicin|Three patients will undergo transarterial chemoembolization of the prostate using beads loaded with 10.0 mg of doxorubicin.
88995331|NCT04414163|Experimental|IMC-001|Single Dose level (IMC-001 20mg/kg, every 2 weeks)
88995332|NCT04396899|Other|EHM Implantation|All patients will receive EHM implant
88995333|NCT04394585|Experimental|Smart phone app group|Patients used smart phone app based human coaching program for 3 months postoperatively.
88995334|NCT04394585|Active Comparator|Nutritional consultation group|Patients have two consulting with clinical nutritionist at 1 month and 3 months postoperatively.
89049114|NCT02905877||Functional neurological disorders|Initially especially patients diagnosed with a functional tremor.
89666854|NCT04903938||Non-criminal group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
89666855|NCT04903938||Control group|The study groups were determined as those with criminal antisocial personality disorder, those with non-criminal antisocial personality disorder and the control group. Those with antisocial personality disorder were divided into criminal and non-criminal groups according to their criminal records. The number of groups was determined as three with the control group.
89666856|NCT04913844||Skiers group|"The skiers group was formed from licensed ski athletes (17 male, 17 female) who have been active in sports for at least the last 2 years.~There will be no interventions. Physical performance tests and observational assessments will be conducted."
89666857|NCT04913844||Control group|"The control group was composed of non-athletic and age-matched participants (17 male, 17 female) with no skiing experience.~There will be no interventions. Physical performance tests and observational assessments will be conducted as in the Skiers Group."
89666858|NCT04904016|Experimental|Intervention FlowOx treatment|Each participating subject will be provided with one FlowOx™ system, which will be used about 1 hour per day every day of the week for a 4-week period with the option to extend the treatment time to up to 6 months if the patients would like to continue.
89666859|NCT04398888|Experimental|BXD treatment|"Participants will be diagnosed and treated by Chinese medicine practitioners (CMPs) with at least 5 years of clinical experience. CMPs will differentiate syndrome and prescript herbs in a semi-standardized protocol, which consists of a base Chinese medicine decoction, Banxia Xiexin Decoction (BXD), and the additional syndrome-specific herbs.~The modified decoction will be prepared in a conventional decocting method at the Chinese medicine pharmacy in the clinic (HKBA-HKU CMCTR) and will be packaged into bags by the auto-decocting machines. Participants will take the decoction twice per day, 5 days per week, for 3 weeks."
89666860|NCT04398888|No Intervention|Waitlist|Participants in the waiting list control group will be observed for a three-week waiting period. Rescue medication is not restricted.
89666861|NCT04397250|Experimental|High-intensity interval training|Participants will be asked to perform four 30 minutes bouts of high-intensity interval exercise per week.
89666862|NCT04397250|No Intervention|Control|Participants will be asked to continue their habitual lifestyle
89666863|NCT03054714|Active Comparator|group A|exchange of the infected catheter with a new one over a guidewire
89666864|NCT03054714|Active Comparator|group B|removal of the infected catheter followed by delayed placement of a new catheter 3 to 10 days later
89666865|NCT04905966|Experimental|Nutrition education + Physical activity intervention|Physical Activity and Nutrition Education: An additional 45 minute weekly physical education class and 5 weekly active break sessions of 10 minutes each will be added to the provisions of the children's curriculum. In addition, schools will receive high intensity nutrition education, that is, 3 weekly nutrition education classes of one hour in each session over a period of 6 months.
89666866|NCT04905966|No Intervention|Control|Schools receiving a lower intensity nutrition education served as control. This group received 3 sessions of 1 hour with a total of 3 educational sessions over the 6 month period. The educational material was the same as the intervention group but the development of lessons was not as specific and deep as the intervention group.
89666867|NCT01383759|Experimental|Bortezomib/Dexamethasone (BD) , STC & Maintenance BD|This is a pilot study to gain information and estimate the toxicity/tolerability of 1-3 cycles of BD, followed by HDM/ASCT, and maintenance therapy with BD in patients with MIDD associated with multiple myeloma and AL amyloidosis.
89666868|NCT04906122|Experimental|Experimental group|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
89666869|NCT04906122|No Intervention|Control Group|Control Group: No additional attempt or routine call will be made to grandmother and mothers in the control group. The questionnaires will be given to the mothers at the same time for filling the surveys after birth, one month, 3 and 6 months follow up will be done with grandmothers and mothers.
89666870|NCT01332435||Early 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
88995336|NCT04351334||Patients with ALK-positive NSCLC|
88995337|NCT04347798||Inflammatory arthritis patients on biologic + anti-malarial|Patients in northern Alberta receiving hydroxychloroquine or chloroquine +/- other disease modifying anti-rheumatic drug + biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker)
88995338|NCT04347798||Inflammatory arthritis patients on biologic + NO anti-malarial|Patients in northern Alberta receiving a biologic (anti-TNF inhibitor or anti-IL-6 blocker or B-cell depletor or JAK kinase inhibitor or T-cell c-stimulation inhibitor or IL-17 blocker) +/- any disease modifying anti-rheumatic drug except for anti-malarials (hydroxychloroquine or chloroquine)
88995339|NCT04335669|Active Comparator|Arm A (Platinum-based dose dense EC):|ddEC x 4 + pembrolizumab→ PK x 4 + pembrolizumab, Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2). Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.*
89049115|NCT02905877||Organic neurological disorders.|Initially especially patients diagnosed with a an organic action tremor (e.g. essential tremor or dystonic tremor).
89049116|NCT02905877||Healthy control|Healthy age matched controls
89049117|NCT04626180|Active Comparator|Regular Extubation|
89049118|NCT04626180|Experimental|Pre Extubation Manual Hyperinflation|
89049119|NCT02905682|Experimental|Desmopressin|Desmopressin ODT
89049120|NCT02905682|Placebo Comparator|Placebo|Placebo ODT
88995340|NCT04335669|Experimental|Arm B (Platinum-based with capecitabine):|"CEX x 4→ PK x 4, Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).Pembrolizumab is given as a 400 mg iv dosis every 6 weeks for the duration of preoperative chemotherapy.*~*The addition of pembrolizumab is strongly recommended to all participating patients. However, patients with a documented contraindication, or unwilling to receive immunotherapy may be included in the study without the administration of pembrolizumab."
88995341|NCT04332939|Experimental|Exercise + real tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.~For the first week, participants will receive 5 daily sessions of anodal tDCS (2 mA, 20 min)."
88995342|NCT04332939|Sham Comparator|Exercise + Sham tDCS|"Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week.~For the first week, participants will receive 5 daily sessions of sham tDCS."
88995343|NCT04332055|Experimental|ERVIN PLUS|The doctor and the patient will have access to the ERVIN generated data
88995344|NCT04332055|No Intervention|ERVIN MINUS|The doctor and the patient will not have access to the ERVIN generated data
88995345|NCT04298983|Experimental|Abemaciclib + ADT+ RT|Abemaciclib at 150 mg by mouth twice daily, androgen deprivation therapy (ADT), and radiation therapy in conjunction with ADT.
89666871|NCT01332435||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (more than 30 days but less than 6 months after initiation of AB)
89666872|NCT04903782||Children and adolescents with newly diagnosed malignancy|
88995348|NCT04255043|Experimental|IVUS-guided DCB|In the IVUS guidance group, IVUS assessment will be used before procedure, post-procedure, and at the follow-up.
88995349|NCT04255043|Active Comparator|Angiography-guided DCB|In the Angiography guidance group, DCB treatment will be guided by routine coronary angiography.
89049121|NCT04654377|Experimental|Personalised education|"Greetings~Recording clinical/imaging data.~Questionnaires administration.~Explaining the disease and possible outcome in the context of clinical/lab/imaging data.~Answering specific queries from patients and care givers."
89666873|NCT03584763|Active Comparator|Bi-Weekly Umbilical Artery Doppler|will undergo Doppler every other week
89666874|NCT03584763|Experimental|Weekly Umbilical Artery Doppler|will undergo Doppler every week
89666875|NCT04913688||suspected DVT group|If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, the patients become eligible for study subjects.
89666876|NCT01384539|Experimental|Cholecalciferol|Cholecalciferol 4000 IU capsule by mouth daily x 1 month then 2000 IU capsule by mouth daily x 5 months
89666877|NCT01384539|Experimental|Calcitriol|Calcitriol 0.25 mcg capsule by mouth daily x 1 month then 0.5 mcg capsule by mouth daily x 5 months
89666878|NCT04902924|Experimental|Repeated cold-water immersion|In this arm, the participants undergo repeated cold water immersion at 10°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crest
89666879|NCT04902924|Active Comparator|Repeated warm-water immersion|In this arm, the participants undergo repeated warm water immersion at 40°C for 2 x 5 min. Between the immersion, a break will be conducted 2.5 min. Participants will be immersed up to the iliac crestParticipants will be immersed up to the iliac crest.
89666880|NCT04902924|Other|Control|In this arm, the participants undergo the control intervention which comprises to remain seated for 12.5 min. The participants, that will perform the muscle damaging protocol under hypoxia will also be treated with the control condition.
89666881|NCT04903158|Experimental|Test group|Test formulation of SHR3680
89666882|NCT04903158|Other|Reference group|Reference formulation of SHR3680.
89666883|NCT01387581||Without MelaFind|Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
89666884|NCT01387581||With MelaFind|Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion
89666885|NCT01387581||Experts Without MelaFind|PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
89666886|NCT04905576|Experimental|Relaxation training following daily radiation|All relaxation sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving relaxation will learn exercises to release tension through muscle relaxation, breathing, and imagery
89666887|NCT04905576|Experimental|Healing touch therapy following daily radiation|All Healing Touch sessions will be given individually, and will be provided by trained nurses or research assistants. Patients receiving Healing Touch will receive a series of standardized therapeutic techniques designed to promote optimal flow of energy throughout the body.
89666888|NCT04905576|Active Comparator|No intervention|The no intervention group will receive no special intervention other than standard medical care, which includes the regular medical care given by the patient's physician and health care professionals.
89666889|NCT04905030|Experimental|Immigrant mother stratum|The receiver is an immigrant mother born in Eritrea, Somalia, Syria, Afghanistan, Iran or Iraq.
89666890|NCT04905030|Experimental|Educ 1 stratum|The receiver is a mother born in Sweden whose education does not exceed 3 years of high school.
89666891|NCT04905030|Experimental|Educ 2 stratum|The receiver is a mother born in Sweden whose education is at least 3 years of high school but no more than high school diploma.
89666892|NCT04905030|Experimental|Educ 3 stratum|The receiver is a mother born in Sweden whose education is at least some college (undergrad) but does not exceed an undergraduate degree
89666893|NCT04905030|Experimental|Educ 4 stratum|The receiver is a mother born in Sweden whose education is an undergraduate degree plus at least some graduate education
89666894|NCT04913454|Experimental|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks).
89666895|NCT04913454|Active Comparator|Cognitive training only|Cognitive training only (1 hour per day, per 5 days/week, for a total of 8 weeks).
89666896|NCT03421197|Experimental|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg once per day
89666897|NCT03421197|Experimental|PPC-06 400 mg BID|Tepilamide Fumarate 400 mg twice per day
89666898|NCT03421197|Experimental|PPC-06 600 mg BID|Tepilamide Fumarate 600 mg twice per day
89049122|NCT04654377|No Intervention|Standard communication|"Greetings~Recording clinical/imaging data.~Administration of questionnaire.~Addressing general queries from patients and care givers."
89049123|NCT04626258|Active Comparator|Active comparator: Fluconazol|Once a month one capsule Fluconazol 150 mg
89666899|NCT03421197|Placebo Comparator|Placebo BID|White placebo tablet to mimic Tepilamide Fumarate
89666900|NCT04904874|Other|flourescein staining, miboscore|
89666901|NCT04902534|Experimental|Naoqingzhiming Tablets|"Naoqingzhiming Tablets, specification:500mg(contains echinacoside 180mg) Single dose ascending. Qualified subjects will enter 6 dose groups in order from low to high: 180mg, 360mg, 720mg, 1080mg, 1620mg and 2160mg, with increasing dose design The first group (180mg) is a pre-experiment. Two subjects were selected and all received the test drug.~Groups 2 to 6 received the experimental drug in 8 patients per group. Multi-dose ascending was divided into two groups: 360mg and 720mg. 10 subjects in each group received the test drug 3 times a day for 14 consecutive days."
89666902|NCT04902534|Placebo Comparator|placebo (without active ingredients echinoside)|Placebo Tablets, specification: 500mg(without echinoside) Single dose. Groups 2 to 6 received the placebo in 2 patients per group. Multi-dose ascending. Two people in each group received placebo 3 times a day for 14 consecutive days.
89666903|NCT04913532|Experimental|Hypofractionation with SIB|Hypofractionation with SIB
89666904|NCT01332981||Cohort|
89666905|NCT04913376|Experimental|Hilotherapy|
89666906|NCT04913376|No Intervention|Standard care|
89666907|NCT01333527|Experimental|Group A (early ROM)|Group A (early ROM) will use the sling for comfort only
89666908|NCT01333527|Active Comparator|Group B (usual care)|Group B (usual care) will be immobilized in a sling for 6 weeks.
89666909|NCT04904640||CLS stem|CLS Zimmer stem implantation (single wedge, tapered stem) using the 3D CT based software for surgical pre-operative planning
89666910|NCT04904640||Wagner cone stem|Wagner cone Zimmer stem implantation (conical tapered stem) using the 3D CT based software for surgical pre-operative planning
89666911|NCT04904640||Aptafix stem|Aptafix Ortho stem implantation (anatomical stem) using the 3D CT based software for surgical pre-operative planning
89049124|NCT04626258|Experimental|L-Mesitran|The first month every day apply L-mesitran, the next five months apply L-mesitran every week on the vagina
89666912|NCT04904328|Active Comparator|Lumishade® active lens|Treatment of photosensitive migraine with a Lumishade® active device.
89666913|NCT04904328|Sham Comparator|Lumishade® sham lens|Treatment of photosensitive migraine with a Lumishade® sham device.
89666914|NCT04902222||Patients undergoing primary hip or knee arthroplasty|Patients undergoing primary hip or knee arthroplasty
89666915|NCT04902456|Experimental|Power Chain and Crimpable hook for En-masse retraction|"Retraction will start on a 0.017x0.025 Stainless Steel wire using elastomeric chain ( force applied will be 212 g per side ) extending between the crimpable hooks and the miniscrew"
89666916|NCT04902456|Experimental|T-loop|"Closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine."
89666917|NCT04894422||No face mask|Volunteers who did not wear a face mask
89666918|NCT04894422||Cotton face mask|Voluntarily wearing a cotton face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
89666919|NCT04894422||Surgical face mask|Voluntarily wearing a surgical face mask for 4 hours, following the government's guidelines during the COVID-19 pandemic.
89666920|NCT04904406|Experimental|dolutegravir/lamivudine|50 mg dolutegravir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
89666921|NCT04904406|No Intervention|dolutegravir/abacavir/lamivudine|50 mg dolutegravir, 600 mg abacavir and 300 mg lamivudine (co-formulated) once daily for 48 weeks
89666922|NCT00985751|Experimental|Group 1|
89666923|NCT00985751|Experimental|Group 2|
89666924|NCT00985751|Experimental|Group 3|
89049125|NCT04626102|No Intervention|Enrollment|"Participants were recruited by using a convenience sampling method. Potential participants were reached through lecturers and professors who are teaching classes at different universities in Istanbul, Turkey.~Participants were asked to fill out a questionnaire package covering Demographic Information Form, Eating Disorders Examination Questionnaire (EDEQ), Eating Attitudes Test - 40 (EAT-40), Body Image Satisfaction Questionnaire (BISQ), and Sociocultural Attitudes towards Appearance Questionnaire-4-Revised (SATAQ-4R). Filling out the questionnaire package took approximately 25-minutes."
89049126|NCT04626102|Experimental|Intervention Period|"Participants were randomly assigned to one of these conditions:~Experimental condition: Healthy Eating Attitudes and Behaviours Group Program - 6 weekly sessions, each session was about 45-minutes to 60-minutes~Active control condition: Eating Disorders and Body Dissatisfaction: A Group Work - single session about 1.5 hours to 2 hours~Wait-list control condition: Participants in this condition were informed that they will be asked to fill out questionnaires that sent to them, and at the end of 6 months, they will be invited to participate in Healthy Eating Attitudes and Behaviours Group Program."
89214450|NCT00896636||Follicular|Pre-menopausal women who undergo rFNA procedure during the follicular phase of their menstrual cycle.
89214451|NCT00896636||Menopause|Women who have entered menopause.
89666925|NCT00985751|Experimental|Group 4|
89666926|NCT00985751|Experimental|Control Group|
89666927|NCT04884828||one group|patients from the Pulmonology Service of the Corporació Sanitària Parc Taulí (Sabadell, Barcelona) who met the following criteria: over 18 years of age, hospital admission for acute chronic respiratory failure, home NIV (single-limb system with intentional leakage) users for more than 6 months with adequate compliance (greater than or equal to 5 hours/night). Patients with underlying psychiatric disease were excluded. The study was conducted during the patient's predischarge phase (the same day or the day before)
89666928|NCT03050190|Experimental|Therapeutic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
89666929|NCT04901832|Experimental|Experimental Group|The intervention in this group is stretching exercises with the aim of prevention and reduction of leg muscle cramps among patients undergoing hemodialysis
89666930|NCT04901832|No Intervention|Control Group|The participants in this group used as reference group
89214452|NCT00129259|Experimental|Anti-CD3 mAb Plus Diabetes Standard of Care Treatment|"Subjects receive 1.) a 14-day course of anti-CD3 monoclonal antibody (mAb) intravenously (IV) comprised of daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 days of 826 µg/m2 [Cycle 1] and, when eligible per protocol, receipt of a second 14-day course after a 12-month interval (at month 13)[Cycle 2]. Note: Prior to May 2007, the course of IV daily doses of anti-CD3 mAb were: 57 µg/m2, 115 µg/m2, 230 µg/m2, 460 µg/m2, and 10 days of 919 µg/m2 and, when eligible per protocol, a second course after a 12-month interval (at month 13). 2.) and intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
89214453|NCT00129259|Active Comparator|Diabetes Standard of Care Treatment|"Subjects receive intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization."
89214454|NCT00896714|Experimental|Closed loop anesthesia|
89214455|NCT00943254|Experimental|Arm 1|"Patients randomized to this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based and DVD materials"
89666931|NCT02435173|Experimental|Part I: CDZ173|Participants consecutively received CDZ173 10 mg twice a day (b.i.d.) from Day 1 to Day 28, CDZ173 30 mg b.i.d. from Day 29 to Day 56 and CDZ173 70 mg b.i.d. from Day 57 to Day 84.
89666932|NCT02435173|Experimental|Part II: CDZ173|Participants received CDZ173 70 mg b.i.d. from Day 1 to Day 85.
89666933|NCT02435173|Placebo Comparator|Part II: Placebo|Participants received Placebo b.i.d. from Day 1 to Day 85.
89666934|NCT04901520|Experimental|High Intensity Training (HIT)|Participants trained at 80-90% of 1RM for 12 weeks, twice per week.
89666935|NCT04901520|Experimental|Moderate Intensity Training (MIT)|Participants trained at 65-75% of 1RM for 12 weeks, twice per week.
89666936|NCT04901520|Experimental|Low Intensity Training (LIT)|Participants trained at 50-60% of 1RM for 12 weeks, twice per week.
89666937|NCT04901520|No Intervention|Control Group (CG)|Participants did not participate in any training and they advised to do their daily activity
89666938|NCT04893642|Active Comparator|Abdominal suture rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
89666939|NCT04893642|Active Comparator|Abdominal resection rectopexy|Patients were randomized first into either an abdominal or a perineal approach. The abdominal group was then further randomized to suture rectopexy or resection rectopexy.
89666940|NCT04893642|Active Comparator|Perineal Delorme|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
89666941|NCT04893642|Active Comparator|Perineal Altemeier|Patients were randomized first into either an abdominal or a perineal approach. The perineal group was then further randomized to Delorme's operation or Altemeier's operation.
89666942|NCT03052140|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 14 days, followed by Treatment B for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
89666943|NCT03052140|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 14 days, followed by Treatment A for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
89666944|NCT04901130|Experimental|AQCS-aided group|Patients in AQCS-aided group will go through colonoscopy examination with the assitance of AQCS.
89666945|NCT04901130|No Intervention|Control group|Patients in control group will go through conventional standard colonoscopy examination without the assistance of the AQCS.
89666946|NCT02325505||Tuberous sclerosis complex|All patients with TSC, LAM or AML followed at Hospital das Clínicas, University of São Paulo Medical School will be included in the proposed study. Patients of all ages will participate in the study.
89666947|NCT04901052|Experimental|n-3 supplementation group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus Omega 3 supplementation, the dosage was 2 capsules per day, containing 1.5 g of omega 3, of which 1000 mg were EPA and 500mg DHA. The omega 3 capsules were obtained from the same batch.
89214456|NCT00943254|Experimental|Arm 2|"Patients in this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based material"
89214457|NCT00943254|No Intervention|Arm 3|Patients randomized to control receive the diagnosis of individual cardiovascular risk factors with paper-based educational material
89214458|NCT04017572|Active Comparator|Standard treatment|APD-treatment with a net volume of 12 L 1.36 % anhydrous glucose peritoneal dialysis solution during 540 minutes.
89214459|NCT04017572|Active Comparator|Optimized treatment|APD-treatment with a net volume of 14 L 2.27 % anhydrous glucose peritoneal dialysis solution during 280 minutes followed by a net volume of 10 L 0.1 % glucose dialysis fluid during 200 minutes.
89214460|NCT00940524|Experimental|Chemotherapy|A phase I study designed to determine the dose of dasatinib that can be safely administered with cytarabine and high-dose mitoxantrone in Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia patients.
89214461|NCT00186901|Placebo Comparator|1A|Nutritional counseling + placebo
89214462|NCT00186901|Experimental|1B|Nutritional counseling + supplementation with calcium, 1000mg/day + vitamin D, 800 units/day, for a 2 year period
89214463|NCT00893126||Subjects with severe psoriasis|Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan.
89214464|NCT00893126||Subjects without psoriasis|Subjects 18 to 55 who do not have psoriasis or rheumatologic conditions, including rheumatoid arthritis and systemic lupus erythematosus. This group of subjects will complete a CCTA (Coronary CT Angiogram)scan.
89666948|NCT04901052|Placebo Comparator|Placebo group|The nutritional strategy consisted a hypocaloric diet high in n-3. A 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study plus placebo capsules (2 capsules per day made from sunflower oil)
89666949|NCT04884516|Other|Intervention arm|Participants take retinol gummy once a day
89666950|NCT04346329|Placebo Comparator|Control|Controlled group with placebo medication similar to hydroxychloroquine (loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days)
89666951|NCT04346329|Experimental|treated|hydroxychloroquine with a loading dose of 800 mg of hydroxychloroquine the first day followed by 400 mg/week for 90 days
89666952|NCT04892784|Experimental|Press tack needle acupuncture|
89666953|NCT04892784|No Intervention|Control|
89666954|NCT04892550|Experimental|Traction group|"Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.~In addition, the participants in the intervention group will receive the Denneroll™ thoracic traction orthosis. All participants will begin at 3-minutes per session of DTTO application, each visit they will be encouraged to increase the duration by 2-3 minutes, until such time they will be able to reach the goal of 15-20 minutes per session."
89666955|NCT04892550|Active Comparator|Control group|Participants in both groups will complete a 10-week, 3 x per week, 30 sessions total multimodal program consisting of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises. The multimodal program will be delivered by the same physiotherapist, with 10 years of experience and training in the specific manual techniques in order to minimize inter-therapist variation and enhance fidelity.
89666956|NCT02317003|Experimental|Intervention PPIL|Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
89666957|NCT02317003|Active Comparator|Control OR|Oral recommendation of physical exercise delivered by the family doctor.
89666958|NCT04883736|Experimental|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
89666959|NCT04883736|Active Comparator|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
89666960|NCT04883736|Placebo Comparator|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
89666961|NCT01387815||Topical/Traditional Systemic Agent|Participants who initiated treatment with a new topical agent that was not used before or already being treated with topical agent and not responding, thereby requiring a change of treatment type, frequency, or dose and all participants who initiated treatment with a new systemic agent that was not used before alone or in combination with topical agents.
89666962|NCT01387815||Adalimumab|Participants treated with adalimumab alone or in combination with topical agents.
89666963|NCT04883580|Experimental|experimental group|
89666964|NCT04883580|Active Comparator|control group|
89666965|NCT04883034|Placebo Comparator|pain management post total knee arthroplasty with analgetic oral|Patients in control group were given analgesic (etoricoxibe) on a daily basis, with the option to increase the dose if pain persisted, up to a maximum of 120 mg per day.
89666966|NCT04883034|Active Comparator|pain management post total knee arthroplasty with adductor canal block|On postoperative day 14 (POD 14), the ACB was performed for ACB group
89666967|NCT02410057|Active Comparator|Standard infant formula|Standard infant formula
89666968|NCT02410057|Experimental|Protein-reduced whey formula|Protein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula
88995350|NCT04254419|Experimental|NK cell infusion|"For source PBMCs from the patient, up to 3ml/kg (maximum 150ml) of heparinized peripheral blood will be drawn. NK cell product will be manufactured by a GMP facility. Once the NK cell goes through the appropriate procedures, it will undergo a lot release testing and cryopreservation by day 14 for infusion.~If NK cells fail to meet release criteria or are insufficient in number for the dose level assigned, collection of PBMCs may be repeated up to 2 additional times.~Duration of study therapy is up to 12 weeks and nine doses of NK cells."
88995351|NCT04241809||A: Notified TB with sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
88995352|NCT04241809||B: Notified TB without sputum laboratory confirmation|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
88995353|NCT04241809||C: Not Notified for TB|"Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling.~Repeat bioaerosol sampling will be conducted at 14 days."
88995354|NCT04241120|Experimental|Experimental group - HabitAware condition|This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
88995355|NCT04241120|Placebo Comparator|Control group - reminder bracelet condition|This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull.
89214465|NCT00888056|Experimental|ARM A|Bilateral chronic electrical stimulation of the hypothalamus/fornix
89214466|NCT00943332||spica casting|
89214467|NCT00943332||intramedullary nailing|
89214468|NCT00943332||submuscualr plating|
88995356|NCT04240574|Other|Micro Water Jet Technology (Debritom)|"Debritom is a hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.~All subject will get the Debritom."
89214469|NCT04036370|Active Comparator|PECS group|In addition to routine analgesic protocol; before anaesthesia induction; following the PECS I + II block, a continuous infusion catheter will be placed at the PECS II block level under the guidance of USG, and local anesthetic infusion will be started via the catheter at the end of the operation.
89214470|NCT04036370|Sham Comparator|Control group|Peroperative and postoperative routine analgesic protocol will be performed with no additional intervention (block).
89666969|NCT02410057|Experimental|Protein-reduced α-lactalbumin formula|Protein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula and in standard infant formula
89666970|NCT02410057|No Intervention|Breast-feeding|Exclusive breast-feeding
89666971|NCT01596582|No Intervention|Standard Care|Subjects randomized to the control arm will review the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled visit with their provider.
89666972|NCT01596582|Experimental|Risk Assessment|Subjects randomized to the experimental arm will complete the ACNI risk assessment tool after reviewing the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled office visit with their provider.
89666973|NCT04745767|Experimental|Group 1: A1(T1), B(T2), C(T2 Fed)|Participants will be randomly placed into 6 sequences within Group 1. All participants in Group 1 will receive TAK-994 as Treatment A1 (T1 Formulation) and Treatment B (T2 Formulation) under fasted conditions and Treatment C (T2 Formulation) under fed conditions at different times within three periods.
89666974|NCT04745767|Experimental|Group 2: A2(T1), D(T3), E(T3 Fed)|Participants will be randomly placed into 6 sequences within Group 2. All participants in Group 2 will receive TAK-994 as Treatment A2 (T1 Formulation) and Treatment D (T3 Formulation) under fasted conditions and Treatment E (T3 Formulation) under fed conditions at different times within three periods.
89666975|NCT04745767|Experimental|Group 3: A3(T1), F(T4), G(T4 Fed), H(T5)|Participants will be randomly placed into 6 sequences within Group 3. Participants in Group 3 will receive TAK-994 as Treatment A3 (T1 Formulation), Treatment F (T4 Formulation), and Treatment F (T5 Formulation) under fasted conditions and Treatment G (T4 Formulation) under fed conditions at different times within 4 periods.
89666976|NCT02401633|Experimental|CO-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions only
89666977|NCT02401633|Active Comparator|S-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions and rescue breaths in a 30:2 ratio
89666978|NCT01596504|Experimental|Lixisenatide 20 μg|Subcutaneous injection of lixisenatide10 μg once daily (QD) for 2 weeks followed by 20 μg QD for 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
89666979|NCT01596504|Active Comparator|Liraglutide 1.2 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for 7 weeks under fasted conditions, on top of insulin glargine with or without metformin.
89666980|NCT01596504|Active Comparator|Liraglutide 1.8 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for another 1 week and 1.8 mg QD for next 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
89666981|NCT02396251|Experimental|HA experimental|HA experimental only
89666982|NCT02396251|Active Comparator|HA comparator|HA experimental + HA comparator
89666983|NCT04899960|No Intervention|Observational Group|
89666984|NCT04899960|No Intervention|Control (Validation) Group|
89666985|NCT04899960|Experimental|İnterventional Group|
89214471|NCT00943410|Active Comparator|Surgical Candidate|After 5 consecutive weeks of treatment with Radiation and Herceptin, these subjects will receive mastectomy excision
89214472|NCT00943410|Active Comparator|Non-Surgical Candidate|After 5 weeks of consecutive treatment with radiation and herceptin, these subjects will not be eligible for surgery. They will continue with radiation and herceptin for an additional 2 weeks.
89214473|NCT00186121|Experimental|Anastrozole + Goserelin|Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily. No dose attenuation or escalation was allowed for either goserelin or anastrozole.
89666986|NCT04892394|Experimental|Video Group|Detailed visual video information was given to the video group patients before endodontic treatment by the clinician.
89666987|NCT04892394|Experimental|Control Group|Basic verbal information was given to the control group patients before endodontic treatment by the clinician.
89666988|NCT01389765|Experimental|LY2216684 administered in fasted then fed state|Period 1: Single 18-mg (milligram) oral dose of LY2216684 administered in fasted state. Period 2: Single 18-mg oral dose of LY2216684 administered in fed state. Periods will be separated by a minimum of 7 days.
89666989|NCT01389765|Experimental|LY2216684 administered in fed then fasted state|Period 1: Single 18-mg oral dose of LY2216684 administered in fed state. Period 2: Single 18-mg oral dose of LY2216684 administered in fasted state. Periods will be separated by a minimum of 7 days.
89666990|NCT04900194|Experimental|MBSC group|counseling group
89666991|NCT04900194|No Intervention|Control group|standard care group
89666992|NCT01334229|Experimental|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
89666993|NCT01334229|Placebo Comparator|Placebo|Placebo for 6 weeks
89666994|NCT04883268|Experimental|Intervention Group|Participants in the intervention group completed the Expand Your Horizon programme (Alleva et al., 2015).
89666995|NCT04883268|No Intervention|Comparison Group|Participants in the comparison group did not complete any intervention (i.e., this was a waitlist comparison group).
89666996|NCT05024539||Regorafenib group|Patients were given only regorafenib orally
89666997|NCT05024539||Joint group|The patient was treated with regorafenib orally and in combination with other medications
89666998|NCT04892316||Junior doctor group|Patients receive assisting devices fitting services from junior doctors
89666999|NCT04892316||Senior doctor group|Patients receive assisting devices fitting services from senior doctors
89667000|NCT04892316||Algorithm assisted group|Patients receive assisting devices fitting services from junior doctors assisted by the machine learning model
89667001|NCT01390077|Experimental|Nitisinone|all subjects will receive open-label nitisinone
89667002|NCT02292979|Active Comparator|ABVD|Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
89667003|NCT02292979|Experimental|AVD+BV|Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles
89667004|NCT02616900|Experimental|eSight Eyewear|Main arm
89667005|NCT04882956|Active Comparator|BEOVU|Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
89667006|NCT04882956|Active Comparator|Eylea|Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months
89667007|NCT01404039|Experimental|Motor Learning (ML) sighted|"In this arm, subject will perform motor Learning with visual feedback - ML sighted.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
89667008|NCT01404039|Experimental|Motor Learning (ML) blind|"In this arm, subject will perform motor Learning without visual feedback - ML blind.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
89667009|NCT01404039|Placebo Comparator|Motor Learning (ML) control group|In this arm, subject will perform simple hand movements - control group. There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session.
89667010|NCT01404039|Experimental|Somatosensory Learning (SL sighted)|"In this arm, subject will perform sensory Learning with visual feedback - SL sighted.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
89667011|NCT01404039|Experimental|Somatosensory Learning (SL blind)|"In this arm, subject will perform sensory Learning without visual feedback - SL blind.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
89667012|NCT01404039|Experimental|Somatosensory Activation (S activation)|"In this arm, subject will receive simple sensory stimulation over their left index finger - Sactivation.~There will be an anticipated total of 10 subjects in this experimental arm.This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
89667013|NCT01404039|Placebo Comparator|Somatosensory Learning (SL) control group|"In this arm,the subjects will not receive any somatosensory input (SL control group).~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
89667014|NCT01404039|Experimental|Observational Task (OT) - real|In this arm, the subjects will perform an observational task - observation of hand movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
89667015|NCT01404039|Placebo Comparator|Observational Task (OT) - control group|In this arm, the subjects will perform a controlled observational task - observation of geometric shapes. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
89667016|NCT01404039|Experimental|Mental Imagery (MI) - real|In this arm, the subjects will perform mental imagery - mental imagery of finger movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
89667017|NCT01404039|Placebo Comparator|Mental Imagery (MI) - control group|In this arm, the subjects will perform a controlled task - simple mental calculation. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
89667018|NCT01404039|Experimental|transcranial direct current stimulation - tDCS real|tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. 15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session.
89667019|NCT01404039|Placebo Comparator|transcranial direct current stimulation - tDCS sham|"tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. The stimulation will be stopped after 30seconds.~15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session."
89667020|NCT02394535|Experimental|Treatment (chemotherapy, radiation therapy)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, 15, 22, and 29 and capecitabine PO BID on days 1-5 (Monday-Friday). Patients also undergo radiation therapy QD on days 1-5 (Monday-Friday). Treatment continues for 51/2 weeks in the absence of disease progression or unacceptable toxicity.
89667021|NCT03052062|Experimental|Lipidrive|Dose 1 : 2,6 g (4 capsules) Lipidrive per day during 12 weeks Dose 2 : 5,2 g (8 capsules) Lipidrive per day during 12 weeks, 2 weeks (wash-out period) between the 2 doses
89667022|NCT04891848||migraine with aura|51 patients with MA
89667023|NCT04891848||migraine without aura|51 patients with migraine without aura
89667024|NCT04891848||tension type headache|48 patients with tension type headache
89667025|NCT04891848||healthy controls|80 healthy participants
89667026|NCT02285959|Experimental|Intra Arterial Bevacizumab|Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks
89667027|NCT01404429|Active Comparator|Methotrexate 7.5 mg per week|
89667028|NCT01404429|Experimental|Methotrexate 15 mg per week|
89667029|NCT03051906|Experimental|Experimental|Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
89667030|NCT04816188|Experimental|Exercise and Activity Modification|
88995357|NCT04238689|Experimental|Group 1 - 0.1mg/kg TB31F|0.1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. Subjects will be observed for the occurrence of any adverse events. There will be a minimum of 48 hours between TB31F administration to each subsequent volunteer. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
89667031|NCT02010931||primary|subjects who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)
89667032|NCT01390233|Active Comparator|Urinary Balloon Catheter Only|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. The catheter will be deflated and removed after 6 hours. If spontaneously expelled from the uterus, time of expulsion will be noted. Six hours after insertion of catheter, a digital exam will be performed and Bishop score recorded. If no active labor at time of catheter removal or expulsion, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
89667033|NCT01390233|Active Comparator|Prepadil Only|Prepidil Only : Prepidil gel will be inserted into the vaginal fornix according to manufacturer's direction. No oxytocin or other intervention will commence until 6 hours after insertion of gel. Six hours after insertion of gel, digital exam will be performed and Bishop score recorded. If no active labor 6 hours after the administration of gel, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
89667034|NCT01390233|Experimental|Combined Urinary Catheter & Prepidil Gel|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. Prepidil gel will be inserted through the catheter into the lower uterine segment, in a dose equivalent to manufacturer's recommendation. No oxytocin or other intervention will commence until 6 hours after insertion of the catheter and administration of prepidil gel (even if catheter is spontaneously expelled). After 6 hours, digital exam will be performed and Bishop score recorded. If no active labor, standardized protocol of oxytocin will commence.
89667035|NCT03051360|Active Comparator|PCSK9 inhibitor|Patients will receive bi-weekly PCSK9 inhibitor .
89667036|NCT03051360|Placebo Comparator|Placebo|Patients will receive bi-weekly placebo.
89667037|NCT04892160|Other|Guided Imagery First/Virtual Reality Second|Patients will be played a guided imagery experience first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the virtual reality intervention.
89667038|NCT04892160|Experimental|Virtual Reality First/Guided Imagery Second|Patients will have the VR interactive experience played first during one of the following procedures: port access, dressing changes, and IV sticks. The second scheduled procedure will be the same procedure as the first and occur within 5 to 40 days. At the time of their second procedure, they will receive the guided imagery intervention.
89667039|NCT02006095||Neuroimaging Correlates|
89667040|NCT03051048||Group 1|The patient received reperfusion therapy between 1999 January 1 and 2009 December 31
89667041|NCT03051048||Group 2|The patient received reperfusion therapy between 2010 January 1 and 2016 December 31
89667042|NCT05026567|Active Comparator|Reference Product A|
89667043|NCT05026567|Experimental|Experimental B|
89667044|NCT05026567|Experimental|Experimental C|
89667045|NCT05026567|Experimental|Experiment D|
89667046|NCT01391013|Experimental|Monotherapy|Monotherapy: darunavir/ritonavir (DRV/r) will be administered for 48 weeks.
89667047|NCT01391013|Experimental|Combination therapy|DRV/r along with 2 nucleoside reverse transcriptase inhibitors (NRTIs) will be administered for 48 weeks and whenever possible, participants should take these medications at the same time. Switch of NRTIs will be allowed in the event of suspected toxicity/intolerance, providing this change can be linked to a documented adverse event (AE)/serious AE.
89667048|NCT01891747|Experimental|L-methylfolate with Bevacizumab & Temozolomide|28-day cycle, dose levels L-methylfolate: Phase I 15 mg (once a day) 30 mg (15 mg twice a day) 60 mg (30 mg twice a day) 90 mg (45 mg twice a day) Phase II will use the MTD of L-methylfolate daily with bevacizumab & temozolomide.
89667049|NCT04899570|Experimental|Zanubrutinib combined with R-CHOP|"The experimental arm will be treated zanubrutinib combined with R-CHOP regimen for 8 cycles. The interim evaluation will be performed after 4 cycles, and the patients who can't achieve PR or CR will be withdrawn from this trial and receive salvage regimens.~After 8 cycles of ZR-CHOP, the patients will be followed for 2 years to evaluate the PFS."
89667050|NCT02283931|Active Comparator|One handed uterine displacement|Uterine displacement using one hand
89667051|NCT02283931|Active Comparator|two handed uterine displacement|Uterine displacement using two hands
89667052|NCT02283931|Active Comparator|30 degrees uterine displacement|Uterine displacement using a 30 degrees wedge
89667053|NCT04892004|No Intervention|Control group|Standard information defined as the standard care, unplanned, provided for Heart Failure patients and not personalized.
89667054|NCT04892004|Experimental|Interventional group|A nurse provides the intervention with expertise in Heart Failure and addresses reinforcements on: a) an explanation on signs and symptoms of Heart Failure and how to recognise them; b) importance on daily fluid management, by planning 1.5-2 litres of liquids per day (e.g., soup, milk, coffee, water, tea and yoghurts); and c) when doctors or nurses should be contacted (when symptoms escalation or a weight gain of 2 kg in three days or 5 kg in a week were detected).
88995358|NCT04238689|Experimental|Group 2 - 1mg/kg TB31F|1 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
89667055|NCT04397016|No Intervention|Arm 1: Usual Care|"Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.~Usual Care-Participating clinicians have treatment options discussion with patients with slow-growing prostate cancer. Visits are audio-recorded and/or described by patient self-report measure."
89214474|NCT00897026||Group 1|Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
89214475|NCT00897182||Group 1|This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
89214476|NCT00186043|Experimental|Quetiapine/Seroquel|Quetiapine/Seroquel up to 800 mg/day
89214477|NCT00186043|Placebo Comparator|Placebo|Placebo
89214478|NCT00897260|Experimental|1|
89214479|NCT00185965|Experimental|Lymphoma, B-cell low-grade (BCL)|Recurrent low-grade B-cell lymphoma patients (at least one prior treatment failure)
89214480|NCT00185965|Experimental|Mycosis fungoides (MF)|"Mycosis fungoides patients must have failed or have been intolerant of at least 1 topical or 1 systemic treatment~Recurrent mycosis fungoides patients (at least one prior failure of topical or systemic treatment)"
89214481|NCT00607880|Active Comparator|Standard Port|Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.
89214482|NCT00607880|Experimental|Vortex Implantable Access Port|Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.
89214483|NCT02541890|Experimental|Work place intervention|Work place intervention in addition to rehabilitation program.
89667056|NCT04397016|Experimental|Arm 2: Option Grid|"Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer.~Decision Aid-Participating surgeons use an encounter decision aid to discuss treatment options with patients who have slow-growing prostate cancer. Visits are audio-recorded and/or evaluated by patient self-report measure."
89667057|NCT02274415|Experimental|PCV vaccine following by the PSV vaccine|Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
89667058|NCT02274415|Active Comparator|vaccine Pneumo 23|Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)
89667059|NCT03049956|Experimental|Patients with clinical suspicion of ocular myasthenia gravis|
89667060|NCT03049722|Experimental|AVOPT Patient|
89667061|NCT04891926|Experimental|Hormonal therapy|Patients choosing to start hormoanl treatment using ural or transdermal estrogen.
89667062|NCT02267863|Experimental|Dose Escalation and Expansion|APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.
89667063|NCT04892238||Treatment-naïve|Subjects without previous experience of treatment provided for H.pylori infection
89667064|NCT04892238||treatment experienced|Subjects who were previously tested positive for H.pylori infection and who were treated for H.pylori infection with at least 2 antibiotics in combination with proton pump inhibitor not less than 6 weeks before the 13C-urea breath test
89667065|NCT01890187||Advanced dry AMD with geographic atrophy|Patients diagnosed with advanced dry AMD with geographic atrophy
89667066|NCT03049878|Active Comparator|analgesic group|preoperative oral dose of paracetamol-codeine
89214484|NCT02541890|No Intervention|Rehabilitation program only|Rehabilitation program without intervention at the work place.
89667067|NCT03049878|Placebo Comparator|placebo group|preoperative placebo (starch)
89667068|NCT01391325|Other|Allopurinol|Treatment.
89214485|NCT01076569||Ancillary-Correlative (molecular analysis)|Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome SNP genotyping, expression, and methylation profiling.
89214486|NCT00893282|Experimental|BackStop|Intracorporeal lithotripsy with the use of an anti-retropulsion device.
89214487|NCT00893282|Active Comparator|Control|No anti-retropulsion device will be used during lithotripsy.
89214488|NCT00127933|Experimental|HER2-NEU Positive|
89214489|NCT00127933|Experimental|HER2-NEU Negative|
89214490|NCT03875313|Experimental|600 mg CB-839 + 1 mg Talazoparib|600 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with advanced or metastatic solid tumors.
89667069|NCT01986205|Experimental|Hyperbaric Oxygen|100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions
89667070|NCT01986205|Placebo Comparator|Minimal pressure air|Regular air at minimal pressurization for 60 minutes, 40 sessions
89667071|NCT04899726|Experimental|Intervention|Oncology patients candidate for rectal surgery (tumors located up to 15 cm from the anal margin) and meet inclusion criteria. Rectoscope (P201630551) allows the identification of the distal section margin.
89667072|NCT04899648|Experimental|Behavioral Intervention|Receives nutrition and exercise intervention classes
89667073|NCT04899648|No Intervention|Control Group|Does not receive any intervention classes
89667074|NCT04891458|Experimental|Patients received lighter sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 0-2.
89667075|NCT04891458|Experimental|Patients received heavier sedation with propofol after spinal anesthesia|Continuous infusion of propofol at a rate of 1.0-4.0mg/kg per hour until the end of surgery to achieve MOAA/S 3-5.
89667076|NCT04891458|Experimental|Patients received lighter sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 0-2.
89214491|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: ccRCC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received ≥ 2 prior systemic regimens including ≥ 1 vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy.
89214492|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: TNBC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with incurable/locally advanced or metastatic triple-negative breast cancer (TNBC) estrogen receptor (ER)-, progesterone receptor (PR)-, and human epidermal growth factor receptor 2 (HER2)-negative who received ≥ 1 prior line of cytotoxic chemotherapy with no prior poly adenosine diphosphate ribose polymerase (PARP) inhibitor therapy for TNBC or platinum-based chemotherapy for metastatic TNBC.
89214493|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: CRC|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with with incurable/locally advanced or metastatic colorectal cancer (CRC) who received appropriate oxaliplatin or irinotecan- and fluorouracil (5-FU)-based chemotherapy with or without bevacizumab.
89214494|NCT03875313|Experimental|800 mg CB-839 + 1 mg Talazoparib: Other Histology|800 mg CB-839 taken twice daily and 1 mg talazoparib taken once daily in participants with other tumor types (prostate, urinary bladder, pancreas, and stomach).
89214495|NCT01008267||SWL under general anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general anesthesia.
89214496|NCT01008267||SWL under general selective anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general selective anesthesia, using a bronchial blocker.
89667077|NCT04891458|Experimental|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|Continuous infusion of dexmedetomidine at a rate of 0.2-0.7 mcg/ kg per hour until the end of surgery to achieve MOAA/S 3-5.
89667078|NCT04899414|Experimental|Stage III/IV or Stage I/II NUAT- NKTCL or Relapsed or Refractory NK/T- cell lymphoma|4-6 cycles of induction DAPT followed by Auto HSCT as consolidation for CR/PR fit patients ,then by PD-1 as maintenance treatment (up to 16 cycles) for received Auto-HSCT
89667079|NCT02267161|Experimental|neuropsycological tests|Psychometric scales for infants at 3 years of age
89667080|NCT04899258|Other|Pre-surgery and post-surgery|femtosecond assisted LASIK
89667081|NCT03008655|Active Comparator|Nd-YAG|ND-YAG only
89667082|NCT03008655|Experimental|Nd-YAG and intradermal tranexamic acid|Nd-YAG combine with intradermal tranexamic acid
89667083|NCT03049800||FEP - Treatment as Usual|First Episode Psychosis patients who receive treatment as usual while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
89667084|NCT03049800||FEP - Targeted Cognitive Training|First Episode Psychosis patients who receive targeted cognitive training exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
89667085|NCT03049800||FEP - General Cognitive Exercises|First Episode Psychosis patients who receive general cognitive exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
89667086|NCT03049800||Healthy Controls|Age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
89667087|NCT01391559|Experimental|arformoterol|beta-2 agonist bronchodilator
89667088|NCT01391559|Active Comparator|salmeterol|beta-2 agonist bronchodilator
89214497|NCT01008345|Experimental|ezetimibe|will receive the active treatment with ezetimibe and statin
89214498|NCT01008345|Placebo Comparator|placebo|
89667089|NCT04756921||Patients cohort|Patients with HER2 positive MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included.
89667090|NCT03049566||preoperative questionnaires|Patients on long-term acetylsalicylic acid undergoing non-cardiac surgery
89667091|NCT01335789|Active Comparator|Oxytocin|intranasal administration
89667092|NCT01335789|Placebo Comparator|saline|intranasal administration
89667093|NCT04891536|Experimental|Patients with histologically confirmed recurrent prostate cancer after primary radiation therapy|
89667094|NCT01894165|Experimental|ALXN1101|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
89667095|NCT01894165|Placebo Comparator|Placebo|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
89667096|NCT03051828||fencing and patients with breast cancer|patients operated for breast cancer followed at the Hospital Rene Dubos
89214499|NCT06089811|Experimental|Prebiotic|
89214500|NCT06089811|Experimental|L-Tryptophan|
89214501|NCT06089811|Placebo Comparator|Placebo|
89214502|NCT06089798||PIFB Group|The patients in this group will be applied pecto-intercostal fascial block before surgical incision additional to general anesthesia.
89214503|NCT06089798||Nonblock Group|The patients in this group will be given only standard general anesthesia.
89214504|NCT06089785||patients with liver cell failure|patients with liver cell failure and any complications
89214505|NCT06089772|Experimental|Group I|Group I (n=14) received HVLA spinal manipulation
89214506|NCT06089772|Active Comparator|Group II|Group II (n=14) underwent foam roller stretching,
89667097|NCT02202135|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
89667098|NCT02202135|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
89667099|NCT00985673|Experimental|Flulaval/placebo/unadjuvanted Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
89667100|NCT00985673|Experimental|Flulaval/placebo/Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
88995359|NCT04238689|Experimental|Group 3 - 3mg/kg TB31F|3 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days. Escalation to the next higher dosage group will be dependent upon no safety signals arising.
88995360|NCT04238689|Experimental|Group 4 - 10mg/kg TB31F|10 mg/kg of monoclonal antibody TB31F is administered intravenously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
88995361|NCT04238689|Experimental|Group 5 - 100mg TB31F|100mg of monoclonal antibody TB31F is administered subcutaneously to 5 subjects. TB31F administration will be staggered such that the first subject will be administered mAb TB31F and observed for the occurrence of any adverse events. The second subject will not receive their dose of TB31F sooner than 2 days after the first subject has received TB31F. The remaining three subjects will receive their TB31F dose no sooner than 2 days after the second subject has been administered TB31F, with at least a one hour interval in administration of TB31F between each subject. Subjects will be followed-up for 84 days.
88995362|NCT04236609|Active Comparator|Abluminus DES+ sirolimus- eluting stents (SES)|Enrolled patients will undergo angioplasty with Abluminus DES+ sirolimus- eluting stents (SES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the Abluminus DES+ sirolimus- eluting stents (SES).
88995363|NCT04236609|Active Comparator|XIENCE Everolimus-Eluting Stents (EES)|Enrolled patients will undergo angioplasty with XIENCE Everolimus-Eluting Stents (EES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the XIENCE Everolimus-Eluting Stents (EES).
88995364|NCT04235504|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy (MDI+FGM or MDI+CGM) for 6 months during the Study Phase. During the Continuation Phase of 6 months Control Arm will start using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0
88995365|NCT04235504|Experimental|Treatment Arm|The Treatment Arm will use the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0 for 6 months during the Study Phase and other 6 months during the Continuation Phase.
88995366|NCT04232774|Experimental|Treated by the study device|
89667101|NCT00985673|Experimental|Flulaval/unadjuvanted Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
89667102|NCT00985673|Experimental|Flulaval/Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
89667103|NCT00985673|Experimental|Unadjuvanted Arepanrix/placebo/Flulaval Group|subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
89667104|NCT00985673|Experimental|Arepanrix/placebo/Flulaval Group|subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
89667105|NCT05585281|Experimental|Participants receiving Fluzoparib+ QL1101|Participants will be administered QL1101 7.5 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Fluzoparib will be administered orally twice daily continuously throughout each 21-day cycle. On Day 1 of each cycle, fluzoparib will be administered upon completion of QL1101 infusion. The starting dose of fluzoparib will be based on the participant's Baseline actual body weight or platelet count.
89667106|NCT01335867|Experimental|Vigabatrin|Vigabatrin titrated to 3 grams daily for 8 weeks
89214507|NCT06089772|Active Comparator|Group III|Group III (n=14) received a combination of HVLA spinal manipulation and foam roller stretching,
89214508|NCT06089772|Sham Comparator|Group IV|Group IV (n=14) underwent sham manipulation as the control group
89667107|NCT01335867|Placebo Comparator|Placebo|Identical placebo daily for three weeks
89667108|NCT02249923||Pulmonary Arterial Hypertension|
89667109|NCT04891146||Inhalation anesthesia|Sevoflurane for opioid remifentanyl used
89667110|NCT04891146||Total Intravenous Anesthesia|Propofol for opioid remifentanyl used
89667111|NCT04890990|Active Comparator|Black girl, control (BC)|~120-second video of a Black adolescent girl, without depression
89667112|NCT04890990|Active Comparator|Black girl, depressed (BD)|~120-second video of a Black adolescent girl, depressed
89667113|NCT04890990|Active Comparator|Black girl, depressed, adjusted (BDa)|~120-second video of a Black adolescent girl, depressed - adjusted for the specifics of being a Black girl (as informed by a focus group of Black girls and women)
89667114|NCT01894711||Patients with HER2 positive tumors|Patients with HER2 positive tumors treated with trastuzumab or not treated with trastuzumab
89667115|NCT01336413|Active Comparator|Arm 1|Pregnenolone
89667116|NCT01336413|Placebo Comparator|Arm 2|Placebo
89667117|NCT04275401||patients|patients with clinical presentions of change in muscle tone
89667118|NCT04275401||volunteers|healthy volunteers with normal muscle tone
89667119|NCT00985439|Experimental|Diclofenac Test (lower dose)|One 18-mg Diclofenac Test Capsule and 1 placebo capsule
89667120|NCT00985439|Experimental|Diclofenac Test (upper dose)|One 35-mg Diclofenac Test Capsule and 1 placebo capsule
89667121|NCT00985439|Active Comparator|Celecoxib 400 mg|
89667122|NCT00985439|Placebo Comparator|Placebo|
89667123|NCT02984111|Active Comparator|group A|20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes
89667124|NCT02984111|Active Comparator|group B|20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes
89667125|NCT02984111|Placebo Comparator|control|50 ml normal saline infusion during aortic cross clamp in 45-60 minutes
89667126|NCT02618928||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 8, 12, or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
89667127|NCT01948609||Treated with RRSO|Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.
89667128|NCT01948609||No RRSO treatment|Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.
89214509|NCT06089746|Experimental|Feasibility|Patients with LSS will receive DME and training to support continuous maintenance of flexion posture during the 6 week trial. All participants will be asked to wear actigraphs and pedometers intermittently and to complete questionnaires and mobility assessments.
89667129|NCT01535131|Active Comparator|Furlow palatoplasty|standard procedure
89667130|NCT01535131|Experimental|modified Furlow palatoplasty|standard procedure plus modification
89667131|NCT04412148|Active Comparator|Intralesional Steroids|
89667132|NCT04412148|Placebo Comparator|Control|
89667133|NCT01530061|Experimental|Preschool Children age 4-6 years|Preschool children participate in eating either an egg breakfast or a bagel breakfast.
89667134|NCT01530061|Experimental|Teenagers 14-17 years of age|Teenagers participate in eating either an egg breakfast or a bagel breakfast.
89667135|NCT04890522|Experimental|Experimental group|5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days, and intravenous infusion of cisplatin 80 mg/m2 on day 1 and day 28, and intravenous infusion of JS001 240mg on day 1 and day 21, every 60 days.
89667136|NCT04890522|Active Comparator|Control group|gemcitabine at a dose of 1,000 mg/m2 by intravenous infusion on days 1, 8, and intravenous infusion of cisplatin at a dose of 80 mg/m2 on day 1, and intravenous infusion of JS001 240mg on day 1, every 21 days.
89667137|NCT01525069|Experimental|Arm A (HAI FUDR alone)|"14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
89667138|NCT01525069|Experimental|Arm B (HAI FUDR + gemcitabine)|"Consists of Cohort B1, B2, and B3. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR and gemcitabine.~Gemcitabine IV will be given on Days 1, 8, and 15 of each 28 day cycle in Cohort B1~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle in Cohort B2 & B3~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
89667139|NCT01525069|Experimental|Arm C (HAI FUDR + gemcitabine + oxaliplatin)|"Consists of Cohort C1, C2, C3, and C4. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR, gemcitabine, and oxaliplatin.~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle.~Oxaliplatin IV will be given on Days 1 and 15 of each 28 days cycle.~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
89667140|NCT04898868|Experimental|vaginal delivery with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
89667141|NCT04898868|Experimental|vaginal delivery with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
89667142|NCT04898868|Experimental|CS with cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
89667143|NCT04898868|Experimental|CS with cord milking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The newborns will be taken care by the nurse. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
89667144|NCT02249065|Experimental|Mirvaso Gel|Brimonidine topical gel, 0.33%
89667145|NCT04389619|Experimental|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
89667146|NCT04389619|Active Comparator|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
89667147|NCT00983957|Experimental|BMS-790052 plus Ortho Tri-Cyclen®|
89667148|NCT01894867|Experimental|magnesium|will get magnesium for 6 weeks
89667149|NCT01894867|Placebo Comparator|placebo|will get placebo for 6 weeks
89667150|NCT03049332|Experimental|All participants|HIV+ Chinese women in China and a family member will be recruited for the pilot testing of the intervention.
89667151|NCT01521403|Active Comparator|Metronidazole|Metronidazole 3x500 mg per day for 10 days
89667152|NCT01521403|Placebo Comparator|Placebo|Placebo 3x1 tablet per day for 10 days
89667153|NCT04881942|Experimental|e-Vapor Product A|Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion [2.5% nicotine by weight {NBW}])
88995367|NCT04232657|Experimental|Romosozumab Treatment (baseline to month 11)|Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.
88995368|NCT04232657|Placebo Comparator|Placebo (baseline to month 12)|Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.
88995369|NCT04232657|Active Comparator|Denosumab (month 12 to month 24)|Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).
88995370|NCT04232566||Weight loss surgery|Gastric bypass surgery will be followed by weight loss as standard of care. Liver fibrosis by elastography will be determined before surgery.
88995371|NCT04216277|Experimental|Procalcitonin in addition to usual care|Procalcitonin values will be disclosed to the attending physician and assist in antibiotic guidance in addition to usual care
88995372|NCT04216277|No Intervention|Usual care|Usual best standard care. No procalcitonin values disclosed to attending physician .
88995373|NCT04199780|Experimental|Group 1- real tDCS and real CBI|4 active treatments of tDCS and active cognitive behavioral intervention (CBI)
88995374|NCT04199780|Experimental|Group 2- real tDCS and sham CBI|4 active treatments of tDCS and education-only-control cognitive intervention
89667154|NCT04881942|Experimental|e-Vapor Product B|Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic [4.0% NBW])
89667155|NCT04881942|Experimental|e-Vapor Product C|Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint [3.5% NBW])
89667156|NCT04881942|Experimental|e-Vapor Product D|Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol [4.0% NBW])
88995375|NCT04199780|Experimental|Group 3- sham tDCS and real CBI|4 sham treatments of tDCS and active cognitive behavioral intervention (CBI)
88995376|NCT04199780|Sham Comparator|Group 4- sham tDCS and sham CBI|4 sham treatments of tDCS and education-only-control cognitive intervention
88995377|NCT04195737|Experimental|Root coverage with ossix volumax collagen matrix|Evaluation of root coverage achieved by collagen matrix in conjunction with coronally advanced flap in patients with multiple gingival recession.
88995378|NCT04195737|Active Comparator|Root coverage with connective tissue graft|Evaluation of root coverage achieved by connective tissue graft in conjunction with coronally advanced flap in patients with multiple gingival recession
89667157|NCT01336959|Experimental|Open Label - BCT197 Part A|10mg single dose of BCT197
89667158|NCT01336959|Experimental|BCT197 Part B|Single dose of 50mg BCT197
89667159|NCT01336959|Placebo Comparator|BCT 197 Placebo Part B|Single dose of matching placebo to 50mg BCT197
89667160|NCT03072251||Anyone|Any individual may complete this survey
89667161|NCT04882020||AHI ≤ 5|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≤ 5 events / hour; prior blood collection between 7-9 am and questionnaires.
89667162|NCT04882020||AHI ≥ 30|Individuals aged 65 to 80; both sexes; Informed Consent Form with prior signature for participation in the MEDIDAS cohort study; previous performance of ambulatory polysomnography with adequate technical quality and AHI ≥ 30 events / hour; prior blood collection between 7-9 am and questionnaires.
89667163|NCT04881864|Experimental|Tele-EF|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
89667164|NCT04126811|Experimental|Apatinib and Chemotherapy Test Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
89667165|NCT04126811|Active Comparator|Apatinib Group|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
89667166|NCT04126811|Active Comparator|Chemotherapy Group|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
89667167|NCT04881786|No Intervention|Untreated teeth control group|Premolars without orthodontic forces
89667168|NCT04881786|Experimental|Moderate force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 45º with a force of 56 g. Forces were measured with an orthodontic dynamometer. For 7 days
89667169|NCT04881786|Experimental|Severe force group|Premolars were submitted to tipping and extrusion orthodontic movements, the activation angle was 90º with a force of 224 g. Forces were measured with an orthodontic dynamometer. For 24 hours
89667170|NCT04127201|Experimental|Online intervention, en_línea|Participants will be provided with a username and a password to acess to a website. en_línea program is an online adaptation of the LEARN program. The five treatment areas are: Lifestyle, Exercise, Attitudes, Relationships and Nutrition. We have designed and developed a website (www.programaenlinea.org) with 17 weekly treatment sessions and an exclusive mobile application for self-recording.
89667171|NCT04127201|Active Comparator|Standard group therapy|Participants in this arm will received a 10 sessions of standard primary care group therapy. Sessions 1 and 2 will be weekly and sessions from 3 to 10 will be biweekly. Sessions, between 8 and 10 participants, will be conducted by a specialized psychologist and they will last 90 minutes. Treatment areas will be the same as en_línea, beginning with nutrition and exercise and a progressive incorporation of the other topics. Material to work at home and self-recording will be provided in paper.
89667172|NCT04127201|No Intervention|Control group|Participants in the control group only will receive a biweekly newsletter by email without feedback. They will be provided with material and instructions to self-record their daily meals and exercise. The newsletter only will content basic information about nutrition and exercise.
89667173|NCT04126655|Experimental|Arfolitixorin.|Drug: Arfolitixorin Drug: 5-FU Per operative i.v. bolus injection of Arfolitixorin in combination with 5-FU
89667174|NCT04126655|Active Comparator|Calciumfolinate.|Drug: Calciumfolinate Drug: 5-FU Per operative i.v. bolus injection of Calciumfolinate in combination with 5-FU
89667175|NCT01406223|Active Comparator|varenicline|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline, smokers in this group will also receive placebo bupropion and placebo patches.
88995379|NCT04173585|Experimental|Bortezomib-Gemtuzumab Ozogamicin Treatment|"one cycle of combined chemotherapy:~Bortezomib (1.3 mg/m2) sc on day 1 and 3. Dose will be given 3 hours prior to Cytarabine on day 1 and 3~Cytarabine (1g/m² twice daily) iv over 3 hours on day 1, 2 and 3 Gemtuzumab Ozogamicin (3 mg/m²,up to a maximum of one 5 mg vial) iv over 2 hours on day 1 after first dose of Cytarabine and day 4~Pegfilgrastim 6 mg sc on day 8 (optional)"
88995380|NCT04172987|Experimental|Ethinyl Estradiol + Norgestimate (EE/NGM) Alone (Period 1)|Participants received a 28-day packet of a combination oral contraceptive (OC) containing 21 days of tablets that consist of active ingredients (0.035 mg ethinyl estradiol (EE) and 0.25 mg norgestimate (NGM)) self-administered orally once-daily (QD) on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day.
88995381|NCT04172987|Experimental|EE/NGM + Tirzepatide (Period 2)|Participants received a 28-day packet of a combination OC containing 21 days of tablets that consist of active ingredients (0.035 mg EE and 0.25 mg NGM) self-administered orally QD on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day and a single dose 5 mg tirzepatide administered subcutaneously (SC).
89667176|NCT01406223|Active Comparator|NRT (nicotine patches only)|21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
89667177|NCT01406223|Active Comparator|varenicline + bupropion|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus bupropion at a dose of 150mg once per day. Subsequently, the dose of varenicline will be 1 mg twice per day and the dose of bupropion will be 150 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline and bupropion, smokers in this group will also receive placebo patches.
89667178|NCT01406223|Placebo Comparator|Post-quit NRT|Nicotine patches at 21 mg/24 h for 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
89667179|NCT02230969||peginterferon beta-1a|Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.
89667180|NCT04881552||Group 1|non-spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade 0-II)
89667181|NCT04881552||Arm 2|spontaneous reperfusion group at initial emergency coronary angiography (TIMI flow grade III)
89667182|NCT01408329|Sham Comparator|Control|Sham altitude changes - The CVAC device consists of a small pod-like chamber attached to a computer system that controls a strong pump that can draw air rapidly out of the chamber to increase the simulated altitude. The sham-treated group (SH) was exposed to regular, slowly-fluctuating pressures that reached a maximum altitude of 607 m for all 30 sessions. Sham sessions mimicked the noises and initial pressure-change sensations created in the active sessions, thus giving naıve subjects the impression that they were experiencing altitude treatment. All subjects were blind to their elevation throughout the intervention.
89667183|NCT01408329|Experimental|Hypoxic intervention|Cyclic Hypobaric Hypoxia (CHH) subjects were given 40 min sessions inside the CVAC device per day (two 20 min sessions sequentially per day), 3 days a week for 10 weeks, for a total of 30 sessions or 20 hours. After familiarization sessions, pre-programmed sessions were administered, progressing from Tier 1 to 5. Subjects rotated through three pre-programmed sessions per Tier and each session varied the pattern and rate of hypoxic fluctuations, so that subjects would experience a constantly changing stimulus at each elevation. Five weeks were allotted to progress from Tier 1 (3048 m) to Tier 4 (5486 m). At Tier 5 (6096 m), there was an additional 5 weeks of exposure.
89667184|NCT02984189|Experimental|Inspiratory Critical Pressure Group|Inspiratory Critical Pressure will be used for training and will be determined, from a progressive inspiratory threshold-loading test will start with 50%MIP followed by 10%MIP increments, every 3min until subjects reached a load that there were unable to sustain for at least 1min (PThMAX). On another day, the subjects will perform a constant inspiratory loading test against a resistance of 95%, 100% and 105%PThMAX, for as long as they could tolerate. The intensity loads will be applied according the results of block randomization. The time elapsed until task failure was defined as inspiratory muscle endurance time, and will use to set the PThC. The respiratory work done (inspiratory pressure values) will be plotted in abscissa and the time-to-exhaustion in ordinate, and a linear regression going through the 3 points will be applied using the pressure-1/t relationship. The slope of the parallel line displaced downward projecting to the origin produce the PThC value.
89667185|NCT02984189|Active Comparator|60% Maximal Inspiratory Pressure Group|60% of maximal inspiratory pressure will be used for training.
89667186|NCT02984189|Sham Comparator|Sham Group|6 cmH20 will be used for training.
89667187|NCT04881474|Active Comparator|ibuprofen and paracetamol|
89667188|NCT04881474|Active Comparator|paracetamol only|
89667189|NCT00981149|Experimental|duloxetine study drug|Drug
89667190|NCT00981149|Placebo Comparator|Placebo|Placebo
89667191|NCT04881006|Experimental|Test Product|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Drug: Dapagliflozin 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
89667192|NCT04881006|Active Comparator|Reference Product|Manufactured by AstraZeneca Pharmaceuticals LP Drug: Farxiga® 10 mg tablets A single 10 mg dose (1 tablet) of the assigned drug product will be administered according to the randomization scheme with 240±5 mL of room temperature potable water.
89667193|NCT01408719|Experimental|5g LMW beta glucan|5 gram low molecular weight barley beta-glucan diet for 35 days
89667194|NCT01408719|Experimental|3g HMW beta glucan|3 gram high molecular weight barley beta-glucan diet for 35 days
89667195|NCT01408719|Experimental|3g LMW beta glucan|3 grams of low molecular weight beta-glucan diet for 35 days
89049127|NCT02905604|Experimental|dmPFC iTBS|Repetitive transcranial magnet stimulation (rTMS) over the dorsomedial prefrontal cortices at 90% of the resting motor threshold of the foot flexors. The rTMS is given in 20 trains to the left and right dmPFC, respectively. Each train consists of 10 bursts at 5 Hz (theta-frequency), and each burst consists of 3 pulses at 50 Hz. The stimulation is intermittent with 2 seconds of stimulation, 8 seconds off. After a 15 minute break the whole protocol i applied again, resulting in 2400 pulses/day. Treatment is delivered daily at 10 week days.
89667196|NCT01408719|Placebo Comparator|Control|control diet containing negligible amount of beta glucan
89667197|NCT04395131|Other|Clearum HF Dialysis Subjects|All subjects enrolled in the study and treated with the Clearum HF hemodialyzer
89667198|NCT01595646|Placebo Comparator|Saline|Saline placebo taken twice per day via intranasal route.
89667199|NCT01595646|Experimental|Insulin Detemir|20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
89667200|NCT01595646|Experimental|Insulin|20IU Insulin, administered twice per day (40IU total per day) via intranasal route
89667201|NCT01907191|Experimental|Liposomal bupivacaine|Ultrasound guided injection of liposomal bupivacaine for patients undergoing hip arthroscopy
89667202|NCT01907191|Active Comparator|Bupivacaine|Bupivacaine (around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy
89667203|NCT01395537|Experimental|Lapatinib With Carboplatin and Paclitaxel|
89667204|NCT04898712|Experimental|Tranexamic Acid Arm|"Participants in the experimental arm will receive tranexamic acid (TXA) during surgery for CSDH evacuation with a single 1000mg intraoperative intravenous (IV) dose. Participants with a body weight 60-100kg will also receive a post-operative dose regimen of 500 mg TXA orally, 3 times a day (TID).~Weight deviations from this body weight range will be considered with a dose adjustment of 1000mg TXA two times a day (BID) for a body weight >100 kg, and 500 mg TXA BID for body weight <60kg."
89667205|NCT04898712|Placebo Comparator|Placebo Control Arm|Participants in the control arm will placebo according to the same administration regimen.
89667206|NCT01906957|Experimental|Elderly healthy subjects|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
89667207|NCT01906957|Experimental|Patients with metabolic syndrome|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
89667208|NCT01906957|Experimental|coronary patients|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
89667209|NCT01906957|Experimental|heart failure patients|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
89667210|NCT03049410|Active Comparator|iRARC|Intracorporeal Robot Assisted Radical Cystectomy
89667211|NCT03049410|Active Comparator|Open Radical Cystectomy (ORC)|Open Radical Cystectomy
89667212|NCT00981461|Active Comparator|LLT Device 2009 9 Beam|HairMax LaserComb
89667213|NCT00981461|Sham Comparator|control device|control device
89214510|NCT06089733|Experimental|ABSK201 and Itraconazole/Rifampicin|"Part A: Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.~Part B: Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg."
89667214|NCT04409808|Experimental|IRIS vitrectomy device|all subjects in this study are in the experimental treatment arm and vitrectomy by use of prototype IRIS vitrectomy device
89667215|NCT04898556|Active Comparator|Active Treatment|Patients who will undergo treatment with Intrarosa (Prasterone 6.5mg) in ovules, will apply one ovule a day before going to bed for 12 weeks.
89667216|NCT04898556|Placebo Comparator|Control Group|Patients who will not undergo any treatment for vulvovaginal atrophy for 12 weeks.
89667217|NCT02317549|Experimental|Tranexemic Acid|Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube
89667218|NCT02317549|Placebo Comparator|Placebo|Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube
89667219|NCT04898088|Experimental|Conventional Therapy|
89667220|NCT04898088|Experimental|Conventional Therapy with Add-On MSC therapy|
89667221|NCT05583643|Other|Phase 1 therapy|
89667222|NCT05583643|Active Comparator|Phase 1 therapy with atorvastatin loaded into cubosomal in-situ gel|
89667223|NCT05583643|Active Comparator|Phase 1 therapy with atorvastatin loaded into in-situ gel|
89667224|NCT02618616|Experimental|ZPL-389|Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.
89667225|NCT02618616|Placebo Comparator|Placebo|Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
89667226|NCT01396239|Experimental|AVI-4658 (Eteplirsen)|"50 mg/kg eteplirsen for 28 weeks~30 mg/kg eteplirsen for 28 weeks"
89667227|NCT01396239|Placebo Comparator|Placebo / Delayed Treatment|"3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks.~3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks."
89667228|NCT02225275|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive obinutuzumab IV over 3-4 hours on days 1, 2, 8, and 15 of course 1 and day 1 of courses 2-6 and lenalidomide PO QD on days 9-28 of course 1 and days 1-28 of all subsequent courses. Treatment with obinutuzumab repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive lenalidomide PO QD in the absence of disease progression or unacceptable toxicity.
89667229|NCT04890756||Reliability Group|100 Healthy Adults
89667230|NCT04890756||Validity Group|45 Healthy Adults
89667231|NCT04881084|Experimental|Digital storytelling group (Group 1)|Participants will be randomly assigned to the digital storytelling group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six digital storytelling videos which will be assessed using a between-subjects design.
89667232|NCT04881084|Active Comparator|Social marketing/fundraising group (Group 2)|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
89667233|NCT04389697|Experimental|Intervention arm|Clear fluids and food up to up to 1 hour before the procedure
89667234|NCT04389697|No Intervention|Control arm|Fasting for solids for up to 6 hours and fluids up to 2 hours before the procedure
89667235|NCT04890678|Experimental|22 residentsat risk for PU development|"22 residents at risk for PU development, defined by a Braden score < 12 and/or a Braden subscale 'Mobility' score ≤ 2 and/or the presence of non-blanchable erythema in the sacral area.~aged 65 years or over"
89667236|NCT04890678|Experimental|18 residents at least one PU category III-IV in the sacral area|18 residents at least one PU category III-IV in the sacral area aged 65 years or over
89667237|NCT01897441|Experimental|Stratum A (HER2-positive disease)|Patients receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes weekly for 12 weeks. Beginning 2-3 weeks after the last dose of paclitaxel, patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks
89667238|NCT01897441|Experimental|Stratum B (paclitaxel followed by AC)|Patients receive paclitaxel, doxorubicin hydrochloride, and cyclophosphamide as in Stratum A.
89667239|NCT01897441|Experimental|Stratum C (AC followed by paclitaxel)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive paclitaxel IV over 1 hour weekly for 12 weeks.
89667240|NCT01411137|Experimental|IPX066|Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
89667241|NCT04890288|Experimental|Intervention group - High flow|High-flow nasal cannula oxygen 2L/kg/min using OptiFlow system by Fisher&Paykel and an oxygen inspiration concentration FiO2 of 1.0; enabling apneic oxygenation during laryngoscopy.
89667242|NCT04890288|Experimental|Intervention group - Low flow:|Low-flow oxygen (100%, 0.2 l/kg/min) via conventional neonatal nasal cannula (Intersurgical, Wokingham, Berkshire, United Kingdom) enabling apneic oxygenation during laryngoscopy.
89667243|NCT04890288|No Intervention|Conventional|Conventionally practiced standard of care with preoxygenation with facemask with an FiO2 of 1.0, followed by bag mask ventilation after induction before oral intubation without apneic oxygenation.
89667244|NCT03008499|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89667245|NCT03008499|No Intervention|Control|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89667246|NCT04430556|Other|Volumetric changes in response to sertraline or escitalopram|
89667247|NCT01411527||Cross- sectional cohort|Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children
89667248|NCT01411527||Longitudinal cohort|"209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).~116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study. Thus, the total number of participants in The COPENHAGEN Puberty Study was 2020 children."
89667249|NCT03051594|Active Comparator|visual tactile assessment|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after visual tactile assessment.
89214511|NCT06089720|Experimental|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|The nine orthodontic patients will receive 36 orthodontic molar tubes coated with ZnO nanoparticle in split-mouth cross quadrant manner, In each patient, two diagonal quadrants (i.e., upper right and lower left, or vice versa) will randomly assigned to each coated OMT and UOMT groups. evaluation will be after 2 weeks for microbial assessment biofilm in addition to plaque & gingival index. patients will be follow up for 3 month to evaluation bond failure rate.
89667250|NCT03051594|Active Comparator|caries detector dye|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using caries detector dye to determine the excavation endpoint.
89667251|NCT03051594|Experimental|fluorescent camera|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using fluorescent camera to determine the excavation endpoint.
89667252|NCT02216851|Experimental|Restylane Perlane|Single injection of Restylane Perlane in nasal dorsum and/or nasal root
89667253|NCT02216851|No Intervention|No-treatment control|No-treatment control group do not receive any treatment during the main study period
89667254|NCT04890210|Experimental|Early Diet Group|"1st diet: 100 ml of clear fluid (1 hour after esophageal variceal ligation)~2nd diet: 100 ml of clear fluid (4 hours after the 1st diet)~3rd diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 4 hours after the 2nd diet~4th diet: soft porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 3rd diet~5th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 4th diet~6th diet: porridge (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 5th diet~7th diet: soft rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 6th diet~8th diet: regular rice (the amount will be calculated according to patient's caloric needs) which will be given 6 hours after the 7th diet"
89667255|NCT04890210|Active Comparator|Late Diet Group|"1st diet : 100 ml of clear fluid (6 hours after esophageal variceal ligation)~After the 1st diet (Day 1): 6x100 ml of clear fluid for 24 hours~Day 2: soft porridge (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 3: porridge (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 4: soft rice (the amount will be calculated according to patient's caloric needs) for 24 hours~Day 5: regular rice (the amount will be calculated according to patient's caloric needs) for 24 hours and beyond"
89667256|NCT01893853|Other|Water|Electrolyte- and mineral-free water with exercise intervention
89667257|NCT01893853|Placebo Comparator|Placebo|Calorie- and electrolyte-free, sweetened flavored water with exercise intervention
89667258|NCT01893853|Experimental|Carbohydrate-electrolyte beverage|Commercially-available flavored beverage carbohydrate-electrolyte beverage with Exercise Intervention
89667259|NCT04757077||GROUP 1|Patients 6-24 weeks after delivery with postpartum PGP (Patients with symptoms and signs of PGP, PGP confirmed with dedicated functional tests).
88995382|NCT04138381|Other|selinexor as a single agent and in combination with imatinib|"This is a single-arm, two-cohort, open label phase Ib/II trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW (Cohort B). The study will consist of:~Cohort A: an initial escalation phase (Ib) evaluating increasing doses of selinexor in combination with fixed doses of imatinib administered in repeated 28-day cycles in advanced/metastatic, imatinib-resistant GIST patients, followed by en expansion phase (II) testing for safety and preliminary evidence of antitumor activity~Cohort B: single-agent, fixed selinexor dose in the same target population"
88995383|NCT04033055|Experimental|CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
88995384|NCT04033055|Active Comparator|CycloMesh™ soaked in saline solution 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
88995385|NCT04015596|Experimental|Intervention|Participants receive Naproxen Sodium.
88995386|NCT04015596|Placebo Comparator|Placebo|Participants receive placebo.
88995387|NCT03985722|Experimental|Unlimited cycles of Olaratumab and Trabectedin|"The study is a phase I, non-randomised, one-armed, multicenter trial, open-label,.~The dose escalation rules include patients in blocks of 3 o 6 patient. Treatment is a combination of unlimited cycles of oralatumab and trabectedin."
88995388|NCT03966105||Patients with LSS surgery indication|
88995389|NCT03939416|Experimental|POLD concept treatment|Patients treated with rhythmic mobilizations according to the POLD concept, in addition to the standart treatment
88995390|NCT03939416|Active Comparator|CONTROL|Patients treated with the standart treatment
88995391|NCT03929523|Experimental|HOPE group|hypothermic oxygenated perfusion
88995392|NCT03929523|Active Comparator|Control group|classic static cold storage
88995393|NCT03890432|Experimental|GLUCOSAFE 2|Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
88995394|NCT03890432|Active Comparator|Local protocol control group|Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
89667260|NCT04757077||GROUP 2|Patients 6-24 weeks after delivery, with no symptoms and signs of PGP.
89667261|NCT01396551|Experimental|Transponder implantation|Implantation of anchored Beacon transponder in the lung
89667262|NCT04897854|Active Comparator|Immediate treatment|The treatment schedule will be direct (start within 3 weeks of bate of diagnosis) FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.
89667263|NCT04897854|Active Comparator|Delayed treatment|"The treatment schedule will be delayed treatment (based on symptoms) with FOLFIRINOX or nab paclitaxel in combination with gemcitabine per investigator's choice. Dosage and frequency of administration will be according to local protocol.~Chemotherapy will start as soon as one of the following criteria is met:~Decline in performance status to ECOG < 1 or Karnofsky < 80%~Weight loss more than 5% of the total body weight from the time of study entry~Persistent nausea requiring medication~Pain requiring regular narcotic analgesics~Development of clinically significant third-space fluid collections~Liver function deterioration in the presence of progressive liver metastases"
89667264|NCT01894945||Patients with suspected lymphoma.|
89667265|NCT04897932|Active Comparator|Adult nocturia|Use of device over 28 days
89667266|NCT04897932|Active Comparator|Adult urge urinary incontinence|Use of device over 28 days
89667267|NCT04897932|Active Comparator|Adult frequency urinary incontinence|Use of device over 28 days
89667268|NCT04897932|Active Comparator|Adult functional incontinence|Use of device over 28 days
89667269|NCT01892527|Experimental|Tivantinib plus Cetuximab|Single arm
89667270|NCT01399827|Active Comparator|Omega-3 Fatty Acids|1060 mg EPA Omega-3 Fatty Acids
89667271|NCT01399827|Placebo Comparator|Placebo|
89667272|NCT04897386|Experimental|Duvalizumab Combined With Neoadjuvant Chemotherapy|
89667273|NCT04755985|Experimental|ARM 1|Period 1 : Reference Drug(AD-2132) Period 2 : Test Drug(AD-213-B)
89667274|NCT04755985|Experimental|ARM 2|Period 1 : Test Drug(AD-213-B) Period 2 : Reference Drug(AD-2132)
89667275|NCT04879836||Teething Ring + Teething Gel|
89667276|NCT04879836||Teething Ring|
89667277|NCT05050591|Experimental|Single-Arm Study|This is a prospective trial of the clinical utility of a patient-specific silicone stent implant for patients with complex airway disease, requiring an airway stent. The aim of this study is to observe the outcomes associated with the implants. Current stents have been suboptimal for treating benign stenosis of the airway and we are seeking to create a better treatment option. We hypothesize, based on the previous compassionate-use cases, that placing a patient-specific silicone stent will effectively alleviate symptoms associated with stenosis of the airway. The main measure of effectiveness will be patient-reported outcomes.
89667278|NCT04889820|Active Comparator|The Control group|- The patients who are assigned into control group take a curative surgery within 2 weeks after successful SEMS placement. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during 6 months (total 12 cycles).
89667279|NCT04889820|Experimental|The Experimental group|- The patients who are assigned into the experimental group take a neoadjuvant FOLFOX chemotherapy within 2 weeks after successful SEMS placement. After three cycles of FOLFOX, they will take a curative surgery. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during about 4 months (total 9 cycles). The perioperative FOLFOX chemotherapy in the experimetal group will be totally 12 cycles during 6months.
89667280|NCT04879758|No Intervention|Control Group|The control group will receive a Fitbit device and general lifestyle advice e-leaflet, which includes information about T2D, health impacts of T2D and lifestyle advice on 4 major risk markers of T2D (e.g., PA, diet, smoking, weight management) as recommended by the World Health Organization.
89667281|NCT04879758|Experimental|Intervention Group - Genetic Risk Estimate|This intervention group will receive an estimated genetic risk of T2D in addition to the Fitbit and e-leaflet.
89667282|NCT04879758|Experimental|Intervention Group - Genetic Risk Estimate + Fitbit Functions|This intervention group will receive a Fitbit device, but have a Fitbit step goal set 10% higher than their baseline step count, and use its prompt functions, in addition to the genetic risk estimate and e-leaflet.
89667283|NCT04879446|Experimental|A-PRF Test Group|Advanced Platelet Rich Fibrin liquid applied into the implant cavity and implant surface. That is the only difference between A-PRF control group and A-PRF test group.
89667284|NCT04879446|Experimental|CGF Test Group|Concentrated growth factor liquid applied into the implant cavity and implant surface. That is the only difference between CGF control group and CGF test group.
89667285|NCT04879446|Experimental|A-PRF Control Group|Dental implant applications were made with traditional methods.
89667286|NCT04879446|Experimental|CGF Control Group|Dental implant applications were made with traditional methods.
89667287|NCT04897308|Active Comparator|Suprascapular nerve block|This group will include will under go suprascapularnerve block as following :10 ml of .5% bupivacaine and 2 ml of methylpradnisolon 40mg/ml
88995395|NCT03890432|Other|Historical control group|"Retrospective data with standard care before the beginning of the pilot study in order to minimize the cross-over effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time."
89667288|NCT04897308|Active Comparator|Hydrodilatation of shoulder capsule|This group will undergo intraarticular hydrodilatation by injection of :first lidocaine10ml%followed by 1ml of methylprednisolon 40mg/ml and finally 20ml of .9 % sodium chloride slowly in the gleno humeral joint
89667289|NCT04897308|Active Comparator|Hydrodilatation of shoulder interval|This group will undergo interval hydrodilatation by injection of :first mepivacaine 10ml folowed by 20ml of sterile water slowly in the shoulder interval
89667290|NCT02618382|Experimental|All subjects|Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
89667291|NCT01882153|Experimental|Developmentally Based Intervention|
89667292|NCT01882153|Experimental|Behaviorally Based Intervention|
89667293|NCT04897230|Active Comparator|Hatha Yoga Condition|An experienced yoga instructor led the 30 minutes yoga condition session which consisted of 5 minutes warm up, 5 minutes breathing exercises, and 20 minutes yoga poses practice. The yoga props were used according to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably.
89667294|NCT04897230|Placebo Comparator|Control Condition|Participants in the control condition were watching a neutral video on a television.
89667295|NCT02178163|Experimental|Ancillary-Correlative (comprehensive genomic analysis)|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
89667296|NCT04897464|Experimental|Treatment|
89667297|NCT01444105|Active Comparator|iStent|implantation of two iStent devices
89667298|NCT01444105|Active Comparator|SLT|Laser treatment
89667299|NCT04896996|Experimental|Whole eggs (WE)|consume 10 additional eggs per week
89667300|NCT04896996|Experimental|Egg substitute (ES)|consume the yolk-free egg substitute equivalent to 10 eggs per week
89667301|NCT04896996|No Intervention|Control group|Regular school meals
89667302|NCT02177071|No Intervention|INFLIXIMAB AND ANTI METABOLITE|continuing scheduled infliximab treatment and anti-metabolite
89667303|NCT02177071|Other|STOP INFLIXIMAB CONTINUING ANTI METABOLITE|discontinuing infliximab and continuing the anti-metabolite
89667304|NCT02177071|Other|CONTINUING INFLIXIMAB AND discontinuing anti-metabolites|CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE
89667305|NCT04889586|Experimental|Experimental Group|The subjects were clinically assessed with a define clinical protocol. After that, the subjects executed the device test with EMG-biofeedback wearable armband.
89667306|NCT01859221|Experimental|Castration Resistant|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
89667307|NCT01859221|Experimental|Hormone Receptive|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
89667308|NCT01412541|Experimental|Moxy Drug Coated Balloon|Paclitaxel coated balloon catheter
89667309|NCT01412541|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
89667310|NCT04889196|Active Comparator|control group|The group that have caries in primary molars and treat them with hall technique
89667311|NCT04889196|Experimental|experimental group|the group that have caries in primary molars and treat them with silver diamine fluoride (SDF) solution would exert a prevention result in managing early childhood caries ECC
89667312|NCT04878978|Active Comparator|Routine care|Women who present with PPROM or threatened PTL and have routine care
89667313|NCT04878978|Experimental|Amniocentesis and biofire directed antibiotic use|Women who present with PPROM or threatened PTL and randomised to amniocentesis and biofire directed antibiotic treatment
89667314|NCT03049176||HIV+male/HIV-female|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
89667315|NCT03049176||HIV+female/HIV-male|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination
89667316|NCT04896528|Experimental|Avatrombopag|"Avartripopa is a new generation of oral TPO receptor agonist that simulates the biological effects of TPO in vitro and in vivo.~TPO stimulates megakaryocytes through binding and activation of TPO receptor, which is expressed in hematopoietic stem cells, megakaryotic cell lines and platelets.~By binding to the transmembrane region of the thrombopoietin receptor, Ava Tripopa activates the thrombopoietin receptor in humans, stimulates signal transduction and mimics the biological effects of thrombopoietin, leading to an increase in platelet count."
89667317|NCT03051750|Active Comparator|CPT+P|Complex Physical Therapy plus Pressotherapy during three weeks
89667318|NCT03051750|Experimental|Kinesio Taping|Kinesio Taping during three weeks
89667319|NCT04896294|Active Comparator|Group 1 - HAP-containing toothpaste|"The use of HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
89667320|NCT04896294|Experimental|Group 2 - Zn Mg HAP-containing toothpaste|"The use of Zn Mg HAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Zn-Mg-hydroxyapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene. Fluoride free."
89667321|NCT04896294|Experimental|Group 3 - FAP-containing toothpaste|"The use of FAP-containing toothpaste twice daily (using standardised toothbrushing technique) for 4 weeks.~Toothpaste composition: Aqua, Sorbitol, Hydrated Silica, Glycerin, Fluorapatite, Cellulose Gum, Sodium Myristoyl Sarcosinate, Sodium Methyl Cocoyl Taurate, Aroma, Xanthan Gum, Stevia Rebaudiana Extract, Anethole, Tetrasodium Glutamate Diacetate, Tocopheryl Acetate, Eucalyptol, o-Cymen-5-ol, Citric Acid, Vitis Vinifera (Grape) Seed Extract, Tannase, Thymol, Limonene."
88995396|NCT03840746|No Intervention|Habitual diet|participants remain on their habitual diet
88995397|NCT03840746|Experimental|Tomato, onion and lovage soup (TOL)|One tin of soup containing Tomato onion and lovage daily for 6 weeks
89667322|NCT04888806|Experimental|Camrelizumab+ablation +chemotherapy|The enrolled patients received ablation of liver metastases/pulmonary metastasis first, followed by chemotherapy (standard treatment plan for advanced colorectal cancer, determined by the investigator) and camrelizumab treatment (200mg, iv, q3w) one week later. If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times. Sequential chemotherapy and camrelizumab is administered one week after each ablation therapy. Treatment will continue until disease progression, unacceptable toxicity, or voluntary patient withdrawal.
89667323|NCT01895023|Experimental|Dexmedetomidine group|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min and oral saline 30 min before induction of anaesthesia
89049128|NCT02905604|Sham Comparator|dmPFC Sham iTBS|A sham treatment protocol by using a sham coil with two identical sides where one side give active treatment as described above while on the other side the coil is insulated so very little magnetic energy is delivered. The coil has a built in positioning sensors and a software handling the randomization codes prompts the operator which side of the coil that should be directed towards the patient. Superficial transcutaneous electrical nerve stimulation (TENS) is applied over the stimulation site of the dmPFC synchronous wiht the TMS pulses to further mimic the sensation of the active stimulation.
89049129|NCT04626219|Experimental|1|Period of 12 hours where participants eat regulated meals
89667324|NCT01895023|Active Comparator|Midazolam group|The midazolam group received intranasal saline 45 min and oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
89667325|NCT01895023|Placebo Comparator|Placebo Group|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
89667326|NCT04126265|No Intervention|Routine colonoscopy group|The patient underwent routine colonoscopy.
89667327|NCT04126265|Experimental|Artificial intelligence assisted colonoscopy group|The real-time automatic polyp detection system was used to assist the endoscopist.
89667328|NCT03051438|Other|Subxiphoid uniportal VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
89667329|NCT03051438|Other|Three-port VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
89667330|NCT04125797|Active Comparator|Adhesive 1|This arm investigates one type of silicone adhesive (3M2475P) on adult female skin.
89667331|NCT04125797|Active Comparator|Adhesive 2|This arm investigates one type of silicone adhesive (RX1449P) on adult female skin.
89049130|NCT04626219|Experimental|2|Period of 12 hours where participants do not eat anything
89049131|NCT04626063|Active Comparator|Isolated non-steroid anti-inflammatory drug group|A isolated NSAIDs group received 400 mg etodolac twice a day for 10 days in treatment of acute low back pain.
89049132|NCT04626063|Experimental|Non-steroid anti-inflammatory drug plus magnesium group|This group received 400 mg etodolac twice a day and 365 mg magnesium oral supplementation once a day for 10 days in treatment of acute low back pain.
89049133|NCT04626063|Active Comparator|Non-steroid anti-inflammatory drug plus paracetamol group.|This group 400 mg etodolac twice a day and 500 mg paracetamol twice a day for 10 days in treatment of acute low back pain.
89049134|NCT04681976|Experimental|Intervention group|Intervention Group participants will perform a 3-month telematic dance program based on choreographic work, 2 times per week
89049135|NCT04681976|No Intervention|Control group|Control group will follow their daily routine without added exercise
89667332|NCT04125797|Active Comparator|Adhesive 3|This arm investigates one type of silicone adhesive (PS-1243) on adult female skin.
89667333|NCT01413087|Experimental|8 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 8 mg of BC-819
89667334|NCT01413087|Experimental|12 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 12 mg of BC-819
89667335|NCT04896138||ILD Cohort|Patients with Interstitial Lung Disease seen at the UVA ILD or Pulmonary Clinic
89667336|NCT04896138||Control Cohort|Control group of patients and family members of those with an Interstitial Lung Disease
89667337|NCT02158195||Patients|
89667338|NCT02158195||controls|
89667339|NCT04125875||Patients with cirrhosis of esophageal varices|
89667340|NCT04125875||Patients with gastric polyps|
89667341|NCT04878744|Experimental|Noticing the good things about green spaces|"The intervention condition will prompt participants once a day to notice the good things about green spaces, write notes about the 'good things in nature' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of species variety).~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation.~Both the intervention and active control conditions are based on gratitude interventions. Practicing gratitude in controlled psychological intervention settings has been shown to have lasting effects on dispositional gratitude and psychological wellbeing (Seligman et al. 2005)."
89667342|NCT04878744|Active Comparator|Noticing the good things about built spaces|"In the control condition, participants will not be prompted to notice nature, rather they will be prompted to record the good things about the built environment, write notes about the 'good things in built spaces' and answer 4 questions about the context (e.g. were they alone or in company, exercising or passing through, did they feel comfortable in the place, what were their perceived levels of the area being built-up).~Participants were initially asked to use the app for one month. This was found to be associated with poor engagement at feasibility testing and so participants were asked to use the app for 7 days for the evaluation."
89667343|NCT04393415|Active Comparator|patients receiving LGF|
89667344|NCT04393415|No Intervention|patients not receiving LGF nor PRP|
89667345|NCT04393415|Active Comparator|patients receiving Platelet rich plasma|
89667346|NCT04745923||Patients with chronic kidney disease|Having been diagnosed with chronic kidney disease
89667347|NCT04745923||Healthy individuals|Healthy individuals without chronic disease
89667348|NCT04888728|Experimental|DWN12088 and Nebivolol|Period 1 - Nebivolol A mg, Tablet, oral, once daily, Period 2 - DWN12088 X mg, Tablet, oral, twice daily, Period 3 - 1) Nebivolol A mg, Tablet, oral, once daily & DWN12088 X mg, Tablet, oral, twice daily, 2) DWN12088 X mg, Tablet, oral, once daily
89667349|NCT04888728|Experimental|DWN12088 and Paroxetine|Period 1 - DWN12088 X mg, Tablet, oral, once daily , Period 2 - Paroxetine B mg, Tablet, oral, once daily, Period 3 - 1) DWN12088 X mg, Tablet, oral, once daily & Paroxetine B mg, Tablet, oral, once daily, 2) Paroxetine B mg, Tablet, oral, once daily
89667350|NCT04125719|Experimental|Primay PD-1 resistance|Cohort 1 will include 15 patients who progressed within 3 months (primary resistance) of starting PD-1 therapy
89667351|NCT04125719|Experimental|Secondary PD-1 resistance|Cohort 2 will include 15 patients who progressed after at least 3 months of PD-1 therapy
89667352|NCT01428973|Active Comparator|Arm 1|GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
89667353|NCT01428973|Experimental|Arm 2|GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD
89667354|NCT01474863|Active Comparator|Low Dose Citrulline|Low Dose Citrulline
89667355|NCT01474863|Placebo Comparator|Placebo|Placebo IV infusion
89667356|NCT01474863|Active Comparator|High Dose Citrulline|High Dose Citrulline
89667357|NCT04878588||patients receiving esophagectomy|the patients receiving esophagectomy during perioperative period. They receive barium examination and high resolution impedance manometry at the same time
89667358|NCT04125329|Experimental|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
89667359|NCT04888962||Prospective cohort group|This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
89667360|NCT04888962||Control group|This cohort will include pregnant patients without a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.
89667361|NCT02144935||myelitis, transverse or acute flaccid myelitis|Observational study with online survey participation highlighting outcomes recovery. The surveys can be completed by the child and parent, or if too young to participate, parent only. The survey asks how the child is doing after hospitalization within 6 months of diagnosis, and every 4 months until study end in 2024.
89667362|NCT01475175|Experimental|CRT pacing at rest and during exercise|Rest and sub-maximal exercise
88995398|NCT03840746|Experimental|TOL soup with inulin|One tin of Tomato, onion and lovage soup with added inulin for 6 weeks
88995399|NCT03762096|Experimental|Resveratrol|
88995400|NCT03762096|Placebo Comparator|Placebo|
88995401|NCT03758638|Experimental|Healthy Eating & Active Living Taught at Home|"PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum (implementation strategy).~Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits."
89667363|NCT04125641||Elxaban group|AF patients taking Elxaban
89667364|NCT04125407|Experimental|Interventional|"Experimental group will receive one customized pair of sensorimotor foot orthoses (insoles).~Intervention: Other: Sensorimotor foot orthoses with any other supplementary treatment."
89667365|NCT04125407|No Intervention|Control|Control group will receive neither orthotic nor other supplementary intervention.
89667366|NCT00980057|Experimental|Adaptive CRT (aCRT) arm|Intervention: Cardiac resynchronization therapy (CRT-D) with Adaptive CRT algorithm ON
89667367|NCT00980057|Active Comparator|Echo-optimized arm|Intervention: Cardiac resynchronization therapy (CRT-D) with standard biventricular pacing (Adaptive CRT algorithm OFF)
89667368|NCT03006185|Experimental|Split-Person Design: Ablative Fractional Carbon Dioxide (CO2) Laser vs Microdermabrasion|WIthin each participant, two 50 cm2 adjacent test areas were randomized to laser or microdermabrasion pretreatment prior to daylight photodynamic therapy.
89667369|NCT04877886|Experimental|Ultrasound with IV contrast|use ultrasound with IV contrast to perform in acute flank pain patient
89667370|NCT04877886|Active Comparator|CT with IV contrast|to compare with ultrasound with IV contrast in acute flank pain patient
89667371|NCT04877886|Active Comparator|Ultrasound without IV contrast|baseline for the Ultrasound with IV contrast
88995402|NCT03758638|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual
88995403|NCT03705832|Experimental|Active drug|Subjects assigned to the intervention will receive 2 grams daily of Ginger Extract for 56 days.
88995404|NCT03705832|Placebo Comparator|Placebo|Subjects assigned to the placebo group will receive a matching placebo for 56 days.
88995405|NCT03613987|No Intervention|NIPPV|non synchronized non invasive positive pressure ventilation
88995406|NCT03613987|Experimental|NAVA-NIPPV|synchronized non invasive positive pressure ventilation with NAVA
88995407|NCT03602677|Experimental|ICG fluorescence imaging|Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.
88995408|NCT03602677|No Intervention|Standard procedure|Standard colorectal surgery and anastomosis.
88995409|NCT03579901|Other|Primary Breast Augmentation|Subjects age 22 and over, indicated to increase breast size
88995410|NCT03579901|Other|Primary Breast Reconstruction|Subjects age 18 and over, Surgery to replace breast tissue that has been removed due to cancer, prophylactic mastectomy, breast trauma or that has failed to develop properly due to a severe breast anomaly.
89667372|NCT04877886|Active Comparator|CT without IV contrast|baseline for the CT with IV contrast
89667373|NCT04877964||pediatric patients with scoliosis|Patients aged 3-14 years with scoliosis and who request epidural analgesia
89667374|NCT01475643|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5%
89667375|NCT01475643|Active Comparator|Prednisolones acetate|Prednisolone acetate 1.0%
89667376|NCT04393571|Experimental|conventional follow up patients|
89667377|NCT04393571|Experimental|Mobile app follow up patients|
89667378|NCT04124627|Experimental|Single arm study|Ultrasound plus radiographic guidance
89667379|NCT04895826||Back pain and no back pain|Participants with and without back pain will be included in the study and they will be asked to perform standard functional movements that would be used for a physiotherapy assessment for a back condition. The participants will also perform these movements in front of a camera for video recordings to be analysed by the CV system. The measurements by the CV system will be compared to the measurements by the physiotherapist. Additionally, participants will perform and record videos of the same set of movements at home to test the feasibility of the CV system in a home environment.
89667380|NCT04124783|Experimental|Cooling Bolero|
89667381|NCT03051126||Parathyroid Disease Tissue Bank|Participants scheduled for surgical treatment of parathyroid disease and/or patients with MEN1, and/or those presenting with hyperparathyroidism and/or pancreatic lesion, who are scheduled for pancreas tumor intervention.
89667382|NCT04888260||Coronary Artery Disease Group|Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment were included in the patient group.
89667383|NCT04888260||Control Group|The control group consisted of healthy people with normal coronary arteries angiographically
89667384|NCT03004001|Experimental|Alirocumab and atorvastatin|Alirocumab 150 mg bi-weekly and atorvastatin 20 mg/d
89667385|NCT03004001|Placebo Comparator|Alirocumab placebo and atorvastatin|Alirocumab placebo biweekly and atorvastatin 20 mg/d
89667386|NCT01836445|Experimental|Keep It Up! Intervention|The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
89667387|NCT01836445|Active Comparator|HIV Knowledge Control|The control condition reflects HIV information that is currently available on many websites so as to understand how the KIU! intervention improves upon what is currently available online. It is not tailored to YMSM, non-interactive, and focused on HIV/STI knowledge. The control is completed across three sessions done at least 24 hours apart (i.e. at least 3 days).
89667388|NCT04124003|Experimental|rosuvastatin + BMS-963272|
89667389|NCT03237377|Experimental|Durvalumab with Radiation|"Drug: Durvalumab Other Names: MEDI4736~MEDI4736 1500mg via IV infusion every 4 weeks for up to 3 doses/cycles Intervention: Radiation: Thoracic Radiation 5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction~Intervention: Procedure/Surgery: lobectomy patients may proceed to surgery post drug and radiation intervention for lung lobectomy~Intervention: Drug: Standard of care adjuvant chemotherapy patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery"
89667390|NCT03237377|Experimental|Durvalumab and Trememlimumab with Radiation|"Drugs: Durvalumab + Tremelimumab Other Names: MEDI4736 and CP-675 MEDI4736 1500mg via IV infusion every 4 weeks for up to 3 doses/cycles + CP-675 206 75mg via IV infusion every 4 weeks up 3 doses/cycles Intervention: Radiation: Thoracic Radiation 5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction Intervention: Procedure/Surgery: lobectomy patients may proceed to surgery post drug and radiation intervention for lung lobectomy~Intervention: Drug: Standard of care adjuvant chemotherapy patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery"
89667391|NCT04888182|Active Comparator|intervention|Individual nutritional guidance of a protein intake of ≥25 E%.
89667392|NCT04888182|No Intervention|control|Free diet
89667393|NCT04124081|Experimental|Drug group|
89667394|NCT03050580|Experimental|Self-esteem enhancement group|The self-esteem enhancement group service for abused women will receive a six-session program for recognizing strengths and resources through group activities and sharing.
89667395|NCT03050580|Active Comparator|Standard care|The shelter standard care for abused women includes residential accommodations, emotional support, legal, housing and financial advice and referral service.
89667396|NCT04123925|Experimental|Nivolumab|Patients will receive nivolumab at a flat dosage of 240 mg every two weeks on Day -28 and Day-14 (+/- one day) prior to planned surgery on Day 0 or up to +7 days
89667397|NCT04894578|Active Comparator|Group A|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a reverse distal metatarsal minimal-invasive osteotomy
89667398|NCT04894578|Active Comparator|Group B|Patients suffering from midfoot arthritis after failed prior conservative therapy who undergo a fusion of one or more midfoot (tarsometatarsal) joints
89667399|NCT04759079|Experimental|Acupuncture Needles and Antiemetic Drug|
89667400|NCT04759079|Active Comparator|Antiemetic Drug|
89667401|NCT02144467||Large-sample healthy participants|MRI scanning.
89667402|NCT04123769|Experimental|Drug group|
89667403|NCT03048942|Experimental|Cabazitaxel|6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle
89667404|NCT03048942|Active Comparator|Paclitaxel|6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.
89667405|NCT04393025|Other|Intracranial Stenting|25 Patients presented with recurrent Ischemic CVS with Large ICSD received ICS
89667406|NCT04393025|Active Comparator|Aspirin+Clopidogrel|25 Patients presented with recurrent Ischemic CVS with Large ICSD received optimal medical treatment
88995411|NCT03579901|Other|Revision Augmentation|Revision surgery to correct or improve the results of a previous breast augmentation
88995412|NCT03579901|Other|Revision Reconstruction|Revision surgery to correct or improve the results of a previous breast reconstruction.
88995413|NCT03509571|Experimental|Ketogenic Diet Group|Ketogenic diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that included ≈72% total energy as fat, ≈25% as protein, and ≈3% as carbohydrate during enteral feeding and ≈65% total energy as fat, ≈27% as protein, and ≈8% as carbohydrate and fiber during solid feeding. Patients will start receiving ketogenic diet within the 72 hours injury, after completing their baseline measurements.
88995414|NCT03509571|Other|Standard Diet Group|Patients will start to receive standard hospital diet within 72 hours of injury after completing their baseline measurements. Standard diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
89667407|NCT03049020||With levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and suffering with levator ani avulsion
89667408|NCT03049020||Without levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and without levator ani avulsion
89667409|NCT04122989|Experimental|MS-SUPPORT|Group receives access to an online shared decision making tool (an interactive decision aid) for multiple sclerosis.
89667410|NCT04122989|No Intervention|Control|Usual care
89667411|NCT04123301|Active Comparator|Active TBS Arm|Patients randomized to this arm will receive active TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
89667412|NCT04123301|Sham Comparator|Sham TBS Arm|Patients randomized to this arm will receive sham TBS 5 consecutive days of the week (Monday to Friday) in the first 3 weeks and then 2 alternate days of the week (with interval of at least 1 day between sessions) for another 3 weeks.
89667413|NCT04123145|Experimental|CDK-ND|
89667414|NCT05257902|Active Comparator|Treatment group|Participants in the treatment group will take the choline alfoscerate as adjunctive therapy with their own antidepressants.
89667415|NCT05257902|Placebo Comparator|Control Group|Participants in the control group will take the placebo, which would not affect their medical condition, for the adjunctive therapy is the choice of agreement between clinician and participants. If there is the necessity of change in antidepressant or of adjustment of their dosage, investigator can stop the clinical trial and proceed to another treatment.
89667416|NCT04123223|Experimental|Restorative CR Intervention|The restorative remediation intervention will consist of a target of 50 hours (5 hours per week, 1 hour per day, over 3 months) of a sequence of computerized cognitive exercises designed to improve cognitive function through repeated drill-and-practice of exercises largely focused on attention, working memory and verbal episodic memory. Cognitive deficits will be directly targeted by these exercises. Exercises will be started at individually determined levels of difficulty at which each client will be successful, e.g., 80% accuracy. Task difficulty will be increased as performance improves.
89667417|NCT04123223|Experimental|Strategy CR Intervention|Participants in this intervention will be treated for 24 hours (2 hours per week, one day per week over 3 months) with Compensatory Cognitive Training (CCT). The therapy targets four cognitive domains: (a) prospective memory, (b) attention and vigilance, (c) learning and memory, and (d) executive function. The program is a group-based intervention that teaches strategies via interactive, game-like activities to maintain interest and enhance motivation and engagement.
89667418|NCT04123223|Placebo Comparator|Computer Games|Three months of 1-hour, 5-times per week, client-selected computer games.
89667419|NCT01812343|Other|Exercise test|Ankle pressure Index measure before and after Maximal Exercise Tests
89667420|NCT03049098||Success at the simulation|Participant could correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
89667421|NCT03049098||Failed the simulation|Participant could not correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
89667422|NCT02143219|Other|FOLFIRINOX|FOLFIRINOX (D1-D15, for maximum 12 cycles) = Oxaliplatine + Folinic acid + Irinotecan + 5-FU
89667423|NCT04122911|Experimental|Temozolomide|Temozolomide 75mg/m2 metronomic schedule: one week on/one week off in a cycle of 28 days
89667424|NCT02990897|No Intervention|Control Group|Patients with Stage 3,4, or 5 CKD who are randomized to the control arm will receive standard care.
89667425|NCT02990897|Experimental|Intervention Group|Patients with Stage 3,4, or 5 CKD who are randomized to the intervention group will receive care from a physician who has been exposed to the intervention: a clinical decision support message. This clinical decision support message shows the patient's risk of kidney failure over the next 5 years.
89667426|NCT03050424|Experimental|Active|Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight
89667427|NCT03050424|Placebo Comparator|Placebo|Sodium Chloride 0.9%
89667428|NCT01895803||smoking woman 18-60 years old|
89667429|NCT04122599|Other|Melatonin versus standard care|Melatonin is tested versus standard care
89667430|NCT02140879|Placebo Comparator|Capsule 1|Placebo is a mixture of corn and soy oils.
89667431|NCT02140879|Active Comparator|Capsule 2|Active supplement group, will take capsules containing oil '2' which is an algal oil.
89667432|NCT03048708|Experimental|Obese patients treated with bariatric surgery|Patients with morbid obesity who were eligible for and willing to have bariatric surgery performed
89667433|NCT03048708|No Intervention|Obese patients not treated with bariatric surgery|Age and BMI matched patients with morbid obesity who either were not eligible for or were not willing to have bariatric surgery performed - no sufficient number of matched patients has completed the study; the arm of obese patients not treated with bariatric surgery has been discarded for the purpose of the analyses
89667434|NCT01475955|Experimental|Broad Area ALA 1-hour incubation|Broad Area ALA 1-hour incubation
89667435|NCT01475955|Experimental|Broad Area ALA 2-hour incubation|Broad Area ALA 2-hour incubation
89667436|NCT01475955|Experimental|Broad Area ALA 3-hour incubation|Broad Area ALA 3-hour incubation
89667437|NCT01475955|Experimental|Spot ALA 2-hour incubation|Spot ALA 2-hour incubation
89667438|NCT01475955|Placebo Comparator|Vehicle PDT|VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
89667439|NCT04122521||Glioma|Patients suspected of glioma
89667440|NCT04755829||Group 1|Normal screening mammogram (BIRADS 1 or 2)
89667441|NCT04755829||Group 2|Abnormal screening mammogram (BIRADS 3 to 6)
89667442|NCT04887636||Normal women group|I. Women of childbearing age who are physically and mentally healthy, have regular menstruation and are between 20-45 years old; II. Women who are evaluated as normal by vaginal microbiome morphological characterization; III. Women who agree to participate in this study and have signed an informed consent form; IV. Those who have full capacity for civil and legal conduct; V. The quality of vaginal samples meets the evaluation requirements of this program.
89667443|NCT04122365|Experimental|Interventional group|Chest Wall Mobilization Program
89667444|NCT04122365|Other|Control Group|Routine limbs exercises and education
89667445|NCT03048474|Experimental|Nivolumab and Ipilimumab|Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
89667446|NCT04121975|Experimental|Chemoradiotherapy|"Radiation:~Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.~Drug: Endostar 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.~Drug: Cisplatin 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29."
89667447|NCT03048318|Experimental|Arterial and Portal Flushing of Graft|Back table flush of portal vein and graft artery
89667448|NCT03048318|Active Comparator|Portal Flushing only of Graft|Back table flush of portal vein only
89667449|NCT02139319|Experimental|Botulinum toxin|Single intra-articular injection
89667450|NCT02139319|Placebo Comparator|Placebo|Single intra-articular injection
89667451|NCT03830957|Active Comparator|Ivabradine|
89667452|NCT03830957|Active Comparator|metoprolol|
89667453|NCT05257122|Experimental|Arm A|Monotherapy of Fruquintinib
89667454|NCT04390165||Malaysian COVID-19 Cohort|A cohort of COVID-19 positive patients will be recruited from participating Malaysian Ministry of Health-designated COVID-19 treating hospitals across the country.
89667455|NCT04121663|Experimental|Full seam anchor|
89667456|NCT04121663|Active Comparator|Polyether ether ketone bone anchor|
89667457|NCT04121819|Experimental|AraC|cytarabine 100mg/m2 d1-5 subcutaneous
89667458|NCT01476267|Experimental|Single Arm|
89667459|NCT04887714|Experimental|Mask|cloth mask wearing
89667460|NCT04887714|No Intervention|control|control, without mask.
89667461|NCT04062851|No Intervention|GRV group|Gastric residuals will be checked prior to feeds
88995415|NCT03447743|Other|XR-NTX services as usual|Participants will receive on-going XR-NTX injections in a local community clinic
88995416|NCT03440879|Experimental|ADT group|Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
89667462|NCT04062851|Experimental|NO GRV group|Gastric residuals will not be checked prior to feeds
89667463|NCT05189730|Experimental|Total neoadjuvant therapy|The patients would receive neoadjuvant chemoradiotherapy treatment firstly. And then evaluated efficacy according to RECIST 1.1. If patients with cCR would receive surgery treatment after 4-6 weeks. After surgery, patients with pCR would always perform surveillance and patients with non-pCR would receive immunotherapy alone treatment. If patients evaluated as PD, they would receive new treatment regimen after MDT discussed. Other patients with PR and SD would receive 2 cycles of neoadjuvant immunochemotherapy. And then, Efficacy of immunochemotherapy would be evaluated according to RECIST 1.1. For patients suitable for surgery, surgery should be performed after 4-6 weeks of immunotherapy. After surgery, the patients with R0 resection would divided into two groups, if patients with pCR would always perform surveillance and patients with non-pCR would receive immunotherapy treatment. Other patients without R0 resection would receive new treatment regimen after MDT discussed.
89667464|NCT04121273|Experimental|CAR-T cells|CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.
88995417|NCT03440879|No Intervention|No-ADT group|Prostate cancer patients without any history of receiving any form of androgen deprivation therapy
88995418|NCT03433755|Placebo Comparator|Placebo Q2W|Placebo subcutaneous (SC) Q2W for 12 weeks
88995419|NCT03433755|Placebo Comparator|Placebo QM|Placebo SC QM for 12 weeks
88995420|NCT03433755|Experimental|Evolocumab 140 mg Q2W|Evolocumab 140 mg SC Q2W for 12 weeks
88995421|NCT03433755|Experimental|Evolocumab 420 mg QM|Evolocumab 420 mg SC QM for 12 weeks
88995422|NCT03430674|Experimental|Exercise Intervention|Clinic and at home exercise sessions.
88995423|NCT03406507|Experimental|Ravulizumab|Complement inhibitor treatment-naïve and eculizumab-experienced participants received ravulizumab.
89049136|NCT04625985|Experimental|Metformin glycinate|620 mg bid (PO) for 14 days plus standard treatment
89667465|NCT01476345|Experimental|LY2963016|A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
89667466|NCT01476345|Experimental|Lantus|A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
89667467|NCT01413217||Egg Breakfast|This group will be given a breakfast consisting of eggs. A breakfast consisting of eggs induces greater satiety and reduces Lunch Time intake.
89667468|NCT01413217||Cereal Breakfast|This breakfast will consist of a breakfast that will include cereal. A breakfast cereal or white bread increases lunchtime energy intake.
89667469|NCT01406977|Experimental|BPS804 dose escalation|BPS804 IV Setrusumab given in escalating doses from 5mg/Kg to 20mg/Kg
89667470|NCT04121039|Experimental|Apatinib plus POF|Participants will receive apatinib in combination with POF,total 9-12 cycles.Then receive apatinib plus S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89667471|NCT04121039|Active Comparator|POF|Participants will receive POF,total 9-12 cycles.Then receive S-1 until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89667472|NCT01399801|Experimental|hemodynamicaly guided LV lead placement|optimized left ventricular lead placement
89667473|NCT01399801|Active Comparator|Standard lead placement|Standard LV lead placement with no measurements to guide LV lead placement
89667474|NCT04887090|Experimental|Acupuncture and drug compound technology group|Routine perioperative management and transcutaneous electrical acupoints stimulation treatment
88995424|NCT03283150|Active Comparator|Remifentanil|Remifentanil will be administered to subjects during microelectrode recordings (MER).
88995425|NCT03283150|Active Comparator|Propofol|Propofol will be administered to subjects during MER.
88995426|NCT03283150|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered to subjects during MER.
88995427|NCT03249792|Experimental|Arm 1: MK-2118 IT Monotherapy|Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
88995428|NCT03249792|Experimental|Arm 2: MK-2118 IT+Pembro Combo Therapy|Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
88995429|NCT03249792|Experimental|Arm 3: MK-2118 Visceral IT+Pembro Combo Therapy|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
88995430|NCT03249792|Experimental|Arm 4: MK-2118 SC+Pembro Combo Therapy|Participants receive MK-2118 monotherapy via subcutaneous (SC) injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1, 8 and 15, for a total of up to 36 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 36 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.
88995431|NCT03218917|Experimental|Brensocatib 10 mg|Participants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.
88995432|NCT03218917|Experimental|Brensocatib 25 mg|Participants received brensocatib 25 mg QD before breakfast, for 24 weeks.
88995433|NCT03218917|Placebo Comparator|Placebo|Participants received the matching placebo QD before breakfast, for 24 weeks.
88995434|NCT03207841|Experimental|LC/HP group|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake. Dietary fat sources will focus on monounsaturated and polyunsaturated fats, e.g., plant oils and nuts; dietary carbohydrate sources will emphasize whole grains, fruits, vegetables, and legumes; and dietary protein sources will include lean meats, fish, chicken, eggs, and nonfat dairy foods, e.g., fat-free milk and low-fat cheese, consistent with American Diabetes Association and Institute of Medicine guidelines. All LC-HP meals will be provided by UAB Center for Clinical and Translational Sciences (CCTS) Bionutrition Unit and delivered to participants' homes 3 times/week (a sample menu is included in Appendix J). Every delivery will include breakfast, lunch, dinner, and snacks for 2 to 3 days.
89049137|NCT04625985|Placebo Comparator|Placebo|Placebo tablet bid (PO) for 14 days plus standard treatment
89049138|NCT02905760|Experimental|Furosemide|Furosemide and Placebo filling (Glucose 5%).
89049139|NCT02905760|Active Comparator|Fluid expansion|"Placebo furosemide (Glucose 5%) and Vascular filling~The vascular filling is the gold standard in the treatment of acute myocardial infarction"
89667475|NCT04887090|Other|Control group|Routine perioperative management
89667476|NCT04121117||Tobacco detoxication cohort|Patients appointed in a tobacco detoxication consultation
89667477|NCT04120571|Experimental|experimental|Sleep Audiological Intervention Device (SleepAID)
89667478|NCT04120571|Sham Comparator|control|no sound
89667479|NCT01401543|Active Comparator|5 mg LY2452473 + 5 mg Tadalafil|5-mg LY2452473 oral capsule and 5-mg tadalafil oral tablet, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
89667480|NCT01401543|Experimental|LY900010 (particle size #1)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a smaller particle size (d90 = 10 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
88995435|NCT03207841|No Intervention|Control|Control group will not receive the experimental diet and will continue with their usual diets. Participants will complete three 24-hour food recalls (on 2 week days and one day in the weekend) three times (at weeks 1, 4 and 8) during the course of the study to gather dietary information including dietary intake and/or particular aspects of the diet. Participants will be asked to recall foods and beverages they consumed in the 24 hours prior to the interview. Three 24-hour food recalls appear optimal for estimating energy intake.
89049140|NCT04653987||Puncture angle : ≤30 (group I) >30 (group II)|The patients will be divided into two groups based on the puncture angle: ≤30° group and >30° group. The two groups will be retrospectively analyzed for technical success, fluoroscopy time and complications.
89667481|NCT01401543|Experimental|LY900010 (particle size #2)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size (d90 = 25 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
89667482|NCT01401543|Experimental|LY900010 (particle size #3)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size (d90 = 40 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
89667483|NCT05256498|Experimental|Amber UI Stimulation|Short-duration pudendal nerve stimulation
89667484|NCT04887168|Experimental|Compressed|Treatment delivered at higher intensity - twice weekly
89667485|NCT04887168|Experimental|Spaced|Treatment delivered at lower intensity - once weekly
89667486|NCT04120259|Active Comparator|Group 1|Intervention: Metformin Tablet oral 750 mg OD
89667487|NCT04120259|Experimental|Group 2|Intervention: Metformin 750 mg oral plus 2 tablespoons of apple cider vinegar OD
89667488|NCT04392102|Experimental|ZL-2306(Niraparib)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
89667489|NCT04120181||Control|The control group consists of 13 age- and gender-matched subjects who underwent CI surgery but showed no complications. The members of the control group were selected based on hospital records.
89667490|NCT01414413|Experimental|Home assessment and initiation of ART|"Participants with a positive home-based HIV test result will receive a home visit from a study nurse who will complete the following on the first home visit:~Confirmatory fingerprick HIV testing~TB symptom screening~ART eligibility assessment (Word Health Organization clinical staging, sampling of blood for measurement of CD4 count and treatment education)~At a second home visit (within 5 days), participants who are ART eligible (as defined in National ART guidelines) will be initiated onto ART (using National Treatment Programme ART regimens).~Following home initiation of ART, participants in the intervention arm will receive detailed counselling from the study nurse about the need to attend their first 2-week follow-up appointment at the primary health care clinic that serves their household's residence. They will receive a referral slip detailing the date, time and place of their appointment."
89667491|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor. HIV care, including ART, will be started from the primary care clinic.
89667492|NCT05256420|Experimental|Kinesiotape|Application of a kinesiotape bandage on the knee.
89667493|NCT05256420|Sham Comparator|Sham Bandage|Application of a sham bandage on the knee.
89667494|NCT04758845|Experimental|Cocktail|Subjects will consume 1 capsule containing 2B CFU containing .5B CFU Bacillus subtilis DE111, .5B CFU Bacillus coagulans CGI314, .5B CFU Bacillus megaterium MIT411, and .5B CFU Bacillus clausii CSI08 for 45 days.
89667495|NCT04758845|Experimental|CGI314|Subjects will consume 1 capsule containing 1B CFU of Bacillus coagulans CGI314 for 45 days.
89667496|NCT04758845|Experimental|CSI08|Subjects will consume 1 capsule containing 1B CFU of Bacillus clausiiCSI08 for 45 days.
89667497|NCT04758845|Experimental|MIT411|Subjects will consume 1 capsule containing 1B CFU of Bacillus megaterium MIT411 for 45 days.
89667498|NCT04758845|No Intervention|Placebo|Subjects will consume 1 capsule containing maltodextrin for 45 days.
89667499|NCT05256342|Active Comparator|Duloxetine|Eight weeks treatment, one pill a day. Week 1st - 30 mg a day. Weeks 2nd - 8th - 60 mg a day.
89667500|NCT05256342|Active Comparator|Etoricoxib|Eight weeks treatment. 60 mg daily pill ; from the second week adding omeprazol 20 mg daily
89667501|NCT02983721|Active Comparator|Transfemoral|in case of transfemoral approach our preference was to use right femoral route. The groin was prepared and draped and the site was punctured for femoral access after anesthetizing the skin with 2-4 ml of 1% lignocaine. Once the femoral puncture was done 6F sheath of Cordis variety was introduced and 6F Judkins, catheter was introduced and it was guided under fluoroscopic guidance through the aortic route.
89667502|NCT02983721|Active Comparator|Transradial|Our preference was to use the right radial and right femoral routes as they are nearest to operator while facing cardiac monitors, in our hospital. For the radial approach, the wrist was sterilized and draped in usual fashion. Hyperextension over an arm board was done and skin over the puncture site was anesthetized with 2 - 3 ml of 1% lignocaine. A small scaled incision was performed 1 cm proximal to styloid process of radius where arterial pulse was best felt. The radial artery was punctured with a 21 G needle and 6 F sheath (Cardis, Terumo) were introduced into the artery, using Seldinger technique. All patients received verapamil (5mg) to reduce radial artery spasm. Heparin (weight adjusted) was used only in PCIs to prevent artery occlusion and not in elective diagnostic coronary studies. Long 0.038 Terumo guide wire was used under fluoroscopic guidance.
89667503|NCT04754022|Active Comparator|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is <75 g/L (<7.5 g/dL; <4.7mmol/L) intraoperatively and/or postoperatively.
89667504|NCT04754022|Active Comparator|Liberal Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is <95 g/L (<9.5 g/dL; <5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or <85 g/L (< 8.5 g/dL; <5.3mmol/L) on the ward.
89667505|NCT04887012|Experimental|CAR-NK019|All subjects were intravenously administrated with CAR-NK019
89667506|NCT01895881|Experimental|Estradiol Daily|1 mg Estradiol daily for 180 days.
89667507|NCT01895881|Placebo Comparator|Placebo|Placebo for 180 days.
89667508|NCT04125953|Experimental|Intervention|A 3 week intervention with Andullation will be performed, 3 times a week for 20 minutes after completion of the radiotherapy session
89667509|NCT04125953|Placebo Comparator|Control|This group will follow the same intervention protocol, but without the application of the Andullation technology
89667510|NCT04698330|Experimental|Group A|LADA patients are assigned to receive berberine and inulin for 3-month.
89667511|NCT04698330|Experimental|Group B|LADA patients are assigned to receive berberine and placebo(for inulin) for 3-month.
89667512|NCT04698330|Experimental|Group C|LADA patients are assigned to receive placebo(for berberine) and inulin for 3-month.
89667513|NCT04698330|Placebo Comparator|Group D|LADA patients are assigned to receive placebo(for berberine) and placebo(for inulin) for 3-month.
89667514|NCT01797055|Experimental|human apotransferrin|intravenous apotransferrin every 4-8 weeks
89667515|NCT04124549|Sham Comparator|Stand of Care|Patients in the control group received usual care with sham exercise.
89667516|NCT04124549|Experimental|Combined Exercise|The intervention was a 24-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours. Each exercise lasted about 40 minutes.
89667517|NCT04430244|Experimental|DALK using Dehydrated Corneas|Corneal transplantation of anterior lamellar grafts from dehydrated corneas.
89667518|NCT04430244|Active Comparator|DALK using Standard Organ Culture Stored Corneas|Corneal transplantation of anterior lamellar grafts from standard organ culture stored corneas.
89667519|NCT01792609|Active Comparator|Maximum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
89667520|NCT01792609|Active Comparator|Minimum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
89667521|NCT05256186|Experimental|Basketball pre-injury attack program|The intervention group carried out a program for 24 weeks. The participant had to perform the program 3 days per week for 12-15' each day (training days with the team, prior to group activation).
89667522|NCT05256186|No Intervention|Control|The control group performed only the initial, follow-up (12 weeks) and final (24 weeks) evaluations.
89667523|NCT04274543|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of normal saline (0.9%) solution into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
89667524|NCT04274543|Active Comparator|Saline|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear) and knee joint under ultrasound guidance using an 18 gauge x 3.5 inch needle.
89667525|NCT05256030|Experimental|Control-Traditional Rehabilitation Group|"This group will receive a 6-week neurorehabilitation program that includes stretching for spasticity inhibition, strengthening of the antagonist muscle, autogenic inhibition methods, as well as conscious-unconscious balance training and gait training, which are routinely applied in physical therapy and rehabilitation units. The treatment will be applied 5 days a week.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
89667526|NCT05256030|Experimental|Study-Neurodevelopmental Therapy Group|Function-oriented Neurodevelopmental Therapy will be applied to the subjects included in the study and randomly assigned to the study group in different positions such as supine, prone, sitting, standing for 6 weeks, 5 sessions per week, and the goal will be to achieve the task at different speeds. Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
89667527|NCT01791361||Round 1|50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist
89667528|NCT01791361||Round 2|50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1
89667529|NCT01791361||Round 3|50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1
89667530|NCT05255796|Experimental|one-piece|The patients' axial length is over 26 mm and are diagnosed age related cataract or complicated cataract.
89667531|NCT05255796|Experimental|plate-haptic|The patients' axial length is over 26 mm and are diagnosed age related cataract or complicated cataract.
89667532|NCT04632888|Experimental|Study group/Telephone support for breastfeeding follow-up|"Study group: The women in the study group will be provided with a video call every day for the first week after discharge from the hospital, to provide consultancy to the mother on the matters she needs and to be recorded in the Baby Monitoring Form. The general appearance of the baby, observation during sucking, jaundice, drowsiness, reluctance to suck will be observed. The consultancy will be provided to the mother on these issues.~In the following weeks, the consultancy will continue to be given to the study group by making a video talk one week apart.~The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded."
89667533|NCT04632888|No Intervention|Control Group|"Control Group: No additional attempt or routine call will be made to mothers in the control group. The researcher's phone will be given to the mothers in both groups and the incoming calls and their content will be recorded.~The control group will be called to fill in the scales for monitoring purposes."
89667534|NCT03048396|Experimental|Uterus transplantation|
89667535|NCT04886466|Experimental|The trunk movement coordinated and legs coordination during walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in post-stroke patients (study group).
89214512|NCT06089720|Placebo Comparator|orthodontic molar tubes (control)|The nine orthodontic patients will receive 36 the non-coated orthodontic molar tube in split-mouth cross quadrant manner, In each patient, two diagonal quadrants (i.e., upper right and lower left, or vice versa) will randomly assigned to each coated OMT and UOMT groups. evaluation will be after 2 weeks for microbial assessment biofilm in addition to plaque & gingival index. patients will be follow up for 3 month to evaluation bond failure rate.
89214513|NCT06089707|Experimental|4mg buprenorphine|4mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
89214514|NCT06089707|Experimental|8mg buprenorphine|8mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
89214515|NCT06089707|Experimental|16mg buprenorphine|16mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
89214516|NCT06089707|Experimental|24mg buprenorphine|24mg of buprenorphine will be given to a subset of participants immediately after naloxone administration.
89667536|NCT04886466|Experimental|The coordinated movement of the trunk and legs during fast walking in place.|The intervention (active tension of the muscles stabilizing the core) was tested in patients with back pain syndrome, but without neurological deficits (control group).
89667537|NCT04576962||Children aged 14 years or younger|All children in Indiana aged 14 years and younger who received the first dose of HPV vaccine during the 2017 and 2018 calendar years. This is a non-interventional study, with data to be analyzed at the county level only.
89667538|NCT04537962|Placebo Comparator|Colgate Periogard and Peroxyl®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution, following by a 0.12% non-alcoholic chlorhexidine solution
89667539|NCT04537962|Placebo Comparator|Colgate Periogard®|Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution;
89667540|NCT04537962|Placebo Comparator|Colgate Peroxyl®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution
89667541|NCT04537962|Placebo Comparator|Colgate Total 12®|Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate
89667542|NCT04537962|Active Comparator|Toothpaste with sodium monofluorophosphate|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing only 1.1% fluoride, water, glycerin, cellulose, sodium lauryl sulfate, and sodium bicarbonate
89667543|NCT04537962|Active Comparator|Toothpaste with sodium fluoride and zinc|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.32% fluoride, 0.96% zinc, arginine, poloxamer, glycerin, water, hydrated silica, sodium lauryl sulfate, and sodium saccharin
89667544|NCT04537962|Active Comparator|Toothpaste with tin fluoride|Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.454% stannous fluoride, water, sorbitol, hydrated silica, glycerin, tetrasodium pyrophosphate, microcrystalline cellulose, and xanthan gum
89667545|NCT04886076||Participants with RBD|Participants with REM Sleep Behavior Disorder
89667546|NCT04886076||Participants without RBD|Age- and gender-matched controls, without REM Sleep Behavior Disorder
89667547|NCT04519086|Experimental|Low-dose CT for acute appendicitis in patients with BMI >30|Low-dose computed tomography (CT) vs. standard CT for diagnosing acute uncomplicated appendicitis in patients with BMI > 30 Laparoscopic appendectomy
89214517|NCT06089681||Hamstring strain injury history group|Sprinters who have ≥ twice hamstring strain injury occurrence in the past year
89214518|NCT06089681||Control group|Sprinters who match gender, age, BMI, dominant side, training experience, training frequency, PB in 100m with HSI history group and without any hamstring strain injury occurrence in the past year
89214519|NCT06089655|No Intervention|Negative control|no continuous glucose monitoring system nor AI diet application
89214520|NCT06089655|Active Comparator|Positive control|Continuous glucose monitoring system only
89667548|NCT04486560|Experimental|Single Arm: Cryoprobe|Everyone who enrolls in this study will undergo a standard of care bronchoscopy with a transbronchial biopsy using the 1.1mm sheath cryoprobe.
89667549|NCT04126733|Experimental|Regorafenib + Nivolumab|
89667550|NCT04128605|Experimental|Intervention: Suprascapular nerve block (SSNB)|SSNB performed by skilled interventionist who is not blinded for safety reason. 5 mls of Bupivacaine, 5 mls Lidocaine and 10 mls of saline.
89667551|NCT04128605|Active Comparator|Control: Intraarticular shoulder steroid injection (IAS)|"IAS performed by skilled interventionist who is blinded on patient's initial measurement.~40 mg of Triamcenolone Acetate + 2 ml of Lidocaine 1%"
89667552|NCT04345068|Experimental|Calm Meditation|"The intervention will be 8-weeks in duration and will consist of a series of pre-approved meditation classes. Patients will be asked to participate in at least 10 min/day of meditation (i.e., ~70 min/week). Week 1-4 will consist of the 7 Days of Calm followed by the 21 Days of Calm, which are introductory courses offered by Calm and provide basic, introductory meditation classes for beginners. Weeks 5-8 will consist of patients participating in the Daily Calm that Calm provides, consisting of 10-12 min meditation classes that have a unique focus each day. Patients will be instructed to participate in at least 10 min/day of meditation, but will be encouraged to do more if they can."
89214521|NCT06089655|Experimental|Intervention|Continuous glucose monitoring system +AI diet application
89214522|NCT06089642|No Intervention|Control|Usual care
89214523|NCT06089642|Experimental|Virtual Reality therapy|Patients receive virtual reality therapy in the form of active distraction or focussed attention (randomized between those two)
89214524|NCT06089629|No Intervention|Control group|Nonsurgical intervention with speech and myofunctional therapy
89214525|NCT06089629|Experimental|Intervention group|Surgical intervention with frenuloplasty followed by speech and myofunctional therapy
89667553|NCT04345068|Active Comparator|Health Education Podcast|The control group will serve as an active control group and will be matched for time and attention to the intervention group. Participants assigned to the control group will be asked to listen to/view 10-min/day (i.e., ~70 min/week) of health education podcasts via a smartphone app. Topics covered in the health education control vary and will be aimed at providing useful and informative health-related information pertinent to cancer patients. The podcast app was developed by an independent app developer, and it was designed to mirror the type of functionality that the Calm app offers its users.
89667554|NCT04311606|Experimental|Saline and aflibercept|Group 1: Sub-tenon's injection of saline followed by sub-tenon injection of aflibercept
89667555|NCT04311606|Experimental|Hyaluronidase and aflibercept|Group 2: Sub-tenon's injection of hyaluronidase (HA) followed by sub-tenon injection of aflibercept
89214526|NCT06089590||Group Anti-IL23p19|Patients treated with anti-IL23p19 (risankizumab, guselkumab, mirikizumab, brazikumab)
89667556|NCT04311606|Placebo Comparator|Hyaluronidase alone|Group 3: Sub-tenon injection of HA injection alone
89667557|NCT02980835|Experimental|Intervention|Patients who receive injections of A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) at the beginning of surgery and second set of injections containing a mixture of B (contains 10 mL of 0.9% normal saline) and C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) prior to the closure
89667558|NCT02980835|Active Comparator|Control|Participants who receive injection of B (contains 10 mL of 0.9% normal saline) at the beginning of surgery and injectate A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) and injectate C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) at the end of procedure prior to the closure (which mimics standard care) is the control group
89667559|NCT03050034|Experimental|Vital signs wireless monitoring system|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for hospitalization and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS/ NEWS, undergone to continuous monitoring with wireless monitoring system WIN @ Hospital.
89667560|NCT03050034|Active Comparator|Control arm|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for admission and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS NEWS undergone to traditional monitoring performed at regular intervals by the nursing staff.
89667561|NCT03997799|Experimental|uniportal transcervical approache|Uniportal lobectomy with complete lymphadenectomy - transcervical approach with elevation of the sternum
89667562|NCT03997799|Experimental|uniportal intercostal approache|Uniportal lobectomy with complete lymphadenectomy - intercostal approache
89667563|NCT04885842|Experimental|Study Group|injection I-PRF with brackets
89667564|NCT04885842|No Intervention|Control Group|applying brackets only
89667565|NCT04885140|Experimental|Feedback-based health education health education and Routine health education|"Feedback-based health education:(1) Implementation of the feedback method includes information transmission, patient feedback, clarification and correction, and confirmation of understanding.① One day before surgery: Health education team members provided bedside one-on-one education for patients, 15-20 min per session, twice a day.~② One week after surgery: One-on-one education on rehabilitation exercise was conducted for the patients by the health education team members, 15-20 min per session, twice a day.~③ Two to four weeks after surgery: The health education group members guided the patients through functional rehabilitation exercises via WeChat. Each intervention lasted 20-30 min. The patients interacted once through WeChatB1, and their questions were answered at any time.~④ Five to 12 weeks after surgery: The health education group members guided patients through the functional rehabilitation exercises via WeChat."
89667566|NCT04885140|Experimental|Routine health education|"Routine health education:~Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method."
89667567|NCT04871724|Experimental|EDP-938 and Fluconazole interaction|
89049141|NCT04653987||Technical Parameters of all Interventions|Peripheral bile duct diameter, central bile duct diameter, number of punctures, type of drainage and total fluoroscopy time will be noted.
89049142|NCT02905526|Experimental|Intervention|App plus the contraceptive instant messages
89214527|NCT06089590||Group Jak inhibitors|Patient treated with Jak inhibitors (tofacitinib, upadacitinib, filgotinib)
89667568|NCT03829553|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will received 2.67 Gy for 16 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67 Gy for 4 fractions following breast conserving surgery
89049143|NCT02905526|Placebo Comparator|Control|App only
89049144|NCT02905565|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
89049145|NCT02905565|Active Comparator|800 mg of NBP daily|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
89049146|NCT04654065|Experimental|IN-C004|IN-C004
89049147|NCT04654221||Male, BMI <= 24.9|Male subjects with a BMI of less than or equal to 24.9
89049148|NCT04654221||Female, BMI <= 24.9|Female subjects with a BMI of less than or equal to 24.9
89049149|NCT04654221||Male, BMI 25-29|Male subjects with a BMI of 25 to 29
89049150|NCT04654221||Female, BMI 25-29|Female subjects with a BMI of 25 to 29
89049151|NCT04654221||Male, BMI >29|Male subjects with a BMI of greater than 29
89049152|NCT04654221||Female, BMI >29|Female subjects with a BMI of greater than 29
89214528|NCT06089590||Group S1P Modulators|Patient treated with S1P modulators (ozanimod, etrasimod)
89214529|NCT06089590||Group Anti TNF|Patient treated with anti-TNF (infliximab, adalimumab, golimumab) (with a maximal proportion of 25% as 1st first line biologic after conventional treatment (aminosalicylates, corticosteroids, thiopurines, methotrexate))
89214530|NCT06089590||Group Anti integrins|Patient treated with anti-integrins (vedolizumab)
89214531|NCT06089590||Group Anti IL12/23|Patient treated with anti-IL12/23 (ustekinumab)
89667569|NCT03829553|Active Comparator|Conventional radiotherapy|Patients with an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
89667570|NCT04871802|Experimental|Taxifolin Aqua group|Taxifolin Aqua 30 mg per day in addition to standard therapy
89667571|NCT04871802|No Intervention|Control group|No intervention
89667572|NCT03829865||Water-perfused HREM|Healthy volunteers examined with water-perfused high resolution esophageal manometry
89667573|NCT03829865||Solid-state HREM|Healthy volunteers examined with high resolution esophageal manometry with solid-state catheter
89667574|NCT04871880|Experimental|Dietitian led life style modification intervention.|Lifestyle changes supervised by dietitians
89667575|NCT04871880|Experimental|Conventional care (control)|Receive routine care
89667576|NCT04871646|Experimental|CKD-314|Treatment with CKD-314 + SOC
89667577|NCT04871646|Placebo Comparator|CKD-314 Placebo|Treatment with CKD-314 Placebo + SOC
89667578|NCT02976077|Experimental|RC2S+|"RC2S+~Preparation sessions (sessions 1 & 2):~Functional Outcomes Scale - Social Cognition (ERF-CS)~Psychoeducation about social cognitive impairments~Concrete objectives~Cognitive remediation (sessions 3 to 22):~Paper-and-pencil session~Simulation session~Home-based task~Transfer sessions (sessions 23 & 24):~Transfer of skills in dayly life - generalization~Assessment of the achievement of objectives"
89667579|NCT02976077|Active Comparator|Control therapy|"Control therapy~Preparation sessions (sessions 1 & 2):~Functional Outcomes Scale - Neurocognition~Psychoeducation about cognitive impairments~Concrete objectives~Cognitive remediation (sessions 3 to 24):~Paper-and-pencil session~Simulation session~Home-based task"
89667580|NCT04871334|Experimental|Dose Escalation Cohort|Six dose levels of TWP-101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.
89667581|NCT04871334|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
89667582|NCT04759001|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
89667583|NCT04759001|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of water)
89667584|NCT04871256|Experimental|Inver|"Intervention: after screening, patient´s obstruction will be evaluated by anterior rhinomanometry (RNMa), and quality of life wil be scored through ESPRINT scale. ESPRINT is a validated Spanish questionnaire about daily life activity, sleep, psychology and perception of affection by allergic rhinitis.~Symptoms will be evaluated with visual analogue scale (VAS) and clinical history. Symptoms like sneezing, itchy nose, ocular symptoms and/or nasal obstruction. Also medication (intranasal corticosteroid, antileukotrienes, antihistamine eye drops, antihistamine) frequency use will be registered"
89667585|NCT03828695|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
89667586|NCT04871178|No Intervention|Control Group|Care as usual: (i.e. best medical treatment)
89667587|NCT04871178|Experimental|Mindfulness-Based Intervention|Care as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based educational and training program.
89667588|NCT04758923|Active Comparator|Two-Stage|Two-stage approach The treatment process commenced with an intial treatment phase. This will be udertaken Under General anaesthesia and entailed ERCP and endoscopic sphincterectomy
89667589|NCT04758923|Active Comparator|Single stage|Single stage approach Under General anaesthesia a5 trocar method will be used to access the abdominal cavity. Aconventional approach to laparoscopic cholecystectomy will be first udertaken with dissection of calot's triangle. The cystic duct will be pulled laterally to facilitate exposure of the anterior wall of the CBD, and the CBD will be opened longitudinally for a distance of approximately 1 to 1.5 cm using laparoscopic scissors. A5 mm flexible choledoscope will be used to identify the cbd stone which will be removed by flushing with sterile saline, passing a stone basket or electrohydroulic lithotripsy as neccesary to clear the CBD. A T-tube will be inserted into the CBD via the choledochotomy which will be closed by interrupted resorbable sutures before completing the cholecystectomy.
89667590|NCT04758455|Experimental|P53 IHC|P53 staining density and intensity will be calculated. To assess P53 density in a semiquantitative way, a score of 0 will be given assigned if less than 5% of tumour cells expressed p53, 1 if 5% to 50% expressed p53 and 2 if more than 50% stained positive for p53. To evaluate P53 intensity, a score of 0 means weak or absent staining, 1 refers to the intermediate intensity and 2 stands for strong intensity.
89667591|NCT04758455|Experimental|Ki67 IHC|Ki67 proliferation index will be used to detect rapidly proliferating cells which means the percentage of positive Ki67 cells over 5 high power fields. It will be semiquantitatively graded as low, moderate, or high and correlated with histological staging.
89667592|NCT04758455|Experimental|Cyclin A IHC|Regarding Cyclin A, a standard peroxidase-conjugated streptavidin-biotin labelling was used for visualization, with 3,3 diaminobenzidine as chromogen. Level of cyclin A expression will be classified as absent (-), focal (+), moderate (++) diffuse (+++).
89667593|NCT03047304|Other|Women in risk for preterm labor|Women in risk for preterm labor treated with magnesium.
89667594|NCT03828305|Experimental|Training and creation of the Network-CPR|Training in CPR
89667595|NCT03828305|Active Comparator|Control Group|Primary Care Center Emergency Personnel
89667596|NCT03046992|Experimental|YH25448|"Dose Escalation Phase: Consists of 7 Cohorts~Dose Expansion Phase: Consists of 5 Cohorts~Dose Extension Phase: Consists of 2 Cohorts"
89667597|NCT03048630|Experimental|Knowledge and behavioral intervention|Owner and worker trainings regarding knowledge and behaviors associated with workplace chemical exposure reduction
89667598|NCT03048630|Other|Delayed intervention|Delayed knowledge and behavioral intervention
89667599|NCT03139799|Experimental|Puzzle Video Game Intervention|Group T will first receive the experimental and then the control intervention (T-C) In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.
89667600|NCT03139799|Active Comparator|Tablet Newspaper Reading Intervention|Group C will first receive the the control intervention and then experimental and (C-T). In phase I both groups take a baseline measurement (pre-test), then group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task). After phase II (16 weeks) both groups are post-tested again.
89667601|NCT03910530|Experimental|INCMGA00012|Single-agent INCMGA00012.
89667602|NCT03910530|Experimental|INCB001158 75 mg|Single-agent INCB001158.
89667603|NCT03910530|Experimental|INCB001158 100 mg|Single-agent INCB001158.
89667604|NCT03910530|Experimental|INCMGA00012 + INCB001158|Combination of INCMGA00012 and INCB001158.
89667605|NCT03828071|Other|stem cell transplantation|patients enrolled in this study will received autologous hematopoietic stem cell transplantation as the initial treatment.
89667606|NCT03748680|Active Comparator|A|Intensified follow-up schedule
89667607|NCT03748680|Experimental|B|Adjuvant chemotherapy + intensified follow-up schedule
89667608|NCT03827603|Experimental|patients with AIHA and CLL|patients with CLL and in Steroid Refractory AIHA receive ibrutinib 420 mg per day till progression or intolerance
89667609|NCT03589014|No Intervention|Control|Standard Treatments recommended for CCM
89667610|NCT03589014|Experimental|￼Propranolol|Initial oral dose 40 mg bid, uptitrated to 80mg bid doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
89667611|NCT04274387|Experimental|MBSR group|participants who receiving 8-week MBSR between the pretest and posttest
89667612|NCT04274387|No Intervention|passive control group|participants who not undergoing any interventions for 8 weeks between the pretest and posttest
89667613|NCT04274309||Patient's tissues exposed|Tonsil of each patient will be imaged using the medical device
89667614|NCT04274309||Patient's tissues not exposed|Tonsil of each patient will not be imaged using the medical device
89667615|NCT03503838|Experimental|Online Yoga|The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
89667616|NCT03503838|No Intervention|Wait-List Control|The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group.
89667617|NCT03830801|Experimental|IVLCM tethered capsule for biopsies|IVLCM tethered capsule for obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk.
89667618|NCT03050112|Experimental|Congenital cardiopathy|Patients having had surgery in adulthood for a congenital heart disease, at the Brugmann University Hospital. The group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015.
89667619|NCT03827525||Cognitive and Behavioral Therapy|There is no group, the study will be based on single case method. The sudy concerns 5 patients with a Williams Syndrome
89667620|NCT04885374||Amyotrophic lateral sclerosis patients|Amyotrophic lateral sclerosis patients with traditional Chinese medicine
89667621|NCT03827681|Experimental|TIPS + Vasoactive Drug|
89667622|NCT03827681|Active Comparator|SEMS + Vasoactive Drug|
89667623|NCT03048162|Active Comparator|sodium chloride|0.9% isotonic sodium chloride, 500 ml, one package in 30 minutes
89667624|NCT03048162|Active Comparator|Hydroxyethylstarch|6% hydroxyethylstarch, 500 ml, one package in 30 minutes
89667625|NCT03048162|Active Comparator|Ringer-Lactate Infusion Solution Bag|Ringer's lactate, 500 ml, one package in 30 minutes
89667626|NCT04884984|Experimental|CLL1 positive relapsed or refractory acute myeloid leukemia|
89667627|NCT03826979|Experimental|Pilates treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
89667628|NCT03046914|Experimental|HLA-B*5801 screen test|An arm in which a participant takes HLA-B*5801 test before administration of allopurinol
89667629|NCT03826511|Active Comparator|Tiszasüly mud-pack|Patients in the Tiszasüly mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
89667630|NCT03826511|Active Comparator|Kolop mud-pack|Patients in the Kolop mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
89667631|NCT04884906|Experimental|Camrelizumab combined with radiotherapy and chemotherapy|
89667632|NCT03826823|Experimental|infertile women|infertile women undergoing hysterosalpingography for evaluating fallopian tubes
89667633|NCT04885062|Experimental|UH-Participant|Potential participants with suspected OSA will be identified from the schedule of the UH Beachwood and Bolwell sleep labs.Those subjects who satisfy the study inclusion and exclusion criteria will be approached and invited to participate in the study.
89667634|NCT03046758|Experimental|Participants|
89667635|NCT03827369||ICU patient|Pulse pressure of the radical artery was obtained by arterial line. The output of the transducer was connected to an IBM PC for analysis via an A/D converter with sampling rate = 250 datapoints/sec. The pulse spectrum was analyzed with the Fourier transformation using T (period) = 1 pulse time.
89214532|NCT06089564|Active Comparator|Skit video|The video was shown to children lasting for 5 minutes. It was about oral habits, good and bad food. Video was also showed brushing technique.
89667636|NCT04870398|Active Comparator|MTA partial pulpotomy|Profound local anesthesia of the tooth and the surrounding tissues will be achieved The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of MTA. After the placement of MTA, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
89667637|NCT04870398|Active Comparator|Total Fill partial pulpotomy|The tooth will be isolated with a rubber dam and initial caries removal will be performed by using a sterile high speed diamond bur. The deeper layers of caries will be removed by using a series of different diameters sterile low speed burs. After complete caries removal and pulp tissue exposure, first cut of pulp tissue will be performed using a new sterile high speed diamond bur. After the inspection of the surgical field for residual caries and the irrigation of the cavity with physiologic saline solution, a sterile cotton pellet will be gently placed over the pulp tissue for 3 minutes. Once hemostasis is achieved, a blood-filled homogenous tissue without dark or yellowish areas will be considered essential for the placement of Total Fill BC. After the placement of the material, a resin modified glass-ionomer cement will be placed over the capping material and the cavity will be sealed with resin-bonded composite
89667638|NCT02952131|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
89667639|NCT02952131|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
89667640|NCT02952131|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
89667641|NCT03826355|Active Comparator|Stripping technique|The endometrioma is removed according to standard surgery.
89667642|NCT03826355|Experimental|Laser technique|The endometrioma is drained, everted and then the inner wall of the endometrioma is vaporised with CO2 laser
89667643|NCT03825887|Active Comparator|Group A-PCA Morphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
89667644|NCT03825887|Experimental|Group B-PCA Nalbuphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
89667645|NCT03826121|Experimental|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks
89667646|NCT03826121|Placebo Comparator|Placebo|placebo for 12 weeks
89667647|NCT03825809|Experimental|Post-Operative Non Opioid Pain Protocol|"Patients will be administered a post-operative non-opioid pain protocol consisting of:~Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam"
89667648|NCT03825809|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325
89667649|NCT03825731|Experimental|GC022|The patients will receive GC022 CAR-T treatment. GC022 dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.
89667650|NCT03825497|Experimental|Intervention|1) On admission, patients will receive a welcome folder focusing on physical activity; 2) daily during hospitalization, patients will be encouraged to walk along a walk path in the hallway; 3) during hospitalization, patients will be encouraged to consult and use posters with exercises (sit to stand, heel raise, balance); 4) on admission, patients will receive a prescribed walk plan with 3 daily walking sessions to perform during hospitalization (3 times 1 minute, 5 minutes or 10 minutes); 5) during hospitalization patients will be motivated to pick up of clothes and beverages themselves; 6) patients will be discharged with a walk plan to use at home; 7) after discharge the municipality will follow up on patients receiving home care and patients with a rehabilitation plan
89667651|NCT03825497|No Intervention|Usual care|All patients admitted to the control wards will receive usual care during and after hospitalization.
89667652|NCT03825185|Experimental|Transcervical Thymectomy|50 patients were randomized to transcervical thymectomy for treatment of myasthenia gravis.
89667653|NCT03825185|Experimental|TranssternalThymectomy|50 patients were randomized to transternal thymectomy for treatment of myasthenia gravis.
89667654|NCT03825263|No Intervention|Control|Participants receive normal treatment
89667655|NCT03825263|Experimental|Intervention|Participants administer Intermittent Pressure Compression using the Lymphassist in addition to normal treatment
89667656|NCT03824951|Experimental|Anti-CD19 iCAR NK Cells|
89667657|NCT03825029|Experimental|Pillow Group|There will be a pillow placed between the patients legs during their operation.
89667658|NCT03825029|No Intervention|Control Group|They will receive a normal total hip arthroplasty.
89667659|NCT03824873|Active Comparator|internal iliac artery ligation + cesarean hysterectomy|
89667660|NCT03824873|Active Comparator|cesarean hysterectomy|
89667661|NCT03824717|Other|Ropivacaine dosage|Dose finding study - The volume of 0.5% ropivacaine used to achieve surgical anesthesia in infraclavicular brachial plexus block
89667662|NCT03824795|Active Comparator|Group 1: 125mg b.i.d. for 10 days|Patients will be administered an oral dose of 125mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
89667663|NCT03824795|Active Comparator|Group 2: 250mg b.i.d. for 10 days|Patients will be administered an oral dose of 250mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
89667664|NCT03824795|Active Comparator|Group 3: 500mg b.i.d. for 10 days|Patients will be administered an oral dose of 500mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
89667665|NCT04392557|Active Comparator|metformin/alogliptin|metformin/alogliptin (850 mg/12.5 mg or 1000 mg/12.5 mg every 12 hours) for 12 months
89667666|NCT04392557|Active Comparator|metformin/pioglitazone|metformin/pioglitazone (850 mg/15 mg every 12 hours) for 12 months
89667667|NCT04392557|Active Comparator|triple therapy|metformin/pioglitazone (850 mg/15 mg every 12 hours)+alogliptin (12.5 mg every 12 hours) for 12 months
89667668|NCT02115373|Experimental|Phase 1b: Tepotinib 300 mg|
89667669|NCT02115373|Experimental|Phase 1b: Tepotinib 500 mg|
89214533|NCT06089564|Active Comparator|Pictorial|The pictures related to brushing technique and oral health advices such as good and bad habits was provided in the form of laminated cards. The children has taken those cards along with them.
89667670|NCT02115373|Experimental|Phase 2: Tepotinib 500 mg|
89667671|NCT03824171|Experimental|Raloxifene 60mg/Cholecalciferol 800IU to AD-102|Period 1: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
89667672|NCT03824171|Experimental|AD-102 to Raloxifene 60mg/Cholecalciferol 800IU|Period 1: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
89667673|NCT03824093|Active Comparator|AFIX Only|Practices enrolled in the AFIX only arm will receive an in-person AFIX consultation that includes assessment of current HPV vaccination rates and feedback on strategies to increase vaccination rates.
89667674|NCT03824093|Active Comparator|AFIX+ Provider Communication Training|Practices enrolled in the AFIX+ Provider Training arm will receive an in-person AFIX consultation along with a brief communication training for providers and poster and brochure displays in clinic waiting and exam rooms.
89667675|NCT02946125|Experimental|MDD-administered EYN-1601|EYN-1601 Ophthalmic Solution administered using the Eyenovia MDD
89667676|NCT02946125|Active Comparator|Phenylephrine 2.5% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 2.5% administered as an eyedrop
89667677|NCT02946125|Active Comparator|Phenylephrine 10% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 10% administered as an eyedrop
89667678|NCT01895257|Active Comparator|A: systemic chemotherapy LV5FU2 alone|Modified LV5FU2 as described in protocol (6.2.1) D1-2 +/- bevacizumab or cetuximab or panitumumab (according its previous use) every 2 weeks
89214534|NCT06089564|No Intervention|Signed Language|The oral health education related to oral habits, good and bad food was delivered via sign language with the help of children sign language teacher.
89667679|NCT01895257|Active Comparator|B:SIR-spheres+systemic chemotherapy LV5FU2|ARM B: (Hepatic Arterial Infusion) HAI-90Y radioembolization (SIR-spheres injection) + modified LV5FU2 +/- bevacizumab or cetuximab or panitumumab according its previous use (refer to protocol).
89667680|NCT02076061||GOLD stage I|
89667681|NCT02076061||GOLD Stage II|
89667682|NCT02076061||GOLD Stage III|
89667683|NCT02076061||GOLD Stage IV|
89667684|NCT02076061||Smokers/ex-smokers w/o COPD|
89667685|NCT02076061||non-Smokers w/o COPD|
89667686|NCT01894399|Experimental|Cohort 1|100 mg HM61713 single dose in Korean
89667687|NCT01894399|Experimental|Cohort 2|200 mg HM61713 single dose in Korean
89667688|NCT01894399|Experimental|Cohort 3|300 mg HM61713 single dose in Korean
89667689|NCT01894399|Experimental|Cohort 4|200 mg HM61713 single dose in Japanese
89667690|NCT01894399|Experimental|Cohort 5|300 mg HM61713 single dose in Japanese
89667691|NCT01894399|Experimental|Cohort 6|200 mg HM61713 single dose in Caucasian
89667692|NCT01894399|Experimental|Cohort 7|300 mg HM61713 single dose in Caucasian
89667693|NCT03824015|Experimental|KAPA intervention arm|KAPA participants who completed the 24-week commissioned Falls Management Exercise program received six sessions of motivational interviewing over a six-month period. KAPA intervention sessions were held in accessible, community venues located within the local authorities of Derby City, Leicestershire and Rutland Counties. The KAPA intervention was delivered face-to-face by Postural Stability Instructors, in a group setting, using motivational interviewing. Sessions lasted between 60 to 90 minutes. Postural Stability Instructors delivered KAPA intervention sessions by telephone if a participant did not, or was unable to, attend a face-to-face session.
89667694|NCT03824015|Other|Usual care|The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package.
89667695|NCT02945501|Experimental|Subjects Who Received TES SO|Participants will sleep for approximately a two hour period and receive TES SO via the NeuroConn DC Stimulator PLUS during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
89667696|NCT02945501|Sham Comparator|Received SHAM (no TES SO)|Participants will sleep for approximately a two hour period and receive a SHAM (no TES SO) during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
89667697|NCT01353547||Received anti-TNFa therapy|Received anti-TNFa therapy
89667698|NCT01353547||First-degree relative of MS patients|"First-degree relative (child, parent or sibling) of a diagnosed MS patient~A subgroup will be asked to undergo magnetic resonance imaging (MRI). Participants may be asked to donate a stool sample for gut flora analysis and a blood sample for ribonucleic acid (RNA) sequencing."
89667699|NCT01353547||Referred by the Partners MS Center|Referred by the Partners MS Center
89667700|NCT03823313|Experimental|Spiritual Care Assessment and Intervention|
89667701|NCT04392713|Active Comparator|Ivermectin arm|Participants will be administered Ivermectin with standard chloroquine regimen
89667702|NCT04392713|No Intervention|Control arm|This arm will only receive chloroquine as per existing policy of hospital
89667703|NCT02062099|Experimental|Memory complaint /MCI/ mild to moderate MA|Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients
89667704|NCT03823625|Experimental|ARM A: Nivolumab plus Ipilimumab|Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months. Platinum-based chemotherapy will be given up to 6 cycles.
89667705|NCT03823625|Experimental|ARM B: Platinum-based chemotherapy plus Nivolumab|Platinum-based chemotherapy will be given up to 6 cycles. Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months.
89667706|NCT02061787||cardiopulmonary exercise testing|patients diagnosed with pulmonary hypertension, including pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension, were evaluated by cardiopulmonary exercise testing before and after medical or balloon pulmonary angioplasty treatment
89667707|NCT02876861|Active Comparator|Surgery alone|"Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
89667708|NCT02876861|Experimental|Neoadjuvant chemotherapy and Surgery|"Experimental: Neoadjuvant chemotherapy group~Neoadjuvant chemotherapy(Gemcitabine and Cisplatin):~Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.~Surgery:~2-3weeks after Neoadjuvant chemotherapy~Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
89667709|NCT02053909|Active Comparator|Aspirin|One aspirin 81 mg capsule 2 times per day
89667710|NCT02053909|Active Comparator|Ticagrelor|One ticagrelor 90 mg capsule 2 times per day
89667711|NCT02863991|Experimental|ONC201|Single agent ONC201.
89667712|NCT01326715|Active Comparator|mangafodipir|see protocol
89667713|NCT02858219|Experimental|Botulinum toxin|"Injection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total).~First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale)."
89667714|NCT02858219|Placebo Comparator|Saline solution|Injection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
89667715|NCT03823781|Experimental|milrinone|milrinone milrinone will be administered intravenously at a rate of 0.75ug/kg/min for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
89667716|NCT03823781|Placebo Comparator|normal saline|placebo placebo (normal saline) will be administered intravenously for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
89667717|NCT03823079|Experimental|rhTPO arm|"rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
89667718|NCT03823079|Active Comparator|rhIL-11 arm|"rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
89667719|NCT02848703|Experimental|healthy volunteers|
89667720|NCT02839265|Experimental|SBRT + FLT3 Ligand Immunotherapy|"Patients will be treated with stereotactic body radiotherapy (SBRT) to a single pulmonary or extrapulmonary lesion as well as FLT3 immunotherapy.~FLT3 Ligand Therapy (CDX-301)~Daily subcutaneous injections of CDX-301 (75 ug/kg) will be administered for 5 days, beginning on the first day of SBRT.~Additional cycles of SBRT (to distinct lesions) and CDX-301 may be administered every 2-4 months to subjects who demonstrate evidence of clinical benefit (lack of treatment-related toxicity and no disease progression).~Study therapy will be discontinued in cases of treatment-related toxicity or disease progression."
89667721|NCT00988247|Experimental|BDP HFA 320 µg/day|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
89667722|NCT00988247|Placebo Comparator|Placebo|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
89667723|NCT01260402|Active Comparator|Epicardial|
89667724|NCT01260402|Experimental|Endocardial|
89667725|NCT02832401|Active Comparator|Caffeine|200 mg of caffeine powder administered in capsules
89667726|NCT02832401|Placebo Comparator|Placebo|Cellulose powder administered in capsules
89667727|NCT03046524||Parathyroid Carcinoma|Charts from participants with histopathological diagnosis of parathyroid carcinoma.
89667728|NCT03046524||Atypical Parathyroid Neoplasm|Charts from participants with parathyroid tumors with some atypical features found in parathyroid carcinoma, but not enough histologic criteria to make the diagnosis of parathyroid carcinoma.
89667729|NCT02781623||MRI|An MRI will be conducted pre-operatively, 3 months post-operatively, and 1 year post-operatively.
89667730|NCT03044808|Experimental|Lidocain|Patient gets the experimental treatment with IV lidocain 0,5mg/ml, 1,5mg/kg bolus before induction of anesthesia, after that infusion of 1,5mg/kg/h is started and continued until 2 hours after end of surgery.
89667731|NCT03044808|Placebo Comparator|Control|Patients get the same amount in ml and duration as if it was the experimental arm. Only in this arm it is isotonic saline instead.
89667732|NCT00987545|Placebo Comparator|Placebo|
89667733|NCT00987545|Experimental|QAX576|
89667734|NCT04430166|Experimental|PD-1 monoclonal antibody|
89667735|NCT00985127|Experimental|40 mg|40 mg BCX4208
89667736|NCT00985127|Experimental|80 mg|BCX4208
89667737|NCT00985127|Experimental|120 mg|BCX4208
89667738|NCT00985127|Placebo Comparator|sugar pill|
89667739|NCT00985127|Experimental|160mg|BCX4208
89667740|NCT00985127|Experimental|240mg|BCX4208
89667741|NCT00985127|Experimental|320mg|BCX4208
89667742|NCT04430478|Experimental|Volume flow group|Consecutive patients undergoing sequential volume flow measurements using percutaneous DUS
89667743|NCT04877496||Immunocompetent controls|Participants aged at least 18 years, no history of COVID19, no history of anti-CD20 treatment
89667744|NCT04877496||Patients with a treatment history of rituximab|Participants aged at least 18 years, no history of COVID19, history of at least 1 dose of anti-CD20 treatment received since 01/01/2010
89667745|NCT04877340|Other|Standard FNA 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a standard FNA 22G needle
89214535|NCT06089538|Experimental|Delirium patients group|Patients admitted for acute respiratory distress syndrome (ARDS) who developed delirium
89214536|NCT06089538|Active Comparator|Patients without delirium|Patients admitted for acute respiratory distress syndrome (ARDS) who did not developed delirium
89667746|NCT04877340|Experimental|Franseen 22G needle|The pancreatic mass will be puncture, for expert endoscopist, with a FNB 22G needle. The sequence of the use of needles will be randomized.
89667747|NCT02776475|Other|Sacral neuromodulation device turned off|Patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency (implantation for minimum 12 months) will be to have the sacral neuromodulation device turned off for four consecutive weeks.
89214537|NCT06089525||Open reduction and internal fixation (ORIF)|Patient has underwent ORIF to repair a pilon fracture.
89214538|NCT06089525||Primary arthrodesis (PA; ankle fusion)|Patient has underwent PA/ankle fusion to repair a pilon fracture.
89214539|NCT06089512|Placebo Comparator|Control group|group receiving general anesthesia only
89667748|NCT02765789|Experimental|Immunoadsorption|Immunoadsoprtion (Immunosorba). All (anticipated) 8 participants will be treated with immunoadsorption
89667749|NCT04877106|Active Comparator|Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®)|JANUMET®, 50mg/850mg, batch no. M047893, manufactured by MSD Pharma (Singapore) Pte.Ltd
89667750|NCT04877106|Experimental|Sitagliptin Phosphate/metformin Hydrochloride Tablets|50mg/850mg, batch no. 161006, manufactured by Tonghua Dongbao Pharmaceutical Co., Ltd.
89667751|NCT00981617|Experimental|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
89667752|NCT00981617|Experimental|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
89667753|NCT00981617|Experimental|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
89667754|NCT00981617|Placebo Comparator|Placebo|Matching placebo (capsules without active study drug) provided for daily oral administration
89667755|NCT04876716|Active Comparator|Azole monotherapy|"Azole monotherapy~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care."
89667756|NCT04876716|Experimental|Azole + Anidulafungin|"Azole + Anidulafungin~Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care.~Anidulafungin (Ecalta) is available as an intravenous formulation only. It will be used at the licensed dose of a 200mg loading dose on day 1 and 100mg QD thereafter. No dose adjustment is needed in patients with renal or hepatic insufficiency of any grade."
89667757|NCT04865640||Healthy Cohort|The target population for this cohort is healthy adult volunteers who do not have preexisting heart or lung conditions or illness. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders.
89667758|NCT04865640||Pathologic Cohort|The target population for this cohort is adult patients who have been diagnosed with cardiopulmonary conditions. These can include chronic pulmonary conditions, chronic cardiac conditions, and those who are taking diuretic medications, living with heart failure, Chronic Obstructive Pulmonary Disorder (COPD), or recovering from coronary-artery disease-related events. The goal is to recruit a participant population with a range of body types and BMIs and an approximately even split of genders as well as conditions outlined above (e.g. at least 5 each of COPD, HF, recovering from a coronary artery disease-related event, and taking diuretic medication)
89667759|NCT04870008|Active Comparator|2 mm|The side of patient's scar that will receive the sutures placed at 2 mm from wound edge.
89667760|NCT04870008|Active Comparator|5 mm|The side of patient's scar that will receive the sutures placed at 5 mm from wound edge.
89667761|NCT04865484|Experimental|SRES group|Surgical resection plus endoscopic stricturotomy for multiple fibrous stenosis
89667762|NCT04865484|Active Comparator|SRS group|Surgical resection plus strictureplasty for multiple fibrous stenosis
89667763|NCT04865250|Experimental|treatment|ATEZOLIZUMAB; Carboplatin; Nab-Paclitaxel
89667764|NCT04870242||pediatric surgery patients|all pediatric surgery patients, aged from 6 months up to 18 years, underwent surgery between January 2017 to December 2018
89667765|NCT04869774|Active Comparator|Virtual Monitoring|Patients discharged from hospital after colorectal surgery will have virtual monitoring of their surgical incision and symptoms, using the mobile application How2Trak, post-operatively.
89667766|NCT04869774|No Intervention|Standard of Care|Patients discharged from hospital after colorectal surgery will receive standard of care with no virtual monitoring of their surgical incision and symptoms.
89667767|NCT04876872||pediatric patients|whole pediatric patients who admitted to the pediatric emergency unit in Farabi Hospital, Trabzon, Turkey
89667768|NCT04429698|Other|POCUS group|Patients in this group underwent POCUS after primary clinical evaluation with the knowledge of their primary physician. This procedure was performed in the first hour after the patients' primary clinical evaluations to evaluate the predetermined parameters in the study form for the heart, lungs, hepatobiliary, aortic and deep veins.
89667769|NCT04429698|No Intervention|Control group|All processes and results were followed without any intervention in the processes related to the patients in this group and the results were recorded in the study form
88995436|NCT03204240|Experimental|Intervention|This group will receive electrical stimulation induced exercises in addition to their standard care during in-patient rehabilitation (IPR). Standard care will include respiration therapy, bed mobility, transfers, wheelchair mobility skills, bowel and bladder management, tone and spasticity management, and skills for performing other activities of daily living. Exercises will include neuromuscular electrical stimulation (NMES) induced-resistance exercise (RE) (1x/day) and NMES-aerobic exercise (1x/day) for 3 days/week.
89214540|NCT06089512|Active Comparator|paravertebral block group|received single-shot paravertebral block after induction of anesthesia.
89214541|NCT06089512|Active Comparator|mid transverse process block group|received a mid-transverse process -to- pleura block after induction of anesthesia.
89667770|NCT04876482|Sham Comparator|Control|Without the willingness of surgery, those participants waiting for oral appliance (Device), losing weights and using continuous positive airway pressure (Device) were distribute to control group.
89667771|NCT04876482|Experimental|Transoral robotic surgery (TORS)|The participants underwent TORS. TORS is a kind of surgery that the surgeons would remove the tonsils and the fat tissue of tongue base and suspend the soft palate.
89667772|NCT04876482|Experimental|TORS+OPR|The participants started OPR 6 weeks after TORS. Each exercise was repeated 10 times, 1-3 cycles per day, 3-5 sessions per week at their home and performed for 3 months. Patients were supervised by physical therapist once a week for 30 minutes.
89667773|NCT04865328||OAB group|Group with diagnosed overactive bladder.
89667774|NCT04876170|Active Comparator|VS-EFP Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, participants will receive musical feedback driven by their own VS-EFP
89667775|NCT04876170|Sham Comparator|Yoked sham Neurofeedback|"Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop; in this condition, the musical feedback will be provided based on another participant's VS-EFP signal. Hence, each participant from the sham group is paired with a participant from the test group, thus receiving feedback based on the paired test participant. This way, both groups are exposed to the exact proportion of sound manipulation that indicates their success level. To account for a possible contribution of the temporal order of feedback presentation, in half of the control participants, the feedback pattern will be replayed forward (maintaining the original temporal pattern of VS-EFP that the paired participant has received), and in half - backward (flipping the original temporal pattern right-to-left)."
89667776|NCT04869852|Experimental|Mango|85g mango, 4x/week
89667777|NCT04869852|No Intervention|No Mango|No mango intake
89667778|NCT04865562|Experimental|testosterone|7mg testosterone propionate
89667779|NCT04865562|Placebo Comparator|placebo|125 mg 0.5% cholorbutanol, 50mg saline, pH5
89667780|NCT04876326|Active Comparator|Autologous Adipose MSC Group|This group will receive the implantation of autologous mesenchymal stem cell origin of adipose tissue with a dose of 2 x 50 million cells given with a distance of 1 month
89667781|NCT04876326|Active Comparator|Allogeneic Umbilical Cord MSC Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord with a dose of 2 x 50 million cells given a distance of 1 month.
89667782|NCT04876326|Active Comparator|Allogeneic Umbilical Cord MSC and Adipose Secretome Group|This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord as much as 2 x 50 million followed by 2 x 10cc mesenchymal stem cell secretions from adipose tissue intravenously given at a distance of 1 month.
89667783|NCT04865094|Active Comparator|cyclic merocyanine|long-UVA absorber
89667784|NCT04865094|Placebo Comparator|placebo|
89667785|NCT04876560|Active Comparator|CDSS (intervention) group|Personalised nutritional advice: daily dietary programme with specific meals, products, recipes, food portions (in grams) based on the Meditteranean diet together with physical activity guidelines, all generated by a food database clinical decision support system (CDSS). Scheduled phone interviews every 15 days with the appointed dieticians assisted nutritional and lifestyle consultation.
89214542|NCT06089499|Experimental|Get Palliative Care: four educational learning module videos|Get Palliative Care educational learning module videos available online in the public domain. A Webinar: How to Manage Shortness of Breath and Improve Your Quality of Life (2019) presented by Tara Liberman, DO reviews how to live with COPD, where and when palliative care can be implemented, what alternatives to treatment may look like, and final provides a summary of the benefits of palliative care. Each learning module is approximately five to seven minutes in length. The four learning modules are accessible at https://youtu.be/__phRXS4jZs?si=TivFch6cFE6roXDZ. After completing the weekly learning module, the participant will log their viewing in REDCap via a link provided to the participant by the email provided at the time of enrollment.
89667786|NCT04876560|Other|Control group|"General lifestyle advice: based on the updated American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention via scheduled phone interviews every 15 days."
89214543|NCT06089499|No Intervention|Usual Care|Usual care for COPD includes oxygen therapy, steroid therapy, chest radiography, nebulized bronchodilators, and antimicrobial therapy.
89667787|NCT04876014|Experimental|GMBPMI group|Participants in the experimental group will receive GMBPMI. A new participant (a pregnant woman in the second trimester) is expected to complete the 6 EBMI lessons in 6 weeks, and do the mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. Participants will also be asked to keep log of daily mindfulness practice from T0 to T3 using Google Form. The project RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice. The RA is backed up by the PI and co-I's who are experienced mental health practitioner and mindfulness teacher. One of them is an obstetrics and gynaecology specialist.
89667788|NCT04876014|Active Comparator|Perinatal Psycho-education group|To control for attention and placebo effects, every new participant in the control group will receive weekly web-based psychoeducation program for perinatal care. The project RA will also be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences of the psychoeducation program.
89667789|NCT04865172||Patient-caregiver dyads, patients with behavioural variant frontotemporal dementia|20 patient-caregiver dyads, patients with behavioural variant frontotemporal dementia
89667790|NCT04865172||Patient-caregiver dyads, patients with Alzheimer disease|20 patient-caregiver dyads, patients with Alzheimer disease
89667791|NCT04865172||Healthy control dyads|20 healthy control dyads
89214544|NCT06089473|Other|Experimental: Multimodal prehabilitation plus usual outpatient care|A multi-modal intervention including exercise, nutritional, and psychological support.
89667792|NCT03046680|Experimental|Health Coaching|Individualized follow-up, supporting the individual for a better autonomy in personal care.
89214545|NCT06089473|Other|No Intervention: Usual outpatient care|The control group will receive usual outpatient care provided to kidney transplant candidates (which includes medical visits, nutritional, and psychological support).
89214546|NCT06089447|Experimental|Control Group|Participants will receive the intervention immediately
89214547|NCT06089447|Active Comparator|Waitlist Group|Participants will be allocated to a waitlist group and will receive the intervention aft 6 months.
89214548|NCT06089421|Active Comparator|Standard of care telegenetics with a UVA genetic counselor (GC) for pre-test counseling|Pre-genetic test counselling with a genetic counselor from the University of Virginia
89214549|NCT06089421|Experimental|Novel interventional arm of pre-test counseling via GIA|Pre-genetic test counselling through novel chat bot Genetic Information Assistant (GIA)
89214550|NCT06089408|Experimental|Arm I (weighted blanket)|Patients use a weighted blanket for 30 minutes during the infusion appointment.
89214551|NCT06089408|Active Comparator|Arm II (regular blanket)|Patients use a regular blanket for 30 minutes per standard of care during the infusion appointment.
89214552|NCT06089382|Experimental|Sintilimab Plus Lenvatinib|
89214553|NCT06089382|Active Comparator|TACE(one cycle) + active surveillance|
89214554|NCT06089369|Experimental|Sintilimab|
89667793|NCT03046680|Active Comparator|Multiprofessional Team|Physician, nurse, nutrionist usual care.
89667794|NCT04864938||Patients: ICU treated covid-19 patients|Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
89667795|NCT04864938||Control group 1, covid-19 patients treated in the regular wards|As above, without 6 minute walk test or routine chest x-ray
89667796|NCT04864938||Control group 2, persons with covid-19 without hospitalization|As above, but without respiratory testing
89667797|NCT04864938||Control group 3, non-covid controls|As control group 2
89667798|NCT04875546|Active Comparator|Standard treatment|"A 5'A' and '5'R' models~STAR method for quitting"
89667799|NCT04875546|Active Comparator|Integrated Intervention|"A 5'A' and '5'R' models~Receive brief advice on alcohol use based on the FRAMES model~Complete the Alcohol Use Disorders Identification Test"
89667800|NCT04875546|Sham Comparator|Control|Participants will receive two leaflets.
89667801|NCT04864860|Experimental|intervention arm|"The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). This dose was selected to be similar to previous studies that shows no harm or sever adverse effect on participants (12, 14)."
89667802|NCT04864860|Placebo Comparator|placebo arm|"The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/)."
89667803|NCT03046368|No Intervention|Standard cover letter|"The group will receive a standard cover letter to the survey that is designed to have broad appeal:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark."
89667804|NCT03046368|Experimental|Targeted cover letter 1|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sleep problems."
89214555|NCT06089369|Active Comparator|TACE(one cycle) + active surveillance|
89214556|NCT06089356|Active Comparator|zolmitriptane|zolmitriptane tablet daily
89214557|NCT06089356|Active Comparator|topiramate|topiramate tablet daily
89214558|NCT06089356|Active Comparator|valproate|valproate once daily
89214559|NCT06089343||Culprit|Plaques which is related with acute coronary syndrome
89214560|NCT06089343||Non-culprit|Plaques which is not related with acute coronary syndrome
89214561|NCT06089330|Experimental|JMT101+SG001+ Irinotecan|
89214562|NCT06089330|Experimental|JMT101+Irinotecan|
89214563|NCT06089330|Active Comparator|Regorafenib (Stivarga)|
89214564|NCT06089304||Ischemic cohort|All patients sustaining an ischemic event (i.e., cardiovascular death, myocardial infarction, stroke, or stent thrombosis) within 1 year of PCI.
89667805|NCT03046368|Experimental|Targeted cover letter 2|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and contact to family and friends."
89667806|NCT03046368|Experimental|Targeted cover letter 3|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sex"
89667807|NCT03046368|Experimental|Targeted cover letter 4|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and contact to family and friends."
89667808|NCT03046368|Experimental|Targeted cover letter 5|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and sex."
89214565|NCT06089304||Bleeding cohort|All patients sustaining a major bleeding event (i.e., Bleeding Academic Research Consortium type 3-5) within 1 year of PCI.
89667809|NCT03046368|Experimental|Targeted cover letter 6|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sex and contact to family and friends."
89667810|NCT03046368|Experimental|Targeted cover letter 7|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and contact to family and friends."
89667811|NCT03046368|Experimental|Targeted cover letter 8|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and alcohol."
89667812|NCT03046368|Experimental|Targeted cover letter 9|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, alcohol and contact to family and friends."
89667813|NCT03046368|Experimental|Targeted cover letter 10|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as alcohol, sleep problem and contact to family and friends."
89667814|NCT04864704|Active Comparator|Infraspinatus|Subjects infraspinatus stiffness was measured and observed
89667815|NCT04864704|Active Comparator|Erector spinae|Subjects erector spinae stiffness was measured and observed
89667816|NCT04864704|Active Comparator|Gastrocnemius|Subjects gastrocnemius stiffness was measured and observed
89667817|NCT04875858|Active Comparator|healthy old adults aged 70-75 years who received PPSV23|Recruitment of 254 healthy 70-75-year healthy old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
89667818|NCT04875858|Experimental|old adults who have diabetes mellitus aged 70-75 years who rec|Recruitment of 254 healthy 70-75-year diabetic old adults who meet the selection and exclusion criteria and voluntarily agree to participate in this study. Vaccination -Based on guidelines for vaccination. Injecting muscles on the triceps Visit 4 weeks after vaccination ․ Blood sample collection for evaluation of immunogenicity (10 mL) ․ Comparison of GMT and seroconversion rates of IgG antibody titers against 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F) -Comparison of GMT and seroconversion rates of opsonophagocytic killing assay (OPA) for four pneumococcal serotypes (serotypes 5, 6B, 18C, 19A)
89667819|NCT03047850||Study Group|All patients included in this study.
89667820|NCT04865016|Active Comparator|MIOL Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with a low add (+2.75 Diopters [D]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group).
89667821|NCT04865016|Active Comparator|EDOF Group|30 eyes of 15 cataract patients undergoing cataract surgery were implanted with an EDOF (Tecnis Symfony [ZXR00]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
89667822|NCT00984659|Experimental|FSC|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
89667823|NCT00984659|Experimental|SAL|Salmeterol 50mcg DISKUS twice a day
89667824|NCT00984659|Placebo Comparator|Placebo|Placebo DISKUS twice a day
89667825|NCT04864314|Placebo Comparator|Control group|Group supplemented with a daily dose of placebo
89667826|NCT04864314|Experimental|Experimental group|Group supplemented with a daily dose of TetraSOD®
89667827|NCT04875312|Experimental|Group USC|Effect of ultrasound cavitation sessions on sex hormones in obese infertile patients with poly cystic ovarian syndrome
89667828|NCT04875312|Experimental|Group EA|Effect of electro acupuncture on sex hormones in obese infertile patients with poly cystic ovarian syndrome
89667829|NCT00982319|Experimental|Broccoli sprout extract|Patients will be randomized to 14 day intervention of broccoli sprout extract and mango juice consisting of a dose of 100 µmols of sulforaphane dissolved in 150 mL mango juice once a day.
89667830|NCT00982319|Placebo Comparator|Mango juice|Patients will be randomized to 14 day intervention of 150 mL mango juice without broccoli sprout extract extract once a day.
89667831|NCT03044496||Supraclavicular Nerve Block|Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.
89667832|NCT04875468|Active Comparator|Zirconia crown cemented by adhesive resin cement|MultiRein link adhesive resin cement (non MDP, non-calcium and fluoride releasing cement)
89667833|NCT04875468|Experimental|Zirconia crown cemented by self-adhesive resin cement|TheraCem self-adhesive resin cement (MDP, calcium and fluoride releasing cement)
89667834|NCT04875000|Active Comparator|UltraEZ|"Group of patients randomly assigned to receive the the application of the commercial fluoride remineralizing and desensitizing agent UltraEZ (Ultradent Products, Inc, South Jordan, UT, USA) after teeth bleaching"
89667835|NCT04875000|Experimental|Arginine|Group of patients randomly assigned to receive the the application of the 2.5% arginine solution after teeth bleaching
89667836|NCT04875000|Experimental|Nano-hydroxyapatite|Group of patients randomly assigned to receive the application of the 2.5% nano-hydroxyapatite solution after teeth bleaching
89667837|NCT04874844|Other|Test drug group|Phase II Dose Addition Stage JY025 12MG / KG and 16mg / kg Q3W Givenate Combined EGFRTKI (Gifan Totibi 250mg or Erlotini 150mg) QD scheme, 6 cases of each dose group in group (Gifanibini 3 cases of Erlotini); 1 or 2 doses of JY025 in dose expansion phase Q3W administration combined with EGFR-TKI (50mg or Ellotini 150mg) QD scheme, each dose group 6 Examples of subjects (3 cases of Gifeng Tinib and Ellotini).
89667838|NCT04874844|Active Comparator|Group type|Phase III 396 patient JY025 injection and placebo combined with Notes Totibi / Erlotini (Gifeng Totibi 250mg or Erlotini 150mg) Q3W QD treatment group is randomly packet in 1: 1 ratio (in each group) Gifanibi and Erlotini are 2: 1)
89667839|NCT04430088|Experimental|VVZ-149 Injections|
89667840|NCT04430088|Placebo Comparator|Placebo|
89667841|NCT03046290|Active Comparator|Pudendal Block|The anesthesia is produced by blocking the pudendal nerves near the ischial spine of the pelvis.Local anesthetic (mixed of ropivacaine and lidocaine) is injected into the pudendal canal where the pudendal nerve is located.
89667842|NCT03046290|Active Comparator|Penian Block|The anesthesia is produced by blocking the dorsal penile nerves. Local anesthetic (mixed of ropivacaine and lidocaine)is injected under the pubis symphysis just below the Buck fascia where the nerve is located.
89667843|NCT04874688|Active Comparator|IYCF-Only|Infants in the IYCF-only arm will receive white maize and SQ-LNS daily from 6 months of age, and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
89667844|NCT04874688|Experimental|IYCF-Plus|Infants in the IYCF-plus arm will receive orange provitamin A-fortified maize and SQ-LNS daily from 6 months of age, plus powdered NUA-45 sugar beans, moringa leaf powder, and powdered whole egg; and the primary caregiver will receive a series of behaviour-change modules delivered by village health workers.
89667845|NCT03044340|Experimental|erythermalgia patient|patient will be measured chlorine ions impedance with the SUDOSCAN and evaluation on pain du to temperature with the THERMOTEST
89667846|NCT04874298|Experimental|Intervention Arm 1 (Ginger Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use ginger oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
89667847|NCT04874298|Experimental|Intervention Arm 2 (Peppermint Group)|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
89667848|NCT04874298|No Intervention|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
89667849|NCT04874142|Experimental|A Group|Two cohort, single sequence
89667850|NCT04874142|Experimental|B Group|Two cohort, single sequence
89667851|NCT03045900|Active Comparator|Translucent bulk-fill resin composite|*Shaded bulk-fill resin composite. Bulk-fill resin composite which has no shade and could match any other shade. It will be compared for shade accuracy to the haded bulk-fill resin composite.
89667852|NCT03045900|Experimental|Shaded bulk-fill resin composite|*Translucent bulk-fill resin composite Bulk-fill resin composite which has a specific shade and should only be filled in teeth with the corresponding shade
89667853|NCT03045822|Experimental|Patients with cardiac implantable electronic devices|
89667854|NCT04869150||those with myocardial bridges|
89667855|NCT04869150||those without myocardial bridges|
89667856|NCT03823235|Experimental|Culture of human embryo in non-humidified incubator|Embryo culture after in vitro fertilization in incubator with no humidity
89667857|NCT03823235|No Intervention|Culture of human embryo in humidified incubator|Embryo culture after in vitro fertilization in incubator with humidity
89667858|NCT02612064|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
89667859|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
89214566|NCT06089252|Other|HSV-1, HSV-2|All participants were assigned to receive topical treatment with Lazolex® Gel. Patients were given the gel at the end of the screening visit (day 0) by the attending physicians.,e gel was applied to the lesion four times a day over a 10-day period, with the Lrst application at 9 am and the fourth at 9 pm. Patients administered Lazolex® Gel to the a2ected areas themselves.
89667860|NCT04553003|Experimental|glucocorticoid+hepatoprotectant group|glucocorticoid 0.4mg/kg/d+hepatoprotectant for 7d
89667861|NCT04553003|Active Comparator|hepatoprotectant group|hepatoprotectant for 7d
89667862|NCT03044184|Active Comparator|Intervention|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours."
89214567|NCT06089213|Experimental|Interactive services|"Otago exercises performed in real-time or synchronous mode of digital health care. It consists of direct communication between physiotherapist and the patient."
89667863|NCT03044184|No Intervention|Control|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours."
89667864|NCT02928341|No Intervention|No intervention|Current water supply access
89214568|NCT06089213|Active Comparator|Remote telemonitoring|Otago exercises performed remotely, using technologies such as messaging apps. It consists of indirect communication between physiotherapist and the patient.
89214569|NCT06089200|Experimental|Transversus Abdominis Plane Block|Twenty two subjects were given postoperative block administration in the transversus abdominis area on each side with ultrasonography (USG) guidance
89214570|NCT06089200|Active Comparator|Spinal Morphine|Twenty two subjects were given additional morphine 100 µg intrathecally
89214571|NCT06089174|Experimental|Exposed (Runners)|Ultra-endurance runners taking part in an ultra-trail of 72 km, 109 km or 165 km
89667865|NCT02928341|Experimental|Intervention|Received water supply improvement intervention designed to improve access to tap water, consisting of community managed public taps, improved tap water distribution network, refurbished tap connections and promotion of new household tap connections.
89667866|NCT04395209|Experimental|stroke individuals|
89667867|NCT04395209|Active Comparator|healthy individuals|
89667868|NCT03822689|Active Comparator|Gas flow:2L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
89667869|NCT03822689|Active Comparator|Gas flow:5L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
89667870|NCT04868448||Vaccinated participants|Participants who received 1or 2 doses of the Covid-19 vaccines
89667871|NCT04868448||Unvaccinated participants|Participants who have not received any dose of the Covid-19 vaccines
89667872|NCT03822767|Experimental|Experimental Group|sIPV-sIPV-bOPV vaccination schedule
89667873|NCT03822767|Active Comparator|Control Group|wIPV-wIPV-bOPV vaccination schedule
89667874|NCT03047772|Placebo Comparator|Phase A: Atorvastatin|Atorvastatin routine dose + placebo transplantation
89667875|NCT03047772|Experimental|Phase A: Low dose BMMSC|Atorvastatin routine dose + low dose BMMSC Transplantation
89667876|NCT03047772|Experimental|Phase A: Middle dose BMMSC|Atorvastatin routine dose + middle dose BMMSC Transplantation
89667877|NCT03047772|Experimental|Phase A: High dose BMMSC|Atorvastatin routine dose + high dose BMMSC Transplantation
89667878|NCT03047772|Placebo Comparator|Phase B: Atorvastatin|Atorvastatin routine dose + placebo transplantation
89667879|NCT03047772|Active Comparator|Phase B: Atorvastatin+Transplantation|Atorvastatin routine dose+ Optimal dose BMMSC Transplantation
89667880|NCT03047772|Placebo Comparator|Phase B: Intensive Atorvastatin|Atorvastatin Intensive dose + placebo transplantation
89667881|NCT03047772|Experimental|Phase B: Intensive Atorvastatin+Transplantation|Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation
89667882|NCT03822611|Experimental|Targeted Subsidy|In these communities, households identified as vulnerable receive a voucher for a free latrine sub-structure (slab + pit lining), redeemable with local sanitation suppliers.
89214572|NCT06089174|No Intervention|Non-exposed (companions)|Runners' companions not running
89214573|NCT06089148||contrast enhanced mammography, tomosynthesis and MRI|CEDM and tomosynthesis versus MRI
89667883|NCT03822611|No Intervention|No subsidy|In these communities, no household receives a voucher.
89667884|NCT02926235|Experimental|Amino Acid|Patients will be asked to ingest 20g of EAA o two times a day between meals 1 week prior and 2 weeks postoperatively.
89667885|NCT02926235|Placebo Comparator|Placebo|Patients will be asked to ingest 20g of placebo two times a day between meals 1 week prior and 2 weeks postoperatively.
89667886|NCT02926079||Pregnant women diagnosed with gestational diabetes|
89667887|NCT02926079||Pregnant women with normal pregnancy|
89667888|NCT04863690|Experimental|Sleep Intervention System - No Coaching|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations), as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks.
89667889|NCT04863690|Experimental|Sleep Intervention System - Plus Digital Coaching|The procedure will be identical to Group 1 above, but in addition, all participants will also work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
89667890|NCT04863690|Experimental|Sleep Intervention System - Plus Digital Coaching plus Human Coaching|The procedure will be identical to Group 2 above, but in addition, all participants will be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account. Throughout the coaching, all participants will be referred to via their first names or their anonymized login names. In addition, for any challenges that arise, participants will have unlimited access to Muse Customer Care via phone, email, and video where appropriate during normal business hours.
89667891|NCT04863690|No Intervention|Control|The participants in the control group will receive a Muse Device, which they will be free to keep at the end of the study. They will be asked not to open and/or use the Muse device until the entire study is complete. On day 1 of the Study, they will complete the Cambridge Brain Sciences online cognitive assessment battery), plus a longer questionnaire about stress levels, workplace wellness, quality of life, mindfulness and (depending on group), sleep quality. At the completion of the study controls will be offered optional, free group coaching sessions if they complete the study requirements.
89667892|NCT03047538|Active Comparator|Free combination|Free combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks free combination will be changed to fixed combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
89667893|NCT03047538|Active Comparator|Fixed combination|Fixed combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks fixed combination will be changed to free combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
89667894|NCT03822533|Other|Physiotherapist as primary assessor|"The healthcare process will be started with a physiotherapist assessment and treatment. Treatments could involve individual or group treatment including patient education and physical exercise.~Patients can seek a physician anytime after the first assessment with the physiotherapist."
89667895|NCT03822533|Other|Physician as primary assessor|"The Healthcare process will be started with a physician assessment and treatment. Treatments could involve drug prescription, referral to x-ray, referral to other healthcare providers and sick-leave.~Patients can seek a physiotherapist anytime after the first assessment with the physician."
89667896|NCT01728805|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
89667897|NCT01728805|Active Comparator|Vorinostat|vorinostat 400 mg once daily
89667898|NCT03822143|Experimental|Fetus anemia diagnosis|Diagnosis of anemia in the fetus through use of ultrasound data collection
89667899|NCT03045666|Experimental|Intervention group|Patients stable on Macitentan therapy will exercise twice a week for 12 weeks, supervised by physiotherapists. The exercise program includes aerobic and strength exercises, at 2-3 minutes intervals.
89667900|NCT03045666|No Intervention|Control Group|Patients stable on Macitentan therapy that will continue to receive it, without exercise.
89667901|NCT03822455|Active Comparator|OligoG DPI|Active DPI containing the oligosaccharide OligoG and excipients
89667902|NCT03822455|Placebo Comparator|Placebo DPI|Placebo DPI containing lactose and excipients
89667903|NCT04863456|Experimental|HIPA group of Puget grade 1|the tumor abuting or displacing the hypothalamus in the preoperative MR images
89667904|NCT04863456|Experimental|HIPA group of Puget grade 2|hypothalamic involvement (the hypothalamus is no longer identifiable) in the preoperative MR images
89667905|NCT02921477|Experimental|Bosutinib Treatment Arm|Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.
89667906|NCT02921009|Experimental|Crosslinking at different fluence rates|The study will investigate the effectiveness of Transepithelial riboflavin .25% treated with Ultraviolet light at fluence rates of 9mw/cm2 and 18mw/cm2 in the treatment of diagnosed keratoconus, pellucid marginal degeneration or post-LASIK ectasia.
89667907|NCT03822065|Experimental|Sequence 1: LY03005 Fed Crossover to Fasted|Sequence 1 will receive a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 2.
89667908|NCT03822065|Experimental|Sequence 2: LY03005 Fasted Crossover to Fed|Sequence 2 will receive a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 2.
89667909|NCT03821987|Experimental|BFCA regimen|"Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d.~BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT."
89667910|NCT02035813|Experimental|Ribociclib in combination with standard endocrine therapy|Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
89667911|NCT02035813|Experimental|Eriubulin|Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
89667912|NCT01724437|Active Comparator|Loss of pace capture|"Pulmonary vein isolation: Ablation along the ablation line is continued until loss of pace capture along the ablation line is achieved~catheter based pulmonary vein isolation"
89667913|NCT01724437|Active Comparator|Conventional|"Pulmonary vein isolation: Ablation is discontinued when electrical isolation of the pulmonary veins is achieved.~catheter based pulmonary vein isolation"
89667914|NCT04273763|Experimental|Group A|Treatment group
89667915|NCT04273763|Active Comparator|Group B|Control group
89667916|NCT02250469|Active Comparator|Axium SCS System|Implantation with the Axium Neurostimulator
89667917|NCT02250469|Active Comparator|Medtronic SCS System|Implantation with the Medtronic Prime Advanced Dorsal Column Stimulation System
89667918|NCT04392089||COVID-19|Mechanically ventilated COVID-19 patients with severe ARDS included within 3 days from time of intubation
89667919|NCT03821909||Pancreatic cancer|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology.
89667920|NCT03821909||Benign pancreatic diseases|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology, e.g. PCLs.
89667921|NCT03821753||Case|Patients with glycemic variability, defined by a coefficient of variation (CV)> 36%, calculated from continuous glucose measurements data by Free Style Libre® (Abbott)
89667922|NCT03821753||Control|Patients without glycemic variability, defined by a coefficient of variation (CV) ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case group for HbA1c (+/- 0.5%)
89667923|NCT03821441|Experimental|bOPV(Candy)|"bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
89667924|NCT03821441|Experimental|bOPV(Liquid)|"bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops each person;be be equivalent to 0.1ml each person )"
89667925|NCT03821441|Experimental|bOPV（liquid）|bOPV(Liquid):Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral Produced by Beijing Tiantan Biological Products Co., Ltd. 1.0ml each bottle,2 drops each person(be be equivalent to 0.1ml each person).(total content of polio virus≥6.12lgCCID50，type1 polio virus≥6.0 lgCCID50，type 3 polio virus ≥5.5lgCCID50 in each 0.1 ml)
89667926|NCT03821597|Experimental|Sequential compression devices|Sequential compression devices (SCDs) are applied during surgery.
89667927|NCT03821597|Active Comparator|No sequential compression devices|No sequential compression devices are applied.
89667928|NCT03820427||bronchial asthma|Patients with known or suspected asthma.
89667929|NCT03820427||pulmonary healthy controls|Patients without known or suspected pulmonary disease
89667930|NCT03820115|Experimental|Elastic abdominal binder|
89667931|NCT03820115|No Intervention|No binder|
89667932|NCT03820037|Active Comparator|OPC, Ongentys|Single oral doses of 50 mg opicapone, administered using the reference (Ongentys ®) active pharmaceutical ingredient (API) source
89667933|NCT03820037|Experimental|BIA 9-1067|Single oral doses of 50 mg opicapone, administered using the test (BIA 9-1067)
89667934|NCT03821285|Experimental|pulmonary rehabilitation|Pulmonary rehabilitation program
89667935|NCT03821207|Active Comparator|The exercise group|The group will be instructed to perform stretching exercises including the pelvic and lumbar regions 3 times a day for the first 3 days of the menstrual cycle
89667936|NCT03821207|Active Comparator|The abdominal massage group|The group will be instructed to massage the abdomen for 10 mins a day on the first 3 days of the menstrual cycle.The massage is to be applied as effleurage (light touch) clockwise over the abdomen
89049153|NCT04654182|Experimental|Log reduction in bacterial count|Following pre-test period qualifying participants will wash their hands with 4% CHG product 3 times a day over the 5 day study period. Bacterial counts will be taken at 6 and 12 hours after the final wash on day 5 and reductions calculated from the starting count to final count.
89667937|NCT03821207|Placebo Comparator|The control group|The control group will perform no exercise or massage.
89667938|NCT03821363|Experimental|Low dose group|SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
89667939|NCT03821363|Experimental|Middle dose group|SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
89667940|NCT03821363|Experimental|High dose group|SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
89667941|NCT04391933|Other|MRI colon cancer|MRI scan of patients with colon cancer
89667942|NCT03829007|Experimental|PD-L1 imaging|89Zr-durvalumab iv injection followed by a PET/CT scan at day 5 after injection.
89667943|NCT02614560|Experimental|Pre-allo (before stem cell transplant)|Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)
89667944|NCT02614560|Experimental|Post-allo (after stem cell transplant)|Post-allo vadastuximab talirine
89667945|NCT03823859||Healthy volunteers|"Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~Indirect calorimetry~Dual energy X-ray Absorptiometry (DXA)"
89667946|NCT03823859||Patients with thyroid dysfunction|"Patients with Primary hypothyroidism newly diagnosed, Primary hypothyroidism substituted, hyperthyroidism, secondary hypothyroidism~Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~Indirect calorimetry~Dual energy X-ray Absorptiometry (DXA)"
89667947|NCT04863378|Experimental|Walkers|Walkers continuously wear an actigraph watch to assess activity level. Daily sleep behavior is captured on an under-the-mattress sleep sensor. Participants walk 1-mile routes in triads, three times a week for 16 weeks while engaging in prompted conversational reminiscence recorded for a digital archive.
89667948|NCT03828929|Experimental|Vitamin C and Thiamine|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
89667949|NCT03828929|Placebo Comparator|Placebo|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
89667950|NCT04873440|Experimental|Manganese plus Radiotherapy|Subject received standard-of-care radiotherapy or stereotactic body radiation therapy (SBRT) to one metastatic site. Manganese inhalation began 1 week after the start of radiotherapy and lasted up to 6 months. The same systemic therapy before the enrollment will be maintained.
89667951|NCT02915939|Experimental|Treatment Group|The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
89049154|NCT02905409|Active Comparator|4PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 4PD (papillary diameter) group, patients were given 4PD diameter of ILM (internal limiting membrane) peeling in surgery.
89049155|NCT02905409|Experimental|2PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 2PD (papillary diameter) group, patients were given 2PD diameter of ILM (internal limiting membrane) peeling in surgery.
89049156|NCT04625712|Experimental|Group A (experimental arm, surgery intervention)|Cholecystectomy within the first week after a mild acute biliary pancreatitis.
89049157|NCT04625712|Active Comparator|Group B (active comparator, surgery intervention)|Cholecystectomy four weeks later a mild acute biliary pancreatitis.
89049158|NCT02905487||GDM|Mother-child pairs from mothers with GDM diagnosis (ADA, 2012)
89049159|NCT02905487||No GDM|Mother-child pairs from mothers without GDM diagnosis (ADA, 2012)
89049160|NCT02905448|Experimental|Low fat plant-based diet|Low fat plant-based nutrition: low fat plant-based diet supplemented with plant-based meal replacements
88995437|NCT03204240|No Intervention|Control|This group will receive standard care plus passive dynamic exercise of the lower legs (sham treatment for NMES-RE, 1x/day) and transcutaneous electrical nerve stimulation (TENS, sham treatment for NMES-aerobic exercise, 1x/day) during IPR.
88995438|NCT03177681|Experimental|Group 1 - Antibiotics Taken During Past 2 Weeks|"Group 1: Participant was on antibiotics anytime during the past 2 weeks prior to the time of enrollment.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
88995439|NCT03177681|Experimental|Group 2 - No Antibiotics Taken During Past 2 Weeks|"Group 2: Participant has not been on antibiotics in the past 2 weeks.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
88995440|NCT03132675|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab
88995441|NCT03122925||Control|Healthy subjects
88995442|NCT03122925||Friedreich's Ataxia|Diagnosed for Friedreich's Ataxia
88995443|NCT03110744|Experimental|Palbociclib|application on 21 consecutive days of a 28 days cycle
88995444|NCT03056040|Experimental|Ravulizumab|"On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg). Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
88995445|NCT03056040|Active Comparator|Eculizumab|"Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
88995446|NCT03021499|Experimental|Voclosporin|oral, 23.7 mg twice daily (BID)
89667952|NCT02915939|No Intervention|Usual Care Group|The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
89667953|NCT04863066|Experimental|CAR-T-cell therapy|Four patients with plasma HIV RNA <50 copies/ml and CD4+T cell count more than 350 cells/μl receiving at least one-year antiviral treatment are injected intravenously with 1×10^5 CAR-T cells/kg body weight. If the dosage of 1×10^5 CAR-T cells/kg body weight is well tolerated, 5×10^5 CAR-T cells/kg body weight will be infused for another 4 subjects who meet the inclusion and exclusion criteria.
89667954|NCT04867980|Experimental|ABCD|Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be >= 5 days between each dose.
89667955|NCT04867980|Experimental|BDAC|Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be >= 5 days between each dose.
89667956|NCT04867980|Experimental|CADB|Participant will receive a single oral dose of 4 study treatments with the sequences of CADB. The washout period will be >= 5 days between each dose.
89667957|NCT04867980|Experimental|DCBA|Participant will receive a single oral dose of 4 study treatments with the sequences of DCBA. The washout period will be >= 5 days between each dose.
89667958|NCT03821675|Active Comparator|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
89667959|NCT03821675|Sham Comparator|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
89667960|NCT03044262|Experimental|Cohort 7|This is a sub-study testing the effect of real output applied under two adhesive strips (standard adhesive strip and new adhesive strip) on the skin after 8 hours.
89667961|NCT01450085|Active Comparator|GeneXpert|Point of care GeneXpert
89667962|NCT01450085|Active Comparator|LED Microscopy|Point of care LED Microscopy
89667963|NCT01450241|Experimental|Early antibiotic discontinuation|Antibiotic treatment stopped after 72h, regardless of fever.The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
89667964|NCT01450241|Other|Usual practice|Antibiotic treatment continued according to accepted guidelines and current clinical practice. The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
89667965|NCT03045588|Experimental|Low group|This subjects in this group conducts all their morning exercise sessions with high fat oxidation (in a fasted condition). Thus, the subjects in this group after high intensity exercise in the evening do not get any carbohydrates to eat after training until the exercise session the following morning has been conducted.
89667966|NCT03045588|Active Comparator|High group|This subjects in this group conducts all their morning exercise sessions with low fat oxidation (in a fed condition). Thus, the subjects in this group after high intensity exercise in the evening do get carbohydrates to eat after training until the exercise session the following morning has been conducted.
89667967|NCT01314157|Experimental|Physiotherapy treatment technique|"Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with technical isostretching"
88995447|NCT03021499|Placebo Comparator|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
88995448|NCT02924038|Experimental|IMA950/poly-ICLC subcutaneous (subQ) + Varlilumab IV|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously followed immediately by a Varlilumab 3mg/kg infusion (intravenously) -23±2 days (about 3 weeks) before the date of scheduled standard-of-care surgery to remove the WHO grade II glioma. Patients will continue receiving IMA950/poly-ICLC subcutaneous injections every week leading up to surgery (Days -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). After surgery, patients will continue receiving a Varlilumab infusion every 6 weeks immediately following the IMA950/poly-ICLC injection (Weeks A1, A7, A13, and A19).
89667968|NCT01314157|No Intervention|Patients remained on the waiting list|Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with control group.
89667969|NCT04391621|Experimental|Adipose Derived Stem Cell(ADSC) arm|In this arm, the participant selected keloid will receive a single dose intra-lesional Adipose derived Stem cells infiltration. This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6).
89667970|NCT04391621|Active Comparator|Triamcinolone Acetanoide (TAC) arm|"This arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid.~This will be a single dose infiltration of 40mg/cubic centimetres."
89667971|NCT04391465|Experimental|Patients Scheduled for Elective Electrophysiological Study|"High right atrial pacing will occur at the following rates for 60 seconds each, with a rest period of at least 60 seconds between pacing runs:~600 msec (100 bpm)~500 msec (120 bpm)~400 msec (150 bpm)~350 msec (171 bpm)"
89667972|NCT01669122|Experimental|Prototype 1|4mg nicotine lozenge administered orally as a single dose treatment per subject
89667973|NCT01669122|Experimental|Prototype 2|4mg nicotine lozenge administered orally as a single dose treatment per subject
89667974|NCT01669122|Experimental|Prototype 3|4mg nicotine lozenge administered orally as a single dose treatment per subject
89667975|NCT01669122|Active Comparator|Reference Therapy|4mg nicotine lozenge (internationally marketed) to be administered orally as a single dose treatment per subject.
89667976|NCT01311115|Experimental|Group commitment contracts|"In addition to education and counseling, the intervention includes the following components:~Each participant is encouraged to deposit his cigarette money on a weekly basis, to be returned only if the smoker quits successfully within three months.~The project gives a series of two matching contributions of 150 baht each to participants who meet certain deposit requirements.~Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
89667977|NCT01311115|Active Comparator|Education and counseling|Participants in this group receive educational pamphlets about quitting smoking and one-time, group counseling from a nurse trained in smoking cessation counseling.
89667978|NCT01450475|Experimental|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
89667979|NCT01450475|No Intervention|control|A blood cuff was around leg without inflation or deflation.
89667980|NCT03629483|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours (equivalent to dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
89667981|NCT03629483|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
89667982|NCT04873284|Experimental|Fosaprepitant|Patients received intravenous Granisetron plus dexamethasone followed by fosaprepitant infusion
89667983|NCT04873284|Experimental|Aprepitant|Patients received intravenous Granisetron plus dexamethasone followed by oral aprepitant
89667984|NCT04872972|Other|Before/After|Before and after simulation; Institutional faculty and facilities
89667985|NCT01450709||Dialysis patients|
89667986|NCT01450865|Experimental|Placebo first|Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
89667987|NCT01450865|Experimental|Flupirtine first|Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
89667988|NCT01308619|Active Comparator|Oracea®|Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules
89667989|NCT01308619|Active Comparator|placebo|placebo
89667990|NCT01451177|Experimental|Treated|
89667991|NCT02611752|Experimental|CAM2038 q1w, 24 mg|CAM2038 q1w 24 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
89667992|NCT02611752|Experimental|CAM2038 q1w, 32 mg|CAM2038 q1w 32 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
89667993|NCT01307605|Active Comparator|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
89667994|NCT01307605|Active Comparator|Rituximab plus Lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
89667995|NCT04758689|Experimental|Laser acupuncture and aerobic exercise|
89667996|NCT04758689|Experimental|Aerobic exercise|
89667997|NCT01451333|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
89667998|NCT01451333|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
89667999|NCT01702831|Experimental|BuMel + lenalidomide Maintenance|I.V. Busulfan + I.V. Melphalan for conditioning prior ASCT, followed by Lenalidomide maintenance at day 100 after ASCT.
89668000|NCT03047382|Active Comparator|Worthing Hospital site|AKI Care bundle instituted at Worthing site
89668001|NCT03047382|No Intervention|Chichester Hospital site|Continues standard care
89668002|NCT01451801|Other|HBsAg|
89668003|NCT03045510|Experimental|Ultra small dose decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
89668004|NCT01451879||Age 0 months to 65 years|Confirmed diagnosis of Pompe Disease, and clinically prescribed immune modulation regimen with agents such as rituximab, sirolimus, methotrexate, IVIg or other immunomodulatory agents such as pharmacological chaperone Miglustat, N-butyldeoxynojirimycin (NB-DNJ), alone or in combination, at the discretion of their primary/specialist caregiver.
89668005|NCT03045198|Experimental|Azithromycin|oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks
89668006|NCT01451957|Experimental|Exercise|90 min exercise on Day 1
89668007|NCT01451957|Experimental|Sedentary Control|Subjects remain sedentary on Day 1 and will either consume a hyper-caloric or a caloric balanced diet
89668008|NCT04429230|Active Comparator|Real tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
89668009|NCT04429230|Sham Comparator|Sham tPCS|Patients of Huntington's disease will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
89668010|NCT01452035|Experimental|Exercise|
89668011|NCT01452035|No Intervention|Sedentary Control|
89668012|NCT03047460||healthy|"healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses~Intervention: multimodal evoked potentials"
89668013|NCT03047460||multiple sclerosis|"All types of Multiple sclerosis patients:~Aged 18 to 58 years old, inclusive, at the time of informed consent.~Expanded Disability Status Scale (EDSS) 0.0 to 6.5.~Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb~Have no comorbid condition (ie neuropathy) that could affect testing.~Intervention: multimodal evoked potentials"
89668014|NCT01452113|Other|neuropathy|patients with autonomic neuropathy
89668015|NCT01452113|Other|control|patients without autonomic neuropathy (ewing score <= 0.5)
89668016|NCT01694953||Patients with MNGIE|Patients of all races of any gender who are at least 5 years of age with a defect in thymidine phosphorylase may participate in this natural history study.
89668017|NCT02611362|Experimental|Intervention|"Subjects in the intervention group will each receive a smartphone with a data service plan as the active arm. The IMB Gaming Intervention is designed to improve information, motivation, and skills about adherence and HIV preventative behaviors throughout play. The mission of Viral Combat is: kill virus and build strength through taking medicine, learning HIV prevention information, and engaging with healthy characters in order to improve motivation and build skills. Participants will get a game graphic with a supportive message such as Missing you: Get in the Game to their phones. Throughout the gaming intervention subjects will continue routine clinical care visits and HIV testing in the PrEP clinic."
89214574|NCT06089109|Experimental|Maternal Injury and Death Intervention|For this RCT, our research team has created a VIP Corps online, interactive learning management system training. This VIP Corps online training will be offered to students enrolled in a helping profession and in their last program year. Students are randomized to this experimental intervention arm. This training seeks to provide helping professionals with information and resources to identify, intervene, and prevent maternal injuries from interpersonal violence, substance use/disorder (IPV and SU/D). This training will provide students with the knowledge, skills, and efficacy to intervene and build capacity for prevention of maternal injuries and death due to violence.
89214575|NCT06089109|Active Comparator|Development of a Maternal Injury Surveillance System|Proposal of a novel Maternal Injury Surveillance System (MISS) as a complement to the existing maternal mortality surveillance available within Kentucky Violent Death Reporting System (KVDRS)
89668018|NCT02611362|No Intervention|Comparison|This condition will be matched with the IMB Gaming Intervention for appeal, time and attention. Subjects in COMP will each receive smartphones with the same data service plan as the active arm. Smartphones given to participants in COMP will have a stylistically similar non-PrEP, non-IMB game designed by Mission Critical Studios (Dr. Nano X: Incredible Voyage Inside The Body, http://www.youtube.com/watch?v=lyHzSZFzU1Q ). This is the same game that Viral Combat is being adapted from. Therefore, the iPhone game in COMP will have a look and feel that is very similar to our intervention game but without IMB, PrEP, and HIV prevention related content. Similar to the Intervention group, participants will have routine clinical care visits in the PrEP clinic (or more frequently if needed for urgent care).
88995449|NCT02924038|Experimental|IMA950/poly-ICLC subQ only|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every three weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). Patients will not receive Varlilumab.
88995450|NCT02913222|Experimental|Movement Pattern Training (MPT)|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. Movement Pattern Training (MPT) will focus on task-specific training to improve lower extremity movement patterns during basic tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Exercises will include repeated practice of tasks using optimized movement patterns. Verbal cues and visual aids will be used to assist the participant. Difficulty of the task-specific activities will be progressed by varying repetitions performed, increasing load or changing the support surface.
89049161|NCT04653870|Experimental|cyriax manipulation|cyriax manipulation have three types of classes, rotation, extension and anti-deviation, which is further divided into subclasses. On the inferior level of lumber spine L4-L5 and L5-S1rotation intervention of manipulation are capable of having striking effects of decreasing herniation. First of all we have to perform the simple 'stretch' on lumber spine, which is being the little rotation pressure applied on the body. The patient position of the body is in side lying with the effected side upward so that the outside part of the joint are separated easily on the involved side. After that, whenever it is essential by making use of femur as a rigid bar or support, this maneuver is go along with powerful rotation technique.
89668019|NCT04391699|Experimental|CPAP + Heated humidification|CPAP + Heated humidification
89668020|NCT04391699|No Intervention|CPAP alone|CPAP
89668021|NCT02022709|Active Comparator|Selective Serotonin Reuptake Inhibitor|In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
89668022|NCT02022709|Active Comparator|Exposure and Response Prevention|Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.
89668023|NCT01452581|Active Comparator|RBC transfusion|"Administration of up to 2 RBC units on the first postoperative day.~(1 unit at a time followed by evaluation of the primary outcome measure)"
89668024|NCT01452581|Placebo Comparator|Restrictive: Colloid infusion|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
89668025|NCT05272111|Experimental|Fascia Therapy|Group A will receive Fascia therapy
89668026|NCT05272111|Experimental|Facial Manipulation|Group B will receive Facial manipulation
89668027|NCT01452659|Experimental|TAK-385 10 mg QD|
89668028|NCT01452659|Experimental|TAK-385 20 mg QD|
89668029|NCT01452659|Experimental|TAK-385 40 mg QD|
89668030|NCT01452659|Placebo Comparator|Placebo|
89668031|NCT01896349|Experimental|IPT+antidepressant drugs|"Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
89668032|NCT01896349|Active Comparator|Antidepressant Drugs|"Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
89668033|NCT01452737|Experimental|2L Golytely/15mg bisacodyl|Subjects will be asked to take 2L Golytely + 15mg bisacodyl for bowel prep the day before colonoscopy.
89668034|NCT01452737|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep (4L Golytely) prior to colonoscopy.
89668035|NCT04867824|Active Comparator|Control|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
89668036|NCT04867824|Experimental|Case|The neonate will be taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. We will swaddle it, will administer 1 mL of oral sucrose, let the newborn suck for 2 minutes prior to the procedure, and will have a 7 x 7 cm gauze pad with 1 drop of 100% pure vanilla essential oil (Pranarôm España S.L.) placed 2 cm under the nose for 2 minutes prior to starting the frenotomy and during the procedure.
89668037|NCT01895413|Experimental|Mesenchymal stem cells|Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells
89668038|NCT01452815|Placebo Comparator|1|Drug: placebo
89668039|NCT01452815|Experimental|2|10mg TZP-102
89668040|NCT01452815|Experimental|3|20mg TZP-102
89668041|NCT04867512|Experimental|Intervention Group|Participants will be taking one liquid tincture orally per day as well as 2 capsules orally at night. At week 10, non-responders will take another supplement consisting of 2 capsules orally along with the liquid tincture until week 14.
89668042|NCT04755517|Active Comparator|A1|Frequent information of screening results for cytology and/or HPV DNA at the ages of 25 (cytology only) and 28 (cytology only) vs A2
89668043|NCT04755517|No Intervention|A2|infrequent information of cytological screening/ HPV DNA results, only at the age 28 years.
89668044|NCT04755517|Active Comparator|C|The third arm with at 8000 participants devoid of herd effect protection and frequent screening at ages 25 and 28 is enrolled for comparative analyses between A1 vs. C and A2 vs. C.
89668045|NCT03045432|Experimental|video-teaching materials|"regular passive ROM exercise~regular rehabilitation programe~alternative video-teaching materials"
89668046|NCT03045432|Other|control group|"regular passive ROM exercise~regular rehabilitation programe~regular oral-teaching materials"
89049162|NCT04653870|Experimental|lumber decompresion|Spinal decompression therapy has been developed a treatment without surgery for the prolapsed disc and deteriorative spinal disc disease one of the considerable reason for low back pain. This noninvasive interventional treatment for herniated disc and deteriorative disc diseases operated on the principle of remarkably decreasing the pressure on the disc between vertebras.
89049163|NCT04654026||CAA Group|Patients with cardiovascular and cerebrovascular disease with cerebral amyloidosis
89668047|NCT01452893||Type I diabetes|Adult patients with diabetes mellitus type I but normal adrenal function
89668048|NCT01452893||Addison's disease|Adult patients with Addison's disease
89049164|NCT04654026||None CAA Group|Patients with cardio-cerebrovascular disease without cerebral amyloid vascular disease
89049165|NCT04681703|Experimental|Intervention group|In addition to usual care: a 1-h educational and training program conducted by the family nurse (FN) in a dedicated room of the ambulatory care centers. During the program, the nurse instructed patients on how to self-measure blood pressure (BP) using the BP self-measurement device and on the importance of adequate device maintenance. The intervention was carried out by the FN on a daily basis during outpatient visits of the participants to the general practitioner (GP).
89214576|NCT06089096||MCI or SCI patient|At baseline: Cognitive tests, questionnaire, and Home Sleep Apnea Test will be done.
89214577|NCT06089031||BELmicro|No intervention foreseen.
88995451|NCT02913222|Active Comparator|Standard Rehabilitation|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. For the Standard Rehabilitation, focus will be on progressive lower extremity and trunk strengthening and lower extremity flexibility. Patient education will include instruction to modify intensity, frequency or duration of patient-specific tasks. Using current clinical practice guidelines and previous reports, strengthening and flexibility exercises will be prescribed and progressed by varying the repetitions performed or increasing the load.
88995452|NCT02798458|Experimental|SmartPill Test|All subjects will be asked to complete a SmartPill test. The SmartPill capsule is pill-shaped and about an inch long and ½ inch wide, or about the size of a vitamin pill. The receiver unit is about the size of a paperback book. The receiver gets signals from the capsule and stores the signals on a computer chip. The capsule detects the level of acidity, temperature, and pressures in your stomach and intestines and sends the information by radio wave signals to the receiver.
89214578|NCT06089018||Patients with Myotonic Dystrophy Type 1|This group will consist of participants with a confirmed genetic diagnosis of DM1 or DM2.
89214579|NCT06089018||Healthy Controls|This group will consist of participants without a confirmed genetic diagnosis of DM1 or DM2.
89214580|NCT06089005|Experimental|Intervention Group|daily use of the IASTM on the hip, quad and glute muscles for 60s in duration each session
89214581|NCT06088953|Experimental|perception disorder in noise in patients weakened by cognitive disorders.|The CogAudio project aims to detect early and in an ambulatory mode in a memory centre a speech perception disorder in noise thanks to the VRB test in patients weakened by cognitive disorders.
89214582|NCT06088940|Experimental|Probiotic Group (Group 1: Experimental intervention)|Participants will be given a 12-week supply of the probiotic supplement and asked to take 1 capsule daily by mouth at the same time as their first meal of the day.
89214583|NCT06088940|Placebo Comparator|Placebo Group (Group 2: Control condition)|Participants will be given a 12-week supply of the placebo capsules and asked to take 1 capsule daily by mouth at the same time as their first meal of the day.
89214584|NCT06088849|Other|Lactating mothers taking ACE-inhibitors|Lactating mothers who are breastfeeding their infant (0-6 months) while taking ACE-inhibitors.
89668049|NCT01452893||Type I diabetes and Addison's disease|Patients suffering from both, diabetes mellitus type I and Addison's disease
89668050|NCT01452893||healthy controls|healthy controls with normal adrenal function and normal glucose regulation
89668051|NCT00595933|Experimental|1|Each participant will receive an unidentified product to use for a one week period. This will continue until all 7 dry-mouth products have been evaluated.
89668052|NCT03045354|Experimental|Mashed potatoes|Eggs with a side of mashed potatoes
89668053|NCT03045354|Experimental|French fries|Eggs with a side of French fries
89668054|NCT03045354|Experimental|Beans|Eggs with a side of beans
89668055|NCT03045354|Experimental|Traditional breakfast|Cereal, milk, toast and jam
89668056|NCT03045354|Experimental|Breakfast skipping|No breakfast
89668057|NCT01284283|Other|Single|Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
89668058|NCT00588211||1|We will recruit fifteen New York University College of Dentistry (NYUCD) clinic patients who report current tobacco use.
89668059|NCT00588211||2|Second, we will recruit thirty dental clinic smokers (10 per day for 3 days) from the NYUCD waiting room.
89668060|NCT00588211||3|Third, we will survey 200 student participants from Adelphi University.
89668061|NCT00588211||4|Queens Hospital Center with 800 patients.
89668062|NCT02598713|Experimental|Aspiration Markers|Aspiration marker solution will be composed as following: Quinine 83 mg/L suspended in sterile water. After enrollment patients will be challenged with 5 mL of the study solution nebulized in the retropharyngeal space twice a day for two consecutive days.
89668063|NCT04862598|No Intervention|Control|The patient will be positioned on the operating table and have routine monitoring attached (ECG, blood pressure, O2 saturations, end tidal carbon dioxide monitoring (ETCO2). A surgical safety time out will be performed. The patient will receive routine operative and nursing care. The study team member will record highest and lowest heart rate and blood pressure as well as lowest O2 saturation and the total intra-operative dose of fentanyl and midazolam administered to the patient. At the end of the procedure, the patient is assisted into a wheelchair and will return to the recovery area. After 15 minutes of recovery, a member of the study team will give them the post-operative questionnaires which will consist of answering how anxious they felt during the procedure and the 11 question Iowa Satisfaction with Anesthesia scale (ISAS). The patient will then be free to leave once they have met the standard discharge criteria.
89668064|NCT04862598|Experimental|VR Group|The patient wears the VR headset after being positioned on the table and the surgical time out has been completed. The VR scene and accompanying music will continue until the end of the procedure or until the patient wishes for it to be removed. The patient will receive standard operative and nursing care. The study team member will record the intra-operative vitals as detailed in the control group procedure. At the end of the procedure, the patient will be moved to recovery and will receive standard care. At 15 minutes, they will be provided with the anxiety questionnaire and the ISAS. Additional questions will be asked; their level of VR immersion and if they would like to receive the VR technology again if they were to undergo another procedure in the future. They will then be free to leave once they have met the standard discharge criteria.
89668065|NCT02907905|Other|Population homeless or living in slum|Population homeless or living in slum realizing realizing a capillary sampling
89668066|NCT00580489|Active Comparator|Arm C Morphine|Morphine given to trauma patients transported by helicopter
89668067|NCT00580489|Active Comparator|Arm D Fentanyl|Fentanyl given to trauma patients transported by helicopter
89668068|NCT04872504|Experimental|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen
89214585|NCT06088810|Active Comparator|Sleep Education Group|Participants in this group will receive sleep education.
89214586|NCT06088810|Experimental|CoMPoSER Intervention Group|Participants in this group will use a mobile application that plays calming music personalized for sleep enhancement.
89214587|NCT06088771|Experimental|Non-small-cell lung cancer (NSCLC)|Participants will receive neoadjuvant subcutaneous Dupilumab 600mg and intravenous Cemiplimab 350mg on Day 1. Participants will proceed to standard of care surgery for early-stage, resectable NSCLC (within 7 days of Day 15), and will be observed for adverse events and dose limiting toxicities.
89214588|NCT06088758|Experimental|Liver Transplantation with Steatotic Liver|Graft will be selected if 30-60% macrosteatosis and transplanted into liver transplant recipient with MELD of 15-25.
89214589|NCT06088745|Experimental|Treatment main group|11500 subjects in treatment main group will receive 2 doses of LZ901 at D0 and D29. This group will be required to complete a 12 month safety follow-up after full immunization.
89214590|NCT06088745|Placebo Comparator|Placebo main group|11500 subjects in placebo main group will receive 2 doses of placebo at D0 and D29. This group will be required to complete a 12 month safety follow-up after full immunization.
89668069|NCT01659307|Active Comparator|Aspirin 75mg|Aspirin 75mg once daily for 7 days. Administered by mouth.
89668070|NCT01659307|Active Comparator|Aspirin 1200mg|Asprin 600mg twice daily for 7 days. Administered by mouth.
89668071|NCT01659307|Placebo Comparator|Lactose powder|Placebo for 7 days. Administered by mouth.
89668072|NCT01453751|Experimental|Intravenous Injection of AD-SVF|Intravenous administration of AD-SVF.
89668073|NCT03047148||Regional Anesthesia|Hospital records from patients who have undergone surgery in regional anesthesia.
89668074|NCT03047148||General Anesthesia|Hospital records from patients who have undergone surgery in General anesthesia.
89668075|NCT01652833||Round 1|survey of 150 oncologists
89668076|NCT01652833||Round 2|survey of 150 oncologists approximately 12 months after round 1
89668077|NCT01652833||Round 3|survey of 150 oncologists approximately 24 months after round 1
89668078|NCT01649089|Experimental|Treatment (cone biopsy/lymphadenectomy or hysterectomy)|Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
89668079|NCT01453907|Experimental|ETI-204|ETI-204, Anthim
89668080|NCT01453907|Sham Comparator|placebo|
89668081|NCT01594476|Experimental|Levonorgestrel IUS insertion at 3 weeks|IUD placement at 3 weeks after delivery.
89668082|NCT01594476|Experimental|Levonorgestrel IUS insertion at 6 weeks|IUD placement at 6 weeks after delivery.
89668083|NCT04391543|Experimental|Experimental Arm|"4 experimental session (baseline, after treatment, 6 month post treatment and 12 months post treatment) with :~comprehensive interview~cognitive tests~anthropometric measures~postural balance test~critical force test~Astrand-Ryhming test~self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~actimetry~clinical and biological characteristics~determination of inflammatory markers~skeletal muscle index"
89668084|NCT04391387|Active Comparator|16-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour after prone position
89668085|NCT04391387|Experimental|24-hour prone position|measure vital signs, PaO2/FiO2, driving pressure one hour before prone position and 1-hour, 8-hour, 16-hour, 24- hour after prone position
89668086|NCT04391231|Experimental|Pentoxifylline Arm|Pentoxifylline (in suspension with SyrSpend SF)
89668087|NCT04391231|Placebo Comparator|Placebo Arm|Placebo (SyrSpend SF only)
89668088|NCT04867356|Active Comparator|Spinal Stabilization Exercises (SSE)|
89668089|NCT04867356|Experimental|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|
89668090|NCT01453985|Experimental|Full-Thickness-Gastroplication|
89668091|NCT04861974||Robotic Distal Pancreatectomy|
89668092|NCT04861974||Laparoscopic Distal Pancreatectomy|
89668093|NCT04861974||Robotic Gastrectomy|
89668094|NCT04861974||Laparoscopic Gastrectomy|
89668095|NCT04861974||Robotic Funduplication|
89668096|NCT04861974||Laparoscopic Funduplication|
89668097|NCT04861974||Robotic Hernioplasty|
89668098|NCT04861974||Laparoscopic Hernioplasty|
89668099|NCT04861974||Robotic Rectal Resection|
89668100|NCT04861974||Laparoscopic Rectal Resection|
89668101|NCT01454141|Experimental|Peripheral Vision Task|During this task participants viewed a circular array of 15 discs and were asked to move their attention, but not their eyes, clockwise around the array while auditory tones were presented. Following the presentation of a distinct target tone, the discs changed color and participants reported the color of the disc by pressing a designated button on the keyboard. This task was developed to be a non-active control condition, targeting visual and occipital areas of the brain, and therefore allows us to discriminate between the effects of completing a computer-based task from interventions that specifically target the PFC.
89668102|NCT01454141|Experimental|Cognitive Control Training|Cognitive Control Training (CCT) A modified version of the Paced Auditory Serial Addition Task (PASAT) and the Attention Control Intervention were used to train participants' attentional control in accordance with procedures used by Siegle and colleagues.
89668103|NCT04872270|Active Comparator|Caffeine Group|2 week supply of 100mg caffeine + aspirin 325mg + standard pain regimen (experimental)
89668104|NCT04872270|Active Comparator|No Caffeine Group|aspirin 325mg + standard pain (control)
89668105|NCT04861506||acute or subacute thromboembolic occlusions of lower extremity|The patients are confirmed with acute or subacute thromboembolic occlusions of lower extremity, and which are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as PMT pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
89668106|NCT01454453|Experimental|Patients - dose titration|Amisulpride 50-200mg, 4-12 weeks, with brain imaging
89668107|NCT04872192|Active Comparator|transversus|patients received transversus thoracic muscle plane block and injection of 15 ml bupivacaine 0.25% on each side.
89668108|NCT04872192|Sham Comparator|general anaesthesia group|the same bilateral technique was done on both sides and 15 ml saline was injected during each side of TTPB technique.
89668109|NCT01454609|Placebo Comparator|Saline|0.9% normal saline
89668110|NCT01454609|Experimental|Bupivacaine|0.25% bupivacaine
89668111|NCT01454609|Experimental|Bupivacaine with clonidine|0.25% bupivacaine with 1 microgram/kg of clonidine
89668112|NCT04872114|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
89668113|NCT03042390||DArunavir/cobicistat|Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
89668114|NCT01896037|Experimental|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
89668115|NCT01454765||Sperm sample from healthy volunteers|
89668116|NCT03042234|Experimental|Group Insulin-resistant|Insulin-resistant obese adolescents
89668117|NCT03042234|Experimental|Group Insulin-sensitive|Insulin-sensitive obese adolescents
89668118|NCT01454921|Experimental|Intervention I|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
89214591|NCT06088745|Experimental|Treatment immunization group|1500 subjects in treatment immunization group will receive 2 doses of LZ901 at D0 and D29. This group is designed to evaluate the batch-batch immunogenicity consistency among three different batches of LZ901, as well as the immunogenicity and immunogenicity persistence of the LZ901 at 36 months after full immunization.
89214592|NCT06088745|Placebo Comparator|Placebo immunization group|1500 subjects in placebo immunization group will receive 2 doses of placebo at D0 and D29. This group is designed to evaluate the batch-batch immunogenicity consistency among three different batches of LZ901, as well as the immunogenicity and immunogenicity persistence of the LZ901 at 36 months after full immunization.
89668119|NCT01454921|Experimental|Intervention II|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
89668120|NCT01454999|Experimental|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
89668121|NCT01454999|Experimental|CTI + text|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change. Tailored feedback messages based on stage of change will also be sent by cell phone.
89668122|NCT04429776|Experimental|Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results fed back to recruiting clinical team who can choose to use these to influence their tapering decisions.
89668123|NCT04429776|Active Comparator|No Feedback Arm|Trough blood samples taken and analysed at baseline, 6m and 12m. Results not fed back to recruiting clinical team.
89668124|NCT02905799|Experimental|Oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
89668125|NCT02905799|Placebo Comparator|Oral Placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months.
89668126|NCT00507325||Blood Sample + Tumor Sample|Blood samples will be collected. Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
89668127|NCT04867200|Experimental|Group A|"Period 1: Reference drug(Lixiana 60 mg)~Period 2: Test drug(CKD-344 60 mg)"
89668128|NCT04867200|Experimental|Group B|"Period 1: Test drug(CKD-344 60 mg)~Period 2: Reference drug(Lixiana 60 mg)"
89668129|NCT01455077||Obese patients|BMI > 35
89668130|NCT00473941|Experimental|1|Writing in a journal 15 minutes a day
89668131|NCT00473941|Placebo Comparator|2|Control Writing in a journal 15 minutes a day
89668132|NCT01455311||Cystic Pancreatic Tumor Specimens|Specimen collection via EUS Guided Fine Needle Aspiration EchoBrush Sampling
89668133|NCT01895491|Experimental|CohortⅠ|VM206DNA 6mg and VM206Ad 3*10^9VP injected into the brachial muscle
89668134|NCT01895491|Experimental|CohortⅡ|VM206DNA 12mg and VM206Ad 3*10^9VP injected into the brachial muscle
89668135|NCT01895491|Experimental|CohortⅢ|VM206DNA 24mg and VM206Ad 3*10^9VP injected into the brachial muscle
89668136|NCT01455623||Health Care Provider|A person working within the field of CMT.
89049166|NCT04681703|No Intervention|Conrol group|Management of hypertensive patients, usual care: verbal and written instructions during which the family nurse (FN) or general practitioner (GP) advised the patient to follow the recommendations regarding correct HBPM. A written summary of the recommendations was given to all participants by the GP or FN at the end of the training program.
89668137|NCT01455623||Patient with CMT|Any person of any age self-identifying as having CMT and belonging to the Inherited Neuropathies Consortium Contact Registry hosted by the Rare Disease Clinical Research Network.
89668138|NCT01455701|Experimental|Tocilizumab|Participants will receive tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants will have the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants will receive tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reaches 2 years of age or has been treated for one year from baseline, whichever is longer.
89668139|NCT01455935|Active Comparator|Medical Therapy|"Current standard of care per the latest stroke guidelines~Permissive Hypertension up to 220~Antipletelets therapy:~ASA 81 mg PO daily or~Plavix 75 mg PO daily or~Aggrenox 225mg PO twice daily~Anti-inflammatory therapy:~Lipitor 80 mg PO daily or~Crestor 20 mg PO daily"
89668140|NCT01455935|Experimental|Intravenous Thrombolysis|"Full dose Intravenous thrombolysis~0.9 mg/kg~Maximum dose is 90 mg~10% of the dose will be given over one minute~90% of the dose will be infused over 1 hour~Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~Neuro checks every 5 minutes during the infusion~Neuro checks every hour after the infusion for 24 hours"
89668141|NCT01455935|Experimental|Intra-Arterial Therapy|"-Choice of therapy per experienced Endovascular surgeon and includes:~Intra arterial Activase (Maximum dose of 22 mg)~MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~PENUMBRA device (no standard time frame for how long the procedure takes)"
89668142|NCT01456091|Experimental|AIM 4 Teen Moms|
89668143|NCT01456091|No Intervention|Control|
89668144|NCT00468715|Experimental|bicalutamide|This is a multicenter, open-label, phase II study to evaluate the antitumor activity and safety of bicalutamide administered orally daily to patients with ER(-)/PR(-)/AR(+) metastatic breast cancer. Eligible patients who have consented to trial participation will receive bicalutamide at a dose of 150mg PO daily.
89668145|NCT01668966|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.
89668146|NCT01456247|Experimental|TAK-438 10 mg QD|
89668147|NCT01456247|Experimental|TAK-438 20 mg QD|
89668148|NCT01456247|Active Comparator|AG-1749 15 mg QD|
89668149|NCT01604473||Chronic Kidney Disease|Individuals with Chronic Kidney Disease stages IV or V anticipating the need for hemodialysis access through an arterio-venous fistula.
89668150|NCT01456325|Experimental|Onartuzumab+Erlotinib|Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
89668151|NCT01456325|Placebo Comparator|Placebo+Erlotinib|Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
89668152|NCT01598935|Placebo Comparator|Control|placebo
89668153|NCT01598935|Active Comparator|High protein intake|Nutrition - High protein
89668154|NCT01598935|Active Comparator|Low protein intake|Nutrition - Low protein
89668155|NCT01598935|Active Comparator|Medium protein intake|Nutrition - Medium protein
89668156|NCT04866732|Experimental|Needs assessment and feasibility group|Based on our target population's needs/preferences, an existing Physical Activity (PA) program will be modified and tailored to the needs of the target population. We anticipate that this PA program will include the following components: a) PA component - ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to CVD risk factors prevention; c) daily diary to record if they are facing any barriers in completing various components of the intervention; d) problem-solving sessions
89668157|NCT01252849|Experimental|First Arm: One iStent, medication|Device: One iStent, medication
89668158|NCT01252849|Experimental|Second Arm: Two iStents, medication|Device: Two iStent devices, medication
89668159|NCT01252849|Experimental|Third Arm: Three iStents, medication|Device: Three iStent devices, medication
89668160|NCT04866498||Analgosedation in ICU patients after head and neck tumor resection in general anesthesia|Head and neck tumor resections were performed in general anesthesia. Midazolam and etomidate or propofol were used in introduction and then anesthesia was maintenance with sevoflurane. Patients received intravenous continuous infusion of oxycodone as an analgesic component and sedatives (propofol/dexmedetomidine/midazolam) during analgosedation in ICU.
89668161|NCT01896427|Active Comparator|Dexamethazone IO|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
89668162|NCT01896427|Active Comparator|Dexamethasone IM|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
89668163|NCT04866654|Experimental|Study group|Nivolumab, total dose 5760 mg milligram
89668164|NCT01197625|Experimental|DC-vaccine|
89668165|NCT01456403||Carotid endarterectomy patients|Patients scheduled for clinically indicated carotid endarterectomy
89668166|NCT01456637|Experimental|CBT for insomnia with feedback|In this arm participants received internet based self-help CBT for insomnia with e-mail feedback form a therapist.
89668167|NCT01456637|Experimental|CBT for insomnia without feedback|In this arm participants receive internet based self-help CBT for insomnia without feedback from a therapist.
89668168|NCT01456715|Active Comparator|Gardasil, Immunogenicity, Booster dose.|
89668169|NCT01456715|Experimental|Cervarix, Immunogenicity, Booster dose.|
89668170|NCT02609724|Experimental|Fluoroscopy-guided MLD|Information, skin care, compression therapy, exercises and fluoroscopy-guided MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
89668171|NCT02609724|Active Comparator|Traditional MLD|Information, skin care, compression therapy, exercises and traditional MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
89668172|NCT02609724|Placebo Comparator|Placebo MLD|Information, skin care, compression therapy, exercises and placebo MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
89668173|NCT01456793|Experimental|Teen Options to Prevent Pregnancy|
89214593|NCT06088719||axillary surgery group|this group of patients had axillary surgery for axilla staging
89668174|NCT01456793|No Intervention|Usual care services|
89668175|NCT01456871||Healthy adult females|Females, aged 20 to 30 with no history of upper extremity injury or disorder in the non-dominant arm, no history of neurologic or bleeding disorder, and no evidence of Linburg-Comstock syndrome.
89668176|NCT01457027|Experimental|All subjects|
89668177|NCT04866966|Experimental|Intervention Group|The group undergoing the intervention will participate in 90-minute group visits occurring weekly for 4 weeks, then biweekly for a total of 26 weeks/15 visits. Each visit will focus on intensive lifestyle changes. Further, these patients will each have the opportunity to meet one-on-one with a member of the research team at the end of each visit in order to discuss individual goals and progress. Pharmacotherapy therapy changes will be recommended to reduce or avoid use of medication which may contribute to weight gain and medications for weight loss will be prescribed as an individualized treatment strategy during one-on-one time with the pharmacist or physician if the patient can afford it and no contraindications exists.
89668178|NCT04866966|No Intervention|Control Group|The control group will have their measurements done at the beginning and end of the study. They will continue with usual medicare care during the study and will not receive any education from the investigators during the study. They will be offered the option of a delayed intervention after the completion of the study.
89668179|NCT01457105|Experimental|ComVi biliary stent|
89214594|NCT06088719||no axillary surgery group|this group of patients had no axillary surgery for axilla staging
89668180|NCT01895569|Experimental|Type 2 diabetic patients|Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin > 6.5%, and < 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin.
89668181|NCT04861662|No Intervention|Keratinized Mucosa Sufficient (KMS)|Implants exhibiting the width of keratinized mucosa (KM) ≥2 mm at the midbuccal aspect
89668182|NCT04861662|No Intervention|Keratinized Mucosa Deficient (KMD)|Implants exhibiting KM<2 mm at the midbuccal aspect
89668183|NCT04861662|Experimental|Free Gingival Graft (FGG)|Implants with KM<2 mm initially and having surgically increased keratinized mucosa with free gingival graft after prothesis delivery
89668184|NCT01457261|Experimental|Partical size 1|Monodisperse particle delivered with radiolabel
89668185|NCT01457261|Experimental|Particle size 2|Monodisperse particle delivered with radiolabel
89668186|NCT01457261|Experimental|Nebulised salbutamol|Polydisperse particle via a nebuliser
89668187|NCT01457261|Experimental|Salbutamol MDI|Unlabelled salbutamol via a metered dose inhaler
89668188|NCT04778293|Experimental|Experimental Group|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized (random.org), in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
89668189|NCT04778293|No Intervention|Control Group|No intervention
89668190|NCT01457495|Experimental|DTPa 1 Group|
89668191|NCT01457495|Active Comparator|DTPa 2 Group|
89668192|NCT04861194|Experimental|Neurovascular-sparing 5x7.25 Gy MRgRT|MRgRT to the prostate in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb
89668193|NCT04778137|Experimental|CMAB007|75mg×2
89668194|NCT04778137|Active Comparator|Xolair|150mg
89668195|NCT04778215|Experimental|Intervention group|progressive, 8 week lumbar stabilizing program
89668196|NCT04778215|No Intervention|Control group|Continue as usual
89668197|NCT01457651|Active Comparator|Recruitment 40x40|The group where recruitment is performed by increase in airway pressure up to 40 cm H2O for 40 seconds
89668198|NCT01457651|Active Comparator|Recruitment PEAK40|Increase in peak airway pressure up to 40 cm H2O during tidal ventilation
89668199|NCT01457651|Active Comparator|Recruitment 15x300|Recruitment by increase in airway PEEP up to 15 cm H2O for 300 sec
89668200|NCT01457651|Active Comparator|No recruitment|No recruitment is performed: standard respiratory support.
89668201|NCT03043638|Experimental|CAF+ADM+PRP|Surgery will include Coronally advanced flap(CAF) plus acellular dermal matrix (ADM) combined with platelet rich plasma (PRP)
89668202|NCT03043638|Active Comparator|CAF+ADM|Surgery will include only Coronally advanced flap CAF technique including ADM placement without PRP
89668203|NCT01457729|No Intervention|No Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes per day, no more intervention is done.
89668204|NCT01457729|Other|Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes every day. If training time declines to less than 20 minutes per day for one week, a motivation phone call will take place once a week.
89668205|NCT01457807|Experimental|1|AZD3241 300mg extended release formulation 1
89049167|NCT02905253|Experimental|AC-084, single ascending dose (Part A)|AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
89668206|NCT01457807|Experimental|2|AZD3241 300mg extended release formulation 2
89668207|NCT01457807|Placebo Comparator|3|Placebo
89668208|NCT03041922||Healthy group|Every participant passes one ultrasound exam for soft tissues in buttocks in order to measure the elasticity of soft tissues in sitting and lying down positions. This kind of exam may help to predict a development in pressure ulcers
89668209|NCT00401791|Experimental|1|
89668210|NCT00401791|No Intervention|2|
89668211|NCT01457963||pulmonary embolism, deep venous thrombosis|
89668212|NCT04858308|Active Comparator|Test Group|Take both YYC506 and Placebo(Control)
89668213|NCT04858308|Active Comparator|Control Group|Take both Contral and Placebo(YYC506)
89668214|NCT04391153|Active Comparator|conventional samplig|"Patients with biliary strictures udergo ERCP or EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods.~Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology."
89668215|NCT04391153|Active Comparator|Fluorescence in situ Hybridization (FISH)|Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
89668216|NCT04391075||Exposed|Pudendal nerve block provided
89668217|NCT04391075||Not exposed|Pudendal nerve block is NOT provided
89668218|NCT01458041||Group 1|
89668219|NCT01415427|Experimental|BMN 110 Weekly|BMN 110 Weekly: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
89668220|NCT01415427|Experimental|BMN 110 Every Other Week|BMN 110 Every Other Week: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and will receive infusions of placebo on alternating weeks.
89668221|NCT02610816|Active Comparator|1FED|1-food elimination diet: Participants eliminate milk from the diet in Phase 1
89668222|NCT02610816|Active Comparator|4FED|4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
89668223|NCT02610816|Other|1FED Non-Responders (4FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
89668224|NCT02610816|Other|4FED Non-Responders (SGC)|Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2
89668225|NCT01458197|Experimental|Tarafenacin 0.2 mg|Group 1
89668226|NCT01458197|Experimental|Tarafenacin 0.4 mg|Group 2
89668227|NCT01458197|Placebo Comparator|Placebo|Group 3
89668228|NCT04858464||Patients group|Individuals with primary Sjögren's syndrome
89668229|NCT01896505|Experimental|Arm 1|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 30 milligrams per meter square (mg/m^2) orally twice weekly in treatment sequence ABCD (Treatment A: fasted, tablet formulation on Day 1 of Week 1; Treatment B: high-fat meal, tablet formulation on Day 1 of Week 2; Treatment C: low-fat meal, tablet formulation on Day 1 of Week 3; Treatment D: low-fat meal, capsule formulation on Day 1 of Week 4 in Cycle 1 (Weeks 1 to 4).
89668230|NCT01896505|Experimental|Arm 2|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received selinexor 30 mg/m^2 orally twice weekly in treatment sequence BADC (Treatment B: high-fat meal, tablet formulation on Day 1 of Week 1; Treatment A: fasted, tablet formulation on Day 1 of Week 2; Treatment D: low fat meal, capsule formulation on Day 1 of Week 3; Treatment C: low-fat meal, tablet formulation on Day 1 of Week 4 in Cycle 1 (Weeks 1 to 4).All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
89668231|NCT01896505|Experimental|Arm 3|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 50 mg/m^2 first generation tablets twice weekly on Days 1 and 3 of each week within 30 minutes of solid food consumption.
89668232|NCT01896505|Experimental|Arm 4|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m^2 orally in treatment sequence ABC (Treatment A: current [1st generation] tablets on Day 1 of Week 1; Treatment B: new [2nd generation] tablets on Day 1 of Week 2; Treatment C: suspension dose of current [1st generation] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
89668233|NCT01896505|Experimental|Arm 5|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m^2 orally in treatment sequence CAB (Treatment C: suspension dose of current [1st generation] tablets on Day 1 of Week 1; Treatment A: current [1st generation] tablets on Day 1 of Week 2; Treatment B: new [2nd generation] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
89668234|NCT01896505|Experimental|Arm 6|Participants with advanced sarcomas (Liposarcoma, Leiomyosarcoma, and Other sarcoma) received Selinexor 60 mg/m^2 orally in treatment sequence BCA (Treatment B: new [2nd generation] tablets on Day 1 of Week 1; Treatment C: suspension dose of current [1st generation] tablets on Day 1 of Week 2; Treatment A: current [1st generation] tablets on Day 1 of Week 3 in Cycle 1 (Weeks 1 to 3). All participants received the current (1st generation) tablet formula at a dose of 60 mg on Day 3 of Weeks 1-3 of Cycle 1.
89668235|NCT01458509||IVRS ( interactive voice response system) EASP|Telephone Group with Nurse Intervention
89668236|NCT01458509||Web EASP|Web Group with Nurse Intervention
89668237|NCT01458509||IVRS ( interactive voice response system) No EASP|Telephone Group without nurse intervention
89668238|NCT01458509||Web No EASP|Web Group without nurse intervention
89668239|NCT00332605|Experimental|Naltrexone plus N-Acetyl Cysteine|"Naltrexone tablets~N-Acetyl Cysteine: 600mg tablets, daily"
89668240|NCT00332605|Placebo Comparator|Placebo|"Inactive placebo (sugar pill)"
89668241|NCT01458665|Experimental|PRP group|
89668242|NCT01458665|Placebo Comparator|Conventional group|
89668243|NCT01540071|Experimental|NRX 194204|This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.
89668244|NCT01458743|Experimental|Ceftaroline q12h|Ceftaroline 600mg q12h
89668245|NCT01458743|Experimental|Ceftaroline q8h|ceftaroline 600mg q8h
89668246|NCT01458821|Experimental|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
89668247|NCT01458821|No Intervention|No treatment|Subject will make no changes in their usual daily routine. No intervention. Will repeat all study procedures at end of 8 weeks.
89668248|NCT01415583|Placebo Comparator|Saline|Placebo is described in chart
89668249|NCT01415583|Experimental|Dexamethasone|Dexamethasone is described in chart
89668250|NCT04346173|Experimental|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
89668251|NCT04777903||underweight woman with twin pregnancy|underweight (BMI < 18.5 kg/m2)
89668252|NCT04777903||normal weight woman with twin pregnancy|normal (BMI: 18.5-23.9 kg/m2)
89668253|NCT04777903||overweight and obese woman with twin pregnancy|overweight and obese (BMI ≥24 kg/m2)
89668254|NCT01458899|Experimental|A - first fed then fasted treatment|TC-5214
89668255|NCT01458899|Experimental|B - first fasted then fed treatment|TC-5214
89668256|NCT01416129|Active Comparator|Active Comparator: Prosthetic socket standard of care|
89668257|NCT01416129|Active Comparator|Active Comparator: Prosthetic brimless socket|
89668258|NCT01458977|Experimental|TDF/FTC (3 months) + Placebo (6 months)|TDF/FTC (3 months) + Placebo (6 months)
89668259|NCT01458977|Placebo Comparator|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)
89668260|NCT02508311|Active Comparator|Active Oral Beta-2|Subjects will receive 16 weeks of active medication.
89668261|NCT02508311|Placebo Comparator|Placebo|Subjects will receive 16 weeks of placebo medication.
89668262|NCT01459133|Experimental|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
89668263|NCT01417455||Rheumatoid Arthritis|Active Rheumatoid Arthritis patients
89668264|NCT01417455||Ankylosing Spondylitis|Active Ankylosing Spondylitis
89668265|NCT01417455||Controls|Healthy donors age and sex matched to the patients
89668266|NCT01459211|Other|Lenalidomide & Dexamethasone|Lenalidomide, 5mg daily, increased to 10mg after 1st cycle. Dexamethasone, 20mg days 1-4 each cycle
89668267|NCT00198991|Experimental|All patients|All patients are treated upfront according to one arm
89668268|NCT01459289|Active Comparator|leaflet|
89668269|NCT01459289|Active Comparator|counseling|
89668270|NCT01540773|Active Comparator|amino acid supplement|supplements with the proprietary amino acid derivative blend.
89668271|NCT01540773|Placebo Comparator|Placebo|Non-Active
89668272|NCT01459367|Experimental|TAK-438 10 mg QD|
89668273|NCT01459367|Experimental|TAK-438 20 mg QD|
89668274|NCT01459367|Active Comparator|Lansoprazole 15 mg QD|
89668275|NCT04777825|Experimental|HRV biofeedback training|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist. This group of patients will also benefit from the HRV biofeedback training.
89668276|NCT04777825|Other|control|During the inclusion visit, all patients will benefit from a psychoeducation session supervised by the psychologist.
89668277|NCT02612610|Placebo Comparator|Placebo|Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
89668278|NCT02612610|Experimental|Gefapixant 7.5 mg|Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
89668279|NCT02612610|Experimental|Gefapixant 20 mg|Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
89668280|NCT02612610|Experimental|Gefapixant 50 mg|Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
89668281|NCT04777591|Active Comparator|Control - plain bupivacaine|Receives plain bupivacaine TAP block as part of multi-modal pain control intraoperatively
89668282|NCT04777591|Experimental|Experimental - Liposomal bupivacaine|Receives plain bupivacaine + liposomal bupivacaine TAP block as part of multi-modal pain control intraoperatively
89668283|NCT01541553|Active Comparator|PEP005 Gel, 0.015%|Cryotherapy followed by PEP005 Gel, 0.015%
89668284|NCT01541553|Placebo Comparator|Vehicle gel|Cryotherapy followed by vehicle gel
89668285|NCT04390919||high group|high group: monocyte count≥0.445×10*9 cells/L
89668286|NCT04390919||low group|low group: monocyte count<0.445×10*9 cells/L;
89668287|NCT01123447|Active Comparator|Surgery|Isolated ulnar shaft fractures will be treated with open reduction and internal fixation using a limited contact dynamic compression (LC-DC) plate with screws. These will remain at the fracture site for the lifetime of the patient.
89668288|NCT01123447|Active Comparator|Short arm cast|Those individuals randomized to the non-operative treatment group will be treated with a closed reduction and short-arm (below-elbow) cast.
89668289|NCT01459835|Experimental|media diet|advice tips and tools to reduce exposure to violent programming
89668290|NCT01459835|Active Comparator|Nutrition intervention|diet advice
89668291|NCT01418001|Experimental|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|This will be a multicenter single arm phase IB/II trial to evaluate the clinical safety and efficacy of gemcitabine/docetaxel and pazopanib in the neoadjuvant treatment of soft tissue sarcoma.
89668292|NCT02877017|No Intervention|Pre-intervention arm|This arm is the pre-intervention arm of parents and providers before the family safety reporting bundle has been implemented.
89668293|NCT02877017|Experimental|Post-intervention arm|This arm is the post-intervention arm of parents and providers after the family safety reporting bundle has been implemented on the study units.
89668294|NCT00394147|Experimental|Pemetrexed and gemcitabine|pemetrexed 500mg/m2 and gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
89668295|NCT04776889|Active Comparator|Control/statin non-users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy.
89668296|NCT04776889|Experimental|Interventional/statin users|newly diagnosed metastatic prostate cancer patients who underwent surgical castration in the form of bilateral subcapsular orchiectomy and administered rosuvastatin 20 mg/day for 6 months
89668297|NCT01459991|Experimental|Mediterranean|Participants in this arm will follow a Mediterranean style diet, rich in olive oil and fruits and vegetables, and also consume 1 ounce of walnuts daily.
89668298|NCT01459991|Active Comparator|MyPyramid|
89668299|NCT01542255|Experimental|Combined Low Dose Treatment|"A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.~Schema of treatment is:~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv"
89668300|NCT04777123|Active Comparator|sitting position|patients will be left in the sitting position
89668301|NCT04777123|No Intervention|supine position|patients will lie down immediately after injection
89668302|NCT04776967|Active Comparator|Compression Profile 4|Compression Profile/Schedule 4 = 10 minute linear, Total Time Interval of Compression to treatment depth = 10 minutes, Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at treatment depth 45 fsw
89668303|NCT04776967|Active Comparator|Compression Profile 3|Compression Profile/Schedule 3 = 10 minute non-linear, Total Time Interval of Compression to treatment depth = 10 minutes Rate (slope) of compression = Non-Linear rate of compression = 3 fsw/min to a depth of 17 fsw, then 5 fsw/min up to a depth of 38.5 fsw, then 6.5 fsw/min to arrival at the treatment depth of 45 fsw
89668304|NCT04776967|Active Comparator|Compression Profile 2|Compression Profile/Schedule 2 = 15 minute linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Linear rate of compression = 4.5 fsw/min to arrival at the treatment depth 45 fsw
89668305|NCT04776967|Active Comparator|Compression Profile 1|Compression Profile/Schedule 1 = 15 minute non-linear, Total Time Interval of Compression to treatment depth = 15 minutes Rate (slope) of compression = Non-Linear rate of compression = 2 fsw/min to a depth of 13 fsw, then 3 fsw/min up to a depth of 35 fsw, then 5 fsw/min to arrival at the treatment depth of 45 fsw
89668306|NCT01456481|Active Comparator|midodrine hydrochloride pills|
89668307|NCT01456481|Placebo Comparator|oral placebo or sugar pill|
89668308|NCT01418703|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
89668309|NCT01418703|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
89668310|NCT01455155|Experimental|Creative therapy|Conventional physical therapy program (5 times/week) plus creative therapy (Art and Music) 2 times/week for 4 weeks
89668311|NCT01455155|Active Comparator|Control|Conventional physical therapy (5 times/week) for 4 weeks
89668312|NCT04776655|Experimental|Bevacizumab in combination with FOLFIRI chemotherapy|"Bevacizumab will be administrered at a dose of 5 mg/kg iv every 2 weeks. The first dose of Bevacizumab will be administered over 90 minutes. Then, if the first infusion is well tolerated without infusion-related reaction, the second dose will be administered over 60 minutes. Then, if the second dose is also well tolerated without an infusion reaction, all subsequent doses will be administered over 30 minutes.~Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
89668313|NCT04776655|Active Comparator|Cetuximab in combination with FOLFIRI chemotherapy|Cetuximab will be administered at a dose of 500 mg/m² iv every 2 week (14 days/cycle) Dosage form: Intravenous use All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
89668314|NCT01455233|Active Comparator|besivance|ocular antibiotic
89668315|NCT01455233|Active Comparator|vigamox|ocular antibiotic
89214595|NCT06088706|Experimental|Intervention group 1 (O3 20mg)|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 micrograms is injected under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
89668316|NCT00090571||Sib Pairs|Two or more biological siblings affected with JIA.
89668317|NCT01455779|Other|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
89668318|NCT04776733|Experimental|prepackaged group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
89668319|NCT04776733|Active Comparator|restricted diet group|"All colonoscopy were performed in the afternoon. The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation. All the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min in the evening.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast. All the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
89668320|NCT01459679|Active Comparator|VibeX Treatment Group A|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 8 minutes
89668321|NCT01459679|Active Comparator|VibeX Treatment Group B|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 4 minutes
89668322|NCT01459679|Active Comparator|VibeX Treatment Group C|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 2 minutes and 40 seconds
89668323|NCT04776343|Experimental|Telemedecine follow-up|
89668324|NCT04776343|No Intervention|Hospital follow-up|
89668325|NCT04776421||ileostomy group|
89668326|NCT01455857|Experimental|ITCA 650 40 mcg/day|
89668327|NCT01455857|Experimental|ITCA 650 60 mcg/day|
89668328|NCT01455857|Placebo Comparator|ITCA placebo|
89668329|NCT04753645|Experimental|HBCC and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
89668330|NCT04753645|Experimental|No HBCC project and no soap|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
89668331|NCT04753645|Experimental|Soap received but no HBCC|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
89668332|NCT04753645|Experimental|Both HBCC project and Soap received|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
89668333|NCT04866030||NostraData Database|All prescriptions for Intuniv available in the NostraData database in Austrialia will be analyzed in this study.
89668334|NCT04866030||Physician Survey|Physician will collect medical record data of 100 participants who have been prescribed Intuniv at least once during the study period to treat participants with ADHD.
89668335|NCT04595305|Other|Treatment Arm - Standard of Care|Implantation of CRT-P or CRT-D for a clinical indication as per standard of care.
89668336|NCT01419171|Experimental|OMEGA™ Monorail Coronary Stent System|
89668337|NCT04272905||Maternity patients|"> 18 years~Post-natal following any form of delivery~Between 4 and 48 hours after delivery~Able to understand English adequately to give consent and complete the questionnaire"
89668338|NCT04272905||Maternity Unit Staff|"Doctors, midwives and other staff~Work on labour ward"
89668339|NCT03043404|Experimental|Lotus Valve Flex System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
89668340|NCT04849637|Experimental|Standard of care plus adjunctive virgin coconut oil supplementation|Standard of care plus virgin coconut oil
89668341|NCT04849637|No Intervention|COVID-19 Standard of care treatment|Standard of care
89668342|NCT03043248|Experimental|Cohort A|TRK-700 + Digoxin
89668343|NCT03043248|Experimental|Cohort B|TRK-700 + Midazolam
89668344|NCT04843631|Experimental|Arm A: BFI-751|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL BFI-751
89668345|NCT04843631|Active Comparator|Arm B: EU-STELARA®|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL EU- STELARA®
89668346|NCT04843631|Active Comparator|Arm C: US-STELARA®.|On Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL US- STELARA®
89668347|NCT01419249|Other|Retrospective cohort|
89668348|NCT04845737|Other|Fibromyalgia patient group|Sympathetic skin response measurements will be made in patients who meet the diagnosis criteria of fibromyalgia. Vitamin D levels will be measured and hemogram values will be checked in these patients.
89668349|NCT04845737|Other|Control Group|The participant in this group will be chosen from healthy volunteers. Sympathetic skin response will be measured of the participants. Vitamin D levels and hemogram values will be recorded.
89668350|NCT04389463||Cardiac or thoracic surgery in COVID-19 positive patients|
89668351|NCT04389463||Cardiac/thoracic surgery in COVID-19 negative patients|
89668352|NCT04849715|Active Comparator|Treatment Group A|Participants will be administered parsaclisib once daily and will receive Bendamustine and Rituximab periodically for 6 months.
89668353|NCT04849715|Placebo Comparator|Treatment group B|Participants will be administered placebo once daily and will receive Bendamustine and Rituximab periodically for 6 months.
89668354|NCT03045042||Treated patients|Patients with late onset Pompe disease treated with the enzyme replacement therapy
89668355|NCT03045042||Non treated patients|Patients with late onset Pompe disease non treated with the enzyme replacement therapy
89668356|NCT04860648|Experimental|LUS group|patients receive lung ultrasound examination, and doctors give the treatment according to the LUS results
89668357|NCT04860648|No Intervention|Control group|patients receive no lung ultrasound examination and other intervention
89668358|NCT04776187|Active Comparator|Gadodiamide|"Patients who have undergone contrast-enhanced MRI using Gadodiamide contrast agent for clinical purposes.~Generic name: Gadodiamide Injection; Product name: OMNISCAN; Sample specifications: 15ml: 4.305g (a sterile solution containing 287mg/ml gadodiamide)."
89668359|NCT04776187|Experimental|Gadoteric Acid Meglumine Salt|"Patients who have undergone contrast-enhanced MRI using Gadoteric Acid Meglumine Salt contrast agent for clinical purposes.~Generic name: Gadoteric Acid Meglumine Salt Injection; Commodity name: Jia Di Xian; Sample specifications: 15ml: 5.654g (a sterile solution containing 377mg/ml gadoteric acid meglumine salt)."
89668360|NCT04847843|Experimental|Mindfulness Orientated Recovery Enhancement (MORE) Intervention|8-week MORE intervention adapted for preventing weight regain
89668361|NCT04847843|Active Comparator|Control Intervention|8-week control intervention based on the Diabetes Prevention Program's Prevent T2 for Life program.
89668362|NCT03044964|Active Comparator|Ranolazine|At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
89668363|NCT03044964|Placebo Comparator|Placebo|At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
89668364|NCT01419639|Experimental|RAD001|RAD001 taken orally continuously until disease progression or unacceptable toxicity, dosed according to age
89668365|NCT04783831||Biodegradable stent|
89668366|NCT04783831||Non-biodegradable stent|
89668367|NCT02862743|Experimental|patients with metastatic melanoma|patients with metastatic melanoma (stage III unresectable or stage IV)
89668368|NCT03044652|Experimental|Medical Device: WO2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
89668369|NCT03044652|Active Comparator|Drug: Estriol Cream 0.1%|Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
89668370|NCT02856893|Experimental|Osimertinib till progression|Osimertinib until PD according to RECIST 1.1
89668371|NCT02856893|Experimental|Gefitinib till + blood test/progression than Osimertinib|"Gefitinib until emergence of positive T790M status (cfDNA T790M positive progression) followed by Osimertinib until second PD according to RECIST 1.1"
89668372|NCT02856893|Active Comparator|Gefitinib till progression than Osimertinib|Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1
89668373|NCT04783909||PEX|42 eyes with PEX syndrome and coexisting cataract
89668374|NCT04783909||Control|38 eyes with cataract only
89668375|NCT01419795|Experimental|Arm I (lenalidomide, rituximab)|Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.
89668376|NCT01419795|Active Comparator|Arm II (lenalidomide)|Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.
89668377|NCT04857294|Experimental|Discectomy|Unilateral Discectomy
89668378|NCT04783753|Experimental|EDP-514 and Itraconazole interaction (Part 1)|
89668379|NCT04783753|Experimental|EDP-514 and Carbamazepine interaction (Part 2)|
89668380|NCT04783753|Experimental|EDP-514 and Quinidine interaction (Part 3)|
89668381|NCT04845191|Experimental|Experimental: Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
89668382|NCT04845191|Experimental|Experimental: Cohort 2: hAd5-S-Fusion+N-ETSD Subcutaneous and Oral|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Oral on Day 1
89668383|NCT03008265||Colonic cancer resection|
89668384|NCT02087995|Experimental|Continuous Glucose Monitoring System|Single-Arm, CGM Device Glucose challenge performed during a clinic session to obtain accuracy data for the CGM system compared to a venous reference measurement
89668385|NCT04849962|Active Comparator|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
89668386|NCT04849962|Experimental|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
89668387|NCT02856581|Experimental|Intervention group (varenicline and behavioral intervention)|Patients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
89668388|NCT02856581|Placebo Comparator|Control group (placebo and behavioral intervention)|Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
89668389|NCT03042000|Experimental|Group A1|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'radical surgery + adjuvant chemotherapy (ACT)'
89668390|NCT03042000|Active Comparator|Group A2|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'NCRT + radical surgery + ACT'
89668391|NCT03042000|Experimental|Group B1|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with combined chemotherapy (Capox regimen) + radical surgery + ACT'
89668392|NCT03042000|Active Comparator|Group B2|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with single-agent chemotherapy (Capecitabine) + radical surgery + ACT'
89668393|NCT03042000|Experimental|Group C1|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the transanal endoscopic microsurgery (TEM) excision of the lesion.
89668394|NCT03042000|Active Comparator|Group C2|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the radical resection of the lesion.
89049168|NCT02905253|Placebo Comparator|Placebo,single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to AC-084
89214596|NCT06088706|Active Comparator|Intervention group 2 (O3 40mg)|Just like intervention group 1, in this group, a predetermined concentration of 40 micrograms ozone is injected under sterile conditions.According to the standard treatment guidelines of the American College of Rheumatology, 1gram of acetaminophen in two doses of 500 mg is allowed up to two weeks after daily injections, which is applicable to all three groups.
89668395|NCT01044277|Experimental|Group A|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
89668396|NCT01044277|Experimental|Group B|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
89668397|NCT01044277|Placebo Comparator|Group C|Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
89668398|NCT01479543|Experimental|Group A|Volunteers received Probiotic CNCM I-4034.
89668399|NCT01479543|Experimental|Group B|Volunteers receive Probiotic CNCM I-4035.
89668400|NCT01479543|Experimental|Group C|Volunteers are given Probiotic CNCM I-4036.
89668401|NCT01479543|Experimental|Group D|Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
89668402|NCT01479543|Placebo Comparator|Group E|Volunteers receive a Placebo.
89668403|NCT01039285|Experimental|Surfactant instillation|2.5 ml/kg of Surfactant will be instilled in the trachea
89668404|NCT01039285|Placebo Comparator|Placebo instillation|2.5 ml/kg of Air will be instilled in the trachea
89668405|NCT03043482|Experimental|Single VS-105/placebo to healthy|Single ascending dose VS-105 or placebo to healthy subjects
89668406|NCT03043482|Experimental|Multiple VS-105/placebo to healthy|Multiple ascending dose VS-105 or placebo to healthy subjects
89668407|NCT03043482|Experimental|Multiple VS-105/placebo to HD subjects|Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
89668408|NCT04849494||Late preterm AGA infants/Group 1|According to the new BALLARD scoring system gestational age was 34-36 6/7 and those who were at the 10-90th percentile according to the Fenton growth curves
89668409|NCT04849494||Newborns with Intrauterine growth restriction/Group 2|Term or preterm infants below 10th percentile according to the values calculated according to Fenton growth curves
89668410|NCT04849494||Control/Group 3|the healthy term (gestation week 38-42 weeks), AGA newborns, who born between January 2006 and December 2008
89668411|NCT04775563||Rheumatic diseases outpatients|All the rheumatic diseases outpatients from the National Institute of Medical Sciences and General Hospital.
89668412|NCT01480089|Placebo Comparator|Atomized Intraperitoneal Saline (AIS)|Participants randomized to this arm will be given atomized intraperitoneal saline(AIS).
89668413|NCT01480089|Active Comparator|Intraperitoneal Ropivacaine(AIR)|Participants randomized to this arm will receive atomized intraperitoneal ropivacaine (AIR).
89668414|NCT04783129|Experimental|Face-to-face group|Face-to-face group (FFG), in which participants, in groups of 10 persons, followed a multidisciplinary health education program composed of 10 monthly face-to-face lectures
89668415|NCT04783129|Active Comparator|Remote group|Remote group (RG), in which individuals followed 10 monthly remote lectures
89668416|NCT04783129|Sham Comparator|Control group|Control group (CG), in which participants followed no education program (lectures)
89668417|NCT04849572|Active Comparator|Sleep Education|Also referred to as Arm 1. Arm 1 receives sleep education initially.
89668418|NCT04849572|Active Comparator|Delayed Sleep Education|Also referred to Arm 2. Arm 2 receives no initial sleep education.
89668419|NCT03523975|Experimental|Venetoclax, Lenalidomide, Rituximab|Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
89668420|NCT01542645|Experimental|Methadone|Long-acting opioid
89668421|NCT01542645|Active Comparator|Fentanyl|Shorter-acting opioid
89668422|NCT03040518|Experimental|Narrative SMS|"Participants will receive narrative SMS for 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
89668423|NCT03040518|Experimental|Narrative SMS and Endowment Incentive|"Participants will receive narrative SMS for 12 months. In addition, they will receive an endowment incentive for verified weight loss.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
89668424|NCT03040518|No Intervention|Waiting List Control Group|"Participants will be on a waiting list for 12 months to receive the narrative SMS which will commence after 12 month outcome data has been collected. There will be no interim measurements or contacts by the research team. Men are therefore free to choose whether to try to lose weight during the 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
89049169|NCT02905253|Experimental|AC-084, multiple ascending dose (Part B)|AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
89049170|NCT02905253|Placebo Comparator|Placebo,multiple ascending dose (Part B)|Matched placebo administered as multiple ascending doses in parallel to AC-084
89668425|NCT04857450|Sham Comparator|Etomidate|Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
89668426|NCT04857450|Active Comparator|Ketamine-Etomidate|Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
89668427|NCT01542957|Experimental|Cognitive Behavioral + Dilemma Therapy|Combines Group Cognitive Behavioral Therapy with a Individual Dilemma-Focused Intervention
89668428|NCT01542957|Active Comparator|Cognitive Behavioral Therapy|Combined Group and Individual Cognitive Behavioral Therapy
89668429|NCT04857216||Infraclavicular Group|Block Characteristics of Ultrasound Guided Infraclavicular Block with the Perfusion Index
89668430|NCT04857216||Costoclavicular Group|Block Characteristics of Ultrasound Guided costoclavicular Block with the Perfusion Index
89668431|NCT04782583||CAS|
89668432|NCT04782583||TEMOIN|
89668433|NCT01004965||Group 1|"Samples are obtained: 1) pretreatment, 2) at the time of documentation of refractory disease in acute myeloid leukemia (AML) patients who do not achieve complete response (CR) after induction therapy, and 3) at the time of first relapse in patients who achieve CR.~Marrow cells are preferentially used for all samples, but peripheral blood is acceptable if marrow is not available and the blood contains 20% or more blasts."
89668434|NCT04849182|Active Comparator|Vertistop D|Patients with deficiency (<20 ng/mL, <50 nmol/L) or insufficiency (20-30 ng/mL, 50-75 nmol/L) of Vitamin D
89668435|NCT04849182|Active Comparator|Vertistop L|Patients with normal vitamin D levels (>30 ng/mL, >75 nmol/L)
89668436|NCT04849182|No Intervention|Control group|Patients meeting the inclusion criteria with normal levels of vitamin D (>30 ng/mL, >75 nmol/L)
89668437|NCT01420653|Experimental|Maxigesic 325|Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
89668438|NCT01420653|Active Comparator|Acetaminophen|Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
89668439|NCT01420653|Active Comparator|Ibuprofen|Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
89214597|NCT06088706|Placebo Comparator|Control group|Just like intervention group 1, in this group, a syringe containing oxygen without ozone is injected under sterile conditions.
89668440|NCT01420653|Placebo Comparator|Placebo|Placebo tablets, every 6 hours, orally
89668441|NCT04849793|Experimental|Experimental|Before the intervention, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. After rubbing, each individual's pain threshold level will be taken as a basis in order not to cause tissue damage. The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes. In the study group, an average of 13 minutes will be applied to HT7, LI4 and EX-HN3 points (five points in total) for two minutes each. The nursing students participating in the research will be given a total of 12 acupressure intervention remotely, three days a week, for four weeks, at least two hours after dinner and when they are calmest.
89668442|NCT04849793|No Intervention|Control|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
89668443|NCT01543581|Active Comparator|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
89668444|NCT01543581|Placebo Comparator|Inactive placebo|Those to whom the inactive placebo is given.
89668445|NCT04848155|Active Comparator|Older adults with MCI|
89668446|NCT04848155|Active Comparator|Caregivers|
89668447|NCT01421355|Experimental|Atazanavir 300 mg BID|Atazanavir 300 mg BID for 4 days.
89668448|NCT04775251|Experimental|one group|The treatment program consisted of upward rotation exercises for 3 sessions/week, for 6 weeks.
89668449|NCT04844957|Other|Clinical Study of Vitamin D in Children With NMS|Correlation between vitamin D and symptoms severity of autonomic nervous mediated syncope child and it 's RAAS
89668450|NCT01421589|Experimental|Growth Hormone|
89668451|NCT04856670||Control patients undergoing manual cataract surgery|As above
89214598|NCT06088628||DoC patients|Patients with disorders of consciousness.
89668452|NCT04856670||Control patients undergoing FLACS|Femtosecond laser assisted cataract surgery
89668453|NCT04856670||Diabetic patients undergoing manual cataract surgery|As Above
89668454|NCT04856670||diabetic patients undergoing FLACS|As Above
89668455|NCT04848948|Experimental|F.X.Mayr & Biofeedback|two weeks of F.X. Mayr diet and biofeedback
89668456|NCT04848948|Active Comparator|F.X.Mayr|two weeks of F.X. Mayr diet
89668457|NCT04848948|Experimental|VLCD & Biofeedback|two weeks of very low calorie diet and biofeedback
89668458|NCT04848948|Active Comparator|VLCD|two weeks of very low calorie diet
89049171|NCT02905253|Experimental|AC-084, single dose (Part C)|Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
89049172|NCT04625868|Experimental|Soft tissue surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
89668459|NCT04846595|Other|Self questionnaire|The study will be offered to all patients who have been treated for HIV infection for at least 6 months, during a follow-up consultation. A self questionnaire will be administered only once per patient during the usual consultation, there is no follow-up planned.
89668460|NCT04774705|Experimental|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|
89668461|NCT04774705|Placebo Comparator|Control group|For the SNV placebo group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
89668462|NCT04860180|Experimental|A, surgery|adrenalectomy
89668463|NCT04860180|No Intervention|B, observation|conservative follow up
89668464|NCT04390997|No Intervention|Periodontally Healthy|20 participants with bleeding on probing less than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
89668465|NCT04390997|No Intervention|Gingivitis|20 participants with bleeding on probing greater than 10%, probing depths less than 4mm, and no clinical attachment loss which was measured by six sites per tooth
89668466|NCT04390997|Other|Periodontitis|20 participants with bleeding on probing greater than or equal to 30%, probing depths greater than or equal to 5mm at least non-adjacent two teeth in each quadrant of the dentition, and clinical attachment loss greater than or equal to 4mm which was measured by six sites per tooth, and radiographic bone loss on the coronal third of root or severe (vertical/ horizontal) bone loss.
89668467|NCT01422135|Experimental|Abdomen, Buttock, Upper Torso|"Patch was placed on abdomen, buttock then the upper torso excluding breast.~Intervention: AG200-15 patch"
89668468|NCT01422135|Experimental|Abdomen, Upper Torso, Buttock|"Patch was placed on abdomen, upper torso excluding breast then the buttock.~Intervention: AG200-15 patch"
89668469|NCT01422135|Experimental|Buttock, Abdomen, Upper Torso|"Patch was placed on the buttock, abdomen, then the upper torso excluding breast.~Intervention: AG200-15 patch"
89668470|NCT01422135|Experimental|Buttock, Upper Torso, Abdomen,|"Patch was placed on the buttock, upper torso excluding breast then the abdomen~Intervention: AG200-15 patch"
89668471|NCT01422135|Experimental|Upper Torso, Abdomen, Buttock|"Patch was placed on the upper torso excluding breast, abdomen then buttock.~Intervention: AG200-15 patch"
89668472|NCT01422135|Experimental|Upper Torso, Buttock, Abdomen|"Patch was place on the upper torso excluding breast, buttock, then abdomen.~Intervention: AG200-15 patch"
89668473|NCT00962845|Experimental|Hydroxychloroquine|Patients must have tumor accessible for pre-treatment biopsy (see 5.1.2). Patients will be enrolled on the trial, undergo biopsy of their tumors if no banked tumor is available, and then begin an oral dose of HCQ at the dose of 200 mg twice daily. At the end of two weeks the patients will undergo resection of their tumors. HCQ will be given to the patients up to the day of the operation but not resumed postoperatively.
89668474|NCT04390685|Experimental|Tacrolimus ointment|Apply whole arm, in a thin layer, once daily for one year
89668475|NCT04390685|No Intervention|Control|
89668476|NCT04848324|Active Comparator|Intervention group|14 patients (14 hands) who received US-guided corticosteroid hydrodissection
89668477|NCT04848324|Active Comparator|Control group|14 patients (14 hands) who received US-guided corticosteroid injection
89668478|NCT04848246|Experimental|Bupropion|
89668479|NCT04848246|Experimental|Behavioural Change Communication|
89668480|NCT04848246|No Intervention|Control|
89668481|NCT04856514|Experimental|Treatment Group|Participation in 16 week telehealth administration of the PEERS protocol for teens (parallel teen and parent/caregiver groups)
89049173|NCT04625868|No Intervention|Soft tissue surgery - no video|Patients > 18 years old undergoing elective hand surgery (soft tissue) for which the surgeon is planning to prescribe opioids for postoperative pain control.
89049174|NCT04625868|Experimental|Bone/joint surgery - preoperative video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
89049175|NCT04625868|No Intervention|Bone/joint surgery - no video|Patients > 18 years old undergoing elective hand surgery (bone/joint) for which the surgeon is planning to prescribe opioids for postoperative pain control.
89049176|NCT02905175||Rheumatoid arthritis|blood sample specimen and synoviocytes from synovial tissue
89668482|NCT04774939|Active Comparator|EVLA only|Only main trunk/trunks with venous reflux will be treated
89668483|NCT04774939|Active Comparator|EVLA and sclerotherapy of tributaries|Main trunk/trunks with venous reflux will be treated combined with foam sclerotherapy
89668484|NCT04840277|Experimental|Intervention group|Remote hearing aid adjustment. All participants in this group are offered hearing aids possible to adjust remotely.
89668485|NCT04840277|No Intervention|Control group|Traditional hearing aid adjustment
89668486|NCT04774783|Experimental|Low-Level Laser Therapy|Over the course of the study, participants within this group will receive 12 sessions of Low-Level Laser Therapy (LLLT) treatment over a duration of 4 weeks using the Richmar TheraTouch LX2 device. Treatment location will be determined through assessment of each qualifying participant. Treatment sessions will be limited to a single area of the body associated with the qualifying participant's primary pain complaint.
89668487|NCT01544361|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
89668488|NCT01544361|Experimental|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 milligram per kilogram (mg/kg) intravenous infusion over at least 60 minutes on Day 1.
89668489|NCT01544361|Experimental|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
89668490|NCT01544361|Experimental|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
89668491|NCT01544361|Experimental|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
89668492|NCT04781569||Patients with S. aureus infection|
89668493|NCT04781569||healthy participants|
89668494|NCT04390607||Subjects undergoing revision joint surgery|
89668495|NCT04841837|Experimental|Time-restricted feeding|Restrict all calorie intake within a self-selected 10-hours window for 12 weeks, without necessarily altering diet quality and quantity
89668496|NCT04756219|Experimental|Contact Video|Participants randomized to this group will watch a video of a person talking about his recovery after attempting suicide.
89668497|NCT04756219|Experimental|Contact Text|Participants randomized to this group will read a personal story of a person who survived a suicide attempt.
89668498|NCT04756219|Experimental|Education Video|Participants randomized to this group will watch a video of a psychiatrist presenting facts about suicide and suicide prevention.
89668499|NCT04756219|Experimental|Education Text|Participants randomized to this group will read a text containing facts about suicide and suicide prevention.
89668500|NCT04756219|Placebo Comparator|Control Contact|Participants randomized to this group will read a personal story of a person who survived a heart attack.
89668501|NCT04756219|Placebo Comparator|Control Education|Participants randomized to this group will read a text containing facts about heart-attacks and their prevention.
89668502|NCT04856280|Experimental|The kinesiological taping (KT) group (n=15)|6 sessions of taping was applied to the kinesiological taping group, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended. Using the KT ligament technique, it was applied to the supra pubic region with 100% tension in order to reduce contraction in the uterus
89668503|NCT04856280|Active Comparator|The aerobic exercise (AE) group (n=15)|"In the AE group, walking and climbing stairs were given during the menstrual cycle, 45 minutes session per day, 3 days a week over 3 weeks. The exercise protocol consists of 5 minute warm up, 35 min AE and 5 minute cool-down exercises. Warm-up and cool-down exercises include an active range of motion (ROM) exercises for upper and lower extremity. Aerobic exercise includes 30 min of moderate walking and climbing stairs. The aerobic exercise was performed in accordance with the definition of moderate-intensity exercise of the World Health Organization; It was given to the participants that during moderate exercise, the individual should walk with a tempo in a way that he can speak but cannot sing"
89668504|NCT04856280|No Intervention|The control group (n=15)|No intervention was applied to the control group.
89668505|NCT04755751||Pediatric Pompe patients|A retrospective - prospective study evaluating pediatric patients with Pompe before and 2 days after ERT on multiple occasions and different dosing. Evaluation included cardiopulmonary exercise testing (CPET), 6 minute-walking test (6MWT), motor function test (GMFM-88) and self-collected blood samples (on a Guthrie card) for enzyme blood levels.
89668506|NCT01482351|Experimental|MCI/OSA/CPAP Adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was equal to or greater than 4 hours per night over one year. CPAP adherence Intervention was provided by research staff.
89668507|NCT01482351|Experimental|MCI/OSA/CPAP Non-adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was less than 4 hours per night or CPAP use was withdrew for any reason over one year. Attention control intervention was provided by staff.
89668508|NCT04429620||Positive group|Subjects are diagnosed with SARS-CoV2 by qPCR assay.
89668509|NCT04429620||Negative group|Subject were 2 times proved negative SARS-CoV2 by qPCR assay.
89668510|NCT04754971|Experimental|Table|
89668511|NCT04428840|Experimental|on-day|Use of the self-measurement kiosk: measurement of vital signs + completion of short questionnaire
89668512|NCT04428840|No Intervention|Off-day|No use of the self-measurement kiosk
89668513|NCT04773847|Experimental|MimetikOss 3D|
89668514|NCT01545765|Experimental|lidocaine 7% and tetracaine 7%|
89668515|NCT04856124||Treatment resistant depressed outpatients|Subjects had a clinically meaningful response to IV racemic ketamine and remained on other psychotropic medications during treatment with both IV ketamine and IN esketamine. Concomitant medication classes included CNS stimulants (n = 7), atypical antipsychotics (n = 6), selective serotonin reuptake inhibitors (n = 5), serotonin/norepinephrine reuptake inhibitors (n = 4), anticonvulsants (n = 3), antipsychotics (n = 3), mood stabilizers (n = 3), benzodiazepines (n = 2), norepinephrine/dopamine reuptake inhibitors (n = 2), alpha 2 antagonists (n=1), and sedative hypnotics (n = 1). Two patients (20%) previously underwent ECT with partial but transient relief from depressive symptoms, two (20%) failed TMS, and no patients reported any period of greater than 50% improvement during their current depressive episode prior to ketamine treatment.
89668516|NCT04847700|Active Comparator|Minimally invasive vestibular neurectomy|
89668517|NCT04847700|Active Comparator|Tenotomy of the stapedius and tensor tympani muscles|
89668518|NCT02208297|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID)
89668519|NCT02208297|Placebo Comparator|Vehicle Gel (BID)|Vehicle gel administered two times daily (BID)
89668520|NCT05027009|Experimental|Group I (low dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 3 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
89668521|NCT05027009|Experimental|Group II (middle dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 4 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
89668522|NCT05027009|Experimental|Group III (high dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 6 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
89668523|NCT03040440|Active Comparator|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated in 32 participants
89668524|NCT03040440|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube was intubated in 32 participants
89668525|NCT04847622||Target Population|Adults with COVID-19 diagnosed and treated with Remdesivir after Aug 31st2020.
89214599|NCT06088628||Healthy controls|Healthy participants matched by gender and age.
89214600|NCT06088589|Experimental|Speech Sounds|Participants will hear repeated speech sounds while wearing a neuroimaging cap.
89668526|NCT04781803|Experimental|Arm 1|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day 0 after transplantation, mycophenolic acid 1 gram orally (2 tablets 500 mg) from day 0 post-transplant and PT-CY at 50 mg/kg per day on day +3 and +4.
89668527|NCT04781803|No Intervention|Arm 2|Cyclosporine 6 mg/kg orally divided into two doses per day starting in the morning on day +5 of the transplant, mycophenolic acid 1 gram orally (2 tablets of 500 mg) from day +5 post-transplant and post-transplant cyclophosphamide (PT-CY) at 50 mg/kg per day on days +3 and +4
89668528|NCT01422369|Experimental|All Subjects|pitavastatin 4 mg
89668529|NCT04860024||ADHD|"Blood sample for miRNA qRT-PCR~Behavioral and neuropsychological assessments"
89668530|NCT04860024||Healthy|"Blood sample for miRNA qRT-PCR~Behavioral and neuropsychological assessments"
89668531|NCT04021212||Patients with pituitary adenomas resection|Patients suffers from pituitary adenomas and undergo transsphenoidal surgery for at least once
89668532|NCT04781101|Experimental|conventional therapy|conventional therapy
89668533|NCT04781101|Experimental|RoboGait®|Group 1 (n = 13) received conventional therapy (65 min, 2 days/week ×8) and group 2 (n = 13) received 25 minutes of robot-assisted gait training (RoboGait®) in addition to conventional therapy (40 min, 2 days/week ×8).
89668534|NCT01423773|Other|Lotrafilcon A test/lotrafilcon A control|Lotrafilcon A test contact lens worn first, with lotrafilcon A control contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
89668535|NCT01423773|Other|Lotrafilcon A control/lotrafilcon A test|Lotrafilcon A control contact lens worn first, with lotrafilcon A test contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
89668536|NCT05023343|Active Comparator|Active|Unilateral transmuscular quadratus lumborum block using 30 mL 0.75% ropivacaine
89668537|NCT05023343|Placebo Comparator|Placebo|Unilateral transmuscular quadratus lumborum block using 30 mL isotonic saline
89668538|NCT04773535||healthy Volunteers|Adult (>18y) healthy volunteers without previous injuries or pathologies of the hand and upper extremity
89668539|NCT04847076|Experimental|m-health version of WWWT intervention|Include: a) Psychoeducational information for understanding and managing infant behavior and on parenting. This information will be delivered through instant messaging service for mobile phones (i.e., Whatsapp) 3 times a week for four-week period. Each module will include a very brief video offering information regarding a specific topic, a proposed personal exercise and the invitation to assess the perceived usefulness of the information received. Some modules include links to external, complementary information from the Chilean Infancy Policy. b) Contact with the program facilitator. It will allow mothers to ask questions that arise from the topics addressed in the psychoeducational videos. The answers seek to promote the understanding and elaboration of the contents, and operate by providing expert support; c) A virtual group meeting.
89214601|NCT06088472|Experimental|TIL injection treatment group|
89214602|NCT06088459|Experimental|NWRD06 by electroporation|Patients will be assigned to three dose groups:1mg, 4mg, and 8mg. Each patient will be administered NWRD06 by electroporation in entire study period. The Maximum Tolerated Dose of NWRD06 will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
89668540|NCT04847076|Other|TREATMENT AS USUAL|TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age. The objective of the routine health care check is to carry out a comprehensive evaluation of the child's development and growth, guide parents and caregivers regarding child development, health and upbringing of the child. Also, promoting exclusive breastfeeding, healthy mother/child bonding (by detecting relevant alterations in this area) and encouraging paternal participation in upbringing and care of the child. Finally, in the health check-ups at 2 and 6 months of age of the child, Edinburgh Postpartum Depression Scale is used for screening depressive symptoms in mothers. At risk cases are referred for mental health assessment and care.
89668541|NCT04773613|Experimental|Experimental SLP|Infant placed in a SLP on the researcher's lap. Head of the infant symmetrically placed between the shoulders, supported by the researcher's. Shoulder girdle higher than the pelvic girdle, head and back in a straight line - a slight natural bend of the body is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
89668542|NCT04773613|Other|Experimental SEP|Infant placed in a SEP on the researcher's lap. The head rests on the researcher's hand. Shoulder girdle higher than the pelvic girdle, head and back in a straight line at an angle of 30-45° to the ground - slight, natural body bend is allowed. Legs bent at an angle of approx. 90° in the natural flexion of the knee and ankle joint. The infant's arms close to the midline (on the bottle or researcher's hands)
89214603|NCT06088433|Experimental|SAPT|Ticagrelor SAPT 90mgBID for 1 month, followed by 60mgBID
89214604|NCT06088433|Active Comparator|DAPT|Aspirin 100mgQD+Clopidogrel 75mgQD for 1 month, followed by clopidogrel 75mgQD
89214605|NCT06088420|Active Comparator|Intrathcal Morphine Group|Intrathecal morphine administration for post operative pain relief after cesarean section
89214606|NCT06088420|Active Comparator|Quadratus Lumborum nerve block group|Quadratus Lumborum nerve block administration for post operative pain relief after cesarean section
89214607|NCT06088420|Active Comparator|Erector Spinae nerve block group|Erector Spinae nerve block administraion for post operative pain relief after cesarean section
89668543|NCT01424943|Experimental|Stepping Stones Triple P|10-15 sessions of Level 4 Standard Stepping Stones Triple P delivered in family homes
89668544|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
89668545|NCT04855890|Active Comparator|Cryo-Ablation|Cryo-Balloon (Arctic Front Advance ProTM, Medtronic, Minneapolis, MN, USA) will be advanced to the LA and navigated to the PV's using an inner-lumen circular mapping catheter (Achieve AdvanceTM, Medtronic, Minneapolis, MN, USA). After confirming complete PV sealing by the CB using occlusion angiograms cryothermal energy will be applied for min 120 seconds aiming at PV isolation of all PV's according to the clinical standard.
89214608|NCT06088407|Experimental|With tranexamic acid|"Patient undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intraoperatively.~The patients received intravenous 1 gram tranexamic acid in 100ml normal saline 30 minutes before skin incision and a second dose of intravenous 1 gram tranexamic acid in 100 ml of normal saline during wound closure."
89668546|NCT04855890|Active Comparator|High Power Short Duration-Ablation|"A detailed electroanatomical map of the left atrium during sinus rhythm will be acquired using Ensite (Abbott, St. Paul, MN, USA).~Upon completion of the LA map, a second transseptal puncture will be performed in order to insert an ablation catheter. To achieve antral PVI irrigated radiofrequency current ablation will be performed using a power of 70W and a flush rate of 8-30ml/min with a duration of 5 seconds for the anterior and 7 seconds for the posterior LA. Ablation catheters used will contain Flexibilty (Abbott, St. Paul, MN, USA) and TactiFlex (Abbott, St. Paul, MN, USA)."
89668547|NCT04753801|Experimental|Best Possible Self (writing only)|Participants are asked to think and write about their best possible future self (15 min).
89668548|NCT04753801|Experimental|Best Possible Self (writing+imagining)|Participants are asked to think and write about their best possible future self (15 min) and, then to imagine their positive future (5 min).
89668549|NCT04753801|Experimental|Best Possible Self (writing+mindfulness)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief mindfulness sequence (5 min).
89668550|NCT04753801|Experimental|Best Possible Self (writing+recall)|Participants are asked to think and write about their best possible future self (15 min) and subsequently engage in a brief recall imagination task about the past two days (5 min).
89668551|NCT04753801|Active Comparator|Writing about the past|Participants are asked to think and write about activities of the past two days (15 min).
89668552|NCT01547247|Experimental|cap-assisted water immersion colonoscopy|Cap-fitted colonoscopy using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
89668553|NCT01547247|Active Comparator|water immersion colonoscopy|Standard colonoscopy without attached cap using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
89668554|NCT05023109|Experimental|GP+PD-1+Tight|"Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent."
89668555|NCT04781413|Experimental|Experimental|"The phase I trial is a dose escalation design with standard 3+3 followed by expansion cohorts.~Level Nab-PTX S-1 Sintilimab~80 mg/m2 80mg/m2 200mg~100 mg/m2 80mg/m2 200mg~120 mg/m2 80mg/m2 200mg~We start at level 1. The recommended dose (RD) is defined as dose equal to the maximum tolerated dose (MTD). If 1 of three patients experiences dose-limiting toxicities (DLT), three more patients will be enrolled at the same dose level. The MTD is defined as the dose level at which two or more of three patients, or at least two of 4-6 patients, have DLTs during one cycle."
89668556|NCT01547715|Experimental|MenACWY - 2 - 10 Years old|Subjects between 2 and 10 years of age who received one injection of Meningococcal ACWY conjugate vaccine -CRM vaccine on day 1.
89668557|NCT01547715|Experimental|MenACWY - 11 - 18 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
89668558|NCT01547715|Experimental|MenACWY - 19 - 75 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
89668559|NCT04859790|Active Comparator|Active SCAR Intervention|In this arm, participants will complete baseline measures, receive the SCAR intervention, and complete follow-up measures one month following the intervention.
89668560|NCT04859790|No Intervention|Waitlist Control|Participants assigned to the waitlist control condition will complete baseline measures and measures one month following their baseline appointment. After they complete the follow-up measures, they will be offered the SCAR intervention.
89668561|NCT04781023|Experimental|Intervention (Colpofix)|intravaginal gel with carboxymtheyl beta-glucan and polycabophil
89668562|NCT04781023|No Intervention|Control|No intervention (standard of care)
89668563|NCT05026463|Experimental|Inspiratory support level with PMI equal to -2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
89668564|NCT05026463|Experimental|Inspiratory support level with PMI equal to 0|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
89668565|NCT05026463|Experimental|Inspiratory support level with PMI equal to +2|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
89668566|NCT04859634||Zhongshan Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
89214609|NCT06088407|No Intervention|Without tranexamic acid|Patient undergoing surgery for elbow fracture-dislocation randomized to be treated without tranexamic acid intraoperatively
89668567|NCT04859634||Shenzhen Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
89668568|NCT04859634||Beijin Tongren Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
89668569|NCT04859634||Xudong Ophthalmic Center|The participant only needs to take an ultra-widefield fundus image as usual.
89668570|NCT04859634||IKang Physical Examination Center|The participant only needs to take an ultra-widefield fundus image as usual.
89668571|NCT04859634||Yangxi General Hospital People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
89668572|NCT04859634||Guangdong Provincial People's Hospital|The participant only needs to take an ultra-widefield fundus image as usual.
89668573|NCT05023811|Experimental|[14C]RIST4721|[14C]RIST4721 oral solution
89668574|NCT04773769|Experimental|Overall Statistical design|We will treat 9 patients of each tumor type with a tea made of Graviola Leaves. If no responses are observed then the trial will be closed for that particular histological type. Should a response occur, then the trial will continue to the second stage for that cell type until 24 patients are accrued. If 3 or more responses are observed out of 24 cases, then the result will be considered promising.
89049177|NCT02905175||Osteoarthritis|blood sample specimen and synoviocytes from synovial tissue
89049178|NCT04653909|Experimental|Case|A patient who was diagnosed with the calfan syndrome
89049179|NCT04625595|Experimental|350 mg BID (700 mg total daily dose) of active drug or placebo|Low dose, drug IMT-002
89049180|NCT04625595|Experimental|1050 mg QD (1050 mg total daily dose) of active drug or placebo|Moderate dose, drug IMT-002
89049181|NCT04625595|Experimental|700 mg BID (1400 mg total daily dose) of active drug or placebo|Moderate to high dose, drug IMT-002
89049182|NCT04625595|Experimental|1050 mg BID (2100 mg total daily dose) of active drug or placebo|High dose, drug IMT-002
89049183|NCT02905058|Experimental|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
89049184|NCT02905058|Placebo Comparator|Placebo|women will take one placebo tablet one hour before the procedure
89049185|NCT02905136||Patient with confirmed diagnosis of autoimmune encephalitis by|"Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with :~with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr)~or uncharacterized antibodies"
89668575|NCT04859556|Experimental|10k 25G cutter|New cutter, with a 10,000 cut per minute blade
89668576|NCT04859556|Active Comparator|5k 25G cutter|Traditional cutter, with a 5,000 cut per minute blade
89668577|NCT04781335|Active Comparator|Dexycu|
89668578|NCT04781335|Active Comparator|Standard Care Post operative drops|
89668579|NCT04773301|Experimental|LEVOBUPIVACAINE|Patients treated with Levobupivacaine Altan 7.5 mg / ml solution for injection and infusion
89668580|NCT04773301|Experimental|ROPIVACAINE|Patients treated with Ropivacaine Altan 2 mg / ml solution for infusion
89668581|NCT05023031|Experimental|NVP-2102|NVP-2102
89668582|NCT05023031|Active Comparator|NVP-2102-R|NVP-2102-R
89668583|NCT01548339|Active Comparator|Delayed|Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment
89668584|NCT01548339|Experimental|Early|Laparoscopic cholecystectomy performed directly after the initial diagnosis
89668585|NCT04846998|Experimental|Sequence 1|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 1: A-B-C"
89668586|NCT04846998|Experimental|Sequence 2|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 2: A-C-B"
89668587|NCT04846998|Experimental|Sequence 3|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 3: B-A-C"
89668588|NCT04846998|Experimental|Sequence 4|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 4: B-C-A"
89668589|NCT04846998|Experimental|Sequence 5|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 5: C-A-B"
89668590|NCT04846998|Experimental|Sequence 6|"The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3.~*sequence 6: C-B-A"
89668591|NCT04846842|Experimental|Gimatecan group|In Phase II study, patients will receive gimatecan at fixed dose level (0.8mg/m2/d, oral, every 4 weeks) until progressive disease (PD)、complete remission（CR）).
89668592|NCT04780945|Experimental|Olaparib monotherapy|Patients, irrespective of BRCA status, will be treated with olaparib tablet 300 mg bid
89668593|NCT01425879|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89668594|NCT04859478|Other|All eligible patients|All patients undergo the same CT protocol in addition to standard care.
89668595|NCT04773223||Open surgery group|Patients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm
89668596|NCT04773223||Endovascular group|Patients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated, chimney, etc.
89668597|NCT04780633|Experimental|Precede-Proceed based Training Program|The experimental group is the group in which five training sessions interventions are applied.
89668598|NCT04780633|No Intervention|Control group|The control group is the group in which have no educational intervention.
89668599|NCT01426191||xinzhijun|1.5-3.0g,iv,bid or tid for 5-12 days
89668600|NCT05025527|Experimental|bpMRI|Man receive the bpMRI for Prostate cancer(PCa) screening
89668601|NCT05025527|Active Comparator|PSA|Man receive the PSA blood test for Prostate cancer screening
89668602|NCT03041766|Experimental|Group 1|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
89668603|NCT03041766|Experimental|Group 2|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 5.0 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
89668604|NCT04773145||Femoral neck fracture|Patients over 80 years when suffering of femoral neck fracture with at least one year follow-up.
89668605|NCT05020379|Sham Comparator|Group N|"The patients in Group N will not receive any intervention. Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol. The pain intensity will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS are the simple and most commonly used scales.11 The numerical scale is most commonly 0 to 10, with 0 being no pain and 10 being the worst pain imaginable."
89668606|NCT05020379|Experimental|Group ESPB|The patients in the group ESPB will be placed in sitting pozition. A convex probe ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS)
89668607|NCT01548885|Experimental|Study Staff Test BGMSs|All testing and lancings were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems(BGMS): FreeStyle Freedom Lite® BGMS; ACCU-CHEK® Aviva BGMS; TRUEtrack® BGMS; OneTouch® Ultra®2 BGMS; CONTOUR® NEXT EZ BGMS.
89668608|NCT03041532|Experimental|proximal retroflexion|Procedure: The endoscopy explore right colon with frontal view and a second look with proximal retroflexion
89668609|NCT03041532|Active Comparator|frontal view of right colon|Procedure: The endoscopy explore right colon with frontal view and frontal view
89668610|NCT05021315|Experimental|Iodine group|50 women who received preoperative vaginal cleansing with 10% povidone-iodine.
88995453|NCT02798458|Experimental|Endoscopic Mucosal Resection|An additional small group of subjects will also be asked to complete a Sigmoidoscopy (an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed. In the Endoscopy Mucosal Resection (EMR) procedure we will use an instrument called an endoscope (a lighted, flexible tube) to take a tissue sample from the rectum. This is the same type of instrument used in a routine colonoscopy
89668611|NCT05021315|No Intervention|Control group|50 women who did not receive preoperative vaginal cleansing even with tap water.
89668612|NCT04780711||Diagnostic Group|Demographic data, symptoms for TMJ of the students will be recorded. Physical examination will be included range of motion of temporomandibular joint, right and left TMJ lateral range of motion, whether there is a gradual opening, during deflection and deviation during the opening and subluxation for palpation and measurements. Opening and closing clicks, crepitation and popping will be recorded during palpation. Deep palpation of the skin, masseter and temporal muscles will be determined, posture analysis will be recorded and dental interventions, missing teeth, orthodontic treatments and bruxism histories will be taken. An appropriate diagnosis will be determined for students who are found to have pathology as a result of all these examinations and information about this diagnosis will be provided.
88995454|NCT02726581|Experimental|Investigational Arm|"Nivolumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
88995455|NCT02726581|Active Comparator|Control Arm|"Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
88995456|NCT02726581|Experimental|Exploratory Arm|"Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
88995457|NCT02700048|Placebo Comparator|Placebo|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
88995458|NCT02700048|Experimental|Treatment with intra-nasal Naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
88995459|NCT02683447||CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
88995460|NCT02678429|Active Comparator|DBS programming, standard of care|DBS settings determined from the standard Neurologist symptomatic response first then change to settings from Atlas
88995461|NCT02678429|Experimental|DBS progamming from Atlas|DBS settings determined from the a functional atlas first then change to settings determined by standard of care
88995462|NCT02638766|Other|Unique arm|Regorafenib 160mg once a day, frequency: 3 weeks on/1 week off in cycles of 28 days
88995463|NCT02599116|Other|Microbiome cohort|"Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires.~Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires~Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires"
88995464|NCT02535832|Placebo Comparator|Placebo|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the placebo arm. Participants will take matching placebo throughout the 15 weeks of treatment.
88995465|NCT02535832|Active Comparator|Pioglitazone|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the pioglitazone arm. Participants will start by taking increasing doses for three weeks as follows: 1 capsule (15 mg) per day for 7 days, 1 capsule per day (30 mg) for 7 days, and 1 capsule (45mg), if tolerated. Participants will continue this dose (45 mg) throughout the 12 weeks of treatment.
89214610|NCT06088394|Experimental|The patients will do pelvic floor exercises and acupuncture|The patients will perform pelvic floor exercises and acupuncture 3 times per week for 12 weeks
89668613|NCT02835989|Experimental|CP@Home Intervention|"The experimental group will receive the CP@Home program. The main elements of this program include BP assessment, diabetes risk assessment, falls risk assessment, heart failure risk assessment, neurologic assessment, psychiatric assessment, depression screening, health-related quality of life analysis (including pain, mobility, anxiety/depression, ADLs), social isolation screening, and food and income security. The program is targeted at referrals to appropriate community resources, identification and referral of high-risk patients to their family physician (FP), as well as regular communication of participants' health information to their physician.~The intervention will be implemented by community paramedics from the local paramedic service who have undergone a structured training program (4 hours of online, interactive training modules, including case studies and the observation of an intervention visits led by another paramedic) to assure intervention fidelity."
89668614|NCT02835989|No Intervention|Control|Usual Care
89668615|NCT00858793|Experimental|A|
89668616|NCT01426581|Experimental|Educational Intervention A|Intervention: Teach to Goal
89668617|NCT01426581|Experimental|Educational Intervention B:|Brief Intervention
89668618|NCT03041454|Experimental|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers. Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
89668619|NCT03041454|No Intervention|Traditional systematic review format|Control participants will be asked to read and answer questions using a traditional systematic review format.
89668620|NCT00854893|Experimental|anodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
89668621|NCT00854893|Experimental|cathodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, cathodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
89668622|NCT00854893|Experimental|sham (placebo)|sham stimulation (placebo condition): 30 seconds during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
89668623|NCT03041376|Experimental|Walking intervention|
89668624|NCT03041376|No Intervention|Control|
89668625|NCT01427517|Experimental|NAC in PD|single intravenous administration of N-acetylcysteine in PD patients
89668626|NCT01427517|Experimental|NAC in GD|single intravenous administration of N-acetylcysteine in GD patients
89668627|NCT01427517|Experimental|NAC in controls|single intravenous administration of N-acetylcysteine in control subjects
89668628|NCT03041142|Experimental|Interdisciplinary Intervention|"Children 3 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy.~Mothers~1 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy."
89668629|NCT03041142|Active Comparator|Routine|Mothers and children followed their routine activities
89668630|NCT04846452|Experimental|NSCLC patients with negative driver genes|Patients with negative driver genes advanced or metastatic NSCLC will receive sintilimab combined with anlotinib hydrochloride and platinum-containing dual-agent chemotherapy regimens as first-line treatment.
89668631|NCT04772677|Experimental|BEAM - Infant|BEAM Infant will be delivered via mobile application to mothers with a 6-17 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
89668632|NCT04772677|Experimental|BEAM - Preschool|BEAM Preschool will be delivered via mobile application to mothers with a 18-36 month old child. It will include 15-30-minute lessons on mental health and parenting and a closed community forum. Mental Health videos will provide information and tools via The Unified Protocol, a best-practice program to address dysregulated emotions across mood and anxiety disorders. Parenting Videos will help parents understand their children's challenging behaviours and teach proactive approaches to prevent negative interactions and promote a positive relationship. A closed online community forum will be facilitated by a mental health clinician and parent coach. Weekly Zoom meetings will be facilitated by clinicians where participants can meet with other participants, ask questions about the program content, or discuss the week's materials.
89668633|NCT05029349|Other|VOC analysis|VOC analysis in exhaled air in patients hospitalised for stable severe COPD
89668634|NCT04780243|No Intervention|Pre-intervention group|Pre-intervention group: women participated during the base line assessment will be labeled as Pre-intervention group
89668635|NCT04780243|Experimental|postintervention group|Postintervention group: women participated after the intervention was initiated will be labeled as postintervention group.
89668636|NCT05023733||1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1|One to two contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1 whose condition requires the use of interbody fusion.
89668637|NCT04859244|Experimental|Part 1: GS-441524 (QD, 7 days)|750 mg GS-441524 administered QD for 7 days
89668638|NCT04859244|Experimental|Part 2: GS-441524 (TID, 3 days)|750 mg GS-441524 administered TID for 3 days
89668639|NCT04772833||Autopsy group|Patients with COVID-19 infection confirmed by PCR, whose death is related to active COVID-19 infection or its complications.
89668640|NCT04845906||Healthy volunteers|There will be 4 separate StatLock™ devices being tested, which will be randomly applied to the participants on their inner (ventral) forearms. Each participant will have 2 separate devices applied, one to each arm. Those participants who have the StatLock ™ Arterial Plus, StatLock™ Dialysis II, or the StatLock IV Select, will also have the foam strip applied.
89668641|NCT04846062|Active Comparator|Intervention|Intervention arm will receive nutrition behavior Children's mothers/caregivers will receive explanatory education and behavior about micronutrient essentiality and utilization. Also, dietary diversification and demonstration in the process of enriching child complimentary food will be given for participants every month for the consecutive six months. Posters and video shows will be used.
89668642|NCT04846062|Active Comparator|control|Control arm will not receive nutrition behavior
89668643|NCT03041064|Experimental|SPF 50/SPF 100|SPF 50 assigned to left side of face and body. SPF 100 assigned to right side of face and body
89668644|NCT03041064|Experimental|SPF 100/SPF 50|SPF 100 assigned to left side of face and body. SPF 50 assigned to right side of face and body
89668645|NCT04780165|Experimental|Single-arm|
89668646|NCT03042624|Experimental|Fermented rice|7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
89668647|NCT03042624|Placebo Comparator|Maltodextrins|7 g of maltodextrins powder to be diluted in milk or water
89668648|NCT05022719|Experimental|PillCam Colon2 procedure with MB-MMX|PillCam Colon2 procedure with MB-MMX
89668649|NCT04772443|Experimental|DWJ1506|
89214611|NCT06088394|Experimental|The patient will do pelvic floor exercises|"The patient will perform pelvic floor exercises 3 times per week for 12 weeks. pelvic floor muscles exercises involves repetitive contraction and relaxation of the pelvic floor muscles in an attempt to strengthen the muscles .~Each training session involved three training rounds and each round lasted for five minutes. Women will be instructed to perform PFMC and rest with 10min break between each round. They will be instructed to perform two to three sets of PFE repetitions per day, with 8-10 PFMC lasting for 10 s each set. All women will be asked to document their practice of PFE in PFE diary to assess their compliance."
89214612|NCT06088368|Active Comparator|in-plane needle guidance|Ultrasound -guided lumbar plexus block
89214613|NCT06088368|Active Comparator|out-of-plane needle guidance|Ultrasound -guided lumbar plexus block
89668650|NCT04772443|Experimental|DWJ1507|
89668651|NCT04772443|Active Comparator|DWC202011|
89668652|NCT04772443|Active Comparator|DWJ1177|
89668653|NCT05026151||non-CO|Consecutive persistent critically ill patients requiring more than 10 days of mechanical ventilation, admitted just before the first COVID-19 wave
89668654|NCT05026151||COVID|Consecutive persistent critically ill COVID-19 patients requiring more than 10 days of mechanical ventilation, admitted during the first COVID-19 wave
89668655|NCT04840524|Other|Conventional preparation design (Chamfer finish line with Butt joint incisal preparation design)|conventional treatment
89668656|NCT04840524|Experimental|New preparation design (Feather edge finish line with feather edge incisal preparation design)|New preparation design
89668657|NCT04779853||Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM|serum samples will be taken and tested by enzyme-linked immunoassay (ELISA) using the SAVYON SeroPertussisTM kits (Savyon Diagnostics Ltd, Israel).
89668658|NCT04855110|Active Comparator|Day 2 warfarin group|warfarin will be administered on day 2 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
89668659|NCT04855110|Active Comparator|Day 5 warfarin group|warfarin will be administered on day 5 after caesarean section (in a dose that achieves therapeutic level as indicated by the cardiology consultant)
89668660|NCT04272749|Experimental|Dairy and non-dairy milks|Questionnaires and consumption behaviors of dairy and non-dairy milks
89668661|NCT01485393|Experimental|Healthy Control Subjects: Zolpidem, Then Dexmedetomidine|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Zolpidem induced-sleep and then a night of Dexmedetomidine induced-sleep.
89668662|NCT01485393|Experimental|Healthy Control Subjects: Dexmedetomidine, Then Zolpidem|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Dexmedetomidine induced-sleep and then a night of Zolpidem induced-sleep.
89668663|NCT04854876|Experimental|Vaccinated with 1st dose of COVID-19 Vaccine & treated with 5-ALA Phosphate/SFC|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) and that will be treated with 150mg 5-ALA Phosphate/SFC for 28 days
89668664|NCT04854876|No Intervention|Vaccinated with 1st dose of COVID-19 Vaccine|100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) only (Control)
89668665|NCT04772287|Experimental|Toripalimab|
89668666|NCT04772287|Placebo Comparator|Placebo|
89668667|NCT01890005|Experimental|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
89668668|NCT01890005|Placebo Comparator|Placebo|Placebo (identical to low dose aspirin (100 mg)) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
89668669|NCT04797390|Active Comparator|Advanced Pneumatic Compression Device (APCD)|Daily self-administered treatment with the Flexitouch® Plus system (FT)
89668670|NCT04797390|Active Comparator|Usual Care|Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
89668671|NCT04854720|Experimental|Group 1 (Fuji II LC-Fuji Triage)|In Group 1, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Fuji® II LC, GC Corporation, Tokyo, Japan) (test 1). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
89668672|NCT04854720|Experimental|Group 2 (Clinpro XT Varnish-Fuji Triage)|In Group 2, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Clinpro™ XT Varnish, 3M ESPE, St. Pauls, Miniapolis, MN, USA) (test 2). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
89668673|NCT04854720|Experimental|Group 3 (Beautiful Flow- Fuji Triage)|In Group 3, newly erupted mandibular permanent first molars were sealed with Giomer containing fissure sealant material (Beautifil Flow, Shofu, Kyoto, Japan) (test 3). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).
89668674|NCT04429074||Group 1 (Registrar)|Group 1 (Registrar): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a registrar (young specialist surgeon)
89668675|NCT04429074||Group 2 (Consultant)|Group 2 (Consultant): Patients who underwent minimally invasive distale pancreatectomy for benign or borderline pathology operated on by a consultant (expert)
89668676|NCT04854330|Active Comparator|Ketone ester|A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml. Immediately following ingestion of the ketones, participants will be given 20 ml of calorie-free sparkling spring water (The Holywell Water Company Ltd, UK) in an attempt to remove any remaining flavour of the supplement.
89668677|NCT04854330|Placebo Comparator|Placebo|In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
89668678|NCT04854252|Experimental|Inflammatory response to opioid vs opioid free anesthesia|Patients were randomly assigned to two anesthesia groups: opioid-containing (n=20) or opioid-free (n=20). The opioid used in the opioid-containing anesthesia group was fentanyl.
89668679|NCT04854174|Experimental|Healthy Volunteer|Healthy Volunteer
89668680|NCT01890083|Active Comparator|Health Education|Participants will three attend heath education sessions per week for 26 weeks.
89214614|NCT06088316|Experimental|Group-A|Group A will receive amoxicillin-esomeprazole high dose dual therapy that is amoxicillin 1gm 8 hourly after meal & esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.
89668681|NCT01890083|Experimental|Exercise|Participants will engage in a public health dose of moderate-to-vigorous aerobic exercise for 26 weeks.
89214615|NCT06088316|Active Comparator|Group-B|Group-B patients will receive levofloxacin containing triple therapy that is Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal & Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
89668682|NCT03040830|Experimental|Egg retrieval arm|67 ICSI cases are started daily 100 mg IM prontogest on the day of egg retrieval until the day of pregnancy test.
89214617|NCT06088251|Experimental|Nutri Training|Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.
89668683|NCT03040830|Active Comparator|Embryo transfer arm|66 ICSI cases are started daily 100 mg IM prontogest on the day of embryo transfer until the day of pregnancy test.
89668684|NCT04390295|Experimental|SHR3824+Metformin, Placebo+Metformin|once daily for SHR3824 and placebo, three times daily for metformin, 24 weeks
89668685|NCT04390295|Experimental|SHR3824 5 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
89668686|NCT04390295|Experimental|SHR3824 10 mg+Metformin|once daily for SHR3824, three times daily for metformin, 52 weeks
89668687|NCT01890239|Experimental|Care Programme for the Last Days of Life|The Care Programme for the Last Days of Life will be implemented in the acute geriatric hospital wards randomized to the experimental group. Subsequently, older patients hospitalized in one of these experimental wards and for who the multidisciplinary team has decided that he or she has entered the dying phase, will benefit from this Care Programme.
89668688|NCT01890239|No Intervention|Usual care|Care will be provided as usual, also for patients who have entered the dying phase.
89668689|NCT02609178|Experimental|FGP design (FGP, AVR)|use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
89668690|NCT02609178|No Intervention|conventional design (CON)|use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
89668691|NCT02348645|Active Comparator|Decompression with fusion|Spinal decompression surgery with instrumented spinal fusion
89668692|NCT02348645|Active Comparator|Decompression alone|Midline-sparing spinal decompression alone
89668693|NCT03030235|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg oral tablet, once daily, for 12 weeks
89668694|NCT03030235|Placebo Comparator|Placebo|Dapagliflozin matching placebo oral tablet, once daily, for 12 weeks
89668695|NCT04853784||Totally laparoscopic colon surgery|Totally laparoscopic colon surgery/intracorporeal anastomosis
89668696|NCT04853784||Laparoscopic-assited colon surgery|Laparoscopic-assited colon surgery/extracorporeal anastomosis
89668697|NCT01890395|Other|blood collection|procedure: Blood draws as the intervention
89668698|NCT04845672|Experimental|2% chlorhexidine gluconate|4% Chlorhexidine gluconate solution and one to one water will be used to create a 2% Chlorhexidine gluconate solution.
89668699|NCT04845672|Active Comparator|soap-free body cleaning solution|It supports and protects the natural barrier function of the skin's natural protective layer.
89668700|NCT01890551|Other|affected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
89668701|NCT01890551|Other|unaffected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
89668702|NCT04444141|Experimental|AK104|AK104 450mg IV every 2 weeks (Q2W)
89668703|NCT04845594|Experimental|MySmileBuddy|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will receive a family-focused intervention called MySmileBuddy.
89668704|NCT04845594|No Intervention|Control|Children, aged 24-71 months of age, who have tooth decay will be enrolled, along with their caregiver, and will not receive any intervention.
89668705|NCT01890629|Experimental|Gemigliptin + Metformin|Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks
89668706|NCT01890629|Active Comparator|Sitagliptin + Metformin|Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks
89668707|NCT01890629|Active Comparator|Glimepiride + Metformin|Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks
89668708|NCT04845204|Active Comparator|Relaxation Treatment|Relaxation treatment (RT) is applied additional to standard physiotherapy treatment. RT includes 8 sessions (2 times a day, for four days after surgery) of relaxation exercises.
89668709|NCT04845204|Active Comparator|Standard Exercises|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
89668710|NCT02088385|Experimental|Hemospray|Hemospray (TC-325, Cook Medical Inc, Winston-Salem, NC, USA), an adsorptive nanopowder hemostatic agent
89668711|NCT02088385|Active Comparator|Combined Conventional Technique|Standard dual therapy with saline adrenaline injection and hemoclip / heater probe application
89668712|NCT04845360|Experimental|pregnancy and differences in gender can be found in the radial arterial pulse|Establishing the meridian through harmonics of blood pressure waves could be a powerful tool to qualitatively and quantitatively indicate physiologic and pathologic factors.
89668713|NCT04845438|Active Comparator|hand-sewn gastroenteroanastomosis|
89668714|NCT04845438|Active Comparator|stapler gastroenteroanastomosis|
89668715|NCT01890863|Experimental|Sequence 1|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): ABBA, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
89668716|NCT01890863|Experimental|Sequence 2|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): BAAB, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
89668717|NCT02955511|Active Comparator|Blade MAC size 3|"Patient will be intubated using a:~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)"
89668718|NCT02955511|Active Comparator|Blade MAC size 3.5|"Patient will be intubated using a:~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)"
89668719|NCT02955511|Experimental|Inscope Blade size 3.5|"Patient will be intubated using a:~Inscope DL-blade size 3.5"
89668720|NCT02816255|Placebo Comparator|Full Face Mask with same CPAP Pressure|After the two week period all will switch to a full face mask with half using the same CPAP pressure.
89668721|NCT02816255|Active Comparator|Full Face Mask with new Pressure|After the two week period all will switch to a full face mask with half using with a new cpap pressure derived from our formula.
89668722|NCT02815631|Experimental|Cardiogoniometry (CGM)|"Every patient involved in the study will undergo a series of CGM recordings whilst having their FFR procedure. These recordings will all be done whilst they are in the catheterisation laboratory and will be taking at the following points during the procedure.~First baseline recording - taken when the patient first enters the catheterisation laboratory and is prepped for their procedure.~Second baseline recording - taken when the FFR guide wire is in place in the coronary artery being assessed.~Maximal hyperaemia recording - this will be taken when the patient is at maximal hyperaemia during their adenosine infusion for their FFR procedure.~The patients involvement will then be finished in the study and will be cared for as per clinical practice.~If the CGM records a result of anything less than 0, it will be regarded as a positive result."
89668723|NCT02815631|Active Comparator|Fractional flow reserve (FFR)|"Every patient involved in the study will undergo an FFR assessment of their coronary arteries. These recordings will all be done whilst they are in the catheterisation laboratory. They will have the following recordings:~A baseline FFR will be recorded once the pressure wire has been advanced down the coronary artery being assessed.~Maximal hyperaemia FFR will be recorded during adenosine infusion.~An FFR ratio of <0.80 will be regarded as a positive result."
89668724|NCT02815553|Experimental|Cardiac tumors|
89668725|NCT04844112|Experimental|Experimental arm|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.~Then additional planning ultrasound using automatic CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
89668726|NCT01890941|Experimental|KCT-0809 Lower Dose|
89668727|NCT01890941|Experimental|KCT-0809 Higher Dose|
89668728|NCT01890941|Placebo Comparator|Placebo|
89668729|NCT04375722|Experimental|tACS 10 Hz low frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 10-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
89668730|NCT04375722|Experimental|tACS 40 Hz high frequency|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 40-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.
89668731|NCT04375722|Sham Comparator|tACS sham|High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups.
89668732|NCT02875483|Placebo Comparator|Standard Scheduling|Group allocated to follow standard surgical scheduling practices
89668733|NCT02875483|Experimental|Expedited Scheduling|Group allocated to expedited scheduling practices
89668734|NCT04374474|Sham Comparator|Control Group|The participants, randomly assigned to this arm, will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care). Besides, it will be prescribed nasal irrigation twice a day.
89668735|NCT04374474|Experimental|Olfactory Retraining Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining and will also be given an essential oil retraining kit, which they will use twice a day. Besides, it will be prescribed nasal irrigation twice a day.
89668736|NCT04374474|Experimental|Olfactory Retraining_Budesonide Group|The participants, randomly assigned to this arm, will receive instructions on olfactory retraining, the olfactory training kit and it will be prescribed nasal irrigation with Budesonise, twice a day.
89668737|NCT04272515|Experimental|BA patients and their parents|"Collection of blood samples from BA patients and their parents~Collection of explanted liver tissue and skin biopsy of BA patients"
89668738|NCT02811601|Experimental|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery
89668739|NCT04272437|Experimental|TRA group|"Tokoro Combination and Rehmannia and Akebia Formula (TRA) in each one batch number were manufactured by Chuang Song Zong Pharmaceutical Co., Ltd., a famous manufacturer of concentrated herbal extract granules in agreement with the standards of good manufacturing practices (GMP) in Kaohsiung City, Taiwan.~TRA contains Tokoro Combination and Rehmannia and Akebia Formula Tokoro Combination and Rehmannia and Akebia Formula consists of Dioscorea Hypoglaucae Rhizoma, Acori Graminei Rhizoma, Linderae Radix, Alpiniae Oxyphyllae Fructus, Poria, Rehmanniae Radix, Akebiae Caulis, Lophatheri Hebra, and Glycyrrhizae Radix at a 2:2:2:2:1:1.3:1.3:1.3:2.5 ratio."
89668740|NCT04272437|Placebo Comparator|placebo group|The placebo was also prepared as granules by Chung Song Zong Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of TRA.
89668741|NCT02983097|Experimental|R²-DHAP|"Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide~Dosage:~Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c.~peripheral stem cell collection after cycle 1 or 2"
89668742|NCT03040284|Experimental|aneurysmal subarachnoid hemorrhage|
89668743|NCT04853706|Other|Delirium|
89668744|NCT04341025|Other|Single Arm|Patients are compared to themselves before and after the treatment.
89668745|NCT04271891|Experimental|With WBPC|Intensive rehabilitation programs :The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks additional WBPC: The duration will be 30 minutes a time
89668746|NCT04271891|Placebo Comparator|Control|Intensive rehabilitation programs: The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks without WBPC.
89668747|NCT01891097|Active Comparator|Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
89668748|NCT01891097|Experimental|Acupuncture plus auricular acupuncture|Subjects will be treated with electroacupuncture plus auricular acupuncture for 3 weeks. The acupuncture regimen, is the same as in electroacupuncture group. In additional to electroacupuncture, subjects will receive auricular acupuncture using borneol. The following 6 ear acupoints points will be selected: Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex. In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours. We will check for skin irritation at each treatment visit.
89668749|NCT01891097|No Intervention|Waiting-list control|This group will receive no treatment. Subjects will be assessed at baseline and the 4th and 7th week; afterwards, they will be randomized to one of the other two groups in the ratio of 1:1.
89668750|NCT01891175|Experimental|Intermittent pneumatic compression|With intermittent pneumatic compression of the lower extremities (Covidien / Kendall SCD ™ sequential compression systems) plus phenylephrine perfusion (usual treatment)in elective caesarean section under spinal anaesthesia.
89668751|NCT01891175|Active Comparator|Only pheniyephrine perfussion|No intermittent pneumatic compression of the lower extremities in elective caesarean section under spinal anaesthesia.
89668752|NCT01891253||ventilated patients|ventilated patients in an internal medicine ICU with existing PiCCO invasive hemodynamic monitoring
89668753|NCT04771585|No Intervention|Study Part A|Aerosol number and size spectrum characterization of 30 subjects, stratified by age groups, including 10 professional singers. Subjects will be examined twice within 14 days to assess reproducibility of aerosol emission.
89668754|NCT04771585|Experimental|Study Part B|From the 30 subjects of Part A, the 10 highest-emitting subjects will be assessed a third time, wearing four different classes of face masks consecutively with increasing aerosol filtering capacity.
89668755|NCT01891409|Other|Single arm|Single arm study study for use of Shang Ring device for male circumcision in children
89668756|NCT04771507|Experimental|Intermittent ibrutinib|Intermittent treatment with ibrutinib.
89668757|NCT01891565|Experimental|Activity Feedback|Feedback
89668758|NCT01891565|No Intervention|No Feedback|
89668759|NCT02807545|Experimental|Physical Therapy Exercise Group|"Each patient assigned to the SSE group will attend at least 8 hours of supervised exercise training led by a Schroth-based certified physical therapist over the course of 6 months. Ideally, patients will be seen for 7 sessions.~Patients will perform a home exercise program for 15 minutes a day, 5 days a week, when they can independently execute their prescribed exercises. An exercise log initialed by the guardian will help families keep track of their exercise adherence and serve as a way to monitor exercise adherence for patients who may not have a smartphone, tablet, or computer.~Patients will also be able to meet with the therapists at their return-to-clinic visits and every 2-3 months thereafter until their 1 year follow-up to assess performance quality, maintain motivation, and progress intensity. Patients will be withdrawn if they do not achieve 80% exercise adherence within 6 months."
89668760|NCT02807545|No Intervention|Control Group|Patients randomized to this group will continue receiving standard-of-care treatment from their orthopaedic physician which includes regularly scheduled clinic visits and observation. Observation consists of no treatment of the scoliosis, only routine clinical assessment by the orthopaedic surgeon to detect curve progression every 3 to 6 months.
89668761|NCT02347865||wave 1|postmenopausal women with osteoporosis treated with Prolia
89668762|NCT02347865||wave 2|postmenopausal women with osteoporosis treated with Prolia
89668763|NCT02713321||Health Home patients|The cohort is made up of patients with type 2 diabetes, insured by Medicaid, and eligible for participation in a Medicaid Health Home (either due to HIV infection, serious mental illness, substance abuse, or multiple chronic conditions). One group will include patients who participate in the Health Home program.
89668764|NCT02713321||non-Health Home patients|The second group will include patients who do not participate in the Health Home program, but have type 2 diabetes, are insured by Medicaid, and meet eligibility requirements for the Health Homes.
89668765|NCT01891799||PMTCT Options Evaluation|All HIV positive pregnant women not on ART engaging in PMTCT services at the study sites will be included. This will include HIV+ women not on ART enrolling in PMTCT services and pregnant women newly testing HIV+ in the ANC. All women will eventually receive the intervention of Option B+ as each clinic transitions from Option A to B+.
89668766|NCT01891877||Current or Former Football Players|Any former or current high school or college football players who carries sickle cell trait.
89668767|NCT01550367|Experimental|Hydroxychloroquine + IL-2|One course of treatment (84 days) will consist of high dose (600,000 IU/kg) bolus IL-2 administered intravenously every 8 hours on days 1-5 and 15-19 (maximum 14 doses/5 days of administration) and hydroxychloroquine (HCQ) orally started two weeks prior to IL-2 infusions and continued while able to take oral medication for up to 3 courses.
89668768|NCT04779463||Mechanical Ventilated patients|All patients are invasively mechanically ventilated at least 24 hours, and are clinically stable as ready to undergo a spontaneous breathing trial.
89668769|NCT01891955|Active Comparator|Diet A|Healthy diet with grains and dairy
89668770|NCT01891955|Active Comparator|Diet B|Healthy diet without grains and dairy
89668771|NCT04389983|Active Comparator|Healthy, under 65 years|Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter (All MCT doses administered as a single dose at time 0)
89668772|NCT04389983|Active Comparator|Healthy, over 65 years|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.~(All MCT doses administered as a single dose at time 0)"
89668773|NCT04389983|Active Comparator|Alzheimer's Disease subjects|"Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.~(All MCT doses administered as a single dose at time 0)"
89668774|NCT04779619||Non-clinical Control|people who score below clinical cut off on measures of anxiety and depression (scoring <10 on PHQ-9 and <8 on GAD-7) and emotionally unstable personality traits (BSL-23) and are not currently using mental health services
89668775|NCT04779619||Clinical Group A|people who are accessing treatment through IAPT services and score above clinical cut off on measures of anxiety and/or depression (>9 on PHQ-9 and/or >7 on GAD-7) but below clinical cut off on a measure of emotionally unstable personality traits (BSL-23)
89668776|NCT04779619||Clinical Group B|people who are accessing treatment through IAPT services and score above clinical cut off on (BSL-23) a measure of emotionally unstable personality traits (irrespective of their scores on the PHQ-9 and GAD-7)
89668777|NCT01892111|Experimental|structured exercise program (SET)|SET one month before and during ARTs. IVF/ICSI procedure.
89668778|NCT01892111|No Intervention|no intervention|IVF/ICSI procedure.
89668779|NCT04771039||patients with chronic inflammatory bowel disease who consulted in ophthalmology|
89668780|NCT01427595|Experimental|Metformin, progesterone , estrace|12 weeks Metformin oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (2X) oral estrace, 0.5-1 mg once a day for seven days (2X)
89668781|NCT04770883|Experimental|Internet based cognitive behavioral therapy group|80 patients will be randomized to receive iCBT. Psychological therapy is effective in IBS patients. The treatment takes 10 weeks and is divided into five successive steps. Patients have to report that they have worked through a treatment step to get access to the next. The patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half of the treatment on step 5, in which exposure exercises are introduced. A psychologist/CBT therapist will manage the online therapeutic contact with the patients.
89668782|NCT04770883|Experimental|Low FODMAP group|80 patients will then be randomized to receive Low FODMAP diet. FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols) are poorly absorbed short-chain carbohydrates including fructose (in excess of glucose), lactose, polyols, fructans and galacto-oligosaccharides. The concept of considering all these molecules collectively as a treatment for IBS is relatively new. Understanding of FODMAPs comprises mechanisms of action such as luminal distension from their osmotic effect and rapid fermentation to hydrogen. These findings have led to increased application of the low FODMAP diet to manage IBS symptoms. Treatment will undergo 10 weeks supervised monotherapy with low FODMAP diet. This will be done with the help of professional dieticians in Örebro region, who will meet the patients and inform them how this diet works as well as follow up.
89668783|NCT04770883|Active Comparator|Control group|The control Group (40 patients) will wait for 10 weeks before being randomised to treatment with either iCBT or low FODMAP diet.
89668784|NCT04390061|Experimental|tofacitinib+HYQ|Tofacitinib 10mg cp twice a day + Hydroxychloroquine 200mg cp three times a day, both for 14 days
89668785|NCT04390061|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 200mg cp three times a day for 14 days
89668786|NCT02212977|Active Comparator|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
89668787|NCT02212977|Experimental|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
89668788|NCT04754659|Experimental|Suprarenal|Individuals that are treated with a suprarenal stentgraft for a previously diagnosed AAA.
89049186|NCT03454854|Experimental|APP-assisted anti-thrombotic therapy|Intelligent response system:real-time receiving data or events that doctor or patient terminal upload,then spontaneously evaluate the thrombosis and bleeding risk based on code of point built-in,respectively send messages to doctor and patient after this, then doctors direct the patients to adjust treatment schedule.Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal APP, establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
89668789|NCT04754659|Active Comparator|Infrarenal|Individuals that are treated with an infrarenal stentgraft for a previously diagnosed AAA.
89049187|NCT02905097||Arthroplasty cohort|A cohort of patients who will undergo knee replacement surgery and will receive Triathlon Tritanium (cementless) tibial implant.
89049188|NCT03454815|Experimental|Patency Group|apical patency was maintained during chemomechanical preparation
89049189|NCT03454815|No Intervention|Non Patency Group|Apical patency was not maintained during chemomechanical preparation
89668790|NCT01892813|Experimental|Tailored intervention|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.
89668791|NCT01892813|Active Comparator|Enhanced standard of care|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.
89668792|NCT04770649||COVID-19 vaccine recipients|Subjects who have an appointment to receive a COVID-19 vaccine, and are able to provide samples prior to and after their first vaccine dose.
89668793|NCT01892891|Experimental|VBY-036|VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
89668794|NCT01892891|Placebo Comparator|Placebo comparator|Placebo
89668795|NCT00716443|Active Comparator|Pliaglis® Cream|tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
89668796|NCT00716443|Active Comparator|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
89668797|NCT01892969||HEART AND LUNG FAILURE|Patients with Heart failure or Respiratory Failure with Hyperglycemia
89668798|NCT01893047|No Intervention|no music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
89668799|NCT01893047|Experimental|live music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
89668800|NCT01893047|Experimental|recorded music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
89668801|NCT02802293|Active Comparator|Standard rTMS Aiming|Active repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left DLPFC using the standard aiming strategy with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
89668802|NCT02802293|Active Comparator|Anterior DLPFC targeting|Active rTMS will be delivered to the left anterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
89668803|NCT02802293|Active Comparator|Posterior DLPFC targeting|Active rTMS will be delivered to the left posterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
89668804|NCT00684619|Experimental|Arm A|Nelarabine
89668805|NCT00650143|Active Comparator|1|"Application G-CSF (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100 mg each day for 28 days.~n=74"
89668806|NCT00650143|Placebo Comparator|2|"NaCl 0.9% applied twice daily over a period of 5 days and oral Placebo given once a day for 28 days.~n=74"
89668807|NCT01893125|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
89668808|NCT01893125|Placebo Comparator|Placebo|Placebo 1 cap tid 21 days
89668809|NCT04770961|Sham Comparator|Cryoablation|1. Cryoablation of intercostal nerves + Sham ESP catheter with saline infusion.
89668810|NCT04770961|Experimental|ESP + Cryoablation|2. Cryoablation of intercostal nerves + ESP catheter with local anesthetic infusion.
89668811|NCT04758221|Experimental|Single arm : Composite coronal build up strip crown|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
89668812|NCT04753489|Other|Sequence TR|17 subjects assigned to the sequence TR will receive a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
89668813|NCT04753489|Other|Sequence RT|17 subjects assigned to the sequence RT will receive a single 10 mg dose of the reference product Xarelto® (1 x 10 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg dose of the test product Rivaroxaban (1 x 10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, after overnight fasting. The tablet must be swallowed whole and must not be chewed or broken.
89668814|NCT04753567|Experimental|Actual pain patch|
89668815|NCT04753567|Placebo Comparator|Sham patch|
89668816|NCT02791997|Experimental|Brain-damaged patients|
89668817|NCT02791997|Experimental|Control participants|
88995466|NCT02428712|Experimental|FORE8394|"Group A: Phase 1-Dose Escalation: Adult patients.~Group B: Phase 1-Dose Escalation: Pediatric patients.~Phase 2a-Dose Extension: Adult patients with advanced unresectable solid tumors will be enrolled among two cohorts.~Cohort 1: Activating BRAF V600 mutations (glioma patients only)~Cohort 2: Activating BRAF non-V600 mutations~Phase 2a-RP2D Confirmation: Adult patients.~Phase 2a-RP2D Redefinition and Extension:~Cohort 3: Activating BRAF V600 or activating non-V600 mutation~Cohort 4: Activating BRAF non-V600 mutations~Phase 2a-RP2D Redefinition:~Cohort 6A: Advanced activating BRAF-mutated solid tumors~Cohort 7A: Advanced activating BRAF-mutated solid tumors~Cohort 8A: Advanced activating BRAF-mutated solid tumors"
88995467|NCT02425904|Experimental|Recurrent or Refractory Langerhans Cell Histiocytosis (LCH) + Clofarabine|"Participants with recurrent or refractory LCH defined as with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen.~Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles."
89668818|NCT02791997|Experimental|Migraine patients|
89668819|NCT04753333|Experimental|Experimental|The participants in the experimental group will receive Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for four weeks.
89668820|NCT04753333|Placebo Comparator|Control|The participants in the experimental group will receive Sham EMG-BF guided isometric quadriceps strengthening without patellar taping five days a week for four weeks.
89668821|NCT04754347|No Intervention|Control|Routine Colonoscopy
89668822|NCT04754347|Experimental|Experimental|Routine Colonoscopy with the use of Skout
89668823|NCT04769557|Experimental|Paracetamol|Paracetamol
89668824|NCT04769557|Placebo Comparator|Placebo|placebo
89668825|NCT04758299|No Intervention|Standard care|information from an FDA authorized home test kit for what actions to take for a negative or positive COVID-19 test
89668826|NCT04758299|Experimental|Decision science-based design|Information from a decision science-based design (of similar length to the FDA authorized home test kit information) for what actions to take for a negative or positive COVID-19 test
89668827|NCT04757909|Experimental|Monthly Haemoglobinometry|
89668828|NCT04757909|No Intervention|Routine monitoring|
89668829|NCT05606497||Early-onset FGR|
89668830|NCT05586893|Experimental|Electroacupuncture|The acupuncture electrical stimulation was performed by the EL 608 electroacupuncture device (NKL, Brusque - SC, Brazil, ANVISA 80191680002). For the stimulation of the acupuncture points, we selected a biphasic wave, 2 HZ of frequency, 6 mA of wavelength, and 5 seconds at resting time. The total stimulation time was 20 minutes.
89668831|NCT05586893|Experimental|Acupuncture therapy|"The acupuncture points were bilaterally punctured by a stainless steel acupuncture needle (length 30mm x diameter 0.25) (Dongbang, Boryeong, Chungnam- Korea). We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher."
89668832|NCT05586893|No Intervention|Control Group|Infrared images were captured at the first assessment (P0), 10 minutes later (P10), 20 minutes later (P20) and 30 minutes after the first assessment (P30). All analyzes were performed using QuickReport software, version 1.2 (FLIR Systems). No application of interventions between assessments.
89668833|NCT04778995|Experimental|Manager nurses (Experimental group)|Manager nurses who participated in the structured training program based on qualitative data. Web based training program was the intervention for this group.
89668834|NCT04778995|No Intervention|Manager nurses (Control group)|Manager nurses who were not included to the structured training program based on qualitative data. No intervention was performed for this group.
89049190|NCT02905019|Active Comparator|Standard Dose x3 (Group 1)|R21 with Matrix-M1. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0, 28 and 56.
89668835|NCT02308709|Experimental|Ventilation image-guided radiotherapy|Patients will receive 4D CT ventilation image-guided personalized radiotherapy treatment that selectively avoids irradiating highly-functional lung regions
89668836|NCT01893437|Experimental|Single oral dose group|
89668837|NCT04778917|Experimental|Small dose low molecular weight heparin|Low molecular weight heparin calcium 100 units / kg/day, subcutaneous injection, 5-10 days of treatment or D-dimer recovery normal.
89668838|NCT04778917|Experimental|High dose of low molecular weight heparin|low molecular weight heparin calcium 200 units /kg/day, subcutaneous injection, treatment for 7 days or D-dimer return to normal.
89668839|NCT04778917|Placebo Comparator|Vacuity contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
89668840|NCT04778917|No Intervention|contrast group|Conventional treatment for children with pneumonia, without the use of low molecular weight heparin.
89668841|NCT04778683|Experimental|VR Group|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing.
89668842|NCT04778683|No Intervention|Control Group|The same evaluations were performed in children in the control group who received routine clinical care.
89214618|NCT06088251|Active Comparator|Standard Nutrition Education|Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
89214619|NCT06088225|Experimental|Distance -image screen|Distance -image screen is a device to make image in the distance of 6-meters when reading and learning at near. The investigators will ask the subjects to use the distance - image screen for 12 month
89214620|NCT06088121|Active Comparator|ATNC MDD-V1|ATNC MDD-V1 treatment, synchronized TMS and cognitive training stimulation
89668843|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)|"For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:~Immuno-oncology included PD-L1 IHC combined positivity score >10, high microsatellite instability, tumor mutation burden >15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab."
89214621|NCT06088121|Sham Comparator|Sham TMS + Real Cog|The Control arm subjects will receive daily treatments five days a week for 6 consecutive weeks of Sham treatment of TMS and real cognitive training which is similar to the real treatment in visit frequency and procedure.
89214622|NCT06088108|Experimental|Single arm|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
89668844|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (HER2 amplified)|HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
89668845|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EFGR amplified)|EGFR amplified. These patients received ABT-806.
89668846|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)|FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.
89668847|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)|MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
89668848|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EGFR expressing)|EGFR expressing. These patients received standard cytotherapy plus ABT 806.
89668849|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (All negative)|All negative. These patients received standard cytotherapy plus Ramucirumab.
89668850|NCT02213289|Other|Non-ITT: Standard Therapy|Patients without monoclonal antibodies available received standard cytotherapy.
89668851|NCT05606185|Active Comparator|Two step retraction|teeth will be retracted in two stages
89668852|NCT05606185|Experimental|En masse retraction|teeth will be retracted in one stage
89668853|NCT05606107|Active Comparator|Glucocorticoid group|
89668854|NCT05606107|Experimental|Tofacitinib group|
89668855|NCT02776007|Experimental|Libre Flash CGMS (Continuous Monitoring System)|Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
89668856|NCT02776007|Active Comparator|SMBG|Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
89668857|NCT04778605||Patients with septic shock stabilized between H6 and H24 of treatment under noradrenaline.|
89668858|NCT00053989|Experimental|All patients|All patients enrolled on study
89668859|NCT05606029||Patients who underwent cholecystectomy for benign conditions|In those who underwent cholecystectomy for benign conditions, the histopathological analysis showed the malignancy.
89668860|NCT05605717||Pre specified group|Fibroscan Abdominal ultrasound Lab investigation
89668861|NCT02085473|Active Comparator|Cohort 1|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'W' mL/min.
89668862|NCT02085473|Experimental|Cohort 2|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'X' mL/min.
89668863|NCT02085473|Experimental|Cohort 3|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Y' mL/min.
89214623|NCT06088082|No Intervention|CONTROL GROUP|) will receive standard routine postoperative analgesia at our institute.
89214624|NCT06088082|Experimental|TREATMENT GROUP|The patients will be divided into two groups; group-1 (n= 50) will receive pre-procedure right US-guided TAP and bilateral PRS blocks with bupivacaine 0.25% 20 ml for TAP block and 10 ml for PRS block .
89668864|NCT02085473|Experimental|Cohort 4|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Z' mL/min.
89668865|NCT02085551|Experimental|Mechanical thrombectomy by the Indigo System|
89668866|NCT02740595|Experimental|Nicotine|Use an e-cig filled with liquid with nicotine
89668867|NCT02740595|Experimental|no nicotine|Use an e-cig filled with liquid without nicotine
89668868|NCT02740595|Sham Comparator|sham comparator|Use an empty e-cigarette (sham control)
89668869|NCT01893593|Other|Control|Usual care
89668870|NCT01893593|Active Comparator|Intervention|Multifaceted intervention to improve clinical systems
89668871|NCT02708537||PRGF in candidates for sperm donors|Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.
89668872|NCT02705495|Active Comparator|acupuncture|12 acupuncture treatments according to a standardized protocol, plus recommendation for use of cranberry products
89668873|NCT02705495|Other|Control|Recommendation for use of cranberry products only
89668874|NCT02702219|Experimental|Dynamic streching|Mobility training of the hamstrings muscles to be performed every day
89668875|NCT02702219|Active Comparator|Static stretching|Static stretching of the hamstrings muscles to be performed every day
89668876|NCT02701907|Other|breast cancer|In this study, we aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. We will focus our analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
89668877|NCT02701907|Other|non-small cell lung cancer|"In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies.~The investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed"
89214625|NCT06088056|Experimental|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
89668878|NCT02701907|Other|kidney cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
89668879|NCT02701907|Other|colorectal cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
89668880|NCT02701907|Other|ovarian cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
89668881|NCT02701907|Other|skin cutaneous melanoma|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
89668882|NCT01893671||LASIK|Subjects undergoing routine LASIK for the correction of myopia or hyperopia.
89668883|NCT02686697|Experimental|L-Carnosine|oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
89668884|NCT02686697|Placebo Comparator|Placebo|matching placebo
89668885|NCT02983019||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis
89668886|NCT02983019||Therapy without interferons' inducers|Therapy according to routine practice Groups will be splitted during the final data analysis
89668887|NCT02679677|Sham Comparator|Control|Whole body vibration training as sham procedure (5Hz) 3 times a week, 3x2 minutes, for 6 weeks.
89668888|NCT02679677|Experimental|Intervention|Whole body vibration training (12 Hz up to 30 Hz) 3 times a week, 3x2 minutes, for 6 weeks.
89668889|NCT02669069|Active Comparator|PS1|
89668890|NCT02669069|Active Comparator|PS2|
89668891|NCT02669069|Active Comparator|PS3|
89668892|NCT02665481|Experimental|MBSR|Mindfulness-Based Stress Reduction consists of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content includes instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life.
89668893|NCT02665481|Experimental|Exercise|The exercise protocol is optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty.It consists of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months.
89668894|NCT02665481|Experimental|MBSR + Exercise|"This condition will receive both MBSR and exercise as described above. Participants in this condition will come in once weekly to receive MBSR and twice weekly to receive exercise classes, with at-home exercise the other two days as well as daily, at-home mindfulness practice. After the initial classes participants will also attend additional weekly or monthly sessions until completion of the study.~Note that at each site a pilot group is undergoing MBSR + Exercise (not randomized, separate from the RCT)."
89668895|NCT02665481|Active Comparator|Health Education|Health Education is a group-based intervention that increases health-related knowledge and action. Health Education improves chronic disease management.Health Education consists of ten weekly 2.5-hour classes, followed by monthly classes for approximately 15 months.
89668896|NCT02214147|Experimental|Alisertib: Normal Hepatic Function|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range [ULN] and alanine aminotransferase [ALT] level ≤ ULN.
89668897|NCT02214147|Experimental|Alisertib: Moderate Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin > 1.5-3 x ULN and any ALT level.
89049191|NCT02905019|Active Comparator|High Dose (Group 2)|R21 with Matrix-M1. Two vaccinations with 50µg R21/50µg Matrix-M1 on days 0 and 28 and one vaccination with 10 µg R21/ 50 µg Matrix M1 on day 56.
89522110|NCT03413111|No Intervention|Standard double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, NK precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
89522111|NCT04448015|Experimental|Enhanced Perinatal Care|Pregnant women enrolled in the study will receive enhanced perinatal care from community healthcare providers that have participated in the perinatal OUD education curriculum.
89522112|NCT03413033||Group 1|43 participants will produce the vowel /a:/ three times as baseline during 5 seconds in habitual, comfortable speaking pitch and loudness. Thereafter, participants will produce series of a semi-occluded vocal tract exercises (resonance tube or lip trill). Afterwards, subjects will produce the vowel /a:/ three times once again. Electroglottographic signals will be captured before and after each exercise. A 15 minutes voice rest will be taken between exercises by all subjects.
89522113|NCT04511325|Other|Potato Regimen Arm|All participants will be randomly assigned to receive the potato regimen daily for the 12-week treatment period, separated by a 2-week washout.The potato regimen (75 grams of baked white russet potato with the skin) and refined grain (100 grams of long grain white rice) regimen will be matched for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day.
89049192|NCT02905019|Active Comparator|Combination (Group 3)|R21 with Matrix-M1, ChAd63 ME-TRAP and MVA ME-TRAP. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 , 28 and 56. Plus one vaccination with ChAd63 ME-TRAP on day 7 and one vaccination with MVA ME-TRAP on day 63.
89049193|NCT02905019|No Intervention|Control Group 4a|These volunteers will not be vaccinated and will serve as infectivity controls when groups 1-3 undergo challenge.
89049194|NCT02905019|No Intervention|Control Group 4b|These volunteers will not be vaccinated and will serve as infectivity controls when group 5-7 and sterilely protected volunteers from groups 1-3 undergo challenge.
89049195|NCT02905019|No Intervention|Control Group 4c|These volunteers will not be vaccinated and will serve as infectivity controls if any volunteers from groups 5 and 7 are rechallenged.
89049196|NCT02905019|Active Comparator|Fractional Dose (Group 5)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28 and one vaccination with 2µg R21/ 50 µg Matrix-M1 on day 56.
89522114|NCT04511325|Other|Refined Grain Regimen Arm|All participants will be randomly assigned to the calorie-matched refined grain daily for the 12-week treatment period, separated by a 2-week washout.The refined grain (100 grams of long grain white rice) regimen will be matched to the potato regimen for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day. Long-grain boiled white rice also has a similar glycemic index to that of a baked white potato.
89522115|NCT03412955|Experimental|Eribulin|Patients enrolled into the study will receive Eribulin 1.4mg/m2 on days 1 and 8 of a 21-day treatment cycle till disease progression or non-tolerable toxicity.
89522116|NCT05229159||BiPOCS group|All patients of our centers admitted for postoperative care after cardiac surgery with cardiopulmonary bypass and receiving a bioelectrical impedance analysis at the admission.
89522117|NCT01328041|Experimental|dolutegravir|dolutegravir plus background antiretroviral therapy optimised at Day 8
89522118|NCT03412721|Experimental|Laser analgesia|Procedure: Laser analgesic procedure Performing protocol for pre-emptive laser analgesia with Er:YAG laser (Litetouch, Syneron) switched on.
89522119|NCT03412721|Placebo Comparator|Placebo analgesia|Procedure: Placebo analgesic procedure Performing imitation of laser analgesic protocol with Er:YAG laser (Litetouch, Syneron) switched off - no pulse energy applied.
89522120|NCT05229081|Other|Vaccine education|The intervention arm refers to the arm in which the pharmacist gives vaccination education.
89522121|NCT05229081|No Intervention|Standard of Care|The control arm refers to the arm that includes patients who receive routine health care services without vaccination education provided by the pharmacist.
89522122|NCT03418415|Experimental|Renal denervation|Procedure: Renal denervation
89522123|NCT03418337|Experimental|dexilansoprazole group (Dexilant 60 mg)|After randomization, 60 subjects will receive oral dexlansoprazole (Dexilant 60 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
89522124|NCT03418337|Active Comparator|lansoprazole group (Takepron OD 30 mg)|After randomization, 60 subjects will receive oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
89214626|NCT06088017|Experimental|Sequence 1|"Period 1: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 2: CKD-391(2) - A single oral dose of 1 tablet under fasting condition~Period 3: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 4: CKD-391(2) - A single oral dose of 1 tablet under fasting condition"
89214627|NCT06088017|Experimental|Sequence 2|"Period 1: CKD-391(2) - A single oral dose of 1 tablet under fasting condition~Period 2: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition~Period 3: CKD-391(2) - A single oral dose of 1 tablet under fasting condition~Period 4: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition"
89522125|NCT03412487|Active Comparator|premature ovarian failure|women under 40 years old with History of oligomenorrhea or amenorrhea for 1 year or more FSH level >20 IU/L at least 2 occasions 4-6 weeks apart (FSH level 20-40 IU/L indicates ovarian insufficiency, while level above 40 IU/L indicates complete failure).
89522126|NCT03412487|Active Comparator|Control group|A group of female patients presented with infertility but with regular menses and normal ovarian function (according to history, general examination, gynecological examination and FSH level).
89214628|NCT06087965|Experimental|Fingolimod group|0.5mg/day oral fingolimod over a course of 3 consecutive days
89214629|NCT06087965|No Intervention|Control group|No fingolimod will be administered.
89214630|NCT06087952|Other|Continue anticoagulation|Patients with high recurrent VTE risk and low major bleeding risks are advised to continue anticoagulant therapy.
89214631|NCT06087952|Other|Discontinue anticoagulation|Patients with low recurrent VTE risk are advised to discontinue anticoagulant therapy.
89522127|NCT04435977|Experimental|Cabozantinib|Drug: Cabozantinib Subjects who meet all study eligibility criteria will take tablets containing 60 mg of cabozantinib once daily orally. Required dose reductions will be in decrements of 20 mg cabozantinib (maximum two dose reductions).
89522128|NCT03414125|Active Comparator|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
89522129|NCT03414125|Experimental|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences.~Choice Strategy outreach invitation includes: 1) invitation letter, 2) option grid comparing FIT and colonoscopy 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
89522130|NCT03418181|Other|Standard Haemodialysis|Thrice weekly dialysis (control arm) - dialysis dose will not be adjusted according to Residual Kidney Function and subjects will be dialysed initially for 3.5-4 hours thrice weekly to ensure a target minimum eKt/V of 1.2.
89522131|NCT03418181|Experimental|Incremental dialysis|"Twice weekly dialysis - dialysis dose will be adjusted according to Residual Kidney Function.~Patients will commence dialysis for 3.5-4 hours twice weekly and have residual renal urea clearance formally measured by interdialytic urine collection at the end of the week following dialysis initiation. Subsequent to this, dialysis dose will be adjusted."
89522132|NCT03424447|No Intervention|Non stimulated|Prospective data obtained from non stimulated patients
89522133|NCT03424447|Experimental|Stimulated|Prospective data obtaied from stimulated patients
89522134|NCT04510857|Experimental|MOVE-IT Home Exercise Program (HEP)|Participants will be asked to employ the MOVE-IT system for upper extremity practice at home 1 hour/day, 5 days/week over a 10-week period.
89522135|NCT04510857|Active Comparator|Usual Care Treatment (UCT) Control|Children in the UCT group will be followed as they continue to receive their previously prescribed therapy services. These children will not receive any treatment services through the study as UCT group participants.
89522136|NCT02608307||AYA patients|Adolescence and young adults (AYA) who meet eligibility criteria and consent to participate in the study.
89522137|NCT02608307||Parents of AYA patients|Parents of AYA patients who meet eligibility criteria and consent to participate in the study.
89522138|NCT02608307||Health Care Providers (HCPs)|Health care providers who meet eligibility criteria and consent to participate in the study.
89522139|NCT03411967|Experimental|apatinib combine with docetaxel|Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd
89522140|NCT03410173|Experimental|Taurine|2.4mg/d for 12 weeks
89522141|NCT03410173|Placebo Comparator|Placebo|2.4mg/d for 12 weeks
89522142|NCT05168293||Entecavir group|
89522143|NCT05168293||Tenofovir group|
89522144|NCT02410772|Active Comparator|Regimen 1|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
89522145|NCT02410772|Experimental|Regimen 2|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
89668898|NCT02214147|Experimental|Alisertib: Severe Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin > 3 x ULN and any ALT level.
89049197|NCT02905019|No Intervention|Long-term Efficacy (Group 6)|Volunteers in this group have received vaccinations in a different malaria vaccine trial. These volunteers will not receive any vaccinations in this trial, but will undergo controlled human malaria infection as part of this study.
89668899|NCT05586581|Experimental|People living with treated suppressed HIV infection (PLWH)|"40 PLWH participants will be scanned using anatomical magnetic resonance imaging (MRI) and undergo two SV2A (11C-UCB-J) PET scans with arterial sampling and full radio metabolite analysis to obtain measures of synaptic density at baseline and 24 months (2 years). For each SV2A PET, up to 20 millicurie (mCi) of [11C], UCB-J will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes.~A subset of PLWH (n=20) will participate in TSPO (11C-PBR28) PET scans on the same day as the baseline SV2A PET scan. For a TSPO PET, up to 20 mCi of [11C], PBR28 will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes."
89668900|NCT05586581|Experimental|HIV-Negative Control (HIV-)|30 HIV-Negative Control (HIV-) participants will be scanned using anatomical magnetic resonance imaging (MRI) and undergo two SV2A (11C-UCB-J) PET scans with arterial sampling and full radio metabolite analysis to obtain measures of synaptic density at baseline and 24 months (2 years). For each SV2A PET, up to 20 mCi of [11C], UCB-J will be administered by an intravenous line (IV) with a scan duration of up to 120 minutes.
89668901|NCT02086331|Active Comparator|Healthy|Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria
89668902|NCT02086331|Active Comparator|PAD|Symptomatic peripheral arterial disease
89668903|NCT02086331|Active Comparator|DM|Symptomatic diabetic peripheral neuropathy
89668904|NCT02214615|Active Comparator|Carbamazepine|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.
89668905|NCT02214615|Placebo Comparator|Placebo|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
89668906|NCT02663219|Experimental|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
89668907|NCT02663219|No Intervention|Control|Standard of care
89668908|NCT02661503|Active Comparator|BEACOPP|4 or 6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Doxorubicin (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will bev given a total of six cycles.
89668909|NCT02661503|Experimental|BRECADD|4 or 6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Doxorubicin (A) Dacarbazine (D) Dexamethasone (D). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will be given a total of six cycles.
89668910|NCT01554891||Cohort 1|100 OEF/OIF/OND veterans returning to Joint Base Lewis-McChord and Fort Bragg who screen positive for TBI on the Post Deployment Health Assessment (PDHA) TBI screen
89668911|NCT01554891||Cohort 2|100 OEF/OIF/OND veterans seeking care at Northern New England VA Research Consortium (NNEVARC) VA Medical Centers (VAMCs) who screen positive for TBI on VA Level 1 TBI screen
89668912|NCT01554891||Cohort 3|200 participants in WRNMMC and Fort Belvoir Community Hospital Brain Indices Study (100 with mild TBI; 100 without mild TBI).
89668913|NCT02650817|Experimental|Elacestrant (formerly RAD1901)|To receive daily oral elacestrant
89668914|NCT01430091|Active Comparator|Prasugrel clinical formulation|A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
89668915|NCT01430091|Experimental|Prasugrel (ODT) - on tongue|A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
89668916|NCT01430091|Experimental|Prasugrel (ODT) - apple juice|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
89668917|NCT01430091|Experimental|Prasugrel (ODT) - chewed|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
89668918|NCT01430091|Experimental|Prasugrel (ODT) - under tongue|A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
89049198|NCT02905019|Active Comparator|Standard Dose x2 (Group 7)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28.
89049199|NCT03454776|Active Comparator|Unloader One brace|Patients receiving an active brace, Unloader One with active straps facilitating unloading of affected knee compartment
89049200|NCT03454776|Placebo Comparator|Placebo brace|Patients receiving a dummy, lookalike or placebo brace without active straps that facilitate unloading of the affected knee compartment
89049201|NCT02904941|Experimental|Amniotic Membrane Dressing|Children allocated to this arm will receive skin dressings made out of human amniotic membrane. Dressings will be replaced every 72 - 96 hours.
89049202|NCT02904941|Active Comparator|Synthetic Dressing|Children allocated to this arm will receive skin dressings made out of silicone as part of their wound care. Dressings will be replaced every 72 - 96 hours.
89049203|NCT03454737|Experimental|mesenchymal stem cells|
89049204|NCT03454737|Active Comparator|Pure platelet-rich plasma|
89668919|NCT02607228|Experimental|Alobresib Dose Escalation|Participants who have progressed on either abiraterone and/or enzalutamide will be enrolled to receive increasing doses of alobresib up to 9 mg to determine the MTD.
89668920|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Escalation|Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive less than or equal to MTD of alobresib in combination with enzalutamide 160 mg once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of alobresib may be increased.
89668921|NCT02607228|Experimental|Alobresib Dose Expansion (Group 1)|Participants will receive a dose less than or equal to MTD of alobresib (based on safety, pharmacodynamics (PD), and tolerability).
89668922|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 2)|Participants will receive a dose less than or equal to MTD of alobresib plus enzalutamide (based on safety, PD, and tolerability).
89668923|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 3)|Participants will receive alobresib plus enzalutamide (dose will be equivalent to the dose chosen for Group 2).
89668924|NCT01430169|Experimental|AA4500|"collagenase clostridium histolyticum (AA4500) contains purified collagenase AA4500 (clostridium histolyticum) consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.~2 injections of AA4500 0.58 mg were administered 24 hours apart."
89668925|NCT03008577|No Intervention|Ambient operating room temperature of 67°F|These patients will have an operating room temperature of 67°F for cesarean delivery, the standard of care at our institution.
89668926|NCT03008577|Active Comparator|Ambient operating room temperature of 75°F|Intervention: Ambient operating room temperature of 75°F for cesarean delivery, which is closer to World Health Organization recommendations.
89668927|NCT02638883|Experimental|Implanted|Subjects will be implanted with the Hybrid SRW cochlear implant.
89668928|NCT03040752|Active Comparator|Nifedipine|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
89668929|NCT03040752|Active Comparator|Ritodrine|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor.
89668930|NCT01430325|Sham Comparator|Sea Level Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion"
89668931|NCT01430325|Experimental|Sea Level Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion"
89668932|NCT01430325|Sham Comparator|Altitude Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Altitude Equivalent 1.2 atm abs (5.1 psig) breathing regular air 20-minute chamber excursion"
89668933|NCT01430325|Experimental|Altitude Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Altitude Equivalent 1.5 atm abs (9.6 psig) breathing 100% oxygen 20-minute chamber excursion"
89668934|NCT02637947|Experimental|Magnetic navigation|Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
89668935|NCT02637947|Active Comparator|Manual navigation|Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.
89668936|NCT02636933||59 prematurely born children|Lung function assessment of 59 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR)
89668937|NCT02636933||93 full-term born children|Lung function assessment of a Control group of full-term born children (N=93), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
88995468|NCT02425904|Experimental|LCH-related disorders + Clofarabine|"Participants with LCH-related disorders defined as who require systemic chemotherapy including participants with Rosai Dorfman Disease (RDD) who have not responded to or recurred after treatment with corticosteroids. Erdheim Chester Disease (ECD) subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor.~Patient will receive Clofarabine administered via IV on days 1-5, 25 mg/m2/day per cycle for 2 cycles. At the end of cycle 2 if no disease progression, will continue with same dose for maintenance treatment for 4 additional cycles."
88995469|NCT02406209|Experimental|NS2|NS2 ophthalmic drops (0.5%) in the affected eye
88995470|NCT02406209|Experimental|NS2 and Pred Forte|NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
88995471|NCT02406209|Active Comparator|Pred Forte|Prednisolone acetate ophthalmic suspension (1%) in the affected eye
89214632|NCT06087952|Other|Randomised to continue anticoagulation|Patients with intermediate recurrent VTE risk or high recurrent VTE risk and high major bleeding risk are randomised to continue or discontinue anticoagulant therapy.
88995472|NCT02313428|Experimental|Standard of Care with Topical Oxygen Treatment|patients who have a chronic wound, will receive their receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities).
88995473|NCT02313428|No Intervention|Standard of Care only|patients that have a chronic wound will receive only their standard of care treatment.
88995474|NCT02295722|Experimental|Gemcitabine/Melphalan Condition + ASCT|"Day -1 -~IV gemcitabine 1.5-2.5 g/m2 (depending on dose level assigned) administered as a loading bolus of 75 mg/m2, followed by a continuous infusion of 10 mg/m2/min.~immediately following gemcitabine - IV melphalan 200 mg/m2 over 5 minutes.~Day 0~•Stem cell infusion~Patients will be assigned a dose level using the continual reassessment method based on the toxicity data available at the time of their enrollment. The dosing will start at 1.5 g/m2 and will increase by 0.5 mg/m2 at each level to a maximum of 2.5 g/m2. Dose-limiting toxicity is defined as grade 3 mucositis or skin toxicity lasting more than 3 days before downgrading, or any grade 4 non-hematological toxicity."
88995475|NCT02284308||Patients with any subtype of NSCLC, primary UICC Stage III, age ≥ 75 years|All registered patients will undergo a geriatric assessment to assess vulnerability. Based on this assessment, patients are offered treatment according to the discretion of the physician and patient.
89214633|NCT06087952|Other|Randomised to discontinue anticoagulation|Patients with intermediate recurrent VTE risk or high recurrent VTE risk and high major bleeding risk are randomised to continue or discontinue anticoagulant therapy.
89214634|NCT06087913|Experimental|Active|TAF/EVG (20/16mg) vaginal insert
89214635|NCT06087913|Placebo Comparator|Placebo|Matching placebo insert
89214636|NCT06087900|Experimental|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
89214637|NCT06087900|Experimental|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
89668938|NCT03008421|Experimental|Study group (GBS positive w/o infection)|Treatment with study medication twice daily for 2 weeks (from study visit 1 to study visit 2)
89668939|NCT03008421|Placebo Comparator|Placebo group (GBS positive w/o infection)|Treatment with placebo twice daily for 2 weeks (from study visit 1 to study visit 2)
89668940|NCT01668654|Experimental|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
89668941|NCT02634359|Other|IVF Treatments- Frozen Embryo transfer|Consenting women that arrive to IVF clinic for frozen embryo transfer on spontaneous cycle Study Intervention: Ultrasound and Blood test to detect Ovulation. At home, HR, RR and movements will be contactlessly measured using EarlySense home device
89668942|NCT02634359|Other|IVF Treatments- Clinical Evaluation|"Consenting women that arrive for cycle evaluation or insemination on spontaneous cycle (infertile women).~Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device"
89668943|NCT02634359|Other|No IVF|Healthy women volunteers with regular menstrual cycles - not using contraceptives Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device
89668944|NCT01431105|Experimental|Atorvasatin|Atorvastatin dose titration to maximum tolerated dose
89668945|NCT03038958|Active Comparator|Isobaric 2-chloroprocaine|The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy
89668946|NCT03038958|Active Comparator|Hyperbaric prilocaine 2%|The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy
89668947|NCT02633267|Experimental|Usual Vocational Services + CBT|This is the experimental intervention - Usual vocational services at a vocational services center plus additional cognitive behavioral therapy at vocational service center.
89668948|NCT02633267|Active Comparator|Usual Vocational Services|This is the care as usual intervention - Vocational services as usually delivered to service seeking clients
89668949|NCT04840290|Experimental|Sintilimab Plus Platinum Doublet Chemotherapy|Specified dose on specified days Sintilimab
89668950|NCT02630069|Experimental|CDP-choline+supportive psychotherapy|CDP-choline 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
89668951|NCT02630069|Placebo Comparator|Placebo+supportive psychotherapy|Placebo 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
89668952|NCT02630069|No Intervention|Healthy control|No intervention
89668953|NCT04843956|Experimental|Patients with solid pancreatic lesions|Patients who will undergo endoscopic ultrasound biopsy. Samples of at least 3 passes will be obtained, each pass obtained with a different technique (capillary with suction, capillary without suction and wet suction)
89668954|NCT01431339|Active Comparator|Vancomycin with possible switch to oral linezolid|
89668955|NCT01431339|Experimental|Dalbavancin|
89668956|NCT02627261||patients with multiple myeloma|blood samples and bone marrow aspirates will be collected in patients at different time point
89668957|NCT03040206||Nodal PTCL|"newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative) between January 1, 2005 and Jun 30, 2016~initially treated with curative intent~Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment"
89668958|NCT02623517||Enrolled Subjects|The Enrolled Subjects group will comprise of 75 individuals who will be followed for 12 months for their atrial fibrillation condition. Data will be collected from subjects' devices for 12 months, and any needed changes or additions to therapy will be done. (ie: ablation, pacemaker setting changes, medication control).
89668959|NCT02623517||Registry Subjects|The Registry Subjects group will comprise of screened patients who do not exhibit symptoms of atrial fibrillation at the time of screening. The already collected data from the patient's device during the screening visit will be kept and put into a registry.
89668960|NCT04843878||Positive|Subjects that tested positive for COVID-19 based on the clinical gold standard PCR test.
89668961|NCT04843878||Negative|Subjects that tested negative for COVID-19 based on the clinical gold standard PCR test.
89668962|NCT04853160||All Participants With Gout|Participants with gout, initiating febuxostat therapy on or after 01 June 2016 will be included in the study.
89668963|NCT04852380||Patients treated by PRP injection|
89688700|NCT02929927|Experimental|Control group|Rubber dam isolation, tooth disinfection，acess to the pulp of the chamber, microbiological sample with two sterile paper points, then mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer, then take the sample again, drying the canal and fill the canal with a commercial calcium hydroxide-based paste. After 2 weeks, the canals were filled with AH-Plus sealer and Gutta-percha by vertical condensation. The teeth were take crown restoration. Follow up at 3, 6, 12 and 24 months.
88995476|NCT02282059||sunitinib group|patients with progressive, unresectable, advanced or metastatic well-differentiated pNET
89668964|NCT04852770|Experimental|Trial-Based Cognitive Therapy|TBCT (de Oliveira, 2008) is a novel transdiagnostic approach (Wenzel, 2017). It has been shown to be effective for depression (Hemanny et al., 2019), social anxiety disorder (Neufeld et al., 2020; Caetano et al., 2018; de Oliveira et al., 2011; Powell et al., 2013), and PTSD (Duran et al., 2020). TBCT differs from other CBT approaches in that it introduces a new, organized, and systematic approach to change dysfunctional negative core beliefs, and allows cognitive, emotional, and experiential work to be done simultaneously (de Oliveira, 2016). Interestingly, it incorporates a courtroom metaphor to challenge dysfunctional core beliefs conceptualized as self-accusations (de Oliveira, 2016). TBCT is an example of assimilative psychotherapy integration that relies on Beckian CBT (de Oliveira, 2016). It incorporates and integrates components of other psychotherapies (Delavechia et al., 2016).
89668965|NCT04852770|Active Comparator|Mindfulness-Based Health Promotion|The Mindfulness-Based Stress Reduction (MBSR) program was created by Jon Kabat-Zinn and colleagues at the University of Massachusetts Medical Center in 1979, and it is an intervention whose effects on mental health and quality of life has produced several studies worldwide, both in clinical and non-clinical populations. Several protocols have been developed based on the MBSR aimed at specific publics, such as the Mindfulness-Based Health Promotion (MBHP) program developed by the Mente Aberta - Brazilian Center for Mindfulness and Health Promotion. The MBHP program was inspired by the original MBSR model but adapted to the context of the Brazilian Health Care (SUS) system, addressing chronic conditions and mental disorders as well (TROMBKA et al., 2018; LOPES et al., 2019; SALVO et al., 2018).
89668966|NCT04852770|Active Comparator|Positive psychotherapy|Positive psychotherapy (PPT) seeks to understand positive emotions, psychological potentialities and healthy human / social / institutional functioning, and to apply this knowledge to help people and institutions, with a focus on prevention and promotion of mental health (SELIGMAN et al., 2005). Originally, PP focused on happiness and subjective well-being (SELIGMAN, 2010; SELIGMAN; CSIKSZENTMIHALYI, 2000). Then, the studies gained a broader view of psychological well-being and another similar proposal entitled PERMA, which is composed of the following five spheres: positive emotions - P; engagement - E; relationships - R; meaning - M; and achievement - A. (RYFF, 2013; SELIGMAN, 2012). Although positive psychology aims to be a way of looking at life, some psychotherapeutic proposals, such as positive psychotherapy (PPT), have been developed, and clinical studies have been replicated in different clinical and cultural contexts (RASHID; SELIGMAN, 2019; RICHES et al., 2016).
89668967|NCT01431573|Experimental|Wake Therapy + light box +/- lithium|"Bipolar patients must take lithium; others do not take lithium~all patients are hospitalized for a week during which they do not sleep on alternating nights~for six weeks, including the week in the hospital all patients sit in front of bright lights at specified times and for specified durations"
89668968|NCT02588807|Experimental|Spirit1|Patients will take a daily nutritional supplement for 8 months
89668969|NCT05586425|Experimental|Emotion Regulation Skills + Treatment as Usual|Emotion Regulation Skills (ERS), a version of Dialectical Behaviour Therapy Skills Training, is a type of skills-focused therapy for individuals who experience severe emotion dysregulation.
89668970|NCT05586425|Active Comparator|Treatment as Usual|Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
89668971|NCT04843644|Experimental|honey|"Honey, 10 grams per pack, calories 33.4 calories, protein 0.05 grams, fat 0.07 grams, fructose + glucose 7.0 grams, sodium 0 mg.~Usage is three times a day after three meals. After oral care is required before use, use 10 grams of longan honey, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink, or gargle within 30 minutes of use."
89668972|NCT04843644|Experimental|propolis|"Oil-soluble green propolis, propolis 100 mg / mL, dilute green propolis 200 times with edible oil, drink 0.5 mL each time, 3 times a day (a total of 50 mg).~Usage: three times a day, after three meals. After oral care is required before use, draw about 0.5ml of green propolis into the mouth, circulate in the oral cavity for at least 30 seconds, and slowly swallow. Do not eat, drink or gargle within 30 minutes of use."
89668973|NCT04843644|Placebo Comparator|control|Routine care to encourage oral care three times a day.
89668974|NCT02588105|Experimental|Safety and Tolerability|All patients will receive AZD0156 as a monotherapy or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents to assess safety and tolerability
88995477|NCT02066285|Experimental|Pazopanib|Single arm of pazopanib 800 mg (2x400 mg or 4x200 mg) given as a single agent once daily continuously.
88995478|NCT01964989|Experimental|aQIV|flu vaccine
88995479|NCT01964989|Active Comparator|non-adjuvanted comparator|flu vaccine
88995480|NCT01934309|Experimental|TB reminders|Receive existing reminders plus new patient-specific reminders about TB screening, prevention, and treatment
88995481|NCT01934309|No Intervention|No TB reminders|Only receive existing reminders; no TB reminders
88995482|NCT01575860|Experimental|Phase I/II (Maintenance Lenalidomide in Lymphoma)|Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.
88995483|NCT01416831|Active Comparator|Arm A: IL-2 Monotherapy|Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2. Crossover patients will be included in Arm A.
88995484|NCT01416831|Experimental|Arm B: SBRT + IL-2|Patients will receive two doses of radiation before receiving high-dose IL-2.
88995485|NCT00635700|Experimental|Ziprasidone|Patients will be treated with Ziprasidone for 6 months
88995486|NCT00635700|Placebo Comparator|Placebo|Patients will be treated with placebo for 6 months
88995487|NCT00634257||Patients|Patients with advanced cancer receiving palliative care.
88995488|NCT00634257||Caregivers|Primary caregivers of Patients with advanced cancer receiving palliative care.
88995489|NCT00582075|Experimental|Radiosurgery 15-24 Gy + Adjuvant Temozolomide|
88995490|NCT00558961|Experimental|I|Gleevec Chlorambucil
88995491|NCT00507923|Experimental|Group I (Tibetan yoga)|Participants participate in Tibetan yoga sessions consisting of deep breathing or stretching exercises over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions.
88995492|NCT00507923|Active Comparator|Group II (stretching)|Participants participate in stretching exercise sessions over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
89668975|NCT04840368|Experimental|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
89668976|NCT04840368|Active Comparator|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min, and a cool down of 10 min (muscle stretching and relaxation). They will be performed individually, outside, at a self-selected intensity, with no supervision.
89668977|NCT01488279|Active Comparator|Dexamethasone 2.5mg and Sitagliptin100mg|Participants received Dexamethasone 2.5 mg plus Sitagliptin 100 mg daily for 8 days
89668978|NCT01488279|Placebo Comparator|Dexamethasone 2.5mg and placebo tablet|Participants received Dexamethasone 2.5 mg plus Sitagliptin-matched placebo tablet daily for 8 days.
89668979|NCT03040050|Other|Men scheduled for prostate biopsy randomized to Control|
89668980|NCT03040050|Experimental|Men scheduled for a prostate biopsy randomized to Intervention|
89668981|NCT01490073|Active Comparator|Active nitroglycerin ointment|
89668982|NCT01490073|Placebo Comparator|Placebo ointment|
89668983|NCT04852536||HD-tDCS4x1|All data will be acquired from patients of the triple-blind clinical trial that will investigate the effectiveness of treatment for neuropathic pain after brachial plexus injury with HD-tDCS. There will be collection and analysis of EEG data before the clinical trial protocol, to later assess the prediction of response to the technique employed. At the end, they will be grouped into responders and non-responders to HD-tDCS, according to the numerical scale of pain, with assignments serving as targets for the analyzes with machine learning. The labels for clinical improvement used to classify machine learning will be determined based on the data obtained in the baseline and post-treatment assessments, according to similar studies. Thus, the EEG data of these patients will be retrospectively examined, identifying possible neurophysiological characteristics and biomarkers related to the frequency bands that allow predicting which patients are most likely to improve with this treatment.
89668984|NCT01490151|Experimental|TTR controller|The intervention will consist of using the TTR controller (Medtronic) for post-prandial glucose control following high and low glycemic meals
89668985|NCT04041336|Experimental|All participants|All participants will have measurements taken. There are no comparators or controls in this feasibility study
89668986|NCT04852146||Professional|The sample of professionals will be made up of doctors and nurses of the emergency structures (pre and intra-hospital), doctors and nurses of interventional cardiology and ambulance drivers practising in an establishment of the 7 participating SAMU zones
89668987|NCT04852146||Patient|The patient sample will consist of patients included in the REANIM registry during the study period (the entire period of the stepped wedge randomised controlled trial).
89668988|NCT02584517||GCA|Patients referred with suspected GCA, whose final diagnosis is GCA
89668989|NCT02584517||Not GCA|Patients referred with suspected GCA, whose final diagnosis is another disorder
89668990|NCT01556061|Experimental|D-MAC video laryngoscopy|The Dblade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with CMAC blade.
89668991|NCT01556061|Active Comparator|C-MAC video laryngoscopy|The CMAC blade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with D-blade
89668992|NCT02564159|Experimental|High-risk patient for malnutrition acquired in ICU|Patients admitted in ICU and treated with mechanical ventilation with expected duration of 48 hours or more
89668993|NCT02564159|Other|Controls patients: Elective surgery|"Controls patients: Elective surgery (neurosurgery, thoracic surgery, vascular surgery)~- Patients admitted in a post-operative care unit of the university hospital of Nantes after elective surgery with expected duration ICU length of stay < 48 hours"
88995493|NCT00507923|Active Comparator|Group III (usual care)|Participants receive usual care and wear actigraph activity monitor and complete a sleep diary for 7 days. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
88995494|NCT00326456|Experimental|carboplatin and liposomal doxorubicin|
88995495|NCT00326456|Active Comparator|carboplatin and paclitaxel|
88995496|NCT00244842|Placebo Comparator|Placebo Comparator: 1|Placebo
88995497|NCT00244842|Active Comparator|Voclosporin 0.2 mg/kg po BID|Voclosporin 0.2 mg/kg po BID
88995498|NCT00244842|Active Comparator|Voclosporin 0.3 mg/kg po BID|Voclosporin 0.3 mg/kg po BID
88995499|NCT00244842|Active Comparator|Voclosporin 0.4 mg/kg po BID|Voclosporin 0.4 mg/kg po BID
89668994|NCT03038646|Experimental|Regimen A|32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state
88995500|NCT04688827|Experimental|training group 1: low-intensity resistance training|
88995501|NCT04688827|Experimental|training group 2: moderate-intensity resistance training|
89668995|NCT03038646|Experimental|Regimen B|32 mg MIN-101 MR administered in the fasted state
89668996|NCT03038646|Experimental|Regimen C|32 mg MIN-101 MR administered in the fasted state
89668997|NCT03038646|Experimental|Part 2 selected dose|32 mg MIN-101 of MR administered in the fed state
89668998|NCT03008109|Experimental|EGFR-TK inhibitor plus RH-endostatin|EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7
89668999|NCT04851990|Experimental|Large Patch|"To Better Days Large Patch~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
89669000|NCT04851990|Experimental|Small patch|"To Better Days Small Patch~1 patch applied daily by 9am - in situ for 24 hours Dosage: vitamin D 30,000 IU + dextrose 13mg"
89669001|NCT02731235|Other|Control|Prophylactic stroke medication and recommendations for lifestyle changes
89669002|NCT02731235|Active Comparator|Exercise|Prophylactic stroke medication and recommendations for lifestyle changes AND high-intensity training at home, 5 days a week in 12 weeks
89669003|NCT02562443|Experimental|rigosertib + best supportive care (BSC)|
89669004|NCT02562443|Active Comparator|Physician's Choice (PC) + best supportive care (BSC)|
89669005|NCT04843098|Experimental|Single arm, open label|Phase 1a: All subjects receiving TL117 alone (20-120 mg); Phase 1b: All subjects receiving TL117 (MTD-1 or MTD) plus Paclitaxel; Phase 2: All subjects receiving TL117 in combination with Paclitaxel at RP2D
89669006|NCT01490931|Experimental|Ketorolac nasal spray 31.5 mg|Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
89669007|NCT04842942|Experimental|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
89669008|NCT04843020|Experimental|Drug subcutaneous injection|Monthly injection of ION 682884, administered subcutaneously at a dose of 45 mg.
89669009|NCT01556451|Experimental|Zoster Vaccine Live|Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1
89669010|NCT04839432||Crystalloids group|Patients had only a balanced crystalloid solution in the priming of the cardiopulmonary bypass (pre interventional group)
89669011|NCT04839432||albumin group|Patients had only a 4% albumin solution in addtion to a very low volume of a balanced crystalloid solution in the priming of the cardiopulmonary bypass (post interventional group)
89669012|NCT02562365|Experimental|A: three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
89669013|NCT02562365|No Intervention|B: Follow-up|No interevention
89049205|NCT02904980|Experimental|Technical Training Group|15 children diagnosed with DCD
89049206|NCT02904980|Experimental|Quiet Eye Training Group|15 children diagnosed with DCD
89669014|NCT02559635|No Intervention|No bowel stimulation|Patients undergoing loop ileostomy closures without having had bowel stimulation beforehand
89669015|NCT02559635|Experimental|Bowel stimulation|Patients undergoing loop ileostomy closures having undergone bowel stimulation beforehand
89669016|NCT01557699|Experimental|PMV via Puffhaler® Device|The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
89669017|NCT01557699|Experimental|PMV via SoloventTM device|The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
89669018|NCT01557699|Active Comparator|Licensed Subcutaneous Measles Vaccine|Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.
89669019|NCT02542319|Experimental|Magnesium|Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
89669020|NCT02542319|Placebo Comparator|Placebo|Matching placebo tablets twice daily for 12 months.
89669021|NCT02608476|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
89669022|NCT02608476|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
89669023|NCT01491633|Experimental|Dasatinib|Dasatinib 140 mg by mouth each day
89669024|NCT02539823|Placebo Comparator|Control|Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
89669025|NCT02539823|Experimental|CBD 400mg|Subjects will receive 400mg of cannabidiol
89669026|NCT02539823|Experimental|CBD 800mg|Subjects will receive 800 mg of cannabidiol
89669027|NCT04851600||Early introduction|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
89669028|NCT01433913|Experimental|Arm I (metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 4-12 weeks.
89669029|NCT01433913|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-12 weeks.
89669030|NCT02527031|Active Comparator|Pre hospital ECMO|ECMO Insertion on pre hospital setting for a refractory cardiac arrest
89669031|NCT02527031|Active Comparator|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
89669032|NCT04839120|Active Comparator|MDPK67b|
89669033|NCT04839120|Placebo Comparator|Placebo|
89669034|NCT04851054||Patients after surgery for colon cancer with intention to cure|Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers participating in the study, who will undergo elective surgical resection with potentially curative intention
89669035|NCT01558791|No Intervention|Arm 1|"Participants will be screened as usual. These participants will have the TBI screening as usual, without the educational intervention."
89669036|NCT01558791|Experimental|Arm 2|Participants will be given the TBI handout (educational intervention) along with the usual TBI screen.
89669037|NCT02509793|Experimental|Tetrabenazine|Xenazine (tetrabenazine), pill, dosage titrated to effect, three times a day, 12 weeks
89688701|NCT02929927|Experimental|Experimental group|Rubber dam isolation，tooth disinfection，acess to the pulp of the chamber, microbiological sample with two sterile paper points, then mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO for 1 min, then 17%EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer, drying the canal, aPDT, then take the sample again. then dried the canals and filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation. The teeth were take crown restoration. Follow up at 3, 6, 12 and 24 months.
89669038|NCT04842396|Experimental|Experimental: Motorized cycle ergometer|"The exercise group cycles 20 minutes per session on the MOTOmed Muvi 3 days per week for 6 weeks at an intensity guided by the perception of effort.~A cycling cadence is fixed between 25 and 30 rpm for all sessions since that cadence is comfortable for every participant. Researchers adjust resistance on the motorized cycle to increase the external load until it reached the level required to reach the intensity of effort programmed by the OMNI-RPE. The six weeks are programmed in the form of two intensity-differentiated training phases of three weeks. In the first training phase (i.e., the first three weeks), participants are requested to cycle simultaneously with the upper and lower limbs at an intensity equivalent to a perception of 3 (i.e., easy to somewhat moderate) on the OMNI-RPE (0-10)."
89669039|NCT04842396|No Intervention|Control group|Participants are evaluated the week before and the week after the experimental group finishes the training period (pre- vs. postintervention) to facilitate an examination of the changes in body composition, functional performance, and resting cardiovascular state.
89669040|NCT02508467|Experimental|Fisogatinib (BLU-554)|Fisogatinib (BLU-554) capsules for oral administration.
89669041|NCT04838730|Experimental|single-arm|Hanita CleaRing device (CE approved; AMAR Certificate)
89669042|NCT01559649||Group 1|Veterans admitted to MEDVAMC with a suspected ischemic or hemorrhagic stroke will be recruited. Individuals with a history of neurological disease other than stroke, head and neck structural surgery, or history of dysphagia unrelated to the current stroke will be excluded from participation. Individuals who are obtunded, medically unstable, greater than 5 days post-admission will be excluded. Patients with language or cognitive deficits who are judged by the attending neurologist to not have capacity to provide informed consent will be eligible to participate, but they must have an authorized representative available within 24 hours of admission to provide consent. Patients will undergo swallowing screening and videofluoroscopic swallowing study to establish validity of screening items
89669043|NCT01559649||Group 2|Stroke ward nurses. The nurses will administer and interpret the swallowing screening items. Speech pathologists will also make blinded, simultaneous interpretations of the screening items. Nurse and speech pathologist interpretation will be used to establish nursing reliability.
89669044|NCT04842474|Experimental|Gaze stability and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
89669045|NCT05586347|Experimental|group N|Nicardipine was infused after initiation of CPB
89669046|NCT05586347|Placebo Comparator|group C|Give the same volume of normal saline
89669047|NCT04842318|Experimental|BR+R|Induction Therapy: Rituximab Combined With Bendamustine Maintenance Treatment: Rituximab
89669048|NCT04842318|Experimental|RCHOP+R|Induction Therapy: Rituximab Combined With Cyclophosphamide, Vincristine, Doxorubicin, Prednisone Maintenance Treatment: Rituximab
89669049|NCT04842318|Experimental|R2+R2|Induction Therapy: Lenalidomide Combined With Rituximab Maintenance Treatment: Lenalidomide Combined With Rituximab
89669050|NCT01436799|Experimental|Desflurane|anaesthesia was induced with thiopental sodium 2 mg kg-1, alfentanil 10 μg kg-1 and rocuronium 0.6 mg kg-1. Anesthetic maintenance by desflurane
89669051|NCT01436799|Active Comparator|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1, alfentanil 10 μg kg-1, and rocuronium 0.6 mg kg-1. A commercially available target controlled infusion (TCI) pump (Orchestra®, Fresenius Vial, France) was used and the pharmacokinetic set used to calculate target effect-site concentrations for propofol was Schnider and colleagues' model
89669052|NCT03038724|Other|Targeted testing|Patients complete a questionnaire on risk factors for HIV acquisition and are offered rapid (fingerprick) HIV testing if their questionnaire responses indicate they have HIV risk factors
89669053|NCT03038724|Other|Non-targeted screening|Patients offered a brief information on HIV and HIV testing and are then offered rapid (fingerprick) HIV testing without completing an HIV risk factor assessment
89669054|NCT04842240||Patients undergoing implant based immediate breast reconstruction.|Patients will undergo either pre- or sub-pectoral implant based immediate breast reconstruction.
89214638|NCT06087900|Experimental|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
89669055|NCT01437501|Experimental|Broccoli Sprout Extract Beverage|
89669056|NCT01437501|Placebo Comparator|Placebo beverage|
89669057|NCT04842162|Experimental|Patients with head and neck cancer|
89669058|NCT02505347|Experimental|No splint|will be able to move the arm as tolerated following surgery.
89669059|NCT02505347|Active Comparator|Splint|will receive a splint following surgery for 6 weeks.
89669060|NCT01560975|Experimental|Sensimed Triggerfish|
89669061|NCT04851132|Experimental|Exprimental Arm|IMRT plus Durvalumab
88995502|NCT04688437||Patients with degenerative scoliosis|
89214639|NCT06087900|Sham Comparator|Control|The CON group did not have any intervention but usual care.
89669062|NCT02504489|Active Comparator|Docetaxel (D)|A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
89669063|NCT02504489|Experimental|Docetaxel + Plinabulin (DP)|The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On Day 8, patients must be given an anti-emetic prophylactically before the plinabulin infusion. If emesis persists after Day 8, with a grade >1, plinabulin will be reduced to 20 mg/m2. Patients from the DP Arm who stop treatment with docetaxel due to toxicity or another medically acceptable reason, may continue treatment with plinabulin alone as previously described.
89669064|NCT04850976|Experimental|Self-Assembled Modified Macintosh Videolaryngoscope (SAM-VL) group|The self-assembled modified Macintosh videolaryngoscope (SAM-VL) used in this study was constructed from a portable video camera with Wi-fi connection (Wi-fi Endoscope Video Camera model YPC99) attached to a no. 4 Macintosh Laryngoscope blade (Riester® no.7040). The video signal is transmitted to an Android-based mobile phone (Android version 7.0). The portable 2 megapixels video camera is 8 mm in diameter with 8 Light Emitting Diode (LED) lights for adjustable lighting level and 3 meters cable length. Video resolution output is 640x480 pixels (VGA) and 1280x720 pixels (HD). The camera has 70º visual angle with focus length of 4- 6cm and is water-resistant. The camera was taped to the Macintosh blade at a distance of 5 cm from the distal end of the blade, using transparent waterproof Leukofix® tape.
89669065|NCT04850976|Active Comparator|McGrath MAC® videolaryngoscope (McGrath) group|The McGrath MAC® videolaryngoscope used in this study was equipped with disposable blade no.4
89669066|NCT01494051|Active Comparator|High carbohydrate diet|Diet composition of 10% long-chain fatty acids, 20% medium-chain triglycerides, 12% protein and 68% carbohydrate is the current standard of care in long-chain fatty acid oxidation disorders.
89669067|NCT01494051|Experimental|High protein diet|Diet composition of 10% long-chain fatty acids, 20% medium chain triglycerides, 25% protein and 45% carbohydrate is the comparison diet. Fat content is the same between treatments; only the carbohydrate to protein ratio varies.
89669068|NCT03038490|Experimental|Study group|The treatment group would be given 2 Sackets of an oral mixture of arginine, glutamine and HMB (ABOUND) every day for a maximum period of 4 weeks, either orally or via enteral feeding.
89669069|NCT03038490|No Intervention|Control group|All patients would be assessed by a dietitian to ensure them receiving nutritional support of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding method. During the study period, vitamin C and zinc supplement would not be given.
89669070|NCT04757597|Experimental|RIC group|RIC treatment and regular treatment.
89669071|NCT04757597|No Intervention|Regular treatment|Regular treatment alone.
89669072|NCT01495221|Other|Intravitreal aflibercept|All eligible patients will receive intravitreal aflibercept injection (2.0mg) every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months) through Week 24. Patients can be dosed as frequently as 2 mg every 4 weeks (monthly) upon investigator discretion.
89669073|NCT02488343|Experimental|Behavioral Intervention|Participants in this group will receive tailored psychological intervention to promote adherence to their drug therapy.
89669074|NCT02488343|No Intervention|Non Intervention group|Participants in this group will be observed but will not receive any intervention.
89669075|NCT04841850||Hazelnut allergic children under oral immunotherapy|"Children Under eighteen years of age~Convincing clinical history of hazelnut allergy~Positive hazelnut prick test or specific IgE~Under IOT hazelnut protocol in pneumology and allergology-paediatric departement of the Mother and Child Hospital in Bron"
89669076|NCT04850742|Experimental|Cryopreserved aorta|After resection of a segment of tracheal or bronchial lesion, reconstruct the airway with cryopreserved aortic allograft.
89669077|NCT04850586|Experimental|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
89669078|NCT04850586|No Intervention|Control Group|Routine education was given to the patients in the control group. Routine education was administered by a nurse working in the clinic after the patients were admitted to the hospital. The patients in this group were not trained by a multidisciplinary team. In the routine training, patients were only informed about preoperative preparation.
89669079|NCT02446925|Experimental|Surefire® Infusion System|Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
89669080|NCT02446925|Active Comparator|Standard End-hole catheter|Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.
89669081|NCT03038178|Experimental|LAI plus multi-drug regimen|once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
89669082|NCT04850352|Experimental|Heukcha Extracts|Take Heukcha Extracts capsule once daily for 8 weeks.
89669083|NCT04850352|Placebo Comparator|Placebo|Take placebo capsule once daily for 8 weeks.
89049207|NCT04625322|No Intervention|Referral to outpatient specialty for HCV care|Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care. TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment. Patients who do not attend the initial visit will be rescheduled. After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
89214640|NCT06087887||tumor size 0-1cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 0-1 cm.
89669084|NCT04841694|Experimental|Probiotic|Participants will be taking a probiotic supplement that they will be taking by mouth once per day
89669085|NCT02440919|Other|Hyperoxygenation - 100% FiO2|Hyperoxygenation involved supplying 100% fraction of inspired oxygen (FIO2).
88995503|NCT02915887|Experimental|cervical taping|Participants received treatment including elastic taping application to the neck. They were assessed 3 times: Pre taping, 20 minutes post-taping on day 1, and 7 days post-taping.
89669086|NCT02440919|Other|Hyperoxygenation - 20% FiO2|Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
89669087|NCT02440919|Other|Hyperinflation - Basal FiO2|Ventilator hyperinflation, with keeping the oxygen already offered to the patient.
89669088|NCT02440919|Other|Hyperinflation - 20% FiO2|Ventilator hyperinflation and hyperoxygenation involved supplying 20% oxygen.
89669089|NCT02983409||Pstone|Adult Patients (> 18years) who were diagnosed as the urinary stone in the ED. All patients who visited the ED with compalin of acute pain, and urinary stone was idenfied by urinary CT in the ED.
89669090|NCT02424617|Active Comparator|Arm A|designed to determine the maximum dose of bemcentinib that can be safely administered in combination with erlotinib administered at the approved oral dose level of 150 mg daily. It is anticipated that a maximum of three bemcentinib dose levels will be evaluated, with up to approximately 18 participants enrolled. In the absence of unacceptable toxicity, participants will be allowed to continue receiving bemcentinib in combination with erlotinib until disease progression.- (Arm completed)
89669091|NCT02424617|Active Comparator|Arm B|will incorporate a Simon-like two-stage design with relaxed stopping for futility to evaluate the safety, pharmacokinetics and clinical activity of bemcentinib in combination with erlotinib in participants with an activating EGFR mutation who have progressed after receiving prior EGFR TKI inhibitors or who have progressed after osimertinib.
89669092|NCT02424617|Active Comparator|Arm C|will evaluate the safety, pharmacodynamics and clinical activity of bemcentinib when administered in combination with erlotinib in participants with an activating EGFR mutation who have received at least twelve weeks of erlotinib without disease progression (Open to enrolment).
89669093|NCT02424617|Other|Run in Arm|The primary goal of the Run-in Cohort is to establish the safety and tolerability of bemcentinib administered as a single agent. Eligible participants will have either exhausted existing licensed therapies or be unsuitable for treatment with existing licensed therapies for NSCLC. bemcentinib will be administered at a loading dose of 600 mg on Day 1 and Day 2 of Cycle 1, followed by 200 mg daily thereafter (Arm completed)
89669094|NCT02415413|Experimental|Carlizomib lenalidomide and low dose dexamethasone|"Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.~High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).~Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).~Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone"
89669095|NCT04346303|Other|Short-term Interactive Video Games|Short-term video games will be applied to patients with mental illness who are staying in communities. Games will be applied in a group-activity format with 8 to 12 patients in each session. The interventions will be conducted at a two sessions per week for a 3-week long period. There are 3 time points for data collection, including 2-weeks before the intervention, the week before the intervention, and the week after the intervention. Each patient will be his/her own controlled comparison.
89669096|NCT04757441|Experimental|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire (ELDOA)|Participants will receive conventional treatment along with ELDOA stretching exercises protocol at L5, S1.
89669097|NCT04757441|Other|Group B: Conventional treatment|Participants will receive only conventional treatment (Control)
89669098|NCT04745741||IB-positive group|Patients with level IB metastasis and histologically confirmed positive by biopsy.
89669099|NCT02382965||ultrasound|
89669100|NCT02376647|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation (≤13cmH2O)
89669101|NCT02376647|Active Comparator|Conventional ventilation|Mechanical ventilation with limited tidal volume (8mL/kg of predicted body weight) and plateau pressure (≤30cmH2O)
89669102|NCT01894061|Experimental|Bevacizumab and NovoTTF-100A|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle.The dose of bevacizumab will be 10 mg/kg of actual body weight.
89669103|NCT01561053|Experimental|High Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
89669104|NCT01561053|Experimental|Low Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
88995504|NCT02915926|Active Comparator|OT|standard OT
88995505|NCT02915926|Experimental|OT+OPC|occupational performance coaching
88995506|NCT03160378|Experimental|Intervention|The participants in the intervention group will receive treatment as usual + 10 sessions of organizational skills training
88995507|NCT03160378|Other|Control|Control participants will receive treatment as usual.
88995508|NCT03142984|Experimental|Phase 1|"An open use test in a cohort of newborn babies to confirm the tolerability and evaluate the acceptability of a new Baby Wash & Shampoo product and Baby Lotion.~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
88995509|NCT03142984|Experimental|Phase 2|"An evaluator blind, randomized, controlled trial to determine whether a wash and lotion regimen used for 12 weeks can strengthen the skin barrier in newborns when compared to standard skincare practices without massage.~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
88995510|NCT02915770|Experimental|participants receive cholangiojejunostomy|participants will receive hepatectomy、cholangiojejunostomy and T-tube Drainage
89669105|NCT01561053|Experimental|Low Albumin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
89669106|NCT01561053|No Intervention|Control (sham) group|Simulated plasma exchange procedure
89669107|NCT02338349|Experimental|Elacestrant|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of elacestrant.~Part B, Safety Expansion: Once the MTD has been identified and/or a RP2D has been selected, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary efficacy of the RP2D.~Part C, Tablet Introduction: A cohort of patients will be enrolled to evaluate the safety, tolerability, and PK of a tablet dosage form at 400 mg QD.~Part D, Dose Expansion: A cohort of patients will be enrolled to evaluate the safety, tolerability, PK and preliminary anti-tumor effect of elacestrant in tablet dosage form at 400 mg QD PO in a group of patients with a more homogeneous prior treatment history"
89669108|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Adult Group|Subjects 18-60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
89669109|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Elderly Group|Subjects above 60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
89669110|NCT03008343|Experimental|Electroporation and natural killer|In this group, the patients will receive regular irreversible electroporation (IRE) treatment in combination with multiple natural killer (NK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89669111|NCT03008343|Active Comparator|Electroporation|In this group, the patients will receive regular irreversible electroporation (IRE) treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89669112|NCT01561833|Experimental|Sorafenib|Sorafenib, 400 mg PO twice daily
89669113|NCT02607306|Experimental|Insulin degludec/liraglutide OD|
89669114|NCT02607306|Active Comparator|Insulin degludec OD|
89669115|NCT02607306|Active Comparator|Liraglutide OD|
89669116|NCT02315885|Placebo Comparator|placebo alcohol|<0.05% alcohol
89669117|NCT02315885|Active Comparator|alcohol middle dose|alcohol dose=0.45g/kg for women and 0.5g/kg for men
89669118|NCT02315885|Active Comparator|alcohol high dose|alcohol dose=0.90g/kg for women and 1.0g/kg for men
89669119|NCT04839276|Experimental|Injection Laryngoplasty with PRF and Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is added to 4 mL of PRF and is smoothed by pushing it back and forth 15 times on a 2-tube 10 mL piston tube connected to a three-way connector. 3 mL of the mixture of fat and PRF is injected using a 12 G laryngoplasty syringe until medialization is achieved.
89669120|NCT04839276|Active Comparator|Injection Laryngoplasty with Autologous Fat|Autologous microlobular fat is harvested from abdominal fat (area under the umbilical). 4 mL of microlobular fat is mashed by pushing it back and forth 15 times in a container of 2 piston tubes (10 mL) connected to a three-way connector. The crushed fat is injected as much as 3 mL using a 12 G laryngoplasty syringe until medialization is achieved.
89669121|NCT04850664|Experimental|CBOT + TAU|CBOT consists of 40 cycles of olfactory stimulation and OFC training tasks, lasting ~45 minutes, once daily over 3 months. Treatment-as-usual (TAU) is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
89669122|NCT04850664|Sham Comparator|Sham + TAU|Sham is a CBOT device that uses artificially-scented compressed room air instead of olfactory stimulants and has no OFC cognitive tasks. Similar to the CBOT, sham will be used daily for 45 minutes. TAU is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
89669123|NCT01562379|No Intervention|No food|A control in which mothers will receive nutrition education about continued breastfeeding and adequate complementary feeding throughout the period of 6-18 months of age.
89669124|NCT01562379|Active Comparator|Plumpy Doz|In this control arm children will receive prepackaged, lipid-based Plumpy'Doz (Nutriset, Mulaunay, France) for daily consumption as a snack.
89669125|NCT01562379|Experimental|Wheat Soy Blend (WSB++)|Children will receive a WFP-developed Wheat-Soy Blend (WSB++) snack to be consumed daily.
89669126|NCT01562379|Experimental|Chickpea based complementary food supplement|Children will receive a Chickpea based complementary food supplement to be consumed daily.
89669127|NCT01562379|Experimental|Rice based complementary food supplement|Children will receive a locally developed rice based complementary food supplement.
89669128|NCT01440543|Experimental|Water/CO2|water immersion during colonoscope insertion and CO2 insufflation during colonoscope withdrawal
89669129|NCT01440543|Experimental|Water/Air|Water immersion during colonoscope insertion and air insufflation during colonoscope withdrawal
89669130|NCT01440543|Experimental|CO2/CO2|CO2 insufflation during both colonoscope insertion and withdrawal
89669131|NCT01440543|No Intervention|Air/Air|room air insufflation during both colonoscope insertion and withdrawal
89669132|NCT01495689|Active Comparator|Usual Care|Usual care for smoking cessation will be delivered to the control arm which comprises of strong physician advice, brief counseling from the clinic nurse +/- a prescription for smoking cessation aid if requested and willing
89669133|NCT01495689|Experimental|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
89669134|NCT03040128|Placebo Comparator|placebo|normal saline infusion
89669135|NCT03040128|Experimental|minocycline|intravenous minocycline
89669136|NCT03039972||Pulmonary Hypertension|Adult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages
89669137|NCT04841928|No Intervention|Waitlist control|Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
89669138|NCT04841928|Experimental|Mindful attention|Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
89669139|NCT04841928|Experimental|Decentering|Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
89669140|NCT04841928|Experimental|Values and committed action|Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
89669141|NCT04841928|Experimental|Mindful attention + Decentering|Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component. Total number of sessions: 4 (4 contact hours).
89669142|NCT04841928|Experimental|Mindful attention + Values and committed action|Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
89669143|NCT04841928|Experimental|Decentering + Values and committed action|Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
89669144|NCT04841928|Experimental|Mindful attention + Decentering + Value-based action|Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component. Total number of sessions: 6 (6 contact hours).
89669145|NCT01563003|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 16 weekly CBT sessions. This intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposures to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases
89669146|NCT01563003|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
89669147|NCT04850040|Experimental|Camrelizumab+Apatinib Mesylate+Oxaliplatin|An study of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.
89669148|NCT02302235|Active Comparator|Ketogenic Diet|Treatment will consist of ketogenic diet. KGD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. Diet will be started at the time of initiation of radiation treatment.
89669149|NCT02302235|Other|Standardized diet|The subjects will be taken standard diet in a 1:1 ratio.
89669150|NCT03038334|Experimental|Magnesium sulfate|All participants will apply magnesium sulfate transdermally a total of 250mg equivalent to 2 mEq every four hours per day for 90 days.
89669151|NCT01441245|Experimental|Continuous furosemide infusion|The group that received the continuous infusion of furosemide (cIV), consisted of 30 patients;
89669152|NCT01441245|Experimental|Intermittent furosemide infusion|The group that received the bolus infusion of furosemide (iIV), consisted of 27 patients
89669153|NCT02301611|Experimental|Treatment|autologous TLPLDC (active vaccine)
89669154|NCT02301611|Placebo Comparator|Placebo|unloaded YCWP + autologous DC (control)
89669155|NCT04023318|Experimental|Integrated Lifestyle Intervention|
89669156|NCT03039816|Active Comparator|Active|The patients were randomly assigned to active (Nasaleze cellulose powder) or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
89669157|NCT03039816|Placebo Comparator|Placebo|The patients were randomly assigned to active or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
88995511|NCT02915770|Active Comparator|participants receive no cholangiojejunostomy|participants will receive hepatectomy and T-tube Drainage
88995512|NCT02915653|No Intervention|Control|Control: not receiving any intervention
88995513|NCT02915653|Experimental|Intervention 1|Receiving educational materials on a new diagnostic service
88995514|NCT02915653|Experimental|Intervention 2|Receiving educational materials on a new diagnostic service
88995515|NCT02915809|Experimental|GC3110B Vaccine Group|Participants randomized to receive a single dose of GC3110B vaccine (Biological: GC3110B vaccine).
88995516|NCT02915809|Active Comparator|GCFLU Quadrivalent Inj.|Participants randomized to receive a single dose of GCFLU Quadrivalent Inj. vaccine (Biological: GCFLU Quadrivalent Inj. vaccine).
88995517|NCT02915497|No Intervention|Treatment As Usual + Resilience-Based Supportive Therapy|Routine psychosocial management of trauma patients, including Manualized Resilience-Based Therapy.
88995518|NCT02915497|Experimental|Abbreviated Early Prolonged Exposure Therapy|AEPET, including Manualized Resilience-Based supportive Therapy.
88995519|NCT02915692||ERASE Silver Coated Foley Catheters|Subjects given silver catheters from an ERASE CAUTI Tray.
88995520|NCT02915692||Comparator Silver Coated Catheter|Comparator silver urinary catheter
88995521|NCT02915146|Active Comparator|NB-UVB monotherapy|Narrowband ultraviolet B monotherapy will be used
89669158|NCT03039894||Intervention|The middle school selected 2 advisory classrooms to participate in the Gradebook game during 6th grade. Students in these 2 classrooms were block randomized to teams by baseline grade book and student engagement scores. These small student teams stay together for an entire year and meet once or twice a week. Teams are led by 8th grade student team captains, picked by school staff for their positive leadership skills. Every 2 weeks throughout the year, teams are randomly matched in head-to-head competition. In each 2-week-long game (i.e. Gradebook Game), individual team members accrue points from teachers and administrators for academic performance, effort, and school behavior. Team wins are announced and public scoreboards are updated frequently. The investigators will collect student survey data at baseline and after the intervention, approximately 5-6 months apart.
89669159|NCT03039894||Control|The middle school has chosen three 6th grade classrooms that will not play the Gradebook game. The investigators will collect school gradebook and behavior information weekly for 8 to 10 time points before and after the intervention is implemented. Students will complete a survey at baseline and after the intervention, approximately 5-6 months apart.
89669160|NCT01563081|Experimental|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution
89669161|NCT04838886|Experimental|Exercise group|The intervention group will be received telerehabilitation-based pilates training three times a week for 6 weeks.
89669162|NCT04838886|No Intervention|Waitlist|The control group will be a wait-list group without any additional specific treatment.
89669163|NCT04372992|Experimental|Early stoma closure|Ileostomy closure between 30 and 40 day after rectal resection
89669164|NCT04372992|Active Comparator|Delayed stoma closure|Ileostomy closure 15 days from the end of adjuvant therapy (up to 60 days)
89669165|NCT04833738|Active Comparator|Electrotherapy|
89669166|NCT04833738|Active Comparator|corticosteroid|
89669167|NCT04833738|Active Comparator|hyaluronic acid|
89669168|NCT02277977|Experimental|Contrast enhanced ultrasound|Contrast enhanced ultrasound during septic shock
89669169|NCT01441401||Gabapentin|Peadiatric subjects taking Gabapen Tablets and syrup.
89669170|NCT02271815||Oral Hygiene|Oral Hygiene
89669171|NCT04371588||Deep neuro-muscular blockade|
88995522|NCT02915146|Active Comparator|NB-UVB + UVA1|Narrowband ultraviolet B combined with ultraviolet A1 phototherapy will be used
88995523|NCT02915419|Active Comparator|group A|prp revascularization
88995524|NCT02915419|Experimental|group B|treatment of affected teeth using platelet rich fibrin by applying prf in steril root canal
88995525|NCT02915107|Experimental|Biofreedom|Experimental: Biofreedom BioFreedom stent at index procedure
88995526|NCT02915107|Active Comparator|Orsiro|Active comparator: Orsiro Orsiro stent at index procedure
88995527|NCT02914990|Experimental|BPI-15086|BPI-15086, orally administered daily
88995528|NCT02915068|No Intervention|Control|Physicians do not receive focused education and training on patient-centered communication with the EHR
88995529|NCT02915068|Experimental|EHR-PACE|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
88995530|NCT02914756||Sepsis|Patients suffering from Severe sepsis or Septic chock at the ICU.
88995531|NCT02914756||Non-Sepsis|Patients being treated at ICU but not suffering from severe sepsis/septic chock
88995532|NCT00405899||Immunotherapy|Patients starting immunotherapy
88995533|NCT00405899||Non-immunotherapy|Patients being treated using methods other than immunotherapy
88995534|NCT02914678|No Intervention|Existing treatment|Business as usual: Ambulance personnel use existing treatment approach (a total of 2 μg/kg fentanyl per transport)
89669172|NCT04371588||Moderate neuro-muscular blockade|
89669173|NCT02268695|Active Comparator|EXTREME: Cisplatin, 5-FU and Cetuximab|"Chemotherapy: 6 cycles (every 3 weeks) of Cisplatin (100 mg/m² iv on Day1), 5FU (4000 mg/m² total dose starting on day 1 and during 96h in continuous infusion), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If cisplatin is not tolerated and/or when the total cumulative dose of cisplatin (including prior administration) reaches 600 mg/m², cisplatin has to be replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Cetuximab maintenance : cetuximab continuation (250 mg/m² iv weekly) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
89669174|NCT02268695|Experimental|TPEx: Cisplatin, Docetaxel and Cetuximab|"Chemotherapy: 4 cycles (every 3 weeks) of Cisplatin (75 mg/m² iv on Day1), Docetaxel (75 mg/m² iv on Day1), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If Cisplatin is not tolerated, cisplatin is replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Primary prophylactic administration of GCSF must be administered systematically after each cycle of chemotherapy.~Cetuximab maintenance : cetuximab continuation (500 mg/m² iv every two weeks) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
89669175|NCT01495923|Experimental|Epidural steroids|Injection of steroids into the epidural space
89669176|NCT01495923|Active Comparator|Gabapentin|Titration of gabapentin to effect
89669177|NCT02268461|Active Comparator|rTMS|repetitive Transcranial Magnetic Stimulation (rTMS)
89669178|NCT02268461|Sham Comparator|Sham rTMS|Sham repetitive Transcranial Magnetic Stimulation (Sham rTMS)
89669179|NCT04838340|Active Comparator|Standart care|Standart care group will leave in the hospital's usual care and no intervention will be applied.
89669180|NCT04838340|Experimental|Hypnobirthing group|Hypnobirthig training intervention will be applied to the Hypnobirthing group for 4 weeks and 3 hours a week and usual care will be provided by healthcare professionals.
89669181|NCT05585723||students at the university|
89669182|NCT05585723||teenagers|
89669183|NCT05585723||parents of teenagers|
89669184|NCT01496157|Experimental|Patients with Primary Prostate Cancer|Patients will be imaged with 18F-DCFBC
89669185|NCT01894139|Experimental|High-protein/Low-GI Diet|High-protein (25-28 E%), especially marine- and dairy-protein (8-10 E%) and low-GI (GI<55) ad libitum Diet in accordance with the principles of palatability and sustainability of the New Nordic Diet.
89214641|NCT06087887||tumor size 1-2 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 1-2 cm.
89669186|NCT01894139|Active Comparator|Low-protein/High-GI Diet|Ad libitum diet based on the Danish National Guidelines (NNR) (protein 10-20 E%; no information on restricting glycaemic load (GI ~ 60)) and in accordance with the principles of palatability and sustainability of the New Nordic Diet.
89669187|NCT02261909||normal creatinine|pts receiving an iv-contrast enhanced CT with normal baseline renal function
89669188|NCT02261909||elevated creatinine|pts receiving an iv-contrast enhanced CT with abnormal baseline renal function
89669189|NCT04841460|Experimental|Low-fat ground beef|Participants will consume 25 low-fat ground beef patties, 5 patties per week for 5 weeks.
89669190|NCT04841460|Experimental|High-fat ground beef|Participants will consume 25 high-fat ground beef patties, 5 patties per week for 5 weeks.
89669191|NCT01564485|Experimental|Cardiac CT|Patients randomized to cardiac CT will obtain a non-invasive assessment of their coronary arteries.
89669192|NCT01564485|Active Comparator|Usual Care|Patients randomized to usual care will be assigned to continuing usual medical care with their primary care physician
89669193|NCT04428996|Experimental|Arm AB|"A means SCIT program, and B means treatment as usual. Arm AB will receive a 60-minutes manual-guide SCIT session each week for 20 times first, then receive treatment as usual.~Before the SCIT session, after the SCIT session and after 20 weeks treatment as usual, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
89669194|NCT04428996|Experimental|Arm BA|"A means SCIT program, and B means treatment as usual. Arm BA will first receive treatment as usual, then a 60-minutes manual-guide SCIT session each week for 20 times.~At the first week, before and after the SCIT session, participants receive evaluations of clinical symptoms, emotional perception, theory of mind, and attributional bias.~There are three main themes of the SCIT: 1) introduction and emotion, 2) figuring out situation and 3) integration: checking it out. After each theme of the intervention, participants will fill out a satisfaction survey."
89669195|NCT05583851|Experimental|Digi-ACT Intervention group|22 day long interactive mobile app intervention with daily activities. The intervention will include 5 total modules: psychoeducation on depression/anxiety and the cancer journey; acceptance; cognitive fusion; mindfulness; and committed valued living. There will be different games and reward components for the Through out the course of the intervention, participants will also do video journals to reflect on the different modules and activities they do.
89669196|NCT05583851|Active Comparator|Psychoeducational Video Control group|22 day long mobile app where participants will be given a 15 minute long psychoeducational clip from a publicly available online seminar (from the Hong Kong College of Psychiatrists) on a bi-daily basis. Through out the course of the intervention, participants will also do video journals to reflect on the content of the different video clips.
89669197|NCT03037944|Experimental|Group A-LNG|"The Levonorgestrel releasing intrauterine device - IUD- will be Metraplant-E, which is used in this study for group A, is a modified Levonorgestrel-releasing intrauterine system from the old IUD Metraplant, Metraplant-E design has a T-shaped frame containing Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque, All the T frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate, Levonorgestrel and Barium Sulphate, ensure more exposure of the endometrial surface to the system and hence expect more endometrial suppression."
89669198|NCT03037944|Experimental|Group B-COCs|Group B will receive combined oral contraceptive pills (Yasmin) COCs which will be Monophasic pills that have a constant dose of both estrogen and progestins in each of the hormonal active pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets, provides an oral contraceptive regimen, it will be used continuously for 6 months with stoppage after 3 months for withdrawal bleeding.
89669199|NCT03039582||Probable grad 2|Perineal laceration Probable grad 2
89669200|NCT03039582||Suspected grade 3|Perineal laceration Suspected grade 3
89669201|NCT03039582||Probable grad 3|Perineal laceration Probable grad 3
89214642|NCT06087887||tumor size 2-3 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 2-3 cm.
89214643|NCT06087887||tumor size 3-4 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 3-4 cm.
89669202|NCT01444287|Placebo Comparator|Spectacles No Lenses|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
89669203|NCT01444287|Experimental|narafilcon B|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
89669204|NCT01444287|Active Comparator|polymacon|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
89669205|NCT01444287|Active Comparator|lotrafilcon A|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
89669206|NCT03039504|Experimental|Potensa|succinate-based dietary supplement
89669207|NCT03039504|Placebo Comparator|Placebo|placebo
89669208|NCT03039348||Breast reconstruction|The patients choosing for breast reconstruction after mastectomy for breast cancer.
89669209|NCT03039348||No breast reconstruction|The patients not choosing breast reconstruction after mastectomy for breast cancer.
89669210|NCT03036306|Experimental|1.0 % SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 1.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
89669211|NCT03036306|Experimental|3.0% SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 3.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
89669212|NCT03036306|Placebo Comparator|Placebo cream|Subjects randomized to this arm will have both lateral hip wounds treated with Placebo cream. Intra-subject hip wound treatment is randomly allocated
89669213|NCT01444911|Experimental|Vaginal Renewal Program|
89669214|NCT01444911|Active Comparator|Standard of care|This will consist of still vaginal dilator and/or lubricant.
89669215|NCT03038022|Experimental|MGL-3196|Study Drug
89214644|NCT06087887||tumor size 4-5 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 4-5 cm.
89669216|NCT03038022|Placebo Comparator|Placebo|Matching Placebo
89669217|NCT03037788|Experimental|WO3979|Formulation containing WO3979 for topical application
89669218|NCT03037788|Experimental|WO3970|Formulation containing WO3970 for topical application
89669219|NCT03037788|Experimental|WO3992|Formulation containing WO3992 for topical application
89669220|NCT03037788|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
89669221|NCT02205177|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
89669222|NCT02205177|Experimental|Minimal Contact w/ Anxiety Coach (MC-AC)|In this condition the therapist will meet with the patient and primary care giver for an initial 50-minute, face-to-face session to provide a tutorial on the use of Anxiety Coach. The therapist is expected to review the patient's progress via the web-based portal and communicate with the patient electronically at least once per week for a total of at least 6 and up to 12 weeks of intervention. Therapists will be allowed 2 additional face-to-face sessions if necessary and still remain in protocol.
89669223|NCT02254265|Experimental|OTX-101 0.05%|OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
89669224|NCT02254265|Experimental|OTX-101 0.09%|OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
89669225|NCT02254265|Placebo Comparator|Vehicle|Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
89669226|NCT04838496|Experimental|Single-arm study|All patients will receive induction chemotherapy consisting of 4-6 cycles of FOLFOXIRI. Restaging will be performed after 4 cycles with a pelvic MRI and a thoraco-abdominal CT-scan. In case of stable or responsive disease, the remaining 2 cycles of FOLFOXIRI will be provided. In case of progressive, but still resectable disease, chemoradiation will be provided immediately, without the remaining 2 cycles of FOLFOXIRI. Restaging will be performed after chemoradiation. In case of resectable disease, surgery is performed.
89669227|NCT04756973|Active Comparator|Standard weight loss|A 12 week small group weight loss intervention delivered via video teleconference technology.
89669228|NCT04756973|Experimental|Standard weight loss plus self-compassion skills training|A 12 week small group weight loss intervention delivered via video teleconference technology.
89669229|NCT04840758|Experimental|SABR+Sintilimab|Stereotactic ablation radiotherapy (SABR) was performed sequentially on the primary and secondary lesions. Sintilimab was used 2 weeks after the end of SABR. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles.
89669230|NCT03039270|Active Comparator|Control (Without sonic activation)|Desensitizing gel applied without sonic activation, for 10 minutes, previously to the in-office bleaching.
89669231|NCT03039270|Experimental|With sonic activation (SMART Device®)|Desensitizing gel applied with sonic activation, 30 seconds per tooth, previously to the in-office bleaching.
89669232|NCT03060161|Experimental|Health in the right measure|"Nutrition counseling and guidance for regular physical activity. An individualized physical exercise program will be proposed according to each participant's level of physical activity and health conditions.~Participants will also receive individualized nutritional guidance. Throughout the project, collective motivational activities will be carried out to promote healthy eating (culinary workshops, talk wheels and others) and individual activities with all participants, in order to evaluate the adherence of nutritional guidelines and to exchange experiences among them."
89669233|NCT04838184||Dental patients|Patients with an edentulous mandible who are demanding and receiving an implant-supported fixed dental prosthesis in the mandible
89669234|NCT02215161|Experimental|Treatment (selinexor)|Patients receive selinexor PO on days 1 and 3 of weeks 1-3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89669235|NCT03039426|Experimental|Group Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
89669236|NCT03039426|Active Comparator|Group Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
89669237|NCT02205515|Other|Radiotherapy|SBRT or EBRT
89669238|NCT04837950|Experimental|Before pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview before pulling diaphragmatic suture
89669239|NCT04837950|Experimental|After pulling diaphragmatic suture|Measurement of pleural cavity volume and visual overview after pulling diaphragmatic suture
89669240|NCT01446705||No Exchange|Patients in this arm will represent Veterans seen at the Indianapolis VA Medical Center (VAMC) for whom information exchange has not been activated.
89669241|NCT01446705||Enrolled in Exchange|"Patients in this arm will represent Veterans seen at the Indianapolis VAMC for whom information exchange has been activated by the patient choosing to opt-in."
89669242|NCT04833036|Active Comparator|c-CetuIRI|Irinotecan combined with cetuximab
89669243|NCT04833036|Experimental|s-IRI-CetuIRI|single irinotecan first, then irinotecan plus cetuximab sequentially after PD
89669244|NCT03059381||Fycompa-treated epilepsy participants|Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
89669245|NCT04832880|Experimental|Control arm (dexamethasone arm)|IV dexamethasone 6 mg for 10 days
89669246|NCT04832880|Experimental|Remdesivir arm|IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10
89669247|NCT04832880|Experimental|Baricitinib arm|IV dexamethasone 6 mg for 10 days + baricitinib 4 mg die for 10 days. For patients aged > 75 years or estimated GFR < 60 ml/min*1.73m2, baricitinib dose is reduced to 2 mg for 10 days.
89669248|NCT04832880|Experimental|Remdesivir + baricitinib arm|"IV dexamethasone 6 mg for 10 days + remdesivir IV 200 mg on day 1, followed by 100 mg die until day 10 + baricitinib 4 mg die for 10 days.~For patients aged > 75 years or estimated GFR < 60 ml/min*1.73m2, baricitinib dose is reduced to 2 mg for 10 days."
88995535|NCT02914678|Experimental|More liberal treatment|Ambulance personnel use a more liberal treatment approach (a total of 3 μg/kg fentanyl per transport)
88995536|NCT00405977|Placebo Comparator|Physiologic saline|
88995537|NCT00405977|Active Comparator|Magnesium sulphate|
88995538|NCT02914327|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
88995539|NCT02914249|Experimental|Orange juice|Orange juice: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) plus 100% orange juice (500 mL/d) during 12 weeks.
88995540|NCT02914249|No Intervention|Control|Control: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) during 12 weeks.
88995541|NCT02914015|Experimental|Continuous QLB+postoperative IPCA|Single-injection of QLB (quadratus lumborum block) is given preoperatively followed with continuous infusion+ postoperative IPCA (intravenous patient control analgesia)
88995542|NCT02914015|Active Comparator|IPCA|Postoperative IPCA (intravenous patient control analgesia) is given alone
88995543|NCT02914093|Experimental|IMT-feasibility|Single arm intervention
88995544|NCT02914054|Active Comparator|Conventional Prednisone receiving group|Patients in PDN arm received PDN
89669249|NCT01447017|Experimental|DPK-060 2% ear drops|DPK-060 2% ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
89669250|NCT01447017|Placebo Comparator|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
89669251|NCT01894217|Experimental|Genetic testing|Genetic testing and reporting for SLCO1B1*5 allele
89669252|NCT03037866|Experimental|LifeSkills Training for College|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the intervention group (n=2000) will participate in the LST program adapted for college which consists of six 30-minute online sessions (content-specific instruction and skills building activities along with opportunities to apply newly acquired knowledge and practice new skills) and three 60-minute small groups sessions (facilitator-led sessions with fellow incoming students that complement the online modules).
89669253|NCT03037866|No Intervention|Treatment as Usual (Control)|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the control group (n=2000) will not participate in LST but will receive the sexual violence and substance abuse educational content normally provided by their schools.
89669254|NCT01894295|Experimental|Vitamin D analogue|1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.
89669255|NCT01894295|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram
89669256|NCT02171351|Experimental|effect of neuromuscular electrostimulation (NMES)|
89669257|NCT02171351|Experimental|effect of neuro electrostimulation (NES)|
89669258|NCT02171351|Experimental|effect of voluntary contractions (VC)|
89669259|NCT03037554|Experimental|Lateralized Thermal Sleepwear|For two consecutive nights subjects will wear Sleepwear with Lateralized Thermal Characteristics
89669260|NCT03037554|Sham Comparator|Sham-Lateralized Sleepwear|For two consecutive nights subjects will wear Sham-Lateralized Sleepwear
89669261|NCT04788186|No Intervention|Continue beta blocker therapy|Participants in this arm will continue their beta blocker therapy as per their usual clinical care
89669262|NCT04788186|Experimental|De-prescribe beta blocker therapy|Beta blocker therapy will be de-prescribed in this arm
89669263|NCT04550117|Experimental|Intraspinal Pressure Monitoring|A fiberoptic pressure monitoring device will be placed into the subarachnoid space at the site of traumatic spinal cord injury
89669264|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 100 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
89669265|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
89669266|NCT01498419|Active Comparator|Drug Sensitive: Rifafour|Drug Sensitive Participants: Rifafour was administered orally once daily for 8 weeks according to weight: 30 kg to 37 kg: two tablets; 38 kg to 54 kg: three tablets; 55 kg to 70 kg: four tablets; ≥71 kg: five tablets
89669267|NCT01498419|Experimental|Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)|Multi Drug-Resistant Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
89669268|NCT04825314|Active Comparator|Bactiguard urethral catheter|Group A: Fifty Patients with urethral catheter using noble metal alloy coated catheter (Bactiguard AB, Stockholm ,Sweden).
89669269|NCT04825314|Active Comparator|Silicone Foley urethral catheter|Group B: Fifty Patients with urethral catheter using silicone Foley catheter (Well Lead, Guangzhou, China).
88995545|NCT02914054|Active Comparator|Dxamethasone receiving group|In HD-DXM arm, DXM was administered
89669270|NCT01567371|Experimental|LiDCO rapid monitor|
89669271|NCT04551599|Experimental|Part 1: Sequence 1|"Healthy, young, adult participants will receive danicopan once each Period as follows:~Period 1: Danicopan administered under fed conditions.~Period 2: Danicopan administered under fasted conditions.~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
89669272|NCT04551599|Experimental|Part 1: Sequence 2|"Healthy, young, adult participants will receive danicopan once each Period as follows:~Period 1: Danicopan administered under fasted conditions.~Period 2: Danicopan administered under fed conditions.~There will be a washout period of at least 7 days between the dose of danicopan in Period 1 and the dose of danicopan in Period 2."
89669273|NCT04551599|Experimental|Part 2|Healthy, elderly, male participants will receive a single dose of danicopan under fed conditions.
89669274|NCT04825002|Experimental|Urinary multimarker sensor arm|A urine of this group will be collected and measured using a newly developed urinary multimarker sensor (ANXA3, PSMA, ERG, ENG)
89669275|NCT01448421|Experimental|Keystone Heart Embolic Deflection Device|Protected Transcatheter Aortic Valve Replacement
89669276|NCT04824924|Experimental|HVAG regimen|
89669277|NCT01567839|Experimental|4% Lidocaine|1.8 mL of 4% lidocaine with 1:100,000 epinephrine
89669278|NCT01567839|Experimental|4% Articaine|1.8 mL of 4% articaine with 1:100,000 epinephrine
89214645|NCT06087887||tumor size 5-6 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 5-6 cm.
89214646|NCT06087887||tumor size 6-7 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 6-7 cm.
89214647|NCT06087887||tumor size 7-8 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 7-8 cm.
89214648|NCT06087887||tumor size 8-9 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 8-9 cm.
89214649|NCT06087887||tumor size 9-10 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of 9-10 cm.
89214650|NCT06087887||tumor size >10 cm|No intervention. Select small bowel adenocarcinoma patients with tumor size of >10 cm.
89669279|NCT01567839|Experimental|4% Prilocaine|1.8 mL of 4% prilocaine with 1:200,000 epinephrine
89669280|NCT04553705|Experimental|Omega-3/thymoquinone supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA) (3% thymoquinone) per day for one month.~In addition to the standard care"
89214651|NCT06087874|Experimental|Probiotics|Vivomixx® is a multi-strain probiotics product.
89669281|NCT04553705|Experimental|Omega-3/thymoquinone / Indian Costus supplementation|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Indian Costus) per day for one month.~In addition to the standard care"
89669282|NCT04553705|Experimental|Omega-3/thymoquinone / Quinine pills|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(1g Quinine) per day for one month.~In addition to the standard care"
89669283|NCT04553705|Experimental|Omega-3/thymoquinone / Anise seed capsule|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(450mg anise seed) per day for one month.~In addition to the standard care"
89669284|NCT04553705|Experimental|Omega-3/thymoquinone / Deglycyrrhizinated Licorice|"10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA & 200-300mg DHA), (3% thymoquinone),(Deglycyrrhizinated Licorice 800 mg ) per day for one month.~In addition to the standard care"
89669285|NCT04553705|Active Comparator|Active Comparator: standard care|The standard protocol care for COVID-19 approved from ministry of health at Saudi arabia
89669286|NCT04831866||Surveillance Cohort|Surveillance Cohort: Schools participating in this cohort will be performing surveillance testing weekly on approximately 10-20% of students and 100% of staff.
89669287|NCT04831866||Exposure Cohort|Exposure Cohort: Schools participating in this cohort will be performing exposure testing on students and staff who have been identified as having close contact with school members diagnosed with SARS-CoV-2 infection.
89669288|NCT02140151|No Intervention|Sham|Sham Injection
89669289|NCT02140151|Active Comparator|Quarterly Ranibizumab 0.5mg|Quarterly intravitreal injection of 0.5mg ranibizumab
89669290|NCT01500525||asthmatic children|children diagnosed by a specialist as asthmatic patients
89669291|NCT01500525||non-asthmatic children|children who are healthy and who do not have respiratory syndrom
89669292|NCT04837872|Experimental|Multimodal Physical Therapy (MPT)|The multimodal physical therapy (MPT) program consisted of manual therapy, therapeutic exercise, and utilization of a static progressive splint (Joint Active Systems SPS Knee, Effingham, IL). Although the primary focus of this study was on improving knee flexion ROM, two protocols were developed: one to improve flexion deficits and one to improve extension deficits. Participants in the MPT group received physical therapy 2x per week for 4 weeks. They were instructed to use the static progressive splint(s) 3x per day for 30 minute sessions (90 minutes total per day) for each splint (e.g., 90 minutes for flexion splint, 90 minutes for extension splint).
89214652|NCT06087874|Placebo Comparator|Placebo|Maltose-containing placebo product
89214653|NCT06087848|Experimental|MSC Intervention Group|"Participants will receive 100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cells in one intravenous infusion.~Additional systemic treatments can be repeated after a minimum of 3 months and data will be collected to investigate the potential preventive benefits it provides for the above indications. Additional doses are optional for all study participants enrolled in the study and will be managed in a separate consenting process. Study participants opting for an extra dose must at the time of the extra dose meet the same inclusion and exclusion criteria as participants being included for the first dose"
89214654|NCT06087809|No Intervention|Control|No intervention
89214655|NCT06087809|Experimental|Education and feedback|"Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email."
89214656|NCT06087809|Experimental|Clinical decision support|"Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration."
89214657|NCT06087809|Experimental|Combined group|Clinicians within practices assigned to the combined group received both interventions as described above.
88995546|NCT02913976|Experimental|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
89669293|NCT02135315|Experimental|intensive controle group|The end point in this group was to maintain the systolic blood pressure (SBP) between 110 and 120 mmHg using continuous intravenous Isosorbide Dinitrate perfusion, and Labetalol if needed.
89669294|NCT02135315|Active Comparator|standard control group|The end point in these group was to maintain the systolic blood pressure under 140 mmHg using continuous intravenous Isosorbide Dinitrate perfusion, and Labetalol if needed.
89669295|NCT04837560|Experimental|Temporarily or permanently wheelchair users which suffer from Venous Edema|Temporarily or permanently wheelchair users which suffer from Venous Edema
89669296|NCT01894373|Experimental|CIK, psoriasis|
89214658|NCT06087796|Active Comparator|Topical betamethasone|"Group A will include 20 patients and will receive topical betamethasone valerate 0.1% cream.~Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner."
89214659|NCT06087796|Experimental|Topical pentoxifylline|"Group B will include 20 patients who will receive topical pentoxifylline 2% gel.~Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner."
89214660|NCT06087796|Experimental|Topical metformin|Group C will include 20 patients who will receive topical metformin 10% gel. Treatment will be applied twice daily for 6 months or until complete resolution, whichever is sooner.
89214661|NCT06087783|Experimental|Muscle-targeted nutritional support|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
89214662|NCT06087783|Other|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted nutritional intervention such as nutritional counseling with or without oral nutritional supplement
89214663|NCT06087744|Experimental|NeuroN-QI|Randomized dyads in the experimental group will be asked to do at least one session weekly (ideally 3) skin-to-skin contact (SSC) lasting 2 hours until the age of 36 weeks. Auditory sensory stimulation by mothers or fathers (reading a book) will be carried out during the first 10 minutes during the SSC sessions. The SSC will be followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
89214664|NCT06087744|Active Comparator|SSC alone|Randomized dyads in the control group will be asked to do at least one session weekly (ideally 3) skin-to-skin contact (SPC) lasting 2 hours until the corrected age of 36 weeks. During these sessions, light and noise levels will not be controlled or accompanied of auditory stimulation. SSC periods will not be followed by a calm and rest period with a olfactory stimulation.
89214665|NCT06087718|Experimental|Maastro applicator in combination with chemoradiotherapy|The intervention is similar to the treatment of arm B of the published OPERA trial, however the endoluminal boost will be given using the Maastro applicator instead of a CXRT device.
89214666|NCT06087666|Experimental|FICare intervention|FICare implementation model will be demonstrated by setting 5 pilots in non-FICare-experienced NICUs from NL, TR, RO, UK, ZM (AMC, GU, CLUJ, UHS, and UNZA, partners, respectively) and 2 pilots in clinical sites who have recently implemented FICare from ES and NL (SERMAS and OLVG).
89214667|NCT06087666|No Intervention|control intervention|A cohort of patients born at the non-FICare clinical sites (AMC, GU, CLUJ, UHS, and UNZA) from the start of the study (November 2022) to the time assigned to start the intervention. A 3-month washout period will be established for staff training and site readiness.
89669297|NCT04831632||people aged 50-75|men and women aged 50-75 who belong to Hospital El Cruce's coverage area and do not have personal history of colorectal cancer or inflammatory bowel disease, personal or family history of syndromes of predisposition to known cancers, or family history of colorectal cancer in a first-degree relative aged less than 60
89669298|NCT02124395||Primary Hyperoxaluria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
89669299|NCT02124395||Cystinuria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
89669300|NCT02124395||Dent Disease|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
89669301|NCT02124395||APRT deficiency|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
89214668|NCT06087653|Experimental|Study ARM1 - Vld (Velcade-lenalidomide-dexamethasone)|Bortezomib SC at 1.3 mg/m2 on Days 1, 8, 15, and 22 of each 28-day cycle Lenalidomide 400 mcg/hr continuously for 28 of 28-day cycle Dexamethasone 40mg orally on Days 1, 8, 15 and 22 of each 28-day cycle (age 75 or over 20 mg.
89214669|NCT06087575|Experimental|Supira System|Ventricular support indicated for use during elective or urgent high-risk percutaneous coronary interventions.
89214670|NCT06087562|Experimental|preop iPACK block|Patients will receive a preoperative ultrasound-guided Interspace between the Popliteal Artery and Capsule of the Posterior Knee (iPACK) block with 20 mL 0.5% ropivacaine. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindray TE9) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the distal femoral shaft and popliteal artery. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in-plane, from the anteromedial aspect of the knee, toward the space between the popliteal artery and femur. 20 mL 0.5% ropivacaine is injected into the space between the popliteal artery and femur. The needle is withdrawn, and the needle entry site is wiped clean.
89669302|NCT04428138||Patients with Inguinal hernia|Patients presenting with inguinal hernia will undergo vascular in-office visit and echo duplex of aorta, carotid arteries and lower limb arteries in order to detect any abnormalities related to arterial disease (aneurysm, stenosis, flow alteration).
89522146|NCT02410772|Experimental|Regimen 3|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg"
88995547|NCT02913976|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
89522147|NCT03814317|Experimental|Study Group|"Sarcoidosis patients with interstitial lung disease and precapillary pulmonary hypertension based on right heart catheterization (RHC).~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
89522148|NCT03127319|Experimental|apatinib and docetaxel zoledronic|apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
89522149|NCT03127319|Active Comparator|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
89522150|NCT03411811|Active Comparator|Usual Care|
89522151|NCT03411811|Experimental|Dextrose|
89522152|NCT03412331|Active Comparator|Control Group|NPT including scaling and root planing was applied to 12 subjects with ultrasonic and hand instruments until the operator feels that root surface is clean, hard and smooth.
89522153|NCT03412331|Experimental|Test Group|Following NPT, toluidine blue O mediated PDT was performed with a LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark) to 12 subjects. The dye (0.1 mg/ml) was applied with a canula into the periodontal pockets. After 3 minutes, the subjects rinsed their mouths with sterile saline solution for removal of excessive dye. Then, the applicator of photosensitizer was inserted until the bottom of the periodontal pocket and photoinactivation was performed in 6 sites per tooth for 10 seconds of each sites with a total of 60 seconds per tooth.
89522154|NCT03424369||Eustachian tube unobstructed|
89522155|NCT03424369||Eustachian tube dysfunction|
89522156|NCT03418025|Experimental|Group I (Exercising Together program)|"Exercise Intervention. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.~EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a DVD of a partnered strength training exercise program to continue on their own after radiation is completed."
89522157|NCT03418025|Active Comparator|Group II (pre and post testing)|Questionnaire Administration & Survey Administration. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
89522158|NCT03410095||Sleep apnea patients|80 patients recently diagnosed with severe sleep apnea will participate in the Brain Changes in Sleep Apnea Study.
89522159|NCT03417947|Placebo Comparator|Placebo|Placebo identical to the vitamin D bolus in taste and appearance. The placebo will be administered once, at the beginning of the study. The oral liquid placebo will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.
89522160|NCT03417947|Experimental|Vitamin D bolus|The vitamin D bolus is an oral liquid supplement that will be administered once, at the beginning of the study. The oral liquid vitamin D bolus will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.The dose of vitamin D3 contained in the bolus is 300 000 IU.
89522161|NCT03905811|Experimental|Active|Terazosin administered 5 mg once daily p.o. for 12 weeks
89522162|NCT03905811|Placebo Comparator|Placebo|Placebo administered once daily p.o. for 12 weeks
89522163|NCT01648790|Experimental|5 mg Prasugrel (ODT1)|5 mg Prasugrel as orally disintegrating tablet without Magnasweet® (ODT1) formulation administered once in the fasted state.
89522164|NCT01648790|Experimental|5 mg Prasugrel (ODT2)|5 mg Prasugrel as orally disintegrating tablet containing Magnasweet® (ODT2) formulation administered once in the fasted state.
89522165|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Suspension|5 mg Prasugrel as ODT2 formulation dispersed in water administered once, in the fasted state.
89522166|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Fed|5 mg Prasugrel as ODT2 formulation administered once, following a standardized breakfast.
89522167|NCT01648790|Experimental|2 mg Prasugrel (ODT2)|2 mg Prasugrel as ODT2 formulation administered once in the fasted state.
89522168|NCT03127163|Other|Mild Keratoconus|"A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution.~We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group."
89522169|NCT03411733||acne vlugaris group|Included recruited patients with acne vulgaris Intervention: Blood and stool samples collection
89522170|NCT03411733||Control group|Included healthy participants Intervention: Blood and stool samples collection
89522171|NCT03771885|Experimental|Group A|4 weeks place followed by 4 weeks IMP
89522172|NCT03771885|Experimental|Group B|4 weeks IMP followed by 4 weeks placebo
89522173|NCT03409393|Experimental|Intervention Group|The COPUS intervention plus usual care (OPUS treatment).
89522174|NCT03409393|Other|Control Group|Usual care (OPUS treatment).
89522175|NCT03652077|Experimental|INCAGN02390|
88995548|NCT02913898|Experimental|IBLT (information bias learning task)|Computerised task in which most information is provided by positive outcomes. Completed for 10 mins per day every day for 2 weeks.
89522176|NCT03417791||kidney function recovery|the registry and follow up of consecutive patients with increased serum creatinine during hospital in 2007
89522177|NCT03409315||Moxifloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of moxifloxacin.
89522178|NCT03409315||Levofloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of levofloxacin
89522179|NCT03409315||Moxifloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of moxifloxacin.
89522180|NCT03409315||Levofloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of levofloxacin.
89522181|NCT04470687|Experimental|Carotid plaque or stenosis ultrasound enhanced UF assesment|symptomatic or asymptomatic patients with atheromatous carotid stenosis scheduled for carotid endarterectomy
89522182|NCT05171309|Experimental|Camrelizumab in combination with apatinib plus NK cell|"Drug: Apatinib 250 mg once daily (QD) oral dosing.~Other Names:~• Apatinib Drug: Camrelizumab 200 mg intravenously every 2 weeks.~Other Names:~• Camrelizumab Drug: NK cell Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days"
89522183|NCT03409237||Group 1|Mannitol 0.2-0.3 g/kg 4 times/day.
89522184|NCT03409237||Group 2|Hypertonic saline solution 3%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
89522185|NCT03409237||Group 3|Hypertonic solution saline 4%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
89522186|NCT03409237||Group 4|Hypertonic saline solution 7%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
89522187|NCT03570489|Active Comparator|Exercise|Use of an ergometric bicycle where patients will bicycle 5 Days a week for 20 minutes at a predetermine level
89522188|NCT03570489|Sham Comparator|Relaxation|Patients will listen to a relaxation exercise involving muscle relaxation. This takes about 20 minutes and will be performed 5 Days/week
89522189|NCT03408847|Active Comparator|MC-EVOO in addition to steroid therapy|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
89522190|NCT03408847|Placebo Comparator|Refined olive oil and steroid therapy|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
89522191|NCT03332121|Experimental|B001,B001 dose escalation|5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg
89522192|NCT03424291|Experimental|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
89522193|NCT03412175|Experimental|Behavioral Intervention|Participants in the lifestyle intervention arm will receive 6 individual visits with a CREATION Health Specialist over a 3 month period, and one follow up visit at 6 months. The visits include one 2 hour-long initial assessment, four 60-minute motivational interview sessions, and two 60-minute reassessments. Visits will focus on tailoring the intervention care plan to each individual, goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, self-regulatory techniques, and provision of psychosocial support using motivational interviewing techniques.
89522194|NCT03412175|No Intervention|Control Group|Participants in the control group will receive usual care as provided by their primary care physician. Participants in the control group will complete biometrics, surveys, and assessments at Visits 0, 5 and 6.
89522195|NCT03411655|Active Comparator|Ambu® Aura-ITM|
89522196|NCT03411655|Active Comparator|Ambu Aura GainTM|
89522197|NCT03408691|Active Comparator|Test product|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks
89522198|NCT03408691|Placebo Comparator|Control product|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks
89522199|NCT03408691|No Intervention|No product|no product
89522200|NCT05170373|Active Comparator|ESP group|
89522201|NCT05170373|No Intervention|control group|
89522202|NCT03408535|Other|Eriksholm Guide to Better Hearing|The Eriksholm Guide to Better Hearing is an online rehabilitation program. The program is made up of 5-weekly modules that cover different topics. Each module includes self-studies, training, and professional video coaching in hearing loss, hearing aids, and communication strategies.
89522203|NCT04413513|Experimental|Integrated Attention Training Program|"The intervention group (I) will receive integrated attention training program (IATP) on a variety of structured attention tasks by an intervention instructor. It is considered to be simple and safe but effective enough for cognitive health promotion."
89522204|NCT04413513|Placebo Comparator|Health Education|The control group (C) will receive health educational sessions on health concerns and physical diseases commonly found in old age during the invention period.
89522205|NCT04447859|Active Comparator|label recommended titration|eight-week titration regimen as recommended in by the product label (0.25mg/week for 4 weeks, 0.5mg/week for 4 weeks, 1mg/week for the remainder of the therapy)
89522206|NCT04447859|Experimental|Slow semaglutide titration|A slower 16-week titration regimen (initiate treatment at 0.0675mg/week and increase the dose by 0.0675mg weekly until a dose of 1mg/week is reached)
89669303|NCT04824690|Experimental|Virtual Reality Group|The virtual reality group watched a 1.5-minute VR video showing the operating theater and explaining the perioperative process. After the surgery, this group watched cartoons during the first standard nursing procedures after the effect of the anesthesia wore off.
89669304|NCT04824690|No Intervention|Control Group|The control group received conventional care and education regarding the perioperative process of surgery.
89669305|NCT04837170|Experimental|S (+)-Ketamine group|"Drug: Conventional therapy + S (+)-Ketamine In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection,but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~Bolus intravenous injection before skin incision, the dose is 0.1~0.5 mg/kg;~Bolus intravenous injection (dose 0.1~0.5 mg/kg) before skin incision +continuous intravenous infusion (dose of 0.1~0.25 mg/kg/h) during operation;~Continuous intravenous infusion after surgery with a dose of 0.02~0.1 mg/kg/h for 24~48 h."
89049208|NCT04625322|Experimental|Receive HCV care during inpatient admission by a hospitalist|CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred. An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive. Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay. At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.
89049209|NCT02904824|Experimental|ADRC, adipose derived regenerative cells|Biological: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
89049210|NCT02904824|Active Comparator|CAF, centrifuged autologous fat|Biological: Autologous fat tissue processed by centrifugation. Route of administration: Injection inside a paralyzed vocal cord.
89049211|NCT04653519|Experimental|Virtually guided minimally invasive preparation|
89049212|NCT02904746|Experimental|Intervention|Participants receiving the Make It! intervention
89049213|NCT02904746|No Intervention|Control|Care as usual
89049214|NCT02904785|Experimental|Extracorporeal Shock Waves|Focused shock waves delivered by an electromagnetic generator with a focus of 5.0cm deep on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks.
89049215|NCT02904785|Sham Comparator|Sham Extracorporeal Shock Waves|Sham focused shock waves delivered by an electromagnetic generator on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks. A foam will be placed in the probe as to stop the energy to be transmitted to the patient's knee, so no focused shockwaves will be delivered.
89049216|NCT01212991|Experimental|Enzalutamide|
89049217|NCT01212991|Placebo Comparator|Placebo|
89049218|NCT04625439|Experimental|Personality Feedback|The intervention arm will read about the Five-Factor model and receive a feedback report with individualized personality results and self-management recommendations.
89049219|NCT04625439|No Intervention|No-feedback Control|The control arm will read about the Five-Factor model but will not receive feedback or their personality results until after the study.
89049220|NCT02904551|Experimental|Experimental|Free gingival grafts
89049221|NCT02904551|Active Comparator|Control|Oral prophylaxis
89049222|NCT04625400|Experimental|post intubation tracheal stenosis patients|all ICU patients who were mechanically ventilated will be assessed for the possibility of presence of tracheal stenosis using spirometery and dyspnea will be assessed using (mMRC) score, chest X-ray to assess the location of tracheal stenosis and finally flexible bronchoscopy to confirm the presence of stenosis and identify the proper management.
89049223|NCT02904434||Voriconazole|Children (2-17 years old) will receive oral voriconazole as prescribed by their physicians as standard of care for the duration of the study.
89049224|NCT04653792|Experimental|Pregabalin|Participants received Pregabalin 75mg capsule twice daily from preoperative day to 1 week postoperative
89049225|NCT04653792|Placebo Comparator|Pregabalin Placebo|Participants received Pregabalin placebo capsule matching Pregabalin twice daily from preoperative day to 1 week postoperative
89669306|NCT04837170|Active Comparator|Control group|Drug: Conventional therapy Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
89688702|NCT02693665|Experimental|FACE-TC Intervention|Adolescent/family dyads randomized to the experimental condition receive Family Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention - 3 sessions scheduled one week apart of approximately 60 minutes duration each. Session 1 - Lyon Advance Care Planning Survey-Adolescent & Surrogate versions. Session 2 - Respecting Choices Interview facilitated by trained/certified facilitator with adolescent and family. Focuses on patient's understanding of their illness, possible complications, goals of care and treatment preferences in 3 bad outcome situations; and the Session 3 - Five Wishes an advance directive.
89049226|NCT02904473|Experimental|GROWell|GROWell incorporates 4 elements: phone coaching, goal setting, self-monitoring of behavior and skills training. These interactions take place on a study subject's cell phone, through text messaging, and phone calls with a dietician coach. At study initiation, the subject takes a short survey, after which the intervention algorithm assigns up to 4 tailored behavior change goals from the GROWell library. Goals are tailored to the subject's needs as indicated by the initial survey. Subjects self-monitor adherence weekly via text, responding to prompts from the system regarding their level of success with a given goal. Via text they receive immediate tailored feedback regarding their current adherence and long-term progress.
89049227|NCT02904473|No Intervention|Attention Support Control (ASC)|The ASC control arm of the study involves one coaching call at baseline, regarding prenatal diet. Weekly text or IVR messages will focus on pregnancy, labor, delivery, and early infancy education.
89049228|NCT02904473|No Intervention|Usual Care (USC)|The USC will receive no intervention. They will simply complete baseline and follow-up CASI and blood draw.
89214671|NCT06087562|Experimental|preop placebo block|Patients will receive a preoperative ultrasound-guided Interspace between the Popliteal Artery and Capsule of the Posterior Knee (iPACK) block with 20 mL 0.5% ropivacaine. Using appropriate sterile precautions, and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindray TE9) equipped with either a linear 15-6 megahertz (MHz), or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the distal femoral shaft and popliteal artery. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in-plane, from the anteromedial aspect of the knee, toward the space between the popliteal artery and femur. 20 mL 0.9% normal saline is injected into the space between the popliteal artery and femur. The needle is withdrawn, and the needle entry site is wiped clean.
89214672|NCT06086821|Active Comparator|3-Months|Periodontal Re-evaluation performed three months after Step 2 have been completed.
89214673|NCT06086821|Experimental|6-Months|Periodontal Re-evaluation performed six months after Step 2 have been completed.
89214674|NCT06086535||BRILMA block|Patients receiving BRILMA blockade. BRILMA blockade will be performed at the end of surgery at the level of the 3rd, 4th and 5th intercostal spaces of the right hemithorax.
89669307|NCT04824300|Active Comparator|erector spinae plane block group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.Group ESPB was applied before general anesthesia by the same anesthesiologist with block experience. In the sitting position, using an ultrasound-guided linear probe (6-13 MHz) on the side to be operated, T3 is marked 3 cm from the lateral of the spinous processes and with the in-plane technique, a 22G block needle (100mm, B-Braun, Germany) in the cranio-caudal direction first After it was observed that the erector spina muscle was separated from the transverse process with -2 ml normal saline, 20 ml 0.5% bupivacaine and 100 mg lidocaine were administered. And the drug was found to spread to the craniocaudal line at the ESP on ultrasound.Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
89669308|NCT04824300|No Intervention|non block control group|All patients were monitored with standard monitoring (electrocardiography (ECG), noninvasive blood pressure, peripheral oxygen saturation (SpO2)), bispectral index (BIS, Medtronic, Mineapolis) and ANI (analgesia nociception index) -90-120 min) data were recorded.15 minutes before the end of the surgery, 1 gr paracetamol and 100 mg tramadol were given to the control group. Postoperative pain of the patients was evaluated using VAS (visual analogue scale).
89669309|NCT02113553|Experimental|Triptorelin|Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy
89669310|NCT04831710|Experimental|Sintilimab+Chidamide|Participants will receive Sintilimab,200mg, ivd, d1; Chidamide,30mg,po,biw,d1-21; repeated every 3 weeks(up to 1 year) until disease progression, intolerable toxicity, death, or termination of the study for any reason.
89669311|NCT03037320|Experimental|group A|root coverage to be performed by semilunar vestibular incision technique
89669312|NCT03037320|Other|group B|root coverage by coronally advanced flap
89669313|NCT03036228|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution or tablets to be taken BID. Each cycle is defined as 28 days.
89669314|NCT03035994|Experimental|Overloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% greater than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
89669315|NCT03035994|Experimental|Underloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% lower than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
89669316|NCT03035994|Experimental|Average|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at the average of each participant's baseline vertical ground reaction force between limbs. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
89669317|NCT03035994|No Intervention|Control|Participants will walk for 20 minutes on a force-instrumented treadmill and will not be provided biofeedback.
89669318|NCT02099591|Experimental|Age group: > = 12y to < 18y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
89669319|NCT02099591|Experimental|Age group: > = 12y to < 18y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
89669320|NCT02099591|Experimental|Age group: > = 6y to < 12y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
89669321|NCT02099591|Experimental|Age group: > = 6y to < 12y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
89669322|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Lower dose|Naloxegol Dose equivalent to 12.5mg in adults which will be administered once daily for up to 6 months.
89669323|NCT02099591|Experimental|Age group: > = 6mo to < 6y - Higher dose|Naloxegol Dose equivalent to 25mg in adults which will be administered once daily for up to 6 months.
89669324|NCT01568073|Experimental|BIA 9-1067|OPC, Opicapone
89669325|NCT01568073|Active Comparator|Entacapone|Comtan®; Active comparator
89669326|NCT01568073|Placebo Comparator|Placebo|PLC, Placebo
89669327|NCT02091011||Cohort group|Subjects who have been implanted within 30 days with a commercially available Boston Scientific ICD or a CRT-D device
89214675|NCT06086535||Intercostal nerve cryoanalgesia|Patients receiving intercostal nerve cryoanalgesia. The cryoanalgesia technique will be performed by the surgeon before the closure of the minithoracotomy, at the level of the 3rd, 4th and 5th intercostal spaces on the right hemithorax.
89214676|NCT06086015|Experimental|Active group|
89214677|NCT06086015|Placebo Comparator|Sham group|
89214678|NCT06085651||PSI group|we divided all patients into two groups according to their RSH in the final follow-up time: PSI group (RSH≥20mm)
89214679|NCT06085651||Non-PSI|we divided all patients into two groups according to their RSH in the final follow-up time: Non-PSI group (RSH≤20mm)
89669328|NCT04274933|Experimental|Dose Escalation: Venetoclax and Capecitabine|Venetoclax at various doses will be administered in combination with capecitabine until a recommended dose is determined.
89669329|NCT04274933|Experimental|Dose Expansion: Venetoclax and Capecitabine|Venetoclax at the dose identified in Dose Escalation administered in combination with capecitabine.
89669330|NCT04757129||thrombolysis success group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
89669331|NCT04757129||thrombolysis failure group|Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.
89669332|NCT04395287||Preschool children|Attending public preschools in Svendborg, Denmark, at the time of recruitment
89669333|NCT02071511|Active Comparator|control group|Ablation of ventricular arrhythmias
89669334|NCT02071511|Sham Comparator|intervention group|Ablation of ventricular arrhythmias + renal denervation
89669335|NCT02603952|Placebo Comparator|Placebo + Oseltamivir 75 mg|Participants will receive a single intravenous (IV) infusion of placebo (matched to MEDI8852) on Day 1 and oseltamivir 75 milligrams (mg) capsules orally twice a day (BID) from Day 1 to Day 5.
89669336|NCT02603952|Experimental|MEDI8852 750 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 750 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
89669337|NCT02603952|Experimental|MEDI8852 3000 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
89669338|NCT02603952|Experimental|MEDI8852 3000 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1.
89669339|NCT01501929|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he/she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subjects will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
89669340|NCT01501929|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subject will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
89669341|NCT04824456|Experimental|bilateral sagittal split osteotomy using chisels.|The final split is completed with Smith forceps and flag separators
89669342|NCT02049593|Experimental|Arm A (PARP inhibitor BMN-673, temozolomide)|Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89669343|NCT02049593|Experimental|Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)|Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89669344|NCT01449513|Active Comparator|PEP005 Gel 0.05%|active ingredient of PEP005: Ingenol mebutate
89669345|NCT01449513|Placebo Comparator|Placebo Gel|Vehicle of PEP005 Gel
89669346|NCT04824222|Experimental|A - SOC+IMP|The FMT (fecal microbiota transplantation) will be administered along with the standard COVID 19 pharmacological treatment (SOC- Standard of care). The FMT will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
89214680|NCT06084832|Experimental|Binge Drinking|
89214681|NCT06084832|Active Comparator|Binge Drinking-control|
89214682|NCT06083922|Experimental|Arm A will include patients with cast nephropathy|Planned 8 cycles of CyBorD-Dara SC, treatment will be left to the discretion of the treating physician. It is recommended that patients eligible for ASCT undergo ASCT after 8 cycles of induction and that patient ineligible for ASCT, continue maintenance Bortezomib/Dexamethasone administered every other week with daratumumab SC administered every 4 weeks, for a period of 2 years from start of treatment.
89669347|NCT04824222|Placebo Comparator|B - SOC+placebo|Using standard COVID 19 pharmacological treatment (SOC- Standard of care). The placebo will be administered orally in one dose - in double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules).
89669348|NCT02049047|Experimental|Everolimus|oral everolimus
89214683|NCT06083922|Experimental|Arm B will include all other MGRS associated diseases with the exclusion of AL amyloidosis|Planned 8 cycles of CyBorD-Dara SC, treatment will be left to the discretion of the treating physician. It is recommended that patients eligible for ASCT undergo ASCT after 8 cycles of induction and that patient ineligible for ASCT, continue maintenance Bortezomib/Dexamethasone administered every other week with daratumumab SC administered every 4 weeks, for a period of 2 years from start of treatment.
89214684|NCT06082947|Experimental|HSCT using TCR αβ/CD19+ depleted grafts|Allogeneic HSCT using the TCR αβ/CD19+ depleted platform and grafts from alternative donors (MUD, MMUD and haploidentical)
89669349|NCT04824378||label 1|Baseline data measurement of this group of patients: arm circumference（positive） and ICG (positive).
89669350|NCT04824378||label 2|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (positive).
89669351|NCT04824378||label 3|Baseline data measurement of this group of patients: arm circumference（negative） and ICG (negative).
89688703|NCT02693665|No Intervention|Treatment As Usual (TAU)|Adolescent/family dyads randomized to the treatment as usual (TAU) condition receive written information on advance care planning, but no active intervention.
89049229|NCT04625010|Experimental|Group 2 (Swaddling group)|Swaddling group: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
89049230|NCT04625010|Experimental|Group 3 (Maternal Holding group)|Maternal holding group: Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
89669352|NCT05573789||Patients with prostate cancer|Patients with recurrent locally advanced, metastatic and/or high-grade operable prostate cancer and available formalin-fixed paraffin-embedded tumor tissue. Patients received treatment at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology. Tumor molecular profiling was performed.
89669353|NCT04778358|Experimental|OOCYTE DONORS|Administration of a higher dose of Rekovelle (follitropin delta) to increase the ovarian response to 17 oocytes (the optimal range being 15 to 25 oocytes) in an oocyte donor population without compromising safety and efficacy.
89669354|NCT01449747|Active Comparator|study group|sitagliptin hypo-response patients
89669355|NCT01449747|Sham Comparator|control group|sitagliptin response patients
89669356|NCT03035838|Other|Treatment|There is only one arm in this study. Intracranial pressure and brain swelling will be monitored before and after administration of fosaprepitant
89669357|NCT04837326|Experimental|Heel Lance Blood Sampling in Facilitated Tucking Position|The infants were put in facilitated tucking position by an experienced newborn nurse. They were put in facilitated tucking position so that their arms and legs were in a flexed midline position close to their trunk in a side-lying position. They were positioned so that they could move their extremities freely. They were held in facilitated tucking position for 120 seconds before the procedure. They were kept in facilitated tucking position until the blood sample was taken from the right heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
89049231|NCT04625010|No Intervention|Group 1|In the control group, the heel stick procedures were conducted using the standard method and the neonates received no interventions during the procedures.
89049232|NCT02904668|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-management program and manual therapy program
89049233|NCT02904668|Active Comparator|Control group|"The intervention consisted of 45-minute manual therapy sessions. Manual therapy included hands-on muscular mobilization techniques (aimed at improving soft tissue function), specific articular mobilization techniques (to improve overall joint function and decrease any restrictions in movement at single or multiple segmental levels in the cervical spine), and coordination or stabilization techniques (to improve postural control, coordination, and movement patterns by using the stabilizing cervical musculature)"
89049234|NCT02904590||IBD patients|Incidental patients with IBD controlled (including Crohn's disease, Ulcerative colitis and unclassified colitis)
89049235|NCT02904707||Questionary EQ-5D|"The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.~Finally, a pain assessment questionnaire by Numeric Evaluation Scale before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient."
89049236|NCT04653558||definite LNB|patients with definite early Lyme neuroborreliosis
89049237|NCT04653558||possible LNB|patients with possible early Lyme neuroborreliosis
89049238|NCT00553397||Live Lung Donors|Participants had a living donor lobectomy at one of the two participating study centers, the University of Southern California and the Washington University Medical Center between 1993 and 2006.
89049239|NCT04653441|Experimental|Child-only Intervention|The children in this arm will receive only child intervention curriculum (peer group activities). The child intervention includes 20 hours of facilitator-guided programming delivered in 10 sessions in a peer-group setting and aims to increase resilience by developing a number of skills including positive thinking, emotional regulation, coping, and problem solving.
89669358|NCT04837326|Experimental|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|The mother, whose privacy was protected, embraced the infant for 120 seconds before the procedure. The infant was embraced by the mother during the heel lance blood sampling from the left heel using a lancet. They were released 60 seconds after the procedure and monitored for 120 seconds. The blood samples were taken by the researcher after inserting the lancet in the first try.
89688704|NCT00932035|Experimental|Arm I (reverse mapping guided axillary lymph node dissection)|Patients receive isosulfan blue dye SC and then undergo reverse mapping-guided axillary lymph node dissection.
89688705|NCT00932035|Active Comparator|Arm II (control)|Patients undergo standard axillary lymph node dissection and then receive isosulfan blue dye SC.
89049240|NCT04653441|Experimental|Child+Caregiver Intervention|The children in this arm will receive child intervention and their caregivers will receive the caregiver intervention, At the caregiver level, caregivers receive 10 hours of facilitator-guided programming delivered in five sessions that aims to increase positive parenting skills and build the capacity of the caregiver to engage in self-care and seek support.
89049241|NCT04653441|Experimental|Child+Caregiver+Community Intervention|The children in this arm will received child intervention; their family will receive caregiver intervention and community-based intervention. At the community level, trained community advocates (e.g., teachers, village nurses) conduct monthly home visits and organize a series of community-based activities over a period of two years to promote cohesion and strength within local communities and to increase community support for affected families.
89049242|NCT04653441|No Intervention|Attention Control|Children and caregivers who do not receive any intervention activities
89669359|NCT04837326|Experimental|Heel Lance Blood Sampling Using White Noise|The 'Don't Let Your Baby Cry, PT.2' track from the 'Colic' album by Orhan Osman using the 'The Happiest Baby' album by Dr. Harvery Karp which was composed only of intrauterine was made listened to the infants via Xperia Ultra Mp3 Player for 120 seconds before and 120 seconds after the heel lance blood sampling procedure. While white noise was made listened to the infants before, during and after the procedure, Digital Sound LeverMeter brand noise measurement device was put at a distance of 50 cm from the infant and the ambient noise level was adjusted as 55 dB. The blood samples were taken by the researcher after inserting the lancet in the first try.
89669360|NCT04837326|No Intervention|Control Group|Suitable environmental conditions (ambient temperature, silent environment, etc.) were ensured in the study room for the infant's comfort. A saturation probe was inserted to the right wrist of the infant to monitor him/her. A video record was taken for 120 seconds without any intervention to the infants before and after the heel lance blood sampling procedure. The blood samples were taken by the researcher after inserting the lancet in the first try. Heel lance was performed in clinical routine for preterm infants in the control group.
89669361|NCT05460221|Active Comparator|Optimized oil group|Each participant will consume 25 mL/day during 6 months of an Optimized extra virgin olive oil obtained by mixing different varieties of oils rich in bioactive compounds (it contains approx. 490 ppm of bioactive compounds).
89669362|NCT05460221|Experimental|Functional oil group|Each participant will consume 25 mL/day during 6 months of a Functional olive oil prepared with the same Optimized oil and enriched with triterpenic acids obtained from the olive tree (approx. 490 ppm of polyphenols and 380 ppm of triterpenic acids).
89669363|NCT05460221|Placebo Comparator|Control Group|Each participant will consume 25 mL/day during 6 months of a Control extra virgin olive oil prepared from the same Optimized oil washed to eliminate bioactive compounds (approx. 125 ppm of polyphenols).
89669364|NCT04830540|No Intervention|Control|Participants assigned to the control group will be asked to continue wearing their typical shoes and to complete every two weeks the footwear and injury log provided
89669365|NCT04830540|Experimental|Intervention|Individuals assigned to the intervention group will be provided with 2 styles of the OOFOS recovery shoes, and will be asked to wear the OOFOS slide, sandal and/or closed toe shoes as their primary footwear outside training and competition for the 6 weeks between study visits. Intervention participants will also be asked to complete a daily shoe wear log and a shoe comfort assessment survey every other week.
89669366|NCT00054847|Active Comparator|Saphenous Vein Graft|Saphenous Vein Graft
89669367|NCT00054847|Active Comparator|Radial Artery Graft|Radial Artery Graft
89214685|NCT06082830|No Intervention|Control|The control arm will not receive any intervention materials.
89669368|NCT01569087|Experimental|Empegfilgrastim 3 mg|Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy
89669369|NCT01569087|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy
89669370|NCT01569087|Active Comparator|Filgrastim|Patients will receive filgrastim subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
89669371|NCT02024087|Experimental|Dalantercept 0.6 mg/kg plus sorafenib 400 mg|Cohort 1: Participants received dalantercept 0.6 mg/kg by subcutaneous (SC) injection once every 3 weeks plus sorafenib 400 mg orally (PO) once daily
89669372|NCT02024087|Experimental|Dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 2: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
89669373|NCT02024087|Experimental|Expansion cohort - dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 3: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
89669374|NCT04830930|Experimental|Sequence 1|Period 1: fasted condition/ Period 2: fed condition
89669375|NCT04830930|Experimental|Sequence 2|Period 1: fed condition/ Period 2: fasted condition
89669376|NCT04823832|Active Comparator|ERCP group|endoscopic retrograde cholangiopancreaticography with plastic stent insertion
89669377|NCT04823832|Active Comparator|PTD group|ultrasound guided percutaneous transhepatic catheter insertion
89669378|NCT04823520|Active Comparator|Group 15% concentration|30 patients MDA will be done to one half of the face then TCA 15% will be applied to the whole face.
89669379|NCT04823520|Active Comparator|Group 20 % concentration|30 patients will receive MDA to one side of the face , TCA 20% will then be applied to the whole face.
89669380|NCT01895621|Experimental|Lipoic|Median nerve decompression at the wrist, followed by Alpha lipoic acid post median nerve decompression: lipoic acid, 800 mg daily for 40 days from the day of the operation, tablets.
89669381|NCT01895621|Placebo Comparator|placebo|Median nerve decompression at the wrist, followed by placebo in the same form frequency and duration as alpha lipoic acid
89669382|NCT04836702||Left ventricular function|"Depressed LV function~LV ejection fraction < 50%~LV systolic function; defined as mild / mod / sev decreased~LV diastolic function; defined as mild (g1 ) / mod (g2) / sev ( g3) decreased~Normal LV function"
89669383|NCT04836702||Right ventricular function|"Depressed RV function~a. RV systolic function defined as mild / mod / sev decreased~Normal RV function"
89669384|NCT04836702||Valvular lesions|"Moderate or severe valvular lesions~Aortic stenosis~Aortic regurgitation~Mitral stenosis~Mitral regurgitation~Tricuspid regurgitation~Clinically normal valvular lesions~No valvular lesion~Mild stenosis / regurgitation of above mentioned lesions"
89669385|NCT01519583|Experimental|Basic Pedometry Intervention|Basic pedometry intervention: Participants will have a goal of obtaining 10,000 steps/day (with no direction with regards to walking intensity/speed/cadence)
89669386|NCT01519583|Experimental|Enhanced Pedometry Intervention|Enhanced pedometry Intervention: Participants will have the goal of obtaining 10,000 steps/day and at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min);
89669387|NCT01519583|Placebo Comparator|Control Group|Control group: Will maintain their usual activity and return for follow-up measures
89688706|NCT04362397|Experimental|A (first group to receive the intervention)|This arm will receive the attention, care, and self-care training first.
89688707|NCT04362397|Experimental|B (second group to receive the intervention)|This arm will not receive intervention in the first month and will receive it after this period.
89669388|NCT05618418||Hospital admitted patients with alcoholic hepatitis|"Inclusion criteria:~Age ≥ 18 Bilirubin > 50 micromol/L History of large alcoholic consumption in period prior to hospital admission (in the last six months) No bile-duct obstruction (investigated through US, CT og MRI)~Exclusion criteria:~Hepatocellulary carcinoma Viral hepatitis Autoimmune hepatitis Portal thrombosis Pregnancy Expected survival for less than one year caused by other diseases (based on decision from project responsible doctors)"
89669389|NCT01517711|Experimental|Tramadol ER|Tramadol in an extended release formulation with an initial dosage of 100 mg daily, increased weekly over the next two weeks, as tolerated, to a maximum of 300 mg daily
89669390|NCT01517711|Placebo Comparator|Placebo capsule|Lactose encapsulated to match appearance of experimental drug
89669391|NCT04830384|Experimental|Fully Active|LLLT & Music Therapy
89669392|NCT04830384|Active Comparator|LLLT Only|LLLT Therapy
89669393|NCT04830384|Placebo Comparator|Music Only|Music Therapy
89669394|NCT04830384|Sham Comparator|Placebo|No Therapy
89669395|NCT04836078|Placebo Comparator|Plain chitosan gel group|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement . Randomization will be performed and concealment from the assessors. For root conditioning purpose, Group (I) ; will be injected subgingivally with chitosan 2% gel .
89669396|NCT04836078|Active Comparator|Chitosan gels containing free Simvastatin|Will be injected subgingivally with simvastatin microsponges dispersed into chitosan 2% gel. .
89669397|NCT04836078|Experimental|Chitosan gels containing Simvastatin microsponges|This group will be injected subgingivally with free simvastatin dispersed into chitosan 2% gel containing .
89669398|NCT01517477|Experimental|First Arm: One iStent|Device: One iStent
89669399|NCT01517477|Experimental|Second Arm: Two iStents|Device: Two iStent devices
89669400|NCT01517477|Experimental|Third Arm: Three iStents|Device: Three iStent devices
89669401|NCT04830150|Experimental|supportive interventions group|Supportive and educational nursing interventions about reducing maternal stress levels in the experimental group included the following: the NICU was physically described to mothers on the first day they visited their infants, mothers were introduced to team members, and given information about how to obtain information about their baby, visiting hours and conditions.
89669402|NCT04830150|No Intervention|control group|Mothers did not have any other intervention applied by the researchers during routine operation while their infants were in the unit.
89669403|NCT01516619|Experimental|romiplostim|
89669404|NCT04823598|Active Comparator|Reference group|Coached pushing and Finnish manual perineal protection
89669405|NCT04823598|Experimental|Study group|Uncoached pushing and Hands-poised perineal protection
89669406|NCT00055237|Experimental|Cohort 1: Pts with HIV-associated Kaposi's Sarcoma|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
89669407|NCT00055237|Experimental|Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected)|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
89669408|NCT04309812|Active Comparator|Short Stimulation|1 minute duration of stimulation per day for 30 days
89669409|NCT04309812|Experimental|Long Stimulation|30 minutes duration of stimulation per day for 30 days
89669410|NCT01895699|Experimental|contrast group (Ioversol)|Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
89669411|NCT01895699|Placebo Comparator|Placebo group|
89669412|NCT01895699|Other|alpha-lipoic acid group|Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.
89669413|NCT01451385|Experimental|COV795|Participants receive 2 tablets of COV795 every 12 hours for up to 35 days
89669414|NCT01496963||group a)|Patients with pulmonary artery pressure (PAP) assessed (by echocardiogram) <36 mmHg or a tricuspid regurgitant jet velocity (TG) <3 m / sec and data on PAP and mean left ventricular ejection fraction (LVEF) > 50%
89669415|NCT01496963||group b)|"Patients with:~PAP estimated (by echocardiography)> 40 mmHg or TG> 3.2 m / sec and LVEF> 50% As indicated by the Guidelines, patients b) with increased PAP (TG> 3.2 m / sec or> 40 mm Hg) will be further studied using RHC and vasoreactivity testing. Angio CAT, 6MWT and BNP."
89669416|NCT01496963||group c)|patients with PAP estimated (by echocardiography) in the range of values > 3 m / sec (TG) and <3.2 m / sec or> 36 mm Hg and <40 mmHg and LVEF> 50%
88995549|NCT02913898|Placebo Comparator|IBLT control|Computerised task in which information is provided by both positive and negative outcomes. Completed 10 mins per day every day for 2 weeks
88995550|NCT02913937|Active Comparator|Needle irrigation|Endodontic irrigation will be done using an endodontic needle.
89669417|NCT04836156|Experimental|Neoadjuvant therapy base on PTC drug screening for triple negative early breast cancer|Patients with triple negative subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
89669418|NCT04836156|Experimental|Neoadjuvant therapy base on PTC drug screening for luminal like early breast cancer|Patients with luminal like subtype will receive neoadjuvant chemotherapy based on PTC drug screening.
89669419|NCT04755959||Stroke|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of Ischemic Stroke, between the years 2016-2020 as documented in an institutionally approved data base of stroke, who will consent to provide access to their data from Google Take Out service.
89669420|NCT04755959||Acute myocardial infarction|Individuals hospitalized in the Tel-Aviv Sourasky Medical Center with a diagnosis of acute myocardial infarction as documented in an institutionally approved data base of myocardial infarction, who will consent to provide access to their data from Google Take Out service.
89669421|NCT04755959||Healthy controls|Unaffected spouses or volunteers who will consent to provide access to their data from Google Take Out service.
88995551|NCT02913937|Experimental|Passive ultrasonic irrigation|Endodontic passive ultrasonic irrigation will be done using an endodontic needle followed by passive ultrasonic agitation.
88995552|NCT00150098|Experimental|lifestyle counselling|Education
88995553|NCT02913859|Experimental|pelvic radiotherapy|long-term hormonal therapy (LHRH agonist and/or antiandrogens) plus radiotherapy to the pelvis and prostate
88995554|NCT02913859|Active Comparator|No pelvic radiotherapy|long-term hormonal therapy ( LHRH agonist and/or antiandrogens) alone
89214686|NCT06082830|Experimental|Intervention|The trial duration will be four weeks. The intervention arm includes five components: personalized goal, meal timing, nutrition skills, home food environment, and engagement strategies. The specific number, design and content of the text messages for each component will be prepared and vetted by the investigators and by adolescents and parents through CHOP's Family Partners Program prior to study launch. The text messages will be sent through the REDCap Twilio integration.
89214687|NCT06082544|Experimental|Mini-screw implant-supported pontics placed palatally perpendicular to the alveolar ridge|Mini-screw implant-supported pontics placed palatally perpendicular to the alveolar ridge (horizontally placed) using JEIL SCREW 1.6*8 MM 16-G2-008
89214688|NCT06082544|Experimental|Mini screw implant supported pontics placed at the crest of the ridge|Mini screw implant supported pontics placed at the crest of the ridge (vertically placed) using JEIL SCREW 1.6* 10 MM 14-G2-f010
89214689|NCT06082544|Active Comparator|Removable partial denture.|removable partial denture with conventional technique
89214690|NCT06080204|Experimental|Octreotide group|Patients in the octreotide group received octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months, with the start of clinical intervention following surgery.
89669422|NCT04836234|Experimental|intervention group|Participants will receive Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum. They will be instructed to chew the gum for pain relief after the separator and initial arch wire placement if required. Chew the gums for 10-12 minutes and as much as they want whenever they feel discomfort or pain. They are free to take any medication when necessary and respond to the questionnaires on the amount of chewing gum and analgesics used.
89669423|NCT04836234|No Intervention|Control group|Participants will not receive any prescription after the separators and initial arch wires placement. They will be specifically asked not to chew chewing gum. As in the intervention group, they can take any medication when they feel necessary and respond to the questionnaires on the amount of analgesics used.
89669424|NCT01463423|Experimental|Limited Primary Non-small Cell Lung Cancer (NSCLC)|Participants with limited primary NSCLCs (graded as T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0)
89669425|NCT01463423|Experimental|History of NSCLC|Participants with prior history of NSCLC and new limited primary NSCLC lesion(s)
89669426|NCT01463423|Experimental|Advanced Lung Cancer Including Metastatic Lung Cancer|Participants with more advanced lung cancer or lung metastases from a variety of different cancers.
89669427|NCT01502787|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
89669428|NCT01502787|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
89669429|NCT01455467|Active Comparator|One iStent|Implantation of one iStent in conjunction with cataract surgery
89669430|NCT01455467|Active Comparator|Two iStent|Implantation of two iStent devices in conjunction with cataract surgery
89669431|NCT01440179|Experimental|SAR3419|Administered for one to two induction cycles, followed by maintenance cycles up to 6 cycles.
89669432|NCT00056563|Active Comparator|1|Deep Brain Stimulation
89669433|NCT00056563|Active Comparator|2|Best Medical Therapy
89669434|NCT01503333|No Intervention|Control|The control condition will complete data collection activities and receive their usual school offerings.
89669435|NCT01503333|Experimental|Physical activity intervention|Receiving Physical activity intervention which includes individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
89669436|NCT04829838|Experimental|Intravenous levetireacetam|Drug:Intravenous levetireacetam will be given at a loading dose of 20-30mg/kg then it will be added in maintainance dose of (5-30mg/kg/day)
89669437|NCT04829838|Experimental|intravenous phenytoin|Intravenous phenytoin will be given in loading dose of 20mg/kg then it will be added in maintainance dose i-e 5-8mg/kg/day
89214691|NCT06080204|No Intervention|Control group|No adjuvant therapy after surgery.
89214692|NCT06079307|No Intervention|Control|Won't receive an oxygenated mouthwash nor oxygenated mouth foam yet will be provided a fluoridated toothpaste and a toothbrush (20 participants)
89669438|NCT01571427|Placebo Comparator|Control group|No daily conversational sessions with interviewers using webcam/internet. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
89669439|NCT01571427|Active Comparator|Active social engagement group|Engage in 30 minutes video chat daily (5 times per week, except weekend) with interviewers for 6 weeks. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
89669440|NCT01428557||Heart Failure patients (Breathe I)|Patients admitted with clinical diagnosis of decompensate heart failure, > 18 years old.
89669441|NCT01428557||Heart Failure patients (Breathe Extension)|Patients admitted with clinical diagnosis of decompensate heart failure, > 18 years old.
89669442|NCT04822974|Experimental|STUDY ARM|blood samples collection
89669443|NCT05605327|Experimental|EUS-guided gastroenterostomy|
89669444|NCT05605327|Active Comparator|Laparoscopic gastroenterostomy|
89669445|NCT01425671||Schizophrenic patients, family members|Schizophrenia Spectrum Disorder Patients
89669446|NCT01425671||Controls|Normal controls
89688708|NCT04362241|Experimental|Dextenza|Sustained release Dexamethasone 0.4mg
89688709|NCT04362241|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate Ophthalmic drops
89669447|NCT04835922|Experimental|Intercostal Nerve Block|• In Group I (ICBN group): Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine at the termination of PCNL under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each).
89669448|NCT04835922|Active Comparator|Peritract infiltration|In Group P (PTI): Single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given on completion of PCNL by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position). Then the surgical wound and intervention site will be covered with an occlusive dressing.
89669449|NCT04822896|Experimental|Kinesthetic Motor Imagery|They will be asked to imagine the exercises kinesthetically from a first person perspective (as if they were doing it themselves).
89669450|NCT04822896|Experimental|Visual Motor Imagery|They will be asked to imagine the exercises visually from a third person perspective (as if they were watching from the mirror / from the mirror while doing it themselves).
89669451|NCT04822896|Active Comparator|Real Physical Movements|They will be asked to actually do the exercises shown in the video.
89214693|NCT06079307|Experimental|Oxygenated mouthwash Group|Provided with oxygenated mouthwash bottle 2 per individual for 3 months (40 bottles in total). -20 participants -
89669452|NCT02318303|Placebo Comparator|GSP 301 Placebo NS|
89669453|NCT02318303|Experimental|GSP 301-1 NS (QD)|
89669454|NCT02318303|Experimental|GSP 301-2 NS (BID)|
89669455|NCT02318303|Active Comparator|Olopatadine HCl-1 NS (QD)|
89669456|NCT02318303|Active Comparator|Olopatadine HCl-2 NS (BID)|
89669457|NCT02318303|Active Comparator|Mometasone Furoate-1 NS (QD)|
89669458|NCT02318303|Active Comparator|Mometasone Furoate-2 NS (BID)|
89669459|NCT04822428|Experimental|study group(A)|Group (A): included Twenty patients who received osteopathic manipulative techniques, 1 session per week for 3 weeks.
89669460|NCT04822428|No Intervention|Control group(B)|Group (B): included twenty patients who received analgesic drugs only.
89669461|NCT04822506|Experimental|Routine perioperative management and PEA|Routine perioperative management and perioperative electroacupuncture (preoperative, intraoperative, postoperative)；
89669462|NCT04822506|Active Comparator|Routine perioperative management and postEA|Routine perioperative management and postoperative electroacupuncture
89669463|NCT01380665|Other|There is one group of 100 patients|50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;
89669464|NCT01451775|Experimental|Treatment A|high dose of empagliflozin after overnight fasting for at least 10 h
89669465|NCT01451775|Experimental|Treatment B|high dose of empagliflozin after a standardised high fat breakfast
89669466|NCT01451775|Experimental|Treatment C|low dose empagliflozin after overnight fasting for at least 10 h
89669467|NCT04835610||PVI values|PVI values measured at the finger and forehead areas in pediatric patients
89669468|NCT04835610||no control group|no control group
89669469|NCT03035682|Active Comparator|Traditional Group|The control group will receive traditional PT services as deemed clinically appropriate via examination to include traditional home exercise prescription.
89669470|NCT03035682|Experimental|Augmented Media Group|The Augmented Media group will receive traditional PT services as deemed clinically appropriate via examination and include home exercise prescription via a mobile health application.
89669471|NCT01453413|Other|People with type 2 diabetes|People with type 2 diabetes who were in attendance at a diabetes conference were asked for their perceived Blood Glucose (BG) value. Then, after staff measured BG on a Blood Glucose meter, subjects were informed of their BG value.
89669472|NCT00156013|Experimental|1|Clofarabine 4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles.
89669473|NCT01358669|Active Comparator|Denosumab|In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant
89669474|NCT01358669|Placebo Comparator|Placebo|Placebo
89669475|NCT01357733|Other|Interim FDG PET/CT|Single arm study with diagnostic imaging study as the intervention.
89669476|NCT00156247|Experimental|etanercept with acitretin|open-label
89669477|NCT03036774|Experimental|Diabetic patient|Diabetic patients (type 1 or type 2 diabetes) with scheduled surgery . Ultrasonic measurement of antral area
89669478|NCT03036774|Other|Non diabetic patient|"Patients with scheduled surgery without history of diabetes or a current, treated or untreated, diabetic disease.~Ultrasonic measurement of antral area"
89669479|NCT01453569|Experimental|sodium oligo-mannurarate 900mg|
89669480|NCT01453569|Experimental|sodium oligo-mannurarate 600mg|
89669481|NCT01453569|Placebo Comparator|Placebo|
89669482|NCT00156715|Experimental|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
89669483|NCT04829370|Active Comparator|PLT|All subjects are treated with fractional carbon dioxide laser, then applied 2 mL PLT solution (dissolved in normal saline) on the right face.
88995555|NCT02913820||snowfall >5cm/d|impact of snowfall and its correlation with acute myocardial infarctions is analyzed. Other precipitation (rainfall) changes in atmospheric pressure and temperature will be variables to be corrected for.
89669484|NCT04829370|Placebo Comparator|Saline|All subjects are treated with fractional carbon dioxide laser, the left face (control group) be applied 2 mL normal saline
89688710|NCT05620069|Experimental|Music listening at bed time|
89688711|NCT05620069|No Intervention|Treatment as usual|
89669485|NCT04835454||control group|The control group consisted of healthy men with no cancer and no chronic diseases. They will be age-matched with patient group and recruited among men subjected to the routine periodic medical examination.
89669486|NCT04835454||Prostate cancer group|Patients who are confirmed to have prostate cancer based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue with no other coexisting cancers or prostate cancer treatment
89669487|NCT04835454||benign prostatic hyperplasia group|Patients who are confirmed to have benign prostatic hyperplasia based on digital rectal examination (DRE), trasrectal ultrasonography and histopathological examination of biopsy tissue
89669488|NCT01326455|Other|Terumo Control|
89669489|NCT01326455|Active Comparator|Terumo Fast Release|
89669490|NCT01326455|Active Comparator|Clo-Sur P.A.D.|
89669491|NCT01573533|Experimental|Rituximab|
89669492|NCT04752709|Experimental|Active Group A|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A.
89669493|NCT04752709|Active Comparator|Active Group B|Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B.
89669494|NCT04835532|Experimental|Control group|"Vertical alveolar bone augmentation was performed by GBR technique before implantation.~BIO-OSS+ BIO-GIDE barrier membrane"
89669495|NCT04835532|Experimental|Treatment group 1|"Vertical alveolar bone augmentation was performed by GBR technique and tenting screws before implantation.~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws"
89669496|NCT04835532|Experimental|Treatment group 2|"Vertical alveolar bone augmentation was performed by GBR technique in combination with tenting screws and A-PRF, I-PRF before implantation.~BIO-OSS+ BIO-GIDE barrier membrane+ tenting screws+A-PRF, I-PRF"
89669497|NCT04828512||normal glucose tolerance (NGT)|In the 75-g OGTT, an FPG level of < 100 mg/dL or a 120-min PG level of < 140 was diagnosed as NGT.
89669498|NCT04828512||impaired glucose intolerance (IGT)|In the 75-g OGTT, an FPG level of 100-125 mg/dL (5.6-6.9 mmol/L) or a 120-min PG level of 140-200 mg/dL (7.8-11.1 mmol/L) was diagnosed as IGT.
89669499|NCT04828512||newly diagnosed DM (subclinical DM)|In the 75-g OGTT, a basal FPG level ˃126 mg/dL (7.0 mmol/L) or a 120-min PG level ˃200 mg/dL (11.1 mmol/L) was considered as newly diagnosed DM (hereafter referred to as subclinical DM).
89669500|NCT01454505|Experimental|Stage B/AL-53817|Stage B: AL-53817 nasal spray solution, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
89669501|NCT01454505|Placebo Comparator|Stage B/Vehicle|Stage B: Vehicle nasal spray, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
89669502|NCT04835220|No Intervention|Control Group|Electronic pill bottle cap (MEMs bottle cap) with no Telehealth calls
89669503|NCT04835220|Other|Telehealth intervention group|Electronic pill bottle cap (MEMs bottle cap) with regular telehealth visits to the veterans at the VAMCs on the stewardship program. These visits will involve contacting the veterans by telephone, administering a questionnaire to review their medication-taking behavior for oral chemotherapy, and potentially contacting the treating oncologist in the event that the veterans are at risk of non-adherence (based on their responses).
89669504|NCT04828122||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89669505|NCT04828122||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89669506|NCT04828122||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89669507|NCT04828122||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89669508|NCT04822116|No Intervention|standard of care|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol."
89669509|NCT04822116|Active Comparator|goal directed intraoperative haemodynamic optimization|"Standard of care defined as standard operating procedure, including a goal directed intraoperative haemodynamic optimization protocol. Additional application of a non-invasive haemodynamic optimization protocol in the post anaesthesia care unit."
89669510|NCT01455519|Placebo Comparator|Sugar pill|Subjects may receive a pill with no medicine.
89669511|NCT01455519|Active Comparator|Hydromorphone ER|Subjects received study drug: Hydromorphone ER
89669512|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 1|GM-CSF, Sargramostim 250 μg/m^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.
89669513|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 2|GM-CSF, sargramostim 150 μg/m^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m^2 per day if applicable based on toxicity and white blood cell count.
89669514|NCT04822038|Active Comparator|Scleroderma patients with hypovitaminosis D and dietary recommendations|Patients with scleroderma and hypovitaminosis D who receive dietary recommendations
89669515|NCT04822038|Active Comparator|Scleroderma patients with hypovitaminosis D and Vitamin D supplementation|Patients with scleroderma and hypovitaminosis D who receive Vitamin D supplementation
89669516|NCT04821882|No Intervention|Control|Healthy participant
89669517|NCT04821882|Experimental|Dextrose treatment|IC/PBS patients had been treated by intravesical instillations of hyaluronic acid and/or botox for more than 6 months
89669518|NCT01576809|Experimental|Upper Respiratory Tract Infection|
89669519|NCT04835142|Experimental|Double blind control period|"experiment arm： All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.~control arm: All eligible subjects will receive Erbitux in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks."
89669520|NCT04835142|Experimental|Open single period|All eligible subjects will receive A140 in combination with mFOLFOX-6 chemotherapy regimen every 2 weeks.
89688712|NCT04362319||Anaesthesiology clinicians|Including Consultants, Specialists and Medical officers serving in the Department of Anaesthesiology and Intensive Care
89669521|NCT01456143|Experimental|HRME with proflavine|High Resolution Microendoscopy (HRME) imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer. 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa. HRME is used to capture images of suspicious areas sprayed with proflavine hemisulfate.
89669522|NCT00158197|Experimental|continuous voucher schedule|Those in the continuous condition will receive a contingency management voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
89669523|NCT00158197|Experimental|intermittent predictable schedule|Those in the intermittent predictable condition will earn a contingency management voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
89669524|NCT00158197|Experimental|intermittent unpredictable schedule|Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, & F for 12 wks and complete measures 1x/wk.
89669525|NCT00158197|No Intervention|standard|Participants assigned to the standard condition will not receive vouchers for the provision of clean urines. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
89669526|NCT01456299|Placebo Comparator|Control|The control group, which received an infusion of normal saline.
89214694|NCT06079307|Experimental|Oxygenated mouth foam Group|Provided with oxygenated mouth foam/ day- 20 participants- 2 oxygenated mouth foam bottle per individual for 3 months (40 bottles in total).
89214695|NCT06077929||Rhinosinusitis|Patients with rhinosinusitis
89669527|NCT01456299|Active Comparator|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
89669528|NCT01456299|Active Comparator|Remifentanil 2|"Remifentanil 2: The R2 group, which received a target effect-site remifentanil concentration of 2 ng/ml."
89669529|NCT00158743|Active Comparator|Digoxin immune fab|Digibind treatment plus standard of care
89669530|NCT00158743|Placebo Comparator|placebo (sodium chloride)|
89669531|NCT00161473|Active Comparator|prazosin|
89669532|NCT00161473|Placebo Comparator|placebo (inert substance)|
89669533|NCT01319981|Experimental|Hyper-CMAD + Rituximab|Odd Courses 1, 3, 5, 7: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 1 & 3; Imatinib oral 600 mg days 1-14 Course 1 then continuously; Cyclophosphamide 300 mg/m2 IV every; 12 hours for 6 doses; Mesna 600 mg/m2/day IV Days 1-3; Doxorubicin 50 mg/m2 IV CVC Day 4; VSLI 2.25 mg/M2 IV Day 1 & 8; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 µg/kg/day; Dexamethasone 40 mg IV or P.O. daily days 1-4 and days 11-14 +/- 3 days.
89669534|NCT01319981|Experimental|Hyper-CMAD|Courses 2, 4, 6, 8: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 2 & 4; Imatinib oral 600 mg; Methotrexate 200 mg/m2 IV over 2 hours followed by 8-0- mg/m2 over 22 hours on Day 1; Solu-Medrol 40 mg IV hours approximately every 12 hours +/- 2 hours for 6 doses days 1-3 +/- 3 days; Decadron 40 mg IV or orally 4 times Days 1-4; Ara-C 3 gm/m2 IV every 2 hours, 4 doses on Days 2-3; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 mg/kg/day.
89669535|NCT01458561|Experimental|BioFoam Surgical Matrix|Control of bleeding using BioFoam Surgical Matrix as a surgical adjunct
89669536|NCT01458561|Active Comparator|Gelfoam Plus|Control of bleeding using Gelfoam Plus as a surgical adjunct
89669537|NCT05605171|Experimental|Posterior reconstruction urethrovesical anastomosis.|The intervention comprised of a 2-stitch approximation of the free edge of the Denonvilliers' fascia and posterior bladder wall cranially, to the posterior aspect of the rhabdosphincter and the posterior median raphe caudally, respectively, following prostate extraction. The aim of this approach is to ultimately restore the length of the urethrosphincteric complex, prevent its caudal retraction, and avoid undue tension on the subsequent vesicourethral anastomosis, and provide a posterior support to the urethral sphincter complex to facilitate its effective contraction.
89669538|NCT05605171|Active Comparator|Conventional urethrovesical anastomosis.|The conventional is fashioned with a continuous running technique that uses two sutures. The first suture is passed in a clockwise hemicircumferential manner, starting from outside in on the bladder neck at the 5 o'clock position and inside out on the urethra up toward the 12 o'clock position. The second suture is similarly run in a counter- clockwise hemicircumferential direction. The running sutures are snug down after each apposition to ensure there is no slack, and finally tied together with several knots at the 12 o'clock position.
89669539|NCT01897987|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
89669540|NCT01897987|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
89669541|NCT01459653||Only 1 group|Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
89669542|NCT01265459|Experimental|Durolane 3ml|Durolane 3 ml is an Intraarticular hyaluronic acid
89669543|NCT01265459|Experimental|Durolane 4.5|Durolane 4.5 is an Intraarticular hyaluronic acid
89669544|NCT01265459|Experimental|Durolane 6 ml|Durolane 6 ml is an Intraarticular hyaluronic acid
89669545|NCT01897363||Infants with Prader-Willi Syndrome|Infants between ages 2 to 12 months of age with Prader-Willi Syndrome.
89669546|NCT01223963||Macrolane|Women that have had breast enhancement with Macrolane Volume Restoration Factor.
89669547|NCT00066781|Experimental|Cohort I (closed to accrual 11/17/05)|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be escalated or de-escalated after course 1 depending on toxicity. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89669548|NCT00066781|Experimental|Cohort II|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89669549|NCT01898143|Other|Whole body vibration in COPD|Patients with COPD GOLD III or IV
89669550|NCT01898143|Other|Whole body vibration in ILD|PAtients with interstitial lung disease
89669551|NCT02603172|Experimental|Part A: Cohort 1|Subjects will receive a single dose of GSK3039294 (Dose level 1) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 2 on Day 15 (Period 2).
89669552|NCT02603172|Experimental|Part A: Cohort 2|Subjects will receive a single dose of GSK3039294 (Dose level 3) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 4 on Day 15 (Period 2).
89669553|NCT02603172|Experimental|Part B: Cohort 3a|Subjects will receive repeat dosing of GSK3039294 for a total of 21 days. The dose will be escalated every week throughout the study duration. Subjects will first receive a low dose given once daily. After 7 days, if well tolerated, the total daily dose will be increased and, GSK3039294 will be given, for example, as twice daily dosing for 7 days. At the end of this 7 day period and if previous dosing was well tolerated, the dose will be increased to a maximum daily dose that will not exceed pre-clinical safety exposure limits. On Day 4 and 5 GSK3039294 will be administered under fasted and fed conditions, respectively, to investigate the food effect on the PK.
89669554|NCT02603172|Experimental|Part B: Cohort 3b|Subjects will be enrolled in Cohort 3b only if required for further investigation. Subjects will receive GSK3039294 for 21 consecutive days and more than one dose level or regimen may be investigated, for example on the first 10 days the dose may be administered thrice daily, and on the last 11 days may be administered twice daily.
89669555|NCT02603172|Experimental|Part C: Cohort 4|Subjects will receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.
89669556|NCT05604157|Active Comparator|Tourniquet|25 participants with tourniquet application
89669557|NCT05604157|No Intervention|No tourniquet|25 participants without tourniquet application
89669558|NCT01896167|Active Comparator|Hypoxia|Inhalation of air with 8-12% oxygen content
89669559|NCT01896167|Placebo Comparator|Atmospheric air|Inhalation of atmospheric air, with oxygen content at 21%
89669560|NCT01431755|Other|Restylane SubQ|
89669561|NCT01431755|Other|Restylane SubQ Lidocaine|
89669562|NCT05602753||Smokers|All patients who participate in the study will complete the smoking history questionnaire and the carbon monoxide breath test. All patients with positive carbon monoxide breath test indicative of active nicotine exposure will be provided a structured smoking cessation program that includes information, counseling from their surgeon, or a trained health care professional and referral to a smoking cessation program.
89669563|NCT05602753||Non-Smokers|Subjects who self-declared as non-smokers
89669564|NCT05602753||Declared non-smokers with elevated Co2|subjects who self-declared as non-smokers but who tested positive for elevated Co2,
89669565|NCT01146275|Other|Participants in the Pilot study 31GB0601|"This is an additional safety follow up 7-years post treatment, for subjects enrolled in a pilot study using a previous formulation of Macrolane for breast augmentation.~Radiological breast examinations - MRI of breast, mammography and ultrasound of breast"
89669566|NCT01119053|Sham Comparator|Arm I|In this branch of study, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
89669567|NCT01119053|Experimental|Arm II|Within this space of time, study participants obtain the VNS therapy at once.
89669568|NCT00066937|Experimental|Nortriptyline Oral Capsule/CBT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.
89669569|NCT00066937|Experimental|Benztropine Oral Product/CBT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.
89669570|NCT00066937|Experimental|Nortriptyline Oral Capsule/Disease MGT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.
89669571|NCT00066937|Active Comparator|Benztropine Oral Product/Disease MGT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.
89669572|NCT01064375|Experimental|CEA DNA prime (cohort I)|5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
89669573|NCT01064375|Experimental|CEA DNA boost (cohort II)|10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
89669574|NCT01064375|Experimental|CEA DNA prime + GM-CSF (cohort III)|5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
89669575|NCT01061411|Experimental|Treatment (sunitinib malate, dalteparin)|Patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in week 6 during course 1. In all subsequent courses, patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in weeks 1-6. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89669576|NCT04828044||Microwave Ablation/ Coagulation Arm|These patients will receive microwave ablation using MedWaves Microwave Ablation/ Coagulation System.
89669577|NCT01505673|Active Comparator|Liraglutide|
89669578|NCT01505673|Placebo Comparator|Saline injection|
89669579|NCT04828356|Experimental|Foot reflexology group|The first researcher received hands-on training about reflexology application before the study started. The researcher applied foot reflexology on the patients with liver transplantation in the experimental group in one session (30 minutes) after the operation. Patient confidentiality was maintained in all procedures. The patient identity form was implemented before reflexology application. Pain and comfort levels were assessed as the pre-test. Then, venous blood was taken to determine the plasma β-End level. Foot reflexology was first applied on the right foot, which is effective on the sympathetic nervous system, for 15 min and then, on the left foot, which is effective on the parasympathetic nervous system, for 15 min. Same process was performed on the left foot and the reflexology application was completed within 15 min. Venous blood was taken again to assess the β-End level as the post-test after the application, and the NPS and PCQ were implemented again.
89669580|NCT04828356|No Intervention|No treatment group|The patient identity form, NPS and PCQ were applied on the patients in the control group as the pre-test. After the questions were answered, venous blood was taken to determine the plasma β-End level. No intervention other than clinical protocol was applied on the control group, and after taking venous blood after 30 minutes to determine β-End level, the NPS and PCQ were re-applied as the post-test.
89669581|NCT04828200||sarcopenic patints with knee ostheoarthritis|12 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients with sarcopenia.All subjects were evaluated by the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria for the diagnosis of sarcopenia.
89669582|NCT04828200||non sarcopenic patients with knee ostheoarthritis|90 patients between the ages of 50-70, who have been followed up with the diagnosis of knee Ostheoarthritis (OA) patients.
89669583|NCT04828200||control group|33 patients between the ages of 50-70, who have been followed up not being exposed to be sarcopenia or knee OA
89669584|NCT04834986|Experimental|Tislelizumab combined with Lenvatinib|
89669585|NCT04828278|Placebo Comparator|Treatment 1|1,600 mg of Placebo (maltodextrin)
89669586|NCT04828278|Active Comparator|Treatment 2|1,500 mg of ASI (bonded arginine silicate) + 100 mg of inositol (nooLVL)
89669587|NCT00057577|Experimental|Cognitive therapy plus medications|Participants will receive antidepressant medication plus cognitive therapy
89669588|NCT00057577|Experimental|Medications alone|Participants will receive maintenance of antidepressant medication alone
89669589|NCT01507155|Experimental|Patient-Reported Measures|Patients age 18 and older with a diagnosis of Major Depressive Disorder or Generalized Anxiety disorder who received genetic testing using the Genecept Assay and completed patient scales.
89669590|NCT01507155|Experimental|Clinician-Reported Outcomes|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
89669591|NCT02247141|Experimental|Subgam®|
89669592|NCT03037086||One single cohort|One single cohort of NSCLC patients with disease diagnosis between January 2010 and December 2014. The locally advanced or metastatic NSCLC patients should have initiated 1st line palliative chemotherapy by end of 2014.
89669593|NCT04827654|Experimental|Intervention group|Families in the intervention arm will receive a program of 4 weeks of access to fruit and vegetables through direct access (produce box) and a gift card to the grocery store for purchase of preferred produce.
89669594|NCT04827654|No Intervention|Control Group|Families in the control group will not receive any produce boxes or gift cards during the study period. At the end of the study period they will receive gift cards of equivalent amount.
89669595|NCT01896245|Active Comparator|sevoflurane 1,0|sevoflurane 1,0: sevoflurane is administered with a concentration of 1,0 MAC
89669596|NCT01896245|Active Comparator|sevoflurane 1,2|sevoflurane 1,2: sevoflurane is administered with a concentration of 1,2 MAC
89669597|NCT01896245|Active Comparator|sevoflurane 1,4|sevoflurane 1,4: sevoflurane is administered with a concentration of 1,4 MAC
89669598|NCT04821804|Experimental|Experimental|local application of HYADENT BG on both donor and recipient sites
89669599|NCT04821804|Placebo Comparator|control|application of normal saline on both donor and recipient sites
89669600|NCT04756115||CASES|Adults (age<18 years) diagnosed with a first episode of critical limb ischemia revascularized at our center from January 2016 to July 2019.
89669601|NCT04835064|Experimental|Nab-paclitaxel and Gemcitabine|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15;Gemcitabine 1000 mg/m2 was given intravenously for more than 30min on days 1, 8, and 15, and repeated every 4 weeks.
89669602|NCT04835064|Experimental|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
89669603|NCT05618106|Experimental|low FODMAP diet|Cross-over design with 3 variations
89669604|NCT00819221|Experimental|1|
89669605|NCT04827888||underweight|patients who underwent one of the 25 common orthopaedic surgeries and have a body mass index (BMI) of <18.5kg/m2
89669606|NCT04827888||normal-weight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 18.5kg/m2 and 24.9kg/m2
89669607|NCT04827888||overweight|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 25kg/m2 and 29.9kg/m2
89669608|NCT04827888||mildly obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI between 30kg/m2 and 34.9kg/m2
89669609|NCT04827888||moderately-to-severely obese|patients who underwent one of the 25 common orthopaedic surgeries and have a BMI ≥35kg/m2
89214696|NCT06075732|Experimental|ACTIVATE Leaders|This is a one group pretest-posttest design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by ACTIVATE triad leaders and researchers. The investigators will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention. PRISM, a Dissemination and implementation (D&I) D&I-based model can guide the implementation of the ACTIVATE program for successfully expansion and maintenance in community settings, especially for under-resourced populations.
89214697|NCT06075433||complex coronary artery disease|"<Clinical factors>~Age 75 or older History of diabetes (those who have had diabetes in the past or are taking diabetes medication) History of chronic kidney disease (GFR <60ml/min/1.73m2) or dialysis History of stroke History of coronary artery bypass surgery Left ventricular dysfunction (LVEF <40%) Severe valve disease Troponin positive acute coronary syndrome <Lesion/procedure factors>~Left main lesion Chronic total occlusion Bifurcation lesion with branches larger than 2 mm Calcified lesion (moderate to severe calcified lesion) Restenosis (in-stent restenosis) Multivessel PCI Three or more stents implanted (≥3 stents implanted) When the stent length of one lesion is more than 50 mm (total stent length >50 mm in a lesion)"
89669610|NCT01507779|Experimental|Influenza vaccine|Received 0.50 mL of inactivated monovalent influenza vaccine (IVACFLU), administered intramuscularly, on days 0 and 21
89669611|NCT01507779|Placebo Comparator|Placebo|Received placebo, administered intramuscularly, on days 0 and 21
89669612|NCT01896323|Experimental|CC-223|CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2
89669613|NCT01896323|Active Comparator|Ketokonazole|Ketoconazole administration on study days 1 through 8 of Period 2
89669614|NCT04827498||Myocardial ischemia without obstructive coronary stenosis|
89669615|NCT00808613|Active Comparator|Optetrak Posterior Stabilized TKR|Subjects in this arm will receive an Optetrak Posterior Stabilized total knee system.
89669616|NCT00808613|Active Comparator|Optetrak Hi-Flex TKR|Subjects in this arm will receive an Optetrak Hi-Flex total knee system.
89669617|NCT03037008|Active Comparator|continent men after RALP|perineal sonography, questionnaires, 24h pad tests
89669618|NCT03037008|Active Comparator|incontinent men after RALP|perineal sonography, questionnaires, 24h pad tests
89669619|NCT04378127|Experimental|educational program + traditional medical care|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
89669620|NCT04378127|No Intervention|traditional medical care|traditional medical care
89669621|NCT00068341|Experimental|Arm I (neoadjuvant therapy)|see intervention description
89669622|NCT00068341|Experimental|Arm II (neoadjuvant therapy)|please see intervention description
89669623|NCT00068341|Experimental|HER2/neu negative patients|please see intervention description
89669624|NCT04827264||Return to Play Testing using Checklist|"Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with the Safe return to play following ACL reconstruction checklist"
89669625|NCT04827264||Return to Play Testing using Clinical Judgment|Participants will be evaluated prospectively for return to play following ACL reconstruction by testing with clinical judgement
89669626|NCT01462305|Experimental|goLITE|light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks
89669627|NCT01462305|Active Comparator|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
89669628|NCT05600257||Screening cohort|Women received mammography screening
89669629|NCT05600257||Diagnostic cohort|Women received clinical breast examination
89669630|NCT02605824|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
89669631|NCT02605824|Placebo Comparator|0.9% saline|Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.
89669632|NCT01896661|Experimental|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
89669633|NCT01896661|Active Comparator|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
89669634|NCT04821258|Experimental|MICODIGEST 2.0 supplement|Treatment with MICODIGEST 2.0 will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20mL/day (10mL before breakfast and 10 mL before dinner) for 4-6 weeks.
89669635|NCT04821258|Placebo Comparator|Placebo|Treatment with placebo will initiate with 10mL/day (before breakfast or before lunch) for 7 days, and rise to 20 mL/day (before breakfast and before dinner) for 4-6 weeks.
89669636|NCT02095561|Experimental|HPV Self testing|HPV self testing offered by CHWs during home visits
89669637|NCT02095561|No Intervention|HPV at health centers|Community Health Workers instructed women about cervical cancer and HPV testing and advised them on how to seek screening at health centers.
89669638|NCT04821180||patients treated by angle stable plate PHILOS|
89669639|NCT04821180||patients treated by reverse total shoulder arthroplasty SMR|
89669640|NCT01462773|Experimental|Treatment (enzyme inhibitor, interferon therapy)|Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22 and recombinant interferon alfa-2b SC on days 1, 3, and 5 (days 1 and 3 only in week 4 course 1) of weeks 1-4. Treatment repeats every 5 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
89669641|NCT04821024||mild-moderate disability|Those whose neck disability index value is 5-34
89669642|NCT04821024||high disability|Those whose neck disability index value is 35 and above
89669643|NCT02096029|Experimental|Nicotine Replacement Therapy (NRT)|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
89669644|NCT02096029|Active Comparator|Ask, Advise, Refer (physician brief advice)|Ask, Advise, Refer (physician brief advice)
89214698|NCT06075420||complex coronary artery disease|"<Clinical factors>~Age 75 or older~History of diabetes (those who have had diabetes in the past or are taking diabetes medication)~History of chronic kidney disease (GFR <60ml/min/1.73m2) or dialysis~History of stroke~History of coronary artery bypass surgery~Left ventricular dysfunction (LVEF <40%)~Severe valve disease~Troponin positive acute coronary syndrome~<Lesion/procedure factors>~Left main lesion~Chronic total occlusion~Bifurcation lesion with branches larger than 2 mm~Calcified lesion (moderate to severe calcified lesion)~Restenosis (in-stent restenosis)~Multivessel PCI~Three or more stents implanted (≥3 stents implanted)~When the stent length of one lesion is more than 50 mm (total stent length >50 mm in a lesion)"
89214699|NCT06072768|Experimental|15-day taper prednisone|This will be for 30 days. Participants will be allocated to the 15-day strategy preferentially until enrollment goals have been met; once completing the 15-day strategy, many participants will also be eligible to complete the 150-day strategy, and may subsequently enroll in it if they wish. Participants that are not eligible for the 15-day strategy, but are eligible for the 150-day strategy, will be enrolled in the 150-day strategy.
89214700|NCT06072768|Experimental|150-day taper prednisone|This will be for 180 days. Participants who are not eligible for the 15-day strategy, but are eligible for the 150-day strategy, will be enrolled in the 150-day strategy.
89214701|NCT06072703|Active Comparator|Active rTMS|1 Hz (LF) and 10 Hz (HF) rTMS stimulation will be delivered at 90% of the resting motor threshold for 40 min each week day for two weeks.
89669645|NCT04834830||Patients with pleural effusion|In patients with pleural effusion and indication for diagnostic and/or therapeutic procedures (thoracocentesis, drainage of fluid, indwelling pleural catheter (IPC) management, and/or video-assisted thoracoscopic surgery), pleural fluid will be examined for various cytokines and PD1-lymphoctyes.
89214702|NCT06072703|Sham Comparator|Sham rTMS|"Low-frequency (1Hz) active rTMS stimulation will be delivered with an inert sham stimulation coil for 40 min each week day for two weeks."
89214703|NCT06071741||PCI group|Patients undergoing Percutaneous Coronary Intervention
89669646|NCT02205801|Active Comparator|superficial cervical block, active|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.25% Marcaine.
89669647|NCT02205801|Placebo Comparator|local wound infiltration, placebo|After induction of general anesthesia the surgeon will perform local wound infiltration using 0.9% Saline.
89669648|NCT02205801|Active Comparator|local wound infiltration, active|After induction of general anesthesia the surgeon will perform a local wound infiltration using 0.25% Marcaine.
89669649|NCT02205801|Placebo Comparator|superficial cervical block, placebo|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.9% saline.
89669650|NCT02096107|Active Comparator|Low intensity Tacrolimus|Low tacrolimus, everolimus, and steroids
89669651|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
89669652|NCT01508013|Experimental|Appearance-Focused Website Intervention|This is a Internet-based appearance-focused prevention intervention based on the Behavioral Alternatives Model.
89669653|NCT01508013|Active Comparator|Control Website|Control participants viewed an Internet site designed to provide drug and alcohol education for teens.
89669654|NCT00068575|Experimental|Postoperative Chemoradiation Regimen|Postoperative Cisplatin 30 mg/m^2 intravenous (IV) weekly for 6 doses, Interferon Alfa-2b 3 million units subcutaneous (SQ) on Monday, Wednesday and Friday days 1-19 and 29-45 for 17 total doses, and 5-fluorouracil (5-FU) 175 mg/m2/day by continuous intravenous infusion days 1-19 and 29-45 with concurrent Radiation Treatment.
89669655|NCT00784823|Experimental|Phase I Cohort - Bortezomib 1 mg/m2|Bortezomib at 1 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
89669656|NCT00784823|Experimental|Phase I Cohort - Bortezomib 1.3 mg/m2|Bortezomib at 1.3 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
89669657|NCT00784823|Experimental|Phase I Cohort - Bortezomib 1.6 mg/m2|Bortezomib at 1.6 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
89669658|NCT00784823|Experimental|Phase II Cohort|Bortezomib at 1.6 mg/m2 on days -4 and -1 before transplantation with melphalan 200 mg/m2 given on day -2.
89669659|NCT04428684|Experimental|Pepti 3.6 treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
89669660|NCT04428684|Active Comparator|Zoladex 3.6 mg treatment|Patients treated with goserelin depot 3.6 mg. One injection on Day 0 and a second injection on Day 28
89669661|NCT01509105||Group1|
89669662|NCT00773357|Experimental|Guanfacine|guanfacine 3mg/day
89669663|NCT00773357|Placebo Comparator|Placebo|placebo control
89669664|NCT05617950|Experimental|salicylic acid|30% salicylic acid
89669665|NCT05617950|Active Comparator|cryotherapy|liquid nitrogen
89669666|NCT00763607||1|Radically resected Non small cell lung cancer patients in stage I-III
89669667|NCT01509183|Active Comparator|Intervention Group|Intervention group (IG) participants received access to and feedback from the Propeller Health System (formerly Asthmapolis System).
89669668|NCT01509183|No Intervention|Control Group|Control group (CG) participants were outfitted with sensors from the Propeller Health System, but did not receive feedback.
89214704|NCT06070220|Experimental|client-centered intervention group|
89214705|NCT06070220|Experimental|control group|
89669669|NCT04834752||Patients tested for COVID-19|Patients who were tested for COVID-19 nasopharyngeal polymerase chain reaction (PCR)
89669670|NCT04834674|Experimental|DEB-TACE combined with apatinib and PD-1 antibody|The participants will receive the combined treatment of local therapy (DEB-TACE, oxaliplatin and gemcitabine), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
89669671|NCT04834596||patients without hepatic metastases|hepatic scanner of 100 patients with colorectal cancer without hepatic metastases will be analysed
89669672|NCT04834596||patients with synchronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with synchronous hepatic metastases will be analysed
89669673|NCT04834596||patients with metachronous hepatic metastases|hepatic scanner of 100 patients with colorectal cancer with metachronous hepatic metastases will be analysed
89669674|NCT04834050|Experimental|Rheumatoid arthritis patients|
89669675|NCT04834050|Experimental|Knee Osteoarthritis patients|
89669676|NCT04834050|Experimental|Healthy patients|
89669677|NCT00611117|Experimental|1|High intensity exercise and high fat diet
89669678|NCT00611117|Experimental|2|Low intensity exercise and high fat diet
89669679|NCT04820322|Placebo Comparator|control cookie|a sugarsnap cookie baked specifically for this trial
89669680|NCT04820322|Active Comparator|Fibersym cookie|a sugarsnap cookie baked using the same methodology for the control cookie but with the resistants starch RS4, Fibersym, added
89669681|NCT05618964|Experimental|Group A: Deep Neck Flexors & Extensors exercises|"Group A Patients will receive:~Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine~Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position~Segmented extension movement with the head bent down onto their chest in a horizontal direction,"
89669682|NCT05618964|No Intervention|Group B: Standardized Physical Therapy|"Standardized Physiotherapy treatment will be:~Hot pack for 10 minutes,~SNAG manual therapy at Cervical spine 6 repetitions for 60 seconds.~Superficial neck muscles (upper trapezius, Levator scapulae, Pect.Major) stretching for 3 times with 30 seconds and~Neck isometrics 10 times with 6 seconds hold. Both groups will come thrice per week for a total of 4 weeks. Pre and post treatment values of both groups will be analyzed"
89669683|NCT04826406|Experimental|Camrelizumab+Apatinib|
89669684|NCT05617872|Placebo Comparator|Saline|20ml saline infused into duodenum and suction for 5 minutes via EUS
89669685|NCT05617872|Experimental|Vinegar 20ml|20ml vinegar infused into duodenum and suction for 5 minutes via EUS
89669686|NCT05617872|Active Comparator|Vinegar 40ml|40ml vinegar infused into duodenum and suction for 5 minutes via EUS
89669687|NCT05617872|Active Comparator|Vinegar 20ml, 0-5min|20ml vinegar infused into duodenum and pancreatic juice collected via EUS suction during the first 5 minutes
89669688|NCT05617872|Active Comparator|Vinegar 20ml, 5-10min|20ml vinegar infused into duodenum and pancreatic juice collected via EUS suction during the 5-10 minutes
89669689|NCT05617872|Active Comparator|Vinegar 20ml, 10-15min|20ml vinegar infused into duodenum and pancreatic juice collected via EUS suction during the 10-15 minutes
89669690|NCT04820088|Experimental|Intervention Arm|The educational intervention will be TTACS, the training program with simulated roleplays. Each participant will be asked to schedule 10 hours of time to utilize the simulation. In order to ensure all participants adhere to the minimum intervention requirements, each will be asked to schedule training time with a member of the research team. Participants will attend an initial training session where each participant will receive a short orientation about the product and its capabilities. Participants will attend an initial training session at one of two sites Psychology Department at Towson University or SIMmersion's office in Columbia, MD based on participant preference. Subsequent training sessions may be completed at Towson, SIMmersion or can be completed individually. Participants will receive confirmation emails the day before a scheduled session and a phone call to reschedule any missed sessions.
89669691|NCT04820088|No Intervention|Contro Arm|Students randomized to the control group will be given an electronic copy of the Guidelines for Psychological Practice with Transgender and Gender Non-Conforming People (APA, 2015) and asked to take notes in the pdf document. The amount of time students spend on the document and note-taking will be recorded and notes will be analyzed for content. As an incentive, the participants in the control group will be given access to TTACS after they complete the post-intervention assessment.
89669692|NCT04819932|Experimental|group1|subject take DWC202008 and DWC2020091 on a fasted condition, and after wash out period, take DWJ1451 with on a fasted condition
89669693|NCT04819932|Experimental|group2|subject take DWJ1451 on a fasted condition, and after wash out period, take DWC202008 and DWC202009 with on a fasted condition
89669694|NCT04317144|Active Comparator|Web-based follow-up programme|Participant randomized to the Web-based follow-up programme receive access to web-portal called www.1177.se
89669695|NCT04317144|Active Comparator|No follow-up.|Participants does not receive the web-based follow-up programme. e-questionnaires are sent out.
89669696|NCT01896401|Experimental|InSeal's Vascular Closure Device|Use of the experimental VCD to close the access site of the artery
89669697|NCT00437255|Active Comparator|1|Clobex® Spray
89669698|NCT00437255|Active Comparator|2|Taclonex® Ointment
89669699|NCT04826172|Experimental|IMB-1018972 200mg|
89669700|NCT04826172|Placebo Comparator|Placebo|
89669701|NCT03036696||Pregnant Mothers Interview|(1) 18 years old or over, (2) between 28-38 weeks of pregnancy, (3) lives in Gainesville, Florida, and (4) are committed to exclusively breastfeeding through 6 months.
89669702|NCT03036696||Breastfeeding Mothers Interview|(1) 18 years old or over, (2) actively breastfeeding infant less than 12 months of age, and (3) lives in Gainesville, Florida.
89669703|NCT02324673|Experimental|Low Dose Cannabidiol Oral Solution [10 mg/kg/day]|Low Dose [10 milligrams/kilogram/day (mg/kg/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
89669704|NCT02324673|Experimental|Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]|Mid Dose [20 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
89669705|NCT02324673|Experimental|High Dose Cannabidiol Oral Solution [40 mg/kg/day]|High Dose [40 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
89669706|NCT00373217|Experimental|Group 1|Patients in group one will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin in week 1. Treatment may repeat every 3 weeks for up to four courses. They will then undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to four courses.
89669707|NCT00373217|Experimental|Group 2|Patients in group two will undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to eight courses. Some patients may undergo a second surgery within 6 weeks after completing the fourth course of chemotherapy and undergo tumor and/or lymph node tissue collection.
89669708|NCT02605122|Experimental|Solithromycin|Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
89669709|NCT02605122|Active Comparator|Standard of Care|Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.
89669710|NCT01579305|Experimental|Juvéderm® Volbella with Lidocaine|Subjects injected with Juvéderm® Volbella with Lidocaine in their lips
89669711|NCT01579305|Active Comparator|Restylane-L®|Subjects injected with Restylane-L® in their lips
89669712|NCT00212147|Experimental|General anesthesia with nitrous oxide|
89669713|NCT00212147|Active Comparator|General anesthesia without nitrous oxide|
89669714|NCT04311684||Patients with proteinuria|Patients with newly diagnosed glomerulonephritis with different range of proteinuria at the age between 18-65 years and estimated glomerular filtration rate (GFR) ≥60 ml/min will be included for urine protein measurements
89669715|NCT04311684||Healthy volunteers|Healthy men/women between age group 18-65 years will be included for urine protein measurements
89669716|NCT00198341|Experimental|1|Radiological arm (Clinical Visit + X-Ray Chest)
89669717|NCT00198341|Experimental|2|Scan ARM : Clinical Visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous type)
89669718|NCT02216097|Experimental|Treatment|
89669719|NCT02216097|Placebo Comparator|Placebo|
89669720|NCT04819776|Experimental|Iloperidone|
89669721|NCT04819776|Placebo Comparator|Placebo|
89669722|NCT01466751|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
89669723|NCT01466751|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
89669724|NCT01454102|Experimental|Arm A: Nivolumab + Gemcitabine + Cisplatin|"Nivolumab solution intravenously every 3 weeks until progressive disease (PD) or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Gemcitabine solution intravenously on Day 1 and Day 8 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
89669725|NCT01454102|Experimental|Arm B: Nivolumab + Pemetrexed + Cisplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Pemetrexed solution intravenously on Day 1 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
89669726|NCT01454102|Experimental|Arm C: Nivolumab + Paclitaxel + Carboplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Paclitaxel solution intravenously on Day 1 of every cycle for 4 cycles~Carboplatin area under curve (AUC) 6 solution intravenously on Day 1 of every cycle for 4 cycles"
89669727|NCT01454102|Experimental|Arm D: Nivolumab + Bevacizumab maintenance|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Bevacizumab administered prior to intravenous infusion on Cycle 1 Day 1 followed by intravenous infusion every 3 weeks on Cycle 2 onwards and until PD or discontinuation due to toxicity"
89669728|NCT01454102|Experimental|Arm E: Nivolumab + Erlotinib|"Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Erlotinib tablet by mouth daily until PD or discontinuation due to toxicity"
89669729|NCT01454102|Experimental|Arm F: Nivolumab|Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes
89669730|NCT01454102|Experimental|Arm G: Nivolumab + Ipilimumab|"In Squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered until PD or discontinuation due to toxicity"
89669731|NCT01454102|Experimental|Arm H: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
89669732|NCT01454102|Experimental|Arm I: Nivolumab + Ipilimumab|"In squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
89669733|NCT01454102|Experimental|Arm J: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
89669734|NCT01454102|Experimental|Arm K: Nivolumab|"In squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered as switch maintenance therapy. A cycle is 2 weeks"
89669735|NCT01454102|Experimental|Arm L: Nivolumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes as switch maintenance therapy. A cycle is 2 weeks"
89669736|NCT01454102|Experimental|Arm M: Nivolumab|"NSCLC subjects with untreated, asymptomatic brain metastases and have no evidence of cerebral edema~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered for up to an hour as monotherapy. A cycle is 2 weeks"
89669737|NCT01454102|Experimental|Arm N: Nivolumab + Ipilimumab|"In subjects with any histology (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
89669738|NCT01454102|Experimental|Arm O: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
89669739|NCT01454102|Experimental|Arm P: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
89669740|NCT01454102|Experimental|Arm Q: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
89669741|NCT01454102|Experimental|Arm R: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
89669742|NCT01454102|Experimental|Arm S: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
89669743|NCT04192253|Experimental|neo-adjuvant Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
89669744|NCT03036618|Placebo Comparator|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
89669745|NCT03036618|Experimental|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
89669746|NCT04833972|Experimental|Experimental: V1: Binary Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has binary (yes/no) response options."
89669747|NCT04833972|Experimental|Experimental: V2: Categorical Response Options|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire has categorical response options: all or almost all; more than half, but fewer than 90%; fewer than half, but more than 10%; very few, or no one"
89669748|NCT04833972|Experimental|Experimental: V3: Open-Ended Numerical Estimate|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. Each question in this version of the survey questionnaire permits the study participant to provide an open-ended numerical estimate."
89669749|NCT01466985|Experimental|Panel A: Doravirine 25 mg or Placebo|Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.
89669750|NCT01466985|Experimental|Panel B: Doravirine 200 mg or Placebo|Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
89669751|NCT01466985|Experimental|Panel C: Doravirine or Placebo|Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.
89669752|NCT04825782||Pregnant Women exposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
89669753|NCT04825782||Pregnant Women unexposed to antimalarials during pregnancy|Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
89669754|NCT01467063|Active Comparator|Glutamine|
89669755|NCT01467063|Placebo Comparator|Placebo|
89669756|NCT04825938|Experimental|Toripalimab + Carboplatin + Nab-paclitaxel|"Toripalimab (IV), dose= 240mg , day=1 , cycle length: 21 days.~Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days.~Nab-paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days."
89669757|NCT04826016|Experimental|PHASE Ib - ARM A: POL6326 (balixafortide) + eribulin|On day 1 and 8 of each 21-day cycle (+/- 1 day) fixed eribulin dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) combined with increasing doses of POL6326 (balixafortide) starting at a dose of 11 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Eribulin will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 2 to 5 min. Up to 4 additional cohorts may be introduced
89669758|NCT04826016|Experimental|PHASE Ib - ARM B: POL6326 (balixafortide) + nab-paclitaxel|On day 1, 8 and 15 of each 28-day cycle (+/- 1 day) fixed nab-paclitaxel dose of 100 mg/m2 combined with increasing doses of POL6326 (balixafortide) starting at a dose of 5.5 mg/Kg will be administered both intravenously. POL6326 (balixafortide) will be administered following a biphasic regimen (0,5 mg/Kg of POL6326 (balixafortide) dose during the first 30 min of treatment, the remaining dose during the following 3 h and 30 min for a total of 4h. Nab-paclitaxel will be administered within 45 min after the end of the POL6326 (balixafortide) infusion over 30 min. Up to 5 additional cohorts may be introduced
89669759|NCT04826016|Experimental|PHASE 2 - ARM A: POL6326 (balixafortide) + eribulin|MTD/RDP2 POL6326 (balixafortide) (from arm A phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 1.4 mg/m2 eribulin over 5 min Intravenous infusion on days 1 and 8 in 21-day cycles (+/- 1 day).
89669760|NCT04826016|Experimental|PHASE 2 - ARM B: POL6326 (balixafortide) + nab-paclitaxel|MTD/RDP2 POL6326 (balixafortide) (from arm B phase Ib) will be administered over 4h intravenous infusion (biphasic regimen as detailed above/ phase Ib) followed by 100 mg/m2 nab-paclitaxel over 30 min Intravenous infusion on days 1, 8 and 15 in 28-day cycles (+/- 1 day).
89669761|NCT04833660|Experimental|rTMS group|"Each patient will receive five consecutive sessions (Monday to Friday for 1 week).~Patients in the rTMS group will administer rTMS over the optimal scalp site at 10 Hz, with an intensity of 90% of the MT and a duration of 5 seconds, for a total of 20 trains separated by 55-second intertrain pauses (a total of 1,000 pulses). The coil will be placed tangentially to the scalp at an approximate angle of 45° tilted backward and laterally. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods."
89669762|NCT04833660|Sham Comparator|sham group|Patients in the sham group will administer sham stimulation using the same protocol, except that the angle of the coil is 90° (i.e., perpendicular, rather than tangential) to the skull. Oral medication dosages of all patients will unchanged during the stimulation and follow-up periods.
89669763|NCT01509807|Active Comparator|Group 1|IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
89669764|NCT01509807|Experimental|Group 2|EXPAREL (bupivacaine liposome injectable suspension)
89669765|NCT04818996|Experimental|Mediterranean Diet|In the study, the participants were applied a diet compatible with the Mediterranean diet for 8 weeks.
89669766|NCT00070135|Experimental|Treatment (fludarabine, busulfan, allogeneic PBSC)|"PREPARATIVE REGIMEN: Patients receive fludarabine IV over 30 minutes on days -7 to -3 and busulfan IV over 2 hours 4 times per day (every 6 hours) on days -4 and -3.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO or IV BID on days -2 with taper between days 90-120, and stopping by days 150-180. Patients also receive methotrexate IV on days 1, 3, 6, and 11 and rabbit antithymocyte globulin IV over 4-6 hours on days -4 through -2.~ALLOGENEIC PBSC: Patients undergo allogeneic PBSC transplant on day 0. Patients then receive filgrastim SC daily beginning on day 12 and continuing until blood counts recover."
89669767|NCT04816500|Experimental|RIC group|Device: Remote ischemic conditioning RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
89669768|NCT04816500|Other|Regular treatment|
89669769|NCT01583985|Active Comparator|Opioid-intensive|Opioid-intensive prescribing strategy
89669770|NCT01583985|Active Comparator|Opioid-avoidant|Opioid-avoidant prescribing strategy
89669771|NCT04816344||Group MP (n=35)|"The patients were separated into four groups according to the anaesthetic agents given.~Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage."
89669772|NCT04816344||Group MK (n=35)|Premedication was applied as intranasal 0.2 mg/kg midazolam, then 1 mg/kg ketofol (10% ketamine + 10% propofol) iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg iv ketofol was given as additional dosage.
89669773|NCT04816344||Group DP (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg of propofol iv bolus as an anaesthetic agent was administered, and if necessary propofol 0.5 mg/kg iv was given as additional dosage.
89669774|NCT04816344||Group DK (n=35)|Premedication was applied as intranasal 1 mcg/kg dexmedetomidine, then 1 mg/kg ketofol iv bolus as an anaesthetic agent was administered, and if necessary 0.5 mg/kg ketofol iv was given as an additional dosage.
89669775|NCT00073333|Active Comparator|1|Social skills training and exposure
89669776|NCT00073333|Active Comparator|2|Exposure treatment
89669777|NCT00073333|Placebo Comparator|3|Placebo
89669778|NCT02602080||FA patients under popliteal block + spinal + sedation|Foot and ankle patients under popliteal block+ spinal+ sedation
89669779|NCT02602080||TSA patients under brachial plexus block + general (LMA)|Total shoulder arthroscopy patients under brachial plexus block + general (LMA)
89669780|NCT02602080||TSA patients under brachial plexus block + sedation|Total shoulder arthroplasty patients under brachial plexus block + sedation
89669781|NCT01467999|Experimental|Guanfacine|Guanfacine, 4mg given once daily
89669782|NCT01469715|Experimental|GBP-CGM|All participants will wear one active GBP-CGM and one inactive GBP-CGM
89669783|NCT04816656|Experimental|Experimental arm|All patients were presented the digital PROMs platform during their chemotherapy
89669784|NCT04816266||Myopic patients|
89669785|NCT04816266||Hypermetropic patients|
89669786|NCT04816266||Emmetropic people|
89669787|NCT05617482|Active Comparator|Ultrasound guided ilioinguinal, iliohypogastric TAP block|In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.
89669788|NCT05617482|Active Comparator|Ultrasound guided transversus abdominis plane block|The transducer will be placed at between the lower rib margin and the iliac crest, the 23-gauge Quincke spinal needle needle passed through the external oblique and internal oblique muscle till reaching the transversus abdominis sheet. 20 ml of 0.25% bupivacaine will be injected
89669789|NCT05617482|Active Comparator|Ultrasound guidedQuadratus lumborum block|The transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
89669790|NCT04816422|Experimental|Proprioceptive neuromuscular facilitation|Bilateral upper extremity pattern for trunk by Chopping, Lifting 2. Bilateral lower extremity pattern for trunk. 3. Trunk lateral flexion. 4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion.
88995556|NCT02913742|Experimental|monitoring by depth electrode|Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive a QOLIE-31-P questionnaire, in addition to standard post-operative care.
88995557|NCT04688281|Active Comparator|GUARDIX-SG®|Treat GUARDIX-SG 5ml prefilled syringe after surgery
88995558|NCT04688281|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
88995559|NCT02913781|Experimental|polar body removal|polar body removal by zona drilling with laser then suction by injecting pipette then ICSI procedure is done
89669791|NCT04816422|Active Comparator|Conventional treatment|"Procedure Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
89669792|NCT01470027|Active Comparator|N-acetylcysteine 1800mg|N-acetylcysteine 1800mg/day for 30 days
89669793|NCT01470027|Active Comparator|N-acetylcysteine 3600mg|N-acetylcysteine 3600mg daily for 30 days
89669794|NCT01470027|Placebo Comparator|Placebo|Placebo effervescent tablets daily for 30 days
89669795|NCT04819230|Experimental|Bias Modification|Attention (ATT) and interpretation (ITT) bias training. Participants complete the ATT and ITT tasks twice per week for four weeks. The ATT trains attention toward neutral stimuli and away from negative stimuli. On trials with one neutral and one threat word, the probe will always follow the location of the neutral word. Therefore, there is a contingency between the valence of the word and the location of the probe. Participants will be asked to indicate which type of probe had appeared in each trial by pressing a corresponding button as rapidly and accurately as possible. The ITT trains participants to make benign (vs. threatening) interpretations of socially-ambiguous scenarios. For each trial, a word suggesting a socially threatening or benign interpretation is presented then replaced by a sentence describing a socially-ambiguous scenario. Participants indicate if they thought the word and sentence were related. Participants will receive corrective feedback after each trial.
89669796|NCT04819230|Placebo Comparator|Control Condition|"A combination of attention (ATT-C) and interpretation (ITT-C) control tasks~These tasks are identical to the experimental tasks (ATT and ITT) with the exceptions that:~ATT-C: It is designed to train attention toward neither neutral nor the threat stimuli. This will be achieved by having an equal number of probes follow the location of the threatening word and the neutral word.~ITT-C: It is not designed to train benign interpretations of ambiguous social scenarios. Thus, no feedback will be given during the inter-trial interval, rather participants will see a blank screen between trials.~Participants will complete both the ATT-C and ITT-C tasks twice per week for four weeks, totaling to eight experimental sessions."
89669797|NCT04427670|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group.
89669798|NCT04427670|Other|Group intervention|Group intervention will be provided to the experimental group.
89669799|NCT04783649||High risk group|Women in the age group between 25 and 65 years old without prior history of malignancy referred to colposcopy
89669800|NCT04783649||Population sample|A population sample of women in the age group between 25 and 65 years old from several primary healthcare facilities to primary cervical screening
89669801|NCT04783805||Spontaneous HSIL regression|Patients that have spontaneous regression of HSIL throughout follow-up. Patients in this group will be further classified into 3 subgroups: total resolution (no colposcopic lesion, normal pathology by biopsy and cytology, and negative HPV for the HPV type initially detected); partial resolution (regression of colposcopic lesion, negative cytology and biopsies, but persistence of the initial hrHPV detected); and lesion regression (HSIL no longer detected, but persistent LSIL in either cytology, histology or colposcopy).
89669802|NCT04783805||Conization|Women who have cervical conization for any reason during follow-up. Patients in this group will be further classified according to indication criteria: failure to meet criteria for conservative management or persistence of HSIL after 24 months of follow-up.
89669803|NCT01470651|Experimental|Armodafinil|Active medication
89669804|NCT01470651|Placebo Comparator|Sugar pill|Inactive pill, matched to look like active medication
89669805|NCT04783493|Active Comparator|ACTIVE|In the active group, non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold, this determined by abdominal muscle contractions, found from single pulses, applied gradually every 10 seconds until the contractions appear. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds.
89669806|NCT04783493|Placebo Comparator|PLACEBO|In the placebo group, a coil will be allocated in the T2-T3 thoracic region, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated. To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS).
89669807|NCT01471041|Experimental|Venous Window Needle Guide|Venous Window Needle Guide will be implanted onto deep, un-cannulatable arteriovenous fistula
89669808|NCT04783337|Experimental|HR-pQCT (high resolution computertomograph)|"This arm is the inverventional group for all collected cases. No other arms are available as comparator or control. All patients are treated the same.~Description of the intervention in the section Intervention."
89669809|NCT01512225|Experimental|Domperidone for days 1 to 28|Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28
89669810|NCT01512225|Placebo Comparator|Placebo for days 1 to 14 and domperidone for day 15-28|Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28
89669811|NCT04783025|Experimental|Intervention Group (IG)|The participants in the IG will receive BGCTS, a blended training programme
89669812|NCT04783025|Active Comparator|Control Group (CG)|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staff.
89669813|NCT04782557|Experimental|EUS-guided PVA and HVA|Patient will undergo EUS-guided PVA and HVA
89669814|NCT01472445|Experimental|Non-obese (Body Mass Index ≤ 25)|Non-obese participants receive Vitamin D at 400 or 10,000 IU/day
89669815|NCT01472445|Experimental|Obese (Body Mass Index > 25)|Obese participants receive Vitamin D at 400 or 10,000 IU/day
89669816|NCT04782635|Experimental|AI group|"Care givers will be selected through permuted block.~They will be explained the procedure of intervention and written consent will be asked.~Mobile application will be installed in their mobile.~They will be explained the working of mobile application~Application will make a standard diet plan for the child according to the requirements of the child~Then the child will use the application for one month.~After one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application.~Nutritional status of the patient will be monitored including weight, height, clinical signs, dietary history and will be updated in application.~Then patient will follow the application for one month~After another one month patient will visit the doctor for routine checkup, during the visit patient will be asked for the usefulness of the application and nutritional status will be measured"
89669817|NCT04782635|Other|usual care group|"Caregivers (Mothers/fathers/guardians) will be selected through permuted block.~Patient weight, height, clinical signs will be noted.~Caregivers will be handed over pamphlet regarding dietary instructions on discharge.~After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted including weight, height, clinical signs and dietary history.~Patient will leave hospital with no added dietary instruction.~After one month patient will visit the doctor for routine checkup, during the visit nutritional status of the patient will be checked and noted weight, height, clinical sign, and dietary history."
89669818|NCT04782089|Experimental|Camrelizumab+Fluzoparib|
89669819|NCT04782011|Experimental|ATC/DDD arm|The intervention is the introduction of the ATC/DDD including the training of healthcare workers on its importance and usage in monitoring antibiotic use. The unit of intervention will be a health facility. Antibiotic prescriptions and antibiotic utilization records for adult patients (in-patients and ambulatory) from the selected facilities will be enrolled in the study.
89669820|NCT04782011|No Intervention|Control arm|The health care workers will continue with standard practice. However, the research team will collect data on antibiotic prescriptions and antibiotic utilization for adult patients (in-patients and ambulatory) from the selected facilities. The data will be compared with that of the intervention arm.
89669821|NCT01584609|Experimental|Penumbra System with Separator 3D|
89669822|NCT01584609|Active Comparator|Penumbra System alone|
89669823|NCT04755023|Experimental|Treatment Arm|Administration of 6 cycles of chemotherapy
89669824|NCT02247219|Experimental|Intervention|'Counselling and education individually and in groups'
89669825|NCT02247219|Other|Waiting list control|The waiting list group waits 6 months after assessment and allocation and is reassessed after 6 and 12 months. Both groups are reassessed after 24 months, and the second part of the study is a one group longitudinal cohort study.
89669826|NCT04781621|Experimental|Robotic Gait Training|Patients in the Robotic Gait Training (RGT) group will receive 90 minutes per week of RGT once patients are deemed clinically appropriate as defined by being able to tolerate standing for 15 minutes without orthostatic intolerance. The duration of treatment will span the patient's length of stay in inpatient rehabilitation. The Ekso Bionics Ekso GT™ robotic exoskeleton will be used for RGT.
89669827|NCT04781621|Active Comparator|Usual Care Gait Training|Usual Care (UC) gait training including body weight-supported treadmill training (BWSTT) and conventional overground walking.
89669828|NCT02604342|Experimental|Alectinib|Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
89669829|NCT02604342|Active Comparator|Premetrexed/Docetaxel|Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.
89669830|NCT04781777|No Intervention|Control group|Dexmehtasone and local anesthetics in carpal tunnel syndrome
89669831|NCT04781777|Active Comparator|Insulin group|insulin added to dexamehtasone and local anesthetics
89669832|NCT04781075|Experimental|TAP Block with Exparel|TAP Block with 20 mL (266mg) of liposomal bupivacaine with 25 mL (5 mg/mL) of bupivacaine diluted in 55 mL of normal saline
89669833|NCT04781075|Active Comparator|TAP Block with bupivicaine|TAP Block with 30 mL (5mg/mL) of bupivacaine diluted in 70 mL of normal saline
89669834|NCT01585779||Contour 3D® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Contour 3D® ring will occur in conjunction with another concomitant surgical repair procedure
89669835|NCT01585779||Tri-Ad® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Tri-Ad® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Tri-Ad® ring will occur in conjunction with another concomitant surgical repair procedure
89669836|NCT04825392|Experimental|HX008|
89669837|NCT04780919|Experimental|Treatment Group (A)|Group of patients with Achilles tendinopathy which are treated by focused extracorporeal shockwave therapy once a week for 5 weeks. ESWT parameters: 0,12 mJ/mm2, 10 Hz, 1300 shocks.
89669838|NCT04780919|Sham Comparator|Sham Group (B)|Group of patients with Achilles tendinopathy in which sham extracorporeal shockwave therapy is applied once a week for 5 weeks. Total applications are 5, applicated weekly. Sham ESWT parameters are same as in Group A (0,12 mJ/mm2, 10 Hz, 1300 shocks) but with modified applicator which does not allow wave transmission.
89669839|NCT04816110|Experimental|mineralized plasmatic matrix with collagen membrane|
89669840|NCT04816110|Active Comparator|mineralized plasmatic matrix without collagen membrane|
89669841|NCT05565963|Experimental|Intervention group.|12-week intervention, with a 12-week follow-up. Device:1 computer virtual reality online software and 3 large projectors were used to project videos on the wall in a wrap-around state.
89669842|NCT05565963|No Intervention|Control group.|No intervention with a 12 week follow-up.
89669843|NCT02604264|Active Comparator|ClearGuard HD end cap|Treatment
89669844|NCT02604264|No Intervention|Standard hemodialysis end cap|Control
89669845|NCT04780529|Experimental|Patients with late malignant digestive tract tumor|Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on. because of this is a open, single arm trail, there is no control group.
89669846|NCT04411992|Experimental|Allocated to Vibration intervention (1) A|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
89669847|NCT04411992|No Intervention|Allocated to Control intervention (1) B|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
89669848|NCT04411992|Experimental|Allocated to Vibration intervention (2) B|Patient information form, visual pain form and satisfaction scale were applied before injection application for all of the patients. The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection with vibration will be applied to the ventrogluteal region of the patients .
89669849|NCT04411992|No Intervention|Allocated to Control intervention (1) A|The height, weight and BMI of the patients will be measured by the attending nurse. Intramuscular antibiotic injection without vibration will be applied to the ventrogluteal region of the patients.
89669850|NCT04780373||Development cohort|
89669851|NCT04780373||Validation cohort|
89669852|NCT01512849|Experimental|TA-7284 Low|
89669853|NCT01512849|Experimental|TA-7284 High|
89669854|NCT04816032|Experimental|Pennebaker's expressive writing|Three consecutive days for 20 minutes daily of expressive writing. The topic of the traumatic traveling experience, focalizing the attention on the deeper emotions, thoughts, and feelings.
89669855|NCT04816032|Active Comparator|Writing about different aspects of their knowledge|Three consecutive days for 20 minutes daily of neutral writing. Different topics of own knowledge Description of the city, their room, their place where they live, or easy procedure like, how to make a coffee (or something else), their population, trying to remain free from deep emotions, thoughts, or feelings.
89669856|NCT04816032|No Intervention|Control|No intervention
89669857|NCT03945383|Experimental|Treatment with IPL device|The Emerald IPL device is applied by the Investigator or designee to the right and left side of the body. Treatment areas are 2x4 cm2 for the leg and bikini line areas. The entire axilla and face (upper lip) area will be treated due to the small area involved.
89669858|NCT04780451|Experimental|Omega|
89669859|NCT04780451|Placebo Comparator|Placebo|
88995560|NCT02913625|Experimental|Ultrasound guided retroclavicular block|Patients assigned to this group will receive an ultrasound guided retroclavicular brachial plexus block
88995561|NCT02913625|Active Comparator|Ultrasound guided infraclavicular block|Patients assigned to this group will receive an ultrasound guided infraclavicular brachial plexus block
89669860|NCT01586091|Placebo Comparator|Placebo|Placebo per os at time 0 hours + placebo per os at 12 hours.
88995562|NCT02913547|Experimental|Treatment group|"Each subject will serve as his/her own control, while comparing results before treatment, and after 6 weeks of treatment.~Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual."
88995563|NCT02913703|Experimental|Healthy subjects - Preprandial AG (Acyl Ghrelin)|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG (Acyl Ghrelin) bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
89669861|NCT01586091|Active Comparator|Levocetirizin|Levocetirizin 5mg at time 0 and placebo per os at 12 hours
89669862|NCT01586091|Active Comparator|Fexofenadine|Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours
89669863|NCT02601300|Experimental|GED-0301 160 mg once daily (QD)|Patients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
89669864|NCT04779749||COVID positive <20 weeks|Case groups 1 will include pregnant patients infected by SARS-CoV2 before 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
89669865|NCT04779749||COVID positive >20 weeks|Case groups 2 will include pregnant patients infected by SARS-CoV2 after 20 weeks' gestation during the period starting on February 1st 2020 and ending on November 30th 2020.
89669866|NCT04779749||Control|Patients not infected by SARS-CoV2 during pregnancy during the period starting on February 1st 2020 and ending on November 30th 2020
89669867|NCT04818606|Experimental|Intervention (MORE) Group|Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings. Pre-recorded guided meditations created by study personnel using scripts from the MORE manual will be provided to participants to facilitate their daily practice.
89669868|NCT04818606|No Intervention|Control Group|This group will undergo treatment as usual (TAU) over the course of the eight-week time period of parallel group comparison. This may or may not involve regularly scheduled, standard visits with other medical personnel, including primary care, specialized medical services, or complementary and integrative health practitioners (e.g., acupuncture). Participants will be asked to refrain from altering therapeutic approaches to pain management during this time unless medically necessary and will be asked to report any changes made to their treatment plan on a daily basis.
89669869|NCT04779671|Experimental|VR group|
89669870|NCT04779671|Active Comparator|control group|
89669871|NCT05565573|Experimental|Medroxyprogesterone acetate|Administered MPA at a dosage of 500 mg/d concurrently
89669872|NCT05565573|Experimental|LNG-IUS|Go through LNG-IUS insertion
89669873|NCT04807686|Active Comparator|traditional algorithm|
89669874|NCT04807686|Experimental|notched-type algorithm|
89669875|NCT04389359|Experimental|HCQ group (dialysis)|"Dialysis patients will receive Hydroxychloroquine sulfate 200 mg capsules or tablets (oral administration), as 600mg weekly in divided doses, given as 200mg after each dialysis session.~Non-dialysis patients will receive Hydroxychloroquine sulfate, 400mg twice daily for two days, then 400mg weekly.~Maximum treatment duration will be 26 weeks (6 months)."
89669876|NCT04389359|No Intervention|Control|Patients will continue with their usual medicines and clinical care without additional HCQ.
89669877|NCT04807452|Active Comparator|Strength and balance training|Exercises like ROMS, stretching, static balance and dynamic balance
89669878|NCT04807452|Experimental|Aerobics training|Control Group received aerobic training.
89669879|NCT04779515|Experimental|Low-pressure|Participants undergone laparoscopic cholecystectomy by creation of a low-pressure pneumoperitoneum, set at 8-10 mm Hg
89669880|NCT04779515|Active Comparator|Standard-pressure|Participants undergone laparoscopic cholecystectomy by creation of a standard-pressure pneumoperitoneum, set at 12-14 mm Hg
89669881|NCT01587027|Active Comparator|Sequence A|Aminophylline, Methazolamide, Aminophylline and Methazolamide
89669882|NCT01587027|Active Comparator|Sequence B|Methazolamide, Aminophylline, Aminophylline and Mathazolamide
89669883|NCT04779281|Experimental|Oral Rehydration Salts supplemented with L. Rhamnosus GG|a supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
89669884|NCT04779281|Experimental|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
89669885|NCT01587105|No Intervention|Control|Usual Care Group
89669886|NCT01587105|Experimental|Comprehensive Care Management Service|Care Coordination through the Comprehensive Care Management Service at Seattle Children's Hospital
89669887|NCT01471340|Experimental|Mometasone Furoate/Formoterol MDI BID|MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
89669888|NCT01471340|Active Comparator|Mometasone Furoate MDI BID|MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)
89669889|NCT04818528|Experimental|Constraint Induced Movement Therapy and Routine Physical Therapy|Patients received constrained induced movement therapy and routine physical therapy for up to 6 hrs/day, 5 days/week for 4 weeks.
89669890|NCT04818528|Active Comparator|Routine Physical Therapy|Patients received routine physical therapy for 5 days/week for 4 weeks.
89669891|NCT04754789|Active Comparator|group for loading with statin before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.~Patients will be randomly assigned (1:1) to receive two 80-mg loading doses of atorvastatin, the first loading dose will be administered in the Emergency Room before transfer to Cath Lab, the second dose of 80-mg atorvastatin will be administered 24 hours afterthe first dose."
89669892|NCT04754789|Placebo Comparator|group receive the routine guidelines management before PPCI|"All patients will receive the routine guidelines advised management before and after primary PCI.~Patients will be randomly assigned (1:1) to receive only the routine management."
89669893|NCT04780997|Experimental|Virtual Realty|Microsoft Xbox Kinect® was used for virtual reality exercises
89669894|NCT04817904|Experimental|Statin-Treated|"This arm will be receiving:~Cisplatin along with conventional nephroprotective interventions (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)~Rosuvastatin 10 mg/day"
89669895|NCT04817904|No Intervention|Statin-Free|"This arm will be receiving:~-Cisplatin along with conventional nephroprotective interventions only (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)"
89669896|NCT04754867|Experimental|"discontinued-smoker age-progressed"|"Participants in the discontinued smoker age-progressed virtual reality condition will see two rendering of themselves in optimal health twenty years into the future, a frontal and profile view."
89669897|NCT04754867|Experimental|"discontinued-smoker + continued smoking age-progressed"|"Participants in the discontinued smoker + continued smoking age-progressed virtual reality condition will see two frontal renderings of themselves twenty years in the future, one in optimal health and one incorporating appearance-related medical consequences of moderate-heavy smoking over twenty years (e.g., skin that is dry and discolored, increased wrinkles, etc.)."
89669898|NCT04754867|Experimental|Current self virtual reality images|Participants in the current self virtual reality condition will see their present age self in a virtual reality rendering.
89669899|NCT04807062|Experimental|DTPFs treated with structural bicortical autologous ICBG combined with TBTM|
89669900|NCT04754555||subacute phase|between 7 days and 6 months post-stroke;
89669901|NCT04754555||chronic phase|minimum 6 months post-stroke
89669902|NCT04778891|Experimental|Intervention group|In addition to usual care provided by general practitioner (GP) and other health care providers, a pharmacist-practitioner in collaboration with GPs from the study setting provided CMM services to patients in the intervention group. Based on the pre-defined inclusion criteria, GPs were selecting patients and referring them to the pharmacist. The individual consultation with the patient was held at the private counselling area where pharmacist and patient were able to talk face-to-face apart from the other patients. The initial assessment lasted 60-90 minutes and the follow-up evaluations 30-60 minutes. Alternatively, patients were followed-up by telephone. Communication with GPs took place in a written (electronic consultation system Health net. PRO; e-mail) and, if needed by face-to-face conversation. Each patient in the intervention group needed to agree to participate in the study by signing an Informed consent form.
89669903|NCT04778891|No Intervention|Control group|Patients in the control group received the usual care which includes GP and other health care provider visits. Data for the patients pertaining to the control group were provided by the 'control' GP and collected parallel with the intervention group. 'Control' GP profile corresponded to the profile of GPs included in the intervention group - the number of years of professional experience in the primary health care less than ten.
89669904|NCT04815408|Experimental|NIC|"Neoadjuvant treatment BGB-A317 200mg q3 weeks (total 3 dosing) Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)~Interval debulking surgery and HIPEC~Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
89669905|NCT04815408|Active Comparator|NC|"Neoadjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 q3 weeks (total 3 dosing)~Interval debulking surgery and HIPEC~Adjuvant treatment Chemotherapy regimen: albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5, Bevacizumab 7.5mg/kg q3 weeks (total 3 dosing)"
89669906|NCT01588821|Experimental|Treatment Arm|Cabozantinib
89669907|NCT04778735|Other|Pediatric Patients with Liver Transplantation|
89669908|NCT04778813|Experimental|Artemether-lumefantrin (AL)|"The tablets will be given orally according to patients' age and under supervision of study team as follows:~Day 0: H0 and H8~Day 1: H24 and H36~Day 2: H48 and H60"
89669909|NCT04778813|Experimental|Dihydro-artemisinin-piperaquin (DHA-PPQ)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
89669910|NCT04778813|Experimental|Artesunate-Pyronaridin (As-Pyr)|The tablets will be given orally according to patients' age and under supervision of study team as follows. A single dose will be given on day 0, 1 and 2
89669911|NCT05565183|Experimental|Patients with diagnosed Atrial fibrillation and an indication of catheter ablation|
89669912|NCT04817982|Experimental|Perineural dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Dexamethasone will be added perineurally in this arm on the same day as the 'systemic dexamethasone' group.
89669913|NCT04817982|Active Comparator|Systemic dexamethasone|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as the 'perineural dexamethasone' group. Thereby, this ulnar nerve block will only be affected by the perineurally added dexamethasone that is absorbed and redistributed systemically.
89669914|NCT04817982|Placebo Comparator|Placebo|Bilateral ulnar nerve blocks with bupivacaine. Placebo (saline) will be added perineurally in this arm on the same day as lidocaine group. This will be the actual placebo group.
89669915|NCT04817982|Active Comparator|Perineural lidocaine|Bilateral ulnar nerve blocks with bupivacaine. Lidocaine will be added perineurally in this arm on the same day as the actual placebo group.
89669916|NCT04779047|Active Comparator|group 1|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days plus tocilizumab 800 mg once
89669917|NCT04779047|Active Comparator|group 2|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days and Ivermectin 36 mg at day 1,3 and 6 plus tocilizumab 800 mg once.
89669918|NCT05565027|Active Comparator|Pneumotachograph|The subject stood on the turntable of the instrument and grasped the postural fixator with both hands up. The subjects pinched their nose and breathed through the disposable filter mouthpiece connected to the pneumotachograph, taking care not to leak air at the corners of the mouth. The subjects were instructed to perform tidal breathing, deep inhalation, deep exhalation, etc., and to monitor lung volume by pneumotachograph.
89669919|NCT05565027|Experimental|Dynamic digital radiography|The subject stood on the turntable of the instrument and grasped the postural fixator with both hands up. The subjects pinched their nose and breathed through the disposable filter mouthpiece connected to the pneumotachograph, taking care not to leak air at the corners of the mouth. The subjects were instructed to perform tidal breathing, deep inhalation, deep exhalation, etc., and to monitor lung volume by dynamic digital radiography analysis.
89669920|NCT04817748||Acute ST segment elevation myocardial infarction（STEMI）|the patients' coronary and venous blood were drawn for metabolomics study
89669921|NCT04817748||Acute non ST segment elevation myocardial infarction（NSTEMI）|the patients' coronary and venous blood were drawn for metabolomics study
89669922|NCT04817748||Acute myocardial infarction with no obstructive coronary atherosclerosis（MINOCA）|the patients' coronary and venous blood were drawn for metabolomics study
89669923|NCT04817748||Patients with normal coronary artery（NCA)|the patients' coronary and venous blood were drawn for metabolomics study
89669924|NCT04779203||Osseodensification|Osseodensification is a novel, biomechanical osteotomy preparation technique that preserves bone through a non-excavating drilling process utilizing specially designed burs with a tapered geometry and specially designed flutes progressively expand the osteotomy whilst compacting bone into its walls and apex.
89669925|NCT04779203||Standard Drilling|Utilizing conventional drilling technique with standard bone drilling techniques.
89669926|NCT04817592||Age1(20-25)|The groups are divided as per age
89669927|NCT04817592||Age2(25-30)|
89669928|NCT04817592||Age3(30-35)|
89669929|NCT04817592||Age4(35-40)|
89669930|NCT04817592||Age5(40-45)|
89669931|NCT04778033||Vaccinated Men|Fertile men who were vaccinated with the BNT162b2 COVID-19 Vaccine
89669932|NCT05564871|Experimental|Occupation-based teleintervention|20 children and their parents will be participate in Occupation-based teleintervention.
89669933|NCT05564871|Experimental|Occupation-based in person intervention|20 children and their parents will be participate in Occupation-based in person intervention.
89669934|NCT04817436|Active Comparator|Without adapted physical activity program (APA)|
89669935|NCT04817436|Experimental|With adapted physical activity program (APA)|
89669936|NCT04778345|Experimental|18F-FDG PET/CT and 68Ga-FAPI PET/CT scan after abdominal enhanced CT|After the patient received abdominal enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT were further performed. The interval between 18F-FDG PET/CT and 68Ga-FAPI PET/CT was 2 days to 1 week.
89669937|NCT04817280||Ice Swimmers Group.|No intervention. Data obtained from Polish ice swimmers reported by them retrospectively in the questionnaire.
89669938|NCT04806828||HF|Preoperative classification of inguinal hernia
89669939|NCT04777487|Experimental|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and GCF obtained.
89669940|NCT04777487|Experimental|Gingivitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
89669941|NCT04777487|Experimental|Periodontitis|Full-mouth clinical periodontal measurements recorded and GCF obtained.
89214706|NCT06060470|Experimental|Virtual reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 10 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The first six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song. The first 6 weeks are conducted in the laboratory. The next four weeks are conducted in the participants home via telerehabilitation. The four week sessions consisted of 3 sessions/week."
89669942|NCT01515345|Active Comparator|standard therapy|standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)
89669943|NCT01515345|Experimental|individualized therapy|dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer
89669944|NCT01492400|Experimental|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
89669945|NCT01492400|Active Comparator|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
89669946|NCT04815018||Patients with New Cases of SARS-CoV-2|Newly recruited residents who have been identified as positive through Ohio's Post-Acute Regional Rapid Testing (PARRT) Program will undergo at at least 4 weeks, but no more than 8 weeks, of nasal swab and exhaled breathe particles specimen collection for Covid testing. Previously enrolled residents will submit weekly collections of nasal swab specimens and exhaled breathe particles once they exhibit respiratory-related symptoms, or once a test is ordered by the provider for suspicion of exposure. Collection will continue until these subjects fulfill their 8 weeks of testing.
89669947|NCT04815018||Patients without SARS-CoV-2|This cohort will consist of previously enrolled residents who submitted nasal swabs and exhaled breathe particles for Covid testing once a week for 8 weeks. The patients will have been identified as negative for a SARS-CoV-2 infection each week.
89669948|NCT00168337|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
89669949|NCT00168337|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
89669950|NCT00168337|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
89669951|NCT04748198|Experimental|Study group|Intracorneal ring segments are implanted for treatment of keratoconus, and posterior corneal surface is assessed preoperatively and postoperatively.
89669952|NCT04776863||Smokeless tobacco|Individuals using smokeless tobacco
89669953|NCT04776863||No smokeless tobacco|Individuals who do not use smokeless tobacco
89669954|NCT01515657|Experimental|PL2200 Aspirin Capsules|Investigational drug arm; crossover design
89669955|NCT01515657|Active Comparator|Immediate-Release Aspirin Tablets|Active comparator; crossover design
89669956|NCT01515657|Active Comparator|Enteric-coated aspirin caplets|Active comparator; crossover design
89669957|NCT04776785|Experimental|Group 1|"In Group 1, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).~At the 6th and 12th months after the clinical applications, Profluorid® Varnish application will be repeated for test 1 and control lesions."
89669958|NCT04776785|Experimental|Group 2|"In Group 2, one lesion will be received self-assembling peptide P11-4 solution (Curodont™ Repair, Credentis AG, Windisch, Switzerland) followed by 5% NaF varnish (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (test 1). The other lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2).~At the 6th and 12th months after the clinical applications; Profluorid® Varnish application will be repeated for test 1 lesions, and MI Varnish™ application will be repeated for test 2 lesions."
89669959|NCT04776785|Active Comparator|Group 3|"In Group 3, one lesion will be received CPP-ACP varnish containing 5% NaF (MI Varnish™, GC America Inc., Alsip, IL, USA) (test 2). The other lesion will be received 5% NaF varnish alone (Profluorid® Varnish, VOCO GmbH, Cuxhaven, Germany) (control).~At the 6th and 12th months after the clinical applications; MI Varnish™ application will be repeated for test 2 lesions, and Profluorid® Varnish application will be repeated for control lesions."
89669960|NCT01515891|Experimental|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
89669961|NCT00073957|Experimental|Y-90 Ibritumomab Tiuxetan|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab and central nervous system prophylaxis with Cytarabine or liposomal cytarabine
89669962|NCT04354428|Placebo Comparator|Ascorbic acid and Folic acid|Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5)
89669963|NCT04354428|Experimental|Hydroxychloroquine and Folic Acid|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5])
89669964|NCT04354428|Experimental|Hydroxychloroquine and Azithromycin|HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5).
89669965|NCT04354428|Experimental|Lopinavir-ritonavir|LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10)
89669966|NCT04354428|Placebo Comparator|Ascorbic acid|Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days
89669967|NCT04754009|Active Comparator|Treatment as Usual (TAU)|Participants assigned to treatment as usual group are required to see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
89669968|NCT04754009|Experimental|Trauma-Sensitive Yoga + TAU|Participants assigned to the Trauma-Sensitive Yoga group will attend a 1-hour long session of yoga once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
89669969|NCT04754009|Experimental|Chen Style Tai Chi + TAU|Participants assigned to the Chen Style Tai Chi group will attend a 1-hour long session of tai chi once a week for 12 weeks. Participants will be required to concurrently see a mental health professional for the 12 week treatment period. How often they seek counseling is up to the participant.
89669970|NCT01517529||10 Hepatitis C infected subjects|10 chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin therapy (NR) and are therefore eligible for combined treatment with Protease Inhibitor therapy.
89669971|NCT04753775|Experimental|22 patients were assigned to Group-A|22 patients were assigned to Group-A
89669972|NCT04753775|Placebo Comparator|22 patients were assigned to Group-B|22 patients were assigned to Group-B
89669973|NCT04775849|Experimental|Intraoperative Berger Space Imaging|Intraoperative OCT imaging of the space between the posterior capsule and the anterior hyaloid
89669974|NCT01589601|No Intervention|Usual heart failure care|Patients will be managed by a cardiologist-directed team with expertise in the diagnosis and treatment of heart failure. Until discharge, inpatient care will focus on symptom relief and initiation of evidence-based therapies. Additional goals of care will include treatment of co-morbidities and patient education designed to assist with self-management techniques. However, after discharge, which is where the study actually takes place, patients will only receive outpatient follow-up with a heart failure cardiologist or nurse practitioner who will focus on medication titration to evidence-based dosing, titration of diuretic therapy, assessment of compliance with medical and dietary regimens, and serial monitoring of end-organ function.
89669975|NCT01589601|Active Comparator|Usual care + palliative care|Patients will receive an interdisciplinary, multicomponent palliative care intervention combined with state of the art heart failure management designed to assess and manage the multiple domains of quality of life at the end of life for patients with advanced heart failure, including physical symptoms, psychosocial concerns, and spiritual concerns, and to facilitate advance care planning.
89669976|NCT02090075|Active Comparator|apixaban|apixaban 5 mg or 2.5 mg po bid
89669977|NCT02090075|Placebo Comparator|warfarin|warfarin with target INR of 2-3
89669978|NCT04775615|Experimental|Treatment group A|
89669979|NCT04775615|Experimental|Treatment group B|
89669980|NCT04775615|Experimental|Treatment group C|
89669981|NCT04775693|Experimental|RE|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as both an inpatient (2 days a week RE) and an outpatient (3 days a week RE).
89669982|NCT04775693|Active Comparator|SOC|Participants receive standard of care gait training only as both an inpatient (at least 2 days a week) and an outpatient (at least 3 days a week).
89669983|NCT04775693|Experimental|RE/SOC|Participants use the robotic exoskeleton (RE) in addition to their standard of care gait training as an inpatient (2 days a week RE) and standard of care only as an outpatient (at least 3 days a week).
89669984|NCT01591005|Experimental|CEA with sonolysis|endarterectomy with sonolysis (continual transcranial Doppler monitoring)
89669985|NCT01591005|Placebo Comparator|CEA without sonolysis|endarterectomy without sonolysis
89669986|NCT01591005|Experimental|carotid stenting with sonolysis|carotid stenting with sonolysis (continual transcranial Doppler monitoring)
89669987|NCT01591005|Placebo Comparator|carotid stenting without sonolysis|carotid stenting without sonolysis
89669988|NCT04775303|Experimental|experimental group|Cyclosporine 0.1% (Ikervis®) eye drop - one drop once daily
89669989|NCT04817514|Experimental|specific shoulder rehabilitation protocol group (SRG);|
89669990|NCT04817514|Experimental|specific protocol of shoulder rehabilitation plus aerobic exercise group (ARG)|
89669991|NCT04817358||Demirjian method|According to the Demirjian method, the development of the seven left mandibular permanent teeth (except the third molar) were rated on the eight-stage scale from A to H. Each stage of mineralization was given a score, total dental maturity score was evaluated according to standard tables for boys and girls
89669992|NCT04817358||Willems method|Willems' method was determined using the Demirjian calcification stages but scores were evaluated according to Willems' specific tables
89669993|NCT04817358||Nolla method|In the Nolla method, the development of seven left mandibular and maxillar teeth were defined on 10 stages. If the tooth was between stages an appropriate fraction (0.2, 0.5 or 0.7) was added. The total score was determined according to the tables prepared for girls and boys as recommended by Nolla
89669994|NCT04816968|Experimental|Arm A - Cefepime|Continuous infusion of Cefepime at home.
89669995|NCT04816968|Experimental|Arm B - Piperacillin/tazobactam|Continuous infusion of Piperacillin/tazobactam at home.
89669996|NCT04816968|Experimental|Arm C - Meropenem|Continuous infusion of meropenem at home.
89669997|NCT04816968|Experimental|Arm D - Vancomycin|Continuous infusion of vancomycin at home.
89669998|NCT02210247|Active Comparator|Cohort 1|Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
89669999|NCT02210247|Active Comparator|Cohort 2|Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
89670000|NCT02210247|Active Comparator|Cohort 3|Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
89670001|NCT02210247|Active Comparator|Cohort 4|Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
89670002|NCT02210247|Active Comparator|Cohort 5|Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).
89670003|NCT02596854|Experimental|Neurological MRI|Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.
89670004|NCT04775459||Surfactant administration without using score LUS|"It is a retrospective cohort : preterm newborns from august 2019 to december 2019 needed a surfactant administration.~The surfactant was administrated only if the fraction of inspired oxygen (FiO2) >30% among the Guidelines of 2019"
89670005|NCT04775459||Surfactant administration using score LUS|"It is a prospective cohort : preterm newborns from january 2021 to juin 2020 needed a surfactant administration.~The surfactant is administrated if FiO2 >30% OR if score LUS >8/18 among the literature"
89670006|NCT05563077|Experimental|Moderate-intensity interval training (MIIT)|24 participants with resistant hypertension will perform moderate-intensity interval training.
89214707|NCT06060470|Active Comparator|Control|Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
89670007|NCT05563077|Experimental|Moderate-intensity continuous training (MICT)|24 participants with resistant hypertension will perform moderate-intensity continuous training.
89670008|NCT05563077|No Intervention|Usual care|24 participants with resistant hypertension will maintain usual care for 4 months.
89670009|NCT04774835|Active Comparator|Standard aPS|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor.
89670010|NCT04774835|Experimental|aPS + HIVST|Subjects receive standard assisted partner services from their local HIV testing services (HTS) counselor as well as the option to do HIV self-testing (HIVST) instead of testing at the local HTS location.
89670011|NCT04806204|Experimental|music therapy before the angiography|Patients in the Intervention 1 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes before the CAG procedure. Since individuals are in the CAG unit collectively before the procedure, headphones will be used in order not to disturb other individuals. After the interviews, musical types will be arranged as instrumental, non-verbal, at 70 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice. Instrumental works will be uploaded to the portable MP3 player provided by the researchers.
89670012|NCT04806204|Experimental|music therapy during the angiography|Patients in the Intervention 2 group will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the CAG hall during the CAG procedure. After the interviews, musical types will be arranged as instrumental, non-verbal, 75 decibels, approximately 60 metronome per minute, in terms of rhythm and duration, and will be played according to the individual's choice.
89670013|NCT04806204|No Intervention|control group|After the polyclinic controls of the patients, on the day of the CAG procedure, data collection forms will be applied in the CAG unit 30 minutes before the procedure. Routine care will be applied to patients in this group and music therapy will not be applied. The physiological parameters of the patient will be measured by the clinical nurse 15 minutes after the procedure, and data collection forms will be applied again 20 minutes later.
89670014|NCT04774757|Experimental|Systemic therapy sequenced PALND|All received systemtic therapy (at most two lines).
89670015|NCT01591161|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
89670016|NCT01591161|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
89670017|NCT04806438|Active Comparator|Group A (nebulized lignocaine group)|Patients will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
89670018|NCT04806438|Active Comparator|Group B (nerve block group)|Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice.
89670019|NCT04774679|Experimental|Biopsy Arm|All patients who underwent EUS Guided biopsy
89670020|NCT04806126||Virtual Mentoring Program Participants|Physicians credentialed at Satellite Healthcare will be eligible to participate along with nephrology fellows from training programs affiliated with credentialed physicians.
89670021|NCT03975738||A GP Surgery|A selection of healthcare workers from a GP Surgery to be recruited
89670022|NCT03975738||A Patient and Public Involvement and Engagement Group|A selection of healthcare workers from a Patient and Public Involvement and Engagement Group to be recruited
89670023|NCT03975738||Young Person's Steering Group|A selection of patients from a Young Person's Steering Group to be recruited
89670024|NCT03975738||An Acute Trust|A selection of healthcare workers from an Acute Trust to be recruited
89670025|NCT03975738||Hayward Hospital Social Care Team|A selection of healthcare workers from the Hayward Hospital Social Care Team to be recruited
89670026|NCT03975738||A Hospice|A selection of healthcare workers from a Hospice to be recruited
89670027|NCT03975738||West Midlands Cares|A selection of healthcare workers from a the West Midlands Cares Group to be recruited
89670028|NCT03975738||CRN Clinical Research Speciality Leads (CRSL)|A selection of healthcare workers from a group of CRN (Clinical Research Network) Clinical Research Speciality Leads (CRSL) to be recruited
89670029|NCT03975738||CRN Sub Speciality Leads (SSL)|A selection of healthcare workers from a CRN Sub Speciality Leads (SSL) to be recruited
89670030|NCT03975738||A District General Hospital|A selection of healthcare workers from a A District General Hospital to be recruited
89670031|NCT02211495|Active Comparator|No device|Treated with best medical therapy
89670032|NCT02211495|Experimental|Device|As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
89670033|NCT00074035|Experimental|Pentostatin|treatment of pts with refractory graft vs host disease
89670034|NCT02319317|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
89670035|NCT02319317|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
89670036|NCT04798326|Experimental|MW032|MW032 injection (120mg) by subcutaneous injection once on the first day of treatment.
89670037|NCT04798326|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day of treatment.
89670038|NCT05617248|Experimental|Experimental: Self-efficacy training (App)|This group will receive a digital one week self-efficacy training with three training sessions per day and EMA (10 per day).
89214708|NCT06058455|Experimental|IDEA3 sexual assault resistance intervention|IDEA3 curriculum will be delivered by pairs of trained facilitators over Zoom to reach up to 8 pairs of female-identified university students in four, 3-hour units. The four units will be spread over two to four weeks' time.
89214709|NCT06058455|Active Comparator|Consent workshop|Randomized participants who do not receive the intervention will receive one 60-minute session consisting of an internet delivered (Zoom) consent workshop.
89214710|NCT06056557|Experimental|Interventional|All patients will receive the intervention. That is, all patients will undergo ablation with the experimental catheter (device).
89214711|NCT06054880|Placebo Comparator|Saline|116 subjects treated with 5 ml of saline then crossover to treatment arm
89214712|NCT06054880|Experimental|High Dose|58 subjects randomly treated with 5 mL of drug
89214713|NCT06054880|Experimental|Low Dose|58 subjects randomly treated with 2.5 mL of drug
89214714|NCT06053021|Experimental|Intervention|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
89670039|NCT05617248|No Intervention|Control|This group will receive EMA questionnaires for one week (10 per day).
89670040|NCT04773977|Experimental|IBI362 liquid formulation|Participants received single subcutaneous injection of IBI362 liquid formulation
89670041|NCT04773977|Experimental|IBI362 lyophilized powder|Participants received single subcutaneous injection of IBI362 lyophilized powder
89670042|NCT01591317|Experimental|Prasugrel - 60 mg/10 mg|Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days
89670043|NCT01591317|Experimental|Prasugrel - 30 mg/7.5 mg|Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days
89670044|NCT01591317|Experimental|Prasugrel - 30 mg/5 mg|Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days
89670045|NCT04773743|Experimental|chronic nonspecific low back pain|Remotely delivered yoga intervention
89670046|NCT00074815|Experimental|MedMgmt+CBT|Participants will receive the following interventions: 1)SRI medication management with a psychiatrist plus, 2) cognitive behavioral therapy with a psychologist.
89670047|NCT00074815|Experimental|MedMgmt+I-CBT|Participants will receive the following interventions 1)SRI medication management plus, 2) instructional cognitive behavioral therapy. Both of these will be implemented by the same psychiatrist.
89670048|NCT00074815|Active Comparator|MedMgmt Only|Participants will receive the intervention SRI medication management with a psychiatrist
89670049|NCT01592799|Other|Influenza Group|Children <15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.
89670050|NCT04773431|Experimental|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
89670051|NCT04774367|Other|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps|
89670052|NCT04774367|Other|Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps|
89670053|NCT04772729|Active Comparator|Insulin Aspart|Patients will use the continuous subcutaneous insulin infusion of insulin aspart (Novo Rapid, Novo Nordisk) and RT-CGM for 4 weeks.
89670054|NCT04772729|Experimental|Insulin Fiasp|Patients will use the continuous subcutaneous insulin infusion of insulin faster aspart (Fiasp, Novo Nordisk) and RT-CGM for 4 weeks.
89670055|NCT01519713|Experimental|Adults Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
89670056|NCT01519713|Experimental|Adolescents Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
89670057|NCT01519713|Experimental|Children Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
89670058|NCT04772105|Experimental|2.5mg of BAT5906|Specification: 10mg/0.2ml/piece; route of administration: intravitreal injection; dose: 2.5mg/eye/time, 50μl; medication duration: once every 4 weeks, 6 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
89670059|NCT04772105|Experimental|4mg of BAT5906|Specification: 16mg/0.2ml/piece; route of administration: intravitreal injection; dose: 4mg/eye/time, 50μl; medication duration: once every 4 weeks, 3 consecutive times, then every 4 weeks Followed up once (the investigator judged to administer the drug as needed) and observed until the 48th week.
89670060|NCT05562375|Experimental|Patients|73 patients are to be recruited from the ones that go to the oral medicine service at the university clinic of Rey Juan Carlos in Madrid that present a compatible clinic diagnostic compatible with oral potentially malignant disorders. Each patient will receive first an intraoral exploration, taking note of location and size of the injury. After that, an exploration with the GOCCLES® device will be made, also taking note of the location and size data. Thereafter, the blue toluidine stain will be used, taking note of the size and location of the marked areas. Pictures will be taken through all the steps. Finally, a biopsy will be made of the area or areas the clinic considers and/or marked by the device or the toluidine blue.
89670061|NCT04772495||Study group|with Multiple sclerosis
89214715|NCT06049940|Experimental|Experimental Group|630 Participants (including 30 subjects in phaseⅠ, 600 subjects in phase Ⅲ ) will receive one dose of experimental vaccine or control vaccine.
89214716|NCT06049940|Active Comparator|Control Group|630 Participants (including 30 subjects in phaseⅠ, 600 subjects in phase Ⅲ ) will receive one dose of experimental vaccine or control vaccine.
89214717|NCT06048510|Experimental|Pregnant women|"Pregnant women, with gestational age at inclusion <28 weeks of amenorrhea, with or without risk factors for GDM will be included in the first consultation at the Maternity Hospital (Bordeaux University Hospital).~Determination of glycation markers (HbA1c, glycated albumin, and skin autofluorescence)."
89214718|NCT06045819||Patients with composite complete remission|Patients in composite complete remission following the first cycle of venetoclax (400 mg/day, orally, after a ramp-up phase of the first 3 days) + azacytidine (75mg/m²,intravenous, at the start of each cycle from day 1 to day 7)
89670062|NCT04772495||Control group|not Multiple sclerosis
89670063|NCT02090777|Other|Health Coach|Health Coach is conducted to see if it improves ophthalmic care for glaucoma patients.
89670064|NCT04772339||Healthy Adults|Healthy adults aged between 18-30
89670065|NCT04771949||All patients coming to the University Clinic of Dentistry|All patients coming to the dental University Clinic will be screened for the inclusion in the study.
89670066|NCT00075829|Active Comparator|Auto transplants plus Therapy|One autologous transplant along with a second autologous transplant will be preformed followed by one year of Dexamethasone and Thalidomide maintenance therapy.
89670067|NCT00075829|Active Comparator|Auto transplants|One autologous transplant along with a second autologous transplant will be preformed followed by one year of observation.
89670068|NCT00075829|Active Comparator|Auto and Allo transplants|One autologous transplant and one non-myeloablative allogeneic transplant will be preformed and followed by one year of observation.
89670069|NCT02218203|Placebo Comparator|Placebo- 0mg/kg Lido|Placebo in combination with 0mg/kg LBM lidocaine
89670070|NCT02218203|Experimental|Placebo - 1mg/kg Lido|Placebo in combination with 1mg/kg LBM lidocaine
89670071|NCT02218203|Experimental|Placebo - 2mg/kg Lido|Placebo in combination with 2mg/kg LBM lidocaine
89670072|NCT02218203|Experimental|Placebo - 4mg/kg Lido|Placebo in combination with 4mg/kg LBM lidocaine
89670073|NCT02218203|Experimental|Low Dose Dex - 0mg/kg Lido|Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine
89670074|NCT02218203|Experimental|Low Dose Dex - 1mg/kg Lido|Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine
89670075|NCT02218203|Experimental|Low Dose Dex - 2mg/kg Lido|Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine
89670076|NCT02218203|Experimental|Low Dose Dex - 4mg/kg Lido|Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine
89670077|NCT02218203|Experimental|Medium Dose Dex - 0mg/kg Lido|Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine
89670078|NCT02218203|Experimental|Medium Dose Dex - 1mg/kg Lido|Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine
89670079|NCT02218203|Experimental|Medium Dose Dex - 2mg/kg Lido|Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine
89670080|NCT02218203|Experimental|Medium Dose Dex - 4mg/kg Lido|Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine
89670081|NCT02218203|Experimental|High Dose Dex - 0mg/kg Lido|High dose dextromethorphan in combination with 0mg/kg LBM lidocaine
89670082|NCT02218203|Experimental|High Dose Dex - 1mg/kg Lido|High dose dextromethorphan in combination with 1mg/kg LBM lidocaine
89670083|NCT02218203|Experimental|High Dose Dex - 2mg/kg Lido|High dose dextromethorphan in combination with 2mg/kg LBM lidocaine
89670084|NCT02218203|Experimental|High Dose Dex - 4mg/kg Lido|High dose dextromethorphan in combination with 4mg/kg LBM lidocaine
89670085|NCT04771559|Other|Cancer patients|Covid-19 antibody levels of patients will be measured
89670086|NCT04771559|Other|Healthy control|Covid-19 antibody levels of healthy controls will be measured
89670087|NCT02592876|Experimental|19A+RICE|Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide
89670088|NCT02592876|Active Comparator|RICE|Rituximab, ifosfamide, carboplatin, and etoposide
89670089|NCT03007641|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire.~Phase 2 - Providers participate in an hour long didactic session, and begin enrolling eligible metastatic breast cancer (MBC) patients. Enrolled MBC patients complete a comprehensive geriatric assessment (CGA). Providers complete a treatment plan questionnaire and a CGA utility questionnaire.~Phase 3 - Providers are administered a final questionnaire evaluating their overall view of this educational intervention."
89670090|NCT02763137|Active Comparator|Standard LD/CD|Standard LD/CD administered at patient's usual dose and frequency
89670091|NCT02763137|Experimental|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of LD/CD at a dose equivalent to the patient's regular dose of standard LD/CD
89670092|NCT01896739|Experimental|Experimental group with 0-2-4-6 schedule|HB at 0, Eutravac at 2-4-6
89670093|NCT01896739|Active Comparator|Active comparator group with 0-2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
89670094|NCT01896739|Experimental|Experimental group with 2-4-6 schedule|Eutravac at 2-4-6
89670095|NCT01896739|Active Comparator|Active comparator group with 2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
89670096|NCT02704169|Experimental|Spatially registered endoscopy for H&N cancer|
89670097|NCT04797936|Active Comparator|Treatment group BNO 1030|BNO 1030
89670098|NCT04797936|Other|Control group|Standard care
89670099|NCT04771247|Experimental|CLEAR|Patients with GERD post LSG will undergo CLEAR (cardia band ligation).
89670100|NCT00176839|Experimental|Treatment Arm|Patients treated with therapy plan consisting of Busulfan every 6 hours on days -7 through -4, Cyclophosphamide 60 mg/kg/day IV x 2 days, Melphalan 140 mg/m on day -1, antithymocyte globulin (ATG), G-CSF (granulocyte colony-stimulating factor) and stem cell transplantation on day 0.
89670101|NCT04797624||Baseline group|The baseline group included the patients diagnosed with gastric cancer between January 1, 2019, and December 31, 2019, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
89670102|NCT04797624||Pandemic group|The pandemic group included the patients diagnosed with gastric cancer during the period between March 1, 2020, and December 31, 2020, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. Gastric cancer surgery for adequate patients.
89670103|NCT04771325|Other|Arm 1|Women are normally escorted to the health facilities by one or more family members and or friends. Women usually labor in an open first stage room where more than one woman is admitted sometimes with curtains to separate the beds with one person allowed besides her to provide support. The support persons do not have designated roles to play during this process. Routine analgesia is not given neither is continuous fetal monitoring. Midwives,
89670104|NCT04771325|Experimental|Arm 2|One session of training on admission in labor. The training will focus on emotional and physical support; emotional support including being Present, demonstrating a caring and positive attitude, saying calming verbal expressions, using humor, praise, encouraging and acknowledging efforts during the process of pushing the baby. Physical support including supporting her to change position favoring upright positions, walking with her, giving her drinks and food, massage, reminding her to go and pass urine, helping her find a comfortable position for pushing, wipe her face with cool cloth and help her breast feed
89670105|NCT00176917|Experimental|Treatment Arm|All patients treated with chemotherapy and transplantation.
89670106|NCT02664155|Experimental|DOA : Direct Oral Anticoagulants|"The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:~Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months~Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months."
89670107|NCT02664155|Active Comparator|SOC : Standard Of Care|The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.
89670108|NCT04770701|Experimental|Ahah drug|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.~Characterized by rapid loss of resistance: AIDS~Dermatitis, mouth ulcers, skin rash, itching, weight loss~Hepatitis C virus (HCV) (+), Hepatitis B virus (HBV) (+), Tuberculosis (+)~Ahah composition contains the following ingredients (concentrated extracts of plants):~Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg"
89670109|NCT04770701|Experimental|Ahah Placebo|"Participants have a decline in CD4 + T-lymphocytes is the hallmark of the human immunodeficiency virus (HIV)-1 infection.~Characterized by rapid loss of resistance: AIDS~Dermatitis, mouth ulcers, skin rash, itching, weight loss~Hepatitis C virus (HCV)(+), Hepatitis B virus (HBV)(+), Tuberculosis (+)~Ahah composition placebo (Ahah not containing concentrated extracts of plants Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)"
89670110|NCT04770077||Group S|Spray before intubation
89670111|NCT04770077||Group C|Intubation directly
89670112|NCT04770389|Placebo Comparator|Placebo|placebo obicetrapib + placebo ezetimibe; once daily
89670113|NCT04770389|Experimental|Combination therapy|5 mg obicetrapib + 10 mg ezetimibe; once daily
89670114|NCT04770389|Experimental|Obicetrapib monotherapy|5 mg obicetrapib + placebo ezetimibe; once daily
89670115|NCT04770389|Experimental|Ezetimibe monotherapy|placebo obicetrapib + 10 mg ezetimibe; once daily
89670116|NCT04753619|Experimental|Niclosamide group: NCS group|NCL + standard therapy
89670117|NCT04753619|No Intervention|Control group|Control group
89670118|NCT04753463||Residents of Ophthalmology working on COVID-19 departments|Residents of ophthalmology working on COVID-19 departments and dealing with SARS-CoV-2 positive patients
89670119|NCT04753463||Residents of Ophthalmology working on general ophthalmic departments|Residents of Ophthalmology working on general ophthalmic departments and not dealing with SARS-CoV-2 positive patients
89670120|NCT01492088|Experimental|Brentuximab vedotin: Phase 1|Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
89670121|NCT01492088|Experimental|Brentuximab vedotin: Phase 2|Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
89670122|NCT04753151|Experimental|Tranexamic acid|Patients scheduled for liver transplantation and allocated for treatment with tranexamic acid (Group 1).
89670123|NCT04753151|Placebo Comparator|Placebo|Patients scheduled for liver transplantation and allocated for treatment with placebo (Group 2).
89670124|NCT04769609||Concentrated growth factor (CGF) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CGF
89670125|NCT04769609||Collagen membrane (CM) group|Reconstructive surgical therapy of peri-implantitis using a bone substitute combined with CM
89670126|NCT05606549|Experimental|marital self disclosure|
89670127|NCT05606549|No Intervention|Routine care|
89670128|NCT05606471|Active Comparator|VLCD only|Participants in this group will be placed on a very-low calorie diet with a daily energy intake limit of 800 kilocalories. 600 kilocalories will be made up of total meal replacement products supplied by Lighterlife UK. The remaining 200 kilocalories will be flexible for participants to add additional vegetables to supplement the total meal replacement products, allowing some variety to the diet.
89670129|NCT05606471|Active Comparator|Semaglutide only|Participants will be asked to self-administer the GLP-1 agonist Semaglutide weekly, as per clinical practice. They will be asked to start at 0.25mg and increase every two weeks (if tolerated) to the maintenance dose of 1mg, which they will continue until the end of the study.
89670130|NCT05606471|Experimental|Combined VLCD plus Semaglutide|Participants in this group will both partake in the VLCD, and take the weekly dose of Semaglutide (as described above).
89670131|NCT01594515|Experimental|BI 1015550 low dose A|Powder for oral solution
89670132|NCT01594515|Experimental|BI 1015550 low dose B|Powder for oral solution
89670133|NCT01594515|Experimental|BI 1015550 low dose C|Powder for oral solution
89670134|NCT01594515|Experimental|BI 1015550 low dose D|Powder for oral solution
89670135|NCT01594515|Experimental|BI 1015550 medium dose A|Powder for oral solution
89670136|NCT01594515|Experimental|BI 1015550 medium dose B|Powder for oral solution
89670137|NCT01594515|Experimental|BI 1015550 medium dose C|Powder for oral solution
89670138|NCT01594515|Experimental|BI 1015550 high dose A|Powder for oral solution
89670139|NCT01594515|Experimental|BI 1015550 high dose B|Powder for oral solution
89670140|NCT01594515|Placebo Comparator|Placebo|Solution for oral administration
88995564|NCT02913703|Experimental|Healthy subjects - Preprandial saline|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
88995565|NCT02913703|Experimental|Healthy subjects - Prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 5 hour fast, they will receive a prandial AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
88995566|NCT02913703|Experimental|Healthy subjects - Preprandial & prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive another AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
88995567|NCT02913703|Experimental|Diabetic subjects - Preprandial AG|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
88995568|NCT02913703|Experimental|Diabetic subjects - Preprandial Saline|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
88995569|NCT00171171|Experimental|Deferasirox|
88995570|NCT02913430|Active Comparator|Arm A|fulvestrant administered 500mg IM Q28 days plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
88995571|NCT02913430|Active Comparator|Arm B|Tamoxifen is administered orally, at a dose of20mg PO Qdaily plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
88995572|NCT02913469|Experimental|morphine+metoclopramide|administrated intravenous morphine 5mg and metoclopramide 10mg
89670141|NCT05606393|Experimental|traditional speech therapy and additional virtual reality training group|Each participant received 1-hour traditional speech therapy(ST) and additional 30-minute VR training immediately after each session of traditional ST. All participants received 3 sessions of treatment every week for 3 weeks.
89670142|NCT05606393|Active Comparator|traditional speech therapy group|Each participant received 1-hour traditional speech therapy(ST) only for each session. All participants received 3 sessions of treatment every week for 3 weeks.
88995573|NCT02913469|Active Comparator|morphine|avenous morphine 5mg and 0.9%normal saline 2ml
88995574|NCT02913469|Sham Comparator|metoclopramide|intravenous metoclopramide 10mg and 0.9%normal saline 2ml
88995575|NCT02913469|Placebo Comparator|placebo|intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml
89670143|NCT05606081|Experimental|Use of risk prediction scores|The prediction model is being used to identify patients who are at highest risk for colorectal cancer based on their risk scores.
89670144|NCT05606003|Experimental|Multi-level Multi-Component Intervention (MLI)|Individuals receive COVID-19 CHW-delivered education and navigation, 2-1-1 helpline referrals, and social marketing messaging.
89670145|NCT05606003|Experimental|Community Just-in-Time-Adaptive Intervention (JITAI)|Individuals receive MLI intervention components that are informed by real-time data and community stakeholder feedback.
89670146|NCT05606003|No Intervention|Comparison Condition|Individuals receive standard exposure to ongoing city and county COVID-19 communication and testing.
89670147|NCT02516501|Active Comparator|Control|Control group that will not receive advice to follow a ketogenic diet or reduce carbohydrates.
89670148|NCT02516501|Experimental|Intervention group 1|Patients who will receive each radiotherapy (RT) fraction after an overnight fast and subsequently ingest a ketogenic breakfast consisting of (i) up to 250 ml of a medium chain triglyceride drink (betaquik, vitaflo) plus (ii) 10g amino acids (MyAmino, dr. reinwald gmbh + co kg).
89670149|NCT02516501|Experimental|Intervention group 2|Patients who will follow a ketogenic diet throughout the whole period of RT, Patients don't have to fast prior to each RT fraction, but will receive MyAmino analogous to Intervention group 1.
89670150|NCT05605925|Active Comparator|Control arm|4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
89670151|NCT05605925|Experimental|Intervention arm|IVN 600 mcg/kg/day for 3 days + 4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
89670152|NCT01520727|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (Opicapone, OPC) - 10 mg
89670153|NCT01520727|Experimental|BIA 9-1067 25 mg|BIA 9-1067 (Opicapone, OPC) - 25 mg
89670154|NCT01520727|Experimental|BIA 9-1067 50 mg|BIA 9-1067 (Opicapone, OPC) - 50 mg
89670155|NCT01520727|Experimental|BIA 9-1067 100 mg|BIA 9-1067 (Opicapone, OPC) - 100 mg
88995576|NCT02913352|Active Comparator|Latarjet procedure|Open Latarjet-Patte procedure. Surgery. Anterior glenoid bone graft from coracoid. Fixation with 2 screws.
88995577|NCT02913352|Experimental|Modified Eden-Hybinette Procedure|Surgery. Modified Eden-Hybinette surgery, with capsular repair on the iliac bone Anterior glenoid bone graft from iliac bone. Fixation with 2 screws.
88995578|NCT02913508|Experimental|Vedolizumab 300 mg IV Q8W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, and then every 8 weeks (Q8W) (Weeks 6 and 14).
89670156|NCT01520727|Experimental|BIA 9-1067 200 mg|BIA 9-1067 (Opicapone, OPC) - 200 mg
89670157|NCT01520727|Experimental|BIA 9-1067 400 mg|BIA 9-1067 (Opicapone, OPC) - 400 mg
89670158|NCT01520727|Experimental|BIA 9-1067 800 mg|BIA 9-1067 (Opicapone, OPC) - 800 mg
89670159|NCT01520727|Experimental|BIA 9-1067 1200 mg|BIA 9-1067 (Opicapone, OPC) - 1200 mg
89670160|NCT01520727|Placebo Comparator|Placebo|Placebo (PLC): single-dose
89670161|NCT01596231|Placebo Comparator|Placebo|This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session.
89670162|NCT01596231|Active Comparator|Kudzu|Kudzu 2mg
89670163|NCT01855607|Experimental|topical menthol|Patients with neuropathic pain will receive topical menthol following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.
88995579|NCT02913508|Experimental|Vedolizumab 300 mg IV / 160 mg SC Q3W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously (SC), every 3 weeks (Q3W) (Weeks 6, 9, 12, 15 and 18).
89670164|NCT01855607|Active Comparator|placebo lotion|Patients with neuropathic pain will receive placebo lotion following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.
89670165|NCT01896635|Active Comparator|FMT infusions|FMT infusions constituted from stool provided by healthy, screened donors
89670166|NCT01896635|Placebo Comparator|Placebo arm|Placebo infusions
89670167|NCT01596699|Experimental|Patients with Myeloid Malignancies|
89670168|NCT01596699|Experimental|Patients with Non-Malignancies|
89670169|NCT01148849|Experimental|Cohort 1: 0.1 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
89670170|NCT01148849|Experimental|Cohort 2: 0.3 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
89670171|NCT01148849|Experimental|Cohort 3: 1.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
89670172|NCT01148849|Experimental|Cohort 4: 3.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
89670173|NCT01148849|Experimental|Cohort 5: 6.0 mg/kg weekly for 4 weeks|Anti-HER2 monoclonal antibody (margetuximab)
89670174|NCT01148849|Experimental|Cohort 6: 10 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
89670175|NCT01148849|Experimental|Cohort 7: 15 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
89670176|NCT01148849|Experimental|Cohort 8: 18 mg/kg weekly every 3 weeks|Anti-HER2 monoclonal antibody (margetuximab)
89670177|NCT05605457|Experimental|PRG barrier coat|It is a light cured surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix.
89670178|NCT05605457|Active Comparator|Resin modified glass ionomer|Resin modified glass ionomer (Fuji II LC, GC, Japan). RMGIC are glass-ionomer cements with small quantity of monomers and initiators so the acid-base reaction is supplemented by a second polymerization reaction.
89670179|NCT01522131|Other|Bioresorbable membrane will be used as the control|Bioresorbable membrane alone (control)
89670180|NCT01522131|Experimental|laser with bioresorabable membrane (test)|
89670181|NCT03007797||vaccination rate- pregnant- influenca|
89670182|NCT05566743|Experimental|the maintenance arm|in this arm patients will receive 4 months of induction FOLFRINOX then maintenance capecitabine
88995580|NCT02913508|Experimental|Vedolizumab 300 mg IV / 108 mg SC Q2W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Q2W) (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
89670183|NCT05566743|Other|the control arm|in this arm patients will receive 4 months of FOLFRINOX then kept under follow-up
88995581|NCT02913508|Experimental|Vedolizumab 480 mg SC / 160 mg SC Q3W|Vedolizumab 480 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously, every 3 weeks (Weeks 6, 9, 12, 15 and 18).
88995582|NCT02913508|Experimental|Vedolizumab 324 mg SC / 108 mg SC Q2W|Vedolizumab 324 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
89214719|NCT06045819||Patients without composite complete remission|Patients not in composite complete remission following the first cycle of venetoclax (400 mg/day, orally, after a ramp-up phase of the first 3 days) + azacytidine (75mg/m²,intravenous, at the start of each cycle from day 1 to day 7)
89670184|NCT00076219|Experimental|Intensive renal replacement therapy|In the intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 6 times per week, and continuous venovenous hemodiafiltration was provided at 35 mL/kg/hour.
89670185|NCT00076219|Active Comparator|Less-intensive renal replacement therapy|In the less-intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 3 times per week, and continuous venovenous hemodiafiltration was provided at 20 mL/kg/hour.
89670186|NCT05605145||Immunocompromised patients|"Patients with immunocompromised conditions, including but not limited to HIV infection, long-term systemic use of corticosteroids, use of immunosuppressive agents, hematologic malignancies, solid tumors, hematopoietic stem cell transplantation, solid organ transplantation, radiotherapy and/or chemotherapy for malignancies,primary immunodeficiency disease.~Typical clinical manifestations of PJP such as fever,nonproductive cough, shortness of breath, and progressive hypoxemia.~Radiological abnormalities suggestive to PJP in bilateral lungs revealed by chest computed tomography (CT).~Respiratory tract samples were collected for qPCR and/or mNGS detection."
89670187|NCT01522755||Patients implanted with the CapsureFix MRI pacing lead|Patients implanted with the CapsureFix MRI pacing lead model 5086
89670188|NCT01523613|Active Comparator|ROCK - Single Restorations|ChemFil Rock glassionomer restoration
89670189|NCT01523613|Active Comparator|Fuji IX GP - Single Restorations|Fuji IX GP Extra glassionomer restoration
89670190|NCT01523613|Active Comparator|Rock AND Fuji - Paired Restorations|"ChemFil Rock glassionomer restoration AND Fuji IX GP Extra glassionomer restoration.~While this is not truly a separate arm for outcome analysis, this arm represents those individuals who had paired restorations, one of each: 1 ChemFil Rock restoration and 1 Fuji IX GP restoration."
89670191|NCT01896713|Other|Diagnostic: Single Arm|Imaging (MS3TMRI)
89670192|NCT05566509||Breast Conservative Surgery|The patients who had minimally invasive surgery.
89670193|NCT05566509||Mastectomy|The patients who had invasive and destructive surgery.
89670194|NCT05596721|Experimental|Azithromycin + ICS/LABA|Azithromycin: 500mg, po, 3 times per week for 12w ICS/LABA: Budesonide and Formoterol Fum arate Powder for Inhalation, 1 inhale, bid for 12w
89670195|NCT05596721|Placebo Comparator|ICS/LABA|ICS/LABA: Budesonide and Formoterol Fum arate Powder for Inhalation, 1 inhale, bid for 12w
89670196|NCT00076687|Experimental|1|
89670197|NCT00076687|Experimental|2|
89670198|NCT00076687|Placebo Comparator|3|
89670199|NCT00952445|Experimental|T0903131 Besylate|1.0 mg
89670200|NCT00952445|Experimental|T0903131 Besylate (higher dose)|10.0 mg
89670201|NCT00952445|Placebo Comparator|Placebo|Once daily, oral
89670202|NCT01525173|Active Comparator|ALPHAGAN® P and LUMIGAN®|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
89670203|NCT01525173|Active Comparator|LUMIGAN® Alone|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
89670204|NCT04752995|Other|high tibial osteotomy|Under general anesthesia, a one-cm vertical skin incision was done at the medial subcutaneous border of the tibia, one fingerbreadth below the tibial tuberosity. This was confirmed by intra-operative C-arm images. Longitudinal periosteal incision was done with minimal dissection. Incomplete medial transverse osteotomy including both anterior and posterior cortex was performed using drill bit or small thin osteotome.Osteotomy was completed manually by osteoclasis of the lateral cortex to provide postoperative stability by the preserved lateral periosteum. No fibular osteotomy was needed in the present study.
89670205|NCT01525563||Subjects with irregular Menstrual cycle|Adult subjects with irregular menstrual cycle and can be treated with Duphaston as per locally approved label can be enrolled.
89670206|NCT01896791|Active Comparator|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation: the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2mili Ampere, 20min, 10 days.
89670207|NCT01896791|Placebo Comparator|Sham Stimulation|Sham Stimulation: appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
89670208|NCT03007563|Experimental|newborn infants checked for jaundice|an experimental way of bilirubin concentration estimation from smartphone pictures is applied and compared with two standard methods: bilirubin concentration measured in standard blood samples, and bilirubin concentration measured by transcutaneous device.
89670209|NCT05442593|Experimental|Pre-adolescents|Acute plyometric training
89214720|NCT06032715|Active Comparator|BI (Brief Intervention)|Patients whose GPs have been taught the behavioral BI intervention aiming to reduce prolonged use of Z-hypnotics.
89670210|NCT05442593|Experimental|Adolescents|Acute plyometric training
89670211|NCT01526343|Experimental|Reveal XT|
89670212|NCT05566197|Experimental|Intervention|This group will receive dietary adjustment and nutrition counseling.
89670213|NCT05566197|Active Comparator|Control|This group will receive standard diet and nutrition counseling.
89670214|NCT01526577|Experimental|LC23-1306|experimental drug
89670215|NCT01526577|Placebo Comparator|placebo|LC23-1306 placebo
89670216|NCT01526577|Active Comparator|Ticagrelor|active comparator
89670217|NCT03001947||IgAN patients|Biopsy-proven primary IgAN patients
89670218|NCT01894451|Experimental|89Zr-bevacizumab-PET/CT Scan|"89Zr-bevacizumab-PET/CT will be performed at baseline, after 2 cycles of preoperative chemotherapy, and at the completion of preoperative chemotherapy.~The 89Zr-bevacizumab-PET/CT imaging procedure is detailed in Appendix A and is briefly described below.~Participants will be injected with 1 mCi of 89Zr-bevacizumab intravenously and PET/CT images will be obtained at 3-4 days after 89Zr-bevacizumab administration to allow time for antibody accumulation in the tumor. Imaging will be performed on a Centers for Quantitative Imaging Excellence (CQIE) qualified PET/CT scanner at the Dana-Farber Cancer Institute. After the baseline scan, subsequent scans will be obtained on the same PET/CT scanner for an individual participant."
89670219|NCT01527045|Experimental|Prevention (donor statin treatment)|See Detailed Description
89670220|NCT02756195||Neonates receiving first-time non-cardiac surgery|No intervention will be administered. This is a prospective observational patient safety study focusing on the safety of care delivered to neonates in perioperative care settings. Neonates who receive NICU care both pre- and post-operatively will be eligible for this study.
89670221|NCT00078403|Experimental|Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.
89670222|NCT00078403|Experimental|Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).
89670223|NCT00078403|Experimental|Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)|At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA <600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly & RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA >=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.
89670224|NCT01976585|Experimental|rhuFlt3L/CDX-301|intratumoral injections on days 1-5 and 8-11. and Poly-ICLC intratumoral injection weekly, weeks 2-8
89670225|NCT01897519|Experimental|Arm 1 lower dose ABT-719|
89670226|NCT01897519|Experimental|Arm 2 intermediate dose ABT-719|
89670227|NCT01897519|Experimental|Arm 3 high dose ABT-719|
89670228|NCT01897519|Placebo Comparator|Arm 4 Placebo|
89670229|NCT01894529||Ischemic stroke|Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis
89670230|NCT01894529||Healthy subjects|Age-matched individuals free of acute neurological injury
89670231|NCT00178711|Active Comparator|hypothermia|Induction and maintenance of moderate hypothermia to 33 degrees celsius achieved within 2.5 hours of injury and maintained for 48 hours.
89670232|NCT00178711|No Intervention|control|treated at normothermia
89670233|NCT02647619|Active Comparator|Needle aponeurotomy|percutaneous transection or pretendinous palmar dupytren cord
89670234|NCT02647619|Active Comparator|Xiapex|Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
89670235|NCT01527513|Experimental|Eslicarbazepine acetate (BIA 2-093)|
89670236|NCT01527513|Placebo Comparator|Placebo|
89670237|NCT03007251|Experimental|"Eurythmy Therapy Movement R"|"EYT exercise R: Positioned between two steps and forearms parallel to the ground, the patient performs a rolling movement like wheels on a wagon. The movement is positioned below shoulder height and is initiated from the shoulder blade."
89670238|NCT03007251|Experimental|"Eurythmy Therapy Movement L"|"EYT exercise L: In a circular and flowing movement the patient leads his hands upwards in front of his body and down again laterally. During elevation of the arms, the patient performs a small hop onto the toes and into knock knees. Lowering his arms, he releases the legs and straightens up again."
89670239|NCT03007251|Experimental|"Eurythmy Therapy Movement B"|"EYT exercise B: The patient describes an embracing movement with both arms and the left leg while balancing on one foot. He then returns to the initial position and repeats the movement using the other leg."
89670240|NCT03007251|Active Comparator|Normal movements during walking or standing|Control exercise: Participants slowly walk across the room, their arms swinging in a natural way. This was designed to control for the most basic upright movement, shifting thermoregulation from resting conditions to exercise conditions, triggering non-thermal factors.
89670241|NCT03001791|Experimental|Er:YAG laser|Excisional biopsy of fibrous hyperplasia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
89670242|NCT03001791|Experimental|CO2 laser|Excisional biopsy of fibrous hyperplasia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
89670243|NCT03001791|Experimental|Scalpel|Excisional biopsy of fibrous hyperplasia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
89670244|NCT03002025|Experimental|Cohort 1: JNJ-64304500 50 milligram (mg) or placebo|Participants (Japanese) will receive single subcutaneous (SC) dose of JNJ-64304500 50 mg or placebo on Day 1.
89670245|NCT03002025|Experimental|Cohort 2: JNJ-64304500 150 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 150 mg or placebo on Day 1.
89670246|NCT03002025|Experimental|Cohort 3: JNJ-64304500 400 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 400 mg or placebo on Day 1.
89670247|NCT03002025|Experimental|Cohort 4: JNJ-64304500 150 mg or placebo|Participants (Caucasian) will receive single subcutaneous (SC) dose of JNJ-64304500 150 mg or placebo on Day 1.
89670248|NCT03006861|Experimental|Oral creatine supplementation|21 g/d oral creatine for 7 days
89670249|NCT03006861|Placebo Comparator|Oral placebo supplementation|21 g/d oral placebo for 7 days
89670250|NCT03007017|Experimental|Arm 1|Patients selected for this arm will receive the left kidney from the new method of organ retrieval.
89214721|NCT06032715|No Intervention|BAU (Business as usual)|"Patients whose GPs have not yet been taught the BI intervention. Patients only assessed in parallel with BI group by masked assessors using same instruments as for active comparator.~This group also constitutes an open cross-over group to active intervention once the masked 6 months phase is completed."
89214722|NCT06025305||Patients who underwent coronary CT angiography and intravascular ultrasound within 3 months|
89214723|NCT06025305||Patients who underwent coronary CT angiography and optical coherence tomography within 3 months|
89670251|NCT03007017|Active Comparator|Arm 2|Patients selected for this arm will receive the normal standard of care operational kidney from retrieval.
89670252|NCT03001635|Experimental|conventional treatment and oxytocin|26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
89670253|NCT03001635|Placebo Comparator|conventional treatment only|26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.
89670254|NCT04351425|Experimental|study group|study group will be shifted from incubator to an unheated open cot a weight of 1400 grams
89670255|NCT04351425|Active Comparator|control group|control group will be shifted from incubator to an unheated open cot at a weight of 1600 grams
89670256|NCT02592798|Experimental|Abatacept|"Double Blind Periods 1 and 2 (DB1 and DB2): Abatacept IV administered on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~Open Label Period (OLE): Abatacept IV administered every 28 days"
89670257|NCT02592798|Placebo Comparator|Placebo|"Double Blind Periods 1 and 2 (DB1 and DB2): Normal Saline or Dextrose 5% in Water (D5W) administer on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~Open Label Period (OLE): Abatacept IV administered every 28 days"
89670258|NCT02981277|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
89670259|NCT02981277|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
89670260|NCT01530243|Placebo Comparator|Placebo|
89670261|NCT01530243|Active Comparator|Terazosin|
89670262|NCT01530243|Active Comparator|Tolterodine|
89670263|NCT01530243|Active Comparator|Tolterodine + Terazosin|
89670264|NCT04797546|Experimental|Adductor Canal Block|With mild sedation, a continous bupivacaine 0.1% infusion catheter is placed in the adductor canal. Afterwards, patients are placed under General Anesthesia, and surgery starts. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
89670265|NCT04797546|Active Comparator|Patient Controlled Morphine Analgesia|Patients are placed under General Anesthesia, and after surgery, a Morphine patient controlled analgesia delivery system is installed. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
88995583|NCT02913235|Experimental|Oral hygiene discontinuation group|The intervention of the present study is discontinuation of regular oral hygiene procedures for a period of 10 days. Discontinuation of oral hygiene will allow undisturbed biofilm formation (supragingival dental plaque) along the gingival margin of the teeth. After 10 days all individuals will resume regular oral hygiene. Clinical registrations and collection of microbiological samples (supragingival and saliva) will be performed at baseline and 4, 7 and 10 days after discontinuation of regular oral hygiene, and will be repeated 14 days after regular oral hygiene has been resumed.
89670266|NCT02980809|Experimental|Apatinib and topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5, apatinib 250mg/d, every 21 days, until disease progression.
89670267|NCT02980809|Placebo Comparator|Topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days, until disease progression.
89670268|NCT00078559|Experimental|Alemtuzumab|
89670269|NCT04797702|Experimental|Experimental group|Glumetinib combined with Toripalimab
89670270|NCT04805814|Active Comparator|Intervention Group|All randomised participants will receive stratified medicine. The subjects will undergo stress perfusion CMR as an adjunct to invasive coronary angiography. The CMR results will be disclosed to the clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and CMR findings.
89670271|NCT04805814|Sham Comparator|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also undergo stress perfusion CMR but the results will not be disclosed. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and CMR findings.
89670272|NCT00081653|Experimental|1|
89670273|NCT00081653|Active Comparator|2|
89670274|NCT00078715|Experimental|Yohimbine then Placebo|Participants are randomized to receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep. After 8 days they receive placebo administered over 3 minutes during REM sleep.
89670275|NCT00078715|Experimental|Placebo then Yohimbine|Participants are randomized to receive placebo administered over 3 minutes during REM sleep. After 8 days they receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
89670276|NCT04805580|Active Comparator|intrathecal block|patients (25) will receive unilateral intrathecal block using 1.5 ml of hyperbaric bupivacaine
89670277|NCT04805580|Active Comparator|Quadratus lumborum block|patients (25) will receive quadratus lumborum block by an anterior approach using 30 ml of bupivacaine 0.25%
89670278|NCT04398745|Experimental|Part 1: Participants with normal/mild impaired renal function|Participants with normal or mildly impaired renal function (Normal: individual glomerular filtration rate [iGFR]: >=90 milliliter per minute; Mild impairment: iGFR: 60-89 mL/min will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
89670279|NCT04398745|Experimental|Part 1: Participants with severe renal impairment|Participants with severely impaired renal function (iGFR: 15-29 mL/min) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
89670280|NCT04398745|Experimental|Part 2: Participants with ESRD (not on dialysis)|Participants with ESRD (iGFR: <15 mL/min) not on dialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
89670281|NCT04398745|Experimental|Part 2: Participants with ESRD (on hemodialysis)|Participants with ESRD (iGFR: <15 mL/min) on hemodialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
89670282|NCT04805034||HBeAg positive/HBsAg positive|
89670283|NCT04805034||HBeAg seroconversion /HBsAg loss|
88995584|NCT02913157|Experimental|Hydroxychloroquine|Oral Hydroxychloroquine, 200mg BID
88995585|NCT02913118|Experimental|standard antibiotic treatment +AS injection|Andrographolid Sulfonate Injection (AS Injection) plus one of 3 antibiotics in China CAP Guideline
88995586|NCT02913118|Placebo Comparator|standard antibiotic treatment + AS placebo|AS placebo (NS injection) plus one of 3 antibiotics in China CAP Guideline
89670284|NCT01530399|Experimental|MDCO 1|MDCO-2010: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
89670285|NCT01530399|Experimental|MDCO 2|MDCO-2010: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
89670286|NCT01530399|Experimental|MDCO 3|MDCO-2010: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
89670287|NCT01530399|Experimental|MDCO 4|MDCO-2010: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
88995587|NCT02913391|Experimental|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group (RG) used noninvasive ventilation (NIV) associated with recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV until 30 minutes with pressure support for a tidal volume of 6 mL/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen (FiO2) for a peripheral oxygen saturation (SpO2) ≥ 95%.
89214724|NCT06017440|Experimental|adolescents with obesity|There is only one arm as this is an acute randomized study comparing two differents conditions within the same sample of participants.
89214725|NCT06016959|Experimental|Individualised dietetic advice|Participants will receive 5 sessions receiving individualised nutritional counselling advice from a registered dietitian.
89214726|NCT06016959|Placebo Comparator|Diet sheet|Participants will receive a diet sheet around poor appetite.
89214727|NCT06014775|Experimental|Intervention（Anti-CD38 antibody）|10 enrolled subjects : once a week x 8 doses
89670288|NCT01530399|Placebo Comparator|Saline|Commercially available saline (0.9% NaCl solution)
89214728|NCT06007651|Experimental|LY3885125 (Part A)|Single ascending doses of LY3885125 administered subcutaneously (SC)
89214729|NCT06007651|Placebo Comparator|Placebo (Part A)|Placebo administered SC
89670289|NCT01530399|Active Comparator|Tranexamic acid|Tranexamic acid: 12 mg/kg loading dose; 5 mg/kg/h infusion; 0.556 mg/mL CPB priming
89670290|NCT05192915|Other|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
89670291|NCT04804956||Early-rectal cancer|The patients to be included in this group will be those with Stage I (initial tumor stage). The tumors classified in stage I will be tumors in which the invasion of the submucosa and / or the invasion of the muscularis propria occur. This group will include patients diagnosed preoperatively with tumor stage T1-T2 N0.
89670292|NCT04804956||Advanced-rectal cancer|The patients to be included in this group will be those with Stages II and III, that is, advanced tumors at the time of preoperative diagnosis. Tumors included in this group invade the perirectal fat and / or the surface of the visceral peritoneum and / or invade or adhere to adjacent organs or structures. In addition, any tumor stage with lymph nodes without distant metastases will be included in this group.
89670293|NCT04804956||Synchronous metastasis -rectal cancer|The patients to be included in this group will be those with Stage IV (disseminated tumor stage) in the initial study of the disease. Patients with distant metastases in one organ or more than one organ will be included.
89670294|NCT01530477|Experimental|Skeletal|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)],(total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
89670295|NCT01530477|Experimental|Body Composition|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of the three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], (total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
89670296|NCT01530477|Experimental|Skeletal & Body Composition|"Skeletal and Body Composition was not a cohort that was actively recruited to, it is a cohort for reporting purposes. Subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)]Subjects were able to consent and enroll to both Skeletal and Body Composition cohorts and these subjects will be counted for under this joint cohort."
89670297|NCT04804878||Biospeciman Repository and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
89670298|NCT04814160|Active Comparator|autogenous bone graft|autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
89670299|NCT04814160|Experimental|mix of bioactive glass and autogenous bone graft|1:1 mix of bioactive glass and autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting
89670300|NCT01531335|Active Comparator|Standard care|Patients will receive normal nutritional regime of around 25 kcal per kg.
89670301|NCT01531335|Experimental|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg
89670302|NCT04804410|Experimental|Dielectric Properties of Tissue Samples from Thoracic Malignancies and Corresponding Normal Tissues|Our plan is to analyze 3-5 tissue probes acquired from 30 patients with a variety of thoracic malignancies. The investigators will plan to acquire tissue from each type of malignancy including: lung cancer, esophageal cancer and pleural based tumors. Tissue will be acquired in the operating room. Impedance measurements will be collected on multiple sections of excised tissue and will be translated into dielectric properties. After acquisition of data, the investigators will assess the data and continue to acquire patients to obtain significant estimates of overall tissue properties in each type of tumor. After undergoing an informed consent process in accordance with IRB approval, patients with be formally enrolled. All tumor electric property data will be stored securely and remain anonymous of patient identifying data.
89670303|NCT02596620|Experimental|Sequential therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
89670304|NCT02596620|Active Comparator|Triple therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days
89670305|NCT00180271|Experimental|CRT-D|CRT-D: Cardiac resynchronization therapy with defibrillation.
89670306|NCT00180271|Active Comparator|ICD|ICD: Implantable cardioverter defibrillator
89670307|NCT03001401|Active Comparator|iDesign|Eyes will under LASIK using iDesign platform for treatment of sphere and cylinder power
89670308|NCT03001401|Active Comparator|SMILE|Eyes will under SMILE using Visumax platform for treatment of sphere and cylinder power
89214730|NCT06007651|Experimental|LY3885125 (Part B)|Repeat doses of LY3885125 administered SC
89214731|NCT06007651|Placebo Comparator|Placebo (Part B)|Placebo administered SC
89214732|NCT06005038|Experimental|pSOPT|personalized cognitive training with a close-loop parasympathetic nervous system monitored component
89214733|NCT06005038|Placebo Comparator|MLA|computerized mental leisure activities
89670309|NCT00180661||Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN/BTS Guidelines
89670310|NCT00180661||Moderate Asthma|Asthma patients on steps 2/3 of Asthma treatment according to SIGN/BTS Guidelines
89670311|NCT00180661||Mild Asthma|Asthma patients on steps 1 of asthma treatment (steroid naive).
89670312|NCT01531959|Active Comparator|Midodrine|
89670313|NCT01531959|Placebo Comparator|Placebo|
89670314|NCT00181207|Experimental|Active|Pneumatic Compression Device used twice daily for 20 minutes each time for 12 weeks
89670315|NCT00181207|Placebo Comparator|Sham|Device looked and sounded like a pneumatic compression device, but was not inflating nor deflating.
89670316|NCT02092441|Active Comparator|Alcohol prep pad group|isopropyl alcohol prep pad
89670317|NCT02092441|Placebo Comparator|Normal Saline prep pad|normal saline prep pad
89670318|NCT01532349|Active Comparator|400 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 400 IU/day (2,800 IU/weekly), which is the recommended dietary allowance. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
89670319|NCT01532349|Active Comparator|4000 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 4000 IU/day (28,000 IU weekly) according to the KDOQI recommended supplementation for children with mild 25D deficiency. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
89670320|NCT03006783||Cross-face nerve graft treated|People treated by a solitary cross-face nerve graft or in combination with another procedure.
89670321|NCT03006783||Hypoglossal-facial treated|People treated with a solitary hypoglossal-facial anastomosis.
89670322|NCT00181285|Sham Comparator|Sham high frequency chest wall oscillation|Sham high frequency chest wall oscillation
88995588|NCT02913391|Active Comparator|control group (CG)|After extubation the patient who was randomized to the Control Group (CG) used noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, FiO2 for a SpO2 ≥ 95%.
88995589|NCT02913079|Experimental|Sit-stand desk|During this condition, participants will sit or stand as much as they like throughout a workday.
88995590|NCT02913079|Placebo Comparator|Sitting|During this condition, participants will work in the sitting position only.
88995591|NCT02912962|Experimental|Intervention Group|"Cognitive testing 1, 12 intervention sessions, Cognitive testing 2, Approximately a 12 week wait (no intervention), Cognitive testing 3.~The intervention is a 12 week, individualized, one-on-one self-regulation intervention where adolescents will learn to attain, change, or maintain an appropriate level of alertness ."
88995592|NCT02912962|Experimental|Waitlist|Cognitive testing 1, Approximately a 12 week wait (no intervention), Cognitive testing 2, 12 intervention sessions, Cognitive testing 3
88995593|NCT02913040|Experimental|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
88995594|NCT02913040|Active Comparator|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
88995595|NCT02912923|Experimental|Start with Visual + Force|Participants will complete a set of trials while receiving Visual + Force Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force + Game Scores Feedback.
88995596|NCT02912923|Experimental|Start with Visual + Force + Game Scores|Participants will complete a set of trials while receiving Visual + Force + Game Scores Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force Feedback.
88995597|NCT02912884||PV|Patients with a diagnosis of polycythaemia vera.
88995598|NCT02912884||ET|Patients with a diagnosis of essential thrombocythaemia.
88995599|NCT02912728|Active Comparator|CGM + Family Behavioral Intervention|CGM training for CGM groups using a standard curriculum will take place at the 1, 3 and 6 week visits in addition to the training at baseline. The family behavioral intervention will be delivered by a study coordinator (separate coordinator from the CGM instruction) at the 1, 3, 6, 13 and 19 week visits and is expected to take approximately 30 minutes.
89670323|NCT00181285|Active Comparator|Active high frequency chest wall oscillation|Active high frequency chest wall oscillation
89670324|NCT03001245|Experimental|IPC|Interpersonal Counseling
88995600|NCT02912728|Active Comparator|Standard CGM|"Each participant will be asked to use a CGM sensor on a daily basis, inserting a new sensor as needed with a maximum of 7 days of wear per sensor.~A home BGM will be used for calibration of the CGM sensor. Additional BGM glucose measurements may be performed by the participant at any time, particularly prior to making a real-time management decision based on the CGM glucose reading.~Participants will be instructed to use the CGM as per the FDA labeling."
88995601|NCT02912728|No Intervention|BGM - usual care control group|A BGM will be used for a finger stick blood glucose check with a recommendation of at least 4 times a day. BGM data will be downloaded and reviewed with the participant at each visit.
88995602|NCT02912767||SLN cohort|Patients who underwent hysterectomy only or with SLN mapping alone.
88995603|NCT02912767||LND cohort|Patients who underwent hysterectomy with standard lymphadenectomy, with or without SLN mapping.
88995604|NCT02912845|Experimental|20 IU/kg KamRAB + Active Anti-Rabies Vaccine|
88995605|NCT02912689|Experimental|Neurally adjusted ventilator assist|Neurally adjusted ventilator assist (NAVA) during NIV for exacerbation of COPD.
89670325|NCT03001245|Active Comparator|ST|Standard treatment
89670326|NCT00181363|Experimental|Mamma board|use of the mamma board during radiotherapy
89670327|NCT03007875|Experimental|High-activity natural killer|In this group, the patients will receive multiple times of high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89670328|NCT03007875|No Intervention|ControL|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89670329|NCT03001323|Experimental|Degludec|Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
89670330|NCT03001323|Active Comparator|Standard long-acting|Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR <30 ml/hr.
89214734|NCT06001814|Experimental|One-Mind One-Heart|One-Mind One-Heart (OM-OH) is intended to be a mindfulness-based, behavior change intervention to reduce psychological and behavioral cardiovascular disease risk.
89670331|NCT03006549|Experimental|Emergency Manual|emergency manual present
89670332|NCT03006549|No Intervention|No Emergency|NO emergency manual present
88995606|NCT02912689|Active Comparator|Pressure support ventilation|Pressure support ventilation (PSV) during NIV for exacerbation of COPD.
89670333|NCT03001089|Active Comparator|Fludrocortisone 10 µg tablets|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
89670334|NCT03001089|Placebo Comparator|placebo oral tablet|Oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
89670335|NCT01532817|Experimental|alphacore|noninvasive neurostimulation of the vagus nerve
89670336|NCT01532973|Experimental|GT1 HCV 10-mg Elbasvir (Panel A)|Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
89670337|NCT01532973|Experimental|GTI HCV 50-g Elbasvir (Panel B)|Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
89670338|NCT01532973|Experimental|GT1 HCV 5-mg Elbavir (Panel C)|Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
89670339|NCT01532973|Experimental|GT1 HCV 200-mg Elbasvir (Panel D)|Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
89670340|NCT01532973|Experimental|GT3 HCV 10-mg Elbasvir (Panel E)|Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
89670341|NCT01532973|Experimental|GT3 HCV 50-mg Elbasvir (Panel F)|Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
89670342|NCT01532973|Experimental|GT3 HCV 100-mg Elbasvir (Panel G)|Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
89670343|NCT01532973|Experimental|GT3 HCV 200-mg Elbasvir (Panel H)|Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
89670344|NCT01532973|Experimental|GT1a HCV 10-mg Elbasvir (Panel I)|Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
89670345|NCT01532973|Experimental|GT1a HCV 50-mg Elbasvir (Panel J)|Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
89670346|NCT03000621||Patients with liver injury|
89670347|NCT03000621||Healthy subjects|
89670348|NCT01533207|Experimental|Arm I (chemotherapy)|Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
89670349|NCT01533207|Other|Arm II (no treatment)|Patients undergo clinical observation.
89670350|NCT00182767|Experimental|Treatment (ixabepilone and doxorubicin)|Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.
89670351|NCT02596230||Patients with acute VTE|Patients will be enrolled for cross sectional characterization of baseline characteristics
89670352|NCT02596230||Dabigatran|Patients treated with dabigatran for acute VTE will be followed for one year
89670353|NCT02596230||vitamin K antagonist|Patients treated with VKA for acute VTE will be followed for one year
89670354|NCT01533597|Active Comparator|Solifenacin|
89670355|NCT01533597|Experimental|Solifenacin plus Tamsulosin|
89670356|NCT01534689|Experimental|Erchonia FX-405™ Laser|The Erchonia FX-405™ Laser is a dual-diode laser emitting 15.5-17.5 milliWatts (mW) of 635 nanometer (nm) red laser light and 23.5-25.5 mW 405 nm blue laser light. The the power reaching the surface of the skin is 1 mW
89670357|NCT03006627|Active Comparator|Male group|All male patients scheduled for upper abdominal surgeries
89670358|NCT03006627|Active Comparator|Female group|All female patients scheduled for upper abdominal surgeries
89670359|NCT03000543|No Intervention|Vitamin A pool size in infants without inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
89670360|NCT03000543|Experimental|Vitamin A pool size in infants with inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
89670361|NCT04804176|Active Comparator|5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation|The study used 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS.
89670362|NCT04804176|Active Comparator|GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation|The study used GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS
89670363|NCT04804176|Sham Comparator|the control group|The instrument is not working, only in exhaust mode.
89670364|NCT03000699|Experimental|Cognitive Bias Modification|64 training paragraphs, approximately 10-20 seconds each, digitally recorded and presented stereophonically through headphones, delivered over the course of one week.
89670365|NCT03000699|No Intervention|Assessment-Only Control|No training will be provided.
89214735|NCT06001814|Active Comparator|Education|The education session will provide information on behaviors important for cardiovascular disease risk reduction.
89214736|NCT05993091|Experimental|MT+AR group|The experimental group will receive 40 minutes of MT, followed by 40 minutes of AR training and 10 minutes of functional practice. Figure 2 provides an illustration of the hybrid regimen of MT+AR.
89670366|NCT04796688|Experimental|Fludarabine + Cyclophosphamide + AT19 cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (300 mg/kg) on days -5, -4, and -3, followed by the infusions of AT19 cells on day 0-2. The study will be divided into three groups: B-ALL, B-CLL, and B-cell lymphoma. Doses of 0.5×10^7, 1.0×10^7, and 2.0×10^7 CAR+ T cells (with an allowance of ±20%) will be tested in each group in the 3+3 dose-escalation study. Each dose group has 3 patients. If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.The maximum dose could be extended.
89670367|NCT04796532|No Intervention|Control|No intervention. The control group will maintain their normal physical and dietary activity.
89670368|NCT04796532|Experimental|Homebased HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Homebased HIIT group participants will attend HIIT workout sessions supervised by a specialised instructor via a videoconference application. This group will have 16 week follow-up.
89670369|NCT04796532|Experimental|Traditional HIIT|16-week exercise program with HIIT with a frequency of 3 days/week. The Traditional-HIIT group participants will attend presential HIIT workout sessions supervised. This group will have 16 week follow-up.
89670370|NCT04796376|Other|Cutting seton|A piece of surgical thread that's left in the fistula for several weeks to keep it open. This allow it to drain and help its heal.
89670371|NCT04796064|Experimental|low-intensity aerobic training group|
89670372|NCT04796064|Experimental|high-intensity aerobic training group|
89670373|NCT01535001|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
89670374|NCT01535001|Active Comparator|Standard treatment|Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
89670375|NCT04814238||mini-David|
89670376|NCT04814238||mini-Yacoub|
89670377|NCT04814238||mini-Bentall|
89670378|NCT03000777|Experimental|Melatonin plus Zinc|Melatonin plus Zinc
89670379|NCT03000777|Placebo Comparator|Placebo|Isomaltose
89670380|NCT04796142|Experimental|Reconciliation|Interventional trial without drugs
89670381|NCT02212587|Experimental|TOBI Podhaler|
89670382|NCT04427124||Prospective|Patients admitted into the hospital will receive care based on a multidisciplinary team approach and Institutional critical limb ischemia protocol.
89214737|NCT05993091|Active Comparator|AR group|The comparison group will receive 80 minutes of AR training combined with 10 minutes of functional practice.
89670383|NCT04427124||Retrospective|A retrospective analysis of all patients with CLI admitted to the hospital from 2017-2019 will serve as a baseline comparator for overall CLI care and long-term mortality out to 2 years will be analyzed in the retrospective cohort using the national death index. Patients will be identified by the following ICD codes: 440.22 (ASVD of extremities with rest pain), 440.23 (ulceration), and 440.24 (gangrene).
89670384|NCT03006237|Experimental|IV IS-001 drug|IV IS-001 given during hysterectomy performed with da Vinci® Si/Xi Surgical System
89670385|NCT04803864|Experimental|Roxadustat|Early and short-term Roxadustat treatment
89670386|NCT04803864|No Intervention|Control|Patients only receive conventional therapies as recommended by guidelines.
89670387|NCT03006159|Experimental|Cohort 1|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 5 mg SHR0534 or matching placebo.
89670388|NCT03006159|Experimental|Cohort 2|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 10 mg SHR0534 or matching placebo.
89670389|NCT03006159|Experimental|Cohort 3|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 25 mg SHR0534 or matching placebo.
89214738|NCT05993091|Active Comparator|CT group|The control group will receive 90 minutes of conventional occupational therapy, including 10 minutes of functional practice. Examples of functional practice include chopping vegetables, pouring water from a kettle, folding a towel, etc.
89670390|NCT04814004|Experimental|hCD19.IL15.CAR-iNKT cells|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89670391|NCT03006003|Experimental|Raloxifene group|Raloxifene treatment
89670392|NCT03006003|Active Comparator|Comparator group|Alendronate treatment
89670393|NCT03006003|No Intervention|Control group|To refuse anti-osteoporosis treatment
89670394|NCT04813770|Experimental|Theory-based messages|Theory-based health messages about COVID-19 and COVID-19 vaccination, the necessity of COVID-19 vaccination to oneself and others, and COVID-19 vaccine regulatory approval processes. These messages are based on publicly available information and are hypothesised to increase perceived necessity and reduce concerns about vaccination, and target known barriers to vaccine uptake.
88995607|NCT02912611|Other|Moderate and High risk for AKI|
89214739|NCT05985382|Experimental|Lower Body Resistance Exercise|Participants will perform a leg extension exercise with weight that is 75% of their estimated 1-repetition maximum (1-RM) for 3 sets of 10 repetitions.
89670395|NCT04813770|Active Comparator|General messages|General messages about the COVID-19 virus and the vaccination programme. These messages do not target necessity and concerns, but are anticipated to promote understanding of the pandemic.
89670396|NCT03000465||Patients|Patients undergoing laparoscopic colorectal surgery
89670397|NCT04426734|Experimental|Dextenza|"Sustained Released 0.4 mg Dexamethasone intracanalicular insert in both upper and lower punctum.~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
89670398|NCT04426734|Active Comparator|Topical Pred Forte 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
89670399|NCT03005847|Experimental|FPP arm|active treatment with fermented papaya preparation
89670400|NCT03006081|Experimental|2mg intravitreal aflibercept injection|2mg intravitreal aflibercept (Eylea) injection at baseline, 1M, 2M, 3M, 4M, and 5M
89670401|NCT04795518||Cross sectional study by questionnaire among group of pediatric dentistry|"An interviewed questionnaire is divided into two parts. The first part of the questionnaire will investigate the socio-demographic characteristics of the respondents. The second part of the questionnaire is divided into five sections to cover the following items:~Use of antibiotics pattern~Knowledge about antibiotics~Sources of information"
89670402|NCT01535937|Experimental|Ketamine|0.5 mg/kg of ketamine IV over 40 minutes
89670403|NCT01535937|Active Comparator|midazolam|0.025 mg/kg IV over 40 minutes
89670404|NCT04813848|Experimental|Varnish fluoride|Varnish fluoride to be applied on the surface of exposed dentin
89670405|NCT04813848|Active Comparator|Bonding agent|Bonding agent to be applied on the surface of exposed dentin
89670406|NCT04813536||nurses in Assiut university hospitals|currently working nurses exposed to shift work
89670407|NCT04813536||control group|currently working nurses not exposed to shift work
89670408|NCT02999841|Experimental|Group A|Acarbose
89670409|NCT02999841|Active Comparator|Group B|Vildagliptin
89670410|NCT04795050|Experimental|Intervention|
89670411|NCT04795050|No Intervention|Control|
89670412|NCT01537029|Experimental|Doxorubicin and cyclophosphamide|
89670413|NCT04795206||Cohort 1: Main Cohort|All eligible participants with CHM in IRIS Registry will be included.
89670414|NCT04795206||Cohort 2: Trial-Matched Cohort|Only male participants with CHM from Cohort 1 to match Biogen's IST study population using propensity score matching will be included.
89670415|NCT01667562|Experimental|Erlotinib|Erlotinib will be administered as a single daily oral dose of 150 milligrams until disease progression, death or unacceptable toxicity.
89670416|NCT01667562|No Intervention|Diagnostic Phase|Participants with advanced or metastatic NSCLC were tested for EGFR mutations. Participants who did not have an EGFR mutation were excluded from the study.
89670417|NCT04803318|Experimental|Combination treatment of 3 inhibitors|Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.
89670418|NCT01537185|Experimental|Cohort 1 SPWCV+Alum 100 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
89670419|NCT01537185|Experimental|Cohort 2 SPWCV+Alum 300 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
89670420|NCT01537185|Experimental|Cohort 3 SPWCV+Alum 600 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
89670421|NCT01537185|Placebo Comparator|Normal Saline Injection|"placebo group within each cohort receive 3 injections of normal saline 28 days apart~normal saline injection: 3 cohorts of normal saline injection"
89670422|NCT04803162||patients with eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group. EoE patients were then treated for 8 weeks with PPs - omeprazole in the dose of 20 mg twice daily. After 8 weeks, each patient in the EoE group again passed all the tests (the protocols were identical to those used for qualifying patients to the project).
89670423|NCT04803162||patients without eosinophilic esophagitis|Each project participant completed a health and existing disease questionnaire and the GIQLI. Quantification of IL-5, IL-13 and TGF-β1 serum levels was performed using enzyme immunoassays. From each participant during the esophagogastroduodenoscopy, 6 oesophageal mucosa biopsy specimens were collected. The obtained material was sent for histopathological examination to assess peak eosinophil count (PEC). After completing medical examinations, the project participants were divided according to the histopathological criterion's fulfillment for the diagnosis of EoE. Patients with ≥15 eosinophils/HPF in the biopsy samples constituted the group of patients with EoE, while the remaining patients - the control group.
89670424|NCT04813068||Interview arm|Group of patients who have agreed to have a qualitative interview on the topic of recurrence of lung cancer
89670425|NCT02999217|Active Comparator|Treatment|1 g of intravenous iron isomaltoside given postoperatively for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
89670426|NCT02999217|Placebo Comparator|Control|The same amount of intravenous saline for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
89049243|NCT02904278|Experimental|Teen Pocket PATH® Mobile Application|"Participants in this group will receive the mobile application for improving adherence to their post-transplant medications, along with standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken. Additionally, the mobile app. will inform the investigators, by way of automated text messaging, of treatment adherence.~Duration of participation: up to 12 months post heart transplantation."
89049244|NCT02904278|Other|Control Group: Standard of Care|"Participants in the control group will receive standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~Duration of participation: up to 12 months post heart transplantation."
89049245|NCT00557700|Placebo Comparator|2|Administration of placebo
89049246|NCT00557700|Experimental|1|Administration of inhaled tiotropium bromide
89049247|NCT02904161||first stage|For the first stage, 60 healthy volunteers, 10 patients with stage 4 breast cancer and 10 patients with other types of cancer will be recruited.
89049248|NCT02904161||second stage|For the second stage, approximately 65 breast cancer patients will be recruited.
89049249|NCT00557739|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
89214740|NCT05985382|Experimental|Upper Body Resistance Exercise|Participants will perform a shoulder press with weight that is 75% of their estimated 1-repetition maximum (1-RM) for 3 sets of 10 repetitions.
89214741|NCT05984316|Experimental|exercise group|
89214742|NCT05981768|Experimental|Part 1: Cytisinicline 3 mg Once Daily (QD), Fasting|3 mg cytisinicline tablet administered in the morning, between 7:00 and 9:00 AM, in fasting conditions on Day 1 (Period 1) or Day 3 (Period 2). Participants will fast overnight for at least 10 hours before cytisinicline administration and will continue to fast for 4 hours after dosing.
89214743|NCT05981768|Experimental|Part 1: Cytisinicline 3 mg QD, Fed|3 mg cytisinicline tablet administered in the morning, between 7:00 and 9:00 AM, in fed conditions on Day 1 (Period 1) or Day 3 (Period 2). After an overnight fasting of at least 10 hours, participants will consume a standard high-fat-high-calorie meal within 30 minutes. Cytisinicline will be administered with 240 mL of water within 5 minutes after completion of the meal.
89214744|NCT05981768|Experimental|Part 2: Cytisinicline 3 mg 3 Times Daily (TID)|3 mg cytisinicline tablet administered TID each day on Day 5 to 8 (Period 3) as follows: Dose 1 will be administered in the morning between 7:00 and 9:00 AM,; Dose 2 at 5 hours (±10 minutes) after Dose 1; Dose 3 at 5 hours (±10 minutes) after Dose 2. Cytisinicline will be administered on an empty stomach (cytisinicline given at least 2 hours before food or 1 hour after food).
89214745|NCT05980793|Active Comparator|Surgical treatment|PIP joint denervation is performed through a volar approach.
89214746|NCT05980793|Active Comparator|Non-surgical treatment|An education and exercise program.
89214747|NCT05973019|Experimental|rTMS with 10 Hz|6 times/per week for 2 weeks, total 12 times rTMS.
89214748|NCT05966948|Experimental|Hypertonic Dextrose Prolotherapy|This group received a Hypertonic dextrose intra articular is 25%, while extra articular 20% injection on day 1 and day 30 with same dose.
89214749|NCT05966948|Placebo Comparator|Normal Saline|This group received Normal Saline injection on day 1 and day 30.
89214750|NCT05966688|Experimental|SPR720 1000 mg|Healthy participants will receive SPR720 1000 milligrams (mg), orally, once daily (QD) for 7 days.
89214751|NCT05966688|Experimental|Azithromycin 500 mg|Healthy participants will receive azithromycin 500 mg, orally, QD for 7 days.
89214752|NCT05966688|Experimental|Ethambutol 800 mg|Healthy participants will receive ethambutol 800 mg, orally, QD for 7 days.
89214753|NCT05966688|Experimental|SPR720 1000 mg + Azithromycin 500 mg + Ethambutol 800 mg|Healthy participants will be co-administered SPR720 1000 mg, azithromycin 500 mg, and ethambutol 800 mg, orally, QD for 7 days.
89214754|NCT05966688|Experimental|Azithromycin 500 mg + Ethambutol 800 mg|Healthy participants will be co-administered azithromycin 500 mg, and ethambutol 800 mg, orally, QD for 7 days.
89214755|NCT05960513|Experimental|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Participants will receive three weekly online instructions (90 minutes each) by trained instructors in addition to standard care. Weekly 60 minutes follow-ups will include 10 minutes of breathing exercises followed by 33 minutes of guided meditation practice, and then focus on participants' experiences with breathing exercise followed by meditation during the week, additional observations, and a review of relevant knowledge to support their home practice.
89214756|NCT05960513|No Intervention|No Intervention|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
89214757|NCT05956405|Experimental|Amygdala & Insula Retraining + Mindfulness|
89214758|NCT05956405|Active Comparator|Relaxation condition|
89214759|NCT05955326|Experimental|Sovateltide (Tyvalzi™) + Standard treatment|A total of 80 patients will be enrolled in the experimental arm. Three doses of sovateltide (each dose of 0.3 μg/kg body weight) will be given as an IV bolus in each patient (randomly assigned to this group) over one minute at an interval of 3 ± 1 hours on day 1, day 3, and day 6 (total dose/day: 0.9 μg/kg body weight). All patients will receive standard stroke treatment as provided by the specific hospital setup. Patients will be closely monitored for the qualifying stroke, followed for 3 months, and assessed for safety and efficacy parameters. Efforts will be made to administer the drug at the same time on days 1, 3, and 6.
89670427|NCT01537419|Active Comparator|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
89670428|NCT01537419|Experimental|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
89670429|NCT02595528|Experimental|AGN-199201 and AGN-190584 Vehicle|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
88995608|NCT02912416|Experimental|Probiotics|Capsule with probiotics
89670430|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose A|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
89670431|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose B|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
89670432|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose C|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
89670433|NCT02980965|Experimental|neoadjuvant chemo-endocrine therapy|In the experimental arm, patients received concurrent chemotherapy (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles) with endocrine therapy (letrozole with or without leuprorelin) as a neoadjuvant treatment
89670434|NCT02980965|Active Comparator|neoadjuvant chemotherapy alone|In the control group, patients received neoadjuvant chemotherapy alone (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles)
89670435|NCT02247375|Experimental|Low dose of BIIL 284 BS|
89670436|NCT02247375|Experimental|High dose of BIIL 284 BS|
89670437|NCT02247375|Placebo Comparator|Placebo|
89670438|NCT01538745|Experimental|Ketamine|0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.
89670439|NCT01538745|Active Comparator|Morphine|0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.
89670440|NCT04803396|Placebo Comparator|Placebo|Placebo was administered once a day (oad) as matching oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
89670441|NCT04803396|Experimental|50 mg DF2755A|"The experimental drug was administered once a day (oad) as one oral capsule of 50 mg.~The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions."
89670442|NCT04803396|Experimental|150 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
89670443|NCT04803396|Experimental|300 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
89670444|NCT04803396|Experimental|600 mg DF2755A|The experimental drug was administered once a day (oad) as oral capsules. The administration took place at around 8:00 a.m with 200 mL of tap water, in sitting position, in fasting conditions.
89670445|NCT02981199|Active Comparator|Micro-SCT|"patients treated with microtransplantation. [VMD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; melphalan 60mg/m2 d1; dexamethasone 20mg d1,2,4,5,8,9,11,12) + low dose allogeneic stem cell transplantation]×4cycles; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×1cycle; then maintenance therapy with thalidomide 100mg/d.~microtransplantation = [VMD regimen chemotherapy+ low dose allogeneic stem cell transplantation]×4cycles"
89670446|NCT02981199|Active Comparator|Auto-SCT|patients treated with Auto-SCT. conditioning with Mel+Vel regimen (melphalan 200mg/m2 d-2, bortezomib 1.3mg/m2 d-6,-3,+1,+4) + autogeneic stem cell transplantation; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×4cycle; then maintenance therapy with thalidomide 100mg/d.
89670447|NCT01539135|Active Comparator|Hi-Lo endotracheal tube|Hi-Lo endotracheal tube with barrel shaped cuff with 20 cc of methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
89670448|NCT01539135|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube with taper shaped cuff with 20 cc methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
89670449|NCT04426578|Experimental|Perhexiline|
89670450|NCT04426578|Placebo Comparator|Placebo|
89670451|NCT04802694|Experimental|Water-based barrier tape|The infants in experiment 1 group will be applied water-based barrier tape will be used to fix the nasogastric tube
89670452|NCT04802694|Experimental|Hydrocolloid barrier tape|The infants in experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube.
88995609|NCT02912416|Placebo Comparator|Placebo|Capsule with placebo
89670453|NCT04802694|Active Comparator|Adhesive product|The silk plaster used in clinic routinely will be used for control group infants to fix the nasogastric tube.
89670454|NCT03005691||Whiplash-Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The minimum will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
89670455|NCT03005691||Whiplash-no Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The maximun will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
89670456|NCT03005691||Non-injured|Subjects without whiplash syndrome. The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
89670457|NCT04802928|Placebo Comparator|A|Placebo tablets.
89670458|NCT04802928|Experimental|B|
89670459|NCT05365425|Experimental|Tgfenon|Choline fenofibrate (135mg as fenofibric acid) 1 tablet once daily oral administration regardless of diet
89670460|NCT05365425|Active Comparator|Policosanol 10|Policosanol 10mg 1 tablet once daily oral administration
89670461|NCT03005457|Experimental|Stroke|
89670462|NCT03005457|Experimental|Hemiparesis other|
89670463|NCT02595450||Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
89670464|NCT04802850|Experimental|Real MWM|Real mobilization with movement
89670465|NCT04802850|Sham Comparator|Sham MWM|sham or placebo mobilization with movement
89670466|NCT05616078|Experimental|laser treatment|LP-Nd:YAG laser treatment
89670467|NCT05616078|Active Comparator|cryotherapy|cryotherapy with liquid nitrogen
89670468|NCT02998125||before and after total knee arthroplasty|assess the functional outcome before and 6 months after total knee arthroplasty
89670469|NCT04794738|Experimental|Treatment group A|
89670470|NCT04794738|Experimental|Treatment group B|
89670471|NCT04794738|Placebo Comparator|Treatment group C|
89670472|NCT04794738|Active Comparator|Treatment group D|
89670473|NCT04794426|Active Comparator|control group|The group that have caries in primary molars and treat them with Hall Technique
89670474|NCT04794426|Experimental|experimental group|The group that have caries in primary molars and treat them with Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC.
89670475|NCT03005613|Active Comparator|sacrospinous ligament fixation group|The patients will receive sacrospinous ligament fixation operation.
89670476|NCT03005613|Experimental|ischial spine fascia fixation group|The patients will receive ischial spine fascia fixation operation.
89670477|NCT04794348|Active Comparator|Fresh Frozen Plasma (FFP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL of fresh frozen plasma. After completion of warfarin dosing, approximately 810 mL of fresh frozen plasma will be intravenously administered to the subject.
89670478|NCT04794348|Experimental|Freeze Dried Plasma (FDP)|Subjects will undergo plasmapheresis to generate approximately 1200 mL, that will be manufactured into freeze dried plasma units. After completion of warfarin dosing, approximately 810 mL of freeze dried plasma will be intravenously administered to the subject.
89670479|NCT05270655|Experimental|Cognitive-behavioural intervention|Five sessions of cognitive-behavioural intervention will be delivered on a weekly basis.
89670480|NCT05270655|No Intervention|Usual care|Participants in the control group will receive the usual psychosocial care provided by the staff nurses. To offer them attention, a research assistant in each hospital will meet them every week for 30 minutes to ask them about treatment adherence and any other concerns. The parents will be invited to attend it if they want to do so. Each participant will be given an appointment slip and reminded with a phone call two days before the next appointment. For participants whose medical appointment is more than a week, the research will contact them via phone.
89670481|NCT02592018|Experimental|Secukinumab|All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.
89670482|NCT05672979|Experimental|Brolucizumab treated|"Intravitreal brolucizumab 6mg injection.~Initial treatment consists of a loading dose of three intravitreal injections of brolucizumab at monthly intervals. After 3 loading doses, patients are followed by monthly observation visits until the month 6 and bimonthly afterwards until disease-recurrence interval is determined (It can be monthly as per the investigator's judgement.). Following loading phase, the first treatment interval is determined by patients' disease recurrent interval, 1 month shorter than first recurrence interval (maximum first injection interval is 16 weeks). The injection interval is shortened if there is any fluid change or decreased visual acuity. If the criteria for treatment adjustment were not met and residual fluid was decreased from the previous visit, the injection interval is maintained. And the interval is extended if there was no fluid on OCT. The minimum and maximum injection intervals are 8 and 16 weeks, respectively."
89670483|NCT03005535|Active Comparator|Vitaminized corn oil|Vitaminized corn oil (plus B6 and E vitamins), 30 g per day, per 8 weeks, with meals (15 g per meal)
89670484|NCT03005535|Placebo Comparator|Olive oil|Olive oil (not extra-virgin), 30 g per day, per 8 weeks, with meals (15 g per meal)
88995610|NCT02912377|Experimental|Arm 1; B12019 / Neulasta|2 single doses of B12019 followed by one dose of Neulasta
88995611|NCT02912377|Experimental|Arm 2; Neulasta / B12019|2 single doses of Neulasta followed by one dose B12019
88995612|NCT02912494|Experimental|JR-131|
88995613|NCT02912494|Active Comparator|Darbepoetin alfa|
88995614|NCT02912221|No Intervention|Control|Participants will be reimbursed for participation in the study but will not receive other encouragements for meeting fitbit and step count goals
88995615|NCT02912221|Active Comparator|Incentive|An incentive will be used for this arm to encourage participants to meet their step goals
88995616|NCT02912260|Experimental|MGL-3196|Study Drug
88995617|NCT02912260|Placebo Comparator|Placebo|Matching Placebo
88995618|NCT02912533|Experimental|JR-131|
89670485|NCT04794504|Experimental|Botox Injection Group|Two weeks pre-operatively, patients in the Botox injection group will receive intramuscular injections of Botox totaling 100U bilaterally (50U/side). 10 U will be injected into the temporalis (over 5 sites) and 40 U will be injected into the masseter muscle (over 4 sites). Botox will be reconstituted from a powdered form in 2cc of 0.9% sterile saline, and appropriate volumes will be administered.
89670486|NCT04794504|Placebo Comparator|Saline Injection Group|Two weeks pre-operatively, patients in the saline injection group will receive intramuscular injections of Botox totaling the same volumes administered for Botox patients above, across the same number of sites in the temporalis and masseter muscles bilaterally.
89670487|NCT03005223|Experimental|Study effect of DWC20163 on DWC20155/DWC20156 PK|To study effect of DWC20163 on DWC20155/DWC20156 PK
89670488|NCT03005223|Experimental|Study effect of DWC20155/DWC20156 on DWC20163 PK|To study effect of DWC20155/DWC20156 on DWC20163 PK
89670489|NCT02591238|Placebo Comparator|non-smoker + placebo|non-smoker oral placebo
89670490|NCT02591238|Active Comparator|non-smoker + melatonin|non-smoker oral melatonin
89670491|NCT02591238|Placebo Comparator|smoker + placebo|smoker oral placebo
89670492|NCT02591238|Active Comparator|smoker + melatonin|smoker oral melatonin
89670493|NCT04794114|Experimental|orthosis in hemiplegia|
89670494|NCT02997579|Experimental|patellar resurfacing|patellar resurfacing TKA
89670495|NCT02997579|No Intervention|patellar non-resurfacing|patellar non-resurfacing TKA
89670496|NCT04813302|Experimental|Gingival recession treatment|Gingival recession treatment by means of a coronally advanced flap and a connective tissue graft
89670497|NCT04813146|Experimental|Synchronized Lifestyle Modification Program (SLP)|Synchronized Lifestyle Modification Program ( Synchronization of dietary intake with the natural circadian rhythm of the body)
89670498|NCT04813146|Experimental|Synchronized Lifestyle Modification Program along with Physiotherapy|Synchronized Lifestyle Modification Program along with Physiotherapy (Synchronization of dietary intake and Physiotherapy including aerobic, resistance, flexibility and balance exercises)
89670499|NCT04813146|Experimental|Physiotherapy|Physiotherapy (aerobics, resistance, flexibility and balance exercises)
89049250|NCT00557739|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
89049251|NCT00557739|Active Comparator|3|0.1% mometasone furoate
89049252|NCT00557739|Active Comparator|4|0.05% nortriptyline HCl
89049253|NCT00557739|Active Comparator|5|0.1% nortriptyline HCl
89049254|NCT00557739|Placebo Comparator|6|Vehicle (placebo)
89049255|NCT02904122|Other|Teleconsultation|Teleconsultation using a specific camera SoproCare®6
89049256|NCT02904317||Misprostol vaginal insert for labour induction|69 patients matching the inclusion criteria and received MVI for labour induction
89049257|NCT02904317||Oral misoprostol for labour induction|69 patients matching the inclusion criteria and received OM for labour induction
89049258|NCT00557778||1|Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
89049259|NCT00557778||Group 2|Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
89049260|NCT02903888||BAY86-5028|Women aged 18 to 29 years that use Jaydess for contraception
89049261|NCT02903927|Experimental|CT LUCIA|
89049262|NCT02903927|Active Comparator|Acrysof IQ Sn60WF|
89049263|NCT04624542||group 1|Thirty individuals diagnosed with unilateral chronic PFPS from both genders and age between 18-35 years who will be referred from an orthopedic surgeon.
89049264|NCT04624542||control group|-30 healthy active individuals ranging from 18-36 yrs as a controlled group
89049265|NCT02904083|Experimental|specific training of professionals|patients from centers where professionals have received specific training
89049266|NCT02904083|Active Comparator|control training of professionals|patients from centers where professionals have received control training
89049267|NCT02904044||Injured/Case|Secondary school pupil injured during a physical activity lesson between 2012-2014 in south of Reunion Island
89049268|NCT02904044||Control|Same age and gender than case in the same classroom and during the same physical activity lesson
89049269|NCT04653168|Experimental|LY3041658 Low Dose|LY3041658 administered by subcutaneous (SC) injection.
89049270|NCT04653168|Experimental|LY3041658 High Dose|LY3041658 administered by SC injection.
89670500|NCT04813146|No Intervention|Control Group|No Intervention will be given to this group ( conventional medicine will be given to these patient )
89670501|NCT02221947|Active Comparator|Bryostatin 1|single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
89670502|NCT02221947|Placebo Comparator|placebo|single dose of placebo, intravenous infusion over 1 hour
89670503|NCT04802460|Experimental|virtual reality|Patients assigned to the VR group will be engaged with the VR using a publicly available VR set. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
89670504|NCT04802460|No Intervention|control arm|Patients in the control arm will undergo standard of care office hysteroscopy. Both study groups will be directed to take 800mg ibuprofen 1 hour prior to scheduled surgery as standard pain management in our office.
89670505|NCT03005301|Experimental|Experimental group|Selected acupoints will be stimulated by the new intelligent electro-acupuncture instrument.
89670506|NCT03005301|Active Comparator|Control group|Selected acupoints will be stimulated by the Hwato electroacupuncture instrument.
89670507|NCT04427436||Patients|Mild Cognitive Impairment (clinical determination)
89670508|NCT04427436||Control|Healthy Elderly
89670509|NCT03004989||Programme 1|RTW group in day clinics
89670510|NCT03004989||Programme 2|RTW group in day clinics for people with fibromyalgia
89670511|NCT03004989||Programme 3|My work and I
89670512|NCT04347018|Experimental|BRIUS|BRIUS orthodontic appliance (wire) will be used to treat the patients. BRIUS appliance will be engaged to regular orthodontic brackets intra-orally to initiate orthodontic treatment at the University at Buffalo Orthodontic Clinic.
89670513|NCT04347018|Active Comparator|Preadjusted edgewise full fixed appliance|regular full fixed orthodontic appliance (FFA) appliances will be used to treat patients. These are regular orthodontic brackets with standard orthodontic wires used to treat patients at the University at Buffalo Department of Orthodontics
89670514|NCT05672745|Experimental|WB-LIFE|
89670515|NCT04427514|Experimental|CAPD group|Standard CAPD therapy wtih telemedicine system
89670516|NCT04793256|Experimental|intervention|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride). Group (1)
89670517|NCT04793256|Active Comparator|comparator|Resin based fissure sealant (3M Clinpro Sealant, light cure, low viscosity, fluoride release).group (2)
89670518|NCT01322646|Active Comparator|Driver Training|Driver Education Program Practice driving on a driving simulator Provision of the CarChipPro to the family
89670519|NCT01322646|Experimental|STEER Program|Driver Education STEER Program
89670520|NCT02247921|Experimental|Rehabilitation|nurse-led caregiver-delivered rehabilitation
89670521|NCT02247921|No Intervention|Usual care|The patients in the control arm will receive conventional care in terms of access to rehabilitation in hospital, timeliness of discharge and follow-up, without any explicit provision of caregiver training or accelerated discharge.
89670522|NCT04813224|Experimental|TRAUMA CENTERED EMDR-BASED TREATMENT|"Phase 1) Client history before session 1 Phase 2) Preparation for the treatment of the traumatic event, with psycho education and regulation strategies.~Phases 3 to 6) Gives the sense of Safety (safe place, past resource, desired future-PC, timeline) control structure, order, differentiation of past & present (move concretely between past danger to present safety) EMD strategy gives containment boundaries to current T-Episode.~Phase 7) Session closure A group debriefing of the experience will take place, and some of the stabilization exercises Phase 8) Re-Evaluation This phase will take place immediately after the group intervention. It assesses which participants may need individual attention and which may need further evaluation to identify the nature and extent of their symptoms."
89670523|NCT04813224|Active Comparator|TRAUMA-FOCUSED CBT-BASED TREATMENT|TF-CBT is an evidence-based therapeutic approach to improve symptoms of PTSD as well as affective or cognitive and behavioral problems. The treatment will consist of three phases that will include: Psychoeducation, Relaxation-Mindfulness, Emotional regulation skills, Cognitive coping skills, Narration and processing of trauma, Exposure / Desensitization of memories of the trauma, Self-esteem and future goals. The treatment is composed by 3 phases: 1) Phase 1: TF-CBT Coping Skills for Complex Traumas. Phase 2: Narration of trauma and processing of complicated trauma. Phase 3: Consolidation and closure of the treatment. Each case is delivered to the participants in a maximum of 3 sessions per phase.
89670524|NCT04945161|Experimental|Arm A: N = 6 ON101 plus SoC|"Twelve (12) eligible subjects with DFUs will be enrolled. These 12 subjects will be randomly assigned to receive either ON101 treatment plus SoC (Arm A) or Placebo plus SoC (Arm B) for six weeks. Treatment arm allocation will be done through randomization in a double-blind fashion.~SoC will be provided from screening to the end of treatment. The SoC includes evaluation to ensure adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment via regular changing of dressings, and management of infection through oral antibiotics, if necessary."
89670525|NCT04945161|Placebo Comparator|Arm B: N = 6 Placebo plus SoC|"Twelve (12) eligible subjects with DFUs will be enrolled. These 12 subjects will be randomly assigned to receive either ON101 treatment plus SoC (Arm A) or Placebo plus SoC (Arm B) for six weeks. Treatment arm allocation will be done through randomization in a double-blind fashion.~SoC will be provided from screening to the end of treatment. The SoC includes evaluation to ensure adequate arterial flow, wound cleaning, removal of necrotic, infected and/or nonviable tissue by debridement, maintenance of moist wound environment via regular changing of dressings, and management of infection through oral antibiotics, if necessary."
89670526|NCT02247999||Cohort|HIV-infected women attending HIV care and treatment clinics in Pune, Chennai, andBelgaum in India.
89670527|NCT04793178|Active Comparator|Oxygen Reserve Index Blinded Group|Aneshesist will be blinded for oxygen reserve index monitoring (ORI, Masimo Corporation), but he will be allowed to use pulse oxymetry and end-tidal carbon dioxide monitoring to manage the respiratory conditions and depth of sedation.
89049271|NCT04653090||Varus group|Radiographic stem axis was assessed on standard anteroposterior hip radiographs performed at the 3-month follow-up visit. Alignment was evaluated as described by Reina et al., by the angular deviation of the anatomic femoral axis and the stem axis. The 3 degrees minimal-value was considered to be the threshold defining a varus stem.
89049272|NCT04653090||Neutral group|Alignment between anatomic femoral axis ans stem axis was less than 3°.
89670528|NCT04793178|Experimental|Oxygen Reserve Index Group|Aneshesist will be allowed to use pulse oxymetry, end-tidal carbon dioxide and oxygen reserve index (ORI) monitoring. He will manage the depth of sedation, respiaratory conditions.
89670529|NCT05672433|Active Comparator|Cafestol|Participants in this arm ingest 6 mg cafestol capsules twice daily with breakfast and dinner.
89049273|NCT04653012|Experimental|Macro-microelectrode implantation|Implantation of macro-micro electrodes of the Adtech Benkhe-Fried type in epileptic patients who are undergoing evaluation with intracranial EEG electrodes
89049274|NCT02903849|Experimental|Control|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will receive standard reminders generated by Wellness Connection.
89049275|NCT02903849|Experimental|Treatment|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will see the motivating messages they wrote at the beginning of the Challenge, in addition to Wellness Connection's standard reminders.
89049276|NCT04653129|Experimental|Group (A): Primary nerve repair with autologous fat graft|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope with autologous fat grafting around site of repair
89049277|NCT04653129|Active Comparator|Group (B): Standard primary nerve repair|Standard nerve repair will be performed with 9/0 nylon sutures, under magnification by an operating microscope without fat grafting.
89049278|NCT04681547|Experimental|Genicular nerve block|An ultrasound-assisted genicular nerve block will be performed. 4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves.
89049279|NCT04681547|Active Comparator|Local infiltration Analgesia|Administration of ropivacaine 0.2% 150 ml will be performed.
89670530|NCT05672433|Placebo Comparator|Placebo|Participants in this arm ingest placebo capsules twice daily with breakfast and dinner.
89049280|NCT04624464||Cohort 1: VRE negative at admission|"150 patients meeting the following inclusion criteria:~≥ 18 years~Patients with malignant primary disease and current inpatient admission to a normal ward with expected inpatient stay of at least 15 days~High risk of exposure to antibiotics during the stay~Written informed consent of the patient after clarification has been given~Exclusion criteria:~Already known current or documented past colonisation or infection by VRE~Simultaneous participation in other studies is only an exclusion criterion if the other study explicitly excludes participation in observational studies or if the other study complicates the interpretation of the endpoints of AEGON (e.g. double-blind study on antibiotic use)."
89670531|NCT04801836|Experimental|Treatment Arm|Subjects will receive 15 mg E4 orally once daily for 21 consecutive days
89049281|NCT04624464||Cohort 2: VRE positive at admission|"A total 20 known VREf-positive patients meeting the following inclusion criteria:~Intestinal VREf colonization already known at the time of admission (e.g. based on examinations during previous stays or in external facilities)~Accommodation in a single room or alternatively multi-bed room with single occupancy on standard wards~Expected stay of at least 7 days"
89049282|NCT04681391||anodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During anodal tDCS, the anode was placed over right temporoparietal junction, and the cathode was placed over left supraorbital area.
89049283|NCT04681391||cathodal|For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. During cathodal tDCS, the cathode was placed over right temporoparietal junction, and the anode was placed over left supraorbital area.
89670532|NCT04801836|Placebo Comparator|Placebo Arm|Subjects will receive matching placebo orally once daily for 21 consecutive days.
89670533|NCT02997189|Active Comparator|OTO-104|One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
89670534|NCT02997189|No Intervention|Control|The ear not receiving OTO-104 will receive no treatment
89670535|NCT04812990||hepatitis c patients|50 patients will be recruited for study group from consecutive patients previously diagnosed by hepatitis C regardless of the etiology of the condition and regularly attending at Soad Kafay hospital. Participants with history of smoking and alcoholism that could affect their oral health status were excluded.
89670536|NCT04812990||clinically healthy patients|populations will be randomly recruited from the out-patient of dental diagnosis clinic in Misr University For science & technology university to include total 50 clinically healthy participants, with no history of liver disease, or any other chronic debilitating illness, or habit of smoking or drinking, , as well as history of an intervention or condition that could affect the oral mucosa (e.g., history of radiotherapy and/or not receiving any medication that could affect oral health.
89670537|NCT05672277|Experimental|Group 1|Group 1 will be applied TENS three days per week
89670538|NCT05672277|Active Comparator|Group 2|Group 2 will be applied TENS one day per week
89670539|NCT04801914||Matrix Metalloproteinases|Value of serum matrix metalloproteinase activity before and one month after PTBD
89670540|NCT02222181|Experimental|Pharmacotherapy follow-up|patients with Alzheimer's disease
89670541|NCT04812756|Experimental|Texting intervention|This is a single arm study in which all participants received a pedometer and text messages for the 12 week intervention period. Participants received a content message and a message requesting them to report the number of steps from their pedometer daily.
89670542|NCT04801992||MINI WELL Ready (SIFI SpA, Italy)|Extended depth of focus intraocular lens implantation
89670543|NCT03004677|Experimental|Continuous skin-to-skin contact|Infants assigned to SSC will rest skin-to-skin on parents' chest 24 hours a day for four days alternating between the parents.
89670544|NCT03004677|Active Comparator|Standard Care|Infants and parents will receive standard care provided in the NICU
89670545|NCT04812600||Cardiac Rehabilitation|Individuals assigned to phase II (outpatient) cardiac rehabilitation program will undergo their normal exercise routines while the investigators make the measurements pre and post exercise at 0 week, and following 1 and 4 weeks of exercise.
89670546|NCT03004521|Active Comparator|Lithium|Lithium will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
89670547|NCT03004521|Experimental|Quetiapine|Quetiapine will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
89670548|NCT04792944||No treatment|Those are the patients that do not receive any treatment for the aneurysm, neither endovascular nor surgical
89670549|NCT04792944||External ventricular drain only with neither embolization nor clipping|These patients will be treated with an external ventricular drain only with neither embolization nor clipping
89670550|NCT04792944||Embolization|These patients will be treated endovascularly
89670551|NCT04792944||Programmed surgical clipping|These patients will be treated no on an emergency basis with surgical clipping of an aneurysm that has bled
89670552|NCT04792944||Emergency surgical clipping with cisternal urokinase administration|These patients with undergo emergency surgical clipping with cisternal urokinase administration
89670553|NCT04792944||Patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping|This group will include patients with incidental brain aneurysm discovery with no SAH and programmed aneurysm clipping
89670554|NCT02248077|Active Comparator|AutoloGel|AutoloGel consists of platelet-rich plasma (PRP) gel produced from the patient's own peripheral blood and pharmaceutical additives including calcium chloride, thrombin and ascorbic acid. The AutoloGel product is obtained by processing the patient's own blood using the AutoloGel System. After the final AutoloGel formulation is produced it is used immediately for patient's specific ulcer care.
89670555|NCT02248077|Other|Usual and Customary Care (UCC)|Standard of care
89670556|NCT05616936|Experimental|Group I|Intervention side: application of i-PRF with distalization of maxillary first molar that will be performed on intervention sides according to a standardized protocol.
89670557|NCT05616936|No Intervention|Group II|Control side: distalization of maxillary first molar that will be performed without any intervention
89670558|NCT05616936|Experimental|Group A|levelling and alignment assisted with Injectable Platelet-rich fibrin (i-PRF) according to a standardized protocol.
89670559|NCT05616936|No Intervention|Group B|leveling and alignment will be commenced without Injection of Injectable platelet-rich fibrin (i-PRF)
89670560|NCT05616936|Experimental|Group a|Will includes 9 patients who will receive intrusive arch after leveling and alignment assisted Injectable Platelet-rich fibrin (i-PRF) according to a standardized protocol.
89670561|NCT05616936|No Intervention|Group b|Will includes 9 patients who will receive intrusive utility arches after leveling and alignment without Injection of Injectable platelet-rich fibrin (i-PRF)
89670562|NCT05671809||NCRT with surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is NCRT with surgery.
89670563|NCT05671809||NCT with surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is NCT with surgery.
89670564|NCT05671809||surgery|Rectal cancer patients who will undergo sphincter-preserving therapy, that is surgery.
89670565|NCT04792710|Experimental|Intervention arm|This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose
89670566|NCT04792710|Placebo Comparator|Control arm|This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose
89670567|NCT04792632||Intervention|Intervention is the use of Veye Lung Nodules during the reading of the CT scans
89670568|NCT02995629|Experimental|green (532 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
89670569|NCT02995629|Experimental|yellow (577 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
89670570|NCT04792398|Experimental|Sleep Bruxism Subjects|"Ultrasound guided BTX-A injection: 25 units (divided in two injections) in each masseter muscle.~One-time intervention. Effect observation by measuring various biosignals (EMG, EOG, EEG), bite force, chewing efficiency, psychometric assessments."
89670571|NCT05671731|Experimental|Intervention|"The intervention group received Beneo Synergy 1 - 4gm twice/school day in 4 ounces orange juice with calcium for 12 weeks. We started with 1gm then increased the next day by a gram to reach the 4gm dose.~Intervention group participants completed Project FUN (8 module online nutrition and physical activity program) individually (password protected) in the school computer lab along with a workbook also used to check intervention completion."
89670572|NCT05671731|No Intervention|Control|The control group participated in usual school activities only completing pre and post measures.
89670573|NCT04792242|Active Comparator|goal directed therapy|svo2,haematocrite value,urine output,mean arterial pressure and central venous pressure
89670574|NCT04792242|Active Comparator|PCO2 gap algorithm|PCO2 gap,haematocrite value,Spo2,cardiac index
89670575|NCT04792476|Active Comparator|Active Comparator: Experimental group|The experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
88995619|NCT02912299||Septic patients|Patients admitted to the ICU that fulfill the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
88995620|NCT02912299||CABG patients|Patients admitted to the ICU after coronary artery bypass grafting. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
88995621|NCT02912299||Patients before hip replacement|Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
88995622|NCT02912338|Experimental|Resistant Training Group|sandbag 2-5lb, grip ball, twice/week, Duration:12 weeks
88995623|NCT02912338|Active Comparator|Control Group|not change lifestyle
88995624|NCT02912182|Placebo Comparator|Placebo|Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
88995625|NCT02912182|Active Comparator|Short treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
88995626|NCT02912182|Active Comparator|Standard treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg
88995627|NCT02912026|Experimental|Intravenous|Intravenous AUC0-infinity
88995628|NCT02912026|Experimental|Oral|Oral AUC0-infinity
88995629|NCT02911987|Experimental|the 'cardio' HIT group|Group 1 receives HIT exercise, aimed only at improving cardiovascular endurance (the 'cardio' HIT group).
88995630|NCT02911987|Experimental|the 'general' HIT group|Group 2 receives HIT exercise aimed at improving both cardiovascular and general muscle condition (the 'general' HIT group ).
88995631|NCT02911987|Experimental|the 'lumbar' HIT group|Group 3 receives HIT exercise, aimed at improving both cardiovascular condition and specific trunk muscle condition (the 'lumbar' HIT group).
89670576|NCT04792476|No Intervention|No Intervention: Control group|"The control group will only receive the conventional treatment offered in the clinical program. For 12 weeks, parients will attend 8 visits with mental health specialist nurse, where they will receive information, oral and written, to comply with the recommendations for physical exercise: 150-300 min/week of moderate physical activity or 75-150 min/week of vigorous physical activity.~In both groups (experimental and control), patients will be informed of the risk of weight gain, and they will be advised, regardless of the group assigned, to watch their diet and increase physical exercise until they meet the weekly recommendations."
89670577|NCT03004209|Other|EPO|Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
89670578|NCT04801134|Other|Food insecurity|Food insecure families will be assigned education and community resources needed.
89670579|NCT05668065|Experimental|CoronaVac/CoronaVac|Biological: Coronavac Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
89670580|NCT05668065|Active Comparator|CoronaVac/BNT162b2|"Biological: CoronaVac/BNT162b2 First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2."
89670581|NCT03422653|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
89670582|NCT03422653|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
89670583|NCT04800978|Experimental|BVAC-C+Durvalumab|"• Part A: The primary objective of the part A is to assess the maximum tolerable dose of BVAC-C combined with durvalumab 1500 mg as defined by dose-limiting toxicities (DLTs), and to find the maximum tolerated dose (MTD) that can be safely used for Part B (single arm phase II).~• Part B: The primary objective of the part B is to evaluate the safety and clinical efficacy, as measured by 6-month PFS rate, of the combination therapy of durvalumab and BVAC-C in patients with HPV 16 or 18 positive cervical cancer recurrent after or refractory to first-line platinum-based chemotherapy +/-bevacizumab."
89670584|NCT03004599|Other|Transcatheter Aortic Valve Implantation (TAVI)|
89670585|NCT05615766|Experimental|Device Intervention|The intervention group who will be undergoing rehabilitation using the robotic exoskeleton in addition to the assigned traditional rehabilitation programme on their dominant arm only.
89670586|NCT05615766|No Intervention|Control|the matched control group will be the same subjects undergoing traditional rehabilitation only on their non-dominant arm.
89670587|NCT02222337|Active Comparator|Nueva Vida Intervention|Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
89670588|NCT02222337|No Intervention|Usual Care|Usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family therapy.
89670589|NCT02092987|Experimental|NYU Caregiver Intervention|The New York University (NYU) caregiver intervention arm received the NYU caregiver intervention in addition to social work support and educational materials.
89670590|NCT02092987|Active Comparator|REACH OUT|The Resources for Enhancing Caregiver Health Offering Useful Treatments (REACH OUT) intervention arm received the REACH OUT caregiver intervention in addition to social work support and educational materials.
88995632|NCT02911987|Experimental|the 'combined' HIT group|Group 4 receives HIT exercise which is a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'combined' HIT group). These trainings will take place in the REVAL Rehabilitation Research Center on the campus of Hasselt University in Diepenbeek.
88995633|NCT02911987|Active Comparator|control group|Group 5 receives MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group)
88995634|NCT02911870|Experimental|Part A, SNAC|Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.
88995635|NCT02911870|Placebo Comparator|Part A, placebo|Single dose at corresponding dose levels.
88995636|NCT02911870|Experimental|Part B, SNAC, Placebo, Moxifloxacin|Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.
88995637|NCT02892214||Hypertonic pelvic muscle dysfunction|In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
88995638|NCT02892214||Hormonally mediated PVD|The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
88995639|NCT02892214||Neuroproliferative PVD|In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.
88995640|NCT02872402|Experimental|Intervention group|"At 2-mo postpartum, women will start the 1-yr lifestyle intervention that will consist of 7 face-to-face individual sessions of 1-hr (at 2, 3, 4, 5, 6, 9, 12 mo postpartum and a follow-up at 18 mo). Metabolic and anthropometric measurements will be assessed at 2,6,12 and 18 mo postpartum. In addition, 7 individual sessions of 30 min between face-to-face sessions will be carried out on the phone.~Benefits of exclusive breastfeeding, healthy eating and physical activity will be portrayed at each visit ."
88995641|NCT02872402|Active Comparator|Active control lifestyle intervention|Women in the control group will come to the testing unit at 2, 6, 12 and 18 mo postpartum for metabolic and anthropometric measurements and at 3, 4, 5, 9 mo for weight measurements only. They will receive standard lifestyle recommendations in the form of written information at each visit.
88995642|NCT02843230||Avastin Combine with MRI, DSC and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
89670591|NCT04791774|Active Comparator|Protein group|Patients receive 20 grams of Intrinsically labelled milk protein.
89670592|NCT04791774|Experimental|Free amino acid group|Patients receive 20 grams of free amino acids equivalent to the milk protein labelled with 13C-Phenylalanine
89670593|NCT00183469|Active Comparator|lamotrigine plus divalproex ER|Participants will take active lamotrigine and active divalproex ER
89670594|NCT00183469|Placebo Comparator|lamotrigine plus placebo divalproex ER|Participants will take active lamotrigine and placebo
89670595|NCT04791618|Active Comparator|Health360x only (High tech)|"Access to Health360x technology only for 6 months Behavioral: Health360x Participants will receive Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self- management skills. Every participant will view an orientation video which will include information on how to access Health360 from home and other internet connected devices; how to use activity monitors provided by the study and sphygmomanometer. They will receive an introduction to heart health curriculum, quizzes and discussion forums. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the Helath360x application will be available online and by phone.~The Health360x application will send messages to participants in this arm reminding them to perform study related activities."
89670596|NCT04791618|Experimental|Health360x plus Coach (High tech High touch)|"Health360x technology plus health coach Behavioral: Health360x plus health coach Participants will receive all of the resources in Arm A and Health coach interactions.~The Health coach will send messages to participants in this arm reminding them to perform study related activities. The coach interactions will be focused on helping with attainment of self- management behaviors"
89049284|NCT04681391||sham (as a control condition)|same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds.
89670597|NCT02248155||RLS patients|
89670598|NCT03003819|Active Comparator|Control Collagen Wound Dressing|Bovine collagen sponge used to control bleeding, stabilize blood clots and protect dental wounds
89670599|NCT03003819|Active Comparator|Test Collagen Matrix|Bilayer, porcine collagen matrix for soft tissue regeneration used as a socket seal in extraction socket grafting
89670600|NCT02597946|Experimental|all patients|Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.
89670601|NCT05655585|Experimental|Active Release Technique|Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
89049285|NCT04652817|Experimental|MMI-22-04-2019|Sodium hyaluronate at a concentration of 2.5% (25 mg/ml) with 1,4-Butanediol diglycidyl ether (BDDE) acting as a cross-linking agent administered once or twice depending on the individual necessity.
89049286|NCT04681586|Experimental|Bright white light|
89049287|NCT04681586|Placebo Comparator|Dim red light|
89670602|NCT05655585|Experimental|Mulligan Bent Leg Raise|Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
89670603|NCT02995941||Raters|No interventions will be administered. Raters will be state licensed as physical therapists working as outpatient physical therapists in the St. Luke's University Health Network.
89670604|NCT02995941||Patients|No interventions will be administered as a component of this study. Patients will be recruited from a convenience sample of consecutive patients presenting for physical therapy consultation for shoulder pain.
89670605|NCT04812132|Active Comparator|Women|
89670606|NCT04812132|Active Comparator|Men|
89670607|NCT04800432|Experimental|Feasibility and acceptability of ADAPT+|ADAPT+ is a family-based obesity intervention for high-risk Latino youth and their parents living in rural communities that incorporates culture-specific components and mindfulness-based approaches to promote adaptive health behaviors in a high-risk and underserved population.
89670608|NCT04800432|Active Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) provides publicly available material in both English and Spanish on the role of diet and exercise in pediatric obesity in a one-time information session.
89670609|NCT03003975|Active Comparator|PVI by single cryoballoon application|"A single cryoballoon application for pulmonary vein isolation will be guided by a Multipolar Recording Catheter (Achieve Mapping Catheter), passed through the inner lumen of the cryoablation catheter. A single application of 4 minutes will be used per vein guided by recording of loss of electrograms and by a defined drop of temperature within 2 minutes application. If a stable position with adequate occlusion of the vein the Achieve catheter should be located proximally for evaluation of entrance block during application, but can be advanced deeper for stability and then retracted to the ostium to evaluate vein isolation (entrance block).~If the vein then is isolated after a single application, the operator can move on to the next vein."
89049288|NCT04624269|Experimental|Hydroxychloroquine sulfate Tablets|drug:Hydroxychloroquine sulfate Tablets,0.1mg bid po
89049289|NCT04624269|Placebo Comparator|placebo|drug:placebo,0.1mg bid po
89049290|NCT02903810|Experimental|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
89049291|NCT04652739|Experimental|Lycopene|
89049292|NCT04652739|Active Comparator|Corticosteroids|
89049293|NCT02904005|Other|Depressed patients|Depressed patients with a recent suicide attempt or without any personal history of suicide attempt
89049294|NCT02903498|Experimental|UFT treatment|Uracil and Tegafur
89049295|NCT02903498|No Intervention|comparator|no treatment, follow-up at regular time
89049296|NCT04624347|Experimental|Acess to Videos and Movement curves|with caregivers' access to videos and movement curves (4 days)
88995643|NCT02843230||Avastin and Temozolomide Combine with DSC, MRI and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Temozolomide treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
88995644|NCT02843230||Avastin and Lomustine Combine with MRI, DSC, and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Lomustine treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 6 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
88995645|NCT02712814||Hormonally mediated PVD|"The entire vestibule is tender~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)"
88995646|NCT02712814||Congenital Neuroproliferative PVD|"The entire vestibule is tender~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule"
88995647|NCT02712814||Acquired neuroproliferative PVD|"The entire vestibule is tender~Secondary PVD, The pain had begun after a severe allergic reaction or vaginitis.~Normal appearing vestibule"
88995648|NCT02712814||Hypertonic pelvic muscle dysfunction|"The pain is at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule~Pelvic floor muscles are tight and tender~Primary or Secondary PVD"
88995649|NCT02712814||Neuroproliferative +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule~Pelvic floor muscles are tight and tender"
88995650|NCT02712814||Hormonally +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)~Pelvic floor muscles are tight and tender"
88995651|NCT02911636|Experimental|Arm 1|Pelvic SABR with intra-prostatic SABR
89670610|NCT03003975|Active Comparator|PVI by 2 cryo applications|Cryoballoon ablation with a conventional guidewire passed through the inner lumen of the catheter for stability will be used. Ablation will be performed with 2 consecutive applications for 4 minutes each in each vein guided by degree of occlusion and temperature drop at the discretion of the physician.
89670611|NCT02248233|Experimental|Saline + citicoline|The control group will receive physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days. Patients will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment.
89670612|NCT02248233|Experimental|Nimodipine|"The treatment group will receive 10 mg of nimodipine in 500 ml of physiological saline via intravenous drip, at a rate of 1-2 drops per minute initially, increasing gradually until systolic pressure decreases by 10 mmHg. Maximum drip speed is 10 drops/minute, administered once a day for 7 consecutive days. The nimodipine must be kept in the dark. Blood pressure and heart rate will be monitored throughout the administration period.~Patients in control group will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment."
89670613|NCT04349280|Experimental|Participants receiving bintrafusp alfa|Participants will receive bintrafusp alfa.
89670614|NCT04812054|Experimental|Hypothermic oxygenated machine perfusion|Allografts will be subject to end-ischemic hypothermic oxygenated perfusion at 12 degrees Celsius through both hepatic artery and portal vein after a period of simple cold storage at 4 degrees Celsius and immediately prior to implantation. The perfusion will last at least 2 hours and the period will be prolonged in case of ongoing hepatectomy, in order to perform graft implantation immediately after perfusion.
89670615|NCT04812054|Active Comparator|Simple cold storage|Allografts will be stored in perfusate at 4 degrees Celsius from the procurement until implantation.
89670616|NCT04577547|Experimental|Dietary Guidelines (DGA) diet with weight loss (WL) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with Physical Activity Guidelines for Americans (PAGA)-recommended exercise
89670617|NCT04577547|Experimental|DGA diet with WL & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with no exercise
89670618|NCT04577547|Experimental|DGA diet weight maintenance (WM) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with PAGA-recommended exercise
89670619|NCT04577547|Experimental|DGA diet WM & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with no exercise
89670620|NCT04577547|Experimental|Western diet with WL & exercise|Western-type menu to provide a calorie level to promote weight loss with PAGA-recommended exercise
89670621|NCT04577547|Experimental|Western diet with WL & no exercise|Western-type menu to provide a calorie level to promote weight loss with no exercise
89670622|NCT04577547|Experimental|Western diet WM exercise|Western-type menu to provide a calorie level to promote weight maintenance with PAGA-recommended exercise
89670623|NCT04577547|Experimental|Western diet WM no exercise|Western-type menu to provide a calorie level to promote weight maintenance with no exercise
89670624|NCT04811742|Experimental|immersion bathing group|Immersion bathing was started by placing the baby's whole body, except for the head and neck, into a bathtub of warm water with a depth of 13-14 cm. The baby was shampooed and cleaned in the tub. Then, the baby was taken out of the water and rinsed over the tub. Finally, the baby was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
89670625|NCT04811742|Experimental|showering group|Shower was started by keeping the baby's face down and firmly gripping the baby from his/her armpit and head by one of the nurse's hands. The baby was washed under running water with the other hand. The second nurse assisted to ensure the flow of water. After the baby was rinsed, he/she was wrapped with a towel, taken to the radiant and dried, thus the process of bathing was completed.
89670626|NCT03003897||Soluble Fiber Treatment|Participants receiving soluble fiber.
89670627|NCT03003897||Placebo Treatment|Participants receiving placebo.
89670628|NCT04800042|Other|Patients with scheduled major surgery|Patients with scheduled major surgery
89670629|NCT04800120|Active Comparator|Study Group|Identified COVID 19 patients receiving the intervention of Hyperbaric Oxygen Therapy
89670630|NCT04800120|No Intervention|Control Group|Historical control of COVID 19 patients who were previously treated and did not receiving Hyperbaric Oxygen Therapy
89670631|NCT04799730||SLE cases in remission|according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI <5
89670632|NCT04799730||SLE cases in activity|according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI ≥ 5
89670633|NCT04799730||Control group|Healthy age and sex matched subjects.
89670634|NCT03003663|Experimental|SensableCare System|Device:The interrupted time series design will alternate between the following on a monthly basis: (1) standard medical care and (2) standard medical care and the SensableCare System.
89670635|NCT04790838||Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
89670636|NCT04790838||Reference Product|ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK
89670637|NCT04791072|Experimental|Telecoaching group|They will be given breathing exercise training and will be asked to do it every day for 8 weeks. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. They will be called by phone once a week and encouraging speeches will be made.
89670638|NCT04791072|Active Comparator|Control Group|They will be given breathing exercise training and will be asked to do it every day. In addition to breathing exercises, the use of incentive spirometry and aerobic exercise training will be provided. They will be asked to do breathing exercises, use of incentive spirometry and strengthening exercises for at least 20 minutes every day and 5 times a week. There will be no interviews in the control group.
89670639|NCT03003273|Experimental|arm (A) - stoppage of antibiotics|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
89670640|NCT03003273|Active Comparator|arm (B) - oral antibiotics till ANC ≥ 500|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.
89670641|NCT04791150|Experimental|Patient with cancer immunotherapy treatment|All patients starting immunotherapy treatment will complete a questionnaire to identify rheumatological side effects, each time they come for treatment.
89670642|NCT04811586|Experimental|one-step Hybrid Coronary Revascularization (HCR)|One-step HCR is defined as off-pump MIDCAB LIMA-LAD revascularization immediately followed by PCI for at-least one non-LAD lesion(or LAD-diagonal lesion) with DES implantation in a hybrid operating room.
89670643|NCT04811586|Active Comparator|Percutaneous Coronary Intervention (PCI)|PCI will be performed using standard technique at the discretion of interventional cardiologist with DES implantation in a routine catheter lab.
89670644|NCT03003429|Experimental|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
89670645|NCT04790760|Experimental|Continuous Glucose Monitoring|Participants will wear a CGM device on the back of both their left and right arm for 6 weeks.
89670646|NCT05571345|Experimental|PF614 50 mg|PF614 50 mg capsule (1 x 50 mg capsule over-encapsulated and 1 x placebo to match PF614 capsule)
89670647|NCT05571345|Experimental|PF614 100 mg|PF614 100 mg capsule (1 x 100 mg capsule and 1 x placebo to match PF614 capsule)
89670648|NCT05571345|Experimental|PF614 200 mg|PF614 200 mg capsule (2 x 100 mg capsules)
89670649|NCT05571345|Active Comparator|Oxycodone IR 40 mg|Oxycodone HCl 40 mg (2 x 20 mg capsules over-encapsulated to match PF614 capsules).
89670650|NCT05571345|Placebo Comparator|Placebo|Placebo capsules to match PF614 (2 x placebo capsules)
89670651|NCT03003507|Active Comparator|Diet 1|Low-carbohydrate Enteral Formula With Fructose
89670652|NCT03003507|Active Comparator|Diet 2|Low-carbohydrate Enteral Formula Without Fructose
89670653|NCT03003351||Fistula|Patients with Fistulaê that are not caused by Crohn's disease
89670654|NCT03003351||Fistula and Crohn's disease|Patients with Fistulae that are caused by underlying Crohn's disease
89670655|NCT03003585|Active Comparator|Fiberoptic bronchoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
89670656|NCT03003585|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
89670657|NCT02597712|Experimental|Treatment|Patients will take 25 mg YF476 once daily for 12 weeks
89670658|NCT02597712|Placebo Comparator|YF476 Placebo|Patients will take matching placebo once daily for 12 weeks
89049297|NCT04624347|No Intervention|No Acess to Video and Movement curves|without caregivers' access to videos and movement (4 days)
89049298|NCT02903459||Males|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration, using perimetry; evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in males aged between 18 and 26.
89670659|NCT02248311||Patients/Control Group|Observational
89670660|NCT02248311||Patients/Group Control|Observational
89670661|NCT04799574|Experimental|music therapy activity|The music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle.
89670662|NCT04799574|Placebo Comparator|Health education lecture|routine activities of community
89670663|NCT02248389|Experimental|Ablation arm|Each person in study will receive ablation of their renal tumor followed by standard partial nephrectomy.
89670664|NCT02981121|No Intervention|Conventional Management|A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
89049299|NCT02903459||Young Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in young adults females aged between 18-26.
89049300|NCT02903459||Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in adult females aged between 40-60.
89670665|NCT02981121|Experimental|Life style modification|"Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit).~Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day)~Diet remedies: Train Calorie intake, nutrient intake and Monitoring."
89670666|NCT02981121|Active Comparator|Metformin|After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
89670667|NCT02597478|Experimental|Low-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
89670668|NCT02597478|Experimental|High-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
89670669|NCT04811274||Patients|Minor patients with alveolar proteinosis by mutations of the MARS gene.
89670670|NCT04811274||Controls|Minors patients without alveolar proteinosis.
89670671|NCT04799184|Experimental|Group I Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug/ml completing a volume of 20 ml."
89670672|NCT04799184|Active Comparator|Group II no Epi|"The ESP will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine completing a volume of 20 ml."
89670673|NCT02221557|Experimental|New alloplastic bone graft material|
89670674|NCT05562297|Experimental|sintilimab + nab-paclitaxel + gemcitabine|Experimental: sintilimab + nab-paclitaxel + gemcitabine nab-paclitaxel at 125 mg/m^2 on days 1, and 8; gemcitabine at 1000 mg/m^2 on days 1, and 8; sintilimab at 200mg on day 1;
89670675|NCT04790292|Active Comparator|group M|group M 10mg morphine +0.25% bupivacaine
89670676|NCT04790292|Active Comparator|group MD|group MD 10mg morphine + 8mg dexamethasone +0.25% bupivacaine
89670677|NCT03003195|Experimental|Vaccination: P10s-PADRE/MONTANIDE ISA 51 VG|100mL vaccination on Weeks 1, 2, 3 and 8
89670678|NCT04811430||Randomized Traditional|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
89670679|NCT04811430||Radomized Cue Needle Tracking technology|Randomized to traditional ultrasound guided peripheral insertion placement vs placement with Cue needle tracking technology
89670680|NCT02248467||eugonadal|50 eugonadal subjects
89670681|NCT02248467||untreated hypogonadal|25 asymptomatic hypogonadal subjects
89670682|NCT02248467||treated hypogonadal|25 symptomatic hypogonadal subjects treated - In the present study, we decided to monitor only sexual symptoms of androgen deficiency due to the fact that testosterone replacement therapy (TRT) should be expected to improve them in the time span until surgery. These patients will be treated with TRT as per clinical practice.
89670683|NCT04790136|Experimental|GLA-015|GLA-015 (Glatt Pharmaceutical Services GmbH & Co. KG, Germany); 5.051 g granules containing 1500 mg cannabidiol to be dispersed in water; oral multiple dose administration twice daily over 7 consecutive days after a light meal
89670684|NCT04790136|Active Comparator|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|"DAC C-052 Cannabidiol / NRF 22.10 Ölige Cannabidiol-Lösung 100 mg/ml (Oily cannabidiol solution 100 mg/ml) (Glatt Pharmaceutical Services GmbH & Co. KG, Germany; according to DAC/NRF specifications); 15 ml solution containing 1500 mg cannabidiol; oral multiple dose administration twice daily over 7 consecutive days after a light meal"
89670685|NCT02247609|Experimental|CAR T cells|Autologous 4th generation anti-CD19-CAR T cells
89670686|NCT05472597||nuMoM2b Heart Health Study Cohort|A large and diverse (both geographically and demographically) group of adult women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospective collected thereafter.
89670687|NCT04790214|Experimental|Stable CHF patients|Stable CHF patients on stage II/III based on the New York Heart Failure classification
89670688|NCT04789824|Experimental|Investigation group|Eye Hygiene (warm compress, eyelid massage, and eyelid cleaning)
89670689|NCT04789824|No Intervention|Control Group|No intervention
89670690|NCT04798404||Exercise Intervention in 20 collective sessions|104 elders recruited among the community (mean age: 82.1 ± 5.7, 72 women and 32 men), diagnosed in initial consultation with mobility disability risk (sedentary or/and pre-frail/frail or/and sarcopenia at least probable) who participated in 20 collective sessions twice a week and two hours per week, and have been seen for reassessment in final consultation.
89670691|NCT03003039|Experimental|GB241|GB241:375 mg/m2, iv, one infusion
89670692|NCT03003039|Active Comparator|Rituximab|Rituximab: 375 mg/m2, iv, one infusion
89670693|NCT04798560||Patients undergoing Whipple operation|After Whipple operation patients will be observed for complications and emphasis will be given on the presence of postoperative pancreatic fistula (POPF) according to the ISGPF 2016 definition. There will be to arms of patients. The first will include patients that do not develop POPF or either develop Biochemical Leak (Grade A). The second group consist of patients that develop either Grade B or Grade C POPF
89049301|NCT02903459||Females|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration using perimetry, evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in females aged between 18 and 26.
89049302|NCT04623957|Experimental|ForgTin|Patients randomized into group 1 will receive the ForgTin Medical Device for a duration of 3 months.
89049303|NCT04623957|No Intervention|No intervention|Patients randomized into group 2 will receive no device for a duration of 3 months.
89049304|NCT04652427|Experimental|Use Dexmedetomidine Hydrochloride to maintain a sedative|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
89670694|NCT05446233|Experimental|[14C] Antaitavir Hasophate|Eligible healthy male subjects received a single oral 100 mg (radioactivity of 200µCi) dose of [14C] Antaitavir Hasophate
89670695|NCT03002961|Experimental|Cohort 1|Subjects to receive low dose of RBP-6000 subcutaneously as a single injection
89670696|NCT03002961|Experimental|Cohort 2|Subjects to receive medium dose of RBP-6000 subcutaneously as a single injection
89670697|NCT03002961|Experimental|Cohort 3|Subjects to receive high dose of RBP-6000 subcutaneously as a single injection
89670698|NCT03002961|Experimental|Cohort 4|Subjects would receive medium dose RBP-6000 as a single injection after up to 12 mg daily dosing of sublingual (SL) suboxone tablets for 7 days
89670699|NCT04789512||Covid-19 players|Female volleyball players with Covid-19
89670700|NCT04789512||non-Covid-19 players|Female volleyball players with non Covid-19
89670701|NCT04810728|Experimental|Extract Psidii guava|2 Capsule of extract Psidii guava, three times daily
89670702|NCT04810728|Active Comparator|Standard therapy|Standard therapy for Covid-19 patient (vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
89670703|NCT04786938|Experimental|Saccharomyces boulardii|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34) plus S. boulardii CNCM I-745 (approximately 22.5 x109 CFU
89670704|NCT04786938|No Intervention|No intervention|Conventional treatment (amoxicillin 1 g three times a day, tinidazole 1g four times a day, and omeprazole 40mg twice a day; n=34)
89670705|NCT04214691|Experimental|Treatment Sequence 1: Reference Drug + Test Drug (RT)|Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.
89670706|NCT04214691|Experimental|Treatment Sequence 2: Test Drug + Reference Drug (TR)|Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8H ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.
89670707|NCT04786392|Active Comparator|Lutein supplement|"Supplement containing 5 mg powdered lutein, capsule filler microcrystalline cellulose.~To be administered once."
89670708|NCT04786392|Experimental|Blended food beverage|Blended food beverage containing 5 mg lutein from baby spinach. To be administered/consumed once.
89670709|NCT04786392|Experimental|Whole food|Consumption of 5 mg of lutein from baby spinach. To be administered/consumed once.
89670710|NCT04786314|Experimental|Hot Water Application Group|Pregnant women will apply hot water to their legs before going to sleep for a week, depending on the groups they are in.
89670711|NCT04786314|Experimental|Cold Water Application Group|Pregnant women will apply cold water to their legs before going to sleep for a week, depending on the groups they are in.
89670712|NCT04786314|No Intervention|Control Group|There will be no intervention other than routine follow-up and maintenance.
89670713|NCT03002883|Placebo Comparator|Usual Care|"Students referred to student health for tobacco cessation resources including campus Quit Kits"
89670714|NCT03002883|Active Comparator|Brief Motivational Interviewing|Students received brief motivational interviewing by a student peer educator about tobacco cessation
89670715|NCT03002883|Active Comparator|Direct referral to quitline|Students were directly referred to the state quitline for follow-up counseling
89670716|NCT04789356|Active Comparator|High-risk individuals (with comorbidities)|Public safety and security (police officers and law enforcement, fire department), and high school and college/university professionals of the state government public education network who present at least one of the comorbidities included in the National Plan for the Operationalization of Vaccination Against COVID-19 will be invited to receive the CoronaVac vaccine
89670717|NCT04789356|No Intervention|Low-risk individuals (without comorbidities)|Participants with low risk (without comorbidities as a risk factor for severe COVID-19 according to the national plan for the implementation of vaccination against COVID-19) will not receive the vaccine within the scope of the research project.
89670718|NCT03002493|Experimental|Eribulin mesylate + Rifampicin|
89670719|NCT04788810|Experimental|Oral route|Volunteers receiving d12-Cl2BPA via oral route
89670720|NCT04788810|Experimental|Dermal route|Volunteers receiving d12-Cl2BPA via oral route
89670721|NCT05340387|Experimental|Balance Resistance Aerobic Cognitive Exercises (BRACE)|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
89670722|NCT05340387|Active Comparator|Otago's Exercises|Otago's protocol is combination of warm up, strengthening, balance and flexibility exercises.
89670723|NCT04786470|Active Comparator|Local Anaesthetic Infusion|
89670724|NCT04786470|Sham Comparator|Saline Infusion|
89670725|NCT04785846||Single Group|Adult patients with coronary artery disease undergoing percutaneous coronary intervention on vessels with a diameter less than or equal to 2.5 mm.
89670726|NCT02219997|Experimental|ACRYSOF IQ IOL|ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
89670727|NCT02219997|Active Comparator|Clear IOL|Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
89670728|NCT04788732||1-Inhalation Anesthesia|patients in this group will be anesthetized only with an inhaled anesthetic ( Sevoflurane ).
89670729|NCT04788732||2-Total Intravenous Anesthesia|the patients in this group will be anesthetized with only intravenous drugs such as benzodiazepícos (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not to relaxing neuromuscular (nondepolarizing/depolarizing), and adjuvant drugs such as dextrocetamina, dexmedetomidine, lidocaine, and magnesium sulfate.
89670730|NCT04788732||3-Balanced anesthesia|the patients in this group will be anesthetized with blends of anesthetic inhaled (Sevoflurane) and intravenous drugs such as benzodiazepine (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not with neuromuscular relaxants (nonpolarizing/depolarizing) and adjuvant drugs such as dextrocetamine, dexmedetomidine, lidocaine, and magnesium sulfate.
89670731|NCT04809480||Non-COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from January 2017 up to February 2020
89670732|NCT04809480||COVID19 patients|All acute invasive fungal rhinosinusitis patients managed in our hospital from February 2020 up to December 2020 with positive COVID19 PCR test
89670733|NCT04788030||Digital nerve reconstruction with muscle-in-vein conduits|
89670734|NCT04787952||Group 1= healthy subjects|"Inclusion criteria to the group 1 (healthy males) N=20:~BMI <25 kg/m2;~RR<140/90mmHg;~age 21-43 years~fasting glycemia <100mg/dl; 2h-OGTT <140mg/dl;~no chronic disease"
89670735|NCT04787952||Group 2 = overweight/obese subjects|"Inclusion criteria to the group 2 ( overweight/obese males ) N=20:~Blood pressure < 140/90 mmHg (well controlled by inh ACE; no beta-blockers)~No chronic disease~BMI > 25 <35kg/m²~fasting glycemia <100mg/dl; 2h-OGTT <140mg/dl;~age 21-43 years"
89670736|NCT04785768|Experimental|PCA with continuous + bolus dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours;（2）PCA hydromorphone with continuous infusion where dose/h was the total equianalgesic over the previous 24h divided by 24 and bolus dosage for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h；lockout time = 10 minutes；（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
89670737|NCT04785768|Experimental|PCA with bolus-only dose|（1）Intravenous PCA with hydromorphone after successful titration of 24 hours; (2)PCA hydromorphone with bolus-only where dosage was 10%-20% of the total equianalgesic over the previous 24h administrated as needed;（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
89670738|NCT04785768|Active Comparator|Oral opioid|（1）Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours；(2)Oral sustained-released morphine where total equianalgesic over the previous 24h/2×75% every 12h/day and immediate-release morphine for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h； (3)Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；(4)The treatment regimen was continued for 7 days.
89670739|NCT02223351|Other|400mg ASP2151|400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir
89670740|NCT02223351|Other|1200mg ASP2151|1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir
89670741|NCT05615298||Cancer|"Negative image data: Has been interpreted as negative in screening mammograms~Benign image data: Has a suspicious lesion for breast cancer in screening mammograms but confirmed as a benign through the follow-up biopsy or has been interpreted as a benign in screening mammograms and confirmed as a benign in the further diagnostic images taken after at least two years from the screening mammograms."
89670742|NCT05615298||Non-cancer|Has a suspicious lesion for breast cancer in screening mammograms and confirmed as a cancer (malignant) through the follow-up biopsy.
89670743|NCT02223429|Experimental|OT + placebo|The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
89670744|NCT02223429|Experimental|AVP + placebo|The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
89670745|NCT04785612|Experimental|RSVPreF|A single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume
89670746|NCT04785612|Placebo Comparator|Placebo|A single intramuscular injection of Placebo to match active vaccine
89049305|NCT04652427|Placebo Comparator|Sedative were maintained with a 0.9% sodium chloride injection|Slow static injection at a load-loaded dose of 1.0/g/kg (half of the load dose in ophthalmology surgery), infusion time of 10 to 15 min, followed by the maintenance phase, maintenance dose set at an initial 0.6/g/kg/h, maintenance during administration The researchers, using the results of the OAA/S assessment, made a comprehensive judgment to adjust the infusion rate in the range of 0.2 to 1.0/g/kg/h to obtain the desired sedative effect, and anaesthetic can be performed when the study drug was given a duration of 15 minutes and the required sedative level was reached. Maintain the administration until the end of the operation.
89049306|NCT02903576|Active Comparator|injection of hESC-RPE in suspension|6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
89049307|NCT02903576|Active Comparator|injection hESC-RPE seeded in a substrate|15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
89049308|NCT04623918|Experimental|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
89049309|NCT04623918|Active Comparator|Control rice|Control rice (C4)
89049310|NCT04624308|Experimental|TPF inductive chemotherapy plus Toripalimab and radiotherapy plus Toripalimab|TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or >75%PR. If not, operation is suggested.
89049311|NCT04624425|Experimental|Segmental breathing exercises|Segmental breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
89049312|NCT04624425|Active Comparator|Buteyko breathing exercises|Buteyko breathing exercises, Treatment session will be last for 10-15 minutes. For 2 Weeks
89049313|NCT02903771|Experimental|Part A and Part B|"Part A (Dose Escalation):~Part A is a Dose Escalation study to determine the Maximum Tolerated Dose of Cantrixil as a monotherapy.~The tolerance of Cantrixil in combination with standard chemotherapy agents will also be examined.~Part B (Expansion Cohort):~An expansion cohort of an additional 12 patients will be recruited at the MTD."
89049314|NCT04623879||F508del homozygous adult CF patients|F508del homozygous adult CF patients who commenced treatment with LUM-IVA
89214760|NCT05955326|Placebo Comparator|Normal Saline (Dose: Equal volume) + Standard Treatment|A total of 80 patients will be enrolled in this arm. Three doses of an equal volume of normal saline will be administered as an IV bolus in each patient (randomly assigned to this group) over one minute at an interval of 3 ± 1 hours on day 1, day 3, and day 6. All patients will receive standard stroke treatment as provided by the specific hospital setup. Patients will be closely monitored for the qualifying stroke, followed for 3 months, and assessed for safety and efficacy parameters. Efforts will be made to administer the drug at the same time on days 1, 3, and 6.
89214761|NCT05948007|Experimental|Neurofeedback group|12 training sessions within 6 weeks, starting with FAA modulation followed by the frontal midline theta upregulations.
89214762|NCT05948007|Sham Comparator|Sham neurofeedback group|Same dosage as the neurofeedback group
89214763|NCT05948007|Active Comparator|Pain management protocol|The PMP includes cognitive behavioral therapy techniques, and pain neuroscience education.
89214764|NCT05948007|No Intervention|Care as usual|Providing medical care as they would normally receive, including a post-surgery exercise program.
89214765|NCT05941494|Experimental|Propofol-based anesthetic maintenance with phenylephrine used as the vasopressor|Propofol-based anesthetic maintenance with phenylephrine used as the vasopressor. Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min. Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
89214766|NCT05941494|Experimental|Propofol-based anesthetic maintenance with ephedrine used as the vasopressor|Propofol-based anesthetic maintenance with ephedrine used as the vasopressor. Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min. The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
89670747|NCT04788498|Experimental|Laparoendoscpoic single site surgery LESS|35 patients undergoing laparoscopic ovarian cystectomy A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
89670748|NCT04788498|Active Comparator|Conventional multiport laparoscopy|35 patients undergoing laparoscopic ovarian cystectomy It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
89670749|NCT03002337|Experimental|Aromatherapy massage|Ten aromatherapy group received 70 minutes of aromatherapy massage once biweekly by certified aromatherapy therapist for 20 weeks.
89670750|NCT03002337|Experimental|Yoga exercise|The yoga group participated in two weekly 70-minute yoga sessions led by a midwife certified as a yoga instructor for 20 weeks
89670751|NCT03002337|No Intervention|Control|the control group received only routine prenatal care.
89670752|NCT04787796|Experimental|The Self-built-in M-ECG recorders have passed the electrical.|We shall conduct this prospective clinical study to define the specific patterns of multichannel ECG change in adults with suspected CAD or ACS. For multichannel ECG (M-ECG) examination, the signal will be recorded with a Self-built-in ECG recorder.
89670753|NCT05316285|Experimental|Yoga Group|It will consist of students who choose the Yoga for a Healthy Life lesson. For 14 weeks, one day a week and 60 minutes a day, theoretical and practical yoga training will be applied.
89670754|NCT05316285|No Intervention|Control Group|The control group will consist of students who chose the Fashion and Beauty lesson.
89670755|NCT04341558|No Intervention|Baseline|During this baseline period, postoperative monitoring will be continued as normal by nursing and medical staff without intervention. No training of family members will take place
89670756|NCT04341558|Active Comparator|Intervention|Family carers will be trained to perform and document basic vital signs whilst they provide personal care to their relatives after surgery in order to supplement patient monitoring conducted by nursing staff.
89670757|NCT03002649|Experimental|Tofacitinib|All subjects will be provided Tofacitinib 11mg tablets for oral administration once daily. 12-week treatment period with optional 4-week treatment extension period.
89670758|NCT04787718|Experimental|Almond|Participants will consume 2.0 oz of raw, shelled, unsalted almonds.
89670759|NCT04787718|Active Comparator|Control group|an isocaloric (2.0 oz raw almonds) amount of unsalted pretzels daily.
89214767|NCT05941494|Experimental|Sevoflurane-based anesthetic maintenance with phenylephrine used as the vasopressor|"Sevoflurane-based anesthetic maintenance with phenylephrine used as the vasopressor.~Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery. Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml)."
89670760|NCT05280561|Experimental|DHM group|This arm is to evaluate DHM effects on the intervention of stress-induced insomnia during the pandemic. DHM granular preparation contains DHM 200 mg plus same excipients as placebo. The 244 participants were taken DHM granular preparation, which was dissolved in ~100 ml water for oral administration, once daily for 20 days.
89670761|NCT05280561|Placebo Comparator|Control group|The placebo contained excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
89670762|NCT04785222|Experimental|DB|Group DB: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
89670763|NCT04785222|Active Comparator|BP|Group BP: Bilateral infraorbital nerve block with 0.5% plain bupivacaine, a volume of 2 ml per side
89670764|NCT04785222|Placebo Comparator|NS|Group NS (control): Bilateral infraorbital nerve block with normal saline 2 ml per side
89670765|NCT04808856|Experimental|ACTH|Adrenocorticotropic Hormone
89670766|NCT04808856|Active Comparator|Methylprednisolone|Methylprednisolone
89049315|NCT04624035|Active Comparator|Implantable Collamer Lens (ICL, V4c with central hole) in treatment of myopia in adults.|Implantation of ICL (V4c with central hole) for treatment of myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the ICL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
89214768|NCT05941494|Experimental|Sevoflurane-based anesthetic maintenance with ephedrine used as the vasopressor|Sevoflurane-based anesthetic maintenance with ephedrine used as the vasopressor. Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery. The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
89214769|NCT05937893|Other|Alcohol consumer (AC) participants|Adult volunteers who are alcohol consumers drawn from both an outpatient population and recruited heavy drinkers from the community.
89214770|NCT05937893|Other|Healthy participants|Healthy adult volunteers who are not dependent on alcohol.
89214771|NCT05932238|Experimental|Systane Hydration Preservative Free (PF)|1-2 drops in each eye four times a day for 30 days
89214772|NCT05932238|Experimental|Systane Hydration Preserved|1-2 drops in each eye four times a day for 30 days
89670767|NCT04787406|Active Comparator|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
89670768|NCT04787406|Active Comparator|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
89670769|NCT04787406|Sham Comparator|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
89670770|NCT02221869|Experimental|Xyrem|Active Xyrem at a dose ≤9 g/night
89670771|NCT02221869|Placebo Comparator|Xyrem Placebo|Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
89670772|NCT04787016|Experimental|Pilate training|The participants of this group perform pilate training along with conventional cricket training.
89670773|NCT04787016|No Intervention|Conventional training|The participants perform only conventional cricket training.
89670774|NCT02247687|Other|Counseling arm|Counseling without antiretroviral treatment modification
89670775|NCT02247687|Active Comparator|Switch arm for protease inhibitor|Switch arm for protease inhibitor : intervention is the switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
89670776|NCT02247687|Active Comparator|Addition of Isentress® (raltegravir)|"Drug: Addition of Isentress® (raltegravir) arm~• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling"
89670777|NCT02248779||treated < 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
89670778|NCT02248779||treated ≥ 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
89670779|NCT02995863|Experimental|Experimental Group|Rigid rocker sole footwear
89670780|NCT02995863|Active Comparator|Control Group|Therapeutic footwear
89670781|NCT04784676|Experimental|nanohybrid composite blocks|nanohybrid composite CAD/CAM blocks
89670782|NCT04784676|Active Comparator|ceramic blocks|ceramic CAD/CAM blocks emax
89670783|NCT03002181|Experimental|PNE group|Pain neurophysiology education group.
89670784|NCT03002181|Experimental|Red Flag group|Red Flags education group.
89670785|NCT04869267|Experimental|ACT group|Participants in the intervention group will receive ACT intervention, consisting of four individual sessions (First session by face to face, the last three sessions by Wechat) of 60-90 min each (once/week), in addition to usual care.
89214773|NCT05931432|No Intervention|Usual Care|"Participants will be asked to complete an ICF and baseline survey at enrollment. They will be given survey assessments at 0, 18 and 30 months. Survey assessments will include validated measures on well-being, depression, anxiety, stress, resilience, and job satisfaction of physicians.~The control group will have access to usual care well-being resources at Penn Medicine. These include links, classes, groups, social media sites such as Penn Cobalt which require self-awareness to find the resources and access them. In this context, the individual has to pull the resources they need and there may be several barriers to completing each step"
89214774|NCT05931432|Experimental|Comprehensive Well-Being Intervention|"Participants will be asked to complete an ICF and baseline survey at enrollment. Participants will complete a full assessment using validated instruments at enrollment, 18 months and 30 months (depression, anxiety, stress, resilience, and job satisfaction). Participants will also complete the brief well-being index (WBI, nine questions) every 3 months over 30 months. The primary endpoint is assessed at 18 months. A secondary endpoint of persistence of effect is measured at 30 months.~The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions."
89214775|NCT05930730|Experimental|Comvigen (Bivalent, ChulaCov19 BNA159.2)|
89214776|NCT05930730|Active Comparator|BIVALENT Pfizer/BNT vaccine|
89214777|NCT05929482|Experimental|Infección de Amor (Infectious Love)|71 Latinas will view four IA intervention episodes, one per week immediately after the baseline survey and orientation. Participants will receive an email to their preferred email address with a password to access to the episode on the IA's website: www.telenoveladeamor.com Each 10-minute episode can be watched more than once during the week and presents a situation with notable HIV risk and ways the characters avoided risk (e.g., condom use) or confronted consequences of poor practices (e.g., HIV infection). The one week time frame for each episode is needed to provide time to review and reflect about IA's content and modify HIV prevention behaviors. It will also allow Latinas to obtain information and support from the team and referral if needed. This time frame was effective to improve behaviors in previous studies.
89214778|NCT05929482|Experimental|Wait-listed|A wait-listed control group of 71 Latinas will receive IA in the same manner as the intervention group. Latinas will start watching the telenovela episodes 7 months after their baseline survey (after T3 survey). Latinas will be informed at recruitment of this group condition and the study randomization. During the waiting time, participants will be called on a monthly basis to encourage participation and refer to services if needed.
89214779|NCT05928091|No Intervention|Control group|Doctors will manage bleeding as usual.
89214780|NCT05928091|Experimental|Experimental group|Investigators will call a phone number, and an expert will guide them to manage the bleeding.
89214781|NCT05926453||Maximal CPET|One maximal cardiopulmonary exercise test with simultaneous registration of direct gas measurements and the variables necessary for estimated cardiorespiratory fitness.
89214782|NCT05924191|Experimental|Experimental Group|Experimental group (n=30 surgeries) - the participants will receive the FBM, 1 hour before the surgical procedure, plus a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
89214783|NCT05924191|Active Comparator|Control Group|Control group (n=30 surgeries) - patients will receive conventional treatment with Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019), plus simulation of FBM application. The Laser device will be disconnected and will be applied to the same points as in the experimental group, in the immediate pre-operative period (Baseline).
89214784|NCT05923593|Experimental|Oral nutritional supplement|Oral nutritional supplement that contains MAG oil
89214785|NCT05916144|Experimental|Group 1|The group in which grandparents actively participate in baby care, Grandparents with a score of 6 and above in the One Day of Life (Annex-5) questionnaire will be included.
89214786|NCT05916144|No Intervention|Group 2|The group whose primary caregivers are mothers only
89214787|NCT05912088|Experimental|Intervention Group|The strength and balance activities of the sLiFE program will be carried out. Participants will be invited to participate in groups of about 14 people in Primary Care Heath Centers.
89214788|NCT05912088|Placebo Comparator|Control Group|Participants will receive the usual health advice.
89214789|NCT05869266|Active Comparator|Professional-fitting|"Subject receives hearing aids and a licensed professional performs the hearing aid fitting using professional programing tools, and the thresholds that were obtained from the traditional audiometry.~Subject uses the professionally fitted hearing aids for two weeks then completes COSI and the IOI-HA questionnaires."
89214790|NCT05869266|Active Comparator|Self-fitting|"Subject receives hearing aids, downloads the Tuned self fitting App and performs self-fitting of the hearing aids including a self-hearing test.~Subject uses the self fitted hearing aids for two weeks then completes COSI and the IOI-HA questionnaires."
89214791|NCT05866835|Experimental|Athlete|healthy, adult or minor (16 years or older), high-level sportsmen and women, volunteers
89214792|NCT05863819||Mobocertinib|Participants with EGFR ex20ins positive locally advanced or metastatic NSCLC who have received mobocertinib in China's routine clinical practice setting will be observed in this study. The observation period for each participant is planned to be 18 months, starting from the participant who received mobocertinib enrolled in this study and ending at the earliest occurrence of the completion of 18 months of follow-up, death, loss to follow-up, or withdrawal from the study.
89670786|NCT04869267|Other|Usual care group|Participants randomized to the control group will receive usual care, including treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge.
89670787|NCT04808154|Experimental|test drug|Powder for oral solution of SNP-630.
89670788|NCT04784910|Experimental|DWP14012 20mg|orally, once daily
89670789|NCT04784910|Active Comparator|Lansoprazole 15mg|orally, once daily
89670790|NCT01625013|Experimental|Synvisc-One|
89670791|NCT00083551|Active Comparator|Thalidomide|Thalidomide 400 qod during induction.100 mg qd between transplants, post transplant pat. 200 mg qd. During year one of maintenance therapy pt will take 100mg of Thal qod and 50 mg of thal qod during second year of maintenance
89670792|NCT00083551|Active Comparator|No Thalidomide|During induction, consolidation, and maintenance steps patient receives no thalidamide
89670793|NCT01625169|Other|HIV + pregnant women|Etravirine pharmacokinetics in breast milk and plasma. Etravirine 200mg PO BID for 14 days with PK on days 5 and 14
89670794|NCT05614206|Experimental|Toddlers at elevated likelihood of developing autism with autistic signs, with early intervention|Toddlers at elevated likelihood of developing autism with clinical autistic signs who receive an early intervention from 18 to 24 months
89670795|NCT05614206|No Intervention|Toddlers at elevated likelihood of developing autism with autistic signs, without early intervention|Toddlers at elevated likelihood of developing autism with clinical autistic signs who do not receive an early intervention
89670796|NCT05614206|No Intervention|Toddlers at elevated likelihood of developing autism without autistic signs who received monitoring|Toddlers at elevated likelihood of developing autism without clinical autistic signs who only received assessment and monitoring
89670797|NCT05614206|No Intervention|Typically developing toddlers who received monitoring|Typically developing toddlers who only received assessment and monitoring
89670798|NCT01471028|Experimental|ELAD Treatment|This group will receive treatment with ELAD plus standard of care treatment.
89670799|NCT01471028|Other|Standard of care (Control)|This group will receive standard of care treatment as defined in the protocol.
89670800|NCT03933813|Experimental|IV Iron Sucrose|Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period
89670801|NCT04765761|Active Comparator|PLMA with Introducer'|PLMA placed in position with the help of the introducer-tool and then the introducer-tool retained in place throughout the institution and duration of positive pressure ventilation.
89670802|NCT04765761|Active Comparator|PLMA without Introducer|PLMA placed in position with the help of the introducer-tool and then the introducer-tool removed before institution of positive pressure ventilation.
89670803|NCT01628523||All ED patients requiring mechanical ventilation|
89670804|NCT04808232|Experimental|health education and progressive muscle relaxation exercise|Health education and progressive muscle relaxation exercise training was given to women in this group.
89670805|NCT04808232|Experimental|progressive muscle relaxation exercise|Progressive muscle relaxation exercise training was given to women in this group.
89670806|NCT04808232|No Intervention|Control group|women in this group were not intervened.
89670807|NCT01491854|Other|Monitoring of long-term safety|Long-term safety follow-up after the end of treatment with Omnitrope (single arm)
89670808|NCT05473104|Experimental|experimental group|Teens and parents participate in the training once a week for 14 consecutive weeks in parallel groups.
89670809|NCT05473104|No Intervention|waiting-list group|Teens and parents participate in the training in a second moment, immediately after the experimental group concluded the program, once a week for 14 consecutive weeks in parallel groups.
89670810|NCT01628601||POAG or OHT|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
89670811|NCT01470248|Experimental|Arsenic Trioxide Treatment|This is a single arm study. All patients will be treated with the investigational agent, Arsenic Trioxide, according to the dose and schedule indicated in the protocol.
89670812|NCT04122378|Experimental|Treatment Arm|Acupuncture will be provided up to once daily for one or more days till the day of discharge or 5 days, whichever occurs first. Patients will continue to receive their standard pain management regime including IV opioids, ketorolac and fluids. Minimum number of sessions received by the acupuncture group will be one.
89670813|NCT04122378|No Intervention|Control Arm|Standard of care for SCD patients who are hospitalized for acute pain and typically includes IV opioids, ketorolac and fluids.
89670814|NCT05472636||Patients|Patients under the age of 18 who were admitted to the dermatology outpatient clinic between 2008-2021 and diagnosed with granuloma annulare
89670815|NCT01629615|Experimental|BKM120|
89670816|NCT05472480||Chronic Venous Disease Patients|Consecutive patients admitted to Vascular Surgery Units.
89670817|NCT05472480||Carotid Stenosis Patients|Consecutive patients admitted to Vascular Surgery Units.
89670818|NCT05472480||Abdominal Aortic Aneurysm Patients|Consecutive patients admitted to Vascular Surgery Units.
89670819|NCT05472480||Peripheral Artery Disease Patients|Consecutive patients admitted to Vascular Surgery Units.
89670820|NCT05472246|Experimental|VR group|VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure.
89670821|NCT05472246|No Intervention|Control group|Control group will undergo the routine anesthesia procedure.
89670822|NCT01629771||Lymphatic Filariasis|
89670823|NCT01629771||Patients without Lymphatic Filariasis|
89670824|NCT01490918|Placebo Comparator|Acarbose placebo, Metformin, Sitagliptin|The Acarbose placebo should be changed into real Acarbose from the 16th week.
89670825|NCT01490918|Experimental|Sitagliptin, Metformin, Acarbose|Metformin, Sitagliptin, Acarbose group
89670826|NCT01490918|Other|Metformin placebo, Sitagliptin, Acarbose|The Metformin placebo should be changed into real Metformin from the 16th week.
89670827|NCT02230761|Experimental|XOPH5 Ointment|XOPH5 Ointment is the investigational drug to be studied.
89670828|NCT02230761|Placebo Comparator|Placebo Ointment|Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.
89670829|NCT04053504|Experimental|Intervention|Behavioral intervention delivered by parent peer leaders.
89670830|NCT04053504|No Intervention|Standard Care|Standard diabetes care
89670831|NCT02230995|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
89670832|NCT02230995|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
89670833|NCT05072184|Active Comparator|ESP block|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
89670834|NCT05072184|Sham Comparator|Control|The patients will be randomized into two groups: ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of saline on each side
89670835|NCT02995083|Active Comparator|Knee injection with corticosteroids|Using clinically accepted methods, subjects will undergo a palpation guided injection of corticosteroids into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
89670836|NCT02995083|Placebo Comparator|Knee injection with saline|Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
89670837|NCT02995083|Sham Comparator|Knee injection with air|Using clinically accepted methods, subjects will undergo a palpation guided injection of air into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
89670838|NCT04981626||Control|"Females~Age : matched for the AN group~No present or past eating disorders~No past or current psychotic disorders~No current substance abuse or dependence.~No current psychiatric medication"
89670839|NCT04981626||AN group|"Females~16 years ≤ Age ≤ 25 years~Diagnostic of AN according to DSM-5 criteria~No past or current psychotic disorders~No current substance abuse or dependence (excluding tobacco).~No current psychiatric medication"
89670840|NCT01490840|Experimental|E-training|Fingolimod as baseline immunomodulatory multiple sclerosis treatment was prescribed as per clinical practice. During phase 1, participants randomized to this arm had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day. After 6 months, Phase 2, the same Phase 1 regimen applied.
89670841|NCT01490840|Experimental|Waiting|Fingolimod as baseline immunomodulatory multiple sclerosis treatment is prescribed as per clinical practice. During Phase 1, participants randomized to this arm did not receive e-training exercise. After a 6 months waiting period, phase 2, participants had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day.
89670842|NCT02248935||Repair with Alyte or Restorelle Y-Mesh|Women who underwent their index robotic-assisted laparoscopic sacrocolpopexy at Morristown Medical Center or Overlook Medical Center using either the Alyte Y-mesh or Restorelle Y-smartmesh between 1/2007 and 8/2011.
89670843|NCT03753360|Other|Intervention Group|internet-based mindfulness meditation program
89670844|NCT03753360|Other|Active Control Group|relaxing music
89670845|NCT03448185|Placebo Comparator|Control|Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.
89670846|NCT03448185|Experimental|Exercise and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.
89670847|NCT03448185|Active Comparator|Yoga and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.
89670848|NCT03448185|Active Comparator|Exercise control|Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.
89670849|NCT04426422|Experimental|metformin group|all the patients were treated with metformin 1500-2000mg daily for 3 months.
89670850|NCT01631331|Experimental|Treatment (vismodegib and Mohs surgery)|Patients receive vismodegib PO daily for 3-6 months based on the size of basal cell carcinoma and then undergo Mohs surgery.
89670851|NCT05471778|Experimental|comedy movie group|Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the comedy group on the first evening after surgery. 25-minute comedy film was watched. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
89670852|NCT05471778|Experimental|Music group|Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the music group on the first evening after surgery. 25 minutes of music (nature sound) was played. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
89670853|NCT05471778|No Intervention|Control group|In the follow-up of the patient, no application was made other than clinical protocols. Sociodemographic information form, kinesiophobia scale and numerical pain scale were administered to the patients in the control group on the first evening after surgery. No intervention was made. Afterwards, the kinesiophobia scale and the numerical pain scale were applied again.
89670854|NCT04573101|No Intervention|Before intervention|Participants answer questionnaire before any stimulus is given.
89670855|NCT04573101|No Intervention|After intervention|Participants answer questionnaire after the series of stimulus is given.
89670856|NCT04573101|Experimental|N1 (Ney - Improvisation- Saba Re)|Improvisation with Ney, on Saba maqam on Re.
89670857|NCT04573101|Experimental|O1 (Oud - Improvisation- Saba Re)|Improvisation with Oud, on Saba maqam on Re.
89670858|NCT04573101|Experimental|Q1(Qanun - Improvisation- Saba Re)|Improvisation with Qanun, on Saba maqam on Re.
89670859|NCT04573101|Experimental|N2 (Ney - Improvisation- Saba Sol)|Improvisation with Ney, on Saba maqam on Sol.
89670860|NCT04573101|Experimental|O2 (Oud - Improvisation- Saba Sol)|Improvisation with Oud, on Saba maqam on Sol.
89670861|NCT04573101|Experimental|Q2 (Qanun - Improvisation- Saba Sol)|Improvisation with Qanun, on Saba maqam on Sol.
89670862|NCT04573101|Experimental|N3 (Ney - Improvisation- Kurd Re)|Improvisation with Ney, on Kurd maqam on Re.
89670863|NCT04573101|Experimental|O3 (Oud - Improvisation- Kurd Re)|Improvisation with Oud, on Kurd maqam on Re.
89670864|NCT04573101|Experimental|Q3 (Qanun - Improvisation- Kurd Re)|Improvisation with Qanun, on Kurd maqam on Re.
89670865|NCT04573101|Experimental|N4 (Ney - Improvisation- Kurd Sol)|Improvisation with Ney, on Kurd maqam on Sol.
89670866|NCT04573101|Experimental|O4 (Oud - Improvisation- Kurd Sol)|Improvisation with Oud, on Kurd maqam on Sol.
89670867|NCT04573101|Experimental|Q4 (Qanun - Improvisation- Kurd Sol)|Improvisation with Qanun, on Kurd maqam on Sol.
89670868|NCT04573101|Experimental|N5 (Ney - Known music- Kurd Re)|Known music with Ney, on Kurd maqam on Re. (El Rabii)
89670869|NCT04573101|Experimental|O5 (Oud - Known music- Kurd Re)|Known music with Oud, on Kurd maqam on Re. (El Rabii)
89670870|NCT04573101|Experimental|Q5 (Qanun - Known music- Kurd Re)|Known music with Qanun, on Kurd maqam on Re. (El Rabii)
89670871|NCT04573101|Experimental|N6 (Ney - Known music- Kurd Sol)|Known music with Ney, on Kurd maqam on Sol. (El Rabii)
89670872|NCT04573101|Experimental|O6 (Oud - Known music- Kurd Sol)|Known music with Oud, on Kurd maqam on Sol. (El Rabii)
89670873|NCT04573101|Experimental|Q6 (Qanun - Known music- Kurd Sol)|Known music with Qanun, on Kurd maqam on Sol. (El Rabii)
89670874|NCT04573101|Experimental|N7 (Ney - Known music- Saba Re)|Known music with Ney, on Saba maqam on Re. (Howa Sahih)
89670875|NCT04573101|Experimental|O7 (Oud - Known music- Saba Re)|Known music with Oud, on Saba maqam on Re. (Howa Sahih)
89670876|NCT04573101|Experimental|Q7 (Qanun - Known music- Saba Re)|Known music with Qanun, on Saba maqam on Re. (Howa Sahih)
89670877|NCT04573101|Experimental|N8 (Ney - Known music- Saba Sol)|Known music with Ney, on Saba maqam on Sol. (Howa Sahih)
89670878|NCT04573101|Experimental|O8 (Oud - Known music- Saba Sol)|Known music with Oud, on Saba maqam on Sol. (Howa Sahih)
89670879|NCT04573101|Experimental|Q8 (Qanun - Known music- Saba Sol)|Known music with Qanun, on Saba maqam on Sol. (Howa Sahih)
89670880|NCT01490450|Placebo Comparator|PBO: Placebo matching BMS-945429|
89670881|NCT01490450|Experimental|BMS-945429 (25mg)|
89670882|NCT01490450|Experimental|BMS-945429 (100mg)|
89670883|NCT01490450|Experimental|BMS-945429 (200mg)|
89670884|NCT04350255|Active Comparator|Trident II Hemispherical cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Hemispherical acetabular cup
89670885|NCT04350255|Active Comparator|Trident II Tritanium cup (Stryker Orthopaedics)|Total hip arthroplasty using non cemented Trident II Tritanium acetabular cup
89670886|NCT01632267||Depression and anxiety|Subjects with a primary diagnosis of depression or anxiety disorder.
89670887|NCT05611944|Experimental|I&S arm|The 150 participants of the experimental arm will be assigned to the I&S group and they will be inserted bilateral Nelton drains of 24 sizes in the subcutaneous space after the closure of the rectus sheath. Their wound will be irrigated with 500cc Normal saline at running speed followed by suction for a full day. The procedure will be repeated for three consecutive days. The drains will be removed on the fourth postoperative day.
89670888|NCT05611944|No Intervention|control|The 150 participants of the non-intervention group will be assigned to the control arm, The wound will be closed by interrupted mattress stitches without the insertion of subcutaneous drains.
89670889|NCT04076150|Experimental|Patients Receiving Optimum TAV|Patients with symptomatic severe aortic stenosis that will be treated via transcatheter aortic valve implantation procedure
89670890|NCT01632423||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
89670891|NCT05466318|Experimental|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
89670892|NCT05466318|Active Comparator|BEAM|Treated with BCNU, etoposide, cytarabine and melphalan (BEAM) therapy followed by autologous hematopoietic stem cell transplantation.
89670893|NCT05464914|No Intervention|Conventional upper immediate denture|Conventional upper immediate denture without any surgical lining
89670894|NCT05464914|Active Comparator|Upper immediate denture lined by surgical dressing|Upper immediate denture lined by surgical dressing using CEO Pack dressing
89670895|NCT01632735|Experimental|Mobile Continuing Care|Behavioral: 12-week Structured Texting intervention focused on recovery monitoring, feedback for self-management, social support and education
89670896|NCT01632735|No Intervention|Standard Continuing Care as Usual|Continuing care as usual to 12-step facilitation (Anonymous group)
89670897|NCT01633827|Placebo Comparator|Placebo|Subjects will receive both a sugar pill and room air during their overnight sleep studies
89670898|NCT01633827|Active Comparator|Treatment|Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies
89670899|NCT01469546|Experimental|Axitinib (AG-013736)|A prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma who have received no more than two prior lines of systemic therapy for recurrent or metastatic head and neck cancer.
89670900|NCT03502980|Active Comparator|Peripherally inserted central venous catheters|Bard PowerPICC
89670901|NCT03502980|Active Comparator|Midline|Bard PowerMidline catheter
89670902|NCT04875390|Other|group E|Intraoperative Erector spina plane block ( 0.3 ml/kg bupivacaine 0.25% at thoracic level 7 and 0.3 ml/kg bupivacaine 0.25% bupivacaine at thoracic level 11, totaling 0.6 ml/kg of 0.25% bupivacaine) will be performed after the surgery is completed.
89670903|NCT04875390|Other|group L|Intraoperative local infiltration (0.6 ml/kg of 0.25% bupivacaine will be given to the wound lips at the end of the surgery.
89670904|NCT03281811|Experimental|Treatment (aminolevulinic acid hydrochloride, PDT, RT)|Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks.
89670905|NCT05613894|Experimental|Dose Escalation (Part 1)|Part 1 will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the MTD and/or recommended dose and schedule
88995652|NCT02911597|Experimental|A: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase A and B. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase A will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
89670906|NCT05613894|Experimental|Dose Expansion Cohort (Part 2)|Expansion Phase to assess identified MTD and schedule from Part 1.
89670907|NCT00081497|Experimental|Fabrazyme 1.0 mg/kg every 2 weeks|This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.
89670908|NCT05613738|Experimental|1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
89670909|NCT05613738|Experimental|1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
89670910|NCT05613738|Experimental|2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
89049316|NCT04624035|Active Comparator|Acrylic Implantable Intraocular Lens (IPCL, V2) in treatment of myopia in adults|Implantation of IPCL for treatment of Myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the IPCL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.
89049317|NCT04624386||Postmenopausal/Study|Women older than 45 years of age and who have not had any menstruation for the past 12 months are considered as having entered menopause. These women are included in this group.
89670911|NCT04159467|Active Comparator|Group 1- diet therapy (control)|Control group undergoing a low calorie diet will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and after 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
89670912|NCT04159467|Experimental|Grupo 2 - low calorie diet + PFMT (experimental)|"The experimental group will receive supervised pelvic floor muscle training in addition to a hypocaloric diet. Women will be instructed to perform daily pelvic floor muscle training at home. 4 sets of 10 maximal voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary contractions of the pelvic floor muscles. The 4 sets will be performed in 2 different positions (sitting and standing). Once a month, they will receive a supervised in-person session using the same protocol described above, in the other weeks of the month will receive a session supervised by telephysiotherapy once a week. In addition to supervised sessions, women will be encouraged to perform the protocol three more days a week. In addition, they will be instructed to perform the knack maneuver."
89670913|NCT00081263|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib once daily for 14-18 weeks.
89670914|NCT00081263|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for 14-18 weeks.
89670915|NCT01490294|Experimental|Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.01 mmol/kg body weight (BW) (0.01mL/kg) for stress magnetic resonance imaging (MRI) via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.01 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
89670916|NCT01490294|Experimental|Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.025 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.025 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
89670917|NCT01490294|Experimental|Gadobutrol 0.05 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.05 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.05 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
89670918|NCT01490294|Experimental|Gadobutrol 0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.1 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.1 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
89670919|NCT02602457|Experimental|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise training
89670920|NCT02602457|Experimental|High-Intensity Interval Training|High-Intensity Interval Training
89670921|NCT04426344|Experimental|Group A - core warming|Patients randomized to Group A will have core warming with the ensoETM device initiated in the ICU or other clinical environment in which they are being treated. The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and standard of care arms during the study period (72 hours).
89670922|NCT04426344|No Intervention|Group B - Control Group|Group B is serving as the control group who will not have the ensoETM device used.Control group patients will be managed as per standard of care currently utilized in the ICU, which will include the use of other methods of temperature management as warranted. This would include warming with a forced air blanket only in hypothermic patients (core temperature < 36°C) or antipyretic therapy for febrile patients, as requested by the treating physician.
89670923|NCT03436667||Orthopedic surgery|Pediatric patients presenting for ambulatory orthopedic procedures
89670924|NCT05613582|Experimental|Primary Motor Cortex (M1)|Subjects were randomly assigned to receive tDCS stimulation at the primary motor cortex (M1)
89670925|NCT05613582|Experimental|Primary Sensory Cortex (S1)|Subjects were randomly assigned to receive tDCS stimulation at the primary sensory cortex (S1)
89670926|NCT05613582|Experimental|Dorsolateral Prefrontal Cortex (DLPFC)|Subjects were randomly assigned to receive tDCS stimulation at the dorsolateral prefrontal cortex (DLPFC)
89049318|NCT04624386||Premenopausal/Control|Healthy women who are still having regular menstruations are included in this group
89670927|NCT05613582|Sham Comparator|Sham|The sham intervention procedure was carried out similarly to the experimental group, but in the following group, the device would only conduct electric current in the first and last 30 seconds of the intervention.
89670928|NCT05613504|Active Comparator|Treatment group A|Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment.
89670929|NCT05613504|Sham Comparator|Treatment group B|Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week).
89670930|NCT05613504|No Intervention|control|The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy.
89670931|NCT05087381|Experimental|Fluvoxamine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.
89049319|NCT04624191|Experimental|Intervention Group|Intervention group participants will be asked to measure their oxygen saturation on a daily basis.
89049320|NCT04624191|No Intervention|Control Group|Usual Care
89049321|NCT02903264||GDM group|Gestational diabetes mellitus patients under treatment of an endocrinologist
89049322|NCT02903264||Control|Healthy non-pregnant females
89670932|NCT05087381|Experimental|Fluvoxamine in Combination with Bromhexine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.
89670933|NCT05087381|Experimental|Fluvoxamine in Combination with Cyproheptadine Arm|The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.
89670934|NCT05087381|Experimental|Niclosamide Arm|The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.
89670935|NCT05087381|Experimental|Niclosamide in Combination with Bromhexine Arm|The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.
89670936|NCT05087381|No Intervention|Usual Care Arm|The control group received treatment according to the latest usual care medical guidelines provide by ministry of Thailand at that time.
89670937|NCT05613348|Experimental|humanized CAR19T2 T cell to B-cell acute lymphoblastic leukemia/lymphoma|Patients received fludarabine and cyclophosphamide (Flu/Cy) for lymphodepletion (Cy at 300-500 mg/m2/dose for four days and Flu at 20-30 mg/m2/dose for two days) before CAR19T2 T cells administration. This CAR19T2 T cell will be infused over 30 minutes on days Day 0.
89670938|NCT01638507|Other|Resolute Integrity|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity Stent)
89670939|NCT04958291|Experimental|Administration of Dose A of CC-99677 or Placebo|Administration of Dose A of CC-99677 or Placebo
89670940|NCT04958291|Experimental|Administration of Dose B of CC-99677 or Placebo|Administration of Dose B of CC-99677 or Placebo
89670941|NCT04958291|Experimental|Administration of Dose C of CC-99677 or Placebo|Administration of Dose C of CC-99677 or Placebo
89670942|NCT01639443|Experimental|Fast-tracked|"'Predictive no-show overbooking' intervention. Patients who volunteer to enroll in fast-track line, which gives them an opportunity to overbook their appointment for endoscopy earlier in a predictive no-show slots."
89670943|NCT01639443|No Intervention|Control|Patients who are scheduled routinely
89670944|NCT05611398||Lactate Level Under 2 mmol/L|Patients with a lactate level below 2
89670945|NCT05611398||Lactate Level Over 2 mmol/L|Patients with a lactate level above 2
89670946|NCT00080483|Experimental|1|Testosterone transdermally 5 g a day and somatropin subcutaneously 2 µg/kg body weight a day
89670947|NCT00080483|Active Comparator|2|AndroGel transdermally 5 g a day for two years
89670948|NCT05248620|Active Comparator|Active|Amoxicillin/clavulanic acid 500/125mg, tablets, will be administered before each hemodialysis for 6 months
89670949|NCT05248620|Placebo Comparator|Placebo|Placebo tablets, similar to the active drug, will be administered before each hemodialysis for 6 months
89670950|NCT01639599|Placebo Comparator|dexamethasone|dexamethasone 5mg iv during anesthesia induction
89670951|NCT01639599|Active Comparator|dexamethasone, haloperiol 1mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 1mg iv 30 min before end of anesthesia
89670952|NCT01639599|Active Comparator|dexamethasone + haloperidol 2mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 2mg iv 30 min before end of anesthesia
89670953|NCT00089141|Active Comparator|Mycophenolate mofetil|Patients receive oral mycophenolate mofetil twice daily.
89670954|NCT00089141|Placebo Comparator|Placebo|Patients receive oral placebo twice daily
89670955|NCT05611320|Experimental|Awareness Campaign|Raise awareness among parents about how and why to use local produce in their kid's meals.
89670956|NCT05611320|Experimental|Online Shopping|Provide information about an online shopping platform where the parents can shop for local produce online, and have it delivered, to disrupt their current ingredient-selection habits.
89670957|NCT02227329|Experimental|Ethanol Lock and Normal Saline|All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
89670958|NCT02227329|Active Comparator|Heparin and Normal Saline|All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).
89670959|NCT05615142|Experimental|LDRT+SBRT Combined with PD-1 Inhibitors|"Part A-Dose escalation cohort. DOSE LEVEL: Low Dose Radiotherapy (LDRT) dose from 2 Gy to 6Gy (2 Gy/f) + partial stereotactic body radiation therapy (SBRT) dose at 10 Gy to 30 Gy (10 Gy/f) + PD-1 inhibitor (dose as recommended in the instruction manual).~Part-B - Expansion cohort. LDRT and partial SBRT doses at MTD determined in Part A + PD-1 inhibitor (dose as recommended in the instruction manual)."
89670960|NCT02227485|Active Comparator|Chlorhexidine (0.2%)|Chlorhexidine (0.2%) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
89670961|NCT02227485|Experimental|Punica granatum Pleniflora mouth rinse|Punica granatum Pleniflora (Golnaar) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
89670962|NCT05614986||Patients with Mild Cognitive Impairment Undergoing TAVR|Patients will be treated with standard of care. In addition, patients will complete the mini MoCA at 3 time points
89049323|NCT04624152|Experimental|Normobaric Hypoxia|"Large weather balloons will be filled with a normobaric hypoxic inspirate (FiO2 = 0.15) produced by a nitrogen generator (CAT 12; Colorado Altitude Training, Boulder, CO) to simulate an altitude of 2600 m (8500 ft). Participants breathed this inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
89214793|NCT05860439||Telangiectasias Group - Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Previously treated with PDHG, no new interventions were performed.
89670963|NCT03172897|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.
89049324|NCT04624152|Placebo Comparator|Normobaric Normoxia|"Large weather balloons will be filled with room air (FiO2 = 0.21). Participants breathed this normobaric normoxic inspirate through a two-way non-rebreathing valve (2700; Hans Rudolph, Kansas City, KS) and an oronasal mask (7450 V2; Hans Rudolph, Kansas City, KS).~Participants breathed this inspirate from 15 minutes before the pre-heading time point until the conclusion of the 0h post-heading time point."
89670964|NCT03172897|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.
89670965|NCT01640379|Experimental|TECH-N|Participants receive the Technology Enhanced Community Health Nursing Visit (CHN) within 5 days during which Sister to Sister and clinical assessment performed and text-messaging support
89670966|NCT01640379|No Intervention|Control|Participants receive enhanced standard of care
89670967|NCT05346497||Bentall|Patients who underwent Bentall procedure for ATAAD
89670968|NCT05346497||David|Patients who underwent David procedure for ATAAD
89670969|NCT05346497||ARR|Patients who underwent aortic root reconstruction procedure except Bentall and David procedure for ATAAD
89670970|NCT05346419|Experimental|Postmenopausal Osteopenia-osteoporosis patients|All participants were treated for 6 months with risedronate 35 mg and vitamin D 2800 IU once a week, with additional daily vitamin D supplementation of 4000 IU.
89670971|NCT00084409|Experimental|Arm I|Patients receive oral iloprost twice daily for 6 months in the absence of unacceptable toxicity.
89670972|NCT00084409|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months in the absence of unacceptable toxicity.
89670973|NCT02600286|Experimental|1|"Arm (1) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
89049325|NCT02903225|No Intervention|Usual Care|usual care and no changes in their previous physical activity
89049326|NCT02903225|Active Comparator|Cardiac Rehabilitation|Exercise Training program on a 3-days/week basis during 24 weeks (68-74 sessions). Each session started with a 10-min warm-up walking period followed by 20-min of breathing exercises and free non-resistance movements of limbs. This stage was followed by pedaling during 20-minutes at a circuit resistance training protocol using a stationary cycle-ergometer. Each session ended with a cool down period (5-minutes) including diverse stretching maneuvers of engaged muscle groups. The initial bicycle-ergometer workload (WL) was defined as 50% of the maximum achieved in the previous stress testing
89049327|NCT02903342|Experimental|Intervention|Parents will be asked to read a leaflet. They will then complete a survey and re-complete the survey via telephone two weeks later.
89049328|NCT02903342|No Intervention|Control|Parents will be asked to complete a survey and re-complete the survey via telephone two weeks later.
89049329|NCT04623606|No Intervention|Prospective Control (Untreated) and historical controls|Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database
89049330|NCT04623606|Experimental|Treatment|Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.
89049331|NCT02903303|Other|Treatment|There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.
89049332|NCT00562107|Experimental|1|AAIsafeR /SafeR Patient randomized with the SafeR switched ON
89049333|NCT00562107|Experimental|2|DDD(R) mode. Patients randomized with the SafeR mode switched OFF
89049334|NCT02903186|Experimental|Nutrition messages|The intervention will focus on reinforcing the WIC breastfeeding messages, preventing overfeeding (i.e. using spoon to feed baby, not adding baby food or cereal to bottle, not placing their babies to sleep with a bottle, feeding their babies without distractions, etc), delaying introduction of solid foods, and delaying and reducing baby juice consumption. Constructs in the transtheoretical model such as self-efficacy and decisional balance will be used to address key determinants of behavior change to ensure relevance to the audience, and will target individuals both at the earlier and later stages of change. The messages are written at a grade 5 level in Spanish (PR site) and English (Hawaii site) and will be sent on different days and times of the week.
89049335|NCT02903186|Active Comparator|General health messages|The control group will receive weekly SMS about general infant's health issues, such as placing the infant on his/her back to sleep, the timeline for immunizations, the proper use of car seats, asthma and other respiratory conditions common among small children, and other health information relevant to infants. The investigators will follow the same protocol (schedule, length, language, etc.) as for the intervention messages.
89049336|NCT00562146||1|Successful progression of spiral tube to duodenum within 3 days
89049337|NCT00562146||2|Failure of progression to duodenum within 3 days
89049338|NCT02903147|Experimental|Functional Meta-Cognitive Intervention|The intervention is aimed to improve human factors of professional bus drivers
89049339|NCT02903147|Active Comparator|Control group|The control group had the employer's training - The company holds routine covert inspections, summons to conversations with the security offices and records in the drivers' personal files.
89049340|NCT02903108|Active Comparator|Boric acid group|Oral prophylaxis followed by 0.75% boric acid drug in gel form placed in intrabony defects
89049341|NCT02903108|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
89214794|NCT05860439||Telangiectasias Group - Hypertonic Glucose 75% (HG)|Previously treated with HG, no new interventions were performed.
89670974|NCT02600286|Experimental|2|"Arm (2) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
89214795|NCT05860439||Reticular Veins Group (PG3T) - Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Previously treated with PDHG, no new interventions were performed.
89214796|NCT05860439||Reticular Veins Group (PG3T) - Hypertonic Glucose 75% (HG)|Previously treated with HG, no new interventions were performed.
88995653|NCT02911597|Experimental|B: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase B and A. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase B will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
88995654|NCT02911441|Experimental|Treatment Group|Receives 8-12 weeks of one-on-one Cognitive Behavioral Therapy sessions
88995655|NCT02911441|No Intervention|Control Group|Receives no intervention during data-collection phase. Participants in this group will receive the intervention post-data collection.
88995656|NCT02911363|Active Comparator|Capitvator Cassette|The EMR specimen will be processed using the Captivator Cassette.
88995657|NCT02911363|Active Comparator|Standard of Care Processing|The EMR specimen will be prepared per Standard of Care.
88995658|NCT02911480|Experimental|oxytocin intravenous 0.1 IU|single dose of 0.1 International Units (IU) intravenous (IV) oxytocin
88995659|NCT02911480|Experimental|oxytocin intravenous 1 IU|single dose of 1 IU IV oxytocin
88995660|NCT02911480|Experimental|oxytocin intravenous 10 IU|single dose of 10 IU IV oxytocin
88995661|NCT02911480|Experimental|oxytocin tablet 20 IU|single dose of 20 IU tablet oxytocin
88995662|NCT02911480|Experimental|oxytocin tablet 200 IU|single dose of 200 IU tablet oxytocin
88995663|NCT02911207|Experimental|Intervention arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during the following six months
88995664|NCT02911207|Active Comparator|control arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during six months but they will start 6 months later after randomization
88995665|NCT02911168|Active Comparator|Proximal Intercostal Block|See Intervention Section
88995666|NCT02911168|Active Comparator|Paravertebral Block|See Intervention Section
88995667|NCT02911051|Experimental|Actreen Hydrolite Cath|a new hydrophilic coated catheter for Urinary Intermittent Catheterisation
88995668|NCT00150644|Experimental|1|
88995669|NCT00150644|Experimental|2|
88995670|NCT00150644|Placebo Comparator|3|
88995671|NCT02911012||Study Group|The identified population will be assessed on VTE risk according to the risk score PADUA, CAPRINI, KHORANA, and IMPROVE for BLD risk.
88995672|NCT02910778|Experimental|Atorvastatin|80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
88995673|NCT02910778|Placebo Comparator|Placebo|Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15
88995674|NCT02910817|Experimental|Metformin-treated group|51 overweight and obese women (BMI>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle
88995675|NCT02910817|Placebo Comparator|Placebo|A cohort of fifty-one cross matched PCOS women
89670975|NCT02600286|Experimental|3|"Arm (3) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
89670976|NCT03831165|Experimental|melatonin 3mg + Acyclovir 400mg|Group I - melatonin 3mg + Acyclovir 400mg
89670977|NCT03831165|Active Comparator|Acyclovir 400mg|Group II - Acyclovir 400mg twice a day
89670978|NCT03831165|Placebo Comparator|placebo + melatonin 3mg|Group III - placebo + melatonin 3mg
89670979|NCT02588664|No Intervention|Usual Care|Participating hospitals randomized to the usual care group will provide their usual, post-acute stroke care to their patients.
89670980|NCT02588664|Active Comparator|COMPASS Intervention|Participating hospitals randomized to the intervention will change the structure and process for delivery of post-acute stroke care.
89670981|NCT00088621|Experimental|Lurasidone 80 mg tablet|Lurasidone 80mg oral tablet taken once a day
89670982|NCT05574985|Experimental|Research Group|People 6 to 15 months after the completion of basic immunization with inactivated COVID-19 vaccine were vaccinated one dose of the study vaccine
89670983|NCT05574985|Active Comparator|Control Group|People 6 to 15 months after the completion of basic immunization with inactivated COVID-19 vaccine were vaccinated with one dose of control vaccine
89670984|NCT05574985|Experimental|Observation group ①|People 6 to 9 months after the completion of the inactivated COVID-19 vaccine booster immunization were vaccinated one dose of the study vaccine
89670985|NCT05574985|Experimental|Observation group ②|People 6 to 15 months after the completion of basic immunization with COVID-19 recombinant vaccine were vaccinated one dose of the study vaccine
89670986|NCT01642485|Active Comparator|Moxifloxacin 400 mg fasted|Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.
89670987|NCT01642485|Experimental|Moxifloxacin 400 mg fed|"Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.~Additionally, Caucasian vs Japanese subjects were analysed."
89670988|NCT00187369|Other|Caesarean Section|delivery by CS
89670989|NCT00187369|Other|Vaginal Birth|delivery by VB
89670990|NCT04773366|Experimental|Group 1|"Multisystem patients (≥2 organs/systems) with involvement of one or more Risk organs, i.e. hematopoietic system, liver or spleen.~All patients in this group receive an initial therapy (Week 1~6) followed by a consolidation continuation therapy (Week 7~22) and maintenance continuation therapy (Week 25~52)."
89670991|NCT04773366|Experimental|Group 2|"Multisystem patients, but without involvement of Risk organs.~All patients in this group receive an initial therapy (Week 1~6) followed by continuation therapy (Week 7~52)."
89670992|NCT04773366|Experimental|Group 3|"Includes patients with single system, multifocal or with single system, unifocal and special site (Isolated lesion of special site) or with single system, unifocal and CNS risk or with single system, unifocal i.e. thyroid, lung, thymus, hypothalamic-pituitary or with single system, unifocal and other functionally critical anatomical sites.~All patients in this group receive an initial therapy (Week 1~6) followed by continuation therapy (Week 7~52)."
89670993|NCT04773366|Experimental|Group 4|"Patients with single system, unifocal i.e. bone, skin or lymph node (not the draining lymph node of another LCH lesion).~All patients in this group enter into observation after local therapy. Chemotherapy only apply to patients with disease reactivation during observation."
89670994|NCT04714541|Experimental|Ketogenic Diet Adoption Followed by Ketamine Infusion|All 5 Participants Will Be Educated to Adopt a Ketogenic Diet, As Outpatient. After at Least 4 Weeks on the Diet, They Will Have A Series of Titrated Intravenous Ketamine Infusions Over A 2 Week Period
89670995|NCT02414724|Experimental|Treatment (ribociclib, gemcitabine hydrochloride)|Patients receive ribociclib PO on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88995676|NCT02910934|Experimental|IRS|This arm is comprised of village clusters that have received indoor residual spray with Actellic CS.
88995677|NCT02910934|No Intervention|non-IRS|This arm is comprised of village clusters that will not receive indoor residual spray
88995678|NCT02910505|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
88995679|NCT02910622||Oncogramme breast|Taking a fragment of breast tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
88995680|NCT02910622||Oncogramme ovarian|Taking a fragment of ovarian tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
88995681|NCT02910661||Patients|Focus groups (n=6-8/group) will be conducted at 4 sites selected to maximize racial diversity and to ensure availability of adequate numbers in each age group (Montreal (incl. the McGill University Health Centre (MUHC), Centre Hospitalier Universitaire-Ste. Justine & CHUM ), Pittsburgh, Seattle, and St. Louis). Separate focus groups will be conducted with patients clustered by patient age to maximize homogeneity in developmental stage. Purposive sampling will be employed to ensure that each focus group includes patients with combinations of characteristics that are likely to account for variation in perspectives, including the major racial and ethnic groups, both sexes, time since transplant, and level of adherence.
88995682|NCT02910661||Parents|Focus groups (n=6-8/group) will be conducted at Pittsburgh & Seattle. Focus groups will be conducted with parents clustered by patient age (12-14 y. & 15- 17 y.)
89522207|NCT03411577|Experimental|Behavioral Intervention|The adolescent HIV/STI risk-reduction intervention aims to: (a) increase knowledge of HIV risk and prevention; (b) strengthen behavioral beliefs regarding abstinence and safer sex; (c) increase self-efficacy and intentions to avoid unsafe sex; and (d) increase sexual communication and refusal skills. The mother component includes much of the same prevention knowledge and addresses parent-teen sexual risk communication, monitoring, and sexual role modeling. Interventions are held on two consecutive Saturdays for 6 hours each day. Mothers' groups meet separately from daughters' groups, although the groups will come together for the last module of each day.
89670996|NCT02788149|Experimental|STUDY GROUP|Model development group: This group will get Ultrasound of neck exam followed by polysomnography. We will use this group to identify the ultrasonographic parameters that have strong association of predicting obstructive sleep apnea. We will use these these predictors to estimate the patient's probability of severe OSA, which then will be used to test the receiver operating characteristic (ROC) curve of diagnosing severe OSA. The optimal cut-off value of the ROC curve will be defined as the one with the least (1 - sensitivity)2+ (1- specificity)2 in the model-development group. This formula will then tested in the validation group.
89670997|NCT02788149|Active Comparator|validation group|One third patients in the cohort will be randomly assigned to this group. This group will get ultrasound of neck exam followed by polysomnography. The predictors will be tested in his group.
89670998|NCT00187681|Experimental|OCT1-variant Group|Subjects with OCT1-variant alleles will be dosed with 2 doses of Metformin
89670999|NCT00187681|Experimental|OCT1-reference Group|Subjects with OCT1-reference alleles will be dosed with 2 doses of Metformin
89671000|NCT00083759|Active Comparator|natalizumab|
89671001|NCT00083759|Placebo Comparator|placebo|
89671002|NCT03714399||ICUAW group|The physical and psychological effects of ICUAW on patients undergoing aortic valvular surgery will be observed. Physical function and HRQoL will be analysed and correlated with RFcsa. Additionally, biological markers will be used to understand molecular and genomic profiles.
89671003|NCT02412228|Experimental|Ixazomib Regimen|"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
89671004|NCT05613270|Experimental|18F-FES PET/CT|Inject 18F-FES and then perform PET/CT scan.
89671005|NCT05147610|Experimental|patients requiring an IOP (intra-Ocular Pression) measurement|group representing adults patients in ophthalmologic consultation requiring an IOP measurement
89671006|NCT01646151||Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
89671007|NCT03692481|Experimental|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
89671008|NCT05614830|Experimental|Intervention group|
89671009|NCT05614830|Active Comparator|Control group|Usual physical therapy protocol 4 sessions, two sessions per week each session will include a group of therapeutic exercises
89671010|NCT05614674||Healthy group|People who don't suffer from low back pain
89671011|NCT05614674||People with low back pain|People who are suffering from low back pain. The pain level has to be at least 3 out of 10 according to Visual Analog Scale (VAS) to be in this group.
89671012|NCT01828710|Sham Comparator|Myo-inositol normospermic|29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid
89671013|NCT01828710|Active Comparator|Myo-inositol OAT|13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid
89671014|NCT01828710|Placebo Comparator|Folic acid normospermic|20 normospermic patients treated with 400 µg of folic acid
89671015|NCT03555825|Active Comparator|60 Minutes ArmeoSpring (1:1)|60 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
89049342|NCT02902796|Active Comparator|Treatment group A|Group A will consist of sequence of treatment with 3 stimulation modes. They are, in order, 1000 hertz, standard, and burst stimulation. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
89049343|NCT02902796|Active Comparator|Treatment group B|Group B will consist of sequence of treatment with 3 stimulation modes. They are, in order, burst stimulation, standard, and 1000 hertz. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
89049344|NCT00562224|Experimental|Arm 1|All study subjects will receive PCI-24781 (study drug).
89671016|NCT03555825|Experimental|60 Minutes ArmeoSpring (2:1)|60 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
89671017|NCT03555825|Active Comparator|30 Minutes ArmeoSpring (1:1)|30 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
89671018|NCT03555825|Experimental|30 Minutes ArmeoSpring (2:1)|30 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
89671019|NCT01759212|Experimental|Stem cells implantation|Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.
89671020|NCT02232009|Other|3.0 T Neonatal Scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
89671021|NCT00088699|Experimental|Ketamine, Then Placebo|Ketamine and placebo infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg.
89671022|NCT00088699|Experimental|Placebo, Then Ketamine|Placebo and Ketamine infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg
89671023|NCT05138094|Active Comparator|Minimally invasive two-stage resection|Minimally invasive resection of the primary colorectal carcinoma and liver metastases in two stages. The liver metastases or the colorectal carcinoma can be resected during the first surgical procedure.
89671024|NCT05138094|Experimental|Minimally invasive simultaneous resection|Minimally invasive resection of both the primary colorectal carcinoma and the liver metastases in one procedure.
89671025|NCT00089011|Experimental|Arm I (nonmyeloablative conditioning with fludarabine and TBI)|Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
89671026|NCT00089011|Experimental|Arm II (nonmyeloablative conditioning with TBI)|Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.
89671027|NCT05614596|Active Comparator|CT guided for patient with chronic low back pain|CT guided treatment in patients with low back pain
89671028|NCT05614596|Active Comparator|Flouroscopic guided for patient wit chronic low back pain|Flouroscopic guided treatment in patients with low back pain
89671029|NCT00470496|Experimental|Treatment (intraoperative PDT)|Patients receive HPPH IV over 1 hour on day 1. Patients undergo surgery followed by laser light exposure to the entire tumor bed on day 2.
89671030|NCT01898377|Experimental|Imatinib mesylate, Mycophenolate mofetil|"MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd~Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)~Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance."
89671031|NCT00347412|Experimental|Group A: NOV-002 plus Chemotherapy|NOV-002 in combination with Paclitaxel and Carboplatin
89671032|NCT00347412|Active Comparator|Group B: Chemotherapy Alone|Paclitaxel and Carboplatin
89671033|NCT00189475|Active Comparator|Montelukast|Treated for 4 months with montelukast 4 mg per day
89671034|NCT00189475|Placebo Comparator|Placebo|Treated for 4 months with placebo
89671035|NCT04625634|Experimental|Consecutive work|Subjects will complete 2 consecutive days of simulated firefighting tasks in the heat. The simulated work consists of 20 minutes of simulated structural work in a hot environment, followed by 20 minutes of seated rest in a temperate room, mimicking a typical recovery period in structural firefighting. Subjects then re-enter the environmental chamber and complete 23 minutes of simulated overhaul work in a temperate environment.
89671036|NCT00193375|Experimental|Intervention|Patients received carboplatin [area under the concentration-versus-time curve of 5 intravenously (IV) day 1 every 3 weeks x 4), irinotecan (50mg/m2 IV days 1 and 8 every 3 weeks x 4], and radiation (1.8 Gy daily to a total of 61.2 Gy beginning with the 3rd cycle). Cycles 3 and 4 were 28 days each; with restaging after 4 cycles. Patients without progressive disease received bevacizumab (10 mg/kg IV every 14 days x 10).
89671037|NCT04603950|Experimental|study group|The first 20 patients received Continue Adductor Canal Block + Infiltration between the Popliteal Artery and Capsule of the Knee
89671038|NCT04603950|Sham Comparator|control group|The second 20 patients received Continue Adductor Canal Block alone
89671039|NCT05014152|Experimental|Single group|"This study is specially designed according to its age range and customized/non-customized range, and meets the requirements of ISO 80601-2-56 test population (table). Comply with the age range and population requirements of ISO 80601-2-56, as well as clinical and subject trials, including news to the population over five years old, and hopefuls must account for at least 30% of the total and less than 50% of the total.~Each subject uses Q-temp-w1 to measure axillary temperature and obtains 3 temperature values, and at the same time uses a reference body temperature patch (Omron thermometer MC-171W) to measure the other side axillary temperature, and 1 is measured Temperature value data. Perform clinical efficacy analysis based on the measurement results. The main evaluation indicators of the trial include clinical bias, limits of agreement, and clinical repeatability."
89671040|NCT00193453|Experimental|Intervention|Newly-diagnosed unresectable stage III/IV NSCLC patients were treated with docetaxel-30mg/m2 IV; gemcitabine-1000mg/m2 IV days 1, 8; cetuximab-400mg/m2 IV day 1, then 250 mg/m2 IV weekly. Patients received up to 6 cycles (21-d).
89671041|NCT00184717|Experimental|0.033 mg / NN-220|In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
89671042|NCT00184717|Experimental|0.067 mg / NN-220|In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
89671043|NCT00184717|No Intervention|No treatment|No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
89671044|NCT00184717|Experimental|No treatment --> 0.033 mg|In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
89671045|NCT00184717|Experimental|No treatment --> 0.067 mg|In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
89671046|NCT05614518|Experimental|18F-NaF-PET/CT|"Patients undergo an 18F-NaF-PET/CT scan and an 99mTc-MDP-BS±SPECT scan within a time frame of 7 days.~Generic Name: Sodium Fluoride F-18 injection Dosage Form: Injection Dosage: Administer 5-10 mCi as an intravenous injection Frequency and Duration: Single dose"
89671047|NCT05614518|Active Comparator|99mTc-MDP-BS±SPECT|"Patients undergo an 18F-NaF-PET/CT scan and an 99mTc-MDP-BS±SPECT scan within a time frame of 7 days.~Generic Name: Technetium[99mTc] Methylenediphosphonate Injection Dosage Form: Injection Dosage: Administer 10-25 mCi as an intravenous injection Frequency and Duration: Single dose"
89671048|NCT00091507|Experimental|1 -- GIK|GIK = glucose-insulin-potassium; In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin; infused at 1.5 ml/kg/hour for a total of 12 hours.
89671049|NCT00091507|Placebo Comparator|2 -- Placebo|Dextrose 5%, infused at 1.5 ml/kg/hour for total of 12 hours.
89671050|NCT05611164|No Intervention|Sperm selected by embryologist without software assistance|"For each patient, oocytes collected following one ovarian stimulation cycle are randomly distributed in two groups (no intervention and experimental arms), in a sibling oocyte study design. In the no intervention arm, the individual spermatozoa for injection are selected subjectively by the embryologist."
89214797|NCT05858710|Experimental|IV DPPG2-TSL-DOX|"DPPG2-TSL-DOX (20 or 40 or 50 mg/m^2) + regional hyperthermia (RHT)~3 dose levels are planned in this study: dose level 1 will be receiving 20 mg/m^2 DPPG2-TSL-DOX dose level 2 will be receiving 40 mg/m^2 DPPG2-TSL-DOX dose level 3 will be receiving 50 mg/m^2 DPPG2-TSL-DOX~Participants are to be treated with DPPG2-TSL-DOX infusion over 30 minutes and RHT every three weeks (one cycle = 21 days), receiving up to 6 cycles in total:~In the first cycle (cycle 1), DPPG2-TSL-DOX application will be performed without RHT in all participants for safety precaution.~In cycles 2-6, DPPG2-TSL-DOX will be applied in parallel with RHT. Dexrazoxane as cardioprotectant will be provided for participants overcoming a cumulative dose of 300 mg/m^2 DOX."
89214798|NCT05852873|Active Comparator|Nirmatrelvir-ritonavir|Participants will receive a standard 5-day treatment course nirmatrelvir plus ritonavir in addition to standard of care. The participants will receive 2 tablets nirmatrelvir 150 mg twice daily and 1 tablet ritonavir 100mg twice daily, both for a duration of 5 days. The tablets have been encapsulated to maintain blinding.
89214799|NCT05852873|Placebo Comparator|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets in addition to standard of care. The participants will receive 3 tablets twice daily for 5 days. The placebo tablets have the same shape and appearance as the active comparator product. The tablets containing placebo and active comparato have both been encapsulated in the same way to maintain blinding.
89214800|NCT05849259|Experimental|Dementia Care Quality at Home|Each HBPC practice will receive the Dementia Care Quality at Home intervention.
88995683|NCT02910661||Healthcare professionals|One focus group of healthcare professionals (HCP) representing the variety of multidisciplinary transplant team members at each center will be convened. We will aim for 4-8 HCP per group; however, the number will be dictated by the composition and size of the transplant team at each site. We expect variability in the organization of care across the 7 sites, which represent 2 countries and small to large program sizes; including all sites will capture this variability.
89214801|NCT05845359|Experimental|Methadone group|Patients in this group will receive intraoperative methadone.
89214802|NCT05845359|No Intervention|Control group|Patients in this group will receive saline (placebo), instead of methadone
89214803|NCT05838222|Experimental|Intervention Group|The intervention group will receive 3 sessions of SFBT from a licensed therapist in addition to treatment as usual
89214804|NCT05838222|Active Comparator|Control|This group will be the treatment as usual group who will receive primary care treatment without the SFBT intervention
89671051|NCT05611164|Experimental|Sperm selected with AI assistant SiD|"For each patient, oocytes collected following one ovarian stimulation cycle are randomly distributed in two groups (no intervention and experimental arms), in a sibling oocyte study design. In the experimental arm, the spermatozoa selection for injection is performed based on the recommendation of the AI assistant SiD."
89671052|NCT04757688|Experimental|Cardiac radioablation (CRA)|CRA delivered via linear accelerator (stereotactic body radiotherapy) to the suspected arrhythmogenic substrate to a dose of 25 Gy in 1 fraction.
89671053|NCT04439760|No Intervention|control study.|No intervention
89671054|NCT04439760|Active Comparator|superior cervical block.|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
89671055|NCT04431414||Group 1|Persons that are positive for SARS-CoV-2 and are asymptomatic
89671056|NCT04431414||Group 2|Persons that are positive for SARS-CoV-2 with recent onset of mild symptoms (not hospitalized)
89671057|NCT04431414||Group 3|Persons that are positive for SARS-CoV-2 and are symptomatic hospitalized patients
89671058|NCT05611086|Experimental|NAC Group|Participants of this group was given capsules containing 600mg N-acetylcysteine
89671059|NCT05611086|Placebo Comparator|Placebo|Participants of this group was given capsules containing lactose
89671060|NCT04338750|Experimental|Telephone Acceptance and Commitment Therapy Intervention for Caregivers (TACTICs)|Participants in the ACT arm will learn new and more adaptive ways to respond to challenges, including anxiety and the irreversibility of dementia and its behavioral manifestations.
89671061|NCT04338750|Active Comparator|minimally-Enhanced Usual Care (mEUC)|Participants randomized to mEUC will receive educational, science-based reading and resources, including a listing of Alzheimer's Association sponsored support groups closest to their home address.
89671062|NCT04928742|Experimental|Treatment (9-week online CBT group)|Participants assigned to the treatment group will participate in a 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. All participants in the treatment group will be mailed a hardcopy of the program manual.
89671063|NCT04928742|No Intervention|Control (treatment as usual)|The control group will receive standard postnatal care from Niagara Region Public Health, their obstetrician, midwife, and/or family physician.
89671064|NCT05614440|Active Comparator|Only local anesthetic group|
89671065|NCT05614440|Experimental|Tramadol group|
89671066|NCT05613192|Active Comparator|Placebo|Group 1: patients receive the standard conventional therapy in addition to placebo for 4 months.
89671067|NCT05613192|Experimental|Cholecalciferol|Group 2: patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
89671068|NCT00194779|Experimental|Treatment (neoadjuvant therapy, adjuvant therapy)|See Detailed Description.
88995684|NCT02910388|Experimental|LLETZ with colposcopy|The LLETZ procedure will be performed under direct colposcopic vision
88995685|NCT02910388|Active Comparator|LLETZ without colposcopy|The LLETZ procedure will be performed without colposcopy
88995686|NCT02910427|Placebo Comparator|Na salt|regular salt
88995687|NCT02910427|Active Comparator|K salt|potassium-enriched salt
88995688|NCT02910427|Active Comparator|K/Mg salt|potassium and magnesium-enriched salt
88995689|NCT04687930|Active Comparator|Active genicular nerve block group|group 1 will receive genicular nerve block. The injection and US examination will be done by two experienced sonographers. They were blinded to clinical data. Patients will also be blinded for the injected substance. Each point will be injected with 2 ml of Lidocaine hydrochloride 2 % (Xylocaine, Astrazeneca). The injection will be done using the 3 point technique (superior medial, superior lateral, and inferior medial genicular nerves).
89214805|NCT05837533|Experimental|Intervention group|Patients will receive information about their diagnosis, treatment and/or prognosis through the systematic communication model under study used by their oncologist during their medical consultation.
88995690|NCT04687930|Other|intra-articular steroid injection group|while group 2 received intra-articular triamcinolone under ultrasound guidance and through injecting the supra-patellar bursa.
88995691|NCT03777904||Children with high serum ferritin|Children with very high serum ferritin levels and confirmed iron toxicity will have a urine sample and blood sample drawn at the same time. Both samples will have ferritin levels and iron content measured and compared for correlation.
88995692|NCT03759925|Experimental|Nutritional Support|The intervention consists of home delivery of medically-appropriate food support (DASH and diabetic diet compliant) in the form of prepared meals and/or groceries and monthly individual nutritional counseling with a Registered Dietician.
88995693|NCT03759925|No Intervention|Standard of Care|The control group will receive standard of care follow up care after their hospitalization for acute decompensated heart failure.
88995694|NCT00150839|Active Comparator|1|Probands receive mirtazapine and venlafaxine
88995695|NCT00150839|Placebo Comparator|2|Patients receive mirtazapine and placebo
88995696|NCT04723914|Experimental|Treatment group|Dual target CAR-T cell therapy
88995697|NCT00150878|Other|12 Gy/Cyclophosphamide|Standard intensity conditioning
88995698|NCT00150878|Experimental|8 Gy /Fludarabine|Reduced-intensity conditioning
89671069|NCT05474664|Experimental|protein-losing enteropathy after Fontan operation|single-arm with protein-losing enteropathy after Fontan operation
89671070|NCT00093847|Experimental|1 Oral SAMe Tosylate|Participants receiving the oral SAMe tosylate
89671071|NCT00093847|Placebo Comparator|2 Oral Placebo Pill Twice Daily|Participants receiving placebo
89671072|NCT02096575|Experimental|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~In addition, the Nitrous oxide group will receive two placebo pills. Nitrous oxide will be administered via a disposable scented nasal mask to blind patients to the intervention. Nitrous oxide will be administered at a fixed ratio of 60% nitrous oxide and 40% oxygen. The nasal mask will be placed on the patient's nose and the nitrous oxide will be administered continuously."
89671073|NCT02096575|No Intervention|Standard care group|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~The standard care group will receive one 5/325 mg Percocet, and 1 mg of lorazepam, 30 minutes before the procedure. The standard care group will receive oxygen by mask intraoperatively."
89671074|NCT05614362|Experimental|Channa striatus extract|Channa striatus group was given 3x1 500mg dose of Channa striatus for 21 days
89671075|NCT05614362|Placebo Comparator|Placebo|Placebo group was given 3x1 dose of maltodextrin for 21 days
89671076|NCT04338984|Active Comparator|General anesthesia alone (AG)|"Opioid based analgesia:~Fentanyl 5 mcg/kg is standard dose at induction. Further dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
89671077|NCT04338984|Experimental|Erector Spinae Plane Block and General Anaesthesia (ESPAG)|"Bilateral single shot erector spinae plane block with Ropivacaine 0.5% (total dose 3mg/kg) and Dexamethasone 8mg per every 20ml Ropivacaine 0.5% is performed before induction of general anaesthesia. A minimum 30 minutes interval is allowed before skin incision.~Fentanyl 5 mcg/kg is standard dose at induction; rescue dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline).~Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol."
89671078|NCT05614284|Experimental|Virtuous|Virtuous +/- Local Bone
89671079|NCT05614284|Active Comparator|Autograft|Autograft +/- Allograft Chips
89671080|NCT04208724|Experimental|Training program|Community-based organizations participate in the support program, consisting of 2 half-day training workshops over 2 weeks, and 30-minute bi-weekly consultations in order to adapt and implement the cancer screening intervention for community members.
89671081|NCT04148508|Experimental|Tailored Emotional Competence|Self-help Tailored Emotional Competence delivered via mobile app
89671082|NCT04148508|Active Comparator|Cognitive-behavioural Approach|Self-help cognitive-behavioural approach delivered via mobile app
89671083|NCT04148508|Placebo Comparator|Self-monitoring|Self-help self-monitoring delivered via mobile app
89671084|NCT00095563|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
89671085|NCT05473806|Experimental|Pioglitazone 15mg|pioglitazone hydrochloride. PO. 2 tablets once a day.
89671086|NCT05473806|Experimental|Evogliptin 5mg|Evogliptin tartrate. PO. 1 tablets once a day.
89671087|NCT00089609|Experimental|Main cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days. Thalidomide 200 mg by mouth daily throughout the cycle. Prednisone 10 mg by mouth daily throughout the cycle. Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
89671088|NCT00089609|Experimental|Expansion cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes and Bevacizumab 15 mg/kg intravenously was given for 2 cycles. After two cycles Prednisone 10 mg by mouth daily and Thalidomide 200 mg by mouth daily was added.
89671089|NCT00195013|Experimental|Glutamine|10 grams three times a day (orally) for four days and then stop
89671090|NCT00195013|Placebo Comparator|Placebo|10 grams three times a day (orally) for four days and then stop
89671091|NCT04661514|Experimental|Safety, Tolerability, and Treatment|On dosing day, each participant will receive 1 x 25 mg treatment bottle containing 5 x 5 mg oral capsules of psilocybin. The administration session will last approximately 4-6 hours and will be supported by a lead therapist and an assisting therapist.
89671092|NCT04095702|Experimental|Weighted Pacifier|Patient will receive a weighted pacifier for 48 hours of their stay in the NICU.
89671093|NCT04095702|Placebo Comparator|Non-Weighted Pacifier|Patient will receive a standard non-weighted pacifier for 48 hours of their stay in the NICU.
89671094|NCT04678505|Experimental|Panel A: Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of 100 mg MK-3402 via intravenous (IV) infusion on Day 1.
89671095|NCT04678505|Experimental|Panel B: Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
89671096|NCT04678505|Experimental|Panel C: Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
89671097|NCT04678505|Experimental|Panel D: Healthy Participants|Healthy matched control participants will receive a single dose of 100 mg MK-3402 via IV infusion on Day 1.
89671098|NCT04678505|Experimental|Panel E: End-Stage Renal Disease (ESRD) Undergoing Hemodialysis|Participants with ESRD undergoing HD will receive a single dose of 100 mg MK-3402 via IV infusion after HD on Day 1 of Period 1 and before HD on Day 1 of Period 2. There will be at least a 6-day washout period before dosing in Period 2.
89671099|NCT00195403||1|
89671100|NCT05612958|Experimental|DKM-410|Participants are injected with an appropriate amount(up to 2.0ml) depending on the degree of nasolabial folds at baseline
89671101|NCT05612958|Active Comparator|Juvederm ULTRA PLUS XC 1.0ml|Participants are injected with an appropriate amount(up to 2.0ml) depending on the degree of nasolabial folds at baseline
89671102|NCT04678349|Experimental|PHGG|Patient who met inclusion criteria and consented during intervention period will be assigned as PHGG group. Surgical medical officer will obtain consent from eligible subject. After consented, subjects will be assessed weight and PG-SGA during admission. They will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar once allowed orally. Staff nurse in charged will monitor compliance of subject on the PHGG. Daily stoma output & consistency will be recorded and daily energy protein intake will be assessed by dietitian in charged. Renal profile will be taken daily as routine procedure for patients with ileostomy.
89671103|NCT04678349|Other|CG|Historical records of patients with ileostomy under conventional care from January 2016 to June 2019 (before started on PHGG) will be assessed and traced retrospectively from the medical system. Data will be recorded in data collection sheet.
89671104|NCT00197119|Active Comparator|Group Twinrix Adult|Subjects received Twinrix™ Adult (720/20) in a 0, 6 month schedule in the primary study.
89671105|NCT00197119|Active Comparator|Group Twinrix Junior|Subjects received Twinrix™ Junior (360/10) in a 0, 1, 6 month schedule in the primary study.
89671106|NCT04643327|Experimental|Active arm|125mg Levetiracetam capsules taken twice daily (morning and evening) for 14 days
89671107|NCT04643327|Placebo Comparator|Placebo arm|125mg maize starch-based placebo capsules taken twice daily (morning and evening) for 14 days
89671108|NCT05404789|Other|Diabetic Subjects|Individuals with history of diabetes mellitus
89671109|NCT05404789|Other|Subjects with history of arrhythmia|Individuals with history of cardiac arrhythmia
89671110|NCT05404789|Other|Control Subjects|Individuals without history of either Diabetes or cardiac arrhythmia
89671111|NCT03088241|Experimental|Intervention|switch to second-line ART
89671112|NCT03088241|No Intervention|Control|Standard of care: no switch to second-line ART
89671113|NCT00095875|Experimental|Arm I|Patients receive induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil. Treatment repeats every 21 days for 3 courses. Patients achieving a pathologic complete response at the primary site and a clinical complete response in the neck then receive carboplatin once weekly and undergo concurrent radiotherapy once daily, 5 days a week, for 7 weeks. Patients with a partial response at the primary site (i.e., positive biopsy), stable disease, or radiographic evidence of persistent disease in the neck receive docetaxel once weekly for 4 weeks and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
89671114|NCT00095875|Experimental|Arm II|Patients receive cisplatin IV on weeks 1 and 4 and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
89671115|NCT03086993|Experimental|Melphalan/PHP|Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
89671116|NCT03086993|Active Comparator|Cisplatin and Gemcitabine|Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
89671117|NCT04089072|Experimental|Control group|Patients in the control group will have phenylephrine infusion starting at 50 mcg/min and titrated to maintain a MAP >65 mmHg as a third line vasopressor. Maximum dose of Phenylephrine is 300 mcg/min.
89671118|NCT04089072|Experimental|Intervention group|Patients enrolled in the intervention group will receive 2 mg/kg IBW (Ideal Body Weight) bolus, given over 15 mins, of ProvayBlue® followed by a concomitant infusion at 2 mg/kg/hr (IBW) mixed in D5W, which will continue for 24 hours. ProvayBlue® ( Methylene Blue) will be used as the third-line vasopressor.
89671119|NCT00006227|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
89671120|NCT04087980|Experimental|Poseidon System Treatment|
89671121|NCT00096109|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89671122|NCT04062942||DDD patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.
89671123|NCT00097669|Active Comparator|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug)|Active Treatment Arm: VITATOPS study tablet (folate 2 mg, B6 25 mg, B12 500 ug). Taken daily for the duration of the study.
89671124|NCT00097669|Placebo Comparator|Placebo Tablet|Placebo Treatment Arm: The placebo tablet will have the same appearance, taste and texture as the vitamin preparation and contains excipients, coating and coating aids.
89671125|NCT00010439|Experimental|1 Alendronate for 12 months|Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.
89671126|NCT05473494|Experimental|training group|
89671127|NCT05473494|Active Comparator|control group|
89671128|NCT04463940||Umbilical cord arterial blood|participant's umbilical cord arterial blood will be obtained
89671129|NCT04463940||Umbilical cord venus blood|participant's umbilical cord Venus blood will be obtained
89671130|NCT04463940||Maternal blood|participant's blood will be obtained
89671131|NCT01898455|Experimental|Intranasal Cooling|RhinoChill Intranasal cooling, administered for 20 minutes. 10 treatment sessions per participant.
89671132|NCT04452708||HFNC at 30-60L/min|HFNC at 50-60L/min with humidification at 37C (Airvo 2, Fisher & Paykel, Auckland, New Zealand) will be applied for patients with moderate type 1 respiratory failure
89671133|NCT04452708||NIV|NIV (Respironics V60) via oronasal mask (Quattro, ResMed) will be reserved for patients with type 2 respiratory failure
89671134|NCT04452708||Conventional nasal oxygen|Oxygen 1-5 L/min via nasal cannula for those with mild type 1 respiratory failure
89671135|NCT04392336|Experimental|Trust/Respect feedback|Clinicians with consumers in this arm receive feedback on trust/respect in addition to symptom feedback.
89671136|NCT04392336|No Intervention|No Trust/Respect feedback|Clinicians with consumers in this arm do not receive feedback on trust/respect and only receive symptom feedback.
89671137|NCT00200161|Active Comparator|Metronomic Therapy Cohort|Concurrent temozolomide and radiotherapy plus lose dose of temozolomide
89671138|NCT00200161|Experimental|Dose-Dense Therapy Cohort|Concurrent temozolomide and radiotherapy plus high dose of temozolomide
89671139|NCT00200785|Active Comparator|Garlic powder in ambient water|high allicin
89671140|NCT00200785|Experimental|garlic powder in boiling water|no allicin
89671141|NCT00016913|Experimental|Neo-Adj ChemoTx + ablation prior to RT|Patients with localized high-risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg/m^2 intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3-dimensional conformal or intensity-modulated radiotherapy (total dose of 77.4 gray [Gy] in 1.8-Gy fractions). All patients received androgen deprivation therapy with either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.
89671142|NCT05558046||Low Ovarian Reserve|Patients diagnosed as low ovarian reserve were recruited to the study who have Antimüllerian Hormone level of 1 ng/ml or lower. Patients with low ovarian reserve were diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. Male infertility is an exclusion.
89671143|NCT05558046||Unexplained Infertile (Control group)|Patients diagnosed as unexplained infertility (UI) were recruited to the study who have Antimüllerian Hormone level of 1.5 ng/ml or higher as a control group. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy.
89671144|NCT00201409|Experimental|1|Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).
89671145|NCT00201409|Placebo Comparator|2|Participants will be randomized to receive placebo.
89671146|NCT03889080||SCN9A-group|Patients with SCN9A-associated small fiber neuropathy
89671147|NCT03889080||Skin biopsy|Patients with SFN confirmed with a decreased intra-epidermal nerve fiber density (IENFD)
89671148|NCT03889080||Control|Age- and gender-matched healthy controls
89671149|NCT03773406|Active Comparator|Offline tDCS-before therapy|Participants will receive 20 minutes of tDCS prior to the 40 minute speech-language therapy session.
89671150|NCT03773406|Active Comparator|Offline tDCS-after therapy|Participants will receive 20 minutes of tDCS after the 40 minute speech-language therapy session.
89671151|NCT03773406|Active Comparator|Online tDCS|tDCS will be applied at the beginning of the 40 minute speech-language therapy session and will last for 20 minutes.
89671152|NCT03773406|Sham Comparator|Sham tDCS|Sham tDCS will be applied at the beginning of the 40 minute speech-language therapy session.
89671153|NCT00023309|Experimental|Lamivudine and adefovir|
89671154|NCT00023309|Active Comparator|Adefovir|
89671155|NCT02233101|Active Comparator|Oral Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
89671156|NCT02233101|Active Comparator|Intravenous Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
89671157|NCT00098059|Experimental|Famciclovir, pediatric oral formulation|single-arm
89671158|NCT02440581|No Intervention|Control, low turnover|No intervention in low turnover osteoporosis control group.
89671159|NCT02440581|Experimental|Treatment, low turnover|Low turnover osteoporosis group treated with teriparatide and cinacalcet.
89671160|NCT02440581|No Intervention|Control, high turnover|No intervention in high turnover osteoporosis control group.
89671161|NCT02440581|Experimental|Treatment, high turnover|High turnover osteoporosis group treated with alendronate.
89671162|NCT01359150|Experimental|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).|CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.
89671163|NCT01359150|Placebo Comparator|Treatment Group 2:Placebo CP-690,550 (100 subjects).|Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
89671164|NCT00098371|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for > 6 months after completion of treatment may receive 6 additional courses of flavopiridol.
89671165|NCT04745988|Experimental|Lenvatinib Plus Pembrolizumab|One cycle is 21 days, with Lenvatinib plus Pembrolizumab repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
89671166|NCT04745988|Experimental|Lenvatinib, Pembrolizumab Plus FLOT|One cycle is 21 days, with Lenvatinib, Pembrolizumab plus FLOT repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
89671167|NCT01647945|Placebo Comparator|Placebo|
89671168|NCT01647945|Experimental|FK506 level < 2|
89671169|NCT01647945|Experimental|FK506 level 2-3|
88995699|NCT03782740|Experimental|Dysmenorrhea Melatonin 10 mg|In the dysmenorrhea group: 2 capsules with 5 mg melatonin will be given in the evening for seven days consecutively during menstruation for two mentrual cycles. Compared with placebo.
89671170|NCT01647945|Experimental|FK506 level 3-5|
89671171|NCT03755076|Experimental|Perceptual cuing|Two perceptual cues will be provided: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context. The effect of the two cues on bimanual coordination will be determined.
89671172|NCT01648491|Experimental|Stem Cell treatment|Muscle Biopsy and Injection of autologous stem cells
89671173|NCT00100165|Experimental|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg twice per day in a blinded capsule.
89671174|NCT00100165|Experimental|3-(2,4 dimethoxybenzylidene anabaseine)75 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg twice per day in a blinded capsule.
89671175|NCT00100165|Placebo Comparator|placebo|Patient receives placebo twice per day in a blinded capsule.
89671176|NCT04351191|Active Comparator|HCQ Regular dose|Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
89671177|NCT04351191|Experimental|HCQ Loading dose|Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
89671178|NCT04351191|Active Comparator|CQ regular dose|Cholorquine 500 mg BID for 5 days plus standard of care
89671179|NCT04351191|Placebo Comparator|Placebo|Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)
89671180|NCT01469000|Experimental|250 mg Gefitinib/500 mg Pemetrexed|250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib taken orally QD.
89671181|NCT01469000|Active Comparator|250 mg Gefitinib|250 milligrams (mg) Gefitinib taken orally QD
89671182|NCT02995317||Fall accidents|
89671183|NCT00201877|Experimental|Velcade and Rituximab|"Rituximab 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13, and 14 prior to Velcade™ administration.~Velcade™ 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, and 14"
89671184|NCT05557500|Experimental|Fibromyalgia patients with use of rtms sessions for treatment|Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions
89671185|NCT05557500|Experimental|Fibromyalgia pt with use of sphenopalatine ganglion block as treatment|Pain killing intervention for pain control of myofacial pain in fibromyalgia patients
89671186|NCT05399628|Experimental|Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter|Participants will be assigned to perform the procedure with a LISA catheter with a marked tip
89671187|NCT05399628|Active Comparator|Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter|Participants will be assigned to perform the procedure with a LISA catheter with an unmarked tip
89671188|NCT05335291||Group I|
89671189|NCT01490060|Experimental|Single Dose Day 1|Arm 1, Single Dose: Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 or Day 1 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
89671190|NCT01490060|Experimental|Two Doses Day 1 + Day 4|Arm 2, Two Doses: Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 or Day 1 + Day 4 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
89671191|NCT05391672|Other|Repair group|Repair of partial torn ACL by suturing stump and fixation to femoral footprint by anchors
89671192|NCT05391672|Other|Augmentation group|We will use hamstring graft in which fixation of graft will be by adjustable loop devices for femoral part fixation & Bioscrews +/- staples for tibial part fixation
89671193|NCT01652001|Experimental|Malic Acid 1%|"Intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride 0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain).~Spray was transferred by foreign personnel into identical opaque flasks(without any brand name)labeled A."
89671194|NCT01652001|Placebo Comparator|Control|Control group was given a placebo with opaque flask(without any brand name)labeled B and with the same presentation and composition than Experimental group (excepting 1% malic acid).
89671195|NCT03557892|Experimental|CSII+CGM|
89671196|NCT03557892|Active Comparator|MDI with degludec|
89671197|NCT04090736|Experimental|Arm A: Pevonedistat plus Azacitidine|Pevonedistat 20 mg/m2 IV on days 1, 3, and 5 plus Azacitidine 75 mg/m2 subcutaneous administered on a 5-on/2-off [weekend]/2-on schedule in 28-day cycles (intravenous Azacitidine can be administered for any patients who have non-tolerated local reactions)
89671198|NCT04090736|Active Comparator|Arm B: Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off [weekend]/2-on schedule in 28-day cycle (intravenous azacitidine can be administered for any patients who have non-tolerated local reactions)
89671199|NCT05557344|Active Comparator|Oral acetaminophen arm|they will receive oral acetaminophen, placebo (saline) IV
89671200|NCT05557344|Active Comparator|IV acetaminophen arm|they will receive IV acetaminophen, placebo oral
89671201|NCT01653405|Experimental|Intervention Group|VA patients treated at anticoagulation clinics at 8 sites in VISN 1. The intervention included a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
89671202|NCT01653405|No Intervention|Control Group|VA patients treated at anticoagulation clinics at 116 sites outside of VISN 1.
89671203|NCT00101413|Experimental|Sorafenib|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles
89671204|NCT04089332|Experimental|Enrolled, eligible|Single arm for eligible subjects
89671205|NCT03515226|Active Comparator|Traditional Training|20 hours of didactic education and training in CBT principles, depression assessment and cultural competency and 25 hours in dyad role playing of CBT manualized treatment sessions with supervision.
89671206|NCT03515226|Experimental|ITS based training|Traditional training plus the addition of an algorithmic based training computer program that trains clinicians in clinical micro-competencies.
89671207|NCT01452152|Experimental|Genotype-directed, clopidogrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
89671208|NCT01452152|Experimental|Genotype-directed, prasugrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
89671209|NCT01452152|No Intervention|Standard of Care|Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.
89671210|NCT03373656|Experimental|low antibody titers|Antibody titers lower than protection level
89671211|NCT03373656|Other|high antibody titers|Antibody titers higher than protection level
89049345|NCT02902718|Experimental|mē device|The subjects will perform treatments with the mē device at the clinic under the supervision of the study personnel at the baseline visit, 1 week and 2 week visits, and 1 month and 2 month visits. In addition the subject will be expected to perform treatments at home according to the following schedule: daily treatments at home for 5 days a week during the first month, followed by 2 treatments a week during the 2nd month, and optionally 1 time a week during the 3rd month.
89049346|NCT04623645|Experimental|ultrasound group|patient using ultrasound technique.probe will be placed over submandibular area, the thyrohoid muscle and thyrohyoid membrane will be identified between greater horn fo hyoid bone and thyroid cartilage , 3 ml of lignocaine will be placed on space between thim and the procedure will repeated on contra lateral side.
89049347|NCT04623645|Active Comparator|anatomical blind group|patient using anatomical land mark technique, internal branch of superior laryngeal nerve will be blocked slightly anterior to greater horn of hyoid bone . by 3 ml lignocaine . the procdure will be repeated on contra lateral side .
89671212|NCT05612334|Experimental|Experimental|The data collection forms used in the research were applied in the treatment group at the first polyclinic visit (0. month) via face-to-face interviews. First, they were informed about the benefits of exercise and walking. They were also informed about the duration and type of exercise and what should be considered before, during, and after exercises. Then, an informative training booklet prepared by the researcher containing the same information was given to them. An exercise program (5 minutes warm-up-30 minutes walking-5 minutes cooling down) was demonstrated to the patient by the researcher, and then the patient performed the first exercise under the supervision of the researcher. Beginning with the second exercise, the patient performed a 40-minute exercise program, 3 days a week, for 3 months. During this period, the researcher regularly made phone calls once a week to motivate the patient and check whether the patient performed the exercise program.
89671213|NCT05612334|Placebo Comparator|Placebo|The breathing exercise group, which constitutes the placebo-control group, was first informed about correct breathing techniques by the researcher, and an informative training brochure prepared by the researcher, containing correct breathing exercise information, was given to them. The exercise was performed by the researcher and shown to the patient. The first exercise was performed by the patient under the supervision of the researcher. They were informed about the continuation of the breathing exercise program for 3 months, once a day for 10 minutes, starting from the 2nd exercise. Regular phone calls were made once a week.
89671214|NCT05612334|No Intervention|No intervention|The control group was contacted by regular phone calls once a week to monitor their compliance with the treatment, to encourage them to express their problems, if any, and to motivate them for the treatment process.
89671215|NCT01451762|Placebo Comparator|Placebo|.9 normal saline IV
89671216|NCT01451762|Active Comparator|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
89671217|NCT01451762|Active Comparator|50 mg diphenhydramine IV|50 mg diphenhydramine IV administered before surgery
89671218|NCT01654107|Experimental|Persistence Targeted Smoking Cessation|Persistence Targeted Smoking Cessation - 8 weeks counseling + 12 weeks nicotine lozenge
89671219|NCT01654107|Active Comparator|Clearing The Air|Clearing the Air Smoking Cessation intervention - 8 weeks counseling + 12 weeks nicotine lozenge
89671220|NCT03253926|Experimental|Lorcaserin + Marijuana|
89671221|NCT03253926|Placebo Comparator|Placebo + Marijuana|
89671222|NCT03085680|Experimental|Curcumin|Participants will be given identical capsules containing curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
89671223|NCT03085680|Placebo Comparator|Placebo|Participants will be given identical capsules containing placebo (microcrystalline cellulose) and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
89671224|NCT04334538|Active Comparator|S-RUTF|Children will receive approximately 175 kcal/kg/d of standard ready to use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
89671225|NCT04334538|Experimental|oat-RUTF|Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
89671226|NCT01468844|Experimental|Minocycline|Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months
89671227|NCT01468844|Placebo Comparator|Placebo|Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months
89671228|NCT03029598|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30 minutes on days 8 and 15. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89671229|NCT00203203|Experimental|Stem Cell Therapy|Subject is randomized to receive Stem Cell Therapy (intramyocardial injection of stem cells) via NOGA mapping.
89671230|NCT00203203|Other|Control, then Stem Cell Therapy|"Subject is randomized to receive a NOGA mapping and no injections at time of active enrollment.~At 6 months, subject is offered stem cell therapy."
89671231|NCT01451606|Placebo Comparator|Placebo pill|A pill that looks like the active drug, but does not contain any active ingredients.
89671232|NCT01451606|Active Comparator|Duloxetine|The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
89671233|NCT00204373|Experimental|single group|This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.
89671234|NCT03026738|Experimental|Laparoscopic anterior mesh rectopexy|A superficial peritoneal window will be made over the right part of the sacral promontory and extended caudally over the right outer border of the mesorectum down to the right side of the pouch of Douglas. In females, the vagina will be retracted anteriorly and a careful dissection of the rectovaginal septum will be performed down to the pelvic floor. A strip of polypropylene (3×20 cm) mesh will be introduced and sutured as distally as possible on the anterior rectal wall/ perineal body with three, interrupted nonabsorbable sutures.The posterior wall of the vagina will be fixed to the mesh using absorbable sutures. The mesh is then secured tension-free to the sacral promontory using three absorbable sutures. The mesh will be peritonealized by suturing the free edges of the previously divided peritoneum over the mesh to provide additional ventral elevation of the enterocele and avoid small bowel adhesions to the mesh.
89049348|NCT02902835|Active Comparator|Referral to treatment (Control)|The control group will receive a referral to buprenorphine treatment by the research staff.
89671235|NCT03026738|Active Comparator|Laparoscopic posterior mesh rectopexy|"Mobilization of the mesorectum posteriorly from the sacral promontory to the pelvic floor. Lateral stalks will not be divided. Bowel resection and circumferential division of the peritoneum will not be done in this study. A T-shaped polypropylene mesh will be placed with the vertical leg laying flush with the anterior surface of the sacrum, and secured to the promontory and sacrum with three absorbable sutures. The mesh wings will be sutured to the lateral sides of the rectum/mesorectum with two absorbable sutures on each side. The visceral peritoneum will be left open."
89671236|NCT03026270|Other|seven layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
89671237|NCT03026270|Other|ten layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
89671238|NCT03026192||no PDA|These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
89671239|NCT03026192||hsPDA|These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography
89671240|NCT01654263|Experimental|Group IA: Pneumococcal vaccine-naive, age 55 - 64|Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to 147 subjects vaccine-naive adults
89671241|NCT01654263|Experimental|Group IB: Pneumococcal vaccine-naive, age 65 - 74|Open- label, PCV13 given as 0.5 mL IM injection to 147 subjects vaccine-naive adults
89671242|NCT01654263|Experimental|Group IIA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
89049349|NCT02902835|Experimental|BUP-FAST Intervention|Thirty-six participants will each be paired with a trained peer mentor who will provide the BUP-FAST intervention.
89049350|NCT04623762|No Intervention|Control group|yoga was not done
89049351|NCT04623762|Experimental|Experimental group|yoga was done
89671243|NCT01654263|Experimental|Group IIAA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
89671244|NCT01654263|Experimental|Group IIB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
89049352|NCT02903069|Experimental|Stage 1: Concomitant Treatment|"MRZ + TMZ + RT~Patients who complete Concomitant Treatment may continue on to Adjuvant Treatment."
89049353|NCT02903069|Experimental|Stage 1: Adjuvant Treatment|MRZ + TMZ
89671245|NCT01654263|Experimental|Group IIBB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
89671246|NCT01005615|Sham Comparator|No FES Cycling|
89671247|NCT01005615|Active Comparator|FES Cycling|
89671248|NCT01654887|Experimental|Lung Ultrasound|LUS first with the option of obtaining CXR second
89671249|NCT01654887|Active Comparator|Chest X-Ray|CXR first followed by LUS second
89671250|NCT01655043|Experimental|coronary artery disease patients|Patients with suspected coronary artery disease prospectively recruited for myocardial perfusion MRI. All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar, Lantheus) at both stress and rest. Stress to be induced using 5 ml intravenous (IV) regadenoson (Lexiscan, Astellas US LLC), and the effects of regadenoson were reversed with 50 mg IV aminophylline following the completion of stress imaging.
89671251|NCT02249325|Experimental|Probiotic dietary supplement|Florajen3 oral probiotic (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum) taken daily beginning at 28 weeks gestation.
89671252|NCT02249325|No Intervention|Placebo|Women in the comparison group did not take a placebo.
89049354|NCT02903069|Experimental|Stage 2: Dose-Expansion|"MRZ + TMZ + RT followed by MRZ + TMZ~In Stage 2 (dose-expansion): a minimum of 12 and up to approximately 18 additional evaluable patients will be enrolled in a cohort in which Concomitant Treatment (MRZ + TMZ + RT) is followed by Adjuvant Treatment (MRZ + TMZ) to confirm the MTD for each treatment regimen as determined in the Dose-Escalation (Stage 1), and to assess preliminary activity of the recommended Phase 2 dose (RP2D)."
89049355|NCT02903069|Experimental|Optune Arm|MRZ + TMZ + Optune
89049356|NCT04623723|Sham Comparator|Perio Slim (PS)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with PS (DS-016A, EMS® Piezon, Switzerland) scaler tip
89049357|NCT04623723|Active Comparator|Conventional scaler tip|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with conventional (FS-407, EMS® Piezon, Switzerland) scaler tip
89049358|NCT02902679|Experimental|End Stage Renal Disease Subjects|Subjects given a single oral dose of BMS-986177 before (Period 1) and after (Period 2) a hemodialysis session
89671253|NCT03065049|Experimental|Peer-PA+Fitbit|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
89671254|NCT03065049|Active Comparator|Fitbit Only|Participants will be given a Fitbit activity tracker along with brief advice for increasing physical activity.
89049359|NCT04623840|Experimental|Exercised group|.(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
89049360|NCT04623840|Active Comparator|non-exercised group|(n=30) will be sedentary obese men with ED. All participants will receive only five milligrams of tadalafil, one time per day, for eight weeks.
89049361|NCT02902640||Acute Bronchitis Participants|Participants with acute bronchitis for whom the treating physician has decided to initiate treatment with Balsamic Bactrim, will be observed. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling. The study protocol does not enforce any treatment.
89049362|NCT04623528||Pericarditis patients with constrictive physiology|Patients with pericarditis and signs of constrictive physiology (increased ventricular coupling)
89049363|NCT04623528||Pericarditis patients without constrictive physiology|Patients with pericarditis but without signs of constrictive physiology (normal ventricular coupling)
89049364|NCT04623528||Dilated cardiomyopathy patients with biventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular and right ventricular ejection fraction less than 35%
89671255|NCT03065049|No Intervention|Usual Care|Participants do not receive any intervention but participate in the assessments only.
89671256|NCT00658983|Experimental|1|Autologous Platelet Enriched Gel
89671257|NCT00658983|Active Comparator|2|Metalloproteinase Inhibitor (Promogran)
89671258|NCT02249247|Experimental|Low dose of BIIL 284 BS|
89671259|NCT02249247|Experimental|Medium dose of BIIL 284 BS|
89671260|NCT02249247|Experimental|High dose of BIIL 284 BS|
89671261|NCT02249247|Placebo Comparator|Placebo|
89671262|NCT00473343|Experimental|Metvix® PDT|Participants with basal cell carcinoma (BCC) lesions were administered to photodynamic therapy (PDT) with Metvix® cream 160 milligrams per gram (mg/g) applied for three hours, followed by illumination using non-coherent light with a fluency of 75 Joule per centimeter square (J/cm*2) and fluency rate of 70-200 milliwatt per centimeter square (mW/cm*2) up to 13 weeks.
89671263|NCT00032591|Active Comparator|Arm 1|Patient Self-Testing (PST) of prothrombin time by international normalized ratio (PT-INR or INR) with weekly testing
89671264|NCT00032591|Other|Arm 2|High quality anticoagulation management (HQACM) with conventional monthly testing
89671265|NCT01657617|Experimental|Radiation Therapy|Boost Stereotactic Body Radiation Therapy (SBRT)
89671266|NCT02905929|Experimental|Sitting Less group|The 'reduce sitting' intervention group will receive three in-person health coaching sessions followed by five counseling phone calls. Participants will wear a thigh worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. At each in-person health coaching session participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. In addition to the three initial in-person counseling sessions using the ActivPAL feedback, participants will receive phone calls from the health educator biweekly to help overcome barriers, to work on self-monitoring and planning skills, and to prepare relapse prevention. Tools to help prompt standing, including a standing desk, will also be provided.
89671267|NCT02905929|Active Comparator|Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention developed and tested by the investigators in previous studies. This group will receive one in-person coaching session followed by seven phone coaching sessions.
89671268|NCT03087227|Experimental|NEUTROSIS Intervention Group|The NEUTROSIS Intervention group captures daily its temperature and the occurrence of other symptoms on the smartphone application. This information is then transmitted instantly to the hospital care team through the NEUTROSIS shared information system. The medical oncologist will be alerted in case of fever and will contact the patient.
89671269|NCT03087227|No Intervention|CONTROL Group|The control group will monitor daily its temperature and the occurrence of other symptoms on a paper surveillance diary and will have to contact the health team in case of fever as done in the usual care.
89671270|NCT05346341|Experimental|Minimally invasive techniques|
89671271|NCT01660191|Active Comparator|Pitavastatin 4mg|Pitavastatin 4mg tablet by mouth once daily for 12 weeks
89671272|NCT01660191|Active Comparator|Atorvastatin 20mg|Atorvastatin 20mg tablet by mouth once daily for 12 weeks
89671273|NCT01660191|Active Comparator|rosuvastatin 5 mg|rosuvastatin 5 mg tablet by mouth once daily for 12 weeks
89671274|NCT00033917|Active Comparator|1|indomethacin
89671275|NCT00033917|Placebo Comparator|2|placebo
89214806|NCT05837533|No Intervention|Control group|Patients will receive information about their diagnosis, treatment and/or prognosis through their usual care provided by their oncologist during their medical consultation.
89049365|NCT04623528||Dilated cardiomyopathy patients with preserved right ventricular systolic dysfunction|Patients with nonischemic dilated cardiomyopathy and left ventricular ejection fraction less than 35%, and right ventricular function >45%
89049366|NCT04623528||Patients with pulmonary arterial hypertension|Cohort of patients with pulmonary hypertension, either idiopathic or secondary to pulmonary emboli
89049367|NCT04623528||Control group|Cohort of subjects with no evidence of pericarditis, pulmonary hypertension, dilated cardiomyopathy and normal findings at cardiovascular magnetic resonance imaging
89214807|NCT05834946|Experimental|Group T-A|7 patients with history of periodontitis
89214808|NCT05834946|Experimental|Group T-B|7 patients with history of periodontitis
89671276|NCT02341287|Active Comparator|Warming hydrogel glove, then non-thermal glove|In the first two-week period, subjects will wear a warming hydrogel glove. In the second two-week period, subjects will wear a non-thermal glove. Also a actigraph to monitor sleep latency.
89671277|NCT02341287|Placebo Comparator|Non-thermal glove, then warming hydrogel glove|In the first two-week period, subjects will wear a non-thermal glove. In the second two-week period, subjects will wear a warming hydrogel glove. Also an actigraph to monitor sleep latency.
89214809|NCT05834946|Active Comparator|Group C-A|7 patients without history of periodontitis
89671278|NCT01660737||PASCALLERG® tablets in patients with hay fever|Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.
89671279|NCT00036569|Experimental|Interferon Alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
89671280|NCT01660815|Experimental|Healthy Volunteers|Cognitively normal, healthy volunteers at least 45 years of age.
89671281|NCT01968941|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT)
89671282|NCT01968941|Active Comparator|Conventional Radiotherapy|Conventional Radiotherapy (CRT)
89671283|NCT01660893|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and oxymetazoline HCl 0.05%
89671284|NCT01660893|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
89671285|NCT01660893|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
89671286|NCT01661283|Experimental|Arm A|All patients with MPNST will continue everolimus 10 mg daily and bevacizumab 10 mg/kg dose every 14 days
89671287|NCT05046093|Experimental|Single intervention arm - transbronchial cryobiopsy|Patients enrolled in this single arm will have lung nodules biopsied by transbronchial cryobiopsy.
89671288|NCT05042661|Experimental|acupuncture-like transcutaneous electrical nerve stimulation|"The experimental group received acupuncture-like transcutaneous electrical nerve stimulation three times a week for 4 weeks.~Invention and control groups are 4 weeks and 3 weeks respectively. Each time will be for 20 minutes acupuncture-like transcutaneous electrical nerve stimulation treatment"
89671289|NCT05042661|No Intervention|Control group:conventional therapy|The control group will receive routine care.
89671290|NCT01946373|Experimental|Chemotherapy + T cells + IL-2|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.
89671291|NCT01946373|Experimental|Chemotherapy + T cells + IL-2 + DCV|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
89671292|NCT04980417|Experimental|concomitant cholecystectomy|concomitant cholecystectomy with bariatric procedure
89671293|NCT04980417|Active Comparator|delayed cholecystectomy|delayed cholecystectomy
89671294|NCT01662297|Active Comparator|Quetiapine|Veterans remaining on quetiapine for insomnia.
89671295|NCT01662297|Active Comparator|Trazodone|Veterans switching from quetiapine to trazodone for the treatment of insomnia.
89671296|NCT01662531|Experimental|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.
89671297|NCT01600287|Experimental|IAADS group|dosage of propofol adjusted automatically by IAADS
89671298|NCT01600287|Active Comparator|Manual group|dosage of propofol adjusted manually
89671299|NCT00040937|Experimental|treatment arm|thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance
89671300|NCT01662765|Experimental|Surgery|"Circular incision 2-3 mm below the skin level in the umbilicus through the subcutaneous fat towards the linea alba. Dissection of the subcutaneous tissue within the umbilicus and its deep connection to preperitoneal fat through the linea alba. Excision of the umbilical complex containing pilonidal cyst 3 mm below the umbilical ostium.~Approximation of the subcutaneous tissue with a single purse-string absorbable suture. The specimen, including the umbilical complex (pilonidal cyst, and involved skin and subcutaneous tissue), was transferred to department of pathology for histopathological examination."
89671301|NCT01662765|Active Comparator|Conservative|"Conservative treatment described as follow:~Under local anesthesia, extracting all protruding hair, and curetting the granulation tissue and pilonidal cyst deep in the umbilicus.~postoperative management include antibiotic treatment with ampicilline plus sulbactam and ornidazole, shaving surrounding skin, washing twice daily, and keeping umbilicus dry."
89671302|NCT04756895|Experimental|Bayesian method|Pharmacists will perform vancomycin dose adjustments according to AUC0-24h/MIC using the Bayesian method with a web application
89671303|NCT04756895|Active Comparator|Standard method|Pharmacists will perform vancomycin dose adjustments according to trough levels of vancomycin.
89671304|NCT02234115|Experimental|Leuprolide Mesylate 50mg|All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
89671305|NCT04757285||control group|25 healthcare personnel volunteers not working in quarantine hospitals of matched age
89671306|NCT04757285||healthcare providers worked in Intensive Care Units|"35 physicians (28 males and 7 females) and 35 nurses (10 males and 25 females). All volunteers were in good physical health Exclusion criteria included hypertension, diabetes mellitus, obesity BMI ≥30, subjects with serum sodium ≤135 or ≥ 145 mmol /L at baseline or females receiving contraceptive pills.~Assigned participants were clinically evaluated for as hypertension, DM, dyslipidemia, renal function."
89671307|NCT02234427|Experimental|Aspirin|
89671308|NCT01663779|Experimental|Ultrasound radial artery catheter|Ultrasound guided radial artery catheterization.
88815727|NCT01040858|Placebo Comparator|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
89214810|NCT05834946|Active Comparator|Group C-B|8 patients without history of periodontitis
89671309|NCT01663779|Active Comparator|Palpation based artery catheterization|Blind insertion of radial artery catheterization
89671310|NCT01692951||Lung adenocarcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.
89671311|NCT01692951||Control matched to adenocarcinoma|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
89671312|NCT01692951||Lung squamous cell carcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.
89671313|NCT01692951||Control matched to squamous cell|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
89671314|NCT01600677|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with an EMMA MDU for use in their homes for the 90-day period immediately following discharge.
89671315|NCT01600677|Active Comparator|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
89671316|NCT00041717|Active Comparator|fampridine-SR 50mg/day|
89671317|NCT00041717|Placebo Comparator|Placebo|
89671318|NCT01694199|Active Comparator|Active study device with PRFE|This study arm receives pulsed radiofrequency energy (PRFE) from an active test device.
89671319|NCT01694199|Sham Comparator|Sham study device with no PRFE|This study arm receives no pulsed radiofrequency energy (PRFE) from a sham test device.
89671320|NCT01694667|Active Comparator|Omega-3 Fatty Acids|Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA
89671321|NCT01694667|Placebo Comparator|Placebo|Placebo packets will have same orange-flavored pudding with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
89671322|NCT01663935|Other|Levodopa/carbidopa 4mg/kg/day|Treatment drug taken orally three times daily
89671323|NCT01664559|Placebo Comparator|Placebo with 1cc normal saline IM|If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.
89671324|NCT01664559|Experimental|Toradol, 30mg in 1cc IM|If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.
89671325|NCT01664793|Experimental|Intervention Group Year 1|The 4 Pillars Immunization Toolkit along with donated vaccines for early season vaccination, staff education and support.
89671326|NCT01664793|No Intervention|Control Group Year 1|Control sites will not receive assistance with increasing influenza vaccination in Year 1, they will follow guidelines for usual care.
89671327|NCT01894685|Experimental|Mesalazine|Mesalazine, 3 grams once daily for six months
89671328|NCT01894685|Placebo Comparator|Placebo|Placebo, 3 grams, once daily for six months
89671329|NCT01601067|Experimental|Arm 1: Integrated Prolonged Exposure Therapy|Integrated Prolonged exposure Psychotherapy (I-PE; PE integrated with elements of Integrated Cognitive Behavioral Therapy for alcohol use disorder)
89671330|NCT01601067|Active Comparator|Arm 2: Seeking Safety|Seeking Safety
89671331|NCT04761497|Experimental|active music therapy|Each session consisted of: song of welcome (patients had to greet and introduce themselves), rhythmic exercise (three songs were used; therapist and patients kept rhythm by clapping their hands), dance exercises (three songs were used; patients should make free body movements in response to music), game of recognition of songs and interpreters (four songs were used) and song of goodbye.
89671332|NCT04761497|Experimental|passive music therapy|The therapist and the patients were seat listening to the music recorded in a CD. The therapist told patients which the name and the interpreter of each song of the list.
89671333|NCT04761497|Placebo Comparator|control|Patients were watching nature videos for the same duration than the interventions. A therapist was with them facilitating the activity.
89671334|NCT03080753|Experimental|Intersphincteric implants|Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper
89671335|NCT01897181|Active Comparator|Hearing aids|Patients who agree to use hearing aids
89671336|NCT01897181|No Intervention|No hearing aids|Patients who did not agree to use hearing aids
89671337|NCT01956539||Heart Failure|All patients over 18 years with chronic heart failure, and all patients hospitalized for acute heart failure de novo or not. The diagnosis of heart failure is the responsibility of the cardiologist including patient.
89671338|NCT01695291|Placebo Comparator|Placebo|Participants randomized to placebo will receive pills that are identical in appearance to the study drug but contain no active medication.
89671339|NCT01695291|Experimental|Minocycline Augmentation|Those randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline (minimum 50 mg/day and maximum 200 mg/day). After randomization, participants will receive child proofed bottles that contain enough study medication until the next visit with an additional 3 days coverage in case of scheduling issues. All participants will have a minocycline level drawn at week 12 to confirm treatment adherence. Minocycline is FDA-approved in those ages 8 and above for treatment of infections and acne and has a favorable risk-benefit profile.
89671340|NCT01601691|Experimental|Spacer|Subjects with spacer injection
89671341|NCT00048737|Experimental|90Y Zevalin in ASCT|Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
89671342|NCT01695369|Active Comparator|Senofilcon A|Senofilcon A; Comfilcon A
89671343|NCT01695369|Experimental|Comfilcon A|Comfilcon A; Senofilcon A
89671344|NCT01951937|Active Comparator|Fish Meals|3 Fish meals per week for 4 months
89671345|NCT01951937|Placebo Comparator|Placebo|Habitual diet
89671346|NCT01604109|Active Comparator|Tooth Mousse|10% w/v Calcium Phosphopeptide Amorphous Calcium Phosphate paste
89671347|NCT01604109|Placebo Comparator|placebo control paste|the paste without Calcium phosphopeptide - Amorphous Calcium Phosphate
89671348|NCT01894763|Active Comparator|Small-diameter stent|Placement of a 23 mm self-expandable metal stent
89671349|NCT01894763|Active Comparator|Large-diameter stent|Placement of a 28-mm self-expandable metal stent
89671350|NCT01666197|Experimental|diclofenac potassium 25 mg tablet|
89671351|NCT01666197|Placebo Comparator|placebo|
89671352|NCT01697709|Placebo Comparator|Placebo|Placebo medication
89671353|NCT01697709|Experimental|quetiapine|Quetiapine treatment
89671354|NCT00048815|Active Comparator|citalopram|Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.
89671355|NCT00048815|Experimental|St. John's Wort|Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.
89671356|NCT00048815|Placebo Comparator|Placebo|Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.
89671357|NCT01605435|Experimental|Ghrelin Group 1|Dose finding with each of the first two participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 2ug/kg (second visit) , 5 ug/kg (third visit), and 10 ug/kg (fourth visit).
89671358|NCT01605435|Experimental|Ghrelin Group 2|Dose finding with each of the final three participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 5ug/kg (second visit) , 7.5 ug/kg (third visit), and 10 ug/kg (fourth visit).
89671359|NCT03089801||Tablet Recipients|Veteran patients who have received a VA-issued tablet for tablet-enabled video telehealth.
89671360|NCT03089801||Usual Care|Veteran patients who match tablet recipients based on sociodemographic/clinical characteristics but have not received a VA-issued tablet.
89671361|NCT01605669||Aortic stenosis patients|Patients with varying degrees of aortic stenosis without significant additional valvular disease will be considered eligible for this study. All participants will recieve a transthoracic echocardiogram and recorded cardiac auscultation.
89671362|NCT01605903|Experimental|Treatment with Ibuprofen|Children in the experimental group will receive grape-flavored ibuprofen 100mg/5 mL. Ibuprofen will be dispensed at 10mg/kg (max dose 600 mg) will be dispensed Q6 hours x 9 days.
89671363|NCT01605903|Active Comparator|Treatment with Acetaminophen|Children in the active comparator group will receive grape flavored acetaminophen 160 mg/5 ml. Acetaminophen will be dispensed at 15 mg/kg (max dose 650/mg) Q6 hours x 9 days.
89671364|NCT02228499||Asthma|children with asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
89671365|NCT02228499||Controls|Children with no history of asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
89671366|NCT01698333|Experimental|122-0551|
89671367|NCT01607853|Experimental|Daivobet® gel|
89671368|NCT04449731||Adult population (> 18 years old)|Around 30000 adults (> 18 years old) from 22 different countries.
89671369|NCT03089723|Experimental|Lavage with Saline (LS)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to joint lavage with physiologic saline solution 2 to 5 mL (injection with a 30x8 needle and drained with the same needle after removal of the syringe. After emptying of the joint, 1mL saline solution will be injected.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
89671370|NCT03089723|Experimental|Lavage with Osteonil® Mini (LO)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to lavage with physiologic saline solution and Osteonil® Mini 1mL of 10mg will be injected in the 1st CMC joint.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
89671371|NCT01610427|Experimental|HIV-1 Group|Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected. No investigational vaccine was administered.
89671372|NCT01700517|Sham Comparator|control group|Spinal anesthesia with 0.5% isobaric bupivacaine, in isolation. Punctures in the femoral and popliteal areas were made to mask the femoral and sciatic block, respectively, with no infusion of any medication.
89671373|NCT01700517|Experimental|Femoral nerve block|In addition to the spinal anesthesia, block of the femoral nerve guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. The technique used was femoral area puncture, at the level of the crural fold of skin, with a 0.5% (125mg) ropivacaine associated to 75 mcg of clonidine.
89671374|NCT01700517|Experimental|sciatic nerves block|In addition to the spinal anesthesia and femoral block, the anesthesia of the sciatic nerve at the top of the popliteal fossae was realized, also guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. 0.5% ropivacaine was injected associated to 75mcg clonidine.
89671375|NCT00101647|Experimental|1|
89671376|NCT01669785|Active Comparator|Group C|"NUPRO Classic Prophy Paste~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains no Novamin or Fluoride..~Leave in contact for 60 seconds, rinse with water and expectorate."
89671377|NCT01669785|Experimental|Group A|"NUPRO Sensodyne Prophy Paste w/ Novamin~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 15% Novamin. Does not contain Fluoride.~Leave in contact for 60 seconds, rinse with water and expectorate"
88815728|NCT01091948|Active Comparator|Fiberoptic Intubation|Subjects will be intubated with the Fiberoptic laryngoscope.
89671378|NCT01669785|Experimental|Group B|"NUPRO Sensodyne Prophy Paste w/ Novamin w/ Fluoride~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 1.23% fluoride ion and 15% Novamin.~Leave in contact for 60 seconds, rinse with water and expectorate."
89671379|NCT01669863|Experimental|Use of ECMO in non-intubated patients|ECMO will be used in non-intubated patients with ARDS
89671380|NCT00053495|Experimental|Group 1: ACAM2000 Dose 1|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units (PFU)/mL on Day 0.
89671381|NCT00053495|Experimental|Group 2: ACAM2000 Dose 2|Participants will receive a single dose of ACAM2000 smallpox vaccine, 2.0x10-8th plaque-forming units/mL on Day 0.
89671382|NCT00053495|Experimental|Group 3: ACAM2000 Dose 3|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0
89671383|NCT00053495|Experimental|Group 4: ACAM2000 Dose 4|Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0
89671384|NCT00053495|Active Comparator|Group 5: Dryvax® Vaccine|Participants will receive a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0
89671385|NCT01670487|Active Comparator|Vapocoolant (Pain Ease Medium Stream)|Application of the stream steadily 4 to 10 seconds onto the cannulation site.
89671386|NCT01670487|Placebo Comparator|Nature's Tears|Apply sterile water (see manufacturer above) steadily 4-10 seconds onto the cannulation site.
89671387|NCT03434015||Left atrial appendage closure|"All patient referred to a department of interventional cardiology for percutaneous left atrial appendage closure may be included.~All centers practicing this procedure in France will participate to the present study, whatever the technique used. The patients included in the protocol will be followed as part of the care by centers that will have carried out the procedure."
89671388|NCT03089645|Experimental|Part 1|MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors
89671389|NCT03089645|Experimental|Part 2|Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors.
89671390|NCT03089645|Experimental|Part 3|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC
89671391|NCT02587962|Experimental|Birinapant in combination with pembrolizumab|Birinapant in combination with pembrolizumab
89671392|NCT02229513|No Intervention|Control|Normal cesarean technique.
89671393|NCT02229513|Experimental|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
89671394|NCT01671423|Active Comparator|Prednisone|In addition to standard care for cellulitis, subject will receive a single 60 mg dose of Prednisone orally during their initial visit.
89671395|NCT01671423|Placebo Comparator|Placebo|In addition to standard care for cellulitis, subjects will receive a single placebo pill to take during their initial visit.
89671396|NCT02092181|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 mg daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or, for those in the placebo arm, two placebo tablets.
89671397|NCT02092181|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
89671398|NCT02992509|Other|Treatment|This pilot study group is a prospective observational study. It is not blinded and there is no control. This is a single arm study (treatment group) which will receive intravesical electrical stimulation with a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks.
89671399|NCT01672827|Experimental|[18F]Flutemetamol|
89671400|NCT03089489||Lung recipients with PGD|in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
89671401|NCT03089489||Lung recipients PGD Free|In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
89671402|NCT01700907|Active Comparator|group DES|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
89671403|NCT01700907|Active Comparator|group SEVO|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
89671404|NCT03089567|No Intervention|CONTROL GROUP|Patients waiting for treatment under general Anesthesia without any intervention
89671405|NCT03089567|Active Comparator|Sodium Fluoride Varnish|Sodium Fluoride Varnish will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
89671406|NCT03089567|Experimental|Silver Diamine Fluoride|Silver Diamine Fluoride will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
89671407|NCT03431987||Marijuana Users|
89671408|NCT05299320||Patients with Post-Covid|Being between the ages of 18-30, - Being a volunteer - Having had Covid-19 in the last 3 month Exclusion Criteria - Presence of neurologic and oncologic disease - Presence of orthopedic surgery - Presence of active Covid-19 disease - Any cardiopulmonary disease
89671409|NCT05299320||Healthy Person|Being between the ages of 18-30, Being a volunteer, not having Covid-19 before
89671410|NCT01612221|Experimental|Patients receiving N-acetylcysteine|Patients receiving NAC (N-acetylcysteine)
89671411|NCT01612221|Placebo Comparator|Placebo Group|Participants not receiving NAC (N-acetylcysteine)
89671412|NCT00105001|Active Comparator|Arm I (MMF and tacrolimus)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD.
89671413|NCT00105001|Experimental|Arm II (MMF and tacrolimus alternate schedule)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD.
89671414|NCT00105001|Experimental|Arm III (MMF, tacrolimus, and sirolimus)|Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80.
89671415|NCT02642640|Other|melatonin-placebo|subjects will receive melatonin first and placebo second
89671416|NCT02642640|Other|placebo-melatonin|subjects will receive placebo first and melatonin second
89671417|NCT01701375|Experimental|Arm 1|"PD 0332991 will be given orally days 1,2,3~Cytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6~Mitoxantrone will be given over 2 hour infusion day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose"
89671418|NCT05556408|Other|High-Resolution Solid-State Manometry|Before catheterization, the patients were monitored by pulse oximetry, electrocardiogram, automatic noninvasive arterial blood pressure and bispectral index (BIS). Before the insertion of the manometric catheter an intravenous cannula was inserted. The manometric catheter was placed through the nose until the pressure from the lower esophageal sphincter to the stomach could be recorded. After confirming the position of the catheter, the catheter was taped to the nose.
89671419|NCT00054353|Experimental|Related Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
89671420|NCT00054353|Experimental|Unrelated Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
89671421|NCT05556330|Experimental|horizontal ridge augmentation by computer guided autogenous cortical shell technique|
89671422|NCT05556330|Active Comparator|horizontal ridge augmentation by free hand autogenous cortical shell technique|
89671423|NCT00207883||Landmark|Procedure/Surgery: Use of landmarks for central line placement
89671424|NCT00207883||Ultrasound guided|Procedure/Surgery: Use of ultrasound for central line placement
89671425|NCT02526420|Experimental|Cohort A: Somavaratan in Older Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects >= 35 years of age
89671426|NCT02526420|Experimental|Cohort B: Somavaratan in Younger Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects < 35 years of age
89671427|NCT02526420|Experimental|Cohort C: Somavaratan in Women on Estrogen|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)
89671428|NCT01701999|Experimental|Vaccine|
89671429|NCT02384928|Experimental|Shinbaro pharmacopuncture group|The Shinbaro pharmacopuncture group will receive 8 interventional sessions of Shinbaro pharmacopuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and acupuncture at 5 acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
89671430|NCT02384928|Active Comparator|Acupuncture group|The acupuncture group will receive 8 interventional sessions of acupuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and 5 other acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
89671431|NCT02384928|Active Comparator|Usual care group|The usual care group will receive conventional medicine 2 times/day and 2 sessions/week of physical therapy over 4 weeks. Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics, which include aceclofenac, tramadol hydrochloride, talniflumate, diclofenac sodium, and loxoprofen sodium. All groups will take 4 educational program sessions supervised by physicians once a week.
89671432|NCT00208975|Active Comparator|Fludarabine and Mitoxantrome followed by GM-CSF and Rituximab|"Initial patients (n=9) received fludarabine (25 mg/m2 IV) and mitoxantrone (10 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m2 IV) and cyclophosphamide (250 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8. All patients received dditional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
89671433|NCT01702233|Experimental|Traumeel S inj.|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
89671434|NCT01702233|Active Comparator|Fortecortin/Dexamethasone 8 mg inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
89671435|NCT01702233|Placebo Comparator|Saline inj.|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
89671436|NCT04389151|Other|The experimental group|
89671437|NCT05231928|Experimental|Argon Laser Iridoplasty|Argon Laser is applied to the anterior iris surface after pharmacological miosis and instillation of ocular surface anesthetic using YAG capsulotomy lens or Abraham Iridotomy lens as auxiliary lenses. Laser is applied at sites and with parameters that are tailored for each case according to exact iris configuration, iris colour and pupil diameter.
89049368|NCT04624893||Pola BR/R|Patients with R/R DLBCL who are enrolled in the Pola CUP program in China, and treated with Pola-BR or Pola-R regimens.
89671438|NCT00214045|Active Comparator|Flexible Cystoscopy|Flexible Cystoscopy
89671439|NCT00214045|Active Comparator|Rigid Cystoscopy|Rigid Cystoscopy
89671440|NCT01880892|Experimental|Post cricopharyngeal myotomy|Subjects scheduled to undergo an endoscopic criocopharyngeal myotomy, which is the standard treatment for a Zenker's diverticulum, will have levels of laryngopharyngeal reflux measured after the procedure.
89671441|NCT01440374|Experimental|Part 1, Open Label|100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.
89671442|NCT01440374|Experimental|Part 2, eltrombopag arm|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
89671443|NCT01440374|Experimental|Part 2, placebo arm|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
89671444|NCT01440374|Experimental|part 3 extension|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
89671445|NCT02914171|Experimental|Treatment arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
89671446|NCT02914171|Other|Control arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.
89671447|NCT00107575|Active Comparator|Standard treatment (ST)|Standard smoking cessation treatment (ST)
89671448|NCT00107575|Experimental|ST-BI|Standard treatment plus a brief alcohol intervention
89671449|NCT05700240||Orthokeratology treatment|
89671450|NCT05700240||single-vision spectacle correction|
89671451|NCT05549856|Experimental|Dry suction group|22G Franseen needle biopsy with dry suction technique(The puncture needle be filled with air)
89671452|NCT05549856|Active Comparator|Wet suction group|22G Franseen needle biopsy with wet suction(The puncture needle be filled with saline before sugry)
89671453|NCT05555472|Active Comparator|Care-as-usual Halt-condition|Participants in this arm will follow the regular Halt-intervention. Halt professionals, not trained in YIM-approach, will be instructed to follow their regular working procedure. On average, the intervention consists of 3 meetings: an initial meeting, an intervention meeting, and a closing meeting. The aim is to complete the intervention within 100 days (min.-max.: 1-6 meetings, 1-20 hours). During the initial meeting, compulsory activities are screening and risk assessment, reflection on the committed offense/crime, and parental involvement. Based on these activities, the duration and the content of the intervention are determined. Professionals can select activities from 5 different modules: (1) reflection on behaviour, (2) parental involvement, (3) social skills training, (4) victim-offender reconciliation, and (5) future. A form of victim-offender reconciliation, however, is compulsory. Professionals are required to register relevant information regarding the Halt-process.
89671454|NCT05555472|Experimental|Halt-plus-YIM-condition|Participants in this arm will follow the Halt-plus-YIM-intervention. YIM trained Halt professionals implement the YIM approach in their regular working procedure in 7 steps: (1) during risk assessment, they support youth in identifying a YIM; (2) during the course of the study, professionals will be instructed to motivate and explain the YIM approach in cases with 3 or more meetings; (3) if a YIM is nominated, a meeting between the professional and the YIM takes place; (4) to 'position' the YIM, a joint meeting is arranged to discuss expectations/goals of all involved parties; (5) interim contact between professional and YIM takes place; (6) a joint evaluative meeting takes place; (7) if agreed upon, closure of Halt's engagement takes place. Note, the YIM often remains involved after this completion. Professionals register on the Halt- and YIM-process and whether the approach was deployed: 'NO' (i.e., only step 1), 'PARTLY' (i.e., steps 1 and 2) or 'YES' (i.e., at least step 3 or 4).
89671455|NCT00214903||1|New users of oral continuous combined HRT containing drospirenone
89671456|NCT00214903||2|New users of oral continuous combined HRT containing other progestagens
89671457|NCT04742868|Experimental|Arm 1 QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with bone will be used as graft for the surgery.
89671458|NCT04742868|Experimental|Arm 2 HAMSTRING TENDON GRAFT|Hamstring tendon with bone will be used as graft for the surgery
89671459|NCT04742868|Experimental|Arm 3. QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without bone will be used as graft for the surgery.
89671460|NCT00217399|Experimental|Treatment|"PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days 1-28.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.~PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I."
89671461|NCT04742556|Experimental|BI 3011441|
89671462|NCT04739670|Experimental|Atezolizumab, Bevacizumab, Gemcitabine and Carboplatin|Atezolizumab 1200 mg Day 1 of each 21 day cycle IV, Bevacizumab 15 mg/kg Day 1 of each 21 day cycle IV, Gemcitabine 1000 mg/m2 Day 1 and 8 of each 21 day cycle IV, Carboplatin AUC 5 Day 1 of each 21 day cycle IV
89671463|NCT00108277|Experimental|Raise CO2|Raise CO2 - biofeedback-assisted breathing training to raise baseline pCO2
89671464|NCT00108277|Active Comparator|Lower CO2|Lower CO2 - biofeedback-assisted breathing training to lower baseline pCO2
89671465|NCT00108277|No Intervention|Waitlist|Waitlist - treatment as usual
89049369|NCT02902328||MRI data collection|A group of 30 subjects will be scanned on a 3 Tesla (T) and on a 7T MRI scanners. The images will be compared.
89214811|NCT05829824|Experimental|CareConnect (Intervention)|Participants will receive automated 'CareConnect' calls/SMS text at enrollment. The call protocol will include up to 2 calls on 2 consecutive days if no response to the first call. If there is no response to call, a follow up SMS 3-4 days later. Each CareConnect contact will include (1) assessment, (2) motivational enhancement tailored to participants' tobacco use status and importance of quitting; and (3) multiple referral options (UCSF Fontana Tobacco Treatment Center (FTTC)/tobacco treatment specialist, Quitline, or smokefreeTXT from smokefree.gov), offered after the motivational enhancement message. CareConnect will notify the UCSF tobacco treatment specialist of participants acceptance of any of the referral options. Referral options will be documented by the specialist on the participants electronic health record (EHR). All participants who have completed the CareConnect call will be contacted by research staff for a 3-month survey to be completed online or by telephone.
89671466|NCT05286619|Experimental|Pembrolizumab plus Platinum and Gemcitabine|Pembrolizumab 200 mg will be administered as 30-minute IV infusion Day 1 of every 3 weeks. Pembrolizumab will be administered first followed by the platinum and gemcitabine infusions. Cisplatin will be administered on Day 1 and 8 of each 3-weeks treatment cycle with a dose of 35 mg/m2 for 60 minutes. Carboplatin will be administered on Day 1 of each 3-weeks treatment cycle given as a dose of AUC 5 for 60 minutes. Gemcitabine will be administered on Day 1 and 8 of each 3-weeks treatment given as a dose of 1250 mg/m2 for 30 minutes. AEs associated with pembrolizumab exposure, including coadministration with additional compounds, may represent an immunologic aetiology. If one or all of the chemotherapy components is discontinued, subjects can continue with pembrolizumab up to the full 35 cycles.
89671467|NCT01897597|Experimental|BI 144807 PfoS Treatment A|intermediate dose of BI 144807
89671468|NCT01897597|Experimental|BI 144807 PfoS Treatment C|high dose of BI 144807
89671469|NCT01897597|Experimental|BI 144807 Tab Treatment B|intermediate dose of BI 144807
88815729|NCT01091948|Active Comparator|GlideScope® Video Laryngoscope|Subjects will be intubated with the GlideScope® Video Laryngoscope.
89671470|NCT01897597|Experimental|BI 144807 Tab Treatment D|high dose of BI 144807
89671471|NCT01897597|Experimental|BI 144807 Tab Treatment E|intermediate dose of BI 144807, fasted
89671472|NCT01897597|Experimental|BI 144807 Tab Treatment F|intermediate dose of BI 144807, fed
89671473|NCT01897597|Experimental|BI 144807 Tab Treatment G|intermediate dose of BI 144807, fasted
89671474|NCT02745067|Other|Enhanced cognitive behavioral therapy|Enhanced cognitive behavioral therapy (CBT-E) for eating disorders
89671475|NCT01897675|Active Comparator|Incision and Drainage with Packing|Abscess is cared for in the standard fashion, using an incision and drainage with packing (wick) placement. Packing to be changed every 2-3 days, at the discretion of the treating clinician, until abscess is considered resolved
89671476|NCT01897675|Experimental|Loop Drainage|Abscess is cared for using a minimally invasive abscess drainage with loop placement technique. Two (or more) stab incisions are made in the abscess, the cavity is probed and pus is drained, and a vessel loop is inserted and tied off. The patient manipulates the loop 3 times per day, and removes the loop when all redness is gone and no more pus is present
89671477|NCT00559182|Experimental|Parts A and B: MK-8033|Dose Escalation Study
89671478|NCT00559182|Experimental|Part C: MK-8033 +/- omeprazole|Crossover Study
89671479|NCT05549310|Active Comparator|CPAP group|"CPAP group : The first stage:receiving CPAP treatment for 6 hours / night, for 1 month. Patients in the treatment group first use pressure titration, select the appropriate pressure after treatment.~The second stage ( cohort study ) : After one month of the first stage of treatment, patients voluntarily continued to receive treatment and observers were included in the second stage of treatment. CPAP group continued to receive corresponding treatment for 6 months."
89671480|NCT05549310|Experimental|HFNC group|"HFNC group : The first stage:receiving HFNC treatment for 6 hours / night, for 1 month. Patients in the treatment group first use pressure titration, select the appropriate pressure after treatment.~The second stage ( cohort study ) : After one month of the first stage of treatment, patients voluntarily continued to receive treatment and observers were included in the second stage of treatment. HFNC group continued to receive corresponding treatment for 6 months."
89671481|NCT00218023|Experimental|Modafinil plus MI, CM, and CBT|"The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
89671482|NCT00218023|Experimental|Levodopa/Carbidopa plus MI, CM, and CBT|"Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
89671483|NCT00218023|Experimental|Naltrexone HCl plus MI, CM, and CBT|"Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase II.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
88815730|NCT01109576|Experimental|DSL workshop participants|Three to five Veterans with DSL.
88815731|NCT01041248|Experimental|Tocilizumab|Single arm open label study. In this arm patient will receive 8mg/kg of Tocilizumab q 2 weeks iv.
89214812|NCT05829824|Other|AutoReach (Control)|Participants will receive automated AutoReach calls/Short Message Service (SMS) text at enrollment provides one referral option (speaking with a tobacco treatment specialist) and an option for sending information on cessation resources. All participants who have completed the AutoReach call will be contacted by research staff for a 3-month survey to be completed online or by telephone.
89214813|NCT05827406||Group 1: item set 1|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 1) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We assume 50 % participation to receive 100 responses.
89671484|NCT00218023|Placebo Comparator|Placebo plus MI, CM, and CBT|"Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
89671485|NCT00054665|Experimental|Part A: PS-341 Alone|1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
89671486|NCT00054665|Experimental|Part B: PS-341 & EPOCH|"PS-341: level 1: 0.5 mg/m^2 intravenous (IV) days 1, 4; level 2: 1.0 mg/m^2 IV days 1, 4; level 3: 1.5 mg/m^2 IV days 1, 4; level 4: 1.7 mg/m^2 IV days 1, 4.~EPOCH: Etoposide: 50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion; Doxorubicin: 10 mg/m^2 day CIV days 1-4, 96 hour infusion; Vincristine: 0.4 mg/m^2 day CIV days 1-4, 96 hour infusion; Cyclophosphamide: 750 mg/m^2 day IV day 5 bolus; Prednisone: 60 mg/m^2 by mouth twice a day days 1-5; Filgrastim: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycles every 21 days."
89671487|NCT01897259|Active Comparator|Corticosteroid Injections|Patients will receive 1 cc Kenalong 10 mg injection to the site every 6 weeks until clinical symptoms have resolved. They will also receive an anesthetic of 1cc 1% lidocaine in conjunction with the corticosteroid injection.
89671488|NCT01897259|Active Comparator|Prolotherapy|Participants receive 1cc 50% Dextrose and 1 cc Sodium Morrhuate to the site every 6 weeks until symptoms resolve. These participants will also receive an anesthetic of 1cc 1% lidocaine.
89671489|NCT01897259|Placebo Comparator|Placebo|Participants will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
89671490|NCT01897259|Active Comparator|Physical Therapy|Participants will be prescribed NSAIDS (Diclofenac 75 mg BID) for 2 weeks. Participants will attend therapy for muscle stretches, soft tissue mobilization, and gradual strengthening.
89671491|NCT00476190|Experimental|Arm A|Complete remission achieved after Induction Phase
89671492|NCT00476190|Experimental|Arm B|Failure to achieve complete remission after the Induction Phase
89671493|NCT00218335|Experimental|Intervention Condition|Participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
89671494|NCT00218335|Active Comparator|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
89671495|NCT00057551|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
89671496|NCT00057551|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
89671497|NCT00057551|Active Comparator|Medication Only|Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine
89671498|NCT05555316|Experimental|TACE combined with Lenvatinib|Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg).
89671499|NCT00218491|Experimental|1200mg N-Acetylcysteine|1200mg N-Acetylcysteine
89671500|NCT00218491|Experimental|2400mg N-Acetylcysteine|2400mg N-Acetylcysteine
89671501|NCT00218491|Placebo Comparator|Matching Placebo|Matching Placebo
89671502|NCT05700864|Experimental|Oxervate® (cenegermin)|OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj
89671503|NCT05555160|Experimental|Single-chamber valve tip conductive PICC catheter|
89671504|NCT05555160|Experimental|Single - chamber valve non - tip conductive PICC catheter|
89671505|NCT00221299|Active Comparator|Group1a-rhPTH&RIS-Placebo(Y1)&RIS(Y2)|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - re-randomized to risedronate (35mg/wk) tablets for second year.
89671506|NCT00221299|Active Comparator|Group1b-rhPTH&RisendronatePlacebo|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - continue on risedronate placebo tablets for second year.
89671507|NCT00221299|Active Comparator|Group2-rhPTH&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
89671508|NCT00221299|Active Comparator|Group3-rhPTH-Placebo&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), placebo SC injections of normal saline daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
89671509|NCT05554848|No Intervention|control group|patients will receive normal saline instead of dexmedetomidine and MgSo4 .
89671510|NCT05554848|Active Comparator|dexmedetomidine group|patients will receive the same of dexmedetomidine as MD group in addition to normal saline instead of Magnesium Sulfate .
88815732|NCT02179892|Active Comparator|Group 1-Exparel|Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
89671511|NCT05554848|Active Comparator|Dexmedetomidine Mgso4 group|patients will receive dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period (Precedex ; Hospira Worldwide ,Lake Forest, IL).(20) and receiving Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
89671512|NCT05554536|Other|Single arm intervention|All patients will undergo a PEEP titration trial in each surgery step (before pneumoperitoneum, during pneumoperitoneum, after pneumoperitoneum). The PEEP titration trial will be done in steps of 2 cmH2O, starting from clinical PEEP 16 cmH2O and ending to PEEP 6 cmH2O. Each PEEP level will be kept for 2 minutes. The PEEP titration trial will be stopped in case of haemodynamic instability or severe desaturation (Spo2 < 92%). Each PEEP titration trial will be recorded using Electrical impedance tomography (EIT).
89671513|NCT00057785|Experimental|IMRT +/- chemotherapy|Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+
89671514|NCT03431051|Active Comparator|Healthy Beverage Initiative|A Healthy Beverage Initiative and health education will be implemented at two hospital campuses.
89671515|NCT03431051|No Intervention|Control Arm|No change in beverages or education at two hospital campuses.
89671516|NCT04323306|Active Comparator|Cohort 1 SAD|5 mg MMV533 with single ascending dose
89671517|NCT04323306|Active Comparator|Cohort 2 SAD|Single ascending dose to be determined after SRC review of previous cohort.
89671518|NCT04323306|Active Comparator|Cohort 3 SAD|Single ascending dose to be determined after SRC review of previous cohort.
89671519|NCT04323306|Active Comparator|Cohort 4 SAD|Single ascending dose to be determined after SRC review of previous cohort.
89671520|NCT04323306|Active Comparator|Cohort 5 SAD|Single ascending dose to be determined after SRC review of previous cohort.
89671521|NCT04323306|Active Comparator|Cohort 6 SAD|Single ascending dose to be determined after SRC review of previous cohort.
89671522|NCT04323306|Active Comparator|Cohort 7 SAD|Single ascending dose to be determined determine after SRT review of previous cohort. Dose will not exceed 400 mg.
89671523|NCT04323306|Active Comparator|Part 2: Food Effect|Open label, 2-period cross-over, randomized, pilot food effect study to provide preliminary information on the effect of a high-fat meal on the pharmacokinetics of a single-dose oral administration of MMV533 determined to be safe in Part 1.
89671524|NCT01892423|Experimental|Cetaphil Moisturizing Lotion Daily Advance|Each subject had Cetaphil Moisturizing Lotion Daily Advance applied
89671525|NCT05548998||High flow cohort (HFA)|Patients, whose maintenance phase of anesthesia is managed with a fresh gas flow ≥ 1L/min, were included in this cohort.
89671526|NCT05548998||Low flow cohort (LFA)|Patients, whose maintenance phase of anesthesia is managed with a fresh gas flow < 1L/min, were included in this cohort.
89671527|NCT01666782|Experimental|High-Dose Influenza Vaccine|
89671528|NCT01666782|Active Comparator|Standard Trivalent Influenza Vaccine|
89671529|NCT05548842|Experimental|Combined group|This group takes the combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill for 12 weeks.
89671530|NCT05548842|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks.
89671531|NCT00058019|Experimental|Treatment (chemotherapy)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or if the patient becomes a candidate for stem cell transplantation.
89671532|NCT01439360|Experimental|D-QIV|Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).
89671533|NCT01439360|Active Comparator|Control|In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).
89671534|NCT05548686|Experimental|Adapted Physical Activity|Patients benefiting from adapted physical activity
89671535|NCT05548608||Group I (Healthy control)|Group I consists of patient relatives and patients who applied to the outpatient clinic for another ailment.
89671536|NCT05548608||Group II (chronic low back pain due to LSS )|Group II consisted of patients diagnosed with LSS and confirmed by MRI findings.
89671537|NCT05548608||Group III (undergoing surgery due to LSS )|Participants who had surgery for LSS at least 3 months ago were included in Group III.
89671538|NCT04752839||Exposed Workers|Workers who have been exposed during COVID 19 pandemic.
89671539|NCT00110461|Active Comparator|1|Aripiprazole 10 mg tablet
89671540|NCT00110461|Active Comparator|2|Aripiprazole 30 mg tablet
89671541|NCT00110461|Placebo Comparator|3|Placebo
89671542|NCT05700162|Experimental|Photograph|As soon as the mother starts to express her milk, she will be asked to look at the photo of her baby sent to her on whatsapp for 5 minutes.
89671543|NCT05700162|Experimental|Video|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on whatsapp.
89671544|NCT05700162|Experimental|Live Broadcast|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp.
89671545|NCT05700162|Experimental|Control Group|The mother will be asked to express both breasts for 15 minutes every 3 hours. No additional application will be made.
89671546|NCT05548530||Stereotactic intracranial hematoma puncture treatment group|Check the CT slice of the patient's brain, find out the patient's largest hematoma level, measure the coordinates of the puncture center, locate and mark the skull surface according to the measured coordinates, select the puncture point under the stereotaxic instrument, Mainly avoid important blood vessels, nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
89214814|NCT05827406||Group 2: reduced item set 1|We analyze data from group 1 and optimize item set 1 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 1 fails to validate, we may need to change it and recruit additional groups to optimize it.
89214815|NCT05827406||Group 3: item set 2|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 2) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
89671547|NCT05548530||drug treatment group|General treatment: Based on high-level nursing care and close and continuous attention to the patient's vital signs, the patient is instructed to stay in bed continuously, give oxygen, and instruct the patient to avoid emotional agitation, etc. ②Special treatment: use hemostatic drugs, control blood pressure to prevent rebleeding, control blood sugar, control body temperature, anti-epilepsy, prevent infection, dehydration and lower intracranial pressure, etc. Multisystem complications such as tract hemorrhage should be actively managed.
89671548|NCT05558670||coma|
89671549|NCT05558670||VS/UWS|
89671550|NCT05558670||MCS|
89671551|NCT05558670||EMCS|
89671552|NCT05548218|No Intervention|New diagnosis of diabetes control group|
89671553|NCT05548218|Experimental|New diagnosis of diabetes intervention group|
89671554|NCT05548218|No Intervention|Uncontrolled diabetes control group|
89671555|NCT05548218|Experimental|Uncontrolled diabetes intervention group|
89671556|NCT00061373|Experimental|MRI Selected Patients|"Patients are eligible for the MRI arm if all clinical and all MRI inclusion and exclusion criteria are met.~A single dose of aspirin 81 mg orally (or rectal dose equivalent), a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide."
89671557|NCT00061373|Experimental|non-MRI Selected Patients|"Patients are eligible for the non-MRI arm if all clinical inclusion-exclusion criteria are met, if MRI is contraindicated or if MRI compromises iv tPA delivery within 3-hours of symptom onset.~A single dose of aspirin 81 mg orally (or rectal dose equivalent) and a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide.~--------------------------------------------------------------------------------"
89671558|NCT03089177|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden.
89671559|NCT03089177|No Intervention|Wait List Control Group|Participants randomized to the Wait List Control Group will remain on community gardening waiting lists and will not receive the garden intervention.
89671560|NCT01897337|Experimental|Aprepitant group|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room (Before patient get in the operating room)
89671561|NCT01897337|Placebo Comparator|placebo group|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
89671562|NCT03089333|Experimental|Dapagliflozin|Dapagliflozin 10mg daily for 12 weeks.
89671563|NCT03089333|Active Comparator|Glibenclamide|Glibenclamide 5mg daily for 12 weeks.
89671564|NCT05553990||Acute ischemic stroke with active tumor|Acute ischemic stroke with active tumor
89671565|NCT05553990||Acute ischemic stroke without active tumor|Acute ischemic stroke without active tumor
89671566|NCT00112723|Experimental|Treatment (alvocidib)|"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I."
89671567|NCT04327206|Experimental|BCG vaccine|Participants will receive a single dose of BCG vaccine (BCG-Denmark). The adult dose of BCG vaccine is 0.1 mL injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
89671568|NCT04327206|Placebo Comparator|0.9% Saline|Participants will receive a single 0.1 mL dose of 0.9%NaCl injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).
89671569|NCT01894997|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 3 second duration over a period of 5 minutes."
89671570|NCT00113425|Experimental|Laser Therapy|V-Beam laser, Candela Corp., 595 nm wavelength
89671571|NCT00113425|No Intervention|Control|Untreated
89671572|NCT05543226|Experimental|PHGG|
89671573|NCT05543226|Placebo Comparator|without PHGG|
89671574|NCT02096731||LABA + tiotropium|
89671575|NCT02096731||LABA mono|
89671576|NCT02096731||neither tiotropium nor LABA|
89671577|NCT02096731||tiotropium + LABA|
89671578|NCT02096731||tiotropium mono|
89671579|NCT05543148||normal hearing with subjective hearing difficulty|
89671580|NCT05543148||mild hearing loss (unaided)|
89671581|NCT05543148||moderate hearing loss (unaided)|
89671582|NCT05543148||moderate hearing loss (aided)|
89671583|NCT05553756|No Intervention|preoperative clear liquid|Patients will drink 200 ml of clear liquid two hours before Cesarean section
89671584|NCT05553756|Active Comparator|preoperative maltodextrin|Patients will drink 200 ml of maltodexin two hours before Cesarean section
89671585|NCT00115297|Experimental|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
89671586|NCT00115297|Placebo Comparator|Placebo|Participants who are 2 to 3 years old received 5-mg montelukast placebo tablets and participants who are 12 months to 2 years old received 4-mg montelukast placebo granules.
89671587|NCT05543070|Experimental|Low-dose Radiotherapy|Involved-site radiotherapy (3 Gy*4f) in one week
89671588|NCT00116857|Active Comparator|Sertraline/omega-3 supplement|
89671589|NCT00116857|Placebo Comparator|Sertraline/corn oil|
89671590|NCT05547828|Other|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
89671591|NCT01672983|Experimental|Arm 1|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
89671592|NCT01672983|Experimental|Arm 2|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
89671593|NCT01672983|Experimental|Arm 3|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
89671594|NCT01672983|Experimental|Arm 4|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
89671595|NCT01672983|Experimental|Arm 5|Participants with HCV GT2 received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
89671596|NCT01672983|Experimental|Arm 6|Participants with HCV GT2 received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
89671597|NCT00117559|Experimental|TEL-CBT|Telehealth, problem solving based treatment provided over the telephone
89214816|NCT05827406||Group 4: reduced item set 2|We analyze data from group 3 and optimize item set 2 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 2 fails to validate, we may need to change it and recruit additional groups to optimize it
89671598|NCT00117559|No Intervention|Treatment as Ususal|Control group, no treatment provided
89671599|NCT04426032||Patients with RRI between 0.6 and 0.7|Normal renal resistive index
89671600|NCT04426032||Patients with RRI more than 0.7|High renal resistive index
89671601|NCT04752241|Experimental|IMAP|Inferior Mesenteric Artery Preservation Performing left hemicolectomy and anterior rectal resection the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
89671602|NCT04752241|Active Comparator|IMAS|Inferior Mesenteric Artery Ligation Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
89671603|NCT00119041|Experimental|Telemedicine CBOC|"Designated CBOC's were involved in the intervention phase where their Diabetes Mellitus (DM) patients were asked to participate in a telemedicine visit.~The Behavioral: The Diabetes Treatment Satisfaction Questionnaire given during this phase along with the Behavioral: Diabetes Empowerment Scale and the Behavioral: CBOC's undergo half-day joint-clinics via teleconference."
89049370|NCT04623450|Experimental|High Carbohydrate Meal|A smoothie including maltodextrin and low-fat strawberry yoghurt - 289 kcal, 61g carbohydrate, 6.7g protein, 1.9g fat.
89049371|NCT04623450|Experimental|High Fat Meal|A smoothie including double cream and low-fat strawberry yoghurt - 312 kcal, 13.3g carbohydrate, 7g protein, 25.5g fat.
89049372|NCT04623450|Experimental|High Protein Meal|A smoothie including whey protein and low-fat strawberry yoghurt - 307 kcal, 13.6g carbohydrate, 57g protein, 2.7g fat.
89049373|NCT02902406||normal oral mucosa|
89049374|NCT02902406||oral precancerous lesion or oral cancer|
89049375|NCT04623294||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
89049376|NCT04623294||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
89049377|NCT04623294||Deep coma patients for HLH Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
89049378|NCT04623294||Deep coma patients for LHL Oxygen|Deep coma patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by the NIRS instrument for hemodynamic parameter.
89049379|NCT04623294||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
89049380|NCT04623294||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
89671604|NCT00119041|No Intervention|Control CBOC|The CBOC's not involved in the intervention phase had their patients not be involved in the telemedicine visit, but traditional education.
89671605|NCT00119041|No Intervention|Provider Interviews|Qualitative interviews with providers
89671606|NCT00228943|Experimental|Acute tryptophan depletion|Full-strength tryptophan depletion
89671607|NCT00228943|Active Comparator|Control|Half-strength tryptophan depletion drink used as a control
89671608|NCT00229957|Experimental|Intervention|Intervention
89671609|NCT00229957|No Intervention|Control|Control group received usual care in primary care.
89049381|NCT02902523|Active Comparator|Viread ® tablet 300mg|Tenofovir disoproxil fumarate
89049382|NCT02902523|Experimental|HUG116 tablet 245mg|Tenofovir disoproxil
89049383|NCT04623060|Experimental|Intervention|3 sessions/week for 6 weeks
89049384|NCT02902562|Other|Study Visit|You will have a Contrast Enhanced Ultrasound (CEUS) and contrast Magnetic Resonance Imaging (MRI) which will take about 2 hours.
89671610|NCT05183893|Experimental|Experimental: L-Citrulline|5 g of L-citruline + 5 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the product, which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
89049385|NCT00562263|Experimental|Lifestyle Modification|Parents are randomized to attend 12 educational sessions covering strategies to manage children's health behaviors.
89049386|NCT00562263|No Intervention|Control|Teen participates in lifestyle intervention, but parent does not attend parent education sessions
89671611|NCT05183893|Experimental|Experimental: Citrulline-malate|8g of citrulline-malate + 2 g of additives. The dose to be administered is that recommended on the labeling and nutritional information of the products which has been produced under GMP procedures and approved by the EFSA (Lifepro®).
89671612|NCT05183893|Placebo Comparator|Placebo|10g of maltodextrin plus additives (Lifepro®).
89671613|NCT05170867|Experimental|Probiotic group|Two capsules of Hafnia alvei HA4597™ probiotic/day (5 x 107 CFU/day) for 60 days
89671614|NCT05170867|Placebo Comparator|Placebo group|Two identical capsules of placebo/day for 60 days
89671615|NCT01879085|Experimental|Combination therapy|Dose Level\Docetaxel IV\ Gemcitabine IV\Vorinostat PO\Pegfilgrastim 1\75 mg/m2\900 mg/m2\300 mg once daily\6 mg on day 9 2\75 mg/m2\900 mg/m2\200 mg twice daily\6 mg on day 9 3\75 mg/m2\900 mg/m2\300 mg twice daily\6 mg on day 9 4\75 mg/m2\900 mg/m2\400 mg twice daily\6 mg on day 9
89671616|NCT01439204|Active Comparator|Abatacept (BMS-188667) manufactured at Lonza, NH facility|
89671617|NCT01439204|Experimental|Abatacept (BMS-188667) manufactured at Devens, MA facility|
89671618|NCT04068818||Eyes with normal anterior segment|
89671619|NCT04068818||Eyes with anterior segment abnormalities|
89671620|NCT01612767|Experimental|Pro-Kinetic Energy Stent|
89671621|NCT00063635|Active Comparator|1|Metformin, 500 mg, twice daily
89671622|NCT00063635|Active Comparator|2|Vitamin E, 400 IU, twice daily
89671623|NCT00063635|Placebo Comparator|3|Matching placebo
89671624|NCT04068662|Experimental|Pregnant Moms' Empowerment Program|Five session group therapy program covering safety planning, resilience and coping, infant care and parenting.
89671625|NCT04068662|Active Comparator|Nondirective Support Group|Five session nondirective support group with two co-leaders who assist in facilitating open discussion on women's self-identified discussion topics.
89671626|NCT01439126|Active Comparator|Subjects on KAPVAY™ (clonidine hydrochloride)|Subjects in the KAPVAY™ arm receive their optimal dose of KAPVAY™ for the 26-week randomized-withdrawal period (Period 3)
89671627|NCT01439126|Placebo Comparator|Subjects on Placebo|Subjects in placebo arm tapered off optimal dose of KAPVAY™ (ie, Period 2 Maintenance Dose) at weekly intervals in decrements of 0.1 mg/day until reaching dose of 0 mg/day; subjects then receive only placebo for the rest of the study
89671628|NCT01873235||Main Cohort|This is an observational prospective cohort study of adults with autosomal dominant polycystic kidney disease (ADPKD) with estimated GFR at least 15cc/min/1.73m2. There are no therapeutic interventions in this observational cohort study.
89671629|NCT01613313|Experimental|Dose #1|single injection 0.058 mg Collagenase Clostridium Histolyticum
89671630|NCT01613313|Experimental|Dose #2|single injection 0.15 mg Collagenase Clostridium Histolyticum
89671631|NCT01613313|Experimental|Dose #3|single injection 0.29 mg Collagenase Clostridium Histolyticum
89671632|NCT01613313|Experimental|Dose #4|single injection 0.44 mg Collagenase Clostridium Histolyticum
89671633|NCT04402775|No Intervention|Vascular clamps|Patients randomized to the use of vascular clamps to obtain a bloodless field during arteriovenous fistula surgery (standard protocol).
89671634|NCT04402775|Experimental|Tourniquet|Patients randomized to the use of a tourniquet to obtain a bloodless field during arteriovenous fistula surgery.
89671635|NCT01897415|Experimental|Autologous T cells|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
89671636|NCT01865045||no treatment|no treatment
89671637|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 1 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
89049387|NCT02902367|Experimental|Intervention:|Outdoor walking and strength exercise, Three months, daily SMS.
89049388|NCT02902367|Other|Control group|Usual care; no restriction for exercise, Three months
89049389|NCT04623255|No Intervention|STANDARD OF CARE|Standard patient care for severe COVID-19
89049390|NCT04623255|Active Comparator|Plasma exchange|Standard patient care for severe COVID-19 with. plasma exchange daily for 5 days x 3 courses as required
89049391|NCT02902289|Experimental|Ibuprofen 200 mg/5 mL oral suspension|Single dose of 1 ibuprofen 200 mg/5 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
89049392|NCT02902289|Active Comparator|MOMENT 200 mg coated tablet|Single dose of 1 MOMENT 200 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
89049393|NCT04623411|Experimental|Intervention Group|Neonatal resuscitation training with classical method and serious game simulation method
89049394|NCT04623411|Experimental|Control Group|Neonatal resuscitation training with classical method.
89049395|NCT02902133|Other|Acetazolamide Arm|Acetazolamide 500 mg twice per day for 5 consecutive days post standard-of-care endoscopic skull base surgery
89049396|NCT04623333|Experimental|TQB2450 injection|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
89049397|NCT04623021|No Intervention|Standard of Care|Standard of Care Treatment for COVID-19 Infection
89049398|NCT04623021|Experimental|Nafamostat + Standard of Care|Nafamostat mesylate on top of standard of care
89049399|NCT02902016|Experimental|Lactase expression induction by GED|
89049400|NCT04622748||COVID-19|Recovered COVID-19 patients in Wuhan
89049401|NCT04622748||Healthy Control|Uninfected people in Wuhan
89049402|NCT04622826|Experimental|sequential immune plasma infused patients|immune covid 19 plasma infusion
89671638|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 2 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
89671639|NCT01449812|Active Comparator|CONTROL GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
89671640|NCT01703169|Experimental|Eltrombopag|Single arm study. Dose Escalation.
89671641|NCT00066677|Experimental|rhuMAB-VEGF|bevacizumab 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks until disease progression, unacceptable toxicity or patient preference.
89671642|NCT00066677|Experimental|rhuMAB-VEGF and Docetaxel|rhuMAB-VEGF,bevacizumab: 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks docetaxel, Taxotere: 35 mg/m2 given intravenously over 1 hour on days 1, 8, and 15 of each 28 day cycle. Treatment continued until evidence of disease progression, unacceptable toxicity, or patient preference.
89671643|NCT04752683||Organisation 1|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
89671644|NCT04752683||Organisation 2|All participants in this cohort will be from one organisation (to be confirmed). A minimum of 110 participants will be sought from this organisation.
89671645|NCT02334800|Experimental|Healthy Volunteers|Cohort of Healthy Volunteers
89671646|NCT02334800|Experimental|Mild Hepatic Impairment|Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
89671647|NCT02334800|Experimental|Moderate Hepatic Impairment|Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
89671648|NCT02334800|Experimental|Severe Hepatic Impairment|Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
89671649|NCT01673919|Experimental|RoActemra/Actemra|
89671650|NCT01675635|Experimental|OxyNorm Capsules|To determine the efficacy and safety of OxyNorm Capsules.
89671651|NCT01675635|Active Comparator|Morphine tablet|To determine the efficacy and safety of Morphine tablet.
89671652|NCT01615809|Experimental|Amphotericin B (ABELCET®)|"Drug: AMPHOTERICIN B Dosage form: Abelcet® 5mg/ml administered by inhalation. Dosage: 10 ml (50 mg) for the first week with a frequency twice a week. Dosage: from the second week onwards 5 ml (25 mg) with a frequency of a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.~Duration: 4-5 prophylaxis courses defined as each administration period during a neutropenia period, with a 4-6 weeks length considering the duration of neutropenia."
89671653|NCT01617369|Experimental|Acute Hypertonic Saline Effect|2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.
89671654|NCT01617369|Active Comparator|Sustained Hypertonic Saline Effect|2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.
89671655|NCT01676415|Active Comparator|Prednisone|Oral steroid medication
89671656|NCT01676415|Active Comparator|Topical Mometasone|Topical steroid medication
89671657|NCT04325256||study group|All pregnant women who will attend the labor unit for induction of labour due to different indications during the study period will be invited to participate in the study.
89671658|NCT05547516|Active Comparator|Standard infusion chemotherapy (including gemcitabine, mitomycin, Epirubicin, etc.)|Standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.) was dissolved in 50mL normal saline or glucose and perfused into the bladder for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery.
89671659|NCT05547516|Active Comparator|BL-5ALA-PDT|Bl-5ala-pdt protocol: 1.5g 5ALA, dissolved in 50mL normal saline, was infused into the bladder for 2h before surgery and before each cystoscopy, and blue laser irradiation was performed under flexible cystoscopy at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
89671660|NCT01617603|Experimental|High polyphenol milk chocolate|High polyphenol milk chocolate containing approximately 1 mg/g of epicatechin
89671661|NCT01617603|Active Comparator|Nestle Noir 70 % chocolate|Nestle Noir 70 % chocolate containing approximately 1 mg/g of epicatechin
89671662|NCT01617603|Placebo Comparator|Low polyphenol milk|Low polyphenol milk control (matched to product 1 as closely as possible for milk content, carbohydrate, fat and calories, made from cocoa butter, sugar, milk powder and small amount of cocoa liquor to improve taste, giving approximately 0.05mg/g epicatechin.
89671663|NCT01618227|Experimental|Rehabilitation with static progressive splinting|Static progressive splinting is a well-established adjunct for restoring motion in stiff joints. Such splints apply a static stress relaxation force to the wrist and forearm tissues, which is sequentially increased as motion is achieved.
89671664|NCT01618227|Experimental|Rehabilitation without splinting|
89671665|NCT01620567|Placebo Comparator|chickpeas/potatoes|1 potato/day or 1 cup chickpeas
89671666|NCT01620567|Active Comparator|avocados|1 avocados/day
89671667|NCT05542680|Experimental|Group 1|In the intervention group, the special cushion for semi recumbent position was used
89671668|NCT05542680|No Intervention|Group 2|Routine nursing intervention
89671669|NCT01678443|Experimental|Treatment (yttrium-90 anti-CD45 monoclonal antibody BC8)|Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
89671670|NCT01707225|Experimental|Octreotide LAR Depot|Once enrolled in the study subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.
89671671|NCT05547282|Other|Low-dose radiotherapy combined with conventional radiotherapy after immunotherapy failure|"The chest, abdomen and pelvis were located by enhanced CT, and the target area was delineated. The lesions were visible lymph nodes with short diameter ≥1cm, and there were metastases confirmed by two associate chief physicians by enhanced MR and PET/CT examination results.~The primary lesion, the largest metastatic lesion or the lesion causing symptoms were selected and divided into 1.8-2Gy/F,40Gy-60Gy. For the remaining lesions, at least one easily evaluated and measurable lesion was selected as the observation lesion, and the unselected lesions (≤10 lesions) were given 1.6Gy/f, 1f/w, 4-6 times.~Immunotherapy regimens are administered according to the specific dose and interval of the original immunization regimen, such as concurrent chemotherapy or antiangiogenic drug therapy regimens. He used Nivolumab, Pembrolizumab, Troripalimab and Camrelizumanb.~Immunotherapy was performed at a frequency of 3 weeks in combination with radiotherapy until progression."
89671672|NCT05547126|Active Comparator|Anodal tDCS + dual-task training|"The anodic electrode (5x5 cm) will be applied to the primary motor area (C3/C4) ipsilateral to the lesion and the reference electrode (6x9 cm) to the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted a protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session."
89671673|NCT05547126|Active Comparator|tDCS dualsite + dual-task training|"Two active electrodes (5x5 cm) will be used, which will be positioned over the primary motor area (C3/C4) and over the dorsolateral prefrontal cortex (F3 or F4) in the ipsilateral hemisphere. For this stimulation modality, two active electrodes (anodic) and a reference electrode (6x9 cm) will be used on the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted a protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session."
89671674|NCT05547126|Placebo Comparator|tDCS sham + dual-task training|"Two electrodes will be used, which will be positioned over the primary motor area (C3/C4) and a reference electrode (6x9 cm) will be used on the deltoid muscle region, however the device will be configured in sham mode.~Simultaneously with the tDCS sessions, participants will be submitted a protocol based on motor and cognitive dual-task training. The dual-task training will have a total duration of 20 minutes in each session."
89671675|NCT01707381|Active Comparator|Timolol Maleate|Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks.
89671676|NCT01707381|Experimental|BOL-303259-X|BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks.
89671677|NCT05552742|Active Comparator|Conservative Rehabilitation|Only conservative rehabilitation treatment was applied to the patients in group 1.
89671678|NCT05552742|Experimental|Conservative Rehabilitation + Virtual Balance Training|Conservative rehabilitation treatment and virtual balance study were applied to the patients in group 2.
89671679|NCT05552586|Active Comparator|Melatonin group|Melatonin Group (n=11) patients will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
89671680|NCT05552586|Placebo Comparator|Control group|Control group (n=11) patients will receive placebos with the same appearances and packaging at the same dose and time as those in the melatonin group.
89671681|NCT01708317|Other|ACASI|The group of patients that agreed to participate in the study and answer questions on our Audio-enhanced Computer-Assisted Self-Interview (ACASI)
89671682|NCT00069329|Experimental|NOMID treatment arm|All patients enrolled received daily doses of subcutaneous injection of increased doses of anakinra starting at 0.5mg/kg/day up to a maximum 10mg/kg/day to achieve disease remission.
89671683|NCT05542368||Patients with IBD|"All patients were subjected to history taking and physical examination with emphasis on history of autoimmune disease, extraintestinal manifestations of IBD, neck examination for goiter, symptoms and signs of thyroid dysfunction.~b) Laboratory investigations: Thyroid function test (include T3-T4- TSH)~ESR - CRP - thyroid antibodies: (Anti TPO -Anti Thyroglobulin)~c)-Imaging:~Neck U/S on thyroid gland to identify patients with ultrasonographic evidence of autoimmune thyroiditis (diffuse hypoechogenicity or heterogenicity echotexture or both) and to detect thyroid nodularity.~d ) Endoscopic findings regarding diagnosis of IBD confirmed by histopathological examination"
89671684|NCT05542368||Healty individuals as a control group|"All patients were subjected to history taking and physical examination with emphasis on history of autoimmune disease, extraintestinal manifestations of IBD, neck examination for goiter, symptoms and signs of thyroid dysfunction.~b) Laboratory investigations: Thyroid function test (include T3-T4- TSH)~ESR - CRP - thyroid antibodies: (Anti TPO -Anti Thyroglobulin)~c)-Imaging:~Neck U/S on thyroid gland to identify patients with ultrasonographic evidence of autoimmune thyroiditis (diffuse hypoechogenicity or heterogenicity echotexture or both) and to detect thyroid nodularity."
89671685|NCT01853735||bowel injury, NPO|Patients with bowel injury who remain nil-per-os (fed nothing)
89671686|NCT01853735||bowel injury, EN|Patients with bowel injury who are fed by enteral nutrition (EN)
89671687|NCT01853735||no bowel injury, NPO|Patients without bowl injury who remain nil-per-os (fed nothing)
89671688|NCT01853735||no bowel injury, EN|Patient without bowl injury who are fed by enteral nutrition (EN)
89671689|NCT03088865|Experimental|Initial Specimen Diversion|Aspirating first blood volume into a regular blood collection tube
89671690|NCT03088865|Active Comparator|Standard practice|Aspirating first blood into blood culture bottles (Standard practice)
89049403|NCT02901977|Experimental|ACE inhibitor|Ramipril tablets 10 mg od for 12 weeks
89049404|NCT02901977|Active Comparator|Alpha receptor blocker|Doxazosin tablets 8 mg od for 12 weeks
89049405|NCT04622631||PRRT positive|patients who have good response to prrt treatment - the tumor and/or the metastatic disease show no uptake/activity on PET-CT scans
89049406|NCT04622631||PRRT negative|no response to PRRT treatment
89671691|NCT05552274|Placebo Comparator|SAD Cohorts 1 to 2: Participants receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo
89049407|NCT02902094|Experimental|Experimental|Drug eluting angioplasty balloons
89049408|NCT02902094|Active Comparator|Control|Non-drug eluting balloons
89049409|NCT04681235|Experimental|Training Group|Training Group recieved 10 sessions on VR (Grail Motekforce, Netherlands) during two weeks. One session lasted 40 minuties.
89049410|NCT00553553|Active Comparator|1|IV morphine group
89049411|NCT00553553|Experimental|2|Remifentanil-intrathecal morphine group
89214817|NCT05827406||Group 5: item set 3|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 3) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
89671692|NCT05552274|Experimental|SAD Cohorts 1 to 2: Participants receiving ECC4703|Participants in each SAD cohort will be randomized to receive up to 4 escalating doses (1 mg, 4 mg, 12 mg, 32 mg, 80 mg, 160 mg, 320 mg or 400 mg).
89671693|NCT05552274|Placebo Comparator|MAD Cohorts 1 to 4: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 14 days.
89671694|NCT05552274|Experimental|MAD Cohorts 1 to 4: Participants receiving ECC4703|Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (40 mg, 80 mg, or 160 mg) for 14 days.
89671695|NCT05552040|Experimental|START NOW Group|START NOW is an evidence-informed psychotherapy composed of a total of 32-skills-based-sessions, originally designed for inmates in correctional systems. A previous study of incarcerated individuals found that for each additional session of START NOW completed, a 5% reduction in the incident rate of disciplinary reports was noted.10 In fact, individuals with a higher overall security risk score also had a greater reduction in the number of disciplinary reports with more sessions attended, suggesting that START NOW is an effective behavioral intervention for those who need it most. A follow-up study on these same participants concluded that START NOW appears to have a beneficial clinical effect with each session completed being associated with a 5% decrease in subsequent psychiatric hospital days.
89671696|NCT05552040|Active Comparator|Treatment-as-Usual (TAU) Group|TAU groups are weekly sessions required in an OBOT clinic and focus primarily on supportive therapeutic techniques.
89671697|NCT00072449|Experimental|Rituximab monotherapy|Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
89671698|NCT05551962|Active Comparator|First group|The patients undergo implant placement in combination with an increase in the thickness of soft tissues using a free connective tissue graft from the tuber region on the maxilla or palate.
89671699|NCT05551962|Experimental|Second group|"The patients undergo implant placement in combination with an increase in the thickness of soft tissues using collagen matrix Fibro-Gide"
89671700|NCT05546736|Experimental|iCanWork Intervention|iCanWork includes 6 1-hour sessions with a VRC and 1 to 4 1-hour sessions with an OT. In the positive event that a participant has returned to work during the study, three of the six VRC sessions are reserved to support the participants in their transition to the workplace.
89671701|NCT05546736|No Intervention|Control|Participants randomized to the control group will receive their usual care and will be referred to the Cancer Work website for educational resources related to RTW. If they contact the team with RTW-related questions, they will be referred to their care teams.
89671702|NCT04756661|Experimental|Carbetocin|Patient received 100 mcg of carbetocin intravenous over one minute immediately after delivery of the baby.
89671703|NCT04756661|Active Comparator|Oxytocin plus misoprostol|Patient received 10 units of oxytocin IV drip and 400 mcg of misoprostol rectally after anesthesia.
89671704|NCT05699694|Experimental|Experimental Stemregen|Experimental product encapsulated will be consumed orally with a glass of water. Six capsules per day will be consumed daily for 6 months.
89671705|NCT00072761|Active Comparator|Transfusion Group|Participants allocated to the transfusion arm will receive blood transfusion therapy every 4-6 weeks for 36 months.
89671706|NCT00072761|No Intervention|Observation Group|Participants allocated to the observation arm will be treated according to standard care and will receive a quarterly physical examination by a study hematologist for 36 months.
89671707|NCT01708629|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
89671708|NCT01708629|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
89671709|NCT01708629|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
89671710|NCT01708629|Placebo Comparator|Placebo|Administered by SC injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
89671711|NCT05551884||Training cohort|Training cohort was set to develop the novel non-invasive model based on metabolomics technology for HVPG.
89671712|NCT05551884||Validation cohort|Validation cohort was set to validate the novel non-invasive model based on metabolomics technology for HVPG.
89671713|NCT03089021|Experimental|mulligan mobilization|mobilization for spinous process or facet with neck movement 10 repetetions for 3 times.
89671714|NCT03089021|Experimental|maitland mobilization|maitland mobilization for spinous process or facet joint for 2 min and repeated 3 times.
89671715|NCT00073073|Experimental|Exemestane|exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects.
89671716|NCT05551572||septic samples|patients undergoing revision surgery for prosthetic joint infection
89671717|NCT05551572||aseptic samples|patients undergoing revision surgery for prosthetic replacement without infection
89671718|NCT01466660|Experimental|afatinib|afatinib once daily.
89671719|NCT01466660|Active Comparator|gefitinib|gefitinib once daily
89671720|NCT05711043|Experimental|Intervention group|Endoscopic sutured gastroplasty with endomina device
89671721|NCT05711043|No Intervention|Control group|Standard diabetes care
89671722|NCT00075335|Experimental|AMD 3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
89671723|NCT05551494||Endometriosis group|Cases will include women aged 18-45 with a surgical diagnosis of endometriosis in the previous 24 months or with a current nonsurgical diagnosis of endometriosis who report having lived in the past ten years in the Lombardy area. At study entry, we will collect urinary sample.
89214818|NCT05827406||Group 6: reduced item set 3|We analyze data from group 5 and optimize item set 3 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 3 fails to validate, we may need to change it and recruit additional groups to optimize it
89214819|NCT05827406||Group 7: item set 4|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 4) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
89214820|NCT05827406||Group 8: reduced item set 4|We analyze data from group 7 and optimize item set 4 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 4 fails to validate, we may need to change it and recruit additional groups to optimize it.
89214821|NCT05827406||Group 9: item set 5|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 5) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
89671724|NCT05551494||Control group|Control group are women aged 18-45 attending our outpatient clinic for periodical gynaecological care, contraception, or cervical cancer screening programme, and without a previous clinical or surgical diagnosis of endometriosis who report having lived in the past ten years in the Lombardy area. At study entry, we will collect urinary sample.
89671725|NCT03088787||Patients for TAVR|Patients for TAVR
89671726|NCT05541900|Active Comparator|TEC-Sacredness|Active condition of the intervention. For the active intervention group, the three match types are as follows: (1) a self-related word paired with a life-related stimulus; (2) a sacredness of life-related stimulus paired with a pleasant stimulus; and (3) a neutral stimulus paired with a neutral stimulus.
89671727|NCT05541900|Placebo Comparator|TEC-Control|Control condition of the intervention. The control paradigm maintains the same parameters, however, all three match pairings will be neutral.
89671728|NCT01466348|Experimental|Paracetamol and Caffeine|Paracetamol and caffeine
89671729|NCT01466348|Active Comparator|Paracetamol|Paracetamol
89671730|NCT01680783|Other|Usual Care|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
89671731|NCT01680783|Experimental|Non invasive ventilation via helmet|Patients requiring more than 8 hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet instead of face mask for treatment of respiratory failure
89671732|NCT05551338|Experimental|Intervention|Patients will be asked to perform two 30-minute sessions per week of training using serious games over a 3-month period in their home setting in addition to their conventional care
89671733|NCT05551338|No Intervention|Control|Patients will undergo only their conventional care
89671734|NCT02235285|Experimental|breast augmentation,reoperation|A retrospective chart review was performed to examine a total of 162 patients received the same brand of implants for primary breast augmentation under sedative anesthesia (propofol infusion) in a single surgeon's practice.
89671735|NCT01466270|Experimental|Arm I|Patients receive donepezil hydrochloride PO QD.
89671736|NCT01466270|Placebo Comparator|Arm II|Patients receive placebo PO QD.
89671737|NCT05699382|Active Comparator|a study group (SG) in which participants practiced mindfulness through the application for 6 weeks|a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
89671738|NCT05699382|No Intervention|control group|Waiting for the intervention
89671739|NCT02235831|Experimental|DACP MF|DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
89671740|NCT02235831|Active Comparator|DACP|DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
89671741|NCT02235831|Active Comparator|DACP MF (Low Add)|DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
89671742|NCT05546112|Experimental|Experimental group|Transcutaneous trigeminal nerve stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day
89671743|NCT05546112|Sham Comparator|Control group|Sham stimulation applied using clinical trial medical device (YPS-401B) for 20 minutes every night before going to bed, 28 times for 4 weeks at 1 time / 1 day
89671744|NCT02235987|Other|Octreotide, then ascending DG3173|Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
89671745|NCT01466192|Experimental|MP-424|
89671746|NCT05541666||The Emotional Freedom Technique Group|"After the patients in the case group are determined, the scales will be introduced. The patient information form, State-Trait Anxiety Inventory and Visual Analog Scale will be filled. After that, the emotional freedom technique will be explained.~On the postoperative 1st and 2nd days, firstly pain and anxiety levels will be measured with the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales. And then one session of emotional freedom technique that is approximately 30 minutes, will be applied. And after all, the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales will be applied again."
89671747|NCT05541666||Control Group|The patient in the control group will be interviewed on the preoperative 1sy day and the scales will be introduced, The patient information form, State-Trait Anxiety Inventory and Visual Analog Scale will be filled. On the postoperative 1st and 2nd days, no application will be made other than the clinical protocols and the State Anxiety Inventory, the Visual Analog scale and SUE(Subjectıve Unıts Of Experience) scales will be applied to the patient.
89671748|NCT02236767|Experimental|rTMS Treatment|NeuroStar Transcranial Magnetic Stimulation Therapy System
89671749|NCT04616066|Experimental|Dates Arm|Consumption of Khalas dates (3 dates =30g undried dates) twice daily (phytoestrogen content 329ug/100g)
89671750|NCT04616066|Experimental|Raisins Arm|Consumption of Raisins (30g twice daily, phytoestrogen content of 9.6ug/100g)
89671751|NCT05541588|Active Comparator|ESPB|Erector Spinae Plane Block group
89671752|NCT05541588|Active Comparator|QLB|Quadratus Lumborum Block group
89671753|NCT00120523|Experimental|1|Pimecrolimus
89671754|NCT00120523|Active Comparator|2|Topical corticosteroids
89671755|NCT01438814|Experimental|linagliptin + metformin|patients to receive linagliptin +metformin QD
89671756|NCT01438814|Active Comparator|metformin|patients to receive metformin BID
89671757|NCT04425876|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib combined with FOLFIRINOX followed by maintenance Fluzoparib monotherapy
89671758|NCT01681095|Experimental|Cardioplegia: Custodiol HTK Solution|"Custodiol HTK (histidine-tryptophan-ketoglutarate) cardioplegia: One liter of HTK solution (Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) contains the following components: 15 mmol/L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine, 2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chloride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310 mOsm/kg, pH 7.02-7.20.~Custodiol-HTK was delivered to establish and maintain cardiac arrest. After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. Custodiol-HTK was delivered at a temperature of 4°C - 10°C."
89671759|NCT01681095|Active Comparator|Cold Blood Cardioplegia|"Cold Blood Cardioplegia: One liter of cold blood cardioplegic solution, mixed at a ratio of 4:1 per Beaumont standard of care (blood /cardioplegic solution), contains the following in a 500 cc bag of D5W (dextrose 5% in water): 50meq/L potassium chloride, 37.5 meq/L sodium bicarbonate and 7.5 meq/L magnesium sulfate.~After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 8°C."
89671760|NCT05541432|Active Comparator|Home exercise|Home exercise program, with biweekly group virtual education and exercise classes.
89671761|NCT05541432|Experimental|Supervised strength training (group 1)|In-person, supervised muscle strengthening exercises twice weekly at a specific intensity.
89671762|NCT05541432|Experimental|Supervised strength training (group 2)|In-person, supervised muscle strengthening exercises twice weekly at a specific intensity.
89049412|NCT04622982|Experimental|All participants|Obese subjects with BMI >= 30 and with one or more of metabolic comorbidities (type 2 diabetes mellitus, dyslipidemia, high blood pressure, hyperuricemia, and others).
89049413|NCT02901938|Experimental|cemented femoral stem group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo implantation of cemented femoral stem.
89049414|NCT02901938|Experimental|cannulated compression screws group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo percutaneous internal fixation with cannulated compression screws.
89049415|NCT04622202|Active Comparator|pregabalin|oral capsule pregabalin 150 mg.
89049416|NCT04622202|Placebo Comparator|multivitamin|oral multivitamin capsule.
89049417|NCT02901782|Experimental|Personalized titanium plate|Ten males and two females with a mean age of 22.8 years were recruited. They all had bone tumor around the knee.
89049418|NCT04622475|Experimental|Treatment|Fecal Microbiota Transplant (FMT) Capsule
89049419|NCT04622358|Experimental|AD-214-02/Rabeprazole|Period 1 : Test Drug(AD-214-02) Period 2 : Reference Drug(Rabeprazole)
89049420|NCT04622358|Experimental|Rabeprazole/AD-214|Period 1 : Reference Drug(Rabeprazole) Period 2 : Test Drug(AD-214-02)
89049421|NCT02901665|No Intervention|Pre-FCC Intervention|Pre-intervention group. No intervention will be administered.
89049422|NCT02901665|Active Comparator|Post-FCC Intervention|Following unit-wide implementation of FCC intervention consisting of communicating to families an expectation that they spend 4 hours per day in the NICU with their infants.
89671763|NCT00121225|Experimental|Arm I|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
89671764|NCT05134987|Experimental|NNC0363-0845 followed by insulin detemir|Participants will get subcutaneous (under the skin) injections of insulin NNC0363-0845 (study medicine) up to 6 times daily for 3 days. After a 4-21 days wash-out period with no injections they will get subcutaneous injections of insulin detemir up to 6 times daily for 3 days.
89049423|NCT00562341||bariatric surgery|description of enrollees
89049424|NCT02901587|Experimental|Lu AF35700 (10 mg/day)|Lu AF35700 10 mg/day for 6 weeks
89049425|NCT02901587|Experimental|Lu AF35700 (30 mg/day)|Lu AF35700 30 mg/day for 6 weeks
89049426|NCT02901587|Experimental|Quetiapine (Seroquel XR® 800 mg/day)|Quetiapine (Seroquel XR®) 800 mg/day for 6 weeks
89049427|NCT04622397|Active Comparator|Group T (tranexamic acid),n=15|Group T: tranexamic acid 10 mg/kg will be injected locally
89049428|NCT04622397|Placebo Comparator|Group S (saline) (n=15)|Group S saline will be injected
89049429|NCT02901509||CHIK +|People with chikungunya diagnosis (serodiagnosis)
89049430|NCT02901509||CHIK -|People without chikungunya diagnosis (negative serology)
89049431|NCT02901704|Experimental|renal denervation|Iberis Multielectrode Renal Denervation System (AngioCare)
89049432|NCT02901704|Sham Comparator|Sham procedure|Renal anigography
89049433|NCT02901743|Active Comparator|GroupI (Test)|20 patients with renal insufficiency chronic and chronic periodontitis underwent scaling and root planing. Clinical parameters( GI,PD,CAL) were assessed at baseline and after 3 months. 2ml blood was drawn to assess serum creatinine levels and urine analysis was done at baseline and after 3 months for urinary albumin: creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema Denticola and Tannerella Forsythia by PCR.
89049434|NCT02901743|Active Comparator|Group II- (Control)|20 patients with chronic periodontitis who underwent scaling and root planing.Clinical parameters(GI,PD,CAL)were assessed at baseline and after 3 months. 2ml blood was drawn to assess seum creatnine levels and urine analysis was done at baseline and after 3 months for serum urinary Albumin:Creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema denticola and Tannerella Forsythia by PCR.
89049435|NCT02901392||Artificial urinary sphincter AMS-800®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AMS-800®
89671765|NCT05134987|Experimental|Insulin detemir followed by NNC0363-0845|Participants will get subcutaneous (under the skin) injections of insulin detemir up to 6 times daily for 3 days. After a 4-21 days wash-out period with no injections they will get subcutaneous injections of NNC0363-0845 (study medicine) up to 6 times daily for 3 days.
89671766|NCT04426188|Sham Comparator|Without mouthguard|Heading series without mouthguard from machine-projected soccer balls at standardized speeds
89671767|NCT04426188|Experimental|With mouthguard|Heading series with mouthguard from machine-projected soccer balls at standardized speeds
89671768|NCT01684917|Experimental|Life style advice|reduce energy intake by 20% less than estimated energy expenditure.
89671769|NCT01684917|Active Comparator|UK background diet|Diet where energy intake will be matched with estimated energy expenditure.
89671770|NCT01684917|Other|Metabolomic inquiry|This inquiry took place prior to the randomized controlled trial and include 50 volunteers who will then be asked to volunteers of the weight loss study. Were randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option.
89671771|NCT04239235|Experimental|Intervention|Community Reinforcement Approach and Family Training is a 10-session rolling group for the support person.
89671772|NCT04239235|No Intervention|Control|This condition is for support persons who do not receive CRAFT. They will receive no intervention or usual care services available at the clinic.
89671773|NCT05545800|Experimental|metformin+empagliflozin+insulin glargine|metformin+empagliflozin+insulin glargine
89671774|NCT05545800|Experimental|IDegLira|IDegLira
89671775|NCT05545800|Active Comparator|premixed insulin analogues|premixed insulin analogues
89671776|NCT00230737|Experimental|A|Melatonin 0.4 mg
89671777|NCT00230737|Experimental|B|Melatonin 4.0 mg
89671778|NCT00230737|Placebo Comparator|C|
89671779|NCT02325687|Experimental|Treated OSA (CPAP-compliant)|"Treated OSA patients will have previously been diagnosed with OSA, and are currently CPAP-compliant. CPAP compliance is defined by daily use of a CPAP machine for at least 4 hours. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
89671780|NCT02325687|Experimental|Untreated OSA (non-CPAP-compliant)|"Patients in the untreated OSA group will have previously been diagnosed with OSA, but for some reason do not use a CPAP machine every night. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
89671781|NCT02325687|Experimental|Control (No suspicion of OSA)|"Patients in the control group will not have previously been diagnosed with OSA, and are currently not at high risk. We will determine overall risk for OSA using the STOP-BANG questionnaire. Patients with a STOP-BANG score <3 are considered to have minimal risk for OSA and will be included in the control group.~Intervention: Lumbar Puncture (Standard-of-Care)"
89671782|NCT05545722|Experimental|life coaching group with diabetes|Individuals with diabetes in the intervention 1 group will be interviewed for 'life coaching with diabetes'. Coaching is a set of systems that make people think deeply and reveal their own awareness and potential. A coach is a person who deliberately applies all these systems with awareness. Life coaching sessions with diabetes are based on the philosophy of coaching. Sessions are continued with questions that will enable the individual to realize the deficiencies in diabetes self-management. It helps the person with diabetes to discover solutions.This training will last for 3 months, once in 10 days. A total of 9 interviews will be provided.
89671783|NCT05545722|Experimental|Standard diabetes education|Standard diabetes education will be given to individuals with diabetes in this group. This training will last for 3 months, once in 10 days. A total of 9 interviews will be provided.
89671784|NCT05545722|No Intervention|control group|only pre-test and post-test were applied to this group. The patients in this group are the patient group who received training from the diabetes nurse of the hospital.
89671785|NCT05545644|Experimental|Brief Family-Involved Treatment for Alcohol Use Disorder (B-FIT_|Up to 3 sessions of family-involved treatment for patients with alcohol use disorder (AUD) and a family member: Session 1; psychoeducation; increasing supportive behaviors, enhancing positive activities. Session 2: Improving communication; recovery contracts. Session 3: Review of session1 & 2 interventions; continue with communication skills.
89671786|NCT05545644|Active Comparator|Treatment as Usual (TAU|Treatment as usual in inpatient AUD rehabilitation program, including daily therapy groups, individual counseling, and health and recreational activities.
89671787|NCT00231283|Experimental|1|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
89671788|NCT04425564|Active Comparator|Classic (A)|patients recieving classic XELOX (oxaliplatin 130mg/m2 and capecitabine 1000mg/m2 bid)
89049436|NCT02901392||AdVance/AdvanceXP®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AdVance/AdvanceXP®
89671789|NCT04425564|Experimental|metronomic (B)|patients recieving low dose capecitabine (2000mg daily divided in two doses for 8 weeks) and oxaliplatin (30mg/m2 weekly for eight weeks) followed by 2 weeks rest.
89214822|NCT05827406||Group 10: reduced item set 5|We analyze data from group 9 and optimize item set 5 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 5 fails to validate, we may need to change it and recruit additional groups to optimize it.
89671790|NCT05550792|Active Comparator|Optimizer device|"100 patients were enrolled sequentially, 100 patients were implanted with an optimizer smart against the background of optimal drug therapy for heart failure~100 patients were implanted with a CCM Optimizer device without an atrial lead, per the protocol specifications recived optimal drug therapy CHF The following studies were performed in the 100 patients with CHF and AF before implantation of the MCC device and after 2 and 6 и 12 months of follow-up: 12-channel ECG with an estimate of the width of the QRS complex, transthoracic EchoCG,Speckle-tracking EchoCG,Myocardial work, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), Holter ECG, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ)."
89671791|NCT05550792|No Intervention|Without Optimizer device|100 patients were enrolled sequentially,100 patients received only optimal drug therapy for chronic heart failure 100 patients ( Without Optimizer device ) with CHF and AF before study and after 2 and 6 и 12 months of follow-up: 12-channel ECG with an estimate of the width of the QRS complex, transthoracic EchoCG,Speckle-tracking EchoCG,Myocardial work, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), Holter ECG, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ).
89671792|NCT01685463|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technology that can focally stimulate the brain of an awake individual. The brain stimulation techniques could theoretically improve the efficacy of smoking cessation.
89671793|NCT01685463|Placebo Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rTMS determination, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT Transcutaneous Electrical nerve stimulation device.
89671794|NCT00123409|Experimental|Telephone Disease Management|Telephone based disease management or counseling used to promote a reducution in alcohol misuse
89671795|NCT00123409|Placebo Comparator|Usual Care|Usual Care
89671796|NCT05541198|No Intervention|Control Group|"Routine clinical care continued to be provided to the patients in the control group.~Routine maintenance applications include the following parameters;~Risk assessment using Braden Risk Scale~Positioning~Elevate the heels."
89671797|NCT05541198|Experimental|Intervention Group|"A pressure injury care bundle was developed in line with the relevant literature. After the development of the bundle, a 30-minute training program was applied to the nurses on general information about pressure injuries, the pressure injury care bundle, and how to use the bundle. The training program was carried out in four separate sessions arranged according to the working schedules of 40 nurses providing services in ICU.~Care Bundle include this parameters;~Risk Assessment~Skin Assessment~Skin Care~Positioning~Regulation of Nutrition and Liquid Management"
89671798|NCT05550558|Experimental|Anlotinib + Camrelizumab|Anlotinib 12 mg QD p.o for 2 weeks and then stop for 1 week plus Camrelizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
89671799|NCT01686165|Experimental|Belinostat Yttrium Ibritumomab Tiuxetan|Patients receive belinostat IV over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
89671800|NCT05419323||Traditional clinical pathway for OSA|"After referral, patients will have an initial encounter with a sleep care provider which might include in-person visits, telephone clinics, or video conferencing.~Intervention/Treatment: Patients in Arm 1 will receive routine care for OSA at one of the participating VA Sleep Medicine clinics."
89671801|NCT05419323||DREAM clinical pathway for OSA|"After referral, patients will not have an initial encounter with a care provider. After a clinician conducts a chart review of medical records, patients in the DREAM pathway will be referred for sleep testing.~Intervention/Treatment: Patients in Arm 2 will receive routine care for OSA at one of the participating VA Sleep Medicine clinics."
89671802|NCT05419323||Negative predictive value of HSAT|"Results of sleep tests will be compared for patients who undergo both HSAT and polysomnographic (PSG) procedures.~Intervention/Treatment: Patients in Arm 3 will undergo~a) HSAT sleep testing followed by PSG testing, or b) simultaneous administration of PSG and HSAT sleep testing."
89671803|NCT00123643|Experimental|Rosiglitazone|
89671804|NCT00123643|Active Comparator|Glyburide|
89671805|NCT02249637||Inguinal Orchidopexy|Patients with diagnosed palpable low inguinal cryptorchidism underwent inguinal approach as originally described by Schuller and Bevan.
89671806|NCT02249637||Novel Technique (Circumcision incision)|Patients with diagnosed palpable low inguinal cryptorchidism underwent novel technique- circumcision incision orchidopexy.
89671807|NCT00235573|Experimental|Vitamin B12 supplement|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12 were administered 6 hours apart.
89671808|NCT05545488|Experimental|Experimental group|Before preparing for pelvic training, information was given about virtual training applications, 1-2 minutes of practical information about both virtual glasses and pelvic training. Afterwards, the woman was taken to the gynecological examination table and, as the doctor began the examination, virtual glasses were put on the woman and a virtual reality application containing both sound and image was performed for 5-15 minutes. In the meantime, the pelvic examination was performed by the physician, the researcher accompanied the woman at all stages of the pelvic examination process and provided care based on ethical principles, which cared for the woman, respected, protected privacy.
89671809|NCT05545488|No Intervention|Control group|The control group was accompanied by the woman at all stages of the pelvic examination process, and the care service that cared for the woman, was respectful, privacy was protected and based on ethical principles was given in the same way, but the virtual glasses initiative was not applied.
89214823|NCT05827406||Group 11: item set 6|A group of patients with psychiatric problems, consecutively recruited from 5 specific sites in Stockholm, are asked to participate in the study. If they agree to participate, they will respond to a group of item sets (item set 6) that measure relevant psychopathological dimensions. Two hundred patients are asked to participate. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
89671810|NCT05710809|Experimental|Intervention group|Patients in the intervention groups will receive adjuvant or first line palliative chemotherapy (for metastatic disease). In addition, all patients will undergo three months' targeted specialized physical group-based exercise and Comprehensive Geriatric Assessment with corresponding interventions
89671811|NCT05710809|No Intervention|Usual care group|Patients in the usual care groups will receive standard treatment with adjuvant or first line palliative chemotherapy (for metastatic disease). If the patients have other health complaints, these will, as current standard procedure, be treated by oncologist or by referral to general practitioner
89671812|NCT05541042||patients with glioblastoma|
89671813|NCT05545410|Other|healthy volunteers|
89671814|NCT01687179|Experimental|"Sirolimus and Hydroxychloroquine"|"Subjects will take Sirolimus at an initial dose of 2mg followed by dose adjustment to keep Sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial. In addition to Sirolimus subjects will receive Hydroxychloroquine at 200 mg daily for 6 months. Once safety is established at the lower dose (Sirolimus and Hydroxychloroquine 200 mg), subjects enrolled henceforth will receive Sirolimus and Hydroxychloroquine 400 mg (200 mg twice a day) for 6 months."
89671815|NCT05344677|Experimental|trendlenburg position group|in which the women will be positioned in a Trendelenburg position (20 °) once fully awake and cooperative in the recovery room and will remain in this posture for the first 24 hrs postoperatively. The maximum time allowed in a straight-up position will be three 15-min intervals over a 24-h period
89671816|NCT05344677|Experimental|warm pad application group|in this group warm pad (38◦C -40◦C) will be applied on the shoulder after four hours postoperatively for a period of 5-10 minutes. Each woman will be asked to place heat pads when needed during the first 24 hours.
89671817|NCT05344677|Experimental|deep breathing group|the researcher will instruct women after the end of surgery and upon consciousness to take slowly deep breathing while observing her chest and hold her breath for about 5 seconds and then exhale slowly, repeating this deep breathing technique five times after full vigilance within the first 3 hours after surgery. Then, the process will be repeated 6, 12, and 24 h later. The patient will be instructed about this type of breathing before surgery by researchers
89671818|NCT05710731|Experimental|low-reality simulation Group|In this group, urinary catheterization will be performed through a plastic half-hip model.
89671819|NCT05710731|Experimental|Computer Based Simulation Group|In this group, urinary catheterization will be performed through a computer-based full-body model.
89671820|NCT05710731|Experimental|Virtual Reality Simulation Group|In this group, urinary catheterization will be performed through a software based on virtual reality technology.
89671821|NCT00124579|Experimental|bortezomib with thalidomide and dexamethasone|bortezomib with thalidomide and dexamethasone
89671822|NCT02326233|Experimental|Pen of SB5|Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
89671823|NCT02326233|Active Comparator|PFS of SB5|PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)
89671824|NCT05540730||Obstetric brachial plexus paralysis|
89671825|NCT05540730||Control|
89671826|NCT05550168|Experimental|Intervention (Laser group)|The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
89671827|NCT05550168|No Intervention|Contralateral (Non-laser group)|Laser was not applied to the contralateral side of the intervention group (n=10) and the individuals in the control group (n=10); thus, no application was made to accelerate tooth movement
89671828|NCT05550168|No Intervention|Control (Non-laser group)|Laser was not applied to the contralateral side of the intervention group (n=10) and the individuals in the control group (n=10); thus, no application was made to accelerate tooth movement
89671829|NCT05710653|Experimental|HTNex|The participants will adhere to 12 weeks of exercise training, three times a week.
89671830|NCT05710653|No Intervention|HTNcg|These participants will maintain their normal lifestyle without intervention.
89671831|NCT05710653|Experimental|ELEex|The participants will adhere to 12 weeks of exercise training, three times a week.
89671832|NCT05710653|No Intervention|ELEcg|These participants will maintain their normal lifestyle without intervention.
89671833|NCT05710653|Experimental|NTex (Control Group-exercise)|The participants will adhere to 12 weeks of exercise training, three times a week.
89671834|NCT05710653|No Intervention|NTcg (Control Group-no exercise)|These participants will maintain their normal lifestyle without intervention.
89671835|NCT05550090||Patients with liver metastasis from breast cancer requiring antitumor therapy|Patients with liver metastasis from breast cancer requiring antitumor therapy
89671836|NCT01688895||Participants with Protoporphyrias|Individuals with a documented diagnosis of Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
89671837|NCT00124735|Experimental|Rocuronium bolus maintenance|Rocuronium bolus maintenance
89671838|NCT00124735|Experimental|Rocuronium continuous infusion maintenance|Rocuronium continuous infusion maintenance
89671839|NCT05545254||Breast cancer patients and their family members who have undertaken genetic testing|In this study, 259 participants were recruited from November 2019 to March 2022. All participants originated from a genetic counseling clinic of a cancer center in Shanghai, China. 259 participants were contact, and among them, 158 participants finally agreed to participate and completed the survey.
89671840|NCT00125515|Placebo Comparator|Placebo|Placebo plus oral naltrexone
89671841|NCT00125515|Active Comparator|Memantine 30 mg bid|Memantine 30 mg bid plus oral naltrexone
89671842|NCT00125515|Active Comparator|Memantine 15 mg bid|memantine 15 mg bid plus oral naltrexone
89671843|NCT01898767||Mild asthma|Diagnosis of mild asthma as defined by pre-albuterol forced expiratory volume in the first second (FEV1) of >70% predicted.
89049437|NCT02901392||VIRTUE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with VIRTUE®
89671844|NCT05338827|Experimental|Polyvinyl Chloride Tube group|The PVC tube used is a stiff tube with an anterior curvature of approximately 130°, which retains the additional curvature imposed by its passage through the ventilation conduit of the ILMA. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
89671845|NCT05338827|Experimental|Wire-Reinforced Tube group|In contrast to the PVC tube, the WR tube is flexible with a slightly anterior curvature. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
89671846|NCT00125593|Placebo Comparator|Placebo|Placebo = Arm 1. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 1 patients taking 2 tablets (placebo simvastatin plus ezetimibe tablet with a placebo simvastatin tablet) during the first year. After the first year, all Arm 1 patients took one tablet (placebo simvastatin plus ezetimibe tablet).
89671847|NCT00125593|Active Comparator|Simvastatin 20mg plus Ezetimibe 10mg|Simvastatin 20mg plus ezetimibe 10mg = Arm 2. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 2 patients taking 2 tablets during the first year (active simvastatin plus ezetimibe tablet with a placebo simvastatin tablet). After the first year, all Arm 2 patients took one tablet (active simvastatin 20mg plus ezetimibe 10mg tablet).
89671848|NCT00125593|Other|Simvastatin 20mg|Simvastatin 20mg alone = Arm 3. After 1 year, those initially allocated to Arm 3 were re-randomized to simvastatin 20mg plus ezetimibe 10mg (Arm 3b) daily or placebo (Arm 3a). A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with Arm 3 patients taking 2 tablets (a placebo simvastatin plus ezetimibe tablet with an active simvastatin tablet) during the first year. After the first year, all Arm 3a and Arm 3b patients took one tablet (active or placebo simvastatin plus ezetimibe tablet).
89671849|NCT01689441|Experimental|Calcitriol|Calcitriol 2mcg IV x 1
89671850|NCT01689441|Placebo Comparator|Placebo|Normal saline 2cc IV x 1
89671851|NCT01898845|Experimental|LEE011|LEE011
89671852|NCT02249715|Experimental|rDTMS|
89671853|NCT01897831|Experimental|xin te mie|1.5-3.0g,iv,bid or tid for 7-14 days
89671854|NCT01690923|Experimental|Nasal Mask First, then Pillows Mask|"Nasal mask is used for 7 nights, then followed by Pillows mask for 7 nights.~[Nasal mask=Mirage Activa, Micro, FX; Pillows mask=Swift FX]"
89671855|NCT01690923|Experimental|Pillows Mask, then Nasal Mask|Pillows mask for 7 nights, then followed by Nasal mask is used for 7 nights. [Nasal mask=MMirage Activa, Micro, FX; Pillows mask=Swift FX]
89671856|NCT00236977|Experimental|Venofer|iron sucrose injection
89671857|NCT00236977|Active Comparator|Ferrous Sulfate|oral iron
89671858|NCT04753177|Experimental|Neoadjuvant combined hormone therapy|Ribocyclib, fulvestrant, triptorelin
89671859|NCT04753177|Active Comparator|Chemotherapy (the control)|doxorubicin, cyclophosphamide, paclitaxel
89671860|NCT01691313|Experimental|vanoxerine 200mg|vanoxerine HCl 200mg single dose (2x 100 mg oral capsule)
89671861|NCT01691313|Placebo Comparator|placebo|placebo to match vanoxerine oral capsule
89671862|NCT01691313|Experimental|vanoxerine 300mg|vanoxerine HCl 300 mg single dose (3x 100mg oral capsules)
89671863|NCT01691313|Experimental|vanoxerine 400mg|vanoxerine HCl 400 mg single dose (4x 100 mg oral capsules)
89671864|NCT04753099|Experimental|Intervention|Receives occupation-based coaching via telehealth
89049438|NCT02901392||INVANCE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with INVANCE®
89049439|NCT04621773||PGS(Preimplantation Genetic Screening)|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via preimplantation genetic screening procedure
89049440|NCT04621773||SP(spontaneous pregnancy )|patients with two times or more unexplained pregnancy loss, who wants to be pregnant via spontaneous pregnancy.
89049441|NCT02901119|Experimental|Whey protein|Patients are instructed to consume 20g of whey protein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
89049442|NCT02901119|Active Comparator|Casein|Patients are instructed to consume 20g of casein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
89049443|NCT02901158||Critical care patients|Mechanically ventilated patients in the critical care unit
89049444|NCT02901158||OR-patients|Mechanically ventilated patients in the operating room
89049445|NCT04621695|Other|Rubber band ligation|Rubber band ligation is performed by a suction device that allows a rubber band to be applied at the base of the haemorrhoid via a proctoscope. Maximal suction force used is 40 mmHg. A maximum of 3-4 bands are used per session. This rubber band constricts the blood supply causing it to become ischaemic before being sloughed approximately 1-2 weeks later. The resultant fibrosis reduces any element of haemorrhoidal prolapse that may have been present. No sedation is required for this day-care procedure. Patients are asked to administer an enema 2 hours prior to the procedure.
89671865|NCT04753099|No Intervention|Control|No intervention Will receive the occupation-based coaching via telehealth after the 12-weeks
88995700|NCT03782740|Experimental|Endometriosis Melatonin 20 mg|In the endometriosis group: 4 capsules with 5 mg melatonin will be given every evening during eight weeks. Compared with placebo.
89671866|NCT00127231|Experimental|1 Brief Intervention|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
89671867|NCT00127231|Active Comparator|2 Standard Care Arm|
89671868|NCT00079001|Experimental|Zoledronic acid + androgen deprivation therapy|4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progression on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).
89671869|NCT00079001|Active Comparator|Placebo + androgen deprivation therapy|Placebo bu IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.
89671870|NCT00238615|Experimental|Chemotherapy+Radiation+Surgery|"Concurrent weekly docetaxel at 20 mg/m2 and weekly carboplatin at an AUC of 2 with thoracic radiotherapy of 180-200cGy/day for 5/7 days to 45 Gy.~Complete surgical excision 3-6 weeks after completion of chemoradiotherapy.~No Surgery if patient is deemed unable to tolerate surgery, with completion to 61 Gy radiation~Consolidation after surgery: Docetaxel given at 75 mg/m2 every 3 weeks with carboplatin at AUC 6 every 3 weeks with concomitant growth factor support."
89671871|NCT02243943|Experimental|Sugammadex|Subjects in this arm will be reversed with sugammadex 2-4 mg/kg
89671872|NCT02243943|Active Comparator|neostigmine|subjects in this arm will be reversed with neostigmine 1.0-2.5 mg and atropine 0.5-1.0mg
89671873|NCT02249403|Experimental|Talsaclidine, 6 mg tid|
89671874|NCT02249403|Experimental|Talsaclidine, 12 mg tid|
89671875|NCT02249403|Experimental|Talsaclidine, 24 mg tid|
89671876|NCT02249403|Experimental|Talsaclidine, 36 mg tid|
89671877|NCT02249403|Experimental|Talsaclidine, 36 mg bid|
89671878|NCT02249403|Placebo Comparator|Placebo|
89671879|NCT03088631|Active Comparator|Metformin group|
89671880|NCT03088631|Placebo Comparator|Placebo group|
89671881|NCT00131677|Active Comparator|active immediate|participants in this arm start study product immediately upon enrollment
89671882|NCT00131677|Placebo Comparator|placebo immediate|participants in this arm start study product immediately upon enrollment
89671883|NCT00131677|Active Comparator|active delayed|persons in this arm start study product 9 months after enrollment
89671884|NCT00131677|Placebo Comparator|placebo delayed|participants in this arm start study product nine months after enrollment
89671885|NCT02245815|Experimental|use probiotics boucardii|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
89671886|NCT02245815|Experimental|use probiotics Multi-species|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
89671887|NCT02092415|Experimental|Normal subjects|Normal subjects, all of whom undergo brief application of junctional tourniquet
89671888|NCT00240487|Active Comparator|Nitric oxide first|Subjects will be randomized to receive Nitric Oxide (NO) immediately after study entry, given at 10 parts per million (ppm) for the first 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide (NO) will be turned off and subjects will receive no intervention (no nitric oxide) for the next 4 hours of study participation. During this time, all subjects will receive standard clinical are. Blood gases will be monitored once an hour for 4 hours.
89671889|NCT00240487|Active Comparator|Delayed nitric oxide|Subjects will be randomized to receive no intervention (no nitric oxide) for he first 4 hours of study participation. During this time, all subjects will receive standard clinical care. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide will be turned on and subjects will receive 10 ppm of nitric oxide for the next 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours.
89671890|NCT02126917|Experimental|HC-ER + 40% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol.
89671891|NCT02126917|Experimental|HC-ER + 20% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol.
89671892|NCT02126917|Experimental|HC-ER + 0% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol.
89671893|NCT01895075|Experimental|Inhaled budesonide|Inhaled budesonide 1mg/dose (2ml) three tid
89671894|NCT01895075|Placebo Comparator|Normal saline|Normal saline inhalation 2ml tid
89671895|NCT03088709|Experimental|All patients will receive Haploidentical|"The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.~GVHD Prevention Treatment:~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days."
89671896|NCT00241969|Experimental|Behavioral and Nutrition Treatment|The behavioral and nutrition treatment combines individualized nutritional counseling that targeted increasing energy and fat intake and parent training in behavioral child-management skills based on social learning theory to improve meal-time behaviors.
88995701|NCT00532168|Experimental|1|tenofovir plus emtricitabine plus efavirenz
88995702|NCT00532168|Experimental|2|tenofovir plus emtricitabine plus lopinavir-ritonavir
88995703|NCT00532168|Experimental|3|tenofovir plus emtricitabine plus atazanavir-ritonavir
88995704|NCT00532207|Experimental|A|
88995705|NCT04723836|Active Comparator|TT genotype active comparator group|5mg riboflavin per day from 16th gestational week
88995706|NCT04723836|Experimental|TT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
89671897|NCT00241969|Active Comparator|Education and Attention Control|The education and attention control treatment provides education and served as a behavioral placebo in terms of controlling for attention and contact frequency provided. Families are provided with information including general nutrition, enzyme therapy, respiratory infection control, and typical child development anticipatory guidance and safety for preschool- aged children.
89671898|NCT05709951|Active Comparator|Functional exercises|Piriformis stretching Cobra pose Sit up Bridging exercise
89671899|NCT05709951|Active Comparator|Core Stability Exercises|Pelvic bridging Plank Cat and camel Curl up
89671900|NCT02092649|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
89671901|NCT02092649|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
89671902|NCT05163327||Healthy Volunteer|10 Volunteers (Male or Female), aged18 or over, with no known history of Coronary Artery Disease
89671903|NCT05163327||Known Coronary Artery Disease|10 Volunteers (Male orFemale), aged 18 or over,with a known significant (defined as => 70% stenosis) single or 2 vessel Coronary Artery Disease
89671904|NCT01897909||HIV positive with H. pylori infection|HIV positive patients with H. pylori infection
89671905|NCT01897909||HIV positive without H. pylori infection|HIV positive patients without H. pylori infection
89671906|NCT01897909||HIV negative|HIV negative blood donors
89671907|NCT00084149|Experimental|Cyclosporin|Cyclosporin arm (Arm A) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily, 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily, and liquid cyclosporin A (CsA) (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r.
89671908|NCT00084149|Experimental|No Cyclosporin|The No Cyclosporin arm (Arm B) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily and 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily for all 48 weeks
89671909|NCT02247063|Sham Comparator|Placebo|The subjects in the placebo arm will participate in 5 daily M1 High-Definition Transcranial Direct Current Stimulation (HD-tDCS) sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application.
89671910|NCT02247063|Experimental|Experimental|The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes.
89671911|NCT01801943|Experimental|Cognitive Remediation Therapy Group|30 minute Cognitive Remediation Therapy and 60 minute Healthy Living Class three time per week
89671912|NCT01801943|Experimental|Walking Intervention Group|60 minutes of walking and 30 minutes of reading stimulation three times a week
89671913|NCT01801943|Experimental|Combination Group|30 minutes of Cognitive Remediation therapy and 60 minutes of walking three times a week
89671914|NCT01801943|Experimental|Healthy Living Group|60 minute Healthy Living Class and 30 minutes of reading stimulation three times a week.
89671915|NCT02959905|Experimental|medium-dose lymphodepletion regimen|Patients will receive medium-dose lymphodepletion regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
89671916|NCT02959905|Experimental|low-dose lymphodepletion regimen|Patients will receive low-dose lymphodepletion regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
88995707|NCT04723836|Placebo Comparator|TT genotype placebo group|Placebo supplement from 16th gestational week
89671917|NCT02959905|Experimental|No lymphodepletion regimen|Patients will only receive TSA-CTL.
89671918|NCT00134017|Experimental|Bone marrow transplant|Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis
89671919|NCT04783051|Active Comparator|IPTp-SP|The IPTp-SP group will be pregnant women who will receive the standard regimen recommended by the Malaria National Control Program (MNCP) at week 16, 28, 32 and 36 of their pregnancy
89671920|NCT04783051|Experimental|ISTp-US-Py|The ISTp-US-Py group will comprise pregnant women who will be screened monthly from the beginning of the 2nd trimester with ultra-sensitive -RDT and who will be treated with Pyramax® if the test is positive
89671921|NCT00084383|Experimental|GVAX pancreatic cancer vaccine|"5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination"
89671922|NCT00243061|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89671923|NCT00139399|Active Comparator|Saphenous vein|Saphenous vein aortocoronary bypass graft
89671924|NCT00139399|Experimental|Radial artery|Radial artery aortocoronary bypass graft
89671925|NCT00245557|No Intervention|Healthy Controls|Healthy Controls undergo MRI and neuropsychological testing
89671926|NCT00245557|Experimental|Depressed|Depressed subjects receive experimental drug
88995708|NCT04723836|Active Comparator|CT genotype active comparator group|5mg riboflavin per day from 16th gestational week
88995709|NCT04723836|Experimental|CT genotype experimental group|5mg riboflavin + 400µg 5-methyltetrahydrofolate per day from 16th gestational week
88995710|NCT04723836|Placebo Comparator|CT genotype placebo group|Placebo supplement from 16th gestational week
88995711|NCT00150995|Experimental|Tetrathiomolybdate|Patients will be started on a dose of 60mg Tetrathiomolybdate at bedtime and 40mg 3 times per day.
88995712|NCT00532246|Experimental|A|raloxifene
88995713|NCT00532246|Placebo Comparator|B|placebo
89671927|NCT00245635|Experimental|Fluoxetine|Fixed/flexible dosing regimen of fluoxetine based on weight of subject and reaction to dosage, varying between 10mg and 80mg tablets once a day.
89671928|NCT00245635|Placebo Comparator|Placebo|Placebo tablets will be given 1/day for the duration of the study with a dosing schedule equivalent to that of the drug.
89671929|NCT00141115|Experimental|Levetiracetam|Levetiracetam 1500 mg BID
89671930|NCT00249379|Experimental|Acamprosate|Subjects randomized to receive acamprosate
89671931|NCT00249379|No Intervention|No medication|No medication intervention (subjects do not receive acamprosate), but do receive Building Social Networks counseling
89671932|NCT00141739|Experimental|GVHD prophylaxis|GVHD prophylaxis with etanercept
89671933|NCT00142597|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
89671934|NCT00142597|Sham Comparator|Sham Treatment|Sham acupuncture is used.
89671935|NCT00143845|Experimental|Immunosuppression Taper|Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).
89671936|NCT00086957|Experimental|ZD1839, Trastuzumab and Docetaxel|
89671937|NCT00144391|Experimental|Transdermal Testosterone Gel|Transdermal Testosterone Gel (2 mg per pump), 2 pumps per day for 6 months
89671938|NCT00144391|Placebo Comparator|Placebo|Placebo 2 pumps per day for 6 months
89671939|NCT00145249|Active Comparator|Standard Therapy|Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
89671940|NCT00145249|Experimental|Fluconazole Low Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 400 mg/day for the first 14 days, then the randomized dose of fluconazole at 400 mg/day respectively for an additional 8 weeks.
89671941|NCT00145249|Experimental|Fluconazole High Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 800 mg/day for the first 14 days, then the randomized dose of fluconazole at 800 mg/day respectively for an additional 8 weeks.
89671942|NCT00153803|Experimental|1|Erlotinib (Tarceva) 150mg: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
89671943|NCT00153803|Placebo Comparator|2|Matched Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
89671944|NCT00252967|Placebo Comparator|Placebo|Placebo taken daily
89671945|NCT00252967|Experimental|Atorvastatin|Atorvastatin at a dose of 80 mg daily
89671946|NCT01895153||pentosan polysulfate cohort|pentosan polysulfate monotherapy
89671947|NCT01895153||hydrodistension(HD) cohort|hydrodistension(HD) monotherapy
89671948|NCT01895153||combination cohort|combination therapy of pentosan polysulfate and hydrodistension.
89671949|NCT01783223||Intoxicated patients|patients in the Emergency Department who appear to be intoxicated with ethanol.
89671950|NCT00088985|Experimental|Dendritic Cell Vaccine|Dendritic Cells: Dosage: 20 x 106 dendritic cells (DCs) given per treatment Vinorelbine:25 mg/m2 will be administered i.v biweekly Trastuzumab: 6mg/Kg administered by i.v. biweekly
89671951|NCT00156923|Experimental|Medisorb naltrexone 380 mg|
89671952|NCT00156923|Experimental|Medisorb naltrexone 190 mg|
89671953|NCT00093041|Experimental|Zalutumumab 0.15 mg/kg|
89671954|NCT00093041|Experimental|Zalutumumab 0.5 mg/kg|
89671955|NCT00093041|Experimental|Zalutumumab 1 mg/kg|
89671956|NCT00093041|Experimental|Zalutumumab 2 mg/kg|
89671957|NCT00093041|Experimental|Zalutumumab 4 mg/kg|
89671958|NCT00093041|Experimental|Zalutumumab 8 mg/kg|
89671959|NCT00158249|Placebo Comparator|placebo|matched capsules
89671960|NCT00158249|Experimental|citicoline|2 gm/day
89671961|NCT01769885|Experimental|Treatment (tivozanib and surgery)|Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
89671962|NCT01895231|Experimental|Iron isomaltoside 1000|Monofer® 1000 mg IV infusion over 15 minutes
89671963|NCT01895231|Placebo Comparator|Placebo|0.9 % saline Infusion over 15 min
89671964|NCT04745663|Experimental|Povidone-Iodine 0.3 %|A tampon is soaked in diluted PI 0.3% and placed on the inside of the lower eyelid of one eye, where it will release iodine molecules for 20 minutes before being removed.
89671965|NCT04745663|Active Comparator|Povidone-Iodine 5 %|Eye drops of 5% PI is the standard disinfection before eye surgery. The drops will be dripped in one eye and allowed to work for 2 minutes.
89671966|NCT01747577|Experimental|Solifenacin group|
89671967|NCT01747577|Placebo Comparator|Placebo group|
89671968|NCT00094211||Low Walkability/Low Income|Participants reside in a low walkability, low income neighborhood
89671969|NCT00094211||Low Walkability/High Income|Participants reside in a low walkability, high income neighborhood
89671970|NCT00094211||High Walkability/Low Income|Participants reside in a high walkability, low income neighborhood
89671971|NCT00094211||High Walkability/High Income|Participants reside in a high walkability, high income neighborhood
89671972|NCT01736345||Telephone Disclosure|Telephone Disclosure: Participants randomized to telephone disclosure will be asked to provide a personal identifier that the participant will be asked at the time of their telephone disclosure to ensure their identity.
89671973|NCT01736345||In Person Disclosure|Individuals opting out of randomization but still willing to participate in the research will be placed in the self-select in-person arm.
89671974|NCT00159263|Placebo Comparator|Placebo|placebo
89671975|NCT00159263|Experimental|Formoterol|Oxis(®) 12 μg
89671976|NCT00159263|Experimental|Budesonide low dose|Pulmicort(®) 200 μg
89671977|NCT00159263|Experimental|Budesonide high dose|Pulmicort(®) 800 μg
89671978|NCT00159263|Experimental|Budesonide/formoterol combination single|single 100/6 μg SYM100
89671979|NCT00159263|Experimental|Budesonide/formoterol combination double|double 200/12 μg SYM200
89671980|NCT00159419|Active Comparator|Alendronate|1 mg/kg po qd rounded to nearest 10 or 20 mg dose
89671981|NCT00159419|Active Comparator|Pamidronate|3 mg/kg IV q4 months
89671982|NCT00159965|Active Comparator|sertraline|flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
89049446|NCT04621695|Other|Hemorrhoidectomy|"There are two main excisional procedures currently carried out: open (Milligan and Morgan) and closed (Ferguson). Both have the intention of excising the haemorrhoidal cushions. The procedure is performed under either general or spinal anaesthesia in a day-care setting.~Patients were asked to administer an enema 2 hours prior to the procedure."
89049447|NCT02901197|Active Comparator|Education and Reminder|This arm will consist of participants in a location that receive with web based training and exposure to reminder posters in the workplace.
89671983|NCT00159965|Placebo Comparator|placebo|flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
89671984|NCT00096161|Experimental|pentostatin, DLI, mycophenolate mofetil, cyclosporine|"Group I (pentostatin, DLI): Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.~Group II (pentostatin, DLI, mycophenolate mofetil, cyclosporine): Patients receive treatment as in group I. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD."
89671985|NCT00097253|Experimental|Lavender|
89671986|NCT00097253|Experimental|Citrus|
89671987|NCT00097253|Placebo Comparator|Water|
89671988|NCT01898039|Experimental|A2/4-1BBL melanoma vaccine|"On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.~On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered at the day care unit. On day 14 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed. Four additional doses of the vaccine will be administered at intervals of 21 days."
89671989|NCT00099047|Experimental|Arm I (celecoxib)|Patients receive celecoxib PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
89671990|NCT00099047|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
89671991|NCT02851797|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily
89671992|NCT02851797|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily
89671993|NCT05709795|Experimental|Confluent areas|Ablation first of confluent areas of low wave speed and high voltage in the CTI
89671994|NCT05709795|Experimental|Wave Speed|Ablation first of areas of low wave speed in the CTI
89671995|NCT05709795|Active Comparator|Voltage|Ablation first of areas of high voltage in the CTI
89671996|NCT05709795|Active Comparator|CTI line|Direct CTI line performance (gold standard)
89671997|NCT00166205|Experimental|Gastric Band|Single-arm study, all subjects banded.
89671998|NCT00253435|Experimental|All the patients enrolled in the study|"This is a single arm study. The following description applies to all the patients who are enrolled in the study:~On Day -21, patients receive 131I-MIBG infusion.~On Day -7, Day -6, Day -5, patients receive Carboplatin, Etoposide, Melphalan.~On Day -4, patients receive Carboplatin, Etoposide.~On Day -3, Day -2, Day -1, patients rest.~On Day 0, patients receive peripheral blood stem cell infusion.~Dosing of Carboplatin, Etoposide and Melphalan is based upon whole body dosimetry (cGy) estimates.~Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0.~Local radiation therapy is to be given to previously non-irradiated primary and metastatic sites of disease."
89671999|NCT05034081|Experimental|group A|to know the effect of post-bariatric body contouring surgery on weight loss and metabolism
89049448|NCT02901197|Active Comparator|Policy Change|This arm's participants will not receive an active intervention (education and reminders), however, policy change will take place in this location.
89672000|NCT05034081|No Intervention|group B|compare this group of patients with group A to detect weight changes and metabolic changes without any post-bariatric intervention
89672001|NCT05033847|Experimental|Subject last vaccination time is within 30-90 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 30-90 days
89672002|NCT05033847|Experimental|Subject last vaccination time is within 91-180 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days
89672003|NCT05033847|Experimental|Subject last vaccination time more than 181 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 181 days
89672004|NCT02098993|Experimental|Unfractionated heparin|"Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions."
89672005|NCT02098993|No Intervention|Standard of care|Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
89672006|NCT00147043|Experimental|Autologous Stem Cells|
89049449|NCT02901002||Patient|Patients suffering from CRPS of the lower limb Patients with sensory testing in the two hand and neuropsychological evaluation
89049450|NCT02901002||Control|Healthy controls match by age, gender, Body Mass Index Healthy volunteers with sensory testing in the two hand and neuropsychological evaluation
89672007|NCT00166361|Experimental|Memokath 051 Ureteral Stent|Subjects assigned to this arm received a Memokath 051 Ureteral Stent.
89672008|NCT00166361|Active Comparator|JJ Stent|Subjects assigned to this arm received a JJ stent.
89672009|NCT00100841|Experimental|Treatment (combination chemotherapy)|Patients receive cetuximab IV over 60-120 minutes on day 1 in weeks 1-8. Patients also receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 48 hours on days 1 and 2 of weeks 1, 3, 5, and 7. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
89672010|NCT04911543|Experimental|Part A: [18F]-JNJ-70099731|Participants will receive an intravenous (IV) bolus injection of [18F]-JNJ-70099731 on Day 1 of Part A to investigate the total body bio-distribution and measure the radiation dosimetry of [18F]-JNJ-70099731.
89672011|NCT04911543|Experimental|Part B: [18F]-JNJ-70099731|Participants will receive an IV bolus injection of [18F]-JNJ-70099731 on Day 1 of Part B to measure the uptake, distribution, and clearance of [18F]-JNJ-70099731 and to model the tissue specific kinetics of [18F]-JNJ-70099731 in the human brain with the appropriate arterial input function.
89672012|NCT04911543|Experimental|Part C: [18F]-JNJ-70099731|Participants will receive an IV bolus injection of [18F]-JNJ-70099731 on Day 1 of each period of Part C to determine the test-retest variability in the regional brain kinetics and binding properties of [18F]-JNJ-70099731.
89672013|NCT02094755||Single cohort|Single cohort will receive Blood draw only.
89672014|NCT04836273|Experimental|120 µg dasiglucagon|Subcutaneous 120 µg dasiglucagon self-administration
89672015|NCT04836273|Placebo Comparator|Placebo|Subcutaneous placebo self-administration
89672016|NCT05709249|Active Comparator|intervention group|Subjects in the intervention group will be treated with XLJDOD compound granule.
89672017|NCT05709249|Placebo Comparator|control group|Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).
89672018|NCT00101933|Experimental|1|Active Stimulation
89672019|NCT00101933|Sham Comparator|2|No Stimulation
89672020|NCT00149227|Active Comparator|Non-ARB|'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs
89672021|NCT00149227|Experimental|Valsartan|Valsartan add-on treatment
89672022|NCT00445965|Experimental|131I-3F8|This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.
89672023|NCT02096081|Experimental|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
89672024|NCT02096081|Active Comparator|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
89672025|NCT01709799|Experimental|Cognitive Training plus Exercise|"Physical exercise will be achieved using traditional methods of aerobic exercise. Participants may choose between walking on a treadmill or riding on a stationary bike (Choices include recumbent or traditional sit-up bike.)~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
89672026|NCT01709799|Active Comparator|Cognitive Training plus Exergames|"Physical exercise in this group will be achieved using the Nintendo Wii Sports Resort and Wii Sports video games. A standardized gaming plan will be used for all participants, with play starting at 15 mins. and increasing 5 mins each week after, up to a maximum of 40 play minutes.~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
89672027|NCT01709799|Active Comparator|Cognitive Training|Participants will complete 80 mins/day during the 4th, 8th, 12th and 16th weeks of the intervention.
89672028|NCT04789083|Experimental|Group 1 (Propolis)|Medical therapy and propolis
89672029|NCT04789083|Experimental|Group 2 (Nurse Coaching/ Nursing education)|Medical treatment and nurse coaching
88995714|NCT00532285|Experimental|Paclitaxel/Gemcitabine|paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8) every 3 weeks, 4 cycles
89672030|NCT04789083|Placebo Comparator|Group 3 (Plassebo)|Medical treatment and plassebo will be applied.
89672031|NCT01710891|Active Comparator|Direct Laryngoscopy|Patients will undergo their first intubation attempt with direct laryngoscopy using the CMAC device without video assistance. The video monitor with be covered with a hood.
89672032|NCT01710891|Experimental|CMAC|Patients will undergo their first intubation attempt using the CMAC videolaryngoscope using video assistance
89672033|NCT02242617|Active Comparator|MAS-PAP|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)
89672034|NCT02242617|Active Comparator|PAP-MAS|Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)
89672035|NCT00254995||Menactra Vaccine Recipients|Participants who received Menactra vaccine as part of routine medical care during the study period in Kaiser Permanente.
88995715|NCT00151034|Experimental|Herceptin|"Herceptin - 4mg/kg day 1 of cycle 1; 2mg/kg day 8 and 15 of cycle 1 and subsequent cycles.~Paclitaxel - 200mg/m^2 on day 1 Carboplatin - AUC 5 on day 1 Gemcitabine - 800 mg/m^2 on day 1 and 8"
88995716|NCT02817451|Experimental|Study Group A|HIV exposed and infected infants
89672036|NCT00254995||Age-Matched Control|Each individual receiving Menactra vaccine served as their own control for evaluation of acute (Days 0-30) events (short-term surveillance). For the 6-month (long-term) surveillance, for each person receiving Menactra vaccine, a control matched on age (± 1 year), sex, and month of vaccination was selected who received a received tetanus and diphtheria toxoids (Td), hepatitis A, hepatitis B, or hepatitis A/hepatitis B combination vaccine as part of routine medical care during the same month 1 year earlier in Kaiser Permanente
89672037|NCT02247765|Experimental|Arterial Line|CO-Oximetry value obtained as a comparator. Obtained during motion conditions.
89672038|NCT02247765|Experimental|Motion|The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.
89672039|NCT04663945|Experimental|Intervention|"This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions.~Other: remote controlled exercise plus home exercise~Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise"
89672040|NCT04663945|No Intervention|Control|"This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training.~Other: basic education"
89672041|NCT01790347|Experimental|Exercise group|
89672042|NCT01790347|No Intervention|Control group|Sedentary pregnant women
89672043|NCT02240589|Experimental|Memantine|24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.
89672044|NCT02240589|Placebo Comparator|Placebo|24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.
89672045|NCT02103127|Experimental|755nm Alexandrite laser with lens array|
89672046|NCT00258349|Experimental|Arm I|Patients will receive vorinostat by mouth twice a day for 2 weeks. They will also receive a 90-minute infusion of trastuzumab in week 1.
89672047|NCT01713621|Experimental|OZ439 100mg|Single dose of 100mg of OZ439 administered as an oral suspension
89672048|NCT01713621|Experimental|OZ439 500mg|Single dose of 500mg of OZ439 administered as an oral suspension
89672049|NCT01899157||Survey|"Thai naive HIV-infected patients~Thai HIV-infected patient reciering highly active antiretroviral therapy"
89672050|NCT01714323|Other|Standard care|At discharge, the participant receives the standard care provided by the hospital. This consists of a handout with information to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
89672051|NCT01714323|Experimental|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication and (2) Interactive Voice Response (IVR) Triage to Telephone Counseling.
89672052|NCT00258817|Experimental|Influenza Virus Vaccine Naïve|Subjects have never received Influenza virus vaccine in the past
89672053|NCT00258817|Experimental|Influenza Virus Vaccine-primed|Subjects have received Influenza virus vaccine in the past
89672054|NCT05683899||Group A|141 days with AI scores displayed
89672055|NCT05683899||Group B|141 days with AI scores not displayed
89672056|NCT00259285|Experimental|A|
89672057|NCT01715883|Experimental|Sodium Nitrite|"Sodium Nitrite will be administered at three time points:~At the time of organ procurement, a pre-prepared syringe of sodium nitrite will be added to each of the 2.8 liter bags of Perfadex solution to flush the donor lungs.~At the time of transplant just prior to reperfusion of lungs, the donor lungs are flushed with a cold pneumoplegia solution after the bronchial (1st) anastomosis and with warm pneumoplegia solution after the portal vein (3rd, last) anastomosis. The drug will be added to pneumoplegia solution just prior to both the flushes.~Sodium Nitrite will be delivered intravenously to the recipient immediately prior to lung reperfusion as a single infusion at rate of 4 mL/min for the first 30 min, followed by 2.2 mL/min for the next 60 min."
89672058|NCT01716039|Active Comparator|MTX 12.5|Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
89672059|NCT01716039|Active Comparator|MTX 25 mg|Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
89672060|NCT01716039|Placebo Comparator|Placebo|Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab
89672061|NCT01716195|Experimental|Response Adapted Chemoradiation|Paclitaxel 175 mg/m2 + Carboplatin area under curve (AUC) 6 followed by response adapted Radiation Therapy (5 - 6 weeks) + Paclitaxel
89672062|NCT04492059|Experimental|Blood flow restriction augmented physical therapy|The group will undergo traditional physical therapy with the augment of blood flow restriction therapy under the supervision of trained physical therapists.
89672063|NCT04492059|Active Comparator|Traditional physical therapy|The group will undergo traditional physical therapy without the augment of blood flow restriction therapy under the supervision of trained physical therapists.
89672064|NCT02249481|Active Comparator|Group F|Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
89672065|NCT02249481|Experimental|Group A|Adductor canal catheter delivering 0.0625% L- Bupivacaine: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
89672066|NCT01717053|Experimental|Abiraterone acetate|Abiraterone Acetate, Radiotherapy and Short Term Androgen Deprivation. Prednisone will be prescribed concurrently with Abiraterone acetate.
89672067|NCT01666314|Other|Placebo + Orteronel 200 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 (28 days) followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
89672068|NCT01666314|Experimental|Orteronel 200 mg (Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
89672069|NCT01666314|Other|Placebo + Orteronel 300 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
89672070|NCT01666314|Experimental|Orteronel 300 mg (Japan)|Orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
89672071|NCT01666314|Other|Placebo + Orteronel 200 mg (Ex-Japan)|"Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles outside of Japan (Ex-Japan) for up to 3.1 years.~Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study."
89049451|NCT04621656||Type 2 Diabetes|Individuals that have been previously diagnosed with Type 2 Diabetes. Those with Fasting Blood Glucose levels 126 mg/dL in two separate tests and/or HbA1C values greater than 6.5%. Individuals may take Metformin, SGLT2 inhibitors, of GLP-1 therapeutics. Not including those using Insulin therapeutics.
89049452|NCT04621656||Pre-Diabetes|Individuals that have been previously diagnosed with Pre-Diabetes. This group may include individuals with pre-diabetes that may be unaware of their condition. HbA1C values between 5.7% and 6.4%.
89049453|NCT04621656||Healthy|Individuals that have not been previously diagnosed with Metabolic Syndromes including Type 2 Diabetes, obesity, or increased levels of blood sugar. HbA1C values below 5.7%.
89049454|NCT04681664|Experimental|50 % fat diet|In the high fat group the subjects were assigned to the diet containing in average 50 % fat, 25 % proteins and 25 % carbohydrates for four weeks.
89049455|NCT04621461|Placebo Comparator|Experimental Arm #1|Placebo
89049456|NCT04621461|Experimental|Experimental Arm #2|Zinc sulfate
89049457|NCT02901236|Active Comparator|Mitomycin C|Standard Guarded Trabeculectomy will be performed. In this arm 0.02% of mitomycin C (Kyowa, Japan) will be applied on bare sclera under the conjunctiva for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
89672072|NCT01666314|Experimental|Orteronel 200 mg (Ex-Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
89672073|NCT01666314|Other|Placebo + Orteronel 400 mg (Ex-Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
89672074|NCT01666314|Experimental|Orteronel 400 mg (Ex-Japan)|Orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
89672075|NCT01717209|Experimental|Combined nitric oxide and prostacyclin|iNO (20 ppm continuously) and iPGI2 (0.05 micrograms/kg/min continuously)
89672076|NCT05545176||out of hospital cardiac arrest patients in Asia countries|
89672077|NCT05545098||JIA patients|"Assessment of Survivin and Lubricin in the serum and in the Synovial fluid if available in JIA patients~Assessment of activity using Juvenile arthritis disease activity score in 27 joints (JADAS 27) in the studied JIA patients.~Identifying the prevalence of functional disability in JIA children and adolescents using the childhood health assessment questionnaire (CHAQ).~performing MSUS on the involved joints."
89672078|NCT05545098||control group|Assessment of Survivin and Lubricin in the serum
89672079|NCT01666002|Experimental|Treatment|"st visit: Patient will come into clinic for initial laser treatment with Nd:YAG 1064 nm laser fitted with special handpiece.~nd visit: 2 weeks after initial laser treatment, patient will be seen for second treatment with Nd:YAG 1064 nm laser fitted with special handpiece."
89672080|NCT01666002|No Intervention|Placebo|"st visit: For the control group, no treatment will be given.~nd visit: 2 weeks after initial visit, patient will be seen for second visit"
89672081|NCT05550012|No Intervention|standard-dose CT|those patients undergo standard-dose liver CT in portal vein and delayed phase
89672082|NCT05550012|Experimental|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase
89672083|NCT05535582||Patients with SMuRFs|Patients with acute myocardial infraction with a history of at least one standard modifiable risk factor (SMuRF; smoking, diabetes mellitus, dyslipidemia, hypertension)
89672084|NCT05535582||SMuRF-less Patients|Patients with acute myocardial infraction without history of any SMuRF
89672085|NCT00260689|Experimental|Horse ATG/CsA taper|h-ATG (Anti-thymocyte globulin (horse)) + 6 months CsA (Cyclosporine) followed by an 18 month CsA taper
89672086|NCT00260689|Experimental|Rabbit ATG/CsA|r-ATG (Anti-thymocyte globulin (rabbit)) + 6 months CsA (Cyclosporine)
89672087|NCT00260689|Experimental|Alemtuzumab|Alemtuzumab administered for 10 days
89672088|NCT05535504|Experimental|real rTMS|Use the real rTMS coil
89049458|NCT02901236|Active Comparator|Bevacizumab|Standard Guarded Trabeculectomy will be performed. In this arm at the end of the case and after conjunctival closure 1.25mg of bevacizumab (Avastin; Genentech, San Francisco, CA) will be injected into the the anterior chamber through a paracentesis.
89049459|NCT02900963|Other|Nutrition state determination|"Determination of nutritional state and inflammatory status:~weekly assessment of patient's weight biological parameters (albumin, transthyretin, orosomucoid) and weekly assessment of patient's weight"
89672089|NCT05535504|Sham Comparator|sham rTMS|Use the sham rTMS coil
89672090|NCT05544942|Experimental|GCWB1001|1 capsule once a day
89672091|NCT05544942|Active Comparator|Placebo|1 capsule once a day
89672092|NCT00262639|Experimental|I|2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.
89672093|NCT00262639|Placebo Comparator|II|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
89672094|NCT01899235|Active Comparator|Stent|drug eluting stent (Resolute)
89672095|NCT01899235|Experimental|drug eluting balloon|drug eluting balloon (Elutax)
89672096|NCT05698446||Open Modified Broström +Suture tape augmentation group|Patients who accept a modified Broström +Suture tape augmentation operation
89672097|NCT05698446||Anatomic reconstruction operation group|Patients who accept an anatomic reconstruction
89672098|NCT04752943|Experimental|Children and caregivers receiving TipsByText messages|
89049460|NCT04621617|Active Comparator|Albumin + Midodrine + SMT|Human albumin plus oral midodrine
89049461|NCT04621617|Active Comparator|Albumin + SMT|Human albumin plus placebo of midodrine
89049462|NCT04621617|Placebo Comparator|SMT|standard medical therapy plus placebo of midodrine
89049463|NCT02900612|Experimental|WA (Water Aerobics Training)|Water aerobics training.
89049464|NCT02900612|Experimental|WR (Water Resistance Training)|Resistance aquatic training.
89049465|NCT02900612|Active Comparator|CG (Control Group)|Control Group.
89672099|NCT04752943|No Intervention|Children and caregivers not receiving TipsByText texts|
89672100|NCT01062451|Placebo Comparator|Placebo|
89672101|NCT01062451|Active Comparator|Perindopril|
89672102|NCT01062451|Active Comparator|Candesartan|
89672103|NCT04639843|Experimental|1- Experimental Treatment: Dose Escalation|Duvelisib (PO BID) at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of C1 and days 1-14 of all other cycles of each 21- day cycle (max 8 cycles) with CC-486 (5-azacitidine) (PO) at 300mg/day on days 1-10, romidepsin at 12mg/m2 (IV) on Days 1 and 8 of each cycle and doxorubicin (IV) at 25 mg/ m2 on Day 1 of cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy), to determine RP2D of duvelisib and doxorubicin
89672104|NCT04639843|Experimental|2 - Experimental Treatment: Dose Expansion|Duvelisib (PO BID) at RP2D on days -14 to 14 of C1 and days 1-14 of all other 21-day cycle (max 8 cycles) with CC-486 (5-azacitidine) at 300mg/day (PO) on days 1-10, romidepsin at 12mg/m2 (IV) on days 1 and 8 of each cycle, and doxorubicin at 25 mg/m2 on day 1 of Cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy
89672105|NCT01718691|Experimental|SyB L-0501＋rituximab|
89672106|NCT05699148||Children with cystic fibrosis aged 6 to 11 years|Group of children who have at least one copy of Phe508del gene mutation and are eligible for starting on the modulator elexacaftor/ tezacaftor/ ivacaftor (ETI). This group will have baseline MRI scans before starting ETI and aiming to have subsequent scans post starting ETI (6 months to 1 year post starting ETI)
89672107|NCT05699148||Control Group|Age and gender matched controls with no history of cystic fibrosis or gastrointestinal disease. This group will undergo one set of scans only.
89672108|NCT05539950|Experimental|Cardiopulmonary rehabilitation with health education|The participants will participate in cardiopulmonary rehabilitations programs under the supervision of therapists 3 times a week, 12 weeks in total. Recommendations for individualized exercise prescription and lifestyle modification will be given to the participants as well.
89672109|NCT05539950|Active Comparator|Health education|The participants will be given recommendations for individualized exercise prescription and lifestyle modification.
89672110|NCT01790425|Experimental|water colonoscopy|The water (study) method: Warm water (body temperature) will be infused into colon to open the lumen for water infusion colonoscopy. Higher rate of complete colonoscopy will be achieved.
89672111|NCT01790425|Active Comparator|Air Colonoscopy|The air (conventional) method: Air is pumped gently (insufflation) into the colon will be used to open the inside space of the colon and aid in colonoscope insertion
89672112|NCT05697900|Active Comparator|Creatine monohydrate|5 g of creatine monohydrate per day for eight weeks
89672113|NCT05697900|Experimental|Creatine hydrochloride|5 g of creatine hydrochloride per day for eight weeks
89672114|NCT05697900|Placebo Comparator|Placebo|5 g of maltodextrin per day for eight weeks
89672115|NCT04388995|Experimental|observed patients|
89672116|NCT04425642|Experimental|Glucose/Amino acids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose and amino acids according age and weight
89672117|NCT04425642|Experimental|Glucose/Amino acids/Lipids|Patients who will require nutritional support will receive parenteral nutrition consisting of glucose, amino acids and lipid emulsions according age and weight
89672118|NCT00266851|Active Comparator|Azithromycin|Active adjunctive treatment
89672119|NCT00266851|Placebo Comparator|Placebo|Adjunctive placebo
89672120|NCT00266851|Other|Observational Cohort|Eligible participants who declined randomization, offered enrollment in parallel, open-label azithromycin treatment arm
89672121|NCT01899313|Experimental|CBT- based SMS text messaging intervention|cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
89672122|NCT01899313|Placebo Comparator|Placebo Texts|Placebo texts will be given instead of interventional texts
89672123|NCT01665768|Experimental|Everolimus and Rituximab|Everolimus daily for one year and IV rituximab four times during that year.
89672124|NCT01720173|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89672125|NCT05697744||obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
89672126|NCT05697744||Morbid obese|Vidiac score Mallampati score upper lip bite test Thyromental distance Mandible ramus length Mouth opening distance
89672127|NCT04436523|Experimental|Blood flow restriction|The blood flow restriction arm will include the use of the pneumatic tourniquet applied to the operative lower extremity throughout post-operative rehabilitation sessions. The tourniquet pressure will be titrated to 80% of the measured extremity arterial limb occlusion pressure with the participant lying supine.
89672128|NCT04436523|Sham Comparator|Standard rehabilitation|The standard rehabilitation arm will undergo the same rehabilitation protocol as the experimental arm. A tourniquet will still be applied, but will only be inflated to 20 mmHg, a pressure that will not occlude blood flow.
89672129|NCT00017563|Experimental|Docetaxel, Mitoxantrone, Conventional Surgery|"Drug: Docetaxel-35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.~Drug: Mitoxantrone-Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.~Procedure/Surgery: Conventional Surgery- Prostatectomy will be scheduled 2-4 weeks after the last dose of chemotherapy"
89672130|NCT00018031|Experimental|1|Weekly Injection of peginterferon alfa-2b and weight based ribavirin (1-1.2g/day) for 48 weeks
88995717|NCT02817451|Experimental|Study Group B|HIV exposed and uninfected infants
88995718|NCT05467696|Experimental|Sequence 1 Fed:Fasted|Period 1: CTP-543 12 mg fed Period 2: CTP-543 12 mg fasted
88995719|NCT05467696|Experimental|Sequence 2 Fasted:Fed|Period 1: CTP-543 12 mg fasted Period 2: CTP-543 12 mg fed
89672131|NCT05539482|Experimental|Community-Based Health Education Group|The collaborators will design the Community-based education approach (based on the core intervention package). Collaborators will be required to submit a brief standardized proposal to the academic investigators for review and approval, to ensure that all intervention programs have the same core intervention content and can be implemented appropriately. Collaborators will be able to use any reasonable strategies, such as social media platforms, information technology, posters, leaflets, and videos, to implement the programs . The use of incentives will be encouraged to improve participation. Each programs will last for 3 months. A booster session will be conducted at the mid of the intervention.
89049466|NCT01212757|Experimental|Apremilast 20mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
89049467|NCT01212757|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
89049468|NCT01212757|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
89672132|NCT05539482|Active Comparator|Health Information Sharing Group|The collaborators will design the community-based education approach and deliver health information to the participants. Researchers will provide some information, while collaborators need to self-collect the rest. Collaborators also need to submit a proposal to ensure the feasibility of intervention programs and the accuracy of health information. Collaborators can use any reasonable strategies to implement the programs . The use of incentives will be encouraged to improve participation. Each programs will last for 3 months. A booster session will be conducted at the mid of the intervention.
89672133|NCT01720251|Placebo Comparator|placebo|SC injections of placebo
89672134|NCT01720251|Experimental|AllerT low dose|SC injections of AllerT 25 or 50 micrograms
89672135|NCT01720251|Experimental|AllerT full dose|SC injections of AllerT 50-100 micrograms
89672136|NCT00267085|Experimental|CML Vaccine|Imatinib mesylate subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
89672137|NCT05539248|Experimental|Dose escalation CAN106 in cohort 1|Subjects are administered CAN106 20 mg/kg IV maintenance dosing.
89672138|NCT05539248|Experimental|Dose escalation CAN106 in cohort 2|Subjects are administered CAN106 40 mg/kg IV maintenance dosing.
89672139|NCT05539248|Experimental|Dose escalation CAN106 in cohort 3|Subjects are administered CAN106 80 mg/kg IV maintenance dosing.
89672140|NCT04278885|Experimental|Lanadelumab|
89672141|NCT04487353|Experimental|Experiment Group|"The Labor Evaluation Information Scale (LEIS) was administered as a pre-test before applying to 30 students who had taken a course on childbirth. After the pre-test, the application was carried out with the Labor mechanism application developed with virtual reality technology (VRT-LMA). Immediately after the application, data were collected with the LEIS, sense of presence scale and cognitive load scale. Post-test was performed again with the Labor Evaluation Information Scale (LEIS) 5 weeks after the application."
89672142|NCT04487353|No Intervention|Control Group|"Before the theory training, the Assessment Knowledge Scale (LEIS) was administered as a pre-test to 31 students in the control group who had taken a course on obstetrics. After the pre-test, theory training including birth knowledge was given. Labor mechanism application developed with virtual reality technology (VRT-LMA) was not applied to the control group. After 4 hours of theoretical training, the final test was performed using LEIS. After 5 weeks, the last test was repeated."
89672143|NCT05591976|Experimental|Exercise group|Participants are assessed for outcomes prior to intervention, mid-way through intervention and immediately after intervention.
89672144|NCT02249793||Study group|Healthy volunteers
89672145|NCT00267631||At Risk Body Weight|Children with a BMI greater and equal to 85%
89672146|NCT00267631||Normal Body Weight|Children with a BMI of 25 to 75%
89672147|NCT02250417|Experimental|Wave Surface, Then Non Wave Surface|Subjects sleep first for a whole night in the sleep laboratory with the Wave sleep surface. They then return to the sleep laboratory and sleep without the Wave sleep surface.
89672148|NCT02250417|Experimental|Non Wave Surface, Then Wave Surface|Subjects sleep first for a whole night in the sleep laboratory without the Wave sleep surface. They then return to the sleep laboratory and sleep with the Wave sleep surface.
89672149|NCT05539170|Experimental|"micro parenting intervention"|"Parents will be instructed to bring the completed questionnaires with them to the university lab. Then, in the lab, parents will be observed interacting with their child. Following these baseline conditions, half of the parents will receive the micro parenting intervention-in the form of individual positive feedback concerning their parenting and their child's behavior."
89672150|NCT05539170|No Intervention|care-as-usual condition|Participants in the care-as-usual control condition receive no immediate positive parenting feedback but will also be taken aside without their child, receiving only the instructions of the experiment.
89672151|NCT05697666||Moderate to severe ARDS adult patients under mechanical ventilation and neuromuscular blockade|no intervention
89672152|NCT04476511|Active Comparator|Slower Loading Dose|30.000IU cholecalciferol once weekly for ten weeks
89672153|NCT04476511|Active Comparator|Moderate Loading Dose|30.000IU cholecalciferol twice weekly for five weeks
89672154|NCT05543772|Experimental|Normal saline|Study will be held in King Fahad University Hospital during a year after obtaining the IRB approval. Selection of study participants will be depending on their health status and the investigators will exclude pediatric participants. Two blood samples will be collected from participants. First one is after the insertion of the intravenous peripheral line. The second is after fluid infusion through the same line. Samples will be sent to the laboratory then. Results will be collected and analyzed.
89672155|NCT05539092|Experimental|intervention group|the researcher will change angle of bed from 15° to 45°. The severity of pain will be assessed for five times starting immediately after sheath removal. Vascular complications monitoring scales will be assessed I for five times starting immediately after sheath removal.
89672156|NCT05539092|No Intervention|control group|positioning the patients in supine for 6 hours and the affected leg was straight and immobilized. The severity of pain will be assessed for five times starting immediately after sheath removal. Vascular complications monitoring scales will be assessed I for five times starting immediately after sheath removal.
89672157|NCT05543460|Experimental|Corticopuncture-facilitated MARPE|Patients will be treated using Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) with corticopunctures .along the mid-palatal suture
89672158|NCT05543460|Active Comparator|Conventional MARPE|Patients will be treated using Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) without corticopunctures.
89672159|NCT05613933|Experimental|Intervention arm|In the intervention arm, dentists will receive information on the study 8 weeks before the start of the study and will be invited to consent to participate or to opt out
89672160|NCT05613933|No Intervention|Control arm|In the clusters randomized to the control arm, no intervention will be performed and no information will be sent to dentists.
89672161|NCT05591664||GROUP 1|There will be 38 patients diagnosed with gestational diabetes in the study group.
89672162|NCT05591664||GROUP 2|There will be 80 normal pregnant women in the control group
89672163|NCT04157049||Alpha-1 Diagnosed Individuals|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
89672164|NCT04157049||Carriers of Alpha-1|Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains <40% of the identified PiZZ individuals in the US.
89672165|NCT00026221|Experimental|Arm I (monoclonal antibody and biological therapy)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive low-dose interferon alfa (IFN-alpha) SC on days 1-14.
89672166|NCT00026221|Experimental|Arm II (monoclonal antibody)|Patients receive bevacizumab as in arm I.
89672167|NCT00026221|Experimental|Arm III (monoclonal antibody and biological therapy)|Patients receive bevacizumab as in arm I. Patients also receive high-dose IFN-alpha SC on days 1, 3, 5, 8, 10, and 12.
89672168|NCT05538936|Experimental|Baby SPA|Baby SPA application time: It is done regularly from the first month, at least once a month. The ideal time for application is the first six months. The water in the tub is prepared to be 33°C. The baby, whose clothes are taken off, wearing a waterproof diaper suitable for the tub and a neck ring, is taken into the tub. The application usually takes 10-15 minutes, depending on the baby's reactions to the water for the first time. After the parent and baby get used to the process, the time can be increased to 30 minutes. In this process, the baby's hands, abdomen, and legs are made to recognize the water and the baby's movements are monitored. Care is taken that the baby does not drink the water. After the application period is over, the baby is removed from the tub and dried with a towel. Finally, the baby is massaged for 10-15 minutes and dressed.
89672169|NCT05538936|Experimental|Massage|Massage can be applied to all age periods. Before starting the massage application in babies, some preparations are made. Ambient temperature (24-26 OC) is adjusted, it is regulated so that there is no airflow, dim light, and low noise levels are ensured. 1-2 towels, a soft cushion or massage table, baby oil lotion, clean diapers, and clean clothes are prepared for the massage. There is no standard time interval for the application of massage. It can be done at least one hour after the baby's feeding, at any time of the day when he is not stressed and sleeps. Massage application time is 15-30 minutes depending on the baby's reactions may vary between.
89672170|NCT05538936|No Intervention|Control|It is the control group in which no intervention was applied.
89672171|NCT03974178|Experimental|Fexinidazole|"Patients with a body weight ≥ 35 kg:~1800 mg (3 tablets) from day 1 to 4~1200 mg (2 tablets) from day 5 to 10~Patients with a body weight ≥ 20 and < 35 kg:~1200 mg (2 tablets) from day 1 to 4~600 mg (1 tablet) from day 5 to 10"
89672172|NCT00028093|Experimental|Pefinterferon+Ribavirin|Patients with chronic hepatitis C virus (HCV) infection genotype 1 peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients <75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
89672173|NCT00028093|Active Comparator|Peginterferon|patients with chronic hepatitis C virus (HCV) infection genotype 1 were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
89672174|NCT01721967|Experimental|Ranolazine|Ranolazine, 500 mg for 60 days
89672175|NCT04026451|Experimental|Intervention|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SEF95 obtained by SedLine® monitor to keep a SAS 1-2. The target of SEF95 will be 10-13 Hz to keep SAS 1-2.
89672176|NCT04026451|Active Comparator|Control|Critical care patients with an indication of deep sedation and mechanical ventilation will be sedated with an infusion of propofol and fentanyl guided by SAS (1-2). SedLine® monitor will be also used in these patients but the screen will be covered.
89672177|NCT01722435||OST completers|Patients who are likely to complete OST during the next 12 or 18 months
89672178|NCT00029107|Other|Immediate treatment|Patients receive treatment with four weekly infusions of rituximab 375mg/m2 immediately following randomization.
89672179|NCT00029107|Other|Delayed treatment|Patients treated with standard therapy (corticosteroids, plasma exchange, etc.). After 6 months, they are eligibile to cross over and receive four weekly infusions of rituximab.
89672180|NCT04389229|Experimental|UTIL-01|Single dose autologous unmodified tumour infiltrating lymphocytes
89672181|NCT04389229|Experimental|CoTIL-01|Single dose autologous gene modified tumour infiltrating lymphocytes
89672182|NCT04330417|Experimental|EMG Glove Group|A total of 12 sessions of robot-assisted hand training for 6 consecutive weeks.
89672183|NCT04330417|Active Comparator|Control Group|A total of 12 session of standard hand therapy sessions in 6 consecutive weeks.
89672184|NCT01899625|Active Comparator|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
89049469|NCT01212757|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
89672185|NCT01899625|Active Comparator|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
89672186|NCT03775044|Experimental|Experimental: Medherent Device|All participants get the Medherent device. There is only one arm to this study.
89672187|NCT04083885|Experimental|Virtual Reality|Participants receive 8 weeks of home-based or facility-based virtual reality training, supervised remotely and asynchronously, in addition to their usual activity.
89672188|NCT04083885|No Intervention|Usual Care|Participants perform their usual activities.
89672189|NCT04021329|Other|EMDR Therapy|One arm will be a group subjected to EMDR Therapy
89672190|NCT04021329|Other|CBT Therapy|other arm will be a group subjected to CBT Therapy
89672191|NCT05538546||Cohort 1|Population: Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000) at baseline.
89672192|NCT05538546||Cohort 2|Population: Patients don't meet Baveno VI criteria (with a liver stiffness ≥ 20kPa or with a platelet count ≤150,000) at baseline, but don't have varices requiring treatment (proved by endoscopy at baseline)
89672193|NCT05538468||Stroke Patients Group|The kinesiophobia scores of the patients were evaluated by (Tampa Kinesiophobia Scale) and (Visual Analog Scale- Kinesiophobia Assessment), depression severity (Beck Depression Inventory), postural control (Postural Assessment Scale), pain severity (Visual Analog Scale).
89672194|NCT04425798||Patients with LEV application|LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.
89672195|NCT04425798||Patients without LEV application|LGG patients with GRE do not take any medicine or receive any treatment preoperatively.
89672196|NCT00271219|Experimental|Buprenorphine|Buprenorphine
89672197|NCT00271219|Active Comparator|Methadone|Methadone
89672198|NCT00271375|Experimental|Arm 1: Caring for you, Caring for me Educational Intervention|Educational Intervention
89672199|NCT00271375|Experimental|Arm 2: Caring for you, caring for me + social worker|Educational + Social Work Intervention
89672200|NCT00271375|Placebo Comparator|Arm 3: Control group usual care|Control group usual care
89672201|NCT02240667||Subjects with atrial fibrillation|
89672202|NCT03246516|Experimental|Questionnaire|Auto and hetero questionnaire
89672203|NCT01727895|Experimental|Beta-glucan|Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
89672204|NCT01727895|No Intervention|Control group|
89672205|NCT00272311|Active Comparator|1|81 mg Aspirin
89672206|NCT00272311|Active Comparator|2|162 mg Aspirin
89672207|NCT00272311|Active Comparator|3|325 mg Aspirin
89672208|NCT00272311|Active Comparator|4|650 mg Aspirin
89672209|NCT00272311|Active Comparator|5|1300 mg Aspirin
89672210|NCT05538156|Other|Control group|The internal limiting membrane is not removed
89672211|NCT05538156|Other|Intervention group|The internal limiting membrane of the posterior pole is removed
89672212|NCT00038857|Experimental|CD34 PBPC|CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m^2 Fludarabine over 4 days on days -6, -5, -4, -3 and 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
89049470|NCT00562419|Experimental|1|CT-322
89049471|NCT00562419|Experimental|2|CT-322 and irinotecan hydrochloride
89049472|NCT02900768|Experimental|Exercise Group|Patients in the intervention group will receive supervised and unsupervised exercise program after their bone marrow transplant.
89049473|NCT02900768|No Intervention|Control Group|Patient will receive standard of care within the hospital as an inpatient and outpatient after their bone marrow transplant.
89672213|NCT05538078|Experimental|intervention|Ozone gel
89672214|NCT05538078|Active Comparator|active comparator|nonsurgical periodontal treatment(scaling)
89672215|NCT04549831||SARS-CoV-2 PCR positive individuals|Adult (> o equal to 18 years) SARS-CoV-2 PCR positive individuals with different clinical outcome: from asymptomatic to severely affected COVID-19 patients.
89672216|NCT03097068|Experimental|0.3 mg Lucentis|Aqueous Humor sample post injection of 0.3 mg Lucentis
89672217|NCT04262947|Active Comparator|Conventional Method|Placement of peripheral venous catheter using conventional methods
89672218|NCT04262947|Experimental|VeinViewer Visualization Only|Use of a VeinViewer to visualize the most suitable target. Once the target has been identified and marked, the device will be placed aside and the peripheral venous catheter will be placed using conventional methods
89672219|NCT04262947|Experimental|Constant Imaging with VeinViewer|Identification of the most suitable target and placement of a peripheral venous catheter under constant imaging with a VeinViewer
89672220|NCT01729845|Experimental|Treatment (decitabine, MEC)|"Patients receive decitabine IV on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).~INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy."
89672221|NCT05695794|Other|the group with a bed head height of 45 degrees|The bed head height of the patients in this group will be adjusted to 45 degrees. This group was determined as the control group since the patients were given a 45-degree head height as a standard in the hospital where the study would be conducted.
89672222|NCT05695794|Experimental|the group with a bed head height of 30 degrees|The bed head height of the patients in this group will be adjusted to 30 degrees. This group was determined as the experimental group since the patients were given a 45-degree head height as a standard in the hospital where the study would be conducted.
89672223|NCT01729923|Experimental|Treatment (capecitabine, celecoxib, radiation therapy)|"Patients proceed to surgery, radiation therapy with ADAPT therapy followed by maintenance ADAPT therapy, or ADAPT therapy. Eligible patients undergo surgical resection at baseline or upon achievement of resectable disease after radiation therapy.~RADIATION + ADAPT: Patients undergo radiation therapy 5 days per week and receive capecitabine PO BID and celecoxib PO BID 5 days per week during radiation.~ADAPT: Patients receive capecitabine PO BID on days 1-14 and celecoxib PO BID on days 1-21. Courses repeat every 21 days for up to 3 years in the absence of disease progression or unacceptable toxicity."
89672224|NCT02584452|Active Comparator|Continuous Adductor Canal Nerve Catheter|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal continuous nerve catheter using normal saline bolus followed by 1/8% bupivacaine infusion through catheter at 8cc/h.
89672225|NCT02584452|Active Comparator|Long Acting Single Bolus Adductor Canal Nerve Block|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine and 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve.
89672226|NCT01732263|Experimental|SSP-004184 (Child-Pugh A Liver Impaired)|The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation. Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15. It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
89672227|NCT01732263|Experimental|SSP-004184 (Child-Pugh B Liver Impaired)|
89672228|NCT01732263|Experimental|SSP-004184 (Child-Pugh C Liver Impaired)|
89672229|NCT01732263|Experimental|SSP-004184 (Matched Healthy Subjects)|
89672230|NCT01732419|Experimental|Home-based training|"After the first three supervised training sessions in the hospitals, patients in the home-based training group are instructed to wear a heart rate monitor during exercise training at home. Prescribed exercise exists of two or three exercise sessions per week, of one hour at 70 - 85% of their maximum heart rate.~Once a week the heart rate data is uploaded and evaluated by an exercise specialist together with the patient by telephone."
89672231|NCT01732419|Active Comparator|Centre-based training|Patients in the centre-based training group will perform all trainings sessions under direct supervision of a physical therapist specialized in CR. Training sessions will be performed on an cycle ergometer, starting with a warm up phase of 5 min, followed by 50 min of cycling at 70-85% of the maximal HR and a cooling down period of 5 min. During the training period, physical therapists will record attendance, training duration and actual training intensity. After the 12-week training period patients receive individual advice from their physical therapist on physical activities.
89672232|NCT05698212|Active Comparator|Cohort 1|Endometriosis diagnosed at stage 1 or 2
89672233|NCT05698212|Active Comparator|Cohort 2|Endometriosis diagnosed at stage 3 or 4
89672234|NCT05698212|Other|Cohort 3|"Control--Not suspected of having and absence of endometriosis confirmed by diagnostic test.~This group has uterine tissue biopsy and laparoscopy for non-endometriosis indication, i.e. tubal ligation"
89672235|NCT05537532|Experimental|Competition group|"Programs with at least five interns were grouped into program-based teams. Interns within the same residency institution in programs that did not meet this criterion were grouped into institution-based teams, with a minimum of five participants per team.~For each week, an eligible team is randomized to either a steps competition or non-competition group with 50/50 chance. For those randomized to competition arm, teams were assigned an opponent team by total randomization, by which the opponent team was assigned regardless of institution and specialty."
89672236|NCT05537532|Experimental|Non-competition group|For each week, an eligible team is randomized to either competition or non-competition group with 50/50 chance.
89672237|NCT01860612|Experimental|PMA Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
89672238|NCT01860612|Experimental|Compassionate Use Cohort|Study participants that do not meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
89672239|NCT01860612|Experimental|Continued Access Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the Continued Access cohort, after enrollment in the PMA cohort is complete.The fellow eye can be treated 1 month after the primary eye.
89672240|NCT05536986||Observation group of newly oligodendroglioma patients with high-level psychological stress|The patients had high threshold levels of perceived psychological stress, fear, anxiety, and depression as assessed by psychologists
89672241|NCT05536986||Observation group of newly oligodendroglioma patients with low-level psychological stress|The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
89672242|NCT05679102|Active Comparator|Amlopdipine only|Newly diagnosed hypertensive patients who will be given only amlodipine.
89672243|NCT05679102|Active Comparator|Amlodipine and Atorvastatin|Newly diagnosed hypertensive patients who will be given Amlodipine and Atorvastatin.
89049474|NCT02900729|Experimental|Renal Denervation plus Medications|Renal denervation procedure after randomization plus maintenance of baseline standardised triple anti-hypertensive medications for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days
89049475|NCT02900729|Active Comparator|Medications|Maintenance of baseline standardised triple antihypertensive medications after randomization for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days, after which, subjects will be allowed to cross over to perform renal denervation if they still meet the inclusion criteria for the study.
89049476|NCT00562536|Experimental|A 1|Delayed umbilical cord clamping 30-45 seconds.
89049477|NCT00562536|No Intervention|A 2|Immediate umbilibcal cord clamping
89672244|NCT05698134|Active Comparator|Standard of care|Participants will receive blood products transfusion based on prevailing institution protocol, which is based on Platelet count and coagulation parameters (APTT, PT/INR)
89672245|NCT05698134|Experimental|ROTEM guided Group|Participants will receive blood products transfusion based on ROTEM results
89672246|NCT05588934|Placebo Comparator|Placebo Dose Both Nights|Participants will be administer non-caffeinated, placebo gum during both nights of Phase 2.
89672247|NCT05588934|Active Comparator|Standard Caffeine Dose Both Nights|Participants will be administer the standard caffeine recommendation (200mg/2 hr. up to 800mg/24 hr.) using caffeinated and non-caffeinated gum during both nights of Phase 2.
89672248|NCT05588934|Active Comparator|Optimized Caffeine Dose Both Nights|Participants will be administer the optimized caffeine recommendation (0-300mg/2 hr. up to 800mg/24 hr.) potentially using caffeinated and non-caffeinated gum, depending on optimized dosage, during both nights of Phase 2.
89672249|NCT05588934|Active Comparator|Placebo Dose 1st Night/Standard Caffeine Dose 2nd Night|Participants will be administer non-caffeinated, placebo gum during the first night of Phase 2. Then, participants will be administer the standard caffeine recommendation (200mg/2 hr. up to 800mg/24 hr.) using caffeinated and non-caffeinated gum during the second night of Phase 2.
89672250|NCT05588934|Active Comparator|Placebo Dose 1st Night/Optimized Caffeine Dose 2nd Night|Participants will be administer non-caffeinated, placebo gum during the first night of Phase 2. Then, participants will be administer the optimized caffeine recommendation (0-300mg/2 hr. up to 800mg/24 hr.) potentially using caffeinated and non-caffeinated gum, depending on optimized dosage, during the second night of Phase 2.
89672251|NCT05587452||Healthy group|People without colorectal adenoma or cancer
89672252|NCT05587452||Advanced adenoma group|People with colorectal adenoma
89672253|NCT05587452||Colorectal cancer group|People with colorectal cancer
89672254|NCT05536674|No Intervention|No SMS reminder|This group will receive no reminder
89672255|NCT05536674|Experimental|Short SMS with no additional information|"Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer. Contact your family doctor today to arrange an appointment."
89672256|NCT05536674|Experimental|Short SMS + NCDC link|"Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer. Contact your family doctor today to arrange an appointment. More information on the official NCDC website"
89672257|NCT05536674|Experimental|"SMS with reserved for her framing + NCDC link"|"Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer. Her vaccine is reserved at the policlinic. Contact your family doctor today to arrange an appointment. More information on the official NCDC website"
89672258|NCT05536674|Experimental|SMS with safety information + NCDC link|"Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer. The vaccine has been given safely to more than 118 million girls worldwide. Contact your family doctor today to arrange an appointment. More information on the official NCDC website"
89672259|NCT02243007|Experimental|Folfirinox-ARM A|"Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel~Treatment will be administered on an outpatient basis and will include intravenous administration of the FOLFIRINOX regimen on predetermined days.~After completion of FOLFIRINOX all patients without progressive disease will proceed with radiation therapy with the standard dose of capecitabine.~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
89672260|NCT02243007|Experimental|Gemcitabine/nab-Paclitaxel- Arm B|"Treatment will be administered on an outpatient basis. Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel).~Intravenous administration of the Gemcitabine/Nab-paclitaxel regimen on predetermined days of each 28 day treatment cycle (unless a delay is mandated by toxicity criteria). A cycle of Gemcitabine/Nab-paclitaxel will constitute a 28 day treatment period.~After Gemcitabine/Nab-paclitaxel, all patients without progressive disease will proceed to radiation therapy with the standard dose of capecitabine~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
89049478|NCT02900690||recombinant activated factor VII (NovoSeven®)|Group using the Novoseven
89049479|NCT02900690||Standard care|without use of the Novoseven
89049480|NCT00562653||1|infective endocarditis patients before treatment
89049481|NCT00562653||2|infective endocarditis treatment after treatment
89049482|NCT00562653||3|control
89049483|NCT01190410|Experimental|Certolizumab pegol: high-dose group|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
89672261|NCT05536596|Experimental|Citoneurone|Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneurone). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive peripheral neural disorders.
89672262|NCT05536596|Experimental|Melatonin|Group B will receive the pharmacology treatment with 10 mg Melatonin. One capsule orally at night for 60 days.
89672263|NCT05536596|Experimental|Hydroxycobalamin|Group C will receive the pharmacology treatment with 1 mg hydroxycobalamin (vitamin B12). One capsule daily for 60 days.
89672264|NCT05536596|Placebo Comparator|Placebo|The controls will receive 1 capsule placebo containing 5 mg starch to be taken once daily.
89672265|NCT05317377|Active Comparator|Structured Exercise|Structured hand exercises will be applied in 45-minute sessions (16 sessions total), 2 days a week, over 8 weeks in addition to participants' routine physical activities.
89672266|NCT05317377|Experimental|Leap Motion Based Exergame (LMBE)|"ErgoActive and HandROM exercise apps focusing on hand exercises and fine motor skills will be applied in 45-minute session (16 sessions total), 2 days a week, over 8 weeks in addition to participants' routine physical activities."
89672267|NCT03469011|Experimental|Imatinib oral100mg tablets|"A standard 3+3 trial design will be utilized for the imatinib dosing. In general, patients will be treated in cohorts of 3-6 with escalating doses of imatinib using oral 100mg tablets.~Dose Level -1=100mg, +1=200mg (starting dose for cohort 1), +2=300mg, +3=400mg, +4=600mg (if needed)."
89672268|NCT03430791|Experimental|Nivolumab Monotherapy|Nivolumab 240 mg IV every 2 weeks for maximum of 24 months. TTF (Optune) for max of 24 months
89672269|NCT03430791|Experimental|Nivolumab+Ipilimumab|"Nivolumab 3 mg/kg IV with ipilimumab then 240 mg every 2 weeks for maximum of 24 months.~Ipilimumab 1 mg/kg IV every 6 weeks maximum of 4 times. NovoTTF200A (Optune) TTF for maximum 24 months"
89672270|NCT05316909|Experimental|Baby doll with remote controlled jaw|In this arm, standardized patients will use the Newborn Oral Assessment and Latch Simulator (NORALSim) to demonstrate and teach newborn positioning and attachment in the simulation.
89672271|NCT05316909|Active Comparator|Standard care/doll|In this arm, standardized patients will use a cloth doll/standard treatment to demonstrate and teach newborn positioning and attachment in the breastfeeding skills workshop.
89672272|NCT05463978||Females/Males treated with Sculptra Aesthetic in non-facial areas|Sculptra Aesthetic administration in non-facial areas
89672273|NCT04851327|Experimental|High energy|"Child will be given a high energy drink: a flavoured high energy milk or juice-based drink, used clinically to supplement the diet of preschool children (either Pediasure plus or Duocal). This will provide 1.5 kcals per ml in various flavours as preferred. The amount given will supply 10% of the child's daily energy requirements per Kg - for example for a 2-year-old child weighing 15 KG this would be 80 mls of drink supplying 120 Kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing a range of pre-packaged foods of known energy content suitable for their age, chosen in consultation with the parents."
89672274|NCT04851327|Experimental|Low energy|"Child will be given a low energy drink of the same volume selected to be as similar as possible to the high energy drink, made either of skim milk or sugar free fruit juice, with a similar sugar free flavour; for above example this will supply 25 kcal.~They will be given 10 minutes to drink the preload and 30 minutes after this they will eat lunch containing the same range of pre-packaged foods as above."
89672275|NCT05470179|Active Comparator|Hybrid hyrax distalizer|Inverted hyrax with 2 miniscrews for 6 months for maxillary molar distal movement in class II angle malocclusion
89672276|NCT05470179|Active Comparator|Pendulum distalizer device|Modified pendulum with miniscrews for 6 months for maxillary molar distal movement in class II angle malocclusion
89672277|NCT05536128|Experimental|Olaparib,Fulvestrant|"Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.~Fulvestrant should be administered on days 1, 15, 29, and then once monthly at 500 mg per dose."
89672278|NCT05392842|Placebo Comparator|Placebo group|plain mucoadhesive fast dissolving film
89672279|NCT05392842|Experimental|Treated group|Corchorus Olitorius Buccal Films
89672280|NCT05535894||Unresectable Pancreatic Cancer|Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
89672281|NCT05316675|Active Comparator|Group 1|:(25)patients will be treated by oral isotretinoin; 0.5 -1 mg/kg/day in two divided doses for 6 months.
89672282|NCT05316675|Active Comparator|Group 2|:(25) Patients will be treated by oral isotretinoin; 0.5 -1 mg/kg/day for seven days each month for 6 pulses.
89672283|NCT05316675|Active Comparator|Group 3|:(25) Patients will be treated by oral isotretinoin; 0.1-0.2 mg/kg/day for 6months
89672284|NCT05316675|Active Comparator|Group 4:|(25) Patients will be treated by oral isotretinoin;20mg /day for one month then the dose increased in monthly steps to reach the standard dosing for 6 months
89672285|NCT02586012|Experimental|TBW, LBM, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on IBW (Ideal Body Weight).
89672286|NCT02586012|Experimental|LBM, IBW, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on TBW (Total Body Weight).
89672287|NCT02586012|Experimental|IBW, TBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on IBW (Ideal Body Weight); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
89672288|NCT02586012|Experimental|TBW, IBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
89672289|NCT02586012|Experimental|LBM, TBW, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on IBW (Ideal Body Weight).
89672290|NCT02586012|Experimental|IBW, LBM, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on, IBW (Ideal Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on TBW (Total Body Weight).
89672291|NCT02249559||GK subthalamotomy|Evaluate the safety and efficacy of unilateral GK subthalamotomy for PD in patients deemed poor candidates for DBS.
89672292|NCT05316363|Experimental|OMT Intervention Arm|Patients treated with 4 techniques for 8 minutes in the supine position. OMT systematically administered to address the 4 body regions - cervical spine, thoracic spine, ribs and diaphragm. The techniques utilized for this study include: suboccipital release, diaphragmatic release, rib raising and paraspinal inhibition of the thoracic spine. Each technique administered for approximately 2 minutes.
89672293|NCT05316363|No Intervention|Control|Patients lie supine on the treatment table and rested quietly for a total of 8 minutes.
89672294|NCT05316207|Active Comparator|Intervention Group|IG was formed from 40 patients who received routine care, treatment and education services of the clinic after open heart surgery, and whose routine controls were determined by the randomization method. The patients in the IG would call by the researcher at least four times, at the end of the first, second, third and fourth weeks after discharge, to provide education and counseling via tele-nursing. In these phone calls, the current problems of the patient, if any, and the issues that should be paid attention to during the home care process after open heart surgery were explained.It was stated that, unlike the patients in CG, patients in IG would be called by the researcher at least four times at the end of the first, second, third and fourth weeks after discharge to provide education and counseling via tele-nursing.
89049484|NCT01190410|Experimental|Certolizumab pegol: low-dose group (weight adjusted)|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
89049485|NCT01190254|Experimental|Asenapine 2.5 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks.
89049486|NCT01190254|Experimental|Asenapine 5.0 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period.
89049487|NCT01190254|Placebo Comparator|Placebo|Participants receive placebo asenapine tablets sublingually BID for 8 weeks.
89049488|NCT02887066||Patients with thoracic pain and suspicion of ACS|
89049489|NCT04315987|Experimental|NestaCell®|A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
89049490|NCT04315987|Placebo Comparator|Placebo|Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
89049491|NCT04621383|Experimental|whey protein plus collagen group|Participants received a dose of 30 grams of whey protein plus 20 grams of collagen seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
89049492|NCT04621383|Placebo Comparator|whey protein plus maltodextrin group|Participants received a dose of 30 grams of whey protein plus 20 grams of maltodextrin seven days a week splitted in two servings a day, first one in morning, second one in evening. Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
89049493|NCT04621539||Infected without an SMO|Defined as an acute infection not associated with admission to the intensive care unit (ICU), mechanical ventilation, or the use of vasopressors.
89049494|NCT04621539||Infected with an SMO|defined as an acute infection associated with intensive care unit (ICU) admission, mechanical ventilation, or vasopressor use.
89049495|NCT04621305|Placebo Comparator|group P (Placebo group)|Patients were assigned to group P (Placebo group) using a computer-generated random number table
89049496|NCT04621305|Experimental|group B (Bolus group)|Patients were assigned to group B (Bolus group) using a computer-generated random number table
89049497|NCT04621305|Experimental|group C (continuous infusion group)|Patients were assigned to group C (continuous infusion group) using a computer-generated random number table
89049498|NCT00553592|Experimental|Drug|Bicifadine
89049499|NCT00553592|Experimental|Drug: 2|Bicifadine
89049500|NCT00553592|Placebo Comparator|Control|Placebo of Bicifadine
89049501|NCT04620954|Experimental|Intervention|
89049502|NCT04621032||OSA +|Patients with visceral obesity and newly diagnosed Obstructive Sleep Apnea (during the study)
89049503|NCT04621032||OSA -|Patients with visceral obesity in whom Obstructive Sleep Apnea diagnosis have been excluded (during the study)
89049504|NCT00562692|Experimental|A|Nesiritide
89049505|NCT00562692|Placebo Comparator|B|Placebo
89049506|NCT02900534|Experimental|Internet-based self-help|The self-help programme consists of 10 text-based sessions and one supportive E-Mail a week. The programme employs cognitive-behavioural interventions. The theoretical background is the Dual Process Model by Stroebe and Schutt (1999).
89049507|NCT02900534|No Intervention|Waiting control group|
89049508|NCT04621110|Experimental|intranasal dexmedetomidine and fentanyl|Dexmedetomidine (precedex®) and fentanyl will be administered by intranasal routes, seeing if both sedative (dexmedetomidine) and analgesic (fentanyl) can give enough sedation for procedure
89049509|NCT04621110|Active Comparator|intravenous ketamine and midazolam|ketamine (ketalar®) and midazolam intravenous will be using to compare the efficiency of intranasal drugs
89049510|NCT04620720|No Intervention|control group|routuine analgesics wil be given
89049511|NCT04620720|Experimental|intervention group|patient will receive cap gabapentin 1200 mg 2 hours before surgery
89672295|NCT05316207|No Intervention|Control Group|The patients in the CG were formed from 40 patients who received routine care, treatment and education services of the clinic after open heart surgery, and who were determined by the randomization method, whose routine controls were made after discharge. No application was made to the patients in the CG by the researcher within the scope of the study. However, the researcher gave the phone number to the patients in the CG in terms of their right to receive ethical and professional care, and it was stated that they could call between 10:00 and 22:00 if needed. The reasons for calling the investigator from the CG were recorded .
89672296|NCT02582814|Experimental|dapagliflozin 5mg + insulin|dapagliflozin tablet 5mg + adjustable insulin
89672297|NCT02582814|Experimental|dapagliflozin 10mg + insulin|dapagliflozin tablet 10mg + adjustable insulin
89672298|NCT01736865|Placebo Comparator|placebo|One placebo pill daily for 1 year
89672299|NCT01736865|Active Comparator|cholecalciferol|One cholecalciferol pill daily for 1 year
89672300|NCT05690100|Experimental|Ozone Gel|Ozone is a potent oxidant with marked antimicrobial activity and the potential to act as a metabolic and host immune modulator.The routes of ozone administration are topical and regional for both gaseous and aqueous forms .Ozone gel is contains ozonated extra virgin olive oil and Arnica montana extract, containing essential fatty acids Ozone gel was claimed to have analgesic (Tasxdemir et al,2016) and anti-inflammatory effect its high content of essential fatty acids and the effect of ozone, natural extra virgin olive oil (I. Lezcano,et al.2000). Ozone gel has a beneficial role in wound healing, Its wound healing properties may be due to enhancing blood circulation and immune response.(M.colombo et,al 2019), Generic name : GeliO3 Dosage form : Gel Frequency/Duration : Once on this interval : 0,3,7,14
89672301|NCT05690100|Experimental|Hyaluronic Acid 0.2%|"HA was Known for hygroscopicity that allows it to maintain conformational stiffness and to retain water.(Yıldırım et al., 2017b) .Another major feature is viscoelasticity that provides stability and elasticity to tissues and delays penetration of viruses and bacteria (Finn, Schow and Schneiderman, 1992) .~In periodontology, HA has been advocated as monotherapy(Hammad et al., 2011) or as an adjunct to non-surgical and/or surgical (Fawzy El-Sayed et al., 2012) periodontal treatment to reduce inflammation and promote wound healing.~HA gel was used in two different concentrations 0.2% and 0.8% versus negative control in the management of post-operative pain after FGG surgery and it was found effective with more superior results for the 0.2% concentration (Yıldırım et al., 2017b).~Generic name : GingiGel Dosage form : Gel Frequency/Duration : Once on this interval : 0,3,7,14"
89672302|NCT04716972||Online Survey|Online survey
89672303|NCT04716972||Interviews|Interviews
89672304|NCT05332080|Experimental|Telerehabilitation via application on cell phone|The patients in this group had application installed on their cell phones to access the online content, where they received advice on self-care and the type of exercises to be performed. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned 4-week objectives. Participants in both groups were provided with written exercise material, training, and advice on how to return to work and leisure activities. Each patient made a weekly record of the therapy he/she performed, including the day, type, and time of development of his/her exercises
89672305|NCT05332080|No Intervention|In-person rehabilitation|The patients in this group received an in-person rehabilitation program and was considered the control group, this group received for two weeks a 10-session program for two weeks that included external heat application, stretching, mobilization, strengthening, and occupational therapy. Moreover, it was complemented with occupational therapy focused on improving essential functions and strengthening extrinsic and intrinsic hand musculature, effectiveness in wrist mobility, and simulation of specific activities for reincorporation to work
89672306|NCT01736943|Experimental|Bortezomib + Doxil|Bortezomib will be given subcutaneously at 1.5mg/m2 on days 1, 4, 8 and 11 of a 3 week cycle. Doxil will be administered once every three weeks as a single intravenous infusion at a dose of 40 mg/m2 (day 4 of each cycle).
89672307|NCT05503680|Experimental|Yoga group|The experimental group is people living with HIV who will receive 120 minutes per week of yoga intervention.
89672308|NCT05503680|No Intervention|Control group|In this study, the control group will receive standard care where participants usually receive various program from The local HIV clinic including general education program, health check-up, and oral antiretroviral regimen
89672309|NCT04622163|Experimental|Secondary Mentor Plus Career Development Resources|Subjects will be assigned a secondary mentor for 6 months. Subjects will also receive career development resources.
89672310|NCT04622163|Other|Career Development Resources Alone|Subjects will not be assigned a secondary mentor. Subjects will receive career development resources only.
89672311|NCT05487144|Experimental|Treatment|
89672312|NCT01738737|Experimental|Stretching|Seven stretching exercises for lower limbs during 24 sessions
89672313|NCT01738737|Experimental|Placebo laser + Stretching|application of placebo laser therapy during nine sessions plus stretching exercises during 24 sessions
89672314|NCT01738737|Experimental|Active laser + Stretching|application of active laser therapy during nine sessions plus stretching exercises during 24 sessions
89672315|NCT01738737|Experimental|Active Laser|Application of active laser only during 24 sessions
89672316|NCT01738737|No Intervention|Control|Control group that will receive a small book with informations about knee osteoarthritis and postural orientation.
89672317|NCT01739361|Experimental|Acetaminophen|Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
89049512|NCT02900222|Experimental|Choroid Plexus Coagulation|Patients with communicating hydrocephalus will be treated with endoscopic choroid plexus coagulation.
89672318|NCT01739361|Placebo Comparator|Placebo|Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
89672319|NCT01742949|Active Comparator|Thermosmart|Subjects receive heated humidification
89049513|NCT04620642||Registry group|Patients over 18 years old, hospitalized in the neurovascular unit of the Pierre Wertheimer Neurological Hospital (Hospices Civils de Lyon), for an ischemic stroke treated by thrombolysis and / or mechanical thrombectomy and not opposed to this research
89049514|NCT02900417|Experimental|sitagliptin|All the patients will receive sitagliptin 100mg daily.
89049515|NCT04620876|Experimental|Bimodal and coaxial high resolution imaging of the retina|Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT)
89049516|NCT04620408|Experimental|Group A|The subjects in group A did not have breakfast at D1, then were given an SHR4640 tablet. The subjects in group A had a high-fat breakfast on D8. After eating 30min, the subjects in group A were given SHR4640 tablet.
89049517|NCT04620408|Experimental|Group B|Group B had high-fat breakfast on D1, no breakfast on D8, and the rest was the same as group A.
89049518|NCT02900183|Experimental|ARC-AAT Injection|Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses
89049519|NCT04620525||Participants with the relevant condition|Participants with the relevant condition
89049520|NCT04620525||Healthy controls|Healthy controls
89049521|NCT02900495|Experimental|Suprapubic TENS|electrodes, 'transcutaneous electric nerve stimulation' placed onto the lower abdomen in the suprapubic region directly over the bladder
89049522|NCT02900495|Experimental|Posterior Tibial TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the posterior tibial nerve behind the medial malleolus of the ankle and another electrode on the bottom of the foot
89049523|NCT02900495|Experimental|Parasacral TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the S3 foramen on the sacrum on each side of the midline in the lower back/upper buttocks
89672320|NCT01742949|Placebo Comparator|No humidification|Subjects use dry CPAP / APAP
89672321|NCT01743729|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution (5.0%)
89672322|NCT01743729|Placebo Comparator|Placebo|
89672323|NCT01743963|Experimental|Decision Support Intervention|Clinical pharmacists mediated computerized decision support
89672324|NCT01743963|Active Comparator|Usual Care|Clinicians' typical approach for GID monitoring
89672325|NCT01744353|Experimental|Dose level 1|Abraxane 125 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
89672326|NCT01744353|Experimental|Dose level 2/ MTD|Abraxane 150 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
89672327|NCT01744353|Experimental|Dose level 3|Abraxane 175 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
89672328|NCT01744821|Active Comparator|Arm A: Vitamin D3 Group|Patients will take Vitamin D3 by mouth in the weeks prior to and including the morning of surgery. If blood test done at the start of the study shows that patients have a low (< or = 30 ng/ml) Vitamin D level, patients will be given two 25,000 IU Vitamin D3 Tablets (for a total of 50,000 IU) to take once a week until surgery. If baseline Vitamin D level is >30ng/ml, patients will be given on 2,000 IU Vitamin D3 tablet to take once a day until day of surgery.
89672329|NCT01744821|Placebo Comparator|Arm B: Placebo Group|Patients will take a placebo by mouth prior to and including the morning of surgery. If bloods tests done at the start of study show that the patients have a low (< or = 30 ng/ml) Vitamin D level, patients will be given 2 placebo tablets to take once a week until surgery. If baseline Vitamin D level is > 30 ng/ml, patients will be given on placebo tablet to take once a day until surgery.
89672330|NCT04369365|Active Comparator|Arm A: Azithromycin|weekly oral azithromycin 1500mg for a maximum of 8 weeks
89672331|NCT04369365|Placebo Comparator|Arm B: Placebo|weekly oral placebo for a maximum of 8 weeks
89672332|NCT01745055|Experimental|CP-690,550 (tofacitinib) 30 mg q12h|Individual dose of methotrexate with the addition of CP-690,550 30 mg q12h
89672333|NCT05302323|Other|Disposable Drapes|group using disposable surgical drapes
89672334|NCT05302323|Other|Reusable Drapes|group using reusable surgical drapes
89672335|NCT01745133|Placebo Comparator|vehicle|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
89672336|NCT01745133|Active Comparator|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
89672337|NCT01745133|Active Comparator|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
89672338|NCT01745211|Experimental|755nm Alexandrite laser with array handpiece|Device: 755nm Alexandrite laser with array handpiece
89672339|NCT04769271|Active Comparator|Scaling and Root Planing (SRP)|
89672340|NCT04769271|Experimental|Scaling and Root Planing with tea tree oil|
89672341|NCT04246359|Experimental|RP induction and maintenance|"1. Induction phase:~Rituximab: 375mg / m2, ivd, d1;~Pegylated interferon α-2b: 135 μg (500,000 U), H, d1, 8 Repeated every 21 days, Maximum 6 cycles 2. Maintenance phase:~1) Rituximab: 375mg / m2, ivd, d1; 2) Pegylated interferon α-2b: 135 μg (500,000 U), H, d1,30 Repeated every 2 months, Maximum 12 cycles"
89672342|NCT02258139|Experimental|Study Group 1|1st overnight visit with no contact lens; 2nd overnight visit randomized to either left or right eye for B&L Investigational Contact Lens
89672343|NCT04147689|Experimental|Treated labia majora|Labia majora are treated at Baseline visit (V1) and a touch-up may be performed 4 weeks after Baseline (V2) if needed
89049524|NCT02900495|Placebo Comparator|Shoulder TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the scapula on the shoulder/back
89672344|NCT05213169|Experimental|Apomorphine|"Apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: titration phase from 0 to 4 mg/h (5 days), maintenance phase at 4 mg/h, titration-maintenance phase with possible increase up to 6 mg/h depending on tolerance (18 days).~Domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects 2 days before the initiation of apomorphine and maintained at least 7 days before an optional tapering off in the absence side effects."
89672345|NCT05213169|Placebo Comparator|Isotonic saline|Sodium chloride infusion following the administration procedure described for apomorphine
89672346|NCT04108221|Experimental|Arm A : c-TAP Block performed by surgeon|c-TAP Block Block performed by surgeon
89672347|NCT04108221|Active Comparator|Arm B : us-TAP Block performed by anesthetist|us-TAP Block by anesthetist
89049525|NCT04620837|Experimental|Treatment Arm|Tislelizumab：200mg Q3W IV Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated.
89049526|NCT02900027|Experimental|IONIS-APOC-III-LRx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
89049527|NCT02900027|Placebo Comparator|Placebo (Normal Saline)|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
89214824|NCT05827406||Group 12: reduced item set 6|We analyze data from group 11 and optimize item set 6 for the best measurement with the least number of items. Then, we recruit 200 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the reduced item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced item set 6 fails to validate, we may need to change it and recruit additional groups to optimize it.
89672348|NCT05199987|Active Comparator|Standard Occupational Therapy|This group will receive standard occupational therapy sessions
89672349|NCT05199987|Experimental|Occupational Therapy with Breathing Control Exercises|This group will receive the same component of the control group + breathing control exercises
88815733|NCT02179892|Active Comparator|Group 2-Bupivacaine and Dexamethasone IV|Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.
89049528|NCT04620447|Active Comparator|Mindfulness Meditation|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 7~Final number of participants: 118~Mindfulness Meditation intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
89672350|NCT05192265|Experimental|Pyramax™|Artesunate-pyronaridine is indicated for the blood-stage treatment of the two dominant strains of malaria: P. falciparum and P. vivax. The medicine is also available in a child-friendly granule formulation to enhance palatability in this vulnerable population. Dosing was administered according to body weight: 5 - <8kg - one sachet daily for 3 days; 8 - <15Kg - two sachets daily for 3 days; 15 - <20 Kg - three sachets daily for 3 days; 20 - <24 Kg - one tablet daily for 3 days; and 24 - <45 Kg - two tablets daily for 3 days.
89672351|NCT05192265|Active Comparator|Coartem™|"We used the standard six-dose regimen of artemether-lumefantrine dispersible tablets twice daily according to body weights. Each dispersible tablet contains 20mg of artemether/120mg of lumefantrine) and the patients were dosed as follows: 5 -<15Kg one tablet, 15 - <25 Kg two tablets, 25 - <35 Kg three tablets, and ≥35 Kg four tablets at the following dosing intervals:~0 hour - 1st dose;~8 hours - 2nd dose;~24 hours - 3rd dose;~36 hours - 4th dose;~48 hours - 5th dose~60 hours - 6th dose."
89672352|NCT02240823|Experimental|adipose derived stem cells|
89672353|NCT01748643|Experimental|Deep neuromuscular blockade, reversal with sugammadex|a continuous rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with Sugammadex 4mg/kg. Patients are extubated when the train of four ratio is > 0.9.
89672354|NCT01748643|Active Comparator|normal neuromuscular blockade, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when TOF ratio > 0.9.
89672355|NCT02585934|Experimental|RVT-101|RVT-101 adjunct to 5 mg or 10 mg donepezil
89672356|NCT02585934|Placebo Comparator|Placebo|Placebo adjunct to 5 mg or 10 mg donepezil
89672357|NCT00106535|Experimental|Tocilizumab 4 mg/kg + Methotrexate|Tocilizumab 4 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
89672358|NCT00106535|Experimental|Tocilizumab 8 mg/kg + Methotrexate|Tocilizumab 8 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
89672359|NCT00106535|Placebo Comparator|Placebo + Methotrexate|Placebo intravenously (IV) every 4 weeks plus methotrexate (MTX) 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
89672360|NCT02582658||Chronic infection of HCV GT1 or GT4|Participants with confirmed chronic hepatitis C genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) ± Ribavirin (RBV) according to standard of care and in line with the current local label
89672361|NCT05689476|Experimental|NAVA group|Nava ventilation
89672362|NCT01748799|Other|Sequence 1|Self-titrated placebo - Self-titrated Sativex - Fixed dose Sativex - Fixed dose placebo
89672363|NCT01748799|Other|Sequence 2|Fixed dose placebo - Fixed dose Sativex - Self-titrated Sativex - Self-titrated placebo
89672364|NCT01748799|Other|Sequence 3|Fixed dose placebo - Fixed dose Sativex - Self-titrated placebo - Self-titrated Sativex
89672365|NCT01748799|Other|Sequence 4|Fixed dose Sativex - Fixed dose placebo - Self-titrated placebo - Self-titrated Sativex
89672366|NCT01748799|Other|Sequence 5|Self-titrated Sativex - Self-titrated placebo - Fixed dose Sativex - Fixed dose placebo
89672367|NCT01748799|Other|Sequence 6|Self-titrated Sativex - Self-titrated placebo - Fixed dose placebo - Fixed dose Sativex
89672368|NCT01748799|Other|Sequence 7|Self-titrated placebo - Self-titrated Sativex - Fixed dose placebo - Fixed dose Sativex
89672369|NCT01748799|Other|Sequence 8|Fixed dose Sativex - Fixed dose placebo - Self-titrated Sativex - Self-titrated placebo
89672370|NCT04708626||Extended Cohort: Patients tested for any neuronal antibody in the Swedish population|All patients tested for any neuronal antibody in serum or CSF between 2015 and 2019 in Sweden.
89672371|NCT04708626||Core Cohort: Patients with a positive neuronal antibody test belonging to the Uppsala-Örebro region|All patients belonging to the Uppsala-Örebro health care region (a region in the middle of Sweden with a population of approximately 2.1 million), that tested positive for any neuronal antibody in serum or cerebrospinal fluid between 2015-2019.
89672372|NCT00168311|Experimental|Active Treatment|Bilateral high frequency (10 Hertz) rTMS
89049529|NCT04620447|Active Comparator|Cognitive Behavior Therapy|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 19~Final number of participants: 102~Cognitive Behavior Therapy intervention was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
89672373|NCT00168311|Sham Comparator|Sham rTMS|Bilateral Sham rTMS
89672374|NCT05696886|Active Comparator|Group A received Pethidine alone in the period between January 2021 and December 2021,|received Pethidine alone in the period between January 2021 and December 2021, while
89672375|NCT05696886|Active Comparator|Group B got Tramadol with pethidine in the period between January 2022 and December 2022.|Group B got Tramadol with pethidine in the period between January 2022 and December 2022.
89672376|NCT01748955|Active Comparator|Bupropion|Participants will receive bupropion XL for 8 weeks.
89672377|NCT01748955|Active Comparator|paroxetine CR|Participants will receive Paroxetine CR for 8 weeks.
89672378|NCT05687448|Experimental|Experimental Group|Patients treated with apixaban 5 mg twice daily (BID)
89672379|NCT05687448|Active Comparator|Active Comparator group:|Patients treated with warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
89672380|NCT02253537||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
89672381|NCT01749501|Active Comparator|Rocuronium|0.6 mg/kg once
89672382|NCT01749501|Placebo Comparator|Placebo|Placebo
89672383|NCT02254473|Experimental|Wedge Insert|Patients will receive a wedge insert
89672384|NCT02254473|Placebo Comparator|Flat insert|Patients will receive a flat insert
89672385|NCT02255175|Experimental|Perimenopausal women, depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
89672386|NCT02255175|Active Comparator|Perimenopausal women, non-depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
89672387|NCT03833583|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
89672388|NCT03833583|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
89672389|NCT02585778|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with other antihyperglycemic drugs for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
89672390|NCT02585778|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.
89672391|NCT05122143|Experimental|Sequence 1|Treatment sequence for the 3 treatment exposure visits is ABC.
89672392|NCT05122143|Experimental|Sequence 2|Treatment sequence for the 3 treatment exposure visits is BCA.
89672393|NCT05122143|Experimental|Sequence 3|Treatment sequence for the 3 treatment exposure visits is CAB.
89672394|NCT05122143|Experimental|Sequence 4|Treatment sequence for the 3 treatment exposure visits is ACB.
89672395|NCT05122143|Experimental|Sequence 5|Treatment sequence for the 3 treatment exposure visits is BAC.
89672396|NCT05122143|Experimental|Sequence 6|Treatment sequence for the 3 treatment exposure visits is CBA.
89672397|NCT03899103|Experimental|Repeated Courses of Rituximab Only|First course Course Rituximab at Randomization. Prophylactic 2nd and 3rd course rituximab re-administration will be done at 8 months and 16 months of follow-up if B cell count normalize.
89672398|NCT03899103|Active Comparator|Rituximab and Mycophenolate Mofetil|First course Course Rituximab at Randomization. Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards.
89672399|NCT03895515||Fiasp®|Participants with type 1 diabetes who have switched to a basal-bolus insulin regimen with Fiasp® as the bolus insulin, from a basal-bolus insulin regimen with any other bolus insulin.
89672400|NCT05102955||1/Observational Questionnaires|All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters(physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
89672401|NCT04749537||Ankylosing Spondylitis|100 patients who were diagnosed with AS between the ages of 18-65
89672402|NCT04749537||Healthy Volunteers|100 healthy volunteers compatible with age.
89672403|NCT05094531|Experimental|Intervention group|"Participants of this experimental group will have to attend the prevention program which is organised in eight 2-hour workshops, one every other week.~Groups of 10-12 participants will be established prior to the first session of the program and will remain the same throughout the program."
89672404|NCT05094531|No Intervention|No-intervention group|Participants of the no-intervention group will not have to attend the prevention program.
89672405|NCT05092854|Active Comparator|PR Lotion Topical Solution|Dose Dependent Response: Different doses relative to the participant's body weight will be provided for provision onto the skin before beginning data collection procedures. The 'larger' dose will be composed of 0.8g/kg of the PR Lotion while the 'smaller' dose will be composed of 0.4g/kg of the PR Lotion. Participants will be instructed to apply the lotion primarily to their lower extremities and upper extremities as needed. This lotion will be applied once during the Intervention session of each phase completed and will remain on the skin for approximately 3.5 hours.
89672406|NCT05092854|Placebo Comparator|Placebo Lotion Topical Solution|A dose of lotion relative to the participant's body weight will be provided for provision onto the skin before beginning data collection procedures. This dose will be approximately 0.8g/kg of the Placebo Lotion. Similar to the PR Lotion, participants will be instructed to apply the lotion primarily to their lower extremities and upper extremities as needed. This lotion will be applied once during the Intervention session of each phase completed and will remain on the skin for approximately 3.5 hours.
89688713|NCT01384513|Experimental|Treatment (Allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28."
89672407|NCT05092854|Experimental|Hydration Status|Participants will be asked to partake in 5 total Intervention trials. Upon arrival to each trial, the participant will be asked to complete an 18-24 fluid restriction protocol to ensure their arrival within a dehydrated state. Depending on the phase randomization assigned to each participant, they will either be provided fluids to consume that will bring them back to an estimated level of 1% dehydration (total of 3/5 trials completed) or they will not be given any fluids to consume during the duration of the trial (total 2/5 trials completed). Participants will be considered completed with project participation upon the completion of each of the five trials outlined.
89672408|NCT05092854|Active Comparator|aminoVITAL - Amino Acid Rehydration Supplement|Participants will be provided with 3 servings of a commercially available amino acid rehydration supplement for consumption after the completion of the dehydrated heat stress intervention. Participants will be instructed to consume each serving in a time-dependent manner over the 24-hour period after dismissal from the laboratory after completion of the Intervention session.
89672409|NCT05092854|Placebo Comparator|Placebo Drink Supplement Solution|Participants will be provided with 3 servings of a placebo rehydration supplement for consumption after the completion of the dehydrated heat stress intervention. Participants will be instructed to consume each serving in a time-dependent manner over the 24-hour period after dismissal from the laboratory after completion of the Intervention session.
89672410|NCT05695404||"The Digital arm"|Surgeons had a virtual 3D reconstruction of the patient's pulmonary anatomy by the Visible Patient Planning (VP) software
89672411|NCT05695404||"The Digital+Object arm"|Surgeons had at their disposal on the operating field, in a transparent sterile bag, the 3D printed model, made from the virtual 3D VP software of the patient's lung anatomy
89672412|NCT01751451|Experimental|Abiraterone acetate|"Group 1~Abiraterone acetate 1000 mg daily x 8 months~Prednisone 5 mg once daily x 8 months"
89672413|NCT01751451|Experimental|Abiraterone acetate and Degarelix|"Group 2~Abiraterone acetate 1000 mg daily x 8 months~Prednisone 5 mg once daily x 8 months~Degarelix subcutaneous depot injection q 1 month x 8 months"
89672414|NCT01751451|Experimental|Degarelix|"Group 3~• Degarelix subcutaneous depot injection q 1 month x 8 months"
89672415|NCT01438424|Experimental|Entecavir, 1.0 mg, with or without lamivudine|
89672416|NCT02580240|Placebo Comparator|Placebo|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
89672417|NCT02580240|Experimental|hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
89672418|NCT05677542||Axial Spondyloarthritis Patients|Patients with Axial Spondyloarthritis
89672419|NCT05677542||Psoriatic Arthritis Patients|Patients with Psoriatic Arthritis
89672420|NCT01465958|Active Comparator|Intravenous GAMUNEX-C|
89672421|NCT01465958|Experimental|Subcutaneous GAMUNEX-C|
89672422|NCT05299866|Experimental|S-ketamine group|The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.
89672423|NCT05299866|Placebo Comparator|Control group|The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.
89672424|NCT01753557|Experimental|Treatment-Naive|
89672425|NCT01753557|Experimental|Treatment-Relapsed|
89672426|NCT02250807|Experimental|Simeprevir and Sofosbuvir|Subjects will receive oral capsule of Simeprevir 150 milligram (mg) along with oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
89672427|NCT03811587|Experimental|Treatment group|Diabetes type 2 patients will take a fasting mimicking diet of 5 consecutive days a month, for a duration of 12 months. Besides this, they will receive usual diabetes care from the general practitioner.
89672428|NCT03811587|No Intervention|Control group|Diabetes type 2 Patients will have no intervention, they will receive usual diabetes care from the general practitioner.
89672429|NCT00168389|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
89672430|NCT00168389|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
88815734|NCT01092338|Active Comparator|4000IU|Subjects in this arm take a daily dose of 4000IU of Vitamin D3
89672431|NCT00168389|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
89672432|NCT02252133|Other|DT1, then 1DAVTE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
89672433|NCT02252133|Other|1DAVTE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
89672434|NCT05677230|Experimental|Balloon Occluded/plug assisted Retrograde Transvenous Obliteration.|Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.
89672435|NCT05677230|Active Comparator|Endoscopic Variceal Obturation|endoscopic variceal glue therapy will be done till obturation every 3 weekly.
89672436|NCT02252445|Active Comparator|Propofol|Propofol will be administered as the anesthetic maintenance agent.
89672437|NCT02252445|Experimental|Sevoflurane|Sevoflurane will be administered as the anesthetic maintenance agent.
89672438|NCT05694468|Other|Control and Intervention group|In this non-random one-group repeated measures study with a mixed approach (quantitative and qualitative analysis), participants were tested on two occasions 4 weeks apart (baseline measure), and then engaged in the psychomotor relaxation program twice weekly for 8 weeks. Participants were tested again after the intervention program (post-test). The participants took part in a psychomotor relaxation program comprised by two 20-minute sessions per week for 8 weeks, with the whole class, and combined body awareness, muscle tone regulation and breathing exercises.
89672439|NCT04592952|Experimental|Single-Arm|"Provocation Phase: Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.~Open-Label Treatment Phase: Erenumab packed in a SureClick® Autoinjector Pen (AI)"
89672440|NCT05232318|Active Comparator|leveling and alignment using fixed orthodontic appliance|leveling and alignment using fixed orthodontic appliance
89214825|NCT05827406||Group 13: combined item sets|In this group, we aim to combine the optimized item sets in item sets 1-6. We recruit 1000 new patients from the five sites in Stockholm with psychiatric issues for the psychometric validation of the combined item set. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment.
89214826|NCT05827406||Group 14: reduced combined item sets|We analyze data from group 13 and optimize the combined item set for the best measurement with the least number of items and the least number of dimensions. We estimate a 50% participation rate, with the potential to modify that number based on the response rate of the previous recruitment. If the reduced combined item set fails to validate, we may need to change it and recruit additional groups to optimize it.
89214827|NCT05816070|Experimental|IVIEW-1201|
89214828|NCT05816070|Active Comparator|Ofloxacin Eye Drops|
89214829|NCT05795413||PECS Block with Liposomal Bupivacaine|The patients in this cohort will undergo a PECS block with Liposomal Bupivacaine before their mastectomy. Patients will receive Liposomal Bupivacaine in combination with 0.25% Bupivacaine in a 1:1 mixture for the purpose of post-operative pain control.
89214830|NCT05795413||No PECS block|The patients in cohort will not undergo a PECS block. Pain will be controlled in the usual fashion with IV and oral medications.
89214831|NCT05795192|Experimental|SB17170 of 50mg, Single dose|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 50mg capsule, QD for 1 day(single).
89214832|NCT05795192|Placebo Comparator|Placebo of 50mg, Single dose|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 50mg, QD for 1 day(single).
89214833|NCT05795192|Experimental|SB17170 of 150mg, Single dose|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 100mg and 50mg capsules, QD for 1 day(single).
89214834|NCT05795192|Placebo Comparator|Placebo of 150mg, Single dose|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 100mg and 50mg capsules, QD for 1 day(single).
89214835|NCT05795192|Experimental|SB17170 of 250mg, Single dose|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg capsule, QD for 1 day(single).
89214836|NCT05795192|Placebo Comparator|Placebo of 250mg, Single dose|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg capsule, QD for 1 day(single).
89214837|NCT05795192|Experimental|SB17170 of 500mg, Single dose, Food-effect|"Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 2 capsules, QD for 1 day(single).~Food-effect test for the expected efficacy dose~1st period without a meal~Wash out period more than 7 days~2nd period with a high-fat meal"
89672441|NCT05232318|Experimental|leveling and alignment using clear aligner|leveling and alignment using clear aligner
89672442|NCT05232318|Experimental|leveling and alignment using clear aligner with low level laser therapy|leveling and alignment using clear aligner with low level laser therapy
89672443|NCT02093819|Experimental|BI 416970 single rising dose part|single rising dose given as tablet
89672444|NCT00176423|Experimental|galantamine|galantamine, 24mgs, p.o., qday
89672445|NCT00176423|Placebo Comparator|placebo|placebo, 3 tablets, p.o., qday
89672446|NCT05225532|Experimental|LA group|Patients randomized to procedure performed in the left atrium
89672447|NCT05225532|Active Comparator|RA group|Patients randomized to procedure performed in the right atrium
89672448|NCT02094443|Experimental|Alisporivir 300 mg BID|Alisporivir (ALV) 300 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
89672449|NCT02094443|Experimental|Alisporivir 400 mg BID|ALV 400 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
89672450|NCT05673798||training cohort|The investigators used the training cohort to develop the predictive nomogram with potential risk factors( initial response to chemotherapy)
89672451|NCT05673798||validation cohort|The investigators used the validation cohort to verify the clinical utility and predictive ability
89672452|NCT00110513|Experimental|Recombinant Human Antithrombin (rhAT) Infusion|Intravenous infusion of rhAT.
89672453|NCT05691426||Test|Periodontitis patients
89672454|NCT05691426||Control|Periodontally healthy patients
89672455|NCT00176891|Experimental|Laronidase ERT Treatment|Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
89672456|NCT05696574|Experimental|Vaginal Misoprostol group|Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
89672457|NCT05696574|Experimental|Oral Misoprostol group|Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
89672458|NCT05696496|Experimental|Patients with sleep disorders (TS+)|"video polysomnography; the new ESM intelligent duvet device"
89672459|NCT05696496|Experimental|control group without sleep disorder (TS-)|"video polysomnography; the new ESM intelligent duvet device"
89672460|NCT04411602|Experimental|Treatment with Convalescent Plasma|SARS-CoV-2 convalescent plasma from approved donors will be transfused into severely ill patients with confirmed COVID-19 severe respiratory distress. Plasma will be administered on days 0, 2,4, 6 and 8.
89672461|NCT00112151|Experimental|LowT+Resistance Training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~1 year standard Progressive Resistance Training(PRT) program"
89672462|NCT00112151|Experimental|LowT+No Resistance training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)~No exercise program"
89672463|NCT00112151|Experimental|HighT+Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~1 year standard Progressive Resistance Training(PRT) program"
89672464|NCT00112151|Experimental|HighT+No Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)~No exercise program"
89214838|NCT05795192|Placebo Comparator|Placebo of 500mg, Single dose, Food-effect|"Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 2 250mg 2 capsules, QD for 1 day(single).~Food-effect test for the expected efficacy dose~1st period without a meal~Wash out period more than 7 days~2nd period with a high-fat meal"
89214839|NCT05795192|Experimental|SB17170 of 1000mg, Single dose|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 4capsules, QD for 1 day(single).
89214840|NCT05795192|Placebo Comparator|Placebo of 1000mg, Single dose|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 2 250mg 4 capsules, QD for 1 day(single).
89214841|NCT05795192|Experimental|SB17170 of 1500mg, Single dose|Optional dose Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 6 capsules, QD for 1 day(single).
89214842|NCT05795192|Placebo Comparator|Placebo of 1500mg, Single dose|Optional dose Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg 6 capsules, QD for 1 day(single).
89214843|NCT05795192|Experimental|SB17170 of 250mg, Multiple dose for 7days|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 1 capsule, QD for 7 days(multiple).
89214844|NCT05795192|Placebo Comparator|Placebo of 250mg, Multiple dose for 7days|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 1 capsule, QD for 7 days(multiple).
89214845|NCT05795192|Experimental|SB17170 of 500mg, Multiple dose for 7days|Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 2 capsules, QD for 7 days(multiple).
89214846|NCT05795192|Placebo Comparator|Placebo of 500mg, Multiple dose for 7days|Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 2 capsules, QD for 7 days(multiple).
89214847|NCT05795192|Experimental|SB17170 of 1000mg, Multiple dose for 7days|Optional dose Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 4 capsules, QD for 7 days(multiple).
89672465|NCT00112151|Active Comparator|Placebo+Resistance Training|"Placebo Group applies two 2.5 gm placebo packets~1 year standard Progressive Resistance Training(PRT) program"
89672466|NCT00112151|Placebo Comparator|Placebo+No Resistance Training|"Placebo group applies two 2.5 gm placebo packets~No exercise program"
89672467|NCT05162742|Active Comparator|Colchicine|75 patients will receive colchicine tablets
89672468|NCT05162742|Placebo Comparator|Placebo|75 patients will receive placebo tablets
89672469|NCT04303026|Active Comparator|Treatment Group|Participants receiving active treatment with two infusions of Zoledronic Acid 5 mg with 3 months interval mixed in 100 ml 0.9% saline
89672470|NCT04303026|Placebo Comparator|Placebo Group|Participants receiving Placebo with two infusions of 100 ml 0.9% saline with 3 months interval.
89672471|NCT00113321|Experimental|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days.
89672472|NCT01753713|Experimental|Anti-angiogenic Therapy Naive Patients|Patients who have progressed without anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89672473|NCT01753713|Experimental|Anti-angiogenic Therapy Patients|Patients who have progressed on anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89672474|NCT05669742|Active Comparator|Group 1 as control group|
89672475|NCT05669742|Active Comparator|Group two as Empagliflozin|
89672476|NCT04238364|Experimental|EI-1071 Tablet|EI-1071 tablet(s) administered orally as single ascending dose(SAD), multiple ascending daily dose(MAD)
89672477|NCT04238364|Placebo Comparator|Placebo|EI-1071 tablet(s) administered orally as single ascending dose(SAD), multiple ascending daily dose(MAD)
89672478|NCT00177047|Experimental|Chemotherapy and Transplant Treatment|Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.
89672479|NCT05083533|Experimental|tele-rehabilitation|For the tele-rehabilitation online group, hamstring stretching exercises were performed with cameras and mutually via online applications.
89672480|NCT05083533|Active Comparator|home exercise|The home exercise group, the exercises were conveyed in the form of a brochure, in written form, on the necessary information. It was recorded how many days the home exercise group did the exercises on a weekly basis.
89672481|NCT03592329|Experimental|active tVNS + SRT A|active tVNS and Stress Reduction Training A
89672482|NCT03592329|Experimental|active tVNS + SRT B|active tVNS and Stress Reduction Training B
89672483|NCT03592329|Other|sham tVNS + SRT A|sham stimulation and Stress Reduction Training A
89672484|NCT03592329|Other|sham tVNS + SRT B|sham tVNS and Stress Reduction Training B
89672485|NCT04198584|Experimental|VC-CBCS Intervention|The VC-CBCS intervention was delivered via WebEx videoconferencing technology and included 14, 2-hour long sessions that involved group-based psychoeducation, cognitive and behavioral skills training, stress management, relaxation practice and healthy lifestyle habits to support overall health and liver health. Intervention materials included a hard copy Patient Workbook and audio-recorded relaxation techniques.
89672486|NCT04198584|No Intervention|Standard of Care (SC)|Participants randomized to SC received no intervention and were followed by medical providers in clinic per clinical practice guidelines and clinicians discretion.
89672487|NCT01756209|Active Comparator|Acetaminophen|Acetaminophen 15 mg/kg oral single dose (n=40)
89672488|NCT01756209|Active Comparator|Ibuprofen|Ibuprofen 10 mg/kg oral single dose (n=40)
89672489|NCT01756209|Experimental|Acetaminophen + magnesium 400 mg|Acetaminophen 15 mg/kg oral single dose (n=40) + magnesium 400 mg
89672490|NCT01756209|Experimental|ibuprofen + magnesium 400 mg|ibuprofen 10 mg/kg oral single dose (n=40) + magnesium 400 mg
89672491|NCT00116207|Experimental|ORAL ANTIOXIDANT|Allopurinol (300mg daily), ALA (600mg twice daily) nicotinamide (750 mg twice daily) Given orally These drugs were given together as a combination and not as individual treatment.
89672492|NCT00116207|Placebo Comparator|Placebo|Placebo administered twice daily.
89688714|NCT05613907||Pre-intervention|This group comprises patients who have been referred into the CLTI clinic service prior to their first assessment. These patients will be given a structured outcome questionnaire like the EuroQoL 5D questionnaire that asks them to describe their symptoms
89214848|NCT05795192|Placebo Comparator|Placebo of 1000mg, Multiple dose for 7days|Optional dose Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 4 capsules, QD for 7 days(multiple).
89214849|NCT05788081|Experimental|Arm A- BMS-986369 + Rituximab|Rituximab 375mg/m2 IV infusion Q4W + BMS-986369 0.4mg po D1-D14 of each cycle for 8 cycles, followed by Rituximab 375mg/m2 IV infusion Q12W in participants with CR/PR at end of induction
89214850|NCT05788081|Experimental|Arm B- Nivolumab + BMS-986369 + Rituximab|Nivolumab 480mg IV infusion Q4W, Rituximab 375mg/m2 IV infusion Q4W and BMS-986369 0.4mg po D1-D14 of each cycle for 8 cycles, followed by Rituximab 375mg/m2 IV infusion Q12W in participants with CR/PR at end of induction
89672493|NCT04129398|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation will be administered once daily for up to 28 weeks, beginning up to 7 days post-transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A (CsA) and 480 mg once daily for participants not receiving CsA. IV infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
89672494|NCT03461991|Other|Patients scheduled for corneal transplantation|
89672495|NCT00178919|Experimental|Autonomic Failure Patients|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in Patients with Autonomic Failure.
89672496|NCT00178919|Experimental|Controls and hypertensives|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in normal volunteers and hypertensive subjects.
89672497|NCT02581488|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks.
89672498|NCT02581488|Active Comparator|Product containing silver|Products containing silver will be applied per Investigator instructions and instructions for use/package insert for up to six weeks.
89672499|NCT01757067|Active Comparator|ablation procedure vs medical therapy|PVC ablation vs medical therapy
89672500|NCT01757067|No Intervention|Compare 2 arms for safety, symptoms|Compare control of PVC's between 2 groups.
89672501|NCT00179777|Experimental|Hydrolysed infant formula|Hydrolysed infant formula
89672502|NCT00179777|Placebo Comparator|Nonhydrolysed infant formula|Nonhydrolysed cow's milk based infant formula
89672503|NCT01757301|Active Comparator|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
89672504|NCT01757301|Experimental|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
89672505|NCT05033301|No Intervention|Specialist-led Ned Clinic|Participants enrolled in specialist-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist for one year.
89672506|NCT05033301|Experimental|Nurse-led Ned Clinic|Participants enrolled in the nurse-led version of the Ned Virtual Clinic will be prompted to complete their PROs (EPIC-26 survey) and PSA/testosterone lab tests in accordance to their pre-specified follow-up surveillance protocol determined by the specialist. In addition, men will be asked to complete another set of PROs that will be monitored by a trained oncology nurse, in between their specialist visits.
89672507|NCT01759251||vestibular vertigo|Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label
89672508|NCT02581410|Experimental|GSK1437173A Group|Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
89214851|NCT05786222|Experimental|Cluster 1|"Buildings randomized to Cluster 1 will receive the CSH-delivered intervention at Months 2-7. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders in the 8th month following the end of the intervention period."
89672509|NCT02581410|Active Comparator|Control Group|Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
89214852|NCT05786222|Experimental|Cluster 2|"Buildings randomized to Cluster 2 will receive the CSH-delivered intervention at Months 9-14. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders in the 8th month following the end of the intervention period."
89214853|NCT05786222|Experimental|Cluster 3|"Buildings randomized to Cluster 3 will receive the CSH-delivered intervention at Months 16-21. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders in the 8th month following the end of the intervention period."
89672510|NCT01897805|Experimental|Heart-protecting Musk Pill|Patients will get standard treatment for coronary artery disease plus 2 Heart-protecting Musk Pills each time, three times a day by mouth for 24 months
89672511|NCT01897805|Placebo Comparator|Placebo|Patients will get standard treatment for coronary artery disease plus 2 placebo pills each time, three times a day by mouth for 24 months
89672512|NCT05696340||JIA patients|Children diagnosed with JIA between 4 and 24 months before the start of the study, treated and followed in a pediatric rheumatology center (old enough to answer the questions)
89672513|NCT05696340||Parents of JIA patients|Parents of a child diagnosed with JIA between 4 and 24 months prior to the start of the study (treated and followed in a pediatric rheumatology center)
88815735|NCT01092338|Active Comparator|7000IU|Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3
88815736|NCT01110434|Experimental|Topiramate|Topiramate (200 mg daily)
88815737|NCT01110434|Placebo Comparator|Sugar pill|
89672514|NCT05696340||Health care professionals|Physician with experience in the initial management of JIA patients (between symptom onset and first visit with a pediatric rheumatologist)
89672515|NCT05696262|Experimental|6-walking program|Perform 6 minutes of walking exercise 3 times a day, 3 days a week, in a comfortable manner.
89672516|NCT05696262|No Intervention|Usual care|Usual care
89049530|NCT04620447|Active Comparator|Novel 'Intelligent Virtual Reality Therapy System' (IVRTS)|"A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 10~Final number of participants: 115~Novel 'Intelligent Virtual Reality Therapy System' (IVRTS) was conducted on a sample of 118 patients diagnosed with Acrophobia co-morbid with generalized anxiety who underwent the intervention at The University College of Medical Sciences and GTB hospital.~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
89049531|NCT04620447|No Intervention|Control Group|"A 7-week intervention course (In this case, no intervention) was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy.~Number of Participants: 125~Dropouts: 0~Final number of participants: 125~study carried out A-B-A research design which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."
89049532|NCT02900144|Experimental|Modified CBIT Treatment Arm|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
89049533|NCT02900144|Active Comparator|Standard CBIT Treatment Arm|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
89049534|NCT04620018|Active Comparator|Pre and post op Antibiotic|subjects received prophylactic antibiotic orally (Amoxicillin 2mg ,1 hour before surgery) and post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
89049535|NCT04620018|Active Comparator|Pre-op antibiotic|subjects received only prophylactic antibiotic (Amoxicillin 2mg ,1 hour before surgery)
89049536|NCT04620018|Active Comparator|Post-op antibiotic|subjects received post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days)
89049537|NCT02900105|Experimental|Letrozole|Participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months
89049538|NCT02899910|Experimental|Yoga with health education|12 week yoga program coupled to standardized health education for weight loss
89672517|NCT00180323|Experimental|Renewal CRT (CRT ICD)|Single arm study only. All patients will undergo advanced echocardiographic examination pre-operative, pre-discharge after implantation and at 3 and 6-months follow-up. AV-delay optimization will be performed using aortic VTI (Velocity Time Integral) measured by continuous wave Doppler in a modified 4-chamber view. During optimisation aortic VTI will be measured at different heart rates reached by increasing atrial pacing 10, 20 and 30 beats above intrinsic heart rate (IHR).
89672518|NCT05152602||Unilateral ESP block group|The group who underwent laparoscopic cholecystectomy and underwent unilateral ESP block for postoperative analgesia.
89672519|NCT05152602||Bilateral ESP block group|The group who underwent laparoscopic cholecystectomy and underwent bilateral ESP block for postoperative analgesia.
89049539|NCT02899910|Active Comparator|Health education|Standardized health education for weight loss
89049540|NCT04619940|Experimental|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
89672520|NCT05152602||Control group|The group that underwent laparoscopic cholecystectomy and underwent 1mg/kg tramadol and 50mg dexketoprofen for postoperative pain.
89672521|NCT00181961|Experimental|Maca Root 1500mg|Patients receiving 1500mg of maca root
89672522|NCT00181961|Experimental|Maca Root 3000mg|Patients receiving 3000mg of maca root
89672523|NCT04359420|Experimental|BC-Predict|"Women will be sent an invitation letter one to two days after their breast screening invitation letter, directing prospective participants to the online risk assessment platform. Once participants have consented to the study online, they will be directed to the BC-Predict risk assessment questionnaire. Assessment of the online questionnaire during the pilot phase estimated that most women would be able to complete this within 30 minutes.~Women who complete the questionnaire will receive 10-year breast cancer risk estimates once they have screened negative for breast cancer, based on the Tyrer-Cuzick model, incorporating mammographic density, and for some women, SNPs (single nucleotide polymorphisms). Women who are identified as being at high (>8%) or moderate (5% and <8%) 10-year risk will be offered a consultation to discuss prevention options including prescription of chemoprevention drugs and/ or more frequent mammography as part of the NHS Breast Screening Programme."
89672524|NCT04359420|Active Comparator|NHS-Breast Screening Programme|Usual care in the NHS Breast Screening Programme, which involves mammography every 3 years for the majority of women
89672525|NCT00122369|Experimental|Self-hypnotic Relaxation|A research assistant displayed defined behaviors of empathic attention and read to the patient a self-hypnotic relaxation script. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
89049541|NCT04619940|Active Comparator|Standard goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
89672526|NCT00122369|No Intervention|Standard Care|Patients received the routine standard treatment which included application of lidocaine as local anesthetic. This is not considered a unique intervention in terms of the trial. Omitting local anesthetic actually would have been an intervention deviating from routine care.
89672527|NCT00122369|Active Comparator|Empathic Attention|A research assistant displayed defined behaviors of empathic attention. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
89672528|NCT04312542||SRP with minocycline HCl microspheres|Participants in this cohort received the intervention of minocycline HCl microspheres, 1 mg in the interventional phase of the trial.
89672529|NCT04312542||SRP without minocycline HCl microspheres|Participants in this cohort did not have minocycline HCl microspheres, 1 mg administered during the interventional phase of the trial.
89672530|NCT00122447|Active Comparator|Anti-inflammatory agent|Aspirin (ASA)
89672531|NCT00122447|Active Comparator|Angiotensin receptor blocker (ARB)|Olmesartan (ARB)
89672532|NCT00122447|Active Comparator|Antioxidant|Alpha lipoic acid (ALA)
89672533|NCT00122447|Placebo Comparator|Placebo|Aspirin placebo once a day Olmesartan placebo once a day Alpha lipoic acid placebo twice a day
89672534|NCT01664130|Experimental|Treatment (SBRT)|Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-20 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity.
89672535|NCT00125957|Experimental|Wellbutrin first, then Placebo|Subjects randomly assigned to the Wellbutrin then Placebo group will receive 100mg BID of Wellbutrin at the first visit following intake (Week 0).Subjects will be increased to 150mg Wellbutrin BID at Week 1 unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of bupropion qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on Wellbutrin 100mg BID. At Week 4, subjects will cross-over to placebo and will continue to take placebo until Week 8.
89672536|NCT00125957|Experimental|Placebo first, then Wellbutrin|Subjects randomly assigned to the Placebo then Wellbutrin group will receive placebo until Week 4 when they will cross-over to active drug. At Week 4, subjects will be assigned 100mg Wellbutrin BID. At Week 5, Subjects will be increased to 150mg Wellbutrin BID unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of Wellbutrin qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on bupropion 100mg BID. Subject will continue on the assigned dosage until Week 8 of study.
89672537|NCT00183443|Placebo Comparator|DVP + placebo|Participants will receive divalproex ER at a therapeutic dose, plus placebo
89672538|NCT00183443|Active Comparator|DVP + Quetiapine|Participants will receive divalproex ER at a therapeutic dose, plus quetiapine up to 800 mg
89672539|NCT00183443|Active Comparator|DVP + Lithium|Participants will receive divalproex ER at a therapeutic dose, plus lithium at a therapeutic blood level
89672540|NCT02579928|Experimental|Ketamine|Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).
89672541|NCT02579928|Experimental|Midazolam|Participants were randomly assigned to receive a dose of 0.045mg/kg of Midazolam (administered Intravenously over 40 minutes with a the maximum total dose allowed in this study of 4.5mg),
89672542|NCT00183677|Experimental|Escitalopram|Participants will receive open treatment with escitalopram.
89672543|NCT00186017|Experimental|Olanzapine/Zyprexa|Olanzapine/Zyprexa 2.5 mg up to 8 per day for 1 week
89672544|NCT00186017|Placebo Comparator|Placebo|Placebo was taken in the same manner as olanzapine with up to 8 per day for 1 week
89672545|NCT00041119|Active Comparator|Arm I (CA for 4 courses)|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89672546|NCT00041119|Experimental|Arm II (CA for 6 courses [closed to accrual 12/15/2007])|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89672547|NCT00041119|Experimental|Arm III (paclitaxel for 4 courses)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89672548|NCT00041119|Experimental|Arm IV (paclitaxel for 6 courses [closed 12/15/2007])|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89672549|NCT00126113|Experimental|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
89672550|NCT00126113|Other|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
89672551|NCT00186875|Other|Treatment|Participants receive chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplant, and natural killer cell transplant as outlined in the Interventions section, including etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase.
89672552|NCT01760187|Experimental|Cohort 1|12 Japanese and 12 Caucasian subjects. 10 out of 12 will receive 10 mg lomitapide and 2 will receive placebo.
89672553|NCT01760187|Experimental|Cohort 2|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 20 mg lomitapide and 2 will receive placebo.
89214854|NCT05786222|Experimental|Cluster 4|"Buildings randomized to Cluster 3 will receive the CSH-delivered intervention at Months 23-28. Tenant surveys will be administered 1 month prior to and 12 months following the start of the intervention period.~At all clusters, an all-staff survey will be administered at Months 1, 8, 15, 22, and 29. A sustainment survey will be administered to selected staff-leaders in the 8th month following the end of the intervention period."
89672554|NCT01760187|Experimental|Cohort 3|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 40 mg lomitapide and 2 will receive placebo.
89672555|NCT01760187|Experimental|Cohort 4|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 60 mg lomitapide and 2 will receive placebo.
89049542|NCT04619784|Experimental|Treatment Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Patients will receive 12 sessions of pilates. Patients will be evaluated before treatment, after treatment, at the 3rd and 6th months.
89049543|NCT04619784|Other|Control Group|Demographic features will be questioned and recorded in the data recording form through face to face interview in patients who meet the inclusion criteria; evaluations will be made regarding muscle thickness and pain. Their routine medical treatments were continued
89049544|NCT02899871||Control|patients treated with anti-TNF not presenting any joint symptoms.
89049545|NCT02899871||case|aetiology of joint symptoms
89672556|NCT00551460|Experimental|Treatment|"Induction:~ATRA 45mg/m2 PO D1-CR Gemtuzumab Ozogamicin 9 mg/m2 IV D1 Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk D10-CR~Consolidation 1 and 2:~Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk x 5 weeks, repeat after 2 weeks rest~Consolidation 2 and 3:~ATRA 45 mg/m2 PO D1-7 Daunomycin 50 mg/m2/d IV D1-3~Consolidation 5 and 6:~GO 9mg/m2 IV D1~Maintenance:~ATRA 45 mg/m2/d PO D1-7 every 14 days 6-MP 60 mg/m2/d PO daily for 1 year Methotrexate 20 mg/m2 PO once/wk for 1 year"
89672557|NCT04751617|Experimental|Pulmonary rehabilitation (intervention)|This group will be covered by pulmonary rehabilitation.
89672558|NCT04163731||stable patient, referred for a VO2 peak test|All stable patients above 18 years, referred for a VO2 peak test as part of their standard management in the Louis Pradel Hospital (Hospices Civils de Lyon, Lyon) and without acute clinical event in the last 3 months. All patients who accept to participate will undergo a self-questionnaire of 10 minutes.
89672559|NCT03395613|No Intervention|Standard management|Standard sterile gauze dressing on surgical groin wound.
89672560|NCT03395613|Experimental|NPWT management|Negative Pressure Wound Therapy dressing on surgical groin wound.
89672561|NCT00126737|Active Comparator|Arm 1|Group assigned to both a Weight Control Nutritional Program and home-based exercise program (Ex+WC).
89672562|NCT00126737|Active Comparator|Arm 2|Group assigned to a Weight Control Nutritional Program (WC).
89049546|NCT04619667|Active Comparator|High flow nasal cannula (HFNC)|HFNC will be applied by means of a dedicated device (AIRVO2, Fisher & Paykel Healthcare, Auckland, New Zealand). Gas flow will be set at 50 L/min, and humidification chamber will be set at 31°C.
89049547|NCT04619667|Active Comparator|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet."
89049548|NCT04619667|Active Comparator|HFNC+CPAP|"HFNC+CPAP consists in the contemporaneous application of HFNC and CPAP through helmet. HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity, while CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
89049549|NCT02899832||NIRS|Near Infra Red Spectroscopy.
89049550|NCT04619862|Experimental|Medication|"Gabapentin is clinically started at a low dose and titrated to clinical effect or maximum target dose, whichever is lower.~The starting dose of gabapentin will be 5 mg/kg administered as oral liquid or via gastric or jejunal routes. On Day 1 of the study, the gabapentin will be administered once at bedtime and then increased according to a preset schedule. The dose will be increased every 3rd - 4th day in a step wise fashion of 13% - 50%, starting with the evening dose in order to accommodate sedation. The maximum dose for subjects will be as follows: < 15 kg to 60 mg/kg day and ≥15 kg to 45 mg/kg/day."
89049551|NCT04619862|Placebo Comparator|Placebo|Participants on this arm receive placebo, masked and dispensed according to the same preset schedule as the Medication arm.
89049552|NCT05425121|Active Comparator|Core stability protocol|Participants in this group will undergo core stability exercise program . Each exercise plan will be progressively increased.
89672563|NCT00126737|Active Comparator|Arm 3|Group assigned to a home-based exercise program (Ex).
89672564|NCT00126737|No Intervention|Arm 4|Usual care and non- specific health information (C).
89049553|NCT05425121|Experimental|Core Stability with surface electromyography biofeedback|Participants in this group will undergo core stability exercise program with surface electromyography biofeedback. Each exercise plan will be progressively increased with application of surface electromyography biofeedback.
89672565|NCT04751539|Experimental|AND017 single dose escalation|Subjects will be administrated with single dose of AND017 capsule from 1 mg to 50 mg during Part A.
89049554|NCT01190839|Experimental|Infliximab|Infliximab Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
89049555|NCT01190839|Placebo Comparator|Placebo|Placebo Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
89049556|NCT05425043|Experimental|Granulocytes|Patient to receive pooled granulocytes for 7 days concurrently. 10 participants will be approached for this arm.
89049557|NCT05425043|No Intervention|Control|Non-randomised control arm, where patients who are receiving a stem cell transplant, as described in the eligibility criteria, are asked for a blood sample. This is to establish a baseline versus the experimental arm. 10 participants will be approached for this arm.
89049558|NCT02887261|Other|Power Port|patients who received power injectable port
89049559|NCT02887261|Active Comparator|Conventional Port|patients who received conventional port ( not power injectable)
89049560|NCT04619277||Ulsan Medical Center|Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center, Ulsan, South Korea
89049561|NCT04619277||Queen Elizabeth Hospital|Cardiology Department and Clinical Research Center, Queen Elizabeth Hospital II, Kota Kinabalu, Malaysia
89214855|NCT05772078||Compliers|Attending to SPT every 4-6 months
89672566|NCT04751539|Placebo Comparator|AND017 repeated dose escalation|Subjects will be administrated with repeated dose of AND017 from 4 mg to 30 mg for 10 consecutive days during Part B.
89672567|NCT04751539|Placebo Comparator|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
89672568|NCT04751227||1|Modafinil 100-200 mg daily for wakefulness in a cohort of adult patients admitted to our COVID and non-COVID intensive care unit (ICU) between January 2017 and June 2020
89672569|NCT00273793|Experimental|1|Shaping intervention for hard-to-treat smokers
89672570|NCT00273793|Active Comparator|2|fixed criterion intervention for hard-to-treat smokers
89672571|NCT00273793|Other|3|Non contingent incentives available to hard to treat smokers
89672572|NCT00273793|Experimental|4|Ascending incentives values used in Smokers with Early Success
89672573|NCT00273793|Active Comparator|5|fixed value incentives are used in Smokers with Early Success
89672574|NCT00273793|Other|6|Non contingent incentives are available to Smokers with Early Success
89672575|NCT00127439|Experimental|Robotic Assisted Locomotor Training|A robotic stepping device in concert with a body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. The robotic device provides the appropriate kinematics associated with standing and stepping.
89672576|NCT00127439|Experimental|Manually Assisted Locomotor Training|A body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. Therapists and trainers promote the appropriate kinematics associated with standing and stepping.
89672577|NCT04350801||high risk MCI|MCI patients with amyloid beta positive (based on peripheral blood level)
89672578|NCT04350801||low risk MCI|MCI patients with amyloid beta negative (based on peripheral blood level)
89672579|NCT02579772|Active Comparator|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC) pills
89672580|NCT02579772|Placebo Comparator|Placebo|Treatment with placebo pills
89672581|NCT03224091||Patients at Psychiatric Center Ballerup|
89672582|NCT03224091||Healthy Controls|
89672583|NCT03224091||Healthy Controls recovered from an eating disorder|
89672584|NCT05535036|Experimental|dexamethasone group|patients received 8mg(2ml) of intravenous dexamethasone after spinal anesthesia
89672585|NCT05535036|Placebo Comparator|placebo group|patients received 2ml of a saline solution after spinal anesthesia
89672586|NCT00044005|Experimental|Lurasidone 20 mg|Lurasidone 20 mg oral tablet
89672587|NCT00044005|Experimental|Lurasidione 40 mg|Lurasidone 40 mg oral tablet
89672588|NCT00044005|Experimental|Lurasidone 80mg|Lurasidone 80mg oral tablet
89672589|NCT03135873|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at a daily dosage of 2.1 g for a 6 month period.
89049562|NCT04619277||Pecking University Shougand Hospital|Department of Cardiology, Peking University Shougang Hospital, Peking, China
89049563|NCT04619277||Ulsan University Hospital|Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
89049564|NCT04619277||Kangwon National University School of Medicine|Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea
89049565|NCT04619277||Korea University Guro Hospital|Cardiovascular Center, Department of Cardiology, Korea University Guro Hospital, Seoul, South Korea
89049566|NCT01190215|Experimental|Fluarix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 dose of Fluarix vaccine. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
89049567|NCT01190215|Active Comparator|Havrix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
89049568|NCT04619238||no urinary incontinence|patients without UI
89049569|NCT04619238||stress urinary incontinence|patients with SUI
89049570|NCT04619238||overactive bladder|patients with OAB
89049571|NCT04619238||mix urinary incontinence|patients with MUI
89049572|NCT04619238||Urge|patients with urge incontinence
89049573|NCT05424965||normal weight without gestational diabetes|BMI < 25; normal glucose tolerance
89049574|NCT05424965||normal weight with gestational diabetes|BMI < 25; impaired oral glucose tolerance
89049575|NCT05424965||overweight without gestational diabetes|BMI 25 - 29.9; normal glucose tolerance
89049576|NCT05424965||overweight with gestational diabetes|BMI 25 - 29.9; impaired glucose tolerance
89049577|NCT05424965||obese without gestational diabetes|BMI >= 30; normal glucose tolerance
89049578|NCT05424965||obese with gestational diabetes|BMI >= 30; impaired glucose tolerance
89214856|NCT05772078||Erratic compliers|Attending to SPT once a year or sporadically
89214857|NCT05772078||Non compliers|Non-attenders to SPT
89672590|NCT03135873|Placebo Comparator|Placebo|This arm of patients will receive placebo for a 6 month period.
89672591|NCT01897129||Early pregnancy|Women in early pregnancy at around the time of the nuchal translucency scan. The prevalence of HPV will be determined
89672592|NCT01897129||Chorionic villous sampling|Women undergoing chorionic villous sampling for the purpose of prenatal diagnostics.
89672593|NCT01897129||Spontaneous abortion|Women with miscarriage at a gestational age up to 22 weeks
89672594|NCT01897129||Preterm birth|Women with spontaneous preterm birth/premature primary rupture of membranes at a gestational age week 22-32
89672595|NCT01897129||Vaginal delivery at term|Women with spontaneous vaginal delivery at term (week 37+0-)
89672596|NCT01897129||Elective ceaserean section at term|Women undergoing elective cesarean section at term (week 37+0-)
89672597|NCT04311840||SAH patients with nimodipine|Patients with SAH receiving nimodipine as prevention of vasospasms and as a nootropic drug.
89672598|NCT04311840||SAH patients without nimodipine|Patients with SAH not receiving nimodipine as prevention of vasospasms and as a nootropic drug or in whom the drug has been temporarily discontinued.
89672599|NCT02989701|Experimental|Single arm|
89672600|NCT01790737|Active Comparator|A|Cyclophosphamide plus filgrastim
89672601|NCT01790737|Active Comparator|B|Filgrastim
89672602|NCT05534958||Healthy|
89049579|NCT04619394|No Intervention|Control Group (CG)|Control Group (CG): Formed by those pregnant women who do not perform any physical exercise, only the basic and instrumental activities of daily life (ABVD and AIVD respectively) and intensity of the physical labor load of very light to moderate. The period from 10-12 SG to 37-41 SG.
89049580|NCT04619394|Active Comparator|Experimental Group 1 (GE1)|Experimental Group 1 (GE1): Created for pregnant women who carry out their own program of each monitor in the different sports centers and public and private swimming pools in the South of the Autonomous Community of Galicia. These own programs will all have the same format: initial warm-up phase, main part of indicated and personalized exercises for pregnancies and final phase with a return to calm.
89672603|NCT05534958||Mild Cognitive Impairment|
89672604|NCT05534958||Early Dementia|
89672605|NCT04953156||Nitroglycerin|data of patients meeting the eligibility criteria and received nitroglycerine infusion will be retrieved from medical records.
89049581|NCT04619394|Active Comparator|Experimental Group 2 (GE2)|Experimental Group 2 (GE2): In this third and last group, we incorporated the AIPAP program into the exclusive programs of each monitor in the various public and private sports centers and swimming pools in the South of the Autonomous Community of Galicia. The researcher trained in this method, together with the monitors who voluntarily wish to do so, will translate said format and program into their sessions.
89049582|NCT00553865|Experimental|Group 1|OJP-2028 1mg/day
89049583|NCT00553865|Experimental|Group 2|OJP-2028 2mg/day
89049584|NCT00553865|Experimental|Group 3|OJP-2028 4mg/day
89049585|NCT00553865|Placebo Comparator|Group 4|Placebo
89049586|NCT00553865|Other|Group 5|Reference drug
89672606|NCT04953156||Dexmedetomidine|patients will receive dexmedetomidine bolus dose of 1 mic/kg over 20 minutes followed by intravenous infusion of 0.2-0.7 mic/kg/hr adjusted according to each patient hemodynamic response
89672607|NCT01761747|Experimental|Ponatinib Treatment Arm|Ponatinib taken by mouth daily
89672608|NCT00045487|Experimental|OSI-774|
89672609|NCT05432310|Experimental|Autologous mobilized peripheral blood (mPB) transduced with EFS ADA lentiviral vector|Evaluate safety and efficacy of this autologous gene therapy
89049587|NCT00562770|Active Comparator|1|Valacyclovir
89049588|NCT00562770|Active Comparator|2|Valganciclovir
89049589|NCT04619550|Other|Exercise intensity|Jogging or walking at RPE 9, 11, 13, and 15
89049590|NCT05424692|Experimental|PTC test group|The adjuvant chemotherapy scheme was selected according to the 3D drug sensitivity test results of micro tumor (PTC) in vitro
89049591|NCT05424692|No Intervention|control group|Making adjuvant chemotherapy strategy based on clinical experience
89049592|NCT04618965|Placebo Comparator|Control (Placebo) group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
89049593|NCT04618965|Experimental|Intrathecal dexmedetomidine group|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
89049594|NCT04618965|Experimental|Intravenous dexmedetomidine group|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
89049595|NCT04618926||intubating Laryngeal Tube Suction Disposable|intubating Laryngeal Tube Suction Disposable Airway control
89672610|NCT00278863|Active Comparator|S-1|
89672611|NCT00278863|Active Comparator|Capecitabine|
89672612|NCT00128219|Experimental|GBS III-TT|A single dose of GBS III-TT vaccine administered intramuscularly (IM) containing 50 mcg of GBS III capsular polysaccharide and 32 mcg of tetanus toxoid.
89672613|NCT00128219|Active Comparator|Td|The control group will receive a single dose of Tetanus and Diphtheria Toxoids (Td) vaccine.
89672614|NCT01762059|Experimental|Bi-homonal Bionic Pancreas|Closed-loop blood glucose control with a bi-hormonal bionic endocrine pancreas designed by Edward Damiano and Firas El-Khatib of Boston University. The device will deliver insulin lispro (Humalog) and glucagon based on blood glucose levels estimated by a continuous glucose monitoring device (Dexcom G4 Platinum) and a proprietary dosing algorithm. Blood glucose control will be automated for 5 days during which volunteers will sleep in a hotel and roam freely in downtown Boston during the day. There will be no restrictions on diet or exercise.
89672615|NCT01762059|Active Comparator|Usual Care|Usual care for 5 days (insulin pump therapy according to usual practice), volunteers will sleep at home and maintain their usual schedule during the day, there will be no restrictions on diet or exercise, they will wear a blinded CGM
89672616|NCT04751695|Experimental|CoronoVac Vaccine Group|
89049596|NCT04618926||intubating laryngeal Tube suction Disposable|intubating laryngeal Tube Suction Disposable
89049597|NCT05424653|Experimental|Severe Symptomatic Aortic Regurgitation|Patients will be treated with transcatheter aortic valve system
89049598|NCT01190449|Experimental|Arm I|Patients receive high-dose ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
89049599|NCT01190449|Experimental|Arm II|Patients receive a lower dose of ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
89049600|NCT01190176|Experimental|HPV-062 study subjects Group|HPV-015 (NCT00294047) study subjects who had normal cervical cytology, but tested positive for oncogenic HPV infection at their concluding HPV-015 (NCT00294047) study visit or were pregnant, so that no cervical sample could be collected at their concluding HPV-015 (NCT00294047) study visit.
89672617|NCT01808547|Experimental|ISV-303|
89672618|NCT01808547|Placebo Comparator|Durasite Vehicle|
89672619|NCT00187655|Other|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
89672620|NCT03056313|Experimental|proactive support of labor|delayed labor; 1 cm opening and painful contractions
89672621|NCT03056313|Active Comparator|support of labor as usual|delayed labor; 3-4 cm opening of the cervix and regular contractions
89672622|NCT02991651|Experimental|Dose Level 1|IRX4204 5 mg/day PO + erlotinib 100 mg/day PO
89672623|NCT02991651|Experimental|Dose Level 2|IRX4204 5 mg/day PO + erlotinib 150 mg/day PO
89672624|NCT02991651|Experimental|Dose Level 3|IRX4204 10 mg/day PO + erlotinib 150 mg/day PO
89672625|NCT02579616|Experimental|24 mg Lenvatinib|Participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent).
89672626|NCT00131573|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
89672627|NCT00131573|Sham Comparator|2|No stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
89672628|NCT01897883||One Group|Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.
89672629|NCT01899703|Experimental|GSK2330672|Subject will receive GSK2330672 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either (i) GSK2330672 followed by placebo; OR (ii) placebo followed by GSK2330672.
89672630|NCT01899703|Experimental|Placebo|Subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either GSK2330672 followed by placebo; OR placebo followed by GSK2330672.
89672631|NCT00134381|Active Comparator|active drug|bilateral comparison of green tea constituent
89672632|NCT00134381|Placebo Comparator|placebo|bilateral comparison of placebo vehicle
89672633|NCT01899781|Experimental|with antibiotic and without antibiotic|
89672634|NCT01790893|Experimental|intravitreal aflibercept injection|"Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.~."
89672635|NCT01790893|Experimental|intravitreal aflibercept|Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months.
89672636|NCT04043910|Experimental|Single-sided deaf group|30 children will be included in this group
89672637|NCT04043910|Active Comparator|Normal hearing group|30 children will be included in this group
89672638|NCT02256111|Experimental|ENZ+ADT+Usual care|The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.
89672639|NCT02256111|Experimental|ENZ+ADT+Exercise|The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training.
89672640|NCT01790971|Active Comparator|Intrathecal morphine|100μg of morphine will be added to the intrathecal mixture.
89672641|NCT01790971|Active Comparator|No Intrathecal morphine|Morphine will not be added to the intrathecal mixture.
89672642|NCT03989934|Experimental|The Mind in Action|The Mind in Action is a mindfulness intervention developed by the Holistic Life Foundation (HLF), a Baltimore-based non-profit organization. The curriculum will be delivered over approximately 40 sessions and will follow HLF's typical program modifications for high school students (i.e., sustained focus on breath work and meditation). Each program session will include an initial exercise of focusing on the breath to center oneself, followed by the introduction and practice of different breathing techniques (e.g., rhythmic breathing) that enhance calmness and reduce physiological arousal, and concluding with a brief guided meditation. Instructors will describe benefits of the practices for health and stress management. Participants are given assignments between sessions to reinforce lessons (e.g., breathing exercises or periods of meditation).
89672643|NCT03989934|Active Comparator|Healthy Topics|Adapted from the Glencoe Health Curriculum (McGraw Hill), Healthy Topics is designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
89672644|NCT00189137|Active Comparator|doxorubicin and ifosfamide|
89672645|NCT00189137|Experimental|gemcitabine and docetaxel|
89672646|NCT02099461|Other|No treatment|Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.
89672647|NCT02099461|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
89672648|NCT02099461|Experimental|Denosumab 120 mg|Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
89672649|NCT02262039|Active Comparator|Conventional Pressure|Conventional Insufflation with 15mmHg target pressure
89672650|NCT02262039|Experimental|Low Pressure (VTI)|Valveless recirculating insufflation (VTI) with 10mmHg target pressure
89672651|NCT01898351|Other|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
89672652|NCT02256189|Other|Sitagliptin first, then placebo|Sitagliptin treatment for four weeks, then washout for four weeks, then placebo for four weeks
89672653|NCT02256189|Other|Placebo first, then sitagliptin|Placebo for four weeks, then washout for four weeks, then sitagliptin for four weeks
89672654|NCT03930810||FIC1-deficiency and Bsep-deficiency|
89672655|NCT04650594|Experimental|case group|Patients with knee bone malignancy
89672656|NCT02256345|Active Comparator|KNO3 active comparator|KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
89672657|NCT02256345|Placebo Comparator|KCl placebo comparator|KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
89672658|NCT00193037|Experimental|Liposomal Doxorubicin|Liposomal doxorubicin 40 mg/m2 by 1 hour IV infusion repeated every 28 days.
89672659|NCT00193037|Experimental|Docetaxel|Weekly docetaxel 36 mg/m2 by 30 minute IV infusion on days 1, 8, and 15 of the 28 day cycle
89672660|NCT02100007|Experimental|ME-344|ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
89672661|NCT05392764|Experimental|Empagliflozin|Patients will be randomized 1:1 to either empagliflozin or placebo.
89672662|NCT05392764|Placebo Comparator|Placebo|Placebo matching empagliflozin
89672663|NCT01809639|Experimental|Progesterone|400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
89672664|NCT01809639|Placebo Comparator|Placebo|
89672665|NCT01763931|Experimental|Digoxin|Digoxin administration for 2 weeks prior to surgery.
89672666|NCT01763931|No Intervention|No drug administration prior to surgery|Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.
89672667|NCT02822625|Experimental|arm 1|Patients, followed in the institut and for whom a new application of QUTENZA® is required, will receive standard care.
89672668|NCT02822625|Active Comparator|arm 2|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.~Patients will receive QUTENZA® according to standard procedure with a standardized hypnotic message"
89672669|NCT02822625|Placebo Comparator|arm 3|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.~Patients will receive QUTENZA® according to standard procedure with a music therapy"
89672670|NCT01664052|Experimental|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
89672671|NCT01664052|Experimental|ESS 305/ESS 505 (Essure, BAY1454032/Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
89672672|NCT02817945|Experimental|68Ga-NOTA-3P-TATE-RGD PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-3P-TATE-RGD in one dose intravenously and underwent PET/CT scan 45-60 min later.
89672673|NCT01765647|Experimental|AGY|All participants will receive the same, open-label dose of AGY
89672674|NCT02800863||Dorsal Root Ganglion (DRG) Stimulation|
89672675|NCT02783859|Experimental|Active arm: Amoxicillin-clavulanic Acid|8 days of oral amoxicillin-clavulanic Acid 400/57 duo formulation (70-90mg/kg/day, twice daily dosing: max 980mg per day)
89672676|NCT02783859|Placebo Comparator|Placebo arm|8 days of oral placebo (equivalent volume as the active arm)
89672677|NCT04670094||Covid19 infection related patients|"Patients over the age of 18 hospitalized for SARS-CoV-2 up to end of June 2020 in the San Gerardo Hospital and other centers will be included.~Patients are followed until discharge from hospital or death."
89672678|NCT04769193|Experimental|Adipeau face cream|Cosmetic cream
89672679|NCT04670016||Patient/Caregiver dyad diagnosed with DIPG|"All of these criteria must be met for a patient to be eligible for this study:~Patient aged >2 and <21 years treated with a repeat course of radiation for DIPG~Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).~Enrollment within 14 days of starting re-irradiation (RT2).~Patients with malignant transformation of the first tumour are eligible.~There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.~The patient is treated at a site where the study is approved by the local ethics board~Consent, and, if applicable, assent, has been obtained according to institutional standards"
89672680|NCT04670016||Patient/Caregiver dyad with re-RT for a recurrent brain tumour|"All of these criteria must be met for a patient to be eligible for this study:~Patient aged >2 and <21 years treated with a repeat course of radiation for a recurrent or progressive brain tumour (stratum 2).~Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).~Enrollment within 14 days of starting re-irradiation (RT2).~Patients with malignant transformation of the first tumour are eligible.~There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.~The patient is treated at a site where the study is approved by the local ethics board~Consent, and, if applicable, assent, has been obtained according to institutional standards"
89672681|NCT01765803|Experimental|Mellaril (thioridazine)|A single 50 gm dose of thioridizine (Mellaril) will be given orally at the beginning of the study
89672682|NCT02566395|Experimental|Haploidentical Stem Cell Transplantation|Subjects will receive pretransplantation conditioning of total-body irradiation (1,200 cGy delivered in 8 fractions over 4 days [Days -9 through -6] and cyclophosphamide (60 mg/kg IV daily x 2 on Days -3 and -2). Donor lymphocyte infusion will occur on day -6; donor CD34+ cells will be infused on Day 0.
89672683|NCT05646576|Experimental|Palliative Care Intervention (PEACE) Group|"Participants will be randomly assigned, and stratified by disease, to the PEACE Group.~Participants will meet with palliative care (PC) clinician within 1 week of T-cell collection and within 72 hours of hospital admission for ACT.~Participants will meet with PC clinician at least 2 x weekly during hospitalization.~PC clinician will follow participants up to one year after randomization (or enrollment for the open pilot) and will meet participant at least 2 x weekly during inpatient hospitalizations.~Participants will complete follow-up study assessments on pre-determined days per protocol. The assessments will be filled out remotely or via paper.~Participants will complete exit interviews in the open pilot only."
89672684|NCT05646576|Active Comparator|Usual Care Group|Participants will be randomly assigned, and stratified by disease, to the Usual Care Group and will receive standard care for ACT.
89672685|NCT01811355|Active Comparator|Mexiletine|Mexiletine, capsule, 150mg, PO BID, 14 days
89672686|NCT01811355|Placebo Comparator|Placebo|Placebo, capsule, PO BID, 14 days
89672687|NCT01812681||Low vitamin D level|The premature infants with low cord blood vitamin D level
89672688|NCT01812681||Normal Vitamin D|The premature infants with normal vitamin D level
89672689|NCT05534334|Active Comparator|Control arm|Surgical excision of the gingival pyogenic granuloma
89672690|NCT05534334|Experimental|Intervention|Intralesional injection with corticosteroids solution (1.8 mL of 100 mg hydrocortisone)
89672691|NCT01767285|Experimental|Immediate Postpartum Etonogestrel Implant|Etonogestrel implant placed in the hospital after delivery, before discharge home.
89672692|NCT01767285|Active Comparator|Delayed postpartum etonogestrel implant|These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
89672693|NCT01465802|Experimental|Cohort I|Arm A: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline placebo orally BID for 4 weeks Arm B: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline 100 mg orally BID for 4 weeks
89672694|NCT01465802|Experimental|Cohort II|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
89672695|NCT01465802|Experimental|Cohort III|Cohort III is an interrupted dosing schedule of dacomitinib in the first cycle only
89672696|NCT01813149|Experimental|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at affected and unaffected sites.
89672697|NCT01814241|Experimental|Open label peanut OIT|Open label orally ingested peanut flour with maintenance dose of 1450mg
89672698|NCT00137969|Experimental|Rituximab 1000 mg + prednisone|Participants will receive rituximab 1000 mg intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
89672699|NCT00137969|Placebo Comparator|Placebo + prednisone|Participants will receive placebo intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
89672700|NCT01746693|Experimental|amblyopia ex anisometropia|20 male and female volunteers with amblyopia ex anisometropia
89049601|NCT04206280|Experimental|Pedometer group|This group will be given a pedometer following radical prostatectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 2,000/day. POD 3-6: 3,000/day. POD 7-9: 4,000/day. POD 10-14: 5,000/day.
89049602|NCT04206280|Active Comparator|Control group|This is the control group. Following radical prostatectomy, subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
89049603|NCT04618848||Adult Oncology Patients|Adult oncology patients
89049604|NCT04316065|Other|Group 1|15 subjects, Cross-over, Single dose of comparator on day 1, Single dose of YHP1906 on day 8
89049605|NCT04316065|Other|Group 2|15 subjects, Cross-over, Single dose of YHP1906 on day 1, Single dose of comparator on day 8
89049606|NCT01190098|Experimental|Lacosamide|
89049607|NCT01190098|Placebo Comparator|Sugar pill|
89049608|NCT04618887||Meige sydrome patients|
89049609|NCT02885857|Experimental|Shenyan kangfu Tablets|Shenyan Kangfu Tablets；Each weighing 0.48g；Oral；Once five, three times a day
89049610|NCT04314739|Active Comparator|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
89049611|NCT04314739|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
89049612|NCT00562848|Experimental|Subjects enrolled in single dose escalation cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
89049613|NCT00562848|Experimental|Subjects enrolled in gastric emptying cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
89049614|NCT00562848|Experimental|Subjects enrolled in gastro-enteral contractility cohort|Eligible subjects will receive GSK962040 and placebo in the fasted state in crossover manner.
89049615|NCT02885740|Experimental|Atrial fibrillation in normal heart|Patients having atrial fibrillation in normal heart
89049616|NCT02885740|Active Comparator|Control|Patients having a junctional supraventricular tachycardia in normal heart
89049617|NCT01190020|Active Comparator|Lubiprostone|24mcg BID for 4 weeks, oral medication
89049618|NCT01190020|Placebo Comparator|Placebo|24mcg BID for 4 weeks (placebo), oral medication
89049619|NCT01189435|Experimental|erlotinib|This will be a single institution, single-arm, two-stage, open-label study of erlotinib in the treatment of patients with recurrent EGFR-mutant lung cancer following completion of adjuvant erlotinib or gefitinib therapy.
89049620|NCT05424614||intracerebral hemorrhage group|Patients with the intracerebral hemorrhage who presented to the hospital within 24 hours of symptom onset
89672701|NCT01746693|Experimental|amblyopia ex strabismus|20 male and female volunteers with amblyopia ex strabismus
89672702|NCT01746693|Experimental|control subjects|20 healthy male and female control subjects
89672703|NCT01437878|Experimental|iloprost|single dose inhalation using the power disc-6 with I-neb Adaptive Aerosol Delivery (AAD) system
89672704|NCT01437878|Placebo Comparator|placebo|matching placebo using the power disc-6 with I-neb AAD system
89672705|NCT01814787|Experimental|CHICA Type 2 Diabetes Module|Children treated at the two intervention clinic sites will have be treated using the CHICA system AND will be provided access to the newly developed CHICA Type 2 Diabetes Module. The CHICA Type 2 Diabetes Module will assist pediatricians in identification of those children 10 years of age or older who are at increased risk for type 2 diabetes, it will provide pediatric physicians guidelines to screen for type 2 diabetes, and it will coordinate the diagnosis and long-term management of the condition.
89672706|NCT01814787|No Intervention|Usual Care|Those patients who are assigned to the control group will have the CHICA system but will NOT be cared for using the CHICA Type 2 Diabetes Module. The CHICA system will notify the physician of the child's BMI percentile on the physician worksheet. However, the CHICA system will not ask for any additional information related to risk factors for type 2 diabetes on the pre-screening form, no advice will be provided to the physician on the physician worksheet, nor will just-in-time documents or automated reminder calls be made available. Identification of patients at risk for type 2 diabetes and care of those patients will occur through routine practices for that clinic.
89672707|NCT01746615|Experimental|30 Patients with BRVO in one eye|
89672708|NCT01746615|Experimental|30 healthy age and sex matched controls|
89672709|NCT04767308|Experimental|Arm 1|"The tolerability and safety of CT125A cells will be assessed according to the 3+3 dose escalation design. There will be three dose levels, 1×10^6, 2×10^6, and 3×10^6, CAR+T cells/kg. For each level, 1-3 subjects will be enrolled. If no dose limited toxicity (DLT) occurs, next level will be assessed for DLT. If DLT occurs in one subject, 3 more subjects will be enrolled in this cohort for the evaluation of DLT. If DLT occurs in ≤ 1/6 subjects, next level will be assessed for DLT. If DLT occurs in ≥ 2 subjects, no more subjects will be enrolled in this cohort and dose escalation will be canceled. For each cohort, following subjects can only receive CT125A infusion at least 14 days after the first subject received CT125A infusion. If DLT occurs in 2 subjects at Dose Level 1, whether to explore a lower dose will be determined by the investigator. After dose escalation phase is completed, the dose for extension phase will be determined based on safety and PK data."
89672710|NCT00138125|Experimental|Arm I|see intervention description for details
89672711|NCT01815333|Experimental|Feraheme|Magnetic resonance imaging (MRI) acquired prior to the injection of Feraheme® and repeated at approximately 48 hours and 72 hours from the time of injection (scan time). The scan time will be adjusted, as needed. The MRI scan prior to the Feraheme injection is the routine scan. The scans at 48 and 72 hours are investigational.
89672712|NCT01465178|Active Comparator|2000 IU vitamin D3|Cholecalciferol 2,000 IU capsules
89672713|NCT01465178|Placebo Comparator|Placebo|Non-matching placebo, gelatin filled capsules
89672714|NCT00138203|Experimental|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89672715|NCT01768845|Experimental|Transplant|After a preparative regimen the patient will receive an infusion of one or two umbilical cord blood unit(s) (UBC). The UBC unit(s) will be thawed according to methods of Rubinstein et al. If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis. On day +30, +60, +100, +180, and +365 the chimeric status of patients will be interpreted by variable number tandem repeat (VNTR) analysis. Immune reconstitution (Digeorge Panel) will also be checked at these time points.
89672716|NCT00139997|Experimental|LED phototherapy device|Litebook treatment devices: LED phototherapy device, used for 30 min before 8 am
89672717|NCT00139997|Placebo Comparator|Inactivated Negative Ion Generator|Equivalent exposure to inactivated negative ion generator
89672718|NCT01815645|Active Comparator|Standard treatment Alone|Participants in the Standard Treatment Alone group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted
89672719|NCT01815645|Experimental|ST+CM|Participants in the Standard treatment plus Contingency Management (ST+CM) group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted plus CM.
89672720|NCT00200889|Experimental|auricular tVNS|active and inactive auricular transcutaneous vagus nerve stimulation (tVNS)
89672721|NCT00140231|Active Comparator|Metreleptin|r-metHuLeptin self-administered subcutaneously
89672722|NCT00140231|Placebo Comparator|Placebo|Placebo, administered in same method as active arm.
89672723|NCT01732809|Active Comparator|abobotulinumtoxin A|Patients were randomized to the side of the forehead (left or right) in which the products were administered. All the patients received abobotulinumtoxin A in one of the sides of the forehead.
89672724|NCT01732809|Active Comparator|onabotulinumtoxin A|Patients were randomized to the side of the forehead (left or right) in which the products were administered. All the patients received onabotulinumtoxin A in one of the sides of the forehead.
89672725|NCT00194129|Experimental|Lithium plus Divalproex|Patients assigned to the combination group were continued on lithium and blinded divalproex.
89672726|NCT00194129|Placebo Comparator|Lithium plus placebo|Patients assigned to lithium monotherapy underwent divalproex-placebo substitution at a rate of 250 mg decrements every week until discontinued.
89672727|NCT01733277||With neuropathic pain (PainDETECT ≥ 13)|Magnetic Resonance Imaging (MRI)
89672728|NCT01733277||No neuropathic pain (PainDETECT<13)|Magnetic Resonance Imaging (MRI)
89672729|NCT04749381|Experimental|TCM group|Rectal cancer patients randomized to this group will have acupoint application with traditional Chinese medicine.
89672730|NCT04749381|Placebo Comparator|Control group|Rectal cancer patients randomized to this group will have acupoint application with placebo .
89672731|NCT01817907|Placebo Comparator|Placebo|Subjects will receive a sugar pill during their placebo night sleep study.
89049621|NCT05306158|Experimental|CC+ECIG Condition|Combustible Cigarette (CC) and Electronic Cigarette (ECIG) users will be trained to avoid CC and ECIG-related images and approach positive images.
89522208|NCT03411577|No Intervention|Control Group|"The control / comparison group is essentially a no intervention / wait-list control group. However, during pilot testing, participants expressed a strong desire to engage in some type of health activity. As a result, the control group members, both mothers and daughters, participated in a brief educational activity on reducing risk for cardiovascular disease. The educational activity was limited to a few hours on one Saturday. Participants returned the following week to complete post-test questionnaires along with the participants in the experimental group."
89522209|NCT04412889|Experimental|CAR-T treatment group|The patients will receive BCMA/CD19 dual-target CAR-T cell treatment. BCMA/CD19 dual-target CAR-T cell dosage ranges from 2×10^5 to 1×10^6 CAR+T/Kg.
89522210|NCT04447937||Multiple Sclerosis and Related Diseases|Individuals with one or more immunoglobulin level results and medical histories available for data collection will be included. Subjects will be 18 years of age or older at the time of data collection.
89522211|NCT03407521|Active Comparator|study group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with isosorbide mononitrate 20mg once
89522212|NCT03407521|Placebo Comparator|control group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with placebo
89522213|NCT03255993|Experimental|SPH3127 100mg|A single dose of SPH3127 50 mg*2 qd *7 days
89522214|NCT03255993|Placebo Comparator|Placebo to SPH3127 100mg|A single dose of placebo matching to SPH3127 50mg*2 qd *7 days
89522215|NCT03255993|Experimental|SPH3127 200mg|A single dose of SPH3127 100 mg*2 qd *7 days
89522216|NCT03255993|Placebo Comparator|Placebo to SPH3127 200mg|A single dose of placebo matching to SPH3127 100mg*2 qd *7 days
89522217|NCT03255993|Experimental|SPH3127 400mg|A single dose of SPH3127 100 mg*4 qd *7 days
89522218|NCT03255993|Placebo Comparator|Placebo to SPH3127 400mg|A single dose of placebo matching to SPH3127 100mg*4 qd *7 days
89522219|NCT03424135|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
89522220|NCT03424135|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
89522221|NCT03411941||Treatment-naïve nAMD patients|Patient data for whom treatment with IVT aflibercept injection was initiated as first-line treatment according to the SmPC and the SERV Guideline, in treatment-naive patients with newly diagnosed of nAMD in routine clinical practice.
89522222|NCT03249753|Experimental|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
89522223|NCT03249753|Experimental|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
89522224|NCT03424057|Experimental|Group 1|"Group 1 were treated with the new technique (Asymmetric Primary Closure and Additional Skin Excision).~In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume."
89522225|NCT03424057|Active Comparator|Group 2|Group 2 were treated with the standard Karydakis technique.
89522226|NCT03411785|Experimental|CPC+ practices|This is the intervention group, and includes the practices that were selected and agreed to participate in the CPC+ model.
89522227|NCT03411785|No Intervention|Comparison practices|Comparison practices are the control group. This group includes practices not participating in the model that were matched to the CPC+ practices and whose outcomes will be compared to those of the CPC+ practices.
89522228|NCT04413435||Confirmed COVID-19 cases|Patients with PCR test positive were considered as the confirmed COVID-19 cases.
89522229|NCT04413435||Suspected COVID-19 cases|The suspected COVID-19 cases were defined as follows: those who were interpreted in favor of the suspected covid-19 on c-CT by radiologists in addition to the typical symptoms of the novel coronavirus disease such as cough, high fever (>38,5 °C), or dyspnea, and those with a history of contact with another confirmed COVID-19 patient in addition to typical symptoms.
89522230|NCT05170555|Experimental|68Ga-PSMA, PET/CT and 177Lu-EB- PSMA-617 therapy|All patients diagnosed with RCC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
89522231|NCT03423901|Experimental|ABO/HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 12 ABO and HLA incompatible kidney transplantation (KT)
89522232|NCT03423901|Experimental|ABO incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 28 ABO incompatible kidney transplantation
89522233|NCT03423901|Experimental|HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 20 HLA incompatible kidney transplantation
89522234|NCT05228223|Active Comparator|Group S|Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.
89522235|NCT05228223|Active Comparator|Group SN1|Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg after TOF count is 1-2.
89522236|NCT05228223|Active Comparator|Grup SN2|Patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg after TOF count is 1-2.
89522237|NCT03406819|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
89522238|NCT03406819|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
89522239|NCT03406819|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
89522240|NCT05170217|Experimental|CBD:THC 0:1|Inhalation of cannabis containing only THC
89522241|NCT05170217|Experimental|CBD:THC 1:1|Inhalation of cannabis containing THC and CBD
89522242|NCT05170217|Experimental|CBD:THC 2:1|Inhalation of cannabis containing THC and CBD
89522243|NCT05170217|Experimental|CBD:THC 3:1|Inhalation of cannabis containing THC and CBD
89522244|NCT04356105|Active Comparator|Minimal Stimulation Group|Minimal dose stimulation ovarian induction protocol given to poor responders, involving letrozole, low dose recombinant FSH and GnRH antagonist
89522245|NCT04356105|Active Comparator|Microflare Group|Microflare ovarian induction protocol given to poor responders, involving OCP, GnRH agonist, high dose recombinant FSH
89522246|NCT03411551|Active Comparator|Forearm Bier's block|Forearm intravenous regional anesthesia (Bier's block)
89522247|NCT03411551|Experimental|Peripheral Nerve Block|Ultrasound-guided peripheral nerve block (regional anesthesia)
89522248|NCT03406195|Experimental|healthy older adults|Healthy older adults who will receive TMS
89522249|NCT04347681|Experimental|Treatment Group|We are aiming to include 40 patients (recipients) who have COVID 19 but have not recovered yet as per the inclusion criteria.
89522250|NCT04347681|No Intervention|control group|Patients who only consent for sharing their clinical and laboratory data will serve as a control group to compare the efficacy of the convulsant plasma. Age and sex matched historical control could be used if need.
89522251|NCT05170061|Active Comparator|Nebivolol|Nebivolol, 20 mg daily for 1 week followed by 40 mg daily for 3 weeks, followed by 1 week down-titration to 20 mg daily
89522252|NCT05170061|Active Comparator|Valsartan|Valsartan, 160 mg daily for 1 week followed by 320 mg daily for 3 weeks, followed by 1-week down-titration to 160 mg daily
89522253|NCT05170061|Active Comparator|Nebivolol/valsartan|Combination of nebivolol/valsartan 20/160 mg daily for 1 week followed by 40/320 mg daily for 3 weeks, followed by 1-week down-titration to 20/160 mg daily
89522254|NCT04235205|Experimental|Elobixibat and cholestyramine|The investigational product per dosing (elobixibat 10mg and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
89522255|NCT04235205|Experimental|Elobixibat|The investigational product per dosing (elobixibat 10mg and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
89522256|NCT04235205|Experimental|cholestyramine|The investigational product per dosing (elobixibat placebo and cholestyramine powder 9g) are orally administered once daily for 16 weeks.
89522257|NCT04235205|Placebo Comparator|Placebo|The investigational product per dosing (elobixibat placebo and cholestyramine powder placebo) are orally administered once daily for 16 weeks.
89522258|NCT02520635||TEMODAL® standard therapy regimen|4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
89522259|NCT02520635||post-surgery supra-early TEMODAL® chemotherapy|Within 24 hours after surgery, Supra-early TEMODAL® Chemotherapy is administered orally at 75mg/m2/day for 28 days for patients pathologically confirmed as GBM. 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
89522260|NCT03411421|Experimental|Part 1 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio in Cohorts 1 to 3. AL-794 will be administered at a 100 milligram (mg) loading dose (LD) on the morning of Day 1, followed by a 50 mg maintenance dose (MD) on the evening of Day 1 and twice-daily (BID) on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days), at the discretion of the Sponsor and Principal Investigator (PI).
89522261|NCT03411421|Experimental|Part 2 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio. AL-794 will be administered as 100 mg LD on the morning of Day 1, followed by a 50 mg MD on the evening of Day 1 and BID on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days). Based on the results of Part 1, the duration of dosing may be modified.
89522262|NCT05169827||PD-OFF|"Patients with PD who have previously been included in the Personalized Parkinson Project return for fMRI measurements in an off-medicated state (12h withdrawal). N = 60.~The PD-OFF group undergoes a single testing session."
89672732|NCT01817907|Active Comparator|Trazodone|Subjects will receive trazodone during their treatment night sleep study
89672733|NCT00140621|Experimental|Agalsidase Beta|Agalsidase beta 1 milligram per kilogram (mg/kg) intravenously once every 2 weeks up to 156 weeks.
89672734|NCT00143819|Active Comparator|1|bilateral comparison
89672735|NCT00143819|Placebo Comparator|2|bilateral comparison
89672736|NCT01445678|Experimental|CXA-201 and Metronidazole as treatment for cIAI|
89672737|NCT01445678|Active Comparator|Meropenem as treatment for cIAI|
89672738|NCT01818063|Experimental|Arm 1 (paclitaxel, carboplatin)|Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89672739|NCT01818063|Experimental|Arm 2 (veliparib, paclitaxel, carboplatin)|Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89672740|NCT03769194|Active Comparator|VLA15 low dose|VLA15 low dose with Alum.
89672741|NCT03769194|Active Comparator|VLA15 medium dose|VLA15 medium dose with Alum.
89672742|NCT03769194|Active Comparator|VLA15 high dose|VLA15 high dose with Alum.
89672743|NCT03769194|Placebo Comparator|Placebo|
89672744|NCT00147017||Smokers|All subjects had a smoking history of >15 pack years
89672745|NCT00147017||Ex-smokers|Ex-smokers had ceased smoking for >6 months.
89672746|NCT00147017||Emphysema lung transplant|The emphysema subjects were all undergoing lung transplants.
89672747|NCT01465022|Active Comparator|Study Arm A|Study Arm A is one of two interventions (Combined estrogen-progestin pill)
89672748|NCT01465022|Active Comparator|Study Arm B|Study Arm B is one of two interventions (Progestin-only pill)
89672749|NCT02258217|Experimental|Single arm|Acthar 80 units subcutaneously for five consecutive days.
89672750|NCT04064450||Heart Failure|Individuals with asymptomatic or symptomatic heart failure
89672751|NCT04064450||Population Controls|Individuals free of heart failure and echocardiographic cardiac dysfunction
89672752|NCT00149669|No Intervention|Work Plus Naltrexone Prescription|Participants were prescribed naltrexone, but were not be required to ingest it to work. Participants could work and earn money, independent of whether or not they continued to take naltrexone.
89672753|NCT00149669|Experimental|Work Plus Naltrexone Contingency|Participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose (employment-based reinforcement of naltrexone ingestion).
89672754|NCT03719976|Experimental|Healthcare navigation workshops|All enrolled caregivers and parents will partake in the group-based educational intervention.
89672755|NCT00255125|Placebo Comparator|Arm Placebo|Placebo
89672756|NCT00255125|Experimental|Arm Soy Supplement|Soy Supplement
89672757|NCT02258373|Experimental|CGM Only|"Participants will be instructed to check the blood glucose with the standard study BGM for calibration of the CGM and for specific circumstances that are specified in the protocol. This group will make management decisions based on the CGM glucose value without a BGM confirmation measurement as long as the participant is confident that the CGM glucose value is not erroneous.~In addition, participants will be instructed to make a BGM measurement on the blinded study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia and a standard BGM measurement has not been made. The participant may be asked to make post-prandial blinded BGM measurements at selected times."
89672758|NCT02258373|Active Comparator|CGM+BGM|Participants will be instructed to perform BGM measurements for sensor calibration according to Dexcom specifications and measure the blood glucose whenever a diabetes management decision is made. A BGM measurement is to be made on the study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia. Additional BGM measurements can be made on the study BGM at any time that the participant desires.
89672759|NCT03664128||pregnant women positive for anxiety|"100 pregnant women who screen positive for anxiety symptoms (>21 on the Perinatal Anxiety Screening Scale). Participants are matched for age, parity, and gestational age at enrollment.~Coping with Anxiety through Living Mindfully (CALM) Pregnancy: Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants)"
89672760|NCT03664128||healthy pregnant controls|100 matched healthy pregnant women. Participants are matched for age, parity, and gestational age at enrollment.
89672761|NCT01899131|Other|platform-switch tapered internal implants|2 platform-switch tapered internal implants placed in 10 participants.clinical and radiographic assessment in 6,12,24, month post implant insertion
89672762|NCT01464788|Experimental|Low dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
89672763|NCT01464788|Experimental|High dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
89672764|NCT01464788|Active Comparator|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
89672765|NCT04749303|Active Comparator|Large screen|This is a high definition screen which gives a 76cm height and 67cm width (area: 5092cm2) endoscopic image.
89672766|NCT04749303|No Intervention|Standard screen|This is a high definition screen which gives a 37.5cm height and 32.5cm width (area: 1218.75cm2) endoscopic image.
89672767|NCT05521308|Experimental|Participants with Hearing Loss|Individuals with hearing loss that meet the candidacy to wear hearing aids. All interventions are associated with the fitting of binaural hearing aids with various coupling methods. All participants will be assessed under all interventions.
89214858|NCT05770869|Experimental|ALIBIRD mHealth platform|Participants are followed-up using the ALIBIRD mHealth platform. The ALIBIRD platform is made up of a mobile application for patients and a web application for the healthcare team. Through the ALIBIRD mobile application, patients regularly register Patients Reported Outcomes (PROs) and Patients Reported Outcome Measures (PROMs) regarding lifestyle (diet, physical activity, sleep, mood), and get access to individualized recommendations in order to assume more responsibility for achieving the best outcomes from their care. Moreover, the patient application includes features for tracking the appearance of symptoms, with alerts sent to the healthcare team in response to these parameters. In addition, the application contains articles and educational information.
89214859|NCT05765448|Active Comparator|Soy-based control meal|Bowl of soup noodles prepared with 10g soy protein isolate soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
89214860|NCT05765448|Experimental|Laver/nori macroalgae (Porphyra umbilicus) whole biomass-based treatment meal|Bowl of soup noodles prepared with 10g Laver/nori macroalgae (Porphyra umbilicus) whole biomass soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
89214861|NCT05765448|Experimental|Laver/nori macroalgae (Porphyra umbilicus) protein isolates-based treatment meal|Bowl of soup noodles prepared with 10g Laver/nori macroalgae (Porphyra umbilicus) protein isolates soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
89214862|NCT05765448|Experimental|Microalgae (Chlorella vulgaris) whole biomass-based treatment meal|Bowl of soup noodles prepared with 10g microalgae (Chlorella vulgaris) whole biomass soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
89214863|NCT05765448|Experimental|Microalgae (Chlorella vulgaris) protein isolates-based treatment meal|Bowl of soup noodles prepared with 10g microalgae (Chlorella vulgaris) protein isolates soup base and consumed with a pack of plain crackers (approximately 65g available carbohydrate in total).
89214864|NCT05762536|Active Comparator|Docetaxel or cabazitaxel (SOC)|
89214865|NCT05762536|Experimental|Docetaxel or cabazitaxel with darolutamide|
89214866|NCT05754073|Experimental|1. Intranasal Oxytocin|Intranasal oxytocin spray (30 IU twice daily) for 12 months in the double-blinded phase followed by intranasal oxytocin spray (30 IU twice daily) for 6-months in the open-label phase
89214867|NCT05754073|Placebo Comparator|2. Placebo|Intranasal placebo spray (30 IU twice daily (total 60 IU per day) for 12 months followed by intranasal oxytocin spray (30 IU twice daily) for 6-months in the open-label phase
89522263|NCT05169827||Healthy controls|"Healthy individuals who are matched on age and sex with respect to the PD-OFF group. N = 60.~The healthy group undergoes baseline and two year follow-up testing sessions."
89522264|NCT05169827||PD-ON|"Patients with PD who are included in the Personalized Parkinson Project. N = 360.~Available data will be used. There will be no further data collection in this group."
89522265|NCT03404947|Experimental|Ethanol|Participants will ingest ethanol (in the form of 40% ethanol) at an ingestion rate of 0.1 grams/kg lean body mass/hour in a solution with water.
89522266|NCT03404947|No Intervention|No Ethanol|Participants will ingest a volume matched beverage of water only.
89522267|NCT03411473|Experimental|AGEN1884 with pembrolizumab|AGEN1884 in combination with pembrolizumab
89522268|NCT03404869|Other|Treatment with ORL-1M - D-mannose|
89522269|NCT04184349|Active Comparator|Local Anesthetic (LA Group)|
89522270|NCT04184349|Active Comparator|B group|
89522271|NCT05169749|Other|Control-Service Nurse Group|Patient education lasting 20-30 minutes was provided by the nurse who gives care in the surgical inpatient floor before the surgery. The nurse provided the patient's admission to the postoperative surgical inpatient floor and follow-up.
89522272|NCT05169749|Experimental|Experimental-Nursing Visiting Group|The nursing visit was done by the operating room nurse who will be involved in the patient's surgery, and the patient education lasted 20-30 minutes. The nurse, who carried out the nursing visit, welcomed the patient in the operating room, was next to the patient before anesthesia, and followed the patient to the recovery room after surgery.
89522273|NCT02520739|Placebo Comparator|Virgin Olive Oil|Virgin olive oil obtained by traditional procedures (VOO);
89522274|NCT02520739|Experimental|Optimized High Phenolic Content Oil|Optimized virgin olive oil with a high phenolic content (OHPCO);
89522275|NCT02520739|Experimental|Functional Olive Oil|Functional olive oil (FOO) with both high phenolic compounds and triterpene content.
89522276|NCT03864003|Experimental|Experimental group|Participants randomized to the experimental group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a Community Health Worker.
89522277|NCT03864003|Active Comparator|Control Group|Participants randomized to the control group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a non-Community Health Worker (undergraduate student in Speech, Language, and Hearing Sciences).
89522278|NCT03411395|Placebo Comparator|Placebo drink|A standardized breakfast meal will be provided together with carbonated water containing aroma
89522279|NCT03411395|Experimental|5AA+CrPic Water Dose 1|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA and CrPic
89522280|NCT03411395|Experimental|5AA+CrPic Water Dose 2|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/2 of Dose 1) and CrPic
89522281|NCT03411395|Experimental|5AA+CrPic Water Dose 3|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/4 of Dose 1) and CrPic
89522282|NCT03423823|Experimental|Study Drug Arm|Receiving 1.25mg of 0.05mL of Ziv-aflibercept intravitreal injection every month
89522283|NCT03423823|Other|Control Arm|Receiving bevacizumab, ranibizumab, or aflibercept intravitreal injection every 5 to 12 weeks (varied intervals based on individual need for treatment)
89522284|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase I|Phase I: Single arm, non-randomized study in metastatic breast cancer patients. S81694 given intravenously every two weeks at different doses on D1 and D15 last for 28 days. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.
88995720|NCT00151073|Experimental|Zoledronate Alone|Zoledronate is given alone for the first cycle. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
88995721|NCT00151073|Experimental|Docetaxel and Estramustine|Docetaxel and Estramustine are given for the first cycle of therapy. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
88995722|NCT05467618|Experimental|Intra-Oral Surgical approach|The mandibular fracture was reduced using an intra-oral surgical approach.
88995723|NCT05467618|Experimental|Extra-Oral Surgical approach|An External/Facial approach was used to reduce the mandibular bone fracture.
88995724|NCT05467579|Active Comparator|Healthy subjects|Healthy patients that will serve as controls will recruited having the same demographic characteristics of the experimental group i.e., age, sex, vertebral maturation stage and the same cranio-facial features, skeletal class II, class II division 1 malocclusion, mandibular retrognathia, normal/hyperdivergent growth pattern.
88995725|NCT05467579|Experimental|JIA subjects|Young people aged from 10 to 14 years old with skeletal class II, class II division 1 malocclusion, mandibular retrognathia, normal/hyperdivergent growth pattern, and affected by juvenile idiopathic arthritis
88995726|NCT05467540|Experimental|Pain reduction in patients with vertebral metastatic lesions treated with SPINERY System|
88995727|NCT00151112|Experimental|1|combination of lateral position and 20° Trendelenburg Position
88995728|NCT00151112|Active Comparator|2|standard positioning
89672768|NCT01444898|Experimental|Exenatide|All subjects enrolled in this study will be given Exenatide for 6 months. Exenatide: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
89672769|NCT00201773|Experimental|Exemestane & Celecoxib|Patients will receive exemestane 25 mg orally per day for 8 weeks. Starting in the 9th week, patients will receive celecoxib 400 mg orally twice per day for 8 weeks in addition to exemestane.
89672770|NCT04701996||cohort|sero-surveillance will start in a cohort of 800 adults (18-50y). In case of an established outbreak, this sample will be extended to 400 children (0-17y) and 400 elderly (50+y).
89672771|NCT00256217|Experimental|Anastrozole|
89672772|NCT01419626|No Intervention|Negative Control|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste.
89672773|NCT01419626|Sham Comparator|Device with Water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
89672774|NCT01419626|Experimental|Device with Mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
89672775|NCT00256451|Experimental|ALC and NAL|alcohol and active naltrexone
89672776|NCT00256451|Active Comparator|Sham ALC and NAL|"sham alcohol and active naltrexone"
89672777|NCT00256451|Placebo Comparator|placebo pill and ALC|placebo naltrexone and alcohol
89672778|NCT00256451|Placebo Comparator|placebo pill and Sham ALC|placebo naltrexone and placebo (non-alcoholic) alcohol
89672779|NCT05515380|Experimental|8-stage model based exercise training|8-stage model based exercise training
89672780|NCT05515380|Active Comparator|Conventional exercise training|Conventional exercise training
89672781|NCT01819311|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program
89672782|NCT01819311|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
89672783|NCT03582618|Experimental|Sorafenib + CVM-1118|"Cycle 0 (at least 3 weeks): sorafenib tolerability assessment period (sorafenib alone)~400mg BID daily (starting dose); The subject will be assessed for the need for a dose reduction in sorafenib during this period.~Cycle 1+ (28-day cycles): combination period (sorafenib+CVM-1118)~Tolerable dose of sorafenib and CVM-1118 150 (starting dose) or 200 mg BID will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
89672784|NCT00257309|Active Comparator|Thrombolysis|Weight adjusted tenecteplase bolus + Unfrationated heparin
89672785|NCT00257309|Active Comparator|Primary angioplasty|Primary angioplasty
89672786|NCT05533788|Other|Fed states in healthy subjects|Fed states in healthy subjects
89672787|NCT05533788|Other|Fasted states in healthy subjects|Fasted states in healthy subjects
88995729|NCT05467501|Experimental|Ultrasound group|Therapeutic ultrasound application. US parameters are 0.8 W/cm for intensity, 3 MHz for frequency and 5 min application. The device that will be used is medserve, England (the head of the device is 5cm). The physical therapy will by 6 sessions (every day). PT sessions will be done by the same physical therapist.
88995730|NCT05467501|Active Comparator|placepo group|group B will have a non-steroidal anti-inflammatory drug as prescribed by the same orthopedist and 2 session of massage with the head of ultrasound.
88995731|NCT00532324|No Intervention|A|Pregnant women not receiving CA-MRSA decolonization therapy.
88995732|NCT00532324|Other|B|Pregnant women receiving CA-MRSA decolonization therapy.
88995733|NCT05467384|Experimental|Newly Diagnosed Hypertensive patients|These are the patients that have been clearly diagnosed with diabetes for the first time.
88995734|NCT05467384|No Intervention|Healthy Controls|Healthy Control Group
88995735|NCT05467189||treatment|The use of antineoplastic agents depends on the clinical practice.
88995736|NCT05466760||Patient recently diagnosed breast cancer who will undergo surgery|surgery treatment only
88995737|NCT05466760||Patients with recently diagnosed breast cancer who will undergo NAC.|Patients with recently diagnosed breast cancer who will undergo NAC before surgery.
88995738|NCT00532363||Obese asthmatics|Obese subjects with asthma (on inhaled corticosteroids)
88995739|NCT00532363||Non obese asthmatics|Non obese subjects with asthma (on inhaled corticosteroids)
89672788|NCT01444742|Experimental|Clofarabine + Cytarabine|"Induction:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)"
89672789|NCT01770483|Experimental|study group|Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
89672790|NCT01770483|Active Comparator|control group|Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
89672791|NCT05533710|Experimental|Group A : erector spinae block.|patients will receive bilateral ultrasound guided erector spinae block.
89672792|NCT05533710|Experimental|Group B : transversus abdominis plane block.|patients will receive bilateral ultrasound guided transversus abdominis plane block.
89672793|NCT00257933|Active Comparator|1|High dose prednisolone
89672794|NCT00257933|Experimental|2|Lower dose prednisolone alternating with placebo
89672795|NCT01734525|Experimental|Anidulafungin|Patients at risk will receive therapy with anidulafungin
89672796|NCT05507970|Experimental|Part 1 Single Ascending Dose Cohort A|100 mg MMV367 or placebo, oral solution, fasted,
89672797|NCT05507970|Experimental|Part 1 Single Ascending Dose Cohort B|"Single ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted"
89672798|NCT05507970|Experimental|Part 1 Single Ascending Dose Cohort C|"Single ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted"
89672799|NCT05507970|Experimental|Part 1 Single Ascending Dose Cohort D|"Single ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted"
89672800|NCT05507970|Experimental|Part 1 Single Ascending Dose Cohort E (optional)|"Single ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted"
89672801|NCT05507970|Experimental|Part 2 Food Effect|Open label, 2-period cross-over, randomized, food effect study to provide preliminary information on the effect of a high-fat meal on the pharmacokinetics of a single-dose oral administration of MMV367 determined to be safe in Part 1.
89672802|NCT05507970|Experimental|Part 3 Multiple Dose Cohort A|"Double-blinded, randomised, placebo-controlled, multiple-dose study.~Intervention: MMV367 or placebo, oral solution, fasted. Once daily for 3 days."
89672803|NCT05507970|Experimental|Part 3 Multiple Dose Cohort B (optional)|"Multiple ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted. Once daily for 3 days."
89672804|NCT05507970|Experimental|Part 3 Multiple Dose Cohort C (optional)|"Multiple ascending dose to be determined after SAC review of previous cohort.~Intervention: MMV367 or placebo, oral solution, fasted. Once daily for 3 days."
89672805|NCT01819935||linezolid (Zyvox)|
89672806|NCT01819935||Vancomycin|
89672807|NCT00258011|Experimental|Aldurazyme (laronidase) treatment|Patients received weekly infusions of JC0498 (laronidase) at an intravenous dose of 100 Units/kg (0.58 mg/kg) body weight for up to 73 weeks.
89672808|NCT05639868|Active Comparator|T-CPR|Participants perform telephone-assisted CPR based on the European Resuscitation Council (ERC) 2021 guidelines.
89672809|NCT05639868|Experimental|V-CPR|Participants perform video-assisted CPR based on the European Resuscitation Council (ERC) 2021 guidelines.
89672810|NCT05639868|No Intervention|Unassisted CPR|CPR without dispatcher instructions.
89672811|NCT04769115|Other|Response to Alerts|Monitor patients daily for response to temperature changes and provide referral to doctor as needed
89672812|NCT00260195|Experimental|School-based cognitive behavioral support group|Ten group lessons facilitated by a teacher or school counselor that focuses on psycho-education, development of a trauma narrative, approaching trauma-related situations, social problem solving, and cognitive skills.
89672813|NCT00260195|No Intervention|Wait-list control group|Waiting list
89672814|NCT01821105|Experimental|Preoperative PET and CT Scans|Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
89672815|NCT01899209|Experimental|Group A|STARR
89672816|NCT01899209|Experimental|Group B|Laparoscopic ventral Rectopexy
89672817|NCT05533398|Experimental|Stress ball use|They were asked to use the ball for at least 10 minutes during the dialysis treatment and when they felt stressed or unwell at home/work.
89672818|NCT05533398|No Intervention|Control group|During the control condition, patients received standard care and did not use stress ball.
89672819|NCT00264641|Experimental|High RAS activity|10 healthy men were characterized by having high basal RAS activity.
89672820|NCT00264641|Experimental|Low RAS activity|10 healthy men were characterized by having either a low basal RAS activity.
89672821|NCT01735617|Experimental|Hydrocortisone Modified Release Capsules|Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
89672822|NCT00208091|Experimental|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
89672823|NCT02989779|Experimental|Active/Placebo crossover|NK1 Antagonist 7 days followed by placebo 7 days.
89672824|NCT02989779|Active Comparator|Placebo/Active Crossover|Placebo for 7 days followed by NK1 Antagonist 7 days.
89672825|NCT00208949|Active Comparator|G-CSF(Granulocyte Colony-Stimulating Factor )|Single use of G-CSF(Granulocyte Colony-Stimulating Factor ) G-CSF 7.5 µg/kg twice a day
89672826|NCT00208949|Active Comparator|Granulocyte CSF+Granulocyte Macrophage CSF|Combined use of G-CSF(Granulocyte Colony-Stimulating Factor ) and GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) (G-CSF 7.5 µg/kg / GM-CSF 7.5 µg/kg.)
89672827|NCT01771965|No Intervention|Usual care|No intervention.
89672828|NCT01771965|Experimental|CB Intervention|Cognitive Behavioral one-on-one single session administered by phone
89214868|NCT05747950|Other|Vibration group|"Vibration is defined as a mechanical stimulus characterized by oscillating movements.~has been defined.The first method is a hand held as a local vibration application that can be applied directly to the widest part of the muscle with the object.is named. The second method, called whole body vibration, is a vibration source applied on the platform. Participants immediately after the sessions in addition to conventional physiotherapy.~Upper extremity flexor on the hemiplegic side in supine position, 8 weeks, 3 sessions per week with a CE certified vibration device with a frequency of 50-110 Hz and an amplitude of 1-4 mm. Local vibration will be applied for 15 minutes each."
89522285|NCT03411161|Active Comparator|paclitaxel phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~Paclitaxel given intravenously on D1, D8, and D15 at 80 mg/m² during a 28-day cycle."
89522286|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~S 81694 given intravenously on D1 and D15 at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
89522287|NCT03411343|Active Comparator|Interscalene Block|Patients randomized to receive an intesrcalene block.
89522288|NCT03411343|Experimental|Costoclavicular Infraclavicular Block|Patients randomized to receive a costoclavicular infraclavicular block.
89522289|NCT05227911||Abdominal Surgery Group|Participant undergoing abdominal surgery for any indication
89522290|NCT04833933||Control group|"Initially in DISCO trial : no intervention, usual care~In DISCO-SET trial : survey (the same in the 4 groups)"
89522291|NCT04833933||Questionnaire|"Initially in DISCO trial : Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.~In DISCO-SET trial : survey (the same in the 4 groups)"
89522292|NCT04833933||Coordination|"Initially in DISCO trial : Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).~In DISCO-SET trial : survey (the same in the 4 groups)"
89522293|NCT04833933||Questionnaire + Coordination|"Initially in DISCO trial :~Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.~Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).~In DISCO-SET trial : survey (the same in the 4 groups)"
89522294|NCT03411005|Experimental|Metabolic availability of lysine in Sorghum|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked sorghum with or without lentils, which will all be provided by the investigators."
89522295|NCT04447573|Experimental|BCMA CAR-T cells|Patients will be treated with BCMA CAR-T cells
89522296|NCT04841759|Experimental|"Post COVID-19 fatigue at baseline yes"|SARS-CoV2 survivor who attends the exercise program and suffers from post-COVID-19 fatigue Syndrome according to the Post-Covid-19-Functional Scale (PCFS)
89522297|NCT04841759|Active Comparator|"Post COVID-19 fatigue at baseline no"|SARS-CoV2 survivor who attends the exercise program and doesn't suffer from post-COVID-19 fatigue Syndrome according to the Post-Covid-19-Functional Scale (PCFS)
89522298|NCT03972579|Active Comparator|Graded exposure therapy|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
89522299|NCT03972579|Active Comparator|Pacing + mindfulness|Weekly 60-min sessions with an occupational therapist and psychologist over 8 weeks.
89522300|NCT03411265|Experimental|RETAIN|Participants who meet criteria will receive the RETAIN self-administered, e-health application intervention.
89522301|NCT03410849|Active Comparator|Gastric Bypass|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
89522302|NCT03410849|Active Comparator|Sleeve Gastrectomy|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
89522303|NCT03394183|Experimental|Peripheral Artery Disease Participants|Patients diagnosed with peripheral artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre.
89522304|NCT03394183|Active Comparator|Coronary Artery Disease Participants|Patients diagnosed with coronary artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre. The responses to cardiac rehabilitation for participants with coronary artery disease will be compared to participants with peripheral artery disease.
89522305|NCT05168137|Placebo Comparator|Placebo|prescribed placebo of colchicine
89522306|NCT05168137|Active Comparator|Colchicine|Prescribed colchicine 0.6 mg PO daily
89522307|NCT03410771||ICU patients on amoxicillin/clavulanic acid|
89522308|NCT03410771||ICU patients on piperacillin/tazobactam|
89522309|NCT03410771||ICU patients on meropenem|
89522310|NCT03410771||ICU patients on vancomycin|
89522311|NCT05226819|No Intervention|H. pylori negative group|No Intervention
89522312|NCT05226819|Other|H. pylori positive and successful eradication group|H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed and the result show that H. pylori is eradicated. At the same time, Patients with successful eradication are instructed to conduct 13C-UBT examination after 6 months,1year and every year after drug withdrawal.
89522313|NCT05226819|Other|H. pylori positive and eradication failure group|H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed and the result show that H. pylori is not eradicated.
89672829|NCT00266279|Experimental|Treatment with Study Drugs|Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.
89672830|NCT01773135||preterm group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation > 1 and < 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver preterm (before 37 weeks of gestation)
89672831|NCT01773135||full term group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation > 1 and < 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver full term (after 37 weeks of gestation)
89672832|NCT01736085|No Intervention|Material Group|Subjects will receive self-help materials
89672833|NCT01736085|Active Comparator|Materials plus Voucher|Subjects will receive self-help materials and a voucher for 2 week's worth of nicotine patches
89672834|NCT01736085|Active Comparator|Materials plus Patches|Subjects will receive self-help materials and a 2 week's worth of nicotine patches
89672835|NCT01736085|Active Comparator|Counseling|Subjects will receive up to 5 sessions of telephone counseling
89672836|NCT01736085|Active Comparator|Counseling plus Voucher|Subjects will receive up to 5 sessions of telephone counseling plus a voucher for 2 week's worth of nicotine patches.
89672837|NCT01736085|Active Comparator|Counseling plus Patches|Subjects will receive up to 5 sessions of telephone counseling plus 2 week's worth of nicotine patches.
89672838|NCT00209417|Active Comparator|Iodixanol 320-Arm 1|Iodixanol 320 mg I/mL
89672839|NCT00209417|Active Comparator|Iopamidol 300-Arm 2|Iopamidol 300 mg I/mL
89672840|NCT00210353|Active Comparator|ARM A|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment; two weeks rest; chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
89672841|NCT00210353|Experimental|ARM B|rituximab 375 mg/m2 iv, d1, d8, d15, d22 chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment two weeks rest chlorambucil 6 mg/m2 os daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
89672842|NCT00210353|Experimental|ARM C (Since April 2006)|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
89672843|NCT00267059|Experimental|Lenalidomide|
89672844|NCT01899287|Experimental|education in skin care|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
89672845|NCT01899287|No Intervention|no intervention|The control group will not have access to the group education, the profession specific information and the social guidance or the telephone hotline.
89672846|NCT01736241|Experimental|LY3053102|A single 2-, 7-, 20-, 50-, 150-, or 405-milligrams (mg) dose of LY3053102 was subcutaneously administered to newly randomized participants in 6 escalating dose level cohorts. The dose was escalated based on the safety results over at least a 7-day evaluation period postdose. The dose escalation occurred over 13 weeks proceeding according to tolerability at each dose level.
89672847|NCT01736241|Placebo Comparator|Placebo|A single dose of LY3053102-matching placebo was administered subcutaneously to 1 newly randomized participant in each LY3053102-dose level cohort over 13 weeks.
89672848|NCT00213239|Experimental|Propofol 4 mg/kg group|First patient in this arm will receive a bolus of propofol 4 mg/kg followed by remifentanil 0.5 mcg/kg. Subsequent patients randomized to this arm will receive propofol 4 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)
89672849|NCT00213239|Experimental|Propofol 2 mg/kg group|First patient in this arm will receive a bolus of propofol 2 mg/kg followed by remifentanil 1 mcg/kg. Subsequent patients randomized to this arm will receive propofol 2 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)
89672850|NCT01444430|Experimental|1|Symbicort
89672851|NCT01444430|Active Comparator|2|budesonide
89672852|NCT01878825|Experimental|Fluviral 18-60 Years Group|Subjects aged between 18 and 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89672853|NCT01878825|Experimental|Fluviral >60 Years Group|Subjects aged > 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm
89049622|NCT05306158|Active Comparator|CC Only Condition|Participants in this arm will be trained to avoid only combustible cigarette images, not electronic cigarettes images.
89672854|NCT00214097|Experimental|Level 1|64.7 Gy/22 fractions of 2.94 Gy
89672855|NCT00214097|Experimental|Level 2|58.08 Gy/16 fractions of 3.63 Gy
89672856|NCT00214097|Experimental|Level 3|51.6 Gy/12 fractions of 4.3 Gy
89672857|NCT00214487|Experimental|Bifocal Contact Lenses|Use of bifocal contact lenses to control the progression of myopia
89672858|NCT00214487|Placebo Comparator|Control|Single vision soft contact lenses
89672859|NCT01774149|Active Comparator|Delayed Diastat|Mobile phone application Few Touch Application (FTA) in the regular version, with Diastat turned on in week 12 post-enrollment.
89672860|NCT01774149|Experimental|Diastat|Few Touch Application with Diastat module turned on in week 4 post-enrollment.
89672861|NCT01899365||Multifaceted|"brief structured interview with the physician about pneumococcal risk and vaccination,~information sheet delivered to patients with explanation about risk and benefit of APV,~letter given to patient for his/her general practitioner stating that the patient is at-risk for pneumococcal infection and could benefit of APV,~3 SMS every 2 weeks to remind patients talking of pneumococcal risk with general practitioner."
89672862|NCT01899365||Control|"information sheet delivered to patients with explanation about the aim of the study,~brief interview with the physician about study."
89672863|NCT01898507|Experimental|Low nicotine cigarettes|"Participants will smoke their own brand cigarettes during a baseline 5 day period, followed by a 15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.~Other: Low nicotine cigarettes"
89672864|NCT01899443||Total hip and knee replacement patients|This study will select up to 20 high volume (>275 cases annually) public and private hospitals across Australia. A random sample of c.2200 patients with diagnosis of osteoarthritis undergoing primary total hip or knee replacement surgery will be recruited.
88995740|NCT00151229|Active Comparator|strict control|systolic blood pressure control: less than 140 mm Hg
89522314|NCT03397901|Experimental|transverse colostomy|Diverting transverse colostomy were conducted under general or epidural anesthesia in the operating room. The transverse colon was pulled out through one 2*2cm incision. The omentum was dissected from transverse colon, and a double-cavity stoma of transverse colon was then created.
89522315|NCT05216757|Active Comparator|Iguratimod group|subjects with Iguratimod
89522316|NCT05216757|Placebo Comparator|placebo group|subjects with placebo
89522317|NCT03397823||head and neck cancer pre RT|head and neck cancer patients before and after RT
89522318|NCT03397823||head and neck cancer treated|head and neck cancer patients treated with radiotherapy
89522319|NCT03397823||control group|age gender matched subjects
89522320|NCT03126409|Experimental|No-Touch vein harvesting technique|During saphenous vein harvesting, surrounding tissue of the vein is preserved, and manual distension of the vein graft is avoided
89522321|NCT03126409|Active Comparator|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
89522322|NCT02520869|Active Comparator|swim-up|swim-up technique for semen processing
89522323|NCT02520869|Active Comparator|zeta test|zeta test technique for semen processing
89522324|NCT02375295|Experimental|Arm A: 2 weeks Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose.
89522325|NCT02375295|Active Comparator|Arm B: 12 weeks/3 months Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose followed by a suppressive dose for another 10 weeks (total = 12 weeks or 3 months).
89522326|NCT03397745|Other|BIS group|Patients who received the esophageal surgery
89522327|NCT04736147|Experimental|JNJ-64300535|Participants will receive an electroporation-mediated intramuscular (IM) injection of JNJ-64300535 vaccine.
89522328|NCT05169281|No Intervention|Control|Usual care consisted of a text message hyperlink to nearby disposal locations.
89522329|NCT05169281|Experimental|Intervention|Intervention participants were mailed an at-home disposal packet timed to arrive between post-operative days four and seven based on prior data collection on reported use.
89522330|NCT03397511|Experimental|Usual Care+Financial Incentive|Smoking cessation counseling couples with financial incentives
89522331|NCT04787809|Experimental|Living Well Intervention Group|Participants in the Living Well treatment group will receive a brief digital intervention informed by Acceptance and Commitment Therapy.
89522332|NCT04787809|No Intervention|Control Group|Participants in the control group will not receive any intervention. These individuals will have the option to access the intervention at the conclusion of their study participation.
89522333|NCT02356575|Active Comparator|Acupuncture Group|In the acupuncture group, patients will receive ten treatments of acupuncture over eight weeks.
89522334|NCT02356575|Active Comparator|CBT-I Group|In the CBT-I group, patients will receive seven sessions of CBT-I over eight weeks.
89522335|NCT03410537|Experimental|Taurine Supplementation|Taurine 2.4mg/d for 12 weeks
89522336|NCT03410537|Placebo Comparator|Placebo|Placebo 2.4mg/d for 12 weeks
89522337|NCT03394105|Experimental|intrapleural docetaxel administration|Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
89522338|NCT03126773||BAY86-4891|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Angeliq Micro is indicated are fit for participation in this non-interventional study.
89522339|NCT03393949|Experimental|Group M|Patients in Group M received methylprednisolone 1mg•kg-1
89522340|NCT03393949|Experimental|Group C|Patients in Group C received isotonic saline 1mg•kg-1
89522341|NCT03126929||Vegetative state|patients lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R and GCS
89522342|NCT03126929||Minimally conscious state|Patients display inconsistent, but reproducible and discernible signs of awareness using CRS-R and GCS
89522343|NCT03126929||Emergence from MCS|Patients regain accurate communication and/or functional use of objects using CRS-R and GCS
89522344|NCT04678947|Experimental|BARF scale|"Nursing staff (which may include patient technicians and nursing assistants) will use the scale to assess the patient's nausea for the entire duration of the admission. These assessments will take place in conjunction with vital sign monitoring, every 4 hours. The associated script will be read while the laminated scale is shown to the patient.~The nurse will then log the patient's response in the patient's electronic medical record"
89522345|NCT04678947|No Intervention|No intervention|-Patients in the control group will proceed with their inpatient chemotherapy admissions without any interventions. These admissions will take place prior to the admissions of the experimental group, so as not to bias providers.
89522346|NCT04707677|Active Comparator|CONTROL GROUP|Implant surgery placement. Tissue Level SLA Titanium implant (Straumann Standard Plus Narrow Neck CrossFit®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.
89522347|NCT04707677|Experimental|TEST GROUP|Implant surgery placement. Tissue Level Ceramic monotype implant was placed (Straumann PURE Ceramic implants®; Institut Straumann, Basel, Switzerland). The implant had a diameter of 3.3 mm and a polished neck of 1.8 mm. The length of the implants was 8, 10 and 12 mm and was chosen according to the patient's anatomy.
89522348|NCT03397849|Active Comparator|intervention using mobile technology (IMT) plus usual care|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan).
89522349|NCT03397849|No Intervention|Only usual care|Patients that are randomized to only usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.
89672865|NCT00267293|Active Comparator|A|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg)
89672866|NCT00267293|Experimental|B|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and an appropriate dose of Acetaminophen (15 mg/kg)
89672867|NCT00267293|Experimental|C|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and at time 3 hours is given an appropriate dose of Acetaminophen (15 mg/kg)
89672868|NCT01436162|Experimental|Antidepressant + SPD489|
89672869|NCT01436162|Placebo Comparator|Antidepressant + Placebo|
89672870|NCT02579382|Placebo Comparator|TDF + placebo|"Main Study Phase: Tenofovir disoproxil fumarate (TDF) 300 mg tablets orally once daily for up to 48 weeks + placebo administered orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
89672871|NCT02579382|Experimental|TDF + Vesatolimod 1 mg|"Main Study Phase:TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 1 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
89672872|NCT02579382|Experimental|TDF + Vesatolimod 2 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 2 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
89672873|NCT02579382|Experimental|TDF + Vesatolimod 4 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 4 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
89672874|NCT01774851|Experimental|Arm 1a|MM-111 + Paclitaxel + Trastuzumab
89672875|NCT01774851|Active Comparator|Arm 1b|Paclitaxel + Trastuzumab
89672876|NCT05533320|Experimental|Supportive care (PSCS)|Patients undergo scalp cooling using the PSCS 30 minutes before, during, and for up to 2 hours after completion of chemotherapy for 6 chemotherapy sessions.
89672877|NCT01436084|Experimental|SB1518|400 mg orally a day for 28 day cycle.
89672878|NCT02990013|Experimental|Treatment arm|All patients will be in the treatment arm where they will be subject to skin testing with various cleansing agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
89672879|NCT02259699|Experimental|Decision Aid (PCOA)|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
89672880|NCT02259699|No Intervention|UC (Standard care)|Standard pamphlets will be given to patients to educate them about IV and IV/IP therapies.
89672881|NCT01419314|Experimental|Splinting application|Participants will be asked to wear a pair of LE night splints for the duration of the study (6 weeks) at night/during sleep only.
89672882|NCT01419314|Placebo Comparator|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study.
89672883|NCT03440112|Active Comparator|Clarithromycin (Not used anymore as of 4/2020; study aborted)|Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.
89672884|NCT03440112|Placebo Comparator|Placebo (Not used anymore as of 4/2020; study aborted)|Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.
89672885|NCT03440112|Active Comparator|Transdermal flumazenil (added 4/2020 as safer alternative for clarithromycin)|Added in April 2020. Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
89672886|NCT03440112|Placebo Comparator|Placebo cream (added 4/2020)|Added in April 2020. Placebo will be taken exactly as the transdermal flumazenil arm: Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
89672887|NCT01775865|Experimental|Salsalate|Salsalate capsule 1.5 g/day twice per day by mouth for 4 weeks
89049623|NCT05306158|Sham Comparator|Sham Condition|Participants will pull and push all pictures of CC and ECIG images equally with no preference towards one or the other.
89672888|NCT01775865|Placebo Comparator|Placebo|Placebo capsule twice per day by mouth for 4 weeks
89672889|NCT01775865|No Intervention|Young Control|No intervention; Baseline measurements only
89672890|NCT01821417|Experimental|Microtextured dental implant|Randomized for microtextured dental implant treatment
89672891|NCT01821417|Active Comparator|Dental implant|Randomized dental implant treatment with machined-collar implants
89672892|NCT01822119|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~One implant magnet~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
89672893|NCT01419236|Experimental|Testosterone Solution 2% 60 milligrams (mg)|Testosterone Solution 2% 60 mg applied topically once daily with possible 1-time titration to 30 milligrams per day (mg/day) or 90 mg/day for 16 weeks
89672894|NCT01419236|Placebo Comparator|Placebo|Placebo solution applied topically once daily for 16 weeks
89522350|NCT04447365||control|10 patients who have had no device-monitored for ventricular tachycardia/ ventricular fibrillation the 3 months prior to recruitment will comprise a group of controls
89672895|NCT01822197|Experimental|Phototherapy|Bright light phototherapy will be administered for 30 minutes daily over one week in the morning (Days 0-7)
89672896|NCT03323658|Experimental|Prevention (bexarotene)|Group 1 will apply 10mg bexarotene topically to one breast QOD for 4 weeks; Group 2 will apply 10mg bexarotene topically to one breast QOD for 1 week and then daily for 3 weeks after confirmation that toxicity is at an acceptable range; Group 3 will apply 10mg bexarotene topically to one breast QOD for 1 week, then daily for 1 week, and then 20mg daily for 2 weeks after confirmation that toxicity is at an acceptable range.
89672897|NCT01776645|Experimental|Compassion cultivation training|
89672898|NCT04576728|Experimental|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
89672899|NCT04576728|Placebo Comparator|Placebo|Human albumin 1%
89672900|NCT01879059|Experimental|Exercise|5 days of inactivity followed by a 1 day return to physical activity
89672901|NCT01443026|Experimental|Lycopene|Lycopene 30 mg/day
89672902|NCT01443026|Placebo Comparator|Placebo|Placebo
89672903|NCT01879371|Active Comparator|Ibuprofen (Brufen®)|film-coated tablet
89672904|NCT01879371|Active Comparator|Ibuprofen (Nurofen Immedia®)|film-coated tablet
89672905|NCT01879371|Experimental|Ibuprofen+caffeine|fixed-dose-combination (FDC)
89672906|NCT01733745|Experimental|SYSTANE® Family|SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.
89672907|NCT01733745|Active Comparator|Standard of Care|Microfiber towels (as warm compresses, with or without saline eye drops) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, 1 time a day. Duration of treatment was 3 months.
89672908|NCT03297450|Active Comparator|Aphasia therapy and tDCS|
89672909|NCT03297450|Sham Comparator|Aphasia therapy and sham-tDCS|
89049624|NCT05304286|Active Comparator|ACT Group Intervention|We will evaluate the effects of an Acceptance and Commitment Therapy (ACT) one-day group intervention (with 1-month post group zoom booster session) on the functional near-infrared spectroscopy (fNIRS) signal in groups of adolescents and adult patients diagnosed with CPSP at >3 months post major orthopedic surgery.
89049625|NCT05304286|No Intervention|Treatment as Usual|Treatment as Usual (TAU) for those with CPSP
89049626|NCT05424575||Group Nonfrail (Group NF)|Modified fraility index was calculated in all patients. Modified fraility index < 0.27 were included to Group NF.
89049627|NCT05424575||Group Frail (Group F)|Modified fraility index was calculated in all patients. Modified fraility index ≥ 0.27 were included to Group F.
89049628|NCT01165996|Experimental|Arm I: decitabine|INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts &lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
89049629|NCT04619433|Experimental|Treatment group A|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
89049630|NCT04619433|Placebo Comparator|Treatment group B|Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
89049631|NCT02886871|Experimental|Personalized Steps Goal|Step Goal Delivery by Smartphone
89049632|NCT02886871|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
89049633|NCT04652388|Experimental|Nutritional counseling|Children with autism spectrum disorders to whom administer nutritional counseling
89049634|NCT04652388|No Intervention|Controls|No intervention
89049635|NCT04619160|Active Comparator|propofol|
89049636|NCT04619160|Active Comparator|sevoflurane|
89049637|NCT01165684|Experimental|Step-wise|
89049638|NCT01165684|Active Comparator|Basal-bolus|
89049639|NCT01189201|Experimental|BI 10773/linagliptin FDC SID|medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
89672910|NCT03297450|Sham Comparator|Standard of care and sham-tDCS|
89672911|NCT03276468|Experimental|Experimental|Combination of venetoclax, atezolizumab and obinutuzumab
89672912|NCT05533008|Experimental|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
89672913|NCT05533008|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
89672914|NCT01442714|Experimental|Azacitidine plus Lenalidomide|Patients will receive a single dose of azacitidine 75 mg/m² SC or IV on days 1 to 7, followed by lenalidomide 50 mg PO daily on days 8 to 28 of a 42-day cycle.
89672915|NCT01777425||rhinosinusitis patients|patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.
89672916|NCT05328921||Antihypertensive drugs group|Changes in IOP among patients on antihypertensive drugs
89672917|NCT05328921||Antihistaminic drugs group|Changes in IOP among patients on antihistaminic drugs
89672918|NCT05328921||Antihypertensive and antihistaminic drugs group|Changes in IOP among patients on both antihypertensive and antihistaminic drugs
89672919|NCT05328843|Experimental|Group A|Subjects with mild renal insufficiency (CKD stage 2, GFR: 60-89 mL/min)
89672920|NCT05328843|Experimental|Group B|Subjects with moderate renal insufficiency (CKD stage 3, GFR: 30-59 mL/min)
89672921|NCT05328843|Experimental|Group C|Subjects with normal renal function (GFR: ≥ 90 and < 130 mL/min)
89672922|NCT01418378|Active Comparator|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
89672923|NCT01418378|Active Comparator|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
89672924|NCT04071860||discovery and learning cohort|Data from this cohort will be used to develop the software algorithms
89672925|NCT04071860||Validation|Data from this cohort will be used to validate the software algorithms
89672926|NCT05532852|Sham Comparator|standard-of-care|
89672927|NCT05532852|Experimental|standard-of-care plus Paxlovid|
89672928|NCT05503368|Experimental|Autologous Cellular Micro-grafts suspension added to non cultured epidermal suspension (NCES)|Under local anesthesia, a 2.5 mm punch biopsy will be used to extract 3 scalp tissue specimens from the patient's occiput behind the ear, using Rigeneracons medical device (CE certified class I; Human Brain Wave, Turin, Italy). The collected specimens will be placed in Rigeneracons by adding 1.5 mL of sterile physiologic solution to the device. The device then generates a cellular suspension by rotation of Rigeneracons at 80 RPM for 2 minutes. Subsequently, the obtained suspension is diluted with an additional 3 mL sterile physiologic solution. The resulting suspension will be added to NCES and placed on one of the derma braded vitiligo patches
89672929|NCT05503368|Active Comparator|Follicle cell suspension added t NCES|• Under local anesthesia, 1 mm punch will be used to extract hair-follicles from occipital scalp behind the ear. Depending on the area to be transplanted, one hair follicle will be etracted for each 1 cm2. The extracted hair-follicles are washed with phosphate buffered saline (PBS) for about 3 times. The hair-follicles are then incubated with 0.25% trypsin - 0.05% ethylene diamine tetra acetic acid (EDTA) at 37°C for 90 min to prepare the single cell suspension. Within 15-20 min of incubation, the cells start loosening from each other. The hair-follicles are subsequently placed in another tube of trypsin and EDTA. At the end of three such cycles, a thin keratinous shaft is left behind. The cell suspensions of all the tubes are added in a single tube. The final cell pellet is obtained by centrifuging the combined cell suspension at 1000 rpm for 5 min. The resulting suspension will be added to NCES and placed on a comparable derma braded lesion
89672930|NCT05503368|Active Comparator|Non cultured epidermal suspension (NCES)|Melanocyte keratinocyte pellet will be prepared. Donor skin will be harvested from the gluteal region ; using a sterile shaving blade mounted on a Kocher's forceps. Cell Suspension will be prepared by placing the donor skin in 0.25% trypsin-EDTA (GIBCO) solution for 40 minutes at 37 ᴼC. sample and trypsin will be poured into a labelled petri dishes then neutralized using ringer's lactate. All the steps will be performed in a laminar air flow bench under strict aseptic conditions. The epidermis will be detached from the dermis which will be discarded. Then the epidermis will be cut into tiny pieces and scrapped so that no pigment is left on the surface. Afterwards, they will be transferred to sterile falcon tubes and centrifuged for 10 minutes at 1,000 rpm. The floating epidermal fragments and supernatant fluid will be removed, leaving the cell pellet containing epidermal cells rich in melanocytes and Keratinocytes at the bottom.
89672931|NCT04310592|Experimental|Dose escalation/MTD or MPD determination in MRD positive AML patients|Cyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
89672932|NCT04310592|Experimental|Dose escalation/MTD or MPD determination in Relapsed/Refractory AML patients|Cyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
89672933|NCT05501574|Experimental|Tacrolimus Inhalation Powder|Single arm open label
89672934|NCT01779141||CSII|Patients using CSII with or without CGM.
89672935|NCT05497752|Experimental|cervical rehabilitation group|Positional release technique on trapezius muscle, suboccipital muscle release, pectoralis muscle stretching
89672936|NCT05497752|Active Comparator|control group|shoulder and neck exercises
89672937|NCT01779219|Active Comparator|iMRI-guided|Intervention: iMRI-guided brain tumour biopsy. The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet imager will be used in all cases. After the patient's positioning, the preoperative reference examination is routinely carried out. The entry point, target and optimal biopsy trajectory are then defined by the operator on the basis of the obtained iMRI images. Serial tissue samples are collected. Following each operation, a control iMRI (T1-weighted, axial, 4 mm scan examination) is routinely performed to confirm and document the proper targeting and to exclude postoperative hyperacute intraparenchymal bleeding.
89672938|NCT01779219|Active Comparator|non-iMRI|Intervention: Stereotactic frameless brain tumour biopsy. A frameless STx biopsy is performed for each patient from the control group with the use of a neuronavigation system. The entry point, target and optimal biopsy trajectory are defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
89672939|NCT01435928|Experimental|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
89672940|NCT01435928|Placebo Comparator|Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
89672941|NCT02262507|Experimental|Device wearing|All subjects who meet the study criteria and volunteer to participate will be included in the study. Subjects will undergo repeat oto-acoustic measures both wearing the device and not wearing the device. The intervention will be the auto-acoustic measurement - taken while wearing the collar and then again when not wearing the collar.
89672942|NCT05328609|Active Comparator|Intervention arm|Semaine - The Daily
89672943|NCT05328609|No Intervention|Control arm|No intervention for the time period
89672944|NCT05328531|Experimental|Genakumab for injection 50mg (Ib)|subcutaneous injection, single dose
89049640|NCT01189201|Experimental|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
89049641|NCT01189201|Experimental|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
89049642|NCT01189201|Experimental|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
89049643|NCT05424497||No outcome provided|
89049644|NCT05424497||outcome positive|
89049645|NCT05424497||outcome negative|
89049646|NCT05424497||implicit bias group|
89049647|NCT01188967|Experimental|GSK598809|Active medication
89049648|NCT01188967|Placebo Comparator|Placebo|Placebo
89049649|NCT04316728|Other|negative Patients|Adult HCWs with no signs or symptom of coronavirus infection and no known previous history of contact with patients positive for COVID-19, working in a primary care setting and Adult patients with at least 2 chronic medical conditions routinely attending a General Practioner (GP) practice or an outpatients departments or a primary care facility
89049650|NCT04652271||Patients undergoing pancreatic surgery|Patients undergoing any type of pancreatic surgery.
89049651|NCT02885935|Experimental|Recommended protein intake|Subjects consumed diets with a macronutrient distribution of 10% protein, 55% carbohydrates, and 35% fat for 4 weeks.
89672945|NCT05328531|Experimental|Genakumab for injection 100mg (Ib)|subcutaneous injection, single dose
89672946|NCT05328531|Experimental|Genakumab for injection 195mg (Ib)|subcutaneous injection, single dose
89672947|NCT05328531|Experimental|Genakumab for injection 100mg (II)|Genakumab for injection, subcutaneous injection, single dose Placebo for Compound Betamethasone Injection, intramuscular injection, single dose
89672948|NCT05328531|Experimental|Genakumab for injection 195mg (II)|Genakumab for injection, subcutaneous injection, single dose Placebo for Compound Betamethasone Injection, intramuscular injection, single dose
89672949|NCT05328531|Active Comparator|Compound Betamethasone Injection 1ml (II)|Compound Betamethasone Injection, 1 ml, intramuscular injection, single dose Placebo for Genakumab for injection, 100mg, subcutaneous injection, single dose
89672950|NCT05328453||Pregnant women at 15-24 gestation.|Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
89672951|NCT01416272|Experimental|KeraSoft IC Soft Contact Lenses|KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
89672952|NCT05327907||Training cohort|Training cohort consists of the patients diagnosed with intrahepatic cholangiocarcinoma who collected from January 2010 to July 2021 retrospectively.
89672953|NCT05327907||Internal validation cohort|Internal validation cohort consists of the intrahepatic cholangiocarcinoma patients who enrolled from September 2021 of Qilu Hospital prospectively.
89672954|NCT05327907||External validation cohort|External validation cohort consists of the intrahepatic cholangiocarcinoma patients who enrolled from September 2021 of Shandong Province Hospital, Jinan Military General Hospital and Jinan Central Hospital prospectively.
89672955|NCT01828515|Experimental|Vilazodone and Hydrocortisone, then Placebo and Hydrocortisone|Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment. After a 23 day medication washout the procedure will be repeated using placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment.
89672956|NCT01828515|Experimental|Placebo and Hydrocortisone, then Vilazodone and Hydrocortisone|Placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment. After a 23 day medication washout the procedure will be repeated using Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment.
89672957|NCT01828593|Placebo Comparator|Placebo|Matching Placebo
89672958|NCT01828593|Active Comparator|SBI 2.5 g|Serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g
89672959|NCT01828593|Active Comparator|SBI 5.0g|Serum-derived bovine immunoglobulin protein isolate (SBI)5.0g
89672960|NCT01828983|Experimental|Telephone support groups|Telephone support groups, each with participants and a trained group leader. Each hour-long telephone group will meet bi-monthly for six months for a total of 12 meetings. Groups are structured with education, skills building, and support. Participants will receive and use a Spouse Workbook with information and activities.
89672961|NCT01828983|Active Comparator|Education webinars|Education Webinar session topics are the same that are covered in the intervention arm without telephone interaction/support and skills building components. Each session is 30-minutes. Each participant receives a Spouse Workbook with information and activities.
89672962|NCT01781169|Experimental|Obese group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
89672963|NCT01781169|Experimental|Normal-weight group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
89672964|NCT00216125|Other|Pre-Randomization|Prior to randomization patients received Cisplatin 50 mg/m^2 days 1,8,29,36 + Etoposide 50 mg/m^2 days 1-5, 29-33 + Radiation 5940 cGy (180 cGy/day). Patients with CR, PR or SD with manageable toxicity were randomized to either Docetaxel arm or Observation only arm.
89672965|NCT00216125|Active Comparator|Consolidation Docetaxel|Docetaxel 75 mg/m^2 q3wk X 3 cycles.
89672966|NCT00216125|No Intervention|Observation Only|Patients were followed for Observation.
89672967|NCT01781403|Experimental|Capecitabine, Temozolomide, Radiotherapy|"The total dose of radiotherapy will be 50.4 Gy, with a daily dose of 1.8 Gy administered on 5 days of each week, comprising a total of 45 Gy to the whole pelvis, followed by a 5.4 Gy boost to the primary tumor.~The doses and schedules for capecitabine will be fixed, with only temozolomide being prescribed using a dose-escalation schedule. Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break)."
89672968|NCT01781481||Children and youth with IBD|Children/youth (ages 8-17) with confirmed diagnoses of IBD.
89672969|NCT00218387|Experimental|200mg Modafinil|200mg Modafinil
89672970|NCT00218387|Experimental|400mg Modafinil|400mg Modafinil
89672971|NCT00218387|Placebo Comparator|Matching Placebo|Matching Placebo
89672972|NCT00218465|Experimental|GW468816|Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial
89672973|NCT00218465|Placebo Comparator|Placebo|Placebo, 200 mg/day, for a 5-week trial
89672974|NCT04090463|Experimental|IORT group|"Intraoperative administration of 10 to 20 Gy after surgery or as an in situ treatment in case resection will not be performed"
89672975|NCT01898585|Experimental|Zelboraf Arm|
89672976|NCT00220961|Placebo Comparator|Placebo|Placebo tablet similar to pioglitazone tablet
89672977|NCT00220961|Active Comparator|Pioglitazone|Pioglitazone tablet similar to placebo tablet
89672978|NCT00221117|Active Comparator|Conventional Occupational Therapy (COT)|Conventional Occupational Therapy pertaining to hand function represents the current best practice activities against which the FET was compared. The COT included the following: (a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; (b) task-specific, repetitive functional training; (c) strengthening and motor control training using resistance to available arm motion to increase strength; (d) stretching exercises; (e) electrical stimulation applied primarily for muscle strengthening (this was neither FES nor FET, but electro muscular stimulation); (f) practice of activities of daily living (ADLs) including self-care where the upper extremities were used as appropriate; and (g) caregiver training.
89688715|NCT05613907||Post-intervention|"This group comprises patients from the pre-intervention group who have undergone a revascularisation procedure. These patients will be given the same structured questionnaire to complete post procedurally.~They will also be invited to complete the same questionnaire at 12 months post revascularisation"
89214869|NCT05747950|Other|Modified Constraint-Induced Movement Therapy group|Modified Constraint-İnduced Movement Therapy is a rehabilitation technique that promotes 'repetitive' use of the affected upper extremity in people with upper extremity neurological motor deficits. Constraint-İnduced Movement Therapy upper extremity after stroke it is a rehabilitation approach used to increase functional use. post stroke Approximately 20-25% of surviving patients can meet the motor criteria of mCIMT. Participants In addition to conventional treatment, they can use their intact extremities at home with a shoulder stabilization orthosis.Restraint, grasping on the hemiplegic side, using spoons and forks, combing hair daily life activities, 8 weeks, 3 days a week, and approximately 3 hours Modified Constraint-İnduced Movement Therapy m(CIMT) will be applied.
89214870|NCT05747950|Other|Control group|Control group in the training group, will be given a program that includes joint range of motion exercises, strengthening exercises, mobility and transfer activities, and various activities in order to increase participation in daily life activities as a routine conventional treatment in 60-minute sessions, 3 days a week, for 8 weeks.
89214871|NCT05724082|Experimental|Clean air intervention|See detailed description
89522351|NCT04447365||high burden of ventricular arrhythmias|20 patients will comprise a group of patients with high burden of ventricular arrhythmias, defined as patients with at least one sustained episode of VT/VF requiring ICD therapies in the 3 months preceding study enrollment.
89522352|NCT03836937|Experimental|Obeticholic acid|Patients diagnosed as NAFLD with raised ALT will be treated with both life style modification and Obeticholic acid. Obeticholic acid will be given as 10 mg twice daily. Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
89522353|NCT03836937|No Intervention|Lifestyle modification|Patients diagnosed as NAFLD with raised ALT will be given only life style modification.Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
89522354|NCT05169125|Active Comparator|Group A: standard hemodialysis.|patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
89522355|NCT05169125|Active Comparator|Group B: lower dialysate sodium hemodialysis.|patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L).
89522356|NCT03397433|Experimental|Intervention|"In this arm, an Information Technology physician assist tool will be used to predict best available therapy for patients coming to the hospital with either pneumonia, cellulitis, intraabdominal infection, or complicated urinary tract infection.~Intervention: After review of the information technology recommendation by a board certified Infectious Disease physician, the recommendation will be discussed with the primary care physician and treatment implemented."
89522357|NCT03397433|No Intervention|Control|In the two control hospitals there will be no use of the information technology tool for implementation of initial treatment (No intervention). No notes will be placed in the electronic health record and no contact as a result of this research will be made with the medical care team.
89522358|NCT03397693||1|Women with unexplained infertiltiy with no treatment given
89522359|NCT03397693||2|Women with Poly Cystic Ovary Syndrome (PCOS) who are not being treated with drugs of ovulation induction.
89522360|NCT03397693||3|Control fertile women with no treatment given.
89522361|NCT03402529|Other|CESM|
89522362|NCT04447391|Experimental|Exercise group|Exercise group who performed a combined exercise and 300 kcal/day deficit diet during 12 weeks.
89522363|NCT04447391|Placebo Comparator|Control group|Control group who performed 300 kcal/day deficit diet during 12 weeks.
89522364|NCT03410459|Active Comparator|Gastric Bypass|Patients ≥ 5 years after laparoscopic gastric bypass receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
89522365|NCT03410459|Active Comparator|Sleeve gastrectomy|Patients ≥ 5 years after laparoscopic sleeve gastrectomy receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
89522366|NCT03759015|Other|Health education|This arm's subjects are tasked to create an original 10-minute theater that is required to use the guidelines about physical activity and diet/nutrition.
89522367|NCT03397615|Active Comparator|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
89522368|NCT03397615|No Intervention|Non betadine douches|subjects didnot received a vaginal preparation prior to caesarean delivery
89522369|NCT04435743||DLBCL|Treatment-naive or relapsed/refractory CD20+ diffuse large B-cell lymphoma patients who receive induction therapy containing lenalidomide.
89522370|NCT04435743||FL/MCL/MZL|Treatment-naive or relapsed/refractory CD20+ follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma patients who receive induction therapy containing lenalidomide.
89522371|NCT04435743||Maintenance|B-cell non-Hodgkin lymphoma patients who achieve complete or partial remission after induction therapy and receive maintenance therapy containing lenalidomide.
89522372|NCT04447079||'Before' and 'After' Arm|"Before Arm - This refers to the rate of Emergency Department visits in the pre-intervention period (12 months).~After Arm - This refers to the rate of Emergency Department visits in the post-intervention period (12 months) following the START of intervention."
89522373|NCT03393715|Experimental|Perindopril morning|10 mg of perindopril oral tablet once daily in the morning for 56 days
89522374|NCT03393715|Active Comparator|Perindopril evening|10 mg of perindopril oral tablet once daily in the evening for 56 days
89522375|NCT03410381|Experimental|Group using the application EMMA|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months. Assessment of the predictive value of the algorithm for suicidal risk, acceptbability and satisfaction
89522376|NCT03397537|Other|the postmenopausal|2.5 mg letrozole every day for six months
89522377|NCT03397537|Experimental|the premenopausal|2.5 mg letrozole daily along with a GnRH analogue for ovarian suppression, which was administered as an intramuscular injection of 3.75 mg triptorelin every 28 days for 6 months.
89522378|NCT03612921|Active Comparator|oral group|the patients will receive oral amantadine sulfate using the dose 100 mg 90 minute prior to the surgery and infusion of100cm I.V saline
89214872|NCT05720611|Active Comparator|Intervention group|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden. Participants will be asked to engage in a closed Facebook group.
89214873|NCT05720611|Placebo Comparator|Control Group|Participants in this group will complete all questionnaires but will not receive the digitally delivered course or access to Facebook.
89522379|NCT03612921|Active Comparator|I.V group|the patients will receive 100 mg I.V amantadine sulfate infusion over 60minute prior to the surgery and placebo tablet 90 minute prior to the surgery
89522380|NCT03612921|Placebo Comparator|control group (group C)|the patients will receive placebo tablet 90 minute prior to the surgery and infusion of 100cm I.V saline over 60minute prior to the surgery
88995741|NCT00151229|Active Comparator|moderate control|systolic blood pressure control: 140 mm Hg to 149 mm Hg
88995742|NCT05466604|Experimental|hyaluronidase|
88995743|NCT05466604|No Intervention|hyaluronidase control|
88995744|NCT05466604|Experimental|dexamethasone|
88995745|NCT05466604|No Intervention|dexamethasone control|
88995746|NCT05466565||Nucleoside analog alone group|planning or ongoing treatment with entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and no addition or switch Patients on the pegylated interferon alfa-2b program
88995747|NCT05466565||In the continuous treatment group of peginterferon|the subjects started oral antiviral drugs from the 2nd day after operation, and simultaneously took peginterferon alfa-2b in combination from the 4th to 8th week after operation, and stopped after 96 weeks. Continue oral antiviral drugs with peginterferon
89522381|NCT03410303|Other|Intraoperative ultrasound|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
89522382|NCT03393559|Experimental|Group L|leg elevation during the beach chair position
89522383|NCT03393559|No Intervention|Group C|Patients' leg will be straightened without any intervention.
89522384|NCT03716037|Experimental|Physical Activity|Physical Activity for Life (PAL) is an 8-week exercise program, meeting three times per week for one hour sessions.
89522385|NCT03716037|No Intervention|Contact Control|those in the attentional contact control group will receive a phone call from research personnel three times per week asking them about their physical exercise routines.
89522386|NCT03397277|Experimental|Screened positive intervention video|Safety behaviour promoting video
89522387|NCT03397277|Sham Comparator|Screened positive control video|Pregnant women who screen positive for IPV using the AAS who are randomized into viewing the control video
89522388|NCT04413045||C Group|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
89522389|NCT03401437||Retrospective cohorte|Patients seen in consultation between January 2017 and August 2017, who have already completed the SF-36 questionnaire (pre-operative, M1 and M3), the HAD and ANSM questionnaires (pre-operative and M3)
89522390|NCT03401437||Prospective cohorte|Patients seen in consultation between August 2017
89522391|NCT03410225|Experimental|CAMI-TPP|Young men, ages 15 to 24 years, will be receiving a modified CAMI aimed at Teen Pregnancy Prevention (CAMI-TPP).
89522392|NCT03410225|Active Comparator|CAMI-Fitness|Young men, ages 15 to 24 years, will be receiving CAMI aimed at healthy diet, physical activity and tobacco avoidance (CAMI-Fitness).
89522393|NCT03400891|Experimental|Intervention|This group received 14 sessions (one every 15 days) of one hour in the classroom, to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
89522394|NCT03400891|No Intervention|Control|2 session of 1 hour each to give general information about fruit and vegetables intake and health.
89522395|NCT03393481|Experimental|MAA868 dose 1|MAA868 dose 1, single administration, subcutaneous
89522396|NCT03393481|Experimental|MAA868 dose 2|MAA868 dose 2, single administration, subcutaneous
89522397|NCT03393481|Active Comparator|Enoxaparin|Enoxaparin 40mg, once daily (o.d.) for 10 days
89522398|NCT05168345|Experimental|IBD patients|"Arm 1: IBD patients, patients of other chronic GI disease' and healthy volunteers~Both groups will be asked to fill in the knowledge questionnaire and the self-assessment of knowledge questionnaire once, during their routine visit to the GI department. Results of the questionnaire will be compared between the groups.~IBD Patient's knowledge will also be subjectively assessed by their treating physician during their routine clinical visit, and knowledge scores will be compared (physician and questionnaire). Patients who will agree, will be asked to fill in the knowledge questionnaire a second time after two weeks for reliability testing. Patients will be recruited to represent all stages of diagnosis and all patient age groups. This will be done by recruitment of six main participant groups stratified by age (18-23 years, 24-36 years, 42-52 years, 53-70 years) and disease duration (<1 year since diagnosis, ≥1 year since diagnosis)"
89522399|NCT01936857|Experimental|Buprenorphine/naloxone|Office based treatment of opioid dependence with buprenorphine/naloxone
89522400|NCT01936857|Active Comparator|Methadone Maintenance Therapy|Referral to methadone maintenance therapy for treatment of opioid dependence.
89522401|NCT03393403|Experimental|Dexmedetomidine_iv group|Dexmedetomidine 0.5mcg/kg (diluted in normal saline) intravenously infusion for 30min
89522402|NCT03393403|Experimental|Dexmedetomidine_adj group|Dexmedetomidine 0.5mcg/kg (adding to local anesthetic) perineural single bolus for subcostal TAP block 0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min
89522403|NCT03393403|Active Comparator|Control group|0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min No dexmedetomidine use
89522404|NCT03410147|Other|Concentration A|Concentration of 13C-sodium octanoate in enteral nutrition is 0.3 mg/ml
89672979|NCT00221117|Experimental|Neuroprosthesis-FES Therapy|The FES Therapy began by designing stimulation protocols to generate power (circular grip and lateral pinch) and precision (opposition with 2 and 3 fingers) grasps on demand. The stimulation sequence (protocol) for power and precision grasps was developed for each patient individually using the Compex Motion electric stimulator. Compex Motion is a fully programmable transcutaneous (surface) stimulator that uses self-adhesive surface electrodes.
89672980|NCT04751513|Experimental|Experimental group|The experimental group will receive acupressure on six auricular points.
89672981|NCT04751513|No Intervention|Control group|The control group will receive no intervention.
89672982|NCT00222131|Placebo Comparator|1|Placebo
89672983|NCT00222131|Active Comparator|2|Esomeprazole
89672984|NCT00225017|Experimental|A|"ARM A: Switch current PI to atazanavir 400 mg once daily plus current > 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) for 24 weeks.~Subjects currently on ritonavir (RTV) (400 mg BID or greater) or RTV-boosted PI (<400 mg/day) , or tenofovir (TDF) as backbone NRTI therapy, will switch to ATV 300 mg boosted with RTV 100mg once daily."
89672985|NCT00225017|Active Comparator|B|ARM B: Continue current antiretroviral regimen (single or RTV-boosted PI plus > 2 NRTIs) for 24 weeks
89672986|NCT01782963|Experimental|Treatment Arm|"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)~Consolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15"
89672987|NCT01829217|Experimental|Sunitinib|42 day cycle, taken orally every day for the first 28 days followed by 14 days off
89672988|NCT05327751|Active Comparator|Celecoxib arm|This arm will include 22 patients who will receive 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks) in addition to 200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle. The study duration will be the duration of the 6 cycles.
89672989|NCT05327751|Placebo Comparator|Control arm|This arm will include 22 patients who will receive 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks).
89672990|NCT02096861|Experimental|CT-P13 - CT-P13|CT-P13 followed by CT-P13 from Week 30
89672991|NCT02096861|Active Comparator|CT-P13 - Remicade|CT-P13 followed by Remicade from Week 30
89672992|NCT02096861|Active Comparator|Remicade - Remicade|Remicade followed by Remicade from Week 30
89672993|NCT02096861|Experimental|Remicade - CT-P13|Remicade followed by CT-P13 from Week 30
89672994|NCT01829919|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate) Capsules taken orally with 240 mL of water for 20 days.
89672995|NCT02097485|Active Comparator|Abametapir Lotion 0.74% w/w|Topically administered to hair and scalp for 10 minutes application.
89672996|NCT02097485|Placebo Comparator|Vehicle Lotion|Administered to scalp and hair for 10 minutes application.
89672997|NCT01829997|Experimental|nanOss Bioactive 3D BVF|Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
89672998|NCT05327517|Experimental|Surgery|Patients receive esophagectomy or neoadjuvant therapy plus esophagectomy
89672999|NCT05327517|Active Comparator|Definitive chemoradiotherapy|Patients receive definitive chemoradiotherapy
89673000|NCT02097641|Experimental|Human Mesenchymal Stromal Cells (hMSCs)|A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
89673001|NCT02097641|Placebo Comparator|Plasma-Lyte A (placebo)|A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes.
89673002|NCT04751903|Experimental|Oral motor stimulation|After the infants were assessed by a neonatologist, Oral motor stimulation was administered to the experimental group thrice a day (at 9:00, 12:00, 15:00 hours) for 15 minutes right before feeding, over a 14-day period.
89673003|NCT04751903|No Intervention|Control group|The preterm infant' the control group were only fed by the researcher thrice a day (at 9:00, 12:00, 15:00 hours) over a 14-day period.
89673004|NCT00274781|Experimental|ATO + GO|Arsenic Trioxide 0.25 mg/kg D1-5 Week 1/Twice Weekly W2-12 + Gemtuzumab Ozogamicin 3 mg/m^2 D8 for 1 or 2 Cycles of 12 Weeks each
89673005|NCT04752605|Experimental|Intervention|play sessions included as a part of normal early childhood education; parents' evening for all parents; parents' group for the parents of children that have difficulties in self-regulation and that are offered more individualized small group activity
89673006|NCT04752605|No Intervention|Control|normal early childhood education
89673007|NCT00278525|Experimental|stem cell trasplantation|intervention as stem cell transplantation after conditioning regimen
89673008|NCT00278525|Active Comparator|standard of care|medication as standard of care will be given
89673009|NCT00226577|Experimental|Pre-Surgery Chemotherapy|
89673010|NCT01830699|Active Comparator|Rilonacept|160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
89673011|NCT01830699|Placebo Comparator|Corticosteroid|80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once
89673012|NCT05327049|Experimental|no intervention|No Intervention: conventional selective caries removal without treatment After taking the first sample of dentin, the cavity will be restored
89673013|NCT05327049|Experimental|diode laser treatment|After selective caries removal the cavity was irradiated in contact mode with continuous wave of radiation through a 400µm flexible fiber that was inserted inside the cavity with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. Irradiation time was 15 seconds and repeated three times for 15 seconds interval with contact, pulsed mode and the output power was adjusted at 1.30 Watt.
89673014|NCT05327049|Experimental|Aloe Vera treatment|After selective caries removal the lesions were treated with aloe Vera paste which was prepared by mixing aloe Vera powder by distilled water until a thick paste is formed. the paste was applied to the prepared floor by condenser to cover the remaining carious lesion
89673015|NCT00280241|Experimental|FLUDARABINE, CYCLOSPHOSPHAMIDE AND RITUXIMAB|
89688716|NCT03035617|Placebo Comparator|Controlled Arm|Mesh will be soaked in normal saline solution as is routinely done.
89673016|NCT01830933|Experimental|BreastCARE Intervention|"Intervention Clinic Patients: The RA will welcome the patient upon arrival at the clinic and again explain study procedures and field any questions. The RA will have the patient sign the HIPAA authorization form and then demonstrate how to enter information and answer questions on the tablet-PC and the patient will indicate their consent electronically before beginning the assessment.~Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patietns before she meets with her doctor."
89673017|NCT01830933|No Intervention|BreastCARE Comparison|"Patients will be randomized into the intervention or comparison groups at the time of recruitment. Block-randomization will be used to assign patients to intervention or comparison groups.~Comparison Clinic Patients. Contact and baseline interview procedures will be the same for patients from the comparison clinics, however there will be no computer assessment at the time of their clinic visit. An RA will meet the patient 10 minutes prior to her appointment time to obtain written HIPAA authorization."
89673018|NCT01899755|Experimental|GSK2800528 Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
89673019|NCT01899755|Placebo Comparator|Placebo Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
89673020|NCT01899755|Active Comparator|Adalimumab Arm|In Cohort 4, all subjects will receive adalimumab 40 mg (0.8 mL solution) as subcutaneous injection
89673021|NCT01899833|Experimental|99mTc-EC-DG, Diagnostic|99mTc-EC-DG (25 ± 5 mCi, up to 250 µg EC-DG) will be administered by intravenous (IV) bolus injection. Other Name:Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose
89673022|NCT00229619|Experimental|Rituximab (Rituxan)|This is a non-randomized, off label, pilot study of humanized anti CD20 rituximab (Rituxan®) in patients with moderate aplastic anemia, pure red cell aplasia or Diamond-Blackfan anemia who have either failed to respond to at least one prior course of immunosuppressive therapy (PRCA/DBA patients only)or who have relapsed disease after prior immunosuppressive therapy (PRCA/DBA patients only).
89673023|NCT02260401|Experimental|Individualized report|Each patient in this group will receive an individualized report with their own outcome data (pain and function) during the first year of the LESS trial. They will receive these reports at 18 months.
89673024|NCT02260401|No Intervention|Individualized Reports after 24 months|Patients in this group will receive the individualized report, but will not receive it until after the conclusion of the study at 24 months. They will serve as the control group.
89673025|NCT05326737||The study population|The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program and for a predefined list of surgeries.
89673026|NCT00281021|Experimental|Erlotinib and Digoxin|Erlotinib plus Digoxin
89673027|NCT01786161|Experimental|Vancomycin with continuous infusion|24 hours continuous infusion
89673028|NCT01786161|Active Comparator|Vancomycin with intermittent dose interval|infusion rate 1000mg/hr
89673029|NCT00230009|No Intervention|Assessment only|
89673030|NCT00230009|Experimental|Brief intervention session|
89673031|NCT01898663|Experimental|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DCs + CIK cells
89673032|NCT01786239|Experimental|Omega-3 capsules & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
89673033|NCT01786239|Other|Placebo & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
89673034|NCT00282815|Active Comparator|1|CPAP
89673035|NCT00282815|Sham Comparator|2|sham CPAP (placebo)
89673036|NCT01787175|Experimental|Integrated Medication Manager|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
89673037|NCT01787175|No Intervention|Standard EHR|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
89673038|NCT01832259|Placebo Comparator|Placebo arm|Participants receiving placebo
89673039|NCT01832259|Experimental|Pazopanib arm|Participants receiving Pazopanib
89673040|NCT01832961|Experimental|flutter valve exercises|30 minutes of breathing exercises with flutter device
89673041|NCT01832961|Sham Comparator|flutter-sham exercises|30 minutes of breathing exercise with flutter-sham device
89673042|NCT01833117|Experimental|FID 119515A|FID 119515A, 1 drop instilled in the study eye, single dose
89673043|NCT01833117|Active Comparator|Blink|Blink® Tears, 1 drop instilled in the study eye, single dose
89673044|NCT01833741|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
89673045|NCT05326503|Experimental|Meal with polyphenol supplement (PPS)|Iron-rich test meal labelled with stable iron isotope as ferrous sulfate, consumed with the polyphenol supplement.
89673046|NCT05326503|Placebo Comparator|Meal with placebo|Iron-rich test meal labelled with stable iron isotope as ferrous sulfate, consumed with placebo supplement (maltodextrin).
89673047|NCT05326503|Experimental|Drink with PPS|Iron-fortified drink labelled with stable iron isotope as ferrous sulfate, consumed with the polyphenol supplement.
89673048|NCT05326503|Placebo Comparator|Drink with placebo|Iron-fortified drink labelled with stable iron isotope as ferrous sulfate, consumed with placebo supplement (maltodextrin).
89214874|NCT05709470||Children and adolescents with congenital heart defects|Children and adolescent between 5-18 years of age, born with a congenital heart defect, living in Denmark at the inclusion time. A parent to each child/adolescent should also participate. Participants are found though the Danish registries by a diagnosis of congenital heart defect. The diagnosis of Congenital Heart Defect most be giving at one of the four University Hospitals in Denmark. These criteria were applied to ensure the validity of the diagnoses.
89522405|NCT03410147|Other|Concentration B|Concentration of 13C-sodium octanoate in enteral nutrition is 1.0 mg/ml
89522406|NCT03410147|Other|Concentration C|Concentration of 13C-sodium octanoate in enteral nutrition is 3.0 mg/ml
89522407|NCT03399955|Experimental|Arm 1: Paromomycin + Miltefosine|Paromomycin 20 mg/kg/d IM for 14 days combined with Miltefosine allometric BID PO dosing for 42 days
89522408|NCT03399955|Experimental|Arm 2: Ambisome + Miltefosine|AmBisome® 5mg/kg/d IV infusion at D1, D3, D5 and D7 (20 mg/kg total dose) combined with Miltefosine allometric BID PO dosing for 28 days
89522409|NCT03397199|Experimental|Apatinib + S-1|Apatinib + S-1
89522410|NCT01932645||Prostatitis patients|We will enroll patients from the outpatient clinic who are suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation). Patients with these symptoms and identified as having prostatitis will be approached to enroll.
89522411|NCT01932645||Controls|Male patients seen in the outpatient clinic who do not have prostatitis (not suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), and do not have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation)) will be approached to enrol as controls.
89522412|NCT04708327|Placebo Comparator|Placebo|Dosing Period 1: Placebo (five capsules) Dosing Period 2: Placebo (one capsule)
89522413|NCT04708327|Experimental|STAT-205|Dosing Period 1: 22.5 mg STAT-205 (five 4.5 mg capsules) Dosing Period 2: 4.5 mg STAT-205 (one capsule)
89522414|NCT04651361|Active Comparator|Naldebain group|Patients assigned to Naldebain® group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance.
89522415|NCT04651361|Placebo Comparator|Placebo group|Patients assigned to placebo group will receive a single intramuscular injection of 2 ml solvent containing benzyl benzoate and sesame oil into the gluteus muscles under ultrasound-guidance.
89522416|NCT03397043|Experimental|Healthy females|All participants receive the intervention: Protein intake (dose). This consists of varying levels of dietary protein intakes, in the form of crystalline amino acids, ranging from 0.2-3.0 g/kg/d
89522417|NCT03396965|Experimental|Mini-c-arm|Fluoroscopically aided reductions
89522418|NCT03396965|No Intervention|Standard|
89522419|NCT05184309|Experimental|Conventional exercise group|Conventional Exercises
89522420|NCT05184309|Experimental|Serious game group|Serious Games
89522421|NCT03396887|Experimental|Smartphone Application Users|"The experimental group will receive the smartphone intervention along with treatment as usual for 3-months. The smartphone application (UControlDrink) includes twice daily text message recovery support, relapse prevention cognitive behavioural therapy, 12 sessions in total, drinking and recovery activity logs where participants detail their abstinence, drinking and recovery activity engagement on a daily basis. Craving intervention in the form of a calm button to deal with cravings and prevent relapse and gamification, a system of encouraging positive behaviour with the awarding of points to achieve various status levels, is used to increase adherence and compliance with treatment recommendations."
89522422|NCT03396887|Active Comparator|Control Group|The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
89522423|NCT03399877|Active Comparator|Combining electromygraphy with uroflowmetry|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography
89522424|NCT03399877|Active Comparator|Uroflowmetry|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform uroflowmetry solely.
89522425|NCT03399877|Experimental|Uroflowmetry-Combining electromygraphy with uroflowmetry|Children who assigned Group C firstly perform uroflowmetry solely. and subsequently perform uroflowmetry-electromyography.
89522426|NCT05110807|Experimental|TQB3617|0.1mg, once daily, was used as the initial dose, and the medication stage was divided into single administration and continuous administration stages. The single administration was given once, and the continuous administration stage was entered 7 days after drug withdrawal. The drug was administered continuously until the disease progressed.
89522427|NCT04566965||Full-Time CCHMC Employees|All CCHMC full-time residents and fellows who have some direct contact with patients and their families as part of normal workplace duties.
89522428|NCT04353765||cabozantinib arm|
89522429|NCT04353765||non cabozantinib Tyrosine Kinase Inhibitors (TKI) arm|
89522430|NCT03410069|Experimental|IKORUS UP|
89522431|NCT04010097|Experimental|Horton group|The test involves chewing a chewing gum for 4 minutes plus a standard Horton disease diagnostic
89522432|NCT04010097|Active Comparator|N Horton Group|The test involves chewing a chewing gum for 4 minutes
89522433|NCT03407573|Active Comparator|Restrictive|Restrictive transfused when Hb at or below 70
89522434|NCT03407573|Active Comparator|Liberal|Will receive blood transfusion when Hb drops below or equal to 90
89522435|NCT03289065||FOS Participant|FOS is a disease registry open to all Fabry participants irrespective of treatment status or type of treatment.
89522436|NCT03393247|Active Comparator|infliximab and azathioprine at week 0|infliximab and azathioprine combination at week 0
89522437|NCT03393247|Active Comparator|infliximab and azathioprine at week 14|infliximab and azathioprine combination at week 14
89522438|NCT03407027|Experimental|Quadratus triamcinolone|Quadratus lumborum muscle and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
89522439|NCT03407027|Experimental|Gluteus triamcinolone|Gluteus maximus and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
89522440|NCT03407027|Active Comparator|Quadratus without triamcinolone|Quadratus lumborum muscle and fascia infiltration with 10ml of levobupivacaine 0,25%.
89049652|NCT02885935|Experimental|Elevated protein intake|Subjects consumed diets with a macronutrient distribution of 20% protein, 45% carbohydrates and 35% fat for 4 weeks.
89049653|NCT05424458|Experimental|single-arm|"Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.~In the first month after definitive prosthesis placement, patients were recalled to complete the MDAS, OES and OHIP questionnaires for the second time. Changes of overall MDAS, OSE and OHIP score were defined as the score after definitive prosthesis placement minus that before the treatment. Negative score changes indicated score decrease of the second questionnaire compared to the first one. Positive score changes indicated score increase."
89673049|NCT05323929|Experimental|deep ESD group|Performed according to the ESD standard procedure, the depth of dissection includes the SM3 layer (submucosa 1/3 layer)
89049654|NCT04618380||Bilateral trifocal implantation|Bilateral implantation of trifocal diffractive intraocular lenses (Panoptix, Alcon) targeting emmetropia
89049655|NCT04618380||Myopic monovision|The dominant eye defocus is targeted to -0.50 diopters while the recessive one to -1.25 diopters with bilateral implantation of monofocal intraocular lenses (SN60WF, Alcon)
89673050|NCT05323929|Experimental|shallow ESD group|Performed according to the ESD standard procedure, the depth of dissection does not include the SM3 layer (submucosa 1/3 layer)
89673051|NCT02261727|Placebo Comparator|Placebo|Placebo theophylline, one tablet twice daily, and Placebo prednisone, one tablet once daily
89673052|NCT02261727|Active Comparator|Low-dose theophylline arm|Theophylline 100 mg twice daily
89673053|NCT02261727|Active Comparator|Theophylline and Prednisone arm|Theophylline 100 mg twice daily plus prednisone 5 mg once daily
89673054|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 1|Ganetespib 100 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
89673055|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 2|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
89673056|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase II Expansion|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
89673057|NCT02261961|Experimental|Nutritional Supplement|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
89673058|NCT02261961|Placebo Comparator|Placebo|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
89673059|NCT01835379|Experimental|Oasis|Oasis
89673060|NCT01835379|Other|Standard|Standard Care
89673061|NCT05300841|Active Comparator|Dydrogesterone group|Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
89673062|NCT05300841|Active Comparator|Dydrogesterone plus estradiol valerate group|will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
89673063|NCT00232505|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.
89673064|NCT00232505|Experimental|Cetuximab and Carboplatin|Patients receive cetuximab as in arm I and carboplatin IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89673065|NCT01787799|Experimental|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)
89673066|NCT00232583|Active Comparator|Metfomin and Insulin|Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration
89673067|NCT00232583|Active Comparator|Metformin, Pioglitazone and Glyburide|Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration
89673068|NCT00232739|Experimental|1|
89673069|NCT01895387|Experimental|Whole grains and legumes|
89673070|NCT01895387|Placebo Comparator|Refined rice|
89049656|NCT04618380||Hybrid monovision|Hybrid monovision combines a monofocal intraocular (SN60WF, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one
89049657|NCT04618380||Premium monovision|Participants received a bifocal hybrid (refractive at the centre, diffractive at the periphery) intraocular lens (Restor +2.50 diopters, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one, targeting emmetropia in both eyes.
89673071|NCT01789905||Tigecycline (Tygacil)|Subjects who are treated with tigecycline
89673072|NCT01790685|Other|CRVO|Central Retinal Vein Occlusion
89673073|NCT01790685|Other|BRVO|Branch Retinal Vein Occlusion
89673074|NCT00233519|Experimental|Cohort 1- Two Escalating Doses of Iplex|0.5 and 1.0 mg/kg/day
89673075|NCT00233519|Active Comparator|Cohort 2 - Three Escalating Doses of Iplex|0.5, 1.0, and 2.0 mg/kg/day
89673076|NCT01435772|Experimental|BMN 701 20mg/kg|BMN 701 20mg/kg IV every other week
89673077|NCT01435772|Experimental|BMN 701 10mg/kg|BMN 701 10mg/kg IV every other week
89673078|NCT01435772|Experimental|BMN 701 5mg/kg|BMN 701 5mg/kg IV every other week
89049658|NCT05424107|Experimental|Non-nutritional intervention|Children with a prediabetic status that followed up the sessions without nutritional intervention by a health care professional
89049659|NCT04652232|Active Comparator|Treated group|This group will receive the RV3466F lotion and a neutral shampoo
89049660|NCT04652232|Other|Control group|This group will receive a neutral shampoo
89049661|NCT04652349|Experimental|HGP1910|
89673079|NCT01691261|Experimental|Treatment|PF-05206388 Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane
89673080|NCT01838655|Experimental|Nitisinone|Oral administration of nitisinone
89673081|NCT00050089|Active Comparator|No ARDFP+Standard-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Standard-ART
89673082|NCT00050089|Active Comparator|No ARDFP+Mega-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Mega-ART
89673083|NCT00050089|Active Comparator|ARDFP+Standard-ART|Antiretroviral Drug-Free Period (ARDFP) and Standard-ART
89673084|NCT00050089|Active Comparator|ARDFP+Mega-ART|Antiretroviral Drug-Free Period (ARDFP) and Mega-ART
89673085|NCT00282971|Experimental|Inhaled Insulin|Inhaled insulin plus oral therapy
89673086|NCT00282971|Other|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
89673087|NCT01791049|Experimental|Active|Single escalating doses of TD-1607, administered intravenously
89673088|NCT01791049|Placebo Comparator|Placebo|Placebo
89673089|NCT05202093|Experimental|Electric toothbrush A|Use Oclean electric toothbrush A to brush teeth twice daily for 8 weeks
89673090|NCT05202093|Active Comparator|Manual toothbrush|Use Oral B manual toothbrush to brush teeth twice daily for 8 weeks
89673091|NCT05202093|Experimental|Electric toothbrush B|Use Oclean electric toothbrush B to brush teeth twice daily for 8 week
89673092|NCT04027153|Experimental|Fee Arm|Participants in this arm will pay a fee (based on an income sliding scale) to have their medication delivered to their location of choice.
89673093|NCT04027153|Active Comparator|Standard of Care Arm|Participants in this arm will pick up their medication refill at the local clinic
89673094|NCT01791465|Experimental|Bydureon treatment|Treatment for 16 weeks with extended-release Exenatide (Bydureon)
89673095|NCT00283283|Experimental|Male, Age 18 -49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
89673096|NCT00283283|Experimental|Male, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
89673097|NCT00283283|Experimental|Female, Age 18 - 49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
89673098|NCT00283283|Experimental|Female, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
89673099|NCT00283283|Experimental|Male, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
89673100|NCT00283283|Experimental|Male, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
89673101|NCT00283283|Experimental|Female, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
89673102|NCT00283283|Experimental|Female, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
89673103|NCT04484701||PSMA-11 PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
89049662|NCT04652349|Experimental|HCP1903|
89049663|NCT04652349|Active Comparator|HGP1909|
89049664|NCT04652349|Active Comparator|HGP1911|
89673104|NCT00285467|Experimental|Doxercalciferol|doxercalciferol 1 mcg capsule orally daily for 3 months. This is a form of vitamin D that does not require activation by enzymes in the liver and kidney.
89673105|NCT00285467|Active Comparator|Cholecalciferol|cholecalciferol 4000 IU capsule orally daily for one month, then 2000 IU capsule daily orally for 2 months. this form of vitamin D requires activation by cells of the body.
89673106|NCT05198193|Experimental|Control - Older Adults|Participants age 60 years old or above.
89673107|NCT05198193|Experimental|Positive - Older Adults|Participants age 60 years old or above.
89673108|NCT05198193|Experimental|Negative - Older Adults|Participants age 60 years old or above.
89673109|NCT05198193|Experimental|Control - Younger Adults|Participants age between 30 and 59 years old.
89673110|NCT05198193|Experimental|Positive - Younger Adults|Participants age between 30 and 59 years old.
89673111|NCT05198193|Experimental|Negative - Younger Adults|Participants age between 30 and 59 years old.
89673112|NCT00281671|Placebo Comparator|Placebo|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
89673113|NCT00281671|Experimental|Nesiritide|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
89673114|NCT05171439|Experimental|Surufatinib|All subjects will receive study treatment in 28-day cycle, Surufatinib 300mg, orally, QD , the treatment will continue until one of the following conditions occurs: progression of disease, death, intolerable toxicity, or the end of study treatment (as other criteria specified in the protocol are met), whichever occurs first.
89673115|NCT01688765||First Episode Psychosis Patients|Individuals experiencing a first episode of psychosis
89673116|NCT01688765||Healthy Controls|Psychiatrically healthy individuals
89673117|NCT05247593||Dayingpian exposure group 1|The exposure of interest is Dayingpian. Patients in this group take Dayingpian combined with conventional mood stabilizers. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
89673118|NCT05247593||Non-exposure group|The non-exposure group is the patients who do not take Dayingpian. Patients in this group take conventional mood stabilizers. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
89688717|NCT03035617|Experimental|Intervention Arm|Mesh will be soaked in .5% bupivacaine solution before application.
89049665|NCT01188811|Experimental|Arm 1: lipoic acid|28 subjects receive oral lipoic acid 1200mg daily
89049666|NCT01188811|Placebo Comparator|Arm 2: placebo|28 subjects receive placebo daily
89049667|NCT01183234|Experimental|SPD544 (Equasym XL)|
89049668|NCT01183234|Experimental|Methylphenidate hydrochloride (Metadate CD )|
89673119|NCT05247593||Dayingpian exposure group 2|The exposure of interest is Dayingpian. Patients in this group take Dayingpian as monotherapy for bipolar disorder. The psychiatrist does not assign specific interventions to the study participants. The course of observation is 12 weeks.
89673120|NCT01676753|Experimental|Treatment (Dinaciclib, Pembrolizumab)|Pembrolizumab will be administered on Day 1, every 3 weeks at a fixed dose of 200 mg IV. Dinaciclib will be administered D1 and D8 of a 21 day cycle by 2-hour intravenous infusion starting at Dose Level (DL) 1 of 12 mg/m^2. Further dose escalation cohorts are defined as follows: DL 2: 18 mg/m^2, DL 3: 25 mg/m^2, DL 4: 33 mg/m^2, and DL 5: 50 mg/m^2
89673121|NCT01794039|Experimental|Arm A (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may crossover to arm B.
89673122|NCT01794039|Experimental|Arm B (pomalidomide, dexamethasone)|Patients receive pomalidomide PO daily on days 1-21 and dexamethasone as in arm A. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89673123|NCT00281827|Experimental|Treatment Arm|Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.
89673124|NCT00235547|Active Comparator|contraception-Immediate start|contraception after abortion and before leaving the clinic, observed by clinic staff
89673125|NCT00235547|Active Comparator|Contraception-Delayed start|instructed to begin contraception the first Sunday after leaving the clinic
89673126|NCT01898741|Experimental|irradiation|24 Gy in 3 fractions
89673127|NCT00282841|Experimental|All stroke code patients|After written informed consent Code Stroke patients will undergo a contrast-enhanced transcranial ultrasound study to visualize the intracranial arteries. To do so, an ultrasound contrast agent (Definity) will be administered intravenously and transcranial ultrasound will be applied via the temporal bone window on both sides. Goal is to visualize and assess the intracranial arteries bilaterally. This includes the following vessel segments on both sides: middle cerebral artery (M1,M2,M3 segments), anterior cerebral artery (A1,A2 segments), posterior cerebral artery (P1,P2 segments), internal carotid artery (C1/2,C3/4 segments).
89673128|NCT05144451|Experimental|TCD arm|All patients will be evaluated with TCD for prediction of the post-transplant neurological complications
89673129|NCT01898819|Experimental|dexmedetomidine|dexmedetomidine infusion from beginning of the anesthesia to just before returning to horizontal position
89673130|NCT01898819|Placebo Comparator|saline|Saline infusion from same time period.
89673131|NCT05142657||Case|Patients who have gallstone pancreatitis
89673132|NCT05142657||Control|Patients who have only gallstone
89673133|NCT00283075|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
89673134|NCT01794741|Active Comparator|Dymista nasal spray|azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months
89673135|NCT01794741|Active Comparator|fluticasone propionate nasal spray|fluticasone propionate nasal spray 50mcg per spray per nostril twice a day
89673136|NCT05091801|Experimental|Control + Intervention|We will explore our hypothesis using a fixed-order within-subjects study design in a group of healthy participants. Each participant will have one week of normal dietary habits and one week of increased chewing time. We will collect stool samples three times per week in order to measure microbial abundance and metabolism.
89673137|NCT00283933|Experimental|Migalastat|Migalastat 150 milligrams (mg) was administered orally QOD during the 24-week treatment period and then during the optional 24-week extension period.
89673138|NCT04446871|Placebo Comparator|Standard care|Placebo
89673139|NCT04446871|Experimental|Methylene blue|Methylene blue
89673140|NCT01791283||Healthy volunteers|Healthy volounteers with no previous medical history, age between 20-40. Both male and female. Subjects are provided extensive information about the study and the obligations and expectations included. All subjects sign a witnessed informed consent before inclusion.
89673141|NCT01795833|Experimental|Text Messages|Short text messages related to healthy lifestyle will be sent to half the subjects three times per week, in addition to one off 'one-to-one structured education' during the study period.
89673142|NCT01795833|No Intervention|Control|Half of the subjects who has received only one off 'one-to-one structured education about healthy lifestyle during the study period
89673143|NCT04752787|Experimental|Experimental|Experimental group 1: Breastfeeding training for successful breastfeeding in twin babies will be given to the online training group. The training will be carried out by the researchers (DM) and (SYC) using visual training tools (power point presentation, simultaneous breastfeeding animations in twin babies and breastfeeding guide). Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. In the first session, about 45 minutes of online slide-assisted training on successful breastfeeding in twin babies and the importance of breast milk will be conducted and questions of pregnant women will be answered. Total training will take approximately one and a half hours.
89673144|NCT04752787|Active Comparator|Active comparator|"Experimental group 2: Breastfeeding training for successful breastfeeding in twin babies will be given to the QR supported online training group. Due to the Covid-19 pandemic process, it will be carried out online and remotely. Training on successful breastfeeding in twin babies will be carried out in two sessions at a time. Total training will take approximately one and a half hours.~In the guideline, there will be 4 vieos ralted to Breastfeeding and Feeding with Breast Milk in Twin Babies, Breastfeeding Techniques and Positions in Twin Babies, Expressing Breastfeeding, Storing and Feeding it to Babies and Problems Encountered in Breastfeeding and its Solutions, and simultaneous breastfeeding used in breastfeeding twin babies and also there will be a total of 7 QR codes, 3 of which are related to the animations (Animation 1-2-3) of the positions (double cradle grip, double football grip, combination of armpit and cradle grip-parallel grip)."
89673145|NCT04752787|No Intervention|Control Groups|Pregnant women in the control group will be followed up in line with the routine health monitoring and information of the hospital.
89673146|NCT01899859|Active Comparator|Cohort 1|Patient receives dose of GR-MD-02 or placebo
89673147|NCT01899859|Active Comparator|Cohort 2|Patient receives dose of GR-MD-02 or Placebo
89673148|NCT01899859|Active Comparator|Cohort 3|Patient receives dose of GR-MD-02 or placebo
89673149|NCT01841619|Active Comparator|IVIg as a monotherapy|IVIg will be used as a first line treatment. Topical treatment will be stopped at the beginning of IVIg therapy.
89673150|NCT00284557|Experimental|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
89673151|NCT00284557|Active Comparator|Health education materials only|Those allocated to Group 2 were provided with a standardized packet of health education materials addressing the recommended items from the expert committee guidelines (e.g., dietary recommendations using the Food Guide Pyramid and the Traffic Light Diet, a general prescription to increase physical activity to 60 minutes daily). They were also given a community resource list that provides contact and program information for community-based obesity treatment activities in their area.
89673152|NCT04085419|Active Comparator|denosumab|denosumab 60 mg subcutaneously every 6 months
89673153|NCT04085419|Active Comparator|zoledronic acid|zoledronic acid 5 mg intravenously once a year
89673154|NCT02989623|Experimental|Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)|Patients receive copper Cu 64 TP3805 IV over 5 minutes and 30 minutes and 2 hours later, undergo whole body Positron Emission Tomography/Computed Tomography (PET/CT) imaging over 1 hour.
89673155|NCT02263131|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
89673156|NCT02263131|Active Comparator|TIV PFS|VAXIGRIP Prefilled Syringe INJ.
89673157|NCT02033005||Breastfed infants|>80% of feeds consisting of breast milk at both scanning points
89673158|NCT02033005||Formula-fed infants|>80% of feeds consisting of formula milk at both scanning points
89673159|NCT02033005||Mixed-fed infants|20%-80% of feeds consisting of breast milk.
89673160|NCT02263833||Overall Participants|Participants not previously on erythropoietin-stimulating agent (ESA) therapy and participants on ESA therapy who were switched to Mircera
89673161|NCT04400617||Assisted-living residents|The target population will be inactive men and women residents of the Brenda Strafford Foundation (> 50 yrs. old). We expect the participants to be classified as inactivity, which will be defined as an engagement in < 3 sessions/week of 20 min or more of vigorous exercise. Participants should be able to move independently without the assistance of a wheelchair.
89673162|NCT04400617||Control group|Volunteers from the Brain in Motion II (BIM II) study (NCT03035851). The BIM II study aims to examine the mechanisms whereby exercise may improve sleep and cognition in men and women aged 50 to 80 years old. As the baseline measurements of the BIM II study are similar to the assessments proposed in this study, the assisted living residents will be matched with older individuals of the same age and cognitive performance who live independently to answer the last research question.
89673163|NCT02263911|Experimental|Baricitinib Test Treatment 1 (T1)|Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
89673164|NCT02263911|Experimental|Baricitinib Reference Treatment 1 (R1)|Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
89673165|NCT02263911|Experimental|Baricitinib Test Treatment 2 (T2)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
89673166|NCT02263911|Experimental|Baricitinib Reference Treatment 2 (R2)|Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
89673167|NCT02263911|Experimental|Baricitinib Test Treatment 2 with Meal (T2F)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods.
89673168|NCT00052429|Experimental|High-Dose Radiation Therapy Plus Chemotherapy|"Phase I~Radiotherapy: Patients receive radiotherapy once daily 5 days a week for 6 weeks beginning on day 1.~Concurrent chemotherapy: Patients receive cisplatin IV over 20-30 minutes on days 1-5 and 22-26.~Adjuvant chemotherapy: Approximately 2-5 weeks after the completion of radiotherapy, patients receive fluorouracil IV continuously on days 1-4 and cisplatin IV over 20-30 minutes on days 1-5 and 22-26. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. In the absence of dose-limiting toxicity in 1 whole cohort of patients, study proceeds to phase II. Phase II~Patients are treated as in phase I. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter."
89673169|NCT01435616|Experimental|LY2605541|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the personal physician, for 52 or 78 weeks
89673170|NCT01435616|Active Comparator|Glargine|Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks
89673171|NCT03972397|Experimental|Intercostal Nerve Cryoablation plus SOC Pain Control|Standard of Care (SOC)
89673172|NCT03972397|Active Comparator|Standard of Care (SOC) Pain Control|
89673173|NCT01797159|Experimental|Hippocampal-sparing PCI|Hippocampal-sparing PCI 25 Gy in 10 fractions
89673174|NCT03722797||Unilateral Transtibial Amputation|Individuals with a unilateral, transtibial amputation.
89673175|NCT03722797||Controls|Healthy adults without a lower-limb amputation who have been matched to participants in the Unilateral Transtibial Amputation group based on age, sex, and body mass index.
89673176|NCT01797471|Experimental|LEAD RT|"Lattice Extreme Ablative Dose (LEAD) Radiation Therapy (RT) on Day 1 at dose of 18 Gy followed by;~Conventionally fractionated radiation therapy beginning on day 2 at 2 Gy per fraction for 30 fractions for a total dose of 60 Gy;~Conventional Platinum Chemotherapy Doublet at discretion of treating physician beginning on day 2."
89673177|NCT00286741|Experimental|Medical group visits|Medical group visits
89673178|NCT00286741|No Intervention|Treatment as Usual control|control
89049669|NCT04618497|Experimental|Inhalational methoxyflurane (Penthrox)|
89049670|NCT04618497|Active Comparator|Intramuscular ketorolac|
89673179|NCT04351035||Children with CNS tumours|Patients newly diagnosed with CNS tumours in children younger than 18 y/o, who were under in-patient treatment, were labeled as candidate cases in the CNOG-MC001 cohort for reviewing.
89673180|NCT00287053|Experimental|Placebo|Divalproex Sodium
89673181|NCT00287053|Placebo Comparator|Placebo Comparator|Placebo Comparator
89673182|NCT01842789|Other|Acessa Procedure w/o TAG|Acessa Procedure without the use of Targeting Animation Guidance
89673183|NCT01842789|Other|Acessa Procedure with TAG|Acessa Procedure with Targeting Animation Guidance
89673184|NCT01435460|Experimental|Alrex|Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%
89673185|NCT01435460|Active Comparator|Patanol|Ophthalmic solution containing olopatadine, 0.1%
89673186|NCT00236951|Active Comparator|Venofer + erythropoietin (responders)|
89673187|NCT00236951|Active Comparator|erythropoietin only (responders)|
89673188|NCT00236951|Active Comparator|Venofer+erythropoietin(non-responders)|
89673189|NCT00236951|Active Comparator|erythropoietin only (non-responders)|
89673190|NCT00287287|Experimental|Lenalidomide (Revlimid)|Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.
89673191|NCT04871061|Active Comparator|PENG Block|For patients with hip fracture and having hip surgery this study evaluates the analgesic effects of Pericapsular Nerve Group (PENG) block for positioning before spinal anesthesia.
89673192|NCT04871061|Active Comparator|Control|in this group, standardised opioid doses (drug: Fentanyl) will be used for analgesia for positioning pain
89673193|NCT01844193|No Intervention|Standard Therapy|This arm of the study will follow the standard therapy course after total knee arthroplasty.
89673194|NCT01844193|Experimental|Standard Therapy + NMES|This arm will follow the standard course of therapy but also incorporate daily neuromuscular electrical stimulation into the daily therapy regimen after total knee arthroplasty through use of the Compex Rehab device.
89673195|NCT00287989|Experimental|150 PRE|Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2
89673196|NCT00287989|Experimental|1,500 PRE|Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2
89673197|NCT00287989|Experimental|1,500 POST|Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.
89673198|NCT01798641|Experimental|Open Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be open at this time. The adjustment is done in the out-patient clinic.
89673199|NCT01798641|Placebo Comparator|Closed Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be closed during this time. The adjustment is done in the out-patient clinic.
89673200|NCT04829409|Active Comparator|paravertebral block|Patients receive ultrasound-guided paravertebral block
89673201|NCT04829409|Active Comparator|ESP block|Patients receive ultrasound-guided erector spinae plane (ESP) block
89673202|NCT04829409|Experimental|MTP block|Patients receive ultrasound-guided mid-point transverse process to pleura (MTP) block
89673203|NCT00288067|Experimental|Treatment (fenretinide, rituximab)|"PHASE I: Patients receive fenretinide PO BID on days 1-5. Treatment repeats weekly for at least 4 weeks in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive fenretinide PO BID on days 1-5 in weeks 1-8 and rituximab IV once weekly in weeks 5-8. Treatment continues in the absence of disease progression or unacceptable toxicity."
89673204|NCT00285779|Placebo Comparator|Placebo injection|patients receive normal saline injection twice weekly for weeks 1-12
89673205|NCT00285779|Experimental|Etanercept|patients receive etanercept injection twice weekly for weeks 1-12.
89673206|NCT04350333|Experimental|CBT-I group|Five sessions composed of: psychoeducation on sleep change during pregnancy and postpartum; sleep hygiene principles; stimulus control technique, sleep restriction technique (f this technique will be too difficult for the participants to be apply, a replacement and less disabling technique will be applied: sleep compression); psychoeducation on the child's sleep at birth and on the change in the sleep-wake cycle in the early stages of the child's life; cognitive control technique; cognitive reconstruction technique and de-catastrophization; relapses prevention.
89673207|NCT04350333|Active Comparator|Assertive communication training|Five sessions composed of: psychoeducation and explanation of the importance of emotional and cognitive factors for good sleep. Psychoeducation about the concept of assertiveness, explanation of the passive, aggressive and assertive style; explanation and exercises regarding self-esteem and positive self-image; explanation of the development of sleep of the child in the first years of life; explanation and exercises on the phase of the management of feedback and requests; conflict management; relapses prevention.
89673208|NCT02104141||Operated Subjects|ROIA Interbody Cage with VerteBRIDGE plating
89673209|NCT02983175|Experimental|ultrasound assessment of gastric content|
89673210|NCT01435382|Experimental|Group A|
89673211|NCT01435382|Experimental|Group B|
89673212|NCT01435382|Experimental|Group C|
89673213|NCT01435382|Experimental|Group D|
89673214|NCT01801449|Experimental|Rilonacept Treatment|Rilonacept loading dose of 4.4 mg/kg/week followed by maintenance dose of 2.2 mg/kg/week. Total duration of the study 24 months. Maintenance dose could be escalated to 4.4 mg/kg/week or further to 6.6 mg/kg/week for 3 months only.
89673215|NCT03596203|Experimental|Treatment group|
89673216|NCT00286325|Experimental|Treatment Rituximab|Open label study all subjects treated with rituximab
89673217|NCT00289315|Experimental|Arm 1|Primary (Environmental) Prevention of Weight Gain
89673218|NCT00289315|Experimental|Arm 2|Primary (Envrironmental) and Secondary (Behavioral) Weight Gain Prevention Program
89673219|NCT00289315|Experimental|Arm 3|Control - no Environmental or Behavioral Program intervention
89673220|NCT04502810|Experimental|High-level laser therapy|Real high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
89673221|NCT04502810|Sham Comparator|Sham High-level laser therapy|Sham high-level laser therapy laser 12 biweekly sessions (6 consecutive weeks of biweekly treatments)
89673222|NCT00238355|Experimental|Voriconazole plus Caspofungin|
89673223|NCT01802151|Placebo Comparator|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules once daily for 4 weeks.
89673224|NCT01802151|Experimental|B. subtilis R0179 (10 billion CFU)|"B. subtilis R0179 (approximately 10 billion CFU/capsule) once daily for 4 weeks.~* CFU (Colony Forming Unit)"
89673225|NCT01802151|Experimental|B. subtilis R0179 (1 billion CFU)|B. subtilis R0179 (approximately 1 billion CFU/capsule) once daily for 4 weeks.
89673226|NCT01802151|Experimental|B. subtilis R0179 (0.1 billion CFU)|B. subtilis R0179 (approximately 0.1 billion CFU/capsule) once daily for 4 weeks.
89673227|NCT00289471||Cognitive Screening|Cognitive screening
89688718|NCT02245633||vitamin D levels deficient|Diabetic hemodialysis patients with vitamin D levels deficient
89673228|NCT01414166|Experimental|ERN/LRPT group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive ERN/LRPT for 16 weeks.
89673229|NCT01414166|Placebo Comparator|Placebo group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive placebo for 16 weeks.
89673230|NCT01898975||500ml fluid loading|All enrolled patients
89673231|NCT01791439|Experimental|Lidocaine|Patients in this arm will have gauze soaked with lidocaine applied to the peritonsillar pillars.
89049671|NCT05423873|Other|Vitamin C Serum and Moisturizing Sunscreen SPF 45|"Dual Regimen:~Vitamin C Serum Tinted Moisturizing Sunscreen SPF 45"
89049672|NCT04618575|Experimental|Ursodeoxycholic acid combined with total glucosides of paeony|
89673232|NCT01791439|Placebo Comparator|Saline|Application of saline to the glossopharyngeal nerve.
89673233|NCT01434680|Experimental|MenC-CRM LIQ (Liquid Formulation)|Subjects received 1 injection of MenC-CRM vaccine,liquid formulation.
89673234|NCT01434680|Experimental|MenC-CRM ROS (Rosia)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy
89673235|NCT01434680|Active Comparator|MenC-CRM EMV (Emeryville)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA
89673236|NCT00290329|Experimental|Group A|
89673237|NCT04058678|Sham Comparator|CONTROL|"A control group composed of women with normal ovarian reserve (30 to 45 yerras old) is needed to compare telomeric and fertility parameters with the group of women with compromised ovarian reserve. Note that the term normal ovarian reserve referred to older women indicates women that still have follicles in their ovaries -and thus, normal AMH values-, even though the number may be lower tan at a younger age or the quality of oocytes may be lower tan in younger women. In other words, women in the control group irrespective of their age, will have a greater number of follicles compared to women belonging to the group with compromised ovarian reserve."
89673238|NCT04058678|Experimental|EXPERIMENTAL|A group of women with diminished ovarian reserve that will take an inactive substance has been included to avoik biases and to set the fertility base line for women with compromised ovarian reserve.
89673239|NCT00286949|Other|Atomoxetine (Strattera)|Open-Label Uncontrolled Active Drug Intervention, No comparator
89673240|NCT00291343|Experimental|TRITANRIX™-HEPB/HIB-MENAC +MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses of Tritanrix™-HepB/Hib-MenAC vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one booster dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
89673241|NCT00291343|Active Comparator|TRITANRIX™-HEPB/HIBERIX™+MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses Tritanrix™-HepB/Hiberix™ vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
89673242|NCT04751981|Experimental|Patient Specific Guide|Patients randomized into this group will have pedicle screws placed with the aid of patient specific surgical guides.
89673243|NCT04751981|Other|Navigation|Patients randomized into this group will have pedicle screws placed with conventional navigation.
89673244|NCT00287339|Experimental|1|40mg Esomeprazole BID
89673245|NCT00287339|Placebo Comparator|2|placebo capsules
89673246|NCT00291655|Experimental|Levetiracetam (LEV)|
89673247|NCT03380221|Experimental|Watermelon|
89673248|NCT03380221|Active Comparator|Low fat cookies|
89673249|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh A|Participants with chronic liver disease and classified as Child-Pugh Grade A had a score of 5-6 (out of 15) which correlates with a good prognosis. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
89673250|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh B|Participants with chronic liver disease and classified as Child-Pugh Grade B had a score of 7-9 (out of 15) which correlates with significant functional liver compromise. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
89673251|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh C|Participants with chronic liver disease and classified as Child-Pugh Grade C had a score of 10-15 (out of 15) which correlates with decompensated liver disease. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
89673252|NCT01846455|Experimental|HCV Without Hepatic Impairment|Participants with hepatitis C virus (HCV) without hepatic impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
89673253|NCT01846455|Active Comparator|No Hepatic Disease or Impairment|Participants with no hepatic disease or impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
89673254|NCT03366415|Experimental|Induction chemotherapy+IMRT+adjuvant chemotherapy|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), followed by gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles.
89673255|NCT03366415|Active Comparator|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 30 mg/m² every week.
89673256|NCT01896583|Experimental|ASP7147|ASP7147, 300 mg, tablet, twice per day for 4 weeks oral
89673257|NCT01896583|Placebo Comparator|Placebo|oral
89673258|NCT00292591|Active Comparator|cholecalciferol-400 IU|Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
89673259|NCT00292591|Experimental|cholecalciferol 2000 IU|Experimental group receiving 2000 IU total vitamin D3/day.
89673260|NCT00292591|Experimental|cholecalciferol 4000 IU|Experimental group receiving 4000 IU/day cholecalciferol
89688719|NCT02245633||vitamin D levels sufficient|Diabetic hemodialysis patients with vitamin D levels sufficient
89673261|NCT01847001|Experimental|Propranolol + Neoadjuvant Chemotherapy|"Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.~Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and~Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).~If your tumor is HER2 positive, you will also receive trastuzumab and pertuzumab.~After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor.~DOT imaging will be done at 4 additional time points, including beo."
89673262|NCT01847469|Experimental|Zonisamide|Participants in this arm will receive zonisamide for 12 weeks.
89673263|NCT01847469|Placebo Comparator|Placebo|Participants in this arm will receive placebo medication for 12 weeks.
89673264|NCT01804101|Experimental|Arm I (lower-dose liposomal cytarabine-daunorubicin CPX-351)|"INDUCTION/RE-INDUCTION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.~CONSOLIDATION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
89673265|NCT01804101|Experimental|Arm II (closed to accrual effective 4/21/14)|"INDUCTION/RE-INDUCTION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.~CONSOLIDATION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
89673266|NCT01847547||Dabigatran|
89673267|NCT01847547||Warfarin|
89673268|NCT00287729|Active Comparator|2403 mg/day pirfenidone|2403 mg/day pirfenidone dose group.
89673269|NCT00287729|Placebo Comparator|placebo|Placebo equivalent.
89673270|NCT01433978|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, once daily and allow to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
89673271|NCT01433978|Active Comparator|Eltrombopag (Core Study)|Eltrombopag will be administered orally as 25 mg, 50 mg, or 75 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 50 mg eltrombopag once daily and allow to have their dose titrated up (maximum dose of 75 mg eltrombopag) or down (minimum dose of 25 mg eltrombopag) depending on their response to study drug.
88995748|NCT05466565||In the pegylated interferon pulse medication group|the subjects started oral antiviral drugs from the second day after the operation, and at any time point from the 4th to the 8th week after the operation, the subjects were combined with peginterferon alfa-2b. After every 8 weeks of combined use, stop for 4 weeks (continuous oral NA is maintained during the period), and perform periodically until pegylated interferon is stopped after 96 weeks, and oral antiviral drugs are continued
88995749|NCT04723875|Experimental|Adjuvant chemotherapy group|"Participant will receive 3 cycles of adjuvant chemotherapy if having any of the following factors；participant will receive 6 cycles of adjuvant chemotherapy if having ≥2 of the following factors.~Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 2cm"
88995750|NCT04723875|No Intervention|Control group|The participants receive no intervention.
88995751|NCT05466019|Experimental|Toripalimab combined with FLOT regimen|The enrolled patients will receive 3 cycles of FLOT regimen +Toripalimab treatment before surgery, and every 2 weeks is a treatment cycle (Q2W). After completing the 3 cycles of treatment, the patient undergoes surgical resection.Toripalimab combined with FLOT regimen were maintained for 4 cycles after surgery.
88995752|NCT05465902|Experimental|Inactivated COVID-19 vaccines cohort group 1|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
88995753|NCT05465902|Active Comparator|Inactivated COVID-19 vaccines cohort group 2|Participants who received 2 doses of Inactivated COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment, N=100 Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
88995754|NCT05465902|Experimental|mRNA COVID-19 vaccines cohort group 1|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
88995755|NCT05465902|Active Comparator|mRNA COVID-19 vaccines cohort group 2|Participants who received 2 doses of mRNA COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: mRNA COVID-19 vaccine (Moderna)
88995756|NCT05465902|Experimental|Viral Vector COVID-19 vaccines cohort group 1|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
88995757|NCT05465902|Active Comparator|Viral Vector COVID-19 vaccines cohort group 2|Participants who received 2 doses of Viral Vector COVID-19 vaccines with the second dose at least 6 months (≥180 days) prior to enrolment. N=100 Intervention: Viral Vector COVID-19 vaccine (AstraZeneca)
88995758|NCT00151346|Active Comparator|CSE|"Subjects assigned to this group will receive combined spinal-epidural (CSE) to relieve pain during labor. For CSE, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer directly into the spinal canal (a smaller amount than is given for traditional epidural), followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. CSE is not experimental."
89049673|NCT04618575|Other|Ursodeoxycholic acid only|
89049674|NCT04680338|Active Comparator|Cardiac magnetic resonance imaging|Cardiac magnetic resonance (CMR) stress perfusion imaging with feedback of clinically actionable findings
89214875|NCT05709470||Heart-healthy children and adolescents|Heart-healthy, sex- and age matched children and adolescents (5-18y). A parent to each child/adolescent should also participate. Participants are found though the Danish registries by not having a diagnosis of congenital heart defect.
89673272|NCT01433978|Experimental|Avatrombopag (Open-label Extension)|Participants who meet the eligibility requirements for the Open-label Extension (OLE) Phase or who discontinue the Core Study early because of lack of treatment effect will be eligible to continue into the OLE Phase for up to 104 weeks of open-label avatrombopag therapy. Participants who enter the OLE from the Core Study will receive a starting dose of open-label avatrombopag which will be determined by the last dose of study drug at the End of Treatment (EOT) Visit (Visit 22) of the Core Study. Participants who discontinue the Core Study early because of lack of treatment effect and enter the OLE will receive open-label avatrombopag at a starting dose of 20 mg once daily of open-label avatrombopag.
89673273|NCT01804257|Experimental|Digital Health Feedback System (DHFS)|Ingestion Sensor, Wearable Sensor
89214878|NCT05696158|Experimental|MHNA-003|6-week digital therapy program designed to reduce the severity of tinnitus symptoms
89214879|NCT05693766|Active Comparator|Physician's Choice of Endocrine-based Therapy_Non-Luminal A subtypes|
89214880|NCT05693766|Experimental|Capecitabine_Non-Luminal A subtypes|
89214881|NCT05691244|Active Comparator|Normal Saline + Standard of care|Normal saline will be used as a comparator. It will be available in a 5.0 mL vial. Three doses will be administered as an IV bolus over one minute every 3 hours ± 1 hour on day 1. The dose will be repeated on days 3 and 6 post randomization. The study drug will be administered as an IV bolus dose over 1 minute within 24 hours of the stroke onset.
89214882|NCT05691244|Experimental|Sovateltide + Standard of care|The test product is sovateltide. It is available as a lyophilized injection containing 30 µg of sovateltide in a 5.0 mL vial. Three doses of 0.3 μg/kg will be administered as an IV bolus over one minute every 3 hours ± 1 hour on day 1. The dose will be repeated on days 3 and 6 post randomization. The study drug will be administered as an IV bolus dose over 1 minute within 24 hours of the stroke onset.
89214883|NCT05945160|Experimental|Nutritional Supplements Group|Alpha Lipoic Acid will be administered as two 300 mg capsules taken once daily CoQ-10 will be administered as two 200mg capsules daily.
89214884|NCT05945160|No Intervention|Standard of Care Group|Standard of care treatment for vestibular function.
89214885|NCT05670223|Experimental|Open Pilot Group|Participants (N=30) will be recruited across two churches, MorningStar Baptist Church and People's Baptist Church, to examine the feasibility and acceptability of the HAIL Online platform. Participants will complete the 8-week F&S! exercise program (with access to the adjunct HAIL online platform), which will be delivered in-person as well as remote, and then continue to use the HAIL online platform during the 3-mo follow-up.
89214886|NCT05661266||Single cohort of MS patients with EDSS 0-8.0|Confirmed diagnosis of MS with an EDSS score ranging from 0 and 8.0.
89673274|NCT00289211|Experimental|C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV). If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
89673275|NCT00289211|Placebo Comparator|Placebo|Matching placebo (saline) administered IV. If there was no response to treatment 60 minutes after the first dose, a second placebo (saline) dose could be administered.
89214889|NCT05628636|Experimental|Arm 1|Days 1-3: 5 g BID 4-6: 10 g BID 7-9: 15 g BID 10-21: 20 g BID
89214890|NCT05628636|Experimental|Arm 2|Days 1-3: 10 g BID 4-6: 10 g BID 7-9: 10 g BID 10-21: 20 g BID
89214891|NCT05628636|Experimental|Arm 3|Days 1-3: 15 g TID 4-6: 10 g TID 7-9: 10 g TID 10-21: 15 g TID
89214892|NCT05612412|Experimental|Morning Exercise|Morning exercise session
89214893|NCT05612412|Experimental|Evening Exercise|Evening exercise session
89214894|NCT05612074|Experimental|Nitric Oxide|High dose inhaled nitric oxide (targeting 250 ppm and not exceeding 300 ppm) in a nitrogen-oxygen-air mixture, at two different FiO2 levels (0.21 and 0.8) will be delivered intermittently with a dedicated system and a snug-fitting facemask to healthy volunteers three times per day for 5 days. The subjects will be monitored before, during and after the administration
89673276|NCT01804881|Experimental|Lifestyle counseling|Group program using Craving Change(tm) material was the intervention for dietary counseling, 6 group sessions
89673277|NCT01804881|Placebo Comparator|Wait list control|Wait list, offered group program using Craving Change(tm) material at end of study
89673278|NCT02267577|Experimental|Healthy Adults Volunteers|Men and women over the age of 18 will have their blood pressure measured with both the Sphygmo: Automatic Blood Pressure Monitor device and the GE Dinamap ProCare automatic blood pressure monitor.
89673279|NCT01619111|Active Comparator|standard therapy|standard chemo- or endocrine therapy
89673280|NCT01619111|Experimental|standard therapy + lapatinib|standard chemo- or endocrine therapy + lapatinib
89673281|NCT02267811|Experimental|Fixed Orthodontic Treatment with OrthoPulse™|Subjects assigned to this group receive orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
89673282|NCT02267811|Experimental|Fixed Orthodontic Treatment|Subjects assigned to this group receive orthodontic treatment with no OrthoPulse™ treatment.
89673283|NCT01433354|Experimental|AFQ056 Treatment|All patients will initiate treatment with AFQ056 at a starting dose of 25 mg b.i.d. The dose will be titrated from 25 mg b.i.d to 50 mg b.i.d., 75 mg b.i.d. and 100 mg b.i.d. at weekly intervals. Dose adjustments (up- and down-titrations) will be permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose, not to exceed 100 mg b.i.d.
89673284|NCT01895465|Experimental|A slitted diaper|An ordinary pediatric urine collection bag used in the ED that will be used together with the slitted diaper
89214895|NCT05600582|Experimental|10e7 PFU dose 3 injections|10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
89673285|NCT04430283|Experimental|FDY-5301 Low Dose (1 mg/kg)|FDY-5301 will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.
89673286|NCT04430283|Experimental|FDY-5301 High Dose (2 mg/kg)|FDY-5301 will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.
89049675|NCT04680338|No Intervention|Control|No intervention, following the natural course of coronary atherosclerosis
89049676|NCT04618536|Experimental|Inorganic sunscreen|
89049677|NCT04618536|Experimental|Organic sunscreen|
89049678|NCT04679987||paroxysmal Af|
89049679|NCT04679987||no paroxysmal Af|
89049680|NCT05423795|Other|Comparator Arm|Classic expertise (as routinely performed in the participating ICU)
89049681|NCT05423795|Experimental|Telemedicine-based intervention|Telemedicine-based expert advice.
89049682|NCT05423561|Other|hypertrophic non-union developing after femoral transverse diaphyseal fractures|
89049683|NCT04651959|Experimental|AVICOD then AVIGAN|Participants first received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state. After a washout period of 24 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
89673287|NCT04430283|Placebo Comparator|Placebo|"Placebo will be administered intravenously once daily for up to 7 days. Dosage will be determined on a body weight basis, according to treatment assignment and using the subject's body weight (estimated or actual) determined at screening.~Other Names:~Saline"
89673288|NCT00240539|Experimental|HBsAg(+) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen negative [HBeAg(-)] mothers, who received 4 doses of Engerix™ in the primary study.
89049684|NCT04651959|Experimental|AVIGAN then AVICOD|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 24 hours, they then received AVICOD 200 mg FT manufactured by Pharma Plant in a fasting state.
89049685|NCT01165216|Experimental|Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
89049686|NCT01165216|Experimental|Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
89049687|NCT04651881|Experimental|Group 1|"Period 1: Reference drug~Period 2: Test drug 1~Period 3: Test drug 2"
89049688|NCT04651881|Experimental|Group 2|"Period 1: Test drug 2~Period 2: Reference drug~Period 3: Test drug 1"
89049689|NCT04651881|Experimental|Group 3|"Period 1: Test drug 1~Period 2: Test drug 2~Period 3: Reference drug"
89049690|NCT04651881|Experimental|Group 4|"Period 1: Test drug 2~Period 2: Test drug 1~Period 3: Reference drug"
89673289|NCT00240539|Experimental|HBsAg(+) & HBeAg(+) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen positive [HBeAg(+)] mothers, who received 4 doses of Engerix™ in the primary study.
89673290|NCT00240539|Experimental|HBsAg(+) & HBeAg(+) 5-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen positive [HBeAg(+)] mothers, who received 5 doses of Engerix™ in the primary study.
89673291|NCT00240539|Experimental|HBsAg(-) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen negative [HBsAg(-)] and hepatitis B envelope antigen negative [HBeAg(-)] mothers, who received 4 doses of Engerix™ in the primary study.
89673292|NCT00295009|Active Comparator|1-Level Fusion|Spinal fusion at a single lumbar level.
89673293|NCT00295009|Experimental|1-Level ProDisc|Total disc replacement with the ProDisc device at one spinal lumbar level.
89673294|NCT00295009|Active Comparator|2-Level Fusion|Spinal fusion at two adjacent lumbar levels.
89673295|NCT00295009|Experimental|2-Level ProDisc|Total disc replacement with the ProDisc device at two adjacent lumbar levels.
89673296|NCT00295009|Experimental|1-level ProDisc (non-randomized)|Total disc replacement with the ProDisc device for non-randomized subjects at one spinal lumbar level.
89673297|NCT00295009|Active Comparator|2-Level ProDisc (Continued Access)|Total disc replacement with the ProDisc device for non-randomized subjects at two spinal lumbar levels (only followed out to 24 months)
89673298|NCT01727193|Active Comparator|Azathioprine|cholinesterase inhibitors+Glucocorticoid +Azathioprine
89673299|NCT01727193|Active Comparator|Leflunomide|cholinesterase inhibitors+glucocorticoid+Leflunomide
89049691|NCT04651881|Experimental|Group 5|"Period 1: Test drug 1~Period 2: Reference drug~Period 3: Test drug 2"
89049692|NCT04651881|Experimental|Group 6|"Period 1: Reference drug~Period 2: Test drug 2~Period 3: Test drug 1"
89049693|NCT05367427|Experimental|Bifidobacterium Longum|Consumption of 2 capsules/day of Bifidobacterium Longum CECT 7347 (1x10e4.5 CFU/capsule).
89049694|NCT05367427|Placebo Comparator|Placebo|Consumption of 2 placebo capsules/day filled with cornstarch
89049695|NCT05423405|No Intervention|control|Treatment as usual with pharmacotherapy and other complementary therapies
89049696|NCT05423405|Sham Comparator|Sham|No actual acupoint pressed but same settings as in acupressure therapy
89049697|NCT05423405|Experimental|Intervention|Treatment as usual plus acupressure intervention with selected acupoints pressure
89049698|NCT04652310|Active Comparator|Extended-Short Nail|Implantation of TFNA extended-short nail (235 mm)
89049699|NCT04652310|Active Comparator|Long nail|Implantation of TFNA long nail (260-480 mm)
89049700|NCT04652115|Experimental|Defibrotide|Defibrotide IV
89049701|NCT05423171|Experimental|MANUS|Children and youth living with cerebral palsy will take part in a 60-hour intensive bimanual therapy at Peps at Université Laval, during which they will play games and exercise to promote spontaneous use of the most affected hand. Participants will take part to pre-evaluation and 1-week and 6-month post-intervention.
89049702|NCT01580553|Placebo Comparator|Levocarnitine|
89049703|NCT01580553|Active Comparator|L-carnitine|
89214896|NCT05600582|Experimental|10e7 PFU dose 5 injections|10e7 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
89214897|NCT05600582|Experimental|10e8 PFU dose 3 injections|10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)
89673300|NCT00289757|Experimental|Havrix Group|"Subjects who received 2 doses of Havrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Havrix Group for data analyses during the long term follow-up."
89673301|NCT01849419|Experimental|Single group|Healthy volunteers received all drug conditions (MDMA, oxytocin, and placebo) using a within-subjects design.
89673302|NCT00295867|Experimental|Zoledronic Acid|Patients women with early stage breast cancer and evidence of occult malignant cells in bone marrow aspirates following adjuvant chemotherapy will receive zoledronic acid (Zometa) 4mg, given intravenously over 15 minutes, once a month for two years.
89673303|NCT01850745||Control|Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program
89673304|NCT01850745||Validation cohort|Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
89673305|NCT01850745||Pilot cohort|Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
89673306|NCT04360395|No Intervention|Neurotypical Youth/Young Adults|No intervention administered. The controls will only undergo initial baseline assessments.
89673307|NCT04360395|Experimental|Cerebral Palsy Youth/Young Adults|Baseline and 8 week assessments; 8 week gait therapy
89673308|NCT02271477|No Intervention|Wild-Type|The setting is standard spinal anesthesia and corresponds to our first arm of the study, used as the control sample and statistical reference. During the induction phase, the patient is fitted with non-invasive blood pressure monitoring, three-lead ECG, pulse-oximetry and peripheral intravenous device. Data and vital signs are recorded and an infusion of crystalloid (NaCl 0.9% or Ringer's acetate) is given during the procedure until the beginning of the operation. Total amount of fluid is also recorded before and after the spinal anesthesia.
89673309|NCT02271477|Experimental|Echocardiography|In addition to the current clinical standard, a Trans-Thoracic Echocardiography is performed before spinal anesthesia, with the aim of assessing the patient's volume status; the exam is performed to assess size and collapsing of the Inferior Vena Cava during breathing cycle. According to different pre-established parameters13, the patient is defined as fluid-responsive or unresponsive. If the patient is not responsive, investigators proceed to spinal anesthesia; otherwise they proceed to administration of crystalloid bolus (500 ml of NaCl 0.9% or Hartmann's solution). The patient may receive another bolus so as to reach a non-responsive pattern for echocardiographic evaluation.
89673310|NCT04305561|Other|Ultrasound + Contrast-enhanced ultrasound|"Patients are offered a contrast-enhanced ultrasound (CEUS) examination in addition to conventional imaging. All included patients undergo both CEUS and conventional imaging, enabling them to act as their own controls.~Pilot study: 60 patients Main study: 112 patients"
89673311|NCT04305561|No Intervention|Conventional imaging|"Dual-tracer 99mTechnetium-pertechnetate/ 99mTechnetium-sestamibi subtraction scintigraphy with single-photon emission computerised tomographic/CT fusion imaging (SPECT/CT) combined with conventional ultrasound.~Pilot study: 60 patients Main study: 112 patients"
89688720|NCT02933320|Experimental|Part A: Arm 1: BI-1206 single agent dose escalation phase|BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).
88995759|NCT00151346|Active Comparator|Traditional Epidural|"Subjects assigned to this group will receive traditional epidural to relieve pain during labor. For the traditional epidural, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer into the epidural space, followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. The traditional epidural is not experimental."
88995760|NCT05465863|Active Comparator|Patients|
88995761|NCT05465863|Active Comparator|Healthy controls|
88995762|NCT05465785|Experimental|Pilot batch|Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.
88995763|NCT05465785|Active Comparator|Commercial batch|Three doses of Recombinant COVID-19 vaccine (Sf9 cell) at the schedule of day 0, 21，42.
88995764|NCT04687462|Experimental|Experimental|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
88995765|NCT04687462|Active Comparator|Control|TKRA operation undergoing 2-mm thickness variance polyethylene insert total knee arthroplasty system (Lospa, Corentec)
88995766|NCT05465746||Adults with an indication of SAH screening|Patients who attend the physician's office or the emergency room (ER) with signs and symptoms of high systemic arterial blood pressure will be indicated for ABPM and TTE
88995767|NCT04687618|Experimental|Automatic control of FiO2|Infants randomized to this arm will be monitored using automatic oxygen control system on the High Flow Nasal Cannula. When infants oxygen saturation are out of the target range the OAM module on HFNC will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation in the target range.
88995768|NCT04687618|Active Comparator|Manual Control of FiO2|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
88995769|NCT05465707|Experimental|CM313 2 mg/kg|Once 1 week, intravenous infusion.
88995770|NCT05465707|Experimental|CM313 4 mg/kg|Once 1 week, intravenous infusion.
88995771|NCT05465707|Experimental|CM313 8 mg/kg|Once 1 week, intravenous infusion.
88995772|NCT05465707|Experimental|CM313 16 mg/kg|Once 1 week, intravenous infusion.
88995773|NCT05465707|Placebo Comparator|Placebo|Once 1 week, intravenous infusion.
88995774|NCT05462431|Experimental|web-based deep relaxation exercise intervention|
88995775|NCT05462431|No Intervention|control|
88995776|NCT05460481|Experimental|Experimental: Anlotinib Plus Penpulimab|Anlotinib (10mg qd po d1-14, 21 days per cycle) and Penpulimab (200mg ivgtt d1)
88995777|NCT05451433|Experimental|Intervention Group|Get intervention drug Normagut capsule twice a day
88995778|NCT05451433|Placebo Comparator|Control Group|Get placebo capsule twice a day
88995779|NCT00164463|Experimental|Moxifloxacin|Moxifloxacin 400 mg po qd given 5 of 7 days per week
89673312|NCT01852383|Experimental|Duloxetine|"A minimum 1-week psychotropic medication washout, and a washout of 3 weeks for fluoxetine and monoamine oxidase inhibitors(MAOIs), was required. Duloxetine was prescribed at 20 mg daily for the first week, 30 mg daily for the second week, then 60 mg daily for another 4 weeks. Patients could subsequently be raised to 90 mg daily for another 2-4 weeks and then to a maximum dose of 120 mg daily.~At all visits, the study psychiatrist had the option of adjusting the dose based on clinical response and side effects.~Administration was as a single a.m. dose."
89673313|NCT04272333|Experimental|CIVO Microdose Injection of Motolimod and Nivolumab|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at least four hours to up to four days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeutic microdoses of motolimod, nivolumab, or motolimod combined with nivolumab. Each microdose is simultaneously injected in a columnar fashion through each of 8, 5, or 3 needles (in a device configuration determined by tumor dimensions) into a single solid tumor or effaced metastatic lymph node.
89673314|NCT02273115|Active Comparator|Nulliparous - Foley only|Nulliparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
89673315|NCT02273115|Active Comparator|Nulliparous - Foley and oxytocin|Nulliparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
89673316|NCT02273115|Active Comparator|Multi(primi)parous - Foley only|Multiparous and primiparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
89673317|NCT02273115|Active Comparator|Multi(primi)parous - Foley and oxytocin|Multiparous and primiparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
89673318|NCT04263675||GDM+|Women with history of gestational diabetes
89673319|NCT04263675||GDM-|Women without history of gestational diabetes
89673320|NCT01853085||Patients with POAG or OHT|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
89673321|NCT02989467|Active Comparator|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
89673322|NCT02989467|Placebo Comparator|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
89673323|NCT01853553|Experimental|Spironolactone|Active arm
89673324|NCT01853553|Placebo Comparator|Sugar Pill|Placebo
89673325|NCT00290147|Experimental|1.0 mg of D1ME100 vaccine|1.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
89673326|NCT00290147|Experimental|5.0 mg of D1ME100 vaccine|5.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
89673327|NCT05748561|Experimental|Experimental group|The patients will receive intravenous erythropoietin - 10,000 IU every 24 hours for 5 days.
89673328|NCT05748561|Placebo Comparator|Control group|The patients will receive intravenous methylprednisolone - 1 g every 24 hours for 5 days.
89673329|NCT04113525|Experimental|Active Stimulation + Robotic Wrist Therapy|Two courses of five consecutive days of 20 minute trans-spinal and trans-peripheral nerve active stimulation (total of 10 sessions) combined with a six-week intensive wrist robotic training program.
89673330|NCT04113525|Sham Comparator|Sham Stimulation + Robotic Wrist Therapy|Two courses of five consecutive days of 20 minute trans-spinal and trans-peripheral nerve sham stimulation (total of 10 sessions) combined with a six-week intensive wrist robotic training program.
89673331|NCT00290537|Experimental|Part One: ZD6474|First part of two part treatment, Part One: three 3-week cycles 300 mg of ZD6474 daily. Second part, Part Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks.
89673332|NCT00290537|Experimental|Part Two A: ZD6474 300 mg|Second part of study where participants randomized to receive 300 mg of ZD6474 daily (group A)
89673333|NCT00290537|Experimental|Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel|Second part of study where participants randomized to receive 100 mg of ZD6474 daily plus carboplatin AUC 6.0 IV over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks (group B).
89214898|NCT05600582|Experimental|10e8 PFU dose 5 injections|10e8 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)
89214899|NCT05586971|Experimental|Tigulixostat 100mg|Tigulixostat 100mg, Once a day (QD) for up to 12 months
89673334|NCT00552591|Experimental|1|Family Heart Health Program
89673335|NCT00552591|No Intervention|2|Usual Care
89673336|NCT00290615|Experimental|Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab|"Capecitabine - oral administration of 850 mg/m2 every 12 hours on days 1-14. Oxaliplatin - IV administration of 130 mg/m2 over 2 hours on day 1 of a cycle. Bevacizumab- IV administration of 7.5 mg/kg over 30-90 minutes on day 1 of a cycle.~Cetuximab at an initial dose of 400 mg/m2 over 120 minutes and subsequently 250 mg/m2 over 60 minutes on day 1 of a cycle.~Cycles are 21 days."
89673337|NCT00291161|Experimental|Partners in Dementia Care|"PDC is telephone-based care consultation intervention jointly delivered by care consultants in the VA and local Alzheimer's Association. The steps in care consultation included 1) Assessment of medical and non-medical care needs; 2) Development of a care plan that addresses needs of patients and caregivers; 3) on-going monitoring of the status, progress, and barriers encountered; and 4) Reassessment of care needs for patients and caregivers.~PDC assisted families by: 1) providing disease-related education and information, 2) offering emotional support and coaching, 3) linking families to medical and non-medical services and resources, and 4) mobilizing and organizing the informal care network."
89673338|NCT00291161|No Intervention|Usual Care|Patients and caregivers at the three control VA settings were given a packet of educational materials on dementia and usual-care community resources.
89673339|NCT00297115|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
89673340|NCT00297115|Placebo Comparator|Placebo|once daily
89673341|NCT01854177|Active Comparator|Aprepitant|Aprepitant 125 mg
89673342|NCT01854177|Placebo Comparator|Placebo|Inert capsule
89673343|NCT00291317|Experimental|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD).
89673344|NCT01893515|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
89673345|NCT01893515|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
89673346|NCT03904017|Experimental|Hyperoxia|Will receive 15liters per minute supplemental oxygen via a partial non-rebreather facemask.
89673347|NCT03904017|Placebo Comparator|Placebo|will receive 15liters per minute medical air via a partial non-rebreather facemask.
89673348|NCT00243191|Other|imatinib mesylate|
89673349|NCT00299221|Active Comparator|Monotherapy|Tacrolimus alone
89673350|NCT00299221|Active Comparator|Combination therapy|tacrolimus with mycophenolate mofetil
89673351|NCT03799731|Experimental|Cohort I: GM102 single agent|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22 of each 28-day cycle
89673352|NCT03799731|Experimental|Cohort II: GM102 + trifluridine/tipiracil|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22, and trifluridine/tipiracil will be orally administered at the dose of 35 mg/m² twice daily on Days 1 to 5 and days 8 to 12 of each 28-day cycle
89673353|NCT03799731|Experimental|Cohort II expansion: GM102 + trifluridine/tipiracil|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22, after a loading dose of 10 mg/kg q1w during 28-day cycle 1, and trifluridine/tipiracil will be orally administered at the dose of 35 mg/m² twice daily on Days 1 to 5 and days 8 to 12 of each 28-day cycle
89673354|NCT00299689|Experimental|Intervention|Single-arm: Ontak
89673355|NCT00244985|Experimental|Arm 1: Rituximab and Doxorubicin HCI Liposome|Patients receive rituximab IV over 3-8 hours on day 1 and doxorubicin HCl liposome IV over 1-3 hours on day 3
89673356|NCT05748249|Active Comparator|First arm Vertistop® L.|"BPPV patients will be assigned to the first arm have a sufficient serum concentration of Vitamin D between 31 and 100 ng/mL (76 and 250 nmol/L), which will be treated with Vertistop® L."
89673357|NCT05748249|No Intervention|Second arm No Therapy|"BPPV patients will be assigned to the second arm having serum concentrations of Vitamin D Sufficient between 31 and 100 ng/mL that will not be treated"
89673358|NCT05748249|Experimental|Third arm Vertistop® D|"In the third arm, patients with serum values of Vitamin D insufficient i.e. between 20 and 30 ng/mL (50- 75 nmol/L) or deficient i.e. less than 20 ng/mL (50 nmol/L) which they will instead be treated with Vertistop® D."
89049704|NCT05423054|Experimental|abdominal massage group|"Patients will be positioned on their back while their knees will be flexed.~Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~The PR will be standed on the right side of the patient during the massage practice.~The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
89049705|NCT05423054|No Intervention|Control group|The Control group will receive routine care in the intensive care unit
89049706|NCT04618107|Experimental|Wide awake surgery|Wide awake local anaesthesia was used as mode of aneasthesia for tendon repair surgery. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
89049707|NCT04618107|Active Comparator|General anaesthesia|Tendon repair surgeries were performed under general anaesthesia. Functional outcome of in terms of active range of motion was calculated via Strickland method and American Society for the surgery of the hand criteria at sixth week of surgery using goniometer
89049708|NCT05423015|Experimental|Lactobacillus casei (Probiotic)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product)
89049709|NCT05423015|Experimental|L. casei strain Shirota plus inulin (Syn-Inulin)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product) and enriched with 3g of inulin.
89049710|NCT05423015|Experimental|L. casei strain Shirota plus fructans from A. salmiana (Syn-A. salmiana)|Consist in a commercial fermented milk food (Soful LT), which Lactobacillus casei was used as a primary base (probiotic product) and enriched with 3g of fructans from A. salmiana.
89214900|NCT05586971|Experimental|Tigulixostat 200mg|Tigulixostat 200mg, Once a day (QD) for up to 12 months
89673359|NCT00300235||1|200 subjects ages 5 to 9.9 years with a diagnosis of HbSS/HbSβ0
89673360|NCT00300235||2|400 subjects ages 10 to 14.9 years with a diagnosis of HbSS/HbSβ0
89673361|NCT00300235||3|400 subjects ages 15 to 24.9 years with a diagnosis of HbSS/HbSβ0
89673362|NCT00300235||4|400 subjects over the age of 25 with a diagnosis of HbSS/HbSβ0
89214901|NCT05586971|Experimental|Tigulixostat 300mg|Tigulixostat 300mg (100mg + 200mg), Once a day (QD) for up to 12 months
89214902|NCT05586971|Active Comparator|Titrated allopurinol (100-800mg)|Allopurinol 100-800mg, three times a day (TID) for up to 12 months. The allopurinol dose will be increased in 100 mg increments up to 800mg.
89214903|NCT05586971|Placebo Comparator|Placebo|Placebo, three times a day (TID) for up to 6 months.
89214904|NCT05578820|Experimental|Dose escalation phase|"Stimotimagene copolymerplasmid will be administered intratumoral once in a dose of 20 mkg of DNA per 1 cm3 of tumor (for cohort 1) and 40 mkg of DNA per 1 cm3 of tumor (for cohort 2).~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
89214905|NCT05578820|Experimental|Two times administration of Stimotimagene copolymerplasmid|"Stimotimagene copolymerplasmid will be administered intratumorally twice with 5-day interval in the optimal dose selected at previous stage of the trial.~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
89673363|NCT00300235||5|250 subjects age 15 and older with a diagnosis of HbSC or HbSβ+
89673364|NCT01857297|Experimental|Adults (aged 18 to 59 years)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
89673365|NCT01857297|Experimental|Older Adults (aged 60 years or older)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
89673366|NCT02274675|Experimental|Robot group|Receive 0.5 hour of robot-assisted therapy for wrist and forearm and 1.5 hours of daily standard rehabilitation therapy
89673367|NCT03682263|Experimental|Full Service Treatment|The Full Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services, as well as Medication Management Support (MMS) from a Nurse Care Coordinator (NCC).
89673368|NCT03682263|Experimental|Basic Service Treatment|The Basic Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services.
89673369|NCT03682263|No Intervention|Usual Services|Members of the Usual Service group seek services as they normally would (or would not) in their community. At the time of randomization, each Usual Services group member receives a comprehensive manual describing mental health and employment services in their local community, as well as state and national resources.
89673370|NCT02265783|Other|Nellcor USB Pulse Oximeter Monitor Interface Cable Sensor Test|
89673371|NCT00300391|Experimental|haloperidol|Once diagnosed as delirious, randomized to haloperidol 5 mg IV
89673372|NCT00300391|Placebo Comparator|placebo|once diagnosed as delirious, received 5 mg saline placebo
89673373|NCT03655119|No Intervention|Baseline|Youth and parents will complete surveys at index PES visit regarding suicide related risk and protective factors. Parents and youth will complete a follow-up survey at 3 days (parents only) and 2 weeks (parents and youth) post discharge. At 3 days and 2 weeks, parents will complete a survey that evaluates adherence to safety recommendations. The 2-week follow-up survey for parents will also re-assess self-efficacy, parental distress, and mental health treatment stigma. The 2-week follow-up survey for youth assesses mood and suicidal thoughts, perceptions of parent support post discharge, and outpatient treatment. It reassesses suicidal risk, depression, connectedness, and alcohol use.
89673374|NCT03655119|Experimental|Phase I|Families will complete baseline measures, and receive enhanced usual care from PES clinical staff during their visit as well as a parent toolkit that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth. The same follow-up methodology as in Baseline will be utilized.
89673375|NCT03655119|Experimental|Phase II|Families will complete baseline measures and receive Phase I interventions (enhanced care and parent toolkit). Parents will receive caring contacts post discharge, which may occur by phone, text, or email. Caring follow-up messages will provide support, additional education, and problem solving assistance. The same follow-up methodology as in Baseline will be utilized.
89673376|NCT01858545|Experimental|Experimental|MatriStem MicroMatrix and MatriStem Wound Matrix
89214906|NCT05578820|Experimental|Tree times administration of Stimotimagene copolymerplasmid|"Stimotimagene copolymerplasmid will be administered intratumorally three times with 5-day interval in the optimal dose selected at first stage of the trial.~Ganciclovir (Cimeven®) will be administrated intravenous twice a day at 12-hour intervals for 15 days."
89214907|NCT05573984||Vision Cohort 1|Score of ≥ 54 ETDRS letters read and a VF diameter ≥ 10 degrees in every meridian of the central field
89214908|NCT05573984||Vision Cohort 2|Score of ≥ 35 ETDRS letters read and a VF diameter < 10 degrees in any meridian of the central field
89214909|NCT05573984||Vision Cohort 3|Score of < 35 ETDRS letters read
89214910|NCT05570058|Experimental|Cohort 1|12:4 (RXC007 : Placebo) Dose level 1: 12 weeks (84 days) dosing
89214911|NCT05570058|Experimental|Cohort 2|12:4 (RXC007 : Placebo) Dose level 2: 12 weeks (84 days) dosing
89214912|NCT05570058|Experimental|Cohort 3|12:4 (RXC007 : Placebo) Dose level 3: 12 weeks (84 days) dosing
89214913|NCT05570058|Experimental|Cohort 1B|6:2 (RXC007 : Placebo) Dose level 1; 12 weeks (28 days) dosing, Pre- and on-treatment bronchoscopy
89214914|NCT05570058|Experimental|Cohort 3B|6:2 (RXC007 : Placebo) Dose level 3; 12 weeks (28 days) dosing, Pre- and on-treatment bronchoscopy
89214915|NCT05566834|Experimental|Open-label, dose-escalation, safety, Pharmacodynamic, pharmacokinetic study.|One
89214916|NCT05550246|Experimental|AtoOxy Predicted Responders|Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
89214917|NCT05550246|Experimental|AtoOxy Predicted Nonresponders|Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
89214918|NCT05548491|Experimental|AZR-MD-001 1.0%|AZR-MD-001 ointment/semi-solid drug (1.0%)
89214919|NCT05548491|Placebo Comparator|AZR-MD-001 vehicle|AZR-MD-001 vehicle
88995780|NCT00164463|Active Comparator|Isoniazid|Isoniazid 300 mg po qd given 5/7 days per week
89522441|NCT03397303|Experimental|patients with peripheral neuropathies|This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.
89522442|NCT03397303|Other|controls|
88995781|NCT05404360|Experimental|Treatment Group|During the acute treatment phase, subjects will receive daily prefrontal Deep TMS treatment, 5 days a week for 6 consecutive weeks. Following the acute phase, patients will receive semi-weekly Deep TMS stimulation for an additional seven weeks. Treatment will include a total of 44 treatments over 13 weeks.
88995782|NCT05404360|Sham Comparator|Sham Control Group|During the acute treatment phase, subjects will receive daily prefrontal sham treatment, 5 days a week for 6 consecutive weeks. Following the acute phase, patients will receive semi-weekly sham stimulation for an additional seven weeks. Treatment will include a total of 44 treatments over 13 weeks.
88995783|NCT00406016|Experimental|1|
89522443|NCT04512989||Patients undergoing cardiac surgery|
89522444|NCT03189459|Active Comparator|HVP Patient-Subject|"Patients will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~Completion of Home Visit Program intervention."
89522445|NCT03189459|Active Comparator|HVP Caregiver-Subject|"Caregivers enrolling in the study will be asked to participate in the four home visits, which will involve in-home clinical assessments and completion of some questionnaires. After the first home visit, caregivers will be matched with a peer mentor, an individual who was a prior caregiver to someone with PD who is interested in sharing their knowledge, experience, and time to help improve the lives of current caregivers. Once a week, for a period of 4 months between home visits 2 and 3, caregivers will be asked to meet with their peer mentor, who will be trained to serve as a resource and listening ear, in addition to the medical team.~Completion of Home Visit Program and Caregiver Mentorship Program interventions."
89522446|NCT03189459|No Intervention|De-identified Control Subjects|Control subjects will be drawn from the National Parkinson Foundation Parkinson Outcomes Project (POP). Patient-caregiver dyads will be matched on patient gender, age, and HY stage.
89522447|NCT03189459|Active Comparator|HVP Peer Mentors|"Peer mentors enrolled in this study would be asked to complete a five-hour mentor training program. During this training, caregivers will be asked to complete some questionnaires about their background and caregiving experience. After completion of the mentorship training, peer mentors will be paired with a mentee who is a current caregiver enrolled in the home visit study along with their loved one with Parkinson's. Peer mentors will be asked to speak with their mentee once a week for 16 weeks. After a 16 week break, peer mentors will be paired with a second mentee and will repeat the process for another 16-week-long mentoring session.~Completion of Caregiver Mentorship Program intervention."
89522448|NCT01602224|Experimental|100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)|"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.~Bortezomib 1.3 milligram per square meter (mg/m^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for a minimum 8 cycles.~All treatment may continue past 8 cycles."
89522449|NCT01602224|Experimental|300 mg Tabalumab+Dexamethasone+Bortezomib|"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
89522450|NCT01602224|Placebo Comparator|Placebo Comparator: Placebo + Dexamethasone + Bortezomib|"Placebo administered once IV on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
89522451|NCT03399487|Experimental|Arm 1|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.~Patients will be continued to receive study drug until the end of study unless the patients in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's judgment."
89522452|NCT04504097|Experimental|HIV self-testing + m-Health|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics. We will provide a 24-hour contact number to text, managed through WelTel system that will flag these messages in real-time. Participants will also receive a weekly bidirectional SMS hosted by WelTel to check how they are.
89522453|NCT04504097|Active Comparator|HIV self-testing|At the first visit participants will receive a HIVST kit and a detailed description of how to use the HIVST kits, pictorial and written guide for HIVST kits, condoms and lubricant, in addition to contact information for confirmatory testing and linkage to care at MARPI clinics
89522454|NCT04504097|No Intervention|Standard of Care|Participants will receive information about HIV testing, care and support services at MARPI clinics and provide a pamphlet of information about HIV & HIV prevention strategies.
89522455|NCT05161429||DPP4|Patients receiving second line diabetes treatment with dipeptidyl peptidase-4 inhibitors (DPP4) following metformin
89522456|NCT05161429||GLP1-RA|Patients receiving second line diabetes treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) following metformin
89522457|NCT05161429||Basal insulin|Patients receiving second line diabetes treatment with basal insulin following metformin
89522458|NCT05161429||SLGT2|Patients receiving second line diabetes treatment with sodium-glucose cotransporter-2 inhibitors (SLGT2) following metformin
89522459|NCT05161429||SU|Patients receiving second line diabetes treatment with sulfonylureas (SU) following metformin
88995784|NCT05392738||Vivity with i-Stent|Patients with Glaucoma or Ocular Hypertension undergoing simultaneous cataract and i-Stent implantation, with Vivity intraocular lens
88995785|NCT05392738||Glaucoma with Vivity|Patients with Glaucoma or Ocular Hypertension undergoing isolated phacoemulsification with Vivity intraocular lens
88995786|NCT05392738||Healthy with Vivity|Patients with undergoing isolated phacoemulsification with Vivity intraocular lens
88995787|NCT00406055||1|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
88995788|NCT00532558|Experimental|Lapaquistat Acetate 50 mg QD|
88995789|NCT00532558|Placebo Comparator|Placebo QD|
88995790|NCT05386849|Experimental|FUSION closed loop glucose control system|All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours
88995791|NCT05385601||Healthy young athletes (Eye-Tracker®T2 + e-VOG)|Subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
88995792|NCT05385601||Healthy young athletes (e-VOG + Eye-Tracker®T2)|Subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
88995793|NCT05377099|Active Comparator|Laser In situ Keratomileusis (LASIK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after LASIK
88995794|NCT05377099|Active Comparator|Femto-second assisted LASIK (FS-LASIK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after Femto LASIK
89522460|NCT03984045|Experimental|SPG block|SPG block performed by using qtip applicator soaked in 2% lidocaine and placed posteriorly into nasal cavity where it dwells for up to 30 min
89522461|NCT03984045|Active Comparator|Control|Delivered through IV access obtained in all patients.
89522462|NCT05134753|Experimental|Study arm|Patients will undergo sinus augmentation with advanced PRF
89522463|NCT05134753|Placebo Comparator|Controlled arm|Patients will undergo sinus augmentation with PRF
89522464|NCT03661047|Active Comparator|Omega-3 treatment|Daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent ethyl)
89522465|NCT03661047|Placebo Comparator|Placebo|Identical placebo
89522466|NCT05125861|Active Comparator|RIC group|RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. RIC will be conducted twice within 6 to 24 hours from thrombolysis.
89522467|NCT05125861|Placebo Comparator|control group|Sham RIC+Standard medical treatment Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. RIC will be conducted twice twice within 6 to 24 hours from thrombolysis.
89522468|NCT05060991|Experimental|Immunosuppression reduction|Reduction of immunosuppression before and after administration of a third dose of SARS-CoV-2 mRNA vaccine
89522469|NCT05060991|No Intervention|Standard of care|No change to immunosuppression before or after receipt of a third dose of SARS-Co-2 mRNA vaccine
89522470|NCT05115253|Experimental|mHealth HAPA Intervention Group|This intervention group will receive a single one-on-one online behavioural counselling session and daily personalized SMS text message boosters with the aim of increasing the breaking of consecutive work related sedentary behaviour. Counselling strategies will be grounded in the HAPA model, specifically focusing on the creation of an action plan and the development of coping strategies to increase sedentary behaviour breaks. The SMS text message boosters will be personalized based on participant's preferences of timing, type, frequency, and length. The boosters will framed through HAPA principles with content focusing on risk awareness, outcome expectancy, action and coping planning, barriers and resources, and self-efficacy. The intervention will last for three weeks.
89522471|NCT05115253|Experimental|JITAI Group|This intervention group will receive push notifications from a EMA behaviour monitoring mobile application that will be downloaded to each participants' mobile phones. The application will measure and monitor a participant's sedentary behaviour and once a pre-set condition of 30 consecutive sedentary minutes has been reached, the application will administer a push notification notifying the participant to break their sedentary behaviour. The push notifications will ask the participants to stand up, stretch, or lightly walk around to break their current behaviour. The intervention will last for three weeks.
89522472|NCT05115253|No Intervention|Control Group|The control group will receive no intervention or further instruction past the letter of information.
89522473|NCT03397225|Experimental|Intervention group|The lifestyle intervention, including educational sessions were given to the intervention group of diabetes patients. The educational sessions were scheduled every two weeks and a total of four sessions was provided to the intervention group, the session held in the lecture room at the polyclinic. Also, they were received two individual sessions including dietary and physical activity advice during the consultation session in the diabetic clinic at the beginning and at the end of the study.
89522474|NCT03397225|Active Comparator|Control group|Lifestyle intervention, including individual lifestyle consultation, including dietary and physical activity consultation at the beginning and the end of the study, two sessions. This is done after the screening of the participants in the diabetic clinic at the beginning and at the end of the study.
89522475|NCT03397225|No Intervention|Anonymous data|The patients, n = 60, were recruited randomly and anonymously from the same diabetes clinic, and the HbA1c data was taken from the anonymous patients at two points over the 12-month study duration.
89522476|NCT03399409|Experimental|Motivational Interviewing|
89522477|NCT03399409|Active Comparator|Anti-inflammatory information program|
89522478|NCT03399331|Experimental|group 1|Efficacy of Manuka honey on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
89522479|NCT03399331|Experimental|Group 2|Efficacy of olive oil on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
89214920|NCT05546697|Active Comparator|Yoga-based Intervention|Yoga classes will be gentle and physically accessible for people who are naïve to yoga. Teachers will frequently guide participants to focus on their breathing and coordinate movements with breath. Teachers will offer variations on the postures and encourage participants to choose variations that provide some challenge but do not cause strain or pain. Classes will be 1 hour long and include a brief sitting meditation, warm-ups, standing postures, and a final resting meditation. All participants will be invited to attend a synchronous yoga class via a HIPAA-compliant videoconference option once per week during the first 3 months of the study. Classes will be offered at multiple times throughout the week.
89673377|NCT01858545|Active Comparator|Comparator|Cellular Dermal Replacement Tissue
89673378|NCT01859013|Experimental|Topiramate|Four (4) weeks of meal replacement therapy, followed by 28-weeks of topiramate therapy. Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks.
89673379|NCT01859013|Placebo Comparator|Sugar Pill|Four (4) weeks of meal replacement therapy, followed by 28-weeks of placebo (sugar pill) therapy.
89673380|NCT01859247|Active Comparator|Dorsal Premotor rTMS|0.2 Hz rTMS for 15 minutes
89673381|NCT01859247|Active Comparator|Primary motor cortex rTMS|0.2 Hz rTMS for 15 minutes
89673382|NCT01859247|Active Comparator|Supplemental Motor Area rTMS|0.2 Hz rTMS for 15 minutes
89673383|NCT01859247|Active Comparator|Anterior Cingulate rTMS|0.2 Hz rTMS for 15 minutes
89673384|NCT01859247|Sham Comparator|Sham rTMS|0.2 Hz rTMS for 15 minutes
89673385|NCT00294515|Experimental|Valganciclovir up to 100 days|Valganciclovir for up to 100 days post kidney transplant
89673386|NCT00294515|Active Comparator|Valganciclovir up to 200 days|Valganciclovir for up to 200 days post kidney transplant
89673387|NCT01859325|Experimental|Vaccine|HIV-MAG pDNA vaccine prime will be administered at a dose of 3000 g (1500 g of the HIV-1 gag/pol plasmid and 1500 g of the HIV-1 net/tat/vif, env plasmid) at week 0, 4, 12, and 36. Each construct of HIV-MAG pDNA vaccine (1500 g each) will be mixed and combined with 1000 g of the IL-12 pDNA adjuvant. The resulting mixture will be divided into 2 IM injections and administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid with EP using the TDS device. IL-12 pDNA adjuvant will be mixed with the HIV-MAG pDNA vaccine prime, as noted above, and administered at a dose of 1000 g (500 g in each IM injection) at week 0, 4, 12, and 36. rVSV HIV gag booster vaccine--The total dose, 1x107 pfu, will be administered as 1 mL (5x106 pfu) IM injection in the left deltoid and 1 mL (5x106 pfu) IM injection in the right deltoid at week 24 and 48.
89673388|NCT01859325|Placebo Comparator|Placebo|Placebo for the IL-12 pDNA adjuvant and HIV-MAG pDNA vaccine (sodium chloride for injection, USP 0.9%) will be administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid at weeks 0, 4, 12, and 36 with EP using the TDS device. Placebo for the rVSV HIV gag (sodium chloride for injection, USP 0.9%) will be administered as 1 mL IM injection in the left deltoid and 1 mL IM injection in the right deltoid at week 24 and 48.
89673389|NCT00300469|Active Comparator|A|ABT-335 + 20 mg atorvastatin
89673390|NCT00300469|Active Comparator|B|ABT-335 + 40 mg atorvastatin
89673391|NCT00300469|Placebo Comparator|C|ABT-335 monotherapy
89673392|NCT00300469|Placebo Comparator|D|20 mg atorvastatin monotherapy
89673393|NCT00300469|Placebo Comparator|E|40 mg atorvastatin monotherapy
89673394|NCT00300469|Placebo Comparator|F|80 mg atorvastatin monotherapy
89673395|NCT01859637|Experimental|Zarzio®/Filgrastim HEXAL®|Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).
89673396|NCT00295061|Experimental|1 Alpha-1 MP|Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP
89673397|NCT00295061|Active Comparator|2 Prolastin|Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP
89673398|NCT03109275|Active Comparator|Single MRI examination|40 subjects will benefit from a full MRI
89673399|NCT03109275|Sham Comparator|Reproducibility study|10 subjects will benefit from the realization of 3 MRI. An MRI examination performed at the time of inclusion and then an examination, at 3 months and at 9 months (ie 3 examinations per subject).
89673400|NCT02101411||clopidogrel|treated with cloopidogrel
89673401|NCT02101411||ticagrelor|treated with ticagrelor
89673402|NCT02101411||cilostazol|treated with clopidogrel+cilostazol
89673403|NCT00296231|Experimental|Nasal High Frequency Ventilation|Stable infants born at less than 1501 g who are at least 7 days old and undergoing nasal continuous positive airway pressure treatment.
89673404|NCT01860573|Active Comparator|Standard amino acids|Receive 1-2 gm/kg/day amino acids at birth and advanced by 0.5 gm/kg/day for goal of 4 gm/kg/day
89673405|NCT01860573|Experimental|High amino acids|Receive 3-4 gm/kg/day amino acids at birth and advanced to goal of 4 gm/kg/day as soon as possible after birth
89673406|NCT02117141|Experimental|HC-ER 20 mg capsule (fasted)|Single oral dose of a HC-ER 20 mg capsule (fasted)
89673407|NCT02117141|Experimental|HC-ER 20 mg capsule (fed)|Single oral dose of HC-ER 20mg capsule (fed)
89673408|NCT00299741|Experimental|1|Sunitinib
89673409|NCT01860651|Active Comparator|Web-monitoring|"There is two arms for intervention:~1) Patients in treatment with medicine administrated at home and 2) patients in treatment with biologicals."
89673410|NCT01860651|No Intervention|Control|"Patients in treatment with medicine administrated at home: routine outpatient controls, four times a year.~Patients in treatment with biologicals: retrospective routine treatment algorithm"
89673411|NCT00328861|Experimental|NK Cells + IL-2: Melanoma|Melanoma (skin cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
89673412|NCT00328861|Experimental|NK Cells + IL-2: Renal Cell|Renal cell (kidney cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
89673413|NCT00248807|Placebo Comparator|ARM 1|Head-up tilt maneuver without drug in subjects with spinal cord injury
89522480|NCT03399331|Placebo Comparator|Group 3|The control group at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine
89522481|NCT03399253|Active Comparator|Chemotherapy|chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
89522482|NCT03399253|Experimental|Surgery+Chemotherapy|D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
89673414|NCT00248807|Placebo Comparator|ARM 3|Head-up tilt maneuver without drug in able-bodied controls
89522483|NCT03399097||non-obese|non-obese
89522484|NCT03399097||obese|obese
89522485|NCT03399097||previously obese|previously obese
89522486|NCT03397147|No Intervention|Usual Care|Usual Care
89522487|NCT03397147|Experimental|Sleep Coach Jr.|Parents randomized to the intervention condition will receive a binder with the treatment manual, and the intervention will be administered in person (first session) and via telephone (second session) on an individual basis. The first session will focus on parent education and developing a positive bedtime routines, and the second session will be used to address barriers specific to the individual child.
89522488|NCT04498247|Experimental|Panel A|Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Day 1 and Day 57) of 1x10^5 50% tissue culture infectious dose (TCID50) V591 or placebo
89522489|NCT04498247|Experimental|Panel B|Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Days 1 and 57) of 1x10^6 TCID50 V591 or placebo
89522490|NCT04498247|Experimental|Panels C, G|Participants in this 18 to 55 year old cohort (Panel C) or >55 year old cohort (Panel G) will receive 1 dose of 1x10^5 TCID50 V591 or placebo.
89522491|NCT04498247|Experimental|Panels D, H|Participants in this 18 to 55 year old cohort (Panel D) or >55 year old cohort (Panel H) will receive 1 dose of 1x10^6 TCID50 V591 or placebo.
89522492|NCT04498247|Experimental|Panel E|Participants in this 18 to 55 year old cohort will receive 1 dose of 1x10^7 V591 or placebo.
89522493|NCT04498247|Experimental|Panel F|Participants in this 18 to 55 year old cohort will receive 2 doses (Days 1 and 169) of V591 or placebo. Day 1 will be 1x10^4 TCID50 V591 or placebo and Day 169 will be 1x10^5 TCID50 V591 or placebo.
89522494|NCT04498247|Experimental|Panel I|Participants in this >55 year old cohort will receive 2 doses (Days 1 and 57) of 1x10^5 TCID50 V591 or placebo
89522495|NCT04498247|Experimental|Panel J|Participants in this >55 year old cohort will receive 2 doses (Days 1 and 57) of 1x10^6 TCID50 V591 or placebo
89522496|NCT04498247|Experimental|Panel K|Participants in this >55 year old cohort will receive 2 doses (Days 1 and 169) of 1x10^5 TCID50 V591 or placebo
89522497|NCT04498247|Experimental|Panel L|Participants in this >55 year old cohort will receive 2 doses (Days 1 and 169) of 1x10^6 TCID50 V591 or placebo
89522498|NCT03397069|Placebo Comparator|Group C(control)|Peribulbar block without midazolam (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml)
89522499|NCT03397069|Experimental|Group M1|Peribulbar block with midazolam 50 µg (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml)
89522500|NCT03397069|Experimental|Group M2|Peribulbar block with midazolam 100 µg(peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml
89522501|NCT03396991||Study Group|In the study Group the investigators enrolled 26 patients scheduled for hallux valgus surgery and treated with a new analgesici approach. After sub-gluteal sciatic nerve block with short acting local anesthetic (mepivacaine 2%, 15 ml), each patient received an ultrasound-guided Posterior Tibial Nerve Block (PTNB) with levobupivacaine 0,5% (7-8 ml). The investigators measured: the intensity of pain at the baseline (before the surgery) and at 3, 6, 12 and 24 hours (h) using a Visual Analogue Scale (VAS); the consumption of oxycodone in the first 24 hours after surgical treatment and the motor recovery using modified Bromage score.
89522502|NCT03396991||Control group|The investigators compared the study group with a control group of 26 patients previously scheduled for the same surgery and treated with another post-operative analgesia technique more frequently used in our hospital: local infiltration (Local Infiltration Anesthesia, LIA) with levobupivacaine 0, 5% (15 ml) performed by the surgeon directly on the operative site.
89522503|NCT03396497|Experimental|LYC-55716 + pembrolizumab|Subjects will receive combination treatment until disease progression or unacceptable toxicity, or up to a maximum of 24 months.
89522504|NCT03405623|Active Comparator|Dynamic needle tip positioning|In DNTP, SAX is used, and additionally, when the needle tip is imaged in the screen as an hyper-echoic point, the practitioner (a) moves the US probe proximally a bit, and (b) the needle is advanced until the needle tip reappears in the screen. In this manner, the practitioner repeats (a) and (b) until the needle is inserted 1 cm into the lumen of vessel, and then the catheter is inserted to finish the procedure.
89522505|NCT03405623|Active Comparator|Conventional long-axis|
89522506|NCT03405467||lightning accident|patients suffered injuries due to lightning strike
89522507|NCT03405467||frostbite|patients suffered injuries due to local hypothermia leading to frostbite injuries
89522508|NCT03405467||cpr and aed|patients suffered cardiac arrest in alpine region treated with or without automated external defibrillatior
89522509|NCT03405467||flight accident|patients suffered injuries due to use of a flying vehicle in mountainous regions.
89522510|NCT03405233|Experimental|Group A|Double vein cuff PTFE graft both at the inflow and outflow ends
89522511|NCT03405233|Active Comparator|Group B|Single vein cuffed PTFE graft at the outflow end
89522512|NCT03405233|Active Comparator|Group C|PTFE graft without vein cuff will be used
89673415|NCT00248807|Active Comparator|ARM 2|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in subjects with spinal cord injury
89673416|NCT00248807|Active Comparator|ARM 4|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in able-bodied controls.
89673417|NCT01860807|Experimental|Ibudilast|Ibudilast 50 mg twice daily
89673418|NCT01860807|Placebo Comparator|Placebo|matching placebo twice daily
89673419|NCT01790321|No Intervention|Pump water|Untreated pump water (pump water recognised as improved water source by WHO)
89673420|NCT01790321|Placebo Comparator|Filtered water|Pump water purified by the LSF-filtering device
89673421|NCT01790321|Experimental|Zinc water|Pump water purified and zinc-fortified by the LSF-filtering device
89673422|NCT00330421|Experimental|Group I (sarcomas of extremity, closed accrual as of 5/30/07)|Patients receive oral sorafenib twice daily on days 1-14. Patients undergo surgical resection of the tumor on approximately day 15. Once patients recover from surgery (and radiotherapy if indicated), patients who demonstrate a clinically and pathologically significant response (≥ 25% reduction in tumor size or ≥ 25% necrosis in the surgical specimen) may continue sorafenib as above for a maximum of 6 months in the absence of disease progression or unacceptable toxicity and at the discretion of the principal investigator. Biopsy tissue and blood samples are examined for biomarkers and interstitial fluid pressure (IFP) is measured at baseline and immediately before surgery.
89673423|NCT00330421|Experimental|Group II (metastatic or inoperable sarcomas)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56.
89673424|NCT04350645|Active Comparator|Tranexamic acid group|Tranexamic acid group will receive 1g slow bolus of tranexamic acid over 2 minutes at least 5 minutes before skin incision (at the end of spinal/general anaesthesia)
89673425|NCT04350645|Placebo Comparator|Control group|The placebo group will receive normal saline 0.9% (same amount as the tranexamic acid)
89673426|NCT01790399|Experimental|Identification of sentinel node(s)|
89673427|NCT01890161|Experimental|AXP1275|AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days
89673428|NCT01890161|Placebo Comparator|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules) once daily for 14 days
89673429|NCT01861587|Experimental|Real tDCS:Active Comparator|For Real tDCS, stimulation will be delivered in 20-minute-sessions using 2mA current. The anode will be placed over left BA9 or the motor cortex corresponding with the painful area (if applicable). The cathode will be placed over right BA43 (for GI pain) or right BA9 (located via the international 10-20 EEG system).
89673430|NCT01861587|Experimental|Sham tDCS: Sham Comparator|For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
89673431|NCT00330733|Placebo Comparator|Placebo|Matching placebo
89673432|NCT00330733|Active Comparator|Salsalate Therapy|Salsalate
89673433|NCT05192369|Experimental|Treatment A: Therapeutic Dose|Single oral dose of 12mg CTP-543
89673434|NCT05192369|Experimental|Treatment B: Supratherapeutic Dose|Single oral dose of 48mg CTP-543
89673435|NCT05192369|Placebo Comparator|Treatment D: Placebo|Single oral dose of 1 Placebo tablet
89673436|NCT05192369|Active Comparator|Treatment C: Positive Control|Single oral dose of 400mg Moxifloxacin
89673437|NCT02841085||Genetic sample|Blood sample or saliva collection to genetic research
89673438|NCT05185973|Experimental|"For-Baby powder supplement"|For-baby supplements provided as powder containing dry yeast powder, biovita mixed probiotics, synergy probiotics and other nutrients such as glucose, xylitol, chocolate powder, chocolate flavor powder, organic galactose oligosaccharide, chicory extract powder, vegetable Cream substitute, silicon dioxide, milk flavor powder, whole milk powder, zinc oxide, vitamin B12, vitamin B6, enzyme mixed preparation, vitamin C, organic alpha rice powder, folate 0.4mg, thiamine, leucin, isoleucin, valine, glutamine, and magnesium chloride.
89673439|NCT05185973|Placebo Comparator|Micronutrient powder|Micronutrient powder containing containing glucose 236.3mg, xylitol 150mg, chocolate powder 600mg, chocolate flavor powder 45mg, organic galactose oligosaccharide 60mg, chicory extract powder 60mg, vegetable Cream substitute 135mg, silicon dioxide 45mg, milk flavor powder 30mg, whole milk powder 75mg, zinc oxide 11.2mg, vitamin B12 2.6mg, vitamin B6 2mg, enzyme mixed preparation 2mg, vitamin C 1mg, organic alpha rice powder 1mg, folate 0.4mg, thiamine 0.5mg, and maltodextrin 1,541mg.
89673440|NCT01862133||Patient Preferences|Patients were eligible if they had visited their primary care physician at least twice in the previous 1 year and were fluent in English. Each patient subject used an online program to record their preferences what each of their providers can see. The electronic medical record (EMR) will then apply them to data displays.
89673441|NCT01862133||Primary Care Providers|All healthcare providers (physicians, nurses, and other clinic staff) were eligible to participate in this study. For those enrolled, display of patient data in the EMR was dictated by the patient subject's preferences for who should see what data.
89673442|NCT04388917||Clip Group|Use of Hemo-lock hemostatic clips during tumor resection to prevent bleeding
89673443|NCT04388917||No Clip group|No Hemo-lock hemostatic clips used during tumor resection
89673444|NCT01792219|Experimental|interprofessioal education module|an interprofessional education module will be given to learn to collaborate interprofessionally.
89673445|NCT00301873|Experimental|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
89673446|NCT02989233|Active Comparator|Brochure-Female-8/10|Female 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673447|NCT02989233|Active Comparator|Brochure-Male-8/10|Male 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673448|NCT02989233|Active Comparator|Model-Female-8/10|Female 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673449|NCT02989233|Active Comparator|Model-Male-8/10|Male 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673450|NCT02989233|Active Comparator|Video-Female-8/10|Female 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673451|NCT02989233|Active Comparator|Video-Male-8/10|Male 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673452|NCT02989233|Active Comparator|Brochure-Female-11/13|Female 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673453|NCT02989233|Active Comparator|Brochure-Male-11/13|Male 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673454|NCT02989233|Active Comparator|Model-Female-11/13|Female 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673455|NCT02989233|Active Comparator|Model-Male-11/13|Male 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673456|NCT02989233|Active Comparator|Video-Female-11/13|Female 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673457|NCT02989233|Active Comparator|Video-Male-11/13|Male 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
89673458|NCT01892839|Experimental|high dialysate flow, larger dialyzer|high dialysate flow, larger dialyzer
89673459|NCT01892839|Active Comparator|low dialysate flow, smaller dialyzer|low dialysate flow, smaller dialyzer
89673460|NCT05747781|Active Comparator|Pilot Phase|12 patients with glaumatous optic neuropathy
89673461|NCT05747781|Placebo Comparator|Validation Phase|66 patients with glaumatous optic neuropathy 12 subjects with no known visual impairment
89673462|NCT00251225|Experimental|Hormone Refractory Prostate Cancer|Gleevec + Docetaxel: Daily Oral Gleevec in Combination with Every-Three-Week Intravenous Docetaxel
89673463|NCT02979327|Experimental|Adderall first, then Placebo|Participants will receive an Adderall capsule at the first study visit, then a Placebo capsule at the second study visit.
89673464|NCT02979327|Experimental|Placebo first, then Adderall|Participants will receive a Placebo capsule at the first study visit, then an Adderall capsule at the second study visit.
89673465|NCT05747703|Experimental|Ria Treatment Platfrom|The Ria Treatment Platform is a telehealth approach that includes medical assessment, prescription of clinically appropriate medications for alcohol use disorder, individual and group coaching, educational video modules, and monitoring of breath alcohol concentrations through a Bluetooth-enabled breathalyzer.
89673466|NCT05747703|No Intervention|waitlist control|Patients in this arm will not be provided treatment during the study period.
89673467|NCT02882295||writer's cramp|patients assessed without, then with Botulinum Neurotoxin injections
89673468|NCT02882295||control|age and gender matched
89673469|NCT05951218|Experimental|inhibition technique|In the first group, patients will receive inhibition treatment of the TP.
89673470|NCT05951218|Sham Comparator|placebo|The second group will receive a placebo treatment.
89673471|NCT05951153|Experimental|Tributyrin nutritional supplement|Children between the ages of 2-17 with planned allogeneic hematopoietic cell transplantation with myeloablative preparative regimen, who also have standard of care nasogastric tube placement or existing gastric tubes will receive a daily dose of tributyrin.
89673472|NCT05951127|Experimental|Additional Local Consolidative Esophagectomy Group|The patient in this arm will go on esophagectomy base on tracitional systemic therapy.
89673473|NCT05951127|No Intervention|Traditional Systemic Therapy Group|The patients in this arm will receive traditional therapy, including chemotherapy, immunotherapy, radiotherapy, ect.
89673474|NCT05951114||Patients with diaphragm weakness|Diaphragm weakness will be defined as thickening fraction <=20 % at the time of extubation
89673475|NCT05951114||Patients without diaphragm weakness|Diaphragm thickening fraction >20 % at the time of extubation
89673476|NCT05951088||atrial fibrillation patients|AF patients hospitalised at the cardiology department or coming for an outpatient visit
89673477|NCT05951088||heart failure patients|HF patients hospitalised at the cardiology department or coming for an outpatient visit
89673478|NCT05951075|Experimental|Power Prenatal for Sperm|This is a single arm study. Participants will take supplements for 4 months. The supplements is Power Prenatal for Sperm (active ingredients - https://birdandbe.com/the-power-prenatal-for-sperm)
89673479|NCT05951062|Experimental|five sessions of educational interview|The intervention included five educational sessions focused on anti-hypertensive medication-related information, the importance of medication refills, motivation, self-management and self-check skills.
89673480|NCT05951062|Other|treatment as usual|usual care provided by facility,such as regular blood pressure checking and meals
89673481|NCT05951010|Experimental|Transcranial direct current stimulation (tDCS)|Participants underwent anodal stimulation delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min.
89673482|NCT05950971|Experimental|Rate control strategy group|Patients are given diltiazem or esmolol to control heart rate less than 110/min.
89673483|NCT05950971|Experimental|Rhythm control strategy group|Patients are given amiodarone for conversion of cardiac rhythm to sinus rhythm.
89673484|NCT05950958|Experimental|Multimodal therapy group|"Continuous regional cerebral oxygen saturation and processed electroencephalogram (EEG) are monitored.~Multimodal therapy with conventional care are provided to prevent delirium. Ongoing orientation: 3 times per day Sensory correction: the hearing device and the glasses are supplied. Cognitive stimulation: a portable monitor is used to provide visual stimulation, and a directional speaker is used to avoid disturbing the alarm of the patient's life supportimng system.~Sleep promotion: the lights are turned off from 10 pm to 7 am, and the indirect light source is used if necessary."
89688721|NCT02933320|Experimental|Part A: Arm 2: Combination of BI-1206 with rituximab escalation phase|Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).
89673485|NCT05950958|No Intervention|Conventional care group|"Continuous regional cerebral oxygen saturation and processed electroencephalogram (EEG) are monitored.~Conventional care: If sedation is required, dexmedetomidine is considered as the first-line sedative drug. The sedation is interrupted daily and the possibility of awakening is assessed. Pain with NRS score above 3, is controlled with opioid.~For patients with Richmond Agitation Sedation Scale (RASS) -4 or -5, possible items are provided."
89673486|NCT05950932|Experimental|Treatment-Placebo|This arm will assume firstly the supplement product (Melissa phytosome) and later the placebo.
89673487|NCT05950932|Experimental|Placebo-Treatment|This arm will assume firstly the placebo and later the supplement product (Melissa phytosome).
89673488|NCT05950893|Experimental|Experimental|PMI represents the difference between plateau airway pressure and peak airway pressure (plateau - peak) during an end-inspiratory airway occlusion.
89673489|NCT05950880|Experimental|High intensity exercise + Conventional physical therapy|Patients in this group will receive High-intensity exercise + Conventional physical therapy
89673490|NCT05950880|Active Comparator|Conventional physical therapy|Patients in this group will receive Conventional physical therapy
89673491|NCT05950828|Experimental|SkillTalk|Participants will receive one week of access to SkillTalk, a subscription-based microskills video training library designed to enhance the skills of high school sex educators to implement the frequently used core components of sexual and reproductive health (SRH) curricula.
89673492|NCT05950828|No Intervention|Business as usual|"Control group will receive business as usual."
89673493|NCT05950815|Experimental|PM1015|Subjects will be administered PM1015 via intravenously (IV) once in first cycle, then administered PM1015 every 2 weeks (Q2W ) after 3 weeks
89673494|NCT05950776|Experimental|1x10E7 IU (low dose)|1x10E7 IU MVA-SARS-2-S Intervention: Biological: MVA-SARS-2-S vaccinations (days 0 & 28)
89673495|NCT05950776|Experimental|1x10E8 IU (high dose)|1x10E8 MVA-SARS-2-S Intervention: Biological: MVA-SARS-2-S vaccinations (days 0 & 28)
89673496|NCT05950776|Placebo Comparator|Placebo|Days 0 & 28
89673497|NCT05950750||All Patients|Non interventional observational
89673498|NCT05950737|Experimental|sentinel node biopsy|All patients have undergone completion neck dissection following SNB in the process of standardization. The SNB was localized by peritumoral infiltration of the nano colloid, followed by dynamic planar imaging for 30 minutes, and then SPECT was performed. The surgery was performed on the same day within 6 hours of localisation, and intraoperatively, either methylene blue or indocyanine green was used as an adjunct. Appropriately labelled sentinel nodes were assessed on the frozen section, which was then sectioned into 2-3mm slices perpendicular to the longest axis of the node and submitted entirely for microscopic evaluation. A minimum of 2 sections were evaluated, one stained with Toluidine blue and the other with rapid Haematoxylin and Eosin (HE) stain. The nodes were subsequently subjected to histopathological processing.
89673499|NCT05950711|Experimental|Ketamine-MBCT Intervention|One Arm: Combination of MBCT with a single ketamine infusion
89673500|NCT05950698||Obese patients submitted to bariatric surgery|"50 patients, both females and males, aged between 18 and 60 years, who will be submitted to bariatric surgery with Roux-en-Y reconstruction reduction gastroplasty technique.~Patients will be evaluated for five times: before the bariatric surgery and 3-6-12-24 months after the bariatric surgery."
89673501|NCT05950672|Experimental|CAT Intervention Group|The experimental group will take part in the CAT intervention (Table 1) after baseline assessments. All cat-training methods will be positive reinforcement based, using owner-approved food, toys and social reinforcers (e.g. petting).
89673502|NCT05950672|No Intervention|CAT Control Group|Control participants will not participate in the CAT intervention. After the completion of the third assessment (end of proposal-related data collection), control participants will be offered the opportunity to participate in cat training classes.
89673503|NCT05950659|Experimental|Intervention|
89673504|NCT05950659|No Intervention|Control|
89673505|NCT05950555|Active Comparator|Patients given saline|10 cc/hour isotonic is given throughout the operation.
89673506|NCT05950555|Active Comparator|Patients given dexmedetomidine.|Dexmedetomidine 0.1 µg/kg IV bolus followed by 0.2 µg/kg/hr infusion throughout surgery.
89673507|NCT05950555|Active Comparator|Patients given ketamine.|Ketamine 0.2 mg/kg bolus followed by 0.1 mg/kg/hr infusion throughout surgery.
89673508|NCT05950542||Group A|Vitiligo lesions on the face will be treated with cream (Olumiant)2mg twice daily and excimer light308nm DEKA, Florence,Italy twice weekly for 12 weeks.
89673509|NCT05950542||Group B|Vitiligo lesions on the face will be treated with excimer light308nm (DEKA,F lorence,Italy) only twice weekly for 12 weeks.
89673510|NCT05950529|Experimental|Group A|Experimental lozenge with the enzyme Polyphenol oxidase plus green coffee extract
89673511|NCT05950529|Experimental|Group B|Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor
89673512|NCT05950529|Placebo Comparator|Group C|Placebo lozenge Control (sorbitol only)
89673513|NCT05950529|Other|Group D|No Product Control
89673514|NCT05950516|Experimental|QLG2065|"Up to 1.0 mg semaglutide (QLG2065)~Metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day)."
89673515|NCT05950516|Active Comparator|Ozempic|"Up to 1.0 mg semaglutide (Ozempic)~Metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day)."
88995795|NCT05377099|Active Comparator|Photorefractive Keratectomy (PRK)|Measurement of the deformation amplitude ratio, integrated radius and stress strain index as corneal biomechanical indices in refractive patients before and after PRK
89673516|NCT05950503||mCRC patients|Patients with mCRC with liver-only metastases
89673517|NCT05950490||Group A|Cerebrospinal fluid IL-10 was normal
89673518|NCT05950490||Group B|Cerebrospinal fluid IL-10 was normal or elevated
89688722|NCT02933320|Experimental|Part B: Arm1: BI-1206 single agent expansion phase|Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.
88815738|NCT01042496|Active Comparator|Bipolar Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC) before and after treatment with Lamotrigine.
89214921|NCT05546697|Active Comparator|Behavioral Activation|The goal of Behavioral Activation Psychotherapy is to help people identify and (re)engage in meaningful and positive activities through psychoeducation, identification of values and associated activities, goal setting, problem-solving, and monitoring of goal completion. There will be a BA manual for therapists and training provided by study staff on the manual (e.g., asynchronous and synchronous training sessions). BA therapists will be community clinicians. BA will be provided individually via telehealth and will be billed to participant insurance. At the start of BA treatment, participants will be oriented to the time-limited nature of BA, with the expectation that they will attend 8 sessions over the course of 3 months.
89214922|NCT05545852|Experimental|Study Group|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
89673519|NCT05950347|Active Comparator|Active Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
89673520|NCT05950347|Sham Comparator|Sham Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
89673521|NCT05950308||HC|Healthy control
89673522|NCT05950308||OFA|Received ofatumumab
89673523|NCT05950308||OCR|Received ocrelizumab
89673524|NCT05950308||S1P|Received sphingosine-1-phosphate receptor modulator
89673525|NCT05950230||Cases|45 Patients with history and results of recovered COVID-19 infection.
89673526|NCT05950230||Control|45 Patients with negative history of COVID-19 infection.
89673527|NCT05950204|Active Comparator|Group A|100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children > 9 years and 20,000 UI/week = 2,857 UI/d in those < 8 years for 6 weeks
89673528|NCT05950204|Active Comparator|Group B|1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children > 9 years and 20,000 UI/week = 2,857 UI/d in those < 8 years for 6 weeks
89673529|NCT05950165|Experimental|CHO-H01|Subjects will receive CHO-H01.
89673530|NCT05950152|Experimental|meloxicam injection 30 mg|meloxicam injection 30mg every 24 hours for up to 2 doses.
89673531|NCT05950152|Experimental|meloxicam injection 60 mg|meloxicam injection 60mg every 24 hours for up to 2 doses
89673532|NCT05950152|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 2 doses
89214923|NCT05545852|Active Comparator|Control Group|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
89673533|NCT05950100|No Intervention|Control group|Participants in the control group will not receive the intervention with virtual reality, but they will also receive, on the first postoperative day, the physiotherapeutic care offered by the institution, carried out by the hospital's physiotherapist and with the same duration as the other group (GRV), and constituted by the physiotherapeutic procedures commonly used in the hospital (respiratory physiotherapy maneuvers, kinesiotherapy and walking). During each physiotherapy session, in both groups, the visual analogue scale will be applied.
89673534|NCT05950100|Experimental|Virtual reality group|Participants will receive the same care provided by the hospital, in addition to the application of the use of virtual reality
89673535|NCT05950061|Experimental|Sertraline|Sertraline
89673536|NCT05950061|Experimental|Escitalopram|Escitalopram
89673537|NCT05949931|Experimental|Concurrent penpulimab and AVD|Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
89673538|NCT05949931|Experimental|Sequential penpulimab and AVD|Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
89673539|NCT05949840|Experimental|Expressive Interviewing + Survey|Intervention with Expressive Interviewing computer system. Participants spent roughly 10-15 minutes each in conversation with an automated computer chat system. Participants answered a survey about mental health and social outcomes immediately before the intervention and two weeks after the intervention.
89673540|NCT05949840|No Intervention|Survey Only|No intervention. Participants answered a survey about mental health and social outcomes at time of recruitment and two weeks afterward.
89673541|NCT05949827||Active Comparator: LSA-1|Light Scheduling Algorithm-1 (LSA-1): High circadian effective irradiances + Blue Enriched Light episodes
89673542|NCT05949827||Active Comparator: LSA-2|Light Scheduling Algorithm-2 (LSA-2): High circadian effective irradiances without Blue Enriched Light episodes.
89673543|NCT05949827||Active Comparator: LSA-3|Light Scheduling Algorithm-3 (LSA-3): Irradiance levels comparable to conventional hospital lighting (control group).
89673544|NCT05949775|Experimental|single arm|Neoantigen mRNA Personalised Cancer in combination with Stintilimab Injection. Participants will receive a total of 9 cycles of PCV every 21 days
89214924|NCT05536518|Other|Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)|
89214925|NCT05534633|Other|Participants requesting test(s) for HIV, HCV, and/or syphilis|
89673545|NCT05949762|Experimental|Venetoclax in Combination With Azacitidine and HA Regimen|"Details for:~Venetoclax 200mg d1-10 Azacitidine 100mg/d (or 50-75mg/m2/d), d2-7 Hautriacontin 2mg/m2/d, d3-7 Cytarabine 100mg/m2/d, d3-8 (infusion 24h)"
89688723|NCT02933320|Experimental|Part B: Arm 2: Combination of BI-1206 with rituximab expansion phase|Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.
89688724|NCT05613829||patients with burn injury|
88815739|NCT01042496|Active Comparator|Control Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
89214926|NCT05534100||Healthy Control|
89214927|NCT05534100||PTSD|
89214928|NCT05531591|Experimental|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
89214929|NCT05531591|Experimental|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
89214930|NCT05531591|Experimental|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
89214931|NCT05531591|Experimental|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 mEq/L (milliequivalents/liter).
89214932|NCT05531591|Experimental|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
89214933|NCT05529654|Experimental|Impella Arm|Impella 5.5 with SmartAssist
89214934|NCT05527405|Experimental|Caregiver Training Program|This condition will involve the implementation of an assistive technology software (named the MapHabit System) with an added Caregiver Training Program into the daily care of individuals with mild to moderate stages of Alzheimer's disease and related dementias. The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application will be made available to families through compatible tablets.
89673546|NCT05949736|Experimental|The Clinical Symptom Changes of Music Therapy in a Randomized Controlled Study.|This study investigates the clinical symptom changes of the Music Therapy (MT) group through a randomized controlled trial, aiming to explore the short- and long-term efficacy of MT for individuals experiencing mental sub-health. The study includes one-month and six-month post-treatment follow-ups to assess the lasting effects of MT intervention.
89673547|NCT05949736|Experimental|The changes of objective markers of the music therapy.|This study examines the changes in objective markers resulting from Music Therapy (MT) intervention. It explores alterations in behavior, biological features, and neuroimaging data to understand the potential biological mechanism underlying the efficacy of music therapy. By analyzing these objective markers, the study aims to gain valuable insights into the impact of MT on individuals' mental well-being.
89673548|NCT05949723|Experimental|Golf simulator device training|
89673549|NCT05949697|Other|Dry Eye Drink|
89673550|NCT05949671|Experimental|Mediterranean groups|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
89673551|NCT05949671|Experimental|Gluten-Free groups|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (GFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
89673552|NCT05949671|Experimental|Mediterranean Gluten-Free groups|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
89673553|NCT05949671|No Intervention|control group|Patients in the control group (n=10) did not receive any special dietary intervention.
89673554|NCT05949528||Healthy controls (HCs)|Healthy controls (HCs)
89673555|NCT05949528||Emerged from Minimally Conscious State (EMCS)|Emerged from Minimally Conscious State (EMCS): recovery of functional object uses or communication from chronic
89673556|NCT05949528||Minimally conscious state (MCS)|Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
89673557|NCT05949528||Vegetative state (VS)|Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
89673558|NCT05949502|Experimental|Low shrinkage giomer.|Low-shrinkage bioactive material (giomer) will be applied according to the manufacturer's instructions. Centripetal technique will be performed to restore the proximal wall followed by oblique incrementation of approximately 2 mm thick composite resin. This will be followed by light curing of each increment for 40 seconds using light curing unit till the whole cavity is filled.
89673559|NCT05949502|Active Comparator|Nano-hybrid resin composite|Nano-hybrid resin composite will be applied according to the manufacturer's instructions. Centripetal technique will be performed to restore the proximal wall followed by oblique incrementation of approximately 2 mm thick composite resin. Composite increments will be adapted obliquely on each cusp. This will be followed by light curing for 40 seconds using light curing unit of each increment till the whole cavity is filled.
89673560|NCT05949489||Knee Osteoarthritis|Patients with physician-diagnosed knee osteoarthritis
89673561|NCT05949476|No Intervention|Control Group|extraction of the lower third molar will be performed according to the standard protocols of the structure
88815740|NCT01111058|Experimental|Everolimus (RAD001)|Subjects will receive Everolimus 10 mg daily
89214935|NCT05527405|Active Comparator|The MapHabit System|This control condition will act as the active comparator to the experimental condition. The same assistive technology, the MapHabit System, will be given to a separate group of participants. The difference here will be that the software will be a version that does not include the caregiver training program.
89214936|NCT05522036|Experimental|Patients treated with Methy ALA & 35 minutes white light illumination|Only patients with a minimum of 9 clinically diagnosed grade I and II AK lesions of the scalp (according to the classification by Olsen et al. suggesting the existence of field cancerization, are included in the study. All patients are informed about the purpose of the study and gave informed consent before inclusion. The illumination begins 10 min after the application of MAL cream to the treatment area. In this study, the duration of the light exposure is reduced to 35 min to achieve a PpIX-weighted daylight of 4 J/cm2. MAL cream is removed after the illumination procedure leading to an incubation time of 45 min.
89214937|NCT05508594|Experimental|CT001|
89214938|NCT05508594|Placebo Comparator|Placebo|
89214939|NCT05508594|Active Comparator|Sufentanil 27 mcg|
89214940|NCT05508594|Active Comparator|Ketamine 27 mg|
89214941|NCT05508594|Active Comparator|Sufentanil 13 mcg|
89214942|NCT05508594|Active Comparator|Ketamine 13 mg|
89214943|NCT05508594|Active Comparator|Sufentanil 40 mcg|
89214944|NCT05508594|Active Comparator|Ketamine 40 mg|
89214945|NCT05508594|Active Comparator|Sufentanil 13 mcg/Ketamine 13 mg|
89214946|NCT05508594|Active Comparator|Sufentanil 13 mcg/Ketamine 27 mg|
89214947|NCT05508594|Active Comparator|Sufentanil 13 mcg/Ketamine 40 mg|
89673562|NCT05949476|Experimental|Trial Group|In this group ozone will be used, in two formulations: gaseous, injected into the site of the pre- and post-surgery operation, and topical, in the form of a gel, applied at the end of the operation and for home use according to the therapeutic scheme prescribed at the time of resignation
89673563|NCT05949463|Experimental|Intermittent group|The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).
89673564|NCT05949463|Active Comparator|Control group|The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy developed in the intermittent group.
89673565|NCT05949411|Other|Screening|D-42 to D-7
89673566|NCT05949411|Other|Lactulose|D0
89673567|NCT05949411|Other|Meal 1|D14+/-7
89673568|NCT05949411|Other|Meal 2|D16+/-7
89673569|NCT05949411|Other|Meal 3|D18+/-7
89673570|NCT05949385|Experimental|ZX-7101A and Itraconazole|D1 and D31 Take ZX-7101A tablet 40mg (1 tablet, 40mg/ tablet）,oral，fasting； D26-D50 Itraconazole capsule 200mg(2 capsules, 100mg/ capsule) ，oral in 30min after breakfast.
89673571|NCT05949372|Experimental|Experimental Group : (Biological Breastfeeding Position)|The first breastfeeding after birth will take place within the first half hour - two hours. The second breastfeeding will be performed 2 hours after the first breastfeeding, and the third breastfeeding will be performed at the 24th hour. Three measurements will be made in total.The mother is half-sitting, in the most comfortable position where she can make eye contact with her baby. The baby's head is placed on the mother's chest with her legs on the mother's stomach. With this position, gravity fixes the baby's whole body to that of its mother. The breastfeeding duration will be measured with a chronometer in the breastfeedings at these measurement hours. In order to determine the breastfeeding time, after the mother and baby are positioned, the stopwatch will be started when the baby takes the first breast into his mouth. Data collection forms will be filled.
89673572|NCT05949372|Experimental|Experimental ( armpit / football breastfeeding position):|The first breastfeeding after birth will take place within the first half hour - two hours.The second breastfeeding will be performed 2 hours after the first breastfeeding, and the third breastfeeding will be performed at the 24th hour.Three measurements will be made in total.The baby's head is placed on the breast that is breastfed and the feet are laid flat so that they pass under the armpit of the breastfed side.While the mother's hand on the breastfeeding side holds the baby's head, the other hand directs the breast towards the baby and breastfeeding is initiated.The breastfeeding duration will be measured with a chronometer in the breastfeedings at these measurement hours.In order to determine the breastfeeding time, after the mother and baby are positioned, the stopwatch will be started when the baby takes the first breast into his mouth. Data collection forms will be filled.
89214948|NCT05508594|Active Comparator|Sufentanil 27 mcg/Ketamine 13 mg|
89214949|NCT05508594|Active Comparator|Sufentanil 27 mcg/Ketamine 40 mg|
89214950|NCT05508594|Active Comparator|Sufentanil 40 mcg/Ketamine 13 mg|
89214951|NCT05508594|Active Comparator|Sufentanil 40 mcg/Ketamine 27 mg|
89214952|NCT05508594|Active Comparator|Sufentanil 40 mcg/Ketamine 40 mg|
89214953|NCT05505630|Experimental|Saline first injection; ketamine second injection|Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
89214954|NCT05505630|Experimental|Saline first injection; midazolam second injection|Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion midazolam at the second injection visit
89214955|NCT05505630|Experimental|Saline first injection; dexmedetomidine second injection|Subjects in this arm will receive a single intravenous infusion of placebo at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
88815741|NCT01111058|Experimental|Placebo|Subjects will receive double-blind placebo
89214956|NCT05505630|Experimental|Ketamine first injection; Saline second injection|Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion placebo at the second injection visit.
89049711|NCT04618224||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language~30 patients with low vision (LVG) with adequate literacy of written Greek language~These patients are tested on the digital reading test DDART."
89049712|NCT04618224||Study group|The same patients as those in the control group (NVG, LVG) are tested on the online version of the Greek digital reading test DDART (wDDART).
89049713|NCT04618146|Placebo Comparator|Group C|given intrathecal bupivacaine 12.5 mg.
89049714|NCT04618146|Active Comparator|Group M25|given intrathecal bupivacaine 12.5mg + morphine 25 microgram.
89049715|NCT04618146|Active Comparator|Group M50|given intrathecal bupivacaine 12.5mg + morphine 50 microgram.
89049716|NCT05422898|Experimental|Gist|Gist-based messages on COVID-19 vaccination and moderated group discussions in a private Facebook group
89049717|NCT05422898|Placebo Comparator|Information|Link to Facebook COVID-19 Information Center
89049718|NCT04651842||HOMA IR high|classified based on equal tertile of HOMA IR level into 3 equal groups ( high>6.6)
89049719|NCT04651842||HOMA IR intermediate|classified based on equal tertile of HOMA IR level into 3 equal groups ( intermediate 4.6-6.6, )
89049720|NCT04651842||HOMA IR low|classified based on equal tertile of HOMA IR level into 3 equal groups (low ≤ 4.6, )
89049721|NCT05422859|Other|MobiDig|50 patients will have access to a mobile phone application for 3 months.
89049722|NCT05422313||56 patients with RA.|Patients age is > 20 years old.
89049723|NCT05422313||: 30 age-matched Healthy|Individual must be without a prior history of chronic inflammation or any form of arthritis. - .
89049724|NCT04651647||Bone graft group|The bone graft group (n=19) who underwent open nailing with open bone graft for aseptic subtrochanteric nonunion
89049725|NCT04651647||Non bone graft group|The non-BG group (n=18) who underwent closed reamed nailing without bone graft for aseptic subtrochanteric nonunion
89049726|NCT04651686|Experimental|Bronchial artery protection|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
89049727|NCT05421962|Experimental|Midazolam and Fentanyl|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with 1 mcg kg-1 of fentanyl (Panpharma; SanMed) and 0.5 mg kg-1 of propofol (Fresenius Kabi; Amicus Pharma).
89049728|NCT05421962|Experimental|Midazolam and Ketamine|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with ketamine (Inresa Arzneimittel) 0.5 mg kg-1 and 0.5 mg kg-1 of propofol.
89049729|NCT05421962|No Intervention|Midazolam and Propofol|Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with 1 mg kg-1 of propofol.
89049730|NCT00557817|No Intervention|1|No medication given
89049731|NCT00557817|Active Comparator|2|Aranesp 300 µg/15 days
89049732|NCT00557817|Active Comparator|3|Aranesp 300 µg/15 days. Venofer 200 mg on days 28, 42, and 56 after the transplant.
89049733|NCT05421182|Other|Interview of the trusted person of evacuated patient|"The interview of the trusted person of evacuated patient will be done 8 months (+/-2 months) after the medical evacuation.~The interview will be carried out by a psychologist or by a doctor from the ICU"
89049734|NCT05421182|Other|Interview of the trusted person of the not evacuated patient|The interview of the trusted person of the not evacuated patient will be done 8 months (+/-2months) after the ICU admission The interview will be carried out by a psychologist or by a doctor from the ICU.
89049735|NCT04651530|Active Comparator|Phaco|Cataract surgery only
89049736|NCT04651530|Experimental|Phaco+ECP|Cataract surgery combined with endoscopic cyclophotocoagulation
89049737|NCT05420480|Active Comparator|Two-Field lymph node dissection (106recR negative by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, esophagectomy and Two-Field lymph node dissection will be performed."
89049738|NCT05420480|Experimental|Three-Field lymph node dissection (106recR negative by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
89049739|NCT05420480|Other|Three-Field lymph node dissection (106recR positive by intra-operative frozen section pathology)|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
89049740|NCT04651491||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel)
89049741|NCT03455231|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation
89049742|NCT04617873|Experimental|Deep bain stimulation and Spinal cord stimulation therapy|The patients in this group will receive bilateral STN-DBS and SCS stimulation
89214957|NCT05505630|Experimental|Ketamine first injection; midazolam second injection|Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion midazolam at the second injection visit.
89214958|NCT05505630|Experimental|Ketamine first injection; dexmedetomidine second injection|Subjects in this arm will receive a single intravenous infusion of ketamine at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
89214959|NCT05505630|Experimental|Midazolam first injection; Saline second injection|Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion placebo at the second injection visit.
89214960|NCT05505630|Experimental|Midazolam first injection; ketamine second injection|Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
89673573|NCT05949346|Experimental|MFNT Intervention (Treatment Group)|Parents of children with dyslexia who are randomized in Treatment Group will first take part in a pre-tested 4-session MFNT intervention programme. The parents will participate in lectures, group discussions, video demonstrations, and in-group exercises offered in these four mentored sessions, while their children will attend the second and fourth sessions.
89673574|NCT05949346|Experimental|MFNT Intervention (Wait Listing Control Group)|Families of children with dyslexia who are randomized in Wait Listing Control Group receive services as usual by the school personnel during the intervention period. The 4-session MFNT intervention program will be delivered to them after the intervention period.
89673575|NCT05949320|Experimental|e-MI intervention group|1200 participations are randomized to the e-MI group. They are asked to download the e-MI app and exposed to the related content for 90 days.
89673576|NCT05949320|No Intervention|Waiting list control group|400 participants are randomized to the waiting list control group. They will commence the e-MI intervention after the completion of the e-MI group.
89673577|NCT05949307|Experimental|Acupuncture group|receive acupuncture treatment
89673578|NCT05949307|Experimental|Laser acupuncture group|receive laser acupuncture treatment
89673579|NCT05949307|Sham Comparator|Sham laser acupuncture group|receive sham-laser acupuncture treatment
89673580|NCT05947994|Experimental|Intracranial stenting with Credo® Stent|Symptomatic ischemic stroke patients were treated with Credo® Stent
89673581|NCT05947929|Experimental|treadmill exercise Group|30 women will perform treadmill exercise following low food map diet three times \weak for 3 months
89673582|NCT05947929|Experimental|acupuncture Group|30 women will receive acupuncture session following low food map diet three times \ weak for 3 months.
89673583|NCT05947734|Experimental|robotic|
89673584|NCT05947734|No Intervention|Control|
89673585|NCT05946369||Neutrophil to lymphocyte ratio less than 3|Patients are classified into 2 groups according to NLR < or ≥ 3 and follow up the 2 groups for recurrence or regression of bladder urothelial tumor and documentation of BCG failure
89673586|NCT05946369||Neutrophil to lymphocyte ration more than or equal 3|Patients are classified into 2 groups according to NLR < or ≥ 3 and follow up the 2 groups for recurrence or regression of bladder urothelial tumor and documentation of BCG failure
89673587|NCT05946317|Experimental|Lingual nerve function assessed after removal of Impacted mandibular third molar|"20 patients who had have an impacted mandibular third molar indicated for extraction by lingual split technique with using Walter's lingual retractor for retracting lingual flap.~The neurological function of the lingual nerve was assessed after the demise of local anesthesia, then the location of the disorder and taste function and healing time are determined by sensory neurological tests on a graphic map that divides the tongue into sextants."
89673588|NCT05945134|Experimental|Visual and auditory feedback STS training group|The interactive interface of visual and auditory feedback system was designed using LabVIEW and integrated force plates for training. Signals from the pressure detectors of the seat and two force plates on the floor will be converted to the indication of the body weight distribution (indicated by the size of the two circles of both legs, larger circle represented the more weight beard on the leg) and the movement path of the overall center of pressure (indicated by a mobile solid dot).
89673589|NCT05945134|Active Comparator|Conventional STS training group|Only verbal and visual cues which were commonly used by the therapist.
89673590|NCT05941208|No Intervention|control group|
89673591|NCT05941208|Active Comparator|study group|receiving post operative continuous fascia iliaca compartement block for 24 hours
89673592|NCT05937503|Experimental|Manual therapy|Manual therapy group
89673593|NCT05937503|Other|Conventional physiotherapy|Conventional physiotherapy group
89673594|NCT05931692||Normal Adults|Adults over 18 years old
89673595|NCT05931692||Parkinson Disease|adults with Parkinson's Disease at stage I to III Hoehn and Yahr scale
89673596|NCT05915442|Experimental|Treatment with quemliclustatm, etrumadenant, zimberelimab and SBRT|Subjects with metastatic prostate cancer will receive quemliclustat and etrumadenant for 4 weeks prior to metastasis-directed SBRT (Stereotactic Body Radiation Therapy). Within one week of completing SBRT, subjects will also start zimberelimab.
89673597|NCT05907148|Active Comparator|Routine Physical therapy along with Coordination exercises|The Control group training will consist of active joint mobilization, muscle stretching, motor coordination exercises and additionally will receive 30-minute general balance training. Active joint mobilization will be carried out with the patient in the supine, prone (if possible), or sitting positions. Muscle stretching will be carried out mainly in the supine, prone (if possible), and standing positions. Motor coordination exercises will be carried out in a supine position, sitting and standing positions.
89673598|NCT05907148|Experimental|sensory Integration training group along with Routine physical therapy|experimental group training will consist of active joint mobilization, muscle stretching, motor coordination exercises and additionally 30 minutes of sensory integration therapy.
89673599|NCT05905549||extended pancreatic transection cohort|cases in which the pancreatic transection was performed at the pancreatic neck beyond the left side of the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy, as judged by postoperative abdominal CT scan.
88815742|NCT02246738||Cohort1|
88815743|NCT02246738||Cohort 2|
89214961|NCT05505630|Experimental|Midazolam first injection; dexmedetomidine second injection|Subjects in this arm will receive a single intravenous infusion of midazolam at the first injection visit and a single intravenous infusion dexmedetomidine at the second injection visit.
89214962|NCT05505630|Experimental|Dexmedetomidine first injection; Saline second injection|Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion placebo at the second injection visit.
89214963|NCT05505630|Experimental|Dexmedetomidine first injection; ketamine second injection|Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion ketamine at the second injection visit.
89214964|NCT05505630|Experimental|Dexmedetomidine first injection; midazolam second injection|Subjects in this arm will receive a single intravenous infusion of dexmedetomidine at the first injection visit and a single intravenous infusion midazolam at the second injection visit.
89214965|NCT05500885|Experimental|Active PEMF therapy for chronic ankle instability|Participants will be randomized into 1:1 allocation, blocked randomization with 20 participants in the PEMF group and 20 participants in the sham group. Each allocation will be assigned with a unique RFID (generated during block randomization by the PEMF supplier service) recognizable by the PEMF machine.
89214966|NCT05500885|Sham Comparator|Sham PEMF therapy for chronic ankle instability|Control group will receive sham treatment on top of a standard rehabilitation (muscle strengthening and balance training).
89214967|NCT05498441|Experimental|Personalized HD-tDCS|"The experimental arm will receive the personalized HD-tDCS treatment with parameters as follows:~Neuroimaging biomarker-guided personalized selection for central electrode polarity: anode or cathodal;~Neuroimaging biomarker-guided personalized selection for stimulation site: dorsalmedial prefrontal cortex or occipital cortex;~Schedule: 2 sessions per day, five days per week for a total of 20 sessions over 2 weeks."
89214968|NCT05498441|Active Comparator|Routine HD-tDCS|Routine stimulation arm will receive the same scheme of HD-tDCS, but the stimulation target is L-DLPFC with anode as central electrode.
89214969|NCT05492201|Experimental|LY3873862 (Part A)|LY3873862 administered orally as single dose.
89214970|NCT05492201|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
89214971|NCT05492201|Experimental|LY3873862 (Part B)|LY3873862 administered orally as multiple doses.
89214972|NCT05492201|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
89214973|NCT05491551|Experimental|Mindfulness-Based Treatment|Using mindfulness and meditative strategies to control craving
89214974|NCT05491551|Experimental|Cognitive Behavioral Therapy|Thinking of negative consequences to control craving
89214975|NCT05491551|No Intervention|Control|No regulatory strategy
89214976|NCT05487820|Experimental|Patients with reconstructed flap monitored by tissue CO2|Patients scheduled for reconstructive flap surgery are monitored postoperatively with IscAlert biosensor measuring local tissue CO2 and temperature in the reconstructed flap
89214977|NCT05483062|Experimental|toothpaste with active ingredient of galla chinensis|
89214978|NCT05483062|Active Comparator|toothpaste with stannous fluoride|
89673600|NCT05905549||conventional pancreatic transection cohort|cases in which the pancreatic transection was performed at the pancreatic neck above the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy, as judged by postoperative abdominal CT scan.
89673601|NCT05883202|Experimental|Connect®|Restoration of multiple implants with a Connect® abutment between the implant and the prosthesis.
89673602|NCT05883202|Active Comparator|Multi-unit|Restoration of multiple implants with a conventional multi-unit abutment between the implant and the prosthesis.
89673603|NCT05859113|Experimental|Ziacom Galaxy dental implant with internal connical prosthetic connection|Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
89673604|NCT05859113|Active Comparator|Ziacom Zinic dental implant with internal hexagonal prosthetic connection|Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
89673605|NCT05858775||Nulliparous cohort|Nulliparous pregnant woman
89673606|NCT05858775||Multiparous cohort|Multiparous pregnant woman
89673607|NCT05847946|Experimental|Kinesiotape application|In addition to core stabilization and pelvic floor exercises, kinesiotape will be applied to the paraspinal muscles in the lumbar region 2 times a week for a total of 8 times.
88815744|NCT02246738||Cohort 3|
88815745|NCT02246738||Cohort 4|
88815746|NCT02246738||Cohort 5|
89673608|NCT05847946|Active Comparator|Core stability and pelvic floor exercises group|Participants will perform core stabilization and pelvic floor exercises 5 days a week for 4 weeks.
89673609|NCT05838144|Active Comparator|Acapella|Will use Acapella device 3 times per day for 15 minutes for 7 days beside medications and routine physical therapy program.
89673610|NCT05838144|Placebo Comparator|Only routine physical therapy program|Only they will receive medications and routine physical therapy program.
89673611|NCT05819528||Patients enrolled|Patients with a diagnosis primary cardiac lymphoma. The study includes patients with PCL diagnosed from 01/01/2000 to 31/12/2020.
89673612|NCT05803668||patients who developed gall stones|
89673613|NCT05803668||patients who did not develope gall stones|
89673614|NCT05794672|Experimental|Part A|"Part A1: Each subject in three of the single inhaled dose cohorts will receive a single inhaled dose A, B, or C elarekibep and placebo in the fourth cohort.~Part A2: Each subject will receive a single Intravenous (IV) dose D elarekibep in one cohort."
89673615|NCT05794672|Experimental|Part B|Each subject will receive multiple inhaled doses C elarekibep or placebo twice daily (BID) for 6 days in the first cohort and a single inhaled dose on Day 7 in the second cohort.
89673616|NCT05789394|Experimental|Treatment (AMSCs)|Patients receive AMSCs IT and undergo Ommaya reservoir placement during a craniotomy on study. Patients also undergo MRI on study and during follow-up, as well as blood sample and CSF sample collection on study.
89673617|NCT05781828||Laboratory investigation|Complete blood count, liver function tests, prothrombin time(PT), prothrombin concentration(PC), international normalized ratio (INR), renal chemistry and electrolytes
89673618|NCT05775146|Experimental|SBRT to the metastatic liver +/- lung lesions|All rectal cancer patients included in the trial will receive short course radiation to the pelvis (with 25 Gy in 5 fractions) followed by chemotherapy with either 6 cycles of 3 weekly CAPOX chemotherapy or 9 cycles of 2 weekly FOLFOX. All colon cancer patients will receive 6 cycles of 3 weekly CAPOX or 9 cycles of 2 weekly FOLFOX. Patients will proceed for SBRT to the metastatic liver +/_ lung lesions and resection of the colorectal primary. Treatment planning is to be done using CT simulation or conventional simulation (Fluorocscopy) as per institutional practice. Simple beam arrangements, such as parallel opposed beams, are favored wherever possible.
89673619|NCT05761587||cancer patients|Questionnaires
89673620|NCT05742165|Experimental|Time-Restricted Eating - 6 Hours (TRE6)|Participants will be instructed to consume all daily food and beverages during their allotted 6-hour time period.
89673621|NCT05742165|Experimental|Time-Restricted Eating - 10 Hours (TRE10)|Participants will be instructed to consume all daily food and beverages during their allotted 10-hour time period.
89673622|NCT05727085||twins|
89673623|NCT05701956|Experimental|Intravenous tenecteplase+endovascular thrombectomy|Patients will receive intravenous tenecteplase (0.25mg/kg, max 25mg) plus endovascular thrombectomy.
89673624|NCT05701956|Active Comparator|Endovascular thrombectomy alone|Patients will receive endovascular thrombectomy alone.
89673625|NCT05674825|Experimental|Group 1: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 1 subjects will comprise treatment naïve subjects with localized disease and (i) are eligible for neoadjuvant treatment, (ii) have unresectable disease, or (iii) are medically unfit for surgical resection.
88815747|NCT02246738||Cohort 6|
88815748|NCT02246738||Cohort 7|
88815749|NCT02246738||Cohort 8|
89049743|NCT05419739||Group 1|Children under 18 years of age with traumatic brain injury
89049744|NCT00563004|Active Comparator|A|Patients receive the herbal medication DBCARE for 3 months
89049745|NCT00563004|Placebo Comparator|B|PATIENTS RECEIVE PLACEBO PILLS
89049746|NCT05419583|No Intervention|Standard care|Patients will continue to be treated by the clinical team based on NHS guidelines. They will receive no additional visits from the study however may be asked to participate in qualitative interviews at the end of the study about their usual care. The standard care pathway may involve further investigation with clinically indicated tests or treatments and no appropriate tests or treatments will be withheld.
89049747|NCT05419583|Experimental|Complex intervention|A structured risk assessment for coronary disease or left ventricular impairment and management plan delivered by a cardiologist to guide targeted investigation and treatment. This may include imaging with coronary computed tomography angiography (CCTA), invasive coronary angiography, transthoracic echocardiography or cardiac MRI. Treatments may include antiplatelet and anticoagulant therapy, statin therapy or treatments for heart failure as indicated in line with international guidelines.
89049748|NCT04651764|Experimental|Robotically assisted transanal endoluminal resection of rectal lesion|
89049749|NCT04651803||Traumatic brain injury patients|Traumatic brain injury patients admitted in intensive care unit.
89049750|NCT04617600|Active Comparator|Mineral trioxide aggregate (MTA)|Survival rate of cariously exposed vital primary molars using MTA+ Curamed (UI, Kwiatkowskiego 1, 37-450 Staleya Wola, Polka)
89049751|NCT04617600|Experimental|TheraCal PT|Survival rate of cariously exposed vital primary molars using TheraCal PT (BISCO Dental Products, Schamberg IL, U.S.A.)
89049752|NCT04651608|Experimental|manuel acupressure|In this group, manual acupress was applied to children receiving chemotherapy with moderate and high emetogenic effects.
89673626|NCT05674825|Experimental|Group 1: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 1 subjects will comprise treatment naïve subjects with localized disease and (i) are eligible for neoadjuvant treatment, (ii) have unresectable disease, or (iii) are medically unfit for surgical resection.
89673627|NCT05674825|Experimental|Group 2: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 2 will comprise treatment naïve subjects with metastatic disease.
89673628|NCT05674825|Experimental|Group 2: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 2 will comprise treatment naïve subjects with metastatic disease.
89673629|NCT05674825|Experimental|Group 3: Targeted agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 3 will comprise subjects with metastatic or unresectable disease who have received at least one prior systemic therapy, whether matched or unmatched.
89673630|NCT05674825|Experimental|Group 3: Standard of care agent|Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 3 will comprise subjects with metastatic or unresectable disease who have received at least one prior systemic therapy, whether matched or unmatched.
89673631|NCT05660434|Experimental|Intervention Group|Adults (>18 years) who are currently receiving treatment for SUD in the outpatient treatment program at West Virginia University Chestnut Ridge Center (WVUCRC) (n = 340 approx.). In addition, participants can be at any level of treatment, including peer recovery coach program. Inclusion criteria are patients diagnosed with SUD who have completed intensive acute phase 1 treatment, and who desire to pursue continuous recovery phases (per facility protocol). All participants must be alert and oriented, provide written consent, and be able to read and write English. Exclusion criteria are patients diagnosed with severe mental illness (who cannot consent to participate), have a medical history of asthma or other serious respiratory disease, and known allergy to citrus.
89214979|NCT05481034|Experimental|Simplified carbohydrate estimation first, exact carbohydrate estimation second|"In the first study period, participants will use the CamAPS FX system and adopt the simplified meal announcement (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit. In the second study period, Participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals."
89214980|NCT05481034|Experimental|Exact carbohydrate estimation first, simplified carbohydrate estimation second.|"In the first study period, participants will use the CamAPS FX system and insert the estimated grams of carbohydrates into the application as exactly as possible in order to bolus for their meals. In the second study period, participants will use the CamAPS FX system and adopt the simplified meal announcement (SMA) option to bolus for their meals. SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit."
89214981|NCT05477134|Experimental|The study cohort consisting of youth with type 2 diabetes and healthy controls|"In Study Day 1, participants will be given a primed dose of stable isotopes followed by continuous intravenous infusions for 5 hours. The investigators will use the following isotopes: U-13C6-Arg, 5,5-2H2-Cit, 15N2-Orn, 2H5-Phe, Na13CO3, and 13C5-Orn.~On Study Day 2, participants will drink a 75-gram glucose solution prior to an oral glucose tolerance test.~On Study Day 3, participants will drink a 75-gram glucose solution and will be injected 5-gram arginine into their veins."
89214982|NCT05474989|Experimental|Verum|Subjects in the treatment arm will receive 150 μg LSD (first session) and 150 or 250 μg LSD (second session).
89214983|NCT05474989|Active Comparator|Active placebo|Subjects in the control arm will receive 10 µg LSD at the first session and 10 µg LSD at the second session.
89214984|NCT05459376|Experimental|Intervention Group|Participants in the intervention group will receive an assessment, classification as to McKenzie method (MDT) syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine ; will receive basic information about low back pain (LBP), its prevalence and prognosis; plus how and why to exercise; and types of responses that may occur in response to the exercise program. Guidance for performing the exercises at home. Dry suction cup application with 6 size 1 acrylic cups (4.5 cm internal diameter) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae, bilaterally according to the acupoint boundaries, B23, B24 and B25 . This group will consist of performing MDT exercises and dry cupping with 2 suctions for 10 minutes, 2 times a week, for 8 weeks.
88815750|NCT02246738||Cohort 9|
88815751|NCT01111370|Experimental|CGM|continuous glucose monitoring system
88815752|NCT01112228||Obese patients|Obese patients for Bariatric surgery
89673632|NCT05660434|No Intervention|Control Group|Adults (>18 years) who are currently receiving treatment for SUD in the outpatient treatment program at West Virginia University Chestnut Ridge Center (WVUCRC) (n = 340 approx.). In addition, participants can be at any level of treatment, including peer recovery coach program. Inclusion criteria are patients diagnosed with SUD who have completed intensive acute phase 1 treatment, and who desire to pursue continuous recovery phases (per facility protocol). All participants must be alert and oriented, provide written consent, and be able to read and write English. Exclusion criteria are patients diagnosed with severe mental illness (who cannot consent to participate), have a medical history of asthma or other serious respiratory disease, and known allergy to citrus.
89673633|NCT05656963||Idiopathic membranous nephropathy|Patients with idiopathic membranous nephropathy proved by renal biopsy
89673634|NCT05656963||Non-Idiopathic membranous nephropathy|Other primary glomerular diseases except membranous nephropathy
89673635|NCT05656963||Diabetic kidney disease|Patients with clinical diagnosis of diabetes and kidney disease
89673636|NCT05621369||Participants with Psoriasis|People who report a diagnosis of Psoriasis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
89673637|NCT05621369||Participants with Psoriatic Arthritis|People who report a diagnosis of Psoriatic Arthritis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
89673638|NCT05621369||Participants without Psoriasis or Psoriatic Arthritis|People who report no prior diagnosis of Psoriasis or Psoriatic Arthritis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).
89673639|NCT05609188|Experimental|Cash now|"Participants allocated to the cash now arm will receive a $500/month Guaranteed Income (GI) during the first twelve months of follow-up (Phase 1) and no GI in the second twelve months of follow-up (Phase 2)."
89673640|NCT05609188|Other|Cash in a year|"Participants allocated to the cash in a year arm will receive no Guaranteed Income (GI) during the first twelve months of follow-up (Phase 1) but will receive a $500/month GI in the second twelve months of follow-up (Phase 2)."
89673641|NCT05605275||Gram negative|Patients who had at least one blood culture with a gram- isolate during hospitalisation in the surgical ICU
89673642|NCT05605275||Gram positive|Patients who had at least one blood culture with a gram+ isolate during hospitalisation in the surgical ICU
89673643|NCT05593627|Experimental|lithium carbonate|Patients undergoing heart valve surgery with cardiopulmonary bypass will take 250mg lithium carbonate .
89673644|NCT05593627|Placebo Comparator|calcium carbonate|Patients undergoing heart valve surgery with cardiopulmonary bypass will take 500mg calcium carbonate.
89673645|NCT05585385|Experimental|Backward Walking Training|The patients will receive BW training in addition to the traditional physical therapy program for 6 weeks.
89673646|NCT05585385|Experimental|Balance Training|The patients will receive balance training on the Biodex balance system in addition to the traditional physical therapy program for 6 weeks.
89673647|NCT05585385|Active Comparator|conventional treatment|The patients will receive the traditional physical therapy program only for 6 weeks.
89673648|NCT05582096|Experimental|LY3457263 + Tirzepatide|LY3457263 administered subcutaneously (SC) in combination with tirzepatide given SC.
89673649|NCT05582096|Placebo Comparator|Placebo + Tirzepatide|Placebo administered SC in combination with tirzepatide given SC.
89673650|NCT05577715|Experimental|MORAb-202|
89673651|NCT05573100|Experimental|CU06-1004 100mg|CU06-1004 100 mg tablets. Dosed at 100 mg (1 capsule) QD within 30 minutes after meal on each evening
89673652|NCT05573100|Experimental|CU06-1004 200mg|CU06-1004 100 mg tablets. Dosed at 200 mg (2 capsules) QD within 30 minutes after meal on each evening
89049753|NCT04651608|Experimental|sea-band acupressure|In this group, sea-band acupressure was applied to children receiving chemotherapy with moderate and high emetogenic effects.
89049754|NCT05406089||The short-term antiviral therapy (STAT) group|The short-term antiviral therapy (STAT) group was defined as individuals who received HBV antiviral ( antiviral treatments consisted of adefovir (10 mg/day), entecavir (0.5 mg/day), and lamivudine (100 mg/day) )at least 24 weeks before hepatectomy (antiviral therapy still continued during perioperative period). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
89049755|NCT05406089||The perioperative antiviral therapy (PAT) group|The perioperative antiviral therapy (PAT) group was defined as individuals who received antiviral treatment perioperatively ( antiviral treatments consisted of adefovir (10 mg/day), entecavir (0.5 mg/day), and lamivudine (100 mg/day) ). Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and characteristics of this group were collected and recorded for subsequent analysis.
89049756|NCT04651335|Active Comparator|Concentric|uses an afferent virtual reality program
89049757|NCT04651335|Active Comparator|Eccentric|uses an efferent virtual reality program
89049758|NCT04651023|Placebo Comparator|control group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (0g NnEx) per day with or after meals.
89049759|NCT04651023|Experimental|low concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (1g NnEx) per day with or after meals.
89673653|NCT05573100|Experimental|CU06-1004 300mg|CU06-1004 100 mg tablets. Dosed at 300 mg (3 capsules) QD within 30 minutes after meal on each evening
89673654|NCT05553275|Active Comparator|Group 1:Usual Care|
89673655|NCT05553275|Experimental|Group 2: Permissive Care|
89673656|NCT05545540|Experimental|Intervention arm|Patients will be issued Mp3 players and speakers with music files in Mp3 formatted by the randomization team. The intervention arm will be issued the first movement (8 minutes, 22 seconds) of Mozart's Sonata for Two Pianos in D Major, K448. They will be exposed to it once a day during wakefulness for two consecutive months.
89673657|NCT05545540|Placebo Comparator|Control arm|Patients will be issued Mp3 players and speakers with music files in Mp3 formatted by the randomization team. The control arm will receive the first movement (8 minutes, 34 seconds) of Mozart's Fantasia for Piano in C Minor, K 475. Although from the same composer, the control sonata has been found not to have neurostimulating properties. They will be exposed to it once a day during wakefulness for two consecutive months.
89049760|NCT04651023|Experimental|high concentration of NnEx group|During the 12-week study period, the participants consumed two bottles (2 *200 mL) of the experimental beverage (2g NnEx) per day with or after meals.
89049761|NCT05395832|Experimental|TAU + multicomponent treatment VIRTUAL FIBROWALK at sea|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session at sea will be added to solve doubts and emphasize the most important points of therapy
89049762|NCT05395832|Active Comparator|TAU + multicomponent treatment VIRTUAL FIBROWALK in nature|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session in nature will be added to solve doubts and emphasize the most important points of therapy
89673658|NCT05529472|Experimental|CSI Peripheral Orbital Atherectomy System (OAS)|Treatment with OAS followed by POBA (pre-dilation) and DCB (Medtronic IN.PACT Admiral)
89673659|NCT05527834|Experimental|Cohort 1|Cohort 1 will assess the impact of a high fat meal.
89049763|NCT05395832|Active Comparator|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
89049764|NCT04651062|Experimental|endocuff|all patients having performed a screeningscolonoscopy and being randomized to colonoscopy with the use of endocuff
89049765|NCT04651062|Active Comparator|no cuff|all patients participating in a screeningscolonoscopy being randomized to colonoscopy without the use of endocuff
89049766|NCT05394779|Experimental|DTXO APP|"Patients randomized to Group A (experimental group) will be administered the Mediterranean based dietary program by means of App DTXO. The dietary program will be administered through the DTXO application. Each patient will select the assigned daily menu or the proposed alternatives; The dietary program is personalized according to the patients caloric intake needs and to their nutritional restrictions.~Patients randomized to Group A (experimental group) will be administered the Physical activity program by means of App DTXO. The activity program will be administered through the DTXO application based on the individual's background fitness level.~Patients randomized to Group A (experimental group) will be invited to follow a psycho-behavioral program to increase awareness of the behaviors and habits related to obesity, consisting of multimedia and educational content, self-assessment and dynamic exercises."
89049767|NCT05394779|Placebo Comparator|PLACEBO APP-Control group|"Patients randomized in Group B (control group) will be delivered a dietary program, according to the current standard of care and will be printed on paper with the information on the Mediterranean diet and general educational content related to food. The control arm will also be equipped with a placebo App to ensure the patient's blindness to treatment allocation and there will be asked to the patient to complete weekly the Diet Adherence questionnaire.~Patients randomized in Group B (control group) will be advised to perform regular physical activity and provided with educational material and some tips on physical activity; no formal plan will be provided, as currently done in standard clinical practice.~Patients randomized in Group B (control group) will receive printed educational material with generic content and advice for self-help support and followed as per standard clinical practice. The placebo App will be used as a data entry tool for questionnaires."
89673660|NCT05527834|Experimental|Cohort 2|Cohort 2 will be conducted to assess the impact of an alternative lower fat meal if administration with high fat meal has a food effect on drug exposure.
89049768|NCT04651101||vitamin D deficient|those patient with vitamin D level below 30 ng/dl
89673661|NCT05527834|Experimental|Cohort 3|Cohort 3 will evaluate realistic fasting intervals and/or additional meal types if administration with food has a food effect on drug exposure.
89049769|NCT04651101||non vitamin D deficient|those patient with vitamin D above 30 ng/dl
89049770|NCT05387408|Other|participating union health fund|"The investigators will recruit three health funds into a single arm trial. Each health fund will receive the intervention, Workplace Opioid Prevention Guidelines. The intervention is a set of guidelines containing information and suggested changes the health fund may make to their health and safety program specifically to prevent and manage opioid abuse in their workforce. The health fund the investigators receive the intervention after completing baseline data collection. The investigators will provide assistance with using the intervention as needed over a 6 month period of time, and measure changes the health fund makes to their health and safety program based on information in the guidelines. At 6 months, the investigators will repeat baseline data collection for the efficacy trial."
89049771|NCT05380700|Experimental|Virtual Reality Stimulation|All participants will be receiving the standard care and additionally the VR stimulation during their stay in the intermediate care unit.
89049772|NCT05376761|Experimental|DEX for STN-DBS|
89673662|NCT05502250|Experimental|Single-arm|4 cycles of gemcitabine and cisplatin (GP) + tislelizumab followed by 13 cycles of tislelizumab
89673663|NCT05502107|Experimental|PRESS Intervention|Study sites will participate in the intervention phase for 6 to 18 months, depending on the order of cluster randomization. Sites will switch from the baseline phase in approximately 6 month blocks, with all sites delivering the intervention for the final 6 months of the study.
89673664|NCT05502107|No Intervention|Standard of Care|Study sites will participate in the standard of care phase to collect baseline data for 6 to 18 months, depending on the order of cluster randomization. All sites are in the baseline phase for the first 6 months then sites will switch one at a time, every 6 months, to the intervention phase of the study.
89673665|NCT05493800|Experimental|Part 1, MIT-001 5 mg group|"Part 1, MIT-001 5 mg, once a day IV administration for 30 minutes before conditioning regimen administration 0.5~1 hr.~5 subject were enrolled sequentially."
89673666|NCT05493800|Experimental|Part 1, MIT-001 10 mg group|"Part 1, MIT-001 10 mg, once a day IV administration for 30 minutes before conditioning regimen administration 0.5~1 hr.~6 subjects were enrolled sequentially."
89049773|NCT04617561|Active Comparator|Ursodeoxycholic Acid group|Ursodeoxycholic Acid 13-15mg/kg/d
89673667|NCT05493800|Experimental|Part 1, MIT-001 20 mg group|"Part 1, MIT-001 20 mg, once a day IV administration for 30 minutes before conditioning regimen administration 0.5~1 hr.~5 subjects were enrolled sequentially."
89673668|NCT05493800|Experimental|Part 1, MIT-001 30 mg group|"Part 1, MIT-001 30 mg, once a day IV administration for 30 minutes before conditioning regimen administration 0.5~1 hr.~It was optional but did not ptoceed according to Steering committee's decision because low level of MIT-001 is enough to show the efficacy and safety of MIT-001."
89673669|NCT05493800|Experimental|Part 2, 5mg of MIT-001 low dose group|"Part 2, MIT-001 low dose, once a day IV administration for 30 minutes before conditioning regimen administration 0.5~1 hr.~15 subject will be enrolled parallelly."
89673670|NCT05493800|Experimental|Part 2, 20mg of MIT-001 high dose group|"Part 2, MIT-001 high dose, once a day IV administration for 30 minutes before conditioning regimen administration 0.5~1 hr.~15 subject will be enrolled parallelly."
89673671|NCT05493800|Placebo Comparator|Part 2, placebo(normal saline) group|"Part 2, placebo(normal saline), once a day IV administration for 30 minutes before conditioning regimen administration 0.5~1 hr.~15 subject will be enrolled parallelly."
89673672|NCT05486793|Experimental|Written Exposure Therapy (WET)|Participants randomized into this arm will receive the WET intervention administered by mental health clinicians.
89673673|NCT05486793|Experimental|Community Health Workers- Written Exposure Therapy (CHW-WET)|Participants randomized into this arm will receive the WET intervention administered by community health workers.
89673674|NCT05486793|Active Comparator|Emotion Focused Supportive Therapy (EFST)|Participants randomized into this arm will receive the EFST intervention.
89673675|NCT05460104|Experimental|Expérimental|Virtual Reality Exposure Therapy will be realised.
89673676|NCT05460104|Active Comparator|Control|Standard care without VRET
89673677|NCT05457868||Salbutamol|Exposure group
89673678|NCT05457868||Long-acting muscarinic antagonists (LAMA)|Reference group
89673679|NCT05440825|Experimental|VRelax|Participants will be using Virtual Reality relaxation (VRelax) in addition to treatment as usual
89673680|NCT05440825|Active Comparator|Relaxation exercises|Participants will be using relaxation exercises in addition to treatment as usual
89673681|NCT05435638|Experimental|KM-001 1% cream|"KM-001 1% cream will be applied to the affected area twice daily for 12 consecutive weeks.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves"
89673682|NCT05434065|Experimental|Celebrex treatment arm|Celecoxib 200 mg/dose, started within 6 h after onset, then one dose per day for 21 days.
89673683|NCT05434065|No Intervention|Control arm|No trial medication will be given.
89673684|NCT05423301|Experimental|experimental|
89673685|NCT05423301|Active Comparator|control|
89673686|NCT05416138|Experimental|TMS over the left prefrontal cortex|Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the left dorsolateral prefrontal cortex (DLPFC) at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing and stimulation per session is approximately 40 minutes (in 4 blocks with breaks in-between).
89673687|NCT05416138|Sham Comparator|TMS over the head vertex|Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the head vertex at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing per session is approximately 40 minutes (in 4 blocks with breaks in-between).
89673688|NCT05406817|Experimental|SNDX-5613|"Participants will be administered a single dose of SNDX-5613 (containing ~100 microcuries [14C]-SNDX-5613) in the AME part of the study.~Each dose administered after the first dose in the AME part of the study will be nonradiolabeled SNDX-5613. SNDX-5613 may continue to be administered following completion of the AME part of the study. Doses will be administered in continuous 28-day cycles until either PD or unacceptable toxicity."
89673689|NCT05402007|No Intervention|Control|The control group will not receive intervention during the study.
89049774|NCT04617561|Experimental|Ursodeoxycholic Acid+Low Dose Glucocorticoid group|Ursodeoxycholic Acid 13-15mg/kg/d+Methylprednisolone 12mg/d in induction period and 2-4mg/d in maintenance period
89673690|NCT05402007|Active Comparator|Face-to-face intervention|The face-to-face intervention group will perform pulmonary rehabilitation at the professional-oriented Rehabilitation Center.
89673691|NCT05402007|Active Comparator|Home intervention|The home intervention group will carry out home intervention through a self-explanatory exercise booklet.
89673692|NCT05398757|Other|Midazolam|For sedation during surgery, patients will receive i.v. midazolam in dose 0.05 - 0.07 mg/kg.
89673693|NCT05398757|Active Comparator|Propofol|For sedation during surgery, patients will receive i.v. propofol in dose 25-27 mcg/kg/min.
89673694|NCT05398757|Active Comparator|Dexmedetomidin|For sedation during surgery, patients will receive i.v. dexmedetomidin in dose 0.5 mcg/kg/h
89673695|NCT05382585||Head neck cancer|Histologically diagnosed cases of head and neck cancer
89673696|NCT05378269|Placebo Comparator|Placebo|Vaginal insert
89673697|NCT05378269|Experimental|DARE-VVA1 1mg|vaginal insert
89673698|NCT05378269|Experimental|DARE-VVA1 5mg|vaginal insert
89673699|NCT05378269|Experimental|DARE-VVA1 10mg|vaginal insert
89673700|NCT05378269|Experimental|DARE-VVA1 20mg|vaginal insert
89049775|NCT04617483|Experimental|Aged 26-45, Commercial Scale|Commercial scale inactivated SARS-CoV-2 vaccine in adults aged 26-45 years.
89049776|NCT04617483|Experimental|Aged 18-59, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in adults aged 18-59 years.
89049777|NCT04617483|Experimental|Aged ≥60, Pilot Scale|Pilot scale inactivated SARS-CoV-2 vaccine in elderly aged above 60 years.
89049778|NCT04617288|Experimental|Mean and standard deviations of age and height between group A and B|100 subjects with a mean age of 30.82±6.75 (group A, 31.42±6.67; group B, 30.82±6.82) ranging from 20 to 45 years, with a mean height of 165.52±7.85 (group A, 164.92±7.79; group B, 166.12±7.87) centimeters
89673701|NCT05377203|Experimental|Group A|Quadruple combination of half doses therapy for 4 weeks→Wash out for 2 weeks →Dual combination of standard dose therapy for 4 weeks.
89673702|NCT05377203|Experimental|Group B|Dual combination of standard dose therapy for 4 weeks→Wash out for 2 weeks →Quadruple combination of half doses therapy for 4 weeks.
89673703|NCT05372770|Experimental|Group 1: Transgender women using Flourish|"After gender-confirming surgery, this group will use the Flourish Vaginal Care System for six months, ramping up usage with healing. They will use Balance external wash beginning day 6 after surgery; Restore® vaginal moisturizing gel on dilators beginning day 6 after surgery; Restore every other day at bedtime with BiopHresh homeopathic/probiotic suppository every 3rd day at bedtime beginning week 6 after surgery through end of study at 6 months."
89673704|NCT05372770|No Intervention|Group 2: Transgender women not using Flourish|After gender-confirming surgery, this group will use only KY jelly on dilators beginning day 6 after surgery according to routine care; they will use any standard hygiene product (soap, body wash, etc) of their choice except products used by Group 1 through the end of the study at 6 months.
89673705|NCT05372770|Other|Group 3: Cisgender women|This group will use the Flourish Vaginal Care system for 6 months: Balance external wash daily; Restore intravaginal gel every other day at bedtime; BiopHresh homeopathic/probiotic suppository every 3rd day at bedtime through the end of study.
89673706|NCT05370625|Experimental|Totum-854|2.65-g dose of Totum-854 dietary supplement, a mix of 6 plant extracts. Five capsules per day to consume orally in two intakes Other names: active product
89673707|NCT05370625|Placebo Comparator|Placebo|Five capsules per day to consume orally in two intakes
89673708|NCT05367973|Experimental|IVR: Estradiol 80 ug/day + progesterone 4mg/day|12-week IVR 80/4
89673709|NCT05367973|Experimental|IVR Estradiol 160 ug/day + progesterone 8 mg/day|12-week IVR 160/8
89673710|NCT05363774|Experimental|Single ascending dose (SAD) part|Participants will receive up to six dose levels of subcutaneous NNC0519-0130 or matching placebo in a sequential manner with the dose increasing between cohorts.
89673711|NCT05363774|Experimental|Multiple ascending dose (MAD) QD part|MAD QD part comprises two cohorts in participants with overweight or obesity and a cohort in participants with type 2 diabetes (T2D). The participants in first cohort will receive NNC0519-0130 or matching placebo subcutaneously up to 5 dose levels, and the participants in the second MAD QD cohort will receive NNC0519-0130 or matching placebo orally up to 5 dose levels.
89673712|NCT05363774|Experimental|Type 2 diabetes (T2D) part|Participants will receive NNC0519-0130 or matching placebo up to 2 dose levels with dose escalation within the cohort.
89673713|NCT05363774|Experimental|MAD QW part|MAD QW part comprises two cohorts in participants with overweight or obesity and who are otherwise generally healthy. The participants in first cohort will receive NNC0519-0130 and 2nd cohort will receive matching placebo subcutaneously up to 6 dose levels.
89673714|NCT05363618|Active Comparator|Product Tolerability Arm|Study Product MHS-1031 1g (1.4 ml) per day
89673715|NCT05363618|Placebo Comparator|Placebo Tolerability Arm|Placebo (Neotame 7.92 mcg/g, phosphoric acid, and sterile water) 1.4 ml per day
89673716|NCT05358262|Experimental|Intervention using the Airvo device|Patients randomized to this group will receive the standard of care as well as wear the Airvo (equipment to provide high heated humidity) starting on Day 0 of their transplant for a minimum of 4 hours a day (to be worn in one continuous block of time). The humidity is delivered by nasal cannula that goes into your nose, similar to wearing oxygen. The equipment stands on a pole and plugs into a power outlet. Patients may take off the equipment for short periods of time. Eg to go to the bathroom.
89673717|NCT05358262|No Intervention|Standard of Care|"Patients randomized into this group will receive the usual standard of care for mucositis.~The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes."
89673718|NCT05350488||Stroke Survivors <1 year|Group A will include participants that are less than 1 year out from their most recent stroke.
89673719|NCT05350488||Stroke Survivors >1 year|Group B will include participants that are greater than 1 year out from their most recent
89673720|NCT05350488||Caregivers|Group C will include participants' identified caregivers.
89673721|NCT05325736||sleeve gastrectomy surgery|participants undergoing sleeve gastrectomy surgery for weight reduction
89673722|NCT05325736||gastric bypass surgery|participants undergoing gastric bypass surgery for weight reduction
89673723|NCT05325736||cholecystectomy|participants undergoing cholecystectomy
89673724|NCT05323552||Hernia repair with laparoscopic TEP approach without curare and without orotracheal intubation.|Patients will undergo laparsocopic TEP hernia repair without curare and without orotracheal intubation.
89673725|NCT05322954|Experimental|Oral Psilocybin|Psilocybin with psychological support: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
89673726|NCT05310253|Experimental|Fludrocortisone & TSST - BPD patients|intake of 0.4mg fludrocortisone (orally) before stress
89673727|NCT05310253|Experimental|Fludrocortisone & TSST - Healthy controls|intake of 0.4mg fludrocortisone (orally) before stress
89673728|NCT05310253|Experimental|Placebo pills & TSST - BPD patients|intake of placebo pill before stress
89673729|NCT05310253|Experimental|Placebo pills & TSST - Healthy controls|intake of placebo pill before stress
89673730|NCT05310253|Experimental|Fludrocortisone & Placebo-TSST- BPD patients|"intake of 0.4mg fludrocortisone (orally) before no stress"
89673731|NCT05310253|Experimental|Fludrocortisone & Placebo-TSST - Healthy controls|"intake of 0.4mg fludrocortisone (orally) before no stress"
89673732|NCT05310253|Experimental|Placebo pills & Placebo-TSST - BPD patients|"intake of placebo pill before no stress"
89673733|NCT05310253|Experimental|Placebo pills & Placebo-TSST - Healthy controls|"intake of placebo pill before no stress"
89049779|NCT04617288|Experimental|Between group comparison of VAS, NDI and ROM|VAS, NDI and Neck ROM between two groups were compared at pretest (0 day) and posttest (end of two weeks)
89049780|NCT04617249|Active Comparator|Giving median anesthesia|
89049781|NCT04617249|Active Comparator|Giving paramedian anesthesia|
89673734|NCT05296265|Experimental|Active VR treatment|Subjects assigned to the Active VR treatment will begin by selecting an avatar, with features such as gender and skin color that can be chosen according to preference. During treatment, they will participate in a variety of games and activities developed and used by our teams including Kick, Dog Food, Quest for Fire, Chess, Checkers, Sudoku, and surfing the internet. Subjects will have substantial flexibility to select games according to their interests but will be required to spend at least 30 minutes in each session in games that require forceful, large amplitude, movements of the amputated lower limb (e.g., Quest for Fire, Kick). Time spent and level of engagement as measured by movements of the avatar or, in the case of chess, checkers, solitaire, Sudoku, and internet surfing, the number of clicks produced with each leg will be recorded for each activity using custom software
89673735|NCT05296265|Experimental|Distractor VR treatment|"Subjects assigned to the Distractor VR treatment will participate in REAL i-Series immersive VR experience (REAL system), which has been demonstrated to reduce pain in several studies but lacks the hypothesized active ingredients of our Active VR treatment (visual and auditory feedback of movement of an extrapolated amputated limb). Subjects will navigate through pleasant and relaxing VR environments; they will not see any rendering of their body and make no movements with their legs"
89673736|NCT05286515|Experimental|Hybrid Preoperative Physical Therapy (PT)|
89673737|NCT05286515|Active Comparator|Control Standard Physical Therapy (PT)|
89673738|NCT05277766|Experimental|Nal-IRI (Onivyde) - 30mg/m²|PIPAC with Onivyde (30 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
89673739|NCT05277766|Experimental|Nal-IRI (Onivyde) - 45mg/m²|PIPAC with Onivyde (45 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
89673740|NCT05277766|Experimental|Nal-IRI (Onivyde) - 60mg/m²|PIPAC with Onivyde (60 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
89673741|NCT05277766|Experimental|Nal-IRI (Onivyde) - 75mg/m²|PIPAC with Onivyde (75 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
89673742|NCT05277766|Experimental|Nal-IRI (Onivyde) - 90mg/m²|PIPAC with Onivyde (90 mg/m²) will be administered every 4 to 6 weeks for 3 cycles.
89673743|NCT05274633||Participants With PNH|Data will be collected on participants who were already treated with eculizumab for at least 26 weeks and who started ravulizumab treatment as per clinical practice.
89673744|NCT05274581||Course participants|Course participants er general practitioners who have signed-up to participate in an ultrasound course
89673745|NCT05263310|Experimental|Educational Video and Action Plan handout|"Patients in the intervention arm will be given access to an educational video (Prepare for Your Diabetes Care) and will be supported in viewing the video and the Action Plan handout.~This program will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps with the participant's primary care provider."
89673746|NCT05263310|Active Comparator|Usual Care|Patients in the control arm will continue with usual care and also complete baseline, 6-month, and 12-month surveys
89673747|NCT05235568|Other|Valvosoft|Treatment with VALVOSOFT device
89673748|NCT05224089|Experimental|Liposomal Bupivacaine/Bupivacaine HCL|20mL 1.3% Exparel (266mg) + 60mL 0.25% bupivacaine (150mg) + 20mL normal saline. Total 100mL divided into 10mL syringes, 30 mL left TAP, 30mL right TAP, 20mL left rectus, 20mL right rectus.
89673749|NCT05224089|Active Comparator|Regular Bupivacaine Arm|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL of normal saline. Total 100mL divided into 10mL syringes, 30mL left TAP, 30mL right TAP, 20mL left rectus, 20mL right rectus.
89673750|NCT05208606|Experimental|Wawokiya Health Advocate|Patients and caregivers allocated to the Wawokiya Health Advocate arm will receive a palliative intervention consisting of regular needs assessments and home visits. After the first 2 visits, visits will occur bi-weekly, though a WHA may increase or decrease frequency of visits pending patient and caregiver needs and cancer status. The first two study visits will follow the same broad structure-structure of follow up visits will be flexible based on patient and caregiver needs. The location of study visits will vary and may include the local IHS site, cancer centers, and the patient's home depending on health status. Patients will be randomized to either receive home visits upon enrollment or be placed on a waitlist.
89673751|NCT05208606|No Intervention|Waitlist Arm|Patients enrolled into the waitlist group will not receive any additional services beyond what is available to them in their standard course of care. Patients randomized to the waitlist group will be asked to identify a primary caregiver upon enrollment. Data collection procedures will occur as described below. While on the waitlist, any services available for patients and their families will be according to the standards of their local providers and primary cancer providers.
89673752|NCT05205252|Active Comparator|Arm 1-Tazemetostat plus tafasitamab-cxix (CD19 Ab)/lenalidomide|"Participants with R/R, diffuse large B-cell lymphoma (DLBCL) will receive tazemetostat, tafasitamab, and lenalidomide for approximately 1 year.~After approximately 1 year, participants will receive tazemetostat and tafasitamab."
89673753|NCT05205252|Active Comparator|Arm 2-Tazemetostat plus lenalidomide|Participants with R/R DLBCL will receive tazemetostat and lenalidomide for approximately 1 year. After approximately 1 year, participants will receive tazemetostat alone.
89049782|NCT05349383||Antibody-Drug Conjugate (ADC)|Sepsis-related toxicities induced by antibody-drug conjugate(ADC). Case reported in the FDA Adverse Event Reporting System (FAERS) of Sepsis-related toxicities of patient treated by ADC, with a chronology compatible with the drug toxicity Intervention: Drug: ADC
89673754|NCT05205252|Active Comparator|Arm 3- Tazemetostat plus BTKi (acalabrutinib)|Participants with R/R mantle cell lymphomawill (MCL) will receive tazemetostat and acalabrutinib for the entire study.
89673755|NCT05205252|Active Comparator|Arm 4-Tazemetostat plus CD38 mAbPD (daratumumab/pomalidomide/dexamethasone)|"Participants with R/R multiple myelomawill (MM) will receive tazemetostat, daratumumab, pomalidomide, and dexamethasone for the entire study.~Daratumumab may be given intravenously or subcutaneously during this study."
89673756|NCT05205252|Active Comparator|Arm 5- Tazemetostat plus CD20/CD3 BsAb (mosunetuzumab)|Participants with R/R follicular lymphoma will receive tazemetostat and mosunetuzumab for approximately 1 year. After approximately 1 year, participants will receive tazemetostat alone.
89214985|NCT05459376|Sham Comparator|Sham Group|The sham group will follow the same principles of evaluation, classification and intervention according to the McKenzie method (MDT) (described in the intervention group) and will have a placebo dry cup application with 6 size 1 acrylic cups (4.5 cm internal diameter) with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of placebo dry cupping for 10 minutes, 2 times a week, for 8 weeks. However, cups will be prepared with small holes <2 mm in diameter to release negative pressure in seconds.
89214986|NCT05456477|Experimental|Beef|Subject will consume beef entrees each day of the study period, and will not consume any additional meat, poultry, seafood, and eggs, other than the study entrees.
89214987|NCT05456477|Active Comparator|Poultry|Subject will consume poultry entrees each day of the study period, and will not consume any additional meat, poultry, seafood, and eggs, other than the study entrees.
89214988|NCT05445414|Experimental|Intervention group|"Participants randomized to the intervention group will be asked to use the SteWARdS Antibiotic Defense app-an evidence-based serious game app developed by the study team-for a minimum of five days. They will also need to complete three sets of questionnaires - one set at baseline, one set after completing the quest in the app, and another set 6-10 weeks after they complete the quest in the app."
89214989|NCT05445414|No Intervention|Control group|Participants randomized to the intervention group would be asked to complete two sets of questionnaires - one set at baseline and another set 6-10 weeks later.
89214990|NCT05436808|Experimental|Radiation Treatment|
89214991|NCT05422339|Experimental|Gamified Intervention|This condition will involve the implementation of an assistive technology software (named the MapHabit system) with added gamification features into the daily care of individuals with mild to moderate stage of dementia. The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application will be made available to families through compatible tablets.
89214992|NCT05422339|Active Comparator|Non-gamified Intervention|This control condition acted as the active comparator to the experimental condition. The same assistive technology, the MapHabit system, will be given to a separate group of participants. The difference here will be that the software will be a version that does not include gamification features.
89214993|NCT05422339|Other|Exploratory Intervention|The exploratory condition will be given the same MHS version as the active comparator (control condition). However, for this group, participants will also engage in virtual reality games throughout the duration of the study. These virtual reality games are integrated with the MHS and includes cognitive games revolving around mental acuity, motor skills, etc.
89214994|NCT05388604|Experimental|Treatment|Subjects are to be treated with the RF device, followed by the microneedling device. Parameters may be adjusted throughout the treatment and will determined by the Clinician. Subjects will receive up to 4 treatments, spaced approximately 4 weeks apart.
89214995|NCT05379946|Experimental|Phase 1b Dose escalation of D-1553 plus IN10018|Phase 1b will evaluate up sequential cohorts with different doses of IN10018 together with D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.
89214996|NCT05379946|Experimental|Phase 2 Doseexpansion of D-1553 plus IN10018|Phase 2 will include more subjects to further evaluate the safety and efficacy of D-1553 in combination with IN10018 in patients with solid tumors with KRasG12C mutation.
89214997|NCT05347914|Experimental|Mindfulness|
89673757|NCT05191030|Experimental|Experimental (High-Stress) Arm|"Participants undergoing the experimental (high-stress) arm are exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993). Participants are given five minutes to prepare for a five-minute speech task followed by a five-minute mental arithmetic task in front of two panelists wearing white lab coats (i.e., a male and female research assistant). The speech task posits the participant in a mock interview, with the two panelists listening to the speech in an unresponsive, neutral manner and asking standardized probing questions. Participants undergoing the mental arithmetic task are instructed to subtract odd numbers (i.e., 7 and 13) from a large number (i.e., 2935) as quickly as possible. If the participant makes a mistake, the panelist interrupts them and instructs them to start the task again from the beginning. The panelists also constantly remind the participant to go faster if they start to slow down with the task."
89673758|NCT05191030|No Intervention|Control Arm|Participants undergoing the control arm are presented with low-stress equivalents to the speech and mental arithmetic tasks from the experimental (high-stress) arm. For the speech task, participants are instructed to talk out loud to themselves for five minutes about a movie or book of their choice. Their speech is recorded using a small audio recorder device the research assistant prepares. For the mental arithmetic task, participants are instructed to count by increments of 15 starting from zero to the largest number they can reach. Participants are left in the room alone for the task for five minutes, after which the participant self-reports to the research assistant the number they reached.
89673759|NCT05181696||COVID-19 pneumonia patients|Patients treated at the University Hospital Osijek Respiratory Center with pneumonia caused by SARS-CoV-2
89214998|NCT05338879||Cohort 1|Participants with r/r FL grade 1-3a who were treated with at least 2 prior systemic therapies in the real-world setting.
89673760|NCT05173805|Experimental|YL-15293|"Single arm, open, single and multiple doses; Dosage form: YL-15293 tablets Specification: 50mg, 200mg Storage conditions: refrigerated and sealed at 2-8℃~Way of administration:~Single-dose study: Oral administration, once a day, with warm water, fasting administration, fasting 1 hour before and 2 hours after administration. Multiple administration studies: oral administration, warm water delivery, fasting administration, fasting 1 hour before administration and 2 hours after administration, continuous administration for 21 days as a treatment cycle. The way of taking the medicine is twice a day."
89688725|NCT04361773|Active Comparator|Photobiomodulation group|In this group, PBM will be applied daily using LED devices until the lesion presents healthy granulation tissue, absence of necrosis and purulent secretion and, therefore, is suitable for primary closure, closure by flap or graft or for healing by second intention. At this point, the protocol will be finalized.
89688726|NCT04361773|Sham Comparator|Sham group|Sham group participants will receive the application of the disconnected device, for the same period. The characteristic sound of the device will be activated by means of recording.
89688727|NCT02933476|Experimental|Vibrotactile Stimulation Treatment|All patients will receive the vibrotactile stimulation treatment. No deception will be used.
89673761|NCT05160688|Experimental|Contingency management|Contingency management (CM) is an incentive-based intervention providing patients with tangible rewards as reinforcement for positive behaviors like abstinence from drug use. Incentives are provided with each urine sample that is drug-free and are increased with each subsequent drug-free urine sample. Participants in the CM condition will receive increasing payments for abstinence: $30 on day 3, $45 on day 5, $60 on day 7, $75 on day 14, $90 on day 21, $105 on day 28, and $120 on day 42. Participants in both conditions also receive increasing payment for visit attendance: $10 on day 1, $15 on day 3, $20 on day 5, $25 on day 7, $30 on day 14, $35 on day 21, $45 on day 28, and $55 on day 42. At the end of the baseline visit, participants in the CM condition will sign a behavioral contract with study staff that clearly outlines expectations as well as the payment schedule.
89673762|NCT05160688|No Intervention|No intervention|Participants in this condition will be monitored and will not receive any compensation for cannabis abstinence.
89673763|NCT05153356||Parkinson Disease patients|To examine the relationship between in-home continuous measures of tremor, bradykinesia, mobility, and dyskinesia acquired over a 7-day period, from 2 mobile health technologies (Personal Kinetigraph, Kinesia 360) with one-time in-clinic measures of motor functional ability pertaining to the same 7-day period as assessed by Part 2 of the MDS-UPDRS, Part 4 of the MDS-UPDRS, Neuro-QOL, and PDQ-39. This will be examined in n=20 patients (10 patients assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks). Patients will then be following for an observational period of an additional 6 months.
89673764|NCT05144633||Acute Respiratory failure|Patients presenting to the Emergency Department in acute respiratory failure. These patients may or may not have a diagnosis of chronic lung disease.
89673765|NCT05131165|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices. At recruitment participant will be explained the importance of pill-taking. All participants (including in the control group) will receive a leaflet containing detailed information on how to establish healthy pill-taking routines. Finally, clinic staff will counsel participants on how to select an already regularly routine behavior that occurs at roughly the same time each day that forms the basis of their implementation plan.
89673766|NCT05131165|Experimental|Intervention group receiving messages (Messages Group)|"Participants will receive the same information as those in the Control Group, but in addition, receive the Daily Text Message Intervention."
89673767|NCT05131165|Experimental|Intervention group receiving messages and incentives (Incentives Group)|"Participants will receive the same information as the Control group. Additionally, they will receive the Daily Text Message Intervention and will be eligible for prize drawings."
89673768|NCT05129618|Active Comparator|Product Tolerability Arm|active product: MHS 1031 Panosyl-isomaltooligosaccharides liquid 1 g (1.4 ml) per day
89673769|NCT05129618|Placebo Comparator|Placebo Tolerability Arm|Placebo liquid 1 g (1.4 ml) per day
89673770|NCT05125237||Amiloride|Exposure group
89673771|NCT05125237||Triamterene|Reference group
89673772|NCT05125224||Dihydropyridine calcium channel blocker|Exposure group
89673773|NCT05125224||Hydrochlorothiazide|Reference group
89673774|NCT05119972|Experimental|part1:ZSP1603 dose1|
89673775|NCT05119972|Experimental|part1:ZSP1603 dose2|
89673776|NCT05119972|Experimental|part1:ZSP1603 dose3|
89673777|NCT05119972|Experimental|Part2: ZSP1603 dose|
89673778|NCT05119972|Placebo Comparator|Part2: placebo|
89673779|NCT05108896|Other|Aspiration in Acute Respiratory Failure Survivors|All participants will receive a tracheal ultrasound within 72 hours prior to extubation, collection of demographic and hospital clinical information, administration of 3 screening tests (study defined algorithm test, 3-ounce water swallow test, TOR-BSST) addressing swallowing function within 24 hours post-extubation, and a fiberoptic endoscopic examination of swallowing (FEES) exam.
89673780|NCT05105451||Patients in the control group were followed up without dNCR postoperatively.|If the MOCA or MMSE assessment all show a negative resluts at all time point.
89673781|NCT05105451||Patients in the case group were followed up with dNCR postoperatively.|If the MOCA assessment is positive at any time point after surgery, and there is a positive MMSE at any time point after surgery(no need for both MOCA and MMSE to be positive at the same time), it is defined as the occurrence of dNCR.
89673782|NCT05073432|Experimental|Experimental|Electronic completion of Geriatric Assessment and Conjoint Analysis with result output.
89673783|NCT05035056||CT Coronary Angiogram with quantitative characterization of plaque|Participants (103) from Intensive Medical Therapy [IMT] and 103 from the Usual Care [UC] group in the WARRIOR trial) will undergo CTA at the Year 3 follow-up visit (can be as early as 2 years) at their respective enrollment study sites. Quantitative characterization of plaque analysis will be conducted at Cedars-Sinai Medical Center using Autoplaque plaque analysis software.
89673784|NCT06232564|Experimental|Open Label, Single Arm, Phase II Study|This is an open label, single arm, phase II multicentre study designed to evaluate the efficacy and safety of pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy in patients with HG-NETs who are chemotherapy-naïve for their metastatic disease. The study will be conducted in up to 10 sites and will recruit up to a maximum of 20 evaluable participants.
89673785|NCT06232551|Experimental|At-risk patients for which an alert is sent during the intervention phase|Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), thereby meeting criteria for alerting during the intervention phase
89673786|NCT06232551|Active Comparator|At-risk patients during the baseline phase|Patients found to be at an increased risk for VTE but a low risk for bleeding (based upon eVTE risk assessment), and who meet criteria for alerting, but for whom no alert is sent during the baseline phase
89673787|NCT06232525|Active Comparator|transobturator tape operation group|Patients who are decided to undergo surgery due to stress urinary incontinence are the group who will undergo TOT surgery through a lottery system where the computer program will decide on the surgeon who will perform the surgery, without being told which surgery they will have (both surgeries will be performed through the mid-urethral approach and the patient will not be told whether mesh is used or not).
88815753|NCT01043432||Moderate/severe TBI and history of suicidal behavior Group 1|Moderate/severe TBI and history of suicidal behavior
89673788|NCT06232525|Active Comparator|urethral ligament plication group|Patients who are decided to undergo surgery due to stress urinary incontinence are the group who will undergo urethral ligament plication surgery through a lottery system where the computer program will decide on the surgeon who will perform the surgery, without being told which surgery they will have (both surgeries will be performed through the mid-urethral approach and the patient will not be told whether mesh is used or not).
89673789|NCT06232512|Experimental|Exploratory Arm|Individuals will complete standardized balance and walking tasks with and without sensory substitution from the haptic device system.
89673790|NCT06232486||Herpes zoster patients|The patient was diagnosed with herpetic neuralgia and the course of disease was ≤3 months;
89673791|NCT06232473|Experimental|Patient Education|The patient education program consists of three individual sessions (consultations with the participant's doctor, one to one and a half hour duration each) and one group session (three hours in groups of up to 16 participants). The program focuses on providing patients with a positive and evidence-based understanding of their illness by providing an individualized bio-psycho-social explanation of multisystem functional somatic disorder.
89673792|NCT06232473|Active Comparator|Enhanced Usual Care|Inclusion consultation and final visit at end of treatment (week 12) are the only contacts provided to participants randomized to receive enhanced usual care.
89673793|NCT06232473|Experimental|Duloxetine and Enhanced Usual Care|"Duloxetine will be given as capsules orally once daily. Participants will commence with 2 weeks of 30 mg duloxetine and then increase the dose to 60 mg duloxetine (two capsules). If participants are unable to increase in dose due to adverse events, but still tolerate the initial dose of 30 mg duloxetine, this dose is kept for the remaining part of the trial. Treatment will continue for 8 weeks on highest dosis until primary endpoint (end of treatment). The dose is then reduced to 30 mg duloxetine for 1 week after which the study drug is discontinued.~In addition, participants will recieve enhanced usual care as described above."
89673794|NCT06232473|Placebo Comparator|Placebo and Enhanced Usual Care|"Participants will recieve the active placebo benztropine mesylate 0,5 mg. In order to best mimic the dosage increase of the duloxetine treatment program a passive placebo RAP will be added for the 8 weeks of high dosage treatment. Benztropine mesylate and passive placebo will be given as capsules orally, and will be re-encapsulated by the hospital pharmacy to assure identical appearance to the duloxetine capsules. Participants will commence with 2 weeks of 0.5 mg benztropine mesylate (one capsule) and continue with 0.5 mg benztropine mesylate and passive placebo RAP (two capsules) for 8 weeks. This will be end of treatment. Participants will then be asked to reduce to one capsule (0.5 mg benztropine mesylate) for 1 week after which the study drug is discontinued.~In addition, participants will recieve enhanced usual care as decribed above."
89673795|NCT06232473|Experimental|Patient Education and Duloxetine|Participants in this arm will recieve patient education as described above. In addition, participants will recieve duloxetine as described above.
89673796|NCT06232473|Experimental|Patient Education and Placebo|Participants in this arm will recieve patient education as described above. In addition, participants will recieve the placebo treatment as described above.
89673797|NCT06232460|Experimental|H80|5g, 10g and 20g dose escalation
89673798|NCT06232447|Experimental|Cigarette Type Switching|Participants will be switched from smoking menthol cigarettes to non-menthol cigarettes
89673799|NCT06232395||malignant group|Subjects diagnosed with gastric cancer.
89673800|NCT06232395||non-malignant group|Healthy individuals and subjects with gastritis, gastric ulcer, gastric polyp or other benign gastric diseases.
89673801|NCT06232382|Experimental|Hypnosis Audio|20 minutes audio
89673802|NCT06232382|Experimental|Mindfulness meditation|20 minutes audio
89673803|NCT06232382|Placebo Comparator|Natural text audio|20 minutes audio
89049783|NCT05349383||Common cancer drug therapies other than ADC|"Sepsis-related toxicities induced by Common cancer drug therapies other than ADC.~Case reported in the FDA Adverse Event Reporting System (FAERS) of Sepsis-related toxicities of patient treated by Common cancer drug therapies other than ADC, with a chronology compatible with the drug toxicity~Intervention:~Drug: Chemotherapy, targeted therapy, immunotherapy and so on."
89049784|NCT05344820|Experimental|Mandala Intervention|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
89049785|NCT05344820|No Intervention|Control|No intervention will be applied to the control group
89049786|NCT04617171|Experimental|Benralizumab|Benralizumab 30 mg given in the form of subcutaneous injection every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
89049787|NCT04617171|Placebo Comparator|Placebo|Normal Saline given subcutaneously every 4 weeks for the first three doses, then every 8 weeks subsequently up till Week 48.
89673804|NCT06232356||Study population|The study population will consist of adult subjects (healthy or with respiratory disease - COPD) between 18 and 80 years of age, who will be enrolled in the pulmonary function laboratories of the participating hospitals, from among those listed above, who are attended to a functional respiratory examination.
89673805|NCT06232343|Experimental|Experimental|This group followed a resisted training programmed with a parachute
89673806|NCT06232343|Other|Controlled|This group perform sprinters with no external resistance training
89673807|NCT06232330|Experimental|Group A|TOA and conventional therapy
89673808|NCT06232330|Experimental|Group B|PNF and conventional therapy
89673809|NCT06232317|Experimental|Virtual Reality Software|Participants in this arm will receive cognitive exercises using ReCognitionVR virtual reality software
89673810|NCT06232317|Active Comparator|Traditional Orientation Methods|Participants in this arm will receive cognitive exercises using traditional (standard-of-care) orientation methods,
89673811|NCT06232304|Experimental|TEACH|Participants will undergo a cognitive behavioral coping skills program and continue medical treatment as usual.
89673812|NCT06232304|No Intervention|Control|Participants will only continue medical treatment as usual.
89049788|NCT04617054|Experimental|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106|
89049789|NCT05337488||Subject with solitary drinking behaviour|A convenience sample of 40 solitary drinkers aged between 10 and 24 will be invited to undergo complete a questionnaire and an individual semi-structured interviews.
89049790|NCT00557934|Experimental|1|
89049791|NCT04679753|Active Comparator|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)
89673813|NCT06232239|Experimental|Sequence 1- Empagliflozin test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Empagliflozin Tablets 10 mg test product, treatment 2= Empagliflozin Tablets 10 mg reference product.
89673814|NCT06232239|Experimental|Sequence 2-Empagliflozin reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Empagliflozin Tablets 10 mg test product, treatment 2= Empagliflozin Tablets 10 mg reference product.
89673815|NCT06232226|Other|Neuropsychological assessment|Determination of the neuropsychological profile
89673816|NCT06232213||experimental group|The results of PTC microtumor model were used to guide treatment, including 12 cases of ovarian cancer and 8 cases of endometrial cancer.
89673817|NCT06232213||control group|Patients who did not use the PTC model to guide treatment during the same period included 12 cases of ovarian cancer and 8 cases of endometrial cancer.
89673818|NCT06232135||Females|CBCT scans of the females enrolled in the study are to be analyzed for the assignment of a calcification stage to their lower left third molar according to the modified Demirjian method.
89673819|NCT06232135||Males|CBCT scans of the males enrolled in the study are to be analyzed for the assignment of a calcification stage to their lower left third molar according to the modified Demirjian method.
89673820|NCT06232122|Experimental|68Ga-FAPI ,PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
89673821|NCT06232109|No Intervention|ASN51|
89673822|NCT06232109|Experimental|ASN51 + Fluvoxamine|
89673823|NCT06232109|Experimental|ASN51 + Itraconazole|
89673824|NCT06232109|Experimental|ASN51 + Paroxetine|
89673825|NCT06232083|Experimental|PLDR+αPD-1|
89673826|NCT06232070||Standard Pathway Arm|All participating patients will have their mammograms reported using the standard of care. The mammograms randomised to the Standard Pathway arm will be reported using the current standard of care, which involves two human readers; The readers will be blind to Lunit INSIGHT MMG report
89673827|NCT06232070||Lunit Assisted Arm|All participating patients will have their mammograms reported using the standard of care. Those randomised to the Lunit assisted arm will also undergo double reader process , ensuring the current standard of clinical care is provided. In addition to that, the Lunit INSIGHT MMG report will also be available to the readers. Within this arm, each reader will be presented with a Likert scale to rank their level of agreement with the Lunit INSIGHT MMG report
89673828|NCT06232044|Experimental|Phase I (iberdomide, belantamab mafodotin, dexamethasone)|Patients receive iberdomide orally on days 1-21 and 29-49, belantamab mafodotin IV on day 1, and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo a bone marrow biopsy and aspiration and blood sample collection throughout trial.
89673829|NCT06232044|Active Comparator|Phase II, Arm I (belantamab mafodotin, dexamethasone)|Patients receive belantamab mafodotin IV on day 1 and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients who progress may cross over to Arm II. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo a bone marrow biopsy and aspiration and blood sample collection throughout trial.
89673830|NCT06232044|Experimental|Phase II, Arm II (iberdomide, belantamab mafodotin)|Patients receive iberdomide orally on days 1-21 and 29-49, belantamab mafodotin IV on day 1, and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo bone marrow biopsy and aspiration and blood sample collection throughout trial.
89673831|NCT06232018|Active Comparator|Skin adhesive|"Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson & johnson, Somerville, NJ)~Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson & johnson, Somerville, NJ)~After subticular sutures was done~Intervention : 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson & johnson, Somerville, NJ)"
89673832|NCT06232018|Active Comparator|skin adhesive + polyester mesh|"Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson & johnson, Somerville, NJ)~Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson & johnson, Somerville, NJ)~After subticular sutures was done~Intervention : 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson & johnson, Somerville, NJ)"
89673833|NCT06232005|Active Comparator|25 Patients with recurrent urethral stricture undergoing visual internal urethrotomy only.|Standard procedure of visual internal urethrotomy only for urethral stricture
89049792|NCT04679753|Active Comparator|Brainsway DTMS with High Frequency Stimulation (HF)|Brainsway DTMS with High Frequency Stimulation (HF)
89673834|NCT06232005|Experimental|25 Patients with recurrent urethral stricture undergoing visual internal urethrotomy with intralesio|intralesional injection of mitomycin-c following the standard visual internal urethrotomy
89673835|NCT06231992|Active Comparator|opioid based anesthesia|I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
89673836|NCT06231992|Active Comparator|opioid free anesthesia|- IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance. Dexamethasone I.V (8 mg) will be given before induction of general anesthesia. magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h).
89049793|NCT00558051|Active Comparator|Intradermal administration|Intradermal administration
89049794|NCT00558051|Active Comparator|Intranodal administration|Intranodal administration
89049795|NCT00558051|Active Comparator|Intralymphatic infusion|Intralymphatic infusion
89049796|NCT04679714|Experimental|Single-arm study of PLAR Implant and Delivery System|All enrolled patients will receive the study device
89049797|NCT00558090|Active Comparator|A|patients receive 2,5 mg morphine iv, before the first intervention on the day after admission in the ICU
89049798|NCT05323604||Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
89049799|NCT00558129|Experimental|Investigational|X-STOP® PEEK IPD
89049800|NCT00558129|Active Comparator|Control|Laminectomy
89673837|NCT06231979|Experimental|Dexmedetomidine group|Patients will receive US-guided ESPB with 18 mL of bupivacaine 0.25 % and 1 μg/kg DEX diluted with saline to reach total volume 20 mL per side.
89673838|NCT06231979|Experimental|Bupivacaine group|Patients will receive US-guided ESPB with 18 mL of bupivacaine 0.25 % and 2 mL normal saline 0.9 % per side as control group.
89673839|NCT06231966|Experimental|Rosuvastatin/ezetimibe combination therapy|Combination therapy of high-intensity dose rosuvastatin and ezetimibe
89673840|NCT06231966|Active Comparator|Rosuvastatin monotherapy|Rosuvastatin monotherapy for treat-to-target (LDL cholesterol < 70 mg/dL)
89673841|NCT06231953||Cancer patients|Patients who have diagnosed as invasive cancers
89673842|NCT06231953||Healthy volunteers|Subjects who have done cancer screening tests
89673843|NCT06231940|Experimental|Complex Decongestive Therapy (CDT) in venous insufficiency|
89673844|NCT06231940|No Intervention|Control group|
89673845|NCT06231927|Experimental|Single arm|This is an open feasibility trial with single group of individuals receiving the SOLAR intervention program.
89673846|NCT06231914|Experimental|Fractional 1064-nm Picosecond laser|Fractional 1064-nm Picosecond laser for 3 sessions, at 4-week interval
89673847|NCT06231901|Experimental|coop plus traditional occupational therapy|This group received the traditional occupational therapy plus CO-OP approach.
89673848|NCT06231901|Experimental|GDT plus traditional occupational therapy|This group received the traditional occupational therapy plus Goal directed training.
89673849|NCT06231901|Other|traditional occupational therapy|This group only received the traditional occupational therapy .
89673850|NCT06231888||Press|
89673851|NCT06231888||Vacuum|
89673852|NCT06231875||Press|
89673853|NCT06231875||Vacuum|
89673854|NCT06231862||Suspected/documented bacterial sepsis|Patients have evidence of an acute bacterial infection with organ dysfunction
89673855|NCT06231862||Suspected/documented viral sepsis|Patients have evidence of an acute viral infection with organ dysfunction
89673856|NCT06231862||Infection negative systemic inflammation (SIRS)|Patients have no active infection but exhibit SIRS
89673857|NCT06231849||normal subjects without opioid intoxications.|1. Individuals of male gender aged between 20 to 35 years old
89673858|NCT06231849||individuals with opioid use disorders.|Individuals of male gender aged between 20 to 35 years old with opioid use disorders.
89673859|NCT06231836|Active Comparator|High flow nasal cannula group|
89673860|NCT06231836|Active Comparator|Nasal cannula group|
89673861|NCT06231823|Experimental|extraction of the compromised first permanent molars at 8-10 years children|extraction of badly decayed FPM at the E,F developmental stages of the second permanent molar.
89673862|NCT06231784|Other|Lumina Implantation|Patients implanted with LUMINA IOL
89673863|NCT06231732|Active Comparator|treatment arm|The frequency of the stimulation was 77.5Hz and the intensity was 15mA. Each participant was treated twice a day for 40 minutes each time, with an interval of more than 3 hours between the two sessions for 30 days
89673864|NCT06231732|Sham Comparator|sham-treatment arm|The frequency of the stimulation was 77.5Hz and the intensity was 0mA. Each participant was treated twice a day for 40 minutes each time, with an interval of more than 3 hours between the two sessions for 30 days
89673865|NCT06231693||Trastuzumab-deruxtecan|
89673866|NCT06231667|Experimental|Education|The health literacy training was implemented in a total of 4 sessions, each session lasting 30 minutes, with an interval of one week. Various teaching methods and techniques were used in the trainings.
89673867|NCT06231667|No Intervention|Control|
89673868|NCT06231654|Experimental|patents|the child will be placed in a dedicated, quiet, well-lit office with their parents. The following data are then collected: sex, age, phototype according to Fitzpatrick's classification. The child sits in a chair facing a camera connected to a laptop running Caducy® Medical Device software. At the same time, and following the usual procedure, three ECG electrodes will be positioned on the patient.
89673869|NCT06231641|Active Comparator|Active treatment condition|Lemborexant at a 5mg dose is delivered in a film-coated tablet
89673870|NCT06231641|Placebo Comparator|Placebo condition|Placebo is delivered in a film-coated tablet
89688728|NCT04361695|Active Comparator|Ketoprophenum|A tablet with 10 mg Ketoprophenum is taken per os 2 hours before surgery
89688729|NCT04361695|Placebo Comparator|Placebo|A tablet containing starch is taken per os 2 hours before surgery
89049801|NCT04616976||convalescent plasma therapy group|the patients received convalescent plasma therapy
89049802|NCT04616976||Control group|the patients with similar situation without convalescent plasma therapy
89049803|NCT05293847|Experimental|Telerehabilitation exercises|Exercises about postural structures on the cervical and thoracal region. Bilateral pectoral stretching, chin tack exercises, cervical isotonic exercises, stretching of the upper trapezius and longus Colli, scapular region strengthening, shoulder capsular stretching, Wand exercises for 12 weeks and 3 times a week.
89049804|NCT04616742|Experimental|[14C]SHR6390|
89049805|NCT04616703||BMI < 25 kg/m2|Those with NFAT and BMI < 25 kg/m2.
89688730|NCT03035773|Experimental|ARM A|SCP document delivered to the patient & Primary Care Provider
89688731|NCT03035773|Experimental|ARM B|SCP document provided to the patient in an in-person survivorship visit and copy sent to PCP
89688732|NCT03035773|Experimental|ARM C|SCP document provided to the patient in an in-person survivorship visit with an additional follow-up visit and copy of the document sent to PCP
88815754|NCT01043432||Moderate/Severe TBI and no history of suicidal behaviorGroup|Moderate/Severe TBI and no history of suicidal behavior
89049806|NCT04616703||BMI 25-30 kg/m2|Those with NFAT and BMI 25-30 kg/m2.
89049807|NCT04616703||BMI > 30 kg/m2|Those with NFAT and BMI > 30 kg/m2.
89049808|NCT04651140|Active Comparator|Tremor group|Participants in the tremor group have tremor as the main clinical manifestation
89673871|NCT06231628|Experimental|Patients|"A single arm with patients with advanced cancer who have all of the following:~refractory pain and/or gait disturbance caused by pelvic bone metastasis, did not respond to conservative treatment.~osteolytic lesion (in predominance) suitable for the pain.~limited life expectancy (less than 3 years) or stopping medical treatment.~Exclusion criteria:~There are no absolute contraindications for the procedure; however, the relative contraindications are:~patients in poor condition with an expected survival period of less than 3 months.~patients with stable course, with long life expectancy (more than 3 years) or those considered candidates for major pelvic surgery including tumor removal and hip arthroplasty.~presence of bone destruction with soft tissue mass contaminating important organs, nerves and blood vessels (improvement is not expected).~Patients refusing to give a written consent to the study protocol."
89673872|NCT06231615|Experimental|Treatment group|Patients in this group are the group to which fascia exercises are applied.
89049809|NCT04651140|Active Comparator|Stiff group|Participants in the tremor group have stiff as the main clinical manifestation
89049810|NCT05287217|Active Comparator|Group 1: Scheduled pain control|Group 1 patients will be instructed to take 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 consecutive days after surgery regardless of whether they experience pain or not.
89049811|NCT05287217|Active Comparator|Group 2: Pain control as needed.|Group 2 patients will be instructed to take the 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 days after surgery only when needed to control pain.
89049812|NCT05278403|Active Comparator|Control group|Conventional neurological physiotherapy treatment.
89673873|NCT06231615|Other|Control group|Patients in this group are the group to which conventional physiotherapy and breathing exercises are applied.
89673874|NCT06231589|No Intervention|Control|111 Males have normal Teratozoospermia index (TZI) less than 1.6. Semen processing is done by double layer density gradient method only.
89673875|NCT06231589|Experimental|Sperm selection group PICSI or MACS (SS-Group)|"90 Males with high TZI and sperm selection techniques such as PICSI or MACS are performed. Semen processing is done by double layer density gradient method followed by:~(1) In case of PICSI: adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Individual bound sperm selection is done followed by ICSI.~or (2) In case of MACS: Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for ICSI."
89673876|NCT06231589|No Intervention|No sperm selection group (NO SS-Group)|63 Males with high TZI more than 1.8 and no sperm selection techniques are performed. Semen processing is done by double layer density gradient method only.
89673877|NCT06231576|Experimental|Hospital|Prehabilitation at the hospital, with guidance by a dedicated physiotherapist physically present.
89673878|NCT06231576|Experimental|Digital|Prehabilitation at home, with guidance from a dedicated physiotherapist through a digital platform, realtime.
89673879|NCT06231576|No Intervention|Control|Information about the general benefit of a healthy lifestyle at inclusion, thereafter no further follow-up prior to surgery.
89673880|NCT06231563|Experimental|Ketamine|intravenous ketamine infusion 0.5 mg/kg
89673881|NCT06231563|Placebo Comparator|Remimazolam|intravenous remimazolam infusion 0.25 mg/kg
89673882|NCT06231537|No Intervention|Control Group|Health professionals, including dentists (CD), dental hygienists (TSB), dental assistants (ASB), nurses, and general practitioners, will continue providing care to users in accordance with the existing Service Card protocols in the city of Rio de Janeiro. This ensures on-demand service for users seeking dental care. Additionally, they will continue to facilitate participation in the Tobacco Control Program for interested individuals, following the established protocol of the city of Rio de Janeiro. Notably, members of the control group will not partake in the qualification process conducted by this research project. However, in the event of positive results at the research's conclusion, consideration will be given to extending qualification opportunities to the control group as well.
89673883|NCT06231537|Experimental|Active Screening Group|"Health professionals (Community Health Agents, dentists, dental hygienists, dental assistants, nurses, and general practitioners) will undergo training focused on preventing OC, considering risk factors and highlighting the significance of preventive oral examinations for early diagnosis. Dentist and general practitioners will receive training to conduct oral examinations, enabling them to identify suspicious lesions and potentially malignant disorders. The qualification process will be conducted through face-to-face meetings and/or videoconferencing, supplemented by educational material delivered via the widely used messaging application (WhatsApp).~Following qualification, tobacco users and excessive alcohol users will be invited to visit the Family Clinic for oral preventive examination. After six months, in the event that a user does not attend the Family Clinic, the Health Team will conduct an active search, through home visits or community outreach in bars."
89673884|NCT06231537|Experimental|Campaign Group|"Health professionals (Community Health Agents, dentists, dental hygienists, dental assistants, nurses, and general practitioners) will be training focused on preventing OC, risk factors and highlighting the significance of preventive oral examinations for early diagnosis. Dentist and general practitioners will receive training to conduct oral examinations, enabling them to identify suspicious lesions and potentially malignant disorders. The qualification process will be conducted through face-to-face meetings or videoconferencing.~Following qualification, tobacco and excessive alcohol users will be invited to visit the Family Clinic for oral examination. After six months, a public awareness campaign, over one month, will be conducted in the Family Clinics. This campaign will provide guidance on risk factors, signs and symptoms, and the importance of oral examinations."
89673885|NCT06231524||Validation cohort|A cohort of consecutive patients from the Sixth Affiliated Hospital of Sun Yat-sen University is used for model validation.
89673886|NCT06231485|Experimental|Socialization and sex education (STEPS2)|Weekly virtual one hour one-on-one sessions with Study Health Educator on the STEPS2 curriculum for 6-weeks. Topics include: the human body, decision-making, sexually transmitted diseases, pregnancy, birth control, pregnancy and parenting, and going to the doctor.
88815755|NCT01043432||No TBI and a history of suicidal behavior Group 3|No TBI and a history of suicidal behavior
89049813|NCT05278403|Experimental|Experimental group|Conventional neurological physiotherapy treatment with the use of virtual reality and video games.
89673887|NCT06231485|Other|Nutrition and physical activity (STYH)|"The comparison curriculum has been shown in a previous study to improve knowledge around nutrition and exercise, but should not change sexual and reproductive health outcomes.~Weekly virtual one hour group sessions (6-10 participants) with Study Health Educator on the Steps To Your Health (STYH) curriculum for 6-weeks. Topics include: nutrition, exercise, stress management, changing your way of thinking, and behaviors to stay healthy."
89673888|NCT06231472|Active Comparator|Group A with preoperative fluid infusion|Group A patients received fluid infusion calculated according to hourly weight before surgery.
89673889|NCT06231472|No Intervention|Group B without preoperative fluid infusion|No intervention was made to patients in group B.
89673890|NCT06231459|Experimental|Evolocumab|Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response.
89673891|NCT06231433|Experimental|Women affected by Systemic Sclerosis and vulvovaginal atrophy|CO2 vaginal laser
89673892|NCT06231407|Experimental|Recovery Oriented CBTp Med Check|Resident physicians will provide medication appointments, supervised by their attending physician (Stovall) and CT-R supervisor (Brinen). They will conduct their appointment per protocol detailed in a treatment manual. No additional/special information needs to be recorded in medical record, beyond the clinical notes expected per VAPOC policy. Appointments will be a standard length.
89673893|NCT06231407|Active Comparator|Treatment as Usual|Patient will attend traditional medication management check appointments with psychiatry residents.
89673894|NCT06231303||Patient with lupus nepheritis|
89049814|NCT04650906|Experimental|Intervention group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
89049815|NCT04650906|No Intervention|Control group|The intervention group gets information about the Mindhelper website and the control group does not get information about the Mindhelper website.
89049816|NCT04650750|Experimental|Xiao-Feng-San; Shian-Fang-Hwa-Ming-Yiin|Xiao-Feng-San 2g+ Shian Fang Hwa Ming Yiin 2g; twice a day for two months
89049817|NCT04650750|Placebo Comparator|Placebo|Similar placebo 4g twice a day for two months
89049818|NCT04650711|Experimental|Study group|All eligible participants as one group accept P16INK4A testing, with cytology and/or hrHPV assay.
89049819|NCT04650828||Experimental:person with TDF+LDT|TDF combined with LDT for 12 months
89049820|NCT04650828||Active comparator:person with TDF|TDF monotherapy was continued for 12 months
89049821|NCT04650360|Experimental|Postoperative Intervention Educational Program|The intervention group will receive an educational program during admission. The health educational program will consist of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics will be addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls
89673895|NCT06231303||Healthy persons of the same age|
89673896|NCT06231277|Experimental|BH002|Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
89673897|NCT06231251|Active Comparator|control group|exposed to low caloric diet (15 calories/kilogram) and exercise
89049822|NCT04650360|No Intervention|Control|The patients in the control group will not receive any educational program. These patients will be treated according to routine protocols
89673898|NCT06231251|Active Comparator|endoscopic band ligation|endoscopic reduction of ghrelin rich gastric mucosa with band ligation will be applied starting from the fundus till the mid body in 3-4 rows 1-2 cm apart for luminal reduction
89673899|NCT06231251|Active Comparator|endoscopic argon plasma coagulation|argon plasma mediated reduction of gastric mucosa rich in ghrelin receptors by appling argon to stomach mucosa from fundus to mid body
89673900|NCT06231238|Experimental|Balance ACT|Participants randomised to Balance ACT will receive 10 therapy sessions with a therapist.
89673901|NCT06231238|No Intervention|Treatment as usual|Information leaflet about PCS/LC.
89673902|NCT06231225|No Intervention|control group|not assign respiratory training
89673903|NCT06231225|Experimental|treatment group|assign respiratory training
89673904|NCT06231199|Experimental|gastrocnemius release|the patients will receive gastrocnemius release manually and by foam roller three times a week for four weeks plus conventional treatment
89673905|NCT06231199|Active Comparator|conventional treatment|the patients will receive conventional treatment three times a week for four weeks
89673906|NCT06231186|Experimental|iHD-SRT|isotoxic high dose SRT
89673907|NCT06231173|Experimental|Experimental|Visual feedback therapy and conventional therapy
89673908|NCT06231173|Active Comparator|Controlled|Conventional therapy
89673909|NCT06231160||Systematic Therapy Combined With Microwave Ablation|Perform microwave ablation for patients with pancreatic cancer, and then conduct chemotherapy according to the guidelines two to three weeks later
89673910|NCT06231160||Systematic Therapy|Using the same chemotherapy method as the experimental group
89049823|NCT04650555|Experimental|Single Ascending Dose Cohort 1|500 mg BIO 300 Oral Powder administered as a single dose
89049824|NCT04650555|Experimental|Single Ascending Dose Cohort 2|1000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
89049825|NCT04650555|Experimental|Single Ascending Dose Cohort 3|2000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose
89673911|NCT06231147|Experimental|Group A|horse riding simulator sessions with mirror visual feedback
89673912|NCT06231147|Other|Group B|horse riding simulator sessions without mirror visual feedback
89673913|NCT06231134|Active Comparator|Conventional surgery|
89673914|NCT06231134|Experimental|Dioad laser|
89673915|NCT06231134|Experimental|Electrosuregry|
89673916|NCT06231121||Patients|Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.
89688733|NCT03035149|Experimental|Weight Management Program|Obese subjects participate in a year long medically supervised weight management program.
89673917|NCT06231082|Active Comparator|Group one - percutaneous (P)|Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
89673918|NCT06231082|Active Comparator|Group two - EUS FNB (E)|"EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique"
89673919|NCT06231069|Experimental|Multi-nutrient supplementation during training|
89673920|NCT06231069|Placebo Comparator|Placebo during training|
89673921|NCT06231056|Experimental|Probiotic supplement group|Participants in this group received probiotic iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215) - dosage 1 sachet per day, during the 24-36 weeks of their gestation period.
89673922|NCT06231056|No Intervention|Control group|No probiotic supplementation. Participants in this group did not received probiotic iNatal® during 24-36 weeks of their gestation period.
89673923|NCT06231043|Experimental|Drug1|Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.
89673924|NCT06231043|Active Comparator|Drug2|Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse.
89673925|NCT06231017|Experimental|Adebrelimab + Cetuximab+ Chemotherapy|Adebrelimab + Cetuximab+ Chemotherapy
89673926|NCT06231004||Experimental group|Take glucocorticosteroid at once in the morning and use the following course of treatment: 6 tablets/day for 7 days-- 5 tablets/day for 2 days-- 4 tablets/day for 2 days-- 3 tablets/day for 2 days-- 2 tablets/day for 2 days-- 1 tablets/day for 2 days--surgery
89673927|NCT06230991|Experimental|SIM05|One sachet twice daily for 16 weeks
89049826|NCT04650555|Experimental|Single Ascending Dose Cohort 4|Single dose to be determined based on the safety and pharmacokinetic profiles in cohorts 1-3
89673928|NCT06230978|Active Comparator|Standard of care|The first 16 patients will receive standard medication counseling from the pharmacist
89049827|NCT04650555|Experimental|Multiple Single Dose Cohort 5|Highest dose or maximum tolerated dose from the Single Ascending Dose study administered as a single dose given daily for 6 consecutive days
89049828|NCT04650477|Active Comparator|Fixated in the EP position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the extension-pronation (EP) position
89049829|NCT04650477|No Intervention|Fixated in the neutral position|Long head of biceps tenodesis was performed for 25 patients whose joints were fixated while forearm in the neutral position (elbow 90 degrees flexed and hands positioned with the thump pointing up
89049830|NCT05181683|Experimental|Co-formulated casirivimab+imdevimab SC|Randomized 1:1
89049831|NCT05181683|Experimental|Co-formulated casirivimab+imdevimab IV|Randomized 1:1
89049832|NCT04650516|Experimental|Endocare treatment|Patients will receive the treatment on a dedicated virtual reality headset to display the Endocare® application, with high quality headphones
89049833|NCT04650516|Active Comparator|Digital control treatment|Patients will receive the digital control on a dedicated tablet to display the digital control, with high quality headphones
89049834|NCT04650321|Experimental|Home infusion of ocrelizumab|Patients will receive infusion of ocrelizumab at home, instead of at clinic.
89049835|NCT05153525|Experimental|Intermittent boluses group|Thirty children with ARDS will be managed with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
89049836|NCT05153525|Experimental|Intravenous infusion for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
89049837|NCT04649970||malignant uropathy|Antegrade double-J stent
89049838|NCT05127863|Experimental|2 to 5 ASD or TDL patients|2 to 5 ASD or TDL patients, 8 to 14 years old, with no intellectual disability.
89049839|NCT04649892|Experimental|Naltrexone|A 12 week Naltrexone flexible dose administration plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
89049840|NCT04649892|Placebo Comparator|Placebo|A 12 week placebo matching tablets plus 4 sessions of a psychoeducational intervention and 4 eye-tracking sessions
89049841|NCT05125796|Active Comparator|paracetamol|1000 mg intravenous paracetamol
89049842|NCT05125796|Experimental|Dexketoprofen Trometamol|50 mg intravenous Dexketoprofen Trometamol
89049843|NCT05125796|Experimental|topical lidocaine|%5 lidocaine 5 gr topical
89049844|NCT05125796|Placebo Comparator|placebo|100 mL intravenous normal saline+ placebo topical pomade
89049845|NCT04616859|Experimental|Alcohol and Energy Drink (AmED)|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml"
89673929|NCT06230978|Experimental|Habit workup arm|The second 16 patients will receive the habit workup in addition to medication counseling
89673930|NCT06230965|Other|conventional ventilation strategy group|The conventional ventilation strategy group used a conventional ventilation strategies: tidal volume（VT）=10-12 ml/kg, respiratory rate（f）=12 beats/minute, end-expiratory positive pressure（PEEP）= 0 cm H₂O, fraction of inspired oxygen = 0.5
89673931|NCT06230965|Experimental|lung protective ventilation strategy group|"The lung protective ventilation strategy group used the lung protective ventilation strategies~: tidal volume（VT）=6-8 ml/kg, f=12 breaths / minute,end-expiratory positive pressure（PEEP） = 6-8 cmH₂O, and fraction of inspired oxygen = 0.5 . After mechanical ventilation every 30 minutes (continuous positive airway pressure 30 cmH₂O for 30 seconds)."
89673932|NCT06230939||Parkinson's Disease Group|The study will be conducted in collaboration with Gazi University Faculty of Health Sciences and Nigde Omer Halisdemir University. The study data will be obtained from individuals diagnosed with PD admitted to the Neurology Outpatient Clinic of Nigde Omer Halisdemir University Training and Research Hospital. Necessary permissions were obtained from all institutions. All evaluations will be collected in a single meeting using the face-to-face interview method. It is calculated that 80% power will be reached with a margin of error of 0.05 when 84 individuals diagnosed with PD are included in the study.
89673933|NCT06230926||Parkinson's Disease Group|The study will be conducted in collaboration with Gazi University Faculty of Health Sciences and Niğde Ömer Halisdemir University. The study data will be obtained from individuals diagnosed with PD admitted to the Neurology Outpatient Clinic of Niğde Ömer Halisdemir University Training and Research Hospital. Necessary permissions were obtained from all institutions and questionnaire developers. Since at least 5-10 times the number of items in the questionnaire (7 items) must include at least 5-10 times the number of participants in order to perform factor analysis, a pretest of the questionnaire will be applied to individuals with PD with at least 35-70 participants.
89673934|NCT06230913|Experimental|Kinesiotaping group|To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
89673935|NCT06230913|Active Comparator|Pressure garment group|The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
89673936|NCT06230887|Experimental|Building Spiritual Strength|Spiritually integrated group intervention for moral injury.
89673937|NCT06230887|Active Comparator|Present Centered Group Therapy|Coping strategies group intervention addressing broad spectrum trauma symptoms
89673938|NCT06230861|Experimental|Quercetin tablets 500mg 1 x pe|Quercetin tablets 500mg 1 x per day
89673939|NCT06230861|Placebo Comparator|Placebo|
89049846|NCT04616859|Active Comparator|Alcohol and Energy drink Placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)"
89049847|NCT04616859|Active Comparator|Alcohol placebo and Energy drink|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL"
89049848|NCT04616859|Placebo Comparator|Alcohol placebo and Energy drink placebo|"The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).~Women: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL"
89673940|NCT06230848|No Intervention|Attention Control|Infants in the attention control group will receive standard of care.
89673941|NCT06230848|Experimental|M-MILK|Infants in the M-MILK group will receive the M-MILK intervention in addition to standard of care.
89673942|NCT06230835|Experimental|Intervention Group|The intervention of the study will be the Community Health Workers implementation strategy
89673943|NCT06230835|No Intervention|Control Arm|Routine hypertension care
89673944|NCT06230809|Experimental|Intervention|
89673945|NCT06230809|No Intervention|Waitlist|Waitlist, participants will be included after 8 weeks.
89673946|NCT06230796|Experimental|FES-cycling|30 minutes of active leg cycling with FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks
89673947|NCT06230796|Sham Comparator|SHAM-cycling|30 minutes of active leg cycling with Sham FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks
89673948|NCT06230731|Experimental|Vascular abnormality group|People with acquired vascular abnormalities in the proximal colon
89673949|NCT06230731|Active Comparator|Control group|People with healthy colon
89673950|NCT06230653||MMG on dominant arm|Mechanomyography-device will be examined on the dominant arm.
89673951|NCT06230653||MMG on non-dominant arm|Mechanomyography-device will be examined on the non-dominant arm.
89673952|NCT06230640||cardiac surgery with cardiopulmonary bypass|Any subject undergoing cardiac surgery with cardiopulmonary bypass and at high risk of bleeding and transfusion.
89673953|NCT06230601|Experimental|experimental group|cough trick method will be used in the blood collection process from the children in the experimental group.
89049849|NCT04616937|Active Comparator|Galacto-oligosaccharides (GOS) Group|Daily dose of GOS over 4 weeks
89049850|NCT04616937|Placebo Comparator|Placebo group|Daily dose of maltodextrin over 4 weeks
89049851|NCT05053607|Other|1. Single Arm Cohort Receiving Digital Health Coaching|"All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data.~Participants have the option to participate in a one time interview about their treatment experience."
89049852|NCT04616586|Experimental|Arm A|Drug - Siltuximab
89049853|NCT04616586|Other|Arm B|Comparator - Normal Saline
89049854|NCT04616469|Active Comparator|Root canal treatment using RaCe rotary system|Canal shaping using RaCe rotary system powered with endodontic motor with real time torque monitoring capacity
89673954|NCT06230601|Active Comparator|Active comprator|Pinwheel Blowing method will be used in the blood collection process from the children in the experimental group.
89673955|NCT06230601|No Intervention|control group|Routine application of the unit will be made
89673956|NCT06230562|Experimental|Case group|
89673957|NCT06230562|Active Comparator|Control group|
89673958|NCT06230510|Experimental|Whole Milk|Whole Milk consumption for one year
89673959|NCT06230510|Experimental|1% Milk|1% Milk consumption for one year
89673960|NCT06230458|Other|Asthma patients without reversibility|Asthma patients without reversibility
89673961|NCT06230432||healthy control|
89673962|NCT06230432||mild acute pancreatitis|
89673963|NCT06230432||moderately severe acute pancreatitis|
89673964|NCT06230432||severe acute pancreatitis|
89673965|NCT06230419||The cerebral trauma group|
89673966|NCT06230380|No Intervention|Control group|Patients will be operated with a standard exploratory PTX, with visual identification of PTGs. Unilateral or bilateral parathyroid exploration will be determined by the surgeon, depending on preoperative imaging and intraoperative findings. Usually, the procedure will be terminated when intraoperative parathyroid hormone (PTH) measurement shows a >50% decline, after removal of suspected pathological PTGs.
89673967|NCT06230380|Experimental|Surgery with EleVision IR camera system|"Patients randomized to the experimental group will have surgery performed in the exact same manner as in the control group.~In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern."
89673968|NCT06230367|Experimental|SHAG (Sexual Health Advocacy for Guys)|Young people assigned to the intervention arm will receive ~9 weeks of daily text messages that talk about healthy sexuality and ways to reduce HIV risk. After a 3 month 'quiet' period, they will receive a week of review messages. Messages are based upon the information-motivation-behavioral model of preventive behavior.
89673969|NCT06230367|Placebo Comparator|Attention-matched control|Young people assigned to the control arm will receive ~9 weeks of daily text messages that talk about healthy lifestyle, such as self-esteem and physical exercise. After a 3 month 'quiet' period, they will receive a week of review messages.
89673970|NCT06230341|Experimental|Learning system benefits MSPs|MSPs benefit from a learning system (described in the intervention section). MSPs are encouraged to report PSIs through the web platform provided after the initial training in each MSP and during the period of methodological support.
89673971|NCT06230315||Cervical spine surgery patients|Patients undergoing multilevel cervical spine surgery at Upstate University hospital
89673972|NCT06230276|Experimental|Intervention with and without premeal bolus|
89673973|NCT06230263|Experimental|DAILIES TOTAL1® for Astigmatism|DAILIES TOTAL1® for Astigmatism
89673974|NCT06230263|Active Comparator|Spherical Contact Lenses|DAILIES TOTAL1® Spherical Contact Lenses
89673975|NCT06230237|Active Comparator|Professional support|Participants randomly assigned to this groups will receive the self-administered psychotherapy via the Internet a with telephone psychotherapeutic support.
89673976|NCT06230237|Active Comparator|Non professional support|Participants randomly assigned to this group will receive the self-administered psychotherapy via the Internet without telephone psychotherapeutic support.
89673977|NCT06230198|Experimental|Implementation of a policy of routine retrograde autologous priming|sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery
89673978|NCT06230198|Experimental|Implementation of crystalloid priming during cardiac surgery|sites implement crystalloid priming use during cardiac surgery
88995796|NCT05364268||Trial Population|The trial population will be enrolled from adults presenting for elective, outpatient COVID-19 testing at a single center, potentially with multiple testing locations (subject to local needs at the time of the trial). The investigational device will be provided to Participants via a cell phone preloaded with Common off-the-shelf original equipment manufacturer (COTS OEM) software and the investigational Dx SaMD. The investigational device will be evaluated during a single encounter in which an FCV-SDS will be collected. No follow-up visits or participant contacts will be involved in this trial.
88995797|NCT04687384|Experimental|Robotic-assisted surgery|Patients undergoing robotic-assisted colectomy for colonic neoplasm
88995798|NCT04687384|Active Comparator|Laparoscopy|Patients undergoing conventional laparoscopic colectomy for colonic neoplasm
88995799|NCT00151580|Experimental|1|Ribavirin maintenance treatment
88995800|NCT00151580|Placebo Comparator|2|
88995801|NCT00532597|Experimental|O|
88995802|NCT00532597|Active Comparator|L|
88995803|NCT00532636|Active Comparator|1|Children 1-5 years of age
88995804|NCT00532636|Active Comparator|2|Children 6-10 years of age
88995805|NCT00171912|Experimental|imatinib mesylate (STI571)|
88995806|NCT05338567||Open/laparoscopic surgery|Small bowel length measurement by laparoscopy or laparotomy
88995807|NCT05338567||3D reconstruction|Small bowel length measurement by 3D digital model
88995808|NCT05332015|Active Comparator|Oral hydration with normal water|Oral hydration with drinkable normal water daily additional 2 liters for 5 days
88995809|NCT05332015|Active Comparator|Oral hydration with distilled water|Oral hydration with distilled water daily 2 liters for 5 days
88995810|NCT00532675|Experimental|PAN 5 mg|Panobinostat 5 mg
88995811|NCT00532675|Experimental|PAN 10 mg|Panobinostat 10 mg
88995812|NCT00532675|Experimental|PAN 20 mg|Panobinostat 20 mg
88995813|NCT00532675|Experimental|PAN 25 mg|Panobinostat 25 mg
88995814|NCT05300659|No Intervention|Standard Care|
88995815|NCT05300659|Experimental|ARNI care|
88995816|NCT00164619|Experimental|1|Standard STD clinic services and the VOICES/VOCES intervention
88995817|NCT00164619|Active Comparator|2|Standard STD clinic services
88995818|NCT05299957||oropharyngeal squamous cell carcinoma|a total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker, or intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Each enrolled patients will undergo detail clinical examination, including human papillomavirus test.
89673979|NCT06230159|Active Comparator|Menthol cigarette|Participants participate in an ad libitum smoking session with a menthol cigarette for this condition. Participants also participate in an ad libitum smoking session with either their usual brand cigarette or the menthol study cigarette at the end of each study visit.
89673980|NCT06230159|Active Comparator|Non-menthol cigarette|Participants participate in an ad libitum smoking session with a non-menthol control cigarette for this condition. Participants also participate in an ad libitum smoking session with either their usual brand cigarette or the non-menthol study cigarette at the end of each study visit.
89673981|NCT06230159|Active Comparator|Cigarette with synthetic cooling agents|Participants participate in an ad libitum smoking session with a synthetic cooling agent cigarette for this condition. Participants also participate in an ad libitum smoking session with either their usual brand cigarette or the synthetic cooling agent study cigarette at the end of each study visit.
89673982|NCT06230146|Experimental|Insulin group|Group I (n=15): Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\ml solution) Dose: injection of 0.1 ml\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas.
89673983|NCT06230146|Experimental|Botulinum toxin group|Group II (n=15): Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
89673984|NCT06230146|Experimental|Triamcinolone acetonide group (control group)|Group III (control group) (n=15): Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
89673985|NCT06230133|Experimental|mindfulness based stress reduction (MBSR) intervention|MBSR intervention include 8 sessions. Each session took place once a week, 2 h per session, and lasted 8 consecutive weeks. Each session covered specific exercises and topics within the context of mindfulness practice and training. Participants were required to attend at least seven out of eight lessons, and to practice MBSR at least once per day as the homework. We provided participants with a series of audio recordings of MBSR exercises to help them do better. Participants were required to hand in the records of homework assignments before each intervention session, and they shared and discussed their homework assignments with other partners at the beginning of the intervention session. Additionally, the authors encouraged practitioners to develop an ability to bring mindfulness into the varied circumstances of daily living (e.g. Mindful running, mindful eating, mindful walking, and even mindful talking), especially stressful situations.
89673986|NCT06230133|No Intervention|Control condition|Participants in the control condition received university medical courses and physical training as usual.
89673987|NCT06230120|Experimental|Spinal Cord Stimulation|A stimulation electrode is placed in the epidural space between the T4-T7 spinal levels and connected to an external electrical pulse generator, which is used for stimulation. The stimulus intensity is initially increased in a ramp-like fashion using high-frequency stimulation at 1000 Hz, with pulse widths of 90 microseconds and intensities increasing from 2 to 14 mA to establish the sensation threshold. After establishing the sensation threshold, the 75 % subthreshold of sensation is used as the stimulation intensity during the active stimulation period.
89673988|NCT06230120|Sham Comparator|Sham|For sham treatment, a similar procedure for establishing the sensation threshold is used, and stimulation at the 75 % subthreshold intensity is initiated, but the stimulation device is turned off 30 seconds after the sensation subthreshold is established.
89673989|NCT06230094|Experimental|Group A ( moderate intensity training)|warm up protocol to reach maxHR 50% than moderate intensity exercise. Group A will be given moderate intensity exercise i.e brisk walk will be performed.(HR will be between 50-60%).
89673990|NCT06230094|Experimental|Group B( high intensity training)|warm up protocol to achieve 70% of maxHR . group Bwill be given highintensity exercise i.e skipping rope ( HR will be between 70-85%).
89673991|NCT06230029|Experimental|Music Listening|"The presentation of the music listening session will be standardized and will be as follows: Make yourself comfortable; we will first choose the musical style; then adjust the volume; put on the headphones; then the mask; let us know if something is wrong; we can take off the headphones or the mask at any time if you wish; we will stay by your side.~The following data will be collected just before the headset is put on and just after its removal:~heart rate using a previously disinfected chest belt (PolarH10®)~blood pressure~level of anxiety (according to the validated SFQ and VAS scales)~Music listening session will last 15 minutes, at the end of which the headphones will be removed before the patient is transferred to the operating room."
89673992|NCT06230029|No Intervention|No Music|"Heart rate variability monitoring while NOT listening to music. The presentation for the patients included in the group without music will be as follows: Make yourself comfortable; we will first put on the headphones but there will be no music; let us know if anything is wrong; we can remove the headphones or mask at any time if you wish; we will stay by your side.~The following data will be collected just before the headset is put on and just after its removal:~heart rate using a previously disinfected chest belt (PolarH10®)~blood pressure~level of anxiety (according to the validated SFQ and VAS scales)~The session will last 15 minutes, at the end of which the headphones will be removed before the patient is transferred to the operating room."
89049855|NCT04616469|Experimental|Root canal treatment using TruNatomy rotary system|Canal shaping using TruNatomy rotary system powered with endodontic motor with real time torque monitoring capacity
89049856|NCT05038787|Experimental|LY3473329|LY3473329 administered orally.
89049857|NCT05038787|Placebo Comparator|Placebo|Placebo administered orally.
89049858|NCT04988321|Active Comparator|Primary motor cortex (M1)|Stimulation of the M1
89049859|NCT04988321|Active Comparator|Dorsolateral prefrontal cortex (DLPFC)|Stimulation of the DLPFC
89049860|NCT04616508|Experimental|Behavioral testing|
89049861|NCT00553943|Experimental|Rituximab + Cytarabine|
89049862|NCT00563238|No Intervention|Control|
89049863|NCT00563238|Active Comparator|Metoprolol|
89049864|NCT04679558|Active Comparator|Comparator|Preventive protocol
89214999|NCT05334381|Experimental|Adapted STAT-ED|The intervention will assist the family in following up with mental health referral recommendations provided by ED staff and eliciting families' preferences in regards to race and gender of providers, convenience of provider, and type of treatment. This assistance could involve help with the initial telephone contact, getting to appointments, and preparing for the appointments. The patient navigator will communicate with the family in person, by telephone, and/or by text messaging as per family's preference. This once to twice a week communication with both the youth and their parent will promote mental health care initiation and identify barriers and problem-solving solutions.
89215000|NCT05334381|Active Comparator|Standard Enhanced Treatment|After discharge from the Children's Hospital of Philadelphia emergency department, the participant will be given a list of resources and referrals for mental health treatment by the hospital social work team. Phone call contact will be made to follow up on the initiation of treatment from the referral recommendations given at discharge.
89215001|NCT05332639|Experimental|Intervention Arm|Personalized Risk Estimation for Crohn's Disease (PRE-CD) tool
89215002|NCT05332639|Active Comparator|Comparator arm|Standard Crohn's Disease Education
89673993|NCT06229899||metabolically healthy individuals with obesity|Individuals with BMI ≥30 , those without criteria of metabolic syndrome other than an increase in waist circumference (blood pressure ≥130/85 mmHg, fasting blood sugar ≥100 mg/dl, triglycerides ≥150 mg/dl, HDL-cholesterol <40 mg/dl in men and <50 mg/dl in women) and without prediabetes
89673994|NCT06229899||metabolically unhealthy individuals with obesity|Individuals with BMI ≥30 , and have one of the followings: blood pressure ≥130/85 mmHg, fasting blood sugar ≥100 mg/dl, triglycerides ≥150 mg/dl, HDL-cholesterol <40 mg/dl in men and <50 mg/dl in women
89673995|NCT06229782|Other|ODUS|"Orbital Doppler ultrasonography (ODUS)~Patients in whom brain death was suspected and the diagnostic procedure was initiated underwent ODUS .ODUS were performed during the apnoea test and the first neurological examination. At the second neurological examination at 12 hours, ODUS were repeated."
89673996|NCT06229639|Active Comparator|Tracheostomy Plug|Patients receive tracheostomy plug during night 2.
89673997|NCT06229639|Experimental|Passy-Muir Valve|Patients receive Passy-Muir Valve during night 1.
89673998|NCT06229574|Experimental|intervention group|The effect of breastfeeding education given with virtual reality glasses on breastfeeding success and breastfeeding self-efficacy will be evaluated. The education given during pregnancy will be evaluated on the first and seventh days after birth.
89673999|NCT06229574|No Intervention|control group|Breastfeeding success and breastfeeding self-efficacy of women included in this group during pregnancy will be evaluated on the first and seventh days after birth.
89674000|NCT06229314|Experimental|IMT Group|The IMT group received IMT at 60% of the measured MIP value. IMT was administered using the Powerbreathe device (Powerbreathe Plus, Warwickshire, England) twice a day with 30x2 breaths. The device was adjusted weekly based on the patient's current MIP value, and training continued at 60% of the MIP value.
89674001|NCT06229314|Sham Comparator|Control Group|The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks.
89674002|NCT06229210|Experimental|Lumateperone|
89674003|NCT06229119|Other|ICL|ICL implantation
89674004|NCT06229093|Sham Comparator|Older Adults (OA)|The assignment of older adults to OA and OAg will be randomized. The within-subjects factor of stimulation modality includes 2 levels, to be administered in counterbalanced order: Visual (V, i.e., lights-only) and Audiovisual (AV, i.e., music-plus-lights). Each subject will be aware that they are receiving V and AV stimulation, and thus infer that we are comparing these two forms of stimulation and therefore assessing the effects of music. However, and important to the design of this study, all subjects will be blinded with respect to their group assignment; i.e., they will not know, until post-study debriefing, about the other arms of the study, and that the gamma-band stimulation is an active ingredient of the intervention.
89674005|NCT06229093|Experimental|Older Adults Gamma (OAg)|The assignment of older adults to OA and OAg will be randomized. The within-subjects factor of stimulation modality includes 2 levels, to be administered in counterbalanced order: Visual (V, i.e., lights-only) and Audiovisual (AV, i.e., music-plus-lights). Each subject will be aware that they are receiving V and AV stimulation, and thus infer that we are comparing these two forms of stimulation and therefore assessing the effects of music. However, and important to the design of this study, all subjects will be blinded with respect to their group assignment; i.e., they will not know, until post-study debriefing, about the other arms of the study, and that the gamma-band stimulation is an active ingredient of the intervention.
89674006|NCT06229080|Experimental|Test group|short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver.
89674007|NCT06228911|Experimental|insulin treated group|
89674008|NCT06228911|Experimental|non-insulin treated groups|
89674009|NCT06228846|Experimental|Study treatment|Method of Administration: Single dose period: Single oral ; Multiple dose period: Oral , QD.
89674010|NCT06228625|Active Comparator|Control Group|Conventional exercise training will be given to the control group for 6 weeks, 5 days a week, for 45 minutes. Conventional exercises will be applied to this group under the supervision of a physiotherapist for 5 days in our unit.
89674011|NCT06228625|Experimental|Body Awareness Training Group|After the first evaluation, the training group will be given basic body awareness exercise training for 6 weeks, 2 days a week, for 45 minutes. This group will be given to basic body awareness exercises under the supervision of a physiotherapist for 2 days in our unit. Individuals in this group will be applied basic body awareness exercisea program in addition to conventional exercises.
89674012|NCT06228625|Experimental|Rehabilitative Game Exercise Group|Individuals in this group will be applied a video-based rehabilitative game exercise program in addition to conventional exercises. A digital game network called 'Active Arcade Game' will be used for rehabilitative game exercises. Rehabilitative Game Exercise Group for 6 weeks, 2 days a week, for 45 minutes. This group will be given to basic body awareness exercises under the supervision of a physiotherapist for 2 days in our unit.
89674013|NCT06228326|Experimental|Dose Escalation of KB707 Administered via Nebulization|Dose escalation of single-agent KB707 in 3 cohorts in a standard 3+3 design.
88815756|NCT01043432||No TBI and no history of suicidal behavior Group 4|No TBI and no history of suicidal behavior
89674014|NCT06228326|Experimental|Dose Expansion of KB707 Administered via Nebulization|Dose expansion of single-agent KB707 in approximately 60 subjects with advanced solid tumor malignancies affecting the lungs, including approximately 40 subjects with non-small cell lung cancer.
89674015|NCT06228118||Subjects enrolled in method comparison study only|
89674016|NCT06228118||Subjects enrolled in both the method comparison study and lay user study|
89674017|NCT06228014||Patients with any kind of skin pathologies|Adult patients (≥ 18 years) with skin pathologies seen in the primary care service of health centers referring to Cruces and Basurto University Hospitals. Patients participating in this study did not receive any specific treatment as part of the research protocol. Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study.
89674018|NCT06226896||Dapagliflozin + RAS inhibitor|In addition to ACEI/ARB treatment, patients will receive dapagliflozin 10mg once daily for 24 months.
89674019|NCT06226896||RAS inhibitor only|Patients will continue ACEI/ARB treatment for 24 months.
89674020|NCT06226662|Experimental|NM8074|6 subjects will receive a biweekly dose of 20 mg/kg of NM8074 plus SOC (cyclophosphamide/azathioprine or rituximab plus corticosteroids)
89674021|NCT06226662|Placebo Comparator|Placebo|6 subjects will receive a biweekly dose of placebo plus SOC (cyclophosphamide/azathioprine or rituximab plus corticosteroids)
89674022|NCT06226493|Experimental|TaVNS intervention|Before starting applying taVNS, patients will be assessed using the FMA-U and the mRS for motor recovery as well as the MOCA for cognitive recovery. Resting state EEG will be recorded with eyes open during 15 minutes using our 64 electrodes cap (actiCHamp Plus; brainproducts.com), just after the behavioral assessment is performed. On the same day, patients will receive taVNS for 45 minutes, during therapy. The stimulation parameters, will be as follows: 250ms square pulses at 20 Hz. The electrical stimulation will given for 45 minutes a day for 10 working days (5 days a week for 2 weeks). The amplitude will be 1.7mA but may be reduced to 1.0mA if the patient is unable to tolerate due to discomfort or pain. After the last taVNS session is applied, outcome measures will be administered again by the research team. A follow-up at 6 months after the end of the last session will be conducted over the phone using the adapted version of the mRS and the MOCA.
89674023|NCT06226246|Experimental|HEROS VR|Trainee trained by HEROS VR CPR training program
89674024|NCT06226246|Active Comparator|Conventional HEROS|Trainee trained by conventional HEROS CPR training program
89674025|NCT06226025|Experimental|Melatonin|Oral medication will be taken for 28 days on the afternoon or evening of the participants first intervention session and continue daily for the remainder of the treatment period.
89674026|NCT06226025|Placebo Comparator|Placebo|Oral medication will be taken for 28 days on the afternoon or evening of the participants first intervention session and continue daily for the remainder of the treatment period.
89674027|NCT06225739||Pregnant women|Electronic pregnancy register will be created based on local ANC register to monitor pregnancy outcomes across all sites. Pregnant women of all ages attending antenatal care (ANC) facility will be registered
89674028|NCT06225739||Pregnant women/ Health care providers|In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
89674029|NCT06225531|Experimental|Autobiographical Memory Based Intervention|"All participants will be placed into the intervention arm, in which the participants will receive 6 autobiographical memory based intervention sessions, lasting approximately one hour.~Baseline lengths will vary from 3 - 5 sessions, with the initial session lasting approximately one hour, and follow up sessions lasting approximately 30 minutes. This randomisation is 1) to enable the effects of treatment to be separated from the effects of time seen clinically and 2) in order to control for the therapeutic value of contact."
89674030|NCT06225362|Experimental|Quatera 700|
89674031|NCT06225362|Active Comparator|Centurion Vision System|
89674032|NCT06225323|Experimental|Lidocaine group|Patients will receive Lidocaine infusion for 6 hours
89674033|NCT06225323|Placebo Comparator|Control group|Patients will receive normal saline infusion for 6 hours
89674034|NCT06225284|Experimental|Arm A|"After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 3 days of randomization and during neoadjuvant chemotherapy treatment. The protocol-defined chemotherapy will be given 7 to 14 days after GnRH agonist injection. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.~Anthracycline/cyclophosphamide combination or dose-dense schedule: anthracycline/cyclophosphamide combination (Use of dose-dense schedule or not will be stratified.)~Taxane (docetaxel or paclitaxel) ± optional platinum (Use of platinum or not will be stratified.)"
89674035|NCT06225284|No Intervention|Arm B|"Anthracycline/cyclophosphamide combination or dose-dense schedule: anthracycline/cyclophosphamide combination (Use of dose-dense schedule or not will be stratified.)~Taxane (docetaxel or paclitaxel) ± optional platinum (Use of platinum or not will be stratified.)"
89674036|NCT06225154|No Intervention|No intervention|Periodontally healthy subjects with type 2 diabetes mellitus or systemically healthy didn't have an initial periodontal treatment
88995819|NCT05293600|Placebo Comparator|Placebo|This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).
89049865|NCT04679558|Experimental|Intervention|Adding chlorhexidine to the preventive protocol
89049866|NCT03454542|Experimental|Menicon DSRB Redesign|Menicon DSRB Modified Lens Design is a single use contact lens with revised thickness specifications worn for 6 hours or more.
89049867|NCT03454542|Active Comparator|Menicon DSRB Original Design|Menicon DSRB Initial Lens Design is a single use contact lens with the original thickness specifications worn for 6 hours or more.
89674037|NCT06225154|Experimental|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a quadrant-wise manner at 1-week intervals for periodontitis patients systemically healthy or with type 2 diabetes mellitus.
89674038|NCT06225089|No Intervention|control group|All patients will receive routine monitoring ( ECG monitoring, SpO2, noninvasive blood pressure, and EtCO2) and routine anesthesia management. 20 gauge to patients IV Cannulation will be provided and isotonic fluid will be started according to the fluid calculation. General anesthesia induction 1mg midazolam IV, 2 mg/kg propofol IV, 1.5 mcg /kg fentanyl IV, 0.6 mg/kg rocuronium It will be done by giving IV. Patients will be intubated and the minimum amount of anesthesia required for maintenance alveolar Sevoflurane + 50% oxygen + 50% air will be given so that the concentration (MAC) value is 1 and 0.05 mcg/kg/min. remifentanil infusion will begin. The patients will then be released to the surgical team. After the surgical procedure is completed, all patients are given IV paracetamol 1 g 3x1, IV tenoxicam 20 mg 2x1, and IV dexamethasone 8mg will be administered 1x1. All patients will be administered IV 1mg/kg tramadol as rescue analgesic when NRS is 3 or above
89674039|NCT06225089|Active Comparator|pericapsuler nerve block group|all patients are given IV paracetamol 1 g 3x1, iv tenoxicam 20 mg 2x1, and IV dexmethasone 8mg will be administered 1x1. Patients in Group P will also receive a pericapsuler nerve block. All patients will be administered IV 1mg/kg tramadol as rescue analgesic when NRS is 3 or above. 4mg IV to all patients with nausea and vomiting Ondansetron will be administered. Once patients are extubated, they will be transferred to the postanesthetic care unit (PACU) for observation.
89674040|NCT06224985||Malformation|
89674041|NCT06224985||Tumors|
89674042|NCT06224985||Controls|
89674043|NCT06224179|Experimental|Group A|Group A received ultrasound guided subcostal TAP block with 30 ml of local anesthetics and additives
89674044|NCT06224179|Experimental|Group B|Group B received ultrasound guided both subcostal and posterior TAP block with 30 ml of local anesthetics and additives at each side
89674045|NCT06223230|Experimental|Study group|First-line treatment received standard antitumor therapy and nutritional psychological interventions with and without vomit management
89674046|NCT06223230|No Intervention|Control group|First-line treatment receives standard antitumor therapy
89674047|NCT06223178|Experimental|Thumb-tack needle acupuncture|53 Patients in this group will achieve 24 sessions treatment of thumb-tack needle in 12 consecutive weeks. Treatment will be operated by trained acupuncturists.
89674048|NCT06223178|Sham Comparator|Sham acupuncture group|A sham thumb-tack needle, which has no difference in appearance with the verum thumb-tack needle but is lack of needle, are used for 53 patient in this group. 24 sessions of treatment will be performed in 12 consecutive weeks. Treatment will be operated by trained acupuncturists.
89674049|NCT06222645|Active Comparator|Indocyanine green (ICG) imaging system|Using Indocyanine green (ICG) imaging system fluorescence imaging to assess gastrointestinal tissue blood perfusion during gastrointestinal surgery
89674050|NCT06222645|Experimental|imaging photoplethysmography (iPPG)|Using imaging photoplethysmography (iPPG) to assess gastrointestinal tissue blood perfusion during gastrointestinal surgery
89674051|NCT06221917|Active Comparator|Face-to-face|Face-to-face teaching method
89674052|NCT06221917|Experimental|Live-streaming|Live-streaming teaching method
89674053|NCT06220383|Experimental|Hall technique|In the Hall technique method, an orthodontic separator was placed 2 days before the procedure to create distance for the crown in the mesial and distal contact areas of the tooth on which the crown will be placed. A stainless steel crown was cemented on the tooth with glass ionomer cement without local anesthesia, caries cleaning or any preparation. The participant was asked to close the teeth tightly for 2-3 minutes.
89674054|NCT06220383|Active Comparator|Conventional technique|In the conventional technique, after the area to be anesthetized was dried, topical anesthetic solution (Locanest 10% spray lidocaine, Avixa, Turkey) was applied to the mucosa with a cotton pellet for one minute. For infiltrative anesthesia, 4% articaine solution (Ultracaine DS Forte ampoule, Sanofi-Aventis GmbH, Germany) containing 1 ml of 1:100,000 epinephrine was applied. Preparation was made on the mesial, distal and occlusal sides of the tooth. The decay was cleaned and the cavity was filled with glass ionomer cement (Ketac Molar Easymix, 3M™ ESPE™, St. Paul, MN, USA). The stainless steel crown was bonded with glass ionomer cement (Ketac Cem Easymix, 3M™ ESPE™, St. Paul, MN, USA).
89674055|NCT06217744|Experimental|Automated Intervention|The intervention will last for 3 months, with two psychoeducational modules delivered per month.
89674056|NCT06217744|Experimental|Blended Intervention|The intervention will last for 3 months, with two psychoeducational modules delivered per month. In addition, regular synchronous or asynchronous psychoeducational sessions conducted by a licensed psychologist will be held with the participants.
89674057|NCT06217744|No Intervention|Waitlist|This group will undergo the evaluations on the same schedule like the active groups. No intervention will be done.
89674058|NCT06215833||Group ( p )|This group will undergo anesthesia via total intravenous anesthesia using Propofol in induction and maintenance
89674059|NCT06215833||Group ( s )|This group undergo anesthesia via total inhalational anesthesia using sevoflurane in induction and maintenance
89674060|NCT06215677|Experimental|Neoadjuvant immunotherapy|
89674061|NCT06214325|Experimental|Music Therapy|Participants will receive 2 in-person music therapy sessions during hospital admission and 2 virtual music therapy sessions post-discharge.
89674062|NCT06214026|Experimental|Locked ankle articulation|The design is a randomized cross-over clinical trial following an A1-B1-B2-A2 design. In the locked condition, the 20 degree of frontal plane ankle motion is eliminated by a physical lock. The A conditions will be with the usual foot. The B conditions are randomized to the locked and unlocked investigational foot.
89674063|NCT06214026|Experimental|Unlocked ankle articulation|The design is a randomized cross-over clinical trial following an A1-B1-B2-A2 design. In the unlocked condition, the 20 degree of frontal plane ankle motion is enabled. The A conditions will be with the usual foot. The B conditions are randomized to the locked and unlocked investigational foot.
89674064|NCT06211309|Active Comparator|co.mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
89674065|NCT06211309|Placebo Comparator|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
88815757|NCT03013244|No Intervention|Waitlist Control|Participants in this condition completed assessments at baseline, 1 week, and 5 weeks.
89674066|NCT06211309|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
89674067|NCT06207461||massage group|patients with gastrointestinal function injury caused by medical diseases or with high risk of malnutrition who got massage
89674068|NCT06207461||non-massage group|patients with gastrointestinal function injury caused by medical diseases or with high risk of malnutrition who got no massage
89674069|NCT06205433|Experimental|IHSS Basic Training|Individuals in the treatment group will be invited to participate in CCA's IHSS Basic training program. The program is a 30 hour online course for IHSS providers, which teaches fundamental caregiving skills. Training includes personal care, infection control, nutrition and body mechanics, medication adherence, and home safety.
89674070|NCT06205433|No Intervention|Control|No intervention is delivered to the control group. The control group will be unable to access CCA's training programs for two years following random assignment.
89674071|NCT06201793|Active Comparator|control group|control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months.
89674072|NCT06201793|Active Comparator|Minocycline group|minocycline group, n = 23) will receive 1 g mesalamine three times daily plus 100 mg minocycline orally twice daily for 6 months.
89674073|NCT06198283|Experimental|Group A|This group will be treated by low level laser therapy with pressure garments
89674074|NCT06198283|Active Comparator|Group B|This group will receive low level LASER therapy without pressure garment
89674075|NCT06198270|Other|Close Kinetic Chain Exercise|Control Group (Close Kinetic Chain Exercise)
89674076|NCT06198270|Experimental|Neuromuscular training with K-Tape|Experimental Group (Neuromuscular training with K-Tape
89674077|NCT06198257|Active Comparator|group A|Spider cage therapy along with strengthening exercises
89674078|NCT06198257|Active Comparator|group B|Modified suits therapy along with strengthening exercise
89674079|NCT06198244|Experimental|Experimental Group|TENS was applied on abdomen along with baseline movements and stretches were given to experimental group.
89674080|NCT06198244|Active Comparator|Control Group|Baseline movements and stretches were given to control group
89674081|NCT06198231|Experimental|Pilates exercises|The experimental group will receive the same program of exercises given to the control group, 45 minutes of Pilates exercises (such as back twists, single leg circles, standing splits, alternate toe touches, ball leg lifts).The Pilates exercises will be aimed at improving lower-limb strength, flexibility, and coordination, and they will be performed on a mat, using a medical ball. The focus will be on maintaining core contraction, spinal and pelvic alignment, and respiration rhythm. Ten repetitions of Pilates exercises will be performed, with a 2-minute rest period between repetitions.
89674082|NCT06198231|Active Comparator|Flexibility ,strength and endurance excercises|Control group will perform flexibility exercises for the hip (flexors and adductors), knee (flexors and extensors), and calf muscle, with a hold of 15 sec ,5 repetitions. Strengthening exercises for core muscles (curl-ups, prone extension),hip extensors (in prone position), hamstrings, quadriceps (knee extension in high sitting).Walking in all directions, standing on rough and soft surfaces, stepping down and up, walking,standing on one limb with both eyes closed and open. Each session will start with a 5-minute warm-up and 5-minute cool-down, session duration 45 minutes,3 times a week.
89674083|NCT06198218|Experimental|Scapular mobilization|This Experimental group will be treated with manual scapular mobilization in upward rotation and downward rotation, adduction and abduction of scapula. Sets of 10 repetitions were applied with a rest interval of 30 seconds between set for 20 minutes, activity based scapular mobilization(Codman pendulum exercises, scapular pushups, band wall apart ,wall ball circles and advance study wall pushups) along with conventional physical therapy program(heating,EMS,stretching for tight muscles , strengthening exercises and graduated active exercises) for 25 minutes
89674084|NCT06198218|Active Comparator|Conventional physical therapy program|This group will receive conventional physical therapy program including ( heating to improve circulation and release muscle tension ,EMS ,stretching for stiff muscle, weight bearing, strengthening exercises and graduated active exercises)for 20 minutes along with activity based scapular mobilization( Codman pendulum exercises, ban wall apart, wall ball circles, scapular pushups and advance study wall pushups)for 20 minutes with 5 minute resting interval.
89674085|NCT06198205|Experimental|Group A|Students will participate in fundamental motor skills(FMS) program that will include 12 basic motor skills.
89674086|NCT06198205|Experimental|Group B|Group B students will do their regular afterschool programs unstructured child's free play
89674087|NCT06198192|Active Comparator|Balance Exercises|This group will receive conventional exercises for balance.
89049868|NCT04934228|Placebo Comparator|Placebo|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of placebo to the research coordinator to give to the research participant.~The placebo is an inert substance with no intended medical value and is used as a negative control for comparison with the study drug.~Participants will receive a Placebo Pill; has no active ingredients but is made to look like the study drug."
89049869|NCT04934228|Experimental|Clonidine|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of clonidine to the research coordinator to give to the research participant.~Planned use in this study~Condition/disease indication(s): Vascular function and blood flow~Subject population: Hypertension~Dose(s): 0.1 mg (oral)~Administration: Oral~Dosing regimen: 0.1 mg twice daily by mouth"
89674088|NCT06198192|Experimental|Pilates Exercises|This group will receive Pilate exercises along with Balance exercises
89674089|NCT06198179|Experimental|Experimental group|"these individuals will receive the upper limb children action-observation training (UP-CAT) with visual feedback~UP-CAT:~Individual tasks like modelling compound,board games,cards,magnets,glass bead to do bracelets,painting and crafting (making a grass man,making musical instruments with cardboard),cooking (making juice cocktails,fruit skewers,chocolate fondue),building towers, making puzzles & water games including filling a bucket with a sponge/bottle,filling & throwing water balloons.~To maximize the variety of the actions we included different objects (e.g.coins,bottles, stamps,modelling compound) to be grasped with different grasp types (whole hand,pinch, tripod grasp) and in different orientations of the wrist.~Visual feedback:~Mirror in front of patient will be used. After the baseline assessment,the patient in the experimental group will receive the upper limb children action-observation training with visual feedback Time of rehabilitation will be 1 hour/subject."
89049870|NCT04934228|Experimental|Hydrochlorothiazide (HCTZ)|"KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of Hydrochlorothiazide to the research coordinator to give to the research participant.~Planned use in this study~Condition/disease indication(s): Hypertension~Subject population: Hypertension~Dose(s): 25 mg/day~Administration: Oral~Dosing regimen: 12.5 mg twice per day"
89049871|NCT03454503||First cohort|Newly diagnosed patients
89674090|NCT06198179|Other|Control group|"This will receive the upper limb children action-observation training (UP-CAT).~UP-CAT:~Following tasks will be performed by children~Individual tasks like modelling compound,board games,cards,magnets,glass bead to do bracelets,painting and crafting (making a grass man,making musical instruments with cardboard),cooking (making juice cocktails,fruit skewers,chocolate fondue),building towers, making puzzles & water games including filling a bucket with a sponge/bottle,filling & throwing water balloons~To maximize the variety of the actions we included different objects (e.g. coins,bottles, stamps,modelling compound) to be grasped with different grasp types (whole hand,pinch, tripod grasp) & in different orientations of the wrist.After the baseline assessment,the patient in the experimental group will receive the UL children action-observation training with visual feedback Time of rehabilitation will be 1 hour per subject."
89674091|NCT06198166|Experimental|Cuevas Medek|"This group will receive CME In a following procedure: supporting the patient in balance at the leg level and with slight posterior support. Then, once kept in the air for few seconds, slight up and down oscillations will make. These oscillations will reflexively induce an increase in tone of the body extensors, but also of the lower limbs. Always from the same position, gait movements will be imitated. At the beginning, due to poor coordination between muscle groups, the child may tend to go outside the support base and therefore we have to run following his center of gravity. The action is similar to the one when someone try to maintain balance of a cane in the palm and have to move his hands according to the cane's oscillation until he manage to regain balance"
89674092|NCT06198166|Active Comparator|Standard kinetic programs|This group will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
89674093|NCT06198140|Experimental|Myofascial Release and Quick icing|Experimental group will receive myofascial release & quick icing.
89674094|NCT06198140|Active Comparator|Myofascial Release|In control group the individuals will receive only myofascial release on ankle planterflexors.
89674095|NCT06198127|Experimental|Experimental group; combination of core stability exercises and kinesio-taping|combination of core stability exercises and kinesio-taping were used in experimental group
89674096|NCT06198127|Active Comparator|Control group; only core stability exercises|only core stability exercises were given to control group
89674097|NCT06198114|Experimental|Multi Sensory Integration|This group will be treated with activity based training In which place different( nuts, screws, bullets, coins, paper clips, coloring ,scissor cutting with different shapes , Simulated feeding (by collecting beans with a spoon and transferring them into a container),transfer light and heavy weight objects into empty box.
89674098|NCT06198114|Active Comparator|Conventional Therapy|This group will be treated with traditional therapy in which Place toys/objects inside and encourage the student to reach in and pull them out as well as put them back in. Give the student objects that can be put together and pulled apart. Encourage the students to use two hands in an organized manner to manipulate objects (e.g., grasp/release, twist/turn, rotate and examine, open/close, stack, nest).
89674099|NCT06198088|Experimental|experimental group|The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.
89674100|NCT06198088|Other|control group|exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
89674101|NCT06198075|Other|Control group|Subjects will receive 6 weeks of general physical therapy,3 times/week for 30 min each session. The exercise program will include lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor and stair walking. Final assessment will be done after 6 weeks
89688734|NCT03035149|No Intervention|Normal Weight Controls|Normal weight age and sex-matched controls. Unlike the obese subjects, the controls did not participate in the Weight Management Program. Pulmonary function, exercise performance and dyspnea results for normal weight controls were compared against the results for obese subjects.
89688735|NCT03035383|Experimental|Purse String Technique|Thyroidectomy closure is performed using purse string technique.
89049872|NCT03454503||Second cohort|Patients switched from reference product (Glivec® )
89049873|NCT03454464|Sham Comparator|Conventional operation group|Conventional operation group,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure.
89049874|NCT03454464|Experimental|central neck dissection first group|central neck dissection first group,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
89049875|NCT03454386|Active Comparator|Active Treatment|"Stress Management and Resilience Training Program~This group will be initially enrolled in the program."
89049876|NCT03454386|Other|Control|"Self-Management Stress Reduction Program~This group will be placed in a self-management stress reduction program. During this time these participants will be given a popular stress reduction book to read over 12 weeks. They will complete questionnaires at weeks 4 and 12. After the 12 weeks, this group will be enrolled in the online SMART program and complete assessments at week 24 (upon completion of the program."
89049877|NCT04915781||Tobacco users|Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers. For FinSote 2018 and 2020, we will also compare never users of (1) smokeless tobacco (snus), (2) electronic cigarettes with and without nicotine or (3) nicotine replacement therapy products with respective former, occasional and daily users.
88815758|NCT03013244|Experimental|The Body Project: More Than Muscles|Participants in this condition competed the 2-session dissonance-based eating disorder prevention protocol (2 hours per session).
89049878|NCT04616157|Experimental|ICBT-I|The ICBT-I treatment program is a web-based intervention consisting of six chapters/sessions that adolescents go through during six consecutive weeks.The program starts with psychoeducation regarding sleep disorders and the rationale for a cognitive behavioral intervention. The main focus for the treatment is behavioral interventions, mainly sleep restriction and stimulus control. The intervention also addresses problem solving, maintenance of treatment gains, relapse prevention and relaxation techniques. Caregivers will not actively participate in the treatment. During the treatment phase participants will be in contact with a therapist through standardized forms in the program.
89049879|NCT04900844|Experimental|CGuard group|Single experimental arm compared vs. objective performace goal
89049880|NCT04616391|No Intervention|MDI group:|The patient continues MDI treatment as per routine procedures
89049881|NCT04616391|Experimental|AHCL group|The patient will use MiniMed 780G AHCL system
89049882|NCT03455153||Most active|COPD patients with higher physical activity levels as defined by daily step counts.
89049883|NCT03455153||Least active|COPD patients with lower physical activity levels as defined by daily step counts.
89049884|NCT04616430|Placebo Comparator|Control|Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
89049885|NCT04616430|Active Comparator|Topical Endoxifen 10mg/breast/day|10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
89049886|NCT04616430|Active Comparator|Topical Endoxifen 20mg/breast/day|20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil
89049887|NCT04891796||Current smokers|Individuals who, at the time of the survey, smoke any forms of tobacco product either daily or occasionally.
89049888|NCT04891796||Ex-smokers|Individuals who were formerly smokers but, at the time of the survey, do not smoke at all.
89049889|NCT04891796||Never Smokers|Individuals who, at the time of the survey, have never smoked at all.
89049890|NCT04616040||unresectable locally advanced/recurrent or metastatic esophageal cancer|
89049891|NCT04616118|Experimental|Phone|Participants randomized to this arm will receive usual care via telephone only
89049892|NCT04616118|Experimental|Video|Participants randomized to this arm will receive usual care via video call
89049893|NCT00553982|Experimental|1|Patellar resurfacing
89049894|NCT00553982|Active Comparator|2|Patellar retention
89049895|NCT04615962|Experimental|SNG100|Combination of low potency steroid with hydrating and moisturizing agents
89049896|NCT04615962|Active Comparator|Hydrocortisone|This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash).
89049897|NCT04615962|Active Comparator|Mometasone furoate|This medication is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.
89049898|NCT04881929|Experimental|KN026 + Docetaxel|KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles
89049899|NCT04615767|Experimental|D-chiro-inositol|Volunteers are orally administered with 1 g D-chiro-inositol per day (two doses in capsules of 500 mg each, one in the morning and the other one in the evening) for thirty days
89049900|NCT04881227|Experimental|Chatbot condition|Participants randomly assigned to this arm will access to a Chatbot condition, in which they had the opportunity to interact with the chatbot on COVID-19 vaccine hesitancy.
89049901|NCT04881227|Active Comparator|Control condition|Participants randomly assigned to this arm will access to a brief text describing the way vaccines work.
89049902|NCT04616001|Experimental|IVIG|IVIG 0.5gram/kg IVPB using actual body weight daily x 4 days
89049903|NCT04615611|Experimental|salbutamol|salbutamol, 800 microgram from metered dose inhaler
89049904|NCT04615611|Placebo Comparator|placebo|placebo
89049905|NCT04615728||pre-COVID cohort|Patients recruited from 1st November 2019 to 9th March 2020
89049906|NCT04615728||COVID cohort|Patients recruited from 10th March 2020 to 5th July 2020
89049907|NCT04832165|Experimental|Muscle inspiratory strength training|An 8-week muscle inspiratory muscle strength training
89049908|NCT04832165|No Intervention|No training program|No intervention
89049909|NCT04798586|Experimental|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
89674102|NCT06198075|Experimental|Experimental group|Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted. Final assessment will be done after 6 weeks.
89674103|NCT06198062|Experimental|Paraffin wax bath therapy|Heat therapy for the relief of joint pain and stiffness was established using paraffin and prolonged stretching. When used as a treatment method, paraffin wax is heated to a temperature between 115 and 118 degrees. One step of the paraffin treatment is cleaning. (1) Drying the damaged area and making sure the skin is covered in plastic, (2) Wrapping any small open wounds in plastic, (3) Applying paraffin wax to the affected area, (4) Stretching the affected extremity for 20 minutes, (5)Covering the area with an ACE bandage or a towel to prevent the wax from cooling too quickly
89688736|NCT03035383|Active Comparator|Conventional technique|Thyroidectomy closure is performed using conventional technique.
89688737|NCT02933866|Experimental|DSXS topical|applied once daily for 28 days
89688738|NCT02933866|Placebo Comparator|Vehicle topical|applied once daily for 28 days
89688739|NCT03035305|Experimental|SMC and LNS (intervention group)|Children included in the 9 health areas of the intervention group receiving both lipid-based nutrient supplement and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
89049910|NCT04614831||Psoriasis and Psoriatic Arthritis|The study population consists of adults who self-report to have been diagnosed with psoriasis with or without concomitant psoriatic arthritis
89215003|NCT05312632|Experimental|Safinamide Mesilate|Participants with parkinson's disease will be administered Safinamide Mesilate 50 milligram (mg) tablet, orally, once daily as add-on therapy to levodopa for up to 2 weeks. After 2 weeks, at the discretion of an investigator, dose of Safinamide Mesilate will be increased to 100 mg tablets (two tablets of 50 mg each), orally, once daily for up to 18 weeks.
89215004|NCT05301114|Experimental|Intervention participants|Among patients who completed the social needs screening as a part of standard of care, all stage I-IV Black cancer survivors will be invited to participate in a six-month community health worker intervention. The community health worker will assess social needs and provide six months of support.
89215005|NCT05287594|Experimental|TRAINER|The TRAINER group will receive an integrated exercise program, led by a peer-trainer, including a neuromuscular warm-up and high intensity interval training at their respective fire stations 2 times per week for 6 weeks.
89674104|NCT06198062|Experimental|Muscle energy technique|Reciprocal inhibition, hypertonic antagonists can reflexively inhibiting their agonist muscle. Therefore, in the presence of short and tight antagonist muscles, restoring normal muscle tone and length should be first addressed. MET involves the subject to voluntarily contract the muscle in a precisely controlled direction against the therapist's counter force. Its therapeutic effects are to reduce pain, reduce muscle tone, stretch tightened muscles, strengthen the weak muscles, improve local circulation and mobilize joint restrictions. Anatomical structures that contribute to stiffness at the joint states that the joint capsule, surrounding inter-muscular fasciae and muscles, tendons and skin tissue account for restriction at the joint. Relaxation of the antagonist muscle occurs due to actively contracting the agonist muscle
89674105|NCT06198049|Experimental|Pilates Training|Group A 17 participants will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week.
89215006|NCT05287594|No Intervention|Waitlist Control|The waitlist control group will not receive training during the course of the study, but will be offered the opportunity to receive the integrated exercise program after the study ends.
89215007|NCT05282212||Dental Implant Surgery|Subjects scheduled for a revision surgery after developing infection after implant surgery
89674106|NCT06198049|Experimental|Balance Proprioception Exercises|Group B 17 participants will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. The program will be included four prescribed exercises: (a) exercise without any material, (b) exercise with a ball only, (c) exercise with a balance board only, and (d) exercise with a ball and a balance board. Also for gait and dynamic balance activity training use of Cobblestones walking mat that affects postural control. Walking task on the Cobblestone walking mat included: walking backward, walking sideways, and walking under dim light conditions. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
89674107|NCT06198036|Active Comparator|Group A: Application of Hold-Relax PNF Technique|A hold-relax technique that entails stretching the muscle to its maximum length. Participant will be in supine position. The hamstring muscle will be stretched for 7 to 10 seconds while the individual reported only a slight stretch in the muscle. The participant then attempts to lower his leg towards the table while being resisted by the researcher, isometrically contracting his hamstring muscle for 3 seconds. The patient then instructed to relax for five seconds. The researcher then passively stretched the muscle until a slight sensation of stretch was experienced. The stretch will maintain for seven seconds. There were five repetitions of this sequence, each one 20 seconds apart from the previous one
89674108|NCT06198036|Active Comparator|Group B: Application of Muscle Energy Technique|Group B will receive a Muscle Energy Technique (MET) applying the reciprocal inhibition principle. Participant will be in supine lying and the affected muscle held in a mid-range position. The Reciprocal Inhibition-MET group stretched for 10 to 60 seconds after performing an isometric contraction of the muscle opposite the one that needed to be stretched for 7 to 10 seconds (30%-50% of the time) followed by 5 second rest interval. With a pause of 20 seconds in between each repetition, this sequence was performed five times(52). The readings for Active knee Extension (AKE), TUG test and WBFPS before and after treatment session determined the improvement regarding the treatment outcomes.
89674109|NCT06197971|Other|Instrument Assisted Soft Tissue Mobilization|The therapist will assess the hamstrings to identify areas of restriction or dysfunction. They will use the Graston Technique instruments to apply strokes and movements along the length of the muscle fibers. Sweeping strokes, cross-fiber friction, and circular motions patterns will be applied. The duration of the IASTM treatment will be 15-30 minutes.
89674110|NCT06197971|Other|Therapeutic Cupping Technique|After thorough assessment of the Hamstring area, a thin layer of lubricant will be applied on the area about to be cupped. Stationary cupping technique will be used for a duration of 5-15 minutes with multiple Silicone Cups applied on the Hamstrings. For cupping the hamstrings, cups with a diameter of around 1.5 to 2.5 inches (3.8 to 6.4 cm) will be suitable considering the large area of treatment
89674111|NCT06197932|Other|Routine exercise and running training|15 participants were in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol. In pre measurements I assessed the strength of big toe of right and left feet, using the hip and toe dynamometer in kilograms. Further I assessed height of vertical jump in centimeters, than I assessed horizontal jump in centimeters. For balance Y -balance test is measured, test is measured for agility T test I measured, after assessment of all variables I gave them plan for big toe strengthening ask them to do repetitions about 15 in three sets twice a day, for 4 weeks after pre measurements, with intensity should be moderate. Asked them to perform 5 exercises twice a day. After 4 weeks measured all variable in same units and used the same instruments that used in pre measurements.
89215008|NCT05272813|Experimental|MS-553 Low Dose|MS-553 Low Dose PO BID
88815759|NCT01112696|Other|Sensor|All subjects that wear sensors (all subjects)
89215009|NCT05272813|Experimental|MS-553 Mid Dose-1|MS-553 Mid Dose-1 PO BID
89215010|NCT05272813|Experimental|MS-553 Mid Dose-2|MS-553 Mid Dose-2 PO BID
89215011|NCT05272813|Experimental|MS-553 High Dose|MS-553 High Dose PO BID
89674112|NCT06197932|Experimental|Big Toe Strengthening Exercise|Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for 4 weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
89674113|NCT06197607|Other|control group|The control group will receive thera putty hand exercises.
89674114|NCT06197607|Active Comparator|experimental group|The experimental group will receive sensory stimulation along with theraputty hand exercises.
89674115|NCT06197594|Experimental|Proprioceptive neuromuscular facilitation techniques|"GROUP A (experimental group)~PNF based exercises for trunk control duration 45 min 5 session/week for 6 weeks; Resist person concentric contraction while move in sitting .Resist eccentric control as th lie down. Balance using stabilizing reversals or rhythmic stabilization .Resist shoulder pelvis ,head.Trunk exercises dynamic reversals and combination of isotonic to increase trunk strength and coordination .Resist at scapula and lifting combinations for irradiation. Trunk flexion and extension. Reaching forward and to side with return,for this hip flexion, extension ,lateral motion and rotation with the trunk remaining stable Bridging exercises Lower trunk rotation .Weight shifting in long leg sitting"
89674116|NCT06197594|Active Comparator|Rebound Therapy|"Rebound Therapy lying down on trampoline bouncing created.10 times.Hip kneeling bounce and Standing bouncing with physio balls .Jump on trampoline. Learning front drops, seat drops for 5 minutes.~Resist person concentric contraction while move into sitting .Resist eccentric control as they lie down. Balance using stabilizing reversals to increase trunk stability .Resist shoulder pelvis, head.Trunk exercises: use dynamic reversals and combination of isotonic to increase trunk strength and coordination .Resist at scapula and lifting combination for irradiation. Trunk flexion and extension. Reaching forward and to side with return,for this hip flexion , extension ,lateral motion and rotation with trunk remaining stable Bridging exercises Lower trunk rotation .Weight shifting in long leg sitting"
89674117|NCT06197308|Experimental|PCS patients|
89674118|NCT06197295|Experimental|Solifenacin with vaginal estrogen cream|Solifenacin 5mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.
89674119|NCT06197295|Active Comparator|Combination pharmacotherapy|Combined solifenacin 5mg and mirabegron 25mg once per day.
89674120|NCT06196983|Experimental|Experimental group, Rhythmic aerobic exercises|Rhythmic aerobic exercises were used in experimental group.
89674121|NCT06196983|Active Comparator|control group, strength and balance exercises|only strength and balance exercises were given to control group.
89674122|NCT06196957|Experimental|Buteyko technique|"GROUP A'(Buteyko technique)~Participant in group A will be instructed to perform the Buteyko breathing exercise.~Patient either on the sitting position or standing position.~Patient will be relaxed the shoulder and rest lower back against the back of chair.~Close the mouth while only breathing through nose.~Breath into the diaphragm and chest should be still.~Exhale slowly, then hold the breath.~Use the index finger and thumb to plug the nose, Hold the breath until there is urge to breath Then inhale~Repeat several times. With in 15 minutes."
89674123|NCT06196957|Active Comparator|Senobi technique|"GROUP B (Senobi techniques)~Senobi breathing exercise will be performed from standing, Arms will be extended firmly,~The neck was extended so as face the ceiling. And the patient instructed to avoid over exertion~Take a deep breath, hold for 3 second and then exhale through mouth.~The time of exercise will be 15 minutes."
89674124|NCT06196268|Experimental|core strengthening exercise|Patients in Group A will receive core strengthening exercises along with the warm up exercises (lumbar stretches). CSE will constitute of abdominal hollowing, Side Bridge, supine extension bridge, straight leg rise from prone, alternate arm and leg raise from quadruped, and prone bridge. Total treatment will be of 60 mins with thrice a week for 6 weeks.
89674125|NCT06196268|Experimental|Pilates exercise|Patients in Group B will receive Pilates exercises along with warm up exercises which includes hundreds, one leg stretch, shoulder bridge, hip twist, scissors, side kicks. Total treatment will be of 60 mins with thrice a week for 6 weeks.
89674126|NCT06193980||Previously mechanically ventilated|"Patients who have received prolonged mechanical ventilation (7 days or more) within the medical ICU or surgical ICU at Health Sciences Centre Winnipeg.~OR~Patients previously enrolled in Microvascular Monitoring in Circulatory Shock and Sepsis (MiMICSS) research study (NCT05985525)"
89674127|NCT06193980||Healthy|Healthy volunteers, matched for age and sex, with participants in the previously mechanically ventilated cohort.
89674128|NCT06190197|No Intervention|Control group|No prophylactic antibiotics post operatively. Participants will receive antibiotics only if needed post-operatively such as for infection
89674129|NCT06190197|Experimental|Treatment group|Prophylactic antibiotics postoperatively.
89674130|NCT06190067|Experimental|Azacitidine Plus PD-1 therapy|Patients were treated by Azacitidine plus PD-1 therapy
89674131|NCT06187129||diabetic children and adolescent with type 1 diabetes|nerve ultrasound and nerve conduction study
89674132|NCT06187129||healthy age matched group|nerve ultrasound
89049911|NCT04798040|No Intervention|Control group|"Routine treatment and nursing care of the clinic will be applied to the patients without any application.~Routine interventions applied to the control group during silicone drain removal in the clinic:~The patient will be informed about the procedure.~The consent of the patient who agrees to participate in the study will be obtained.~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale .~The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.~The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
89215012|NCT05267587|Experimental|Hypofractionated Stereotactic Radiosurgery prior to resection|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected on Days 1-3 (3 consecutive days). If there are additional non index brain metastasis, they will be treated with standard stereotactic radiosurgery at the time of fSRS. Participants will then undergo stereotactic craniotomy for surgical resection of the index metastasis within 5 days following completion of fSRS.
89674133|NCT06183957|Experimental|hydrotherapy group|When women in this group are taken to their labor rooms (when the dilation is 4-5cm), they should be standing or standing, depending on their preferences, on their waist, abdomen or whole body, with the temperature of the water between 32-37 °C (the temperature preferred by the woman will be applied) for at least 20 minutes. Sitting shower application will be performed under the observation of the researcher midwife. The temperature of the flowing water will be measured with a bucket and a thermometer that helps evaluate the temperature. The application will be repeated when the dilation is 6-8 cm.
89674134|NCT06183957|No Intervention|Control group|Women in this group will not undergo any treatment other than routine hospital protocol (midwifery care). Additionally, the vital signs (blood pressure, pulse) of the participants will be measured and recorded hourly by the midwife. These data will be recorded in each participant's file.
89674135|NCT06181149|Experimental|Group 1|
89674136|NCT06181149|Experimental|Group 2|
89674137|NCT06181149|Experimental|Group 3|
89674138|NCT06181149|Experimental|Group 4|
89674139|NCT06180798|Active Comparator|cold snare endoscopic mucosal resection (C-EMR)|All procedures will be performed by experienced endoscopists (>3 years of experience/>1000 polypectomies) with the patient in the left lateral position under propofol sedation.submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.
89674140|NCT06180798|Sham Comparator|Hot snare endoscopic mucosal resection (H-EMR)|All procedures will be performed by experienced endoscopists (>3 years of experience/>1000 polypectomies) with the patient in the left lateral position under propofol sedation.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.
89674141|NCT06180343|Experimental|Mandala coloring group|"Participants will be asked to choose the pages they want from the 12 colored felt-tip pen paint sets and mandala coloring book given to each participant by the researcher, and color them in the colors they want, for 6 weeks, once a week, at any time of the day and for an average of 20-30 minutes each time.~Participants will be asked to send a message before they start painting the mandala, and after the process, they will be asked to take a picture of the mandala they have painted and send it to the researcher. If the participants forget to color the mandala, a reminder message will be sent by the researcher twice a week."
89674142|NCT06180343|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms. Participants will be asked by telephone by the researcher twice a week for 6 weeks whether they have taken any action to reduce their anxiety symptoms. Participants who use any of the pharmacological or non-pharmacological practices to reduce anxiety symptoms will be excluded from the study.
89674143|NCT06179966|Experimental|Dance group|The application will be taught to the participants' spouses by the researcher after they are admitted to labor, and the spouses will be asked to do it to the participants at regular intervals.
89674144|NCT06179966|Experimental|Massage group|After admission to travaya, the researcher will teach the pregnant woman's husband practically and the spouses will massage the participants' backs at certain intervals.
89674145|NCT06179966|No Intervention|Control Group|Routine midwifery care will be provided, and no applications other than routine midwifery care will be performed.
89674146|NCT06178029|Active Comparator|conventional rehabilitation|20 multiple sclerosis patients will receive conventional rehabilitation
89674147|NCT06178029|Active Comparator|conventional rehabilitation and acupuncture|20 multiple sclerosis patients will receive conventional rehabilitation and acupuncture treatment.
89674148|NCT06176755|Experimental|Treadmill training with weighted ankle cuffs|Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently
89674149|NCT06176755|Active Comparator|Treadmill training|Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently.
89674150|NCT06176469||Population-level and representative cohort|
89215013|NCT05263180|Experimental|Experimental: EMB-09|Participants enrolled at different time will receive EMB-09 once a week (IV) at different ascending dose levels.
89215014|NCT05260671|Experimental|Penpulimab+cetuximab|Erbitux 500 mg/m2 without immunotherapy for 14 days prior to the first cycle. Cetuximab Injection 500 mg/m2 and Penpulimab Injection 200 mg are intravenously infused on Day 1 (D1) of Cycle 1, with 14 days as one cycle. Penpulimab for up to 96 weeks (48 cycles)
89215015|NCT05253924||Preterm children (PT)|gestational age at birth <37
89215016|NCT05253924||Full-term children (FT)|gestational age at birth ≥ 37 weeks
89215017|NCT05233371||Infants at high risk of developmental delay|
89215018|NCT05223413|Active Comparator|Remote Ischemic Conditioning|Remote Ischemic Conditioning (RIC): Patients will undergo weekly RIC during the entire span of the chemotherapy period. Each RIC session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation
89215019|NCT05223413|Sham Comparator|simulated RIPC (Sham)|Control group (Sham): Patients will undergo weekly simulated RIC (sham) during the entire span of the chemotherapy period. Each sham session will include four cycles of 5 min blood pressure cuff inflation followed by 5 min deflation.
89215020|NCT05221931|Active Comparator|DES group|"Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography.~In DES group, latest second-generation DES will be used (Ultimaster Tansei) during the index procedure"
89215021|NCT05221931|Experimental|DCB group|"Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography.~In DCB group, Agent (Boston Scientific, USA), Prevail (Medtronic, USA), or SeQuent Please, SeQuent Please NEO (B-Braun, Germany) will be used during the index procedure."
89215022|NCT05212428|Experimental|Screening (biospecimen collection, genetic analysis)|Participants receive a saliva kit, register with Helix then undergo collection of saliva sample which is returned o Helix. Participants also receive an online link to complete the About Me family history. Once sequencing is completed by Helix, ancestry/trait information and genetic findings are shared with participants and their primary provider, if applicable. Participants with positive results are offered genetic counseling and are encouraged to seek clinical confirmatory testing. Following clinical confirmation, results are scanned into the electronic health record. Participants may also undergo the collection of blood, urine, and stool samples for future studies.
89215023|NCT05198245||Pregnancies in women with migraine and exposure to rimegepant|
89215024|NCT05198245||Pregnancies in women with migraine exposed to other medications|Pregnancies in women with migraine exposed to other medications indicated for the treatment of migraine
89215025|NCT05198245||Pregnancies in women without migraine|
89215026|NCT05197595|Experimental|Compassion condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
89215027|NCT05197595|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extracurricular activity.
89215028|NCT05195476||Individuals diagnosed with OCD|Individuals diagnosed with OCD
89215029|NCT05195476||Healthy controls|Individuals who have not been diagnosed with any psychiatric disorders
89215030|NCT05186948||Breast cancer patients (stages I-IIIA)|200 patients with an initial diagnosis of breast cancer stages I-IIIA and scheduled chemotherapy, fulfilling the eligibility criteria
89215031|NCT05186948||healthy control|Group of 30 healthy control participants, matched for age and sex, with no evidence or history of significant neurodegenerative disorder affecting brain function.
89215032|NCT05184569|Experimental|Verdiperstat|Verdiperstat 2 tablets twice daily (600mg total daily) by mouth for 24 weeks.
89215033|NCT05184569|Placebo Comparator|Placebo|Placebo 2 tablets twice daily by mouth for 24 weeks.
89674151|NCT06176027|Experimental|Azacytidine plus CAOLD regimen|Patients were treated by Azacytidine plus CAOLD regimen
89674152|NCT06175884|Experimental|Good communication skills|Participants will watch a video about the pain neuroscience education in which physiotherapist will develop qualities of good communication while he will be giving information and explanation about chronic musculoskeletal pain.
89674153|NCT06175884|Experimental|Poor communication skills|Participants will watch a video about the pain neuroscience education in which physiotherapist will not develop qualities of good communication while he will be giving information and explanation about chronic musculoskeletal pain.
89674154|NCT06175884|No Intervention|Control|Participants will not watch any video
89674155|NCT06168721||Expert panel|This group will be composed of experts in primary care physiotherapy.
89674156|NCT06166875||Derivation Sample|80 patients will be recruited as a derivation sample to calculate the regression equation
89674157|NCT06166875||Validation Sample|80 patients will be recruited as a validation sample to test the performance of the equation
89674158|NCT06166706||Neonates|"neonates up to 44 weeks postmenstrual age or up to 60 weeks post menstrual age if born premature (GA <37 weeks) undergoing general anaesthesia with mechanical ventilation.~No intervention will be administered."
89674159|NCT06166706||Infants|Infants of 1 month to 1 year old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
89674160|NCT06166706||Toddlers|Toddlers of 1 to 3 years old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
89215034|NCT05180422|Experimental|Dose Expansion|AMG 510/MVASI
89215035|NCT05161533|Experimental|Treatment (durvalumab, chemotherapy, radiation therapy)|"INDUCTION: Patients receive standard of care chemotherapy consisting of carboplatin or cisplatin and etoposide. Patients also receive durvalumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive durvalumab IV on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning cycle 5 or 6 of durvalumab, patients undergo hypofractionated radiation therapy."
89674161|NCT06166706||Preschool|Children of preschool age 3 to 6 years old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
89674162|NCT06166706||School-aged and adolescents|School aged children and adolescents of 6 to17 years old, undergoing general anaesthesia with mechanical ventilation. No intervention will be administered.
89674163|NCT06165705|Experimental|Amblyopia therapy with Curesight outside FDA limited ranges|Severity of amblyopia and age range outside FDA study
89674164|NCT06163300||Control|Healthy volunteers
89674165|NCT06163300||Disease|Patients affected by disease
89674166|NCT06160700||Immunotherapy Only|Subjects who are currently receiving immunotherapy only.
89674167|NCT06160700||Chemo-Immunotherapy Control Arm|Subjects who are receiving chemo-immunotherapy.
89674168|NCT06160700||No Active Therapy Control Arm|Subjects who are no currently receiving active therapy.
89674169|NCT06159153|Experimental|Dynamic Ultrasonography assessment|Patients admitted for ACL injury and indication for arthroscopy will have dynamic ultrasound evaluation that will be compared with an MRI.
89674170|NCT06155097|No Intervention|Control Group|Patients will not receive any regional injections
89674171|NCT06155097|Active Comparator|The transversus thoracis muscle plane block (TTP) group|Patients will receive the TTP block with administration of 20 ml volume of local anesthetics (Lidocaine 2% + Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) bilaterally
89674172|NCT06155097|Active Comparator|The parasternal intercostal nerve block (PSI block) group|Patients will receive the PSI block with administration of 20 ml volume of local anesthetics (Lidocaine 2% + Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) bilaterally
89674173|NCT06154226|Experimental|Pantoprazole group|Pantoprazole (40 mg iv every 12 hours/q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on postoperative (POD) 1 for a total of 4 doses over 2 days. There will be no other modifications in patient care.
89049912|NCT04798040|Experimental|Cold application group|The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale. A gel pad with a temperature of -10 ° C and a homogeneous distribution when cooled will be placed so that the patient is in full contact with the silicone drain.Since the skin temperature must fall below 13.6 ° C for cold application to have a local analgesic effect, the application will be terminated when the patient's skin temperature is 13.6 ° C by measuring every one minute during the cold application and the physician will be informed that the patient is ready.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale15 minutes after the removal of the silicone drain.
89049913|NCT04798040|Experimental|Lavender oil group|"All patients who accept the study will be tested for lavender oil before the procedure to exclude sensitivity to lavender. Patients in the lavender group will be given oxygen with a lavender oil covered face mask 15 minutes before the silicone drain is removed. Two drops of 2% lavender oil will be applied with a cotton swab inside the oxygen face mask.~The patient will mark the pain he feels due to the silicone drain on the Numeric Rating Scale.The patient will mark the pain again from the Numeric Rating Scale immediately after the procedure.The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain."
89674174|NCT06154226|Active Comparator|Famotidine Group|Famotidine (20 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on POD 1 for a total of 4 doses over 2 days. There will be no other modifications in patient care.
89674175|NCT06151288|Experimental|Group 1|Participants will receive a single low dose of VAX-31 administered as an intramuscular injection at Day 1.
89674176|NCT06151288|Experimental|Group 2|Participants will receive a single mid dose of VAX-31 administered as an intramuscular injection at Day 1.
89674177|NCT06151288|Experimental|Group 3|Participants will receive a single high dose of VAX-31 administered as an intramuscular injection at Day 1.
89674178|NCT06151288|Active Comparator|Group 4|Participants will receive a single intramuscular injection of the standard dose of PCV20 at Day 1.
89674179|NCT06147596||Soccer|Healthy volunteers that participate in the study by playing a regular soccer game for the sake of the HEADLINE study
89674180|NCT06144424|Experimental|EP262 150 mg|
89049914|NCT04798040|Experimental|Oxygen administration|The patient will be informed about the procedure. Consent of the patient who agrees to participate in the study will be obtained. Patients in the oxygen administration group will be given 2 lt/min oxygen with a face mask 15 minutes before the silicone drain is removed. The patient will mark the pain he feels due to the silicone drain on Numeric Rating Scale. The patient will re-mark the pain from Numeric Rating Scale immediately after the procedure. The patient will fill the Numeric Rating Scale 15 minutes after the removal of the silicone drain. Before the procedure, as soon as the procedure is over and 15 minutes after the procedure, the patient's vital signs will be measured.
89049915|NCT04785053|Active Comparator|Healthy young participants|a group of 20 cognitively intact younger participants (age 21-35)
89049916|NCT04785053|Active Comparator|Healthy older participants|A group of 20 cognitively intact older participants (age 55+)
89049917|NCT04785053|Active Comparator|Older MCI/mild AD participants|A group of 20 cognitively impaired older participants (age 55+)
89049918|NCT04776551|Other|group (1)|group (1) who are complaining of acute scaphoid fractures,we will do percutaneous trans trapezial fixation of scaphoid by Herbert screw.Short arm circular cast including the thumb will be applied. After 3 weeks, cast will be removed and exercises will start.
89049919|NCT04614675|Active Comparator|Transarticular lateral release (TALR)|TALR The first toe is pulled distally for access into the lateral aspect of first MTPJ. A No.15 beaver blade is advanced from the medial incision laterally to divide the lateral capsule vertically and adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
89674181|NCT06144424|Placebo Comparator|Placebo|
89674182|NCT06144268|Active Comparator|Density Gradient Centrifugation (DGC)|During this procedure, raw semen sample is placed on 2 gradients: a lower phase (80%) and an upper phase (40%) followed by centrifugation. The composition of the gradients include a colloidal suspension of silica particles. At the end of centrifugation, each spermatozoa is situated at the gradient level that matches its density. The highly motile, morphologically normal, viable spermatozoa form a pellet at the bottom of the tube.
89674183|NCT06144268|Experimental|ZyMōt Multi (850µL)|ZyMōt Multi (850µL) is a flow-free dual chambered single-use device. The first chamber contains a sample inlet and a fluid channel separated from the second collection chamber by an 8-μm microporous membrane. Channel dimension and membrane porosity are designed to optimize the sorting and collection of the most motile sperm. Sorting is accomplished by the passage of sperm through the micropores of the membrane. This procedure does not require any preliminary semen processing, all centrifugation steps being eliminated.
89674184|NCT06143293|Experimental|Order 1 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F1=1Hz, F2=10Hz, F3=30Hz, period 1,2 and 3 respectively"
89688740|NCT03035305|Other|SMC only (control group)|Children included in the 9 health areas of the control group receiving seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
88815760|NCT03013478|No Intervention|Standard treatment as usual (TAU)|Treatment normally offered at this primary care clinic
89049920|NCT04614675|Active Comparator|Percutaneous lateral release (PCLR)|PCLR A 0.5 cm stab wound is made at lateral aspect of first MTPJ. A No. 15 beaver blade is advanced into the lateral side of MTPJ with a quarter of the blade inside the joint and verified with fluoroscope. The blade is turned laterally to face the adductor hallucis tendon. The adductor tendon is divided with lateral movement of the blade and varus manipulation of proximal phalanx. A click is heard as adequate release of adductor hallucis tendon. Same intraoperative stress test is performed and recorded under fluoroscope to confirm correction.
89049921|NCT04614285|Experimental|Partial excavation|The treatment will be performed after applying local anesthetic according to individual needs. The intervention group will receive partial removal of the carious lesion; In the inner part of the lesion, the caries removal will be limited to reach leathery or slightly soft dentin by probing. The restorations will be placed according to evidence based methods and the material used according to the operators material of choice.
89674185|NCT06143293|Experimental|Order 2 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F2=10Hz, F3=30Hz, F1=1Hz, period 1,2 and 3 respectively"
89674186|NCT06143293|Experimental|Order 3 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F3=30Hz, F1=1Hz, F2=10Hz, period 1,2 and 3 respectively"
89674187|NCT06143293|Experimental|Order 4 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F1=1Hz, F3=30Hz, F2=10Hz, period 1,2 and 3 respectively"
89674188|NCT06143293|Experimental|Order 5 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F2=10Hz, F1=1Hz, F3=30Hz, period 1,2 and 3 respectively"
89674189|NCT06143293|Experimental|Order 6 assignment|"individuals 18 years of age and older who are implanted with a VNS device (standard of care), which consists of patients who have been diagnosed with drug resistant epilepsy or major depressive disorder.~Frequency order: F3=30Hz, F2=10Hz, F1=1Hz, period 1,2 and 3 respectively"
89674190|NCT06143254|Experimental|Symbolic Gesture Training Group|Caregivers of children who are assigned to the SGT group will participate in three caregiver training meetings to learn how to use infant signing in combination with verbal training to promote the speech and language development of their child. These meetings will take place 1 month (meeting 1), 2 months (meeting 2) and 3 months (meeting 3) after baseline assessments are performed (T0). Each meeting will take two hours. After the first training session (meeting 1), caregivers will start using the symbolic gestures to support verbal in- and output at home with their child.
89674191|NCT06143254|Active Comparator|Verbal Training Group|Caregivers of children who are assigned to the VT group will participate in three caregiver training meetings to learn how to use verbal training to promote the speech and language development of their child. These meetings will take place 1 month (meeting 1), 2 months (meeting 2) and 3 months (meeting 3) after baseline assessments are performed (T0). Each meeting will take two hours. After the first training session (meeting 1), caregivers will start using supporting verbal in- and output at home with their child.
89674192|NCT06143254|No Intervention|No Intervention Control Group|Standard clinical care at this moment at the Cleft Palate Teams of the University Hospitals of Ghent and Leuven includes providing information to caregivers about speech-language development and encouraging caregivers to communicate with their children. This information will be orally provided by an SLP during a standard clinical appointment at the cleft team at the age of 12 months. A brochure including this information will be provided. Caregivers of children who will be assigned to group C will have the opportunity to receive the most effective intervention (SGT or VT) after finishing the study.
89674193|NCT06141031|Experimental|Phase I|During Phase 1, up to 2 dose levels of TTI-101 with SBRT will be tested using a 3 + 3 dose-escalation design to determine the RP2D. Up to 3 participants may be enrolled with either 0/3 or 1/3 DLT in order to more fully evaluate the safety and tolerability at a given dose level. Therefore, a minimum of 9 patients (3 at dose 0, and 6 at dose 1) and maximum 18 (6 patients at each dose level) will be enrolled in the phase 1.
89674194|NCT06141031|Experimental|Phase II|An additional 12 patients will be enrolled in phase 2 so that total of 18 patients are treated at RP2D in phase 2 (the 6 patients treated at RP2D in phase 1 will be rolled over to phase 2) of TTI-101 in combination with SBRT on + 3-5 days prior to the first fraction of the SBRT.
89674195|NCT06139601|Other|Body empowerment intervention program|All study participants will complete a single session body empowerment program.
89674196|NCT06136871|Experimental|Cognitive Orientation to daily Occupational Performance (CO-OP)|Each CO-OP session will last 45 minutes and subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
89674197|NCT06136871|Active Comparator|Inactive Control Group|Subjects will complete one session per week over the course of 10 weeks. All sessions will be delivered remotely via the Zoom platform.
89674198|NCT06135116||periodontally healthy|twenty persons without any signs of periodontal disease. This was determined by the absence of attachment loss and bleeding upon probing either ˂ 10% or probing depth ˂3 mm.
89674199|NCT06135116||chronic gingivitis|twenty persons exhibiting generalized chronic gingivitis exhibiting signs of erythema, bleeding on probing up to 20%, edema, probing pocket depth less than 3 mm and no periodontal attachment loss.
89674200|NCT06135116||chronic periodontitis|twenty patients having severe generalized form of chronic periodontitis exhibiting PPD ≥ 6 mm, CAL ≥ 5mm and bone loss affecting at least six teeth as observed in dental periapical radiograph
89674201|NCT06132074|Experimental|Intervention-arm|Immediate scheduling and participation of Uppsala Tjej- och Transjour's intervention.
89049922|NCT04614285|Active Comparator|Complete excavation|The treatment will be performed after applying local anesthetic according to individual needs. The control group will receive the same treatment procedure as the intervention group, but the excavation procedure will include total removal of the carious tissue. The total caries removal will be ensured with hardness on probing and the visual examination. Photographs will be used as benchmark.
89674202|NCT06132074|Active Comparator|Wait-list control-arm|Wait-listed group, will await intervention for 6-8 months. After follow-up measurements, this group will receive the intervention.
89674203|NCT06131710|Experimental|Isolated Strengthening Exercises|Isolated strengthening exercises refers to set of exercises that are used to treat a specific part of body. In our study, isolated strengthening exercises including 10 repetition of 3 sets of legs extensions,10 repetition of 3 sets squats and 10 repetition of 3 sets lunges are used. These exercises aim to improve the pain and range of motion of knee by acting on quadriceps.
89674204|NCT06131710|Experimental|Combined Strengthening Exercises|The Combined strengthening group will perform the same isolated strengthening exercises, but with the addition of proximal strengthening exercises for the hip and core muscles. These exercises include 10 repetitions of bridging(3 sets), 10 repetitions of clamshells(2 sets), 10 repetition of 3 sets of legs extensions,10 repetition of 3 sets squats,10 repetition of 3 sets lunges and 10 repetitions of planks(2 sets).
89674205|NCT06128135||Prosthesis Users|30 participants, aged between 18 and 60, will be part of the study. The users must have at least 6 months of experience using upper limb prostheses. They will be asked a 15-question survey about their upper limb prostheses.
89674206|NCT06128135||Therapists|10 therapists that have experience working with prostheses. They will be asked a 9-question survey about upper limb prostheses that they usually handle.
89674207|NCT06128135||Relatives|30 of the prosthesis users' relatives who live with the person and see the daily difficulties of using the device. They will be asked a 9-question survey about the device that their relatives costume to use.
89674208|NCT06120556||Severe Insulin Resistant Diabetes (SIRD)|"Patients with SIRD are characterized by high BMI and high insulin resistance and low HbA1c. These patients likely develop diabetic kidney disease.~Defined according to the simplified algorithm proposed by Bello-Chavolla et al. requiring the following data: age at diabetes diagnosis, age, BMI, height, waist circumference, HbA1c, fasting blood glucose, fasting triglycerides, HDL cholesterol"
89674209|NCT06120556||Mild Age-Related Diabetes (MARD)|"Patients with MARD are characterized by late onset diabetes without extreme features.~Defined according to the simplified algorithm proposed by Bello-Chavolla et al. requiring the following data: age at diabetes diagnosis, age, BMI, height, waist circumference, HbA1c, fasting blood glucose, fasting triglycerides, HDL cholesterol"
89674210|NCT06120556||Mild Obesity-related Diabetes (MOD)|Patients with MOD are characterized by high BMI without insulin resistance. Defined according to the simplified algorithm proposed by Bello-Chavolla et al. requiring the following data: age at diabetes diagnosis, age, BMI, height, waist circumference, HbA1c, fasting blood glucose, fasting triglycerides, HDL cholesterol
89674211|NCT06120556||Severe Insulin Deficient Diabetes (SIDD)|"Patients with SIDD are characterized by high HbA1c and rapid progression to insulin therapy. These patients likely develop retinopathy, even in the first years after diagnosis.~Defined according to the simplified algorithm proposed by Bello-Chavolla et al. requiring the following data: age at diabetes diagnosis, age, BMI, height, waist circumference, HbA1c, fasting blood glucose, fasting triglycerides, HDL cholesterol"
89674212|NCT06110273|Active Comparator|m-Health Control|This arm receives a digital fitness tracker, digital scale, and basic information about behavioral approaches for weight gain prevention.
89674213|NCT06110273|Experimental|Fit for Duty Mobile|This arm receives a digital fitness tracker; digital scale; smartphone app which delivers a behavioral weight gain prevention intervention; and periodic coaching calls.
89674214|NCT06096675|Experimental|cardiac rehabilitation group|Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.
89674215|NCT06096675|No Intervention|control group - no intervention|Control Group will have baseline 6-minute walk test and CPET testing followed by a repeat 6-minute walk test and CPET test in 12-14 weeks
89674216|NCT06096623|Experimental|electronic patient-reported outcome (ePRO) questionnaires.|Subjects with colon or breast carcinoma will respond to weekly electronic patient-reported outcome (ePRO) questionnaires.
89674217|NCT06092216|Experimental|Spesolimab|900 mg of spesolimab intravenously (IV)
89674218|NCT06086834|Experimental|McKenzie Retraction Exercises|McKenzie Retraction Exercises along with hot pack.
89674219|NCT06086834|Experimental|Bruegger's Exercise|Bruegger's Exercise along with hot pack.
89674220|NCT06084455|Experimental|Aerobic exercise|30 minutes of aerobic exercise will be performed by the participants before and after cortical connectivity measurements.
89674221|NCT06082479|No Intervention|control group|no application of any type of cryotherapy.
89049923|NCT04614012|Experimental|hyperimmune plasma|treated with hyperimmune plasma
89049924|NCT04713371|Other|Single arm. Subjects receiving treatment.|Efficacy of Cryosurgical Freezing and Multiplex Immunochemotherapy as determined by overall response rate of radiographic changes according to iRECIST criteria.
89674222|NCT06082479|Active Comparator|cryotherapy group|after the completion of the mechanical preparation. A 2.5 x5 centimetre gel pack was placed in the mouth on the vestibular surface of the treated tooth.
89674223|NCT06082271|Active Comparator|Cortisone (C)|To improve the outcome of the arthroscopy during the procedure, cortisone is injected for anti-inflammatory purposes at the end of the surgical procedure.
89674224|NCT06082271|Experimental|Hydrolyzed Collagen Peptides|The use is alternative to cortisone
89674225|NCT06075745|Experimental|Vaccine Arm|Participants in this arm will receive two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine
89674226|NCT06075745|Placebo Comparator|Placebo Arm|Participants will receive two doses of matching placebo of the Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine
89674227|NCT06075251|Experimental|I-InTERACT-North|Virtual stepped-care positive parenting program.
89049925|NCT04614090||99 warfarin patients|warfarin patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture. All patients on warfarin were reversed if necessary to INR≤1.5 before surgery using vitamin K and/or four-factor prothrombin complex concentrate (PCC)
89049926|NCT04614090||99 patients without anticoagulants|As a 1:1 ratio control group matched for age, gender and surgical implant. All patients were operated within 24 h with a cephalomedullary nail due to a trochanteric or subtrochanteric hip fracture.
89674228|NCT06075251|No Intervention|Care as Usual|The CAU group will receive no direct parent treatment other than clinical care provided in cardiac follow-up (i.e., child assessment and consultation), which will be documented at each follow up. At end of trial, participants randomized to CAU will have the option to participate in I-InTERACT-North.
89674229|NCT06073782|Experimental|Education Group|"The training material will be created by researchers by reviewing national and international guidelines for colonoscopy practices. Using the Colonoscopy Patient Preparation Guide, individuals will be given face-to-face, information and preparation training on colonoscopy preparation, its importance, the preparation medication to be used and the procedure process for an average of 15-20 minutes in a private room in the unit. After the training, individuals will be given the Colonoscopy Patient Preparation Guide brochure developed by the researchers."
89674230|NCT06073782|Experimental|Text Message Group|Individuals will be subjected to the routine colonoscopy preparation procedure of the hospital by the investigator. Starting three days before the colonoscopy is performed, individuals will be informed via text messages about the foods and beverages that they can consume in their diet and those that are forbidden to consume until the morning of the colonoscopy, the amount of fluids they should consume daily, the use of medication, the use of soda and enema, appointment time reminders.
89674231|NCT06073782|No Intervention|Control Group:|Individuals in the control group will be subjected to the standard procedure applied in the clinic. No additional education and educational brochures will be given to these patients and text message reminders will not be applied.
89674232|NCT06072534|Active Comparator|Miva 3|"Mivacurium chloride (Mivacron®) 0.3 mg/kg 3 times effective dose (ED) 95 iv during induction recording intubation condition during rapid sequence intubation within 90 sc monitoring hemodynamic changes during intubation ,time to recover to T1"
89674233|NCT06072534|Active Comparator|Miva 4|"Mivacurium chloride (Mivacron®) 0.4 mg/kg 4 times effective dose (ED) 95 iv during induction~recording intubation condition during rapid sequence intubation within 90 sc monitoring hemodynamic changes during intubation,time to recover to T1"
89674234|NCT06069765|No Intervention|Standard group|Children in this group will continue with their daily activities such as conventional physiotherapy and occupational therapy, even psychology, and their physical activities such as swimming or playing football.
89674235|NCT06069765|Experimental|TUPEX group|Children in this group will continue with their daily activities and will add the TUPEX program during 8 weeks.
89674236|NCT06069063|Experimental|Zafirlukast cross-over to Placebo|This group will receive the Zafirlukast pre-treatment nasally (400 mcg in 150 mcl in each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril) in the first study visit. In the second study visit, they will receive a placebo pre-treatment nasally (150 mcl each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril).
89688741|NCT02935036|Experimental|ADPS topical product|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
88995820|NCT05293600|Active Comparator|Interventional arm|This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).
88995821|NCT00532714|No Intervention|Irinotecan plus capecitabine|Irinotecan 80 mg/m2 (intravenously once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period) Capecitabine (orally at a dose of 1,000 mg/m2 twice daily 3-week cycles (2 weeks of treatment followed by a 1-week rest period))
88995822|NCT05283070||Control|Volunteers without preexisting chronic pain and/or mental health issues
88995823|NCT05283070||Patients with chronic pain|Patients with chronic pain and/or mental health issues
88995824|NCT00151736|Experimental|Chlorambucil|Regime A
88995825|NCT00151736|Experimental|R-etodolac with chlorambucil|Regime B
88995826|NCT05242939|Experimental|The Group of Cartoons|The cartoons that are suitable for the child's age and gender will be watched. The child will be asked which cartoon he would like to watch. The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher. Due to the COVID-19 pandemic, cartoons will be watched on the parent's phone. Parents who do not have an internet connection will also be provided with internet access by the researcher. The child will watch cartoons on their parent's phone.
88995827|NCT05242939|Experimental|The Group of Game|723 / 5.000 Çeviri sonuçları The group whose video games will be played will be told to choose the game they want before the process. Due to the COVID-19 pandemic, video games will be played on the parent's phone. Parents who do not have an internet connection will also be provided with internet access by the researcher. The child will play the video game on their parent's phone.
88995828|NCT05242939|No Intervention|Rutin Care Group|In the control group, the institution's routine nebula application will be performed and no intervention will be made. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
88995829|NCT00164697|Experimental|1|Parenting group
88995830|NCT00164697|No Intervention|2|"Families in this usual care comparison group were not prevented from utilizing any service that would otherwise be available to them, even if the service was similar to the services received in the intervention arm of the study."
88995831|NCT04725578|Experimental|Telehealth Single Session Consultation|
88995832|NCT04687345||Propeller Flap|The propeller flap is based on a perforator that serves as a pivot joint, allowing the flap to rotate up to 180°. It provides the advantages of greater freedom of movement and versatility in flap design.
88995833|NCT04687345||Rotation Flap|The rotation flap is primarily supplied by the perforator artery accompanied by the random supply from the skin base. It is also associated with a lower venous congestion risk.
89674237|NCT06069063|Experimental|Placebo cross-over to Zafirlukast|This group will receive a placebo pre-treatment nasally (150 mcl each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril) in the first study visit. In the second study visit, they will receive the Zafirlukast pre-treatment nasally (400 mcg in 150 mcl in each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril).
89674238|NCT06062017|Experimental|Water and Potassium|N=20, 10 males, 10 females. Following the two-week habitual run-in period, this group will receive 2000mg potassium supplementation/day for 14 days. This will be achieved by taking capsules filled with potassium citrate powder.
89674239|NCT06062017|Active Comparator|Water alone|N=20, 10 males, 10 females. Following the two week habitual run-in period, this group will be subject to a placebo supplementation for 14 days. This will be achieved via ~6000 mg of dextrose powder in vegan capsules broken out over 6 capsules/day.
89674240|NCT06062017|No Intervention|Habitual consumption|N=40, 20 males, 20 females. All participants will be monitored after two weeks of habitual water and potassium consumption prior to being randomized into two weeks of water alone or water and potassium.
89674241|NCT06056102|Experimental|Participant Cohorts|"Safety Run-in phase (2 subjects at UPenn)~Cohort 1 (3-6 subjects)~Cohort 2 (3-6 subjects)~Cohort 3 (3-6 subjects)"
89674242|NCT06049316|Experimental|Scapular stabilization exercises|Scapular stabilization exercises
89674243|NCT06049316|Active Comparator|Scapular functional exercises|Scapular functional exercises
89674244|NCT06049303|Experimental|Paraffin wax bath therapy and Maitland joint mobilization techniques|Paraffin wax bath therapy and Maitland joint mobilization techniques
89674245|NCT06049303|Active Comparator|Maitland knee joint mobilization|Maitland knee joint mobilization
89674246|NCT06049277|Experimental|Mulligan techniques with manual traction|Mulligan techniques with manual traction
89674247|NCT06049277|Active Comparator|McKenzie extension exercises with manual traction|McKenzie extension exercises with manual traction
89674248|NCT06049264|Experimental|Thoracic Spine Manual Traction with Mobilization|Thoracic Spine Manual Traction with Mobilization
89674249|NCT06049264|Active Comparator|Thoracic Spine Manual Traction with Manipulation|Thoracic Spine Manual Traction with Manipulation
89674250|NCT06049251|Experimental|ELDOA exercises|ELDOA exercises
89674251|NCT06049251|Active Comparator|Lumbar SNAGS and motor control exercises|Lumbar SNAGS and motor control exercises
89674252|NCT06048250|Experimental|Treatment (mezigdomide)|Starting between 30 and 90 days after infusion of idecabtagene vicleucel, patients receive mezigdomide PO on days 1-21 or days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT during screening. Patients also undergo bone marrow aspiration and blood sample collection throughout the study.
89674253|NCT06046547|Experimental|Pulmonary rehabilitation with palliative care education|The experimental group will participate in PR with palliative care education.
89674254|NCT06046547|Active Comparator|Pulmonary rehabilitation|The control group will participate in traditional PR.
89674255|NCT06042569|Experimental|Arm I: (Dose-reduced docetaxel, cyclophosphamide)|Patients receive dose-reduced docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89674256|NCT06042569|Active Comparator|Arm II: (Standard dose docetaxel, cyclophosphamide)|Patients receive standard dose docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89674257|NCT06036160|Experimental|Integrated care|
89674258|NCT06035393|Experimental|Treatment group A|Drug1 dose 1+Drug 3
89674259|NCT06035393|Experimental|Treatment group B|Drug1 dose 2+Drug 2+Drug 3
89674260|NCT06035393|Experimental|Treatment group C|Drug1 dose 3+Drug 2+Drug 3
89674261|NCT06035393|Other|Treatment group D|Drug 2+Drug 4
89674262|NCT06035159|Other|online psychotherapy|All participants have access to the psychotherapeutic intervention, which consists of 6 modules. Initially, we want to get information about the feasibility, comprehensibility and satisfaction of the participants with the tool. Secondly, the effectiveness of the intervention will be assessed through a pre-post measurement.
89674263|NCT06032117||Post infectious irritable bowel syndrome group|Participants will have post-infectious IBS (as identified via Rome IV criteria or previous physician diagnosis)
89674264|NCT06032117||Healthy control group|Participants will not have post-infectious IBS, matched on age group, sex, and race/ethnicity.
89674265|NCT06026098|Experimental|Case Report with Artificial Intelligence|Medical students, resident physicians, or attending physicians report rare cases with using Artificial Intelligence.
89674266|NCT06026098|No Intervention|Case Report without Artificial Intelligence|Medical students, resident physicians, or attending physicians report rare cases without using Artificial Intelligence.
89674267|NCT06023667|Experimental|SMART-IBD|The SMART-IBD app consists of educational content, medication reminders, and weekly app engagement challenges. App users will participate in weekly challenges that focus on topics such as adherence, sleep, and diary usage. Participants in this arm will complete one month of run-in diaries, one month of diaries during intervention, and one month of diaries post-intervention.
89674268|NCT06023667|No Intervention|Attention Control|Participants in this arm will not receive any intervention content. Participants in this arm will complete one month of run-in diaries, one month of diaries during intervention and one month of diaries post-intervention.
89674269|NCT06016621|No Intervention|Support as usual control Group|Participants allocated to 'support as usual' will receive routine support from their general practitioners (GPs), mental health and education/allied health professionals. Support as usual is defined as normal practice for each school in addition to the usual support from the specialist teaching teams for autism in the area, or any other additional therapies intended to support communication skills or wellbeing for autistic children. They will not receive the individual music therapy intervention or any extra support services from the research team. Any concomitant treatment or therapeutic interventions that participating children might receive will be recorded during assessment sessions before randomisation, and following the primary endpoint, specifying the kind and amount or frequency of intervention.
89688742|NCT02935036|Placebo Comparator|Placebo Control|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
89674270|NCT06016621|Experimental|Improvisational Music Therapy|Participating children randomised to the Improvisational Music Therapy (intervention) Group will receive 30-minute individual music therapy sessions two times per week over a 12-week period. These will be delivered by academically trained Health and Care Professions Council (HCPC)-registered music therapists in the United Kingdom (master's level or equivalent) with clinical experience of working with autistic children. Each child in the intervention arm will receive 24 sessions of music therapy over a 12-week period. A music therapy training manual will be used to guide music therapists.
89674271|NCT06016127|Active Comparator|Cryoneurolysis|Subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine
89674272|NCT06016127|Active Comparator|Radiofrequency ablation|Subjects will receive RFA to the medial branch nerves of the lumbar spine
89674273|NCT06011616|Experimental|interventional group|"Superficial and Deep Sensory training: 5 sets of 9 min, 3 times a week for 8 weeks.~Motor training: 5 sets of 9 min, 3 times a week for 8 weeks. Conventional therapy: 30 min, 3 days for 8 weeks"
89674274|NCT06011616|Active Comparator|control group|Motor training: 5 sets of 9 min, 3 times a week for 8 weeks. Conventional therapy: 30 min, 3 days for 8 weeks
89674275|NCT05997264|Experimental|Full Dose Schedule 1|This study group will receive full dose AV7909 (0.5mL) at study days 1, 15, 181 and 366. A placebo full dose (0.5 mL) will be administered between the second and third dose of AV7909 at study day 29.
89674276|NCT05997264|Experimental|Full Dose Schedule 2|This study group will receive of AV7909 full dose (0.5 mL) at study days 1, 29, 181 and 366. A placebo full dose (0.5 mL) will be administered between the first and second dose of AV7909 at study day 15.
89674277|NCT05997264|Experimental|Half Dose Schedule 1|This study group will receive of AV7909 half dose (0.25 mL) at study days 1, 15, 181 and 366. A placebo half dose (0.25 mL) will be administered between the second and third dose of AV7909 at study day 29.
89674278|NCT05997264|Experimental|Half Dose Schedule 2|This study group will receive of AV7909 half dose (0.25 mL) at study days 1, 29, 181 and 366. A placebo full dose (0.25 mL) will be administered between the first and second dose of AV7909 at study day 15.
89674279|NCT05995496|Experimental|Participants with Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
89674280|NCT05995496|Active Comparator|Participants without Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
89674281|NCT05986565|Experimental|Website treatment|This arm will receive access to the FMF teacher adapted website.
89674282|NCT05986565|Active Comparator|delayed treatment control|This arm will get the same intervention as the experimental arm delayed by 6 weeks.
89674283|NCT05980000|Experimental|Arm 1: Ramucirumab and Pembrolizumab|Patients receive ramucirumab IV and pembrolizumab IV every 3 weeks. Cycles are 21 days in length. Treatment will continue until progression or unacceptable toxicity for up to 35 cycles of treatment.
89674284|NCT05980000|Active Comparator|Arm 2: Pembrolizumab monotherapy|Patients receive pembrolizumab IV every 3 weeks. Cycles are 21 days in length. Treatment will continue until progression or unacceptable toxicity for up to 35 cycles of treatment.
89674285|NCT05977738|Experimental|Dose group 1: 16 mg|Pitavastatin 16 mg via oral route in the form of daily tablets for 6 days before SOC surgery
89674286|NCT05977738|Experimental|Dose group 2: 32 mg|Pitavastatin 32 mg via oral route in the form of daily tablets for 6 days before SOC surgery
89674287|NCT05977738|Experimental|Dose group 3: 48 mg|Pitavastatin 48 mg via oral route in the form of daily tablets for 6 days before SOC surgery
89674288|NCT05976035|Active Comparator|Exercise & Supplement Group|Exercise & Supplement group will take supplements that are prescribed by the orthopedist every day for 8 weeks in addition to a structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks.
89674289|NCT05976035|Active Comparator|Exercise Group|Exercise group will follow a structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks.
89674290|NCT05975840|Active Comparator|FLU Q-PAN H5N8 Formulation 1_B Group|Medically stable participants receive two doses of FLU Q-PAN H5N8 Formulation 1 vaccine and AS03B adjuvant. Participants receive the first dose at Day 1 and the second dose at Day 22.
89674291|NCT05975840|Active Comparator|FLU Q-PAN H5N8 Formulation 1_A Group|Medically stable participants receive two doses of FLU Q-PAN H5N8 Formulation 1 vaccine and AS03A adjuvant. Participants receive the first dose at Day 1 and the second dose at Day 22.
89674292|NCT05975840|Active Comparator|FLU Q-PAN H5N8 Formulation 2_B Group|Medically stable participants receive two doses of FLU Q-PAN H5N8 Formulation 2 vaccine and AS03B adjuvant. Participants receive the first dose at Day 1 and the second dose at Day 22.
89674293|NCT05975840|Active Comparator|FLU Q-PAN H5N8 Formulation 2_A Group|Medically stable participants receive two doses of FLU Q-PAN H5N8 Formulation 2 vaccine and AS03A adjuvant. Participants receive the first dose at Day 1 and the second dose at Day 22.
89674294|NCT05975541||case (patients having chronic infections)|Individuals aged between 18-65 years, presenting obesity (BMI between 30-40 kg/m2), type 2 diabetes, and chronic infections (i.e. urinary tract infections, periodontitis, herpetic infections) at the basal time.
89674295|NCT05975541||control (patients without chronic infections)|Individuals aged between 18-65 years, presenting obesity (BMI between 30-40 kg/m2) and type 2 diabetes.
88995834|NCT00532792|Experimental|Group 1|
89674296|NCT05969496|Experimental|Combination Pembrolizumab and Axitinib|Neoadjuvant therapy with the combination of Pembrolizumab and Axitinib will be given for eligible RCC patients with an IVC TT for a total of 12 weeks. Patients will then undergo imaging with a contrast enhanced, diffusion weighted imaging MRI of the abdomen to evaluate the IVC TT response. A CT chest will also be done to ensure there is no progression of disease. Patients can undergo definitive surgery per treating Urologist within 2 weeks (+/- 7 days) after end of treatment scan.
88995835|NCT00532792|Experimental|Group 2|
89674297|NCT05967507|Experimental|Intervention group|0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
89674298|NCT05967507|Active Comparator|Control group|2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen with the Optiflow (Fisher & Paykel Healthcare, Auckland, New Zealand) during tracheal intubation performed with the C-MAC videolaryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
89674299|NCT05962892||No Intervention|
89674300|NCT05962788|Experimental|Open Label|All subjects will receive open label voclosporin initially at the same number of capsules as assigned at Week 24 (End of Study Visit) in AUR-VCS-2020-03 (VOCAL ; NCT05288855). At the Investigator's discretion and after consultation with the Medical Monitor, dose titration up or down in the study will be permitted up to the maximum dose that was studied in AUR-VCS-2020-03.
89674301|NCT05960929|Experimental|Treatment Arm|A single dose of Calfactant at 6ml/kg administered via the Infasurf Aero™ Nebulizer until completion.
89674302|NCT05960929|Sham Comparator|Control Arm|Low flow respiratory air alone through the InfasurfAero™ Nebulizer until completion.
89674303|NCT05960019|Experimental|Fermented milk product|Dietary supplement (Maziwa Mala) This is a type of cultured dairy milk, that is prepared through mesophilic fermentation of milk that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
89674304|NCT05960019|Experimental|Fermented cereal based porridge|Dietary supplement (Uji) This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
89215036|NCT05156606|Experimental|treatment|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
89215037|NCT05132439|Experimental|Metformin ER 1000mg|daily by mouth
89674305|NCT05960019|Active Comparator|Standard of Care|Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the participants prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
89674306|NCT05959980|Experimental|Surgical arm|Will undergo posterior cervical fixation surgery within 4 weeks of randomization
89674307|NCT05959980|No Intervention|Cervical collar arm|Will be given cervical collar for regular use
89674308|NCT05953142|No Intervention|Control|Patients in this group will receive the usual treatment according to the Surviving Sepsis Campaign guidelines.
89215038|NCT05132439|Placebo Comparator|Matching placebo|daily by mouth
89674309|NCT05953142|Experimental|Dobutamine|Patients in this group will receive, in addition to usual care, dobutamine in continuous infusion for a period of 48 hours after the randomization.
89674310|NCT05951049|Experimental|A (AT-02)|Subjects will receive AT-02 via intravenous infusion once every two or 4 weeks for 104 weeks (52 total AT-02 administrations).
89674311|NCT05939635|Active Comparator|Group M-TAPA|A bilateral M-TAPA (60 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
89674312|NCT05939635|Active Comparator|Group EOIB|A bilateral EOIB (60 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
89674313|NCT05936190|Active Comparator|Group L1|Group who gets 1 mg/kg/min IV lidocaine infusion during surgery
89674314|NCT05936190|Experimental|Group L2|Group who gets 2 mg/kg/min IV lidocaine infusion during surgery
89674315|NCT05933733||Salvage treatment after locoregional recurrence|Participants who previously completed standard treatment for breast cancer and experienced locoregional recurrence alone will be undergo salvage treatment including surgery and/or radiation therapy.
89674316|NCT05933434|Active Comparator|Intervention|"Single intraarticular knee injection with allogenic adipose derived mesenchymal stem cells (AD-MSC)~20 million AD-MSC in 10 mL saline"
88815761|NCT03013478|Active Comparator|TAU plus CBT4CBT program|Treatment normally offered at this clinic PLUS 8 weeks of CBT4CBT computerized therapy.
88815762|NCT01094522|Experimental|Methadone|One half the Study patients will be randomized to receive a loading dose of IV methadone, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
88815763|NCT01094522|Active Comparator|Morphine|One half the Study patients will be randomized to receive a loading dose of IV morphine, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
88815764|NCT02178800|Experimental|Group 1: GSK1265744|Participants in Cohorts 1 and 2 will receive one GSK1265744 tablet orally every day from study entry through Week 4. They will then receive an injection of GSK1265744-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
88815765|NCT02178800|Placebo Comparator|Group 2: Placebo|Participants in Cohorts 1 and 2 will receive one placebo tablet orally every day from study entry through Week 4. They will then receive an injection of placebo-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
88815766|NCT01044212|Active Comparator|Docusate|Docusate is the standard of care regimen
89674317|NCT05933434|Placebo Comparator|Control|"Single intraarticular knee injection with saline alone~10 mL saline"
89674318|NCT05931120|Experimental|Dry needling|dry needling with multimodal physical therapy approach containing hurdler stretch and extended triangular pose
89674319|NCT05931120|Experimental|IASTM|IASTM with multimodal physical therapy approach containing hurdler stretch and extended triangular pose
89215039|NCT05113667|Experimental|Clinical pharmacist-led services|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program
89215040|NCT05113667|No Intervention|Control group|Usual care
89215041|NCT05113316|Experimental|Messy Memories App Group|"Subjects will download and have access to the Messy Memories application in addition to completing self-report measures electronically at pre-determined time points. While the subject uses the app, the participant will input information related to their mood over the past few days (affect rating sliders), their level of distress before and after the memory processing, answers to questions about revisiting the memory, answers to questions in the social connection and self-care modules including assessment of, for example, sleep pattern, eating habits, and exercise habits.~The Messy Memories app will also collect data on how frequently and for how long each participant uses the app. Each response will trigger a prompt within the app, and will be recorded with a timestamp (date and time) to indicate when the participant provided a particular response. For all participants, self-report measures will be collected at weeks 4, 8, 12, and 16."
89674320|NCT05931107|Experimental|Stress ball practice group (Stress ball squeezing)|Patient information form, IBS symptom severity score, IBS quality of life scale and Depression-Anxiety-Stress scale will be administered by the researcher using face-to-face interview technique (pre-test) to the patients in both groups.The patients in the experimental group will be told how to use the stress ball in the room in the outpatient clinic and each patient will be given a stress ball. The first sessions of the patients will be held together with the patient in the outpatient clinic. Patients will apply a stress ball (squeezing the stress ball) once a day at home. In order to ensure the continuity of the stress ball application, the phone numbers of the patients will be taken and a reminder message will be sent every day. The patients' IBS symptom severity score will be evaluated every week.The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
89674321|NCT05931107|No Intervention|Control group|"Patients who come to the outpatient clinic will be met, information will be given about the research, and consent will be obtained from the patients who agree to participate in the research. The groups of the patients who meet the inclusion criteria will be determined according to the randomization list.~Patient information form, IBS symptom severity score, IBS quality of life scale and Depression-Anxiety-Stress scale will be administered by the researcher using face-to-face interview technique (pre-test) to the patients in both groups.~Stress ball attempts will not be made to the patients in the control group. Phone numbers of patients in this group will be taken. Patients' IBS symptom severity score will be evaluated every week.~Patients in both groups will continue to use routine treatments for 4 weeks. After the research is completed, the patients in the control group will be given a stress ball according to their wishes and will be informed about its application."
89674322|NCT05931094|Experimental|AR group|Augmented Reality based games
89674323|NCT05931094|Active Comparator|Traditional therapy group|Traditional therapy
89674324|NCT05930288|Experimental|Walking exercise|Patients receive routine care and exercise as required.
89674325|NCT05930288|No Intervention|Control|Patients receive only routine care.
89674326|NCT05924828||Healthy|participants without periodontitis
89674327|NCT05924828||periodontitis|participants with stage-3 periodontitis
89674328|NCT05913609|Experimental|Yaari Extractor group|Prospective experimental arm
88995836|NCT00532792|Experimental|Group 3|
88995837|NCT00532792|Experimental|Group 4|
88995838|NCT00532792|Experimental|Group 5|
89674329|NCT05913609|No Intervention|Control group|Historical control arm - retrospective review of medical records at the same study sites
89674330|NCT05910866|Experimental|Left bundle branch area pacing (LBBAP)|Implant of the ventricular lead of the pacemaker in the left bundle branch area
89674331|NCT05910866|Active Comparator|Right ventricular pacing (RVP)|Implant of the ventricular lead of the pacemaker in a conventional site for pacing (apex/paraapical interventricular septum)
89674332|NCT05891431|Experimental|Untire app|"Participants will be given access to the Untire app.~Untire is a mHealth app and a registered medical device (ICD10 code R53.83 Fatigue) introduced in 2018 to treat Cancer Related Fatigue in adults."
89688743|NCT03035071|Experimental|minimally invasive esophagectomy|minimally invasive (laparoscopic) gastric mobilisation and gastric tube formation.
89522513|NCT03396419||Acute Isch. Stk pts treat. w/SPG stimul.|"Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol.~Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed.~Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle.~The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol."
88995839|NCT00532792|Experimental|Group 6|
88995840|NCT00532792|Experimental|Group 7|
88995841|NCT00532792|Experimental|Group 8|
88995842|NCT00532792|Experimental|Group 9|
88995843|NCT00532792|Placebo Comparator|Group 10|
88995844|NCT04687423|Experimental|Experimental: phase I dose exploration|FCN-011 will be given orally in ascending doses in patients with advanced solid tumor , until the maximum tolerated dose or recommended dose is reached.
88995845|NCT04687189|Experimental|Women with a known history of submucosal fibroids|
88995846|NCT04687189|Experimental|Women recruited from a general population subject to I/E criteria|
88995847|NCT00532831||Obese asthmatics|Obese subjects with asthma (on inhaled bd only)
88995848|NCT00532831||Non-obese asthmatics|Non-obese subjects with asthma(on inhaled bd only)
88995849|NCT00406094|Experimental|1|montelukast
88995850|NCT00406094|Placebo Comparator|2|placebo
88995851|NCT00532870|Active Comparator|1|laparoscopy
88995852|NCT00164736|Active Comparator|Maternal ARVs & Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & daily nutritional supplement given to the mother
88995853|NCT00164736|Active Comparator|Infant NVP & Nutrition Supplement|Extended infant nevirapine for prophylaxis & daily nutritional supplment given to the mother
88995854|NCT00164736|Active Comparator|Maternal ARVs & No Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & no nutritional supplement given to the mother
89674333|NCT05885880|No Intervention|Standard of Care|Subjects in this arm will receive the standard of care, either routine screening for clinical trials or no screening, according to standard institutional protocol. Potential clinical trials, if identified, will be offered to subjects according to the usual institutional process.
89674334|NCT05885880|Experimental|Blue-button screening|Subjects assigned to this arm will have deidentified data elements transferred from their EHR to the Blue-button tool for identification of clinical trials for which they may be eligible. After review by clinical research staff, appropriate trials will be offered to subjects.
89674335|NCT05885139|Active Comparator|Active Stimulation|Active sessions will last 1 hour of stimulation per day for 2 weeks. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
89674336|NCT05885139|Sham Comparator|Sham Stimulation|In the sham condition, subjects will be asked to wear the device for 1 hour per day for 2 weeks. During 1 hour use per day, the actual stimulation will last only 1 minute and then will shut off.
89674337|NCT05882032|Experimental|LY3502970 (Mild Hepatic Impairment)|LY3502970 administered orally.
89674338|NCT05882032|Experimental|LY3502970 (Moderate Hepatic Impairment)|LY3502970 administered orally.
89674339|NCT05882032|Experimental|LY3502970 (Severe Hepatic Impairment)|LY3502970 administered orally.
89674340|NCT05882032|Experimental|LY3502970 (Normal Hepatic Function)|LY3502970 administered orally.
89674341|NCT05878795|Experimental|Written Exposure Therapy-for Suicide Prevention (WET-SP) +TAU|Participants randomized into this arm will be offered WET-SP which will consist of 5 treatment sessions, conducted daily while the participant is hospitalized, allowing for the largest dose of treatment possible while inpatient. If a patient is discharged prior to the completion of WET-SP, the remaining sessions will be conducted in outpatient sessions. Participants in this arm will also be offered TAU.
89674342|NCT05878795|Active Comparator|Treatment as usual (TAU)|Participants randomized into this arm will be offered TAU which consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). Participants will engage with the provider team daily throughout the duration of hospitalization.
89674343|NCT05876663|Experimental|Kinesio Taping along with conventional physiotherapy protocol|"All baseline measurements will be collected in the beginning. In participant of experimental group the K-tape will be first applied from the anterior aspect of the acromion process of the scapular to the spinous process of the fourth thoracic vertebra (T4). Then, the K-tape will be applied from same origin to the insertion at the spinous process of the tenth thoracic vertebra (T10). K-tape will be applied with 50% tension of its original length.~The K-tapes will be replaced with new ones every two days for six weeks. The outcome measures will be assessed after every two weeks i.e. pre-assessment, on week 2, week 4, and week 6.~Primary outcome measures include the effect of kinesio taping on pulmonary function (via Digital Spirometry) and chest expansion (via Measuring Tape).Secondary outcome measures include FSP and pectoralis minor index (via Digital Vernier Caliper)"
89674344|NCT05876663|Active Comparator|Conventional physiotherapy protocol|"Stretching exercise for Pectoralis Minor and Major muscle: Participant in supine lying try to touch the tip of shoulder with the bed surface e.g. retraction. Than in supine raise/abduct the arm at 90 and 120 degrees; try to drop down from the surface of the bed. Hold for 10 seconds 10 reps. 2 sessions per day for 6 weeks.~Strengthening of Rhomboids: Participant in sitting position instructed to depress and retract the shoulder at the same time .Hold for 20 seconds 10 reps. 2 sessions per day for 6 weeks.~Strengthening of lower and mid trapezius: In prone lying abduct arms to the side 90 degrees. Raise arms form surface of bed like an aero plane wings. Take a weight of 1 kg in hands and hold for 10 sec and 10 reps. 2 sessions per day for 6 weeks.~Deep Breathing exercise: participant instructed to take a slow and deep breath inhaling through nose and exhaling through mouth. 10 rep 3 sessions per day for 6 weeks.~Education regarding posture correction."
89674345|NCT05876637|Experimental|Left Nostril Breathing|The intervention protocol include healthy young females age 18-25 years.. All baseline measurements will be taken , Afterwards, the Cold pressor test would be performed for 1 minutes to induce acute stress while the BP would be monitored for every 30 seconds. At the end of the test, again the BP would be monitored. Out of all the recordings, the BP measuring the highest value would be recorded as final. We will then subtract the normal resting BP by highest value of the recording for each participant. Change in BP of systolic by 25mmHg and diastolic by 20mmHg will be considered hyper reactive. Then the hyper reactive subjects will be divided into two groups. Experimental group will receive left nostril breathing. CPT will be performed again at 4, 8 and 12 weeks to monitor the BP, heart rate and Spo2 likewise to check for any decline in sympathetic activity.
89674346|NCT05876637|Active Comparator|Conventional|The conventional protocol include healthy young females age 18-25 years. All baseline measurements will be taken, Afterwards, the Cold pressor test would be performed for 1 minutes to induce acute stress while the BP would be monitored for every 30 seconds. At the end of the test, again the BP would be monitored. Out of all the recordings, the BP measuring the highest value would be recorded as final. We will then subtract the normal resting BP by highest value of the recording for each participant. Change in BP of systolic by 25mmHg and diastolic by 20mmHg will be considered hyper reactive. Then the hyper reactive subjects will be divided into two groups Group A(Experimental) and Group B(Conventional). Controlled group will receive simple deep breathing exercises ,3 sessions per week for 12 weeks. CPT will be performed again at 4, 8 and 12 weeks to monitor the BP, heart rate and Spo2 likewise to check for any decline in sympathetic activity.
89674347|NCT05876403|Active Comparator|Conventional|"The protocol for controlled group will consist of 35-60years old participants with moderate to severe COPD.~At baseline measurements will be collected and COPD assessment test (CAT) and Modified Borg Scale will be taken. Participants will then be made to perform breathing and aerobic exercises (3sessions per week) for 6 weeks and after every 2 weeks outcome measures will be evaluated using chest expansion, spirometry, and 6 minutes walk test (6MWT) along with CAT and Modified Borg Scale."
89049927|NCT04683614|Experimental|Fresh frozen plasma|early administration of fresh frozen plasma
88815767|NCT01044212|Experimental|Bowel medications|Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
88815768|NCT02174510|Experimental|20mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
89674348|NCT05876403|Experimental|PNF Techniques|The same protocol will be followed for the 30 participants of experimental group where after the baseline measurements, participants will perform breathing and aerobic exercises along with PNF techniques (3 sessions per week for 6 weeks). The outcome Measures will be measured after every 2 weeks through Spirometry, CAT, Modified Borg Dyspnea Scale and 6 minutes walk test
89674349|NCT05863572|Active Comparator|Treatment as usual|Training primary care workers in diagnosis and treatment; training community health workers in detection and referral.
89674350|NCT05863572|Experimental|Strengthening care in collaboration with people with lived experience of psychosis in Uganda|Trainings done in collaboration with people with lived experience of psychosis; as well as additional home visits conducted by people with lived experience of psychosis.
89674351|NCT05858216|Other|Chlor-Trimeton|Package recommended dose of over the counter Chlor-Trimeton will be administered to assess voice function before and 3 hours after taking it.
89674352|NCT05854485|Experimental|Hybrid multi-muscle FES+Robot|Participants will be receive hybrid upper extremity training involving the combination of REACH robotic device and multi-muscle FES. Water based electrodes will be positioned on the Triceps, Anconeus, wrist and finger extensors. Stimulation intensity of FES will be set at the participants tolerance level. The FES induced muscle contraction timing will be triggered in synchrony with the robotic movement. The training will be a multi-directional reach movement and hand opening re-training.
89674353|NCT05854485|Active Comparator|Robot only|Participants will receive upper extremity training with the REACH robotic device. The training will be a multi-directional reach movement re-training.
89674354|NCT05843409|No Intervention|Control|Normal drug therapie or usual treatment
89674355|NCT05843409|Experimental|Intervention|Normal drug therapie or usual treatment with add Mindfulness-based stress reduction (MBSR)
89674356|NCT05842473|Active Comparator|TMS active + language therapy|TMS (active) using theta burst protocol over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by one session per week during 6 months. Each TMS session is followed by language training.
89674357|NCT05842473|Sham Comparator|TMS sham + language therapy|TMS (sham) using theta burst protocol over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by one session per week during 6 months. Each TMS session is followed by language training.
89674358|NCT05826509|Active Comparator|Control arm|
89674359|NCT05826509|Experimental|Experimental arm|
89674360|NCT05820451||Left sided device|All patients implanted with a left sided support Impella device - this includes but is not limited to Impella 2.5, Impella CP, Impella 5.0, Impella 5.5.
89674361|NCT05820451||Right sided device|All patients implanted with a right sided support Impella device -this includes the Impella RP
89674362|NCT05807711|Active Comparator|Experimental: Intervention group|"Adult end stage renal disease patients maintained on hemodialysis three times a week for at least 3 months with resistant hypertension as determined by pre-dialysis BP > 140/90 mm Hg, post-dialysis BP > 130/80 mm Hg despite the use of three or more drugs.~Patients will be assigned to take one tablet daily containing L-methylfolate and methylcobalamine.~Patients will be followed over a period of 3 months after which blood pressure measurement and blood sampling would be repeated and compared to baseline values."
89674363|NCT05807711|No Intervention|No Intervention: Control group|"Adult end stage renal disease patients maintained on hemodialysis three times a week for at least 3 months with resistant hypertension as determined by pre-dialysis BP > 140/90 mm Hg, post-dialysis BP > 130/80 mm Hg despite the use of three or more drugs.~Patients will be followed over a period of 3 months after which blood pressure measurement and blood sampling would be repeated and compared to baseline values."
89674364|NCT05805774|Active Comparator|Group A - DFR|
89674365|NCT05805774|Active Comparator|Group B - ORIF|
89674366|NCT05803096|Active Comparator|Self-Administered Nitrous Oxide|"Patients will receive SANO in addition to periprostatic bupivacaine nerve block for the duration of prostate biopsy.~After the Urologist describes the procedure, the SANO group will have nitrous oxide turned on to 30%, ensuring that the patient is relaxed but still conversant through the procedure. The nitrous will be adjust up or down based on the patient's response to the question are you feeling the nitrous and are you happy at this level. The range will be between 25 - 45%. At the end of the procedure, the SANO group will be turned down to 0% nitrous oxide, and 100% oxygen will be administered through the mask for an additional 2-3 minutes as the patient is cleaned up and repositioned to the supine position."
89674367|NCT05803096|Placebo Comparator|Oxygen|Patients will receive 100% oxygen at 10 Liters/minute for the duration of prostate biopsy.
89674368|NCT05795582|Experimental|diabetic patients with peripherial arterial disease|Patients will be included during a vascular medicine consultation for follow-up or screening for vascular pathology. Each subject will have their upstroke time measured by a new method of measurement using the device POPMETRE® (Axelife, France).
89674369|NCT05787574|Experimental|Group A: Emapalumab (for isolated Interferongamma mediated disease)|Participants in this group will receive emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.
89674370|NCT05787574|Experimental|Group B: Fludarabine and Dexamethasone (for generalized autoinflammation)|Participants in this group will receive fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.
89674371|NCT05782296||Cohort|Women in active labor following rupture of membranes and placement of an IUPC and/or FSE for obstetric indications
89674372|NCT05768880|Experimental|Arm A - DIPG|
89674373|NCT05768880|Experimental|Arm B - DMG & recurrent/refractory tumors|
89674374|NCT05765812|Experimental|Phase 1: Arm A - Debio 0123 + Temozolomide|Participants will receive Debio 0123, escalating doses along with temozolomide (TMZ) in each 28-day cycle for up to 2 years.
89688744|NCT03035071|Active Comparator|open esophagectomy|open gastric mobilization and gastric tube formation
88995855|NCT00164736|Active Comparator|Infant NVP & No Nutrition Supplement|Extended infant nevirapine for prophylaxis & no nutritional supplment given to the mother
88995856|NCT00164736|Active Comparator|No Drugs & Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & daily nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
89674375|NCT05765812|Experimental|Phase 1: Arm B - Debio 0123 + Temozolomide + Radiotherapy|Participants will receive Debio 0123, escalating doses along with TMZ and concomitant administration of radiotherapy (RT) for up to 6 weeks.
89674376|NCT05765812|Experimental|Phase 2: Debio 0123 RP2D + Temozolomide|Participants will receive Debio 0123 RP2D along with TMZ in each 28-day cycle for up to 2 years.
89674377|NCT05759026|Experimental|control condition|The patient will be randomized so that the kind of intervention will be determined in a random way.
89674378|NCT05759026|Experimental|with VR|The patient will be randomized so that the kind of intervention will be determined in a random way.
89674379|NCT05759026|Experimental|with VR personalised|The patient will be randomized so that the kind of intervention will be determined in a random way.
89674380|NCT05753202|Active Comparator|Left dorsolateral prefrontal cortex|15 sessiones of anodal tDCS over the left dorsolateral prefrontal cortex (2 mA, 20 minutes) associated with cognitive training.
89674381|NCT05753202|Active Comparator|Left M1|15 sessiones of anodal tDCS over the left M1 (2 mA, 20 minutes) associated with cognitive training.
89674382|NCT05751135|Experimental|Focal muscle vibration group 1|Focal muscle vibration with frequency of 80 Hz will be provided 3 days along with stretching, strengthening and positioning for 8 weeks
89674383|NCT05751135|Experimental|Focal muscle vibration group 2|Focal muscle vibration with frequency of 100 Hz will be provided 3 days a week along with stretching, strengthening and positioning for 8 weeks.
89674384|NCT05751135|Active Comparator|Control group|Stretching, strengthening and positioning in 3 sessions a week for 8 weeks
89674385|NCT05748951|Experimental|Tear Duct Plug|A device inserted into the tear duct to block tear drainage
89674386|NCT05745168||MSM-TGW|
89674387|NCT05740670|Experimental|Dr. Kellyann's Bone Broth|During the bone broth phases, each week will be separated into 'fasting days' and 'feeding days'. There will be 2 non-consecutive fasting days and 5 feeding days per week. On fasting days, participants will be instructed to consume 1 packet of bone broth every 2 hours, for a total of 7 packets/day. On feeding days, participants will consume 3 meals/day, made up of 'Yes' foods portioned according to instructions provided in the Bone Broth Diet Quick Reference Guide and 1 packet of bone broth, twice a day, as snacks between meals. If a bone broth serving is missed participants are instructed to consume the serving as soon as they remember. Participants will be advised not to exceed 7servings of bone broth on fasting days and 2 servings on feeding days. During the maintenance phase, participants will not consume any bone broth.
89674388|NCT05728229|Experimental|Experimental Group (GS)|GS patients, in addition to the pharmacological therapy foreseen by the clinical conditions, will take 1 sachet a day of SiderAl® Med, a food for special purposes, for 28 days. GS patients will take the food for special purposes during hospitalization (between T0 and T1) and during the 1 month of returning home (between T1 and T2). During the second month of returning home (between T2 and T3), GS patients will no longer take the food for special purposes.
89674389|NCT05728229|No Intervention|Control Group (GC)|The patients of the GC, on the other hand, will continue to take the drug as required by their clinical conditions and will not take the SiderAL® Med food for special purposes, but will only be observed and evaluated at the various time-points foreseen by the study.
89674390|NCT05725759||Rehabilitation Arm|Participants will participate in outpatient physical and/or occupational therapies while participating in the tofersen early access program (EAP)
89674391|NCT05716009|Experimental|Phase 1a Dose Escalation of tagraxofusp-erzs in r/r AML|"Tagraxofusp-erzs and gemtuzumab ozogamicin (GO) will be administered every 4 weeks with 28 days defined as a treatment cycle. Tagraxofusp-erzs dose escalation for cycles 1-4 in combination with fixed dose GO.~This is a dose escalation design . The dose-limiting toxicity (DLT) period will be the 28 days following the first dose of GO. The initial dose level 1 (DL1) cohort will receive GO 3mg/m2 (capped at a maximum dose of 4.5mg) intravenously (IV) on cycle 1 days 1, 4, and 7 and tagraxofusp-erzs at an initial dose of 7μg/kg/day on days 10, 11, 12. For subsequent cycles of DL1, GO will continue to be administered at a dose of 3mg/m2 IV on day 1 and tagraxofusp-erzs will be administered IV at a dose of 7μg/kg/day on days 4,5,and 6. Subsequent escalation dose levels will receive tagraxofusp-erzs doses of 7mcg/kg/day, 9mcg/kg/day or 12mcg/kg/day. Initial cycle doses of tagraxofusp at these levels will be given on Days 5,6 and 7, then in subsequent cycles on days 1,2 and 3."
89674392|NCT05716009|Experimental|Phase 1b recommended Phase 2 dose (RP2D) of tagraxofusp- erzs in r/r AML|This is dose expansion at the RP2D of tagraxofusp. Participants with relapsed or refractory acute myeloid leukemia (r/r AML) will receive the RP2D of tagraxofusp-erzs, as determined in Phase 1a, and gemtuzumab at a dose of 3mg/m2 (max absolute dose of 4.5mg) on days 1,4, and 7 of cycle 1 and day 1 of subsequent cycles.
89674393|NCT05714761|Other|Postpartum glucose sensor|Will wear glucose sensor for 10 days postpartum and at time of glucose tolerance test.
89674394|NCT05714410|Active Comparator|PHGG fiber|Partially Hydrolyzed Guar Gum (PHGG) in powder formulation, is to be consumed orally adding water or juice. One serving per day.
88995857|NCT00164736|No Intervention|No Drugs & No Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & no nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
88995858|NCT05163730|Other|Panbio™ COVID-19/ Flu A&B Rapid Panel|"One nasal swab sample will be collected from both nostrils by operators and will be used to perform the Panbio™ COVID-19/ Flu A&B Rapid Panel test either in a laboratory or in a non-laboratory setting (e.g. GP centre or hospital clinic). Each Panbio™ COVID-19/ Flu A&B Rapid Panel result will be photographed by the observer at the time of test interpretation.~Nasopharyngeal samples will be collected and used for RT-PCR testing as per local procedures.~Nasal samples must always be collected prior to the Nasopharyngeal sampling."
88995859|NCT05142046||Pediatric cardiac surgery|The group consists of all the children who undergo cardiac surgery in our institution from 2008 to 2018. The age limit was from birth to 16 years old.
89674395|NCT05714410|Placebo Comparator|Placebo Maltodextrin|Maltodextrin in powder formulation is to be consumed orally adding water or juice. One serving per day.
88995860|NCT00172068|Experimental|Treatment Group|
88995861|NCT00172068|Active Comparator|Control Group|
88995862|NCT05119816|Experimental|music therapy group|Patients receive an individual intervention of receptive music therapy during biopsy
89522514|NCT03399019|Experimental|Dexmedetomidine|"Dexmedetomidine~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
89522515|NCT03399019|Active Comparator|Propofol|"Propofol~: 0.75-3 mg/kr/hr continous infusion Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
88995863|NCT05119816|No Intervention|Control group|Patients receive standard care
89522516|NCT03399019|Active Comparator|Midazolam|"Midazolam~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
89522517|NCT04452383|Active Comparator|propofol (P)|patients will receive only propofol intravenous for sedation
89522518|NCT04452383|Active Comparator|propofol ketamine (pk)|patients will receive ketamine in addition to propofol intravenous for sedation
89522519|NCT05036941|Experimental|Arm 1|Acteev™ system (Acteev™ N95 masks YQD8008 during shifts+ Acteev™ fabric masks in community)
89522520|NCT05036941|Active Comparator|Arm 2|Standard system (standard N95 masks during shifts+ fabric masks in community)
89522521|NCT04447547|Experimental|SL1904B CAR-T|Patients will be treated with CD19 CAR-T cells
89522522|NCT03396757|Active Comparator|Standard strategy|RRT will be initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours (identical to the delayed strategy in AKIKI).
89522523|NCT03396757|Experimental|Delayed strategy|RRT will be considered only if one potentially severe following situation occurs (noticeable hyperkalemia, or acidosis or pulmonary edema due to fluid overload resulting in severe hypoxemia which do not respond rapidly to medical treatment) or if serum urea concentration reaches 50 mmol/L.
89522524|NCT03396263|Experimental|Online personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
89522525|NCT03396263|Experimental|Face-to-face personalised advice|Face-to-face delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive nutritional advice face-to-face (in person or via video chat).
89522526|NCT03396263|Placebo Comparator|Control|Non-personalised advice Control group. Online (web-based) delivery of non- personalised dietary, weight and physical activity advice based on the UK general health guidelines. This arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non- personalised).
89522527|NCT03392779|Experimental|ZSP1601(single dose)-25 mg while fasted(Cohort 1)|ZSP1601 25 mg /Placebo
89522528|NCT03392779|Experimental|ZSP1601(single dose)-50 mg while fasted(Cohort 2)|"ZSP1601 50 mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
89522529|NCT03392779|Experimental|ZSP1601(single dose)-100 mg while fasted(Cohort 3)|"ZSP1601 100 mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
89522530|NCT03392779|Experimental|ZSP1601(single dose)-175 mg while fasted(Cohort 4)|"ZSP1601 175 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
89522531|NCT03392779|Experimental|ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)|"ZSP1601 275 mg/Placebo~Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4."
89522532|NCT03392779|Experimental|ZSP1601(single dose)-350 mg while fasted(Cohort 6)|"ZSP1601 350 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5."
89522533|NCT03392779|Experimental|ZSP1601(food effect)-100 mg (Cohort FE)|"Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8."
89522534|NCT03392779|Experimental|ZSP1601(multiple doses)-50 mg (Cohort 7)|"50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE~ZSP1601 50 mg/Placebo for 14 Days."
89522535|NCT03392779|Experimental|ZSP1601(multiple doses)-100 mg (Cohort 8)|"Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7.~ZSP1601 100 mg/Placebo for 14 Days."
89522536|NCT02520557||Case|Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), or drug reaction with eosinophilia and systemic symptoms (DRESS) or symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL) will be considered a potential case. Blood draw or Saliva.
89522537|NCT02520557||Control|Controls will be individuals who have used ESL for at least 6 weeks and who have not developed SCAR. Blood draw or saliva.
89522538|NCT02520479|Experimental|sandwich protocols|"sandwich protocols: Patients with newly diagnosed ENKTL is given 2 cycles of P-CHOP[cyclophosphamide(CTX), 750 mg/m2 day 1; vincristine(VCR), 1.4 mg/m2 day 1 (maximal dose 2 mg),adriamycin(ADM) 50 mg/m2 day 1; dexamethasone(DXM) 10 mg days 1-8; Pegaspargase 2500 international unit day 1] before radiotherapy(RT) and then two consolidation cycles after RT."
89522539|NCT03396679||CASPAR criteria agreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in agreement compare to Ultrasound examination
89522540|NCT03396679||CASPAR criteria disagreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in disagreement compare to Ultrasound examination
89522541|NCT02520947|Experimental|Bispectral index|The group that desflurane titrated according to bispectral index monitoring
89522542|NCT02520947|Other|Minimum alveolar concentration|The group that desflurane consumption titrated according to minimum alveolar concentration monitoring
89522543|NCT05002153|Experimental|Fecal Microbiota Transplantation (FMT)|FMT capsules administration - intervention arm
89522544|NCT05002153|Placebo Comparator|Placebo|Placebo capsules administration
89674396|NCT05712174|Experimental|[18]F-PSMA-1007 PET/CT or PET/MRI|All participants will undergo a single [18]F-PSMA-1007 PET/CT or PET/MRI scan. Intravenous bolus injection of 4 MBq/kg +/- 10% of [18]F-PSMA-1007, up to a maximum of 400 MBq.
89674397|NCT05693922|Experimental|Delta-beta tACS|Participants will receive a single session intervention of behavioral activation (BA) psychotherapy. Stimulation will be delivered via the NeuroConn DC-STIMULATOR MC at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. The tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
89674398|NCT05693922|Sham Comparator|Active-sham tACS|Participants will receive a single session intervention of behavioral activation (BA) psychotherapy. The active sham condition includes brief stimulation, mimicking the skin sensations associated with tACS, assisting with blinding the participant's assignment.
89674399|NCT05690685|Experimental|Silver I Alginate Non-Woven Dressing (Hydro-Alginate)|Subjects will undergo treatment of their chronic or acute wound (Pressure ulcer, and Donor sites) as indicated in the instructions for use with Silver I Non-Woven Dressing
89674400|NCT05689658|Experimental|Brazilian Diabetes Prevention Program Group|The program will be based on the American Diabetes Prevention Program (DPP), whose published results are used as a reference for prediabetic care patients in the Brazilian Diabetes Guideline. In order to reach the weight loss goal estimated at 0.5 to 1 Kg per week and 150 minutes of moderate physical activity per week, the program will offer individual and group visits, qualitative guidelines for improving diet, lifestyle and self-care.
89674401|NCT05689658|Active Comparator|Diet Group|Diet prescription for weight loss
89674402|NCT05675605|Experimental|Phase 1 Dose Escalation|Multiple doses of TY-1091 for oral administration. Intervention: Drug: TY-1091
89674403|NCT05675605|Experimental|Phase 2 Dose Expansion|Multiple doses of TY-1091 for oral administration. Intervention: Drug: TY-1091
89674404|NCT05673876|Experimental|GDC-8264, 35 mg|Participants will receive oral GDC-8264, 35 milligrams (mg), once daily (QD) for 28 days.
89674405|NCT05673876|Experimental|GDC-8264, 75 mg|Participants will receive oral GDC-8264, 75 mg, PO, QD for 28 days.
89674406|NCT05672251|Experimental|Treatment (oncastuximab tesirine, mosunetuzumab)|Patients receive loncastuximab tesirine IV and mosunetuzumab IV on study. Patients also undergo PET/CT scan, biopsy, and collection of blood samples on study.
89674407|NCT05672147|Experimental|Treatment (anti-CD33 CAR T-cells)|Patients undergo lymphodepletion therapy 3-5 days prior to CAR T cell infusion and receive anti-CD33 CAR T-cells IV on day 0. Patients with persistent CD33+ AML who are > 28 days past the initial CAR T infusion, have additional product available and did not experience a dose-limiting toxicity, may optionally receive anti-CD33 CAR T-cells IV.
89674408|NCT05671718|Experimental|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
88995864|NCT05117164|No Intervention|control group|Patients will receive enteral feeding based on the practice of the leading physician.
89674409|NCT05671718|No Intervention|Physician-Led Treatment Hospital Based|Representing standard of care, primary care clinics will refer to hospital-based, physician-led care who will provide outpatient treatment. The typical clinical operations involve initiation of new patients once or twice weekly and PCCs are required to schedule a clinic day/time for the patient prior to referral (generally < 72 hours from the time of referral). All individuals receiving care at this site will receive care at the district RR-TB treatment program for the catchment area. For HIV co-infected persons, their HIV treatment is also transferred to the RR-TB physician with details about the HIV treatment communicated in the transfer of care letter. Physicians often cover multiple clinics and routinely take on call sessions on the weekend, due to staffing limitations, thus preventing their sole focus on the RR-TB program and limiting the number of days the RR-TB clinic offers new patient visits and, in most cases, days for follow-up visits.
89674410|NCT05670743|Experimental|Silver diamine fluoride|Silver diamine fluoride, 38%, topical, single application
88995865|NCT05117164|Experimental|intervention|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
88995866|NCT05095987|Experimental|One day discharge after laparoscopic Appendectomy|
88995867|NCT00151970|Active Comparator|Methylphenidate Transdermal System|The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
88995868|NCT00151970|Placebo Comparator|Placebo|The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
88995869|NCT00151970|Active Comparator|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
88995870|NCT05077501|Experimental|ACD856|
88995871|NCT05077501|Placebo Comparator|Placebo|
88995872|NCT05075317|Active Comparator|Standard cardiac rehabilitation|The 16-week program consists of physician-directed risk factor management, an individualized aerobic and resistance exercise prescription, and virtual education on disease management and lifestyle behaviors (including exercise safety, stress management, and heart-healthy nutrition), and an assessment with a registered dietitian and individualized recommendations for a heart-healthy diet. Additionally, selected patients with identified issues such as depression, anxiety, trouble sleeping, anger and social and emotional issues will receive one-on-one counselling with a psychologist or social worker.
89049928|NCT04683614|Experimental|Low dose norepinephrine|low dose epinephrine 5 mic/kg/hr
89049929|NCT04613895|Experimental|fed state group|just after a meal
89049930|NCT04613895|Experimental|fasted state group|before a meal
89049931|NCT04613700|Active Comparator|Secretin|
89049932|NCT04613700|Placebo Comparator|Placebo|
89674411|NCT05669612|Active Comparator|Dairy based protein|"Milk protein isolate~For bioavailability sessions: 20 grams of protein dissolved in water 200 ml water Then 50g per day (2 x 25g serves dissolved in 200 ml water) over 2 weeks"
89674412|NCT05669612|Experimental|Mixed protein|"Milk and plant based protein mix~For bioavailability sessions: 20 grams of protein dissolved in water 200 ml water Then 50g per day (2 x 25g serves dissolved in 200 ml water) over 2 weeks"
89674413|NCT05669612|Experimental|Plant-based protein 1|"Plant based protein mix~For bioavailability sessions: 20 grams of protein dissolved in water 200 ml water Then 50g per day (2 x 25g serves dissolved in 200 ml water) over 2 weeks"
89674414|NCT05669612|Experimental|Plant-based protein 2|"Plant based protein mix with fiber~For bioavailability sessions: 20 grams of protein dissolved in water 200 ml water Then 50g per day (2 x 25g serves dissolved in 200 ml water) over 2 weeks"
89674415|NCT05667025|Active Comparator|Conservative Rehabilitation|Conservative Rehabilitation
89674416|NCT05667025|Active Comparator|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation
89674417|NCT05663645|Experimental|Health insurance educational guide|Eligible individuals will receive a health insurance educational guide to support choosing among 5 health plans for IVF coverage. They will also receive receive a one-page guide with a link to the Open Enrollment website that is available to all employees during the open enrollment period.
89674418|NCT05663645|No Intervention|Usual care|Eligible individuals will receive a one-page guide with a link to the Open Enrollment website that is available to all employees during the open enrollment period.
89674419|NCT05663528||orotracheal intubation group|Composed of Patients who were intubated after 48 hours of admission to the intensive care unit
89674420|NCT05663528||non-intubated group|Composed of patients who were not intubated during their stay in the intensive care unit
89674421|NCT05662189|Other|long standing type 1 diabetes (> 20 yrs)|68Ga-exendin4 PET-CT scan +mixed meal test
89674422|NCT05662189|Other|newly diagnosed type 1 diabetes (< 5yrs)|68Ga-exendin4 PET-CT scan +mixed meal test
89674423|NCT05662189|Other|long standing type 2 diabetes (> 20 yrs)|68Ga-exendin4 PET-CT scan +mixed meal test
89674424|NCT05662189|Other|newly diagnosed type 2 diabetes (<6 months)|68Ga-exendin4 PET-CT scan +mixed meal test
89674425|NCT05662189|Other|pre-diabetes|68Ga-exendin4 PET-CT scan +mixed meal test
89674426|NCT05662189|Other|hyperinsulinemic|68Ga-exendin4 PET-CT scan +mixed meal test
89674427|NCT05662189|Other|control|68Ga-exendin4 PET-CT scan +mixed meal test
89674428|NCT05648357|Experimental|Participants receiving Fluarix tetra vaccine|Participants aged 65 years and above receive 1 dose of Fluarix tetra vaccine.
89674429|NCT05647590|Experimental|NSCLC patients|Patients with non-small cell lung cancer (NSCLC) will be enrolled in the study.
89674430|NCT05642039|Experimental|Mindfulness Course Group|Participants will participate in the mindfulness course that would last 6 weeks.
89674431|NCT05642039|Experimental|HS Educational Course Group|Participants will participate in the mindfulness course that would last 6 weeks.
89674432|NCT05639543|Active Comparator|INT-787|Participants will be randomized to receive INT-787 (escalating doses through the cohorts)
89674433|NCT05639543|Placebo Comparator|Placebo|Participants will be randomized to receive matching placebo
89674434|NCT05633394|Experimental|AtaCor EV Temporary Pacing Lead System|Subjects implanted with the AtaCor StealthTrac Lead Model AC-101400
89674435|NCT05621187|Other|All patients|
89674436|NCT05620121||Minimally invasive IH surgery|Minimally invasive approach to incisional hernias in non-electice settings
89674437|NCT05620121||Laparotomic IH surgery|Laparotomic approach to incisional hernias in non-electice settings
89674438|NCT05615363|Experimental|OPC 131461 10mg group|OPC-131461 5 mg tablet ｘ 2
89674439|NCT05615363|Experimental|OPC 131461 5mg group|OPC-131461 5 mg tablet and placebo tablet
89674440|NCT05615363|Experimental|OPC 131461 2mg group|OPC-131461 1 mg tablet ｘ 2
89674441|NCT05615363|Experimental|OPC 131461 1mg group|OPC-131461 1 mg tablet and placebo tablet
89674442|NCT05615363|Placebo Comparator|Placebo|Placebo tablet
89674443|NCT05611892||18F-FDS PET/CT|a single intravenous dose of 18F-FDS followed by PET/CT scan.
89674444|NCT05610852|Active Comparator|Transvesical Single Port Robotic Partial Prostatectomy|Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to Prostatectomy. Prostatectomy consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.
89674445|NCT05610852|Active Comparator|High-intensity focused ultrasound (HIFU)|Participants will have a multiparametric prostate MRI and diagnostic prostate biopsy with confirmed localized prostate tumor prior to HIFU. HIFU consists of a single treatment. All participants will have a postoperative visit at 3 days after surgery, followed by phone calls at 1 week, 2 weeks and 4 weeks, followed by office visits at 6 weeks, 3 months, 6 months, 9 months, 1 year, 2 years and 3 years. Participants will be followed indefinitely as per standard of care.
89674446|NCT05609604|Active Comparator|active tDCS|This group will receive 30 minutes of active stimulation from tDCS
89674447|NCT05609604|Placebo Comparator|sham tDCS|This group will receive 30 minutes of sham (placebo) stimulation from tDCS
89674448|NCT05609552||Tuberculosis patients|Patients with confirmed TB [culture confirmed or positive by genotypic testing with GeneXpert, Accuporobe, etc.] by genotype and/or culture testing positive for M. tuberculosis
89674449|NCT05603273|No Intervention|standard wound care|normal wound care according to current clinical practice
89674450|NCT05603273|Experimental|non-weight bearing exercise + standard wound care|normal wound care according to current clinical practice with the addition of a weekly exercise routine
89674451|NCT05601908|Experimental|VR Relaxation|a 5-week course of 20-min sessions of VR relaxation
89674452|NCT05596084|Experimental|Bio-oss bovine bone graft with maxillary sinus augmentation and implant placement|A 2 cc Bio-oss bovine bone graft will be used for maxillary sinus augmentation before placing an implant on one side of the bilateral atrophic maxillary posterior regions. Then, 6 months after the surgery, the implant will be placed in accordance with the standard protocol
89674453|NCT05596084|Experimental|Titanium-Platelet Rich Fibrin with maxillary sinus augmentation and implant placement|A Titanium-Platelet Rich Fibrin will be used for maxillary sinus augmentation before placing an implant on other side of the bilateral atrophic maxillary posterior regions. Titanium platelet-rich fibrin was prepared by centrifugation at 2700 rpm for 14 minutes in accordance with standard protocols. Then, 6 months after the surgery, the implant will be placed in accordance with the standard protocol
89674454|NCT05592288|Experimental|Intervention group|The study universe will consist of adults of the ages 45-65 who have received a diagnosis of prediabetes and are registered at the Family Health Center No. 9. PREDIABE-TR mobile app usage (six months).
89674455|NCT05592288|No Intervention|Control grup|The study universe will consist of adults of the ages 45-65 who have received a diagnosis of prediabetes and are registered at the Family Health Center No. 9. Routine practice (Brochures of the Public Health Directorate, Mobile apps of the Ministry of Health, etc.)
89674456|NCT05588661|Experimental|Perturbation Exercises|Perturbation Based Balance Training
89674457|NCT05588661|Experimental|Whole Body Vibration|Whole Body Vibration Therapy
89674458|NCT05579223|Experimental|Intrathecal Hydromorphone Group (ITHM)|Dosage Form: Hydromorphone Hydrochloride Injection 2mg:2ml. Dosage: 75 μg+ 5% glucose injection diluted to 1.5ml. Frequency and Duration: i.t., st
89674459|NCT05579223|Placebo Comparator|Intrathecal Placebo Group (ITPO)|Dosage Form: 5% glucose injection, 100ml/Package. Dosage: 1.5ml. Frequency and Duration: i.t., st
89674460|NCT05577091|Experimental|Autologous Tris-CAR-T cell|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity.
89674461|NCT05574335|Experimental|Adults with T1D 0.08 mg/kg SQ dose|Cohort 1 Group1: 0.08 mg/kg SQ dose for a total of 12 weeks
89674462|NCT05574335|Experimental|Adults with T1D 0.12 mg/kg SQ dose|Cohort 1 Group 2: 0.12 mg/kg SQ dose for a total of 12 weeks
89674463|NCT05574335|Experimental|Adults with T1D 0.18 mg/kg SQ dose|Cohort 1 Group 3:0.18 mg/kg SQ dose for a total of 12 weeks
89674464|NCT05574335|Experimental|Adults with T1D 0.22 mg/kg SQ dose|Cohort 1 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks
89674465|NCT05574335|Experimental|Children with T1D 0.08 mg/kg SQ dose|Cohort 2 Group 1:0.08 mg/kg SQ dose for a total of 12 weeks
89674466|NCT05574335|Experimental|Children with T1D 0.12 mg/kg SQ dose|Cohort 2 Group 2:0.12 mg/kg SQ dose for a total of 12 weeks
89674467|NCT05574335|Experimental|Children with T1D 0.18 mg/kg SQ dose|Cohort 2 Group 3: 0.18 mg/kg SQ dose for a total of 12 weeks
89674468|NCT05574335|Experimental|Children with T1D 0.22 mg/kg SQ dose|Cohort 2 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks
89674469|NCT05569044|Other|Control Group|No intervention
89674470|NCT05569044|Experimental|Oral Rehydration Solution|ORS with carbohydrate
89674471|NCT05569044|Experimental|Water|Water with flavor
89674472|NCT05561556|Experimental|MitoQ|8-week MitoQ supplementation (20 mg daily capsule).
89674473|NCT05561556|Placebo Comparator|Placebo|8-week placebo matched in appearance to MitoQ supplementation (20 mg daily capsule).
89674474|NCT05559944|Experimental|Expressive Writing|Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community. A general list of the types of stressors and contexts commonly described will be provided to participants, given that meta-analytic research supports that providing examples enhances the efficacy of expressive writing.
89674475|NCT05559944|Experimental|Self-Affirmation|Participants will respond to one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.
89674476|NCT05559944|Placebo Comparator|Control|Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
88995873|NCT05075317|Experimental|Standard cardiac rehabilitation + TRE|Participants in this group will receive the same standard assessment and individualized recommendations as the comparator group, but will also be counselled to restrict their eating to between 11 am and 7 pm during the program starting the evening of the consultation. They will also be advised to perform their home-based exercise sessions during the fasting period in the morning.
89674477|NCT05558761|No Intervention|Control Group|this group will take mesalamine 1 g three times daily
89674478|NCT05558761|Active Comparator|Pentoxifylline group|his group will take mesalamine 1 g three times daily plus pentoxifylline 400 mg two times daily
89674479|NCT05556681||Treated with the investigational BD™ Sirolimus Drug Coated Catheter|Patients treated with the BD™ Sirolimus Drug Coated Catheter
89674480|NCT05551715|Other|Untreated eyes|Participants in the untreated arm will undergo an ophthalmic examination only once.
89674481|NCT05551715|Other|Refractive surgery|Participants on this arm will undergo two ophthalmic examinations, one before and one after surgery. For refractive surgery participants, refractive surgery will be performed as part of the habitual clinical practice. All other additional tests performed as part of the clinical trial are all non-invasive.
89674482|NCT05551715|Other|Cataract surgery|Participants on this arm will undergo two ophthalmic examinations, one before and one after surgery. For cataract surgery participants, cataract surgery will be performed as part of the habitual clinical practice. All other additional tests performed as part of the clinical trial are all non-invasive.
89674483|NCT05545969|Experimental|Neoadjuvant and Adjuvant Therapy|Neoadjuvant pembrolizumab & lenvatinib for 6 weeks followed by definitive surgery then adjuvant pembrolizumab alone for 46 weeks
89674484|NCT05544136|Experimental|Participants with Squamous Cell Carcinoma Head and Neck Cancer|Participants will be hypoxia-negative T0-3N1-2B small cell carcinoma head and neck cancer/SCC HNC patients (HPV-OPC, HPV- UPC with nodal metastasis(es), HPC, or LXC) who are eligible for definitive CRT with de-escalated radiation concurrent with 2 cycles of SOC chemotherapy. Hypoxia status will be determined by the absence of hypoxia radiotracer uptake on 18F-FMISO PET/CT imaging
89674485|NCT05541679|Experimental|Group A|
89674486|NCT05541679|Experimental|Group B|
89674487|NCT05521698|Experimental|ARM 1 (apalutamide,TURBT)|Patients receive apalutamide PO QD on days 1-21. Patients undergo TURBT on day 21. Up to 28 days of treatment is permitted in the absence of unacceptable toxicity. Patients undergo blood specimen collection at baseline and at time of TURBT.
89674488|NCT05521698|Active Comparator|ARM 2 (TURBT)|Patients undergo TURBT on day 21. Patients undergo blood specimen collection at baseline and at time of TURBT.
89674489|NCT05521152|Experimental|(Group N)|1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion and the syringe will be set on 2 ml/h
89674490|NCT05521152|Placebo Comparator|(Group S)|equivalent volume of saline will be prepared in 50 mL syringe and the infusion will be set on 2ml/kg
89674491|NCT05517590|Active Comparator|Tranexamic acid and group (Group I)|In Group I, 1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
89674492|NCT05517590|Placebo Comparator|Saline group (Group II)|Group II placebo will be administered to the control group, and 100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
89674493|NCT05515692|Experimental|Treatment (electron beam radiotherapy)|Patients undergo radiotherapy simulation on day -14 using either a clinical setup or CT simulation at the discretion of the treating radiation oncologist. Patients then undergo electron beam radiotherapy on day 0. Patients also undergo skin biopsies at baseline, day 28, and day 168 after radiotherapy, and high frequency ultrasound (HFUS) scans on days 28, 56, 84, 112, 140, and 168 after radiotherapy.
89674494|NCT05514457|Experimental|remediation group 1|dyslexic children
89674495|NCT05514457|Experimental|remediation group 2|dyslexic children
89674496|NCT05504252|Experimental|Experimental Arm|"The study has a start-up single-arm design consisting of 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 4 individual cycles before radiologic response assessment and patient stratification to continued therapy or not.~Patients who present less than 10% target lesion reduction at the first radiologic response assessment will proceed to standard-of-care treatment at the Clinical Investigator's discretion.~Patients who present 10% or higher target lesion reduction at the first radiologic response assessment will continue with alternating 2 cycles of the Nordic FLOX regimen and 2 cycles of nivolumab in a go-and-stop schedule until progressive disease on ongoing therapy (defining PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first."
89674497|NCT05494983|Other|Session 1 : Peripheral Session (left) - session 2 Central Session (right)|"The susceptibility to develop peripheral sensitization will be assessed at the first experimental session, the stimulation will occur at the left forearm.~The susceptibility to develop central sensitization will be assessed at the second experimental session, the stimulation will occur at the right forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
89674498|NCT05494983|Other|Session 1 : Peripheral Session (right) - session 2 Central Session (left)|"The susceptibility to develop peripheral sensitization will be assessed at the first experimental session, the stimulation will occur at the right forearm.~The susceptibility to develop central sensitization will be assessed at the second experimental session, the stimulation will occur at the left forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
89674499|NCT05494983|Other|Session 1 : Central Session (left) - session 2 Peripheral Session (right)|"The susceptibility to develop central sensitization will be assessed at the first experimental session, the stimulation will occur at the left forearm.~The susceptibility to develop peripheral sensitization will be assessed at the second experimental session, the stimulation will occur at the right forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
89674500|NCT05494983|Other|Session 1 : Central Session (right) - session 2 Peripheral Session (left)|"The susceptibility to develop central sensitization will be assessed at the first experimental session, the stimulation will occur at the right forearm.~The susceptibility to develop peripheral sensitization will be assessed at the second experimental session, the stimulation will occur at the left forearm.~In both experimental sessions, participants will have to fill questionnaires about the use of medications, the Stanford Sleepiness Scale, the Leeds Sleep Evaluation Questionnaire, and the first part of the State and Trait Anxiety Questionnaire. During sensory stimulation, an infrared camera will be used to measure pupil diameter which constitute an indirect correlate of stimulus-evoked phasic variations in activity of the locus coeruleus. In order to measure autonomic reactivity to pain stimuli, the heart rate variability will be measured by recording electrocardiography."
89674501|NCT05484570||Diagnosed|Patients who are diagnosed with a DNA Repair Disorder
89674502|NCT05484570||Control|Healthy family members of enrolled diagnosed participants.
89674503|NCT05483855||Objective 1: Telehealth Visit|Any rheumatology patient, seen and treated by a participating physician, who is 19 years and older, with the target condition(s) of interest, and is already scheduled for a telehealth visit.
89674504|NCT05483855||Objective 2: ArthritisPower App|Patients diagnosed with Rheumatoid Arthritis who already have a pre-scheduled in-office visit.
89049933|NCT04613544||Atrial Fibrillation|Atrial fibrillation diagnosed patients.
89049934|NCT04672109|Experimental|Anodal-tDCS|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the supraorbital area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
89674505|NCT05483764||Paraplegia|
89674506|NCT05483764||Control|
89674507|NCT05475808|Active Comparator|Splint|Patients in Group 1 will be applied to only static wrist splint treatment for 8 week.
89674508|NCT05475808|Active Comparator|Tendon and nerve gliding exercise|Patients in Group 2 will be applied to tendon and nerve gliding exercises for the wrist in addition to static wrist splint treatment for 8 week.
89674509|NCT05475808|Active Comparator|local steroid injection|Patients in Group 3 will be applied to local steroid injection to wrist in addition to static wrist splint treatment for 8 week.
89674510|NCT05475366|Experimental|Molecular screening for prediction of response|L1 chemotherapy regimen (FOLFIRINOX vs Gemcitabine plus nab-paclitaxel (GemnabP)) will be selected based on transcriptomic signatures applied to the pre-therapeutic biopsy of newly diagnosed PDAC patients.
89674511|NCT05469711|Experimental|Arm 1:|Gamification
89674512|NCT05469711|No Intervention|Arm 2|Monitoring
89674513|NCT05454046||Women|
89674514|NCT05454046||Men|
89674515|NCT05452824|Experimental|Tai Chi Prehabilitation|8 weeks Tai Chi prehabilitation prior to radical prostatectomy
89674516|NCT05452824|Placebo Comparator|Usual Care|Usual care
89674517|NCT05450991||Hirschsprung's Disease|Infants, children and adults cared for in Alder Hey Children's Hospital from the neonatal period onward with histologically confirmed Hirschsprung's disease.
89674518|NCT05450991||Anorectal Malformations|Infants, children and adults cared for in Alder Hey Children's Hospital from the neonatal period onward with an anorectal malformation.
89674519|NCT05443165|Experimental|Symptom self-management with an online decision support system|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be applying symptom self-management with an online decision support system, will be expected to additionally manage their symptom self-management using with this system. Participants in the intervention group will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses, and to use the decision support system for symptom self-management according to symptom severity. During the follow-up period, a short SMS message will be sent to the patients on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy cycles. In the third month, after the follow-up phase of the study is completed, the patients in the intervention group who come to the hospital for follow-up or treatment will receive post-tests.
89674520|NCT05443165|Active Comparator|Symptom self-management with an education booklet|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS. During the follow-up period, a short SMS message will be sent to the patients on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy cycles. In the third month, after the follow-up phase of the study is completed, the patients in the intervention group who come to the hospital for follow-up or treatment will receive post-tests.
89674521|NCT05440032||Synovial fluid testing with semi-quantitative leukocyte esterase test strip|Using a drop of synovial fluid, sample will be analyzed via the point-of-care device to measure amount of leukocyte esterase in the sample
89674522|NCT05440032||Synovial fluid testing with Roche Chemstrip|Using a drop of synovial fluid, sample will be analyzed via a urine test-strip to measure amount of leukocyte esterase in the sample
89674523|NCT05438914|Experimental|Reverse Shoulder Arthroplasty with subscapularis repair|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
89674524|NCT05438914|No Intervention|Reverse Shoulder Arthroplasty without subscapularis repair|The subscapularis will not be repaired.
89674525|NCT05435235|Experimental|Dapagliflozin arm|Patients who received Dapagliflozin 10 mg daily starting 48h prior to PCI and continuing for 48h post-PCI.
89674526|NCT05435235|No Intervention|Standard of care|Patients who received the standard of care.
89674527|NCT05425225|Experimental|Low level LASER therapy|low level laser therapy in continues wave at a wavelength in the near infrared of 830nm. Power density will be 670 mW/cm2. The treatment time per point will be 30 seconds. Probe head will be placed with light pressure on the calf muscles. Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds
89674528|NCT05425225|Active Comparator|Conventional physical therapy|sustained stretching (10 seconds hold), strengthening exercise, balance training and gait training
89674529|NCT05425212|Experimental|Functional activation with kinesio tapping|given 5 cm wide kinesio tape at tibialis anterior and gastrocnemius to facilitate dorsiflexion of the ankle and inhibit planter flexion simultaneously along with conventional treatment.
89674530|NCT05425212|Active Comparator|Conventional physical therapy|strengthening and stretching, combined with Ankle ranges and Hip strengthening. (6) The exercises performed will be Calf stretches, Heel and Toe raises, Hip marching in sitting/standing; Heel walk; Pebble picking; Single leg standing; and Ankle range of motions
89674531|NCT05425082|Active Comparator|Motor relearning program|"Emphasis of MRP is on practice of specific activities, the training of cognitive control over muscles & movement. Components of activities & conscious elimination of unnecessary muscle activity.• Based on 3 factors -~Elimination of unnecessary muscle activity~Feedback~Practice"
89674532|NCT05425082|Experimental|Neurodevelopmental therapy|"The abnormal patterns must be stopped not by modifying the sensory input, but by giving back to the patient the • The hemiplegic side should be incorporated into all treatment activities to reestablish symmetry and increased functional use~Treatment should produce a change in the quality of movement and functional performance of the involved side~Increase active use of the involved side~Provide practice to improve motor performance that led to motor learning lost or undeveloped control over his output in developmental sequence"
89674533|NCT05422521|Experimental|identification of predictive and prognostic biomarkers|
89688745|NCT03034837|Active Comparator|Resin sealant|"Sealing pit and fissures of the included permanent first molars using SDI conseal f resin sealant material once at the baseline of the study."
89674534|NCT05413473|Experimental|MR guided radiotherapy|"MR-guided radiotherapy using the Alberta linac-MR P3 system. Contemporary radiotherapy techniques and fractionation schedules will be conducted in the following graduated stages with overlap between stages allowed:~Stage 1: Parallel-opposed pair treatments (palliative) Stage 2: 4 field box and breast treatments (curative or palliative) Stage 3: Radical treatments - multi-field 3DCRT (curative) Stage 4: Radical treatments - multi-field IMRT (curative)"
89674535|NCT05411653|Experimental|Virtual reality training with motor imagery|Xbox Kinect VR with MI training Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session
89674536|NCT05411653|Active Comparator|Conventional physical therapy|a range of motion exercises, muscle strengthening, functional training, balance training, and gait training. T
89674537|NCT05410964||Single Arm|
89674538|NCT05410652||Fecal kit group|Collect stool samples from patients who meet the inclusion criteria. DNA was extracted from fecal samples. After that, the extracted DNA was sequenced by first generation sequencing. Finally，the mutation sites of extracted DNA were detected by fecal gene detection kit.
89674539|NCT05410652||Sanger Sequencing group|Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
89674540|NCT05410652||Drug sensitivity test group|Gastroscopy was performed on patients who met the inclusion and exclusion criteria to obtain samples of gastric mucosa. Helicobacter pylori culture and drug sensitivity test were performed on gastric mucosa samples in vitro. Finally, the drug sensitivity test results were collected.
89674541|NCT05410418|Experimental|Mosunetuzumab and Polatuzumab Vedotin|Patients receive CD3xCD20 bispecific antibody mosunetuzumab administered subcutaneously in combination with CD79b directed ADC polatuzumab vedotin administered intravenously. Mosunetuzumab and polatuzumab vedotin are given in combination for 6 cycles. Mosunetuzumab is given on Days 1, 8, and 15 of cycle 1 and then Day 1 thereafter, and polatuzumab vedotin is given on Day 1. After 6 cycles, patients continue on mosunetuzumab alone for 2 additional cycles. Patients undergo scans at the end of cycle 8, and if those scans show a complete response, patients will stop any further treatment and will enter follow-up. Patients with a partial response or stable disease on scans at the end of cycle 8 may receive up to 9 additional cycles of mosunetuzumab in the absence of disease progression or unacceptable toxicity. All cycles are planned to be 21 days.
89674542|NCT05408910|Experimental|Treatment|Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
89674543|NCT05408910|Placebo Comparator|Placebo|Participants in this arm will receive placebo three times daily for 14 days.
89674544|NCT05395065||SDF/FV|Topical Application of 38% silver diamine fluoride and 2.5% sodium fluoride varnish at baseline and 6 months
89674545|NCT05382728|Experimental|TY-9591+placebo Osimertinib|TY-9591 (160mg orally, once daily) plus placebo Osimertinib (80mg orally, once daily), in accordance with the randomization schedule.
89674546|NCT05382728|Active Comparator|Osimertinib+placebo TY-9591|Osimertinib (80mg orally, once daily) plus placebo TY-9591 (160mg orally, once daily), in accordance with the randomization schedule.
89674547|NCT05379738|Experimental|adapted physical activity|6 sessions of physical activity
89674548|NCT05379712|Experimental|Multimodal Nutrition Therapy|"To assess a multimodal nutrition therapy (primary nutrition intervention+ adjuvant nutrition therapy) with features adapted for patients with cancers of the head and neck receiving chemo-radiotherapy treatment, to maintain oral dietary intake during treatment. The regimen consists of 2 medical foods, each taken on an unrestricted basis (as and when preferred by each patient).~Resource® Support Plus, a nutritionally complete Medical Food specifically for the dietary management of oncology patients with (risk of) malnutrition.~BOOST® Soothe, a Medical Food formulated as a clear oral nutritional supplement for cancer patients with sensory alterations or oral discomfort due to cancer treatments, in particular chemo- and/or radiotherapy."
89674549|NCT05379712|No Intervention|Standard of Care|In this setting patients rely on oral dietary intake. Ordinary, commercially available ingredients and food products are consumed. The standard of care includes weekly consultation with specialist oncology Registered Dietitian.
89674550|NCT05375669|Experimental|ISIS IOM System|Total intravenous anesthesia (TIVA), surgery and TES MEP monitoring will proceed routinely without modification and normally involves acquiring many MEPs over several hours. The only departure from standard care will be the placement of two small accelerometers and a brief MEP sequence before skin incision to determine chronaxie and compare the effect of an equivalent increase of I or D on MEP amplitude and movement.
89049935|NCT04672109|Experimental|Cathodal-tDCS|Cathodal transcranial direct current stimulation (tDCS) will be applied for 20 mins. Cathode on the primary motor area (M1) of non-dominant hemisphere and Anode on the supraorbital area of dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
89674551|NCT05373901|Experimental|Dinutuximab beta cohort|Patients who received dinutuximab beta as maintenance therapy
89674552|NCT05370131|Experimental|Avatar-Based Education Program in Hydrocephalus (ABEP-H)|The avatar-based education program in hydrocephalus (ABEP-H) aimed to help parents acquire the knowledge and develop the skills necessary for the care of hydrocephalus children with VP shunts and prevent shunt infection and dysfunction. The intervention group participants will be sent usernames and passwords they can change by accessing their profiles. The main researcher will show them how to log into the program and use it on their phones and computers. This interview will take about 40 minutes. Afterward, they are expected to use the program for six months on a regular basis. Their login frequency and duration will be monitored. After six months, they will be asked to fill out the System Usability Scale (SUS). Moreover, each participant will be phoned once every two weeks as a reminder.
89674553|NCT05370131|No Intervention|Control Group|The control group will receive the standard care procedures of the hospital.
89674554|NCT05365386|Experimental|Tixel Treatment|All subjects will undergo 1-3 treatments (determined by the investigator assessment), 3-4 weeks apart with the Tixel device.
89674555|NCT05343871|Experimental|Priming Group 1: Sinovac Prime, AZD1222 ½ dose (Brazil only)|
89674556|NCT05343871|Active Comparator|Priming Group 1: Sinovac Prime, AZD1222 full dose (Brazil only)|
89674557|NCT05343871|Experimental|Priming Group 1: Sinovac Prime, BNT162b2 1/3 dose|
89674558|NCT05343871|Experimental|Priming Group 1: Sinovac Prime, BNT162b2 1/2 dose|
89674559|NCT05343871|Active Comparator|Priming Group 1: Sinovac Prime, BNT162b2 full dose|
89674560|NCT05343871|Active Comparator|Priming Group 1: Sinovac Prime, Sinovac full dose|
89674561|NCT05343871|Experimental|Priming Group 2: AZD1222 Prime, AZD1222 ½ dose (Brazil only)|
89674562|NCT05343871|Active Comparator|Priming Group 2: AZD1222 Prime, AZD1222 full dose (Brazil only)|
89674563|NCT05343871|Experimental|Priming Group 2: AZD1222 Prime, BNT162b2 1/3 dose|
89215042|NCT05113316|No Intervention|Treatment as usual (TAU) Group|Subjects will not receive any study treatments or have access to the app but may seek standard treatment if they choose, in addition to completing self-report measures. For 8 weeks, TAU group will participate in the study under treatment as usual. For weeks 9-16, the TAU group will then switch and have full access to the Messy Memories App to review and use for a limited amount of time. Subjects will download and have access to the Messy Memories application in addition to completing self-report measures electronically at pre-determined time points. While the subject uses the app, the participant will input information related to their mood over the past few days, their level of distress before and after the memory processing, answers to questions about revisiting the memory, answers to questions in the social connection and self-care modules including assessment of, for example, sleep pattern, eating habits, and exercise habits.
89215043|NCT05109793||Cohort|Late infantile or juvenile onset for GM1 or GM2 Gangliosidosis. The study anticipates to include a total of approximately 35 patients.
89674564|NCT05343871|Experimental|Priming Group 2: AZD1222 Prime, BNT162b2 1/2 dose|
89674565|NCT05343871|Active Comparator|Priming Group 2: AZD1222 Prime, BNT162b2 full dose|
89674566|NCT05343871|Experimental|Priming Group 3-B: BNT162b2 Prime, AZD1222 ½ dose (Brazil only)|
89674567|NCT05343871|Active Comparator|Priming Group 3-B: BNT162b2 Prime, AZD1222 full dose (Brazil only)|
89674568|NCT05343871|Experimental|Priming Group 3-B: BNT162b2 Prime, BNT162b2 1/3 dose (Brazil only)|
89674569|NCT05343871|Experimental|Priming Group 3-B: BNT162b2 Prime, BNT162b2 1/2 dose (Brazil only)|
89674570|NCT05343871|Active Comparator|Priming Group 3-B: BNT162b2 Prime, BNT162b2 full dose (Brazil only)|
89674571|NCT05343871|Experimental|Priming Group 3-P: Natural Infection Prime, BNT162b2 1/3 dose (Pakistan only)|
89674572|NCT05343871|Experimental|Priming Group 3-P: Natural Infection Prime, BNT162b2 1/2 dose (Pakistan only)|
89674573|NCT05343871|Active Comparator|Priming Group 3-P: Natural Infection Prime, BNT162b2 full dose (Pakistan only)|
89215044|NCT05108298|Experimental|Intervention arm|5 domain-specific HRQOL measures
89674574|NCT05343286|Experimental|APAP group: adapted and personalized physical activity|12 weeks of adapted and personalized physical activity
89674575|NCT05343286|Active Comparator|APA group: adapted physical activity|12 weeks of generic physical activity
89674576|NCT05343286|Sham Comparator|Control group: no physical activity|no physical activity
89674577|NCT05340062||pediatric patients with ICP device|"In children requiring ICP, TCD and ONSD will be measured:~within 30 minutes before to the placement of the ICP (if possiblel)~at least twice a day after placement of the invasive ICP for the first 48 hours~Each measurement will include:~The measure of the invasive ICP~Calculation of invasive CPP (invasive MAP-invasive ICP)~TCD: FVs, FVd, FVm, from which the nCPP will be obtained with the formula FVdICP. The nICP will be obtained from invasive MAP minus nCPP.~The measurement of the nICP ONSD (2) for a total of 2 measurements preferably from the side where the invasive ICP device is positioned.~Measurements (TCD and ONSD) will be done by two operators blinded by each other in order to evaluate the inter-operator variability"
89674578|NCT05337124||Lupkynis Treatment Group|
89215045|NCT05108298|Other|Control arm|5 pre-selected HRQOL measures
89674579|NCT05330351||Pediatric Trauma Patients|Pediatric patients (<18 years old) who have suffered a traumatic event requiring surgical fixation within 48 hours prior to time to arrival in the operating room.
89674580|NCT05325177|Active Comparator|Group 1 infants|(n=15) will receive three doses of standard-dose Ibuprofen. (10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
89674581|NCT05325177|Active Comparator|Group 2 infants|(n = 15) will receive three doses of high-dose Ibuprofen Motrin. (20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
89674582|NCT05304039||Asthma exacerbation|Patients with an asthma exacerbation who are diagnosed with mild to severe asthma according to the GINA guidelines
89674583|NCT05299164|Experimental|Liposomal mitoxantrone hydrochloride 16 mg/m^2 (with a caret included)|
89674584|NCT05299164|Experimental|Liposomal mitoxantrone hydrochloride 18 mg/m^2 (with a caret included)|
89674585|NCT05299164|Experimental|Liposomal mitoxantrone hydrochloride 20 mg/m^2 (with a caret included)|
89674586|NCT05299164|Experimental|Liposomal mitoxantrone hydrochloride 22 mg/m^2 (with a caret included)|
89674587|NCT05299008||Infants with diagnosis of tracheobronchomalacia treated with bethanechol|Infants with a diagnosis of tracheobronchomalacia by dynamic computed tomography and showing > 50% cross-sectional diameter collapse at 40 to 60 post menstrual age
89674588|NCT05284253|Experimental|Gold microparticles|Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
89674589|NCT05284253|Active Comparator|Gold thiosulphate|Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
89674590|NCT05281861|Experimental|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|The onlays will be constructed from Zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic system
89674591|NCT05281861|Active Comparator|Lithium disilicate (IPS e-max press) ceramic onlay restoration|The onlays will be constructed from Lithium disilicate (IPS e-max press) glass ceramic system
89674592|NCT05276401|Experimental|Active|Dosage Form: Topical Antimicrobial Gel; Dosage: 5% Gel, 10% Gel; Frequency: BID for 28 days
89674593|NCT05276401|Placebo Comparator|Placebo|Dosage Form: Topical Gel; Dosage: Placebo; Frequency: BID for 28 days
89674594|NCT05274451|Experimental|Experimental LYL797|ROR1-targeted CAR T cells
89674595|NCT05264792|Active Comparator|Routine Implementation Support|All 14 health facilities will continue to receive existing routine implementation support. The facilities allocated to the control arm (n=7) will receive routine implementation support only.
89674596|NCT05264792|Experimental|Enhanced Implementation Support|In addition to routine support, Enhanced Implementation Support will be provided to 7 facilities allocated to the 'intervention arm'.
89674597|NCT05260528|Active Comparator|Standard arm|
89674598|NCT05260528|Experimental|Investigational arm|
89674599|NCT05260125|Experimental|Ultrasound-guided Suprascapular Nerve Block|Ultrasound-guided Suprascapular Nerve Block
89674600|NCT05260125|Active Comparator|Anatomical Landmark-guided Suprascapular Nerve Block|Anatomical Landmark-guided Suprascapular Nerve Block
89674601|NCT05258409|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
89674602|NCT05258409|Experimental|Body Project: More than Muscles (MTM)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
89674603|NCT05250089|Experimental|Emergency physicians|"Each participant will have to carry out two simulation sessions. The first simulation will correspond to the usual evaluation, that is to say it will take place on a day that will not be preceded by night duty during the three previous nights.~The second simulation will correspond to the assessment twenty-four hours after the end of a call, in the post-recovery period. The participant must therefore have performed a night shift the day before the day when the simulation takes place. This call must have a minimum duration of twelve hours on night shifts."
89674604|NCT05246670|Placebo Comparator|BID placebo|Patients receive placebo PO BID for 8 weeks.
89674605|NCT05246670|Experimental|Higher-dose PEA|Patients receive PEA PO BID for 8 weeks as long as there is not any unacceptable toxicity.
89674606|NCT05246670|Experimental|Lower-dose PEA|Patients receive PEA PO QD for 8 weeks as long as there is not any unacceptable toxicity.
89674607|NCT05246670|Placebo Comparator|QD placebo|Patients receive placebo PO QD for 8 weeks.
89674608|NCT05236660|Experimental|Multimodal care|Multimodal personalised treatment
89674609|NCT05236660|No Intervention|Usual care|Usual care as offered to high-risk patients as offered in the Netherlands
89674610|NCT05232877|Experimental|tDCS combined with simultaneous cognitive training|
89674611|NCT05232877|Sham Comparator|cognitive training with a combined sham tDCS|
89674612|NCT05225935|Experimental|image-guided VT ablation strategy|Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
89674613|NCT05225935|Active Comparator|conventional VT ablation strategy|Catheter ablation performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
89674614|NCT05225922|Experimental|Experimental|Communication Partner Training:The group will receive usual care in addition to a CPT program, which will consist of face-to-face education and counselling sessions, a manual and telephone support.
89674615|NCT05225922|Active Comparator|Comparison Group|This group will receive usual speech therapy sessions.
89674616|NCT05224973|Experimental|speech therapy combined with digital fine motor stimulation|At the beginning of the swallowing rehabilitation session, a fine manual motor training is practiced during the first ten minutes of the session. Training consists of activities requiring increasing precision and different types of grips
89674617|NCT05224973|Active Comparator|speech therapy only|standard swallowing rehabilitation session
89674618|NCT05220046|Experimental|Psilocybin Treatment Arm|Participant with pancreatobilliary cancer will receive 25mg of psilocybin in one 8-hour monitored session with supportive counseling before and after session.
89674619|NCT05220046|No Intervention|Family Observation Group|The study participant will select a family member who will provide parallel data regarding distress related to pancreatobiliary cancer.
89674620|NCT05213234|Other|Morning Medication Administration|Subjects are directed to take their medication between 06:00 and 10:00.
89674621|NCT05213234|Other|Night Medication Administration|Subjects are directed to take their medication between 18:00 and 22:00.
89674622|NCT05209360|Experimental|Arm 1|Testing Order: NoCDO, CDO, Lateral, Medial
89215046|NCT05100069||Brigatinib Tablets|Brigatinib 90 milligrams (mg), tablet, orally, once daily for up to 7 days, followed by 180 mg, tablets, once daily for 51 weeks. Participants received interventions as part of routine medical care.
89674623|NCT05209360|Experimental|Arm 2|Testing Order: NoCDO, CDO, Medial, Lateral
89674624|NCT05209360|Experimental|Arm 3|Testing Order: NoCDO, Medial, CDO, Lateral
89674625|NCT05209360|Experimental|Arm 4|Testing Order: NoCDO, Medial, Lateral, CDO
89674626|NCT05209360|Experimental|Arm 5|Testing Order: NoCDO, Lateral, Medial, CDO
89674627|NCT05209360|Experimental|Arm 6|Testing Order: NoCDO, Lateral, CDO, Medial
89674628|NCT05203627|Experimental|Arm I (telehealth session, guidebook)|Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.
89674629|NCT05203627|Active Comparator|Arm II (standard nutritional support)|Patients receive standard nutritional support.
89674630|NCT05201976|Active Comparator|Intervention|Virtual cardiac rehab program delivered through the CardaHealth platform.
89674631|NCT05201976|Active Comparator|Control|Clinically ordered standard of care cardiac rehab program (in-person).
89674632|NCT05199662|Placebo Comparator|Control group|Placebo administered as a single bolus injection over 5 seconds
89674633|NCT05199662|Experimental|Intravenous tenecteplase (TNK)|Intravenous thrombolysis with Tenecteplase (TNK) at a dose of 0.25 mg/Kg (maximum 25mg, administered as a bolus over 5 seconds)
89674634|NCT05199194|Experimental|Mechanical Thrombectomy preceded by TNK|Subjects assigned to this arm will receive an intravenous bolus of tenecteplase (0.25mg/kg) before the mechanical thrombectomy.
89674635|NCT05199194|Placebo Comparator|Mechanical Thrombectomy preceded by Placebo|Subjects assigned to this arm will receive an intravenous bolus of matching placebo (with the same volume of infusion as of 0.25mg/kg of tenecteplase) before the mechanical thrombectomy.
89674636|NCT05195606|No Intervention|Control group|There is no standard sensory stimulation program for comatose patients with head trauma in the hospitals where the research will be conducted. Therefore, the control group will receive routine practice.
89215047|NCT05087550||Liver Transplantation patients|
89674637|NCT05195606|Experimental|Auditory stimulus (Intervention A)|Auditory stimulus for patients in this group
89674638|NCT05195606|Experimental|Tactile stimulus (Intervention B)|Tactile stimulus for patients in this group
89674639|NCT05193656||Detecting bladder tumor|Patients with hematuria, or previous bladder tumor
89674640|NCT05192213|Experimental|Intervention|"1,5 g of vitamin C every 6 hours + 200 mg of thiamine every 12 hours + 50 mg of hydrocortisone every 6 hours~For 7 days or until patient's discharge/death"
89674641|NCT05192213|Placebo Comparator|Control|"Placebo 1 for vitamin C every 6 hours + Placebo 2 for thiamine every 12 hours + 50 mg of hydrocortisone every 6 hours~For 7 days or until patient's discharge/death"
89674642|NCT05189470|Other|Control group|These participants will receive the usual care of the respective outpatient clinics.
89674643|NCT05189470|Experimental|Intervention group|Participants that are randomized to the intervention group will receive both inforatio technique and usual care. Inforatio technique will be applied at baseline, 3, 6, 9 and 12 week- follow-up as long as the ulcers have a diameter of minimum four mms and have not developed infection, necrosis, positive probe-to-bone test, exposure of joint or tendon; or underlying osteomyelitis. In addition, inforatio technique will not be applied on ulcers that are covered by scab if the wound care staff assess that the scab should not be removed from the ulcer.
89049936|NCT04672109|Experimental|Dual-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied for 20 mins. Anode on the primary motor area (M1) of dominant hemisphere and Cathode on the primary motor area of non-dominant hemisphere. Current intensity is fixed at 2 mA and current will flow continuously. The scope of intervention is to investigate effect of tDCS on muscle strength.
89049937|NCT04672109|Sham Comparator|Sham-tDCS|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 or the motor area (M1) for 20 mins. Anode on dominant hemisphere, Cathode on non-dominant hemisphere. The scope of intervention is to investigate effect of tDCS on muscle strength.
89674644|NCT05185895|Sham Comparator|Start with: Concentric (normal) cycling|
89674645|NCT05185895|Experimental|Start with: Eccentric cycling|
89674646|NCT05183984|Experimental|ARM A: carboplatin/paclitaxel + niraparib|carboplatin AUC 5-6 + paclitaxel 175 mg/m² q3w, 5 cycles, followed by niraparib 200* or 300 mg/d for 2 years.
89674647|NCT05183984|Experimental|ARM B: carboplatin/paclitaxel/bevaziumab + niraparib/bevacizumab|carboplatin AUC 5-6 + paclitaxel 175 mg/m² + bevacizumab 15 mg/kg q3w, 5 cycles, followed by bevacizumab 15 mg/kg q3w for 15 months + niraparib 200*or 300 mg/d for 2 years.
89674648|NCT05182151||Patient|istradefylline 40mg daily over 12 week period
89674649|NCT05174663|Experimental|Almond-enriched diet dose 1|Participants will be instructed to ingest 1.5 oz of almonds daily for 16 weeks. The 1.5 oz of almonds can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of almonds daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
89674650|NCT05174663|Experimental|Almond-enriched diet dose 2|Participants will be instructed to ingest 2.5 oz of almonds daily for 16 weeks. The 2.5 oz of almonds can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of almonds daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
89674651|NCT05174663|Other|Nut-free diet|Participants will be instructed to ingest the control snack (Iso-caloric [to 1.5 oz of almonds] control snack of chocolate chip cookies or Oreo cookies) daily for 16 weeks. The control snack can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of snack daily. If a dose is missed, participants should take the missed dose as soon as the participants remember.
89674652|NCT05162261|Experimental|Tixel Group|Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
89674653|NCT05162261|Active Comparator|LipiFlow|LipiFlow: Screening and baseline visits,Treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
89049938|NCT00563394|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
89049939|NCT00563394|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
89049940|NCT04660877|Experimental|Cheddar chese|Once enrolled, participants will either ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (~1 month) for Metabolic Study #2.
89049941|NCT04660877|Active Comparator|Milk|Once enrolled, participants will ingest 20 grams of protein from 1) cheese or 2) milk for the first Metabolic Study and then the other product when they return after the washout period (~1 month) for Metabolic Study #2.
89049942|NCT04653350|Experimental|HIT-MMEX Group|In this group Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
89049943|NCT04653350|Active Comparator|Control Group|In this Group Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training & balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
89049944|NCT00563433|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
89049945|NCT00563433|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
89049946|NCT04652102|Experimental|Randomized Observer-blinded Phase 2b: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
89674654|NCT05156983|Experimental|TAK-330 25 IU/kg|Participants will receive TAK-330, 25 international unit per kilogram (IU/kg) single intravenous infusion on Day 1 (prior to surgery) as an initial dose and an additional dose of 25 IU/kg TAK-330 can be administered during the surgery if deemed necessary by the surgeon. The total dose of TAK-330 administered to the participant should not exceed 50 IU/kg or 5,000 IU, whichever is smaller.
89049947|NCT04652102|Placebo Comparator|Randomized Observer-blinded Phase 2b: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
89674655|NCT05156983|Active Comparator|SOC 4F-PCC|Participants will receive 4F-PCC (excluding Prothromplex Total and activated 4F-PCC) as standard of care (SOC) on Day 1 (prior to surgery). The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
89674656|NCT05150704|Experimental|Experimental arm|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
89674657|NCT05150704|Placebo Comparator|Control arm|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
89674658|NCT05150652|Experimental|Neoadjuvant Endocrine Therapy|Participants will begin treatment with Anastrozole. If not tolerated well, participants will discontinue and begin treatment using Letrozole. If not tolerated well, participants will discontinue and begin treatment using Exemestane. If not tolerated well, participants will discontinue and begin treatment on Tamoxifen.
89674659|NCT05146219|Experimental|TY-9591 Tablets|TY-9591 Tablets 160mg/d
89674660|NCT05141383|Other|Patients with prostate cancer|Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level> 4 ng / ml
89674661|NCT05141383|Other|Patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate|Patients with suspected prostate cancer (MRI or digital rectal examination), or prostatic hyperplasia with a PSA level> 4 ng / ml
89674662|NCT05141383|Other|Healthy donors|Male from 50 to 70 years old with a PSA level <4 ng / mL
89674663|NCT05137782|Experimental|Arm 1|Patients and care partners receive specialty primary care and participate in pre- and post- functional MRI scans to measure the effects of the specialty palliative care intervention.
89674664|NCT05137652|Other|Control group|single needle approach for 40 patients in which nerve is traditionally been targeted.
88995874|NCT05074771|Experimental|ARC intellicare|"Study participants will use ARC intellicare at home, to carry out usability tests and a collection of useful data in order to optimise the system. After enrolment and training session, patients will receive an ARC unit to be used autonomously for the following 30 days.~45 minutes 5 days / week for 4 weeks of personalized training will be carried out by the enrolled subjects: 4 weekly sessions will be unsupervised, while one will be supervised remotely by a therapist in telepresence, thanks to the integrated audio-video channel."
88995875|NCT03457246|Experimental|D-Pigment rich texture|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by test product ( D-pigment rich texture).
88995876|NCT03457246|Placebo Comparator|Hydrance optimale riche|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by reference product (Hydrance optimale riche)
88995877|NCT05062876|Active Comparator|R-T|Period 1 : Test Drug(AD-214) Period 2 : Reference Drug(AD-2141)
89674665|NCT05137652|Experimental|Study group|40 patients will receive the three needle approach.
89674666|NCT05135949||Operative|Internal fixation of the displaced olecranon fracture.
89674667|NCT05135949||Non Operative|Conservative treatment as determined by the treating surgeon.
89674668|NCT05120193|Experimental|Sphere-9 Catheter|Sphere-9™ Mapping and Ablation Catheter; Affera Mapping System; Affera Ablation System
89674669|NCT05120193|Active Comparator|THERMOCOOL SMARTTOUCH SF|THERMOCOOL SMARTTOUCH® SF Catheter; SMARTABLATE® System; CARTO® 3 System
89674670|NCT05115474||Participants with TNBC (triple negative breast cancer)|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
89674671|NCT05115474||Participants with Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
89674672|NCT05115474||Participants with Hormone Receptor (HR) +Breast Cancer|Participants will undergo a screening brain MRI. Patients will undergo a second brain MRI at first systemic progression or at 6 months whichever event occurs sooner.
89674673|NCT05100836||Single arm all comers supported with Impella 5.5|
89674674|NCT05097196|Experimental|Step Aerobic Group|Step aerobic exercise
89674675|NCT05091268|Experimental|Exercise group|"All participants will attend a four-hour pain education session including gynecologist, psychologist, sexologist, and physiotherapist at Akershus University Hospital.~The education will be held twice, with half of the participants at the time. The training group will then attend a 60 minutes weekly group training session led by a physiotherapist with specialist training in women's health, over a period of four months. In addition, participants will perform a progressive home exercise program performed daily over the same period. The focus will be general strength training using own body weight and cardiovascular fitness (walking, low-impact aerobic exercise), stretching, and relaxation."
89674676|NCT05091268|No Intervention|Pain education group|No further follow-up
89674677|NCT05086497|No Intervention|Conventional Array Mapping Layout|Participants in this study arm will still receive Optune array layout mapping based on standard MR imaging sequences.
89674678|NCT05086497|Experimental|Advanced MR Imaging Array Mapping Layout|Participants in this study arm will receive Optune array layout mapping created from advanced MR imaging sequences obtained through trial enrollment.
89674679|NCT05079464|Experimental|Exercise primed tDCS|Individuals randomized to this group will receive exercise at University Health Network-Toronto Rehabilitation Institute followed by active tDCS.
88995878|NCT05062876|Active Comparator|T-R|Period 1 : Reference Drug(AD-2141) Period 2 : Test Drug(AD-214)
88995879|NCT04687111|Active Comparator|Control|Valsartan 40mg bid titrated to maximum dose of 160mg bid
88995880|NCT04687111|Experimental|Intervention|Sacubitril/Valsartan 50mg bid titrated to maximum dose of 200mg bid
88995881|NCT00164775|Active Comparator|Imipramine|Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
88995882|NCT00164775|Placebo Comparator|Placebo|Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks
89049948|NCT04652102|Experimental|Randomized Observer-blinded Phase 3: CVnCoV vaccine|Participants will be vaccinated with CVnCoV 12 µg vaccine on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
89674680|NCT05079464|Other|Exercise primed Sham stimulation|Individuals randomized to this group will receive exercise at University Health Network-Toronto Rehabilitation Institute followed by sham tDCS.
89674681|NCT05079464|Other|Treatment as usual (exercise education) & tDCS|Individuals randomized to this group will receive routine advice about physical activity, and active tDCS.
89674682|NCT05079464|Other|Treatment as usual (exercise education) & sham stimulation|Individuals randomized to this group will receive routine advice about physical activity, and sham tDCS.
89674683|NCT05060783||Renal Call Carcinoma|Patrients with renal cancer
89674684|NCT05060783||Oncocytoma|Patients with oncocytoma
89674685|NCT05060783||Healthy persons|Patients with CT scan shows no renal cancer
89674686|NCT05054530|Experimental|GMA106|9 different dosages will be subcutaneously injected into the abdomen.
89674687|NCT05054530|Placebo Comparator|Matching placebo|9 different dosages will be subcutaneously injected into the abdomen.
89674688|NCT05040178||Male and Female Adult and Pediatric Participants|Patients treated with Carbaglu for the treatment for hyperammonemia due to Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
89674689|NCT05035459||Conventional heart failure management group|Patients with ≥ 3 B-lines will be divided into the conventional heart failure management group and the LUS-BL-guided intensive heart failure management group at 1:1 ratio. Patients in the conventional heart failure management group will receive conventional guideline recommended HF therapy post discharge and be followed up at 2-month interval post discharge by clinical visit. LUS-BL will be assessed at 2-month interval post discharge also in this group, but results will be enveloped.
89674690|NCT05035459||LU-BL guided intensive heart failure management group|The group with ≥ 3 B-lines will be divided into the conventional heart failure management group and the LUS-BL-guided intensive heart failure management group at 1:1 ratio. Patients in the LUS-BL-guided intensive heart failure management group will receive optimized HF medication and medication will be adjusted according the status of LUS-BL during the follow-up at 2-month interval.
89674691|NCT05008926|Experimental|Naloxegol|"Administration of Naloxegol 25 mg per day by nasogastric tube (NG) or orogastric tube (OG). The administration should be started within the first 24 hours after the patient is admitted to intensive care unit and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.~Management of constipation and gastroparesis according to the recommendations."
89674692|NCT05008926|Placebo Comparator|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
89674693|NCT05008224|Experimental|Pembrolizumab Monotherapy + Chemotherapy + Pembrolizumab Consolidation|"Participants receive pembrolizumab monotherapy followed by chemotherapy with doxorubicin in combination with vinblastine & dacarbazine (AVD) or chemotherapy with escalated bleomycin in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, & prednisone (escBEACOPP) followed by pembrolizumab consolidation.~All participants receive pembrolizumab monotherapy intravenous (IV) for 3 cycles (cycle length = 3 weeks (wks); up to 9 wks). All participants receive AVD IV for 2 cycles (cycle length = 4 wks; up to 8 wks) after Positron Emission Tomography (PET) 2. Participants who are PET 3 -ve, or +ve & age ≥ 60 years, receive up to 4 additional cycles of AVD IV (cycle length = 4 wks, up to 16 wks), or up to 4 cycles of escBEACOPP IV if PET 3 +ve, age <60 years; cycle length = 3 wks; up to 12 wks. All participants receive pembrolizumab consolidation IV for 4 cycles (cycle length = 6 wks; up to 24 wks). Total treatment duration is up to 57 wks."
89674694|NCT05005130|Experimental|Cluster 1 (George)|3 months without TASKPEN (Standard of Care) and 6 months with TASKPEN.
89674695|NCT05005130|Experimental|Cluster 2 (Chilengi)|6 months without TASKPEN (Standard of Care) and 3 months with TASKPEN
89674696|NCT04986956|Placebo Comparator|Placebo|The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.
89674697|NCT04986956|Active Comparator|Whole coffee cherry extract|Whole coffee cherry extract (WCCE; otherwise known as the generally-recognized-as-safe (GRAS) supplement Neurofactor(TM)), is a proprietary, safe, powdered extract of whole coffee cherries from coffea arabica with high levels of polyphenols and substantially low (<2%; <4mg) levels of caffeine. The only content of the supplement is WCCE - there are no excipients, binders, or flow agents, nor are there any other materials. The coffee cherry is subjected to a food-grade water ethanol extraction; thus, after extraction, only 100% coffee-based components remain. 200mg of WCCE will be administered daily for 28 days.
88995883|NCT00533026|Active Comparator|A|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60mg QD, PO for the 14 days. Duloxetine doses were tapered, subjects received 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
88995884|NCT00533026|Active Comparator|B|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60 mg QD, PO for 4 days followed by duloxetine 120 mg QD, PO for 10 days. Duloxetine doses were tapered, subjects received 60mg QD, PO for 4 days followed by 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
88995885|NCT00152126|Other|1|
88995886|NCT05043883|Experimental|Single Group|Index EP Procedure: Ablation of atrial fibrillation
88995887|NCT05039593|Experimental|first group|The patients in the first group will be given oral care with 0.12% chlorhexidine twice a day.
88995888|NCT05039593|Experimental|second group|The patients in the second group will be given oral care with 0.12% chlorhexidine 3 times a day.
88995889|NCT05039593|Experimental|third group|The patients in the third group will be given oral care with 0.12% chlorhexidine 4 times a day.
88995890|NCT00425451|Experimental|PerioChip Plus|
88995891|NCT00425451|Experimental|Flurbiprofen Chip|
88995892|NCT00425451|Active Comparator|PerioChip|
88995893|NCT00425451|Placebo Comparator|Placebo Chip|
88995894|NCT05001451|Experimental|GDX012 Suspension for IV Infusion|Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells
88995895|NCT00152204|Experimental|1|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
88995896|NCT00152204|No Intervention|2|
89049949|NCT04652102|Placebo Comparator|Randomized Observer-blinded Phase 3: Placebo|Participants will be administered the matching placebo on Day 1 and Day 29 in the deltoid area, preferably in the non-dominant arm.
89674698|NCT04975503||Young Women|Young women, aged 18 to 50 years, with documented atherosclerotic cardiovascular disease
89674699|NCT04975503||Older Women|Older women, aged >50 years, with documented atherosclerotic cardiovascular disease
89674700|NCT04974099|Experimental|RoadMAB dashboard system|The intervention includes utilizing Clinical and Patient Decision Support Software (RoadMABTM) that will guide the selection of the first infliximab dose followed by subsequent infliximab dose and dosing interval during the maintenance phase. During induction, three infusions will occur at 0, 2 and 6 weeks, respectively. The RoadMABTM dashboard will utilize PK modeling software to provide an infliximab starting dose recommendation (range of 5-12 mg/kg) based on the patients biochemical profile. As noted, dosing frequency (weeks) during induction will not be altered during this study. Following the first three doses, the clinician will be informed of their patients PK profile within the RoadMABTM program and with a shared document (paper). RoadMABTM will provide additional dosing recommendations after each infusion (based on the latest drug concentration measures and blood biomarkers) with the final dose and interval selected by the treating physician.
89674701|NCT04972292|Experimental|Group 1: FDC of codeine 30 mg/dipyrone 500 mg from Eurofarma Laboratórios SA|Subjects randomized to this group will receive one (1) experimental drug tablet + one (1) Tylex® placebo tablet when the postoperative pain becomes moderate to intense (≥ 40 mm at a VAS of 0-100 mm). Then, subjects will be instructed to use the study treatment whenever it is necessary for pain relief, respecting a minimal interval of six (6) hours between two administrations, for up to 3 days (72 hours after the initial dose).
89674702|NCT04972292|Active Comparator|Group 2: Tylex® (codeine 30 mg/paracetamol 500 mg)|Subjects randomized to this group will receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet when the postoperative pain becomes moderate to intense (≥ 40 mm at a VAS of 0-100 mm). Then, subjects will be instructed to use the study treatment whenever it is necessary for pain relief, respecting a minimal interval of six (6) hours between two administrations, for up to 3 days (72 hours after the initial dose).
89674703|NCT04968509|Experimental|Treatment with PCSK9 inhibitors and conventional lipid-lowering therapy based on statins|Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
89674704|NCT04968509|Other|Treatment with only conventional lipid-lowering therapy based on statins|Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
89674705|NCT04968119|Experimental|Arm A (telehealth intervention)|Patients participate in telehealth exercise sessions at home over 30 minutes with a trainer 3 days a week for 8 weeks (24 total sessions).
89674706|NCT04968119|Active Comparator|Arm B (delayed exercise intervention)|Patients maintain their normal activities of daily living for 8 weeks before participating in the telehealth exercise program as described in Arm I.
89674707|NCT04964960|Experimental|Pembrolizumab with standard of care chemotherapy treatment|Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).
89674708|NCT04962373||Adolescents|Adolescents with a contract for Brief admission by self-referral
89674709|NCT04962373||Parents|Parents to adolescents with a contract for Brief admission by self-referral
89674710|NCT04962373||Staff|Health care providers who work with adolescents with a contract for Brief admission by self-referral
89674711|NCT04952480|Experimental|Dose-escalated adaptive chemoradiotherapy|Concurrent with standard of care platinum doublet based chemotherapy (cisplatin + etoposide), radiation treatment plan will be delivered in three sequential phases with two scheduled replans during the treatment along with scaled dose limits for organs-at-risk: Phase 1 dose prescription = 14 Gy in 7 fractions; Phase 2 dose prescription = 10 Gy in 5 fractions starting the day after the final (7th) fraction is delivered; Phase 3 dose prescription = either a) 70 Gy in 35 fractions, or if this cannot be safely reached without exceeding the dose limit of an organ-at-risk, b) the maximum safe prescribe-able dose tolerance specified in the protocol. Either 3D conformal radiotherapy or IMRT planning and delivery techniques will be employed, including contouring relevant thoracic organs-at-risk. All CT simulation scans will be without contrast.
89674712|NCT04927923|Active Comparator|hope-focused motivational interview-experimental group|"Volunteering to participate in research~Being over the age of 18~Being able to read and write"
89674713|NCT04927923|No Intervention|control group|"Volunteering to participate in research~Being over the age of 18~Being able to read and write"
88815769|NCT02174510|Experimental|40mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
88815770|NCT02174510|Experimental|80mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
88815771|NCT01113008|Experimental|Remote postcondtioning|Patients assigned to remote ischemic postconditioning (randomized controlled trial)
88815772|NCT01113008|Placebo Comparator|Control group|
88815773|NCT00585195|Experimental|1|
88815774|NCT01113398|Experimental|AMG 102 with Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg prior to AMG 102, which will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg. Subjects will receive infusions every 2 weeks.
88815775|NCT03013556|Active Comparator|Group A,TDF|The subjects in group A will be treated by TDF for 96 weeks
88815776|NCT03013556|Experimental|Group B,TDF+PEG|The subjects in group B will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
88815777|NCT03013556|Experimental|Group C,TDF+PEG|The subjects in group C will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks
88815778|NCT01113632|Experimental|Ofatumumab 1000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 1000mg weekly for a total of 8 weeks
88815779|NCT01113632|Experimental|Ofatumumab 2000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 2000mg weekly for a total of 8 weeks
89674714|NCT04925986|Experimental|Group 1A: PD-L1 1-49%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
89674715|NCT04925986|Experimental|Group 1B: PD-L1 1-49%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) 1-49% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
89674716|NCT04925986|Experimental|Group 2A: PD-L1 ≥ 50%, Main Study Population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily, beginning on cycle 1 day 1 (C1D1).
89674717|NCT04925986|Experimental|Group 2B: PD-L1 ≥ 50%, Pembrolizumab run-in population|Participants with PD-L1 Tumor Proportion Score (TPS) ≥ 50% receive Pembrolizumab 200mg intravenous (IV) for one dose alone, beginning on cycle 1 day 1 (C1D1). On Cycle 2 Day 1 (C2D1), participants receive Pembrolizumab 200mg intravenous (IV) once every 3 weeks (Q3w) and Sitravatinib 100mg PO (by mouth) daily.
89674718|NCT04917575|Experimental|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing, risk assessment tool, and HIV and pre-exposure prophylaxis (PrEP) locators embedded within the game.
89674719|NCT04917575|Active Comparator|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
89674720|NCT04914338|Experimental|Supportive care (MDT-intervention)|Patients participate in the MDT-intervention including access to a HCT physician, a geriatrician, physical or occupational therapist, dietician, and a social worker for three months before HCT and up to 100 days after HCT.
89674721|NCT04910815|Experimental|Primary recruitment|Capsules will be ingested within 30 minutes prior to endoscopy pre- and post-antimicrobial intervention (if the patients has had a treatment) to determine if it can be used to identify increased microbial load through gas detection, and to identify responders to therapy.
89688746|NCT03034837|Experimental|ART sealant|"Sealing pit and fissures of the included permanent first molars using 3M ESPE KetacTM Molar Easymix glass ionomer cement material once at the baseline of the study."
89049950|NCT04652102|Experimental|Open-label Phase|"After unblinding, the trial will shift from a randomized observer-blinded to an open-label design, and the following cohorts will be defined:~Cohort A: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to receive an authorized/licensed vaccine for preventing COVID-19 (AV) as standard of care through their national vaccination program.~Cohort B: participants who received at least 1 dose of CVnCoV in the randomized observer-blinded phases and choose to remain in the trial without receiving any AV.~Participants on the placebo arm will be withdrawn."
89049951|NCT00563472|Active Comparator|1|10 mg estetrol
89049952|NCT00563472|Active Comparator|2|20 mg estetrol
89049953|NCT00563472|Active Comparator|3|20 mg estetrol and 150 microg desogestrel
89049954|NCT00563472|Active Comparator|4|20 mg E4 and 200 mg progesterone
89049955|NCT04679597||total neoadjuvant therapy|Total neoadjuvant therapy consisted of 12 weeks of induction chemotherapy with CAPOX or FOLFOX, chemoradiotherapy with capecitabine and six to eight weeks of consolidation chemotherapy with CAPOX or FOLFOX prior to surgery.
89049956|NCT04679597||standard therapy|Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)
89049957|NCT04613856|Active Comparator|Current Best Practice - 237 mL water bolus|
89049958|NCT04613856|Experimental|New Intervention - 500 mL water bolus|
89049959|NCT04609397|Experimental|Hemay005 high dose group|In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.
89049960|NCT04609397|Experimental|Hemay005 lower dose group|In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.
89049961|NCT04609397|Placebo Comparator|Placebo|In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.
89049962|NCT04613193|Active Comparator|Strict BP intervention group|SBP < 120 mmHg and a reduction in SBP of >= 15 mmHg
89049963|NCT04613193|Other|Conventional BP control group|In patients < 75 years: SBP = 135 mmHg In patients >/= 75 years: SBP = 145 mmHg
89049964|NCT04613310|Other|Saliva and nasopharyngeal swabs|One patient will have 4 swabs taken, 2 saliva for PCR and RDT, 2 nasopharyngeal for PCR and RDT
89049965|NCT04578080|Experimental|Anodal-tDCS & PT|"Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area (M1) of affected hemisphere, Cathodal on the supraorbital area of unaffected hemisphere.~Current intensity is fixed at 1.5 mA and current will flow continuously. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity."
89049966|NCT04578080|Active Comparator|Sham-tDCS & PT|Anodal transcranial direct current stimulation (tDCS) will be applied for 20 mins before conventional physical therapy (about 1 hours). Anodal on the motor area of affected hemisphere, Cathodal on the supraorbital area of affected hemisphere. Physical therapist will give an intervention program base on the same basic conventional physical therapy treatment. The scope of intervention is administered to improve motor functions and brain activity.
89049967|NCT04612998|Sham Comparator|Comparator group|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
89049968|NCT04612998|Active Comparator|Active control group|Active control group consisted of patients performing CSEA in the sitting position.
89049969|NCT04545476|Experimental|APIS Biomaterial on the Head|Participants in this group will receive the experimental APIS Biomaterial on the Head. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
88995897|NCT04686877|Experimental|STAPLE group|For patients in STAPLE group, intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided aspiration followed by urokinase clot irrigation (every 12 h for up to 5 days or until reduction of ICH to ≤10 mL). CT will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset. On the 1st, 3rd, 5th, and 7th day of post-operation, patients will be re-examined using CT. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
88995898|NCT04686877|No Intervention|Conservative treatment group|We used the 2015 ASA/AHA and 2020 Chinese multidisciplinary expert consensus recommendations for treatment of spontaneous intracerebral hemorrhage, including a standard approach to monitoring patients' airways, ventilation, intracranial pressure, sedation, and pharmacological treatment of intracranial mass effect. Patients allocated to the standard medical care group had follow-up CT scans and other monitoring assessments on the same schedule as those in the STAPLE group. Conventional craniotomy and hematoma evacuation can be performed when cerebral hernia or rebleeding happened.
88995899|NCT00152243|Experimental|1|UFT (uracil, tegafur)
88995900|NCT00152243|Other|2|Surgery alone
88995901|NCT00172107|Placebo Comparator|1|Placebo drug injectable subcutaneously
89674722|NCT04910815|Active Comparator|Active SIBO Arm - Rifaximin|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of Rifaximin (550g) 1 capsule twice a day for 14 days. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
89674723|NCT04910815|Placebo Comparator|Active SIBO Arm - Placebo|"If increased microbial load is determined through culture of aspiration during initial endoscopic procedure, randomised administration of placebo capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch. The post-antimicrobial endoscopic procedure will be conducted at 6 weeks post the start of treatment.~These hydrogen concentration results will be compared to the following conventional breath tests in a crossover study design. Immediately after the endoscopic procedure, the patient will undergo a FOS challenge recording hydrogen breath samples for 2 hours in 20 min intervals while they recover from the endoscopic procedure. A standard Glucose breath test will be performed by the patients at home not earlier that 8 hours after the endoscopic procedure."
88995902|NCT00172107|Experimental|2|50 mcg PTH(1-84)
89215048|NCT05086250|Experimental|Arm A: Ketamine Followed by Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
89215049|NCT05086250|Experimental|Arm B: Placebo Followed by Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
89215050|NCT05083923|Experimental|Diroximel Fumarate (DRF)|Japanese and Chinese participants will initiate treatment with DRF 231 milligrams (mg), oral capsule, twice daily on Day 1 through Day 7, followed by DRF 462 mg, oral capsules, twice daily from Day 8 up to Week 48.
89674724|NCT04905797||Deliberate self-harm|Individuals with psychiatric disorders and persistent DSH
89674725|NCT04905797||Clinical cases who ceased self-harm|Individuals with psychiatric disorders who have ceased DSH
89674726|NCT04905797||Clinical cases with no self-harm|Individuals with psychiatric disorders who never had DSH
89674727|NCT04905797||Healthy controls|Healthy controls who never had DSH
89674728|NCT04897438|Experimental|Intervention|Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. If absolute levels of dd-cfDNA are > 50 copies/ml, the patients receive a kidney allograft biopsy. Additionally, kidney allograft biopsies are performed according to standard of care as determined by the treating physicians.
89674729|NCT04897438|No Intervention|Control|Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. These measurements are not used to guide kidney allograft biopsies. Those are performed according to standard of care as determined by the treating physicians.
89674730|NCT04893317|Experimental|Ablation in the ventricle with the Adagio VT cryoablation system|all study subjects will receive an ablation procedure using the Adagio Medical VT Cryoablation System
89674731|NCT04886479|Experimental|Daily Disposable Silicone Hydrogel Contact Lens Wearers|Participants wore Test Lens for 3 hours
89674732|NCT04886479|Experimental|Daily Disposable Hydrogel Contact Lens Wearers|Participants wore Test Lens for 3 hours
89674733|NCT04886479|Active Comparator|Non-lens Wearers|Participants did not receive Test Lens
89674734|NCT04883060|Experimental|Intervention|Patients undergoing ventriculoperitoneal surgery where the midline localizer was used
88995903|NCT00172107|Experimental|3|75mcg PTH(1-84)
88995904|NCT00172107|Experimental|4|100 mcg PTH(1-84)
88995905|NCT04945837|Other|unique study arm|Initial socio-demographic questionnaire 5 timepoints psychologic and self-administered questionnaires
88995906|NCT04686955|Experimental|Group A|Group A will receive Xiao-Xian-Gui-Fu-Tang three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 6 weeks. Post-follow-up will be 4 weeks later.
88995907|NCT04686955|Placebo Comparator|Group B|Group B will receive a placebo three times per day for 6 weeks, then entry 2 weeks wash-out period. Then switch to receive the Xiao-Xian-Gui-Fu-Tang for another 6 weeks. Post-follow-up will be 4 weeks later.
88995908|NCT00152282|Experimental|1|
88995909|NCT00152282|Experimental|2|
88995910|NCT00152282|Experimental|3|
88995911|NCT00152282|Placebo Comparator|4|
88995912|NCT04916041||Vivity|Patients who have undergone bilateral implantation of Vivity intraocular lens
88995913|NCT04916041||Eyhance|Patients who have received bilateral implantation of an Eyhance intraocular lens
89688747|NCT03034759|Experimental|All participants|+Pediatric patients with T1D. All comparisons will be made within group pre and post intervention.
89674735|NCT04880382|Other|Standard Arm A: treatment by ICI will be continued|After achieving objective response between 6 and 12 months after treatment onset, for these patients ICI treament will continue as per market authorization
89674736|NCT04880382|Experimental|Experimental Arm B: treatment by ICI will be discontinued|After achieving objective response between 6 and 12 months after treatment onset, for these patients first-line or second line regimen should be discontinued. Patients will be followed as per standard management.
89674737|NCT04875195|Experimental|Arm 1|Pembrolizumab (MK-3475), 400 mg, Q6W, intravenous (IV) infusion, Day 1 then Q6W up to 18 doses.
89674738|NCT04870671|Experimental|High Adherence|TDF/FTC (300/200 mg), 7 pills/week. Total of 14 pills
89674739|NCT04870671|Experimental|Low Adherence|TDF/FTC (300/2200 mg), 3 pills/week. Total of 6 pills
89674740|NCT04849741|Experimental|zilganersen|Zilganersen will be administered by intrathecal bolus (ITB) injection once every 12 weeks through Week 49. The 60-week double-blind treatment period will be followed by the open-label and long-term extension periods, where participants will receive zilganersen by ITB injection from Week 61 to Week 229.
89674741|NCT04849741|Placebo Comparator|Placebo|Matching placebo will be administered by ITB injection once every 12 weeks through Week 49. It will be followed by the open-label and long-term extension periods, where participants will receive zilganersen by ITB injection from Week 61 to Week 229.
89674742|NCT04847063|Experimental|1/ HIPEC: Oxaliplatin Randomized treatment assignment|HIPEC with intraperitoneal oxaliplatin and IV 5-FU, randomly assigned
89674743|NCT04847063|Experimental|2/ HIPEC: Mitomycin C Randomized treatment assignment|HIPEC with intraperitoneal mitomycin C, randomly assigned
89674744|NCT04847063|Experimental|3/ HIPEC: Cisplatin, Doxorubicin Randomized treatment assignme|HIPEC with intraperitoneal cisplatin and doxorubicin, in addition to IV sodium thiosulfate, randomly assigned
89674745|NCT04847063|Experimental|4/ HIPEC: Cisplatin, Mitomycin C Randomized treatment assignme|HIPEC with intraperitoneal cisplatin and mitomycin C, in addition to IV sodium thiosulfate, randomly assigned
89674746|NCT04841226|Active Comparator|Silq ClearTract™ 100% Silicone 2-Way Foley Catheter|Up to 82 subjects
88995914|NCT04916041||EMV|Patients who have undergone bilateral implantation of Vivity intraocular lens
88995915|NCT04916041||Panoptix|Patients who have undergone bilateral implantation of Panoptix intraocular lens
88995916|NCT04916041||Rayner Trifocal|Patients who have undergone bilateral implantation of Rayner trifocal intraocular lens
89674747|NCT04841226|Active Comparator|Silver-coated Latex 2-Way Foley Catheter|Up to 82 subjects
89674748|NCT04841226|Active Comparator|Silicone-coated Latex 2-Way Foley catheter|Up to 82 subjects
89674749|NCT04837001|Experimental|FDY-5301|FDY-5301 will be administered as a single IV bolus injection.
89674750|NCT04837001|Placebo Comparator|Placebo|Placebo (normal saline) will be administered as a single IV bolus injection.
89674751|NCT04804189|No Intervention|Control Group|Up to 30 4-H Shooting Sport Clubs that will not receive Guardians 4 Health intervention.
88995917|NCT00152321|Experimental|A|Multifaceted intervention
88995918|NCT00152321|Active Comparator|B|Usual Care
88995919|NCT04914364||Patients who have tested positive for COVID-19|"Patients who are designated as COVID recovered in the electronic medical record and who fit the inclusion criteria."
88995920|NCT00164853|Active Comparator|Standard sphincterotomy (ES)|After deep cannulation, a pull-type sphincterotomy will be performed with a 25mm sphincterotome (eg clever cut, Olympus, Tokyo, Japan) with division of sphincter up to the duodenal wall. A complete sphincterotomy is defined by the free passage of a fully bowed sphincterotome with a 25m wire and spontaneous bile drainage.
88995921|NCT00164853|Active Comparator|Sphincterotomy plus balloon dilation (ESBD)|After complete sphincterotomy, a 3-cm long 15mm diameter CRE balloon is passed over a guidewire across the lower end of common bile duct. The contrast filled balloon is inflated to the size of the bile duct for around 30 seconds until waisting is abolished.
88995922|NCT04687150|Active Comparator|The study group|The study group with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit
89674752|NCT04804189|Experimental|Intervention Group|Up to 30 Randomized 4-H Shooting Sport Clubs that will receive Guardians 4 Health intervention.
89674753|NCT04788576||Patients with heart failure with preserved ejection fraction (HFpEF)|Subject with preserved ejection fraction (ejection fraction > 50%) and with dyspnea on exertion (NYHA Grade 2 or more) and diagnosed as HFpEF using HFA-PEFF scoring system (HFA-PEFF ≥5 or 2-4 with abnormal stress test or invasive hemodynamic test)
89674754|NCT04770623|Experimental|Chemotherapy|"Second line treatment will be as follows~Docetaxel at 30 mg/m2 over 500 cc normal saline over 1 hour infusion~Irinotecan at 185 mg/m2 with a maximum of 300 mg given over 500 cc normal saline over 2 hours infusion~The whole regimen is to be cycled every 2 weeks for a maximum of 6 months with interim and end of treatment evaluation"
89674755|NCT04765514|Active Comparator|Standard Arm: TMZ with concurrent RT (combined modality arm)|"Patients will receive a total of 21 days of Temozolomide (TMZ), with 15 days of TMZ administered daily with concurrent RT. TMZ will be delivered at a dose of 75 mg/m2, given daily with RT for 15 days, one hour before each session of RT.~After a 4-week break, patients will receive six cycles of adjuvant TMZ according to the standard 5-day schedule (days 1-5) every 28 days, up to 6 cycles as tolerated by the patient. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events, intractable nausea or fatigue."
89674756|NCT04765514|Experimental|Biomarker based treatment|"MGMT (+) Temozolomide monotherapy: Patients will receive Temozolomide (TMZ) at a dose of 75 mg/m2 daily for 21 consecutive days. This will be followed by six cycles of TMZ according to the standard 5-day schedule (days 1-5) every 28 days. The dose will be 150 mg/m2 for the first cycle and increased to 200 mg/m2 beginning with the second cycle, so long as there are no hematologic adverse events. Dose will be determined using body surface area (BSA) calculation.~MGMT methylation (-) RT monotherapy: Participants will receive radiation treatment with 40Gy / 15 fractions over a period of 21 days (3 weeks)."
89674757|NCT04760769|Experimental|Tavapadon|Participants will receive a Tavapadon tablet at a dose of 5 milligrams (mg) to 15 mg once daily (QD) orally during 58-week treatment period.
89674758|NCT04753697|Experimental|Administration of CC-93538|CC-93538 360 mg Subcutaneously (SC) once weekly for 24 weeks followed by CC-93538 360 mg SC once weekly for 24 weeks
89674759|NCT04753697|Experimental|Administration of CC-93538 and Placebo|"CC-93538 360 mg SC once weekly for 24 weeks followed by CC-93538 360 mg SC once every other week for 24 weeks.~During the Maintenance Phase, matching placebo will be administered once every other week on alternate weeks to maintain the blind."
89674760|NCT04753697|Placebo Comparator|Administration of Placebo|Matching placebo SC once weekly for 24 weeks followed by matching placebo SC once weekly for 24 weeks
89674761|NCT04752657|Experimental|Experimental Group|The experimental group will receive the physical function survey at weeks 2, 10, 18, and 26; the physical activity survey at weeks 2, 14, and 26; the events survey at weeks 2, 6, 10, 14, 18, 22, and 26. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
89674762|NCT04752657|Active Comparator|Control Group|The control group will receive the physical function survey at weeks 0, 8, 16, and 24; the physical activity survey at weeks 0, 12, and 24; the events survey at weeks 0, 4, 8, 12, 16, 20, and 24. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
89215051|NCT05044832|Experimental|Personalized Music|Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit in addition to standard care.
89674763|NCT04745962||Procedural group|
89674764|NCT04740775|Experimental|LiquiBand Exceed|Surgical wound closure using the LiquiBand Exceed Topical Skin Adhesive
89674765|NCT04740775|Experimental|Liquiband Rapid|Surgical wound closure using the LiquiBand Rapid Topical Skin Adhesive
89674766|NCT04738825|No Intervention|Treatment as Usual (TAU)|Participants randomized to TAU will receive a health handout on HIV risk reduction approaches, including PrEP and OUD-related care, and where to access such services. They will receive standard care as provided by the community-based organization and by their medical provider.
89674767|NCT04738825|Experimental|Contingency Management with stepped care to PrEP Adherence and Support Services (CoMPASS)|"Participants randomized to Compass will also receive a health handout on HIV risk reduction approaches. They will also receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12, will be stepped up to receive PrEP adherence and support services (n=5)."
89674768|NCT04738474|Experimental|PRISM Intervention|Subjects in this group will receive the PRISM intervention
89674769|NCT04738474|Placebo Comparator|Usual Care|Subjects in this arm will receive usual care
89674770|NCT04725422||disease modifying anti-rheumatic drug, DMARD|"Methotrexate 1 mg/kg (max 25 mg) PO or SQ weekly~Sulfasalazine 30 mg/kg (max 1000 mg) PO twice daily~Leflunomide 10-20 mg PO daily"
88995923|NCT04687150|Placebo Comparator|The control group|The control group will be given colored water at same timepoints
88995924|NCT00152360|Experimental|Xenical (Orlistat)|Investigating the effectiveness of Xenical on cardiovascular risk factors in the patients of St. Paul's Hospital Lipid Clinic
88995925|NCT00533104|Experimental|BM-MNC|Patients are implanted with bone marrow - mononuclear cells
88995926|NCT00533104|Experimental|PB-MNC|Patients are implanted with peripheral blood - mononuclear cells
88995927|NCT00533143|Experimental|2|Non-invasive ventilation
88995928|NCT04686994|Experimental|ASC41|ASC41 two tablets, once daily, from Day 1 to Day 28.
88995929|NCT04686994|Placebo Comparator|ASC41 placebo|ASC41 placebo two tablets, once daily, from Day 1 to Day 28.
88995930|NCT02938117|Experimental|CON : concentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
88995931|NCT02938117|Experimental|EXC : eccentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
88995932|NCT02277145|Experimental|treatment group|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions
88995933|NCT00172224||osteoporosis|
89674771|NCT04725422||tumor necrosis factor inhibitor, TNFi|"Adalimumab (subcutaneous) 10-40 mg SQ every other week~Etanercept (subcutaneous) 12.5-50 mg SQ every week~Infliximab (intravenous) 10 mg/kg (max 1000 mg) i.v. at week 0,2, 6 then every 4 weeks~Golimumab (subcutaneous or intravenous) 2 mg/kg (max 200 mg) at every 4 weeks"
88995934|NCT02938078|Experimental|Treatment Eye|One eye will be treated with Avenova; the other eye will not be treated. The investigator is masked as to which eye is receiving Avenova product.
88995935|NCT02938078|No Intervention|Non-Treatment Eye|One eye will be treated with Avenova; the other eye will not will be treated. The investigator is masked as to which eye is receiving Avenova product.
88995936|NCT02938039|Active Comparator|Ambu LMA|Ambu Laryngeal Mask Airway device of different sizes for age
88995937|NCT02938039|Active Comparator|I-Gel LMA|I-Gel Laryngeal Mask Airway device of different sizes for age
88995938|NCT02938234|Experimental|Single-arm study|High caloric, high protein ONS, single dose of 400 kcal/day for 7 consecutive days, oral administration
88995939|NCT02938000|Experimental|Theraband group|This group will be furnished with Thera-band, and link to exercise video, with plans for regular exercise as described previously, in addition to usual post stroke care.
88995940|NCT02938000|Placebo Comparator|Usual Care Group|This group will have usual post stroke care, and will be advised to get regular exercise.
88995941|NCT00152438|Experimental|1|Oral micronized progesterone
88995942|NCT00152438|Placebo Comparator|2|Placebo
88995943|NCT02937961|Experimental|Early SLED|
88995944|NCT02937961|Active Comparator|Late SLED|
88995945|NCT02937649|Experimental|Laparoscopic sleeve gastrectomy using 48-Fr bougie|Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie
88995946|NCT02937649|Active Comparator|Laparoscopic sleeve gastrectomy using standard care bougie|Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)
88995947|NCT02937922|Active Comparator|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
89215052|NCT05044832|No Intervention|Standard of Care|Those assigned to the Standard of Care arm will only receive standard of care in the preoperative holding area as well as in the post-operative care unit
89215053|NCT05036629|Experimental|MRI protocol|Feasibility and use of methods developed in clinical research protocols or cognitive: the reproducibility of the parameters of acquisition, of the design of the activation paradigms development and results according to people will be an important element for the future integration of these methods in clinical or cognitive research protocols.
89215054|NCT05035511|Experimental|Responders vs Non-responders|After the tDCS outcome recorded immediately after tDCS treatment, participants will be categorized into responders and non-responders based on the percentage of change in the total SRS score (primary outcome). Participants that show reductions of at least 10% in the total SRS scores as compared to baseline scores will be considered responders.
89215055|NCT05030493||Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
89674772|NCT04725422||bisphosphonate|"Pamidronate 1 mg/kg (max 90 mg) (intravenous)*:~Option 1: every month Option 2: 3 consecutive days every 3 months~Zoledronic acid 0.0125-0.05 mg/kg (max 4mg) (intravenous): every 3-6 months. * Both options may use lower dose of 0.5 mg/kg at the initiation of the treatment. All options allow concurrent use of NSAIDs."
89674773|NCT04725422||non-steroidal anti-inflammatory drugs|"Naproxen 10 mg/kg (max 500 mg) PO twice daily~Indomethacin 1 mg/kg (max daily dose 150 mg) PO twice or three times daily~Meloxicam 0.1-0.3 mg/kg (max 15 mg) PO daily~Piroxicam 10-20 mg PO daily~Ibuprofen 10 mg/kg (max 800 mg) PO 3-4 times daily"
89674774|NCT04720131|Experimental|Camrelizumab combined with Apatinib and Capecitabine|Camrelizumab was administered 200mg iv every 3 weeks. Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle) Apatinib:A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle). The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group. The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
89674775|NCT04713228|Experimental|Pregnant with Pre-eclampsia|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
89674776|NCT04713228|Experimental|Pregnant with gestational hypertension|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
89674777|NCT04713228|Active Comparator|Pregnant without Hypertension - Control|There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit is not applicable to the control group.
89674778|NCT04710550|Experimental|Safety/Dosimetry Cohort|
89674779|NCT04710550|Experimental|Traumatic Brain Injury|
89215056|NCT05030493||Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg mFOLFOX6 + bevacizumab combination therapy, once every two weeks
89674780|NCT04710550|Experimental|AD/MCI|
89674781|NCT04710550|Active Comparator|Healthy Controls|
89674782|NCT04707261|Experimental|Dapagliflozin|Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT
89674783|NCT04707261|Placebo Comparator|Placebo|Standard-of-care therapies for heart failure, including sacubitril/valsartan or ACEI/ARB, beta-blocker, MRA, ICD and CRT
89674784|NCT04705779|Experimental|HARMONY|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
89674785|NCT04705779|Active Comparator|Nutrition and Exercise Education Workgroup (NEEW)|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
89674786|NCT04701762|Experimental|videolaryngoscopy|Initial intubation performed using GlideScope videolaryngoscope.
89674787|NCT04701762|Active Comparator|conventional direct laryngoscopy|Initial intubation performed using direct laryngoscopy.
89688748|NCT02158273|Active Comparator|TRICOR (fenofibrate)|
89215057|NCT05026814||Women with FGM/C|Women who requested clitoral reconstruction after FGM/C between 01/2013 until 04/2021 and underwent multidisciplinary care consisting of psychosexual care (PC) with or without CR. To be included the women had to attend at least one session with the psychologist as part of psychosexual care.
89215058|NCT05023382||Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily.
89215059|NCT05018247|Active Comparator|Urgent revascularization with Optimal Medical Therapy|Revascularization will be performed via either Percutaneous Coronary Intervention or Coronary Artery Bypass Graft, and the selection of the specific procedure will be at the discretion of the patient and their physician(s). Patients will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
89674788|NCT04684966|Experimental|Experimental group (EG)|"Randomized intervention in the NMES (GE) group:~Patients in the NMES group will receive, in addition to conventional rehabilitation, combined quadriceps femoris and triceps surae NMES.~Detail of the NMES :~Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (possibility of 16 electrodes).~One device per lower limb of each patient is necessary: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.~Stimulation frequency: 50hz.~Pulse duration: 400 μs.~Contraction time: 6 seconds.~Rest time: 6 seconds.~The intensity must generate a visible muscular contraction and must be well supported. by the patient.~The voluntary contraction accompanies the electrical stimulation.~Surface electrode 50 × 50 mm."
89674789|NCT04684966|Sham Comparator|Control group (CG)|"Patients in the control group (GC) will receive, in addition to the classical rehabilitation, the combined sham NMES of the quadriceps femoris and triceps surae.~Detail of the NMES :~It is carried out 5 times a week for 4 weeks, supervised by a physiotherapist.~The device used will be the same as in the EG group.~Stimulation is performed in a semi-seated position, biphasic current, 8 channels in total (16 electrodes can be used).~One device per lower limb of each patient is required: 4 electrodes are placed on the quadriceps and 4 electrodes on the triceps, on each lower limb.~Stimulation frequency: 5hz.~Pulse duration: 100 μs.~Contraction time: 6 seconds.~Rest time: 6 seconds.~The intensity must generate a visible muscle contraction and must be well supported by the patient.~The voluntary contraction accompanies the electrical stimulation.~Surface electrode 50 × 50 mm."
89674790|NCT04665765|Experimental|Treatment (PolaR-ICE)|"SALVAGE THERAPY: Patients receive polatuzumab vedotin IV on day 1, rituximab IV on day 1, etoposide IV on days 1-3, carboplatin IV on day 2, and ifosfamide IV on day 2 or days 1-3. Treatment repeats every 21 days for up to 2-3 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response or stable disease by C2D15 may receive 1 additional cycle of PolaR-ICE IV.~CONSOLIDATION THERAPY: Within 30-60 days after ASCT, patients receive polatuzumab vedotin IV on day 1. Treatment repeats every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity."
89674791|NCT04663724|Experimental|Experimental Computer-Based Treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
89674792|NCT04663724|Active Comparator|Comparator Computer-Based Treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
89674793|NCT04657094|Experimental|Treatment (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with acalabrutinib may be continued beyond 12 cycles for a maximum of 36 cycles if, in the opinion of the treating physician, the patient might benefit from ongoing therapy.
89674794|NCT04655924|Experimental|Active Intervention|Intervention delivered to patients by digital health platform.
89674795|NCT04655924|Active Comparator|Active Control|Intervention delivered to patients by digital health platform.
89674796|NCT04655144|Experimental|Dexamethasone Arm|A total of 5mg dexamethasone will be administered into each uterine artery (10mg total) prior to uterine artery embolization.
89674797|NCT04655144|Placebo Comparator|Saline Arm|A volume of normal saline, equal to the total volume delivered in the Dexamethasone Arm, will be administered into each uterine artery prior to uterine artery embolization.
89674798|NCT04621825|Experimental|Assigned intervention|"ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam.~Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with ActivHeal Silicone PHMB Adhesive and Non Adhesive Foam."
89674799|NCT04609579|Experimental|SNX281 Monotherapy|"SNX281 will be administered weekly in Cycle 1 and then once every 3 weeks of each cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 66 participants will take part in this arm of the study.~Subjects enrolled in the dose expansion phase of this arm may be eligible to add pembrolizumab (KEYTRUDA®) to their SNX281 therapy following identification of the maximum tolerated dose (MTD) or optimal dose of SNX281 in combination with pembrolizumab (KEYTRUDA®). Subjects must, in the opinion of the Investigator, have demonstrated tolerance to SNX281 and have experienced sub-optimal response to therapy (i.e., disease stability for 4 cycles or progression on treatment with SNX281 at any time)."
89674800|NCT04609579|Experimental|SNX281 in Combination with pembrolizumab (KEYTRUDA®)|SNX281 will be administered in 3 of the 4 weeks in Cycle 1 and then once every 3 weeks of each cycle thereafter. Participants will also receive pembrolizumab (KEYTRUDA®) once every cycle for up to 6 cycles. The combination of SNX281 and pembrolizumab (KEYTRUDA®) will be given for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Participants who are, in the opinion of the investigators, benefitting from treatment may be allowed to continue treatment with SNX281 and pembrolizumab (KEYTRUDA®) (or SNX281 alone) beyond Cycle 6 with Sponsor approval. It is expected that up to approximately 68 participants will take part in this arm of the study.
89674801|NCT04605731|Experimental|Treatment (durvalumab, tremelimumab)|Patients undergo standard of care radioembolization with Yttrium-90 SIR-spheres intra-arterially over 60-90 minutes on day -14. Patients then receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on day 1. Cycles with durvalumab repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
89049970|NCT04545476|Experimental|APIS Biomaterial on the Lower Extremities|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities. One layer of APIS® will be applied to the post-operative wound covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape. The biomaterial will be reapplied if it is completely absorbed at follow up and the wound depth below the epithelial level.
89674802|NCT04594733|Active Comparator|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Participants will be randomized to 8 weeks of placebo, minimum 2 week washout period, and then 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily) followed by a final 2 week washout
89688749|NCT02158273|Placebo Comparator|Sugar Pill|
89049971|NCT04545476|Active Comparator|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
89674803|NCT04594733|Active Comparator|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|Participants will be randomized to 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily), minimum 2 week washout period, and then 8 weeks of placebo followed by a final 2 week washout
89674804|NCT04585906|Experimental|Sessions with a community mental health specialist|"Those randomized into the intervention group will receive 4-8 hour-long sessions with a community mental health specialist, taking place over approximately 12 weeks. The common elements treatment approach intervention (called My Pathway to Healing) includes psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping. The exact number of sessions delivered will depend on presentation and symptom level using a stepped care approach where participants receive only what they need, but the provider can provide additional sessions if needed (i.e., increased element dosage; additional optional elements for specific issues)."
89674805|NCT04585906|Active Comparator|Case management|This study employs a randomized control design in which participants in the control group will receive case management and offered the intervention upon completion of their enrollment period.
89674806|NCT04579952|Experimental|Intervention Group|The IG will receive a 20 minute program of active tDCS (2mA intensity, anode placed on primary motor cortex controlateral to the TKA, cathode placed on controlateral supraorbital region) followed by a 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
89674807|NCT04579952|Placebo Comparator|Control Group|The CG will receive a 20 minute program of sham tDCS (15 seconds of activation and then no stimulation, same position of IG) followed by the same 30 minute exercise program, 5 days a week, for 2 consecutive weeks.
89674808|NCT04570657|Experimental|MEDI3506 Dose 1|Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506
89674809|NCT04570657|Experimental|MEDI3506 Dose 2|Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506
89674810|NCT04570657|Placebo Comparator|Placebo|Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.
89674811|NCT04566601|Experimental|BI 1358894 5mg|
89674812|NCT04566601|Experimental|BI 1358894 25mg|
89674813|NCT04566601|Experimental|BI 1358894 75mg|
89674814|NCT04566601|Experimental|BI 1358894 125mg|
89674815|NCT04566601|Placebo Comparator|Placebo|
89674816|NCT04559256|Other|Tricuspid Cardiopulmonary Exercise testing|Patient receiving cardiopulmonary exercise testing
89674817|NCT04558229|No Intervention|Standard of Care Clinician Counseling|
89674818|NCT04558229|Experimental|Additional Standardized Counseling|
89674819|NCT04556773|Experimental|Module 1: T-DXd + capecitabine|T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use
89674820|NCT04556773|Experimental|Module 2: T-DXd + durvalumab + paclitaxel|T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use
89674821|NCT04556773|Experimental|Module 3: T-DXd + capivasertib|T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use
89674822|NCT04556773|Experimental|Module 4: T-DXd + anastrozole|T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral
89674823|NCT04556773|Experimental|Module 5: T-DXd + fulvestrant|T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use
89674824|NCT04553068|Experimental|EVO100 gel|EVO100 vaginal gel, 5 g
89674825|NCT04553068|Placebo Comparator|Placebo gel|Placebo vaginal gel, 5 g
88995948|NCT02937922|Active Comparator|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60% of a maximum repetition (1-RM) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
89049972|NCT04545476|Active Comparator|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
89674826|NCT04542499|Experimental|Tavapadon|Participants will receive a tavapadon tablet titrated 5 to 15 milligrams (mg) once daily (QD) orally for 27 weeks.
89674827|NCT04542499|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
89674828|NCT04535843||myasthenia gravis|300 MG patients are anticipated for precision diagnosis and disease monitoring.
89674829|NCT04522154|Other|MR-TTE|Patient receiving cardiac magnet resonance imaging and echocardiography
89674830|NCT04506008|Experimental|Group I (UH HRT)|Patients undergo HRT daily for a total of 5 fractions followed by surgery.
89674831|NCT04506008|Experimental|Group II (MH HRT)|Patients undergo HRT daily for a total of 15 fractions followed by surgery.
89674832|NCT04494295||AURORA|Aurora® Surgiscope used for MIS evacuation of supratentorial hematoma
89674833|NCT04470635||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
89674834|NCT04470635||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
89674835|NCT04470635||Healthy children with gingivitis|Systemically healthy children with gingivitis
89674836|NCT04470635||Healthy children and healthy gingiva|Systemically healthy children with healthy gingiva
89674837|NCT04451668|Experimental|FT218|once nightly sodium oxybate extended release oral solution (FT218)
89674838|NCT04424719|Other|Patients with uveal melanoma|
89674839|NCT04421768|Experimental|systematic cervical exam training--retrospective measures|Effects of systematic cervical exam training on Labor and Delivery Care The total number of exams per hour of labor or triage stay and exam discrepancy between 2 examiners who performed exams less than 30 minutes apart will be compared between the 6 month time period before the unit wide training and 6 months after completing training
89688750|NCT02819284|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
89688751|NCT02819284|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
89674840|NCT04421768|Experimental|systematic cervical exam training--prospective measures|Effects of systematic cervical exam training on Labor and Delivery care Patient will be approached to obtain consent for them to have 2 cervical exams performed one after the other when an exam is clinically indicated. The discrepancy between the 2 examiners will be compared between the 6 month time period before the unit wide training and 6 months after completion of the training.
89674841|NCT04412954|Experimental|Intervention|Health coach with Smartphone application for diet and physical activity
89674842|NCT04412954|No Intervention|Control|No intervention, using a Smartphone application for sleep monitoring
89674843|NCT04334304|Active Comparator|Posterior Stabilized TKA without robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA without robot-assistance
89674844|NCT04334304|Experimental|Posterior Stabilized with robot-assistance|A TKA procedure will carried out: Posterior Stabilized TKA with robot-assistance
89674845|NCT04334304|Experimental|Bicruciate retaining TKA without robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA without robot-assistance
89674846|NCT04334304|Experimental|Bicruciate retaining TKA with robot-assistance|A TKA procedure will carried out: Bicruciate retaining TKA with robot-assistance
89674847|NCT04312594|Experimental|Jaktinib 50mg BID|Patients receive the dose of Jaktinib Hydrochloride Tablets orally 50mg twice daily (BID) for 24 weeks.
89674848|NCT04312594|Experimental|Jaktinib 75mg BID|Patients receive the dose of Jaktinib Hydrochloride Tablets orally 75mg twice daily (BID) for 24 weeks.
89674849|NCT04312594|Placebo Comparator|Placebo|Patients receive the dose of placebo orally twice daily (BID) for 24 weeks.
89674850|NCT04303195|Experimental|NG101 - 5 mg|NG101 5 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
89674851|NCT04303195|Experimental|NG101 - 10 mg|NG101 10 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
89674852|NCT04303195|Experimental|NG101 - 20 mg|NG101 20 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
89674853|NCT04303195|Placebo Comparator|Placebo|Placebo-matching, capsules, orally, QID (4 times a day) for up to 12 weeks
89674854|NCT04298567||Treatment|Female and male patients with a diagnosis of CAD or symptomatic PAD will be enrolled within 4 weeks after the decision for treatment with rivaroxaban 2.5mg [BID] plus ASA 75mg [OD] has been made by the investigator.
89674855|NCT04296864|Placebo Comparator|Placebo|Placebo of Dupilumab
89674856|NCT04296864|Experimental|Dupilumab|one loading dose of Dupilumab 600 mg followed by Dupilumab 300 mg weekly for a total of 16 weeks
89674857|NCT04289402|Experimental|Personalized tDCS|Baseline MRIs will enable personalization of tDCS via current flow modeling for optimization to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA. Each 20-minutes session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
89674858|NCT04289402|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
89674859|NCT04279158|Experimental|patients with optic ataxia (OA)|
89674860|NCT04279158|Experimental|patients with hemispatial neglect|
89674861|NCT04279158|Experimental|patients with attention-deficit hyperactivity disorder|
89674862|NCT04279158|Active Comparator|Healthy volunteers|
89674863|NCT04243356|Experimental|Nurse Encounter Group|Nurses that are assigned to this group will be asked to take surveys before and immediately following the post-ICU clinic encounter with a patient that they had cared for in the ICU during a follow-up care visit with the former ICU - patient.
89674864|NCT04243356|Other|Nurse Control Group|Nurses assigned to this group will only complete surveys and will not see a former patient in a post-ICU visit.
89674865|NCT04233255||Patients with muscle disease(myositis, hereditary myopathy)|Includes 32 symptomatic patients with muscle disease subdivided into two subgroups (a) 16 patients with acute inflammatory myositis; And (b)16 patients with hereditary myopathy. The patients will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline,after 6 months and after 12 months. The number and location of studied muscles will be determined according to pattern of clinical presentation.
89674866|NCT04233255||Healthy volunteers as control group|Includes 32 healthy volunteers as control group. They will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline. Their age, sex, number and location of studied muscles will be matched with patients' group.
89688752|NCT04361461|Experimental|Group 1|Hydroxychloroquine (400 mg)
88995949|NCT02937922|Active Comparator|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
88995950|NCT04725461|Experimental|Low cost lower limb socket testing|Fabrication and testing of a low cost lower limb prosthetic socket and ensure this socket has appropriate suspension, comfort and f unction for a transtibial amputee.
88995951|NCT02937844|Experimental|Anti-PD-L1 CSR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg.
89688753|NCT04361461|Experimental|Group 2|Hydroxychloroquine (400 mg) + azithromycin (500 mg)
89688754|NCT03002506|Experimental|ceftolozane/tazobactam|One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.
88995952|NCT02937883|Experimental|empowerment intervention|Empowerment intervention
89688755|NCT03034993|Experimental|Text Messaging|This group will receive text messages with appointment reminders, medication taking education and motivation, and for reporting of mood.
89674867|NCT04220554|Experimental|Intervention group|"Intervention group:~All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream.~During the study period, a nurse or pharmaconomist will deliver;~Improved support and instructions to the patients~Patients will receive a diary and access to more consultations."
89674868|NCT04220554|No Intervention|Non-intervention group|"All participants will be instructed how to use of the medication according to the fingertip unit for topical steroids. All participants will be prescribed topical drugs based on shared decision between the prescriber and patient. The topical drugs will be either moderate corticosteroids (clobetasone-17-butyrate or hydrocortisone-17-butyrate), potent corticosteroids (betamethasone-17-valerate and betamethasone, mometasone furoate, fluocinolone acetonide or fluocinonide), very potent corticosteroids (clobetasol propionate), corticosteroids with antimicrobials (betamethasone and clioquinol, betamethasone and fusidic acid or fluocinolone acetonide and clioquinol), corticosteroid with calcipotriol or calcipotriol cream."
89674869|NCT04220489|Experimental|Ketamine Group|Participants will receive a 1 mg/kg dose of intravenous ketamine 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr ketamine with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
89674870|NCT04220489|Placebo Comparator|Placebo Group|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
89674871|NCT04219540|Experimental|extended-release buprenorphine (XR-B)|Subjects who agree to XR-B treatment will receive an XR-B injection to the abdomen. The injection is a liquid medication in the amount of either 100 or 300 mg buprenorphine in 1.5 cc volume and will last in the body for about 30 days. The medication is stored in a small nodule under the skin of the belly where it was injected. The buprenorphine is gradually released into the body over time for a 30-day period.
89674872|NCT04219540|Experimental|extended release naltrexone XR-NTX|Subjects who agree to XR-NTX treatment will receive an injection of XR-NTX to the outer upper part of your buttock. The injection is a liquid medication in the amount of 380 mg naltrexone in 4 cc volume (about 1 teaspoon) and will last in your body for about 30 days. Following release, visits with study physicians at Bellevue Hospital will offer further counseling or medication treatment referrals, the option to receive additional XR-NTX injections once a month following the first injection and continued encouragement to avoid relapses and stay on treatment.
89674873|NCT04219540|No Intervention|Treatment as Usual (TAU)|In this group you will not receive any study medication. You will be able to receive any treatments available to individuals in the jail or prison who are not in the study. Trained study staff at the first two visits will provide counseling focusing on relapse and overdose prevention, treatment engagement, and navigating re-entry challenges.
89674874|NCT04201093|Experimental|Tavapadon 5 mg|Participants will receive tavapadon tablet titrated up to 5 milligram (mg) once daily (QD) orally for 27 weeks.
89674875|NCT04201093|Experimental|Tavapadon 15 mg|Participants will receive tavapadon tablet titrated up to 15 milligram (mg) QD orally for 27 weeks.
89674876|NCT04201093|Placebo Comparator|Placebo|Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.
89674877|NCT04195555|Experimental|Treatment (ivosidenib)|Patients receive ivosidenib PO QD. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89674878|NCT04195061||Cardiopulmonary exercise testing|
89674879|NCT04177004|Experimental|Group A (conditioning, goat milk, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
89674880|NCT04177004|Active Comparator|Group B (conditioning, transplant, prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
89674881|NCT04171531|Active Comparator|Botox A® injection|A dose of 100 units of Botulinum toxin A will be injected into the bladder. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
89674882|NCT04171531|Active Comparator|Mid-urethral sling|Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Follow up visits at 2 weeks, 3 and 6 months post intervention to collect clinical and patient-reported outcomes.
89674883|NCT04170621|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
89049973|NCT04492670|Experimental|Tui-na and oral Chinese medicine|8 sessions of 20 minutes Tui-na for 4 weeks and take study medication (Herbal granules) twice daily concomitantly for 4weeks
89674884|NCT04168385|Experimental|Maralixibat|Participants will all receive Maralixibat oral solution
89674885|NCT04168112|Experimental|Group A|Intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days).
89049974|NCT04492670|Other|Tui-na|8 sessions of 20 minutes Tui-na for 4 weeks
89522545|NCT03396185|Experimental|Icotinib|Patients with EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
89522546|NCT03392701|Experimental|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
89522547|NCT03392701|Placebo Comparator|Placebo|NaCl
89522548|NCT05168189||Ivabradine Group|patients with chronic coronary syndrome using Ivabradine for heart rate control or as anti-anginal treatment.
89522549|NCT05168189||Non-Ivabradine Group|patients with chronic coronary syndrome NOT using Ivabradine for heart rate control or as anti-anginal treatment.
89522550|NCT03398941|Experimental|Combined group|
89522551|NCT05168111||patients of Diquat poisoning|
89522552|NCT05168111||normal persons|
89522553|NCT05000671|Experimental|Cohort 1|Drug: STC314/Placebo injection Continuous infusion at rate 58.3mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)
89522554|NCT05000671|Experimental|Cohort 2|Drug: STC314/Placebo injection Continuous infusion at rate 87.5mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)
89522555|NCT04413773|Active Comparator|Treatment as usual|Treatment as Usual, Explanation of standard procedures before, during and after surgery by nurse
89522556|NCT04413773|Experimental|Treatment as usual + Video|Treatment as usual and additionally Video
89522557|NCT03398863|Active Comparator|Cleaning of uterine cavity|Cleaning of uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
89522558|NCT03398863|No Intervention|Not cleaning of uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
89522559|NCT05167799||Cardiac Amyloidosis patients|"Patients with established diagnosis of amyloid TTR Cardiomyopathy, baseline ejection fraction ≥25% and ≤45%, at least one hospitalization due to worsening heart failure over the year before entry into the registry.~Already implanted with ICD or PM if needed, fullfilling the indication for CCM implantation."
89522560|NCT04369547|Experimental|Roflumilast|Participants will ingest a capsule containing 250mcg of the phosphodiesterase-4 inhibitor roflumilast. Their baseline TMS evoked potentials (TEP) will be recorded over 100 single TMS pulses prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the left dorsolateral prefrontal cortex (DLPFC). TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
89522561|NCT04369547|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however, this capsule will be contain a placebo. Their baseline TEP will be recorded over 100 single TMS pulses prior to receiving TBS to the left DLPFC. TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.
89522562|NCT03392623|Other|Control group|Macules of melasma without any treatment
89522563|NCT03392623|Experimental|Niacinamide group|Macules of melasma treated with topical Niacinamide cream 4% for 8 weeks
89522564|NCT03392623|Experimental|Retinoic acid group|Macules of melasma treated with topical retinoic acid 0.05% for 8 weeks
89522565|NCT03392623|Placebo Comparator|Sunscreen group|Macules of melasma treated with sunscreen cream with a 50 sun protection factor for 8 weeks
89522566|NCT03396107|Active Comparator|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
89522567|NCT03396107|Placebo Comparator|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
89522568|NCT04976491||CD-C-Food group|During the first 3 months，participants received EEN；In the second 3months , CD-C-Food group received received CD-C-food .
89522569|NCT04976491||EEN group|During the period, participants received EEN for 6 months.
89522570|NCT04359797|Active Comparator|Usual Care|Participants randomized to this arm will remain in their natural choice of position, which is anticipated to favor a supine, semi-recumbent position.
89522571|NCT04359797|Active Comparator|Prone|Participants randomized to this arm will be encouraged to lay in a completely prone position for as much time as is tolerable during hospitalization.
89522572|NCT03398785|Experimental|Intevention|Adrenal Artery Ablation
89522573|NCT03398785|No Intervention|Control|No intervention, but treated with standard anti-hypertensive drigs
89522574|NCT03392545|Experimental|Combined immune adjuvants and radiation|Patients with malignant gliomas will receive combined immune adjuvants (GM-CSF, TLR ligands) and radiation. The safety and efficacy will be analyzed.
89522575|NCT03396029|Experimental|Individually tailored lifestyle feedback|Written, standardized individually tailored lifestyle feedback based on participants responses to a lifestyle questionnaire, and a leaflet on healthy lifestyle mailed to the participant.
89522576|NCT03396029|Experimental|Standard leaflet|A leaflet on healthy lifestyle mailed to the participant.
89522577|NCT03396029|No Intervention|Control|No contact with the participant.
89522578|NCT03126695|Experimental|Treatment Sequence 1 (ADBC)|"Subjects were randomized to treatment sequence ADBC:~On Day 1, following an overnight fast of at least 10 hours, each subject will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
89522579|NCT03126695|Experimental|Treatment Sequence 2 (BACD)|"Subjects were randomized to treatment sequence BACD:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
89522580|NCT03126695|Experimental|Treatment Sequence 3 (CBDA)|"Subjects were randomized to treatment sequence CBDA:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
89674886|NCT04168112|Active Comparator|Group B|Patients are placed on standard postoperative regimen of postoperative fluoroquinolone (or other class in case of allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye QID x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: QID x1 week, TID x 1 week, BID x 1 week, and Qday x 1 week.
89674887|NCT04143243|Active Comparator|ACT on Life|"Acceptance and Commitment Therapy plus Education, Resources and Support ('ACT on Life').~The ACT+ERS intervention will include: 1) Acceptance and Mindfulness Training (2-3 hours); 2) Committed Action Training (2-3 hours) involving helping Veterans clarify what matters most to them and what they want to stand for in life, how they want to behave, and what sorts of strengths and qualities they want to develop; and; 3) Education, Resources, and Support (1 hour)."
89674888|NCT04143243|Placebo Comparator|Education, Resources, and Support|Information provided in the ERS workshop was compiled from existing VHA and community resources. Veterans will be educated about 1) symptoms of depression, anxiety and PTSD and how these conditions do and do not impact daily life and functional ability; 2) common difficulties and challenges with reintegration into civilian life; 3) mild TBI, differences between civilian and Veteran TBIs, shared/crossover symptoms (for example, memory and concentration difficulties, sleep disturbance, irritability can be symptoms of depression, PTSD, and mild TBI); 4) chronic pain; how it is often often misinterpreted as on-going damage, leading to fear of physical activities and resulting in increased sedentary behavior and declines in physical functioning; and 5) treatment options and resources. Basic resource counseling will include guidance on the evidence-based treatments available at VHA. Problem solving, relaxation, and deep breathing techniques will be covered
89674889|NCT04131504||Phase I - Cross-sectional Study (CD and Suspected IBD)|150 children and young adults who have been previously diagnosed with CD (anti-TNF naïve) or suspected of having IBD (based on clinical symptoms and laboratory testing) who are scheduled for a clinically-indicated colonoscopy are eligible to be enrolled in this cohort.
89674890|NCT04131504||Phase I - Cross-sectional Study (healthy volunteers)|20 healthy controls will be enrolled at Cincinnati Children's Hospital only. Once demographics, past medical/surgical history and biospecimens (blood/stool) are collected, controls will complete participation.
89674891|NCT04131504||Phase II - Longitudinal Study of Participants with CD|70 children and young adults who have been diagnosed with CD (anti-TNF naïve) and are scheduled to receive infliximab (or adalimumab) are eligible to be enrolled in this cohort.
89674892|NCT04125732|Experimental|AdVEGFXC1 at 1x10^9 vp|
89674893|NCT04125732|Experimental|AdVEGFXC1 at 1x10^10 vp|
89674894|NCT04125732|Experimental|AdVEGFXC1 at 4x10^10 vp|
89674895|NCT04125732|Experimental|AdVEGFXC1 at 1x10^11 vp|
89674896|NCT04125459||Individuals with Gout|This arm will be getting a biopsy as well as a blood draw
89674897|NCT04125459||Controls|These individuals will not be getting a joint biopsy and will just get a blood draw
89674898|NCT04105699||Device: Blood sampling|
89674899|NCT04085510|Experimental|Contrast-enhanced mammogram|All women will receive both 3D mammography and contrast-enhanced mammography for breast cancer screening; the order of interpretation will vary for each of two radiologists
89674900|NCT04081753|Experimental|TMD Group|Temperature Monitoring Device Group - The interventional group, who will be given the temperature monitoring device and will be monitored remotely.
89674901|NCT04081753|No Intervention|Historic cohort Group|Historic cohort group will be enrolled from medical record
89674902|NCT04081636|Active Comparator|Systematic Transrectal biopsy (TR-Bx)|Ultrasound guided; needle inserted through the rectum to reach the prostate
89674903|NCT04081636|Active Comparator|Targeted Transrectal biopsy (TR-Bx)|MRI-guided; needle inserted through the rectum to reach the prostate
89674904|NCT04081636|Experimental|Systematic Transperineal biopsy (TP-Bx)|Ultrasound guided; needle inserted directly through the skin to reach the prostate
89049975|NCT04613037|Experimental|Treatment arm|Fecal Microbial Transplantation in adults with Atopic Dermatitis
89049976|NCT04613115||Group A|patients without uremia and variant arteries
89049977|NCT04613115||Group B|patients without uremia, but with variant arteries
89674905|NCT04081636|Experimental|Targeted Transperineal biopsy (TP-Bx)|MRI-guided; needle inserted directly through the skin to reach the prostate
89674906|NCT04061603|Experimental|iCLAS Ablation|Ablation of the left and right atrium with the Adagio Medical iCLAS System
89674907|NCT04052022||1|Patients with TB who have already initiated treatment and are suspected to have paradoxical reactions, as well as patients taking TB treatment without signs of paradoxical reactions.
89674908|NCT04036461|Experimental|Arm 1 (CC-99712 monotherapy)|CC-99712 will be administered via intravenous (IV) infusion.
89674909|NCT04036461|Experimental|Arm 2 (CC-99712 and BMS-986405 combination)|CC-99712 will be administered via IV infusion. BMS-986405 will be administered orally.
89674910|NCT04005352|Experimental|Brolucizumab 6 mg|3 x 4-week injections and one 8-week Intra-vitreal injection, followed by Treat-to- Control treatment from Week 16 up to Week 60/62.
89049978|NCT04613115||Group C|patients with uremia ,without variant arteries
89049979|NCT04613115||Group D|patients with uremia and variant arteries
89049980|NCT04613427||Unruptured intracranial aneurysm|Patients admitted at Haukeland University Hospital in the study period for treatment of UIA.
89049981|NCT04613427||Aneurysmal subarachnoid hemorrhage|Patients admitted at Haukeland University Hospital in the study period for treatment of aSAH.
89049982|NCT04612842|Experimental|Motivational Interviewing (MI) goup|The MI experimental group will receive all the same measurements as the control group, and in addition, receive MI-based communication about fall prevention at eight occasions during the 12-month period. MI is an evidence-based communication approach for various health behavior change.
89049983|NCT04612842|No Intervention|Control group|The control group participants will only receive study measurements at baseline, 3-, 6-, and 12-months after the benchmark STEADI clinic visit.
89049984|NCT04612881||fitostimoline vaginal pessaries|
89049985|NCT04464161|Experimental|Arm 1|The treatment arm will receive 6 week supply of daily Ensure protein drinks, while the control arm will be instructed to continue their current diet. This includes 2 weeks pre-operatively and 4 weeks post-operatively.
89049986|NCT04464161|No Intervention|Arm 2|The control group will be instructed to continue to their regular diets.
89674911|NCT04005352|Active Comparator|Aflibercept 2 mg|3 x 4-week injections and one 8-week Intra-vitreal injection, followed by Treat-to- Control treatment from Week 16 up to Week 60/62
89215060|NCT05018247|Other|Optimal Medical Treatment with delayed revascularization|OMT without revascularization for a minimum of approximately 105 days if clinically stable. At their first follow-up visit (Day 105±20), patients will be offered the option of continued medical treatment or elective revascularization consistent with informed patient preference and clinical judgement. Patients, in consultation with their physicians, may elect to undergo revascularization at any time thereafter and will be followed for one year after randomization. Follow-up visits will occur at Baseline, Day 105, and Day 365. At each visit, a rest-stress PET assessment will be performed, and adverse events related to study procedures and cardiac disease will be captured.
89215061|NCT05014438|Placebo Comparator|Placebo|
89215062|NCT05014438|Experimental|Treatment BMS-986166 Dose 1|
89674912|NCT03970278||All Participants|All participants enrolled in study 401GSDIA02 will have received a single IV dose of DTX401 during their participation in study 401GSDIA01 (NCT03517085).
89674913|NCT03969992|Other|nCPAP alone|Standard of Care (nasal continuous positive airway pressure-nCPAP) with instilled bolus surfactant when medically necessary
89674914|NCT03969992|Experimental|Drug: Low Dose AeroFact|AeroFact-low dose SF-RI 1
89674915|NCT03969992|Experimental|Drug: High Dose AeroFact|AeroFact-high dose SF-RI 1
89674916|NCT03964727|Experimental|Sacituzumab Govitecan-hziy|Participants with non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), endometrial cancer, or metastatic small cell lung cancer (mSCLC) will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle until disease progression (PD), toxicity or withdrawal of consent.
89674917|NCT03962933||Flexcystoscopy/Uromonitor|Control cystoscopy every 4 - 8 and 12 months as a standard procedure, And Urine test (Uromonitor) every 4 months
89674918|NCT03962920|Active Comparator|Surgical treatment + antibiotics|Use antibiotic
89674919|NCT03962920|Placebo Comparator|surgical treatment + placebo|Use placebo
89674920|NCT03952039|Experimental|Fedratinib 400mg/day|Will include up to 128 subjects receiving fedratinib 400 mg self-administered Investigational Product (IP) on an outpatient basis, once daily preferably together with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
89674921|NCT03952039|Active Comparator|Best Available Therapy (BAT)|Best-available Investigator-selected therapy included a number of available compounds to treat MF and/or its symptoms and was chosen by the investigator for each subject. Therapy changed at different times during the treatment period. No investigational agents (e.g. not approved for the treatment of any indication) were allowed. BAT also included the choice of no treatment.
89674922|NCT03949517|Experimental|68-Ga RM2+68-Ga PSMA11|68-Ga RM2 first followed by 68-Ga PSMA11 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
89674923|NCT03949517|Experimental|68-Ga PSMA11+68-Ga RM2|68-Ga PSMA11 first followed by 68-Ga RM2 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
89674924|NCT03940586|Experimental|Letermovir|Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
89674925|NCT03935464|Experimental|Intervention Arm|POC adherence testing by a urine TFV assay with feedback
89674926|NCT03935464|No Intervention|Standard of Care|Follow Kenya's PrEP guidelines on standard adherence counselling
89674927|NCT03931109||PHPT w/ Osteoporosis|Primary hyperparathyroidism patients with osteoporosis undergoing parathyroidectomy
89674928|NCT03931109||PHPT w/o Osteoporosis|Primary hyperparathyroidism patients without osteoporosis undergoing parathyroidectomy
89674929|NCT03931109||Thyroid w/ Osteoporosis|Thyroid disease patients with osteoporosis undergoing thyroidectomy
89674930|NCT03929289|Experimental|Social Facilitation|Cognitive tasks during the 2 functional Magnetic Resonance Imaging (fMRI) observed or not by a subject's known peer.
88995953|NCT02937883|No Intervention|regular care|Regular care, care as usual
88995954|NCT02937727|Experimental|MRI compatible and LFP recordable implantable stimulator|
89215063|NCT05014438|Experimental|Treatment BMS-986166 Dose 2|
89215064|NCT05014438|Experimental|Treatment BMS-986166 Dose 3|
89215065|NCT05014438|Experimental|Treatment Branebrutinib|
89674931|NCT03914846|Experimental|Cohort I (ultrasound)|Patients with skin lesions undergo at least 1 ultrasound during the consultation. Patients may undergo at most 2 additional scans after the standard of care approach for non-malignant lesions at the discretion of the radiation oncologist and/or dermatologist.
89674932|NCT03914846|Experimental|Cohort II (ultrasound)|Skin cancer patients who undergo surgery or radiation undergo 2-5 ultrasounds over a 1 year period (a baseline ultrasound scan may be performed prior to treatment, followed by 1 scan during and/or after radiation, and additional ultrasounds may be conducted [at the discretion of the treating physician] upon completion of radiation and/or surgery, at approximately 1, 6, and 12 month follow-up examinations).
89674933|NCT03914846|Experimental|Cohort III (ultrasound)|Participants with inflammatory skin disorders (psoriasis, eczema, alopecia, acne) undergo ultrasound at baseline and follow-up visits.
89674934|NCT03865992|Experimental|Arm I (nanoemulsion curcumin)|Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.
89674935|NCT03865992|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.
89674936|NCT03865264|Active Comparator|Living Liver donor|"Recovery enhancement program:~At least 6 weeks of physical and relaxation skills training pre-transplant.~Taking nutritional drink for 5 days before and after the surgery.~Opioid sparing pain management."
89674937|NCT03865264|Active Comparator|Living Kidney donor|"Recovery Enhancement Program~At least 4 weeks of physical and relaxation skills training pre-transplant.~Taking nutritional drink for 5 days before and after the surgery.~Opioid sparing pain management."
89674938|NCT03865264|No Intervention|Living Kidney donor (Control)|"Subjects maintain the same lifestyle without practicing physical training, relaxation skills or nutritional drink before and after the surgery.~To control post-op pain, subject will use medication per standard of care, including PCA pump."
89674939|NCT03857373||Renal Cancer|Patients identified with RCC
89674940|NCT03845582|Experimental|ALK-001|Capsule
89674941|NCT03845582|Placebo Comparator|Placebo|Capsule
89674942|NCT03827694||Patients with possible PIFI|
89674943|NCT03817905|Experimental|Patient navigator|Participant meets the patient navigator at their colonoscopy appointment and discusses any problems they experienced in getting the colonoscopy done. Participant will tell navigator in their own words their experience and whether they faced any barriers to scheduling and colonoscopy completion.
89674944|NCT03814304|Experimental|Personalized tDCS|Personalized tDCS: This intervention is designed to facilitate the excitability of the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
89674945|NCT03814304|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
89674946|NCT03789097|Experimental|Combination therapy|Vaccination with Flt3L, Radiation, and Poly ICLC combined with Pembrolizumab
89674947|NCT03782974|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
89674948|NCT03782974|Placebo Comparator|Placebo|Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.
89674949|NCT03776253|Experimental|Supportive care (CFS)|"Patients attend CFS psychosocial intervention consisting of 7 nurse-led sessions (session 1 in-person and sessions 2-7 via video conferencing) over 45 minutes each for 8 weeks. Patients also complete home practice assignments comprising attention training technique and mindfulness practice after each session.~Patients complete self-report questionnaires at baseline (T1), 8 weeks (T2) and 12 weeks (T3)."
89674950|NCT03769298|Experimental|Envarsus XR|Envarsus XR (extended release) will be administered orally, once-daily, for 6 months.
89674951|NCT03756168|Experimental|All subjects|
89674952|NCT03731221|Experimental|Bupi HCl plus liposomal bupi|PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine
89674953|NCT03731221|Active Comparator|Bupi HCl plus saline|PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline
89674954|NCT03728335|Experimental|Treatment (enasidenib mesylate)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
88995955|NCT02937805|Experimental|Moisturizing vaginal and vulvar sea buckthorn oil cream|Moisturizing non-hormonal vaginal and vulvar cream containing sea buckthorn oil as active ingredient (medical device product in development). Administered twice or once per day for 5 weeks. Post-menopausal women n= 55 + 45. Pre-menopausal women n=15
89674955|NCT03706170|Experimental|Vegetative State|For patients in vegetative state (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
89674956|NCT03706170|Experimental|Minimally Conscious State|For patients in minimally conscious state (n = 15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
89674957|NCT03706170|Experimental|Acquired Brain damaged patients without DOC|Acquired Brain damaged patients without disorder of consciousness (patients without DOC) For patients with acquired brain damage without disorder of consciousness (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography
89674958|NCT03706170|Experimental|Healthy subjects|For healthy subjects (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
88995956|NCT02937805|Active Comparator|Moisturizing vaginal and vulvar cream|Moisturizing non-hormonal vaginal and vulvar cream (commercial medical device cream already on the market, not containing sea buckthorn oil). Administered once - twice per day for 5 weeks. Postmenopausal women n=55
88995957|NCT02937805|No Intervention|Control|No moisturizing vaginal and vulvar cream for 5 weeks. Postmenopausal women n=55
88995958|NCT02937532|Placebo Comparator|GHE + TOBT training|Subjects will receive general health education and task-oriented balance training.
88995959|NCT02937532|Active Comparator|CBT + TOBT training|Subjects will receive group-based cognitive behavioral therapy and task-oriented balance training.
88995960|NCT02937493||Migration Background|Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
89049987|NCT04612959|Experimental|Psychosexual care|The psychosexual caring program will be conducted online psychoeducation as a group intervention. The program includes four sessions with home assignments and home readings papers.
89049988|NCT04612959|No Intervention|Standard care|Standard care includes the information given by the nurse about the treatment methods to be applied once.
89674959|NCT03703297|Experimental|Durvalumab + Placebo|Durvalumab monotherapy: Durvalumab (1500 mg intravenous [IV]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.
89674960|NCT03703297|Experimental|Durvalumab + Tremelimumab|Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.
89688756|NCT03034993|Placebo Comparator|Control|This group will receive simple text messages about general health promotion, such as about the importance of drinking water on hot days, using sunscreen, etc.
89674961|NCT03703297|Placebo Comparator|Placebo + Placebo|Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.
89674962|NCT03698370|Experimental|Arm I (Ga68-NeoBOMB1 and Ga68 PSMA-R2|Participants receive gallium Ga 68 DOTA-NeoBOMB1 IV and 45 minutes later, undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 PSMA-R2 IV then undergo PET/MRI 45-60 minutes later.
89674963|NCT03698370|Experimental|Arm II (Ga68 PSMA-R2 and Ga 68-NeoBOMB1)|Participants receive gallium Ga 68 PSMA-R2 IV and 45-60 minutes later undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 DOTA-NeoBOMB1 IV then undergo PET/MRI 45 minutes later.
89674964|NCT03696030|Experimental|Treatment (HER2-CAR T cells)|Patients receive HER2-CAR T cells via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.
89674965|NCT03693677|Experimental|Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively|"Nal-IRI plus 5-FU/LV and Nab-Paclitaxel plus Gemcitabine alternately every two months~Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.~Nab-Paclitaxel + Gemcitabine (6 injections, one injection three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel plus Gemcitabine at the dose of :~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
89674966|NCT03693677|Experimental|Nal-IRI/5-FU/LV|Nal-IRI plus 5-FU/LV Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
89674967|NCT03693677|Active Comparator|Nab-paclitaxel/Gemcitabine|"Nab-Paclitaxel plus Gemcitabine Nab-Paclitaxel + Gemcitabine (6 courses, one course three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel + Gemcitabine at the dose of :~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
89674968|NCT03685942|Experimental|active light therapy|Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment
89674969|NCT03685942|Placebo Comparator|placebo light therapy|People receive usual treatment and use a placebo light therapy device (175 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.
89674970|NCT03684213|Active Comparator|Control (Norepinephrine)|Subjects will be administered norepinephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
89674971|NCT03684213|Experimental|Norepinephrine + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
89674972|NCT03684213|Experimental|Norepinephrine + L-NAME|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) at the same rate and for the same time as the control arm.
89674973|NCT03684213|Experimental|Norepinephrine + L-NAME + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and combined L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
89674974|NCT03674411|Experimental|FLU, CY, TBI + MGTA-456 infusion|
89674975|NCT03668067||Photoscreener (2WIN)|Accommodation, refraction and ocular alignment are estimated by infrared photoscreener using the photoscreener device. Photoscreener screening makes use of light crescent quantification from off-axis flash-to-lens in a camera.
89674976|NCT03668067||school bus skiascopy|Refractive error estimated by child-friendly skiascopy rack holding lenses from +1.00 D to +10.00 D and -5.00 D. Skiascopy is a common, old-fashioned form of retinoscopy.
89674977|NCT03661320|Active Comparator|Arm A: Gemcitabine/Cisplatin (GC) Chemotherapy|
89674978|NCT03661320|Experimental|Arm B: Nivolumab + GC Chemotherapy|
89215066|NCT05014048|Active Comparator|vitamin D3|20 mikrog vitamin D3 daily, 3 months
89215067|NCT05014048|Placebo Comparator|Placebo|Placebo
89215068|NCT05010577|Experimental|BX004-A|Participants will be randomized to receive standard dose of nebulized bacteriophage
89674979|NCT03655470|Experimental|Safety Planning|This brief intervention, consists of an in-person and follow-up phone call that are based on cognitive behavioral principles designed to help identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of nonsuicidal self-injury or suicidal behavior.
89674980|NCT03655470|Active Comparator|Standard Care|"If a teen has a positive screen for suicide risk, the Probation Officer completes a secondary screener built into the court screening instrument to determine whether there is concern of current and/or imminent risk. If a teen endorses nonsuicidal self-injury more than once in the prior year, then the Probation Officer asks about frequency and severity. If there is ongoing concern of risk for self-injurious behavior, then the Probation Officer arranges for a crisis evaluation in the Emergency Department. If the teen is not judged to be at imminent risk, the Probation Officer makes a referral back to the current treatment provider or to a community mental health clinic. In either case, the parents and youth receive a packet with mental health resources"
89674981|NCT03610555||Current website|Show patient one of the website
89674982|NCT03610555||New patient centered website|Show patient another (different) of the website
89674983|NCT03604913|Active Comparator|A(aortic valve sparing operation)|Undergo aortic valve sparing root replacement operation
89674984|NCT03604913|Active Comparator|B(Bentall operation)|Undergo Bentall operation
89674985|NCT03571568|Experimental|BI-1206 IV|BI-1206 IV Standard 3+3 Dose-Escalation Design
89674986|NCT03571568|Experimental|BI-1206 SC|BI-1206 SC Adaptive Dose Escalation Design (Bayesian logistic regression model (BLRM)
89674987|NCT03570619|Experimental|Metastatic CRPC|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort A.
89674988|NCT03570619|Experimental|Solid Tumors (non-prostate)|Patients with all other metastatic subtypes will be enrolled in cohort B
89674989|NCT03570619|Experimental|Metastatic CRPC with Monotherapy|Patients with metastatic castration resistant prostate cancer (mCRPC) will be enrolled in cohort C once enrollment to cohort A has been completed.
89674990|NCT03568461|Experimental|CTL019|All patients who received tisagenlecleucel infusion.
89674991|NCT03559049|Experimental|Rucaparib and Pembrolizumab Maintenance|"All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days).~This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle)."
89674992|NCT03543254|Experimental|BoNT-A injected|BoNT-A (Botulinum toxin A) injected in the head on specific sites and in half the usual concentration
89674993|NCT03511625|Experimental|Acthar|80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.
89674994|NCT03511625|Active Comparator|Depo Medrol|40 milligrams of Depo Medrol will be injected intramuscularly one time
89674995|NCT03480282|Experimental|Prognosis Information and Provider Scripts|Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.
89674996|NCT03447769|Experimental|canakinumab|Participants received 200mg of canakinumab subcutaneously every 3 weeks for up to 18 cycles (approximately 54 weeks)
89674997|NCT03447769|Placebo Comparator|Placebo|Participants received canakinumab placebo subcutaneously every 3 weeks for up to 18 cycles (approximately 54 weeks)
89674998|NCT03446651|Experimental|Lysine Chloride|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.
89674999|NCT03446651|Placebo Comparator|Placebo|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Placebo group will receive placebo.
89675000|NCT03442751|Experimental|Epithelium-on CXL Treatment Group|Study eye receives Test Article A, Test Article B, and exposed to cross-linking dose of UVA light generated by the KXL medical device system
89675001|NCT03442751|Sham Comparator|Sham Treatment/Control Group|Sham eye receives Placebo and and exposed to mock dose of UVA light generated by the KXL medical device system
89675002|NCT03389698||Cohort A|Cognitively normal control participants aged 20 - 40 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.
89215069|NCT05010577|Placebo Comparator|Placebo|Participants will be randomized to receive nebulized placebo
89675003|NCT03389698||Cohort B|Cognitively normal control participants aged 65 - 85 years. Participants will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 21 minutes of scan time.
89675004|NCT03389698||Cohort C|Amnestic mild cognitive impairment (aMCI) patients aged 65 and older. Participants in Cohort C will be matched by age and gender to participants in Cohort B. Participants in Cohort C will undergo a 3T brain scan that will last up to 60 minutes using the GRASP DCE-MRI sequence performed during the first 9 minutes of scan time.
89675005|NCT03388190|Active Comparator|Control Arm|The control arm will consist of intermittent treatment with the Nordic FLOX regimen in terms of 8 cycles before break until disease progression, when therapy is reintroduced and administered for another 8 cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
89675006|NCT03388190|Experimental|Experimental Arm|The experimental arm will consist of repeat 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 8 individual cycles before break until disease progression, when therapy is reintroduced and administered for another total of 8 individual cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
89675007|NCT03306472|Active Comparator|Arm A: Letrozole|Arm A: 15 days of Letrozole 2.5mg daily
89675008|NCT03306472|Experimental|Arm B: Letrozole + Megestrol Acetate (40mg)|Arm B: 15 days of Letrozole 2.5mg daily + Megestrol acetate 40mg daily
89215070|NCT05008783|Experimental|AK104 + Oxaliplatin + Capecitabine|AK104 in combination with Oxaliplatin and Capecitabine
89215071|NCT05008783|Placebo Comparator|Placebo + Oxaliplatin + Capecitabine|Placebo in combination with Oxaliplatin and Capecitabine
89215072|NCT05004090||children with ND|children with neurodevelopmental disabilities (ND) age between 3 and 24 months (chronologically or corrected in the case of children born preterm).
89215073|NCT05004090||Typical developed children (TD)|children with typical development age between 3 and 24 months (chronological).
89215074|NCT04993235||Sotos Syndrome|Children and adolescents with Sotos Syndrome
89215075|NCT04993235||Beckwith-Wiedemann Syndrome|Children and adolescents with Beckwith-Wiedemann Syndrome
89675009|NCT03306472|Experimental|Arm C: Letrozole + Megestrol Acetate (160mg)|Arm C: 15 days of Letrozole 2.5mg daily + Megestrol acetate 160mg daily.
89675010|NCT03301883|Experimental|Tocilizumab|Participants weighing greater than or equal to (>/=) 30 kilograms (kg) will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W), and participants weighing less than (<) 30 kg will receive tocilizumab 12 mg/kg IV infusion Q2W for 52 weeks. After Week 12, the dose of tocilizumab can be adjusted for non-transient changes in body weight (shifting from <30 to >/=30 kg) over a minimum of three consecutive dosing visits. MTX, NSAIDs, and oral corticosteroids (CSs) are permitted but not required during the study.
89675011|NCT03288675|Active Comparator|Active aiTBS - active CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive active CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
89675012|NCT03288675|Experimental|Active aiTBS - sham CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive a control training for a period of 4 weeks in combination with an antidepressant (SSRI)
89675013|NCT03288675|Experimental|Sham aiTBS - aiTBS - active CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week receive CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
89675014|NCT03288675|Experimental|Sham aiTBS - aiTBS - sham CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week control training for a period of 4 weeks in combination with an antidepressant (SSRI)
89675015|NCT03286686|Experimental|Experience 1|
89675016|NCT03286686|Experimental|Experience 2|
89675017|NCT03286686|Experimental|Experience 3|
89675018|NCT03286686|Experimental|Experience 4|
89675019|NCT03286686|Experimental|Experience 5|
89675020|NCT03286686|Experimental|Experience 6|
89675021|NCT03267888|Experimental|Radiation therapy, pembrolizumab|Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
89675022|NCT03265431|Active Comparator|Control|Normal subjects without history of cardiac disease or arrhythmia
89675023|NCT03265431|Experimental|Arrhythmia|This cohort consist of patients with history of recurrent VT and scheduled for EAM-guided catheter ablation as part of their clinical treatment
89675024|NCT03265431|Experimental|Treatment Failure|A subset of the Arrhythmia cohort, this group will undergo a second imaging session. This subset corresponds to patients from the Arrhythmia cohort presenting with recurrent ventricular arrhythmia following initial EAM-guided catheter ablation and requiring repeated ablation. It is estimated that 30% of the Arrhythmia cohort patients will require repeat ablation based on rate of repeat ablation procedures at MGH. T
89675025|NCT03255967|Experimental|QI program care|DSM-H performance improvement program Patients in the performance improvement group will receive care from a care team who has received the DSM-H performance improvement program
89675026|NCT03255967|Active Comparator|Control|Receive usual care from a care team who has not received the performance improvement program
89675027|NCT03240003|Experimental|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of standard GC-MRT
89675028|NCT03240003|Active Comparator|non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
89675029|NCT03240003|Experimental|GC-MRT-modified|Group 3 will receive a 4-week (8-sessions) course of modified GC-MRT.
89675030|NCT03233646||Case|Patients with (MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)
89675031|NCT03233646||Controls|Controls will be recruited from the relatives/attendants of study participants or will be patients themselves and will not have a neurodegenerative disease diagnosis.
89675032|NCT03188393|Experimental|Diagnostic (biopsy of breast)|After completion of neoadjuvant therapy, patients undergo stereotactic biopsy of breast tumor any time prior to breast conserving surgery. Patients then undergo breast conserving surgery as per standard of care. Patients may also undergo postoperative radiation therapy per standard of care or adjuvant therapy at the investigator's discretion.
89675033|NCT03151811|Experimental|Arm A: Melflufen+Dexamethasone|Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.
89675034|NCT03151811|Active Comparator|Arm B: Pomalidomide+Dexamethasone|Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.
89675035|NCT03141970|Experimental|Intervention: Prednisolone|Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
89675036|NCT03141970|No Intervention|No intervention|Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
89675037|NCT03139630||HIV-infected patients|HIV-infected adult male or female patients who are HIV treatment naive and initiate antiretroviral therapy including a protease inhibitor during the follow up period.
89675038|NCT03139630||HIV-uninfected patients|HIV-uninfected adult male or female patients.
89675039|NCT03065231|Active Comparator|EVD|Patients will have extraventricular drain to manage CSF subarachnoid blood.
89675040|NCT03065231|Active Comparator|LD|Patients will have lumbar drain to manage CSF subarachnoid blood.
89675041|NCT03016338|Experimental|Niraparib +TSR-042|200/300 mg Niraparib by mouth once a day for 21 days cycle. 500 mg of TSR-042 intravenously on the first day of each cycle.
89675042|NCT03011814|Experimental|Arm I (durvalumab)|Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
89215076|NCT04993235||Control group|Adolescents with typical development
89675043|NCT03011814|Experimental|Arm II (durvalumab, lenalidomide)|Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
89675044|NCT03006536|Experimental|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
89675045|NCT03006536|Sham Comparator|Sham|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
89675046|NCT02970448|Experimental|LITT with Radiation and Temozolomide|Laser interstitial thermal therapy (LITT) followed by Radiation therapy, three-dimensional conformal radiotherapy (3D-CRT) or intensity modulation radiation therapy (IMRT), 60 Gy/30 fractions. Radiation given with chemotherapy Temozolomide
89675047|NCT02950259|Experimental|IRX-2 Regimen -Early Stage Breast Cancer|Enrolled subjects with early stage breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
89675048|NCT02950259|Experimental|IRX-2 Regimen -Triple Negative Breast Cancer|Enrolled subjects with triple negative breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
89675049|NCT02947685|Experimental|Arm A|Palbociclib 125 mg daily + AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt) until confirmed disease progression
89675050|NCT02947685|Active Comparator|Arm B|AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant) until confirmed disease progression
89675051|NCT02887586|Experimental|Auricular Needling group|Patients will receive auricular needling for 4 weeks .
89675052|NCT02887586|No Intervention|control group|This group will receive no treatment. Subjects will be assessed at baseline and the 2th, 4th and 8th week.
89675053|NCT02865564|Active Comparator|Intervention group|The intervention group will receive 5 drops, a minimum of 100 million live Lactobacillus reuteri DSM 17938 a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
89675054|NCT02865564|Placebo Comparator|Placebo group|Placebo group will receive 5 drops of maltodextrin in the some oil suspension a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
89675055|NCT02832050|Experimental|Intervention|"The play therapy intervention consists of a standard of care delivered by a play specialist. The play specialist delivers interventions aimed in assisting the child through the process of undergoing procedures. The intervention is semi-structured in order to facilitate a systematic approach which remains individualised and child-centred.~The intervention requires patients to be classified as 'high risk' or 'low risk' for procedure-related anxiety. This is assessed for all patients at baseline based on parent and clinician opinion. The play specialist may re-classify patients at the initial assessment or at any point whilst working with the child. If this occurs, clear documentation of the rationale for this will be recorded. Patients classified as high risk receive additional preparation sessions as detailed in the standard of care."
89675056|NCT02832050|Placebo Comparator|Comparator|The comparator group will receive standard care of patients having blood tests within the Trust, which does not include the specific intervention of a play therapist routinely. As part of standard care if a child becomes particularly distressed a clinician may make a decision to refer the child for play therapy. If this occurs during the study period the child will be referred to the play specialist delivering the intervention for the study. The child will then receive play therapy as in the described intervention. They will be excluded from the main analysis but data will still be collected and analysed descriptively.
89675057|NCT02831049|Experimental|1|alcohol retrieval / alcohol extinction
89675058|NCT02831049|Active Comparator|2|soft-drink retrieval / alcohol extinction
89675059|NCT02831049|Active Comparator|3|alcohol retrieval / soft-drink extinction
89675060|NCT02803437||Xofigo / Cohort 1|Patients suffered from CRPC with bone metastases are enrolled after the physician's decision of Xofigo treatment under the routine clinical practice.
89675061|NCT02775461||Hereditary Pancreas Cancer Syndrome|Patients that have a diagnosis or any family history of a hereditary pancreas cancer syndrome, such as, but not limited to, Familial Pancreatic Cancer, hereditary pancreatitis, FAMMM syndrome, FAP and its variants, HNPCC (Lynch syndrome), Peutz-Jeghers syndrome, or BRCA1 and/or BRCA2 germline mutations.
89675062|NCT02775461||Personal or FHx of Pancreas Cancer or Pancreas Cysts|Patients that have personal or family history of pancreatic cancer or pancreatic cysts.
89675063|NCT02775461||Inflammatory Pancreatic Diseases|Patients that have a personal or family history of pancreatic dysplasia or inflammatory pancreatic diseases.
89675064|NCT02737566|Experimental|Standard Care + Financial Incentives|Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
89675065|NCT02737566|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
88995961|NCT02937493||Non Migration Background|If the following criteria is not fulfilled: Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
88995962|NCT02937415|Experimental|Waterpipe smokers group|Three waterpipe cafes located in Ankara were visited. 50 waterpipe smokers aged 18-40 years, enrolled in the study and created the working group. At the same time, there were also cigarette smokers among these people. Breath carbon monoxide, pulmonary function tests were performed both before and after smoking waterpipe and parameters of oxidative stress and antioxidant status were measured in blood samples after smoking waterpipe.
89215077|NCT04982367|Experimental|Sirolimus-eluting balloon angioplasty|Using Sirolimus Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
89675066|NCT02706951|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
89675067|NCT02706951|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
89675068|NCT02706951|Experimental|Methotrexate / Upadacitinib 30 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
89675069|NCT02706951|Experimental|Methotrexate / Upadacitinib 15 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
89675070|NCT02685891|Active Comparator|playing tones|During slow-wave sleep short tones (50ms, 50dB) will be played
89675071|NCT02685891|Sham Comparator|Playing no tones|During slow-wave sleep no tones will be played
89675072|NCT02682316|Active Comparator|usual standard dry gauze used for wound management|Patients who are randomized to the standard dry gauze arm will have the standard dry gauze placed at time of wound closure. Their dressing will be removed on post-operative day 2 as per routine departmental practice.
89675073|NCT02682316|Experimental|Prevena Negative Pressure Wound Therapy System (NPWT)|Patients who are randomized to the Prevena Therapy System arm will have the Prevena Incision Management System device placed at time of wound closure. The device will be removed on day of discharge from the hospital or post-operative day 7, whichever comes first.
89675074|NCT02651662|Experimental|Dose escalation phase|Safety assessment of odronextamab in combination with cemiplimab and selection of recommended phase 2 dose (RP2D) regimen(s) for the combination of odronextamab and cemiplimab.
89675075|NCT02651662|Experimental|Dose expansion phase|RP2D administration of the combination treatment.
89675076|NCT02649699|Other|Additional 3D MRI scans|Participating patients will receive additional 3D MRI scans during pre and post RT planning for their primary brain tumors.
89675077|NCT02632305|Experimental|Treatment|"Eligible patients will receive nab-paclitaxel in combination with gemcitabine + cisplatin at the recommended phase II dose based on the phase I study completed in metastatic pancreas cancer patients.~The doses of study drugs will be as follows:~nab-Paclitaxel 100 mg/m2 day 1 and 8 every 21 days~Cisplatin 25 mg/m2 day 1 and 8 every 21 days~Gemcitabine 800 mg/m2 day 1 and 8 every 21 days~Nab-paclitaxel will be administered first followed by cisplatin and then gemcitabine on day 1 and 8 of each treatment cycle. Cycles will be 3 weeks in length (21 days)."
89675078|NCT02628405|Experimental|Treatment (R2-ICE)|Patients receive lenalidomide PO daily on days 1-14, rituximab IV on day 1, ifosfamide IV over 24 hours on day 2, carboplatin IV over 1-2 hours on day 2, and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CMR, PMR, or NMR may receive 2 more cycles per physician discretion. After completion of 2 cycles of R2ICE treatment, patients achieving objective status of CMR, PMR or NMR may proceed to SCT during the event monitoring phase.
89675079|NCT02609386|Experimental|Regimen 1|IRX Regimen with IRX-2, cyclophosphamide, indomethacin, zinc-containing multivitamin, and omeprazole as neoadjuvant and adjuvant therapy.
89675080|NCT02609386|Active Comparator|Regimen 2|Regimen 1 but without IRX-2
89675081|NCT02607709|Placebo Comparator|Nephroureterektomy|scheduled to receive routine standard open or robot assisted nephroureterectomy without lymphadenectomy
89675082|NCT02607709|Experimental|Nephroureterektomy + Lymphadenectomy|scheduled to received mapped lymphadenectomy in conjugation with nephroureterectomy
89675083|NCT02576717|Experimental|1 mg RPC1063 (Ozanimod) oral capsule|1 mg RPC1063 (Ozanimod) oral capsule daily
89675084|NCT02554474|Active Comparator|Immediate Group|Time spent in Moderate/Vigorous Physical Activity (MVPA) was measured with a SenseWear Mini sensor over a 7-day period. The mean time was calculated in bouted MVPA per day. A bout is defined as >= 10 consecutive minutes or more at the level of >= 3 METs (i.e., the lower bound of MVPA), with allowance for interruption of up to two minutes below the threshold.
89675085|NCT02554474|Placebo Comparator|Delay Group|Time spent in sedentary activity was measured with a SenseWear Mini sensor over a 7-day period. The mean daily time spent in sedentary activity was calculated with an energy expenditure of <=1.5 METs, occurring in bouts of >= 20 minutes during waking hours.
89675086|NCT02535845|Experimental|Self-persuasion group|HPV information plus self-persuasion intervention in a tablet-based application (Project Voice)
89675087|NCT02535845|Active Comparator|Information only group|HPV information only in a tablet-based application (HPV Informational Video)
89675088|NCT02517307|Experimental|glycerol/saline FAOD|Glycerol/Saline co-infusion hyperinsulinemic euglycemic clamp among subjects with a fatty acid oxidation disorder (FAOD)
89675089|NCT02517307|Experimental|intralipid FAOD|Intralipid/Heparin co-infusion hyperinsulinemic euglycemic clamp among subjects with a fatty acid oxidation disorder (FAOD)
89675090|NCT02517307|Experimental|glycerol/saline Control|Glycerol/Saline co-infusion hyperinsulinemic euglycemic clamp among normal matched control subjects (control)
89675091|NCT02517307|Experimental|intralipid Control|Intralipid/Heparin co-infusion hyperinsulinemic euglycemic clamp among normal matched control subjects (control)
89675092|NCT02499354|Active Comparator|Oral Iron|Ferrous Sulfate 325mg (oral) tabs morning and evening
89675093|NCT02499354|Active Comparator|IV Iron|Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart
89675094|NCT02488967|Active Comparator|Arm I (AC-->WP)|Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable toxicity.
89215078|NCT04982367|Active Comparator|Paclitaxel-eluting balloon angioplasty|Using Paclitaxel Coated Balloon Catheter in the treatment of stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
89215079|NCT04979442|Experimental|RAIN-32 (Milademetan)|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle.
89215080|NCT04979442|Active Comparator|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks.
89675095|NCT02488967|Experimental|Arm II (AC-->WP + carboplatin)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
89675096|NCT02437396||Treatment naive GD1|Type 1 Gaucher disease subjects who are naive to any treatment
89675097|NCT02437396||Treated GD1|Type 1 Gaucher disease who are stable on therapy (on the specific ERT and/or SRT and specific dose for at least 2 years)
89675098|NCT02437396||Healthy Volunteers (No longer recruiting)|Age matched healthy controls. No new participants will be enrolled to this arm.
89675099|NCT02399410|Experimental|bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
89675100|NCT02369835|Experimental|Arm I (modified Dakin's solution)|Participants apply modified Dakin's solution (0.005% to 0.010%) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
89675101|NCT02369835|Placebo Comparator|Arm II (placebo)|Participants apply placebo solution (saline) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
88995963|NCT02937415|Active Comparator|Control group|The control group consisted of 50 people of the same age and sex, who had never smoked neither cigarette nor waterpipe. Breath carbon monoxide, pulmonary function tests were performed and parameters of oxidative stress were measured in blood samples.
88995964|NCT00165009|No Intervention|DUAL THERAPY|DUAL THERAPY
88995965|NCT00165009|Experimental|'Resolution clip|'Resolution clip
88995966|NCT02937337|Experimental|Videostylet|Laryngeal mask airway insertion using video stylet guided technique
88995967|NCT02937337|Active Comparator|Blind|Laryngeal mask insertion using standard index finger-guided technique
88995968|NCT02937220|Experimental|Monolithic zirconia crowns|New crown material to restore dental implants
88995969|NCT02937220|Active Comparator|metal ceramic crowns|conventional crown material for restoring dental implants
89675102|NCT02367859|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID every 12 hours plus trametinib daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression.
88995970|NCT02937259|Experimental|Self-admission|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
88995971|NCT02937298|Experimental|Control Meal|Control meal using standard breakfast foods.
89215081|NCT04968132|Active Comparator|Standard care group|This group will receive standard perioperative care, surgical treatment, and pain medications.
89675103|NCT02362503|Experimental|A1: BMS-663068|Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
89675104|NCT02362503|Active Comparator|B1: Placebo + BMS-663068|Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
89675105|NCT02362503|Experimental|BMS-663068|BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
88995972|NCT02937298|Experimental|Berry Treatment|This will consist of standard breakfast foods plus a berry smoothie.
88995973|NCT02937298|Experimental|Sea Buckthorn Treatment|This will consist of standard breakfast foods plus a sea buckthorn berry smoothie.
88995974|NCT02937298|Experimental|Wild Garlic Treatment|This will consist of standard breakfast foods plus a wild garlic dip.
88995975|NCT02937103|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD123-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
88995976|NCT02936908||Ventilatory support|Adult patients presenting a neuromuscular disease, with involvement of respiratory or bulbar muscles
88995977|NCT00152633|Active Comparator|Losartan|Treatment with Losartan.
88995978|NCT00152633|Active Comparator|Betablocker|Treatment with Metoprolol.
88995979|NCT02937181|Experimental|open fractures type II and III|Every patients will receive Ceftaroline in an open label, single arm
88995980|NCT02937025|Experimental|Left Atrial Appendage Closure Device Group|Device:LAmbre Left Atrial Appendage Occluder（Shanghai Push Medical Device Technology CO.td） to close the left atrial appendage
89215082|NCT04968132|Experimental|Opioid reduction group|Patients will participate in a multicomponent pathway coordinated by a trained coordinator who will facilitate patient participation and engagement with each interventional component.
89215083|NCT04968054|Active Comparator|Propofol group|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively
89675106|NCT02337985|Experimental|Treatment (R-EPOCH, rHIV7-shI-TAR-CCR5RZ-transduced HSPC)|"Patients receive prednisone PO BID on days 1-5; rituximab IV on day 1; etoposide IV over 96 hours, doxorubicin hydrochloride IV over 96 hours and vincristine sulfate IV over 96 hours on days 1-4; and cyclophosphamide IV over 30-60 minutes on day 5. Patients then receive filgrastim SC QD beginning on day 6 and continuing until absolute neutrophil count recovers. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells IV on day 0 (48 hours after the final combination chemotherapy course.)"
89675107|NCT02292589|Experimental|Frontal Stimulation|Left dorsolateral prefrontal cortex stimulation
89675108|NCT02292589|Experimental|Temporal Stimulation|Left temporal cortex stimulation
89675109|NCT02292589|Experimental|Sham Stimulation|Sham stimulation
89675110|NCT02224924|Active Comparator|autologous blood patch injection (ABPI)|
89675111|NCT02224924|Experimental|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|
89675112|NCT02159495|Experimental|Treatment (lymphodepletion, T-cell immunotherapy)|Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at > 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
89675113|NCT02153580|Experimental|Group I (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.~Disease status: Patients with Non-Hodgkin lymphoma (NHL)."
89675114|NCT02153580|Experimental|Group II (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.~Disease status: Patients with Chronic lymphocytic leukemia (CLL) and/or Prolymphocytic Leukemia (PLL)."
89675115|NCT02152956|Experimental|Cohort 0-a|
89675116|NCT02152956|Experimental|Cohort 0-b|
89675117|NCT02152956|Experimental|Cohort 0-c|
89675118|NCT02152956|Experimental|Cohort 0-d|
89675119|NCT02152956|Experimental|Cohort 1|
89675120|NCT02152956|Experimental|Cohort 2|
89675121|NCT02152956|Experimental|Cohort 2a|
89675122|NCT02152956|Experimental|Cohort 3|
89675123|NCT02152956|Experimental|Cohort 6|
88995981|NCT02937064||Controls|Controls
88995982|NCT02937064||ACL subjects|Subjects with anterior cruciate ligament injuries.
88995983|NCT02937064||OA1, doubtful OA|Subjects with doubtful osteoarthritis.
88995984|NCT02937064||OA2, mild OA|Subjects with mild osteoarthritis.
89675124|NCT02152956|Experimental|Cohort 7|
89675125|NCT02152956|Experimental|Cohort 8|
89675126|NCT02152956|Experimental|MTD Expansion|
89675127|NCT02152956|Experimental|MTD expansion with Ruxolitinib|
89675128|NCT02149849|No Intervention|Standard lateral positioning|
89675129|NCT02149849|Experimental|Modified lateral positioning|Modified lateral positioning. This will ensure less pressure and stretch on shoulder than standard lateral positioning.
89675130|NCT02127164|Experimental|"Veraflo device, Dakin's solution"|
89675131|NCT02117089|Experimental|Device-assisted rehabilitation|
89675132|NCT02112565|Experimental|Treatment (RNR inhibitor COH29)|Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89675133|NCT02081755|Experimental|Everolimus and Tacrolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) Tacrolimus Dosing: 0.05 mg/kg BID
89675134|NCT02081755|Active Comparator|Tacrolimus and Myfortic or CellCept or Imuran|Myfortic: 360 mg to 1080 mg BID OR CellCept: 500 mg to 1500 mg BID OR Imuran: 0.5mk/kg to 2mg/kg QD AND Tacrolimus Dosing: 0.05 mg/kg BID
88995985|NCT02937064||OA3, moderate OA|Subjects with moderate osteoarthritis.
88995986|NCT02937064||OA4, severe OA|Subjects with severe osteoarthritis.
88995987|NCT02936791||Individuals diagnosed with PKD|Individuals that have been diagnosed and meet the study's definition of early stage PKD.
88995988|NCT02936791||Individuals with a family history of PKD|Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD
88995989|NCT02936791||Normal individuals for the comparison|Normal volunteers with no family history of PKD or other kidney diseases.
88995990|NCT02936674|Experimental|Light 1|Light 1 will have an altered color composition as compared with a standard LED bulb.
89675135|NCT02051257|Experimental|Arm 1 (autologous TCM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
88995991|NCT02936674|Active Comparator|Light 2|Light 2 will be a standard LED bulb.
88995992|NCT02936713|Experimental|1=Functional Gastro-Intestinal Disorder (FGID)|1=FGID study group: 40 evaluable FGID subjects with a functional gastrointestinal disorder (FGID) complaining of excessive gas evacuation per anus (i.e excessive flatulence), aged from 18 to 75 years that will consume a 3-day specific and controlled mild flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
88995993|NCT02936713|Experimental|2=Non-FGID|2=Non-FGID study group: 60 evaluable non-FGID subjects aged from 18 to 75 years that will consume a 3-day specific controlled high flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
88995994|NCT03457831||Status Epilepticus|Convulsive and Non-Convulsive Status Epilepticus ; and Pseudo Status Epilepticus
88995995|NCT03457753|Experimental|Subjects with ALS|Riluzole Oral Soluble Film (ROSF) 50 mg will be administered in subjects with ALS twice daily. It is intended that at least five (5) of the twenty-five (25) subjects enrolled will be subjects scoring greater than 20 on the Eating Assessment Tool (EAT-10) (representative of ALS patients reporting moderate swallowing impairments in a patient report validated scale).
88995996|NCT03457714||Guided I-CBT for persons with SCI|Persons with spinal cord injury
88995997|NCT02936830|Placebo Comparator|Control|21 individuals with dentin hypersensitivity will receive a placebo solution of glycerol diluted in water in a 1:1 concentration applied on the sensitive area by the dentist
88995998|NCT02936830|Active Comparator|Fluoride group|21 individuals with dentin hypersensitivity will receive 5% Sodium Fluoride varnish applied on the sensitive area by the dentist
89675136|NCT02051257|Experimental|Arm 2 (autologous TN/MEM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
89675137|NCT01996696|Experimental|Metformin|Metformin 500 mg PO TID x 30-36 months
89675138|NCT01996696|Placebo Comparator|Placebo|Identical placebo TID x 30-36 months
89675139|NCT01984138|Experimental|Estring|ESTRING
89675140|NCT01984138|Active Comparator|REPLENS|Replens
89675141|NCT01953263|Experimental|Autologous Muscle Fiber Fragments|Autologous Muscle Fiber Fragments administered via a single,direct injection into the bladder neck sphincter region
89675142|NCT01907074|Experimental|Cholates Compound|
89675143|NCT01891318|Experimental|Treatment (radiosurgery, surgery)|Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
89675144|NCT01811498|Experimental|SIACI of Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab
89675145|NCT01553149|Experimental|Arm I (low-dose lenalidomide)|Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89675146|NCT01553149|Experimental|Arm II (high-dose lenalidomide)|Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89675147|NCT01522469|Experimental|Crenolanib Besylate|
89675148|NCT01478737|Sham Comparator|Sham|Vitrectomy only
88995999|NCT02936830|Experimental|Nanohydroxyapetite|21 individuals with dentin hypersensitivity will receive 15% nanohydroxyapetite paste applied on the sensitive area by the dentist
88996000|NCT04756414|Experimental|Treatment group|Patients recieve treatment from standard protocol at a gastroenterology unit. No specific adjustments is made for study purposes. Baseline data is collected before treatment and then again after treatment (POST).
88996001|NCT04690270|Experimental|Sumatriptan 100 mg|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
88996002|NCT04690270|Placebo Comparator|Placebo|Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.
88996003|NCT02936518|Experimental|Intervention|
88996004|NCT02936362|Other|Sourdough bread, white bread|Consumption of sourdough bread for one week, 2 week washout, consumption of white bread for one week
88996005|NCT02936362|Other|White bread, sourdough bread|Consumption of white bread for one week, 2 week washout, consumption of sourdough bread for one week
88996006|NCT02936440||critical patients with AKI|Critical patients with AKI will be followed up to 12 weeks after diagnosis
88996007|NCT02936557|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
88996008|NCT02936401|Experimental|MBSR|Participants in this arm enter the 8-week MBSR course immediately after the baseline visit.
88996009|NCT02936401|Experimental|CONTROL|Participants in the waitlist control arm will receive standard of care for 16 weeks after the baseline visit, and then will be offered an identical 8-week MBSR course.
88996010|NCT02936128|Experimental|TruSkin®|Cryopreserved skin allograft
88996011|NCT02936128|Active Comparator|Wound Cover|Active Comparator for Venous Leg Ulcers
88996012|NCT02936284|Experimental|Music Enhancement|37 weekly Music Together classes for one year, then 12 monthly Music Together classes the following year.
88996013|NCT02936284|Active Comparator|Play Date|37 weekly group Play Date sessions for one year, then 12 monthly group Play Date sessions the following year.
88996014|NCT02936167|Experimental|Ringer Lactate|fluid
88996015|NCT02936167|Experimental|Plasmalyte|fluid
88996016|NCT00152828|Experimental|Celecoxib|Celecoxib
88996017|NCT02935933|Active Comparator|Paravertebral block with bupivacaine|patients received 20 ml of bupivacaine 0.25% paravertebrally in 3 levels, divided into 6-7 ml in each level
88996018|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + morphine|patients received 20 ml of bupivacaine 0.25% +5 mg morphine paravertebrally in 3 levels, divided into 6-7 ml in each level.
89675149|NCT01478737|Active Comparator|Intravitreal Ozurdex|Intravitreal Ozurdex after vitrectomy
89675150|NCT01468337|Experimental|Interferon gamma-1b|"Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. A single dropperette contains 1 mL of topical interferon gamma-1b (Actimmune®) at a concentration of 200 µg/mL, which is equivalent to 28 drops. Each drop provides a dose of 7 µg of investigational product.~All participants will receive interferon gamma-1b for two weeks. Doses of interferon gamma-1b eye drops will be escalated among participants during this initial 2-week period; however, additional doses will be dispensed to participants if needed at Week 4 or after the initial 8-week study period. Participants eligible for additional doses after 8 weeks will be administered the maximum dose of 4 drops 4 times daily for a total daily dose of 112 μg."
89675151|NCT01437449|Experimental|Cisplatin + Docetaxel + Cetuximab|Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.
89675152|NCT01437189|Experimental|Parkinson's disease patients with depression|It is a self-controlled study only contains one arm, aims to investigate the effects of Sertraline on depression in Parkinson's disease
89675153|NCT01341600|Experimental|Clopidogrel in poor metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 poor metabolizers (PM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
89688757|NCT02822950|Other|Ceftazadime/avibactam|Ceftazadime/avibactam 2500 mg (1250 mg for CrCl 31-50 mL/min) IV over 120 minutes, every 8 hours [other antibiotics can also be administered as needed]. Patients will receive at least 3 doses (steady-state) of Avycaz prior to obtaining serum samples.
89215084|NCT04968054|Experimental|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
89215085|NCT04951804|Active Comparator|EUS-CPN with bupivacaine|Endoscopic ultrasound guided celiac plexus neurolysis with absolute alcohol 20 mL preceded by injection of 10 ml of bupivacaine 0.5%.
89215086|NCT04951804|Experimental|EUS-CPN without bupivacaine|Endoscopic ultrasound guided celiac plexus neurolysis with absolute alcohol 20 mL only.
89215087|NCT04941469|Experimental|Specifically optimized off-the-counter foot orthosis|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type."
89215088|NCT04941469|Active Comparator|Plain off-the-counter foot orthosis|The control device for this study would be the plain original Formthotics (Original Dual Hard).
89675154|NCT01341600|Experimental|Clopidogrel in intermediate metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 intermediate metabolizers (IM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
89675155|NCT01341600|Experimental|Clopidogrel in extensive metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 extensive metabolizers (EM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
89675156|NCT01341600|Experimental|Omeprazole/Clopidogrel in PM|PM participants who have completed Arm 1 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
89675157|NCT01341600|Experimental|Omeprazole/Clopidogrel in IM|IM participants who have completed Arm 2 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
89675158|NCT01341600|Experimental|Omeprazole/Clopidogrel in EM|EM participants who have completed Arm 3 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
89675159|NCT01311713|Experimental|CEP-9722 Dose 1 QD|Participants will receive Dose 1 of CEP-9722 tablet once daily (QD) orally with a standard meal for up to 6 cycles of 28 days each.
89675160|NCT01311713|Experimental|CEP-9722 Dose 1 BID|Participants will receive Dose 1 of CEP-9722 tablets twice daily (BID) orally with a standard meal for up to 6 cycles of 28 days each.
89675161|NCT01311713|Experimental|CEP-9722 Dose 2 BID|Participants will receive Dose 2 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
89675162|NCT01311713|Experimental|CEP-9722 Dose 3 BID|Participants will receive Dose 3 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
89675163|NCT01311713|Experimental|CEP-9722 Dose 4 BID|Participants will receive Dose 4 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
89675164|NCT01311713|Experimental|CEP-9722 Dose 5 BID|Participants will receive Dose 5 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
89675165|NCT01311713|Experimental|CEP-9722 Dose 6 BID|Participants will receive Dose 6 of CEP-9722 tablets BID orally with a standard meal for up to 6 cycles of 28 days each.
88996019|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + dexmedetomidine|patients received 20 ml of bupivacaine 0.25% + 1 μg/kg dexmedetomidine paravertebrally in 3 levels divided into 6-7 ml in each level.
89215089|NCT04940299|Experimental|Cohort 1 (ipilimumab, nivolumab, tocilizumab)|"Patients with melanoma will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.~Cohort 1 will be divided into 2 sub-groups: sub-group 1 of 25 patients, and subgroup 2 of 10 patients that will consist of varying Tocilizumab administration doses. For sub-group 1, Tocilizumab 162mg will be administered subcutaneously every 2 weeks starting week 0, up to 12 weeks for a total of 6 doses. For sub-group 2 , Tocilizumab 162mg will be administered subcutaneously once every week starting at week 0 up to week 6 followed by Tocilizumab administered subcutaneously every 2 weeks starting at week 6 up to 12 weeks for a total of 9 doses."
89675166|NCT01303068|Experimental|CF patients, 13C urea breath test kit|CF patients with Pseudomonas infection tested with 13C urea breath test
89675167|NCT01303068|Active Comparator|Healthy controls, 13C urea breath test kit|Healthy subjects using 13C urea breath test kit
89675168|NCT01260870|Experimental|Cotavance|
89675169|NCT01260870|Active Comparator|Standard balloon angioplasty|POBA
89675170|NCT01120795|Experimental|pegylated interferon and ribavirin|Anti hepatitis C agents
89675171|NCT01038765|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
89675172|NCT01038765|No Intervention|Waiting list control group|3-month waiting list group
89675173|NCT00928226|Experimental|Arm 1 - 24 Grey SRS|24 Grey administered as 8 Gy x 3 fractions
89675174|NCT00928226|Experimental|Arm 2 - 27 Grey SRS|27 Grey administered as 9 Gy x 3 fractions
89675175|NCT00928226|Experimental|Arm 3 - 30 Grey SRS|30 Grey administered as 10 Gy x 3 fractions
89675176|NCT00928226|Experimental|Arm 4 - 33 Grey SRS|33 Grey administered as 11 Gy x 3 fractions
88996020|NCT02936011|Other|CTO PCI with Absorb BVS|Single arm observational after successful CTO PCI with Absorb BVS after antegrade or retrograde dissection and re-entry
89675177|NCT00898755||Ancillary-Correlative (tissue sample collection)|"Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:~NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry"
89675178|NCT00890604|Other|Standard interventions for temperature control used in protocolized, stepwise fashion|Normothermia Protocol- use of standard interventions in protocolized fashion (physical cooling, antipyretics)
89675179|NCT00890604|No Intervention|Standard fever management/prevention interventions used in ad hoc fashion|standard interventions for fever prevention used in ad hoc fashion based on nurse decision making
88996021|NCT02935777|Experimental|Pomegranate Extract|"POMANOX® pomegranate extract capsules with water by mouth, once. Dosage: 2 capsules~Capsules weigh1.083g and contain: 210mg punicalagin, 328mg other pomegranate polyphenols (e.g. flavonoids and ellagic acid), 0.37mg anthocyanins and maltodextrin."
88996022|NCT02935777|Placebo Comparator|Placebo|Identical placebo capsules by mouth, administered once. Dosage 2 capsules. Each capsule contains maltodextrin to provide PE capsule energy equivalent i.e.6.52 kcal or 27.28kJ.
88996023|NCT00152867|Active Comparator|1|Dexamethasone
88996024|NCT00152867|Placebo Comparator|2|Placebo
88996025|NCT02935972|Active Comparator|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
88996026|NCT02935972|Active Comparator|Local|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
88996027|NCT02935972|Active Comparator|Combined|received intravenous diazepam 5 mg slowly just before TRUS probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
88996028|NCT02935855|Active Comparator|Nondiabetics (group 1)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
88996029|NCT02935855|Active Comparator|Diabetics (group 1)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
88996030|NCT02935855|Active Comparator|Nondiabetics (group 2)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
88996031|NCT02935855|Active Comparator|Diabetics (group 2)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
88996032|NCT00152906|Experimental|Stereotactic RT or highly conformal RT|
88996033|NCT04702555||Vitalis Pharmaceuticals (VTS)-Aspirin and Ketamine|An oral combination drug of VTS-Aspirin and ketamine (VTS-K) would facilitate the shift from IV opioids to a non-IV therapy for patients presenting to the ED with acute MSK pain. This formulation has a potential to provide effective analgesia in the ED with reduced side effects. VTS-K's proprietary oral formulation of established, safe, and well-understood APIs, makes it uniquely appropriate for use in the ED. VTS-K is administered orally, which is suitable for resource-poor environments in which the healthcare setting may be inadequate as well as suitable to improve the throughput of ED Patients by reducing their length of stay. This is especially pertinent given the alternative of IV opioids for pain management of acute MSK pain, which requires both clinical monitoring and equipment, whereas VTS-K promotes weaning off opioids, alleviating the resource consumption.
88996034|NCT02935504|Experimental|Program In Support of Moms PRISM|PRISM includes MCPAP for Moms and training, implementation support, and toolkits for Ob/Gyn practices on depression screening, assessment and treatment.
88996035|NCT02935504|Active Comparator|MCPAP for Moms|Consists of access to psychiatric consultation and resources and referrals through MCPAP for Moms - MCPAP for Moms is available free of charge to all Ob/Gyn practices in Massachusetts.
88996036|NCT02935582||Enstilar®|Patients for whom a new treatment strategy has been decided which involves start of topical treatment with Enstilar® according to the current local labelling
88996037|NCT02935582||Other topical|Patients for whom a new treatment strategy has been decided which involves start of topical treatment not including Enstilar®
88996038|NCT02935660|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
88996039|NCT02935465|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
88996040|NCT02935465|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
88996041|NCT02935621|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
88996042|NCT02935621|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
88996043|NCT02935426|Experimental|Cyanoacrylate group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with application of cyanoacrylate tissue adhesive
88996044|NCT02935426|Active Comparator|Suture group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with polytetrafluoroethylene (PTFE) continuous interlocking sutures
88996045|NCT02935153|Experimental|B Cell Malignancies|Experimental: B Cell Malignancies The trial will be conducted in a manner of simon two-stage design with Anti-CD22-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
88996046|NCT02935114|Experimental|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)~37% Carbamide Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
88996047|NCT02935114|Active Comparator|35% Hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)~35% Hydrogen Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
89215090|NCT04940299|Experimental|Cohort 2 (ipilimumab, nivolumab, tocilizumab)|Patients with urothelial cancer will receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment with ipilimumab and nivolumab repeats every 3 weeks for 4 doses, then treatment with nivolumab repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Starting on week 1, patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses) in the absence of disease progression or unacceptable toxicity.
89215091|NCT04940299|Experimental|Cohort 3 (ipilimumab,, nivolumab, tocilizumab)|Patients with NSCLC receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 2 weeks for up to 2 years. Patients also receive tocilizumab SC every 2 weeks for up to 12 weeks (6 doses). Treatment continues in the absence of disease progression or unacceptable toxicity.
89215092|NCT04936204|Experimental|Group 1 ConnettivinaBio Plus cream|ConnettivinaBio Plus cream is a topical preparation constituted by Principal component: Hyaluronic acid sodium salt 0.2% Other components: Silver Sulfadiazine 1%, The medication should be applied once a day as a thin layer to cover the entire surface of the wound previously cleansed
89215093|NCT04936204|Active Comparator|Group 2 ConnettivinaBio cream|ConnettivinaBio Cream is a topical preparation constituted by Principal component: Hyaluronic acid sodium salt 0.2% The medication should be applied once a day as a thin layer to cover the entire surface of the wound previously cleansed
89215094|NCT04931771|Experimental|vFFR guided revascularization|
89215095|NCT04931771|Active Comparator|FFR guided revascularization|
89215096|NCT04915131|Other|Bloomlife MFM-Pro|
89215097|NCT04897334|Active Comparator|Transcranial Direct Current Stimulation (tDCS) + cognitive therapy|Participants will undergo 5 daily sessions of tDCS for 20 minutes using a montage in which an anode (2 mA) is placed over left dorsolateral prefrontal cortex and the cathode will be place on the right supraorbital area. Subjects will participate in cognitive therapy during stimulation.
89215098|NCT04897334|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS) + cognitive therapy|Participants will undergo 5 daily sessions of sham tDCS for 20 minutes using a montage in which an anode (2 mA) is placed over left dorsolateral prefrontal cortex and the cathode will be place on the right supraorbital area. Subjects will participate in cognitive therapy during stimulation.
89215099|NCT04887337|Active Comparator|Arthroscopic stabilization|Patients will have an initial evaluation with a diagnostic shoulder arthroscopy and examination under anesthesia will be performed to confirm the degree of anterior instability and assess range of motion of the affected shoulder. Diagnostic arthroscopy will commence with the use of 3 standard shoulder portals (posterior viewing and two anterior working portals for suture passing), and a detailed arthroscopic examination will be performed. Once the soft tissue tear (including the labrum, and capsule labrum ligaments) is identified, it will be mobilized using a rasp or elevator and a burr will then be used to create a surface for a bleeding bone bed. Capsulolabral repair will then commence with the labrum fixed to the glenoid using suture anchors (the Bankart repair). Following surgery, subjects in this group will follow the same rehabilitation protocol as the comparison group.
89675180|NCT00842283||dermatologic diseases|skin tissue sample
89675181|NCT00659776|Active Comparator|Inflammatory lesions|Subjects with dural, central nervous system (CNS) parenchymal based inflammatory, vascular or demyelinating lesions.
89675182|NCT00659776|Active Comparator|Vascular lesions|subjects will include those with vascular CNS lesions such as ischemic stroke, transient ischemic attack (TIA) with suspected carotid embolic origin, or vasculopathy involving the carotids, (including diagnosed carotid stenosis >50%) the aorta, or the arteries of the extremities, or diagnosed thrombosis of the intraabdominal, pelvic or extremity veins.
89675183|NCT00659776|Active Comparator|Lymph nodes|Subjects with enlarged cervical lymph nodes in which inflammatory processes (reactive lymph nodes) is part of the differentials.
89675184|NCT00617656|Active Comparator|A: Control|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
89675185|NCT00617656|Experimental|B1: Experimental group B1|Low RAP expression and any levels of BRCA1 expression: Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
89675186|NCT00617656|Experimental|B2: Experimental group B2|Intermediate or high RAP expression and low or intermediate BRCA1 expression: Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
89675187|NCT00617656|Experimental|B3: Experimental group B3|Intermediate or high RAP expression and high BRCA1 expression: Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
89675188|NCT00451022||Cohort 1|Subjects previously participating in gene transfer or other immunotherapy studies at the NCI or extramural sites receiving therapeutic agents as part of a multi-site trial.
89675189|NCT00090662||Healthy volunteer|Healthy volunteer
89675190|NCT05030597|Experimental|68Ga-DOTA-FAPI and 18F-FDG PET/CT|Investigators recruit patients whom are clinically highly suspected oral cancer or recurrence after treatment. Patients undergo 68Ga-DOTA-FAPI and 18F-FDG PET/CT imaging within one week.
89675191|NCT05025384|Experimental|Intervention|Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique.
89675192|NCT05025384|No Intervention|No Intervention|No intervention
89675193|NCT05022680|Experimental|Participants were used app to record their diet and steps every day|Experimental group was the mHealth with peer led to improved their physical activity during pregnancy. Participants received app to record and monitor their physical activity every days and using it until childbirth.
89675194|NCT05022680|No Intervention|non-mhealth|control group was the traditional prenatal care during pregnancy.
89675195|NCT05016947|Experimental|Venetoclax + Inotuzumab Ozogamicin with Dexamethasone|"Phased 28 day treatment cycles with lead in:~Lead In Cycle: Dose escalated venetoclax 1x daily for days 1-3 with and Dexamethasone daily for days 1-3 lead in, 7 days total.~Induction Cycle 1: Dose escalated venetoclax 1x daily for days 1-21, Dexamethasone daily for days 1-4, Inotuzumab ozogamicin on days 1, 8, and 15~Induction Cycle 2: Dose escalated venetoclax 1x daily for days and Inotuzumab ozogamicin on days 1, 8, and 15~Consolidation Cycles: Up to 5 cycles of dose escalated Venetoclax 1x daily for days and Inotuzumab ozogamicin on days 1, 8, and 15"
89675196|NCT04992416|Experimental|SMV with ATBG around implant|SMV mixed with ATBG around immediately placed dental implants in the extraction sockets
89675197|NCT04992416|Active Comparator|ATBG around implant|ATBG around immediately placed dental implants in the extraction sockets
89675198|NCT04987944|Experimental|BHV3500|Zavegepant 150 mg BID
89675199|NCT04987944|Placebo Comparator|Placebo|Matching placebo 150 mg BID
89675200|NCT04980066|Experimental|sticky bone and EDTA|treatment of gingival recession using sticky bone after root surface biomodification with EDTA
89675201|NCT04980066|Active Comparator|Sticky bone|treatment of gingival recession using sticky bone
89675202|NCT04963712|Experimental|Zadaxin-HIV(n=20)|Study participants will be given Zadaxin (1.6 mg subcutaneous injection, once a day) in the first 2 weeks, and changed frequency (1.6 mg subcutaneous injection, twice a week) in the successive 22 weeks.
89675203|NCT04911920|Other|Patients with lateral epicondylitis|Patients with lateral epicondylitis who are treated with at least one ACP injection.
89675204|NCT04888845|Active Comparator|Structured interview and Safety Plan|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach. The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
89675205|NCT04888845|Active Comparator|Structured interview and Crisis Response Plan|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach. Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
89675206|NCT04888845|Active Comparator|Narrative assessment and Safety Plan|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis. The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk."
89675207|NCT04888845|Active Comparator|Narrative assessment and Crisis Response Plan|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis. Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation."
89049989|NCT04612803||IBS-D + dermatographism|IBS-D patients with dermatographism. Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
89049990|NCT02204345|Experimental|RO5479599 + Carboplatin + Paclitaxel|RO5479599 800 milligrams (mg) will be administered in the Safety Run-In Phase by intravenous infusion q3w on Day 1 of 3-weekly cycles (each cycle of 21 days) in combination with carboplatin (to produce an area under the curve [AUC] of 6 mg/milliliter [mL]*minute) and paclitaxel 200 mg per square meter (mg/m^2) by intravenous infusion q3w for 4 to 6 cycles. Thereafter, RO5479599 will be continued as a monotherapy (carboplatin and paclitaxel may be continued at the investigator's discretion) until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
89049991|NCT04612647|Experimental|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)-[Parents and Children-Workshop Group]. In addition to the workshops, this group and the home-based group will receive information (activity booklets) and physical education (physical activity)-related equipment.
89675208|NCT04783012|Experimental|Home removal of catheter after surgery|Patients randomized to home removal will be assigned to remove their catheters on postoperative day (POD) 2 (or if Th/F surgery, POD 4 or POD 3, respectively). They will be handed an instructional packed with visual, written and video instructions for catheter removal.
89675209|NCT04783012|Active Comparator|Office removal of catheter after surgery|Patients randomized to office removal will be assigned to return to the office on POD 2 (or if Th/F surgery, POD 4 or POD 3, respectively) for standard nurse visit with backfill, catheter removal and voiding trial in the office.
89675210|NCT04754243|Experimental|Study group|Will receive ANTIUI protocol
89049992|NCT04612647|Experimental|Home-based group|Participants in the home-based group will not participate in the four half-day workshops, but they will receive the same information (activity booklets) and physical activity equipment as the workshop group (during intervention)-[Parents and Children-Home Group].
89049993|NCT04612647|No Intervention|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-[Parents and Children-Control Group]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks and 3 months after the completion of the 12-week period. Immediately following the follow-up test (3 months after the intervention), participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
89049994|NCT02187302|Experimental|CRLX101 + bevacizumab|"CRLX101 in combination with bevacizumab:~CRLX101 15 mg/m^2 IV on days 1 and 15 of a 28-day cycle;~bevacizumab 10 mg/kg IV on days 1 and 15 of a 28-day cycle."
89049995|NCT02187302|Active Comparator|Standard of Care|Standard of care treatment include one of the following agents to which the patient can have no prior exposure: sorafenib; everolimus; pazopanib; axitinib; bevacizumab; sunitinib, or other approved drug considered by the Medical Monitor to represent an acceptable standard of care therapy
89675211|NCT04754243|Active Comparator|Control group|Will receive standard protocol in IUI and unexplained infertility
89675212|NCT04750616|Experimental|Oral niacinamide|
89675213|NCT04750616|Placebo Comparator|Matched placebo|
89675214|NCT04697576|Experimental|Cohort I (resectable Stage I-III melanoma)|Patients receive an influenza vaccine IM on day 0 and intratumorally on days 2 and 14 in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on day 28.
89675215|NCT04697576|Experimental|Cohort II (unresectable Stage IV)|Patients receive an influenza vaccine IM on day 0 and intratumorally on days 2, 14, 28, 42, 56, 70, 84, and 98 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care (single- or dual-agent) ipilimumab, nivolumab, relatlimab, or pembrolizumab.
89675216|NCT04673422|Experimental|Montelukast|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
89049996|NCT02179151|Placebo Comparator|Placebo|Intervention: ZGN-440 Placebo for Injectable Suspension
89215100|NCT04887337|Active Comparator|Rehabilitation including a period of immobilization followed by physical therapy|Subjects in this group will use an internal-rotation shoulder immobilizer, using a standard sling for 6 weeks from the day of enrollment. Subjects will be advised to maintain range of motion (ROM) in the elbow and wrist during this period of time. The immobilizer can be removed for passive pendulum exercises and elbow ROM during the period of immobilization up to 4 times per day. Formal physiotherapy commences at 4 weeks post-enrollment, with a goal of return to activities or sport at 6-months post-enrollment.
89215101|NCT04879199|Experimental|Typically Developing (TD) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) who are typically developing, 3) able to stand and walk alone without using assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
89215102|NCT04879199|Experimental|Spastic Cerebral Palsy (sCP) children|Static stability and Dynamic stability measurement in children with: 1) between the age of 7 and 18 years, 2) with the diagnosis of spastic CP or CP similar (both unilateral and bilateral), functionally classified level I or II according to the Gross Motor Function Classification System (GMFCS) [98], 3) being able to stand and walk alone without assistance or assistive devices, 4) able to place their feet flat on the force platforms, and 5) with enough German language skills to follow the instructions.
89215103|NCT04868565|Experimental|ongoing caffeine with oxygen supplement (group 1)|"samples assigned to the ongoing caffeine with oxygen supplement (group 1) will continue caffeine administration combining with oxygen supplement until the patients are weaned from oxygen."
89675217|NCT04673422|Placebo Comparator|Placebo|a 10 mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
89675218|NCT04665713||Normal|children whose BMI are in the normal range(From P5 to P85)
89675219|NCT04665713||Overweight|children whose BMI are above the normal range(over P85)
89675220|NCT04646356|Experimental|Tacrolimus immediate-release capsules|subjects will be treated with a 6 months course of oral low-dose tacrolimus capsules to be taken twice daily starting dose of 0.025 mg/kg/day, adjusted to maintain drug blood levels of 2-5ng/ml
89675221|NCT04645810|Experimental|Experimental: High-Dose-Rate prostate brachytherapy|High-Dose-Rate brachytherapy, 2 fractions
89675222|NCT04628936|Experimental|KZR-616 45 mg + standard therapy (open-label)|All patients will receive a SC injection of 30 mg KZR-616 at Visit 1 (Day 1), followed by weekly SC injections of 45 mg KZR-616 up to a maximum of 96 weeks. Study drug administration will end for all patients in Study KZR-616-003E when the last patient enrolled has completed 48 weeks of dosing.
89675223|NCT04623801|Experimental|Participants with papillary microcarcinoma (PTMC)|Participants with papillary microcarcinoma (PTMC) who have elected to proceed with thyroidectomy rather than an observational management approach will be considered as potential candidates for this trial.
89675224|NCT04620239|Experimental|padeliporfin VTP|"Induction Treatment phase:1-3 padeliporfin VTP treatments provided 4 weeks (28 +/-3 days) apart.~Maintenance Treatment Phase: Repeated maintenance VTP treatments during this period will be provided for patients who show evidence of tumor recurrence that is deemed treatable."
89675225|NCT04618016||With Vitamin E|
89675226|NCT04618016||Without Vitamin E|
89675227|NCT04586452|Experimental|AAA Group (Aim 3A)|40 (20 men; 20 women) participants with a diagnosis of AAA (above 40 years) will undergo a PET/CT scan prior to their scheduled surgical repair of their condition. The radiotracer, 64Cu-DOTA-ECL1i, will be injected to detect CCR2+ inflammatory cells. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
89675228|NCT04586452|Experimental|Non-AAA Group|10 (5 men; 5 women) participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard of care. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
89675229|NCT04586452|Other|Ex Vivo Human AAA Specimens (Aim 2A)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens.
89675230|NCT04586452|Other|Radiotracer and CCR2 (Aim 2B)|Tissue samples obtained from an existing tissue bank as well as discarded tissue obtained from participants in this study will be examined to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair.
89675231|NCT04586452|Experimental|AAA Group (Aim 3B-Reproducibility)|20 (10 men; 10 women) will receive a second PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results. A dosage range of 8-10 mCi (296-370 MBq) is planned for 64Cu-DOTA-ECL1i. A PET-certified medical professional will draw and administer the 64Cu-DOTA-ECL1i tracer. The dosage will be assayed in a dose calibrator before and after the administration.
89675232|NCT04567849|No Intervention|Control|No intervention control group
89675233|NCT04567849|Experimental|Nudge: call provider|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call their recent Women's Health provider (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
89675234|NCT04567849|Experimental|Nudge: call tele-nurse|This group will receive a patient portal message the morning after completing their procedure. The message will encourage patients to call Geisinger's nurse triage hotline (with appropriate phone number listed) if any questions or concerns arise about their healthcare.
89675235|NCT04553731|Experimental|The mHealth-based program|The experimental group used the mHealth app and Mi Smart Band 5 on managing and preventing excessive GWG among overweight and obese women during pregnancy
89675236|NCT04553731|No Intervention|The standard antenatal treatments with no mHealth-based elements|controls received standard antenatal treatments with no mHealth-based elements
89675237|NCT04528706|Experimental|MIN-102|
88996048|NCT02935231|Experimental|Nicotine Replacement Therapy|This experimental group receives health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
88996049|NCT02935231|Experimental|Minimal Cessation Advice & Nicotine Replacement Therapy|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
88996050|NCT02935231|Experimental|Minimal Cessation Advice|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet.
88996051|NCT02935231|Active Comparator|Control|This control group receives a health warning leaflet.
88996052|NCT00172380|Experimental|docetaxel and cisplatin|docetaxel 36mg/m2 and cisplatin 75mg/m2
88996053|NCT02935387|Experimental|Taper methotrexate, then golimumab|Taper methotrexate 25>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50>0mg/month during 24 weeks.
88996054|NCT02935387|Active Comparator|Taper golimumab, then methotrexate|Taper golimumab 50>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25>0mg/wk during 24 weeks.
88996055|NCT02935075|Experimental|Reduced dose|Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.
88996056|NCT02935075|Active Comparator|Standard dose|Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.
88996057|NCT02934919|Experimental|nalmefene|
88996058|NCT00172419|Experimental|Atorvastatin|
88996059|NCT02934880|Experimental|Immediate APA|intervention: 10 sessions of APA within the 5 weeks (2 sessions per week) following the randomization
88996060|NCT02934880|Active Comparator|Delayed APA|intervention: 10 sessions of APA in 5 weeks (2 sessions per week) , 3 months after randomization
88996061|NCT02934958|Active Comparator|FIT Positive|Referral to GI or Primary Care. Patients will be referred to MD for pre-colonoscopy vist.Standard of Care.
88996062|NCT02934958|Experimental|FIT Positive Choice|Offered Chioce of Direct referral. Patients will be given a choice to advance to directly having a colonoscopy screening.Colon Cancer Screening Navigation.
88996063|NCT02934997||Community-Acquired Sepsis|The Adult ED at UF JAX is a high volume, high acuity ED which treats approximately 90,000 patients per year. All CA-sepsis patients will be recruited from the UF JAX ED. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours presenting to the UF Health Jacksonville Emergency Department (ED) will be approached for enrollment.
89049997|NCT02179151|Experimental|ZGN-440 Injectable Suspension (1.8 mg)|Intervention: ZGN-440 for Injectable Suspension
89049998|NCT02179151|Experimental|ZGN-440 Injectable Suspension (2.4 mg)|Intervention: ZGN-440 for Injectable Suspension
89675238|NCT04508023|Experimental|Rivaroxaban|Participants will receive rivaroxaban 10 milligram (mg) tablet orally once daily for 35 Days along with standard of care treatment (SOC).
89675239|NCT04508023|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily for 35 Days along with SOC.
89675240|NCT04505098|Active Comparator|Intervention|
89675241|NCT04505098|No Intervention|Usual Care|
89675242|NCT04504981|Other|Y2Prevent Intervention|Y2Prevent will include several intervention components (i.e., My Legacy, Sources of Influence, Healthy Relationships, Goal Setting, Health and Self-Efficacy, and Mentorship). These intervention components are intended to assist participants: a) explore future adult identity and envision a positive future, b) develop behavioral skills related to problem-solving and goal-setting, c) develop behavioral skills related to communication, negotiation and conflict resolution with romantic and sexual partners, d) identify ways to safeguard their future by taking responsibility for their health, e) obtain information about HIV transmission and HIV prevention, including HIV testing, treatment as prevention (TaSP) and the availability of PrEP and PEP for prevention, and f) a participant-identified mentor to provide support and encouragement related to behavior change and implementing their future goals and plans.
89675243|NCT04484636|Other|Hepatocellular Cancer|molecular profiling - hepatocellular cancer (HCC)
89675244|NCT04484636|Other|Cholangiocarcinoma|molecular profiling - intra- and extrahepatic cholangiocellular carcinoma (CCA)
89675245|NCT04484636|Other|Gallbladder Cancer|molecular profiling - gallbladder carcinoma (GBCA)
89675246|NCT04484636|Other|Pancreatic Cancer|molecular profiling - pancreatic cancer (PanCa)
89675247|NCT04484636|Other|Oesophageal Cancer + Stomach Cancer|molecular profiling - esophagogastric cancer (EC/GC)
89675248|NCT04451746|Other|Tableted hormonal drugs for contraception|Tableted hormonal drugs for contraception, 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
89675249|NCT04425018|Experimental|Paclitaxel + Pertuzumab + Margetuximab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days~Paclitaxel- via IV, Day 1,8,15 of each cycle~Margetuximab via IV, Day 1 of each cycle~Pertuzumab via IV, Day 1 of each cycle"
89675250|NCT04425018|Experimental|Paclitaxel + Pertuzumab + Trastuzumab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days~Paclitaxel- via IV, Day 1,8,15 of each cycle~Pertuzumab via IV, Day 1 of each cycle~Trastuzumab via IV, Day 1 of each cycle"
89675251|NCT04327635|Experimental|PEP in Coronary Stent Implantation|Patients undergoing a percutaneous coronary intervention (PCI) and possible stent placement procedure will receive a one-time intracoronary infusion of PEP within 20 minutes after stent placement or post-dilation (whichever comes last).
89675252|NCT04300595|Active Comparator|general anesthesia (Group G)|Patients receive general anesthesia with intravenous opioids and local infiltration of saline (Group G)
89675253|NCT04300595|Active Comparator|Local anesthesia (Group L)|Patients receive general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).
89675254|NCT04279652|Experimental|Supervised exercise group|The treatment program was determined as 3 sessions per week for 8 weeks and 60 minutes per session. The treatment program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
89675255|NCT04279652|Active Comparator|Home exercise group|The exercise program, which is prepared for the individual, will be applied to the home exercise group with 60 minutes of 3 times a week.
89675256|NCT04279652|No Intervention|Control group|Children will not be included in any treatment program. The assessments will be done again 8 weeks later.
89675257|NCT04272060|Experimental|CT Angiography|Research CT angiography.
89675258|NCT04272060|Active Comparator|Conventional Angiography|Standard medical care which includes cardiac catheterization and invasive coronary angiography.
89675259|NCT04256954|Experimental|Peer navigation|Those who are assigned to the intervention arm will receive peer navigation service by a trained peer navigator who will link them with mental health, medical and substance use services in the community.
89675260|NCT04256954|No Intervention|Standard of Care|SOC consists of TAU + monitoring and emergency referral, as is required to fulfil ethical obligations to trial participants. To determine the naturalistic effects and costs of adding peer navigation intervention, participants in both conditions can receive any other treatment available to them and we will not exclude participants receiving other treatment. We will carefully characterize TAU for each condition as part of our service utilization assessment.
89675261|NCT04212026|Experimental|Nivolumab|"Nivolumab treatment will be given every 2 weeks at a standard flat dose of 240 mg for a total of 5 doses, and the IRE procedure will be performed using the standard setting to ablate tumors at the level of the liver that is well tolerated by the patients. Two weeks after the last dose of nivolumab (Week 8), radiological restaging will be performed (=Week 10)."
89675262|NCT04210492|Experimental|45 Gy|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
89675263|NCT04201444|Experimental|Patient group|
89675264|NCT04201444|Active Comparator|Remission control group|
89675265|NCT04201444|Active Comparator|Bilateral surrenalectomy control group|
89675266|NCT04187144|Experimental|Gepotidacin|Participants will be administered oral doses of 1500 milligrams (mg) gepotidacin plus nitrofurantoin matching placebo BID; approximately every 12 hours for 5 days.
89675267|NCT04187144|Active Comparator|Nitrofurantoin|Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.
89675268|NCT04172038|Experimental|Phase I: Physical Therapy (PT)|Initial Randomization: The initial PT treatment session will occur within 7 days of enrollment in the study. Precise dosage (i.e, number of PT sessions) will be at the discretion of the physical therapist directing the participant's care, up to a maximum of 2-3 sessions per week over the 6-week Phase I treatment period.
89215104|NCT04868565|Active Comparator|discontinuing caffeine with oxygen supplement (group 2)|"samples assigned to the discontinuing caffeine with oxygen supplement (group 2) will discontinue caffeine immediately after randomization, while oxygen supplement is going on."
89215105|NCT04858776|Experimental|Treatment|
89215106|NCT04858776|Sham Comparator|Control|
89215107|NCT04849416|Experimental|LOXO-305|LOXO-305 administered orally.
89215108|NCT04848142||Primary Group (parent-child)|parents (i.e., guardians/caregivers) and children age ≥ 8 years,will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment. Optional qualitative interviews may be completed individually for participants (age ≥ 12 years with P/LP variant and aware of results, or their parent)
89215109|NCT04848142||Parent Only Group|parents of children age < 8 years, will complete questionnaires to examine the impact of germline variant disclosure on parent adjustment, parenting, and child adjustment.
89215110|NCT04825847|Active Comparator|Electroencephalographic (EEG)-guided group|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
89675269|NCT04172038|Experimental|Phase I: Move to Health (M2H)|"Initial Randomization: M2H is a key component of Army Medicine's System for Health, along with the Performance Triad. It is a person-centered, holistic, and experience-centric approach to promoting healthy behaviors (nutrition, physical activity, sleep, instrinsic factors, extrinsic factors). Precise dosage (i.e, number of M2H sessions) will be at the discretion of the health coaches. Sessions may be delivered in-person or utilize technology including text messaging, telephone, e-mail, video chat, app-based self-management etc."
89675270|NCT04172038|Experimental|Phase II: Combine PT & M2H|Sequential Randomization: Participants randomized to receive a combination of PT and M2H as a Phase II intervention will continue their Phase I treatment (either M2H or PT). The participant will begin the treatment component that was not part of their Phase I intervention.
89675271|NCT04172038|Experimental|Phase II: MORE Mindfulness|Sequential Randomization: Participants randomized to receive mindfulness as a Phase II intervention will discontinue their Phase I treatment. The Mindfulness-Oriented Recovery Enhancement (MORE) treatment was designed specifically to address symptoms and underlying mechanisms of chronic pain in the military context and is led over 8 individual sessions.
89675272|NCT04159545||Participants treated with DAAs|"Participants identified through the standard pathway of care as receiving Direct-Acting Antiviral (DAA) drugs to treat chronic hepatitis C with a history of problematic substance use.~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
89675273|NCT04159545||Control Group|"Participants identified through the standard pathway of care as having HCV positive antibodies who spontaneously clear the infection.~Participants will be interviewed on 3 occasions over the course of 2 years. Participants views, meanings and value of cure will be explored through semi-structured interviews.~Participants will also complete quantitative questionnaires to measure changes in drug taking behaviours of drugs used and frequency (WHO ASSIST 3.0 Q2), Map social networks (SIM-AIRing), Measure wellbeing in terms of economic and social value (Short Warwick- Edinburgh Mental Wellbeing Scale (SWEMWBS) and financial inclusion, household income and employment data)."
89675274|NCT04017468|Active Comparator|Treatment Arm|The powdered vancomycin will be placed subcutaneously over the closed muscle fascia (suprafascially) at the end of the surgery during wound closure.
89675275|NCT04017468|No Intervention|Control Arm|The control group receiving only a standard preoperative antimicrobial prophylaxis administered intravenously.
89675276|NCT03996824||AAV viral transduction|Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
89675277|NCT03987282|Active Comparator|Enhanced usual care (EUC)|The EUC consists of provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
89675278|NCT03987282|Experimental|Fully Implemented Seek-Test-Treat-Retain (FI-STTR) model|The FI-STTR care model will include the usual care supplemented by continuing education and coaching of medical staff at HIV/AIDS and MMT clinics and by provision of additional peer-based counseling intervention
89675279|NCT03976310|Other|The study population|The study population corresponds to severe eosinophilic asthma patients (see eligibility criteria).
89675280|NCT03949764|Experimental|HCV Positive Study Participants|Study participants will be administered a standard 12-week course of sofosbuvir/velpatasvir (Epclusa®).
89215111|NCT04825847|Active Comparator|Standard Care (SC) group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at [0.8-1.2] MAC.
89215112|NCT04815473|Other|Patients treated with AndraValvulotome|
89215113|NCT04804280||Preterm children (PT)|"gestational age at birth: 26+0 to 31+6 weeks;~absence of documented neurological pathology;~absence of sensory deficits;~absence of malformative syndromes and/or major malformations."
89215114|NCT04804280||Full-term children (FT)|"gestational age at birth ≥ 37 weeks;~birth weight ≥ 2,500g;~APGAR 5' ≥ 7~delivery without any complications for baby and/or mother;~no prenatal and/or postnatal clinical conditions;~no hospitalizations at the time of birth or postpartum;~absence of malformative syndromes and/or major malformations."
89215115|NCT04796415|Experimental|DEMA-Pro|The DEMA-Pro intervention will be administrated. Subjects will attend six weekly, 1-hour telephone sessions.
89215116|NCT04786340|Placebo Comparator|Placebo: 4 mL of matching placebo topical solution.|The placebo solution contains the same ingredients as the active solution with the exception of the active WST-057. It is dispensed with a pump to deliver 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.
89675281|NCT03949764|No Intervention|Control (Pike County)|After completion of the study, we will compare HCV incidence and prevalence rates in Perry County (intervention) and Pike County (control). This will be measured through data provided by the local health departments of each county. Confidential Hepatitis C screening will be conducted in some cases, and resources will be provided to those testing positive but they will not receive treatment as part of this study.
89675282|NCT03930212|Experimental|Progesterone|received rectal progesterone suppositories 400 mg once daily
89675283|NCT03930212|Placebo Comparator|Control group|received placebo suppositories rectally once daily.
89675284|NCT03913208|Experimental|Study group|Will be subjected to priority to freeze
89675285|NCT03913208|Active Comparator|Control group|Will receive fresh embryo transfere
89675286|NCT03903536||Thrombectomy|Patients with thrombosed external hemorrhoids undergoing thrombectomy
88996064|NCT02934997||Hospital-Acquired Sepsis|UFH (Gainesville) is a Level 1 Trauma Center and surgical tertiary care center with 24 trauma intensive care unit (ICU) and 24 surgery ICU beds and are the primary ICUs for almost every surgical patient in the hospital and the location for recruitment for Project #1 of the Sepsis P50. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours in the UFH Surgical ICU will be approached for enrollment.
88996065|NCT02934763|Placebo Comparator|Placebo|Saline solution by target controlled infusion
88996066|NCT02934763|Active Comparator|Propranolol at 5ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml
88996067|NCT02934763|Active Comparator|Propranolol at 15ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml
88996068|NCT04689958|Experimental|Experimental Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline and vitamin D 5000 IU once daily (experimental group).
88996069|NCT04689958|Active Comparator|Control Group|Receive standard therapy consists of gabapentin, pregabalin, or amitriptyline
88996070|NCT02934841|Experimental|Conbercept|The patients are followed on a monthly basis until 12 months. Three intravitreal injections of conbercept at a dosage of 0.5 mg are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
88996071|NCT02934841|Sham Comparator|sham|The patients are followed on a monthly basis until 12 months. Three intravitreal sham injections are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
88996072|NCT02934724||Vaccinated|"Women born in 1997, resident to Norway in 2009, vaccinated by the quadrivalent HPV vaccine.~Interventions:~Self sample from vagina using Rover's Evalyn Brush~Self sample from the oral cavity using COPAN's FloqSwab~Questionnaire"
88996073|NCT02934724||Un-vaccinated|"Women born in 1997, resident to Norway in 2009, not vaccinated by the quadrivalent HPV vaccine~Interventions:~Self sample from vagina using Rover's Evalyn Brush~Self sample from the oral cavity using COPAN's FloqSwab~Questionnaire"
88996074|NCT02934412|Experimental|SHR-1314 20mg|20mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
88996075|NCT02934412|Experimental|SHR-1314 40mg|40mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
88996076|NCT02934412|Experimental|SHR-1314 80mg|80mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
88996077|NCT02934412|Experimental|SHR-1314 160mg|160mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
88996078|NCT02934412|Experimental|SHR-1314 240mg|240mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
88996079|NCT02934607|Active Comparator|Treatment A|2 x 160/4.5 µg Symbicort pMDI administered with no spacer device; no activated charcoal (systemic exposure).
88996080|NCT02934607|Experimental|Treatment B|2 x 160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; no activated charcoal (systemic exposure).
88996081|NCT02934607|Active Comparator|Treatment C|160/4.5 µg Symbicort pMDI administered with no spacer device; with activated charcoal (lung exposure).
88996082|NCT02934607|Experimental|Treatment D|160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; with activated charcoal (lung exposure).
89675287|NCT03903536||Local excision/ Hemorrhoidectomy|Patients with thrombosed external hemorrhoids undergoing local excision/ hemorrhoidectomy
89675288|NCT03898908|Experimental|COMBO450|"Encorafenib - Orally, 75 mg and 50 mg capsules Binimetinib - Orally, 15 mg tablets~In each cohort, patients will be treated with encorafenib 450 mg once daily and binimetinib 45 mg twice daily until PD or death."
89675289|NCT03893617|Active Comparator|Propranolol group|This group will receive a single oral dose (80mg) of propranolol in a blinded capsule during their acute stress study visit.
88996083|NCT02934685|Experimental|hypofraction|70 Gy in 28 fractions over 5.6 weeks
88996084|NCT02934685|Active Comparator|convention|80Gy in 40 fractions over 8 weeks
88996085|NCT00153257|Other|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
88996086|NCT00153257|No Intervention|No device|standard anterior colporrhaphy
88996087|NCT02934334||MDD|Major Depressive Disorder
88996088|NCT02934490|Experimental|Treatment group|
88996089|NCT00165282|No Intervention|Usual Care|Normal standard of care
88996090|NCT00165282|Active Comparator|Nurse education|Meets with oncology nurse
88996091|NCT00165282|Experimental|Mindfulness training|Taught Mindfulness meditation
89675290|NCT03893617|Placebo Comparator|Placebo group|This group will receive a single blinded capsule containing no active medication during their acute stress study visit.
89675291|NCT03856047|Experimental|NNC0174-0833, 4.5 mg|Patients will receive 4.5 mg of NNC0174-0833 once a week as injections for 26 weeks.
89675292|NCT03856047|Experimental|NNC0174-0833, 2.4 mg|Patients will receive 2.4 mg of NNC0174-0833 once a week as injections for 26 weeks.
89675293|NCT03856047|Experimental|NNC0174-0833, 1.2 mg|Patients will receive 1.2 mg of NNC0174-0833 once a week as injections for 26 weeks.
89675294|NCT03856047|Experimental|NNC0174-0833, 0.6 mg|Patients will receive 0.6 mg of NNC0174-0833 once a week as injections for 26 weeks.
89675295|NCT03856047|Experimental|NNC0174-0833 0.3 mg|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
89049999|NCT02163746|Active Comparator|CO2 (carbon dioxide) laser|Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
89050000|NCT02163746|Active Comparator|Surgical Deroofing|Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
89050001|NCT02160665|Placebo Comparator|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
89050002|NCT02160665|Other|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
89050003|NCT02160665|Active Comparator|Test:Tazarotene Cream, 0.05%|Test: Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
89050004|NCT04611984|Experimental|Piezocision|Piezocision was performed on the mesial and distal side of the maxillary right canine tooth which was served as the piezocision group. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
89050005|NCT04611984|Active Comparator|Control|Maxillary left canine served as the control group and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
89050006|NCT04633707|Experimental|Adjunctive morning BLT group|treat participants with adjunctive BLT in the morning
89675296|NCT03856047|Placebo Comparator|Placebo 2.4 mg (NNC0174-0833)|Patients will receive 2.4 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
89675297|NCT03856047|Placebo Comparator|Placebo 4.5 mg (NNC0174-0833)|Patients will receive 4.5 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
89675298|NCT03856047|Placebo Comparator|Placebo 1.2 mg (NNC0174-0833)|Patients will receive 1.2 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
89675299|NCT03856047|Placebo Comparator|Placebo 0.6 mg (NNC0174-0833)|Patients will receive 0.6 mg of placebo (NNC0174-0833) once a week as injections for 26 weeks.
89675300|NCT03856047|Placebo Comparator|Placebo 0.3 mg (NNC0174-0833)|Patients will receive 0.3 mg of NNC0174-0833 once a week as injections for 26 weeks.
89675301|NCT03856047|Active Comparator|Liraglutide 3.0 mg|Patients will receive 3.0 mg of liraglutide once daily as injections for 26 weeks.
89675302|NCT03856047|Placebo Comparator|Placebo 3.0 mg (Liraglutide)|Patients will receive placebo 3.0 mg(liraglutide) once daily as injections for 26 weeks.
89675303|NCT03855566|Other|Intervention|Enrolled participants will receive the intervention.
89675304|NCT03737136|No Intervention|Plasmapheresis|5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375mg/m2 rituximab at the end of last session
89675305|NCT03737136|Active Comparator|Plasmapheresis plus Bortezomib|Drug 5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375ml/m2 rituximab at the end of last session plus bortezomib Injections 1.3mg/m2 intravenously on days 1, 4, 8, and 11
89675306|NCT03734523||Pilot Group: 12 week study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for 12 weeks. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
89675307|NCT03734523||Study Group: 6 month study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for six months. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
89675308|NCT03647163|Experimental|Safety Run-in Dose Level 1|Patients with pembrolizumab refractory solid tumors will receive a single IV dose of 5e10 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
89050007|NCT04633707|Experimental|Adjunctive afternoon BLT group|treat participants with adjunctive BLT in the afternoon
89050008|NCT04633707|Placebo Comparator|Adjunctive placebo therapy group|treat participants with adjunctive dim red light in the afternoon
89050009|NCT02138630|Placebo Comparator|Placebo|
89050010|NCT02138630|Experimental|Capsaicin|"Single Capsule, Capsimax 100 mg, ingested 60 min prior to exercise"
89050011|NCT04612023|Active Comparator|1 mL NyDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 1 mL NyDYN injection.
89050012|NCT04612023|Active Comparator|2 mL NuDYN Injection|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL NyDYN injection.
89050013|NCT04612023|Placebo Comparator|Placebo of Sterile Saline|30 patients (out of 90) will be blind to and randomly assigned to a 2 mL dose of sterile saline.
89050014|NCT02137343|Experimental|Rilotumumab|Rilotumumab plus Cisplatin and Capecitabine (CX).
89050015|NCT02137343|Placebo Comparator|Placebo|Rilotumumab-placebo plus Cisplatin and Capecitabine (CX).
89050016|NCT02125253|Experimental|Mometasone Furoate Nasal Spray, 50 mcg|Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
89050017|NCT02125253|Active Comparator|Nasonex Nasal Spray, 50 mcg|Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
89050018|NCT02125253|Placebo Comparator|Placebo Nasal Spray|Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
89050019|NCT02116244|Experimental|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily for 12 weeks
89050020|NCT04611555||CI users|
89050021|NCT04633083|Other|Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbosacral level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbosacral level ii. Scapular plane abduction under 150°~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
89675309|NCT03647163|Experimental|Safety Run-in Dose Level 2|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) or non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
89675310|NCT03647163|Experimental|Expansion NEC|Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
89675311|NCT03647163|Experimental|Expansion NSCLC arm|Patients with pembrolizumab refractory non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
88996092|NCT02934646|Experimental|Subacute stroke patients|Elbow passive/active robotic treatment provided by NEUROExos Elbow Module
88996093|NCT02934373|Active Comparator|A New Sound Processor|Sound Processor is the next generation sound processor.
89675312|NCT03647163|Experimental|Expansion Part D|Patients with non small cell lung cancer (NSCLC) or Neuroendocrine Carcinoma (NEC) will receive a single IV dose of VSV-IFNβ-NIS on Day 4 in combination with ipilumumab + nivolumab at standard labeled dose administered on Day 1 then every 21 days up to 2 years.
89675313|NCT03635749|Active Comparator|DAPT + immediate high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.
89675314|NCT03635749|Other|DAPT + delayed high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.
89675315|NCT03635749|Other|Aspirin+immediate high-intensity statin|This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.
89675316|NCT03635749|Placebo Comparator|Aspirin+delayed high-intensity statin|This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.
89675317|NCT03599453|Experimental|Treatment (chemokine modulation therapy)|Participants undergo pre-treatment biopsy. Participants then undergo chemokine modulation therapy consisting of celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV over 30-60 minutes on days -11 to -9, and -4 to -2. Participants then undergo additional biopsy. Following biopsy and chemokine modulation therapy, participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
89675318|NCT03573960|Experimental|Lenvatinib 24 mg|Participants will receive 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily with or without food in 28-day cycles until disease progression or until unacceptable toxicity occurs.
89675319|NCT03554291|Experimental|Famotidine|"20mg of oral famotidine (pill) daily~Other names: Pepcid"
89675320|NCT03554291|Placebo Comparator|Placebo|Daily oral placebo (pill)
89675321|NCT03553576|Experimental|Low volume bolus|6.25 mL administration at 250 ml per hour of a greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL)
89675322|NCT03553576|Experimental|High volume bolus|10 mL administration of a lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL).
89675323|NCT03525431|Experimental|Whole Exome Sequencing|Following consent and collection of standardized phenotypic data, probands and biological parents will undergo WES with variant analysis conducted utilizing primary gene lists based on referring clinical indication. After results provision and follow up 6-12 months later, clinical utility will be assessed in those with a positive result (pathogenic or likely pathogenic variant) and those with negative results (no variant returned or a VUS) using specific outcomes at each site to examine effectiveness for both the child and family.
89675324|NCT03464461|Placebo Comparator|0 mg|0 mg ketorolac - placebo
89675325|NCT03464461|Active Comparator|10 mg|10 mg ketorolac - low dose ketorolac
89675326|NCT03464461|Active Comparator|30 mg|30 mg ketorolac - usual dose ketorolac
88996094|NCT02934373|No Intervention|Subject's own sound processor|
88996095|NCT02934139|Experimental|Cavosonstat (N91115) 400 mg|Every 12 hour oral dosing of N91115 for 7 days
88996096|NCT02934139|Experimental|Cavosonstat (N91115) 600 mg|Every 12 hour oral dosing of N91115 for 7 days
88996097|NCT02934139|Experimental|Cavosonstat (N91115) 1200 mg|Once daily oral dosing of N91115 for 7 days
88996098|NCT02934139|Experimental|Cavosonstat (N91115) 800 mg|Every 12 hour oral dosing of N91115 for 7 days
88996099|NCT02934139|Placebo Comparator|Placebo|Matched placebo. Oral dosing every 12 hour or once daily for 7 days
88996100|NCT02934100|Active Comparator|Group 1 - ESWT Treatment|Patients treated with Extracorporeal Shock Wave Therapy once a week for 10 weeks
88996101|NCT02934100|Active Comparator|Group 2 - Body Wave|Patients treated with electric field diathermy three times a week for 5 weeks
88996102|NCT02934100|Active Comparator|Group 3 - Ultrasound|Patients treated with ultrasound therapy three times a week for 5 weeks
88996103|NCT02934100|Sham Comparator|Group 4 - Control group|Patients treated with sham laser therapy three times a week for 5 weeks
88996104|NCT00172536|Other|Control|Received oral general education about proper diet, regular physcial activity and other medical care if necessary
88996105|NCT00172536|Experimental|Exercise training|Received a supervised structure treadmill training
88996106|NCT02934295|Experimental|Pregnant women|
88996107|NCT02934022|Other|Maraviroc|
88996108|NCT02934256|Experimental|Icotinib，treatment effect evaluation|Patients use Icotinib hydrochloride tablets during the course of treatment. The drug dosage is 125mg/m3/d. Every course of treatment lasts three months. Patients are designed to receive total four courses of treatment if there is no disease progression.
88996109|NCT02933983||Control group (healthy)|Participants who do not suffer from acute or chronic airway infections
88996110|NCT02933983||CRS patients|Patients who suffer from chronic rhinosinusitis
88996111|NCT04651543||no control X-Ray|patients with a proximal humeral fracture without one-week X-Ray control
88996112|NCT04651543||one-week X-Ray control|patients with a proximal humeral fracture with one-week X-Ray control
88996113|NCT02934061|Experimental|Tizaspray®|Tizaspray® administered intranasally in patients with acute low back pain
88996114|NCT02934061|Active Comparator|Sirdalud®|Sirdalud® 2 mg tablets administered in patients with acute low back pain
89050022|NCT04633083|Other|No Signs of impingement|"a. non- limited ROM i. Endorotation control until lumbar level ii. Scapular plane abduction above 150° b. limited ROM i. Endorotation control lower then lumbar level ii. Scapular plane abduction under 150°~Intervention: clinical data, imaging data, movement analysis, EOS measurements, ROM simulation"
89675327|NCT03456115|Experimental|Mechanical Nasal Dilator|All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
89675328|NCT03440437|Experimental|FS118 weekly|The initial cohorts will enroll sequentially as single-participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design followed by an expansion cohort of participants with SCCHN and an expansion SCCHN cohort in combination with Paclitaxel.
89675329|NCT03374956|Experimental|Intervention group|Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
89675330|NCT03374956|Active Comparator|Control Group|Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine
89675331|NCT03334682|Experimental|spironolactone|Spironolactone ARROW ® 75 mg, 150mg, orally, once a day during all the trial (12 months: 6 months on double-blinded spironolactone then 6 months on open-label spironolactone), + topical therapy during all the trial (benzoyl peroxide 5%)
89675332|NCT03334682|Active Comparator|doxycycline|(Doxycycline Sandoz 100 mg), 100mg/day during 3 months followed by placebo during 3 months, on double-blinded + topical therapy during all the trial (benzoyl peroxide 5%
89050023|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
89050024|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
89050025|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
89675333|NCT03221374|Experimental|Mindfulness Based Stress Reduction|Participants will attend an 8-week Mindfulness Based Stress Reduction (MBSR) course between pre- and post-testing.
89050026|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
89050027|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
89050028|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
89675334|NCT03221374|No Intervention|Waitlist|Participants will be added to a waitlist intervention group for 8-weeks between pre-and post-testing.
89675335|NCT03219879|Experimental|Telephone-administered continuation therapy|Cognitive-behavioral continuation therapy (T-CT) delivered over the telephone by trained psychotherapist
89050029|NCT02114060|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
89050030|NCT04677998||Personalized surveillance and intervention protocol|
89675336|NCT03219879|Active Comparator|Usual care|Treatment as usual
89050031|NCT00560898|Experimental|2|contact lenses disinfected in multipurpose solution
89050032|NCT00560898|Experimental|3|contact lenses disinfected in multipurpose solution
89050033|NCT00560898|Experimental|4|contact lenses disinfected in multipurpose solution
89050034|NCT00560898|Experimental|1|contact lenses disinfected in multipurpose solution
89675337|NCT03112603|Experimental|Ruxolitinib|Ruxolitinib for the treatment period and extension period.
89675338|NCT03112603|Active Comparator|Best Available Therapy|Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
89675339|NCT03075917|Experimental|Experimental|questionnaire for allergic rhinitis control children from 5 to 11 years old who complete a self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
89675340|NCT03073317|Experimental|INTERVENTION|Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
89675341|NCT03073317|No Intervention|CONTROL|Usual clinic control
89675342|NCT03050216|Experimental|Cy, FLU, Haplo NK and ALT-803|"Preparative Regimen of Fludarabine and Cyclophosphamide~ALT-803 Activation of Donor NK Cells~ALT-803 to Facilitate NK Cell Survival and Expansion"
89675343|NCT02984241|Active Comparator|eHealth Coping Skills Training + Coach|Access to StopSpinningMyWheels.org + Coach Support
89675344|NCT02984241|Active Comparator|eHealth Coping Skills Training Only|Access to StopSpinningMyWheels.org
89675345|NCT02984241|Active Comparator|eHealth Usual Web Care|Access to StopSpinningMyWheels.org usual care
89675346|NCT02829593|Experimental|type 1 diabetes|type 1 diabetes >5 years duration
89050035|NCT02104388|Experimental|SJP-0035 Ophthalmic Solution|Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
89050036|NCT02104388|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic Solution|Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
89050037|NCT04611828|Experimental|Philips SmartSleep Device|"Participants will be instructed to sleep wearing the SmartSleep device at home for eight weeks, which will include three (3) two-week periods, one each of the following (in randomized order):~continuous fixed interval (ITI): SmartSleep will provide 1 Hz, inter-tone interval stimulation continuous during deep sleep opportunities~block: SmartSleep will provide 5s ON versus 5s OFF,1Hz inter-tone interval stimulation~in-phase adjustable: SmartSleep will provide constant stimulation with tones timed to be delivered during each upstate of the slow wave~Between periods 1 and 2 and between periods 2 and 3, subjects will undergo one week of sham condition during which SmartSleep will record EEG during sleep using a no-volume sham stimulation"
89050038|NCT04678037|Active Comparator|Group A (PROs assessment every 2 weeks)|
89675347|NCT02829593|Placebo Comparator|healthy controls|
89675348|NCT02736266|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered at the dose of 200mg, as a 30-minute intravenous infusion, every 3 weeks, for a total of 3 cycles prior to radical cystectomy.
89675349|NCT02725528|Active Comparator|collagenase injection|This procedure will be performed either in a minor procedure room or the hand clinic as per surgeon's routine practice. Collagenase will be administered with or without local anesthesia. As this is a pragmatic study there may be more than one digit injected at a time just as surgery occurs on more than one digit at a time. A recently published study by Gaston et al confirmed that two concurrent injections of collagenase to 2 affected joints in the same hand are generally well tolerated and the frequency of most adverse events (AEs) is similar to those reported in studies that use single sequential injections.
89675350|NCT02725528|Active Comparator|limited palmar fasciectomy|The Dupuytren's cord will be excised under local anesthesia in a minor procedure room setting or main operating room under local or general anesthetic depending on the complexity of the disease and the surgeon's routine. As this is a pragmatic study comparison of collagenase injections (novel intervention) to limited palmar fasciectomy as it is actually presently performed in all settings academic or community (local in minor room or general/local anesthetic in the main operating room) will be examined. Surgery will be performed according to the operating surgeon's preferred technique i.e. zig-zag Brunner incision or straight incision with z-plasty closure of the skin.
89675351|NCT02661451|Experimental|TAVR (with SAPIEN 3 THV) and OHFT|Transcatheter heart valve and Optimal Heart Failure Therapy
89675352|NCT02661451|Active Comparator|OHFT|Optimal Heart Failure Therapy
89675353|NCT02629614|Experimental|TAPS Stimulation|Temporal Afferent Patterned Stimulation (TAPS) is alternating bursts of TENS stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
89675354|NCT02629614|Sham Comparator|Sham Stimulation|0 amplitude stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
89675355|NCT02627963|Experimental|Tivozanib hydrochloride|Participants randomized to this arm will receive the study drug, tivozanib hydrochloride.
89675356|NCT02627963|Active Comparator|Sorafenib|Participants randomized to this arm will receive the comparator drug, sorafenib.
89675357|NCT02589691|Experimental|Rocuronium|Intra-venous injection during induction anesthesia of 0.3 mg/kg (1 mL/kg) of rocuronium
89675358|NCT02589691|Placebo Comparator|Placebo|Intra-venous injection during induction anesthesia of 1 mL/kg of sodium chloride 0.9%
89675359|NCT02585258|Experimental|prednisolone|prednisolone 5 mg per day
89675360|NCT02585258|Placebo Comparator|placebo|placebo capsules once per day
89675361|NCT02525432|Experimental|Autologous BMMNC Infusion|Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.
89675362|NCT02525432|Placebo Comparator|Placebo Infusion|"Subjects randomized to the placebo control group will undergo a sham bone marrow harvest."
89675363|NCT02408952|Experimental|Primary Care Physician|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered is by the primary care physician
89675364|NCT02408952|Experimental|Behavioral Medicine Specialist|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered by the behavioral medicine specialist
89675365|NCT02408952|No Intervention|Usual Care|Care is administered as usual
89675366|NCT02394626|Experimental|Surgery followed by adjuvant second-line therapy|Surgery followed by adjuvant second-line therapy
89675367|NCT02394626|Active Comparator|Second-line therapy alone|Second-line therapy alone
89675368|NCT02339545||All Enrolled Subjects|All subjects will receive Coronary Flow Reserve (CFR) measurements post successful orbital atherectomy treatment and stenting.
89675369|NCT02203604|Experimental|Treatment (aldesleukin, ipilimumab)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 and high-dose aldesleukin IV on days 22-26 and 43-47.~MAINTENANCE: Beginning on weeks 24, patients without disease progression or unacceptable toxicity receive ipilimumab IV over 90 minutes once every 12 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity."
89675370|NCT02132611|Experimental|Diamondback 360® Coronary OAS Micro Crown|Diamondback 360® Coronary Orbital Atherectomy System Micro Crown
89675371|NCT01989013|Other|biweekly intervention|biweekly intervention
89675372|NCT01941030|Experimental|Orbital Atherectomy System|Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
89050039|NCT04678037|Active Comparator|Group A (PROs assessment every 4 weeks)|
89050040|NCT04633044|Placebo Comparator|Placebo|400 mg of lactose daily for 12 weeks
89050041|NCT04633044|Experimental|Supplement|400 mg of betaine daily for 12 weeks
89050042|NCT02104076|Experimental|Evolution® Biliary Stent-Fully Covered|
89050043|NCT04632849|Experimental|GEM + CGM|A self-directed lifestyle intervention for controlling Type 2 Diabetes
89050044|NCT04611438|Experimental|CBD|The patient would be on cannabidiol for 24 weeks and would go through laboratory, electroencephalography, and neuropsychological tests before, during, and after intervention.
89050045|NCT02096666|Experimental|Single arm|
89050046|NCT04632693|Experimental|CAF with SCTG and vitamin C|Coronally advanced flap with subepithelial connective tissue graft and vitamin C.
89050047|NCT04632693|Active Comparator|CAF with SCTG|Coronally advanced flap with subepithelial connective tissue graft.
89050048|NCT02093429|Experimental|INCB047986 4 mg|Participants will receive INCB047986 4 mg once daily for at least 16 weeks.
89675373|NCT01941030|Active Comparator|Balloon Angioplasty|Balloon Angioplasty (BA) alone
89675374|NCT01899339||pulmonary embolism|patients with submassive pulmonary embolism
89675375|NCT01342380||Seroquel|Participants who received Seroquel
89675376|NCT01342380||Pioglitazone|Participants who received pioglitazone
89675377|NCT01228240|Experimental|Metformin, Apo-metformin|Participants under treatment with non-generic Metformin (manufactured by Apotex Canada).
89675378|NCT01228240|Active Comparator|Metformin, Pars Minoo|Participants under treatment with generic Metformin (manufactured by Pars Minoo).
89675379|NCT00701220|Active Comparator|Ischemic Cardiomyopathy|Patients with Ischemic Cardiomyopathy receiving Lipitor (Atorvastatin calcium).
89675380|NCT00701220|Active Comparator|Non Ischemic Cardiomyopathy|NonIschemic Cardiomyopathy receiving Lipitor (Atorvastatin calcium) treatment
89675381|NCT00701220|No Intervention|Healthy Subjects|Healthy subjects with no history of high cholesterol, heart disease, or heart attacks
89675382|NCT00677924|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with Irinotecan
89675383|NCT00677924|Experimental|Zalutumumab 16 mg/kg|Zalutumumab in combination with Irinotecan
89675384|NCT00251303|Experimental|riluzole|Active drug put into 10-mg capsule form,,prepared by Clinical Center Pharmacy. Dose up to 120 mg daily, divided. Brand name Rilutek.
89675385|NCT00251303|Placebo Comparator|placebo|Placebo Capsules designed to mimic active drug capsules
89675386|NCT00303823|Experimental|Arm I|Patients receive oral green tea extract once daily for 16 weeks in the absence of unacceptable toxicity.
89675387|NCT00303823|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 16 weeks in the absence of unacceptable toxicity.
89675388|NCT00300677|Experimental|voriconazole|voriconazole twice daily
89675389|NCT00303901|Experimental|cryosurgery|cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
89675390|NCT00252629|Active Comparator|Therapeutic nasal CPAP|Comparing change of veterans reported outcomes before and after 3 weeks treatment of therapeutic nasal CPAP with the change on sham nasal CPAP.
89675391|NCT00252629|Sham Comparator|Sham nasal CPAP|Comparing change of symptoms and veterans reported outcomes before and after treatment of 3 weeks on sham nasal CPAP with the change on therapeutic nasal CPAP
89675392|NCT00559845|Experimental|Bevacizumab|Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.
89675393|NCT00303979||Cohort A (longitudinal)|Longitudinal Cohort: Approximately 15,000 patients followed at baseline, 12 months and 24 months
89675394|NCT00303979||Cohort B (6 Month)|6 Month Cohort: Approximately 10,000 patients reviewed at single time point
89675395|NCT00303979||Cohort C (18 Month)|18 Month Cohort: Approximately 10,000 patients reviewed at single time point
89675396|NCT00304187|Experimental|Erythromycin|Subjects with Bulimia Nervosa will take erythromycin.
89675397|NCT00304187|Placebo Comparator|Placebo|Participants will take matched placebo.
89675398|NCT01867515|Active Comparator|Younger normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~age between 18 and 35~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
89675399|NCT01867515|Active Comparator|Hearing-impaired listeners|"individuals with bilateral sensorineural hearing losses with thresholds between 25 and 70 dB HL and no losses greater than 70 dB HL at frequencies of 4000 Hz or below~age 18 to 65 Acoustic distortion of speech"
89675400|NCT01867515|Active Comparator|Older normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~age between 36 and 65~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
89675401|NCT00324701|Experimental|Telepsychology|therapy done at patients house
89675402|NCT00324701|Active Comparator|Face-to-face therapy|therapy delivered at the VAMC
89675403|NCT02482389|Experimental|Single arm 7 Gray (Gy) fraction of radiotherapy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
89675404|NCT00324857|Placebo Comparator|Arm 1/Attention Control|Subjects randomized to the attention control arm received a patient educational booklet about OA published by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This booklet provides a brief educational program that summarizes how to live with knee OA but does not specifically mention joint replacement
89675405|NCT00324857|Active Comparator|Arm 2/Decision Aid (DA)|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
89675406|NCT00324857|Active Comparator|Arm 3/ Motivational Interview (MI)|Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain
89675407|NCT00324857|Active Comparator|Arm 4/ DA and MI|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.~Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain"
89675408|NCT00334633|Active Comparator|control|metronidazole 500 BID for 7 days
89675409|NCT00334633|Active Comparator|tinidazole 500|tinidazole 500 BID for 7 days
89675410|NCT00334633|Active Comparator|tinidazole 1 gm|tinidazole 1 gm BID for 7 days
89675411|NCT01790477|Experimental|Auricular Acupuncture|Use of auricular acupuncture in bilateral ears
89675412|NCT01790477|No Intervention|Control|
89675413|NCT01393964|Experimental|Arm 1: Lenalidomide + Dexamethasone +Elotuzumab|Severe Renal Impairment
89675414|NCT01393964|Experimental|Arm 2: Lenalidomide + Dexamethasone +Elotuzumab|End-stage renal disease
89675415|NCT01393964|Experimental|Arm 3: Lenalidomide + Dexamethasone +Elotuzumab|Normal renal function
89215117|NCT04786340|Experimental|WST-057 active: 4 mL of WST-057 (4%; 146 mg of pirenzepine free base monohydrate) topical solution|The WST-057 is the active topical solution and contains pirenzepine free base monohydrate. It is dispensed with a pump to deliver (with 4 pumps) 4 mL to the calves (mid-calf sock line), ankles and the tops of both feet. Both solutions (active and placebo) are applied once-a-day for 12 weeks.
89215118|NCT04739358|Experimental|Monotherapy|"Dose Escalation Phase for participants with MET-driven NSCLC.~Dose Expansion Phase: CNS Efficacy Dose Expansion Cohort for participants with MET-driven NSCLC and measurable CNS disease."
89215119|NCT04739358|Experimental|Combination Therapy|"Dose Escalation Phase for participants with evidence of MET-driven acquired -resistance.~Dose Expansion Phase for participants with evidence of MET-driven acquired -resistance with or without measurable CNS disease."
89215120|NCT04734743|Other|Cystic fibrosis|
89215121|NCT04730167||Retired Motorsport Pilots|Concussion assessment
89215122|NCT04728048|Experimental|Dural puncture epidural (group DPE)|"The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA). In group DPE, a single dural puncture with confirmation of free-flow CSF will be performed. If there is no free-flow CSF return through the spinal needle, the epidural catheter will be threaded 4-5cm in the epidural space and the patient will still be assigned to the DPE group, as per intent-to-treat protocol."
89215123|NCT04728048|Active Comparator|Standard epidural (group EPL)|The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA).In Group EPL, no dural puncture will be performed and the catheter will be threaded 4-5cm in the epidural space.
89215124|NCT04721002||Participants With Multiple Myeloma|Participants with newly diagnosed and relapsed/refractory multiple myeloma will receive standard of care. Bone marrow and blood samples will be collected.
89215125|NCT04717635|Experimental|Canakinumab|All participants receive canakinumab (ACZ885) as open-label study medication. Participants are administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed is 300 mg.
89675416|NCT04721171|Active Comparator|Intervention group|The Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
89675417|NCT04721171|Sham Comparator|Placebo Group|The sham is similar in appearance to the Bridge device but does not deliver any electrical stimulation and is a sham that is designed to look identical to the Bridge device. It is placed on the external ear at the beginning of the study and removed by the patient after 5 days.
89675418|NCT01869075|Experimental|AMI - Knowledge Translation toolkit|AMI - Knowledge Translation (KT) toolkit includes use of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
89675419|NCT01869075|No Intervention|AMI - Usual Care|Usual care
89675420|NCT01869075|Experimental|MGS - Knowledge Translation Toolkit|Knowledge Translation toolkit involves use of pre-printed orders, audit and feedback, pharmacist as reminder and education of staff
89215126|NCT04714411||Retrospective Cohort|A historical matched case cohort
89215127|NCT04714411||Prospective Cohort|Subjects will be screened daily via review of the EMR reports of inpatient admissions. Those receiving antibiotics with a notated source of skin/soft tissue infection or OM will be further reviewed to determine if the source of infection is a DFI with or without suspected or confirmed Acute osteomyelitis.
89215128|NCT04713735|Placebo Comparator|Control: Placebo|Control: Placebo
89215129|NCT04713735|Experimental|Investigational: 600 mg bovine lactoferrin supplement|Investigational: 600 mg bovine lactoferrin supplement
89215130|NCT04678557|Experimental|Sentinel units (aka Cohort 1)|VC-01 Combination Product; Up to ten (10) VC-01 sentinels
89215131|NCT04678557|Experimental|Dose-finding units (aka Cohort 2)|VC-01 Combination Product; Up to twelve units implanted of which up to nine (9) are VC-01-DF (dose-finding) implants and the rest are VC-01 sentinels
89215132|NCT04652752|Experimental|CONNETTIVINA HI TECH patch|CONNETTIVINA HI TECH patch will be applied to eligible patients. CONNETTIVINA HI TECH will be renewed every two day, according with general principles of wound management
89215133|NCT04647656|Active Comparator|HBOT treatment group|40 daily hyperbaric oxygen treatment sessions will be administered 5 days per week
89215134|NCT04647656|Sham Comparator|HBOT sham group|40 daily Sham non-hyperbaric oxygen treatment will be administered 5 days per week
89215135|NCT04636905||Survivorship Wellness Group|Participants will be enrolled in a 15 week program to assess quality of life and general health outcomes
89215136|NCT04620551|Experimental|PD with DBS|Patients with Parkinson's Disease who opt for DBS surgery and consent to participate in the sleep study.
89215137|NCT04599946|Experimental|Experimental formula|Infant and follow-on goat milk formula
89215138|NCT04599946|Active Comparator|Control formula|Infant and follow-on cow milk formula
89215139|NCT04591808|Experimental|S05167|
89215140|NCT04591808|Active Comparator|Lipitor®|
89215141|NCT04591808|Active Comparator|Coversyl®|
89675421|NCT01869075|No Intervention|MGS - Usual Care|Usual Care
89675422|NCT01869075|Experimental|HFS - Knowledge Translation Toolkit|Knowledge Translation Toolkit consists of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
89675423|NCT01869075|No Intervention|HFS - Usual Care|Usual Care
89675424|NCT01790555|Experimental|Namisol|The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).
89675425|NCT01790555|Other|Diazepam/Placebo|"The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).~Before surgery, diazepam is used as an active comparator, to aid in blinding. After surgery, an inactive placebo is used as an inactive comparator."
89215142|NCT04589065|Experimental|Selective Cytopheretic Device|
89215143|NCT04588545|Experimental|Radiation Therapy followed by 10 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 1 of 4 with 10 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
89215144|NCT04588545|Experimental|Radiation Therapy followed by 20 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 2 of 4 with 20 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
89675426|NCT00335257||1|Users of OCs containing DRSP
89675427|NCT00335257||2|Users of OCs containing other progestins
89675428|NCT05747313|Experimental|Study group|"Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal."
89675429|NCT00304265|Experimental|6th Dose Pertussis Vaccine Group|Participants received 6th dose of pertussis vaccine
89675430|NCT00304265|Experimental|5th Dose Pertussis Vaccine Group|Participants received 5th dose of pertussis vaccine
89215145|NCT04588545|Experimental|Radiation Therapy followed by 40 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 3 of 4 with 40 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
89215146|NCT04588545|Experimental|Radiation Therapy followed by 80 mg Pertuzumab and 80 mg Trastuzumab|Treatment will be initiated with radiation therapy (RT), either whole brain radiation therapy or focal brain/spine radiation therapy. Participants will be treated at dose level 4 of 4 with 80 mg pertuzumab along with 80 mg trastuzumab via Ommaya reservoir over 2-5 minutes. Pertuzumab and trastuzumab will be administered sequentially. Participants will be observed 30 to 60 minutes before commencing the next agent. Participants will be treated twice a week for 4 weeks, once a week for 4 weeks, and then once every 2 weeks.
89215147|NCT04551053|Experimental|Group A : ruxolitinib +parsaclisib|Participants will receive parsaclisib starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
89675431|NCT00335725|Experimental|Fostimon|Fostimon is an highly purified FSH preparation.
89675432|NCT00335725|Active Comparator|Gonal-F|Gonal-F is a recombinant FSH preparation.
89675433|NCT01791673|Experimental|Ultrasound Glaucoma treatment|Cyclocoagulation using High Intensity Focused Ultrasound (HIFU)
89675434|NCT01393730|Experimental|Abiraterone+prednisone+dutasteride|Abiraterone acetate 1000mg orally once per day + prednisone 5mg orally once per day for two months, followed by abiraterone 1000mg orally once per day + prednisone 5mg orally once per day + dutasteride 3.5mg orally once per day in 28-day cycles until symptomatic or radiographic progression
89675435|NCT00336817|Active Comparator|Myfortic Group|Subjects in the Myfortic arm will receive Myfortic 360mg or 720 mg BID for 90 days
89675436|NCT00336817|Active Comparator|CellCept Group|Subjects in the CellCept arm will receive CellCept 500mg or 1000mg BID for 90 days
89675437|NCT01393106|Experimental|Idelalisib|Participants will receive up to 300 mg of idelalisib twice daily.
89675438|NCT05267353|No Intervention|Usual care|All patients received care as usual. Patients receive wound care and pain management post-surgery. Before RT, generally advising to do neck stretch and mouth opening exercises. Telephone follow-up was not provided to usual care group. Furthermore, patients in usual care group went to receive physical therapy were free to do. During the follow-up period, well-trained research nurses (assessors) recorded their physical therapy sections.
89675439|NCT05267353|Experimental|Exercise intervention programs|Based on our previous literature review, we will have two major parts of exercises in our intervention: (1) Upper Body Exercise (stretching in shoulder and neck, and mouth-opening); and (2) General Physical Function Training.
89675440|NCT00553059|Experimental|Arm I: Palonosetron, Dexamethasone + Dronabinol|Palonosetron hydrochloride intravenous (IV) and dexamethasone IV 30 minutes before chemotherapy administration on day 1, and oral dronabinol 3 times a day for 5 days beginning 30 minutes before chemotherapy administration on day 1.
89675441|NCT00553059|Active Comparator|Arm II: Palonosetron + Dexamethasone|Palonosetron hydrochloride and dexamethasone as in arm I, and oral placebo 3 times a day for 5 days beginning 30 minutes before chemotherapy on day 1.
89675442|NCT04389385|Experimental|COVID-19 STCs -Exo therapy|"In addition to the best available treatment, participants will receive inhaler COVID-19 STCs -Exo therapy *.~Biological: Inhaler CSTH-Exo treatment will be applied daily x 5 times (2.0 x 108 nano vesicle / 3 ml; on day 1 to day 5).~* If the improvement contribution is observed in the parameters, this application period could be extended"
89675443|NCT02989311|Active Comparator|Study 1:Morning test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the morning test meal A:12 mg of iron as ferrous sulfate given as 2 mg of 57Fe and 10mg of 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
89215148|NCT04551053|Placebo Comparator|Group B : ruxolitinib + placebo|Participants will receive placebo starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
89215149|NCT04545489|Experimental|Intervention group|Participants randomized to the intervention will have 4 visits over 12 months with study staff. In addition, they will also receive focused communication from the interventionist (nurse or pharmacist), with additional BP monitoring support and medication management for 12 months.
89215150|NCT04545489|Active Comparator|Education control group|Participants randomized to the education control group will have 4 visits over 12 months and will receive education materials related to CVD risk reduction.
89215151|NCT04496154|Experimental|Omega-3 fatty acids|3 oral softgels (600 mg EPA and 300 mg DHA / softgel), Triple Strength Omega-3 from Webber Naturals
89215152|NCT04490655|Experimental|Active somatosensory training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that focuses on the retraining of both motor and somatosensory functions, for a maximum of one hour per session.
89215153|NCT04490655|Active Comparator|Motor-based training group|Chronic stroke patients will be randomized to receive 15 sessions of robotic-based training intervention that is purely motor based, for a maximum of one hour per session.
89675444|NCT02989311|Active Comparator|Study 1:Afternoon test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the afternoon test meal B:12 mg of iron as ferrous sulfate given as 2 mg of 58Fe and 10mg of 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
89675445|NCT02989311|Active Comparator|Study 2: Consecutive meals+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meals:Test meal A will contain 12mg of ferrous sulphate given as 2mg 54Fe and 10mg 56Fe. Test meal B will contain 12mg of ferrous sulphate given as 2mg 57Fe and 10mg 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
89675446|NCT02989311|Active Comparator|Study 2:Alternate meal+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meal C: 12mg of ferrous sulphate given as 2mg 58Fe and 10mg.~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
89675447|NCT00869713|Other|primary vaccination with boost|Inactivated, Dried (TSI-GSD 200), RVF Vaccine
89675448|NCT04047134|Experimental|Experimental Group (EG)|The Experimental Group (EG) will observe and execute/repeat Activities of Daily Living (ADL) actions.
89675449|NCT04047134|Active Comparator|Control Group (CG)|The COntrol Group (CG) will observe landscapes and perform the same actions observed by their peers but after verbal instructions.
89675450|NCT02015611|Placebo Comparator|Placebo|Matched bottle/pill placebo
89675451|NCT02015611|Experimental|Vitamin D|2,000 IU Vitamin D3 per day
89675452|NCT01872819|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
89675453|NCT01413542|Placebo Comparator|Placebo then sitagliptin (DPP4 inhibition) group 1|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to bradykinin and substance P are studied after administration of placebo or sitagliptin (DPP4 inhibition).
89675454|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then placebo group 1|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to substance P and bradykinin are studied after administration of sitagliptin (DPP4 inhibition) or placebo
89675455|NCT01413542|Placebo Comparator|Placebo then sitagliptin group 2|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to glucagon-like peptide-1 and brain natriuretic pepdie are studied after administration of placebo or sitagliptin (DPP4 inhibition).
89215154|NCT04450797|Active Comparator|US -G VPS placement|
89215155|NCT04450797|Active Comparator|Stereotactic navigation for VPS placement|
89215156|NCT04446273|Experimental|PRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The PRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist).
89215157|NCT04446273|Active Comparator|DRI group|The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The DRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).
89215158|NCT04441203|No Intervention|Control|Heart failure clinic follow up
89215159|NCT04441203|Active Comparator|CardioMems|The treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group.
89215160|NCT04415333|Experimental|Sodium Butyrate [5 mmol] first, then Sodium Butyrate [80 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 mL total). After a 7-days washout period, they will return to testing office to self-administer the other enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 mL total).
88996115|NCT02934217|Experimental|Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
89675456|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then comparator group 2|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to glucagon-like peptide and brain natriuretic peptide are studied after administration of placebo or sitagliptin (DPP4 inhibition).
89675457|NCT05267795|Experimental|Operationalization|The experiment used a 2x2 within-subjects design in which participants either listened to music or underwent a silent control period and either performed an active foot tapping task, or a passive control task with no movement resulting in four experimental trial types: (a) Music Active (music with tapping); (b) Music Passive (music without tapping); (c) Silence Active (silence with tapping); and (d) Silence Passive (silence without tapping). The allocation of the music excerpts to the task (active, passive) was random, and the order of the four experimental trial types was counterbalanced.
89675458|NCT05267275|Experimental|extended resection with splenic flexure mobilization|
89675459|NCT05267717||Control/Normal (no-pessary) group|"All participants will must meet the criteria in order to be eligible: a singleton gestation, pregnant women recruited between 18+0 - 24+6 weeks of gestation, maternal age ≥18 years, the ability to sign approved consent form to participate in the study.~Moreover for a normal cohort are being enrolled only asymptomatic pregnant women with no risk factors for spontaneous preterm birth"
89675460|NCT05267717||Pessarry group|"All participants will must meet the criteria in order to be eligible: a singleton gestation, pregnant women recruited between 18+0 - 24+6 weeks of gestation, maternal age ≥18 years, the ability to sign approved consent form to participate in the study.~Moreover both for a pessary cohort additional cohort-specific criteria need to be met. Those are: suspected short cervix and confirmotian with transvaginal ultrasound - TVUS (CL < 3rd percentile at gestational age at measurement) according to Salomon at al."
89675461|NCT04389125|Experimental|Improvement of Blood Flow group|One packet once a day, after breakfast (1.5 g/day, 1.5 g/day as an Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures)
89675462|NCT04389125|Placebo Comparator|Placebo group|One packet once a day, after breakfast (1.5 g/day)
89675463|NCT05267119||Hijab|Women wearing hijab whose scalp sample was taken for microbiome analysis
89675464|NCT05267119||No hijab|Women not wearing hijab whose scalp sample was taken for microbiome analysis
89675465|NCT01873989|Experimental|Testosterone replacement|Testosterone replacement for hypogonadism.
89675466|NCT01873989|Other|Waitlist control|This arm involves watchful waiting.
89675467|NCT01432730|Experimental|Gefapixant 600 mg>Placebo|Gefapixant, 600 mg, twice daily (BID), taken orally for 2 weeks followed by a 2-week washout period and then placebo to gefapixant, BID, taken orally for 2 weeks.
89675468|NCT01432730|Experimental|Placebo>Gefapixant 600 mg|Placebo to gefapixant BID, taken orally for 2 weeks followed by a 2-week washout period and then gefapixant, 600 mg, BID, taken orally for 2 weeks.
89675469|NCT01897207|Experimental|Dendritic cell application|
89675470|NCT04441229|Experimental|Treatment Group|Patients age 12-24 diagnosed with pediatric-onset Multiple Sclerosis
89675471|NCT04067245|Other|Tetrasodium EDTA cathether lock solution|There is only one arm in this study where home parenteral nutrition patients who meet the inclusion criteria will receive tetrasodium EDTA catheter lock solution.
89675472|NCT05267249|Experimental|Autotransplantation|Autotransplantation and apicoectomy of mature teeth
89675473|NCT01875159|Experimental|Caffeine|Caffeine citrate 6 mg/kg/day
89675474|NCT01875159|No Intervention|Active Comparator: no caffeine|Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA.
89675475|NCT04065685|Active Comparator|CG|control group receiving the usual care, the standardized information on anticipated directives
89675476|NCT04065685|Active Comparator|IG p+r|intervention group with patients and her/his relative
89675477|NCT04065685|Active Comparator|IG p|intervention group with patients without relative
89675478|NCT01432574|Experimental|Gardasil Vaccine|Vaccine Administration: A total of 3 injections (shots) at 3 separate visits.
89675479|NCT01875783|Experimental|OCT imaging|All study participants will undergo optical coherence tomography imaging and will be referred to a retina specialist for further standard care evaluation and management if they are identified as having diabetic macular edema or the scan quality is not sufficient to evaluate macular status.
89675480|NCT00339079|Experimental|Cognitive Behavioral Therapy (CBT)|Patients in this arm only received Cognitive Behavioral Therapy (CBT). Six, 60 minute weekly sessions were followed by 4 bi-weekly sessions and 3 monthly booster sessions.
89675481|NCT00339079|Placebo Comparator|Placebo|Patients only received placebo pills accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
89675482|NCT00339079|Experimental|Fluoxetine|Patients only received the SSRI Fluoxetine. Medication was adminstered on a fixed-flexible dosing regimen, beginning at 10mg/day for 2 weeks, then 20 mg/day for 2 weeks, 40 mg/day for two weeks, 60 mg/day for 2 weeks, and 80 mg/day (the target dose) thereafter. This was accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
89675483|NCT00339079|Experimental|Combined CBT and Fluoxetine|Patients in this arm received both CBT and the fluoxetine medication. Both interventions were administered in the same way as when adminstered alone in the other arms.
89675484|NCT01392560|Experimental|BI 10773|Oral once daily
89675485|NCT01875861|Experimental|Intervention|Evidence-Based Quality Improvement plus external facilitation to promote uptake of quality improvement tools and improvement strategies available as part of a national initiative (the MIAMI Project) to disseminate recommendations, tools, and improvement strategies relevant to metabolic monitoring and management.
89675486|NCT01875861|No Intervention|Comparison|"Usual care, in the context of the MIAMI Project."
89675487|NCT00342355|Active Comparator|AZT+DDI+EFV|Zidovudine,Didanosine,Efavirenz ( Zidovudine 600 mg once daily,Didanosine <60 kg/125 mg twice daily or >60kg/200 mg twice daily,Efavirenz 600 mg once daily)
89050049|NCT02093429|Experimental|INCB047986 6 mg|Participants will receive INCB047986 6 mg once daily for at least 16 weeks.
89050050|NCT02093429|Experimental|INCB047986 10 mg|Participants will receive INCB047986 10 mg once daily for at least 16 weeks.
89675488|NCT00342355|Active Comparator|AZT+DDI+r/LPV|Zidovudine,Didanosine,Lopinavir/Ritonavir(AZT 600 mg once daily,DDI 100 mg twice daily,r/LPV 400mg/100mg twice daily)
89675489|NCT00342355|Active Comparator|d4T+3TC+EFV|Stavudine,Lamivudine,Efavirenz(d4T 40 mg twice daily,3TC 300 mg once daily,EFV 600 mg once daily)
89675490|NCT00342355|Active Comparator|d4T+3TC+r/LPV|Stavudine,Lamivudine,Lopinavir/Ritonavir(d4T 40m mg twice daily,3TC 300 mg once daily,r/LPV 400mg/100mg twice daily)
89675491|NCT00306163|Active Comparator|1|Ciclesonide 160 µg
89675492|NCT00306163|Active Comparator|2|Fluticasone 100 µg
89675493|NCT01861665|Active Comparator|Marcaine administered pre-incision.|Pre-operative administration, using both the specific drug - Marcaine 0.25%- and total amount - 5cc per incision.
89675494|NCT01861665|Active Comparator|Marcaine administered post-incision|Marcaine 0.25% administered post-incision, total amount 5cc per incision.
89675495|NCT00330161|Experimental|Treatment (vorinostat)|"Patients receive oral vorinostat (SAHA) once daily on days 1-21. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) after 4 courses receive an additional 3 courses. All other patients may continue treatment in the absence of disease progression or unacceptable toxicity.~Blood samples are taken on day 15 of course 1, day 1 of course 2, during the last week of course 4, and at completion of study treatment. Blood is examined for interleukin (IL)-6, IL-6 receptor, and gp130 levels."
89675496|NCT00552279|Experimental|Cervarix-12 Group|Women received 3 doses of Cervarix TM (human papillomavirus (HPV) vaccine) administered according to a 0, 1, 12-month schedule
89675497|NCT00552279|Active Comparator|Cervarix-6 Group|Women received 3 doses of Cervarix TM (HPV vaccine) administered according to a 0, 1, 6-month schedule.
89675498|NCT01898273|Experimental|Single|I-124-CLR1404, open-label
89675499|NCT00309751|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
89675500|NCT00309751|Active Comparator|Atorvastatin 20 mg QD|Atorvastatin 20 mg once daily
89675501|NCT04380233|Experimental|Investigational Drug Group|A 8-weeks double-blind treatment period with a Proprietary Chinese Medicine (consists of 4 kinds of Chinese herbs at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
88996116|NCT02934217|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
88996117|NCT02933905||Non-PVD subjects|Patients with no PVD on SD-OCT at basal visit
88996118|NCT02933905||PVD subjects|Patients with PVD on SD-OCT at basal visit
88996119|NCT02933710||IMOJEV® Vaccine Group|Participants who are 12 months and older and who are given a first dose of IMOJEV® during a routine health care visit
88996120|NCT02933515|Experimental|Yoga and occupational therapy|twice a week for 8 weeks. one hour of group occupational therapy for fall risk factor management and one hour of yoga for balance
89675502|NCT04380233|Placebo Comparator|Placebo Group|A 8-weeks double-blind treatment period with Placebo Capsules (at 0.43g/capsule in weight), 3 capsules at one time, 3 times a day, oral administration 10-15 minutes before meals
89675503|NCT01876329||Rheumatoid Arthritis|Patients with seropositive or seronegative Rheumatoid Arthritis
89675504|NCT01876329||Autoimmune Thyroid Disease (AITD)|Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.
89675505|NCT01876329||Control|Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses
89675506|NCT04346095|Experimental|Oral Sedative|"Participants will receive oral triazolam 30 minutes prior to surgery.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg~Followed by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.~Vitals will monitored by the operating room nurses."
89675507|NCT04346095|Active Comparator|Intravenous Sedative|"This group will receive an intravenous sedative. The sedative is limited to midazolam, fentanyl, propofol.~Follow by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine.~IV and monitoring will be performed by anesthesiologist or CRNA."
89675508|NCT02988999|Experimental|D-allulose|D-allulose 5 gm 3 times a day
89675509|NCT02988999|Active Comparator|erythritol|erythritol 5 gm 3 times a day
89675510|NCT04751305|Experimental|ACE Remote Maintenance Program with Health Coaching|The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels. Additionally, the health coaching intervention received weekly zoom calls that were focused on being participant-centered, built on a coach participant relationship, and included participant-determined goals, a self-discovery process to find solutions, patient accountability, and education.
89675511|NCT04751305|Active Comparator|Only ACE Remote Maintenance Program|The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also participants received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels.
88996121|NCT02933788|Experimental|Cilostazol group|Cilostazol Cilostazol 200mg tablet by mouth, once daily for 14 days
88996122|NCT02933788|Active Comparator|Aspirin group|Acetylsalicylic acid Acetylsalicylic acid 100mg tablet by mouth, once daily for 14 days
88996123|NCT02933593|Active Comparator|labetalol|labetalol
88996124|NCT02933593|Active Comparator|hydralazine|Hydralazine
88996125|NCT02933593|Active Comparator|nifedipine|nifedipine
88996126|NCT02933632|Active Comparator|Standard Assistance Protocol-SAP|Patients underwent physical therapy once a day. Patients receive intervention by Physical Therapy-SAP.
88996127|NCT02933632|Active Comparator|Accelerated Rehabilitation Protocol-ARP|Patients underwent physical therapy three times a day. Patients receive intervention by Physical Therapy-ARP.
88996128|NCT02933749|Active Comparator|The sitting|The sitting position Device sCtO2 Device BIS
88996129|NCT02933749|Active Comparator|The prone|The prone position Device sCtO2 Device BIS
88996130|NCT02933398|Active Comparator|Laparoscopic Assisted Partial Nephrectomy|Current standard for partial nephrectomies.
89675512|NCT01876485|Experimental|Arm 1: Empowering Patients in Chronic Care (EPIC)|Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
89675513|NCT01876485|Active Comparator|Arm 2: Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
89675514|NCT00313729|Experimental|Temozolomide|Temozolomide
89675515|NCT00559377|Experimental|Diagnostic FMISO AND FDG PET|Patients receive ^18F FMISO IV over 1 minute followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior ^18F FDG PET scan as part of their routine clinical management undergo ^18F FDG PET scanning at baseline.
89675516|NCT05266885||Male and Female|(37 male, 63 female)
89675517|NCT01790191|Experimental|RE group|Repeated consumption of artichoke purée. This group was exposed to basic artichoke puree from Exposure 1 to 10 (E1 to E10)
89675518|NCT01790191|Active Comparator|FFL group|Repeated consumption of artichoke purée. This group (Flavor-flavor learning group) was exposed to sweet artichoke puree from Exposure 1 to 10 (E1 to E10).
89675519|NCT01790191|Active Comparator|FNL group|Repeated consumption of artichoke purée. This group (Flavor-nutrient learning group) was exposed to fat, energy-dense artichoke puree from Exposure 1 to 10 (E1 to E10).
89675520|NCT05531019|Experimental|Dietary Supplement with sea urchin egg extract|Ingestion of dietary supplement with 0,025% of Echinochrome A (ingested 3ml twice a day for 90 days), 1,5mg daily consumption from sea urchin egg extract (Arbacia dufresnii)
89675521|NCT05531019|Placebo Comparator|Control|Ingestion of 3ml twice a day for 90 days of placebo
89675522|NCT05266651|Active Comparator|tadalafil group|5 mg of Tadalafil on daily bases for one month duration
89675523|NCT05266651|Placebo Comparator|placebo group|the patients will receive oral tablets without any active substance for one month
89675524|NCT05266573|Experimental|Exercise Participants with Limited Mobility|"The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components:~Warm Up: Walking which is progressively increased from 6 to 15 minutes. Dual task activity is introduced as tolerated by the participants. Participants are able to utilize assistive devices and there were additional supports provided.~Stretching, Strengthening and Balance Activities: Gradual progression of activities and repetitions for 30 minutes that are tailored by the exercise instructor to each participant. Exercises are led by the trainer and performed at the balance bar, in a chair, or in standing. Task oriented activities included items such as: weight shifting, forward/backward/side stepping, squats, forward/backward/side leg raises, toe raises, seated trunk rotations, sit to stand, forward trunk bending, arm rotations, and marching.~Walk/Obstacle Course: The final 6 to 15 minutes included challenged walking through an obstacle course."
89675525|NCT01790269||fingolimod treated patients|Indication for on-label treatment with fingolimod (Gilenya®) according to the current approval
89675526|NCT05746689|Experimental|glucocorticoid and sirolimus combination therapy|"Prednisone acetate 0.8mg/Kg/d (maximum dose 60mg/d), reduced by 5mg every 14 days, reduced by 2.5mg every 2 weeks after 30mg/d until discontinuation. At the same time, treatment for prevention or control of osteoporosis was given.~Sirolimus: 2mg/day for the first three days and 1mg/day thereafter. The plasma drug concentration was monitored at 14 days, 12 weeks, and 48 weeks of medication to maintain a plasma drug concentration of 4-15 ug/L."
89675527|NCT01412060|Experimental|Cariprazine - Open-label Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
88996131|NCT02933398|Active Comparator|Robotic Assisted Partial Nephrectomy|Possible new standard for partial nephrectomies.
88996132|NCT02933359||Normal Tissue|Bone fragments and their associated bone marrow will be collected from patients at the time of surgery without any additional dissection or incisions. Bone will be finely minced and then plated in tissue culture flasks as previously reported by other groups [7].
88996133|NCT02933437|Experimental|Healthy Volunteers|Once screened by the investigators, the participants will undergo ajmaline provocation, cardiac magnetic resonance imaging and genotype evaluation
88996134|NCT00153530|Active Comparator|1|1 chemotherapy with radiotherapy
89675528|NCT01412060|Experimental|Placebo - Double-blind Treatment Phase|Participants received placebo orally once a day for 26 to 72 weeks.
89675529|NCT01412060|Experimental|Cariprazine - Double-blind Treatment Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks
88996135|NCT00153530|Experimental|2|chemotherapy without radiotherapy
88996136|NCT04690075|Experimental|Intervention|To receive routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
88996137|NCT04690075|Placebo Comparator|Control|To receive routine nutrition management for 12 weeks.
88996138|NCT02933164|Experimental|Arms|Evaluation of the effectiveness of modified Sensor designs on the longevity (up to 180 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate safety of the Senseonics CGM System usage, while in the clinic and during home use.
88996139|NCT02933125|Experimental|Intervention group|The youths in the intervention group will participate in a weekly 10-session out-patient motivational enhancement psychotherapy (MEP) program. In addition to this, these youths' caregivers will be referred to simultaneously take part in a weekly 10-session out-patient parenting skill training (PST) program at Kaohsiung Chang Gung Memorial Hospital.
88996140|NCT02933125|Active Comparator|Comparison group|The comparison group consists of substance-using adolescents that receive only standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court. The protection officers provide the adolescents with moral education, as well as counseling in their work or studies.
89675530|NCT00345865|Experimental|NHL with irradiation|Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
89050051|NCT00563745|Experimental|Telemedicine|Patients were submitted to a Telemedicine program for 1 year
89050052|NCT00563745|No Intervention|Control group|Patients were submitted to usual care (i.e: educational plan and outpatient visits every 3 months)
89050053|NCT04677764|Experimental|Wii Fit Group|Received Standard of care and Wii Fit protocol consisted of strength, balance, and aerobic programs that were performed on the Wii Fit balance board (Nintendo Inc., Kyoto, Japan). For muscle strengthening exercise, lunges, single-leg extensions, sideways leg lifts, single leg twists, and rowing squats were performed. For exercise that enhances balancing sense, the soccer heading, ski slalom, penguin, table tilt, and balance bubble games were used. Aerobic games as hula hoop, super hula hoop and basic step.
89050054|NCT04677764|Other|Standard of care group|On discharge from the hospital, patients in the SOC group were given instructions on how to perform physical therapy and occupational therapy exercises after discharge. After education, patients could perform the physical therapy and occupational therapy exercises either at their own home or a gym.
89050055|NCT04677686||Pre-implementation phase (October 2018 - September 2019)|"During this time period, 137 patients underwent colorectal surgery. Only basic measures for preventing SSI were performed:~Hair was removed in the operating field with a clipper instead of shaving hair.~Blood glucose was monitored only during the operation.~Antibiotic prophylaxis was applied 60 minutes before the operation.~The application of an antibiotic prophylaxis was repeated if the operation lasted longer than 4 hours.~Measures of warming were only applied during the operation and in the recovery room.~Instruments and gloves were changed after finishing the anastomosis."
89050056|NCT04677686||Implementation phase (October 2019 - September 2020)|"During this phase, additional measures have been introduced:~Implementation of wound protectors during colorectal surgery.~Colorectal operations were only performed with the support of an experienced consultant surgeon."
89050057|NCT04677686||Post-implementation phase (October 2020 - September 2021)|"During this phase, additional measures are implemented.~Close monitoring of blood glucose. During the stay in the recovery room and for 48 hours post-operative, blood glucose is monitored closely. Moreover, if blood glucose is higher than 9 mmol/l, the patient will be treated with insulin. This measure is applied to diabetic as well as to non-diabetic-patients.~The measures of warming will be intensified. First of all, during the operation and during the stay in the recovery room patients will be placed on warming mattresses. Moreover, a warming towel will be placed on the operating field directly after the operation.~The patients will be asked to take a shower the night before surgery. In case of an emergency operation, patients will be asked to wash the axilla, trunk, genitalia, groins and umbilicus"
89050058|NCT04632342|Experimental|Experimental group 1|HL301 1,200mg/day
89050059|NCT04632342|Experimental|Experimental group 2|HL301 1,800mg/day
89050060|NCT04632342|Placebo Comparator|Control group|Placebo
89050061|NCT00563901||1|Adults with a high risk for high blood pressure from the ALLHAT study
89050062|NCT04611711|Other|decitabine＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine (10mg ivgttqd, d1-5) combined with TQB2450 injection (1200mg ivgtt, d5)
89050063|NCT04611711|Other|decitabine + anlotinib ＋ TQB2450 injection (PD-L1 monoclonal antibody)|Decitabine and Anlotinib (decitabine 10mg ivgtt qd, d1-5; Anlotinib 8mg po.qd, d5-18) combined with TQB2450 injection (1200mg ivgtt, d5), using the traditional 3+3 experimental design (First enroll 3 subjects. If 1 case of DLT is observed, 3 more subjects need to be added to the same dose group to further evaluate the toxicity) to observe DLT to evaluate MTD. The trial starts from the 8mg dose of Anlotinib Start.
89050064|NCT00554879|Experimental|1|Acupuncture
89050065|NCT00554879|Sham Comparator|2|Sham Acupuncture
89215161|NCT04415333|Experimental|Sodium Butyrate [80 mmol] first, then Sodium Butyrate [5 mmol]|After a randomized assignment in the crossover design, participants with hypertension will come to the testing office to self-administer the first enema with a concentration of 80 mmol sodium butyrate in a 0.9% saline solution (60 mL total). After a 7-day washout period, they will return to the testing office to self-administer the other enema with a concentration of 5 mmol sodium butyrate in a 0.9% saline solution (60 mL total).
89215162|NCT04415333|No Intervention|Control|African Americans with normal blood pressure (control group) will not perform self-administration of the enema. They will submit to 1 blood draw and wear the 24-hour ambulatory blood pressure monitor for 1-day.
89675531|NCT00345865|Experimental|HL without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
89675532|NCT00345865|Experimental|NHL - HIV infected with irradiation|Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
89675533|NCT00345865|Experimental|NHL - HIV infected without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
89675534|NCT00345865|Experimental|NHL without radiation and cyclosporine|Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
89675535|NCT00551421|Experimental|Arm I|"Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I)."
89675536|NCT00348205|Experimental|Technolas 217z Zyoptix System|Bausch & Lomb Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software.
89675537|NCT01791751|Experimental|Clomifene Citrate|Clomifene Citrate 50 mg
89675538|NCT01791751|No Intervention|Control|No intervention
89675539|NCT05266261|Active Comparator|Non-diabetes|postmenopausal women with normal glucose tolerance
89675540|NCT05266261|Experimental|diabetes|postmenopausal women with type 2 diabetes
89675541|NCT03022383||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the DRI OCT Triton Plus device
89675542|NCT05745363|Experimental|AL2846 capsule|AL2846 capsules monotherapy, 28 days as a treatment cycle.
89675543|NCT00317239|Experimental|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
89675544|NCT00317239|Active Comparator|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
89675545|NCT05266105|Experimental|Dose Escalation|This portion of the study will evaluate the safety and pharmacology of a range of OP-1250 doses administered daily with Palbociclib in subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer
89675546|NCT05266105|Experimental|Dose Expansion|This portion of the study further explores the clinical activity, safety and pharmacology of OP-1250 in combination with Palbociclib and estimates preliminary data of anti-tumor efficacy
89675547|NCT01891643|Experimental|Arm 1: Lenalidomide + Dexamethasone|"Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug~Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug"
89675548|NCT01891643|Experimental|Arm 2: Lenalidomide + Dexamethasone + Elotuzumab|"Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)~Dexamethasone 28 mg tablets by mouth once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15(cycles 3-18); Day 1 (cycle 19 & beyond)]~Dexamethasone 40 mg tablets by mouth once daily [Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 & beyond)]~Dexamethasone 8 mg IV (intravenous) solution once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18); Day 1 (cycle 19 & beyond)]~Elotuzumab 10 mg/kg IV solution weekly [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18)]~Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 & beyond)~Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug"
89675549|NCT05265871||Refractory chronic cough|Subjects would be performed induced sputum test, ATP and capsaicin cough provocation test.
89675550|NCT05265871||Healthy control|Subjects would be performed induced sputum test, ATP and capsaicin cough provocation test.
89675551|NCT05265793|Experimental|Camrelizumab Combined With Apatinib|"Apatinib tablets: 250mg qd.po, 4 weeks as a cycle, continuous medication until disease progression, death or intolerable toxicity;~Camrelizumab: administered intravenously with a fixed dose of 200mg, administered intravenously (without preventive medication), each infusion for 30min (no less than 20min, no more than 60min), administered once every two weeks until disease progression, death or intolerable toxicity. The maximum period is 2 years.~The curative effect was evaluated every 8 weeks."
89675552|NCT04005599|Active Comparator|Remifentanil group|Intravenous anesthesia with propofol and remifentanil
89675553|NCT04005599|Experimental|Magnesium group|Intravenous anesthesia with propofol and magnesium sulfate
89675554|NCT01792193||Parkinson's disease|Patients with Parkinson's disease
89675555|NCT01792193||Control|Healthy controls
89675556|NCT00330863|Experimental|Injectable|Participants assigned to receive long-acting injectable risperidone
89675557|NCT00330863|Active Comparator|Oral|"Participants assigned to receive oral atypical antipsychotic medication"
89675558|NCT01899521|Placebo Comparator|Placebo zinc and placebo SAMe|Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily
89675559|NCT01899521|Active Comparator|Active zinc and placebo SAMe|Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily
89675560|NCT01899521|Active Comparator|Placebo zinc and active SAMe|Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily
89675561|NCT01899521|Active Comparator|Active zinc and active SAMe|Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily
89675562|NCT01790009|Active Comparator|Flavanol Rich drink|Flavanol-rich drink containing 800 mg/75 Kg of Body Weight (BW)
89675563|NCT01790009|Active Comparator|Flavanol rich drink|Flavanol Intervention drink 400 mg/75 Kg BW
89675564|NCT01790009|Active Comparator|Acetaminophen|2 tabletsx500 mg
89675565|NCT05461989||primary hypertension|adolesence primary hypertension patients
89675566|NCT05461989||secondary hypertension|adolesence secondary hypertension patients
89675567|NCT02106065|Experimental|In-person Education and Skill-Building Rehabilitation (ESBR-i) Condition|Education and Skill-Building Rehabilitation delivered in clinic
89675568|NCT02106065|Experimental|Education and Skill-Building Rehabilitation over Video (ESBR-V) Condition|Education and Skill-Building Rehabilitation delivered via video telehealth.
89675569|NCT02106065|Active Comparator|Usual Care Condition|Usual Care plus supplemental paper education materials
88996141|NCT02933086|Experimental|G1: exercises for lumbar stabilization|G1, will perform therapy with specific exercises for lumbar stabilization including the Swiss ball as therapeutic resource
88996142|NCT02933086|Experimental|G2: conventional therapy|G2, will perform conventional therapy including stretching of lower limbs and trunk.
88996143|NCT02932930|Active Comparator|QLB group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine"
89675570|NCT02989077||Group A|Having combined coronary and cerebral ischemia.
89675571|NCT02989077||Group B|Having only coronary ischemia
89675572|NCT02989077||group C|Having only cerebral ischemia
89675573|NCT05737329|Other|Transdermal estradiol gel 0.1% 1.5mg/ day|Patient will be given Hormone Replacement Therapy (HRT) in the form of: Transdermal estradiol gel 0.1% 1.5mg (Gel sachet) in continuous daily regimen. The progesterone component of HRT (200mg micronized progesterone administered vaginally) will be given for 14 days, starting from day 14 through day 28 of each cycle.
89675574|NCT05737329|Other|Transdermal estradiol gel 0.1% 2.0mg/ day|Patient with insufficient effect from previous treatment estradiol gel 0.1% 1.5mg will be given HRT in the form of: Transdermal estradiol gel 0.1% 2.0mg (Gel sachet) in continuous daily regimen. The progesterone component of HRT (200mg micronized progesterone administered vaginally) will be given for 14 days, starting from day 14 through day 28 of each cycle.
89675575|NCT05267015|Active Comparator|coronally advanced flap with connective tissue graft|After randomization a subepithelial connective tissue graft along with coronally advanced flap is applied to one maxillary quadrant to cover the recession.
89675576|NCT05267015|Experimental|coronally advanced flap with platelet rich fibrin membranes|After randomization platelet rich fibrin membranes along with coronally advanced flap are applied to the other maxillary quadrant to cover the recession.
89675577|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject
89675578|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject light|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject Light
89675579|NCT00317941|Active Comparator|IFNB-1a 44 mcg (Rebif) via Rebiject II|Interferon beta-1a ([IFNB-1a] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II
89675580|NCT04346069|Other|Regular speech therapy|Regular speech therapy will be provided to the controlled group
89675581|NCT04346069|Other|Parent-child interaction therapy|Parent child interaction therapy will be provided to the experimental group
89675582|NCT04751565|Experimental|Tissue level implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients with tissue level implant~Primary outcome~The primary outcome will be based on probing depth (PD)"
89675583|NCT04751565|Experimental|Bone level implant Group|"Evaluation of healing of peri-implant mucositis after non-surgical supra and subgingival debridement in patients with bone level implant~Primary outcome~The primary outcome will be the change in Bleeding on Probing (BOP) (Lang, Joss, Orsanic, Gusberti, Siegrist, 1986)."
89675584|NCT03984383||Lung-derived endothelial cells|Every patient of more than 18 years undergoing lung cancer surgery in the department of thoracic surgery of the University Hospital of Lille.
89675585|NCT03984383||Umbilical cord-derived endothelial cells|Every patient of more than 18 years giving birth in the University Hospital of Lille in the absence of significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC the day of the childbirth.
89675586|NCT02277639|Experimental|Bone Marrow Failure Syndrome|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
89675587|NCT02277639|Experimental|Immunodeficiency / Dysregulation|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
89675588|NCT01790087|Experimental|ANX-188 Therapeutic dose level|IV administration. 100 mg/kg for one hour followed by 30 mg/kg/hour for five hours
89675589|NCT01790087|Experimental|ANX-188 Supratherapeutic dose|IV administration. 300 mg/kg for one hour followed by 200 mg/kg/hr for five hours
89675590|NCT01790087|Placebo Comparator|Saline|IV administration. Six hour infusion.
89675591|NCT01790087|Active Comparator|Moxifloxacin|Oral tablet. 400 mg.
89675592|NCT01791907|Experimental|Structured education in carbohydrate counting|A structured education in carbohydrate counting, a course inspired by the DAFNE program (Dose Adjustment For Normal Eating)
89675593|NCT01791907|Experimental|Structured education in healthy food choices and low GI|"A new, structured education for heart healthy food choices and low glycemic index in type 1 diabetes. The education is called My Wellness-LADDER (Lifelong Adult Diet & Diabetes Education Resource) and it is specifically designed to provide high long-term adherence through improved empowerment and transformative life style change."
89675594|NCT01791907|No Intervention|Regular routine|
89675595|NCT05134207|Experimental|oral carbohydrate solution|Oral carbohydrate solution was given orally to the experimental group as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the intervention.
89675596|NCT05134207|No Intervention|control|From 24:00 on the night before the surgical intervention, food and water intake was prohibited for the patients in the control group.
89675597|NCT04239131|Other|All Patients|It is a single arm study. Skin prick testing and laboratory Tests are carried out on all patients in the same way
89675598|NCT04750837|Active Comparator|Platelet rich plasma group|chronic diabetic foot ulcer was treated by platelet rich plasma
89215163|NCT04409457|Other|Participants with Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
89675599|NCT04750837|Sham Comparator|conventional dressing group|chronic diabetic foot ulcer was treated by conventional dressing
89675600|NCT00332579|Active Comparator|A|Naltrexone
89675601|NCT00332579|Placebo Comparator|B|Placebo
89675602|NCT00318409|Active Comparator|Bupropion|buproprion XL 300mg daily
89675603|NCT00318409|Placebo Comparator|Placebo|placebo 300mg daily
89675604|NCT00333437|Experimental|Treatment|Mycophenolate Mofetil
89675605|NCT04389307|Other|Group 1: Bladder Training - Control group|Specific goals are to correct faulty habit patterns of frequent urination, improve control over bladder urgency, prolong voiding intervals, increase bladder capacity, reduce incontinence episodes and restore patient confidence in controlling bladder function
89675606|NCT04389307|Active Comparator|Group 2: Bladder Training+Intra Vaginal Electrical Stimulation|IVES was performed in lithotomy position via Enraf Nonius Myomed 632 device with a vaginal probe. IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24-session treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback
89675607|NCT04190849||Non-alcoholic fatty liver disease patients|Children (<18 years) with a diagnosis of NAFLD with radiological demonstration of increased liver fat and exclusion of other causes.
89675608|NCT04129619|Experimental|ORP-101 50 mg|ORP-101 (50 mg) once daily
89675609|NCT04129619|Experimental|ORP-101 100 mg|ORP-101 (100 mg), once daily
89675610|NCT04129619|Placebo Comparator|Placebo|Matching placebo, once daily
89675611|NCT00353119|Placebo Comparator|Placebo then etanercept|Patients randomized to initiate the study with placebo for the first 12 weeks - Group 1 then crossed over to etanercept 50mg twice weekly for weeks 12 to 24
89675612|NCT00353119|Active Comparator|Etanercept|Patients randomized to etanercept - Group 2. Patients received etanercept 50 mg subcutaneously twice weekly for 24 weeks
89675613|NCT00353431|Active Comparator|1|"Conventional insulin group:~In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician."
89675614|NCT00353431|Experimental|2|"Intensive insulin therapy algorithm:~The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake."
89675615|NCT05266547||OCT guided group|
89675616|NCT05266547||angiography guided group|
89675617|NCT01790789|Experimental|Stress reduction program|
89050066|NCT04632537|Active Comparator|TICE BCG (for intravesical use, Merck) BCG LIVE|Participants randomized to the BCG arm will receive Tice® BCG (for intravesical use) BCG LIVE is a live freeze-dried vaccine made from an attenuated strain of Mycobacterium bovis. The freeze-dried vaccine will be delivered in vials, each containing 1 to 8 x108 colony forming units (CFU). Tice® BCG (for intravesical use) BCG LIVE will be reconstituted in ~5 mL of preservative-free saline, as needed for yielding 2- x107 CFU/ mL. [34] Administration of 0.1 mL will contain 2x106 CFU, which accounts for approximately 0.1 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally. A sterile tuberculin 1mL syringe and sterile fine short needle (25 or 26 gauge with 3/8-3/4 length), will be used for each injection. The injection should be made slowly after inserting the needle ~2 mm into the superficial layer of the dermis of the upper arm (usually deltoid area), to make a symmetrical superficial bleb.
89050067|NCT04632537|Placebo Comparator|placebo vaccine|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
89050068|NCT02092922|Experimental|Filanesib|
89050069|NCT04611594|Experimental|Fluid restriction|Prescription to ingest approximately 20 ml / kg of ideal weight.
89675618|NCT01790789|Other|Attention control|
89675619|NCT01793545||Endometrial Cancer Cohort|Women with abnormal bleeding or other conditions associated with increased risk ofendometrial cancer.
89675620|NCT02983253||Patients with HHT|blood sample of patients with HHT
89675621|NCT02983253||probands|blood sample of healthy controls
89675622|NCT05266391||group 1|patients who received US-guided subacromial corticosteroid injections
89675623|NCT05266391||group 2|patients who underwent blind subacromial corticosteroid injections
89675624|NCT01790945||No treatment Study|Population of subjects will have been diagnosed with mild NPDR, Moderate NPDR, Severe NPDR, PDR and DME
89675625|NCT00353977|Experimental|ALVAC-CMV (vCP260) Vaccinated group|Patients who were vaccinated with ALVAC-CMV (vCP260)
89675626|NCT00320281|Placebo Comparator|placebo|Normal saline injections were used for placebo injections. Injections were based on treatment plan determined in clinical setting by study PI and physical therapist. 25 cc syringe was used and amount of saline injected was unit based on muscles to be injected according to the treatment plan.
89675627|NCT00320281|Active Comparator|Botulinum toxin A|Botulism toxin A dosage was based on plan developed in clinical setting with study PI and physical therapist. Drug was dosed in 25 cc syringe,diluted with normal saline and injections occured based on treatment plan.
89675628|NCT01792375|Active Comparator|Concurrent membrane sweeping with Dinoprostone|
89050070|NCT04611594|No Intervention|Control|Prescription to ingest approximately 30 ml / kg of ideal weight, considered a normal amount of daily water intake.
89050071|NCT02092454|Experimental|Benzocaine|Topical otic solution, every 1-2 hours, for up to 3 days
89675629|NCT01792375|Active Comparator|Dinoprostone|
89675630|NCT02108821|Experimental|Fecal Microbiome Transplantation|Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour
89675631|NCT02108977|Experimental|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
89675632|NCT02108977|Active Comparator|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
89675633|NCT01392326|Experimental|Group 1|Secukinumab (75mg)
89675634|NCT01392326|Experimental|Group 2|Secukinumab (150 mg)
89675635|NCT01392326|Placebo Comparator|Group 3|
89675636|NCT04890769||Participants|Patients with exuding wounds
89675637|NCT00320671|Experimental|Participants will take aripiprazole|Participants will take aripiprazole
89675638|NCT00320671|Experimental|Participants will take risperidone|Participants will take risperidone
89675639|NCT00320749|Experimental|capecitabine, docetaxel, gemcitabine|Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.
89675640|NCT00322231|Experimental|ZOSTAVAX™ / Placebo|Zoster vaccine live on Day 1 (Period 1), placebo on Week 4 (Period 2)
89675641|NCT00322231|Experimental|Placebo / ZOSTAVAX™|Placebo on Day 1 (Period 1), zoster vaccine live on Week 4 (Period 2)
89675642|NCT00354913|Experimental|Imatinib mesylate+hydroxyurea|All patients receive imatinib mesylate and hydroxyurea orally on a daily, continuous basis. Dosing of imatinib mesylate is adjusted for patients who are also receiving p450-inducing anti-epileptic drugs.
89675643|NCT01432262|Experimental|Group 1|=> 65 years of age
89675644|NCT01432262|Experimental|Group 2|50 to 64 years of age
89675645|NCT00322309|Experimental|Mirtazapine|"Mirtazapine administration as follows:~Days 1-4 15mg of mirtazapine daily Days 5-9 30mg of mirtazapine daily Days 10-78 45mg of mirtazapine daily Days 79-81 30mg of mirtazapine daily Days 82-84 15mg of mirtazapine daily"
89675646|NCT00322309|Placebo Comparator|Placebo- Sugar pill|Matched Placebo given daily days 1-84
89675647|NCT04751149|Experimental|Early Urinary Catheter Removal|Urinary Catheter will be removed the first postoperative day after rectal resection
89675648|NCT04751149|Experimental|Medium Urinary Catheter Removal|Urinary Catheter will be removed the third postoperative day after rectal resection
89675649|NCT04751149|Experimental|Late Urinary Catheter Removal|Urinary Catheter will be removed the fifth postoperative day after rectal resection
89675650|NCT04407728|Experimental|precocious EchoMorpho-T1|Women whose fetus is at high risk of congenital heart disease after the 1st trimester screening echo (EchoT1), will benefit from an early morphological ultrasound centered on the heart (EchoMorpho-T1) by a sonographer referent between 11 and 14 weeks +/- of an early fetal heart ultrasound (EchoCoeur-T1) between 11 and 15 weeks by a cardio-pediatrician in the event of an abnormality with the EchoMorpho-T1.
89675651|NCT04046744|Active Comparator|BAX|
89675652|NCT04046744|Experimental|BAX-Asso|
89675653|NCT01792453|Experimental|240 mL water drink|Volunteers will be asked to drink 240 mL water drink
89675654|NCT01793857||Study Group|Approximately 1300 primary caregivers of at least one child aged 6 months to less than 30 months who were interviewed during a clinic visit in Panama.
89675655|NCT01410890|Experimental|Alglucosidase alfa|Participants received intravenous (IV) infusion of Alglucosidase alfa 20 milligrams per kilogram (mg/kg) body weight on Day 1. Infusion was administered at an initial rate of approximately 1 milligram per kilogram per hour (mg/kg/hr) with allowed rate increased of 2 mg/kg/hr every 30 minutes, if there were no signs of infusion-associated reactions (IARs), until a maximum rate of approximately 7 mg/kg/hr was reached.
89675656|NCT01431950|Experimental|FF 100mcg once daily|Inhaled corticosteroid (ICS)
89675657|NCT01431950|Experimental|FF 200mcg once daily|Inhaled corticosteroid
89675658|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 1|Influenza Virus Vaccine Formulation 1
89675659|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 2|Influenza Virus Vaccine Formulation 2
89675660|NCT00551031|Active Comparator|Fluzone® Elderly Group|
89675661|NCT00551031|Active Comparator|Fluzone® High-dose Group|Participants enrolled at age ≥ 65 years
89675662|NCT00551031|Active Comparator|Fluzone® Adults Group|Participants enrolled at age 18-49 years.
89675663|NCT01431716|Experimental|EFI/ACT-385781A|EFI/ACT-385781 administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump
89675664|NCT00322465|Experimental|Doxycycline|Doxycycline 100 mg orally twice daily (2 pills/day = 200 mg/day) for 7 days plus placebo azithromycin orally single dose and placebo tinidazole.
89675665|NCT00322465|Experimental|Doxycycline + Tinidazole|Doxycycline 100 mg orally twice daily for 7 days plus placebo azithromycin single dose plus tinidazole 2 gm orally single dose (4 tablets at 500 mg each).
89675666|NCT00322465|Experimental|Azithromycin|Azithromycin 1 gram (gm) orally single dose (2 tablets at 500 milligrams (mg) each) plus doxycycline placebo twice daily for 7 days plus tinidazole placebo single dose.
89675667|NCT00322465|Experimental|Azithromycin + Tinidazole|Azithromycin 1 gm orally single dose (2 tablets at 500 mg each) plus doxycycline placebo twice daily for 7 days plus tinidazole single dose (4 tablets at 500 mg each).
89675668|NCT00322777|Experimental|Spirituality Group|Arm where participants began the intervention (the Spirituality Teaching Program) upon recruitment for an 8 week period. Therefore, the program was initiated at week 1 of the trial.
89675669|NCT00322777|Active Comparator|Waitlist Control Group|Arm where participants began the intervention (the Spirituality Teaching Program) after an 8 week wait period. Therefore, the program was initiated at week 8 of the trial. Between week 1 and week 8, participants did not complete the program and were instructed to carry out their day to day activities as before.
89675670|NCT00558831|Active Comparator|Benzoyl Peroxide|Benzoyl Peroxide (BP) 2.5%
89675671|NCT00558831|Active Comparator|Benzoyl Peroxide plus moisturizing lotion|Benzyol Peroxide 2.5% plus moisturizing lotion
89675672|NCT01431638|Experimental|Canakinumab 150mg|Canakinumab 150mg in prefilled syringe subcutaneously
89675673|NCT04674033||Consumer|Participants who self-report regular consumption of non-nutritive sweeteners (>/=5 servings/week) based on a pre-screening dietary survey.
89675674|NCT04674033||Non-Consumer|Participants who self-report no consumption of non-nutritive sweeteners (0 servings/week) based on a pre-screening dietary survey.
89675675|NCT03021993|Experimental|Nivolumab|Nivolumab (OPDIVO) will be administered every two weeks for up to four doses prior to surgery at 3mg/kg
89675676|NCT01392170|Experimental|PEG-IFNá-2a|PEG-IFNá-2a (Pegasys) 45 mcg subcutaneously as single weekly dose.
89050072|NCT02092454|Placebo Comparator|Placebo|Topical otic solution, every 1-2 hours, for up to 3 days
89050073|NCT02083289|Experimental|Experimental Arm 1|ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
89050074|NCT02083289|Active Comparator|Active Comparator Arm 2|Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.
89675677|NCT00558753|Placebo Comparator|1 Placebo|Half of the patients will receive PO placebo for 14 days
89675678|NCT00558753|Experimental|2 Pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
89675679|NCT01391546|Experimental|ZOSTAVAX intramuscular (IM) route|Single dose of 0.65 mL via IM injection
89675680|NCT01391546|Active Comparator|ZOSTAVAX subcutaneous (SC) route|Single dose of 0.65 mL via SC injection
89675681|NCT03025490|No Intervention|standard of Care|Patient undergoing sedation, treatment team does not have capnography data available.
89675682|NCT03025490|Experimental|Capnography|Patient undergoing sedation, treatment team does have capnography data available.
89675683|NCT01410110|Experimental|Cognitive Training + Work Therapy|"Cognitive Training using auditory and visual Positscience software 5 hours/per week for 13 weeks.~Work Therapy for 15 hours per week at half minimum wage doing entry level duties at medical center job sites, supervised by regular medical center staff."
89675684|NCT01410110|Active Comparator|Work Therapy Only|Same work therapy but for 20 hours per week.
89675685|NCT01391000|Experimental|Laser CO2|
89675686|NCT01391000|Active Comparator|TENS|
89675687|NCT02275767|Experimental|Combination 50% cortical/50% cancellous FDBA|Ridge preservation with Combination 50% cortical/50% cancellous freeze-dried bone allograft (FDBA)
89675688|NCT02275767|Active Comparator|100% cortical FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
89675689|NCT02275767|Active Comparator|100% cancellous FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
89675690|NCT05397717||Spontaneous pneumothorax|A. Inclusion criteria i. All patients with a confirmed diagnosis of spontaneous pneumothorax on admission or during the hospital stay ii. Age greater than 18 years old iii. Chinese ethnicity iv. Able to sign written informed consent to participate in the study B. Exclusion criteria i. Pneumothorax was not found by thoracic imaging ii. Traumatic pneumothorax (including iatrogenic pneumothorax) iii. Pneumothorax with recent (within one month) lung resection surgery, that may be due to staple line issues iv. Trapped lung or non-expandable lungs, without evidence of air leakage v. Patients with psychiatric disease or cognitive impairment that may limit their ability of understanding or giving consent to the study
89675691|NCT00324259|Active Comparator|Arm 1 (6 mg estradiol)|6 mg of estradiol daily (2 mg tid).
89675692|NCT00324259|Active Comparator|Arm 2 (30 mg estradiol)|30 mg of estradiol. (10 mg tid)
89675693|NCT04600141|Active Comparator|Group 1 - Therapeutic anticoagulation|"(I) intravenous UFH started at a dose of 18 IU/kg/h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value; OR~(II) subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours."
89675694|NCT04600141|Active Comparator|Group 2 - Prophylactic anticoagulation|"(I) subcutaneous UFH 5,000 IU every 8 hours; OR~(II) subcutaneous LMWH - enoxaparin 40 mg daily."
89675695|NCT04600141|Experimental|Group 3 - Therapeutic anticoagulation with tocilizumab|"(I) Intravenous UFH initiated at a dose of 18 IU / kg / h, adjusted according to a nomogram to achieve a TTPa of 1.5 to 2.0 times the reference value associated with 8 mg / kg / tocilizumab infusion / intravenous dose in a single dose; OR~Subcutaneous LMWH - enoxaparin 1 mg / kg per dose every 12 hours associated with an infusion of tocilizumab 8 mg / kg / dose in a single dose."
88996144|NCT02932930|Placebo Comparator|Control group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline"
88996145|NCT02932813|Experimental|Intervention Group|"THINK intervention:~The program will have activity and fitness sessions lasting two hours, three times a week for a total of nine months. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence."
88996146|NCT02932813|No Intervention|Control Group|This group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre, mid, and post testing protocol as the intervention group, but will not receive the THINK program.
88996147|NCT02932969|Experimental|Panel 1 Arm|BMS-986231 and BMS-986231 Placebo intravenously
88996148|NCT02932969|Experimental|Panel 2 Arm|BMS-986231 and BMS-986231 Placebo intravenously
88996149|NCT02932969|Experimental|Panel 3 Arm|BMS-986231 and BMS-986231 Placebo intravenously
88996150|NCT00153647|Active Comparator|1|Cap-assisted Colonoscopy
88996151|NCT00153647|Placebo Comparator|2|Regular Colonoscopy
88996152|NCT04642378|Experimental|iNCDSS group|Artificial intelligence assisted insulin titration system group
88996153|NCT04642378|Active Comparator|Routine treatment group|Physician decided insulin titration group
88996154|NCT04608136|Experimental|Yolk ketogenic diet|consume carbohydrate < 10% and 3 whole eggs supplement per day in 12 weeks
88996155|NCT04608136|Experimental|White ketogenic diet|consume carbohydrate < 10% and 6 white eggs supplement per day in 12 weeks
88996156|NCT04608136|Active Comparator|Control group|decrease consumption of diet from typical (decreased energy 20%) but consume carbohydrate in normal level
88996157|NCT02933047|Active Comparator|Outpatient LH|Patients in the intervention group are discharged within 6 to 8 hours after total laparoscopic hysterectomy.
88996158|NCT02933047|Placebo Comparator|Inpatient LH|Patients in the control group follow regular hospitalization and are discharged within 24 hours after total laparoscopic hysterectomy.
88996159|NCT02932852|Active Comparator|GROUP I|lipoaspiration and transplantation of ADAS alone without scaffold
88996160|NCT02932852|Active Comparator|GROUP II|Lipoaspiration and transplantation of scaffold (human corneal decellularized lamina) without ADAS
88996161|NCT02932852|Active Comparator|GROUP III|Lipoaspiration and transplantation of ADAS cellularized on scaffold (the human corneal decellularized lamina)
88996162|NCT00153686|Experimental|Capsule Endoscopy|Capsule Endoscopy examination of small intestine
89675696|NCT04600141|Experimental|Group 4 - Prophylactic anticoagulation with tocilizumab|"(I) subcutaneous UFH 5,000 IU every 8 hours associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose; OR~(II) subcutaneous LMWH - enoxaparin 40 mg daily associated with an infusion of tocilizumab 8 mg / kg / intravenous dose in a single dose."
89675697|NCT00324415|Experimental|CMT with Radiation Therapy|"All patients will receive combined modality therapy (CMT) with 2 cycles of cisplatin and 5-FU chemotherapy, given concurrently with radiation therapy. CMT consists of:~Cetuximab 400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose).~Cisplatin 75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)~5-FU 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)"
89675698|NCT00390559|Experimental|ActiveP/ActiveC|21 mg patch/Nicotine-containing cigarette
89675699|NCT00390559|Experimental|PlaceboP/ActiveC|0 mg patch/nicotine-containing cigarette
89675700|NCT00390559|Experimental|Active P/PlaceboC|21 mg patch/no nicotine cigarette
89675701|NCT00390559|Experimental|PlaceboP/PlaceboC|0 mg patch/no nicotine cigarette
89675702|NCT02107339|Experimental|methadone group|Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
89675703|NCT02107339|Active Comparator|Hydromorphone group|Patients will receive hydromorphone 2 mg at the end of the surgical procedure
89675704|NCT00390949|Experimental|Intervention arm|Peer education with female sex workers and potential male clients. Strengthened syndromic management of STIs with community-based promotion activities
89675705|NCT00390949|No Intervention|Control|Standard of care
89675706|NCT00392041|Experimental|Eszopiclone|
89675707|NCT00392041|Placebo Comparator|Placebo|
88996163|NCT00153686|Other|Mesenteric Angiogram|Mesenteric Angiogram of the small intestine
88996164|NCT02932774|Experimental|Cetirizine 10 mg|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
88996165|NCT02932774|Active Comparator|loratadine 10 mg|Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
88996166|NCT02932774|Placebo Comparator|placebo|Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
88996167|NCT02932696|Experimental|Exercise training|"Patients in this arm were encouraged to participate in an exercise training program, and they accepted to do so.~Intervention: Cardiac training program"
88996168|NCT02932696|No Intervention|No exercise training|Patients in this arm were encouraged to participate in an exercise training program, and they refused to do so.
88996169|NCT02932423|Other|1 - Snack|Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
88996170|NCT02932423|Other|2 - No snack|Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
88996171|NCT02932384|Active Comparator|Control-Passport Only|"Complete a needs assessment and develop a written Passport to Wellness, an itemized set of health promoting behaviors and services aligned with lifestyle and goals. Participants are compensated based on the items they complete, services they attend."
88996172|NCT02932384|Experimental|Intervention-Passport and Peer Mentor|"In addition to the Passport to Wellness developed with project staff, study participants will select a peer mentor trained in motivational interviewing. The peer mentor will help guide the participant to complete passport items. Part of passport development will include compensation for meeting with peer mentors to form strategies for meeting goals and addressing barriers/challenges that arise."
89675708|NCT01792765|No Intervention|Control Arm|This arm will undergo ureteroscopy using conventional fluoroscopy to guide the procedure and visualize scope position, safety wire status, etc.
89675709|NCT01792765|Experimental|Ultrasound guidance|This arm will have intraoperative ultrasound guidance to determine safety wire position and for scope guidance.
89675710|NCT01390844|Experimental|Boceprevir|PEG + RBV for 4 weeks followed by BOC + PEG + RBV for 32 weeks. At the Treatment Week 36 visit, participants with undetectable HCV-RNA at Treatment Weeks 8 and 12 will proceed to 36 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 8 and undetectable HCV-RNA at Treatment Week 12 will continue on BOC + PEG + RBV until Treatment Week 36, receive placebo + PEG + RBV until Treatment Week 48, and then proceed to 24 weeks of post-treatment follow-up. Participants with any HCV-RNA result at Treatment Week 8 and detectable HCV-RNA at Treatment Week 12 will discontinue treatment and proceed to 24 weeks of post-treatment follow-up.
89675711|NCT01390844|Active Comparator|Control|PEG + RBV for 4 weeks followed by BOC placebo + PEG + RBV for 44 weeks. Participants with undetectable HCV-RNA at Treatment Week 12 and at subsequent assays will continue on placebo + PEG + RBV through Treatment Week 48 and proceed to 24 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 12 may roll over to Cross-Over BOC treatment beginning with Treatment Week 14.
89675712|NCT01430624|Experimental|PPRS video|Prevention of post sexual assault stress
89675713|NCT01430624|Active Comparator|PIRI video|Pleasant imagery and relaxation instruction
89675714|NCT01430624|No Intervention|Standard care|Treatment as usual
89675715|NCT00395161|Experimental|zinc selenium glutamine metoclopramide|metoclopramide, zinc, selenium, and glutamine
89675716|NCT00395161|Placebo Comparator|enteral whey protein and IV saline|saline, sterile water, whey protein
89675717|NCT01430468|Experimental|Glenoid Positioning System|For the patients randomized to the GPS group, the surgeon will be given the GPS patient specific instrumentation and a model of the glenoid surface showing the exact placement and fit of the GPS alignment instruments.
89675718|NCT01430468|No Intervention|Standard Group|Each surgeon will use their standard methods of pre-operative planning using the pre-operative x-rays and CT scan.
89675719|NCT02076776|Active Comparator|Repetitive Task Practice (RTP)|This group focuses on RTP.
89675720|NCT02076776|Experimental|Voluntary cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
89675721|NCT02076776|Experimental|Assisted cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
89675722|NCT01792843||Parkinson's disease|Patients with Parkinson's disease according to international criteria
89675723|NCT04052672|Active Comparator|Randomized Intervention|The intervention will consist of an exercise intervention, a combination of supervised exercise classes and in home exercises and open label nutritional supplement.
89675724|NCT04052672|No Intervention|Randomized - Control|The control will consist of a single group educational session which will include the discussion of general advice on health, exercise and nutrition as well as open label nutritional supplement
89675725|NCT01794013|Active Comparator|Parent trianing|The parent training group will learn about DIR/ Floortime™ model approach through one on one coaching for 1 hour at the beginning of the study, the end of 1st and 3th month and through 2 hours DVD lecture and a pocket book.
89675726|NCT01794013|Active Comparator|Routine care|The children in the control group will continue their standard routine care.
89675727|NCT01409564|Experimental|Cilostazol|Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.
89675728|NCT01409564|Placebo Comparator|Placebo|Placebo group means dementia patients group receiving donepezil with placebo.
89675729|NCT01794091|Experimental|Eplerenone|In a subgroup of 50 patients, 25 will be randomized to eplerenone to assess effects on fibrotic index pre- and post-6 months of therapy.
89675730|NCT01794091|Placebo Comparator|Sugar pill|
89675731|NCT01390298||Observational|Adult patients scheduled for elective unicompartmental or total knee replacement surgery or total hip replacement will be consented to participate
89675732|NCT01794169|Experimental|Azacitidine|Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.
89675733|NCT01794169|Active Comparator|DA|"Two courses of DA in accordance with the Swedish National treatment program (reduced doses):~In case one induction course was given:~First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.~Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~In case two induction courses were given:~First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5."
89675734|NCT01390220|Experimental|USL261|intranasal midazolam 5mg
89675735|NCT01390220|Experimental|Placebo|Intranasal placebo
89675736|NCT00357331|Experimental|Potassium Citrate|Potassium Citrate 20 meq twice daily
89675737|NCT00357331|Placebo Comparator|Placebo|Placebo
89675738|NCT00357955|Experimental|MEDIC|Multidisciplinary education and diabetes intervention for cardiac risk reduction
89675739|NCT00357955|No Intervention|usual care|usual care
89675740|NCT00550173|Experimental|Pemetrexed + Erlotinib|Pemetrexed 500 milligrams per meter squared (mg/m^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
89675741|NCT00550173|Active Comparator|Erlotinib|Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
89675742|NCT00550173|Active Comparator|Pemetrexed|Pemetrexed 500 mg/m^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.
89675743|NCT04163107|Experimental|Combination treatment of carfilzomib/dexamethasone/HCQ|
88996173|NCT02932540||Healthy controls|healthy controls subjects who have age, sex and Blood pressure matched with the acute ischaemic stroke patient
88996174|NCT02932540||AIS patient-transient arm|transient change of head position from lying flat (0 degree) to sitting up (30 degree)
88996175|NCT02932540||AIS patient - persistent lying flat|lying flat (0 degree) head position for the first 24 hours in the hospital admission
88996176|NCT02932540||AIS patient - persistent sitting up|sitting up ( 30 degree) head position for the first 24 hours in the hospital admission
88996177|NCT00153764|Placebo Comparator|multivitamin|1 tablet morning and evening
88996178|NCT04690309|Active Comparator|Patients treated with human insulin preparations|Treatment with human regular insulin administered subcutaneously before breakfast, lunch and supper and with Neutral Protamine Hagedorn insulin (isofane insulin) administered subcutaneously before sleep.
89675744|NCT01429298|Experimental|Hydromorphone|2 mg of IV dilaudid will be administered over 2-3 minutes as initial dose.
89675745|NCT01429298|Active Comparator|Usual care|The attending physician administers whatever IV opioid he/she deems appropriate in whatever dose he/she chooses for initial dosing
89675746|NCT00397579|Experimental|SL-401|Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
89675747|NCT04141657||Group 1 (0-17 years)|We will observe the treatment course in ICU pediatric patients, register adverse events (AEs) and serious adverse events (SAEs) if occur, and assess patient health status at the end of the performed therapy.
89675748|NCT01408706|Active Comparator|Miller enema air tip|The Miller enema air tip rectal balloon is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy.
89675749|NCT01408706|Active Comparator|Radiadyne Immobilizer|The Radiadyne Immobilizer Treatment Device is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy
89675750|NCT02988531|Experimental|PET/MR|Participants to have PET/MR scan
89675751|NCT04045886|Experimental|Online Educational Modules group|anesthesia residents are randomized to watch educational videos which is the intervention.
89675752|NCT04045886|Active Comparator|Reading two research papers group|anesthesia residents are randomized to read 2 research papers which is the active comparator
89675753|NCT01408628|Experimental|Internet Insulin Education|"Single arm study; intervention represented by subjects' participation in 4 synchronous (live) interactive Internet classes."
89675754|NCT01389752|Experimental|LY2216684 without Charcoal, then with Charcoal|Period 1: Single 18-mg (milligram) (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg (gram/kilogram) of Activated Charcoal. Periods will be separated by a minimum of 7 days.
88996179|NCT04690309|Active Comparator|Patients treated with insulin analogues|Treatment with insulin analogues lispro administered subcutaneously before breakfast, lunch and supper and with glargine administered subcutaneously before sleep.
89675755|NCT01389752|Experimental|LY2216684 with Charcoal, then without Charcoal|Period 1: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg of Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Periods will be separated by a minimum of 7 days.
89675756|NCT01428128|Experimental|Arsenic Trioxide|
89675757|NCT01407926||Nurse-Led Mental Health Promotion Group|Interprofessional nurse-led strategy involving regular home visits over 6 months by an RN and PSW. The RN will conduct a comprehensive health assessment and screen clients for risk factors for depression and other chronic conditions, implement health promotion strategies to address this risk factors and enhance health, review their medications, conduct in-home exercise , refer clients to other health services
89675758|NCT00358501|Experimental|Defibrotide|Defibrotide treatment
89675759|NCT00358501|No Intervention|Historical Control|Historical control group
89675760|NCT03655639||Premature Birth|Premature babies born under 29 weeks gestational age, admitted into the neonatal intensive care unit within 7 days of life.
89675761|NCT01427972|Experimental|0.2 milligrams (mg) LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
89675762|NCT01427972|Experimental|1.5 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
89675763|NCT01427972|Experimental|10 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
89675764|NCT01427972|Active Comparator|50 mg Eplerenone|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
89675765|NCT00336323|Active Comparator|1|Laser photocoagulation at baseline
89675766|NCT00336323|Experimental|2|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
89675767|NCT00336323|Experimental|3|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
89675768|NCT00336323|Experimental|4|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
89675769|NCT00336323|Experimental|5|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
89675770|NCT01427738|Experimental|Arm A: Topical GV solution|Topical GV 0.00165% solution (5 mL swish and gargle for 1 minute and expectorate [spit] 2 times per day [BID]) for 14 days
89675771|NCT01427738|Active Comparator|Arm B: Nystatin oral suspension|Nystatin oral suspension (5 mL of 100,000 units/mL swish for 1 minute and swallow 4 times per day [QID]) for 14 days
89675772|NCT01426958|Active Comparator|treatment A|1 tablet afatinib single dose
89675773|NCT01426958|Experimental|treatment B|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
89675774|NCT01426958|Experimental|treatment C|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
89675775|NCT05266157|Active Comparator|Usual care|"Skin care, exercise and compression stocking:~The patient has to wear custom-made compression thigh stocking(s) in case of unilateral/ bilateral swelling of the leg and has to wear a bermuda in case of swelling of the midline region. The patient continues the skin care and continues/ restarts exercise therapy with the home physical therapist 2 times a week. Frequency of exercises is gradually decreased: M1-3 2x/w, M4-6 1x/w, M7-9 1x/M; M10-12 only self-exercises."
89675776|NCT05266157|Experimental|Additional manual lymph drainage|"Usual care + manual lymph drainage. Manual lymph drainage is performed by the home physical therapist. Every session lasts for 30 minutes.~Frequency of manual lymph drainage is gradually decreased: M1-3 2x/w, M4-6 1x/w, M7-9 1x/M; M10-12 only self-MLD."
89675777|NCT00337181||Vaccine Group|Received vaccination in RV144
89675778|NCT00337181||Placebo Group|Received placebo in RV144
89675779|NCT00397813|Experimental|Arm A - Dose Level 1|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 1 - 300 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
89675780|NCT00397813|Experimental|Arm A - Dose Level 2|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 2 - 400 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
89675781|NCT00397813|Experimental|Arm A - Dose Level 3|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 3 - 450 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
89050075|NCT02081300|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
89675782|NCT00397813|Experimental|Arm B - Dose Level 1|"Arm B - patients with MDS-RAEB or CMML Dose Level 1 - 300 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
89675783|NCT00397813|Experimental|Arm B - Dose Level 2|"Arm B - patients with MDS-RAEB or CMML Dose Level 2 - 400 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
89675784|NCT00397813|Experimental|Arm B - Dose Level 3|"Arm B - patients with MDS-RAEB or CMML Dose Level 3 - 450 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
89675785|NCT01791023|Experimental|Physical exercise|Physical exercise
89675786|NCT01791101|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
89675787|NCT00398983|Experimental|Decitabine 20 mg/m^2|20 mg/m^2 intravenous (IV) daily for 5 days
89675788|NCT00398983|No Intervention|No Study Drug|Continue current therapy.
89675789|NCT01791179|Experimental|Substance Abuse Treatment Group|
89675790|NCT00358579|Active Comparator|Adrenaline|
89675791|NCT00358579|Active Comparator|Vasopressin|
89675792|NCT00338039|Experimental|Chemotherapy + Chemoradation|Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 intravenous (IV)/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
89050076|NCT02081300|Other|Topical testosterone gel 1.62 %|Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28
89050077|NCT04611360|Experimental|Anodal Transcranial Direct Current Stimulation Group|Anodal Transcranial Direct Current Stimulation and Conventional training exercises
89050078|NCT04611360|Active Comparator|Conventional Training Exercises Group|Conventional Training Exercises : Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk
89050079|NCT04677881|Placebo Comparator|Wholegrain bread with yeast|The control group will be given min. 5 slices of bread baked with yeast per day.
89050080|NCT04677881|Experimental|Wholegrain bread with sourdough|The experimental group will be given min. 5 slices of bread baked with sourdough per day.
89050081|NCT00563940||1|
89050082|NCT00563940||2|
89050083|NCT02074007|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period"
89050084|NCT02074007|Placebo Comparator|Placebo Comparator|"Topical ear drops~Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period."
89050085|NCT00563979|Active Comparator|1|VitaluxPlus®
89675793|NCT00358657|Experimental|Treatment (chemo, total-body irradiation, transplant)|See Detailed Description
89675794|NCT00340379|Active Comparator|Ziprasidone|Subjects in this arm received ziprasidone with a placebo to maintain the blind
89675795|NCT00340379|Active Comparator|Sertraline/Haloperidol|Subjects in this arm received a combination of sertraline and haloperidol with a placebo to maintain the blind. Sertraline dosage was 150-200mg/day and haloperidol was 6-8mg/day based on tolerance.
89675796|NCT02982811|No Intervention|Control group|Therapy as usual, i.e. occupational therapy, physiotherapy, etc.
89050086|NCT00563979|Active Comparator|2|Omega 3
89050087|NCT02072954|Experimental|Asenapine Sublingual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days
89050088|NCT02072954|Active Comparator|Saphris Subligual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.
89050089|NCT04632147|Experimental|Pranayama Group|Participants in this group will apply a 45-minute training program at home, consisting of 5 minutes of Ujjayi pranayama, 5 minutes of Nadi-Shodhana pranayama and 5 minutes of Sukha pranayama, 7 days a week for 8 weeks, 3 times a day. In addition, they will perform a 15-minute session 3 day a week for 8 weeks, under the online supervision of a physiotherapist. The training program will last 8 weeks.
89050090|NCT04632147|No Intervention|Control Group|No intervention will be made to this group.
89050091|NCT04632108|Experimental|ASKB589 Injection|Experimental: ASKB589 Injection ASKB589 Injection treatment. This phase 1/II trial will include two stages, a dose escalation stage and an expansion stage.
89675797|NCT02982811|Experimental|Experimental group|Therapy as usual together with 3x45min training with i-ACT system during 6 weeks.
88996180|NCT02931955||Venom Group|"The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
88996181|NCT02931955||Pollen Group|"The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
88996182|NCT02931955||Control Group|"The investigators plan to include 10 control persons without a clinical history of allergies. Blood and stool samples will be collected at seven/four times respectively.~The patients will receive usual standard of care and no intervention."
88996183|NCT02932189|No Intervention|Control|Procedure: Ventilator weaning in the conventional way with a tracheal collar.
88996184|NCT02932189|Experimental|Intervention|"Procedure: Ventilator weaning with a tracheal collar after inspiratory muscle training with an isokinetic device.~Device: K5 Power Breath"
88996185|NCT02931994|No Intervention|Group A Phase 1|50% of sample are randomly assigned to Group A and are to utilise conventional flossing technique in the first phase of 6-weeks
88996186|NCT02931994|Active Comparator|Group B Phase 1|50% of sample are randomly assigned to Group B and are to utilise knotted floss technique in the phase 1 of 6-weeks
88996187|NCT02931994|Active Comparator|Group A Phase 2|After a washout period of 2 weeks, those from Group A will use the knotted floss technique for a period of 6 weeks.
88996188|NCT02931994|No Intervention|Group B Phase 2|After a washout period of 2 weeks, those from Group B will use the conventional floss technique for a period of 6 weeks.
88996189|NCT00153881|Experimental|1|Docetaxel/Carboplatin every 3 weeks for 2 cycles then concommitant chemotherapy and radiation Docetaxel weekly for 5 doses without premedication, then Capecitabine will be given orally, one dose prior to each fraction or irradiation (28 cycles).
88996190|NCT02932033|Active Comparator|Tack fixation|consecutive patients with bilateral inguinal hernias will be recruited for TEP repair. Mesh fixation methods with spiral tack is randomly assigned to one side, then comparative fixation method to the contralateral side. In group of active comparator, after randomization, the target inguinal hernia side of the patient has the mesh fixed with titanium spiral tacks.
88996191|NCT02932033|Experimental|Synthetic glue fixation|The same patient, his contralateral side of inguinal hernia, has the mesh fixed with synthetic glue.
88996192|NCT02931916||healthy group|recruited for evaluation of system reliability
88996193|NCT02931916||Chronic Ankle Instability group|recruited for evaluation of system validity
88996194|NCT02931799|Experimental|Nurse Follow-Up and Electronic Monitoring|
89675798|NCT00342563|Experimental|Mecamylamine- Smoker|
89675799|NCT00342563|Placebo Comparator|Placebo-Smoker|
89675800|NCT00342563|Experimental|Mecamylamine- Non-Smoker|
89675801|NCT00342563|Placebo Comparator|Placebo-Non-Smoker|
89675802|NCT00358735|Experimental|ActiveCare CECT|The ActiveCare CECT device is a mobile compression device used to prevent venous thromboembolic events, used after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery.
89675803|NCT00358735|Active Comparator|LMWH (Enoxaparin)|Enoxaparin (LMWH) will be used, following a protocol that is considered a standard of care for this patient population. 40mg QD for the remainder of the 10 days.
89675804|NCT04053803|Experimental|Open Label|
89675805|NCT00359203|Placebo Comparator|Dual chamber pacemaker|Dual chamber pacemaker programmed ODO (switched OFF)
89675806|NCT00359203|Active Comparator|Dual chamber pacemeker|Medtronic dual chamber pacemaker programmed ON and with Rate Drope Response programmed ON
89675807|NCT01795339|Experimental|AZD3293|Part 1: Up to 6 sequential cohorts of healthy elderly subjects are planned, with multiple ascending doses, starting with 5 mg (subject to confirmation by the Safety Review Committee) Part 2: Up to 16 mild-to-moderate AD patients administered one to up to 3 dosage levels of AZD3293
89675808|NCT01795339|Placebo Comparator|Placebo|Part 1: Placebo given (2 subjects in each cohort) Part 2: Placebo given (up to 4 subjects)
89675809|NCT02109419||All participants|All participants, including control, mild cognitive impairment, and dementia.
89675810|NCT02000011|Other|standard strategy|
89675811|NCT02000011|Experimental|experimental strategy|
89675812|NCT04024007||Dialysis patients|Intensive care dialysis patients (Continuous Venous Hemofiltration with citrate). Dialysis performed according to the standard indications of the service. Patients are dialysed with the prismaflex system on AN69ST membranes.
89675813|NCT01794325|Active Comparator|Trans-radial access|Coronary angiography performed through trans-radial access
89675814|NCT01794325|Active Comparator|Trans-femoral access|Coronary angiography performed through trans-femoral access
89675815|NCT04022603|Experimental|Optiflow nasal googles|Oxygen provided by means of high throughput nasal googles (Optiflow, Fisher&Paykel- New Zealand).
89675816|NCT04022603|Active Comparator|Venturi mask|Oxygen provided by means of a Venturi mask.
89675817|NCT00359983|Experimental|MenHibrix 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of MenHibrix co-administered with Pediarix and Prevnar and a 4th dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
89675818|NCT00359983|Active Comparator|ActHIB 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a 4th dose of ActHIB co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
89675819|NCT00359983|Experimental|ActHIB 3-dose + MenHibrix 4th-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
89675820|NCT01791335||COPD patients receiving NIV|
89675821|NCT03824249|Experimental|Spontaneous breathing|Performance of indirect calorimetry in spontaneously breathing children through the use of indirect calorimetry.
89215164|NCT04409457|Other|Participants without Bulimia Nervosa|"Participants are randomly assigned (in even numbers across the two groups) to scan order:~A. These participants are first scanned after 16 hours of fasting on one day, and are next scanned after a standardized meal on a second day.~B. These participants are first scanned after a standardized meal on one day, and are next scanned after 16 hours of fasting on a second day."
88996195|NCT02931799|Active Comparator|Minimal Intervention|
88996196|NCT02931760|Active Comparator|subcutaneous pacemaker|The patients who are randomized to receive a subcutaneously implanted pacemaker
88996197|NCT02931760|Active Comparator|intramuscular pacemaker|The patients who are randomized to receive an intramuscular implanted pacemaker
88996198|NCT02931643|Placebo Comparator|High fat challenge breakfast|High fat breakfast without mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
88996199|NCT02931643|Experimental|High fat challenge breakfast with mixed-spices|High fat breakfast with mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
88996200|NCT02931877|Experimental|Sevoflurane|Maintenance of anesthesia with sevoflurane during the cardiac valvular surgery.
88996201|NCT02931877|Active Comparator|Propofol|Maintenance of anesthesia propofol during the cardiac valvular surgery.
88996202|NCT00180219||1|20 to 22 years
88996203|NCT00180219||2|30 to 32 years
88996204|NCT00180219||3|40 to 42 years
88996205|NCT00153998|Active Comparator|1|Cetuximab and FOLFIRI
88996206|NCT00153998|Active Comparator|2|Cetuximab and FOLFOX
88996207|NCT02931604|Experimental|Sinus irrigation|Sinus irrigation intervention
88996208|NCT02925208||Cochlear Implant|Patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
88996209|NCT02925130|Experimental|Inhaled Salbutamol|Acute inhalation of 800 microgram Salbutamol
88996210|NCT02925130|Experimental|Oral Salbutamol|Acute oral intake of 4 mg Salbutamol
88996211|NCT02925130|Placebo Comparator|Placebo|Acute oral intake of a placebo
88996212|NCT02924974|Sham Comparator|Control|subcutaneous lidocaïne and intravenous loading dose of morphine
88996213|NCT02924974|Experimental|Intervention|Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age
88996214|NCT02924896|Other|randomization 1|Palm Olein, Interesterified Palm Olein, Soybean Oil
88996215|NCT02924896|Other|randomization 2|Palm Olein, Soybean Oil, Interesterified Palm Olein
88996216|NCT02924896|Other|randomization 3|Interesterified Palm Olein, Palm Olein, Soybean Oil
88996217|NCT02924896|Other|randomization 4|Interesterified Palm Olein, Soybean Oil, Palm Olein
88996218|NCT02924896|Other|randomization 5|Soybean Oil, Interesterified Palm Olein, Palm Olein
88996219|NCT02924896|Other|randomization 6|Soybean Oil, Palm Olein, Interesterified Palm Olein
88996220|NCT02925052|Experimental|GTG|Gastric tube placement using the Gastric Tube Guide
88996221|NCT02925052|Other|Conventional|Gastric tube placement using a conventional method, according to local protocol.
88996222|NCT00154076|Experimental|1|
89050092|NCT02061332|Experimental|Intranodal Vaccine|An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.
89675822|NCT03824249|Experimental|NIV-CPAP|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 centimeters of water (cmH2O). CPAP will be applied via single-limb circuit with intentional leak.
89675823|NCT03824249|Experimental|NIV-PS|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 cmH2O and Pressure support (PS) of 8 cmH2O. Non-invasive ventilation will be applied via single-limb circuit with intentional leak.
89675824|NCT04388735||Newly Diagnosed MM 1st Line and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~Both patients with or without identified caregivers will complete a one time series of questionnaires.~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete."
89675825|NCT04388735||MM receiving 1-3 prior lines of therapy and Caregivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~Both patients with or without identified caregivers will complete a one time series of questionnaires.~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
89675826|NCT04388735||MM patients receiving ≥ 4 lines of therapy and Cargivers|"This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires.~Patients will be asked to identify a caregiver (e.g. a relative or friend) upon whom they rely for help and has an in-person contact with the patient at least 2x per week.~Both patients with or without identified caregivers will complete a one time series of questionnaires.~The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete"
89675827|NCT00345371|Active Comparator|Topiramate|Subjects will receive topiramate (in tablet form) up to 200 mg/day for 13 weeks.
89675828|NCT00345371|Placebo Comparator|Placebo Oral Tablet|After randomization subjects will receive topiramate matched placebo (in tablet form), up to 200 mg/day for 13 weeks.
89675829|NCT03006276|Experimental|DFN-15 Active|DFN-15 Active
89675830|NCT03006276|Placebo Comparator|DFN-15 Placebo|DFN-15 Placebo
89675831|NCT00350363|Active Comparator|1 hour gatifloxacin|presence of conjunctival bacteria 1 hour after administration of topical gatifloxacin
89675832|NCT04801667|Experimental|Coronavac vaccine|Kidney transplant recipients receiving the coronavac vaccine
89675833|NCT02578992|Experimental|Head-lift Position|The patients' head was placed in the head-lift position(A 7 cm high pillow was set beneath the patients' head with head in neutral position) and then the patient was intubated with Trachway by single-handed chin lift technique
89675834|NCT02578992|No Intervention|Neutral Position|The patients' head was placed in the neutral position and then the patient was intubated with Trachway by single-handed chin lift technique
89675835|NCT00351299|Experimental|Infusion of dexmedetomidine|infusion 0.3-0.7 dexmedetomidine
89675836|NCT00351299|Other|Standard of Care|Standard of care per treating physician preference
89675837|NCT02909868|Experimental|RV location|All included subjects will undergo the PV loop test with 'BackBeat PHC' ON and OFF
89675838|NCT01793597||clopidogrel|previous treatment with clopidogrel
89675839|NCT01793597||ticagrelor|previous treatment with ticagrelor
89675840|NCT04303416|Experimental|Patients|Patients before and after the treatment
89675841|NCT05330286|Experimental|Pediatric Formulation|Part 1 - healthy participants receiving pediatric formulation
89675842|NCT05330286|Experimental|Adult Formulation|Part 1 - healthy participants receiving adult formulation
89675843|NCT05330286|Experimental|Adult formulation fasted state|Part 2- healthy participants receiving adult formulation in fasted conditions
89675844|NCT05330286|Experimental|Adult formulation Fed state|Part 2- Part 2- healthy participants receiving adult formulation in fed conditions
89675845|NCT00352001|Experimental|Lenalidomide and Azacitidine|
89675846|NCT00401401|Experimental|Zalutumumab 4 mg/kg|Zalutumumab 8 weekly infusions
88996223|NCT00154076|Active Comparator|2|
88996224|NCT02924779||Women during labour|Women receiving lumbar epidural anaesthesia for pain during birth
88996225|NCT02924740|Active Comparator|control|pelvic floor muscle training
88996226|NCT02924740|Experimental|intervention|vaginal tampon training.
88996227|NCT00154115|Experimental|1|Levosimendan
88996228|NCT00154115|Placebo Comparator|2|
88996229|NCT02924662||Kellgren and Lawrence classification I|Grade I Kellgren and Lawrence radiographic changes.
88996230|NCT02924662||Kellgren and Lawrence classification II|Grade II Kellgren and Lawrence radiographic changes.
88996231|NCT02924662||Kellgren and Lawrence classification III|Grade III Kellgren and Lawrence radiographic changes.
88996232|NCT02924662||Kellgren and Lawrence classification IV|Grade IV Kellgren and Lawrence radiographic changes.
88996233|NCT02924506|Other|Fixed Core|Cervical arthroplasty with fixed core prothesis
88996234|NCT02924506|Other|Movable Core|Cervical arthroplasty with movable core prothesis
88996235|NCT00154154|Active Comparator|A|General Psychiatric Management
88996236|NCT00154154|Experimental|2|Dialectal Behaviour Therapy
89675847|NCT00401401|Experimental|Zalutumumab 8 mg/kg|Zalutumumab 8 weekly infusions
89675848|NCT00401401|Experimental|Zalutumumab 12 mg/kg|Zalutumumab 8 weekly infusions
89675849|NCT00401401|Experimental|Zalutumumab 16 mg/kg|Zalutumumab 8 weekly infusions
89675850|NCT00352781|Experimental|Nicotine Replacement + Behaviour Therapy|Nicotine Replacement Therapy as per monograph & behavioural intervention
89675851|NCT03587519|Experimental|Early ileostomy closure|Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
89675852|NCT03587519|Active Comparator|Late ileostomy closure|Late ileostomy closure will be performed 8 - 12 weeks after IPAA.
89675853|NCT01794481|No Intervention|Usual Care|Participants allocated to usual care will receive their usual treatment program which will include dietician counseling as needed. As part of standardized care, participants will not be encouraged to begin a new exercise program(patients needing physical therapy at time of enrollment will be excluded.
89675854|NCT01794481|Experimental|Resistance Exercise Training|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
89675855|NCT02843568|Active Comparator|Standard of Care|"Subjects undergo four-dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning. Subjects undergo laboratory biomarker analysis, including spirometry, diffusion capacity (DLCO), and lung volumes (FEV, FEV1). Subjects complete a self-assessment, RTOG defined acute evaluation toxicity evaluation, RTOG late toxicity evaluation, and constitutional assessment.~Radiation doses between 60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation schemes are utilized. Treatment volumes are at the discretion of the treating radiation oncologist and should follow standard of care."
89675856|NCT02843568|Experimental|Pulmonary Function Damage Reduction|All criteria and specifications in the standard of care arm are applicable for this arm, including the same 4DCT scans, and laboratory biomarker analysis. Subjects randomized to this arm of the trial will have the same prescribed radiation dose to the tumor volume and held to the same radiation dose criteria as the subjects in the standard of care arm (60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation). The fundamental difference will be radiation doses for these subjects will be redistributed away from regions predicted to cause the greatest reduction in pulmonary function if damaged.
89675857|NCT05242679|Experimental|Myofascial Release Group|Participants were treated with a conventional physiotherapy program along with myofascial release with a tennis ball.
89675858|NCT05242679|Active Comparator|Conventional Physiotherapy Group|A conventional physiotherapy program was provided including range of motion/flexibility exercises, strength training, postural control, functional mobility exercises, lower limb functional exercises, and gait training.
89675859|NCT04270981|Experimental|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250|single administration of 960 mg (4 × 240 mg capsules) acoziborole in oral and fasted condition
89675860|NCT01793675||haploidentical transplant|transplant with haploidentical donor
89675861|NCT04345939||GenSeizer|Sputum and lavage fluids are tested for pathogens using GenSeizer
89675862|NCT04345939||PCR reverse hybridization|Sputum and lavage fluids are tested for pathogens using PCR reverse hybridization
89675863|NCT04345939||Target sequencing after incubation|Sputum and lavage fluids are tested for pathogens using Target sequencing after incubation
89675864|NCT03533465|Experimental|Complicated Grief Treatment (CGT)|10 adults with CG who successfully completed Aim 1 and will also participate in open complicated grief treatment (CGT), during which they will complete additional subjective and objective sleep assessments.
89050093|NCT02061332|Experimental|Intralesional Vaccine|The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.
89050094|NCT02061332|Experimental|Intranodal + Intralesional Vaccine|You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.
89675865|NCT01793753||Propofol|Chronically constipated children ages 2-6 years who will receive anesthesia for anorectal manometry including propofol per standard of care
89050095|NCT04631874|Experimental|Sequence A(RT)|Reference drug (Champix) -> washout -> test drug (CDFF0318)
89050096|NCT04631874|Experimental|Sequence B(TR)|Test drug (CDFF0318) -> washout -> reference drug (Champix)
89675866|NCT00360685|Other|TAC + MMF|Tacrolimus and Mycophenolate
89675867|NCT00360685|Other|TAC+MTX|Tacrolimus and Methotrexate
89050097|NCT02057315|Experimental|ELS-M11|Topical 5% ELS-M11 (3 g)
89050098|NCT02057315|Placebo Comparator|Placebo|A matching formulation with no active ingredient
89675868|NCT04270825|Experimental|CBT with IPT|Group CBT with IPT will consist of 20 weekly two-hour sessions and has been developed for the proposed study based on the protocols for group CBT for HD and group IPT. Treatment includes strategies from CBT, including cognitive restructuring, behavioral exposures, and organizational strategies, as well as strategies from IPT, including role-play, interpersonal skills building, communication analysis, and decision analysis.
89675869|NCT03797209||AXIOS Patient|
89675870|NCT00558519|Experimental|Treatment (chemotherapy, radiotherapy)|"Patients are given a series of leukemia treatments that are divided into several sequential courses and different chemotherapy combinations of treatment. Please see the Detailed Description section for more information."
89675871|NCT03380195|Experimental|Watermelon juice|
89675872|NCT03380195|Active Comparator|Sport drink|
89675873|NCT03380195|Active Comparator|Sugar water|
89675874|NCT03380195|Placebo Comparator|Water|
89675875|NCT04271137|Other|Orbital fractues|Orbital fractures
89675876|NCT01792271|Placebo Comparator|AB: 7% HS home tx, then 0.12% NaCl|"Inhaled Inhaled 7% HS (hypertonic saline) home treatment' , then 0.12% sodium chloride solution home treatment.~The intervention consists of the subject receiving both concentrations of inhaled sodium chloride solution, each during a different home treatment periods. Subjects randomized to order AB will receive inhaled 7% NaCl (sodium chloride solution) mist during the first home treatment period, then 0.12% NaCL during the second home treatment period."
89675877|NCT01792271|Placebo Comparator|BA: 0.12% NaCl home tx, then 7% HS|Subjects randomized to order BA will receive inhaled 0.12% NaCl mist during the first home treatment period, then Inhaled 7% HS home treatment during the second home treatment period.
89675878|NCT00403117|Placebo Comparator|Placebo, Marijuana (0% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89050099|NCT04610931|Experimental|Cybertherapy|use of cybertherapy (6 sessions) in addition to cognitive behavioral therapy (6 sessions) + pharmacological treatment
89675879|NCT00403117|Experimental|Placebo, Marijuana (3.27% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89050100|NCT04610931|Active Comparator|Treatment as usual|Treatment as usual is a cognitive behavioral therapy (6 sessions) + pharmacological treatment
89050101|NCT02053103|Experimental|PF-05175157|
89050102|NCT02053103|Placebo Comparator|Placebo|
89050103|NCT04631679||Group A: anemic patients with iron treatment|For Group A anemic patients (hemoglobin levels below 13g/dL in men and 12g/dL in women) with iron deficiency (transferrin saturation below 20% or ferritin serum level below 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or a combination of both) and are treated with a single intravenous dose of 500 milligrams of ferric carboxymaltose in 100ml 0,9% sodium chloride solution as iron supplementation directly (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).
89050104|NCT04631679||Group B: non-anemic patients without iron treatment|For Group B, non-anemic patients (hemoglobin levels above 13g/dL in men and 12g/dL in women) without iron deficiency (transferrin saturation above 20%, ferritin serum levels above 300μg/L) are screened in the Anesthesia pre-assessment clinic 1-4 days prior to cardiosurgical procedure (valve repair/implementation, aortocoronary bypass or both combined) and are not treated with iron supplementation.
89050105|NCT02049164|Experimental|AR08 0.5 mg/day|AR08 QD oral dosing for 14 weeks
89675880|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89675881|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89050106|NCT02049164|Experimental|AR08 1.0 mg/day|AR08 QD oral dosing for 14 weeks
89050107|NCT02049164|Experimental|AR08 2.0 mg/day|AR08 QD oral dosing for 14 weeks
89050108|NCT02049164|Placebo Comparator|Placebo|Placebo QD oral dosing for 14 weeks
89675882|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89675883|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89675884|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89215165|NCT04400253|Experimental|Intervention group|The intervention group will receive a 18-week in-person program. The program includes the following components: multi family group counseling, group exercise classes, mother group discussion, daughter group discussion and Fitbit.
89215166|NCT04400253|No Intervention|Control group|The group group will receive print materials about physical activity.
89215167|NCT04388761|Experimental|Intra parenchymal injection|5 subjects will receive AMSCs via direct injection into the kidney parenchyma only
89215168|NCT04388761|Experimental|Intra-arterial infusion|5 subjects will receive AMSCs via intra-arterial infusion only
89215169|NCT04388761|Experimental|Intra parenchymal injection & Intra-arterial infusion|5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion
89675885|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89675886|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89675887|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
89675888|NCT04602299|Experimental|Set the minimum time of gastroscopy|
89675889|NCT04602299|No Intervention|Observe the procedure time of gastroscopy|
89675890|NCT00558285|Experimental|indacaterol/glycopyrrolate 600/100 μg|"Two capsules indacaterol/glycopyrrolate 300/50 μg delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
89675891|NCT00558285|Experimental|indacaterol/glycopyrrolate 300/100 μg|"One capsule indacaterol/glycopyrrolate 300/100 μg and one placebo capsule delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
89675892|NCT00558285|Experimental|indacaterol/glycopyrrolate 150/100 μg|"One capsule indacaterol/glycopyrrolate 150/50 μg and one capsule 50 μg glycopyrrolate delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
89675893|NCT00558285|Active Comparator|indacaterol 300 μg|"One capsule indacaterol 300 μg and one placebo capsule delivered via s single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
89675894|NCT00558285|Placebo Comparator|placebo|"Two placebo capsules delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
89675895|NCT01792921||control waitlist|
89675896|NCT01389596|Placebo Comparator|Placebo|
89675897|NCT01389596|Experimental|Pregabalin Level 1 (max 150 mg/day)|
89675898|NCT01389596|Experimental|Pregabalin Level 2 (max 600 mg day)|
89675899|NCT02832323|Other|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) and 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
89675900|NCT04567277|Experimental|Early VPS|
89675901|NCT00558207|Experimental|1|ARQ 197
89675902|NCT00558207|Active Comparator|2|Gemcitabine
89675903|NCT05343351|Experimental|Out of Plane arm|The patient group who was injected using the ultrasound-guided out of plane injection method.
89675904|NCT05343351|Experimental|In Plane arm|The group of patients who were injected using the ultrasound-guided in-plane injection method.
89675905|NCT00407485|Experimental|Treatment (ziv-aflibercept)|Patients receive 4 mg/kg VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
89675906|NCT00354887|Experimental|Oxaliplatin + Capecitabine|Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.
89675907|NCT01794559|Experimental|Informed by PEER Interactive Report|"The PEER Interactive Report -This study is prospective in nature. For subjects in the experimental group, the treating physician will follow the guidance of the subject's PEER Interactive Report as regards sensitivity to on-label medications and classes of medication.~The subjects will be washed out of all current medications prior to having an EEG, which is necessary to generate the PEER Interactive Report. The wash out period for outpatients is no longer than 14 days.~The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health."
89675908|NCT01794559|No Intervention|No Report|This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. PEER Interactive Report is not provided to the investigator. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health.
89675909|NCT02985320|Experimental|Phase I Adult Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of high dosage investigational sIPV"
89675910|NCT02985320|Experimental|Phase I Adult Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of medium dosage investigational sIPV"
89675911|NCT02985320|Experimental|Phase I Child Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of high dosage investigational sIPV"
89675912|NCT02985320|Experimental|Phase I Child Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of medium dosage investigational sIPV"
89675913|NCT02985320|Experimental|Phase I Infant Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of high dosage investigational sIPV"
89675914|NCT02985320|Experimental|Phase I Infant Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of medium dosage investigational sIPV"
89675915|NCT02985320|Experimental|Phase I Infant Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of low dosage investigational sIPV"
89215170|NCT04338893|Active Comparator|ROSA Total Knee Robotic Instrumentation|Total knee arthroplasty performed with ROSA Total Knee Robotic instrumentation
89215171|NCT04338893|Active Comparator|Conventional TKA Instrumentation|Total knee arthroplasty performed with conventional instrumentation
89675916|NCT02985320|Experimental|PhaseⅡExperimental Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of high dosage investigational sIPV"
89675917|NCT02985320|Experimental|PhaseⅡExperimental Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of medium dosage investigational sIPV"
89675918|NCT02985320|Experimental|PhaseⅡExperimental Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of low dosage investigational sIPV"
89675919|NCT02985320|Active Comparator|PhaseⅡControl Group -commercialized sIPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention:Three-dose regimen of commercialized sIPV"
89675920|NCT02985320|Active Comparator|PhaseⅡ Control Group -commercialized IPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of commercialized IPV"
89675921|NCT04537247|Experimental|Open partial nephrectomy (Group A)|patients in this group will have open partial nephrectomy for their renal tumors.
89675922|NCT04537247|Experimental|Robotic partial nephrectomy (group B)|patients in this group will have robotic partial nephrectomy for their renal tumors.
89675923|NCT05338047|Placebo Comparator|Generic pegfilgrastim|One 6mg subcutaneous dose of generic pegfilgrastim in day+1 after autotransplant
89675924|NCT05338047|Active Comparator|Brand name pegfilgrastim|One 6mg subcutaneous dose of brand name pegfilgrastim in day+1 after autotransplant
89675925|NCT04407884|Experimental|study arm|Subjects will receive an active study device.
89675926|NCT02111863|Experimental|Lymphocyte Depleting Prep Regimen|Patients will receive a lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of 4-1BB selected tumor infiltrating lymphocytes (TIL) plus IV aldesleukin.
89675927|NCT04031768|Other|0-2-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~0 minutes 2 minutes 5 minutes 5 minutes"
89675928|NCT04031768|Other|0-5-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~0 minutes 5 minutes 2 minutes 5 minutes"
89675929|NCT04031768|Other|2-0-5-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~2 minutes 0 minutes 5 minutes 5 minutes"
89675930|NCT04031768|Other|5-0-2-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~5 minutes 0 minutes 2 minutes 5 minutes"
89675931|NCT04031768|Other|2-5-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~2 minutes 5 minutes 0 minutes 5 minutes"
89675932|NCT04031768|Other|5-2-0-5 minutes rest group|"The order of rest periods for participants randomized to this arm will be:~5 minutes 2 minutes 0 minutes 5 minutes"
89675933|NCT02660411|Active Comparator|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
89675934|NCT02660411|Experimental|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
89215172|NCT04293939||Preterm children|Children born before the 37th week of gestation: clinical sample
89675935|NCT02078492|Experimental|Group 1 - 10 mg of Ketorolac|Subjects will be administered 10 mg of Ketorolac for pain relief.
89675936|NCT02078492|Experimental|Group 2 - 15mg|Subjects will be administered 15mg of Ketorolac.
89675937|NCT02078492|Experimental|Group 3 - 30mg|Subject will receive 30mg of Ketorolac as a part of standard care.
89675938|NCT04498949|Experimental|Exprimental|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
89675939|NCT04498949|Active Comparator|Treatment as usual|Treatment as usual care, Recieve consulting not included unified protocol Recieve supportive cares
89675940|NCT04528563|Experimental|Ketorolac Tromethamine|IV ketorolac tromethamine, 0.5 mg/kg to a maximum of 30 mg plus IV morphine placebo;
89675941|NCT04528563|Active Comparator|Morphine Sulfate|IV morphine 0.1 mg/kg to a maximum of 5 mg plus IV ketorolac placebo
89675942|NCT01405898|Experimental|Beetroot Juice|
89675943|NCT01405898|Placebo Comparator|Nitrate-free beetroot juice|
89675944|NCT03086317|Active Comparator|Standard Catheter-Directed Thrombolysis|Participants randomized to this arm will receive standard catheter-directed thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
89675945|NCT03086317|Active Comparator|Ultrasound-Accelerated Thrombolysis|Participants randomized to this arm will receive ultrasound-accelerated thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
89675946|NCT00355199|Experimental|R-HDS|R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.
89675947|NCT00355199|Active Comparator|R-CHOP|Rituximab-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone).
89675948|NCT01389128|Active Comparator|Control Group|Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
89675949|NCT01389128|Experimental|Intervention Group|Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: pelvic mobility , lumbosacral massage and warm shower.
89675950|NCT04493567|Experimental|Part A: 1 x BMS-986036 via auto-injector or pre-filled syringe|
89675951|NCT04493567|Experimental|Part B: 2 x BMS-986036 via auto-injector or pre-filled syringe|
89675952|NCT01793987|No Intervention|control: shaver|
89675953|NCT01793987|Experimental|Coblation polypectomy|
89675954|NCT01961531|Experimental|Accuboost APBI|28Gy delivered in 5 daily fractions
89675955|NCT00363805|Experimental|Green Tea|Patients receive green tea beverage and placebo capsules for 6 months.
89675956|NCT00363805|Experimental|Polyphenon E|Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.
89675957|NCT00363805|Placebo Comparator|Placebo|Patients receive placebo beverage and placebo capsules daily for 6 months.
89675958|NCT01388816|Placebo Comparator|Placebo capsule|
89675959|NCT01388816|Experimental|DRL-17822 50 mg|
89675960|NCT01388816|Experimental|DRL-17822 150 mg|
89675961|NCT01388816|Experimental|DRL-17822 300 mg|
89675962|NCT01794065||Cypher|100 patients who have received a Cypher stent during their coronary intervention
89675963|NCT01794065||Taxus Express|100 patients who have received a Taxus Express stent during their coronary intervention
89675964|NCT01794065||Endeavor|100 patients who have received an Endeavor stent during their coronary intervention
89675965|NCT01794065||Promus/Xience V|100 patients who have received a Promus/Xience V stent during their coronary intervention
89675966|NCT01794065||Promus Element|100 patients who have received a Taxus Element stent during their coronary intervention
89675967|NCT01665521|Experimental|HEART Pathway|The HEART Pathway will be used for real time clinical decision making. Physicians will receive care recommendations according to the HEART Pathway, based on HEART score and serial cardiac biomarkers. This will help physicians identify low-risk patients for early discharge with no objective cardiac testing.
89675968|NCT01665521|No Intervention|Usual Care|Conventional Care cardiac testing. Patients will undergo cardiac testing as determined by their treating physicians.
89675969|NCT01791647|Active Comparator|myo-inositol|1500 mg/day myoinositol
89675970|NCT01791647|Active Comparator|metformin|1500 mg/day of metformin
89675971|NCT00363883|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat (SAHA) twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89675972|NCT00356057|Active Comparator|1|Biventricular pacing group with Closed Loop Stimulation rate adaptation (Protos CLS device)
89675973|NCT00356057|Active Comparator|2|Biventricular pacing group with accelerometer based rate adaption (Stratos LV device)
89675974|NCT00356057|Active Comparator|3|Right Ventricular pacing group with accelerometer based rate adaption (Stratos LV device)
89675975|NCT00364819|Experimental|1|rituximab 1000 mg IV on days 1 and 15, given over 5 - 6 hours
89675976|NCT04524351|Active Comparator|Posiphen, 80mg (Parkinson's Participants)|Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
89675977|NCT04524351|Active Comparator|Posiphen, 40mg (Parkinson's Participants)|Posiphen Oral Capsule, 40mg, taken once per day for 25±2 days.
89675978|NCT04524351|Active Comparator|Posiphen, 20mg (Parkinson's Participants)|Posiphen Oral Capsule, 20mg, taken once per day for 25±2 days.
89675979|NCT04524351|Active Comparator|Posiphen, 10mg (Parkinson's Participants)|Posiphen Oral Capsule, 10mg, taken once per day for 25±2 days.
89675980|NCT04524351|Active Comparator|Posiphen, 5mg (Parkinson's Participants)|Posiphen Oral Capsule, 5mg, taken once per day for 25±2 days.
89675981|NCT04524351|Placebo Comparator|Placebo (Parkinson's Participants)|Placebo Oral Capsule, taken once per day for 25±2 days.
89675982|NCT04524351|Placebo Comparator|Placebo (Alzheimer's Participants)|Placebo Oral Capsule, taken once per day for 25±2 days.
89675983|NCT04524351|Active Comparator|Posiphen, 80mg (Alzheimer's Participants)|Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
89675984|NCT02107157|Experimental|755nm Alexandrite laser with cap array|
89675985|NCT04523961|Active Comparator|2.5 g of lidocaine 23% / tetracaine 7% ointment|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion for 60 minutes.
89675986|NCT04523961|Active Comparator|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream|Patients undergoing 1927 nm fractional thulium fiber laser treatment of the face for photodamage as part of normal clinical care will have randomly assigned half of the face applied with 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion for 60 minutes.
89675987|NCT01792505|Experimental|Biological/Vaccine|
89675988|NCT01794221|Active Comparator|Stitches only|Stitches only closing circumcision wound
89675989|NCT01794221|Experimental|Stitches and skin adhesive|application of 2-octyl cyanoacrylate skin adhesive.
89675990|NCT00365053|Experimental|Treatment (belinostat)|Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89675991|NCT05309967|Experimental|GLUMA|Glutaraldehyde + Hydroxyethyl methacrylate (GLUMA® Desensitizer)
89675992|NCT05309967|Placebo Comparator|PLACEBO|DISTILLED WATER
89675993|NCT03668561|Experimental|Treatment (CALIGALOC)|Wearing of the Caligaloc orthosis
89675994|NCT00555789|Active Comparator|1|mycophenolic and tacrolimus
89675995|NCT00555789|Experimental|2|mycophenolic and tacrolimus
89675996|NCT04288895|Experimental|Vortioxetine|flexible-dose
89675997|NCT01792739|Experimental|Kadit B|Probiotic Lactobacillus casei variety rhamnosus granules
88999217|NCT03004404|Experimental|BA Part: R/T2/T1|"Participants were orally administered 25 mg of BI 730357 as film-coated tablet (Reference treatment R) in fasted state.~Followed by 25 mg of BI 730357 film-coated tablet in a fed state (test treatment T2), a high-fat, high-calorie breakfast was served 30 min before dose administration.~Participants received 25 mg of BI 730357 powder for reconstitution of an oral solution (PfOS) reconstituted in solvent for oral solution 2.5 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) (test treatment T1) in fasted state.~The 3 treatments were administered with 240 mL of water and were separated by a washout period of at least 8 days. One authorized employee of the trial site was witness of the administration of the trial medication."
89215173|NCT04293939||Full-term children|Children born after the 37th week of gestation: control sample
89215174|NCT04293523||Hemophilia A patients|All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.
89675998|NCT01792739|Placebo Comparator|Kadit A|Placebo
89675999|NCT05289765|Experimental|Group 1|Ecological Extra Virgin Olive Oil
89676000|NCT05289765|Active Comparator|Group 2|Conventional
89676001|NCT04110431|Experimental|LBBP group|In this arm, An right artrial (RA) lead and an implantable cardioverter defibrillator (ICD) lead are conventionally implanted. A left bundle branch pacing(LBBP) lead is attempted to be placed. If LBBP failed, a left ventricular(LV) pacing lead is implanted instead.
89676002|NCT04110431|Active Comparator|BivP group|In this arm, an RA lead , an ICD lead and a LV pacing lead are placed. If the implantation of LV pacing lead is unsuccessful due to unavailable coronary sinus branches(venae cordis magna or venae cordis media is not recommended), capture above 3.5V/0.5ms or refractory phrenic nerve stimulation,a LBBP lead is placed instead.
89676003|NCT00554385|Experimental|1|
89676004|NCT00365209|Experimental|2g (curcumin)|Patients receive 2 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
89676005|NCT00365209|Experimental|4g (curcumin)|Patients receive 4 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
89676006|NCT01792895|Active Comparator|Manipulation group|This Technique will be applied over four sessions, during two weeks
89676007|NCT01792895|Active Comparator|Mobilisation|This treatment will be applied on cervical spine during four sessions, over two weeks
89676008|NCT01792895|Active Comparator|Mobilization with movement|This Technique will be applied over four sessions, during two weeks
89676009|NCT05183919|Experimental|AKL-T01|Digital treatment
89676010|NCT02109497|Other|Caffeine Dosing|Single dose of caffeine 100 mg administered
89676011|NCT04350411|Experimental|Conventional diathermy|DIEP/ MS-TRAM breast reconstruction free flap raise performed with conventional diathermy
89676012|NCT04350411|Experimental|PEAK PlasmaBlade™|DIEP/ MS-TRAM breast reconstruction free flap raise performed with PEAK PlasmaBlade™
89676013|NCT00409825|Experimental|Part 1|Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection. A subject in whom Part 2 is performed during the last scheduled injection of 17-OHPC (at or around 35 0/7 weeks) will have the option to participate in Part 3, in which 10 cc of blood will be drawn serially over 21 days after completing Part 2. Blood will be drawn on days 9, 11, 14, 17, 20, 24, 28 after the last injection. Part 4: At the time of labor and delivery, subject will have 10cc of blood removed from a maternal peripheral vein. 10cc of blood will be collected from the placenta/umbilical cord after delivery.
89676014|NCT02104427|Experimental|TG-0054 combined with G-CSF|1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal
89676015|NCT03832803|Experimental|Empty Bladder|Empty bladder prior to treatment.
89676016|NCT03832803|Other|Full Bladder|Conventional drinking protocol - 200ml water prior to treatment.
89676017|NCT00410059|Experimental|Erlotinib|Erlotinib 150 mg by mouth daily x 28 days.
89676018|NCT04749147|Experimental|Black and White Print|The survey concerns the patients' chest pain, perception of their safety, and their comfort with their discharge. This group's survey will be printed in black and white and feature black and white graphics.
89676019|NCT04749147|Experimental|Red Print|The survey concerns the patients' chest pain, perception of their safety, and their comfort with their discharge. This group's survey will be printed in red text and feature red graphics.
89676020|NCT00310427|Experimental|LY686017|Subjects received 50 mg of the NK1 antagonist LY686017 orally on a daily basis.
89676021|NCT00310427|Placebo Comparator|Placebo|Subjects received placebo orally on a daily basis
89676022|NCT01792999|No Intervention|Non-contrast KBCT|About 187 subjects, who had diagnostic imaging of the breast including mammography and were categorized as Breast Imaging-Reporting and Data System(BIRADS) scores 1, 2, 3, 4, or 5, received KBCT imaging without contrast injection.
89676023|NCT01792999|Experimental|Contrast-enhanced KBCT|About 231 subjects, who had diagnostic imaging of the breast including mammography and were scheduled for biopsy or surgery, received contrast-enhanced KBCT imaging of the affected breast before biopsy or surgery.
89676024|NCT04749069|Experimental|Continuous infusion of remifentanil|In continuous infusion group of patients, remifentanil was infused at a dose of 0.1 µg/kg/min and the additional bolus dose of 0.1 µg/kg was given if required. Before start of the operation, in both groups of patients, intravenous remifentanil at a bolus dose of 0.1 µg/kg was administered slowly in a duration of 60 seconds.
89676025|NCT04749069|Experimental|Patient-controlled sedoanalgesia (PCSA) of remifentanil|In PCSA group of patients, remifentanil was given by bolus PCSA using a pump (Pain Management Provider, Abbott Laboratories and Eczacibasi-Baxter, Ireland). In PCSA group of patients, remifentanil infusion was at a dose of 0.05 µg/kg, a bolus dose of 0.1 μg/kg with a lock-out time of three minutes.
89676026|NCT00411463|Experimental|Psychotherapy|Subjects randomized to the Psychotherapy arm will receive Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
89676027|NCT00411463|Experimental|Medication|Subjects randomized to the medication arm will receive the FDA approved medication Seroquel (quetiapine)
89676028|NCT03239015|Experimental|Targeted Drug Therapy Group|All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib. If no durggable target, PD-1/L1 inhibitor plus anti-angiogenic agent was used.
89676029|NCT00356993|Experimental|NRT + Behavioural Support|Nicotine Replacement Therapy plus Behavioural Intervention
89676030|NCT01793077||Prostate Cancer patients|
89676031|NCT00555477|Experimental|anastrozole|
89676032|NCT04019249|Experimental|Experimental: Healthy Weight Coaching|Intervention: Healthy Weight Coaching.
89676033|NCT02109731|Experimental|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
89676034|NCT00365599|Experimental|Vorinostat and Tamoxifen|As outlined in Intervention descriptions
89676035|NCT00358007|Experimental|Cone Beam CT|
89676036|NCT02421133|Experimental|Transitional care program.|The transitional care program from hospital to home will be implemented at three steps: during the patient's stay in hospital, the day of the discharge and during 4 weeks after discharge.
89676037|NCT02421133|Other|standard care program|No intervention liable to affect the care provided to the patients, the organization of care or the practices of health care professionals will be implemented during the control period (time steps without intervention).
89676038|NCT00554619|Experimental|GSK1325760A|
89676039|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
89676040|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
89050109|NCT02047214|Experimental|TPI 287 + bevacizumab|All subjects will be administered TPI 287 as an IV infusion (1-hour target duration) once every 3 weeks (Days 1 and 22) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29) of a 42-day cycle. The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg). The planned dose escalation levels are 140, 160, 170, and 180 mg/m2; subsequent dose levels will be increased in increments of 10 mg/m2. If dose de-escalation below the starting dose level of 140 mg/m2 is required, dose levels of 130 and 120 mg/m2 will be used. Once the MTD is identified, 6 additional subjects will be enrolled at the MTD to better characterize the toxicity profile at this level. Subjects may continue on treatment unless they meet one or more of the discontinuation criteria outlined in the protocol.
89050110|NCT04632186|Experimental|Intervention|"3 sessions with 3 different interventions 1) Transcutaneous electric nerve stimulation (TENS)- at the shoulder according to current best evidence and practice 2) EXOPULSE Mollii suits- local stimulation at the shoulder, 3) EXOPULSE Mollii suit- according to current best experienced practice~The order in which the participants´ receive the different treatments will be randomized.~Each session lasts for approximately 2.5 hours (approximately 60 min for assessment, 30 min for settings and adjustments and 60 min for treatment)"
89050111|NCT04631991||Non-pathological high myopia|Comprehensive ophthalmologic examination
89676041|NCT02104739|Placebo Comparator|Saxagliptin, then Exenatide, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
89676042|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
89676043|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
89676044|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
89676045|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
89676046|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
89676047|NCT02104739|Experimental|Saxagliptin, then Exenatide, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
89676048|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
89676049|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
89050112|NCT04631991||Control|Comprehensive ophthalmologic examination
89050113|NCT04631757|Experimental|Camrelizumab plus Chemoradiotherapy|Patients with initial unresectable proximal gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive camrelizumab 200mg q3w, SOX regimen (oxaliplatin 130mg/m2, d1, Q3w + S-1 40-60mg bid, d1-d14, Q3w), and intensity modulated radiotherapy for tumors and high-risk lymphatic drainage areas (45Gy/25d). Resectable patients after conversion therapy will receive D2 resection.
89050114|NCT02032277|Active Comparator|Arm A|Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
89676050|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
89215175|NCT04280978||Aquired Brain Injury|Suitable potential participants would be children with ABI, at least 6 months post onset, from 6 to 11 years old, without diagnosis of aphasia, dysarthria, apraxia, and/or sensorial difficulties (visual and hearing), with Italian as a first language.
89215176|NCT04279587|Experimental|Residential camp participant|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at a regional camp.
89215177|NCT04253821|Active Comparator|Forward head posture|
89215178|NCT04253821|Active Comparator|Non-Forward head posture|
89215179|NCT04249622|Experimental|Arm I (rifaximin, pertuzumab-based chemotherapy)|Patients that experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy receive rifaximin PO BID on days 1-5 and standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
89676051|NCT00411619|Experimental|Everolimus|As this was a non-randomized, open-label, single arm study, all patients in the study received treatment with everolilmus
89676052|NCT02277093|Experimental|Pacritinib|"Pacritinib is an oral drug which will be taken on an outpatient basis daily on a 28-day cycle at a dose of 200 mg twice a day (BID)~Pacritinib should be take at approximately the same times every day with a glass of water, with or without food"
89676053|NCT00412087|Experimental|Cholecalciferol 2000 IU|Women at 12-16 weeks' gestation are enrolled into the study to receive 2000 IU/day vitamin D3 for one month. After the run-in dose, the subjects are randomized to one of two treatment groups: either 2000 or 4000 IU/day to be taken throughout pregnancy until delivery.
89676054|NCT00412087|Experimental|Cholecalciferol 4000 IU|Women are randomized to one of 2 treatment groups: 2000 or 4000 IU vitamin D3/day
89676055|NCT00312923|Experimental|Policosanol|20 mg daily of policosanol
89676056|NCT00312923|Placebo Comparator|Placebo|20 mg of microcrystalline cellulose daily
89676057|NCT01793155|Experimental|Inspiratory muscle training|Inspiratory muscle training for two weeks following surgery
89676058|NCT01793155|Placebo Comparator|Standard physiotherapy|Breathing exercises, cough/hugh, advice on early and active mobilization
89676059|NCT01794377|Active Comparator|40 of an endurance training|Endurance training at 50% of VO2 peak measured by indirect calorimetry. Dietary Supplement: supplementation in fruits and vegetables.
89676060|NCT01794377|Experimental|30 minutes of a high intensity training|"This arm consist of an interval strength training for 30 min on bicycle ergometer (which include strengthening exercises in an high intensity interval training).~Dietary Supplement: supplementation in fruits and vegetables."
89676061|NCT00412243|Experimental|Clofarabine + Cyclophosphamide|Clofarabine 40 mg/m^2 daily for 3 Days + Cyclophosphamide starting 200 mg/m^2 every 12 hours for 3 days
89676062|NCT04317963||Cases|Patients who have received bezlotoxumab 10 mg/kg intravenously in addition to standard CDI treatment.
89676063|NCT04317963||Controls|Patients who have received only standard CDI treatment.
89676064|NCT02047591|Experimental|Relaxing-touch method|
89676065|NCT02047591|No Intervention|Usual care|
89676066|NCT01426412|Experimental|LY3015014 intravenously (IV)|A single dose of LY3015014 up to 10.0 milligrams per kilogram (mg/kg) administered IV
89676067|NCT01426412|Experimental|LY3015014 IV Japanese|Single dose of LY3015014 10.0 mg/kg administered IV to Japanese participants. Added per protocol amendment effective October, 2012.
89676068|NCT01426412|Placebo Comparator|Placebo IV|Administered IV once only
89676069|NCT01426412|Experimental|LY3015014 subcutaneously (SC)|A single dose of LY3015014 up to 3.0 mg/kg administered SC
89676070|NCT01426412|Experimental|LY3015014 SC + Statin|A single dose of LY3015014 up to 3 mg/kg administered SC in addition to participant's dose of statin
89676071|NCT01426412|Placebo Comparator|Placebo SC|Administered SC once only
89676072|NCT00315341|Experimental|Buprenorphine/Nx|For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
89676073|NCT00315341|Active Comparator|Methadone|For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
89215180|NCT04249622|Active Comparator|Arm II (pertuzumab-based chemotherapy)|Patients that do not experience PIGT after receiving first standard of care cycle of pertuzumab-based chemotherapy continue receiving standard of care pertuzumab-based chemotherapy on day 1. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
89215181|NCT04249544|Experimental|Impulsive group, placebo then pramipexole|half of the impulsive group will first get the placebo on the first day and pramipexole on the second day
89215182|NCT04249544|Experimental|Impulsive group, pramipexole then placebo|half of the impulsive group will first get the pramipexole on the first day and the placebo on the second day
89215183|NCT04249544|Experimental|Non-impulsive group, placebo then pramipexole|half of the non-impulsive group will first get the placebo on the first day and the pramipexole on the second day
89215184|NCT04249544|Experimental|Non-impulsive, pramipexole then placebo|half of the non-impulsive group will first get the pramipexole on the first day and the placebo on the second day
89676074|NCT02277249|Other|Transvaginal digoxin|Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
89676075|NCT02277249|Other|Transabdominal digoxin|Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
89676076|NCT04767620|Experimental|study groups|The study group was treated with Rugdenzengsheng No. 1 prescription for 2 courses.
89676077|NCT04767620|No Intervention|control groups|The control group was treated with observational treatment and follow-up in outpatient clinic.
89215185|NCT04230980|Experimental|Gabapentin|Participants receive Gabapentin 600mg tablet taken pre-operatively and 300mg taken three times a day for 3 days.
89215186|NCT04230980|Placebo Comparator|Placebo|Participants receive Placebo tablet taken pre-operatively and three times a day for 3 days
89676078|NCT02988765|Experimental|Invasive vulvar cancer (IVC)|"Vulvar carcinoma (stromal infiltration > 1 mm)~Histotypes different from squamous cells carcinomas are included"
89676079|NCT04767542|Sham Comparator|Paracetamol|Patients with emergency LC will be administered intravenously 1 gr vial of paracetemol in 30 minutes during the awakening phase.
89676080|NCT04767542|Active Comparator|Transversus Abdominis Plane Block|With USG, the lateral part of the latissumus dorsi muscle attaches to the external lip of the iliac crest, just behind the middle axillary line and the end is directed slightly cranially, first through the external oblique muscle and fascia, then the internal oblique muscle and fascia, and after hydrodissection with saline for about 15-20 ml of local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally
89676081|NCT00316355|Active Comparator|Traditional CBT|Cognitive-behavioral therapy (CBT) that incorporates exposure with ritual prevention (EX/RP)
89676082|NCT00316355|Experimental|Stepped-Care CBT|Stepped-care CBT
89676083|NCT01794533|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
89676084|NCT01794533|Active Comparator|Lidocaine with Epinephrine + fentanyl|
89676085|NCT00412867|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
89676086|NCT03641027|Experimental|Increased physical activity|Increased physical activity daily before surgery. Standard care during hospital stay and continued training after discharge.
89676087|NCT03641027|Other|Standard care|Standard care
89676088|NCT00413335|Active Comparator|1|Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
89676089|NCT00413335|Placebo Comparator|2|Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
89676090|NCT00414271|Experimental|Docetaxel and Capecitabine in gastric cancer|Intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
89676091|NCT02110147|Experimental|Uridine Triacetate to Replace Uridine|Replacement therapy for oral uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. The starting dose of uridine triacetate will be 60 mg/kg/day which may be escalated to 300 mg/kg/day of oral uridine triacetate. The dose may be given once a day or as equally divided doses twice a day.
89676092|NCT00414817|Experimental|Automated Phone-Based Refill Reminders|Intervention Arm: Participants randomly assigned to this study arm may receive up to 8 automated phone calls from the BREATH EASY Medication Reminder Program over the course of the 19 month intervention period.
89676093|NCT00414817|No Intervention|Usual Care|"Usual Care: Participants randomly assigned to this arm received the same introductory letter as those in the intervention arm, giving them the opportunity to opt out, but were subsequently selected to be in the usual care study arm, and therefore, receive no intervention."
89676094|NCT01795651||Take-Home message|
89676095|NCT00360971|Experimental|Palifermin|Concurrent radiation therapy, cisplatin, and palifermin followed by neck dissection for indicated patients.
89676096|NCT00360971|Placebo Comparator|Placebo|Concurrent radiation therapy, cisplatin, and placebo followed by neck dissection for indicated patients.
89050115|NCT02032277|Placebo Comparator|Arm C|Placebo + placebo + paclitaxel followed by AC.
89050116|NCT02032277|Placebo Comparator|Arm B|Placebo + carboplatin + paclitaxel followed by AC
89050117|NCT04611009|Experimental|motor training|intervention: motor training
89050118|NCT04611009|Active Comparator|awareness training|intervention: mindfulness exercises
89050119|NCT00560976|Experimental|Iron Saccharate (Venofer)|IV Iron Saccharate (Venofer)100 mg
89050120|NCT02026349|Active Comparator|favipiravir|
89050121|NCT02026349|Placebo Comparator|placebo|
89050122|NCT04611048|Experimental|Main study|Several electrophysiological and behavioural tests will be performed to properly diagnose the patients/check that the healthy controls do not suffer of neuropathy.
89050123|NCT04611126|Other|Without Ipilimumab|"At Step 1, 6 patients will be treated without Ipilimumab pre tumor harvest. If feasible and tolerable, as defined by no additional SAE/SAR compared to the previously completed pilot studies at CCIT-DK, the trial will move to Step 2.~Depending on the safety and feasibility on step 2, 6 more patients can be included at step 1."
89050124|NCT04611126|Other|With Ipilimumab|"At Step 2, 6 patients will be included. Ipilimumab 3 mg/kg will be administered 2-6 weeks pre tumor harvest.~If no additional SAE/SAR compared to the previous completed pilot study at CCIT-DK is observed additional 6 patients can be included at Step 2. If on the other hand Step 2is not found safe additional 6 patients can be included at Step 1"
89050125|NCT04611165|Experimental|single|"Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~Prescription dose to PTVs as according to the following schema:~PTV1: 30 - 50 Gy /10 fx, 5Gy fraction dose, 5 days/week (The prescribed dose to PTV will be decided by physician depending on the dose-volume histogram (DVH) constraints of the normal tissues, such as liver, bowel, etc. The detail of DVH constraints of normal tissues are summarized in the following table) PTV2: 30 Gy /10 fx, 3Gy fraction dose, 5 days/week"
89050126|NCT02014649|Experimental|20mg Laninamivir Octanoate|Dry Powder plus placebo
89050127|NCT02014649|Experimental|40mg Laninamivir Octanoate|Dry Powder
89050128|NCT02014142|Experimental|Group A. L-PPDS single occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
89050129|NCT02014142|Experimental|Group B. L-PPDS double occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
89215187|NCT04218968|Experimental|carvedilol therapy|Twice daily oral doses of adrenergic blocker 12.5 mg or 25mg, according to patient tolerability.
89676097|NCT01791881|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
89676098|NCT01791881|Experimental|Botulinum toxin type A(Hugeltox)|Botulinum toxin type A(Hugeltox)
89676099|NCT03636503|Experimental|Rituximab +Utomilumab+Avelumab|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Utomilumab is administered intravenously over 1 hour once every 4 weeks~Avelumab is administered intravenously over 1 hour once every 2 weeks"
89676100|NCT03636503|Experimental|Rituximab+Utomilumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Utomilumab is administered intravenously over 1 hour once every 4 weeks~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
89676101|NCT03636503|Experimental|Rituximab+Avelumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Avelumab is administered intravenously over 1 hour once every 2 weeks~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
89676102|NCT00371293|Active Comparator|1|Participants will receive CPAP therapy.
89676103|NCT00371293|Active Comparator|2|Participants will take part in a weight loss program.
89676104|NCT00371293|Experimental|3|Participants will receive CPAP therapy and take part in a weight loss program.
89676105|NCT05288101|Active Comparator|Control|Patients in CON group received a personalized diet and dry weight adjustment by BIVA. Anthropometrical, biochemical, dietary, QoL, handgrip strength (HGS) and bioimpedance measurements were performed. Malnutrition Inflammation Score (MIS) was applied
89676106|NCT05288101|Experimental|Supplemented|Patients in SUPL group received a simultaneous intervention consisting of a personalized diet, 245 mL/d ONS and dry weight adjustment through BIVA, Anthropometrical, biochemical, dietary, QoL, handgrip strength (HGS) and bioimpedance measurements were performed. Malnutrition Inflammation Score (MIS) was applied
89676107|NCT01791959|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
89676108|NCT01791959|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
89676109|NCT03448159|Experimental|Fluoxetine Hydrochloride|Fluoxetine (Prozac) will be administered to this group. A ramp up period of 3-5 weeks will take place where the patient takes 10mg of Prozac per day. After that, the participant will take the regular dose of 20mg for the duration of the exercise intervention (12 weeks).
89676110|NCT03448159|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. During the 3-5 week ramp up period for the experimental group, these participants will take a placebo identical to the 10mg Prozac capsule. After that, the participant will take a placebo identical to the 20mg Prozac capsule for the duration of the exercise intervention (12 weeks)."
89676111|NCT00361439|Active Comparator|Mometasone|Mometasone intranasal steroid therapy daily for 2 weeks
89676112|NCT00361439|Placebo Comparator|Placebo|2 puffs of placebo spray in each nostril once daily
89676113|NCT00371449||hearing aid users|hearing aid users
89676114|NCT00361595|Experimental|open label|5 mg zoledronic acid in a single 15 minute IV
89676115|NCT03438487||Flucelvax Trivalent or Quadrivalent Influenza Vaccine|Flucelvax Trivalent or Quadrivalent exposure in pregnancy
89676116|NCT03458117|Experimental|Talimogene Laherparepvec (T-VEC)|Intralesional injections of T-VEC up to 4.0 mL of 10 to the 6 plaque-forming Units/mL (PFU/mL)
89676117|NCT00417859|Active Comparator|TKA mobile|TKA mobile
89676118|NCT00417859|No Intervention|TKA|TKA fix
89676119|NCT01792037|Active Comparator|Etomidate|After taking of the blood samples, patients in Group I will be intubated with 0.3 mg/kg etomidate iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
89676120|NCT01792037|Active Comparator|etomidate, steroid|After taking of the blood samples, patients in Group II will be intubated with 0.3 mg/kg etomidate iv following a 2mg/kg methylprednisolone iv Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
89676121|NCT01792037|Active Comparator|midazolam|"After taking of the blood samples, patients in Group III will be intubated with 0.01 mg/kg midazolam iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.~Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired."
89676122|NCT00373399|Placebo Comparator|Inactive Marijuana (0, 1.8, or 3.9% THC)|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Inactive marijuana (0% THC) served as a placebo comparator. Participants received an inactive marijuana cigarette (0% THC; provided by NIDA) in 1 of the 3 outpatient sessions in randomized order.
89676123|NCT00373399|Experimental|Active Marijuana|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Participants received active marijuana cigarettes (1.8, or 3.9% THC; provided by NIDA) over 2 of 3 outpatient sessions in randomized order.
89676124|NCT04271267||Acute Rejection Cohort|The subset of samples corresponding to biopsy-proven acute rejection
89676125|NCT04271267||Rejection-free Cohort|The subset of samples corresponding to a transbronchial biopsy free of acute cellular rejection.
89215188|NCT04208464|Experimental|Immediate-start arm|Participants will receive 4mg baracitinib daily for 24 weeks from the baseline visit in week 0. After treatment participants will be followed up for 12 weeks.
89676126|NCT00418015||Labor analgesia|Labor analgesia receiving fentanyl labor analgesia
89676127|NCT00418015||Cesarean delivery analgesia|Cesarean delivery analgesia consisting of spinal fentanyl and morphine
88996237|NCT02924194|Experimental|nbM stimulation ON for 3 months (GPi also on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation ON for a period of 3 months (GPi also on). No usual treatment is withheld. PD drug doses will be stable unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor Unified Parkinson's Disease Rating Scale (UPDRS) rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
88996238|NCT02924194|Experimental|nbM stimulation OFF for 3 months (GPi is on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
88996239|NCT02924467|No Intervention|No intervention: Usual Care|Patients in this group will not receive any influenza vaccine reminder notifications.
88996240|NCT02924467|Experimental|1 Notice|Patients in this group will receive one influenza vaccine reminder notification via autodialer across the 2016 influenza season.
88996241|NCT02924467|Experimental|2 Notices|Patients in this group will receive up to two influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
88996242|NCT02924467|Experimental|3 Notices|Patients in this group will receive up to three influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
88996243|NCT02924233|Experimental|Sym004 + nivolumab|"Phase 1b, dose-escalation:~Dose Level 1: Sym004 + nivolumab (Q2W)~Dose Level 2: Sym004 + nivolumab (Q2W)~Dose Level -1: Sym004 + nivolumab, if needed"
88996244|NCT02924233|Experimental|Sym004 (RP2D) + nivolumab|"Phase 2b, dose-expansion:~Receiving Sym004 in the RP2D in combination with nivolumab (Q2W)"
88996245|NCT02924233|Active Comparator|Nivolumab|"Phase 2b, dose-expansion:~Receiving nivolumab monotherapy (Q2W)"
88996246|NCT02923999|Experimental|Dose cohort 1|P2G12 0.125g
88996247|NCT02923999|Experimental|Dose cohort 2|P2G12 0.25g
88996248|NCT02923999|Experimental|Dose cohort 3|P2G12 0.5g
88996249|NCT02923960|Active Comparator|Standard ONS|liquid oral nutritional supplement
88996250|NCT02923960|Experimental|Diabetes specific ONS 1|liquid oral nutritional supplement with novel carbohydrate blend
88996251|NCT02923960|Active Comparator|Diabetes specific ONS 2|liquid oral nutritional supplement with novel carbohydrate blend
88996252|NCT00154193|Active Comparator|Cyclosporine|
88996253|NCT02923843|Experimental|intervention|Comprehensive Geriatric Assessment
88996254|NCT02923843|No Intervention|control|Standard care
88996255|NCT00187863||Exercise induced pain perception|
88996256|NCT00187863||Surgical pain perception|
88996257|NCT04046848|Experimental|Cohort 1|"50 IU/kg (n=4): single-period investigation with a single sc dose of 50 IU/kg OCTA101 profiled up to 72 hours after dosing in adult male patients with severe hemophilia A.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 2, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
88996258|NCT04046848|Experimental|Cohort 2|"100 IU/kg (n=4): single-period investigation with a single sc dose of 100 IU/kg OCTA101 profiled up to 96 hours after dosing in adult male patients with severe hemophilia A.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 3, alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
88996259|NCT04046848|Experimental|Cohort 3|"50 IU/kg (n=8): two-period investigation of a single iv dose of 50 IU/kg Human-cl rhFVIII (Nuwiq) profiled for up to 72 hours after dosing followed by sc dose of 50 IU/kg OCTA101 profiled up to 72 hours in adult male patients with severe hemophilia A.~Treatments will be administered in fixed sequence, with Human-cl rhFVIII first.~Following review of safety and tolerability data by Data Monitoring Committee, proceed with Cohort 4 and 5 alongside daily prophylactic dosing (40-60 IU/kg) for 3 months."
88996260|NCT04046848|Experimental|Cohort 5|(n=4): Three-period investigation of single sc doses of 20, 40, and 60 IU/kg OCTA101 profiled up to 72 hours after dosing. Treatments were to be administered in fixed dose-ascending sequence.
89050130|NCT04631289||metformin/non-metformin group|"Preadmission metformin exposure was defined as a record of metformin usage in Medications on admission in MIMIC-III.~Metformin group included non-AKI type 2 diabetes patients with preadmission metformin exposure.~Non-metformin group included non-AKI type 2 diabetes patients without preadmission metformin exposure."
89050131|NCT04631328|Experimental|Intervention|Growing Together program
89050132|NCT04631328|No Intervention|Control|
89050133|NCT04631250|Experimental|Right: daylight illumination|The right side of the face was treated using daylight PDT
89050134|NCT04631250|Experimental|Left face: conventional illumination with red light|The left side was treated with conventional PDT.
89050135|NCT02009423|Experimental|Masitinib|masitinib-treatment arm
89050136|NCT02009423|Placebo Comparator|Placebo|placebo-treatment arm
89050137|NCT04610619||RYR1 related malignant hyperthermia/rhabdomyolysis|
89050138|NCT02006030|Experimental|ADI-PEG 20 + TACE|ADI-PEG 20 plus concurrent transarterial chemoembolization
89050139|NCT02006030|Active Comparator|Transarterial chemoembolization (TACE)|transarterial chemoembolization alone
89676128|NCT00362453|Experimental|Tai Chi|The Tai Chi program was based on the classical Yang Style. Patients participated in 60-minute Tai Chi sessions twice a week for 12 weeks. Each session included warm up and review of Tai Chi principles and techniques; Tai Chi exercises; breathing techniques; and various relaxation methods. The classes were taught by a Tai Chi master with over 20 years' experience conducting Tai Chi Mind-Body exercise programs. Several modifications were developed to achieve the physical and mental goals of the study for knee OA, accommodate knee OA symptoms and limit dropouts. Subjects were instructed to practice Tai Chi at least 20 minutes a day at home and encouraged to maintain their usual physical activities, but not to participate in additional new strength training other than their Tai Chi exercises.
89676129|NCT00362453|Placebo Comparator|Wellness Education and Stretching|The wellness education and stretching program provided an active control for the attention being paid to the Tai Chi group. The control group attended two 60-minute class sessions per week for 12 weeks. Each session started with 40 minutes of didactic lessons on OA knowledge, nutrition, and physical and mental health education. The final 20 minutes consisted of stretching exercises involving the upper body, trunk and lower body, each stretch being held for 10 to 15 seconds. Participants were also instructed to practice at least 20 minutes of stretching exercises per day at home. They were encouraged to maintain their usual physical activities, but not to participate in additional strength and mind-body exercise programs other than their stretching exercise.
89676130|NCT00418093|Experimental|Chemotherapy|All patients received oxaliplatin, gemcitabine, and bevacizumab
89676131|NCT00374335|Other|infants with cutaneous hemangiomas|
89676132|NCT05287789|Experimental|Squatting position by footstool|"After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a footstool at the appropriate height on the water closet type toilet.~The patients used footstools in the hospital and throughout a week after discharge at home for defecation."
89676133|NCT05287789|No Intervention|Control Group|The control group received the routine care provided to all the patients in the clinic with no additional interventions.
89676134|NCT03855371|Experimental|Decitabine plus arsenic trioxide|decitabine: 20mg/m2/d, intravenously, d1-d5, q4w arsenic trioxide: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
89676135|NCT00554229|Experimental|ZD4054|ZD4054 10 mg oral tablet once daily
89676136|NCT00554229|Placebo Comparator|Placebo|Matching Placebo, oral tablets once daily
89676137|NCT03284723|Experimental|PF-06804103|Study Treatment
89676138|NCT03284723|Experimental|PF-06804103+Combination Regimen|Study Treatment
89676139|NCT00374803|Experimental|Mycophenolic Acid (Myfortic) Preload|Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter
89676140|NCT00374803|Active Comparator|Mycophenolic Acid (Myfortic) Standard|Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
89676141|NCT03854357|Experimental|Additional Isolated Subscapularis Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
89676142|NCT03854357|Active Comparator|Standard Post-Operative TSA Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
89676143|NCT00418951|Experimental|Liposomal amphotericin B: 3 mg/kg|3 mg/kg intravenously (IV) three times per week
89676144|NCT00418951|Experimental|Liposomal amphotericin B: 9 mg/kg|9 mg/kg IV once per week
89676145|NCT00418951|Experimental|Voriconazole: 400 mg|400 mg oral twice daily day 1 followed by 200 mg twice daily
89676146|NCT00363077|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89676147|NCT00363077|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89676148|NCT00550017|Experimental|1|
89676149|NCT00375973|Experimental|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
89676150|NCT00375973|Placebo Comparator|Placebo|Placebo comparator to Duloxetine
88996261|NCT04046848|Experimental|Cohort 6|(n≥16): Following an initial 4 to 6-week run-in period with Nuwiq iv prophylaxis, >3-6 months daily prophylactic treatment with 12.5 IU/kg OCTA101 sc, then 25 IU/kg OCTA101 sc for a further 6-7 months (exact dosing depends on available vial sizes). In case of two spontaneous bleeding episodes, after having completed at least 3 months with 12.5 IU/kg OCTA101 daily treatment the individual treatment dose will be increased from 12.5 to 25 IU/kg. Site of administration (abdomen or thigh) to be chosen by the patient. A further treatment phase with 40 IU/kg OCTA101 will be discussed with the DMC, once results of earlier dosing phases are available.
88996262|NCT00180453|Experimental|1|Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
88996263|NCT00180453|Active Comparator|2|Abbott Vascular MULTI-LINK VISION® BMS
88996264|NCT04024423||Related M. abscess isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
88996265|NCT04024423||Unrelated M. abscessus isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
88996266|NCT04024423||Related M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
88996267|NCT04024423||Unrelated M. avium isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
89050140|NCT04631094|Experimental|Group 1|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken
89050141|NCT04631094|Experimental|Group 2|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.
89050142|NCT04631094|Experimental|Group 3|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken
89676151|NCT03235817|Experimental|Spontaneous ventilation|
89676152|NCT03235817|Experimental|Pressure support ventilation|
89676153|NCT03235817|Active Comparator|Pressure control ventilation|
89676154|NCT02110121|Experimental|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
89676155|NCT02110121|Experimental|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
89676156|NCT00421603|Active Comparator|Adderall-XR and Topiramate|Adderall-XR (60 mg/day) and Topiramate (300mg/day)
89676157|NCT00421603|Placebo Comparator|Placebo|Placebo
89676158|NCT01794611|Experimental|Laryngoscopy|Patients will be intubated by an experienced anesthesiologists. Anesthesiologist first uses Macintosh laryngoscope then KingsVision videolaryngoscope and lastly C-MAC videolaryngoscope to intubate patients. Cormack-Lehane scores, the time from the start of laryngoscopy to visualization of the vocal cords and the time from the visualization of the vocals from the successful intubation will be recorded. The success of the intubation will be assessed with bilateral chest auscultation. If visualization of the vocal cords or placing of the endotracheal tube was not successful after 60 seconds with a particular laryngoscope, it will be left out and patient will be ventilated for 1 minutes and then pass to other laryngoscopes.
89676159|NCT00376363|Active Comparator|Ahmed implant,1|Ahmed glaucoma drainage implant for intraocular pressure control
89676160|NCT00376363|Active Comparator|Baerveldt implant|Baerveldt glaucoma drainage implant for intraocular pressure control
89676161|NCT00363779|Experimental|LGL Patients administered cyclosporine|Large Granular Lymphocyte Leukemia (LGL) is a low grade non-Hodgkins lymphoma characterized by tissue invasion of the marrow, spleen, and liver. Cyclosporine 5-10 mg/kg/day was administered as an oral preparation given every 12 hours. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml.
89676162|NCT00376597|Experimental|Arm I (lymphedema education)|Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. Patients are also contacted by telephone at 9 and 15 months.
89676163|NCT00376597|Experimental|Arm II (lymphedema education, physical therapy)|Description Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I. Patients also complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises.
89676164|NCT01405820|Active Comparator|Natalizumab 300 mg Intravenous (IV) Every 4 Weeks|Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
89676165|NCT01405820|Experimental|Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks|Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
89676166|NCT01405820|Experimental|Natalizumab 300 mg IV Every 12 Weeks|Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
89676167|NCT01405820|Experimental|Natalizumab 300 mg SC Every 12 Weeks|Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
89676168|NCT01405820|Experimental|Natalizumab 150 mg IV Every 12 Weeks|Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
89676169|NCT01405820|Experimental|Natalizumab 150 mg SC Every 12 Weeks|Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
89676170|NCT01405742|Experimental|Arm A|"The intervention for Arm A is 40 IU/kg recombinant factor VIII (rFVIII) by once-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given thrice-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds."
89676171|NCT01405742|Experimental|Arm B|"The intervention for Arm B is 40 IU/kg recombinant factor VIII (rFVIII) by thrice-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds"
88996268|NCT04024423||Related M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with highly related isolates.
88996269|NCT04024423||Unrelated M. intracellulare isolates|Characterize the source(s) of direct or indirect patient-to-patient transmission of NTM within an individual CF healthcare setting among participants with unrelated isolates.
88996270|NCT00154349|Experimental|imatinib mesylate|
88996271|NCT02923804|Experimental|Omega-3|3 capsules of 1g concentrated omega-3 taken daily for 6 months
88996272|NCT02923804|Placebo Comparator|Olive oil|3 capsules of 1g olive oil taken daily for 6 months
88996273|NCT02923765|Active Comparator|combined training (CT)|additional aerobic training by a stepper : 35 minutes/session, 5 sessions/week and 4-5 weeks
88996274|NCT02923765|No Intervention|usual rehabilitation (UR)|Usual rehabilitation, without additional aerobic training
88996275|NCT02923765|No Intervention|healthy participant (HP)|healthy control
88996276|NCT00187941|Other|CellCept|CellCept + Prograf or Neoral + Steroids
89050143|NCT04631094|Experimental|Group 4|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.
89050144|NCT04631094|No Intervention|Group 5|The group that will undergo standard hospital blood collection procedure.
89050145|NCT03455036|Experimental|Whole body vibration training|Healthy female subjects complete whole body vibration training (10 x 1 min exposure)
89050146|NCT04610814||Blood products during transport|Administration of appropriate blood products during transport
89050147|NCT04610814||Standard of Care|Receiving standard prehospital air medical care
89050148|NCT01998035|Experimental|R/O: Level -1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Day 8), cycle length (28 days)
89676172|NCT00321269|Active Comparator|Single Illness Managment|This intervention includes standard disease self-management coaching for heart failure and helps patients set goals for fluid management, restricted salt-intake, and medication adherence.
89676173|NCT00321269|Experimental|Comorbid Illness Management|This intervention includes the same self-management coaching found in the comparator arm, but also includes discussion of ways to cope and manage mood.
89676174|NCT00422695||HIV +|Groups divided according to CD4 counts
89676175|NCT00422695||Healthy Controls|HIV -ve subjects
89676176|NCT01794767|Active Comparator|0,9% NaCl flush|for children enrolled in this group, the nurse will perform the flushing of peripheral venous catheter using flush-solution as a bolus with saline 0.9% NaCl in the amount (ml) needed to fill the entire circuit of the catheter. The flushing will be performed routinely at the end of each fleboclisis
89676177|NCT01794767|Experimental|Heparin 50U/ml|for children enrolled in this group, the nurse will perform the washing of peripheral venous catheter using flush-solution as a bolus with heparin 50U/ml in the amount (ml) needed to fill the entire circuit of the catheter. The washing will be performed routinely at the end of each fleboclis
89676178|NCT01425632|Experimental|TAU-284 Low|
89676179|NCT01425632|Experimental|TAU-284 High|
89676180|NCT01425632|Placebo Comparator|Placebo|
89676181|NCT00321971|Experimental|PST-MCI/AD Caregiving|The experimental Intervention (PST-MCI/AD Caregiving) focuses on training in adaptive problem-solving attitudes and skills (Problem-Solving Therapy or PST). It was adapted from a manualized protocol for PST use in primary care. Our adaptation sought to enhance problem-solving skill levels of family caregivers as they began to face a variety of potential caregiving stressor.
89676182|NCT00321971|Active Comparator|NT-MCI/AD Caregiving|"The comparison Intervention (Caregiver Nutritional Training (NT-MCI/AD) was based on the United States Department of Health and Human Services (USDHHS) 2005 My Pyramid Dietary Guidelines for Americans over Age 50. We chose a nutrition-based comparison intervention because information about dietary practices is not likely to affect mental health outcomes. The NT intervention was matched to the PST-based intervention in terms of number and duration of sessions."
89676183|NCT02076152|Experimental|FMISO PET & MRI Group 1|"Bevacizumab:~-- Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~FMISO PET Scan~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~The PET scan will be approximately 60-75 minutes.~MRI -- Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
89676184|NCT02076152|Experimental|FMISO PET & MRI Group 2|"Bevacizumab + CCNU:~Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~CCNU will be administered at a dose of 110 mg/m2 every 42 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~-FMISO PET Scan~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~The PET scan will be approximately 60-75 minutes.~- MRI~Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
89676185|NCT03025958|Experimental|Nimotuzumab|Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).
89676186|NCT00380029|Experimental|Erlotinib|erlotinib given before and after transurethral resection of a bladder tumor, TURBT
89676187|NCT01405508|Experimental|Placebo tablets / Brivaracetam bolus|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
89676188|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV bolus|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"
89676189|NCT01405508|Experimental|Placebo tablets / Brivaracetam infusion|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
89676190|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV infusion|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
89676191|NCT00426283|Experimental|Flovent 1760 mcg|Fluticasone propionate 880 mcg twice daily for 3 months
89676192|NCT00426283|Placebo Comparator|Placebo|Placebo twice daily for 3 months
89676193|NCT00383071|Active Comparator|Cohort 1|H5N1 vaccine - 90 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
89676194|NCT00383071|Active Comparator|Cohort 2|H5N1 vaccine - 120 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
89676195|NCT00383071|Active Comparator|Cohort 3|H5N1 vaccine - 180 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
89676196|NCT00383071|Active Comparator|Cohort 4|H5N1 vaccine - 180 mcg IM every 4 weeks x 2 doses, injection site randomized to either deltoid or gluteus Apheresis - if HAI titer above 1:160
89676197|NCT00322439||Etanercept|Participants received etanercept (Enbrel) treatment at the dose and regimen determined by the investigator and were evaluated for up to 5 years at 6-month intervals. During this period, participants may have discontinued etanercept therapy, may have switched to another anti-psoriatic therapy, may have used etanercept in combination with other anti-psoriatic therapies, or may have discontinued any or all antipsoriatic treatments.
89676198|NCT05287165|Experimental|IM96 CAR-T cells|
89676199|NCT01795027|Experimental|S-1 plus Oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
89676200|NCT01795027|Active Comparator|S-1 single|S-1 40~60mg twice daily for 14 days in 3 weeks for totally 16 courses after D2 resection
89676201|NCT00365261|Active Comparator|eszopiclone|active drug
89676202|NCT00365261|Placebo Comparator|placebo|placebo
89676203|NCT00426517|Experimental|Matched related donor stem cell transplant|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 10 mg/kg total dose given intravenously over 2 days
89676204|NCT00426517|Experimental|Matched unrelated donor stem cell transplant|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day
89676205|NCT00426517|Experimental|Matched unrelated donor stem cell transplant (MUD-non CGD)|Conditioning with ATG 40 mg/kg total dose over 4 days IV, Busulfan 5 mg/kg total dose over 2 days IV, and TBI 300 cGy in two fractions at day -2
89676206|NCT00426517|Experimental|Matched unrelated donor transplant (MUD-CGD) cord blood|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day
89676207|NCT00365417|Experimental|Doxorubicin+Cyclophosphamide+Bevacizumab|
89676208|NCT00427297|Experimental|NVP-containing|Infants randomized to this arm will receive nevirapine-containing HAART regimen
89676209|NCT00427297|Active Comparator|NVP-sparing|Infants randomized to this arm will receive nevirapine-sparing HAART
89676210|NCT00384241||Children|Children age 15-19, self reported as African American of European Origin, healthy non-smoker, with normal blood pressure, exposed to an activity to that results in induced stress
89676211|NCT00384241||Parents|Collection of buccal swab Parent of participants in the Children Arm
89676212|NCT04271111|Experimental|Active treatment|Computerized intervention aimed at reducing perceived hostility.
89676213|NCT04271111|Active Comparator|Control condition|Computerized intervention aimed at increasing overall physical health.
89676214|NCT00427765|Experimental|Busulfan + Melphalan|Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days
89676215|NCT00366275|Experimental|In vivo purging autotransplant|
89676216|NCT04346017|Experimental|Ventilation support|The experimental group will include Covid-19 infected patients with non-invasive or invasive ventilation support (BCRSS score ≥3).
89676217|NCT04346017|Other|Control group|The control group will include Covid-19 infected patients who don't have respiratory problems justifying a transfer to intensive care.
89676218|NCT00384865|Active Comparator|Aspirin 81 mg + Simvastatin 40 mg|"Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months~Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months"
89676219|NCT00384865|Active Comparator|Aspirin 81 mg + Placebo|"Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
89676220|NCT00384865|Active Comparator|Placebo + Simvastatin 40 mg|"Placebo taken orally, once a day for 6 months~Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months"
89676221|NCT00384865|Placebo Comparator|Placebo + Placebo|"Placebo taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
89676222|NCT00323453|Experimental|Experimental Arm|The experimental arm will undergo open appendectomy utilizing the Alexis® retractor (wound protection device utilized intraoperatively), followed by standardized wound closure.
89676223|NCT00323453|Placebo Comparator|Control Arm|Open appendectomy and standardized wound closure
89676224|NCT03599479|Experimental|Virtual reality group|"After experiencing the VR machine in the transfer bed for 5 minutes, the subject moves to the operating room.~After the subject moves to the surgical bed, he/she takes the appropriate position for the fluoroscopic pain intervention, and wears the virtual reality device (headset, headphone, smartphone).~After the subject starts the VR program, the practitioner starts the fluoroscopic pain intervention.~Lidocaine skin infiltration and description of the practitioner during the intervention are performed with the intervention when necessary."
89676225|NCT03599479|No Intervention|Conventional group|The fluoroscopic pain intervention is performed using only local anesthetics and description of the practitioner during the intervention as in the conventional cases.
89676226|NCT01795729|Experimental|1: Coronary stent+optimal medical therapy|Coronary stent on top of optimal medical therapy
89676227|NCT01795729|Active Comparator|2: Optimal medical therapy|Optimal medical therapy
89676228|NCT01405196|Other|10 mg of PF-04236921|
89676229|NCT01405196|Other|50 mg of PF-04236921|
89676230|NCT01405196|Other|200 mg of PF-04236921|
89676231|NCT01405196|Other|Placebo|
89676232|NCT00367601|Experimental|1|Bevacizumab + erlotinib; if no progressive disease observed, combination or single-agent treatment will continue until unacceptable toxicity or progressive disease.
89676233|NCT00385801|Placebo Comparator|Placebo|Identical placebo tablets and injections
89676234|NCT00385801|Active Comparator|risperidone consta|Risperidone 1-2 mg tablets and Risperidone 25 mg injections
89676235|NCT01759901|Experimental|Pringle|Intermittent vascular inflow occlusion applied during liver resection
89676236|NCT01759901|No Intervention|Non-Pringle|No vascular inflow occlusion applied during liver resection
89676237|NCT00429403|Experimental|Goserelin|3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy.
89676238|NCT00429403|No Intervention|No Goserelin|
89676239|NCT05286931|Experimental|N. gonorrhea (gyrA wildtype) -Ciprofloxacin Treatment Arm|Participants who are N. gonorrhea (NG) positive and gyrA WT, will receive ciprofloxacin 500 mg PO x 1.
89676240|NCT00367679|Experimental|Single Arm|800 mg pazopanib oral daily
89676241|NCT00368459|Experimental|raloxifene|oral raloxifene 120 mg once daily
89676242|NCT00368459|Placebo Comparator|placebo|identical appearing oral placebo
89676243|NCT01402700|Experimental|Visi-Pro™ Balloon Expandable Stent System|The objective of the study is to confirm the safety and effectiveness of the Visi-Pro stent in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
89676244|NCT00429949|Experimental|Dasatinib|"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.~In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle."
89676245|NCT05286775|Experimental|Clinical treatment and Knee educational program|Medical knee treatment combined with knee educational educational program
89676246|NCT05286775|Active Comparator|Knee educational program|Knee educational program
89676247|NCT02078726|Active Comparator|Glucagon|1 mg glucagon given during colonoscopy
89676248|NCT02078726|Placebo Comparator|Placebo|1 mL normal saline
89676249|NCT04027010|Experimental|"Healthy U tablet application"|Healthy U is a self-administered intervention implemented through a tablet app with interactive learning experiences, including videos, digital games, quizzes, and role-plays. Healthy U takes youth 3-4 hours to complete. The goals of Healthy U are to: 1) Increase male youth's perception of vulnerability to unplanned fatherhood, STDs and HIV; 2) Increase male youth's self-efficacy for negotiating condom use with their partners; 3) Increase male youth's self-efficacy for using condoms correctly and consistently every time they have sex; and 4) Increase male youth's engagement with goals and dreams for their future.
89676250|NCT04027010|No Intervention|Treatment as usual|The counterfactual condition for the study is a business-as-usual condition. OYA does not provide much programming to youth in its facilities related to sexual health and pregnancy prevention.
89676251|NCT00431041|Experimental|Solifenacin|Solifenacin succinate: 5 mg tablets, taken orally, once daily
89676252|NCT00431041|Active Comparator|Oxybutynin IR|Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day
89050149|NCT01998035|Experimental|R/O: Level 1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
89215189|NCT04208464|Experimental|Delayed-start arm|After the baseline visit in week 0, participants will wait for a 12 week treatment delay and will then receive 4mg baracitinib daily from week 12-week 36 (i.e. for 24 weeks). After treatment participants will be followed up for 4 weeks for safety.
89215190|NCT04201223|Experimental|FLARE Intervention|Participants will be randomized to receive an intervention that works with melanoma survivors and their children as a family unit to improve melanoma preventive behaviors.
89676253|NCT00390611|Active Comparator|Paclitaxel/Carboplatin/Sorafenib|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV, Day 1 Sorafenib 400mg PO bid
89676254|NCT00390611|Active Comparator|Paclitaxel/carboplatin|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV
89676255|NCT00432601|Experimental|Arm 1|Patients will receive Michigan Cancer Consortium decision aid.
89676256|NCT00432601|Active Comparator|Arm 2|Patients will receive National Comprehensive Cancer Network decision aid.
89676257|NCT01793389|Active Comparator|Subepithelial connective tissue graft|Soft tissue harvested from palatum of the subjects.
89676258|NCT01793389|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
89676259|NCT00391079|Experimental|A|
89676260|NCT00391079|Placebo Comparator|B|
89676261|NCT00387751|Experimental|Arm I|Patients receive oral sorafenib tosylate on days 1-5, 8-12, 15-19, and 22-26 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
89676262|NCT01795235|Other|Saline s.c. injection and placebo tablet|Saline s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
89676263|NCT01795235|Other|glucagon s.c. injection and placebo tablet|1 mg glucagon s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
89676264|NCT01795235|Other|Saline s.c. injection and atenolol tablet|Saline s.c. injection and 100 mg atenolol tablet
89676265|NCT01795235|Other|glucagon s.c. injection and atenolol tablet|1 mg glucagon s.c. injection and 100 mg atenolol tablet
89050150|NCT01998035|Experimental|R/O: Level 2|Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
89215191|NCT04201223|No Intervention|Standard Education|Participants will be randomized to receive information on child sun protection that is publicly available.
89676266|NCT00391469|No Intervention|control treatment|
89676267|NCT00387829|Active Comparator|1|Use of DuraGen Plus Adhesion Barrier Matrix as an adhesion barrier in the spine
89050151|NCT01998035|Experimental|R/O: Level 3|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
89050152|NCT01998035|Experimental|R/O: Level 4|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
89676268|NCT00387829|No Intervention|2|Control arm is surgery alone (no adhesion barrier)
89676269|NCT01512407|Experimental|Hepatectomy plus TACE|Transarterial chemoembolisation will be performed 4 to 6 weeks after hepatectomy
89676270|NCT01512407|No Intervention|Hepatectomy alone|
89676271|NCT01793207||Normal|Subjects who had a normal colonoscopic examination (No polyps, masses or any evidence of colorectal neoplasia)
89676272|NCT01793207||colorectal cancer|Patients with endoscopic and histopathological evidence of colorectal cancer
89676273|NCT01793207||Adenoma|Patients with colorectal adenomas only detected on colonoscopy
89676274|NCT01793207||Hyperplastic polyps|Patients with hyperplastic polyps detected on colonoscopy.
89676275|NCT00388453|Active Comparator|1|Healthy volunteers with no history of GERD or EERD or Proton Pump Inhibitor (PPI) use
89676276|NCT00388453|Experimental|2|subject is known to have GERD based on symptoms and previous positive response to PPI
89676277|NCT00388453|Experimental|3|subject is known to have EERD based on symptoms and previous positive response to PPI
89676278|NCT00392951|Experimental|Sirolimus treatment|Sirolimus treatment
89676279|NCT00389467|Active Comparator|1 Mechanical Embolectomy|Participants will be randomized to receive mechanical embolectomy treatment either with the Merci Retriever or Penumbra System and standard medical care or treatment with standard medical care alone.
89676280|NCT00389467|No Intervention|2|standard medical care
89676281|NCT02982967|Other|Physical Activity|Single-arm study with recreational physical activity intervention by 10 weeks (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
89676282|NCT01424930|Experimental|Abiraterone+prednisone (low-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
89050153|NCT01998035|Experimental|R/O: Level 5|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
89050154|NCT01998035|Experimental|R/O: Level 6|Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
89050155|NCT04630899|Experimental|Active Joint Mobilization|
89050156|NCT04630899|Experimental|Passive Joint Mobilization|
89050157|NCT01991210|Experimental|DNIB0600A|DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
89050158|NCT01991210|Active Comparator|PLD|PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
89050159|NCT04611243||COVID survivors|
89050160|NCT04611243||Vaccination with CoronaVac vaccine|
89676283|NCT01424930|Experimental|Abiraterone+prednisone (high-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
89050161|NCT04611243||Vaccination with BionTech vaccine|
89050162|NCT04611243||third dose vaccination with CoronaVac vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
89676284|NCT00389857|Experimental|Influenza vaccine-naive group|Participants have never received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0 and Day 28, respectively.
89050163|NCT04611243||third dose vaccination with BionTech vaccine|We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
89050164|NCT01979939|Experimental|A 1: DCV/ASV/BMS-791325 in treatment-naive subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
89050165|NCT01979939|Experimental|A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
89050166|NCT04610970|Experimental|TQ-B3525 tablets|TQ-B3525 tablet administered orally.
89050167|NCT04677530|Experimental|Part 1: JNJ-40411813 or Matching Placebo|Participants will receive a single oral dose of JNJ-40411813 or a matching placebo in Cohorts 1, 2, and 3.
89050168|NCT04677530|Experimental|Part 2: JNJ-40411813|Participants will receive a single oral dose of JNJ-40411813 in Cohort 4.
89676285|NCT00389857|Experimental|Influenza vaccine-primed group|Participants have received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0.
89676286|NCT01424306|Experimental|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days.
89676287|NCT01424306|Experimental|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days.
89050169|NCT04677530|Experimental|Part 3: JNJ-40411813 or Matching Placebo|Participants will receive a multiple oral dose of JNJ-40411813 or a matching placebo in Cohort 5 and optional Cohort 6.
89050170|NCT00564057|Experimental|1|candesartan 8-16 mg once daily
89676288|NCT01424306|Experimental|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days.
89050171|NCT00564057|Active Comparator|2|lercanidipine 10-20 mg once daily
89050172|NCT04630743|Other|Cognitive and Behavioral Intervention|Non-pharmacological strategies for the Management of episodic breathlessness
89050173|NCT04630782||Aim 1|"The investigators will compare PET-MRI imaging and stool biomarkers between patients with VEDOSS/early SSc (n=40) and those with late SSc (n=20) not on immunosuppressive treatment.~Participants will undergo a PET-MRI scan once at baseline."
89050174|NCT04630782||Aim 2|"In early SSc patients (n=35), the investigators will determine change in biomarker levels from pre-treatment baseline to 6 months (primary end-point) and 12-months (secondary end-point) following MMF treatment.~Participants will undergo PET-MRI scans at baseline, 6-month and 12-month."
89050175|NCT04630782||Exploratory aim|"In patients with VEDOSS/early SSc (n=15) not on immunosuppressive treatment, the investigators will characterize imaging and stool biomarker changes over one year.~Participants will undergo PET-MRI scans at baseline and 12-month."
89050176|NCT04630704||Non vascular repeatibility|This cohort of patients with palpable pulses will be used to test inter- and intra- observer variability for the Pedra system
89676289|NCT02110381|Active Comparator|Device Guided Breathing/Combination Therapy|Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
89676290|NCT02110381|Active Comparator|Isometric Hand Grip/Combination Therapy|Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
89676291|NCT05286463|Experimental|group A|received low-intensity pulsed ultrasound using bee venom (BV) gel for 5 minutes for each session, three times a week, for three consecutive weeks postoperative and received regular medical care.
89676292|NCT05286463|Sham Comparator|group B|received low-intensity pulsed ultrasound using only plain gel without BV gel for 5 minutes for each session, three times a week, for three consecutive weeks postoperative and received regular medical care.
89676293|NCT04271527|Experimental|cognitive targeted biopsy|a cognitive fusion targeted biopsy combined with a systematic biopsy
89676294|NCT04271527|Active Comparator|software targeted biopsy|software-based fusion targeted biopsy combined with a systematic biopsy
89676295|NCT01795183|Experimental|Amisulpride|Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week
89676296|NCT01424228|Placebo Comparator|Placebo|Placebo 2 mg tablet once daily before breakfast
89676297|NCT01424228|Active Comparator|prucalopride|Prucalopride 2 mg once daily before breakfast
89676298|NCT01795885|Experimental|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the show 16 and Pregnant once a week for 4 weeks."
89676299|NCT01795963|Placebo Comparator|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
89676300|NCT01795963|Active Comparator|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress.
89676301|NCT01796041|Experimental|IV Injection of ICG|
89676302|NCT01796119|Experimental|Ridge Splitting|"Dental implants placed using ridge splitting technique. To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
89676303|NCT01796119|Active Comparator|Implants placed using drilling technique|"Dental implants placed in the ridge with sufficient thickness using drilling technique.~To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
89676304|NCT04750681|Placebo Comparator|Control|Each capsule contained 275mg of maltodextrin. Capsules were similar to the saffron investigation product (chlorophyll capsules).
89676305|NCT04750681|Experimental|Saffron|Each capsule contained 259,5mg of maltodextrin and 15,5mg of saffron extract (Saffr'activ® SAF 3C PIM) that corresponds to 1,6mg of dry saffron extract, 0,9mg of crocins (5.82%) and 0,7mg of safranal (4.6%).
89676306|NCT04750603|Placebo Comparator|Salbutamol|Salbutamol (Salbutrim, Trima) inhaler (400 µg) via spacer + Relvar® Ellipta placebo
89676307|NCT04750603|Active Comparator|FF/VI|Placebo Salbutamol inhaler + Relvar® Ellipta (92/22 µg, GSK, UK)
89050177|NCT04630704||Non vascular physiology|This cohort of patients with palpable pulses will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
89050178|NCT04630704||CLTI physiology|This cohort of patients with CLTI will assess the ability of Pedra to detect perfusion changes in response to physiologic stimuli.
89050179|NCT00564096|Active Comparator|Real TMS|10 patients will be given 20 minutes stimulation with real deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 20 consecutive working days.
89050180|NCT00564096|Placebo Comparator|Sham & real TMS|10 patients will be given 20 minutes stimulation with sham deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 10 consecutive working days, and thereafter 20 sessions of real TMS with the same parameters (=Left Tempor-oparietal Cortex in frequency of 1 Hz with 120% motor threshold).
89050181|NCT04677452|Experimental|JWCAR129|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JWCAR129
89050182|NCT04677296|Experimental|VS002A|Amino acid based ORS/medical food (VS002A). Initial treatment dosing with VS002A will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
89050183|NCT04677296|Active Comparator|Standard WHO-ORS|Standard WHO-ORS. Initial treatment dosing with WHO-ORS will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
89050184|NCT04610541|Experimental|Remdesivir-HU|"Day 1 - single loading dose of remdesivir-HU 200 mg given by intravenous infusion~• Day 2 onwards - 100 mg given once daily by intravenous infusion."
89050185|NCT04677335|Experimental|Nutraceutical|Nutraceutical capsules taken once daily for 12 weeks
89050186|NCT04677335|Placebo Comparator|Control|Placebo capsules taken once daily for 12 weeks
89676308|NCT01423916|Active Comparator|Arm 1 (OPC-34712, placebo)|Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.
89676309|NCT01423916|Active Comparator|Arm 2 (OPC-34712, placebo)|Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.
89676310|NCT01423916|Active Comparator|Arm 3 (moxifloxacin, placebo)|Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.
89676311|NCT01423916|Active Comparator|Arm 4 (moxifloxacin, placebo)|Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.
89676312|NCT01796743||Controls|Age and gender matched controls ('control' group) with acute MI with similar degree of troponin elevation who are managed based solely on the basis of clinical or angiographic data alone.
89676313|NCT01796743||Cardiac MRI|Hospitalized patients with acute MI with a clinically-indicated CMR ordered will be enrolled. Data for T2 mapping will be added to the clinically prescribed cardiac MRI scan.
89676314|NCT00436969|Active Comparator|Control|Subjects randomized to the control arm injection of prescribed anesthetic and corticosteroid, shall receive an equivalent volume (8 mL's).
89676315|NCT00436969|Experimental|Investigational|Subjects randomized to the active treatment in this study will receive a one-time dose of 8 mL's of Orthovisc derived from non-animal source bacterial fermentation, S. Equi.
89676316|NCT00455689|Experimental|Developed hot flashes|Subjects who developed hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
89676317|NCT00455689|Experimental|Did not develop hot flashes|Subjects who did not develop hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
89676318|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1200 mg|
89676319|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1400/1600 mg|
89676320|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1200 mg|
89676321|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg|
89676322|NCT00395057|Experimental|AGN 211745 Solution 1000 ug|AGN 211745 Solution 1000 ug
89676323|NCT00395057|Experimental|AGN 211745 Solution 300 ug|AGN 211745 Solution 300 ug
89676324|NCT00395057|Experimental|AGN 211745 Solution 100 ug|AGN 211745 Solution 100 ug
89676325|NCT00395057|Active Comparator|Ranibizumab 500 ug|Ranibizumab 500 ug
89676326|NCT05287919|Other|Control group|Patients received the standard physical therapy (SPT) programme only (passive mobilization) twice a day.
89676327|NCT05287919|Experimental|Low-frequency NMES group|Patients submitted to low-frequency NMES and SPT twice a day.
89676328|NCT05287919|Experimental|Medium-frequency NMES group|Patients submitted to medium-frequency NMES and SPT twice a day.
89676329|NCT00371267|Experimental|Arm 1: Telephone-delivered CBT|Telephone-delivered cognitive behavior therapy for pain management
89676330|NCT00371267|Active Comparator|Arm 2: Telephone patient education|Telephone-delivered patient education regarding management of chronic pain
89676331|NCT00438451|Active Comparator|Levetiracetam|Levetiracetam
89676332|NCT00438451|Active Comparator|Carbamazepine|Carbamazepine
89676333|NCT00438451|Active Comparator|Lamotrigine|Lamotrigine
89676334|NCT00456547||Postpartum hysterectomy|Women that require postpartum hysterectomy for post-delivery bleeding.
89676335|NCT00456547||Cesarean delivery case controls|Women that deliver by cesarean that presented with risk factors for bleeding but did not require post delivery hysterectomy
89676336|NCT00456625|Experimental|Group Engerix™-B|Subjects received a dose of Hepatitis B vaccine approximately 20 years after the primary neonatal vaccination
89676337|NCT00439465|Other|Ex-vivo expanded effector cells|Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)
89676338|NCT00457795|Experimental|brimonidine 0.1%|brimonidine 0.1%
89676339|NCT04749979|Active Comparator|giving agonist ( eg. decapeptyl )|Giving women agonist
89676340|NCT04749979|Active Comparator|Giving HCG (eg. choriomon )|Giving women HCG
89676341|NCT01423604|Experimental|Capecitabine and ruxolitinib|
89676342|NCT01423604|Placebo Comparator|Capecitabine and placebo|
89676343|NCT00441259|Experimental|JE-CV Group|Participants will receive Japanese encephalitis chimeric virus vaccine (JE-CV)
89676344|NCT00441259|Active Comparator|MBDV Group|Participants will receive the mouse brain-derived vaccine (MBDV)
89676345|NCT01402544|Other|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg Intravitreal Injection, monthly, open-label, for the duration of 1 year
89676346|NCT01401842|Experimental|Strengthening Exercise|Lumbar ext. high intensity progressive resistance exercise
89676347|NCT01401842|Active Comparator|Stabilization Exercise|Low intensity core stabilization exercise
89676348|NCT01422824||Cohort|
89676349|NCT00460525|Active Comparator|Rabies Vaccine|Rabies vaccine administered on Days 0, 30, and 60.
89676350|NCT00460525|Experimental|FMP2.1/AS02A|50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.
89676351|NCT00460993|Experimental|Group 1|Lunesta Active drug (eszopiclone) 1 mg during 1st week of active drug. If sleep efficiency does not improve does increases to 2 mg for 2nd week of active drug administration.
89676352|NCT00460993|Placebo Comparator|Group 2|"Sugar pill packaged and supplied by Sepracor. One pill weeks one and two of intervention.~Weeks 3 and 4 this Placebo group crosses over to active drug. 1 mg week 3 increasing to 2mg week 4 if sleep efficiency does not improve."
89676353|NCT00441883|Experimental|PF-03187207 and Latanoprost Vehicle|One drop of each, once daily in study eye for 28 days
89676354|NCT00441883|Active Comparator|Latanoprost 0.005% and PF-03187207 Vehicle|One drop of each, once daily in study eye for 28 days
89676355|NCT00461773|Active Comparator|bevacizumab|brief exposure bevacizumab
89676356|NCT00461773|Active Comparator|bevacizumab and letrozole|brief exposure bevacizumab and letrozole
89676357|NCT00461851|Experimental|Chemotherapy plus sorafenib|Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
89676358|NCT00442507|Experimental|1|Patients will be treated with erlotinib 150 mg oral daily and Avastin 15 mg/kg intravenously each cycle of therapy (each cycle is 21 days or every 3 weeks). The first infusion of Avastin will be administered over 90 minutes. If tolerated, the second infusion will be given over 60 minutes and in 30 minutes for the subsequent treatments. Treatment will be administered until disease progression or intolerable side effects.
89676359|NCT05286073|Experimental|Hyflex EDm|The canals were prepared and shaped with one file (25/~) and finished with 40/.04 using crown down technique. Torque controlled endodontic motor was used with a rotational speed of 500 rpm and torque of 2.5Ncm (25 Nm).
89676360|NCT05286073|Experimental|F6 SkyTaper|The canals were prepared and shaped with one file (25/~) and finished with 40/.04 using crown down technique. Torque controlled endodontic motor was used with a rotational speed of 500 rpm and torque of 2.5Ncm (25 Nm).
89676361|NCT05286073|Experimental|One Shape|Canals were prepared and shaped with single rotational file system One Shape with the sequence of Endoflare (12, 0.12), One G (18, 0.03) and One Shape (12.06) connected to endodontic motor with rotational speed of 400rpm and 4 Ncm torque as recommended by manufacturer.
89676362|NCT05286073|No Intervention|Control|In the control group, no endodontic instrumentation and shaping was done in the canals. Only the necrotic pulp tissue was extirpated from the canals with the help of barbed broaches and then the specimens were analyzed for fracture testing.
89676363|NCT01401530|Experimental|E7777|
89676364|NCT01387022|Experimental|Tenofovir, lamivudine and efavirenz|
89676365|NCT01387022|Active Comparator|Zidovudine, lamivudine and efavirenz|
89676366|NCT00395135|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
89676367|NCT00395135|Placebo Comparator|Matching Placebo BID|Matching placebo tablet each morning and evening
89676368|NCT01386944||Neupro® Treatment|Routine treatment (1,2,3 mg/24 h) as per approved label in the European Union (EU).
89676369|NCT00395291|Experimental|MK-0677 then Placebo|MK-0677 and Placebo - All subjects were given MK-0677 for a 30 +/- 7 days and then they were given a placebo for 30 +/- 7 days.
89676370|NCT00395291|Experimental|Placebo then MK-0677|MK-0677 and Placebo - All subjects were given Placebo for a 30 +/- 7 days and then they were given MK-0677 for 30 +/- 7 days.
89676371|NCT01386788||Smoke Inhalation patients|Closed space fire, Soot deposits, Altered mental status Blood specimen before intravenous antidote treatment (cyanide measurement) Known delay between end of smoke exposure and blood sampling
89676372|NCT00445315|Experimental|2|
89676373|NCT00445315|Experimental|3|
89676374|NCT00445315|Experimental|1|
89676375|NCT00445315|Experimental|4|
89676376|NCT00445315|Placebo Comparator|5|
89676377|NCT00395993|Experimental|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
89676378|NCT00395993|Active Comparator|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
89676379|NCT04388137||infants aged 0-3|No intervention.
89676380|NCT04388137||children aged 4-18|No intervention.
89676381|NCT00374231|Experimental|Immunosuppression|All the patients who enroll in this study will receive the same medications (tacrolimus, mycophenolate mofetil, and a short course of steroids) to prevent rejection of the liver transplant. All participants will be gradually taken off prednisone if they are 90 days or longer post liver transplant and have not had a rejection in the last 30 days.
89676382|NCT00400205|Experimental|Recipients of Docetaxel, Cisplatin, 5-Fluorouracil|Participants with squamous cell carcinoma receiving chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil.
89676383|NCT00445705|Placebo Comparator|Placebo|Part A: Placebo every 12 hours for 4 weeks
89676384|NCT00445705|Experimental|AGN 203818 3 mg|Part A: 3 mg AGN 203818 every 12 hours for 4 weeks
89676385|NCT00445705|Experimental|AGN 203818 20 mg|Part A: 20 mg AGN 203818 every 12 hours for 4 weeks
89676386|NCT00445705|Experimental|AGN 203818 60 mg|Part A: 60 mg AGN 203818 every 12 hours for 4 weeks
89676387|NCT01386554|Experimental|80 U Acthar|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) two times per week
89676388|NCT01386554|Placebo Comparator|1.0 mL Placebo|Placebo (1.0 mL) two times per week
89676389|NCT01386554|Experimental|40 U Acthar|Acthar (Repository Corticotropin Injection) 40 U (1.0 mL) two times per week
89676390|NCT00400439|Experimental|dalcetrapib (RO4607381)|
89676391|NCT00400439|Placebo Comparator|placebo|
89676392|NCT00448201|Active Comparator|Methotrexate Only Arm|GVHD Prophylaxis with Methotrexate
89676393|NCT00448201|Active Comparator|2 Doses ATG + Methotrexate|GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate
89676394|NCT00448201|Active Comparator|2 Doses ATG|GVHD prophylaxis with 2 doses ATG
89676395|NCT00448201|Active Comparator|3 Doses ATG|GVHD prophylaxis with 3 doses ATG
89676396|NCT05287607||Newborn Infants|Newborn infants delivered at study hospital and admitted to neonatal unit. Babies anticipated to stay for at least 5 days.
89676397|NCT01386008|Other|enfilcon A + senofilcon A|Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
89676398|NCT00375167|Experimental|Recovery Workbook Intervention|12-week Recovery Intervention: The intervention is a 12-week group-based intervention. The intervention is informed by the Recovery Workbook- a validated intervention for people with serious mental illness. The intervention includes 2 hour sessions for 12 weeks that focus on the following areas: Introduction to the intervention; Recovery; Knowledge and Control; Managing life stress; Enhancing personal meaning; Building personal support; and Setting personal goals. The total time period of the intervention is 24 hours. Participants in this arm also receive treatment as usual.
89676399|NCT00375167|No Intervention|Treatment as usual|The participants in the control arm will continue to receive treatment as usual. TAU is Assertive Community Treatment. Assertive Community Treatments are structured to meet set fidelity standards that are evidence-based. This arm did not receive any intervention.
89676400|NCT00375713|Experimental|Levocetirizine|Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
89676401|NCT00375713|Active Comparator|Cetirizine|Cetirizine + Levocetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
89676402|NCT00465595|Experimental|Low Dose First, High Dose Second|The Low-Dose-1st Group received the low dose of psilocybin on the first session and the high dose on the second session
88996277|NCT02923687|Active Comparator|Buccal infiltration of Ketorolac|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, case group will receive a supplemental buccal infiltration of 30 mg/mL of Ketorolac tromethamine (Alborz-Darou Co. Qazvin, Iran).
89676403|NCT00465595|Experimental|High Dose First, Low Dose Second|The High-Dose-1st Group received the high dose of psilocybin on the first session and the low dose on the second session
89676404|NCT05285995|Experimental|The music group|In the music group, on the basis of the routine preoperative care, the preferred music was selected from the music library as the intervention content on the day of surgery according to the preference of the children in the 1-day preoperative visit. If there was no preference, the music was played randomly. During the intervention, the same multimedia audio system (Wanderer EDIFIER R1700BT) was used to play music for 30-40 minutes, the volume was controlled at 35-80dB, and adjusted in time according to the feedback of the children.
89676405|NCT05285995|Experimental|The animation group|The children in animation group also chose their favorite cartoons as the intervention content on the basis of preoperative care. The same pad (Lenovo TB3-850F) was used to play pre-selected cartoons, and volume as the music group. During the intervention period, the children in intervention group were also accompanied by a nurse, who was also responsible for the implementation and maintenance of the intervention program.
89676406|NCT05285995|No Intervention|The control group|No interventions except routine preoperative visits and conventional care were performed for the control group.
89676407|NCT00376805|Experimental|All Treated Patients|All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.
89676408|NCT01793363|Experimental|tracheotomized patients|
89676409|NCT05287139||Hospital Beneficência Portuguesa de SP - BP1|Patients from private institutions.
89676410|NCT05287139||Hospital Pérola Byington - HPB2|Patients from public institutions.
89676411|NCT00448357|Experimental|GVHD prophylaxis|"Subjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine .~Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus."
89676412|NCT00450073|Active Comparator|Vitamin D3|Vitamin D3=cholecalciferol 50,000 IU weekly
89676413|NCT00450073|Active Comparator|vitamin D2|The intervention is an oral tablet of vitamin D2 (ergocaliferol 50,000 IU weekly) for 12 weeks.
89676414|NCT00450073|Active Comparator|Sunlamp|The intervention is the use of a Sunlamp (Sperti) to the skin 5 times a week for 12 weeks
89676415|NCT00467077|Experimental|Gefitinib and PEG-IFNa Treatment|Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).
89676416|NCT00400829|Experimental|Arm I|Patients receive 1.4 mg/m2 eribulin mesylate IV over 1-2 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89676417|NCT04388371|Experimental|Prior to subject taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
89676418|NCT04388371|Experimental|subjects taking sirolimus or everolimus|To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
89676419|NCT01795391||Tegaderm HP|Patients whose intravasculare devices dressings are made exclusevely with Tegaderm HP dressings.
89676420|NCT01795391||Advanced|Patients whose intravasculare devices dressings are made exclusevely with Advanced dressings
89676421|NCT01995929||neurogenic dysphagia|Patients suffering from neurogenic dysphagia due to several reasons (e.g. Parkinson´s disease).
89676422|NCT00467389|Experimental|Oral Placebo First|Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil
89676423|NCT00467389|Experimental|Donepezil First|Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo.
89676424|NCT00377741|Experimental|1|
89676425|NCT05287061|Experimental|Cardiac Rehabilitation (CR) + Multicomponent Psychological Program (MPP):|The patients who are assigned to this treatment arm will have access to a psychological intervention program, which will use techniques from the positive psychology and motivational interviewing to work on several modules: Health pills (phase I), CR in phase II identical to the standar, and MPP interspersed in Phase II of the conventional program. An individualized program will be included in this branch, which will be added to the follow-up carried out in primary care. It will contain a post-traumatic growth module, an emotion management module, and an intention consolidation module.
89676426|NCT05287061|No Intervention|Cardiac Rehabilitation (CR)|The patient will follow the usual process of cardiac rehabilitation.
89676427|NCT00379145|Experimental|Trabectedin|Trabectedin IV over 24 hours every 3 weeks
89676428|NCT00382031|Active Comparator|zalutumumab|Zalutumumab in combination with Best Supportive Care
89676429|NCT00382031|Other|Control|Best Supportive Care
89676430|NCT04270799||Lung Nodules|"A cohort of 1000 patients with incidental lung nodules will be identified using clinical records at participating NHS sites.~Link-anonymised CT scan images and data will be stored using a central database for radiomics and artificial intelligence research, to predict the risk of malignancy."
89676431|NCT00382265|Active Comparator|Tamsulosin|Tamsulosin 0.4mg PO qd for 28 days
89676432|NCT00382265|Placebo Comparator|Placebo|Placebo PO qd for 28 days
88996278|NCT02923687|Placebo Comparator|Buccal infiltration of Normal saline|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the control group will receive normal saline as placebo.
88996279|NCT02923492|Experimental|In-person Therapy by ED Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered by ED staff in-person.
89676433|NCT05286905|Active Comparator|Patients who receive cephalomedullary nail|Patients who receive cephalomedullary nail
89676434|NCT05286905|Active Comparator|Patients who receive proximal femur locking plate|Patients who receive proximal femur locking plate
89676435|NCT01795001||late-onset FECD|tissue samples from patients with late-onset Fuchs' endothelial corneal dystrophy (FECD)
89676436|NCT01795001||normal control|tissue samples from patients with normal corneas
89676437|NCT01795001||non-FECD edematous control|tissue samples from patients with corneal edema but without FECD
89676438|NCT00383747|Active Comparator|Nicotine Patch|
89676439|NCT00383747|Placebo Comparator|Placebo Nicotine Patch|
89676440|NCT01421342|Active Comparator|Switching: Bupropion-SR|Switching: Bupropion-SR
89676441|NCT01421342|Active Comparator|Augmenting: Antidepressant + Bupropion-SR|Augmenting: Antidepressant + Bupropion-SR
89676442|NCT01421342|Active Comparator|Augmenting: Antidepressant + Aripiprazole|Augmenting: Antidepressant + Aripiprazole
89676443|NCT00403403|Placebo Comparator|Placebo+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
89676444|NCT00403403|Experimental|Bevacizumab+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
89676445|NCT03025568|Active Comparator|group 1|Patient will receive partial denture constructed from Bre_flex
89676446|NCT03025568|Experimental|group 2|Patients will receive removable partial denture constructed from PEEK
89676447|NCT00405353|Experimental|crossover treatment with Androgel|6 months pretreatment, 12 months treatment intervention with Androgel 10 grams of gel containing 100mg of testosterone
89676448|NCT01384760|Active Comparator|Lifestyle modification program|"At the 1st session, the dietitian carried out a complete behavioral assessment, with emphasis on patient's current eating and lifestyle patterns, specific eating-related behaviors, knowledge of risks associated with current eating patterns, and concerns and feelings about specific lifestyle changes. In the subsequent follow up visit, the dietitian reviewed the 7-day food diaries to ensure nutritional adequacy and treatment compliance, and also offered recommendations for controlling caloric intake.~Patients were encouraged to see an exercise instructor who designed an individualized suitable exercise regime with cardiovascular and resistance exercises for the patients to perform at home. Subjects were encouraged to perform 30-minute aerobic exercise 2-3 times a week."
89676449|NCT01384760|Placebo Comparator|Simple lifestyle advice|Subjects in control group received simple lifestyle advice from a clinician at baseline and month 6. This was a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects were encouraged to perform regular 30-minute exercise 2 to 3 times per week. This was to resemble routine clinical practice.
89676450|NCT00405509||Confirmed respiratory virus|
89676451|NCT00405509||Unconfirmed respiratory infection|
89676452|NCT00406133|No Intervention|Standard intensive glucose monitoring|Patients in the control group were given blood glucose meters and test strips and asked to perform home blood glucose monitoring at least four times daily.
89676453|NCT00406133|Active Comparator|Continuous Glucose Monitoring (CGM)|Patients in the CGM group were instructed to use the CGM device on a daily basis and to verify the accuracy of the glucose measurement with a home blood glucose meter (provided by the study) before making management decisions (as per the regulatory labeling of the devices).
89676454|NCT01384292|Experimental|1 (part A and B)|Oral treatment
89676455|NCT01384292|Experimental|2 (part A and B)|Oral treatment
89676456|NCT01384292|Placebo Comparator|3 (part A only)|Oral treatment
89676457|NCT01401452||Participants with psoriasis and at least one co-morbid disease|Participants with moderate to severe plaque psoriasis with at least one co-morbid disease and/or symptom such as hypertension, psoriatic arthritis confirmed by a rheumatologist or other appropriate specialist, obesity, diabetes, metabolic syndrome or depression
89676458|NCT02982707|Experimental|Mild Hepatic Subjects|Subjects are given a single dose of BMS-986177
89676459|NCT02982707|Experimental|Moderate Hepatic Subjects|Subjects are given a single dose of BMS-986177
89676460|NCT02982707|Experimental|Healthy Match Subjects|Subjects are given a single dose of BMS-986177
89676461|NCT00450463|Active Comparator|Flutamide Alone|Patients receive flutamide orally 3 times a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising prostatic specific antigen (PSA) levels) without metastatic disease (as evidenced on scans), may receive vaccine treatment as defined in arm II beginning 4 weeks after flutamide therapy is discontinued.
89676462|NCT00450463|Experimental|Flutamide + Vaccine + Sargramostim|Patients receive flutamide orally 3 times a day on days 1-28. Patients also receive recombinant vaccinia PSA vaccine subcutaneously (SC) on day 1 of course 1 only and recombinant fowlpox PSA vaccine SC on day 1 of all subsequent courses. Patients receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising PSA levels), discontinue flutamide but may continue to receive vaccine treatment.
89676463|NCT00407381|Experimental|Ranibizumab|Ranibizumab (RBZ) intravitreal injection alone
89676464|NCT00407381|Active Comparator|Laser|Laser photocoagulation
89676465|NCT00407381|Experimental|Laser with Ranibizumab|Laser following intravitreal injection of RBZ
89676466|NCT00384449|Experimental|Lucentis (ranibizumab)|Lucentis (ranibizumab)
89676467|NCT01401062|Experimental|Arm 1 (Fresolimumab 1 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
89676468|NCT01401062|Experimental|Arm 2 (Fresolimumab 10 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 10 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
89676469|NCT00452335|Experimental|Lubiprostone 12 mcg QD|Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (<6 years of age and able to swallow capsules) who are at least 12 kg body weight
89676470|NCT00452335|Experimental|Lubiprostone 12 mcg BID|Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight
88996280|NCT02923492|Experimental|Remote Therapy by Research Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered remotely (over video) by research staff.
88996281|NCT02923492|No Intervention|Comparison Group|This group will not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
88996282|NCT02923414|Active Comparator|Standard escalating shocks|Patients will be randomized to a standard escalating shock protocol using the energy settings: 125, 150, 200 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
88996283|NCT02923414|Active Comparator|High energy shocks|Patients will be randomized to a high energy shock protocol using the energy settings: 360, 360, 360 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
88996284|NCT02923375|Experimental|Cohort A|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)
89676471|NCT00452335|Experimental|Lubiprostone 24 mcg BID|Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight
89676472|NCT00386243|No Intervention|Usual Care|Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.
89676473|NCT00386243|Experimental|Stepped Care|Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.
89676474|NCT01400516|Experimental|Teriparatide|The participants who are in treatment arm received teriparatide 20 μg, subcutaneous injection, 1 injection per day, with a biologic for 12 months. A second year of teriparatide was offered to all interested participants. All participants received daily 1000 milligrams (mg) of calcium citrate, 800 IU of vitamin D and a Tumor Necrosis Factor (TNF) antagonist.
89676475|NCT01400516|Other|Control Arm|The participants randomized to the control arm had the same testing as those in the treatment arm and were offered teriparatide, if determined to be effective in healing bone erosions, after the first 12 months. All participants received daily 1000 mg of calcium citrate, 800 IU of vitamin D and a TNF antagonist.
89676476|NCT01796275|Experimental|Group A|Subjects will have a core session intervention and booster intervention; questionnaire evaluation is conducted at baseline, post-session, pre-booster and 3 month after core session.
89676477|NCT01796275|Experimental|Group B|Subjects will only have a core session intervention; Questionnaire evaluation are conducted at baseline (T1-baseline), post-session (T2), 4 weeks after core session (T3) and 3 month after core session (T4).
89676478|NCT01796275|Other|Group C|Group C is a waiting list control, only questionnaire evaluations can be conducted at T1-baseline, T3- tea gathering and T4- 3 month after baseline evaluation; when finish T4 evaluation, the core session and booster can be optionally conducted subsequently.
89676479|NCT01796431|Experimental|Eviplera®|Participants will take Eviplera every day for 14 days. Levels of the active ingredients, Tenofovir disoproxil fumarate, emtricitabine, rilpivirine hydrochloride will be measured in in blood after the drug intake has been stopped in order to understand how long these drugs persist in the blood.
89676480|NCT01383356|Experimental|Linagliptin/Metformin medium dosecombo|patient to receive a single medium dose combination tablet containing Linagliptin and Metformin once daily
89676481|NCT01383356|Active Comparator|Linagliptin plus Metformin medium dose|patient to receive two individual tablets: Linagliptin and Metformin (medium dose)
89676482|NCT02111447|Active Comparator|Sevoflurane, propofol, Nasal oxygen|After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
89676483|NCT02111447|Active Comparator|Sevoflurane, Propofol, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
89676484|NCT02111447|Active Comparator|Sevoflurane, sevoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
89676485|NCT02111447|Active Comparator|Sevoflurane, isoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
89676486|NCT01796821|Placebo Comparator|Vehicle gel|vehicle gel is used as a control group. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
89676487|NCT01796821|Active Comparator|SR-T100 gel with 1.0 % SM|SR-T100 contains 1.0% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
89676488|NCT01796821|Active Comparator|SR-T100 gel with 2.3% SM|SR-T100 contains 2.3% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
89215192|NCT04195685|Experimental|NFB Intervention and Delayed Intervention|The NFB system will read and interpret a participant's brain wave pattern which will be instantaneously fed back to the participant providing information, to which a participant can respond accordingly. The NFB specialist assumes a coaching role with people training on the NFB special use system to assist in the achievement of a focused relaxed state, which enhances the overall brain functioning. The significance and unique aspect of NFB is the direct impact on physiological dysregulation, which is the basis of this treatment approach. Twenty, one-hour, NFB training sessions will be provided to each participant in the intervention group and Delayed intervention group (those participants who completed the Control Group activities) by a trained NFB specialist over an 8-10-week period. Participants in the intervention group will receive up to 5-sessions but usually 3 sessions a week
89215193|NCT04195685|No Intervention|Control Group|Participants in the control group will continue with their usual treatment and will receive a 15-minute call once a week for eight weeks from an Investigator on a health topic. This will help to keep members of the control group engaged in the project and receive the same information that is offered to the intervention group members. The health topics that are generally discussed during NFB sessions include sleep hygiene, basic nutritional concepts, beverage choices, positive thinking, thought reframing, fitness, daily calming activity, and enhancement of focus strategies.
89215194|NCT04192344|Experimental|ABSK021|"Dose escalation of oral ABSK021 with a starting dose of 25mg once daily will be guided by3+3 escalation rules based on safety data until an MTD has been identified or a RDE. For each dose, patients will first receive a single dose ABSK021 tablet(s) by mouth at Day -3 and be followed by a 3-day off as a run-in period to access the safety and PK of single-dose. Then, patients will continuously receive ABSK021 once daily (QD) in repeated 28-day cycles."
89215195|NCT04184882|Experimental|ASP0367 group|Participants will be dosed investigational product (IP) at the low dose for 2 weeks and then at the high dose for 10 weeks with the total duration of 12 weeks in the DB part and OLE part, respectively.
89215196|NCT04184882|Placebo Comparator|Placebo to ASP0367 group|Participants will be dosed matching placebo in the DB part. In OLE part, participants will dosed IP at the low dose for 2 weeks and then at the high dose for 10 weeks with the total duration of 12 weeks.
89215197|NCT04164225|Experimental|Qigong|Qigong exercises, focused on a mind-body connection
89676489|NCT05966545|Active Comparator|intraocular foreign body extraction via the limbus|pars plana vitrectomy and intraocular foreign body removal via the limbus, after complete removal of adhesions around intraocular foreign body, then the foreign body will be grasped using basket forceps, and it will be brought to anterior chamber and then removed through limbal incision. The external earth magnet will be applied close to the limbus to prevent its slippage from the forceps if needed.
89676490|NCT05966545|Active Comparator|intraocular foreign body extraction via the pars plana route|pars plana vitrectomy and intraocular foreign body removal via pars plana route, after complete removal of adhesions around intraocular foreign body, then IOFB will be grasped using basket forceps, and while the IOFB removed through the sclerotomy an external earth magnet will be applied close to the sclerotomy after enlargement the sclerotomy to prevent its slippage from the forceps and falling down onto the posterior pole if needed.
89676491|NCT05966493|Experimental|NEXAGON® (lufepirsen ophthalmic gel) High Dose Concentration|Lufepirsen (High dose concentration) applied topically weekly for 4 to 8 weeks.
89676492|NCT05966493|Experimental|NEXAGON® (lufepirsen ophthalmic gel) Low Dose Concentration|Lufepirsen (Low dose concentration) applied topically weekly for 4 to 8 weeks.
89676493|NCT05966493|Placebo Comparator|NEXAGON Vehicle (ophthalmic gel)|Vehicle applied topically weekly for 4 to 8 weeks.
89676494|NCT05966454|Experimental|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive up to 24 hours of SOC post-operative antibiotics."
89676495|NCT05966454|Active Comparator|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care with simple appendicitis will receive 24 hours of post-operative SOC antibiotics~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive 4 days of post-operative SOC antibiotics."
89676496|NCT05966441|Experimental|Experimental group|Patients will receive their Paclitaxel-based chemotherapy along with Curcumin at a dose of oral 2g daily till the end of chemotherapy.
89676497|NCT05966441|Placebo Comparator|Control group|Patients will receive their Paclitaxel-based chemotherapy only
89676498|NCT05966428|Active Comparator|Control Group|Conventional Exercises
89676499|NCT05966428|Experimental|Intervention Group|Conventional Exercises + Sensory Integration Therapy
89676500|NCT05966415|Experimental|Endocalyx Pro|"Endocalyx is a food supplement that is distributed by Microvascular Health Solutions LLC in Alpine, Utah.~Patients will receive 4 capsules Endocalyx per day, for 8 consecutive weeks. The capsules are orally administered and can be taken with water, on an empty stomach or with food.~If possible, the patient will take 2 capsules in the morning, and 2 capsules in the afternoon. If preferred by the patient, the 4 capsules could also be taken once daily in the morning."
89676501|NCT05966415|Placebo Comparator|Placebo|"Placebo pills will be provided by Microvascular Health Solutions and are matched with the Endocalyx capsules. The placebo capsules contain no active pharmaceutical ingredients and contain solely widely used excipients.~Patients will receive 4 capsules of the placebo per day for 8 consecutive weeks. The capsules are orally administered and can be taken with water, on an empty stomach or with food. If possible, the patient will take 2 capsules in the morning, and 2 capsules in the afternoon. If preferred by the patient, the 4 capsules could also be taken once daily in the morning."
88996285|NCT02923375|Experimental|Cohort B|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)
88996286|NCT02923453|Placebo Comparator|Placebo|1g/meal of placebo three times per day (3g/day) for 8-weeks.
89215198|NCT04164225|Active Comparator|P.Volve|P.Volve exercises, focused on just physical movement
89215199|NCT04147819|Experimental|Dose escalation of BAY2701439|The target population consists of participants with advanced HER2-expressing/amplified breast, gastric or gastroesophageal cancer.
89676502|NCT05966402|Experimental|Virtual Reality|
89676503|NCT05966402|No Intervention|standard care|
89215200|NCT04147819|Experimental|HER2 overexpressing breast cancer|Dose expansion of BAY2701439
89215201|NCT04147819|Experimental|HER2 low expressing breast cancer|Dose expansion of BAY2701439
89215202|NCT04147819|Experimental|Other HER2 overexpressing advanced carcinomas|Dose expansion of BAY2701439
89215203|NCT04140448||UWFA-RVO-ME|Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab
89215204|NCT04125589|Experimental|Speaking Activity and Talking Activity|Participants will engage in a speaking activity first and a talking activity second.
89676504|NCT05966363||CBCT|Patients receiving a Cone Beam of the rocks as part of a cochlear implant position check at Besançon University Hospital
89676505|NCT05966363||CT|Patients receiving a CT scan of the rocks at Besançon University Hospital, all indications combined
89676506|NCT05966350||Sensory neuronopathies (SNN)|Patients with Sensory neuronopathies (SNN) will be included.
89676507|NCT05966350||another peripheral neuropathy|Patients with small fiber neuropathy, chronic polyradiculoneuritis or other axonal neuropathy) will be included.
89676508|NCT05966350||dysimmune context without associated neuropathy.|Patient with dysimmune context without associated neuropathy will be included.
89676509|NCT05966337|Active Comparator|Control group 1 (usual care)|Patients undergo physiotherapy treatment twice daily, transitioning from the ICU to the ward. The treatment plan spans several days, starting on the first postoperative day after ICU discharge. In the ICU, Day 1 includes diaphragmatic breathing exercises, coughing stimulus, upper limb exercises (shoulder flexion/extension, abduction), and lower limb exercises (thigh flexion, dorsiflexion/plantarflexion). Day 2 involves diaphragmatic breathing, coughing stimulus, upper limb exercises, lower limb exercises, cycling for 3 minutes, and respiratory device exercises. Upon moving to the ward on Day 3, patients perform diaphragmatic breathing, coughing stimulus, upper limb exercises, lower limb exercises, and a 5-minute walk. Day 4 focuses on diaphragmatic breathing, coughing stimulus, and a 10-minute walk. Finally, on Day 5, patients engage in diaphragmatic breathing, coughing stimulus, and a 15-minute walk.
89676510|NCT05966337|Experimental|Intervention group 2 (CPAP)|They will be submitted to the same care as the control group, adding NIV with nasal CPAP 10cmH2O for 1 hour using device and brand approved by ANVISA, during the 5 days of hospitalization, both in the ICU and in the ward. The frequency of the sessions will be two (2) per day, in the morning and in the afternoon. Flexibility of time for carrying out the procedure is also planned, since in a hospital environment the patient can often undergo exams, other behaviors that may make it difficult to apply the protocol at the initially scheduled time. After the fifth day, the patient will be reassessed with the same instruments reported.
89676511|NCT05966337|Experimental|Intervention group 2 (BIPAP):|They will undergo the same care as the control group, adding NIV with nasal BIPAP with IPAP of 13cmH2O and EPAP 8 cmH2O for 1 hour, using equipment and brand approved by ANVISA, during the 5 days of hospitalization, both in the ICU and in the ward . The frequency of the sessions will be two (2) per day, in the morning and in the afternoon. Flexibility of time for carrying out the procedure is also planned, since in a hospital environment the patient can often undergo exams, other behaviors that may make it difficult to apply the protocol at the initially scheduled time. After the fifth day, the patient will be reassessed with the same instruments reported.
89676512|NCT05966207|Experimental|Individual Cognitive Stimulation|"The Individual Cognitive Stimulation (ICS) program to be implemented is called Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers (MD3). It was specifically designed to be applied in a home context, with informal/family caregivers taking charge of implementing the stimulation sessions (Apostolo, Silva, Costa & Bobrowicz-Campos, 2019; Yates et al., 2015). The MD3 program has been translated and validated for the Portuguese culture and language (Silva, 2019)."
89676513|NCT05966181|Experimental|experimental group|They will perform repetitive simulation (standard patient simulation according to scenarios) with the students in the experimental group.
89676514|NCT05966181|Other|control group|A single simulation will be applied to the control group (standard patient simulation according to scenarios).
89676515|NCT05966064|Active Comparator|Denosumab|Denosumab randomized at baseline and 3 months in a double-blinded fashion and in case of open label at 6 and 9 months
89676516|NCT05966064|Placebo Comparator|Placebo|Placebo randomized at baseline and 3 months in a double-blinded fashion.
89676517|NCT05965986|No Intervention|Standard of Care Group|A group consisting of the current standard of care at HULC, which is a WebEx pre-operative education class lead by a physiotherapist and occupational therapist.
89676518|NCT05965986|Experimental|Online only|a group consisting of an online pre-rehabilitation program 6 weeks before surgery
89676519|NCT05965986|Experimental|Online and PT|a group consisting of an online pre-rehabilitation program 6 weeks before surgery + therapist
89676520|NCT05965973|Experimental|Low fat diet|During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
89676521|NCT05965973|Experimental|High fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
89688758|NCT03034681|Other|Vojta|Vojta therapy consists in activating certain overall and innate locomotion patterns or complexes: reflex creeping and reflex rolling, which provokes the contraction of striated muscle in the entire body in a determined coordination with the central nervous system (CNS). These patterns are triggered from different positions (prone, supine and side lying) and only with certain stimulation. They contain all the locomotion components: automatic postural control, uprighting and phase movements. This therapy allows for the changing from pathological patterns to painless and cheaper patterns. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
89215205|NCT04125589|Experimental|Talking Activity and Speaking Activity|Participants will engage in a talking activity first and a speaking activity second.
89215206|NCT04120493|Experimental|Cohort 1|Low dose rAAV5-miHTT (6x10^12 gc/subject).
89215207|NCT04120493|Experimental|Cohort 2|High dose rAAV5-miHTT (6x10^13 gc/subject).
89676522|NCT05965947|Experimental|Medical Nutrition Therapy|The intervention group will be scheduled for three one-on-one sessions with a Registered Dietitian, where they will receive nutrition education and counseling. Sessions with the Registered Dietitian will include a review of the client's nutrition assessment data, development of problem list with the client, nutrition diagnosis, assessment of motivation to change, a discussion of barriers and facilitators, an intervention plan, goal setting, and monitoring and evaluation. Because individuals with brain injury may not do their own grocery shopping and meal preparation, caregivers will be encouraged to attend sessions. Checklists will be used to ensure treatment fidelity across participants and nutrition sessions. Sessions will be conducted by telehealth and will be recorded for fidelity checks and ongoing research team training. Sessions will be scheduled approximately 2 weeks apart.
88996287|NCT02923453|Active Comparator|Ginseng Extract|CNT2000 (Chai-Na- Ta Corp., Langley, BC) American ginseng extract 1g/meal of placebo three times per day (3g/day) for 8-weeks.
89676523|NCT05965947|No Intervention|Nutrition Handout Packet|The control group will receive a packet of nutrition education handouts from the MyPlate program found at USDA.gov. The handouts are publicly available and represent nutrition information that could be readily accessed by individuals who want to change their dietary habits, but do not have access to services from a Registered Dietitian.
89676524|NCT05965934|Experimental|Direct Sodium Removal (DSR) Infusate 2.0|Participants will receive a peritoneal dialysis catheter implant. DSR is to be started 14 days after catheter implantation (= D1) for a period of 4 weeks (D28) on top of optimized usual care for HF, while loop diuretic treatment is suspended. Participants then enter enter a 3 month safety follow-up period (D29-D120) until the end of study (D120).
89676525|NCT05965934|No Intervention|Optimized Usual Care for HF|IV loop diuretic treatment is to be started (or continued) after a 14 days observation period (= D1) and can be continued for up to 4 weeks (D28). Participants then enter enter a 3 month safety follow-up period (D29-D120) until the end of study (D120).
89676526|NCT05965804||Healthy Adults|30 healthy adult participants aged 18-45 years performing the McMurray knee examination test
89676527|NCT05965791||Healthy Adults|30 healthy adult participants aged 18-45 years performing the Phalen's wrist flexion test
89676528|NCT05965778|Experimental|T2769|
89676529|NCT05965778|Active Comparator|Vismed® Multi|
89676530|NCT05965765|Experimental|Total Knee Arthroplasty|Individuals who have previously undergone Unilateral total knee arthroplasty
89676531|NCT05965765|Active Comparator|Osteoarthritis without surgery|According to Kellgren-Lawrence, individuals diagnosed with osteoarthritis between II and IV
89676532|NCT05965765|Active Comparator|Control Group|healthy individuals who have not had any knee problems in the last 6 months
89676533|NCT05965713|Experimental|BCI treatment Group using the IpsiHand|"Phase 1: Group 1 subjects will receive an IpsiHand Screening System to complete a remote EEG Screening. Subjects will undergo an EEG screening protocol to ensure that a consistent control signal will be present to control the IpsiHand device. After an EEG screening session is complete, the participants screening data will be analyzed to ensure that sufficient cortical signals are present. Randomization for assignment to group 1 or 2 will then occur. Once assigned to group 1, if consistent signals are found, the participant will then continue to Phase 2.~Phase 2: Group 1 subjects will be provided with a Neurolutions IpsiHand BCI system, which combines a novel powered exoskeleton with a commercial EEG amplifier and active electrode system. The exoskeleton opens and closes the patient's hand in a three-finger pinch grip. Patients will use the BCI system on a minimum of 5 days per week for 12 weeks. Patients will complete five or more 10-minute runs of the BCI task per day."
89676534|NCT05965713|Experimental|Standard of Care - Home Exercise Program for Upper Extremity|"Phase 1: Group 1 subjects will receive an IpsiHand Screening System to complete a remote EEG Screening. Once randomized, the participant will be assigned to group 2 to begin standard of care treatment at home.~Phase 2: After being assigned to Group 2, subjects will serve as the control group in the study. Subjects will receive a customized home range of motion exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks to control for the non-specific motor and sensory effects of BCI training. To help ensure compliance with the at-home portion of the protocol in the control group, participants will receive daily virtual monitoring from the study clinical specialist."
89676535|NCT05965674|Active Comparator|The sacral ESPB group (Group S)|Patients in Group S underwent a procedure where a high-frequency linear ultrasound probe (Clarius, 205-2980 Virtual Way, Vancouver, BC, Canada V5M 4X3 MyLabFive; Esaote Europe BV Philipsweg 1 6227 AJ, Maastricht, the Netherlands) was positioned on the transverse plane, specifically on the fifth spinous process. The probe was then moved downwards to visualize the first and second median sacral crest. Next, the transducer was placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) was injected between the erector spinae muscles and the intermediate sacral crest. The same procedure was performed on the contralateral side.
89676536|NCT05965674|No Intervention|The control group (Group N)|It will not be performed any extra intervention, just rutin clinic protocol.
89676537|NCT05965661|Other|Virtual reality upper limb hand training|The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.
89676538|NCT05965661|Other|Virtual reality control training|The PD patients randomized in the control group will receive virtual reality control training.
88996288|NCT02923258|Experimental|Experimental|Concurrent Chemoradiotherapy With Docetaxel and IMRT
88996289|NCT02923258|Active Comparator|Control|Concurrent Chemoradiotherapy With Cisplatinum and IMRT
88996290|NCT02923297|Other|Parkinson's disease patients|blood sampling
88996291|NCT02923336|Other|Smart pill|Single group, before and after, the same group is going to be its own control
88996292|NCT02923219|Experimental|Stem cells separation|Stem cells separation: The adipose-derived stem cells are separated from vacuumed fat obtained through liposuction of abdomen, hip, thigh and so on. It was confirmed the adipose-derived stem cells can be induced differentiation into fat cells under the special condition in the current literature.Stem cells are used to treat wrinkles and facial rejuvenation.
89215208|NCT04120493|Sham Comparator|Cohorts 1, 2|Imitation (sham) surgery
89215209|NCT04120493|Experimental|Cohort 3|"Low dose rAAV5-miHTT (6x10^12 gc/subject).~High dose rAAV5-miHTT (6x10^13 gc/subject)."
89215210|NCT04106570|Experimental|YOMH|Young obese metabolically healthy Description: Aged from 20 to 40 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l.
89215211|NCT04106570|Experimental|YOMD|"Young obese with metabolic disorders~Description: Aged from 20 to 40 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l."
89215212|NCT04106570|Experimental|MAOMH|"Middle-Age obese metabolically healthy~Description: Aged from 40 to 50 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l."
89215213|NCT04106570|Experimental|MAOMD|Middle-Age obese with metabolic disorders Description: Aged from 40 to 50 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l.
89215214|NCT04106570|Experimental|EOMH|"Elderly obese metabolically healthy~Description: Aged from 50 to 70 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l."
89215215|NCT04106570|Experimental|EOMD|"Elderly obese with metabolic disorders~Description: Aged from 50 to 70 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l."
89215216|NCT04087096|Experimental|Denosumab|Denosumab 60mg subcutaneous injection every 6 months
89215217|NCT04087096|Placebo Comparator|Placebo|Placebo subcutaneous injection every 6 months
89215218|NCT04069299||Participants receiving PET scan|Participants with metastatic poorly-differentiated neuroendocrine carcinomas of the GI tract
89215219|NCT04067297|No Intervention|Control Arm|The 14 communities that are in the control arm of the trial will receive usual standard of care. The usual standard of care will follow clinical daily practice patterns provided by family physicians in Ontario for CVD prevention. This follows the periodic standard of care provided by Canadian cholesterol, hypertension, and diabetes best practice guideline recommendations utilized based on each physician's clinical judgement, physical assessment, and discretion. Patients also typically have access to existing cardiovascular prevention materials offered online through publicly available websites.
89215220|NCT04067297|Experimental|Intervention Arm|The 14 communities that are in the intervention arm of the trial will receive a multicomponent intervention that provides both physicians and patients with access to a 'toolbox' of lipid management resources. The components planned for the 'toolbox' are all evidence-based interventions and chosen after consultations with Canadian family physicians and implementation science experts based on their potential for scalability to the entire population, cost and practicality. Online tools will be used and the trial will leverage pre-existing implementation initiatives (e.g., newsletters, listservs) wherever possible to minimize study costs and increase accessibility.
89215221|NCT04047563|Active Comparator|Normal Saline + Standard of care|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
89215222|NCT04047563|Experimental|PMZ-1620 (sovateltide) + Standard of care|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
89215223|NCT04037397|Active Comparator|Antiarrhythmic Medications|Patients randomized to the antiarrhythmic drug group are administered medications approved for treatment of AF by the regulatory bodies of each participating country. The selection of antiarrhythmic drugs and dosages is left to the discretion of the investigator, and will follow the AHA/ACC/HRS general guidelines
89215224|NCT04037397|Active Comparator|Radio Frequency Catheter Ablation|Patients randomized to radiofrequency catheter ablation will undergo isolation of the pulmonary veins with confirmation of entrance block into each vein. The CARTO TM(Biosense Webster, CA) system will be used to reconstruct the atrial geometry and assist for mapping and ablation. Ablation will be performed using approved ablation devices (Biosense Webster, CA).
89215225|NCT04023045|Active Comparator|Habitual Prosthesis|Participant's prescribed prosthesis
89215226|NCT04023045|Experimental|Assist-Knee|Experimental knee prosthesis
89676539|NCT05965648|Other|Families FORWARD|This is a single-arm trial of a new transition planning program for families of youth on the autism spectrum. The program includes six or seven bi-weekly parent sessions, three of which are optional for the youth to attend. The program will be facilitated by community-based service providers who work with transition-aged youth on the autism spectrum and/or their families.
89676540|NCT05965635|Experimental|Experimental|
89676541|NCT05965622|Experimental|ABFT + TAU|"Attachment Based Family Therapy (ABFT) is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Parent(s)/caregiver(s) will be involved in the therapy.~In the experimental group, patients will receive ABFT as an add-on therapy besides treatment as usual (TAU)."
89676542|NCT05965622|Placebo Comparator|TAU|Treatment as Usual (TAU) contains all regular interventions that are currently used to treat suicidality. In the TAU group, a limited number of systemic family therapy sessions will be given (maximum 4 sessions).
89676543|NCT05965596|Experimental|the intervention group|Participants in the intervention group will receive a psychoeducational intervention program
89676544|NCT05965596|Sham Comparator|the control group|those in the control group will receive the routine care provided for all gynecological cancer patients in the study setting.
89676545|NCT05965453||Participants received thoracic endovascular aortic repair with Castor single branch stent graft|Participants who have an inadequate proximal landing zone received thoracic endovascular aortic repair by meant of the Castor single branch stent graft
89676546|NCT05965388||Chronic hepatitis B patients treated with nucleoside analogues or interferon|Chronic hepatitis B patients treated with nucleoside analogues or interferon
89676547|NCT05965375||Occasional premature ventricular contractions group|Premature ventricular contractions (PVCs) occur when an electrical impulse originates from an ectopic focus within the ventricle or the interventricular septum, causing premature depolarization of the ventricle before the impulse from the sinoatrial node has reached the ventricle. Occasional PVCs refer to PVCs that occur less than 6 times per minute.
89676548|NCT05965375||Frequent premature ventricular contractions group|Premature ventricular contractions (PVCs) occur when an electrical impulse originates from an ectopic focus within the ventricle or the interventricular septum, causing premature depolarization of the ventricle before the impulse from the sinoatrial node has reached the ventricle. Frequent PVCs refer to PVCs that occur more than 6 times per minute.
89215227|NCT04006769|Experimental|Entacapone & Imatinib mesylate|"Entacapone 200mg tablet (Orion pharma,Switzerland) by mouth, three times a day and then escalated to final dose of 1.0 grams three times per day within one week, until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first.~And Imatinib mesylate 400mg tablet by mouth, once a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first."
89215228|NCT03999138||Single Arm|
89215229|NCT03974061|Experimental|Brief Acceptance and Commitment Therapy|Participants randomized to the Acceptance and Commitment Therapy (ACT) arm will receive one, 1-hour intervention session followed by five weekly 30-45 minute intervention sessions delivered via telephone.
89215230|NCT03974061|Active Comparator|Brief Alcohol Intervention|Participants randomized to the Brief Alcohol Intervention (BI) will receive the following telephone-based sessions over the duration of six weeks: a 30-45 minute session of a brief alcohol intervention, a 5-10 minute booster call, a reminder phone call for the next intervention session, a 30-45 minute intervention session, a 5-10 minute booster, and a reminder phone call for the post-treatment appointment.
89215231|NCT03936998|Experimental|vancomycin plus VE416 before PNOIT|active vancomycin plus VE416 before PNOIT
89215232|NCT03936998|Experimental|Vancomycin plus VE416 with PNOIT|active vancomycin plus active VE416 with active PNOIT
89676549|NCT05965375||Short runs of ventricular tachycardia group|Premature ventricular contractions (PVCs) occur when an electrical impulse originates from an ectopic focus within the ventricle or the interventricular septum, causing premature depolarization of the ventricle before the impulse from the sinoatrial node has reached the ventricle. Short runs of ventricular tachycardia refer to three or more consecutive PVCs that occur within 30 seconds.
89676550|NCT05965375||Sustained ventricular tachycardia group|Sustained ventricular tachycardia (VT) is defined as ventricular arrhythmia that lasts for at least 30 seconds and has a heart rate exceeding 100 bpm, or requires termination before 30 seconds due to hemodynamic instability.
89215233|NCT03936998|Experimental|Placebo plus VE416 with PNOIT|placebo vancomycin plus active VE416 with active VE416
89215234|NCT03936998|Active Comparator|Placebo plus placebo with PNOIT|placebo vancomycin and placebo VE416 with active peanut oral immunotherapy
89676551|NCT05965375||Ventricular fibrillation group|Ventricular fibrillation refers to the complete disappearance of QRS waves, ST segments, and T waves in the ECG, replaced by different shapes, varying amplitudes, and extremely irregular ventricular fibrillation waves.
89676552|NCT05965323|Experimental|Intervention|The students in this arm will receive comic books and their parents videos on the benefits of preventive measures of COVID-19
89676553|NCT05965310|No Intervention|Standard Post-Operative Rehabilitation|No intervention, patients will receive the standard level of care.
89676554|NCT05965310|Active Comparator|Virtual Psychological Intervention|An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
89676555|NCT05965297|Experimental|DeltaFil|Class II restorations are placed in primary molars after conventional cavity preparation.
89676556|NCT05965297|Active Comparator|Riva Self Cure HV|Class II restorations are placed in primary molars after conventional cavity preparation.
89676557|NCT05965284|Other|Azathioprine treatment arm|Patients will be treated with Azathioprine 100mg per day for 12 months combined with prednisone no more than 10mg daily. The dosage of prednisone is tapered in the study period while sustained remission achieved. All included patients will be treated with TMPco 2 tablets per day during the study period if not contraindicated or intolerant.
89676558|NCT05965284|Experimental|Telitacicept treatment arm|Patients will be treated with Telitacicept 160mg per week combined with Azathioprine 100mg per day for 12 months combined with prednisone no more than 10mg daily. The dosage of prednisone is tapered in the study period while sustained remission achieved. All included patients will be treated with TMPco 2 tablets per day during the study period if not contraindicated or intolerant.
89676559|NCT05965245|Experimental|Suubi-Mhealth|Participants in this condition will receive the Suubi-Mhealth intervention delivered via a smart phone app.
89676560|NCT05965245|Other|Waitlist Control|Participants in this condition will receive the Suubi-Mhealth intervention after the active treatment group. They will also receive a smart phone without the Suubi-Mhealth app at the same time as the intervention group.
89215235|NCT03917407|Active Comparator|Arm1: DUR-928 treatment for moderate alcoholic hepatitis|Enrolled alcoholic hepatitis patients would have MELD of 11-20; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with moderate alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
89215236|NCT03917407|Active Comparator|Arm 2: DUR-928 treatment for severe alcoholic hepatitis.|Enrolled alcoholic hepatitis patients would have MELD of 21-30; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with severe alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
89215237|NCT03901534|Other|Moderate to Severe OSA - treated|Moderate-to-severe OSA Treated with and adherent to Auto-CPAP
89215238|NCT03901534|Experimental|Moderate to Severe OSA - withdrawal|Moderate-to-severe OSA Withdrawal of Auto-CPAP
89676561|NCT05965206||Intervention group|Participants receive a follow-up phone call from a pharmacist approximately 7 business days after receiving intravenous chemotherapy infusion
89676562|NCT05965206||Control group|Participants do not receive a follow-up phone call from a pharmacist after receiving intravenous chemotherapy infusion
89676563|NCT05965154|Experimental|Carrilizumab combined with bevacizumab plus capecitabine|This study is a one-arm, exploratory study and does not involve randomization.There was only one trial group of carrilizumab plus bevacizumab plus capecitabine.
89676564|NCT05965141|Experimental|Aribulin in combination with carboplatin and bevacizumab|This is a one-arm study without randomization. There was only one trial group of Aribulin combined with carboplatin and bevacizumab.
89676565|NCT05965102|Experimental|Tirelizumab in combination with chemotherapy monotherapy|This study is a one-arm, exploratory study and does not involve randomization. There was only one trial group of tirellizumab plus chemotherapy monotherapy.
89676566|NCT05965076|Active Comparator|Standard|Patients will be professionally treated with standard dental hygiene treatment, and they will use a standard toothbrush for their domiciliary oral hygiene.
89215239|NCT03897673|Experimental|Early Iron|Children in the immediate iron group will receive iron syrup for the first three months (84 days) and placebo syrup for the fourth month.
89215240|NCT03897673|Experimental|Delayed Iron|Children in the delayed iron group will receive placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months.
89215241|NCT03897673|No Intervention|Community Control Children|Healthy, non-anemic community children will be enrolled from the same households and villages as the children with malaria. They will not have ZPP tested or receive iron, but they will also be under the same illness surveillance as the children with malaria.
89215242|NCT03853564|Experimental|Video-Feedback Group (VFG)|Dyads of mothers and their infant with developmental disability who are exposed to the video-feedback intervention focused on different domains of mother-infant quality of interaction (number of sessions: 6).
89215243|NCT03853564|Sham Comparator|Phone-Call Group (PCG)|Dyads of mothers and their infant with developmental disability who are not exposed to the video-feedback intervention, instead they receive phone calls focused on obtaining descriptions of different domains of infant behavioral development (number of sessions: 6)
89215244|NCT03836482|Experimental|Selective Cytopheretic Device|
89215245|NCT03812302|Experimental|DOTATATE|All 15 GCA patients will undergo 68-Ga HA-DOTATATE PET/CT imaging at baseline, in addition to FDG PET/CTA (as part of standard of care). DOTATATE PET/CT imaging will be repeated at 6 months follow-up.
89676567|NCT05965076|Experimental|Glycine|Patients will be professionally treated by adding glycine perio-flow in the treatment, and they will use a standard toothbrush for their domiciliary oral hygiene.
89676568|NCT05965076|Experimental|Angled toothbrush|Patients will be professionally treated with standard dental hygiene treatment, and they will use an angled toothbrush for their domiciliary oral hygiene.
89676569|NCT05965076|Experimental|Glycine - Angled toothbrush|Patients will be professionally treated by adding glycine perio-flow in the treatment, and they will use an angled toothbrush for their domiciliary oral hygiene.
89676570|NCT05965050|Other|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
89676571|NCT05965050|Experimental|Ultrasound Therap|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
89676572|NCT05964985|Placebo Comparator|Normal saline in quadratus lumborum block|After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side.
89676573|NCT05964985|Active Comparator|Ropivacaine in quadratus lumborum block|After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side.
89676574|NCT05964985|Active Comparator|Compound lidocaine in quadratus lumborum block|After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side.
89676575|NCT05964985|Active Comparator|Compound lidocaine and esketamine in quadratus lumborum block|After the induction of anesthesia, 0.6% compound lidocaine and 0.4 mg/kg esketamine are used for bilateral quadratus lumborum block in a volume of 20 mL of each side.
89676576|NCT05964959|Experimental|Intervention|"In the intervention group, the nurse and participant will be using the Mouth Education Program (MEP) to discuss causes, consequences and interventions for dry mouth in a structured manner, ultimately leading to an appropriate, individual treatment plan.~The MEP is based on current clinical, national palliative care guidelines on dry mouth care."
89676577|NCT05964959|Active Comparator|Control|The control group will receive care as usual, provided by their trusted, treating clinicians and care teams. Questionnaires will be administered by researchers.
89676578|NCT05964933|Active Comparator|Complete Pulpotomy|The tooth will be treated with Complete Pulpotomy.
89676579|NCT05964933|Active Comparator|Pulpectomy and Root Canal Treatment|The tooth will be treated with Pulpectomy and Root Canal Treatment.
89676580|NCT05964894|Experimental|Ergonomic training group|The ergonomic training group received a 12-week ergonomic training program.
89676581|NCT05964894|No Intervention|No training group|The no training group did not receive any training program.
89676582|NCT05964803||Males living with HIV|Males living with HIV and followed by infectious diseases clinic will be directed to Urology department.
89676583|NCT05964803||HIV-negative controls|Males admitted to Infectious Diseases clinic and documented to be HIV-negative.
89676584|NCT05964790|Experimental|HS-10380|Participants received HS-10380 tablet orally once daily for 28 days.
89676585|NCT05964790|Placebo Comparator|Placebo|Participants received placebo tablet matching HS-10380 1.5mg tablet orally once daily for 28 days.
89676586|NCT05964777|Active Comparator|Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation|"rTMS and tACS have a profound impact on cognitive impairment.,The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000.~tACS has 5 high-precision targets, the total current is 2mA, and the stimulation frequency is 40hz. Under true stimulation, the current fade in and out time is 10 seconds, and the stimulation time is 30 minutes."
89215246|NCT03803852|Experimental|0°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impress on axis 0°
89215247|NCT03803852|Experimental|45°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impresson axis 45°
89215248|NCT03803852|Experimental|90°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impress on axis 90°
89215249|NCT03803852|Experimental|135°|Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impresson axis 135°
89215250|NCT03792841|Experimental|Part 1 Dose-exploration: acapatamab treatment|Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD.
89215251|NCT03792841|Experimental|Part 1 Dose-expansion: acapatamab treatment|Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D.
89215252|NCT03792841|Experimental|Part 2: acapatamab + Pembrolizumab|Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.
89215253|NCT03792841|Experimental|Part 3: acapatamab + Etanercept Prophylaxis|Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only.
89215254|NCT03792841|Experimental|Part 4: acapatamab 24 Hour Monitoring|Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring.
89215255|NCT03792841|Experimental|Part 5: acapatamab Outpatient Cohort|Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring.
89215256|NCT03792841|Experimental|Part 6: acapatamab + Cytochrome P450 (CYP) Cocktail Drug Interaction|Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.
89215257|NCT03772730||Group 1|Multiply injured patients having at least one operative orthopaedic injury to the pelvis, acetabulum, femur, or diaphyseal tibia with planned definitive fixation to occur prior to discharge.
89215258|NCT03727724|Experimental|Afatinib plus cetuximab|"Afatinib, 40 mg once daily, orally.~Cetuximab, 500 mg/m² intravenously, every 2 weeks.~Treatment will be continued until tumor progression (according RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
89215259|NCT03724110||Pre-Telestroke|Retrospective collection of defined metrics for all TIA patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
89215260|NCT03724110||Post-Telestroke|Prospective collection of defined metrics for all TIA patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
89215261|NCT03714555|Active Comparator|Nab-Paclitaxel/Gemcitabine + DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Nab-Paclitaxel-Gemcitabine with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
89215262|NCT03714555|Active Comparator|FOLFIRINOX +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with FOLFIRINOX and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
89215263|NCT03714555|Active Comparator|Single-Agent Gemcitabine +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Single-Agent Gemcitabine and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
89215264|NCT03701295|Experimental|Treatment (pinometostat, azacitidine)|Patients receive pinometostat IV continuously on days 1-28 and azacitidine IV over 10-40 minutes or SC for 7 of the first 10 days of the cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89215265|NCT03697720|Experimental|Primary Dysmenorrhea|We will look at the effects of naproxen 500mg use on pain starting just before and during menses.
89215266|NCT03635983|Experimental|Combination|NKTR-214 + Nivolumab
89215267|NCT03635983|Experimental|Monotherapy|Nivolumab
89215268|NCT03626662|Placebo Comparator|Placebo|Single Ascending Dose Cohorts
89215269|NCT03626662|Experimental|AMG 890|Single Ascending Dose Cohorts
89215270|NCT03610971|Experimental|Combination Therapy + Remission Phase|"Combination therapy followed by treatment free remission (TFR) phase.~Combination Therapy: Ruxolitinib plus BCR-ABL Tyrosine Kinase Inhibitors (TKIs).~All eligible patients will begin ruxolitinib in combination with their BCR-ABL TKI on cycle 1 day 1 of the combination phase. For cycle 2 and beyond, if day 1 of a cycle is delayed, day 1 procedures should be repeated if out of the specified window and day 1 of the cycle is considered the day study drug is restarted. They will continue combination therapy for a total of 12 cycles. Each cycle will be approximately 28 days.~At the end of 12 cycles ruxolitinib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, participants will discontinue their BCR-ABL TKI and be monitored off treatment."
89215271|NCT03596385|Experimental|Beta-blocker therapy|"This is a strategy (pragmatic) trial. In patients allocated to Beta-blocker therapy, beta blocker agent and dose are decided by treating physician.~betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol"
89215272|NCT03596385|No Intervention|Control (no beta-blocker therapy).|Do not receive beta -blocker therapy
89215273|NCT03564197|Other|Nivolumab|nivolumab containing treatment according to label
89215274|NCT03549000|Experimental|NZV930 Monotherapy|Single Agent NZV930
89215275|NCT03549000|Experimental|NZV930 with PDR001 Doublet Therapy|Combination of NZV930 with PDR001
89215276|NCT03549000|Experimental|NZV930 with NIR178 Doublet Therapy|Combination of NZV930 with NIR178
89215277|NCT03549000|Experimental|NZV930 with NIR178 & PDR001 Triplet Therapy|Combination of NZV930 with NIR178 and PDR001
89676587|NCT05964777|Placebo Comparator|Repetitive Transcranial magnetic stimulation and sham transcranial alternating current stimulation|"the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000.~tACS has 5 high-precision targets, the total current is 2mA, and the stimulation frequency is 40hz. Under sham stimulation, the current fade in and out time is 10 seconds, the other 29 minutes and 40 seconds, no real current passes through."
89215278|NCT03517449|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
89215279|NCT03517449|Active Comparator|Treatment of Physician's Choice|Participants will receive either of the following treatments: doxorubicin 60 milligram per square meter (mg/m^2) administered by IV on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m^2 OR paclitaxel 80 mg/m^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
89676588|NCT05964777|Placebo Comparator|Sham repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation|"The stimulus intensity was 20% of MT in the ShamComparator arm, and the remaining parameters were the same as the Active Comparator arm.~tACS has 5 high-precision targets, the total current is 2mA, and the stimulation frequency is 40hz. Under true stimulation, the current fade in and out time is 10 seconds, and the stimulation time is 30 minutes."
89676589|NCT05964751||patinets with lupus nephritis|patients diagnosed as lupus nehpritis
89676590|NCT05964751||pathents without lupus nephritis|sle pathients not diagnosed as lupus nephritis
89676591|NCT05964751||controls|controls will be matched for sex, age, and level of schooling withot history of connective tissue disorders, systemic active disease and renal history
89676592|NCT05964738|Experimental|Diuretics withdrawal|
89676593|NCT05964738|Active Comparator|Diuretics maintenance|
89676594|NCT05964660||VT Patients|Patients with indication for catheter ablation of ventricular arrhythmia and preprocedural contrast-enhanced cardiac computed tomography for cardiac structure characterization.
89676595|NCT05964634||myopic glaucoma|Patiens who have high myopia with primary open angle glaucoma
89676596|NCT05964634||healthy myopia|Patiens who have high myopia without primary open angle glaucoma
89676597|NCT05964608|Experimental|Treatment group|"Pre-tests were applied to the men (Personal Information Form and PEDT) and their spouses (Personal Information Form, FSFI, and SQOL-F) just before the behavioral treatment was applied to the men in the treatment group. In the first interview with the men, the researchers delivered information about behavioral therapy and set therapy days and hours. Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed."
89676598|NCT05964556||Functional Movement Screen and Isokinetic Muscle Evulation of Knee Muscles|Functional movement screen was evaluated with 7 basic parameters determined by Gray Cook Isokinetic muscle measurements were performed with an ISOMED 2000
89676599|NCT05964543|Experimental|Phase Ib: Dose escalation Q-1802+XELOX,|"According to 3+3 design, a dose of Q-1802 with two dose groups from low to high and one cycle fixed-dose XELOX will be given in DLT observation period. After DLT observation period, Q-1802+XELOX will be given by investigator,s decision until the subject meets study treatment discontinuation criteria."
89676600|NCT05964543|Placebo Comparator|Phase II: Q-1802 + XELOX Vs XELOX ;|Phase II:Participants will be randomized to group A and B. Group A:receive a dose of Q-1802 at Cycle 1 Day 1 followed by a same dose in subsequent cycles every 2 weeks. Additionally, participants will receive XELOX (capecitabine/oxaliplatin) treatment until investigator confirmed disease progression or a total of 8 treatments (each cycle is defined as approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive Q-1802 a every 2 weeks each cycle and capecitabine every 3 weeks at the investigator's discretion until the subject meets study treatment discontinuation criteria. Group B:Participants will receive XELOX (capecitabine/oxaliplatin) treatment alone until a total of 8 treatments (each cycle is defined as approximately 21 days). subjects may continue to receive capecitabine every 3 weeks at the investigator's discretion.
89676601|NCT05964530|Experimental|Watch and wait group|In this group, the patients with clinically complete response will undergo non-surgical treatment (watch-and-wait group)
89676602|NCT05964530|Active Comparator|Surgical group|In this group, the patients with clinically complete response will undergo surgical treatment (LAR with anal preservation or APR)
89676603|NCT05964439|Experimental|HoloUS app for ultrasound visualization|This is a single-arm study. Each study participant will evaluate HoloUS app and serve as their own control.
89676604|NCT05964426||Parent and Infant Information Form|This form consists of a total of 19 questions in line with the literature, including the parents' age, education level, family type, place of residence, whether they have other children, how many days their baby is, gender of the baby, maternal blood type, paternal blood type, and whether the baby is given formula in addition.
89676605|NCT05964426||Parent Information Form on Neonatal Jaundice|This form consists of a total of 6 questions in line with the literature, including whether the parent has sufficient information about neonatal jaundice, from whom he/she received the information, what his/her reaction will be if his/her baby gets jaundice, and information about the causes, symptoms and side effects of jaundice.
89676606|NCT05964426||Turkey Health Literacy Scale (TSOY-32)|It is a 32-question scale developed based on the Conceptual Framework of the European Health Literacy Scale Study. The Turkish Health Literacy Scale (TSOY-32) was developed to assess health literacy in literate people over the age of fifteen. Unlike the original scale, the scale consists of eight components including two dimensions (treatment and service, disease prevention and health promotion) and four processes (accessing health-related information, understanding health-related information, evaluating health-related information, and using/applying health-related information). The overall internal consistency coefficient of the scale was 0.92. The Cronbach's alpha coefficient of the first dimension 'Treatment and Service Subdimension' is 0.88. The Cronbach's alpha coefficient of the second dimension 'Disease Prevention and Health Promotion Dimension' is 0.86. Permission to use the scale was obtained.
89676607|NCT05964023|Experimental|pBFS rTMS|3 sessions of active rTMS would be delivered to the pBFS-guided left DLPFC daily, with a session of 1800 pulse.
89676608|NCT05964023|Active Comparator|5-cm rTMS|"3 sessions of active rTMS would be delivered to the 5-cm rule guided left DLPFC daily, with a session of 1800 pulse."
89676609|NCT05963360||Frailty in Older people|Older people, 50 and above.
89676610|NCT05963269|Active Comparator|Students receiving computer game support in intramuscular injection learning|After learning intramuscular injection with demonstration, a group of students reinforcing intramuscular injection training for 1 week with a computer-assisted game designed by the researcher.
89676611|NCT05963269|No Intervention|Group of students learning intramuscular injection only by demonstration|Group of students learning intramuscular injection by demonstration method without computer-assisted games
89676612|NCT05961644|Experimental|Experimental|Drug: Cladribine at a dose of 1.8 mg/kg of body weight. Cladribine will be given subcutaneously over 6 visits every 5-6 weeks.
89676613|NCT05961644|Placebo Comparator|Control|Comparator: Placebo matched to the subcutaneous injection of cladribine.
89676614|NCT05961631||Positive Fluid Balance 500ml or more|Fluid Balance measured using Bio-electrical Impedance Analysis
89676615|NCT05961631||Fluid Balance 500ml or less|Fluid Balance measured using Bio-electrical Impedance Analysis
89676616|NCT05958433|Active Comparator|standard postoperative education.|These patients will receive stoma care and stoma education beginning on postoperative day1.
89676617|NCT05958433|Experimental|preoperative rehabilitation group|The rehabilitation group will receive preoperative stoma education in addition
89676618|NCT05958355|Experimental|Functional postural control training|The training includes (1) Maintaining a stationary posture in a standing position for a total of 10 minutes, (2) Posture control training involving unilateral lower limb stepping movements for a total of 10 minutes, and (3) Advanced walking task training, including sudden stops, turns, ball raises, and obstacle crossing during walking, for a total of 10 minutes.
89676619|NCT05958355|Active Comparator|Treadmill training|The subjects in the control group performed a 30-minute walking session on a treadmill at a self-selected speed.
89676620|NCT05939245|Experimental|Administration of continuous furosemide intravenous|
89676621|NCT05939245|Placebo Comparator|Administration of continuous placebo intravenous|
89676622|NCT05937451|Active Comparator|Intervention group|The intervention group receives the prediction results daily until the patient is discharged or up to 7 days after admission.
89676623|NCT05937451|No Intervention|Usual care group|The usual-care group does not receive analysis results. The user-care group continues the existing treatment.
89676624|NCT05934877|Experimental|ASK-PrEP|"ASK-PrEP is a 5-session PrEP navigation intervention, with text-messaging support, to advance through the PrEP Care Continuum by identifying the individual needs and barriers to PrEP care, including substance use and behavioral health needs; adherence goal(s); and methods to achieve adherence.~Intervention/treatment: PrEP navigation + text messaging Participants receive 5 PrEP navigation sessions within 3 months plus a weekly culturally specific, scripted text message. Participants that do not respond to the ASK-PrEP intervention at the 3-month assessment are re-randomized (1:1) and stepped up to receive ASK-PrEP plus CM or CM alone."
89676625|NCT05934877|Experimental|Education and Information|"The Standard of Care (SOC) intervention includes a 20-30-minute session of PrEP information and where to access PrEP in Los Angeles. The same session is repeated at the 3-month assessment.~Participants randomized to the SOC arm receive 2 educational/informational sessions on PrEP misconceptions, uptake, and adherence. The sessions occur at baseline and the 3-month assessment."
89676626|NCT05934578|Experimental|Fontan Group - Exercise Training|Online rehabilitation: 36 sessions of aerobic exercise training for two months
89676627|NCT05934578|No Intervention|Fontan Control Group - No Exercise Training|Patients will not participate in the exercise program and will continue with their usual routine.
89676628|NCT05925439|Experimental|Tuohy needle group|Ultrasound-guided S1 transforaminal epidural block with Touhy needle
89676629|NCT05925439|Active Comparator|Quincke needle group|Ultrasound-guided S1 transforaminal epidural block with Quincke needle
89676630|NCT05899933|Experimental|Implantoplasty group|6 weeks after completion of non-surgical peri-implant therapy, participants with peri-implant probing pocket depth ≥ 5mm and presence of bleeding on probing and/or suppuration will receive resective surgical treatment. Implantoplasty will be applied as an implant surface modification method.
89676631|NCT05899933|Experimental|Erythritol Air-abrasive device group|6 weeks after completion of non-surgical peri-implant therapy, participants with peri-implant probing pocket depth ≥ 5mm and presence of bleeding on probing and/or suppuration will receive resective surgical treatment. Implant surface decontamination with an air-abrasive device with erythritol powder will be applied.
89676632|NCT05899933|Other|Control group|Participants with healthy implants will be the comparator group for the microbiological analysis.
89676633|NCT05890417|Experimental|Questionnaires|Female Sexual Function Index (FSFI) and WHO Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and at 6 months after starting hormone replacement therapy.
89676634|NCT05888246|Experimental|Diagnostic test|Diagnostic test: magnetocardiogram.
89676635|NCT05884814|Placebo Comparator|Control|Habitual physical activity
89676636|NCT05884814|Active Comparator|Morning exercise|Exercise training between 6-10am
89676637|NCT05884814|Active Comparator|Afternoon exercise|Exercise training between 4-8pm
89676638|NCT05878925|Experimental|Aroma|Preterm infants on CPAP support will be exposed to either vanilla or strawberry aroma. A pen with and without vanilla or strawberry aroma will be used to apply the aroma to the inner surface of the CPAP mask.
89676639|NCT05878925|Placebo Comparator|Control|Preterm infants on CPAP support will be exposed to placebo. The placebo pen will contain the carrier solution and natural coloring agents but no aroma.
89676640|NCT05878730||good-responders (GR) to lithium in euthymic BD-1 individuals|
89676641|NCT05878730||non-responders (NR) to lithium in euthymic BD-1 individuals|
89676642|NCT05858463|Experimental|Intervention group|High Intensity Interval training: 1 min at maximal workload followed by 1 min rest, repeated during a maximum of 40 min.
89676643|NCT05858463|Active Comparator|Control group|Low intensity continuous exercise training set at the level of the ventilatory threshold, lasting for a maximum of 40 min
89676644|NCT05834790|Experimental|MAR group|The participants in this group will attend the MAR oral health education program
89676645|NCT05834790|Active Comparator|lecture-based group|The participants in this group will attend the lecture oral health education program
89676646|NCT05834790|No Intervention|controlled group|The participants in this group will not attend any oral health education program
89215280|NCT03480360|Other|Johns Hopkins' conditioning regimen|Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant
89215281|NCT03452826|Experimental|Antibiotic therapy according to the result of mPCR|Combined use of a respiratory broad panel Multiplex polymerase chain reaction (mPCR) (performed on a lower respiratory tract sample : bronchoalveolar lavage fluid or tracheal aspirate, otherwise sputum) and procalcitonin.
89215282|NCT03452826|No Intervention|Antibiotic therapy at discretion of ICU physicians|Antibiotic therapy at discretion of ICU physicians
89215283|NCT03444948|Experimental|3 radiofrequency ablation procedures|Subject will undergo 3 radiofrequency ablation procedures at 1 month intervals (EUS-RFA using Habib Tm as a probe)
89676647|NCT05824078|Active Comparator|Open procedure|"The study intervention involved in this project is the randomized allocation of the patient who requires surgical treatment of their perilunate injury to receive either an open or arthroscopic approach for the procedure.~Once the patient is in agreement to have surgery and has consented to partake in the study, they will be randomly allocated to either open perilunate surgery or arthroscopic perilunate surgery.~Both surgical approaches are well-recognized, common, standard-of-care procedures."
89676648|NCT05824078|Active Comparator|Arthroscopic Procedure|"The study intervention involved in this project is the randomized allocation of the patient who requires surgical treatment of their perilunate injury to receive either an open or arthroscopic approach for the procedure.~Once the patient is in agreement to have surgery and has consented to partake in the study, they will be randomly allocated to either open perilunate surgery or arthroscopic perilunate surgery.~Both surgical approaches are well-recognized, common, standard-of-care procedures."
89676649|NCT05808686|Sham Comparator|Ischemic Conditioning-Low|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-Low group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 10 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
89215284|NCT03444948|Active Comparator|standard medical care|Subject will receive standard medical care, including pain relief drugs
89215285|NCT03434548||Cohort 1|Healthy controls. Multi-modal MRI imaging.
89215286|NCT03434548||Cohort 2|"People with Huntington's (without symptoms, early disease stage, and later disease stage), and healthy controls~People with HD divided in groups according to disease stage:~Without symptoms (approximately HD-ISS stage 0 or 1)~Early disease (approximately HD-ISS stage 2)~Later disease stage (approximately HD-ISS stage 3)"
89215287|NCT03422783|Experimental|Included patients|There is only one arm in this study. Intervention will be electrical forearm stimulus under general anesthesia and the response of NOL index following this stimulus and its correlation with postoperative parameters such as pain and opioid consumption in post anesthesia care unit.
89215288|NCT03410836|Experimental|intravenous lidocaine (IVL)|Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.
89215289|NCT03410836|Placebo Comparator|Placebo|Will receive the same volume of normal saline for the entire duration of anesthesia.
89215290|NCT03390595|Experimental|Avelumab plus gemcitabine/carboplatin|2 cycles of induction avelumab 10mg/kg every 2 weeks followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.
89215291|NCT03390595|Active Comparator|Gemcitabine/carboplatin alone|patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.
89215292|NCT03387761|Experimental|Cohort 1: Ipi + Nivo|"Day 1: Ipilimumab 3 mg/kg i.v.~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v."
89215293|NCT03387761|Experimental|Cohort 2a: high-Ipi + low-Nivo|"Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v.~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
89215294|NCT03387761|Experimental|Cohort 2b: low-Ipi + high-Nivo|"Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v.~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
89215295|NCT03367312|Experimental|Pulmonary Hypertension Patients on Inhaled Prostacyclin|10 subjects will Pulmonary Hypertension on a stable dose of Inhaled Prostacyclin for treatment of PH.
89215296|NCT03354169|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
89215297|NCT03354169|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
89215298|NCT03325946||Children and Adults with Cerebral Palsy|
89215299|NCT03325946||Children and Adults with Microcephaly|
89215300|NCT03325946||Children and Adults with other Neuromotor Impairments|
89215301|NCT03325946||Children who have had a stroke|
89215302|NCT03288545|Experimental|EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L|Dose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
89215303|NCT03288545|Experimental|Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
89215304|NCT03288545|Experimental|Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
89676650|NCT05808686|Experimental|Ischemic Conditioning-High|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
89676651|NCT05803343|Experimental|Regulating Together-Canine (RT-Canine)|Participants in this Arm will receive the Regulating Together-Canine intervention.
89676652|NCT05803343|Active Comparator|Regulating Together-Standard (RT-Standard)|Participants in this Arm will receive the Regulating Together-Standard intervention.
89676653|NCT05783921|Experimental|TQB2618 injection +Penpulimab injection+Chemotherapy (Paclitaxel+Cisplatin or Carboplatin)|TQB2618 injection combined with Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, 21 days as a treatment cycle. After 4~6 cycles, TQB2618 injection combined with Penpulimab injection, 21 days as a treatment cycle.
89676654|NCT05783921|Active Comparator|Penpulimab injection + Chemotherapy (Paclitaxel+Cisplatin or Carboplatin)|Penpulimab injection combined with Paclitaxel, Cisplatin or Carboplatin, 21 days as a treatment cycle. After 4~6 cycles, Penpulimab injection, 21 days as a treatment cycle.
89676655|NCT05775042|Experimental|Group A|CM338 will be injected subcutaneously.
89676656|NCT05775042|Experimental|Group B|CM338 will be injected subcutaneously.
89676657|NCT05775042|Experimental|Group C|CM338 will be injected subcutaneously.
89676658|NCT05745298|Experimental|AFES and RMT Paraplegia Group|Patients with a diagnosis of paraplegia will receive co-treatment with abdominal functional electrical stimulation (AFES) and respiratory muscle training (RMT) for 2 weeks.
89676659|NCT05745298|Experimental|AFES and RMT Tetraplegia Group|Patients with a diagnosis of tetraplegia will receive co-treatment with abdominal functional electrical stimulation (AFES) and respiratory muscle training (RMT) for 4 weeks.
89676660|NCT05740098|Experimental|Best practices|Participants will receive the Five As plus a referral to a quit line.
89676661|NCT05740098|Experimental|Best practices and financial incentives|Participants will receive the Five As, a referral to a quit line, and financial incentives contingent on biochemically confirmed smoking abstinence
89676662|NCT05740098|Experimental|Best practices, financial incentives, and NRT|Participants will receive the Five As, a referral to a quit line, financial incentives contingent on biochemically confirmed smoking abstinence, and nicotine replacement therapy (NRT) provided in the form of both nicotine patches and gum/lozenge for dual therapy.
89676663|NCT05730413|Active Comparator|Once Daily Regimen|Patients who take bisoprolol 5 mg per day.
89676664|NCT05730413|Experimental|Twice Daily Regimen|Patients who take bisoprolol 2.5 mg twice per day.
89676665|NCT05720455|Experimental|Fexofenadine HCL + pseudoephedrine HCL|Participants will take a tablet containing fexofenadine 60 mg and pseudoephedrine 120 mg twice daily for 10 days (+/- 3 days based on investigator's clinical judgement)
89676666|NCT05702450|Experimental|Group P1|CM310, Subcutaneous
89676667|NCT05702450|Active Comparator|Group P2|CM310, Subcutaneous, as the parallel control group
89676668|NCT05679557|No Intervention|Conventional|"Perioperative care as usual according to exciting principles and guidelines"
89676669|NCT05679557|Experimental|Geriatric|Perioperative geriatric assessment and tailored interventions in relation to radical cystectomy.
89676670|NCT05648955|Experimental|Test product|An enriched high protein and high energy oral nutrition supplement (ONS)
89676671|NCT05648955|Active Comparator|Control product|standard isocaloric high energy normal protein isocaloric ONS
89676672|NCT05641753|Experimental|4-Week LDL-Cholesterol (LDL-C)-Reduction Treatment|"Treatment consists of: Evolocumab (140 mg; 2 injections, one administered at baseline visit and another self-administered 2 weeks later), and; Atorvastatin (up to 80mg dose; 1 tab per day for 30 days, starting at baseline visit post-assessment). Participants with statin intolerance will be provided with a 1-month supply of ezetimibe 10 mg to replace Evolocumab and Atorvastatin.~Additional procedures: Blood draws.~Optional procedures: Glycocalyx testing, PET/CT, or Endothelial Cell Collection."
89676673|NCT05627700|Experimental|AVL200 IOL|The AVL200 is a modular fluid-filled, shape-changing intraocular lens (IOL) designed to restore visual function across a range of focal points
89676674|NCT05626621|Active Comparator|Azelastine and Mometasone Nasal Spray|The study intervention will be saline irrigation (240 mL) followed by azelastine spray (137 mcg/spray) and mometasone spray (50 mcg/spray). Participants will have to dissolve the salt packet in a 240 mL sinus rinse bottle to create the saline solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the saline solution for each side followed by 2 sprays per nostril of both of the nasal sprays.
89676675|NCT05626621|Experimental|Mometasone Nasal Irrigation|The study intervention will be mometasone (1 mg/capsule). Participants will be required to dissolve the contents of the capsule into a 240 mL sinus rinse bottle along with the salt packet to create the rinse solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the rinse solution for each side.
89676676|NCT05626621|Experimental|Azelastine and Mometasone Nasal Irrigation|The study intervention will be azelastine (1mg) and mometasone (1 mg). The azelastine and mometasone will be provided in one capsule identical to the mometasone capsule. Participants will be required to dissolve the contents of the capsule into a 240 mL sinus rinse bottle along with the salt packet to create the rinse solution. All participants will be instructed to perform the following twice a day: irrigation of right and left nasal cavity with half of the rinse solution for each side.
89676677|NCT05624931|Experimental|Treatment Condition: Brief CBT-Based Intervention|This group (n=30) will be guided through an adaptation of Life Steps, a single-session, cognitive behavioral therapy (CBT)-based medication adherence intervention that has been used to increase PrEP adherence. Participants will also receive four additional intervention sessions.
89676678|NCT05624931|Active Comparator|Control Condition: Enhanced Treatment as Usual|Participants randomized to the control condition (n= 30) will receive enhanced treated as usual.
89676679|NCT05602740||MINDRHYTHM HARMONY|Passive Recording of the head pulse
89676680|NCT05593094|Experimental|ZN-A-1041 50mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle"
89676681|NCT05593094|Experimental|ZN-A-1041 100mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle"
89676682|NCT05593094|Experimental|ZN-A-1041 200mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle"
89676683|NCT05593094|Experimental|ZN-A-1041 400mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle"
89676684|NCT05593094|Experimental|ZN-A-1041 600mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle"
89676685|NCT05593094|Experimental|ZN-A-1041 800mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle"
89676686|NCT05593094|Experimental|ZN-A-1041 1000mg|"Phase 1a:~Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle"
89676687|NCT05593094|Experimental|1b: ZN-A-1041 + T-DM1 3.6 mg/kg iv.|"Phase 1b Arm1:~If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
89676688|NCT05593094|Experimental|1b: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.|"Phase 1b Arm2:~If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
89676689|NCT05593094|Experimental|1b: ZN-A-1041 + PHESGO / Herceptin plus Perjeta|"Phase 1b Arm3:~If the MTD of ZN-A-1041 is identified in Phase 1a study: The 2 tentative dose levels of ZN-A-1041 are MTD-1 (Level 1) and MTD (Level 2)~If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level of ZN-A-1041 in Phase 1a will be used in Phase 1b study."
89676690|NCT05593094|Experimental|1c: ZN-A-1041 + T-DM1 3.6 mg/kg iv.|"Phase 1c Arm1:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
89676691|NCT05593094|Experimental|1c: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.|"Phase 1c Arm2:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
89676692|NCT05593094|Experimental|1c: ZN-A-1041 + Herceptin plus Perjeta/PHESGO|"Phase 1c Arm3:~The dose levels of ZN-A-1041 in the Phase 1c study will be the recommended doses determined in the Phase 1b study."
89676693|NCT05591118|Experimental|Catheter-Directed Therapy (CDT) plus Anticoagulation|Participants will receive CDT consisting of mechanical thrombectomy (MT) or intrathrombus catheter-directed thrombolysis (CDL) using FDA-cleared devices for pulmonary embolism (PE). The exact technique and devices used will be at the discretion of the endovascular physician, within parameters defined by the PE-TRACT Manual of Operations (MOP) and accepted standard care. Before and after CDT, patients will receive standard PE therapy as in the no-CDT Arm.
89676694|NCT05591118|Active Comparator|No Catheter-Directed Therapy (No-CDT)|Standard anticoagulant therapy (FDA-approved regimen) for the treatment of PE.
89676695|NCT05590403|Experimental|Adults HA-RSV Group|Healthy adults (HA) 50-59 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.
89676696|NCT05590403|Placebo Comparator|Adults HA-Placebo Group|HA 50-59 YOA, who receive 1 dose of placebo at Day 1.
89676697|NCT05590403|Experimental|Adults AIR-RSV Group|Adults at increased risk (AIR) 50-59 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.
89676698|NCT05590403|Placebo Comparator|Adults AIR-Placebo Group|Adults AIR 50-59 YOA, who receive 1 dose of placebo at Day 1.
89676699|NCT05590403|Experimental|OA-RSV Group|Older adults (OA) ≥60 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.
89676700|NCT05577728||New use of semaglutide injection|Exposure group
89676701|NCT05577728||"New initiation of standard of care"|(SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) Reference group
89676702|NCT05577156||Patients|
89676703|NCT05575817|Experimental|Patient online grief tutorial|Participants will be given access to an online 9-module interactive tutorial about grief to be used in conjunction with a course of Prolonged Grief Disorder Therapy.
89676704|NCT05551845||Subject use both KD-595 Arm Automatic Electronic BPM and mercury sphygmomanometers|
89676705|NCT05541276|Experimental|Melatonin|Participants receive melatonin solution for injection 1 mg/mL in a dosage of 0.15 mg/kg body weight as a single intravenous injection approximately 30 minutes before end of surgical procedure.
89676706|NCT05541276|Placebo Comparator|Placebo|Participants receive isotonic sodium chloride (9mg/mL) intravenously once approximately 30 minutes before end of surgical procedure in a volume equivalent to the melatonin group for the same weight.
89676707|NCT05517174|Experimental|High-Dose Quadrivalent Influenza Vaccine|QIV-HD single injection at Day 0
89676708|NCT05517174|Active Comparator|Standard-Dose Quadrivalent Influenza Vaccine|QIV-SD single injection at Day 0
89676709|NCT05498493|Experimental|Cognitive Rehabilitation|Active Group participants will receive nine 1.5-h sessions of virtual (via Zoom platform) group-based training, three individual virtual 1-h training sessions, and approximately 20 h of home practice and CCT over 12 weeks.
89676710|NCT05498493|Active Comparator|Brain Health Education Program|The control group format will be twelve 1.5 or 1 h virtual sessions over 12 weeks, in addition to 20 h of home practice of a computerized control program (e.g., consisting of publicly available computer games such as sudoku and crossword puzzles).
89676711|NCT05493761|Experimental|"Denosumab"|35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive denosumab.
89676712|NCT05493761|Active Comparator|"Alendronate"|35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive alendronate.
89676713|NCT05492994|Experimental|Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
89676714|NCT05487664|Active Comparator|Auricular Neurostimulation (Active 1)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-ABVN Only stimulation (15Hz stimulation of cymba conchae)"
89676715|NCT05487664|Active Comparator|Auricular Neurostimulation (Active 2)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-ATNS Only stimulation (100Hz stimulation of the tragus)"
89215305|NCT03288545|Experimental|Cohort D: Enfortumab Vedotin + Cisplatin in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days
89676716|NCT05487664|Active Comparator|Auricular Neurostimulation (Active 3)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Combo stimulation (stimulation of both the 15Hz cymba conchae and 100HZ tragus)"
89676717|NCT05487664|Sham Comparator|Auricular Neurostimulation (Sham 1)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Sham (15Hz stimulation of the earlobe)"
89676718|NCT05487664|Sham Comparator|Auricular Neurostimulation (Sham 2)|"•Within the MRI scanner, each participant will be connected to a series of tAN electrodes that stimulate the following ear target~-Sham (100Hz stimulation of the earlobe)"
89676719|NCT05480228|Experimental|NRD135S.E1 80mg/day|NRD135S.E1 as a potential treatment for moderate to severe painful diabetic peripheral neuropathy (PDPN). While the activity of NRD135S.E1 has been extensively studied, its molecular target is not known, though it does not appear to work through any of the opioid receptors or molecular pathways currently targeted by available analgesics. The best evidence suggests it may act, at least in part, through modulating the Lyn kinase signaling pathway In clinical studies, NRD135S.E1 has been well tolerated at all dose levels tested in single-dose (up to 1,200 mg) and repeat-dose regimens (up to 300 mg/day over 5 days or 150 mg over 3 weeks), and it has been shown to have predictable pharmacokinetics with dose-dependent increases in exposure.
89676720|NCT05480228|Placebo Comparator|Matching placebo|A matching placebo comparator will be used.
89676721|NCT05474339|Experimental|Cardiac rehabilitation group|
89676722|NCT05474339|No Intervention|Control group|
89676723|NCT05463796||HEREDITARY RISK|"Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data.~Tissue samples will be collected during a routine visit.~Participants will be asked to donate any of the following tissue types:~Blood~Buccal swab (saliva) or mouthwash~Urine~Stool~Biopsy or surgical tissue (i.e., bone marrow)~Bodily fluids~Other tissues"
89676724|NCT05463796||EXPOSED HIGH RISK|"Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data.~Tissue samples will be collected during a routine visit.~Participants will be asked to donate any of the following tissue types:~Blood~Buccal swab (saliva) or mouthwash~Urine~Stool~Biopsy or surgical tissue (i.e., bone marrow)~Bodily fluids~Other tissues"
89676725|NCT05463796||PRECURSOR LESIONS|"Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data.~Tissue samples will be collected during a routine visit.~Participants will be asked to donate any of the following tissue types:~Blood~Buccal swab (saliva) or mouthwash~Urine~Stool~Biopsy or surgical tissue (i.e., bone marrow)~Bodily fluids~Other tissues"
89676726|NCT05463796||FAMILY MEMBERS|These family members will be identified by the patients participating in the study. Blood, buccal cells, or saliva or oral rinses will be collected in one of three ways from family members of patients (i) at the time of consent; (ii) via a mailed blood kit or saliva kit; or (iii) at a separate appointment scheduled by the consented participant
89676727|NCT05455827|Experimental|Intervention A|Enhancing condition differences between guilt and indignation BOLD activations of subgenual anterior cingulate cortex.
89676728|NCT05455827|Active Comparator|Intervention B|Minimising condition differences between guilt and indignation BOLD activations of subgenual anterior cingulate cortex.
89676729|NCT05451641|Experimental|Wide-rigid cuff|The wide-rigid cuff will be randomly assigned to one of the subject's arms.
89676730|NCT05451641|Experimental|Narrow-elastic band|The narrow-elastic band will be randomly assigned to another arm of the subject.
89676731|NCT05439057|Experimental|Remimazolam group|Remimazolam is started during induction of anesthesia at the rate of 0.3 mg/kg/hr and stopped 20 minutes before end of operation.
89676732|NCT05439057|Placebo Comparator|Control group|0.9% normal saline is started during induction of anesthesia at the rate of 0.3 ml/kg/hr and stopped 20 minutes before end of operation.
89676733|NCT05434663|Experimental|Treatment Group|
89676734|NCT05434351||Chinese women with moderate to severe symptoms of genitourinary syndrome of menopause|It is a single-group study.
89676735|NCT05418478|Experimental|Intervention group|"Study group intervention: 7 sessions of transtheoretical model-based interview (2 in the first month, a total of 7 times, once a month), a structured disease education through transtheoretical model-based telehealth practices, and 6-month follow-up.~After the participants are included in the study, a health education structured according to the Transtheoretical model will be given to the patients in the study group through tele-health applications.~The patients in the intervention group will be trained through tele-health practices for at least 25-30 minutes on a transtheoretical basis, every 2 weeks in the first month and once a month in the following months. Tele-health applications include phone monitoring, SMS notification and application applications.~In the 6-month follow-up, there will be 2 follow-ups as pre-test (1st month) and post-test (6th month).~Behavioral: 7 sessions of behavior change training based on the transtoerytic model"
89676736|NCT05418478|No Intervention|Control|"No notification will be made to the relatives of the patients in the control group. Control group patients will be called for routine control in line with their usual plans. After a total of 6 months from the beginning, the self-care and treatment compliance levels of the patients in the control group will be examined.~There will be 2 follow-ups as pre-test (1st month) and post-test (6th month)."
89676737|NCT05408468|Experimental|FAMCOPE-ICU|A digital eHealth emotion regulation and coping intervention.
89676738|NCT05408468|No Intervention|Usual Care|The care and support routinely provided to SDMs of critically ill patients.
89676739|NCT05405673||Colorectal neoplasia screening/surveillance cohort|Subjects with average risk of colorectal neoplasias requiring screening/surveillance colonoscopy
89676740|NCT05405257|Placebo Comparator|Placebo|Placebo infusion: IV 0.9% NaCl, rate is 200ml over 40 minutes. Total of three infusions in three consecutive days (one per day)
89676741|NCT05405257|Active Comparator|Oxytocin|Treatment infusion: IV 1IU Oxytocin in 200ml of 0.9% NaCl, rate is 200ml over 40 minutes. Total of three infusions in three consecutive days (one per day)
89215306|NCT03288545|Experimental|Cohort E: Enfortumab Vedotin + Carboplatin in 1L|Enfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days
89215307|NCT03288545|Experimental|Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L|Enfortumab vedotin and gemcitabine on days 1 and 8 every 21 days
89215308|NCT03288545|Experimental|Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L|Enfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days
89215309|NCT03288545|Experimental|Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 every 21 days
89215310|NCT03288545|Experimental|Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
89676742|NCT05401292|Active Comparator|Iodine or Chlorhexidine Preparation|Standard of care with only skin preparation of iodine or chlorhexidine solution prior to sterile draping before surgery.
89676743|NCT05401292|Active Comparator|Iodine or Chlorhexidine Scrub Brush Pre-Scrub with Isopropyl Alcohol and Chlorhexidine Soap|"In addition to standard of care skin preparation with iodine or chlorhexidine solution prior to sterile draping, patients will also receive an additional pre-scrub with isopropyl alcohol and chlorhexidine soap. The operative extremity will be scrubbed for 2 minutes with chlorhexidine soap with a scrub brush until the entire extremity is covered. Isopropyl alcohol will then be wiped onto the skin with a gauze and allowed to evaporate (dry)."
89676744|NCT05394545|Experimental|Nu-V3 treatment arm|Treatment with the Nu-V3 Device.
89676745|NCT05394545|No Intervention|Observation treatment arm (SOC, control)|Observation following stable standard of care.
89676746|NCT05381740|Experimental|cHMC rTMS + Upper Limb Training Training|Real Repetitive Transcranial Magnetic Stimulation given to facilitate the Contralesional Higher Motor Cortices+ Upper Limb Training
89676747|NCT05381740|Sham Comparator|Sham rTMS + Upper Limb Training Training|Sham Repetitive Transcranial Magnetic Stimulation over Contralesional Higher Motor Cortices+ Upper Limb Training
89676748|NCT05375630|Placebo Comparator|Placebo|micro-crystalline cellulose placebo (one 380 mg tablet per day)
89676749|NCT05375630|Active Comparator|Vitamin K2|micro-crystalline cellulose (one 380 mg tablet per day) where vitamin K2 (K2VITAL® 0.2% DELTA powder) is mixed into the formulation to a final vitamin K2 concentration of 240 μg/tablet
89676750|NCT05364476|Experimental|16 weeks digital intervention with online and offline support|This study is a single-arm, non-randomized clinical trial, which will collect participant's baseline data, apply relevant assessment scales, collect data using a comprehensive digital intervention in 16 weeks to evaluate the improvement of relevant markers post intervention.
89676751|NCT05364281||Study Group|Patients younger than 18 years, who were scheduled for elective adenoidectomy or adenotonsillectomy operation.
89676752|NCT05358535|Experimental|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.
89676753|NCT05358535|Experimental|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.
89676754|NCT05349188|Experimental|Melatonin 3 mg|"Individuals will receive a kit with medication adherence devices containing melatonin 3 mg in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the 3mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 3 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 3 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
89215311|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin Monotherapy|Enfortumab vedotin on days 1 and 8 every 21 days
89215312|NCT03288545|Experimental|Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab|Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
89215313|NCT03288545|Experimental|Cohort L: Enfortumab vedotin in MIBC in perioperative setting|Enfortumab vedotin on days 1 and 8 and every 21 days
89215314|NCT03274414|Experimental|Unresectable paranasal sinus/nasal cavity malignancy|
89676755|NCT05349188|Active Comparator|Melatonin 0.5 mg|"Individuals will receive a kit with medication adherence devices containing melatonin 0.5 mg in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the 0.5 mg of melatonin. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive melatonin 0.5 mg, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The melatonin 0.5 mg intervention will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
89215315|NCT03267316|Experimental|Dose escalation|Cohorts of 3 subjects will receive once weekly (Q1W) treatment with CAN04. The Dose Limiting Toxicity (DLT) observation period for each dose level will be the first 21 days of treatment with CAN04. [Completed December 2018]
89215316|NCT03267316|Experimental|Monotherapy (Q1W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W).
89215317|NCT03267316|Experimental|Monotherapy (Q1W/Q2W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W).
89215318|NCT03267316|Experimental|Combination - NSCLC (NCG)|Subjects with NSCLC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (cisplatin/gemcitabine).
89215319|NCT03267316|Experimental|Combination - PDAC|Subjects with PDAC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine).
89676756|NCT05349188|Placebo Comparator|Placebo Pill|"Individuals will receive a kit with medication adherence devices containing the placebo pills in one of three smart electronic pill bottles labeled A, B, and C. Participants will not be aware which of the pill bottles contains the placebo. Participants will be randomized to take pills in 6 alternating intervention periods 2 weeks in length. During periods where participants were randomized to receive the placebo, they will receive a nightly text notification 1 hour before bed instructing them to take a pill from the corresponding smart pill bottle. The placebo will be administered in 2 intervention periods each 2 weeks in length (4 weeks total)."
89676757|NCT05317819|Experimental|Drug: ADI-PEG 20|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
89676758|NCT05317819|Placebo Comparator|Drug: Placebo|Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
89676759|NCT05314582||TURP patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic prostatectomy (TURP).
89676760|NCT05314582||TURP patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic prostatectomy (TURP).
89676761|NCT05314582||TUR-BT patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent endoscopic bladder tumor resection (TUR-BT).
89676762|NCT05314582||TUR-BT patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent endoscopic bladder tumor resection (TUR-BT).
89676763|NCT05314582||Open prostatectomy patients using anticoagulant/antiaggregant medication|Patients who used anticoagulant/antiaggregant medication for any reason (eg: coronary artery disease, atrial fibrillation, cerebrovascular disease) before surgery and underwent open prostatectomy (OP).
89676764|NCT05314582||Open prostatectomy patients not using anticoagulant/antiaggregant medication|Patients with no history of anticoagulant/antiaggregant medication and underwent open prostatectomy (OP).
89676765|NCT05307627||Long-term (>5 years) LDN users|Participants who have been using LDN for over 5 years
89676766|NCT05307627||intermediate-term (1-5 years) LDN users|Participants who have been using LDN for at least 1 year, but shorter than 5 years.
89676767|NCT05307627||short-term (<12 months) LDN users|Participants who have been using LDN for less than a year. This group will serve as the control group.
89676768|NCT05298306|Experimental|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion on separate days at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, LAT8881 will be given as a single intravenous infusion. The dose will be determined from the results of Part A."
89676769|NCT05298306|Placebo Comparator|Placebo|Matching placebo will be given as a single intravenous infusion in Part A and Part B
89676770|NCT05291338||HCC patients|116 hepatocellular carcinoma patients underwent TACE
89676771|NCT05289596|Experimental|Evidence-based digital therapy to treat insomnia|Participants will be assigned an evidence-based digital therapy to treat insomnia (Sleep Healthy Using the Internet (SHUT-i)
89676772|NCT05268237|Experimental|Part 1: Open Label|Part 1 of the trial will utilise an open label, single ascending dose, repeated treatment design. It will involve 3 subjects, each of whom will receive three single ascending doses of SL liraglutide (3, 12, 30mg and subcutaneous (SC) liraglutide (active comparator) with a mixed meal tolerance test (MMTT), separated by 1 week washout between doses.
89676773|NCT05268237|Experimental|Part 2: Investigator blind|Part 2 of the trial will utilise an investigator-blind, sponsor open, placebo-controlled, randomised, repeated treatment study design. It will involve 12 subjects. Each subjects will receive one of three possible doses of SL-liraglutide (to be decided by the Safety Monitoring Committee following analysis of the results from Part 1), SL-placebo or SC liraglutide in a randomised order with MMTT separated by 1 week washout between doses.
89050187|NCT04677023|Other|Admira fusion X--tra® bulk|The special ORMOCER® compound molecules in Admira Fusion x-tra reduce the volume shrinkage to an extremely low level (1.25 % by volume) in conjunction with very low shrinkage stress (3.87 MPa). Admira Fusion x-tra is the bulk fill version of Admira Fusion. This means that this restorative material can be applied in layers of up to 4 mm and then reliably cured. This makes placing posterior restorations particularly quick and economical. The universal shade U further simplifies handling, as it provides aesthetic results by adapting, chameleon-like, to the surrounding dental substance
89215320|NCT03267316|Experimental|Combination - PDAC (1 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
89215321|NCT03267316|Experimental|Combination - PDAC (2,5 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
89215322|NCT03267316|Experimental|Combination - non-squamous NSCLC (NCP)|Subjects with non-squamous NSCLC will receive CAN04 on Day 1 and 8 in cycles of 21 days in combination with standard-of-care therapy (carboplatin/pemetrexed).
89676774|NCT05265923|Experimental|CM310|CM310, 600mg for the initial dose, and 300mg for subsequent doses, subcutaneous injection (SC), every 2 weeks (Q2W)
89676775|NCT05265923|Placebo Comparator|Placebo|"Double blind treatment period : Placebo~Maintenance treatment period : CM310, 600mg for the initial dose, and 300mg for subsequent doses, subcutaneous injection (SC), every 2 weeks (Q2W)"
89676776|NCT05249062|Experimental|intervention|The intervention being piloted in this study is a novel system of supporting older individuals with multiple long-term conditions to self-manage their chronic conditions through the daily use of a digital health product that can also facilitate the remote monitoring of a person's health status.
89676777|NCT05228873||Investigational arm|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days plus the Standard of Care (SOC) for the treatment of COVID-19 acute stage based on the Vietnam Ministry of Health guideline at this time
89676778|NCT05228873||• Controlled arm|Patient who receive the Standard of Care (SOC) for the treatment of COVID-19 acute stage based on the Vietnam Ministry of Health guideline at this time
89215323|NCT03257631|Experimental|Pomalidomide|Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
89215324|NCT03256812|Experimental|ICT-based ECG monitoring group|Continuous monitoring with ICT-based ECG monitoring will begin from the time of participation in the trial in the ICT-based monitoring group. Depending on the lifestyle pattern of the patient, the specific time will be set to allow 30 min of monitoring per day, even if there are no symptoms. If symptoms do appear, additional monitoring will be performed for at least 10 more minutes. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group.
89215325|NCT03256812|Active Comparator|Holter monitoring group|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in the Holter monitoring group
89215326|NCT03164460|Experimental|Group I (SBRT)|Patients undergo SBRT every other day for a total of 5 treatments.
89215327|NCT03164460|Experimental|Group II (IMRT/IMPT)|Patients undergo IMRT/IMPT once daily (Monday-Friday) for up to 30-35 treatments.
89215328|NCT03152058|Experimental|Certolizumab Pegol|"All participants are administered certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter.~1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
89215329|NCT03129139|Experimental|Regimen A (monotherapy)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day off schedule. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
89215330|NCT03129139|Experimental|Regimen B (combination)|MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
89215331|NCT03129139|Experimental|Regimen C (monotherapy in Gastric Cancer)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.
89215332|NCT03122639|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
89676779|NCT05227092|Experimental|3D OPTIMIZED WMN MPRAGE|"At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set."
89676780|NCT05216302|No Intervention|Usual Care|Patients allocated to this arm will continue with their schedule chemotherapy with no additional intervention
89676781|NCT05216302|Experimental|Prehabilitation|Patients allocated to this arm will participate in a weekly group-based exercise intervention (nordic walking) and receive health education through a booklet, videos of the exercises and face-to-face sessions prior to each nordic walking session. Chemotherapy will continue as scheduled.
89676782|NCT05177887|Experimental|Traumacel PULVIS|Traumacel PULVIS will be poured into the bleeding area directly or using an applicator Traumacel ENDO Applicator.
89676783|NCT05177796|Experimental|Treatment (panitumumab,pembrolizumab,neoajuvant chemotherapy)|"CYCLES 1-4: Patients receive pembrolizumab IV over 30 minutes and panitumumab IV over 30-60 minutes on day 1 of cycle 0. Cycle 0 continues for 7 days in the absence of disease progression or unacceptable toxicity. Patients then receive panitumumab IV over 30-60 minutes on days 1, 8, and 15 of cycles 1-3 and days 1 and 8 of cycle 4, pembrolizumab IV over 30 minutes on day 1 of cycles 2-4, paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1, 8 and 15 of cycles 1-4. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~CYCLES 5-8: Patients receive standard of care treatment, including pembrolizumab IV over 30 minutes, doxorubicin IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
89676784|NCT05165524|Active Comparator|Laser|
89676785|NCT05165524|Active Comparator|Cream|
89215333|NCT03122639|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
89215334|NCT03117920|Experimental|Minnelide|0.67 mg/m2 Minnelide daily as a 30min iv infusion on days 1-21 of each 28 day cycle, followed by a 7 day rest period (D 22-28).
89676786|NCT05165524|No Intervention|Control|
89676787|NCT05163899|Active Comparator|Surgery|Filum release
89215335|NCT03098459||Critically Ill Trauma Patients|Non-intervention observational prospective cohort study
89215336|NCT03096054|Experimental|Part 1 a dose escalation|Phase where groups of patients will receive increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targets the cancer cells.
89215337|NCT03096054|Experimental|Part 2 an expansion|Phase where a larger group of patients will receive the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug is working.
89676788|NCT05163899|No Intervention|Observation|Medical Management only
89215338|NCT03094793|Experimental|abnormal EEGs|
89215339|NCT03055767|Other|OnabotulinumtoxinA/Saline Placebo|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
89676789|NCT05160168|Experimental|Dose Escalation|Participants with unresectable or metastatic GIST who will receive orally administered THE-630.
89676790|NCT05160168|Experimental|Expansion Cohort 1|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib, sunitinib, regorafenib and ripretinib who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
89215340|NCT03055767|Other|Saline Placebo/OnabotulinumtoxinA|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
89215341|NCT03032835||Study participants|No intervention
89215342|NCT03025308|Experimental|Blinded Phase: Filgotinib 200 mg|Filgotinib 200 mg plus placebo to match (PTM) filgotinib 100 mg for up to 6 years
89215343|NCT03025308|Experimental|Blinded Phase: Filgotinib 100 mg|Filgotinib 100 mg plus PTM filgotinib 200 mg for up to 6 years
89215344|NCT03025308|Experimental|Open Label Phase: Filgotinib 200 mg|Filgotinib 200 mg for up to 6 years
89215345|NCT03025308|Experimental|Open Label Phase: Filgotinib 100 mg|Filgotinib 100 mg for up to 6 years
89215346|NCT02918864|Experimental|ION-ASD|ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training).
89215347|NCT02918864|Active Comparator|Facilitated Play|The active comparison condition is a facilitated play therapy group.
89215348|NCT02916979|Other|Conditioning Regimen|Fludarabine, Busulfan, Rabbit ATG, Methotrexate
89215349|NCT02716116|Experimental|Part 1: Dose Escalation Component|TAK-788 treatment for participants with advanced NSCLC.
89215350|NCT02716116|Experimental|Part 2: Expansion Cohort 1|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have either not received or not shown an objective response to an EGFR tyrosine kinase inhibitors (TKI), and who have no active, measurable central nervous system (CNS) metastases.
89215351|NCT02716116|Experimental|Part 2: Expansion Cohort 2|TAK-788 treatment for NSCLC participants with HER2 exon 20 activating insertions or point mutations and no active, measurable CNS metastases.
89215352|NCT02716116|Experimental|Part 2: Expansion Cohort 3|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions or HER2 exon 20 activating insertions or point mutations and active, measurable CNS metastases.
89215353|NCT02716116|Experimental|Part 2: Expansion Cohort 4|TAK-788 treatment for NSCLC participants with other targets against which TAK-788 is active (examples include EGFR exon 19 deletions or exon 21 substitutions [with or without T790M mutations] and other uncommon EGFR activating mutations), without active CNS metastases.
89215354|NCT02716116|Experimental|Part 2: Expansion Cohort 5|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have previously shown an objective response to an EGFR TKI and subsequently progressed without active CNS metastases.
89676791|NCT05160168|Experimental|Expansion Cohort 2|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib, sunitinib and 0-1 additional lines of therapy in the advanced/metastatic setting, who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
89676792|NCT05160168|Experimental|Expansion Cohort 3|Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib (including in the adjuvant setting) and who have not received additional systemic therapy for advanced GIST, who will receive orally administered THE-630 at the recommended Phase 2 dose based on the dose escalation phase.
89676793|NCT05158218|Active Comparator|Cerebral Palsy Youth/Young Adults Physical Therapy|Baseline and 8 week assessments; 8 week gait therapy
89676794|NCT05158218|Experimental|Cerebral Palsy Youth/Young Adults Robotic Exoskeleton|Baseline and 8 week assessments; 8 week gait therapy using robotic exoskeleton
89676795|NCT05154162|Experimental|Experimental|Pelvic PSMA PET ± transperineal targeted prostate biopsy
89676796|NCT05154162|Other|Control|No pelvic PSMA PET + transperineal template prostate biopsy
89676797|NCT05151341|Experimental|Case|Patient in whom newly diagnosed, or recurring / progressing bladder cancer is strongly suspected after initial fibroscopy
89676798|NCT05151341|Experimental|Control|Patient attending or hospitalized for urolithiasis, urinary infections, superior excretory stones or with non suspect urinary symptomatology
89215355|NCT02716116|Experimental|Part 2: Expansion Cohort 6|TAK-788 treatment NSCLC participants with EGFR exon 20 activating insertions, who have not received prior systemic anticancer treatment for locally advanced or metastatic disease without active CNS metastases
89215356|NCT02716116|Experimental|Part 2: Expansion Cohort 7|TAK-788 treatment for participants with solid tumors other than NSCLC with EGFR/HER2 mutations against which TAK-788 is active without active CNS metastases.
89215357|NCT02716116|Experimental|Part 3: Extension Cohort|TAK-788 treatment for participants with previously treated locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations.
89215358|NCT02702414|Experimental|Cohort 1: Hepatocellular Carcinoma (HCC)-Prior Systemic Therapy with Sorafenib|Participants with previously systemically treated HCC received a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.
89676799|NCT05140174|Experimental|RHIS Informed Psychotherapy|Therapists will be trained in Radical Healing and Internalized Stigma (RHIS) and meet with their clients as part of their usual care for 15 tele-psychotherapy sessions
89676800|NCT05104489|Experimental|Low Dose|50 mcg of antigen with 250 mcg of Al(OH)3
89676801|NCT05104489|Experimental|Median Dose|100 mcg of antigen with 250 mcg of Al(OH)3
89676802|NCT05104489|Experimental|High Dose|100 mcg of antigen with 500 mcg of Al(OH)3
89676803|NCT05104489|Placebo Comparator|Placebo|250 mcg of Al(OH)3
89676804|NCT05088278|Active Comparator|HS|Patients who underwent anatomical single-bundle ACL reconstruction with hamstrings
89676805|NCT05088278|Active Comparator|BPT|Patients who underwent anatomical single-bundle ACL reconstruction with patellar tendon
89676806|NCT05088278|Experimental|Over-the-top plus lateral plasty|Patients who underwent ACL reconstruction with Over-the-top plus lateral plasty technique
89676807|NCT05081791|Experimental|Exercise Training|This group will engage in a 12-week exercise training program
89676808|NCT05081791|No Intervention|Control group|Usual care. Patients in this group will be offered the same program at the end of the study
89050188|NCT04677023|Other|GrandioSO x-tra® bulk|a nano-hybrid composite which is in a class of its own. It is distinguished by outstanding handling and excellent physical properties, modelled on the natural tooth.its the packable bulk fill material for the highest standards in durability and aesthetics.GrandioSO x-tra has outstanding surface hardness, at 223 MHV, which is closer to natural tooth enamel, compared with other bulk fill composites. Because of this, GrandioSO x-tra ensures restorations which are abrasionresistant and dimensionally stable over the long term. In addition to the surface hardness, reliable curing is very important when larger increments are used. Here as well, GrandioSO x-tra achieves an outstanding result and, at the 219 MHV measured at a depth of 4 mm, it even significantly exceeds the values measured for other bulk fill composites at the surface.
89050189|NCT04630548|Active Comparator|post placental IUD insertion|Following placental delivery, uterine cavity will be examined to exclude the presence of malformations or fibroids. Uterus will be stabilized by grasping it at fundus and the copper IUD (CuT 380 IUD) will be placed (within 10 minutes following the placental delivery) through the uterine wall incision high up in the uterine fundus (either by hand or using its applicator).
89050190|NCT04630548|Active Comparator|post puerperal IUD insertion|IUD will be inserted 6 - 8 weeks following caesarean delivery (during the post puerperal visit).
89050191|NCT01975610|Experimental|CC-292 375mg|Treatment
89050192|NCT01975610|Placebo Comparator|Placebo|Control
89050193|NCT04610424|Experimental|Cooperative Parent Mediated Therapy|"Cooperative Parent Mediated Therapy (CPMT) is a targeted parent-mediated intervention focused on the ASD core symptoms (Bearss et al., 2015). CPMT is based on the most significant models of parent training for ASD, in the perspective of Naturalistic Developmental Behavioral Interventions-NDBI with specific attention to the promotion of cooperative interactions (Schreibman et al., 2016). The aim of CPMT is to improve parental skills, to enable parents promoting the following seven target skills in their child: socio-emotional engagement, emotional regulation, imitation, communication, joint attention, play and cognitive flexibility and cooperative interaction. An individualized treatment plan is designed for each child in order to determine his developmental level and treatment goals (Valeri et al., 2019)."
89050194|NCT04610424|Active Comparator|Control|Control group
89050195|NCT04677101||Subjects with NASH documented by liver biopsy|One hundred subjects with NASH documented by liver biopsy and no evidence of another form of liver disease with a BMI ≥30 and ≤55 kg/m2.
89050196|NCT04677101||Healhy Donor|Fifty subjects with normal liver who underwent laparoscopic elective cholecystectomy, but otherwise in healthy conditions, will be used as controls.
89050197|NCT04630470|Placebo Comparator|The placebo control group|Each patient received the massage therapy with baby oil on both lower leg areas for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
89050198|NCT04630470|Experimental|The study group|Each patient received the massage therapy with lavender oil on both lower legs for 10 minutes on each leg, for 4 weeks, three times a week, in the first half of the HD session (first 2 hours).
89050199|NCT04677062|Experimental|GV-328|"The treatment should be carried out for 4 days. Children between 3 and 6 years old had to consume 4 pills a day, children between 7 and 10 years old 5 pills, and children between 11 and 13 years old up to 6 pills. The patient had to slowly thin the tablet in the mouth, maintaining direct contact with the area to be treated.~The study consisted of 2 visits, one initial and one final. In the initial visit , the documentation (informed consent) and the treatment were delivered. During this visit, baseline assessments of pain level, functional limitation, marginal mucosal edema, and lesion size were recorded. In addition, a photograph of the area to be treated was taken. Parents were also given a chart, in which they had to record the intensity of pain daily using the Wong-Baker face scale."
89050200|NCT04610463|Other|Standard|Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism
89050201|NCT04676984|Other|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
89050202|NCT01972178|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
89050203|NCT01972178|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
89050204|NCT01972139|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization.
89050205|NCT01972139|Other|Control|Subjects randomized prior to enrollment closure were treated with sham renal denervation (angiography only). Once enrollment was closed and the protocol revised, no control subjects crossed-over.
89050206|NCT01969838|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match ruxolitinib.
89050207|NCT01969838|Active Comparator|Ruxolitinib|Participants will receive ruxolitinib plus placebo to match momelotinib.
89050208|NCT04630314||Consecutive patients treated with covered stents post PCI CAP|
89050209|NCT01165177|Experimental|GSK1437173A group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
89050210|NCT01165177|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
89050211|NCT04610385||ileal conduit|
89050212|NCT04610385||cutaneous ureterostomy|
89050213|NCT01967810|Experimental|Arm 1|ANG1005 administered to bevacizumab-naive recurrent GBM participants
89050214|NCT01967810|Experimental|Arm 2|ANG1005, with or without bevacizumab, administered to bevacizumab-refractory recurrent GBM participants
89050215|NCT01967810|Experimental|Arm 3|ANG1005 administered to recurrent WHO Grade III anaplastic glioma participants
89050216|NCT04610268|Experimental|tDCS group|The anode of tDCS is placed on the occipital lobe and the cathode on the frontal lobe, or the anode of tDCS is placed on the left temporal lobe and the cathode on the right temporal lobe.
89050217|NCT01966601|Experimental|TRV027 dose #1|TRV027 dose #1 via continuous IV infusion
89050218|NCT01966601|Experimental|TRV027 dose #2|TRV027 dose #2 via continuous IV infusion
89050219|NCT01966601|Experimental|TRV027 dose #3|TRV027 dose #3 via continuous IV infusion
89050220|NCT01966601|Placebo Comparator|Placebo|Placebo via continuous IV infusion
89676809|NCT05077215|Experimental|Arm 1: EG-007+ Len+Pem Regimen|
89676810|NCT05077215|Active Comparator|Arm 2: Len+Pem Regimen|
89676811|NCT05059080||Participants Diagnosed with COVID-19|Participants were previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]).
89676812|NCT05058170||Renal transplant patients|
89676813|NCT05047692|Experimental|Group 1: Low dose|The subject will receive a single dose of AdCLD-CoV19-1(5.0x10^10VP) as an intramuscular injection.
89676814|NCT05047692|Experimental|Group 2: High dose|The subject will receive a single dose of AdCLD-CoV19-1(1.0x10^11VP) as an intramuscular injection.
89676815|NCT05028829|Experimental|Group A: Atorvastatin 20 mg|Atorvastatin 20mg will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
89676816|NCT05028829|Placebo Comparator|Group B: Placebo to Match (PTM)|PTM will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
89676817|NCT05012163|Experimental|Pennsylvania (PA) Lottery Scratch-Off Financial Incentive|"Participants in this arm will receive a message stating that they will receive a PA lottery $1 scratch-off ticket if they get a flu shot at an upcoming appointment. The message will mention that they could win $5,000 (the top prize for the scratch-off game).~Note: $1 scratch-off products vary over time; at study implementation, an active game with top prize of $5,000 (or the next-highest top prize) will be selected and will define the prize in the raffle absent upfront odds"
89676818|NCT05012163|Experimental|Certain Cash Payout Financial Incentive|Participants in this arm will receive a message stating that they will receive $1 in cash if they get a flu shot at an upcoming appointment.
89676819|NCT05012163|Experimental|Reminder / Active Control (No Financial Incentive)|Participants in this arm will receive a message stating that they can get a flu shot at an upcoming appointment. These participants will not be offered a financial incentive for getting a flu shot.
89676820|NCT05012163|No Intervention|No Treatment Control|No additional contact beyond standard Geisinger flu shot communications
89676821|NCT05009251|No Intervention|No-Contact Control|Subjects in the no-contact control arm will receive no additional pro-vaccination intervention beyond the health system's normal efforts. Although some patients are currently targeted for flu vaccination encouragement due to a conventional non-ML assessment that they are at high risk for complications, these patients are not told that they are at high risk or that they have been targeted.
89676822|NCT05009251|Experimental|Reminder Control|Subjects in the reminder control arm will receive messages reminding them to get the flu shot without being advised of their risk status.
89676823|NCT05009251|Experimental|High Risk Only|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications, without specifying how or why the health system believes this to be the case.
89676824|NCT05009251|Experimental|High Risk with Explanation Based on Medical Records|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via review of their medical records and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
89676825|NCT05009251|Experimental|High Risk with Explanation Based on Algorithm|Subjects in this treatment arm will receive messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by a computer algorithm and will be provided a human-understandable short list of the top factors from their medical record that explain their risk.
89676826|NCT04939610|Experimental|Phase 1: Dose Escalation|Up to 30 patients with solid tumors.
89676827|NCT04939610|Experimental|Phase 2: Specific Solid Tumors|Up to 192 participants treated with [177Lu]Lu-FAP-2286 in tumor-specific participant groups in monotherapy and in combination with chemotherapy.
89676828|NCT04912505|Experimental|Single arm|Sequential variations of daily aspirin intake time
89676829|NCT04882813||Dapagliflozin|Exposure group
89676830|NCT04882813||Sitagliptin|Reference group
89676831|NCT04879407||Warfarin|Reference group
89676832|NCT04879407||Rivaroxaban|Exposure group
89676833|NCT04849520|Experimental|High flow|Application of high flow nasal cannula during apnea
89676834|NCT04849520|Active Comparator|Buccal|Application of buccal oxygenation during apnea
89676835|NCT04846764|Active Comparator|Healthy volunteers|"60 healthy volunteers (aged 18-40 and 60-80) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Visit 1~Neuropsychological tests~A cranial MRI~Visit 2~• Neuropsychological tests"
89676836|NCT04846764|Experimental|Patients with neurological diseases of the central nervous system|"36 patients will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Visit 1~Neuropsychological tests~A cranial MRI~Visit 2~• Neuropsychological tests"
89050221|NCT04610073|Experimental|Interactive multimedia training|the intervention group 1 completed the pretest knowledge, attitude, and behavior questionnaire. Then, interactive multimedia was made available to this group. The questionnaire was completed again by the group, one week after completion of training, and then one month afterward.
89676837|NCT04846712||patients with a first ankle sprain|50 patients with a first ankle sprain will be included. Data will be collected of medical record.
89676838|NCT04840979|Experimental|Cognitive Impairment|Subjects diagnosed with Alzheimer's disease (AD) or mild cognitive impairment (MCI) will have one PET scan with 11C-ER176, with arterial sampling. If the subject lacks known AD-biomarkers, they may undergo a 18F-florbetaben PET scan prior to the 11C-ER176 PET scan. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
89676839|NCT04840979|Active Comparator|No Cognitive Impairment|Healthy volunteers who are cognitively normal will have one PET scan with 11C-ER176, with arterial sampling. If the subject lacks known AD-biomarkers, they may undergo an 18F-florbetaben PET scan prior to the 11C-ER176 PET scan. Genome-wide genetic analysis will be performed. Participants will undergo an annual clinical evaluation and blood sample collection for 5 years to establish the trajectory of AD-related serum biomarkers and syndromic diagnoses.
89676840|NCT04839692|Other|Young females (21-30 years old)|young healthy females (21-30 years old) from all phototypes who have thin or moderately thick lips
89676841|NCT04839692|Other|post menopausal females|post menopausal females from all phototypes who have thin or moderately thick lips
89676842|NCT04796545|Experimental|SING IMT System model NG SI IMT 3X|All participants will be implanted with the SING IMT System model NG SI IMT 3X.
89676843|NCT04788069|Active Comparator|Wholemeal bread|Treatment with wholemeal bread
88996293|NCT02923141|Active Comparator|Neutral Writing + Contingency Management|Participants will attend four attention-matched control sessions, consisting of face-to-face administration of psychological measures and neutral writing exercises. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
88996294|NCT02923141|Active Comparator|Expressive Writing + Contingency Management|Participants will attend four expressive writing sessions focusing on traumatic or stressful events. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
88996295|NCT02922907|Experimental|Arabinoxylan Rice Bran|BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
88996296|NCT02922907|Placebo Comparator|Placebo|Placebo for BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
88996297|NCT02923102|Active Comparator|Aloysia citriodora extract|Dietary Supplement: Aloysia citriodora extract
88996298|NCT02923102|Placebo Comparator|Placebo Formulation|Dietary Supplement: Maltodextrin (no active ingredient)
88996299|NCT02923024|No Intervention|Usual Care|This arm will be usual care and there will be no intervention.
88996300|NCT02923024|Experimental|Information|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent.
89676844|NCT04788069|Active Comparator|Sourdough bread|Treatment with sourdough bread
89676845|NCT04788069|Active Comparator|Bread with sourdough|Treatment with bread with sourdough
89676846|NCT04769466|Experimental|Staff|Staff will be trained in the platform, and complete life story interviews with residents at their facilities. Upon completion of training, staff will complete surveys regarding it's effectiveness and utility, and following the completion of the interview, the resident's life story books, summary materials, and staff tools will be delivered four weeks later. Life story materials are meant to assist staff in providing more personalized care and a mechanism for residents to feel more deeply understood.
89676847|NCT04769466|Experimental|Residents|Residents will be screened for their cognitive status and compete interviews with a researcher prior to participation in the life story interview. Residents will then be interviewed again at T3 about four weeks after the life story books, summaries, and staff materials have been delivered.
89676848|NCT04766502|Experimental|Blood sample (20ml) and Quality of Life Survey|
89676849|NCT04760795||coping strategy based on problem|59 geriatric patients will be included on the group: coping strategy based on problem
89676850|NCT04760795||coping strategy based on emotion|59 geriatric patients will be included on the group: coping strategy based on emotion
89676851|NCT04744077|Sham Comparator|Control|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
89676852|NCT04744077|Experimental|Student|Student Co-PI will manage this Instagram account created for the study. Although the student is a Kinesiology student and works within the health field, she will not disclose this information on the account. Instead, she will present herself as a general college student. By withholding her major and career aspirations, we hope to get unbiased feedback on what participants think about the content being presented. The content presented will be identical to study arm #3.
89676853|NCT04744077|Experimental|Scientist|"The PI will manage this Instagram account created for the study. The PI is a certified exercise physiologist and holds a PhD in Rehabilitation Sciences. She will disclose this information on the account. This group is the study's gold standard because it will provide evidence-based content delivered by an exercise scientist."
89676854|NCT04742166|Experimental|Side to side gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively~At Day 90:~a blood test for albumin and prealbumin~a GIQLI questionnaire (quality of life score) to be completed by the patient"
89676855|NCT04742166|Active Comparator|Terminolateral gastrojejunal reconstruction|"The post-operative care: usual practise Follow-up: 90 days postoperatively~At Day 90:~a blood test for albumin and prealbumin~a GIQLI questionnaire (quality of life score) to be completed by the patient"
89676856|NCT04740424|Experimental|FS222 Q4W|The initial cohorts will enroll sequentially as single participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design. Additional participants will be recruited into the PK/PD expansion cohorts at dose levels deemed safe during dose escalation. Once a tolerated dose has been established participants will be recruited into tumour-specific expansion cohorts.
88996301|NCT02923024|Experimental|Information and Financial Incentives|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent. Physicians will be incentivized to see patients immediately via phone call or in office visit. Physicians receive a financial incentive for calling the member within 48 hours of trigger event and will receive a larger financial incentive for seeing the patient for an office visit within 7 days of trigger event.
88996302|NCT04705688||Left Atrial Appendage Occlusion|Patients undergoing left atrial appendage occlusion.
88996303|NCT02922946|Experimental|Entinostat 5mg in 2-Way Crossover|"Treatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast."
89676857|NCT04736420||Warfarin|Reference group
89676858|NCT04736420||Rivaroxaban|Exposure group
89676859|NCT04717726|Experimental|MT|Participants in the MT group will be supplemented with Milk Thistle extract for 12 weeks
89676860|NCT04717726|Experimental|LAC|Participants in the LAC group will be supplemented with Lactobacillus Gassri for 12 weeks
89676861|NCT04717726|Experimental|EX|Participants in the EX group will perform aerobic exercise, 5 days per week for 12 weeks
89676862|NCT04717726|Experimental|MT + EX|Participants in the MT + EX group will be supplemented with Milk Thistle extract and exercise for 12 weeks
89676863|NCT04717726|Experimental|LAC + EX|Participants in the LAC + EX group will be supplemented with Lactobacillus Gassri and exercise for 12 weeks
89676864|NCT04717726|Placebo Comparator|CON|Participants in the CON group will be supplemented with maltodextrin pills made to look like the pills received by the MT and LAC groups for 12 weeks
89676865|NCT04715646|Experimental|Brivaracetam|LTFU study participants: Up to 5mg/kg/day (for study participants weighing 11kg to less than 20kg) and up to 4mg/kg/day (for study participants weighing 20kg to less than 50kg) and no more than 200mg/day Directly enrolled (DE) study participants: 1mg/kg/day to 4mg/kg/day and no more than 200mg/day.
89676866|NCT04691817|Experimental|Atezolizumab and Tocilizumab|Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days
89676867|NCT04671485|Active Comparator|ARM A : standard care|standard care : Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
89676868|NCT04671485|Active Comparator|ARM B : standard care + Autohypnosis|"In addition to the standard care, the patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
89676869|NCT04671485|Active Comparator|ARM C : standard care + Musicotherapy|"In addition to the standard care, the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
89676870|NCT04646668|Active Comparator|E-Cigarette then Heat not burn.|We will use a 1:1 fashion randomization to product order (combustible cigarette, e-cigarette, heat-not-burn device.
89676871|NCT04646668|Active Comparator|Heat not burn then E-Cigarette|We will use a 1:1 fashion randomization to product order combustible cigarette, heat-not-burn device, e-cigarette.
89676872|NCT04641351|Experimental|corticosteroid|"Triamcinolone extended release (32 mg) administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.~Knee injury and Osteoarthritis Outcome Score (KOOS) pain at 6 and 12 months~T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months~Morphologic grading of cartilage using the MOAKS score at 3 and 12 months~3D bone shape from MRI Osteoarthritis Knee Score (MOAKS) using statistical shape modeling at 3 and 12 months~Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
89676873|NCT04641351|Placebo Comparator|Placebo|"Normal saline of 5 mL administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy.~KOOS pain at 6 and 12 months~T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months~Morphologic grading of cartilage using the MOAKS score at 3 and 12 months~3D bone shape from MRI using statistical shape modeling at 3 and 12 months~Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months"
89676874|NCT04603300|Active Comparator|Active treatment|INT301 dosing as determined by cohort assignment
89676875|NCT04603300|Placebo Comparator|Placebo|Placebo as determined by cohort assignment
89676876|NCT04594811|Experimental|Dose escalation|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.~Nivolumab will be administered on Day 1 of every 4 week cycle (Q4W)."
89676877|NCT04594811|Experimental|Phase 2: NT-I7 and Nivolumab|"NT-I7 will be administered on Day 1 of alternate 4 weeks cycles (Cycle 1, 3, 5 etc.) (Q8W) at the recommended phase 2 dose (RP2D) identified during Dose escalation phase.~Nivolumab will be administered on Day 1 of every 4 week cycle (Q4W)."
89676878|NCT04593056||Warfarin|Reference group
89676879|NCT04593056||Rivaroxaban|Exposure group
89676880|NCT04588051|Experimental|Cabozantinib|
89676881|NCT04566380|Experimental|ONO-4538 Monotherapy cohort|480 mg of ONO-4538 IV Q4W or 240 mg of ONO-4538 IV Q2W per the investigator's choice
89676882|NCT04566380|Experimental|Combination therapy cohort|ONO-4538 at 360 mg IV Q3W or 480 mg IV Q4W, and Combination therapies (S-1 + Oxaliplatin [SOX] therapy , Capecitabine + Oxaliplatin [CapeOX] therapy , Bevacizumab or Temozolomide) selected by the principal investigator or subinvestigator in the Parent Study will be continued in this study.
89676883|NCT04561180|Placebo Comparator|Arm 1: SOC + DEX + EG-009A placebo|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A placebo for 3 additional weeks.
89676884|NCT04561180|Experimental|Arm 2: SOC + DEX + Low Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A Low dose for 3 additional weeks.
89676885|NCT04561180|Experimental|Arm 3: SOC + DEX + High Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A High dose for 3 additional weeks.
89676886|NCT04560023|Experimental|Exposition to multimedia content|Ad hoc design multimedia content in a tablet (video with sound and subtitles).
89676887|NCT04560023|No Intervention|Standard procedures|Standard procedures.
89676888|NCT04546555|Placebo Comparator|No pacing|
89676889|NCT04546555|Experimental|Bachmann's bundle pacing|
89676890|NCT04546555|Experimental|Bachmann's bundle and His bundle pacing|
89676891|NCT04546555|Experimental|Bachmann's bundle, His bundle and nocturnal pacing|
89676892|NCT04504396|Experimental|PB-119 once-weekly-subcutaneous injection|PB119 (polyethylene glycol exenatide) is a long-acting GLP-1RA for injection, which will be administered 150μg once-weekly subcutaneously to patients in active drug group for 24 weeks.
89676893|NCT04504396|Placebo Comparator|Placebo once-weekly-subcutaneous injection|PB-119 150μg matched placebo which will be used in placebo group for 24 weeks.
89050222|NCT04610073|Experimental|illustrated booklet|First, the intervention group 2 completed the pretest knowledge, attitude, and behavior questionnaire. Then, illustrated booklet was made available to this group. The questionnaire was completed again by the group one week after completion of training, and then one month afterward.
89050223|NCT04610073|Experimental|No Intervention|In the control group, no intervention was performed. Only before the intervention, one week and one month after the intervention, they completed the knowledge, attitude and behavior questionnaires.
89050224|NCT03454269|Active Comparator|PD patients with visual hallucinations (PD-VH)|PD patients without hallucinations or illusions
89050225|NCT03454269|Active Comparator|Patients with illusions (PD-I)|PD patients with Illusions and without hallucinations
89050226|NCT03454269|Active Comparator|Patients without visual hallucinations or illusions (PD-nVHI))|PD patients without Illusions and with hallucinations
89050227|NCT01165138|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
89050228|NCT01165138|Experimental|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily for 12 weeks
89050229|NCT01165138|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 12 weeks
89050230|NCT01963598|Experimental|Group 1|Dosing regimen 1
89050231|NCT01963598|Experimental|Group 2|Dosing regimen 2
89050232|NCT01963598|Experimental|Group 3|Dosing regimen 3
89050233|NCT01963598|Experimental|Group 4|Dosing regimen 4
89050234|NCT00561054|No Intervention|1|CISPLATIN gENCITABINE cETUXIMAB
89050235|NCT04206358|Experimental|treatment group|The Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection (JS001), Once every 2 weeks
89050236|NCT00554957||NBC|All dancers with the National Ballet of Canada will be given the opportunity to participate in the study.
89050237|NCT00554957||TDT|All dancers with the Toronto Dance Theatre will be given the opportunity to participate.
89050238|NCT00554957||KDC|All members of the Kibbutz Contemporary Dance company will be given the opportunity to participate.
89050239|NCT00554957||BDC|All dancers with the Batsheva Dance Company or Ensemble will be given the opportunity to participate.
89050240|NCT00554957||RSB|All dancers with the Royal Swedish Ballet will be given the opportunity to participate.
89050241|NCT00554957||RDB|All dancers with the Royal Danish Ballet will be given the opportunity to participate.
89050242|NCT00561093|Experimental|A|Group A (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
89050243|NCT00561093|Experimental|B|Group B (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline while undergoing hemodialysis and the following non-dialysis day (6 days per week)
89050244|NCT00561093|Experimental|C|Group C (n=25) Placebo dietary supplement to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
89050245|NCT00561093|Placebo Comparator|D|Group D (n=25) Placebo to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
89050246|NCT01960010|Active Comparator|1% MIM-D3|1% MIM-D3 Ophthalmic Solution
89050247|NCT01960010|Placebo Comparator|Vehicle|Vehicle
89050248|NCT01165021|Experimental|Pemetrexed + Cisplatin|
89050249|NCT04314622|Experimental|Supaglutide (Part A)|Four investigational doses of Supaglutide administered weekly (or bi-weekly) and subcutaneously (SC) in T2DM patients.
89676894|NCT04504370|Experimental|PB-119 once-weekly-subcutaneous injection|PB119 (polyethylene glycol exenatide) is a long-acting GLP-1RA for injection, which will be administered 150μg once-weekly subcutaneously to patients in active drug group for 24 weeks.
89676895|NCT04504370|Placebo Comparator|Placebo once-weekly-subcutaneous injection|PB-119 150μg matched placebo which will be used in placebo group for 24 weeks.
89676896|NCT04500223|Experimental|Cervical Cranioflexion exercise plus cardiopulmonary exercise|subjects who received Cervical Cranioflexion exercise plus cardiopulmonary exercise
89676897|NCT04500223|Active Comparator|Cervical stretch exercise plus cardiopulmonary rehabilitation|subjects who received Cervical stretch exercise plus cardiopulmonary rehabilitation
89676898|NCT04495881|Experimental|sitagliptin|sitagliptin 100mg
89676899|NCT04486625|Experimental|Cohort 1|Normal renal function
89676900|NCT04486625|Experimental|Cohort 2|Severe renal impairment (not on dialysis)
89676901|NCT04479423|Experimental|Soda water|400ml soda water was drunk to obtain good vision before undergoing MCE examination.
89676902|NCT04479423|No Intervention|water|900ml clear water(100 ml water of simethicone solution was not included) was drunk to obtain good vision before undergoing MCE examination.
89676903|NCT04476017|Experimental|Part A: SAGE-718 3 mg|Participants received SAGE-718 3 milligrams (mg) tablets, once daily with food in the morning for 14 days.
89676904|NCT04476017|Experimental|Part B: SAGE-718 3 mg|Participants received SAGE-718 3 mg tablets, once daily with food in the morning for 28 days.
89676905|NCT04453917|Experimental|Patients with active PML|Patients with neurological symptoms (< 3 months) with brain MRI lesions suggestive of PML and positive PCR in cerebrospinal fluid for JCV
89676906|NCT04444765||Patients with bicarbonate-based intermittent dialysis|Dialysate is composed by electrolytes, including calcium, and bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with acids (citric acid, chloride acid or acetic acid).
89676907|NCT04444765||Patients with acetate free biofiltration dialysis|Acetate free biofiltration (AFB-K)is a technique that does not require dialysate acidification
89676908|NCT04433234|Experimental|DS-5141b 2.0 mg/kg|Participants who will receive DS-5141b 2.0 mg/kg once weekly.
89676909|NCT04433234|Experimental|DS-5141b 6.0 mg/kg|Participants who will receive DS-5141b 6.0 mg/kg once weekly.
89676910|NCT04422639|Experimental|Arm I (pre-operative SRS/SRT)|Patients undergo SRS or SRT within 15 days of randomization followed by surgery within 15 days of radiation completion. Patients may undergo additional SRS or SRT if disease returns after treatment.
89676911|NCT04422639|Active Comparator|Arm II (post-operative SRS/SRT)|Patients undergo surgery within 15 days of randomization followed by standard-of-care SRS or SRT within 30 days of surgery. Patients may undergo additional SRS or SRT if disease returns after treatment.
89676912|NCT04416490||Patients|Patients with high-risk stage II or stage III primary colon cancer who have received curative resection
89676913|NCT04384107|Experimental|V114|Participants will receive a single 0.5 mL subcutaneous injection of V114 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months of age.
88996304|NCT02922946|Experimental|Entinostat 5mg in 3-Way Crossover|"Treatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal.~Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast."
89050250|NCT04314622|Placebo Comparator|Placebo(Part A)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
89676914|NCT04384107|Active Comparator|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|Participants will receive a single 0.5 mL subcutaneous injection of PCV13 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months of age.
89676915|NCT04382521|Experimental|Text Message Intervention (TMI)|Participants in the TMI condition will receive daily text messages through an adaptive algorithm plus separate twice-weekly tailored messages focused on a specific health goal.
89676916|NCT04382521|Other|Wait-list Control Group (WLC)|Waitlist Control group participants will begin to receive the full 12-week Text Message Intervention (with all components, e.g., phone check-ins) after completing follow-up assessments at Weeks 12 and 24. Participants in this group will receive no text messages or other study-specific interventions during the first 24 weeks of the study.
89676917|NCT04334278|Experimental|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
89676918|NCT04334278|Active Comparator|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth. To control for in between session practice, participants will receive an mp3 recording and informational handout to complete after each session.
89676919|NCT04298697|Experimental|TDF/FTC for one week|The first 10 participants (Arm A) will take TDF/FTC for three consecutive days of one week and will have biologic specimens collected at 8 study time points.
89676920|NCT04298697|Experimental|TDF/FTC for four weeks|The second 10 participants (Arm B) will take TDF/FTC for three consecutive days for four weeks and will have biologic specimens collected at 20 study time points.
89676921|NCT04291651||Retrospective|The registry will be populated with a retrospective cohort of patients previously identified as having pancreatic cysts.
89676922|NCT04291651||Prospective|The prospectively enrolled patients in this study are the primary population of interest.
89676923|NCT04275089|Experimental|Reia Vaginal Pessary|
89676924|NCT04260698|Experimental|omidubicel|"Omidubicel is a cryopreserved stem/progenitor cell based product comprised of:~Ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (cultured fraction (CF))~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. CF and NF, will be kept frozen until they are thawed and infused on the day of transplantation."
89676925|NCT04243577|Experimental|Experimental Sensors|This arm will include the use of the experimental wearable sensors we are developing.
89215359|NCT02702414|Experimental|Cohort 2: HCC-Systemic Therapy Naïve|Participants with HCC who had not received treatment for systemic disease received a pembrolizumab 200 mg IV infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.
89215360|NCT02511015||Family Member Control Subjects|Family members, of enrolled EOPD subjects, who themselves do not have Parkinson disease or Parkinsonism can be enrolled as controls on this study.
89215361|NCT02511015||Healthy Control Subjects|Age 18 years to 80 years old with no history or family history of Parkinson disease or Parkinsonism.
89215362|NCT02511015||Parkinson Subjects|Age 18 years to 80 years old with a history of early onset Parkinson disease or Parkinsonism (Presentation within the first five decades of life).
89215363|NCT02505464||Pregnant Women & their fetuses/infants|Information about pregnant women and their fetuses/infants, including the medical history, prenatal, perinatal, and postpartum periods (6 weeks after delivery) and throughout the treatment (e.g.surgery) for the child's medical condition (up to approx. child is @ 6 months of age), will be collected in this repository. The analysis of this information may help in understanding of the causes of fetal anomalies.
89215364|NCT02491632|Experimental|Arm I (high-dose dexamethasone, physical activity)|Patients receive high-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
89676926|NCT04243577|Active Comparator|Conventional Sensors|This arm will include the use of the conventional sensors: regular snap on sEMG electrodes and IOPI device bulb.
89676927|NCT04241601|Active Comparator|low dose interleukin-2|Commercially available aldesleukin with a UK marketing authorisation will be used and will be initially prepared as per SmPC. Active and Placebo doses appearing identical at point of issue and administration.
89676928|NCT04241601|Placebo Comparator|Placebo|Commercially available dextrose 5% injection with a UK marketing authorisation at equivalent dose volume will be used for the placebo formulation. Placebo and Active doses appearing identical at point of issue and administration.
89676929|NCT04182113|Experimental|1 Hz rTMS Stimulation first, then 20 Hz rTMS Stimulation, then sham rTMS|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
89676930|NCT04182113|Experimental|1 Hz rTMS Stimulation first, then sham rTMS, then 20 Hz rTMS Stimulation|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
89676931|NCT04182113|Experimental|20 Hz rTMS Stimulation first, then 1 Hz rTMS Stimulation, then sham rTMS|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
89676932|NCT04182113|Experimental|20 Hz rTMS Stimulation first, then sham rTMS, then 1 Hz rTMS Stimulation|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
89676933|NCT04182113|Experimental|sham rTMS first, then 1 Hz rTMS Stimulation, then 20 Hz rTMS Stimulation|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
89676934|NCT04182113|Experimental|sham rTMS first, then 20 Hz rTMS Stimulation, then 1 Hz rTMS Stimulation|Subjects will receive one session of each: low frequency rTMS within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 120% of motor threshold (MT), for a total of 1200 pulses, high frequency rTMS within the following stimulation parameters: 20 Hz, at 120% of MT, 60 trains (1.0 second per train), 20 pulses per train, inter-train interval of 15 seconds, for a total of 1200 pulses over 16 minute, Sham stimulation session targeting the precuneus. The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
89676935|NCT04154345|Experimental|Painful exercises|The pain allowed during exercises ranges between 4 and 7 on NPRS (Numeric Pain Rating Scale)
89676936|NCT04150965|Active Comparator|Arm A - Elotuzumab|Patients receive Elotuzumab in combination with pomalidomide and dexamethasone. Arm A begings in Phase 2 portion.
89676937|NCT04150965|Experimental|Arm B - Anti LAG-3 Single Agent|Patients receive Anti-LAG-3 as a single agent for 1 Cycle in Phase 1 portion.
89676938|NCT04150965|Experimental|Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-LAG-3 in combination with pomalidomide and dexamethasone.
89050251|NCT04314622|Experimental|Supaglutide (Part B)|Two investigational doses of Supaglutide administered weekly (or bi-weekly) and SC in T2DM patients.
89676939|NCT04150965|Experimental|Arm C - Anti-TIGIT Single Agent|Patients receive Anti-TIGIT as a single agent for 1 Cycle in Phase 1 portion.
89676940|NCT04150965|Experimental|ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone|Cycle 2 and beyond Patients receive Anti-TIGIT in combination with pomalidomide and dexamethasone.
89676941|NCT04136353|Experimental|Darolutamide|"Darolutamide 600mg (2 x 300mg tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
89676942|NCT04136353|Placebo Comparator|Placebo|"Placebo (2 tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
89676943|NCT04107129||Known Endometriosis|Known Endometriosis undergoing IVF with PGTA
89676944|NCT04107129||Unexplained Infertility|Unexplained Infertility undergoing IVF with PGTA
89676945|NCT04107129||Low Risk Controls|Low Risk Controls undergoing IVF with PGTA
89676946|NCT04096326|Placebo Comparator|Cohort 1: Placebo|Participants received AGN-151586-matching placebo, intramuscular (IM) injections in the glabellar complex on Day 1 in Cohort 1.
89050252|NCT04314622|Placebo Comparator|Placebo (Part B)|Placebo administered weekly (or bi-weekly) and SC in T2DM patients.
89050253|NCT00561132|Experimental|1|
89050254|NCT00561132|Placebo Comparator|2|
89050255|NCT02886754|Active Comparator|National e-learning programme only (HSE)|National e-learning programme only Recent successful completion the National e-learning programme by certificate will be displayed. Students then complete a student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
89050256|NCT02886754|Active Comparator|Simulation (S)|Simulation Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to standard simulation using the same series of paper cases as PBP which prompt simulated phone calls but no requirement to meet a proficiency benchmark. 4 hours will be allotted to this training. Following training participants will complete the student satisfaction survey and will then proceed directly for performance assessment to the high-fidelity simulation suite.
89050257|NCT02886754|Experimental|Proficiency-Based Progression (PBP)|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to PBP simulation using the same series of paper cases as S which prompt simulated phone calls. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks. Following training participants will complete the student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
89050258|NCT01956812|Experimental|Arm A IMMU-107 and gemcitabine|IMMU-107 and low dose gemcitabine
89676947|NCT04096326|Experimental|Cohort 1: AGN-151586|Participants received AGN-151586 lowest dose, IM injections in the glabellar complex on Day 1.
89676948|NCT04096326|Placebo Comparator|Cohort 2: Placebo|Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 2.
89676949|NCT04096326|Experimental|Cohort 2: AGN-151586|Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
89676950|NCT04096326|Placebo Comparator|Cohort 3: Placebo|Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 3.
89050259|NCT01956812|Active Comparator|Arm B Placebo and low dose gemcitabine|Placebo and low dose gemcitabine
89676951|NCT04096326|Experimental|Cohort 3: AGN-151586|Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
89676952|NCT04096326|Placebo Comparator|Cohort 4: Placebo|Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 4.
89676953|NCT04096326|Experimental|Cohort 4: AGN-151586|Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
89676954|NCT04096326|Placebo Comparator|Cohort 5: Placebo|Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 5.
89676955|NCT04096326|Experimental|Cohort 5: AGN-151586|Participants received AGN-151586 highest dose, IM injections in the glabellar complex on Day 1.
89676956|NCT04072822|Active Comparator|Prednisone|Standard of care plus prednisone 40 mg orally once daily on Days 1-30 and matching placebos for Anakinra (1 syringe s.c. once daily on Days 1-14), and zinc (matched pill once daily on Days 1-90).
89676957|NCT04072822|Active Comparator|Anakinra and Zinc|Standard of care plus Anakinra (100 mg s.c.) once daily on Days 1-14 zinc sulfate 220 mg once daily on Days 1-90, and placebo for prednisone (matched pill once daily on Days 1-30).
89676958|NCT04072783|Other|Patients with craniosynostosis|Patients with craniosynostosis will undergo pre - and post-operative imaging studies. The surgery will be performed for these patients as standard of care. They will also be tested fro neurodevelopment.
89676959|NCT04070989|Experimental|Posterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the posterior approach
89676960|NCT04070989|Experimental|Lateral Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the lateral approach
89676961|NCT04070989|Experimental|Anterior Approach|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem implanted via the anterior approach
89676962|NCT04052581||POEM-TIF|All participants will undergo the POEM-TIF in the same session.
89676963|NCT04031846|Experimental|V114|Full-term infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
89050260|NCT01182844|No Intervention|Control|Usual care
89676964|NCT04031846|Active Comparator|Prevenar 13™|Full-term infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
89676965|NCT04005183||All patients|Patients undergoing nephrectomy at the University Health Network are eligible for enrolment. All renal cell carcinoma histological subtypes and stages are eligible. Tumor, blood and urine samples are acquired at the time of nephrectomy.
89676966|NCT03943030|Experimental|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
89676967|NCT03943030|No Intervention|Group control|The group will not receive pulmonary rehabilitation intervention. Patients will be guided and maintain their daily and routine lives normally during the evaluation process. However, a baseline evaluation will be performed, which will be repeated after 9 weeks: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes commonly used in the assistance to assess PR will also be measured.
89676968|NCT03893448|Experimental|V114|Participants receive 4 total 0.5 mL intramuscular (IM) vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will receive other vaccinations (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
89676969|NCT03893448|Active Comparator|Prevnar 13™|Participants receive 4 total 0.5 mL IM vaccinations at ~2, 4, 6, and 12 to 15 months of age. Participants will also receive other vaccines (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
89676970|NCT03868670|Experimental|Responsive Neurostimulation|Surgical arm. Patients expected to receive treatment.
89676971|NCT03848455||Parkinson's disease group|"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;~Newly diagnosed primary PD patients, diagnosed within 3-6 months;~informed consent to the study;~age > 18 older."
89676972|NCT03848455||Non-parkinson group|Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.
89676973|NCT03730948|Experimental|All subjects|All subjects will receive the vaccine and be followed per the schedule of procedures.
89676974|NCT03730818|Experimental|Water-based Exercise Group|"The Water-based Exercise Group will compromise participants attending a 2 weekly exercise intervention each session lasting 1 hour for 12 weeks.~Each session will consist of:~10 minutes of warm-up: general mobilisation, walking, active stretching~40 minutes of global training: 20 minutes of endurance exercise and 20 minutes of resistance exercises targeting large main muscle groups involved in daily life activities (squats, lateral hip abduction, row, etc.) using body weight and elastic bands~10 minutes of cooling down: stretching, breathing exercises and relaxation Intensity will be monitored with the modified Borg Scale to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
89676975|NCT03730818|Active Comparator|Land-based Exercise Group|"The land-based exercise group will attend as well 2 weekly sessions lasting 1 hour each for 12 weeks.~Each session will consist of the same structure as the Water-based Exercise Group including:~10 minutes warm up~40 minutes of global training (20 minutes of endurance exercise and 20 minutes of resistance training)~10 minutes cool down. The exercises will be adapted from the water-based exercise group to match the requirements on the water-based exercise group. Intensity will be monitored with the Perceived Rate of Exertion Scale (modified Borg Scale, Borg 1982) to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
89676976|NCT03692871|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).
89676977|NCT03692871|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).
89676978|NCT03667846|Placebo Comparator|Placebo|Placebo
89676979|NCT03667846|Experimental|Topiramate|Week 0-1: 25 mg qhs Week 1-2: 25 mg qAM, 25 mg qhs Week 2-3: 25 mg qAM, 50 mg qhs Week 3-4: 50 mg qAM, 50 mg qhs Week 4-5: 50 mg qAM, 75 mg qhs Week 5-6: 75 mg qAM, 75 mg qhs Week 6-7: 75 mg qAM, 100 mg qhs Week 7-8: 100 mg qAM, 100 mg qhs Week 8-10: 100 mg qAM, 100 mg qhs Week 10-12: 100 mg qAM, 100 mg qhs Week 12-14: 2-week taper
89676980|NCT03658447|Experimental|177Lu-PSMA + Pembrolizumab|200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
89050261|NCT01182844|Experimental|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
89050262|NCT01164865|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
89050263|NCT01164865|Active Comparator|Clear Care|Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
89676981|NCT03638895|Active Comparator|ECAL group|Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
89676982|NCT03638895|Placebo Comparator|SC group|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
89676983|NCT03610516|Experimental|CFZ533|Investigational drug CFZ533 will be administred as multiple doses
89050264|NCT04630587|Experimental|Indirect restorations|For the indirect technique, the cavities are prepared according to the common principles for inlays/onlays. Digital impressions are taken of each tooth with a digital impression system (3Shape TRIOS® Intraoral Scanner).The dentist, utilizing the scanner's CAD SW, designs the 3D restoration. The design is imported from the scanner SW into the Rayo 3DToothFill SW to manufacture the mould and the restoration. After printing the mould, it is transferred to the Rayo robot which manufactures the restoration by casting filling material layers in the mould. The automated filling and curing procedures in the Rayo 3DToothFill robot are directed by Rayo 3DToothFill SW. After the manufacturing process is finished, the dentist cements the finished restoration into the cavity with a dual-cure resin cement (G-CEM LinkAce®).The indirect fillings are manufactured chair-side from the same composite material as in the direct technique.
89050265|NCT04630587|Active Comparator|Direct restorations|The direct composite restorations are performed based on normal treatment practices. For both direct and indirect restorations, commercially available short-fibre reinforced composite material (everX Flow, GC) is used for core material (replacing dentin) and flowable composite material (G-ænial® Universal Injectable, GC) for surface (replacing enamel), according the manufacturer´s instructions. The occlusion and articulation are checked and adjusted, and the restoration is finished with polishing instruments.
89676984|NCT03610516|Placebo Comparator|Placebo|Investigational drug matching placebo will be administered as multiple doses
89676985|NCT03565900|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic graft-versus-host-disease (GVHD) during the first year after HSCT will receive V114 instead of PNEUMOVAX™23 as their fourth dose.
89676986|NCT03565900|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic GVHD during the first year after HSCT will receive Prevnar 13™ instead of PNEUMOVAX™23 as their fourth dose.
89676987|NCT03531762|Experimental|Sequence 1: Treatment A-B-C|Participants received single oral dose of 500 milligrams (mg) of Tepotinib alone in fed state on Day 1 of Treatment period 1 (Treatment A) followed by single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 2 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 2 (Treatment B) followed by single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 3 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 3 (Treatment C). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
89050266|NCT01952990|Experimental|Kovacaine Mist|"Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Total dose is based on weight. Subjects weighing 10 to <20 kg will receive 1 intranasal spray of 100 μL. Subjects weighing 20 to <40 kg will receive 2 intranasal sprays of 100 μL (total dose 200 μL.~Subjects weighing 40 kg or more will receive 2 intranasal sprays of 200 μL (total dose 400 μL)."
89050267|NCT04311853||practitioner interviews|phone interviews conducted
89050268|NCT04314310|Active Comparator|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
89050269|NCT04314310|Placebo Comparator|placebo|equal volume of normal saline
89050270|NCT02886793|Experimental|FDG|all patients will undergo a PET scan and will receive 18F fludeoxyglucose
89050271|NCT04610307|Placebo Comparator|control group|patients receiving 1 % plain xylocaine
89050272|NCT04610307|Experimental|intervention group|patients receiving buffered 1 % xylocaine
89050273|NCT01952132|Experimental|OMS643762 Low Dose|Orally administering OMS643762 low dose daily for 14 days
89050274|NCT01952132|Experimental|OMS643762 High Dose|Orally administering OMS643762 high dose daily for 14 days
89050275|NCT01952132|Placebo Comparator|Placebo|Orally administering placebo daily for 14 days
89050276|NCT01952132|Experimental|OMS643762 Medium Dose|Orally administering OMS643762 medium dose daily for 14 days
89050277|NCT00561171|Experimental|1|high dose
89050278|NCT00561171|Experimental|2|lower dose
89050279|NCT01951742|Placebo Comparator|Vehicle|vehicle without ANT-1401
89050280|NCT01951742|Experimental|Dose 1|lowest dose
89050281|NCT01951742|Experimental|Dose 2|second lowest dose
89050282|NCT01951742|Experimental|Dose 3|mid-level dose
89050283|NCT01951742|Experimental|Dose 4|second highest dose
89050284|NCT01951742|Experimental|Dose 5|highest dose
89050285|NCT04610229|Experimental|Treated with hypofractionation|1
89050286|NCT01951235|Experimental|Imeglimin (Dose 1)|
89050287|NCT01951235|Experimental|Imeglimin (Dose 2)|
89050288|NCT01951235|Experimental|Imeglimin (Dose 3)|
89050289|NCT01951235|Experimental|Imeglimin (Dose 4)|
89050290|NCT01951235|Placebo Comparator|Placebo|
89050291|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation S|"Experimental equine Imunoglobulins antiSARSCov Formuation S"
89050292|NCT04610502|Experimental|Equine immunoglobulin anti SARS-CoV-2 formulation M|"Experimental equine Imunoglobulins antiSARSCov Formuation M"
89676988|NCT03531762|Experimental|Sequence 2: Treatment A-C-B|Participants received single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 1 (Treatment A) followed by single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 2 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 2 (Treatment C) followed by single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 3 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 3 (Treatment B). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
89676989|NCT03531762|Experimental|Sequence 3: Treatment B-A-C|Participants received single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 1 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 1 (Treatment B) followed by single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 2 (Treatment A) followed by single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 3 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 3 (Treatment C). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
89676990|NCT03531762|Experimental|Sequence 4: Treatment B-C-A|Participants received single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 1 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 1 (Treatment B) followed by single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 2 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 2 (Treatment C) followed by single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 3 (Treatment A). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
89676991|NCT03531762|Experimental|Sequence 5: Treatment C-A-B|Participants received single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 1 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 1 (Treatment C) followed by single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 2 (Treatment A) followed by single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 3 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 3 (Treatment B). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
89676992|NCT03531762|Experimental|Sequence 6: Treatment C-B-A|Participants received single oral dose of 500 mg Tepotinib in fed state on Day 5 of Treatment period 1 with 40 mg omeprazole once daily on Day 1 to 5 of Treatment period 1 (Treatment C) followed by single oral dose of 500 mg Tepotinib in fasted state on Day 5 of Treatment period 2 with 40 mg of omeprazole once daily on Day 1 to 5 of Treatment period 2 (Treatment B) followed by single oral dose of 500 mg of Tepotinib alone in fed state on Day 1 of Treatment period 3 (Treatment A). A washout period of at least 14 days was maintained between the Tepotinib single dose administrations.
89050293|NCT01949324|Experimental|NT-501 Implant procedure|The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
89050294|NCT01949324|Sham Comparator|Sham procedure|Non-penetrating sham procedure to mimic implant procedure
89050295|NCT01164475|Experimental|Fixed Dose Plerixafor|10 microgram per kilogram (mcg/kg) granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by 20 milligram (mg) plerixafor SC injection (fixed dose) in evening of Day 4 (10 to 11 hours prior to first apheresis), and then 10 mcg/kg G-CSF SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of cluster of differentiation 34 (CD34+) stem cells (greater than or equal to [>=] 5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
89050296|NCT01164475|Active Comparator|Weight-Based Plerixafor|G-CSF 10 mcg/kg SC injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by plerixafor 0.24 milligram per kilogram (mg/kg) SC injection (weight-based dose) in evening of Day 4 (10 to 11 hours before first apheresis), and then G-CSF 10 mcg/kg SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of CD34+ stem cells (>=5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
89050297|NCT04609995|No Intervention|No financial incentive|No financial incentives will be provided for completing a PrEP evaluation
89050298|NCT04609995|Active Comparator|Fixed incentive|A fixed incentive ($25 Amazon.com gift card) will be provided for completing a PrEP evaluation
89050299|NCT04609995|Active Comparator|Lottery incentive|An entry into a lottery for a 20% chance to win a $100 Amazon.com gift card will be provided for completing a PrEP evaluation
89676993|NCT03485924|Active Comparator|EUS-FNA with ROSE|EUS/FNA with ROSE will be performed using standard techniques via 22-g FNA needle (Cook Medical EchoTip Ultra or Boston Scientific Expect or Medtronic Beacon). Lesions will be identified using EUS and punctured with the FNA needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNA specimens will be processed for ROSE using standard techniques with bedside smear slide evaluation and liquid-based cytology and cell-block preparation.
89676994|NCT03485924|Active Comparator|EUS-FNB without ROSE|EUS/FNB without ROSE will be performed using similar techniques for tissue acquisition as FNA using 22-g FNB needle (Medtronic SharkCore or Boston Scientific Acquire). Lesions will be identified using EUS and punctured with the 22-g FNB needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNB samples will be placed directly into formalin containers and sent to be processed by surgical pathology.
89676995|NCT03464344|Other|Patients with cortical superficial siderosis.|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
89676996|NCT03464344|Other|Patients without cortical superficial siderosis|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
89050300|NCT01942265|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
89050301|NCT01942265|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
89215365|NCT02491632|Experimental|Arm II (low dose dexamethasone, physical activity)|Patients receive low-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
89676997|NCT03464045||type 2 diabetes patients|
89676998|NCT03462459|Experimental|Vancomycin|125 mg, oral capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
89676999|NCT03462459|Placebo Comparator|Placebo|125 mg placebo capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
89677000|NCT03455452||Cohort 1: Nivolumab|Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC
89677001|NCT03455452||Cohort 2: Nivolumab + Ipilimumab|Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC
89677002|NCT03443869|Experimental|Letermovir|LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400 mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks
89677003|NCT03443869|Active Comparator|Valganciclovir|900 mg VGCV tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks
89677004|NCT03433898|Experimental|Part 1|
89677005|NCT03433898|Experimental|Part 2|
89677006|NCT03433898|Experimental|Part 3|
89677007|NCT03418987||Deformities of the spinal column|Patients with adolescent idiopathic scoliosis or adult degenerative scoliosis, treated or untreated.
89677008|NCT03369587|Experimental|Diverging lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of diverging lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
89677009|NCT03369587|Active Comparator|Parallel lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of parallel lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
89677010|NCT03284541|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
89677011|NCT03284541|Active Comparator|Existing Public Health Practice|The control condition consists of the single-session Couples-Based HIV Counseling and Testing protocol for HIV-negative couples, the single-session Life-Steps medication adherence protocol for HIV-positive couples, or both intervention delivered jointly to serodiscordant couples
89677012|NCT03260140|Experimental|behavioral lifestyle intervention|The investigators will provide participants with the the behavioral lifestyle intervention
89677013|NCT03260140|No Intervention|usual care control|participant in this arm will continue with usual care
89677014|NCT03253796|Experimental|GLM SC QM (Full Treatment Regimen)|Period 1: participants are treated with open-label (OL) GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded SC GLM QM for up to 12 months
89677015|NCT03253796|Experimental|GLM SC Q2M (Reduced Treatment Regimen)|Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded GLM SC every other month alternating with matching placebo to GLM every other month for up to 12 months
89677016|NCT03253796|Placebo Comparator|Placebo (Treatment Withdrawal Regimen)|Period 1: participants are treated with OL GLM SC QM for up to 10 months; Period 2: participants are treated with double-blinded placebo for up to 12 months
89677017|NCT03253796|Experimental|OL GLM Retreatment|Participants who experience a disease flare during double-blinded treatment in Period 2 will discontinue blinded treatment and receive OL GLM SC QM.
89677018|NCT03241940|Experimental|Treatment (CD19/CD22-CAR T cells, chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and cyclophosphamide IV over 60 minutes on day -2. Patients then receive CD19/CD22-CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22-CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
89677019|NCT03132116|Experimental|Gentamicin|intra-nodal injection of gentamicin
88996305|NCT02922595|Active Comparator|Intubation through ILMA®|The ILMA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. The Intervention will be the intubation through ILMA. We will measure the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
89677020|NCT03132116|Placebo Comparator|Placebo|intra-nodal injection of placebo
89677021|NCT03073733|Experimental|Test (jCell injection) dose level 1|single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
89677022|NCT03073733|Other|Sham treated Control|"a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the study eye)"
88996306|NCT02922595|Experimental|Intubation through ILTS®|The ILTA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. It will be proceeded to the intubation through ILTS and the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
88996307|NCT02922712|Experimental|NISE 100mg|Nise 100mg given BD for 3 weeks
88996308|NCT02922790|Active Comparator|Control|"Subjects will review standard health information on the health consequences of smoking.~Subjects will have blood drawn but it will not be tested for DNA damage."
88996309|NCT02922790|Active Comparator|Biomarker feedback|"Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage.~Subjects will have blood drawn and the feedback will be presented at Visit 2."
88996310|NCT02922790|Active Comparator|Biomarker feedback plus|"Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage.~Subjects will have blood drawn and the feedback and images will be presented at Visit 2."
88996311|NCT02922673|Experimental|Treatment group|7 day treatment with placebo - first LPS challenge - 7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - second LPS challenge
88996312|NCT02922673|Active Comparator|Prophylaxis group|7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - first LPS challenge - 7 day treatment with ASA (no loading dose on first day) - second LPS challenge
88996313|NCT02922673|Placebo Comparator|Placebo group|7 day treatment with placebo - first LPS challenge - 7 day treatment with placebo - second LPS challenge
88996314|NCT02922556|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training (Moodify) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
88996315|NCT02922556|Active Comparator|Active Comparator|Commercially available computerized training (Games) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
88996316|NCT02922517||patients with obstructive HCM|patients with HCM (obstructive or no obstructive)
88996317|NCT02922517||controls|patients without HCM
88996318|NCT02922517||patients with non obstructive HCM|patients with non obstructive HCM
88996319|NCT02922205||RYGB surgery|Obese patients eligible for laparoscopic Roux-en-Y gastric bypass (RYGB) surgery.
88996320|NCT04705610|Experimental|Radiologically Isolated Syndrome (RIS)|
88996321|NCT04705610|Experimental|Clinically Isolated Syndrome (CIS)|
88996322|NCT04705610|Experimental|Relapsing-Remitting MS (RRMS)|
88996323|NCT04705610|Experimental|Secondary Progressive MS (SPMS)|
88996324|NCT04705610|Experimental|Primary Progressive MS (PPMS)|
88996325|NCT04705610|Experimental|Healthy volunteer|
88996326|NCT00188058|Active Comparator|Minimal alveolar distension|PEEP is set for a total PEEP (PEEP + intrinsic PEEP) between 5 and 9 cm H2O
88996327|NCT00188058|Experimental|Maximal alveolar distension|PEEP is set for a plateau pressure between 28 and 30 cm H20
88996328|NCT02922283|Experimental|IL2-PET scan|[18F]FB-IL2 PET scan, Tumor biopsy, CT scan, Biopsy of non-target tissue
88996329|NCT02922049|Other|pCLE vs. biopsies with histopathology|"The investigators will compare diagnostic accuracy and sensitivity of pCLE with standard biopsies in patients with esophageal and gastric lesions and in patients after completed endoscopic treatment of BORN.~All samples taken by biopsies will be correlated with the images taken by pCLE in the detection of lesions, intestinal metaplasia, dysplasia and buried glands."
88996330|NCT02922400|Experimental|Social Cognition Assessment and Training|Assessment and training program to enhance social function
88996331|NCT02922244|No Intervention|Standard skin care|standard skin care
88996332|NCT02922244|Placebo Comparator|Control|Moisture Cream
88996333|NCT02922244|Active Comparator|Cucumber cream|Apply Cucumber cream everyday after radiation therapy on the treatment aria skin.
88996334|NCT02922244|Active Comparator|Centella cream|Apply Centella asiatica cream everyday after radiation therapy on the treatment aria skin.
89050302|NCT01942265|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
88996335|NCT02922244|Active Comparator|Thunbergia cream|Apply Thunbergia cream everyday after radiation therapy on the treatment aria skin.
88996336|NCT02922166|Experimental|SRX246|SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
88996337|NCT02922166|Placebo Comparator|Placebo|Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
88996338|NCT04705493||CASE GROUP|Lidco rapid examination and echo examination were done to septic shock patients then the passive leg raising test was done and fluid responder cases were given mini fluid challenge and fluid challenge
88996339|NCT02922127|Other|Ulipristal Acetate|20 women will randomized to daily use of 10mg of ulipristal acetate
88996340|NCT02922127|Other|Combined Oral Contraceptive|20 women will be randomized to daily use of a combined oral contraceptive pill
88996341|NCT02922322|Active Comparator|Pilates Group|The Pilates Group was composed by 15 participants evaluated before and after 16 sessions of intervention with mat Pilates exercises.
88996342|NCT02922322|No Intervention|Control Group|The control group was composed by 15 participants that received no intervention
88996343|NCT02921854|Experimental|All included patients|3 times Blood withdrawal for each patient (25ml each)
88996344|NCT02921659|Placebo Comparator|Placebo|placebo, 500 mg, 2x/day for 6 weeks
88996345|NCT02921659|Active Comparator|Niagen™|Niagen™ (nicotinamide riboside chloride, ChromaDex, Inc.) 500mg, 2x/day for 6 weeks.
89215366|NCT02354469||Contact/Collision Sport Athletes|Collegiate athletes who participate in contact or collision sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
89215367|NCT02354469||Non-contact Sport Athletes|Collegiate athletes who participate in non-contact sports will be assessed on a comprehensive battery of tests during pre-season and post-season assessments.
89215368|NCT02354469||Post-Concussion|Collegiate athletes who sustain a concussion will be assessed on a comprehensive battery of tests from the time of injury and incrementally throughout the following year post-injury.
89677023|NCT03073733|Experimental|test (jCell injection) dose level 2|single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
89677024|NCT03029143|Experimental|Lead-in Period: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion once at Day 1 and at Week 2. Participants who were non-responders based on partial Mayo score at Week 6 and who had high vedolizumab clearance (>0.14 L/day) at Week 5 were eligible for Randomized Treatment Period (RTP). Participants who were responders (Lead-In Failures) entered the 18-week follow-up period and discontinued the study.
89677025|NCT03029143|Experimental|Randomized Treatment Period (RTP): Standard Treatment Arm|Following Lead-in Period, participants received vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) at Weeks 6, 14 and 22 as standard treatment plus 18 weeks follow-up.
89677026|NCT03029143|Experimental|RTP: Dose Optimized Arm|Following Lead-in Period, participants received vedolizumab 600 mg, IV infusion at Week 6, followed by Regimen A: vedolizumab 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up, or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up based on drug clearance.
89677027|NCT02971137|Experimental|Smoking Cessation plus CBI (SMK-CBI)|An intervention that includes a proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
89677028|NCT02971137|Active Comparator|Smoking Cessation Standard (SMK-STD)|A contact-equivalent control that provides standard smoking cessation telephone counseling
89677029|NCT02959164|Experimental|Decitabine and Gemcitabine|"Decitabine, Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Gemcitabine fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle."
89677030|NCT02953262|Experimental|Encouragement Arm 1|Participants in this encouragement condition will receive a mailed brochure with basic My HealtheVet content and a training guide with (a) insights from other Veterans on how to use My HealtheVet for diabetes self-management, (b) step-by-step guidance for how to sign up for My HealtheVet and, (c) detailed guidance on how to learn to use key features.
89677031|NCT02953262|Experimental|Encouragement Arm 2|Participants in this encouragement condition will receive the same brochure and training guide as Arm 1 but will also be offered optional attendance at one of several group training sessions.
89677032|NCT02953262|Experimental|Encouragement Arm 3|Participants in this encouragement condition will receive the same as in Arm 2 (brochure, training guide, and group training offer) but will also be offered a one-on-one My HealtheVet training session.
89677033|NCT02953262|Other|Brochure Only Comparison Arm|The Comparison condition will only receive a mailed brochure with basic My HealtheVet content during the trial. (The training guide will be mailed to them after completion of the interview at the end.)
89677034|NCT02924116|Experimental|Bioboosti|Treatment with the Bioboosti device for two weeks. The device produces a pulsed micro-magnetic field. Subjects will use it once a day for about one hour, before habitual sleep time.
89677035|NCT02924116|Experimental|Sustained Efficacy|"Treatment with Bioboosti device for a year. In order to see if the device has sustained efficacy in treating insomnia.~Subjects will use it once a day for about one hour, before habitual sleep time."
89677036|NCT02924116|Experimental|Insomnia and migraine|Treatment with the Bioboosti device for a month. Subjects will use it once a day for about one hour, before habitual sleep time.
89677037|NCT02904863|Experimental|patients with HUS|
89677038|NCT02899598|Experimental|Pregnant women|
89677039|NCT02899039|Experimental|IgG4-related disease|Subjects suffering from IgG4-related disease
89677040|NCT02899039|Active Comparator|Sjögren syndrome|Subjects suffering from Sjôgren syndrome
89677041|NCT02899039|Active Comparator|Healthy controls|Healthy subjects
89677042|NCT02886247||participants|individuals with a personal or family history of pancreas tumors
89677043|NCT02870517|Experimental|Relaxing Music|Participants will listen to relaxing music through noise-cancelling headphones during induction.
89677044|NCT02870517|Active Comparator|No Music|Participants will wear noise-cancelling headphones during induction but no music will be played through them.
89215369|NCT02354469||Healthy Control|Collegiate athletes who do not sustain a concussion but match the demographic profile of an individual enrolled as a post-concussion subject, will be assessed on the same tests and in a similar timeline as post-concussion subjects.
89215370|NCT02270580|Experimental|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
89215371|NCT02270580|Active Comparator|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
89215372|NCT02086188|Experimental|Mirabegron|Mirabegron - 25mg (one tablet) taken by mouth daily with option to up-titrate to 50mg daily (two tablets) taken by mouth daily
89215373|NCT02086188|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth daily and two tablets taken by mouth daily if subject chooses up-titration
89215374|NCT01854229|Active Comparator|Prospective pump candidates|New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump
89677045|NCT02838303|Other|Group A|Initial spray session: organophosphate. Crossover spray session: placebo
89677046|NCT02838303|Other|Group B|Initial spray session: placebo. Crossover spray session: organophosphate
89677047|NCT02803502|Experimental|hemophilia|Patients with severe hemophilia (or moderate hemophilia if presence of hemorrhages) under prophylaxy and subjected to a pharmacokinetic profile of factor VIII
89677048|NCT02763579|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
89677049|NCT02763579|Active Comparator|Placebo + Carboplatin + Etoposide|Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
89677050|NCT02737748|Experimental|TWB-103 Group|Subjects will receive TWB-103 2 to 3 times till 100% re-epithelialization or up to 10 days (around once every 3 days).
89677051|NCT02737748|Placebo Comparator|Placebo Group|Subjects will receive placebo 2 to 3 times till 100% re-epithelialization or up to 10 days (around once every 3 days).
89677052|NCT02730299|Experimental|NiCord® (omidubicel)|"NiCord® is a cryopreserved stem/progenitor cell based product comprised of:~ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF))~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation."
89677053|NCT02730299|Active Comparator|Unmanipulated CBU(s)|
89677054|NCT02633644|Experimental|Treated with Harmony System|Implantation and activation of the Harmony endovascular neurostimulator
89677055|NCT02623699|Placebo Comparator|Part A-SAD: Combined Placebo|Participants will be administered tofersen-matching placebo once by intrathecal bolus injection on Day 1 of Cohorts 1, 2, 3, and 4 respectively.
89677056|NCT02623699|Experimental|Part A-SAD: Cohort 1: Tofersen 10 mg|Participants will be administered tofersen 10 mg once by intrathecal bolus injection on Day 1.
89677057|NCT02623699|Experimental|Part A-SAD: Cohort 2: Tofersen 20 mg|Participants will be administered tofersen 20 mg once by intrathecal bolus injection on Day 1 of Cohort 2 after the safety review of Cohort 1.
89677058|NCT02623699|Experimental|Part A-SAD: Cohort 3: Tofersen 40 mg|Participants will be administered tofersen 40 mg once by intrathecal bolus injection on Day 1 of Cohort 3 after the safety review of Cohort 2.
89677059|NCT02623699|Experimental|Part A-SAD: Cohort 4: Tofersen 60 mg|Participants will be administered tofersen 60 mg once by intrathecal bolus injection on Day 1 of Cohort 4 after the safety review of Cohort 3.
89677060|NCT02623699|Placebo Comparator|Part B-MAD: Combined Placebo|Participants will be administered tofersen-matching placebo, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection.
89677061|NCT02623699|Experimental|Part B-MAD: Cohort 5: Tofersen 20 mg|Participants will be administered tofersen 20 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection.
89677062|NCT02623699|Experimental|Part B-MAD: Cohort 6: Tofersen 40 mg|Participants will be administered tofersen 40 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety and PK review of Cohort 5.
89677063|NCT02623699|Experimental|Part B-MAD: Cohort 7: Tofersen 60 mg|Participants will be administered tofersen 60 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety, PK review and SOD1 PD review of Cohort 6.
89677064|NCT02623699|Experimental|Part B-MAD: Cohort 8: Tofersen 100 mg|Participants will be administered tofersen 100 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety, PK review and SOD1 PD review of Cohort 7.
89677065|NCT02623699|Placebo Comparator|Part C-Pivotal: Placebo|Participants will be administered tofersen-matching placebo, 3 loading doses administered once every 2 weeks on Days 1, 15, 29 followed by 5 maintenance doses administered once every 4 weeks on Days 57, 85, 113, 141, 169 up to 24 weeks by intrathecal bolus injection.
89677066|NCT02623699|Experimental|Part C-Pivotal: Tofersen 100 mg|Participants will be administered tofersen 100 mg, 3 loading doses administered once every 2 weeks on Days 1, 15, 29 followed by 5 maintenance doses administered once every 4 weeks on Days 57, 85, 113, 141, 169 up to 24 weeks by intrathecal bolus injection.
89677067|NCT02618577|Experimental|Edoxaban|"Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
89677068|NCT02618577|Active Comparator|ASA or Placebo|Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
89677069|NCT02572791|Experimental|Periodic personal decolonization|All household participants will perform chlorhexidine body washes twice weekly for 3 months and apply mupirocin ointment to the anterior nares twice daily for five consecutive days each month for 3 months.
89677070|NCT02572791|Experimental|Household environmental hygiene|In addition to their usual cleaning, households will be asked to perform targeted household hygiene focusing on sources known to harbor S. aureus and serve as reservoirs for transmission.
89215375|NCT01854229|Active Comparator|Previous IDE study subjects continuing with the therapy|Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.
89215376|NCT01743313||Hip and knee replacement recipients|"Hip and knee replacement recipients (with osteoarthritis) enrolled previously into Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study (NCT01021826)."
89215377|NCT01675440||Severe (≥3-4+) Mitral Valve Regurgitation|Mitral valve regurgitation ≥3-4+
89215378|NCT01675440||Severe (≥3-4+) Tricuspid Valve Regurgitation|Tricuspid valve regurgitation ≥3-4+
89677071|NCT02572791|Experimental|Integrated personal/household hygiene|Participants in households randomized to this arm will perform the Periodic Personal Decolonization plus the Household Environmental Hygiene, described above in arms 1 and 2.
89677072|NCT02501642|Experimental|Concussion Coach group|"After informed consent and randomization, participants will complete baseline study measures and will receive an iPod touch® with the Concussion Coach Explorer version"
89677073|NCT02501642|Other|Treatment as usual|Treatment as usual
89677074|NCT02475954|Active Comparator|TH-CBT + Standard Care|Cognitive-behavioral therapy delivered via telehealth with a focus on decreasing depressive symptoms in Parkinson's Disease (PD).
89677075|NCT02475954|Other|Standard Care|VA standard care depression in Parkinson's Disease (PD)
89677076|NCT02459587|Experimental|Crisis Line Facilitation (CLF)|Crisis Line Facilitation
89677077|NCT02459587|Placebo Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care
89677078|NCT02360137||Patients with carotid plaque|Patients with carotid plaque treated using only drugs
89677079|NCT02360137||Patients with carotid stenosis|Patients with carotid stenosis indicated to carotid endarterectomy
89677080|NCT02307747|Experimental|trauma patients|Blood samples will be collected every 4 hours during 24 h, between day 2 and day 4 after inclusion
89677081|NCT02189018|Active Comparator|Control|Ad lib activity at home
89677082|NCT02189018|Experimental|Active Exercise|Active exercise on treadmill
89677083|NCT02189018|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
89215379|NCT01675440||End Stage Renal Disease (ESRD)|End stage renal disease requiring renal replacement therapy or a creatinine clearance (CRCL) <20 cc/min, but not on dialysis
89215380|NCT01675440||Low Gradient Low Output Aortic Stenosis|Low gradient low output aortic stenosis
89215381|NCT01675440||Failed Bioprosthetic Surgical Aortic Valve|Stenosed, insufficient or combined bioprosthetic surgical aortic valve failure
89215382|NCT01675440||2 or More Conditions|2 or more of the listed conditions
89215383|NCT01361399|Experimental|Arm 1|
89215384|NCT01361399|Active Comparator|Arm 2|
89215385|NCT01361399|Active Comparator|Arm 3|
89215386|NCT01361399|Placebo Comparator|Arm 4|
89215387|NCT01332682|Experimental|Resistance Training and Nutrition Counseling|
89215388|NCT01332682|Other|Nutrition Counseling|
89677084|NCT02189018|Experimental|Weight loss and active exercise|Weight loss plus active exercise on treadmill
89677085|NCT02038361|Experimental|blood sample|
89677086|NCT02035280||Elderly suffering of spine deformity|Spinal deformity patients over the age of 60 years undergoing elective surgery and requiring fusion of at least 5 levels.
89677087|NCT02013505|No Intervention|Instructions printed on a paper.|There will be no intervention.
89215389|NCT01236729||Knee replacement recipients|Patients (aged 75 years or over) with late-stage arthritis who have undergone or are undergoing primary knee replacement
89215390|NCT01116622|Experimental|Daily oral erlotinib and bexarotene capusles|Open label dose-ranging trial
89215391|NCT01064479|Experimental|Arm A (combination chemotherapy and erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.
89677088|NCT02013505|Experimental|Paper and video instructions|.Instructions printed on paper and a educational video.
89677089|NCT01991249|Experimental|blood sample|
89677090|NCT01973972|Experimental|Weight management/shared medical appointment (WM/SMA)|Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
89677091|NCT01973972|Active Comparator|Shared medical appointments (SMA)|Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
89677092|NCT01966120|Active Comparator|BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with BF-200 ALA.
89677093|NCT01966120|Placebo Comparator|Placebo to BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid.
89677094|NCT01908725|Experimental|Lamazym|1 mg Lamazym/kg body weight
89677095|NCT01798589|Experimental|Ethylenediamine dihydrochloride|Ethylenediamine dihydrochloride in methylcellulose 50 mcg/cm2 Ethylenediamine dihydrochloride in polyvinylpyrrolidone 50 mcg/cm2 Methylcellulose (negative control 1) Polyvinylpyrrolidone (negative control 2)
89677096|NCT01511614|Active Comparator|active tDCS|(1) anodal left-dlPFC + cathodal right-vmPFC stimulation, with anode over the left dlPFC and cathode over the right-vmPFC; (2) cathodal left-dlPFC + anodal right-vmPFC stimulation, in which polarity is reversed between the two electrodes
89688759|NCT03034681|Active Comparator|TENS|TENS procedure used at our unit consists in applying a high frequency current (80Hz), which is the most effective way to combat pain, for a phase duration of 60-200 microseconds at a comfortable range. Electrodes are placed on the skin over the sciatic nerve path, the (-) cathode on the most painful area as it is the most stimulating and the (+) another is placed distal. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
89215392|NCT01064479|Active Comparator|Arm B (combination chemotherapy and placebo)|Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.
89215393|NCT00640978|Experimental|Erlotinib + RAD001|Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
89215394|NCT00449748|Experimental|RAD001|Oral 10 mg daily for 30 days
89215395|NCT03999255|Experimental|Patients undergoing intrarenal surgery|
89215396|NCT00556998|Experimental|1|
89215397|NCT00528801||Cases (CLOSED)|These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).
89215398|NCT00528801||Controls (CLOSED)|These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level
89215399|NCT01564563|Placebo Comparator|Placebo|
89677097|NCT01511614|Sham Comparator|sham tDCS|To simulate the experience of tDCS stimulation, current is ramped on and turned off at the beginning and end of the tDCS session. An additional sham option is to have the current ramp up and down only at the beginning of the sham session, and not at the end. This second sham is supported in the literature as an effective blinding technique, which subjects cannot distinguish from active stimulation (Gandiga et al 2006, Brunoni et al 2012) . One of these sham options will be used for data that will be analyzed together, to be determined based on equipment capabilities and preliminary analysis of blinding efficacy in our cross over design. We will assess the efficacy of sham condition by providing participants and the investigator with a questionnaire on the MRI/tDCS session, wherein they will report whether they thought the tDCS session was active or sham. The MRI operator (or other non protocol personnel) will control active/sham conditions.
89677098|NCT00977860|Other|SBRT|
89677099|NCT00840944|Experimental|ZOMATRIP|GnRH agonist triptorelin plus somatropin
89677100|NCT00579566||1|Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum
89677101|NCT00386477|Experimental|Vag prep|Vagina cleansed prior to performing cesarean
89677102|NCT04024046||Control - Placebo|"Placebo Drink-Mix Daily for 180 days~Placebo Capsules Daily for 180 days"
89677103|NCT04024046||Group 1|"Uqora Drink-Mix Daily for 180 days~Placebo Capsules Daily for 180 days"
89677104|NCT04024046||Group 2|"Uqora Drink-Mix Daily for 180 days~Uqora Capsules Daily for 180 days"
89677105|NCT00453193|Experimental|Alemtuzumab + Pentostatin|Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
89677106|NCT00387023|Experimental|Zevalin + Rituximab|Rituximab 250 mg/m^2 intravenous (IV) over 4-6 hours for 2 weeks, + Zevalin 5 millicurie (mCi)/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
89677107|NCT02985476|Active Comparator|Interventional|Care as usual plus 8 weekly ELIJAH health reports shared with the participant and General Practitioner for 6 months i.e.: My history, My plan, My Update delivered via post or by email (dependant on participant preference) in addition to care as usual.
89677108|NCT02985476|No Intervention|Observational|Care as usual dictated by disease pathway of diagnosed inflammatory bowel disease i.e.; access to out-patient and in-patient hospital based care and community health resources via General Practitioner.
89050303|NCT01942265|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
89215400|NCT01564563|Experimental|Low dose|
89215401|NCT01564563|Experimental|High dose|
89215402|NCT00945204|Experimental|access to intermediate care clinics|
89215403|NCT00945204|No Intervention|usual care|
89215404|NCT00945360|Experimental|aromatase inhibitors: Letrozole|All consenting patients will be started on Letrozole at a dose of 2.5 mg/day for 8 weeks.
89215405|NCT00943566|Experimental|Sufentanil Transdermal Delivery System|Experimental drug
89215406|NCT00943566|Active Comparator|Control|Sustained release morphine sulfate
89215407|NCT01008657|Experimental|"extranodular no touch multipolar RFA"|
89677109|NCT00472849|Experimental|OFAR (Phase I)|Oxaliplatin starting dose 30 mg/m^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose (MTD) reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
89677110|NCT00472849|Experimental|OFAR MTD (Phase II)|Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
89050304|NCT01942265|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
89050305|NCT01942265|Experimental|Group 9|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
89050306|NCT01942265|Experimental|Group 8|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 21
89050307|NCT01942265|Experimental|Group 7|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
89215408|NCT01008657|Active Comparator|intranodular multipolar RFA|
89215409|NCT00940680|Experimental|amlodipine/losartan 5/100mg|
89215410|NCT00940680|Active Comparator|losartan 100mg|
89215411|NCT00945438|Experimental|Group 1|Participants aged 18 to 59 years at enrollment.
89215412|NCT00945438|Experimental|Group 2|Participants aged 60 years or older at enrollment.
89050308|NCT01942265|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 21
89050309|NCT01942265|Experimental|Group 10|100 subjects receive 45 mcg sanofi A/H7N9 antigen on Day 0 and 21
89050310|NCT01164007|Experimental|Dacarbazine + Bevacizumab|Participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease will receive dacarbazine and bevacizumab until disease progression, unacceptable toxicity, participant withdrawal, or physician decision to discontinue.
89050311|NCT01941836|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
89050312|NCT01941836|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
89050313|NCT01941836|Active Comparator|ezetimibe 10mg/day|Orally, once daily in morning as capsules
89050314|NCT01941836|Experimental|ETC-1002 120 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
89050315|NCT01941836|Experimental|ETC-1002 180 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
89050316|NCT04610151|Experimental|Guided Imagery|Guided Imagery Intervention:The pretest data of the patients with a pain score of 4 or higher according to VAS were collected. Afterwards, the experiment group patients were applied guided imagery.
89050317|NCT04610151|No Intervention|No-Reflexology Application , control group.|No intervention was applied on the control group patients.
89050318|NCT04630041|Experimental|Social Needs Assessment|Patients in the Emergency Department will complete a social needs assessment screener that may refer them to 211 services
89050319|NCT04629885|Experimental|Oxytocin 400 IU|1mL Oxytocin 400 IU vaginal gel once daily for 12 weeks
89050320|NCT04629885|Placebo Comparator|Placebo|1mL Placebo vaginal gel once daily for 12 weeks
89050321|NCT01939184|Experimental|WC3055-01F|WC3055 12.5 mg tablet once daily for 12 weeks
89050322|NCT01939184|Experimental|WC3055-02F|WC3055 25 mg tablet once daily for 12 weeks
89050323|NCT01939184|Experimental|WC3055-03F|WC3055 50 mg tablet once daily for 12 weeks
89050324|NCT01939184|Experimental|WC3055-04F|WC3055 75 mg tablet once daily for 12 weeks
89050325|NCT01939184|Placebo Comparator|WC3055-07P|Placebo tablet once daily for 12 weeks
89050326|NCT04630119||Study group of female homemakers with chronic neck pain|All female patients aged between 18-55 years with chronic neck pain (pain lasting for more than 3months) who were homemakers were included in the study. All participants reported the presence of pain in the preceding one week
89050327|NCT04629768|Other|Duodenal EMR + PuraStat|PuraStat will be applied to the defect after duodenal EMR of the lesion
89050328|NCT01163851|Experimental|PF-04950615 (RN316)|
89050329|NCT04609917||trainee group|Patients with native papilla who underwent selective biliary cannulation with trainee involvement
89050330|NCT04609917||non-trainee group|Patients with native papilla who underwent selective biliary cannulation without trainee involvement
89050331|NCT02885662|Experimental|CS-3150|CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.
89050332|NCT00561210|Experimental|I|Total enteral tube feeding
89050333|NCT00561210|Active Comparator|II|Total enteral tube feeding
89050334|NCT01938599|Experimental|AM001|AM001 Cream, 7.5%. 2x daily for 12 weeks.
89050335|NCT01938599|Placebo Comparator|Vehicle|Placebo of AM001 Cream. 2x daily for 12 weeks.
89050336|NCT04610034|Experimental|"Resilient Caregivers"|Intervention program
89050337|NCT04610034|Other|Control group|Care as usual
89050338|NCT01917383|Experimental|Trabodenoson Plus Latanoprost|Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop
89050339|NCT01917383|Active Comparator|Timolol Plus Latanoprost|A Beta-blocker eye drop plus a prostaglandin analogue eye drop
89050340|NCT00564135|Experimental|A B C|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
89215413|NCT01564719|Experimental|Immediate-intervention arm|This is a holistic health intervention. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
89215414|NCT01564719|Experimental|One-year waitlist arm|This holistic health intervention arm for Cohort 2 was the same as Cohort 1's, only the intervention delivery was smoother (e.g., Naturally Slim offered at more start times). Cohort 2 waited for one year before beginning the intervention.
89215415|NCT01564719|Experimental|Two-year waitlist arm|This holistic health intervention arm for Cohort 3 was the same as Cohort 2's, only Cohort 3 waited for two years and received the stress management program meQuilibrium rather than Williams LifeSkills.
89215416|NCT00940758|Experimental|PEP02|
89677111|NCT01399736|Active Comparator|FFR-guided revascularisation strategy|In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of >0.80 will not be treated.
89677112|NCT01399736|Placebo Comparator|randomised to guidelines group|In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
89677113|NCT00453895|Experimental|Sunitinib|"Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.~treatment will continue until progressive disease or unacceptable toxicity"
89677114|NCT04481425|Other|intervention group|Text messages will be sent to the subjects through the investigator, including giving popularization of psychiatric knowledge, coping skills, emotional regulation strategies, and brief care. Two or three times a week for two months.
89677115|NCT04481425|No Intervention|control group|Subjects both collected in the outpatient department and the ward were randomly divided into the control group and regularly followed up.
89677116|NCT00528541|Active Comparator|BOTOX®|botulinum toxin type A (BOTOX®)
89677117|NCT00528541|Active Comparator|Dysport®|botulinum toxin type A (Dysport®)
89677118|NCT00409565|Experimental|Cetuximab plus bevacizumab|Cetuximab plus bevacizumab
89677119|NCT00475501|Experimental|Arm 1|testosterone enanthate
89677120|NCT00475501|Experimental|Arm 2|finasteride
89677121|NCT00475501|Experimental|Arm 3|testosterone enanthate + finasteride
89677122|NCT00475501|Placebo Comparator|Arm 4|placebo
89677123|NCT04750421|Experimental|Transillumination Venolux®|Transillumination using Venolux was used to visualize veins in the hemiface before hyaluronic acid injections
89677124|NCT04750421|No Intervention|Comparator group|No vascular exploration methods were used on the other hemiface
89677125|NCT00529555|Sham Comparator|Scaling and root planing + SHAM TX|sham treatment
89677126|NCT00529555|Placebo Comparator|Scaling and root planing + Vehicle|Placebo
89677127|NCT00529555|Active Comparator|Scaling & root planing + Periocline Gel|Minocycline HCL 2.1%
89677128|NCT00387335|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89677129|NCT01797757|Active Comparator|Fish oil enriched with EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
89677130|NCT01797757|Active Comparator|MAG-EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
89677131|NCT01797757|Active Comparator|MAG-EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
89677132|NCT01797757|Active Comparator|Fish oil enriched with EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
89677133|NCT04388423|Experimental|Group S|
89677134|NCT04388423|Experimental|Group C|
89677135|NCT01796899|Other|Brivaracetam 10 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 10 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 10 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
89677136|NCT01796899|Other|Brivaracetam 50 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 50 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 50 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
89677137|NCT01796899|Other|Brivaracetam 75 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 75 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 75 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
89215417|NCT01792752|Experimental|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. The neighborhoods will receive the intervention at different times throughout the study period, but once the intervention is initiated in a neighborhood it will continue being implemented in that neighborhood until the end of the study period.
89215418|NCT01792752|No Intervention|Control / Neighborhood(s) not receiving the intervention|The neighborhood(s) not receiving the intervention will act as a control while the intervention is initiated and implemented in other neighborhoods. All neighborhoods will receive the intervention but at different times throughout the study period. Once the intervention is initiated in a neighborhood, that neighborhood will continue receiving the intervention until the end of the study period.
89215419|NCT00945516|Active Comparator|Flared end FCSEMS|Flared end FCSEMS will be inserted for the benign bile duct stricture.
89215420|NCT00945516|Active Comparator|Anchoring FCSEMS|Anchoring FCSEMS will be inserted for benign bile duct stricture
89215421|NCT00527397|Experimental|B|Type 2 Diabetes Mellitus (DM) who has not yet treated by Insulin
89215422|NCT00527397|Experimental|C|Type 2 DM who has already treated by Insulin
89215423|NCT00527397|Experimental|A|Type 1 DM
89215424|NCT00943956|Experimental|Everolimus|Everolimus + radiation
89215425|NCT01564797|Active Comparator|Education Intervention|A series of 5 home-based lay health educator-led education sessions (Home Health Parties (HHP)), to educate a Hispanic population about diabetes, management of diabetes, and diet and exercise
89215426|NCT01564797|No Intervention|Control Arm|A delayed intervention where the intervention was delivered after the hA1c level was measured for the second time (3 months after the baseline measurement)
89215427|NCT00945828|Experimental|Annual Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
89215428|NCT00945828|Experimental|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
89215429|NCT01564875|Experimental|Simvast CR|"Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.~Placebo with the same appearance and formulation as that of Zocor Tab, 1 tablet once daily to be administered between 6 and 9 p.m."
89215430|NCT01564875|Active Comparator|Zocor|"Placebo with the same appearance and formulation as that of Simvast CR Tab, 1 tablet once daily to be administered between 6 and 9 a.m.~Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m."
89215431|NCT00944112|Experimental|Restrictive RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70g/L with a target Hb concentration of 71-90g/L during the intervention period.
89215432|NCT00944112|Experimental|Liberal RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90g/L with a target Hb concentration of 91-110g/L during the intervention period.
89215433|NCT04012086|Experimental|physical therapy (PT)|The physical therapy program consisted of 6 individual sessions/week, each lasting 60 minutes for 4 weeks in addition to their usual pharmacological therapy
89215434|NCT04012086|No Intervention|No physical therapy (CT)|Subjects in CT group received only standard medication.
89215435|NCT01529814|Experimental|New abutment connection implant|Implant with new abutment connection
89215436|NCT01529814|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
89677138|NCT01796899|Other|Brivaracetam 100 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 100 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 100 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
89677139|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of 10 mL of BRV intravenous bolus injection (10 mg/mL) will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 100 mg (10 mg/mL)~Form: Intravenous bolus injection~Frequency: Once daily~Duration: 1 day"
89677140|NCT00477451|Placebo Comparator|RCT Placebo|Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
89677141|NCT00477451|Experimental|RCT Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
89677142|NCT00477451|Experimental|Open Label Inhaled Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
89677143|NCT00477451|Experimental|Initial Inhaled Alprazolam 2 mg|Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
89677144|NCT00477685||OculusGen Collagen Matrix|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
89677145|NCT00530803|Active Comparator|EMLA Cream|Participants will have a dose of EMLA Cream applied to the venipuncture site 1 hour before the procedure. Dosage based on age and weight: 4-6 years old and heavier than 10kg will receive 10g of EMLA; 7-12 years old and more than 20kg will receive 20g of EMLA.
89215437|NCT00944190|Experimental|Self-management Intervention|Telephone based self management intervention targeted at pain, fatigue, depression, and cognitive difficulties.
89215438|NCT00944190|Active Comparator|Education|Education about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
89215439|NCT00945984||LESS|Patients who underwent LESS radical nephrectomy
89215440|NCT00945984||Conventional laparoscopy|Patients who underwent conventional laparoscopic radical nephrectomy
89215441|NCT00944268|Experimental|Liquid and solid|
89215442|NCT00527319|No Intervention|Group A, control group|Supportive care only
89677146|NCT00530803|Active Comparator|Synera Patch|Participants will have a Synera Patch applied to the venipuncture site 20 minutes prior to the procedure.
89677147|NCT04372927|Experimental|Treatment (chemotherapy, durvalumab, radiation therapy)|Patients with squamous cell cancer receive standard of care chemotherapy consisting of cisplatin on days 1, 8, 29, and 36, and etoposide on days 1-5 and 29-33. Cycles repeat every 4 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell cancer receive standard of care chemotherapy consisting of cisplatin and pemetrexed on days 1, 22, and 43. Cycles repeat every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. All patients receive durvalumab IV over 1 hour Q4W. Radiation to the primary tumor will be given over 8-15 fractions during weeks 1-3 of chemotherapy. For patients who have residual disease in the mediastinal lymph nodes at week 9, radiation will be given to the lymph nodes starting week 11. Durvalumab is given for 2 years after completion of radiation in the absence of disease progression or unacceptable toxicity.
89677148|NCT01381874|Experimental|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.
89677149|NCT01381874|Experimental|Abiraterone acetate + Prednisone/Prednisolone + Exemestane|Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
89050341|NCT01163617|Experimental|Current/Physiolis Syringe|Self-injection using current syringe at Week 0 (Visit 1), self-injection using Physiolis syringe at Week 2 (Visit 2) (Phase A)
89050342|NCT01163617|Experimental|Physiolis/Current Syringe|Self-injection using Physiolis syringe at Week 0 (Visit 1), self-injection using current syringe at Week 2 (Visit 2) (Phase A)
89050343|NCT01163617|Experimental|Current/Physiolis Autoinjector|Self-injection using current autoinjector at Week 0 (Visit 1), self-injection using Physiolis autoinjector at Week 2 (Visit 2) (Phase A)
89050344|NCT01163617|Experimental|Physiolis/Current Autoinjector|Self-injection using Physiolis autoinjector at Week 0 (Visit 1), self-injection using current autoinjector at Week 2 (Visit 2) (Phase A)
89050345|NCT01163617|Experimental|Physiolis Autoinjector at 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at storage temperature (2° to 8°C) (Phase B)
89050346|NCT01163617|Experimental|Current Autoinjector 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at storage temperature (2° to 8°C) (Phase B)
89050347|NCT01163617|Experimental|Physiolis Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at room temperature (20° to 27°C) (Phase B)
89050348|NCT01163617|Experimental|Current Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at room temperature (20° to 27°C) (Phase B)
89050349|NCT01911767||Dimethyl fumarate|Exposure to dimethyl fumarate since the first day of her last menstrual period (LMP) prior to conception or at any time during pregnancy
89050350|NCT01911767||Peginterferon beta-1a|Exposure to Peginterferon beta-1a since 17 days prior to the first day of her LMP prior to conception or at any time during pregnancy.
89050351|NCT01911767||Disease Modifying Therapy (DMT) Unexposed|Never received DMT therapy; discontinued treatment with any DMT at least more than 5× half-life prior to Day 1 of her LMP and throughout the entire pregnancy.
89050352|NCT04629846|Experimental|Trastuzumab Plus（+） QL1209 + Docetaxel|Prior to surgery: trastuzumab, QL1209, and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: QL1209 Drug: Trastuzumab Procedure: Surgery
89050353|NCT04629846|Active Comparator|Trastuzumab Plus（+） Pertuzumab + Docetaxel|Prior to surgery: trastuzumab,pertuzumab , and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: Pertuzumab Drug: Trastuzumab Procedure: Surgery
89050354|NCT01910012|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
89050355|NCT01182337|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
89677150|NCT01381874|Experimental|Exemestane|Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
89050356|NCT01182337|Placebo Comparator|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
89050357|NCT01182298||Hepatitis C|latino participants with Hepatitis C
89050358|NCT01909427|Placebo Comparator|Placebo/CNTO 6785 200 mg+Methotrexate (MTX)|
89050359|NCT01909427|Experimental|CNTO 6785 200 mg+MTX|
89050360|NCT01909427|Experimental|CNTO 6785 100 mg+MTX|
89050361|NCT01909427|Experimental|CNTO 6785 50 mg+MTX|
89050362|NCT01909427|Experimental|CNTO 6785 15 mg+MTX|
89050363|NCT04629573|Active Comparator|Group 1|Epidural Anesthesia
89050364|NCT04629573|Active Comparator|Group 2|General Anesthesia
89050365|NCT01909232|Experimental|Active rTMS treatment|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
89050366|NCT01909232|Sham Comparator|Sham rTMS treatment|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
89050367|NCT04609449|Experimental|Long biliopancreatic limb|Patients submitted to long biliopancreatic limb Roux-en-Y gastric bypass.
89050368|NCT04609449|Active Comparator|Standard biliopancreatic limb|Patients submitted to standard Roux-en-Y gastric bypass.
89050369|NCT01887002|Experimental|Experimental Arm 1|ONO-2952 Active tablets, every day for 2 weeks
89050370|NCT01887002|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 2 weeks
89050371|NCT00564174|Experimental|a|
89677151|NCT01399190||Bevacizumab|Participants will receive bevacizumab in combination with capecitabine and oxaliplatin.
89677152|NCT00531661|Active Comparator|TREATMENT Group|Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System
89050372|NCT00564174|Active Comparator|b|Low dose aspirin only
89050373|NCT01878461|Placebo Comparator|Vehicle|Proper quantity twice a day
89050374|NCT01878461|Experimental|M518101|Proper quantity twice a day
89677153|NCT00531661|Placebo Comparator|CONTROL Group|Standard of care HF management
89677154|NCT01381718|Experimental|Arm I|Participants receive modafinil orally (PO) once daily (QD) on days 1-42.
89050375|NCT01163266|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 8 weeks.
89050376|NCT01163266|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
89050377|NCT01163266|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
89050378|NCT04629456|Experimental|group 1|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
89215443|NCT00527319|Active Comparator|Group B, Low Dose VT-122|VT-122 (dose of etodolac: 400 mg/day) + supportive care
89215444|NCT00527319|Active Comparator|Group C, High Dose VT-122|VT-122 (dose of etodolac: 800 mg/day) + supportive care
89677155|NCT01381718|Placebo Comparator|Arm II|Participants receive placebo PO QD on days 1-42.
89677156|NCT00410189|Experimental|ZD6474|ZD6474 300 mg by mouth daily for 28 Days.
89677157|NCT00479089|Active Comparator|Weekly Docetaxel|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy.
89677158|NCT00479089|Active Comparator|Weekly Docetaxel + ZD1839|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy. ZD1839 250 mg by mouth daily, without break.
89677159|NCT01398956|Experimental|Levetiracetam|Twice daily (morning and evening) orally
89677160|NCT00410423|Experimental|Bortezomib 0.7mg/m^2|Bortezomib in combination with mitoxantrone, etoposide and cytarabine
89677161|NCT00410423|Experimental|Bortezomib 1.0mg/m^2|
89677162|NCT00410423|Experimental|Bortezomib 1.3mg/m^2|
89677163|NCT00387959|Experimental|Unrelated Donor Umbilical Cord Transplant|Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilixal Cord Blood
89677164|NCT00410891|Experimental|topical antibiotic|topical gatifloxacin 4 times per day
89677165|NCT01795157|Experimental|CCADSS|questionnaire completed using i-Pad
89677166|NCT01795157|Active Comparator|pen-paper|Questionnaire completed using pen and paper
89677167|NCT04750187|Experimental|Hypo-pressive abdominal exercise program|
89677168|NCT04750187|No Intervention|No training program|
89677169|NCT01381562|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
89677170|NCT01381562|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
89677171|NCT01381562|Active Comparator|Meropenem 1G|q8h administered via IV infusion, plus saline placebo
89677172|NCT04749953|Active Comparator|Autogenous bone graft alone|Maxillary sinus floor augmentation with particulated autogenous bone graft alone from the zygomatic buttress area and simultaneously implant placement
89677173|NCT04749953|Experimental|Mixture of 50% autogenous bone graft and 50% Symbios biphasic biomaterial|Maxillary sinus floor augmentation with a mixture of 50% particulated autogenous bone graft from the zygomatic buttress area and 50% Symbios biphasic bone graft material (Biomaterial, 1.0 mm to 2.0 mm) with simultaneously implant placementand
89215445|NCT00562302|Experimental|Bio-Seal Group|Bio-Seal Plug Implanted
89215446|NCT00562302|No Intervention|Control Group|Control group with no intervention
89215447|NCT00946062|Active Comparator|regular O&M-training|orientation and mobility training in use of the identification cane as provided by mobility trainers
89677174|NCT04749953|Experimental|Mixture of 50% autogenous bone graft and 50% Symbios xenograft granules|Maxillary sinus floor augmentation with a mixture of 50% particulated autogenous bone graft from the zygomatic buttress area and 50% Symbios xenograft granules (Biomaterial, 1.0 mm to 2.0 mm) with simultaneously implant placement
89677175|NCT00411749|Experimental|V501|"V501 vaccination Quadrivalent HPV (Types 6, 11, 16,~18) L1 VLP Vaccine Injection~cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle [VLP] Type 6,~Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6."
89677176|NCT00411749|Placebo Comparator|Placebo|Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen
89677177|NCT01381016|Other|Group 1 - Normal Weight|"Group 1: Normal weight (BMI 18-25 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
89677178|NCT01381016|Experimental|Group 2 - Obese|"Group 2: Obese (BMI >30 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
89677179|NCT00412451|Experimental|Ocriplasmin 25µg|25µg ocriplasmin intravitreal injection versus sham injection
89677180|NCT00412451|Experimental|Ocriplasmin 75µg|75µg ocriplasmin intravitreal injection versus sham injection
89677181|NCT00412451|Experimental|Ocriplasmin 125µg|125µg ocriplasmin intravitreal injection versus sham injection
89677182|NCT00412451|Sham Comparator|sham injection|Sham injection
89677183|NCT01398410|Experimental|Rabeprazole 5 mg|
89677184|NCT01398410|Experimental|Rabeprazole 10 mg|
89677185|NCT00412529|Experimental|Telbivudine|
89677186|NCT00412529|Active Comparator|Entecavir|
89677187|NCT00412841|Experimental|Atorvastatin|Atorvastatin 40mg
89677188|NCT00412841|Placebo Comparator|Placebo|Tablets identical to atorvastatin 40mg
89677189|NCT01796483|Active Comparator|healthy Volunteers|
89677190|NCT01796483|Experimental|Patients|
89677191|NCT00414167|Experimental|1|Bupropion
89677192|NCT00414167|Placebo Comparator|2|Placebo
89677193|NCT00414635|Other|Control Arm with Week 24 Crossover|Subjects randomized to the control arm will remain on daily dosing of the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily for 24 weeks. After 24 weeks of daily therapy subjects on this arm may be eligible to cross over to the experimental arm regimen of the coformulated single tablet of 600 mg efavirenz +300 mg tenofovir df +200 mg of emtricitabine on the 5/2 intermittent dosing treatment schedule for the remainder of the study.
89677194|NCT00414635|Experimental|5/2 Intermitent Treatment Arm|Subjects randomized to the 5/2 intermittent dosing treatment schedule regimen will be prescribed the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily, for 5 consecutive days per week followed by 2 days off of these medications, 600 mg efavirenz, 300 mg tenoforvir dt and 200 mg emtricitabine, for 48 weeks.
89677195|NCT00531817|Experimental|Tocilizumab 8 mg/kg + DMARDs|
89677196|NCT00531817|Placebo Comparator|Placebo + DMARDs|
89677197|NCT00415493|Experimental|Order 1|Cold-dry air provocation followed (on a separate day) by Warm-moist air provocation
89677198|NCT00415493|Experimental|Order 2|Warm-moist air provocation followed (on a separate day) by Cold-dry air provocation
89677199|NCT01380782|Experimental|Bevacizumab Naive|Bevacizumab naive subjects
89677200|NCT01380782|Experimental|Prior Bevacizumab|Patients previously treated with bevacizumab
89050379|NCT04629456|Experimental|Group 2|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion(24).
89050380|NCT01873703|Experimental|pracinostat plus azacitadine|"60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
89050381|NCT01873703|Placebo Comparator|Placebo with Azacitadine|"Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
89050382|NCT04629261|Experimental|Users with no incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will not receive a discount fee for enrollment.
89050383|NCT04629261|Experimental|Users with incentive|Participants who are interested on get involved into the ECOBICI program, and who randomly will do receive a discount fee for enrollment.
89677201|NCT01793441|Placebo Comparator|Placebo|Participants will receive placebo matching to RG7314 in each stage (Stage I, II, III and IV) for 12 weeks.
89677202|NCT01793441|Experimental|RG7314|Participants will receive RG7314 orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
89677203|NCT01398176|Experimental|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
89677204|NCT01398176|Experimental|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
89677205|NCT01796561|Active Comparator|Olive leaf extract liquid|20ml of polyphenol-rich olive leaf extract liquid to be consumed daily for 6 weeks
89677206|NCT01796561|Placebo Comparator|Placebo liquid|20ml of polyphenol-free placebo liquid (containing water, glycerin, flavours, colours and aromas) to be consumed daily for 6 weeks
89677207|NCT01796639||kidney transplantation patients with living-donor grafts|
89677208|NCT00455663|Experimental|Cognitive Adaptation Training|In home treatment using environmental supports such as signs, labels, alarms, checklists and the organization of belongings to bypass cognitive impairment, cue and sequence adaptive behavior and improve a wide range of functional outcomes.
89677209|NCT00455663|Experimental|Pharm-Cognitive Adaptation Training|Uses Supports from Cognitive Adaptation Training designed only to promote adherence to medication and treatment follow up.
89677210|NCT00455663|Active Comparator|Treatment As Usual|Medication follow up and limited case management provided by local mental health authority
89677211|NCT00534001|Experimental|Arm I (1-week run-in)|Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
89677212|NCT00534001|Experimental|Arm II (4-week run-in)|Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
89677213|NCT00481351|Experimental|group1 ezetimibe|6 week wash out, followed by 06 week ezetimibe 10mg once a day e then 6 week ezetimibe 10mg plus sinvastatin 20mg for more 6 week.
89677214|NCT00481351|Active Comparator|group 2 simvastatin|6 week simvastatin 20mg once a day followed by 6 week simvastatin 80mg once a day.
89677215|NCT00481507|Placebo Comparator|Placebo|
89677216|NCT00481507|Experimental|Kefir|
89677217|NCT01397786|Experimental|OPC-34712|
89677218|NCT00455975|Experimental|Weekly Avastin|Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity
89677219|NCT00455975|Experimental|Bi-weekly Avastin|Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity
89677220|NCT04016012|Experimental|Intervention arm|Participants in the intervention group will receive local zambian foods and standard health care for eight (8) weeks.
89677221|NCT04016012|No Intervention|Control arm|The control group will have their usual (standard) diet in their home and receive standard health care for eight (8) weeks.
89677222|NCT05366192|Experimental|Paxlovid stage 1 group|Subjects in stage 1 will be treated with nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
89677223|NCT05366192|Experimental|Paxlovid stage 2 group|In stage 2, subjects will be treated with nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
89677224|NCT05368922|Experimental|Experimental: Virtual Reality Group|Children will receive a virtual reality rehabilitation protocol for their most affected upper limb for four weeks, on the basis of three sessions a week, in addition to their usual care. Virtual reality will be applied to participants for 30 minutes and will be based on two perceptual-motor tasks.
89677225|NCT05368922|No Intervention|Control group|Children who will be randomized to the control group will follow their usual care for four weeks (usual motor activity, including classical rehabilitation and sports or physical activities). The rehabilitation protocol will be proposed after the second post-test
89050384|NCT04629261|No Intervention|Non-users|Participants with an age range similar to the intervention groups, who work or lives nearby ECOBICI's bicycle station, that are not enrolled in the ECOBICI program or in a health related program (ex. reducing weight).
89050385|NCT01870505|Experimental|Arm A: BYL719 plus Letrozole|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
89050386|NCT01870505|Experimental|Arm B: BYL719 plus Exemestane|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
89050387|NCT01870505|Experimental|Arm C: BYL719 plus Letrozole|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle. The starting dose of BYL719 in Arms C will be 250mg daily. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
89050388|NCT01870505|Experimental|Arm D: BYL719 plus Exemestane|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added. Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle. For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
89050389|NCT04629612|Experimental|Regional anesthesia|Regional block applied according to surgical area
89050390|NCT04629612|No Intervention|No Regional anesthesia|No regional anesthesia applied
89050391|NCT01868516|Placebo Comparator|Placebo|One tablet of placebo to be administered orally twice a day.
89050392|NCT01868516|Experimental|0.5 mg dexmecamylamine (TC-5214)|One tablet of 0.5 mg dexmecamylamine to be administered orally twice a day.
89050393|NCT01868516|Experimental|1 mg dexmecamylamine (TC-5214)|One tablet of 1 mg dexmecamylamine to be administered orally twice a day.
89050394|NCT01868516|Experimental|2 mg dexmecamylamine (TC-5214)|One tablet of 2 mg dexmecamylamine to be administered orally twice a day.
89050395|NCT00564213|Experimental|1|A single intraoperative topical application of mitomycin C 0.02% for 15 seconds
89050396|NCT00564213|Experimental|2|A single intraoperative topical application of mitomycin C 0.02% for 30 seconds
89050397|NCT01861847|Placebo Comparator|Placebo Group|Placebo Comparator
89050398|NCT01861847|Active Comparator|Drug group|7 Keto-DHEA
89050399|NCT04629144|Experimental|Belimumab|Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.
89050400|NCT04629144|Placebo Comparator|Placebo|Placebo of Belimumab administered subcutaneously weekly from week 0 to week 24.
89050401|NCT01855880|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
89050402|NCT01855880|Experimental|AbGn-168H: High Dose|Subject to receive high dose of AbGn-168H intravenously
89050403|NCT01855880|Placebo Comparator|Placebo AbGn-168H|Subject to receive placebo
89050404|NCT01851083|Experimental|autologous bone marrow mononuclear cells|a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
89050405|NCT01851083|Placebo Comparator|placebo infusion|a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
89050406|NCT04609839||Patient admitted to intensive care unit for COVID-19|
89677226|NCT04013672|Experimental|Arm A - Have not received immunotherapy|Arm A is patients with first recurrence of glioblastoma who have failed prior chemotherapy and radiation but have not received any immunotherapy.
89677227|NCT04013672|Experimental|Arm B - Have failed prior anti-PD1 therapy|Arm B is an exploratory arm of 10 patients who have failed prior anti-PD1 therapy.
89050407|NCT01850381|Experimental|GM608|4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
89677228|NCT02078882|Experimental|Abatacept 125 mg weekly|Open label treatment with Abatacept
89677229|NCT04012736||Celiac disease|Celiac disease subjects enrolled after diagnosis and before gluten free diet initiation
89677230|NCT04012736||Control|Healthy controls with no chronic condition
89677231|NCT00458237|Experimental|Ph I: Everolimus L1 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
89677232|NCT00458237|Experimental|Ph I: Everolimus L2 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
89677233|NCT00458237|Experimental|PhII: Everolimus MTD + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus at the MTD by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
89677234|NCT04344938||medical personel|
89677235|NCT04344938||non medical personel|
89677236|NCT05264909|Experimental|Transcranial Direct Current Stimulation TDCS|"Each subject will receive transcranial electrical stimulation at primary motor located in Cz based on the EEG 10-20 international system. The program include 18 sessions with a frequency of 3 times per week during 6 weeks. Therefore, during tDCS sessions, subjects will receive stimulation for 15 minutes with a current of 1.5 milliamp using 7x5 cm electrodes.~During the stimulation, the patient must simultaneously perform gait training for 30 minutes where the speed of each step is guided by the frequency of biaural rhythms and beats, constantly heard through hearing aids. Additionally, the length of the passage will be indicated by white stripes (50 cm long and 5 cm wide), placed perpendicular along a walkway of 6.5 m.~Thus, each session will be monitored on safety aspects of the subjects with emphasis on skin problems and other possible side effects of tDCS."
89677237|NCT05362838|Active Comparator|robotic-assisted laparoscopy|The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port will be placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two to three ports (5/8 mm) for the robotic arms.
89677238|NCT05362838|Active Comparator|conventional laparoscopy|Laparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery.
89677239|NCT05367908||Cohort 1: MMM (Moderna Vaccine Series)|Participants who have only received Moderna COVID-19 vaccines (that is, the 2-shot series and a booster).
89677240|NCT05367908||Cohort 2: PPP (Pfizer Vaccine Series)|Participants who have only received Pfizer COVID-19 vaccines (that is, the 2-shot series and a booster).
89677241|NCT05367908||Cohort 3: V (Other Combination of Vaccines)|Participants who have received any other combinations of boosters authorized in the United States, such as the 2-shot Pfizer series and a Moderna booster (PPM), the 2-shot Moderna series and a Pfizer booster (MMP), or the 1-shot Johnson and Johnson vaccine with either a Moderna or Pfizer booster.
89677242|NCT00418457|Active Comparator|General anesthesia and opioid|General anesthesia followed by opioid administration
89677243|NCT00418457|Active Comparator|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
89677244|NCT05365568|Experimental|LBBAP for CRT-p|
89677245|NCT05365568|Experimental|LBBAP for CRT-d|
89050408|NCT01850381|Placebo Comparator|Placebo comparator|2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
89050409|NCT00555074|Experimental|1|Sodium Tungstate
89050410|NCT00555074|Placebo Comparator|2|
89677246|NCT05365568|Active Comparator|BiV for CRT-p|
89677247|NCT05365568|Active Comparator|BiV for CRT-d|
89677248|NCT00482911|Experimental|Cohort 1-lenalidomide & cyclophosphamide|Participants first started on 2 Interventions (Dose A-QD) in Cycle 1, with 10 mg Lenalidomide (Len) once daily and 50 mg Cyclophosphamide (Cyc) once daily; 25 mg Sunitinib (Sun) was added once daily as a 3rd Intervention (Dose B-QD) from Cycle 2 onwards. Doses were adjusted in subsequent cycles depending on toxicity, including incremental step downs to 5/25/12.5 mg Len/Cyc/Sun once daily (Dose C-QD) or once every other day (Dose C-QOD).
89677249|NCT00482911|Experimental|Cohort 2-sunitinib & cyclophosphamide|2 participants started Cycle 1 with Dose B as described above and had adjusted-dosing as described for Cohort 1. The remaining 7 participants began Cycle 1 with 10 mg Len, 25 mg Cyc and 12.5 mg Sun once daily (Dose D-QD). Doses were adjusted in subsequent cycles depending on toxicity, including step up to 10/50/12.5 mg Len/Cyc/Sun once daily (Dose E-QD) and step down to Dose D once every other day (Dose D-QOD).
89677250|NCT01397162|Experimental|BI 54903 - low dose|BI 54903 low dose 2 puffs twice daily (b.i.d.) via Respimat inhaler plus hydrofluoralkane (HFA) metered dose inhaler (MDI) matching placebo 2 puffs b.i.d.
89677251|NCT01397162|Experimental|BI 54903 - medium dose|BI 54903 medium dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
89677252|NCT01397162|Experimental|BI 54903 - high dose|BI 54903 high dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
89050411|NCT04609488||COVID|
89050412|NCT04609488||non-COVID|
89050413|NCT00555113||1|pseudoxanthoma elasticum
89050414|NCT04609605|Experimental|patients with acute pulmonary embolism|speckle tracking echocardiography for patient with acute pulmonary embolism
89050415|NCT01847573|Experimental|Cohort 1: HT-100 tablet, Dose 1|"Single dose administration: Dose 1~Multiple dose administration: Dose 1"
89050416|NCT01847573|Experimental|Cohort 2: HT-100 tablet, Dose 2|"Single dose administration: Dose 2~Multiple dose administration: Dose 2"
89050417|NCT01847573|Experimental|Cohort 3: HT-100 tablet, Dose 3|"Single dose administration: Dose 3~Multiple dose administration: Dose 3"
89050418|NCT01847573|Experimental|Cohort 4a: HT-100 tablet, Dose 4|"Single dose administration: Dose 4~Multiple dose administration: Dose 4"
89050419|NCT01847573|Experimental|Cohort 4b: HT-100 tablet, Dose 5|* Multiple dose administration: Dose 5
89050420|NCT01847573|Experimental|Cohort 5: HT-100 tablet, Dose 6|* Multiple dose administration: Dose 5
89050421|NCT01846793|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
89677253|NCT01397162|Active Comparator|Fluticasone propionate|Fluticasone propionate 2 puffs twice b.i.d via HFA MDI plus placebo BI 54903 via Respimat inhaler 2 puffs b.i.d.
89677254|NCT01397162|Placebo Comparator|Placebo|Placebo Respimat inhaler 2 puffs b.i.d. and placebo HFA MDI, 2 puffs b.i.d.
89050422|NCT04609254|Experimental|First Group|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
89050423|NCT04609254|Experimental|Second Group|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
89677255|NCT00460421|Experimental|Palifermin Dose Escalation|A 3 dose escalation design. Sucessive cohorts of patient (9 patients per group) will each be administered Palifermin as an IV bolus injection (40, 60 or 80 µg) once daily for 3 consecutive days before the start of conditioning regimen (chemotherapy and total body irradiation) and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
89677256|NCT00483223|Experimental|Single Arm|Cisplatin or carboplatin (1 arm, 2 cohorts)
89677257|NCT01397084|Other|esomeprazole 20 mg|esomeprazole 20 mg
89050424|NCT04609254|Experimental|Third group|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
89677258|NCT00419315|Experimental|Alcohol Care Management|Care management for alcohol dependence delivered in primary care
89050425|NCT01846481|Experimental|RBP-8000 100mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
89050426|NCT01846481|Experimental|Placebo/RBP-8000 100mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000"
89677259|NCT00419315|Active Comparator|Usual Care|Usual care included a referral to specialty addiction treatment
89677260|NCT00420017|Experimental|Amiodarone|Intravenous amiodarone
89050427|NCT01846481|Experimental|RBP-8000 200mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
89677261|NCT00420017|Other|Control|Control
89677262|NCT00484393|Experimental|Tetracaine|Tetracaine 4% gel 1g applied to injection site
89677263|NCT00484393|Placebo Comparator|Placebo|Placebo cream (Aquatain) 1g applied to inejction site
89677264|NCT00485485|Experimental|Imatinib Mesylate + Docetaxel|Imatinib 400 mg orally daily; Docetaxel 60 mg/m^2 by vein over 1 hour every 3 weeks
89677265|NCT00422201|Experimental|Prospective, open-label, study of mifepristone|Eligible subjects will start study treatment at the dose of 600 mg/day (given as one 200 mg tablet tid, per os). Total duration of treatment will not exceed 12 months. At the end of 12-month treatment, investigators may petition to extend treatment on a case-by-case basis.
89677266|NCT01396148|Experimental|Children with GIST|children ages 6yrs-<18yrs
89677267|NCT01396148|Experimental|Young adults with GIST|young adults ages 18yrs-<21 yrs
89677268|NCT00485953|Experimental|Active Medication Group|risedronate 35 mg weekly
89677269|NCT00485953|No Intervention|Placebo Group|Placebo
89677270|NCT00422279|Experimental|supraalevolar|Bone inductive implant (Nobel Replace Tapered Groovy) placed in the supralveolar position
89677271|NCT00422279|Experimental|Other|Bone inductive implant (Nobel Replace Tapered Groovy) placed in extraction socket
89677272|NCT05222399|Experimental|LY3871801 (Period 1)|LY3871801 solid dispersion suspension administered orally.
89677273|NCT05222399|Experimental|LY3871801 (Period 2)|LY3871801 crystalline freebase tablet administered orally.
89050428|NCT01846481|Experimental|Placebo/RBP-8000 200mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000"
89050429|NCT04609293||Camrelizumab+apatinib+Hypofractionated radiation therapy|"Camrelizumab:200mg every 2 weeks for 1 years or until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Apatinib:250mg everyday until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.~Radiation: one week following completion of the second immunotherapy, hypofractionated radiotherapy with marginal dose of 50Gy/2Gy/25f and tumor center dose of local hyperfraction increase 24-32Gy/8-12Gy/3-4f will be performed 3-5 times. The routine radiotherapy will be started at the same time as the third immunotherapy and 25 times routine radiotherapy will be completed before the fifth or sixth immunotherapy."
89050430|NCT01844180|Experimental|Experimental Arm 1|ONO-2952 low dose every day for 4 weeks
89050431|NCT01844180|Experimental|Experimental Arm 2|ONO-2952 high dose every day for 4 weeks
89050432|NCT01844180|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 4 weeks
89050433|NCT04609059|Experimental|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
89677274|NCT00486031|Other|balsalazide disodium tablets,3.3 g BID,|
89677275|NCT04019834|Experimental|regional nerve block with local anesthesia|Treatment Arm (n=55) will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes and perform regional nerve blocks. A block needle will be passed into the fascial plane an injectate will be deposited . The injectate in the active arm will contain a local anesthestic and dexamethasone.
89677276|NCT04019834|Placebo Comparator|regional nerve block with normal saline|Placebo Comparator Arm (n=55). Patients will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue.
89677277|NCT01396070|Experimental|Brentuximab vedotin|Novel antibody-drug conjugate, 1.8 mg/kg intravenously every 3 weeks
89677278|NCT05366504|Active Comparator|Group A|
89677279|NCT05366504|Placebo Comparator|Group B|
89677280|NCT02108171|Active Comparator|dexmedetomidine|intranasal dexmedetomidine
89677281|NCT02108171|Placebo Comparator|placebo|intranasal saline
89677282|NCT01395914|Experimental|100 mg QD|100 mg yellow coated, oval tablet; oral administration once daily
89677283|NCT01395914|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
89215448|NCT00946062|Experimental|standardised O&M-training|standardised orientation and mobility training in use of the identification cane as provided by mobility trainers who received instruction in using the standardised protocol
89215449|NCT04012632||cases|Early puberty cases of Han Chinese
89215450|NCT04012632||controls|Controls were matched to cases at 1:1 by age (± 3 months)
89215451|NCT00134719|Experimental|MenHibrix Group|Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
89215452|NCT00134719|Active Comparator|ActHIB + Meningitec Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
89215453|NCT00134719|Active Comparator|ActHIB/PedvaxHIB Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.
89677284|NCT00534235|Active Comparator|Posterolateral Fusion w/Pedicle Screws|Control: Posterolateral fusion and implantation of pedicle screws after decompression
89677285|NCT00534235|Active Comparator|coflex Interlaminar Technolgy|Investigative: Implantation of coflex Interlaminar Technology after decompression
89677286|NCT04766840|Experimental|IM73 CAR-T|"Drug: IM73 CAR-T Cells~Fludarabine~Cyclophosphamide"
89677287|NCT03025178|Experimental|Central venous catheterization|Central venous catheterization will be performed using 4Fr central venous catheter at left internal jugular vein in infant. The tip of central venous catheter will be confirmed by transthoracic echocardiography. The actual insertion depth of central venous catheter will be compared to the predicted insertion depth derived from two calculation methods using height and the distance between the anatomical landmarks.
89677288|NCT04011176|Placebo Comparator|Standard treatment + placebo|Placing the microcurrent pads on the patient but not turning on the microcurrent box for 30 minutes once a week for 6 weeks
89677289|NCT04011176|Experimental|Standard treatment + Microcurrent Therapy|100-300µA microcurrent delivered for 20-300 minutes, once a week for 6 weeks
89677290|NCT00534937|Active Comparator|Standard compression|Patients in this arm will receive current standard of care (once-weekly short-stretch compression wrapping).
89677291|NCT00534937|Experimental|Flexitouch|Patients in this arm will receive once-a-week short stretch compression wrapping AND once-daily Flexitouch pump application (including Flexitouch application once-a-week in the clinic setting).
89677292|NCT03940807|Experimental|Ultra-long protocol group|All women will receive one intra-muscular administration of 11.25 mg Gonadotropin Releasing Hormone (GnRH) agonist (triptorelin acetate) on luteal phase of their menstrual cycle. Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period. Ovarian stimulation will be started after 90 days desensitization.
89677293|NCT03940807|Active Comparator|Long protocol group|All women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous application of 0.1mg of GnRH agonist (triptorelin acetate) started on luteal phase of their menstrual cycle. Ovarian stimulation will begin after 15 days desensitization.
89677294|NCT00461045|Experimental|MRZ 0.5 mg/m^2|Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
89677295|NCT00535873|Experimental|Lenalidomide|Lenalidomide starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
89677296|NCT00461513||Intervention|The PCDM intervention will include evaluation of CHF care by the collaborative care team, with diagnostic and therapeutic treatment recommendations based on current ACC/AHA national clinical practice guidelines, daily telemonitoring and patient self-care support utilizing the VA telemonitoring system, and screening and treatment for comorbid depression. The Collaborative Care (CC) team at each site will consist of a primary care provider, cardiologist, and psychiatrist, who are local opinion leaders, as well as a nurse site coordinator and pharmacist. For a given intervention patient, there will be an initial assessment of care by the CC team following the enrollment visit. Each intervention patient will be re-reviewed by the CC team a minimum of 2 additional times (at 6-weeks and 6 months). In addition, patients will have daily telemonitoring, and their care will be reviewed by the CC team if the telemonitoring data suggests clinical deterioration.
89677297|NCT00461513||Usual Care|Patients randomized to the usual care arm will continue to receive care at the discretion of their regular VA providers (for a given patient, this could include cardiology specialty care in addition to PCP care, participation in site-specific CHF programs such as CHF patient education classes, etc.), in direct continuity with the care they were receiving prior to enrollment. Patients in the usual care group will also be given information sheets that outline self-care for CHF, and will be provided with a scale, if needed, at the enrollment visit. Patients in the usual care group will have the same amount of interaction with the study team as the intervention patients (i.e. complete questionnaires at the same frequency; have the same study visits). PCPs of usual care patients will be notified of the results of all screening studies (patient survey results, lab tests) as we have done in previous studies.
89677298|NCT00487669|Experimental|Paclitaxel Poliglumex with Pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued.
89677299|NCT00488059|Experimental|Phase I|Phase 1: ENF 90mg SC BID): In the first phase or cohort phase of day I-1 through Week I-12 of the trial all patients received enfuvirtide (ENF) 90 mg subcutaneously (SC) twice daily (BID) + Isentress® [raltegravir] (RAL) 400-mg orally (PO) BID + optimized background (OB) with at least 1 fully active antiretroviral (ARV) agent excluding nucleoside reverse transcriptase inhibitor (NRTIs).
89677300|NCT00488059|Experimental|Phase II|"In the randomized comparator Phase II of the trial- (Day II-1 through Week II-16): Virologic responders confirmed HIV-1 RNA ≤50 copies/mL from Phase I were randomized to 1 of 2 treatment arms of~(Phase II Arm A: Phase I then ENF 90mg SC BID): ENF 90 mg SC BID + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs or (Phase II Arm B: Phase I then ENF 180mg SC QD): ENF 180 mg SC once daily (QD) + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs."
89215454|NCT00940836|Active Comparator|Resfenol|"Patients in this arm will receive 15 capsules containing a combination described below. They are instructed to take one capsule at 7, 11, 15, 19 and 23h every day, starting after baseline evaluation. The duration of the treatment goes from 48 to 72 hours, depending on patient availability for the second evaluation.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
89215455|NCT00940836|Placebo Comparator|Placebo|"Patients in this arm will receive 15 capsules of placebo, that they are instructed to take in the same posology and in the same duration than the active comparator.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
89215456|NCT03999177|Experimental|Kinect-TOLF prototype|
89215457|NCT05104827|Experimental|Healthcare providers|Healthcare providers employed in COVID-19 departments are referred to integrative oncology-trained practitioners for an evaluation of their two main concerns, followed by a 30-minute individually tailored integrative care.
89215458|NCT00940914|Other|pain disorders|patients with Parkinson's disease presenting pain disorders
89215459|NCT00940914|Other|without pain disorders|patients with Parkinson's disease without pain disorders
89215460|NCT00944424|Experimental|Arm A|Arm A = Docetaxel + High dose Vitamin D2
89677301|NCT02124889|Experimental|Weekly surveys|Subjects will take the multivitamin, and will also receive weekly Internet surveys asking them questions about the multivitamin treatment.
89677302|NCT02124889|No Intervention|No Survey|Subjects will take the multivitamin.
89677303|NCT02319967|No Intervention|Enhanced usual care|Inhaler technique education and distribution of spacers to all participants.
89677304|NCT02319967|Experimental|ED-only|Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
89677305|NCT02319967|Experimental|ED-plus-home|"Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.~Home visits by a community health worker (CHW)."
89677306|NCT02120443|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 monitored a common peripheral IV site over a 24 hour observation period.
89677307|NCT00536341|Experimental|lenalidomide, fludarabine, rituximab|"Phase I Non-stratified, dose-escalation: >=3 patients per dose level. Safety and tolerability will be evaluated every 2 weeks during the active treatment. Doses of lenalidomide will be escalated, while the fludarabine and rituximab doses remain fixed.~Phase II The Phase II regimen will be chosen following a review of the Phase I data. Following selection of the Phase II schedule, 40 treatment naive patients will be enrolled and treated with the Phase II regimen every 28 days for up to 6 courses. For those patients achieving a CR after 3 cycles, one additional cycle of treatment will be administered beyond CR confirmation."
89677308|NCT02122471|Experimental|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
89677309|NCT02122471|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
89677310|NCT02122471|Experimental|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
89677311|NCT00461591|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
89677312|NCT00461591|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
89677313|NCT02982733|Active Comparator|ABS|Ankaferd blood stopper
89215461|NCT00944424|Active Comparator|Arm B|Docetaxel + Standard dose Vitamin D2
89215462|NCT00944502|Experimental|Dexamethasone and complex vitamins|"Group A: Vitatonus dexa injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablet:~1 tablet orally every 8 hours for 10 days."
89215463|NCT00944502|Active Comparator|Dexamethasone|"Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablet:~1 tablet orally every 8 hours for 10 days."
89215464|NCT04754295|Experimental|STANDARD|In this arm standard monitoring of vital signs will be used during operation.
89215465|NCT04754295|Experimental|GDT|A non-invasive hemodynamic monitor STARLINK™SV will be used in addition to standard monitoring.
89215466|NCT00946140||Patients with ovarian cancer currently undergoing treatment|All of the patients will be treated per their treatment protocols by their physicians and they will be referred to this study for the DCE-MRI scans at baseline, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
89215467|NCT00949962|Active Comparator|Arm I|Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
89215468|NCT00949962|Experimental|Arm II|Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.
89215469|NCT04115007|Experimental|Arm A|Standard of care + Stereotactic Body Radiotherapy to oligometastases
89215470|NCT04115007|Active Comparator|Arm B|Standard of care
89677314|NCT02982733|Placebo Comparator|CS|Conventional sterile gauze
89677315|NCT02982733|Active Comparator|TR BAND|Dedicated hemostatic device
89677316|NCT00462449|No Intervention|1|Individuals randomized into this group will only receive specialized therapy associated with this population.
89677317|NCT00462449|Experimental|2|In addition to appropriate therapy, this group will receive the FES device and be given instruction on how to complete specialized exercises utilizing this device.
89677318|NCT00534209|Experimental|Arm I: Allogeneic B7.1/HLA-A1|"Patients will receive Allogeneic B7.1/HLA-A1 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.~Given intradermally."
89677319|NCT00534209|Placebo Comparator|Arm II: Placebo|Patients receive a placebo vaccine intradermally once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
89677320|NCT00534365|Active Comparator|1|Tension-free vaginal tape procedure (TVT)
89677321|NCT00534365|Active Comparator|2|TVT-SECUR device
89677322|NCT00423683|Experimental|1- Arixtra Alone|Arixtra Alone
89677323|NCT00423683|Active Comparator|2 Arixtra+ filter|Arixtra + filter
89677324|NCT00424619|Active Comparator|1|50 000 IU Vitamin D2
89677325|NCT00424619|Active Comparator|2|100 000 IU Vitamin D2
89677326|NCT00424619|Placebo Comparator|3|Placebo
89050434|NCT04609059|Placebo Comparator|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
89050435|NCT04676750|Experimental|MBSR|receives 8-week MBSR course
89050436|NCT04676750|No Intervention|control|receives intervention after experiment finishes
89050437|NCT04601298||AUS|
89050438|NCT04601298||FLUS|
89050439|NCT04601181|Experimental|ThisCART22 cells injection|In this arm，allogeneic anti-CD22 CAR T Cells(ThisCART22 cells) is used to treat patients with refractory or relapsed CD22 positive B cell malignancies.
89050440|NCT04676828|Experimental|SPECT functional avoidance treatment|SPECT-based radiation therapy given taken functional distribution in the lung into account, that avoids highly functional lung volumes sparing them from radiation.
89050441|NCT04676828|No Intervention|Standard treatment|CT-based radiation therapy given over 5- 6.5 weeks.
89050442|NCT04676789|Experimental|Intervention/treatment|Patients will receive sintilimab,200mg,ivdrip,day1; pegaspargase,2,500 unit/m2 deep intramuscular injection at three different sites,day 1, every 3 weeks for 4 cycles before radiation.Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent sintilimab of 200mg and pegaspargase,2,500 unit/m2 will be administered every 3 weeks for 2 cycles during IMRT for patients who do not achieve complete remission to previous induction therapy. After radiotherapy or CCRT, patients achieving CR with positive plasma EBV-DNA or partial response will continue with sintilimab maintenance up to 2 years.
89050443|NCT01811576|Active Comparator|recombinant human growth hormone|Daily subcutaneous dose
89050444|NCT01811576|Experimental|TV-1106|Titration dose levels of TV-1106
89215471|NCT04012866|Experimental|SEQ (sequential training group)|The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
89215472|NCT04012866|Experimental|DUAL (dual training group)|The dual training group (DUAL) will receive aerobic exercise training and computerized cognitive training simultaneously. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
89677327|NCT00425477|Experimental|Bexarotene + GM-CSF|BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.
89677328|NCT00427037|Placebo Comparator|Placebo|Placebo
89677329|NCT00427037|Active Comparator|Cholecalciferol|D3
89677330|NCT02113241|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
89677331|NCT02113241|Placebo Comparator|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
89677332|NCT00427661|Other|AHCT in High Risk SCD|Intervention: Busulfan; Fludarabine; cyclosporine A and MMF
89677333|NCT00427973|Experimental|AZD2171|Patients will receive AZD2171 (cediranib maleate) 30mg by mouth once a day. Treatment may continue for as long as benefit is shown. Patients will undergo MRI and CT scan of the liver before beginning treatment, 3 days after the first dose of AZD2171, and after finishing course one. Patients will also undergo blood collection periodically for laboratory studies. Laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, and pharmacological study will be performed.
89677334|NCT01795703|Experimental|Abiraterone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
89677335|NCT00429143|Experimental|Haploidentical Allogeneic Transplantation|Patients undergoing hematopoietic stem cell transplant from a partially matched related donor
89677336|NCT00430625|Experimental|VPRIV®-45 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)
89677337|NCT00430625|Experimental|VPRIV®-60 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)
89677338|NCT00432341|Experimental|BOTOX®|Botulinum toxin type A (BOTOX®)
89677339|NCT00432341|Active Comparator|Dysport®|Botulinum toxin type A (Dysport®)
89677340|NCT00433745|Experimental|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
89677341|NCT01395758|Experimental|tivantinib (ARQ 197) plus erlotinib arm|"Eligible subjects will be randomly assigned to receive erlotinib plus tivantinib (ARQ 197).~Treatment will be open-label and continue until progression of disease, unacceptable toxicity, or another discontinuation criterion is met."
89050445|NCT04609371|Experimental|self-care tools|"Arms Assigned Interventions Experimental: self-care tools~The tools are adapted from those successfully deployed in the DIRECTsc depression self-care project focusing on patients with depressive symptoms, but abbreviated to meet the needs of the proposed short-term intervention for a broader sample of patients to include those with anxiety symptoms and with minimal symptoms. Tools will include individual chapters of the Antidepressant Skills Workbook; the mood monitoring tool; a workbook on managing worry; relaxation audio files and information on exercise and healthy eating. In view of the short duration of the intervention (8 weeks), a maximum of 2 tools will be sent to each participant.~An algorithm will determine which self-care tools, matched to the specific mental health symptoms reported by participants, will be sent to the participants."
89050446|NCT04609371|Experimental|coaching|Participants will receive the algorithm-determined self-care tools, matched to the specific mental health symptoms reported by participants as in the first arm. They will ALSO be offered up to 3 coach calls. Coaching by a trained lay coach will be structured and guided by a manual. Trained lay coaches will call participants in the week following delivery of the toolkit to guide them through the self-care toolkit over an 8-week period. Coaches will contact participants a maximum of 3 times, with calls expected to average 15-20 minutes. Call content will be guided by a structured coaching manual adapted from those used in the team's previous two RCTs of the self-care materials. The coaches will follow structured agendas, keep records of all contacts.
89050447|NCT01810484|Active Comparator|Group 1|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment only; Treatment Area B will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area C will be treated with CO2 laser treatment only"
89050448|NCT01810484|Active Comparator|Group 2|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area B will be treated with CO2 laser treatment only; Treatment Area C will be treated with Ultherapy® treatment only"
89050449|NCT01810484|Active Comparator|Group 3|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with CO2 laser treatment only; Treatment Area B will be treated with Ultherapy® treatment only; Treatment Area C will be treated with Ultherapy® treatment and CO2 laser treatment"
89050450|NCT04600830|Experimental|Dry Needling Group|Dry needling will be applied to the myofascial trigger points of the gastrocnemius muscle. With the dry needle (0.3 x 40 mm. Myofib, Toledo, Spain). Thus, insert the needle until you get the first twitch response. Once the first twitch response is obtained, the needle will move about 2-3 mm vertically quickly. Twenty-five insertions without leaving the skin. The approximate frequency of 1 Hz for 25 to 30 seconds.
89050451|NCT04600830|Active Comparator|Foam Roller Group|The myofascial self-release technique with the FR Black Roll PRO (Bottighogen, Switzerland). The subject will move his body in the same direction as the muscle fibers, using his hands to propel and get the roller to slide back and forth. The device will only be applied at the muscular level, avoid the area of the Achilles tendon. It will be repeated on the contralateral leg. A total of three 60-second steps is executed on each leg and a 30-second break between both.
89215473|NCT04012866|Active Comparator|CI (control intervention group)|The control intervention group (CI) will receive a control training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
89215474|NCT00946218||Part A|Children with presumptive dengue infection enrolled for empiric cost modeling with retrospective clinical estimation and comparison of test performance to the standard of care.
89677342|NCT01395758|Active Comparator|Chemotherapy arm|Investigator's choice of single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered in 3-week cycles according to the approved label until disease progression or unacceptable toxicity. Subjects who discontinued chemotherapy can be switched to the crossover arm (tivantinib plus erlotinib) and continue treatment until disease progression or unacceptable toxicity.
89677343|NCT00462605|Experimental|Arm I|Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.
89050452|NCT04600869|Experimental|Nursing Group|Nurses in the control group accepted the other non-fertility (standard) nursing training for the intervention, whereas those in the experimental group accepted the oncofertility training. Based on research ethics and design, a standard education course was held for the control group after completing data collection in the nursing experimental group. We began to recruit patients into the patient experimental group after all nurses completed their educational courses.
89677344|NCT03025022|Experimental|14C-JNJ-42847922 40 miiligram (mg)|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 on Day 1.
89677345|NCT03024944|Experimental|Brain Imaging with 18F-THK-5351|This group consists of 30 adult subjects: 10 with Type 2 diabetes, 10 with pre-diabetes, and 10 with normal glucose tolerance. Each subject will receive a baseline scan and a follow-up PET scan with 18F-THK-5351.
89677346|NCT02120287|Experimental|BZ-SRS with Bevacizumab|"All patients will receive Border Zone Stereotactic Radiosurgery (BZ-SRS) and additionally receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by 10 mg/kg/day every 14 days until progression.~One to 14 days before BZ- SRS procedure, patients at centers with MRS experience will undergo standard brain MRI /MRS"
89677347|NCT00534833|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
89677348|NCT00534833|Active Comparator|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
89677349|NCT00462839|Experimental|Calibrated drapes viewed first|Caregivers were shown calibrated drape demonstrating level of blood and asked to estimate amount of blood in collection bag. These same individuals were then crossed over and shown non-calibrated drapes and asked to estimate the amount of blood they contained.
89677350|NCT00462839|Active Comparator|Non-calibrated drapes viewed first|Standard vaginal delivery drape (non-calibrated) was shown to caregiver who was asked to estimate amount of blood. These same individuals were then crossed over and shown calibrated delivery drapes and asked to estimate the amount of blood they contained.
89677351|NCT00535301|Placebo Comparator|Anterior Colporrhaphy (sutured repair)|Anterior vaginal prolapse repair with anterior colporrhaphy (no graft) using sutures.
89677352|NCT00535301|Active Comparator|Perigee (grafted repair)|Anterior vaginal prolapse repair with graft
89050453|NCT01804829|No Intervention|Observational Control|Subjects who attain HCV RNA <100 IU/ml and are randomized to the control arm will receive standard post-transplant immunosuppressant therapy and be followed for a 34 week period.
89050454|NCT01804829|Experimental|Civacir® 10% at 200 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir 200 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
89050455|NCT01804829|Experimental|Civacir® 10% at 300 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir® 300 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
89050456|NCT00565422|Experimental|Single Arm|Escitalopram
89050457|NCT01804088|Experimental|Stent|
89050458|NCT04608747|Experimental|Intervention arm|After an overnight fast, participants subjected to baseline measurements and blood and urine collection and then consumed an amount of 50 g of tahini. Blood and urine collection and other measurements were repeated 4 h postprandially.
89050459|NCT01802723|Experimental|LIPO-202, Low|Drug: salmeterol xinafoate
89050460|NCT01802723|Experimental|LIPO-202, Mid|Drug: salmeterol xinafoate
89050461|NCT01802723|Experimental|LIPO-202, High|Drug: salmeterol xinafoate
89050462|NCT01802723|Experimental|LIPO-202, Placebo|Drug: Placebo
89050463|NCT04600908||Non-physician staff|All non-physician staff who have had commuting accidents
89050464|NCT01789736|Experimental|PG286|PG286 Ophthalmic Solution q.d. O.U.
89050465|NCT01789736|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
89050466|NCT01789736|Active Comparator|Travoprost 0.004%|Travoprost 0.004% q.d. O.U.
89050467|NCT04600947|Experimental|LP002|Participants will receive LP002 10 mg/kg by intravenous (IV) infusion every 2 weeks (Q2W) for up to 24 months.
89050468|NCT01789268||Full-Term Healthy Infants (> /=37 weeks gestational age)|130 male and female term infants born at a gestational age of 37 0/7 to 41 6/7 weeks (Healthy comparator) will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
89050469|NCT01789268||Preterm Infants (<36 weeks gestational age)|150 male and female preterm infants born at gestational age 23 0/7 to 35 6/7 weeks will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
89050470|NCT00564330|Active Comparator|esomeprazole|Esomeprazole 20mg twice daily
89050471|NCT00564330|Placebo Comparator|placebo|Placebo tablet twice daily
89050472|NCT01783808|Experimental|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
89050473|NCT01783808|No Intervention|Control group|The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.
89050474|NCT04600635||patients with a medical history of obesity|Patients included are subject who entered a structured program of care for their obesity, with or without bariatric surgery.
88996346|NCT02921932|Active Comparator|Intervention|"In the interventional arm, patients will be given:~A 'Threshold' Inspiratory Muscle Trainer~A nutritional assessment: if needed, dietary supplements prescribed (i.e Ensure, Glucerna).~Cognitive exercise in the form of the 'Memory' card game will be taught to the patients and the caregiver (if available), to be done twice a day.~Patients will be provided with a protocol activities log and a study assistant will be conducting a telephone conversation on day 1, 4 and 7 to encourage compliance to the protocol and answer any queries with regards to the research study."
88996347|NCT02921932|No Intervention|Control|In the control arm, patients will be given the standard education materials regarding surgery and carry out daily activities as usual until the admission of the surgery.
88996348|NCT04689100|Experimental|Dose Escalation Cohort|"Monotherapy: Six dose levels of JMT101 will be tested according to an accelerated titration method followed by a conventional 3 + 3 study design.~Combined with chemotherapy: Three dose levels of JMT101 will be tested by a conventional 3 + 3 study design.~The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
88996349|NCT04689100|Experimental|Dose Expansion Cohort|Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.
88996350|NCT02921698||FRED®|
88996351|NCT00406250|Experimental|Bevacizumab|
88996352|NCT03878056||Transvaginal mesh|Vaginal surgery (UpholdTM Lite Vaginal Support, Boston Scientific)
88996353|NCT03878056||Robotic sacral colpopexy|Robotic surgery (Artisyn® Y-Shaped Mesh - Ethicon)
88996354|NCT02921620|Experimental|PRX-102|PRX-102 infusions every 2 weeks
88996355|NCT02921620|Placebo Comparator|Placebo|Placebo infusions every 2 weeks
88996356|NCT02921347|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation
88996357|NCT02921347|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
88996358|NCT00188175|Experimental|IMRT for lower limb soft tissue sarcoma|
88996359|NCT02921269|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88996360|NCT02921542||Homogenous Lesions|
88996361|NCT02921542||Heterogenous Lesions|
88996362|NCT02921542||Calcific Lesions|
88996363|NCT02921542||Restenotic Lesions|
88996364|NCT02921308||With BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
89050475|NCT00564369|Experimental|1|2006 CDC recommendations
89050476|NCT00564369|Active Comparator|2|Prior CDC recommendations
89215475|NCT00946218||Part B|Children with definitive dengue infection enrolled for gene expression analysis.
89215476|NCT00950040|Experimental|Brief alcohol intervention|Brief alcohol intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
89215477|NCT00950040|Active Comparator|General Health Education|General health education intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
89215478|NCT00950196|Experimental|amantadine (PKMERZ)|
89677353|NCT00434993|Active Comparator|Albuterol Sulfate|
89677354|NCT00434993|Placebo Comparator|Placebo|
89677355|NCT01395524|Experimental|NKTR-118 12.5mg|
89677356|NCT01395524|Experimental|NKTR-118 25mg|
89677357|NCT01395524|Placebo Comparator|Placebo|
89677358|NCT01395368||Brain Speed Test|Brain Speed Test
89677359|NCT05366348|Experimental|Horse-back riding|The study group received horse-back riding training for eight weeks.
89677360|NCT05366348|No Intervention|Control group|Sedentary adolescent individuals who do not ride horses
89677361|NCT04011020|Experimental|Treatment of T1D with Stem Cell Educator therapy|Recruited T1D subjects will receive one treatment with SCE therapy.
89677362|NCT04011020|Experimental|Conventional insulin therapy|Control group will receive conventional insulin therapy.
89677363|NCT01394978|Other|Control|No treatment.
89677364|NCT01394978|Experimental|ProGEL Pleural Air Leak Sealant with standard surgical closure|Standard surgical closure (suturing or stapling of visible air leaks incurred during resection of lung parenchyma) plus Progel Pleural Air Leak Sealant.
89677365|NCT01394978|Experimental|ProGEL Pleural Air Leak Sealant without standard surgical closure|Progel Pleural Air Leak Sealant without standard surgical closure (without suturing or stapling of visible air leaks incurred during resection of lung parenchyma).
89677366|NCT04338698|Active Comparator|Control Intervention|Hydroxychloroquine
89677367|NCT04338698|Experimental|Comparator 1|Azithromycin
89677368|NCT04338698|Experimental|Comparator 2|Oseltamivir
89215479|NCT01565031||controlled asthmatics, down-titration|Adults (age between 18 and 80) with asthma under control (see definitions) during the last 3 months, treated with a combination of ICS and long-acting beta-agonist (LABA).
89215480|NCT04012554|Experimental|avoiding chest drainage tube placement after resection of lung|This group of patients underwent avoiding chest drainage tube placement after VATS of the lung.
89215481|NCT04012554|Other|indewlling chest drainage tube after resection of lung|This group of patients underwent indewlling chest drainage tube after VATS of the lung.
89215482|NCT01565109|Experimental|Single arm study|"Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU~Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks"
89215483|NCT00526071|Experimental|Migalastat|Migalastat was administered orally, 150 mg QOD, 250 mg QD for 3 days, 4 days off per week for 2 months, or 500 mg QD for 3 days, 4 days off per week for up to 10 months, depending on the approval date of the protocol amendments at each site. Participants received migalastat for up to 56 months.
89677369|NCT04338698|Experimental|Comparator 3|Hydroxychloroquine + Azithromycin
89677370|NCT04338698|Experimental|Comparator 4|Hydroxychloroquine + Oseltamivir
89677371|NCT04338698|Experimental|Comparator 5|Oseltamivir + Azithromycin
89677372|NCT04338698|Experimental|Comparator 6|Hydroxyquinine + Oseltamivir + Azithromycin
89677373|NCT04338698|No Intervention|Observational Cohort|Non-consenting to randomization
89677374|NCT01394276||Tocilizumab|Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra [Tocilizumab (TCZ)] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed. Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
89677375|NCT00435539|Experimental|ocriplasmin 75µg single injection|Ocriplasmin 75µg single injection versus sham injection
89677376|NCT00435539|Experimental|ocriplasmin 125µg single injection|Ocriplasmin 125µg single injection versus sham injection
89677377|NCT00435539|Experimental|ocriplasmin 175µg single injection|Ocriplasmin 175µg single injection versus sham injection
89677378|NCT00435539|Experimental|ocriplasmin 125µg multiple injections|Ocriplasmin 125µg multiple injections. Subjects who did not achieve resolution of VMT by the day 28 visit (i.e. non-responders) were given an open-label injection of ocriplasmin 125µg. Subjects who still did not achieve resolution of VMT by the day 56 visit were given a second open-label injection of ocriplasmin 125µg.
89677379|NCT00435539|Sham Comparator|sham injection|sham injection
89677380|NCT00462917|Experimental|Pleiotropic info, in-person disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed in-person during an APOE-based genetic risk assessment
89677381|NCT00462917|Experimental|AD-only info, phone disclosure|Alzheimer's disease risk information only is disclosed via telephone during an APOE-based genetic risk assessment
89677382|NCT00462917|Experimental|Pleiotropic info, phone disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed via telephone during an APOE-based genetic risk assessment
89677383|NCT00462917|Active Comparator|AD-only info, in-person disclosure|Alzheimer's disease risk information only is disclosed in-person during an APOE-based genetic risk assessment
89677384|NCT04407416|Active Comparator|Healthy subjects|The breath of all patients with positive FIT (fecal immunochemical test) but negative colonoscopy will be sampled using a breath sampler
89677385|NCT04407416|Active Comparator|Colorectal Cancer patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colorectal cancer detected by colonoscopy will be sampled using a breath sampler
89677386|NCT04407416|Active Comparator|Colonic Polyps patients|The breath of all patients with positive FIT (fecal immunochemical test) and a colonic polyp detected by colonoscopy will be sampled using a breath sampler
89677387|NCT05366036||Participants with MS|Participants with relapsing-remitting MS who are newly prescribed and will start treatment with Tecfidera in a real-world clinical practice setting will be observed prospectively for up to 24 months.
89677388|NCT00464711|Other|Escitalopram|single arm
89215484|NCT00525915|Experimental|Arm A: Chemo with Radiation Treatment|For 5 weeks, Chemo of 5-FU 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.
89215485|NCT00525915|Experimental|Arm B: Pre-Op Chemo + Chemo with Radiation Treatment|Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)
89215486|NCT05191329||study group|40 patients with non surgical presbyopic correction e.g. glasses and 80 patients that underwent pseudophakic presbyopic correction with multifocal or trifocal IOLs
89215487|NCT00521079|Experimental|vBloc|Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).
89215488|NCT00521079|Sham Comparator|Placebo|Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).
89677389|NCT01795781||Patients receiving a new anticoagulant|Patients are receiving dabigatran for atrial fibrillation or rivaroxaban for osteoarthritis of hip or knee undergoing total hip or knee replacement respectively
89215489|NCT03107117|Experimental|Computer counseling|a computer-assisted adolescent motivational intervention called e-toke plus an online parenting program - Parenting Wisely
89215490|NCT03107117|Active Comparator|Standard care|Standard care is typically referral to counseling for substance use
89215491|NCT02579837|No Intervention|Usual Screening|Participants randomized to the Usual Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care).
89522581|NCT03126695|Active Comparator|Treatment Sequence 4 (DCAB)|"Subjects were randomized to treatment sequence DCAB:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
89522582|NCT04616443|Experimental|Dose escalation|"The HX008 injection is combined with OH2 injections at 10ˆ6 and 10ˆ7 CCID50/mL at a fixed dose of 200 mg, respectively.~OH2 will be injected individually in the first week, followed by every two weeks while HX008 will be injected every three weeks after the first injection which will be in the second week."
89522583|NCT03403907|Experimental|Probiotic|Probiotic administration
89522584|NCT04610593|Experimental|Intervention Group|This group will receive a Mindfulness-based intervention for 8 weeks, and after the intervention this participants will continuous their treatment as usual
89522585|NCT04610593|No Intervention|Treatment as Usual|Patients in the control group received treatment as usual in the hemodialysis setting: Carry out hemodialysis sessions three times a week, on alternate days, for approximately 4 hours added to appointments and procedures performed by professionals from different areas (medicine, nursing, nutrition, physical education, social work, pharmacy, psychology).
89522586|NCT03398629||IUGR group|Estimated fetal weight below10th percentile for gestational age associated with Abnormal Doppler flow in the umbilical cord (umbilical artery pulsatility index (PI)>95th percentile).
89522587|NCT03398629||Structural anomaly group|Fetus/neonates/infants who are diagnosed as congenital malformations, deformations, disruptions, dysplasias by ultrasound.
89522588|NCT03398629||Chromosomal anomaly group|Fetus/neonates/infants diagnosed by genetic amniocentesis or chorionic villus sampling for increased risk for fetal aneuploidy or fluorescence in situ hybridization.
89522589|NCT04647643||Paclitaxel Drug Coated Balloon|Patients treated with paclitaxel drug-coated balloon
89522590|NCT04647643||Paclitaxel Drug Coated Stent|Patients treated with paclitaxel drug-coated stent
89522591|NCT05166941|Experimental|Experimental group|It is a closed group in which the training program is implemented.
89522592|NCT05166941|No Intervention|Control Group|No training program was applied to this group.
89522593|NCT04167761|Experimental|Ertugliflozin|Ertugliflozin, also known as Steglatro, will be administered once daily for 5 days at a dose of 15mg orally.
89522594|NCT04167761|Active Comparator|Glipizide|Glipizide will be randomized to either 2.5mg or 5mg oral dose once daily for 5 days.
89522595|NCT04567381|Active Comparator|Treatment as Usual|Treatment as Usual (TAU)/Control. Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
89522596|NCT04567381|Experimental|Enhanced Services|Enhanced Services/Treatment (ES). Participants randomized to the ES intervention will receive intensive community-based case management.
89522597|NCT03401177|Experimental|Naproxen & Heavy resistance training|Naproxen: 500 mg x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
89522598|NCT03401177|Placebo Comparator|Placebo & Heavy resistance training|Placebo oral tablet: pill manufactured to mimic naproxen tablet x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
89522599|NCT04152785|Experimental|GHG|Information given regarding greenhouse gas emissions via a GHG score
89522600|NCT04152785|Experimental|Nutrition|Information given regarding nutrition via a nutrient profiling score
89522601|NCT04152785|Experimental|GHG+nutrition|Information given regarding GHG and nutrition via a combined score
89522602|NCT04152785|Placebo Comparator|No logo|No information given
89522603|NCT04446715|Experimental|Sufentanil Group|Patients will receive sufentanil 5 μg in addition to 0.5% heavy bupivacaine spinal anesthesia
89522604|NCT04446715|Experimental|Meperidine Group|Patients will receive meperidine 12.5 mg in addition to 0.5% heavy bupivacaine spinal anesthesia
89522605|NCT04079387|Experimental|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°."
89522606|NCT04079387|Active Comparator|ENDOTRACHEAL TUBE ALONE|The control group consists in intubating the trachea with an endotracheal tube alone (i.e, without stylet).
89215492|NCT02579837|Experimental|On-Site Screening|"Participants randomized to the On-Site Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care). However, they will also undergo non-mydriatic ultra-widefield (UWF) retinal imaging (both 100 and 200 degrees) using the Optos 200Tx UWF retinal imaging device in the Ophthalmology Department on the same day as their Diabetes Clinic visit.~Half of this group will by random allocation undergo optical coherence tomography (OCT) using the Zeiss Cirrus OCT, which may or may not be done on the same day (for practical reasons regarding availability of OCT at the hospital)."
89215493|NCT00521001|Experimental|everolimus + temozolomide|"Patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, 22-26, and 29-33 and oral temozolomide once a day on days 8-12 for course 1 only. For course 2 and all subsequent courses, patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, and 22-26 and oral temozolomide once a day on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~All patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for relative numbers of T, B, and NK cells via flow cytometry, quantitative immunoglobulin levels (IgG, IgM, and IgA), Tetramer/ELISPOT CTL frequencies to CMV/EBV immunodominant antigens, V beta T cell spectratyping, and VEGF levels via ELISA.~After completion of study treatment, patients are followed every 8 weeks."
89215494|NCT04887701|Experimental|Non-hormonal device therapy|Daily non-hormonal device therapy
89215495|NCT04887701|Sham Comparator|Sham Therapy|Daily non-hormonal sham device therapy
89215496|NCT00134563|Experimental|Teriflunomide 7 mg|Teriflunomide 7 mg once daily for 108 weeks
89677390|NCT01796015|Other|For the 97 patients|"day 0: ultrasound of ONSD (= 4 measurements: 1 transverse and 1 sagittal for each eye) + transcranial Doppler at T-15 (15 minutes before ICP measurement), within 1h following ICP measurement, and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~day 1: ONSD ultrasound + transcranial Doppler in the morning and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~days 2 and 3 : same as day 1~when leaving the intensive care unit: Pediatric Overall Performance Category (POPC) scale"
89677391|NCT01796015|Other|For the control group|one single ONSD in addition to their usual care (4 measurements: 1 transverse and 1 sagittal for each eye) in the morning in absence of painful sensation
89677392|NCT01796015|Other|For the learning curve|minimum 15 ONSD ultrasounds will be performed by each of the 15 intensive care doctor or interns expected. One ONSD ultrasound corresponds to 2 measurements: 1 transverse and 1 sagittal. Each volunteer will have maximum 30 ONSD ultrasound measures over a 1 month period.
89677393|NCT02078180|Active Comparator|generic bupropion IR75|One oral dose of generic bupropion IR75
89677394|NCT02078180|Active Comparator|generic bupropion IR100|One oral dose of generic bupropion IR100
89677395|NCT02078180|Active Comparator|generic bupropion SR100|One oral dose of generic bupropion SR100
89677396|NCT02078180|Active Comparator|generic bupropion SR150|One oral dose of generic bupropion SR150
89677397|NCT02078180|Active Comparator|generic bupropion XL150|One oral dose of generic bupropion XL150
89677398|NCT02078180|Active Comparator|generic bupropion XL300|One oral dose of generic bupropion XL300
89677399|NCT00535613|Experimental|1|propofol
89677400|NCT00535613|Sham Comparator|2|no propofol
89677401|NCT04010552|Experimental|NALIRINOX treatment|Patients will be treated with NALIRINOX, a combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin. Treatment regimen will consist of 8 cycles of neoadjuvant NALIRINOX prior to surgery and trial duration is expected to be 24 months.
89677402|NCT04010240||Retrospective cohort|For eligible subject, tumor material will be tested by immunohistochemistry (Pan-Trk ICH testing with mAb EPR17341).
89677403|NCT00535769|Placebo Comparator|Electronic monitor + no text message|The control or placebo comparator group of subjects will receive the study sunscreen with the attached electronic monitor. They will be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If the subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
89215497|NCT00134563|Experimental|Teriflunomide 14 mg|Teriflunomide 14 mg once daily for 108 weeks
89215498|NCT00134563|Placebo Comparator|Placebo|Placebo (for teriflunomide) once daily for 108 weeks
89215499|NCT04019171|Experimental|interval exercise training|
89677404|NCT00535769|Experimental|Electronic monitor + Text message|The text message experimental group of subjects will receive the study sunscreen with the attached electronic monitor. In addition, this group will receive daily text messages on their cellular phone to remind them to apply the sunscreen. The text message will also contain the daily weather information. This group will also be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
89677405|NCT03595670||experimental group|"• Patients diagnosed bipolar in mania, depression or euthymic phases according DSM-IV critiera by psychiatrist~standardized questionnaires and interview will be performed"
89677406|NCT00466661|Experimental|Acamprosate|666 mg p.o. TID
89677407|NCT00466661|Placebo Comparator|Placebo|Matching placebo
89677408|NCT05360576|Experimental|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|Test Product
89677409|NCT05360576|Active Comparator|NuvaRing® (etonogestrel/ethinyl estradiol 11.7/2.7 mg)|Reference Product
89677410|NCT00535925|Active Comparator|Standard of Care (SoC) therapy|Control group patients will continue their SoC therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
89677411|NCT00535925|Experimental|Multifactorial Intensified therapy|"An intensive multifactorial intervention according Scientific Guidelines is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.~In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (<130/80 mmHg)."
89677412|NCT00211172|Experimental|Beta-blocker adherence after an AMI|Patients received two mailings about the importance of beta blocker use.
89677413|NCT00211172|No Intervention|Usual care|Patients received usual care.
89677414|NCT01796093||Digoxin cross-over ivabradine|Digoxin 0,125 mg once a day 5 days per week during 3 months. Ivabradine, 7,5 mg b.id. during 3 months.
89677415|NCT00537511|Experimental|Dose-finding arm: Pomalidomide + Cisplatin + Etoposide|Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m^2 and IV etoposide 100 mg/m^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.
89677416|NCT00435929|Experimental|1|
89677417|NCT00435929|Experimental|2|
89677418|NCT00436475|Other|1|Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
89677419|NCT00436475|Other|2|Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
89677420|NCT00436475|Other|3|Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
89677421|NCT00436475|Other|4|Vitamin D3-Placebo plus Calcium-Placebo
89677422|NCT00210626|Active Comparator|PROCRIT|
89677423|NCT00210626|Placebo Comparator|Placebo|
89677424|NCT00538213|Experimental|Adjuvanted influenza vaccine GSK576389A Group|Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A.
89677425|NCT00538213|Active Comparator|Fluarix young Group|Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
89677426|NCT00538213|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
89677427|NCT03595514|Active Comparator|Single Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
89677428|NCT03595514|Experimental|Double Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
89677429|NCT05368220||Patients with non-autoimmune diabetes (type 2 diabetes)|"Any case of non-T1D defined as:~Debut >30 years of age OR~Debut <30 years of age AND negative autoantibodies~treated at Steno Diabetes Center Copenhagen"
89677430|NCT05368220||Patients with gestational diabetes|"Any case of diabetes diagnosed in pregnancy treated at the following obstetric clinics in the Capital Region in Denmark:~Rigshospitalet, Nordsjællands Hospital, Herlev Hospital, Hvidovre Hospital"
89677431|NCT03595436|Experimental|Pea Protein Breakfast Preload|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preloads will be standardized to ~325 kcal. The preloads will include the same fat content but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
89677432|NCT03595436|Placebo Comparator|Carbohydrate Control Breakfast Preload|The study participants will be provided with a control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
89677433|NCT03595436|Active Comparator|Whey Protein|The study participants will be provided with an active control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein amount and type and carbohydrate amount. All ingredients are GRAS listed and approved.
89677434|NCT00215852|Active Comparator|1|500 IU
89677435|NCT00215852|Active Comparator|2|1000 IU
89677436|NCT00215852|Active Comparator|3|2000 IU
89677437|NCT03595046|Experimental|erector spinae plane block group (group E)|ultrasound-guided erector spinae plane block
89677438|NCT03595046|Active Comparator|thoracic paravertebral block group (group P)|ultrasound-guided thoracic paravertebral block
89677439|NCT00217022|Active Comparator|Budesonide|9 mg daily
89677440|NCT00217022|Placebo Comparator|Placebo|three tablets daily
89677441|NCT03997994|Experimental|Experimental: DCB Treatment|Stricture patients treated by DCB
89677442|NCT00538759|Experimental|EBRT|External beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
89677443|NCT00538759|Sham Comparator|Control|Sham external beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
89677444|NCT05369312|Experimental|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-442096 administered, once daily (QD).
89677445|NCT05369312|Experimental|Dose Expansion|Oral tablets administered at MTD/RP2D defined dose. Each treatment cycle will be 21 days in duration with BPI-442096 administered, once daily (QD)
89050477|NCT01779947|Experimental|Estradiol Vaginal Insert 10 mcg|Estradiol Vaginal Insert 10 mcg - Test Product
89050478|NCT01779947|Active Comparator|Vagifem Tablets 10 mcg|Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug
89050479|NCT01779947|Placebo Comparator|Placebo|Placebo for the test product Estradiol Vaginal Tablets 10 mcg
89050480|NCT00564408|Experimental|I|
89050481|NCT01773785|Experimental|SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
89050482|NCT04608864|Experimental|varicocelectomy arm|The varicocelectomy procedure will be performed three months before ICSI for men with with male-factor infertility and were diagnosed clinically with varicocele
89050483|NCT04608864|No Intervention|Control (No varicocelectomy) arm|Couples with male-factor infertility and males were diagnosed clinically with varicocele will undergo ICSI
89215500|NCT04019171|No Intervention|waiting list|
89215501|NCT03966547|Experimental|Local anesthetic|
89215502|NCT03966547|Placebo Comparator|Isotonic NaCl|
89215503|NCT01326325|Experimental|Ketamine|Ketamine PANFARMA
89215504|NCT01326325|Placebo Comparator|Not Ketamine|NaCl
89677446|NCT03594968||polycystic ovary syndrome (PCOS)|"Presence of ≥2 of the following:~oligomenorrhea and/or anovulation~Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism."
89677447|NCT03594968||healthy|healthy patients who had no polycystic ovary
89677448|NCT00538915|Experimental|Nabi-IGIV Infused Every 3- or 4-Weeks|
89677449|NCT03598946|Experimental|Human Papilloma Virus Test urinary|Urinary Test by a kit which is send to the woman's house
89677450|NCT05369702||CASE(coronary artery disease)|Patients with confirmed coronary artery disease
89677451|NCT05369702||CONTROL|People without coronary artery disease
89677452|NCT03594812|Experimental|Experimental group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region.
89677453|NCT03594812|Placebo Comparator|Placebo group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region but the radiofrequency device was switched off- Radiofrequency without power.
89677454|NCT00490009|Experimental|Bexxar + Total Body Irradiation (TBI)|Bexxar will be administered with pre-medications acetaminophen, diphenhydramine, and potassium iodide (KI).
89677455|NCT03769532|Experimental|Pembrolizumab + Azacitidine|"Pembrolizumab (IMP): 200 mg i.v. (fixed dose) / Azacitidine (SOC): 75 mg/m2 s.c.~maximum duration of treatment: up to 24 weeks"
89677456|NCT00490477|No Intervention|CONVENTIONAL|
89677457|NCT00490477|Active Comparator|POLYMYXIN-B|an extracorporeal LPS removal
89677458|NCT00491491|Experimental|Z-BEAM|ibritumomab tiuxetan (zevalin) BEAM
89677459|NCT00491491|Active Comparator|standard BEAM|standard BEAM chemotherapy
89677460|NCT00492583|Placebo Comparator|Placebo|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of placebo drink.
89677461|NCT00492583|Experimental|Bifidobacterium lactis (BB-12)|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of active drink.
89677462|NCT00492973|Active Comparator|Control|Patients in the active comparator group will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
89677463|NCT00492973|Experimental|Corticosteroid|Patients in the Corticosteroid group will have the same medications as the Control Group with the addition of a corticosteroid (methylprednisolone acetate)
89677464|NCT03594656|Experimental|Early-start Group|Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks
89215505|NCT01326403|Experimental|Group A|Patients will receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
89215506|NCT01326403|Experimental|GROUP B|Patients will receive IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
89215507|NCT01326403|Placebo Comparator|GROUP C|A control group will only receive placebo in the emergency room and in the OR.
89215508|NCT00520845|Experimental|Treatment Arm|Either docetaxel or pemetrexed given with celecoxib
89677465|NCT03594656|Placebo Comparator|Delayed-start Group|Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks
89677466|NCT00494143|Active Comparator|Conventional Prosthetic foot|A conventional prosthetic foot that has limited energy storage and return capabilities. It is standardized and used by all subjects in the study.
89215509|NCT00185731|Experimental|80 mg Atorvastatin|Atorvastatin, 80 mg tablet, will be taken orally by the patient daily, beginning on study day 1.
89215510|NCT00582491|Experimental|I|Modafinil 400mg orally everyday for 16 days
89215511|NCT00582491|Placebo Comparator|II|Placebo orally everyday for 16 days
89215512|NCT00520767|Experimental|Melphalan, Dexamethasone, Bortezomib,|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
89215513|NCT02390453|Experimental|Combined Cognitive and Physical|This consists of 45 minutes of Cognitive arm + 45 minutes of Physical arm (90 minutes total), 3 days a week for 12 weeks (36 sessions).
89215514|NCT02390453|Active Comparator|Cognitive|This consists of 45 minutes of cognitive modules from Posit Science, 3 days a week for 12 weeks (36 sessions).
89215515|NCT02390453|Active Comparator|Physical|This consists of 45 minutes of multi-modal physical exercise, 3 days a week for 12 weeks (36 sessions).
89677467|NCT00494143|Active Comparator|Prescribed Prosthetic foot|the Prosthetic foot that the subject had prescribed for them by their clinical providers and was worn prior to study initiation
89677468|NCT00494143|Experimental|CESR foot|the experimental CESR, controlled energy storage prosthetic foot
89677469|NCT03595202|Other|Step1:4㎎ TID|TS-143 12mg total dose/day or Placebo
89677470|NCT03595202|Other|Step2:11㎎ TID|TS-143 33mg total dose/day or Placebo
89677471|NCT03596684|Experimental|citrulline|citrulline 5g/d
89677472|NCT03596684|Placebo Comparator|Placebo|pure mixture of amino acids: alanine, aspartate, glycine, proline, serine, histidine
89677473|NCT03832868|Experimental|Pre-visit decision aid|Patients receiving the decision aid pre-visit will be given a paper copy of the decision aid in the waiting room and will have a minimum of 15 minutes to review it - either in the waiting room or in the exam room while waiting for the electrophysiologist.
89677474|NCT03832868|Experimental|Post-visit decision aid|Patients receiving the decision aid after the encounter will meet with the electrophysiologist first and receive the aid afterward.
89677475|NCT05630534|Experimental|Minocycline|This intervention arm will receive oral or intranasal minocycline capsules 100 mg Q12H, first dose 200 mg, start on the fifth day of cerebral hemorrhage, for 14 days
89677476|NCT05630534|Placebo Comparator|Control（starch）|This arm will receive oral or intranasal administration of identically packaged placebo capsules (starch) 100 mg Q12H, first dose 200 mg, start on the fifth day of cerebral hemorrhage, for 14 days
89677477|NCT05630456|Experimental|Intervention Group|In the intervention group, the researcher gave feedback on the subjects' exercise amount through telephone contact every 2 weeks during the 12-week study period. Through phone consultations, they answered questions about exercise or discussed problems, encouraged to continue exercising, answered questions or discussed problems related to wearable devices and apps, and encouraged continuous data transmission.
89677478|NCT05630456|Placebo Comparator|Control Group|In the case of the control group, physical activity is monitored by itself through wearable devices and smartphone apps without phone counseling.
89677479|NCT03594578|Experimental|Episodic future thinking|"Participants will complete a guided interview designed to elicit a number of personalized events that are likely to occur during various future time frames (e.g., 1 day, 1 week, 3 months, 1 year, etc.), as well as text cues designed to prompt episodic future thinking (e.g., In 3 months, I will be at my daughter's wedding). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
89677480|NCT03594578|Sham Comparator|Episodic recent thinking (control)|"Participants will complete a guided interview designed to elicit a number of personalized events that occurred in the recent past (e.g., earlier today, yesterday), as well as text cues designed to prompt episodic thinking (e.g., Earlier today, I was playing tennis with my wife.). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
89677481|NCT00495079|Experimental|Marqibo|Eligible subjects received study drug at 2.25 mg/m^2 intravenously via peripheral or central venous access over 60 minutes (± 10 minutes).
89677482|NCT03024242|Experimental|Tight vaginoscope|The vaginoscope was extracted and loaded inside a thick rubber ring before its reinsertion inside the vagina again. To avoid leakage from the center of the thick rubber ring, the vaginoscopy is inserted through a premade central cruciate incision.
89677483|NCT00495157|Experimental|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
89677484|NCT00495157|Experimental|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
89677485|NCT00495157|Experimental|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
89677486|NCT03595748|Experimental|Peer mentorship intervention|This arm of mentees will be assigned to weekly telephone calls with a matched mentor over a period of 3 months.
89677487|NCT03595748|No Intervention|Usual Care|This arm of mentees will not get a telephone intervention by an assigned mentee
89677488|NCT00539539|Active Comparator|Feedback On|Automated real-time feedback on CPR Process activated
89677489|NCT00539539|No Intervention|Feedback Off|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
89677490|NCT02982655|Experimental|Individualized BP lowering|Management policy is to lower the systolic or diastolic BP by 10-15% within 2 hours of randomization and sustained for 7 days. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
89677491|NCT02982655|Active Comparator|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the Chinese Society of Neurology (CSN) in 2014. The attending clinician may consider commencing BP treatment and sustained for 7 days if the systolic BP > 200 mmHg or diastolic BP >110 mmHg in patients with ischemic stroke, and systolic BP > 180 mmHg or diastolic BP > 110 mmHg in patients with cerebral hemorrhage.
89677492|NCT03594188|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
89677493|NCT03594188|Active Comparator|local anesthesia|Patients in this group will have RF ablation for treatment of HCC under local anesthesia.
89677494|NCT04407182|Experimental|Viusid Plus Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.~A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care.~Treatment duration: 21 days."
89677495|NCT04407182|No Intervention|Control|"A total of 60 subjects will be randomized 2: 1 in this study. 20 Control patients will be assigned to standard of care.~Treatment duration: 21 days."
89677496|NCT04407338|Experimental|B-DYN Device|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
89050484|NCT01758458|Experimental|Treatment (autologous T cells and aldesleukin)|"Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.~Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats at least every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection."
89050485|NCT04608981|Experimental|Prednisolone premedication|Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
89677497|NCT04407338|Active Comparator|Conventional bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
89677498|NCT00539695|Experimental|IL2 Administration|"SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT.~Time will be measured as 'week beginning with first IL-2 injection.'~T cell Induction via IL-2 to reduce GVHD"
89677499|NCT03593954|Experimental|JNJ-61393215 2 mg + Ritonavir 100 mg|Participants will receive suspension of JNJ-61393215 2 mg (Day 1 and 5) orally and tablet of Ritonavir 100 mg twice a Day (Day 4-14) orally.
89677500|NCT03593642|Placebo Comparator|Control Group|Erector spinae bilateral catheters with continuous infusion iso saline during 48h after surgery Day 0 to day 2
89677501|NCT03593642|Experimental|Regional analgesia group|Erector spinae bilateral catheters with continuous infusion Ropivacaine 0.1 or 0.2%, depending on age, infusion during 48h after surgeryDay 0 to day 2
89677502|NCT03590210|Experimental|Group A - L-sarcoma|Patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
89677503|NCT03590210|Experimental|Group B - non-L-sarcoma|Patients with unresectable or metastatic soft tissue sarcoma other than liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (GIST excluded) will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
89677504|NCT03596372|Experimental|Patients with Solid tumors|Dose escalation with patients having solid tumors. Patients receive escalating doses of BAY1834942 intravenously for 1 hour on Day 1 of each 21-day cycle (Q3W). If the Q3W scheme does not result in sufficient exposure, the scheme is replaced with an once-weekly (QW) dosing scheme.
89677505|NCT03596372|Experimental|Patients with Gastric cancer|"Expansion with patients having gastric and/or gastroesophageal adenocarcinoma:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
89677506|NCT03596372|Experimental|Patients with Colorectal cancer|"Expansion with patients having colorectal cancer:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
89677507|NCT03596372|Experimental|Patients with Non-small-cell-lung cancer|"Expansion with patients having adeno Non-small-cell-lung cancer:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
89677508|NCT03596372|Experimental|Low-dose expansion|Expansion with patients having the same cancer type (gastric cancer, or colorectal cancer, or non-small-cell lung cancer) and receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part with a dose lower than the maximum tolerated dose (MTD).
89677509|NCT05632328|Experimental|COHORT 1: AGEN1423 Plus Balstilimab|Treatment is AGEN1423 plus balstilimab for 4 cycles (8 weeks) followed by balstilimab alone for up to 2 years. AGEN1423 will be administered in a total of 4 doses. Balstilimab will be administered every 2 weeks.
89677510|NCT05632328|Experimental|COHORT 2: AGEN1423 Plus Balstilimab and Chemotherapy|Treatment is AGEN1423 plus balstilimab in combination with gemcitabine and nab-paclitaxel for 2 cycles (8 weeks) followed by balstilimab in combination with gemcitabine and nab-paclitaxel for up to 2 years. AGEN1423 will be administered in a total of 4 doses. Balstilimab will be administered once every 2 weeks.
89677511|NCT05632016|No Intervention|group N|patients will not receive erector spinae block (ESP)
89677512|NCT05632016|Active Comparator|group E|patients will receive bilateral bilevel erector spinae block (ESP)
89677513|NCT03593174|Experimental|Ossur Rigid Dressing|Use of ORD, which is a type of Removable Rigid Dressing (RRD), as a post tibial amputation dressing modality.
89677514|NCT03593174|Active Comparator|Elastic bandage|Use of the elastic bandage as a post amputation dressing modality.
89677515|NCT05631782|Active Comparator|Control group|losartan tablets were taken orally (J20180054; Hangzhou Merck Pharmaceutical Co., Ltd.; specification 50 mg) at a dose of 50 mg per day. Furosemide was injected intravenously (TCM approved by H41021056; Suicheng Pharmaceutical Co., Ltd.; specification 20 mg: 2mL) at a dose of 100 mg per day. Uremic clearance granule was mixed with water and taken (Z20073256; Kangchen Pharmaceutical (Khorgos) Co., Ltd.; Specification 5 g) at a dose of 5 g at 6:00,12:00 and 10 g at 22:00 every day. Treatment lasted for 10 - 14 days.
89050486|NCT04608981|Experimental|Diclofenac potassium premedication|Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
89677516|NCT05631782|Experimental|Treatment group|Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
89677517|NCT03599726|Experimental|Active study drug: Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
89677518|NCT03599726|Placebo Comparator|Placebo study drug: Placebo|Placebo 5 mg per day for week 1-2 or 5-6
89050487|NCT04608981|Placebo Comparator|Placebo|Placebo tablet 1 hour before starting endodontic treatment.
89050488|NCT04600557|Experimental|Self-compassion only|Describing a shameful experience using a self-compassionate prompt and receiving no verbal responses from confederates
89050489|NCT04600557|Experimental|Compassion from others only|Describing a shameful experience using a neutral prompt and receiving compassionate responses from confederates
89050490|NCT04600557|Experimental|Self-compassion plus compassion from others|Both describing a shameful experience using a self-compassionate prompt and receiving compassionate responses from confederates
89050491|NCT04600557|Active Comparator|Sharing-only control|Describing a shameful experience using a neutral prompt and receiving no verbal responses from confederates
89050492|NCT01737905|Experimental|Arm T|Experimental arm utilizing Epinephrine HFA-MDI (E004)
89050493|NCT01737905|Placebo Comparator|Arm P|Placebo comparator arm utilizing Placebo-HFA
89677519|NCT03593096|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
89677520|NCT03593096|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
89677521|NCT03592862|Experimental|HTL0018318 high dose|oral capsule, once daily
89677522|NCT03592862|Experimental|HTL0018318 mid dose|oral capsule, once daily
89677523|NCT03592862|Experimental|HTL0018318 low dose|oral capsule, once daily
89677524|NCT03592862|Placebo Comparator|Placebo|oral capsule, once daily
89677525|NCT03599570|Experimental|Intervention|Arm 1 will receive the STOP-HPV performance feedback intervention
89677526|NCT03599570|No Intervention|Control|Arm 2 will receive standard of care
89677527|NCT03592784|Experimental|Food Order Therapy + Medical Nutrition Therapy|
89677528|NCT03592784|Active Comparator|Medical Nutrition Therapy Alone|
89677529|NCT00466817|Experimental|Valganciclovir|Six months of oral Valganciclovir.
89677530|NCT00466817|Placebo Comparator|Placebo|Six weeks of oral Valganciclovir followed by placebo to complete the six month time period.
89677531|NCT03592706|Experimental|IKC and TACE|IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)
89677532|NCT03592706|Active Comparator|TACE|TACE (Transcatheter Arterial Chemoembolization)
89677533|NCT04406870|Experimental|Intervention|patients with propranolol-resistant IHHE are given propranolol combined with sirolimus
89677534|NCT03592628|Placebo Comparator|Standard Instructions|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care.
89677535|NCT03592628|Experimental|Enhanced Instruction|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care AND they received an additional printed visual diagram.
89677536|NCT03592550||Group A|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing.
89677537|NCT03592550||Group B|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing and in repeat spirometer assisted breath hold.
89677538|NCT03592394|Active Comparator|Somatic IVR (s-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on encouraging disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
89677539|NCT03592394|Active Comparator|Distractive IVR (d-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
89215516|NCT02390453|Active Comparator|Active Control|This consists of 45 minutes of group discussion of health and successful aging, 2 days a week for 12 weeks (24 sessions).
89215517|NCT04074707|Experimental|oral iron supplementation|Participants go through 3 cycles of oral iron Supplementation (daily dosing, alternate-day dosing, every third-day dosing)
89677540|NCT00438191||1|Subjects who wear the splint whenever the feel the need.
89677541|NCT00438191||2|Subjects who wear the splint whenever possible.
89677542|NCT03985514|Active Comparator|Antibiotic treatment|Patients will receive in-hospital intravenous antibiotics (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3). Surgery if no symptom relif occur.
89677543|NCT03985514|Other|Clinical observation|"Patients are followed by in-hospital Active observation (watchful waiting) according to clinical routine. Patients are observed until either, recovery and dismissal from hospital, or decision for intervention (surgery) is taken."
89677544|NCT00540007|Experimental|Cohort 1 - Lenalidomide daily on days 1-21|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~Lenalidomide 25 mg per day PO daily on days 1-21 of a 28 day cycle."
89677545|NCT00540007|Experimental|Cohort 2 - Lenalidomide daily on days 1-28|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~Lenalidomide 25 mg per day PO daily on days 1-28 of a 28 day cycle."
89677546|NCT03592316|Experimental|Lower Extremity Amputation Pathway|Patients will follow the Lower Extremity Amputation Pathway, which will include pre-operative consultations and earlier progression with physical therapy post-operatively.
89677547|NCT02982889|Experimental|LIQ865A bupivacaine formulation|Liquidia's PRINT bupivacaine free base/PLGA (poly D,L-lactic-co-glycolic acid) suspension for subcutaneous injection at doses ranging from 150mg to 600mg
89677548|NCT02982889|Experimental|LIQ865B bupivacaine formulation|Liquidia's PRINT bupivacaine free base suspension for subcutaneous injection at doses ranging from 150mg to 600mg
89677549|NCT02982889|Placebo Comparator|Diluent for LIQ865|Negative control for subcutaneous injection. Each subject will act as his own control, receiving a LIQ865 formulation subcutaneous injection in one calf, and a diluent subcutaneous injection in his other calf
89677550|NCT02982889|Active Comparator|0.5% bupivacaine hydrochoride|Positive control arm to be used with one of the LIQ865 cohorts, with each subject acting as his own positive control (i.e., one leg will receive subcutaneous injection of LIQ865A or LIQ865B, and the other leg will receive subcutaneous injection of 0.5% bupivacaine hydrochloride).
89677551|NCT03599258|Other|Arm 1|Skylife device
89677552|NCT03599258|Active Comparator|Arm 2|Standard therapy
89677553|NCT03599180||Knee Osteoarthritis group|KOA patients without accept treat in the past month
89677554|NCT03599180||Control group|Heathly volunteers
89215518|NCT04679051|Experimental|8 hours time in bed|Participants will be asked to spend 8 hours time in bed with the aim of achieving one week of normal sleep duration (7 to 8 hours).
89215519|NCT04679051|Experimental|11 hours time in bed|Participants will be asked to spend 11 hours time in bed with the aim of achieving one week of long duration sleep as defined as 9+ hours of sleep.
89677555|NCT03984344|Experimental|Active iTBS|iTBS will be delivered at 80% of resting motor threshold, consisting of a triplet of 50Hz bursts, repeated at 5Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 minutes and 9 seconds, to the left dorsolateral prefrontal cortex.
89677556|NCT03984344|Experimental|Active cTBS|Continuous TBS will be delivered at 80% of RMT and will be applied as 600 pulses in a 40-second train of uninterrupted 50Hz bursts to the right dorsolateral prefrontal cortex.
89677557|NCT03984344|Sham Comparator|Sham TBS|Sham stimulation will be given at the right or left dorsolateral prefrontal cortex (counterbalanced) for 40 seconds or 3 minutes and 9 seconds (counterbalanced), at the same frequency as active TBS (50Hz), however a sham coil will be used.
89677558|NCT03592160|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
89677559|NCT03592160|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
89677560|NCT04194164|Experimental|Fluid intake app|Participants in this arm will use the fluid intake app to help them decrease interdialytic fluid intake. Participants will take a survey to assess the efficacy of the fluid app..
89677561|NCT00499447|Experimental|Radiofrequency Ablation with External Beam Radiation|Radiofrequency Ablation (RFA)under computerized tomography guidance followed 3-4 weeks later with External Beam Radiation Therapy
89677562|NCT03592082|Active Comparator|Standard care alone|Participants will receive standard antibiotic therapy for Clostridium Difficile (CDiff) infection without additional adjuvant therapy.
89677563|NCT03592082|Experimental|Standard care with Bismuth subsalicylate (BSS)|Participants will receive BSS524 mg ((2) 262 mg tablets) four times per day for 14 days in addition to standard antibiotic therapy.
89677564|NCT03592004||Guangdong General Hospital|
89677565|NCT03592004||Cancer Hospital Chinese Academy Of Medical Sciences|
89677566|NCT03592004||Beijing Friendship Hospital|
89677567|NCT03592004||Yunnan Cancer Hospital|
89677568|NCT03592004||Liaoning Cancer Hospital|
89677569|NCT03592004||The First Hospital Of China Medical University|
89677570|NCT03592004||Affiliated Hospital Of Hebei University|
89677571|NCT00499915|Experimental|Secondhand Smoke Reduction and Asthma Education|Parents of children in the experimental group will receive asthma education at NICU discharge as well as a secondhand smoke reduction program.
89677572|NCT00499915|Active Comparator|Asthma Education|Parents of children in the active comparator group will receive asthma education at NICU discharge.
89677573|NCT03591926|Experimental|"BAL Arm"|Subjects in this arm will undergo a bronchoalveolar lavage (BAL) procedure at baseline and after two weeks of treatment.
89677574|NCT03591926|Experimental|"Non-BAL Arm"|Subjects in this arm will not undergo any BAL procedures.
89677575|NCT03250195|Other|PET/MRI|All participants will have a PET/MRI performed
89677576|NCT03591848|Experimental|DECISIF|Exposed to an online support decision tool, in addition of the standard oral information
89677577|NCT03591848|Active Comparator|IRIS|Exposed to a standard oral information
89677578|NCT03599102|Experimental|LOVED intervention|Intervention group receives the LOVED program, an 8-week program where participants receive video education modules, and weekly video chat sessions with other end-stage renal disease patients and a prior living kidney African American recipient. The program aims to increase knowledge and skills on how to promote individual strategies on how to ask for a kidney from others.
89677579|NCT03599102|No Intervention|Standard Care|Standard interaction with transplant center and physician care.
89677580|NCT03598868|Experimental|Vortioxetine|Vortioxetine 5-20 mg
89677581|NCT03598868|Placebo Comparator|Placebo|Placebo augmentation
89677582|NCT03591692|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
89677583|NCT03591692|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
89677584|NCT00501631|Active Comparator|VIVITROL 380 mg|Administered via intramuscular (IM) injection once every 4 weeks.
89677585|NCT00501631|Placebo Comparator|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
89677586|NCT05631704|Experimental|Part 1: Cohort 1: Participants receiving VH4524184 DL1|Eligible participants will receive VH4524184 Dose Level 1 (DL1) during Cohort 1 of Part 1 of the study.
89677587|NCT05631704|Placebo Comparator|Part 1: Cohort 1: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL1 during Cohort 1 of Part 1 of the study.
89677588|NCT05631704|Experimental|Part 1: Cohort 2: Participants receiving VH4524184 DL2|Eligible participants will receive VH4524184 DL2 during Cohort 2 of Part 1 of the study.
89677589|NCT05631704|Placebo Comparator|Part 1: Cohort 2: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL2 during Cohort 2 of Part 1 of the study.
89677590|NCT05631704|Experimental|Part 1: Cohort 3: Participants receiving VH4524184 DL3|Eligible participants will receive VH4524184 DL3 during Cohort 3 of Part 1 of the study.
89677591|NCT05631704|Placebo Comparator|Part 1: Cohort 3: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL3 during Cohort 3 of Part 1 of the study.
89677592|NCT05631704|Experimental|Part 1: Cohort 4: Participants receiving VH4524184 DL4|Eligible participants will receive VH4524184 DL4 during Cohort 4 of Part 1 of the study.
89677593|NCT05631704|Placebo Comparator|Part 1: Cohort 4: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL4 during Cohort 4 of Part 1 of the study.
89677594|NCT05631704|Experimental|Part 1: Cohort 5: Participants receiving VH4524184 DL5|Eligible participants will receive VH4524184 DL5 during Cohort 5 (optional) of Part 1 of the study.
89677595|NCT05631704|Placebo Comparator|Part 1: Cohort 5: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL5 during Cohort 5 (optional) of Part 1 of the study.
89050494|NCT03454958||Data collection|Data will be collected at four time points over the course of approximately one year and nine months. Participating couples (women and men) will be recruited during the first trimester of their first pregnancy. First measurement will take place in the week of the first routine ultrasound scan (week 12 of pregnancy) (=T0). First follow-up measures will take place six weeks postpartum (=T1). The second and third follow-up measurements will take place at six months postpartum (=T2) and twelve months postpartum (=T3).
89050495|NCT01730768|Experimental|AQW051 10 mg/day|Two 5mg AQW051 capsules will be taken orally daily by patients from Day 1 until Day 84.
89050496|NCT01730768|Placebo Comparator|Placebo to AQW051|Matching placebo administered orally.
89050497|NCT04600245|Experimental|M-FAM|Will undergo the procedure with assistance from the M-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
89677596|NCT05631704|Experimental|Part 1: Cohort 6: Participants receiving VH4524184 DL6|Eligible participants will receive VH4524184 DL6 during Cohort 6 (optional) of Part 1 of the study.
89677597|NCT05631704|Placebo Comparator|Part 1: Cohort 6: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 DL6 during Cohort 6 (optional) of Part 1 of the study.
89677598|NCT05631704|Experimental|Part 2: Cohort 7: Participants receiving VH4524184 RL1|Eligible participants will receive VH4524184 Repeat dose Level 1 (RL1) during Cohort 7 (Part 2) of the study.
89677599|NCT05631704|Placebo Comparator|Part 2: Cohort 7: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 RL1 during Cohort 7 (Part 2) of the study.
89677600|NCT05631704|Experimental|Part 2: Cohort 8: Participants receiving VH4524184 RL2|Eligible participants will receive VH4524184 RL2 during Cohort 8 (Part 2) of the study. If Cohort 8 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of VH4524184
89677601|NCT05631704|Placebo Comparator|Part 2: Cohort 8: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 RL2 during Cohort 8 (Part 2) of the study. If Cohort 8 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of Placebo matching VH4524184.
89677602|NCT05631704|Experimental|Part 2: Cohort 9: Participants receiving VH4524184 RL3|Eligible participants will receive VH4524184 RL3 during Cohort 9 (Part 2) (optional) of the study. If Cohort 9 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of VH4524184.
89677603|NCT05631704|Placebo Comparator|Part 2: Cohort 9: Participants receiving Placebo|Eligible participants will receive Placebo matching VH4524184 RL3 during Cohort 9 (Part 2) (optional) of the study. If Cohort 9 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of Placebo matching VH4524184.
89677604|NCT05631704|Experimental|Part 3: Cohort 10: VH4524184 Fasted/ VH4524184 Fed|Eligible participants will receive VH4524184 under fasted condition in Treatment Period 1 followed by VH4524184 under fed condition in Treatment Period 2 during Cohort 10 (Part 3) of the study. Treatment Periods will be separated by a washout period.
89677605|NCT01887067|Experimental|Renal denervation therapy|
89677606|NCT03591536|Other|pentoxifylline oral|50 adult patient underwent elective CABG intervention to be administered will be receiving main drug (pentoxifylline )oral 400 mg' every 8 hours from three days before surgery and on the day of surgery effect of intervention regarding antioxidant
89677607|NCT03591536|Placebo Comparator|placebo|50 adult patient underwent elective CABG received oral placebo pill resembling completely to pentoxifylline 400 mg, every 8 hours from three days before surgery and on the day of surgery
89677608|NCT03598712|Experimental|Compression by chest bandage urgo K2®|"After the second puncture, the local compression by thoracic bandage will be put in place.~The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.~During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.~The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation."
89677609|NCT03598712|Active Comparator|punctures|"After the second puncture, the patient will be seen at the same frequency as in the experimental arm.~The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical."
89677610|NCT00501943|Active Comparator|Riluzole|Riluzole + Avonex
89677611|NCT00501943|Placebo Comparator|Placebo|placebo + Avonex
89677612|NCT03598634|Active Comparator|Epi-on cross-linking|Intervention: Drug: Riboflavin 0.15 in 20% dextran solution
89050498|NCT04600245|Experimental|CARTOSOUND-FAM|Will undergo the procedure with assistance from the CARTOSOUND-FAM syetem Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months
89050499|NCT04608708||Group 1. Periapical Cemento-Osseous Dysplasia|In Periapical Cemento-Osseous Dysplasia , the lower anterior teeth are usually affected. In these lesions, normal bone is replaced by fibrous tissue that contains amorphous vascularised calcifications. In the early stage, it can mimic a periapical lesion, but it is usually associated with vital teeth, without any clinical complaint, and it requires no intervention. Histopathologically, the lesion is similar to fibrous dysplasia and ossifying fibroma.
89050500|NCT04608708||Group 2. Focal Cemento-Osseous Dysplasia|It occurs in a single area of the posterior teeth. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
89050501|NCT04608708||Grup 3. Florid Cemento-Osseous Dysplasia|When the lesions involve two or more quadrants of the jaw, it is defined as Florid Cemento-Osseous Dysplasia. Its radiographic and histolopathological features are similar to Periapical Cemento-Osseous Dysplasia
89050502|NCT01730027|Experimental|ADC3680|ADC3680 oral once daily
89677613|NCT03598634|Active Comparator|Epi-off cross-linking|intervention: Drug: Riboflavin 0.15 in 15% dextran solution supplemented with Tris-hydroxymethylaminomethane and sodium ethylenediaminetetraacetic acid
89677614|NCT04008134|No Intervention|Standard recommendation (ORS)|Participants received the standard recommendation on oral rehydration solution use
89677615|NCT04008134|Experimental|mHealth with no home visits|Participants received the health facility delivery of CHoBI7, plus bi-weekly mHealth (voice and text) reminders for 12 months
89677616|NCT04008134|Experimental|mHealth with home visits|Participants received the health facility delivery of CHoBI7, plus two home visits and bi-weekly mHealth (voice and text) reminders for 12 months
89677617|NCT03591302|Experimental|Immune tolerance, Kidney transplantation|Intervention: HLA matched living donor recipients of a functioning kidney transplant graft at one year will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance such as to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
89677618|NCT03598556|Experimental|Vitamin D3 Supplementation Arm|This arm will receive 180,000IU vitamin D3 every 3 months from baseline through week 96.
89677619|NCT03598556|Placebo Comparator|Placebo Arm|This arm will receive placebo every 3 months from baseline through week 48, followed by 180,000IU vitamin D3 every 3 months from week 48 through week 96.
89677620|NCT03024476|Experimental|Intensive management arm|"Description:~Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan~Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).~Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.~Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee."
89677621|NCT03024476|Active Comparator|Control arm|"Description:~Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians.~Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups)."
89677622|NCT03024086|Experimental|DWJ1252|DWJ1252 + Placebo of Gasmotin
89677623|NCT03024086|Active Comparator|Gasmotin|Gasmotin + Placebo of DWJ1252
89677624|NCT03598400|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
89677625|NCT03598400|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
89677626|NCT03598400|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
89677627|NCT03598322|Active Comparator|Dextrose 1mL|Dextrose injection, Dextrose 1mL, active comparator
89677628|NCT03598322|Experimental|Dextrose 2mL|Dextrose injection, Dextrose 2mL
89677629|NCT03598322|Experimental|Dextrose 4mL|'Dextrose injection, Dextrose 4mL
89677630|NCT05631314||operative treatment|This group will consist of patients who underwent operative treatment for a distal radius fracture.
89677631|NCT05631314||non-operative treatment|This group will consist of patients who underwent non-operative treatment for a distal radius fracture.
89677632|NCT04009070|Active Comparator|Acupuncture|"Group A: Acupuncture group:Group A: Acupunctur will be applied to the Acupunctur group 24 hours prior to bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally on the tibia) . The tape (Needle Press) will stay for 24 hours.~Needle Press: Pres Needle: 0.22x1.5 mm needle"
89677633|NCT04009070|No Intervention|Control Group|Group C: Control group
89677634|NCT04008602|Active Comparator|Experimental: Quick Icing|Group receiving the application of cold on the ventral side of the thigh (bilaterally) for 30 seconds, using the technique of ice beakers dynamically.
89677635|NCT04008602|Active Comparator|Experimental: Prolonged Cold|"Group receiving the intervention of ice bag for a period of eight minutes n the ventral side of the thigh (bilaterally)."
89677636|NCT04008602|No Intervention|Control:|Group that does not receive intervention and that will rest for ten minutes.
89677637|NCT05631158||Early Parkinson's disease|All the participants will undergo five clinical examination, four MRI scans and one fasting blood test in total in this serial study.
89677638|NCT05631158||Healthy Controls|This cohort will undergo the same procedure of the patient's group.
89677639|NCT05631080|No Intervention|Surveillance with medical treatment for bladder outlet obstruction|Patients with low-risk prostate cancer who were elected for active surveillance protocol will have only medical treatment for control of their lower urinary tract symptoms secondary to bladder outlet obstruction
89677640|NCT05631080|Active Comparator|Surveillance with anatomical endoscopic enucleation of the prostate for bladder outlet obstruction|Patients with low-risk prostate cancer who were elected for active surveillance protocol will be offered anatomical endoscopic enucleation of the prostate for control of their lower urinary tract symptoms secondary to bladder outlet obstruction
89677641|NCT03591224|Active Comparator|Intervention|Pharmacist optimizing antidepressant therapy using the patient's personalized pharmacogenomic report to make recommendations.
89677642|NCT03591224|Placebo Comparator|Control|Pharmacist optimizing antidepressant therapy based on standard of care
89677643|NCT05631002||Patients with benign spinal tumor|
89677644|NCT05631002||Patients with intermediate spinal tumor|
89677645|NCT05631002||Patients with malignant spinal tumor|
89677646|NCT03590912|No Intervention|Wait and watch (Group D)|Wait and watch for 1 month
89677647|NCT03590912|Experimental|Mometasone spray (Group B)|Standard dose of mometasone furoate nasal spray (one spray in each nostril once daily) for one month will be given
89677648|NCT03590912|Experimental|antibiotic + histaminic + oxymetazoline drops (Group A)|This group will receive oral cefpodoxime (10 mg/kg/day in two divided dose for a week) plus oral histaminics and oxymetazoline drops. Standard dose of oral histaminics (levocetirizine, 1.25 mg for age below six years, 2.5 mg for older age) for a month plus oxymetazoline nasal drops (Nasivion 0.025%) for two weeks will be given
89677649|NCT03590912|Experimental|Oral steroid (Group C)|Patients in this group will receive one mg/kg/day of oral prednisolone (Oral steroid) in two divided dose for a week followed by half mg/kg/day in two divided dose for next one week
89677650|NCT03598010|Experimental|Lenodiar Pediatric in Acute/Prolonged Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
89677651|NCT03598010|Experimental|Lenodiar Pediatric in Chronic Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
89677652|NCT00503113|Experimental|1|
89677653|NCT00503113|Experimental|2|
89677654|NCT00503113|Active Comparator|3|
89677655|NCT00542971|Experimental|Sorafenib + Idarubicin + Ara-C|Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m^2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m^2 IV over 24 hours daily (days 1-4)
89677656|NCT00504751|Experimental|Study Treatment|This is a single arm study
89677657|NCT03994484|Experimental|HA121-28 tables|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
89688760|NCT02935738|Experimental|Prednisolone treated men / positive SPA / IVF|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
89688761|NCT02935738|Experimental|Prednisolone treated men / negative SPA / ICSI|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were admitted to intracytoplasmic sperm injection (ICSI) cycles.
88996365|NCT02921308||Without BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
88996366|NCT00406484|Experimental|1|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
88996367|NCT00406484|Active Comparator|2|Standard drug counseling
88996368|NCT03835585|Experimental|Gun lock|Participants will be provided a gun lock and video instructions for its proper use, in addition to standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling).
88996369|NCT03835585|Active Comparator|Standard intervention|Participants will be provided standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling) without a gun lock. A gun lock and video instructions will be provided upon completion of the study.
88996370|NCT02921464||Group A|Group A - without known pre-existing SIHD
88996371|NCT02921464||Group B|Group B - with known pre-existing SIHD.
88996372|NCT00188214|Other|CT perfusion scan|
88996373|NCT02921503|Experimental|Topical Corticosteroids App Users|Practitioners will asked to use a novel application during their patient encounters over the next three months. This application should not modify treatment, it will only act as a vehicle to present evidence based research. Patients will not be subjects of this research, as the app is only presenting best practice which the physicians should be aware of.
88996374|NCT02920840|Active Comparator|Intermittent theta-burst stimulation|Intervention: application of 200 TMS triplet bursts (at 100 Hz, inter-burst interval 200ms) over left dorsolateral prefrontal cortex
88996375|NCT02920840|Experimental|Negative-peak-triggered-TMS|Intervention: application of 200 brain-state dependent 100 Hz TMS triplet bursts triggered at the negative peak phase of the ongoing endogenous alpha-band oscillation (as detected by surface EEG over left dlPFC)
88996376|NCT02920840|Active Comparator|Open-loop replay TMS|"Intervention: application of the same sequence of TMS pulses as in condition Negative-peak-triggered-TMS, i.e. irrespective of ongoing brain state over left dlPFC"
88996377|NCT02920801|Experimental|saxagliptin group|saxagliptin group consumed saxagliptin 5mg per day for 12 week
88996378|NCT02920801|Active Comparator|metformin group|metformin group consumed metformin 1500mg per day for 12 week
88996379|NCT00180843|Placebo Comparator|saline control|nebulized saline
89215520|NCT03873987|Active Comparator|Current Formulation of Oritavancin|Three single-use vials, each containing 400 mg (1200 mg total) of oritavancin diphosphate (as the free base) and the inactive component mannitol. Oritavancin vials will be reconstituted with SWFI and further diluted in D5W for a total volume of 1000 mL and infused intravenously over 3 hours.
89677658|NCT01013779|Experimental|Arm A|Conventional radical radiotherapy in this trial means that those patients with microscopic disease receive a dose of 50Gy using daily incremental fractions of 2Gy over 25 fractions and those with macroscopic disease receive 54Gy in 27 fractions.
89677659|NCT05630846|Experimental|MMRV(H)NS Group|Healthy children aged 4 to 6 years of age receive 1 dose of an investigational measles, mumps, and rubella (MMR) at release potency and varicella at high (V[H]NS) potency vaccine on Day 1.
89677660|NCT05630846|Experimental|MM(H)RVNS Group|Healthy children aged 4 to 6 years of age receive 1 dose of an investigational measles, rubella (MR), and varicella (VNS) at release potency and mumps at high (M[H]) potency vaccine on Day 1.
89677661|NCT05630846|Experimental|M(L)M(L)R(L)V(L)NS Group|Healthy children aged 4 to 6 years of age receive 1 dose of an investigational measles, mumps, rubella (MMR), and varicella (VNS), all at low (L) potency vaccine on Day 1.
89677662|NCT05630846|Active Comparator|MMRV_Lot 1 and Lot 2 Pooled Group|Healthy children aged 4 to 6 years of age receive 1 dose of a marketed measles, mumps, rubella (MMR), and varicella (V) vaccine of Lot 1 or of 1 vaccine dose of a marketed MMRV vaccine of Lot 2 on Day 1.
89677663|NCT03590756|Experimental|High mango group|250g (1.5 cup) of mango intake per day, 4 days a week for 16 weeks
89677664|NCT03590756|Other|Low mango group|85g (0.5 cup) of mango intake per day, 4 days a week for 16 weeks
89677665|NCT04407494||COVID-19|Healthcare workers and adult outpatients attending the COVID-19 screening center of the University Hospital of Montpellier, France.
89677666|NCT00557947|Experimental|I|Dermabond Protape-Incision segments are randomized & patient is own control
89677667|NCT00557947|Active Comparator|II|Intradermal Suture - Incision segments are randomized & patient is own control. Investigator selected suture on the basis of standard local practice.
89677668|NCT03590600|Experimental|Cohort 1: 125 mg BTZ-043 fasting|N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
89677669|NCT03590600|Placebo Comparator|Cohort 1: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
89677670|NCT03590600|Experimental|Cohort 2: 250 mg BTZ-043 fasting|N=8, 250 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
89677671|NCT03590600|Placebo Comparator|Cohort 2: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
89677672|NCT03590600|Experimental|Cohort 3: 500 mg BTZ-043 fasting|N=8, 500 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
89677673|NCT03590600|Placebo Comparator|Cohort 3: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
89677674|NCT03590600|Experimental|Cohort 4: 1000 mg BTZ-043 fasting|N=8, 1000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
89677675|NCT03590600|Placebo Comparator|Cohort 4: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
89677676|NCT03590600|Experimental|Cohort 5: 2000mg BTZ-043 fasting|N=8, 2000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
89677677|NCT03590600|Placebo Comparator|Cohort 5: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
89677678|NCT00506155|Experimental|Neoadjuvant Chemotherapy with M-VAC + Avastin|Avastin 10 mg/kg by vein over 90 minutes. Cisplatin 70 mg/m^2 by vein over 4 hours. Doxorubicin 30 mg/m^2 by vein over 15 minutes. Methotrexate 30 mg/m^2 by vein over 30 minutes. Vinblastine Sulfate 3 mg/m^2 by vein over 30 minutes.
89677679|NCT03590522||Group I:|Thirty heart failure patients
89677680|NCT03590522||Group II:|Twenty healthy controls
89677681|NCT03597542|Experimental|Maltodextrin|Participants will consume 56g of maltodextrin dissolved in 500mL of water.
89677682|NCT03597542|Experimental|Egg|Participants will consume 36g of spray-dried egg powder (equivalent to 3 eggs) dissolved in 500mL of water.
89677683|NCT03590444|Active Comparator|Prompt laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on the same day (prompt' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on the same day [Ranibizumab (Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
89677684|NCT03590444|Active Comparator|Deferred laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on one week prior to laser treatment (deferred' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on one week prior to laser treatment [Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
89677685|NCT00506857|Experimental|Busulfan + Fludarabine|Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.
89677686|NCT04006496|Experimental|Experimental: Intervention|In-patient, Chemotherapy patients in this arm will receive the expressive writing intervention twice each week for two weeks. These writing samples will be reviewed and analyzed. These patients will receive coaching from an expert expressive writing coach and will be allowed to ask questions and receive guidance. All patients will receive standard of care treatment in addition to the intervention.
89050503|NCT01730027|Placebo Comparator|Placebo|Placebo oral once daily
89050504|NCT01730027|Active Comparator|montelukast|montelukast oral once daily
89050505|NCT04600284|Experimental|Sequence 1|Period 1: AD-2101 Period 2: AD-2102 Period 3: AD-2101 + AD-2102
89050506|NCT04600284|Experimental|Sequence 2|Period 1: AD-2101 Period 2: AD-2101 + AD-2102 Period 3: AD-2102
89050507|NCT04600284|Experimental|Sequence 3|Period 1: AD-2102 Period 2: AD-2101 Period 3: AD-2101 + AD-2102
89050508|NCT04600284|Experimental|Sequence 4|Period 1: AD-2102 Period 2: AD-2101 + AD-2102 Period 3: AD-2101
89050509|NCT04600284|Experimental|Sequence 5|Period 1: AD-2101 + AD-2102 Period 2: AD-2101 Period 3: AD-2102
89050510|NCT04600284|Experimental|Sequence 6|Period 1: AD-2101 + AD-2102 Period 2: AD-2102 Period 3: AD-2101
89050511|NCT01715012|Experimental|ST266|ST266 sprayed to the skin graft and donor site
89050512|NCT01715012|Placebo Comparator|Saline|Saline (placebo)sprayed to the skin graft and donor site
89677687|NCT04006496|No Intervention|Control|Patients in the control group will not interface with the expressive writing coach for guidance nor have their writing samples reviewed and analyzed. All patients in the control arm will still receive standard care
89677688|NCT03590132|Experimental|SAAF|participants in this arm receive the SAAF intervention at age 11-12.
89677689|NCT03590132|Experimental|SAAF-T|participants in this arm receive the SAAF-Teen intervention at age 14-15.
89677690|NCT03590132|Experimental|SAAF SAAF-T|participants in this arm receive SAAF at age 11-12 and later receive SAAF-Teen at age 14-15
89677691|NCT03590132|No Intervention|Control|These participants receive no interventions.
89677692|NCT03024632||trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a trial of labor
89677693|NCT03024632||No trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a a repeat cesarean section
89677694|NCT04005170|Experimental|PD-1 group|All patients will receive standard fractionation radiation therapy (RT) scheme: 50.4 Gy in 28 fractions over 5-6 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 and 2 cycles of toripalimab 240 mg on days 1, 22 followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
89677695|NCT04766528|Experimental|Mediterannen diet|The MED diet was abundant in fiber, micronutrients and plant-based proteins. The diet was rich in essential FA like monounsaturated fatty acids (MUFA) and n-3.
89677696|NCT04766528|Experimental|Canadian diet|The NAM diet had a high content in saturated fatty acids (SFA) and simple sugar and was low in fiber.
89677697|NCT03597386||All Participants|
89677698|NCT03597308|Active Comparator|Opioid Group|
89677699|NCT03597308|Active Comparator|NSAID group|
89677700|NCT03597308|Active Comparator|Acetaminophen|
89677701|NCT03597230|Experimental|patients operated on for pancreatic resection|All consecutive patients operated on for pancreatic resection
89677702|NCT03762122|Experimental|Rogaratinib|Rogaratinib is given at a dose of 600 mg twice daily in continuous 28-days cycles, without treatment breaks (except for toxicity management). Trial treatment is continued until evidence of tumor progression, unacceptable toxicity, consent withdrawal or withdrawal by the investigator.
89677703|NCT03596996|Experimental|Ferrous Sulfate|Children 6 to 23 months of age will receive a tablet that contains the equivalent of 12.5 mg of elemental iron. Children over 24 months will receive a tablet that contains the equivalent of 30 mg of elemental iron.
89677704|NCT03596996|Placebo Comparator|Placebo|
89677705|NCT00507559|Experimental|AAA Repair System|
89677706|NCT00508105|Active Comparator|subscapularis peel|
89677707|NCT00508105|Active Comparator|osteotomy|
89677708|NCT04750135|Placebo Comparator|Control group|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
89677709|NCT04750135|Experimental|Metformin group|participants will receive 500 mg Metformin TID for 8 consecutive weeks in addition to the standard therapy
89677710|NCT05633342||Healthy average-risk cohort|Individuals representing the general population who self-declare to have no cancer history and have no indications suggestive of underlying cancer development. Subjects will be recruited from a state-of-the-art population study.
89677711|NCT05633342||Increased-risk (genetic/familial) cohort|Individuals carrying certain germline mutations that predispose the subjects to an increased risk of having cancer than the general population. Subjects will be recruited from Cancer Genetics Service (CGS).
89677712|NCT05633342||High-risk cohort|Individuals diagnosed with diseases that have a high risk of progressing to cancer.
89677713|NCT05633342||Malignant cohort|Individuals diagnosed with cancer.
89677714|NCT03598088|Other|Healthy Sexually Active Women|Healthy, sexually active women who are not at risk for pregnancy due to previous female tubal sterilization will receive both Ovaprene and the Caya diaphragm throughout the course of the trial. The purpose of the Caya Post Coital Test (PCT) cycle is to ensure that in this study population and at these sites, results that are expected to be observed in a PCT cycle with an approved vaginal barrier can be replicated.
89677715|NCT00558571|Placebo Comparator|Placebo|
89677716|NCT00558571|Experimental|BI 10773 low dose|
89677717|NCT00558571|Experimental|BI 10773 medium dose|
89677718|NCT00558571|Experimental|BI 10773 high dose|
89677719|NCT03970382|Experimental|NeoTCR-P1|Single dose of NeoTCR-P1
89677720|NCT03970382|Experimental|NeoTCR-P1 plus nivolumab|Single dose of NeoTCR-P1 plus nivolumab 480mg IV every four weeks for up to 6 doses.
89677721|NCT03970382|Experimental|NeoTCR-P1 plus IL-2|Single dose of NeoTCR-P1 plus IL-2 500,000 IU/m2 SC twice daily (BID) for 7 days.
89677722|NCT03978728||ECMO patients|Patients with ECMO support
89677723|NCT00508183|Active Comparator|single row fixation|
89677724|NCT00508183|Active Comparator|double row fixation|
89677725|NCT01797133|Active Comparator|Fellow arm|Patients in this arm will receive the ID fellow-based antibiotic pre-authorization intervention.
89677726|NCT01797133|Active Comparator|Pharmacist arm|Patients in this arm will receive the pharmacist-based antibiotic pre-authorization intervention.
89677727|NCT05632874|Experimental|Breathing Exercise|
89677728|NCT01797913|Experimental|gemcitabine|
89677729|NCT03596294|Experimental|Treatment sequence AB|"Period A:~Saline + clazosentan~Period B:~Rifampicin + clazosentan"
89677730|NCT03596294|Experimental|Treatment sequence BA|"Period B:~Rifampicin + clazosentan~Period A:~Saline + clazosentan"
89677731|NCT00537407|Experimental|Treatment Arm A|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg subcutaneously (sc) once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
89677732|NCT00537407|Experimental|Treatment Arm B|Debio 025 (alisporivir) 400 mg orally once daily for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
89215521|NCT03873987|Experimental|Kimyrsa|A single vial containing 1200 mg of oritavancin, HPβCD, and mannitol. Kimyrsa vials will be reconstituted with SWFI and further diluted with 0.9% sodium chloride for a total volume of 250 mL and infused intravenously over 1 hour.
89215522|NCT03018587|Experimental|All subjects|All subjects will receive 1 truSculpt radiofrequency treatment in desired area.
89215523|NCT04072913|Other|Control group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
89215524|NCT04072913|Other|Low grade lesion group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
89215525|NCT04072913|Other|High grade lesions group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
89215526|NCT04072913|Other|Cancer group|Study of the expression of matrix metalloproteinases and their tissue inhibitors
89215527|NCT02579213||women candidates for amniocentesis|pregnant women candidates for amniocentesis between 17-33 gestational weeks
89215528|NCT04072679|Experimental|Sintilimab+IBI305|Sintilimab: 200mg (D1, q3w） IBI305: 7.5mg/kg or 15mg/kg (D1, q3w）
89215529|NCT02579291|Experimental|Dry needling|The experimental group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system. In addition, this group will receive a single session of dry needling into the tibialis posterior muscle with a disposable stainless steel needle (0.3mm x 50mm)
89215530|NCT02579291|Active Comparator|Bobath|This group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system.
89215531|NCT00474760|Experimental|1|
89215532|NCT02579681|Experimental|BG00012|BG00012 administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter.
89215533|NCT00528645|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily for up to 2 years in the absence of disease progression or unacceptable toxicity. Blood samples are obtained at baseline and periodically during study to determine levels of circulating tumor cells for defined translational studies.
89215534|NCT04072757|Active Comparator|Intervention Group|The cooking skill building/nutrition education workshops will be led by a multidisciplinary team comprised of: a chef/instructor, a nutritionist and/or registered dietitian, MD and/or Preventive Medicine Resident, and Yale-Griffin Prevention Research Center staff. The cooking/nutrition education workshop sessions will be approximately 45 minutes and will: include a plant forward approach to healthy eating; integrate nutrition and health-related information and cooking instruction (i.e. knife skills, equipment use); show participants how to prepare meals that are simple, nutritious, affordable, and delicious; provide recipes and nutrition information aimed at improving dietary intake and health status; and provide an enjoyable program that participants will look forward to attending. Fruit and vegetable prescription vouchers will be redeemed at ShopRite grocery stores (Ansonia and Shelton locations) and Griffin Hospital's farmers market, where redemption will be tracked.
89677733|NCT00537407|Experimental|Treatment Arm C|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg sc once weekly for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
89677734|NCT00537407|Experimental|Treatment Arm D|Debio 025 (alisporivir) 800 mg orally once daily + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
89677735|NCT00537407|Experimental|Treatment Arm E|Debio 025 (alisporivir) orally at a loading dose of 400 mg twice daily for 7 days followed by 400 mg/day for 22 days + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
89677736|NCT05632796|Experimental|tailored pfannenstiel incision according to the fetal head OFD|Pfannenstiel incision performed according to the occipitofrontal diameter of the fetal head
89677737|NCT04193384||Group 1≤ (G1≤)|Group 1≤ (G1≤) - patients that performed bariatric surgery for ≤ 1 year
89677738|NCT04193384||Group 1> (G1>)|Group 1> (G1>) - patients that performed bariatric surgery for > 1 year
89677739|NCT00214916|Active Comparator|A|conventional insulin therapy (using Actrapid IV)
89677740|NCT00214916|Experimental|B|intensive insulin therapy (using actrapid IV)
89677741|NCT00469391|Experimental|GI Sleeve|medical device that mimics gastric bypass mechanism for weight-loss
89677742|NCT00469391|Sham Comparator|Sham Control|
89215535|NCT04072757|Placebo Comparator|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
89215536|NCT00524745|Active Comparator|0,2,6 month vaccination schedule|
89677743|NCT00438971|Experimental|Duloxetine|
89677744|NCT04388267||Septic shock|Patients with septic shock, according to the Sepsis 3 definition, regardless of the origin
89677745|NCT04388267||Major vascular surgery|Patients who underwent elective or emergent major vascular surgery abdominal aortic surgery (open or endovascular surgery)
89677746|NCT00219284|Experimental|Immediate switch|Patients were switched the day after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
89677747|NCT00219284|Active Comparator|Delayed switch|Patients were switched 4 weeks after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
89215537|NCT00524745|Active Comparator|0,3,9 month vaccination schedule|
89215538|NCT00524745|Active Comparator|0,6,12 month vaccination schedule|
89215539|NCT00524745|Active Comparator|0,12,24 month vaccination schedule|
89677748|NCT00509041|Experimental|Dasatinib|Use of dasatinib in treatment of pts with previously treated malignant mesothelioma
89677749|NCT00470717|Other|Phone calling|Weekly telephone call. There are not two arms to the study. The primary intervention is phone calling weekly to assess ability to complete phone call and obtain feeding data.
89677750|NCT03035851|Experimental|Aerobic exercise|Participants will take part in a supervised 6-month-long aerobic (walk/jog) training program held 3 days/week. Each session will include a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions will follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cool-down, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise will increase from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity will be based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity will build from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
89677751|NCT03035851|Other|Stretch and Strength|A control group will meet on a similar schedule as the exercise group for sessions on stretching and toning but without aerobic exercise. Based on prior RCTs of similar interventions the investigators expect this control to be ineffective or minimally effective, but anticipate that it will increase participant enthusiasm and retention. All assessments will be conducted in this arm.
89677752|NCT00545155||Geriatric EMS Patients|Cohort for reliability and concurrent validity testing.
89677753|NCT03596060|Active Comparator|General anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will be randomly assigned to undertake surgery under general anesthesia in the first 48 hours. Anesthetics to be used are propofol, fentanyl and rocuronium. Maintenance will be achieved with remifentanyl and propofol (TIVA) and the depth of anesthesia will be monitored by BIS. Morphine will be administered bolus IV immediately postoperatively.
89677754|NCT03596060|Active Comparator|Regional anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will will be randomly assigned undertake surgery under regional anesthesia (spinal) at least 5 days after the discontinuation of clopidogrel. Anesthetics to be used are chirochaine 0.5% and fentanyl.
89677755|NCT00473837|Active Comparator|Treatment|Subjects initially treated with Co-arthemeter, and then continued on weekly chloroquine till day 90
89677756|NCT00473837|Placebo Comparator|Control|Subjects initially treated with Co-arthemeter, and then continued on weekly placebo till day 90
89215540|NCT04073693|Active Comparator|BRCA|They were in treatment with BRCA and standard treatment based on nutritional intervention and physical exercise.
89215541|NCT04073693|Placebo Comparator|Placebo|They only were on standard treatment based on nutritional intervention and physical exercise.
89215542|NCT01017796|Experimental|A. Experimental|1200mg acetylcysteine and 2g ascorbic acid at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
89215543|NCT01017796|Placebo Comparator|B. Control|200ml 0,9% normal saline IV
89677757|NCT02122549|Experimental|HWD1000|Subjects using HWD1000
89677758|NCT03024008|Experimental|Intervention Arm|"Clinical Interventions:~Blood tests: complete blood count, full blood chemistry and biochemistry including phosphate, alkaline phosphatase, calcium, renal and liver function, and coagulation. Serology tests: HIV, Hepatitis B, Hepatitis C.~Xray~Urine Test~CT~Liposuction - harvest of 50-300ml autologous adipose tissue from the subject's abdomen~Single transplantation of Investigational Medicinal Product BonoFill-II into long bone extra-articular comminuted fracture or large bone defect/critical gap"
89677759|NCT00509197|Active Comparator|Active treatment group (A)|Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group
89677760|NCT00509197|Placebo Comparator|Control group treated with placebo (B)|treatment with placebo
89677761|NCT00442013|Experimental|Lansoprazole|Participants in this group will receive lansoprazole on a daily basis for 6 months. There are two doses of Lansoprazole solutab provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
89677762|NCT00442013|Placebo Comparator|Matching placebo|Participants in this group will receive a matching placebo on a daily basis for 6 months. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
89677763|NCT02121067|Experimental|LNG-IUS placed at 2 weeks postpartum|Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum
89677764|NCT03595826|Experimental|1. Neurostimulant pharmaceutical drugs..|1.Participants receiving medicinal drugs, such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.
89677765|NCT03595826|Experimental|2. Exercise Intervention|Participants receiving a minimum of 8 sessions of exercise intervention, for the duration of an hour each session. Exercises will be to build muscle tone, improve core stability, enhance balance, improve fine and gross motor skills and visual motor integration.
89677766|NCT03595826|Experimental|3. Neurostimulants + Exercise intervention|See Arms 1 and 2 above. Both interventions administered together: Pharmaceutical drugs plus exercise intervention
89677767|NCT03595826|Experimental|4. Control Group|Participants will not receive any intervention during the research process. They will be given an intervention after the research is completed.
89677768|NCT00509587|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89677769|NCT00509665|Experimental|Gemcitabine+doxorubicin|
89677770|NCT00513799|Active Comparator|1: Hygiene Education|"Intensive education on prevention of skin infections through improvements in personal hygiene (also serves as control group)"
89677771|NCT00513799|Active Comparator|2: Hygiene education + mupirocin|Application of mupirocin in the nasal mucosa alone
89677772|NCT00513799|Active Comparator|Education + mupirocin + chlorhexidine|A combination of nasal application of mupirocin and chlorhexidine showers
89677773|NCT00513799|Active Comparator|4: Education + mupirocin + bleach baths|A combination of nasal application of mupirocin and bathing in dilute bleach water
89677774|NCT00514501|Experimental|Iodofiltic Acid I 123|
89677775|NCT00561145|Experimental|Young men|Energy restriction period
89677776|NCT00561145|Experimental|Elderly men|Energy restriction period
89677777|NCT00442169|Experimental|Group 1: WN02 Low Dose (Part 1)|Low Dose in healthy adults in Part 1 against a placebo control.
89677778|NCT00442169|Experimental|Group 2: WN02 Medium Dose (Part 1)|Medium dose level in part one healthy subjects against a placebo control.
89677779|NCT00442169|Experimental|Group 3: WN02 High Dose (Part 1)|High dose level in part one healthy subjects against a placebo control
89677780|NCT00442169|Placebo Comparator|Group 4: Placebo (Part 1)|Participants will receive a single dose of saline in Part 1 on Day 0
89677781|NCT00442169|Experimental|Group 5: WNO2 High Dose (Part 2)|Participants enrolled in Part 2 and received a single dose of West Nile Virus vaccine.
89677782|NCT00442169|Placebo Comparator|Group 6: Placebo (part 2)|Participants will receive a single dose of saline in Part 2 on Day 0
89677783|NCT00515203|Placebo Comparator|II.|5 thrombocytopenic (as defined per protocol) subjects
89677784|NCT00515203|Experimental|I.|15 thrombocytopenic (as defined per protocol) subjects
89677785|NCT00216476|Experimental|001|Risperidone Long Acting Injectable (LAI) 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
89677786|NCT00216476|Active Comparator|002|Quetiapine Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
89677787|NCT00216476|Other|003|Aripiprazole 10-30 mg oral once daily for 104 weeks
89677788|NCT00561457|Experimental|Iliac Stenting|Stent placement in the iliac artery
89677789|NCT00515437|Experimental|1|1500U Myobloc
89677790|NCT00515437|Experimental|2|2500U Myobloc
89677791|NCT00515437|Experimental|3|3500U Myobloc
89677792|NCT00515437|Placebo Comparator|4|pooled placebo
89677793|NCT00474617|Experimental|Participants 18 to 64 years old|Participants to receive an intravenous (IV) single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of second twitch (T2) with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
89677794|NCT00474617|Experimental|Participants 65 to 74 years old|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
89215544|NCT01783535|Experimental|Stratum A|"Participants with early bilateral or unilateral (unifocal or multifocal) retinoblastoma (R-E I-III, IC A-B; R-E IV with IC A or B; or IC C with limited sub-retinal seeding), and participants with bilateral disease in whom the advanced eye has been enucleated upfront (without any high risk histopathology) and the remaining eye has early stage disease (as defined above).~Interventions (see detailed description): vincristine, carboplatin, topotecan, filgrastim or PEG-filgrastim, and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
89677795|NCT00474617|Experimental|Participants 75 years and older|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
89677796|NCT00562315|Other|FACBC PET-CT and ProstaScint CT|Participants diagnosed with localized prostate carcinoma with subsequent definitive therapy or suspicion of recurrent cancer will undergo an FACBC PET-CT scan and the ProstaScinct CT.
89677797|NCT00216086|Experimental|Investigational Treatment|"Irinotecan 200 mg/m2 IV, day 1~Capecitabine 1000* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid~EUS~Neoadjuvant Chemotherapy~Preoperative Radiation~Surgery~Adjuvant Chemotherapy (at discretion of treating physician)"
89677798|NCT00474851|Experimental|Norethindrone acetate + estrogens|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.
89677799|NCT00474851|Placebo Comparator|norethindrone acetate + placebo|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.
89677800|NCT00545623|Active Comparator|ACU+RR|acupuncture + relaxation response CD
89677801|NCT00545623|Active Comparator|SHAM+RR|sham acupuncture + relaxation response CD
89677802|NCT00545623|Active Comparator|ACU+EDU|acupuncture+control CD
89677803|NCT00545623|Sham Comparator|SHAM+EDU|sham acupuncture+control CD
89677804|NCT00215150|Other|Open Label Treatment|8 weeks of open label treatment with sertraline
89677805|NCT00215150|Other|Randomization Ziprasidone|8 weeks of treatment with sertraline augmented with ziprasidone
89677806|NCT00215150|Other|Randomization Placebo|8 weeks of treatment with sertraline augmented by placebo
89677807|NCT04192994|Active Comparator|Group 1: Antibiotic injection|A total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected with a 30-gauge needle into the vitreous cavity of the affected eyes in the randomized group, as soon as the diagnosis is confirmed.
89677808|NCT04192994|Active Comparator|Group 2: Pars Plana Vitrectomy|Randomized patients will undergo PPV. Briefly, a blepharostat will be placed followed by instillation of a drop of 5% iodine-povidone over the eye. Under a surgical microscope, three 23-gauge or 25-gauge sclerotomies will be performed. Vitreous core vitrectomy will be performed, and a fluid-gas exchange with balanced saline solution (BSS) or 5,000 grams of silicone oil as a vitreous substitute. At the end of surgery, all sclerotomies will be sutured with Vicryl 7.0 and a total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected into the vitreous cavity. As soon as the diagnosis is confirmed.
89677809|NCT04199234|Experimental|experimental group|60 mg Encapsulated Iron
89677810|NCT04199234|Active Comparator|control group|60 mg Iron sulphate
89677811|NCT04198844||Warfarin user|
89677812|NCT04198844||Apixaban user|
89677813|NCT04198610|No Intervention|healthy|Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.
89677814|NCT04198610|No Intervention|chronic gingivitis|Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm, relative attachment loss (RAL) ) less than or equal to 3mm and more than to 25% sites with gingival bleeding present (BOP)
89677815|NCT04198610|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.~Non surgical periodontal therapy (SRP) was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy"
89677816|NCT03023852|Experimental|Panel 1: Group 1|Participants will receive Treatment A (JNJ-63623872 600 milligram (mg) (2*300 mg) oral tablets [reference]) followed by Treatment B (JNJ- 63623872 600 mg (2*300 mg) concept oral tablet formulation 1 (test 1) and then Treatment C (JNJ-63623872 600 mg (2*300 mg) concept oral tablet formulation 2 (test 2). Each treatment period will be separated 7 days washout period.
89677817|NCT03023852|Experimental|Panel 1: Group 2|Participants in Group 2 will receive Treatment A followed by Treatment C and then Treatment B with a washout period of minimum 7 days.
89677818|NCT03023852|Experimental|Panel 1: Group 3|Participants in Group 3 will receive Treatment B followed by Treatment A and then Treatment C with a washout period of minimum 7 days.
89677819|NCT03023852|Experimental|Panel 1: Group 4|Participants in Group 4 will receive Treatment B followed by Treatment C and then Treatment A with a washout period of minimum 7 days.
89677820|NCT03023852|Experimental|Panel 1: Group 5|Participants in Group 5 will receive Treatment C followed by Treatment A and then Treatment B with a washout period of minimum 7 days.
89677821|NCT03023852|Experimental|Panel 1: Group 6|Participants in Group 6 will receive Treatment C followed by Treatment B and then Treatment A with a washout period of minimum 7 days.
89677822|NCT03023852|Experimental|Panel 2: Group 7|Participants in Group 7 will receive Treatment D [JNJ-63623872/37.5 mg Oseltamivir oral fixed dose combination (FDC) tablet concept formulation (test 3)] followed by Treatment E (JNJ-63623872 600 mg, administered as 2*300 mg and Oseltamivir 75 mg, administered as 1*75 mg). Both treatment periods will be separated with a minimum of 7 days washout period.
89677823|NCT03023852|Experimental|Panel 2: Group 8|Participants in Group 8 will receive Treatment E followed by Treatment D with a washout period of minimum 7 days.
89677824|NCT00214136|Experimental|1|prostate radiation to 70Gy, lymph nodes to 56Gy
89677825|NCT00213980|No Intervention|Observation|Observation only for 12 months
89215545|NCT01783535|Experimental|Stratum B|"Participants considered candidates for conservative management including those:~Participants with bilateral retinoblastoma who have R-E IV-V and IC D in one eye~Participants with advanced unilateral (unifocal or multifocal) retinoblastoma (R-E IV-V and IC D-E) who demonstrate foveal sparing by the tumor during EUA. Due to foveal sparing, these patients have potential for vision preservation.~Interventions (see Detailed Description): vincristine, topotecan, carboplatin, etoposide, filgrastim or PEG-filgrastim and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
89215546|NCT01783535|Experimental|Stratum C|"Participants with advanced (R-E IV-V and IC D-E) unilateral retinoblastoma who require upfront enucleation. Participants will be assessed and treated by low, intermediate or high risk.~Interventions (see Detailed Description): vincristine, cyclophosphamide, MESNA, doxorubicin, etoposide, carboplatin, filgrastim or PEG-filgrastim, enucleation"
89215547|NCT01783535|Experimental|Stratum D|"Participants with bilateral retinoblastoma who may require upfront enucleation for one eye due to advanced disease (R-E IV-V and IC E).~Interventions (see Detailed Description): vincristine, carboplatin, topotecan, etoposide, enucleation, filgrastim or PEG-filgrastim, focal therapy, including cryotherapy, laser photocoagulation, thermotherapy (and thermo-chemotherapy) and episcleral plaque brachytherapy, and external beam radiation or proton beam radiation in select cases."
89215548|NCT05001646|Experimental|In-home EMF protection device|
89215549|NCT00495040|Experimental|Proton Radiotherapy|Proton radiotherapy 87.5 CGE with 2.5 Gy/fraction for 35 treatments.
89215550|NCT04073537|Experimental|Experimental group|Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
89215551|NCT04073537|Placebo Comparator|Placebo group|Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and paclitaxel 175mg/m^2 D1 q3w, carboplatin AUC 5mg/mL/min D1 q3w.
89215552|NCT03998631|Placebo Comparator|Saline Flush|This is the control arm. The TEVAR or TAVI device will be flushed with at least 60mL of standard saline to reduce bubbles in the reservoir prior to deployment. This is the standard of care.
89677826|NCT00213980|Active Comparator|Zoledronate|Zoledronate
89677827|NCT04190498||NASH-related HCC|The study is focused on patients suffering from NASH-induced HCC. Each patient with NASH-related HCC will be paired with 2 patients with non NASH-related HCC (HCV-induced CHC).
89677828|NCT04190498||HCV-related HCC|HCV-related HCC has been chosen as control population for several reasons: HCV represent a common etiology of HCC; with a distinct pathophysiology distinct from that of post-NASH HCC; populations with post-NASH and post-HCV CHC share similar epidemiological characteristics.
89677829|NCT00516217|Experimental|Galaximab|Induction: 500 mg/m^2 by IV over 60 minutes days 1, 8, 15 & 22 Extended Induction: 500 mg/m^2 by IV every 4 weeks until disease progression or unacceptable toxicity
89677830|NCT04001504|Experimental|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV during index ACS hospitalization
89677831|NCT04001504|Active Comparator|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV 30 days after randomization
89677832|NCT04198532|Experimental|Complex Regional Pain Syndrome(CRPS) group|Stroke patients with complex regional pain syndrome
89677833|NCT04198532|Other|Control Group|Stroke patients without complex regional pain syndrome
89677834|NCT00564265||GIST|GIST from all gastrointestinal origins: esophagus, stomach, duodenum, jejunum, ileum, colon and rectum
89677835|NCT04198298|Active Comparator|Group 1 EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
89677836|NCT04198298|Active Comparator|Group 2 ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
89215553|NCT03998631|Experimental|Carbon Dioxide and Saline Flush|Carbon dioxide flush of the TEVAR or TAVI device followed by saline flush.
89215554|NCT01020760|No Intervention|No posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to avoid supine posturing for seven days after surgery, but will not be advised to posture in the face down or prone position.
89677837|NCT04198298|Active Comparator|Group 3 Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
89677838|NCT04199936|Experimental|EMG leg|Quadriceps muscle group of postoperative patients randomly selected leg which will undergo electrical muscle stimulation for upto 2 hours on each postoperative day
89677839|NCT04199936|No Intervention|Control leg|Quadriceps muscle group of postoperative patients leg not selected to undergo electrical muscle stimulation
89677840|NCT00516919|Experimental|1|Xenical + behavioral intervention
89677841|NCT00516919|Active Comparator|2|Placebo + behavioral intervention
89677842|NCT04199858|Experimental|Nocebo induction|Conditioning and evocation of a nocebo response to a sham (inert) medication contained in a blue or a brown jar, controlled within subjects.
89677843|NCT00547105|Experimental|erlotinib in combination with SBRT|Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib
89677844|NCT04198064|Experimental|Group A- Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/~2 cups of %0.9 saline solution) during the insertion of the cystocopy tube during their cystoscopy."
89677845|NCT04198064|Other|Group B- No Bag Squeeze|Participants will receive a standard cystoscopy procedure.
89677846|NCT03969368|Experimental|Treatment Group|Treatment with the investigational device - rPMS
89215555|NCT01020760|Experimental|Face down posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to posture in the face down or prone position for 50 minutes per hour for seven days.
89677847|NCT03969368|Active Comparator|Control Group|Control group
89677848|NCT04388215|Experimental|Treatment group|"Drug: CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg~- CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
89677849|NCT04388215|Active Comparator|Comparator group 1|"Drug: CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D013(placebo) 80mg~- CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D337(placebo) 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks"
89215556|NCT01020916|Experimental|Target Temperature 33°C|
89215557|NCT01020916|Active Comparator|Target Temperature 36°C|
89677850|NCT04388215|Active Comparator|Comparator group 2|"Drug: CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg~- CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg, orally, 1 tablet once a day for 8 weeks"
89215558|NCT02664363|Experimental|EGFRvIII CAR T cells|Dose escalation cohorts for 4 dose levels will be considered: #1: 4.5 x 10^6/kg, #2: 1.5 x 10^7/kg, #3: 4.5 x 10^7/kg, and #4: 1.5 x 10^8/kg. Starting at dose level 1, cohorts of 3-6 subjects will be accrued at each dose level.
89215559|NCT01020994|Experimental|LAS41003|
89215560|NCT01020994|Active Comparator|LAS189962|
89215561|NCT01020994|Active Comparator|LAS189961|
89677851|NCT04195100|Active Comparator|Low dose pilocarpine|low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day
89677852|NCT04195100|Active Comparator|High dose pilocarpine|high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day
89677853|NCT04199546|Other|A child with Coffin-Lowry Syndrome|A boy with a known CLS diagnosis with a history of coughing during eating, long-lasting wheezing, sputum and inability to intake solid food will be included.
89677854|NCT06069479||Conservative group|Children with trigonocephaly that are treated conservatively.
89677855|NCT06069479||Surgical group|Children with trigonocephaly that are treated surgically.
89215562|NCT00494026|Experimental|Pemetrexed + Carboplatin|
89215563|NCT01018108|Other|I|Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6 weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I ADAM before and after completion of acupuncture.
89215564|NCT00524589|Experimental|Dexamethasone and Calcitriol|Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.
89215565|NCT04074837|Placebo Comparator|Placebo|Placebo liquid suspension.
89215566|NCT04074837|Active Comparator|NNI-362, 10 mg|NNI-362 at 10 mg in liquid suspension
89215567|NCT04074837|Active Comparator|NNI-362, 20 mg|NNI-362 at 20 mg in liquid suspension
89677856|NCT06069466||ARDS patient|
89677857|NCT06069453|Experimental|Group A|Solution containing Hyaluronic Acid (HA) sodium salt and Hydeal-D
89677858|NCT06069453|No Intervention|Group B|standard management according to institutional protocol
89677859|NCT06069440|Experimental|swimmers|
89215568|NCT04074837|Active Comparator|NNI-362, 60 mg|NNI-362 at 60 mg in liquid suspension
89677860|NCT06069388|Experimental|Diaphragm technique|The continuity between the diaphragm and the lumbar spine demonstrates the existence of an anatomical and functional connection between them. Changes in the mobility of the diaphragmatic domes in addition to improvement in spirometric parameters when carrying out a diaphragm stretching technique. This makes us think that the mobility of the lumbar spine may be compromised by diaphragm dysfunction.
89677861|NCT06069388|Active Comparator|conventional physiotherapy|"Application of the tetrapolar transcutaneous electrical neurostimulation (TENS) device with the I-tech Mio-care equipment in the analgesia program with an intensity of between 10-20 milliamps, according to the patient's tolerance, with an application time of 15 minutes in the lumbar paravertebral area on both sides. 250w infrared lamp at a distance of 1m from the patient, with an application time of 10 minutes. Ultrasound on the quadratus lumborum muscle area with a frequency of 1Mhz, at an intensity of 1.2w/cm2 and with an application time of 10 minutes. Ischemic compression and analytical stretching of the quadratus lumborum, multifidus and iliocostalis muscles, constant pressure with the thumb on each muscular trigger point (MTrP) for between 30 s and 2 min the intensity of the pressure will be adjusted to a level at which each subject reports comfortable pain, that is, between the pain threshold and the maximum tolerable pain"
89677862|NCT06069362|Experimental|Manual physiotherapy and neurodynamic exercises|"The treatment applied forms part of the routine clinical practice and includes the following:~Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve root.~Home neurodynamic sliders of the upper limb and cervical mobility exercises."
89215569|NCT04074837|Active Comparator|NNI-362, 120 mg|NNI-362 at 120 mg in liquid suspension
89677863|NCT06069323|Active Comparator|Active ASD group|The rTMS will be administered 18 times, twice per week, with the following stimulation parameters: 1.0 Hz frequency, 90% MT, 180 pulses per session with 9 trains of 20 pulses each with 20-30s intervals between the trains.
89677864|NCT06069323|Sham Comparator|Sham ASD group|18 rTMS sessions will be administered, placing the coil perpendicular to the scalp of the stimulation site, to avoid stimulation.
89677865|NCT06069323|Active Comparator|Active ADHD group|The rTMS will be administered 18 times, twice per week, with the following parameters: 5-10 Hz frequency, 90% MT, 180 pulses per session with 9 trains of 20 pulses each with 20-30 s intervals between the trains.
89677866|NCT06069323|Sham Comparator|Sham ADHD group|18 rTMS sessions will be administered, placing the coil perpendicular to the scalp of the stimulation site, to avoid stimulation.
89677867|NCT06069310||Healthy control subjects|Healthy control subjects withouth asthma nor chronic rhinosinusitis or other chronic respiratory diseases
89215570|NCT04074837|Active Comparator|NNI-362, 240 mg|NNI-362 at 240 mg in liquid suspension
89215571|NCT01015066|Active Comparator|buprenophine/naloxone|Participants with this arm will receive 4-16 mg/d buprenorphine/naloxone (Suboxone).
89215572|NCT01015066|Experimental|Naltrexone|Participants assigned to this arm will receive 50 mg/d naltrexone.
89215573|NCT01021072|Experimental|MTD|The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored.
89215574|NCT00472030|Experimental|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
89215575|NCT00472030|Active Comparator|Prednisone|The control arm of the study will receive standard prednisone therapy to a maximum dose of 0.5 mg/kg/day.
89215576|NCT00127855|Experimental|MenHibrix Formulation 1 Group|Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
89215577|NCT00127855|Experimental|MenHibrix Formulation 2 Group|Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
89215578|NCT00127855|Experimental|MenHibrix Formulation 3 Group|Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
89215579|NCT00127855|Active Comparator|Menjugate Group|Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
89215580|NCT00127855|Active Comparator|ActHIB Group|Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
89677868|NCT06069310||Chronic rhinosinusitis with nasal polyps (CRSwNP) patients with comorbid severe asthma|Patients that have chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid severe asthma will be enrolled
89677869|NCT06069310||Chronic rhinosinusitis with nasal polyps (CRSwNP) patients without asthma|Patients that have chronic rhinosinusitis with nasal polyps (CRSwNP) without asthma will be enrolled
89677870|NCT06069297|Experimental|Multimodal Prehabilitation|A 4-week long preoperative intervention including exercise training, nutritional therapy and anxiety reduction techniques
89677871|NCT06069297|No Intervention|Usual care|Usual preoperative care
89677872|NCT06069271|No Intervention|Rest|Subjects in the control group were instructed to complete the general warm up followed by a 10-minute rest period.
89677873|NCT06069271|Experimental|Exercise|The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
89677874|NCT06069258||Bahraini adults with type 2 diabetes|Male and female Bahraini adults aged 20-75 years with controlled type 2 diabetes (i.e. HbA1c <9 on medication).
89677875|NCT06069245|Placebo Comparator|Placebo|Gelatin capsules
89677876|NCT06069245|Experimental|MitoQ|Commercially available MitoQ (80mg)
89677877|NCT06069219||Adult patients received epidural sufentanil during and after abdominal surgery|All patients were premedicated with oral midazolam 7,5 mg and then they were induced into general endotracheal anesthesia according to a standardized protocol, with propofol 1-3 mg/kg, fentanyl 1-2 ug/kg and rocuronium bromide 0.6 mg/kg. Anaesthesia was continued with sevoflurane or desflurane MAC 1 to maintain mean arterial pressure with a value of +/- 20% of the original value. The epidural sufentanil infusion was started with bolus during anesthesia and continued after surgery as long as was necessary.
89677878|NCT06069141|Active Comparator|single-dose BPG plus doxycycline|single-dose benzathine penicillin G (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days)
89677879|NCT06069141|Placebo Comparator|single-dose BPG|single-dose benzathine penicillin G (2.4 MU intramuscularly once)
89677880|NCT06069128|Experimental|Neurotrigger device treatment arm|treatment with Neuro-trigger device for blinking stimulation for a duration of 14 days
89677881|NCT06069115||Main cohort group|All participants will be included in the same group, with no subgrouping within this study.
89677882|NCT06069089||Controlled beta thalassemia major|Controlled beta thalassemia major Hb>9g/dl , serum ferritin <500ng/ml
89677883|NCT06069089||Uncontrolled beta thalassemia major|Uncontrolled beta thalassemia major Hb<9g/dl , serum ferritin >500ng/ml
89677884|NCT06069050|Experimental|Surgical group|SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
89677885|NCT06069037|Experimental|SALT surgery|SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume
89677886|NCT06069011|Experimental|Interdisciplinary|Interdisciplinary model for management of low acuity msk complaint
89677887|NCT06069011|Active Comparator|Usual care|usual care
89677888|NCT06068972||MolecuLight cohort|The MolecuLight bacterial imaging procedure was used in combination with standard of care clinical wound assessment.
89677889|NCT06068972||Standard of Care cohort|Standard of care clinical wound assessment.
89677890|NCT06068946|Placebo Comparator|VK2735 (Placebo)|Placebo
89677891|NCT06068946|Experimental|VK2735 (Dose #1)|VK2735 is a peptide GLP-1 and GIP dual agonist
89677892|NCT06068946|Experimental|VK2735 (Dose #2)|VK2735 is a peptide GLP-1 and GIP dual agonist
89677893|NCT06068946|Experimental|VK2735 (Dose #3)|VK2735 is a peptide GLP-1 and GIP dual agonist
89677894|NCT06068946|Experimental|VK2735 (Dose #4)|VK2735 is a peptide GLP-1 and GIP dual agonist
89677895|NCT06068829||Exposed group 1|Intravenous methylprednisolone (IVMP) plus Inebilizumab
89677896|NCT06068829||Exposed group 2|IVMP plus Rituximab (RTX)
89677897|NCT06068816|Experimental|Nutrient Dense Drink|"Experimental: Nutrient-dense drink Nutrient-dense drink on top of standard care~200 kcal~15 grams of (whey) protein, 8 grams of fat, and 17 grams of carbohydrates including only 0.2 g lactose~400 IU vitamin D, 250 mg Ca, 10-20 % of the other vitamins/minerals~Servings :~• 100 ml water for dissolving 46 g of the served powder"
89677898|NCT06068816|No Intervention|Standard Care|"Standard care comprising:~Standard care only will be provided nutritional counseling to achieve a better nutritional state"
89677899|NCT06068803|Experimental|Ketone drink|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 4-week supplementation period. Physical activity and blood glucose will be monitored using wearable devices.
89677900|NCT06068803|Placebo Comparator|Placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 4-week supplementation period. Physical activity and blood glucose will be monitored using wearable devices.
89677901|NCT06068790|Other|HoLEP surgery|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
89677902|NCT06068777|No Intervention|Control group|with no interference before dental anesthesia and extraction
89677903|NCT06068777|Active Comparator|Rosemary group|children inhaled two drops of rosemary oil for 3 minutes before the procedures of dental anesthesia and extraction of a primary molar,
89677904|NCT06068777|Active Comparator|Lemongrass group|children inhaled two drops of lemongrass oil, for 3 minutes before the procedure of dental anesthesia and extraction of a primary molar
89677905|NCT06068751|Active Comparator|Aerobic Exercise|Aerobic Exercise
89677906|NCT06068751|Active Comparator|Neck Exercises|Neck Exercises
89677907|NCT06068725|No Intervention|No invention: Control Group|Data collection tools were applied to individuals in the control group on day 0 (Z0), day 30 (Z1) and day 90 (Z2) of follow-up. Data collection tools applied to the control group are as follows: Patient Introduction Form, Heart Failure Symptom Status Scale, Minnesota Living with Heart Failure Questionnaire,Michel Uncertainty in Illness Scale - Community Form.
89677908|NCT06068725|Experimental|Experimental: application group|Two 15-minute training videos (30 minutes in total) prepared for symptom management will be shared on the phones of the patients/relatives in the application group and the patients and their relatives will be informed by watching the training video.Data collection tools were applied to individuals in the application group on day 0 (Z0), day 30 (Z1) and day 90 (Z2) of follow-up. Data collection tools applied to the application group are as follows: Patient Introduction Form, Heart Failure Symptom Status Scale, Minnesota Living with Heart Failure Questionnaire,Michel Uncertainty in Illness Scale - Community Form.
89677909|NCT06068712|Experimental|Within-Subjects Attentional Information|All Participants receive all levels of the attentional cue (target, distractor, or neutral cue).
89677910|NCT06068699|Experimental|Postcards|Participants who received a postcard.
89677911|NCT06068699|No Intervention|Controls|Participants did not receive a postcard (usual care).
89677912|NCT06068686|Experimental|Vildagliptin|Group I (N=35) are patients who the endocrinologist prescribed them Vildagliptin 50mg /tab plus their Metformin 500mg /tab once daily for 12 weeks to control their blood sugar level.
89677913|NCT06068686|Active Comparator|Glimepiride|Group II (N=35) are patients who the endocrinologist prescribed them Glimepiride 3mg / tab plus Metformin 500mg /tab once daily for 12 weeks.
89677914|NCT06068647|Experimental|Thoracic ultrasonographic, tomographic and patch-based cardio-respiratory evaluations|"Ultrasonographic findings will be obtained with clinical machines. Additionally, ultrasonographic scans as acquired with research platform will also be gathered. Metal cutaneous landmarks will be positioned and left during computed tomography scans, indicating the areas of ultrasonographic assessment. This method will support a more accurate comparison between ultrasonographic patterns and CT scans peripheral lung findings.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. The sensors will be applied to the upper chest. The following information will be collected by each sensor: ECG, respiratory effort, respiratory flow, activity, position, and sound pressure level."
89677915|NCT06068634||Current Patients|Current patient is defined as any patient who has had any type of visit at a participating clinic within the last 6 months of the date of study initiation.
89677916|NCT06068621|Experimental|Venetoclax Combined With CACAG Regimen|Venetoclax combined with CACAG regimen for newly diagnosed AML. Recipients were randomized and those entering the experimental group received azacytidine, cytarabine,aclacinomycin,chidamide,venetoclax and granulocyte colony-stimulating factor. Azacytidine was used as 75 mg/m2/day from day 1 to day 7. Cytarabine was used as 75-100 mg/m2 bid from day 1 to day 5. Aclacinomycin was used as 20 mg/day on days 1,3,5. Chidamide was used as 30 mg/day on days 1,4,8,11. Venetoclax was used as 400 mg/day from day 1 to day 14;Combined with posaconazole, reduced to 100 mg/day;Combined with voriconazole, reduced to 200 mg/day.Granulocyte colony-stimulating factor was used as 300 μg/day from day 0 until agranulocytosi recovery .
89677917|NCT06068621|Active Comparator|"3+7 Regimen"|Idarubicin+cytarabine(IA) regimen or daunorubicin+cytarabine(DA) regimen for newly diagnosed AML.Recipients were randomized and those entering this group received IA or DA induction chemotherapy. With the IA regimen,recipients received idarubicin(8-10 mg/m2) for three days and cytarabine(75-100 mg/m2, every 12 hrs) for seven days. With the DA regimen,recipients received daunorubicin(60 mg/m2)for three days and cytarabine(75-100 mg/m2,every 12 hrs)for seven days.
89677918|NCT06068608|Experimental|TNM005 dose level 1/placebo|TNM005 on dose level 1 /placebo
89677919|NCT06068608|Experimental|TNM005 dose level 2/placebo|TNM005 on different dose level 2 /placebo
89677920|NCT06068608|Experimental|TNM005 level 3/placebo|TNM005 on dose level 3 /placebo
89677921|NCT06068608|Experimental|TNM005 dose level 4/placebo|TNM005 on dose level 4 /placebo
89677922|NCT06068608|Experimental|TNM005 dose level 5/placebo|TNM005 on dose level 5 /placebo
89677923|NCT06068608|Active Comparator|VARIZIG|VARIZIG 625 IU
89677924|NCT06068595|Other|Patients|Patient with musculoskeletal anomalies
89677925|NCT06068569|Experimental|Healthy patients|Drug: GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile); A total of 50 people will be randomized and receive the study drug (vaccine). Two intramuscular injections of the investigational medicinal product (IMP) will be performed. 1st injection - component I, 2nd injection - component II.
89677926|NCT06068556|Experimental|Healthy patients|Drug: GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition. A total of 50 people will be randomized and receive the study drug. Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II.
89688762|NCT02935738|No Intervention|Control men / positive SPA / IVF|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (more than five) were then admitted to in vitro fertilization (IVF) cycle.
89677927|NCT06068491|Experimental|Arm 1: I-VCALD Intervention|I-VCALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
89677928|NCT06068491|No Intervention|Arm 2: Usual Care|Usual Care Participants will receive the standard of care from their usual VA healthcare provider. The care counselor will not contact the usual care condition participants.
89677929|NCT06068465|Experimental|Pimavanserin tartrate|Pimavanserin, 34 mg, capsule,once daily by mouth for 6 weeks Interventions
89677930|NCT06068465|Placebo Comparator|Placebo|Placebo, capsule, once daily by mouth for 6 weeks
89677931|NCT06068439|Experimental|Treated group|
89677932|NCT06068439|Placebo Comparator|Comparator group|
89677933|NCT06068426|Experimental|TUS SWE|"This arm includes two cohorts:~Children with confirmed diagnosis of ARP or CP~Controls (Children without a history of pancreatic disease)"
89677934|NCT06068413|Experimental|AI-assisted diagnosis|Doctors diagnose the focal liver lesion with the help of AI.
89677935|NCT06068413|No Intervention|common diagnosis|Doctors diagnose the focal liver lesion without the help of AI.
89677936|NCT06068400|Experimental|BCMA/GPRC5D double CAR-T|The study plans to enroll 40 subjects, with a sample size based on actual occurrence and a dosage of 3 × 106/kg ± 20%~1 × 107/kg ± 20% CAR positive T cells
89677937|NCT06068374|Experimental|Break dual task|Subjects will remain seated for three hours; however, every 30 minutes the subjects will be instructed to stand and take short walks with low intensity and perform a cognitive task
89677938|NCT06068374|Active Comparator|Standard break|Subjects will remain seated for three hours, however, every 30 minutes the subjects will be instructed to stand and take short walks at low intensity for two minutes,
89677939|NCT06068374|No Intervention|Control session|Subjects will remain seated for three hours
89677940|NCT06068361||DLB patients|Dementia with Lewy bodies according to the revised criteria of Mc Keith 2017
89677941|NCT06068361||AD patients|Alzheimer's disease according to McKhann et al., 2011 criteria including CSF biomarkers (an abnormal level of beta-amyloid 1-42 protein [Ab42] or a pathological Ab42/Ab40 ratio and an abnormal level of phosphorylated tau [p-tau])
89677942|NCT06068361||Control|Subjective cognitive complaint, with a normal brain MRI and neurological examination, without any elements in favor of a neurodegenerative disease
89677943|NCT06068296|Other|Short term memory assessment in patients with aphasia.|Evaluation of short term memory in a patient population with poststroke aphasia using a dutch version of the Temple Assessment of Language and Verbal Short-Term memory in aphasia (TALSA).
89677944|NCT06068296|Other|short term memory assessment in healthy volunteers|Evaluation of short term memory in healthy volunteers using a dutch version of the Temple Assessment of Language and Verbal Short-Term memory in aphasia (TALSA).
89677945|NCT06068283|Experimental|LOTUS Intervention Arm|A mobile, WebApp-based platform to access the LOTUS intervention content.
89677946|NCT06068283|Active Comparator|Informational Control Arm|An information-only website, with content on HIV transmission, PrEP, harm reduction, and resources for women.
89677947|NCT06068244|Experimental|3D printed crowns|Participants received 3D printed resin crowns
89677948|NCT06068244|Active Comparator|Zirconia crowns|Participants received ready made zirconia crowns
89677949|NCT06068231|Experimental|early loading group|Early Loading Group: Implants were loaded with temporary restorations between 48 hours and 3 months after implantation and had occlusal contact with opposing dentition. The early loading time point was set at 6-8 weeks after implantation in this study.
89677950|NCT06068231|Active Comparator|Conventional Loading Group|Implants were loaded at least 3 months after implantation and had occlusal contact with opposing dentition.
89677951|NCT06068205||Type 1 diabetes with microvascular complications|
89677952|NCT06068205||Type 1 diabetes without microvascular complications|
89677953|NCT06068140||Study Cohort|Patients taking Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate
89677954|NCT06068140||Control cohort|Patients who do not take Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate
89677955|NCT06068114||Diabetic patients|Either type I or type II diabetes mellitus, possibly also suffering from functional dyspepsia or gastroparesis
89677956|NCT06068114||Healthy controls|
89677957|NCT06068101||Patients with papillary thyroid cancer (PTC) and EH (essential hypertension)|Primary Aldosteronism was investigated in all patients with PTC and EH (n= 137), regardless of hypertension severity, under active surveillance at a cancer institute from 2019 to 2022.
89677958|NCT06068101||Patients with EH (essential hypertension) previously investigated for PA (primary aldosteronism)|The control group included 137 (1:1) age,sex and body mass index (BMI) matched individuals from a retrospective cohort of EH previously investigated for PA from 2011 to 2022.
89677959|NCT06068088||Cohort A|Participating patients from 5 radiotherapy center of AP-HP
89677960|NCT06068088||Cohort B|Participating patients from the european hospital Georges-Pompidou
89677961|NCT06068062|No Intervention|Control group|Control group (Group A) undergo traditional teaching of skills as routinely carried out in gynecology department during clinical clerkship of three weeks.
89677962|NCT06068062|Experimental|Experimental group|Group B undergo intervention in the form of learning session where OSCE will be implemented on principles of Team-based learning.
89677963|NCT06068023||Intestinal-type ampullary adenocarcinoma intervention|This cohort consist of patients with intestinal-type ampullary adenocarcinoma who are able to receive adjuvant chemotherapy.
89677964|NCT06068023||Intestinal-type ampullary adenocarcinoma control|This cohort consist of patients with intestinal-type ampullary adenocarcinoma who are able to receive adjuvant chemotherapy but due to logistics or patient preference, are not willing to receive adjuvant chemotherapy.
89677965|NCT06068023||Pancreatobiliary/mixed-type ampullary adenocarcinoma intervention|This cohort consist of patients with Pancreatobiliary/mixed-type ampullary adenocarcinoma who are able to receive adjuvant chemotherapy.
89677966|NCT06068023||Pancreatobiliary/mixed-type ampullary adenocarcinoma control|This cohort consist of patients with Pancreatobiliary/mixed-type ampullary adenocarcinoma who are able to receive adjuvant chemotherapy but due to logistics or patient preference, are not willing to receive adjuvant chemotherapy.
89677967|NCT06067971|Experimental|Laparoscopic surgery with the augmented reality device|
89677968|NCT06067945||NP is given to the non polished group which is group 2|Out of two groups, group 2 is a test group to which rough preparations are assigned
89677969|NCT06067906|Placebo Comparator|control group|
89677970|NCT06067906|Experimental|innovative group|
89677971|NCT06067880||Lower Limb Lymphedema|This was a retrospective cohort propensity score-matched study. Patients with cancer-related unilateral lower limb lymphedema were enrolled.
89677972|NCT06067867||Kidney and Pregnancy clinic consultations|Patients followed at the Kidney and Pregnancy clinic pre-conception, during pregnancy and postpartum and patients subsequently referred to nephrological follow-up
89677973|NCT06067854||Neonates under general anaesthesia without regional anaesthesia|the standard procedure - without regional anaesthesia
89677974|NCT06067854||Neonates under general anaesthesia with regional anaesthesia|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
89677975|NCT06067789|Experimental|Intervention|Intervention arm participants will be allocated to neuraxial anesthesia. The specific approach (spinal, epidural, or combined spinal and epidural) will be at the discretion of the treating anesthesiologist, as the underlying physiologic mechanisms and impacts are similar for both approaches. Allowing clinician discretion will reflect routine standard of care practice and support generalizability. Specific choice of neuraxial anesthetic medications, doses, and adjuncts will also be at the discretion of the attending anesthesiologist, supporting pragmatism. While existing randomized data do not suggest that the sedation level during neuraxial anesthesia leads to differences in outcomes, providers will be requested to maintain sedation at or below a 3 on the Observer's Assessment of Alertness/Sedation scale (OAAS; mild to moderate sedation consistent to responding to verbal stimuli), the same approach used in a recent large pragmatic trial of anesthesia in hip fracture patients.
89677976|NCT06067789|No Intervention|Control|Control group participants will be allocated to general anesthesia. Choice of anesthetic medications and doses will be at the discretion of each anesthesiologist as per routine standard of care, again supporting conduct of a pragmatic and generalizable trial. Similarly, choice of airway management strategies and anesthetic depth will also be based on patient and provider preference, as a recent large randomized trial demonstrates that anesthetic depth is not causally linked to risk of morbidity or mortality after surgery. Details of general anesthesia management and medications will be collected for all patients.
89677977|NCT06067776|Experimental|Treatment (tucatinib, osimertinib, cetuximab)|Patients receive tucatinib 200mg orally BID, osimertinib 80mg orally daily, and cetuximab 250mg/m^2 IV every 2 weeks of a 28-day cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89677978|NCT06067750||Patients referred to Clinical Neurophysiology for Cerebral Function Analysing Monitoring (CFAM)|Patients referred from both adult and paediatric intensive care units
89677979|NCT06067724|Active Comparator|Pelvic and trunk control exercises|Twenty Egyptian male stroke patients will receive 40 minutes of pelvic and trunk control exercises for six weeks after a 30 minutes of traditional physical therapy program.
89677980|NCT06067724|Sham Comparator|Traditional physical therapy|Twenty Egyptian male stroke patients will receive 30 minutes of sham traditional physical therapy program for six weeks.
89215581|NCT00493636|Active Comparator|A (Sorafenib + Gemcitabine or Capecitabine)|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
89677981|NCT06067685||Pregnancies with GDM and BMI > 30|Pregnancies with GDM diagnosed between 24-32 weeks and BMI > 30.
89677982|NCT06067646|Other|Health care providers involved in care for people living with hiv|Semi-structured interviews with health care providers
89677983|NCT06067646|Other|People living with HIV with prior pregnancy or desire to have children|Semi-structured interviews with people living with HIV with prior pregnancy or desire to have children
89677984|NCT06067633|Experimental|Triple-Masked|For articles allocated to the blinded (masked) editorial process, the editorial assistant will delete identifiable/unmasking content of cover page and letters. All articles will be flagged as being in triplemasked editorial process arm in the document title
89677985|NCT06067633|Active Comparator|Usual Procedures|All articles will be flagged as being in usual editorial process arm in the document title. For articles allocated to the usual (double-masked) editorial process, the editorial assistant will leave identifiable/unmasking content of cover page and letters for the editors.
89677986|NCT06067620|Experimental|Robotic right hemicolectomy|Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section (fully minimally invasive right hemicolectomy)
89677987|NCT06067620|Active Comparator|Laparoscopic right hemicolectomy|Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline (standard of care)
89677988|NCT06067607|Experimental|Eye gaze technology intervention|Participants will use eye gaze technology and software activities as an intervention to improve visual abilities.
89677989|NCT06067581|Experimental|BCMA CART|"This study will follow the classic 3+3 design and increase the dose according to three dose groups. Each dose group will have 3-6 eligible subjects selected according to the inclusion/exclusion criteria, with a dose of 1.0 × 10^6, 2.0 × 10^6, 3.0 × Increase the dose by 10^6 CAR-T cells/kg."
89677990|NCT06067529||Premature ovarian insufficiency group|
88996380|NCT00180843|Active Comparator|salbutamol and ipratropium bromide nebules|salbutamol 2.5 mg and ipratropium bromide 0.5 mg
88996381|NCT02921152|Other|all|All patients with early breast cancer
89215582|NCT00493636|Placebo Comparator|B (Placebo + Gemcitabine or Capecitabine)|Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
89677991|NCT06067490|Experimental|RC1416|RC1416(SAD),single ascending (25mg-600mg) of RC1416 by subcutaneous injection
89677992|NCT06067490|Placebo Comparator|Placebo|Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.
89677993|NCT06067477|Active Comparator|Vitamin D Supplement 400 IU|400 IU (10 µg) of Vitamin D3
89677994|NCT06067477|Active Comparator|Vitamin D Supplement 1000 IU|1000 IU (25 µg) of Vitamin D3
89677995|NCT06067477|Active Comparator|Vitamin D Supplement 2000 IU|2000 IU (50 µg) of Vitamin D3
89677996|NCT06065800||STEELEX®|STEELEX® Sternum Set in Patients undergoing cardiac surgery
89677997|NCT06065163|Experimental|Ultrasound Guided Treatment|Patients allocated to this will be guided (diuretic treatment) by ultrasound (VExUS) findings
89677998|NCT06065163|Active Comparator|Clinical Guided Treatment|Patients allocated to this will be guided (diuretic treatment) by clinical congestion score (CCS) findings
89677999|NCT06064058|Experimental|Interventional group|This group were assigned to 6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.
89678000|NCT06064058|Placebo Comparator|Control group|Ordinary painkillers given
89678001|NCT06064058|No Intervention|No Placebo, no intervention group|Nothing was given to them neither 6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction nor painkillers.
89678002|NCT06063382|Experimental|Standard time|40 minutes provided to complete the exam.
89678003|NCT06063382|Experimental|25% extra time|50 minutes provided to complete the exam.
89678004|NCT06063382|Experimental|50% extra time|60 minutes provided to complete the exam.
89678005|NCT06062225|Experimental|Kamikawa reconstruction|Patients will be administered Kamikawa reconstruction after proximal gastrectomy.
88996382|NCT02921074|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
89678006|NCT06062225|Active Comparator|STJI reconstruction|Patients will be administered Single-Tract Jejunal Interposition(STJI) reconstruction after proximal gastrectomy.
89678007|NCT06062225|Active Comparator|SOFY reconstruction|Patients will be administered SOFY reconstruction after proximal gastrectomy.
89678008|NCT06058338|Experimental|Intervention Arm|Intervention arm participants will receive produce prescription services for a defined period of time (4-6months)
89678009|NCT06058338|No Intervention|Control Arm|Control arm participants will not receive produce prescriptions but will receive standard of care services for diabetes management
89678010|NCT06055491|Experimental|Vitamin D3 injection|1.0mL Vitamin D3 injection at ilsilateral deltoid muscle and extensor muscle strengthening exercise with counter force brace in lateral epicondylitis of elbow
89678011|NCT06055491|Placebo Comparator|Saline injection|1.0mL saline injection at ilsilateral deltoid muscle and extensor muscle strengthening exercise with counter force brace in lateral epicondylitis of elbow
89678012|NCT06054503|Experimental|prototype of sensor|The patient is his own control
89678013|NCT06054503|Active Comparator|ventilator|The patient is his own control
89678014|NCT06053255|Experimental|HIFU for Sacroiliitis|High-intensity focused ultrasound delivered to the lateral sacral branch nerve for neurolysis.
89678015|NCT06052449|Experimental|Social determinants of health screening|Participants will receive a social determinants of health screening assessment and referral process in addition to the community-based lung cancer screening educational tool.
89678016|NCT06052449|Active Comparator|Community-based lung cancer screening|Participants will receive a community-based lung cancer screening educational tool.
89678017|NCT06040281|Experimental|Intervention|App-assisted three-week comprehensive rehabilitation individual support in nutrition and exercise
89678018|NCT06040281|Active Comparator|Control|usual care App-assisted
89678019|NCT06028477|Active Comparator|Active stimulation|Participants will receive active stimulation between 2 hours minimum and 4 hours maximum of daily vCR or sham stimulation (2 hours twice daily) at home for the first month (30 days), followed by a minimum of 1.5 hours and a maximum of 2.5 hours of daily vCR
89678020|NCT06028477|Sham Comparator|Sham Stimulation|Participants will receive sham stimulation between 2 hours minimum and 4 hours maximum of daily vCR or sham stimulation (2 hours twice daily) at home for the first month (30 days), followed by a minimum of 1.5 hours and a maximum of 2.5 hours of daily vCR
89678021|NCT06021626|Experimental|CRD3874-SI|Phase 1a: starting dose of 0.1 mg/kg, Phase 1b: RP2D determined during Phase 1a. Cycle 1 & 2: once weekly infusion x 4 (Days 1, 8, 15, 22) over 28-day cycle. Cycle 3 onwards: weekly infusion x 3 (Days 1, 8, 15) over 28-day cycle
89678022|NCT06015360|Experimental|Fat Grafting|The fat grafting procedure will be conducted as per local standard RM protocol. All procedures will be conducted by the study Principal Investigator (PI) who is well practiced in performing this procedure in Head & Neck and breast cancer patients and also in scar revision patients.
89678023|NCT06014502|Experimental|Phase 1a Solid Tumors|IMGS-001 will be administered in escalating doses, with a starting dose of 0.3 mg/kg every 2 weeks escalating up to a maximum dose of 15 mg/kg.
89678024|NCT06014502|Experimental|Phase 1b Ovarian Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
89678025|NCT06014502|Experimental|Phase 1b Colorectal Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
89678026|NCT06014502|Experimental|Phase 1b Triple-negative Breast Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
89678027|NCT06014502|Experimental|Phase 1b Bladder Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
89678028|NCT06014502|Experimental|Phase 1b Gastric or Esophageal Cancer|IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
89678029|NCT06003569|No Intervention|Usual care|School nurses/schools randomized to usual care will continue to receive their usual care from school nurses and then subsequently provide the intervention given their asthma remains poorly controlled at the start of the next school year following enrollment.
89678030|NCT06003569|Experimental|BACK-S|The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly).
89678031|NCT06003569|Experimental|BACK-E|The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
89678032|NCT06003244|Active Comparator|Ambient air|Patient will perform tests on ambient air at 2840 m
89678033|NCT06003244|Experimental|SOT via nasal canula|Supplemental oxygen therapy (SOT) at 3l/min will be provided via a nasal cannula from a small oxygen bottle carried on the back according to standard care
89678034|NCT06003101|Experimental|Bone marrow aspirate concentrate (BMAC)|Patients randomly allocated to receive BMAC will undergo hip arthroscopy and will receive PRP/PPP/BMAC application through the PI's standardized method of harvest, processing, and application.
89678035|NCT06003101|Placebo Comparator|Control|Patients allocated to the control cohort will receive standard of care hip arthroscopy without PRP/PPP/BMAC application.
89678036|NCT06002074|Experimental|Stress management and resilience training|Subjects will receive a 1.5 hour one-on-one stress management and resilience consult by a certified SMART trainer followed by 16 week self-guided on-line training.
89678037|NCT06001801|Active Comparator|Diabetes Prevention Program (DPP) (usual care)|
89678038|NCT06001801|Experimental|DPP plus the INSPIRA intervention|This arm will include the DPP plus additional interventions.
89678039|NCT05999526|Experimental|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
89678040|NCT05999526|Active Comparator|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
89678041|NCT05998577|Experimental|ESM/Traqq|Use of ESM and Traqq for one week to get a personalised analysis of the abdominal pain and triggerfactors that can be used at the outpatient clinic visit to select an effective treatment option.
89678042|NCT05998577|No Intervention|Standard care|Will not be using ESM and Traqq, but will only get a standard outpatient clinic visit together with PDSkeuzehulp to make a decision for a treatment.
89678043|NCT05987527||Treatment group|"Subjects underwent a kidney transplant as per planned standard of care and were administered study drug TX200-TR101 in study TX200-KT02 post transplantation~Assigned interventions - subjects who received TX200-TR101 in clinical study TX200-KT02"
89678044|NCT05987527||Control group|Subjects underwent a kidney transplant as per planned standard of care in study TX200-KT02 with no study drug administered, up to 6 subjects
89678045|NCT05970107|Experimental|ALND + LVB|"The prophylactic LVB cohort will undergo ALND plus ARM and immediate lymphatic reconstruction with lymphaticovenous bypass (LVB). During the ALND, axillary reverse mapping will be used to visualize the lymphatics draining into the axilla, to aid in preserving the draining lymphatic vessels for anastomosis in LVB.~Radiation therapy will be administered as determined by the treating radiation oncologist."
89678046|NCT05970107|Active Comparator|ALND without LVB|"Patients in the ALND alone cohort will undergo ALND plus ARM~Radiation therapy will be administered as determined by the treating radiation oncologist."
89678047|NCT05942859||Retrospective Cohort|Patients who have previously been seen by the local Pulmonary Hypertension service, between 2007 and June 2023, for a suspected diagnosis of pulmonary hypertension, and undergone Right Heart Catheterisation (RHC) will be invited to participate in the study by a member of the direct clinical care team. Their ECG will be analysed using AI technology to develop an algorithm to aid the diagnosis of PH.
89678048|NCT05942859||Prospective Cohort|Patients who are referred to the local PH service, from July 2023, with a suspected diagnosis of pulmonary hypertension, and undergo Right Heart Catheterisation will be invited to participate in the study by a member of the direct clinical care team. Their ECG will be analysed using AI technology to develop an algorithm to aid the diagnosis of PH.
89678049|NCT05940545|Active Comparator|Cohort 1|6 patients will be randomised to starting dose of favipiravir 1800 mg BD (day 1), then 800mg BD Day 2 to 10, or standard of care.
89678050|NCT05940545|Active Comparator|Cohort 2|6 patients will be randomised to starting dose of favipiravir 2600 mg BD (day 1), then 1200mg BD day 2 to 10, or standard of care.
89678051|NCT05940545|Active Comparator|Cohort 3|6 patients will be randomised to starting dose of favipiravir 1800 mg BD (day 1), then 800mg BD Day 2 to 10 plus Ribavirin, or standard of care.
89678052|NCT05940545|Active Comparator|Cohort 4|6 patients will be randomised to starting dose of favipiravir 2600mg BD (day 1), then 1200mg BD day 2 to 10 plus Ribavirin, or standard of care.
89678053|NCT05936684|Experimental|Effect of ProlEx breathing on decision-making if applied before the Eupnea condition|Intervention (behavioral): Block 1: ProlEx, Block 2: Eupnea/Control during decision-making
89678054|NCT05936684|Experimental|Effect of Eupnea breathing on decision-making if applied before the ProlEx condition|Intervention (behavioral): Block 1: Eupnea/Control, Block 2: ProlEx during decision-making
89678055|NCT05935488||Early Liver Disease|A total of 30 subjects with fibroscan confirmed liver fibrosis likely due to non-alcoholic steatohepatitis (NASH) will be recruited.
89678056|NCT05933005|Experimental|D-kit/EF1 group|"The experimental group will use the D-kit/EF1 program on a mobile tablet device at least 5 times a week for 30 minutes each session, for a duration of 12 weeks.~The program will be performed under the supervision of the participant's parents or primary caregivers, following the provided program usage guide."
89678057|NCT05933005|Sham Comparator|Sham group|"The sham group will watch an educational animation video on a mobile tablet device at least 5 times a week for 30 minutes each session, for a duration of 12 weeks.~The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided.~The educational animations are original animations created by DOBAIN Inc.."
89678058|NCT05931146|Experimental|MyNetDiary app group|Smart phone application MyNetDiary will be used to track calories and exercise log. The intervention period would last for 3 months.
89678059|NCT05931146|Experimental|Paper diary group|This group will follow paper diary to track calories and exercise log for 3 months.
89678060|NCT05926544|Experimental|Standard implementation (Stage 1)|Participants begin with the standard implementation interventions for 8-16 weeks, depending on random block assignment.
89678061|NCT05926544|Experimental|Virtual facilitation (Stage 2)|After completing the standard implementation, participants then complete the virtual facilitation intervention for 8-16 weeks, depending on random block assignment.
89678062|NCT05912829||Kowa Group|Patients who had a Kowa lens implanted using the Yamane technique
89678063|NCT05912829||Johnson|Patients who had the ZA9003 (J&J) lens implanted using the Yamane technique
89678064|NCT05907161|Experimental|SRP|The SRP group will receive non-surgical periodontal therapy using an ultrasonic device and curettes in two sessions.
89678065|NCT05907161|Active Comparator|SRP+LASER|The SRP+LASER group will receive non-surgical periodontal therapy using an ultrasonic device and curettes in two sessions. After session 2, irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) will be applied intrasulcular to all sites with PD ≥ 4mm.
89678066|NCT05907161|Active Comparator|SRP+HA|The SRP+HA group will receive non-surgical periodontal therapy using an ultrasonic device and curettes in two sessions. After session 2, a gel containing hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic acid gel) will be applied intrasulcular to all sites with PD ≥ 4mm.
89678067|NCT05899244|Experimental|Muscle limitation subgroup receiving muscle stretching exercice|This subgroup of participants will have to perform 2 muscle stretching exercices every day during a month and to report the frequency of realisation on a smartphone or a web application.
89678068|NCT05899244|Experimental|Muscle limitation subgroup receiving a slider exercice|This subgroup of participants will have to perform two series of ten repetitions of a slider exercice every day during a month and to report the frequency of realisation on a smartphone or a web application.
89678069|NCT05899244|Experimental|Muscle limitation subgroup receiving a tensioner exercice|This subgroup of participants will have to perform two series of ten repetitions of a tensioner exercice every day during a month and to report the frequency of realisation on a smartphone or a web application.
89678070|NCT05899244|Experimental|Neural limitation subgroup receiving a muscle stretching exercice|This subgroup of participants will have to perform 2 muscle stretching exercices every day during a month and to report the frequency of realisation on a smartphone or a web application.
89678071|NCT05899244|Experimental|Neural limitation subgroup receiving a slider exercice|This subgroup of participants will have to perform two series of ten repetitions of a slider exercice every day during a month and to report the frequency of realisation on a smartphone or a web application.
89678072|NCT05899244|Experimental|Neural limitation subgroup receiving a tensioner exercice|This subgroup of participants will have to perform two series of ten repetitions of a tensioner exercice every day during a month and to report the frequency of realisation on a smartphone or a web application.
89678073|NCT05899244|No Intervention|Neural limitation Control subgroup|Participants in this subgroup will not receive an intervention.
89678074|NCT05899244|No Intervention|Muscle limitation Control subgroup|Participants in this subgroup will not receive an intervention.
89678075|NCT05890950|Experimental|K-757 and K-833 combination|
89678076|NCT05890950|Placebo Comparator|Placebo|
89678077|NCT05890352|Experimental|Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)|Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
89678078|NCT05890352|Experimental|Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)|Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
89678079|NCT05890352|Experimental|Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)|Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
89678080|NCT05890352|Active Comparator|Part II, Arm II (tafasitamab, lenalidomide)|Patients receive tafasitamab IV and lenalidomide PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
89215583|NCT00524121|Experimental|Oral Erlotinib|Patients receive oral erlotinib hydrochloride once daily for 1 year
89215584|NCT03996382|Other|Suspicion of cardiac amyloidosis|Patients who display signs of cardiac amyloidosis will be referred for further diagnosis.
89215585|NCT01018342|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
89215586|NCT01018342|Active Comparator|2|Macrobid® Capsules 100 mg
89215587|NCT01074385|Other|Immediate Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions, about a week apart. Subjects will then be asked to complete a questionnaire 1-2 weeks after completing therapy sessions and one month after completing therapy sessions.
89215588|NCT01074385|Other|Wait List Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions; the first session will take place about 6 weeks after registration, with the second session occurring 1-3 weeks after the first. Subjects will then be asked to complete a questionnaire about one month after completing therapy sessions.
89215589|NCT03965767|Placebo Comparator|control|
89215590|NCT03965767|Active Comparator|local group|
89215591|NCT03965767|Active Comparator|systemic group|
89215592|NCT03965767|Active Comparator|combined local and systemic|
89215593|NCT00470626|Experimental|1|Vena Cava Filter
89678081|NCT05890352|Experimental|Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)|Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
89678082|NCT05886673|Experimental|Study treatment|The experimental cream formulation has the same components as the control plus 2% pterostilbene, 1% silibinin and 2% nicotinamide riboside.
89678083|NCT05886673|Other|Control treatment|The control cream formulation is designed to help maintaining skin hydration and texture. It contains common ingredients largely used in cosmetics: stearic acid, cetyl alcohol, liquid vaselin, isopropyl myristate, triethanolamine, methyl paraben, propyl paraben, propylene glycol, ethoxydiglycol, and water.
89678084|NCT05866640|Experimental|Intervention|Placement of the F2 device in the aorta to cover the great cerebral vessels.
89678085|NCT05840380|Active Comparator|exercise+1ASTM group|"In addition to the exercises given to the exercise group to the IASTM group 8-10 repetitions with the device at a 45° angle twice a week for 4 weeks on erector spines, glutes maximus, gluteus medius and hamstrings Superficial and deep fascia will be applied. Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual.~cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied. They will perform the low back pain exercises shown. Pain intensity of all patients at the beginning and end of treatment Visual Analogue Scale and algometer, flexibility sit and lie test, position sense digital inclinometer, functional status Oswestry Disability Index and life Quality will be evaluated with Short Form-36 (SF-36)."
89678086|NCT05840380|Active Comparator|exercise group|The exercise group is; By physiotherapists 3 times a week for 4 weeks They will perform the low back pain exercises shown. Pain intensity of all patients at the beginning and end of treatment Visual Analogue Scale and algometer, flexibility sit and lie test, position sense digital inclinometer, functional status Oswestry Disability Index and life Quality will be evaluated with Short Form-36 (SF-36).
89678087|NCT05826808|Experimental|A|Polysomnographies will be done first for 2 nights at the sleep laboratory in Chur (600 m.a.s.l.) and after a two-week washout period for 2 nights at the participants home elevations (>1000 m.a.s.l.).
89678088|NCT05826808|Experimental|B|Polysomnographies will be done first for 2 nights at the participants home elevations (>1000 m.a.s.l.). and after a two-week washout period for 2 nights at sleep laboratory in Chur (600 m.a.s.l.).
89678089|NCT05820854||Non-valvular atrial fibrillation (NVAF) patients treated with oral anticoagulants|Adult outpatients (≥ 18 years) with NVAF and treated with OAC for at least three months.
89678090|NCT05804461|Experimental|Face-to-face intervention|A three-session face-to-face intervention using Motivational Interviewing with a facilitator; to increase Pre-Exposure Prophylaxis (PrEP) uptake. Pre-post-post evaluations after each session will be administered. Participation will last 150 days from the start to the last follow-up.
89678091|NCT05804461|Experimental|Online intervention|A three-session online intervention using Motivational Interviewing with a facilitator; to increase Pre-Exposure Prophylaxis (PrEP) uptake. Pre-post-post evaluations after each session will be administered. Participation will last 150 days from the start to the last follow-up.
89678092|NCT05804461|No Intervention|Control|No intervention. Pre-post evaluations will be administered.
89678093|NCT05803655|Active Comparator|36-Hour Group|"The women randomized to this group will undergo oocyte pick-up procedure 36 hours after the injection of the ovulation triggering agent.~The choice for ovulation trigger agent is at the discretion of the treating physician. The intervention is not the drug but the interval."
89215594|NCT03966001||Planned Cesarean Group|Pregnant women undergoing a planned cesarean section at 38-42 gestational week.
89215595|NCT03966001||Emergency Cesarean Group|Pregnant women who are planning to give normal birth between 38-42 weeks of gestation but have to been performed an urgent cesarean section due to an emergency such as acute fetal distress, cephalo-pelvic disproportion or another obstetrical condition.
89215596|NCT01074541|Active Comparator|Group 1|UV intensity 10 MIN
89215597|NCT01074541|Active Comparator|Group 2|UV intensity 5 MIN
89215598|NCT01074541|Active Comparator|Group 3|UV intensity 1 MIN
89215599|NCT01074541|Active Comparator|Group 4|UV intensity 20 MIN
89215600|NCT00132769|Experimental|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
89215601|NCT00132769|Placebo Comparator|Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
89215602|NCT00520299|Experimental|Cohort 1|Subjects received ADI-PEG 20 at a dose of 40 IU/m^2
89215603|NCT00520299|Experimental|Cohort 2|Subjects received ADI-PEG 20 at a dose of 80 IU/m^2
89215604|NCT00520299|Experimental|Cohort 3|Subjects received ADI-PEG 20 at a dose of 160 IU/m^2
89215605|NCT02478255|Active Comparator|Patients scheduled to undergo Radiation Therapy (RT)|Patients scheduled to undergo Radiation Therapy (RT) for lung cancer, or other malignancies such as breast cancer or lymphoma that involve significant irradiation of the thoracic cavity.
89215606|NCT02478255|Active Comparator|Healthy volunteers|
89215607|NCT00132691|Active Comparator|1|Immunosuppressant medication implant
89215608|NCT00132691|Active Comparator|2|Systemic corticosteroids with immunosuppressant drugs as needed
89678094|NCT05803655|Experimental|38-Hour Group|"The women randomized to this group will undergo oocyte pick-up procedure 38 hours after the injection of the ovulation triggering agent.~The choice for ovulation trigger agent is at the discretion of the treating physician. The intervention is not the drug but the interval."
89678095|NCT05783466|Other|Low-fat dairy products within a dietary handling for weight loss|3 servings/day of low-fat dairy products: 1 serving of low-fat cheese, 1 serving of low-fat yogurt and 1 serving of (semi-)skimmed milk.
89678096|NCT05783466|Experimental|Whole-fat dairy products within a dietary handling for weight loss|3 servings/day of whole-fat dairy products: 1 serving of whole cheese, 1 serving of whole yogurt and 1 serving of whole milk.
89678097|NCT05783466|Experimental|Whole-fat dairy products enriched with milk polar lipids within a dietary handling for weight loss|3 servings/day of whole-fat dairy products (1 milk, 1 yogurt, 1 cheese) among which 1 serving/day is enriched with milk polar lipids via butterier.
89678098|NCT05780931||Treatment Group|This is the group of study subjects which will undergo study-related rehabilitation procedures.
89678099|NCT05780931||Control Group|This is the group of study subjects which will undergo control (sham) rehabilitation procedures (in addition to all their regularly scheduled treatments and interventions).
89678100|NCT05779501|Experimental|Intervention group|The experimental arm will receive the online strengths use intervention program over a period of 4 weeks, through an LMS software solution.
89678101|NCT05779501|Other|Waiting-list control group|The waiting-list control arm will receive the same intervention immediately after the intervention group finishes and will have filled in the post-test outcomes measures.
89678102|NCT05775562|Other|Diving arm|The standard arm involves all participants in the study. Subjects will perform pre-dive and post-dive examinations to characterize the respiratory impact of deep water diving
89678103|NCT05769829||Cohort 1: Pre-diagnosis/+Gastrointestinal Symptoms|"Up to 450 participants with gastrointestinal symptoms, undergoing endoscopy with biopsy will have blood drawn, metadata collected, and tissue from endoscopy collected for analysis. Additional blood draws at various timepoints during the study; at follow up visits, at time of flare, medication change, surgery, or repeat endoscopy.~In addition to the 450 participants enrolled, 50 more participants that meet inclusion/exclusion for cohort 1 will be enrolled to complete only the initial visit and endoscopy visit. Participants will have blood drawn, metadata collected, and tissue from endoscopy collected for analysis."
89678104|NCT05769829||Cohort 2: Diagnosed Inflammatory Bowel Disease, Pre-treatment|Up to 400 participants recently diagnosed with inflammatory bowel disease but not yet started on a medication regimen to address their symptoms will have blood drawn with metadata attached. Additional blood draws at various timepoints during the study; at follow up visits, at time of flare, medication change, surgery, or repeat endoscopy.
89678105|NCT05769829||Cohort 3: Potential Cross-Reactive Diseases|Patients will be eligible for this cohort if they fail to be diagnosed with inflammatory bowel disease but have a confirmed diagnosis of potential cross reactive disease states including Irritable Bowel Syndrome, Functional Diarrhea, Celiac Disease.
89678106|NCT05769829||Cohort 4: Healthy Controls|Up to 228 participants free from GI symptoms for the last 90 days and no previous medical history or clinical diagnosis of GI illness.
89678107|NCT05744557|Experimental|num Vapocoolant|vapocoolant anesthetic spray (a spray that cools and numbs the skin) to control pain during minor surgical procedures (such as lancing boils, incisions, injections and IV placements) and minor sport injuries
89678108|NCT05743049||Blood specimens|Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma.
89678109|NCT05728411|Experimental|Remote temperature monitoring + enhanced usual care|Enrollment in remote foot temperature monitoring in addition to enhanced usual care (described below)
89678110|NCT05728411|Other|Enhanced usual care|"Usual care is based on the VA's amputation prevention program (PAVE - Preventing Amputation in Veterans Everywhere - VHA Directive 1410), which provides a model of care for patients at risk for amputation as well as patients who have already undergone an amputation.~Usual care will be enhanced by providing resources (e.g., information through written newsletters) relevant to a population of Veterans with diabetes, including information on nutrition and cooking, physical activities, and Whole Health opportunities"
89678111|NCT05726370|Experimental|Pre-Operative Treatment + Salvage Surgery + Adjuvant Treatment|"Participants will complete study procedures as outlined:~Preoperative Phase:~Mandatory biopsy at baseline.~Neoadjuvant treatment (2 cycles):~Cycles 1 - 2 ---Day 1 of 21-day Cycle: Predetermined doses of Pembrolizumab, Cisplatin (or Carboplatin) and Docetaxel.~Salvage Surgery:~-Primary tumor resection and/or lymph node dissection surgery 3-6 weeks from cycle 2 day 1~Adjuvant Phase:~-3-8 weeks post-surgery and upto a total of 15 cycles~--Cycles 3 - 17~---Day 1 of 21-day cycle: Predetermined dose of Pembrolizumab~Follow up appointments"
89678112|NCT05720065|Active Comparator|Botulinum toxin|Single bilateral injection into three standardized points of the masseter muscles and two of the anterior temporalis muscle. The total dose administered is 100 U (10 U/point) which is dissolved in 1 mL of isotonic saline. Thus, 0.1 ml of botulinum toxin solution is injected in each point.
89678113|NCT05720065|Placebo Comparator|Isotonic saline|Single injection of 1 mL isotonic saline (0.9 mg/mL) into the same five points per side in a similar manner as for botulinum toxin.
89678114|NCT05717504|Active Comparator|Disclosure|Group A (disclosure arm): patients and physicians will be informed about all AF episodes identified on ILR lasting for ≥6 minutes.
89215609|NCT00125359|Experimental|1|All eligible patients will receive continuous daily oral erlotinib 150mg with daily bexarotene oral capsules 400mg.
89215610|NCT00524043|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
89215611|NCT00524043|Active Comparator|002|Paliperidone ER 6 mg tablet once daily for 6 weeks
89215612|NCT00524043|Placebo Comparator|003|Placebo Once daily for 6 weeks
89215613|NCT03966703|Experimental|conventional denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
89215614|NCT03966703|Experimental|implant fixed denture|10 patients chewed a 2 color gum for 5 cycles 10, 15 and 20.each sample is retrieved weighted and scanned
89678115|NCT05717504|Active Comparator|Non-Disclosure|Group B (non-disclosure arm): patients and physicians will be only informed about AF episodes identified on ILR lasting for ≥24h. This longer threshold is selected because of its association with increased risk of systemic embolism.
89215615|NCT01076725|Active Comparator|Standard technique group|In the standard technique group(n = 63), the PLMA was inserted by index finger insertion technique.
89215616|NCT01076725|Experimental|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
89215617|NCT01076803|Experimental|Lanreotide (acetate)|
89215618|NCT01076881|Experimental|combined aerobic and resistance training|
89215619|NCT01076881|Active Comparator|resistance training alone|
89215620|NCT00523419|Experimental|Pemetrexed|Participants received pemetrexed 500 milligrams per square meter (mg/m^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.
89215621|NCT03868059|Experimental|LPCN 1021|LPCN 1021 at a 225 mg dose taken twice daily (total daily dose of 450 mg taken as 225 mg in the morning and 225 mg in the evening),
89678116|NCT05714618||Cases (Ischemic stroke): Left and right middle cerebral artery ischemic stroke|Patients presenting with acute onset focal neurological deficits and DWI-MRI evidence of an acute brain infarct of the left or right middle cerebral artery ischemic stroke.
89678117|NCT05714618||Controls (TIA): Patients with acute focal neurological symptoms without brain infarct on MRI.|Patients presenting with acute onset focal neurological deficits presumed to be of vascular origin, WITHOUT DWI-MRI evidence of an acute brain infarct.
89678118|NCT05680519|Experimental|Intervention group|The participants will also be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. The participants will receive a brief telephone intervention using the Ask, Warn, Advise, Refer and Do-it-again (AWARD) model. For the advice step, the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so.
89678119|NCT05680519|Placebo Comparator|Control group|The participants will also be given a Practical Resource Hub for Healthy Life leaflet containing information on various applications. The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. In addition, the research assistant will send regular SMS messages to the participants at a similar frequency to the intervention group, but these messages will contain only general health advice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
89678120|NCT05679908|Experimental|TNX-1900 High Dose|30 IU oxytocin taken intranasally twice daily.
89678121|NCT05679908|Experimental|TNX-1900 Low Dose|30 IU oxytocin taken intranasally once daily. Placebo taken intranasally once daily.
89678122|NCT05679908|Placebo Comparator|Placebo|Placebo taken intranasally twice daily.
89678123|NCT05674851|Experimental|Healthy Volunteer MRI|
89678124|NCT05673382|Experimental|Treatment group|Eight weeks of individually tailored ICBT, were participants receives in total 8 modules out of 20 possible depending on their current problems and described situation with weekly support by a therapist.
89678125|NCT05673382|No Intervention|Control group|The control group is a wait-list control condition. Participants are instructed to wait. After the treatment group has finished their treatment and post-treatment measures has been collected, the control group receive the same treatment as the treatment group got.
89678126|NCT05672992|Experimental|Scleroderma Participants|Participants in this arm will be asked to complete the Fitzpatrick skin type questionnaire to quantify skin tone at the first study visit and the SSPRO questionnaire at the time of enrollment and every six months until the end of the study. At each study visit, a physician will measure the mRSS, which is a method of quantifying skin fibrosis; SFDI measurements, ultrasound, and durometry will then be done. Skin biopsies will be collected from the forearm of each subject annually. A small amount of blood will also be collected from subjects once per year to explore serum biomarkers of fibrosis.
89678127|NCT05672992|Active Comparator|Healthy controls|Participants in this arm will be asked to complete the Fitzpatrick skin type questionnaire to quantify skin tone at the first study visit. At each study visit, SFDI measurements, ultrasound, and durometry will be done. Skin biopsies will be collected from the forearm of each subject annually. A small amount of blood will also be collected from subjects once per year to explore serum biomarkers of fibrosis.
89678128|NCT05672927|Active Comparator|Females, 3-dose standard|Three doses of the 9-valent HPV vaccine to be administered to the comparison group (27-45 years of age) at 0, 2, and 6 months.
89215622|NCT03998865|Experimental|PEEK Provisional Abutment|The provisional crown will be fixed onto a PEEK abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
89678129|NCT05672927|Experimental|Females, 2-dose alternative|Two doses of the 9-valent HPV vaccine to be administered to the experimental group (27-45 years of age) at 0 and 6 months. Additional HPV vaccine dose will be offered after final blood draw at 12 months.
88996383|NCT02921074|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
89215623|NCT03998865|Active Comparator|Titanium Provisional Abutment|The provisional crown will be fixed onto a titanium abutment and then connected to the implant. The bis-acrylic resin used for the provisional crown will not invade the emergence profile of the abutment.
89215624|NCT04028115|Experimental|Interventional|Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. In this, study no randomisation will occur. All patients will receive the same treatment.
89050513|NCT04600401|Experimental|Participants integrate the Mentis Plus+ program|Mentis Plus+ Program was developed based in The Multifactorial Model of Positive Mental Health and its construction resulted from a systematic literature review and validation through focus group. The duration of the Mentis Plus+ program depends on the number of the six factors to be worked on. The Mentis Plus+ lasts at least 7 weeks (1 session per week, lasting 1 hour) and can work individually or in groups (2-12 people). There will be 2 initial sessions of 1 hour each and 3 sessions for each factor to work with duration of 1 hour. Still, a final session and a follow-up session (3-6 months after the program) will be held.
89050514|NCT04600401|No Intervention|Participants on a waiting list (Control Group)|Participants in the control group were told they were on a waiting list for 3-6 months, as a minimum, before they integrate the Mentis Plus+ program. Given the preventive nature of this study, a waiting list control group won't bring risks or damages to participants
89050515|NCT04600440|Experimental|Plasma treatment|Convalescent plasma 200 ml daily during three days
89678130|NCT05672225|Active Comparator|Control group|Continuous channel: normal saline 100ml, 2ml/h (fixed rate) Selector & Bolus channel: fentanyl 20mcg/kg (Total 50ml with normal saline), bolus 1ml/10min lock-out
89678131|NCT05672225|Experimental|Dexmedetomidine group|Continuous channel: dexmedetomidine 10mcg/kg (Total 100ml with normal saline), 2ml/h (fixed rate) Selector & Bolus channel: fentanyl 20mcg/kg (Total 50ml with normal saline), bolus 1ml/10min lock-out
89678132|NCT05659459|Experimental|KIN001|75mg pamapimod oral tablet 5mg pioglitazone oral tablet twice daily for 14 days
89678133|NCT05659459|Placebo Comparator|Placebo|75mg pamapimod-placebo oral tablet 5mg pioglitazone-placebo oral tablet twice daily for 14 days
89678134|NCT05657483||Endometrial cancer patients|At least 18-year-old patients histologically diagnosed with endometrial cancer who will undergo surgical staging of disease after performing full-body CT-scan 30 days before the enrollment.
89678135|NCT05656430|Experimental|Treatment group|Eight weeks of individually tailored ICBT, were participants receives in total 8 modules out of 20 possible depending on their current problems and described situation with weekly support by a therapist.
89678136|NCT05656430|No Intervention|Control group|The control group is a wait-list control condition. Participants are instructed to wait. After the treatment group has finished their treatment and post-treatment measures has been collected, the control group receive the same treatment as the treatment group got.
89678137|NCT05652153|Other|Longitudinal Assessments|Participants in both groups (Dep/SI and Dep/SB) will undergo identical assessments at baseline, 6 months, and 12 months. Assessments will include clinical interviews and rating scales, questionnaires (including a self-report scale of negative urgency), and single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) measurement of cortical inhibition.
89678138|NCT05649358|Experimental|Evaluation of non-invasive lactate sensor|To determine the efficacy and accuracy of the non-invasive lactate sensor
89678139|NCT05634226|Experimental|Hands-free oral-positive pressure device (oPEP)|
89678140|NCT05626816|Experimental|All interventions, Sham applied first|These participants will have all interventions applied, but will be randomly designated to have sham stimulation applied before effective stimulation. This will balance any issue with order of presentation of multiple stimulation sessions.
89678141|NCT05626816|Experimental|All interventions, effective stim applied first|These participants will have all interventions applied, but will be randomly designated to have effective stimulation applied before sham stimulation. This will balance any issue with order of presentation of multiple stimulation sessions.
89678142|NCT05618886|Active Comparator|control group|Education given to all participants included before randomization. Information about UI, PFM and PFMT, together with lifestyle advices such as using the 'knack' (pre-contracting the PFM before coughing and sneezing), maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure. The education session will last 30 minutes, and include a video (https://www.youtube.com/watch?v=XsDpfq10JMI) and a leaflet containing the information given.
89678143|NCT05618886|Experimental|intervention group|Along with education session, twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participants will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary
89678144|NCT05594784|Experimental|Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax|"For Induction cycle, olverembatinib will be given orally 40mg every other day. Patients with CMR, olverembatinib will be reduced to 30 mg every other day.~Induction and consolidation cycles combined with a certain period of venetoclax.~Reduced-intensity chemotherapy regimens consist mainly of vincristine and prednisone. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy."
89678145|NCT05583864|Active Comparator|CONDUIT Porous Titanium Spinal Cage|Solid titanium spinal cage, infused with microscopic, porous canals to allow for adhesion and proliferation of bone graft factors contributing to spinal ossification, and ultimately, spinal fusion between vertebrae demonstrating instability.
89678146|NCT05583864|Active Comparator|PROTI 360 Titanium-Coated PEEK Spinal Cage|Spinal cage composed primarily of a medical-grade polymer: poly-ether-ether-ketone (PEEK), with a titanium coating that is etched, but lacking porous features. These design features also attempt to stimulate spinal vertebrae fusion through bone-graft ossification and enhance vertebral stability.
89688763|NCT02935738|No Intervention|Control men / negative SPA / ICSI|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were then admitted to intracytoplasmic sperm injection (ICSI) cycles.
89050516|NCT04600440|No Intervention|No plasma|Best conventional treatment
89678147|NCT05573009|Experimental|Training Group|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~At least 3-days of the cognitive behavioral approach-based stress reduction program will be given as face to face interviews to the intervention group during hospitalisation, and the remaining sessions will be given at the bedside as long as the hospitalization continues. If the patient is discharged, the remaining 2 sessions will be completed online."
89678148|NCT05573009|No Intervention|Control Group|Routine nursing care will be provided to the control group along with a stress management manual.
89678149|NCT05559749|Experimental|collaborative care|The collaborative care team roles include the care manager/social worker and psychiatrist who interact with the patient participant and the patient's neurologist/neurology provider.
89678150|NCT05559749|Active Comparator|usual neurology care|Ongoing usual neurology care, without the addition of the collaborative care program - current standard care and is thus an ethically appropriate control condition for effectiveness and implementation trials.
89678151|NCT05556902|Experimental|Treatment|Patients that proceed with permanent implantation of a spinal cord stimulator.
89678152|NCT05556902|No Intervention|Control|Patients who do not proceed with permanent implantation of a spinal cord stimulator.
89678153|NCT05555342|Experimental|IRE ablation and radiation therapy|Patients will be treated with IRE ablation directed at the target lesion on day 1. Moderate-dose, single-fraction radiation therapy will be delivered to the target lesion on day 8 to day 15.
89678154|NCT05551481|Experimental|In Group A,(Variolink II, Ivoclar Vivadent).|In Group A, the onlays and overlays were luted adhesively with etch and rinse, dual cure resin cement (Variolink II, Ivoclar Vivadent).
89678155|NCT05551481|Active Comparator|In Group B, (Relyx U200, 3M ESPE).|In Group B the onlays and overlays were luted using a self-adhesive resin cement (Relyx U200, 3M ESPE).
89678156|NCT05547347||Observational (twinkle marker placement)|Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker throughout the trial. Patients undergo a breast ultrasound during screening, on study, and as clinically indicated. Patient also undergoes a mammogram on study and as clinically indicated as well as a MRI as clinically indicated.
89678157|NCT05518786||HUCA|Patients recruited at the University Central Hospital of Oviedo
89678158|NCT05518786||Taulí|Patients recruited at Parc Taulí Foundation/Hospital (Sabadell)
89678159|NCT05518786||Paz|Patients recruited at University Hospital of La Paz (Madrid)
89678160|NCT05516576|Experimental|endoscopic gastroplasty with endomina®|
89678161|NCT05516576|No Intervention|control|
89678162|NCT05509647||Covid-19 patients|Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml. All patients have Covid-19 proven by PCR or nose- or airway swab. Patients admitted to the ICU from the 15th of March 2020 until January 2022.
89678163|NCT05509647||non-COVID-19 patients|Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml. Patients admitted to the ICU between the 1st of January 2014 and the 1st of January 2020 are included.
89678164|NCT05490979|Experimental|Contemplative dyad meditation|
89678165|NCT05490979|Active Comparator|Fast friends|
89678166|NCT05490979|No Intervention|No intervention|
89678167|NCT05489510|Other|Pulsed lighting|
89678168|NCT05489510|Other|Continuous lighting|
89678169|NCT05469269|Experimental|Education and Passive Navigation|This arm receives barber-led education and access to a resource website. Barbers will encourage clients to access the screening website. Other study materials will also be located within the shop. The resource website will be accessible via QR code that will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire.
89678170|NCT05469269|Experimental|Education and Active Navigation|This arm includes all interventions of the first arm plus the addition of a community navigator. The community navigator will be onsite to assist in information delivery and navigation to resources and encourage the completion of the Screener through the QR code. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
89678171|NCT05469269|Experimental|Education and Active Navigation with Community Based Outreach|This arm adds the community navigator and a community outreach screening event. Case Comprehensive Cancer Center Community Outreach and Engagement will offer barber shops an onsite PSA screening event.
89678172|NCT05453929|Experimental|Deep NMB|A TOF count of 0, and a PTC of 1 to 3 will be maintained, as close to 2 twitches as possible
89678173|NCT05453929|Active Comparator|Moderate NMB|A TOF count of 1 to 3 will be maintained, as close to 2 twitches as possible
89678174|NCT05449145|Placebo Comparator|Placebo|MCT oil (first 4-week) plus Omega-3 FA (second 4-week)
89678175|NCT05449145|Experimental|Vitamin D|Vit D (first 4-week) plus Omega-3 FA (second 4-week)
89678176|NCT05437562|Other|Ewing Amputation|Single Arm Pilot Study : To implement lead-in surgeon training and test the feasibility of recruiting and retention of veterans undergoing Ewing Amputation in a single arm study at Atlanta VAMC.
89688764|NCT00932659||Hemodialysis patients|This is a single arm observational study. The single arm consists of adult hemodialysis patients without a prior history of cardiac arrhythmias who will be implanted with a continuous cardiac monitoring device (REVEAL, Medtronic) for an FDA approved indication.
89688765|NCT03034447|Other|Asthma|Children and teenagers with persistent asthma will perform questionnaires, lung function test, and home sleep study
89688766|NCT00939991|Experimental|1|Phase I- Bevacizumab will be administered intravenously every other week. Temozolomide will be administered on a continuous daily dosing schedule. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen.
89050517|NCT00555191|Active Comparator|1|PATIENTS IN THIS ARM IS INSTRUCTED IN FRUCTOSE REDUCED DIET FOR A PERIOD OF 3 MONTHS
89050518|NCT00555191|No Intervention|2|these patients use their usual diet
89050519|NCT04608669|Other|Temperature comparison|
89050520|NCT04608669|Active Comparator|No change|
89050521|NCT00555230|Experimental|1|Rosuvastatin
89050522|NCT00555230|Placebo Comparator|2|Placebo
89215625|NCT00522951|Experimental|Gadobutrol 0.1 mmol/kg bw|Participants received first injection (intravenous [i.v.]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
89215626|NCT00522951|Experimental|Gadobutrol 0.2 mmol/kg bw|Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
89215627|NCT00522951|Experimental|Gadoteridol (ProHance)|Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
89215628|NCT03865953|Active Comparator|LAT8881|1 x 30 mg capsule of LAT8881 taken by mouth, twice daily (morning and evening) during the four-week treatment period.
89215629|NCT03865953|Placebo Comparator|Placebo|1 x 30 mg capsule of placebo, taken by mouth, twice daily (morning and evening) during the four-week treatment period.
89215630|NCT06028061|Active Comparator|Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
89678177|NCT05435586|Experimental|Web Based Breastfeeding Education and Counseling with Digital Game Support|"During pregnancy;~Application of the Individual and Obstetrical Characteristics Evaluation Form of Pregnant Women and Breastfeeding Self-Efficacy Scale Antenatal Form (Pre-Test).(32-34 weeks of gestation)~Program will be applied to 30 women at 35-37 gestational weeks.~Breastfeeding Self-Efficacy Scale (Antenatal form) will be applied to at the end of 37th gestational week.~In the postpartum period;~The LATCH Breastfeeding Diagnostic Tool and Breastfeeding Assessment Scale (IBFAT) will be administered on the first postpartum day.~Program will be applied to 30 women during the first 2 weeks postpartum.~At the end of the postpartum 2nd week, Breastfeeding Behavior and Breast Problems Evaluation Form will be administered.~Breastfeeding Self-Efficacy Scale (Postpartum form) and Breast Problems Evaluation form will be administered at postpartum 8th week."
89678178|NCT05435586|No Intervention|Standardized breastfeeding education|"During pregnancy;~Application of the Individual and Obstetrical Characteristics Evaluation Form of Pregnant Women and Breastfeeding Self-Efficacy Scale Antenatal Form (Pre-Test).(32-34 weeks of gestation)~30 women will receive the routine care applied during pregnancy in the hospital.~At the end of the 37th week, the Breastfeeding Self-Efficacy Scale (Antenatal form) will be administered to the women in the control group.~In the postpartum period;~30 women will receive the standard breastfeeding training in the hospital.~The LATCH Breastfeeding Diagnostic Tool and Breastfeeding Assessment Scale (IBFAT) will be administered on the first postpartum day.~At the end of the postpartum 2nd week, the Breastfeeding Behavior and Breast Problems Evaluation Form will be applied.~Breastfeeding Self-Efficacy Scale (Postpartum form) and Breastfeeding Behavior and Breast Problems Evaluation Form will be administered at the postpartum 8th week."
89678179|NCT05434052||stroke patients|The aim of this study is to adapt the Community Integration Questionnaire-Revised (CIQ-R)scale to Turkish society in stroke patients and to make its validity and reliability in Turkish.
89678180|NCT05426681|Experimental|Glyburide treatment arm|
89678181|NCT05424900|Experimental|REThink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
89678182|NCT05424900|No Intervention|Monitoring|Participants in this arm will be monitored for a total of eight weeks, for comparison with the REThink game intervention (after four weeks).
89678183|NCT05418296|Experimental|Persons residing in long-term care homes|Subjects' ADLs are studied with intervention compared to baseline (without intervention).
89678184|NCT05417347|Active Comparator|Low-fat dairy products|Consumption of low-fat dairy products (4 servings/day with 2 servings/day coming from yogurt)
89678185|NCT05417347|Active Comparator|Full-fat dairy products|Consumption of high-fat dairy products (4 servings/day with 2 servings/day coming from yogurt)
89678186|NCT05417347|No Intervention|Control|Will be recommended to choose low-fat dairy products and alternatives based on recommendations from the 2007 Canadian Food Guide (2 servings/day for adults and 3-4 servings/day for children)
89678187|NCT05406726|Experimental|palmitoylethanolamide (PEA)|Palmitoylethanolamide (PEA) is a lipid based endocannabinoid dietary supplement currently marketed.
89678188|NCT05406726|Placebo Comparator|Placebo|A similar size and shaped capsule containing maltodextrin will be used as a placebo comparator.
89678189|NCT05403736|Experimental|CARMA|Cardiac Aggressive Risk MitigAtion plan with biosensor monitoring
89678190|NCT05402657|Experimental|Frontoparietal ECT Group|Participants will receive ultrabrief right unilateral ECT with a frontoparietal placement of ECT electrodes.
89678191|NCT05402657|Active Comparator|Temporoparietal ECT Group|Participants will receive ultrabrief right unilateral ECT with the conventional temporoparietal placement of ECT electrodes.
89678192|NCT05402527|Other|Fish nutrients - Whey protein - Maltodextrin|Participants will receive fish nutrients, whey protein, and maltodextrin in this order.
89678193|NCT05402527|Other|Fish nutrients - Maltodextrin - Whey protein|Participants will receive fish nutrients, maltodextrin, and whey protein in this order.
89678194|NCT05402527|Other|Whey protein - Fish nutrients - Maltodextrin|Participants will receive whey protein, fish nutrients, and maltodextrin in this order.
89678195|NCT05402527|Other|Whey protein - Maltodextrin - Fish nutrients|Participants will receive whey protein, maltodextrin, and fish nutrients in this order.
89678196|NCT05402527|Other|Maltodextrin - Fish nutrients - Whey protein|Participants will receive maltodextrin, fish nutrients, and whey protein in this order.
89678197|NCT05402527|Other|Maltodextrin - Whey protein - Fish nutrients|Participants will receive maltodextrin, whey protein, and fish nutrients in this order.
89688767|NCT00940537||NAFLD|Non-diabetic, obese with diagnosed NAFLD (HTGC greater or equal to 5.5%)
89688768|NCT00940537||Non-NAFLD|Non-diabetic, obese with no previous diagnosis of NAFLD
89678198|NCT05399407|Experimental|Experimental group: health e-coaching|"Personalised and secure access to the health e-coaching platform for 12 months.~Follow-up by professionals who are specialized in the subject matter (at a distance): a psychologist, a dietician and a teacher of adapted physical activity.~Personalised activities offered to each young adult throughout their follow-up: synchronous and asynchronous activities (video, animation, quizzes, etc.), individual and collective on different themes (expression of emotions, my weight and me, eating well to start with, my image and me, making choices, my way of moving, etc.). The personalisation of the activities will be done in consultation between the professionals and the young adult according to the needs expressed and identified."
89678199|NCT05399407|No Intervention|Control group: Usual Care System|"Control group : - Referral to health professionals in the health care system and, in priority, to the GP declared by the young adult.~- Transmission of the data collected during follow-up visit No. 3 / 0 (T3/T0) to the GP with relay for the implementation of a care plan."
89678200|NCT05396963|Other|Egg white - Whey protein - Maltodextrin|Participants will receive egg white, whey protein, and maltodextrin in this order.
89678201|NCT05396963|Other|Egg white - Maltodextrin - Whey protein|Participants will receive egg white, maltodextrin, and whey protein in this order.
89678202|NCT05396963|Other|Whey protein - Egg white - Maltodextrin|Participants will receive whey protein, egg white, and maltodextrin in this order.
89678203|NCT05396963|Other|Whey protein - Maltodextrin - Egg white|Participants will receive whey protein, maltodextrin, and egg white in this order.
89678204|NCT05396963|Other|Maltodextrin - Egg white - Whey protein|Participants will receive maltodextrin, egg white, and whey protein in this order.
89678205|NCT05396963|Other|Maltodextrin - Whey protein - Egg white|Participants will receive maltodextrin, whey protein, and egg white in this order.
89678206|NCT05386264|Experimental|Expanded autologous T regulatory cells|This is an open-label, non-randomised interventional trial.
89678207|NCT05369468|Placebo Comparator|group 1|Group 1: will receive bilateral ESP block with injection of 20 ml of 0.25% Bupivacaine in each site of injection .
89678208|NCT05369468|Experimental|group 2|Group 2: will receive bilateral ESP block with injection of 18ml of 0.25% Bupivacaine plus 2ml dexmedetomidine 0.5 ug /kg in each site of injection .
89678209|NCT05368623||Sequential Enrollment|Patients aged 22yrs or older who have diabetes will be recruited from primary care settings.
89678210|NCT05350449|Experimental|Loving kindness meditation|Loving-kindness meditation is a contemplative practice that focuses on developing compassion for oneself and others through mindfulness. Participants will be shown the recorded loving-kindness training video during the first week of the intervention. Participants will be encouraged to use the mp3 device with guided meditation recording to practice mindfulness meditation for 20-25 minutes every day for 30 days. We will also provide participants with a diary to record their daily meditation experiences. There will be weekly check in. At 60 days we will do a follow-up data collection.
89678211|NCT05350449|No Intervention|Waitlist control|The arm will eventually get the intervention.
89678212|NCT05348837||Subthalamic nucleus (STN) DBS|Patients undergoing evaluation for subthalamic nucleus DBS implantation will be included in this group.
89678213|NCT05348837||Globus pallidus interna (GPi) DBS|Patients undergoing evaluation for globus pallidus interna DBS implantation will be included in this group.
89678214|NCT05340569|Experimental|DWI-MRI|Patients to undergo DWI-MRI (patients include in the study.
89678215|NCT05307991||Index PrEP participants|This group includes persons 15 years and older who are started on PrEP at the STI clinic. Participants in this group will be followed for 6 months, with follow-up visits at 1, 3, and 6 months, and will be asked to refer sexual partners from the preceding 6 months as well as any new sexual partners throughout the study period. They will also receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
89678216|NCT05307991||Non-PrEP participants|This group includes persons who are eligible to receive PrEP but who decline initiation at their index visit to the STI clinic. These participants will be followed for 6 months, with follow-up visits at 3 and 6 months, and receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. However, at any time during the follow-up period these persons can choose to initiate PrEP. This would not change their follow-up frequency nor their assigned group, and they would continue to be followed for 6 months from the date of initial enrollment. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
89678217|NCT05307991||Partner participants|This group is made up of named/referred partners from the Group 1 (Index PrEP participant) who are eligible for and agree to start PrEP. They will receive identical intervention to that of the Group 1, specifically: this group will be followed for 6 months, with follow-up visits at 1, 3, and 6 months, and will be asked to refer sexual partners from the preceding 6 months as well as any new sexual partners throughout the study period. They will also receive testing for Neisseria gonorrhea, Chlamydia trachomatis, and syphilis (depending on prior results) at baseline, 3, and 6 months. A sub-group of participants will also complete in-depth interviews to contextualize observed behaviors and outcomes.
89678218|NCT05307991||Providers|This group is made up providers involved in the provision of PrEP or other related services including STI management, HIV testing or counseling, or assisted partner notification (aPN). Examples include: clinicians, nurses, HIV testing/aPN counselors, registration staff, community tracers, and clinic management who provide clinical or aPN services. These participants will be asked to complete a survey responding to acceptability, feasibility, and appropriateness of the enhanced PrEP implementation strategy as an integrated strategy within the STI clinic. They will also participate in in-depth interviews. These activities will be completed at baseline and approximately 6 months thereafter.
89678219|NCT05304481|Experimental|Treatment|ATL administration
89678220|NCT05272462|Experimental|Treatment|Participants in this arm will be treated with minoxidil. This treatment will be given daily by mouth.
89678221|NCT05253482|Experimental|Intervention group|The intervention group will undergo 3 successive wet cupping therapy (WCT) sessions once in a month throughout 3 months (On 0, 30, and 60 days
89678222|NCT05253482|No Intervention|Control group|Control group will not receive any intervention
89678223|NCT05248256|Experimental|Radiation Dose Limitations to VMAT|Patients confirmed to have T1-T3 N1-N3 (Stage IIIA-IIIC) or select Stage IV primary adeno- or squamous cell-carcinoma of the lung will be treated per standard of care; concurrent chemoradiotherapy for 6 to 6.5 weeks, followed by consolidative immunotherapy. A CT simulation scan is obtained with the patient in the treatment position allowing the radiation oncologist to delineate intended tumor targets and organs at risk (OAR). Using specialized treatment planning software, a radiation plan is generated with the goal of maximizing tumor coverage with intended prescription dose and minimizing unintended radiation dose to OARs below established thresholds. The primary intervention of this trial will be sparing the thoracic bone marrow. This will be done by delineating the thoracic bone marrow on the CT simulation scan and applying vertebral marrow-specific OAR constraints during treatment planning to optimally spare radiation dose to this structure during treatment
89678224|NCT05240794|Experimental|Experimental group|Participants receive active ABM-01 for the study
89678225|NCT05240794|Placebo Comparator|Placebo Control|Participants receive a digital control for the study
89678226|NCT05232799|Experimental|Care Anywhere with Community Paramedics program|Subjects will be discharged from a pre-hospital setting, Emergency Department or the hospital with community paramedic services ordered and overseen by the treating clinical team per current standard of care.
89678227|NCT05232799|No Intervention|Standard of Care|Subjects will receive continued usual care
89678228|NCT05230134|Experimental|Cervical sympathetic block|"Patients hospitalized in the ICU and developing clinical manifestations of cerebral vasospasm will undergo a computerized tomography (CT) angiography and a CT perfusion scan. If the vasospasm will be confirmed by the CT imaging, a cervical sympathetic nerve block under ultrasound guidance will be performed. The block consists in the deposition of local anesthetic at the cervical sympathetic ganglion that will be visualized with an ultrasound device. A periganglionar catheter will be left in place. A CT angiography and CT perfusion will be repeated to check the effect of the block on the brain vasculature after the block is done.~Patients will have a daily monitoring of their neurological function and of their cerebral blood flow with transcranial doppler in the ICU."
89678229|NCT05222152|Experimental|Chronocort|Chronocort (hydrocortisone modified-release hard capsule) supplied as 5 mg and 10 mg strengths will be administered orally. Chronocort 10 mg will be taken on waking (typically between 06:00 and 08:00 hours) and Chronocort 15 mg will be taken just prior to going to bed (typically between 22:00 hours and midnight).
89678230|NCT05222152|Active Comparator|Plenadren|Plenadren (hydrocortisone modified-release tablet) supplied as 5 mg and 20 mg strengths and administered orally. Plenadren 25 mg will be taken on waking (typically between 06:00 and 08:00 hours).
89678231|NCT05200572|Experimental|Cancer Patients|Dyadic Life Review will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes.
89678232|NCT05188014|Experimental|All participants|All participants will be in a single study arm.
89678233|NCT05141526|Experimental|Non-restrictive satiating intervention|The non-restrictive satiating intervention will include guidelines and recipes to prepare highly satiating meals that will be low in energy density and glycemic index and high in protein, polyunsaturated fats, vitamins and minerals (e.g. calcium), and certain constituents of spices (e.g. capsaicin).
89678234|NCT05141526|Experimental|Conventional restrictive intervention + non-restrictive satiating intervention|Conventional restrictive intervention consisting of a -500 kcal/d calorie deficit (P1) followed by a non-restrictive satiating intervention (P2)
89678235|NCT05141526|Placebo Comparator|Minimal healthy guidelines|Considering recommendations from the latest Canadian Obesity Guidelines, the control group will receive a minimal intervention based on the Canada's Food Guide for Healthy Eating
89678236|NCT05137262|Experimental|Arm A: Standard of Care with dose-dense MVAC|The patient will receive treatment every 14 days for up to 6 cycles in the neoadjuvant setting.
89678237|NCT05137262|Experimental|Arm B: Intervention with dose-dense MVAC plus Durvalumab|Durvalumab will be administered one week prior to the initial cycle of dose-dense MVAC and then with each additional cycle of dose-dense MVAC on Arm B
89678238|NCT05132556|Experimental|Nitrate-rich beetroot juice (~12.8 mmol)|Participants will have blood pressure, arterial stiffness, and blood samples (from venipuncture) assessed before and after the nitrate-rich beetroot juice (~12.8 mmol).
89678239|NCT05132556|Placebo Comparator|Beetroot juice with nitrate removed|Participants will have blood pressure, arterial stiffness, and blood samples (from venipuncture) assessed before and after the beetroot juice with nitrate removed.
89678240|NCT05129475|Experimental|Treatment A|Single oral dose of ritonavir at -12 hours prior to PF-07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
89678241|NCT05129475|Experimental|Treatment B|Single oral dose of ritonavir at -12 hours prior to PF 07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
89678242|NCT05123742||DHCW Subjects|Dental Health Care Workers
89678243|NCT05123742||Patient Subjects|Dental patients
89678244|NCT05119777|Experimental|HArmonyCa Injectable Gel|HArmonyCa injected at the discretion of the Treating Investigator (TI) to the midface for initial treatment and an optional touch-up treatment 14 days later
89678245|NCT05111977|Experimental|Capsule stimulation|Participants in this arm will receive gastric stimulation via the Vibrant capsule
89678246|NCT05111977|Placebo Comparator|Placebo stimulation|Participants in this arm will receive no gastric stimulation via a placebo capsule
89678247|NCT05106465||Konectom|Participants with a diagnosis of MS or clinically isolated syndrome who are enrolled in Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) and who own a smartphone model compatible with the Konectom platform will be enrolled.
89678248|NCT05097625||High Risk Pathway|Risk-stratified surveillance pathway, including non-invasive methods of surveillance such as blood and saliva tests; to monitor for relapse, with any abnormalities triggering imaging
89678249|NCT05097625||Low Risk Pathway|Risk-stratified surveillance pathway, including non-invasive methods of surveillance such as blood and saliva tests; to monitor for relapse, with any abnormalities triggering imaging
89678250|NCT05086289|Experimental|LY3526318|Participants received 250 mg of LY3526318 orally, once daily for the first 4 weeks of treatment period and were switched to placebo once daily for the next 4 weeks of the treatment period.
89215631|NCT06028061|Active Comparator|Quadratus Lumborum Block with adjuvant|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
89215632|NCT06027970|Active Comparator|Treatment|After successful Endoscopic variceal ligation (EVL) the treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days. Both the group will receive standard care of therapy.
89215633|NCT06027970|Placebo Comparator|Control|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days. Both the group will receive standard care of therapy.
89215634|NCT06027957|Experimental|Treatment Regimen|"Experimental: Treatment Regimen.~Leukapheresis to collect white blood cells using Spectra Optia Apheresis system.~T cells selection, transduction, and CAR T-cell manufacturing using CliniMACS Prodigy. During this process, T cells will be genetically modified to express CD19 CAR.~Lymphodepleting chemotherapy conditioning regimen for 3 days.~CAR T-cells targeting CD19 will be infused intravenously at a dose between 1 and 2x10e6 cells/kg for 15-30 minutes.~Following the T-cell infusion, patients will stay in the clinic for approximately 21-28 days to monitor toxicity.~Outpatient follow-up will take place after 1 month, 3 months, and 6 months after infusion."
89678251|NCT05086289|Placebo Comparator|Placebo|Participants received placebo orally, once daily, for 8-weeks treatment period.
89678252|NCT05071144||Pediatric Spine Deformity Patients|Standard of care surgery using robotics coupled with navigation
89678253|NCT05062031|Experimental|DIMS®|Defocus Incorporated Multiple Segments® lenses
89678254|NCT05062031|Active Comparator|Low-concentration atropine + monofocal lenses|
89678255|NCT05046301||Diagnostic (contrast-enhanced mammography)|Patients complete a questionnaire and undergo collection of a blood sample. Patients undergo CEM.
89678256|NCT05045144|Experimental|RSV lot1 Group|Participants randomized to the RSV lot1 Group received one dose of RSV MAT Lot 1 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
89678257|NCT05045144|Experimental|RSV lot2 Group|Participants randomized to the RSV lot2 Group received one dose of RSV MAT Lot 2 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
89678258|NCT05045144|Experimental|RSV lot3 Group|Participants randomized to the RSV lot3 Group received one dose of RSV MAT Lot 3 vaccine intramuscularly at Day 1. Participants were also provided with an option of receiving Flu D-QIV vaccine at Day 31 to allow the participants receive the standard of care.
89678259|NCT05045144|Experimental|RSV+Flu pooled Group|"Participants randomized in this group received one dose of RSVPreF3 vaccine (RSV MAT vaccine) from one of the three lots used (Lot 1, Lot 2 or Lot 3 of same formulation of RSVPreF3 vaccine) and one dose of the Flu D-QIV vaccine on Day 1, and were followed up until the end of the study (Day 181).~The participants in this group were considered for the immunogenicity and safety analyses of the RSV MAT and Flu D-QIV vaccines."
89678260|NCT05045144|Active Comparator|Flu+Placebo Group|"Participants randomized in this group received one dose of Flu D-QIV vaccine co-administered with one dose of placebo at Day 1, and were followed up until the end of the study (Day 181).~This group was considered comparator for immunogenicity and safety analyses for RSV+ Flu Pooled group."
89678261|NCT05040776|Other|Active|Frunexian infusion 0.6 mg/kg/hr or 1 mg/kg/hr. 0.6 mg/kg/hr dose will be completed first.
89678262|NCT05040776|Active Comparator|Institutional Standard|Clinician's choice of prophylaxis strategy
89678263|NCT05037292|Experimental|PAUSE|"Surgical specialty clinics that completed an onboarding training for team members to use the standardized frailty screening incorporated in Veterans' medical records. Veterans identified as frail upon screening will be referred to a multidisciplinary PAUSE Board comprised of members from surgery, anesthesia, geriatrics, palliative care, case management, rehabilitation, nutrition."
89678264|NCT05037292|No Intervention|Usual Care|Surgical specialty clinics that have not yet implemented the PAUSE Intervention. Veterans at these clinics will receive usual perioperative assessment and management by the clinical team.
89678265|NCT05022524|Experimental|Transition-Age Adults|16-25 year old patients on stable dose of antipsychotic medication for treatment of depression or anxiety.
89678266|NCT05017363|Experimental|Intervention Group (ENGAGE)|Therapists will consist of pairs within sites providing similar interventions to similar children so that treatment and child characteristics other than the goal-setting intervention will be similar within each site. Therapists will use principles-based goal-setting approaches and strategies in the goal-setting toolbox. It is anticipated that treatment block lengths will vary from 3-8 sessions over 2-8 weeks, representing typical clinical variation.
89678267|NCT05017363|No Intervention|Usual Care Group (Control)|The control group will comprise usual care.
89678268|NCT05016765|Experimental|Active MNS|Active, self-directed electrical stimulation of the right median nerve
89678269|NCT05014295|No Intervention|Control Group|Survey questions at baseline and at one week. The control group will have had one week to reflect on the questions, and investigators anticipate some influence of this on responses.
89678270|NCT05014295|Active Comparator|Intervention Group|The intervention group will be prompted about accessing their medical records from the major local health systems online, with links to directions provided by each hospital system. They will then be asked to fill out the same questionnaire.
89678271|NCT05000944|Experimental|breakfast omission (BO)|No breakfast will be provided until the lunch time at ~12:30. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
89678272|NCT05000944|Experimental|early-morning breakfast consumption (EM-BC)|A standardised, carbohydrate-rich, low glycaemic index (GI) breakfast will be provided at ~08:30 for EM-BC. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
89678273|NCT05000944|Experimental|mid-morning breakfast consumption (MM-BC).|A standardised, carbohydrate-rich, low glycaemic index (GI) breakfast will be provided at ~10:30 for MM-BC (i.e., two hours after EM-BC). Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
89678274|NCT05000723||PJI patients|"Patients (older than 18 years) with PJI of a total hip replacement treated at University Hospitals Leuven.~Diagnosis of PJI of the hip is made based on the EBJIS 2021 criteria. Patients will receive standard of care."
89678275|NCT04988685||Treatment|The project ́s main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of CAD patients treated with contemporary DCBs.
89678276|NCT04987645|Other|Water-Assisted Colonoscopy|If this intervention is chosen randomly, the trainee will use water only technique for insertion.
89678277|NCT04987645|Other|Water and Air Insufflation|If this intervention is chosen randomly, the trainee will use water and air insufflation technique for insertion.
89678278|NCT04985994||Tuberculosis Patients|"Diagnosed with pulmonary TB after detailed history collection, clinical examination, and laboratory assessment (sputum culture positive).~Aged 18 years or above.~Willing to participate in the study."
89678279|NCT04985994||Healthy Volunteers|"Healthy subjects with no symptoms or history of pulmonary TB~Negative sputum culture~Matched for sex and age (±5 years) with the TB patient group."
89678280|NCT04983875|Experimental|BAC-enhanced group|944 participants will receive a post-mammography results letter which includes information on their BAC results.
89678281|NCT04983875|Other|Waitlist control group|944 participants will receive a post-mammography results letter without BAC information, which is the current standard of care. These patients will receive BAC information following study completion (approximately 6 months after mammography).
89678282|NCT04982029|Experimental|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.
89678283|NCT04982029|Placebo Comparator|Placebo|All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.
89678284|NCT04964674|Experimental|Attentional Tests- Miyake and others|All participants will complete a series of behavioral tasks, including cued visual search with positive, negative, and neutral cues, Miyake executive attention tasks, and a visual working memory task. Single Arm.
89678285|NCT04961905|Experimental|Single tablet fist, fasted|single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition
89678286|NCT04961905|Experimental|FDC fist, fasted|NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition
89678287|NCT04961905|Experimental|Single tablet fist, fed|single tablets of NVP-2002-R1 and NVP-2002-R2 followed by NVP-2002 FDC, fasted condition
88996384|NCT02920879|Other|0 CPAP/ 0 PEEP, driving pressure 10|Patients will be preoxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
88996385|NCT02920879|Other|0 CPAP/ 0 PEEP driving pressure 20|Patients will be pre-oxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 20 cmH2O./PEEP-level, driving pressure
88996386|NCT02920879|Other|10 CPAP / 10 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with PEEP 10 cmH2O and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
88996387|NCT02920879|Other|10 CPAP/ 0 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
88996388|NCT00188292||High-grade disease|Those who had histologic anal high-grade disease.
88996389|NCT00188292||Control|Those who had less than highgrade histologic anal disease
88996390|NCT02920762||Buprenorphine|
88996391|NCT02920762||Fentanyl|
88996392|NCT02920762||Hydromorphone HCl|
88996393|NCT02920762||Morphine Sulfate|
88996394|NCT02920762||Morphine Sulfate Beads|
88996395|NCT02920762||Oxycodone HCl|
88996396|NCT02920762||Oxymorphone HCl|
88996397|NCT02920762||Tapentadol|
88996398|NCT02920567|Experimental|octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
88996399|NCT02920567|Placebo Comparator|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
88996400|NCT02920723|Experimental|Training|"For the patients who were allocated in the control group in the EXESAS study. In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
88996401|NCT02920723|Other|Control|For the patients who were allocated in the training group in the EXESAS study. In this group, patients will receive only diets and physical activity counselling
88996402|NCT02920606|Active Comparator|Endodontic treatment|"The patient will benefit from a conventional treatment : a root canal treatment.~The root canal treatment consists of removing the pulp tissue from all the canals, disinfecting the root canal system with sodium hypochlorite and filling the root with a root canal sealer and gutta percha."
88996403|NCT02920606|Experimental|Pulpotomy|The patient will benefit from an experimental treatment : a pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
88996404|NCT02920645||AVM-related ICH patients|patients that suffered intracerebral hemorrhage (ICH) due to a ruptured artery-venous malformation (AVM)
88996405|NCT02920684|Active Comparator|Passive legs mobilisation|A physiotherapist performs passive legs movement
88996406|NCT02920684|Active Comparator|Passive cycloergometer|A motorized cycloergometer performs passive legs cycling
88996407|NCT02920684|Active Comparator|Muscular electrical stimulation|Quadriceps neuromuscular electrical stimulation
89678288|NCT04961905|Experimental|FDC fist, fed|NVP-2002 FDC followed by single tablets of NVP-2002-R1 and NVP-2002-R2, fasted condition
89678289|NCT04953130|Experimental|Male vaccination + national HPV vaccination programme|Single dose of the 4-valent HPV vaccine (Gardasil®; Merck & Co.) offered to all eligible boys aged 14 to 18 years in the 13 intervention communities. Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
89678290|NCT04953130|Active Comparator|National HPV vaccination programme only|Girls aged 14 years are offered 2 doses of Gardasil® through the Tanzanian national HPV vaccine programme
89678291|NCT04932759|No Intervention|control group|In the control group there will be no music listening
89678292|NCT04932759|Experimental|experimental group|In this group patients will listen to music while their dental treatments are being made.
89678293|NCT04926974|Experimental|Seeing AI Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
89678294|NCT04926974|Experimental|Supervision+ Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
89678295|NCT04926974|Experimental|Aira Smart Phone App|Intervention: Behavioral: Low Vision Rehabilitation
89678296|NCT04925505||BPB success|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the SUCCESS (or failure) of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
89678297|NCT04925505||BPB failure|The study included patients aged between 20 and 70 yr who are to undergo elective shoulder surgery under general anesthesia. Patients undergo general anesthesia induction before the interscalene block is performed. Ultrasound-guided interscalene brachial plexus block will be performed in anesthetized patients before surgery. PI monitor will be applied to both blocked and non-blocked limbs using two separate oximeters. And the (success or) FAILURE of the block will be confirmed by (1) 30% change of heart rate and blood pressure after incision during operation, and (2) pain score, motor and sensory function test after surgery in the post-anesthesia recovery unit.
89678298|NCT04922216|Experimental|Condition 1|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Standard Content + No Choice
89678299|NCT04922216|Experimental|Condition 2|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Standard Content + Choice
89678300|NCT04922216|Experimental|Condition 3|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + No Choice
89678301|NCT04922216|Experimental|Condition 4|Core + Standard Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + Choice
89678302|NCT04922216|Experimental|Condition 5|Core+Standard Diet Monitoring+Daily Activity Goal+Adaptive Timing+Standard Content+No Choice
89678303|NCT04922216|Experimental|Condition 6|Core + Standard Diet Monitoring + Daily Activity Goal + Adaptive Timing + Standard Content + Choice
89678304|NCT04922216|Experimental|Condition 7|Core+ Standard Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
89678305|NCT04922216|Experimental|Condition 8|Core + Standard Diet Monitoring + Daily Activity Goal + Adaptive Timing + Adaptive Content + Choice
89678306|NCT04922216|Experimental|Condition 9|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + No Choice
89678307|NCT04922216|Experimental|Condition 10|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + Choice
89678308|NCT04922216|Experimental|Condition 11|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + No Choice
89678309|NCT04922216|Experimental|Condition 12|Core + Standard Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + Choice
89678310|NCT04922216|Experimental|Condition 13|Core+Standard Diet Monitoring+Weekly Activity Goal+Adaptive Timing+Standard Content+No Choice
89678311|NCT04922216|Experimental|Condition 14|Core + Standard Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Standard Content + Choice
89678312|NCT04922216|Experimental|Condition 15|Core + Standard Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
89678313|NCT04922216|Experimental|Condition 16|Core + Standard Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Adaptive Content + Choice
89678314|NCT04922216|Experimental|Condition 17|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Standard Content+ No Choice
89678315|NCT04922216|Experimental|Condition 18|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Standard Content+ Choice
89678316|NCT04922216|Experimental|Condition 19|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Fixed Timing+ Adaptive Content+ No Choice
89678317|NCT04922216|Experimental|Condition 20|Core + Simplified Diet Monitoring + Daily Activity Goal + Fixed Timing + Adaptive Content + Choice
89678318|NCT04922216|Experimental|Condition 21|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Standard Content+ No Choice
89678319|NCT04922216|Experimental|Condition 22|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Standard Content+ Choice
89678320|NCT04922216|Experimental|Condition 23|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
89678321|NCT04922216|Experimental|Condition 24|Core+ Simplified Diet Monitoring+ Daily Activity Goal+ Adaptive Timing+ Adaptive Content+ Choice
89678322|NCT04922216|Experimental|Condition 25|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Fixed Timing+ Standard Content+ No Choice
89678323|NCT04922216|Experimental|Condition 26|Core + Simplified Diet Monitoring + Weekly Activity Goal + Fixed Timing + Standard Content + Choice
89678324|NCT04922216|Experimental|Condition 27|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Fixed Timing+ Adaptive Content+ No Choice
89678325|NCT04922216|Experimental|Condition 28|Core + Simplified Diet Monitoring + Weekly Activity Goal + Fixed Timing + Adaptive Content + Choice
89678326|NCT04922216|Experimental|Condition 29|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Standard Content+ No Choice
89678327|NCT04922216|Experimental|Condition 30|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Standard Content+ Choice
89215635|NCT06027944|Experimental|Scene|High fidelity scene of nature emitted from a monitor
89678328|NCT04922216|Experimental|Condition 31|Core+ Simplified Diet Monitoring+ Weekly Activity Goal+ Adaptive Timing+ Adaptive Content+ No Choice
89678329|NCT04922216|Experimental|Condition 32|Core + Simplified Diet Monitoring + Weekly Activity Goal + Adaptive Timing + Adaptive Content+Choice
89678330|NCT04903431|Active Comparator|Clinician-administered Crisis Response Plan|Clinicians will administer the Crisis Response Plan to 75 military veterans.
89678331|NCT04903431|Experimental|Self-administered Crisis Response Plan|Participants will complete a self-guided version of the Crisis Response plan online.
89678332|NCT04899167|Experimental|4 years after kidney transplantation|Patients 4 years after KT (N=10); 5 with estimated (e) glomerular filtration rate (GFR) ≤35 mL/min/1.73m2, and 5 with estimated (e) glomerular filtration rate (GFR)>35 mL/min/1.73m2.
89678333|NCT04899167|Experimental|7 years after kidney transplantation|Patients 7 years after KT (N=10); 5 patients with eGFR ≤35 mL/min/1.73m2, and 5 with eGFR>35 mL/min/1.73m2.
89678334|NCT04897867|Experimental|CoolSculpting® Elite System|Participants received up to two CoolSculpting® Elite treatment sessions for the abdomen and flanks plus optional additional body areas 8 weeks apart. At the investigator's discretion, per treatment session, up to 8 treatment cycles were performed for the midsection, and if applicable, up to 2 treatment cycles for the submental area, up to 4 cycles to upper arms, and up to 4 cycles each to inner and/or outer thighs.
89678335|NCT04896151|Active Comparator|Standard MMPI|Participants will be instructed to complete the MMPI-2-RF-EX and other measures under standard conditions (e.g., to not simulate underreporting of suicide risk).
89678336|NCT04896151|Experimental|Simulation MMPI|Participants will be instructed to conceal current suicide risk when completing the MMPI-2-RF-EX and other measures.
89678337|NCT04883671|Active Comparator|Standard of Care (Cohort 1)|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
89678338|NCT04883671|Experimental|Stereotactic Body Radiotherapy (SBRT) 1-5 Metastatic Sites (Cohort 1)|"Participants will be randomly assigned and receive SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer.~After SBRT is completed participant may go on to receive systemic therapy (like chemotherapy, immunotherapy, or targeted therapies) per discretion of their treating physician."
89678339|NCT04883671|No Intervention|Local Ablative Therapy (Cohort 2)|Participants embarking on standard of care local ablative therapy (not limited to radiofrequency, microwave, or cryoablation, bland or chemoembolization, palliative radiotherapy, or surgical metastasectomy) not eligible for cohort 1 will be enrolled and followed.
89678340|NCT04860466|Experimental|Administration of CC-96673|CC-96673 will be administered on a once weekly (Q1W) or once every 2 weeks (Q2W) schedule
89678341|NCT04846504|Active Comparator|MMBFM program with clinician coach support|Telephonic coaching provided by licensed mental health professionals to support and encourage participants' engagement in and completion of the 8-session online MMBFM program.
89678342|NCT04846504|Active Comparator|MMBFM program with peer coach support|Telephonic coaching provided by trained peers with lived experience of perinatal depression to support and encourage participants' engagement in and completion of the 8-session online MMBFM program.
89678343|NCT04846504|Active Comparator|Patient facing strategy intervention arm|Centralized outreach and recruitment of women receiving prenatal care by study team using email, letter, or text, without direct involvement of OB providers.
89678344|NCT04846504|Active Comparator|Patient facing plus clinic facing strategy intervention arm|OB clinic providers' use of printed recruitment materials and/or electronic medical records prompts to recommend/refer women receiving prenatal care to access the MMBFM program. These clinic facing implementation strategies will be added to the patient facing strategies of centralized outreach and recruitment of women receiving prenatal care by study team using email, letter, or text
89678345|NCT04841265|Active Comparator|Vitamin D3|The Vitamin D3 (intervention) arm will receive a total of 800 IU vitamin D3 supplementation per day.
89678346|NCT04841265|No Intervention|Control|The control arm will receive 400 IU vitamin D3 per day from routine antenatal multivitamin supplementation.
89678347|NCT04832594|Experimental|Supplemental MRI|Women randomized to MRI will be examined using a shortened MRI protocol on a Signa Premier 3T MRI scanner. The MRI examination will be reviewed by two radiologists and assigned BI-RADS score. Appropriate clinical work-up will follow according to the BI-RADS score. BI-RADS 3 or higher at initial MRI will be recalled for a second look ultrasound.
89678348|NCT04832594|No Intervention|No MRI (standard-of-care)|"Standard-of-care. Both arms will have had a regular screening mammography examination prior to randomization. The No MRI arm will have no further intervention."
89678349|NCT04829240|Experimental|Intervention condition|Modular cognitive-behavioral anxiety intervention tailored to and personalized for Veterans
89678350|NCT04829240|Active Comparator|Control condition|Usual care anxiety treatment
89678351|NCT04798196|Placebo Comparator|Control group|Participants will receive treatment as usual (TAU).
89678352|NCT04798196|Experimental|ElderTree on laptop (ET- LT)|Participants will receive ElderTree on a laptop.
89678353|NCT04798196|Experimental|ElderTree on smart system (ET- SS)|Participants will receive ElderTree on a smart system.
89678354|NCT04780867|No Intervention|Routine vaccination (Control)|
89678355|NCT04780867|Experimental|Delay vaccination (Experimental)|
89678356|NCT04765696||Persons 55 years or older considering relocation|No intervention is administered.
89678357|NCT04731714|Other|Experimental: rhythmic MNS, then arrhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves rhythmic MNS and the second uses arrhythmic MNS.
89678358|NCT04731714|Other|Experimental: arrhythmic MNS, then rhythmic MNS|Participants will complete two stimulation sessions, at least a week apart. The first session involves arrhythmic MNS and the second uses rhythmic MNS.
89678359|NCT04730037|Active Comparator|Edoxaban group|
89678360|NCT04730037|Active Comparator|Warfarin group|
89678361|NCT04719221|Placebo Comparator|Statin+Ezetimibe|Drug: Statin + Ezetimibe (combined cholesterol therapy)
89678362|NCT04719221|Active Comparator|Statin+Ezetimibe+Evolocumab|Drug: Statin + Ezetimibe (combined cholesterol therapy) and Drug: Evolocumab
89050523|NCT01711346|Experimental|S303 Red Blood Cells (RBCs)|Participants will be assigned to S303 Red Blood Cells (RBCs) and then to Conventional, Untreated Red Blood Cells (RBCs).
89050524|NCT01711346|Active Comparator|Conventional, Untreated Red Blood Cells (RBCs)|Participants will be assigned to Conventional, Untreated Red Blood Cells (RBCs) and then to S303 Red Blood Cells (RBCs).
89050525|NCT01710644|Experimental|Burlulipase|Burlulipase orally, per meal
89678363|NCT04712669|Experimental|Rodatristat Ethyl 300 mg BID|Rodatristat ethyl 300 mg tablet BID + standard of care medication(s) taken for 24 weeks
89678364|NCT04712669|Experimental|Rodatristat Ethyl 600 mg BID|Rodatristat ethyl 600 mg tablet BID + standard of care medication(s) taken for 24 weeks
89678365|NCT04712669|Placebo Comparator|Placebo|Matching placebo tablet + standard of care medication(s) taken for 24 weeks
89678366|NCT04709757|Active Comparator|Intermittent Dosing HF10 30/90|Stimulation delivered at 30 seconds ON and 120 seconds OFF through patient's existing spinal cord stimulator.
89678367|NCT04709757|Active Comparator|Intermittent Dosing HF10 30/360|Stimulation delivered at 30 seconds ON and 360 seconds OFF through patient's existing spinal cord stimulator.
89050526|NCT01710644|Placebo Comparator|Placebo (Caramel in sterile water)|Placebo orally, per meal
89050527|NCT04608942|Experimental|Jett Plasma Medical Lift Application|In the study group, the plasma jet will be applied to the superior and inferior eyelid margin in both eyes.
89050528|NCT04608942|Active Comparator|Mechanical Debridement|In the control group, the mechanical debridement of the superior and inferior eyelid margin with a scalpel blade will be performed.
89678368|NCT04696575|Experimental|Treatment (lamivudine, chemoimmunotherapy)|"INDUCTION: Patients receive lamivudine PO QD on days 1-28. Patients also receive carboplatin IV over 30-60 minutes and atezolizumab IV on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lamivudine PO QD on days 1-28 and atezolizumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: Patients who are not eligible for atezolizumab as outlined in exclusion criteria or who refuse to receive atezolizumab may still be treated in this study with carboplatin and etoposide as the IV drug component, in addition to lamivudine orally administered."
89678369|NCT04694638|Experimental|HFNC and NIPPV|Combined use of prone positioning and non-invasive positive pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC)
89678370|NCT04688866||Pregnant women with cervical insufficiency (Cases)|Pregnant women with a shortened (<25 mm) or dilated cervix in the second trimester (or late first trimester)
89678371|NCT04688866||Pregnant women without cervical insufficiency (Controls)|Pregnant women with a normal-length (>= 25 mm) and closed cervix in the second trimester (or late first trimester)
89678372|NCT04688788|Experimental|Rituximab|Intravenous biosimilar rituximab (Ruxience®) 1000 mg given every 6th month (first 2 infusions 1000mg/1000 mg given 2 weeks apart).
89678373|NCT04688788|Active Comparator|Ocrelizumab|Intravenous ocrelizumab (Ocrevus®) 600 mg every 6th month (first 2 infusions 300 mg/300 mg given 2 weeks apart).
89678374|NCT04683679|Experimental|Arm A|Participants will have triple negative breast cancer diagnosis Treatment will be pembro + RT + olaparib
89678375|NCT04683679|Experimental|Arm B (the study is amended to pause Arm B)|Participants will have triple negative breast cancer diagnosis Treatment will be pembro + RT only
89678376|NCT04683679|Experimental|Arm C (activate new arm)|Participants will have metastatic ER+ breast cancer (ER+ MBC) Treatment will be pembro/SBRT/Olaparib)
89678377|NCT04671329|Other|Affirm Contrast Biopsy|Women 40 years of age or older recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities
89678378|NCT04661995|Experimental|Amplification + Notched Noise Therapy|"Following the baseline assessment, participants will be randomly assigned to one of the study groups. This treatment group will include a Notched Noise Therapy, a 1-10 kHz noise notched within a 1-octave range centered around the psychoacoustic tinnitus pitch match measured. Randomized participants will wear their hearing aids with this loaded software for 8 weeks. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort."
89678379|NCT04661995|Active Comparator|Amplification + Broadband Noise|"Following the baseline assessment, participants will be randomly assigned to one of the study groups. A popular and commonly used sound therapy treatment, this treatment group will listen to a broadband noise, or white noise, that is housed on the manufacturer's hearing aid tinnitus program. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort."
89678380|NCT04661995|Placebo Comparator|Amplification Only|Following the baseline assessment, participants will be randomly assigned to one of the study groups. Hearing aids are ear-level, self-contained, FDA-approved hearing device. Hearing aids help individuals with hearing loss and provide safe amplification/gain to frequencies that have loss.
89678381|NCT04644965||Abdominal Wall Defect|patients born with an abdominal wall defect
89678382|NCT04644965||Control Group|age and sex matched Control Group
89678383|NCT04643795|Experimental|40 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
89678384|NCT04643795|Experimental|60 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
89050529|NCT04600089|Placebo Comparator|Standard of Care|Participants in this group will receive standard of care as well as a saline infusion during the study period.
89050530|NCT04600089|Experimental|Sub-Dissociative Ketamine|Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.
89050531|NCT01704365|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
89050532|NCT01704365|Experimental|Group B|Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
89050533|NCT01704365|Experimental|Group C|Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
89050534|NCT01704365|Experimental|Group D|Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
89050535|NCT01704365|Experimental|Group E|High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
89050536|NCT01704365|Experimental|Group F|High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
88996408|NCT02920684|Active Comparator|FES cycling|A motorised cycloergometer performs a quadriceps neuromuscular electrical stimulation during passive
89678385|NCT04643795|Experimental|80 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
89678386|NCT04643795|Experimental|100 mg MGL-3196 Tablet|Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated
89678387|NCT04641286||Stroke|Individuals admitted to the Hyper Acute Stroke Unit.
89678388|NCT04632381|Active Comparator|Active Arm, Zota Cohort 1|0.01 mg/kg zotatifin
89678389|NCT04632381|Active Comparator|Active Arm, Zota Cohort 2|0.02 mg/kg zotatifin
89678390|NCT04632381|Active Comparator|Active Arm, Zota Cohort 3|0.035 mg/kg zotatifin
89678391|NCT04632381|Placebo Comparator|Placebo|5% dextrose injection, USP
89678392|NCT04628039||COVID Positive|Veterans aged 18 years or older who have a positive SARS-CoV-2 diagnosis (confirmed or presumptive) or who have been discharged home within 2 weeks to 1 year of diagnosis
89678393|NCT04628039||COVID Negative and Lower Respiratory Tract Infection (LRTI)|Veterans aged 18 years or older with a negative SARS-CoV-2 test (PCR and/or antigen test) and diagnosis of LRTI after discharge home or after diagnosis if not hospitalized
89678394|NCT04627428|Experimental|50,000 cells|Six patients will receive single dose of 50,000 RPESC-RPE-4W cells in the eye.
89678395|NCT04627428|Experimental|150,000 cells|Six patients will receive single dose of 150,000 RPESC-RPE-4W cells in the eye.
89678396|NCT04627428|Experimental|250,000 cells|Six patients will receive single dose of 250,000 RPESC-RPE-4W cells in the eye.
89678397|NCT04623775|Experimental|Part 1: Arm A (Nivolumab + Relatlimab Dose 1 + Platinum Doublet Chemotherapy (PDCT))|
89678398|NCT04623775|Experimental|Part 1: Arm B (Nivolumab + Relatlimab Dose 2 + PDCT))|
89678399|NCT04623775|Experimental|Part 2: Arm C (Nivolumab + Relatlimab Dose 2 + PDCT)|
89678400|NCT04623775|Active Comparator|Part 2: Arm D (Nivolumab + PDCT)|
89678401|NCT04621916|Active Comparator|Emicizumab + FVIII weekly|In addition to emicizumab prophylaxis,participants will receive non-prophylactic exposure to FVIII concentrates through weekly 50 IU/kg ±10% doses - the choice of FVIII concentrate is at the discretion of the PI.
89678402|NCT04621916|Active Comparator|Emicizumab only|Participants will only receive emicizumab prophylaxis.
89678403|NCT04578938|Experimental|Ketamine + Cognitive Training|
89678404|NCT04578938|Sham Comparator|Ketamine + Sham Training|
89678405|NCT04578938|Active Comparator|No-infusion (TAU) + Cognitive Training|
89678406|NCT04578938|Sham Comparator|No-infusion (TAU) + Sham Training|
89678407|NCT04571242|Active Comparator|DTM-SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Test treatments, which may identify the type of treatment to study participants. DTM-SCS programming has at least two programs with different pulse rate in the 50 to 1,000 Hz range and each having a maximum pulse width of 1 ms.
89678408|NCT04571242|Active Comparator|Conventional SCS programming|This SCS group will be programmed under the direction of physicians with support of clinical representatives of the Control treatments, which may identify the type of treatment to study participants. Conventional SCS programming is stimulation parameters in the 40-250 Hz frequency range and will be trialed according to standard practice as described in the Intellis labeling/manuals
89678409|NCT04531722|Experimental|drug-resistant temporal lobe epilepsy|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe. The electro-physiological data that will be gathered is not altered and this methodology will not impact standard clinical care, except and will not to extend the duration in the OR - the measurements will occur during the clinical electrocorticography (ECoG; intracranial electroencephalography (iEEG)) procedure by 15 min.
89678410|NCT04521166|Experimental|Setting 1|Hearing aid features presented in this arm include omnidirectional microphone settings and fast-acting compression
89678411|NCT04521166|Experimental|Setting 2|Hearing aid features presented in this arm include omnidirectional microphone settings and slow-acting compression
89678412|NCT04521166|Experimental|Setting 3|Hearing aid features presented in this arm include directional microphone settings and fast-acting compression
89678413|NCT04521166|Experimental|Setting 4|Hearing aid features presented in this arm include directional microphone settings and slow-acting compression
89678414|NCT04515784|Experimental|Active|Active arm- START-PTSD
89678415|NCT04515784|No Intervention|Control|Control arm
89678416|NCT04510662|Experimental|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
89678417|NCT04510662|No Intervention|Control|Patients in this group will receive standard care.
89678418|NCT04508348|Active Comparator|Exclusive Human Milk|Group One will receive an exclusive human milk diet throughout the 28-day feeding period or until hospital discharge
89678419|NCT04508348|Other|Maternal human milk or Formula|Group Two (Control Group) will receive maternal human milk or formula (per standard of care).
89678420|NCT04506944||General population|Whole population of scrub typhus endemic villages
89678421|NCT04506944||hospital case population|cases recruited at study clinics who are not enrolled in general population cohort
88996409|NCT02920411|Experimental|Combined dermatological treatment|"A combined treatment of two emollient products will be applied:~Pediatopic treatment cream during acute stages of atopic dermatitis and~Pediatopic body lotion during stable stages"
88996410|NCT00154622|No Intervention|pain/ disability survey|
89678422|NCT04506944||Serological cohort|random subset of 4000 participants above the age of 10 drawn from general population cohort
89678423|NCT04506320||Patients with Multiple myeloma|Adult with diagnosis of multiple myeloma treated with Allo-HSCT from related - HLA identical or volunteer unrelated donor or haploidentical related donor performed from January 1, 2009 to december 31, 2018
89678424|NCT04494256|Experimental|Part 1: Cohort A|Participants with ALS will receive BIIB105 Dose 1, intrathecally (IT), as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
89050537|NCT01704365|Experimental|Group G|High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
89050538|NCT01704365|Experimental|Group H|High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
89678425|NCT04494256|Experimental|Part 1: Cohort B|Participants with ALS will receive BIIB105 Dose 2, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
89678426|NCT04494256|Experimental|Part 1: Cohort C1|Participants with ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
89678427|NCT04494256|Experimental|Part 1: Cohort D1|Participants with ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
89678428|NCT04494256|Experimental|Part 1: Cohort C2|Participants with polyQ-ALS will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days.
89678429|NCT04494256|Experimental|Part 1: Cohort D2|Participants with polyQ-ALS will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
89678430|NCT04494256|Placebo Comparator|Part 1: Cohorts A-D2: Placebo|Participants with ALS and polyQ-ALS for Cohorts A, B, C1 and C2 will receive matching placebo to BIIB105 as 3 loading doses on Day 1 and two later days, followed by two maintenance doses on two later days, and participants with ALS and polyQ-ALS for Cohorts D1 and D2 will receive matching placebo to BIIB105 as 3 loading doses on Day 1 and two later days, followed by five maintenance doses on five later days.
89678431|NCT04494256|Experimental|Part 2: Cohorts A-C2: Open-Label|Participants who complete Cohorts A, B, C1, and C2 will receive BIIB105 Dose 3, IT, as 3 loading doses on Day 1 and two later days, followed up to thirty-eight maintenance doses, on up to thirty-eight later days.
89678432|NCT04494256|Experimental|Part 2: Cohorts D1, D2: Open-Label|Participants who complete Cohorts D1 and D2 will have a blinded Loading Dose Period, during which those who received placebo in Part 1 will receive BIIB105 Dose 4, IT, as 3 loading doses on Day 1 and two later days, while those who received BIIB105 in Part 1 will receive 2 loading doses of BIIB105 Dose 4, IT, on Days 1 and one later day, and placebo on Day 15. After the blinded Loading Dose Period, participants will receive BIIB105 Dose 4 up to thirty-eight maintenance doses, on up to thirty-eight later days.
89678433|NCT04463654|Experimental|Zero Self-Harm|When randomized to the Zero Self-Harm app the participants will receive an introduction to the app through videos in the app, which explains, amongst others, how to review previous crisis situations and possible strategies for future crisis. This will ensure the navigation and knowledge of the technicalities of the app, in addition to ensure the app can be used privately without personal guidance from e.g a therapist.
89678434|NCT04463654|No Intervention|Treatment as usual|The control group will continue their present course of treatment and/or counseling at non-profit organizations, service centers in the municipalities, at outpatient treatment services for psychiatric disorders and/or care, attention at emergency departments. They will receive no treatment on the nature of NSSI. Participants in the control group will be offered a possibility to download the Zero Self-Harm app after they have completed the last questionnaire at six months, which will be stressed at the initial appointment as well as after collection of all data.
89678435|NCT04428437||Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by lenvatinib.
89678436|NCT04428437||Non-Lenvatinib|Subjects with HCC progression after first line treatment with checkpoint inhibitors will get the treatment by non-lenvatinib.
89050539|NCT01704365|Experimental|Group J|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (Day 0 & Day 28)
89050540|NCT01704365|Placebo Comparator|Group K|Placebo (Day 0 and Day 28)
89050541|NCT00555269||MB|
89050542|NCT00555269||IFCG|
89050543|NCT04600011|Other|TELEREHABILITATION ARM|ARM 1: The TELEREHABILITATION ARM where participants receive the full originally-intended protocol that includes one initial in-person PT/OT evaluation, four virtual PT/OT visits, and one final in-person (or virtual, if in-person is not possible) PT/OT evaluation. The study duration for Arm 1 is about 10 weeks of the primary intervention as described with 3- and 6-month follow-up calls. The mobile virtual platform for Arm 1 is comprised of a tablet on a height-adjustable rotating tablet floor stand with a gooseneck and wheels.
89050544|NCT04600011|Other|VIRTUAL HOME SAFETY EVALUATIONS (HSE)-ONLY ARM|ARM 2: The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
89678437|NCT04415008|Experimental|treatment arm|prospective, open-label, multicenter,single arm
89678438|NCT04412629|Experimental|Cabozantinib|-Cabozantinib 60 mg by mouth daily on days 1-21
89678439|NCT04406857|Experimental|Treatment (ropidoxuridine, capecitabine, radiation therapy)|Patients receive ropidoxuridine PO QD over 7 days per week and capecitabine PO BID over 6 days per week for 6 weeks. Patients also undergo radiation therapy over 1 fraction per day for 5 days per week (Monday-Friday) during weeks 1-5 and for 3 days during week 6 in the absence of disease progression or unacceptable toxicity. Approximately 8-12 weeks after completion of treatment with ropidoxuridine, capecitabine, and radiation therapy, patients undergo standard of care surgery.
89050545|NCT01698281|Experimental|Arm A: AEZS-108|Intervention: AEZS-108 (267 mg/m^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
89050546|NCT01698281|Active Comparator|Arm B: Standard (SCCC)|"commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;~- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle)."
89050547|NCT00565461|Experimental|Group 1|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
89050548|NCT00565461|Experimental|Group 2|40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
89678440|NCT04393454|Experimental|Sirolimus|Participants will be instructed to take 2 mg every day for 28 days (1 cycle). They will be evaluated in the oncology clinic every 2 weeks to make sure they are tolerating the medication well.
89678441|NCT04385381|Experimental|URECA CTO device|investigate the safety and efficacy of the URECA CTO device in facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature.
89678442|NCT04373629|Experimental|attention modulation|
89678443|NCT04373629|Experimental|perceptual modulation|
89678444|NCT04373629|Experimental|naturalistic viewing|
89678445|NCT04367051|Experimental|Withdrawal group|Spironolactone will be discontinued in patients who were receiving optimal medical therapy including angiotensin-converting enzyme or angiotensin receptor blocker or angiotensin receptor neprilysin, beta-blocker, and spironolactone.
89678446|NCT04367051|Active Comparator|Continuation group|Spironolactone will be continued during the study period with other medical therapy in combination.
89678447|NCT04350229|Experimental|EXPERIMENTAL GROUP|"In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.~Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg."
89678448|NCT04350229|Active Comparator|CONTROL GROUP|Pre-chemotherapy with the AC protocol: ondansetron 8mg and dexamethasone 10mg + Pre-chemotherapy with paclitaxel: ranitidine 50mg, ondansetron 8mg, diphenhydramine 50mg and dexamethasone 10mg.
89678449|NCT04335708|Experimental|Intervention|Daily consumption of 5 mL of edible gel with intracellular content of Lactobacillus casei CRL-431 during 30-d
89678450|NCT04335708|Placebo Comparator|Placebo|Daily consumption of 5 mL of edible gel without intracellular content of Lactobacillus casei CRL-431 during 30-d
89678451|NCT04316975|Other|Biopsy: Barrett's Esophagus, Intramucosal adenocarcinoma|"Subjects will undergo standard of care (SOC) standard esophagogastroduodenoscopy (EGD) for the treatment of their condition (BE or IMC). Four (4) research biopsies will be taken from the midpoint of current disease. In cases where EMR (Endoscopic Mucosal Resection) is performed clinically, no research biopsies will be taken. Following CEIM, four (4) additional research biopsies will be collected, from the midpoint of previous BE site.~Laboratory Biomarker Analysis: Correlative studies~Esophagogastroduodenoscopy: Standard of care, research biopsies will be collected if clinical biopsies are taken"
89678452|NCT04314219|Experimental|Arm 1: Intervention|Peripheral blood matched related donor HCT, using myeloablative conditioning regimen (IV Busulfan/IV Fludarabine for AML, IV VP16/TBI for ALL) HCT with cyclophosphamide, and oral tacrolimus (or another calcineurin inhibitor if intolerant for tacrolimus) for GVHD prophylaxis. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV on Day +3 and Day +5 post stem cell infusion (only 2 doses).
89678453|NCT04314219|Active Comparator|Arm 2: Standard of Care|Peripheral blood matched related donor HCT, using myeloablative conditioning regimen (IV Busulfan/IV Fludarabine for AML, IV VP16/TBI for ALL) HCT with methotrexate, and oral tacrolimus (or another calcineurin inhibitor if intolerant for tacrolimus) for GVHD prophylaxis
89678454|NCT04292925|Experimental|Experimental Group|Intervention with the new treatment protocol will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
89050549|NCT00565461|Experimental|Group 3|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
89050550|NCT00565461|Experimental|Group 4|40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
89050551|NCT01858883|Experimental|itacitinib, gemcitabine, nab-paclitaxel, filgrastim|
89050552|NCT01697072|Experimental|Rilotumumab|Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
89050553|NCT01697072|Placebo Comparator|Placebo|Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
89050554|NCT00565500|Experimental|1|
89050555|NCT00565500|Experimental|2|
89678455|NCT04292925|Active Comparator|Control group|Intervention with conventional therapy will include 18 treatment sessions of 45 minutes, between three to five times a week depending on the participant's state, over a period of four to six weeks.
89678456|NCT04291391|Experimental|Individuals without obesity and normoglycemia (NG) (Lean-NG)|Those assigned to the Lean-NG group will receive a North American-type diet diet for 4 weeks.
89678457|NCT04291391|Experimental|Individuals with obesity and NG (Obese-NG)|Those assigned to the Obese-NG group will receive a North American-type diet diet for 4 weeks.
89678458|NCT04291391|Experimental|Individuals with obesity and glucose intolerance (GI) (Obese-GI)|Those assigned to the Obese-GI group will receive a North American-type diet diet for 4 weeks.
89678459|NCT04291391|Experimental|Individuals with obesity and type 2 diabetes (T2D) (Obese-T2D)|Those assigned to the Obese-T2D group will receive a North American-type diet diet for 4 weeks.
89050556|NCT00565500|Placebo Comparator|3|
89050557|NCT04608162|Active Comparator|Group I|Group one received PEMF and exercise (PEMF+EX)
89050558|NCT04608162|Placebo Comparator|Group II|Group two received placebo PEMF and exercise (PPEMF+EX)
89050559|NCT04608162|Active Comparator|Group III|Group three will be treated by PEMF alone (PEMF)
89050560|NCT04608084|Experimental|Treatment group|Participant with moderate to sever ocular surface disease will be treated with autologous platelet rich plasma eye drops
89050561|NCT04600050|Active Comparator|Control group: stroke patients with education|
89050562|NCT04600050|Experimental|Experimental: stroke patients with exercise|
89050563|NCT01691846|Experimental|aleglitazar|
89050564|NCT01691846|Placebo Comparator|placebo|
89050565|NCT04599543|Experimental|Administration of IL3 CAR T-cells|
89050566|NCT01670981|Experimental|ixmyelocel-T|Ixmyelocel-T delivered by catheter-based intramyocardial injection procedure.
89050567|NCT01670981|Placebo Comparator|Placebo|Placebo delivered by catheter-based intramyocardial injection procedure.
89050568|NCT01658501|Experimental|Diet and Exercise|Diet and exercise only.
89050569|NCT01658501|Experimental|Metformin|Metformin only
89678460|NCT04287413|Experimental|Physiotherapist-led primary care model for back pain|The index intervention will incorporate a PT within the primary care team and make them available at the first point of contact for people with low back pain. There will be 4 key components of this intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need (e.g., no insurance coverage for PT).
89678461|NCT04287413|Active Comparator|Usual care|The physician-led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, order diagnostic imaging, prescribe medications and/or refer based on their assessment findings and patient preferences.
89678462|NCT04282720|Other|SurgiMend Mesh|"SurgiMend Mesh - FDA approved noncross-linked bovine dermis biologic mesh. SurgiMend Mesh will be used according to FDA approved recommendations for the use of abdominal wall hernia reinforcement.~SurgiMend is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend is specifically indicated for:~Hernia repair including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias."
89678463|NCT04265430|Experimental|Cohort I (MRI after radiation therapy)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, 3-5 weeks after starting standard of care radiation therapy, and then at 2 months, 6 months, 12 months, and 3 years after completing radiation therapy.
89678464|NCT04265430|Experimental|Cohort II (MRI after surgery)|Patients may receive a contrast agent IV and then undergo an MRI over 45-60 minutes at baseline, and at 5-10 weeks and 12 months after standard of care surgery.
89678465|NCT04230408|Experimental|DURVALUMAB (MEDI4736) + carboplatin-paclitaxel|"Induction chemo-immunotherapy phase:~Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.~Concurrent chemo-immuno-radiotherapy phase:~Radiation therapy concomitantly with: paclitaxel 50 mg/m2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy, carboplatin AUC 2 intravenously every 7 days (+/- 3 days) until completion of radiation therapy and durvalumab 1500 mg intravenously every 21 days (+/- 6 days) for a maximum of 2 doses.~Concurrent chemo-immuno-radiotherapy:~Durvalumab 1500 mg intravenously every 28 days (+/- 7 days) for a maximum of 12 doses"
89678466|NCT04222712|Experimental|TRS01 low dose|
89678467|NCT04222712|Experimental|TRS01 high dose|
89678468|NCT04205487|Experimental|Contingency Management (CM) - Only|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
89678469|NCT04205487|Experimental|Motivational Interviewing (MI) - Only|Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered.
89678470|NCT04205487|Experimental|CM+MI|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription. Participants who do not fill a PrEP prescription at 3 months will then receive 2 sessions of MI.
89678471|NCT04205487|Experimental|MI+CM|Two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered. Participants who do not fill a PrEP prescription at 3 months will receive CM financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
89678472|NCT04196114|Experimental|All patients|All patients implanted.
89678473|NCT04195698|Experimental|Upadacitinib|Participants will be administered with upadacitinib once daily (QD)
89678474|NCT04185363|Experimental|Maralixibat|All subjects will receive Maralixibat oral solution
89678475|NCT04178122|Experimental|Immediate Results|Participants in the Immediate Results arm will receive their genetic testing results from a genetic counselor at baseline following randomization.
89678476|NCT04178122|Experimental|Delayed Results|Participants in the Delayed Results arm will receive their genetic testing results from a genetic counselor 6 months after randomization.
89678477|NCT04161157|Experimental|Pathways|Pathways is designed to help patients identify and pursue values-based goals and address potential goal obstacles, including lung cancer stigma.
89678478|NCT04152161|Experimental|Bacille Calmette Guerin (BCG) group|
89678479|NCT04152161|Placebo Comparator|Placebo group|
89678480|NCT04124900||patients at prostate cancer risk diagnosed|"The study is composed of one single subject cohort. After risk evaluation, prostate biopsies will be performed for diagnostic purposes on all recruited patients. The cases are sorted into two groups after diagnosis:~Group 1: patients at prostate cancer risk diagnosed with significant prostate cancer after prostatic biopsy (Gleason >6).~Group 2: patients at prostate cancer risk diagnosed free of cancer after prostate biopsy. There will be a subdivision within this group in patients without significant prostate cancer ( No cancer o Non-significant prostate cancer (Gleason ≤6))."
89678481|NCT04121949|No Intervention|Control group|"The control group will receive standard-of-care treatment recommended by current ESC guidelines for patients with low to intermediate likelihood of stable CAD using the Diamond-Forrester (DF) score only: Rule-out if DF-score <15%; NIT if DF-score 15-85%.~As per January 2020 the protocol was updated according to the 2019 ESC Guidelines on Chronic Coronary Syndrome:~The control group will receive standard-of-care treatment recommended by current ESC guidelines based on the patients likelihood of stable CAD using the Pre-test Probability score (PTP): Rule-out if PTP≤5%, NIT may be considered if PTP 6-15%, NIT if PTP>15%"
89678482|NCT04121949|Experimental|Intervention group|"The intervention group will undergo a modified diagnostic pathway where a CAD-score <30 rules out stable CAD in the group of patients having a DF-score <15% and a CAD-score ≤20 rules out stable CAD in the group of patients having a DF-score in the range 15-85%, and thus not tested with NIT. Otherwise NIT is performed.~As per January 2020 the protocol was updated according to the 2019 ESC Guidelines on Chronic Coronary Syndrome:~The intervention group will undergo a modified diagnostic pathway where a CAD-score ≤20 rules out stable CAD. If CAD-score >20 NIT is performed."
89050570|NCT01658501|Experimental|Sulfonylurea|Sulfonylurea only
89050571|NCT01658501|Experimental|Metformin and Sulfonylurea|Metformin and Sulfonylurea combination therapy
89050572|NCT01658501|Experimental|PB1023|PB1023 weekly SC injection
89050573|NCT01658501|Placebo Comparator|Placebo Comparator|Placebo (0.9% Sodium Chloride) weekly SC injection
89050574|NCT01658501|Active Comparator|Active Comparator|Active Comparator (Victoza) daily SC injection
89050575|NCT01656239|Experimental|fedovapagon 1 mg|Once daily oral dose of 1 mg fedovapagon for 12 weeks
89678483|NCT04106193|Experimental|Toolkit + Implementation as Usual|Participating clinics assigned to this arm will receive a guiding toolkit and implementation as usual regarding IPV screening practices.
89678484|NCT04106193|Experimental|Toolkit + Blended Facilitation|Participating clinics assigned to this arm will receive a guiding toolkit and blended facilitation to support IPV screening practices.
89678485|NCT04097340|Active Comparator|Attentional Training Group|Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither participant nor the staff members working on the study will know which condition the participant has been randomly assigned to.
89678486|NCT04097340|Placebo Comparator|Control Training Group|Each condition involves use of a smartphone app. One smartphone app includes a task that targets attention directed to substance-related cues while the other app includes a similar task that does not target attention in this way. Neither participant nor the staff members working on the study will know which condition the participant has been randomly assigned to.
89678487|NCT04057287||NASH related Cirrhosis|
89678488|NCT04057287||Healthy Controls|
89678489|NCT04057287||First Degree Relatives of NASH related Cirrhosis|
89678490|NCT04057287||HBV Disease Control|
89678491|NCT04052776|Active Comparator|Buspirone|40mg
89678492|NCT04052776|Active Comparator|Levodopa-Carbidopa|400mg/100mg
89678493|NCT04052776|Active Comparator|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
89678494|NCT04052776|Placebo Comparator|Placebo|Mannitol pill
89678495|NCT04035187|Experimental|Sequence A (fast, medium, oral solution, then slow)|Participants first receive fast tablet, then medium tablet, then oral solution, and then slow tablet. Washout period is (at least) one week.
89678496|NCT04035187|Experimental|Sequence B (medium, slow, fast, then oral solution)|Participants first receive medium tablet, then slow tablet, then fast tablet, and then oral solution. Washout period is (at least) one week.
89678497|NCT04035187|Experimental|Sequence C (slow, oral solution, medium, then fast)|3, 4, 2, 1 Participants first receive slow tablet, then oral solution, then medium tablet, then fast tablet. Washout period is (at least) one week.
89678498|NCT04035187|Experimental|Sequence D (oral solution, fast, slow, then medium)|Participants first receive oral solution, fast tablet, then slow tablet, and then medium tablet. Washout period is (at least) one week.
89678499|NCT04002037|Active Comparator|Triamcinolone 40mg/mL|A corticosteroid injection of Triamcinolone 40mg/mL will be given to subjects to treat their symptoms of trigger finger.
89678500|NCT04002037|Active Comparator|Triamcinolone 10mg/mL|A corticosteroid injection of Triamcinolone 10mg/mL will be given to subjects to treat their symptoms of trigger finger.
89678501|NCT04002037|Active Comparator|Soluble dexamethasone 4mg/mL|A corticosteroid injection of Soluble Dexamethasone 4mg/mL will be given to subjects to treat their symptoms of trigger finger.
89678502|NCT03985384|Active Comparator|Semaglutide|Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
89678503|NCT03985384|Placebo Comparator|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
89678504|NCT03976245|Active Comparator|etanercept|etanercept 50 mg subcutaneously injected per week
89678505|NCT03976245|Active Comparator|tofacitinib|tofacitinib 5 mg orally daily
89678506|NCT03967704|Experimental|Life quality evaluation|"Patients consulting the Emergency Department (SAU) or the rheumatology department of the GHPSJ (referred by a colleague orthopaedic surgeon, rheumatologist, radiologist or other) for a recent symptomatic osteoporotic dorsal or lumbar vertebral fracture, are called for a rheumatology consultation, vertebral fracture consultation.~Patients consulting in the rheumatology department during a spinal fracture consultation at the GHPSJ as well as patients hospitalized in the rheumatology department at the GHPSJ are selected consecutively.~- Arm 1 (intervention): two additional consultations with the rheumatology"
89678507|NCT03929640|Placebo Comparator|Ibuprofen and placebo|Oral administration of ibuprofen 600 mg tablet and placebo tablet every 6 hours
89678508|NCT03929640|Active Comparator|Ibuprofen and acetaminophen|Oral administration of ibuprofen 600 mg tablet and acetaminophen 650 mg tablet every 6 hours
89678509|NCT03919370||Cerebral ischemia|Patients undergoing planned surgery for carotid stenosis
89678510|NCT03919370||Reperfusion|Patients undergoing cerebral trombectomy.
89678511|NCT03919370||Anaesthesia and surgery|Patients without preexisting cerebral injury undergoing abdominal surgery and anaesthesia
89678512|NCT03899090|Experimental|Float Pool|Floating supine in a pool for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
89678513|NCT03899090|Active Comparator|Float Chair|Floating supine in a zero-gravity chair for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)
89050576|NCT01656239|Experimental|fedovapagon 2 mg|Once daily oral dose of 2 mg fedovapagon for 12 weeks
89050577|NCT01656239|Experimental|fedovapagon 4 mg|Once daily oral dose of 4 mg fedovapagon for 12 weeks
89050578|NCT01656239|Placebo Comparator|sugar pill|Once daily oral dose of placebo for 12 weeks
89050579|NCT01651871|Experimental|Treatment Group 1|
89050580|NCT01651871|Experimental|Treatment Group 2|
89678514|NCT03899090|Experimental|Float Pool Preferred|Floating supine in a pool for a preferred amount of time (6 total sessions, up to 2 hours/session, as frequently as they prefer within a 12-week period with a minimum of 24 hours between sessions)
89678515|NCT03887988||Orbital Fracture|Patients with dislocated fracture of the inferior and/or medial orbital wall
89678516|NCT03883711||Patients with acute coronary syndrome or myocardial injury|Incident consecutive patients presenting with acute coronary syndrome or myocardial injury
89678517|NCT03876860|Active Comparator|Standard Dilator|Participants in control arm (active comparator) will receive standard vaginal dilator with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
89050581|NCT01651871|Experimental|Treatment Group 3|
89050582|NCT01651871|Active Comparator|Treatment Group 4|
89050583|NCT01651871|Placebo Comparator|Treatment Group 5|
89050584|NCT01647308|Active Comparator|ISIS-APOCIIIRX|
89678518|NCT03876860|Experimental|Silicone Dilator|Participants in experimental arm will receive standard vaginal dilator with addition of silicone ring with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
89678519|NCT03872349|Experimental|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 7.1% from saturated fat; 20.7% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
89678520|NCT03872349|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 14.4% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
89678521|NCT03852719|Experimental|Delayed Treatment|Participants will receive delayed treatment with bulevirtide 10 mg/day subcutaneously (SC) for 96 weeks after an observational period of 48 weeks.
89678522|NCT03852719|Experimental|Bulevirtide 2 mg/day|Participants will receive bulevirtide 2 mg/day SC for 144 weeks.
89678523|NCT03852719|Experimental|Bulevirtide 10 mg/day|Participants will receive bulevirtide 10 mg/day SC for 144 weeks.
89678524|NCT03785145|Experimental|MT10109L|MT10109L will be injected into the LCL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
89678525|NCT03785145|Placebo Comparator|Placebo|Placebo will be injected into the LCL: initial double-blind treatment on Day 1.
89678526|NCT03764969|Active Comparator|standard smoking cessation program (SCP)|standard smoking cessation program
89678527|NCT03764969|Experimental|SCP + CRT|SCP plus cognitive remediation treatment (CRT)
89678528|NCT03764969|Experimental|SCP + ICHT|SCP plus an implicit computer-based habit-modifying training (ICHT)
89678529|NCT03758326|Other|Eating disorder|Measurement of body image via Body App and relationship to body measurement
89678530|NCT03758326|Other|Healthy comparison|Measurement of body image via Body App and relationship to body measurement
89678531|NCT03756597||Cases Pathway A|"Case pathway A - Intention to diagnose population~Only patients with a very high clinical suspicion based on imaging are scheduled for surgical procedures.Subjects with a confirmed diagnosis of cancer after clinical work-up will be labelled cases. of the study.~Patients with Gastric or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy."
89678532|NCT03756597||Clinical Controls|"Clinical controls represent subjects that:~Are suspected of the same cancer or part of an at risk-group~Have undergone full per-guideline diagnostic work-up, resulting in confirmation the subject does not have cancer (see section 6)~Is matched to the case for age, gender and known risk-factors specific to that tumour type (section 5.4)"
89678533|NCT03756597||Healthy volunteers|Healthy volunteers will be recruited from the clinical research facility at Addenbrooke's Hospital (Cambridge) or from the Cambridge BioResource. These subjects will be selected to have a similar age and sex distribution as the overall PAN-study cases.
89678534|NCT03756597||Substudy Cases|Patients with a confirmed diagnosis of cirrhosis and providing up to 6 samples will be labelled as the washout substudy cases
89678535|NCT03756597||Cases Pathway B|"Case pathway B - Confirmed malignancy population~Patients with a Gastric, Liver or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy. Patients will be recruited by research staff at the clinic they are referred to for diagnosis and/or treatment"
89678536|NCT03724175|Experimental|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks to treat pouchitis in ulcerative colitis patients with antibiotic refractory or antibiotic dependent pouchitis
89678537|NCT03690986|Experimental|Group A (VX15/2503)|Patients receive VX15/2503 IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
89678538|NCT03690986|Experimental|Group B (VX15/2503, ipilimumab)|Patients receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
89678539|NCT03690986|Experimental|Group C (VX15/2503, nivolumab)|Patients receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
89678540|NCT03690986|Experimental|Group D (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
89678541|NCT03690986|Experimental|Group E (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
89678542|NCT03690986|No Intervention|Group F (no treatment)|Patients undergo standard of care surgery.
89678543|NCT03665909|Experimental|Remote activity monitoring|"Receive the remote activity monitoring system (i.e., eNeighbor; see intervention description) over an 18-month period."
89678544|NCT03665909|No Intervention|Control|Control participants do not receive the remote activity monitoring intervention.
89678545|NCT03623100|Experimental|Speech Treatment|Half of the children will be assigned to the traditional speech treatment program which will focus on how to produce sounds in academic vocabulary words.
89678546|NCT03623100|Experimental|Speech Treatment & Perception|Half of the children will be assigned to the traditional speech treatment program and speech perception training program combination. This treatment program will teach children not only how to produce sounds in academic vocabulary words, but to also identify correctly and incorrectly produced sounds in words.
89678547|NCT03616184|Experimental|Ruxolitinib|Patients will receive oral ruxolitinib at a dose of 10 mg twice daily.
89678548|NCT03615690|Experimental|Fasting Mimicking Diet|Three cycles of a 5-day reduced calorie diet
89678549|NCT03615690|Placebo Comparator|Regular Diet Control Arm|
89678550|NCT03610451|Experimental|Floatation-REST|Participants will float supine in a pool of water saturated with epsom salt, in a light and sound attenuated chamber, for up to 60 minutes, on 8 separate occasions. Ratings of the experience will be collected before and after each float.
89678551|NCT03610451|Other|Usual care|Participants will be assessed along the same time periods, i.e., before and after a 60 minute window, on 8 separate occasions. Ratings of the experience will be collected before and after each time period.
89678552|NCT03608059|Experimental|ATG/PTCy|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -2 to -1 and cyclophosphamide (Cy) 50 mg/kg on day +3, cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +4. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +34 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
89678553|NCT03608059|Active Comparator|standard ATG|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -4 to -1 , cyclosporine A (CsA) initiating on day -5 and mycophenolate mofetil (MMF) initiating on day +1 . CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 2 times per day (maximum dose 2g per day) until day +30 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
89678554|NCT03608059|Active Comparator|standard PTCy|The GvHD prophylaxis consisted of cyclophosphamide (Cy) 50 mg/kg on day +3, +4,cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +5. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +35 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
89678555|NCT03597581|Experimental|Single agent RGX-202-01 Dose Escalation|RGX-201-01 is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.
89678556|NCT03597581|Experimental|RGX-202-01 in combination with FOLFIRI Dose Escalation|"RGX-201-01 is administered orally twice or three times daily on days 1-28 of each 28-day cycle. The dose regimen is dependent on the cohort in which the patient is enrolled.~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle."
89678557|NCT03597581|Experimental|Expansion: 2nd Line Colorectal Cancer (CRC) KRAS (+)|"2nd Line CRC RAS (+)~RGX-201-01 is administered orally twice on days 1-28 of each 28-day cycle.~FOLFIRI is administered as follows: irinotecan 180 mg/m2 intravenously over 90 minutes concurrently with folinic acid (leucovorin) 400 mg/m2 intravenously over 2 hours, followed by 5-FU 400 mg/m2 intravenous bolus and then 5-FU 2400 mg/m2 intravenous infusion over 46 hours, on Days 1 and 15 of each 28-day cycle.~Bevacizumab is administered as follows: 5 mg/kg on Days 1 and 15 of each 28-day cycle."
89678558|NCT03574610|Experimental|Subjects with Multiple Sclerosis and Voiding Dysfunction|Subjects with Multiple Sclerosis (MS) and voiding dysfunction (VD). In this group 'Transcranial Rotating Permanent Magnet Stimulator (TRPMS)' device will be used.
89678559|NCT03569085|Experimental|Sevoflurane then isoflurane|
89678560|NCT03528044|Experimental|Patients undergoing bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
89678561|NCT03528044|No Intervention|Control group|Healthy controls with normal BMI.
89678562|NCT03500744|Experimental|Erector spinae plane block|"The ESPB will be performed with ultrasound guidance. After identifying a suitable location between 8th and 10th thoracic spine transverse process, the overlying skin will be infiltrated with local anesthetic. A 22 gauge 90-mm needle will be inserted to make contact with the transverse process and withdraw slightly. Ropivacaine 0.5% 20 mL will be injected at this location. The same procedure will be performed on the other side.~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
89678563|NCT03500744|Sham Comparator|Shame block|"A sham block will be performed by performing ultrasound examination of the back looking for intended location for ESPB placement. Skin will be infiltrated with local anesthetics but ESPB will not be performed.~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
89678564|NCT03483753|Experimental|Vasopressin group|Blinded vasopressin
89678565|NCT03483753|Active Comparator|Norepinephrine group|Blinded norepinephrine
89678566|NCT03452891|Experimental|Simvastatin Methylcellulose|simvastatin in methylcellulose gel
89678567|NCT03452891|Placebo Comparator|Methylcellulose Gel|Methylcellulose gel
89678568|NCT03450850|Other|NOVOTTF-200A|NOVOTTF-200A treatment in Bevacizumab-Naïve Subjects with Recurrent WHO Grade III Malignant Astrocytoma
89678569|NCT03408353||Observational (mammography, questionnaires, blood collection)|Participants complete questionnaires over 15-25 minutes about personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity, and undergo collection of blood samples at baseline and then annually for 5 years. Participants also undergo standard of care mammography at baseline and then annually for 5 years.
89678570|NCT03367962|Experimental|Highly suspected to already have aGVHD|Patients highly suspected to have aGVHD. These patients will undergo a [18F]F-AraG PET-CT scan following a biopsy taken to confirm aGVHD.
89050585|NCT01647308|Placebo Comparator|Placebo|
89050586|NCT04599582|Active Comparator|SP-CL|
89050587|NCT04599582|Active Comparator|Corail|
89050588|NCT04599738|Placebo Comparator|Wheat muffin|Muffin made with 100% wheat flour
89050589|NCT04599738|Experimental|Finger millet grain muffin|Muffin made with 50% wheat flour and 50% finger millet crushed grain
89050590|NCT01643330|Experimental|AAV1/SERCA2a (MYDICAR)|Intracoronary infusion
89050591|NCT01643330|Placebo Comparator|Placebo|Intracoronary infusion
89050592|NCT01642550|Active Comparator|RM-131|Active study drug - RM-131
89050593|NCT01642550|Placebo Comparator|Placebo|Placebo comparator
89050594|NCT04608123||DBS Patients with NFS|Patients with PD treated with STN DBS between 2016 and 2019 who underwent NFS testing in pre and post-op conditions
89050595|NCT01641848|Experimental|Arthritic and injured ankles|InBone TAA
89678571|NCT03367962|Experimental|High risk of developing aGVHD|Patients at high risk of developing aGVHD will undergo a [18F]F-AraG PET-CT scan on day 4 +/- 2 days post transplant. Additionally these patients will be scanned again between day 14-21 post transplant.
89678572|NCT03367962|Experimental|Healthy Subjects|Healthy subject volunteers will undergo preliminary evaluation to ensure eligibility, receive and sign an informed consent, be enrolled in the trial, and then have a [18F]F-AraG PET-CT scan.
89678573|NCT03320330|Experimental|Treatment (pepinemab)|Patients receive pepinemab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
89215636|NCT06027944|Active Comparator|Scrambled scene|The same pixels that are used to create the scene in the alternate arm will be randomly scrambled on the monitor
89678574|NCT03317561||Myocardial injury|Subjects who have had an increase in troponin T level (> 99 percentile) in the perioperative period shall form the cases.
89678575|NCT03317561||Control|Subjects who do not have an increase in troponin T level (< 99 percentile) in the perioperative period shall form the controls.
89678576|NCT03301038|Experimental|All Subjects|SingleArm: Escalating doses of rifampin (5 and 10 mg/kg/day) (SingleArm)
89678577|NCT03300258|Other|Non-Stroke Pilot Group|Robotic therapy. Aerobic therapy. Subjects without stroke, pilot subjects tested during early phases while the device and therapeutic task specifications are developed, and throughout the project while the device and tasks are refined.
89678578|NCT03300258|Other|Non-Stroke Comparison Group|Robotic therapy. Healthy controls enrolled (age 50-85) to contribute to a normative data set on motor learning using the robotic protocols designed for stroke.
89678579|NCT03300258|Experimental|Robotic Training Group|Robotic therapy. Subjects with Stroke who will perform the targeted training task: exercise using novel tasks on a robotic recumbent cycle.
89678580|NCT03300258|Active Comparator|Aerobic Training Group|Aerobic therapy. Subjects with Stroke who will perform aerobic pedaling, duration-matched to the Robotic group.
89678581|NCT03296956|Active Comparator|Day-5 postpartum - Active dietary supplement|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell"
89678582|NCT03296956|Placebo Comparator|Day-5 postpartum - Placebo|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Placebo"
89678583|NCT03296033|Active Comparator|24 Hours group|Group one will be instructed to administer their last dose of enoxaparin at 07:00 in the morning on the day prior to their scheduled surgery date. This will mean that patients who have their surgery scheduled for 07:00 the following day will be 24-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, however this is currently considered normal clinical practice.
89678584|NCT03296033|Experimental|36 Hours Group|Group 2 will be instructed to administer their last dose of enoxaparin at 19:00 in the evening two days prior to their scheduled surgery date. Patients presenting for surgery at 07:00 two days later will be 36-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, but again this mimics normal clinical practice in which the timing of the last dose of self-administered enoxaparin is not routinely adjusted based on the scheduled surgical start time.
89678585|NCT03295981|No Intervention|Control group|The surgical procedure for all patients will include extensive curettage of the lesion to remove macroscopic tumor, high-speed burring of the residual cavity, adjuvant treatment to the residual cavity, followed by packing of the cavity with either polymethylmethacrylate (PMMA) bone cement (Simplex P; Stryker, Mahwah, New Jersey) alone or bone cement with subchondral allograft bone graft. The choice of cavity reconstruction will be at the discretion of the treating surgeon. Traditional local adjuvants (argon beam coagulation, phenol, ethanol, or cryotherapy) will be used depending on surgeon preference. In addition to the above standard treatment, the patients will be randomized into one of two study arms. In Arm 1, the control group, no additional local therapy will be utilized.
89678586|NCT03295981|Experimental|Bisphosphonate group|In Arm 2, the bisphosphonate group, 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement.
89678587|NCT03284788|Experimental|ABT Weight Loss Intervention|Adolescent girls will attend healthy lifestyle sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
89678588|NCT03203603||Offspring of smokers who got vitamin C|Offspring of pregnant smokers randomized to vitamin C during the initial randomized portion of the VCSIP study
89678589|NCT03203603||Offspring of smokers who got placebo|Offspring of pregnant smokers randomized to placebo during the initial randomized portion of the VCSIP study
89678590|NCT03203603||Offspring of pregnant non-smokers|Offspring of pregnant non-smokers who were followed in a similar fashion during pregnancy as the randomized pregnant smokers
89678591|NCT03199365|Experimental|Prevention (TSSC intervention)|Participants undergo two TSSC intervention sessions delivered at participants' homes by trained CHWs over 1.5 hours.
89678592|NCT03119740||open appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open appendectomy (AE)
89678593|NCT03119740||laparoscopic appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open laparoscopic appendectomy (LSK AE)
89678594|NCT03089840|Experimental|Normothermic Machine Perfusion (OrganOx metra)|Donor livers will be placed on the OrganOx metra device for normothermic perfusion before transplantation.
89678595|NCT03082612|Experimental|African American cancer patients|Patients will be required to participate in intervention activities and 5 data collection interviews. Interviews to complete both open-ended interviews and quantitative measures will take approximately 45 minutes. The actual administration of the intervention (viewing of video recordings) will take approximately 30 minutes with all sessions to occur over a 3 week period.
89678596|NCT03082612|Experimental|Family caregivers|Family caregivers will be required to participate in intervention activities and 5 data collection interviews. Interviews to complete both open-ended interviews and quantitative measures will take approximately 45 minutes. The actual administration of the intervention (viewing of video recordings) will take approximately 30 minutes with all sessions to occur over a 3 week period.
89678597|NCT03068819|Experimental|CIML NK cell after T cell DLT (Pilot Pediatric/Young Adult Cohort)|"The recipient will receive standard of care salvage chemotherapy consisting of fludarabine (or cladribine if shortage), cytarabine, and G-CSF (FLAG) to be started 2 to 4 weeks prior to the CIML NK cell infusion. 5-day decitabine is an acceptable alternative for FLAG, and another standard of care salvage chemotherapy regimen, if clinically appropriate and approved by the study PI, may be used.~The donor will undergo non-mobilized leukapheresis on Day -2 or -1. Standard of care DLI (1 x 10^6 CD3+ cells/kg) will be given fresh on day -1.~A second cycle of therapy may be administered > 30 days after the administration of the first course of protocol therapy to maintain response or to treat persistent/relapsed AML, if a patient continues to meet the inclusion/exclusion criteria. Chemotherapy may be omitted before a second infusion of DLI and CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, and ML NK cells administered."
89678598|NCT03068819|Experimental|CIML NK cell after T cell DLT (Phase 2 Adult Cohort)|"The recipient will receive lymphodepleting chemotherapy with fludarabine (or cladribine if shortage) and cyclophosphamide beginning on day -7.~The donor will undergo non-mobilized leukapheresis on Day -2 or -1. T cell dose per standard of care institutional practices and physician discretion will be given frozen for administration on day 30.~A second cycle of therapy may be administered > 30 days after the administration of the first course of protocol therapy to maintain response or to treat persistent/relapsed AML, if a patient continues to meet the inclusion/exclusion criteria. Chemotherapy may be omitted before a second infusion of DLI and CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, and ML NK cells administered. The date of the second NK cell infusion will be considered a second Day 0."
89678599|NCT03021330|Active Comparator|DA Regimen|Patients receive standard DA induction regimen including daunomycin and cytarabine.
89678600|NCT03021330|Experimental|Intermediate Dose of DA Regimen|Patients receive DA induction regimen including daunomycin and intermediate dose of cytarabine.
89678601|NCT03019081|Experimental|Anorexia nervosa-study drug|"Drug: Isoproterenol Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant. The isoproterenol dose will range from 0.1 micrograms to 4.0 micrograms and exposure during each visit will not exceed 25.0 micrograms. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.~Other Names: Isuprel"
89678602|NCT03019081|Placebo Comparator|Anorexia nervosa-placebo|"Drug: Normal Saline Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.~Other Names:~Saline"
89678603|NCT03018418|Experimental|Proton Therapy and Chemotherapy|Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
89678604|NCT02951598||MCI (Amyloid Positive)|Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
89678605|NCT02951598||Mild AD Dementia (Amyloid Positive)|Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
89678606|NCT02951598||MCI (Amyloid Negative)|Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
89678607|NCT02951598||Mild Dementia (Amyloid Negative)|Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
89678608|NCT02947386|Experimental|Treatment (nivolumab, nimotuzumab)|Patients receive nivolumab IV over 60 minutes and nimotuzumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89678609|NCT02874404|Experimental|Group A (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89678610|NCT02874404|Experimental|Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)|Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89678611|NCT02874404|Experimental|Group C (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89678612|NCT02866669|Active Comparator|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
89678613|NCT02866669|Experimental|Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
89678614|NCT02866669|Experimental|Peer coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
89678615|NCT02866669|Experimental|Peer coach and Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. The patients will also be matched with peer advisors who will work with the participants for 12 months.
89678616|NCT02824627|Experimental|Oxytocin|Subjects weighing >40kg will receive a total of 24 IU of oxytocin delivered as 2- 6 IU puffs to each nostril once daily. Subjects weighing < 40kg will receive a total of 12 IU of oxytocin delivered as 1- 6 IU puff to each nostril daily. Subjects will receive 14 to 21 days of daily oxytocin administration.
89678617|NCT02824627|Placebo Comparator|Placebo|Subjects weighing>40kg will 2 puffs of placebo to each nostril daily. Subjects weighing <40kg will receive 1 puff per day. Subjects will receive 14-21 days of placebo administration.
89678618|NCT02743611|Experimental|Arm 1 Does Escalation|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.~Rimiducid may be administered in response to treatment-related toxicity."
89678619|NCT02743611|Experimental|Arm 2 Dose Escalation|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.~Rimiducid may be administered in response to treatment-related toxicity."
89678620|NCT02743611|Experimental|Arm 1 Part 2 Dose Expansion|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701 at the recommended cell dose level.~Rimiducid may be administered in response to treatment-related toxicity."
89678621|NCT02743611|Experimental|Arm 2 Part 2 Dose Expansion|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701 at the recommended cell dose level.~Rimiducid may be administered in response to treatment-related toxicity."
89678622|NCT02668666|Experimental|Investigational Treatment|"71 subjects will be enrolled to determine progression-free survival (PFS) in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies.~Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.~Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously)."
89678623|NCT02508363|Active Comparator|Health Fair Alone (Control)|"No Follow Up Participant does not require referrals or assistance and was not advised to see a provider in the next three months.~Regular follow-up call within two weeks of health fair by IHCD intern or staff. Participant has abnormal values, requires referrals or assistance or was advised to see a provider in the next three months.~Up to 3 call attempts to get participant into needed care. Further contact only by participant request.~Urgent follow-up call or in-person assistance within 1 day of health fair by IHCD intern or staff Participant advised to seek urgent care within one week.~Three total call or in-person attempts to get participant into needed care. Further contact only by participant request The follow up call attempts may extend up to 3 months past the date of health fair to complete any needs the driver may have."
89678624|NCT02508363|Experimental|Health Fair + Navigator Case Management|"• Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.~Navigator Case Management by trained staff~Tailored assistance for any health needs a minimum of once a month 12 months. Assistance includes pre-appointment reminder calls, post-appointment follow up calls, and health promotion reminders.~NCM case management will continue follow-up at a minimum of once per month or as requested by the participant for the study duration and will consistently offer appointment reminders and follow-ups."
89678625|NCT02508363|Experimental|Health Fair + Taxi Health Improvement Promoters|"Health Fair standard services Follow-up call or further in-person assistance within one day for urgent follow-up, or call within two weeks for regular needs. Three call attempts.~Taxi health Improvement Promoters (TIPs)~Weekly check-ins with each participant, in person or by phone, about scheduling of, and attendance at, primary care appointments along with other health or study questions Mosio Text Messaging Program~Send primary care provider recommendations to participant up to three times~Two pre-appointment reminders & one post-appointment check-in~Twice weekly health promotion reminders after primary care appointment"
89678626|NCT02364713|Experimental|Arm A (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89678627|NCT02364713|Active Comparator|Arm B (DOXIL, GEM, TOPA, TAXOL)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15, or paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may also receive bevacizumab IV over 30-90 minutes on days 1 and 15 with pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, or paclitaxel. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89050596|NCT04607811|No Intervention|Control arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will complete study surveys at baseline and the end of the 8 week intervention.
89050597|NCT04607811|Experimental|Gamification arm|Participants will wear the Fitbit device and record their daily step counts during the baseline and 8 week intervention period. Participants will have a weekly step goal they are encouraged to meet. Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
89050598|NCT00555308|Experimental|one|undergo EDTU
89050599|NCT04608006||Vaginal Delivery|Delivered both twins vaginally
89050600|NCT04608006||C-Section Delivery|Delivered both twins by Cesarean Section
89050601|NCT04608006||Vaginal/C-Section Delivery|Delivery first twin vaginally and second twin By C-Section.
89050602|NCT01640756|Experimental|AqueSys Microfistula Implant|
89050603|NCT04599621||patients with unstable angina|This group included patients with frequent anginal attacks, with a burdened history and comorbid conditions.
89050604|NCT01636817|Experimental|60 mg|
89050605|NCT01636817|Experimental|120 mg|
89050606|NCT01636817|Experimental|240 mg|
89050607|NCT01636817|Placebo Comparator|Placebo|
89050608|NCT00564525|Placebo Comparator|1|
89050609|NCT00564525|Experimental|2|Amitriptyline given
89050610|NCT01634087|Experimental|100 mg QD Itacitinib|
89678628|NCT02186600|Active Comparator|Control|Women randomized to the control group will receive calcium and vitamin D intake for 12 months. Calcium intake will be determined by analyzing 3 day dietary intake of calcium at baseline and then prescribing calcium carbonate supplements to ensure women have ~1200 mg of calcium daily. Vitamin D intake will be determined using baseline measures of Serum 25 (OH) D. Subjects who have serum D levels of 30 ng/ml or greater will be prescribed 1,000 IU vitamin D3 daily; subjects with levels of 20-29 ng/ml will be prescribed 2,000 IU Vitamin D3; and subjects with levels of 10-19 ng/ml will be prescribed 3,000 IU Vitamin D3.
89678629|NCT02186600|Experimental|Risedronate|"Subjects in the risedronate group will take 35 mg of the bisphosphonate risedronate weekly for 12 months plus CaD. They will be asked to follow the protocol for administration of risedronate including taking the medication upon arising in the morning with an 8 ounce glass of water, remaining upright for at least 30 minutes, and having no oral intake except water for at least 30 minutes."
89678630|NCT02186600|Experimental|Exercise|Subjects in the exercise group will participate in bone-loading exercises three times weekly in addition to taking CaD for 12 months. Women will exercise at community Young Men's Christian Association's fitness centers (YMCA) and exercises will be monitored by on-site Exercise Trainers. Exercises will consist of high-impact weight-bearing exercises (jogging with weighted vests) and resistance exercises for upper and lower extremities. Progressive increases in weight loads will be prescribed to provide maximal strength gains.
89678631|NCT02105259|Experimental|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for social anxiety disorder during 10 weeks and guided by a psychologist
89678632|NCT02105259|Active Comparator|Waiting list with support|Behavioral: supportive check-ups via the Internet during 10 weeks
89678633|NCT01907789|Experimental|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
89678634|NCT01907789|Experimental|Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
89678635|NCT01907789|Experimental|Risk-Reducing Salpingo-Oophorectomy (RRSO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
89678636|NCT01873833|Experimental|Treatment (chemotherapy, lapatinib ditosylate, trastuzumab)|Patients receive capecitabine by mouth (PO) every day (QD), cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89678637|NCT01567800|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with prostate cancer
89678638|NCT01446744|Active Comparator|Standard arm|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
89678639|NCT01446744|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
89678640|NCT01431209|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89678641|NCT01393795|Placebo Comparator|Tegaderm|
89678642|NCT01393795|Active Comparator|Qutenza|
89678643|NCT01389089|Sham Comparator|Control group|The Control group received ice gel packs and elevation to reduce edema.
89678644|NCT01389089|Experimental|Multi-layer compression bandage|A multi-layer compression bandage was applied to the lower limb and foot of the patient to reduce edema. Additionally, the limb was constantly elevated.
89678645|NCT01389089|Active Comparator|A-V Impulse compression|An A-V Impulse compression device was used to reduce edema.
89678646|NCT01198067|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO on days 1-28 or 1-21. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
89678647|NCT01181375|Experimental|Assays on cervical cancer tissue|
89678648|NCT00928525|Experimental|Imatinib Mesylate|Patients affected by Desmoid Tumor and Chondrosarcoma will receive Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
89678649|NCT00826020|Experimental|Omegaven™|This study will be a prospective, non-randomized, open-label study of Omegaven™ for provision of parenteral lipid calories. The study cohort, receiving the parenteral nutrition (PN) lipid at 1g/kg/day, will be compared to historical controls at University of Nebraska Medical Center (UNMC) where parenteral lipid calories were provided exclusively through soybean-based formulations. The study is planned to enroll 100 patients. The Intestinal Rehabilitation Program at UNMC sees between 20 and 30 new pediatric patients per year, with almost all being PN-dependent and over 75% presenting with a bilirubin ≥ 2mg/dL. Based on these calculations, we estimate 4-5 years to enroll 100 patients.
89050611|NCT01634087|Experimental|100 mg QD Placebo|
89050612|NCT01634087|Experimental|200 mg QD Itacitinib|
89050613|NCT01634087|Experimental|200 mg QD Placebo|
89678650|NCT00818025|No Intervention|Standard of Care|All subjects will receive standard care to prepare for discharge that consists of a one-on-one, pre-discharge educational session delivered by the transplant coordinator prior to hospital discharge and provision of a reference binder for each lung transplant recipient to take home.
89678651|NCT00818025|Experimental|Pocket PATH hand-held device|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
89678652|NCT00816114||Chronic Myelogenous Leukemia|All CML patients in any phase of the disease that received imatinib treatment outside of MDACC clinical trials and has had at least one MDACC clinic visit.
89678653|NCT00754208|Other|methylpehnidate|open-label treatment with methylphenidate
89050614|NCT01634087|Experimental|200 mg BID Itacitinib|
89050615|NCT01634087|Experimental|200 mg BID Placebo|
89050616|NCT01634087|Experimental|600 mg once a day Itacitinib|
89050617|NCT01634087|Experimental|600 mg once a day Placebo|
89678654|NCT00579423|Experimental|vaccine|Patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administrated at the standard dose of 100ug.
89678655|NCT00505245||Observational (questionnaire, QOL assessment, interview)|Participants complete questionnaires and quality of life assessments, and may also complete interviews over 45 minutes periodically.
89678656|NCT04199390|Active Comparator|Clinic-based Physical Therapy|
89678657|NCT04199390|Active Comparator|Home-based Physical Therapy|
89678658|NCT04193774|Placebo Comparator|Drop of artificial tears|A drop op Thealoz duo
89678659|NCT04193774|Active Comparator|Drop op anesthetic|A drop of oxybuprocaïne
89678660|NCT04197674||Peritoneal dialysis group|Patients who randomized to peritoneal dialysis
89678661|NCT04197674||Hemodialysis group|Patients who randomized to conventional in-center hemodialysis
89678662|NCT00547729|Experimental|HeartPOD™ System|Implantation of HeartPOD™ Heart Failure Management System with DynamicRx®
89678663|NCT04199312|Experimental|Muscle Toning, Firming and Strengthening|The EMS device will be evaluated for muscle toning, firming and strengthening in the abdomen.
89678664|NCT00518089|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
89678665|NCT00518089|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
89678666|NCT02985242|Experimental|Empagliflozin/glimepiride placebo|"Empagliflozin 25 mg film-coated tablet p.o. daily and glimepiride matching placebo p.o. daily~Duration of treatment: 12 months"
89678667|NCT02985242|Active Comparator|Glimepiride/empagliflozin placebo|"Glimepiride 2 mg tablet p.o. daily and empagliflozin matching placebo p.o. daily~Duration of treatment: 12 months"
89678668|NCT04197518|Experimental|Children With Enlargement Adenoid and Tonsils|Children With Enlargement Adenoid and Tonsils
89678669|NCT04197440|Experimental|Bam8-22|
89678670|NCT04197440|Experimental|SPT pricks|
89678671|NCT03023774|Other|neupogen|neupogen (granulocyte colony-stimulating factor) 30 IU once intrauterine at the time of ovum pickup
89678672|NCT04021160|Active Comparator|Active Group|A total of 16, every other day sessions of rTMS at 10 Hz frequency will be applied to 4 locations along the perilesional area (see target selection). Intensity will be 100% of motor threshold, 25 trains - 40 pulses per train with 20 seconds intertrain interval and a total of 1000 pulses per session. The coil handle will be directed downwards at 45º of the sagittal plain to ensure that the induced electric field be perpendicular to the underlying gyrus.
89678673|NCT04021160|Sham Comparator|Sham Group|Sham group will receive the same sessions as above with the exact same parameters yet a sham coil identical in shape and size to the active coil will be used instead. The sham coil produces sounds and sensations very similar to the active one.
89678674|NCT03023618|No Intervention|control group|patients before 2014, in which fluids were administered without FloTrac monitoring
89678675|NCT03023618|Active Comparator|case group|patients after 2014, after management of fluid therapy has been guided by FloTrac parameters as a standard clinical practice (NICE protocol)
89678676|NCT04020614||Survey|All of the patients that enrolled in this study will be in this group.
88996411|NCT02920489|Experimental|Individualized epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor. Epidural analgesia will begin when asked by parturients and the numeric rating scale of pain is 5 or higher. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
89678677|NCT04026698|Experimental|Resident and Family Engagement Intervention.|The intervention has three components: leadership coaching for managers, administrators/ directors of care in long-term care settings; a one-day in-person training session for staff and managers; and resident and family led huddles (brief, 15 minute meetings) with staff.
89678678|NCT04029818|Experimental|Probiotic|Volunteers will take a capsule with Bifidobacterium BSL_PS404 (3x109 cfu) daily.
89678679|NCT04029818|Placebo Comparator|Placebo|Volunteers will take a capsule with maltodextrin daily.
89678680|NCT04196426|Experimental|nutrition education group|The nutrition education group receive the intervention first, which include 2 nutrition lessons about osteoporosis and calcium and calcium rich foods. The 2 lessons are delivered in one week for 2 hours each lesson. After this week, participants in the intervention group receive handouts about osteoporosis and calcium once a week for a period of 4 weeks.
89678681|NCT04196426|Active Comparator|delayed nutrition education group|After the intervention group finish their intervention (5 weeks period), post data collection will be administered in both nutrition education and delayed nutrition education group. After this post data collection, the delayed nutrition education group receive the same intervention.
89678682|NCT04196582|Active Comparator|Gastro-laryngeal tube Group (Group G)|Patients wear Gastro-laryngeal tube after receiving general anesthesia for biliopancreatic procedures
89678683|NCT04196582|Active Comparator|LMA Gastro Airway Group (Group L)|Patients wear LMA Gastro Airway® after receiving general anesthesia for biliopancreatic procedures
89678684|NCT03832478|Experimental|Virtual Reality Headset Given|Virtual Reality headset (Samsung Gear VR) with mindfulness meditation app is given for patient use prior to surgery date and for duration of postoperative stay.
89678685|NCT00518713|Experimental|Clobazam Low Dose|
89678686|NCT00518713|Experimental|Clobazam Medium Dose|
89678687|NCT00518713|Experimental|Clobazam High Dose|
89678688|NCT00518713|Placebo Comparator|Placebo|
89678689|NCT03948464|Experimental|Slow release oral morphine (SROM)|Daily witnessed ingestion of SROM (24-hour formulation) for 24 weeks as per provincial and national guidelines for opioid use disorder.
89678690|NCT03948464|Active Comparator|Methadone|Daily witnessed ingestion of methadone for 24 weeks as per provincial and national guidelines for opioid use disorder.
89678691|NCT04020692|Experimental|"intervention  group"|"Patient At D0, the patient receives his discharge drugs prescription and benefits from a pharmaceutical counselling.~At D+3, he benefits from a telephone follow-up (good understanding of the methods of taking drugs, collection of difficulties).~Community pharmacist At D0, he receives the discharge drugs prescription. At D+3, he is contacted to collect information relating to drugs 'dispensation.~The attending physician At D0, he is informed of the patient's discharge and his drugs treatment~At D45, the data collection is based on telephone interviews [attending physician, pharmacist and patient (and if applicable the caregiver)].~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
89678692|NCT04020692|No Intervention|Control group|"At D0, the patient receives his discharge drugs prescription.~At D45, the data collection is based on telephone interviews [attending physician, pharmacist and patient (and if applicable the caregiver)].~It makes possible to collect drugs taken by the patient as well as significant events over the period (acute pathologies, re-hospitalizations, etc.)."
89678693|NCT04196270|Experimental|Ropivacaine|This double-blind dose-finding trial is based on a biased coin up-and-down sequential design, where the volume of local anesthetic administered to each patient depends on the response from the previous one. The TQL block is performed preoperatively, and the first patient recruited receives 20 mL of ropivacaine 0.75%. In case of block failure, the next patient will receive a higher volume (defined as the previous volume with an increment of 2 mL). Given a successful block for the first patient, the next patient will be randomized to either a lower volume (defined as the previous volume with a reduction of 2 mL) or the same volume as the previous patient. The respective probabilities being b=0.11 for a reduced volume and 1-b=0.89 for the same volume. Block success is defined as patient reported numeric rated scale (NRS) pain (NRS value ≤ 3 (0-10/10)), 30 minutes after arrival in the post anesthesia care unit (PACU).
89678694|NCT04020380|Experimental|Azithromycin 250 mg|Azithromycin, 250 mg capsules once a day for a total of 3 months
89678695|NCT00521989|Experimental|CRx-102 (2.7/90)|"2.7 mg prednisolone plus 90 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
89678696|NCT00521989|Experimental|CRx-102 (2.7/180)|"2.7 mg prednisolone plus 180 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
89678697|NCT00521989|Experimental|CRx-102 (2.7/360)|"2.7 mg prednisolone plus 360 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
89678698|NCT00521989|Active Comparator|Prednisolone|"2.7 mg prednisolone~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM."
89678699|NCT00521989|Placebo Comparator|Placebo|"Placebo~Subjects were dose twice daily through day 98."
89678700|NCT04029350|Experimental|Anlotinib Combined With Osimertinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Osimertinib 80mg p.o, qd. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
89678701|NCT04029506||medical staff group|medical staff in Qilu Hospital who recieveing endoscopy for physical examination
89678702|NCT04029506||general population group|general population who recieveing endoscopy for physical examination in Qilu Hospital
89678703|NCT04196036|Active Comparator|Day 3 vitrification|Day of vitrification of supernumerary embryos is day 3
89678704|NCT04196036|Active Comparator|Day 5 vitrification|Day of vitrification of supernumerary embryos is day5
89678705|NCT00548041|Other|Rapid HIV Tested|Subjects have HIV testing by oral swab performed.
89678706|NCT04020770|Experimental|Vibrating Ball|Vibrating ball is held in both hands. Participants complete 5 30-second bouts of 68 Hz vibration with a 1 minute rest in between each bout.
89678707|NCT05560321|Experimental|Intervention|Application of a 24-hour continuously acting quaternary ammonium salt disinfectant: Sani24 (PDI Healthcare Inc.) by study team
89678708|NCT05560321|Active Comparator|Control|Routine disinfection completed by hospital staff
89678709|NCT04020302|Experimental|Shopping group|Participants will receive an 8-week intervention which will include weekly sessions that are delivered in an alternating group-individual format. Sessions will provide participants the opportunity to practice and apply self-monitoring techniques across a variety of shopping tasks and settings to promote generalization and transfer of learning (Phase B).
89678710|NCT04195724|Experimental|Patients with decompensated ascites and receiving TIPS|Patients with decompensated ascites and receiving TIPS will be enrolled. In this study, diagnostic paracentesis will be performed to get the ascites sample before the patients receiving TIPS. Next, the blood sample from superior mesenteric vein and hepatic vein will be collected under the procedure of TIPS.
89678711|NCT00548197|Experimental|Intervention group|Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
89678712|NCT00548197|No Intervention|Control group|no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy
89678713|NCT04029272|Active Comparator|Metformin|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d."
89678714|NCT04029272|Experimental|Metformin+EQW|"Background therapy: Diane-35 one pill by mouth, once daily, beginning on Day 5 of the menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles (3 months)~Metformin: Metformin was initiated at a dose of 250mg q.d. and increased by 250mg up to 500 mg t.i.d.~EQW: Participants will receive long-acting Exenatide once a week for 12 weeks"
89678715|NCT02985164|Experimental|PDSa (Pocket radiation dosimeter a)|"A co-researcher reset and prepared 4 pocket dosimeters (PDS) and labelled as PDSa1, PDSa2, PDSb1 and PDSb2.~The PDSa1 and PDSa2 were placed on the outside and inside of a lead shirt respectively. The shirt-covered box was close to an anesthetic machine. This box would represent anesthetic personnel on duty and marked as position A. Position A was 160 cm. above the floor"
89050618|NCT03454230|Experimental|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
89050619|NCT03454230|No Intervention|Common repositioning practice|pressure ulcer prevention cares are provided according to usual practice. Frequency and modality of positioning applied to the patients are collected.
89050620|NCT01632137|Placebo Comparator|Placebo (vehicle)|
89050621|NCT01632137|Experimental|Rebamipide 2% ophthalmic suspension|
89050622|NCT01626599|Other|Assess product useability|All subjects participate in the same arm. This arm completes the primary objective of product usability.
89678716|NCT02985164|Experimental|PDSb (Pocket radiation dosimeter b)|"The PDSb1 and PDSb2 were placed on the outside and inside of the glass shield of control room respectively. This glass shield would represent all personnel working in the operating theatre and marked as position B.~Position B was 160 cm. above the floor."
89678717|NCT00548431|Experimental|6 mercaptopurine arm|All patients received basic daily 6MP (6-mercaptopurine) (25 mg/m^2) and in addition high-dose methotrexate(HDM) every 3rd week (3 times HDM in total) and PEG-asparaginase every 14th day. Patients increased the dose of 6MP 2 weeks after each HDM if if the myelotoxicity had been acceptable. This means 2 increments since the study stopped 2 weeks after the last HDM
89678718|NCT04195412|Experimental|tDCS|Bihemispheric tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After stimulation, individual and intensive upper limb rehabilitation will be performed.
89678719|NCT04195412|Sham Comparator|Control|Bihemispheric sham tDCS will be applied. The anode will be placed on the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. After sham stimulation, individual and intensive upper limb rehabilitation will be performed.
89678720|NCT04195646|Experimental|EndoVigilant CAD Software assisted Colonoscopy Procedure|The gastroenterologist performing the colonoscopy procedure will be able to observe a standard colonoscopy video on the primary monitor and video augmented by EndoVigilant CAD software on the second monitor. The gastroenterologist will primarily rely on the second monitor but the standard procedure monitor will be always operational and available for maneuvers such as fast insertion, polypectomy etc.
89678721|NCT00522925|Placebo Comparator|1|Matching Placebo
89678722|NCT00522925|Experimental|2|
89678723|NCT00522925|Experimental|3|
89678724|NCT04028882||Non viremic HIV patients under treatment|Patients with various immune activation profiles
89678725|NCT04028726|Active Comparator|Cluster set Resistance Training Protocol|Cluster set configuration is the new training approach that it is being tested.
89678726|NCT04028726|Sham Comparator|Traditional Resistance Training Protocol|Traditional is commonly used in training sessions.
89678727|NCT04028804||FDG PET|FDG PET imagaing
89678728|NCT04028804||FLT PET|FLT PET imaging
89678729|NCT04020146||group 1;|healthy controls (C, n=15),
89678730|NCT04020146||group 2|periodontitis patients with stage 3 grade B; (P, n=15)
89678731|NCT04020146||group 3|peri-implantitis patients (PI, n=15).
89050623|NCT04607694|Experimental|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
89678732|NCT00524017|Experimental|Arm I (treatment)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
89678733|NCT00524017|No Intervention|Arm II (control)|Patients receive regular follow-up care
89678734|NCT02985554|Experimental|Nivolumab|Nivolumab will be administrated intravenously. Standard dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
89678735|NCT05560165|Experimental|PET/CT guided injection of combination of local anesthetic and steroids.|The F-18 Sodium fluoride (NaF) dose will be administered intravenously and the F-18 NaF PET/CT images will be reviewed, and the target nociceptive site will be determined on the basis of increased focal tracer uptake. The joint accessibility, location, and relation with the nearby vital organs will be assessed. The injection will be assisted using a dedicated automated robotic arm system. A combination of corticosteroids and local anesthetic will be injected.
89678736|NCT04028258|Other|Group A: study+wash out+control|Study product (3 weeks) + wash out (2 weeks) + control product (3 weeks)
89678737|NCT04028258|Other|Group B: control+wash out+study|Control product (3 weeks) + wash out (2 weeks) + study product (3 weeks)
89678738|NCT00525421|Experimental|Curcumin|Curcumin C3 Complex
89678739|NCT00525421|Placebo Comparator|Placebo|Placebo
89678740|NCT04195022|Experimental|Chemically activated Composite resin Alkasite|Single placement of composite resin on atypical cavities.
89678741|NCT04195022|Active Comparator|Bulk fill resin composite|Single placement of Bulk fill resin composite on atypical cavities.
89678742|NCT02128867|Experimental|Assisted Autogenic Drainage (AAD)|airway clearance technique for infants :Assisted Autogenic Drainage
89678743|NCT02128867|Experimental|bouncing and AAD|airway clearance technique for infants : bouncing combined with AAD
89678744|NCT02128867|Experimental|bouncing|bouncing . intervention to relax the infant
89678745|NCT03965702|Active Comparator|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
89678746|NCT03965702|Experimental|EV1000 monitoring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Life sciences, Irvine, USA)
89050624|NCT04607694|Active Comparator|Photon radiotherapy|Photon radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
89678747|NCT04194866|Other|Day group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group ( 8:00-12:00)
89678748|NCT04194866|Other|Night group|60 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Night Group (18:00-22:00)
89678749|NCT00525733|Active Comparator|3-drug standard therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ +ritonavir 100 mg QD
89678750|NCT00525733|Experimental|5-drug experimental therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg + ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
89678751|NCT04028336|Experimental|TITRATION|"All patients hospitalized in intensive care and meeting inclusion criteria and without criteria for non-inclusion will be included in this study. All patients will benefit from Lung ultrasound (LUS) and esophageal pressure measurement (Peso) according to the habits of the service. A PEP titration pulmonary opening (PEP-OP) test using a recruitment maneuver was then performed in all patients followed by a new LUS and Peso measurement."
89678752|NCT00526123|Active Comparator|1|symmetric tip catheter
89678753|NCT00526123|Active Comparator|2|conventional split-tip catheter
89678754|NCT04406324||SARS-CoV-2 patients|Patients infected by SARS-CoV-2
89678755|NCT04194710|Active Comparator|Arthroscopic Resection|43 patients will be assigned to this arm. This is the standard technique to treat lateral epicondylitis. After randomization, patients will be informed and the surgery will be scheduled.
89678756|NCT04194710|Experimental|Cytokine rich serum injection|43 patients will be assigned to this arm. After randomization, patients will be informed and the first injection of serum rich cytokines will be scheduled. After 15 days, they will be injected again with serum rich cytokines.
89678757|NCT04026854||Psychiatric nurses|Nurse with a degree in the state or psychiatric sector. Work in a psychiatric ward that offers full hospitalization, a day hospital (HdJ) or a medico-psychological center (CMP).
89678758|NCT04027790||Group 1 - Cancer Patients|Subjects with known colorectal cancer (i.e. AJCC/UICC stages 0, I, II, and III) who provide plasma at least 7 days after diagnosis by colonoscopy, but prior to surgery or treatment
89678759|NCT04027790||Group 2 - Screening Subjects|Prospectively enrolled subjects reporting for screening colonoscopy who provide a blood sample up to 2 weeks prior to bowel prep and prior to colonoscopy. We accept all subjects who meet the institutional criteria as average risk subjects referred for a screening colonoscopy for colorectal cancer, including subjects undergoing a colonoscopy as a follow-up to a positive (non-colonoscopic) test
89678760|NCT04028024|Other|inhibiting systemic inflammatory response|Ulinastatin 5000U/kg in 20ml NS i.v. before occlusion of aorta
89678761|NCT00444821|No Intervention|Surveillance|
89678762|NCT00444821|Experimental|Early Endovascular Repair|
89678763|NCT04027634|No Intervention|Control group|The control group (CG) received routine care and was required to walk during 6-7 pm.
89678764|NCT04027634|Experimental|Baduanjin program|The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
89678765|NCT00526591|Experimental|Low-dose Everolimus Cohort|5mg Everolimus daily continuously for 8 weeks and conventional surgery
89678766|NCT00526591|Active Comparator|High-dose Everolimus Cohort|10mg Everolimus daily continuously for 8 weeks and conventional surgery
89678767|NCT04027478|Active Comparator|FMD (fasting-mimicking diet)|Over the course of three rounds of chemotherapy, patients in the FMD will consume a diet that consists of 10 cal/kg/day and includes 50% fat, 40% carbohydrates, and no more than 10% protein. The diet includes nuts, olives, vegetable broth, broccoli/cauliflower, white rice/puffed rice cake, onion, tea/coffee, almond milk. The diet prohibits meat products, dairy, alcohol, sugar, and artificial sweeteners. Patients will be instructed to drink 2 cups of water each morning, take their usual medications and limit exercise to walking.
89678768|NCT04027478|No Intervention|regular diet|Diet not influenced by a fast-mimicking diet.
89678769|NCT05559775|Experimental|Pemigatinib|Selective FGFR1-3 inhibitor
89678770|NCT04027400|Active Comparator|Primarily visual computer exercises|Participant performs visual computer exercises 30 minutes a day, five days a week for one month.
89678771|NCT04027400|Experimental|Visual+Audio|Participant performs audio computer exercises and some visual computer exercises 30 minutes a day, five days a week for one month
89678772|NCT04194320|Placebo Comparator|"Group I Placebo"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 ml 0.9% normal saline.
89678773|NCT04194320|Active Comparator|"Group II Nalbuphine "|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 10 mg nalbuphine hydrochloride (completed to 2 ml with 0.9% normal saline).
89678774|NCT04194320|Active Comparator|"Group III Dexamethasone"|Ultrasound (US) guided supraclavicular brachial plexus block will be done to the patients who are prepared to undergo upper limb surgeries below the level of the shoulder within the distribution of supraclavicular brachial plexus block using: 30 mL volume of local anesthetics (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) + 2 mL dexamethasone 0.4% (8 mg).
89678775|NCT05559307|Experimental|Xingnaojing injection group|"Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.~Interventions:~Drugs:Xingnaojing injection Other: Standard care (eg. antiplatelet drugs and statins)"
89678776|NCT05559307|No Intervention|Standard care group|"Subjects will receive guidelines-based standard care.~Interventions:~Other: Standard care (eg. antiplatelet drugs and statins)"
89678777|NCT04194242|Experimental|HEC96719 tablets|Including 7 dose groups(0.1、0.2、0.5、1、2、3、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240 mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
89678778|NCT04194242|Placebo Comparator|placebo tablets|Including 7 dose groups(0.1、0.2、0.5、1、2、3、4 mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
89678779|NCT04893499|Experimental|Low-dose mastic group|This arm will consume 600 mL of a sparkling water enriched with Chios mastic per day for a 3-month period.
89678780|NCT04893499|Placebo Comparator|Low-dose control group|This arm will consume 600 mL of a standard sparkling water per day for a 3-month period.
89678781|NCT04893499|Experimental|High-dose mastic group|This arm will consume 600 mL of a sparkling fruit juice enriched with Chios mastic per day for a 3-month period.
89678782|NCT04893499|Placebo Comparator|High-dose control group|This arm will consume 600 mL of a standard sparkling fruit juice per day for a 3-month period.
89678783|NCT04194086|Experimental|posaconazole as antifungal prophylaxis|
89678784|NCT04023266|Experimental|Intravenous N-Acetylcysteine arm|On arrival at the recruiting hospital, eligible and consenting STEMI patients randomly allocated to the experimental arm would be administered an intravenous N-Acetylcysteine bolus of 1200 mg over 0.5 hours (in 5% Dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). A total N-acetylcysteine dose of 29.7 grams is administered over 48 hours.
89678785|NCT04023266|No Intervention|Control arm|Patients randomized to this arm would receive no experimental therapies and would continue to receive all standard guideline recommended medical therapies and interventions.
89678786|NCT00475085|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
89678787|NCT00475085|Experimental|Arm II|Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
89678788|NCT00475085|Active Comparator|Arm III|Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
89678789|NCT00475085|Experimental|Arm IV|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
89678790|NCT00551707|Experimental|CRx-102 (2.7/180)|CRx-102 dose 1 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM titration dose (days 0-13) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM
89678791|NCT00551707|Experimental|CRx-102 (2.7/360)|CRx-102 Dose 2 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 360 mg dipyridamole administered as 1.8 mg prednisolone plus 180 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM
89678792|NCT00551707|Active Comparator|Prednisolone|treatment dose ( days 0-98) total daily dose of 2.7 mg prednisolone administered as 1.8 mg prednisolone at 8 AM and 0.9 mg prednisolone at 1 PM
89678793|NCT00551707|Active Comparator|Dipyridamole|total daily dose during treatment period (days 14-98) 360 mg dipyridamole administered as 180 mg dipyridamole at 8 AM and and 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 90 mg dipyridamole administered 45 mg dipyridamole at 8 AM and 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 180 mg dipyridamole administered as 90 mg dipyridamole at 8 AM and 90 mg dipyridamole at 1 PM
89678794|NCT00551707|Placebo Comparator|Placebo|placebo administered twice per day at 8 AM and 1 PM
89678795|NCT04193930|Other|Soft ovarian stimulation protocol|
89678796|NCT04193930|Other|conventional ovarian stimulation protocol|
89678797|NCT04028648||elderly|150 elderlies (>60 years): community dwelling or living in old
89678798|NCT00445211|Active Comparator|Intra-Aortic balloon Pump with Heparin|Intra-Aortic Balloon Pump (IABP) with Heparin
89678799|NCT00445211|Active Comparator|Intra-Aortic balloon Pump without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin
89678800|NCT04193852|Experimental|Dienogest and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
89678801|NCT04193852|Active Comparator|Dienogest and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water and in a fasting condition.
89678802|NCT03023072||Phase 1|Subjects will use the incontinence pad with incontinence detection notifications turned on
89678803|NCT03023072||Phase 2|Subjects will use the incontinence pad with incontinence notification turned off
89678804|NCT00552409|Experimental|Cholecalciferol|
89678805|NCT00552409|Placebo Comparator|Placebo|
89678806|NCT04028180|Experimental|Midge Repellency|Treatment of forearm with insect repellent and exposure to midges every 1 hour for 12 hours
89678807|NCT03830515|Experimental|Closure of lacerations with microMend|Laceration closure with microMend
89678808|NCT05559151|Experimental|experimental group (group R)|The experimental group (group R) received target controlled infusion of remimazolam benzenesulfonate, and the BIS value was controlled at 50±5.
89678809|NCT05559151|Placebo Comparator|the control group (group P)|the control group (group P) received target controlled infusion of propofol, and the BIS value was controlled at 50±5.
89678810|NCT04193618|Experimental|Conservative surgery for placenta accretta|
89678811|NCT04027244||Primary cohort|Any patient presenting to the Leicester Vascular Institute with SLI during the 2 year recruitment period (minimum 420 patients).
89678812|NCT04027244||Frailty & cognitive additional assessments|Any patient recruited to the primary cohort aged ≥65 years and undergoing an intervention for SLI (minimum 150 patients, target 210 patients).
89678813|NCT04027244||Cardiac MRI additional assessments|Any patient recruited to the primary cohort, with capacity to consent and undergoing an intervention for SLI (minimum 100 patients).
89678814|NCT04027244||Biomarkers additional assessments|Any patient recruited to the primary cohort and undergoing an intervention for SLI (no target recruitment set).
89678815|NCT04027244||Historical cohort|Retrospectively identified cohort of patients presenting to the study site with SLI between 2013 -15 (target 420).
89678816|NCT00553735|Active Comparator|Cyclosporine A 0.05%|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
89678817|NCT00553735|Placebo Comparator|Artificial Tear|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
89678818|NCT04023968|Experimental|YESplus workshop|Your Enlightened Side, plus more (YESplus) is an four-day, 15-hour integrative life skills workshop with a strong emphasis on breathing techniques and social connectedness. In addition to specific contemplative techniques such as yoga, mindfulness meditation, and compassion meditation that help cultivate inner peace, YESplus incorporates discussions and other activities to facilitate social connectedness, leadership, and community service. During the workshop, participants have ample time to learn and practice the Sudarshan Kriya Yoga (SKY) technique, as well as to ask questions. SKY has four sequential, form- and rhythm-specific breathing components interspersed with normal breathing while sitting in a relaxed position with eyes closed, followed by Yoga Nidra. A certified instructor with a minimum of 1,000 hours of SKY instruction training will lead each workshop.
89678819|NCT04023968|Active Comparator|WOW! workshop|"A comparison workshop titled Wisdom On Wellness (WOW!) will be implemented to control for potential expectancy effects, time commitment, group-based interactions, and wisdom/knowledge of YESplus that is anticipated to have beneficial effects on stress management and well-being, allowing for more rigorous evaluation of the contemplative practices and other activities unique to the YESplus workshop. This workshop differs from YESplus due to the increased focus on cognitive approaches to conceptualizing and managing stress (e.g. thoughts about the past and future versus present moment), and absence of physical or somatic activities."
89678820|NCT04027166|Experimental|administration immediate|Methadone will be administered prior to study procedures
89678821|NCT04027166|Experimental|administration delayed|Methadone will be held for four hours until the end of all study procedures.
89678822|NCT05559073||Early referral to ablation within one year after first documented AF diagnosis|
89678823|NCT05559073||Delayed referral to ablation after one year after first documented AF diagnosis|
89678824|NCT04027088|Experimental|Immunonutrition|Oral nutritional supplement: hypercaloric and hyperproteic with immunonutrients: Arginine, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
89678825|NCT04027088|Placebo Comparator|Standard|Oral nutritional supplement: hypercaloric and hyperproteic without immunonutrients
89678826|NCT00543101|Active Comparator|Switch to DRV/r|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
89678827|NCT00543101|Active Comparator|Continue on Current Dual Boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and are followed for an additional 24 weeks
89678828|NCT00553969|Experimental|1|Coreg CR + lisinopril
89678829|NCT00553969|Experimental|2|Coreg CR + placebo
89678830|NCT00553969|Experimental|3|lisinopril + placebo
89678831|NCT00553969|Placebo Comparator|4|placebo + placebo
89678832|NCT03963986|Active Comparator|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
89678833|NCT03963986|No Intervention|STANDARD group|The STANDARD group participants dont receive an access to an online digital platform but they receive an adapted advice sheet.
89678834|NCT00475241|Experimental|Prolonged Exposure Therapy|Prolonged exposure therapy for PTSD
89678835|NCT00475241|Active Comparator|Present Centered Therapy|Present centered therapy for PTSD
89678836|NCT05533567|Experimental|Remimazolam group|"Induction of anesthesia Slowly injects remimazolam 0.4-0.6 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional remimazolam (0.05 mg/kg each time) is allowed. After the LoC, intravenous sufentanil 0.3 ~0.5ug/kg and cisatracurium besylate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~Maintenance of anesthesia remimazolam 0.4~1.2 mg/kg/h and remifentanil 0.1~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
89678837|NCT05533567|Active Comparator|Propofol group|"Induction of anesthesia Slowly injects propofol 2-4 mg/kg (about 1 min) until loss of consciousness (LoC), allowing additional propofol (0.5 mg/kg each time) if sedation is insufficient. after LoC, intravenous sufentanil 0.3 ~0.5ug/kg and cisatracurium besylate 0.1 mg/kg. after sufficient muscle relaxation and blood circulation stabilization, the tracheal tube was inserted under the sliding scope.~Maintenance of anesthesia propofol 4~10mg/kg/h and remifentanil 0.1~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
89678838|NCT03022604|Experimental|C4/Generation 4|12 grams of C4/Generation 4 Extreme
89678839|NCT03022604|Active Comparator|C450X|12 grams of C4X (150% of regular dose)
89678840|NCT03022604|Placebo Comparator|Placebo|12 grams of flavored dextrose
89678841|NCT04193540||ACE questionnaire|Every patient under mechanical ventilation (intubated or tracheotomized), with or without sedatives, able to communicate and alert (RASS -1 to +1), and not delirious (CAM-ICU negative) will be assessed by Johns Hopkins ACE questionnaire by a person not in charge of the patient.
89678842|NCT04026464|Active Comparator|Ibuprofen+Acetaminophen Group|Infants with PDA randomized to the combined treatment group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) and oral acetaminophen (15 mg/kg oral acetaminophen [160 mg/5ml concentration] every 6 hours for a total of 12 doses).
89678843|NCT04026464|Placebo Comparator|Ibuprofen Group|Infants with PDA randomized to the control mono therapy group receiving intravenous ibuprofen (10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently) alone.
89678844|NCT00554671|Experimental|Pharmacist-led Group Visits|Algorithm driven medication titration, Behavioral: Monitoring, Behavioral: Group support, Behavioral: Self efficacy
89678845|NCT00554671|No Intervention|Usual Care|Patient continues on usual care for diabetes
89678846|NCT04192838|Experimental|LVHR|Laparoscopic incisional ventral hernia repair
89678847|NCT04192838|Active Comparator|OVHR|Open incisional ventral hernia repair
89678848|NCT00554749|Other|1 Behavioral intervention|Behavioral intervention in all seven subjects Weekly sessions in the home and the kindergarten using defocused communication and stimulus fading interventions
89050625|NCT01601171||Patients|"Patients with reproductive disorders with or without cleft lip/palate will be recruited for:~completion of medical questionnaire and review of medical records~family tree (including questions on reproductive disorders and cleft lip/palate)~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~smell testing~hearing test~bone density~brain MRI~kidney, testicular/ovarian ultrasound"
89678849|NCT03022214|Experimental|Placebo|5 capsules of placebo (microcrystalline cellulose) taken once in the morning with breakfast and once in the evening with dinner for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal
89050626|NCT01601171||Family members|"Family members of Patients will be recruited for:~completion of medical questionnaire~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~smell testing"
89678850|NCT03022214|Experimental|Intervention|"For presentation to volunteers, the daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~EnduraCell broccoli sprout powder: 3 capsules~Bulk Powders Green tea extract: 1 capsule~Bulk Powders Cinnamon Bark Extract: 1 capsule to be taken for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal"
89678851|NCT04192916||MPN patients treated with DOACs|
89678852|NCT01797991|Active Comparator|Group A (dexamethasone per os)|"Dexamethasone 20 mg per os 12 hours and 6 hours before paclitaxel (form: opaque white capsules)~Matching placebo for dexamethasone IV (NaCl 0,9%) 30 minutes before paclitaxel"
89678853|NCT01797991|Experimental|Group B (dexamethasone IV)|"Dexamethasone 20 mg IV 30 minutes before paclitaxel~Matching placebo for dexamethasone per os (lactose capsule) 12 hours and 6 hours before paclitaxel (form: opaque white capsules)"
89678854|NCT05499247|Experimental|Single Arm|
89678855|NCT00475319|Placebo Comparator|Placebo|0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
89678856|NCT00475319|Experimental|1% OPC-12759 ophthalmic suspension|1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
89678857|NCT00475319|Experimental|2% OPC-12759 ophthalmic suspension|2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
89678858|NCT04026074|Experimental|Fentanyl i.v. (intravenously)|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
89678859|NCT04026074|Experimental|Remifentanil i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
89678860|NCT04026074|Experimental|Clonidine i.v.|Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)
89678861|NCT04026074|Experimental|EMLA salve|Patients will be administered the medication (salve) and additionally will be administered i.v. saline as placebo
89678862|NCT04026074|Placebo Comparator|Placebo|Patients will be administered i.v. placebo (0,9% NaCl) and placebo salve (skin protection salve)
89678863|NCT04026152|Experimental|Resistance training + Unified Protocol|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will also receive four weekly hour-long sessions with a therapist to learn cognitive-behavioural strategies to assist them with managing their anxiety when exercising. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up after they have completed the supervised portion of this study.
89678864|NCT04026152|Active Comparator|Resistance training|Participants randomly assigned to this condition will complete a resistance training program consisting of three weekly hour-long full body exercise sessions. Participants will be supported by a personal trainer for six exercise session during their first month of training and will complete the remaining six sessions during this month independently. Participants will then continue to exercise independently following this first month of intervention. Participants will fill out weekly self-report measures (~20 minutes each time) via the internet during their first four weeks of study participation and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up after they have completed the supervised portion of this study.
89678865|NCT04026152|No Intervention|Waitlist|Participants randomly assigned to this condition will maintain their usual physical activity and exercise routine and not engage in any additional exercise than they were prior to the study. These participants will fill out questionnaires (~20 minutes each time) following randomization into this condition, once per week for four weeks, and at 1-week, 1-month, and 3-months (~20 minutes each time) follow-up. After completing the last follow-up, participants in the waitlist condition will be re-randomized into either the resistance training only or resistance training + Unified Protocol conditions.
89678866|NCT00555997|Active Comparator|1|Patients in group 1 will receive Ziprasidone for the full 12 weeks of the study.
89050627|NCT04599699|Experimental|1|"Simultaneously integrated boost or sequential integrated boost~Simultaneously integrated boost Prostate tumor: starting dose 8.7 Gy per fraction in 5 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy.~Sequential integrated boost Prostate tumor: starting dose 7.25 Gy per fraction in 6 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy."
89050628|NCT04599114|Experimental|VIRTUES Arm|Patients in the VIRTUES arm will be offered enrollment into the virtual atrial fibrillation care platform.
89050629|NCT04599426|Experimental|Test Group|10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.
89050630|NCT04607499||Pregnant women|Pregnant women without intervention
89678867|NCT00555997|Active Comparator|2|Patients in Group 2 will receive placebo for the first 6 weeks of the study, then will receive Ziprasidone for the last 6 weeks.
89678868|NCT00555997|Placebo Comparator|3|Patients in Group 3 will receive placebo for the full 12 weeks of the study.
89678869|NCT00475787|Experimental|Spinal Manipulative therapy|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
89678870|NCT00475787|Sham Comparator|Detuned Ultrasound|"Detuned Ultrasound involves utilizing an ultrasound machine that is set to 0 w/cm2 and US gel is applied to the spine for 11 minutes."
89678871|NCT04407026||Healthy|Healthy control group (n=25) consisted of the volunteers having clinically healthy gingiva, PD≤3 mm, BOP<10% and no sign of clinical attachment loss and radiographic alveolar bone destruction.
89678872|NCT04407026||Gingivitis|Gingivitis group (n=25) had PD≤3 mm with BOP>50% in the entire mouth, and no clinical attachment loss or alveolar bone loss.
89678873|NCT04407026||Stage 3 periodontitis|Stage 3 periodontitis group included the patients exhibiting PD ≥6 mm and interdental CAL ≥5 mm at %30 or more teeth. They had no more than four teeth loss.
89678874|NCT04406012|Active Comparator|block group|Paravertebral group at Thoracic 9-10 vertebrae level with an in-plane technique advanced ultrasound guided 10 ml bupivacaine hydrochloride (Marcaine 0.5%, Astra Zeneca) in 20 ml volume was enjected in the paravertebral area with real-time visualisation It was observed that the local anesthetic drug spread on the pleura and the pleura was pushed. All blocks were performed by the same experienced anaesthesiologist.
89050631|NCT04599348|Experimental|Active Ginseng treatment|People with CFS or Fibromyalgia will receive HRG 80 Red GInseng
89050632|NCT01516346|Active Comparator|Isosorbide dinitrate|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain placebo capsules.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
89215637|NCT06027866||Tracheostomy patients|All consenting participants will receive access to SRAVI (Speech Recognition Application for the Voice Impaired), a communication aid for speech-impaired patients. SRAVI is a software-based mobile application ('app') and can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). SRAVI has been registered with the Medical and Healthcare products Regulatory Agency (MHRA) and CE marked for intended use. SRAVI is based on Visual Speech Recognition (VSR) technology. Specifically, the LipRead technology can determine speech by analysing the movements of a user's lips as they speak into a camera.
89678875|NCT04406012|No Intervention|Control group|Conventional analgesia methods were applied to the control group. Control group was relieved by dexketoprofen 50mg intravenously. If the patient was not relieved with dexketoprofen and VAS score >4, tramadol 1 mg kg-1 was administered intravenously.
89678876|NCT00446147|Placebo Comparator|Placebo|one tablet twice per day, which is identical to pyridoxine
89678877|NCT00446147|Experimental|Pyridoxine|100 mg twice per day
89678878|NCT04357405||Experimental arm|This group consists of 100 EHPAD which will benefit from ECG teletransmission. all data will be collected
89678879|NCT04357405||Control arm|This arm consists of 50 EHPAD that have not benefited from ECG teletransmission. Only the global death occurrence data will be analyzed, no individual data will be collected.
89678880|NCT00476021|Experimental|Postplacental IUD insertion|immediate postplacental levonorgestrel-releasing IUD (Mirena) insertion
89678881|NCT00476021|Active Comparator|Delayed IUD insertion|delayed levonorgestrel-releasing IUD (Mirena) insertion (6-8 weeks after delivery)
89678882|NCT02704364|Experimental|NGM282 Dose 1|NGM282 Dose 1
89678883|NCT02704364|Experimental|NGM282 Dose 2|NGM282 Dose 2
89678884|NCT02704364|Active Comparator|Placebo|Placebo
89678885|NCT05457049||Undetectable MRD|Stage IB-IIIA NSCLC patients who after complete resection. And patients who maintain MRD negativity in two-round MRD landmark test (first in 3-7 days after surgery, second in 1 months ±7 days after surgery) will be enrolled. And patients will be under close dynamic monitoring at least two years.
89215638|NCT06027853|Experimental|CAR-NK cell therapy in Adult subjects with r/r AML|CAR-NK cell therapy in Adult subjects with r/r AML
89215639|NCT06027827||experimental group|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
89215640|NCT06027827||control group|Conventional bone grafting in the center of the fusion
89215641|NCT06027775||Chemotherapy plus Targeted therapy (CT)|The treatment decisions and evaluation of treatment outcomes, such as the assessment of metastases resectability and tumor response, were carried out by the multi-disciplinary team (MDT) comprising experts from each medical centers. In this cohort, initially unresectable colorectal cancer liver metastasis (CRLM) patients who were successfully converted and achieved no evidence of disease status were treated with chemotherapy plus targeted therapy, as adjuvant therapy.
89215642|NCT06027775||Chemotherapy Alone (CA)|In this cohort, initially unresectable colorectal cancer liver metastasis (CRLM) patients who were successfully converted and achieved no evidence of disease status were treated with chemotherapy, as adjuvant therapy.
89215643|NCT06027762||Single-Groupe|
89215644|NCT06027736|Experimental|Intervention group|
89215645|NCT06027736|No Intervention|Control group|
89215646|NCT06027710||Prefabricated allogeneic bone blocks|Group A: horizontal and/or vertical augmentation of Puros® allogeneic bone graft material (Zimmer Biomet, Winterthur, Switzerland) in the upper and/or lower jaw; type: conventional prefabricated bone blocks.
89215647|NCT06027710||CAD/CAM custom milled allogeneic bone blocks|- Group B: horizontal and/or vertical augmentation of allogeneic bone replacement material Puros® (Zimmer Biomet, Winterthur, Switzerland) in the upper and/or lower jaw; type: individually planned, CAD/CAM custom-produced bone blocks
89215648|NCT06027697||Subchondroplasty|"AccuFill Porous Bone Substitute Material (BSM) will be administrated to the patient during a subchondroplasty procedure (treatment visit).~During the inclusion visit and the follow-up visits (Week 3, Week 6; Month 3, Month 6, Month 12, Month 24, Month 36, Month 48) the doctor will proceed the usual clinical exam and the patients will fulfil the validated questionnaires and scales to assess pain, functional impairments and subjective improvement."
89215649|NCT06027658||Non participants|Individuals receiving the standard support for victims of sexual violence (e.g. medical, social, and legal assistance, individual psychotherapy)
89215650|NCT06027658||Participants|Individuals receiving the RECREATION program in addition to standard support for victims of sexual violence
89215651|NCT06027658||Long term participants|Individual receiving the RECREATION program for at least a month
89215652|NCT06027658||Professionals|Professionals associated with long term participants, working with them for standard support
89522607|NCT04069247|Experimental|E-based cognitive behavioral therapy for insomnia (eCBT-I)|The eCBT-I will be delivered by a mobile application (eSleep) developed by BestCare & SuMian BioTech Co., Ltd. which contains a digital, self-paced, and highly interactive programme. It consists of six weekly sessions with animated elements, including an overview of sleep, sleep restriction, stimulus control, cognitive therapy, structured worry time and relapse prevention. Participants will have access to the eCBT-I treatment for 12 weeks.
89522608|NCT04069247|Active Comparator|Health education (HE)|The HE, a psychoeducation/information-approach, also consists of six consecutive sessions which contains information about general sleep knowledge, functions of human organs, nutrition, environmental health, brain health, identification and treatments of common diseases, but the contents are not related to any active therapeutic components of cognitive behavioral therapy for insomnia (CBT-I).Participants will have access to the intervention for 12 weeks.
89522609|NCT03398473|Experimental|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial (SDV)
89522610|NCT03398473|Experimental|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial (MDV)
89522611|NCT04559035|Other|Betadine|"Intervention - twice-a-day nasal lavage Twice-a-day virucidal group: Participants randomized to betadine will receive 2 gallon jugs of distilled water, two NeilMed Sinus Irrigation bottles and 28 salination packets (with some extras), OR one Navage unit with 28 SaltPods (and some extras), and a cardboard receptacle labeled used saline containers to keep track of adherence.~Those randomized to receive betadine will also receive one bottle of povidone-iodine, a one-sheet instruction with photographs demonstrating how to add ½ tsp betadine in addition to the salination packet to the sinus irrigation bottle or Navage unit reservoir prior to SaltPod, along with a ½ tsp measuring spoon."
89522612|NCT04559035|Other|Baking Soda|"Twice-a-day alkalinized group: Participants randomized to alkalinization will receive 2 gallon jugs of distilled water, two Neilmed bottles with 28 saline packets, OR one Navage unit with 28 SaltPods, and a cardboard receptacle labeled used saline containers to keep track of adherence. Those randomized to alkalinization will also receive a box of baking soda, ½ tsp measuring spoon and instructions on how to add the baking soda."
89522613|NCT04535791|Experimental|cholecalciferol (Vitamin D)|cholecalciferol 4,000 IU orally daily (1 capsule) for 30 days
89522614|NCT04535791|Placebo Comparator|Starch|Starch 500 mg orally daily (1 capsule) for 30 days
89522615|NCT03395873|Experimental|Single arm|"Decitabine 20mg/m2 IV day 1-5, every 28 days~Avelumab 10mg/kg IV, day 1, every 14 days"
89522616|NCT04529629||primary aldosteronism|
89522617|NCT04529629||pheochromocytoma|
89522618|NCT04529629||adrenocortical carcinoma|
89522619|NCT03916835|Other|Music Therapy during cleaning care 1|"This group receives music therapy during cleaning care 1 and not during the cleaning care 2.~Each patient will act as their own control"
89522620|NCT03916835|Other|Music Therapy during cleaning care 2|"This group receives music therapy during cleaning care 2 and not during the cleaning care 1.~Each patient will act as their own control"
89522621|NCT04447625|Active Comparator|CE patients receiving OAA|Patients diagnosed with CE receiving the gold standard treatment of oral antibiotic administration (OAA)
89522622|NCT04447625|Experimental|CE patients receiving OAA and IAI|Patients diagnosed with CE receiving a combination of the gold standard treatment of oral antibiotic administration (OAA) and intrauterine antibiotic infusion (IAI)
89522623|NCT03392389|Experimental|mRNA-1653|
89522624|NCT03392389|Placebo Comparator|Placebo|
89215653|NCT06027593|Other|Prescribing Clinicians|During the pre-intervention period which will last up to approximately 24 months, investigators will retrospectively collect data on appropriate antibiotic prescribing for the conditions. In the post-intervention period of approximately 24 months, investigators will implement a provider-focused intervention, consisting of feedback reports to providers using the validated metrics of antibiotic prescribing. These measures are based on national guidelines for appropriate antibiotic prescribing. Following implementation of the intervention, the investigative team will collect the same measures.
89678886|NCT00447083|Experimental|UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with UV. The dose of UV (time of exposure) will be progressively increased from 3 minutes to 9 minutes over the 6 visits to acclimate subjects to UV light. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive UVB tanning bed treatment first, then switch to the non-UVB treatment.
89678887|NCT00447083|Placebo Comparator|Non-UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with non-UV bulbs. The time of exposure will be progressively increased from 3 minutes to 9 minutes over the 6 visits to mirror UVB treatment. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive non-UVB tanning bed treatment first, then switch to the UVB treatment.
89678888|NCT00447083|Experimental|UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of UVB.
89678889|NCT00447083|Placebo Comparator|Non-UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of non-UVB exposure
89678890|NCT04192682|Experimental|Anlotinib Combined With Sintilimab|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
89678891|NCT00556543|Other|Treatment|
89678892|NCT04192292|No Intervention|No Treatment|No change to participants standard care
89678893|NCT04192292|Experimental|Low dose sulphonylurea alone|Participants will be given a single dose of low dose sulphonylurea once daily for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily.
89678894|NCT04192292|Experimental|DPP4 inhibitor alone|Participants will be given a single dose of DPP4 inhibitor once daily for 14 days as a physiological stimulus. The DPP inhibitor given in this study will be sitagliption 100mg orally once daily.
89678895|NCT04192292|Experimental|Low dose sulphonylurea + DPP4 inhibitor|Participants will be given a single dose of low dose sulphonylurea once daily and a single dose of DPP4 inhibitor for 14 days as a physiological stimulus. The sulphonylurea given in this study will be gliclazide 20mg orally once daily and the DPP4 inhibitor will be sitagliptin orally100mg once daily.
89678896|NCT04025762|Experimental|Day and night hybrid closed loop control|"The day and night hybrid closed-loop system (CamAPS FX) will consist of:~Dana RS insulin pump (Sooil)~G6 real-time CGM sensor (Dexcom)~An unlocked android smartphone hosting the CamAPS FX app with Cambridge control algorithm"
89678897|NCT04025762|Active Comparator|Sensor augmented pump therapy|The comparator will consist of Dana RS insulin pump (Sooil) and G6 real-time CGM sensor (Dexcom)
89678898|NCT00448175|Experimental|Urgent PC treatment arm|
89678899|NCT04176835|Experimental|oxytocin|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
89678900|NCT04176835|Placebo Comparator|Placebo|Single-dose intranasal oxytocin or intranasal placebo administered in counterbalanced order
89678901|NCT00476645|Experimental|Fulvestrant|
89678902|NCT01846195|Sham Comparator|no blood draw|CM 1500 with no blood draw
89678903|NCT01846195|Active Comparator|blood draw|CM 1500 with blood draw
89678904|NCT04141202||Exercise group|
89678905|NCT04406402|Experimental|Acute glucose tolerance test|A standard oral glucose tolerance test (75 grams of dextrose in 180 cc of water)
89678906|NCT04406402|Experimental|Acute protein load test|A protein-rich, vanilla-flavored powder (Pro-gym, Telpharma, Is
89678907|NCT04406402|Experimental|Acute fat load test|a 100-gram portion of sweet cream containing 300 Kacls, of which 94% of the ingested calories were fat
89678908|NCT04406402|Experimental|Acute alcohol load test|Vodka (100 cc, 40% alcohol)
89678909|NCT04406402|Experimental|Acute exercise|30 minutes of supervised graded walking on a treadmill according to each subject's individual ability. A goal heart rate was calculated as 70% of the age-adjusted maximal allowable heart rate.
89678910|NCT04406402|Experimental|Lifestyle modification program - 12 weeks|12 weeks of weight-loss dietary program constructed according to the guidelines of the American Diabetes Association. Based on weight, gender, and age, daily dietary allowance varied at 1200-1800 Kcal, 50% carbohydrates, 20% protein, and 30% fat. Participants were also asked to engage in moderate physical activity comprised of a 40-minute walk three times a week. A weekly clinic visit alternating with a weekly telephone contact was also required.
89678911|NCT00477191|Experimental|Etanercept|Etanercept
89678912|NCT04025918|Experimental|vasopressor delivery automated system|vasopressor delivery automated system that administered phenylephrine and ephedrine based on data from continuous non-invasive hemodynamic monitor
89678913|NCT04025918|Active Comparator|manual vasopressor delivery|manual bolus that delivered phenylephrine and ephedrine based on data from non-invasive intermitted blood pressure monitor
89678914|NCT04406246|Experimental|Nitazoxanide early treatment|Health workers with symptoms of COVID-19 not requiring hospitalization will receive an early treatment with nitazoxanide.
89678915|NCT02115347|Experimental|Ertugliflozin 15 mg - Moderate Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
89678916|NCT02115347|Other|Ertugliflozin 15 mg - Healthy Participants|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
89678917|NCT02115347|Experimental|Ertugliflozin 15 mg - Mild Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
89678918|NCT01798147|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
89678919|NCT01798147|Experimental|SIRT|Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres)
89050633|NCT01516346|Active Comparator|Isosorbide dinitrate + Hydralazine|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain the active ingredient Hydralazine.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks.~Dosage of Hydralazine will be 37.5mg (if Stage 1) OR 75mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
89050634|NCT01516346|Placebo Comparator|Placebo|"Research pharmacy-formulated capsules will be given to subjects in two bottles. For this interventional arm, both the bottles will contain placebo capsules.~Dosage will be same regardless of up-titration from Stage 1 dosing to Stage 2 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
89050635|NCT04607304|Experimental|ABCA2 GIRMS|Leftover breath samples analyzed on ABCA2 GIRMS systems, order of analysis randomized
89050636|NCT04599387|Active Comparator|Supervised Exercise arm|
89050637|NCT04599387|Placebo Comparator|Usual care arm|
89050638|NCT01303796|Experimental|Sapacitabine-decitabine alternating|Arm A sapacitabine administered in alternating cycles with decitabine
89678920|NCT04025450|Experimental|Chidamide plus VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
89678921|NCT04025450|Active Comparator|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
89050639|NCT01303796|Active Comparator|Decitabine|Arm C Decitabine
89678922|NCT04024982|Other|Lecture followed by Simulation|Subjects will undergo the lecture on TEE first followed by the simulation session.
89678923|NCT04024982|Other|Simulation followed by Lecture|Subjects will undergo the TEE simulation first followed by the lecture.
89050640|NCT04607187||Normals, Dupuytren's subjects with and without treatment|Ultrasound analysis of patient receiving treatment for Dupuytren's
89050641|NCT04598880|Experimental|Pleinvue|Subjects receive polyethylene glycol + ascorbate (PEG1A) as laxative treatment for colonoscopy preparation.
89678924|NCT02115581|Experimental|Coenzyme Q10|"Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects."
89678925|NCT02115581|Placebo Comparator|Placebo|known cases of idiopathic dilated cardiomyopathy who received placebo
89678926|NCT04192058|Sham Comparator|sham tDCS|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
89678927|NCT04192058|Experimental|active tDCS|The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively.
89678928|NCT04191902||1|control
89678929|NCT04191902||2|treated
89678930|NCT04191980||Patients with a MRI on a 3 Tesla (T) unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 3T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
89678931|NCT04191980||Patients with a MRI on a 1.5 Tesla unit|The total validation cohort is composed of axial T2-weighted images of the prostate obtained from 31 prostate MRIs on a 1.5T unit randomly chosen among the prostate MRIs performed at the Hospices Civils de Lyon in 20162015-2019
89050642|NCT04598880|Experimental|Citrafleet|Subjects receive sodium picosulfate + magnesium citrate (PSCM) as laxative treatment for colonoscopy preparation.
89050643|NCT04598958|Experimental|IMPROVE|A cluster of 6 health facilities are to receive the IMPROVE Intervention. The IMPROVE intervention includes: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees with particular attention to HIV-positive women to minimize loss to follow-up.
89050644|NCT04598958|No Intervention|Standard of care|A cluster of 6 health facilities receive Standard of Care. Routine health facility services offering the national standard of care for pregnant and breastfeeding women in Lesotho
89050645|NCT04607655|Experimental|Oral GB1211, 100 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
89050646|NCT04607655|Experimental|Oral GB1211, 10 mg, twice a day|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
89050647|NCT04607655|Placebo Comparator|Oral GB1211, Placebo, twice a day|Placebo is administered as inhalation once a day
89678932|NCT00477659|Experimental|Donepezil hydrochloride|
89678933|NCT04033627|Experimental|In Vitro T cell depletion|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
89678934|NCT04191278|Active Comparator|Varenicline|An α4β2 nicotinic acetylcholine receptor partial agonist
89678935|NCT04191278|Experimental|Varenicline + mobile app|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications
89678936|NCT04191278|Experimental|Varenicline + mobile app + contingency management|An α4β2 nicotinic acetylcholine receptor partial agonist + a mobile phone application designed to improve adherence to medications + monetary reinforcers for being adherent to medication
89678937|NCT04141046|Sham Comparator|Sham Stimulation|This is a sham/placebo arm that receives some stimulation, mimicking the skin sensations associated with tACS to enhance success of patient blinding.
89678938|NCT04141046|Active Comparator|Theta-tACS|This arm targets theta oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
89678939|NCT04141046|Experimental|Alpha-tACS|This arm targets alpha oscillations in the somatosensory cortex to see if there is a decrease in the experience of depression, pain, or brain fog in lupus patients.
89678940|NCT04148534|Active Comparator|muscle relaxant|patient who will receive muscle relaxant, patients will receive rocronium infusion by (5 mcg/kg/min) , maintain partial NMB TOF count 2 and targeting BIS = (40-60)
89678941|NCT04148534|Placebo Comparator|without muscle relaxant|patient who will not receive muscle relaxant, will recieve normal saline targeting BIS = 40-60.
89678942|NCT04388527|Experimental|Treatment|Penn COVID-19 convalescent plasma
89678943|NCT04747964|Experimental|A single lowest dose of treatment group|
89678944|NCT04747964|Experimental|A single low dose of treatment group|
89678945|NCT04747964|Experimental|A single intermediate dose of treatment group|
89678946|NCT04747964|Experimental|A single high dose of treatment group|
89678947|NCT04747964|Experimental|A single highest dose of treatment group|
89678948|NCT04190966|Active Comparator|Integrated smoking cessation|Integrated smoking cessation delivered by trained health-care practitioners in the thoracic surgical pathway: a three part package of behaviour interventions and pharmacotherapy as per NICE/NCSCT guidance which is supported by an adjunct web-based application.
89678949|NCT04190966|No Intervention|Usual care smoking cessation|Usual care of standard community/hospital based NHS smoking cessation.
89678950|NCT03988387|Experimental|Peer Support PS)|Participants randomized to the PS arm will be assigned a trained peer supporter (PSr) to enhance adherence to PrEP.
89678951|NCT03988387|Experimental|Reminders and Resource Transfer (RRT)|Participants randomized to the RRT arm will receive weekly SMS text messages and resource transfers to enhance adherence to PrEP.
89678952|NCT04145414|Experimental|Cerebral magnetic resonance imaging x2|Cerebral MRI performed at enrolment visit and at +6 weeks (maximum)
89678953|NCT05308303||All cause OHCA|
89678954|NCT05308303||OHCA of non-cardiac origin|
89678955|NCT03748082|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
89678956|NCT03748082|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
89678957|NCT00478361|Experimental|Gemcitabine, Paclitaxel and Doxorubicin|Paclitaxel 135 mg/m^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m^2 IV over 90 min; Doxorubicin 40 mg/m^2 IV over 20 min; treatment may repeat every 2 weeks for up to nine courses. Injection of Pegfilgrastim on day 1.
89678958|NCT02129725|Experimental|sildenafil citrate|In the parent study, subjects are randomized to sildenafil 25 mg tid.
89678959|NCT02129725|Placebo Comparator|placebo oral capsule|In the parent study, subjects are randomized to matching placebo
89678960|NCT04766372|Experimental|Menu of physical activity options|"Participants in all 4 groups will receive this booklet with suggestions of ways to be physically active, e.g. YouTube workouts, cycling or jogging, sports, or design their own using a home-based exercise booklet. Participants are asked to do 3 exercise sessions of 30 minutes per week. Participants are asked to record what activity they did and the duration of the session using a method most convenient for them, e.g. notes on their phone, wall calendar or using an activity log template which we will provide.~."
89678961|NCT04766372|Experimental|Physical activity programme|Participants in the second group with receive the activity menu (as described above) as well as a detailed physical activity programme. This programme includes supportive weekly text messages, access to live workouts and access to an online social community.
89678962|NCT04766372|Experimental|Individual behaviour change support|"Participants in the third group with receive the activity menu (as described above) as well as individual behaviour change support. Each participant is partnered with a trainee sport psychology (Activity Mentor) who they have weekly video calls with to support their health behaviour change."
89678963|NCT04766372|Experimental|Activity Programme & Behaviour Change Support|Participants in the fourth group will receive all of the above (exercise menu, live workouts, social community, support texts and weekly calls with an Activity Mentor).
89678964|NCT05622487|Active Comparator|Neural Therapy|Segmental neural therapy will be administered with intradermal 0.5% lidocaine from cervical 1st to sacral 1st vertebra and upper trapezius region with quaddel injections.. Sham kinesio taping will be applied to the bilateral arms of the patients. Home exercise program; trapezius stretching, cervical, thoracic and lumbar paravertebral muscle stretching exercises will be required to be performed 10 times and every day.
89678965|NCT05622487|Active Comparator|Kinesio Taping|Kinesio taping will be applied with muscle inhibition technique by stretching from the origin to the insertion of the upper trapezius, cervical thoracic and lumbar paravertebral muscles. Sham neural therapy will be applied to the bilateral arms of the patients. Home exercise program; trapezius stretching, cervical, thoracic and lumbar paravertebral muscle stretching exercises will be required to be performed 10 times and every day.
89678966|NCT04024592|Experimental|children|
89678967|NCT03901183|Experimental|Interventional|Participants receive a 8 week nutritional counseling with weekly group meetings to establish a plant-based diet.
89678968|NCT03901183|No Intervention|Control|Waiting list. Participants receive no intervention during study period, equal intervention is offered after the end of study.
89678969|NCT04024748||Patients already scheduled for a FDG test|Subjects will be selected from patients already scheduled for a routine FDG PET/CT test. Only adult patients, 40 years old or older, capable of providing their informed consent, will be selected. Any adult female patients that are pregnant and/or could become pregnant will be excluded. Twenty patients will be recruited.
89678970|NCT04024826|Experimental|Early Follicular Phase (EFP)|This group is comprised of participants at the Early Follicular Phase (EFP) of the menstrual cycle.
89678971|NCT04024826|Experimental|Late Follicular Phase|This group is comprised of participants at the Late Follicular Phase (LFP) of the menstrual cycle.
89215654|NCT06027593|No Intervention|Patients diagnosed with conditions of interest during study period|Interactions between investigators and patients will be limited to review of existing EHR data. Investigators will have no direct contact with patients. The data from the University of Pennsylvania Health System (UPHS) and Children's Hospital of Philadelphia (CHOP) will be extracted from data warehouses that store data from the electronic health record. These data will be used in feedback report generation as well as in outcome assessment. An estimated total of 10,000 inpatients with CAP (adult and pediatric) will be recruited. Similarly, about 500,000 patients (adult pharyngitis and pediatric acute otitis media combined) will be recruited in the outpatient setting.
89678972|NCT04024826|Experimental|Early Luteal Phase|This group is comprised of participants at the Early Luteal Phase (ELP) of the menstrual cycle.
89678973|NCT04024826|Experimental|Late Luteal Phase|This group is comprised of participants at the Late Luteal Phase(LLP) of the menstrual cycle.
89678974|NCT00483509|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
89678975|NCT03049553|Other|HPV-test|Cobas HPV-DNA test is performed on the cervical sample in addition to the routine cytology
89678976|NCT03049553|No Intervention|Routine|Screening with cytology as usual in the cervical screening program
89678977|NCT03864211|Active Comparator|Toripalimab monotherapy|Toripalimab is administrated intravenously (240mg, Q3W) continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
89678978|NCT03864211|Experimental|Thermal ablation plus toripalimab|One to five target lesions will be ablated completely. Toripalimab therapy will be initiated on day 3 or day 14 after ablation ((240mg, Q3W) ). Toripalimab is administrated continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
89678979|NCT02938403|Experimental|In vivo group|Those who receive in vivo counseling and Nicotine Replacement Therapy (NRT)
89678980|NCT02938403|Active Comparator|Controls|Standard smoking cessation counseling and Nicotine Replacement Therapy (NRT)
89678981|NCT03842839|Experimental|Tiotropium (0-12 month) + SABA as needed|"During the 2 years treatment phase patients will be administered with tiotropium bromide (Spiriva) capsule 18μg once daily from baseline to the 12th months.~Any long acting bronchodilator will not be used from the 12 to 24 months.~Salbutamol sulphate aerosol (Ventolin) will be administered as concomitant medication treatment when exacerbation occurs."
89678982|NCT03842839|Experimental|Tiotropium (0-24 month) + SABA as needed|"During the 2 years treatment phase patients will be administered with tiotropium bromide (Spiriva) capsule 18μg once daily from baseline to the 24th months.~Salbutamol sulphate aerosol (Ventolin) will be administered as concomitant medication treatment when exacerbation occurs."
89678983|NCT03842839|Other|SABA as needed only|"During the 2 years treatment phase patients will be administered with salbutamol sulphate aerosol (Ventolin) when exacerbation occurs.~Any long acting bronchodilator will not be used during the 2 years treatment phase."
89678984|NCT04190576|Experimental|Minimally invasive ridge augmentation with LLLT|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) and low-level laser therapy
89678985|NCT04190576|Active Comparator|Minimally invasive ridge augmentation|Subperiosteal minimally invasive aesthetic ridge augmentation with G- Bone (Bone Graft) alone
89678986|NCT05295043|Experimental|HR+/HER2- advanced breast cancer patients receiving CDK4/6 inhibitor combined with endocrine therapy|According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
89678987|NCT04190732|Experimental|Physician phone call|Participants will receive a five-minute phone call from one physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will not have access to patient specific IVF cycle details. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation.
89678988|NCT04190732|No Intervention|Routine care|Participants will receive routine care and no physician phone call will be performed during the waiting period between embryo transfer and the pregnancy test.
89678989|NCT03839563|Experimental|Conventional exercise|This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months. Each session will last 60 min.
89678990|NCT03839563|Experimental|Tai chi chuan|The 8-form Yang-style tai chi chuan intervention will take place at a subject's residence or in the neighborhood once a week for 6 months, and each session will last 60 min.
89678991|NCT03839563|No Intervention|Health education/usual physical activity|After the baseline, the case manager will visit subjects in this group once for comparability with the other two intervention groups and instruct them to maintain their usual physical activity.
89678992|NCT01796405|Experimental|Low-Risk|Multifocal or Low-Risk Multi System Clofarabine, Low Dose, Two Cycles
89678993|NCT01796405|Experimental|High-Risk|High-risk Multi System Clofarabine, Standard Dose, Two Cycles
89678994|NCT04190810|Experimental|Inhibition group|The inhibition group gets the instructions to respond to pictures that are not related to smoking by swiping/pulling them towards themselves, whereas pictures with tobacco-related content shall be ignored. Up on pulling the pictures successively enlarge, whereas they shrink when ignored and slowly fade out.
89678995|NCT04190810|Experimental|Classical AAT group|The classical AAT group is provided with a tablet on which an explicit AAT training is installed. Thus, just as participants in the inhibition group, participants are instructed to react upon non-smoking related images by swiping/pulling towards themselves the picture. Pictures containing tobacco-related content shall be pushed away. Up on pulling pictures enlarge and up on pushing they shrink until they fade out.
89215655|NCT06027580||SPIO group|Standard Care Therapy option 1: parents may self-select this standard care combined option of therapy and use of SPIO® Core-MAX® Expedition thoracolumbosacral orthosis
89678996|NCT04190810|Sham Comparator|Control group|This type of active control group receives the instructions to swipe tobacco-related pictures to the left and non-tobacco related pictures to the right (or vice versa depending on the sequential counterbalancing procedure).
89678997|NCT04190654|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment (Child-Pugh class A score of 5 or 6)
89678998|NCT04190654|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment (Child-Pugh class B score of 7 to 9)
89678999|NCT04190654|Experimental|Healthy Subjects|Healthy adults matched with the subjects in Group A and Group B at 1:1 for age (± 10 years), sex, and BMI (± 20%)
89679000|NCT04190264|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
89679001|NCT04190264|Active Comparator|Cold Water Immersion|Participants, following exercise-induced hyperthermia, will be cooled using cold water immersion. Participants will be immersed up to their chest in cold water (~50-55 Degrees Fahrenheit).
89679002|NCT04190264|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
89679003|NCT03649321|Experimental|Phase 1b|bemcentinib 200 mg oral daily every 21 days. Nab-paclitaxel 100 mg/m^2 Day 1 /8 every 21 days. Gemcitabine 800 mg/m^2 Day 1 /8 every 21 days. Cisplatin 25 mg/m^2 Day 1 /8 every 21 days.
89679004|NCT03649321|Experimental|Phase 2|bemcentinib 200 mg oral daily every 28 days. Nab-paclitaxel 125 mg/m^2 Day 1 /8 /15 every 28 days. Gemcitabine 1000 mg/m^2 Day 1 /8 /15 every 28 days.
89679005|NCT04190108||Case patients|All consecutive, new patients older than 18 years with PsA (CASPAR criteria) at onset observed over 3-year period, who had any abdominal symptoms.
89679006|NCT04190108||Controls|All consecutive new patients meeting the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) at onset.
89679007|NCT04149704|Experimental|ACP video decision aid|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.~In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care~10 minute video decision aid: describing the goals-of-care options .~Follow telephone interview at 3 months"
89679008|NCT04149704|Active Comparator|Standard Care|"The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits.~In-person interview where the patient and caregiver together will randomized to either the video aid intervention or standard care~Receive the verbal description of the three types of care~Follow telephone interview at 3 months"
89679009|NCT03347071||Prevention Course Group|The Prevention Course Group is composed of female student-athletes enrolled in the 7-week prevention course. The course occurs once a week (1 hour, 40 minute sessions) for a total of 7-weeks during the academic semester. Approximately 1 hour of each class session is lecture based, leaving 40 minutes for yoga practice administered by a certified yoga instructor. The course instructor is certified in Eat Breathe Thrive Program delivery. The course teaching assistant is certified in yoga instruction.
89679010|NCT03347071||Control Group|The Control Group is composed of female student-athletes not enrolled in the 7-week prevention course. Female student-athletes in this group will not be enrolled in the course during the period of data collection, nor will they have previously completed the course.
89679011|NCT04190888||Sickle Cell Disease|Patients with sickle cell disease will be followed prospectively
89679012|NCT04149938|Experimental|Lidocaine Patch (Sequence AB)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours.
89679013|NCT04149938|Experimental|Lidocaine Patch (Sequence BA)|Subjects received all study treatments: ZTlido and Lidoderm. On Day 1 (Period 1), three Lidoderm lidocaine patches were applied to the skin on the back for 12 hours. On Day 8 (Period 2), three ZTlido lidocaine topical systems were applied to the skin on the back for 12 hours.
89679014|NCT01797601|Active Comparator|Human Insulin|Nasal spray
89679015|NCT01797601|Placebo Comparator|Placebo solution|Nasal spray
89679016|NCT02984930|Experimental|PPI + mosapride group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
89679017|NCT02984930|Placebo Comparator|PPI + placebo group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus placebo drug of mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
89679018|NCT04149548||pregnant diabetic women|Fetal Ultrasound to diabetic pregnant women
89679019|NCT04149548||non diabetic pregnant women|Fetal ultrasound to non diabetic pregnant women
89679020|NCT02123017|Experimental|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams of crystalline lactulose x three doses
89679021|NCT02123017|Experimental|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams of crystalline lactulose x three doses
89679022|NCT02123017|Experimental|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams of crystalline lactulose x three doses
89679023|NCT04149626|Active Comparator|Group A|Dexmedetomidine sedation
89679024|NCT04149626|Active Comparator|Group B|Midazolam sedation
89679025|NCT04149626|Active Comparator|Group C|Remifentanil sedation
89679026|NCT04149392|Experimental|CGM intervention|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge which will be downloaded at their outpatient follow up clinic visit 6-14 days later. At the follow-up visit medications may be modified based on downloaded glucose data. During the already scheduled post-discharge follow up appointment the CGM sensor data will be downloaded by clinic staff. The diabetes medications will be reconciled and the downloaded data will be reviewed with the patient. Based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
89679027|NCT00486863|Placebo Comparator|Control|Placebo at 12-16 weeks gestation.
89679028|NCT00486863|Experimental|Praziquantel|Praziquantel at 12-16 weeks gestation.
89215656|NCT06027580||Control group|Standard Care Therapy option 2: parents may self-select this standard care option of therapy alone
89679029|NCT02123329|Active Comparator|Control arm|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
89679030|NCT02123329|Experimental|Intervention arm|Participants assigned to the intervention arm will participate in a face-to-face 4-session program at the pharmacy delivered by the study pharmacist at 2-4-week intervals over 8 weeks in addition to nicotine replacement therapy. The sessions will be set at a date and time that is convenient for both the pharmacist and the participant. The pharmacist will deliver the program at a time different from his or her pharmacy duty regular time.
89679031|NCT04148924||Patients|Anyone who is hospitalized in the palliative care service of the Lyon Sud Hospital Center.
89679032|NCT04148924||Doctors|Doctors taking care of patients in the study will be solicited by the research nurse or a study investigator.
89679033|NCT04148924||Nurses|Nurses taking care of patients in the study will be solicited by the research nurse or a study investigator.
89679034|NCT04148924||Caregivers|Caregivers taking care of patients in the study will be solicited by the research nurse or a study investigator.
89679035|NCT05622175|Experimental|Drug: F8IL10|"Overall, 32 patients will participate in case no DLT would occur.~In the standard 3+3 dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of F8IL10 (from 0.5 to 10 mg) in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 3 patients with escalating doses of F8IL10 until the MAD is reached and won't exceed 10 mg dose level. In case a DLT would be detected, further 3 patients will be enrolled for that cohort in order to confirm the MAD or to proceed with the next dose level. Therefore, up to 30 patients could be enrolled in the dose escalation part.~Following successful identification of the RD, the study will proceed with a dose expansion part and 20 patients will be treated at the RD dose level (patients treated at the RD in the course of the dose escalation phase will contribute to the total sample size)."
89679036|NCT01798069|Experimental|Behavioral intervention|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
89679037|NCT01798069|Active Comparator|behavoral intervention|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading medical publication workshops. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
89679038|NCT04149158|Placebo Comparator|Placebo|
89679039|NCT04149158|Experimental|Verum|Sinetrol® Xpur
89679040|NCT04149080|Experimental|SIM Group|Alveolar socket post-extraction filled with Simvastatin covered with polypropylene membrane
89679041|NCT04149080|Placebo Comparator|Control Group|Alveolar socket post-extraction covered with polypropylene membrane
89679042|NCT04148768|Active Comparator|Inferential therapy|Interferential therapy will be given using 4 electrode methods. The 'medium frequency' currents (medium frequency in electromedical terms is usually considered to be 1KHz-100KHz). These medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross & they literally interfere with each other. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation. Pre-Post Y balance test will be used after 4 sessions to measure the improvement in balance in the population
89679043|NCT04148768|Active Comparator|Shortwave diathermy|4 sessions of treatment will be given to the participants with SWD. Pre-post Y balance test will be used to measure balance in the population
89679044|NCT04023500|Active Comparator|Motivational interview|The MI-intervention is used as a part of normal dental hygienist appointment. Dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients. Dental hygienist support patients in decision making although patients were addressed as an active agent.
89679045|NCT04023500|Active Comparator|Prevailing education|In control group prevailing, more professional-centered education is used. Dental hygienist define patients educational needs and give direct instructions how to change behaviour and self-care.
89679046|NCT02123485|Experimental|low frequency rTMS|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week
89679047|NCT02123485|Sham Comparator|Sham-rTMS|Sham right prefrontal rTMS 2 times a week
89679048|NCT04023344|Active Comparator|Humalog® Mix 25|Insulin Humalog® Mix 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
89679049|NCT04023344|Experimental|Insulin Lispro Biphasic 25|Insulin Lispro Biphasic 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
89679050|NCT03932552|Active Comparator|Control|Personalized nutritional therapy
89679051|NCT03932552|Experimental|Exercise|Aerobic exercise + Personalized nutritional therapy
89679052|NCT03931616|Experimental|STEMO deployment|STEMOs are specialized stroke ambulances providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
89679053|NCT03931616|Active Comparator|Regular care|Regular prehospital care consists of normal ambulance care. In suspected life-threatening cases, an emergency physician is sent to the emergency scene in parallel.
89679054|NCT02761837|Active Comparator|IVR call/text|Identify gaps in care and contact patients by IVR phone call or text
89679055|NCT02761837|Active Comparator|Email|Identify gaps in care and contact patients by email
89679056|NCT00452543|Experimental|Escitalopram plus acamprosate|
89679057|NCT00452543|Placebo Comparator|Escitalopram plus placebo|
89679058|NCT04148690|Experimental|Group ANC Intervention|Clinics in the group ANC intervention arm offer group Antenatal Care to women who present for their initial visit prior to 24 weeks provided that they intend to remain in the area for the duration of the pregnancy, and agree to participate in GANC. Women not enrolled in group ANC will receive standard ANC per ministry of health protocols.
89679059|NCT04148690|Active Comparator|Routine ANC|Clinics will offer only standard ANC per ministry of health protocols.
89679060|NCT04990375|Sham Comparator|Early relapse (2-week follow-up)|We compare 5 sessions of active tDCS (2 mA) vs. 5 sessions of sham tDCS (0 mA) to observe if tDCS can reduce early relapse (2-week follow-up). The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
89679061|NCT04990375|Experimental|Craving|We compare scored craving before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
89679062|NCT04990375|Experimental|Working memory|We compare reverse memory span before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
89679063|NCT04990375|Experimental|Depressive symptoms|We compare scored BDI-II before and after 5 sessions of either active (2mA) or sham (0mA) tDCS. The tDCS is applied during 20 minutes while the patient is watching a documentary about nature. For both active and sham tDCS there is 15-second ramping up and down.
89679064|NCT04023032|Experimental|multicomponent cognitive intervention|
89679065|NCT04961359|Experimental|Population Ⅰ|Population Ⅰ has 20 subjects aged 12 to 17 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅠis intramuscular injection of deltoid muscle of upper arm with vaccine.
89679066|NCT04961359|Placebo Comparator|Population Ⅱ|Population Ⅱ has 5 subjects aged 12 to 17 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅱ is a placebo intramuscular injection of deltoid muscle of the upper arm.
89679067|NCT04961359|Experimental|Population Ⅲ|Population Ⅲ has 20 subjects aged 6 to 11 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is intramuscular injection of deltoid muscle of upper arm with vaccine.
89679068|NCT04961359|Placebo Comparator|Population Ⅳ|Population Ⅳ has 5 subjects aged 6 to 11 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅳ is a placebo intramuscular injection of deltoid muscle of the upper arm.
89679069|NCT04961359|Experimental|Population Ⅴ|Population Ⅴ has 20 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅤ is intramuscular injection of deltoid muscle of upper arm with vaccine.
89679070|NCT04961359|Placebo Comparator|Population Ⅵ|Population Ⅵ has 5 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅵ is a placebo intramuscular injection of deltoid muscle of the upper arm.
89679071|NCT04022642|Experimental|HIIT Group|Two HIIT sessions delivered at the beginning of Physical education classes
89679072|NCT04022642|No Intervention|Control Group|Usual programmed Physical education classes
89679073|NCT05621707|Experimental|experimental arm|Two cycles of induction chemotherapy (nab-paclitaxel, 200 mg/m2/day, day1; carboplatin, area under the curve of 5 mg/ml/min, day 1) combined with PD-1 inhibitors （Sintilimab, 200 mg/day, day 1）every 3 weeks followed by concurrent chemoradiotherapy. Patients without progressive disease（PD） will proceed to receive immunotherapy (Sintilimab, 200 mg/day, every 3 weeks) as maintenance treatment for at least 1 year.
89679074|NCT04022720|Experimental|Platelet Rich Fibrin (PRF) Group|Patients randomized to this group will receive treatment with a PRF graft.
89679075|NCT04022720|No Intervention|No Platelet Rich Fibrin Group|Participants in the observational control group will be managed at the time of the complication by standard of care methods.
89679076|NCT04906057|Experimental|Forced Aerobic Exercise (FE)|The FE group (N=10) will complete 45 minutes of FE on the custom-engineered cycle designed to augment pedaling rate to greater than 70 revolutions per minute (RPM's). The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer at their self-selected cadence without assistance.
89215657|NCT06027502|Experimental|Passive Heating|Passive heating will be achieved by approximately 45 min of immersion in a Hot Tub at 40 degrees celsius
89215658|NCT06027450||Patients treated with NHIg|"Patients treated for one of the following indications :~Thrombopenic Idiopathic Purpura (TIP)~Chronic Demyelinating Inflammatory Polyradiculoneuritis (CDIP)~Secondary immune deficiency (SID)"
89215659|NCT06027424||Non-OSA|AHI < 5 events/h (AHI, apnea-hypopnea index, the number of apneas and hypopneas per hour of total sleep time)
89679077|NCT04906057|Active Comparator|Voluntary Aerobic Exercise (VE)|The VE group (N=10) will exercise on an identical semi-recumbent cycle ergometer for 45 minutes at their self-selected cadence without assistance.
89679078|NCT03832088|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated for sarcopenia and balance disorders
89679079|NCT04765904|Active Comparator|Hall Technique|The Hall Technique is a non-invasive treatment for decayed molar teeth. Decay is sealed under preformed (stainless steel) crowns, avoiding drilling
89679080|NCT04765904|Experimental|SDF|a clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride, is a topical therapeutic agent for managing caries lesions in young children
89679081|NCT00565045|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~Stimulation to finger and thumb extensors and flexors only in response to and with an intensity proportional to opening and closing of the contralateral unimpaired hand~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity~Therapy sessions are done with the subject being assisted by the CCFES system."
89215660|NCT06027424||Mild OSA|5 events/h ≤ AHI < 15 events/h
89215661|NCT06027424||Moderate OSA|15 events/h ≤ AHI < 30 events/h
89215662|NCT06027424||Severe OSA|AHI ≥ 30 events/h
89215663|NCT06027398|Experimental|SARS-CoV-2 RNA in masks|. After the participants had worn the masks for 8 h, the nurse collected the filters and placed each into a viral transport medium (VTM) tube This was placed inside a clean plastic bag, sprayed with alcohol, placed in an icebox and sent to the biomolecular laboratory for real-time RT-PCR SARS-CoV-2 testing.
89215664|NCT06027385|Experimental|Tested Newborns|Tested for three mutations in the CTNS gene and one mutation in the SMN1 gene.
89679082|NCT00565045|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation.~Preprogrammed cycles of finger and thumb flexor and extensor stimulation repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~Therapy sessions are done without the stimulation system"
89679083|NCT04022798|Experimental|Experimental group|Neural mobilization (NM), lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
89679084|NCT04022798|Active Comparator|Control group|lumbar stabilization exercise (LSE) and Radial Extracorporeal Shock Wave Therapy (rESWT)
89679085|NCT04022330|Other|Blood sampling|
89679086|NCT05621551|Experimental|Dapagliflozin|Dapagliflozin 10 mg
89679087|NCT05621551|No Intervention|Standard of care|Standard care treatment of diabetes patients during perioperative cardiac surgery in our center
89679088|NCT04022486||Children admitted in the PICU for severe bronchiolitis|Children admitted in the Pediatric Intensive Care Unit (PICU) for severe bronchiolitis between January 1st, 2010 and April 30th, 2018
89679089|NCT00565669|Experimental|Blink Tears|
89679090|NCT00565669|Experimental|Systane|
89679091|NCT04148378||Patients|Patients who have been diagnosed with colorectal cancer.
89679092|NCT04165135||Haemophilia A Without FVIII Inhibitors|
89679093|NCT02132533|Experimental|Nifedipine|Women with preterm labor will receive nifedipine.
89679094|NCT02132533|Experimental|Placebo|Women with preterm labor will receive placebo.
88996412|NCT02920489|Active Comparator|Routine epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor and the cervix is dilated to 1 cm or more. Epidural analgesia will then begin. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute period observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
88996413|NCT02920372|Experimental|EPOETIN ALFA|
88996414|NCT02920255||Electronic Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with electronic calipers.
88996415|NCT02920255||Conventional Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with conventional calipers.
88996416|NCT02920255||X-ray Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with x-rays.
88996417|NCT00188331||1|adjuvant/neoadjuvant chemotherapy
88996418|NCT00188331||2|non-chemotherapy group
88996419|NCT00188331||3|limited metastatic disease or localised recurrence to receive first line metastatic chemotherapy
88996420|NCT02920294|Active Comparator|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
88996421|NCT02920294|Active Comparator|Probiotic 2|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) OD for 14 consecutive days
88996422|NCT02920294|Placebo Comparator|Placebo|Acidified dairy drink without ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
88996423|NCT02920138||Group 5PEEP|Administered 5 cmH2O positive end expiratory pressure group( Group 5PEEP n=30).
88996424|NCT02920138||Group ZEEP|no positive end expiratory pressure group (Group ZEEP n=30)
88996425|NCT02920099||Nutrition Literacy|Participants will be asked to completed the Nutrition Literacy Assessment Instrument (NLAI).
88996426|NCT04688983|Active Comparator|Arm 1|Ponatinib plus standard induction and consolidation
88996427|NCT04688983|Active Comparator|Arm 2|Imatinib plus standard induction and consolidation (comparator arm)
88996428|NCT04688983|Experimental|Arm 3|Ponatinib plus Blinatumomab
88996429|NCT02919865|Other|MRI perfusion imaging|Patients who have received chemoradiation for high grade gliomas and who subsequently developed progressive enhancing lesions on follow-up MR will be asked to participate in this study.
88996430|NCT02920060|Experimental|Levetiracetam|patient in this group will receive intravenous levetiracetam as loading dose of 30 mg/kg at a rate of 50 mg/min
88996431|NCT02920060|Active Comparator|Sodium valproate|patients in this group will receive intravenous sodium valproate 20 mg/kg as loading dose at a rate of 40 mg/min
88996432|NCT03740815|Experimental|Serratus plane block plus sedation|Serratus plane block plus intravenous sedation as anesthetic technique during axillary dissection procedure.
88996433|NCT02919553|Experimental|modified wet-suction technique|Patients in this arm will undergo the modified wet-suction technique. Details in the study description section. After sufficient sampling of the lesion, the needle will be removed and the specimen will be collected.
88996434|NCT02919553|Active Comparator|"Capillary slow pull technique"|"Patients in this arm will undergo the Capillary slow pull technique which will include moving the needle to-and-fro into the lesion. Subsequently the needle will be removed and the specimen will be collected."
88996435|NCT02919709|Experimental|thoracic or abdominal aortic aneurysm|
88996436|NCT02919514|Active Comparator|Physical training on hard surface|Subject will participate in exercise training on a firm surface for 50 min/session, 3 days/week for 6 weeks in total.
88996437|NCT02919514|Experimental|Physical training on sand surface|Subject will participate in exercise training on a sand surface for 50 min/session, 3 days/week for 6 weeks in total.
88996438|NCT02919514|Experimental|Physical training on soft surface|Subject will participate in exercise training on a soft surface for 50 min/session, 3 days/week for 6 weeks in total.
88996439|NCT00154778|Experimental|A|
88996440|NCT02919631|Active Comparator|triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
88996441|NCT02919631|Placebo Comparator|placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day
88996442|NCT02919748|Experimental|Intervention arm|Choral Singing
88996443|NCT02919748|Active Comparator|Control arm|General Health Education Program and Group Activities
89679095|NCT03927482|Experimental|CARES mobile app|Participants in this arm will receive 12 weeks of text messages and use of the smart phone mobile app that provides support for alcohol risk reduction.
89679096|NCT03927482|Active Comparator|Alcohol Education|Those randomized to the control arm will be given access to an online alcohol education intervention; Check Your Drinking (CYD: www.CheckYourDrinking.net). CYD provides normative feedback on the user's drinking habits relative to his/her peers.
89679097|NCT04022408|Experimental|Liquid based cytology|.Liquid-based cytology (LBC), enables cells to be suspended in a monolayer. LBC makes better cytological assessment possible with improved sensitivity and specificity, since fixation is better and nuclear details are well preserved in the technique. Preneoplasticand neoplastic cells are not obscured by other cells, such as normal epithelial and inflammatory cells. LBC techniques are currently applied to cytological samples from several tissues or fluids. They include uterine cervix , endometrium, aspirates from breast , thyroid tumors, ascites and pleural effusion, and urine , LBC technology is suggested as an appropriate diagnostic method for metastatic tumors in cerebrospinal fluid .
89679098|NCT04022408|Active Comparator|Conventional cytology|It is a gold standard for histopathological diagnosis of pancreatobiliary malignancies till date
89679099|NCT05621473|Experimental|trial group|This arm of patients received tunnel PICC interventions
89679100|NCT05621473|Experimental|control group|This arm of patients received normal PICC interventions
89679101|NCT04022174|Experimental|Moderate dosage training|
89679102|NCT04022174|Experimental|Intensive dosage training|
89679103|NCT04022252|Experimental|Tooth Movement|Canine distalization on premolar extracted patients
89679104|NCT04022252|Experimental|Biochemistry measurements|biochemistry analysis of IL-8, OPG, RANKL
89679105|NCT04022252|Experimental|periodontal measurements|gingival and plaque index, blooding on probing, pocket depth
89679106|NCT03926702|Experimental|Radiopharmaceutical administration|All participants receive radiopharmaceutical for positron-emission tomography (PET) study.
89679107|NCT00567229|Experimental|Lenalidomide and Rituximab|This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.
89679108|NCT04148846|Active Comparator|Clinical treatment - old protocol|In group I, patients will receive clinical treatment according to the institution's old protocol for post dural puncture headache.
89679109|NCT04148846|Active Comparator|Clinical treatment - new protocol|In group II, patients will receive clinical treatment, according to the new protocol of the institution.
89679110|NCT04148846|Experimental|Sphenopalatine block|In group III patients will receive clinical treatment, according to the new protocol of the institution, associated with sphenopalatine block.
89679111|NCT00567307|Experimental|The Red Heart Pill 2b (Polypill) (A)|The Polypill is composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
89050648|NCT04607343|Experimental|Assigned Interventions|Patients will undergo a conventional flexible nasopharyngeal laryngoscopy in which the degree of obstruction and the laryngopharyngeal sensitivity during wakefulness will be determined. Electrostimulation will be applied at different submandibular points with increasing intensity until the contraction of the dilation muscles of the airway or until the patient cannot tolerate the electrostimulation. The presence of contraction of stimulated muscles will be determined by external and endoscopic inspection.
89050649|NCT04607265||Ventricular tachycardia (VT) group|NICM patients admitted for a VT ablation with a pre-operative cardiac- MRI.
89679112|NCT00567307|Active Comparator|Standard Practice Group (B)|Standard Practice
89679113|NCT00487565|Other|LCS Complete Posterior Stabilized knee implant|Total knee arthroplasty with a posterior stabilized implant
89679114|NCT04069741|Other|Usual care, no depression|Participants without symptoms of depression who have the opportunity to use a Decision Aid but otherwise receive Usual care
89679115|NCT04069741|Other|Usual care, depression|Participants with symptoms of depression who are randomized to receive Usual care (in addition to the Decision Aid)
89679116|NCT04069741|Active Comparator|Toolkit, depression|Participants with symptoms of depression who are randomized to receive the Toolkit intervention in addition to Usual care
89679117|NCT04406480|Other|90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)|
89679118|NCT00568087|Active Comparator|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
89679119|NCT00568087|Placebo Comparator|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
89679120|NCT00487721|Experimental|Silibin-Phytosome|Subjects in this group will take Silibin-Phytosome 13 grams daily, in three divided doses for 2-10 weeks.
89679121|NCT00487721|No Intervention|Control|Patients in this arm will not take any intervention.
89679122|NCT04021940|Experimental|Dose adjusted ULOD|dose adjusted ULOD using 60J/cm3 applied to the larger ovary. The number of punctures (Np) per ovary will be calculated according to the following formula: Np = 60 J/cm3 divided by 30 W x 4 s.
89679123|NCT04021940|Active Comparator|Fixed dose ULOD|600 J for the larger ovary will be delivered through four punctures, each for 4 s and 40 W
89679124|NCT04148612|Experimental|Opti-Me|Patients in this group will be treated based on the Opti-Me algorithm recommended treatment.
89679125|NCT04148612|No Intervention|Randomization|Patients in this group will be treated by random assignment of treatment.
89679126|NCT00568633|Experimental|Allo-HSCT + TLI + ATG|"Participants achieving complete remission after consolidation therapy & who have 5 of 6 HLA-match sibling donor to provide PBSC harvest for transplant. Pre-transplant subjects receive:~Total lymphoid radiation (TLI) Days -11 to -7, and Days -4 to -1 (2 fractions on day -1)~Anti-thymocyte globulin (ATG) Days -11 to -7~Methylprednisolone Days -11 to -7~Cyclosporine (CSP) Days -4 to +2~5+ of 6 HLA-matched CD34+ cells on Day 0~Mycophenolate mofetil (MMF), Day 0 to Day +28"
89679127|NCT00568633|Active Comparator|Best Standard Care|"Regular medical care for participants who achieve complete remission after standard consolidation therapy, but do not have a 5 of 6 HLA-match sibling donor. Treatment may consist of:~Additional consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~Autologous transplantation~Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~Umbilical cord blood transplantation~Haploidentical transplantation"
89679128|NCT03022838|Active Comparator|Caffeine|Caffeine tablets (Recip) 100 mg, 300-800 mg
89679129|NCT03022838|Placebo Comparator|Placebo|Placebo tablets
89679130|NCT03021980|Experimental|SuperFIT|This is the intervention group. They will receive the intervention SuperFIT.
89679131|NCT03021980|No Intervention|Control|This is the control group. Participants will receive 'care as usual' in this arm.
89679132|NCT05363449|Experimental|UHE-103 Cream|Subjects will apply at least a total of 4 grams* of the test article, covering both feet twice daily for 2 weeks
89679133|NCT05363449|Active Comparator|Naftin (naftifine hydrochloride) Cream, 2%|Subjects will apply at least a total of 5 grams* of the test article, covering the interdigital areas of both feet and to the groin once daily for 2 weeks
89679134|NCT03021824||Moderate-Severe ARDS|All adults admitted to participating ICUs with study-defined moderate-to-severe ARDS.
89679135|NCT04146506||Male|Static Muscle stretching exercises of the knee flexors
89679136|NCT04146506||Female|Static Muscle stretching exercises of the knee flexors
89679137|NCT00489281|Experimental|Transplant - 200 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 200. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
89679138|NCT00489281|Experimental|Transplant - 400 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 400. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
89679139|NCT05362669|Experimental|Experimental - Intervention|SMS invitation to participate in cervical cancer screening using HPV self-sampling.
89679140|NCT05362669|Active Comparator|Active Comparator - Usual Care|Phone call invitation to participate in cervical cancer screening using HPV self-sampling.
89679141|NCT04146584|Experimental|Sofwave Treatment|In this arm (single) patients would be treated twice with Sofwave on the face and/or submental and neck.
89679142|NCT05362513|Active Comparator|Group A(permethrin topical)|Group A received Permethrin 5% twice with a one-week interval, whereas Group B received a single dose of oral ivermectin 200 mcg per kg.
89050650|NCT04607265||Control group|NICM patients without ventricular arrhythmia and a previous cardiac-MRI. The matching with the VT group was based on the age of the patients, the mean LVEF, the time between the initial diagnosis and the MRI examination, and the origin of the NICM.
89050651|NCT01109810||IVIg and SCIg therapy|Patients receiving Ig therapy by IV or SC route in the home or alternate site setting
89679143|NCT05362513|Active Comparator|Group B oral ivermectin|Group A received Permethrin 5% twice with a one-week interval, whereas Group B received a single dose of oral ivermectin 200 mcg per kg
89679144|NCT04148222||Patients|Patients who have been diagnosed with Lyme Disease
89679145|NCT04147910|Experimental|KW-6356|Single oral dose of carbon-14-KW-6356.
89679146|NCT02117999|Experimental|Cross-linking with iontophoresis|Transepithelial cross-linking by using iontophoresis to administer riboflavin into the corneal stroma
89679147|NCT02117999|Active Comparator|Standard corneal cross-linking|Standard corneal cross-linking includes de-epithelialization and stromal soaking by applying drops of riboflavin
89679148|NCT04457297|Experimental|trifluridine and tipiracil|
89679149|NCT04457297|Placebo Comparator|Placebo|
89679150|NCT05362279|Experimental|Test after post-test training|Pre-test will be applied to the nurses in the experimental group before the training. The post-test will be applied to the experimental group, to which the pre-test was applied, one month after the training was given.
89679151|NCT05362279|No Intervention|Test without training|The nurses in the control group are the group to be administered the post-test without any intervention after the pre-test. The post-test will be administered one month after the pre-test.
89679152|NCT04146116|Experimental|Nasal povidone-iodine|Intranasal povidone-iodine (PDI PROFEND) will be applied to the patients' noses before orthopedic trauma surgery and after surgery. This intranasal povidone-iodine was developed under the Tentative Final Monograph for Health-Care Antiseptic Drug Products 21 CFR Parts 333 and 369 (Docket # 75N-183H), Federal Register Volume 59, Number 116, Friday, June 17, 1994, Proposed Rules. However, the product need not be controlled like a pharmaceutical drug. The product may be stored and controlled similarly to an iodine or alcohol skin preparation product.
89679153|NCT05362201|Active Comparator|"the therapeutic position of the ARS were determinded by the minimum protrusive position"|"the therapeutic position of the ARS were determinded by the minimum protrusive position,which was the traditional method to fabricate the anterior repositioning splints,the patients were instructed to protrusive the mandible in a therapeutic position in which the click is eliminated."
89679154|NCT05362201|Experimental|the therapeutic position of the ARS were determinded by the VTO analyse|the therapeutic position of the ARS were determinded by the VTO analyse,first,the participants were constructed to take CBCT and MRI scans,the ideal therapeutic position of the ARS were located in which the temporomandibular joint space distribute well and the condylar recapture the disc,the dentist could determine the amount of condylar movement and performed VTO analyse by assessing the CBCT and MRI scans ,then it could easily realize the final condylar movements with the application of the dental articulator.
88996444|NCT03670147|Experimental|Pain Returns|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
88996445|NCT03670147|Experimental|No Pain|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
88996446|NCT02919319|Experimental|Dose group 1|Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
89679155|NCT04145960||Lymph node metastasis|Axillary lymph node metastasis ≥ 4 Lymph nodes
89679156|NCT02119871|Experimental|Bilateral Open Pleurae|Bilateral open pleurae and usage of right pulmonary vein drainage
89679157|NCT02119871|Active Comparator|Right pleura open|Opening of right pleura and usage of left ventricular apical drainage.
89679158|NCT04147598|Experimental|Low Fat Diet (LFD) to Standard American Diet (SAD)|Week 1 to 4 participants will receive a LFD followed by a washout period of 2 weeks and then week 6 to 10 SAD.
89679159|NCT04147598|Experimental|SAD to LFD|Week 1 to 4 participants will receive a SAD followed by a washout period of 2 weeks and then week 6 to 10 LFD.
89679160|NCT02130583|Experimental|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
89679161|NCT02130583|Active Comparator|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
89679162|NCT02120261|Experimental|TPI with Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
89679163|NCT02120261|Active Comparator|TPI with Lidocaine & Triamcinolone Acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
89679164|NCT00492089|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89679165|NCT00492089|Placebo Comparator|Arm II|Patients receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89679166|NCT01798537|Experimental|Neomycin Colistin Nystatin Vancomycin|"All participating study arm patients will receive SDD from admission to discharge according to the following plan:~ENTERAL MEDICATION (via feeding tube) x 4 times daily:~375 mg Neomycin 100 mg Colistin Sulphate~1 million units Nystatin * 250 mg Vancomycin *~Nystatin will be prescribed only if there is a positive sputum or urine culture for yeast or candida Vancomycin will be prescribed only in case of a positive screen or culture for MRSA"
89679167|NCT01798537|No Intervention|Control|No SDD given for 1 year Screening performed as in intervention arm
89679168|NCT04765826|Experimental|high dose oral steroids|(20 patients) will receive high dose oral mini pulse steroids (dexamethasone 5 mg on two consecutive weekly days for 3 months).
89679169|NCT04765826|Experimental|low dose oral steroids|(20 patients) will receive low dose oral mini pulse steroids (2.5mg dexamethasone on two consecutive weekly days for 3 months
89679170|NCT04765826|Experimental|topical treatment|(20 patients) chosen lesions of comparable size and location in each patient in this group will receive either; super potent topical steroids once every other day, Tacrolimus ointment twice daily for 3 months, or nothing to serve as a control.
89679171|NCT03692221|Experimental|MSC treatment group 1|Low dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 2 x 106/ml concentrated solution
89679172|NCT03692221|Active Comparator|MSC treatment group 2|High dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 4 x 106/ml concentrated solution
89679173|NCT03692221|Active Comparator|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
89679174|NCT04140422|Experimental|Hyperosmolar Eye Drops|5% sodium chloride eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
89679175|NCT04140422|Placebo Comparator|Lubricating Eye Drops|Lubricating eye drops with 0,15% hyaluronic acid; one drop after waking up and one drop 30 min later on study day; investigator administered
89050652|NCT04598763|Other|classic group|"the classic group receives classic olfactory rehabilitation using 4 scents most used in the literature (rose, eucalyptus, lemon, clove)"
89050653|NCT04598763|Other|intensive|"the intensive group receiving olfactory rehabilitation using 8 scents (rose, eucalyptus, lemon, cloves, strawberries, cut grass, lavender, spruce)."
89679176|NCT01797809||Group 1|
89679177|NCT01797341|Experimental|Prograf arm|"patients will self-administer tacrolimus in the form of Prograf (twice daily administration.~Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day."
89679178|NCT01797341|Experimental|Advagraf Arm|patients will self-administer tacrolimus in the form of Advagraf (once daily dosing) Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day.
89679179|NCT04145570|Experimental|Erlotinib HCl 150 mg|Crossover
89679180|NCT04145570|Active Comparator|Tarceva® 150 mg|Crossover
89679181|NCT05353387|Experimental|Intervention Group- Motivational Interviewing|Standard protocols and participation in Motivational Interviews
89050654|NCT00564564|Experimental|Quetiapine augmentation|Quetiapine up to 200mg/day plus SSRI at maximum tolerated or recommended dosage
89050655|NCT00564564|Active Comparator|Clomipramine augmentation|Clomipramine up to 150mg/day plus SSRI at maximum tolerated or recommended dosage
89050656|NCT02894138|Experimental|Alteplase|40 patients: 4-5 minutes of infusion of 10 ml of alteplase 2mg/ml in culprit vessel
89679182|NCT05353387|No Intervention|Control Group|Standard protocols
89050657|NCT02894138|Placebo Comparator|Placebo|40 patients: 4-5 minutes of infusion of 10 ml of NaCl in culprit vessel
89050658|NCT02894138|No Intervention|Observational|10 patients with IMR <30 will undergo the same follow-up as the randomised patients
89050659|NCT00565656|Experimental|A|Bevacizumab
89679183|NCT04145492|Active Comparator|Vitamin K2 group|15 patients will take 90 ug of vitamin K2 (MK-7) daily in addition to the standard therapy for 4 months.
89679184|NCT04145492|Active Comparator|Cholecalciferol group|15 patients will take 10 ug of vitamin inactive vitamin D daily in addition to the standard therapy for 4 months.
89679185|NCT04145492|Active Comparator|Vitamin K2 and Cholecalciferol group|15 patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D to daily in addition to the standard therapy for 4 months.
89679186|NCT04145492|No Intervention|Control group|15 patients will take the standard therapy.
89679187|NCT00548171|Experimental|Boostrix I Group|Subjects who had received the Boostrix™ vaccine in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the same vaccine, intramuscularly in the deltoid region of the non-dominant arm.
89679188|NCT00548171|Active Comparator|Boostrix II Group|Subjects who had received the Td vaccines in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the Boostrix™ vaccine intramuscularly in the deltoid region of the non-dominant arm.
89679189|NCT04147754||Epidural anesthesia|At physician discretion (observational study)
89679190|NCT04147754||Intrathecal morphine|At physician discretion (observational study)
89679191|NCT04147754||Erector spinae block|At physician discretion (observational study)
89679192|NCT01798381|Active Comparator|Essential fatty acids|Omega-3
89679193|NCT01798381|Placebo Comparator|Placebo|Placebo tablet
89679194|NCT04765748||TAAA patients with Cytosorb|Patients suffering from a TAAA larger than 55mm
89679195|NCT04765748||TAAA patients without Cytosorb|Patients suffering from a TAAA larger than 55mm
89679196|NCT05348473|Active Comparator|alpha group|In this group, tips of the seton will be tied as alpha-shaped
89679197|NCT05348473|Sham Comparator|Beta group|The tips of the seton in this group will be overlapped and tied. There is no palpable free ends.
89679198|NCT05348473|Experimental|Comfort group|Knotless seton will be applied
89679199|NCT00492401|Experimental|Treatment (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89679200|NCT04143464|Experimental|Intervention group|"The participants in this group will receive group kyphosis-specific exercise classes given by the certified physical trainer and kyphosis-specific exercise videos.~The intervention arrangement is:~Group learning and practice: a 1-hour kyphosis-specific exercise training session will be provided two times in the first week,~Weekly follow-up: a 1-hour kyphosis-specific exercise will be conducted with reinforcement of learning and remedial teaching by a certified physical trainer once a week for five consecutive weeks after the group learning and practice,~Self-practice: the participant will following the kyphosis-specific exercise videos doing self-practice every day for the whole intervention period lasting six weeks."
89679201|NCT04143464|No Intervention|Control group|No special arrangement
89679202|NCT05400811|Experimental|Group I: MM09 allergoid-mannan conjugates SC (3.000 UTm/mL) + sublingual placebo|"Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3,000 UTm/mL subcutaneous immunotherapy + sublingual placebo.~Subcutaneous active treatment will be administered once a month for 12 months. Sublingual placebo will be administered daily (2 subsequent administrations) for 12 months."
89679203|NCT05400811|Experimental|Group II: MM09 allergoid-mannan conjugates SL (3.000 UTm/mL) + subcutaneous placebo|"Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan sublingual immunotherapy at 3.000 UTm/mL + subcutaneous placebo.~Sublingual active treatment will be administered daily (2 subsequent administrations) for 12 months.~Subcutaneous placebo will be administered once a month for 12 months."
89679204|NCT05400811|Experimental|Group III: MM09 allergoid-mannan conjugates SL (9.000 UTm/mL) + subcutaneous placebo|"Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan sublingual immunotherapy at 9.000 UTm/mL + subcutaneous placebo.~Sublingual active treatment will be administered daily (2 subsequent administrations) for 12 months.~Subcutaneous placebo will be administered once a month for 12 months."
89679205|NCT05400811|Placebo Comparator|Group IV: Placebo|"Mixture of sublingual placebo + subcutaneous placebo. Sublingual placebo will be administered daily (2 subsequent administrations) for 12 months.~Subcutaneous placebo will be administered once a month for 12 months"
89688769|NCT03034369||Safety Net Clinic Patients|A Cohort of patients in 12 different primary care clinics will be studied to measure how changes in different integration factors impacts the following patient reported outcomes at baseline and 12 months: Access to Care, Patient-Provider Relationship, Patient-Clinic Interactions, Stigma, Provider Continuity, Symptom Severity, Diagnoses, and Social Support. Health care claims data will be accessed to analyze Depression Screening, Preventive Screening, Inpatient Hospitalization Utilization, Inpatient Readmissions, and Post-Admission follow-up at baseline and 12 months.
88996447|NCT02919319|Experimental|Dose group 2|Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.
88996448|NCT02919319|Experimental|Dose group 3|Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.
88996449|NCT02919319|Experimental|Dose group 4|Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.
88996450|NCT02919319|Experimental|Dose group 5|Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
88996451|NCT02919202|Experimental|Fluoride Varnish|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
88996452|NCT02919202|Active Comparator|SEDBA|Self-etching Dentine Bonding Agent. Scotchbond Universal by 3M ESPE. Topical application followed by light curing for 20 seconds.
88996453|NCT02919358|Experimental|Music|Exposure to music, twice per day for the study period
88996454|NCT02919358|Other|Control|No intervention; standard care.
89688770|NCT05375695|Experimental|Time-restricted eating|Time-restricted eating for 12 weeks (n=20).
89688771|NCT03034213|Active Comparator|Treatment|Gentrix(TM) Surgical Matrix
89050660|NCT02894021|Active Comparator|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
89679206|NCT04149002|Other|Intervention Arm: Weekly IP3 text messages|"A narrated powerpoint presentation describing the logistical details and medical rationale for components of the IP3. Participants will view the chapters of the presentation that are relevant to their specific IP3. There are a total of 4 possible chapters (lifestyle modifications, cervix length screening/cerclage, progesterone therapy, low dose aspirin). Each chapter of the presentation is ~ 10 - 15 min in length. Each chapter also includes a 4- 5 questions pre-test and the same questions are delivered as a post-test after the presentation.~Print materials including a letter explaining the importance of prenatal care for preterm birth prevention to employers.~Text messages sent weekly to encourage the patient to continue with their IP3 and provide basic pregnancy information~Formal letter of encouragement from provider at 28 weeks gestation"
89679207|NCT04149002|Active Comparator|Control Arm: General pregnancy text messages|"a pre-intervention questionnaire~a narrated powerpoint with general information about the clinic~a post-presentation questionnaire~text messages sent approximately weekly with general pregnancy information (e.g. today your baby is about the size of an apple)~an exit interview"
89679208|NCT03674827|Experimental|Dose escalation (Part 1)|Participants with NSCLC or TNBC were enrolled at escalating dose levels s of the VBIR-2 regimen.
89679209|NCT03674827|Experimental|Dose Expansion (Part 2)|Participants with metastatic NSCLC will be enrolled at the expansion dose level identified during Part 1 of the study.
89679210|NCT04147286|Active Comparator|Atorvastatin (Arm B)|12 weeks of 40 mg atorvastatin therapy per os daily
89679211|NCT04147286|Placebo Comparator|Placebo (Arm C)|Identical placebo tablet is taken per os daily
89679212|NCT00493181|Experimental|Interleukin-11|Starting dose 10 mcg/kg subcutaneously 3 times a week
89679213|NCT04143659|Experimental|LB injection 40mg intramuscular (IM) with 20 mg/ml concentration|27 subjects (18 with BMI <30mg^2; 9 with BMI >=30kg/m^2 and <40kg/m^2) were administered a single dose of levonorgestrel butanoate (LB) injection 40mg intramuscular (IM) using 20 mg/ml concentration
89679214|NCT04143659|Experimental|LB injection 40 mg subcutaneous (SC) with 20 mg/ml concentration|32 subjects (25 with BMI <30mg^2; 7 with BMI >=30kg/m^2 and <40kg/m^2) were administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC) using 20 mg/ml concentration
89679215|NCT04143659|Experimental|LB injection 50mg subcutaneous (SQ) with 70 mg/ml concentration|8 subjects (8 with BMI <40 kg/m2) will be administered a single dose of levonorgestrel butanoate (LB) injection 50mg intramuscular (IM) using 70 mg/ml concentration
89679216|NCT04143659|Experimental|LB injection 60mg Subcutaneous (SQ) with 70 mg/ml concentration|32 subjects (16 with BMI <30mg^2; 16 with BMI >=30kg/m^2 and <40kg/m^2) will be administered a single dose of levonorgestrel butanoate (LB) injection 60mg subcutaneous (SC) using 70 mg/ml concentration
89679217|NCT04143659|Experimental|LB injection 40 mg subcutaneous (SQ) with 70 mg/ml concentration|32 subjects (21 with BMI <30mg^2; 11 with BMI >=30kg/m^2 and <40kg/m^2) were administered a single dose of levonorgestrel butanoate (LB) injection 40mg subcutaneous (SC) using 70 mg/ml concentration
89679218|NCT04388059||Transection at 2 cm from the pylorus|the effect of transection at 2 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
89679219|NCT04388059||Transection at 5 cm from the pylorus|the effect of transection at 5 cm from the pylorus during Laparoscopic sleeve gastrectomy on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
89679220|NCT04147520|Active Comparator|Brief Motivational Interview|Single-session in person conversation focusing on risks associated with alcohol use.
89679221|NCT04147520|No Intervention|Natural History Control|No contact.
89679222|NCT03588962|Experimental|Metal allergy driven restenosis|Patients with angiographically proven in-stent restenosis developed after technically correct implantation. Patch tests for the metals used in stent production will be applicated. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
89679223|NCT03588962|Placebo Comparator|Looking for allergic restenosis|Patients with (technically correctly) implanted stent. Patch tests will be applicated to identify cases with contact allergy. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards.The patients will then be monitored for a 12 months follow-up period in purpose of evaluating the dependance between in-stent restenosis and contact allergy. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
89679224|NCT03595891||Adult with acute PE before the introduction of apixaban|
89679225|NCT03595891||Adult with acute PE after the introduction of apixaban|
89679226|NCT00493805|Experimental|Interventional Study arm (with insulin resistance)|"HOMA IR (homeostasis model assessment-estimated insulin resistance) of > 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg by mouth (PO) administered twice daily (BID) for a variable period depending on their response to treatment."
89679227|NCT00493805|Experimental|Non interventional study arm (without insulin resistance)|"HOMA IR <= 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg PO administered twice daily (BID) for 48 weeks. (Participants are treated according to~European labeling)."
89679228|NCT04145102|No Intervention|negative control|restoration will applied without any treatment
89050661|NCT02894021|Experimental|padding|areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.
89050662|NCT00564603|Placebo Comparator|1|Saline with same volume added to tramadol infusion combined with morphine PCA.
89050663|NCT00564603|Active Comparator|2|Dexamethasone 10mg in 2mL added to tramadol infusion adjunct to morphine PCA.
89050664|NCT02894099|Experimental|Prolonged Sitting Time (PST)|Uninterrupted sitting time of 5 hours
89050665|NCT02894099|Experimental|PST+Light intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of light physical activity
89679229|NCT04145102|Experimental|hesperidine|hesperidine will be applied for remaining caries then restoration will be applied
89679230|NCT04145102|Experimental|propolis|propolis will be applied for remaining caries then restoration will be applied
89679231|NCT04145102|Experimental|silver diamine fluoride|silver diamine fluoride will be applied for remaining caries then restoration will be applied
89679232|NCT03588650|Experimental|HLX20, in patients with solid tumors|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX20 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 1, 3, 10 and 20 mg/kg, starting from 1 mg/kg.
89679233|NCT00494585|Experimental|CEP-701|80 mg orally twice a day for 30 days
89679234|NCT05589428|Placebo Comparator|Placebo|Normal bread
89679235|NCT05589428|Experimental|Low sodium bread|Low sodium bread
89679236|NCT00494975|Experimental|NB-UVB|Narrow band-Ultraviolet B phototherapy
89679237|NCT00494975|Placebo Comparator|UVA|Ultraviolet A Phototherapy
89679238|NCT03590353|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
89679239|NCT03590353|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
89679240|NCT05581628||Celiac Patients Group|Patients previously diagnosed with celiac disease by the gastroenterology clinic.
89679241|NCT05581550|Other|PET imaging|
89679242|NCT05183191|Experimental|Intervention group|
89679243|NCT03588494|Active Comparator|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
89679244|NCT03588494|Experimental|W1-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5～-1).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
89679245|NCT03588494|Experimental|W2-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
89679246|NCT00550277|Other|Treatment|LBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring, all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles. Patients with objective response or stable disease after re-evaluation at week 8 will continue LBH589 at the same dose until disease progression, unacceptable toxicity and/or at the discretion of the investigator.
89679247|NCT03518983|Sham Comparator|Sham Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) by the sham probe.
89679248|NCT03518983|Active Comparator|Active Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) at energy level 7.
89679249|NCT05581316|Experimental|patients who use peripheral venous catheters|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center. The above examinations at the Laboratories of the December 25th State Hospital, Ministry of Health of the Republic of Turkey, were retrieved retrospectively from the hospital database
89679250|NCT05581316|Experimental|patients who use venous catheters|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center. The above examinations at the Laboratories of the December 25th State Hospital, Ministry of Health of the Republic of Turkey, were retrieved retrospectively from the hospital database
89679251|NCT04144946||Healthy control group (CTRL)|Sports active individuals with no history of patellar tendinopathy.
89679252|NCT04144946||Early tendinopathy group (ET)|Sports active individuals with clinical signs of early tendinopathy and debut of symptoms within 90 days.
89679253|NCT04144946||Chronic tendinopathy group (CT)|Sports active individuals with clinical signs of tendinopathy and duration of symptoms >90 days.
89679254|NCT00550589|Experimental|Cidofovir|1.0% topical cidofovir cream
89679255|NCT04144712|Experimental|High Dose arm|subjects will receive the high dose of the drug
89679256|NCT04144712|Active Comparator|low dose arm|subject will receive low dose of the drug
89679257|NCT05099653|Experimental|patients with physical activity|A group of patients with physical activity (protocolized)
89679258|NCT05099653|No Intervention|patients without physical activity|A group of patients without physical activity (protocolised)
89679259|NCT03588338|Active Comparator|Perfalgan|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
89679260|NCT03588338|Other|Control|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
89688772|NCT03034213|Active Comparator|Control|Standard of care mesh
89679261|NCT05099185||Maintenance online post-dilution hemodiafiltration patients|Maintenance hemodialysis patients who undergo hemodialysis 3 times per week with online post-dilution hemodiafiltration process
89679262|NCT04144634|Experimental|Intervention/Strengthening|
89679263|NCT04144634|Sham Comparator|Control/Stretching|
89679264|NCT05068609||Cohort 1|Participants with squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab
89679265|NCT00496379|Experimental|ZK219477|
89679266|NCT05068375||Thrombotic group|Non-critically COVID-19 patients with unusual thrombotic events
89679267|NCT05068375||Non-thrombotic group|Non-critically COVID-19 patients without thrombotic events
89679268|NCT03020420|Experimental|treatment arm|receive cicatricell cream
89679269|NCT03020420|No Intervention|control arm|to treatment
89679270|NCT02124863|Experimental|Intrapulmonary Percussive Ventilation|number of refluxes during 20 min of IPV ( rate : 300/min, p = 10cmH2O) at least 120 min after feeding
89679271|NCT04144244|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips will be used when preparing sperm of male partner and IUI will be made with separated sperm
89679272|NCT04144244|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and IUI will be made with separated sperm
89679273|NCT04144478|Experimental|experimental|Web based education intervention
89679274|NCT04144478|No Intervention|No intervention|Normal polyclinics application
89679275|NCT04998409||Monofocal IOL|
89679276|NCT00497081|Active Comparator|Mirtazapine|mirtazapine 30 mg daily
89679277|NCT00497081|Placebo Comparator|Placebo|placebo 30 mg daily
89679278|NCT04144400|Experimental|BRAVE Group|The BRAVE program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of quiet ego characteristics. The BRAVE intervention (delivered over four weeks) will ask study participants to use the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
89679279|NCT04144400|Active Comparator|Time Management Group|The time management program aims to examine the effectiveness of an intervention strategy designed to increase personal and work outcomes through the strengthening of time management characteristics. The time management intervention (delivered over four weeks) will ask study participants to use the time management version of the app each week, with specific instructions on selecting one section each week and first listening to the longer version and reflect. At least two other times during the week they will be asked to listen to a recording of their choice on the same topic. On the final week (week 5) all participants (experimental and control) will return to the lab to complete post-study assessment tools (SART, post-study on-line questionnaire, provide a urine sample, and weight measurement).
89679280|NCT03906656|Active Comparator|KAFO/SCO|Home use of 3 months with existing knee ankle foot orthosis (KAFO) or existing stance control orthosis (SCO)
89679281|NCT03906656|Experimental|C-Brace|Home use of 3 months with newly fitted C-Brace microprocessor-controlled stance and swing control orthosis.
89679282|NCT01796951|Experimental|Celecoxib, aspirin, followed by aspirin/celecoxib|Celecoxib 200 mg twice daily x3 days, aspirin 325 mg daily x10 days, celecoxib 200 mb twice daily + aspirin 325 mg daily x 3 days
89679283|NCT03281239|Experimental|welder/airport agent|No drug and no placebo were used in this study.
89679284|NCT04838041|Experimental|Combination Therapy and Remission Phase|All eligible patients will begin a combination of asciminib plus imatinib cycle 1 day 1 in the combination treatment phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will discontinue their imatinib and be monitored off treatment.
89215665|NCT06027372||IPF patients with acute exacerbation during test period|"IPF patients completing pulmonary function, overnight SpO2 monitor and LARGAN ECG Holter reqire hospitalization during test period."
89679285|NCT03106285|Experimental|Lactobacillus reuteri DSM17938|Oil drops
89679286|NCT03106285|Placebo Comparator|Placebo|Oils drops
89679287|NCT03588026|Experimental|Arm 1 - 9 months of treatment (rVA576 plus SOC)|6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).
89679288|NCT03588026|Experimental|Arm 2 - 6 months on SOC|6 months on SOC only. Followed by 3 months (SOC plus rVA576).
89679289|NCT03587948||Case group|Children and adolescents with diabetes mellitus
89679290|NCT03587948||Control group|Children and adolescents without diabetes mellitus
89679291|NCT04143620|Other|Neovascular glaucoma|Neovascular glaucoma patients underwent triple procedure
89679292|NCT04143854|Experimental|MBA-P01 24U|Experimental group; Dose: 24U
89679293|NCT04143854|Experimental|MBA-P01 12U|Experimental group; Dose: 12U
89679294|NCT04143854|Placebo Comparator|Placebo|Placebo group; normal saline
88996455|NCT02919397|Experimental|Intervention|If participants are allocated to the intervention group, participants will receive the wearable technology and access to the smartphone application. Motivational messages based on diabetes prevention programme content, and biofeedback messages based on physical activity data provided via the wearable technology, will be received by participants via the application. The diabetes prevention programme educational material will be available via the application.
89679295|NCT04765670|Experimental|Instrument Assisted Soft Tissue Mobilization|"The instruments will be applied to the soft tissue at 30º-60º angles, with multi-directional stroking movements. Instrument Assisted Soft Tissue Mobilization will be applied to the trapezius and sternocleidomastoideus muscles of the participants for 90 seconds."
89688773|NCT03034291|Experimental|Cacao 70%|Consumption for eight weeks of 50 grams of chocolate with 70% cocoa solids equivalent to not less than 430 mg of cocoa polyphenols at each dose.
89688774|NCT03034291|Placebo Comparator|White chocolate|Consumption for eight weeks of 50 grams of chocolate free of cocoa solids as placebo.
89688775|NCT04361305|Experimental|tadalafil combined with dapoxetine|
89688776|NCT04361305|Active Comparator|tadalafil mono group|
89679296|NCT04765670|Experimental|Kinesiotape Application|The application will be made from the insertion of the upper trapezoidal muscle to its origo . During taping, the patient will be allowed to sit in an upright position in a chair with a back, with the scapula fixed, without supporting the arms. Before taping, the patient will be positioned with the shoulder in adduction and the head in lateral flexion towards the contralateral side. The patient will be asked to perform shoulder abduction against resistance, and the insertion area of the upper trapezius fibers will be palpated. The initial 2-3 cm part of the band will be glued to the lateral of the acromion without stretching, after full (100%) stretching is applied to the 2-3 cm part of the band from the insertion area of the upper trapezoid fibers, the patient's head is rotated to the affected side and the arm part of the band is stretched along the muscle fibers. it will be glued up to the hairline without doing it.
89050666|NCT02894099|Experimental|PST+Moderate intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of moderate physical activity
89050667|NCT02894099|Experimental|PST+Moderate intensity Long bouts PA|Sitting prolonged interrupted with breaks of 10 minutes of moderate physical activity
89050668|NCT00565734||Posterior surgical approaches|Posterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM)
89050669|NCT00565734||Anterior surgical approaches|Anterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM).
89679297|NCT03022058|Experimental|Patients with type 1 diabetes mellitus|
89679298|NCT03587558|Experimental|Carvedilol group|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT. Dilatrend® sustained release form of Chong Kun Dang Pharmaceutical will be used (initial dose: 8 mg sustained release form). Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
89679299|NCT03587558|Active Comparator|Flecainide group|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT. Tambocor® of JW Pharmaceutical will be used. Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
89050670|NCT00555347|Active Comparator|Armnodafinil|Armodafinil
89050671|NCT00555347|Placebo Comparator|Placebo|
89050672|NCT00555386|Active Comparator|1|6g of chocolate (supplemented with selenium and isoflavones) per day for the duration of one menstrual cycle (25-35 days)
89679300|NCT03021512||Group 1 (BFG)|(Bifocal group). Subjects that underwent bifocal intraocular lenses implantation. (ie. Phaco with Restor intervention).
89679301|NCT03021512||Group 2 (TFG)|(Trifocal group). Subjects that underwent trifocal intraocular lenses implantation. (ie. Phaco with Panoptix intervention).
89679302|NCT03895346|Experimental|Mindfulness|Class meeting three times a week for six months, led by a certified mindfulness meditation instructor. Includes instruction and practice on techniques such as breathing, body scan, physical sensations, and yoga.
89679303|NCT03895346|Active Comparator|Brain Games and Puzzles|Class meeting three times a week for six months, led by a qualified instructor. Includes teaching and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
89679304|NCT04415905|Experimental|group P|The participants in the group P are anesthetized with propofol.
89679305|NCT04415905|Active Comparator|group S|The participants in the group S are anesthetized with sevoflurane.
89679306|NCT03021356|Active Comparator|Trifecta aortic xenograft|The Trifecta aortic xenograft is implanted in these patients.
89679307|NCT03021356|Active Comparator|Magna Ease aortic xenograft|The Magna Ease aortic xenograft is implanted in these patients.
89679308|NCT02979704|Active Comparator|Rosuvastatin|Intervention: Tablet Rosuvastatin (5-10) mg orally once daily dose for 08 weeks.
89679309|NCT02979704|Active Comparator|Atorvastatin|Intervention: Tablet Atorvastatin (10-20) mg orally once daily dose for 08 weeks
89050673|NCT00555386|Placebo Comparator|2|6g of chocolate (control) per day for the duration of one menstrual cycle (25-35 days)
89679310|NCT02450305||Treated with HBO|QOL questionnaires at 5 time points for those having HBO therapy at least one year post radiation therapy for head and neck cancer, daily x6 weeks
89679311|NCT02450305||Not treated with HBO|QOL questionnaires for those at least one year post radiation therapy for head and neck cancer at 5 times points.
89679312|NCT05580224|Experimental|Patients with hepatocellular carcinoma (equal or less than 3 cm)|Under the guidance of multimodality-ultrasound (US) fusion image, one of the three electrodes was placed across the portal vein branch near the tumor, and the other two electrodes were placed around the tumor through the previously planned approach path. After placement of electrodes, the temperature is maintained at 90-100 degrees Celsius for about 6-30 minutes depending on the size of the tumor, using the combined energy transfer mode that sequentially adds the bipolar mode and/or the monopolar mode.
89679313|NCT05580146|Active Comparator|Zynamite® 15% 150mg|Mango leaf extract (Mangifera indica)
89679314|NCT05580146|Active Comparator|Zynamite® 15% 300mg|Mango leaf extract (Mangifera indica)
89679315|NCT05580146|Active Comparator|Zynamite® 15% 600mg|Mango leaf extract (Mangifera indica)
89679316|NCT05580146|Placebo Comparator|Placebo|Placebo matched for appearance
89688777|NCT04361383|Placebo Comparator|Control group|patients will be operated under general anesthesia.
89050674|NCT01580709|Active Comparator|Multimodality Approach|Patients in the multimodality arm will undergo a single brushing for routine cytology, a second brush sample for Fluorescence In Situ Hybridization and a cholangioscopy with site-directed biopsies for histology.
89050675|NCT01580709|Active Comparator|Multiple brush samples|In patients randomized to multiple brushing samples, subsequent brushings #2-7 will be labeled separately and consecutively and sent to cytology. The cytopathologist will review each specimen for cellularity using a previously validated scoring system and presence of malignancy (positive, highly suspicious, atypical, normal).
89050676|NCT02894294||Intervention district|implementation of the seasonal malaria chemoprevention
89050677|NCT02894294||Control district|no implementation of the seasonal malaria chemoprevention
89050678|NCT00565890|No Intervention|2|No replacement therapy
89688778|NCT04361383|Active Comparator|QLB group|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
89688779|NCT04361383|Active Comparator|ESPB group|patients will receive ultrasound-guided erector spinae plane block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
89679317|NCT03021044|Other|STANDARD OF CARE|The standard of care group will be recommended about medications and a correct life style (physical activity, low salt and low fat diet, no smoking) in order to prevent cardiovascular events. In this 15-minutes talk study doctor will explain to patients and relatives the importance of aerobic physical activity (30-60 minutes daily, moderate intensity, for example speedy walking, for at least 5 days/weekly) with the aim of reducing cardiovascular risk. Patients will also receive a brochure with clear explanations. Study doctor and study coordinator will be helpful for any question and they will ensure that patients and relatives understand the importance of physical activity for cardiovascular health.
89679318|NCT03021044|Experimental|PHYSICAL ACTIVITY INTERVENTION|Besides standard of care, the experimental group will participate to a program of physical activity intervention. Following hospital discharge, participants in stable clinical conditions will be referred by their cardiologist to the exercise-based secondary prevention program. All exercise testing and training sessions will be performed without discontinuing the prescribed medications. On admission to the program, and quarterly during follow-up, each patient will perform a 1-km treadmill walk test as previously described (1k-TWT).
89679319|NCT01797679|Other|Strength Training|"The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.~Intervention: Other: Strength training"
89679320|NCT01797679|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 85% of maximal heart rate.
89679321|NCT01797679|No Intervention|Control Group|The control group will do as usual.
89679322|NCT03587324|Experimental|Experimental: aspirin, clopidogrel|Perioperative measurement of ASA and clopidogrel resistance in patients undergoing vascular treatment
89679323|NCT00604045|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
89050679|NCT02894060|Experimental|blood|blood tests
89050680|NCT02894255|Experimental|PCI and CABG|
89050681|NCT00565929|Experimental|Group A: MVA-BN 1 X 10^7 TCID 50|10 participants to receive vaccine dose 1X10^7 TCID 50; 2 participants to receive placebo.
89679324|NCT00604045|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
89679325|NCT05582954|Experimental|EsteemUp|Participants assigned to this arm will receive a 4 week-guided e-health application - EsteemUp - to improve their self-esteem
89679326|NCT05582954|Active Comparator|EsteemUp -G|This group will receive the same intervention (EsteemUp) with the addition of gamification elements.
89679327|NCT05246683||cohort|Observational evaluation during the hospital stage on diagnosis, treatment and evolution of patients with cardiogenic shock.
89679328|NCT03587246||Pregnant women|
89679329|NCT03587246||non-pregnant women|
89050682|NCT00565929|Experimental|Group B: MVA-BN 1 X 10^8 TCID 50|10 participants to receive vaccine dose 1X10^8 TCID 50; 2 participants to receive placebo.
89050683|NCT00555503||1|Patients who have risk-reduction mastectomy of any type, per protocol inclusion and exclusion criteria.
89050684|NCT04676516|Experimental|Experimental Arm|Participants randomized to treatment with GSK3326595 will be requested to take 15 +/- 3 days of the medication at the dose of 200 mg orally daily (2 capsules of 100 mg) prior to their breast cancer surgery or repeat biopsy. GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
89050685|NCT04676516|No Intervention|No Intervention Arm|Participants will receive no treatment for 15 +/- 3 days prior to breast surgery. There is no placebo in this trial.
89050686|NCT04606758|Active Comparator|PCNL under fluoroscopic control|
89050687|NCT04606758|Active Comparator|PCNL under ultrasound control|
89050688|NCT04598568||balanSys UNI knee prosthesis|Participants treated with a balanSys® UNI knee prosthesis
89050689|NCT04676438||Patients receiving surgery breast surgery for cancer at National Institute of Oncology|No intervention will be administered
89679330|NCT04143152||Diagnostic/prognostic cohort|Patients being evaluated for a potential pancreatic abnormality or for potential treatment for pancreatic adenocarcinoma.
89679331|NCT04143152||Surveillance Cohort|Patients who are being monitored for recurrence following surgical or medical treatment for pancreatic adenocarcinoma
89679332|NCT01798459|Active Comparator|Methylphenidate|Methylphenidate 0.3 mg/kg per os is given before performing a continuous performance test.
89688780|NCT04361071|Active Comparator|Stent|Stent group
89050690|NCT04607031||ischemic stroke patients|20 patients with ischemic stroke, onset within 24 hours, NIHSS≥8
89050691|NCT04676165|Experimental|SAM Group|At discharge from hospital, patients (and/or caregivers) will receive access to Smart About Meds (SAM), a medication management mobile application that has been developed by the McGill Clinical and Health Informatics (MCHI) Research Group.
89050692|NCT04676165|No Intervention|Usual Care Group|At discharge from hospital, patients will be provided with a written discharge prescription to be filled at their community pharmacy, and may or may not receive written or verbal instructions about changes made to therapy.
89050693|NCT04606953|Experimental|Attention Process Training (APT-II)|Patients in the experimental group receive the APT-II training program (Attention Process Training) individually with a psychologist for 8 weeks (2 sessions/week). The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to each patient's profile in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains towards the most problematic daily activities in order to reduce the impact of the patients' cognitive problems in their daily lives.
89050694|NCT04606953|No Intervention|Standard care|Patients in the control group receive standard routine care.
89679333|NCT01798459|Placebo Comparator|Placebo|Placebo is given before performing a continuous performance test.
89679334|NCT04143308|Experimental|Simultaneous training of walking and cognitive group|"Wearable technology (fitness wristband & App)~SWATCH system (App & controller)~3 times a week (30 mins/ each time)~Lasts for 12 weeks~Simultaneous walking and cognitive training"
89679335|NCT04143308|Active Comparator|Cognitive training group|"Wearable technology (fitness wristband & App)~SWATCH system (App)~3 times a week (30 mins/ each time)~Lasts for 12 weeks~Cognitive training while sitting"
89679336|NCT04143308|Active Comparator|Treatment as usual group|1. Keep treatment as usual group at health care system.
89679337|NCT00555321|Experimental|Group 1: Basiliximab+Belatacept (MI) + MMF|
89679338|NCT00555321|Experimental|Group 2: Belatacept (MI) + MMF|
89679339|NCT00555321|Experimental|Group 3: Belatacept Less Intensive (LI) + MMF|
89679340|NCT00555321|Other|Group 4: Tacrolimus + MMF|Other
89679341|NCT00555321|Active Comparator|Group 5: Tacrolimus|
89679342|NCT05583500|Experimental|Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
89679343|NCT03587012|Experimental|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
89679344|NCT03587012|Experimental|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD combined with simultaneous transcranial alternating current stimulation (tACS)
89679345|NCT03904316|Experimental|Biodesign graft tympanic membrane repair|Patient's perforated tympanic membrane will be repaired with an acellular matrix derived from porcine small intestine submucosa, Biodesign Otologic graft
89679346|NCT03904316|Active Comparator|Autograft tympanic membrane repair|Patient's perforated tympanic membrane will be repaired with autologous temporalis fascia.
89679347|NCT02133235|Active Comparator|conventional|insertion of endobronchial blocker and auscultation, fiberoptic confirmation and reposition
89679348|NCT02133235|Experimental|auscultation|insertion endobronchial blocker by auscultation without conventional bronchoscopic reposition
89050695|NCT04675658|Active Comparator|Classroom Intervention|"Physical activity support is provided by integrating daily structured activities in the classroom delivered by physical activity leaders through a video conferencing platform in partnership with the classroom teacher. Activities last about 10 minutes or less and have the flexibility of being integrated with academic lessons or serving as a break from academics.~The activities are simple and get kids moving in place. The activities will be delivered by a research staff member via video conferencing (using the schools preferred platform). A combination of live activities led by the research team and pre-recorded videos will be used (see example below). If live videos do not work for the teacher, they will have the option to only use the pre-recorded videos or receive a list of resources to promote CBPA in their classrooms."
89050696|NCT04675658|Experimental|Classroom Intervention plus family support|"Same components as the Classroom Intervention Arm plus the following:~Family Component: A newsletter will be sent to parents or guardians once every two weeks over the semester and posted on the study website. The newsletters include physical activity information related to safety/protection, skills building, motivation, overcoming barriers, and goal setting and monitoring (all newsletters are included as an appendix). As part of the program, children also receive a Garmin wearable physical activity monitor. Parents or guardians will receive text messages with behavior change messages based on the Garmin data (text message content is included as an appendix). Text messages also contain links to website materials.~Texts will be sent out using the Twilio platform."
89050697|NCT04598490|Experimental|Healed extraction site|Old Extraction Space
89050698|NCT04598490|Experimental|unhealed extraction site|Recent Extraction space
89679349|NCT05246215||STEMI group.|60 participants of patients with STEMI treated with primary percutaneous coronary intervention (pPCI).
89679350|NCT05246215||healthy group.|15 participants of healthy people as a case control.
89679351|NCT05246215||Stable angina group.|15 participants of patients stable angina
89679352|NCT05583266|Placebo Comparator|Pentoxifylline sustained- release tablets placebo group|This group will receive Pentoxifylline sustained-release tablets placebo, 1 tablet twice a day, from the day of randomization to 6 months.
89679353|NCT05583266|Experimental|Pentoxifylline sustained- release tablets group|This group will receive Pentoxifylline sustained-release tablets, 1 tablet twice a day, from the day of randomization to 6 months.
89679354|NCT00607243|Experimental|Conventional dose group|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
89679355|NCT00607243|Experimental|Low dose group|Diluted CJ-50300 2.5 x 10000pfu/dose vaccination
89679356|NCT04143074|Other|intervention|multidisciplinary intervention arm - behavioral intervention by physician, dietician, psychologist and physical activity trainer
89679357|NCT00607321|Experimental|1|Medtronic Bifurcation Stent System
89679358|NCT04142840|Experimental|Dexmedetomidine Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the dexmedetomidine group will be infused with a single dose of 0.7ug/kg dexmedetomidine."
89688781|NCT04361071|Active Comparator|Atherectomy|Atherectomy group
89688782|NCT05351437|Active Comparator|MTx-COVAB36|Cohort 1 - 100 mg IV dose Cohort 2 - 500 mg IV dose Cohort 3 - 1000 mg IV dose Cohort 4 - 2000 mg IV dose MTx-COVAB36 will be administered as a single dose intravenously.
89688783|NCT05351437|Placebo Comparator|Placebo|Placebo (0.9% NaCl) will be administered as a single dose intravenously.
89688784|NCT04361149|Placebo Comparator|Placebo Topical|The cream was a lipobase cream, applied topically to the participants upper back, on their left side.
89688785|NCT04361149|Active Comparator|Capsaicin Topical|Capsaicin Cream (0.075%), applied topically to the participants upper back, on their left side.
89688786|NCT04360915|Experimental|ASK120067 in fast condition|Take ASK120067 tablets orally once in the first day at 160mg in fast condition.
89679359|NCT04142840|Active Comparator|Propofol Group|"General anesthesia will be maintained by sevoflurane and remifentanil. End-tidal carbon dioxide will be controlled between 35 mmHg to 40 mmHg.Mean blood pressure(MAP) will be administrated between 80% and 120% of the baseline.Heart rate is going to be maintained between 50-100 beats per minute.~In consultation with the surgeons and 5 minutes prior to the departure of the operating room,all the anesthesia agents are discontinued and the patient will be transferred to the post-anaesthesia care unit.And reversal agents are given to antagonize the residual muscular relaxant.Once emergence agitation occurs,the patient assigned to the propofol group will be infused with a single dose of 0.5mg/kg propofol."
89679360|NCT04142762|Experimental|Cohort 1: ABI-H2158 + Itraconazole|Oral ABI-H2158 on Days 1 and 9; oral itraconazole once-daily (QD) on Days 6 through 13
89679361|NCT04142762|Experimental|Cohort 2: ABI-H2158 + Rifampin|Oral ABI-H2158 on Days 1 and 12; oral rifampin QD on Days 6 through 16
89679362|NCT04142762|Experimental|Cohort 3: ABI-H2158 + Esomeprazole|Oral ABI-H2158 on Days 1 and 11; oral esomeprazole QD on Days 6 through 11
89679363|NCT04142762|Experimental|Cohort 4: ABI-H2158 + Midazolam|Oral midazolam on Days 1 and 11; oral ABI-H2158 QD on Days 2 through 11
89679364|NCT04142762|Experimental|Cohort 5: ABI-H2158 + Oral Contraceptive|Cycle 1: active oral contraceptive (ethinyl estradiol/levonorgestrel) QD on Days 1 through 21 and oral placebo QD on Days 22 through 28; Cycle 2: active oral contraceptive QD on Days 1 through 21, oral placebo QD on Days 22 through 26, and oral ABI-H2158 QD on Days 11 through 24
89679365|NCT00607867|Active Comparator|Arm 1|A LoBAG30, weight maintenance diet will be given to subjects on metformin. All food will be provided for 5 weeks.
89679366|NCT00607867|Placebo Comparator|Arm 2|A weight maintenance, control diet consisting of 55% carbohydrate, 15% protein, 30% fat will be given to subjects on metformin. All food will be provided for 5 weeks.
89679367|NCT03020264|Experimental|Patients older than 75 years|Collection of hypoglycaemia épisodes with the glycemic sensor FREESTYLE Libre Pro
89679368|NCT03445520|No Intervention|Transition Passport Comparison Group|This group will only receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide.
89679369|NCT03445520|Experimental|Intervention Coaching Group|This group will also receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide. This group will also receive coaching support to implement these resources. The coach will be a member of the research team who will introduce the resources to the family, briefly teach them fundamental information about the transition process, provide brief coaching phone calls, and help parents identify an appropriate person at the school or district who can work with them to complete the Student Snapshot. This group will also use ParentSquare to enhance and encourage communication between parent and members of the child's school team.
89679370|NCT03586778|Experimental|MTEX-DN|dry needling, manual therapy, and therapeutic exercise
89679371|NCT03586778|Active Comparator|MTEX|manual therapy and therapeutic exercise
89679372|NCT04142528||Parkinson's Disease|Smartwatch-based sensor assessment of PD symptoms during standard care
89679373|NCT02138227|Active Comparator|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills.
89679374|NCT02138227|Active Comparator|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
89679375|NCT02138461||bimatoprost|These patients take bimatoprost topically for glaucoma.
89679376|NCT02138461||latanoprost group|These patients take latanoprost topically for glaucoma.
89679377|NCT03586700|Experimental|Xiao zhong fang granules|Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
89050699|NCT04675697|Experimental|Anlotinib+EP|
89050700|NCT04606836|Experimental|Prospective Cases|These cases will be recruited prospectively, and receive the intercostal nerve block(s) on operated site(s). Peri-operative injections of 30 ml of 0.25% Bupivacaine each, injected over the 4th, 5th, and 6th ribs on the operated site(s).
89679378|NCT03586700|Placebo Comparator|Placebo Xiao zhong fang granules|Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
89050701|NCT04606836|No Intervention|Retrospective Controls|Controls will be gathered retrospectively from chart reviews where patient did not receive a intercostal nerve blocker bilaterally.
89050702|NCT04598256||Children who underwent endoscopic procedures|"Children between the ages of 1-18 who were underwent endoscopic procedures~Patients who can be questioned about COVID-19 infection before and on the 7th and 14th days after the procedure~Patients who volunteered to study"
89050703|NCT01163149|Experimental|Cohort 1|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (2.1 mg/kg/week total)
89050704|NCT01163149|Experimental|Cohort 2|Cohort 2: Daily SC injections of 0.5 mg/kg asfotase alfa (3.5 mg/kg/week total)
89679379|NCT02275923|Experimental|Diagnostic|'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
89679380|NCT02139007|Active Comparator|Continuation Arm|Alendronate continuation arm
89679381|NCT02139007|Active Comparator|Discontinuation Arm|Alendronate discontinuation arm
89679382|NCT03833115|Experimental|vaginal gel containing sodium lauryl sulfate|
89688787|NCT04360915|Experimental|ASK120067 in fed condition|Take ASK120067 tablets orally once in the first day at 160mg in fed condition.
89688788|NCT05329675|Sham Comparator|Arm A|one capsule /day
89688789|NCT05329675|Experimental|Arm B|two capsule/day
89688790|NCT05329675|Experimental|Arm C|Three capsule /day
89688791|NCT05290987|Experimental|Advanced Water S-100 ionized nasal spray|2 sprays in each nostril, 6 times a day during 8 days
89050705|NCT01163149|No Intervention|Concurrent Control|Following completion of the Week 24 visit, all patients (including those randomized to the concurrent control cohort) may be eligible to participate in an open-label extension treatment period. In this extension period, all patients will be treated with daily SC injections of 0.5 mg/kg/day asfotase alfa (a total of 3.5 mg/kg/week) for approximately 24 weeks, then subjects will receive 1 mg/kg/day 6 days/week for an additional 48 weeks or until regulatory approval of the drug.
89050706|NCT04676126|Experimental|Experimental|Subjects in the experimental arm will consume 1.5 Tbsp (22.2 mL) of a commercial macular pigment-containing medical food (liquid) once per day and use a carbonic anhydrase inhibitor topical eye drop (2% dorzolamide ophthalmic solution) three times per day in both eyes for 3 months.
89050707|NCT04676126|Placebo Comparator|Placebo|Subjects in the placebo arm will consume 1.5 Tbsp (22.2 mL) of a placebo liquid which resembles the commercial macular pigment-containing medical food (liquid) in taste once per day and use a lubricating eye drop (0.5% sodium + 0.9% glycerin ophthalmic solution) three times per day in both eyes for 3 months.
89050708|NCT04598373||IDT patients|Allocated to an IDT program
89050709|NCT04598373||Non-IDT patients|Not allocated to an IDT program
89050710|NCT04675619|Experimental|Oral pirfenidone|Pirfenidone will be administered orally in 267 mg capsules taken with food. The dose will be titrated over 2 weeks from one capsule three times a day during Week 1 to two capsules three times a day during Week 2 then maintenance dose (three capsules three times a day Week 3.
89050711|NCT04675619|Experimental|Standard care|Standard care
89215666|NCT06027372||IPF patients without acute exacerbation during test period|"IPF patients completing pulmonary function, overnight SpO2 monitor and LARGAN ECG Holter remain stable during test period."
89215667|NCT06027346|Experimental|Bio-008 0.3mg/kg|group1
89679383|NCT04142138|Experimental|nutrition implementation|Volunteers with prehypertension, but otherwise healthy, will complete a screening visit, then be admitted to the In-Patient Unit for fourteen (14) days. Participants will be admitted for 5 days during the week and then go on pass for 2 weekend days each week with packed DASH diet meals. During hospitalization we will: 1) collect samples of blood and urine daily 2) monitor blood pressure, weight and pulse twice daily 3) collect 24-hour urine, twice during the period of two weeks 4) serve participants a menu based on DASH principles, namely low in sodium and high in potassium.
89679384|NCT01590277|Experimental|Active Ethanol and Active Iomazenil|"Participants will receive in a randomized, double-blind, cross-over design, ethanol or placebo and iomazenil or placebo.~Potential Randomizations: a) active ethanol and placebo iomazenil, b) active ethanol and active iomazenil, c) placebo ethanol and active iomazenil, and d) placebo ethanol and placebo iomazenil"
89679385|NCT01590277|Experimental|Active Ethanol and Placebo Iomazenil|"Participants will receive in a randomized, double-blind, cross-over design, ethanol or placebo and iomazenil or placebo.~Potential Randomizations: a) active ethanol and placebo iomazenil, b) active ethanol and active iomazenil, c) placebo ethanol and active iomazenil, and d) placebo ethanol and placebo iomazenil"
89679386|NCT01590277|Experimental|Placebo Ethanol and Active Iomazenil|"Participants will receive in a randomized, double-blind, cross-over design, ethanol or placebo and iomazenil or placebo.~Potential Randomizations: a) active ethanol and placebo iomazenil, b) active ethanol and active iomazenil, c) placebo ethanol and active iomazenil, and d) placebo ethanol and placebo iomazenil"
89679387|NCT01590277|Placebo Comparator|Placebo Ethanol and Placebo Iomazenil|"Participants will receive in a randomized, double-blind, cross-over design, ethanol or placebo and iomazenil or placebo.~Potential Randomizations: a) active ethanol and placebo iomazenil, b) active ethanol and active iomazenil, c) placebo ethanol and active iomazenil, and d) placebo ethanol and placebo iomazenil"
89679388|NCT03586622|Experimental|Low FODMAP diet|Low FODMAP diet (LFD) Each IBS patient randomized to the Australian exclusion diet, Low FODMAP diet (LFD) group (n=52) will when allocated to LFD group have a one-hour counseling to the LFD by a nutritionist at the hospital. Within this one hour a diet anamnesis of the patient will be made in order to register the High FODMAP foods the patient is consuming (important that one find good low FODMAP substitutions). Based on the diet anamnesis optimization of the low FODMAP diet counseling can be made. They will receive hands-out with recipes, tips, meal plans, list of suitable low FODMAP foods and folder of foods they should avoid- most of information in the LFD folder patients will also find in the app 'Low FODMAP diet' which they will receive free of charge.
89679389|NCT03586622|Experimental|VSL#3®|Each IBS patient randomized to the probiotic VSL#3 arm (n=52) will at randomization be given VSL#3 for 4 weeks (56 sachets) together with a leaflet on VSL#3 - holding information on the product from the manufacture regarding storage, nutritional information etc. If the patients have any questions regarding the treatment, they can ask the project investigator handing out the VSL#3 to them. They will be instructed in taking their VSL#3 (2 sachets a day) as described by the manufacturer
89679390|NCT03586466|Experimental|BupreCare|The BupreCare system is an integrated medication management and patient monitoring system, consisting of a smart medication-tracking dispenser and online platform. The dispensing component is a portable smart dispenser and secure pill cartridges that is programmed with an individualized treatment plan for each patient. This arm will be assigned a MedicaSafe device that will have their buprenorphine/naloxone securely stored. Treatment reports of their dispensation history will be collated and available to the treatment team.
89679391|NCT03586466|Active Comparator|Treatment as Usual|This arm represents an active comparator for the experimental group. Subjects in this group will undergo TAU, with no changes to the way that they receive their medication. They will have pill counts bi-weekly to examine adherence.
89679392|NCT03586466|Active Comparator|Treatment as Usual with MEMS|This arm represents a second active comparator for the experimental group. Subjects in this group will receive their medication in a MEMS pill bottle, but otherwise will undergo TAU.
89050712|NCT04675892|Active Comparator|A1 pulley group|A1 pulley division only
89050713|NCT04675892|Experimental|A1 pulley + FDS group|Combination of A1 pulley division and excision of one or both slips of the flexor digitorum superficialis tendon
89215668|NCT06027346|Experimental|Bio-008 1.0mg/kg|group2
89215669|NCT06027346|Experimental|Bio-008 3.3mg/kg|group3
89215670|NCT06027346|Experimental|Bio-008 10.0mg/kg|group4
89215671|NCT06027346|Experimental|Bio-008 20.0mg/kg|group5
89215672|NCT06027346|Experimental|Bio-008 30.0mg/kg|group6
89679393|NCT00570349|Experimental|Low Dose Cohort|Subjects in the low dose cohort receive 20 part per million (ppm) of nitric oxide via nasal cannula over a 44 hour period.
89215673|NCT06027346|Experimental|Bio-008 40.0mg/kg|group7
89679394|NCT00570349|Experimental|High-Dose Cohort|Subjects in the high dose cohort receive 40 ppm of nitric oxide via nasal cannula over a 44 hour period.
89679395|NCT00570349|Placebo Comparator|Nitrogen|100% Nitrogen (placebo) will be administer at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
89679396|NCT03586388|Experimental|Oral immunotherapy protocol|Eligible children receive the oral food challenge (OCD) protocol
89679397|NCT05582486|Experimental|obstetric violence prevention education intervention|"The training program for the prevention of obstetric violence was given to the midwives and nurses in the experimental group by the researcher in the form of group training in the training hall of the relevant institution. The trainings were completed in a total of 16 sessions, two sessions a day and four sessions a week. Sessions were held between 16:00 and 18:00 on weekdays, each lasting approximately 40-45 minutes, with a 10-minute break between sessions. Thus, the training program applied to the experimental group was completed in 4 weeks.~The main purpose of the training program is to prevent obstetric violence perpetrated by midwives and nurses. The training content created for this purpose included the definition of obstetric violence, pregnant and fetus rights, factors causing obstetric violence and strategies to be used to reduce obstetric violence.~Other Names:~• group-ED"
89679398|NCT05582486|Experimental|Standard of care|"Midwives and nurses in this group did not perform any practice.~. group- SB"
89679399|NCT00608491|Active Comparator|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
89679400|NCT00608491|Experimental|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
89679401|NCT02985086|Active Comparator|Immediate induction with antibiotic prophylaxis|Immediate induction with antibiotic prophylaxis
89679402|NCT02985086|Active Comparator|Immediate induction without antibiotic prophylaxis|Immediate induction without antibiotic prophylaxis
89679403|NCT02985086|Active Comparator|Delayed induction with antibiotic prophylaxis|Delayed induction (>= 12 hours after PROM) with antibiotic prophylaxis
89679404|NCT04143542|Experimental|Groups Q|"In abdominal surgeries, USG guided Quadratus Lumborum 2 blocks are performed for postoperative analgesia. For this purpose, Quadratus Lumborum Block 2 (QLB 2) are frequently used blocks.~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
89679405|NCT04143542|Experimental|Groups T|"In abdominal surgeries, USG guided TAP blocks are performed for postoperative analgesia. For this purpose, TAP blocks are frequently used blocks.~The aim to this study was to evaluate the postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward."
89679406|NCT04143542|No Intervention|Groups C|There was no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg, and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with the target of EtCO2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC). Anesthesia will be discontinued and tracheal extubation will be done once the patient fulfills the extubation criteria.Tramadol 100 mg i.v. Before 15 min end of surgery. The patient control analgesia device will administer all patients.
89679407|NCT03586310|Other|4 nights with PSG|For all subjects: 4 nights with polysomnography and ear-EEG
89679408|NCT03586310|Other|12 nights with ear-EEG|"For a subset of the subjects in arm the '4 nights with PSG', a second phase follows in which each subject sleeps 12 nights with only ear-EEG.~If a night's recording is unsuccessful, for whatever reason, up to 6 additional nights may be attempted."
89679409|NCT03586232|Placebo Comparator|Control|Participants will take two placebo pills q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
89679410|NCT03586232|Experimental|Arnica Montana|Participants will take Arnica Montana, 30C oral, pill and a placebo pill q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
89679411|NCT03586232|Experimental|Arnica Montana and Bromelain|Participants will take Bromelain, 500mg oral pill + Arnica Montana, 30C oral, q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
89679412|NCT04186767|Experimental|Weight loss|
89679413|NCT03586076|Experimental|JHL1922|
89679414|NCT03586076|Active Comparator|Pulmozyme|
89679415|NCT05582252||Experimental group|Patients with ICD who received at least one electric shock in 6 months after ICD implantation
89679416|NCT05582252||Control Group|Patients with ICD who didnot received any electric shock in 6 months after ICD implantation
89679417|NCT05582252||Healthy Group|Healthy Volunteers This group will be used for related bioinformatic analysis (DATA analysis stage) but not in statistical analysis
89679418|NCT03021122|Experimental|Arm A (PedAMINES™ / Conventional Method)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of PedAMINES™ first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of a Conventional Method.
89688792|NCT05290987|Placebo Comparator|Nasal spray with purified water|2 sprays in each nostril, 6 times a day during 8 days
89679419|NCT03021122|Active Comparator|Arm B (Conventional Method / PedAMINES™)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of a Conventional Method first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of PedAMINES™.
89679420|NCT04141436|Experimental|Intervention|Intervention Based on Hypnofertility
89679421|NCT04141436|Active Comparator|Control|Routine clinical procedure
89679422|NCT03890900|Other|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
89679423|NCT00609271|Experimental|1|low carbohydrate diet
89679424|NCT00609271|Active Comparator|2|low fat diet
89679425|NCT00609739|Experimental|Cytarabine + Mitoxantrone|This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.
89679426|NCT04141124|Sham Comparator|Control|5 minutes of reading fictitious biological medical results that are almost normal and unrelated to the upcoming scenario. This condition reflects a likely activity in relation to other patients in charge, pending an announced critical situation.
89679427|NCT04141124|Active Comparator|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
89679428|NCT04141124|Experimental|Breathing exercise combined with HRV|5 minutes of relaxing breathing, guided by a computer helping to follow inspiration and expiration and coupled with direct biological feedback on HRV.
89679429|NCT03020654|Experimental|Treatment group|Virtual environment with fast moving objects these are graded in intensity from 1-7. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
89679430|NCT03020654|Active Comparator|Control group|Virtual environment with no movement graded at grade 0. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
89679431|NCT05246059|No Intervention|Control|12 weeks of observation, safety information provided
89679432|NCT05246059|Experimental|Treatment|12-weeks of daily olfactory training
89679433|NCT03421808|Experimental|SYNC TMS|Patients will receive daily left prefrontal transcranial magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm.
89679434|NCT03421808|Active Comparator|Non-Sync TMS|Patients will receive daily left prefrontal transcranial Magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will NOT be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm. This is the way conventional TMS is delivered now and is FDA approved.
89679435|NCT05245903||Parent Study Participants|The single group in this study will consist of individuals enrolled in the parent study (ClinicalTrials.gov identifier NCT04430517). We aim to enroll approximately 40 individuals aged 18 -89 (inclusive) with either MCI or mild AD who will have the Emerald device deployed in their home for up to 12 weeks, spanning the time of approval of parent study screening and formal study enrollment.
89679436|NCT04140812|Active Comparator|Term infants (≥37+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
89679437|NCT04140812|Experimental|Preterm infants (≤32+0 weeks)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS).
89679438|NCT00571987|Other|1|This is a non-randomized one arm study, all subjects receive treatment (radiofrequency ablation).
89679439|NCT03397238||Non-metastatic TC|blood withdrawal, bone marrow aspiration
89679440|NCT03397238||Metastatic TC|blood withdrawal, bone marrow aspiration
89679441|NCT03397238||MNG surgery|blood withdrawal, bone marrow aspiration
89679442|NCT03397238||MNG RAI treatment|blood withdrawal
89679443|NCT03397238||Healthy volunteers|blood withdrawal
89679444|NCT04140656|Active Comparator|Plantar sensitive exercise group|Plantar sensitive exercises:
89679445|NCT04140656|Active Comparator|Textured insole group|Textured insole group
89679446|NCT00610987|Active Comparator|Cefazolin|Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours after surgical repair of the closed limb fracture.
89215674|NCT06027294|Experimental|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive six sessions of ischemic conditioning over the course of two weeks.
89215675|NCT06027294|Sham Comparator|Ischemic Conditioning Sham|There will also be an IC Sham group which is identical to the IC intervention, except the cuff will only be inflated to 10 mmHg, which is not a high enough pressure to occlude arterial blood flow.
89679447|NCT00610987|Placebo Comparator|Placebo|Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo, after the intraoperative dose(s) of cefazolin
89679448|NCT04140578|Experimental|Antibiotic|Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
89679449|NCT04140578|No Intervention|Control|Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration
89679450|NCT00574171|Experimental|1|
89679451|NCT05581862|Experimental|3 Meals+3 Snacks|This group was followed up for 3 months with an energy restricted weight loss plan composed of 3 main meals and 3 snacks
89679452|NCT05581862|Experimental|3 Meals|This group was followed up for 3 months with an energy restricted weight loss plan composed of 3 main meals
89679453|NCT03585998|Experimental|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide/Cisplatin) with durvalumab, and followed by consolidation durvalumab
89679454|NCT00612235||Lamotrigine Monotherapy|Lamotrigine Monotherapy
89679455|NCT00612235||Levetiracetam Monotherapy|Levetiracetam Monotherapy
89679456|NCT00612235||Carbamazepine Monotherapy|Carbamazepine Monotherapy
89679457|NCT00612235||Normal control (no epilepsy)|Normal control (no epilepsy)
89679458|NCT03585842||Pre-test group|Patients from CMP B coming for consultation or day hospital
89679459|NCT03585842||Test group|Patients suffering from DSMV substance use disorder with one or more psychiatric comorbidities
89679460|NCT00613405|Experimental|Stress + cue exposure|Individuals were exposed to the Trier Social Stress Test (TSST) as well as neutral cues and marijana cues.
89679461|NCT00613405|Experimental|No stress + cue exposure|Individuals were not exposed to a stress test, but were exposed to neutral cues and marijuana cues.
89679462|NCT05245435|Other|planned to undergo cytoreductive prostatectomy|planned to undergo cytoreductive prostatectomy
89679463|NCT05245435|Other|newly diagnosed metastatic hormone-sensitive prostate cancer patients|planned to undergo androgen deprivation therapy, and/or treatment with abiraterone acetate, and/or enzalutamide and/or docetaxel
89679464|NCT05245435|Other|metastatic castration-resistant prostate cancer patients|who were not pre-treated with enzalutamide or abiraterone acetate and planned treatment with those drugs
89679465|NCT05245435|Other|primary oligometastatic hormone-sensitive prostate cancer patients|who refuse to undergo cytoreductive radical prostatectomy will serve as control group
89679466|NCT05582408|Active Comparator|Hearing Aid Standard NR1|Hearing Aid with standard Noise Reduction (NR1) serves as reference condition.
89679467|NCT05582408|Experimental|Novel Noise reduction principles|Noise Reduction Principle NR2 and NR3.
89679468|NCT00575029|Experimental|megace treatment|Study subjects will be given 600mg of MA for oral ingestion per day for duration of 8 weeks. They will be monitored every week clinically for the development of adrenal insufficiency by review of symptoms, physical exam, body weight, pulse, and blood pressure. Subjects also will undergo biochemical evaluation of adrenal status every two weeks by measurement of serum electrolytes, serum cortisol, serum adrenocorticotropic hormone(ACTH) levels, and the adrenal response to a low dose ACTH (1µgm) stimulation test(see methods).
89679469|NCT03912584|Other|Optical Coherence Tomographer|
89679470|NCT05219695|Experimental|HMIgFUS|Each study participants' tumors will be imaged using Harmonic Motion Imaging (HMI), an ultrasound elastography method. A central portion of the tumor will then be ablated and monitored using Harmonic Motion Imaging guided Focus Ultrasound (HMIgFUS). Only one portion of the tumor will be ablated; the other portions of the tumor, including tumor margins, will not be ablated. Following ablation, the tumor will be imaged again using HMI.
89679471|NCT00499109|Experimental|E. Dual Agent Chemotherapy|"Experimental Arm E.~Patients received treatment according to gene expression strata with four doublet regimens.~Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.~Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.~High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.~High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group."
89679472|NCT00499109|Active Comparator|C. Standard of Care Control Arm|"Control Arm C: Gemcitabine and Carboplatin (GCb).~All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed."
89679473|NCT03585530|Experimental|treatment group|
89679474|NCT03021590|Experimental|Clarithromycin :Concomitant Therapy|Amoxicillin 1000 mg Tablets, Clarithromycin 500 mg Tablets , Tinidazole 500 mg Tablets and Esomeprazole 20 mg Capsule each every 12 hours for 14 days all by mouth
89679475|NCT03021590|Active Comparator|Levofloxacin :Concomitant Therapy|Levofloxacin 500 mg Tablets Amoxicillin 1000 mg Tablets,Tinidazole 500 mg Tablets and Esomeprazole 20 mg each every 12 hours for 14 days all by mouth
89679476|NCT02125721|Experimental|CBTD Patients|Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period
89679477|NCT03021278|Experimental|Saline Injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl).
89679478|NCT03021278|Experimental|Sham Injection|In the sham injection group, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
89679479|NCT03021278|No Intervention|Control Group|The control group will not receive any kind of pain or pinprick sensation.
89679480|NCT00552695|Active Comparator|1|Lidocaine 70 mg/tetracaine 70 mg skin patch
89679481|NCT00552695|Placebo Comparator|2|
89679482|NCT03899948|Experimental|Teacher Anxiety Program for Elementary Students (TAPES)|Teachers in the experimental condition attend a 6-hour training on the TAPES program. The teachers learn to implement a brief intervention (5 meetings) with the student and his or her parent, utilize classroom anxiety-reduction strategies, and apply relationship enhancement strategies to improve the relationship with the target student and parents.
89679483|NCT03899948|Active Comparator|Teacher Anxiety Training (TAT)|Teachers in this condition receive training about childhood anxiety and classroom anxiety-reduction strategies using a 3-hour typical teacher professional development training format.
89679484|NCT00615433|Experimental|Lurasdione 40mg tablets|
89679485|NCT00615433|Experimental|120mg|
89679486|NCT00615433|Active Comparator|15mg Olz|
89679487|NCT00615433|Placebo Comparator|Sugar pill|
89679488|NCT00553163|Active Comparator|Gut-focussed hypnotherapy (GFH).|Gut-focussed hypnotherapy (GFH).
89679489|NCT00553163|Sham Comparator|Educational sessions|Regular sessions to learn about UC from research nurse
89679490|NCT03585374|Experimental|A_test drug_Methoxyflurane (Penthrox®)|Pain from moderate to severe (NRS score 4-10). 3 ml of methoxyflurane vaporized through the Penthrox® inhaler. The drug is self administered under the supervision of investigators/study nurse. The treatment duration is about 25 minutes. The patient is instructed to breath normally and to close the diluter aperture via his/her forefinger to increase the analgesic effect, if needed. In case of pain increase or insufficient pain relief the investigator is allowed to administer a rescue medication as per local routine practice.
89215676|NCT06027281||Married women who had female genital mutilation|
89215677|NCT06027281||Married women who didn't have female genital mutilation|
89215678|NCT06027203||transrectal biopsy|
89215679|NCT06027203||transperineal biopsy|
89215680|NCT06027164||Study Subjects|Ultrasound scans conducted by novice users and experts on this cohort.
89679491|NCT03585374|Active Comparator|B_comparator_Morphine/Paracetamol/Ketoprofen|"The comparator to be administered will vary according to pain intensity and local clinical practice.~In case of severe pain (NRS score ≥ 7), morphine will be administered at a dose of 0.10 mg/kg body weight.~In case of moderate pain (NRS score 4-6) paracetamol or ketoprofen will be administered respectively at a 1 g and 100 mg dose.~All comparator will be administered by intravenous drip in a maximum 10 minutes time of infusion. .~Maximum time of infusion 10 minutes."
89679492|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 2 Growth Factors|Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)
89679493|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 1 Growth Factor|Growth Factor = granulocyte-colony stimulating factor (G-CSF)
89679494|NCT00615589|Experimental|Flu-Bu4|Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.
89679495|NCT03832244||Simple snoring|Patients undergoing to Sub-mental ultrasonography with Normal sleep: Fewer than 5 events per hour measured in over-night polysomnography
89679496|NCT03832244||Mild OSA|Patients undergoing to Sub-mental ultrasonography with Mild sleep apnea: 5 to 14 events per hour measured in over-night polysomnography
89215681|NCT06027151|No Intervention|Scaling and root planning|Once the patients fulfill the inclusion criteria and are randomly assigned to this group, they undergo scaling and root planning by the consultant. Baseline values are recorded, and patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
89215682|NCT06027151|Experimental|Scaling and root planning plus metronidazole gel|After fulfilling the inclusion criteria and randomly assigning to this group, they undergo scaling and root planning by the consultant. Baseline values are recorded, and 1ml of 1% metronidazole gel is applied subgingivally. The patients are instructed not to spit or rinse for at least one hour. Then patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
89215683|NCT06027151|Experimental|Scaling and root planning plus minocycline gel|After fulfilling the inclusion criteria and being randomly assigned to this group, the patients undergo scaling and root planning by the consultant. Baseline values are recorded, and 1ml of 2% minocycline gel is applied subgingivally. The patients are instructed not to spit or rinse for at least one hour. Then patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
89215684|NCT06027151|Experimental|Scaling and root planning plus combination of metronidazole and minocycline gels|After fulfilling the inclusion criteria and being randomly assigned to this group, the patients undergo scaling and root planning by the consultant. Baseline values are recorded, 1ml of the combination of 1% metronidazole gel and 2% minocycline gel is applied subgingivally. The patients are instructed not to spit or rinse for at least one hour. Then patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
89215685|NCT06027138|Active Comparator|blood flow resistance training|"vertical jump test~1RM tests times pull ups and push ups test"
89215686|NCT06027138|Experimental|slow motion strength training|"vertical jump test~1RM tests times pull ups and push ups test"
89215687|NCT06027073|Active Comparator|omalizumab|standard antiasthmatic therapy and omalizumab
89215688|NCT06027073|Active Comparator|oral tablet HDM-immunotherapy|standard antiasthmatic therapy and oral immunotherapy
89215689|NCT06027073|Active Comparator|combi therapy|standard antiasthmatic therapy and omalizumab, and oral immunotherapy
89215690|NCT06027073|No Intervention|control|
89679497|NCT03832244||Moderate OSA|Patients undergoing to Sub-mental ultrasonography with Moderate sleep apnea: 15 to 29 events per hour measured in over-night polysomnography
89679498|NCT03832244||Severe OSA|Patients undergoing to Sub-mental ultrasonography with Severe sleep apnea: 30 or more events per hour measured in over-night polysomnography
89679499|NCT00575185|Active Comparator|Valomaciclovir|Valomaciclovir 2 grams orally twice daily for 21 days
89679500|NCT00575185|Placebo Comparator|placebo|placebo 2 tablets twice daily for 21 days
89679501|NCT00499655|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
89679502|NCT00499655|Experimental|Arm II|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.
89679503|NCT03585140|Active Comparator|Normal Diet|Participants will receive a normal diet according to their metabolic status.
89679504|NCT03585140|Experimental|Low glycemic diet|Participants will receive a low-glycemic index and load diet according to their metabolic status. Milk and vitamin supplements will be eliminated from the diet.
89679505|NCT03584984|Experimental|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|socket preservation with a mixture of autogenous bone graft acquired at the time of extraction mixed with a 50:50 ratio of Anorganic bovine bone
89679506|NCT03584984|Active Comparator|Anorganic bovine bone graft (ABB)|filling the extraction socket with ABB graft
89679507|NCT03584984|Active Comparator|Absorbable gelatin Sponge|Filling the socket with an absorbable gelatin sponge
89679508|NCT00575887|Experimental|1|
89679509|NCT03219125||Group 1 (cases)|occurence of incident major osteoporotic fracture less than 12 weeks
89679510|NCT03219125||Group 2 (controls)|no history of fragility fracture
89679511|NCT04147052|Experimental|iSLEEPms|Participants randomized to iSLEEPms complete a 4-week online program with telephone support, based on CBT-I.
89679512|NCT04147052|No Intervention|Treatment As Usual|Participants randomized to TAU continue their usual care and are encouraged to avoid starting any new sleep treatment unless deemed necessary by a health care provider.
89679513|NCT00575965|Experimental|Simvastatin|Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression.
89679514|NCT04142060|Experimental|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously
89679515|NCT01797887|Experimental|Ayurveda|Ayurveda Diet and Lifestyle Counseling
89679516|NCT01797887|Active Comparator|Conventional|Standard Conventional Diet and Lifestyle Counseling
89679517|NCT03217097|Experimental|Unmethylated MGMT NET - OX|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
89050714|NCT04598100|Active Comparator|FOCUS-EC|"FOCUS-EC provides developmental guidance, parent education, and key resilience skills that promote positive individual and family coping, including emotional regulation, problem solving, goal setting, communication, and management of deployment & combat stress reminders, which foster parent-child and family cohesion. The intervention is delivered in six 90-minute sessions in the family home. Each session is structured with a check-in, review of the previous week's home activity, primary activity and discussion, selection of a new home activity, and a closing check-out. The family learns and practices the skills during the sessions, commits to practicing the skills during the week, and reports on their experiences the following session so that skills can be reinforced and adjustments made. FOCUS-EC promotes parenting skills and more cohesive family relationships in two key phases: 1) creating a family deployment and reintegration timeline and 2) enhancing parent-child interactions."
89215691|NCT06027060||NSAIDs users|90 patients taking NSAIDs for over 3 months
89679518|NCT03217097|Active Comparator|Unmethylated MGMT NET - ALKY|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
89679519|NCT03217097|Experimental|Methylated MGMT NET - OX|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
89679520|NCT03217097|Active Comparator|Methylated MGMT NET - ALKY|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
89679521|NCT04147988|Other|DONALD T list|adults on the DONALD T list seeking diagnostic advice on autism spectrum disorder or asperger's syndrome
89679522|NCT03623828|Experimental|Apomorphine treatment|"Treatment by apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: 5-days titration phase (increasing doses from 0 to 4 mg/h), 7 days of maintenance at 4 mg/h and 18 days of maintenance phase with possible increase up to 6 mg/h if well tolerated.~Two days before the initiation of apomorphine, domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects. It will be maintained at least 7 days before an optional tapering off in the absence of nausea of vomiting."
89679523|NCT03581006||Intervention Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.~This intervention group will undergo technology based monitoring and behavioral participation in a dietary and exercise program with the intent of weight loss and compliance with a low-calorie Mediterranean diet."
89679524|NCT03581006||Control (Usual care) Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.~This group will receive no dietary or behavioral intervention. They will continue usual care with their home physicians."
89679525|NCT00501995|Experimental|IV Cyclophosphamide (50 mg/kg)|This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .
89679526|NCT03589898|Experimental|Gabapentin|Single dose of gabapentin 900 mg will be given and neuroimaging markers will be measured before and after administration of gabapentin
89679527|NCT03584828|Experimental|Tele-Rehabilitation - intervention|Following the standard rehabilitation intake process the subjects in the Tele-rehaab arm will receive physiologic consultation based on clinical stress tests and clinical data passed from the physician. The Tele-rehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
89679528|NCT03584828|No Intervention|Usual care|The usual care arm will receive general recommendations for a healthy and active lifestyle and community cardiologist and primary care physician according to local guidelines.
89679529|NCT00577135|Experimental|Q12 hour bolus|Furosemide-Q12 hour bolus
89679530|NCT00577135|Experimental|Continuous Infusion|Furosemide-Continuous Infusion
89679531|NCT00577135|Experimental|Low Intensification|Furosemide-Low Intensification
89215692|NCT06027060||non-NSAIDs users|90 non-NSAIDs users undergoing physical examination
89679532|NCT00577135|Experimental|High Intensification|Furosemide-High Intensification
89679533|NCT03583580|Experimental|Accelerated Partial Breast Irradiation|Accelerated partial breast irradiation (APBI) to the region of tumour bed
89679534|NCT00502853|Experimental|1|
89679535|NCT00617539|Experimental|irinotecan and temozolomide|
89679536|NCT03584750|Active Comparator|Intervention group|Floating
89679537|NCT03584750|Placebo Comparator|Control group|Placebo floating
89215693|NCT06026995|Experimental|experimental group|
89215694|NCT06026995|Active Comparator|control group|
89215695|NCT06026982|Experimental|Gut Health Surveys|Participants will take a pre-survey to evaluate their cravings. They will then be started on a regimen of probiotic and prebiotic with a pickle daily for 30 days to improve gut health. Then participants will take the same survey to evaluate if there has been any decrease in cravings.
89215696|NCT06026969||Lyme disease|"Pregnant participants in the Lyme disease cohort will meet CDC criteria for clinical and/or laboratory diagnosis of Lyme disease during pregnancy based on stage of disease. Participants will be enrolled following confirmation that they have been diagnosed by a medical professional per CDC guidelines.~Participants in this cohort may be enrolled during any trimester of pregnancy. Live-born infants will be included in the cohort and followed through age 18 months."
89215697|NCT06026969||Post-treatment Lyme Disease Syndrome (PTLDS) or Chronic Lyme|"Pregnant participants in the PTLDS/Chronic Lyme cohort will have been diagnosed with PTLDS/Chronic Lyme by a health care provider no less than 6 months, but no greater than 3 years, prior to enrollment. Participants will be enrolled following confirmation that they have been diagnosed by a medical professional per CDC guidelines.~Participants in this cohort may be enrolled during any trimester of pregnancy. Live-born infants will be included in the cohort and followed through age 18 months."
89215698|NCT06026943|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
89679538|NCT03584750|No Intervention|No-treatment group|Waiting list
89679539|NCT05214625||Gastroenterology patients|"Patient receiving an endoscopic procedure because of regular care will be considered eligible for inclusion. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases.~Patients will be asked to complete a questionnaire concerning AI. No intervention will be administered."
89679540|NCT05214625||Gastroenterology physicians|"GI physicians (both gastroenterologists and gastroenterology fellows), participating in a yearly gastroenterology and hepatology training day, will be asked for their participation in this study.~Physician will be asked to complete a questionnaire concerning AI. No intervention will be administered."
89679541|NCT03584672||Patients with Multiple Sclerosis|Patients with Multiple Sclerosis (Expanded Disability Status Scale (EDSS) score < 7)
89679542|NCT03584672||Healthy Controls|Healthy people
89679543|NCT03620123|Experimental|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
89679544|NCT03620123|Other|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
89679545|NCT03581162||Patients|Patients with diagnosis of Juvenile Mixed Connective Tissue Disease
89679546|NCT03581162||Controls|Healthy, age-and sex-matched controls
89679547|NCT00578071|Experimental|Treatment|panitumumab, oxaliplatin, capecitabine and EBRT
89679548|NCT03584438|Experimental|Hanlon Real iTBS Protocol 1|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 3600 pulses are delivered over 19 minutes.
89679549|NCT03584438|Experimental|Hanlon Real iTBS Protocol 2|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 1800 pulses are delivered over 9 minutes and 30 seconds.
89679550|NCT03584438|Experimental|Huang Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 190 seconds (a total of 600 TMS pulses).
89679551|NCT03584438|Experimental|Gamboa Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 380 seconds (a total of 1200 TMS pulses).
89679552|NCT03584438|Sham Comparator|Sham iTBS protocol|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin over the left motor cortex (C3) and beneath the coil.
89679553|NCT00555581|Experimental|400 mg daily of Imatinib Mesylate|All patients were treated with imatinib mesylate at a target dose of 400 mg daily by mouth for 12 months. Dose modifications and interruptions were made for AE and were recorded. After 12 months of treatment, imatinib was stopped for 3 months. Patients were reassessed and offered entrance to an extension phase of the trial.
89679554|NCT03589820|Active Comparator|Artificial liver support system group|30 patients will receive treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine.
89679555|NCT03589820|No Intervention|Control group|30 patients will receive treatment of internal medicine.
89679556|NCT03589664||Non-Sternotomy Group|Subjects who have no prior sternotomy
89679557|NCT03589664||Sternotomy Group|Subjects who previously underwent a sternotomy procedure.
89679558|NCT00504023|Experimental|imiquimod|This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).
89215699|NCT06026930|Experimental|Lipus side: canine retraction|application of LIPUS with translation of maxillary canine that will be performed on intervention sides according to a standardized protocol
89215700|NCT06026930|No Intervention|LIPUS side control side|LIPUS side:canine retraction control side
89215701|NCT06026930|Experimental|LLLT side canine retraction|translation of maxillary canine that will be performed with LLLT application according to a standardized protocol
89679559|NCT03020108||Group 1|The group 1 will comprise of 30 patients with benign ovarian cysts such as mature teratoma or simple serous cysts on ultrasound examination.
89679560|NCT03020108||Group 2|The group 2 will comprise of 30 patients with diagnosis of stage 1-2 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
89679561|NCT03020108||Group 3|The group 3 will comprise of 30 patients with diagnosis of stage 3-4 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
89679562|NCT03589586|Experimental|DermACELL AWM + Conventional Care|DermACELL AWM, acellular dermal matrix, plus conventional wound care- DermACELL AWM will be applied at the Baseline visit. Conventional wound care will include advanced wound dressings and multilayer compression.
89679563|NCT03589586|No Intervention|Conventional Care|Conventional wound care will include advanced wound dressings and multilayer compression.
89215702|NCT06026930|No Intervention|LLLT side canine retraction control side|LLLT side canine retraction control side wihout intervention
89215703|NCT06026930|Experimental|LIPUS groupMolar distalization group inrervention side|distalization assisted with LIPUS according to a standardized protocol
89215704|NCT06026930|No Intervention|LIPUS groupMolar distalization group control side|distalization without LIPUS intervention
89522625|NCT03398317|Experimental|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection
89522626|NCT03398317|Active Comparator|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for Oocyte injection.
89522627|NCT03398239|Active Comparator|BPAP ST/T|Non-invasive Ventilation with BPAP ST/T mode
89522628|NCT03398239|Experimental|AVAPS|Non-invasive Ventilation with AVAPS mode
89522629|NCT03126175|Active Comparator|Above elbow immobilization|Above elbow immobililization with short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow. Additional splint with a 15cm width splint on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
89522630|NCT03126175|Experimental|Below elbow immobilization|Below elbow immobilization with exclusively short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow.
89522631|NCT03396523|Experimental|Losartan group|
89522632|NCT03396523|Placebo Comparator|Placebo group|
89522633|NCT03126097|Experimental|JNJ-64155806+COCP+JNJ-64155806 with COCP|Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 [COCP Lead-in Phase]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ-64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 [JNJ-64155806 + COCP Co-administration Phase].
89522634|NCT03398083|Active Comparator|CBD (500 mg)|CBD (500 mg) capsule by mouth one time during the 18 day treatment period
89522635|NCT03398083|Active Comparator|CBD (1000 mg)|CBD (1000 mg) capsule by mouth one time during the 18 day treatment period
89522636|NCT03398083|Active Comparator|THC (2.5 mg)|THC 2.5 mg capsule by mouth one time during the 18 day treatment period
89522637|NCT03398083|Active Comparator|THC (30 mg)|THC 30 mg capsule by mouth one time during the 18 day treatment period
89522638|NCT03398083|Active Comparator|Alprazolam|Alpraxolam 1.5 mg capsule by mouth one time during the 18 day treatment period
89522639|NCT03398083|Placebo Comparator|Placebo Oral Capsule|Placebo capsule by mouth one time during the 18 day treatment period
89522640|NCT03398005|Experimental|CaPre|
89522641|NCT03398005|Placebo Comparator|Placebo|
89522642|NCT03397927|Experimental|orthosis|
89522643|NCT03392233|Experimental|Phase II open lable Study|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time.
89522644|NCT03126721|Experimental|oral midazolam alone|single dose of oral midazolam administered alone in period 1
89522645|NCT03126721|Experimental|oral midazolam administered with multiple doses of PF-06751979|single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2
89522646|NCT03392155|Experimental|Training & Nutrition|Participants receive performance training twice a week for 12 weeks and group and individual nutritional counseling during the 12 weeks.
89522647|NCT04928521|Active Comparator|ESP block with 20 mL local anesthetic solution|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 20 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
89522648|NCT04928521|Active Comparator|ESP block with 30 mL local anesthetic solution|An erector spinae plane block will be performed at the level of the 5th thoracic vertebrae with 30 mL of 0.25% bupivacaine solution under ultrasound guidance before the operation.
89522649|NCT03126565|Experimental|Group A|This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
89522650|NCT03126565|No Intervention|Group B|This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
89522651|NCT03392077||Group A: cervical dilatation|patients who will have cervical dilatation during Caesarean section
89522652|NCT03392077||Group A: non cervical dilatation|patients who will have not cervical dilatation during Caesarean section
89522653|NCT02823847|Experimental|Oral Screening|Participants given a screening interview at baseline. Carbon monoxide testing given to participants at baseline. Participants who want to stop smoking are given referral information for a tobacco cessation program. Participants undergo an oral examination using conventional light, and oral examination using a fluorescence light-based hand held device at baseline, and again two weeks later. Oral lesions still present after two weeks are biopsied. Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation.
89522654|NCT03396289|Active Comparator|Control Group|Patients in this group will receive conventional physiotherapy programme including balance exercises, 3 times a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other 2 sessions will be performed at home.
89215705|NCT06026930|Experimental|LLLT group: distalization intervntion side|distalization will be commenced with application of LLLT according to a standardized protocol
89215706|NCT06026930|No Intervention|LLLT group: distalization control side|distalization will be commenced without application of LLLT according to a standardized protocol
89215707|NCT06026930|Experimental|LIPUS group: leveling and alignment|leveling and alignment assisted with LIPUS according to a standardized protocol
89215708|NCT06026930|Experimental|LLLT group: leveling and alignment|leveling and alignment be commenced with application of LLLT according to a standardized protocol
89215709|NCT06026930|No Intervention|leveling and alignment without intervention|leveling and alignment without intervention
89215710|NCT06026930|Experimental|LIPUS group: Intrusion|intrusion assisted with LIPUS according to a standardized protocol
89215711|NCT06026930|Experimental|LLLT group: Intrusion|intrusion assisted with application of LLLT according to a standardized protocol
89215712|NCT06026930|No Intervention|intrusion control group|intrusion without intervention
89215713|NCT06026904|Active Comparator|Active Comparator: Real Stimulation|The active Stimulation of taVNS lasted 30 mins. The stimulation protocol is preset to a biphasic impulse frequency of 25 Hz with a stimulation duration of 30 s, followed by a 30 s off phase. Behavior and ERPs datasets should be acquired before the first taVNS session and after the last taVNS session.The electrical current is transmitted by a titanium electrode placed at the cymba conchae.
89215714|NCT06026904|Sham Comparator|Sham Comparator: Sham Stimulation|The active Stimulation of taVNS lasted 30 mins. The stimulation protocol is preset to a biphasic impulse frequency of 25 Hz with a stimulation duration of 30 s, followed by a 30 s off phase. Behavior and ERPs datasets should be acquired before the first taVNS session and after the last taVNS session.The electrical current is transmitted by a titanium electrode placed at the earlobe of the midpoint of the outer ear margin.
89215715|NCT06026878|Experimental|gemcitabine, nimotuzumab and toripalimab induction treatment|"Gemcitabine at a dose of 1 g per square meter of body-surface area on days 1 and 8 every 3 weeks for two cycles.~nimotuzumanb 400mg every 3 weeks for two cycles. toripalimab 240mg every 3 weeks for two cycles."
89215716|NCT06026878|Active Comparator|gemcitabine and cisplatin|Gemcitabine at a dose of 1 g per square meter of body-surface area on days 1 and 8 and cisplatin at a dose of 80 mg per square meter on day 1 were administered intravenously once every 3 weeks for two cycles.
89215717|NCT06026865|Experimental|S-adenosylmethionine (SAMe)|Participants randomized to SAMe Group will receive S-adenosyl-L-methionine 1200 mg/daily (as 2400mg SAMe disulfate tosylate) in tablets in two divided doses (800mg in the morning and 400mg midday) over the period of 6 months. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.
89215718|NCT06026865|Placebo Comparator|Placebo|Patients in Placebo Group will receive a placebo of identical appearance, smell and taste, with the same schedule. In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg.In addition, patients will receive standard treatment with ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg b.w.
89215719|NCT06026787|Experimental|Dapagliflozin Arm|During the study duration of 6 months, this cohort will be administered a daily dose of 10 mg dapagliflozin in conjunction with the standard of care for primary nephrotic syndrome based on the KDIGO 2021 guidelines. The conventional treatment regimen may encompass immunosuppressive medications, agents that block the renin-angiotensin-aldosterone system (RAAS), statins, and diuretics as deemed necessary.
89215720|NCT06026787|No Intervention|Control Arm|This cohort will exclusively be subjected to the standard of care tailored for primary nephrotic syndrome. This could encompass administration of immunosuppressive drugs, agents targeting the renin-angiotensin-aldosterone system (RAAS), statins, and diuretics as warranted by individual needs.
89215721|NCT06026748|Experimental|XJ103 Injection|Participants will receive a single dose of XJ103 intravenously.
89215722|NCT06026748|Placebo Comparator|Placebo|Participants will receive a single dose of placebo intravenously.
89215723|NCT06026735||lung cancer with brain metastasis|
89215724|NCT06026735||lung cancer with leptomeningeal metastasis|
89215725|NCT06026722|Experimental|interventional group|patient will follow cognitive behavioral therapy for insomnia 1 per week during 1 month. this therapy will start a month after inclusion.
89215726|NCT06026722|Other|control group (waiting list)|patient will follow cognitive behavioral therapy for insomnia 1 per week during 1 month. this therapy will start 7 month after inclusion.
89215727|NCT06026709|Experimental|usual care + MindWellness group|
89215728|NCT06026709|No Intervention|usual care|
89215729|NCT06026696||Patients treated for acute cerebrovascular pathology cerebrovascular disease|
89215730|NCT06026644||Quality of life assessment|Quality of life questionnaires
89215731|NCT06026631|Experimental|Intervention arm (breast cancer)|Lipidomic analysis for breast cancer patients
89679564|NCT03589508|Experimental|In-Person Sessions: ABCP_P|In-person therapy sessions: 6 Weekly Prevention Session conducted in person (half of participants will attend alone, half of participants will attend with a significant other)
89679565|NCT03589508|Experimental|Video conference sessions: ABCP_T|Video conference therapy sessions: 6 Weekly Prevention Session conducted using videoconference (half of participants will attend alone, half of participants will attend with a significant other)
89679566|NCT03028688|No Intervention|Current standard of care|Participants in the current standard of care will receive the usual anesthesia care for upper GI endoscopy. In addition participants will have transcutaneous PCO2 measurements performed.
89215732|NCT06026631|Other|Control arm (healthy subject)|Lipidomic analysis for healthy subjects
89215733|NCT06026618||cohort 1|non-anemic patients (Hb > 13 g/dL)
89215734|NCT06026618||cohort 2|mildly anemic patients (Hb 12-13 mg/dL) without criteria for IVI therapy
89215735|NCT06026618||cohort 3|patients treated with IVI (Hb < 12mg/dL or Hb 12-13mg/dL with iron deficiency or risk factors for bleeding)
89215736|NCT06026605|Experimental|WTX212A|WTX212A infusion once every 21 days
89215737|NCT06026566|Experimental|Dos of R 0.1|The dosage of Remimazolam Besylate is 0.1 mg/kg
89679567|NCT03028688|Experimental|High flow nasal cannula group|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen and will also have transcutaneous PCO2 measurements performed.
89679568|NCT03589430||1 child A|child A liver cirrhosis
89215738|NCT06026566|Experimental|Dos of R 0.15|The dosage of Remimazolam Besylate is 0.15 mg/kg
89215739|NCT06026566|Experimental|Dos of R 0.2|The dosage of Remimazolam Besylate is 0.2 mg/kg
89215740|NCT06026566|Experimental|Dos of R 0.25|The dosage of Remimazolam Besylate is 0.25 mg/kg
89215741|NCT06026566|Experimental|Dos of R 0.3|The dosage of Remimazolam Besylate is 0.3 mg/kg
89215742|NCT06026566|Experimental|Dos of R 0.35|The dosage of Remimazolam Besylate is 0.25 mg/kg
89679569|NCT03589430||2 child B|child B liver cirrhosis
89679570|NCT03589430||3 child C|child C liver cirrhosis
89215743|NCT06026553|Experimental|Standard post-operative pain management + Ketorolac (Toradol)|Subject will undergo an IVF cycle with ovarian hyperstimulation and oocyte retrieval. Standard protocols will be used for both study groups and involve administration of gonadotropins to stimulate ovarian follicle growth and regular monitoring with ultrasound and serum estradiol and progesterone levels until follicles reach a desired size. Human Chorionic Gonadotropin (HCG) or leuprolide acetate will be administered to trigger final oocyte maturation prior to oocyte retrieval under anesthesia. On the day of oocyte retrieval, the anesthesia provider will provide syringes of IV ketorolac (30 mg if ≥50 kg or 15 mg if <50 kg per manufacturer dosing) or IV placebo (saline). If assigned to the study arm, IV ketorolac will be administered by the anesthesia provider. All enrolled patients will receive standard post-operative pain management. Patients will be contacted post-operatively, to access pain scores and record the amount of the prescribed narcotic medications utilized since discharge.
89215744|NCT06026553|Placebo Comparator|Standard post-operative pain management + Placebo (saline)|Subject will undergo an IVF cycle with ovarian hyperstimulation and oocyte retrieval. Standard protocols will be used for both study groups and involve administration of gonadotropins to stimulate ovarian follicle growth and regular monitoring with ultrasound and serum estradiol and progesterone levels until follicles reach a desired size. HCG or leuprolide acetate will be administered to trigger final oocyte maturation prior to oocyte retrieval under anesthesia. On the day of oocyte retrieval, the anesthesia provider will provide syringes of IV ketorolac (30 mg if ≥50 kg or 15 mg if <50 kg per manufacturer dosing) or IV placebo (saline). If assigned to the control arm, IV placebo (saline) will be administered by the anesthesia provider. All enrolled patients will receive standard post-operative pain management. Patients will be contacted post-operatively, to access pain scores and record the amount of the prescribed narcotic medications utilized since discharge.
89215745|NCT06026527|Experimental|Group M|Magnesium group
89215746|NCT06026527|Placebo Comparator|Group C|Control group
89215747|NCT06026501|Experimental|PE0116+PE0105|PE0116 injection will be given 1mg/kg or 2mg/kg every three weeks and PE0105 injection will be given 3mg/kg every threee weeks until there appears evidence of progressive disease, intolerable toxicity, or the patient discontinues from the study treatment for other reasons.
89215748|NCT06026488||All enrolled patients|All patient who signed the consent form for participation to the study
89215749|NCT06026280|Placebo Comparator|Conventional Job-Search Program|6 weeks of self-guided job-seeking
89215750|NCT06026280|Experimental|DRIVEN App-Based Program|6 weeks of job-seeking guided by the DRIVEN curriculum
89679571|NCT05702762|Active Comparator|Gentamicin|Subjects will be given one (1) injection intramuscular gentamicin 5 mg/kg (actual body weight unless patient is >120% ideal body weight in which case adjusted body weight will be utilized).
89215751|NCT06026215||Group 1|Heart failure patients requiring ventricular assist device implantation will be included into group 1.
89215752|NCT06026215||Group 2|Heart transplant recipients requiring early extracorporeal membrane oxygenation will be recruited into group 2.
89679572|NCT05702762|Active Comparator|Standard of Care|Oral antibiotic prescription
89679573|NCT03584126||Patients with AF|Patients with atrial fibrillation visiting the outpatient clinic; examined by general examination, electrocardiography, ecocardiography and MRI.
89679574|NCT03584126||Control|Healthy adult volunteers; examined by the study physicians by general examination, electrocardiography, ecocardiography and MRI.
89679575|NCT03589274|Experimental|I-FS-CBT|In I-FS-CBT each participant saw a therapist weekly. The first session was 90 minutes long, and subsequent sessions were 60 minutes long. The I-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care.
89679576|NCT03589274|Experimental|G-FS-CBT|The G-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care. The session organization was modified for a closed group format. The group treatment was designed to provide didactic presentation of coping skills and motivational enhancement material, and group discussion and rehearsal of new skills within a supportive atmosphere that facilitated mutual emotional support and support for abstinence.
89679577|NCT05702606|Active Comparator|Control Group|3 rESWT sessions with a time interval of 1 week between each session.
89679578|NCT05702606|Experimental|Experimental Group A|3 rESTW sessions with a time interval of 2 weeks between each session.
89679579|NCT05702606|Experimental|Experimental Group B|3 rESTW sessions with a time interval of 4 weeks between each session.
89679580|NCT03580694|Experimental|Cemiplimab Monotherapy|In a single dose escalation cohort, participants will receive cemiplimab alone.
89679581|NCT03580694|Experimental|Combination Therapy|"Dose Escalation cohorts:~In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination.~In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination.~Dose Expansion cohorts:~In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab."
89679582|NCT03583892||Group A|In the Group A, a single-dose of 600mg gabapentin was used as part of a multimodal analgesic technique.
89679583|NCT03583892||Group B|In the group B gabapentin was not administered.
89679584|NCT03583736|Active Comparator|Rapid first contact virtual visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
89050715|NCT04598100|No Intervention|Web-Based Family Education|Families in the WB condition will be provided access to online educational materials covering topics such as typical child development, effects of early childhood separations, common child reactions to family stress, and the importance of self-care. CDM families in this condition will also have access to the standard services that are available to OEF/OIF/OND veterans through the VHA system, TriCare, and California Department of Veterans Affairs.
89050716|NCT01163032|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
89050717|NCT01163032|Placebo Comparator|placebo|Placebo capsules, PO daily for 6 months
89050718|NCT04675736|Experimental|brushing force|
89050719|NCT05305300|Experimental|Arm A: Primary Immunization|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. A total of 45 subjects will be enrolled in Arm A. Subjects in Group 1-3 will receive two doses of PIKA COVID-19 vaccine via IM administration on Days 0 and 7.
89679585|NCT03583736|Placebo Comparator|First contact in person office visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
89679586|NCT05702528|Experimental|Immediate treatment|The group will begin using the Apollo Neuro device immediately upon entering the study
89050720|NCT05305300|Experimental|Arm B1: Booster Immunization 1|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B1 will enroll subjects who received Inactivated vaccines and will comprise of 15 subjects per dose. In arm B1, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.
89679587|NCT05702528|No Intervention|Waitlist treatment|The group will be assigned to a waitlist and begin using the Apollo Neuro device twelve weeks after entering the study
89679588|NCT03589196|Active Comparator|Photoselective Vaporization|
89679589|NCT03589196|Active Comparator|Plasma Kinetic Vaporization|
89050721|NCT05305300|Experimental|Arm B2: Booster Immunization 2|There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B2 will enroll subjects who received mRNA vaccines and will comprise of 15 subjects per dose. In arm B2, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.
89050722|NCT04606719|Other|Blood Clot|It is induced through apical foramen by penetrating the periapical area by stainless steel file size 30 to fill the root canal system by growth factors also to be considered as scaffold
89679590|NCT03589196|Active Comparator|Transurethral Resection Of The Prostate|
89679591|NCT03503474||CDI cases|
89679592|NCT03503474||CDI negative controls|
89679593|NCT03589118|Experimental|Qi Gong|Qi gong sessions added to usual well defined medical and psychological support
89679594|NCT03589118|No Intervention|Control|Usual well defined medical and psychological support
89679595|NCT03583502|Experimental|Supplemented|krill oil and fish oil supplement
89679596|NCT03583502|No Intervention|Controls|The control group did not receive any supplementation.
89679597|NCT03589040|Other|Ripivirine arm|All subjects will be administered oral ripilvirine 25mg once daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
89679598|NCT03589040|Other|Darunavir arm|All subjects will be administered oral DRV/r 600/100mg twice daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
89050723|NCT04606719|Active Comparator|Standard PRF|Standard Platelet-rich fibrin will be prepared by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 3000 rpm for 10 min. After centrifugation, three layers will formed in the test tube-base layer of RBCs, top layer of a-cellular plasma, and a PRF clot in the middle. This clot will then pressed between two gauze pieces to form a membrane.
89050724|NCT04606719|Experimental|Advanced PRF|A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
89050725|NCT04187755|Active Comparator|Group I|Participants were given ceftazidime as the antibiotic therapy with standard regimens and dose of antibiotic
89050726|NCT04187755|Experimental|Group II|Participants were given cefepime as the antibiotic therapy with standard regimens and dose of antibiotic
89679599|NCT03580538|Experimental|elastic tube group|
89679600|NCT03580460|No Intervention|Waitlist control|After 8 weeks, individuals randomized to this arm receives the computer-delivered smoking cessation counseling intervention
89679601|NCT03580460|Experimental|Computer Delivered Intervention|Individuals receive a 15-20 minute computer delivered smoking cessation counseling intervention
89679602|NCT03583424|Experimental|Treatment (venetoclax, BEAM)|Participants receive venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
89679603|NCT03583346|Experimental|M6495|
89679604|NCT03583346|Placebo Comparator|Placebo|
89679605|NCT00578305|Experimental|Rituximab 500 mg|Participants received rituximab 500 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
89679606|NCT00578305|Experimental|Rituximab 1000 mg|Participants received rituximab 1000 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
89679607|NCT00578305|Placebo Comparator|Placebo|Participants received placebo intravenously (iv) on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants were switched to receive rituximab 1000 mg iv on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
89679608|NCT03583268|Active Comparator|Moderate Intensity Exercise Alone|45 minutes of moderate intensity exercise at 45-55% of maximum aerobic capacity (active participants) or heart rate reserve (sedentary participants) used as a control condition. Participants will consume a glucerna bar at 10pm following this session.
89679609|NCT03583268|Experimental|70% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 70% heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
89679610|NCT03583268|Experimental|80% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 80% of heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
89679611|NCT03583268|Experimental|90% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 90% of maximum aerobic capacity (active participants every two minutes) or heart rate reserve (sedentary participants every 4 minutes). Participants will consume a glucerna bar at 10pm following this session.
89679612|NCT03156374|Experimental|Ovulation test use|Use of both ovulation tests and standardised care
89679613|NCT03583112|Active Comparator|Dapoxetine|In this group, patients received one dapoxetine hydrochloride tablet before MRI scan.
89050727|NCT00555542|Experimental|1|Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15.
89050728|NCT04606563|Experimental|ARBs (Losartan, Valsartan, Azilsartan, Candesartan, Eprosartan, Irbesartan, Olmesartan, Telmisartan)|Patients will initially receive initial dose of oral ARBs, increased to higher dose after 24 hours and then increased to a max dose after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Tolerance is defined as having no severe adverse events 24 hours after the first dose. Investigators and/or attending physicians discretion may dictate that dose will not be increased, at which point dose will stay at initial or higher dose.
89050729|NCT04606563|No Intervention|Usual Care Control|Usual care for duration of hospitalization for up to 3 months if still hospitalized. Due to the lack of clinical guidance from this emergent disease, this may vary dependent on Institution and/or country
89050730|NCT02885584|Experimental|Transpulmonary pressure controlled mechanical ventilation|transpulmonary pressure will be used for ventilation settings
89050731|NCT02885584|No Intervention|Conventional pressure-controlled mechanical ventilation|transpulmonary pressure will not be used for ventilation settings
89050732|NCT00565968|Experimental|Sorafenib dose escalation|
89050733|NCT01162486|Active Comparator|Rifampin control|Rifampin + midazolam
89050734|NCT01162486|Experimental|RPT 1|RPT Cohort 1 - 5 mg/kg
89050735|NCT01162486|Experimental|RPT 2|RPT Cohort 2 - 10 mg/kg
89050736|NCT01162486|Experimental|RPT 3|RPT Cohort 3 - 15 mg/kg
89050737|NCT01162486|Experimental|RPT 4|RPT Cohort 4 - 20 mg/kg
89050738|NCT01162486|Experimental|RPT 5|RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed
89050739|NCT00555698|Experimental|DBS|DBS
89050740|NCT04314427||Gastric by-pass|Roux-en-Y gastric bypass (RYGB); the stomach is divided with staplers to create a small gastric pouch, while the jejunum is divided 30 to 50 cm distal to the ligament of Treitz. The distal limb is then anastomosed to the small gastric pouch and a jejunojejunostomy is performed 50 to 150 cm distal from the gastrojejunostomy.
89050741|NCT04314427||Sleeve gastrectomy|Sleeve gastrectomy reduces the stomach size by vertical stapling
89050742|NCT04598607|Experimental|Hypidone Hydrochloride 60mg|30mg(10mg×3) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
89050743|NCT04598607|Experimental|Hypidone Hydrochloride 80mg|40mg(10mg×4) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
89050744|NCT04598607|Experimental|Hypidone Hydrochloride 100mg|50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3~8.
89050745|NCT04598607|Placebo Comparator|Placebo 60mg|3 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
89050746|NCT04598607|Placebo Comparator|Placebo 80mg|4 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
89050747|NCT04598607|Placebo Comparator|Placebo 100mg|5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3~8.
89050748|NCT02885701|Experimental|No splint|
89050749|NCT02885701|Experimental|Removable Splint|
89050750|NCT02885701|Experimental|Non-removable Splint|
89050751|NCT01162135|Experimental|Open Label Pilot Study|
89050752|NCT04598178||Taiwan Cohort|For normative Taiwan people, cognitive function will be assessed by the Taiwan version of questionnaire Qmci (Qmci-TW) on Day 0, Day 2, Day 180.
89679614|NCT03583112|Placebo Comparator|Placebo|In this group, patients received placebo tablet before MRI scan.
89679615|NCT03156530|Experimental|Auricular acupuncture|Stimulated with needles at three joint points of the lower limb, knee and ankle. Balance assessments will be performed prior to (initial) pacing, 20 minutes after the initiation of the pacing protocol (second evaluation) and after 5 minutes the final evaluation.
89679616|NCT03156530|Placebo Comparator|Control|Not receive stimulation.
89679617|NCT00578383|Sham Comparator|Sham (inactive) Treatment BPD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
89679618|NCT00578383|Active Comparator|Active LFMS treatment in BPD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
89679619|NCT00578383|Sham Comparator|Sham LFMS Comparator: in MD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
89679620|NCT00578383|Active Comparator|Experimental LFMS: in MD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
89679621|NCT05702294|Experimental|Control|"Adult females with no lower urinary tract symptoms will complete a 3-day paper bladder diary. After each void they will transfer their voided volume to the diary pod (vessel that calculates automatically the voided volume) for the duration of these three days.~After three days the reports of the paper diary versus the electronic diary will be compared."
89679622|NCT05702294|Experimental|LUTS ( Lower urinary tract symptoms) arm|"Adult females with lower urinary tract symptoms will complete a 3-day paper bladder diary. After each void they will transfer their voided volume to the diary pod (vessel that calculates automatically the voided volume) for the duration of these three days.~After three days the reports of the paper diary versus the electronic diary will be compared."
89679623|NCT03582644|Experimental|CRYOTHERAPY INTERVENTION|Patients with end stage knee osteoarthritis, both sexes, 60 years or higher
89679624|NCT03580226||Good glycemic control|Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c < 7.0.
89679625|NCT03580226||Poor glycemic control|Poor glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c >= 7.0.
89679626|NCT00578461|Experimental|Stem Cell Transplant|patient's will be recieving a stem cell transplant on study Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation
89679627|NCT03156296|Active Comparator|BUPIVACAINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
89679628|NCT03156296|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
89679629|NCT00578539|Experimental|Stem Cell Transplant|All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.
89050753|NCT00555776|Active Comparator|1|Randomly,half of the subjects are given Gabapentin.
89050754|NCT00555776|Placebo Comparator|2|Randomly,half of the subjects receive placebo.
89050755|NCT04675463|Other|Budesonide/Glycopyrronium/Formoterol arm|52 weeks treatment
89679630|NCT03517085|Experimental|DTX401 Cohort 1|Dose 1 (2.0 × 10^12 GC/kg) with a reactive steroid regimen (6 weeks, at a starting dose of 40 mg/day, after alanine aminotransferase [ALT] elevation)
89679631|NCT03517085|Experimental|DTX401 Cohort 2|Dose 2 (6.0 × 10^12 GC/kg) with a reactive steroid regimen (6 weeks, at a starting dose of 40 mg/day, after ALT elevation)
89050756|NCT04675463|Other|Glycopyrronium/Formoterol arm|52 weeks treatment
89050757|NCT04598334||COVID-19 positive by RT-PCR|specified number of COVID-19 positive patients will be followed up from admission to outcome (discharge/death/referral). Blood samples will be tested at different time points; cytokines and stool microbiota will be tested at the end of the study and we will analyze the study findings.
89050758|NCT04675112|Experimental|group A genetically informed intervention|Group A patients are offered a genetically based approach to tinnitus management that includes a genetic test and at least three office based treatment sessions. A rationally-designed personalized management plan based on the genetic results is based on four single nucleotide polymorphisms (SNPs) of the dopamine and serotonin pathways, namely COMT rs4680, HTR2A rs7997012, HTR2A rs6311, and TPH2 rs4570625, that have been associated with behavioral or cognitive responses
89215753|NCT06026215||Group 3|Heart transplant recipients who have not previously received a VAD will be recruited into group 3.
89679632|NCT03517085|Experimental|DTX401 Cohort 3|Dose 2 (6.0 × 10^12 GC/kg) with an optimized reactive steroid regimen (7 weeks, at a starting dose of 60 mg/day, after ALT elevation)
89679633|NCT03517085|Experimental|DTX401 Cohort 4|Dose 2 (6.0 × 10^12 GC/kg) with a prophylactic steroid regimen (8 weeks, at a starting dose of 60 mg/day, starting on Day 1)
89679634|NCT00619255|Experimental|Intervention|Adolescent Trauma Support Program
89679635|NCT00619255|No Intervention|Control|Usual Care Control Condition
89679636|NCT03582410|Active Comparator|Absorbable suture|laparoscopic sacral colpopexy with absorbable suture
89679637|NCT03582410|Active Comparator|Non absorbable suture|laparoscopic sacral colpopexy with non absorbable suture
89215754|NCT06025838|Experimental|positive feedback|Participants receive positive feedback and reward for their decisions taken during a small game similar to a normal person's life. For example, they are encouraged to exercise, make food, and interact with friends.
89679638|NCT03156140|Experimental|motion|Right hand performs three different motion types
89688793|NCT05147389||Neoplastic bile duct lesions|This group is confirmed by DSOC videos from patients with DSOC-confirmed neoplastic bile duct lesions, coming from each participating group. Each DSOC video corresponds to a complete DSOC procedure in a single patient. The neoplastic bile duct criteria are in accordance with the two following tools: the Robles-Medranda et al and the Mendoza classification. A further follow will be necessary to confirm neoplastic bile duct lesion and the type: pCCA or dCCA, local extension of iCCA, hepatocarcinoma mixed CCA/hepatocarcinoma, gallbladder cancer, pancreas cancer, or any other neoplastic bile duct lesion. Based on follow-up, videos from patients with confirmed non-neoplastic bile duct lesions will be re-assessed and re-classified or finally excluded by an expert blinded to clinical records and who do not participate in videos classification.
89215755|NCT06025838|No Intervention|no feedback|Participants receive no feedback. While they may undertake the same decisions during a small game similar to a normal person's life, they receive no encouragement and are not given reward or positive feedback.
89215756|NCT06024044|No Intervention|Control|The women patients in the control group who underwent hysterectomy were informed that mobilization training would be performed after a postoperative 2-day waiting period. Meanwhile, no intervention was made except for any routine nursing care.
89215757|NCT06024044|Experimental|Mobilization Training|"A face-to-face Patient Information Form was applied to the training group in the first interview before the hysterectomy operation. The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
89679639|NCT00578617|Active Comparator|Pharmacologic Therapy|Pharmacologic Therapy Rate and/or Sinus Rhythm Control: Patients without other heart disease will receive beta or calcium channel blockers as first line rate control therapy. Patients with underlying coronary artery disease will receive beta-blockers, patients with limited ventricular hypertrophy not warranting exclusion would receive either beta- or calcium channel blockers, while patients with heart failure would be expected to receive carvedilol or metoprolol. Patients randomized to drug therapy may be started on a membrane active drug, in an approach consistent with the recommended Guidelines for Management of Subjects with AF. Each patient will be placed on an anti-arrhythmic drug for an appropriate period and the patient cardioverted to sinus rhythm if necessary. Patients will then be followed for a period of up to 3 months, during which dosage adjustment can be made or the drug replaced with a different anti-arrhythmic drug.
89215758|NCT06023550||Complicated sinonasal infection|Group of patients with a complicated sinonasal infection, including local or systemic complications.
89215759|NCT06023550||Complicated ear or temporal bone infection|Group of patients with a complicated ear or temporal bone infection, including local or systemic complications.
89679640|NCT00578617|Active Comparator|Ablation Therapy|Left Atrial Catheter Ablation: The specific choice of ablation catheters will be left to the investigator from the following list: Lifewire TC XLS, Therapy Dual/Thermocouple, NAVI-STAR/NAVI-STAR DS, Celsius Braided Tip, NAVI-STAR Thermo-Cool, Freezor/FreezorMax, Stinger, Blazer II RF/RPM/SteeroCath /XP, Chilli Cooled.
89679641|NCT00505895|Experimental|Fludarabine + Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).~Melphalan 140 mg/m^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 IV infused starting on day -5."
89679642|NCT00505895|Experimental|Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous daily over 30 minutes for 4 Days (Beginning Day -4).~Lower-Dose Melphalan 100 mg/m^2 intravenous over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 intravenous infused starting on day -5."
89679643|NCT03126890||Linezolid TDM (prospective)|Adult patients received linezolid at NTUH. This prospective cohort study will draw blood from every patient to measure the linezolid blood concentration. After blood concentration analysis by high pressure liquid chromatography (HPLC), the investigator will report the concentration to clinicians and dose adjustment is judged by clinician (not the investigators).
89679644|NCT03126890||Linezolid observation (retrospective)|Adult patients received linezolid at NTUH.
89679645|NCT03582332|Active Comparator|Group A in phase 1|Indomethacin 75 mg, extended release capsule twice daily
89679646|NCT03582332|Active Comparator|Group B in phase 1|Indomethacin 25 mg capsule, 2 capsule twice daily
89679647|NCT03582332|Active Comparator|Group A in phase 2|Etoricoxib 90 mg once daily
89679648|NCT03582332|Active Comparator|Group B in phase 2|Etoricoxib 60 mg once daily
89679649|NCT03156218|Experimental|Without ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
89679650|NCT03156218|Experimental|With mild to moderate ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 100 and < 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
89679651|NCT00619723|Active Comparator|Citicoline|Participants will receive active medication throughout the study. Citicoline will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
89215760|NCT06023550||Complicated neck soft tissue infection|Group of patients with a complicated neck soft tissue infection, including local or systemic complications.
89215761|NCT06023550||Complicated laryngeal infection|Group of patients with a complicated laryngeal infection, including local or systemic complications.
89215762|NCT06023420|Experimental|Study group|Herbal formula 5g daily, and Zometa
89215763|NCT06023420|Active Comparator|Control group|Zometa alone
89215764|NCT06023160||Dutch National anti-NMDAR Encephalitis Cohort|Dutch National anti-NMDAR Encephalitis Cohort
89215765|NCT06023160||German anti-NMDAR Encephalitis Cohort (GENERATE)|German anti-NMDAR Encephalitis Cohort (GENERATE)
89215766|NCT06023160||Spanish anti-NMDAR Encephalitis Cohort|Spanish anti-NMDAR Encephalitis Cohort
89215767|NCT06023160||French anti-NMDAR Encephalitis Cohort|French anti-NMDAR Encephalitis Cohort
89679652|NCT00619723|Placebo Comparator|Placebo|Participants will receive placebo identical in appearance to Citicoline throughout the study. Placebo will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
89679653|NCT03582254|Experimental|[18F]-FDG PET/MR|[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital
89679654|NCT01798693|Placebo Comparator|Placebo (maltodextrin)|Maltodextrin
89679655|NCT01798693|Active Comparator|Multi-Nutrient Blend|Blend of vitamins, minerals, and amino acids, given twice daily
89679656|NCT03582098||Idelalisib and Rituximab|Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.
89050759|NCT04675112|Other|group B control|In Group B, treatments are offered randomly taking care to offer CBT to equal number of patients as in Group A. In both groups, during the first visit, patients are offered a simple, few-minute tinnitus update and advice, relevant to their educational level and are being suggested that an average of 4 sessions are required over a period of approx. 4 months for making tinnitus noise less or not bothersome
89050760|NCT01161628|Experimental|Rituxan|All patients receive Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
89679657|NCT00555893|Experimental|Active Drug|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
89679658|NCT00555893|Placebo Comparator|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
89679659|NCT00578929|Experimental|Olopatadine 0.6% 1 Spray|Olopatadine HCl 0.6% 1 spray per nostril twice daily
89679660|NCT00578929|Placebo Comparator|Vehicle 1 spray|Vehicle 1 spray per nostril twice daily
89050761|NCT04675502|Experimental|Supervised Exercise Group|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In this loading program; respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes is taken. Stretching exercises are done during the cooling period. This group was included in an exercise program 2 days a week, 45-90 minutes, for 12 weeks, accompanied by a specialist physiotherapist to the pulmonary rehabilitation unit in the chest diseases ward.
89050762|NCT04675502|Experimental|Home Exercise Group|For patients to do at home (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), sitting and standing exhaustion, and brisk walking to reach 60-85% of the person's maximum heart rate.)), exercises is taught. Patients were asked to do the exercises at home for 45-90 minutes, 2 days a week, for 12 weeks. Participants of the control group are contacted every two weeks via communication methods such as e-mail, message and telephone conversation.Exercise diary is given to all patients and is taken from them at the end of the study.
89050763|NCT04314505|Experimental|Opioid Sparing Protocol|Preemptive(before incision): Parecoxib sodium 40 mg Postoperative: Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses.
89050764|NCT04314505|Active Comparator|Opioid Based Patient Controlled Analgesia|Preemptive(before incision) and Postoperative: the initial setting was 0.01mg/kg*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours; adjusted by the PCA staff
89050765|NCT04606641|Experimental|Goal specific functional tasks with mirror therapy):|"The session will be performed thrice in a week for total of 4 weeks. Each session will last for 20 minutes. Mirror therapy procedure and functional tasks will be explained to the patient before the start of treatment.~In this group, a mirror will be placed in the sagittal plane of the patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror"
89050766|NCT04606641|Active Comparator|Goal specific functional tasks without mirror therapy|"Session will be performed thrice in a week for total 4 weeks. Each session will last for 20 minutes.~The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks as mentioned in the table below Functional tasks will be same in both groups"
89050767|NCT02885467|Active Comparator|Control|Standard total knee arthroplasty performed through medial parapatellar approach
89050768|NCT02885467|Experimental|Intervention|Total knee arthroplasty performed through medial parapatellar approach with identification, ligation, and burial of saphenous nerve branches
89050769|NCT02885545|Experimental|Left atrial appendage occlusion|Patients receiving the Watchman device will have it placed via a percutaneous trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance. Patients will be anticoagulated for at least 45 days after the procedure.
89050770|NCT02885545|Active Comparator|Continuation of prescribed anticoagulant|Patients continuing medical therapy will continue to take their previously prescribed oral anticoagulation (vitamin K antagonist, apixiban or rivaroxaban) for the duration of the study unless a medical reason to alter therapy occurs.
89050771|NCT04598412||Mexican sample|Aged >60 years (n = 187)
89050772|NCT04598412||German sample|Aged >75 years (n = 97)
89050773|NCT04598412||Northamerican sample|Aged >60 years (n = 200)
89050774|NCT04598412||British sample|Aged >70 years (n = 38)
89050775|NCT04606524||study group|25 postmenopausal females will be included in this study
89050776|NCT04606524||control group|25 premenopausal females will be included in this tudy
89050777|NCT04675268|Experimental|7 night home oximetry|Patients will undergo 7 nights home monitoring with oximetry.
89050778|NCT01161472|Experimental|4mg fesoterodine|
89050779|NCT01161472|Experimental|fesoterodine 8mg|
89050780|NCT01161472|Active Comparator|1mg alprazolam|
89050781|NCT01161472|Placebo Comparator|Placebo|
89215768|NCT06023160||Japanese anti-NMDAR Encephalitis Cohort|Japanese anti-NMDAR Encephalitis Cohort
89215769|NCT06023147|Experimental|E-TACE|Procedure: The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at one milliliter/two milliliter (1mL/2mL), and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
89215770|NCT06021743||Sepsis|Patients hospitalized due to the sepsis
89215773|NCT06021392||Wide local excision of pilonidal sinus|
89215774|NCT06021392||Minimal excision of pilonidal sinus|
89522655|NCT03396289|Experimental|Training Group|In addition to conventional physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other sessions will be performed at home.
89522656|NCT03396133|Experimental|Snap group|individuals in this arm used Snap according to the instruction on time and screened at the symptomatic
89522657|NCT03396133|No Intervention|RC group|patients in the RC arm accepted normal methods
89522658|NCT03389815|Experimental|WX-0593 Tablets|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
89522659|NCT03887117|Active Comparator|IQOS-1|"IQOS + Exercise Training Program~Subjects randomized to IQOS use will switch to IQOS use and participate in an exercise training program."
89522660|NCT03887117|Active Comparator|IQOS-2|"IQOS without Exercise Training Program~Subjects randomized to IQOS use will switch to IQOS use, but will not participate in an exercise training program."
89522661|NCT03887117|Active Comparator|Cigarette Smoking|"Cigarette Smoking + Exercise Training Program~Subjects randomized to continued cigarette smoking and participation in an exercise training program."
89522662|NCT03887117|Active Comparator|Smoking Abstinence|"Smoking Abstinence + Exercise Training Program~Subjects randomized to smoking abstinence and participation in an exercise training program."
89522663|NCT03389737|Experimental|Experimental|Experimental group will have monthly contact with the physicians, during which the athletes will receive individualized care and guidance in support of their performance goals.
89522664|NCT03389737|Active Comparator|Control|Control group will not have monthly contact with the physicians.
89522665|NCT03391843|Experimental|FOLFOXIRI+Cetuximab|FOLFOXIRI+Cetuximab regimen:Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h and cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles.
89522666|NCT03389659|Experimental|Vitamin D3 group|vitamin D3 2000IU (400IU*5pills） po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
89522667|NCT03389659|Placebo Comparator|control group|placebo 5 pills po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
89522668|NCT02819791|Active Comparator|Control group|
89522669|NCT02819791|Experimental|Intervention group|
89522670|NCT04447495||SARS-CoV-2 positive|We will enroll patients within a larger clinical validation study of the iAMP® test against the gold standard (the CDC-recommended test) until we have prospectively collected a total of 100 positive cases.
89522671|NCT04447495||Controls|Current SARS-CoV-2 positivity in the region is approximately 20%, therefore, approximately 400 negative control samples will be needed.
89522672|NCT03395561|Active Comparator|green coffe|2 capsuls of green coffe
89522673|NCT03395561|Placebo Comparator|control|2 capsuls
89522674|NCT03399695|Active Comparator|control|spontaneous breathing through a face mask connected to the anaesthesia machine delivering 100% oxygen gas flow (15l/min)
89522675|NCT03399695|Experimental|ohd|spontaneous breathing through a nasal cannula connected to an humidifier device delivering warm (37°C) high flow oxygen(60l/min)
89522676|NCT03395483||Elective, adult colorectal surgical patients|All patients will be monitored by the non-invasive Masimo Radical7 pulseoximeter (Masimo, Irvine, CA, USA) measuring PPI and the MoorVMS-LDF (Moor Instruments Ldt., Axminster, UK) measuring mesenteric tissue blood flow using doppler flowmetry. Patients will be subjected to a haemodynamic challenge using anti-trendelenburg position.
89522677|NCT04414189||Arm A|Patients with suspected sepsis at the time of admission to the ICU
89522678|NCT04414189||Arm B|Patients not currently suspected but at high risk for sepsis.
89522679|NCT03399461||Group 1|Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.
89522680|NCT03399461||Group 2|Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.
89522681|NCT03399461||Group 3|Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.
89522682|NCT04446637|Experimental|Ipratropium/Levosalbutamol|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
89522683|NCT04446637|Active Comparator|Salbutamol + Ipratropium|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
89522684|NCT02520401|Experimental|Test|Probiotic tablet
89522685|NCT02520401|Placebo Comparator|Control|Control tablet
89522686|NCT03389503|Active Comparator|Right radial approach|Right radial approach for coronary angiography and coronary intervention
89522687|NCT03389503|Active Comparator|Left radial approach|Left radial approach for coronary angiography and coronary intervention
89522688|NCT02520323||Blood only|20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.
89522689|NCT02520323||Blood and BAL|10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.
89522690|NCT03389425|Experimental|SIMPLE weightloss group|
89679661|NCT00578929|Experimental|Olopatadine 0.6% 2 sprays|Olopatadine HCl 0.6% 2 sprays per nostril twice daily
89679662|NCT00578929|Placebo Comparator|Vehicle 2 sprays|Vehicle 2 sprays per nostril twice daily
89679663|NCT00556049|Experimental|1|Sunitinib and gemcitabine
89679664|NCT03581864||Group of 14 patients with post-traumatic complete anirirdia|14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions.
89679665|NCT01797107|Experimental|Treatment eye|Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
89679666|NCT01797107|Placebo Comparator|Durasite|Vehicle of Azasite used as placebo
89679667|NCT03155984||Anti-CD20 antibody|Patients with hematological malignancies receiving anti-CD20 antibody therapy
89679668|NCT00620191|Placebo Comparator|Matching Placebo|Placebo identical to metformin
89679669|NCT00620191|Experimental|Metformin|Metformin 1000 mg twice a day
89679670|NCT05701904|Experimental|Local mechanical vibration applied group|"Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.~Pregnant women who were asked to receive tetanus+diphtheria vaccine by their physician and agreed to participate in the study will be informed about the research by the researcher, and their written and verbal consents will be obtained. Then the vaccine will be administered. Td vaccine will be administered to all pregnant women in the study as IM to the deltoid muscle in the arm they do not use dominantly. Five minutes after the vaccination, the individual descriptor form will be applied to all pregnant women, and the pregnant women will score their satisfaction levels with regard to pain and the method used."
89679671|NCT05701904|Experimental|Shotblocker group|"It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injecting. The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.~Pregnant women who were asked to receive tetanus+diphtheria vaccine by their physician and agreed to participate in the study will be informed about the research by the researcher, and their written and verbal consents will be obtained. Then the vaccine will be administered. Td vaccine will be administered to all pregnant women in the study as IM to the deltoid muscle in the arm they do not use dominantly. Five minutes after the vaccination, the individual descriptor form will be applied to all pregnant women, and the pregnant women will score their satisfaction levels with regard to pain and the method used."
89679672|NCT05701904|No Intervention|Control group|"The vaccine will be administered by following the standard intramuscular injection procedure. Five minutes after vaccination, an individual descriptive form will be applied to all pregnant women, and pregnant women will score their pain and satisfaction levels with scales.~Pregnant women who were asked to receive tetanus+diphtheria vaccine by their physician and agreed to participate in the study will be informed about the research by the researcher, and their written and verbal consents will be obtained. Then the vaccine will be administered. Td vaccine will be administered to all pregnant women in the study as IM to the deltoid muscle in the arm they do not use dominantly. Five minutes after the vaccination, the individual descriptor form will be applied to all pregnant women, and the pregnant women will score their satisfaction levels with regard to pain and the method used."
89679673|NCT00506597|Experimental|Erwinase|6 doses of 25,000 Units/m^2 Erwinase® intramuscular/subcutaneously every other day to replace each dose of Pegylated Asparaginase
89679674|NCT01797419|Experimental|GS-5806|Single dose, oral liquid, .5 mL/kg
89679675|NCT01797419|Placebo Comparator|Placebo|Single dose, oral liquid, .5 mL/kg
89679676|NCT03589976|Experimental|Sirolimus|2 mg/day (one 2-mg tablet/day). The dose of sirolimus will be adjusted throughout the trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose of sirolimus will be6 mg/day (three 2-mg tablets/day).
89679677|NCT03589976|Placebo Comparator|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
89679678|NCT00620503|Experimental|Formulation A Fed|Single dose of Proellex 25 mg formulation A, fed
89679679|NCT00620503|Experimental|Formulation B Fed|Single dose of Proellex 25 mg formulation B, fed
89679680|NCT00620503|Experimental|Formulation B Fasted|Single dose of Proellex 25 mg formulation B, fasted
88996456|NCT02919397|Active Comparator|Control|If participants are allocated to the control group, participants will receive the wearable technology and will be able to access their activity data via the smartphone application. Participants will also have have access to the diabetes prevention programme educational material via the application. Participants will not receive motivational messages related to the education content or activity data.
88996457|NCT02919124|Experimental|Echoclip device|Ultrasonography using the echoclip device
88996458|NCT02919085|Experimental|Mobilization|
88996459|NCT02919046|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,29 days,30 days Duration:Total five times
88996460|NCT02918929|Experimental|EDP 305 SAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
88996461|NCT02918929|Experimental|EDP 305 MAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral suspension, once daily for 14 days
88996462|NCT02918929|Placebo Comparator|EDP 305 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
88996463|NCT02918929|Placebo Comparator|EDP 305 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 14 days
88996464|NCT02918812|Experimental|Intracervical lidocaine|This group will comprise of patients that will receive the intracervical block. The study group will receive a total of 60 mg (6 mL) of 1% lidocaine to be injected at four points (12, 4, 6, and 8 o'clock) circumferentially into the cervix (1.5 mL at each point) 5 minutes before proceeding with the hysterosalpingogram.
88996465|NCT02918812|Active Comparator|Intramuscular Diclofenac|This group will comprise of patients that will receive intramuscular diclofenac potassium 75mg 30 minutes before proceeding with the hysterosalpingogram.
89679681|NCT01797497|Experimental|Care plan and coaching group|In the intervention group, parents complete a referral care plan with their children's physicians and receive a brief coaching session about how to exchange information with specialists. Outcome data are collected from parents before and after the specialist visit.
89679682|NCT01797497|No Intervention|Preintervention group|In the preintervention group, no care plan is used and no coaching takes place. Outcome data are collected from parents before and after the specialist visit.
89679683|NCT03581630|Experimental|Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet|
89679684|NCT03581630|Experimental|Breast cancer subjects-Mediterranean Diet|
89679685|NCT03581630|Active Comparator|Healthy subjects-naltrexone/bupropion+Mediterranean Diet|
89679686|NCT03349073|Experimental|T-1101 (Tosylate)|
89679687|NCT00506675|Active Comparator|Intensive|42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
89679688|NCT00506675|Active Comparator|Weaning|For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)
89679689|NCT03580304|Experimental|industrial-physical-cognitive|
89679690|NCT03580304|Experimental|industrial- cognitive-physical|
89679691|NCT03580304|Experimental|physical- industrial- cognitive|
89679692|NCT03580304|Experimental|physical-cognitive- industrial|
89679693|NCT03580304|Experimental|cognitive- industrial-physical|
89050782|NCT04606680|Experimental|Heat application group|Participants will receive heat application at acupoints plus lifestyle modification. Participants will receive heat application treatment once every other day, 3 times per week, for 4 consecutive weeks.
89679694|NCT03580304|Experimental|cognitive-physical-industrial|
89679695|NCT00507767|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO or via PEG tube BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89679696|NCT04405544|Other|Main|patients with COVID-19 and Acute Encephalopathy
89679697|NCT04405544|Other|Control|patients with COVID-19 without Acute Encephalopathy
89679698|NCT00621049|Experimental|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|
89679699|NCT00621049|Active Comparator|Docetaxel and Carboplatin|
89679700|NCT00508469|Experimental|Travalert with travoprost/timolol fixed combination|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
89679701|NCT00508469|Experimental|Travalert with travoprost and timolol|One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.
89679702|NCT03155750|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx every day during the 8-week study period.
89679703|NCT03155750|Active Comparator|sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse.
89679704|NCT05702996|Experimental|Patient with Thrombotic microangiopathies induced by gemcitabine|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
89050783|NCT04606680|Experimental|Medicated plaster group|Participants will receive medicated plaster at acupoints plus lifestyle modification. Participants will receive medicated plaster at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
89679705|NCT00580333|Experimental|Cisplatin/Avastin|Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)
89679706|NCT05013541||Patients included|"Patients with lower urinary tract disorders assessed with multichannel cystometry and presence of rectal contractions.~Measure of amplitude and frequency of rectal contractions function of the bladder sensation and volume of bladder filling."
89679707|NCT00509171|Active Comparator|1-Standard reamer|Standard reamer
89679708|NCT00509171|Active Comparator|2-Use of the Reamer-Irrigator Aspirator|Use of the Reamer-Irrigator Aspirator
89679709|NCT00580645|Experimental|varenicline|varenicline 1mg/day or 2mg/day
89679710|NCT00580645|Placebo Comparator|Placebo|Placebo Controlled
89679711|NCT00580957|Experimental|Blocked|Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
89679712|NCT00580957|Placebo Comparator|Intact|Saline will be used instead of trimethaphan during insulin clamp
89679713|NCT00581347|Other|Outreach|Receives outreach services
89679714|NCT00581347|No Intervention|Standard of Care|Receives standard medical care provided by primary care practice.
89679715|NCT04387903||Reoperation group|The group of patients who underwent pancreaticduodenectomy for management of periampullary tumors and required surgical reintervention afterwards for management of procedure-related complications as pancreatic fistula, bleeding, abdominal collection, biliary fistula, gastric fistula.
89679716|NCT04387903||No reoperation group|The group of patients who underwent pancreaticoduodenectomy for management of periampullary tumors and did not require surgical reintervention.
89679717|NCT00509249|Experimental|Arm I|Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89679718|NCT00624013|Placebo Comparator|Placebo|Placebo 50 mg up to 100 mg daily for 6 months
89679719|NCT00624013|Active Comparator|Sertraline (Zoloft)|Sertraline (Zoloft) 50 mg up to 100 mg daily for 6 months
89679720|NCT02121041|No Intervention|Usual Care|Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.
89679721|NCT02121041|Active Comparator|ABPM Guided|Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.
89679722|NCT00509873|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
89679723|NCT00509873|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
89679724|NCT02133781|Experimental|Age 8-17 years (identical twins )|Participants will be randomized to receive either Fluzone® 2009-2010 Formula or FluMist® 2009-2010 Formula
89679725|NCT02133781|Experimental|Age 18-30 years (non-twins)|Participants will be receive Fluzone® 2009-2010 Formula
89679726|NCT02133781|Experimental|Age >70 years (non-twins)|Participants will receive Fluzone® 2009-2010 Formula
89679727|NCT01855451|Active Comparator|Radiation Therapy + Cetuximab|RT (70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy)
89679728|NCT01855451|Active Comparator|Radiation Therapy + Cisplatin|RT(70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy)
89679729|NCT02134951|Experimental|ketamine|IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
89679730|NCT02134951|Placebo Comparator|Placebo|Placebo group will receive normal saline
89679731|NCT00510497|Experimental|Autologous HIV-1 ApB DC Vaccine|Subjects who will receive ApB Dendritic cell vaccine
89679732|NCT03029780|Experimental|Co-Administration|Nivolumab and Ipilimumab Co-Administration
89050784|NCT04606680|Experimental|Herb-partitioned moxibustion group|Participants will receive herb-partitioned moxibustion at acupoints plus lifestyle modification. Participants will receive herb-partitioned moxibustion at acupoints and lifestyle modification every once every other day, 3 times per week, for 4 consecutive weeks.
89050785|NCT04598061||Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery|Newborns or Infants less than 7 kg undergoing an infra-umbilical surgery
89050786|NCT01161043|Experimental|Sensor|All subjects that wear sensors (all subjects)
89050787|NCT04606875||Control Group|Subjects will have no personal or family psychiatric history and no suicide attempts.
89050788|NCT04606875||Patients with Suicidal Ideation and Low Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported low acquired capability for suicide (Acquired Capability for Suicide Scale <20)
89050789|NCT04606875||Patients with Suicidal Ideation and High Acquired Capability|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >2) and reported high acquired capability for suicide (Acquired Capability for Suicide Scale >60)
89679733|NCT03029780|Experimental|Sequential Administration|Nivolumab and Ipilimumab Sequential Administration
89679734|NCT00624559|Experimental|Celebrex; Low sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
89679735|NCT00624559|Experimental|Celebrex, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
89679736|NCT00624559|Placebo Comparator|Placebo, Low Sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
89679737|NCT00624559|Placebo Comparator|Placebo, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
89679738|NCT00581581||1|Randomized to cooling (original randomized clinical trial): All children, now 6-8 years old who were randomized to cooling in the original trial were included in this arm. Cooling was achieved via the CoolCap system (Olympic Medical/Natus Corporation) in these babies.
89679739|NCT00581581||2|Randomized to standard care (original randomized clinical trial): All children, now 6-8 years old, who were treated using the standard of care at the time (normal temperature) were included in this arm. Infants' temperatures were monitored per standard of care. Most infants were cared for on an open wamer that was servo-controlled to normal body temperature (37 C) or in a standard bassinette.
89679740|NCT00510809|Active Comparator|1|Policosanol 20mg daily
89679741|NCT00510809|Placebo Comparator|2|
89679742|NCT00510809|Active Comparator|3|Policosanol 20mg daily Plus Statin Therapy Already In Use
89679743|NCT02776982|Other|Research procedures|Participants enrolled in study will have confocal endomicroscopy, research biopsies, mucosal impedance, and Bravo ambulatory pH capsule performed at the time of clinically indicated endoscopy.
89050790|NCT04674956|Experimental|Treatment arm|Regimens：anti-PD1 antibody and AG regimens.
89050791|NCT04674956|Placebo Comparator|Control arm|Regimens：Placebo and AG regimens.
89050792|NCT00564720|Experimental|1|GEM/TAR
89050793|NCT00564720|Experimental|2|GEM/OX/TAR
89050794|NCT04674917|Experimental|Group A|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
89050795|NCT04674917|Experimental|Group B|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy
89050796|NCT04674917|Other|Group C|Hot pack , TENS, Mobilization, Exercise therapy
89050797|NCT04606485|Placebo Comparator|Placebo group|"Since acupressure administration was reported to have placebo effects, a placebo group was used to investigate the true effect of acupressure use. The application of placebo may consist of moderate pressure on an incorrect acupuncture point or a light touch on a real acupuncture point. This will allow us to determine the contribution of the placebo effect resulting from direct human contact and interaction in the light touch group.~At postoperative 0, 4, and 8 hours, a light touch was applied to the ST25 (Stomach Meridian 25th point), CV12 (Conception Vessel Meridian 12th point), TH6 (Triple Heater Meridian 6th point) and HT7 (Shenmen point points) for one second. No patients experienced pain or a feeling of pressure."
89215775|NCT06021093||Medical Hypnosis|Study intervention: The hypnotherapy will include 2 individual hypnotherapy sessions plus daily listening to these recorded sessions and to (3 or 4) standardized hypnosis recordings. The individual sessions will be provided by CF and ET, both certified hypnotherapists and health care professionals (respectively nurse and physician). Preferably, these sessions take place during a planned admission for chemotherapy. If preferred by the patient, this can also take place at the hypnotherapist's office. If preferred by the patient, this can also take place at the venue of the hypnotherapist. A large part of the first session will be devoted to answering participants' questions and giving information about hypnosis, followed by exercises as an introduction to hypnosis. The goal of these exercises is to enable participants to increase their awareness and abilities in accessing mental imagery and hypnosis. At the end of the session, information will be provided about the home-based practice.
89215776|NCT06020807||Healthy|Healthy subjects and urology patients without prior history or evidence of bladder cancer
89215777|NCT06019910|Experimental|Snus with or without tobacco|Snus cessation followed by potential snus relapse
89215778|NCT06018415|Experimental|Early time-restricted eating (eTRE)|The eTRE group is instructed to consume all calories from 7 AM to 3 PM each day and fast from 3 PM to 7 AM
89215779|NCT06018415|Experimental|Late time-restricted eating (lTRE)|The lTRE group is instructed toconsume all calories from 11 AM to 7 PM each day and fast from 7 PM to 11 PM
89215780|NCT06017115|Active Comparator|Control group|Group 1: 2 stage approach (cover screw) (12 patients): cover screw is placed over the dental implants in the first surgery and a second surgery will be performed to expose the implants and placing a healing abutment after 2-4 months, DEVICES: COVER SCREW (first surgery) and HEALING ABUTMENT (second surgery)
89215781|NCT06017115|Experimental|Test group|Group 2: Protective plastic cap over different definitive trans-epithelial abutments are placed in the unic surgery performed (36 patients): Definitive transepithelial abutments will be placed the same day of the implant placement surgery. DEVICE: DEFINITIVE TRANSEPITHELIAL ABUTMENT
89215782|NCT06012071|Active Comparator|Tissue-level|Two-piece zirconia implants with tissue-level platform will be supplied to the single gap premolar regions in maxillae.
89679744|NCT00625729|Experimental|Treated Patients|Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.
89679745|NCT02335502||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
89679746|NCT00581971|Experimental|Celecoxib+Carboplatin/Paclitaxel+Radiation Therapy|
89679747|NCT03029234|Experimental|Carfilzomib with Dexamethasone|"Participants will receive carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants will also receive 20 mg dexamethasone IV or orally on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle.~Participants will receive treatment until disease progression, unacceptable toxicity, initiation of new antimyeloma therapy, withdrawal of consent, non-compliance, or intercurrent illness or worsening of a chronic condition, whichever occurs first."
89679748|NCT01670318|Experimental|platinum chromium everolimus-eluting stent|
89679749|NCT03154346||General Population|An unlimited number of participants will be accepted into a Baseline registry. From the Baseline registry, approximately 10,000 participants will be selected for the Baseline Study. Participant enrollment for the Baseline Study will be stratified by age, sex and risk factors and will aim to reflect the race and ethnicity distribution within the U.S.. The population includes a broad range of participants across the health spectrum, including exceptionally healthy participants, participants at risk of disease, and participants with current disease. The study population will be enriched for participants with an elevated risk of primary cardiovascular disease, lung cancer, and/or breast/ovarian cancers.
89679750|NCT03155204|Experimental|Test Product 1|tiotropium pMDI 2 inhalations
89679751|NCT03155204|Experimental|Test Product 2|tiotropium pMDI 2 inhalations
89679752|NCT03155204|Experimental|Test Product 3|tiotropium pMDI 2 inhalations
89679753|NCT03155204|Experimental|Test Product 4|tiotropium pMDI 2 inhalations
89679754|NCT03155204|Active Comparator|Commercial Product|tiotropium Respimat 2 inhalations
89679755|NCT01670396||in-stent restenosis|
89679756|NCT01670396||non-in-stent restenosis|
89679757|NCT03111992|Experimental|Arm A|Dose escalation of single agent CJM112
89679758|NCT03111992|Experimental|Arm B|Dose escalation of CJM112 in combination with a fixed dose of PDR001
89679759|NCT03111992|Experimental|Arm C|Dose escalation of LCL161 in combination with a fixed dose of PDR001
89679760|NCT00626431|Experimental|Leuprolide acetate - Formulation A|Leuprolide acetate 45 mg, 6-month depot
89679761|NCT00626431|Experimental|Leuprolide acetate - Formulation B|Leuprolide acetate, 45 mg, 6-month depot
89215783|NCT06012071|Experimental|Bone-level|Two-piece zirconia implants with bone-level platforms will be supplied to the single gap premolar regions in maxillae.
89215784|NCT06008951|Experimental|Self-chosen music|The self-chosen music playlist will be assembled by the participant in advance.
89679762|NCT01670474|Experimental|fmDLC and rt-PA (2mg/2mL actilysis)|"Surface thrombogenicity of film-coated domain structured double lumen catheters (fmDLC) consisting of a novel reactive polyurethane copolymer coating will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
89679763|NCT01670474|Active Comparator|polyDLC and rt-PA (2mg/2mL actilysis)|"The same procedure will be assessed in the polyurethane double lumen catheter (polyDLC)as with the fmDLC. Indeed, surface thrombogenicity of polyDLC will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
89679764|NCT01670474|Active Comparator|siDLC and rt-PA (2mg/2mL actilysis)|"Same procedure as the previous catheters. Surface thrombogenicity of silicone double lumen catheter (siDLC) will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
89679765|NCT03155360||Infant with colics|"Infants with colics according to Wessel definition :~Recurrent episodes of irritability, fussing or crying from birth to 4 months of age~Episodes last for 3 hours per day ; on 3 days per week ; for 3 weeks~Episodes can not be attributed to another disorder"
89679766|NCT03155360||Infant without colics|
89679767|NCT00582205|Experimental|Paclitaxel, Cisplatin IP|There is only one arm for this study and it represents the participants receiving the intraperitoneal chemotherapy
89679768|NCT05630612|Experimental|Sparsentan|"20 participants with ANCA-associated vasculitis in long-term disease remission.~Participants will undergo a forearm blood flow study where forearm vasodilatation will be assessed in response to acetylcholine (7.5, 15 and 30ug/min) and sodium nitroprusside (1, 2 and 4ug/min). Participants will also receive bradykinin (100, 300 and 1000pmol/min) in order to assess tPA release to measure fibrinolytic capacity.~Participants will also have 24h blood pressure assessed as well as measurements of arterial stiffness, systemic haemodynamics and measures of urinary protein.~After these baseline measures have been obtained the subject will receive 6 weeks of sparsentan. Finally the subject will undergo the same investigations listed above and we will compare to see if measurements obtained differ after treatment."
89679769|NCT05630612|Active Comparator|Irbesartan|"20 participants with ANCA-associated vasculitis in long-term disease remission.~Participants will undergo a forearm blood flow study where forearm vasodilatation will be assessed in response to acetylcholine (7.5, 15 and 30ug/min) and sodium nitroprusside (1, 2 and 4ug/min). Participants will also receive bradykinin (100, 300 and 1000pmol/min) in order to assess tPA release to measure fibrinolytic capacity.~Participants will also have 24h blood pressure assessed as well as measurements of arterial stiffness, systemic haemodynamics and measures of urinary protein.~After these baseline measures have been obtained the subject will receive 6 weeks of irbesartan. Finally the subject will undergo the same investigations listed above and we will compare to see if measurements obtained differ after treatment."
89050798|NCT04606485|Experimental|Experimental group|"As invasive acupuncture may cause hematoma and the wristband method of non-invasive acupressure may cause patient discomfort, itching, swelling of the wrist, and skin destruction, manual acupressure was applied in this study to reduce the risk of complications to a minimum.~The frequency and duration of the application of acupressure was decided from a scan of literature and expert opinion. The first acupressure session was applied in the first postoperative hour immediately after routine treatment and care of the patients who came to the ward from the recovery unit. Acupressure by applying pressure with the thumbs for a total of 12 mins, as 3 mins at each of the ST25, CV12, TH6 and HT7 acupuncture points, was performed at 0, 4 and 8 hours postoperatively. The acupuncture points were determined using the measurements of the patient's own fingers."
89050799|NCT01160770|Experimental|Clobazam|
89050800|NCT00566007|Active Comparator|1|Discectomy/micro discectomy
89679770|NCT04717453||Adult Patients with OTC Deficiency|Eligible subjects will be asked to participate in 5 clinic visits, each lasting up to 3 days. Each visit will assess rate of ureagenesis during the 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis. Patient interview, reported outcomes and cognitive assessments will take place over the 3 days.
89679771|NCT00626743|Experimental|SK3530|Active Drug
89679772|NCT00626743|Placebo Comparator|Placebo|Tablet which has the same appearance and taste but doesn't contain active ingredient
89679773|NCT01670708|Experimental|HOPE|Participation in HOPE program
89679774|NCT01670708|Active Comparator|Probation as Usual|Participation in probation as usual
89050801|NCT00566007|Active Comparator|2|Intradiscal ozone infiltration
89050802|NCT00566007|Active Comparator|3|Intradiscal oxygen infiltration (control arm)
89050803|NCT04314154||Study group|Group of all patients hospitalized in the SMHC and due participate in rehabilitative procedures
89050804|NCT00566046|Experimental|Levetiracetam|
89050805|NCT00566046|Placebo Comparator|Placebo|
89050806|NCT01160614|Experimental|ORF Tablets|ORF Tablets
89050807|NCT00566085|Other|Molecular Breast Imaging|
89050808|NCT04632407|Experimental|"Flax milk"|"A total of 30 women will receive flax (FLX) milk on a daily basis for a total of 4 months. The FLX milk will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3."
89215785|NCT06008951|Experimental|Researcher-chosen music|The researcher-chosen music playlists will primarily be composed by the Music as Medicine research group from Erasmus Medical Center, based on current expert opinion. The playlist will be created with the goal to help while experiencing pain based on previous literature.
89679775|NCT03154190|Active Comparator|Arm A (usual care)|Patients receive usual care.
89679776|NCT03154190|Experimental|Arm B (health care coach support)|Patients undergo health care coach support with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the health care coach after the first oncology appointment to discuss goals of care. The health care coach will contact patient based on patients' ongoing needs (weekly to monthly) and will conduct symptom assessments based on patients' treatment plans and symptoms.
89679777|NCT00582361|Active Comparator|1, A|Group A patients will have a standard dressing applied following initial treatment of their open fracture.
89679778|NCT00582361|Experimental|2, B|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture.
89679779|NCT01670786|Experimental|Iodopovidone 1%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 1% administration into pleural cavity.
89050809|NCT04632407|Experimental|"Oat fibre milk"|"A total of 30 women will receive the oat fiber milk on a daily basis for a total of 4 months. The oat fibre milk will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water."
89050810|NCT02885233|Active Comparator|Free From Falls|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
89679780|NCT01670786|Experimental|Iodopovidone 2%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 2% administration into pleural cavity.
89050811|NCT02885233|Placebo Comparator|Waitlist|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
89050812|NCT00566124|Active Comparator|1|Insulin detemir
89050813|NCT00566124|Active Comparator|2|Insulin glargine
89050814|NCT00566124|Active Comparator|3|NPH insulin
89050815|NCT04632563||Member of BioResource|Any BioResource member who consents to take part in the study and completes the study questionnaire.
89050816|NCT01159912|Experimental|Fluticasone Furoate OD and Placebo BID|Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
89050817|NCT01159912|Active Comparator|Fluticasone Propionate BID and Placebo OD|Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
89050818|NCT01159912|Placebo Comparator|Placebo only BID|Placebo inhalation powder twice daily for 24 weeks
89050819|NCT04606368|Experimental|Interventional cohort|Each subject will serve as their own control. Left side of lower jaw and submental area is control side. Right side of subject's lower jaw and submentum area will receive treatment.
89050820|NCT04632368|Active Comparator|Transcendental Meditation Intervention Arm|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to a randomized group of eligible HCPs ( N=40)providing care during COVID-19 pandemic.
89050821|NCT04632368|No Intervention|Treatment as usual(TAU) Control Arm|Control group consists of eligible HCPs who are randomized to control group(N=40) and would not receive any intervention. At the end of 3 month study period, control group participants would be eligible for TM training.
89679781|NCT05701592||Patients with PCL tear treated with DB-PCLR|Patients with PCL tear treated with DB-PCLR
89679782|NCT00582517|Active Comparator|Group A External Brace|Group A will have a non-invasive range of motion external brace placed following surgery
89679783|NCT00582517|Experimental|Group B Compass Knee Hinge|Group B will have a Compass Knee Hinge placed
89679784|NCT03155048|Active Comparator|oral estradiol group|patients with the usage of 6 milligrams/day oral estradiol
89679785|NCT03155048|Active Comparator|estradiol transdermal patch group|patients with the usage of 3.9 milligrams estradiol transdermal patch
89679786|NCT03155126||Saline group|Patients resuscitated with saline
89679787|NCT03155126||Acetated Ringer's sodium group|Patients resuscitated with Acetated Ringer's sodium
89679788|NCT00513461|Experimental|Arm I (SAMe)|Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
89679789|NCT00513461|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
89679790|NCT00627367|Experimental|Protocolized|"1mg IV hydromorphone followed by an additional 1mg at 15 minutes if the patient answer yes to the question, Do you want more pain medication?"
89679791|NCT00627367|Active Comparator|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clincian
89679792|NCT01670864|Experimental|Counseling group|Study participants in the counseling group will receive a brief on-site face-to-face smoking cessation counseling from our trained smoking cessation counselor on the study site after signing the consent form. They will receive advice on quitting smoking and specific warning about the hazardous effects of smoking on health. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
89679793|NCT01670864|Experimental|SMS intervention group|Study participants in the SMS group will receive SMS text messages on smoking cessation advice and warning on the hazardous effects of smoking on health. The participants will receive a total of 16 tailored SMS messages after recruitment.
89050822|NCT04632680|Experimental|PVI followed by targeting of drivers|Patients will undergo intra-procedural mapping using the ECG-I. The pulmonary veins will be isolated. Drivers will then be targeted as guided by the ECG-I system aiming for termination of AF.
89050823|NCT04606212|Experimental|Losartan group|
89050824|NCT04606212|Placebo Comparator|Placebo group|
89679794|NCT01670864|No Intervention|Control group|Study participants in the control group will not receive any quitting assistance other than the self-help materials from the recruitment sites.
89679795|NCT04387981|Experimental|[14C]-orvepitant|[14C]-orvepitant administered as 30mg single dose in oral solution
89679796|NCT03154892|Experimental|Intracameral injection|Intracameral injection of conbercept for the treatment of NVG
89679797|NCT03154892|Active Comparator|Intravitreal injection|Intravitreal injection of conbercept for the treatment of NVG
89679798|NCT00559013|Active Comparator|1|PSD Veritas Collagen Matrix Reinforcement Arm
89679799|NCT03154736|Experimental|Interview|Individual interview an in a group interview. Socio-economic questionnaire
89679800|NCT00627679|Experimental|Treatment sequence: A, B, D, C|Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5
89050825|NCT04606251|Experimental|Arm 1: Exercise Group|This group will consist of the subjects taken for 6 weeks of exercise.
89050826|NCT04606251|No Intervention|Arm 2: Control Group|This group will consist of the subjects who did not receive any intervention for 6 weeks and were evaluated before and after 6 weeks.
89215786|NCT06008951|Active Comparator|Podcast (control)|The choice of podcast will be based on expert opinion of the sociology department of the Erasmus University Rotterdam.
89215787|NCT06007430|Placebo Comparator|Group 1 (Healthy Control)|24 Patients receiving Placebo Capsule per oral once daily for 60 days.
89215788|NCT06007430|Active Comparator|Group 2 (Healthy control)|26 Patients receiving Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA), one capsule per oral once daily for 60 days.
89215789|NCT06007430|Placebo Comparator|Group 3 (Diabetes Type 2)|23 Patients receiving Placebo Capsule per oral once daily for 60 days.
89215790|NCT06007430|Active Comparator|Group 4 (Diabetes Type 2)|27 Patients Receiving Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA), one capsule per oral once daily for 60 days.
89215791|NCT06005012|Experimental|Semaglutide|2.4 mg weekly for 52 weekly in a 3 ml PDS290 pen-injector containing Semaglutide 3.0 mg/ml for subcutaneous use
89215792|NCT06005012|Placebo Comparator|Placebo|2.4 mg weekly for 52 weekly in a 3 ml PDS290 pen-injector containing 3.0 mg/ml of a placebo solution for subcutaneous use
89679801|NCT00627679|Experimental|Treatment sequence: B, C, A, D|Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5
89679802|NCT00627679|Experimental|Treatment sequence: C, D, B, A|Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5
89679803|NCT00627679|Experimental|Treatment sequence: D, A, C, B|Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5
89679804|NCT03159884|Experimental|3+Q12W|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the additional medication criteria in 12 weeks during treatment, additional injection can be given;"
89679805|NCT03159884|Experimental|3+TAE|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the treatment-extended dosing criteria. When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the extra dosing criteria."
89679806|NCT00514709|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
89679807|NCT00514709|Experimental|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
89679808|NCT01670942||Traumatic Pneumothorax1|hypobaric chamber
89679809|NCT03154814|Experimental|ulinastatin treatment|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
89679810|NCT03154814|Placebo Comparator|control|conventional CPB was applied without ulinastatin treatment
89679811|NCT00561431|Active Comparator|1|Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr
89679812|NCT00561431|Experimental|2|High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr
89679813|NCT01671020|Active Comparator|(R)(T)|Period 1: Fimasartan 60mg → Period 2: Fimasartan 30mg
89679814|NCT01671020|Active Comparator|(T)(R)|Period 1: Fimasartan 30mg → Period 2: Fimasartan 60mg
89215793|NCT06002724||0|
89215794|NCT05997199||Group 1|Patients with vitamin D deficiency and having Vitamin D Replacement
89215795|NCT05997199||Group 2|Control Group. Patients with vitamin D deficiency but not getting Vitamin D replacement
89215796|NCT05992649|Experimental|Aquatic physiotherapy treatment in warm water|The participant is placed supine in the water, supported by the physiotherapist as well as aqua noodles. The physiotherapist supports and moves the participant in the water and adapts to the participant's reaction.
89215797|NCT05989776|No Intervention|Usual care|Usual care information to fertility preservation counseling
89215798|NCT05989776|Active Comparator|Intervention: informational brochure for patients and brief training for oncologists|The intervention is based on information provided to different target populations, using a variety of media, including brochures and videos.
89215799|NCT05987891||Healthy controls|Volunteers will perform treadmill exercise tests. It will be monitored electrocardiogram, heart rate, and blood pressure in the rest state, under exercise, and in the recovery.
89215800|NCT05987488|Experimental|ShigETEC vaccine|The vaccine will consist of a suspension of a live, attenuated Shigella bacterial strain (a clinical isolate of Shigella flexneri 2457T strain) into which the genes for nontoxic forms of the ETEC heatlabile toxin B subunit (LTB) and a mutant heat stable toxin (STm) have been inserted.
89215801|NCT05987488|Placebo Comparator|Placebo|A saline solution with corn starch
89215802|NCT05980702|Experimental|4 courses arm|Drug:Pembrolizumab , Carboplatin,albumin-bound paclitaxel Patients receive Pembrolizumab IV on day 1, albumin-bound paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Then surgery.
89215803|NCT05980702|Active Comparator|2 courses arm|Drug:Pembrolizumab , Carboplatin,albumin-bound paclitaxel Patients receive Pembrolizumab IV on day 1, albumin-bound paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Then surgery.
89050827|NCT04597905||CD Participants|Participants diagnosed with CD from the 7 participating countries will take part in survey to collect data regarding their preferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
89050828|NCT04597905||UC Participants|Participants diagnosed with UC from the 7 participating countries will take part in survey to collect data regarding theirpreferences towards the attributes of treatments based on DCE survey with advanced therapies for IBD, including safety and efficacy profiles, frequency and RoA in a real-world setting and data collection will be conducted in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international patient community.
89050829|NCT04606329|Experimental|LuminoMark inj.|Injection LuminoMark inj. 0.2mL once in this study.
89050830|NCT04606329|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
89050831|NCT04632251|Other|Familiarisation|The first 2 patients per site (N = 10 in total) are considered to be sufficient to enable further familiarisation with the procedure and use of the probe in addition to the usability work and training that the sites did prior to the start of this study.
89050832|NCT04597749|Experimental|Concurrent PSG, HSAT, and Screener App Test|Participants will undergo a single night baseline PSG test with concurrent HSAT tests as well as non-contact screening mobile apps through a smartphone.
89050833|NCT04632797|Active Comparator|Cryocompression|Patients in this group receive cryocompression for the hands.
89050834|NCT04632797|Active Comparator|Cryotherapy|Patients in this group receive cryotherapy for the hands.
89679815|NCT03154970|Experimental|Obstructive sleep apnea group (G OSA)|The cervical stabilization will be performed with craniocervical flexion training aiming to strength the deep cervical flexors. For this purpose a pressure biofeedback device (stabilizer) that allows progressive levels of pressure during exercise(22-30 mmHg) will be used, which will be increased according to the capacity of the individuals (avoiding compensations or pain). The participant will be instructed to perform the craniocervical flexion in the supine position, the duration of the contraction will be 10 seconds followed by 10 seconds of rest (3 sets of 10 repetitions). The sessions will be held 2 times in weeks, for 6 weeks.
89679816|NCT03154970|No Intervention|Control group (GC)|The GC will be reassessed after six weeks and the same G OSA treatment will be offered after this period.
89050835|NCT04632212|Experimental|1|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (ON)
89050836|NCT04632212|Experimental|2|Tax (ON) Food Labels (ON) Ordering (ON) Substitution (OFF)
89050837|NCT04632212|Experimental|3|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (ON)
89050838|NCT04632212|Experimental|4|Tax (ON) Food Labels (ON) Ordering (OFF) Substitution (OFF)
89050839|NCT04632212|Experimental|5|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (ON)
89679817|NCT00515021|Experimental|Daytime then nightime dosing|Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks.
89679818|NCT00515021|Experimental|Nighttime then daytime dosing|Eplerenone - 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks then patients cross over to 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks.
89679819|NCT03159650|Experimental|intravascular ultrasonography guided|
89679820|NCT03159650|Active Comparator|Angiography guided|
89050840|NCT04632212|Experimental|6|Tax (ON) Food Labels (OFF) Ordering (ON) Substitution (OFF)
89050841|NCT04632212|Experimental|7|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (ON)
89050842|NCT04632212|Experimental|8|Tax (ON) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
89050843|NCT04632212|Experimental|9|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (ON)
89050844|NCT04632212|Experimental|10|Tax (OFF) Food Labels (ON) Ordering (ON) Substitution (OFF)
89050845|NCT04632212|Experimental|11|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (ON)
89050846|NCT04632212|Experimental|12|Tax (OFF) Food Labels (ON) Ordering (OFF) Substitution (OFF)
89050847|NCT04632212|Experimental|13|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (ON)
89050848|NCT04632212|Experimental|14|Tax (OFF) Food Labels (OFF) Ordering (ON) Substitution (OFF)
89050849|NCT04632212|Experimental|15|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (ON)
89050850|NCT04632212|No Intervention|16|Tax (OFF) Food Labels (OFF) Ordering (OFF) Substitution (OFF)
89050851|NCT04606017||Vitamain D|This group of patients were supplemented with 125IU/d Vitamin D
89050852|NCT04606017||Control|The other group did not receive the supplementation of 125IU/d Vitamin D
89050853|NCT04632095|Active Comparator|Sternotomy AVR|Aortic valve replacement due to sternotomy
89050854|NCT04632095|Active Comparator|Mini AVR|Aortic valve replacement due to parasternal right anterior mini-thoracotomy
89050855|NCT04597788|Experimental|Protein supplemented very low calorie diet program|The lifestyle intervention using protein supplemented very low calorie meals will be implemented with individual counseling sessions for 12 months. Initial intensive weight loss stage will be delivered during the first 4 month period with total meal replacement to partial meal replacement using protein supplemented very low calorie meals. During the weight loss maintenance stage, regular intermittent very low calorie meal replacement one week per month will be delivered for the entire period. Mobile counseling will be offered to help patients achieve weight loss as well as weight loss maintenance.
89050856|NCT04597788|Active Comparator|Conventional low calorie diet program|The conventional low calorie diet program will be offered to participants assigned to control group using educational material and individual counseling sessions for 12 months. Mobile counseling will be also offered for weight loss and weight loss maintenance.
89050857|NCT04597983|Experimental|2S-hesperidin|This group took 500 mg (capsules) per day at breakfast of 2S-hesperidin (Cardiose®) for 8 weeks
89050858|NCT04597983|Placebo Comparator|Placebo|This group took 500 mg of microcellulose (capsules) per day at breakfast for 8 weeks
89679821|NCT03159728|Experimental|Educative intervention|"Who wish to participate in the program Caring for Caregivers will be the intervention group. The intervention or program Caring for Caregivers to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes four sessions or meetings with the caretaker, induction and three modules, the first is geared to strengthen the knowledge; the second, to strengthen the value and the third, to strengthen patience."
89679822|NCT03159728|No Intervention|Control group|"The control group will receive training about knowledge of chronic disease and care.~In addition, once it confirmed the effectiveness of the intervention participants in the control group will be contacted to contemplate the possibility of receiving the benefits of the intervention."
89679823|NCT03159494|Experimental|Intervention group|10 patients with type 2 diabetes enrolled to perform 8 times of High-Intensity Training. The subjects were tested before and after the training period.
89050859|NCT04631822|Active Comparator|Dexamethasone, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 4 mg dexamethasone."
89050860|NCT04631822|Active Comparator|Dexmedetomedine, combined with bupivacaine for adductor canal block|"All patients will receive spinal anesthesia with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position. Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention.~In this arm, patients will receive 20 ml mixture of 0.25% bupivacaine and 0.5 Mg/kg dexmedetomidine."
89050861|NCT04605705||Group 1|NIRS values will be recorded during the surgery and until 24 hours postoperatively. No intervention will be done.
89050862|NCT04605705||Group 2|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
89679824|NCT03159494|Experimental|Pilot study|6 patients with type 2 diabetes enrolled to perform 6 times of High-Intensity Training. The subjects were tested before and after the training period
89679825|NCT00515177|Experimental|MBSR|A Mindfulness-Based Stress Reduction (MBSR) program that includes 8-weeks of group instruction in mindfulness meditation techniques followed by home practice and monitoring.
89679826|NCT00515177|Active Comparator|PCT Sleeping Pills|A pharmacotherapy control arm (PCT Sleeping Pills) consisting of a state-of-the-art prescription sedative hypnotic, eszopiclone - brand name LUNESTA(R), at a dose of one 3 milligram (mg) pill nightly for a duration of 8 weeks followed by use as needed (same dosage) for 3 months. This drug was approved by the Food and Drug Administration as a sedative for more than short term use.
89050863|NCT04605900|Experimental|Standard Footwear (SF)|Intervention: plantar orthoses, education on foot self-care and appropriate standard footwear.
89050864|NCT04605900|Experimental|Orthopedic Footwear (OF)|Intervention: plantar orthoses, education on foot self-care and orthopedic footwear.
89050865|NCT00560963|Experimental|1 RAD001|
89679827|NCT01671098||Control|Healthy adults
89679828|NCT01671098||Balloon Sinuplasty|Patients who had balloon sinuplasty
89679829|NCT01671098||FESS-Uncinectomy|Patients who had FESS-Uncinectomy
89679830|NCT03159806||Outpatients|Attendees at the nephrology outpatient clinic at Hammersmith Hospital will be invited to take part in microdialysis sampling
89679831|NCT00583375|Active Comparator|Group 1|"Standard Rigid Fixation plus autograft~Standard of Care: Autologous Bone Graft"
89679832|NCT00583375|Experimental|Group 2|Standard Rigid Fixation plus Augment® Bone Graft
89679833|NCT04348760|Experimental|Intervention|Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week
89679834|NCT03078218|No Intervention|Before period group|Strictly observational in order to assess the current screening strategy as it is conducted in real life
89679835|NCT03078218|Experimental|After period group|Consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards
89679836|NCT04664881|No Intervention|Control (standard treatment) Group|Participants will receive routine cardiac treatment
89679837|NCT04664881|Experimental|SmartHeart Device Group|In addition to routine cardiac treatment, participants will wear the SmartHeart device
89679838|NCT00628147|Experimental|Narrow band imaging colonoscope|narrow band imaging colonoscope
89679839|NCT00628147|No Intervention|White Light|Conventional White Light Examination
89679840|NCT01671254|Active Comparator|FishOil + placebo|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and placebo capsule
89679841|NCT01671254|Experimental|FishOil + CBE75|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and citrus bioflavonoids+vitamin E (CBE)(75 mg/capsule/day)
89679842|NCT01671254|Experimental|FishOil + CBE150|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and CBE (150 mg/capsule/day)
89050866|NCT04597515|Experimental|Robot Reduction|The project consists in removing a breast disc at the base, causing a circular sagging skin cut of 2 to 3 cm .
89050867|NCT04631978||Underweight|Comprehensive ophthalmologic examination
89050868|NCT04631978||Control|Comprehensive ophthalmologic examination
89050869|NCT04597281|Experimental|Mediterranean lifestyle|Mediterranean lifestyle, including dietary advice and physical activity advice. In addition, families receive extra-virgin olive oil and fish and two sessions of physical activity per week, for free.
89050870|NCT04597281|No Intervention|Usual care|General care by their pediatricians.
89050871|NCT01159600|Experimental|BI 10773 Arm 2|BI 10773 once daily high dose
89050872|NCT01159600|Placebo Comparator|Placebo|Placebo matching BI 10773
89050873|NCT01159600|Experimental|BI 10773 open-label|BI 10773 once daily high dose open label
89050874|NCT01159600|Experimental|BI 10773 Arm 1|BI 10773 once daily low dose
89050875|NCT04631627|Active Comparator|aspirin group|aspirin,tablet,100/150mg per day,(BMI<30 100mg/d，BMI≥30 150mg/d)，from pregnancy weeks<16 to 35 weeks or the day of delivery.
89050876|NCT04631627|Sham Comparator|control group|with no intervention
89050877|NCT04605627||Chronic coronary syndrome|50 patients with chronic coronary disease
89050878|NCT04605627||Non ST segment-elevation myocardial infarction|75 patients with non ST-elevation myocardial infarction
89050879|NCT04605627||ST-elevation myocardial infarction|75 patients with ST segment-elevation myocardial infarction
89050880|NCT04632017||pPROM|Singleton pregnancies admitted for pPROM to the Obstetrics ward
89050881|NCT04632017||Control group|Healthy pregnant women matched for gestational age
89050882|NCT04597398||Group A|A total of 39 patients underwent the procedure prior to June 2019
89679843|NCT04638283|Experimental|Interventioh group|"The intervention consists of~Eight group sessions of two hours duration, focusing on GMT and ADHD. The Group consists of six participants and is directed by one neuropsychologist and one psychologist.~Four individual sessions with the neuropsychologist/psychologist directing the Group where the participant is guided through the process of formulating GAS-goals.~Bi-weekly Telephone follow up focusing on GAS-goal attainment the thre first months following the Group session phase."
89679844|NCT04638283|No Intervention|Control Group|Participants in the Control Group receive TAU. Participation in the study does not influence decisions regarding pharmacological interventions in either of the groups.
89679845|NCT03154424|Placebo Comparator|Bridging (control group)|External fixation in treatment the distal radius fracture
89679846|NCT03154424|Active Comparator|Nonbridging (tested group)|External fixation in treatment the distal radius fracture improve grip strength?
89679847|NCT00584077||Stable lung transplant recipients|All enrolled subjects receive the same procedures; bronchoscopy with administration of mechanical and chemical irritants to the airway mucosa
89679848|NCT04405310|Experimental|EXP-PC-F2|Patients with Pneumonia due to SARS-COV-2 phase 2 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
89679849|NCT04405310|Placebo Comparator|EXP-NONPC-F2|20 Patients with Pneumonia due to SARS-COV-2 phase 2 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
89679850|NCT04405310|Experimental|EXP-PC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with Hyperimmune Plasma from Convalescent patients and conventional Therapy (Azithromycin and Hydroxychloroquine)
89679851|NCT04405310|Placebo Comparator|EXP-NONPC-F3|20 Patients with Pneumonia due to SARS-VOC-2 phase 3 with conventional Therapy (Azithromycin and Hydroxychloroquine) and 20% Albumin in Hartman Solution.
89679852|NCT01671410|Experimental|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
89679853|NCT01671410|Active Comparator|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
89679854|NCT01671566|Experimental|Home based interval training|12 weeks home based interval training
89679855|NCT01671566|No Intervention|Control group|No structured exercise training.
89679856|NCT02676752||Skin/soft tissue elasticity assessment|Participants will be evaluated for LEF status using the HN-LEF Grading Criteria and neck range of motion using the Cervical Range of Motion Device. Participants also complete study questionnaires, including VHNSS and LSIDS-H&N. Participants undergo ultrasound shear wave elastography over 20-25 minutes. Participants' cancer disease and treatment information will be gathered from their medical records.
89679857|NCT03159338|Active Comparator|treatment group|One side of osteotomies will be considered as a treatment arm (randomly) which Platelet rich fibrin will be used with rigid fixation
89050883|NCT04597398||Group B|11 patients underwent the procedure as of June 2019
89050884|NCT04631354|Experimental|Sequence A|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S-770108 inhaler at a target peak inspiratory flow rate (PIFR) of 15 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 30 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
89050885|NCT04631354|Experimental|Sequence B|Participants will receive a single dose of two radio-labelled 6 mg S-770108 capsules (total 12 mg per dose), by oral inhalation using a S- 770108 inhaler at a target PIFR of 30 L/minute on Day 1 of Period 1 followed by a single dose of two radio-labelled 6 mg S-770108 capsules by oral inhalation at a target PIFR of 15 L/minute on Day 1 of Period 2. There will be a 5 to 13 day washout period between the two treatment periods.
89050886|NCT01159171|Experimental|1|
89050887|NCT04631315|Experimental|Intervention|Difluprednate Ophthalmic Emulsion 0.05%
89679858|NCT03159338|Placebo Comparator|Control group|In control site , placebo gel will be placed before rigid fixation
89679859|NCT00630253|Experimental|Marrow Isolex|bone marrow processed using Isolex 300i (for patients enrolled through April 2010)
89679860|NCT00630253|Experimental|UCB|No processing Notes: sibling donor UCB is used as the stem cell source and co-enroll for unlicensed UCB registry
89679861|NCT00630253|Experimental|Marrow Clinimax|bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)
89679862|NCT03158948|Experimental|MOTREM 1|0.3 mg/kg/h
89679863|NCT03158948|Experimental|MOTREM 2|1.0 mg/kg/h
89679864|NCT03158948|Experimental|MOTREM 3|3.0 mg/kg/h
89679865|NCT03158948|Placebo Comparator|Placebo|
89679866|NCT01671644||Eeva Test Group|Day 3 embryo transfers that used Eeva predictions with morphology grading.
89679867|NCT01671644||Matched case control group|Day 3 embryo transfers using morphology grading only (from a matched concurrent control group).
89679868|NCT01671722|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
89679869|NCT01671722|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
89050888|NCT04631315|Active Comparator|Comparator|Prednisolone Acetate 1% - Phenylephrine 0.12% Ophthalmic Suspension
89050889|NCT02885155||Patients with pulmonary arterial hypertension|
89679870|NCT00584701|Experimental|Risperidone|Risperidone was started at 0.5mg at bedtime for 4 days. If that dosage was tolerated and there were continued behavioral symptoms, the dose was increased to 1mg at bedtime for an additional 4 days. If tolerated and indicated, 0.5mg was added in the morning for a daily total of 1.5 mg.
89679871|NCT03158870||Pheochromocytoma|Patient who underwent surgical procedure for pheochromocytoma
89679872|NCT01671878|Other|Reference Glucose|Glucose standard
89679873|NCT01671878|Experimental|Test Food 1|Cereal
89679874|NCT01671878|Experimental|Test Food 2|Biscuit
89679875|NCT00630409|Experimental|Treatment|Patients will receive 3 cycles of therapy as an outpatient. Each 21-day cycle of therapy will comprise: Gemcitabine: IV on days 1 and 8. Doxil: on day 1. Patients with either responding or stable disease will continue to receive additional 3 cycles of therapy with gemcitabine and Doxil until there is radiological evidence of disease progression or they are unable or unwilling to continue treatment.
89679876|NCT01671956|Experimental|Bertilimumab|Bertilimumab 10 mg/kg will be administered by IV infusion over 30 minutes
89679877|NCT01671956|Placebo Comparator|Placebo|Phosphate buffered saline (PBS) placebo will be administered by IV infusion over 30 minutes.
89679878|NCT00630955|Experimental|1|20 mg memantine
89679879|NCT00630955|Experimental|2|40 mg memantine
89679880|NCT00630955|Placebo Comparator|3|
89679881|NCT00584857|Experimental|Chemotherapy|Single
89679882|NCT03154034||Severe mitral regurgitation|
89679883|NCT03153800|Experimental|Bronchial basal cells|
89679884|NCT00585013|Experimental|Nitric Oxide Delivery Group|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
89679885|NCT00585013|No Intervention|Placebo|Placebo delivery of oxygen at standard dose.
89679886|NCT01672034||Obese, BMI > 35|
89679887|NCT01672112|Other|Codeine|Oral Codeine 60mg 6hrly/prn
89679888|NCT01672112|Active Comparator|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
89679889|NCT05540366|Experimental|Intervention Group|"Myogenous temporomandibular subjects~Physical therapy combined with aerobic exercise: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike."
89679890|NCT05540366|Active Comparator|Control group|"Myogenous temporomandibular subjects~Physical Therapy: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)"
89679891|NCT00585637|Active Comparator|1|No Vitamin D
89679892|NCT00585637|Active Comparator|2|1000 IU of Vitamin D
89679893|NCT00585637|Active Comparator|3|2000 IU of Vitamin D
89679894|NCT00585637|Active Comparator|4|4000 IU of Vitamin D
89679895|NCT01670630|Active Comparator|Sheathed speculum|"Investigators will perform a vaginal speculum examination with either a sheathed or a standard (non sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception."
89679896|NCT01670630|Active Comparator|Standard speculum examination|Investigators will perform a vaginal speculum examination with either a standard or a sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception.
89679897|NCT03158558|Experimental|AM-CBCT for PTSD|Accelerated, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy delivered in a single weekend retreat
89679898|NCT03158792|Active Comparator|Enoxaparin 20 mg|
89679899|NCT03158792|Active Comparator|Enoxaparin 30 mg|
89679900|NCT01798771|Other|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
89679901|NCT01798771|Other|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
89679902|NCT03158480|Experimental|DC-CIK+interferon Group|dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
89679903|NCT03158480|Placebo Comparator|Placebo+interferon Group|saline as placebo plus interferon intervention
89679904|NCT05701202|Experimental|Super-Whey protein|Both protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
89679905|NCT05701202|Active Comparator|Isonitrogenous whey protein|Both protein sources will be given in doses that are considered low/normal, both in relation to recommended dietary advice and commercially available supplements. As such, no adverse reactions or side effects are expected through consumption of these supplementations
89679906|NCT00633919|Active Comparator|Active|SLITone Dermatophagoides Mix
89679907|NCT00633919|Placebo Comparator|Placebo|SLITone Placebo
89679908|NCT01672190|Experimental|Yoga Therapy|Women in the Yoga Therapy Group will receive twice weekly yoga classes for 6 weeks.
89679909|NCT01672190|No Intervention|Control|Women in the Control Group will wait 6 weeks before receiving a gift certificate for yoga classes at an external yoga studio in the San Francisco Bay Area
89679910|NCT01672268|Active Comparator|Standard TAVI procedure|Patients without Cardiac CT measures before TAVI
89679911|NCT01672268|Experimental|Cardiac CT scan before TAVI procedure|patients with cardiac CT measures before TAVI
89679912|NCT03158246|Experimental|Yigu Group|"a single 15-minute infusion of Generic Zoledronic Acid (Yigu®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
89679913|NCT03158246|Active Comparator|Aclasta Group|"a single 15-minute infusion of Original Zoledronic Acid (Aclasta®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
89679914|NCT03157856||Experimental: fluorescence assessment|Medical device: Use of the FEMTO-ST institute medical device to detect prostatic and non prostatic tissue.
89679915|NCT00515411|Active Comparator|Arm A, - Modified DCF|"Drug Dose (mg/m2) Schedule~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments)."
89215804|NCT05977634|Experimental|Transcutaneous tibial nerve stimulation plus bladder training|Patients will receive transcutaneous tibial nerve stimulation for 30 minutes, twice a week, for 6 weeks. Application will be done in an outpatient setting, using disposable surface electrodes.
89215805|NCT05977634|Other|Bladder training|patients will receive only the routine education program that is given to every patient with idiopathic overactive bladder syndrome. This includes education about the anatomy of the urinary system, patient motivation, and frequent bathroom visits in order to avoid incontinence with gradual increase between each visit to the bathroom.
89215806|NCT05976815|No Intervention|Control Group|The control group will receive neoadjuvant chemotherapy alone (standard of care).
89215807|NCT05976815|Experimental|Experimental Group|The experimental group will receive neoadjuvant chemotherapy (standard of care) in conjunction with an exercise intervention. The exercise intervention will be implemented concurrently for the full duration of the neoadjuvant chemotherapy treatment.
89215808|NCT05974748|Active Comparator|Sodium Hypochlorite|5.25% sodium hypochlorite is the gold standard endodontic irrigant. Other Name: NaOCl
89215809|NCT05974748|Experimental|Propolis|Hydroalcoholic 20% propolis will be used as an endodontic irrigant. Other Name: Bee glue
89215810|NCT05973279||Hemiplegic patients|
89215811|NCT05965739|Active Comparator|BrainHQ Active Comparator|5 sessions/week at 30 min/session
89215812|NCT05965739|Experimental|BrainHQ|5 sessions/week at 30 min/session
89679916|NCT00515411|Active Comparator|ARM B - Parent DCF with G-CSF|"Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17~* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg"
89679917|NCT00515411|Active Comparator|Arm C - Modifid DCF + Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
89215813|NCT05965739|Experimental|BrainHQ + PASC CoRE|BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions at 1 hr/session
89679918|NCT00586261|Placebo Comparator|Placebo|Placebo 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
89679919|NCT00586261|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
89679920|NCT03157778|Experimental|Obese men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese men.
89679921|NCT03157778|Active Comparator|Normal-weight men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in normal-weight men.
89679922|NCT03157622|Active Comparator|Exposure in vivo|In the Exposure in vivo (EXP) condition, patients are given a careful explanation of the fear-avoidance model. Patients are encouraged to adopt the model to their individual situation. Factors for the maintenance of chronic pain (such as pain cognitions and pain-related fear) are discussed. Especially, negative consequences of avoidance behavior are highlighted. In preparation of the exposure sessions, patients develop an individual fear hierarchy using the Photo Series of Daily Actives. Subsequently, patients are encouraged to test their fear-avoidance beliefs during behavioral experiments and to reduce avoidance behaviors during individually tailored exposure exercises.
89679923|NCT03157622|Active Comparator|Cognitive Behavioral Psychotherapy|In the Cognitive Behavioral Psychotherapy (CBT) condition, patients are introduced to several strategies to improve their pain management. The principle of graded activity encourages patients to re-engage in former activities by dividing these activities into smaller steps. Predetermined resting periods are offered as a form to prevent patients from phases of excessive demands followed by long terms of recovery. Progressive muscle relaxation is introduced as a technique to improve the experience of pain. The strategy of attention shifting is presented to change their perception of pain. Maladaptive pain-related cognitions are identified and challenged by cognitive interventions.
89679924|NCT03157700|Experimental|REAL media|Participants in this group will be assigned to use the REAL media curriculum.
89679925|NCT03157700|No Intervention|Programming as usual|Participants in this group will participate in 4-H programming as usual. They will have the opportunity to use the REAL media curriculum at the conclusion of the study.
89679926|NCT02744989|Experimental|Active tDCS|Stimulation will be performed using an tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). The anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's Areas (BA) 8, 9, 10, and 46, depending on the patient). The cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day for 5 consecutive weekdays. The twice daily sessions will be separated by at least 2 hours.
89679927|NCT02744989|Sham Comparator|Sham tDCS|
89215814|NCT05965739|Experimental|Brain HQ + tDCS-active|2.0 mA stimulation delivered for 30 min during each BrainHQ session
89215815|NCT05965739|Placebo Comparator|Brain HQ + tDCS-sham|Inactive stimulation delivered for 30 min during each BrainHQ session
89215816|NCT05960318||Adolescents and adults|Adolescents from 12 years old and adults with common cold, nasal mucosa inflammation and/or rhinitis, who have bought the product.
89215817|NCT05960318||Children|Children from 2 to 12 years old with common cold, nasal mucosa inflammation and/or rhinitis, whose parents/caregivers have bought the product.
89215818|NCT05960292|Active Comparator|Vaginal Hysterectomy (Group)|About 28 female patients will have vaginal vault closure by vaginal approach
89215819|NCT05960292|Active Comparator|Abdominal Laparoscopic Hysterectomy (Group)|About 28 female patients will have vaginal vault closure by Abdominal Laparoscopic approach
89215820|NCT05959850|Experimental|Experimental: Active|Ambroxol taken 3x daily. Variation in doses as follow-up progresses. For detailed information, see Intervention Description.
89215821|NCT05959850|Placebo Comparator|Placebo Comparator: Control|Glucose Placebo, taken 3x daily. Variation in doses as follow-up progresses. For detailed information, see Intervention Description.
89050890|NCT04631666|Experimental|Group 1A (uninfected) - 2.5 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 2.5 mg/kg
89050891|NCT04631666|Experimental|Group 1B (uninfected) - 10 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 10 mg/kg
89050892|NCT04631666|Experimental|Group 1C (uninfected) - 40 mg/kg|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
89050893|NCT04631666|Experimental|Group 1D (uninfected) - high dose|SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose higher than 40 mg/kg
89050894|NCT04631666|Experimental|Group 2C (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
89050895|NCT04631666|Experimental|Group 2D (infected) - 40 mg/kg|SARS-CoV-2-infected volunteers will be randomized 2:1 to receive an intravenous infusion of DZIF-10c at a dose of 40 mg/kg or placebo
89050896|NCT02885194|Other|Patients who underwent Deep Brain Stimulation (DBS)|Patients who underwent Subthalamic Nucleus (STN)-DBS at Lyon
89050897|NCT04597203|Experimental|split face - left side|
89679928|NCT05699798|Experimental|Conservative Treatment (CT)|Includes Hotpack, TENS, Ultrasound and home exercise programs. HP, US and TENS applications were applied for 3 weeks, with a total of 15 sessions, 5 sessions per week. HP application for 20 minutes, ultrasound for 5 minutes and TENS for 20 minutes were applied to the patients. The CT protocol was applied to all three groups in the same way.
89679929|NCT05699798|Experimental|Instrument Assisted Soft Tissue Mobilization (IASTM)|Includes Hotpack, TENS, Ultrasound, home exercise programs and Instrument-assisted Soft Tissue Mobilization Technique. The IASTM therapy was applied for three weeks, two sessions per week, for a total of 6 sessions.
89679930|NCT05699798|Experimental|Extracorporeal Shock Wave Therapy (ESWT)|Includes Hotpack, TENS, Ultrasound, home exercise programs and Extracorporeal Shock Wave Therapy treatment. The ESWT therapy was applied for three weeks, two sessions per week, for a total of 6 sessions.
89679931|NCT00515723|Active Comparator|Olanzapine|Participants in this group were randomized to flexibly-dosed treatment with olanzapine.
89679932|NCT00515723|Active Comparator|Risperidone|Participants in this group were randomized to flexibly-dosed treatment with risperidone.
89679933|NCT00515723|Active Comparator|Quetiapine|Participants in this group were randomized to flexibly-dosed treatment with quetiapine.
89679934|NCT00515723|Active Comparator|Ziprasidone|Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.
89679935|NCT04405154|Experimental|Investigational Arm|Camrelizumab every 2 weeks in combination with 6-7 weeks of radiation therapy and every 3 weeks cisplatin.
89679936|NCT00586573|Experimental|Namenda|
89679937|NCT05622227|Experimental|68Ga-P16-093 and 18F-FDG scan|Within 1 week, each patient underwent 68Ga-P16-093 and 18F-FDG PET/CT scan after intravenous administration of 68Ga-P16-093 and 18F-FDG, respectively.
89679938|NCT05459246|Experimental|Virtual reality glasses|"Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes)."
89679939|NCT05459246|No Intervention|Control group|Routine maintenance will be applied
89679940|NCT01799005|Active Comparator|flavanol rich intervention|Ingestion of 410mg flavanols twice a day for 30 days
89679941|NCT01799005|Placebo Comparator|flavanol free intervention|Ingestion of a macro and micro nutrients matched flavanol free drink
89679942|NCT00515879|Experimental|CBT plus d-cycloserine|Participants will receive cognitive behavioral therapy plus D-cycloserine
89679943|NCT00515879|Placebo Comparator|CBT plus placebo|Participants will receive cognitive behavioral therapy plus pill placebo
89679944|NCT03152942|Experimental|Progesterone alone|Progesterone 400 mg once daily until 34 weeks.
89679945|NCT03152942|Active Comparator|Progesterone and aminophylline.|Progesterone 400 mg and aminophylline 225 mg once daily until 34 weeks.
89050898|NCT04597203|Active Comparator|split face - right side|
89050899|NCT04631237||Focus Groups|N=52
89050900|NCT04631237||Cognitive Interviews|N=24
89050901|NCT04631237||Survey|N=600
89050902|NCT04631159|Experimental|Mobile app group|They are required to wear fitness watches to record steps ,patients will need to download and use the Health2Sync app and report blood glucose data weekly, and be monitored and advised by medical personnel.
89050903|NCT04631159|Placebo Comparator|Control group|they are required to wear fitness watches to record steps ,patients will be asked to self-manage and there is no intervention during the tracking process.
89050904|NCT04596774||Group 1|Group 1 patients were applied traditional approach. Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
89050905|NCT04596774||Group 2|Group 2 received Enhanced Recovery After Surgery (ERAS) approach. Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
89050906|NCT04630691||Control|Patients with HbA1c around 6,0
89050907|NCT04630691||T2DM|Patients with HbA1c above 6,5
89050908|NCT04631081|Active Comparator|Occlusive dressing group|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film according. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing
89215822|NCT05955768|Experimental|Trial group|Disposable cervical dilator stick combined with lidocaine hydrochloride injection.
89215823|NCT05955768|Placebo Comparator|Control group|Disposable cervical dilator stick combined with normal saline injection.
89679946|NCT03024866||Electronic Brachytherapy|Previously completed treatment for non-melanoma skin cancer using Xoft eBx Electronic Brachytherapy System
89679947|NCT03024866||Mohs Surgery|Previously completed treatment for non-melanoma skin cancer using Mohs Surgery
89215824|NCT05946954|Experimental|Intervention group Immediate Dentoalveolar Restoration|"After applying anesthesia to the maxillary tuberosity, a full thickness crestal incision was made following the distal contour of the maxillary right second molar. This incision was followed by a palatal release incision to access the donor area.~The flap was raised in the tuberosity area Then, the bone graft was harvested from the underlying bone by using a 1 cm wide flat chisel and a surgical hammer.~The corticocancellous graft was manipulated using a rongeur to reproduce the shape of the peri-implant bone defect.~The graft was carefully inserted to the level of the implant platform Finally, a screw-retained resin provisional crown, relined over a polyetheretherketone (PEEK) anti-rotation abutment, was placed out of occlusion, establishing the ideal emergence profile to accommodate the soft tissues and to promote a thicker and more stable gingival tissue margin"
89215825|NCT05946954|Active Comparator|Control group Ice cream cone technique|"Ice cream cone technique~Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone.~The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.~The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using resorbable sutures to prevent dislodgment of the blood clot and bone grafting material"
89215826|NCT05944900|Experimental|PICC placement according to standard practice + cyanoacrylate glue|"PICC placement will be performed according to standard practice (Safe Insertion of PICC protocol (SIP2) steps).~The catheter will be secured by the Statlock system. Cyanoacrylate glue will be applied on the catheter exit point in accordance with the instructions for use.~A transparent dressing will be applied, with a compress in the event of bleeding."
89215827|NCT05944900|No Intervention|PICC placement according to standard practice|"PICC placement will be performed according to standard practice (Safe Insertion of PICC protocol (SIP2) steps).~The catheter will be secured by the Statlock system. A transparent dressing will be applied, with a compress in the event of bleeding."
89679948|NCT03157544|Experimental|Pain Relief Kit|Immediately following baseline data collection participants will be given the Pain Relief Kit and instructed about the contents. From this kit, a sample of Biofreeze® and TheraBand® Kinesiology Tape will be applied to the participant. The contents of the Pain Relief Kit will include four modes of non-pharmacological interventions that have been previously demonstrated to relieve musculoskeletal pain. Following Baseline data collection, participants will review the content of the Pain Relief Kit with a member of the research staff. During this review the subject will be informed about the recommended use of all the four modes of the non-pharmacological interventions included in the kit. This information will also be included in written form in the Pain Relief Kit.
89679949|NCT00586729|Experimental|Vashe|Vashe Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
89679950|NCT00586729|Active Comparator|5% Mafenide Acetate|5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
89679951|NCT01672346|Active Comparator|Arm I|PVAI with ablation of posterior wall contained within pulmonary veins using energy up to 30 watts and post-ablation adenosine challenge
89679952|NCT01672346|Active Comparator|Arm II|AF ablationPVAI with ablation of posterior wall contained within pulmonary veins using energy up to 40 watts and post-ablation adenosine challenge
89679953|NCT01672424||Group P: High Protein Drink|Patients receiving the high protein drink with 30 grams of protein in 11 fluid ounces.
89679954|NCT01672424||Group C: Ice Chips|The control group consisting patient receiving 11 ounces of ice chips
89679955|NCT00635479|Experimental|VAC Device placement|will have the VAC device used for post-operative management of acetabular fractures and pelvic fractures.
89679956|NCT00635479|Active Comparator|Gauze dressing|will receive current traditional surgical wound management with daily dressing changes in post operative management of acetabular fractures and pelvic fractures.
89679957|NCT00516503|Experimental|Arm I|Patients apply 1 spoonful of baclofen-amitriptyline hydrochloride-ketamine gel> topically to each> area of pain,> numbness,> and/or tingling> on the> feet and/or hands twice daily> for> 4 weeks.
89679958|NCT00516503|Placebo Comparator|Arm II|Patients apply 1 spoonful of placebo gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks.
89679959|NCT03157310|Experimental|Gefitinib|Gefitinib is an selective small molecule epidermal growth factor receptors (EGFRs) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer.
89679960|NCT03157076|Active Comparator|Pacing mode with CLS|
89679961|NCT03157076|Active Comparator|Intrinsic mode|
89679962|NCT00587041|Placebo Comparator|Placebo|Participants received placebo for 6 weeks: 1 placebo packet daily and 1 placebo capsule twice daily
89679963|NCT00587041|Active Comparator|Oxadrop|Participants received Oxadrop for 6 weeks: Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis)
89679964|NCT00587041|Active Comparator|Agri-King Synbiotic|Participants received AKSB for 6 weeks: AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
89679965|NCT03157388|Experimental|Intervention|Combined Vancomycin and Gentamycin and Meropenem
89215828|NCT05938699|Active Comparator|NCX 470 0.1%|NCX 470 0.1% - one drop in the randomized eye once a day for 8 days
89215829|NCT05938699|Placebo Comparator|Placebo|Artificial tears - one drop in the randomized eye once a day for 8 days
89215830|NCT05931315|Active Comparator|CaroRite™|One capsule to be taken immediately post-dinner / with dinner
89215831|NCT05931315|Placebo Comparator|Placebo|One capsule to be taken immediately post-dinner / with dinner
89215832|NCT05926349|Experimental|Andexanet Alfa Group|Patients will receive andexanet alfa as IV bolus followed by an infusion.
89215833|NCT05926349|Active Comparator|Usual Care Group|Patients will receive treatment based on the Investigator's discretion, according to regional, local/institutional guidelines or practices.
89679966|NCT04387825|Experimental|Experimental group|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
89679967|NCT04387825|No Intervention|Control|Evolution and medical therapy effects were observed in the control group.
89679968|NCT01672502|Experimental|Intervention|Firefighters in this group will receive at the beginning of the study an introduction to the study, sleep education, sleep disorder screening survey, health survey, increased sleep opportunities at their fire department, followed later by physiological monitoring of a portion of the firefighters, and then finally an 'end of year' survey at the end of the study.
89679969|NCT01672502|Active Comparator|Control|Firefighters in this group will only receive an introduction to the study and a health survey, followed later by physiological monitoring of a portion of the firefighters, and then at the end of the study will receive the sleep disorders screening survey, sleep education (Intervention group received screening survey and education much earlier at the beginning of the study), and an 'end of year' survey. None of these firefighters will receive the increased sleep opportunities as the Intervention group will.
89679970|NCT02135653||Feasibility Phase: Eischens Yoga Group|
89679971|NCT02135653||Phase II: Eischens Yoga Group|
89679972|NCT05622149|No Intervention|Control|No intervention
89679973|NCT05622149|Experimental|Diet Only|Subjects were given calorie and macronutrient intake goals and were told to hit those goals as closely as possible on a daily basis for 16 weeks.
89679974|NCT05622149|Experimental|Training Only|Subjects were given a 3 times per week supervised resistance training program for 16 weeks
89679975|NCT05622149|Experimental|Diet plus Training|Subjects were given calorie and macronutrient intake goals and were told to hit those goals as closely as possible on a daily basis for 16 weeks. Subjects were given a 3 times per week supervised resistance training program for 16 weeks
89679976|NCT03156920|Active Comparator|Sumatriptan|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of sumatriptan 50 mg
89679977|NCT03156920|Placebo Comparator|Placebo|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of placebo
89679978|NCT05247385|Active Comparator|Prasugrel group|"Prasugrel (60mg loading dose, followed by 10 mg QD for 15 days)~+ Ticagrelor placebo (Placebo loading dose followed by two pills a day)"
89679979|NCT05247385|Active Comparator|Ticagrelor group|"Ticagrelor (180mg loading dose, followed by 90 mg BID)~+ Prasugrel placebo (Placebo loading dose followed by one pill a day)"
89050909|NCT04631081|Active Comparator|Surgical group|In surgical group, coverage with a bipedicled palmar island flap will be performed ambulatory, either on admission if patients are directly oriented to the Hand Surgery department, or within 48h of initial visit for patients addressed from the Emergency department. The flap group will be evaluated on admission, at 48h, and 6 weeks.
89050910|NCT04596813|No Intervention|standard of care|
89050911|NCT04596813|Active Comparator|standard of care and treatment with the Cytosorb® device|
89050912|NCT04630457|Active Comparator|Meridium-RoFT|order of existing prosthesis-Meridium prosthesis-RoFT prosthesis
89050913|NCT04630457|Active Comparator|RoFT-Meridium|order of existing prosthesis-RoFT prosthesis-Meridium prosthesis
89050914|NCT00564798||1|Study Group
89050915|NCT00564798||2|Control Group
89050916|NCT01158118|Experimental|Arm 1 - Donor|"Days 1-5: Mobilization with 5 mcg/kg/day GM-CSF (first 4 donors were mobilized with 10 mcg/kg GM-CSF then changed to 5 mcg/kg for remaining donors)~Day 5: Mobilization with 320 mcg/kg plerixafor IV~Day 5: Leukopheresis~If PBSC collected are not adequate, then donor will be mobilized with GM-CSF and plerixafor IV on day 6 and have leukopheresis collection on day 6."
89050917|NCT01158118|No Intervention|Arm 2 - Recipient|"Conditioning Regimens~fludarabine and busulfan +/- thymoglobulin~fractionated total body irradiation and cyclophosphamide~busulfan and cyclophosphamide~single dose total body irradiation and cyclophosphamide~Day -2 = GvHD prophylaxis~Day 0 or +1 = PBSC transplant~Day +7 until neutrophil engraftment = G-CSF 5 ug/kg/day"
89050918|NCT04630340|Active Comparator|STEADES-2 (Intervention) arm|"Subjects in the intervention arm will fill up the questionnaire embedded in the STEADES app and be inducted to the use of STEADES-2 device by the CRC. The CRC will assist to download the STEADES app into the subject's smartphone; demonstrate the use of the app and the procedure for the serious games; and linkage to the virtual coach. The subject will use the STEADES-2 device to assess their smoking status and play the game according to the stipulations in the protocol. The STEADES-2 app provides a portal for the subject to interact with the assigned virtual coach and for motivation messages to be delivered to them. The primary outcome is total smoking cessation as measured by~exhaled breath carbon monoxide using the STEADES-2 device and~urine cotinine level which indicates the nicotine from the cigarette smoking The secondary outcome is the score using the System Usability Scale (SUS) to assess the use and experience in using the STEADES-2 system"
89050919|NCT04630340|No Intervention|Usual Care|"In the control arm, the subjects will be enrolled into the existing smoking cessation program at the respective polyclinic, which covers smoking cessation advice, together with an exhaled breath analyzed using a commercially available eCO measurement device by a trained nurse counsellor. They will complete a questionnaire and their smoking status will be re-assessed at 12 weeks after their enrolment. The primary outcome is total smoking cessation at the end of the study:~as measured by the exhaled breath carbon monoxide level determined by the STEADES-2 device and~urine cotinine levels which is a marker of nicotine level from smoking"
89050920|NCT04596969|Experimental|SFD Tapioca 20g|20g soluble fiber dextrin derived from tapioca
89050921|NCT04596969|Experimental|SFD Tapioca 40g|40g soluble fiber dextrin derived from tapioca
89050922|NCT04596969|Experimental|SFD corn 20g|40g soluble fiber dextrin derived from corn
89050923|NCT04596969|Experimental|SFD corn 40g|
89050924|NCT04596969|Placebo Comparator|Control|Maltodextrin
89050925|NCT04313920|Experimental|Nutritional Supplement|Ready to drink liquid
89050926|NCT00564837|Experimental|Home-based|Home-based post-operative rehabilitation program with 4 scheduled physiotherapy sessions over the first 3 post-op months
89679980|NCT03156842|Experimental|Fimasartan/Amlodipine, Rosuvastatin|Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin
89679981|NCT03156842|Active Comparator|Fimasartan/Amlodipine|a fixed dose combination of Fimasartan/Amlodipine
89679982|NCT03156842|Active Comparator|Fimasartan, Rosuvastatin|Co-administration of Fimasartan and Rosuvastatin
89679983|NCT01672580|Active Comparator|Random-Cloro|exposure to water chlorination
89679984|NCT01672580|Active Comparator|Random-Vitamin|exposure to vitamin use
89679985|NCT01672580|Experimental|Indegree-Cloro|high in-degree, exposure to water chlorination
89679986|NCT01672580|Experimental|Indegree-Vitamin|high in-degree, exposure to vitamin use
89679987|NCT01672580|Experimental|Nominated-Cloro|nominated by random, exposure to water chlorination
89679988|NCT01672580|Experimental|Nominated-Vitamin|nominated by random, exposure to vitamin use
89679989|NCT00636649|Experimental|A|Escitalopram
89050927|NCT00564837|Active Comparator|Physiotherapy supervised|Physiotherapy-supervised rehabilitation program including 17 scheduled physiotherapy sessions in the first 3 post-op months
89050928|NCT01157845|Experimental|Laboratory assay|
89050929|NCT00561041|Experimental|1|Brief phone aftercare intervention composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
89050930|NCT00561041|Experimental|2|Individual aftercare therapy - composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
89050931|NCT00561041|No Intervention|3|No intervention
89050932|NCT00566241|Experimental|IGF-1|Recombinant human IGF-1
89050933|NCT00566241|Placebo Comparator|Placebo|Placebo
89050934|NCT00561119|No Intervention|Arm 1|Observation after 6 cycles of gemcitabine plus paclitaxel till progression
89050935|NCT00561119|Experimental|Arm 2|Maintenance chemotherapy with gemcitabine plus paclitaxel after 6 cycles of gemcitabine plus paclitaxel till progression
89050936|NCT00566280|Other|Molecular Breast Imaging|
89050937|NCT00561158|Experimental|A|
89050938|NCT00561158|No Intervention|2|
89050939|NCT00566319|Experimental|1|
89050940|NCT00566319|Active Comparator|2|
89679990|NCT00636649|Placebo Comparator|B|Placebo
89679991|NCT03156764||Qp/Qs ratio monitoring|Qp/Qs ratio monitoring
89679992|NCT05061524|Experimental|YH35324|"Part A: A single dose of the YH35324 will be administered subcutaneously in 5 dose groups (0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses~Part B: A single dose of the YH35324 will be administered subcutaneously. The dose of YH35324 will be determined after the safety, tolerability, PK, and PD data in Part A are reviewed"
89679993|NCT05061524|Placebo Comparator|Placebo|"Part A: A single dose of the Placebo will be administered subcutaneously in 5 Cohorts(Dose groups=0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses~Part B: Placebo is not administered in Part B"
89679994|NCT05061524|Active Comparator|Xolair® for injection (Omalizumab)|"Part A: A single fixed dose of the Omalizumab 300mg will be administered subcutaneously in 4 Cohorts(Dose groups of YH35324=1, 3, 6, and 9 mg/kg)~Part B: A single dose of the Omalizumab 300mg will be administered subcutaneously."
89050941|NCT04630223||intrauterine growth retardation|Blood samples are going to be taken from the umbilical cord of the fetuses. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
89050942|NCT04630223||healthy fetuses|Blood samples are going to be taken from the umbilical cord of healthy fetuses without intrauterine growth retardation. Levels of endocan (endothelial cell specific molecule 1) in the samples of umbilical cord blood are going to be measured using human endocan ELISA kits.
89050943|NCT04605471||PMS I study|"'PMS I' was conducted in contrast-enhanced X-ray examination between June 1999 and November 2003 in 27 countries in Europe, Africa and Asia and comprised 74,717 patients of which 2,172 were children and 32,103 were elderly patients.~Ref. Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol. 2008;49(8):902-11."
89050944|NCT04605471||IMAGE study|"'IMAGE' consists of 44,835 patients with contrast-enhanced X-ray examination and was conducted in 21 European and Asian countries from February 2008 to September 2009, 1,451 patients were children, and 15,654 were elderly patients.~Ref. Palkowitsch P, Lengsfeld P, Stauch K, Heinsohn C, Kwon ST, Zhang SX, et al. Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE). Acta Radiol. 2012;53(2):179-86."
89050945|NCT04605471||TRUST study|"'TRUST' assessed the safety and tolerability of Ultravist in patients undergoing cardiac catheterization. It was conducted from August 2010 to September 2011 in China and included 17,513 patients of which 12 were children and 8,918 were elderly patients.~Ref. Chen JY, Liu Y, Zhou YL, Tan N, Zhang B, Chen PY, et al. Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. Int J Cardiovasc Imaging. 2015;31(7):1281-91."
89679995|NCT00636805|Experimental|1|Patient receives IV Aloxi
89679996|NCT03153254|Experimental|Healthy persons|Test upper limb robot assisted therapy device. During 1 session of 1/2 hour.
89679997|NCT03153254|Experimental|Stroke patients|Training with new upper limb robot assisted therapy device. During 2 to 5 sessions of 1/2 hour.
89679998|NCT05247151|Active Comparator|Oxytocin|The patients received either a spray of the synthetic oxytocin (24 I.U. Syntocinon®) with mindfulness-bases grow therapy (MBGT) as a positive social context in each condition. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 30 min before the 50-min session.
89679999|NCT05247151|Placebo Comparator|Placebo|The patients received either a spray of the synthetic placebo (24 I.U.) with mindfulness-bases grow therapy (MBGT) as a positive social context in each condition. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 30 min before the 50-min session.
89680000|NCT03153098||Standard delivery|Participants will receive a behaviour change technique booklet, consultations (baseline, and optional at 3, 6, and 12 months), a booster phone call (week 2), motivational text messages (weeks 3, 6, and 12), and signposting to 12 weeks of exercise classes.
89050946|NCT04605471||Ultravist in CT study|"'Ultravist in CT' was performed with focus on contrast-enhanced CT examination between November 2006 and December 2008 and included 15,168 patients in Germany, Iran, Romania and Saudi Arabia. A total of 417 patients were children, 7,453 were elderly patients.~Ref. Palkowitsch PK, Bostelmann S, Lengsfeld P. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. Acta Radiol. 2014;55(6):707-14."
89050947|NCT04629989|Active Comparator|Low-flow nasal cannula|The standard oxygen delivery system (low-flow nasal cannula) is worn by the patient, without the DTM or the SM
89050948|NCT04629989|Experimental|Double-Trunk Mask|The Double-Trunk Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
89050949|NCT04629989|Experimental|Surgical Mask|The Surgical Mask is placed above the standard oxygen delivery system (low-flow nasal cannula).
89050950|NCT00566358|Experimental|1|Duodenal exclusion
89050951|NCT04629755|Experimental|Intervention|The intervention was delivered via a series of daily text messages to mobile phones. Participants first were delivered an introductory text message at 6:00 pm on Day 7 of the study. This message alerted the participants to expect their first suggestion via text message at 8:00 am the following morning. For the next 14 days (Days 8 - 22), participants received one of 14 suggestions in random order. The specific daily suggestions varied in length and complexity: The simplest ones included text messages and a brief audiofile delivered via text; the more complex suggestions included text messages and a link to a web-page, which included text or embedded audiofiles describing why a suggestion was being made, how to engage in the suggested practice, and audiotaped exchanges between members of the production team describing what it was like to try the practices themselves. Some suggestions were supplemented with additional reminder and check-in text messages at noon and 4:00 pm.
89050952|NCT04629755|No Intervention|Control|Assessment only.
89680001|NCT03153098||Enhanced delivery|Participants will receive the same as intervention but the 12 weeks of exercise will be free and tailored to their needs, and there will be optional exercise 'buddies' available.
89680002|NCT02137447|Experimental|Negative Pressure Wound Therapy|"After the completion of the operation, incisional skin closure was performed using sutures or staples and the wound was then covered with the Negative Pressure Wound therapy Prevena Incision Management System (Kinetic Concepts Inc) as per the manufacturer's instructions of use. Continuous negative pressure was applied at 125 mm Hg.~For inpatients, wounds were assessed every 48 hours by inspection and palpation. The dressing was not routinely removed, but the surrounding skin was assessed for cellulitis. The NPWT dressing was removed between post-operative day 5 and 7"
89050953|NCT04605042|Experimental|WET First group|COOK ECHO-HD 22-C EchoTip Procore needle biopsy in WS-SNP-WS-SNP sequence
89680003|NCT02464904|Experimental|Cryotherapy|Cryospray and biopsies
89680004|NCT02464904|Other|Control|Biopsies
89680005|NCT05246995|Experimental|IBI325 and Sintilimab combination does-escalation|
89680006|NCT03153566|Experimental|study group|include (15) patients will be injected with Tuberculin vaccine 0.3 ml every 2 weeks, vaccine will be injected in the largest wart, 4 sessions will be done then patients will be followed for 2 months
89680007|NCT03153566|Active Comparator|control group|include (15) patients will be treated with cryotherapy every 2 weeks ,4 sessions will be done then patients will be followed for 2 months
89680008|NCT03153566|Experimental|combined group|include (15) patients will be treated with combined cryotherapy and Tuberculin vaccine , one week cryotherapy and the other week Tuberculin vaccine , then patients will be followed for 2 weeks
89680009|NCT01676246|Active Comparator|flupirtine per os single dose|100 mg flupirtine per os, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
89680010|NCT01676246|Active Comparator|flupirtine intravenous|100 mg flupirtine intravenous, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
89680011|NCT01676246|Active Comparator|flupirtine per os steady state|400 mg flupirtine per os, pharmacokinetics of flupirtine, electric pain measurement
89680012|NCT04275830|Experimental|Baseline and HRVB+DS group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to HRVB+DS arm. This group will receive a standardized HeartMath© Inner balance device and HRV biofeedback training session at the start of the two-week intervention period. They will be asked to attend either a group or one-on-one 30-minute HRVB training session and asked to practice their HRV biofeedback skills at home for 10 minutes each day for a two-week period. Participants will also be asked to watch four digital stories of other HCT patients (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
89680013|NCT04275830|Other|Baseline and HRVB waitlist +DS control group|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to HRVB waitlist +DS control arm. After the baseline data collection, during two weeks, they will be provided four digital stories of other HCT patients sharing their experiences (challenges, feelings, strategies, coping, each 2-3 minutes long). At the end of the two-week period, participants will be scheduled for a final in-person session including T2 survey and HRV assessment. They will be also provided HRVB training session at T2.
89680014|NCT03152864|Experimental|Full Package|
89680015|NCT03152864|No Intervention|Sensing Only|
89680016|NCT02014844|Experimental|aldoxorubicin|Subjects will receive either 250 mg/m2 or 350 mg/m2 aldoxorubicin IV.
89680017|NCT01672814|Active Comparator|Keraflex combined with Crosslinking|Vedera KXS microwave system used in conjunction with corneal collagen crosslinking performed with VibeX (Riboflavin ophthalmic solution)and the KXL UV System
89680018|NCT01672814|Active Comparator|Corneal collagen crosslinking alone|Corneal collagen crosslinking alone performed with VibeX (Riboflavin Ophthalmic Solution)and the KXL UV system
89050954|NCT04605042|Experimental|STANDARD first group|COOK ECHO-HD 22-C EchoTip Procore needle in SNP-WS-SNP-WS sequence
89050955|NCT04596696|Other|Single arm Rotavac|Single arm Open Label study without comparator
89050956|NCT04596618|Active Comparator|Forearm Cooling|Participants will be actively cooled during rest breaks.
89680019|NCT00638365|Experimental|1|KB001, a monoclonal antibody
89680020|NCT00638365|Placebo Comparator|2|Placebo
89050957|NCT04596618|No Intervention|No Forearm Cooling|"Participants will participant in passive cooling where they sit in a chair during rest."
89215834|NCT05923775|Active Comparator|Intrafen group|Each patient in this group will be administered intravenous Ibuprofen (400 mg/8 ml i.v. infusion) for pre-emptive analgesic effect 60 minutes before surgical third molar extraction. Before the procedure, each patient in this group will be given 2 ml of local anesthesia.
89215835|NCT05923775|Active Comparator|Ketamine group|Each patient in this group will be administered intravenous 100 ml saline (Poliflex 0.9% isotonic 100 ml solution) for a placebo effect 60 minutes before surgical third molar extraction. Before the procedure, each patient in this group will be given 0.3 mg/kg of ketamine (Ketalar 500 mg) in addition to 2 ml of local anesthesia.
89215836|NCT05923775|Active Comparator|Combined group (Intrafen+Ketamine)|Each patient in this group will be administered intravenous Ibuprofen (400 mg/8 ml i.v. infusion) for pre-emptive analgesic effect 60 minutes before surgical third molar extraction. Before the surgery, each patient in this group will be given 0.3 mg/kg of ketamine (Ketalar 500 mg) in addition to 2 ml of local anesthesia.
89215837|NCT05923775|Placebo Comparator|Control|Each patient in this group will be administered intravenous 100 ml saline (Poliflex 0.9% isotonic 100 ml solution) for a placebo effect 60 minutes before surgical third molar extraction. Before the procedure, each patient in this group will be given 2 ml of local anesthesia.
89680021|NCT04764890|Experimental|Electroacupuncture and manual therapy|Electroacupuncture in several points and manual therapy in the lumbar spine
89680022|NCT04764890|Active Comparator|Manual therapy|Manual therapy in the lumbar spina
89680023|NCT00524225|Experimental|Neumega (Interleukin 11, IL-11)|Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively
89680024|NCT00669019|Experimental|Saracatinib|Patients receive saracatinib 175 mg oral once daily in the absence of disease progression or unacceptable toxicity.
89680025|NCT01673048|Active Comparator|Femoral fracture, ESIN|"Prospectively all patients treated with the 3-nail-configuration for dislocated femoral shaft fractures were enrolled; 25 patients are planned, 18 could be enrolled Comparison will be with own previous data of patients treated with the classical 2-C-shaped ESIN-osteosynthesis"
89680026|NCT05560373|Experimental|The operation group-The treatment group|after operational treatment: ①the best basic treatment ②i.m. huperzine A injection (0.2mg), qd, 8d.
89680027|NCT05560373|Other|The operation group-The control group|after operational treatment: ①the best basic treatment
89680028|NCT05560373|Experimental|The intervention group-The treatment group|after interventional treatment: ①the best basic treatment ②i.m. huperzine A injection (0.2mg), qd, 8d.
89680029|NCT05560373|Other|The intervention group-The control group|after interventional treatment: ①the best basic treatment
89680030|NCT02140957|Experimental|Educational Intervention|Parents in this arm received a 5 minute educational intervention on bottle cessation plus standard nutritional counseling.
89680031|NCT02140957|Placebo Comparator|Control|Parents in this arm received a placebo which consisted of standard nutritional counseling alone.
89680032|NCT04747574|Other|EXO-CD24 exosome treatment|"Group 1, 5 patients are treated with 1x10^8 exosome particles per 2 ml saline.~Group 2: 5 patients are treated with 5x10^8 exosome particles per 2 ml saline.~Group 3: 20 patients are treated with 1x10^9 exosomes particles per 2 ml saline.~Group 4: 5 patients are treated with 1x10^10 exosomes particles per 2 ml saline.~The drug is aerosolized in normal saline for inhalation and administered via a standard hospital-grade inhalation device, QD for 5 days. Study treatment is given as an add-on to the standard of care."
89680033|NCT01676480|Experimental|ADT group|
89680034|NCT01676480|Experimental|Control group|
89215838|NCT05921396|Experimental|Nasal patency before and after pituitary adenoma surgery|Nasal patency in patients with pituitary adenoma indicated to endoscopic transnasal extirpation of the pituitary adenoma.
89680035|NCT05560139|Experimental|experimental group|Participants in the experimental groups received ten -sessions a-tDCS (1.5mA, 20minutes) anodal stimulation of left DLPC over two weeks duration (five sessions per week).
89680036|NCT05560139|Sham Comparator|sham group|The sham group received ten sessions of sham stimulation for 20-minutes in each session.
89680037|NCT00670267|Experimental|Open Label treatment with oral Nadolol|Dose escalation through 1.25mgs, 2.5mgs, 5.0mgs, 10mgs, 20mgs, and 40mgs of nadolol at 2 week intervals as tolerated.
89680038|NCT05621915||conventional oxygen therapy|Patients treated with conventional oxygen in Infectious Diseases Ward.
89680039|NCT05621915||mechanical ventilation|Patients who are mechanically ventilated and treated in ICU.
89680040|NCT05621915||mechanical ventilation and ECMO|Patients who are mechanically ventilated and on ECMO treated in ICU.
89680041|NCT01673204|Experimental|Calcitriol|Calcitriol
89215839|NCT05919862|Experimental|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan.
89215840|NCT05919862|Sham Comparator|Freehand surgery|Freehand implant placement by experienced surgeon.
89215841|NCT05911724||Group I|60 Healthy Subjects.
89215842|NCT05911724||Group II|60 Patients with Stable Angina.
89215843|NCT05911724||Group III|60 Patients with Heart Failure.
89680042|NCT01673204|Placebo Comparator|Placebo|Placebo
89680043|NCT01799395||Lung Cancer|All patients with advanced lung cancer candidate for chemotherapy or chemotherapy + radiation therapy will be enrolled and followed-up for 1 year clinically and radiologically (Chest CT) to verify whether or not central airway obstruction is present at the time of diagnosis or occurs in the year following diagnosis (or in the life span from diagnosis and death in patients who die before 1 year of diagnosis). Furthermore, predictor variables possibly associated with central airway obstruction will be studied.
89680044|NCT05621837||Metastatic melanoma patients|MDSC quantification in Metastatic melanoma patients undergoing first/second-line treatment with BRAF and MEK inhibitors (BRAFi+MEKi) or immune checkpoint inhibitors (antagonists of PD-1 or CTL4, or both) (n=100);
89680045|NCT05621837||hormone receptor positive/Human Epidermal growth factor Receptor-2 negative cancer patients|MDSC quantification in Metastatic HR+(hormone receptor positive)/ HER2-(Human Epidermal growth factor Receptor-2 negative) breast cancer patients already treated with a combination of an hormonal agent and a CDK(Cyclin-dependent kinase)4/6 inhibitor and receiving chemotherapy (n=100);
89215844|NCT05911451|Active Comparator|Arteriovenous fistula|Patients allocated to usual care will be treated according to current guidelines on vascular access creation. These guidelines recommend placing autologous arteriovenous fistulas at the most distal site with adequate blood vessels, preferably in the non-dominant arm. Patients who have already been on hemodialysis treatment using a central venous catheter must be operated within 6 months of dialysis initiation. Because the study aims to compare the different surgical strategies for vascular access creation in a real-life situation, the study will not interfere with clinical practice at the study sites.
89215845|NCT05911451|Experimental|Arteriovenous graft|Patients who are allocated to the arteriovenous graft strategy will have a commercially available prosthetic tube graft implanted for hemodialysis access. Patients who have already been on hemodialysis treatment using a central venous catheter must be operated within 6 months of dialysis initiation. Because the study aims to compare the different surgical strategies for vascular access creation in a real-life situation, the study will not interfere with clinical practice at the study sites.
89215846|NCT05911451|Experimental|Central venous catheter|Patients who are allocated to the central venous catheter strategy will have a dialysis catheter inserted. Because the study aims to compare the different surgical strategies for vascular access creation in a real-life situation, the study will not interfere with clinical practice at the study sites.
89215847|NCT05907694|Experimental|transcatheter PFO closure + optimal medical treatment|Patients will undergoes transcatheter PFO closure (+ optimal medical treatment). Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
89215848|NCT05907694|Experimental|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
89215849|NCT05907031|Active Comparator|active cTBS group|active cTBS combined with speech language therapy
89215850|NCT05907031|Sham Comparator|sham cTBS group|sham cTBS combined with speech language therapy
89215851|NCT05892406|Active Comparator|Static guide|Prosthetically guided Implant placement utilising a 3D printed static guide based on a digital plan
89215852|NCT05892406|Active Comparator|Dynamic navigation|Prosthetically guided Implant placement utilising a dynamic navigation system based on a digital plan
89215853|NCT05892406|Experimental|Robotic system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
89215854|NCT05891990|Experimental|Intervention group|"sticky tooth preparation:~patient's venous blood will be collected using a 21 g needle with a butterfly handle.~The blood in the test tubes will be centrifuged at 700 rpm for 3 min for women and 4 min for men because of a different hematocrit.~The liquid PRF fraction will be collected using a sterile syringe. It gently will be mixed with the demineralized dentin granules and allowed for five-ten minutes for polymerization in order to produce a sticky tooth."
89215855|NCT05891990|Active Comparator|Control group|"Autogenous demineralized dentin graft preparation~Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present), using a high-speed fine finishing stone and saline irrigation.~The pulp will be removed, using a root canal instrument. Subsequently, the remaining dentin will be cut into pieces. These pieces of dentin will be ground using a bone mill to produce dentin particles.~The sorted particles will be immersed in 70% ethanol and 4% H2O2 in a sterile container to remove any soft tissue remnants, bacteria, and smear layer.~Tooth particles will be demineralized using 0.6N HCl for 30 minutes to expose the dentine organic matrix.~After demineralization, the materials will be washed with phosphate-buffered saline (PBS) and dried with sterile gauze."
89215856|NCT05867420|Experimental|ASKG915|Single or multiple ascending dose of ASKG915.
89215857|NCT05860738||As-received NITI archwires|The first group of wires will be investigated in the as-received form (as received from the company without being used clinically).
89680046|NCT05621837||Advanced RCC(renal cell carcinoma) patients|MDSC quantification Advanced RCC patients receiving immune checkpoint inhibitors (antagonists of PD-1, PD-L1 or CTL4, or combinations) or anti-angiogenics alone or combined with immune checkpoint inhibitors; locally advanced/metastatic UC(Urothelial Carcinoma) patients receiving first-line chemotherapy, immune checkpoint inhibitors or combinations (n=100);
89680047|NCT05621837||SCCHN or SCC(Small Cell Carcinoma) patients|MDSC quantification in SCCHN or SCC(Small Cell Carcinoma) patients treated with first-line chemotherapy, cetuximab,immune checkpoint inhibitors or combinations (n=100).
89680048|NCT05621837||NSCLC patients|MDSC quantification in NSCLC patients undergoing radical surgery for stage III cancer (n=100);patients with unresectable/metastatic NSCLC receiving first line treatment with chemotherapy, immune checkpoint inhibitors (antagonists of PD-1, PD-L1 or CTL4) or combinations (n=100).
89680049|NCT05621837||Age and gender-matched healthy donors|Age and gender-matched healthy donors (n=400) will be enrolled in the study, to allow us investigating the same immunological parameters under physiological conditions and define normal values for the myeloid-related biomarkers here assessed.
89680050|NCT00641563|Active Comparator|Dex/Remi followed by Mida/Remi|Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week
89680051|NCT00641563|Active Comparator|Mida/Remi followed by Dexa/Remi|Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week
89680052|NCT02251262|Experimental|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
89680053|NCT00641641|Experimental|antiretroviral therapy|tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.
89680054|NCT03152474|Active Comparator|Solumedrol 20mg|Solumedrol injection will be given in the vein every 8 hrs. for 7 days.
89680055|NCT03152474|Active Comparator|Vitamin A 100,000 IU|Vitamin A injection will be given in the arm muscle for 7 days.
89680056|NCT03152474|Placebo Comparator|Placebo|Placebo will be given in the vein every 8 hrs. for 7 days or given in the arm muscle for 7 days.
89680057|NCT00641797|Active Comparator|Arm 1, Conventional Therapy|Patients will receive standard conventional medication therapy (i.e., meclizine, diphenhydramine, lorazepam, ondansetron).
89215858|NCT05860738||Rapid cycle autoclaved NITI archwires|The second group of archwires will be will be installed in the patients mouth for 4 weeks, and then retrieved, cleaned using ultrasonic cleaner, dried and packaged and finally autoclaved using the rapid cycle (4 mins, 134oC)
89215859|NCT05860738||Universal cycle autoclaved NITI archwires|the third group will be installed in the patients mouth for 4 weeks, and then retrieved, cleaned using ultrasonic cleaner, dried and packaged, the finally autoclaved using the universal cycle (20 mins, 121 oC)
89215860|NCT05860387||Suspicion of IPA at enrolment|Study subjects with suspicion of IPA at enrolment will be included in this study group.
89215861|NCT05860387||Probable or proven IPA at enrolment|Study subjects with probable or proven IPA at enrolment will be included in this study group.
89215862|NCT05859386|Experimental|Mindfulness maintenance program|Participants receive: (1) Four-week course to strengthen and extend skills learned in 8-week MBCT course, (2) Monthly 1.5 hour meeting session, and (3) Monthly check-in survey.
89215863|NCT05859386|No Intervention|Wait-list|Participants receive follow-up measures but no intervention until the end of the wait-list period.
89215864|NCT05852587|Experimental|Xylitol|Patients in this arm will be receiving 7.5g/day of Xylitol over a 4 week period.
89215865|NCT05852587|Placebo Comparator|Sucralose|Patients in this arm will be receiving 250mg/day of sucralose over a 4 week period.
89215866|NCT05845216|Experimental|ACTIVE tPBM|one session of 24-min tPBM with the active device (tPBM helmet with 80 Light-Emitting Diodes (LEDs) emitting red and near-infrared light at 670 - 810nm)
89215867|NCT05845216|Sham Comparator|SHAM tPBM|one session of 24-tPBM with a sham device visually identical to the active device
89215868|NCT05828095|Experimental|Group #1: INO-6160/ 2.0 mg|The dose of INO-6160, 2 mg, will be administered as 2 separate intradermal (ID) injections, one in each arm
89215869|NCT05828095|Experimental|Group #2: INO-6160/ 2.0 mg with Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|"The dose of INO-6160, 2 mg, will be administered as 2 separate intradermal (ID) injections, one in each arm.~The dose of Trimer 4571, 100 mcg, will be administered as 2 injections delivered intramuscularly (IM), one in each arm."
89215870|NCT05824364|Experimental|Case|two-four weeks of on-site cardiac rehabilitation (CR) followed by 12 weeks of telerehabilitation
89680058|NCT00641797|Experimental|Arm 2, Epley Maneuver|Patients will receive vestibular rehabilitation (the Epley Maneuver).
89680059|NCT04333459|Active Comparator|Group 1 - Full Dose Hataan|"Group 1 will be vaccinated with the Full Dose of HTNV DNA vaccine, 2 mg of pWRG/HTN-M(co) with 0.5 mg/each deltoid."
89680060|NCT04333459|Active Comparator|Group 2 - Half Dose Hataan|"Group 2 will be vaccinated with the Half Dose of HTNV DNA vaccine, 1 mg of pWRG/HTN-M(co) with 1.0 mg/each deltoid."
89680061|NCT04333459|Active Comparator|Group 3 - Full Dose Puumala|"Group 3 will be vaccinated with the Full Dose of PUUV DNA vaccine, 2 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
89680062|NCT04333459|Active Comparator|Group 4 - Half Dose Puumala|"Group 4 will be vaccinated with the Half Dose of PUUV DNA vaccine, 1 mg of pWRG/PUU-M(s2) with 1.0 mg/each deltoid."
89680063|NCT00671515|Experimental|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
89215871|NCT05824364|Active Comparator|Control|4 weeks of on-site standard CR
89215872|NCT05821283|Experimental|Physical Activity Group|The Physical Activity (PAG) was included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking).
89680064|NCT00671671|Experimental|Cohort B|
89215873|NCT05821283|Active Comparator|Control Group|The Control Group (CG) was included in the program consisting of only supervised exercises.
89215874|NCT05817877||over 5 hours|people with an average daily phone use of more than 5 hours.
89215875|NCT05817877||under 5 hours|People with an average daily phone use of less than 5 hours.
89215876|NCT05816356|Experimental|Modified release formulation of decitabine and tetrahydrouridine|A modified-release combination formulation of decitabine/THU (2.5 mg/100 mg per capsule given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
89215877|NCT05816356|Active Comparator|Immediate release capsules of decitabine and tetrahydrouridine|Capsules of THU are given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water, followed by a single oral dose of decitabine given 1 hour (± 5 min) later with approximately 240 mL (8 fluid ounces) of ambient temperature water.
89215878|NCT05815498|Experimental|mRNA-1283.222|Participants will receive single intramuscular (IM) injection of mRNA-1283.222 on Day 1.
89215879|NCT05815498|Experimental|mRNA-1273.222|Participants will receive single IM injection of mRNA-1273.222 on Day 1.
89215880|NCT05815277||parents who have children aged from 6 to 12 years|
89215881|NCT05808595|Experimental|AlphaWave® L-Theanine|Participants will be instructed to take one capsule twice daily, once in the morning and once in the evening with water with or without food, starting on Day 1. If a dose is missed participants are instructed to take the missed dose immediately once noticed unless it is noticed within two hours of taking their next dose in which case, participants are instructed to document the missed dose and continue with their regular dosing schedule. Participants will be advised not to exceed 3 capsules daily.
89215882|NCT05808595|Placebo Comparator|Placebo|Participants will be instructed to take one capsule twice daily, once in the morning and once in the evening with water with or without food, starting on Day 1. If a dose is missed participants are instructed to take the missed dose immediately once noticed unless it is noticed within two hours of taking their next dose in which case, participants are instructed to document the missed dose and continue with their regular dosing schedule. Participants will be advised not to exceed 3 capsules daily.
89680065|NCT00671671|Experimental|Cohort A|Dose study drug in subjects who have previously failed to respond to interferon based therapies
89680066|NCT01893320|Experimental|Vosaroxin + Decitabine|"The first 6 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).~Following the phase I portion, patients in phase II receive the following induction:~Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I.~Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I."
89680067|NCT01799707|Active Comparator|vision restoration training|Vision restoration training (VRT): visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
89680068|NCT01799707|Placebo Comparator|Discrimination training|Discrimination training. Here, the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
89680069|NCT00648115|Other|Basic Vocational Services|Veteran receives basic vocational services
89680070|NCT00648115|Active Comparator|Self-Study|Veteran participates in self-study vocational program
89680071|NCT00648115|Active Comparator|Group program|Group based vocational program
89050958|NCT04596462|Experimental|68Ga-FAPI PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
89050959|NCT04629638||covid -19 positive pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-positive pregnant women in the 3rd month after birth.
89050960|NCT04629638||covid -19 negative pregnant women|Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in 250 covid-negative pregnant women in the 3rd month after birth.
89050961|NCT04605120|Experimental|Allogeinic Bone Paste|Supercritical CO2 viral-inactivated allogeinic bone paste derived from human living donor femoral heads
89050962|NCT04629560|Experimental|Miracle Fruit Arm|Patient will be randomly assigned, by a computer generated randomization, to receive one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures.
89050963|NCT04629560|No Intervention|Control Arm (supportive measures only)|standard of care supportive measures
89050964|NCT04605003|Active Comparator|Conventional Autoclave|The conventional autoclave is the gold standard of sterilising all medical equipments.
89050965|NCT04605003|Active Comparator|Novel rig-S|A novel devise used with the high level disinfectant
89050966|NCT04629482||Children with attention deficit hyperactivity disorder with developmental delays|Children with attention deficit hyperactivity disorder with developmental delays
89680072|NCT01799785|Experimental|Aerobic exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
89680073|NCT01799785|Placebo Comparator|Usual care group|These patients will continue with their normal daily activity and will not be provided with supervised aerobic exercise training during the study period.
89680074|NCT04244396||Drug refractory, symptomatic persistent atrial fibrillation|Asian population
89050967|NCT04629482||Children with typical development|Children with typical development
89050968|NCT04596306||UNDER 70 Y-O|
89050969|NCT04596306||OVER 70 Y-O|
89680075|NCT01673360||Elevate PC|Subjects implanted with Elevate PC
89680076|NCT01673360||Mini Arc Pro|Subjects implanted with Mini Arc Pro
89680077|NCT01673360||RetroArc|Subjects implanted with RetroArc
89680078|NCT00672451|Experimental|rhubarb extract|will receive rhubarb extract
89680079|NCT00672451|Placebo Comparator|placebo|receive placebo
89680080|NCT04095871||Patients included|"Patients over 18 years old performed CISC for more than 1 month, exclusive or not, are included.~At home, patients have to complete one diary on the specific duration of a 24-hour CISC and the next day a second diary on the total duration of CISC.~The specific time of CISC described by the timed duration from the moment when the circumstances of care are combined to carry it out : isolated place, nearby equipment.~The total time of CISC described by the timed duration from the moment of the intention to self-catheter until the return to the initial activity."
89680081|NCT01673672|Placebo Comparator|Placebo|7 weekly/biweekly injections of a placebo buffer
89680082|NCT01673672|Experimental|CYT003 low dose|7 weekly/biweekly injections of CYT003 low dose
89680083|NCT01673672|Experimental|CYT003 medium dose|7 weekly/biweekly injections of CYT003 medium dose
89680084|NCT01673672|Experimental|CYT003 high dose|7 weekly/biweekly injections of CYT003 high dose
89680085|NCT01869218||Pre-treatment tumor biopsies|Patients who meet eligibility criteria will undergo a fresh tumor biopsy and collection of research blood samples. Archived tumor specimens will also be obtained and analyzed. At the time of disease progression, fresh tumor biopsies and blood samples will be collected in patients who have evaluable pre-biopsy specimens and who are eligible to be screened for another study.
89680086|NCT01673750||Participants|Participants will have documented HIV infection and are aware of their diagnosis. They will complete a one-time questionnaire.
89680087|NCT03159416|Experimental|Inclisiran (normal renal function)|Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
89050970|NCT04629287|Experimental|KPCXM18 for injection|KPCXM18 ，freeze-dried powder,single and multiple ascending doses, Intravenous route
89050971|NCT04629287|Placebo Comparator|Placebo|Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route
89050972|NCT00564993|Active Comparator|A|"necessary re-intervention (pulmonary valve replacement) after repair of Fallot:~2 Visits with cardiac imaging under rest and stress (Dobutamin) before and after pulmonary valve replacement"
89680088|NCT03159416|Experimental|Inclisiran (mild renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
89680089|NCT03159416|Experimental|Inclisiran (moderate renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
89680090|NCT03159416|Experimental|Inclisiran (severe renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.
89680091|NCT00673075|Active Comparator|1|Encapsulated Nebivolol
89680092|NCT00673075|Active Comparator|2|Encapsulated Carvedilol
89680093|NCT02250014|Experimental|Arm I (cryotherapy, sargramostim)|Patients undergo cryotherapy on day 0 and receive sargramostim subcutaneously on days 1, 3, 5, 8, 10, and 12.
89680094|NCT02250014|Active Comparator|Arm II (cryotherapy, standard of care)|Patients undergo cryotherapy on day 0.
89680095|NCT00651625|Experimental|1|The intervention is the use of the reciprocating procedure device (RPD) (AVANCA Re No. 1091001) (intervention) (Arm 1) with and without ultrasound guidance (intervention) in a syringe and needle procedure in comparison to a conventional syringe (BD Ref 309604) (control, Arm 2).
89680096|NCT00651625|Active Comparator|2|The conventional syringe (BD Ref 309604) is used to performed the syringe and needle procedure and outcome (effect of procedure (pain scores at 2 weeks and 6 months compared to preprocedural pain scores), and procedural pain (pain scores during procedure) are determined) and compared to Arm 1.
89680097|NCT03156608|Experimental|Novii Device ECG/EMG System|These patients will have the Novii ECG/EMG system placed throughout labor and delivery, unless a provider or investigator determines that a different device (internal or external) is necessary for a better signal.
89680098|NCT03156608|Active Comparator|Standard of Care External Monitor|A standard external monitor will be placed throughout labor and delivery, unless a provider or investigator determines that an internal device is necessary for a better signal.
89680099|NCT04022096|Experimental|Tegoprazan 25mg QD|Tegoprazan 25mg tablet, once daily, oral administration
89680100|NCT04022096|Active Comparator|Lansoprazole 15mg QD|Lansoprazole 15mg capsule, once daily, oral administration
89680101|NCT01673906|Experimental|Diagnostic work up|The patients enrolled in the study (see below), with a consistent clinical suspicion of a primary duodenal-pancreatic NET.
89680102|NCT00673153|Experimental|Arm I|"REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .~CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.~MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses."
89680103|NCT00673855|Experimental|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye one time
89680104|NCT00673855|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye 1 time
89680105|NCT03956576|Active Comparator|Chronic Kidney Disease patients|"Forearm blood flow studies~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.~Renal clearance studies~Two standard para-aminohippurate (PAH) / iohexol clearance studies with infusion of either apelin or placebo on each day.~Dose of PAH / iohexol dependent on renal function. Continuous infusion lasting 6.5hours in total.~[[Pyr1]apelin-13 infusions: 1nmol/min and 30nmol/min for 30 minutes each."
89680106|NCT03956576|Active Comparator|Healthy volunteers|"Forearm blood flow studies~- acetylcholine (7.5, 15, 30microgram/min), sodium nitroprusside (1, 2, 4microgram/min) and [Pyr1]apelin-13 (0.3, 1, 3, 10, 30, 100nmol/min). Incremental doses of each lasting 8 minutes with saline washout between drugs.~Renal clearance studies~Two standard para-aminohippurate (PAH) / iohexol clearance studies with infusion of either apelin or placebo on each day.~Dose of PAH / iohexol dependent on renal function. Continuous infusion lasting 6.5hours in total.~[Pyr1]apelin-13 infusions: 1nmol/min and 30nmol/min for 30 minutes each."
89680107|NCT04404842||EvidenceQ Cohort|Adult subjects, aged over 18 years, male and female.
89680108|NCT00654511|Active Comparator|Fentanyl 1|Fentanyl 1 micrograms (mcg)/kilogram (kg)
89680109|NCT00654511|Active Comparator|Fentanyl 2|Fentanyl 2 micrograms (mcg)/kilogram (kg)
89680110|NCT00654511|Experimental|Dex 3|Dexmedetomidine 2 micrograms (mcg)/kilogram (kg)
89680111|NCT00654511|Experimental|Dex 4|Dexmedetomidine 4 micrograms (mcg)/kilogram (kg)
89680112|NCT01670084|Experimental|Treatment (nilotinib, combination chemotherapy)|See Detailed Description
89680113|NCT01670162|Experimental|3 loading doses, then every 2 months|All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.
89680114|NCT04345783|Experimental|Camrelizumab+Apatinib Mesylate+Tegio|
89680115|NCT04763954|Experimental|Game|Group that receives the game intervention (the trial version and the access to level 2 and level 7
89680116|NCT04763954|No Intervention|Control|Group without intervention
89680117|NCT04763954|Experimental|Guidance|Group that receives the game (the same levels as group 1) and email coaching one day after completing the game.
89680118|NCT02142361|Active Comparator|Omafilcon A/Enfilcon A|Subject's habitual hydrogel toric lenses Omafilcon A will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
89680119|NCT02142361|Active Comparator|Ocufilcon D/Enfilcon A|Subject's habitual hydrogel toric lenses Ocufilcon D will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
89680120|NCT02142361|Active Comparator|Methafilcon B/ Enfilcon A|Subject's habitual hydrogel toric lenses Methafilcon B will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
89680121|NCT01676636||Pregnant Women|Women who are 13 to 30 weeks pregnant. Each participant will take all 4 different calcium vehicles and decide which one they prefer.
89680122|NCT04404296|Other|25-gauge 20000 PPV|Eyes will undergo pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
89680123|NCT00675259|Experimental|Neoadjuvant, Surgery, Adjuvant|Neoadjuvant chemotherapy : Nab-paclitaxel and carboplatin on days 1, 8, and 15 in combination with bevacizumab on days 1 and 15 administered every 28 days for 5 cycles followed by 1 cycle with Nab-paclitaxel and carboplatin on days 1, 8, and 15. Definitive surgery with either lumpectomy or mastectomy along with axillary lymph node dissection for all pre neo adjuvant chemotherapy node-positive patients approximately 4-5 weeks after the completion of NCT. Use of additional adjuvant chemotherapy and/or radiation therapy depends upon the treating physicians' judgment. Radiation therapy should begin no sooner than 6 weeks after breast cancer surgery. All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
89680124|NCT01674218|Experimental|Treatment E|PA-824 400 mg plus moxifloxacin 400 mg
89680125|NCT01674218|Active Comparator|Treatment D|PA-824 placebo plus moxifloxacin 400 mg
89680126|NCT01674218|Experimental|Treatment C|PA-824 1000 mg plus moxifloxacin placebo
89680127|NCT01674218|Experimental|Treatment B|PA-824 400 mg plus moxifloxacin placebo
89680128|NCT01674218|Placebo Comparator|Treatment A|PA-824 placebo and moxifloxacin placebo
89680129|NCT00656305|Experimental|ExAblate Treatment Arm|
89680130|NCT00656305|Sham Comparator|ExAblate Sham Arm|
89050973|NCT00564993|Active Comparator|B|"comparison group: with a good result of repair of tetralogy of fallot and good ventricular function:~1 Visit with cardiac imaging under rest and stress (Dobutamin)"
89050974|NCT04629365|Experimental|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
89050975|NCT04629365|Active Comparator|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
89050976|NCT04629404|Experimental|LY03003|
89050977|NCT04629404|Placebo Comparator|Placebo|
89050978|NCT04595916|Experimental|Polyene Phosphatidylcholine|
89050979|NCT04595916|Active Comparator|Magnesium Isoglycyrrhizinate|
89050980|NCT00565071|Other|Field microscopy|Field microscopy is the main method of malaria diagnosis
89680131|NCT01674296||Group 1 (2012-2013)|Monitoring of Dietary Intake, Physical Activity and Stress
89050981|NCT00565071|Other|Paracheck Pf® device|Paracheck Pf® device (Rapid Diagnostic Test) is the main method for malaria diagnosis
89050982|NCT00565071|No Intervention|Presumptive diagnostic method|
89680132|NCT01674296||Group 2 (2013-2014)|Monitoring of Dietary Intake, Physical Activity and Stress
89050983|NCT04628819|Experimental|Babybiane Imedia|Patients receive Babybiane Imedia once daily during seven days.
89050984|NCT04628819|Placebo Comparator|Placebo|Patients receive a placebo with the same consistency and taste as the Babybiane Imedia once daily during seven days.
89680133|NCT03868423|Experimental|Treatment (brigatinib)|Patients receive brigatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89680134|NCT01670240|Active Comparator|Adalimumab|Every second week, mg: 160-80-40-40-40-40 12 weeks in all
89680135|NCT01670240|Placebo Comparator|Placebo|Given as the active comparator, every second week
89050985|NCT04604964||Patients undergoing recto-sigmoid resection plus anastomosis|Patients undergoing recto-sigmoid resection and concurrent anastomosis during debulking surgery (primary or interval debunking surgery) for advanced epithelial ovarian cancer.
89050986|NCT04604886|Experimental|Passive Leg Raising|Passive leg raising (PLR) test is used to predict fluid responsiveness, which is performed by raising the legs of the patient to 45°. Cardiac output will be collected from both PAC and LiDCO before and after PLR.
89050987|NCT04604886|Experimental|Dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
89680136|NCT04404686|Experimental|Indomethacin group|Group of patients receiving Indomethacin for preterm labor treatment.
89680137|NCT04404686|Active Comparator|Nifedipine group|Group of patients receiving Nifedipine for preterm labor treatment.
89680138|NCT00675415|Active Comparator|Capnography|"Capnography: Subjects randomized to capnography-titration arm: The endoscopy team would be made aware of the capnographic abnormalities as they arise.~In this arm, the endoscopy team will have the graphic representation of respiratory activity (capnography) as well as end-epxiratory levels of carbon dioxide in addition to the normal physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography.~This observation phase would take place for a baseline prior to sedation, during the administration of sedation as well as throughout the procedure. Monitoring for the study would stop upon completion of the endoscopic procedure."
89680139|NCT00675415|No Intervention|Standard Monitoring|Subjects randomized to capnography-blinded arm: In this arm, the endoscopy team will not have the graphic representation of respiratory activity (capnography) as well as end-expiratory levels of carbon dioxide available. Only a standard of care physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography at the disposal of the endoscopy team to titrate the sedative medications.
89050988|NCT04595877|Experimental|Dipyrone group|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
89680140|NCT01674374|Experimental|Arm I (SAMITAL)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules PO QID. Patients may continue to receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
89050989|NCT04595877|Placebo Comparator|Placebo group|The placebo will be matched to the study drug for, color, and size. Placebo will be administered in a single dose in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
89050990|NCT04595955|Experimental|Intervention group|This arm uses the CMyLife platform for at least 6 months
89050991|NCT04595955|No Intervention|Control group|This arm does not use the CMyLife platform
89050992|NCT04604769||Daily routine, control group|ICU medical staff were asked about their stress and causes of stress during their daily professional life.
89680141|NCT01674374|Placebo Comparator|Arm II (placebo)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive placebo PO QID. Patients may continue to receive placebo for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
89050993|NCT04604769||During Covid-19|ICU medical staff were asked about their stress and causes of stress in their daily professional life during COVID-19 crisis.
89680142|NCT01674452|Experimental|home-based group|
89680143|NCT01674452|Active Comparator|supervised exercise group|
89680144|NCT01674452|No Intervention|control|Control group:no intervention
89680145|NCT00676585|Placebo Comparator|2|Normal Saline
89680146|NCT00676585|Experimental|1|Hydrocortisone 100mg every 8 hours.
89680147|NCT03856580|Experimental|Self-injection|Participants will be trained on how to self-inject (intramuscular, gluteal muscle) an inert version of injectable cabotegravir. The inert substance is intended to mimic injectable cabotegravir as closely as possible (e.g., injection equipment, location of injection, volume of injection is identical to injectable cabotegravir). Specifically, participants will self-inject their choice of 300mg vitamin B12 or saline (3ml fluid) every 2 months for a total of 6 months (for a total of 4 injections). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as instructions on how to self-inject, FAQs about self-injection, study contact information, etc..
89680148|NCT03856580|Experimental|"Injection by HCP at drop-in clinics"|"Participants will report to a drop-in clinic, where a healthcare provider will inject them with an inert version of injectable cabotegravir. Visits will take <10 minutes, and participants will be able to come whenever they want (when their injection is due) during clinic drop-in hours, which will be staggered in 2-hour windows during each week day. The inert substance that will be injected is intended to mimic injectable cabotegravir as closely as possible (described above). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as drop-in clinic hours, directions to the drop-in clinic site, study contact information, etc..."
89680149|NCT03856580|No Intervention|Control group|Participants will make an appointment when their injection is due to report to our clinic to complete injections. Visits and the injection protocol will follow similar procedures to HPTN-083/084. Participants will not have access to the mHealth adherence app.
89680150|NCT00658411|Experimental|All patients|Deferoxamine for >=2 weeks prior to stem cells
89680151|NCT01674530|Experimental|Lubiprostone|Manufactured by Dr Reddy's Laboratories Ltd( 24 mcg administered for 7 days )
89680152|NCT01674530|Active Comparator|AMITIZA®|Manufactured by Sucampo Pharmaceuticals(24 mcg administered for 7 days)
89680153|NCT01674530|Placebo Comparator|Placebo|Manufactured by Dr Reddy's Laboratories Ltd ( 24 mcg adminstered for 7 days )
89680154|NCT01799551|Active Comparator|Ca CBT|Experimental arm will receive brief version of Culturally adapted CBT for depression. This is based on our previous work in which we adapted CBT for depression in Pakistan
89680155|NCT01799551|No Intervention|Treatment As Usual|Patients in this arm will get only Treatment As Usual, which normally includes regular follow up and medicines.
89680156|NCT00676897|Experimental|1|Simvastatin 40 mg PO or NGT
89680157|NCT00676897|Placebo Comparator|2|Placebo
89680158|NCT03559075||Group 1|Participants will be randomized into group 1 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
89680159|NCT03559075||Group 2|Participants will be randomized into group 2 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
89680160|NCT03559075||Group 3|Participants will be randomized into group 3 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
89680161|NCT03559075||Group 4|Participants will be randomized into group 4 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
89680162|NCT03559075||Group 5|Participants will be randomized into group 5 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
89680163|NCT03559075||Group 6|Participants will be randomized into group 6 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
89680164|NCT03559075||Group 7|Participants will be randomized into group 7 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
89680165|NCT03559075||Group 8|Participants will be randomized into group 8 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
89680166|NCT02115074|Experimental|Fluvastatine Celebrex|dose escalation for Fluvastatine
89680167|NCT03850730|Experimental|Pazopanib|Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline. If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
89680168|NCT01674686|Experimental|A|Sarpogrelate versus placebo
89680169|NCT01674686|Experimental|B|Atorvastatin 80mg versus no statin or simvastatin 20 mg if LDL > 130 mg/dl
89680170|NCT02082392|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
89680171|NCT02082392|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
89680172|NCT02082392|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
89050994|NCT00561509||A|SSRIs
89050995|NCT00561509||B|Dual antidepressants
89050996|NCT04604574|Other|Pre/Post-Intervention|Patients who receive the novel IHSS intervention will be compared to historical controls who received the abstinence-based treatment model.
89680173|NCT02082392|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
89680174|NCT02100800|Experimental|COPD Group|30 patients with diagnosis of COPD
89680175|NCT02100800|Sham Comparator|Control Group|10 volunteers with extrapulmonary neoplasia
89680176|NCT01674764||Early surgical intervention = Cohort 1|≤ 12 hours after the tSCI
89680177|NCT01674764||Late surgical intervention = Cohort 2|> 12 hours and < 14 days after the tSCI
89680178|NCT03849794|Experimental|Experimental group|Chiropractic Care Plus Physiotherapy
89680179|NCT03849794|Active Comparator|Control group|Physiotherapy
89680180|NCT01674842|Experimental|Cisplatin + Radiation Therapy|Cisplatin concurrently with radiation therapy
89680181|NCT04404764||Treated with nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III treated with nusinersen in the Brazilian Unified Public Health System
89680182|NCT04404764||With indication to receive nusinersen at SUS|Patients with Spinal Muscular Atrophy (SMA) 5q types II and III with indication, but not yet receiving nusinersen treatment in the Brazilian Unified Public Health System
89680183|NCT03161132|Experimental|Olaparib 300mg|Olaparib bid orally at 300 mg (tablet formulation) continuously, combined with chemotherapy with Pegylated Liposomal Doxorubicin (up to 6 cycles), then, as monotherapy at the same dose and frequency (300mg bid orally) until progression of disease or unaccepted toxicity.
89680184|NCT03161132|Other|Pegylated Liposomal Doxorubicin (PLD)|PLD 40mg/m2 every 28 days intravenous for up to 6 cycles. This treatment will be combined with Olaparib (as described earlier).
89680185|NCT01674920|Experimental|Choices|"The 3-month twelve-session intervention, Choices, included topics on nutrition, physical activity, and resiliency. Parents, boys and girls met separately. The sessions were developed for delivery by a family physician, two family medicine residents, and a nutritionist, who received training in positive psychology and resilience skills. All children were measured on the same dates, but children were randomly assigned to two cohorts, beginning 6 months apart, to facilitate statistical analysis by having one group experience normal growth on study prior to intervention."
89680186|NCT03844256|Experimental|Regimen A|"Nivolumab monotherapy at 480mg fixed dose administered intravenously (IV) over 60 minutes every 4 weeks for 3 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
89680187|NCT03844256|Experimental|Regimen B|"Nivolumab at 3 mg/kg administered IV over 60 minutes combined with ipilimumab at 1 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
89680188|NCT03844256|Experimental|Regimen C|"Nivolumab at 1 mg/kg administered IV over 60 minutes combined with ipilimumab at 3 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
89680189|NCT01675076|Experimental|Continued NOAC|- Patients continue on their chronic dose of Dabigatran or Rivaroxaban or Apixaban throughout
89680190|NCT01675076|Active Comparator|Interrupted NOAC|"Interrupted Dabigatran:~Discontinue Dabigatran 1 day before surgery if GFR > 50 mL/min or discontinue 2 days before surgery if GFR 30-50 mL/min~Resume Dabigatran at next regular dose timing >or = 24 hours after the end of surgery~Interrupted Rivaroxaban:~Discontinue Rivaroxaban 1 full day before surgery~Resume Rivaroxaban at next regular dose timing >or = 24 hours after the end of surgery~Interrupted Apixaban:~Discontinue Apixaban 1 full day before surgery~Resume Apixaban at next regular dose timing >or = 24 hours after the end of surgery"
89680191|NCT02029430|Experimental|aldoxorubicin|Subjects will receive either 100 or 150 mg/m2 (75, and 110 mg/m2 doxorubicin equivalents) by intravenous infusion (IVI) to 10 subjects in each group.
89680192|NCT01675232|Active Comparator|Soak and smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment immediately to wet skin once a day and dry skin once a day.
89680193|NCT01675232|Active Comparator|Dry smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment to dry skin twice a day.
89680194|NCT01675388|Experimental|Hypothermia|Hypothermia to 33.5 deg Centigrade
89680195|NCT01673438|Experimental|Aldoxorubicin plus doxorubicin|Aldoxorubicin dosages of 175, 240, and 320 (doxorubicin equivalents of 130, 180, and 240 mg/m2) will be administered as a 30 minutes IVI on Day 1 of each cycle. In addition 35 mg/m2 of doxorubicin HCl will be administered as an IVI over > 3 minutes no later than 3 hours, but no more than 6 hours before the start of aldoxorubicin infusion.
89680196|NCT03838796|Active Comparator|lenvatinib|use lenvatinib after liver resection in HCC patients
89680197|NCT03838796|Active Comparator|lenvatinib and TACE|use lenvatinib and TACE after liver resection in HCC patients
89680198|NCT03719690|Experimental|AIM-HN|Tipifarnib, Oral Tablet. Dose Level 1 orally, bid on days 1-7 and 15-21 of 28-day treatment cycles
89680199|NCT03719690|No Intervention|SEQ-HN|HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
89680200|NCT01675466|Active Comparator|early laparoscopy|early laparoscopy, aiming to achieve this within 12 hours
89680201|NCT01675466|Placebo Comparator|active observation|"standard management - the wait and see approach with serial examinations and investigations as deemed necessary"
89680202|NCT04747106|Experimental|plasma exchange|when ADP inhibition >30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
89680203|NCT04747106|No Intervention|standard medical treatment|standard medical treatment
89680204|NCT01675700|Experimental|Myofascial trigger point|Patients diagnosed with myofascial trigger points who will receive a nitroglycerin patch over the trigger point.
89680205|NCT01676558|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
89680206|NCT01675856|Active Comparator|Urgent endoscopy|Oesophagogastroduodenoscopy done within 6hours of first GI specialists consultation
89680207|NCT01675856|Placebo Comparator|Early endoscopy|Oesophagogastroduodenoscopy done within 24hours of first GI specialists consultation
89680208|NCT00678535|Experimental|Cetuximab plus Capecitabine plus Cisplatin|
89680209|NCT00678535|Active Comparator|Capecitabine plus Cisplatin|
89680210|NCT04404374|Active Comparator|A-PRF|Advanced Platelet-Rich Fibrin
89215883|NCT05805709|Experimental|Multimodal Process of Care Intervention|A multimodal process-of-care intervention that includes 1) study physician oversight and follow up care recommendations at the time of hospital discharge; 2) involvement of a nurse navigator to provide kidney-disease related education, coordinate care, and assess symptoms; and 3) pharmacist-led medication reconciliation and review.
89215884|NCT05805709|Active Comparator|Usual Care|After receiving the same written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician as individuals randomized to the multimodal intervention arm, participants randomized to the control arm will receive usual care as specified by their treating providers and will not be followed by nurse navigator, pharmacist, or the study team. The only subsequent study-related activities will be the follow-up study visits for ascertainment of endpoints with the research coordinator.
89215885|NCT05801757|Active Comparator|Propofol group|propofol 2-3mg/kg/h
89215886|NCT05801757|Experimental|R1 group|remimazolam 0.5mg/kg/h
89215887|NCT05801757|Experimental|R2 group|remimazolam 0.75mg/kg/h
89215888|NCT05799755|Placebo Comparator|Placebo plus Standard of Care, then Nintedanib plus Standard of Care|Placebo twice a day (BID) plus standard of care (SOC) Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
89215889|NCT05799755|Active Comparator|Nintedanib plus Standard of Care|Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
89215890|NCT05796089|Experimental|Treatment|Participants will receive Durvalumab concurrently with chemotherapy (etoposide with carboplatin or cisplatin) for 4 cycles.
89215891|NCT05795881|No Intervention|Control group|continuous enteral nutrition: 24 hours a day (standard of care)
89215892|NCT05795881|Experimental|Intervention group|cyclic daytime enteral nutrition: between 8 a.m. and 8 p.m. (same amount of nutrition as control group)
89680211|NCT04404374|Active Comparator|EMD|Enamel Matrix Derivatives
89215893|NCT05794464|Experimental|Catheter ablation and/or electrical cardioversion|Study subjects indicated for catheter ablation and/or electrical cardioversion will be enrolled in this study arm.
89680212|NCT03834116|Experimental|Inspiratory muscle training group|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
89680213|NCT03834116|No Intervention|Control group|The control group will receive standard treatment in a fast-track design.
89680214|NCT01675934|Active Comparator|Adult colonoscope|Use of the adult colonoscope.
89680215|NCT01675934|Active Comparator|Pediatric colonoscope|Use of the pediatric colonoscope.
89680216|NCT00659737|Placebo Comparator|Aprepitant|"Oral Aprepitant pill and placebo transdermal patch at least 1 hour prior to surgical procedure.~Emend (Aprepitant) + Placebo"
89680217|NCT00659737|Active Comparator|Scopolamine|Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.
89680218|NCT00660049|Experimental|SNaP application|"This is an open label pilot study of SNaP Advanced Wound Care System"
89680219|NCT04763876|Active Comparator|15 mg ketorolac intramuscular|Patients who received a single 15 mg dose of ketorolac administered intramuscularly
89680220|NCT04763876|Active Comparator|60 mg ketorolac intramuscular|Patients who received a single 60 mg dose of ketorolac administered intramuscularly
89680221|NCT00680797|Experimental|+T +E|+Testosterone, +Estrogen
89680222|NCT00680797|Experimental|+T -E|+Testosterone, -Estrogen
89680223|NCT00680797|Experimental|-T +E|-Testosterone, +Estrogen
89680224|NCT00680797|No Intervention|-T -E|-Testosterone, -Estrogen
89680225|NCT02081456|Active Comparator|Therapeutic Ultrasound|Therapeutic ultrasound applied for a period of 5 minutes to the most painful region of the neck, then a second 5 minute dose at the most painful region of the upper extremity
89680226|NCT02081456|Experimental|Soft Tissue Mobilization|Passive soft tissue mobilization to the neck and upper extremity
89680227|NCT02984852|Experimental|Treatment sequence ABC|Participants will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) Treatment A (whole tablet) as reference in session 1 then Treatment B(split tablet) as test in session 2 followed by Treatment C (crushed tablet mixed in applesauce) as test in session 3 under fed conditions (standardized breakfast) on Day 1 of each treatment session. There will be a washout period of at least 7 days between consecutive drug intakes.
89680228|NCT02984852|Experimental|Treatment sequence ACB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment A in treatment session 1, then Treatment C in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
89680229|NCT02984852|Experimental|Treatment sequence BCA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment C in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
89215894|NCT05774366|Experimental|Remimazolam group|receives remimazolam for the maintenance of general anesthesia. At the end of surgery, flumazenil is administered as an antagonist of remimazolam.
89215895|NCT05774366|Active Comparator|Desflurane group|receives desflurane for the maintenance of general anesthesia.
89215896|NCT05763082|Experimental|Padagis active product|
89215897|NCT05763082|Active Comparator|Reference product|
89215898|NCT05763082|Placebo Comparator|Padagis placebo product|
89215899|NCT05758714||Hartford Commuters|
89215900|NCT05752019||ETI treatment group > 12 years|CF patients older than 12, whom are eligible to receive elexacaftor/tezacaftor/ivacaftor treatment.
89215901|NCT05752019||Control group > 12 years|CF patients older than 12, whom are not eligible to receive any CFTR-modulator.
89215902|NCT05752019||ETI treatment group < 12 years|CF patients younger than 12, whom are eligible to receive elexacaftor/tezacaftor/ivacaftor treatment.
89680230|NCT02984852|Experimental|Treatment sequence BAC|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment A in session 2 followed by Treatment C in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
89680231|NCT02984852|Experimental|Treatment sequence CAB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment A in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
89680232|NCT02984852|Experimental|Treatment sequence CBA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment B in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
89680233|NCT04764500||travellers to Southeast Asia|Clients planning to travel to Southeast Asia will be recruited
89680234|NCT00660517|Experimental|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray
89680235|NCT00660517|Active Comparator|azelastine Hcl 548 mcg|azelastine Hcl 548 mcg nasal spray
89050997|NCT00561548|Other|A|Patients with active Crohn disease and with azathioprine treatment
89050998|NCT00561548|Other|B|Patient with active crohn disease and without azathioprine disease
89050999|NCT04604730|Experimental|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
89680236|NCT00660517|Active Comparator|fluticasone propionate 200 mcg|fluticasone propionate 200 mcg nasal spray
89051000|NCT04604730|Active Comparator|Anastomosis with protective stoma|Anastomosis with protective stoma
89051001|NCT04604535|Active Comparator|Concentrated beetroot juice|70mL of concentrated beetroot juice with 400mg nitrate
89680237|NCT00660517|Placebo Comparator|placebo|placebo nasal spray
89680238|NCT02253290||Neuromuscular disease|Children and adolescents with Neuromuscular disease children according to neuromuscular convention UZL
89680239|NCT02050490||Before group, no diary|
89680240|NCT02050490||After group, with symptom diary|
89680241|NCT02141581|Experimental|Group A Fluzone® (IM)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone®, administered intramuscularly (IM)~2011-2012, 2012-2013 or 2013-2014 Fluzone was used as appropriate for the current year of study"
89680242|NCT02141581|Experimental|Group B Fluzone® Intradermal (ID)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone® Intradermal, administered intradermally (ID)~2011-2012, 2012-2013 or 2013-2014 Fluzone Intradermal was used as appropriate for the current year of study"
89680243|NCT02141581|Experimental|Group C 2011-2012 FluMist®|"Participants in this group will be randomized to 2011-2012 live attenuated influenza vaccine, FluMist®, administered intranasally.~FluMist was only used in the first year of study."
89680244|NCT03828344|Experimental|hUC-MSC treatment|BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5×10^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.
89680245|NCT03828344|Placebo Comparator|Placebo control|The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit.
89680246|NCT04594226|Experimental|EA combined with medication group|Patients in this group will receive electroacupuncture combined with gabapentin.
89680247|NCT04594226|Active Comparator|Medication group|Participants in this group will only receive gabapentin.
89680248|NCT01568060||Infanrix-IPV group|Infants and children who received at least one dose of Infanrix-IPV as a part of routine practice at a private clinic or hospital in korea
89680249|NCT01676168||hypertrophic scar|1x1cm2 hypertrophic scar of post-burn patients are taked by visiting staff when they accept scar-reconstructive surgery.
89051002|NCT04604535|Placebo Comparator|Placebo|70mL of concentrated beetroot juice with <0.01mmol/L nitrate
89051003|NCT00566436|Active Comparator|REA|Patients presenting with a long occlusion of the superficial femoral artery enrolled in REA arm will undergo remote endarterectomy of the occluded superficial femoral artery
89051004|NCT00566436|Active Comparator|Bypass|Patients presenting with a long occlusion of the superficial femoral artery enrolled in Bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery
89051005|NCT04628702|Experimental|Intervention group|receives tablet-training
89051006|NCT04628702|No Intervention|Control group|no training
89051007|NCT00566475|No Intervention|1|Usual care of type 1 diabetes at the diabetes center
89051008|NCT00566475|Experimental|2|Usual care at the diabetes center supplemented by a telemedicine intervention in the school involving school personnel, the child with diabetes and at least 1 parent of the child. The diabetes center NP conducts videovisits with the school nurse, patient (child) +/- parent monthly.
89051009|NCT04628975|Experimental|with transillumination|The nurses will use the Transillumination method for a period P1. Then these same nurses will use the control method (without transillumination) for a period P2.
89051010|NCT04628975|No Intervention|without transillumination (control method)|The nurses will use the control method for a period P1. Then these same nurses will use the Transillumination method for a period P2.
89051011|NCT00566514|Active Comparator|1|D-ribose 5 grams TID orally
89051012|NCT00566514|Placebo Comparator|2|Dextrose 5 grams TID
89051013|NCT01157377|Experimental|AGN-214868 total dose 500 ng|AGN-214868 injected into the bladder for total dose of 500 ng on Day 1.
89051014|NCT01157377|Experimental|AGN-214868 total dose 1000 ng|AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1.
89051015|NCT01157377|Experimental|AGN-214868 total dose 2000 ng|AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1.
89680250|NCT01676168||normal skin|When the patient accept skin grafting surgery, visiting staff will take 1x1cm2 normal skin.
89680251|NCT04747262|Experimental|SPACE INTERVENTION|counseling
89680252|NCT04747028||Primary dentition|Children from 4 to 6 years old suffering from malnutrition
89680253|NCT04747028||Age 13 to 16|Adolecentsfrom 13 to 16 suffering from malnutrition at present time or during their childhood
89215903|NCT05752019||Control group < 12 years|CF patients younger than 12, whom are not eligible to receive any CFTR-modulator.
89215904|NCT05745870|Experimental|Creatine Monohydrate Supplementation|Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
89680254|NCT03755570||CRT: Main Arm|"Cardiac Resynchronisation Therapy (CRT): Main Arm ~98 participants~Prior to CRT Implantation & Post-Implant 6-Month Device Follow-Up Clinic:~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning, Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
89680255|NCT03755570||ICD and PPM: Control Arm|"Implantable Cardioverter-Defibrillator (ICD) and Permanent Pacemaker (PPM): Control Arm ~98 participants~Prior to ICD or PPM Implantation & Post-Implant 6-Month Device Follow-Up Clinic:~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
89680256|NCT03885518|Active Comparator|Intervention|Participants attending the childcare centers randomized to this arm will receive the stencil activities after baseline assessments have been completed. We will follow-up with assessments after 6-8 weeks
89680257|NCT03885518|Placebo Comparator|Wait-List|Participants attending the childcare centers randomized to this arm will receive the stencil activities approximately 8 weeks after enrolling, after baseline and follow-up assessments have been completed.
89680258|NCT03754088||Cystic fibrosis|Three cystic fibrosis patients who are homozygous for the p.Phe508del mutation.
89680259|NCT03754088||Healthy subjects|Three healthy subjects.
89680260|NCT03991299|Experimental|Botox Arm|Botox will be injected into duodenums of subjects via endoscopy.
89680261|NCT03885362|Experimental|Dexcom G6 and Abbott Freestyle Libre|"Participants will have a Dexcom G6 sensor and Abbott FreeStyle Libre sensor inserted in the abdomen and upper arm respectively. Participants will be asked to swipe the FreeStyle Libre reader across the sensor a minimum of every 8 hours. Participants will be asked to continue their usual regimen of self-monitoring capillary blood glucose (SMBG).~During haemodialysis, a dialysis circuit blood sample will be drawn at 0 (pre-dialysis) 30, 60, 90, 120, 150, 180, 210 and 240 minutes and immediately after dialysis. Samples from the circuit will be analysed on the YSI glucose analyser. Participants will be asked to change the FreeStyle Libre sensors at day 14. The blinded CGM data will be uploaded at the time of each sensor change by the research team."
89680262|NCT03819530|Experimental|Supplementation Group|Receives baseline deworming medication. Intervention: receive daily micronutrient supplementation packets- 4 month supply, to be taken every day. Blood iron and anthropometric measurements taken at 0 and 4 months.
89680263|NCT03819530|No Intervention|Control Group|Receives baseline deworming medication. Blood iron and anthropometric measurements taken at 0 and 4 months.
89680264|NCT02279667|Experimental|Group A|"st period - 16 mL oral suspension 50 mg/mL~nd period - Four 200 mg tablets~rd period - One 800 mg tablet"
89680265|NCT02279667|Experimental|Group B|"st period - One 800 mg tablet~nd period - 16 mL oral suspension 50 mg/mL~rd period - Four 200 mg tablets"
89680266|NCT02279667|Experimental|Group C|"st period - Four 200 mg tablets~nd period - One 800 mg tablet~rd period - 16 mL oral suspension 50 mg/mL"
89680267|NCT03833271|Active Comparator|TNF-alpha inhibitor|
89680268|NCT03833271|Active Comparator|Methotrexate|
89680269|NCT03833271|Active Comparator|Healthy|
89680270|NCT03749564|Experimental|SMT Only|All patients receive 2 SMT sessions in the first week.
89680271|NCT03749564|Experimental|SMT extended|All patients receive 2 SMT sessions in the first week. This arm also involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
89680272|NCT03749564|Experimental|SMT with Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm receives 6 additional sessions of activation exercises."
89680273|NCT03749564|Experimental|SMT with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.~This arm involves 6 additional sessions of mobilizing exercise."
89215905|NCT05745870|Placebo Comparator|Placebo Supplementation|Participants will consume 10g/d maltodextrin for 42 consecutive days
89680274|NCT03749564|Experimental|SMT with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm involves 6 additions sessions including both activation and mobilizing exercises."
89680275|NCT03749564|Experimental|SMT extended with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including both SMT and mobilizing exercises."
89680276|NCT03749564|Experimental|SMT extended with Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including both SMT and activation exercises."
89215906|NCT05736484|No Intervention|Control|Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will complete milestones within the study, such as the Function assessment during the 6, and 12-month timepoints in the study. They will also complete a series of surveys during the 3, 6, 9, and 12-month timepoints in the study. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study.
89680277|NCT03749564|Experimental|SMT extended with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including SMT, activation and mobilizing exercises."
89680278|NCT03155373||A|Asymptomatic/mild symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction >60%)
89680279|NCT03155373||B|Symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction greater than or equal to 60%)
89680280|NCT03155373||C|Patients with impaired pre-operative left ventricular function (defined as left ventricular ejection fraction <60%)
89680281|NCT03985449|Other|Active Implementation phase|See the 'detailed description' section to read about the intervention(s) clinicians will use during the active implementation phase of the randomized stepped-wedge design.
89680282|NCT03984903|Active Comparator|Face-to-face Learning Group|
89680283|NCT03984903|Experimental|Multimedia Learning Group|
89680284|NCT03815396|Experimental|Part 1 Single Ascending Dose|INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
89680285|NCT03815396|Experimental|Part 2 Multiple Ascending Dose|INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
89680286|NCT01931163|Experimental|Everolimus|Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily
89680287|NCT04763642|Active Comparator|Laparoscopic Pancreaticoduodenectomy (LPD)|
89680288|NCT04763642|Active Comparator|Robotic Pancreaticoduodenectomy (RPD)|
89680289|NCT04763642|Placebo Comparator|Open Pancreaticoduodenectomy (OPD)|
89680290|NCT04763486|Experimental|Prophylactic antibiotic treatment|Will be given Cefamezin antibiotic within 6 hours of delivery
89680291|NCT04763486|No Intervention|No intervention|Will not get antibiotic prophylactics
89680292|NCT02988063|Experimental|Compression plus PEM|Patients will receive 4-5 weeks of compression therapy, followed by treatment with 1% polidocanol endovenous microfoam (PEM) and 12 additional weeks of compression therapy. If the treating physician determines that the vein is not closed after a subjective assessment of vein patency via standard-of-care limited duplex imaging, patients will be re-treated with PEM on Day 4.
89680293|NCT03746600|Experimental|Immediate Intervention Group|"Receives the eight-week intervention, Project TRAC: Tracking and Reducing Alcohol Consumption, immediately upon enrollment. This intervention focuses on skill building and motivational enhancement for reducing alcohol consumption."
89051016|NCT01157377|Experimental|AGN-214868 total dose 6000 ng|AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1.
89051017|NCT01157377|Experimental|AGN-214868 total dose 18000 ng|AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1.
89051018|NCT01157377|Experimental|AGN-214868 total dose 60000 ng|AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1.
89051019|NCT01157377|Placebo Comparator|Placebo to AGN-214868|Placebo to AGN-214868 injected into the bladder on Day 1.
89051020|NCT02885116|Placebo Comparator|oxygen supplementation|right heart catheterization will be done in hypoxemic patients with supplemental oxygen
89051021|NCT02885116|Active Comparator|Nasal high flow (NHF) supplementation|right heart catheterization after during NHF (20 min) use with 35 l/min
89051022|NCT02885077|Experimental|High-intensity IMT + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). Training will progress to 80% maximal inspiratory pressure (PiMax). IMT will perform for 12 weeks with two sessions per week. The training protocol will consists of five series with ten repetitions with two minutes or according to patient feedback using the modified Borg scale.The initial charge of training will be 50% of PiMax in the first 2 weeks, with an increase of 55% of PiMax in the 3 week, 60% of PiMax in the 4 week, 65% of PiMax in the 5 week, 70% of PiMax in the 6 week, 75% of PiMax in the 7 week and 80% of PiMax in the 8 week. After the 9 and 12 week training period, the PiMax measurements will be performed weekly to keep 80% of the new PiMax.
89051023|NCT02885077|Sham Comparator|H-IMT sham + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). The sham group will perform for 12 weeks with two sessions per week. The protocol will consists of five series with ten repetitions with two minutes and will train at a constant inspiratory load of no more than 10% of their initial Pimax.
89051024|NCT04628312|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
89051025|NCT00566553|Active Comparator|Grape Seed Extract # 1|200 mg [1 pill]
89051026|NCT00566553|Active Comparator|Grape Seed Extract # 2|200 mg [2 pills]
89051027|NCT00566553|Active Comparator|Grape Seed Extract # 3|200 mg [3 pills]
89051028|NCT00566553|Active Comparator|Grape Seed Extract # 4|200 mg [4 pills]
89051029|NCT01157182|Experimental|Investigational Test Product|Estradiol/Norethindrone acetate 1/0.5 mg Tablets
89051030|NCT01157182|Active Comparator|Reference Listed Drug|Activella® 1/0.5 mg Tablets
89051031|NCT04628390|Experimental|Experimental|The low-power therapeutic diode laser will be applied with a wavelength 810nm ± 15nm, output power 0-2 W CW / 0-4.8 W peak power (pulse mode), for a time of 20 seconds per centimeter at lo along the buccal surface of the root of the upper and lower teeth.
89051032|NCT04628390|Placebo Comparator|Placebo|A simulation of the application of therapeutic laser will be carried out as a placebo effect, for a time of 20 seconds per centimeter along the vestibular surface of the root of the upper and lower teeth.
89051033|NCT01157065|Experimental|AL-78898A|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
89051034|NCT01157065|Active Comparator|Lucentis|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
89051035|NCT00566592|Experimental|1|Oral ethanol, overnight
89051036|NCT00566592|Experimental|2|IV ethanol, overnight
89051037|NCT00566592|Placebo Comparator|3|Placebo, overnight
89051038|NCT00566592|Placebo Comparator|4|Placebo, daytime
89051039|NCT05268406|Experimental|Single arm|All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy
89051040|NCT04604457|No Intervention|Standard of Care|Palliative care specialists would not reach out to primary care providers. Palliative care needs would be met via existing mechanisms.
89051041|NCT04604457|Experimental|Predictive Model|Palliative care specialists review recommendations from the predictive model and contact a patient's primary care provider (PCP) when appropriate to recommend a palliative care consult.
89051042|NCT04628351|Experimental|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
89051043|NCT04628351|No Intervention|Control Group|Routine patient training was given to the patients in the control group by a nurse working in the clinic.
89051044|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 100mg QD (AM)|FP 100mcg BID plus GSK2190915 100mg QD (AM)
89680294|NCT03746600|Other|Waitlist Control Group|"Receives the Project TRAC: Tracking and Reducing Alcohol Consumption alcohol reduction intervention after an 8-week, assessment-only period. This 8-wek intervention focuses on skill building and motivational enhancement for reducing alcohol consumption."
89680295|NCT03815006|Experimental|Free Style Libre 2 device|At the start, a blood sample will be taken for the measurement of HbA1c. Training and education on the use of FSL2 will be provided by the research team. Participants will be advised to use flash glucose monitoring continuously for the next 24 weeks.
89680296|NCT03815006|No Intervention|Self-monitoring of blood glucose|At the start, a blood sample will be taken for the measurement of HbA1c. Masked FSL will be applied for two weeks, during the last two weeks of control period. Education will focus on using fingerstick measurement for treatment optimisation.
89051045|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 300mg QD (AM)|FP 100mcg BID plus GSK2190915 300mg QD (AM)
89680297|NCT03746054|Experimental|active prevention|optimal medical treatment
89680298|NCT03746054|Sham Comparator|usual clinical practice|usual clinical practice in each center
89680299|NCT03874754|Experimental|The iHBE program group|Tailored Technology-Enhance Home-based exercise program (iHBE)
89680300|NCT03874754|No Intervention|Usual Care (Control group)|Participants were required to wear physical activity tracker (Fitbit) and respond to the daily symptoms survey (mEMA) while receiving usual care
89680301|NCT03025269||Relapsing MS patients treated with Ocrelizumab|30 patients diagnosed with relapsing forms of multiple sclerosis and newly beginning treatment with Ocrelizumab according to neurologists' orders
89680302|NCT03029871|Experimental|Arm 1|Nine subjects (3 cohorts, 3 subjects/cohort) with medically inoperable stage I/IIA (T1a - T2b) NSCLC with tumors measuring > 2 to ≤ 5 cm will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels (1 x 1011 vp, 3 x 1011 vp, 1 x 1012 vp). Depending on the location of the target lesion, the adenovirus will be injected either transbronchially (central tumors) or percutaneously under computed tomography (CT)-guidance (peripheral tumors). Two days later, subjects will be administered (orally) a 10 day course of 5-fluorocytosine (5-FC) and valganciclovir (vGCV) prodrug therapy along with 48 Gy (4 fractions of 12 Gy) of SBRT. Prior to and following the adenovirus injection, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify HSV-1 TK gene expression.
89680303|NCT03744026|Experimental|SonoCloud-9 Ultrasound + Carboplatin|SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)
89680304|NCT03872258|Active Comparator|Control|Counseling on physical activity
89680305|NCT03872258|Experimental|Intervention|Add an intensive program of combined exercise for 6 months and use during this period a Smartband, in order to encourage and increase physical activity and decrease sedentary lifestyle
89680306|NCT03806114|Other|Anterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
89680307|NCT03806114|Other|Posterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
89680308|NCT03806114|Other|Anterior Approach No Precautions|This group receives does not precautions and have a total hip arthroplasty with an anterior approach.
89680309|NCT03806114|Other|Posterior Approach No Precautions|This group receives does not receive precautions and have a total hip arthroplasty with a posterior approach.
89680310|NCT03741842|Experimental|COMBO-KEY group|"The participants in the intervention group will receive a home visiting and phone coaching self-management programme (Coaching Ongoing Momentum Building On stroKe rEcovery journeY COMBO-KEY) which is underpinned by Bandura's constructs of self-efficacy and outcome expectation."
89680311|NCT03741842|No Intervention|Usual care group|The participants in the usual care group will receive usual rehabilitation services offered, including services by a community rehabilitation network such as exercise training, physical rehabilitation, or activities organised by stroke support groups.
89680312|NCT03803150|Experimental|PRA approach|PRA extends downward in curvilinear fashion in cervicomastoid skin crease
89680313|NCT03803150|Active Comparator|RT approach|RT begins 5mm below the ear lobe and continues 3 to 3.5cm inferiorly.
89680314|NCT03872024|Experimental|Morbidly obese adult patients|Only one group of patients in the study: morbidly obese adult patients who will have an examination with the XXL probe prototype of the FibroScan 630 Research Model
89680315|NCT03869450|Experimental|Restylane Volyme|According to the treatment algorithm, treated with Restylane Volyme
89680316|NCT03869450|Experimental|Restylane Defyne|According to the treatment algorithm, treated with Restylane Defyne
89680317|NCT03869450|Experimental|Restylane Lyft Lidocaine|According to the treatment algorithm, treated with Restylane Lyft Lidocaine
89680318|NCT04403906|Experimental|PCL Rapid Antigen Test arm|Single arm trial design. Only patients undergoing standard clinical testing (SARS-CoV-2 PCR test) and consenting for additional testing with the PCL rapid antigen test will be included
89680319|NCT01212926|Experimental|analysis of myocardial deformation in 2D strain|
89680320|NCT04747184||Asthmatic patients|Asthmatic patients aged 14-year-old, and more were included in the study. Knowing that patient with the age of 14-year is treated as adults at Al Bashir Hospital. Smokers, patients reported to have taken antibiotics for at least two months before study enrolment, and patients who had other respiratory diseases or infections were excluded from the study.
89680321|NCT04747184||Healthy subjects|Healthy subjects aged 14-year-old, and more were included in the study. Smokers, patients reported to have taken antibiotics for at least two months before study enrolment, and patients who had other respiratory diseases or infections were excluded from the study.
89680322|NCT03795506|Experimental|Active TLA Device|12 week overnight treatment with the active Temperature Controlled Laminar Airflow device.
89680323|NCT03795506|Placebo Comparator|Placebo TLA Device|12 week overnight treatment with the placebo Temperature Controlled Laminar Airflow device.
89051046|NCT01156792|Active Comparator|FP 100mcg BID plus montelukast 10mg QD (PM)|FP 100mcg BID plus montelukast 10mg QD (PM)
89051047|NCT01156792|Active Comparator|FP 100mcg BID plus placebo BID|FP 100mcg BID plus placebo BID
89051048|NCT01156792|Active Comparator|FP/SAL 100/50mcg BID plus placebo BID|FP/SAL 100/50mcg BID plus placebo BID
89051049|NCT04628234||Patients with an onco-hematologic solid tumor in palliative care|
89680324|NCT03795038|Other|Lipoprotein Apheresis MONET and DALI|"Patients routinely treated with MONET:~The first subgroup will be treated first with the MONET adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber System.~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the MONET adsorber system"
89680325|NCT03795038|Other|Lipoprotein Apheresis DIAMED and DALI|"Patients routinely treated with DIAMED:~The first subgroup will be treated first with the DIAMED adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber system.~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DIAMED adsorber System."
89680326|NCT03794882|Experimental|QLB + Medical Management|Subjects will undergo Intervention: Procedure/Surgery: Quadratus Lumborum Block and receive Intervention: Procedure: Standard Medical Management as needed.
89680327|NCT03794882|Active Comparator|Standard Medical Management|Subjects will receive Intervention: Procedure: Standard Medical Management as needed.
89680328|NCT03737006||1-(HLHS) effected pregnancies|Consent,blood draw, nose swab, stool collection,questionnaire and review of medical records.
89680329|NCT03737006||2-Other Congenital Heart Defect (OCHD)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
89680330|NCT03737006||3-Healthy Controls (UC)|Consent, blood draw, nose swab, stool collection, questionnaire and review of medical records.
89680331|NCT03736928|Placebo Comparator|Placebo|Intramuscular single treatment
89680332|NCT03736928|Experimental|AbobotulinumtoxinA dose level 1 or 2|Intramuscular single treatment
89051050|NCT04604145|Other|Positive NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a positive NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
89051051|NCT04604145|Other|Negative NP results|SARS-CoV-2 testing on self-collected saliva specimens, associated with a negative NP result, using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system
89051052|NCT04604223|Experimental|Pioglitazone|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total.
89680333|NCT03736928|Experimental|AbobotulinumtoxinA dose level 3|Intramuscular single treatment
89680334|NCT03736928|Experimental|AbobotulinumtoxinA dose level 4|Intramuscular single treatment
89680335|NCT01101464|Experimental|Asenapine Sequence 1|
89680336|NCT01101464|Experimental|Asenapine Sequence 2|
89680337|NCT01077830||Ezetimibe/Simvastatin 10/40 mg|Participants who received Ezetimibe/Simvastatin 10/40 mg in the base study
89680338|NCT01077830||Placebo|Participants who received placebo in the base study
89680339|NCT01676948|Experimental|Canakinumab - Cohort 1, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
89680340|NCT01676948|Experimental|Canakinumab - Cohort 1, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
89680341|NCT01676948|Experimental|Canakinumab - Cohort 2, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
89680342|NCT01676948|Experimental|Canakinumab - Cohort 2, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
89680343|NCT01676948|Experimental|Cohort 2 - canakinumab dose reduction|
89680344|NCT01676948|Experimental|Cohort 1 - canakinumab dose reduction|
89680345|NCT04403672||COVID-19 positive|ideSHi (CRO) investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.
89051053|NCT04604223|Placebo Comparator|Placebo|Placebo tablets at 45 mg/day will be given for 10 days, after 10 days, the tablets will be reduced to 30 mg/day. The treatment will be continued for 4 weeks (28 days) total.
89051054|NCT04628624|Placebo Comparator|Placebo group|Placebo - capsulated, colour matched potato starch (~450mg per capsule) - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
89051055|NCT04628624|Experimental|Green tea 1|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
89051056|NCT04628624|Experimental|Green tea 2|Capsulated decaffeinated green tea extract (dGTE) (standardised to 70% EGCG concentration, 571mg total per day, containing 400mg EGCG + 150mg quercitin and 150mg alpha lipoic acid - provided by Biocare Ltd., UK using standard 00 vegetable capsules (hydroxypropyl methylcellulose). Dosage: 2 divided doses (1 capsule mid morning, 1 capsule mid afternoon) - daily for 8 weeks.
89051057|NCT01156714|Other|Arm 1: Treadmill Training|Treadmill training with aerobic exercise
89051058|NCT01156714|Other|Arm 2: Memory Training|Memory training with computerized memory program
89051059|NCT01156714|Other|Arm 3: Treadmill and Memory Training|Combination of treadmill training and computerized memory program
89051060|NCT04595643|Experimental|Specialized dysphagia treatment|Dysphagia treatment is provided by occupational therapists specialized in dysphagia.
89051061|NCT02884999||severe trauma patients|Severe trauma patients admitted to the site in the first 24 hours
89051062|NCT04628273||radiolucent stone group|
89051063|NCT04628273||radiopaque stone group|
89051064|NCT04604028|Experimental|Lenalidomide and low-dose cyclophosphamide|Oral lenalidomide and low-dose cyclophosphamide (LC: lenalidomide [Leavdo®] 15 mg daily, day 1 to day 21; cyclophosphamide [Endoxan] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days
89680346|NCT04403672||COVID-19 Negative|"ideSHi investigators will be blinded to the samples provided by IEDCR. That is, ideSHi investigators will not know which of the 60 samples are positive and which of the 60 samples are negative. After RT- PCR run using RealDetect RT-PCR Kit, ideSHi will send the results to the Principal investigator. The Principal investigator will also receive IEDCR results for the same samples. Finally, the PI will compare the results from ideSHi and IEDCR and determine the sensitivity, specificity, positive predictive value and negative predictive value.~In addition, 60 fresh specimens which will be tested at IEDCR will also be tested at ideSHi using RealDetect on a real time basis. These samples will also be blinded by IEDCR and sent to the testing laboratory (ideSHi). Of these 60 samples, 30 will be COVID-19 positive and 30 COVID- 19 negative samples. These fresh samples will be provided to ideSHi for testing and analysis for performance evaluation of RealDetect COVID-19 RT-PCR kit."
89051065|NCT00565149|Experimental|1|Normal Protein (15%) diet
89680347|NCT01677416||Rheumatoid Arthritis Group|RA with at least one year since diagnosis, asymptomatic feet, and age between 18 and 65 years
89680348|NCT01677416||Control group|Absence of known osteoarticular disease
89680349|NCT01676792|Experimental|Lesion reduction|
89680350|NCT03725930|Active Comparator|Clonidine|This arm will receive intra nasal Clonidine as a premedication before surgery
89680351|NCT03725930|Placebo Comparator|Placebo|This arm will receive intra nasal Placebo as a premedication before surgery
89680352|NCT03781388|Experimental|Starting dose of Bupivacaine (9 mg)|The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
89680353|NCT03781388|Experimental|Subsequent dose|
89680354|NCT03652220|Experimental|Intervention|"8 weeks Minimal treatment + MBLM 16 weeks Multimodal specific treatment + MBLM Consolidation~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
89680355|NCT03652220|Active Comparator|Control I|"8 weeks Minimal treatment 16 weeks Multimodal specific treatment~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
89680356|NCT03652220|Active Comparator|Control 2|"Definitions 24 weeks Multimodal specific treatment~Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
89680357|NCT03779204|Experimental|Rent subsidies + Mentorship|Participants in this arm (n = 12) will receive rent subsidies (ranging from $400 - $500/month) for 24 months as part of the intervention and be matched with an adult mentor recruited by one of the community partners.
89680358|NCT03779204|Active Comparator|Rent subsidies only|Participants in this arm (n = 12) will receive rent subsidies only (ranging from $400 - $500/month) for 24 months as part of the comparator group intervention. This group will not receive mentorship.
89680359|NCT03779048|Active Comparator|Behavioral Treatment + Placebo|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
89680360|NCT03779048|Active Comparator|Behavioral Treatment + Medication|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
89680361|NCT03778580|Experimental|pyridoxamine|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid for one year
89680362|NCT03778580|Placebo Comparator|identical placebo|identical placebo po bid for one year
89051066|NCT00565149|Experimental|2|Low Protein (5%) diet
89051067|NCT00565149|Experimental|3|High Protein (25%) diet
89051068|NCT01156675|Experimental|FLEXUS™ Interspinous Spacer|
89051069|NCT01156675|Active Comparator|XSTOP® Interspinous Spacer|
89051070|NCT01156480|Experimental|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
89051071|NCT01156480|Placebo Comparator|Placebo|Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
89215907|NCT05736484|Experimental|Social Support Gamification|"Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 26-week intervention period. Participants will also work with a virtual health coach throughout the intervention period to increase their physical activity.~At the end of the 26 week intervention period, participants will enter a 26 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the Function assessment during the 6, and 12-month timepoints in the study. They will also complete a series of surveys during the 3, 6, 9, and 12-month timepoints in the study. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study."
89215908|NCT05733962|Experimental|Use of the device DBL-4pen|After a 14-day baseline period during which the patient will use a Dexcom G6 Continuous Glucose Monitoring (CGM) and his current therapy (multiple daily injection), the patient will start a 42-day treatment period with the DBL-4pen system followed by an optional 42-day extension period.
89215909|NCT05730543|Experimental|Volbella or Juvederm Ultra XC filler|Injection will not exceed a total of 4 cc of hyaluronic acid filler for combined treatment sessions (initial treatment + possible touch up treatment session).
89215910|NCT05716451|Experimental|Intervention Group|Mobilization incl. support by the Liana. In the intervention group, Liana is used to train trunk stability in a sitting position. If this is successful, the patient is trained to stand. Mobilization to higher levels is performed according to clinical standards.
89215911|NCT05716451|No Intervention|Control Group|Standard of Care without the use of the Liana. In the control group the therapy is carried out according to the ward standard without using the Liana.
89215912|NCT05712772|Experimental|Blue then Red Light|Blue light (480 nm) then Red light (640 nm)
89215913|NCT05712772|Experimental|Red Light then Blue Light|Red light (640 nm) then Blue light (480 nm)
89215914|NCT05711095|Experimental|Fortified plant protein blend|20g of plant-based protein blend fortified with 2 g leucine
89215915|NCT05711095|Experimental|Normal plant protein blend|20g of plant-based protein blend
89215916|NCT05711095|Active Comparator|Whey protein|20g of whey protein
89215917|NCT05708586|Active Comparator|Control|Standard comfort given
89680363|NCT03722342|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
89680364|NCT03722108|Experimental|Regorafenib and Irinotecan|Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle combined with regorafenib 160 mg daily on Day2-8 and D16-22 of a 4 week cycle administered until progression of disease or unacceptable toxicity.
89680365|NCT03722108|Active Comparator|Irinotecan|Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle administered until progression of disease or unacceptable toxicity
89680366|NCT03775070|Experimental|Simvastatin|Simvastatin, 0.5mg/kg/d(maximum 20mg), once daily
89680367|NCT03645824|Experimental|Pacritinib treatment befor allo-SCT|The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.
89215918|NCT05708586|Experimental|Virtual Reality (VR)|
89215919|NCT05705609|Experimental|Mandala art therapy|Mandala art therapy applied group
89215920|NCT05705609|No Intervention|Standard of care|group without Mandala art therapy
89215921|NCT05692167|Active Comparator|Topical dexmedetomidine group|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
89215922|NCT05692167|Active Comparator|Reginal dexmedetomidine group|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
89215923|NCT05682261|Experimental|Multiple micronutrient supplement arm|The participants in this arm will receive United Nations International Multiple Micronutrient-Multiple Micronutrient Supplements. The recommended doses of UNIMMAP-MMS are vitamin A as retinol acetate (800 µg RAE), vitamin D as cholecalciferol (5 µg), vitamin E as alpha-tocopherol succinate (10 mg), vitamin C as ascorbic acid (70 mg), vitamin B1 as thiamin mononitrate (1.4 mg), vitamin B2 as riboflavin (1.4 mg), vitamin B3 as nicotinamide (18 mg), vitamin B6 as pyridoxine hydrochloride (1.9 mg), vitamin B12 as cyanocobalamin (2.6 µg), folic acid (680 µg), iron as ferrous fumarate (30 mg), zinc as zinc oxide (15 mg), copper as copper oxide (2 mg), selenium as sodium selenite (65 µg), iodine as potassium iodide (150 µg). The UNIMMAP-MMS in the tablet form will be used. We will give the supplementation twice a week and follow the study participants for 17 weeks.
89215924|NCT05682261|Experimental|Iron-folic acid supplement arm|The participants in this arm will receive Iron-Folic Acid (IFA) supplements. The recommended doses of iron-folic acid are 30-60 mg of elemental iron and 400 µg of folic acid combined. In this trial, we will use ferrous sulfate with 30 mg of iron and 400 µg of folic acid in the form of capsule. The supplementation will be given to the study subjects twice a week for 17 weeks.
89680368|NCT02083406|Experimental|Treatment A: OZ439 Prototype 1|800mg OZ439 prototype formulation 1 and 960mg PQP single doses
89680369|NCT02083406|Experimental|Treatment B: OZ439 Prototype 2|800mg OZ439 prototype formulation 2 and 960mg PQP single doses
89680370|NCT02083406|Experimental|Treatment C: OZ439 Prototype 3|800mg OZ439 prototype formulation 3 and 960mg PQP single doses
89680371|NCT03773666|Experimental|Durvalumab|-Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
89680372|NCT03773666|Experimental|Durvalumab + Oleclumab|"Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle~Oleclumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle"
89680373|NCT04762784|Experimental|Tocilizumab treatment|Tocilizumab is a recombinant humanized monoclonal antibody against human interleukin-6 (IL-6) receptor. Tocilizumab acts by inhibiting the activity of IL-6 receptor. IL-6 is a pro-inflammatory cytokine whose release can trigger a series of downstream pro-inflammatory responses. Tocilizumab inhibits IL-6 signal transduction by blocking the binding of IL-6 to soluble and membrane-bound IL-6 receptors, thereby reducing pathological inflammatory responses.
89680374|NCT04762784|Active Comparator|Glucocorticoids monotherapy|Glucocorticoids has fast onset of action and multiple anti-inflammatory effects.The conventional protocol is oral prednisone, followed by a slow tapering over 4 weeks. Besides, precautionary measures need to be taken against possible complications brought by the application of corticosteroids such as infections, diabetes mellitus, hypertension, Cushing's syndrome and osteoporosis, etc.
89051072|NCT04595526|Active Comparator|Tracheal suction|Uses the local standard procedure of tracheal suction to obtain secretions from the lower respiratory tract
89051073|NCT04595526|Experimental|Forced expiratory technique and induced sputum|This procedure is without suction. The patient's attempts to deliver a sputum sample after forced exhalation and coughing technique. Regardless of the result the patient then receives hypertonic saline by an inhalation mask to induce the sputum. If the patient cannot deliver a sample, tracheal suction will be performed in order to obtain a specimen for the analyses.
89051074|NCT04628156||Outpatients in Cerebral Palsy Greece - Open Door|Outpatients with a diagnosis of cerebral palsy
89051075|NCT02884960|Experimental|Embozene Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
89680375|NCT00003644|Experimental|Carboplatin, paclitaxel, low dose paclitaxel|carboplatin, paclitaxel followed by low dose paclitaxel 4 weeks later
89680376|NCT00003644|Active Comparator|Carboplatin, paclitaxel|carboplatin, paclitaxel
89680377|NCT02142049|Experimental|Part 1: Dose Level 1|Ibrutinib 560 mg PO + DA-EPOCH-R
89680378|NCT02142049|Experimental|Part 1: Dose Level 2|Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
89680379|NCT02142049|Experimental|Part 1: Dose Level 3|Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
89680380|NCT02142049|Experimental|Part 1: Dose Level 4|Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
89680381|NCT02142049|Experimental|Part 2: RP2D|Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
89051076|NCT02884960|Active Comparator|Embosphere Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
89051077|NCT04627961|Experimental|Patient|Patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease
89051078|NCT04595253|Experimental|acupressure|After recruitment, participants will be randomized to receive acupressure or control group. In the acupressure group, participants will receive acupressure treatment.
89051079|NCT04595253|No Intervention|routine care|After recruitment, participants will be randomized to receive acupressure or control group. In the control group, participants will receive routine care, including routine pain control.
89051080|NCT00561587|Active Comparator|1|
89051081|NCT00561587|No Intervention|2|
89051082|NCT04595487|Experimental|left ventricular septal pacing|Implantation of a pacemaker with the ventricular lead delivered transvenously through the interventricular septum (IVS) to the left ventricular (LV) septum.
89051083|NCT04595487|Active Comparator|right ventricular pacing|Implantation of a pacemaker with the ventricular lead placed in the RV.
89051084|NCT01156363|Experimental|Single Arm|
89680382|NCT03640286|Active Comparator|VeSTAL - active device|The VeSTAL device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
89680383|NCT03640286|Sham Comparator|Sham device|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
89680384|NCT03715244||Study group 1|n=220 patients for routine data of spinal anesthesia with short-acting local anesthetics
89680385|NCT03715244||Study group 2|n= 220 patients for routine data of general anesthesia (current standard)
89680386|NCT03715244||No intervention: Control group postoperative cognitive deficit|n= 90 control subjects aged 18 years or older (without surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
89680387|NCT03634982|Experimental|RMC-4630|RMC-4630 for oral administration
89680388|NCT03714620|Active Comparator|0.15 mg/kg IV Ketamine|
89680389|NCT03714620|Active Comparator|0.3 mg/kg IV Ketamine|
89680390|NCT03634436|Experimental|Cohort 1|A single subcutaneous injection of SHR-1209 dose 1 versus placebo
89680391|NCT03634436|Experimental|Cohort 2|A single subcutaneous injection of SHR-1209 dose 2 versus placebo
89680392|NCT03634436|Experimental|Cohort 3|A single subcutaneous injection of SHR-1209 dose 3 versus placebo
89680393|NCT03634436|Experimental|Cohort 4|A single subcutaneous injection of SHR-1209 dose 4 versus placebo
89680394|NCT03631550|Active Comparator|Active|Relivion Active device
89680395|NCT03631550|Sham Comparator|Sham|Relivion Sham device
89680396|NCT03629288|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and one tablet containing lactose once a day for three days immediately after the scaling and root planning.
89680397|NCT03629288|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500 milligrams (mg) of Azithromycin once a day for three days immediately after the scaling and root planning.
89680398|NCT01676870|Experimental|1x4 aerobic interval training|1x4min aerobic interval training (1-AIT), 3 times a week
89680399|NCT01676870|Experimental|4x4 aerobic interval training|4x4min aerobic interval training (4-AIT), vigorously exercise according to today's guidelines, 3 times a week
89680400|NCT01676870|Active Comparator|traditional moderate training|traditional moderate training (CME), moderate exercise at least 30 min, 5 days a week or more, according to today's guidelines
89680401|NCT04763096|Experimental|tacrolimus|conversion to Advagraf
89680402|NCT05347472|Experimental|Experimental group|In this group, women will receive the smartphone application intervention that will include daily physical therapy exercises program
89680403|NCT05347472|Placebo Comparator|Control group|In this group, women will receive the sham application that includes information and general advice about UI only
89680404|NCT04762940|Active Comparator|Control group|They will receive 24 robotics sessions with Amadeo robot three times a week for movement, but without specifically receiving vibration therapy.
89051085|NCT00561626|Experimental|A|
89051086|NCT00561626|Experimental|B|
89051087|NCT02884921|Active Comparator|Preemptive Paracetamol|Preemptive Paracetamol
89051088|NCT02884921|Active Comparator|Post surgery Paracetamol|Post surgery Paracetamol
89051089|NCT02884921|Placebo Comparator|Placebo|Placebo
89051090|NCT02884882|Other|Emotional induction in stroke population|Six films are presented, each after a relaxation period after which the basal score is measured.
89051091|NCT02884882|Placebo Comparator|Emotional induction in healthy volunteers|Six films are presented, each after a relaxation period after which the basal score is measured.
89051092|NCT01156051|Experimental|Guanfacine Extended-Release Tablets|Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg, and 4mg
89680405|NCT04762940|Experimental|Experimental group|They will recieve three times a week with 24 sessions plus vibration duration of approximately 20 minutes with a high vibration frequency. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible will be conducted prior to robotic treatments with Amadeo.
89051093|NCT01156051|Placebo Comparator|Placebo comparator|Placebo control
89051094|NCT04595409|Experimental|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive subcutaneous injections of FYB202 as detailed in the protocol.
89051095|NCT04595409|Active Comparator|Stelara® (Ustekinumab)|Patients will receive subcutaneous injections of Stelara® as detailed in the protocol.
89680406|NCT03627728|Experimental|regorafenib|Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease
89680407|NCT03627728|Placebo Comparator|placebo|Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease
89680408|NCT03704792|Experimental|Adult CLD Group|Only one group of patients in the study: adult patients with chronic liver disease (CLD), all etiologies combined, who will have a FibroScan 530 Compact examination to calculate the CAP value.
89680409|NCT04403594||MS with spasticity of one lower extremity|A person diagnosed with Multiple Sclerosis and spasticty of one lower extremity. The person must be able to walk 25 feet and cannot have had Botox in the lower extremity on the last 6 months.
89680410|NCT00680953|Experimental|1|Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
89680411|NCT00680953|Placebo Comparator|2|Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
89680412|NCT00680953|Active Comparator|3|Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).
89680413|NCT03154801|Experimental|Paramedical care|paramedical early detection of sexual dysfunction and sexual health counseling
89680414|NCT00681031|Experimental|All Enrolled|Participants received a single dose (0.65 mL) of shingles (herpes zoster) vaccine (live) ZOSTAVAX® by subcutaneous injection at Visit 1 (Day 0)
89680415|NCT00660985|Experimental|Differin® Gel, 0.3%|Gel, 0.3%, 2g, once daily for 30 days
89680416|NCT00660985|Active Comparator|Differin® Gel, 0.1%|Gel, 0.1%, 2g, once daily for 30 days
89680417|NCT03551522|Experimental|Seladelpar 10 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
89051096|NCT04628000||Vitamin D deficiency and COVID19|Vitamin D deficiency and COVID19
89051097|NCT01156012|Experimental|T2345|One drop of T2345
89051098|NCT01156012|Active Comparator|Prostaglandin|One drop
89051099|NCT04627844|Placebo Comparator|Delayed Feeds|"Patients will receive tube feeds beginning at 6 hours after PEG tube placement. This is our institutions current practice~Intervention Type: Dietary"
89051100|NCT04627844|Experimental|Immediate Feeds|"Patients will receive tube feeds beginning immediately after PEG tube placement.~Intervention Type: Dietary"
89051101|NCT04595136|Experimental|COVID19-0001-USR|Group 1 Patients with SARS-COV-2 (COVID19) positive test will receive Investigational Drug administer by nebulization ( COVID-19-0001-USR) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
89051102|NCT04595136|Placebo Comparator|Normal Saline|Group 2 of patients with positive tests intervention SARS-COV-2 (COVID19) with placebo (i.e., normal saline 0.9% NS) plus standard baseline treatment for covid provided by Primary care provider ( Azithromycin, dexamethasone, and/or anticoagulants) Dosage: 3ml Frequency and Duration: Three times a day for 7 days
89051103|NCT04628117|No Intervention|Control|Nutritional counselling by individualized nutritional plan for 8 weeks.
89051104|NCT04628117|Experimental|Oral nutritional supplementation|Nutritional counselling by individualized nutritional plan plus oral nutritional supplementation for renal disease (237 mls per day) for 8 weeks.
89051105|NCT01155661|Experimental|LY2216684 (edivoxetine) + SSRI|
89051106|NCT04627883|Other|Group 1:2|Patients in the control group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2.
89051107|NCT04627883|Other|Group 2:1|Patients in the IRV group had noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1.
89051108|NCT00565188|Experimental|I|
89051109|NCT00565188|No Intervention|C|
89051110|NCT04603833|Experimental|SHR3680+Docetaxel|
89051111|NCT04603833|Active Comparator|SHR3680|
89051112|NCT04603833|Active Comparator|Docetaxel|
89051113|NCT04603716|Experimental|Eccentric Muscle Energy Technique|conventional physical therapy Along with eccentric muscle energy technique
89051114|NCT04603716|Experimental|concentric muscle energy technique|Conventional physical therapy along with concentric muscle energy technique
89051115|NCT04627532|Experimental|Treatment|PF-07304814 assignment
89051116|NCT04627532|Placebo Comparator|Placebo|Placebo assigned
89051117|NCT01580748|Experimental|Treatment arm|single arm study
89051118|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells and dasatinib|Dose levels of CAR-T cells are based on clinical trials of similar foreign products. Meanwhile, dasatinib would be combined as the following regimens: 1) Dasatinib preconditioning CAR-T cells during the manufacturing; 2) Dasatinib for the intervention of cytokine release storm after CAR-T cell infusion; 3) Dasatinib for the intervention of neurotoxicities after CAR-T cell infusion; 4) Dasatinib for the phase of CAR-T cell decreasing.
89680418|NCT03551522|Experimental|Seladelpar 20 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
89680419|NCT03551522|Experimental|Seladelpar 50 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
89680420|NCT03551522|Placebo Comparator|Placebo|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
89680421|NCT03704714|Experimental|Treatment (nivolumab and R-CHOP)|Participants receive nivolumab IV over 30 minutes on day 1. Participants also rituximab IV on day 2, cyclophosphamide IV on day 2, doxorubicin hydrochloride IV over 3-5 hours on day 2, vincristine sulfate IV over 30 minutes on day 2, and prednisone PO on days 2-6 of course 1 and rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV over 3-5 hours on day 1, vincristine sulfate IV over 30 minutes on day 1, and prednisone PO on days 1-5 of courses 2-6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89051119|NCT04603872|Experimental|Administration of CD19/BCMA Targeted CAR T-cells|Dose levels of CAR-T cells are based on clinical trials of similar foreign products.
89051120|NCT04627688|Active Comparator|Standard dietary advices|
89051121|NCT04627688|Experimental|Time restricted feeding|
89051122|NCT04603794|Active Comparator|1% Hydrogen Peroxide Mouth Rinse|30 second oral rinse with 1% Hydrogen Peroxide
89051123|NCT04603794|Active Comparator|0.12% Chlorhexidine Gluconate Mouth Rinse|30 second oral rinse with 0.12% Chlorhexidine Gluconate
89051124|NCT04603794|Active Comparator|0.5% Povidone Iodine Mouth Rinse|30 second oral rinse with 0.5% Povidone Iodine Mouth wash
89051125|NCT04603794|Placebo Comparator|0.9% Normal Saline Mouth Rinse|30 second oral rinse with 0.9% Normal Saline
89051126|NCT04627337|Experimental|Saccharomyces boulardii (1 capsule of 250 ug BID) + Dietary advice|Patients received 1 capsule of Saccharomyces boulardii 250 ug BID plus dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
89051127|NCT04627337|Active Comparator|Dietary advice without medication|Patients received dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
89051128|NCT04603638|Active Comparator|magnesium|participations will be given intravenous magnesium.
89051129|NCT04603638|Placebo Comparator|control|participations will be given intravenous isotonic.
89680422|NCT02984774|Experimental|Infertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
89680423|NCT02984774|Experimental|Fertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
89051130|NCT04627454|Experimental|dynamic cervical implant|dynamic cervical implant in treatment of cervical disc disease
89051131|NCT04627454|Experimental|discectomy|insertion of dynamic cervical implant post cervical discectomy single level
89051132|NCT04603599||benign endometrial changes|
89051133|NCT04603599||endometrial hyperplasia|
89051134|NCT04603599||endometrial cancer|
89051135|NCT04627298|Active Comparator|Video Game|This arm tests use of video game to help preteens in the decision to pursue HPV vaccination. Participants in the intervention group are asked to play the Land of Secret Gardens game and complete 3 tasks: (1) play a shield game with blue spikey virus balls, (2) find hidden objects in 4 different garden sheds, and (3) create a potion (vaccine). Participants in the intervention arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance, the Physical/Emotional/Narrative Presence Scale (PENS) to gauge preteens' immersion in the game, and game play experience.
89051136|NCT04627298|No Intervention|No Video Game|This arm does not test the video game. Participants in the comparison arm are asked to respond to surveys about HPV and HPV vaccine knowledge, vaccination self-efficacy and decisional balance.
89051137|NCT04627220||group 1|Group 1: Pressure of arterial oxygen> 200 mmHg during the coronary surgery
89051138|NCT04627220||group 2|Group 2: Pressure of arterial oxygen<200 mmHg and >80 mmHg during the coronary surgery
89051139|NCT04627259||patient|patients with thumb pain or functional problems
89051140|NCT04603092|Experimental|Disadvantaged women in primary setting receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This group will receive the digital health literacy intervention.
89051141|NCT04603092|No Intervention|Disadvantaged women in primary setting not receiving digital health literacy intervention|The study population will comprise of disadvantaged women dependent on primary healthcare services, who do not have access to digital tools (smartphone, computer, laptop) or Wifi in their home. This control group will not receive the digital health literacy intervention.
89680424|NCT02984774|Other|Control|Ovarian tissue sampling, endometrial sampling from hysterectomy and oophorectomy pieces and peripheric blood sampling during intravenous catheterization during anesthesia.
89680425|NCT02336360|Experimental|Urine Analysis|Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.
89215925|NCT05682261|Placebo Comparator|Control arm|The participants in this arm will receive placebos made of sugar (lactose anhydrous). There is no active ingredient in the placebos. The placebos are lactose powder filled in the capsule. We will give placebos twice a week and will follow the study subjects for 17 weeks. The study subjects in this arm will be compensated with UNIMMAP-MMS at the end of the intervention.
89215926|NCT05670041|No Intervention|Standard follow-up|
89680426|NCT00661141|Experimental|Cohort 1: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
89680427|NCT00661141|Experimental|Cohort 2: Antizol 3.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
89051142|NCT01155583|Experimental|Arm A - Azacitidine/Lenalidomide/Dexamethasone|"Dose Level (DL) 1 - Azacitidine 30mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 40mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 3 - Azacitidine 30mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 4 - Azacitidine 40mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 5 - Azacitidine 50mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR > 60 ml/min) receive azacitidine subcutaneously 1 or 2x per weekly and oral Dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
89215927|NCT05670041|Experimental|Intensified follow-up|Early, intensified follow-up after discharge from TAVI-procedure consisting of telephone consults and an additional visit to the outpaitent clinic.
89215928|NCT05658718||glare group.|Patients subjectively complained about glare and Binoptometer examination showed poor visual quality in dark environments, and they were classified as the glare group.
89680428|NCT00661141|Experimental|Cohort 3: Antizol 5.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
89680429|NCT00661141|Experimental|Cohort 4: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 7.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
89680430|NCT03616730||Heart Disease in pregnancy group|Fifty women will be recruited with structurally and functionally abnormal hearts without a history of chronic hypertension, pre-gestational diabetes, multiple gestations, preeclampsia, autoimmune disease, and anyone with a history of cardiomyopathy but currently normal ejection fraction. Women who are unable to give informed consent will not be included.
89680431|NCT03616730||Control Group|Fifty women will be recruited with structurally normal hearts without a history of chronic hypertension, pre-gestational diabetes, multiple gestations, preeclampsia, autoimmune disease, and anyone with a history of cardiomyopathy but currently normal ejection fraction. Any woman on cardiac or antihypertensive medications (beta blockers, calcium channel blockers, hydralazine) will be excluded. Women who are unable to give informed consent will not be included.
89680432|NCT03702764||VP-SG 01|Study subjects that present concentric coronary plaques
89680433|NCT03702764||VP-SG 02|Study subjects that present eccentric coronary plaques
89680434|NCT03616574|Experimental|Dose Escalation - CA102N Monotherapy|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 of a 28-day cycle
89680435|NCT03616574|Experimental|Dose Escalation - CA102N plus LONSURF|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
89680436|NCT03616574|Experimental|Dose Expansion - CA102N plus LONSURF|The preliminary RP2D of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
89680437|NCT00681265|Experimental|glycerin|One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
89680438|NCT00681265|Active Comparator|polyethylene glycol 400/propylene glycol|The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
89680439|NCT03548324|Active Comparator|HHHFNC|Heated Humidified High Flow Nasal Cannulae
89680440|NCT03548324|Active Comparator|NCPAP|Nasal Continuous Positive Air Pressure
89680441|NCT01677104|Active Comparator|DPP-IV inhibitor|Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues
89680442|NCT01677104|Placebo Comparator|Placebo pill|One placebo tablet before microinjection
89680443|NCT00661453|Experimental|1|All patients will receive VPA and carnitine.
89680444|NCT03547622|Active Comparator|MAT taper with galantamine|Following initial MAT taper, participants will be given up to 16mg daily of galantamine for up to 10 weeks of the active study
89680445|NCT03547622|Placebo Comparator|MAT taper with placebo|Following initial MAT taper, participants will be given up to 16mg daily of placebo for up to 10 weeks of the active study
89680446|NCT00681889|Experimental|Treatment Arm|10 Patients will receive treatment (Ranibizumab)
89680447|NCT03697538|Experimental|Adductor Canal Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
89680448|NCT03697538|Active Comparator|Femoral Nerve Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
89680449|NCT02869945|Other|COMT HH|COMT HH gene
89680450|NCT02869945|Other|COMT HL|COMT HL gene
89680451|NCT02869945|Other|COMT LL|COMT LL gene
89680452|NCT03610022|Experimental|Patients with BCC and annexial carcinoma|Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib
89680453|NCT00682357|Experimental|1|Methylprednisone 80 mg and Lidocaine 20 mg
89680454|NCT00682357|Experimental|2|Methylprednisolone 16 mg and Lidocaine 20 mg
89680455|NCT00682357|Placebo Comparator|3|Placebo and Lidocaine 20 mg
89680456|NCT00662155|Experimental|Continuous 1 (QHS-10)|continued nightly use with 10mg zolpidem
89680457|NCT00662155|Experimental|Partial Reinforcement (PRS-10)|partial reinforcement with 10mg zolpidem (PRS-10 [nightly pill use with 50% active meds and 50% placebos])
89680458|NCT00662155|Experimental|Intermittent (IDS-10)|intermittent dosing with 10mg zolpidem
89680459|NCT00662155|Experimental|Continuous 2 (QHS-5)|continued nightly use with 5mg zolpidem
89680460|NCT03546608|Experimental|Part 1, Child-Pugh Class A: Tepotinib|
89680461|NCT03546608|Experimental|Part 1, Child-Pugh Class B: Tepotinib|
89680462|NCT03546608|Experimental|Part 1, Healthy Participants: Tepotinib|Healthy participants matched to Child-Pugh Class B participants.
89680463|NCT00684541|Experimental|Interpretation Modification Program|The IMP procedure was identical to the word-sentence association paradigm (WSAP; Beard & Amir, 2009) except participants received feedback about their responses. Participants received positive feedback when they endorsed benign interpretations or rejected threat interpretations of the ambiguous sentences on 100% of trials and negative feedback when they endorsed threat interpretations or rejected benign interpretations on 100% of trials. This feedback manipulation was intended to reinforce a benign interpretation bias and extinguish the threat interpretation bias. Participants completed two blocks of 110 training trials in each session. Participants who completed Set A during the WSAP assessment saw Set B during the IMP and vice versa. Each IMP session lasted approximately 20 min.
89680464|NCT00684541|Placebo Comparator|Interpretation Control Condition|The ICC was identical to the IMP, except that participants received positive feedback when they endorsed threat interpretations on half (50%) of the trials and negative feedback when they endorsed threat interpretations for the remaining half (50%) of trials. This frequency was the same for benign interpretations. Thus, the control group was reinforced equally for making threat and benign interpretations. The ICC was not intended to change interpretation significantly in either direction.
89680465|NCT05347394|Experimental|Part A: VX-708|Participants will be randomized to receive a single dose of different dose levels of VX-708.
89680466|NCT05347394|Placebo Comparator|Part A: Placebo|Participants will receive placebo matched to VX-708.
89051143|NCT01155583|Experimental|Arm B - Chronic Kidney Disease (CDK) Cohort|"DL (-1) - Azacitidine 30mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 1 - Azacitidine 40mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 50mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR 30-59 ml/min Chronic Kidney Disease (CKD)) receive azacitidine subcutaneously 1 or 2x per weekly and oral dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
89051144|NCT04603131|Experimental|BBV87 - 10 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths (10, 20 and 30 mcg) administered intramuscularly on Day 0, 29 and 57
89051145|NCT04603131|Placebo Comparator|Placebo|Placebo administered intramuscularly on Day 0, 29 and 57
89051146|NCT04603131|Experimental|BBV87 -30 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
89051147|NCT04603131|Experimental|BBV87 -20 mcg|Inactivated Chikungunya virus vaccine (BBV87) in three dose strengths administered intramuscularly on Day 0, 29 and 57
89051148|NCT04626908|Experimental|Administration of GC022F CAR-T cells|Each subject receive GC022F CAR T-cells by intravenous infusion
89051149|NCT04627181|Experimental|FCM + placebo|"Ferric carboxymaltose: Single dose, 500 mg~Placebo: Single dose"
89051150|NCT04627181|Experimental|B12 + placebo|"Hydroxycobalamine: Single dose, 1000 mcg~Placebo: Single dose"
89051151|NCT04627181|Experimental|FCM +B12|"Ferric carboxymaltose: Single dose, 500 mg~Hydroxycobalamine: Single dose, 1000 mcg"
89051152|NCT04627181|Placebo Comparator|Placebo + placebo|"Placebo: Single dose~Placebo: Single dose"
89051153|NCT04602780||CI users|
89051154|NCT04626830|Experimental|Mobile Application Intervention|Participants in the intervention group will receive 6 months the mobile application (OKTED) for improving symptoms and adherence to oral anticancer agents. The mobile application will consist of three modules. The first module will include OAA-specific information, a calendar in which start/end dates can be record, and a medication reminder. The second module will include information about common and urgent symptoms and recommendations for the management of these symptoms. The last module will comprise a question and answer section.
89051155|NCT04626830|No Intervention|Standard Care|Participants in the control group will receive standard oncology care only.
89680467|NCT05347394|Experimental|Part B: VX-708|Participants will be randomized to receive multiple doses of different dose levels of VX-708. The dose levels will be determined based on the data from Part A.
89680468|NCT05347394|Placebo Comparator|Part B: Placebo|Participants will receive placebo matched to VX-708.
89680469|NCT00662545|Experimental|A|Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine
89680470|NCT00662545|Active Comparator|B|continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine
89680471|NCT03696446|Experimental|Virtual Cardiac Rehabilitation Program|This group will receive access to the NWC (NexJ Connected Wellness TM (NCW) and will be provided with a fitness tracker (Garmin Vivofit 3) to monitor their exercise, sedentary behaviours, and sleep patterns. The NWC platform includes components for education (health library, workbooks etc), collaboration (personal care plan, appointment scheduler, secure messaging system etc), and motivation (motivational messages on their homepage etc). With the Health Coach, participants will engage in: reviews of their risk factor profile and health priorities; goal setting and action planning; problem solving and skill building; and discussions of relapse prevention. Participants will receive a total of seven hours of health coaching delivered across nine sessions over a 26-week period
89051156|NCT04626557||Women with astma|At the 7th -14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
89051157|NCT04626557||Women without asthma|At the 7th - 14th cycle day, an endometrium sample from the uterus lining will be obtained together with sputum, as indicators of the system inflammation expressed both in the lungs and the uterus, and blood samples.
89051158|NCT04602897|Experimental|cough group|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
89680472|NCT03696446|Other|Case Managed Home Program|The Case Managed Home Program (CMHP) is delivered primarily via telephone. Following their CR intake, patients are linked with their CMHP Health Coach and attends their visit (in person or over the phone) which includes a comprehensive review of their health history, current symptoms, medications, activity, and individual concerns. Following this visit, participants will receive a total of 10 individualized telephone calls over a 26 week period. The program action plan is individually formulated based on the participant's goals and learning needs. Participants are provided with educational kits (exercise, nutrition, stress management or prevention) that are based on the principle of single point learning and incorporate behavioural change techniques.
89680473|NCT03693716|Experimental|Dynamic Anterior Stabilization|Arthroscopic Dynamic Anterior Capsular Stabilization with Trans subscapular Long Head of the Biceps Tenodesis
89680474|NCT03539198||Locoregional|Patients with recurrent locoregional head and neck cancer
89680475|NCT03539198||Metastatic|Patients with recurrent metastatic head and neck cancer
89680476|NCT00663169|Experimental|Canakinumab|Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.
89680477|NCT00663169|Active Comparator|Dexamethasone|Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.
89680478|NCT04762004|Experimental|Maternal speech|During the intervention, mothers were asked to speak to their preterm infants in the incubators for 5 min preceding the heel prick procedure and for the subsequent 5 min.
89680479|NCT04762004|Experimental|Maternal singing|During the intervention, mothers were asked to sing to their preterm infants in the incubators for 5 min preceding the heel prick procedure and for the subsequent 5 min.
89680480|NCT04762004|Active Comparator|Standard care|During the control condition (without the mother), the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
89680481|NCT00004418|Experimental|Glyceryl trierucate/glyceryl trioleate|Treatment of all enrolled participants. Dosage form is a liquid oil taken orally. Dose is to provide 20% of daily calories. Daily for duration of trial
89680482|NCT01677494||heart failure with preserved ejection fraction|- Inclusion Elevated BNP EF > 50%
89680483|NCT00663793|Experimental|Oral testosterone|"(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
89680484|NCT00663793|Experimental|Finasteride plus Oral Testosterone|"(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
89680485|NCT00667381|No Intervention|Control|The combination of anatomic landmarks and fluoroscopic localization of the femoral head will be used to guide femoral arterial access.
89680486|NCT00667381|Experimental|Ultrasound|Patients randomized to Ultrasound will have anatomic landmarks checked and real-time ultrasound guidance to aid femoral arterial access.
89051159|NCT04602897|No Intervention|control|the control group received no pain management at all during different steps of IUD insertion
89051160|NCT04626752|Experimental|volunteers|The patient voluntarily signs the informed consent, and the patient meets the entry criteria to diagnose patients with Relapsed Refractory (R/R) Multiple Myeloma (MM)
89051161|NCT04602663|Experimental|follow up every week|Variceal Band ligation every week.
89051162|NCT04602663|Experimental|follow up every 2 weeks|Variceal Band ligation every 2 weeks
89051163|NCT04602663|Experimental|follow up every 3 weeks|Variceal Band ligation every 3 weeks
89051164|NCT04602663|Experimental|follow up every 4 weeks|Variceal Band ligation every 4 weeks
89051165|NCT00561782||Group 1|Spinal cord injured with chronic central neuropathic pain.
89051166|NCT00561782||Group 2|Spinal cord injured without chronic central neuropathic pain.
89051167|NCT00561782||Group 3|Able-bodied without history of chronic pain of any type
89051168|NCT00561782||Group 4|Traumatically Brain Injured with a history of pain that onset after their TBI
89051169|NCT04602585|Experimental|Experimental|After discharge, the program manager will link the participants with a VHT nearest to them. The participants (randomized to the intervention arm) will be informed during the consent procedure that they will undergo 6 psycho-education sessions (1 per month) together with a family member at the participant's residence. The VHTs and participants will meet and schedule appointments for the next engagements. This shall be done on a case by case basis. Some psycho-education sessions could take place in the patient's residence, others in the nearest public space (school or church or mosque compounds). The investigators will document where the majority of these sessions happen. This will help the investigators document feasibility. The PI and RAs will sit in some of the sessions during the pilot phase of data collection to ensure fidelity to the manual.
89051170|NCT04602585|Placebo Comparator|Usual care arm|Participants will receive usual care
89051171|NCT01155466|Experimental|Preladenant 2 mg|Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks
89051172|NCT01155466|Experimental|Preladenant 5 mg|Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks
89051173|NCT01155466|Experimental|Preladenant 10 mg|Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks
89051174|NCT01155466|Placebo Comparator|Placebo|Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks
89680487|NCT02336438|No Intervention|Baseline Phase (Control)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) and scheduled blood draws over 3 hours."
89680488|NCT02336438|Experimental|Treatment Phase (Glucomannan)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) + 5 grams of Glucomannan soluble fiber powder and scheduled blood draws over 3 hours.~For the next five days subjects will take the following amounts of Glucomannan soluble fiber (provided by the investigator) three times a day with meals."
89680489|NCT00667615|Experimental|1|vorinostat in combination with cyclophosphamide, etoposide,prednisone and rituximab,peg-filgrastim or filgrastim
89680490|NCT00667693|Active Comparator|Macintosh laryngoscope|Intubation with a Macintosh laryngoscope
89680491|NCT00667693|Active Comparator|Pentax AWS|Intubation with a Pentax AWS
89680492|NCT03604640|No Intervention|standard care|
89680493|NCT03604640|Experimental|Physical and educational program|
89680494|NCT03687008|Experimental|Adolescents with SVHD|All adolescents will receive the intervention Cogmed. This is an in home, computer based, cognitive intervention to improve working memory, supervised by trained coaches, [25 sessions, each 30-45 minutes, 5 days a week / 5 week duration].
89680495|NCT00667849|Active Comparator|Exogen 4000+|Single arm, Exogen 4000+
89680496|NCT00667849|Sham Comparator|Sham|Single arm, sham (identical device with the exception of administration of ultrasound).
89680497|NCT03532958|Placebo Comparator|Placebo|Normal saline
89680498|NCT03532958|Experimental|Low Dose BNZ-1|0.5 mg/kg QW
89680499|NCT03532958|Experimental|Moderate Dose BNZ-1|2 mg/kg QW
89680500|NCT02998489|Experimental|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
89680501|NCT02998489|Active Comparator|Traditional milk advancement|20 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
89680502|NCT02827513|Experimental|Arm 1|Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth [PO] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.
89680503|NCT02827513|Experimental|Arm 2|Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
89680504|NCT02827513|Experimental|Arm 3|Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
89680505|NCT02827513|Experimental|Arm 4|Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
89680506|NCT03683810|Experimental|Lactoferrin|Participants will receive 4gr lactoferrin per day for a duration of 3 months + standard treatment for anemia
89680507|NCT03683810|Active Comparator|Standard treatment|Participants will receive only the standard treatment for anemia
89680508|NCT01587235|Experimental|Vytorin|
89680509|NCT01587235|Active Comparator|Other Statin|
89680510|NCT03530306|Active Comparator|PS1-PS4|
89680511|NCT03530306|Active Comparator|PS6-PS10|
89680512|NCT03530306|Active Comparator|PS7-PS4|
89680513|NCT03530306|Active Comparator|PS9-PS6|
89680514|NCT00802789||1|Mild to moderate adult asthmatics (≥18years of age) insufficiently treated with ICS or ICS + LABA.
89680515|NCT01796509|Experimental|multidisciplinary follow-up|
89680516|NCT01796509|No Intervention|no follow-up|
89051175|NCT01155466|Active Comparator|Rasagiline 1 mg|Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks
89051176|NCT00561860|No Intervention|1|This pathway represents our standard clinical protocol when a patient has been diagnosed with sleep apnea and CPAP therapy is initiated. After prescription of CPAP, all patients will be seen by our CPAP coordinator and oriented to the device during a 20 minute session. Patients are also provided the telephone number of the CPAP coordinator who can be contacted if any problems or questions arise.
89051177|NCT00561860|Experimental|2|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
89051178|NCT00561899|Experimental|1|SP+AQ
89051179|NCT00561899|Experimental|2|Piperaquine plus SP arm
89051180|NCT00561899|Experimental|3|Du-Cotecxin
89680517|NCT02998099|Experimental|Aged 18-45 years|A single dose of IV rivipansel over 20 minutes.
89680518|NCT02998099|Experimental|Aged 65 and older|A single dose of IV rivipansel over 20 minutes.
89680519|NCT00705133|Experimental|Treprostinil-treated|Patients with pulmonary fibrosis with an advanced pulmonary hypertension phenotype will be treated with parenteral treprostinil in an open-label fashion
89051181|NCT01155388|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
89051182|NCT01155388|Active Comparator|Oral Iron|Participants will receive oral iron: 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
89051183|NCT04313725|Experimental|Boost|Subjects will use the Tangible Boost treatment on their lenses monthly throughout the study.
89680520|NCT02998255|Experimental|Single dose of 2L PEG|2 L of PEG solution was used on the day of colonoscopy.
89680521|NCT02998255|Active Comparator|Split-dose of 4L PEG|Split-dose of 4l PEG was used before and on the day of colonoscopy
89680522|NCT00652717|Experimental|1|arm 1 - Ezetimibe 10 mg daily that was added on Statin Therapy (prescribed clinically suitable dose by the physician).
89680523|NCT00652717|Active Comparator|2|arm 2- simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
89680524|NCT04387591|Experimental|Fu's subcutaneous needling(FSN)|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
89680525|NCT04387591|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in the total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finished, the subjects will receive assessments on Day8 and Day15, separately.
89680526|NCT00553891|Experimental|Nasonex Nasal Spray|
89680527|NCT00553891|Placebo Comparator|Placebo Nasal Spray|
89680528|NCT03599492||Cirrhosis Patients|10 Patients with body mass index (BMI) etiology of cirrhosis
89680529|NCT00684775|No Intervention|Work Plus Naltrexone Prescription|Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.
89680530|NCT00684775|Experimental|Work Plus Naltrexone Contingency|Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.
89680531|NCT03681860|Other|Group 1 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 5 x10^9 vp
88996466|NCT02918539||RAmP Registry Patients|Patients who have a) objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease and b) a positive amyloid scan from either an existing amyloid scan that has been interpreted as positive or a florbetapir F 18 PET scan via protocol addendum
88996467|NCT02918422|Experimental|High Carbohydrate No Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO and 25% fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
89680532|NCT03681860|Other|Group 2 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp
89680533|NCT03681860|Other|Group 3 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 5 x10^9 vp
89680534|NCT03681860|Other|Group 4 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp
89680535|NCT03681860|Experimental|Group 5/6 Randomised Comparison|30 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp followed by MVA85A boost versus 30 adolescents who are EMaBS participants, to receive BCG revaccination
89680536|NCT00685477|Active Comparator|Experimental Sequence ABC|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
89680537|NCT00685477|Active Comparator|Experimental Sequence ACB|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
89680538|NCT00685477|Active Comparator|Experimental Sequence BAC|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
89680539|NCT00685477|Active Comparator|Experimental Sequence BCA|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
89680540|NCT00685477|Active Comparator|Experimental Sequence CAB|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
89680541|NCT00685477|Active Comparator|Experimental Sequence CBA|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
88996468|NCT02918422|Experimental|High Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO 25% and Fat 25% with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
89051184|NCT04313725|Placebo Comparator|Placebo|Subjects will use a Placebo treatment (saline) on their lenses monthly throughout the study.
89051185|NCT04626440||Group 1|Group 1 [(A) subjects who are planning to receive surgery (mastectomy or BCS) as the first-line treatment for BC and followed by adjuvant therapy, or (B) subjects with BC recurrence at screening, who had received surgery for primary BC within 3 years prior to screening, and with primary tumor FFPE tissues available]
89051186|NCT04626440||Group 2|subjects who are planning to receive neoadjuvant therapy as the first-line treatment for BC and followed by surgery
89051187|NCT04626440||Group 3|Group 3-1 (subjects diagnosed with de novo and treatment naïve stage IV BC); or Group 3-2 [(A) stage IV subjects with BC recurrence beyond 3 years after surgery (mastectomy or BCS) or stage IV subjects who had received or are currently receiving treatments for BC].
89051188|NCT04313803||American Fork|CGM usage months 1 and 3
89051189|NCT04313803||Central Orem|CGM usage for month 1
89051190|NCT04313803||North Canyon, Saratoga Springs, and Lehi|CGM usage for 1-3 months
89051191|NCT00565227|Experimental|docetaxel plus vorinostat|
89051192|NCT02884726|Experimental|BMS-986148 intravenous infusion|
89051193|NCT04602273||High Risk MDS|New diagnosed patients treated with Azacitidine 75 mg/sqm SC QD on a 28 days based cycles (both 7-0-0 and 5-0-2 regimens are allowed) until disease progression, unacceptable toxicity, death or investigator decision
89051194|NCT00562016|Experimental|IMPELLA LP 2.5|
89051195|NCT00562016|Active Comparator|IABP Intra-aortic balloon pump|
89051196|NCT04313491|Experimental|Yoga@Work|
89051197|NCT04313764|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
89680542|NCT03594890|Experimental|OVX836 (Intramuscular)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
89680543|NCT03594890|Placebo Comparator|Placebo (Intramuscular)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
89680544|NCT03594890|Experimental|OVX836 (Intranasal)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
89680545|NCT03594890|Placebo Comparator|Placebo (Intranasal)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
89680546|NCT02997943|Experimental|Step 1: Optimal First Line Treatment|"Participants will first be randomized to an optimal first line treatment in order to compare APP vs. APP + coaching. Participants assigned to Step 1 treatment APP will receive a study-specific smartphone application. Participants assigned to Step 1 treatment APP + coaching will receive a study-specific smartphone application plus 12 weekly telephone coaching sessions."
89680547|NCT02997943|Experimental|Step 2: Optimal Strategy to Address Nonresponse|Beginning at week 2, participants who are identified as treatment non-responders will be re-randomized in order to compare two strategies to address non-response: a modest step-up or vigorous step-up treatment augmentation tactic. Step 2 treatment strategy: modest step-up will include provision of an additional mHealth intervention component (push notifications). Step 2 treatment strategy vigorous step-up will include provision of an additional mHealth intervention component (push notifications), plus a traditional weight loss intervention component (coaching, meal replacements). Participants will continue to receive their first line treatment.
89680548|NCT00686257|Experimental|1|Patients receiving NPPV by the 'Total Face Mask'
89680549|NCT00686257|Active Comparator|2|Patients receiving NPPV by 'standard oronasal mask'
89680550|NCT03524924||non-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: < 0.3151361243 Male: < 1.211878526
89680551|NCT03524924||pre-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 0.3151361243 to < 2.1301121973 Male: 1.211878526 to < 3.0052612772
89680552|NCT03524924||frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 2.1301121973 to < 6 Male: 3.0052612772 to < 7
89680553|NCT04403360|Experimental|Erector Spinae plane Block (ESPB) group|The ultrasound-guided ESPB was realized at T12 level (levo bupivacaine 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)after the induction of anesthesia but before the start of the surgery.
89680554|NCT04403360|Active Comparator|Local anesthesia infiltration by the surgeon|The surgeon infiltrates the surgical site after skin incision with local anesthetics (Levo Bupivacaïne 0.25% + epinephrine 1:200.000 4mg.kg-1 body weight)
89680555|NCT05310084|Experimental|Coadministration Group|BNT162b2 and SIIV followed by placebo a month later
89680556|NCT05310084|Experimental|Separate Administration Group|Placebo and SIIV followed by BNT162b2 a month later
89680557|NCT04859114|Active Comparator|Text-only outcome data, 30% survival|Participants in this arm are provided a repeat of the outcome data in a text-only format, displaying a 30% chance of survival.
89680558|NCT04859114|Active Comparator|Text-only outcome data, 60% survival|Participants in this arm view a repeat of the outcome data in a text-only format, displaying a 60% chance of survival.
89680559|NCT04859114|Experimental|Static pictograph outcome data, 30% survival|Participants in this arm view a static pictograph displaying the outcome data and showing a 30% chance of survival.
88996469|NCT02918422|Experimental|Mod. Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 30% CHO, 20% PRO and 50% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
88996470|NCT02918422|Experimental|Low Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 10% CHO, 20% PRO and 70% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
88996471|NCT02918461|Experimental|Emerging from the Haze class|A 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2-2.5 hours for 6 weeks.
88996472|NCT02918383|Other|Indocyanin Green Dye (ICG)|Once the patient is in the operating room, the operative intervention will take proceed as current standard protocol dictates for the described procedure. No changes in operative technique will be undertaken apart from injection of the dye and visualization with the camera. After the articular surface of the distal femur or proximal tibia has been exposed, 2.5 mg of indocyanin green will be injected intravenously by anesthetist through a pre-existing IV line outside the sterile field. The operating surgeon will grade 6 locations on a standard scale of chondromalacia or cartilage damage.
88996473|NCT02918578|Experimental|"Phone group"|see intervention description
88996474|NCT02918578|Experimental|"Phone and SMS group"|see intervention description
88996475|NCT02918578|Active Comparator|"single writing group"|see intervention description
89680560|NCT04859114|Experimental|Static pictograph outcome data, 60% survival|Participants in this arm view a static pictograph displaying the outcome data and showing a 60% chance of survival.
89680561|NCT04859114|Experimental|Iterative pictograph outcome data, 30% survival|Participants in this arm view an iterative pictograph displaying the outcome data and showing a 30% chance of survival.
89680562|NCT04859114|Experimental|Iterative pictograph outcome data, 60% survival|Participants in this arm view an iterative pictograph displaying the outcome data and showing a 60% chance of survival.
88996476|NCT02918188|Experimental|Hydrogen|Patients will receive hydrogen-rich water (4mL/kg three times one day, 0.8 ppm)
88996477|NCT02918344||Standard sagittal split osteotomy group|Patients undergoing sagittal split osteotomy without paste application
88996478|NCT02918344||Cohort/Hydroset group|Patients undergoing sagittal split osteotomy with paste application
89680563|NCT04581863|Active Comparator|COVID Watch|COVID Watch provides text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately. This service is provided free of charge to patients, a benefit to patients without insurance or established primary care. UPHS already offers a version of COVID Watch with pulse oximetry to patients with COVID-19 being discharged from the ED who meet specific criteria: a discharge pulse ox less than 95%, an infiltrate on chest x-ray, are or age of 60 years or older, or who are deemed by the ED clinician to have significant comorbid conditions.
89680564|NCT04581863|Experimental|PCORI Pulse|This arm is COVID Watch + pulse oximeter device. Patients sent a pulse oximeter will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is >3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
89680565|NCT04349891|Experimental|TEA at ST36 and PC6 first and then sham TEA|Patients in this group will be treated with TEA at ST36 and PC6 for 4 weeks, followed with a 2-week washout period and another 4-week period with sham TEA.
89680566|NCT04349891|Experimental|Sham-TEA and then TEA ST36 and PC6|Patients in this group will be treated with sham-TEA for 4 weeks, followed with a 2-week washout period and another 4-week period with TEA at ST36 and PC6.
89680567|NCT02258451|Experimental|Radium-223 dichloride + exemestane/everolimus|Up to 6 cycles of radium-223 dichloride 50kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) (randomized). Participants will also receive exemestane, 25-mg tablet once daily (after a meal), and everolimus, 10 mg once daily (with or without food), and supportive care as per the local or institutional standard of practice.
89680568|NCT02258451|Placebo Comparator|Placebo + exemestane/everolimus|Up to 6 cycles of saline injection (placebo) (randomized). Participants will also receive exemestane, 25-mg tablet once daily (after a meal), and everolimus, 10 mg once daily (with or without food), and supportive care as per the local or institutional standard of practice.
88996479|NCT02918227|Experimental|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
88996480|NCT02918110|Experimental|Cytotec|orally administrated solution of misoprostol (Cytotec®)
88996481|NCT02918110|Experimental|Misodel|vaginal slow release misoprostol (Misodel®)
88996482|NCT02910544||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
88996483|NCT02910193||alcohol-dependent patients|
88996484|NCT02910193||first-degree relatives|Parents, children, siblings of alcohol-dependent patients
88996485|NCT02910193||healthy control subjects|
88996486|NCT02910310|No Intervention|Baseline period|The baseline period will involve data collection on study outcomes before uterine balloon tamponade (UBT) is introduced at study sites.
88996487|NCT02910310|Experimental|Uterine balloon tamponade|The UBT period will involve data collection on study outcomes after providers at sites are trained on UBT use and UBT is introduced into PPH management practice at study sites.
88996488|NCT02910154|Experimental|Weight loss, training, medication|"The intervention program consists of a comprehensive 24-week treatment period of: 1) Body weight loss without significant loss of muscle mass, through low energy diet combined with 2) Exercise training based on interval training and resistance exercise and 3) Optimal medical treatment for hypertension and hypercholesterolemia (with statin and ACE-inhibition). Further, participants in this allocation group receive nutrition counselling.~The diet products are sponsored by Cambridge Weight Plan. No persons with interest in Cambridge Weight Plan will take part in the intervention phase, analyzing phase, data processing, or publication of data in this study."
88996489|NCT02910154|No Intervention|Control|The control group receives 24 weeks of usual care according to guidelines of Danish Cardiology Society. Treatment of angina pectoris in absence of coronary artery disease is normally provided by the patient's general practitioner and does not comprise intensive lifestyle intervention or medical treatment. If control group participants in this study need medical therapy for hypertension or hypercholesterolemia, this will be effectuated by the researcher, MD. Then, control participants will be monitored with blood pressure and LDL blood samples and receive medicine adjustments according to National Prevention Guidelines during the full study period.
88996490|NCT02910076|Experimental|Healthy volunteers|
88996491|NCT02910076|Experimental|Diabetes patients|
88996492|NCT02910115|Other|Control Group|Following delivery of the fetus patients in the control group will have Pitocin® administered to them intravenously according to the usual protocol. The uterus may be wrapped lap sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. At the discretion of the attending obstetrician additional uterotonic medications (Pitocin®, Methergine® Cytotec® and/or Hemabate®) may be given to improve uterine contraction.
88996493|NCT02910115|Experimental|Study Group|"Following delivery of the fetus, patients in the study group also will have Pitocin® administered to them according to the usual protocol.~Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in cold laparotomy sponges saturated in sterile, iced normal saline. The skin of the abdomen will be draped to prevent contact with the cold towels. Additional uterotonic medications may be given at the discretion of the attending obstetrician."
88996494|NCT02910232||1|The groups were orthopedic patients and neurosurgical patients. The samples to fill the voiding space of bone and skull same as autografts.
89051198|NCT04313764|Active Comparator|Group Infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
89051199|NCT04602234|Experimental|LUS group|
88996495|NCT04688086||Women with no personal history of breast cancer|Women who came in for a breast mammography between ages 30 and 80 years were invited to take part in the study. All the women included in the study underwent breast cancer screening first by Thermalytix, the AI-based thermal imaging test, followed by mammography.
88996496|NCT02909803|Experimental|Lentil Variety|Each participant will consume a serving of one of eight lentil varieties (Greenland; Improve; Impower; Imigreen; Asterix; Redberry; Redcliff; Redbow) containing 25g available carbohydrate at separate study visits
88996497|NCT02909803|Active Comparator|White Bread|Each participant will consume a serving of white bread containing 25g available carbohydrate on two separate visits
88996498|NCT02909725|Experimental|Limit accumulation of sedentary time|Group 1 (SR): Participants will be asked to limit the accumulation of prolonged bouts ( >50 minutes) of sedentary time.
88996499|NCT02909725|Experimental|Walk 30 minutes most days of the week|Group 2 (WALK): Participants will be asked to walk 30 minutes per day on most days of the week.
88996500|NCT02909725|Active Comparator|Normal daily routine; Usual Care|Group 3 (UC): Participants will be asked to continue on with their normal daily routine. The usual care group will receive no form of intervention.
88996501|NCT02522260|Active Comparator|Group 1|Intervention Strength/aerobic exercise, weights, bike or treadmill
88996502|NCT02522260|Active Comparator|Group 2|Intervention Aerobic exercise, bike or treadmill
88996503|NCT02522260|Active Comparator|Group 3|Standard supportive care
88996504|NCT02909920|Experimental|Telerehabilitation|The Telerehabilitation group receives a standardized and customized exercises through a web application that allows the Physiotherapist generate videos, images and parameters of each exercise program and send them via email for each patient. Patients are initially supervised by a physiotherapist who will conduct videoconference sessions to ensure proper execution of exercises and encourage patient adherence.
88996505|NCT02909920|Active Comparator|Traditional Physiotherapy|Traditional Physiotherapy group receives assistance in a physiotherapy center through the usual procedure of rehabilitation in Spain consisting in personalized therapy 1 to 1 with a physical therapist and exercise programs for home.
88996506|NCT02909881|Experimental|Endurance trained male cyclists|8 male endurance trained male cyclist will consume varying amounts (0, 1, 1.5 and 2 g/min) of PhytoSpherix (sweet-corn derived sugar) during a 150 min . cycling exercise
88996507|NCT02909842|Experimental|study group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of yoghurt drink, unlabelled drinking fermented milk containing probiotic, Lactobacillus paracasei (IMULUS)
88996508|NCT02909842|Placebo Comparator|control group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of placebo, unlabelled acidified milk with similar physical and sensory appearance to the experimental one
88996509|NCT02909530|Active Comparator|First pass EZ Shot 3Plus then EZ Shot 2|Olympus EZ Shot 3Plus will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 3Plus first), then the 19G and EZ Shot 2 will be used to puncture the pancreatic mass.
88996510|NCT02909530|Active Comparator|First pass EZ Shot 2 then EZ Shot 3Plus|Olympus EZ Shot 2 will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 2 19G first), then the EZ Shot 3Plus will be used to puncture the pancreatic mass.
88996511|NCT02909608||Controls|
88996512|NCT02909608||Children With Pulmonary Hypertension|
89680569|NCT02168270|Experimental|Treatment (ascorbic acid, temozolomide)|Patients receive ascorbic acid IV over 90-120 minutes three times per week and temozolomide orally days 1-28. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89680570|NCT03676556|Active Comparator|Topical lidocaine|23 patients will recieve lidocaine solution before wound treatment
89680571|NCT03676556|Placebo Comparator|Saline serum|23 patients will recieve saline solution before wound treatment
89680572|NCT03520556||docosahexaenoic acid (DHA)|Adults supplemented with DHA in a randomized controlled trial of ≥7 days duration
89680573|NCT03520556||eicosapentaenoic acid (EPA)|Adults supplemented with EPA in a randomized controlled trial of ≥7 days duration
89680574|NCT03520556||control|Adults supplemented with control fatty acids in a randomized controlled trial of ≥7 days duration assessing the effects of EPA and/or DHA
89680575|NCT00686803|Experimental|PL3994 Dose A|PL3994 Dose A
89680576|NCT00686803|Experimental|PL3994 Dose B|PL3994 Dose B
89680577|NCT00686803|Experimental|PL3994 Dose C|PL3994 Dose C
88996513|NCT02909569|Experimental|INCB039110|INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
88996514|NCT02909491||Cases|Inpatient with severe behavioural disorders
88996515|NCT02909491||Controls|Inpatients without severe behavioural disorder and taking no antipsychotics
88996516|NCT02909413|Experimental|Group Desflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into Desﬂurane for maintenance. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
88996517|NCT02909413|Active Comparator|Group Sevoflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into sevoﬂurane for maintenance. The gas flow rate of Sevoflurane group is 2L/ min, include 50％O2 and 1.7-2.0% Sevoflurane.
88996518|NCT02909374|Experimental|Balance training|"The program includes exercise with dual- and multi task performance and is progressive as the exercises can be performed at different levels (basic, moderate, and advanced). The 12-week balance training program will be performed two times per week for one hour each. The training will be lead by physiotherapists or trained leaders. After the balance training the participants will get recommendations for continued physical activity and training, i.e. Physical activity on prescription."
89680578|NCT00686803|Experimental|PL3994 Dose D|PL3994 Dose D
89680579|NCT00686803|Experimental|PL3994 Dose E|PL3994 Dose E
88996519|NCT02909257|Experimental|same dose|patient is exposed to the same previously successful dose
89680580|NCT00686803|Placebo Comparator|Placebo|Placebo
89680581|NCT02144233|Experimental|Occlusal adjustment therapy|Occlusal adjustment therapy consists of the elimination of premature tooth contacts during retruded jaw closure, and the reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance). A resin-composite, placed mainly in the canine tooth, can be used to increases the flatter lateral guidance on the habitual chewing side; overcorrection is expected to compensate for a masticatory preference on the opposite side to the handedness.
89680582|NCT02144233|Placebo Comparator|Placebo occlusal adjustment therapy|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
89680583|NCT02997631|Experimental|MEDi Distraction|The intervention will be the use of the MEDi robot. The robot will be at the child's eye level, and will be programmed to introduce itself, interact with the child, and make encouraging comments about how brave he/she was. The duration of its actions will coincide with the length of the procedure (approximately 5-8 minutes).
89680584|NCT02997631|No Intervention|Standard Care|The control group will receive standard care, which generally includes the use of topical anesthetic cream. This comparison is based on the pragmatic preferences of physicians at the Stollery Children's Hospital as well as precedent in the literature. Overall, it is felt that any new intervention (e.g., the MEDi robot) should be compared to what is currently in practice (i.e., standard care), as no single distraction therapy is consistently and routinely employed in EDs at this time.
89680585|NCT02997787||adenomyosis|First group called adenomyosis was consisted of patients who were pathologically diagnosed pure adenomyosis after hysterectomy
89680586|NCT02997787||leiomyoma|Second group called leiomyoma was consisted of patients who were pathologically diagnosed pure leiomyoma after hysterectomy
89680587|NCT02997787||control|Third group called control group was consisted of healthy patients who were pathologically diagnosed no neoplasm after hysterectomy
89680588|NCT00690235|Other|Placebo|Patients will be given the Placebo for injection twice daily
89680589|NCT00690235|Other|Pramlintide|volunteers are given 180mg of pramlintide, twice daily
89680590|NCT04387279||Inflammatory bowel disease|Patients with inflammatory bowel disease who live in COVID-19 hyperemic area
89680591|NCT00092833|Experimental|1|Ezetimibe
89680592|NCT01799083|Experimental|Decitabine|A continuous 5-day treatment of lower dose decitabine within 4-6 weeks is regarded as a treatment cycle, transfusion of auto-CIK cells or chemotherapy regimen may be used for patients.
89680593|NCT01795573|Other|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg cells given prior to allogeneic stem cell transplant
89680594|NCT01799161|Active Comparator|DS-1|6 week course of gp96 Vaccine: >= 4 x 10^7 cells twice monthly on Day 1. Up to 3 courses, 9 vaccinations.
89680595|NCT01799161|Active Comparator|DS-2|6 week course of gp96 Vaccine: >= 2 x 10^7 cells weekly on Day 1. Up to 3 courses, 18 vaccinations.
89680596|NCT01799161|Active Comparator|DS-3|6 week course of gp96 Vaccine: >= 1 x 10^7 cells twice weekly on Days 1 and 4. Up to 3 courses, 36 vaccinations.
89680597|NCT02997319||Night Shift-Workers|
89680598|NCT02997319||Day Workers|
89680599|NCT02997397||tourniquet (+)|The cases in which the tourniquet technique is used
89680600|NCT02997397||tourniquet(-)|The cases in which the tourniquet technique is not used
89680601|NCT02997007|Experimental|MCI-active|Patients will receive verum tDCS over the angular gyrus on five consecutive days.
89680602|NCT02997007|Sham Comparator|MCI-sham|Patients will receive sham tDCS over the angular gyrus on five consecutive days.
89680603|NCT02997007|Experimental|Healthy Old-active|Participants will receive verum tDCS over the angular gyrus on five consecutive days.
89680604|NCT02997007|Sham Comparator|Healthy old-sham|Participants will receive sham tDCS over the angular gyrus on five consecutive days.
89680605|NCT00006110|Experimental|Neo-adjuvant Herceptin with or without radiation|Chemotherapy followed by Taxol plus Herceptin followed by surgery followed by radiation (or no radiation) followed by additional Herceptin
89051200|NCT04602234|No Intervention|No LUS group|
89051201|NCT04313569|No Intervention|Conservative treatment|Use of medications, like analgesic, muscle relaxants, non-steroidal anti-inflammatory drugs (NSAID) and local painkillers, depending on the patient condition, and physiotherapy, lifestyle and daily activity modification, patient education about positioning of the knee
89051202|NCT04313569|Other|Arthroscopic menisctomy|
89051203|NCT00624793|Experimental|I. Standard|Standard - Formula Acup Protocol
89051204|NCT00624793|Experimental|2. Individualized|Individualized Acup protocol based on TCM diagnosis
89051205|NCT00624793|Sham Comparator|3|(Control Group) Sham acupuncture
89051206|NCT04626089|Experimental|Metformin glycinate|620 mg bid (PO) plus standard treatment for 14 days
89051207|NCT04626089|Placebo Comparator|Placebo|Placebo tablets bid (PO) plus standard treatment for 14 days
89051208|NCT04626323|Experimental|RYGB (intervention arm)|Thirty (30) obese patients with DKD will undergo gastric bypass. Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA. The surgical procedure will consist of a laparoscopic surgery performed by an experienced surgeon (approximately 6000 bariatric surgeries), who is accredited as surgeon of excellence by the Brazilian Society of Bariatric and Metabolic Surgery and Surgical Review and Surgical Review Corporation program since 2009.
89051209|NCT04626323|Active Comparator|BMT (control arm).|Thirty (30) obese patients with DKD will undergo best medical treatment for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary). Other comorbidities, such as hypertension and dyslipidemia, will be treated according to the latest recommendations of the ADA.
89051210|NCT04602039|Experimental|People without Diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
89051211|NCT04602039|Experimental|Participants with Pre-diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
89680606|NCT00006110|Experimental|Non-Herceptin with or without radiation|Chemotherapy followed by Taxol followed by surgery followed by radiation (or no radiation)
89680607|NCT00691327|Experimental|1|Primary reconstruction
89680608|NCT00691327|Experimental|2|Revision-reconstruction
89680609|NCT00691327|Experimental|3|Revision-augmentation
89680610|NCT04403438||patients with behçet's or fmf|
89680611|NCT02997241|Other|high genetic risk and high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
89680612|NCT02997241|Active Comparator|low genetic risk but high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method，randomized design，and chemotherapy for colorectal carcinoma
89680613|NCT02997241|Active Comparator|high genetic risk but low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
89680614|NCT02997241|Other|low genetic risk and low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
89680615|NCT04403750|Experimental|Combined laser-surgical technology|"Combined laser-surgical technology includes 3 steps:~Nd-YAG laser excision of the vitreoretinal traction zone~Pneumatic retinopexy (10% C3F8)~Barrier laser photocoagulation around retinal break after retinal attachment."
89680616|NCT00692185|Experimental|1|Participants will take olanzapine.
89680617|NCT00692185|Placebo Comparator|2|Participants will take matched placebo.
89680618|NCT04348526|Experimental|Corticision|Patients will undergo a corticision procedure in order to accelerate tooth movement
89680619|NCT04348526|Active Comparator|Traditional treatment|Patients will undergo traditional orthodontic treatment without any surgical intervention.
89680620|NCT04270279|Experimental|Xueshuanxinmaining Tablet|"Patients were given Xueshuanxinmaining tablet orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
89680621|NCT04270279|Placebo Comparator|Placebo|"Patients were given Xueshuanxinmaining tablet simulation orally 2 pills each time, 3 times daily for 8 weeks. And patients can take nitroglycerin tablets provided by the sponsor when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
89680622|NCT03515096|Experimental|Eltrombopag|Thrombopoietin- receptor (TPO-R) agonist
89680623|NCT03515096|Placebo Comparator|rhTPO|Recombinant human thrombopoietin (rhTPO)
89680624|NCT00692341|Experimental|Hepatic Function - Mild Impairment|Subjects with mild hepatic impairment (Child Pugh class A, score 5-6)
89680625|NCT00692341|Experimental|Hepatic Function - Moderate Impairment|Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9)
89680626|NCT00692341|Experimental|Hepatic Function - Normal|"Group 1~1) subjects with normal hepatic function"
89680627|NCT03674840|Other|control group|Subjects in this group will go through a cataract surgery with SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
89680628|NCT03674840|Experimental|design group|Subjects in this group will go through a cataract surgery with SBL-3 implantation based on kappa angle(described by Pentacam HR preoperatively) guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
89680629|NCT04762550||Patients undergoing Liver Transplantation|This is a prospective observational study that intends to offer participation to all patients undergoing liver transplantation at Toronto General Hospital. Parameters that will be measured include Thrombin generation, viscoelastic testing utilizing ROTEM, and conventional laboratory testing (INR, aPTT and Fibrinogen level) at five time points: (a) Prior to cross-clamp application; (b) within the first 30 minutes of venous cross clamp removal; (c) after 30 minutes of reperfusion; (d) On arrival in the intensive care unit (ICU) or post-anesthesia recovery unit; and (5) 12 hours post-operatively.
89680630|NCT00524537||Adalimumab (Humira) Treatment|Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.
89680631|NCT03514394|Active Comparator|Usual Care|Usual care administered for depression at clinic.
89680632|NCT03514394|Experimental|Modified Behavioral Activation (Task Sharing)|This intervention will be a modification of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. Specifically, we will introduce a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA. These modifications will be based on clinician and care manager feedback from Phases 1 and 2 of this study.
89680633|NCT00589849||1|
89680634|NCT00525629|Experimental|Walnut Diet|48 Grams of Walnuts Daily
88996520|NCT02909257|Experimental|lower dose|patient is exposed to a lower concentration dose
89680635|NCT00525629|Placebo Comparator|Control Diet|Isocaloric Diet with No Walnuts
89680636|NCT00692419|Experimental|Symptom management nurse intervention|This arm of the study will have a symptom management nurse facilitate the management of pain, sexual dysfunction and depression. The nurse will work with the patient's renal provider to implement appropriate symptom alleviating treatment. The intervention is patient specific and entirely dependent on the treatment recommendation made by the symptom management nurse.
89680637|NCT00692419|Active Comparator|Feedback intervention|This arm of the study will have pain, sexual dysfunction and depression assessed monthly with feedback given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider. The intervention on symptoms is at the discretion of the renal provider. The interventions implemented were patient specific and consisted of therapies the patient's renal provider decided to implement.
89680638|NCT04763018|Active Comparator|Treatment|This arm will receive a function iTEAR
89680639|NCT04763018|Sham Comparator|Sham|This arm will receive sham treatment device
89680640|NCT05559827|Experimental|Isatuximab arm|Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes <10 G / L, and a third at day 29 if reticulocytes <10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
89680641|NCT05559827|No Intervention|comparator arm|No treatment, supportive care will be allowed.
89680642|NCT02122445|Experimental|Low Back Pain|Lower body exercises before and after the application of Cramer Sports Motion tape
89680643|NCT00694603|Experimental|Cetuximab|400mg/m2 IV x 1 and then 250mg/m2 IV weekly
89680644|NCT05559281|Experimental|Group A|
89680645|NCT05559281|Active Comparator|Group B|
88996521|NCT02909218|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
88996522|NCT02909218|Experimental|Early Access to ART for All|HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging
88996523|NCT02908945|Experimental|Group 1|Participants randomized to group 1 will receive a 0.5 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 10 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
88996524|NCT02908945|Experimental|Group 2|Participants randomized to group 2 will receive a 0.25 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
88996525|NCT02908945|Other|Group 3|Participants randomized to the control group will receive an equivalent anesthetic, without the addition of ketamine. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
88996526|NCT04688008|Other|Treatment sequence #1|29 of 58 subjects were given single oral dose of early phase hetrombopag olamine formulation in period 1 and late phase formulation in period 2
88996527|NCT04688008|Other|Treatment sequence #2|29 of 58 subjects were given single oral dose of late phase hetrombopag olamine formulation in period 1 and early phase formulation in period 2
88996528|NCT02939833|Experimental|ropivacaine|patients in this group will receive scalp nerve blocks with 0.5% ropivacaine after anesthesia induction and before skull-pin insertion
88996529|NCT02939833|Placebo Comparator|saline|patients in this group will receive scalp nerve blocks with 0.9% saline after anesthesia induction and before skull-pin insertion
88996530|NCT02939677|Other|Targeted exercise|Targeted exercise intervention
88996531|NCT02939677|No Intervention|care as usual|home based exercises
88996532|NCT02939794|Active Comparator|ferinject|-Patients will receive 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
88996533|NCT02939794|Placebo Comparator|placebo|Patients will receive a placebo drug intravenous approximately 24 hours before surgery
88996534|NCT03458104|Experimental|Vocal Cord Atrophy|Quantify changes in aerodynamic and aeroacoustics patterns in patients with vocal cord atrophy (VCA) before and after voice therapy. To evaluate changes, subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx before and after voice therapy.
88996535|NCT03458104|Active Comparator|Healthy Volunteer|Develop a validated computational model for assessing normative laryngeal aerodynamic and aeroacoustic patterns in healthy elderly individuals. To assess normal laryngeal aerodynamic and aeroacoustic patterns in this cohort, subjects will subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx.
88996536|NCT04853173|Experimental|ambulatory protocol after adult tonsillectomy|prescription of analgesics for outpatient procedure with hospital surveillance
88996537|NCT00155402|Experimental|1|Use of fibrin glue after corneal surgery or transplantation
88996538|NCT04838587||6750 Children <3 years ( 5 sites)|A total of 6750 children from the will be identified from the respective health facility catchment area during the Census stage of the study. Each of the 5 health facilities will identify 1350 children under 3 years of age in their respective catchment area. During the Surveillance stage, the participants will be enrolled into the study if and when they present with diarrhoea at the Health facility.
88996539|NCT04833400|Experimental|Intelligent cardiopulmonary rehabilitation system (ICRS)|The ICRS is very likely to the conventional stationary biking, but with an algorithm that automatically controls the resistance of pedalling, considering the instant heart rate and cadence, to keep the heart rate within the targeted heart rate zone.
88996540|NCT04833400|Active Comparator|Traditional aerobic exercise training (TAET)|"The TAET is performed with stationary biking, with intensity being set as subjective rating of perceived exertion at a somewhat hard to hard level. The resistance of pedaling is ad-justed by the user or physical therapist."
88996541|NCT00533299|Experimental|1|Topotecan hydralazine valproate
88996542|NCT00533299|Placebo Comparator|2|Placebo, hydralazine, valproate
88996543|NCT04785391||Patients with KDIGO stage 2 or 3 AKI|
88996544|NCT00181584|Active Comparator|Group 1|
88996545|NCT00181584|Placebo Comparator|Group 2|
88996546|NCT04769440|Active Comparator|M group (Mg sulphate )|patients will receive 30mg/kg LBW of 10%mgso4 in 100 ml normal saline intravenously over 30 minutes as a loading dose ,followed by 10 mg /kg LBW for 90 minutes
89680646|NCT00590005||Children with severe asthma|This group consists of children with severe asthma as defined per ATS workshop criteria (published in 2000).
89680647|NCT00590005||Children with non-severe asthma|This group includes children with asthma who do not meet the ATS criteria for severe asthma as outlined in the 2000 workshop report.
89680648|NCT03509792|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
89680649|NCT03509792|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
89680650|NCT05559203|Experimental|Intervention group|Digital music and movement resources.
89680651|NCT00590161|Experimental|1|Pentoxifylline (PTX) 400 mg by mouth (PO) three times daily (TID)
89680652|NCT00590161|Placebo Comparator|2|Placebo three times daily (TID)
89215929|NCT05658718||non-glare group|The patients did not complain of glare and the Binoptometer examination showed good visual quality in a dark environment, and they were classified as the non-glare group.
89215930|NCT05650775|Active Comparator|Methylphenidate Trial|3-week methylphenidate trial with weekly dose adjustments.
89215931|NCT05650775|Active Comparator|Mixed Amphetamine Salts Trial|3-week trial of mixed amphetamine salts with weekly dose adjustments.
89215932|NCT05646030|Other|Subjects with known elevated serum CEA|"Before the start of sample collection questionnaire A on paper will be filled in by all study subjects. The order of sample collection will be: automated capillary sampling, lancet capillary sampling and venipuncture. Herein automated and lancet capillary sampling will be performed by the study subjects themselves whereas the venipuncture will be performed by the study personnel. After all sampling has been completed, the subject is asked to complete questionnaire B which will evaluate pain, burden, ease of use and preference.~For subjects in arm A and C this entails the end of the study"
89680653|NCT03672110|Active Comparator|Standard tacrolimus group|Control group: Advagraf will be administered as usual (0.2mg/kg bodyweight), trough levels will be measured every day in the first week after kidney transplantation (TX) and Advagraf dose will be adjusted accordingly.
89680654|NCT03672110|Experimental|Fixed dose tacrolimus group|Study group: Advagraf will be administered per fix dose 5mg/day, trough levels will be blinded during the first week, there will be no adjustments in the first week after TX.
89680655|NCT04825067|Experimental|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
89680656|NCT00590395|Experimental|FDG-PET/CT to determine Cholecystitis|19 patients with suspected acute cholecystitis and a positive HIDA will be included in the study. This is purposely a highly selective population which most likely will have surgical proof of the findings. Subjects will receive an FDG PET/CT exam to determine the presence of gallbladder inflammation/infection(cholecystitis). Please note that 18FDG is an FDA approved radiopharmaceutical.
89680657|NCT00006170|Experimental|Bupropion and Weight Concerns intervention|Bupropion SR and a weight concerns psychosocial intervention
89680658|NCT00006170|Active Comparator|Placebo and Weight Concerns|A matched placebo administered on same schedule as bupriopion and a weight concerns psychosocial intervention for smoking cesstion
89680659|NCT00006170|Active Comparator|Bupropion and standard smoking cessation|Bupropion SR and a time and attention controlled smoking cessation intervention
89680660|NCT00006170|Placebo Comparator|Placebo and standard smoking cessation|A matched placebo administered on same schedule as bupriopion and a time and attention controlled smoking cessation intervention
89680661|NCT02996539||Type 2 diabetes|With Clinical examination and laboratory measurements
89680662|NCT02123849|Experimental|Arm I (continuous aspirin)|Participants receive aspirin PO QD for 12 weeks.
89680663|NCT02123849|Experimental|Arm II (intermittent aspirin)|Participants receive placebo PO QD during weeks 1, 3, 5, 7, 9, and 11 and aspirin PO QD during weeks 2, 4, 6, 8, 10, and 12.
89680664|NCT01798303|Experimental|LY2940094|40 mg LY2940094 oral tablet, QD for 8 weeks
89215933|NCT05646030|Other|Subjects currently undergoing colorectal cancer related follow-up|The subjects of arm B are requested to perform automated capillary and lancet capillary sampling at home following their next two outpatient visits. During these outpatient visits, a reference value blood CEA measurement will be obtained using venipuncture by the personnel of the clinical laboratory of Erasmus MC. The required materials will be sent to the home address of the patient. Sampling will be performed at home and by the subjects themselves. Subjects will have access to the tutorial videos for automated and lancet capillary sampling.
89215934|NCT05646030|Other|Volunteers|"Before the start of sample collection questionnaire A on paper will be filled in by all study subjects. The order of sample collection will be: automated capillary sampling, lancet capillary sampling and venipuncture. Herein automated and lancet capillary sampling will be performed by the study subjects themselves whereas the venipuncture will be performed by the study personnel. After all sampling has been completed, the subject is asked to complete questionnaire B which will evaluate pain, burden, ease of use and preference.~For subjects in arm A and C this entails the end of the study"
89680665|NCT01798303|Placebo Comparator|Placebo|Identically matched placebo oral tablet, QD for 8 weeks
89680666|NCT05347160|Experimental|calcium hydroxide : group 1|Immature permanent molars with immature root filled by ca(oh)2
89680667|NCT05347160|Experimental|biodentine : group 2|clinically and radiographically evaluate BIODENTINE effect on permanent molars with immature root
89680668|NCT05347160|Experimental|platelet rich fibrin : group 3|filling of permanent molars with immature root by platelet rich fibrin
89680669|NCT03505112|Experimental|Goal-directed therapy group|The patients in goal-directed therapy (GDT) group will be managed according to the goal-directed therapy protocol during the surgery.
89680670|NCT03505112|No Intervention|Control group|The patients in control group will be managed according to standard perioperative care.
89680671|NCT05558969|Active Comparator|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia
89680672|NCT05558969|Placebo Comparator|control group|Pregnant will be operated under general anesthesia
89680673|NCT00590707|Active Comparator|Deeper sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 0. This is the deeper sedation arm."
89680674|NCT00590707|Active Comparator|Moderate sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 4-5. This is the moderate sedation arm."
89051212|NCT04602039|Experimental|Participants with Type 2 diabetes|A 4 week supply of a commercial dairy colostrum supplement (Neovite™) given to each participant.
89051213|NCT04601688|Experimental|BRVO: Bevacizumab and intravitreal Dexamethasone|Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
89051214|NCT04601688|Active Comparator|BRVO: Bevacizumab|Participants with BRVO will receive Bevacizumab only.
89051215|NCT04626206||Imaging to asess treatment response post-SRS|"There will be only one group. All recruited patients will have 3 scans, the multi-parametric MRI, contrast-clearance analysis MRI (TRAMs) and 18F-choline-PET/CT.~This is a non interventional study. Only the results of the contrast-clearance analysis MRI (TRAMs) will be used to make clinical decisions (as this is the current standard of care at the recruiting site). The multi-parametric MRI and 18F-choline PET/CT will be treated as research scans."
89051216|NCT04626011|Active Comparator|Group One|Participants receiving full mouth disinfection and extractions in one stage.
89051217|NCT04626011|Active Comparator|Group Two|Participants receiving full mouth disinfection at stage one and extractions at stage two after 7 days.
89051218|NCT04601766|Experimental|Group A|
89051219|NCT04601766|Experimental|Group B|
89051220|NCT04625816|Experimental|Arthroscopic shoulder surgery patients|
89051221|NCT01154452|Experimental|Arm I (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
89051222|NCT01154452|Experimental|Arm II (vismodegib and gamma-secretase inhibitor RO4929097)|Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
89051223|NCT04625894|Experimental|Treatment Arm|Patients with oligometastatic gastrointestinal cancer will receive multisite SABR, followed by Camrelizumab within one week from completion of radiation. Camrelizumab for injection at 200 mg, d1, q2w, 14-day cycle will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
89051224|NCT01154296|Experimental|Rapid HIV Testing w/ Counseling (Group 1)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.
89051225|NCT01154296|No Intervention|Rapid HIV Testing & Information Only (Group 2)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.
89051226|NCT04601025|Experimental|Yoghurt|
89051227|NCT04601025|Experimental|Chickpea+Yoghurt|
89051228|NCT04601025|Experimental|Oat+Yoghurt|
89051229|NCT04625855|Experimental|TBPM-PI-HBr|Healthy subjects meeting eligibility criteria will receive a single dose of 600mg of TBPM-PI-HBr
89051230|NCT04311541||Dexlansoprazole|Participants diagnosed with GERD and initiated treatment with dexlansoprazole MR therapy will be observed prospectively at 150 sites in Russian federation for a period of 2 months.
89051231|NCT04313452|Placebo Comparator|regular diet|50% of energy from carbohydrates, 30% fat and 20% from protein
89051232|NCT04313452|Active Comparator|Mediterranean diet|60% of energy from carbohydrates, 25% fat and 15% from protein
89051233|NCT04313686|Experimental|Mindfulness-based therapy|The mindfulness training program included mindfulness meditation practices, self-enquiries, mindful movement as well as understanding of stress physiology and cognitive awareness in the Breathworks/ Paradigm system of mindfulness-based approaches. Participants were enrolled in 5-10-person groups that met weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
89680675|NCT05557019|Experimental|Booster Balloon Therapy|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
89680676|NCT04387357||Control|Neurologically healthy older adults above the age of 50
89680677|NCT04387357||Experimental|Older adults above the age of 50 with Mild Cognitive Impairment or Dementia
89680678|NCT05549141|Experimental|Group A 1|Treadmill gait training using an electrical stimulator, as first intervention.
89680679|NCT05549141|Active Comparator|Group B1|Treadmill gait training without the use of an electrical stimulator, as second intervention.
89680680|NCT05549141|Active Comparator|Group A2|Treadmill gait training without the use of an electrical stimulator, as first intervention.
89051234|NCT04313686|Active Comparator|No-Intervention|The control group would attend their routine follow-up visits at the neurology outpatient clinic.
89051235|NCT04600986|Experimental|New oocyte triggering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl) and in addition a repeat dose of 0.1 mg s.c triptorelin (decapeptyl) will prescribed 12 h following the first dose.
89051236|NCT04600986|Other|Routine oocyte trigering|The final oocyte maturation will be triggered with a single dose of 0.2 mg s.c triptorelin (decapeptyl), 35 h prior to oocyte retrieval.
89051237|NCT01154218|Experimental|1|"All subjects will receive four treatments in one of the indicated orders:~A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A"
89051238|NCT04601142||glucocorticoid sensitive (GS) group|
89051239|NCT04601142||glucocorticoid resistance (GR) group|
89051240|NCT04625582|Experimental|Face-to-face intervention|90 trainees at Vigo Family Medicine and Community Nursing Training Unit
89051241|NCT04625582|Experimental|Online intervention|70 trainees at Aragón Family Medicine and Community Nursing Training Unit
89051242|NCT04625582|No Intervention|Usual training|180 trainees at Balearic Islands Family Medicine and Community Nursing Training Unit
89051243|NCT00565305|Experimental|Healing Touch|Healing Touch + Standard Treatment Healing Touch treatments daily following standard Radiation Therapy. Standard radiation therapy is part of their medical care and is not administered as part of this study. Protocol of 4 HT techniques will be used including Pain Drain, Chakra connection, Magnetic Unruffling, and Mind Clearing. Treatments will be approximately 20-30 minutes.
89051244|NCT00565305|Active Comparator|Usual Care|Standard Treatment. These patients receive usual medical care but no additional intervention. Standard treatment is not administered as part of this study but as part of their medical treatment.
89051245|NCT04625348|Experimental|residents|daily care of 40 residents will be provided on the Ultracore Repose® mattress
89051246|NCT04625543|Experimental|intervention group|Neoadjuvant immunotherapy (PD-1) plus concurrent chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
89051247|NCT04625543|Active Comparator|controll group|Neoadjuvant chemotherapy (paclitaxel + Cisplatin) will be applied to patients with locally advanced esophageal squamous cell carcinoma with PD-L1>=10% before surgery.
89051248|NCT04601259|Experimental|Orkla corn plaster with Salicylic acid|
89051249|NCT04601259|Active Comparator|Orkla corn protector without salicylic acid|
89051250|NCT04625309|Experimental|Sport|This group will be made up of subjects with a spinal cord injury that are actively participating in adaptive sports teams.
89051251|NCT04625309|No Intervention|No sport|This group will be made up of subjects with a spinal cord injury that are not actively participating in any sports team.
89051252|NCT00565383|Active Comparator|Intravenous fentanyl analgesia|Intravenous fentanyl (50 mcg) analgesia
89051253|NCT00565383|Experimental|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia (intrathecal fentanyl 2.5 mg plus bupivacaine 2.5 mg) single administration
89051254|NCT04625387|Experimental|Dry Needle plus exercise|Group A received Dry Needling along with exercise having 25 individuals. Treatment lasted four weeks duration, twice a week.
89051255|NCT04625387|Experimental|Dry Needling alone|Group B received Dry Needling alone having 25 individuals. Treatment lasted four weeks duration, twice a week.
89051256|NCT04625426|Experimental|3M No-Rinse Cleanser and 3M Cavilon Advanced Skin Protectant|"Skin cleanser: 3M No-Rinse Cleanser. Skin protectant: 3M Cavilon Advanced Skin Protectant (liquid acrylic tetrapolymer skin protectant layer).~The skin cleanser was used during every episode of incontinence and the protectant was applied every three days as recommended by the manufacturer."
89051257|NCT04625426|Experimental|Conveen EasiCleanse and Conveen Critic Barrier|Skin cleanser: Conveen EasiCleanse. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin cleanser was also first used to cleanse the skin, followed by application of the barrier cream, as per the barrier cream manufacturer's instructions.
89051258|NCT04625426|Active Comparator|Soap and water / Incontinence wipes and Conveen Critic Barrier|Skin cleanser: Ordinary soap and water or incontinence wipes. Skin protectant: Conveen Critic Barrier (zinc oxide-based barrier cream). After each episode of incontinence, the skin was cleansed using soap and water or incontinence wipes, followed by application of the barrier cream.
89051259|NCT04625075||Healthy Volunteer|Age and sex matched healthy volunteer
89215935|NCT05631132|Experimental|BAL + NIV|Qualification for a specific type of ventilation (NIV or CPAP) will be carried out in a randomized manner by a specially created online platform. The procedure will be performed subsequently in the same segment of the opposite lung. Once the test is finished, the volume of BAL fluid that has been recovered will be measured.
89680681|NCT05549141|Experimental|Group B2|Treadmill gait training using an electrical stimulator, as second intervention.
89680682|NCT00671528|Experimental|QUADRIDERME® cream|QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
89680683|NCT00671528|Active Comparator|Betamethasone and Gentamicin|Combination of betamethasone diproprionate cream and gentamicin sulfate cream
89680684|NCT00671528|Active Comparator|Betamethasone|Betamethasone diproprionate cream
89680685|NCT05347706|Experimental|AAF-fed group|Amino Acid-Based Formula(NeocateⓇ; Nutricia, London, UK)
89680686|NCT05347706|Experimental|EHF-fed group|Extensively Hydrolyzed Formula(AlfareⓇ; Nestle, Netherlands)
89215936|NCT05631132|Experimental|BAL + CPAP|Qualification for a specific type of ventilation (NIV or CPAP) will be carried out in a randomized manner by a specially created online platform. The procedure will be performed subsequently in the same segment of the opposite lung. Once the test is finished, the volume of BAL fluid that has been recovered will be measured.
89215937|NCT05630222|Active Comparator|Ibuprofen|Ibuprofen 800 mg IV infusion over 20 min.
89215938|NCT05630222|Active Comparator|Morphine|Morphine Sulfate 0.1 mg/kg IV
89215939|NCT05630222|Active Comparator|Ibuprofen plus Acetaminophen|Ibuprofen 400 mg plus Acetaminophen 1000 mg IV infusion over 20 min.
89215940|NCT05618730|Experimental|EXP-TC punctal plug together with artificial tears|EXP-TC: A punctal plug as a delivery system for Tacrolimus. EXP-TC has 3 different sizes (Small, Medium and Big for Wide EXP-TC)
89215941|NCT05618730|Active Comparator|Artificial tears|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories)
89215942|NCT05607160||Cohort 1|Type 2 diabetes patients >= 75 years
89215943|NCT05605249|Experimental|Cue X|"All participants will train with Cue X gamified AR gait-and-balance-exercises in their home environment for 6 weeks. Participants are invited to use Cue X minimally 5 times a week for 30 minutes total, but preferably on a daily basis. The exact exercises, exercise duration and difficulty level will be prescribed by a movement expert and will be evaluated and adjusted every week in telephone calls or during one of the laboratory assessment.~Half of the participants will train with HoloLens 2 and the other half with Magic Leap 2."
89215944|NCT05603494|Experimental|home spirometry group|
89215945|NCT05598619|Experimental|Low dose|Daily dose of 80 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
89215946|NCT05598619|Experimental|Mid dose|Daily dose of 200 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
89215947|NCT05598619|Experimental|High dose|Daily dose of 500 mg Vitamin C (Ascorbic acid) once a day for 12 weeks
89215948|NCT05598619|Placebo Comparator|Placebo|One capsule of 570 mg (consisting microcrystalline cellulose) once a day for 12 weeks
89215949|NCT05597891|Experimental|Investigational Device|The study design includes two cohorts: a Pre-Pivotal Cohort of up to 50 subjects (25 Feasibility and up to 25 Roll-Ins), and a Pivotal Cohort enrolling up to 131 subjects, to yield 100 evaluable subjects at 48 hours post procedure.
89215950|NCT05595317|Experimental|Study group|Traditional physiotherapy + A non-immersive virtual reality game will be played to provide treatment for lower limbs.
89215951|NCT05595317|Sham Comparator|Sham-controlled group|Traditional physiotherapy + A sham non-immersive virtual reality game will be played but not provides treatment for lower limbs.
89215952|NCT05590767||shoulder rotators repair|Patients scheduled to undergo shoulder rotators repair surgery
89215953|NCT05588752|No Intervention|group 1|will receive at induction of spinal anesthesia 100 µg of morphine
89680687|NCT01798121|Experimental|Aplisol|To compare new PPD to reference standard material
89680688|NCT01798121|Placebo Comparator|Reference standard|Response of standard material
89680689|NCT00590863|Active Comparator|SSRI + placebo|Participants will take escitalopram plus placebo.
89680690|NCT00590863|Active Comparator|Escitalopram + Bupropion SR|Participants will take escitalopram + bupropion-SR.
89680691|NCT00590863|Active Comparator|Venlafaxine XR + Mirtazapine|Participants will take venlafaxine-XR + mirtazapine.
89680692|NCT00591019|Active Comparator|modafinil|
89680693|NCT00591019|Placebo Comparator|Placebo|
89680694|NCT02128919|Experimental|Active tDCS|tDCS 2 ma for 20 minutes with anode at DLPFC once a day for 5 days
89680695|NCT02128919|Sham Comparator|Sham tDCS|tDCS 2 ma for 40 seconds with anode at DLPFC for 5 days
89215954|NCT05588752|Experimental|group 2|No morphine in spinal anesthesia but will receive a bilateral TAP block with 20 ml of Bupivacaine 0.25% and dexamethasone 4 mg in the same syringe on each side
89215955|NCT05580939|No Intervention|Control Grup|they receive theoretical first aid training
89215956|NCT05580939|Experimental|Intervention Grup|they receive theoretical first aid training and use web based simulation application
89680696|NCT02996695|Experimental|204,800 PfSPZ of PfSPZ Challenge|204,800 PfSPZ of PfSPZ Challenge every 4 weeks x 3 doses by DVI, n=31
89215957|NCT05579899|Experimental|EVO101 Cream|Active Treatment, BID, 8 weeks
89215958|NCT05579899|Placebo Comparator|Vehicle Cream|Vehicle Treatment, BID, 8 weeks
89215959|NCT05576012|Experimental|SOL-116 single dose (Parts 1 and 2); multiple dose (Part 3) (SC administration)|
89215960|NCT05576012|Placebo Comparator|Placebo single dose (Parts 1 and 2); multiple dose (Part 3) (SC administration)|
89215961|NCT05565768|Experimental|HZN-457|
89215962|NCT05565768|Placebo Comparator|Placebo|
89215963|NCT05564806|Experimental|Intervention/treatment|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
89680697|NCT02996695|Placebo Comparator|NaCl placebo|NaCl placebo every 4 weeks x 3 doses by DVI, n=31
89680698|NCT00359138|Experimental|Desloratadine 5 mg tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
89680699|NCT00359138|Active Comparator|Desloratadine placebo tablet + Levocetirizine 5 mg capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
89680700|NCT00359138|Placebo Comparator|Desloratadine placebo tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
89680701|NCT00003404|Experimental|Adjuvant Radiotherapy|Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.
89680702|NCT00697801|Experimental|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
89680703|NCT00697801|Experimental|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
89680704|NCT00697801|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
89680705|NCT05503979||Substances Users|Substances users confirmed with Viral Load for HCV. after that will be evaluated through laboratory studies (CBC and blood chemistry), HIV/HBV (Hepatitis B Virus) serology, fibrosis status will be evaluated through APRI (AST to Platelet Ratio Index) and FIB-4. The antiviral treatment (sofosbuvir/Velpatasvir) will be chosen according to the characteristics of each patient and follow-up will be maintained according to the national plan with a visit at the end of treatment and 12 weeks after its end to assess SVR. The importance of this project is characterized by minimal monitoring, patients and doctors education by telementoring, multidisciplinary teams and integral treatment.
89680706|NCT02996461|Experimental|Group 1|ZIKV DNA vaccine administered IM via needle and syringe at a single dosage of 4 mg on Day 0, week 4 and week 8.
89680707|NCT02996461|Experimental|Group 2|ZIKV DNA vaccine administered IM via needle and syringe as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
89680708|NCT02996461|Experimental|Group 3|ZIKV DNA vaccine administered IM via needle-free injection device, PharmaJet, as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
88996547|NCT04769440|No Intervention|C group (control )|patients will receive 100 ml of normal saline intravenously over 30 minutes followed by saline infusion for 90 minutes
88996548|NCT04762693||Cough monitoring|All enrolled participants will be asked to install the acoustic surveillance software in their smartphones and use it to record night-time coughs for a minimum 30-day period.
88996549|NCT00533338|Experimental|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling. Packet of questionnaires will be completed.
88996550|NCT00533338|Active Comparator|Standard Care Group|Packet of questionnaires will be completed.
88996551|NCT04678141|Other|Composite and compomer materials|Children aged 5-6 years with at least two carious proximal surface primary molars
88996552|NCT00155558|Experimental|A|
88996553|NCT00533494|Active Comparator|B|Feedback to physicians + reminder letters to patients
88996554|NCT00533494|Active Comparator|A|Feedback information to physicians
88996555|NCT04658914|No Intervention|rotarix only|Rotarix will be administered at 6 and 10 weeks of age following the national Expanded Program for Immunization (EPI) schedule. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
88996556|NCT04658914|Experimental|P2 VP8 only|Parenteral P2-VP8 subunit vaccine will be administered at 6, 10 and 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
88996557|NCT04658914|Experimental|Rotarix + 1 dose P2-VP8|Rotarix will be administered at 6 and 10 weeks of age, followed by parenteral P2-VP8 subunit vaccine at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
88996558|NCT04658914|Experimental|Rotarix + 3 doses P2-VP8|Rotarix and parenteral P2-VP8 subunit vaccine will be coadministered at 6 and 10 weeks of age, with an additional dose of P2-VP8 subunit vaccine administered at 14 weeks of age. A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
88996559|NCT04658446|Experimental|Augmented Reality-Assisted Bonding|The quadrant of the upper arch that shall use the AR-assisted bonding method. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
88996560|NCT04658446|Active Comparator|Digitally-Asssited Indirect Bonding|The quadrant of the upper arch that shall use the digitally-assisted bonding method utilizing a 3D printed tray. From the maxillary central incisor to the maxillary first permanent molar of the same quadrant.
88996561|NCT04628104||COVID-19 patients presented with myocardial infarction|
88996562|NCT04628104||Non-COVID-19 patients presented with myocardial infarction|
88996563|NCT04589923||Group 1 - participants expected to have abnormal oxygen saturation|Within each study session, participants will have their oxygen saturation, heart rate and respiratory rate measured three times using standard of care equipment and methods. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's primary and secondary objectives only. The app does not return any measurements to the user or participant.
89051260|NCT04625075||COVID-19 with myocardial injury|Patients hospitalised with severe COVID-19 infection and evidence of myocardial. Involvement: elevation of plasma cardiac troponin concentration (>99th centile of the upper reference limit), abnormalities on electrocardiography or abnormal echocardiography. Some patients will have suspected myocarditis or takotsubo cardiomyopathy. We will identify subgroups of interest who have left/right ventricular systolic dysfunction ± regional wall motion abnormalities, on echocardiography.
89051261|NCT04625075||COVID-19 without myocardial injury|Patients hospitalised with severe COVID-19 infection but without known elevation of plasma cardiac troponin concentration, clinically significant ECG abnormalities or an abnormal echocardiogram.
89680709|NCT03669302|Sham Comparator|Robotic gait training|Robotic gait training only
89680710|NCT03669302|Experimental|Robotic gait training & low-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at low frequency (0.3 Hz).
89680711|NCT03669302|Experimental|Robotic gait training & high-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at high frequency (30 Hz).
89680712|NCT02996383|Active Comparator|Cemented hemiarthroplasty|Treatment of the fracture by a replacement arthroplasty with a cemented CPT hemiarthroplasty (manafactured by Zimmer company, Warsaw IN, USA) inserted via an anteriolateral approach to the hip
89680713|NCT02996383|Active Comparator|Internal fixation|Internal fixation of the fracture with a screw and plate device (Targon FN plate, Aesculap cooperation, Tuttingham, Germany)
89680714|NCT04541225|Experimental|Phase 1 Dose Escalation|NUV-422 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached.
89680715|NCT03497936|Experimental|Women's Stories|Participants in this group will be randomly assigned to use the Women's Stories intervention.
89680716|NCT03497936|No Intervention|Programming as usual|Participants in this group will be randomly assigned participate in their usual programming.
89051262|NCT04591548||Endometriosis|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
89051263|NCT04591548||Primary infertility|All patients had laparoscopy due to infertility (and endometriosis). All women had BMI in normal range and regular menstrual cycle (21-35 days). Partner's semen analysis was normal in all cases. The investigators excluded patients with hormonal therapy in the last year, irregular menstrual cycle, smokers and patients with autoimmune diseases, malignant or suspected malignant diseases, previous pelvic inflammatory disease, leiomyoma uteri or polycystic ovaries. None of the patients had previous pelvic surgery.
89051264|NCT04625192|Experimental|Sinus lifting with trephine osteotomy|
89051265|NCT04625114|Experimental|Camostat|camostat 100mg 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
89051266|NCT04625114|Placebo Comparator|Placebo|Placebo 3 tablets 3x/day D1->D5 (+ possible extension D6->D10)
89051267|NCT04592133||Scoliosis Patients|
89051268|NCT04592133||Control Group|
89051269|NCT04624880||Participants with HIP previously measured|This cohort of patients will have their genetics analyzed and compared to their HIP scores.
89051270|NCT04624880||Participants without HIP measured|This cohort of patients from the control group of the knee replacement trial (who did not have their HIP measured) will have their genetics, pain, and opioid use analyzed, and compared to the genetics, pain, and opioid use of the hypnosis group from that trial.
89051271|NCT04591470||General population|
89680717|NCT00698035|Active Comparator|Testosterone Cream|Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
89680718|NCT00698035|Active Comparator|Estring|Estring 2mg ring inserted vaginally once every 12 weeks
89051272|NCT04591470||Pazients undergone inguinal hernia correction|
89051273|NCT04624841|Experimental|ICG group|"Participants receive an intravenous injection of 0.05 mg/kg of ICG 45 minutes preoperatively.~A Pinpoint Endoscopic Fluorescence System (Novadac Technologies Inc., Canada) for ICG Fluorescence Observation with the easy switchable white light-fluorescent mode is used.~Before dividing any tubular structure, the fluorescence imaging mode is routinely used again, and fluorescent angiography is performed by re-injecting the same dose of ICG as initially used.~After the division of the cystic duct and artery, the fluorescence imaging mode is applied again to check for bile leakage."
89051274|NCT04624841|No Intervention|No ICG Group|No ICG is administered after randomization of the patient to a control group and hence will not produce any enhancement of the image on A Pinpoint Endoscopic Fluorescence System for ICG Fluorescence Observation. This will continue as a routine Laparoscopic cholecystectomy without fluorescent imaging enhancement.
89051275|NCT04624607|Experimental|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive transspinal stimulation over the thoracolumbar region and non-invasive brain stimulation during assisted stepping.
89051276|NCT04624607|Experimental|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Robotic gait training will be administered along with paired non-invasive brain stimulation and non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping.
89680719|NCT03496844|No Intervention|Routine F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who have had an F-18 fluciclovine-PET/CT scan for routine standard of care for biochemical recurrence. These patients would be asked to participate in the study only if there is a need for a standard of care bone biopsy.
89680720|NCT03496844|Active Comparator|Research F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who would not ordinarily obtain an Axumin-PET scan for routine standard of care but have a need for bone biopsy. This will include patients with metastatic castrate resistant prostate cancer. For example, a patient with known lymph node recurrence of prostate cancer and suspicious finding on a bone scan would be asked to participate in the study and get a F-18 fluciclovine-PET/CT scan prior to the standard of care bone biopsy.
89680721|NCT01793311|Sham Comparator|Group1: Decaffeinated coffee|contains 0.5-2 mg of caffeine
89680722|NCT01793311|Active Comparator|Group2: regular dose coffee|contains 91.8 mg of caffeine
89680723|NCT01793311|Active Comparator|Group3: high dose coffee|contains 144 mg of caffeine
89051277|NCT04624802|Experimental|maternal exercise training group|Pregnant women in experimental group are invited to participate in 16 exercise weekly classes for 40 min including 15 min aerobic exercise，10 min relaxation exercise, and 15 min aerobic exercise, from week 16 to week 32 of gestation, and receive antenatal care and examination regularly.
89051278|NCT04624802|No Intervention|antenatal care group|Pregnant women in antenatal care group receive antenatal care and examination regularly.
89051279|NCT00567177|Active Comparator|1|
89051280|NCT00567177|Placebo Comparator|2|
89051281|NCT04624373||Identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
89051282|NCT04624373||Non identified mutation|The sensitivity of supernatant to identify the mutations detected on cell block (Gold standard).
89051283|NCT04591158|Other|LUS ultrasound and standard of care|Subjects will perform a lung ultrasound in order to determine the ability of patients to take an ultrasound from their homes. The lung ultrasound will be coupled with telehealth clinical support to monitor the severity of COVID-19 patients and provide standard of care. All subjects will receive the lung ultrasound technology and daily calls for teleguidance through the ultrasound and standard of care to monitor symptoms.
89051284|NCT03454607|Experimental|FREE robot|Patients undergoing sinus surgery with the FREE robot
89051285|NCT00567216|No Intervention|G|Endoscopic injection of cyanoacrylate alone
89051286|NCT00567216|Active Comparator|C|Combination of GVO and nadolol
89051287|NCT00562055|Experimental|Arm A|
89051288|NCT00562055|Active Comparator|Arm B|
89680724|NCT05572463|Experimental|Treatment Arm 1|Sintilimab is a recombinant fully human anti-programmed cell death protein 1 (PD-1) monoclonal antibody, and IBI110 is a recombinant fully human anti-lymphocyte activation gene 3 (LAG3) monoclonal antibody. Sintilimab (IBI308) will be administered intravenously (IV) in combination with IBI110 administered intravenously (IV) every 3-weeks (Q3W).
89680725|NCT02995993|Experimental|Moss-aGal|Single administration of 0.2 mg/kg recombinant human alpha-galactosidase A produced in moss (moss-aGal) as intravenous infusion
88996564|NCT04589923||Group 2 - participants expected to have abnormal blood pressure|Within each study session, participants will have their blood pressure and respiratory rate measured three times using standard of care equipment. At the same time, video of the participant's face will be captured using the Lifelight® Data Collect app running on a tablet positioned opposite them. The app will upload the RGB data extracted from this video to the cloud for subsequent analysis and processing aligned to the study's secondary objectives only. The app does not return any measurements to the user or participant.
88996565|NCT00188721||1|Women with confirmed unilateral breast carcinoma or ductal carcinoma in situ (DCIS)
88996566|NCT00188721||2|Women without radiological suspicious lesions, matched to cases by age (± 2.5 years), date of screening mammogram, and screening center.
89680726|NCT03494738||Newborn infants|Neonates born from consented women at the study hospital
89680727|NCT02996071|Active Comparator|low waist to height ratio|laparoscopic sleeve gastrectomy
89680728|NCT02996071|Active Comparator|high waist to height ratio|laparoscopic sleeve gastrectomy
89680729|NCT03493802||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
89680730|NCT03493802||Healthy individuals as controls|Age and gender-matched healthy controls
89680731|NCT02339389||ventilation during labor analgesia|We are simply measuring ventilation changes that occur following labor analgesia.
88996567|NCT04575844|Experimental|Exercise Alone|24 weeks of treatment
88996568|NCT04575844|Experimental|Liraglutide Alone|24 weeks of treatment
88996569|NCT04575844|Experimental|Exercise + Liraglutide|24 weeks f treatment
88996570|NCT00533806|Experimental|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy.
89680732|NCT02129075|Experimental|Arm I (CDX-301, CDX-1401, poly-ICLC)|Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of cycle 1 and only on days 1-3 of cycle 2. Patients also receive CDX-1401 SC or ID on day 1 of each cycle and poly-ICLC SC on days 1-2 of each cycle. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
88996571|NCT00533806|Active Comparator|Relaxation therapy.|Participants will receive relaxation therapy.
88996572|NCT04545346|No Intervention|Wait-listed control|Participants continue care as usual. All all medications must be kept constant during the study period, unless medically necessary.
89680733|NCT02129075|Active Comparator|Arm II (CDX-1401, poly-ICLC)|Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89680734|NCT03662204||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680735|NCT03662204||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680736|NCT03662204||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680737|NCT03662204||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680738|NCT03662204||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680739|NCT03662204||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680740|NCT03662204||Kidney & Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680741|NCT03662204||Pancreatic|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680742|NCT03662204||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
88996573|NCT04545346|Experimental|Low Glutamate diet|Participants are put on the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
89051289|NCT04590729|Experimental|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
89051290|NCT04590729|Experimental|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at moderate intensity every 15 minutes for 3 hours to match the total exercise duration in the first protocol.
89051291|NCT04590729|No Intervention|Sitting|Sitting control.
89680743|NCT03662204||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680744|NCT03662204||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680745|NCT03662204||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
89680746|NCT02775903|Experimental|Azacitidine + Durvalumab|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks (Q4W) in combination with 1500 mg intravenous durvalumab on Day 1 of every 4 week cycle for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
89680747|NCT02775903|Active Comparator|Azacitidine Alone|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
89680748|NCT01679912|Experimental|1: phone to call center|recommendations to phone to the call center for all the patients who have an acute attack
89680749|NCT01679912|No Intervention|2: usual strategy|usual strategy. No intervention (patients does not change their practice)
89680750|NCT04392791|Active Comparator|Treated group|The participants received thermal water therapy
89680751|NCT04392791|No Intervention|Control group|The participants haven't received thermal water therapy
89680752|NCT01679990|Experimental|PLX-PAD Low dose|PLX-PAD double low doses
89680753|NCT01679990|Active Comparator|PLX-PAD high doses|PLX-PAD double high dose
89680754|NCT01679990|Placebo Comparator|Placebo|Double Placebo doses
89680755|NCT01679990|Experimental|PLX-PAD high dose +Placebo|High dose+Placebo
89680756|NCT05461703|Experimental|Planet Nutrition Program (PNP) implemented by nutrition and physical activity advanced students|"The PNP consists of:~Nutrition education sessions: Nutrition advanced students of the University of Sonora will provide 1 face-to-face group class of one hour per week. The PNP handbook will be used to bring the different topics and dynamics to reinforce learning. The program will be focused on establishing some health-related goals.~Physical activity sessions: Three classes of 1 hour per week will be implemented by physical activity advanced students of the University of Sonora, independent of the school's curricular physical activity classes. A physical activity handbook designed by the study team will be used. Children will work on developing different skills.~Parents participation: They will receive one printed brochure with nutrition topics weekly. Also, they will be asked for their Facebook user (to create a private group) or the email to upload the information of the brochure and other didactic materials. Nutrition students will be in charge of providing the information."
89680757|NCT05461703|Experimental|Planet Nutrition (PNP) implemented by school teachers|"The PNP consists of:~Nutrition education sessions: Fourth grade school teachers will provide 1 face-to-face group class of one hour per week. The PNP handbook will be used to bring the different topics and dynamics to reinforce learning. The program will be focused on establishing some health-related goals.~Physical activity sessions: Three classes of 1 hour per week will be implemented by physical activity advanced students of the University of Sonora, independent of the school's curricular physical activity classes. A physical activity handbook designed by the study team will be used. Children will work on developing different skills.~Parents participation: They will receive one printed brochure with nutrition topics weekly. Also, they will be asked for their Facebook user (to create a private group) or the email and upload the information of the brochure and other didactic materials. School teachers will be in charge of providing the information."
89680758|NCT05461703|No Intervention|Control Group|Scholars of this group will continue with their normal school nutrition and physical activity classes. At the end of the study they will have access to the program materials through a web page.
89680759|NCT00700063|Experimental|1|
89680760|NCT00700063|Experimental|2|
89680761|NCT00700063|Experimental|3|
89680762|NCT00700063|Placebo Comparator|4|
89680763|NCT00700063|Experimental|5|
89680764|NCT00700063|Experimental|6|
89680765|NCT00700063|Experimental|7|
89680766|NCT00700063|Placebo Comparator|8|
89680767|NCT03568682|Experimental|Nutritional counseling + urban gardening|Participants in the intervention clinic will receive: 1) nutritional counseling from peer counselors in their clinic (approximately 4-5 sessions administered monthly); 2) training from the Ministry of Agriculture on how to plant and maintain a garden in their home (training workshop and monthly follow-up); and 3) a cooking and nutrition workshop facilitated by project nutritionists once garden produce are available.
89680768|NCT03568682|No Intervention|Usual care control|Participants in the control clinic will receive their usual care from the clinic. After 12 month follow-up, they will be offered the opportunity to receive the intervention.
89680769|NCT03904173||EMIT-1 - Multi-parameter tests|Patients with hormone sensitive HER2 negative primary breast cancer without lymph node metastasis. Treatment recommendations will be based on the Prosigna test result, in addition to conventional clinicopathological parameters.
89680770|NCT01933425|Active Comparator|Deep neuromuscular block followed by no neuromuscular block|"Deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg followed by no neuromuscular blockade with sugammadex 8 mg/kg and placebo reversal.~Measurements of intraabdominal distance during deep neuromuscular blockade and without neuromuscular blockade"
89680771|NCT01933425|Placebo Comparator|No neuromuscular block followed by deep neuromuscular block|"No neuromuscular blockade with placebo followed by deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg and reversal with sugammadex 8 mg/kg.~Measurements of intraabdominal distance during no neuromuscular blockade and during deep neuromuscular blockade."
89680772|NCT04239599|Experimental|Hypofractionation|Hypofractionation: Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost) + 18-36 months of Eligard Hormone injection.
89680773|NCT04239599|Active Comparator|Standard Fractination|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy + 18-36 months of Eligard Hormone injection.
89680774|NCT00594061|Experimental|A|There is no arm to this study--(each participant serves ashis or her own control). Blinding or masking procedures are not included in the design, as it is not possible to conceal the presence or absence of a cochlear implant from device recipients and/or clinical investigators.
89680775|NCT03565172|Experimental|Children with spastic cerebral palsy|"Children with spastic cerebral palsy will be included. They will have 3 phases:~Baseline: 4, 5 or 6 evaluations~Intervention: 9 evaluations before and after every stretching session~Follow-up: 4, 5 or 6 evaluations~The evaluation part will be composed of isokinetic dynamometer with ultrasound and Visual Analog Scale (VAS). The number of evaluations at baseline and follow-up will be randomized before the study by Single Case Experimental Design (SCED) methodology."
88996574|NCT04535635|Experimental|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
89680776|NCT01795417|Experimental|XP200 device RF treatments|Every subject in the study will undergo 4 treatments and will be followed up for 6 months with photoraphic 3 evaluations: before treatment, 3 and 6 months follow-up. Photographs will be scored on a Fitzpatrick scale by 3 blinded evaluators.
89680777|NCT01677728||arm A|patients received chemotherapy alone
89680778|NCT01677728||arm B|patients received target therapy combined with chemotherapy
88996575|NCT04535635|Placebo Comparator|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
88996576|NCT04686721||Patients at risk of developing tracheal stenosis after prolonged intubation or tracheostomy|Patients older than 18 years of age who underwent either prolonged intubation or tracheostomy will be enrolled. A minimum of 2 months follow-up from hospital discharge is required. Patients tested negative for SARS-CoV-2 will be used as a control group
88996577|NCT04475809|Placebo Comparator|Group C|high intra-abdominal pressure
88996578|NCT04475809|Active Comparator|Group L|low intra-abdominal pressure
88996579|NCT04475809|Active Comparator|Group LR|low intra-abdominal pressure with pulmonary recruitment maneuver group
88996580|NCT04475809|Active Comparator|Group LS|low intra-abdominal pressure with intraperitoneal saline infusion group
88996581|NCT00533884||Treatment|Patients undergoing treatment for head and neck, lung, and esophagus cancers
88996582|NCT00409227|Active Comparator|1|double blind placebo control
88996583|NCT00409227|Placebo Comparator|2|placebo control blinded arm
88996584|NCT04475380||All-comer patients requiring PCI|All-comer patients requiring percutaneous coronary intervention (PCI) for the treatment of significant coronary artery of bypass graft lesions that are suitable for treatment with Xience Sierra DES
88996585|NCT04473781|Experimental|Treatment (interstitial brachytherapy)|Patients undergo interstitial brachytherapy for 1-2 fractions in the absence of disease progression or unacceptable toxicity. Patients who undergo 2 fractions may receive both fractions in the same day or on 2 separate days over 2 weeks.
88996586|NCT04462627|Experimental|Covid 19 positive patients|
88996587|NCT04462627|Experimental|Covid 19 negative patients|
88996588|NCT04462627|Experimental|Untested healthy volunteers|
88996589|NCT04442347|Experimental|ARCT-810|Ascending single doses of ARCT-810 administered intravenously
88996590|NCT04442347|Placebo Comparator|Placebo|Single doses of 0.9% Saline administered intravenously
88996591|NCT00406679|Experimental|1|
88996592|NCT00406679|Placebo Comparator|2|
88996593|NCT00406679|Active Comparator|3|
88996594|NCT04441216|No Intervention|Consultation only|Review by Chinese Medicine practitioner only
88996595|NCT04441216|Active Comparator|JinQi JiangTang Fang|JinQi JiangTang Fang (Rhizoma Coptidis, Radix Astragali and Flos Lonicerae)
88996596|NCT04441216|Active Comparator|JM-ELD|JQJT plus extra low dose Ophiopogonis Radix
88996597|NCT04441216|Active Comparator|JM-LD|JQJT plus low doses Ophiopogonis Radix
88996598|NCT00181857||1|Children of Adults with ADHD NOS
88996599|NCT04431154|No Intervention|Experimental: Usual care|Participants randomized to this arm will receive the standard of care (SOC) following the STAR program protocol in various sites in Johannesburg. This will include provision of an HIV self-screening test kit, the standard linkage officer follow-up call following report of a positive HIVSS test and an invitation to i) participate in study visit 1 to have their positive HIVSS result confirmed and complete blood collection for viral load PCR testing and to ii) participate in study visit 2 at 6 months for Viral Load PCR. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
88996600|NCT04431154|Experimental|Experimental: Incentives and linkage promotion|Participants randomized to this arm will receive the same standard HIV self-screen test kit and linkage officer follow-up call including the invitation to i) participate in study visit 1 and ii) study visit 2. In addition, they will receive a financial incentive if they complete a confirmatory HIV test at visit 1 and if they demonstrate viral suppression at study visit 2, approximately 6 months after positive HIVSS result. They will also receive monthly reminders and incentives to pick up HIV medication. Individuals with a positive HIV test result from another Ezintsha study or an affiliated clinic will also be invited to participate in study visit 1 for baseline viral load PCR testing.
88996601|NCT04423159|Experimental|OCV vaccine|Shanchol 1.5mL to be administered orally. Each dose contains V.cholerae O1 Inaba El Tor Strain, Inaba classical strain, ogawa classical strain and O139 strain. As well as Thiomersal and a buffer
89051292|NCT04590807|Active Comparator|Posterior spinal fusion with pedicle screws|
89680779|NCT05322317|Other|Pilot participants|"Participants will participate in ADVANCE-PC training via ECHO and will receive practice facilitation support, if needed.~To assess the feasibility of the ADVANCE-PC training and implementation support, research data will be collected from participating clinicians at three time points. Two data collection points will be pre and post ECHO program training questionnaires about attitudes, experience, and intentions related to ACP and dementia. The third will be an interview at the end of the follow-up period, focusing on barriers to and facilitators of ACP in the context of dementia and the impact of the training and implementation support. Feasibility and acceptability of this intervention will be evaluated using descriptive and qualitative analyses of these data."
89680780|NCT02723019|Experimental|Intervention Group|Volunteer Peer Mentor + Behavioral Health Nurse
89051293|NCT04590807|Active Comparator|Anterior vertebral body tethering|
89680781|NCT02723019|No Intervention|Control|Care as Usual
89680782|NCT03487016|Active Comparator|A: Gemcitabine/nab-Paclitaxel (Standard)|"Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
89680783|NCT03487016|Experimental|B: NAPOLI regimen|"On Day 1 of a 14-day cycle:~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
89680784|NCT03487016|Experimental|C: seq-NAPOLI-FOLFOX|"The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.~NAPOLI:~On Day 1 of a 14-day cycle:~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~mFOLFOX6:~On Day 1 of a 14-day cycle:~Oxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
89680785|NCT02622295|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session electrically induced exercise
89680786|NCT02622295|Experimental|Training Study|Adaptations in gene regulation, metabolic markers, and subject-report metrics in response to up to 3 years of electrically induced exercise
89680787|NCT01677806|Experimental|Percutaneous vertebroplasty|
89680788|NCT01677806|Active Comparator|Conservative therapy|
89680789|NCT02335671|Experimental|Intra-operative Magnetic Resonance Imaging (MRI)|"Preoperative diagnostic MRI~Intra-operative MRI~Standard lumpectomy and sentinel node biopsy if indicated, or standard axillary dissection if clinically indicated~Specimen to Pathology and Mass Spectrometer (Analysis of Tissue Sample)"
89680790|NCT04148807|Experimental|Progressive walking program with gait retraining|Participant will receive 8 gait-retraining intervention sessions.
89051294|NCT00567294|Active Comparator|A|Participants will receive mailed education materials on osteoporosis and medication use.
89680791|NCT04148807|Active Comparator|Progressive walking program|Participant receives 8 sessions of a graded walking program.
89680792|NCT05346926|Experimental|3D-printed cast|Treatment of distal radius fracture with 3D-printed forearm cast.
89680793|NCT05346926|Active Comparator|Conventional cast|Treatment of distal radius fracture with conventional plaster cast.
89051295|NCT00567294|Experimental|B|Participants will receive a telephone coaching program.
89051296|NCT00567294|Experimental|C|Participants will receive a telephone coaching program, and doctors of these participants will receive medication adherence alert notifications.
89051297|NCT04624412|Experimental|Continuous Aerobic Moderate Intensity Exercise|(Treadmill walking exercise) 50% - 70% of max Heart Rate (HR) (3-6 METS)
89051298|NCT04624412|Experimental|Continuous Aerobic (Mild intensity Exercise)|(Treadmill walking exercise) 30% -50 % of max HR (1-3 METS)
89051299|NCT00567333|Other|1|
89051300|NCT00567333|Other|2|
89051301|NCT04623866|Active Comparator|Huaiqihuang Group|Huaiqihuang granules 60g/1.73m2 bid 24 weeks
89051302|NCT04623866|Active Comparator|Valsartan group|Valsartan granules 80mg/1.73m2 based qd 24 weeks
89051303|NCT00562133|Experimental|1|One Day Treatment with Insulin Glulisine
89051304|NCT00562133|Active Comparator|2|One day Treatment with Human insulin
89051305|NCT00567411|Active Comparator|I|Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
89051306|NCT00567411|Active Comparator|A|Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
89051307|NCT00562172|Experimental|1|
89051308|NCT00562172|Active Comparator|2|
89051309|NCT00567450|Active Comparator|B|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
89051310|NCT00567450|Experimental|A|30 ml of ropivacaine 0.75%
89051311|NCT00562211|Experimental|1|
89051312|NCT00562211|Active Comparator|2|
89051313|NCT00567528|Other|1|Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule
89051314|NCT00567528|Other|2|Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules
89051315|NCT01154140|Experimental|A|
89051316|NCT01154140|Active Comparator|B|
89051317|NCT04623749|Active Comparator|Percutaneous US guided FNAC in pancreatic masses|
89051318|NCT04623749|Active Comparator|EUS guided FNAC in pancreatic masses|
89051319|NCT04590768|Experimental|Fermotein™|daily lunch with 11 grams of Fermotein™ dry powder, mixed in bread, soup or a burger
89051320|NCT04590768|Active Comparator|Matched control products|daily lunch with a control bread matched in macronutrient content. Control meat alternative burgers and soup from the local supermarket.
89051321|NCT04623788||Myocarditis|Twenty patients with acute myocarditis will be recruited if the diagnosis has been made by a cardiologist based on clinical, biochemical, electrographic and imaging data. This reflects the diagnostic criteria set out by the European Society of Cardiology (ESC) Task force 2013.
89051322|NCT04623788||Takotsubo Cardiomyopathy|Twenty patients with takotsubo cardiomyopathy will be recruited. The diagnosis will be made according to the Mayo clinic and the European Society of Cardiology (ESC) Heart Failure Association criteria, including a normal coronary angiogram, typical appearances on cardiac imaging including ventriculography, and no evidence of fibrosis on cardiac magnetic resonance imaging.
89051323|NCT04623788||Reversible Ischaemia|Forty patients who have undergone stress echocardiography or magnetic resonance imaging; twenty with positive (areas of reversible akinesis/hypokinesis during pharmacological stress), and twenty with a negative stress result (no reversible wall motion abnormalities during pharmacological stress) as per international guidelines. They will be matched for age and sex.
89051324|NCT04623788||Healthy Volunteer|Twenty healthy volunteers of comparable age and sex to the other cohorts.
89051325|NCT04590612|Active Comparator|Carbidopa-Levodopa|Patients will be randomized to any of the 2 arms. In Levodopa/carbidopa arm, patients will be taking Carbidopa-Levodopa (25-100mg) three times a day for the duration of the study.
89051326|NCT04590612|Experimental|Citalopram|Patients will be randomized to any of the 2 arms. In Citalopram arm, patients will be taking Citalopram (20mg) daily for the duration of the study.
88996602|NCT04724954|Experimental|Rehabilitation Therapy on Experimental Robotic Table and standard of care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited for experimental group.~The investigators will also recruit the 10 caregivers of the experimental subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
88996603|NCT04724954|Sham Comparator|Rehabilitation Therapy as part of Standard of Care|"10 elderly 5 days or more post-CVA admitted to Kessler Institute for Rehabilitation/Kessler Foundation) for inpatient rehabilitation will be recruited as a control group.~The investigators will also recruit the 10 caregivers of the control subjects. Both experimental and control groups will undergo standardized evaluations for motor function/impairment, cognition and emotive states."
88996604|NCT04422457|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-DX600 PET/CT scans
88996605|NCT04420429||Cohort|All patients
88996606|NCT04686448|Active Comparator|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
88996607|NCT04686448|Active Comparator|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
88996608|NCT04402840|Experimental|Stellate Ganglion Block (SGB)|Clinical Stellate ganglion block
89680794|NCT01936389|Experimental|0.5%|0.5% Rho-Kinase Inhibitor
89680795|NCT01936389|Experimental|0.7%|0.7% Rho-Kinase Inhibitor
89680796|NCT03023319|Experimental|Bosutinib and Pemetrexed|Bosutinib and pemetrexed
89680797|NCT01679522|Experimental|Single-port surgery group|Single-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
88996609|NCT04390087|Experimental|Exercise|Upper-body rowing performed up to 30 min, 3 times per week with moderate-to-vigorous intensity
88996610|NCT04390087|No Intervention|Control|The participants allocated to the control group will be asked to maintain their normal lifestyle throughout the intervention period
88996611|NCT00406757|Active Comparator|Pediatric Arm 1|"Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose."
88996612|NCT00406757|Active Comparator|Pediatric Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
88996613|NCT00406757|Active Comparator|Adult Arm 1|"Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose."
88996614|NCT00406757|Active Comparator|Adult Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
88996615|NCT00406757|Active Comparator|Pediatric Arm 3|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
89680798|NCT01679522|Active Comparator|Four-port surgery group|Four-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
89680799|NCT02980653|Experimental|Megestrol|Single arm
89680800|NCT03560648|Other|Reference group|To define the normal muscle aging from HD-sEMG and accelerometer signals correlated to muscular parameters obtained from Dual Energy X-ray Absorptiometry (DEXA), handgrip strength and muscular echography. Data will be collected in healthy volunteers, aged 25 to 75 years old, physically active on IPAQ questionnaire.
89680801|NCT03560648|Other|Test group|"To evaluate the capacity of MFA to detect early muscle aging in  tests  individuals, sedentary volunteers within the same age group (45-55 years old)."
89680802|NCT01936467|Experimental|Standard suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the standard suction FNA technique: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
88996616|NCT00534079|Experimental|Dornase alfa|28 days of sinonasal inhalation (Pari Sinus)
88996617|NCT00534079|Placebo Comparator|isotonic saline|28 days of sinonasal inhalation (Pari Sinus)
88996618|NCT00533221|Active Comparator|Somatotropin|subcutaneous application of somatotropin over 12 weeks followed by 8 weeks wash out period followed by 12 weeks subcutaneous placebo application
88996619|NCT00533221|Placebo Comparator|Placebo|12 weeks placebo subcutaneous application followed by 8 weeks wash out and 12 weeks subcutaneous application of somatotropin
88996620|NCT04893148|Active Comparator|iGlar/Lixi|"Switching to IGlarLixi from insulin glargine iGlar/Lixi starts with the following doses depending on the existing insulin glargine dose: 1) insulin glargine <20 unit/day = iGlar/Lixi 10 unit/day, 2) insulin glargine >=20 unit/day = iGlar/Lixi 20 unit/day.~Training to increase the iGlar/Lixi dosage every 3 days to meet the target fasting blood glucose level to 80~130 mg/day"
88996621|NCT04893148|Active Comparator|Dulaglutide plus insulin glargine|Adding Dulaglutide to insulin glargine. Keep insulin glargine and dulaglutide start at 0.75 mg per week and increase to 1.5 mg per week after 1 month with evaluating compliance and tolerability.
88996622|NCT04883632|Experimental|Volume Lidocaine HQ|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma HQ Facility
89680803|NCT01936467|Experimental|Capillary suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the capillary suction FNA technique: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
89680804|NCT02995759||SE before Seizure Action Plan|450 patients with status epilepticus prior to seizure action plan initiation
89680805|NCT02995759||SE after Seizure Action Plan|450 patients with status epilepticus after seizure action plan initiation
89680806|NCT01677338|Experimental|13C-uracil and 99mTc sulfur colloid|Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.
89215964|NCT05564793|Active Comparator|Control|"The CRT device is implanted according to clinical practice, without pre-implantation planning. The outcome of the procedure is assessed via echography as per clinical practice.~In addition to clinical practice, the subjects are required to fill in a quality-of-life questionnaire and are subject to an ECG mapping procedure with the Amycard 01C device, including non-contrast CT, to assess the distance between left ventricular lead placement and the latest electrical activation site in the absence of planning information."
89215965|NCT05564793|Experimental|Active|A pre-implantation ECG mapping with the Amycard 01C device, including CT, is performed prior to the CRT device implantation. The resulting target area for the left ventricular lead placement is communicated to the implanting physician, who will attempt to reach a point close to the target, using the available venous access. At six-month follow-up, response to the therapy is assessed using echocardiography, and a second ECG mapping with Amycard 01C is performed, to assess the distance between actual implantation site and target in the presence of pre-implantation planning information.
89215966|NCT05561127|Experimental|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
89215967|NCT05561127|Active Comparator|Control|Standard of Care.
89680807|NCT01677338|Experimental|99mTc sulfur colloid|Subjects will consume the Solid Test Meal containing 500 uCi 99mTc sulfur colloid.
89680808|NCT02995447||epilepsy patients|The group consists of patients with therapy refractory epilepsy, in which intracerebral electrodes were implanted to locate the seizure origin and to determine whether the patients are eligible for epilepsy surgery. In an observational study, differences between surface and intracerebral EEG are recorded.
89680809|NCT03557216|Experimental|Complicated diverticulitis|Patients with complicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
89680810|NCT03557216|Experimental|Uncomplicated diverticulitis|Patients with uncomplicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
89680811|NCT03088280|Experimental|3mg/kg Group|Patients will received Thymoglobuline 3mg/Kg (reduced dose)
89215968|NCT05561114|Experimental|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
89215969|NCT05561114|Active Comparator|Control|Standard of Care Endoscopic Dilation
89215970|NCT05553119||Home-based Pulmonary Rehabilitation and Health Coaching|Subjects with symptomatic bronchiectasis (CAT score ≥10) will receive a 12-week intervention with home-based pulmonary rehab (PR).
89215971|NCT05552638|Experimental|Senior Center Members|Participants who are using the provided telehealth stations in senior centers.
89680812|NCT03088280|Active Comparator|6mg/kg Group|Patients will received Thymoglobuline 6mg/Kg (standard dose)
89680813|NCT00594685||Isolated HIT|Hospitalized patients with isolated Heparin-Induced Thrombocytopenia (HIT), diagnosed by a fall in platelet count and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked ImmunoSorbent Assay (ELISA) test
89680814|NCT03087968|Experimental|GS-4997 + Prednisolone|"GS-4997 + Prednisolone for 28 days~HepQuant SHUNT Test"
89680815|NCT03087968|Placebo Comparator|Prednisolone + Placebo|"Placebo + Prednisolone for 28 days~HepQuant SHUNT Test"
89680816|NCT03845049|Experimental|group aflibercept|
89680817|NCT03845049|Placebo Comparator|control group|
89680818|NCT00594997|Experimental|Education|Students who receive an educational intervention which consists of a 45 minute interactive presentation as well as a 30 minute health education entertainment by a juggler.
89680819|NCT00594997|Active Comparator|Control|Students who fill out pre and post surveys and receive the intervention after the post-survey
89680820|NCT03790839|Experimental|Sequential arm ABC|A: Sitagliptin 100 mg QD in the morning on Days 1-5; B: Sitagliptin 100 mg QD in the morning and dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
89680821|NCT03088046|Other|Micronized Progesterone|Administration of 200 mg of vaginal Micronized Progesterone (100 mg every 12 hours) for a 7-day course
89680822|NCT03088124|No Intervention|active surveillance|Active surveillance without androgen deprivation
89680823|NCT03088124|Experimental|active surveillance with Apalutamide|Active surveillance during and after 6 months treatment with Apalutamide
89680824|NCT00700375|Experimental|Sodium bicarbonate|
89680825|NCT00700375|Experimental|Sodium chloride|
89680826|NCT01677884|Experimental|Patients with metastatic CRC|
89680827|NCT02124083|Experimental|Vorinostat|Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.
89680828|NCT02405078|Experimental|Diagnostic (PET/CT, clonotype, metabolic profile)|"Patients receive standard salvage chemotherapy as determined by the treating physician.~Patients undergo FDG PET/CT scans at baseline (between days -21 to 0), on day 4 after completion of first high-dose chemotherapy, on day 21 after completion of the first course of chemotherapy, and on day 42 after the end of the second course of chemotherapy. Blood samples are also collected for tumor-specific clonotype and metabolic profile at baseline (days -5 to 0) and on days 4, 8, 21, and 42."
89680829|NCT00701389|Experimental|Sequence 1: A→C→D→B|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A); Period 2: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 3: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D); Period 4: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B). Each dosing period is separated by a 5-day washout.
89680830|NCT00701389|Experimental|Sequence 2: B→D→C→A|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 2: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D): Period 3: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 4:single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A). Each dosing period is separated by a 5-day washout.
89680831|NCT00701389|Experimental|Sequence 3: C→B→A→D|Participants receive the following: Period 1 :single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C), Period 2: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 3: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A): Period 4: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D). Each dosing period is separated by a 5-day washout.
89680832|NCT00701389|Experimental|Sequence 4: D→A→B→C|Participants receive the following: Period 1: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D), Period 2: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treament A); Period 3: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 4: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C). Each dosing period is separated by a 5-day washout.
89680833|NCT01796587||LoFric Origo|
89051327|NCT04623476|Experimental|Pathophysiological Excision for Chron's disease|Consecutive patients (>18 years old) with a surgical indication for ileocolic Crohn's disease, at their first operation for CD
89051328|NCT04590378||Covid-19 Patients with Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.
89680834|NCT02336594|Experimental|Sequence ABCD|2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.
89051329|NCT04590378||Covid-19 Patients without Pulmonary embolism|Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.
89051330|NCT04590339|Active Comparator|Repositioning the bone window|Computer guided inferior alveolar nerve lateralization and implant placement with subsequent repositioning of the osteotomized bone window.
89051331|NCT04590339|Active Comparator|Augmentation using sticky bone|Computer guided inferior alveolar nerve lateralization and implant placement with grafting around the implant using sticky bone
89051332|NCT04623164|No Intervention|1 Group (Control)|ten students with healthy periodontium
89051333|NCT04623164|Experimental|2 Group|ten patients receiving standard non-surgical periodontal treatment (NSPT)
89051334|NCT04623164|Experimental|3 Group|ten patients receiving standard non-surgical periodontal treatment NSPT + 28-day chronotherapy with complex phytoadaptogens (CFA)
89051335|NCT00562250|Experimental|Arm 1|
89680835|NCT02336594|Experimental|Sequence BACD|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat
89680836|NCT02336594|Experimental|Sequence ABDC|2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
89680837|NCT02336594|Experimental|Sequence BADC|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
89680838|NCT03964181||Students Grades 3-12|
89680839|NCT03964181||Parents of Students Grades K-12|
89680840|NCT03964181||School Based Teachers and Staff Grades K-12|
89680841|NCT01799317|Active Comparator|Treatment with vitamin D2|Vitamin D2 50,000u titrated to serum 25(OH)D values given orally once a month in addition to standard of care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
89680842|NCT01799317|No Intervention|Standard of Care|Standard of Care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
89680843|NCT01677962|Experimental|dendritic cell and Poly-ICLC vaccination|Dendritic cell and Poly-ICLC vaccination will be administered directly into the tumor on Day 0 and Day 14 of Treatment Phase. Subjects will then have standard of care procedures along with injections of Poly-ICLC and dendritic cells for the remainder of the study.
89680844|NCT05161247|Experimental|Zona pellucida sperm selection|"Semen processing: liquefaction followed by centrifugation and swim-up.~Zona pellucida sperm selection: Spermatozoa are selected according to their ability to adhere to zona pellucida proteins obtained from their partners native zona pellucida.~Intracytoplasmic sperm injection (ICSI): Each oocyte is injected with a single morphologically normal spermatozoa. The injection procedure is carried out in a sterilized dish using holding pipette and injection needle."
89680845|NCT05161247|Active Comparator|Conventional sperm selection|"Semen processing: liquefaction followed by centrifugation and swim-up. Samples are incubated until time of injection.~Conventional sperm selection: Spermatozoa are selected according to their morphology.~Intracytoplasmic sperm injection (ICSI): Each oocyte is injected with a single morphologically normal spermatozoa. The injection procedure is carried out in a sterilized dish using holding pipette and injection needle."
89680846|NCT00595153|Active Comparator|B|Asthmatics not on inhaled corticosteroids who will be put on an inhaled steroid during the study
89680847|NCT00595153|No Intervention|A|Healthy, non-asthmatics who will not be put on any intervention
89680848|NCT00595153|Active Comparator|C|Asthmatics, who are already on inhaled corticosteroids who will be put on standardized dose of inhaled corticosteroids
89680849|NCT03419468|Experimental|1|iPad administration of Self Geriatric Assessment Measure (SGAM)
89680850|NCT03419468|Active Comparator|2|Paper survey administration of Self Geriatric Assessment Measure (SGAM)
89680851|NCT05151965||Bankart Repair and Remplissage|Patients will undergo a standard arthroscopic anterior labral repair with a minimum of 3 suture anchors, followed by remplissage with 1 or 2 anchors, at the discretion of the treating surgeon.
89680852|NCT05151965||Latarjet Coracoid Transfer|Patients will undergo a Latarjet coracoid transfer through a deltopectoral approach and horizontal split in the subscapularis at the superior 2/3, inferior 1/3 junction. The coracoid process will be oriented in the conventional manner, with the inferior surface against the glenoid vault, secured with two cannulated screws
89680853|NCT02995291|Placebo Comparator|Control|1.7ml saline water
89680854|NCT02995291|Experimental|OraVerse|1.7ml OraVerse
89680855|NCT02408432|Experimental|Arm I (hMSCs)|Patients receive allogeneic hMSCs IV over 10-20 minutes once weekly for 4 weeks and standard of care drugs for heart failure.
89680856|NCT02408432|Active Comparator|Arm II (standard of care drugs)|Patients receive only standard of care drugs for heart failure.
89051336|NCT00562250|Active Comparator|Arm 2|
89051337|NCT00562250|Active Comparator|Arm 3|
89051338|NCT00562289|Active Comparator|aspirin|aspirin use like antiplatelet
89051339|NCT00562289|Experimental|anticoagulant|Antivitamins K or rivaroxaban or dabigatran or apixaban
89680857|NCT01798043|Experimental|Septal RV lead with >50% pacing (B1)|Cardiac MRI with pacemaker stimulation
89680858|NCT01798043|Experimental|Septal RV lead with <50% pacing (B2)|Cardiac MRI with and without pacemaker stimulation
89680859|NCT01798043|Experimental|Apical RV lead with >50% pacing (A1)|Cardiac MRI with pacemaker stimulation
89680860|NCT01798043|Experimental|Apical RV lead with <50% pacing (A2)|Cardiac MRI with and without pacemaker stimulation
89680861|NCT03087734|Active Comparator|Perpendicular stabilizer|Implantation of regular bar with perpendicular stabilizers
89680862|NCT03087734|Experimental|Oblique stabilizer|Implantation of new model of bar with oblique stabilizers
89680863|NCT04403048|Active Comparator|Patients in which standard provisional approach is preformed|Detailed technique is described in the Detailed study description paragraph
89680864|NCT04403048|Experimental|Patients in which provisional DCB approach is preformed|Detailed technique is described in the Detailed study description paragraph
89680865|NCT00595231|Experimental|SYN111|500 mg 1 week, followed by 1000 mg for 7 weeks
89680866|NCT00595231|Placebo Comparator|Placebo|0 mg tablets
89680867|NCT02400554|No Intervention|Wait List Control|Participants wait one year before receiving the intervention. Three assessments are taken over this period: Month 3, Month 9, and Month 12.
89680868|NCT02400554|Experimental|Yappalli|Yappalli: Participants attend a 12-month behavioral intervention.
89680869|NCT02995603|Experimental|Patient rotation|Patients will be rotated horizontally, using the Nano-X patient rotation system, and asked to complete validated questionnaires to quantify their experience.
89680870|NCT03736733|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
89680871|NCT03736733|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
89680872|NCT01678040||Cardiac Magnetic Resonance|"The CMR examinations will be performed in the cardiac MRI scanner (Siemens Avanto, 1.5 Tesla, Erlangen, Germany) at the Hospital for Sick Children. A brief echocardiogram will be performed using a GE Vivid 7 or Vivid E9 machine (General Electric Medical Systems, Wisconsin, USA) We will image from standard parasternal long axis and apical four-chamber before and after completed hydration."
89680873|NCT02995057||Nickel allergic|Participants have proven nickel allergy
89680874|NCT02474173|Experimental|Treatment (onalespib, paclitaxel)|"SAFETY RUN-IN: Patients receive onalespib IV over approximately 1 hour on day -7.~TREATMENT: Patients receive paclitaxel IV over 60 minutes on day 1, 8, and 15. Patients also receive onalespib IV over 1 hour beginning on days 8 and 15 of cycle 1 and on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89680875|NCT03482102|Experimental|Tremelimumab + Durvalumab + Radiation|"Durvalumab via IV infusion every 28 days for up to 4 doses/cycles~Tremelimumab via IV infusion every 28 days for up to 4 doses/cycles, and then continue durvalumab monotherapy every 4 weeks starting on Week 16 for up to 8 months.~Radiation therapy will only be given during cycle 2"
89680876|NCT02995135|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89680877|NCT01798199|Experimental|Alzheimer disease|
89680878|NCT02402270|Experimental|ECP-019 A (Group A)|
89680879|NCT02402270|Experimental|ECP-019 B (Group B)|
89680880|NCT02402270|Experimental|ECP-019 C (Group C)|
89680881|NCT02402270|Active Comparator|Group D|
89680882|NCT02402270|Active Comparator|Group E|
89680883|NCT00701935|Placebo Comparator|1|
89680884|NCT00701935|Experimental|2|
89680885|NCT03087500||Down Syndrome (DS)|120 clinically confirmed full trisomy 21, age 3-50 years of both sexes will be recruited as the target study population. Half of the individuals (n=60) will be children (3-17 years of age) while half (n=60) will be adults (18-50 years of age)
89680886|NCT03087500||Typically Developing Controls|60 typically developing individuals age 3-50, age and gender matched to at least one participant with DS. Half of the controls (n=30) will be age and gender match to children with DS and half (n=30) will be age and gender matched to adults with DS.
89680887|NCT03087188||Utilization of inhalator|Film sequences will be shown to patients using incorrect application technique in order to improve technique. Learning success will be assessed subsequently and at a follow-up visit after 2-8 weeks
89680888|NCT03432143|Experimental|Community Reviewers|24 community members will receive training and mentoring in reviewing manuscripts. Approximately 284 manuscripts will be randomized into the intervention group over the duration of the study. Manuscripts will be reviewed by both a community member and scientific reviewers.
89680889|NCT03432143|No Intervention|Scientific Reviewers Only|Approximately 284 manuscripts will be randomized into the control group over the duration of the study. Manuscripts will be reviewed by multiple scientific reviewers. Community reviewers will not be involved in reviewing these manuscripts.
89680890|NCT03087266|Experimental|Full- Mouth Scaling and Root Planing|FM-SRP Non-surgical periodontal treatment will be performed in all dentition within 24 hours.
89680891|NCT03087266|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP Non-surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed with one week interval. In each appointment only a quadrant of the dentition will be instrumented."
89680892|NCT02995213|Experimental|Feedback Intervention|
89680893|NCT02984696|Experimental|Hormonal Replace Therapy|1 mg of transdermal estradiol daily and 10mg of oral Medroxyprogesterone acetate from 16th to 24th day of therapy for six months
89680894|NCT00596167|Experimental|Intravenous antibiotics|Intervention: administer intravenous vancomycin, gentamicin and levofloxacin. This study will determine the pharmacokinetics of intravenous vancomycin, gentamicin and levofloxacin in subjects receiving short-daily hemodialysis. There will not be a control arm for this study. The intervention for this arm will be to administer intravenous vancomycin, gentamicin and levofloxacin and draw blood samples at periodic intervals. The blood samples will be tested for these medications and pharmacokinetic analysis will be performed.
89680895|NCT03087032|Experimental|Liraglutide-bolus|'Liraglutide-bolus'(Liraglutide once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
89680896|NCT03087032|Active Comparator|Basal-bolus|'Basal-bolus' (insulin glargine once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding insulin Glargine to prandial insulin Lispro.Dose of insulin will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
89680897|NCT02994745|Experimental|A fixed dose combination group|A fixed dose combination of Fimasartan/Atorvastatin
89680898|NCT02994745|Active Comparator|Co-administration group|Co-administration of Fimasartan and Atorvastatin
89680899|NCT03480074|Active Comparator|Staple Ligation|Arm 1: Staple Ligation
89680900|NCT03480074|Active Comparator|Selective Suture Ligation|Arm 2: Selective Suture Ligation
89680901|NCT03480074|Active Comparator|Single Suture Ligation|Arm 3: Single Suture Ligation
89680902|NCT01678118||minority smokers|A single arm ABA design will be used to pilot a tobacco-focused patient navigation (TPN) intervention for low income, minority smokers.
89680903|NCT00703261|Active Comparator|10 mg Atorvastatin|10 mg atorvastatin + placebo
89680904|NCT00703261|Active Comparator|80 mg Atorvastatin|80 mg atorvastatin + placebo
89680905|NCT04346147|Experimental|Imatinib 400 mg|Imatinib 400 mg 1 tablet 24 hours
89680906|NCT04346147|Experimental|Baricitinib 4 mg|Baricitinib 4 mg 1 tablet 24 hours
89680907|NCT04346147|Experimental|Supportive treatment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
89680908|NCT00703729|Experimental|Cold Compression (CC)|The Game Ready device provides both active, continuous cold and intermittent, pneumatic compression to the post-op shoulder. The first group will use the Game Ready™ Device (CC) for one week following surgery and will use standard ice bags wrapped to the shoulder (IW) for the remainder of the study period.
89680909|NCT00703729|Active Comparator|Ice Wrap (IW)|The ice bag (IW)is secured to the shoulder using an elastic wrap. The second group will use standard ice bags wrapped to the shoulder (IW) for one week following surgery and will use the Game Ready™ Device (CC) for the remainder of the study period
89680910|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
89680911|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
89680912|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
89680913|NCT03478358|Experimental|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
89680914|NCT03478358|Experimental|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7 GBq (100 mCi) of 177LuDOTA-TATE and amino acids (lysine and arginine).
89680915|NCT03478358|Experimental|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7 GBq (100 mCi) of 177LuDOTA-TATE without amino acids (lysine and arginine).
89680916|NCT04200833||group 1|All JIA patients that were switched from adalimumab to golimumab because of Treatment failure of their JIA associated uveitis at the Medical University of Graz Austria from 2010 to 2019
89680917|NCT01678274||Turner syndrome|Females with Turner syndrome
89680918|NCT01678274||Control group|age matched females acting as controls
89051340|NCT00562289|Experimental|Devices for PFO closure|Devices for PFO closure
89680919|NCT01678352|Experimental|Cohort 1|Patients must have undergone surgery or biopsy alone (no postoperative radiation or chemotherapy) and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression (no progression from the initial surgery/biopsy).
89680920|NCT01678352|Experimental|Cohort 2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥ 6 months prior to enrollment, and have a baseline MRI scan within 4 weeks prior to the first vaccine that shows stable disease or regression.
89680921|NCT01678352|Experimental|Cohort 3|Patients with recurrent WHO grade 2 glioma may have received prior external beam radiotherapy and/or chemotherapy. Patients with stable WHO grade 2 glioma must have had prior chemotherapy (at least one cycle of Temozolomide or PCV-based chemotherapy). With regard to the prior therapy in Cohort 3, patients may have had treatment for no more than 2 prior relapses. Relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy) or observation of stable disease. The intent therefore is that patients may have had 3 prior therapies (initial therapy and treatment for 2 relapses). If the patient had a surgical resection for relapsed disease, and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse.
89680922|NCT02994667||Pacemaker After TAVR|The study cohort will comprise all consecutive patients who undergo permanent pacemaker placement for new conduction disturbances after TAVR at THHBP between 1/1/2015 and 12/31/2016.
89680923|NCT01678430|Active Comparator|Ofatumumab-Chlorambucil|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Chlorambucil: 10mg/m2 po days 1-7
89680924|NCT01678430|Experimental|Ofatumumab-Bendamustine|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Bendamustine: 70mg/m2 iv days 1 and 2
89680925|NCT04149743|No Intervention|Randomized Standard of Care|Standard of Care
89680926|NCT04149743|Active Comparator|Randomized Standard of Care with HEMOTAG|Standard of Care with HEMOTAG
89215972|NCT05546554|Experimental|Suvorexant, then Placebo|"Participants will first receive Suvorexant for a 4-week period. A starting dose will be 5 mg at bedtime and can be increased by 5 mg only if needed and if well tolerated on a weekly basis until the maximum dose of 20 mg/day is reached. Participants will be maintained on the lowest effective dose.~Participants will then receive Placebo (fake tablet) for a 4-week period. A starting dose will be 5 mg at bedtime and can be increased by 5 mg only if needed and if well tolerated on a weekly basis until the maximum dose of 20 mg/day is reached. Participants will be maintained on the lowest effective dose."
89215973|NCT05546554|Experimental|Placebo, then Suvorexant|"Participants will first receive Placebo (fake tablet) for a 4-week period. A starting dose will be 5 mg at bedtime and can be increased by 5 mg only if needed and if well tolerated on a weekly basis until the maximum dose of 20 mg/day is reached. Participants will be maintained on the lowest effective dose.~Participants will then receive Suvorexant for a 4-week period. A starting dose will be 5 mg at bedtime and can be increased by 5 mg only if needed and if well tolerated on a weekly basis until the maximum dose of 20 mg/day is reached. Participants will be maintained on the lowest effective dose."
89215974|NCT05540574|Experimental|Zolpidem, then Placebo|"Participants will first receive Zolpidem for a 4-week period. A 5 mg dose of Zolpidem will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated.~Participants will then receive Placebo (fake tablet) for a 4-week period. A 5 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated."
89215975|NCT05540574|Experimental|Placebo, then Zolpidem|"Participants will first receive Placebo (fake tablet) for a 4-week period. A 5 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated.~Participants will then receive Zolpidem for a 4-week period. A 5 mg dose of Zolpidem will be given at bedtime for one week and then will increase to 10 mg if needed and if well tolerated."
89215976|NCT05538234||Non-living organ donors|Group of non-living donors
89215977|NCT05538234||Living organ donors|Group of living organ donors
89215978|NCT05538234||Organ recipients|Group of organ recipients
89215979|NCT05528471|Experimental|Intervention group|Iso-caloric and low fructose /low HFCS diet (~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) (n=35)
89215980|NCT05528471|No Intervention|Control group|Iso-caloric with higher fructose diet (~10% of TEI; HFCS max 20-30% of total fructose intake) (n=35)
89215981|NCT05527574|Experimental|Exercise Intervention Frail|Resistance Exercise Intervention (home video education: resistance training and diet education) for Frail participants
89215982|NCT05527574|No Intervention|Standard of Care or Control Frail|Standard of Care (standard diet and physical activity education) for Frail Participants
89215983|NCT05527574|Experimental|Exercise Intervention Pre-Frail|Resistance Exercise Intervention (home video education: resistance training and diet education) for Pre-Frail participants
89215984|NCT05527574|No Intervention|Standard of Care or Control Pre-Frail|Standard of Care (standard diet and physical activity education) for Pre-Frail Participants
89680927|NCT02853149|Experimental|Spinal Cord Injury (SCI)|Experimental: Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) for Spinal Cord injury individuals enrolled with their caregivers, can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
89680928|NCT02853149|Active Comparator|Caregiver Intervention(CCC)|Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
89680929|NCT02853149|Placebo Comparator|Caregiver Control (CC)|Placebo: This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life. The control group intervention will test benefits of exercise alone while controlling for investigator contact.
89680930|NCT01678664|Experimental|embolization or chemoembolization plus everolimus|After 2 sessions of embolization with microsphere of 100 to 500 µm or chemoembolization with 100 mg of doxorubicine and 10 ml of lipiodol, administered every day, 10 mg of everolimus during 24 months or until progression (hepatic and other site).
89680931|NCT00597493|Experimental|Sorafenib + Temozolomide|"Subjects receive 400mg of Sorafenib twice daily and 50mg/m^2 of Temozolomide once daily~Subjects continue to receive treatment until any of the following: progressive disease, unacceptable toxicity, non-compliance with study guidelines, withdrawal of patient consent, intercurrent non-cancer-related illness that prevents continuation of therapy or regular follow-up, general or specific changes in a subject's condition which render the patient unacceptable for treatment in the judgement of the investigator, or study closure"
89680932|NCT03087422|Experimental|intervention|"The patients in this group will receive daily a text message (SMS) with some orientation about Homecare as an attempt to minimize the side effects of chemotherapy.~The text messages are based on oncology guidelines.The text messages contain information about water intake, emotional support, hygiene, immunity, nutrition, and physical activity. In addition, text messages about prevention and management of symptoms were also developed: nausea and vomiting, diarrhea, constipation, gas, changes in the skin and taste.~Also, the patients allocated in this group will receive the standard care."
89680933|NCT03087422|No Intervention|control|The patients allocated in this group will receive the standard care.
89680934|NCT02708147|Sham Comparator|Conventional treatment|"Conventional treatment means that there will be only contact with physician/paediatrician and maybe drugs prescription.~Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after."
89680935|NCT02708147|Experimental|Physiotheraphy + Conventional treatment|Apart Conventional treatment a Physiotherapy protocol (techniques and education) will be performed on 5 sessions and evaluations will be made after each session as well as on baseline and on the 3th, 5th and 21st days and an interview 30 days after.
89680936|NCT03086954|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
89680937|NCT02999893|Experimental|APR-246|"The trial regimen consists of the investigational agent APR-246, along with standard chemotherapy, Cisplatin and 5-FU. A maximum of 8 cycles of treatment will be given.~APR-246 and 5-FU must both commence on Day 1 and given on days 1 to 4 via intravenous infusion over 6 hours, whilst 5-FU must be given as a continuous infusion over 96 hours.~On Days 2-4, APR-246 must be given first via intravenous infusion over 6 hours, then commence cisplatin via intravenous infusion over one hour.~This is a dose-escalation study to determine the maximum tolerated dose (MTD) of the combination therapy. The 3 dose levels are described as follows:~Dose Level 1:~APR-246 Dose: 75mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI~Dose Level 2:~APR-246 Dose: 100mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI~Dose Level -1:~APR-246 Dose: 50mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI"
89680938|NCT03086720|Experimental|Sodium hypochlorite|Dentin pre-treatment with a experimental solution (sodium hupochlorite), after the dentin acid etching
89680939|NCT03086720|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching
89680940|NCT03990779||Children with congenital cardiac disease|Children with congenital cardiac disease who undergoing surgery
89680941|NCT03450668|Active Comparator|standard incubator|routinely used standard incubator already used in the neonatal unit
89680942|NCT03450668|Experimental|mOm incubator|new test incubator
89680943|NCT03963167||Patient in treatment with BDP/FF/G fixed combination|
89680944|NCT03086252|Experimental|Supportive care (patient-driven RBCT)|Patients undergo red blood cell transfusions (RBCT) based on their perception and/or the presence of anemia symptoms for up to 6 months.
89680945|NCT03963089|Experimental|Study group|"Measure pulse pressure variation and systolic pressure variation after each set of tidal volume to 6mL/kg, 10mL/kg and 14mL/kg. Measure respiratory variation of aortic blood flow peak velocity via transesophageal echocardiography at tidal volume of 10mL/kg.~Measure stroke volume index via transesophageal echocardiography before and 5 min after fluid loading with 10mL/kg of crystalloid."
89680946|NCT00597727|Active Comparator|Blinded Peanut SLIT|Blinded subjects who received peanut sublingual drops for the initial 12 month blinded phase of the study.
89680947|NCT00597727|Placebo Comparator|Blinded Placebo SLIT|Blinded subjects who received placebo sublingual drops for the initial 12 month blinded phase of the study.
89680948|NCT00597727|Other|Ext. maint. open label peanut SLIT|After completing the blinded phase of the study, subjects receiving Blinded Peanut SLIT continued on extended maintenance open-label peanut SLIT for the duration of the study. Subjects receiving Blinded Placebo SLIT were crossed over and underwent the 12 month buildup protocol on open label peanut SLIT and then continued on extended maintenance treatment for the duration of the study.
89680949|NCT00597727|Other|Early unblinded peanut SLIT|Subjects who were unblinded prematurely during the blinded phase of the study and then re-enrolled as an open label cohort.
89680950|NCT00597727|Other|Pilot peanut SLIT rollover cohort|Subjects from the original phase 1 study of peanut SLIT (NCT00429429) who were rolled over into the current protocol as an open label peanut SLIT cohort.
89680951|NCT01678742|Experimental|High-protein diet|
89680952|NCT01678742|Active Comparator|Standard diet|
89680953|NCT03474770|Experimental|BIS-001ER|Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.
89680954|NCT03952169|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
89680955|NCT03952169|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
89680956|NCT04270201||Case group|OSCC patients (n = 60)
89680957|NCT04270201||Control group|Healthy volunteers (n = 240)
89680958|NCT03949907|Other|Nutritional counseling alone|Nutritional counseling consists of a personalized dietary prescription with regular consultation by a registered dietitian and telephone interviews, as well as of the use of oral nutritional supplements, when necessary.
89680959|NCT03949907|Experimental|Supplemental parenteral nutrition plus nutritional counseling|Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.
89680960|NCT04690829||control|control with non-inflammatory related eye disease
89680961|NCT04690829||control (healthy participant)|healthy volunteer
89680962|NCT04690829||uveitis|patients with a diagnosis of uveitis or ocular inflammation
89680963|NCT00707863|Other|Depressed Subjects Age: 18 - 25 yrs|Subjects receiving Escitalopram (trade name: Lexapro) that are in the age range of 18-25
89680964|NCT00707863|Other|Depressed Subjects Age: 16 - 50 yrs|Subjects receiving Escitalopram (trade name: Lexapro) in the age range of 26-50
89680965|NCT00565643|Experimental|HA-CMC Group|Hyaluronic Acid-Carboxymethylcellulose placed as an adhesion barrier
89680966|NCT00565643|Placebo Comparator|Routine Closure Group|Routine Closure without placement of an adhesion barrier
89680967|NCT00708019|Experimental|Low dose|Low dose of the psychoeducational intervention (i.e., 8.0 hours with the intervention nurse over 10 weeks)
89680968|NCT00708019|Experimental|High dose|High dose of the psychoeducational intervention (i.e., 12.3 hours with the intervention nurse over 10 weeks)
89680969|NCT05246501|Experimental|Simulation|
89680970|NCT05246501|Active Comparator|control group|
88996623|NCT04883632|Active Comparator|Volume Lidocaine C1|Subjects randomized to be treated with Saypha Volume Lidocaine manufactured in the Croma Pharma C1 Facility
88996624|NCT04878874|No Intervention|No Intervention:hip flexion|hip flexion pre measurement with extension knee will be performed
89680971|NCT04386733||Cancelled|all adult patients whose surgery was cancelled on the day of the planned procedure
89680972|NCT04386733||Non-cancelled|all adult patients whose surgery was not cancelled on the day of the planned procedure
89680973|NCT05246423||Observation group|Patients with paroxysmal atrial fibrillation, recruited at least two weeks after the last paroxysm
89680974|NCT02321527|Experimental|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™). Ultrasound images and videos of tumor and lymph nodes in underarm area taken. Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery. Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
89680975|NCT03889535|Active Comparator|Resin strip crowns|Current standard full coverage restoration provided for primary incisors. Please see intervention section for detailed description of technique.
89680976|NCT03889535|Experimental|Zirconia crowns|Experimental treatment under study. Zirconia crowns are an alternative restorative option. Please see intervention section for detailed description of technique.
89680977|NCT01798511|Experimental|Nasogastric Tube Feeding|Patients who are to have NTF will receive enteral nutrition within 6 hours after randomisation via a nasogastric tube placed into the stomach. A commercially available low fat semi-elemental feed (Peptisorb®, Nutricia Clinical NZ) will be used. The caloric target will be 2000 kcal per day. Enteral tube feeding will be commenced at a rate of 30 mL/h and increased gradually until 100 mL/h over 24-48 h.
89680978|NCT01798511|Active Comparator|Conventional Nutritional Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case enteral tube feeding will be introduced) or the signs of AP mitigate,in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced.
89680979|NCT02998411||AI treatment and dosage|
89680980|NCT01798277|Active Comparator|Catheter Ablation|Radiofrequency ablation procedure
89680981|NCT01798277|Active Comparator|Medical therapy|Antiarrhythmic drug therapy will include amiodarone or sotalol. Which antiarrhythmic drug will prescribed per patient depends on the observing physician.
89680982|NCT04344847|Other|coincidental GIST during LSG patients|With institutional review board approval from Zagazig University Hospitals 338. A double-centre prospective study was conducted on prospectively collected data of all morbidly. 17 patients in Zagazig University Hospitals, Faculty of Medicine, Egypt and 321 patients done in bariatric surgery excellence unit in a tertiary hospital in Riyadh-KSA.
89680983|NCT00598507|Experimental|Chemotherapy - ZK-EPO|ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.
89680984|NCT00566579|Experimental|A|Double-freezing cryotherapy was done within one month after the primary hpv testing was positive. Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
89680985|NCT00566579|No Intervention|B|Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
89680986|NCT00566813|Active Comparator|Group 1 (Islet Cell Transplant)|1-3 Islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for three months post-transplant and 7-10 ng/mL therafter; tacrolimus dosed to maintain serum trough levels 3-6 ng/mL throughout the study.
89680987|NCT00566813|Active Comparator|Group 2 (Islet Cell Transplant plus)|1-3 islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for 3 months post-transplant and 7-10 mg/mL thereafter; tacrolimus dosed to serum trough levels 3-6 ng/mL throughout the study; etanercept 50 mg IV pre-transplant, 25 mg subcutaneously post-transplant Days 3, 7, 10; exenatide 5-mcg subcutaneously twice daily for I week, then up to 10-mcg twice daily for 6 months after the last islet transplant.
89680988|NCT00088166|Experimental|I|Patients will take hCRF (XERECEPT) 2mg/day and open label-dexamethasone they are currently taking.
89680989|NCT00088166|Placebo Comparator|II|Patient will receive placebo hCRF and any open-label dexamethasone that they are currently taking
89680990|NCT00566969|Placebo Comparator|Sugar Pill|To be compared to active drug
89680991|NCT00566969|Active Comparator|Carvedilol 25 mg|To be compared to placebo and Carvedilol 50 mg
89215985|NCT05527171|Experimental|VR Mindfulness Meditation Group|Participants will complete 8-weeks of virtual reality mindfulness meditation and an advanced neuromuscular training program. Mindfulness meditation is the practice of sustaining attention on the body, breath, or sensations in any given moment and allows for the self-regulation of attention by decreasing rumination about past or future events. During the practice of mindfulness meditation, the individual is aware of all incoming thoughts and feelings, but rather than reacting to them, the individual accepts them. Virtual reality mindfulness meditation has been demonstrated to be superior in inducing mindfulness states when compared to traditional mindfulness meditation. Use of a virtual reality system to implement mindfulness meditation not only decreases the barrier of time to implement psychological interventions, but also improves the clinician's confidence in implementing the intervention as the virtual reality system guides the patient through the mindfulness meditation process.
89215986|NCT05527171|Sham Comparator|VR Sham Group|Participants will complete 8-weeks of virtual reality sham and an advanced neuromuscular training program. Participants will be immersed in a virtual environment but will not receive the mindfulness meditation.
89215987|NCT05527041||Concussed|Subjects age 17-34 years within 72 hours of injury.
89215988|NCT05527041||Non-concussed|In Phase I, uninjured, matched controls. In Phase II, subjects completing baseline concussion testing as part of the standard of care or athletics pre-season.
89215989|NCT05526664||Gaucher Type 1|"The participant was diagnosed with Gaucher type 1 disease~Adults only"
89680992|NCT00566969|Active Comparator|Carvedilol 50 mg|To be compared to placebo and Carvedilol 25 mg
89680993|NCT03086564|Experimental|ADCC & TACE|"The first course :~Patients in the first day of a clinical course will be performed TACE solely and keep 40ml blood sample as baseline sample for scientific research;in the 17th day, 10ml blood will be taken to culture activated dendritic cells;in 29th day, cyclophosphamide(CY) 250mg/m2 is used through an intravenous drip;in 31th day,patients are going to be performed TACE,1-2*10^8 activated dendritic cells are dripped through peripheral vein, 40ml blood sample will be taken for clinical research, simultaneously.~The 31th day in the first course is the same as the first day of the second course, then we come to next therapy course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
89680994|NCT03086564|Active Comparator|TACE|"Every course:~In the first day,patients are performed TACE solely and taken 40ml blood as baseline sample for scientific research;in the 29th day,patients are needed to reach hospital to check related indicators. In the 31th day, patients are performed TACE again.~The 31th day is the same as the first day in the second course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
89680995|NCT05363423||Procedure/Surgery: lateral pedicled nasoseptal flaps applied in Draf III procedure|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Tumors were totally resected under endoscope and lateral pedicled nasoseptal flaps were applied for covering the exposed bone around frontal neo-ostium. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa."
89680996|NCT05363423||Procedure/Surgery: no flaps applied in Draf III procedure|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Tumors were totally resected under endoscope and no flaps were applied."
89680997|NCT00598663|Experimental|Off/On|"6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose [Device: Paradigm® Real-Time pump with Sensor Off feature]~4 month wash out period~6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) [Device: Paradigm® Real-Time pump with Sensor On feature continuously]"
89051341|NCT01154101|Active Comparator|Cohort 2 - 500mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 2 will commence after Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 2 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
89051342|NCT01154101|Active Comparator|Cohort 3 - 1000mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 3 will commence after Cohort 2 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 3 will be administered four SRT2104 capsules at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
89051343|NCT01154101|Active Comparator|Cohort 1 - 250mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 1 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff.~Dosing for Cohort 2 will not commence until Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee."
89051344|NCT04313218||A|recieved carbetocin 100ug iv after immediately after extraction of the fetus during cesarean section
89051345|NCT04313218||B|women who received misoprostol 600ug rectally immediately before sterilization during cesarean section
89051346|NCT04590261|Other|group 1|Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment
89051347|NCT04590261|Other|Group 2|Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, > 5 L/mn Oxygen treatment
89051348|NCT04590261|Other|Group 3|Physician examination in the Pneumology ward, Cochin Hospital
89051349|NCT04590261|Other|Group 4|Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital
89051350|NCT00624871|Active Comparator|A|Infants will receive intravenous ascorbic acid and oral ibuprofen for 3 days
89051351|NCT00624871|Placebo Comparator|B|Infants will receive equivalent amount of placebo
89051352|NCT01153984|Experimental|Erlotinib|Participants will receive 150 milligrams (mg) erlotinib orally daily until disease progression, unacceptable toxicity, withdrawal due to any reason or death.
89215990|NCT05526664||Gaucher Type 3|"The participant was diagnosed with Gaucher type 3 disease~Adults only"
89215991|NCT05526664||Healthy Volunteer|"Healthy participants~Adults only"
89680998|NCT00598663|Experimental|On/Off|"6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) [Device: Paradigm® Real-Time pump with Sensor On feature continuously]~4 month wash out period~6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose [Device: Paradigm® Real-Time pump with Sensor Off feature]"
89680999|NCT04350489||Control|Periodontally healthy group
89681000|NCT04350489||Periodontitis|Patients with periodontitis
89681001|NCT02987673|Experimental|Mini/One anastomosis gastric bypass|Execution of a laparoscopic mini/one anastomosis gastric bypass (MGB/OAGB)
89681002|NCT02987673|Active Comparator|Laparoscopic sleeve gastrectomy|Execution of a laparoscopic sleeve gastrectomy (LSG)
89681003|NCT03731819|Experimental|Follow-up participants|Patients who met eligibility criteria. Participants are going to undergo Abbreviated PB MRI.
89681004|NCT00704353|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
89681005|NCT00704353|Active Comparator|Standard Medical Care|Per product label
88996625|NCT04878874|Experimental|Experimental: hip flexion|hip flexion post experimental application measurement with Magnetic tape Application with extension knee will be performed
88996626|NCT04878874|Placebo Comparator|Placebo Comparator: hip flexion|hip flexion post placebo application measurement with kinesiology tape Application with extension knee will be performed
88996627|NCT02569645|Experimental|Single Arm - Rosuvastatin|This is a single arm, of Rosuvastatin (Crestor®) 40 mg orally daily starting 2 weeks prior to the initiation of radiation at week 1 and stopped 4 weeks after the completion of radiation at the start of week 12 or 13, depending on whether 25 or 30 fractions of radiotherapy are given.
88996628|NCT02500147|Experimental|Metformin|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Metformin ER (extended release) will be administered as two pills of 500 mg each. For the first week subjects will take one pill orally on a daily basis and thereafter will take two pills orally on a daily basis. The intervention will last six months.
88996629|NCT02500147|Placebo Comparator|Placebo|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Subjects randomized to placebo will be instructed to take one pill daily by mouth for one week and then to take one pill daily by mouth for the remainder of six months.
88996630|NCT04686370|Active Comparator|sandblasted acid-etched implants|implant will be installed intraforaminal
88996631|NCT04686370|Experimental|laser treated implants|implant will be installed intraforaminal
88996632|NCT00182052|Active Comparator|Group 1|
88996633|NCT00182052|Placebo Comparator|Group 2|
88996634|NCT00156026|Experimental|1|Immediate Treatment - LEEP - Loop electrosurgical excision procedure
88996635|NCT00156026|No Intervention|2|Colposcopic Follow-up
88996636|NCT01715974|Placebo Comparator|CONTROL|patients with recurrent implantation failure treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
88996637|NCT01715974|Experimental|GM-CSF group|patients with recurrent implantation failure treated with GM-CSF (30 micrograms/day) from the day of embryo transfer through the day of beta hCG test
88996638|NCT00535756|Experimental|1|
88996639|NCT00535756|Placebo Comparator|2|
88996640|NCT00156182|Experimental|1|
88996641|NCT05471479|Experimental|AC as per the Clinical Toxicology Recommendations Collaborative recommendations|
88996642|NCT05471479|Active Comparator|AC as per current practice|
88996643|NCT00535795|Active Comparator|1|Conventional Radiation Therapy (XRT), one fraction per day, from Sunday to Thursday every week.
88996644|NCT00535795|Experimental|2|Conventional Plus accelerated boost Radiation Therapy (XRT), from Sunday to Thursday every week.
88996645|NCT05471362||Cases women who used IUD|Cases: women who had immediate Copper IUD inserted since October 2021 at the 4 public hospitals
89681006|NCT05246033|Experimental|TransCon CNP 50 mcg|TransCon CNP 50 mcg CNP/kg or placebo mimicking TransCon CNP 50 mcg delivered once weekly by subcutaneous injection
89681007|NCT05246033|Experimental|TransCon CNP 100 mcg|TransCon CNP 100 mcg CNP/kg or placebo mimicking TransCon CNP 100 mcg delivered once weekly by subcutaneous injection
89681008|NCT05246033|Placebo Comparator|Placebo|Placebo delivered once weekly by subcutaneous injection
89681009|NCT00598819|Experimental|Healthy Volunteers|Healthy subjects testing the device.
88996646|NCT05471362||Control women who didn't use IUD|Controls: women who gave birth at the same hospitals and not using the immediate Copper IUD
88996647|NCT05471284|Sham Comparator|Control|The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.
88996648|NCT05471284|Experimental|Proximal x Cost x Loss|Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
88996649|NCT05471284|Experimental|Proximal x Cost x Gain|Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
88996650|NCT05471284|Experimental|Proximal x Benefit x Gain|Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
88996651|NCT05471284|Experimental|Proximal x Benefit x Loss|Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
88996652|NCT05471284|Experimental|Distal x Cost x Gain|Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.
88996653|NCT05471284|Experimental|Distal x Cost x Loss|Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.
88996654|NCT05471284|Experimental|Distal x Benefit x Loss|Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.
88996655|NCT05471284|Experimental|Distal x Benefit x Gain|Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.
88996656|NCT05471167||Birth cohort 2010|Children born from 01/07/2010 followed up until 30/06/2016
88996657|NCT05471167||Birth cohort 2011|Children born from 01/07/2011 followed up until 30/06/2017
88996658|NCT05471167||Birth cohort 2012|Children born from 01/07/2012 followed up until 30/06/2018
89681010|NCT00087698|Experimental|A|chemotherapy, surgery then chest radiation x 54 gray (Gy)
89681011|NCT03755739|Experimental|Pembrolizumab via localized infusion|"This group dividied into two subgroups:~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, plus chemotherapy, every 3 weeks.~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a total dose of 150mg via intra-tumor fine needle injection in 5 min, plus doxorubicin, every 3 weeks."
89681012|NCT03755739|Active Comparator|Checkpoint inhibitor (CPI) Pembrolizumab plus chemotherapy via vein infusion|Checkpoint inhibitor (CPI) such as Pembrolizumab is administrated with a total dose of 2mg/kg via vein infusion (30 min), plus chemotherpy every 3 weeks.
89681013|NCT05363033||one group|Using a one-group pretest-posttest design
89681014|NCT05245721|Active Comparator|Nalbuphine|
89681015|NCT05245721|Active Comparator|Bupivacaine|
88996659|NCT05471167||Birth cohort 2013|Children born from 01/07/2013 followed up until 30/06/2019
88996660|NCT05471167||Birth cohort 2014|Children born from 01/07/2014 followed up until 30/06/2020
88996661|NCT05471167||Birth cohort 2015|Children born from 01/07/2015 followed up until 30/06/2021
88996662|NCT05471167||Birth cohort 2016|Children born from 01/07/2016 followed up until 30/06/2022
88996663|NCT05471167||Birth cohort 2017|Children born from 01/07/2017 followed up until 30/06/2022
88996664|NCT05471167||Birth cohort 2018|Children born from 01/07/2018 followed up until 30/06/2022
88996665|NCT05471167||Birth cohort 2019|Children born from 01/07/2019 followed up until 30/06/2022
88996666|NCT05471167||Birth cohort 2020|Children born from 01/07/2020 followed up until 30/06/2022
88996667|NCT05471050|Experimental|tacrolimus and Danazol|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
88996668|NCT05471050|Active Comparator|Danazol|Danazol is given at 200mg bid for 12 weeks.
88996669|NCT05470972|Experimental|Ovarian Endometrioma|Ovarian endometrioma (OE) is in women of reproductive age
88996670|NCT04686019|Experimental|Intervention group|"2 x IMT (5-10 min) 2 times a day 7 days a week for 3 weeks with or without supervision~Log-book~Conventional neurorehabilitation"
88996671|NCT04686019|Active Comparator|Control group|Conventional neurorehabilitation
88996672|NCT04686058|Active Comparator|TCI propofol|Target controlled infusion propofol titrated by the investigator intra-procedure, based on the Modified Observer's Assessment of Alertness and Sedation Scale
88996673|NCT04686058|Active Comparator|PCS propofol|Patient-controlled sedation titrated by the patient to comfort level
88996674|NCT04686058|Active Comparator|midazolam and pethidine|Midazolam and pethidine bolus doses administered by the investigator based on clinical parameters and observation
88996675|NCT00156299|Experimental|Dexamethasone plus Choline Magnesium Trisalicylate|Dexamethasone plus Choline Magnesium Trisalicylate
88996676|NCT00156299|Experimental|Choline Magnesium Trisalicylate|Choline Magnesium Trisalicylate
88996677|NCT00535912|No Intervention|A|¨Chemotherapy by 12 courses of CHOP
88996678|NCT00535912|Active Comparator|B|¨Chemotherapy by 3 courses of CHOP, intensification and autograft
88996679|NCT00535951|Experimental|LBH589|
88996680|NCT00536029||A|Subject with pigmented skin lesion suspect for malignant melanoma
89681016|NCT04402892|Active Comparator|Patients hospitalized for SARS-CoV-2|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
89681017|NCT04402892|Active Comparator|Patients who have recovered from CoV-2-SARS|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
89681018|NCT02987985|Experimental|Opioid-free anesthesia|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis
89681019|NCT02987985|Active Comparator|Opioid-sparing anesthesia|Opioid-sparing preoperative medications, Opioid sparing pre-intubation medications, Opioid-sparing maintenance medications, postoperative nausea and vomiting prophylaxis
89681020|NCT03739749|Active Comparator|Fascia lata autograft|Arthroscopic superior capsular reconstruction using a fascia lata autograft
89681021|NCT03739749|Active Comparator|Fascia lata allograft|Arthroscopic superior capsular reconstruction using a fascia lata allograft
89681022|NCT03739749|Active Comparator|Achilles tendon allograft|Arthroscopic superior capsular reconstruction using an achilles tendon allograft
89681023|NCT03739749|Active Comparator|Bovine pericardium allograft|Arthroscopic superior capsular reconstruction using a bovine pericardium allograft
89681024|NCT03739749|Active Comparator|Swine dermal xenograft|Arthroscopic superior capsular reconstruction using a swine dermal xenograft
88996681|NCT00156338|Experimental|1|volume and sodium restriction
88996682|NCT00156338|Active Comparator|2|volume restriction
88996683|NCT00156338|Active Comparator|3|liberal fluid management
88996684|NCT00536068|Experimental|1, 2, 3, 4|"acetylsalicylic acid 100 mg/po,acetaminophen 3x1g/po~acetylsalicylic acid 100 mg/po,diclofenac 3x50mg/po~acetylsalicylic acid 100 mg/po,naproxen 3x250mg/po~acetylsalicylic acid 100 mg/po,placebo 3x1/po"
88996685|NCT05470660|Experimental|Root coverage using coronally advanced flap combined with micro-needling|modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing
88996686|NCT05470660|Active Comparator|coronally advanced flap combined with Alloderm|modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
88996687|NCT05470582|Experimental|Flu-M, children aged 3-9 years|
88996688|NCT05470582|Active Comparator|Vaxigrip, children aged 3-9 years|
88996689|NCT05470582|Experimental|Flu-M, children aged 6-35 months|
88996690|NCT05470582|Active Comparator|Vaxigrip, children aged 6-35 months|
88996691|NCT05470231|Active Comparator|Beetroot juice|The swimmers ingested a shot of Beet-It 70 ml beetroot juice (BJ)) 3 hours before undergoing a 6x100m crawl intermittent maximal speed performance test.
89681025|NCT03739749|Active Comparator|Collagen allograft|Arthroscopic superior capsular reconstruction using a collagen allograft
89681026|NCT03626129|No Intervention|Traditional rapid deflation|"Group A: At time of sheath removal 15 ml. air is inflated in the TR-band. The sheath is removed. Air is deflated until bleeding, and 1-2 ml. air is then re-inflated to achieve hemostasis, and the volume air inflated is registered (Initial inflated air volume). Every 20 minutes 1/3 of the initial inflated air volume is deflated. If bleeding occurs then air is re-inflated until hemostasis and then additional 1-2 ml. air is inflated. This routine is repeated until hemostasis is achieved (TR-band fully deflated without bleeding)."
89215992|NCT05525390|Active Comparator|Traditional Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life. Participants will complete the PHQ-9 and their activity monitoring and scheduling on separate worksheets.
89215993|NCT05525390|Experimental|XR-Enhanced Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in extended reality (XR). Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick at least four pleasurable activities to enjoy in extended reality. Participants will complete their post-XR surveys and add and schedule activities on separate worksheets.
89215994|NCT05523986|Experimental|Experimental: Treatment group|Vitamin D (2000IU/day) for 6 months
89215995|NCT05523986|Placebo Comparator|Placebo Comparator: Control group|placebo
89215996|NCT05521789|Experimental|Standard of Care + ESB Thoracic|Patients randomized to this group will receive an erector spinae block in addition to the standard of care treatment
89215997|NCT05521789|No Intervention|Standard of Care|Patients randomized to this group will receive standard of care treatment and NO erector spinae block
89681027|NCT03626129|Experimental|Oximetry guided deflation|"Group B: Initial step with sheath removal as in group A. Before departure from the cath.lab. a Patent hemostasis test (see description in Interventions below) is performed. Further action as described in Interventions below."
89681028|NCT03715959|Experimental|Diagnostic (nipple aspiration fluid)|Participants and healthy volunteers undergo collection of nipple aspirate fluid from both breasts.
89681029|NCT00708721|Experimental|All patients|All participants enrolled.
89681030|NCT00087152|Experimental|Imatinib Mesylate & Capecitabine|
89681031|NCT05362799|Active Comparator|GROUP 1|GROUP 1: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
89681032|NCT05362799|Active Comparator|GROUP 2|GROUP 2: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
89215998|NCT05520255|Experimental|18F-PSMA-1007|18F-PSMA-1007, 4 MBq/kg (max 400 MBq; +/- 15%), intravenous, single dose
89681033|NCT05362799|Active Comparator|GROUP 3|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
89681034|NCT05362799|Active Comparator|GROUP 4|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
89681035|NCT01940523|Active Comparator|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
89681036|NCT01940523|Active Comparator|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
89681037|NCT02994199|Experimental|Active video gaming|Participants will engage in active video game play.
89681038|NCT03577379|No Intervention|Control|Patients in the control arm will receive standard of care for their rotator cuff tear, and will not receive the additional whole blood fibrin clot.
89681039|NCT03577379|Experimental|Treatment|Patients in the control arm will receive standard of care for their rotator cuff tear, in addition to, the whole blood fibrin clot.
89681040|NCT02994433|Experimental|Nitrous Oxide|One hour inhalation of nitrous oxide
89681041|NCT02994433|Placebo Comparator|Placebo Gas|One hour inhalation of placebo gas
89681042|NCT02281851||Supplemented|The group consists of well-trained cyclists who habitually consume vitamin/antioxidant supplements for a period longer than 6 months
89681043|NCT02281851||Non-supplemented|The group consists of well-trained cyclists who do not consume vitamin/antioxidant supplements
89681044|NCT01679288|Experimental|ultrasound arm|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
89681045|NCT04388189|Experimental|Duloxetine|Duloxetine 60 mg daily for 8 weeks
88996692|NCT05470231|Placebo Comparator|Placebo|The swimmers ingested a shot of Beet-It (70 ml placebo (PL)) 3 hours before undergoing a 6x100m crawl intermittent maximal speed performance test.
89215999|NCT05509855||Patients treated with WU-CART-007|Patients who received previous treatment with WU-CART-007
89681046|NCT04388189|Active Comparator|Bupropion|Bupropion 150-450 mg daily for 8 weeks
89681047|NCT02994277|Experimental|UVa and ITBA/UNLP algorithm arm|To control glycaemia in T1DM patients through UVa and ITBA/UNLP algorithm
88996693|NCT00536185|Experimental|1|
88996694|NCT00536185|Placebo Comparator|2|
88996695|NCT00156416|Experimental|Meditation group|Participants received 8 weeks of mindfulness meditation instruction and support
89681048|NCT05362643|Experimental|Acupuncture Group|Experimental groups were divided into subgroup A and B and both received a total of 9 acupuncture treatments. However Acupuncture Subgroup A received 3 acupuncture sessions over 3 weeks and Acupuncture Subgroup B received 1 acupuncture session for 9 weeks. The same selection of acupuncture points were applied to both subgroups.
89681049|NCT05362643|Placebo Comparator|Sham Acupuncture Group|"Sham Acupuncture groups were also divided into subgroup A and B and both received a total of 9 treatments. Sham Acupuncture subgroup A received 3 sessions over 3 weeks and Sham Acupuncture subgroup B received 1 session for 9 weeks.~Sham Acupuncture subgroups received acupuncture on non-acupuncture points."
89681050|NCT05362643|No Intervention|Non-Acupuncture Group|Non-acupuncture treatment.
89681051|NCT00599053|Experimental|1|Early treatment with azithromycin
89681052|NCT00599053|No Intervention|2|Expectant (usual) management
89681053|NCT05223023||1/Assessment of the opinions of the physiotherapists|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
89681054|NCT05362565||Patient with salivary sampling|
89681055|NCT02999971|Experimental|circuit class therapy in water|CCT on water. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
89681056|NCT02999971|Experimental|circuit class therapy on land|CCT on land. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
89681057|NCT01941927|Experimental|Trametinib, GSK2141795|"Trametinib (GSK1120212)~Oral~2 mg~Daily~Number of Cycles: until progression or unacceptable toxicity develops~GSK2141795~Oral~25 mg~Daily~Number of Cycles: until progression or unacceptable toxicity develops"
89681058|NCT05220917||SGLT-2i (Comparison 1)|For SGLT-2i vs. DPP4i SGLT-2i - exposure group DPP4i - referent group
89681059|NCT05220917||DPP-4i (Comparison 1)|For SGLT-2i vs. DPP4i SGLT-2i - exposure group DPP-4i - referent group
89681060|NCT05220917||SGLT-2i (Comparison 2)|For SGLT-2i vs GLP-1 RA SGLT-2i - exposure group GLP-1 RA - referent group
89681061|NCT05220917||GLP-1 RA (Comparison 2)|For SGLT-2i vs GLP-1 RA SGLT-2i - exposure group GLP-1 RA - referent group
89681062|NCT05220917||GLP-1 RA (Comparison 3)|For GLP-1 RA vs DPP-4i GLP-1 RA - exposure group DPP-4i - referent group
89681063|NCT05220917||DPP-4i (Comparison 3)|For GLP-1 RA vs DPP-4i GLP-1 RA - exposure group DPP-4i - referent group
89681064|NCT05220917||SGLT-2i (Comparison 4)|For SGLT-2i vs SU SGLT-2i - exposure group SU - referent group
89681065|NCT05220917||SU (Comparison 4)|For SGLT-2i vs SU SGLT-2i - exposure group SU - referent group
89681066|NCT05220917||GLP-1 RA (Comparison 5)|For GLP-1 RA vs SU GLP-1 RA - exposure group SU - referent group
89681067|NCT05220917||SU (Comparison 5)|For GLP-1 RA vs SU GLP-1 RA - exposure group SU - referent group
89681068|NCT05220917||DPP-4i (Comparison 6)|For DPP-4i vs SU DPP-4i - exposure group SU - referent group
89681069|NCT05220917||SU (Comparison 6)|For DPP-4i vs SU DPP-4i - exposure group SU - referent group
89681070|NCT05220917||SGLT2i (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
89681071|NCT05220917||GLP-1 RA (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
89051353|NCT02884375||Elderly cancer patient cohort|Patients aged 70 years or older, who had diagnosis of cancer in participating sites (including hematologic malignancies), and referred to a geriatrician for geriatric assessment (GA)
89681072|NCT05220917||DPP-4i (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
89681073|NCT05220917||SU (Comparison 7)|For SGLT2i vs. GLP-1RA vs. DPP-4i vs. SU (4-way comparison) SGLT2i, GLP-1 RA, and SU - exposure groups DPP-4i - referent group
89681074|NCT05220917||SGLT2i (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
89681075|NCT05220917||GLP-1 RA (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
89681076|NCT05220917||DPP-4i (Comparison 8)|For SGLT2i vs. GLP-1RA vs. DPP-4i (3-way comparison) SGLT2i and GLP-1 RA - exposure groups DPP-4i - referent group
89681077|NCT01942707|Active Comparator|Abdominoplasty without Scarpa´s Facia|Anchor-line abdominoplasty where the Scarpa's Fascia will be removed.
89681078|NCT01942707|Experimental|abdominoplasty with Scarpa's Fascia|Anchor-line abdominoplasty where the Scarpa's Fascia will be preserved.
89681079|NCT00086996|Experimental|Chemo Plus RT, Surgery, Chemo|neoadjuvant fluorouracil, oxaliplatin and radiation therapy followed by conventional surgery and adjuvant fluoruracil and oxaliplatin
89681080|NCT05362253|Experimental|experimental group|The experimental group received micro-conjunctival autograft combined with amniotic membrane transplantation.
89681081|NCT05362253|Active Comparator|control group|The control group received given routine autologous conjunctival transplantation.
89681082|NCT03453203|Placebo Comparator|Control|"Both arms with be diagnosed using tenderpoints In the control arm the tenderpoint will Be palpated for 90 secs with no counterstrain treatment applied.~Both treatment and control groups will remain on their current migraine medication regiment."
89051354|NCT04623203||children with migraine|Children that were diagnosed at the neurology clinic with migraine at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
89051355|NCT04623203||children with TTH|children that were diagnosed at the neurology clinic with TTH at the years 2007-2010. A follow up visit at 2020 of their current headache condition.
89051356|NCT05250271|Other|Treatment sequence 1|Sequence of the treatments: Glucose (15g) - Glucose (5g) -Protein bar
89051357|NCT05250271|Other|Treatment sequence 2|Sequence of the treatments: Glucose (15g) - Protein bar - Glucose (5g)
89051358|NCT05250271|Other|Treatment sequence 3|Sequence of the treatments: Glucose (5g) - Glucose (15g) - Protein bar
89051359|NCT05250271|Other|Treatment sequence 4|Sequence of the treatments: Glucose (5g) - Protein bar - Glucose (15g)
89051360|NCT05250271|Other|Treatment sequence 5|Sequence of the treatments: Protein bar - Glucose (15g) - Glucose (5g)
89051361|NCT05250271|Other|Treatment sequence 6|Sequence of the treatments: Protein bar - Glucose (5g) - Glucose (15g)
89051362|NCT04623359|Experimental|Patients|Patient with constipation will have a high resolution manometry
89051363|NCT04623359|Other|Healthy volunteers|Healthy volunteers will have a high resolution manometry
89051364|NCT01153633|Active Comparator|Prontosan Wound Solution and Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
89681083|NCT03453203|Other|Treatment (conterstrain)|Both arms with be diagnosed using tenderpoints. Treatment arm will be treated with counterstrain technique. Counterstrain is a passive manipulative technique which the tissue being treated is positioned at a point of balance, or ease, AWAY from the restrictive barrier (The most thought of form of manipulative technique is high velocity low amplitude which is typically performed by chiropractors in spinal manipulation which goes TOWARD the restrictive barrier and actually pass through the restrictive barrier). Once a tenderpoint is found in the muscles the area of treatment is placed in a (three dimensional) position that will eliminate the sensation (tenderness).The treatment position is held for 90 seconds or until a release is felt (a decrease in muscle tension). Both treatment and control groups will remain on their current migraine medication regiment.
89681084|NCT01943565|Active Comparator|Hydromorphone 25mcg|The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
88996696|NCT00156416|Active Comparator|Education group|Participants received 8 weeks of healthy living instruction
88996697|NCT00536224|Active Comparator|2|Minimal counseling
88996698|NCT00536224|Experimental|1|Full counseling
88996699|NCT05470192|Experimental|Qigong Exercise Training and Conventional Physiotherapy and Rehabilitation Group|In addition to the conventional physiotherapy and rehabilitation program, qigong exercise training will be given to the qigong exercise training group by a certified physiotherapist who has received qigong training.
89051365|NCT01153633|Placebo Comparator|Normal Saline and Placebo Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
89051366|NCT04590183|Experimental|The experimental group|
89051367|NCT04590183|Sham Comparator|The control group|
89051368|NCT04623281||Observational group|Observational group of 10 haemodialysis patients following usual care for 3 weeks.
89051369|NCT01153321|Experimental|1|Oral treatment
89051370|NCT01153321|Placebo Comparator|2|Oral treatment
89051371|NCT04590456|Experimental|Placebo group|
89051372|NCT04590456|Experimental|PEMF group|
89051373|NCT04589871|Experimental|Group A|Group A received a taping technique in addition to the supervised exercises protocol
89051374|NCT04589871|Active Comparator|Group B|Group B received supervised exercises protocol only
89051375|NCT04622618|Active Comparator|G 300|The patients will receive 300 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
89051376|NCT04622618|Active Comparator|G 600|The patients will receive 600 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
89051377|NCT04622618|Active Comparator|G 900|The patients will receive 900 mg gabapentin orally 1 hour before induction of anesthesia by a sip of water
89051378|NCT04589949|Experimental|ConvP|300 mL convalescent plasma with a minimum of neutralizing antibodies
89051379|NCT04589949|Active Comparator|FFP|300 mL Fresh Frozen plasma
89051380|NCT04622852||Group A: ALPS-PHP device|Patients operated with angular stable plate for displaced PHF with an ALPS plate
89051381|NCT04622852||Group B: Philos device|Patients operated with angular stable plate for displaced PHF with a Philos plate
89051382|NCT04589793|No Intervention|Control|Conventional treatment
89051383|NCT04589793|Active Comparator|Intervention|Motivational interview
89051384|NCT04622891|Experimental|clarithromycin|clarithromycin group
89051385|NCT04622891|Active Comparator|Azithromycin|azithromycin group
89051386|NCT04622891|Placebo Comparator|control|control group
89051387|NCT04622579|Experimental|lenalidomide combined with rituximab|Rituximab 375 mg/m2 i.v d1 q28d； Lenalidomide 10mg Po. d1-21 q28d. After 6 cycles, patients obtained CR or PR will continue with Lenalidomide maintenance till the 24th month.
89051388|NCT04590066|No Intervention|Holdout control|Participants will only receive the standard pharmacy messaging.
89681085|NCT01943565|Active Comparator|Hydromorphone 50mcg|The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
89681086|NCT01943565|Active Comparator|Hydromorphone 100mcg|The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
89681087|NCT05362175||Cross sectional area of umbilical cord and Hadlock's formula|Ultrasound measurement of cross sectional area of umbilical cord within 1 cm from the umbilical cord insertion into the fetal abdomen And Fetal biometry using the standard Hadlock's formula
89681088|NCT03316859|Experimental|Naloxegol|naloxegol 25 mg pill
89216000|NCT05501678|Experimental|Diphenhydramine, then Placebo|"Participants will first receive Diphenhydramine for a 4-week period. A 25 mg dose of Diphenhydramine will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated.~Participants will then receive Placebo (fake tablet) for a 4-week period. A 25 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated."
89216001|NCT05501678|Experimental|Placebo, then Diphenhydramine|"Participants will first receive Placebo (fake tablet) for a 4-week period. A 25 mg dose of matching Placebo will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated.~Participants will then receive Diphenhydramine for a 4-week period. A 25 mg dose of Diphenhydramine will be given at bedtime for one week and then will increase to 50 mg if needed and if well tolerated."
89681089|NCT03316859|Placebo Comparator|Placebo|placebo pill
89681090|NCT04401878|Experimental|the treatment group (A)|Patients who have PDPH are manged by SPGB, they are assessed by NRS before the block, at 30 mins, 2h, 4h, 6h, 12h, and 24hours after block. The patients are also examined by TCD before and after the block.
89681091|NCT04401878|Experimental|control group (B)|The control group (B) of 60 patients with no PDPH were examined by TCD
89681092|NCT01880073|Experimental|FemVue device|FemVue would be used in conjunction with the laparoscopic chromopertubation to determine if it is as effective.
89681093|NCT05216159|Experimental|mHealth HAPA Intervention Group|This intervention group will receive a single one-on-one behavioural counselling session and weekly action and coping planning worksheets delivered through a downloaded smartphone application with the aim of increasing the breaking of consecutive work related sedentary behaviour. Counselling strategies will be grounded in the HAPA model, specifically focusing on the creation of action plans and the development of coping strategies to increase sedentary behaviour breaks. The weekly HAPA based worksheets will be sent out to participants at the beginning of their work week so that they can formulate their own personal action plans and coping strategies for the week to come. They will be prompted to refer back to the information conveyed in one-on-one counselling session where they should try to create action plans that are specific and meaningful to them. The intervention will last for a total of four weeks with the outcomes being measured through questionnaires.
89681094|NCT05216159|No Intervention|Control Group|The control group will receive no intervention or further instruction past the letter of information.
89681095|NCT01679366|No Intervention|Penicillin G|hospitalization of 30 patients given penicilline intraveniously for 72 hours
89681096|NCT01679366|Placebo Comparator|Placebo|30 hospitalized patients will be given placebo with a regular penicillin treatment
89681097|NCT01679366|Experimental|Probiotic|Probiotics will be given to 30 hospitalized patients with regular penicillin treatment
89681098|NCT05362019|Experimental|intervention group|"A mobile phone based service system developed by the research group will be used to provide one-to-one service for the intervention group."
89681099|NCT05362019|Active Comparator|control group|Routine family planning services will be provided to the control group.
89681100|NCT03654105|Experimental|Smoking cessation and Antinflammatory|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
89681101|NCT03654105|Experimental|Smoking cessation|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
89681102|NCT03654105|Experimental|Antinflammatory|reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
89681103|NCT03654105|Other|Control Group|standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
89681104|NCT05361863|Experimental|0.022×0.028-inch slot (Control Group)|Leveling and alignment will be performed with 0.016-inch, 0.016×0.022-inch and 0.019×0.025-inch HANT followed by a working archwire of 0.019×0.025-inch stainless steel (Hangzhou Xingchen 3B Dental Instruments and Materials Co., Hangzhou, China).
89681105|NCT05361863|Active Comparator|0.020×0.028-inch slot|Leveling and alignment will be carried out with 0.016-inch, 0.016×0.022-inch and 0.018×0.025-inch HANT followed by a working archwire of 0.018×0.025-inch stainless steel (Hangzhou Xingchen 3B Dental Instruments and Materials Co., Hangzhou, China).
89681106|NCT05361863|Active Comparator|0.018×0.028-inch slot for the anterior teeth and 0.022×0.028-inch slot for the posterior teeth|Leveling and alignment will be completed with 0.016-inch, 0.016×0.016-inch, and 0.016×0.022-inch HANT followed by a working archwire of 0.016×0.022-inch stainless steel (Hangzhou Xingchen 3B Dental Instruments and Materials Co., Hangzhou, China).
89681107|NCT04388111|No Intervention|Control Group|Patient receives an intraosseous injection of antibiotics into the tibia as per the standard of care for primary total knee arthroplasty under the study providers.
89681108|NCT04388111|Experimental|Intarosseous Morphine|Patient receives an intraosseous injection of antibiotics + 10mg of morphine into the tibia during their total knee arthroplasty.
89681109|NCT01880697|Experimental|TIVc (≥18 to ≤ 60 years) + TIVc (≥ 61 years)|Subjects in each age cohort received one dose of the cell-derived trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVc) formulation 2013/2014 Northern Hemisphere
89681110|NCT03309137|Experimental|Antiseptic device|Patients who are randomized to receive the device will receive Chlorhexidine at a dose of 0.24-0.42 mg/installation into all intravenous lines. The intervention will be administered every 24 hrs and as needed for as long as the intravenous is in place
89681111|NCT03309137|No Intervention|Routine Care|Patients who are randomized to routine care (no device, no intervention) will receive normal saline flush as per standard ICU care.
89216002|NCT05501522|Experimental|Primary series of mRNA-1273 manufactured by ModernaTX, Inc.|participants who received primary vaccination of a mRNA-1273 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
89216003|NCT05501522|Placebo Comparator|Primary series of mRNA-1273 manufactured by ModernaTX, Inc. (Placebo)|participants who received primary vaccination of a mRNA-1273 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
89216004|NCT05501522|Experimental|Primary series of ChAdOx1 nCOV-19 manufactured by Astrazeneca or S.I of India Pvt., Ltd.|participants who received primary vaccination of a ChAdOx1 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
89216005|NCT05501522|Placebo Comparator|Primary series of ChAdOx1 nCOV-19 manufactured by Astrazeneca or S.I of India Pvt., Ltd. (Placebo)|participants who received primary vaccination of a ChAdOx1 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
89216006|NCT05501522|Experimental|A single dose vaccination of Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson & Johnson|participants who received primary vaccination of a Ad26.COV2.S at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
89216007|NCT05501522|Placebo Comparator|A single dose vaccination of Ad26.COV2.S manufactured by Janssen Pharmaceuticals/J&J (Placebo)|participants who received primary vaccination of a Ad26.COV2.S at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive Placebo.
89216008|NCT05501522|Active Comparator|Primary series of BNT162b2 manufactured by Pfizer/BioNTech|participants who received primary vaccination of a BNT162b2 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
89216009|NCT05501522|Placebo Comparator|Primary series of BNT162b2 manufactured by Pfizer/BioNTech (Placebo)|participants who received primary vaccination of a BNT162b2 at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo.
89216010|NCT05501522|Experimental|Primary series of BBIBP-CorV manufactured by Sinopharm|participants who received primary vaccination of a BBIBP-CorV at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
89216011|NCT05501522|Placebo Comparator|Primary series of BBIBP-CorV manufactured by Sinopharm (Placebo)|participants who received primary vaccination of a BBIBP-CorV at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive placebo
89216012|NCT05501522|Active Comparator|Primary series of CoronaVac|participants who received primary vaccination of a CoronaVac at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose of GBP510 adjuvanted with AS03 (Test Vaccine).
89216013|NCT05501522|Placebo Comparator|Primary series of CoronaVac (Placebo)|participants who received primary vaccination of a CoronaVac at least 12 weeks prior to study vaccination will be enrolled and block-randomized in 6:1 ratio to receive one dose Placebo
89216014|NCT05497596|Experimental|Treatment group|Vitamin D (2000IU/day) for 6 months
89216015|NCT05497596|Placebo Comparator|Control group|placebo
89681112|NCT05361629|Active Comparator|NON-SURGERY GROUP|Group 1: Patients whose serum cortisol level was observed before starting the treatment, who were injected with 40 mg of prednol at 4 weeks intervals for 3 months for each lesion. The total monthly dose will not exceed 120 mg, and the total 3-month dose will not exceed 200 mg. In this group of patients, the serum cortisol level should have reappeared on the 2nd or 3rd day following each intralesional administration. In this group of patients, low-dose oral prednol (<30 mg/day) and/or topical prednol cream can be applied twice a day during the treatment.
89681113|NCT05361629|Active Comparator|SURGERY GROUP|"In patients included in Group 2, serum cortisol levels should have been observed before starting treatment. Then the patients should be operated and the mass(s) should be excised. Intraoperatively, not less than 40 mg of prednol should be injected into each mass cavity (it may vary according to the cavity diameter), and the amount applied to all cavities should not exceed 200 mg in total. The amount of prednol administered for each cavity should be recorded. In this group of patients, prednol may have been administered to the cavity walls (Group 2a) or inside the cavity (Group 2b). Serum cortisol levels should be seen in patients 7 to 10 days after the procedure.~Group 2a: 4 Quadrants 40 mg predmol per cavity wall (for < 2cm lesion and an additional 20 mg for each additional 1 cm) Group 2b: 40 mg predmol into the cavity (for < 2 cm lesion and an additional 20 mg for each additional 1 cm)"
89681114|NCT03197675|Sham Comparator|Control group|Participants who are randomized to the control group will not receive any acupuncture. Participants will however be assessed weekly to obtain the same data on their pain scale and other outcome measures as the treatment group. Participants will be evaluated in person during their standard of care clinical follow up appointments at the three month and six month points for in person interviews and data collection .
89681115|NCT03197675|Active Comparator|treatment group|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture, 8 treatments of auricular acupuncture). Pain Numeric Rating Score (NRS) will be evaluated by the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
89681116|NCT01881087|Experimental|Levo-7.5 mg|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 7.5 mg. Single Dose.
89681117|NCT01881087|Experimental|Levo-9.37|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 9.37 mg. Single Dose.
89681118|NCT01881087|Active Comparator|Levo-11.25|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 11.25 mg. Single Dose.
89681119|NCT01944423|Experimental|PSRT_DCS|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill of d-cycloserine (DCS) one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
89051389|NCT04590066|Experimental|Unpacking Risks Treatment|Participants will be asked to think about the risks of catching the flu this flu season and to respond with the location they are most likely to catch the flu out of a list of given options (e.g. at work, at home).
89051390|NCT04590066|Experimental|Unpacking Risks Control|Participants will be asked to think about the risks of catching the flu this flu season and to respond to confirm that they have received the message.
89051391|NCT04590066|Experimental|Active Commitment Treatment|"Participants receive a gain framed notification that they are eligible for a flu shot. In addition, participants are told Many people find it helpful to make a plan to get their shot and are asked to commit by texting back I will get a flu shot. Depending on their response, participants receive a general reminder or a commitment reminder 3 days later."
89051392|NCT04590066|Experimental|Active Commitment Control|Participants receive a gain framed notification that they are eligible for a flu shot. Participants receive a general reminder 3 days later.
89051393|NCT04590066|Experimental|Self-Generated Social Norms Treatment|Participants will first receive a message enjoining them to consider 2 peers who would want them to vaccinate. Then they will be asked to do those peers a favor by getting a vaccine at their next opportunity. They will receive a reminder 3 days later.
89051394|NCT04590066|Experimental|Self-Generated Social Norms Control|articipants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
89051395|NCT04590066|Experimental|Foot-in-the-Door Treatment|Participants will first receive a message enjoining them to encourage someone else to receive a flu vaccine this year. They will then be given a message that they might copy-paste to forward to friends, thereby lowering the effort costs of messaging others. They will receive a reminder 3 days later.
89051396|NCT04590066|Experimental|Foot-in-the-Door Control|Participants will be informed of the opportunity to receive a flu vaccine at their appointment. They will receive a reminder 3 days later.
89051397|NCT04590066|Experimental|Prosocial Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (i.e., protecting loved ones; preserving scarce resources).
89051398|NCT04590066|Experimental|Self-Oriented Condition|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot.
89051399|NCT04590066|Experimental|Prosocial + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also give prosocial reasons for vaccinating (e.g., protecting loved ones; preserving scarce resources). The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
89051400|NCT04590066|Experimental|Self-Oriented + COVID-19|Participants will receive a message describing the condition-specific benefit of getting a flu shot, and a reminder to ask for their flu shot. The message will also emphasize the pandemic (e.g., risk of hospital-acquired COVID-19 infection; wasting scarce resources).
89681120|NCT01944423|Placebo Comparator|PSRT_PBO|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill placebo dose one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
89681121|NCT03112499|Active Comparator|PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who percutaneous nephrolithotomy (PCNL) will be conducted
89681122|NCT03112499|Active Comparator|mini-PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who mini- percutaneous nephrolithotomy (mini-PCNL) will be conducted
89681123|NCT03112499|Active Comparator|RIRS Group|Patients with renal calculi 10-30mm in maximal diameter in who retrograde intrarenal surgery (RIRS) will be conducted
89051401|NCT04590066|Experimental|Dynamic + Static Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before and how many Americans got their flu shot last year.
89051402|NCT04590066|Experimental|Dynamic Norm|Participants will receive a text message encouraging them to get a flu shot and informing them that more American adults are getting their flu shot than ever before.
89051403|NCT04590066|Experimental|Dynamic Norms Control|Participants will only receive a text message encouraging them to get a flu shot. They will not receive any norm information.
89051404|NCT04590066|Experimental|Sharing Humor|Participants will receive a text message encouraging them to get the flu shot. The message will include a joke about the flu and will encourage participants to share the joke with nurses, doctors, or pharmacists.
89051405|NCT04590066|Experimental|Humor Placebo|Participants will receive a text message encouraging them to get the flu shot. This message will include the same joke but participants will not be encouraged to share it.
89051406|NCT04590066|Experimental|No Humor Condition|Participants will receive a text message encouraging them to get the flu shot.
89216016|NCT05495204||IBA+OBR (trials)|Participants in TMB-202 or TMB-301/311 trials who received 800 mg ibalizumab every 2 weeks, with or without a loading dose
89681124|NCT05270603||ICARUS Calculator Raters (Intervention Group)|Surgeons and anesthesiologists will be asked to use the ICARUS Calculator to grade a subset of 10 clinical scenarios selected from a list of the clinical scenarios and examples from the publications of the 5iAE systems
89681125|NCT05270603||Cognitive Grading Raters (Control Group)|Surgeons and anesthesiologists will be asked to use the ICARUS Calculator to grade a subset of 10 clinical scenarios (same as the Intervention group) selected from a list of the clinical scenarios and examples from the publications of the 5iAE systems
89681126|NCT01798667|Placebo Comparator|Placebo|PO administration
89681127|NCT01798667|Experimental|DA-8031 dose 1|PO administration
89681128|NCT01798667|Experimental|DA-8031 dose 2|PO administration
89681129|NCT01798667|Experimental|DA-8031 dose 3|PO administration
89681130|NCT04388657||Covid Intensive arm|Patients included in intensive care admission by one of the principal investigators from the 3 selectioned centers.
89681131|NCT00600925|Experimental|1|Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
89681132|NCT00600925|No Intervention|2|Standard of care, ie, no gentamicin-collagen sponge.
89681133|NCT02673203|Active Comparator|Lean Healthy Control|(BMI <25 kg/m2)
89681134|NCT02673203|Active Comparator|Obese non-diabetic subject|BMI > 30 kg/m2
89681135|NCT02653001|Experimental|Experimental arm|Stool sample collection: Stool samples collected from study participants will be introduced into the colon model to enhance our understanding of the colonic bacterial ecosystem in response to various food components, drugs or biological therapies, and/or to allow investigation the impact of the bacterial ecosystem itself on these added components
89681136|NCT01881867|No Intervention|Cohort I (no therapy)|Patients receive no treatment (observation) after completion of standard sipuleucel-T therapy.
89681137|NCT01881867|Experimental|Cohort II (glycosylated recombinant human interleukin-7)|Patients receive glycosylated recombinant human interleukin-7 SC every week for 4 weeks (on days 0, 7, 14, and 21) beginning 3-7 days after completion of standard sipuleucel-T therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
89681138|NCT01882413||Patients with Planned Cataract Removal|Patients with planned cataract removal surgery are evaluated for the presence of inflammatory dry eye disease. No treatment is administered.
89681139|NCT02338973|Experimental|Interferon Gamma-1b|Topical interferon (IFN) gamma-1b, 112 µg dose, administered in study eye daily for two weeks
89681140|NCT03458403|Experimental|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for.
89681141|NCT00601627|Experimental|Panitumumab|"Chemotherapy concurrent with radiation: Radiation 5 days per week for 5½ weeks; Panitumumab on days 1, 15, and 29 of radiation therapy 5-fluorouracil (5FU) continuous infusion, starting on day 1 and through last day of radiation.~4-6 weeks after completion of radiation therapy: Gemcitabine on days 1, 8, and 15 of each cycle, for 3 cycles; Panitumumab on days 1 and 15 of each cycle, for 3 cycles. Maintenance therapy: Panitumumab on days 1 and 15 of each cycle, for 6 cycles."
89681142|NCT01882725|Experimental|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
89681143|NCT01883427|Placebo Comparator|Placebo: Saline+glucose nasal spray|Subjects received nasal spray containing both saline+glucose twice daily for 3 months
89681144|NCT01883427|Active Comparator|Nasal spray with glucose oxidase+glucose|Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
89681145|NCT02527187|Experimental|Allergic patients to birch pollen|"Allergic patients already diagnosed to be true allergic to birch pollen.~A mean wheal diameter >3 mm obtained in a prick test with histamine dihydrochloride 10 mg/ml.Also presence of serum specific IgE and clinical history of symptomatology related to exposure to birch pollen.~Patients of both gender aged from 5 up to 70 years."
89681146|NCT02527187|Experimental|Non-allergic patients to birch pollen|"Patients already diagnosed to be true non-allergic to birch pollen.~Non clinical history of symptomatology related to the exposure to birch pollen. Previous skin prick test negative and absence or undetectable serum specific IgE to Betula verrucosa~Patients of both gender aged from 5 up to 70 years."
89681147|NCT01947153|Experimental|Fixed dose combination|Linagliptin/Metformin
89681148|NCT01947153|Experimental|Free combination|Linagliptin and Metformin
89681149|NCT05094557|Experimental|Experimental Group 1|Participants from the Experimental Group 1 will engage in a self-conversation through embodied perspective taking (body swapping), according to which they will be embodied alternately in their own virtual representation and in their counsellor's virtual body. They will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle.
89681150|NCT05094557|Experimental|Experimental Group 2|"Participants from the Experimental Group 2 will be embodied in their own body and will participate in a pre-established discourse provided by their virtual counsellor. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle."
89051407|NCT04590066|Experimental|Connecting the Past Self to the Future Self Treatment|"Participants will receive a text message prompt to recall the negative experience of getting sick. When asked, Do you wish you could have avoided getting sick by getting a simple shot?, participants will have the chance to respond Y for yes or N for no. Regardless of their response, they will be prompted with a second text message to connect their past experience with present-day opportunities for preventative care (getting a flu shot) to protect the future self from the flu."
89051408|NCT04590066|Experimental|Connecting the Past Self to the Future Self Control|In the first text message, participants will receive a simple text message encouragement to receive a flu shot. In the second text message, they will receive a reminder of the appointment time and provider name.
89051409|NCT04590066|Experimental|Reverse Inference Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are healthier, wealthier, and more educated.
89051410|NCT04590066|Experimental|Reverse Inference Control Condition|Participants will receive a text message encouraging them to get a flu shot and informing them that Americans who get flu shots are less likely to get the flu.
89051411|NCT04590105|Experimental|App Subject|"Users who were assigned to use a smartphone app downloaded a free app from the iOS App or Google Play stores titled SB Colonoscopy Prep. The app informed subjects about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite."
89051412|NCT04590105|Active Comparator|Written Instruction Subjects|Subjects in the control group were given a three-page document that described the procedure and instructed users on how to take the preparation medications. The written instructions had a list of frequently asked questions about colonoscopies and the URL of a website where users could view the animated video that was included in the app. The written instructions also contained the time and date of the procedure. All subjects were instructed to arrive one hour before their scheduled procedure.
89051413|NCT01153009|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
89051414|NCT01153009|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
89216017|NCT05495204||Non-IBA+OBR (OPERA)|Heavily treatment experienced adults living with HIV in care in OPERA, with documented resistance to ≥1 ARV from each of three ARV classes switching to a new regimen that does not include ibalizumab
89216018|NCT05494723|Experimental|Low-dose|Low-dose YB-1113
89216019|NCT05494723|Experimental|High-dose|High-dose YB-1113
89216020|NCT05491603|Experimental|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with onychomycosis.
89216021|NCT05491603|Experimental|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with onychomycosis.
89216022|NCT05491603|Placebo Comparator|Aqueous Gel|Topical application of aqueous gel on foot/feet affected with onychomycosis.
89216023|NCT05489393||Individuals with DRPLA|This registry is for people with a diagnosis of Dentatorubral-pallidoluysian atrophy (DRPLA)
89216024|NCT05489120|No Intervention|COMPARATOR|Follow-up of the CKD patient according to current practice i.e. low protein diet.
89216025|NCT05489120|Experimental|FLAVIS|Follow-up of the CKD patient according to the current practice i.e. low protein diet with the addition of of low-protein products (FLAVIS).
89216026|NCT05488405|Experimental|Mesalamine treatment|Treatment of patient with mesalamine oral suspension
89216027|NCT05470140|Experimental|Experimental: WU-NK-101|"A non-engineered Natural Killer (NK) cell derived from peripheral blood mononuclear cells (PBMC) that is cytokine-reprogrammed, expanded, and cryopreserved to create an allogeneic enhanced Memory-like anti-tumor NK cell therapy product.~Each 28-day cycle of treatment consists of 3 doses of WU-NK-101 administered on Day 1, Day 8, and Day 15."
89216028|NCT05464602|Experimental|Intervention group Lavender|Each patient in this group received inhalation aromatherapy of lavender oil.
89216029|NCT05464602|Experimental|Intervention group Geranium|Each patient in this group received inhalation aromatherapy of geranium oil.
89216030|NCT05464602|No Intervention|Control group|Each patient in this group did not receive any additional treatment.
89216031|NCT05463380||Hospitalized COVID 19 patients|"Hospitalized adult (>18 years) patients including patients in the emergency ward Positive for SARS-CoV-2 by PCR any time from 14 days before admission date until hospital discharge. Both first and recurrent episodes of COVID-19 will be included.~Having a signed informed consent when required by ethical approval"
89216032|NCT05456152|Experimental|Sublingual zolpidem|1 sublingual tablet (5mg) 30 minutes before bed time during 60 days.
89681151|NCT05094557|Active Comparator|Control Group|Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
89681152|NCT02987595|Experimental|Whole-grain rye then wheat|Whole-grain rye, high lignan Whole-grain rye products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain wheat products for 8 weeks
89681153|NCT02987595|Experimental|Whole-grain wheat then rye|Whole-grain wheat, low lignan Whole-grain wheat products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain rye products for 8 weeks
89681154|NCT02993965|No Intervention|Control 11-17|No additional intervention done aside from usual care for 11-17 year olds
89681155|NCT02993965|Experimental|1 R/R per Dose 11-17|Sending up to one recall notice per dose of HPV vaccine needed for 11-17 year olds
89681156|NCT02993965|Experimental|2 R/R per Dose 11-17|Sending up to two recall notices per dose of HPV vaccine needed for 11-17 year olds
89681157|NCT02993965|Experimental|3 R/R per Dose 11-17|Sending up to three recall notices per dose of HPV vaccine needed for 11-17 year olds
89681158|NCT02993965|No Intervention|Control 11-14|No additional intervention done aside from usual care for 11-14 year olds
89216033|NCT05454033|Experimental|JUVÉDERM® VOLITE™|Participants in the treatment group will receive a single dose at the study initiation. Participants are eligible for touch up treatment.
89216034|NCT05454033|Other|Control - No Treatment|Participants in the control group will receive no treatment. At Month 2, these participants will have the option to receive the treatment.
89681159|NCT02993965|Experimental|Phone R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via autodialer for 11-14 year olds
89681160|NCT02993965|Experimental|Mail R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via mailed postcards for 11-14 year olds
89681161|NCT02476409|Experimental|Tolvaptan|Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily
89216035|NCT05441332|Experimental|Patellofemoral pain syndrome|Kinematic and neuromuscular assessment
89216036|NCT05441241|Experimental|Leap Motion Controller|
89216037|NCT05441241|Active Comparator|Standard care|
89681162|NCT02476409|Placebo Comparator|Placebo|Augmentation of current dose of loop diuretic
89681163|NCT02993887|Placebo Comparator|Mindfulness|Mindfulness (Decentering) only using the Stop, Breathe, Think Smart Phone application
89681164|NCT02993887|Experimental|Resourcefulness and Mindfulness|Resourcefulness Training (a cognitive behavioral intervention that teaches self-help and help-seeking skills) and Mindfulness using the Stop, Think, Breathe app.
89681165|NCT02999737|Other|Platelet Rich Plasma for 4 sessions|Autologous Platelet Rich Plasma injected in the scalp monthly x 3 then every 3 months x 1
89681166|NCT02999737|Other|Platelet rich plasma for 2 sessions|Autologous Platelet Rich Plasma injected in the scalp every 3 months
89681167|NCT01884519|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
89681168|NCT01884519|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
89681169|NCT02468687|Other|N-methyl-pyrrolidone|NMP dose escalation in accelerated phase and standard phase
89681170|NCT02993653|Experimental|Intensity-modulated radiotheapy arm|Intensity-modulated radiotheapy with stereotactic boost or intracavitary radiotherapy
89681171|NCT02429063|Experimental|Bright White Light|Participants use the bright white light intervention for 30 minutes upon waking each morning for 60 days.
89681172|NCT02429063|Experimental|Dim Red Light|Participants use the dim red light intervention for 30 minutes upon waking each morning for 60 days.
89681173|NCT02993809|Experimental|BM-ECs and PRPE|Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
89051415|NCT01153009|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 20 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
89051416|NCT01153009|Active Comparator|Duloxetine 60 mg|Duloxetine 30 mg capsules, orally, once daily for one week then duloxetine 60 mg, capsules, orally, once daily for 7 weeks, then duloxetine 30 mg capsules, once daily, for one week.
89051417|NCT04622111|Experimental|CPL207280|"PART A: 8 cohorts are to receive single dose of IMP.Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
89051418|NCT04622111|Placebo Comparator|Placebo|PART B: 2 Participants from each of 4 cohorts (total of 8 participants) are to receive masking placebo tablet once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
89051419|NCT04622111|Experimental|CPL207280 120 mg + Metformin 750 mg|1 cohort (total of 12 participants) are to receive single dose of IMP in fed and fasted state, IMP with metformin and metformin alone to assess the effect of food and metformin on bioavailability of CPL207280. There is to be one week wash-out between four treatments periods for this cohort.
89051420|NCT04589715|Experimental|electroacupuncture group|patients will receive electroacupuncture at 3 acupoints(Bladder meridian of foot-taiyang 33 and 35#BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 4 weeks, then 3 times/week for 4 weeks, and then once/week for 4 weeks(24 times in total in 3 months), and be followed up for 6 months after treatment. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 ×40 mm at SP 6. Standardized electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6.
89051421|NCT04589715|Sham Comparator|sham electroacupuncture group|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz.
89051422|NCT02884843|Active Comparator|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction Disposable
89051423|NCT02884843|Active Comparator|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
89051424|NCT01152814|Experimental|Arm 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
89051425|NCT04589442|Active Comparator|Standard of Care Dermal Graft|Standard of care cryopreserved cadaveric split thickness skin grafts
89051426|NCT04589442|Experimental|Standard of Care Dermal Graft - Microsurfaced|Microsurfaced cryopreserved cadaveric split thickness skin grafts
89051427|NCT04621994|Active Comparator|Steri Strips Arm|
89051428|NCT04621994|Experimental|Dermabond Arm|
89051429|NCT04205695|Active Comparator|CEMP (closed-ended multiport catheter) group|Infraclavicular closed-ended multiport nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
89051430|NCT04205695|Active Comparator|OESP (open-ended single port catheter) group|Infraclavicular open-ended single port nerve catheter will be included in the patients undergoing upper extremity surgery for postoperative analgesia
89051431|NCT02884531|Experimental|Patient Education and BBAT|Patients will participate in Patient Education and Basic Body Awareness Therapy
89051432|NCT02884531|Active Comparator|Patient Education|Patients will only participate in Patient Education
89051433|NCT04589481|Experimental|candy intake|
89051434|NCT04621721|Experimental|Intervention Group|The intervention will consist of a 16-week, home-based gait/balance training and progressive resistance exercises for lower extremities using resistance power bands. Participants will be given the home-based gait/balance training and progressive resistance exercise training access via a link or by DVD, and the resistance training band, and wide, firm foam surface. The intervention group will begin with light warm-up and stretching activity then a 10 minute each of gait/balance and 10 minutes of resistive (strength) training components. The program begins with light stretching to address any range of motion limitations that may affect ability to maintain balance and postural stability, and consisted of hamstring quadricep, gastroc, and soleus stretches. During stretching exercises, participants held each stretch for 10-15 seconds, repeating each stretch 2-3 times for each lower extremity. Stretching exercises do not change during the intervention.
89681174|NCT02993809|Active Comparator|BM-ECs|Intramuscular injection of bone marrow derived endothelial cells only.
89681175|NCT01886235|Experimental|Diagnosis (intravital microscopy)|Patients receive fluorescein sodium IV followed by intravital microscopic observation over 10-15 minutes during excision of the melanoma.
89681176|NCT02999581|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 10 mg Bitter Orange (Citrus Aurantium) fruit standardized for 30% synephrine (Advantra Z), 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
89681177|NCT02999581|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
89681178|NCT02999581|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
89681179|NCT02993497|Experimental|Respiratory monitoring group|
89681180|NCT05010941||Hypotension prediction index|prediction of hypotension events
89051435|NCT04621721|Active Comparator|Attention Control Group|The Attention Control group will receive an educational intervention via a journal in which to record their clinic appointments, and standardized American Cancer Society pamphlets which have been adjusted to fit within the journal binding for easy reference. At each data collection encounter, the intervention research assistant will discuss the information in each pamphlet, allowing time for questions related to the material. The educational materials consist of 1) Emotions and Breast Cancer; 2) Body Image and Sexuality After Breast Cancer; 3) Follow up Care After Breast Cancer Treatment; 4) Nutrition and Cancer. Sessions last approximately 45-60 minutes and occur at the same intervals as the intervention group and will precede data collection. Attention Control group participants will receive telephone calls every other week which will entail a social visit and reminder of data collection/attention intervention appointments to further equalize contact.
89051436|NCT05244889|Experimental|Digital CBT-I|After assignment to dCBT-I, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session dCBT-I programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of dCBT-I. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
89051437|NCT05244889|Active Comparator|Sleep Hygiene Education (SHE)|After assignment to SHE, participants will complete a baseline assessment of their sleep, migraines and other outcomes and complete a 30-day sleep and headache diary, and wear an actigraphy device for 7 days to record their sleep and light exposure. They will then be given access to the 6-session SHE programme. At month 1, participants will wear an actigraph device for 1 week.. At month 3 participants will complete a 30-day post-treatment assessment including a sleep and headache diary and the same battery of questionnaires as during the baseline assessment. A subset of participants (and providers) will be invited to participate in an interview about uptake of SHE. At month 6, all participants will complete follow-up questionnaires (similar to baseline and post-treatment questionnaires) and one last 30-day assessment of sleep and headaches and wear a 7-day actigraphy device.
89051438|NCT05244187|Experimental|OrthoCor Active System|
89051439|NCT05244187|No Intervention|Standard of care|
89051440|NCT00624949||1|women with Turner syndrome
89051441|NCT00624949||2.|Control women
89051442|NCT04589520|Experimental|HeartBot Group|The HeartBot group downloaded the app and used it daily for 21 days based on a calendar that provided them with step by step outlines of the tools for each day.
89051443|NCT04589520|No Intervention|Control Group|The control group did not download the app and experienced no change to their daily routines.
89051444|NCT04622033|Experimental|Brodalumab 210mg|
89051445|NCT01152580|Placebo Comparator|Sugar pill|
89051446|NCT01152580|Active Comparator|melatonin|
89051447|NCT02884453|Experimental|ibrutinib|ibrutinib delivered orally at a dose of 560mg once daily continuously on a 4 weekly cycle until disease progression or unacceptable toxicity occurs.
89681181|NCT02993419|Experimental|Bacillus licheniformis Intervention|The intervention is use Bacillus licheniformis particles，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
89681182|NCT02993419|Placebo Comparator|placebo Intervention|The intervention is use placebo，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
89681183|NCT01798433|Experimental|One stent technique alone|One stent technique alone for non-true LM bifurcation
89681184|NCT01798433|Experimental|One stent technique + Elective FKB|One stent technique + Elective FKB for non-true LM bifurcation
89051448|NCT02884297|Experimental|surgical termination of pregnancy|Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients for ultrasound angiography during the termination of pregnancy. 2,4 mL are administrated per patient, divided into two injections of 1,2 mL.
89051449|NCT04621799|Experimental|Fibrin Group|Experimental: Non-Autologuos Fibrin (NAF) Subjects in the NAF arm received an injection of non-autologous fibrin
89051450|NCT04621370|Active Comparator|Arm A|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy~Short course radiotherapy (25Gy delivered in 5 fractions) starting on day 1~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy and continuing for 6 cycles in total~Assessment of response will be at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
89051451|NCT04621370|Active Comparator|Arm B|"Durvalumab 1500mg IV over 60 minutes, starting in the week prior to day 1 of radiotherapy, and continuing every 4 weeks until completion of FOLFOX chemotherapy~Long course chemoradiotherapy (50Gy to boost volume, 45Gy to elective volume delivered in 25 fractions) starting on day 1~FOLFOX chemotherapy will be given every 2 weeks, starting approximately 1-2 weeks after radiotherapy for 4 cycles~Assessment of response at approximately 16-18 weeks after day 1 of RT. If the patient is proceeding to surgery, this will be performed at approximately 18-20 weeks after day 1 of RT where possible."
89051452|NCT01152385|Experimental|high|AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)
89051453|NCT01152385|Experimental|Middle|AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)
89051454|NCT01152385|Experimental|low|AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)
89681185|NCT01798433|Experimental|Provisional approach|Provisional approach for true LM bifurcation
89681186|NCT01798433|Experimental|Elective 2-stent|Elective 2-stent for true LM bifurcation
89051455|NCT01152385|Placebo Comparator|4|
89051456|NCT04621487|Active Comparator|concomitant|Concomitant therapy consists of 14 days pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg all twice daily.
89051457|NCT04621487|Active Comparator|tailored|Tailored therapy consists of 14 days antibiotic therapy according to H. Pylori strains antibiotic sensitivity test together with pantoprazole 40 mg twice daily.
89051458|NCT01152190|Experimental|5 milligrams (mg) Tadalafil|
89051459|NCT01152190|Placebo Comparator|Placebo|
89051460|NCT04649853||Acute Wounds|Patient with either traumatic or surgical wounds
89051461|NCT04649853||Chronic Wounds|Patient with chronic wounds either peripheral vascular disease related or surgical/traumatic wound
89051462|NCT04649853||Pressure Injuries Present on Admission|Patient admitted with one or more pressure injury of any stage on admission
89051463|NCT04649853||At Risk for Pressure Injury|Patient admitted with risk for pressure injury and has no pressure injuries at time of admission. Identified as at risk for based on mobility.
89681187|NCT00602953||Healthy volunteers|Normal weight and normal glucose tolerance.
89681188|NCT00602953||Pre-diabetes|Impaired fasting glucose of impaired glucose tolerance.
89681189|NCT00602953||Overweight|Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
89681190|NCT00602953||Type 2 diabetes|Patients with type 2 diabetes.
89051464|NCT04621565|Experimental|Hydrocortisone withholding group|Patients receive no hydrocortisone
89051465|NCT04621565|Active Comparator|Hydrocortisone group|Patients receive routine hydrocortisone
89051466|NCT02884258||Bariatric surgery group|Women undergoing IVF (IVF or ICSI) with a history of bariatric surgery (surgery procedures include sleeve gastrectomies and by-passes). No intervention is involved.
89051467|NCT02884258||Control Group|1. Women undergoing IVF with no history of bariatric surgery and matched to bariatric surgery patients for weight, parity and age. 2. non-operated severely obese women
89051468|NCT04650048|Active Comparator|Active tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
89051469|NCT04650048|Placebo Comparator|Sham tDCS|Both groups will receive an injection with 5 μg (0.5 ml) Nerve Growth Factor (NGF) in the first dorsal interosseous muscle (FDI muscle) prior to the HD-tDCS intervention. This injection a pain model, that is intended to induce muscle soreness and hyperalgesia.
89051470|NCT01151410|Experimental|Aliskiren|Patients will receive one of the following doses based on the their weight: Low weight (≥20 to <50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to <80 kg) patients: Starting dose 75 mg with optional titration to 150 and then 300 mg High weight (≥80 to ≤150 kg) patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
89681191|NCT00602953||Type 1 diabetes|Patients with type 1 diabetes.
89681192|NCT01998191|Active Comparator|Implicit Case note review (nurse)|"Notes to be reviewed using the implicit method by a nurse~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
89681193|NCT01998191|Active Comparator|Implicit Case note review (MDT)|"Notes to be reviewed using the implicit method by an expert physician and nurse team.~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
89216038|NCT05440903|Experimental|Mindfulness|Participants in the experimental arm are asked to use a mindfulness smartphone application called Headspace. Headspace offers pre-recorded introductory mindfulness meditation audio instructions guided by experienced meditation teachers. Study participants are instructed to voluntarily complete 10 minutes of Headspace twice per day for 14 days, a total recommended dose of 280 minutes. Mindfulness practice begins the day after the baseline interview (i.e., intervention day 1). Participants are encouraged to listen at two separate times each day to support habit formation and to maximize daily exposure with low time burden. As participants have minimal prior experience with mindfulness attributed to the study eligibility criteria, all recommended trainings are at the beginner level. Participants have access to all sessions offered and are not restricted to a particular sequence.
89216039|NCT05440903|Placebo Comparator|Psychoeducation|"Participants in the psychoeducation arm listen to TEDTalks audio recordings by experts on field-specific topics. Study participants are instructed to complete 10 minutes of TEDTalks twice per day for 14 days. Sessions were selected by the study team to be of interest to the public yet not include content on meditation, smoking, or content appearing to cue behavior change associated with smoking. Like the Mindfulness condition, participants in the Psychoeducation condition begin the practice the day after the baseline interview. Participants are told to listen at two separate times each day to maximize daily exposure with low time burden. Additionally, participants are instructed to listen with full mindful attention and return attention to the audio when attention drifts to match the Mindfulness instruction and emphasize the importance of sustaining attention for each 10-minute period. Participants have access to all sessions offered and are not restricted to a particular sequence."
89216040|NCT05439941|Experimental|Group 1 (1.6x10^11 total cells of EDP1815, 2 capsules once daily)|EDP1815-207 Cohort 1 participants will receive 1.6x10^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 1)
89216041|NCT05439941|Experimental|Group 2 (6.4x10^11 total cells of EDP1815, 2 capsules once daily)|EDP1815-207 Cohort 2 participants will receive 6.4x10^11 total cells of EDP1815 in EDP1815-208 administered as 2 capsules once daily. (Group 2)
89216042|NCT05439941|Experimental|Group 3 (8.0x10^10 total cells of EDP1815, 1 capsule once daily)|EDP1815-207 Cohort 4 participants will receive 8.0x10^10 total cells of EDP1815 in EDP1815-208 administered as 1 capsule once daily. (Group 3)
89216043|NCT05434598|Experimental|Patients: ChromSeq|ChromoSeq will be performed on bone marrow or peripheral blood DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.
89216044|NCT05434598|No Intervention|Stakeholders (Treating Physicians)|Stakeholders (treating physicians) will complete surveys/questionnaires
89681194|NCT01998191|Active Comparator|Implicit Case note review (physician)|"Notes to be reviewed using the implicit method by an expert physician~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
89681195|NCT02329587|Experimental|ERP plus tDCS|ERP plus anodal tDCS of right inferior frontal gyrus
89681196|NCT02329587|Active Comparator|ERP plus sham tDCS|ERP plus sham tDCS of right inferior frontal gyrus
89681197|NCT02999503|Experimental|Nutritional intervention|Patients subject to nutritional education by CINUSA group protocol
89681198|NCT02999503|No Intervention|No intervention|Patients not subject to nutritional education
89681199|NCT00603889|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will have the same number of concentrations of the Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
89681200|NCT01886937|Experimental|37.5 mg Phentermine daily for 7 days|"In this arm, participants receive 37.5mg phentermine for one week followed by 2 weeks of placebo.~Other names for phentermine:~adipex ionamin"
89681201|NCT01886937|Placebo Comparator|Placebo (for phentermine 37.5mg)|In this arm, participants receive Placebo (for 37.5mg phentermine) for two weeks followed by phentermine 37.5mg for 7 days.
89681202|NCT00708877|Experimental|All participants|
89681203|NCT02993341|Experimental|Tranexamic Acid Wash|Participants in the experimental arm will receive a wash of tranexamic acid topically at the site of surgery.
89681204|NCT02993341|Placebo Comparator|Saline Wash|Participants in the control arm will receive a wash of saline topically at the site of surgery.
89681205|NCT01948947|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
89681206|NCT01948947|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
89681207|NCT01334801||Aortic Stenosis|Restricted aortic valve motion and a peak Doppler aortic velocity > 2.5 m/sec blood draw
89681208|NCT01334801||Aortic regurgitation|Echocardiographic and Doppler evaluation revealing aortic regurgitation with data adequate to calculate regurgitant volume
89681209|NCT01334801||Aortic valve replacement|Mechanical or biological aortic valve replacement
89681210|NCT01334801||Mitral regurgitation|Echocardiographic and Doppler evaluation revealing mitral regurgitation with data adequate to calculate regurgitant volume
89681211|NCT01334801||Mitral valve replacement|Mechanical or biological mitral valve replacement
89681212|NCT01334801||Hypertrophic cardiomyopathy|Patients with known hypertrophic cardiomyopathy who are referred for clinically indicated echocardiography
89681213|NCT01334801||Severe TR with pacemaker / ICD lead|Patients referred for clinically indicated echocardiography who have severe tricuspid regurgitation associated with a pacemaker or defibrillator lead documented by echocardiography
89681214|NCT01334801||Prosthetic valve dysfunction|Patients with prior heart valve replacement or repair referred for clinically indicated echocardiography who demonstrate stenosis, regurgitation, dehiscence.
89681215|NCT01334801||Normal controls|Patients with no heart murmur or history of valve replacement, stenosis, regurgitation, or hypertrophic cardiomyopathy
89681216|NCT01334801||Left ventricular assist device patients|Patients with previously implanted LVAD
89681217|NCT01334801||Renal dialysis patients|Patients on hemodialysis, peritoneal dialysis, or chronic kidney disease with dialysis fistula to be created.
89681218|NCT04270903||Phototype I - II|EPR measurement at the surface of the skin (arm)
89681219|NCT04270903||Phototype III - IV|EPR measurement at the surface of the skin (arm)
89681220|NCT04270903||Phototype V - VI|EPR measurement at the surface of the skin (arm)
89681221|NCT04387799||Negative PCR Covid associated Pneumonia|Patients with pneumonia who test negative to RT-PCR
89681222|NCT04387799||Positive PCR Covid associated Pneumonia|Patients with pneumonia from Covid 19
89681223|NCT04693637|Experimental|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
89216045|NCT05430438|Experimental|Group A|Patients will undergo dialysis (4 sessions) with low dialysate sodium (137 mEq/L) and after a 2-week washout period will undergo dialysis (4 sessions) with standard dialysis sodium (140 mEq/L).
89216046|NCT05430438|Experimental|Group B|Patients will undergo dialysis (4 sessions) with standard dialysate sodium (140 mEq/L) and after a 2-week washout period will undergo dialysis (4 sessions) with low dialysis sodium (137 mEq/L).
89216047|NCT05421078|Placebo Comparator|Placebo|Once-daily placebo
89216048|NCT05421078|Experimental|Experimental 2.5 mg Obicetrapib|once-daily Obicetrapib
89216049|NCT05421078|Experimental|Experimental 5 mg Obicetrapib|once-daily Obicetrapib
89216050|NCT05421078|Experimental|Experimental 10 mg Obicetrapib|once-daily Obicetrapib
89216051|NCT05413174|Experimental|Hypnosis arm|The experimental group will receive an hypnosis session during the ultrasound-guided hepatic biopsy.
89681224|NCT00086684|Experimental|Pentosan polysulfate sodium 100 mg once a day|One 100 mg pentosan polysulfate sodium capsule in the morning and 1 matching placebo capsule in the afternoon and evening for 24 weeks
89681225|NCT00086684|Experimental|Pentosan polysulfate sodium 100 mg three times a day|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning afternoon and evening) for 24 weeks
89681226|NCT00086684|Placebo Comparator|Placebo|Placebo One placebo capsule 3 times a day (morning afternoon and evening) for 24 weeks
89681227|NCT02999425|Experimental|Education|Educational intervention to study participants
89681228|NCT02992873|Experimental|Layperson allocated to fetch an AED and start CPR|In the intervention group mobile lifesavers will be directed to fetch the nearest AED and then attach it to the victim of OHCA. At least 1 volunteer will be directed to start CPR only
89681229|NCT02992873|Active Comparator|Layperson allocated to start CPR|In the control group all mobile lifesavers will be directed to the patient to start CPR.
89681230|NCT02987907|Experimental|treatment group|use dexamethasone 10mg (2ml) I.A. during TACE
89681231|NCT02987907|Placebo Comparator|control group|use normal saline 2ml I.A. during TACE
89681232|NCT02992795||Cohort Ia|Athletes in this cohort serve as control subjects participating in Division 1 Athletics at the University of Wyoming. They will be enrolled once they meet eligibility. Upon enrollment, all athletes will have an initial BrainPulse recording. Once a subject from this cohort sustains an injury, they crossover to Cohort II. Also, a matched control for every concussed subject will be selected from Cohort Ia.
89681233|NCT02992795||Cohort Ib|Athletes in this cohort are subjects currently subscribed to the Head Health Network. They will have a BrainPulse recording completed every week through the entire season. Similarly, if subjects in this cohort sustain an injury, they will crossover to Cohort II.
89681234|NCT02992795||Cohort IIa|Athletes from Cohort I will be assigned to cohort IIa once they sustain an injury other than concussion. They will have been pulled out of the game by the athletic trainer and removed from play until at least the end of the game. Once the subjects have been assigned to Cohort IIa, they will have a BrainPulse recording and a symptom evaluation within 3 days of their injury. After two weeks of recovery, subjects in this cohort will return to Cohort 1 and resume their participation in the study in their respective sub-cohort.
89681235|NCT02992795||Cohort IIb|Athletes in this cohort are injured subjects who sustain a non-penetrating head injury and are confirmed to have had a concussion according to the protocol reference standard and by their physician. All subjects enrolled in this cohort are required to have a BrainPulse recording within 3 days of their injury. Each BrainPulse recording will be accompanied by a symptoms evaluation and medical data collection documented in the case report forms. Subjects will complete 3 weeks of follow-up visits post injury.
89216052|NCT05413174|No Intervention|Habitual Care|The control group will receive the usual medical management during the ultrasound-guided hepatic biopsy.
89216053|NCT05408663|Experimental|Experimental- EXT608|Up to 6 sequential dose escalation cohorts will receive a single dose of EXT608 administered as a subcutaneous injection
89216054|NCT05408663|Placebo Comparator|Placebo comparator|Up to 6 participants will receive matching placebo administered as a subcutaneous injection
89216055|NCT05402449|Placebo Comparator|Placebo group|Subjects received two placebo sachets per day
89216056|NCT05402449|Experimental|Probiotic group|Subjects received two probiotic sachets per day
89216057|NCT05396495|Experimental|Treatment arm|Treatment arm using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
89216058|NCT05396040|Experimental|LOLLI METHODE|regular screening with pooled saliva tests (Lolli-Method)
89216059|NCT05396040|No Intervention|STANDARD OF CARE|STANDARD OF CARE
89216060|NCT05369871|Experimental|Closed-loop system followed by open-loop system|"An interventional cross-over study:~six weeks in closed-loop system with Accu-Chek Insight pump and continuous glucose monitoring (CGM) :consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~followed by six weeks in open-loop system with usual pump and CGM : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks ,~Followed by an optional additional study: 4 weeks in closed-loop system."
89681236|NCT04402814||Arm A (positive for COVID-19)|"One or two samples of your blood that were previously collected for routine care will be obtained from the hospital laboratory and will be tested for the antibodies against COVID-19 virus.~First blood sample obtained: 7 to 12 days following onset of symptoms; and/or~Second blood sample obtained: 12 to 40 days following the onset of symptoms."
89681237|NCT04402814||Arm B (negative for COVID-19)|One sample of blood that was collected for routine care at any point during hospitalization will be obtained from the hospital laboratory and will be tested for the antibodies.
89681238|NCT01887171|Experimental|Tacrolimus + HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
89216061|NCT05369871|Experimental|Open-loop system followed by closed-loop system|"An interventional cross-over study:~six weeks in open-loop system with usual pump and CGM : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~followed by six weeks in closed-loop system with Accu-Chek Insight pump and CGM (including two weeks of adaptation) : consisting of 2 weeks of adaptation where data will not be collected + 4 weeks~Followed by an optional additional study: 4 weeks in closed-loop system."
89681239|NCT01887171|No Intervention|HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.
89681240|NCT00713479|Placebo Comparator|Sugar pill|Sugar pill (placebo) drug dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
89681241|NCT00713479|Active Comparator|Varenicline|Varenicline dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
89681242|NCT01679678|Experimental|PolyHeal 2|Negatively charged 5-micron polystyrene microspheres in Water For Injection
89681243|NCT01679678|Active Comparator|PolyHeal|Negatively charged 5-micron polystyrene microspheres suspended in Dulbecco's Modified Eagle's Medium (DMEM)
89681244|NCT02999347||Cases|Women having undergone at least one pregnancy/delivery after their MUS surgery
89681245|NCT02999347||Controls|Every case will be matched with two controls. The controls will be matched with the study cases' age and year of surgery (+- 2 years of age if a perfect match is not obtainable). These controls have not undergone a subsequent pregnancy/delivery.
89681246|NCT01679756|Experimental|Intracorporeal anastomosis|Laparoscopic right hemicolectomy for cancer. .For the IA group, colon, transverse mesocolon, ileum and terminal ileum mesentery will be resected intracorporeally through a 45 mm endoscopic linear stapler with vascular cartridge. Then, the linear stapler will inserted through two small enterotomies and a mechanical ileo-transverse, side-to-side isoperistaltic intracorporeal anastomosis performed using the vascular cartridge with six rows of closely placed staples. The enterotomies will be then closed using a double layered continuous intra corporeal manual suture with 3-0 Polyglactin 910. The mesenteric defects will be left open. The specimen will be placed in a protective plastic bag and then extracted through a Pfannestiel incision.
89681247|NCT01679756|Active Comparator|Extracorporeal anastomosis|"Laparoscopic right hemicolectomy for cancer. In the EA group, the bowel will be externalized by widening the incision of one of the trocars or by performing a mini-laparotomy at another location (subcostal, suprapubic) protected with a plastic sheet. The ileum and colon will be then resected through a 45 mm endoscopic linear stapler with vascular cartridge (staple height = 3.85 mm) and a side-to-side isoperistaltic mechanical anastomosis will be then performed using the same vascular cartridge. The enterotomies will be then closed using a double layered continuous manual suture using a 3-0 Polyglactin 910.~In both groups, a drain will not routinely inserted."
89681248|NCT02990767||observational women|collecting maternal factors, biophysical and biochemical markers at 11-13 weeks of gestation.
89681249|NCT03470558||Sleeve gastrectomy patients|Patients electing to undergo sleeve gastrectomy will monitor their dietary habits.
89681250|NCT02990689|Active Comparator|809M|bifocal intraocular lens (IOL)
89681251|NCT02990689|Active Comparator|839MP|trifocal intraocular lens (IOL)
89681252|NCT02990689|Active Comparator|SN6AD1|bifocal intraocular lens (IOL)
89681253|NCT02998957|Experimental|AcuTENS|"Stimulation using a portable TENS electrostimulation device at Dingchuan point using a biphasic rectangular wave with a frequency of 2Hz and a pulse width of 200 ms. The stimulation will be achieved using the highest intensity tolerated by the patient without pain during 40 minuts.~Once a day during 5 consecutive days."
89681254|NCT02998957|Sham Comparator|Sham AcuTENS|"Stimulation using a modified portable TENS electrostimulation device at Dingchuan point with no electrical output, even though the screen will light up and display the same data as in the unmodified device during 40 minuts. Patients in this group will be informed that, due to the frequency of stimulation, it is unlikely that they will feel the electric stimulation.~Once a day during 5 consecutive days."
89216062|NCT05351749|Experimental|New-prescription Alert / Existing-prescription notification to prescriber|
89681255|NCT03414086||Myositis in Remission|Subjects who are in remission with their myositis diagnosis.
89681256|NCT03414086||Healthy Controls|Subjects who do not have a myositis diagnosis.
89681257|NCT02992483|Experimental|MIK665|
89681258|NCT02992639|Placebo Comparator|Control group|No calorie restriction group
89681259|NCT02992639|Experimental|Weight loss group|Mild calorie restriction group (300kcal/day intake reduction)
89681260|NCT03085706|Experimental|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
89681261|NCT02999035||corneal sensitivity measurement|"Air jet aesthesiometry and liquid jet aesthesiometry:~All patients will receive the same intervention of corneal sensitivity measurement with air jet aesthesiometry and liquid jet aesthesiometry.~Thresholds represent the intensity of air / liquid jet that can just be perceived by the patients."
89681262|NCT03085550|No Intervention|Control|Conventional dressings management
89681263|NCT03085550|Experimental|Fat grafting only|Patients will undergo conventional fat harvesting as per Coleman technique and infiltration of fat into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
89681264|NCT03085550|Experimental|Fat grafting + Platelet rich plasma|Patients will undergo conventional fat harvesting as per Coleman technique. Fat will be mixed with autologous PRP and infiltrated into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
89681265|NCT02998801|Placebo Comparator|Watch video using IPAD|Patient will watch the educational video using an IPAD
89681266|NCT02998801|Active Comparator|Watch video using VR goggles|Patient will watch the educational video using VR goggles
89681267|NCT03085472||benigh hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively benigh hematoma (less likely to expand and have a relatively good outcome).
89681268|NCT03085472||malignant hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively bad hematoma (more likely to expand and have a relatively poor outcome).
89216063|NCT05351749|Experimental|New-prescription Alert w/ referral option/ Existing-prescription notification to prescriber|
89216064|NCT05351749|Experimental|New-prescription Alert/ Existing-prescription notification to pharmacist|
89216065|NCT05351749|Experimental|New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacist|
89216066|NCT05333783|Experimental|Augmented Reality Exposure Therapy Based on ExposXR software|The intervention arm will receive the assigned intervention in one session. Participants will be called for 2 times for post-assessment.
89216067|NCT05333783|No Intervention|Treatment as Usual|The control arm has no intervention. However, the participants are not given any instruction limiting their encounters with the phobic stimuli. The participants in the control arm will receive the intervention after the post-assessments are completed.
89216068|NCT05324020|Experimental|E- Health medication adherence Intervention group|3 Month monitoring adherence and side-effect management using an eHealth intervention . Participants are in contact with there clinical care team which intervene in cases of non-adherence and/or side-effect reporting.
89216069|NCT05320393|Experimental|Study Drug|40U of PrabotulinumtoxinA-xvfs
89216070|NCT05320393|Active Comparator|OnabotulinumtoxinA|20U of OnabotulinumtoxinA
89216071|NCT05320393|Active Comparator|PrabotulinumtoxinA-xvfs|20U of PrabotulinumtoxinA-xvfs
89216072|NCT05283980|Experimental|Bupivacaine Group|Receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block
89216073|NCT05283980|Placebo Comparator|Control group|Receive up to 25 ml of normal 0.9% sodium chloride for the Pecs block
89216074|NCT05273658|Placebo Comparator|Placebo|Placebo cannabis and placebo alcohol
89216075|NCT05273658|Experimental|Cannabis, No alcohol|18.16% THC, placebo alcohol
89216076|NCT05273658|Experimental|Cannabis, Low dose alcohol|18.16% THC, .07 breath alcohol concentration
89216077|NCT05273658|Experimental|Placebo cannabis, High dose alcohol|<.1% THC, .10 Breath alcohol concentration
89216078|NCT05273658|Experimental|Placebo cannabis, Low dose alcohol|<.1% THC, .07 breath alcohol concentration
89216079|NCT05273190|Experimental|Vibrotactile Stimulation|
89216080|NCT05272501|Experimental|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
89216081|NCT05272501|No Intervention|Usual care|The usual care group may participate in usual activities at the nursing home e.g. physio- and occupational therapy, listening to calming music, holdning hands with care-takers.
89216082|NCT05272254|Experimental|Povidone Iodine|10% povidone iodine + fluoride varnish
89216083|NCT05272254|Placebo Comparator|Placebo|Placebo (iced tea) + fluoride varnish
89216084|NCT05269498|Experimental|CORTEXPLORER MED|Mixed-reality assisted planning of aneurysm clipping with the optical navigation system CORTEXPLORER MED.
89216085|NCT05264896|Experimental|FLOT|"Patients randomized to the FLOT arm would receive perioperative FLOT~Regimen:~Docetaxel 50mg/m2, d1~5-FU 2600 mg/m², d1~Leucovorin 200 mg/m², d1~Oxaliplatin 85 mg/m², d1~Every two weeks 4 cycles pre-op and 4 cycles post-op~Granulocyte colony stimulating factor (GCSF) at 30 mu s.c. daily from Day 4 to Day 7 is recommended.~Two weeks after completion of the 4 cycles of pre-op chemotherapy, reassessment endoscopy and CT scan would be performed. Surgery would be performed 4 weeks after pre-op chemotherapy if no distant metastasis was found on CT scan.~Post-op adjuvant FLOT (x 4 cycles) will be started within 10 weeks after surgery."
89216086|NCT05264896|Active Comparator|XELOX|"Patients randomized to adjuvant XELOX arm would receive chemotherapy after surgery.~Capecitabine - 1,000 mg/m² twice daily.~Oxaliplatin - IV infusion, 130mg/m²"
89681269|NCT02992405|Experimental|FOCUS Resilience Enhancement Program|Those assigned to the immediate treatment group will participate in the 10-week treatment.
89681270|NCT02992405|Experimental|Waitlist Treatment|After the 10-week immediate treatment period, wait-list control participants will be administered the treatment.
89681271|NCT02998723|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
89216087|NCT05259306|Experimental|Treatment-resistant Schizophrenia group|The subject will present for three baseline visits, followed by a treatment visit and subsequently follow-up visits at 24-hours, 48-hours, 1 week, 2 weeks, 1 month, and 3 months. Feasibility will be assessed as well as symptoms via detailed symptom rating scales at each visit. At the treatment visit itself, participants will undergo MR-guided low-intensity focused ultrasound of the MD thalamus.
89216088|NCT05259176|Experimental|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) on the left posterior parietal cortex and rehabilitative treatment with Smania's training
89216089|NCT05259176|Sham Comparator|Placebo stimulation (sham-tDCS)|Placebo stimulation and rehabilitative treatment with Smania's training
89216090|NCT05248919|Active Comparator|12 weeks - treatment with sofosbuvir/velpatasvir (usual regime)|134 first-line treatment failure patients randomly allocated to receive 12 weeks treatment with sofosbuvir/velpatasvir. 1:1 random allocation with stratification for the presence of cirrhosis
89216091|NCT05248919|Active Comparator|24 weeks - treatment with sofosbuvir/velpatasvir (intervention)|134 first-line treatment failure patients randomly allocated to receive 24 weeks treatment with sofosbuvir/velpatasvir. 1:1 random allocation with stratification for the presence of cirrhosis
89216092|NCT05248919|No Intervention|Observational|50 patients with decompensated cirrhosis who will receive 24 weeks of sofosbuvir/velpatasvir.
89681272|NCT02998723|Active Comparator|Late booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
89681273|NCT02998723|No Intervention|Control group|The control group will receive no booster at all.
89216093|NCT05248802|Placebo Comparator|Control|Placebo DLBS2411 2 x 1 caplet daily, given everyday for 4 weeks of study period
89216094|NCT05248802|Experimental|DLBS2411|DLBS2411 caplet 2 x 250 mg daily, given everyday for 4 weeks of study period
89216095|NCT05228574|Active Comparator|High-salt group (group 1)|"All participants will be subjected to a low-salt diet (3.5 grams/day) for six weeks.~Group 1 will receive sodium chloride capsules (6 grams/day) for four weeks. In the last two weeks of the trial, all participants will be treated with amiloride tablets (20 mg daily) in open-label setting."
89681274|NCT04402580|Experimental|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells)~How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~Where: in Hospital~When and how much: once; diluted in 1000 ml of normal saline."
89681275|NCT04402580|Active Comparator|Mycophenolate Mofetil|"Drug Name: Mycophenolate Mofetil (MMF)~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis~Procedures: MMF 1,200 mg/1,73 sqm orally divided in 2 daily doses"
89681276|NCT01275781|Experimental|A|[14C]-AZD9742 1000 mg intravenous over 2 hours
89681277|NCT04402736|Experimental|Modified Barthel Index-based rehabilitation nursing program|Patients received the Modified Barthel Index based rehabilitation nursing from qualified nurses.
89681278|NCT04402736|Other|Usual care|Patients received the usual care.
89681279|NCT00709891|Experimental|cobas® 4800 HPV Test|The cobas 4800 human papillomavirus (HPV) Test combines in a single assay the identification of pooled high-risk oncogenic HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), as well as genotypes 16 and 18 individually.
89681280|NCT03085160|Experimental|Learning to Breathe|Six-week mindfulness-based group program for adolescents
89681281|NCT03085160|Active Comparator|Health Education|Six-week health education group program for adolescents
89681282|NCT00710203|Active Comparator|Pulsed dye laser|Four lesions are selected on each subject for study. One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
89681283|NCT00710203|Active Comparator|Curettage|Four lesions are selected on each subject for study. A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
89681284|NCT00710203|Active Comparator|Electrodesiccation|Four lesions are selected on each subject for study. A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
89681285|NCT00710203|Active Comparator|No treatment|Four lesions are selected on each subject for study. A fourth lesion will not be treated and will serve as a control.
89681286|NCT02990923|No Intervention|Control|In this group, patients will use traditional standard hemodialysis connector and receive typical disinfection management
89681287|NCT02990923|Experimental|Only High-Flow Valve|In this group, patients will use High-Flow Needleless Valve instead of traditional standard hemodialysia connector, but still receiving typical disinfection management
89681288|NCT02990923|Experimental|Both Divices|In this group, patients will receive both High-Flow Needleless Valve and DualCap Disinfection Devices in hemodialysis
89681289|NCT04386109||Neonates COVID-19 positive|1. Neonatal COVID-19 in babies (<29 days old) in neonatal units, paediatric intensive care units and other in-patient locations.
89681290|NCT04386109||Neonates born to COVID-19 positive mothers|2. Neonates (<29 days old) born to COVID-19 positive mothers requiring neonatal care
89681291|NCT00710905|Experimental|ReSTOR|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, Acrysof ReSTOR +4 IOL in the other eye.
89681292|NCT04386421|Experimental|video group|Group A: A 3 minute video will be shown providing information regarding the care of the dentition during Fixed Appliance Treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions. Participants in this group will also receive the same video graphic educational material through their Whats app once weekly for a total duration of 3 months.
89681293|NCT04386421|Experimental|Plaque disclosing tablet|Group B: Plaque-disclosing tablets will be taken by patients on chair-side showing the location of the biofilm. The patients will be given plaque disclosing tablets to be used once weekly for 3 months to evaluate their oral hygiene at home. They will be given written information in the form of leaflets on importance of cooperation and compliance. Participants in this group will receive a reminder log fill, and tablets that are not used will be asked to return to the investigator by the participants to check the compliance.
89216096|NCT05228574|Placebo Comparator|Low-salt group (group 2)|"All participants will be subjected to a low-salt diet (3.5 grams/day) for six weeks.~Group 2 will receive placebo capsules (6 grams/day) for four weeks. In the last two weeks of the trial, all participants will be treated with amiloride tablets (20 mg daily) in open-label setting."
89216097|NCT05214443|Experimental|POEM + F arm|This arm will receive the POEM + F procedure
89216098|NCT05195541|Experimental|Cohort A1|0.02mg/injection，2 injections
89681294|NCT04386421|No Intervention|Control. verbal instructions|Control Group C: Controls will be given only routine verbal OHI and will be briefed on the importance of cooperation and compliance at every orthodontic visit for a period of 3 months study. They will receive a reminder log that they will return at the end of the study to check compliance.
89681295|NCT02992327||Cohort|Patients age ≥ 8 years of age with a GCS >13 presenting to the emergency department with a diagnosis of concussion.
89681296|NCT01887327|Placebo Comparator|Placebo|Participants receive placebo and phototherapy
89681297|NCT01887327|Experimental|Stannsoporfin 3.0 mg/kg|Participants receive stannsoporfin (3.0 mg/kg) and phototherapy
89681298|NCT01887327|Experimental|Stannsoporfin 4.5 mg/kg|Participants receive stannsoporfin (4.5 mg/kg) and phototherapy
89681299|NCT04386889|Other|SLE Vasculitis|20 SLE Female patients will subjected to study of the all vasculitic pattern that may occur.
89681300|NCT04386031||group with antifungal drug|
89216099|NCT05195541|Experimental|Cohort A2|0.04mg/injection，2 injections
89216100|NCT05195541|Experimental|Cohort B1|0.04mg/injection，4 injections
89216101|NCT05195541|Experimental|Cohort B2|0.075mg/injection，4 injections
89216102|NCT05195541|Experimental|Cohort C1|0.075mg/injection，6 injections
89216103|NCT05195541|Experimental|Cohort C2|0.15mg/injection，6 injections
89216104|NCT05195541|Experimental|cohort X1|0.04mg/injection，20 injections
89216105|NCT05195541|Experimental|cohort X2|0.075mg/injection，20 injections
89681301|NCT04386031||A control group|A control group will be taken ,patients undergoing thyroidectomy or parotidectomy
89681302|NCT02987751|Experimental|Glargine + Glulisine|Insulin Glargine + Glulisine (12U/day + 4U/day) at pre-breakfast/dinner for 24 weeks
89216106|NCT05195541|Experimental|cohort X3|0.15mg/injection，20 injections
89681303|NCT02987751|Active Comparator|Premixed Analogue Insulin (70/30)|Premixed analogue Insulin (70/30) 16U/day at pre-breakfast/dinner for 24 weeks
89681304|NCT04387123|Active Comparator|Conventional vaginoscopy|Vaginoscopy without vulvar tightness
89216107|NCT05195541|Placebo Comparator|cohort X|0.15mg of placebo /injection，20 injections
89216108|NCT05184972||Non-reported patients treated for in-hospital cardiac arrest|
89681305|NCT04387123|Active Comparator|Tight vaginoscopy|Vaginoscopy via Darwish sheet
89681306|NCT01889355|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
89681307|NCT04385719|Experimental|Study A Sequence 1|"Single dose remdesivir 150mg IV on Day 1~Wash out period Day 2-7~TDF/3TC 300/300mg tablets OD from Day 8-14 single dose remdesivir 150mg IV on Day 14"
89216109|NCT05184972||Reported patients treated for in-hospital cardiac arrest|
89216110|NCT05177107|Experimental|Group 1: Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
89216111|NCT05177107|Placebo Comparator|Group 2: Placebo|Placebo (normal saline) will be administered using the same schedule and techniques as for Group 1 (phage therapy).
89681308|NCT04385719|Experimental|Study A Sequence 2|"TDF/3TC 300/300mg tablets OD from Day 1-7 single dose remdesivir 150mg IV on Day 7~Wash out period Day 8-14~Single dose remdesivir 150mg IV on Day 15"
89681309|NCT04385719|Experimental|Study B|TDF/3TC/ATV/r 300/300/300/100mg tablets OD from Day 1-7 single dose remdesivir 150mg IV infusion on Day 7
89681310|NCT00082628|Placebo Comparator|Period I: Placebo|Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.
89681311|NCT00082628|Experimental|Period I: Serostim® 4 mg|Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.
89681312|NCT00082628|Experimental|Period II: Serostim® 4 mg to Placebo|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.
89216112|NCT05176873|Experimental|Single dose of DZD8586|Single dose of DZD8586
89216113|NCT05176873|Placebo Comparator|Single dose of Placebo|Single dose of Placebo
89216114|NCT05176509|Experimental|Intervention/treatment|
89216115|NCT05176288|Experimental|Axitinib, Avelumab and Palbociclib|"During each 28 day (+/- 3 days) study cycle, all participants will receive:~Axitinib: 2x Daily until it is determined participant must stop the drug~Palbociclib: Taken 1x time per day on days 8-28 of each cycle until it is determined participant must stop the drug.~Avelumab: Once every 2 weeks continued for up to 2 years or earlier if it is determined participant must stop the study drug"
89216116|NCT05173415|Experimental|Sirius Pintution Group|Patients who are randomized for the Pintution Clip will receive a preoperative ultrasound-guided marking in the axillary lymph nodes that indicate for surgical removal. Surgical procedure is standardized with a handheld probe leading intraoperatively to the marked lymph node and its excision. Successful detection, time of the procedure (beginning of localization intervention to completed lymph node excision), and intra- and postoperative complication rate will be measured. Intra- and postoperative complications are adverse events during the surgery or within 48 hours after the surgery.
89216117|NCT05173415|Active Comparator|HydroMARK(C) Clip Group|Patients who are randomized for the standard clip will receive a preoperative ultrasound-guided marking with HydroMark® Clip in the axillary lymph node that indicate for surgical removal. Surgical procedure is standardized with intraoperative ultrasound-guided wire-localization of the clip and lymph node excision. Successful detection, time of the procedure (beginning of localization intervention to completed lymph node excision), and intra- and postoperative complication rate will be measured. Intra- and postoperative complications are adverse events during the surgery or within 48 hours after the surgery.
89216118|NCT05167565|Experimental|Infants aged around 3 month|80 infants aged around 3 months will be included in this study up to around 12.5 months
89681313|NCT00082628|Experimental|Period II: Serostim® 4 mg to Serostim® 2 mg|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.
89681314|NCT00082628|Experimental|Period II: Placebo to Placebo/Serostim® 4 mg|All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.
89681315|NCT01275859|Experimental|Letrozole, Lapatinib|Letrozole 2.5mg po qd + Lapatinib 1500mg po qd for 18-21 wks
89681316|NCT01950039|Active Comparator|Betaine|
89681317|NCT01950039|Placebo Comparator|Placebo|
89681318|NCT01275937|Other|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days followed by40mg once daily orally for two months.
89681319|NCT01275937|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days followed by 40mg once daily orally for two months.
89216119|NCT05162326|Experimental|BC-101|BC-101 will be injected at the dose of 0.1 mL per linear centimeter along the nasolabial fold, up to 2 mL in total volume for each side of the nasolabial folds.
89216120|NCT05154448|Experimental|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR High Intensity Focused Ultrasound device
89216121|NCT05154448|Sham Comparator|Sham treatment|"The procedure would be done in an identical manner to the NeurolyserXR treatment without any person in the procedure room knowing that this is a sham procedure.~The only difference is that the acoustic energy would not be output from the system during a sham procedure."
89216122|NCT05150340|Experimental|Epoch 1: TAK-771 Ramp up Period|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution. The dose of 10% IGI will be increased from 1/3 of full dose to full dose in 3 weeks for participants who will receive TAK-771 once every 3 week, or from 1/4 of full dose to full dose in 6 weeks for participants who will receive TAK-771 once every 4 week.
89216123|NCT05150340|Experimental|Epoch 2: TAK-771 Treatment Period|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 3, or 4 weeks for up to Week 24.
89216124|NCT05150184||Healthy adults, various ethnicities|Non-interventional
89216125|NCT05127681|Experimental|severe hemophilia A or B patients|30 patients with severe hemophilia A or B (Factor (F)VIII or Factor IX (FIX)≤ 1%) aged 20 to 60 years will be included in this study.
89216126|NCT05127681|Other|healthy men|"Data of healthy men, matching in age- height-weight-ethnicity and smoking-matched with patient will be collected. These data are already available at the Institut national de la santé et de la recherche médicale (INSERM) research unit associated."
89216127|NCT05099341|Experimental|Patients with recurrent depression with a number of depressive episodes ≥ 3|
89216128|NCT05099341|Experimental|Patients with a first depressive episode|
89681320|NCT03029793||Biomarkers and Imaging analysis|This study will prospectively collect the tissue and blood samples of locally advanced esophageal cancer patients, perform CRT resistance biomarkers testing and functional imaging analysis including SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI before treatment, 2-3 weeks after the initiation of CRT, and 4 weeks post-nCRT. The investigators will use advanced statistical tools to establish the model and further validate the model in another group of patients. The investigators will also establish a model for survival prediction.
89681321|NCT04761926|Experimental|single arm|Asessments for the hearing with Ponto 4 sound processor on the implanted ear(s).
89681322|NCT02990455|Experimental|Reduced Nicotine Cigarette - Moderate|Nicotine Research Cigarette Drug Supply Program Category Codes NRC600 and NRC601 (menthol); each cigarette contains 0.8mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
89681323|NCT02990455|Experimental|Reduced Nicotine Cigarette - Low|Nicotine Research Cigarette Drug Supply Program Category Codes NRC102 and NRC103 (menthol); each cigarette contains 0.03mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
89681324|NCT01889667|Experimental|ORMD-0801 Dose # 1|Oral Insulin Formulation
89681325|NCT01889667|Experimental|ORMD-0801 Dose # 2|Oral Insulin Formulation
89681326|NCT01889667|Placebo Comparator|Placebo|Oil Capsules
89681327|NCT00711997|Experimental|BC-819|Intratumoral administration of BC-819
89681328|NCT00712075|Experimental|CBSST+PDA|PDA-Assisted Cognitive-Behavioral Social Skills Training (CBSST+PDA): The CBSST rehabilitation intervention will be combined with the use of a PDA to facilitate homework completion and progress towards recovery goal attainment in consumers.
89681329|NCT00712075|Active Comparator|CBSST|Cognitive Behavioral Social Skills Training (CBSST): CBSST is a psychosocial rehabilitation intervention that combines skills from cognitive behavioral therapy and social skills training to assist consumers in improving functioning and recovery goal attainment.
89681330|NCT00712075|Active Comparator|PDA-Only|PDA-only: To control of device contact, the PDA-only arm will not receive CBSST and will only carry a PDA with access to the basic features of the device.
89681331|NCT01891305|Experimental|VT-1161 200/50mg|
89681332|NCT01891305|Experimental|VT-1161 600/150mg|
89216129|NCT05099341|Active Comparator|Healthy, non-depressed subjects|
89216130|NCT05098028|Experimental|Low Dose Rifaximin ER|twice daily
89216131|NCT05098028|Experimental|Low Dose Rifaximin DER|twice daily
89216132|NCT05098028|Experimental|High Dose Rifaximin ER|twice daily
89216133|NCT05098028|Experimental|High Dose Rifaximin DER|twice daily
89216134|NCT05098028|Placebo Comparator|Placebo|twice daily
89681333|NCT01891305|Experimental|VT-1161 1200/300mg|
89681334|NCT01891305|Placebo Comparator|Matching placebo|
89681335|NCT01276015|Experimental|botulinum toxin A|botulinum toxin A diffusion in cerebral palsy
89681336|NCT03830593||Group 1|laparoscopic adrenalectomy group 1: tumor size as < 6 (group1)
89681337|NCT03830593||Group 2|Laparoscopic adrenalectomy group2: tumor size ≥ 6 cm (group2)
89216135|NCT05091918|Other|MotionSense Wearable|Using MotionSense from pre-op to 90 days post-op during the recovery after primary TKA
89681338|NCT03830593||Learning Curve|The patients, underwent laparoscopic adrenalectomy, were also classified into group A (1-25), B (26-50), C (51-75), and D (76-102) according to the chronological order of their surgery in order to evaluate the learning curve.
89681339|NCT01950663|Experimental|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
89681340|NCT02130635|Experimental|Part A: GSK2269557 1000 MCG|Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
89681341|NCT02130635|Placebo Comparator|Part A: PLACEBO|Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days
89681342|NCT02130635|Experimental|Part B: GSK2269557 100 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
89681343|NCT02130635|Experimental|Part B: GSK2269557 200 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
89681344|NCT02130635|Experimental|Part B: GSK2269557 500 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days
89681345|NCT02130635|Experimental|Part B: GSK2269557 700 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
89681346|NCT02130635|Experimental|Part B: GSK2269557 1000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
89681347|NCT02130635|Experimental|Part B: GSK2269557 2000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
89681348|NCT02130635|Placebo Comparator|Part B: PLACEBO|Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days
89681349|NCT01276093|Experimental|PVI ablation|Pulmonary Vein Ablation
89681350|NCT01276093|Active Comparator|Amiodarone medical treatment|Amiodarone medical treatment
88996700|NCT05470192|No Intervention|Conventional Physiotherapy and Rehabilitation Group|A training will be given including information about the postoperative recovery process, the purpose of respiratory physiotherapy and rehabilitation, the importance of physiotherapy and rehabilitation in the postoperative period, attention to speed up recovery and prevention of complications, breathing exercises, coughing training, posture exercises, early mobilization and its importance, and answering patient questions. . The program includes progressive ambulation and progressive shoulder and rib cage exercises. These exercises will be performed under the supervision of a physiotherapist from the first postoperative day. The exercises will be advanced every day by increasing the number of repetitions.
88996701|NCT00536302|Experimental|1|Collagen Hydrolysate
88996702|NCT00536302|Placebo Comparator|2|
88996703|NCT05469880|Active Comparator|moisturizing cream and 5% benzoyl peroxide gel|Participants apply the 5% benzoyl peroxide gel every evening and the moisturizing cream every morning for 3 months. Then they are divided into 2 groups: one applies the anti-acne face cream every morning for 3 months and the other one the moisturizing cream every morning for 3 months.
88996704|NCT05469880|Experimental|anti-acne face cream and 5% benzoyl peroxide gel|Participants apply the 5% benzoyl peroxide gel every other night and the anti-acne face cream every morning for 3 months. Then they are divided into 2 groups: one applies the anti-acne face cream every morning for 3 months and the other one the moisturizing cream every morning for 3 months.
88996705|NCT00408525|Experimental|1|Donepezil
88996706|NCT05469763|Experimental|Circuit training exercise plus calcium tablets group|Study Group: they will receive circuit training exercise, 3 sessions per week for 12 weeks, in addition to calcium supplements.
88996707|NCT05469763|Other|Calcium tablets group|Control Group: they will receive daily dosage of calcium supplements 1-3 g/ day
88996708|NCT05469529|No Intervention|Bupivacaine|Participants to be given 2ml of 0.5% bupivacaine intrathecally for elective cesarean section deliveries.
88996709|NCT05469529|Active Comparator|Bupivacaine + Dexmedetomidine|Participants to be given 5mcg dexmedetomidine in addition to 2ml of 0.5% bupivacaine intrathecally for elective cesarean section deliveries.
88996710|NCT05469217||Fentanyl dependent patients|15 participants who were treated for fentanyl dependence in treatment centers in Israel
88996711|NCT05469217||Control participants|Healthy control participants from the general public
88996712|NCT05469100|Experimental|Cohort 1: Selpercatinib (Healthy participants)|Single oral dose of Selpercatinib administered in a fasted state to participants with normal renal function.
88996713|NCT05469100|Experimental|Cohort 2: Selpercatinib (Participants with mild renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with mild renal impairment.
88996714|NCT05469100|Experimental|Cohort 3: Selpercatinib (Participants with moderate renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with moderate renal impairment.
88996715|NCT05469100|Experimental|Cohort 4: Selpercatinib (Participants with severe renal impairment)|Single oral dose of Selpercatinib administered in a fasted state to participants with severe renal impairment and not on dialysis.
88996716|NCT05469061|Experimental|Tislelizumab plus Chemotherapy|In the single experimental arm, patients with locally nonresectable disease were subjected to receive neoadjuvant tislelizumab (200mg) plus chemotherapy (FP regimen) for conversion therapy. If conversion therapy succeeds, patients would proceed to surgery and adjuvant therapy. Otherwise, if patients were still not resectable after the conversion therapy, they will be treated by tislelizumab plus chemotherapy with or without palliative radiotherapy .
88996717|NCT00408642|Experimental|1|enhanced adherence support for patients initiating antiretroviral therapy
88996718|NCT00408642|Active Comparator|2|standard adherence support
88996719|NCT05469022|Experimental|Neoadjuvant Lazertinib|Lazertinib as neoadjuvant treatment is administrated for 9 weeks before surgery. After surgical intervention the treatment is administrated upto 3 years to the patients with over stage 2 tumor. Treatment is discontinued in case of unacceptable toxicity or disease progression.
88996720|NCT05468944|Experimental|Transanal group|Participants in this group underwent robotic surgery with transanal specimen extraction
88996721|NCT05468944|Active Comparator|Transabdominal group|Participants in this group underwent robotic surgery with transabdominal specimen extraction
89216136|NCT05082753|Experimental|Ivermectin tablets (3 mg Ivermectin)|
89681351|NCT03370185|Experimental|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
89681352|NCT01892007|Experimental|Cogmed RM (adaptive)|Online training intervention: An adaptive version of Cogmed RM working memory training. Task difficulty (number of to-be-remembered items) increases based on individual performance, in order to maintain average daily performance levels of approximately 60% of trials correct. Participants complete 35-45 minutes of active training per day, 5 days a week for 5 weeks.
89681353|NCT01892007|Placebo Comparator|Cogmed RM (non-adaptive, placebo)|Online training intervention: A non-adaptive placebo version of Cogmed RM working memory training. Tasks are fixed at a low-difficulty practice level (three to-be-remembered items) and do not increase in difficulty over the course of the intervention. Participants complete 35-45 minutes of active placebo training per day, 5 days a week for 5 weeks.
89681354|NCT00725959|Experimental|Facebook Arm|Participants in this arm will have exposure to innovative, dynamic and regularly updated HIV Prevention messages on Facebook
89051471|NCT01151410|Active Comparator|Enalapril|Patients will receive one of the following doses based on their weight: Low weight (≥20 to <50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to <80 kg) patients: Starting dose 5 mg with optional titration to 10 and then 20 mg High weight (≥80 to ≤150 kg) patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
89681355|NCT00725959|Active Comparator|Control arm|Participants in this arm will have exposure to static information on HIV prevention currently available online
89681356|NCT02990143|No Intervention|Glaucoma Drainage implant no Ologen|The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.
89681357|NCT02990143|Active Comparator|Glaucoma Drainage implant with Ologen|the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.
89681358|NCT00557973|Experimental|XP19986 SR1 10 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 10 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
89681359|NCT00557973|Experimental|XP19986 SR1 20 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 20 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
89051472|NCT04588896|Experimental|CGM+LMP|Continuous glucose monitoring (CGM) for 8 weeks in conjunction with lifestyle modification
89051473|NCT04588896|Other|LMP only|Lifestyle modification only
89051474|NCT00562406|Active Comparator|1|laser photocoagulation to the retina at the area of edema
89051475|NCT00562406|Experimental|2|intravitreal injection of ranibizumab
89051476|NCT00562406|Experimental|3|laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab
89051477|NCT04588974||Screening|Sixty-five cirrhotic patients with portal hypertensive symptoms (such as platelets count less than 100,000) will be enrolled to evaluate for the presence and stage of esophageal varices by using a magnetic-assisted capsule endoscope system with or without 3D image processing.
89051478|NCT04588974||Follow-up|Thirty-five cirrhotic patients with a history of endoscopy-confirmed esophageal varices will be included for the follow-up examination by using the magnetic-assisted capsule endoscope system with or without 3D images.
89051479|NCT04588974||Control|Another 40 volunteers with GI symptoms but no known gastrointestinal disease will be enrolled as the control group.
89051480|NCT00562445||1|Peptic bleeding
89051481|NCT00562445||2|Portal hypertension bleeding
89051482|NCT00562445||3|Severe acute pancreatitis
89051483|NCT04649658||Prone position|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to prone position
89051484|NCT04649658||Standard care|Severe and critical COVID-19 patients undergoing non invasive respiratory support subjected to standard care
89051485|NCT04621409|Experimental|liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
89051486|NCT04621409|Placebo Comparator|Placebo|IV infusion of saline, approximately 5 hours
89051487|NCT04588935|No Intervention|Group 1|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, untreated
89051488|NCT04588935|Active Comparator|Group 2|women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, receiving treatment with a combination of bisoprolol and perindopril
89051489|NCT04691258|Active Comparator|Restricted Group (RG)|Intervention with the movement technique traditional of squat exercise.
89051490|NCT04691258|Experimental|Complete Group (CG)|Intervention with the squat exercise technique prioritizing the full range of motion.
89051491|NCT04589169||Positive cohort|Patients who develop delirium
89051492|NCT04589169||Experimental control group|Patients who do not develop delirium
89051493|NCT00562523|Experimental|Arm 1|
89051494|NCT00562562|Other|MOT|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
89051495|NCT04649424|Experimental|CanSwab - 1st|CanSwab will be swabbed first
89051496|NCT04649424|Experimental|CanSwab - 2nd|CanSwab will be swabbed second.
89051497|NCT00567723||1|Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol
89051498|NCT00567723||2|Historical control group: Patients with no lanthanum exposure
89051499|NCT00567723||3|Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product
89051500|NCT05161286||Healthy pain-free cohort|Healthy pain-free Dutch-speaking men and women between the age of 18 and 65 years
89051501|NCT00562679||2 groups|The cohort is grouped according to one group with sleep apnea and one group without sleep apnea
89051502|NCT04588779|Experimental|Graston|Ultrasound, Graston technique, piriformis stretching, home plan (hip abductor and extensor strengthening)
89051503|NCT04588779|Active Comparator|Manual myofascial release|Ultrasound, Manual myofascial release, piriformis stretching, home plan (hip abductor and extensor strengthening)
89216137|NCT05082753|Active Comparator|Stromectol ® tablets (3 mg Ivermectin)|
89681360|NCT00557973|Experimental|XP19986 SR1 30 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 30 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
89681361|NCT00790049|Experimental|ARRY-371797|
89681362|NCT00790049|Placebo Comparator|Placebo|
89681363|NCT01892865|Active Comparator|Historical means method|Operative time will be predicted using historical service means. Schedule will be constructed using this time
89681364|NCT01892865|Experimental|Predictive Modeling System (PMS)|Operative time will be predicted using a regression model. Schedule will be constructed using this time
89681365|NCT00726739|Experimental|Arm I - LMI + aldesleukin|Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89681366|NCT00726739|Active Comparator|Arm II (control) - aldesleukin|Patients receive aldesleukin SC on days 1 and 2. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over and receive treatment on arm I.
89681367|NCT00726739|Experimental|Arm III - Crossover Patients|"Patients who have progressive disease on Arm II were be offered crossover to Arm I provided they continued to meet all study criteria.~Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity"
89681368|NCT00569309|Experimental|Prevnar|The conjugate vaccine for Streptococcus pneumoniae will be administered during weeks 9, 17, and 25 after autologous HSCT - the study nurse will arrange for the vaccine to be administered at the specified time and the patient will be instructed to notify an investigator or study nurse of any side effects of vaccine administration. At the specified times, patients will fill out the quality-of-life assessment. All patients enrolled on this trial will have samples procured for all proposed laboratory correlative studies.
89681369|NCT01952301|Active Comparator|xenogeneic collagen matrix|Xenogeneic collagen matrix device placed on treatment wound bed site
89681370|NCT01952301|Active Comparator|Free Gingival Graft|Traditional free gingival graft (autogenous graft device harvested from patient's palate) placed on treatment site wound bed
89681371|NCT04470089|Experimental|Myramistin 0.005%|
89681372|NCT04470089|Experimental|Myramistin 0.01%|
89681373|NCT04470089|Experimental|Myramistin 0.02%|
89681374|NCT04470089|Placebo Comparator|Placebo|
89681375|NCT00714571|Active Comparator|MST healthy older adults Stage 1|Mnemonic strategy training
89681376|NCT00714571|Active Comparator|MST MCI Stage 1|Exposure training
89681377|NCT00714571|Active Comparator|XP healthy older adults Stage 1|XP healthy older adults Stage 1
89681378|NCT00714571|Active Comparator|XP MCI Stage 1|XP MCI Stage 1
89681379|NCT00714571|Active Comparator|MST healthy older adults Stage 2|MST healthy older adults Stage 2
89681380|NCT00714571|Active Comparator|SCT healthy older adults Stage 2|SCT healthy older adults Stage 2
89051504|NCT04621214||Group-A|Group A were performing their duties on visual triage
89051505|NCT04621214||Group-B|Group A were performing their duties on Audio-visual triage
89051506|NCT04649619|Other|Single-arm-study|Prospective clinical trial with intentional sample selection that aims to describe the results of the gastric Bypass surgery modified by De Melo, for the purpose of endoscopic access to the excluded remaining stomach, as well as to monitor the clinical conditions of comorbidities and the quality of life of the patient.
89051507|NCT04649697|Experimental|Rebamipide|The enrolled subjects will be treated with Rebamipide in mucoadhesive gel for 2 weeks or until complete healing.
89051508|NCT04649697|Experimental|Nanoparticulated Rebamipide|The enrolled subjects will be treated with nanoparticulated Rebamipide in mucoadhesive gel for 2 weeks or until complete healing.
89051509|NCT04649697|Active Comparator|Clobetasol|The enrolled subjects will be treated with Clobetasol in mucoadhesive gel for 2 weeks or until complete healing.
89051510|NCT04621097|Experimental|pulsed electro magnetic field|30 patients will receive the physical therapy program in form of low frequency pulsed electro magnetic field application. with frequency 15hz, and low intensity with flux density of 20 Gauss (2mT), in pulse duration 200 usec , pulsed rectangular pulses for 60 min is applied to the dorsal surface of lower leg , ankle and foot in addition to their regular medications prescribed , 3 times per week for 8 week
89051511|NCT04621097|Experimental|Treadmilltraining|"In this group, 30 patient will receive the physical therapy program in form of supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .~At first , a 5 minutes- warm up period will be allowed, it will include stretching exercises for calf muscles , hamstrings and quadriceps (i.e. each for at least 10 -15 seconds) . Patients should start with walking on the treadmill at a comfortable speed, and should not stop at the onset of leg pain but instead , he/she would continue until moderate pain is reached. At this point, he/she has to rest until pain completely subsides, then walking is resumed again . The intensity of exercise will be determined by claudication pain scale, and should not exceed the score of 4 on this scale. The exercise can be progressed if the patient can walk continuously for 10 minutes without the need to stop."
89051512|NCT04621097|Placebo Comparator|medications|It includes 20 patients who will not receive any physiotherapy intervention. They will receive medical treatment only and will act as a control group.
89051513|NCT04621253|Active Comparator|Ciprofloxacin|Day 1: 750 mg ciprofloxacin capsule in the morning and evening Day 2: 750 mg ciprofloxacin capsule in the morning and evening Day 3: 750 mg ciprofloxacin capsule in the morning and evening Day 4: Study day, 750 mg ciprofloxacin 1h prior to 1000 mg metamizole.
89681381|NCT00569855|Experimental|1|Receive phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery
89681382|NCT02991781|Experimental|COPD Patients|"C.O.P.D. patients: Presence of a post-bronchodilator forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) < 0.70 with symptoms as dyspnea, chronic cough, chronic sputum production~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control"
89681383|NCT02991781|Experimental|Asthma Patients|"Asthma patients: Presence of 2 or more of symptoms of airflow obstruction (cough, wheezing, dyspnea). Airflow obstruction at least partially reversible demonstrated by spirometry with FEV1 increased by >12% following b2 agonist inhalation) or evidence of bronchial hyperresponsiveness by metacholine provocation test (demonstrated by provocative concentration causing a 20% fall (PC20) <8 mg or mannitol provocation test (with FEV1 decrease of 15%)~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control"
89681384|NCT02991781|Experimental|Smokers|"Smokers will consist of a group of patients that are under the age of 35, unemployed and healthy according to a standard clinical evaluation.~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Sham Neurofeedback~Passive Control"
89681385|NCT01893801|Experimental|nab-paclitaxel+Cisplatin+gemcitabine|This is a phase Ib/II open-label, pilot study evaluating the preliminary efficacy and safety of nab-paclitaxel 125mb/m2, cisplatin 25mg/m2, and gemcitabine 1000mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days until development of toxicity that is unacceptable in the opinion of the patient or the Investigator or upon disease progression.
88996722|NCT05468905||Cognitive normal Aging (CN)|Normal aging subjects with normal cognitive function
88996723|NCT05468905||Subjective cognitive impairment (SCI)|"Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
88996724|NCT05468905||Mild cognitive impairment (MCI)|Mild cognitive impairment subjects with memory loss as predominant symptom
88996725|NCT05468905||Alzheimer's disease (AD)|Mild to moderate sporadic and familial Alzheimer disease subjects
88996726|NCT05468905||Vascular cognitive impairment (VCI)|Cognitive impairment subjects caused by cerebral vessel disease
88996727|NCT05468866|Active Comparator|group (I)|Group (I): represents the healthy control individuals (30 person) (recruited from the blood donors at the blood bank)
88996728|NCT05468866|Active Comparator|Group (II)|Group (II): represents the cases of immune thrombocytopenia (70 cases).
88996729|NCT05468788|Experimental|Integrative Community Therapy (ICT) Intervention Arm|Participants will perform scenes related to having a chronic medical condition and they will be guided through conversations about their feelings and coping methods.
88996730|NCT05468788|Sham Comparator|Improvisational Theatre Arm|Participants will perform generic improvisational theatre with no instruction on feelings or coping methods.
88996731|NCT00156650|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (Depo-Medroxyprogesterone) (injected into muscle Day 0 & at Month 3)
88996732|NCT00156650|Active Comparator|2|T gel for 6 months + DMPA (Day 0 & Month 3) + Acyline 300 mcg/kg twice monthly for 12 weeks
88996733|NCT00536419|Placebo Comparator|2|4 days of placebo
88996734|NCT00536419|Experimental|1|MPH-SODAS at day 1 (0.3/mg/kg/day); day 2 (0.7/mg/kg/day);days 3 and 4 (1.0 mg/kg/day)
88996735|NCT00536458|Experimental|radiotherapy|minichep + radiotherapy
88996736|NCT00536458|Active Comparator|B|MINI CHEP
88996737|NCT00536536|Active Comparator|Hospital|Care of Childhood Obesity Clinic (COCO)
88996738|NCT00536536|Active Comparator|Primary Care|Primary care clinics (x2)
88996739|NCT00536614|No Intervention|A|arm A) gemcitabine/cisplatin in combination with Cetuximab arm B) gemcitabine/cisplatin alone
88996740|NCT05468164|Experimental|Selpercatinib and omeprazole administered in ABCD treatment sequence|"Period 1: Single oral dose of Selpercatinib administered in fasted state. Period 2: Single oral dose of Selpercatinib administered in fed state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
88996741|NCT05468164|Experimental|Selpercatinib and omeprazole administered in ABDC treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fasted state. Period 2: Single oral dose of Selpercatinib administered in fed state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
88996742|NCT05468164|Experimental|Selpercatinib and omeprazole administered in BACD treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fed state. Period 2: Single oral dose of Selpercatinib administered in fasted state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
88996743|NCT05468164|Experimental|Selpercatinib and omeprazole administered in BADC treatment sequence.|"Period 1: Single oral dose of Selpercatinib administered in fed state. Period 2: Single oral dose of Selpercatinib administered in fasted state. Period 3: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fed state.~Period 4: Multiple daily oral doses of omeprazole administered along with single oral dose of selpercatinib in fasted state.~Periods 1 and 2, 2 and 3 will be separated by a 7-day washout period. There will be no washout between Periods 3 and 4."
88996744|NCT05468086|Experimental|Solace VR|This arm will include software that provides immersive distraction based content for pain reduction.
88996745|NCT05468047|Experimental|Ketamine administration|These individuals will be provided a personal ketamine-assisted therapy experience as part of an in-person training weekend within a psychedelic-assisted training program.
89681386|NCT00570089|Experimental|Study Drug Ranexa, Then Placebo|"Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.~After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet)."
89681387|NCT00570089|Experimental|Placebo, Then Study Drug Ranexa(Ranolazine)|"Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.~After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval."
89681388|NCT00727597|Experimental|Arm A : Boosted Lexiva plus Epzicom|Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).
89681389|NCT00727597|Experimental|Arm B: Efavirenz plus Epzicom|QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
89681390|NCT04748913|No Intervention|No intervention|
89681391|NCT04748913|Other|Remineralization|
89681392|NCT04386473||Left Bundle Branch Pacing|
89681393|NCT04386473||Right Ventricular Outflow Tract Septal Pacing|
89681394|NCT04387045|Experimental|Guilty feelings|Write for 20 minutes about a situation that in the participant's past life has caused feelings of guilt.
89681395|NCT04387045|Placebo Comparator|Neutral feelings|Write for 20 minutes about a situation that in the participant's past life has caused neutral feelings.
89681396|NCT00571259|Active Comparator|1|Catheter lock with heparin 1,000 units/mL
89681397|NCT00571259|Active Comparator|2|Catheter lock with gentamicin 320 micrograms/mL in sodium citrate 4%
89681398|NCT01893879|Experimental|(RS)2-(3-benzoylphenyl)-propionic acid|"Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed."
89681399|NCT01893879|Placebo Comparator|placebo for study drug|"Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed."
89681400|NCT01276405||Cohort|
89681401|NCT01894503|Experimental|S8 Sinus Implant|Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
89681402|NCT02990065|Experimental|PROTEIN-FORTIFIED DIET|The protein-fortified diet consists on an energy goal based on REE measurement and a protein target based on the most recent literature recommendations (1.2-2 g/kg/die) (2). Daily caloric requirement, and subsequent protein content, of patients enrolled in the intervention group will be calculated using formulas in Table 1 (10, 12, 13). For each patient will be calculated the Resting Energy Expenditure (REE) and daily protein requirement (1.2-2g/kg/die of body weight registered at the admission) and the corresponding caloric intake (1g = 4 kcal). Finally, total daily caloric intake will be calculated by adding kcal from protein (1g = 4kcal) on kcal from non-protein (50% of REE).
89681403|NCT02990065|No Intervention|STANDARD DIET|The standard diet consists on an energy goal based on weight formula (20-25 kcal/kg/die). According to the ICU nutritional protocol, EN is started at an initial rate of 10ml/h, and increased by 20ml/h every 12 hours in the absence of significant gastric residuals (<250ml), with the aim of reaching the energy goal within 72 hours from admission. The EN formulae used are standard (1-1,5 kcal/ml, 40g/l protein). If enteral nutrition is not tolerated or is not indicated, supplemental PN is used to make up the energy shortfall. The PN formula used is standard (1000 kcal/l, 37 g/l protein).
89681404|NCT00571961|Experimental|1|HIV negative subjects currently enrolled in a long-term buprenorphine maintenance therapy program for at least 3 months who have been on stable dose of buprenorphine for at least 3 weeks will be admitted to the General Clinical Research Center (GCRC) for pharmacokinetic (PK) blood draws at intervals over a 24-hour period. Subjects will then receive Kaletra and buprenorphine coadministered for 14 days. Subjects will be admitted to the GCRC for a second PK sampling day.
89681405|NCT02990377|Experimental|RL-supported IVR intervention|Participants in the intervention group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED plus the RL-supported IVR intervention.
89681406|NCT02990377|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED.
89681407|NCT04386655|Experimental|Telemedicine Group|BICS-T is the intervention that will take place over telemedicine software on the iPad provided to participants
89681408|NCT04386655|Active Comparator|In-Person Group|Participants a part of the in-person BICS group will then come to the NRC for the following BICS sessions. This group is the traditional, in-person, BICS group
89681409|NCT00572117|Placebo Comparator|Placebo (inert pill) Arm|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. Subjects will receive placebo pills identical to the active pills (pills that contain the study drug, topiramate) for the 12 treatment weeks of the study and will have the pills discontinued over the next four weeks of the study. All subjects will be re-evaluated at 26 and 52 weeks.
89681410|NCT00572117|Experimental|Topiramate|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. The pills will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
89681411|NCT01895127|Active Comparator|Standard of Care|"Plasmapheresis (PP) x 3, at 40-60 cc/kg.~Immunoglobulin (IVIg), to be administered after each PP"
89681412|NCT01895127|Experimental|Soliris (eculizumab)|"1200 mg first dose (Time: Screening/Week 0, after Biopsy Proven AMR)~900 mg weekly for 4 doses (Weeks 1, 2, 3, 4)~1200 mg week 5~Week 6: If donor specific antibody < 50% of baseline DSA then no further treatment, otherwise 1200 mg weeks 7, 9"
89681413|NCT02991235|Experimental|PRJ212|PRJ212 is a nutritional product with active food ingredients.
89681414|NCT02991235|Placebo Comparator|Placebo|Placebo is like PRJ212 without active food ingredients.
89681415|NCT02992171|Experimental|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
89681416|NCT01276561|Active Comparator|Single Incision Splenectomy|Patients will undergo splenectomy through a single incision in the umbilicus regardless of the technique or equipment used
89681417|NCT01276561|Active Comparator|Laparoscopic Splenectomy|Patient will undergo standard laparoscopic splenectomy, port placement is surgeon dependent
89681418|NCT01953081|Experimental|TD-8954|TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours
89681419|NCT01953081|Active Comparator|Metoclopramide|Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline
89681420|NCT02991313|Experimental|Endocardial Ablation Procedure|ablation with Linear type catheter
89681421|NCT00572897|Experimental|Fludarabine, Melphalan +/- ATG|Fludarabine, Melphalan +/- ATG
89681422|NCT01276717|Experimental|Vorinostat + Carfilzomib|
89681423|NCT01953237|Active Comparator|Control|Individuals randomized to the control condition will be provided with a smartphone free of charge with unlimited use of the phone's voice and internet capabilities. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period. All participants will be contacted by research staff to trouble-shoot problems with the smartphone at the end of the first week, but will receive no additional contact from research staff until the end of the trial.
89051514|NCT04621253|Active Comparator|Fluconazole|Day 1: 400 mg fluconazole in the morning, placebo capsule in the evening Day 2: 200 mg fluconazole in the morning, placebo capsule in the evening Day 3: 200 mg fluconazole in the morning, placebo capsule in the evening Day 4: Study day, 200 mg fluconazole 1h prior to 1000 mg metamizole.
89051515|NCT04621253|Placebo Comparator|Placebo|Day 1: placebo capsule in the morning and evening Day 2: placebo capsule in the morning and evening Day 3: placebo capsule in the morning and evening Day 4: Study day, placebo capsule 1h prior to 1000 mg metamizole.
89681424|NCT01953237|Experimental|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
89681425|NCT04386499|Experimental|Resveratrol|A nutraceutical formulation (trade mark Genante) composed of resveratrol, REVIFAST, folic acid, Vitamin D
89051516|NCT04649463|Active Comparator|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
89681426|NCT04386499|Active Comparator|Folic acid|Folic Acid 400 ug
89051517|NCT04649463|Sham Comparator|Concealed ABPM results|ABPM results were not used in the decision making for adjustments in antihypertensive medication at follow up visit.
89051518|NCT04620902||Dementia|Dementia
89051519|NCT04620902||MCI|Mild cognitive impairment
89051520|NCT04620902||SCD|Subjective cognitive decline
89051521|NCT04620902||HC|Cognitively healthy control
89051522|NCT04588701||persons with anal fistulas|all persons with anal fistulas treated by a single surgeon over 22 years
89051523|NCT00567762|Experimental|1|FK506 ophthalmic suspension
89051524|NCT00567762|Placebo Comparator|2|Base of eye drops
89051525|NCT04620785|Experimental|methylene blue/IPL|"will undergo photodynamic therapy using intralesional 4%methylene blue solution ,after a period of 15 minutes the patient will be subjected to IPL session.~This will be repeated biweekly until complete clearance of the lesion or a maximum four sessions."
89681427|NCT01276795|Experimental|Glucose and whey protein|Patients who are randomly allocated to this group will receive a drink made of anhydrous beet dextrose and pressurized whey protein in water (200 g/L + 100g/L). Patients will sip the drink for 4 hours of the 6 hour study.
89681428|NCT01276795|Active Comparator|Glucose only|The patients who are randomly allocated to this arm will receive a drink composed of anhydrous beet dextrose in water (200g/L). They will sip the drink for 4 hours of the 6 hour study.
89051526|NCT04620785|Experimental|IPL|will undergo biweekly IPL sessions only until complete clearance of the lesion or a maximum four sessions.
89051527|NCT04620785|Placebo Comparator|saline|will undergo intralesional saline.
89051528|NCT04649346||SGA type 1|Observe the function of SGA type 1
89051529|NCT04649346||SGA type 2|Observe the function of SGA type 2
89051530|NCT00567801|Active Comparator|1|conventional embolectomy/thrombectomy
89051531|NCT00567801|Experimental|2|embolectomy/thrombectomy with controlled reperfusion
89051532|NCT04620590|Experimental|Treatment Arm|Patients will receive dapagliflozin 10 mg tablets once daily for 14±1 days.
89051533|NCT04649268|Active Comparator|Optokinetic stimulation treatment with visual motion DVDs|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with visual motion DVDs
89051534|NCT04649268|Experimental|Optokinetic stimulation treatment with Virtual Reality|Customised vestibular rehabilitation programme which includes optokinetic stimulation treatment with Virtual Reality environments delivered with headset (e.g. Oculus Quest headset)
89051535|NCT04691219|Experimental|Mulberry leaves powder plus diet control|
89051536|NCT04691219|Other|Diet control alone|
89051537|NCT04691063|Experimental|Treatment group A|
89051538|NCT04691063|Placebo Comparator|Treatment group B|
89681429|NCT01896687|Experimental|Scrambler therapy|Scrambler therapy applied to region of low back pain for 30 minutes x 10 days
89681430|NCT01896687|Sham Comparator|Sham Scrambler treatment|Sham treatment applied to region above low back pain at nontherapeutic dose for 30 minutes x 10 days
89681431|NCT00573287|Experimental|Clozapine|clozapine: clozapine--tablets, 12.5-100 mg, daily for 24 weeks
89681432|NCT00573287|Active Comparator|Risperidone|risperidone: risperidone--tablets, 0.5-5.0mg daily for 24 weeks
89681433|NCT04385797||Dyads|Community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers
89681434|NCT05735925|Experimental|Hidradenitis Suppurativa (HS) Patients|"Skin swab sampling for bacteriological analysis~Four skin biopsies:~a 6-mm and a 4-mm section skin biopsies on a lesional area (inflammatory nodules) a 6-mm and a 4-mm section skin biopsies on a non lesional area~- blood sample (16 mL)"
89681435|NCT05735925|No Intervention|Healthy Subjects|blood sample (16 mL)
89681436|NCT04385641|Experimental|Dose-finding (Group A)|"In this study, the dose was explored according to the 3+3 mode, in which group A was divided into three dose groups: 1.5*10＾9 group, 2*10＾9 group and 3*10＾9 group. If DLT occurs in one of the first three subjects in each dose group within four weeks after cell infusion, three subjects will continue to be included. If more than 1/6 cases of DLT appear in 6 subjects with 1.5*10＾9 dose, the dose level and/or cell infusion frequency and method will be reduced after discussion between the investigator, the collaborator and DMC. If DLT did not occur in the first 3 subjects within 4 weeks after receiving 1.5*10＾9 cell infusion，another three subjects were enrolled into the group received 2*10＾9 cell infusion. DLT did not occur within 4 weeks after cell infusion, it will increase to 3*10＾9 dose group. That is to say, the first three subjects were included for observation for 4 weeks in the 3*10＾9 dose group, if DLT did not occur, there will be another 3 cases, reaching to 6 subjects."
89681437|NCT04385641|Experimental|Extended research (Group B)|If DLT≤1/6, the dose will not be increased. This dose will also be used as the treatment dose of group B. If DLT is more than 1/6 in the 3*10＾9 dose group, three subjects will be added in 2*10＾9 dose group. If DLT ≤1/6 in 4-week observation, the 2*10＾9 will be the maximum tolerable dose, and will be used as the treatment dose of group B. The subjects in group A were enrolled first, after at least 4 weeks of observation for all subjects, six subjects will be included in group B.
89681438|NCT01896921|Experimental|Maraviroc + Raltegravir or Dolutegravir|Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
89681439|NCT01276873|Experimental|Closed System|Application of Tracheal aspiration closed system, controlled by the use of Open system to tracheal aspiraiton.
89681440|NCT01897077|Experimental|Peanut Allergic|Only one intervention will be given. Peanut allergic study subjects, will receive gradually increasing doses of the dissolving peanut film.
89681441|NCT01897077|Active Comparator|Healthy Volunteers|Healthy volunteers will receive active peanut dissolving films in an expedited manner in order to determine safety dissolving films.
89681442|NCT00749749|Experimental|Bupivacaine collagen sponge|Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.
89681443|NCT00749749|Active Comparator|ON-ON-Q PainBuster Post-op Pain relief SystemQ system|Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.
89681444|NCT02993263|Other|Noncardiac surgery|VectraplexECG System with CEB® will be recorded after surgery and on day 1, 2 and 3 post operatively
89681445|NCT01898013|Active Comparator|Pregnenolone|"Pregnenolone fixed escalating up to 500mg/day will consist of the following schedule:~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): 50mg PO, BID x 1 week, Visit 4 (week 2): 150mg PO, BID x 1 week, Visit 5 (week 3): 250mg PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered by 100mg per day and then discontinued."
89681446|NCT01898013|Placebo Comparator|Placebo|"Placebo will be administered exactly the same as the active comparator (pregnenolone) and will consist of the following schedule:~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): placebo PO, BID x 1 week, Visit 4 (week 2): placebo PO, BID x 1 week, Visit 5 (week 3): placebo PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered in the exact manner as active study medication and then discontinued."
89681447|NCT02991937|Active Comparator|Medical Therapy|Subjects in the medical therapy arm will be treated with piperacillin/tazobactam for at least 24 hours. Ciprofloxacin/metronidazole will be used in penicillin-allergic patients. Subjects will be maintained on nothing by mouth with intravenous fluids for at least 12 hours. Subjects will be transitioned to oral antibiotics when their WBC is normal, they have a decrease in CRP by ≥ 15%, and they have been afebrile for 24 hours on IV antibiotics.
89681448|NCT02991937|Active Comparator|Surgical Intervention|Subjects in the surgical treatment arm will receive intravenous antibiotics until the time of operation, and will be maintained on intravenous fluids and no oral intake until they undergo appendectomy as per standard of care. Appendectomy will occur within 24 hours of enrollment. Subjects in the surgical treatment arm will receive post-operative antibiotics as per standard of care.
89681449|NCT02328807|Experimental|Radio-Frequency Ablation (RFA)|Focal Prostate Radio-Frequency Ablation (RFA). Focal bipolar RFA followed by clinical follow-up visits at 6 weeks, 3 months and 6 months.
89681450|NCT01277107|Experimental|Zaleplon AP formulation|Gastric Retentive Dual Release Zaleplon (Zaleplon AP)
89681451|NCT01277107|Placebo Comparator|Placebo|Identical placebo capsule
89681452|NCT04768959|No Intervention|No Intervention: TAU + waiting list|This control group is a waiting list group. Participants received treatment as usual (TAU). Once the RCT is finished, participants have the chance to participate in the intervention group.
89681453|NCT04768959|Experimental|Experimental: TAU + Feliz-Mente Intervention|Feliz-Mente (third generation psychotherapy):The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
89681454|NCT05735691|Experimental|High-Intensity With Pertubations|30 sessions of high-intensity treadmill training will be conducted. Perturbations that disrupt balance will be applied during the training.
89681455|NCT05735691|Experimental|High-Intensity No Perturbations|30 sessions of high-intensity treadmill training will be conducted on a stable treadmill.
89681456|NCT05735691|Experimental|Moderate-Intensity With Perturbations|30 sessions of moderate-intensity treadmill training will be conducted. Perturbations that disrupt balance will be applied during the training.
89051539|NCT04588467|Active Comparator|Conservative group|Conservative treatment included dietary modification (intake of at lest 3 liters of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application (Lidocaine 2.5%+Prilocaine 2.5%, 2g twice a day) for 10 days
89051540|NCT04588467|Experimental|Surgical group|Thrombectomy and local excision of external hemorrhoids were performed with the patient in the lithotomy position under local infiltrative anesthesia with UltracainDS 1:200000 1.7ml
89051541|NCT04620395|No Intervention|Joint tap|Joint tap and aspiration of synovial fluid
89051542|NCT04620395|Experimental|Punch biopsy|Punch biopsy of a prosthetic joint and extraction of 5-7 biopsies from the synovial membrane
89051543|NCT01151215|Experimental|1|AZD8931 40mg (bd) plus anastrozole 1mg (od)
89051544|NCT01151215|Experimental|2|AZD8931 20mg (bd) plus anastrozole 1mg (od)
89051545|NCT01151215|Placebo Comparator|3|Placebo (bd) plus anastrozole 1mg (od)
89051546|NCT04588389|Active Comparator|Group 1 Standard of Care|Group I will receive the standard of care multimodal pharmacological management.
89681457|NCT05735691|Active Comparator|Moderate-Intensity No Perturbations|30 sessions of moderate-intensity treadmill training will be conducted on a stable treadmill.
89681458|NCT01277185|Active Comparator|Low Calcium Diet (600-1200 mg/d)|
89681459|NCT01277185|Active Comparator|High Calcium Diet (1100-2300mg/d)|
89681460|NCT05735613|Experimental|Osteotome crestal sinus lifting|Full thickness flap elevated, then elevation of sinus floor by Osteotome, then adding the bone graft and implant placement. Measuring the ISQ value by Ostell device then flap sutured. After 6 months of implant placement exposure of implant for prosthetic phase and measuring secondary stability.
89216138|NCT05081986|Experimental|D-cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine one hour prior to receiving theta-burst stimulation (TBS; a patterned stimulation). Their baseline motor evoked potentials (MEP) will be recorded for 20 minutes prior to receiving the first TBS to the motor cortex and change in MEP amplitude will be measured following stimulation up to 60minutes later. They will then receive a second TBS to the motor cortex and change in MEP amplitude will again be measured following stimulation up to 60minutes later.
89216139|NCT05081986|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule one hour prior to receiving theta-burst stimulation (TBS; a patterned stimulation). Their baseline motor evoked potentials (MEP) will be recorded for 20 minutes prior to receiving the first TBS to the motor cortex and change in MEP amplitude will be measured following stimulation up to 60minutes later. They will then receive a second TBS to the motor cortex and change in MEP amplitude will again be measured following stimulation up to 60minutes later.
89216140|NCT05079451|Experimental|Study Participants|Participants will receive an infusion of both study drugs (3BNC117-LS and 10-1074-LS) and will then discontinue antiretroviral therapy two days later.
89681461|NCT05735613|Experimental|osseodensification crestal sinus lifting|Full thickness flap elevated, then elevation of sinus floor by Densah burs, then adding the bone graft and implant placement. Measuring the ISQ value by Ostell device then flap sutured. After 6 months of implant placement exposure of implant for prosthetic phase and measuring secondary stability.
89681462|NCT05735613|Experimental|peizoelectric crestal sinus lifting|Full thickness flap elevated, then elevation of sinus floor through piezoelectric surgery via intralift kit, then adding the bone graft and implant placement. Measuring the ISQ value by Ostell device, followed by flap suturing. After 6 months of implant placement exposure of implant for prosthetic phase and measuring secondary stability.
89681463|NCT02987361|Experimental|treatment group 1|anodal stimulation on the lesioned primary motor cortex DC-STIMULATOR PLUS
89681464|NCT02987361|Experimental|treatment group 2|cathodal stimulation on the non-lesioned primary motor cortex DC-STIMULATOR PLUS
89051547|NCT04588389|Experimental|Group 2 Standard of Care + Quadratus Lumborum Block II|Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block.
89051548|NCT04588389|Experimental|Group 2 Standard of Care + Quadratus Lumborum Block III|Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient.
89051549|NCT04620473|Experimental|Anlotinib+Capeox|neoadjuvant treatment with Anlotinib hydrochloride combined with Capeox
89051550|NCT04620473|Active Comparator|Capeox|neoadjuvant treatment with Capeox
89681465|NCT02987361|Experimental|treatment group 3|dual stimulation such as anodal stimulation on the lesioned side and cathodal stimulation on the non-lesioned side DC-STIMULATOR PLUS
89681466|NCT02987361|Sham Comparator|sham group|sham group
89681467|NCT01274533|Experimental|Lenalidomide|Oral lenalidomide is initiated on Day 1 of Cycle 1 and continues once daily days 1-21 of a 28 day cycle. Subjects may continue participation in the Treatment Phase of the study for 24 months unless disease progression or drug is discontinued for safety reasons.
89681468|NCT01277497|Experimental|Sevelamer carbonate|1,600 mg (2 x 800 mg) three times daily with meals for a total of 12 weeks
89681469|NCT01277497|Active Comparator|Calcium acetate|1,334 mg (2 x 667 mg) three times daily with meals for a total of 12 weeks
89681470|NCT01273597||End-stage kidney disease with secondary hyperparathyroidism|Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
89051551|NCT00637234|Experimental|1|
89051552|NCT00637234|Placebo Comparator|2|
89681471|NCT01273519||RA, PsA, AS|Participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) prescribed Humira (adalimumab) in the usual manner and in accordance with the terms of the local marketing authorization with regards to dose, population and indication.
89681472|NCT01956279|Experimental|Pregnenolone (Arm 1)|Pregnenolone
89681473|NCT01956279|Placebo Comparator|Placebo (Arm 2)|Placebo
89681474|NCT00351793||Combined Deformity <30 degrees|
89681475|NCT00351793||Combined Deformity >30 degrees|
89681476|NCT01272817|Other|Cladribine + melphalan|Cladribine + melphalan conditioning
89681477|NCT01272817|Other|TLI|Total lymphoid irradiation conditioning
89681478|NCT01956435|Other|Excimer Light Treatment Right Leg, Control Left Leg|Excimer light treatment will be performed on the right leg of every subject, no treatment on the left or control leg of the subject.
89681479|NCT01956435|Other|Excimer Light Treatment Left Leg, Control Right Leg|Excimer light treatment will be performed on the left leg of every subject, no treatment on the right or control leg of the subject.
89681480|NCT01277575|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
89681481|NCT01277575|Sham Comparator|Placebo stimulation|Sham stimulation (placebo condition) no intervention
89681482|NCT01957761||Clostridium difficile infection|
89681483|NCT01270087|Other|Adalimumab|
89051553|NCT04581720|Experimental|Participants|The participants will be applied AMG and EMG on each arm of both arms when they finish routine monitoring before the induction of general anesthesia. After the participants being unconscious, we will find each participant's supramaximal current before injecting the neuromuscular blocking agents. During the operation, when the TOF count reaches 4 again and the height of T1 reaches 50% of baseline, we perform TOF tests using 4 currents (Supramaximal current, 0.7×supramaximal current, 0.5×supramaximal current, 0.3×supramaximal current), three times for respective current to figure out that low current can show the same level of TOF ratio as the supramaximal current. When the operation ends and the T1 reaches 100% of baseline, we perform TOF tests with 4 currents again. In the postanesthesia care unit, we use EMG only and perform TOF tests with 4 currents again. The participants can feel pain by the stimulants during the tests, so if they refuse the tests, we stop the tests and record it.
89681484|NCT01277653||PIVKA-II and AFP 6 months|PIVKA-II and AFP measurement every 6 months
89681485|NCT01277653||tumor maker interval every 6 month|tumor maker interval every 6 month
89681486|NCT01958073|Experimental|Conjugated Estrogen Vaginal Cream|Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly
89681487|NCT01958073|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
89681488|NCT01958073|Placebo Comparator|Placebo|Per vagina
89681489|NCT05740215|Experimental|F520 combined with lenvatinib|"F520:~F520 (200 mg) administered intravenously (IV) on Day 1 of each 21-day cycle in the phase Ib and II studies until progressive disease, unacceptable toxicity or ending treatment for other reasons. [Time Frame: up to 2 years post infusion]~Lenvatinib:~In the phase Ib study, three dose groups of 20 mg, 16 mg and 12 mg lenvatinib were designed. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT. The designated dose of lenvatinib administered orally once daily (QD) according to the assigned dose group.~In the phase II study, lenvatinib administered orally once daily (QD) according to recommended phase II dose (RP2D) obtained in phase Ib study."
89681490|NCT01272661|Active Comparator|Enhanced Curriculum|New Enhanced Breastfeeding Curriculum with 11 brief modules
89681491|NCT01272661|Active Comparator|Enhanced Curriculum+Breastfeeding Doula|"Enhanced Curriculum + mother selects a support person to learn about breastfeeding with her and support her postpartum (breastfeeding doula)"
89681492|NCT01272661|Active Comparator|Enhanced Curriculum +Father Support|Enhanced Curriculum+ mother provides father-friendly information about breastfeeding to her partner plus an invitation to an educational group for fathers
89681493|NCT01277731|Experimental|Methylprednisolone replacement|"This study will enroll the patients who were previously experienced dexamethasone-induced hiccup. Patients who experienced dexamethasone-induced hiccup during chemotherapy will enroll to study arm.~Run-in period * Dexamethasone 10mg-20mg q day iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Treatment period * Methylprednisolone 60mg-125mg iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Response will be evaluated by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) and NRS to hiccup at 24hrs after start methylprednisolone.~Nausea and vomiting will be assessed as CTCAE 4.0"
89681494|NCT02283333|Experimental|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
89681495|NCT02283333|Active Comparator|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
89681496|NCT00728923|Experimental|1|Minocycline (NPL-2003)
89681497|NCT01277809|No Intervention|Usual Care|Participants will receive care as usual (Usual Care Group; UCG) that is provided by their long-term care unit.
89681498|NCT01277809|Active Comparator|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program. This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the walking group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
89681499|NCT01277809|Experimental|Walking Program|Participants will walk five times per week under the supervision of a licensed physiotherapist.
89681500|NCT01277965|Other|50% VO2 max, BFR reduced by 50%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
89681501|NCT01277965|Other|50% VO2 max,BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
89051554|NCT02883985|Experimental|Radiation Therapy: 6 Gy/ fraction|All patients will be treated with 6 Gy /fraction delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.
89051555|NCT02940665||Enhanced Recovery After Surgery (ERAS)|ERAS group followed the ERAS protocol. The protocol was implemented 13 months prior to the start of data collection.
89051556|NCT02940665||Conventional|Conventional group received conventional care.
89051557|NCT04588194|Experimental|Romiplostim, Rituximab, Dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21, Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21 and Dexamethasone 40 mg IV/PO days 1-4.
89051558|NCT04587921|Experimental|Patients monitored with oximeter|The first 45 patients will be monitored but the results will not be displayed. The second half of the patients the oximeter will have their monitoring data available online in the ward.
89051559|NCT02940314|Experimental|sequence 1|HGP1103→HIP1503
89051560|NCT02940314|Experimental|Sequence 2|HIP1503→HGP1103
89051561|NCT04581525|Experimental|tDCS of DLPFC|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left dorsolateral prefrontal cortex (DLPFC). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
89681502|NCT01277965|Other|75% VO2 max, BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%.
89681503|NCT01277965|Other|75% VO2 max, pump switched off|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed.
89051562|NCT04581525|Experimental|tDCS of M1|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to the left primary motor cortex (M1). Subjects will undergo stimulation once a day for 10 consecutive weekdays.
89051563|NCT04581525|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Subjects will undergo stimulation once a day for 10 consecutive weekdays.
89051564|NCT04620083|No Intervention|Control Group|For the control group, the participants received conventional therapy which included group activities for reality orientation, reminiscence therapy and activities organized by occupational therapists one hour a day, five days a week.
89051565|NCT04620083|Experimental|Experimental 3-day Normal Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 3 days per week.
89681504|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change.
89681505|NCT01898403|Experimental|Sentinel Lymph Node (SLN) Detection|All patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine green solution for detection of melanoma in lymph nodes. In addition, lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC) will be conducted for all participants with the same objective.
89681506|NCT01901211|Experimental|Exergaming|In this arm, the participants will participate in the exergaming intervention.
89681507|NCT01901211|No Intervention|Comparison Arm|In this arm of the study, participants will engage in their typical physical activity routines for the ten week duration. Participants will receive a call from the RA each week. The RA will ask the child to report on all the physical and social activities that they engaged in for that week.
89681508|NCT00715741|Active Comparator|1|Group 1 will receive 30% oxygen plus PEEP + 3 to 5 cm Water duration of anesthesia and surgery
89681509|NCT00715741|Active Comparator|2|Group 2 will receive 30% oxygen without PEEP for the duration of anesthesia and surgery
89681510|NCT00715741|Active Comparator|3|Group 3 will receive > 90% oxygen plus PEEP + 3 to 5 cm of water for the duration of anesthesia and surgery
89681511|NCT00715741|Active Comparator|4|Group 4 will receive > 90% oxygen and no PEEP for the duration of anesthesia and surgery
89681512|NCT00750373|No Intervention|Conventional|Conventional Treatment based on current guidelines
89681513|NCT00750373|Active Comparator|Surgery|Early surgery within 48 hours of randomization
89681514|NCT05739903|Experimental|Sequence A(Before→ After)|
89681515|NCT05739903|Experimental|Sequence B(After→ Before)|
89681516|NCT02987517|Experimental|Cadence|Runners who use an increased running cadence of 7.5 percent over preferred running cadence.
89681517|NCT02987517|Experimental|Forefoot Strike|Runners who use a forefoot strike instead of a rear foot strike
89681518|NCT00751777|Experimental|Group 1: 37.5 µg LT patch|80 subjects will receive a two vaccination regimen with a LT patch.
89681519|NCT00751777|Placebo Comparator|Group 2: 0 µg LT patch (placebo)|40 subjects will receive a two vaccination regimen with a placebo patch.
89681520|NCT01902459|Active Comparator|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component.
89681521|NCT01902459|Other|Standard of Care|Standard of Care (SoC) is manual compression with or without a topical absorbable hemostat.
89681522|NCT01274611|Active Comparator|Suction-Curettage|
89216141|NCT05053737|Experimental|SBRT with Neoadjuvant Atezolizumab|Patients will undergo SBRT with atezolizumab neoadjuvantly followed by surgery and strictly risk-adjusted adjuvant treatment with radiation with or without chemotherapy according to national guidelines.
89216142|NCT05048004||QMODE intervention|catheter ablation performed using high-power with a maximum of up to 50 W (QMODE) and
89216143|NCT05048004||QMODE+ intervention|catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +)
89681523|NCT01274611|Experimental|Botox|
89681524|NCT05735145|Experimental|concurrent chemoradiotherapy combined with adjuvant chemotherapy|Adjuvant chemotherapy in patients with locally advanced cervical cancer who achieved CR after concurrent chemoradiotherapy
89681525|NCT05735145|Other|concurrent chemoradiotherapy|Observation of patients with locally advanced cervical cancer who achieved CR after concurrent chemoradiotherapy
89681526|NCT00729781|Experimental|Polyester Implants|There is one arm for this study. All subjects in this study will receive the investigational nasal implants. See the detailed description for procedure information.
89681527|NCT01903005|Experimental|Open-label BNX sublingual tablets|Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.
89681528|NCT01278121|Other|Diet A: High-fat diet|"Diet given for 3 days to reset all of the participants"
89681529|NCT01278121|Active Comparator|Diet B: A carbohydrate-restricted diet|The diet will be given for 10 days, 6 meals a day
89681530|NCT00614029|Experimental|A|IMITREX -abd. to Intraject-abd. to IMITREX -thigh to Intraject-thigh
89681531|NCT00614029|Experimental|B|Intraject-abd. to IMITREX -abd. to Intraject-thigh to IMITREX -thigh
89681532|NCT00614029|Experimental|C|Intraject-abd to IMITREX -abd to Intraject-arm. to IMITREX -arm.
89681533|NCT00614029|Experimental|D|IMITREX-abd to Intraject-abd to IMITREX-arm. to Intraject-arm.
89681534|NCT00614029|Experimental|E|IMITREX-arm to Intraject-arm to IMITREX-thigh to Intraject-thigh
89681535|NCT00614029|Experimental|F|Intraject-thigh to IMITREX-thigh to Intraject-arm to IMITREX-arm
89681536|NCT01905423||Paga (annual MDA)|"This group includes eligible residents of the village of Paga. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Paga received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
89681537|NCT01905423||Lewomada (annual MDA)|"This group includes eligible residents of the village of Lewomada. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Lewomada received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
89681538|NCT01905423||Pruda (semiannual MDA)|"This group includes eligible residents of the village of Pruda. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.~Pruda received a total of five rounds of MDA over a period of 24 months (once every 6 months)."
89681539|NCT01905423||Pekalongan (annual MDA)|"This group includes the villages of Banyurip Ageng and Jenggot. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
89681540|NCT01905423||Pekalongan (semiannual MDA)|"This group includes the villages of Kertoharjo and Pabean. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
89681541|NCT01270399||malignant neoplasm's cells|
89681542|NCT01270399||natural cells|
89681543|NCT04345549|Experimental|Ayurveda|All the participants were advised to self-isolate for 7-days and maintain hygiene and self-care as per recommended guidelines. Along with that, participants were advised to constitution based Ayurveda treatment using herbs, life style and yoga.
88996746|NCT05468047|No Intervention|No ketamine administration|These individuals will undergo the same psychedelic-assisted training program as those who receive the ketamine experience and will attend the same in-person training weekend; however, these individuals have opted out of ketamine administration by choice or due to contraindication and will not participate in the personal experience.
88996747|NCT04686214|Experimental|study group|
88996748|NCT04686214|No Intervention|control group|
88996749|NCT05467969||Traditional teaching|A group of participants learned the skills on site
88996750|NCT05467969||Teleteaching|A group of participant who joined the workshop synchronously through the online multiscreen display teleconference platform
88996751|NCT05467930||Participant|Individuals who were positive for COVID-19 and visited CUIMC/ New York Presbyterian (NYP) Hospital
88996752|NCT00536653|Active Comparator|Osteporosis Group|Patients with a presenting T score < -2.5 (osteoporosis), treated with bicalutamide and Ca/VitD
89681544|NCT05734911||patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy|This multi-center, observational, retrospective study collected real-world medical record data of patients with advanced ovarian cancer treated with niraparib as first-line maintenance therapy from fourteen hospitals in China. In reality, these patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death. A total of 199 patients were included in a centralized database ultimately with a median age of 57.0 years (range, 51.0-63.5 years).
89681545|NCT01278355||Pain Patients|
89681546|NCT01270477|Experimental|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment in an hyperbaric oxygen treatment chamber on an recognized treatment table.
88996753|NCT00536653|Active Comparator|Osteopenia Group|Patients with a presenting T score between -1.0 and -2,4 (osteopenia), treated with LHRH agonists and Ca/VitD
88996754|NCT00536653|Active Comparator|Normal Group|Patients with a presenting T score > -1.0(normal BMD), treated with LHRH agonists
88996755|NCT05467852|Active Comparator|Didroxyprogesterone treatment group|Since the first menstrual cycle after surgery, dydrogesterone was administered orally 10mg bid on the 14th to 27th day of each menstrual cycle, planned to be used for 6 menstrual cycles (if the patient conceived naturally during medication, the drug could be stopped), and the patient was instructed to try pregnancy, the observation period was 12 menstrual cycles after surgery.
88996756|NCT05467852|No Intervention|control|No medication was used after surgery, and the observation period was 12 menstrual cycles after surgery
88996757|NCT05466058|Other|cases|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
88996758|NCT05466058|Other|control|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
88996759|NCT05464693||Patients with obstructive biliary disease|Patients admitted to hospital due to obstructive biliary disease secondary to benign and malign etiologies, undergoing ERCP, will be selected. Bile sample will be taken in ERCP procedure with sterile technique. Its macroscopic appearance will be assessed and biliary culture will be performed.
88996760|NCT00156962|Active Comparator|Epoetin alfa RB|
88996761|NCT00156962|Experimental|Epoetin alfa DT|
88996762|NCT05468983|Other|BioHpp hybrid prosthesis( fixed )|4 implants were placed in the mandibular arch by a surgical guide, after 3 months the final prosthesis was constructed by using a digital workflow( CAD-CAM )
88996763|NCT05468983|Other|BioHpp bar supported and retained overdenture|4 implants were placed in the mandibular arch by a surgical guide, after 3 months the final prosthesis was constructed by using a digital workflow( CAD-CAM )
88996764|NCT05603806||RA new treatment starts|Adult rheumatoid arthritis patients starting treatment on adalimumab or upadacitinib
88996765|NCT00536770|Placebo Comparator|A|Placebo + gemcitabine
88996766|NCT00536770|Placebo Comparator|B|Placebo + gemcitabine + erlotinib
88996767|NCT00536770|Active Comparator|C|DN-101 + gemcitabine
88996768|NCT00536770|Active Comparator|D|DN-101 + gemcitabine + erlotinib
88996769|NCT04685512|Experimental|TDF / FTC|2 tablets on Day-1 then 1 tablet/day for 6 days
89216144|NCT05047003||Patients under evaluation for Suspected Concussion|Device: EyeBOX Model EBX-4 (Portable version)
89216145|NCT05043987|Experimental|Part A|"Part A will follow the standard 3+3 dose-escalation design and will be enrolled at dose levels of CPO102 at (0.5, 1, 1.8, 2.5, 3.5, 4.5, 5.5 mg/kg).~Each subject group will receive one dose of CPO-102 every 3 weeks (1 cycle=21 days=1 treatment). For each cohort, the decision whether to dose-escalate will be made once all patients have been enrolled into the cohort and the last patient enrolled has been followed for 21 days (3-week DLT observation period)."
89216146|NCT05043987|Experimental|Part B-Arm 1|Upon attaining a RP2D, Part B-Arm 1 will include approximately 15 patients with pancreatic cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
89216147|NCT05043987|Experimental|Part B-Arm 2|Upon attaining a RP2D, Part B-Arm 2 will include approximately 15 gastric (including gastric esophageal junction) cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).
89216148|NCT05040932|Experimental|YH004|The dose escalation phase includes 7 dose levels of YH004, and the highest dose is up to 10mg/kg. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 16 cycles if patients receive benefits.
89216149|NCT05021484|Active Comparator|Felzartamab|9 doses of felzartamab as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
89216150|NCT05021484|Placebo Comparator|Placebo|9 doses of placebo as an intravenous infusion over 6 treatment cycles at 28 days each. Dosing occurs every week in cycle 1 and every four weeks in cycles 2-6.
89681547|NCT01278433|Experimental|Study Group|Participants receiving their first dose of polio vaccine
89681548|NCT01906515|No Intervention|Control Group|Control Group received standard anesthesia care including intraoperative blood sampling when estimated blood loss was ≥15% of total blood volume and transfusion when hemoglobin was ≤10 g/dL.
89216151|NCT05019885|Experimental|IV Ketamine Hydrochloride|dose 0.5mg/kg of IV Ketamine Hydrochloride over 40 min
89681549|NCT01906515|Experimental|SpHb Group.|Continuous non-invasive hemoglobin monitoring (SpHb monitoring) was provided to the anesthesiologist to influence administration of care
89681550|NCT00730483|Experimental|DEB-TACE|PVA microporous hydrospheres loaded with doxorubicin hydrochloride used for the treatment of unresectable liver metastases from neuroendocrine tumors.
89681551|NCT01907607|Experimental|PD-0332991|"Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib.~PD-0332991 is formulated as gelatin capsules of 100 mg and 25 mg respectively."
89681552|NCT01270633|Other|Treatment|PriMatrix applied to appropriately debrided wound bed and covered with a non-adherent dressing. Dressings applied to maintain moist wound therapy.
89681553|NCT01270633|Active Comparator|Standard of Care|Non adherent dressing applied to appropriately debrided wound bed and moist wound therapy maintained.
89681554|NCT01278511|Experimental|Canadian C-Spine Rule|
89681555|NCT05734833|Experimental|Probiotic|Participants in this study arm will be receiving a 28-day supply of probiotic.
89681556|NCT05734833|Placebo Comparator|Placebo|Participants in this study arm will be receiving a 28-day supply of placebo.
89681557|NCT01909011|Experimental|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
89681558|NCT01909011|Sham Comparator|Sham CES|The CES sham group will receive sham CES (device off)for 20 minutes 5 times per week for two weeks.
89681559|NCT00753337|Experimental|Assurant Cobalt Iliac Stent|Assurant® Cobalt Iliac Stent System
89681560|NCT03029637|Experimental|No preparation resin bonded bridges|RBBs with no or minimal preparation of their abutment teeth
88996770|NCT04685512|No Intervention|usual care|Standard of Care
89681561|NCT03029637|Active Comparator|Routine resin bonded bridges|RBBs with routine tooth preparation of their abutment teeth
89681562|NCT00731341|Experimental|Hysteroscopic cryoablation|Women undergoing hysteroscopic ultrasound guided cryoablation for the treatment of uterine fibroids.
89681563|NCT01911351|No Intervention|standard management|Patients randomized to this arm will receive standard management alone for their minor procedure.
89681564|NCT01911351|Experimental|Nitrous Oxide|Patients randomized to this arm will receive nitrous oxide plus standard management for their minor procedure.
89681565|NCT04276051|Experimental|Cryoablation of the Vagus Nerve Plus Lifestyle Intervention|Participants randomized to receive cryoablation of the vagus nerve as well as standardized dietary and exercise counseling from a registered dietitian and exercise physiologist.
89681566|NCT04276051|Active Comparator|Lifestyle Intervention Only|Participants randomized to receive standardized dietary and exercise counseling from a registered dietitian and exercise physiologist.
89681567|NCT01278589|Experimental|• Plantago asiatica L. extract 5g|
89681568|NCT01278589|Experimental|Plantago asiatica L. extract 10g|
89681569|NCT01278589|Experimental|Plantago asiatica L. extract 20g|
89681570|NCT01278589|Placebo Comparator|Placebo|
89681571|NCT05734677|Experimental|psychotherapeutic intervention with class risk A (low risk, no invasive procedure)|an eight-week emotion regulation group intervention
89681572|NCT05734599||MAFLD-control group|Participants accepted health examinations including vibration-controlled transient elastography in Tongji and Union hospitals who are not MAFLD patients and are willing to participate in this study.
88996771|NCT00536848|Experimental|A|Metronidazole for 10 days, probiotics for 6 months
89681573|NCT05734599||MAFLD-high hardness group|"Participants accepted health examinations including vibration-controlled transient elastography in Tongji and Union hospitals who are defined to have MAFLD and are willing to participate in this study.~The risk of advanced liver fibrosis was estimated based on the LSM value, FIB-4 score, and NAFLD fibrosis score (NFS), and patients were then divided into groups of low and high hardness according to the risk measured, as shown below:~High hardness group:~participants meet one of the following three requirements: LSM≥ 11.4 kPa；9.9<LSM≤11.4 kPa and NFS≥0.676;9.9<LSM≤11.4 kPa and FIB-4≥2.67.~NFS = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × Fasting blood glucose abnormalities / diabetes mellitus (with=1, none=0) + 0.99 × AST/ALT ratio - 0.013 × platelets (×109/L) - 0.66 × albumin (g/dl) FIB-4 = （age(years) x AST [U/L]) / ((PLT [109/L]) x (ALT [U/L])^(1/2))"
89681574|NCT05734599||MAFLD-low hardness group|"Participants accepted health examinations including vibration-controlled transient elastography in Tongji and Union hospitals who are defined to have MAFLD and are willing to participate in this study.~The risk of advanced liver fibrosis was estimated based on the LSM value, FIB-4 score, and NAFLD fibrosis score (NFS), and patients were then divided into groups of low and high hardness according to the risk measured, as shown below:~Low hardness group:~participants who do not meet the requirements of the high hardness group are low hardness group: LSM < 9.9 kPa；9.9<LSM≤11.4 kPa with NFS < 0.676 and FIB-4<2.67.~NFS = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × Fasting blood glucose abnormalities / diabetes mellitus (with=1, none=0) + 0.99 × AST/ALT ratio - 0.013 × platelets (×109/L) - 0.66 × albumin (g/dl) FIB-4 = （age(years) x AST [U/L]) / ((PLT [109/L]) x (ALT [U/L])^(1/2))"
89681575|NCT04385407|Active Comparator|SOF + RBV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:<75 kg, 1000 mg; >75 kg, 1200 mg).
89681576|NCT04385407|Active Comparator|SOF + RBV (Experienced)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:<75 kg, 1000 mg; >75 kg, 1200 mg).
89681577|NCT04385407|Active Comparator|SOF + SMV (Naive)|For treatment-naive participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
89681578|NCT04385407|Active Comparator|SOF + SMV (Expereined)|For treatment-experienced participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
89681579|NCT00731653|Experimental|1|BCI-024 and BCI-049
89681580|NCT00573989|Experimental|Erlotinib|Erlotinib
89681581|NCT02286921|Experimental|Arm A: Testosterone cypionate or testosterone enanthate|Patients on BAT will receive testosterone cypionate or testosterone enanthate administered as an intramuscular injection. A dose of 400 mg of either agent will be injected intramuscularly (IM) every 28 days.
89681582|NCT02286921|Experimental|Arm B: Enzalutamide|Patients randomized to enzalutamide will be prescribed enzalutamide 40 mg tablets and instructed to take 4 tablets per day orally for 28 days/cycle.
89681583|NCT02987439|No Intervention|Standard care group|"Standard medical treatment for the exacerbation of COPD~Standard medical treatment of COPD according to GOLD~A visit by a pulmonary nurse at the patients own home 3-5 days after discharge. Lung function and smoking history is recorded. Correct use of inhaler is instructed.~Visit in the outpatient clinic within the next 2-6 months after discharge as follow-up~In the outpatient clinic they will receive an offer of pulmonary rehabilitation"
89681584|NCT02987439|Experimental|Rehabilitation group|"The group will begin pulmonary rehabilitation during hospital admission. Afterwards a rehabilitation program twice weekly for 7 weeks.~Beside rehabilitation they will receive same treatment as the standard care group"
89681585|NCT05734521||Pregnant women exposed to avalglucosidase alfa|Pregnant women with a confirmed diagnosis of Pompe disease and avalglucosidase alfa exposure during the pregnancy and/or lactation
89681586|NCT05734521||Infants born to mother/father exposed to avalglucosidase alfa|Infants born to mother/father with a confirmed diagnosis of Pompe disease and exposed to avalglucosidase alfa
89681587|NCT00574067|Experimental|Buprenorphine+OTP|Buprenorphine and counseling in prison and continued at opioid treatment program (OTP) upon release.
89681588|NCT00574067|Experimental|Buprenorphine+CHC|Buprenorphine and counseling in prison and continued at a community health center (CHC) upon release.
89681589|NCT00574067|Active Comparator|Counseling + OTP|Counseling only in prison and Buprenorphine upon release at a opioid treatment program (OTP)
89681590|NCT00574067|Active Comparator|Counseling + CHC|Counseling only in prisons and Buprenorphine upon release at a community health center (CHC)
89681591|NCT01913535|Active Comparator|Low Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
89681592|NCT01913535|Active Comparator|High Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
89681593|NCT01913535|Other|Placebo/Low-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 10.0 mg/day for 3 days (in Phase 2)
89681594|NCT01913535|Other|Placebo/High-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 20.0 mg/day for 3 days (in Phase 2)
89681595|NCT01913535|Placebo Comparator|Placebo/Placebo Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
89681596|NCT01914003||CSID Mutations|Individual has one or more known CSID mutations.
89681597|NCT01914003||Control|Individual does not have any known CSID mutations.
89681598|NCT01914159|Experimental|Ranibizumab|
89681599|NCT00575159|Experimental|Arm a|GSK189075
89681600|NCT00575159|Placebo Comparator|Arm b|Placebo
89681601|NCT01915173|Experimental|Supplement + Expanded Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
89681602|NCT01915173|Placebo Comparator|Placebo + Standard Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
89681603|NCT01915173|Experimental|Supplement + Standard Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
89681604|NCT01915173|Placebo Comparator|Placebo + Expanded Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
89681605|NCT01915563|No Intervention|SBT and extubation|After a SBT patients will be extubated as usual
88996772|NCT00536848|Placebo Comparator|B|Metronidazole for 10 days, placebo for 6 months
89681606|NCT01915563|Experimental|SBT and rest 60 min before extubation|After SBT patients will be reconnected to mechanical ventilation during 60 min before extubation
89681607|NCT00576251|Experimental|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop 4 times daily in both eyes
89681608|NCT00576251|Active Comparator|TOBRADEX|TOBRADEX 1 drop 4 times daily in both eyes
89681609|NCT00578279|Other|A|subject randomized to 10ml of dehydrated alcohol
89681610|NCT00578279|Experimental|B|subject randomized to 20ml of dehydrated alcohol
89681611|NCT01916655|Placebo Comparator|Usual Care|standard and typical PAP (Positive Airway Pressure) educational and support protocol
89681612|NCT01916655|Experimental|Self-Management Care|Individualized self-management educational and support protocol
89681613|NCT01916655|Experimental|Self-Management Mobile Care|Individualized self-management educational and support protocol delivered in part by mobile health tool
89681614|NCT00578669|Active Comparator|1|Sequential antidepressant pharmacotherapy with (20mg) fluoxetine, begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
89681615|NCT00578669|Placebo Comparator|2|Sequential placebo medication (dextrose), begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
89681616|NCT01917513|Experimental|G-EYE™ colonoscopy|G-EYE™ colonoscopy
89681617|NCT01917513|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
89681618|NCT00578903|Experimental|Patients|"Patients with a diagnosis of severe aplastic anemia who require an allogeneic stem cell transplant but lack an Human Leukocyte Antigen (HLA) identical family member.~Cytoxan, Campath, TBI-Total Body Irradiation, FK-506, Methotrexate, Stem Cell Infusion"
89681619|NCT01918761|Experimental|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 (i.v) q21d Dacomitinib 45mg/ orally (continuous)
89681620|NCT00579137|Experimental|Participants With SCID or Primary Immunodeficiency Disorder|all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45
89681621|NCT04290377|Active Comparator|Conventional OT + Motor Imagery OT|Conventional OT (30 minutes/day) plus Motor Imagery OT (30 minutes/day) for 10 days.
89681622|NCT04290377|Experimental|Conventional OT + BMI-assisted Motor Imagery OT|Conventional OT (30 minutes/day) plus BMI-assisted motor imagery OT (30 minutes/day) for 10 days.
89681623|NCT00580073|Experimental|1|FOLFOX4 + Cetuximab
89681624|NCT00580151|Experimental|1|
89681625|NCT00580151|Placebo Comparator|2|
89681626|NCT01919697|Experimental|Plecanatide 3.0 mg|Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
89681627|NCT01919697|Experimental|Plecanatide 6.0 mg|Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks
89681628|NCT00580229|Experimental|prednisone|Prednisone 40mg by mouth 30-60 minutes prior to rituximab.
89681629|NCT00580853|Experimental|varenicline|varenicline 2mg/day
89681630|NCT00580853|Experimental|Bupropion|Bupropion 300mg/day
89681631|NCT00580853|Placebo Comparator|Placebo|Placebo Control
89681632|NCT05739045|Experimental|nivolumab combined with SOX|Medication regimen: nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles); Surgery is performed 2 - 6 weeks after the last dose of neoadjuvant therapy, and postoperative adjuvant therapy is initiated at least 4 weeks after surgery.
89681633|NCT00604019|Active Comparator|Dopamine|Patients that get Dopamine as an infusion for hypotension
89681634|NCT00604019|Active Comparator|Norepinephrine|Patients that get norepinephrine as an infusion for hypotension
89681635|NCT05732571|Active Comparator|Breathing Techniques Intervention|A 12 session/six week, twice a week online group-based intervention based on breathing techniques including yoga practice directed by a specialist. Each group will aim for between 3- 6 participants.
89681636|NCT05732571|No Intervention|Usual Care|A six week non-intervention (usual care) period will be recruited to, allowing a comparison to the intervention.
88996773|NCT05592691||Study Cohort|Patients undergoing fascial blocks in elective cardio-thoracic and abdominal surgery.
88996774|NCT04293328|Experimental|Monthly replacement lenses without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
88996775|NCT04293328|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
88996776|NCT04271215||Overweight/Obesity|BMI at diagnosis will be used. Using WHO software (version 3.2.2, World Health Organization, Geneva), the BMI-for-age Z-scores were calculated for each patient. According to WHO classification, patients were categorized as normal (- 1.9999 to 0.9999), wasted (- 2 to - 2.9999), severely wasted (≥ - 3), at risk of overweight (1-1.9999), overweight (2 to 2.9999) and obesity (≥3). In addition, the BMI percentiles cutoffs provided by CDC were: normal (p5-84.9999), underweight (< p5), overweight (p85-94.9999), and obese (≥ p95). The nutritional classification and measurements regarding weight and height recorded in clinical files will be used to classify patients' nutritional status in present research has been previously described.
88996777|NCT00182520|Experimental|1|Topiramate
88996778|NCT00182520|Placebo Comparator|2|placebo
88996779|NCT04257487|Active Comparator|Treatment A|Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months
88996780|NCT04257487|Active Comparator|Treatment B|Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months
88996781|NCT04257487|Placebo Comparator|Treatment C|2 indistinguishable placebo capsules BID, for 12 months
89681637|NCT00581399|Experimental|NO-NUMO Chest Tube|The NO-NUMO™ High Vacuum Body Cavity Drainage System consist of disposable NO-NUMO™ body cavity drainage tubes, disposable Vario™ fluid management canisters Vario™ portable vacuum pump
89681638|NCT00581399|Active Comparator|Standard Chest Tube|Classic PVC Chest Tube
89681639|NCT01922115|Active Comparator|TROSPIUM CHLORIDE|Those with overactive bladder will be administered either a placebo or Sanctura XR extended release (Trospium chloride) for treatment (60 mg).
89681640|NCT01922115|Placebo Comparator|PLACEBO|Subjects may be administered a placebo rather than the Sanctura XR (Trospium Chloride).
89681641|NCT00081770|Experimental|PegIntron 1.5 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
89681642|NCT00081770|Experimental|PegIntron 1.0 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
89681643|NCT00081770|Active Comparator|PEGASYS 180 ug/wk Plus COPEGUS|PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up
89681644|NCT00605423|Active Comparator|1|Dose 0.2 ug/day Medidur implant
89681645|NCT00605423|Active Comparator|2|Dose 0.5 ug/day Medidur implant
89681646|NCT05730699|Experimental|BCD-132 (divozilimab)|Stage 1 and 2 - Intravenous infusion of BCD-132 every 24 weeks
89681647|NCT05730699|Placebo Comparator|Placebo|Stage 1 - Intravenous infusion of Placebo; Stage 2 - Intravenous infusion of BCD-132
89681648|NCT01679834||Cohort|
89681649|NCT00606047||Asymptomatic patients|Asymptomatic, healthy patients (without hip pain or prior hip disease) will be recruited. Patients will undergo a magnetic resonance imaging (MRI) of the hip joints to evaluate for the prevalence of femoroacetabular impingement (FAI).
88996782|NCT00182559|Active Comparator|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
88996783|NCT00182559|Active Comparator|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
88996784|NCT04247347|Experimental|Self-Management|
88996785|NCT04247347|Active Comparator|Usual Care|
88996786|NCT04232254|Active Comparator|Animal Protein - Skewed Distribution|Animal-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
88996787|NCT04232254|Experimental|Plant Protein - Skewed Distribution|Plant-based protein foods with 3 meals per day consisting of 10-, 30-, and 60% of dietary protein for breakfast, lunch, and dinner, respectively.
88996788|NCT04232254|Experimental|Animal Protein - Balanced Distribution|Animal-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
88996789|NCT04232254|Experimental|Plant Protein - Balanced Distribution|Plant-based protein foods with 5 meals per day consisting of 20% of dietary protein per meal.
88996790|NCT00534274|Experimental|TEP FLT|
88996791|NCT00189618|Placebo Comparator|1|
88996792|NCT00189618|Active Comparator|2|
88996793|NCT04177030|Experimental|Group A-Morning First|Within the first week of the study, Group A will consume fruits and vegetables within time-restriction morning window (9am-12pm). Following washout week, Group A will consume fruits and vegetables within time-restriction night window (7pm-10pm) for one week.
88996794|NCT04177030|Experimental|Group B-Night First|Within the first week of the study, Group B will consume fruits and vegetables within time-restriction night window (7pm-10pm). Following washout week, Group B will consume fruits and vegetables within time-restriction morning window (9am-12pm) for one week.
88996795|NCT04175548||surgery for a pertrochanteric fracture|Patients having had surgery for a pertrochanteric fracture at the CHU Brugmann Hospital between January 2013 and May 2019.
88996796|NCT00406796|Active Comparator|1|0.5mg Ranibizumab
88996797|NCT00406796|Active Comparator|2|0.3mg Ranibizumab
88996798|NCT00534391|Placebo Comparator|B|Artificial tear containing antibiotic solution base
88996799|NCT00534391|Experimental|A|combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
88996800|NCT00534586|Active Comparator|1|remifentanil
88996801|NCT00534586|Active Comparator|2|propofol
89681650|NCT01923129|Experimental|24 hour postop catheter removal|group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)
89681651|NCT01923129|No Intervention|72 hour postoperative catheter removal|catheter removed on postoperative day 3 (72 hours postoperatively)
88996802|NCT00534586|Active Comparator|3|sevoflurane
88996803|NCT00534586|Active Comparator|4|s-ketamine
88996804|NCT00534625|Placebo Comparator|1|
88996805|NCT00534625|Experimental|2|150 mg zileuton by intravenous injection
88996806|NCT00534625|Experimental|3|300 mg zileuton by intravenous injection
88996807|NCT04134208|Experimental|Diagnostic (fluciclovine F18, PET-CT)|Within 4 weeks before starting SST, patients receive fluciclovine F18 IV then undergo a PET-CT scan over 30 minutes. Within 22-28 weeks after starting SST, patients receive fluciclovine F18 IV and undergo a second PET-CT scan over 30 minutes.
88996808|NCT04110769|Experimental|Responders|"The investigator will administer neoadjuvant chemotherapy After neoadjuvant chemotherapy, multidisciplinary team will decide to surgery or continuing chemotherapy based on following imaging studies and tumor markers.~The patients who undergo surgery after neoadjuvant chemotherapy will be included responders."
88996809|NCT04110769|Active Comparator|Non-responders|The patients who show cancer progression even after neoadjuvant chemotherapy will be classify with non-responder. And the investigator will change palliative chemotherapy.
88996810|NCT04106830||NMOSD|Patients with neuromyelitis optica spectrum disorders
88996811|NCT04106830||Multiple sclerosis(MS)|Patients with multiple sclerosis
88996812|NCT04106830||Health control(HC)|Healthy people without any neuroinflammation disease
88996813|NCT00406913|Experimental|Mupirocin ointment|
89681652|NCT00581867|Experimental|Intranasal Insulin Aspart|Participants were administered intranasal insulin aspart (40 IU) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
89681653|NCT00581867|Active Comparator|Intranasal Saline (placebo)|Participants were administered intranasal saline (placebo) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
89681654|NCT01925469|Experimental|Benzocaine|Benzocaine spray (14%), an FDA approved drug, will be used to assess whether this provides additional pain relief at time of hysterosalpingogram.
89681655|NCT01925469|Placebo Comparator|Saline spray|A saline placebo spray will be used in the placebo group.
89681656|NCT02139137|Experimental|High Interference Control Condition|Computerized training program requiring participants to repeatedly practice controlling interference on a cognitive task
89681657|NCT02139137|Active Comparator|Low Interference Control Condition|Computerized training program requiring participants to minimally practice controlling interference on a cognitive task
89681658|NCT00583661|Experimental|EXCOR Pediatric|Implantation of the EXCOR Pediatric Ventricular Assist Device
89681659|NCT01925781|Experimental|e-Cigarette|STAM 1100mAh CE4 eGo Clearomizer e-Cigarette
89681660|NCT01925781|Active Comparator|Nicotine polacrilex|Nicotine Replacement gum
89681661|NCT00584285||Corneal Topographer Fluorescein Patterns|Use corneal topography to evaluate fluorescein pattern of rgp contact lens. Used corneal topography to develop theoretical fluorescein patters on a virtual eye. Theoretical lens developed by the topographer was ordered to compare to the actual fluorescein pattern on the actual eye.
89681662|NCT01927575|Active Comparator|Standard X-Ray + CT|Standard X-Ray + CT arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
89681663|NCT01927575|Active Comparator|Standard X-Ray + MRI|Standard X-Ray + MRI arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
89681664|NCT01927575|Experimental|Tomo|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
89681665|NCT01927887|Experimental|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
89681666|NCT01929057||Acne patients|This group consists of patients who have at least moderate to severe acne on their back
89681667|NCT01929057||Healthy Controls|This group contains participants who do not have any active acne lesions on their back
89681668|NCT00081458|Placebo Comparator|placebo|Placebo injectable subcutaneously daily into the thigh or abdomen
89681669|NCT00081458|Experimental|2|teduglutide 0.05 mg/kg/d
89681670|NCT00081458|Experimental|3|teduglutide 0.1 mg/kg/d
89051566|NCT04620083|Experimental|Experimental 5-day Intensive Group|In addition to conventional therapy, the participants in this experimental groups also joined the integrative learning program for 5 days per week. For consistency, Day 1 and 3 of the 3-day protocol were replicated as Day 4 and Day 5 of the 5-day protocol.
89051567|NCT04620044|Experimental|Kaledo Game|Kaledo game, which is a board game, has been developed to inform children about healthy eating. The aim of this game is to teach children calorie balance through the calorie values of foods. Kaledo game gives children the opportunity to stay motivated and have fun. While children are having fun, they also gain the knowledge necessary for healthy eating behavior change. The game is played with 2-4 people. A game session takes 15-30 minutes Children in the playgroup played 15-30 minutes (1 round) Kaledo game every week for 12 weeks.
89051568|NCT04620044|Experimental|Education|"The students in the training group were trained for 20 minutes once a week for 12 weeks. Training subjects were prepared in line with health belief model components.~The following subjects were included in the training content. What is obesity?Risk factors for obesity, Characteristics of obese individuals, What is a healthy diet?Relationship between unhealthy nutrition and obesity, The consequences of unhealthy diet Health problems caused by obesity, What should be done to prevent and control obesity. How should nutrition be to lose weight? Positive results which show up with weight loss, Barriers to a healthy diet, Ways to reduce and eliminate barriers How to take action to lose weight?, Benefits of weight loss, Success stories in the fight against obesity, How are eating habits changed?, How can we achieve self-efficacy to change eating habits?"
89051569|NCT04620044|Experimental|Control|There was no intervention in the control group.
89051570|NCT04620122|Experimental|intervention group|Progressive Muscle Relaxation Training and Music Therapy are applied to the intervention group.
89681671|NCT00610727|Experimental|Inhaled prochlorperazine 0.625 mg vs IV|Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
89681672|NCT00610727|Experimental|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato prochlorperazine 1.25 mg
89051571|NCT04620122|No Intervention|control group|No intervention is applied to the control group.
89051572|NCT04581291|Experimental|Intervention group|
89051573|NCT04581291|Experimental|Control group|
89051574|NCT04620317|Active Comparator|Synbiotic|The product contained three clinically studied active ingredients namely inulin-oligofructose (prebiotic; derived from chicory root), at least 6 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01 (probiotic) and 4 B CFU of Bifidobacterium lactis BB12 (probiotic) per sachet.
89051575|NCT04620317|Placebo Comparator|Placebo|Placebo contains only maltodextrin without any active ingredients, equally same in physical form, freeze-dried white powder with characteristic odor and water soluble as the synbiotic supplement.
89681673|NCT00610727|Experimental|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato prochlorperazine 2.5 mg
89681674|NCT00610727|Experimental|Inhaled prochlorperazine 5 mg|Inhaled Staccato prochlorperazine 5 mg
89681675|NCT00610727|Experimental|Inhaled prochlorperazine 10 mg|Inhaled Staccato prochlorperazine 10 mg
89681676|NCT00610727|Placebo Comparator|inhaled Placebo|inhaled Staccato Placebo (0 mg)
89681677|NCT03081104|Active Comparator|hystroscopy|The procedure will be performed by a gynecological surgeon, under general anaesthesia with the patient in lithotomy position. Antibiotic prophylaxis may be administered, the cervix is grasped with pozzi forceps and dilated up to hegar 9 to facilitate insertion of the hysteroscopy. The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
88815780|NCT01114334|Active Comparator|Guideline-based Medical Management|"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.~The evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications"
88996814|NCT00406913|Active Comparator|Standard of Care sterilization|
88996815|NCT04722900||non-GDM|
88996816|NCT04722900||GDM|
88996817|NCT04076800|Experimental|Acupuncture|
88996818|NCT04076800|Sham Comparator|Sham acupuncture|
88996819|NCT04061161|Active Comparator|Tiotropium respimat|Tiotropium respimat 2.5mcg two actuations once daily
88996820|NCT04061161|Placebo Comparator|Placebo respimat|Placebo respimat two actuations once daily
88996821|NCT04049149|Other|JADE-PRISM group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
88996822|NCT04049149|Other|JADE group|Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
88996823|NCT03966586|Experimental|Enhanced Care|Usual clinical care + intervention components
88996824|NCT03966586|Active Comparator|Usual Care|Usual clinical care and counseling
88996825|NCT00182832|Experimental|1|
88996826|NCT00182832|Active Comparator|2|
88996827|NCT03943654||Children living within study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live within the mobile pharmacy delivery area will receive illness assessments and treatment recommendations over the phone. Immediately following calls a nurse will conduct household visits to complete in-person assessments of the children. Illness progression will be tracked with a 8-12 day follow up call. The phone and in-person assessments will be compared to evaluate safety and accuracy of the healthline.
88996828|NCT03943654||Children living outside study delivery area w/o danger signs|Families who call the healthline service about a sick child (no danger signs) and live outside the delivery area will receive illness assessments and treatment recommendations over the phone. Illness progression will be tracked with a 8-12 day follow up call.
89681678|NCT03081104|Active Comparator|ultrasound guided aspiration|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control. It was possible to keep the dilators and the suction cannula under constant view by slightly tilting the transducer as required. Advancement of any instrument was allowed only under direct ultrasound control.The completeness of the evacuation was confirmed by the scan in these cases.
89681679|NCT03081104|Active Comparator|blind aspiration|The women were allowed to empty their urinary bladder before induction of anesthesia, but catheterization was not performed. After positioning the patient appropriately on the operating table, bimanual pelvic examination was performed under anesthesia to assess the axis and the size of the uterus. A Sim's speculum was inserted into the vagina; the cervix was visualized and grasped using the Vulsellum forceps. The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used. The aspirate was examined to confirm the presence of products of conception. The completeness of the evacuation was checked by gentle sharp curettage and final suctioning at the end of procedure.
89681680|NCT00584831|Active Comparator|Group 2 LSBO|contact lenses worn in this order: lotrafilcon B toric, senofilcon A toric, balafilcon A toric, omafilcon A toric
88996829|NCT03943654||Children who are identified as having danger signs|Families who call the healthline service about a sick child and who are identified as having a danger sign will be directed to the nearest medical facility. Illness progression will be tracked with a 8-12 day follow up call.
88996830|NCT04724993|Experimental|Online Aerobic Dance Exercises|In this group, aerobic dance exercises will be applied online under the supervision of a physiotherapist. And participants will record their physical activities on the Physical Activity Tracking Chart.
88996831|NCT04724993|Experimental|Physical Activity Counseling|In this group, participants will be informed online about physical activity and exercise. And they will record their physical activities on the Physical Activity Tracking Chart too.
88996832|NCT03920800||Conservative management - progression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, with progressive lesions or lesions remaining present after 2 years of follow-up.
88996833|NCT03920800||Conisation|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital by means of conisations.
88996834|NCT03920800||Conservative management - spontaneous regression|Young women with high grade pre-cancerous lesions, followed within the CHU Brugmann Hospital according to a conservative attitude, who showed a spontaneous regression of the lesions during the 2 years follow-up.
88996835|NCT04686643|Experimental|Treatment|AGSAVI
88996836|NCT04686643|Active Comparator|Reference|AGLS
88996837|NCT00534781|Experimental|A|plasma microtenotomy
88996838|NCT00534781|Active Comparator|B|Standard Surgical Debridement
88996839|NCT03750448|Active Comparator|Telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
88996840|NCT03750448|Active Comparator|No intervention|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
88996841|NCT03750448|Active Comparator|Unsupervised rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
88996842|NCT03748810||Triple OADs failure|Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three distinct OADs, including metformin, glimepiride and dipeptidyl peptidase 4 (DPP4) inhibitors.
88996843|NCT03669523|Experimental|Denosumab-nivolumab combination|Both drugs to be continued until progression or unacceptable toxicity and for a maximum of two years
88996844|NCT00535054|Experimental|Tears Again|All subjects shall be treated with Tears Again.
88996845|NCT00535093|No Intervention|1|All patients fulfilling inclusion criteria will be evaluated for GAS infection using both a rapid streptococcus test and also a standard throat culture
88996846|NCT00189852|Experimental|Docobo|telemonitoring at home system for heart failure
88996847|NCT00189852|No Intervention|Control|No telemonitoring system in place
88996848|NCT03493750|No Intervention|Healthplan guide alone|"Nurse applies the daily-practice questionnaire called Healthplan guide to screen and identify people with dental diseases, among those in vulnerable situation, and to sensitize them about the importance of oral hygiene and how to improve it.~After that, the nurse has to state if, from her/his point of view the patient needs dental care or not. Whatever the answer, the nurse makes an appointment to a dental practice, in the 30 following days, and gives it to the patient with a free bus ticket. Randomization is done at that time.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organized but outside this trial."
89051576|NCT04620863|Experimental|tDCS group|Patients randomized to the experimental group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity delivered at anodal and cathodal levels.
89681681|NCT00584831|Active Comparator|Group 3 LOSB|contact lenses worn in this order: lotrafilcon B toric, omafilcon A toric, senofilcon A toric, balafilcon A toric
89681682|NCT00584831|Active Comparator|Group 4 LBSO|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, senofilcon A toric, omafilcon A toric
88815781|NCT01114334|Experimental|Motivational Interview with GBMM|Motivational Interviewing for Depression combined with guideline-based medical management for depression
88815782|NCT00458835|Active Comparator|Ciclesonide 300 mcg intranasally via aqueous nasal spray|
88815783|NCT00458835|Active Comparator|Ciclesonide 300 mcg intranasally via HFA nasal aerosol|
88815784|NCT00458835|Active Comparator|Ciclesonide 320 mcg orally inhaled via HFA MDI|
88815785|NCT01044758|Experimental|aMCI_62.5mg drug first, then placebo|"Amnestic MCI:~62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
88815786|NCT01044758|Experimental|aMCI_Placebo first, then 62.5mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)"
88815787|NCT01044758|Experimental|aMCI_125mg drug first, then placebo|"Amnestic MCI:~125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
88815788|NCT01044758|Experimental|aMCI_Placebo first, then 125mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)"
88815789|NCT01044758|Experimental|aMCI_250mg drug first, then placebo|Amnestic MCI: 250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)
88815790|NCT01044758|Experimental|aMCI_Placebo first, then 250mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)"
88815791|NCT01044758|Placebo Comparator|Control_Placebo first, then placebo|"Healthy control:~placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
88815792|NCT02440659||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
88815793|NCT02440659||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
88815794|NCT02439216|Experimental|Dose 1|Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day
88815795|NCT02439216|Experimental|Dose 2|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day
88815796|NCT02439216|Placebo Comparator|Placebo|Matching placebo
88815797|NCT03013400|Active Comparator|Ebselen|Three Ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
88815798|NCT03013400|Placebo Comparator|Placebo|Three Placebo capsules each containing 200mg taken orally twice a day for 3 weeks
88815799|NCT02439138|Experimental|GS-1101|"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.~-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression."
88815800|NCT01097642|Active Comparator|Ixabepilone|Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.
88815801|NCT01097642|Experimental|Ixabepilone plus Cetuximab|Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.
88815802|NCT02442687|Active Comparator|A|JKB 121, 5 mg twice daily
88815803|NCT02442687|Active Comparator|B|JKB 121, 10 mg twice daily
88815804|NCT02442687|Placebo Comparator|C|Identical appearing placebo
88815805|NCT01115660|Experimental|stroke education|Patients in this arm receive a telephone call by a medication coach who reviews their condition and importance of adherence to medication regimen.
88815806|NCT01115660|No Intervention|control arm|Subjects in this arm received instruction at hospital discharge and a 3-month follow-up call to collect study data.
88815807|NCT00841178|Active Comparator|Surgery|Patients undergo Surgery under a general anaesthetic.
88815808|NCT00841178|Experimental|EVLT|Patients undergo EVLT under a local anaesthetic.
88815809|NCT04341519||Family members|"Age>18y~Non-opposition to participate to the telephone interviews~One family member per patient: the family member the most implicated in the patient's care~3 groups of Family members will be enrolled in the study corresponding to patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia (See below). 1 family member per patient will be recruited."
88815810|NCT04341519||Patients|"Patients:~Age>18y~Admission to the participating ICUs for any cause of acute respiratory failure during the COVID-19 pandemic~Having received invasive or noninvasive mechanical ventilation~Non-opposition to participate to the telephone interviews.~3 groups of patients will be enrolled in the study: patients with COVID-19, patients with seasonal flu and patients with community acquired pneumonia.~COVID group : Patients admitted to the ICU for acute respiratory failure and having a positive 2019-nCOV RT PCR in a respiratory / nasal swab sample (GROUP COVID-19)~Group FLU : patients admitted to the ICU for acute respiratory failure and having a confirmed influenza pneumonia~Group CAP (Community-acquired pneumonia) : patients admitted to the ICU for acute respiratory failure and having a clinically or microbiologically documental community acquired pneumonia with negative COVID-19 and Influenza PCRs."
88815811|NCT04341519||healthcare providers|Two months after the official end of the COVID-19 peak in France, the local investigator will receive a set of 100 questionnaires. He/she will be responsible for proposing survey participation to volunteer healthcare providers. Those who are interested will be given the information letter and the questionnaires in an envelope. Once completed anonymously, they will seal the envelope and give it to the local investigator who will then send us all completed questionnaires by registered post.
88815812|NCT01048424|Experimental|Paced respiration|Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a Urinary Incontinence pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
88815813|NCT01048424|Placebo Comparator|Control|Participants will be given a Urinary Incontinence pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
88815814|NCT02444715|Active Comparator|Standard care (SC)|
88815815|NCT02444715|Experimental|Interventional care (IC)|
89051577|NCT04620863|Sham Comparator|Sham Group|The stimulation setting was exactly the same of the experimental group but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
89051578|NCT04588155||Chronic Low-Back Pain|Subjects diagnosed with Chronic Low-Back Pain in rehabilitation program: functional assessment (with temporal and kinematic analysis) and clinical assessment.
89051579|NCT04588155||Healthy|Healthy subjects: functional assessment (with temporal and kinematic analysis)
89051580|NCT00562757||A|Post myocardial infarction patients who received an ICD, stratified into low versus high WMI groups
89051581|NCT01151137|Experimental|Dronedarone|Dronedarone 400 mg twice a day until the CSED
89051582|NCT01151137|Placebo Comparator|placebo|Placebo (for Dronedarone) twice a day until the CSED
89051583|NCT02940470|Experimental|Calorie restricted diet plus exercise|See Intervention Description
89051584|NCT02940470|Active Comparator|Weight management classes|See Intervention Description
89051585|NCT01151098|Experimental|BTDS 5, 10 or 20|Buprenorphine transdermal patch
89051586|NCT04619771|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
89051587|NCT04619888||HeartLogic cohort|Patients implanted with a defibrillator enabling HeartLogic
89051588|NCT04619849|Experimental|palmaris longus and carpal tunnel|EMG measurements of median and ulnar nerves will be made in patients with palmaris longus muscle.
89051589|NCT04587960|Active Comparator|Primary closure of Cesarean wound|Immediate closure of skin incision where healing occurs by primary intention
89051590|NCT04587960|Experimental|Delayed primary closure of Cesarean wound|Delayed closure of skin incision following regular wound dressing for 2 to 3 days.
89051591|NCT01151020|Experimental|Arm 1|Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
89051592|NCT04619810|Other|Intervention arm|quasi-experimental pre-post study
89051593|NCT01150474|Experimental|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
89051594|NCT01150474|Placebo Comparator|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
89051595|NCT05088044|Experimental|staff nurses|firstly pre-test would conducted for the group then after 7 days post-test would be conducted for the same group intervention which will be given: training on modified early warning score to staff nurses and marking of physiological parameters on MEWS chart
89051596|NCT04587804|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|simultaneous treatment by repetitive pulse magnetic stimulation and radiofrequency energy for toning of abdomen and reduction of subcutaneous fat
89216153|NCT05005429|Experimental|Experimental: Bintrafusp alfa (M7824)|"Bintrafusp alfa (M7824): 1200mg, over 60 minutes IV infusion The treatment will start within 1-5 days from enrollment. The treatment will be administered at day 1 of 14-day intervals .~Treatment will be administered until unacceptable toxicity, loss of clinical benefit, disease progression or completion of 2 years of therapy. If the patient has benefit after 2 years, the trial chair and the sponsor must be consulted to evaluate how to continue with the treatment."
89216154|NCT05002270|Experimental|Arm A0, JAB-21822 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-21822 will be administered alone to determine the MTD and RP2D
89681683|NCT00584831|Active Comparator|Group 5 LBOS|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, omafilcon A toric, senofilcon A
89681684|NCT00584831|Active Comparator|Group 6 SLOB|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, omafilcon A toric, balafilcon A toric
89681685|NCT00584831|Active Comparator|Group 7 SLBO|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, balafilcon A toric, omafilcon A toric
89681686|NCT00584831|Active Comparator|Group 8 SOLB|contact lenses worn in this order: senofilcon A toric, omafilcon A toric, lotrafilcon B toric, balafilcon A toric
89681687|NCT00584831|Active Comparator|Group 9 SBLO|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, lotrafilcon B toric, omafilcon A toric
89681688|NCT00584831|Active Comparator|Group 10 SBOL|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, omafilcon A toric, lotrafilcon B toric
89681689|NCT00584831|Active Comparator|Group 11 OSLB|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, lotrafilcon B toric, balafilcon A toric
89681690|NCT00584831|Active Comparator|Group 12 OSBL|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, balafilcon A toric, lotrafilcon B toric
89681691|NCT00584831|Active Comparator|Group 13 OBLS|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, lotrafilcon B toric, senofilcon A toric
89681692|NCT00584831|Active Comparator|Group 14 OBSL|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, senofilcon A toric, lotrafilcon B toric
89681693|NCT00584831|Active Comparator|Group 15 BLSO|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, senofilcon A toric, omafilcon A toric
89681694|NCT00584831|Active Comparator|Group 16 BLOS|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, omafilcon A toric, senofilcon A toric
89681695|NCT00584831|Active Comparator|Group 17 BSOL|contact lenses worn in this order: balafilcon A toric, senofilcon A toric, omafilcon A toric, lotrafilcon B toric
89681696|NCT00584831|Active Comparator|Group 18 BOLS|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, lotrafilcon B toric, senofilcon A toric
89681697|NCT00584831|Active Comparator|Group 19 BOSL|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, senofilcon A toric, lotrafilcon B toric
89681698|NCT00584831|Active Comparator|Group 1 LSOB|contact lenses worn in this order: lotrafilcon B toric/senofilcon A toric/omafilconA toric/balafilcon A toric
89681699|NCT03081260|Other|Patellar resurfacing|Patellar resurfacing during the total knee prosthesis Anatomic surgery
89681700|NCT03081260|Other|Patellar non-resurfacing|Patellar non-resurfacing during the total knee prosthesis Anatomic surgery
89051597|NCT04619459|Experimental|Newborns receiving Kangaroo Mother Care (KMC)|The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. At Minute 5, the newborns' Apgar scores were assessed and recorded during KMC. The newborn's examination and injections (Hepatitis-B and K vit) were postponed until the first breastfeeding took place. A pediatrician performed a detailed examination of the newborns under the radiant infant warmer after the first breastfeeding. Following the examination, the newborn was positioned on the mother's breast for KMC. During this KMC, the newborn was administered 1 mg K vitamin in the right leg and 0.5 ml Hepatitis-B vaccine in the left leg via intramuscular injections. The KMC session was continued for 3 hours. Care attempt of mothers such as episiotomy repair was taken that the position of KMC.
89051598|NCT04619459|No Intervention|Newborns receiving standard postpartum care (SPC):|He received the standard care of the hospital. KMC not applied.
89051599|NCT04580901|Experimental|Group interpersonal psychotherapy|Group IPT consists of 12 weeks of virtually-delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions, with the first 12 sessions taking place twice weekly (acute phase) for 6 weeks and the last 3 sessions occurring every other week (maintenance phase) for 6 weeks.
89051600|NCT04580901|No Intervention|Usual care|Usual care refers to any care that the women wish to access, and there are no limits on the women in either group. It may include, but is not limited to, the family physician, obstetrician, and/or midwife, participation in regional standard perinatal depression programming, private therapy, online therapies, medication, etc.
89051601|NCT04619303|Experimental|Dexamethasone Implant|Receive 0.7mg dexamethasone implant (Ozurdex) at baseline visit. Monthly review with repeat administration of intravitreal treatment every three months for DMO and laser as clinically indicated.
89216155|NCT05002270|Experimental|Arm A1, JAB-21822 monotherapy, Phare 2, Dose Expansion|JAB-21822 will be administered alone at RP2D in selected cancer type patients to evaluate the preliminary antitumor activity.
89681701|NCT01929291||Boostrix Group|Pre-adolescents (aged (≥10 years to ˂12 years), adolescents (aged ≥12 to ˂19 years), adults (aged 19 to 64 years) and elderly (≥ 65) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.
89051602|NCT04619303|Active Comparator|Bevacizumab|Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.
89681702|NCT03084848|Experimental|Active control|
89681703|NCT03084848|Experimental|Inhibitor control|
89681704|NCT01929759|Other|Drug switching|Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
89681705|NCT03085082||skeletal class II subjects|patients with wits appraisal more than 3 mm measured on a cephalometric x ray obtained during diagnosis
89681706|NCT03085082||skeletal class III subjects|patients with wits appraisal less than -3 mm measured on a cephalometric x ray obtained during diagnosis
89681707|NCT03085082||skeletal class I patients|patients with Wits appraisal between -3 and +3 that is measured from a cephalometric x ray obtained during diagnosis of arch length discrepancy. this group will serve as control and obtained after recruitment of the other 2 groups in 1 to 1 fashion
89051603|NCT01150357|Experimental|Low Dose Aliskiren|Participants received body-weight stratified dose of aliskiren capsules (6.25/12.5/25 mg) once daily. Participants whose body weight ≥ 20 kilogram (kg) to less than < 50 kg received 6.25 mg; ≥50 kg and < 80 kg received 12.5 mg and ≥ 80 kg and ≤ 150 kg received 25 mg of aliskiren.
89051604|NCT01150357|Experimental|Mid dose|Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 37.5 mg; ≥50 kg and < 80 kg received 75 mg and ≥ 80 kg and ≤ 150 kg received 150 mg of aliskiren.
89051605|NCT01150357|Experimental|High dose|Participants received body-weight stratified dose of aliskiren capsules (150/300/600 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 150 mg; ≥50 kg and < 80 kg received 300 mg and ≥ 80 kg and ≤ 150 kg received 600 mg of aliskiren.
89051606|NCT04587765|Experimental|Extra sports group|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
89051607|NCT04587765|No Intervention|Conventional group|The group follows the schedule of school teaching programme. Students arrange their own after-school time after school.
89051608|NCT04619537|Experimental|Anlotinib hydrochloride plus Docetaxel|Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment.
89051609|NCT04587414|Experimental|eHealth + counselling contacts|6-month eHealth physical activity intervention complemented by face-to-face and telephone counselling contacts on physical activity..
89051610|NCT04587414|Experimental|eHealth|6-month eHealth physical activity intervention
89051611|NCT04587414|Other|Usual care|Usual care of type 2 diabetics within the primary health care setting.
89051612|NCT04580862|Experimental|group 1 Non-surgical endodontic retreatment in single visit|Single visit treatments have gained more popularity. Completing the treatment in a single appointment has many advantages including reduction in treatment time and cost, lower risk of micro leakage and recontamination of root canals between appointments
89051613|NCT04580862|Active Comparator|group 2 Non-surgical endodontic retreatment in Two-visit|Two-visit endodontic treatment with intra-canal medication was traditionally found to be effective in decreasing the number of flare-up in all retreatment cases and in reducing postoperative pain of previously symptomatic teeth
89681708|NCT03084692|Experimental|Therapeutic Yoga and Resistance Exercise|The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.
89681709|NCT03437330|Experimental|Empagliflozin (Jardiance®)|Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral
89681710|NCT03437330|Active Comparator|Insulin Glargine (Lantus®)|"Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU FBG 7-8 mmol/L: +3 IU FBG > 8 mmol/L: +5 IU"
89681711|NCT05738577||1|patients with type 1 diabetes aged 20-30 years
89681712|NCT05738577||2|healthy people serve as controls of the same age group
89681713|NCT01271803|Experimental|DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 milligrams (mg) cobimetinib once daily (QD) on Days 1-14, followed by 14 days off on Days 15-28 (14/14 dosing schedule) and oral 720 mg vemurafenib twice daily (BID) on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681714|NCT01271803|Experimental|DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-21, followed by 7 days off on Days 22-28 (21/7 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681715|NCT01271803|Experimental|DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681716|NCT01271803|Experimental|DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-28 (28/0 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681717|NCT01271803|Experimental|DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 28/0 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681718|NCT01271803|Experimental|DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681719|NCT01271803|Experimental|DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 100 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681720|NCT01271803|Experimental|DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681721|NCT01271803|Experimental|DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
88815816|NCT01048658|Active Comparator|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
88815817|NCT01048658|Placebo Comparator|No Sevoflurane|Subject receives standard of care drug regimens for anesthesia with this procedure.
88815818|NCT04341675|Active Comparator|Sirolimus|Sirolimus 6mg on day 1 followed by 2mg daily for the next 13 days or until hospital discharge, whatever happens sooner.
88815819|NCT04341675|Placebo Comparator|Placebo|Matching placebo
88815820|NCT02445807|Experimental|DFD-06 cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
88815821|NCT02445807|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
88815822|NCT00362973||Hormone Receptor Positive Breast Cancer|Patients with hormone receptor positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of aromatase inhibitor and ovarian suppression (if premenopausal).
88815823|NCT00362973||HER-2/neu Positive Breast Cancer|Patients with HER-2/neu positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of trastuzumab.
88815824|NCT01116986|Experimental|1, Patch, Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815825|NCT01116986|Experimental|2, Patch, Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815826|NCT01116986|Experimental|3, Patch, Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815827|NCT01116986|Experimental|4, Patch, Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815828|NCT01116986|Experimental|5, Patch, Gum, No Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815829|NCT01116986|Experimental|6, Patch, Gum, No Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815830|NCT01116986|Experimental|7, Patch, Gum, No Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815831|NCT01116986|Experimental|8, Patch, Gum, No Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815832|NCT01116986|Experimental|9, Patch, No Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815833|NCT01116986|Experimental|10, Patch, No Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815834|NCT01116986|Experimental|11, Patch, No Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815835|NCT01116986|Experimental|12, Patch, No Gum, Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
89681722|NCT01271803|Experimental|Cobimetinib Monotherapy (100 mg or 60 mg)|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule, or oral 100 mg cobimetinib QD on 14/14 dosing schedule of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681723|NCT01271803|Experimental|CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681724|NCT01271803|Experimental|CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
89681725|NCT00585377|Other|1|
89681726|NCT00080288|Experimental|1|Armodafinil 150 mg/day
89681727|NCT00080288|Placebo Comparator|2|Placebo
89681728|NCT05722119|Experimental|Multiplex test|Multiplex Polymerase Chain Reaction (PCR) assay on stool samples, within 2 hours, in patients with acute diarrhea
89681729|NCT05722119|No Intervention|Standard of care tests|Coproculture with direct examination and Clostridium difficile and A-B toxins search, parasitological examination of the stool and search for enteric viruses (rotavirus, adenovirus, norovirus, astrovirus) in patients with acute diarrhea
89681730|NCT05722119|Experimental|Control group without diarrhea|Multiplex Polymerase Chain Reaction (PCR) assay on stool samples in asymptomatic patients
89681731|NCT05499507|Active Comparator|Change of Heart (COH)|Incorporates two, evidence-based individual-level interventions (home blood pressure telemonitoring coupled with the interactive obesity treatment approach, that includes nutrition and physical activity text messages with tailored feedback) and an institutional-level intervention (anti-racism training of providers and staff along with patient feedback to inform respectful care).
89681732|NCT05499507|Experimental|Change of Heart Plus (COH+)|Includes all components of COH plus the addition of interpersonal support for Black women by Black women (community doula care, mental health services, and lactation support).
89681733|NCT02984618|Experimental|Treatment group|Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side
89681734|NCT02984618|Active Comparator|Control group|Patients will receive classic epidural blood patch with 20ml of autologous blood
89681735|NCT03084458|No Intervention|Control|Once consented, recruited ICD patients will complete the baseline psychosocial and quality of life measures. At the first and final visit, a 6-minute walk test will be administered. Participants will be sent text messages to encourage physical activity. Participants will be re-assessed with psychosocial and quality of life measures at 30 and 90 days post enrollment. At the final (90 day) visit participants ICD will be interrogated to obtain accelerometer activity data.
89681736|NCT03084458|Experimental|Fitbit|Same as control condition. In addition, participants in the experimental group will receive a Fitbit device with full instructions and troubleshooting. These participants will be given daily step goals, which will be increased during the course of the study, and be able to monitor their progress using the Fitbit app.
89681737|NCT05721183|Experimental|NOST|"The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."
89681738|NCT05721183|No Intervention|Control|Participants in the no intervention arm arm are asked not to implement NOST.
89681739|NCT01798745|Experimental|Cohort A: JNJ-54452840 20 mg|Each patient will receive 20 mg of JNJ-54452840 as a single dose.
89681740|NCT01798745|Experimental|Cohort A: JNJ-54452840 80 mg|Each patient will receive 80 mg of JNJ-54452840 as a single dose.
89681741|NCT01798745|Experimental|Cohort A: JNJ-54452840 160 mg|Each patient will receive 160 mg of JNJ-54452840 as a single dose.
89681742|NCT01798745|Placebo Comparator|Cohort A: Placebo|Each patient will receive matching placebo as a single dose.
89681743|NCT01798745|Experimental|Cohort B: JNJ-54452840 <= 240 mg|Each patient will receive JNJ-54452840 at a dose of less than or equal to 240 mg as a single dose (dose determined by the Data Monitoring Committee).
89681744|NCT01798745|Placebo Comparator|Cohort B: Placebo|Each patient will receive matching placebo as a single dose.
89681745|NCT01798745|Experimental|Cohort C: JNJ-54452840 for 3 days|Each patient will receive JNJ-54452840 once daily for 3 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
89681746|NCT01798745|Placebo Comparator|Cohort C: Placebo|Each patient will receive matching placebo once daily for 3 days.
89681747|NCT01798745|Experimental|Cohort D: JNJ-54452840 for 5 days|Each patient will receive JNJ-54452840 once daily for 5 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
89681748|NCT01798745|Placebo Comparator|Cohort D: Placebo|Each patient will receive matching placebo once daily for 5 days.
89051614|NCT04587609|No Intervention|Control - Standard UBI|Participants will continue to be monitored as a part of their standard UBI and receive educational material about distracted driving in the enrollment period
89051615|NCT04587609|Other|Free Phone mount|Participants in this arm will be monitored through standard UBI, receive educational material about distracted driving in the enrollment period, and free phone mounts
89681749|NCT01798745|Experimental|Cohort E: JNJ-54452840 weekly|Each patient will receive JNJ-54452840 once weekly on Days 1, 8, 15, and 22 at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
89681750|NCT01798745|Placebo Comparator|Cohort E: Placebo|Each patient will receive matching placebo once weekly on Days 1, 8, 15, and 22.
89681751|NCT01798745|Experimental|Cohort F: JNJ-54452840 multiple dose|Each patient will receive JNJ-54452840 once daily (for 3 or 5 days) or once weekly (up to Day 22) as determined by the Data Monitoring Committee and as explored in Cohorts C, D, and E (daily dose not exceeding 240 mg).
89681752|NCT01798745|Placebo Comparator|Cohort F: Placebo|Each patient will receive matching placebo once daily (for 3 or 5 days) or once weekly (up to Day 22).
89681753|NCT05496777|Other|Intervention arm|Patients planned for pancreatic resection will be included for a home-based prehabilitation program.
89681754|NCT00088010|Experimental|1|
89681755|NCT00088010|Placebo Comparator|2|
89681756|NCT03084380|Experimental|anti-GPC3 CAR-T|Transcatheter arterial chemoembolization (TACE) combine with GPC3-CART infusion
88996849|NCT03493750|Experimental|Oral and dental evaluation|"After application of the Healthplan guide, nurse statement of the need of dental care or not, making of an appointment to the dental practice and gift of a free bus ticket, if the patient is randomized in the experimental group, the nurse completes the evaluation with a mouth inspection in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface. At the end of this exam, the nurse has to state again if, from her/his point of view the patient needs dental care or not.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organised but outside this trial."
88996850|NCT00535210|Other|1|
88996851|NCT00535210|Other|2|
88996852|NCT03429946|Active Comparator|Hypoglycemia and Spironolactone|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of 100 mg of spironolactone - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
88996853|NCT03429946|Active Comparator|Hypoglycemia and Placebo|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
88996854|NCT03429946|Placebo Comparator|Euglycemia and Placebo|Participants undergo two 120-minute euglycemic hyperinsulinemic clamp procedures (90 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
88996855|NCT00189930|Active Comparator|1|High dose
88996856|NCT00189930|Active Comparator|2|Low dose
88996857|NCT00189930|Placebo Comparator|3|
88996858|NCT00158132|Experimental|Propranolol|Propranolol 100mg/day in 3 divided doses
88996859|NCT00158132|Experimental|Amantadine|Amantadine 100mg three times daily
88996860|NCT00158132|Experimental|Propranolol and Amantadine|Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily
88996861|NCT00158132|Placebo Comparator|Placebo|Identical Placebo pills
88996862|NCT00158171|Experimental|1|Nicotine patch
88996863|NCT00158171|Experimental|2|Nicotine gum
88996864|NCT00158171|Placebo Comparator|3|Folic acid
88996865|NCT03457207|Experimental|combined minilaparotomy- laparoscopy approach|women undergo the new technique of surgical treatment of endometriomas of the ovary
88996866|NCT00535522|Experimental|TAK-285|
88996867|NCT00535561|Active Comparator|1|Oral iron treatment only- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
88996868|NCT00535561|Active Comparator|2|Oral iron plus levothyroxine treatment- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
88996869|NCT00158327|Experimental|1|Participants will receive telephone-based collaborative care
88996870|NCT00158327|Active Comparator|2|Participants will receive usual care
88996871|NCT00158366|Experimental|1|Phase 1 participants who will receive behavioral training for 14 weeks
88996872|NCT00158366|Active Comparator|2|Phase 1 participants who will receive social skills training for 14 weeks
88996873|NCT00158366|Experimental|3|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training alone for 24 months in Phase 2
88996874|NCT00158366|Experimental|4|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training plus biweekly booster treatments for 24 months in Phase 2
88996875|NCT03139318|Experimental|GRID Radiotherapy|Patients will be treated with GRID Radiotherapy
88996876|NCT00183261|Experimental|1|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26
89681757|NCT00586001|Experimental|1|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders The UP is a form of transdiagnostic cognitive-behavioral therapy (CBT) for individuals diagnosed with anxiety disorders, depression and related disorders.
89681758|NCT00586001|No Intervention|2|Wait-list control: Participants were asked to wait 16 weeks before receiving treatment.
89681759|NCT02986737|Experimental|ACURATE neo™ and ACURATE TA™ LP|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System
89681760|NCT03080792|Experimental|Exercise|Exercise Intervention, moderate to high-intensity endurance and resistance exercise
89051616|NCT04587609|Other|Commitment + Habit tips|Participants in this arm will receive educational material about distracted driving during the enrollment period, be sent a free phone mount with installation instructions, sign a personalized commitment contract to reduce their phone use, set personal phone use reduction goals, and be sent personalized habit tips framed to help them reduce their handheld phone use while driving;
89051617|NCT04587609|Other|Habit Formation + Social Gamification|Participants in this arm will will receive all treatments assigned to arm 3, plus social gamification feedback, where each week participants are told if they've reach their weekly handheld phone use while driving reduction goal, and receive or lose points based on whether or not they met their goal. Based on their points participants can either move up or down a level. Each week the participants will also be sent a leader board of their ranking within their group.
89216156|NCT05002270|Experimental|Experimental: Arm B, JAB-21822 combination with Cetuximab, Phase 2, Dose Expansion|JAB-21822 will be administered together with Cetuximab in mCRC patients to evaluate the preliminary antitumor activity.
89681761|NCT02986815|Experimental|[11C]Acetate Brain Imaging|[11C]Acetate will be administered The patient will have one intravenous line placed prior to [11C]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which [11C]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.
89681762|NCT03084068|Experimental|Human umbilical cord allograft|Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft
89681763|NCT03084068|Placebo Comparator|Placebo Control|Open Rotator Cuff Repair with standard suture repair
89681764|NCT00611897|Active Comparator|Arm I|The NAC capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after NAC administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
89681765|NCT00611897|Placebo Comparator|Arm II|The placebo capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after placebo administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
89681766|NCT04401644|Experimental|primary arm|There will only be one set of participants with each participants samples and results as the comparator groups. There will be within group comparison of methods of detection of virus by two test methodologies. Post hoc validation of test performance against reference set.
89681767|NCT03080714||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
89681768|NCT03080714||Subjects presenting with Retinal Disease|Subjects with Retinal diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
89681769|NCT03080714||Subjects presenting with Glaucoma|Subjects with Glaucoma will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
89681770|NCT03080324|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
89681771|NCT03080324|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
89681772|NCT03080558|Experimental|endometriosis recto vaginal node|
89681773|NCT03083834|Experimental|healthy subjects|low-dose cosyntropin stimulation test
89681774|NCT03083834|Experimental|hypoadrenal mitotane treated patients|low-dose cosyntropin stimulation test
89681775|NCT03083834|Experimental|hypoadrenal no-mitotane treated patients|low-dose cosyntropin stimulation test
89681776|NCT04761380||stable COPD subjects|
89681777|NCT04761380||age-matched control subjects subjects who did not have any pulmonary disease|
89681778|NCT03402230|Experimental|Arm I (Avmacol lower dose, Avmacol higher dose)|Participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
89681779|NCT03402230|Experimental|Arm II (Avmacol higher dose, Avmacol lower dose)|Participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
89681780|NCT02780609|Experimental|Selinexor Plus HDM HCT|The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; fosaprepitant at 150 IV on days -3 and -2 will be given to patients an an antiemetic.Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.
89681781|NCT05345912|Experimental|Cohort 1|Subjects received 125 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 125 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
89681782|NCT05345912|Experimental|Cohort 2|Subjects received 250 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 375 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
89681783|NCT05345912|Experimental|Cohort 3|Subjects received 125 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 750 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
89681784|NCT03089918|Experimental|Part A (Healthy Adult Male Participants)|Participants will receive intravenous (IV) injection with 370 megabecquerel (MBq) 11C-JNJ-63779586 on Day 1 of Part A.
89681785|NCT03089918|Experimental|Part B (Mild AD and Healthy age- and Gender-Matched Controls)|Participants will receive single IV injection of 11C-JNJ-63779586 on Day 1 of Part B followed by saline flush. During Part B, the dose may be reduced based on whole body dosimetric findings and image quality seen in Part A.
89681786|NCT03080090|Experimental|High Intensity Exercise|Individuals in this condition will engage in aerobic exercise 3 times a week for 25 minutes each at 60% to 85% of age-predicted HRmax and smoking cessation intervention through a national quitline while using nicotine replacement patches.
89681787|NCT03080090|Active Comparator|Low Intensity Exercise|The intervention procedures for this group are identical to the Experimental Group group except that the target training intensity will be low intensity exercise, self-selected at 20% to 40% of age-predicted HRmax.
89681788|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 5g|plant-based protein hydrolysate 1 (5g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times per day for 12-weeks
89681789|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 10g|Plant-based protein hydrolysate 1 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
89681790|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 15 g|Plant-based 1 protein hydrolysate (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
89681791|NCT03083600|Placebo Comparator|Placebo|Cellulose Placebo stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks.
89681792|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 5g|Plant-based protein hydrolysate 2 (5 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
89681793|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 10g|Plant-based protein hydrolysate 2 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
89681794|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 15g|Plant-based protein hydrolysate 2 (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
89681795|NCT03402152|Experimental|NRX-101 vs. Placebo|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral placebo and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
89681796|NCT03402152|Experimental|NRX-101 vs. lurasidone HCl|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral lurasidone and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
89681797|NCT03083522|Experimental|OJS group|admission to Ojeok-san granule
89681798|NCT03083522|Placebo Comparator|Placebo Group|admission to placebo
89681799|NCT05346380|Experimental|During Minimally Invasive Pulmonary Segmentectomy (Group 2)|
89681800|NCT05346380|Experimental|During Minimally Invasive Esophagectomy (Group 1)|
89681801|NCT03084926|Experimental|MP0274|
89681802|NCT03087110|Experimental|Cord blood infusion|Matched sibling donor cord blood cell infusion
89681803|NCT03080246|Active Comparator|Strength Training Group|This group will begin coming to the Clinical Research Center (near the undergraduate campus of Wake Forest University) for exercise classes 2-3 days per week for about an hour each day. The investigators also have a site on High Point University's campus. The class will consist of a 10-minute warm-up, a 20-minute strength training period, 15-minutes of neuromuscular (balance/coordination) training, and a 15-minute cool down. These regular exercise classes at Wake Forest and High Point University will go on for 9 months, followed by another 9 months of option to continue at facility, plus follow-up via email and 2 group meetings/runs at Fleet Feet (at around months 12 and 15).
89216157|NCT04995588|Other|Blood test|Unique blood test for all the participants included in the study to constitute a local biobank to assess in a grouped manner the prespecified outcomes
89216158|NCT04989647|Experimental|A: Surgery only|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*. No further treatment will be administered.~*PLND can be avoided in patients with tumours < 4cm"
89216159|NCT04989647|Experimental|B: Surgery + radiothrerapy|"Radical hysterectomy, sentinel lymph node biopsy and systematic pelvic lymphadenectomy (PLND)*, followed by adjuvant treatment.~*PLND can be avoided in patients with tumours < 4cm"
89216160|NCT04967365||Case patients|500 patients who experience greater than or equal to 3 nights in a pediatric ICU with intensive care instrumentation.
89216161|NCT04967365||Control patients|250 patients who experience an overnight stay in a pediatric ICU without intensive care instrumentation.
89681804|NCT03080246|No Intervention|Running Group|This group will be observed as they follow their usual run-training routine over the course of 18 months. Emails will be sent biweekly for 18 months to update the research team on injury/training status. The group will attend 5 group meetings/runs at Fleet Feet (at around months 1, 3, 6, 12, and 15). After the 18 months, the participants will be offered a free 8-week strength training program at the Clinical Research Center or High Point University.
89681805|NCT00613379|Experimental|Arm 1|10 mg/kg PRO 140, one IV dose (N=10)
89681806|NCT00613379|Experimental|Arm 2|5 mg/kg PRO 140, one IV dose (N=10)
89681807|NCT00613379|Placebo Comparator|Arm 3|Placebo, one IV dose (N=10)
88996877|NCT00183261|Placebo Comparator|2|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26
88996878|NCT05265481|No Intervention|Baseline|In this phase, the investigators will not apply any venodilation method.
88996879|NCT05265481|Active Comparator|Tourniquet applied|The investigators will apply a blood pressure cuff tourniquet inflated to 60 mmHg pressure.
88996880|NCT05265481|Active Comparator|Tourniquet plus manual tapping|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg plus tapping directly over the vein manually.
88996881|NCT05265481|Experimental|Tourniquet plus device tapping|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg plus tapping directly over the vein with a massage device.
89216162|NCT04965064|Experimental|Experimental: Capecitabine and Neratinib.|"Neratinib 240 mg PO QD Daily On-going~Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going"
89216163|NCT04964323||PK Deficiency Diagnosed|Participants previously diagnosed with PK deficiency in Study AG348-C-008 (NCT03481738), will receive routine clinical care.
89681808|NCT03088592|Other|Deep Brain Stimulation|After informed consent is obtained, the patients will undergo routine DBS pre-operative evaluation and diagnostic testing. This includes a pre-operative 3T-MRI with and without gadolinium as well as pre-operative medical clearance by the patient's PCP or general practitioner and/or other medical specialist if necessary. They will also receive a baseline clinical evaluation including both motor function (Unified Parkinson's Disease Rating Scale on and off anti-parkinsonian medication) quality of life assessment (Parkinson's disease Questionnaire-39) and a full neuropsychological evaluation, if not already completed as part of the routine DBS candidacy evaluation within 2 months of surgery. Subjects will have medical clearance from their specialists and be be evaluated by an internal medicine physician prior to surgery and cleared to proceed.
89216164|NCT04952584|Experimental|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~Dose Level 1: 1 × 10^8 CD30.CAR-EBVST cells~Dose Level 2: 4 × 10^8 CD30.CAR-EBVST cells~Dose Level 3: 1 × 10^9 CD30.CAR-EBVST cells"
89216165|NCT04938024|Experimental|People with hyperuricemia (HU) or gout without urate-lowering therapy (ULT)|Participants with HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
89216166|NCT04938024|Experimental|People with hyperuricemia (HU) or gout with urate-lowering therapy (ULT)|Participants with HU or gout who are treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
89216167|NCT04938024|Active Comparator|People without hyperuricemia (HU) or gout without urate-lowering therapy (ULT)|Participants without HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
89216168|NCT04912895|Experimental|SARS-CoV-2 Positive|Participants who test positive for SARS-CoV-2 with the Polymerase Chain Reaction (PCR) test.
89216169|NCT04912895|Active Comparator|Non-COVID-19 Acute Respiratory Illness|Participants who have an acute respiratory illness other than SARS-CoV-2 infection.
89216170|NCT04912895|Other|Healthy Controls|Participants without any acute respiratory illness.
89681809|NCT03080168||Actigraph|"All participants will wear an Actigraph (monitoring device) for the duration of their inpatient stay.~NOTE: In clarification, for both this section and Section 4, this devices is an FDA-regulated monitoring device, but NOT an Intervention in this study."
89216171|NCT04899778|Experimental|Oral Contraceptive Pill|Oral contraceptive, 1/day, for one year
89216172|NCT04899778|No Intervention|No Oral Contraceptive|No intervention
89681810|NCT01271725|Experimental|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
89681811|NCT01271725|Experimental|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
89681812|NCT01271725|Experimental|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
89681813|NCT00587483|Active Comparator|Lidocaine 1.5 mg /kg|Lidocaine is a class I (sodium channel block) antiarrhythmic drug.
89681814|NCT00587483|Active Comparator|Amiodarone 300 mg|Amiodarone is used to treat and prevent certain types of serious, life-threatening ventricular arrhythmias (a certain type of abnormal heart rhythm) when other medications did not help or could not be tolerated. Amiodarone is in a class of medications called antiarrhythmics. It works by relaxing overactive heart muscles.
89681815|NCT00587483|Placebo Comparator|placebo (saline)|
89681816|NCT04279886|Other|Three-dimensional scan arm|
89681817|NCT03401060|Experimental|Experimental medication 1|Denosumab 60 mg subcutaneously injection with prefilled syringe
89681818|NCT03401060|Placebo Comparator|Experimental medication 2|NaCl 0.9%, 20ml phial, solution for injection
89681819|NCT05247437|Experimental|FitD full version|
89681820|NCT05247437|Active Comparator|Digital Self-Help|
89216173|NCT04892706|Experimental|IDP-126 Gel|
89216174|NCT04892706|Placebo Comparator|IDP-126 Vehicle Gel|
89216175|NCT04892706|Active Comparator|Epiduo® Forte Gel|
89216176|NCT04880772|No Intervention|Standard care|Standard Care: Surgery school as per ELHT pre-operative guidelines (includes generic pre-operative information, advice and optimisation e.g correction of anaemia)
89216177|NCT04880772|Experimental|Prehabilitation|Surgery School plus Moderate intensity exercise & Forceval (multivitamin)
89216178|NCT04872517|Experimental|34 head and neck cancer patients, expected to proceed chemotherapy or radiotherapy in hospital.|Total 34 anticipants will recruit in this research. Age was limited between 20years old to 75 years old. All of anticipants agree to join this trail and be followed through treatment , and without underlying disease that threaten life.
89216179|NCT04862208|Experimental|Carbohydrate-based breakfast + exercise|maltodextrin
89681821|NCT01270321|Experimental|Arm A (Everolimus alone)|CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression
89681822|NCT01270321|Experimental|Arm B (Pasireotide alone)|CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression
89681823|NCT01270321|Experimental|Arm C (Everolimus + Pasireotide)|CURRENTLY CLOSED TO ACCRUAL
89681824|NCT01271023|Experimental|Closed-Loop Control|The Control to Range algorithm will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
89216180|NCT04862208|Experimental|Protein-based breakfast + exercise|whey
89216181|NCT04862208|Experimental|Fasted breakfast + exercise|water
89216182|NCT04862208|Sham Comparator|Carbohydrate-based breakfast + no exercise|maltodextrin
89216183|NCT04860128|Experimental|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
89681825|NCT03086486|Experimental|1200mg L x 26 weeks + Pa + B|2 linezolid 600 mg active tablets once daily for 26 weeks plus 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
89681826|NCT03086486|Experimental|1200 mg L x 9 weeks + Pa + B|2 linezolid 600 mg active tablets once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
89681827|NCT03086486|Experimental|600 mg L x 26 weeks + Pa + B|1 linezolid 600 mg active tablet once daily for 26 weeks, 1 placebo linezolid 600 mg tablet once daily for 26 weeks, 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
89681828|NCT03086486|Experimental|600 mg L x 9 weeks + Pa + B|1 linezolid 600 mg active tablets once daily for 8 weeks, 1 placebo linezolid 600 mg half tablet once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks
89681829|NCT00614315|Experimental|FLAIR Endovascular Stent Graft and Delivery System|
89681830|NCT02287779|Experimental|SHP626|9/12 subjects -1x daily dose of 20mg for 12 days 9/12 subjects-1x daily dose of 40mg for 12 days 9/12 subjects-1x daily dose of 80mg for 12 days 9/12 subjects-1x daily dose of 120mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-1x daily dose of 160mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD) for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD; lower or higher than cohort 6) for 12 days 9/12 subjects-1x or 2x daily dose of SHP626 in an escalating titration (doses TBD). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days 9/12 subjects will take a 1x or 2x daily dose of SHP626 in escalating titration (doses TBD; lower or higher dose than cohort 8). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days
89681831|NCT02287779|Placebo Comparator|Placebo|Three subjects per cohort will take a matched placebo
89681832|NCT00732901|Experimental|A (escitalopram)|Escitalopram
89681833|NCT00732901|Experimental|B (placebo)|Placebo
89681834|NCT03083210|Experimental|Lanreotide|Lanreotide, at a dose of 120mg will be administered without dose adjustment, by means of deep subcutaneous injection every 28 days.
89681835|NCT05738265||Shocked patients who take crystalloids|Impact of crystalloids on shocked patients in trauma
89681836|NCT05738265||Shocked patients who take colloids|Impact of colloids on shocked patients in trauma
89681837|NCT05689034|Active Comparator|Azvudine|Azvudine in Patients at Potential Risk of Progressing to Severe COVID-19 Infection
89681838|NCT05689034|Placebo Comparator|Placebo|Placebo in Patients at Potential Risk of Progressing to Severe COVID-19 Infection
89681839|NCT00616109|Experimental|Maintenance Sunitinib|"Main interventional arm of study. Subjects who received maintenance sunitinib experimentally on this study were from a population of (consenting) patients with histologically or cytologically documented Extensive-State Small Cell Lung Cancer (ES-SCLC) who did not progress (were classified as Complete Response or CR, Partial Response or PR, or Stable Disease or SD) after an induction chemotherapy (Cisplatin and etoposide)"
89681840|NCT02330523|Active Comparator|allograft + x-link collagen membrane|Demineralized freeze-dried allograft + x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
89681841|NCT02330523|Active Comparator|xenograft + non-x-link collagen|Xenograft + non-x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
89681842|NCT05688878|Experimental|Experimental group|An exploratory-descriptive qualitative study will be conducted . This study will be conducted with 10 stroke patients receiving threshold electrical stimulation therapy. Threshold electrical stimulation will be applied for 4 weeks, 3 days a week, for one hour. At the end of the 4th week, semi-structured focus group interviews will be held with the patients. . In the semi-structured focus group interviews, the same questions will be asked to all participants and the verbal answers to these questions will be recorded with voice recorders. Compared to taking notes by hand; It will be preferable to record the conversation with a voice recorder because it has advantages such as recording all the interviews and allowing the interviewer to focus on the interview. Thematic analysis method will be used in the evaluation of the data.
89051618|NCT04587609|Other|All + Contest Financial Incentive|Participants in this arm will receive all of the treatments of arm 4 plus be entered into a financial incentive contest where they can either finish in the highest level and split the prize money amongst all participants that reached that level, and the safest driver (driver ranked #1 on the leader board of their group) will receive a small weekly financial prize.
89051619|NCT04619381||African Americans with Coronary Artery Disease|African Americans with Coronary Artery Disease and currently taking clopidogrel
89681843|NCT03390764|Active Comparator|4:1 closure group|Patients randomized to and receiving the intervention small stitch 4:1 technique for closure of the abdominal wall.
89681844|NCT03390764|Active Comparator|RTL plus 4:1 closure group|Patients randomized to and receiving the intervention reinforced tension-line suture plus small stitch 4:1 technique for closure of the abdominal wall.
89051620|NCT00568464|Experimental|A|
89051621|NCT04618835||Emergency presentations|Patients discharged after a presentation to practitioners in the community, primary and secondary care.
89051622|NCT04587063|Active Comparator|Standard Email|"The standard of care email is the same as one used in prior outreach efforts at the health system, emphasizing reduced cost for medications and convenience."
89051623|NCT04587063|Experimental|Email with Healthcare Cost Savings|The email emphasizes future reductions in healthcare costs due to increased adherence with mail-order pharmacy, in addition to mentioning reduced prices for medications. It also uses fear appeals by stating the risk of hospital stays and how mail-order pharmacy could be an easily-achievable way to avoid this negative consequence.
89216184|NCT04860128|Experimental|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
89216185|NCT04860128|Experimental|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
89216186|NCT04860128|Experimental|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
89216187|NCT04860128|No Intervention|Control Group|They will not use any type of sports technology application. They will continue to perform their daily activities without intervention.
89216188|NCT04858789|Experimental|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|The experimental group will receive an 8-session CA-CBI in an online group format.
89216189|NCT04858789|No Intervention|Control|The control (care as usual) group will receive the information about freely available psychological support options. After all the measurements are completed, the control group will be able to receive CA-CBI, too.
89216190|NCT04857658|Active Comparator|extraction treatment|patients will be referred for extraction of the upper and lower first premolars to relieve the crowding.
89216191|NCT04857658|No Intervention|non-extraction treatment|Leveling and alignment of the moderate crowding will be performed through a recall visits of 4 weeks for wire activation. inter-proximal reduction step might be done if needed.
89216192|NCT04855903|Experimental|Arm 1 (early phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 3 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 5 weeks"
89216193|NCT04855903|Experimental|Arm 2 (mid phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 4 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 4 weeks"
89216194|NCT04855903|Experimental|Arm 3 (late phase B)|"2 phases of cognitive training: Phase A : rehabilitation program in standard ergotherapy during 5 weeks Phase B : cognitive training using Covirtua Cognition software during 4 weeks~These 2 phases will be followed by a follow-up phase during 3 weeks"
89216195|NCT04843982|Experimental|esketamine plus propofol|"After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).~After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days."
89681845|NCT04761536||A|patients undergoing ARR with primary anastomosis between November 2016 and December 2020 after centralization of rectal cancer cases
89681846|NCT04761536||B|patients undergoing ARR with primary anastomosis between January 2006 and October 2016
89681847|NCT00249769|Experimental|LJEV then MV|Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.
89681848|NCT00249769|Experimental|LJEV and MV|Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.
89681849|NCT00249769|Experimental|MV then LJEV|Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.
89681850|NCT05688800|Active Comparator|Control group|Each participant include 22 participants will receive conventional physical therapy treatment including TENS, continuous ultrasound ,infra-red radiation and combined stretching and strengthening exercise
89216196|NCT04843982|No Intervention|propofol|After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).
89216197|NCT04836390|Experimental|Treatment Arm|All subjects will receive NK infusions.
89216198|NCT04833699|No Intervention|Control|Group A or the control group did not pick up any therapy except our clinical standard postoperative care (ERAS protocol)
89216199|NCT04833699|Experimental|Study|Group B served as the hot pack group boiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol).
89216200|NCT04827940|Experimental|intervention arm|"Data from the study was collected during the implementation of the Nursing Surgical Diseases class. Students who completed the 4-hour training program on sleep, relaxation exercises and survey practice have been pollsters of the study.~Relaxing music for sleep, prepared by the Turkish Psychological Association, is uploaded to patients' mobile phones. Patients were asked to perform relaxation exercises for a week at bedtime, lasting an average of 30 minutes, and with music every day, taking advantage of nurse observation at the clinic with the patient's declaration in check. Students who took part in the practice served as reminders of patients' compliance with the exercises."
89216201|NCT04827940|Other|Control arm|Those who did not do progressive muscle relaxation exercises or did not practice regularly for a week constituted the control group.
89216202|NCT04824599|Active Comparator|PECS+subcutaneus local anesthetic infiltration|Preoperative ultrasound-led PECS II blockade with ropivacaine 3,75mg/ml (2mg/kg). After surgery - wound infiltration by the surgeon with ropivacaine 2mg/ml (1mg/kg).
89681851|NCT05688800|Experimental|Experimental group 1 :pressure release technique|Each participant include 22 participants will receive the conventional physical therapy treatment in addition to pressure release technique
89681852|NCT05688800|Experimental|Experimental group 2: thoracic spine manipulation|Each participant include 22 participants will receive the conventional physical therapy treatment in addition to thoracic spine manipulation
89681853|NCT03083054|Experimental|Patients|High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
89681854|NCT00249613|Experimental|Women-Only|Substance abuse treatment program for women only
89681855|NCT00249613|No Intervention|Mixed-Gender|Substance abuse treatment program for both women and men
89216203|NCT04824599|Active Comparator|Local anesthetic infiltration|Prior to scrubbing surgeon infiltrates the thought incision area with ropivacaine 3,75/ml (1mg/kg). Perioperatively after removal of the tumor follows the deep infiltration of the wound with ropivacaine 3,75mg/ml (2mg/kg).
89216204|NCT04817800|Experimental|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|
89216205|NCT04817800|Experimental|100 μg Beclomethasone dipropionate, Nasal Spray|
89681856|NCT03082820||Patients|Pain-related evoked potentials (PREP), Quantitative Sensory Testing (QST) and nerve conduction studies (NCS) were performed with patients with peripheral nerve injury.
89681857|NCT03082820||Controls|Pain-related evoked potentials (PREP) and Quantitative Sensory Testing (QST) were performed with healthy adults.
89681858|NCT00733135|Other|Atherectomy with embolic protection|All subjects were treated with atherectomy (with SilverHawk or TurboHawk device) in conjunction with embolic protection (SpiderFX device).
89681859|NCT05688722|Placebo Comparator|Control|Patient positioned in supine conventional position
89681860|NCT05688722|Active Comparator|20 degree head elevation|Patient positioned in 20 degree head elevation position
89681861|NCT05688722|Active Comparator|30 degree head elevation|Patient positioned in 30 degree head elevation position
89681862|NCT05688722|Active Comparator|45 degree head elevation|Patient positioned in 45 degree head elevation position
89681863|NCT05688644||Neurogenic Patients|Patients with underlined relevant neurologic condition, with either neurogenic bladder or bowel, after advanced evaluation of InterStim II
89681864|NCT05688644||Idiopathic|Patients without underlined relevant neurologic condition, after advanced evaluation of InterStim II
89681865|NCT05736627|Experimental|Online setting|Research course delivered digitally (Zoom or Teams meeting rooms) at a distance.
89681866|NCT05736627|No Intervention|Onsite setting|Research course delivered physically in educational facilities.
89681867|NCT00617981|Experimental|1|ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
89681868|NCT00617981|Sham Comparator|2|Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
89681869|NCT05688566|Experimental|zero condition|Then the pedal angle is the angle between the lowest pedal position and the floor. The zero condition is 0 ˚of pedal angle.Participants were asked to step with the consistent cadence at 60 steps/ min by the metronome.Three successful trials will be collected for each condition. Fifteen seconds of data will be collected for each trial.
89681870|NCT05688566|Active Comparator|eversion codition|Then the pedal angle is the angle between the lowest pedal position and the floor. The eversion condition is -10 ˚of pedal angle.Participants were asked to step with the consistent cadence at 60 steps/ min by the metronome.Three successful trials will be collected for each condition. Fifteen seconds of data will be collected for each trial.
89681871|NCT05688566|Active Comparator|inversion condition|Then the pedal angle is the angle between the lowest pedal position and the floor. The inversion condition is +10 ˚of pedal angle.Participants were asked to step with the consistent cadence at 60 steps/ min by the metronome.Three successful trials will be collected for each condition. Fifteen seconds of data will be collected for each trial.
89681872|NCT03837873|Experimental|DLCL002 protocol|Patients will receive R-DA-EDOCH(rituximab, etoposide, dexamethasone, vincristine, cyclophosphamide, doxorubicin) as induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP(rituximab, lenalidomide(only for patients with non-GCB DLBCL), dexamethasone, cisplatin, cytarabine). Patients who achieved CR+good PR(Deauville score 4) after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville score 5) will receive other rescue treatments.
89681873|NCT03082742|Active Comparator|Furosemide|Use of Furosemide, 40mg (1 tablet) per day, over 12 months
89216206|NCT04817800|Active Comparator|RinoClenil® Nasal Spray (100 μg Beclomethasone Dipropionate)|
89216207|NCT04807218|Active Comparator|Nutritional Ketosis Intervention Referral|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
89216208|NCT04807218|Active Comparator|CHHS Standard Care - Delayed Referral to Nutritional Ketosis Intervention|All subjects will be enrolled in Colorado Heart Healthy Solutions (CHHS), which consists of community health worker (CHW) contact and sessions on: 1) cardiovascular disease knowledge; 2) Health behavior change through skill building to improve diet (e.g., portion sizes, increasing fruit/vegetable intake, reducing intake of sugar sweetened beverages, decreasing fast food meals, etc.), increase physical activity, and improve well-being, tailored to individual subjects' risk profile and self-identified goals; and 3) Connection to services including primary care, mental health services if needed, and relevant community programs to address barriers (e.g. food insecurity, need for legal help) or to promote behavior change (e.g. free/low cost exercise programs).
89216209|NCT04804813||Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 26 weeks. Participants received interventions as part of routine medical care.
89216210|NCT04802408|Active Comparator|Baby Shampoo Nasal Wash|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
89216211|NCT04802408|Active Comparator|Listerine Gargle|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
89216212|NCT04802408|Experimental|Combination of Baby Shampoo Nasal Wash and Listerine Gargle|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
89681874|NCT03082742|Active Comparator|Hydrochlorothiazide|Use of Hydrochlorothiazide, 25mg (1 tablet) per day, over 12 months
89681875|NCT05434533|Experimental|preoperative|1 gm of Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) 30 mins before the operation
89681876|NCT05434533|Experimental|uterine incision|1 gm of Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) directly before uterine incision
89681877|NCT05434533|No Intervention|placebo|1ml of normal saline will be given
89216213|NCT04802408|Placebo Comparator|Saline Wash and Gargles|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
89216214|NCT04776720|Experimental|Yoga Program|The 3-month yoga intervention provides instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
89216215|NCT04776720|Active Comparator|Physical Conditioning Program|The 3-month physical conditioning program provides instruction and practice in a variety of exercises and stretches that have been designed by the study physical therapist.
89216216|NCT04749693||Patient with HbA1c >= 8% despite the use of insulin pump and frequent glycemic control|only group included in the study
89216217|NCT04740593|Experimental|Group 1 - High refractive error: Intervention|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the intervention group
89216218|NCT04740593|Other|Group 2 - High refractive error: Control|Children with high refractive error (i.e. exceeding the AAPOS 2003 criteria) at age one, who are randomly assigned to the control group
89216219|NCT04740593|Other|Group 3 - Mild or no refractive error|Children with mild or no refractive error (i.e. not exceeding the AAPOS 2003 criteria) at age one
89216220|NCT04725890|Experimental|Intervention|All eligible participants will receive the DyaMX procedure.
89216221|NCT04712812||Proband with AP-4 Associated HSP|Male or female patients of all ages with (1) onset of hereditary spastic paraplegia symptoms before the age of 18 years and/or (2) the presence of variants in HSP related genes and/or a relative of a person with such a diagnosis.
89216222|NCT04712318|Other|ReLex Smile surgery|"The aim of this study is to investigate the effect of Relex Smile surgery to correct the residual refractive errors (myopic and hyperopic) 6 months after Trifocal IOL Implantation.~At myopic residual refraction (min -0.75 D) (100eyes) 6 months after Trifocal IOL Implantation we used Relex-Smile surgery for treatment."
89216223|NCT04712318|Other|ReLex Smile surgery-fresh corneal lenticule implantation|At hyperopic residual refraction 30 eyes 6 months after Trifocal IOL Implantation we used fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
89216224|NCT04694482||psychiatric patients|Psychometric scales
89216225|NCT04694482||healthy controls|Psychometric scales
89216226|NCT04693663|Other|ReLex Smile surgery|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was between -0.75D till -5.50D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(Viscot-Medster).
89216227|NCT04675151|Experimental|Nyxol + Pilocarpine|1 drop of Nyxol (Treatment 1) and 1 drop of Pilocarpine (Treatment 2)
89216228|NCT04675151|Active Comparator|Nyxol|1 drop of Nyxol (Treatment 1)
89216229|NCT04675151|Active Comparator|Pilocarpine|1 drop of Pilocarpine (Treatment 2)
89216230|NCT04675151|Placebo Comparator|Placebo|1 drop of Placebo (Treatment 1)
89216231|NCT04674670|Experimental|Healthy controls|In this arm, healthy controls will be administered placebo or a dopamine receptor agonist or a dopamine receptor antagonist on separate days to investigate the role of dopamine and fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
89216232|NCT04674670|Experimental|Fibromyalgia patients|In this arm, fibromyalgia patients will receive placebo or a dopamine receptor agonist to investigate the effects of normalizing dopamine transiently on fronto-striatal connectivity and BOLD response in relation to emotional-motivational pain processing.
89216233|NCT04666259|Experimental|Cohort A|40 mg asciminib orally twice daily (BID)
89216234|NCT04666259|Experimental|Cohort B|80 mg asciminib orally once daily (QD)
89216235|NCT04666259|Experimental|Cohort C|200 mg asciminib orally twice daily (BID)
89216236|NCT04659798||Participants with MM|Participants diagnosed with MM who have received treatment within 12 months preceding the enrollment will be observed prospectively. Data will be collected from the participants medical charts and via electronic case report forms (eCRFs).
89216237|NCT04659798||Participants with AL Amyloidosis|Participants diagnosed with AL Amyloidosis who have received treatment within 12 months preceding the enrollment will be observed prospectively. Data will be collected from the participants medical charts and via eCRFs.
89216238|NCT04639674|Experimental|AST-120|"sachet Three times a day. (2g/pack*3pack/box)~1 month"
89681878|NCT03432650|Experimental|QLB Block + Standard of Care|"Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.~Patients will receive a single shot anterior QLB (30cc 0.5% Bupivacaine with 2mg preservative free dexamethasone)."
89681879|NCT03432650|No Intervention|Standard of Care|Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.
89681880|NCT00248833|Experimental|1) 25ug Group B Meningococcal 44/76 MOS NOMV 5D w/o adjuvant|Subjects received 25ug Group B Meningococcal 44/76 MOS NOMV 5D without AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
89681881|NCT00248833|Experimental|2) 25ug Group B Meningococcal 44/76 MOS NOMV 5D with adjuvant|Subjects received 25ug Group B Meningococcal 44/76 MOS NOMV 5D with AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
89681882|NCT00248833|Experimental|3) 50ug Group B Meningococcal 44/76 MOS NOMV 5D w/o adjuvant|Subjects received 50ug Group B Meningococcal 44/76 MOS NOMV 5D without AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
89681883|NCT00668525|Active Comparator|2|Escitalopram low dose
89681884|NCT00668525|Experimental|3|Escitalopram high dose
89681885|NCT00668525|Placebo Comparator|1|Placebo
89681886|NCT03082508|Experimental|Algisyl|Algisyl device (implants) administered during a surgical procedure.
89216239|NCT04639674|No Intervention|Control|No intervention
89681887|NCT03082508|Active Comparator|Standard Medical Therapy|as per protocol
89681888|NCT01271101||anticoagulant|
89681889|NCT05688488|Experimental|Curcumin|
89681890|NCT05688488|Active Comparator|Mitomycin|
89681891|NCT05423457|Experimental|Vegan diet|"Participants were provided with and instructed to eat these foods:~flaxseed meal,~walnuts,~pecans,~extra-virgin olive oil,~Brazil nuts~Taiwanese purple laver (also known as hong-mao-tai or Bangia atropurpurea, and was selected to test for its vitamin B12 bioavailability).~Each Participant has three group sessions and three individual nutrition counseling with a dietitian."
89681892|NCT05423457|Active Comparator|MyPlate (Taiwanese version)|Each Participant has three group sessions and three individual nutrition counseling with a dietitian.
89681893|NCT00669383|Active Comparator|A|Betamethasone (Celestone) 12 mg intramuscular q 24 hours x 2 doses
89681894|NCT00669383|Placebo Comparator|B|Placebo dose intramuscular q 24 hours x 2 doses
89681895|NCT00733993|Experimental|1 Caffeine 150 mg|Caffeine 150 mg
89681896|NCT00733993|Placebo Comparator|2 Placebo|Placebo
89681897|NCT00733993|Experimental|3 Amphetamine|Amphetamine
89681898|NCT00733993|Experimental|4 Caffeine 300 mg|Caffeine 300 mg
89681899|NCT03089762|Experimental|SVF and PRP|
89681900|NCT03029559|Experimental|IH + ITL|Subjects will be exposed to a session of Intermittent hypoxia (IH) (45 minutes, 2 minutes of hypoxia alternating with 1 minute of hyperoxia) followed by 5 sets of Inspiratory threshold loading (ITL) at 80%MIP (10 breaths per set).
89681901|NCT03029559|Experimental|Intermittent hypoxia (IH)|Subjects will only be exposed to a session of intermittent hypoxia.
89681902|NCT03029559|Experimental|Sham IH + ITL|Sham Intermittent Hypoxia + Inspiratory threshold loading (ITL) subjects will be exposed to a single 45-minute session of sham IH (normoxia). This will consist of the subject breathing room air (FiO2=21%) through a 4 way valve connected to the hypoxicator. Exposure to normoxia will be followed by 5 sets of ITL at 80%MIP (10 breaths per set).
89681903|NCT03029559|Sham Comparator|Sham IH|Sham intermittent hypoxia subjects will be exposed to a single 45-minute session of sham IH alone.
89216240|NCT04629547|Experimental|Poor sleep treatment group|100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years
89681904|NCT04279808|Experimental|measured distance|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will measure the distance between the skin puncture site and the outside of anterior wall of the jugular vein. Next, we will insert the dilator on the guidewire by the measured length."
89681905|NCT04279808|No Intervention|conventional method|"In the modified Seldinger's maneuver, after guide-wire insertion into the right internal jugular vein, we will insert the dilator on the guidewire as commonly used method of the practitioners."
89681906|NCT00669539||Combined-Mechanism Amblyopia|
89681907|NCT00669539||Strabismus-Only Amblyopia|
89681908|NCT01271257|Experimental|hourly misoprostol|20 microgram misoprostol intake per hour
89681909|NCT01271257|Active Comparator|traditional misoprostol|80 microgram misoprostol intake per 4 hours
89681910|NCT03089294|Active Comparator|Group A|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 4 (12 sessions totally)
89681911|NCT03089294|Active Comparator|Group B|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 4 (12 sessions totally)
89681912|NCT03089294|Active Comparator|Group C|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 7 (12 sessions totally)
89681913|NCT03089294|Active Comparator|Group D|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 7 (12 sessions totally)
89681914|NCT04385329|Experimental|Experimental group:shock waves extended to gastrocnemius TrP|Focused shock wave therapy was extended from the plantar fascia to the gastrocnemius-soleus trigger points.
89681915|NCT04385329|Active Comparator|Control group: shock waves not extended to gastrocnemius TrP|A standard focused shock wave therapy exclusively targeted at the plantar fascia
89681916|NCT03082430|Other|knee osteoarthritis patients.|therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
89681917|NCT03082352|Experimental|BF-Metoprolol Tablet 100mg|During the study session, healthy subjects will be administered a single dose of BF-Metoprolol Tablet 100mg after an overnight fast of approximately 10 hours
89681918|NCT03082352|Active Comparator|Betaloc Tablet 100mg|During the study session, healthy subjects will be administered a single dose of Betaloc Tablet 100mg after an overnight fast of approximately 10 hours
89681919|NCT02290509|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
89681920|NCT02290509|Active Comparator|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
89681921|NCT03089450|Experimental|CGBIO stent (DES)|The Co-Cr biodegradable polymer DES Sirolimus DRUG Ascorbic Acid(Vitamin C)
89216241|NCT04629547|Placebo Comparator|Poor sleep control grop|100 participants will be randomized to take placebo daily at h.s. for two years.
89216242|NCT04628169||group A|group A : placental tissue of 30 patients with placenta accreta
89681922|NCT03089450|Active Comparator|Biomatrix flex(DES)|The abluminal biodegradable polymer DES BA9™ (BIOLIMUS A9™) DRUG
89681923|NCT03082274||Men age 40-85 years with an initial negative prostate biopsy|Men age 40 - 85 years of age Previous negative prostate biopsy within 30 months.
89681924|NCT04402034|Experimental|Application of tele-rehabilitation|Individuals that will perform the protocol of virtual reality intervention.
89681925|NCT03089528|Experimental|Videolaryngoscopy|the trachea will be intubated using a videolaringoscope
89681926|NCT03089528|Active Comparator|Direct laringoscopy|the trachea will be intubated using a laringoscope
89681927|NCT00618839|Experimental|StrataGraft : cadaver allograft|All patients enrolled received StrataGraft skin tissue and an intrapatient control area treated with cadaver allograft in a split-wound design
89681928|NCT03089372|Active Comparator|Group A|Patients will receive two sessions of LI-ESWT per week for a 3 week period (6 sessions totally)
89681929|NCT03089372|Active Comparator|Group B|Patients will receive one session of LI-ESWT per week for a 6 week period (6 sessions totally)
89681930|NCT03082040|Experimental|intervention group|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks
88996882|NCT05256667|Other|Root canal treatment in single visit - RCT-SV|Group 1- RCT-SV: Endodontic treatment in a single visit using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
88996883|NCT05256667|Other|Root canal treatment in two visits with intracanal dressing - RCT-TVWD|Group 2- RCT-TVWD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by intracanal dressing (calcium hydroxide powder, CPMC, glycerine) and temporary restoration (glass ionomer cement) for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
89051624|NCT04587063|Experimental|Email with Endorsement|The email is a letter from a doctor at the health system's health plan--who may been seen as a trusted source of information--encouraging the benefits of using a mail-order pharmacy.
89051625|NCT04587063|Experimental|Email with Comparison Table|The email includes a table comparing the benefits and drawbacks of mail-order and chain pharmacies, which appeals to their sense of agency and allows them to make the choice that best suits them.
89051626|NCT04587063|No Intervention|No Contact|Members do not receive an email.
89051627|NCT00562796||1|Participants with abdominal obesity without growth hormone deficiency
89051628|NCT00562796||2|Participants with abdominal obesity with growth hormone deficiency
89051629|NCT00562796||3|Participants who are lean controls
89051630|NCT00568503|Active Comparator|1|QAX028 high dose
89051631|NCT00568503|Placebo Comparator|2|Placebo
89051632|NCT00568503|Active Comparator|3|Tiotropium bromide
89051633|NCT00568503|Active Comparator|4|QAX028 medium dose
89051634|NCT00568503|Active Comparator|5|QAX028 low dose
89051635|NCT04619030|Experimental|Augmented Reality Leaflet|Patient Leaflet with Augmented reality component
89051636|NCT04619030|Active Comparator|Traditional Leaflet|Traditional leaflet without Augmented Reality component
89051637|NCT00568542|Active Comparator|1|35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
89051638|NCT00568542|Placebo Comparator|2|Placebo to erythropoetin beta.
89051639|NCT00568620|Experimental|1: Nasogastric feeding tube|
89051640|NCT00568620|Experimental|2: Placement of nasojejunal feeding tube|
89051641|NCT04587102|Active Comparator|whole body viberation :group A|will receive low vibrational training in the form of whole body vibration for 8 weeks
89051642|NCT04587102|Active Comparator|control group (B)|control
89051643|NCT04619147||Patients without invasive fungal infections (IFI)|This will be our control cohort. Most of the patients would have been on posaconazole prophylaxis.
89051644|NCT04619147||Patients with invasive fungal infections (IFI)|This will be the group that we will be interested in. IFI would be diagnosed based on EORTC/ MSG definitions, and most of them would have been on posaconazole prophylaxis. Underlying risk factors of acquiring IFI in this cohort of patients will be compared with that of the control cohort.
89051645|NCT00568659|Experimental|1|
89051646|NCT02940353|Other|Treatment with Trefoil concept|Treatment
89051647|NCT04587258||Breast Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using mammograms.
89051648|NCT04587258||Colorectal Cancer|Subjects will be encouraged through informational videos and social media campaigns to visit their doctors to get screened for breast cancer using colonoscopies
89051649|NCT00562835|Active Comparator|1|Methylprednisolone
89051650|NCT00562835|Placebo Comparator|2|
89051651|NCT04587180||Patients with cutting-through|Patients who had cutting-through during the lateral knotless anchor fixation.
89051652|NCT04587180||Patients without cutting-through|Patients who didn't have cutting-through during the lateral knotless anchor fixation.
89051653|NCT04587219|Experimental|Gam COVID Vac Vaccine|the test drug will be administered according to the prime-boost scheme: the introduction of component 1 (Ad26) will be carried out on the 1st day, and component 2(Ad5)- on the 21st day of the study.
89051654|NCT00568737|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
89051655|NCT00568737|Placebo Comparator|2|0.9% sodium chloride
89051656|NCT00562874|Experimental|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months.
89051657|NCT00562874|Active Comparator|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy flour as an ingredient for 5 days each week for 12 months.
89051658|NCT00562874|Sham Comparator|Wheat Biscuit|75 women and one of their children will receive a biscuit containing pm;u wheat flour as a source of protein as an ingredient for 5 days each week for 12 months.
89051659|NCT04587141|Experimental|Sucrosomial iron|One or two capsules/die of sucrosomial iron will be assumed by the participant, depending on hemoglobin (Hb) concentration and participant body weight, for 8 weeks. Each capsule contains 30 mg of iron.
89051660|NCT04587141|Active Comparator|Ferric gluconate|Ferric gluconate will be administered by iv infusion, 125 mg of elemental iron once or twice weekly for 4 or 8 weeks depending on Hb concentration and patient body weight.
89051661|NCT04587141|Active Comparator|Ferric carboxymaltose|Two or three iv infusions of 500-1000 mg of elemental iron will be given as ferric carboxymaltose, over a 4 week period. Dosage and number of infusions will be established depending on Hb concentration and patient body weight.
89681931|NCT03082040|Other|waiting-list control group|Participants in the control condition will conduct the same breathing training as the intervention group after a four-week waiting list period
89681932|NCT03089138|Experimental|Regan Tangjiang，Simulation Shufengjiere Capsules|
89681933|NCT03089138|Active Comparator|Simulation Regan Tangjiang，Shufengjiere Capsules|
89681934|NCT03089138|Placebo Comparator|Simulation Regan Tangjiang and Shufengjiere Capsules|
89681935|NCT03082118|Experimental|Vesair Arm|Subjects treated with the Vesair Bladder Control System at enrollment.
89681936|NCT03081962|Experimental|Bundle application|The patients in this group will undergo an intraperitoneal irrigation with clindamycin and gentamicin solution, fascial closure with triclosan impregnated sutures and application of Mupirocin ointment over the skin staples
89681937|NCT03081962|Active Comparator|Standard care|The patients in this group will follow a standard care, including decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
89681938|NCT05345756|Experimental|Intraoral Protraction Technique|using intraoral appliance composed of modified lingual arch and miniscrews for indirect anchorage for maxillary protraction after Alt-RAMEC protocol using hybrid expander
89681939|NCT05345756|Active Comparator|Extraoral Protraction Technique|using facemask for maxillary protraction after ALT-RAMEC protocol
89681940|NCT05736315|Experimental|Fermented dairy beverage|Concumption of 3 servings of the fermented dairy beverage a day, during oncological treatment.
89681941|NCT05736315|Placebo Comparator|Placebo|Consumption of 3 servings of the placebo dairy beverage a day, during oncological treatment.
89681942|NCT03088982||Lanmeur multimorbid patients|All multimorbid patients who met 12 FPs in the Lanmeur residential care home in the county of Finistere (in north-west France) from July 2014 to December 2014. These FPs were drawn from those physicians associated with the Lanmeur residential care home.
89681943|NCT03088904|Experimental|Group A: MZ twins (IIV4)|Group A: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89681944|NCT03088904|Experimental|Group B: DZ twins (IIV4)|Group B: Up to 40 healthy dizygotic (DZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), and Day 6-8 and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
89681945|NCT03088904|Experimental|Group C: MZ twins (IIV4 or LAIV4)|"Group C: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).~This group was terminated in 2016 due to ACIP recommendations against the use of LAIV but may be reopened in 2018 pending LAIV4 availability."
89681946|NCT04768491||dacomitinib treatment|Sequential Therapy with Dacomitinib as First-line Treatment Followed by 3rd generation EGFR-TKI in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
89681947|NCT05374863|Experimental|Experimental Group|Neuromuscular electrical stimulation (NMES) active in the upper limbs for 20 minutes and aerobic exercises on the cycle ergometer for 30 minutes.
89681948|NCT05374863|Placebo Comparator|Control Group|NMES-Sham in upper limbs for 20 minutes and aerobic exercises on a cycle ergometer for 30 minutes.
89681949|NCT03081572||Abacavir Group|HIV positive individuals currently taking an abacavir based regimen
89051662|NCT04619342|Experimental|GSMs-TACE+ Surgical Resection Group|After TACE using epirubicin and GSMs (150-350μm or 350-560μm), patients that meet certain criteria will receive surgical resection of PVTT, as specified per protocol.
89051663|NCT04619342|Active Comparator|GSMs-TACE Group|Patients will receive TACE using epirubicin and GSMs (150-350μm or 350-560μm), as specified per protocol.
89051664|NCT04586790|Experimental|midodrine group|midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine
89051665|NCT04586790|Experimental|minirin group|the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin
89051666|NCT04586790|Experimental|control group|the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
89051667|NCT00568815|Experimental|Chemo|
89051668|NCT00568893|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
89051669|NCT00568971|Experimental|weekly chemo|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
89051670|NCT02277405|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
89051671|NCT02277405|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89051672|NCT00562913|Experimental|Arm 1|
89051673|NCT00569088|Experimental|B|A combined treatment would be used in the arm.That means Chinese herb formula would be used with the current Modern Medicine therapy for stroke in this arm.
89051674|NCT00569088|Active Comparator|A|just the current Modern Medicine therapy for stroke would be available in the arm.
89051675|NCT02940158|Other|1/2 cup|1/2 cup serving size arm
89051676|NCT02940158|Other|1/4 cup|1/4 cup serving size arm
89051677|NCT00569244|Experimental|Arm 1|
89051678|NCT00569244|Active Comparator|Arm 2|
89051679|NCT03458156|Experimental|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
89681950|NCT03081572||Tenofovir Group|HIV positive individuals currently taking a tenofovir based regime
89681951|NCT03398252|Experimental|Doxazosin XL|Participants will receive increasing doses of doxazosin XL (0, 4, and 8 mg).
89681952|NCT03398252|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
89681953|NCT04402268||Low risk|Low risk of sudden cardiac death according to HCM Risk-SCD Calculator
89681954|NCT04402268||Intermediate risk|Intermediate risk of sudden cardiac death according to HCM Risk-SCD Calculator
89681955|NCT04402268||High risk|High risk of sudden cardiac death according to HCM Risk-SCD Calculator
89681956|NCT02285283|Placebo Comparator|Placebo|2 capsules by mouth twice a day for 24 weeks
89681957|NCT02285283|Active Comparator|Itraconazole|Two 100mg capsules by mouth twice a day for 24 weeks
89681958|NCT02285907|Experimental|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
89681959|NCT02285907|Experimental|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
89051680|NCT03458156|Experimental|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
89051681|NCT03458156|Experimental|the control group|The patients will be assigned to the control group.
89051682|NCT04586361|Experimental|Experimental group 1|Intraoperative1 kit of Platelet-rich plasma(PRP) injection into knee joint after anterior cruciate ligament (ACL) reconstruction.
89051683|NCT04586361|Experimental|Experimental group 2|Intraoperative1 kit of PRP+Hyaluronic acid(HA) injection into knee joint after ACL reconstruction.
89681960|NCT02285907|Experimental|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
89681961|NCT02285907|Experimental|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
89681962|NCT04402424||Two-Week Rule Colorectal Patients|Patients that the GP has referred to two-week rule colorectal clinics at Royal Surrey County Hospital with bowel symptoms or found to be anaemic
89681963|NCT03429140|Experimental|Group 1 - Gel-One|Gel-One (3ml/30 mg Hyaluronan) one time injection at visit 3
89681964|NCT03429140|Placebo Comparator|Group 1 - Saline Placebo|3 ml saline placebo one time injection at visit 3
89681965|NCT04768179|No Intervention|Arm1 (Control group)|standard of care
89681966|NCT04768179|Experimental|Arm 2|Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
89681967|NCT04768179|Experimental|Arm 3|3-day Ivermectin 600 mcg/kg/day/14-day 75mgASA/day + standard of care (Intervention 2)
89051684|NCT04586361|Placebo Comparator|Experimental group 3|Intraoperative 20 ml normal saline injection into knee joint after ACL reconstruction.
89051685|NCT04618952|Active Comparator|treatment|patients received calcium D
89051686|NCT04618952|Placebo Comparator|control|patients received placebo
89051687|NCT04619069|Active Comparator|Arm 1: Standard of Care|Intermittent Hormone treatment (minimum of 8 months)
89051688|NCT04619069|Experimental|Arm 2: SBRT to mets|"Intermittent Hormone treatment (minimum of 8 months)~+ SBRT to all sites of metastatic disease"
89051689|NCT00569361|Other|A|Collection of nasal epithelial cells by brushing
89051690|NCT02940275||Hypertension|
89051691|NCT02940275||Diabetes mellitus|
89051692|NCT02940275||Hypertension and diabetes mellitus|
89051693|NCT02940275||End stage kidney disease|
89051694|NCT02940275||Kidney transplant recipient|
89051695|NCT02940275||Coronary artery disease|
89681968|NCT03081494|Experimental|spartalizumab (PDR001) + regorafenib|Subjects with metastatic MSS CRC received a combination of spartalizumab and regorafenib.
89681969|NCT05658471|Experimental|Usual Brand E-Cigarette (EC) then SREC|Participants will be admitted to hospital research ward within 32 hours of the orientation visit and begin a standardized session of product use using the usual brand of e-cigarette that participants utilize for nicotine use, and will provide expired carbon dioxide samples, pharmacokinetic (PK) blood samples, urine samples, and have cardiovascular and vital signs monitored. Participants will also be asked to complete nicotine-related questionnaires. Participants will then return within 2 weeks to repeat the procedures using the SREC.
89051696|NCT02940275||Peripheral arterial occlusive disease|
89051697|NCT04580550|Other|Axial length variability|Aim of this study is to evaluate the magnitude of changes in pre and postoperative measurements of AL.
89051698|NCT04618640|Experimental|DTaP-IPV combination vaccine|DTaP-IPV 0.5ml IM boosting
89051699|NCT04586439|Experimental|Panel A: JNJ-73763989|Participants will receive single subcutaneous (SC) injection of low dose of JNJ-73763989 on Day 1.
89051700|NCT04586439|Experimental|Panel B: J NJ-73763989|Participants will receive single SC injection of high dose of JNJ-73763989 on Day 1.
89051701|NCT02940197|Experimental|restricted diet|Mediterrasian diet according to adjusted ideal body weight with 500 calorie restriction
89051702|NCT02940197|Experimental|Non restricted diet|Mediterrasian diet according to adjusted ideal body weight without 500 calorie restriction
89051703|NCT04585932|Active Comparator|Group I (apalutamide, leuprolide, degarelix)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
89681970|NCT05658471|Experimental|SREC then Usual Brand E-Cigarette (EC)|Participants will be admitted to hospital research ward within 32 hours of the orientation visit and begin a standardized session of product use using the SREC, and will provide expired carbon dioxide samples, pharmacokinetic (PK) blood samples, urine samples, and have cardiovascular and vital signs monitored. Participants will also be asked to complete nicotine-related questionnaires. Participants will then return within 2 weeks to repeat the procedures using the usual brand of e-cigarette that participants utilize for nicotine use.
89681971|NCT03081728|Experimental|block|will be given block and continuous infusion with bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
89681972|NCT03081728|Experimental|control|IV analgesia only with diclofenac and paracetamol
89681973|NCT05651217|Experimental|trial group|Patients in this group used the disposable urinary catheter
89681974|NCT05651217|Active Comparator|control group|Patients in this group used super smooth antibacterial urinary catheter
89681975|NCT02986971|Experimental|New IMD|Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
89681976|NCT05687864|Experimental|Polysaccharide superparamagnetic ferric oxide injection|Participants will receive one single dose of 1mg/kg or 2mg/kg or 3mg/kg or 4mg/kg or 5mg/kg of Polysaccharide superparamagnetic ferric oxide injection on Day 1.
89681977|NCT00618917|Experimental|Radiation + MnSOD PL + Paclitaxel + Carboplatin|MnSOD PL (0.3, 3, or 30 mg) + (Paclitaxel + Carboplatin (45mg/m^2)) + Radiation 1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
89681978|NCT05736081|Experimental|Intravitreal dexamethasone implant|All patients were included here and received one intravitreal dexamethasone implant 0.7mg
89681979|NCT00619073|Active Comparator|Clopidogrel + aspirin|The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.
89681980|NCT00619073|Placebo Comparator|Placebo + aspirin|The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.
89681981|NCT05687630|Experimental|Video-assisted group|
89681982|NCT05687630|Active Comparator|Traditional group|
89681983|NCT00620711|Experimental|1|Babies that meet criteria will be offered participation in feasibility trial, there are no other arms.
89681984|NCT05341869|Placebo Comparator|Control|Prior to starting surgery after general anesthesia, the 10 mL of normal saline was performed by the primary surgeon. The syringe was injected with 5 mL on each side into the cervical stroma at 3 and 9 o'clock with a depth of 2 to 3 cm.
89681985|NCT05341869|Experimental|Study|Prior to starting surgery after general anesthesia, thE 10 mL of 0.5% bupivacaine with epinephrine was performed by the primary surgeon. The syringe was injected with 5 mL on each side into the cervical stroma at 3 and 9 o'clock with a depth of 2 to 3 cm.
89681986|NCT04401722|Active Comparator|PD in normal altitude|PD underwent in the area at the level of the sea, normal altitude region
89681987|NCT04401722|Active Comparator|PD in high altitude region.|PD underwent in high altitude region.
89681988|NCT03081338||Study cohort|A mix of incident and prevalent patient cases will be included in order to capture patients at different stages of the disease trajectory.
89681989|NCT00670241|Active Comparator|1|
89681990|NCT00670241|Active Comparator|2|
89681991|NCT00670241|Placebo Comparator|3|
89681992|NCT03088670|Experimental|Gosogliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
89216243|NCT04628169||group B|group B : placental tissue of 30 normal pregnancy as a control group
89681993|NCT03088670|Active Comparator|Vildagliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
89681994|NCT03088358|Experimental|TeaRx 50 mg|TeaRx: 50 mg per day PO (active 25 mg + placebo 50 mg every 12 hours) during 12 days (±2 days)
89681995|NCT03088358|Experimental|TeaRx 100 mg|TeaRx: 100 mg per day PO (placebo 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
89681996|NCT03088358|Experimental|TeaRx 150 mg|TeaRx: 150 mg per day PO (active 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
89681997|NCT03088358|Active Comparator|Enoxaparin|Enoxaparin 40 mg subcutaneous per day (24 hours interval) during 12 days (±2 days)
89681998|NCT03081026||Ages less than 12|Those having ACL Reconstruction surgery during the desired dates at age 12 or less.
89681999|NCT03081026||Ages 12-13|Those having ACL Reconstruction surgery during the desired dates at ages 12 and 13.
89682000|NCT03081026||Ages 14 - 16|Those having ACL Reconstruction surgery during the desired dates at ages 14 - 16.
89682001|NCT00671177|Experimental|Water Immersion Colonoscopy|Water Immersion Colonoscopy
89682002|NCT00671177|Active Comparator|Standard Air Colonoscopy|Standard Air Colonoscopy
89682003|NCT03396068|Experimental|NRX-101|Subjects will be treated with oral NRX-101 (fixed dose combination of D-Cycloserine/lurasidone) that will be titrated to a combined dose of 950mg/66mg per day.
89682004|NCT03396068|Active Comparator|Lurasidone comparator|Subjects will be treated with oral lurasidone in a matched placebo capsule that will be titrated to a dose of 66 mg per day
89682005|NCT00620945|Experimental|1|Treatment Group
89682006|NCT00621179|Active Comparator|Group 1|Positive endometrial alpha v, beta 3 vitronectin expression. Standard controlled ovarian stimulation protocol followed by in vitro fertilization Intervention: No intervention
89682007|NCT00621179|Experimental|Group 2|Intervention: Positive endometrial alpha v beta 3 vitronectin expression, 3 months of leuprolide acetate in depot suspension administration prior to initiation of controlled ovarian stimulation followed by in vitro fertilization
89682008|NCT00621179|Experimental|Group 3|Negative endometrial alpha v, beta 3 vitronectin and administration of leuprolide acetate in depot suspension for 3 months prior to initiation of controlled ovarian stimulation
89682009|NCT00621179|Active Comparator|Group 4|Negative endometrial alpha v, beta 3 vitronectin expression and standard controlled ovarian stimulation protocol followed by in vitro fertilization. Intervention: No intervention
89682010|NCT00247273|Active Comparator|1|5 mg risedronate, once daily for 2 years
89682011|NCT00247273|Experimental|2|150 mg risedronate taken once a month for 2 years
89682012|NCT05685524||Cancer group|Patients aged 18 years or older with high suspicion of cancer diagnosed by endoscopy, other imaging tests, pathological examinations, etc. The cancer types include liver cancer, head and neck squamous cell carcinoma, esophageal cancer, pancreatic cancer, ovarian cancer, colorectal cancer, bladder cancer, cervical cancer, lung cancer and stomach cancer.
89682013|NCT05685524||Non-cancer group|Composed by healthy individuals and patients with non-cancerous diseases including hemorrhoids, enteritis, gastritis, tuberculosis and other non-cancerous diseases.
89682014|NCT05056233|Experimental|Systane Hydration|Systane Hydration lubricant eye drops dosed 4 times a day for 6 weeks (2 weeks prior to surgery and 4 weeks post surgery), with investigator defined post-operative standard of care
89682015|NCT05056233|No Intervention|No Treatment|Investigator defined post-operative standard of care
89682016|NCT00671723|Placebo Comparator|Normal saline|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
89682017|NCT00671723|Active Comparator|Hypertonic saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
89682018|NCT00671723|Active Comparator|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
89682019|NCT05685446|Experimental|175 ml ice water|Ingestion of 175 ml ice water 15 minutes prior to gastroscopy
89682020|NCT05685446|No Intervention|Fasting|Continued fasting
89682021|NCT01799681|Experimental|EXPERIMENTAL|a 4-week indoor and 4-week outdoor balance training with stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
89682022|NCT01799681|Active Comparator|CONTROL|an eight-week training on upper limb stretching and strengthening, hand agility exercise, knot tying and Chinese calligraphy
89682023|NCT02289105|Experimental|Mandatory active choice|The mandatory active choice group will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
89682024|NCT02289105|No Intervention|Control|Participants in the control group will be presented an AD form only and will be encouraged to complete, and submit the form without having to declare the choice of completing or declining the AD.
89682025|NCT01799759|Experimental|Online intervention for parent and child|Children complete 8 online modules of Project FUN Parents complete 6 modules of Project FUN for Parents
89682026|NCT01799759|Other|Instruments only|The waiting list control group only completes instruments and body composition, fitness measures
89682027|NCT00622427|Experimental|Ramelteon then placebo|8 mg tablets every night for 2 weeks, then a 2 week washout,then crossover to placebo tablets for 2 weeks.
89682028|NCT00622427|Experimental|Placebo then Ramelteon|placebo tablets for every night for 2 weeks, then a 2 week washout, followed by 8 mg tablets every night for 2 weeks.
89682029|NCT00622895|Experimental|Treatment: allogeneic UCB after reduced intensity conditioning|Patients receive fludarabine phosphate IV on days -4, -3 and -2, cyclophosphamide IV over 1-2 hours on days -6, -5, 3, and 4, and undergo low-dose TBI on day -1. Patients receive hematopoietic cell transplantation on day 0.
89682030|NCT00734305|Experimental|Dose Escalation|Cohorts of escalating doses of MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D
89682031|NCT01278823|Experimental|surgery|Surgery: laparoscopic roux en y gastric bypass operation
89682032|NCT01278823|Active Comparator|Medical treatment|Medical Treatment: Comprehensive medical management of diabetes including medications, diet intervention, lifestyle modification, exercise regimen
89682033|NCT01799291|Other|Treatment: Decision Making Tutorial|A brief presentation on mood disorders (i.e., Control condition) combined with the intervention (i.e., Treatment condition): a 20-minute training on decision-making errors and cognitive de-biasing strategies.
89682034|NCT01799291|No Intervention|Control|A brief presentation about mood disorders.
89682035|NCT00672737||Males at risk for OSA|"Males at risk for obstructive sleep apnea were invited to have a sleep study either at home or at Stanford Sleep Center.~A week after their sleep study (Polysomnography), all volunteers underwent quantitative sensory testing in the laboratory, during which their pain thresholds and tolerances to heat (Heat pain threshold and tolerance) and cold (Cold pain threshold and tolerance) stimuli were assessed, under two different concentrations (1 and 2 mcg/mL, in randomized order) of remifentanil, a short-acting opioid, given as a computer-controlled infusion."
89682036|NCT05687006|No Intervention|The CTA+CDU Group|Every patient included in the CTA+CDU group preoperatively underwent CT angiography of the abdominal wall. Based on the CTA examination XY coordinates of DIEA perforators localized within the area between 2 cm cranial and 10 cm caudal from the umbilicus and with a vessel calibre of more than 1 mm were determined. The day before the surgery, the main perforators were marked on the patient's abdomen according to the coordinates deducted from the CTA. These perforators were additionally examined using a LOGIQ S8/V1 CDU device with a linear transducer of frequency 4-11 MHz. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
89682037|NCT05687006|Experimental|The CDU Group|All patients included in the CDU group were examined a day before the surgery with the same CDU device by the same sonography surgeon as patients included in CTA + CDU group. During the examination, DIEA perforators were mapped and the following parameters were monitored: 1) XY coordinates of DIEA perforators localized within the area between 2 cm cranial and 10 cm caudal from the umbilicus and with a vessel calibre of more than 1 mm; 2) calibres of perforator arteries and veins; 3) PSV in the perforator artery [cm/s]; 4) velocity in the perforator vein [cm/s]; 5) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. The time duration of the CDU examination was measured.
89216244|NCT04620174|Other|Custom-made zirconia crowns Group|Ten decayed primary molars will be restored with custom-made zirconia crowns.
89216245|NCT04620174|Other|Prefabricated zirconia crowns Group|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
89682038|NCT00673127|Experimental|KHAD|Ketoconazole, Hydrocortisone and Dutasteride Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Dutasteride: 0.5 mg once a day
89682039|NCT01799837|Other|Healthy Controls|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
89682040|NCT01799837|Other|Veterans with PTSD|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
89682041|NCT00246259|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following initiation of Risperidone LAI, and for a maximum of 3 weeks following a dose increase.
89682042|NCT00246259|Active Comparator|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg. Participants will be switched to another oral therapy as per Investigator's discretion.
89682043|NCT04400786|Experimental|On-demand treatment|This group of 98 ankylosing spondylitis patients is prescribed with intermittent Imrecoxib (100mg.prn.po) according to the feeling of pain till 24 weeks. The sulfasalazine (500mg.tid.po) is used.
89682044|NCT04400786|Active Comparator|Continuous treatment|This group of 98 ankylosing spondylitis patients is prescribed with continuous Imrecoxib (100mg.bid.po) for 24 weeks. The sulfasalazine (500mg.tid.po) is used.
89051704|NCT04585932|Experimental|Group II (apalutamide, leuprolide, degarelix, RT)|Patients receive apalutamide PO QD on days 1-28 and ADT consisting of leuprolide IM every 12 weeks or degarelix SC every 4 weeks. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo RT between cycles 4-7 in the absence of disease progression or unacceptable toxicity.
89051705|NCT02940119|Active Comparator|Active PBMT|The volunteers received active phototherapy in each session.
89051706|NCT02940119|Placebo Comparator|Placebo PBMT|The volunteers received placebo phototherapy in each session.
89051707|NCT02939963|Experimental|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC
89051708|NCT02939963|Experimental|pressure support 7 cm H2O PEP 4 cm H2O then ATC|ventilator is set to pressure support ventilation mode at set pressure 7 cm H2O above PEEP level of 4 cm H2O
89682045|NCT00624221|Active Comparator|1|An Eye bank pre-cut the donor grafts used for the corneal transplant procedures.
89682046|NCT00624221|Active Comparator|2|The surgeon dissected the donor grafts used for the transplant procedures.
89682047|NCT03317834||Study Population|Total Knee Replacement with Navio Surgical Systems
89682048|NCT05686928|Experimental|Healing Ointment|Petrolatum-based opaque ointment applied to surgical wound twice daily.
89682049|NCT00673439|Experimental|Fondaparinux|daily subcutaneous injection of fondaparinux (7.5-10 mg)
89682050|NCT03316118|Active Comparator|Group 1|Patient will receive genicular nerve block with bupivacaine
89682051|NCT03316118|Placebo Comparator|Group 2|Patient will receive normal saline as the nerve block
89682052|NCT03029013|Experimental|experimental group|Apatinib and chemotherapy
89682053|NCT00674219|Active Comparator|OCD group|OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
89682054|NCT00674219|Active Comparator|GAD group|GAD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
89682055|NCT03378908|No Intervention|Conventional Treatment 6 meals|Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.
89682056|NCT03378908|Experimental|Intervention Treatment 3 meals|Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).
89682057|NCT00674297|Experimental|Fluvastatin|All patients will take Fluvastatin 40 mg daily for 3 months.
89682058|NCT05608317|Experimental|Supportive Care with Non-Bordered Foam Dressing|All Subjects will use a non-bordered foam dressing as the absorbent primary dressing.
89682059|NCT00246025|Experimental|Dabigatran etexilate 110 mg|Dabigatran etexilate 110 mg capsule, once a day, oral administration
89051709|NCT00569439|Experimental|D5|5% Dextrose Solution in Normal Saline
89051710|NCT00569439|Experimental|D10|
89051711|NCT00569439|Placebo Comparator|NS|
89051712|NCT04618445||Undergraduate students|prevalence of TMD among undergraduate students
89051713|NCT04585971||Subjects|Cerebral blood flow of a subject is measured using three methods in both common carotid and vertebral arteries. 1) Phase-contrast MR 2) Doppler sonography 3) Signal Intensity Gradient (SIG) To determine whether there is a correlation between the measured values, the correlation coefficient is calculated and analyzed.
89051714|NCT00569478|Active Comparator|1|rehabilitation
89682060|NCT00246025|Experimental|Dabigatran etexilate 150 mg|Dabigatran etexilate 150 mg capsule, once a day, oral administration
89682061|NCT00246025|Experimental|Dabigatran etexilate 220 mg|Dabigatran etexilate 110 mg capsule, 2capsules, once a day, oral administration
89682062|NCT00246025|Placebo Comparator|Placebo|matching placebo capsule, once a day, oral administration
89682063|NCT03311594|Experimental|Low Alcohol Consumption and No Pain Induction|Condition 1: Low alcohol consumption Condition 2: No pain group
89682064|NCT03311594|Experimental|Low Alcohol Consumption and Pain Induction|Condition 1: Low alcohol consumption Condition 2: Pain group
89682065|NCT03311594|Experimental|Moderate Alcohol Consumption and No Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: No pain group
89682066|NCT03311594|Experimental|Moderate Alcohol Consumption and Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: Pain group
89682067|NCT03311594|Placebo Comparator|Placebo Alcohol Consumption and No Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: No pain group
89682068|NCT03311594|Experimental|Placebo Alcohol Consumption and Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: Pain group
89682069|NCT03311594|Placebo Comparator|Control and No Pain Induction|Condition 1: No alcohol consumption Condition 2: No pain group
89682070|NCT03311594|Experimental|Control and Pain Induction|Condition 1: No alcohol consumption Condition 2: Pain group
89682071|NCT05019053|Experimental|Coping Crew Intervention|Interested participants who meet the screening criteria will be assigned to receive COPING CREW. First, following informed consent, eligible participants will complete a baseline assessment appointment in the week prior to the group beginning. During the baseline appointment, participants will provide informed consent, be instructed in the use of Microsoft Teams, complete a battery of self-report measures, be given a semi-structured diagnostic interview, and follow instructions to install a mobile app that will be used to track their mood and homework. Then, 4 groups of COPING CREW, with 6 participants per group, will be run. Participants will complete four weekly 60-minute virtual intervention sessions followed by a booster session two weeks later. Participants will complete daily surveys and homework assignments on their mobile devices. Links to follow-up surveys will be sent to participants at 1- and 3-month follow-ups.
89682072|NCT01271335|Experimental|Collagenase (MZ-004)|Local intra-coronary administration of MZ-004 at or into the CTO
89682073|NCT05596929|No Intervention|Control|
89682074|NCT05596929|Experimental|Experimental|
89682075|NCT00624923|Experimental|1- Active Pharmacologic|Salsalate
89682076|NCT00624923|Placebo Comparator|2- Placebo|Placebo
89682077|NCT05593653|Experimental|suvorexant|20mg taken at bedtime for 4 weeks
89682078|NCT05593653|Placebo Comparator|placebo|placebo taken at bedtime for 4 weeks
89682079|NCT00625391|Placebo Comparator|Placebo pill|24 weeks of placebo.
89682080|NCT00625391|Active Comparator|Green Tea Polyphenols (GTP)|24 weeks of green tea polyphenols
89682081|NCT00625391|Active Comparator|Placebo+Tai Chi (TC)|24 weeks of placebo plus Tai Chi exercise.
89682082|NCT00625391|Active Comparator|GTP+TC|24 weeks of green tea polyphenols plus Tai Chi exercise.
89682083|NCT03375866|Active Comparator|Pretzels|
89682084|NCT03375866|Experimental|Mixed nuts|
89682085|NCT00735787|Placebo Comparator|Placebo/Adalimumab|"Loading dose of 2 placebo injections at Week 0 and placebo injections every other week (eow) from Week 1 through Week 15.~In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27."
89682086|NCT00735787|Active Comparator|Adalimumab|80 mg adalimumab loading dose at Week 0 and 40 mg adalimumab eow from Weeks 1 through 15. For subjects who continued in the second period of the study, subjects received 2 placebo injections at Week 16 to maintain the blind. Open-label 40 mg adalimumab eow was administered from Week 17 through Week 27.
89682087|NCT02986893|Experimental|Dietary Intervention Arm|Participants will be assigned to follow a specific dietary intervention for 6 months
89682088|NCT02986893|Experimental|Non-dietary Intervention Arm|Participants will continue their usual diet and will be invited to attend monthly meetings at the MS Center for 6 months
89682089|NCT04349943|Experimental|inflammatory bowel disease|According to the patient's disease condition, tube feeding time, internal and surgical diagnosis and treatment plan, standard step-based nutrition treatment was carried out for the patients with adaptive signs of nutrition treatment, and dynamic nutrition evaluation and efficacy evaluation were carried out.
89051715|NCT00569478|No Intervention|2|controls
89051716|NCT04585698||headache patients|
89051717|NCT04585698||healthy subjects|
89051718|NCT00569517|Experimental|1|6-CBT-sessions for weight loss
89051719|NCT00569517|Experimental|2|Single educational intervention for weight
89682090|NCT05418062|Experimental|Intervention arm|Patients randomised into Group 1 will begin the 8 week group first.
89682091|NCT05418062|Other|Control crossover group|Patients randomised into Group 2 will act as the control for the first 8 weeks and then cross over into the intervention arm.
89051720|NCT00562952|Active Comparator|1|Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
89051721|NCT00562952|Placebo Comparator|2|Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.
89051722|NCT04585347|Experimental|Regimen A|ALZ-801 171 mg tablet, fasting, once
89051723|NCT04585347|Experimental|Regimen B|ALZ-801 205 mg tablet, fasting, once
89682092|NCT00628589|Experimental|Inhaled Loxapine 5 mg|Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours
89682093|NCT00628589|Experimental|Inhaled Loxapine 10 mg|Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours
89682094|NCT00628589|Placebo Comparator|Inhaled placebo|Inhaled Loxapine placebo, may repeat x 1 or 2 after 2 hours
89682095|NCT01278901||Cohort of consecutive patients undergoing EGD treated with PPI|Patients positive for helicobacter pylori undergoing EGD, started on PPI therapy for a month, repeated diagnostic tests for Helicobacter pylori after a month of therapy (urease test, histology and breath test)
89216246|NCT04616144|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal lenticule implantation as allogenic implant that will be taken from myopic patients to implant in hyperopic patients with high astigmatism using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity (far, intermediate, near vision) and secondary objective to stabilize(decrease) high astigmatism by reducing K values. Fresh corneal lenticule implantation as allogenic implant that we took from myopic patients (-5.0D) to implant in hyperopic patients (+4.0 D +3.0cyl) according to high K2 values. The stromal pocket diameter was 8 mm, 4mm super incision and 130-µm cap thickness.
89216247|NCT04604314|Experimental|Endocrown Onlay Restoration|Endocrown onlay preparation = Buccal and lingual walls are intact with an occlusal-gingival height at least equal to half the original crown height of the tooth. Remaining buccal and lingual walls maintain a thickness ≥ 2.0 mm.
89216248|NCT04604314|Experimental|Endocrown Shoulder Restorations|Endocrown shoulder preparation = Buccal and/or lingual walls are less than half the original occlusal-gingival height of the tooth or the buccal or lingual surfaces were previously prepared axially due to a prior restoration.
89216249|NCT04604301|Experimental|Crown, 1.0mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.0 mm delivered with a conventional Calcium Aluminate Ionomer cement
89216250|NCT04604301|Experimental|Crown, 1.5mm thickness, Calcium Aluminate Ionomer Cement|occlusal thickness of 1.5 mm delivered with a conventional Calcium Aluminate Ionomer cement
89216251|NCT04604301|Experimental|Crown, 1.0mm thickness, dual cure resin cement|occlusal thickness of 1.0 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
89216252|NCT04604301|Experimental|Crown, 1.5mm thickness, dual cure resin cement|occlusal thickness of 1.5 mm delivered with Prime and Bond elect Universal Bond in total etch mode with a dual cure resin cement
89216253|NCT04599907|Experimental|Roll-In Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
89216254|NCT04599907|Experimental|Randomized Cohort: N-SWEAT Patch|Subjects will be treated with N-SWEAT Patch
89682096|NCT04813445|Experimental|Xingnaojing injection|"Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.~Interventions:~Drug: Xingnaojing injection Other: Standard care"
89216255|NCT04599907|Sham Comparator|Randomized Cohort: Sham Patch|Subjects will undergo identical procedure with an inactive sham device
89682097|NCT04813445|No Intervention|Standard care|"Subjects will receive guidelines-based standard care.~Interventions:~Other: Standard care"
89682098|NCT01271569|Other|In the treatment arm|
89682099|NCT05686772||First-episode psychosis patients|
89682100|NCT04771871|Experimental|Epirubicin-Cyclophosphamide plus Paclitaxel- Carboplatin|Epirubicin 60mg/m2 with cyclophosphamide 600/m2 every three weeks for four courses followed by paclitaxel 120mg/m2 and carboplatin 6 AUC every three weeks for four courses
89682101|NCT05589207||Invaded Group|Patients whose inferior vena cava vascular wall is invaded according to histopathological examination.
89682102|NCT05589207||Non-invaded group|Patients whose inferior vena cava vascular wall is not invaded according to histopathological examination.
89682103|NCT01278979|Active Comparator|Assessment of perineal tears|Consenting women sustaining perineal tear after child birth
89682104|NCT01278979|Other|Visual and digital assessment|Consenting women that sustained perineal tear after child birth.
89682105|NCT03374930|Other|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
89682106|NCT04386577|Active Comparator|Vitamin D + fish oil|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Each capsule contains 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA).
89682107|NCT04386577|Active Comparator|Vitamin D + fish oil placebo|Dietary supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary supplement: Fish oil placebo
89682108|NCT04386577|Active Comparator|Vitamin D placebo + fish oil|Drug: Omega-3 fatty acids (fish oil), Omacor, 1 capsule per day. Dietary supplement: Vitamin D3 placebo
89682109|NCT04386577|Placebo Comparator|Vitamin D placebo + fish oil placebo|Dietary supplement: Vitamin D3 placebo Dietary supplement: Fish oil placebo
89682110|NCT04766411|Experimental|Unresisted sprint training|Participants will perform an acute training bout of unresisted sprints.
89682111|NCT04766411|Experimental|Resisted sprint training with load equal to 10% of body weight|Participants will perform an acute training bout of resisted sprints with load equal to 10% of body weight.
89682112|NCT04766411|Experimental|Resisted sprint training with load equal to 20% of body weight|Participants will perform an acute training bout of resisted sprints with load equal to 20% of body weight.
89682113|NCT04766411|Experimental|Control trial|Participants will perform no training protocol. They will only perform all the measurements.
89682114|NCT04270669|Experimental|RC28-E 0.5mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 0.5mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
89682115|NCT04270669|Experimental|RC28-E 1.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 1.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
89682116|NCT04270669|Experimental|RC28-E 2.0mg|In the loading phase (from week 0 to week 8), the study eye will receive intravitreal injection of 2.0 mg RC28-E every 4 weeks, for 3 consecutive times; In the PRN phase (from week 12 to week 48), the study eye will receive the same dose on an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
89682117|NCT05233293|Experimental|SpyGlass group|ERCP plus SpyGlass plus RFA group
89682118|NCT05233293|Active Comparator|Cytobrush Group|ERCP plus Cytobrush plus RFA group
89682119|NCT03373604|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
89682120|NCT03373604|Active Comparator|No cognitive impairment|Healthy controls
89051724|NCT04585347|Experimental|Regimen C|ALZ-801 205 mg tablet, after food once
89051725|NCT04585347|Experimental|Regimen D|ALZ-801 342 mg (administered as 2 x 171 mg tablets of ALZ-801), after food, once
89051726|NCT00569556|No Intervention|Usual Care|Patients receive care through primary care provider
89051727|NCT00569556|Experimental|Case Management|Specially trained nurse case managers contact patients by telephone; monitor blood pressure, LDL, and HgbA1C;, and recommend lifestyle and medication changes as needed
89051728|NCT00562991||FeNO group|asthma patients, exhaled NO is used to monitor asthma
89051729|NCT00562991||Symptom group|asthma patients, exhaled NO is not used to monitor asthma
89051730|NCT00569595|Experimental|1|Multi-Level, Patient-Directed, Lifestyle Change, Health Promotion Program
89051731|NCT00569595|Sham Comparator|2|"Patient health counseling program by lay health educators Entitled Fighting Cancer with Advice."
89051732|NCT04618601|Active Comparator|High-dose spironolactone|Participants in this arm will receive high doses of per os spironolactone, defined as doses ≥100 mg daily, on top of standard of care treatment for acute heart failure
89051733|NCT04618601|No Intervention|Standard of care|Participants in this arm will standard of care treatment for acute heart failure, which may include per os spironolactone at a maximum dose of 50 mg daily
89051734|NCT00567918|Experimental|1|FK506 ophthalmic suspension
89051735|NCT00569634|Other|1|
89051736|NCT04618562|Experimental|Revival Active Program|Revival Program included supervised play group, twice a week followed by home practice.
89051737|NCT00569790|Experimental|1|S-1, Irinotecan, Bevacizumab
89051738|NCT04618679||18F-FDOPA PET|Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease.
89051739|NCT00567957|Placebo Comparator|C|Saline starting before induction till entry to abdominal cavity
89051740|NCT00567957|Active Comparator|R|Remifentanil starting before induction till entry to abdominal cavity
89051741|NCT04618094|Experimental|High intensity interval group|
89051742|NCT04618094|Active Comparator|Moderate continous intensity group|
89051743|NCT04618094|No Intervention|non-exercising group|
89051744|NCT00569829|Experimental|1|Cognitive behavioral therapy
89051745|NCT00569829|No Intervention|2|Waitlist
89051746|NCT02940002|Experimental|BAY1003803 0.1% lipophilic cream|BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)
89051747|NCT02940002|Experimental|BAY1003803 0.1% ointment|BAY1003803 0.1% ointment (on plaque and healthy skin)
89051748|NCT02940002|Experimental|BAY1003803 0.01% lipophilic cream|BAY1003803 0.01% lipophilic cream (on plaque and healthy skin)
88996884|NCT05256667|Other|Root canal treatment in two visits without intracanal dressing - RCT-TVWOD|Group 3- RCT-TVWOD: Endodontic treatment in two visits using chemomechanical preparation (rotary NiTi instruments, 5.25% NaOCl, 17% EDTA) and passive ultrasonic irrigation (PUI), followed by temporary restoration (glass ionomer cement) for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed performed, followed by obturation (gutta-percha and epoxy resin-based sealer) and final restoration (composite resin).
88996885|NCT00158522|Experimental|1|
88996886|NCT05250544|Experimental|Stress ball group|For the adolescents in the stress ball group; Before the procedure, the adolescent's fear (with Childeren's Fear Scala (CFS)) will be evaluated and recorded by the adolescent, parent and observer. Then, the stress ball will be introduced to the adolescents and they will be asked to hold it in their desired hands. After explaining how to squeeze the stress ball, the PCR Test will start a few seconds after the adolescent starts to squeeze. As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
88996887|NCT05250544|Experimental|Breathin exercise group|For the adolescents in the breathing exercise group; Before the procedure, the adolescent's fear (with Child's Fear Scala (CFS)) will be evaluated and recorded by the adolescent, parent and observer. Then, the breathing exercise will be introduced and applied to the adolescents. After explaining how to do the breathing exercise, the adolescent will be expected to complete the exercises. The PCR Test process will begin immediately after the exercise is complete. As soon as the process starts, the stopwatch will be started and will be stopped when the process is finished. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
88996888|NCT05195047|Experimental|Probiotics-Placebo-Placebo|1 week of consecutively consuming oral probiotics (1 time/day) followed by SARS-CoV-2 vaccination, then 2 weeks of consecutively consuming oral placebo (1 time/day).
88996889|NCT05195047|Experimental|Placebo-Probiotics-Placebo|1 week of consecutively consuming oral placebo (1 time/day) followed by SARS-CoV-2 vaccination, then consuming oral probiotics (1 time/day) for 1 week and placebo (1 time/day) for 1 week (1 time/day) respectively.
88996890|NCT05195047|Experimental|Placebo-Placebo-Probiotics|1 week of consecutively consuming oral placebo (1 time/day) followed SARS-CoV-2 vaccination, then consuming oral placebo for 1 week (1 time/day) and probiotics for 1 week (1 time/day) respectively.
88996891|NCT05195047|Placebo Comparator|Placebo|1 week of consecutively consuming oral placebo (1 time/day) followed by SARS-CoV-2 vaccination, then 2 weeks of consecutively consuming oral placebo (1 time/day).
88996892|NCT05169229|Experimental|Treatment arm|Combination of vancomycin and tobramycin mixed with allograft and locally administered during revision surgery after total hip arthroplasty.
88996893|NCT05169229|Placebo Comparator|Placebo|Saline locally added to allograft and locally administered during revision surgery after total hip arthroplasty.
88996894|NCT00183378|Active Comparator|1|Routine medical care with education: therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support.
88996895|NCT00183378|Active Comparator|2|Walking: the therapist introduces a walking program and assists the caregiver in establishing a daily walking routine of 30 minutes for the study participant.
88996896|NCT00183378|Active Comparator|3|Light exposure: the therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
88996897|NCT00183378|Active Comparator|4|Combination: the therapist provides education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
88996898|NCT00538057|Experimental|arm 1|study drug
88996899|NCT00538096|Experimental|1|MEDI-538
88996900|NCT00538096|Experimental|2|MEDI-538
88996901|NCT00538096|Experimental|3|MEDI-538
88996902|NCT00538135|Experimental|1|"Cognitive Behaviour Therapy plus Treatment as Usual (CBT plus TAU) for borderline personality disorder.~CBT is a structured, time limited, psycho-social intervention developed to treat Cluster B personality disorder. Patients are encouraged to engage in treatment through a formulation of their problems within a cognitive framework. Interventions focus on the patient's beliefs and behaviour that impair social and adaptive functioning. Thirty sessions of CBT over one year, each lasting up to one hour, are required to work on long-standing problems and develop new ways of thinking and behaving. Priority is given to behaviours that cause harm to self or others. In addition, participants received the usual treatment they would have received if the trial had not been in place"
88996903|NCT00538135|Active Comparator|2|"Treatment as Usual.~All participants received the standard treatment (TAU) they would have received if the trial had not been in place. Although standard treatment may vary across the three sites, and depend on the specific problems of the individual participant, it was thought that all participants would be in contact with mental health services and would have some contact with Accident and Emergency services for repeated self-harm episodes. TAU will be documented carefully after each patient exits the trial."
88996904|NCT00158678|Active Comparator|1|Conventional RT 70Gy + concomitant cisplatin
88996905|NCT00158678|Experimental|2|IMRT 75Gy + concomitant cisplatin
88996906|NCT00538174|Experimental|Arm 1|2.5 mg
88996907|NCT00538174|Experimental|Arm 2|10 mg
88996908|NCT00538174|Experimental|Arm 3|20 mg
88996909|NCT00538174|Placebo Comparator|Arm 4|
88996910|NCT05139823|No Intervention|Control|Controls receive usual care, which is a digital communication to the local home care team including a discharge care plan to the home care system, including information about the discharge diagnoses, and recommendations for particular attention to specific bodily functions and medical treatment regime. The patient's PCP receives a discharge summary from the treating hospital physician as usual.
89051749|NCT02940002|Experimental|BAY1003803 0.01% ointment|BAY1003803 0.01% ointment (on plaque and healthy skin)
89682121|NCT03363932||Perimembranous VSD with high pulmonary flow rate|"It is an observational study, no intervention or examination will be realized for the sole purpose of the study. Patient management will be at the discretion of referral cardiologists according to the practices of the centers.~As part of the usual follow-up of these patients, the participating centers collect the clinical and echocardiography data from inclusion and the following year, as well as data from a functional assessment at baseline and at one year. and the collection of cardiovascular events at 5 years and 10 years of follow-up.~Data from a possible percutaneous or surgical closure procedure will be collected. The indication of VSD closure will be left to the discretion of participating centers. There will be no recommendation for percutaneous or surgical closure of VSD for the sole purpose of this observatory."
89682122|NCT00755131|Experimental|Training Group|Postinfarction patients undergo 6-month exercise-based Cardiac Rehabilitation Program
89682123|NCT00755131|No Intervention|Control Group|Postinfarction patients NOT undergoing 6-months exercise-based Cardiac Rehabilitation program
89682124|NCT05680454|Experimental|The Group of Investigational Vaccine|"For Low-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 20μg、40μg、40μg、20μg、20μg、20μg、20μg、20μg, and 20μg respectively, totaling 220μg of antigens.~For High-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg、40μg、80μg、60μg、30μg、30μg、30μg、30μg and 30μg respectively, totaling 360μg of antigens.~For Mid-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg、40μg、60μg、40μg、20μg、20μg、20μg、20μg and 20μg respectively, totaling 270μg of antigens."
89682125|NCT05680454|Active Comparator|The Group of Active Control Vaccine|Each 0.5-mL single-dose vial of GARDASIL9 contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein, totaling 270 mcg of antigens.
89682126|NCT04944927||Patients with Alternating Hemiplegia of Childhood|"Patients that meet the clinical diagnostic criteria (Aicardi et al, 1995) for typical alternating hemiplegia with or without identified mutations in ATP1A3.~At least one prolonged ECG study available is required."
89682127|NCT04928703|Experimental|Arm 1|Visit 2: Placebo - Placebo; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Ketamine
89682128|NCT04928703|Experimental|Arm 2|Visit 2: Placebo - Ketamine; Visit 3: Placebo - Placebo; Visit 4: Placebo - Ketamine
89682129|NCT04928703|Experimental|Arm 3|Visit 2: Placebo - Ketamine; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Placebo
89051750|NCT02940002|Active Comparator|Clobetasol propionate|Clobetasol propionate ointment 0.05 % (on plaque and healthy skin)
89051751|NCT02940002|Active Comparator|Betamethasone/calcipotriene|Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin)
89051752|NCT04580745|Experimental|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
89051753|NCT04580745|Experimental|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
89051754|NCT04618328|Experimental|ATRA treatment group|ATRA is given at a daily dose of 10 mg twice daily orally for 12 weeks
89051755|NCT04585659|Experimental|Qigong Intervention|60-90 minute community qigong classes, once per week plus at least 10 minutes of home practice
89051756|NCT04585659|No Intervention|Wait-List Control|Participants asked not to do any qigong, yoga or taichi for 10 weeks. Participants have the option to cross-over to the experimental arm after 10 weeks of no intervention.
89051757|NCT04617782|Experimental|Treatment A|5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks
89051758|NCT04617782|Experimental|Treatment B|10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks
89051759|NCT04617782|Active Comparator|Treatment C|10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks
89051760|NCT04617704|Experimental|Experimental:GC012F treatment|BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10^5/kg cells will be administered at Day 0
89051761|NCT00569985|Experimental|Treatment (autologous HCT)|CONDITIONING: Patients receive carmustine IV over 1-2 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANTATION: Patients undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells IV on day 0.
89051762|NCT02939768|Experimental|Exercise training protocols|Participants will be randomized in one of three groups: HIIT, ST or ST combined with HIIT (ST+HIIT). Each training protocol will last 10 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
89051763|NCT02939768|No Intervention|Control period|Before interventions (exercise training protocols), all participants will participate of a control period lasting one month, where participants will be encouraged to maintain their habitual lifestyle and usual diet habits.
89051764|NCT04617665|Other|One-handed mask ventilation|For the one-handed mask ventilation, only one hand can be used to achieve the face mask seal. The left thumb and index finger form a ''C,'' providing anterior pressure over the mask, while the third, fourth, and fifth fingers form an ''E'' to lift the jaw.
89051765|NCT04617665|Other|Two-handed mask ventilation|For the two-handed mask ventilation, the provider's thumb and thenar eminence of each hand are held parallel, adjacent to the mask connector, and depress each side of the mask. The second through fifth digits wrap around and elevate the mandible to draw it anteriorly into the mask establishing both a jaw-thrust and chin-lift maneuver when appropriate.
89051766|NCT00570024|Active Comparator|TA|Active TA
89051767|NCT00570024|Other|AA|
89051768|NCT00570024|No Intervention|Waiting Group|
89682130|NCT04278950|Active Comparator|Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with 0.10% PVP-I (0.01% available iodine). Patients will be instructed to dilute 2.5mL of the betadine (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
89682131|NCT04278950|Placebo Comparator|Placebo Poviodine Iodine Solution|Patients will be randomized into this arm will be provided with a placebo PVP-I solution. Patients will be instructed to dilute 2.5mL of the placebo PVP-I (unmarked bottles) into a 240mL bottle of saline and rinse once per day.
89682132|NCT00755755|Experimental|A (PGL4001 5mg)|PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
89682133|NCT00755755|Experimental|B (PGL4001 10mg)|PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
89682134|NCT00755755|Placebo Comparator|C (placebo)|PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
89682135|NCT05410808||Fibromyalgia patients|Patients diagnosed as having fibromyalgia according to the American College of Rheumatology 2016 classification criteria
89682136|NCT05410808||Healthy controls|Subjects not having fibromyalgia and who live in the same household as the fibromyalgia patients
89682137|NCT05676398||Ambulatory rhythm monitoring|Ambulatory rhythm monitoring by use of patch-type device.
89682138|NCT05672888|Experimental|Jaktinib|Jaktinib 100mg BID
89682139|NCT05672888|Placebo Comparator|Placebo|placebo
89682140|NCT05686616|Active Comparator|SGLT2 inhibitor group|Participants will take dapagliflozin propanediol hydrate 12.3 mg once a day for a total of 48 weeks.
89682141|NCT05686616|No Intervention|Conventional treatment group|Participants will continue the existing medications for severe TR.
89682142|NCT02292537|Experimental|Nusinersen|Nusinersen 12 mg solution via intrathecal (IT) injection on Days 1, 29, 85 and 274.
89682143|NCT02292537|Sham Comparator|Sham procedure|Sham comparator on Days 1, 29, 85 and 274.
89682144|NCT05686538|Experimental|Innate donor lymphocyte infusion (iDLI)|TCRab/CD19 depleted DLI day 14 after routine allogeneic stem cell transplantation
89682145|NCT05686538|No Intervention|Standard of care|Routine allogeneic stem cell transplantation
89682146|NCT00674765|Experimental|1|Seroquel
89682147|NCT00674765|Placebo Comparator|2|Placebo
89682148|NCT05394896|Experimental|HPI group|Conventional therapy and monitoring with ACUMEN sensor (Edwards Lifesciences, Irvine, USA) and Hemosphere platform (Edwards Lifesciences, Irvine, USA) of invasive blood pressure. Strategy to prevent hypotension based on HPI index, Eadyn and dP/dTmax.
89682149|NCT05394896|Active Comparator|Control group|Conventional therapy according to standard monitoring in the operating room which includes invasive blood pressure monitoring.
89682150|NCT00676013|Experimental|Alloderm, Integra, Homograft, Autograft|Burn debridement and grafting using interventions of 1) AlloDerm, 2) Integra, 3) Homograft and 4) Autograft on four separate sites on each patient
89682151|NCT00755911|Experimental|Tissue Repair Cells (TRC)|Subjects will receive Tissue Repair Cell (TRC) therapy plus Gelfoam carrier
89682152|NCT00755911|Sham Comparator|Control|Subjects will receive the control treatment, consisting of Gelfoam carrier without Tissue Repair Cell (TRC) therapy.
89682153|NCT00676793|Experimental|Polyphenon E|This is a single arm study comparing changes within patients before and after receiving the experimental drug Polyphenon E for the duration of the study, between recruitment and surgery for breast cancer.
89682154|NCT00737737|Experimental|Opioid|Participants will receive MS Contin over a 4 week period starting at 15 mg bid. Doses will titrated upwards as tolerated by increments of 15-30 mg to a highest attained dose or a maximum dose of 90 mg
89682155|NCT00737737|Experimental|Placebo|Participants will receive a similar number of placebo tablets which match the study drug with regards to appearance over a period of 4 weeks
89682156|NCT04279418|Experimental|Mixed functional foods group with SCD|Thirty participants in this group will take mixed functional foods for three months.
89682157|NCT04279418|Placebo Comparator|Placebo group with SCD|Thirty participants in this group will take placebo for three months.
89682158|NCT04400552|Active Comparator|ONS Pre-op + ONS Post-op|Oral nutrition supplementation (ONS) pre-operatively and post-operatively up to being discharged from hospital
89682159|NCT04400552|Active Comparator|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Oral nutrition supplementation (ONS) pre-operatively, post-operatively up to being discharged from hospital and an extended oral nutrition supplementation post-operatively up to 3 months
89682160|NCT04400552|Active Comparator|Usual intake Pre-op + ONS Post-op|Follow a meal plan of 2000 kcal / day using conventional foods and oral nutrition supplementation (ONS) post-operatively up to being discharged from hospital
89051769|NCT00570102|Active Comparator|A highly hydrolyzed casein formula|
89051770|NCT00570102|Placebo Comparator|A conventiona cow's milk based formula|
89682161|NCT00245011|Experimental|Samarium-153|Cytoxan+Ifosfamide, Filgrastim pre samarium.'Sm-EDTMP (low dose). once counts recover, Sm-EDTMP (high dose) given. Peripheral blood stem cell transplantation is done 14 days later.
89682162|NCT00628901|Experimental|Arm 1|
89682163|NCT00628901|Active Comparator|Arm 2|
89682164|NCT03307070|Active Comparator|Active Group|Participants who are randomized to begin the Cognitive Behavioral Therapy for individuals with TBI immediately after screening. This treatment is a version of Cognitive Behavioral Therapy (CBT) adapted specifically for patients who have experienced a moderate to severe Traumatic Brain Injury (TBI).
89682165|NCT03307070|Other|Waitlist Control|Participants who are randomized to be put on a waitlist after screening. After 12 weeks of being on the waitlist, participants will be offered the Cognitive Behavioral Therapy for individuals with TBI
89682166|NCT02980419|Experimental|intervention arm|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
89682167|NCT05686460|Experimental|ice massage|The application applied 2 minutes of ice massage 7 times at 15-second intervals. The procedure was performed once on the first day and once on the second day of menstruation.
89682168|NCT05686460|Experimental|music medicine|Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The procedure was performed once on the first day and once on the second day of menstruation.
89682169|NCT05686460|No Intervention|control|On the first and second days of menstruation, their pain levels of were assessed 4 times: when the pain started (pre-test), and then 30, 60 and 90 minutes after the pain started.
89682170|NCT05186181||group RISEN STAR|Patients with Stanford B-type aortic dissection will be treated with endovascular repair with in situ needle fenestration of left subclavian artery.
88996911|NCT05139823|Experimental|Intervention|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-5 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
88996912|NCT05120479|Experimental|Experimental arm|"The intervention will be the application of a Kinesiotape (KT) strip on the anterior side of the forearm.~The day of the intervention will proceed as follows:~Warm-up: The total warm-up time will be 5 minutes. After warm-up, a 1 minute rest will be carried out.~Skin cleansing with 96% alcohol.~Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension)."
88996913|NCT05120479|Sham Comparator|Control arm|"The intervention will be the application of a tape strip on the anterior side of the forearm. Sham tape appears to be kinesiotape but is an inelastic tape.~The day of the intervention will proceed as follows:~Warm-up: The total warm-up time will be 5 minutes. After warm-up, a 1 minute rest will be carried out.~Skin cleansing with 96% alcohol.~Sham tape: exactly the same procedure is followed as experimental arm, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain)."
88996914|NCT00538369|Active Comparator|standard-of-care|The standard-of-care group will receive sedation assessment and monitoring with the Ramsay scale, which is the accepted tool at this university
88996915|NCT00538369|Experimental|standard + BIS|Subjects in the standard-of-care + BIS group will receive sedation assessment and monitoring using the Ramsay scale and values from the bispectral index (BIS) monitor.
88996916|NCT00183417|Experimental|1|Participants will receive cognitive behavioral therapy
88996917|NCT00183417|Active Comparator|2|Participants will receive supportive/expressive therapy
88996918|NCT00183417|Active Comparator|3|Participants will receive bibliotherapy
88996919|NCT00183417|No Intervention|4|Participants in the control condition will receive no treatment
88996920|NCT00538486|Experimental|Group T|Telmisartan
88996921|NCT00538486|Experimental|Group T+M|Telmisartan plus Metformin
88996922|NCT00538486|Experimental|Group C|Candesartan
88996923|NCT00538486|Experimental|Group C+M|Candesartan pus Metformin
88996924|NCT00538486|Active Comparator|Group A|Amlodipine
88996925|NCT00538486|Experimental|Group A+M|Amlodipine plus Metformin
88996926|NCT00538525|Active Comparator|Arm 1|Doxorubicin, Docetaxel, Cisplatin
88996927|NCT00538564|Experimental|Tadalafil|Participants assigned to this arm were given oral 10 mg tadalafil tablets to take 3 times a week for 16 weeks.
88996928|NCT00538564|Placebo Comparator|Placebo|Participants assigned to this arm were given a placebo pill 3 times a week for the first 8 weeks, and then Tadalafil 10 mg 3 times a week for weeks 9-16.
88996929|NCT04685161|Experimental|Surgical extrusion|Novel and alternative treatment option for horizontal crown root fractured maxillary incisors
88996930|NCT04685161|Active Comparator|Fibre post|Treatment modality normally used for crown-root fractured tooth
88996931|NCT00538720|Experimental|Vitamin D|Vitamin D starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
88996932|NCT05553886|Experimental|S086 piece|Sacubitril alisartan calcium tablets,60mg,120mg,180mg,240mg
88996933|NCT05553886|Active Comparator|Sacubitril valsartan sodium tablets|Sacubitril valsartan sodium tablets,50mg,100mg
88996934|NCT00536926|Active Comparator|A|home spirometry alone
88996935|NCT00536926|Experimental|B|Home spirometry with data transfer via cellphone to clinical database
88996936|NCT00190164|Experimental|1|Macular hole surgery with alleviated positioning
88996937|NCT00190164|No Intervention|2|Macular hole surgery with no alleviated positioning
88996938|NCT03457090|Experimental|Patient treated with ECMO|Patient treated with ECMO will have Examination : a TCD and Trans-Thoracic Echocardiography (TTE)
88996939|NCT05432947|Experimental|68Ga-P16-093 and 18F-FDG PET/ CT scan|Within 1 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-P16-093 and 18F-FDG, respectively.
88996940|NCT00190203|Experimental|A|HEMICRANIECTOMY
88996941|NCT03457051|Active Comparator|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint that is made of plastic or metal.
88996942|NCT03457051|Experimental|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced
88996943|NCT04685434||pediatric patients diagnosed with rheumatic diseases.|The Shriners Hospital for Children Upper Extremity Evaluation, the Jebsen-Taylor Hand Function Test, and the Childhood Health Assessment Questionnaire will be administered in children with rheumatic diseases. The Shriners Hospital for Children Upper Extremity Evaluation will be administered two weeks after the first examination and the results will be compared.
88996944|NCT00537355|Active Comparator|TOLAMBA™|
88996945|NCT00537355|Sham Comparator|Histamine|Histamine simulates mild redness/swelling effect seen with active comparator, TOLAMBA™. Prevents study staff from easily identifying subjects who received active comparator.
88996946|NCT05402995|Active Comparator|Standard operative debridement and spanning external fixator (reference/control group)|This is the standard of care management. Patient will go to the operating room (OR) first for irrigation and debridement with normal saline and external fixation. Will return to OR at a later date for definitive fixation.
88996947|NCT05402995|Experimental|Spanning external fixator with Irrisept irrigation (treatment group 1)|Patient will go to the operating room (OR) first for irrigation and debridement with Irrisept (the experimental irrigation solution) and external fixation. Will return to OR at a later date for definitive fixation.
89682171|NCT05663294|Experimental|Partial Breast Irradiation|"Radiation treatment will be started within 120 days after surgery. The fractionation schedule depends on the policy of the treating center, but is mandatory to use CT-based planning. Both once-daily and twice-daily schedule are allowed.~The allowed schedules for external beams radiotherapy are:~40 Gy in 15 fractions;~30 Gy in 5 fractions;~40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours).~The schedule for brachytherapy are:~32 Gy in 8 twice-daily fractions for HDR;~30.3 Gy in 7 twice-daily fractions for HDR;~50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
89682172|NCT00629525|Experimental|RAD001|RAD001 at a dose of 10 mg PO daily
89682173|NCT00244855|Other|No previous treatment|Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
88996948|NCT05402995|Experimental|Antibiotic-coated medullary nail with saline irrigation (treatment group 2)|Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with normal saline.
88996949|NCT05402995|Experimental|Antibiotic-coated medullary nail with Irrisept irrigation (treatment group 3)|Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with Irrisept (the experimental irrigation solution).
88996950|NCT00183651|Experimental|S-DBT|Participants receive standard dialectical behavior therapy
88996951|NCT00183651|Active Comparator|DBT-I|Participants receive individual dialectical behavior therapy plus activities group
88996952|NCT00183651|Active Comparator|DBT-S|Participants receive dialectical behavior therapy group skills plus case management
88996953|NCT00537433|No Intervention|Standard counseling|Families in the control group receive standard care, including routine counseling regarding medications prescribed from their physician and post-visit counseling by the pediatric nursing staff. Dosing instruments are given at the discretion of the physician or nurse.
88996954|NCT00537433|Experimental|Pictogram|Parents randomized to the pictogram-based intervention group receive medication counseling utilizing the pictogram-based medication instruction sheets. These sheets help to facilitate medication counseling, including teaching about dosage and adherence.
88996955|NCT00537472|Experimental|I|
88996956|NCT00537472|Active Comparator|II|
88996957|NCT00183690|Experimental|1|Participants receiving prolonged exposure therapy
88996958|NCT00183690|Active Comparator|2|Participants receiving active psychotherapy
88996959|NCT00159107|Experimental|2|Placebo +Integrative behavior therapy
88996960|NCT00159107|Experimental|3|Acamprosate + treatment as usual
88996961|NCT00159107|Experimental|1|Acamprosate + Integrative behavior therapy
88996962|NCT05357365||Doctor|Doctors of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
88996963|NCT05357365||Nurses|Nurses of the Emergency department conduct questionnaires about occupational, mental, physical factors on their health.
88996964|NCT00190242|Experimental|group1:3 administrations of Havrix|group 1 received immunisation with Havrix (1440IU) at weeks S0, S4, S24
88996965|NCT00190242|Active Comparator|group2: 2 administrations of Havrix|group 2 received usual immunisation with Havrix (1440IU) at weeks S0 and S24
89682174|NCT00244855|Other|Previous treatment|Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
89682175|NCT05182203||JAK inhibitors|RA patients treated with JAK inhibitors
89682176|NCT05182203||TNF inhibitors|RA patients treated with TNF inhibitors
89682177|NCT03359408|No Intervention|Care as usual|Care as usual, no intervention, just observation of natural change/ trajectories over time
88996966|NCT05355259|Experimental|GECKO Active Guidewire Use|All patients will be treated using the GECKO guidewire to facilitate endovascular access to the targeted vessel in order to treat the vascular lesion.
88996967|NCT00159146|Active Comparator|A|Venlafaxine and pindolol
88996968|NCT00159146|Placebo Comparator|B|Venlafaxin and placebo
88996969|NCT00537667|Active Comparator|A|anakinra
88996970|NCT00537667|Experimental|B|anakinra and PEGsTNF-R1
88996971|NCT00538954|Active Comparator|1|Follow a standard Enhanced Recovery After Surgery protocol
88996972|NCT00538954|Experimental|2|Follow a standard Enhanced Recovery After Surgery protocol and will receive 1 g of Magnesium Oxide laxative twice daily from the day after surgery until discharge
88996973|NCT00538954|Experimental|3|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days
88996974|NCT00538954|Experimental|4|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days and will receive postoperative laxative in the form of 20 ml of Magnesium Oxide twice daily form the day after surgery until discharge
88996975|NCT00538993|Experimental|1|Provider receives cue sheet to assist with counseling.
88996976|NCT00538993|No Intervention|2|Provider does not receive cue sheet.
89216256|NCT04598074|Experimental|Opioid Package Prototype (OPP)|Oxycodone 5mg tablets dispensed in the Opioid Package Prototype (OPP) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
88996977|NCT00539071|Active Comparator|Conventional dose|All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks (given as two injections - active 50 mg plus placebo injection).As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 3 unless symptoms warrant a quicker titration) along with the injections.Any oral risperidone the patients receive will be discontinued after Week 4.At Week 6, psychopathology will be assessed with a PANSS. Dose will remain at 50 mg q 2 weeks for those in the conventional Consta dose group.
89682178|NCT03359408|Experimental|Dementia Care Management (DCM)|"Subjects in this arm will be provided with Dementia Care Management adapted to the intersectoral setting."
89216257|NCT04598074|Active Comparator|Usual Care (standard amber vial)|Oxycodone 5mg tablets dispensed in the standard amber vial (usual care) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
89216258|NCT04596293|Experimental|BBT-401-1S (800mg)|"Induction Phase: BBT-401 800mg for 8 weeks~Extension Phase: After 8 weeks,~Participants who achieved clinical remission in the induction phase will continue the same treatment for 8 weeks~Participants who did not achieve clinical remission in the induction phase will receive BBT-401 1600mg for 8 weeks"
89682179|NCT00737893|Experimental|Erythropoietin (EPO)|20,000 units of EPO given on the day before surgery, the day of surgery, and the day after surgery.
89682180|NCT00737893|Placebo Comparator|Placebo|Placebo doses given the day before surgery, the day of surgery, and the day after surgery.
89682181|NCT00631319|Experimental|OROS Hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
89682182|NCT00631319|Placebo Comparator|Placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
89682183|NCT05686382|Active Comparator|group TAP block|TAP block is administered at the end of the surgery, bilaterally, with lateral approach, with 24 ml of 0,5% ropivacaine for each side
89682184|NCT05686382|Experimental|group CWI|A 15 cm long, multihole catheter is placed on the preperitoneal plane before fascia closure; a starting bolus of 10 ml of 0,5% ropivacaine is administered through the catheter, then a continuous infusion of 0,2% ropivacaine at a rate of 5 ml/h is started through a pump and continued for 48 hours
89682185|NCT00244621|Experimental|1|0.05 mg/kg Atacand oral liquid dose
89682186|NCT00244621|Experimental|2|0.20 mg /kg Atacand oral liquid dose
89682187|NCT00244621|Experimental|3|0.40 mg /kg Atacand oral liquid dose
89682188|NCT00680225|Experimental|Lucentis Injection|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
89682189|NCT04760600||IBD GROUPS|PATIENT WITH IBD DISEASE
89682190|NCT04760600||IBS GROUP|PATIENT WIT IBS DISEASE
89682191|NCT04760600||CONTROL 1|CONTROL WITH POSITIVE PARASITIC INFECTION AN POSITIVE GIT SYMTOMS
89682192|NCT04760600||CONTROL2|HEALTHY VOLUNTEARS
89682193|NCT04603391|Experimental|Exposure A|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) CBD 750 mg (administered as 7.5 ml of Epidiolex® solution [100 mg/ml] of CBD)
89682194|NCT04603391|Active Comparator|Exposure B|Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) 7.5 ml of Epidiolex® placebo solution containing no CBD.
89682195|NCT05686148|Experimental|Intervention|Vibration will be applied to the injection site for 5 minutes before the procedure.
89682196|NCT05686148|No Intervention|Control|No application will be made
89682197|NCT01271647|Experimental|chinese herb|
89682198|NCT01271647|Experimental|placebo|
89682199|NCT03368456|Experimental|S4E App Intervention|Participants in the S4E condition will first receive the intervention in the waiting area via iPads provided for them. Content includes the theoretically driven components of Storytelling for Empowerment: (a) Storytelling scenarios, (b) drug use and HIV/STI knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual risk and drug use behaviors, and increase HIV/STI testing, (e) clinician-youth communication, and (f) highlighting prevention principles
89682200|NCT03368456|Placebo Comparator|Usual Care Condition|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
89682201|NCT00738049|Active Comparator|Group 1|Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.
89682202|NCT00738049|Active Comparator|Group 2|Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2
89682203|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 1|Participants randomized to a free mobile mental health application that focuses on meditation.
89682204|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 2|Participants randomized to a free mobile mental health application that assists with coping with COVID-19.
89682205|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 3|Participants randomized to a free mobile mental health application that focuses on positive psychology.
89682206|NCT04536935|Active Comparator|Phase 2: Mobile Mental Health App - 4|Participants randomized to a free mobile application that addresses mental health issues through mood tracking.
89682207|NCT02291133|Experimental|Electrochemotherapy treatment|
89682208|NCT00680459|Experimental|1|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
89682209|NCT00680459|Placebo Comparator|2|heparin flush 10 units/ml lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. heparin flush solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
89682210|NCT04760366|Experimental|Group A (Experimental)|Patients in this group will receive interventional therapy through fascial- muscular lengthening therapy .Patients in this group will also receive the conventional therapy
89682211|NCT04760366|Other|Group B: Conventional treatment|Patients in this group will receive the conventional therapy
89682212|NCT04400864|Experimental|Mediterranean Diet|Nutritional guidelines based on the principals of the Mediterranean Diet
89682213|NCT04400864|Experimental|Paleolithic Diet|Nutritional guidelines based on the principals of thePaleolithic Diet
89682214|NCT00632411|Experimental|Proactive group|Research study staff will contact participant to initiate the program. Half of participants will be randomized to the proactive condition and the other half to the reactive conditions.
89682215|NCT00632411|Experimental|Reactive group|Participant will contact the research study staff to initiate the program.
89682216|NCT04840329|Experimental|Education Arm|
89682217|NCT04840329|No Intervention|Waitlist Control Arm|
89682218|NCT00632489|Experimental|LBH589 with Capecitabine|MTD, LBH589 with Capecitabine
89682219|NCT00632489|Experimental|LBH589 and Lapatinib|LBH589 and Lapatinib
89682220|NCT00632489|Experimental|LBH589, Capecitabine and Lapatinib|LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)
89682221|NCT04387721||Trifocal IOL(Finevision IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted First group: FineVision
89682222|NCT04387721||Trifocal toric IOL (Finevision Toric IOL, PhysIOL)|We will divide the sample into two groups of patients depending on the IOL implanted: Second group: FineVisionToric
89682223|NCT03355274|Experimental|Patients|Patients suspected of thoracic outlet syndrome Transcutaneous oximetry during upper arm manoeuvers
89682224|NCT03355274|Sham Comparator|controls|healthy asymptomatic subjects Transcutaneous oximetry during upper arm manoeuvers
89682225|NCT00243841|Experimental|Radiation Treatment Arm :A|Patients with a score of Childs A Will receive 3 fractions of radiation over 5-10 days
89682226|NCT00243841|Experimental|Radiation Treatment Arm: B|Patients with a score of Childs B will receive 5 fractions of radiation over 2-6 weeks.
89682227|NCT03832400|Experimental|MET-2 20 g|Subjects will be given a once-daily loading dose of 5 grams (g) of MET-2 in the form of 10 MET-2 capsules orally for the first 4 days. For the following 10 days, patients will take 1.5 g MET-2 in the form of three MET-2 capsules taken once-daily
89682228|NCT03832400|Experimental|MET-2 40 g|Subjects will be given a once-daily loading dose of 10 g of MET-2 in the form of 20 MET-2 capsules orally for the first 4 days. For the following 10 days, subjects will take 1.5 g MET-2 in the form of three MET-2 capsules taken once daily
89682229|NCT03832400|Placebo Comparator|Placebo oral capsule|Subjects receive 10 placebo capsules that are identical in appearance to the MET-2 capsules
89682230|NCT00681083|Experimental|1|Heated breathing tube
89682231|NCT00681083|Active Comparator|2|Non heated breathing tube
89682232|NCT05074875||Cohort 1|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohort 1 subjects will undergo Visit 0 after informed consent is obtained. Eligible subjects will return for follow-up at Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks"
89682233|NCT05074875||Cohort 2|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohort 2 subjects will undergo Visit 1, within 4 (+/- 2) weeks of hospital discharge or outpatient infection, after informed consent is obtained. Eligible subjects will return for follow-up Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks."
89682234|NCT05074875||Cohort 3a|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.~Subjects enrolled within ≤ 12 weeks of hospital discharge or outpatient COVID- 19 infection will undergo their first study visit at Visit 1 (Weeks 6-12)."
89682235|NCT05074875||Cohort 3b|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.~Subjects enrolled ≥ 12 weeks from hospital discharge or outpatient COVID- 19 infection will undergo their first visit within 4 weeks before week 24. Subjects that are enrolled into Cohort 3 will be followed until Week 72."
89682236|NCT01798979|Experimental|Midazolam and GLPG0634|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8) and multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
89682237|NCT00738361|Experimental|nab-paclitaxel|Administered via intravenous bolus at a dose of 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
89682238|NCT02337062|Experimental|APD421 + standard anti-emetic|Single dose of IV APD421
89682239|NCT02337062|Placebo Comparator|Placebo + standard anti-emetic|Single dose of IV placebo
89682240|NCT01279213|Active Comparator|paliperidone clozapine BPRS|patients assigned to clozapine plus paliperidone controls at 6 and 12 weeks
89682241|NCT01279213|Placebo Comparator|clozapine plus placebo BPRS|patients assigned to placebo plus clozapine should show less improvement
89682242|NCT00681473|Experimental|Proton Radiation Therapy|Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.
89682243|NCT03301922|Experimental|Work-focused metacognitive therapy|Work-focused metacognitive therapy
89682244|NCT03301922|Other|Waiting list|Waiting list
89682245|NCT00634283|Experimental|antidepressant-experienced|Subjects who had previously been exposed to active antidepressant medication (venlafaxine)
89216259|NCT04596293|Experimental|BBT-401-1S (1,600mg)|"Induction Phase: BBT-401 1600mg for 8 weeks~Extension Phase: After 8 weeks, Participants will continue the same treatment for 8 weeks"
89682246|NCT00634283|Placebo Comparator|antidepressant-naive|Subjects who had previously been exposed to placebo only (and never to active antidepressant medication)
89216260|NCT04596293|Placebo Comparator|Placebo|"Induction Phase: Placebo for 8 weeks~Extension Phase: After 8 weeks,~Participants who achieved clinical remission in the induction phase will continue the same treatment for 8 weeks~Participants who did not achieve clinical remission in the induction phase will receive BBT-401 800mg for 8 weeks"
89216261|NCT04594512|Other|LENTICULE IMPLANTATION|The present study may suggest that this procedure safely, reliably, and effectively increases corneal thickness and improves visual acuity with no adverse effects. It may even provide new avenues in the treatment of corneal ectasia. Stem cells and live keratocytes are well organized based on cornea transparency and in anterior segment OCT.
89216262|NCT04593186|Experimental|Trans-oral magnifying endoscopy with NBI|Transoral magnifying endoscopy with High Definition Upper Endoscope with Narrow Band Imaging enhancement (Olympus GIF-H290Z)
89216263|NCT04592887|Experimental|FLASH radiotherapy for painful bone metastasis(-es)|
89216264|NCT04585750|Experimental|Phase 1 Monotherapy Dose Escalation|Multiple dose levels of daily oral PC14586 (INN: rezatapopt) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 (INN: rezatapopt) to recommend a Phase 2 dose (RP2D).
89682247|NCT01279291|Experimental|KHK2866 as monotherapy|Groups of subjects will receive a weekly infusions of KHK2866 as treatment for advanced cancer. If there no severe side effects, the dose will be increased for future subjects. A total of four groups are anticipated. Once an acceptable dose is determined an additional seven subjects will be treated at that dose.
89682248|NCT01279291|Experimental|KHK2866, gemcitabine+carboplatin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with gemcitabine and carboplatin. The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
89682249|NCT01279291|Experimental|KHK2866, weekly paclitaxel|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with weekly paclitaxel (80 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
89682250|NCT01279291|Experimental|KHK2866, pegylated liposomal doxorubicin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with monthly PLD (40 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
89682251|NCT05628818|Experimental|Anodal tDCS combined with cognitive training, stroke patients|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over the right supraorbital region (Fp2). Each stimulation will be applied for 20 min at 2mA intensity. Stimulation will be continued with the performance of three cognitive training exercises specifically designed to improving working memory, inhibitory control and cognitive flexibility.
89682252|NCT05628818|Sham Comparator|Sham tDCS combined with cognitive training, stroke patients|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over the right supraorbital region (Fp2). Each stimulation will be applied for 1 min at 2mA intensity (sham stimulation). Stimulation will be continued with the performance of three cognitive training exercises specifically designed to improving working memory, inhibitory control and cognitive flexibility.
89682253|NCT02986425|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
89682254|NCT02986425|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
89682255|NCT04400942||Women with uterine myomas undergoing hysteroscopic myomectomy|
89682256|NCT00682565|Experimental|Mid Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
89682257|NCT00682565|Experimental|High Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
89682258|NCT04788537|Experimental|Intervention Group|
89682259|NCT04788537|No Intervention|Nonintervention Group|
89682260|NCT00756613||465 VADT participants|The participants had previously participated in the VADT CSP #465 study
89682261|NCT05685680|Active Comparator|Group A laparoscopic group|group A laparoscopic surgery
89682262|NCT05685680|Active Comparator|Group B|Group B open surgery
89682263|NCT04367883||Hospital admissions among COVID cases in the assigned population of the Terrassa Health Consortium|"Observation of patient characteristics of hospital incomes in Hospital of Terrassa from March 1, 2020.~No intervention is performed."
89682264|NCT04367883||Evolution of COVID cases in patients receiving antihistamines|"COVID cases, hospital admissions and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with antihistamines.~No intervention is performed."
89682265|NCT04367883||Evolution of COVID cases in patients receiving amantadine.|"COVID cases, hospital admissions and deaths related to COVID from march 1, 2020 in patients of the participating institutions receiving chronic treatment with amantadine.~No intervention is performed."
89682266|NCT00635453|Experimental|I, Intervention|"Physicians, nurses and administrative staff of all intervention health centers participated in a training of Dietary Advice in January 2008 based on the Ten Steps for Healthy Feeding for Brazilian Children from Birth to Two Years of Age guideline.13 An experienced nutritionist conducted a standardized session for the health care team to outline the Ten Steps recommendations and strategies and to provide suggestions how best to incorporate these into the consultations. Printed materials were provided to the Health Care Centers for use by these professionals and for access to the Brazilian Ministry of Healthy Nutrition Department´s website. Health staff members received a pocket guide for use during the appointments and waiting room sessions."
89682267|NCT00635453|No Intervention|II, Control|Healthcare centers randomized to the non-intervention group continued their routine medical assistance without any involvement of the research team. No materials were provided to these clinics.
89682268|NCT04329039|Active Comparator|Group 1|Active somatostatin analogue combined with perioperative antibiotics
89682269|NCT04329039|Placebo Comparator|Group 2|Placebo combined with perioperative antibiotics
89682270|NCT02135861|Experimental|Healthy volunteers|All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.
88996978|NCT00539071|Active Comparator|High Dose group|Those who are randomized to high dose Consta will receive Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose after consent. As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 4 unless symptoms warrant a quicker titration) along with the injections. Any oral risperidone the patients receive will be discontinued after Week 4.Psychopathology will be assessed with a PANSS at Week 6. If no improvement since baseline, dose will be increased to two 50 mg injections q 2 weeks for the remainder of the study.
88996979|NCT00539149|Active Comparator|1|
88996980|NCT00539149|Placebo Comparator|2|
88996981|NCT00539227||NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC). Questionnaires taking about 20-30 minutes to complete.
88996982|NCT00539266|Active Comparator|1|non diabetic patients with Fontaine IIb-IV peripheral artery disease
88996983|NCT00539266|Placebo Comparator|2|non diabetic patients with Fontaine IIb-IV peripheral artery disease
88996984|NCT00539266|Active Comparator|3|diabetic patients with Fontaine IIb-IV peripheral artery disease
88996985|NCT00539266|Placebo Comparator|4|diabetic patients with Fontaine IIb-IV peripheral artery disease
88996986|NCT00539344|Experimental|1|
88996987|NCT00539383|Experimental|1|
89682271|NCT02135861|Experimental|Heart failure patients|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.
89682272|NCT02135861|Experimental|Acute decompensated heart failure|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system
89682273|NCT05627024|Experimental|Experimental: 30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
88996988|NCT00539422||I|group I of 15 women with benign breast lesion
88996989|NCT00539422||II|group II of 16 women with breast cancer
88996990|NCT00539422||III|13 women were taken as a control group
88996991|NCT00539812|Other|1|Standard Care only (standard batterer intervention program)
88996992|NCT00539812|Other|2|Brief alcohol intervention combined with standard care
88996993|NCT00539968|Experimental|Docetaxel plus lonafarnib (single arm)|Docetaxel plus lonafarnib
88996994|NCT00540085|Active Comparator|A|Rocuronium dosed after ideal body weight
88996995|NCT00540085|Active Comparator|B|Rocuronium dosed after corrected body weight 20%
88996996|NCT00540085|Active Comparator|C|Rocuronium dosed after corrected body weight 40%
88996997|NCT00540202|Experimental|1.Oral quinine|Patients will be given oral quinine at the dose of 10mg/kg 8 hourly for 7 days
88996998|NCT00540202|Active Comparator|2. Coartem|Tablets
88996999|NCT00540241||Second-line pemetrexed treatment in NSCLC|Patients with NSCLC who will start second-line treatment with pemetrexed.
88997000|NCT00159224|Experimental|Lopinavir/ritonavir monotherapy|Patients with undetectable viral load while on 1st line ARV therapy will be randomized to the expermental arm: Lopinavir/ritonavir monotherapy
88997001|NCT00159224|Active Comparator|Lopinavir/Ritonavir plus 2 NRTIs|Patients randomized to this arm will continue with standard of care triple therapy, based on Lopinavir/Ritonavir plus 2 NRTIs
88997002|NCT00540280|Active Comparator|Surgery alone|Surgery alone
88997003|NCT00540631|No Intervention|P|subcutaneous treatment with placebo Placebo- physiological saline containing histamine-dihydrochloride 0.1mL, 0.2mL, 0.4mL, 0.6mL of strength A(1000TU/mL) followed by 0.1mL, 0.4mL, 0.6mL by strength B (10000TU/mL) in weekly intervals
88997004|NCT00540631|Experimental|A|Active treatment with house dust mite extract
88997005|NCT00540670|Experimental|1|
88997006|NCT00540670|Experimental|2|
88997007|NCT00540670|Experimental|3|
88997008|NCT00540670|Placebo Comparator|4|
88997009|NCT00183573|Experimental|1|Brief Motivational Intervention only
88997010|NCT00183573|Experimental|2|Brief Informational Intervention only
89682274|NCT05627024|Placebo Comparator|Placebo Comparator: 60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
89682275|NCT00635609|Experimental|Doxycycline hyclate (Doryx)|
89682276|NCT00635609|Active Comparator|Doxycycline hyclate|
89682277|NCT04347902|Experimental|PN with SMOFLipid|Parenteral nutrition with MCT/LCT/olive oil/fish oil (SMOFLipid, Fresenius Kabi, Germany, SMOF group)
89682278|NCT04347902|Active Comparator|PN with Olive oil|Parenteral nutrition with Olive oil/LCT 80:20 (ClinOleic, Baxter Healthcare, USA, OO group)
89682279|NCT04347902|Active Comparator|PN with MCT/LCT|Parenteral nutrition with - Medium/long-chain triglycerides 50:50 (Lipofundin, B Braun Germany, MCT/LCT group)
89682280|NCT02137499|Active Comparator|Healthy subjects|Healthy subjects, free from vascular disease
89682281|NCT02137499|Experimental|Superficial venous insufficiency|Clinically symptomatic and ultrasound evidence of superficial venous insufficiency
89682282|NCT02137499|Experimental|Deep venous insufficiency|Clinically symptomatic and ultrasound evidence of deep venous insufficiency
89682283|NCT02137499|Experimental|Deep venous obstruction|Clinically symptomatic and ultrasound evidence of deep venous obstruction
89682284|NCT01799369|No Intervention|Control|Routine post-operative care
89682285|NCT01799369|Experimental|Intervention|Post-operative care influenced by the Surgical Apgar Score
89682286|NCT05618756|Experimental|Cannabidiol|300 mg CBD (KannaSwiss, Kölliken, Switzerland) dissolved in 1 ml hemp oil. Provided orally in gelatin capsules.
89682287|NCT05618756|Placebo Comparator|Placebo|1 ml hemp oil. Provided orally in gelatin capsules.
89682288|NCT03294668|Experimental|KONTAKT Australia|A social skills group training
89682289|NCT03294668|Active Comparator|Super Chef|A social cooking group
89682290|NCT05339984|Experimental|Hepatectomy|Liver resection group
89682291|NCT05339984|Experimental|Liver Transplantation|Liver Transplantation group
89682292|NCT05339984|Experimental|Portal vein embolization|Portal vein embolization group
89682293|NCT05606978|Experimental|FASTb|Participants receive FAST blended (FASTb): a combination of face-to-face and online therapy
89682294|NCT05606978|Active Comparator|FASTr|Participants receive FAST regular (FASTr): face-to-face therapy
89682295|NCT00684047|Experimental|FS Grifols Preliminary Part (I)|Open label administration of FS Grifols to all subjects
89682296|NCT00684047|Experimental|FS Grifols Primary Part (II)|Single-blind, randomized (2:1)
89682297|NCT00684047|Active Comparator|Manual Compression Primary Part (II)|Single-blind, randomized (2:1)
89682298|NCT04301505|No Intervention|control|Usual care.
89682299|NCT04301505|Other|Intervention 1|COPD management checklist will be delivered at the beginning of the study.
89682300|NCT04301505|Other|Intervention 2|COPD management checklist will be delivered at the beginning of the study and repeated after 6 months.
89682301|NCT00636077|Other|HD-C4 Big|3 consecutive treatments with the HD-C4 Big dialyzer.
88997011|NCT00183573|Experimental|3|Brief Motivational Intervention + Intensive Informational Intervention
88997012|NCT00183573|Experimental|4|Brief Motivational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
88997013|NCT00183573|Experimental|5|Brief Informational Intervention + Intensive Informational Intervention
88997014|NCT00183573|Experimental|6|Brief Informational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
88997015|NCT00183885|Experimental|Cisplatin + Mitomycin-C|CDDP 60mg/m2 + Mitomycin-C 12mg/m2
88997016|NCT05090293|Active Comparator|Lifestyle Intervention (LI)|Participants will receive a standard, 12-week, group-delivered cognitive behavioral lifestyle intervention for weight loss.
88997017|NCT05090293|Experimental|Lifestyle Intervention with Body Image Treatment (LIBI)|Participants will receive a standard, 12-week, group-delivered cognitive behavioral lifestyle intervention for weight loss supplemented with a novel body image intervention designed to address body image issues in the context of weight loss.
88997018|NCT00540748|Experimental|A1|
88997019|NCT00540748|No Intervention|A2|
88997020|NCT00540787|Active Comparator|Drug Treatment|
88997021|NCT00540787|Active Comparator|ThermoCool Radiofrequency Catheter|Radiofrequency catheter used.
89682302|NCT00636077|Other|HD-C4 Small|3 consecutive treatments with the HD-C4 Small dialyzer.
89682303|NCT00636077|Other|F160NR|3 consecutive treatments with the F160NR dialyzer.
89682304|NCT00636077|Other|F200NR|3 consecutive treatments with the F200NR dialyzer.
89682305|NCT05315336|Experimental|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
89682306|NCT00636389|Other|HD-C4 First, then 210H|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux HD-C4 dialyzer. Following the third treatment, the subjects will be switched to the Polyflux 210H dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
89682307|NCT00636389|Other|210H First, then HD-C4|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux 210H dialyzer. Following the third treatment, the subjects will be switched to the Polyflux HD-C4 dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
89682308|NCT04747977|Experimental|OTX-DED 0.2mg|Approximately 50 subjects
89682309|NCT04747977|Experimental|OTX-DED 0.3mg|Approximately 50 subjects
89682310|NCT04747977|Placebo Comparator|Hydrogel Vehicle (HV)|Approximately 50 subjects
89682311|NCT04746716||Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury|Patient who had a psychoeducation and Cognitive Rehabilitation After their Mild Traumatic Brain Injury
89682312|NCT04746716||No Psychoeducation and Cognitive Rehabilitation After Mild Traumatic Brain Injury|Patient who hadn't a psychoeducation and Cognitive Rehabilitation After their Mild Traumatic Brain Injury
89682313|NCT04387409|Active Comparator|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension."
89682314|NCT04387409|Placebo Comparator|Placebo|Physiological saline 0.1ml
89682315|NCT04746495|Placebo Comparator|Placebo|Participants will be randomized to receive 4 weeks of placebo and then 4 weeks of Eplerenone.
89682316|NCT04746495|Experimental|Eplerenone|Participants will be randomized to receive 4 weeks of Eplerenone and then 4 weeks of Placebo.
89682317|NCT04387487|Experimental|Video Group|"Video Group~multimedia video information of 4.5 mins regarding procedure, indication and complications related to spinal anesthesia will be shown to patients in intervention group , patient will be allowed to ask questions."
89682318|NCT04387487|No Intervention|non video group|patients in control group will be given verbal information regarding procedure, indication and complication, patient will be allowed to ask questions.
89682319|NCT04257071|Active Comparator|Usual Care|Participants randomized to the usual care study arm will receive the usual care for their MS.
89682320|NCT04257071|Experimental|OOP Cost Communication and Optimization|Participants in this study arm in addition to usual care, will receive a personalized discussion of their OOP cost estimates for treatment obtained through an online price transparency tool, personalized analysis of expenses by financial counselor, and enrollment in any cost optimization opportunities for which they are eligible using a comprehensive financial navigation program.
89682321|NCT00636701|Experimental|Primed rTMS|Receive 10 min. of 6-Hz rTMS Repetitive Transcranial Magnetic Stimulation at 90% RMT (3,600 pulses). Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
89682322|NCT00636701|Placebo Comparator|Unprimed rTMS)|Receive 10 min. of sham rTMS Repetitive Transcranial Magnetic Stimulation. Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
89682323|NCT03286634|Experimental|SR|"Standard Risk (SR) :~CNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD ≥ 1% (treatment will not be de-escalated even MRD <0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) ≥0.01%~SR strategy:~All SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD ≥0.01%.~During the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval."
89682324|NCT03286634|Experimental|LR|"Low Risk (LR):~Time-point #1 (Day 15 induction) Flow MRD <1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) <0.01% AND CNS 1 only~LR strategy:~For LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.~Following re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients."
89682325|NCT03345290|Experimental|Subjects|Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.
89682326|NCT05011682|Experimental|Joslin Diabetes Senter nutrition|all participants will first follow their own usual diet (2 weeks) and then the Joslin Diabetes Senter nutrition plan (2 weeks)
89682327|NCT04400630|No Intervention|Control (TAU)|patients without any intervention + treatment as usual (TAU)
89682328|NCT04400630|Experimental|PE intervention+TAU|Physical exercise (PE) intervention + treatment as usual (TAU)
89682329|NCT00637247|Experimental|imexon + gemcitabine|imexon + gemcitabine
89682330|NCT00637247|Active Comparator|Placebo + gemcitabine|Placebo in combination with gemcitabine
89682331|NCT04998032|Experimental|supaglutide RP3D dose+metformin|Supaglutide Subcutaneous injection once a week for 52weeks,combined with metformin
89682332|NCT04998032|Placebo Comparator|placebo+metformin|Placebo Subcutaneous injection once a week for 52weeks,,combined with metformin
89682333|NCT04388033|Experimental|Safety Evaluation Group|"Basic treatment phase:~The patients have surgery followed by concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days).~Immunotherapy phase:~Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle. Fusion cells will be suspended in 0.5 mL normal saline and then injected intradermally close to a cervical lymph node. IL-12 will be injected subcutaneously at the same side at dose of 6ug twice for interval of one hour."
89682334|NCT04179929|Other|CHEMOTHERAPY|Pediatric-type of chemotherapy
89682335|NCT04179929|Other|allogeneic HSCT|allogeneic HSCT
89682336|NCT04760756|Experimental|This refers to Fragility Fracture Integrated Rehabilitation Management|This refers to Fragility Fracture Integrated Rehabilitation Management and will include comprehensive rehabilitation program and assessment
89682337|NCT02980731|Experimental|Venetoclax|Venetoclax was administered orally once daily (QD) for a planned duration of up to 2 years or until disease progression; median time on treatment was 127 weeks. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
89682338|NCT04994288|Experimental|Supaglutide RP3D high dose|during the IIb phase 140 subjects were randomly assigned to supaglutide 1mg, 2mg ,3mg and placebo ; when these subjects meets the 12wks HbA1C result, an interim analysis will be made andRP3D high dose is confirmed by IDMC accoding to interim analysis. So during the phase 3 , subjets will be assigned to RP3D hign dose, RP3D low dose and placebo
89682339|NCT04994288|Experimental|supaglutide RD3D Low dose|during the IIb phase 140 subjects were randomly assigned to supaglutide 1mg, 2mg ,3mg and placebo ; when these subjects meets the 12wks HbA1C result, an interim analysis will be made and RP3D high dose is confirmed by IDMC accoding to interim analysis. So during the phase 3, subjets will be assigned to RP3D hign dose, RP3D low dose and placebo
89682340|NCT04994288|Placebo Comparator|placebo|placebo injection
89682341|NCT04345835|Active Comparator|prone flexed|prone flexed PCNL position
89682342|NCT04345835|Active Comparator|prone|prone position PCNL
89682343|NCT04400396||target HM fortification|Contemporary cohort fed HM with target fortification
89682344|NCT04400396||standard HM fortification|Historical cohort fed HM with standard fortification
89051771|NCT04617626|Other|Azithromycin|All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment. All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event. For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.
89051772|NCT04585230|Active Comparator|Group 1: (CBD + MO cohort)|Roll on stick containing CBD and mineral oils (CBD + MO cohort)
89051773|NCT04585230|Active Comparator|Group 2: (MO cohort)|Roll on stick containing mineral oils only (MO cohort)
89051774|NCT04585230|Active Comparator|Group 3: (CBD Cohort)|Roll on stick containing CBD only (CBD cohort)
89051775|NCT04585230|Placebo Comparator|Group 4: (Roll-on stick only with NO CBD or MO-placebo cohort)|Roll on stick with neither CBD nor essential oils (Roll-on stick only with NO CBD or MO-placebo cohort)
89051776|NCT04617899|Experimental|Novasight IVUS/OCT|A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter
89051777|NCT04584840|No Intervention|Group 1 (non-surgical treatment)|"Soft diet.~Suspension of the use of prostheses or intraoral devices.~Oral hygiene guidelines.~Topical antiseptics: in the form of mouthrinses with 0.12% chlorhexidine after every meal and clorhexidine gel over the exposed bone or fistula.~Systemic antibiotics: for patients in stage 2 in which active acute infection is detected with Amoxicillin/Clavulanic Acid 875/125 mg every 8 hours for 2 weeks. Those allergic to penicillin will receive clindamycin 300 mg every 8 hours for 2 weeks or Levofloxacin 500 mg / day for 2 weeks. Systemic antibiotic treatment can be prolonged indefinitely until infection and symptoms are controlled."
89051778|NCT04584840|Experimental|Group 2 (surgical treatment)|"Same guidelines of conservative treatment plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment:~Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~Secure a two layered waterproof closure without tension (simple or with local flaps).~Samples will be sent for Pathological and microbiological analysis.~Stitches removal after two weeks~Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
89051779|NCT02939690|Experimental|UVC and surface measurement formula|UVC insertion depth = Umbilicus to nipple distance minus 1cm
89051780|NCT02939690|Active Comparator|UVC and Birth weight based formula|UVC insertion depth=[(3× birth weight (Kg) + 9)/2+1)] cm
89051781|NCT04580784|Experimental|Hypofractionation|Hypofractionated whole breast radiotherapy using a dose of 28.5 Gy over 5 fractions with once weekly fractions.
89051782|NCT02939729|Experimental|Prehabilitation|This group will receive standard preoperative information and education and be provided with a physiotherapy prehabilitation programme. This programme will be carried out from time of consenting to participate in the study until day of admission to surgery for cardiac or thoracic surgery. The prehabilitation programme consists of: walking programme, deep breathing exercises and tidal volume measurement using the incentive spirometer.
89051783|NCT02939729|No Intervention|Standard Care|This group will receive standard preoperative information and education only.
89051784|NCT00570180|Experimental|Single Arm|Please see intervention description for Bortezomib (Velcade)
89051785|NCT02939807|Experimental|advanced HCC, tumor progression with sorafenib|Patients with advanced HCC who have experienced tumor progression with sorafenib will receive ABC294640.
89682345|NCT04400162|Active Comparator|CCT (standard)|This arm consists of the CCT in a standard variant that provides the basic training experience without any added gaming elements.
89682346|NCT04400162|Experimental|CCT (game)|This arm consists of the same CCT as the standard version, however pre-defined gaming elements that are thought to increase usability as well as interest in the intervention have been added.
89682347|NCT03281096|Experimental|Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years
89682348|NCT03281096|Placebo Comparator|Placebo|identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years
89682349|NCT04731987|Experimental|Orange juice (A)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of orange juice naturally rich in hesperidin (drink A) during 6 weeks
89682350|NCT04731987|Placebo Comparator|Control beverage (B)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of control beverage (drink B)- a soft drink with sugar concentration identical to drink A - during 6 weeks
89051786|NCT02939846|Experimental|Trametinib|Subjects will be administrated with trametinib 2 mg once daily until disease progression.
89682351|NCT04731987|Experimental|Control beverage supplemented with hesperidin formulation (B+HESP)|42 subjects between 40 and 65 years old with predisposition to cardiovascular disease will consume daily 330 ml of control beverage (identical to drink B but supplemented with hesperidin to reach level of drink A) during 6 weeks
89051787|NCT04584996||Pancreatic cancer|Patients being evaluated at MDT for suspected Pancreatic Ductal Adenocarcinoma (PDAC), via radiological test (e.g. endoscopic ultrasound (EUS), endoscopic retrograde cholangiography (ERCP), cross-sectional imaging), serum tumour marker (i.e. CA 19-9), or other diagnostic procedure
89051788|NCT04584996||Control|Patients diagnosed and/or due to undergo surgery for benign pathology (e.g. gallstones, chronic pancreatitis, etc); or patients with a diagnosis of a pre-malignant lesion (e.g. pancreatic intraductal papillary mucinous neoplasm); Pancreatic Neuroendocrine Tumour, or a Biliary Tract Cancer (i.e. cholangiocarcinoma; gallbladder cancer; ampullary cancer)
89051789|NCT02939495|Experimental|Study drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet
89051790|NCT04584879|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
89051791|NCT04584879|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
89682352|NCT04976348||Consenting participants|All subjects aged ≥16 years referred to the cardiology or genetic department for heart failure like symptoms (as stated in the ESC 2016 Guidelines) or for cardiac/cardiogenetic screening.
89682353|NCT04725591|Active Comparator|Diabeloop closed-loop glucose control session with the declaration of meals|"Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and MEDISAFE WITH insulin pump.~Subjects are asked to declare their meals for 4 weeks.~A remote monitoring system is provided in closed-loop session."
89682354|NCT04725591|Experimental|Diabeloop closed-loop glucose control session without the declaration of meals|"Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and MEDISAFE WITH insulin pump.~Subjects are asked to not declare their meals for 4 weeks.~A remote monitoring system is provided in closed-loop session."
89682355|NCT02980497|Active Comparator|Listerine Zero Mouthwash (without alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Zero Mouthwash (without alcohol) for 30 seconds.
89682356|NCT02980497|Active Comparator|Listerine Antiseptic Mouthwash (with alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Antiseptic Mouthwash (with alcohol) for 30 seconds.
89682357|NCT02980497|No Intervention|Brush only|Brush only twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush.
89682358|NCT05325086|Experimental|Adapted information arm|"In parallel with an inpatient PR program, 4 visits will be carried out: V0 : Inclusion / V1 : Randomization / V2 : Follow-up / V3: End-stay.~At V1:~Adapted information to the characteristics of a greater openness to experiences will be delivered to patient.~The following questionnaires will be filled : Big Five Inventory BFI-FR, St. George's Respiratory SGRQ, Dyspnea-12, Self-efficacy for managing chronic disease SEMCD-6, Brief Illness Perception B-IPQ, COPD Anxiety Revised CAF-R, Patient Health PHQ-9, Montreal Cognitive Assessment Mini-MoCA~At V2:~*Semi-structured individual interviews will be performed. Questions will relate to the information distributed during V1 (adapted information), allowing to assess the understanding and the appropriation of it.~At V3:~The following questionnaires will be filled: SGRQ,Dyspnea-12,SEMCD-6,B-IPQ,CAF-R~In addition, some questions will be asked to verify the adherence to information and the potential contamination bias"
89682359|NCT05325086|Sham Comparator|Neutral information arm|"In parallel with an inpatient PR program, 4 visits will be carried out: V0 : Inclusion / V1 : Randomization / V2 : Follow-up / V3: End-stay.~At V1:~Neutral information will be delivered to patient.~The following questionnaires will be filled : Big Five Inventory BFI-FR, St. George's Respiratory SGRQ, Dyspnea-12, Self-efficacy for managing chronic disease SEMCD-6, Brief Illness Perception B-IPQ, COPD Anxiety Revised CAF-R, Patient Health PHQ-9, Montreal Cognitive Assessment Mini-MoCA~At V2:~*Semi-structured individual interviews will be performed. Questions will relate to the information distributed during V1 (neutral information), allowing to assess the understanding and the appropriation of it.~At V3:~The following questionnaires will be filled: SGRQ,Dyspnea-12,SEMCD-6,B-IPQ,CAF-R~In addition, some questions will be asked to verify the adherence to information and the potential contamination bias"
89682360|NCT04245501|Experimental|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized 16-session intervention aimed at reducing interpretation bias. In this study, CBM-I is personalized to youth anxiety symptoms. During CBM-I sessions, youth indicate whether word-sentence pairs are related, and are provided with feedback aimed to reduce bias.
89682361|NCT04245501|Placebo Comparator|Interpretation Control Condition (ICC)|"Computerized 16-session intervention that is not believed to significantly modify bias. In this study, youth see stimuli personalized to their anxiety symptoms. During ICC sessions, youth see word-sentence pairs and are required to indicate whether word and sentence are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
89682362|NCT05301686||Patients with Cyclop lesion|Patients with an anterior cruciate ligament reconstruction with a symptomatic Cyclop lesion leading to a arthroscopy within 2 years after primary surgery
89682363|NCT05301686||Patients without Cyclop lesion|Patients without no arthroscopy within 2 years after primary surgery
89682364|NCT02652429|Experimental|Inhaled Nitric Oxide (iNO)|Pulsed iNO 75 mcg/kg IBW/hour
89682365|NCT02294253|Experimental|Buprenorphine/naloxone stabilization|Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
89682366|NCT02295735|Experimental|Mepilex® Border|If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
89682367|NCT02295735|No Intervention|Control|Standard pressure ulcer prevention according to hospital standard
89682368|NCT00684983|Active Comparator|Arm A (lapatinib ditosylate, capecitabine)|Patients receive capecitabine PO BID on days 1-14 and lapatinib ditosylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89051792|NCT04584879|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
89051793|NCT04584879|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
89051794|NCT04584879|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
89051795|NCT04584879|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
89051796|NCT00570219|Experimental|B|Gradual benzodiazepine discontinuation and valproate treatment
89051797|NCT00570219|No Intervention|A|Gradual benzodiazepine discontinuation
89051798|NCT02939534||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
89051799|NCT04584957|Active Comparator|VAC therapy|Prophylactic ciNPWT therapy positioning YES. Patients enrolled for placement of the device over a closed incision immediately post-operatively.
89051800|NCT04584957|No Intervention|Standard Closure|Prophylactic ciNPWT therapy positioning NO. Patients enrolled for standard laparotomic closure without ciNPWT positioning
89682369|NCT00684983|Experimental|Arm B (cixutumumab, lapatinib ditosylate, capecitabine)|Patients receive capecitabine and lapatinib ditosylate as in Arm A. Patients also receive cixutumumab IV over 1 hour on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89682370|NCT04189341|Active Comparator|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
89682371|NCT04189341|Active Comparator|Group T = mTLIP group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
89682372|NCT04189341|No Intervention|Group C = Control group|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
89682373|NCT02337218|Active Comparator|SENSUS Pain Management System|Electrical stimulation device worn on the leg delivering a dose of 50 volts.
89682374|NCT02337218|Sham Comparator|SENSUS Pain Management System - Sham|Electrical stimulation device worn on the leg and programmed to deliver no stimulation.
89682375|NCT02641587|Experimental|CHTP 1.2|Ad libitum use of the CHTP 1.2
89682376|NCT02641587|Active Comparator|CC|Ad libitum use of subject's own preferred non-menthol brand of CC
89682377|NCT00638651|Active Comparator|1|The tattoo will be treated with laser and imiquimod 5% cream
89682378|NCT00638651|Placebo Comparator|2|The tattoo will be treated with laser and placebo topical cream
89682379|NCT00685139|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered after an overnight fast.
89682380|NCT00685139|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered after an overnight fast.
89682381|NCT03338036|Experimental|Heart Rate Variability/Neurofeedback|Participants in this arm of the study will receive HRV biofeedback and neurofeedback. HRV biofeedback will occur twice daily, using an android device and application. Additionally, three times per week they will have one-hour long neurofeedback sessions.
89682382|NCT03338036|No Intervention|Post-Concussed Control Group|Age-matched, previously concussed individuals that have completed the same concussion rehabilitation program (Brain Ex 90) will be recruited for this arm.
89682383|NCT03338036|No Intervention|Non-Concussed Control Group|Age-matched individuals who have not been diagnosed with a concussion in the previous two years
89682384|NCT00685295|Experimental|Arm 1 / Fentora|"Intervention Group:~Subject receives:~placebo oral/swallowed pill~Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet"
89682385|NCT00685295|Active Comparator|Arm 2 / Percocet/Prevacid|"Active Comparator Group:~Subject receives:~Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill~Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet"
89682386|NCT02319291||Participants|P.F.C. Sigma PS150 RP Total Knee System
89682387|NCT00686231|Experimental|Dose Test 15mg NTG|Nitroglycerin 15mg (NTG) applied topically to one wrist and placebo to the other wrist at Visit 1
89682388|NCT00686231|Experimental|Dose Test 30mg NTG|Nitroglycerin 30mg applied topically to one wrist and placebo to the other wrist at Visit 1
89682389|NCT00686231|Experimental|Combination Test 20mg Lidocaine|Lidocaine 20mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 20mg + placebo applied to the other wrist, at Visit 2
89682390|NCT00686231|Experimental|Combination Test 40mg Lidocaine|Lidocaine 40mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 40mg + placebo applied to the other wrist, at Visit 2
89682391|NCT04122053|Experimental|study group|group will receive dietary advice and genotype information
89682392|NCT04122053|Active Comparator|Control group|group will receive dietary advice
89682393|NCT00638885||Group 1|
89682394|NCT04278716||Utilization of a safe return to play checklist|Athletes who were treated for a capsulolabral tear who have undergone arthroscopic capsulolabral repair surgery will be evaluated using an objective checklist prior to being allowed to return to their sport. The utilization and outcome of using this checklist will be evaluated
89682395|NCT05278208|Experimental|Phase I-II|"Pediatric patients (4 -12 years, Phase I) and adolescent and young adult patients (>12years, Phase II) with recurrent/progressive high-grade central nervous system tumors and meningiomas that express SST2A and demonstrate uptake on DOTATATE PET will receive Lutathera once every 8 weeks (1 cycle) for a total of 4 doses over 8 months~Phase I starting dose will be 200 mCi*(BSA/1.73m2), corresponding to the BSA-adjusted FDA approved adult Lutathera dosing. The first cycle will be used as the DLT period. Once MTD/RP2D is established, an efficacy expansion cohort of up to 10 patients will be opened to determine the preliminary efficacy of MTD/RP2D of Lutathera in this cohort~Phase II patients will receive the adult RP2D of 200 mCi every 8 weeks to determine the anti-tumor activity of Lutathera in this patient population, through evaluation of 6-month PFS as the primary efficacy endpoint. Response will be assessed on imaging (brain/spine MRI and DOTATATE PET) following every cycle."
89051801|NCT04610957|Experimental|The 1st group|included eighty (80) women receiving Clomiphene citrate (CC) in the form of (Clomid 50 mg tablet, Sanofi Aventis, France) at dose (100 mg/day in two divided doses, starting from day 3 to day 7 of the cycle), plus Phytoestrogens (Isoflavonoids) in the form of (RosaFem 800 mg tablet, DeluxLab, Egypt) at dose (1600 mg/day in two divided doses (each dose one tablet), starting from day 3 to day 12 of the cycle
89051802|NCT04610957|Experimental|The 2nd group|included eighty (80) women receiving Clomiphene citrate only, at dose (100 mg/day, starting from day 3 to day 7 of the cycle).
89682396|NCT03335774|Active Comparator|Hydrocortisone Acetate Suppository, 25 mg|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
89682397|NCT03335774|Placebo Comparator|Placebo (Vehicle) Suppository|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
89682398|NCT03335540|Experimental|Arm B|Combination therapy determined by biomarker assessment
89682399|NCT03335540|Experimental|Arm C|Combination therapy determined by biomarker assessment
89682400|NCT03335540|Experimental|Arm D|Combination therapy determined by biomarker assessment
89682401|NCT03335540|Experimental|Arm F|Combination therapy determined by biomarker assessment
89682402|NCT03335540|Experimental|Arm G|Combination therapy determined by biomarker assessment
89682403|NCT05265494|Experimental|NESA INTERVENTION|"Group 1: Application of Nesa microcurrents through the NXSIGNAL® generator twice a week.~The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions)."
89682404|NCT05265494|No Intervention|CONTROL-NO INTERVENTION|Group 2: Control group without NESA XSIGNAL® application The same protocol for the analysis of variables is followed, but without performing any type of treatment with the NESA XSIGNAL device.
89682405|NCT04278638|Experimental|with IORT|
89682406|NCT04278638|Active Comparator|without IORT|
89682407|NCT05255822|Experimental|INNA-051 arm 1|INNA-051 intranasal spray low dose administered once on each of Days -4 and -2 prior to viral challenge
89682408|NCT05255822|Experimental|INNA-051 arm 2|NNA-051 intranasal spray high dose administered once on each of Days -4 and -2 prior to viral challenge
89682409|NCT05255822|Placebo Comparator|Placebo|Placebo intranasal spray low dose administered once on each of Days -4 and -2 prior to viral challenge
89682410|NCT00643097|Experimental|Arm I (ACTIVATE)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)-specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, every 2 weeks starting 4 weeks after the completion of radiation. Subsequent vaccinations were given once a month until clinical or radiographic evidence of progression or death.
89682411|NCT00643097|Experimental|Arm II (ACT II STD)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 200 mg/m2 for the first 5 days of a 28 day cycle.
89682412|NCT00643097|Experimental|Arm III (ACT II DI)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 100 mg/m2 for the first 21 days of a 28 day cycle.
89682413|NCT03333668|Active Comparator|Lisdexamfetamine - Placebo|
89682414|NCT03333668|Active Comparator|Guanfacine - Placebo|
89682415|NCT03333668|Experimental|Lisdexamfetamine - Guanfacine|
89682416|NCT05502146|Experimental|Bolus 6 micrograms Noradrenaline group|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride.
89682417|NCT05502146|Active Comparator|Bolus 8 micrograms Noradrenaline group|Mothers in this group will receive a bolus of Norepinephrine 8 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride.
89682418|NCT04027361|Active Comparator|Amphetamine ER Tablets, 20 mg|Double-blind amphetamine extended-release tablets, 20 mg dose, single tablet, administered at baseline
89682419|NCT04027361|Placebo Comparator|Placebo|Matching double-blind placebo tablets, 20 mg dose, single tablet, administered at baseline
89682420|NCT04024085||Participants|adult with a multiple sclerosis diagnosis, able to walk 50 meters without human help, Expanded Disability Status Scale (EDSS) < 7, consulting in a neuro-urology department
89682421|NCT04878380|Active Comparator|Tracking|Throughout the 22 week study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week.
89682422|NCT04878380|Experimental|Goal-Setting|"Throughout the 22 week study, participants in both groups will be rewarded for logging their nightly sleep sessions regularly on their study wearable device, based on a weekly completion bonus for a minimum of 3 nights of sleep preceding weekdays (Sunday - Thursday nights) per week.~During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight."
89682423|NCT03793439|Experimental|Open-label treatment|All subjects will receive tofacitinib 5mg twice daily from week 0 to week 16, and a corticosteroid taper starting at week 16. Participants also undergo spirometry, RNA sequence testing, and laboratory evaluations.
89682424|NCT04672083|Experimental|Cohort 1|6 subjects receiving a single subcutaneous injection of CPT31 (0.01 mg/kg) and 2 subjects receiving matching placebo SC injection
89682425|NCT04672083|Experimental|Cohort 2|6 subjects receiving a single subcutaneous injection of CPT31 (0.04 mg/kg) and 2 subjects receiving matching placebo SC injection
89682426|NCT04672083|Experimental|Cohort 3|6 subjects receiving a single subcutaneous injection of CPT31 (0.12 mg/kg) and 2 subjects receiving matching placebo SC injection
89682427|NCT04672083|Experimental|Cohort 4|6 subjects receiving a single subcutaneous injection of CPT31 (0.24 mg/kg) and 2 subjects receiving matching placebo SC injection
89682428|NCT00687167|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
89051803|NCT00570375|Experimental|Single Arm|All patients will receive 150 mg of Erlotinib
89051804|NCT04617509|Experimental|Part I GS-248 Formulation A|Formulation A given in fasting state.
89682429|NCT00687167|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
89682430|NCT04277780|Experimental|CGM Sensor|Subjects will receive the Libre Pro Freestyle continuous glucose monitor (CGM) sensor that will be applied to their upper arm at the time of hospital discharge. They will be asked to peel off the sensor after 14 days and mail it to the endocrinology clinic in a stamped envelope that will be provided. They will also be provided the conventional diabetes management which will include instructions on fingerstick blood glucose monitoring and logging which they will start after the CGM sensor is removed. The sensor data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time the sensor is placed for further management of their diabetes.
89682431|NCT04277780|Active Comparator|Conventional Diabetes Care|Subjects will receive only the conventional diabetes management at the time of hospital discharge which includes instruction on fingerstick blood glucose monitoring and logging onto a blood glucose log sheet for 14 days. They will then be asked to fax/mail/call-in the blood glucose log. The log data will be analyzed by a clinician who will call the subject regarding any changes to their diabetes management. The subject will then be asked to follow-up at the endocrinology clinic 1-month, 3-month, and 6-month from the time of hospital discharge for further management of their diabetes.
88997022|NCT00159380|Experimental|Healthy volunteers|8 non smokers non asthmatic
88997023|NCT00159380|Experimental|Asthma volunteers|8 asthmatic mild
88997024|NCT00190398|Experimental|1|Carotid angioplasty and stenting with cerebral protection
88997025|NCT00540826||A|A: ADHD-patients receiving non-stimulants (e.g. atomoxetine)
88997026|NCT00540826||B|B: ADHD-patients receiving stimulants
88997027|NCT00540865|Experimental|A|Participants will receive problem-solving therapy and case management
88997028|NCT00540865|Active Comparator|B|Participants will receive case management
88997029|NCT00540904|Active Comparator|sodium bicarbonate|Solution 154 mEq/L of sodium bicarbonate
88997030|NCT00540904|Active Comparator|Sodium chloride|Solution of 154 mEq/L of NaCl
88997031|NCT00540943|Experimental|Single Arm|irinotecan and cetuximab in combination with pazopanib.
88997032|NCT02963259||SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system|Subjects will be implanted with SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
88997033|NCT00541060|Active Comparator|A|250 young patients presenting several carious lesions
88997034|NCT00541060|Placebo Comparator|B|160 young adults totally caries free
88997035|NCT00159497|Active Comparator|1|Standard porouscoated Trilogy Cup
88997036|NCT00159497|Experimental|2|HA coated Trilogy cup
88997037|NCT00541177|Experimental|1|use 0.25% atropine once a week
88997038|NCT00541177|Active Comparator|2|use 0.5% tropicamide everyday
88997039|NCT02963298|Active Comparator|CRRT after cardiac arrest|Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.
88997040|NCT02963298|No Intervention|control|Repetitive testing of blood Glutamate levels without CRRT
88997041|NCT00541333|Active Comparator|Copaxone|
88997042|NCT00541333|Sham Comparator|Sham|
88997043|NCT00541372|Experimental|1|Needle 5 mm
88997044|NCT00541372|Active Comparator|2|Needle length 8 mm
88997045|NCT00159536|Experimental|Metformin|Metformin 1000mg x 2 daily
88997046|NCT00159536|Placebo Comparator|placebo|Placebo x 2 daily
88997047|NCT03456973|Experimental|Nurse AMIE|
88997048|NCT00541489|Placebo Comparator|1|
88997049|NCT00541489|Active Comparator|2|Naproxen 500 mg
88997050|NCT00541489|Experimental|3|Naproxcinod 750 mg
88997051|NCT00190437|Experimental|1|Amoxicillin-clavulanic
88997052|NCT00159575|Experimental|M: Metformin P: Placebo|
88997053|NCT00541567|Placebo Comparator|1|
88997054|NCT00541567|Experimental|2|
88997055|NCT00541567|Experimental|3|
88997056|NCT00541567|Experimental|4|
88997057|NCT00541606|Experimental|Intervention|Received collaborative care including a clinical pharmacist practitioner.
88997058|NCT00541606|Active Comparator|Control|Patients received usual care directed by their physician.
88997059|NCT00541723|Experimental|IncobutolinumtoxinA (Xeomin), 4-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 4 x 0.06 mL (4 x 3 units = 12 units); mode of administration: intramuscular injection."
88997060|NCT00541723|Placebo Comparator|Placebo 4-injection scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 4 x 0.06 mL placebo solution; mode of administration: intramuscular injection.
88997061|NCT00541723|Experimental|IncobotulinumtoxinA (Xeomin), 3-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 3 x 0.08 mL (3 x 4 units = 12 units); Mode of administration: intramuscular injection."
88997062|NCT00541723|Placebo Comparator|Placebo 3-injection Scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 3 x 0.08 mL placebo solution; mode of administration: intramuscular injection.
88997063|NCT00541762|Other|A, 3; B, 3; C, 3|A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
88997064|NCT00541879|Experimental|I|Elementary school children -grades 2-6 participating in Program ENERGY
89682432|NCT00687713|Active Comparator|Bupropion|Subjects will receive bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
89682433|NCT00687713|Placebo Comparator|Placebo|Subjects will receive a matched bupropion placebo 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
89682434|NCT02304159|Experimental|Group A - 16 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks
89682435|NCT02304159|Active Comparator|Group B - 24 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks
89682436|NCT02143973|Experimental|nalbuphine HCl ER|nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.
89682437|NCT04400240|Experimental|Intervention|complete questionnaires and phone sessions
89682438|NCT04400240|No Intervention|Control|complete questionnaires only
89682439|NCT03028701|Experimental|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
89051805|NCT04617509|Active Comparator|Part I GS-248 Formulation B|Formulation B given in fasting state.
89051806|NCT04617509|Other|Part II GS-248 Formulation A or B|Formulation A or B given in fed condition
89051807|NCT00570414|Active Comparator|1|Laryngeal mask airway (LMA)
89051808|NCT00570414|Active Comparator|2|Endotracheal tube (ETT)
89051809|NCT04617431|Experimental|Intervention group|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
89051810|NCT04617431|No Intervention|Control group|"The participants of control group had a wearable device and could upload their dietary diary to the health management platform every day. But no LINE group was created, and no reminding."
89051811|NCT00568035|Active Comparator|QR-333|
89051812|NCT00568035|Placebo Comparator|Placebo|
89051813|NCT04611113|Experimental|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
89682440|NCT02267655|Active Comparator|inhaled Nitric Oxide 30 mcg/kg IBW/hr|30 mcg/kg IBW/hr of inhaled Nitric Oxide Part 1
89682441|NCT02267655|Active Comparator|inhaled nitric oxide 75 mcg/kg IBW/hr|Part 2: 75mcg/Kg IBW/hr
89682442|NCT02267655|Active Comparator|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|Part 3a: Dose tritration 5, 10 and 15 mcg/Kg IBW/hr Part 3b: continuing on dose determined by PI in 3a for 4 weeks
89051814|NCT04611113|Active Comparator|Control nutritional support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
89051815|NCT04611269||Adult, patients with COVID-19 admitted to the ICU requiring mechanical ventilation|"This is a prospective cohort study including patients >18 years RT-PCR positive for SARS Cov-2 admitted to the ICU that require mechanical ventilation. Epidemiological data, comorbidities, previous signs of symptoms of COVID-19. On admission, severity of disease scores, laboratory management data, blood gases and acid-base chemistry,respiratory and mechanical ventilation management,and complications (Development of ARDS, septic shock, acute kidney injury, thromboembolic events, infections and septic shock, will be recorded. If patients die, causes of death will be recorded.Treatments administered by attending physicians will be registered.~Dates of hospital and ICU admission, of death and/or discharge will be recorded.~No intervention will be administered. Follow-up will continue until death or ICU/hospital discharge"
89051816|NCT00568113|Experimental|NAC group|NAC given plus 17Oh progesterone caproate
89051817|NCT00568113|Active Comparator|Progesterone group|17 OH progesterone caproate
89051818|NCT04617392|Active Comparator|controlled group|25 patients after bariatric-metabolic surgery without controlled postprocedural training
89051819|NCT04617392|Experimental|active group|25 patients after bariatric-metabolic surgery with controlled postprocedural training
89682443|NCT02267655|Placebo Comparator|Placebo|Placebo for 75 mcg/kg IBW/hr
89682444|NCT00689819|Active Comparator|BP < 140/90 mmHg|This arm will target a blood pressure of < 140/90 mmHg (or < 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
89682445|NCT00689819|Experimental|BP < 120/80 mmHg|This arm will target a more aggressive blood pressure target of < 120/80 mmHg.
89682446|NCT04858958|Experimental|treated subjects will receive Furmonertinib 160mg/day,|treated subjects will receive Furmonertinib 160mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
89682447|NCT04858958|Experimental|treated subjects will receive Furmonertinib 240mg/day,|treated subjects will receive Furmonertinib 160mg/day, QD, PO, under fasted state, until progressive disease, death or intolerability.
89682448|NCT04858958|Experimental|treatment-naïve subjects will receive Furmonertinib 240mg/day|Treatment naïve patients with EGFR exon 20 insertion mutation positive NSCLC
89682449|NCT04102293|Experimental|Rotary instrumentation using MM files 1|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
89682450|NCT04102293|Active Comparator|Manual instrumentation using K-files 1|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Incremental filling Technique.
89682451|NCT04102293|Experimental|Rotary instrumentation using MM files 2|Rotary instrumentation using MM files (IMD Inc, China), sizes 20-25-30 taper 0.4, length 16 mm, then obturation with Zinc oxide and Eugenol using Disposable syringe technique.
89682452|NCT04102293|Active Comparator|Manual instrumentation using K-files 2|Manual instrumentation using K-files (Mani Inc, Tochigi, Japan), sizes 15-20-25-30-35 then obturation with Zinc oxide and Eugenol using Disposable syringe technique
89682453|NCT00690833|Experimental|topical desonide hydrogel 0.05%|Approximately 40 male and female subjects (about 20 age 3 months to <13 years and 20 age 13 and up) with mild to moderate atopic dermatitis will apply desonate gel twice daily to ATD
89682454|NCT02110641|Active Comparator|In-Person or Telephone-Based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs.
89051820|NCT00568152|Experimental|Low PA apple puree|230grams of low PA apple puree (Golden Delicious) consumed daily for 14 days.
89051821|NCT00568152|Experimental|High PA apple puree|High PA apple puree (Mitchalin) 230grams consumed daily for 14 days
89051822|NCT00568152|Placebo Comparator|Aspirin|75mg dispersable aspirin taken daily for 14 days
89051823|NCT04610879|Active Comparator|Carbamazepine plus sleep intervention|
89051824|NCT04610879|Active Comparator|Carbamazepine plus standard care|
89051825|NCT04610879|Active Comparator|Levetiracetam plus sleep intervention|
89051826|NCT04610879|Active Comparator|Levetiracetam plus standard care|
89051827|NCT04610879|Active Comparator|No AED plus sleep intervention|
89051828|NCT04610879|No Intervention|No AED plus standard care|
89051829|NCT04617236|Experimental|Cultivando la Salud Educational Intervention|After completing eligibility and baseline surveys, Lay health workers delivered an educational intervention for breast and cervical cancer screening. This educational session was delivered in participants' home and lasted between 1-2 hours. Follow-up data was collected 4-6 months post educational session.
89051830|NCT04617236|No Intervention|Control|No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 4-6 months post-baseline survey.
89051831|NCT00568191||1|retinal thickness program Stratus OCT software 4.0
89051832|NCT00568191||2|retinal cube 200x200 program of Cirrus OCT
89051833|NCT00570570|Other|group 1|Muscular Strengthening for paretic knee flexor and extensor
89051834|NCT00570570|Active Comparator|group 2|conventional physiotherapy
89051835|NCT04617119|Experimental|Conventional physical therapy treatment and IMT|"The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.~In addition, the patient will receive inspiratory muscle training (IMT) by using a threshold IMT device. Patient will ask to use the device twice daily. In each time, patient will perform 3 sets of 10 breaths with 1-minute rest between sets.~Exercise intensity will start with 10 % of pre-measured maximal inspiratory pressure.~Once the patient successfully completed 30 breath twice a day, the exercise load will increase 5% more in the subsequent training session.~This treatment protocol will perform daily for 2 weeks."
89051836|NCT04617119|Active Comparator|Conventional physical therapy|The conventional physical therapy treatment for COVID-19 patient will be based on patient medical and physical status.
89051837|NCT00570609|Experimental|CPR Anytime|Participants will be asked to complete the program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
89051838|NCT00570648|Experimental|1|1% sodium hyaluronate (Healoon) applied at the end of surgery to the surface of the corneal transplant
89051839|NCT00570648|No Intervention|2|Nothing applied at the end of surgery
89051840|NCT00563030||1|Patients undergoing CABG with CPB
89051841|NCT00563030||2|Patients undergoing off-pump CABG
89051842|NCT04584450||1|COVID-19 survivors.
89051843|NCT00570804|Other|MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
89051844|NCT00570804|Other|MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
89051845|NCT00570843|Active Comparator|1.|
89051846|NCT00570843|Placebo Comparator|2.|
89051847|NCT04580355|Experimental|FMUD + Placebos|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
89051848|NCT04580355|Active Comparator|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
89051849|NCT00570882|Active Comparator|Sunitinib 4/2|Sunitinib 50 mg PO 4-week on and 2-week off
89051850|NCT00570882|Experimental|Sunitinib 2/1|Sunitinib 50 mg PO 2-week on 1-week off
89051851|NCT00563147|Experimental|A|tivozanib (AV-951) plus temsirolimus
89051852|NCT00570999|Experimental|Arm A|Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
89051853|NCT00570999|Placebo Comparator|Arm B|Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
89051854|NCT04616261|Experimental|SET-HIGH|High volume speed endurance training
89051855|NCT04616261|Experimental|SET-LOW|Low volume speed endurance training
89051856|NCT04616222||CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery
89051857|NCT04616222||Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery
89051858|NCT04584177|Experimental|Arm-hand BOOST + Control|First 4 weeks arm-hand boost program, afterwards, 4 weeks of control program
88997065|NCT00541879|Sham Comparator|II|Elementary school children in grades 2-6 matched to the intervention classes not receiving any intervention
88997066|NCT00541918|Active Comparator|1|propofol
88997067|NCT00541918|Experimental|2|sevoflurane
88997068|NCT00541957|Other|2|Medication prescribed by PCP
88997069|NCT00541957|Experimental|1|Medication prescribed by PCP + behavior therapy
88997070|NCT00190515|Active Comparator|1|5-FU/l-LV
88997071|NCT00190515|Experimental|2|UFT/LV
88997072|NCT00542074|Experimental|1|
88997073|NCT00542074|Active Comparator|2|
88997074|NCT00542113|Experimental|1|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 1
88997075|NCT00542113|Experimental|2|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 2
88997076|NCT00542113|Sham Comparator|3|Parents of elementary school children in grades 2-6 participating in Program ENERGY matched to the intervention groups
88997077|NCT00542152|Active Comparator|CICLO|"Cyclosporine will be administered by continuous intravenous infusion at the initial dose regimen of 2mg/kg per day.~After 24 hours of treatment, cyclosporine trough level will be measured and the dose adapted in order to obtain a cyclosporinaemia level between 150 and 250 ng/ml. Cyclosporinaemia will be reassessed every 48 hours for the duration of the continuous intravenous treatment."
88997078|NCT00542152|Active Comparator|INFLIXIMAB|"INFLIXIMAB (REMICADE) Infliximab in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution, and slowly infused at the dose of 5mg/kg in 2 hours.~In patients with clinical response at D7 (Lichtiger Index score < 10 for 2 consecutive days), two additional infliximab infusions will be administered at the dose of 5mg/kg at D14 and D42."
88997079|NCT00542347|Active Comparator|1|"esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
88997080|NCT00542347|Active Comparator|2|"generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
88997081|NCT00542464|Placebo Comparator|Cohort 1|1.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
88997082|NCT00542464|Placebo Comparator|Cohort 2|2.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
88997083|NCT00542464|Placebo Comparator|Cohort 3|4.0 mg/kg Imprime PGG administered daily over 2 hr for 7 consecutive days
89682455|NCT02110641|No Intervention|Usual Care/Wait List|At 6-months the participants in the Wait List group may choose to participate in the 11 sessions either in-person or via telephone or a combination of the two modes of delivery. They will also be offered the opportunity to return to Yale at 12-months (immediately after the end of the 6-month counseling sessions) to have weight and DEXA measured.
89682456|NCT04349553|Experimental|ZH9PA 1x10^9 CFU|1mL ZH9PA 1x10^9 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
89682457|NCT04349553|Experimental|ZH9PA 1x10^10 CFU|1mL ZH9PA 1x10^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
89682458|NCT04349553|Experimental|ZH9PA 1x10^10 CFU plus ZH9 1x10^10 CFU|1mL ZH9PA 1x10^10 CFU suspension in normal saline and 1mL ZH9 1x10^10 CFU suspension in normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
88997084|NCT00542581|Experimental|The Acrysof toric SN60T3 IOL|Multifocal Intraocular Lens
88997085|NCT00542698|No Intervention|Control|Control group uses 90 minutes of standard diabetes education/ 7 days using the International Diabetes Center curriculum & update phone call at 4 weeks.
88997086|NCT00542698|Experimental|Intervention|Interventional group received standard diabetes education, CGMS monitor, and extra educational topics including CGMS counceling.
88997087|NCT00542737|Active Comparator|Early Intervention Group|
88997088|NCT00542737|Active Comparator|Delayed Intervention Group|
88997089|NCT00542776||1|IBD patients on immunosuppressive therapy
88997090|NCT00542776||2|IBD patients on non-immunosuppressive therapy (e.g., aminosalicylates, antibiotics) or on no medications
88997091|NCT00542854||MP3|4 different brands of MP3 players will be tested at 3 distances from pacemakers and ICDs.
88997092|NCT00542893|Experimental|Group 1|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
88997093|NCT00542893|Experimental|Group 2|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
88997094|NCT00542932|No Intervention|I|
88997095|NCT00542932|Active Comparator|II|Exercise
88997096|NCT00184041|Experimental|Intensified Post-Remission: MTX/LV/PEG-Asparaginase|Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 & 15
88997097|NCT00543049|Other|1 non-continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 50.0 mg once daily. After 28 days, treatment will be paused for 14 days and cycle one is completed, followed by resumption of therapy as cycle one for up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
88997098|NCT00543049|Other|2 continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 37.5 mg once daily continuously. Treatment period up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
88997099|NCT00543166|Placebo Comparator|2|180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
88997100|NCT04684732||Apixaban dose concordant to leaflet|Patients who were prescribed apixaban dose concordant to apixaban leaflet approved by Thai FDA
88997101|NCT04684732||Apixaban dose discordant to leaflet|Patients who were prescribed apixaban dose discordant to apixaban leaflet approved by Thai FDA
89051859|NCT04584177|Experimental|Control + Arm-hand BOOST|First 4 weeks control program, afterwards 4 weeks arm-hand boost program
89216265|NCT04585750|Experimental|Phase 1b Combination Therapy Dose Escalation, Part 1|Multiple dose levels of daily oral PC14586 (INN: rezatapopt) in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab.
89682459|NCT04349553|Placebo Comparator|Placebo|1mL (Cohorts 1 and 2) or 2mL (Cohort 3) normal saline will be mixed with sodium bicarbonate 2%w/v to produce 150mL for oral administration
89682460|NCT04831190|Experimental|Intervention|All participants will be involved in a tailored exercise intervention for 12 weeks.
89682461|NCT05154890|Experimental|Pegtarviliase Cohort 1|Planned for 4 subjects ≥18 years of age dosing at Dose A weekly for a total of 4 doses
89682462|NCT05154890|Experimental|Pegtarviliase Cohort 2|Planned for 4 subjects ≥12 years of age dosing at Dose B weekly for a total of 4 doses
89682463|NCT05154890|Experimental|Pegtarviliase Cohort 3|Planned for 4 subjects ≥12 years of age (≥18 in the US) dosing at Dose C weekly for a total of 4 doses
89682464|NCT05154890|Experimental|Pegtarviliase Cohort 4|Planned for 4 subjects ≥12 years of age (≥18 in the US) dosing at Dose D weekly for a total of 4 doses
89682465|NCT05154890|Experimental|Pegtarviliase Cohort 5|Optional cohort for up to 12 subjects ≥12 years of age (≥18 in the US) dosing at Dose E weekly for a total of 13 doses
89682466|NCT00645047|Experimental|Telemedicine CBT|Cognitive behaviour therapy (CBT) delivered using videoconference telemedicine.
89682467|NCT00645047|Active Comparator|In-Person CBT|Cognitive behaviour therapy (CBT) delivered using in-person consultation.
89682468|NCT04613024|Experimental|Experiment|Topamax randomized group
89682469|NCT04613024|Active Comparator|Control|Gabapentin randomized group
89682470|NCT04819334|Placebo Comparator|Commercially Available Sports Drink A|A commercially available flavored electrolyte solution, The Coca-Cola Company
89682471|NCT04819334|Experimental|Commercially Available Sports Drink B|A commercially available flavored electrolyte solution, PepsiCo
89682472|NCT04819334|Experimental|Commercially Available Sports Drink A with added Amino Acids|he same as sports drink A above (a commercially available flavored electrolyte solution, The Coca-Cola Company), but with the addition of a small amount of amino acids (~2.6 g/100 ml).
89682473|NCT00645827|Experimental|Insulin infusion conversion equation|Insulin infusion conversion equation is used to determine subcutaneous insulin dosing for first 24 hours after cessation of an IV insulin infusion.
89682474|NCT00645827|Active Comparator|Control|Judgment of patient's healthcare provider is used to determine subcutaneous insulin dosing for first 24 hours after cessation of IV insulin infusion.
89682475|NCT04816604|Experimental|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID) over 144 weeks
89682476|NCT01799447|Other|Early intervention|Early intervention. Quasiexperimental study. Inclusion of 150 first times families in intervention and matched with 150 families from control group.
89682477|NCT04746482||exposure group|subjects in this group are single visit
89682478|NCT04399850|Experimental|Patients who receive hypnosis|Patients who receive hypnosis during procedure by experiment physician
89682479|NCT04399850|No Intervention|Control arm|Patient with conventional pain management
89682480|NCT01933815|Experimental|TPI 287 + bevacizumab|"All subjects in phase 1 & subjects randomized to the TPI 287 + bevacizumab arm in phase 2 will be administered a 1-hour IV infusion of TPI 287 once every 3 weeks (Days 1 & 22 of 42-day cycle) & a 30-90 minute IV infusion of bevacizumab once every 2 weeks (Days 1, 15, & 29).~In phase 1, the dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6, while the dose of bevacizumab remains constant (10 mg/kg). The first 5 dose levels will be 140, 150, 160, 170, & 180 mg/m2. Dose levels beyond 180 mg/m2 will be increased in increments of 20 mg/m2. Three subjects will be treated at a dose level halfway between the dose level that exceeds the MTD and the dose level immediately prior to further refine the MTD.~In phase 2, the dose of TPI 287 will be the MTD determined in phase 1, & the dose of bevacizumab will be the same as phase 1 (10 mg/kg).~Subjects may continue on treatment unless they meet one or more of the protocol discontinuation criteria."
89682481|NCT01933815|Active Comparator|Bevacizumab|"All subjects randomized to the bevacizumab alone arm in phase 2 will be administered bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of a 42-day cycle). The dose of bevacizumab will be 10 mg/kg.~Subjects will be withdrawn from the study if they meet one or more of the discontinuation criteria outlined in the protocol; however, treatment with bevacizumab may continue under the FDA approved labeling for bevacizumab at the discretion of the subject's doctor.~All subjects in phase 1 will be administered TPI 287 in combination with bevacizumab (i.e., there will be no bevacizumab alone arm during phase 1)."
89682482|NCT02144519|Experimental|Immediate Intervention|Over the 3 year project, this arm receives the Healthy Eating and Physical Activity intervention after year 1 (baseline) for a total of 2 years (year 2 and 3).
89682483|NCT02144519|Experimental|Delayed Intervention|Over the 3 year project, this arm serves as the no treatment control/comparison group for year 1 and 2 (2 years of baseline) and receives the Healthy Eating and Physical Activity intervention in year 3 for a total of 1 year.
89682484|NCT03480971|Active Comparator|Active 1000 mg Tempol Solution|Patients will take 1000 mg of Tempol a day for the duration of radiation treatment (6-8 weeks)
89682485|NCT03480971|Placebo Comparator|Placebo Solution|Patients will take placebo solution everyday for the duration of radiation treatment (6-8 weeks)
89682486|NCT05148806||Solid organ transplant patients|Patients who have received a solid organ transplant and who have received at least 3 doses of Covid-19 vaccine
89682487|NCT05148806||Rare autoimmune diseases|Patients with a rare autoimmune disease who have received at least 3 doses of Covid-19 vaccine
89682488|NCT05148806||Blood cancer|Patients with acute myeloid and lymphoid blood cancers who have received at least 3 doses of Covid-19 vaccine.
89051860|NCT04580316|Experimental|Experimental group|75 children were managed during intervention using Parental Active Presence.
89682489|NCT04399616|Experimental|Experimental|"The intervention consists of the availability in the patient's medical history of the visual risk map. The patients in the intervention group will have a risk map in their medical history similar to the one presented in image (annex 2), and any care provider will have immediate access to this map which we think will help them to prioritize the implementation of the relevant practices. safe (in relation to the areas that appear in red).~Areas of risk:~Other independent variables will be the areas of risk:~Identification of the patient~Functional autonomy and quality of life~Caregiver~Safe management and use of medicines~Risk of falls~Risk of injuries and pressure ulcers~Symptom control~Risk of infection associated with health care~Patient and family values and beliefs~Social risk~Unplanned hospital admissions / proactive monitoring~Continuity of care 7X24 h~Transfers (between care levels)~Safety culture~Nursing work environment"
89682490|NCT04399616|No Intervention|No intervention|The patients in the control group will have in their medical records the usual records of the comprehensive geriatric assessment.
89682491|NCT00646763|Active Comparator|Abdomen|These subjects will have their cytokine injections administered only to their abdomen.
89682492|NCT00646763|Active Comparator|Extremities|The extremity arm will have their injections administered to their upper and/or lower extremities.
89682493|NCT03237572|Experimental|Arm A: 1st dose of pembrolizumab after HIFU|Pembrolizumab (200 mg) administered intravenously, days 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
89682494|NCT03237572|Experimental|Arm B: 1st dose of pembrolizumab before HIFU|Pembrolizumab (200 mg) intravenously, days 1, 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
89682495|NCT02986347|Active Comparator|Intravenous regional anesthesia (Bier)|The anesthetic technique described by Bier will be done by the anesthesiologist. The following steps were followed: 1)Placement double tourniquet on the proximal portion of the arm 2)Asepsis and antisepsis of the operative limb 3)Puncture and venous catheterization most distal in the limb 4)Elevation of limb for 1 to 2 minutes, next the limb will be spirally wrapped with Esmarch from the distal to proximal 5)The proximal cuff will be inflated 6)Withdrawal of Esmarch and injection of 40ml of lidocaine without epinephrine at 0.5% 7)Removal the canula until the distal cuff is inflated and the proximal cuff is emptied 8)Removal of the club must be done after the surgery, at least 40 minutes after the injection of the anesthetic.
89682496|NCT02986347|Active Comparator|Local anesthesia with adrenaline|Patients will be anesthetized by surgeons, who are familiar with the technique described by Lalonde. Around thirty minutes before surgery, will be infused with 20 ml of an anesthetic solution. The infiltrated solution is composed of 1% lidocaine with epinephrine in 1: 100,000. Initially 10 mL of the solution will be applied slowly in the flexion fold region of the wrist just below the skin and subfascial plane. The needle is moved slowly. The needle is then redirected to the radial side of the proximal palmar region for infiltration of another 2-3 mL of the subcutaneous solution. The remaining 7-8mL in the subdermal plane and anterior to the transverse carpal ligament.
89682497|NCT00649961|Experimental|Melatonin Open Label Single Arm|Infants born less than 31 weeks gestation who are less than 7 days old
89682498|NCT05137028|Experimental|Otago Exercise|Otago Exercise Group
89682499|NCT03344471|Other|women with PTSD after preterm deliver|
89682500|NCT03344471|Other|women without PTSD after preterm deliver|
89682501|NCT01781637|Experimental|omalizumab group|Patients will receive omalizumab.
89682502|NCT01781637|Placebo Comparator|placebo|Patients will receive placebo.
89682503|NCT04783142|Other|High-fiber, low-protein diet|Participants will consume a high-fiber, low-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.
89682504|NCT04783142|Other|Low-fiber, high-protein diet|Participants will consume a low-fiber, high-protein diet for at least 4 weeks. All meals will be provided free of charge. No substitutions will be permitted.
89682505|NCT03330665|No Intervention|Control|No meditation
89682506|NCT03330665|Experimental|Intervention|Meditate using headspace app 3 times a week
89682507|NCT04349397||Pediatric tonsillectomy patients|All patients enrolled into study prior to undergoing tonsillectomy or adenotonsillectomy
89682508|NCT00652145|Experimental|Increase mesalamine dose by 2.4g/day|Increase dose of mesalamine by 2.4 gm per day
89682509|NCT00652145|No Intervention|Maintain mesalmine dose|Maintain current mesalamine dose at 2.4 g/day
89682510|NCT01618851|Experimental|IMRT with SBRT Boost|Patients with clinically localized prostate cancer will be treated with three radiosurgical treatments (6.5 Gy per fraction to PTV) followed by IMRT (45 Gy in 25 fractions) over 6-7 weeks.
89682511|NCT05112770||Patients|Renal transplant patients whose medical follow-up is provided from 2004 to 2020 by the nephrology and adult renal transplantation department of the Necker hospital.
89682512|NCT03233126|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 128
89682513|NCT03241589||Rural Veterans|Originally the aim was to include VA sites who received the direct to patient facing app from OCC. Due to a lack of enrollment, the first arm or group has been redefined as Veterans living in rural areas receiving a request to use the patient facing app.
89682514|NCT03241589||Nonrural Veterans|Originally the comparison group consisted of VA sites to eventually receive the direct to patient facing apps. Since our enrollment at the facility level was low, this arm now consists of Veterans receiving a request to use the patient facing app, living in nonrural areas.
89682515|NCT03231722|Active Comparator|mFOLFOX6 + Panitumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
89682516|NCT03231722|Experimental|mFOLFOXIRI + Panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~Irinotecan 150 mg/sqm iv over 60 minutes day 1, followed by~Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
89682517|NCT02298933|Experimental|Eculizumab|1200 mg IV infusion over 30-40 min
89682518|NCT04349085|Experimental|Effective PBMT/sMF before WOD and Placebo PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
89682519|NCT04349085|Experimental|Placebo PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
89682520|NCT04349085|Experimental|Effective PBMT/sMF before WOD and Effective PBMT/sMF after WOD|PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD.
89682521|NCT04349085|Placebo Comparator|Placebo PBMT/sMF before WOD and Placebo PBMT/sMF after WOD.|PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
89682522|NCT04746326|Other|Conservative treatment|Conservative treatment stopping oral intake, intravenous antibiotic therapy.
89682523|NCT04746326|Other|Operative treatment|Operative procedure Right hemicolectomy Wedge resection of cecum Diverticulectomy + appendectomy Diverticulectomy Appendectomy + drainage
89682524|NCT02959775|Experimental|60 µg dose hepatitis B vaccine|Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
89682525|NCT02959775|Experimental|20 µg dose hepatitis B vaccine|Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
89682526|NCT02959775|No Intervention|Control|Receive no vaccination during the study period
89682527|NCT04399304||Simultaneous|One-stage bilateral high tibial osteotomy
89682528|NCT04399304||Staged|Two-stage bilateral high tibial osteotomy
89682529|NCT04278248|Experimental|experimental group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine(experimental vaccine), 0.5 ml/dose
89682530|NCT04278248|Active Comparator|Positive control group|Received Vaccine: 23-valent Pneumococcal Polysaccharide Vaccine (positive control vaccine), 0.5 ml/dose
89682531|NCT02334267|Active Comparator|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
89682532|NCT02334267|Active Comparator|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
89682533|NCT00693485|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
89682534|NCT00693485|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
89682535|NCT00693485|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
89682536|NCT00693719|Experimental|Etoposide and Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15. Etoposide 50 mg PO x14 days followed by 2 weeks off.
89682537|NCT00653861|Experimental|Juvederm with Lidocaine|Subjects receive Juvederm with Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in one nasolabial fold.
89682538|NCT00653861|Active Comparator|Juvederm|Subjects receive Juvederm without Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in the other nasolabial fold.
89051861|NCT04580316|Placebo Comparator|control group|75 children were managed with passive parent presence.
89051862|NCT00563264|Active Comparator|1|Participants receive monthly newsletter (for 10 months) including general health and reading information for child and mother and incentives for completing the baseline and 2 follow-up assessments
89051863|NCT00563264|Experimental|2|Mothers and preschoolers in the intervention group will receive monthly mailed family kits that encourage interactive mother/child exercises for healthy lifestyle change. Mailings are supported by counseling calls and two in-person motivational/informational group sessions. The content of the intervention addresses parenting skills, healthy eating, and physical activity. Families can earn $40 for returning postcards describing their activities in the past month.
89051864|NCT00571077||A|"This is a a single arm study evaluating the efficacy and accuracy of EIS in detecting malignant thyroid nodules.~PAtients with thyroid nodules scheduled for surgery will undergo EIS examination."
89051865|NCT03454373|Experimental|Incentive for return to care|"Standard of care HIV primary care services, including counseling to return to care, plus a one-time re-start incentive of 22,500 TZS to return to care."
89051866|NCT03454373|No Intervention|Comparator|Standard of care HIV primary care services, including counseling to return to care.
89051867|NCT04584216|Experimental|Steam Eye Mask With Acupoints Stimulation|"The Steam Eye Mask with acupoints stimulation (SEM with acupoints stimulation), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.~Also, on the eyebrow have the acupoints made by nonwoven fabric can use hands to massage.~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes and use hands to massage the acupoints on the eyebrows for the first 3 minutes."
89216266|NCT04585750|Experimental|Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients|Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients.
89216267|NCT04585750|Experimental|Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients|Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients.
89216268|NCT04585750|Experimental|Phase 2 Monotherapy Dose Expansion, Ovarian Cancer Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Ovarian Cancer Cohort participants will have locally advanced or metastatic ovarian cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
89216269|NCT04585750|Experimental|Phase 2 Monotherapy Dose Expansion, Lung Cancer Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
89216270|NCT04585750|Experimental|Phase 2 Monotherapy Dose Expansion, Breast Cancer Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Breast Cancer Cohort participants will have locally advanced or metastatic breast cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
89682539|NCT00654329|Experimental|Dexmedetomidine 1microgram/kilogram|Dexmedetomidine 1microgram/kilogram intranasal
89682540|NCT00654329|Experimental|Dexmedetomidine 2 micrograms/kilogram|Dexmedetomidine 2 micrograms/kilogram intranasal
89682541|NCT00654329|Active Comparator|Fentanyl 2 micrograms/kilogram|Fentanyl 2 micrograms/kilogram intranasal
89682542|NCT00654329|Placebo Comparator|Normal saline placebo|Normal saline placebo intranasal
89682543|NCT00695435|Experimental|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
89682544|NCT00695435|Active Comparator|TOBREX® Ophthalmic Solution|TOBREX® Ophthalmic Solution
89682545|NCT00695435|Active Comparator|TOBRADEX® Ophthalmic Suspension|TOBRADEX® Ophthalmic Suspension
89682546|NCT00654953|Placebo Comparator|1|Placebo capsules
89682547|NCT00654953|Experimental|2|sertraline (200 mg/day)
89682548|NCT00654953|Experimental|3|sertraline (200 mg/day) plus gabapentin (1,200 mg/day)
89682549|NCT01790165|Experimental|TDT067|Active treatment
89682550|NCT01790165|Placebo Comparator|Placebo|Placebo
89682551|NCT02299089|Experimental|CAM2029 10 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
89682552|NCT02299089|Experimental|CAM2029 20 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
89682553|NCT02299089|Experimental|CAM2029 10 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
89682554|NCT02299089|Experimental|CAM2029 20 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
89682555|NCT01129791|Experimental|Raw Milk first|Organic raw cow's milk
89682556|NCT01129791|Placebo Comparator|Pasteurized milk first|Organic pasteurized cow's milk
89682557|NCT01129791|Placebo Comparator|Non-Dairy Milk first|Unflavored soy milk
89682558|NCT00655811|Active Comparator|Capsaicin|Capsaicin 0.1% cream application to the volar side of forearm.
89682559|NCT00655811|Placebo Comparator|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.) to the opposite forearm.
89682560|NCT03931551|Experimental|Interventional Arm|Olaparib tablet 300mg bd po + Herceptin (IV 4 mg/kg body followed by weekly doses of 2 mg/kg, or SC 600 mg every 3 weeks) until progression or unacceptable toxicity.
89682561|NCT02011685|Active Comparator|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.
89682562|NCT02011685|Experimental|HBPTM + Nurse Case Management (NCM)|Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.
89682563|NCT00696293|Experimental|1|"Duloxetine + clinical management~NOTE -- THIS WORK WAS CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD. THE CLINICALTRIALS.GOV DESCRIPTION OF THE STUDY WAS UPDATED 1/5/16 TO UPDATE THE OPEN LABEL NATURE OF THIS WORK. THIS IS WHAT IS REPORTED HERE AND HAS BEEN PEER REVIEWED AND PUBLISHED."
89682564|NCT00696449|Experimental|Frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
89682565|NCT00696449|Experimental|Electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
89682566|NCT00696449|Experimental|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
89682567|NCT00696449|Experimental|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
89682568|NCT00696761|Active Comparator|group1|Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
89682569|NCT00696761|Active Comparator|group2|BOOI≥ 20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
88997102|NCT04684888|Active Comparator|Visumax Femto-flap|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. Refractive surgery was planned for both eyes and they chose the Visumax Femto-LASIK after a complete explanation of all the possible complications, costs, and differences. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
88997103|NCT04684888|Active Comparator|Sub Bowman's keratomileusis (SBK )-Flap group|Fifty eyes of fifty patients with age range 20-38 years, with myopic astigmatism refractive errors, ranged from -2 to- 6 DS and from -1 to -3.00DC, with stable refraction for at least one year before the surgery, normal corneal topography, anterior and posterior segments examinations. They chose LASIK with mechanical SBK microkeratome surgical approach to be their refractive surgery for both eyes after all the possible complications, costs and differences had been explained clearly. The right eye of each patient was taken for analysis, LASIK flap thickness was measured six months after the procedures using the anterior segment OCT, at seven points (one central and 3 points at each side of the horizontal meridian). The three nasal points were located (1mm, 2mm, 3mm respectively) from the center, and the remaining three temporal points located again ( 1mm, 2mm, 3mm) from the center.
89682570|NCT00696761|Active Comparator|group 3|BOOI<20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
89682571|NCT00696761|Active Comparator|group 4|BOOI<20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
88997104|NCT00543244||1|Patients with chronic hepatitis C who receive pegylated interferon plus ribavirin for 24 weeks (genotype 1 or 2) and for 48 weeks (genotype 1)
88997105|NCT03456739||suppurative otitis media with effusion|
88997106|NCT03456739||non suppurative otitis media with effusion|
88997107|NCT03456661|Active Comparator|Levobupivacaine|Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
88997108|NCT03456661|Active Comparator|Levobupivacaine + Dexmedetomidine|Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
88997109|NCT05079295||Group 1|Patients taking anticoagulants or antithrombotics
88997110|NCT05079295||Group 2|Controls
88997111|NCT03456544||VAN-AKI|Patients who had vancomycin associated acute kidney injury.
88997112|NCT03456544||None VAN-AKI|Patients who didn't have vancomycin associated acute kidney injury.
89682572|NCT00656201|Active Comparator|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
89682573|NCT00656201|Active Comparator|Intramuscular Progesterone|"Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.~."
89682574|NCT00759291|Active Comparator|Acipimox|Acipimox treatment QID for 7 days
89682575|NCT00759291|Placebo Comparator|Placebo|Placebo treatment QID for 7 days
89682576|NCT00657605|Experimental|Recombinant methionyl human leptin|Participants with congenital leptin deficiency will receive the Recombinant methionyl human leptin intervention subcutaneously, once a day with a dose of 0.02 to 0.04 mg/kg (adjusted according to weight loss).
89682577|NCT00756405|Active Comparator|Diet Group|Increased antioxidant diet and placebo pill.
89682578|NCT00756405|Active Comparator|Supplement Group|Usual diet and antioxidant supplement.
89682579|NCT00756405|Placebo Comparator|Placebo|Usual diet and placebo pill.
89682580|NCT00697541|Experimental|A|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours
89682581|NCT00697541|Active Comparator|B|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
89682582|NCT04514913||Healthy Controls|Participants with no history of asthma or other lung diseases.
89682583|NCT04514913||Asthmatics without mucus plugs|Participants with asthma and no evidence of mucus plugging.
89682584|NCT04514913||Asthmatics with mucus plugs|Participants with asthma and evidence by MDCT lung scan showing mucus plugging.
89682585|NCT00697697|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
88997113|NCT00543478|Active Comparator|1|Receive active drug Saccharomyces boulardii 250mg twice a day for 8 weeks.
88997114|NCT00543478|Placebo Comparator|2|Placebo will be given twice a day for 10 weeks
88997115|NCT00159926|Experimental|1|With cell saver
88997116|NCT00159926|Active Comparator|2|Without cell saver
88997117|NCT00543634|Active Comparator|1|
88997118|NCT00543634|Active Comparator|2|
88997119|NCT00543673|Experimental|Milk based formula A|Experimental milk based infant formula
88997120|NCT00543673|Active Comparator|Standard formula|standard milk based infant formula
89682586|NCT00697697|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
88997121|NCT00543673|Other|Reference|Human milk
88997122|NCT00543673|Experimental|Milk based formula C|Experimental milk based infant formula
88997123|NCT00184197|Experimental|Botox|
88997124|NCT00184197|Placebo Comparator|placebo|
88997125|NCT00543790|Experimental|1|
88997126|NCT00543829|Experimental|1|4 cycles of doxorubicin and docetaxel with tamoxifen
88997127|NCT00543829|Active Comparator|2|4 cycles of doxorubicin and docetaxel without tamoxifen
88997128|NCT00160043|Experimental|Arm 1|
88997129|NCT00160043|Experimental|Arm 2|
89682587|NCT03889275|Experimental|Cohort 1A: MEDI5395 Dose Level 1 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 1 on Days 1, 4, 8, 10, 12, and 15 followed by durvalumab every 4 weeks (Q4W) starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
88997130|NCT00544024||Reference|Lariam was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
89682588|NCT03889275|Experimental|Cohort 2A: MEDI5395 Dose Level 2 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 2 on Days 1, 4, 8, 10, 12, and 15 followed by durvalumab Q4W starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
89682589|NCT03889275|Experimental|Cohort 3A: MEDI5395 Dose Level 3 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 3 on Days 1, 4, 8, 10, 12, and 15 followed by durvalumab Q4W starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
89682590|NCT03889275|Experimental|Cohort 3A Backfill: MEDI5395 Dose Level 3 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 2 on Day 1 and Dose Level 3 on Days 4, 8, 10, 12, and 15 followed by durvalumab Q4W starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
89682591|NCT03889275|Experimental|Cohort 4A: MEDI5395 Dose Level 4 + Sequential Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 2 on Day 1 and Dose Level 4 on Days 4, 8, 10, 12, and 15 followed by durvalumab Q4W starting from 14 days after the last dose of MEDI5395 for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
89682592|NCT03889275|Experimental|Cohort 1B: MEDI5395 Dose Level 1 + Concurrent Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 1 on Days 1, 4, 8, 10, 12, and 15 and durvalumab Q4W, starting from the same day as third dose of MEDI5395, for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
89682593|NCT03889275|Experimental|Cohort 2B: MEDI5395 Dose Level 2 + Concurrent Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 2 on Days 1, 4, 8, 10, 12, and 15 and durvalumab Q4W, starting from the same day as third dose of MEDI5395, for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
89682594|NCT03889275|Experimental|Cohort 3B: MEDI5395 Dose Level 3 + Concurrent Durvalumab|Participants will receive IV infusions of MEDI5395 Dose Level 3 on Days 1, 4, 8, 10, 12, and 15 and durvalumab Q4W, starting from the same day as third dose of MEDI5395, for maximum of 2 years or until disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity; whichever occurs first.
89682595|NCT04349163||Caregivers|Physicians and nurses working at the Emergency Department, Intensive care Unit, infectious disease Department, Anaesthesiology.
89682596|NCT00698867||Discovery™ Elbow|Discovery™ Elbow minimally constrained
88997131|NCT00544024||T1|Mephaquin was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
88997132|NCT00544024||T2|Mefloquine-AC Farma was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
88997133|NCT00184236|Active Comparator|Aerobic interval training|Aerobic interval training (AIT)
88997134|NCT00184236|Active Comparator|Multitreatment approach|multitreatment approach (MTG)
88997135|NCT04684927|Experimental|MID-C treatment|Follow-up measurements during 5 years post MIC-C system implantationin order to evaluate safety and efficacy parameters.
88997136|NCT00544219|Other|R-Chop 14|Standard treatment
88997137|NCT00544258|Experimental|1|Two days consecutive days of application of 0.05% PEP005 Topical Gel to a 100cm2 contiguous AK treatment area of the arm.
88997138|NCT00544336||Supportive|
88997139|NCT04685083||Patients with Depression in consolidation phase|
88997140|NCT04685083||Patients with Depression in acute onset|
88997141|NCT04685083||Healthy subjects|
88997142|NCT00544375||Neonatal Tissues|Optical measurement neonatal tissues
88997143|NCT00544492|Experimental|A1|Buttonhole cannulation technique
88997144|NCT00544492|Active Comparator|A2|Rope ladder cannulation technique
88997145|NCT00544492|Experimental|B1|Catheter with bevel point
88997146|NCT00544492|Active Comparator|B2|Catheter with cylindrical point
88997147|NCT00544609|Other|Sorafenib|2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib
88997148|NCT00544687|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
88997149|NCT00544687|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
88997150|NCT00544687|Active Comparator|3|0.1% mometasone furoate
88997151|NCT00544687|Active Comparator|4|0.1% nortriptyline HCl
88997152|NCT00544687|Active Comparator|5|Karison® Creme (clobetasol-17-propinate 0.05%)
88997153|NCT00544687|Placebo Comparator|6|Vehicle (placebo)
88997154|NCT00544726|Active Comparator|1|Physical training
88997155|NCT00544726|Placebo Comparator|2|No physical training
88997156|NCT00544765|Experimental|resp: 4xTAC|Patients sufficiently responding (iPR, iCR) will recieve 4 further cycles of TAC
88997157|NCT00544765|Experimental|resp: 6xTAC|Patients sufficiently responding (iPR, iCR) will recieve 6 further cycles of TAC
88997158|NCT00544765|Experimental|nonResp: 4xTAC|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of TAC
88997159|NCT00544765|Experimental|nonResp: 4xNX|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of NX
88997160|NCT00544804|Experimental|Lapatinib|Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer
88997161|NCT00544921|Experimental|50 mg|
88997162|NCT00544921|Experimental|100 mg|
88997163|NCT00544921|Experimental|250 mg|
88997164|NCT00544921|Experimental|500 mg|
88997165|NCT00544921|Experimental|750 mg|
88997166|NCT00544921|Experimental|1000 mg|
88997167|NCT00544921|Placebo Comparator|Placebo|
88997168|NCT02963181|Experimental|Effects of Yohimbine|Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension
88997169|NCT02963181|Experimental|Effects of melatonin on blood pressure|Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves
88997170|NCT00545116|Experimental|a|Active carrier 1: biscuit providing 250 mg hesperidin per piece(6g)
88997171|NCT00545116|Experimental|b|Active carrier 2: liquid skim milk providing 250 mg hesperidin/serve (200 ml) and containing around 300 mg calcium/serving
88997172|NCT00545116|Placebo Comparator|c|Placebo carrier 1: biscuit with the same nutrient composition and appearance as the active biscuit carrier but minus hesperidin
88997173|NCT00545116|Placebo Comparator|d|Placebo carrier 2: liquid skim milk with the same nutrient composition and appearance as the active milk carrier but minus hesperidin
88997174|NCT04684771|Active Comparator|MYOSTIM®|MYOSTIM® 2 bars/day during 12 weeks MYOSTIM® as a food bar. Active ingredient: Pomegranate extract, L-leucine, Creatine, D3 Vitamin, Proteins IP Status: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
88997175|NCT04684771|Placebo Comparator|PLACEBO|PLACEBO 2 bars/day during 12 weeks
88997176|NCT00160316|Experimental|1|
88997177|NCT00545194|Active Comparator|A|sustained release preparation of prostaglandin E2
88997178|NCT00545194|Active Comparator|B|short-acting (instant-released) preparation of prostaglandin E2
88997179|NCT03456505|Experimental|Mindfulness|Participants randomly assigned to the mindfulness meditation condition will meet for five, 15-minute sessions, in which they will receive training in basic mindfulness skills (Wallace, 2006).
88997180|NCT03456505|Active Comparator|Active Listening|Participants randomly assigned to the active listening condition will meet for five, 15-minute sessions, in which they will listen to Gilbert White's The Natural History of Selborne.
88997181|NCT03456466|Experimental|TQB2303|
88997182|NCT03456466|Active Comparator|Rituximab|
89682597|NCT00657917|Experimental|Paromomycin +Gentamicin topical cream|WR279,396 topically twice a day for 20 days
89682598|NCT01959945|Experimental|Study Group 1, Flublok|Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
88997183|NCT03456388|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts . Each cohort will be administered in different dose once for 7 days.
88997184|NCT03456388|Active Comparator|Placebo Enteric-coated Tablets|There will be 7 ascending cohorts. placebo enteric-coate tablets to mimic Ammoxetine Hydrochloride Enteric-coated tablets.
89682599|NCT01959945|Active Comparator|Study Group 2, Fluarix|Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
89682600|NCT01959945|Experimental|Study Group 3, Flublok|Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
89682601|NCT01959945|Active Comparator|Study Group 4, Fluarix|Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
89682602|NCT00700661|Experimental|1|Drug
89682603|NCT00700661|Placebo Comparator|2|Pbo
89682604|NCT03856749|Experimental|Treatment|The wheelchair user and caregiver will be trained together on wheelchair skills using remote technology (Zoom for healthcare and/or Facetime).
89682605|NCT03856749|No Intervention|Control|The wheelchair user and caregiver will receive the same self-study materials provided to the Treatment arm. Usual care, which may include wheelchair skills training for both wheelchair users and caregivers( but which often does not do so to an adequate extent) by wheelchair user's clinical therapist.
89682606|NCT00658385|Experimental|1|GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim, Central venous line placement, Stem cell Collection (leukapheresis)
89682607|NCT00652847|Experimental|group 1|group 1: ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by an observational phase of 6 months.
89682608|NCT00652847|Active Comparator|Group 2|Group 2: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase.
89682609|NCT00652301|Experimental|1|ezetimibe 10 mg tablet plus simvastatin 20 mg tablet
89682610|NCT00652301|Active Comparator|2|ezetimibe 10 mg tablet
89682611|NCT00652301|Active Comparator|3|simvastatin 20 mg tablet
89682612|NCT00652301|Placebo Comparator|4|matching placebo
89682613|NCT01961271|Experimental|Buprenorphine transdermal patch|Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
89682614|NCT01963143|Experimental|Treatment Sequence 1 - Adults|Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
89682615|NCT01963143|Experimental|Treatment Sequence 2 - Adults|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
89682616|NCT01963143|Experimental|Pediatrics|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
89682617|NCT04486599|Experimental|Electromagnetic Navigation|The patient have to low Flow Vascular Abnormality diagnosed by Duplex Ultrasound and MRI. Decision of Ultrasound Guided Percutaneous Foam Sclerotherapy taken in multidisciplinary staff meeting
89051868|NCT04584216|Active Comparator|Steam Eye Mask|"The Steam Eye Mask (SEM), is an eye mask which contains iron (Fe) and generates the heat with the steam (the moist heat) by the oxidative reaction of the iron with oxygen in air.~The temperature of the moist heat is approximately 40 degree C and the moist heat lasts for around 20 minutes."
89682618|NCT01963845|Placebo Comparator|Placebo|Placebo
89682619|NCT01963845|Experimental|Active drug|Sitagliptin 100 mg
89682620|NCT02332863|Active Comparator|Back-loaded needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G back-loaded needle. CRFs will be used to record data for primary and secondary endpoints.
89682621|NCT02332863|Experimental|Preloaded Needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G preloaded needle. CRFs will be used to record data for primary and secondary endpoints.
89682622|NCT01963923|Experimental|Rehabilitation Group|The rehabilitation group must complete at least 16 sessions of the Pulmonary Rehabilitation Program
89682623|NCT01963923|No Intervention|Control Group|The control group must complete only the outcome measures and continue with their clinical routine as specified by their physicians.
89051869|NCT04615793|No Intervention|CONTROL GROUP|The control group will receive flexibility exercises and strength training focusing on the trunk and lower limb muscles, postural control exercise in different positions and different surfaces and general endurance training . Control group will receive intervention in the form of five minutes warm up followed by 12 minutes of walking at their comfortable pace and concluded with a five minutes cool down
89051870|NCT04615793|Experimental|EXPERMINTAL GROUP|The experimental group will obtain Pilate exercises, consist of strengthening,stretching and coordinated exercises on lower and trunk muscle
89051871|NCT04584060||Conventional|Fatsing for at least 6 hours pre-operative, No restriction of IV fluids and traditional analgesia including opiates. Post-operative Ambulation-as per patients' own request, Removal of urinary catheter when patient ambulates, patient will keep fasting for 3 days postoperative, oral fluids for 3 days, semi-solid for another 3 days and then can take full diet, removal of nasogastric tube just before starting oral fluids, drain removal just before discharge.
89216271|NCT04585750|Experimental|Phase 2 Monotherapy Dose Expansion, Endometrial Cancer Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Endometrial Cancer Cohort participants will have locally advanced or metastatic endometrial cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
89682624|NCT01965561|Experimental|CRoC|Use of Combat Ready Clamp (CRoC)
89682625|NCT01965561|Experimental|AAJT|Use of Abdominal Aortic and Junctional Tourniquet
89682626|NCT01965561|Experimental|JETT|Junctional Emergency Treatment Tool
89682627|NCT01965561|Experimental|SJT|SAM Junctional Tourniquet
89682628|NCT02984462|Experimental|screw fixation|Surgical Percutaneous Akin osteotomy with fixation by a percutaneous cannulated screw and forefoot surgery dressing.
89682629|NCT02984462|No Intervention|No fixation|Surgical Percutaneous Akin osteotomy non-fixed, hold by forefoot surgery dressing.
89682630|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
89682631|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
89682632|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
89682633|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
89682634|NCT00658619|Sham Comparator|Sham (no implant) Stage 2|Stage 2: sham in both eyes on Day 1 and Month 6.
89682635|NCT01966419|Active Comparator|Ornithine phenylacetate|Participants receive ornithine phenylacetate for up to 5 days via continuous IV infusion in addition to standard of care (SOC)
89682636|NCT01966419|Placebo Comparator|Placebo|Participants receive matching placebo up to 5 days via continuous IV infusion in addition to SOC
89682637|NCT01966809|Experimental|Photofrin photodynamic therapy.|Photofrin photodynamic therapy. Drug - 2.5 mg/kg, light - 240 mJ/cm2.
89682638|NCT01967121|Experimental|'Compex unit's Active Recovery® program'|The Compex electrical stimulation system utilized in this study is intended for external application with electrodes to create a muscular contraction and help enhance recovery after eccentric muscular activity.
89682639|NCT01967121|Other|Ice application|A randomized pre and post-test research design will be used to compare three interventions (control, ice, compex) to alleviate the physical symptoms of delayed-onset muscle soreness (DOMS).
89682640|NCT01967121|No Intervention|Control|This is a control group where subjects will not perform an intervention.
89682641|NCT04575584|Experimental|Part 1: Molnupiravir 200 mg|200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
89682642|NCT04575584|Experimental|Part 1: Molnupiravir 400 mg|400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
89682643|NCT04575584|Experimental|Part 1: Molnupiravir 800 mg|800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
89682644|NCT04575584|Placebo Comparator|Part 1: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
89682645|NCT04575584|Experimental|Part 2: Molnupiravir|Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
89216272|NCT04585750|Experimental|Phase 2 Monotherapy Dose Expansion, Other Solid Tumors Cohort|Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Other Solid Tumors Cohort participants will have locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
89216273|NCT04580667||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from normal tissues shortly after the start of radiotherapy provides an early indication of patients at high risk of radiation-related toxicity. Blood specimens for RadTox test will be collected: (a) prior to radiotherapy (T0); (b) after the 2nd but before the 4th radiotherapy dose during week 1 (T1); (c) on Week 2 during radiotherapy (T2); and (d) 3 months after completion of radiotherapy (T3).
89216274|NCT04580251||Magnetic marker Magseed|Patients in whom the magnetic marker Magseed is used will be enrolled in this study arm and will undergo targeted axillary dissection.
89216275|NCT04580251||Iodine seed 125I marker|Patients in whom the iodine seed 125I marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
89216276|NCT04580251||Carbon suspension|Patients in whom the carbon suspension marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.
89216277|NCT04574167|Experimental|tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes)
89216278|NCT04574167|Sham Comparator|Sham tDCS with Cognitive Training|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
89216279|NCT04570930|Experimental|Just-in-time adaptive intervention (JITAI)|Participants will wear the Fitbit®, provide daily reports of Health- Related Quality of Life (HRQOL) and receive personalized pushes over a six-month (180 day) period.
89216280|NCT04570930|Active Comparator|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period (without the personalized feedback).
89216281|NCT04570371|Experimental|Intervention|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches in which the intervention will be implemented per the study schedule.
89216282|NCT04570371|No Intervention|Control Arm|Per a stepped-wedge cluster randomized pragmatic clinical trial design, all patients within whole surgical practices will be randomized to implementation tranches. The control arm consists of all patients receiving surgery in implementation tranches in which the intervention has not been implemented yet (per the study schedule).
89682646|NCT04575584|Placebo Comparator|Part 2: Placebo|Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
89682647|NCT04277702|Experimental|Montelukast + standard treatment|
89682648|NCT04277702|Placebo Comparator|Placebo+ standard treatment|
89682649|NCT03258632|No Intervention|Usual Care|Under usual care, when a patient screens positive on the AUDIT-C administered at intake, a provider (social worker, nurse) provides Brief Intervention (BI), i.e., tells the patient that problems are associated with alcohol use, and about recommended drinking limits; notes the patient as ready to change drinking or not, and as agreeing to treatment or not. If the patient agrees to treatment, specialty addiction services are notified.
89682650|NCT03258632|Experimental|Intervention|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
89682651|NCT03257150|Experimental|Study Treatment|Single arm trial of irreversible electroporation using the NanoKnife system for locally advanced pancreatic ductal adenocarcinoma.
89682652|NCT03225794||Controls|Adults living in rural area of Cameroon, not infected with simian foamy viruses
89682653|NCT03225794||Simian Foamy virus infection|Adults living in rural area of Cameroon, infected with simian foamy viruses
89682654|NCT04276766|Experimental|Beetroot|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the beetroot group were asked to consume 140ml beetroot juice (James White Drinks Company, Suffolk, UK). The 140 ml of beetroot juice equate to approximately 8.4 mmol of NO3- ."
89682655|NCT04276766|Placebo Comparator|Placebo|"Following baseline microcirculatory and blood pressure measurements, as well as the collection of urine and saliva samples, participants on the placebo group were asked to consume 140 ml nitrate-depleted beetroot juice (James White Drinks Company, Suffolk, UK)."
89682656|NCT04276844||Non diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test ≥ 16 mm for women and ≥ 18 mm for men
89682657|NCT04276844||Persistent diaphragmatic dysfunction at day 7 post-surgery|Diaphragmatic displacement after sniff test < 16 mm for women and < 18 mm for men
89682658|NCT03725397|Experimental|Outpatients with a transcervical Foley catheter|Women with a transcervical Foley catheter in place that will spend the night at home.
89682659|NCT03725397|Active Comparator|Inpatients with a transcervical Foley catheter|"Women to be admitted to the hospital overnight which has been a standard of care."
89682660|NCT00699491|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 (cixutumumab is given on days 8, 15, and 22 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89682661|NCT03721965|Experimental|Itacitinib + Corticosteroids|
89682662|NCT04399148|Experimental|Sequence 1|Desloratadine - Aprepitant - Ketotifen
89682663|NCT04399148|Experimental|Sequence 2|Aprepitant - Ketotifen - Desloratadine
89682664|NCT04399148|Experimental|Sequence 3|Ketotifen - Desloratadine - Aprepitant
89216283|NCT04567264|Experimental|With stimulation|Implantation of device electrodes subcutaneous in lower tibia area; stimulation of posterior tibial nerves.
89216284|NCT04562805|Experimental|DynamX Bioadaptor|Elixir Medical DynamX™ Sirolimus Eluting Coronary Bioadaptor
89216285|NCT04562805|Active Comparator|Medtronic Resolute Onyx Stent|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
89682665|NCT04672382|Experimental|Morphine|"During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), while two areas will be treated with injections of isotonic saline (0.05 ml, 0.9%) as vehicle. Fifteen minutes after the injections, the measurement of FLPI and wheal size will be conducted in one morphine and one saline treated area.~This measurement will be followed by application of histamine and cowhage in the four areas (two pre-treated with morphine and two pre-treated with vehicle)"
89682666|NCT00699803|Active Comparator|T-Pred|Tobramycin prednisolone acetate combination
89682667|NCT00699803|Active Comparator|Pred Forte|Prednisolone acetate
89682668|NCT01967433|Experimental|Diphenhydramine|Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
88997185|NCT03456349|Experimental|Low dose|HTL0018318
88997186|NCT03456349|Experimental|Medium dose|HTL0018318
88997187|NCT03456349|Experimental|High dose|HTL0018318
88997188|NCT03456349|Placebo Comparator|Placebo|Placebo
88997189|NCT00160355|Other|1|
88997190|NCT00184353||brain metastases|6 patients
88997191|NCT00184353||healthy|13 volunteers
88997192|NCT03456310|Experimental|Trans-perineal ultrasound|Transperineal ultrasonography is done by 2D ultrasound machine, curved probe is placed in the perineum, mid sagittal and axial views are obtained Then it's accuracy is assessed according to findings on dynamic pelvic MRI .
88997193|NCT00545311|Experimental|1|NVA237
88997194|NCT00545311|Experimental|2|NVA237
88997195|NCT00545311|Experimental|3|NVA237
88997196|NCT00545311|Experimental|4|NVA237
88997197|NCT00545311|Placebo Comparator|5|Placebo
88997198|NCT00545350|No Intervention|1|Usual activity / care
88997199|NCT00545350|Experimental|2|"Physical exercise classes plus home exercises:~Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home. The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
88997200|NCT04684693|Experimental|Laser Group|
88997201|NCT04684693|Active Comparator|Control Group|
88997202|NCT00545428|Experimental|1|Rhinoplasty
88997203|NCT00545467|Active Comparator|1|fast tapering of the previous medication within 1 week after initiating aripiprazole for 2 weeks
88997204|NCT00545467|Active Comparator|2|slow tapering of the previous medication within 4 weeks after initiating aripiprazole for 2 weeks
88997205|NCT00160433|Experimental|1|
88997206|NCT00160433|Experimental|2|
88997207|NCT00160433|Experimental|3|
88997208|NCT00160433|Placebo Comparator|4|
88997209|NCT00184392|Experimental|debridement or saline irrigation|1 arm undergo debridement of the nose 1 week and 2 weeks after surgery the other arm rinse their nose with saline irrigation
88997210|NCT00545545|Experimental|Arm 1, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
88997211|NCT00545545|Experimental|Arm 1, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
88997212|NCT00545545|Experimental|Arm 1, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
88997213|NCT00545545|Experimental|Arm 2, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
88997214|NCT00545545|Experimental|Arm 2, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
88997215|NCT00545545|Experimental|Arm 2, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
88997216|NCT00545701|Experimental|1|
88997217|NCT00545857|Experimental|Pioglitazone|
88997218|NCT00545857|Placebo Comparator|Placebo control|
88997219|NCT00184431|Experimental|A|Intensive task specific balance training
88997220|NCT00184431|Active Comparator|B|Traditional physical therapy
88997221|NCT00545935|Active Comparator|1-Methylenblue-Amodiaquine|
88997222|NCT00545935|Active Comparator|2-Methylenblue-Artesunate|
88997223|NCT00545935|Active Comparator|3-Artesunate-Amodiaquine|
88997224|NCT05057260||Long Covid cohort|Long Covid patients managed in the 10 participating sites
88997225|NCT00546013||AAA group, control group|AAA group : with AAA Control group: without AAA
88997226|NCT00546130|Experimental|1|Irinotecan hydrochloride + Cisplatin + Krestin Therapy
88997227|NCT00546169||A|
88997228|NCT04684342|Experimental|cirrhotic ICU Patients|about 150 patients with cirrhosis fulfill- ing the inclusion criteria that will be admitted to Tropical Medicine and Gas- troenterology Department, Al-Rajhi Liver Hospital, Assiut University Hospi- tals) will be evaluated for fungal infection.
88997229|NCT00546208||1|adolescents and young adults who underwent, as newborns, unilateral low loop cutaneous ureterostomy for severe bilateral hydro-ureteronephrosis, and that, afterwards, underwent stomal closure
88997230|NCT00546286|Experimental|1|dorzolamide HCl/timolol maleate
88997231|NCT00546286|Experimental|2|dorzolamide hydrochloride/timolol maleate + prostaglandin
88997232|NCT00546325|Experimental|1|Rimonabant
88997233|NCT00546325|Placebo Comparator|2|Placebo
88997234|NCT00546403|Placebo Comparator|Placebo|Adjunctive treatment with placebo
88997235|NCT00546403|Experimental|Modafinil|Treatment with titrated dose of study drug, modafinil.
88997236|NCT00546442|Placebo Comparator|2|Placebo of metformine 850-2550 mg/daily for 48 weeks
88997237|NCT00546442|Experimental|1|Metformine 850-2550 mg/daily for 48 weeks
88997238|NCT00546832|Placebo Comparator|1|placebo
88997239|NCT00546832|Active Comparator|2|celecoxib 200 mg qd p.o.
88997240|NCT00546832|Experimental|3|TDS-943 40 mg bid topically
88997241|NCT00160784|Active Comparator|Arthroscopic Manipulation|Manipulation of Shoulder performed during arthroscopy
88997242|NCT00160784|Active Comparator|Home exercise program|Shoulder exercise program performed at home to increase shoulder function
88997243|NCT00546949|Active Comparator|decompression|Minimal invasive decompression
88997244|NCT00546949|Experimental|x-stop|X-stop, an interspinous decompression device
89682669|NCT01967433|Placebo Comparator|Placebo|0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
89682670|NCT01799525|Experimental|Hypercapnia|Intervention: SAH patients are subjected to gradual hypercapnia by reduction of respiratory volume in one trial session every day. PaCO2 is raised from normocapnia to 50 mmHg for 10 - 15 minutes and 60 mmHg for 10 - 15 minutes.
89682671|NCT03888014||Treatment group|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
89682672|NCT02299479|Experimental|Intervention|Volunteers will wear a Dexcom G4 Platinum CGM device as well as an activity monitor. Data will be uploaded to study investigators on a regular basis, and recommendations will be made to adjust insulin dosing based upon analysis of these data.
89682673|NCT01968057|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
89682674|NCT01968057|Experimental|Baricitinib + Ciclosporin|Single oral dose of 4 mg baricitinib co-administered with a single oral dose of 600 mg ciclosporin on Day 4
89682675|NCT01968135|Placebo Comparator|Sugar Pill|Placebo Sugar Pill
89682676|NCT01968135|Experimental|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
89682677|NCT00658697|Experimental|Docetaxel, Bevacizumab, and ADT|"Docetaxel:~Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles~Bevacizumab:~Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles~ADT or Luteinizing hormone-releasing hormone agonist (LHRH):~Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)~Bicalutamide:~Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)"
89682678|NCT03873116|Experimental|BCX7353 110mg once daily|BCX7353 capsules administered orally once daily
89682679|NCT03873116|Experimental|BCX7353 150mg once daily|BCX7353 capsules administered orally once daily
89682680|NCT03873116|Placebo Comparator|Placebo|Matching placebo oral capsules administered orally once daily
89682681|NCT01968447|Experimental|hypocapnia|arterial pCO2 of 3.5 kPa
89682682|NCT01968447|Active Comparator|normocapnia|arterial PCO2 of 6.5-7.0 kPa
89682683|NCT01795469|Experimental|Abdominal and LE compression|Zoex compression garment during tilt testing (all straps)
89682684|NCT01795469|Experimental|abdominal compression only|Zoex compression garment use during tilt table testing (straps 4 and 5 fastened around thighs and abdomen)
89682685|NCT01795469|Experimental|Lower extremity compression only|Zoex compression garment use during tilt table testing (straps 1-4, lower extremity and thighs, fastened)
89682686|NCT00659165|Experimental|Insulin Detemir|Insulin Detemir
89682687|NCT00659165|Experimental|Insulin Glargine|Insulin Glargine
89682688|NCT02299791|Active Comparator|Early Intervention|6 study clinics received the ALL intervention starting 6/1/11
89682689|NCT02299791|Active Comparator|Late implementation|5 study clinics received the ALL intervention starting 6/1/12
89682690|NCT00700973|Active Comparator|Arm 1|Substance use disorder usual care
89682691|NCT00700973|Experimental|Arm 2|Interpersonal violence prevention intervention
88997245|NCT00546988|No Intervention|Standard risk IFN|Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
89216286|NCT04555226|Active Comparator|Standard treatment group|Standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
89682692|NCT03864848|Experimental|Treatment|Treatment with the Mitral Touch Implant for Epicardial Annuloplasty.
88997246|NCT00546988|No Intervention|Standard risk PEGIFN|Maintenance treatment with pegylated interferon following autologous stem cell transplantation
88997247|NCT00546988|Experimental|High risk allo|Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
88997248|NCT00546988|No Intervention|High risk auto|Second cycle of high-dose melphalan in subjects without an HLA-identical donor
88997249|NCT00184587|Experimental|candesartan|candesartan cilexetil 16 mg (one tablet/day) in week 1 and 32 mg (2 tablets/day) in week 3, provided for the study by AstraZeneca
88997250|NCT00184587|Placebo Comparator|placebo|placebo one tablet/day in week 1 and 2 tablets/day in week 3, provided for the study by AstraZeneca. Same size, weight, taste and appearance as experimental drug
88997251|NCT05015764|Experimental|Reprieve Cardiovascular System|
88997252|NCT05015764|Active Comparator|Standard of Care|
89682693|NCT02299869|Other|Group 1 - Verde (Competitor-control) vs. Green (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
89682694|NCT02299869|Other|Group 2 - Cinza (Competitor-control) vs. Grey (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
89682695|NCT02299869|Other|Group 3 - Esmeralda (Competitor-control) vs. Jade (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
89682696|NCT02299869|Other|Group 4 - Azul (Competitor-control) vs. Blue (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
89682697|NCT04277624|Experimental|Fezolinetant: Test Formulation then Reference Formulation|Participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 2.
89682698|NCT04277624|Experimental|Fezolinetant: Reference Formulation then Test Formulation|Participants will receive a single oral dose of fezolinetant reference formulation on day 1 of study period 1. After a washout of 5 days the participants will receive a single oral dose of fezolinetant test formulation on day 1 of study period 2.
89051872|NCT04584060||ERAS|Preoperative information, education and counselling, If possible, Clear fluids are allowed up to 2 h and solids up to 6 h prior to induction of anaesthesia, Short acting anesthetic agents,avoid opioid agents, Post operative nausea and vomiting prophylaxis, Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off, Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward, Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube, Removal of urinary catheter-after weaning from the effect of general anesthesia and drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.
89051873|NCT04615637|Experimental|Sensors|All subjects will follow the same experimental procedure: a recording using classical MEG followed by a recording in the same condition with the OPM He4 prototype.
89051874|NCT04584021||Stress study participants|Adults who reported stress problems derived from work
89051875|NCT04615598|Experimental|Action observation group|
89051876|NCT04615598|Placebo Comparator|Placebo group|
89051877|NCT00571116|Experimental|Disulfiram and arsenic trioxide|"Patients receive disulfiram 250 mg PO twice daily and arsenic trioxide IV over 1-2 hours on Monday through Friday, alternating two weeks on treatment followed by two weeks off treatment. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~The Arsenic trioxide dose will be escalated or reduced until a tolerable dose is reached. Arsenic trioxide will be administered at a starting dose of 0.05 mg/kg. If the initial dose is tolerated, the patient will be dose escalated to 0.10 mg/kg/day. If the first dose escalation is tolerated, then a second dose escalation will be attempted to 0.15 mg/kg/day, the current dose recommended for leukemia. Dosing will be continued for two weeks on alternating with two weeks off as long as tolerated to a maximum of 60 doses."
89051878|NCT00571155|Other|1|
89051879|NCT04615481|Experimental|Elliptical Training Group|Total 30 minutes of elliptical cross training, including warm up, progressive elliptical training and cool down.
89051880|NCT04615481|Experimental|Ergo-metric Training Group|Total 30 minutes of ergometric training
89051881|NCT04580433|Experimental|Time-Restricted Feeding|Participants will receive 16:8 TRF.
89051882|NCT04615169|Experimental|multi-component cognitive intervention using simulated everyday tasks (MCI-SET)|the 12-week intervention, 2 hours weekly session of MCI-SET.
89051883|NCT00571233||1|Group one consists of children 1 month - 6 years old who have structurally normal hearts, no heart failure, and a patent ductus arteriosus (PDA).
89051884|NCT00571233||2|Group two consists of children 1 month - 6 years old who have single ventricle physiology. Children with and without heart failure may participate.
89051885|NCT04614857|Experimental|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
89051886|NCT04583865||teleconsultation|Patient with teleconsultation of pre-anesthesia
89682699|NCT03223376|Active Comparator|fruquintinib+paclitaxel|treatment arm (fruquintinib+paclitaxel) : Fruquintinib once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
89682700|NCT03223376|Placebo Comparator|placebo+paclitaxel|control arm (placebo+paclitaxel): Fruquintinib placebo once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
89682701|NCT00659633|Experimental|Lidocaine|Intravenous lidocaine for neuropathic pain
89682702|NCT02300025|Experimental|Cohort 1: Normal function|
89682703|NCT02300025|Experimental|Cohort 2: Mild Hepatic Impairment|
89682704|NCT02300025|Experimental|Cohort 3: Moderate Hepatic Impairment|
89682705|NCT02300025|Experimental|Cohort 4: Severe Hepatic Impairment|
89682706|NCT03204266|Experimental|Immunonutrition: ARS + Omega-3 Fatty Acids|"Participants take 1 ounce (30mls) of Arginine recovery supplement (ARS) four times daily 5 days preoperatively and 14 days postoperatively.~Participants also given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively."
89682707|NCT03204266|No Intervention|No Immunonutrition|Participants receive regular enhanced recovery after surgery (ERAS)/Optimized Surgical Journey (OSJ) education and follow up.
89682708|NCT00295139|Experimental|1|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)
89682709|NCT00295139|Experimental|2|Behavioral Treatment for Substance Abuse in SPMI (BTSAS) + Critical Time Intervention (CTI)
89682710|NCT00295139|Active Comparator|3|Supportive Treatment in Addiction Recovery (STAR)
89682711|NCT04277156|Experimental|Flostrum Baby|"The test product will be Flostrum Baby, which is a food supplement consisting of two bacterial strains: Lactobacillus rhamnosus ATCC 53103 and Lactobacillus reuteri DSM 29063, 5x10^9 CFU and 1x10^8 CFU, respectively, per seven drops.~Flostrum Baby - in children below 12 years of age, 7 drops, twice daily; in children older than 12 years, 14 drops, twice daily."
89051887|NCT04614818||pulmonary lymphoepithelioma-like carcinoma|The primary site of lymphoepithelioma-like carcinoma locates in the lungs.
89051888|NCT04614818||lymphoepithelioma-like carcinoma of thymus|The primary site of lymphoepithelioma-like carcinoma locates in the thymus.
89051889|NCT04614818||lymphoepithelioma-like carcinoma of salivary glands|The primary site of lymphoepithelioma-like carcinoma locates in the parotid gland or submandibular gland.
89051890|NCT04614818||lymphoepithelioma-like carcinoma of stomach|The primary site of lymphoepithelioma-like carcinoma locates in the stomach.
89051891|NCT04614818||lymphoepithelioma-like carcinoma of esophagus|The primary site of lymphoepithelioma-like carcinoma locates in the esophagus.
89051892|NCT04614818||lymphoepithelioma-like carcinoma of liver|The primary site of lymphoepithelioma-like carcinoma locates in the liver.
89682712|NCT04277156|Active Comparator|Dicoflor|"The control product will be Dicoflor, which is a food supplement containing L rhamnosus ATCC 53103, 5x10^9 CFU, per five drops.~Dicoflor - the manufacturer recommends 5-10 drops daily, with no age specification. For the purposes of this study, 5 drops, twice daily, in children below 12 years of age; 10 drops, twice daily, in children older than 12 years."
89682713|NCT00701675|Experimental|Sertraline 50mg|sertraline 50 mg daily
89682714|NCT00701675|Experimental|Sertraline 100mg|sertraline 100mg daily
88997253|NCT05012956|Active Comparator|POP group|Pelvic organ prolapse patients enrolled for sacrocolpopexy surgery at UZ Leuven.
88997254|NCT05012956|Active Comparator|Control group|Patients assigned to gynecologic laparoscopic surgery, other than sacrocolpopexy, at UZ Leuven.
88997255|NCT00547144|Experimental|Gemcitabine|
88997256|NCT00547183|Active Comparator|2|2.5 mg tadalafil
88997257|NCT00547183|Active Comparator|3|5 mg tadalafil
88997258|NCT00547183|Placebo Comparator|1|
88997259|NCT00547261|Experimental|Arm A|1 hour IV infusion D1
88997260|NCT00547261|Experimental|Arm B|1 hour IV infusion D1, D8, D15
88997261|NCT04684186||Endovascular fiducial marker insertion|Fiducial markers are inserted and released near the tumor through femoral puncture. A catheter is led through the venous system to the right heart and from there through the heart into the pulmonary arteries.
88997262|NCT04684186||Bronchoscopic fiducial marker insertion|Fiducial markers are inserted and released near the tumor into the bronchi using an endoscopic route
88997263|NCT00547417|Active Comparator|1|tadalafil
88997264|NCT00547495|Placebo Comparator|1|Placebo tablet
88997265|NCT00547495|Active Comparator|2|5 mg tadalafil
88997266|NCT00547495|Active Comparator|3|10 mg tadalafil
88997267|NCT00547495|Active Comparator|4|20 mg tadalafil
88997268|NCT02277223|Experimental|Interventional|In addition to induction therapy, patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<20kg: 1 gram, twice daily, 20-30 kg: 1.5 grams twice daily, weight>30kg: 2 grams twice daily. For Maintenance, in addition to oral 5-ASA maintenance treatment, responding patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<30kg: 500 milligram, twice daily, weight>30kg: 1 gram twice daily
88997269|NCT02277223|Placebo Comparator|Control|In addition to induction and maintenance therapy, patients will receive matched oral placebo capsules for induction and maintenance (Bara Herbs Inc), twice daily.
88997270|NCT02277262|Experimental|Treatment arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed reinforcing the suture with a swine dermis biological prosthesis positioned sublay
88997271|NCT02277262|Active Comparator|Control arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed by emi-continuous monofilament sutures with an intermediate-reabsorbable-time suture
88997272|NCT00547573|Active Comparator|2|10 mg tadalafil tablet
88997273|NCT00547573|Active Comparator|3|20 mg tadalafil tablet
88997274|NCT00547573|Placebo Comparator|1|placebo tablet
88997275|NCT00547690|Experimental|1|Acupuncture and strength training
88997276|NCT00547690|Other|2|Strength training
88997277|NCT04982419|Active Comparator|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
88997278|NCT04982419|Sham Comparator|Sham remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
88997279|NCT04974385|Experimental|Liposomal Bupivacaine|Experimental group will receive ISNB with admixed LB (10 mL) and 0.5% bupivacaine (10 mL) total of 20 mL.
88997280|NCT04974385|Active Comparator|Non-liposomal Bupivacaine|Comparator group will receive ISNB with 20 mL of 0.5% non-liposomal bupivacaine
88997281|NCT00547885|Active Comparator|1|Active dihydrocodeine, long acting and Placebo dihydrocodeine short acting
88997282|NCT00547885|Active Comparator|2|Placebo dihydrocodeine, long acting and active dihydrocodeine short acting.
88997283|NCT00547963|Experimental|1|two brief counseling sessions delivered to ED patients who report conjoint alcohol and marijuana use
88997284|NCT00548002||1 and 2|Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).
88997285|NCT00548275|Experimental|1|Enhanced Sexual Risk Management (ESRM): Patients assigned to ESRM will attend 4 individual gender-specific interactive counseling sessions, once weekly over a four-week period. They will attend 2 sessions (20 minutes, weeks 2 and 3) followed by 2 sessions (40 minutes, weeks 4 and 5) that will be gender-specific to the patient and gender-matched with the study physicians (one female and one male) who will be trained in HIV testing and risk counseling. Sessions will include skill-building in condom use, safer sex negotiation, self-control of triggers and coping skills, didactic materials, and distribution of written material and address self-perception of risk, barriers to risk reduction, and negotiation of a risk-reduction plan.
88997286|NCT00548275|Active Comparator|2|Standard Sexual Risk Management (SSRM): In SSRM, patients will attend two 10-minute gender non-specific individual educational sessions about HIV/AIDS provided by one of the study physicians who will be trained in HIV testing and risk counseling. Session 1 will coincide with the physician visit at the time of randomization. The patient will receive pre-test counseling at this time and undergo HIV antibody testing. Session 2 will take place 7 days later when the patient returns to receive their HIV test results and post-test counseling. In addition, subjects will receive didactic prevention messages about HIV relevant to their reported risks and will be asked if they have questions regarding this information.
88997287|NCT00548314|Experimental|1|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
88997288|NCT00548314|Experimental|2|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5.
88997289|NCT00548314|Experimental|3|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
88997290|NCT00548314|Active Comparator|4|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5.
88997291|NCT00548353|Experimental|1|MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
88997292|NCT00548353|Placebo Comparator|2|MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
89051893|NCT04614818||lymphoepithelioma-like carcinoma of ovaries|The primary site of lymphoepithelioma-like carcinoma locates in the ovaries.
89051894|NCT04614818||lymphoepithelioma-like carcinoma of cervix|The primary site of lymphoepithelioma-like carcinoma locates in the cervix.
89051895|NCT04614818||lymphoepithelioma-like carcinoma of tonsil|The primary site of lymphoepithelioma-like carcinoma locates in the tonsil.
89051896|NCT04614623|No Intervention|Current Diabetes Management Continued|Continued Insulin Delivery Method and Current Clinic Care of Diabetes
89051897|NCT04614623|Experimental|Video Conferencing+Current Insulin Delivery|Patients continue current insulin delivery modality but receive enhanced clinical management support via video conferencing link by diabetes coordinator
89682715|NCT00701675|Placebo Comparator|Placebo|placebo 50 or 100mg
89682716|NCT01987089|Experimental|CBT-I|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician. Session 1 serves as an orientation. No active treatment is delivered at this time. Sessions 2 & 3 are used to deliver the three main components of the intervention which are Sleep Restriction (SRT), Stimulus Control, and Sleep Hygiene. All but two of the remaining sessions are dedicated to the titration of total sleep time and to ensuring patient adherence. One session (session 5) entails the delivery of a specific form of cognitive therapy. The final session (session 8) is used to engage in a relapse-prevention didactic, i.e., to review first, how insomnia becomes chronic and second, the strategies that are likely to abort an extended episode of insomnia.
89682717|NCT01987089|Placebo Comparator|QDT|"This form of placebo therapy has been commonly used in prior studies investigating behavioral interventions for insomnia. The therapist presents the QDT as a means to eliminate conditioned arousal, occurring after nocturnal arousal using 8 sessions on a weekly basis. The therapist initially helps the subject to develop a chronological 12-item hierarchy of commonly practiced activities on awakening at night, like opening eyes and clock watching. As a next step, the subject develops 6 imaginable scenes of himself/herself engaged in neutral activities like reading a newspaper. The therapist then helps the subject pair the neutral scenes with the items from the 12-item hierarchy, which is then practiced by the subject 2 hours before bedtime."
89682718|NCT01987401||Iraq and Afghanistan Era Veterans|Veterans who served during the Iraq and Afghanistan Era
89682719|NCT04444154|Active Comparator|Control group|oral hygiene advice given orally
89682720|NCT04444154|Active Comparator|Group with active participation|oral hygiene advice given orally and demonstration of brushing methods in the sink with active participation
89051898|NCT04614623|Experimental|AHCL pump without Video Conferencing|Patients switch to use of an Advanced Hybrid Closed Loop pump without Video Conferencing standard support
89051899|NCT04614623|Experimental|AHCL pump+Video Conferencing|Patients will use Advanced Hybrid Closed Loop pump with enhanced clinical support via video conferencing
89051900|NCT00571350|Active Comparator|A|women with vaginal prolapse who underwent TVT O
89051901|NCT04583904||Adults - inpatient|
89051902|NCT04583904||Adults- ambulatory|
89051903|NCT04583904||Children|
89051904|NCT04583631||Chronic adenoiditis|Patients with hypertrophy and those out of hypertrophy were determined and those who had purulant rhinorrhea signs and rate of adenoids-choana below 50% were categorized that chronic adenoiditis.
89051905|NCT04583631||Adenoid hypertrophy|Patients who have snoring and those whose adenoid choana rate is greater than 50% were categorized that adenoid hypertrophy group.
89051906|NCT00571467|Experimental|PRTX-100 (Staphylococcal protein A)|"Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
89051907|NCT00563303|Experimental|H|Hydrocortisone
89682721|NCT04444154|Experimental|Group with video and quizz|oral hygiene advice given orally and an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
89682722|NCT01969539|Experimental|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
89682723|NCT01969539|Experimental|Combivent Respimat - ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation with /CVT-R via ventilator adapter
89051908|NCT00563303|Placebo Comparator|P|Treatment by NaCl (placebo)
89051909|NCT00571506|Experimental|1|Rosiglitazone 4 mg by mouth daily
89051910|NCT00571506|Active Comparator|2|Pioglitazone 30 mg by mouth daily
89051911|NCT04614077||A( saline)|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
89051912|NCT04614077||B specific solution|The vein piece 1 cm is taken from one patient, then the piece is divided and assigned to saline or the specific solution.
89051913|NCT00571545|Experimental|1|Subjects recruited from the community with a history of traumatic brain injury were enrolled into a 10 week supervised exercise program and encouraged to exercise at home as well.
89051914|NCT00571545|Other|2|Controls were wait-listed for the supervised exercise program but were not treated during the 10 week wait period.
89051915|NCT04583397|Experimental|Experimental: WiFi - Sham|first intervention WiFi, second intervention sham
89051916|NCT04583397|Experimental|Experimental: Sham - WiFi|first Intervention sham, second Intervention WiFi
89051917|NCT04614272|Experimental|active prayer group|the active prayer group will mediate over an active type of prayer
89051918|NCT04614272|Experimental|passive prayer group|the passive prayer group will mediate over a passive type of prayer
89051919|NCT04614272|Sham Comparator|control group|the control group will read a poem
89051920|NCT04583436|Experimental|Endovascular recanalization|"Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.~n=45"
89682724|NCT04277312|Experimental|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
89682725|NCT04277312|Experimental|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
89682726|NCT04277312|Experimental|Nourish and Engage|This arm of the intervention delivered both the Nourish and Engage interventions as detailed above.
89682727|NCT04277312|No Intervention|Delayed|The delayed arm of the intervention was the control arm. Schools randomised to this arm of the study were offered the Engage intervention resources after endpoint data collection.
89682728|NCT00659789|Experimental|Vacc-4x|Vacc-4x reconstituted in sterile water (0.1 mL) at a dose of 1.2mg per intradermal administration. Participants are given a total of 6 immunizations over 18 weeks (weeks 1, 2, 3, 4, 16, 18). Recombinant human granulocyte macrophage colony stimulating factor (rhuGM-CSF) Leukine (0.06mg in 0.1 mL) administered intradermally is used as a local adjuvant.
89051921|NCT04583436|Active Comparator|Open surgery|"Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.~n=45"
89682729|NCT00659789|Placebo Comparator|Placebo|Placebo injections consisting of sterile water (0.1 mL) in place of Vacc-4x. Placebo injections consisting of sterile water (0.1 mL) in place of Leukine.
89051922|NCT04583202|Placebo Comparator|Placebo exposure|All patients undergo 2 placebo exposures
89051923|NCT04583202|Experimental|Birch Pollen Exposure|All patients undergo 4 allergen exposures
89051924|NCT04613609|Placebo Comparator|Placebo|E-cigarette containing no nicotine.
89051925|NCT04613609|Active Comparator|Nicotine|E-cigarette containing nicotine
89051926|NCT00571623||1|All subjects act as their own contral
89051927|NCT04613531||Participants with PD|patients with clinically diagnosed Parkinson's disease
89051928|NCT04613531||Participants without PD|participants clinically diagnosed without Parkinsons' Disease
89051929|NCT00571740|Active Comparator|Arm I (second-line therapy)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
89051930|NCT00571740|Experimental|Arm II (second-line therapy)|Patients receive bevacizumab and modified FOLFOX7 as in arm I. Patients also receive cetuximab IV over 2 hours on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
89051931|NCT04613687|Experimental|URGOBD001|Compression bandage
89051932|NCT04580082|Experimental|Mindfulness lessons|"There are 14 lessons in total, each lasting approximately 20 minutes. Participants will be asked to listen to one lesson per day for 14 consecutive days, but to allow for possible missed days, they will have up to 25 days to complete as many of these 14 lessons as they can. The lessons will be delivered via the internet, and participants can use a variety of devices (e.g. smartphone, desktop computer, laptop computer, tablet) to access them. While the lessons cannot be downloaded, they are available for streaming anytime and anywhere there is an internet connection. Participants are welcome to revisit any lesson they have listened to previously, but are not allowed to skip ahead to other lessons until they have completed all preceding lessons. This is done because the lessons build on one another, which means that skipping lessons makes continued participation difficult. We will be able to track each participant's usage pattern and will analyze differences across users."
89051933|NCT04580082|Other|Delayed-start Mindfulness Lessons|"The control group will not receive the intervention until the intervention group has completed lesson listening. During this waiting period, they will receive periodic emails letting them know that their turn to listen to lessons is coming soon.~Once available, the control group will have 25 days to listen to the 14 lessons."
89051934|NCT04583085||CP + CHD group|This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected.
89051935|NCT04583085||CP group|25 patients with chronic periodontitis who were systemically healthy were selected
89051936|NCT04583085||HP group|25 patients who were systemically and periodontally healthy, were considered as HP group.
89051937|NCT04583046|Placebo Comparator|placebo|normal saline inhalation group
89051938|NCT04583046|Experimental|iloprost group|iloprost inhalation group
89051939|NCT00563537|Experimental|1|18F-X PET Scan imaging
89051940|NCT04613765||Non-migrants|"53 non-migrant patients will be enrolled. Non-migrants will be defined as the group of native-born persons with a Belgian nationality or with a foreign nationality but with both parents native-born."
89051941|NCT04613765||Migrants|"60 migrant patients will be enrolled. This group will include both First Generation (FG) migrants defined as the group of foreign-born persons and Second Generation (SG) migrants defined as people native-born but with either a foreign nationality or with one or both parents foreign-born."
89051942|NCT04582929|Experimental|50 unit of Neubotulinum Toxin Type A (Neuronox)|50 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
89051943|NCT04582929|Experimental|100 unit of Neubotulinum Toxin Type A (Neuronox)|100 unit of Neubotulinum Toxin Type A (Neuronox) injection for Cervical Dystonia in patient diagnosed with cervical dystonia according to clinical diagnosis
89051944|NCT04613726|Placebo Comparator|IV 10 ml normal saline|Control group consisted of patients receiving IV 10 ml normal saline.
89051945|NCT04613726|Active Comparator|IV 8 mg ondansetron in 10 ml of normal saline|This group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline,
89051946|NCT04613726|Active Comparator|IV 3 mg granisetron in 10 ml of normal saline|This group consisted of receiving IV 3 mg granisetron diluted in 10 ml of normal saline.
89051947|NCT00568230|Experimental|1|Patient is screened for study, and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
89051948|NCT04613804|Experimental|Toripalimab group|Toripalimab 240mg ivgtt Q21d
89051949|NCT00568269|Active Comparator|Lichtenstein|
89051950|NCT00568269|Experimental|TEP|
89051951|NCT04613258|Active Comparator|SCAR Porridge Group|There were 22 subjects in the intervention group (I) who received 50 g of SCAR porridge once per day, along with dietary counseling.
89051952|NCT04613258|Active Comparator|Counseling Group|21 subjects in the control group (C) who only received dietary counseling
89051953|NCT03453957|Experimental|Professional Development Program|Therapists who participate in workshops and consultation sessions with study trainers during study-related therapy sessions and their participating patients/clients.
89051954|NCT03453957|No Intervention|Control|Therapists who did not participate in workshops and consultations sessions while engaging in study-related therapy sessions and their participating patients/clients.
89051955|NCT04613102|Experimental|interventional arm, phase 2|"All participant of phase 2 will receive CBD cream for their chronic wound treatment.~This is an open-label part of the study."
89051956|NCT04613102|Experimental|Interventional arm, phase 3|"Each participants of the phase 3 will receive the active study medication (AVCN583601) during the entire study treatment period on the one of his body sides, and placebo cream - on the other body side simultaneously (left/right). So, each participant will be his own control.~The research support pharmacy will randomize, which side of the body participant should apply CBD cream on, and provide two jars with the study medications, labeled accordingly ( Left /Right)."
89051957|NCT04582851||Postgraduate students|prevalence of TMD among postgraduate students.
89051958|NCT04582656|Experimental|Targeted microwave ablation|Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion
89051959|NCT04612985|Experimental|Procedures with XACT Robotic System|Device: XACT Robotic System The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous lung procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
89051960|NCT00571896|Experimental|SennaS|This group of participants will receive SennaS to use after surgery.
89051961|NCT00571896|Placebo Comparator|Placebo|This group of participants will receive placebo pills to use after surgery.
89051962|NCT04613180|Placebo Comparator|Group I (control group)|40 patients with obstructive bronchitis who received placebo
89051963|NCT04613180|Active Comparator|Group II|40 patients who received oral montelukast sodium oral, at a dosage of 0.2-0.4 mg/kg/day
89051964|NCT04612634|Experimental|Research Group 1|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
89051965|NCT04612634|Active Comparator|Research Group 2|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. at the age of 18-24 months old, 0.5 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
89051966|NCT04612634|Active Comparator|Research Group 3|150 subjects are administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. at the age of 18-24 months old, 1.0 ml each dose, respectively. Blood samples are collected before vaccination and one month (30 days) later.
89051967|NCT04579965|Other|combined contraceptive pills|treat patients with isthmocele with oral contraceptive pills
89051968|NCT04579965|Other|Misotac|treat patients with isthmocele with misotac.
89051969|NCT04612595||Group A|Group A are males with CKD stage 1-2.
89051970|NCT04612595||Group B|Group B are males with CKD stage 3-4.
89051971|NCT04612595||Group C|Group C are females with CKD stage 1-2.
89051972|NCT04612595||Group D|Group D are females with CKD stage 3-4.
89051973|NCT00568308|Placebo Comparator|1|
89051974|NCT00568308|Experimental|2|
89051975|NCT04580199|Active Comparator|total thyroidectomy|excision of thyroid gland
89051976|NCT04580199|Active Comparator|hemi thyroidectomy|excision half of thyroid gland
89051977|NCT04580199|Active Comparator|ethanol ingection|ingection of ethanol into thyroid nodule under guidance of ultrasound
89051978|NCT04580199|Active Comparator|monopolar radiofrequency|using radiofrequency for ablation of thyroid nodule
89051979|NCT04580199|Active Comparator|laser photocaugulation|using laser for ablation of thyroid nodule
89051980|NCT04612673|Experimental|Treatment|Participants received Sintilimab, 200mg, iv, d1, Q3W,and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
89051981|NCT00572091|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
89051982|NCT04612829|Experimental|Intervention- Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic 1 Lozenge after every 2 hours, 5 times a day. Mode of Administration: Oral Duration of Treatment: 5 days
89682730|NCT04639310|Experimental|XEN496|24-day dose titration period to a top dose of 21 mg/kg/day. Subjects continue at the top dose, or the highest tolerated dose up to the top dose, for 12-week maintenance period. If the subject does not immediately enter into the separate open-label extension (OLE) study, the maintenance period will be followed by a 15-day taper period.
89682731|NCT04639310|Placebo Comparator|Placebo|To maintain the blinded aspect of the study, subjects will be titrated on placebo over the 24-day period and remain at this dose for the 12-week maintenance period. If the subject does not immediately enter into the separate OLE study, the maintenance period will be followed by a 15-day taper period.
89682732|NCT02300727|Active Comparator|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
89682733|NCT02300727|Experimental|Curcumin|Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
89682734|NCT02300727|Other|Curcumin-MTD|"Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)"
89682735|NCT03836612||People with inflammatory bowel disease|Adults (18+) with inflammatory bowel disease registered with a contributing GP practice during the study period
89682736|NCT03836612||Controls|Adults (18+) without inflammatory bowel disease registered with a contributing GP practice during the study period
89682737|NCT00659945|Active Comparator|1|Pre-op Aprepitant plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
89682738|NCT00659945|Placebo Comparator|2|Pre-op Placebo plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
89682739|NCT01534871|Experimental|Exercise|Subjects enrolled in the exercise arm will receive the study intervention.
89682740|NCT01534871|No Intervention|Control|Subjects in the control arm will receive standard of care (e.g. medication and medical supervision) for rheumatoid arthritis. These subjects will not participate in the exercise intervention.
89682741|NCT04387565||Preeclampsia|The diagnosis of LOPE, as will be defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will be established based on the presence of proteinuria and a blood pressure level of ≥140/90 mmHg that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure ≥ 160/110 mm Hg, it will be accepted as mild; and in case these values exceeded this level, it will be accepted as severe.
89682742|NCT04387565||control pregnant group|These participants with normal healthy pregnancies at the third trimester (before birth)
89682743|NCT04387565||control non-pregnant group|A volunteer group of healthy women who visited the gynaecology clinic for routine examinations and women who were admitted for pre-pregnancy tests were invited randomly to this research as a control group.
89682744|NCT02141555|Active Comparator|Vaginal misoprostol|Participants will insert four misoprostol tablets (total of 800 micrograms) deeply into the vagina with their fingers.
89682745|NCT02141555|Experimental|Buccal Misoprostol|Participants will place two tablets of misoprostol between their gum and cheek on each side (total 800 micrograms), then swish and swallow the remnants after 30 minutes.
89682746|NCT01799057|Experimental|Metformin|Metformin at a maximum dose of 1000mg twice daily for 16-18 weeks (i.e. maximum of 2000mg per day).
89682747|NCT01799057|Placebo Comparator|Placebo|Matching placebo twice daily for 16-18 weeks.
89682748|NCT02141867||Noncardiac surgical patients|Noncardiac surgery patients 16 years or older undergoing inpatient surgery
89682749|NCT02320175|No Intervention|Pre-intervention|Before implementation of Patient and Family Centered I-PASS.
89682750|NCT02320175|Experimental|Post-intervention|After implementation of Patient and Family Centered I-PASS.
89682751|NCT02421536|Experimental|Vibrent Smartphone Application|"We propose to pilot the application of the mobile application VibrentTM (research procedure) during a course of head and neck radiotherapy for eligible study subjects. Study subjects will be prospective consented and enrolled and will have baseline out of clinic assessment with the Vibrent smartphone application (research procedure)."
89682752|NCT00661037||1|Patients having VF induction with shock termination at implant
89051983|NCT04612439|Experimental|VABB Elite 10G|Vacuum-assisted Elite 10G
89682753|NCT00661037||2|Patients not having VF induction at implant or during follow-up
89682754|NCT00588809|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
89682755|NCT00588965|Placebo Comparator|1|Subjects are assigned to placebo.
89051984|NCT04612439|Active Comparator|BARD 14G CNB|BARD 14G Core needle
89051985|NCT04612517|Experimental|ZP7570|Four ascending doses of ZP7570
89051986|NCT04612517|Placebo Comparator|Placebo|Corresponding volume of placebo
89051987|NCT00568347||long acting bronchodilator|salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide
89051988|NCT00568347||bronchodilator/ inhaled corticosteroid|fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide
89051989|NCT00568347||C|Fluticasone 100mcg/salmeterol 50mcg
89051990|NCT04612127|Experimental|Experimental group - Spinach|"Consumption for 90 days of spinach extract (1000mg)~Four capsules will be consumed per day, two with breakfast and two with lunch."
89051991|NCT04612127|Placebo Comparator|control group Placebo (sucrose)|Four capsules will be consumed per day, two with breakfast and two with lunch.
89051992|NCT04612361||non impaired sleep group|about 200-250 patients
89682756|NCT00588965|Active Comparator|2|Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.
89682757|NCT00589277|Experimental|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
89682758|NCT00589277|Placebo Comparator|Standard care counseling + standard materials|Standard care counseling + standard care print information
89051993|NCT04612361||insomnia group|about 200 patients
89682759|NCT00702299|Experimental|Receiving Treatment|Dose escalation of day 1 i.p. pemetrexed disodium accrued three patients to each of five dose levels (60-1,000 mg/m2), along with day 2 i.p. cisplatin (75 mg/m2) and day 8 i.p. paclitaxel (60 mg/m2) with a biologic sample preservation procedure
89682760|NCT00702377|Experimental|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops
89682761|NCT00702377|Active Comparator|OPTIVE|OPTIVE Lubricant Eye Drops
89051994|NCT04612361||sleep deprived group|about 200-250 patients
89682762|NCT00703391|Experimental|1|Active Treatment
89682763|NCT00703391|Placebo Comparator|2|Placebo Treatment
89682764|NCT00661583|Experimental|Ranibizumab alone|Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
89682765|NCT00661583|Experimental|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
89682766|NCT00661583|Active Comparator|MMC alone|MMC therapy alone (n=10)
89682767|NCT00661895|Experimental|Intervention|Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).
89682768|NCT00661895|Active Comparator|Control|No intervention
89682769|NCT00590369|Active Comparator|1|KCI VAC type negative pressure wound therapy device
89682770|NCT00590369|Experimental|2|Versatile One (EZCare) negative wound therapy device
89682771|NCT00703937|Experimental|Ferric Carboxymaltose (FCM)|750 mg of iron as undiluted FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg per minute weekly until the calculated iron deficit dose has been administered (to a maximum cumulative dose of 2,250 mg).
89682772|NCT00703937|Active Comparator|Standard Medical Care (SMC) for the treatment of IDA|SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
89682773|NCT00662207|Experimental|Arm 1|Use a vibrator on the patient's bottom to determine if it will induce a bladder contraction; Use an anal dilator to determine if urethral relaxation will occur
89051995|NCT04582071|Experimental|Arm 1 (Psychotherapy, Intervention arm)|Subjects undergoing a 3 step IPAA will receive the four sessions of psychotherapy preceding and following their first surgery only, and receive an additional set of questionnaires again after their third surgery.
89051996|NCT04582071|No Intervention|Arm 2 (Non-Therapy, Control Arm)|Subjects will receive questionnaires which will be administered remotely via telemedicine if patient and psychologist/ research team member are unable to meet in person.
89051997|NCT04582110||Patients with Beta Thalassemia|Patients with previous diagnosis of Beta Thalassemia
89051998|NCT04582110||Control Group|Healthy fellow eyes without actual and previous ocular trauma
89051999|NCT04612205|Experimental|group A|females complain from SUI treated by TECAR and pelvic floor exercises
89052000|NCT04612205|Active Comparator|group B|females treated by pelvic floor exercises only
89682774|NCT01504373||NAVA-PSV|Subject will receive 4 hours of NAVA followed by 4 hours of PSV.
89682775|NCT01504373||PSV-NAVA|Subject will receive 4 hours of PSV followed by 4 hours of NAVA.
89682776|NCT04398212|Placebo Comparator|Non-complaining group|the students in this group are not complaining of CVS symptoms but will be examined to diagnose CVS or exclude it
89052001|NCT00572130|Experimental|Rexin-G Dose 1|
89052002|NCT00572130|Experimental|Rexin-G Dose 2|
89052003|NCT04612088|Experimental|Bariatric Multivitamin|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
89052004|NCT04612088|No Intervention|Waitlist|Bariatric patients that gave their consent in written will be given a Bariatric Multivitamin containing: Serving Size 2 Tablets: Calories 25, Total Fat 0.5 g, Total Carbohydrates 5g, Total Sugars 2 g, Vitamin A 3,000 mcg, Vitamin C 90 mg, Vitamin D 75 mcg, Vitamin E 100.5 mg, Vitamin K 300 mcg, Thiamin 36 mg, Riboflavin 3.4 mg, Niacin 20 mg, Vitamin B6 4 mg, Folate 1,360 mcg, Vitamin B12 1,000 mcg, Biotin 600 mcg, Pantothenic Acid 20 mg, Calcium 170 mg, Iron 45 mg, Phosphorous 130 mg, Iodine 150 mcg, Magnesium 50 mg, Zinc 16 mg, Selenium 70 mcg, Copper 2 mg, Manganese 2 mg, Chromium 120 mcg, Molybdenum 50 mcg, Sodium 15 mg, Mixed Tocopherols 30 mg, Coenzyme Q10 10 mg and Boron 2 mg.The patients will take 2 tablets once a day for three months.
89052005|NCT04611971|Active Comparator|Active Arm: Benlysta + Candin|Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Benlysta injection subcutaneously.
89052006|NCT04611971|No Intervention|Control Arm: Candin|All participants will receive a single dose of Candin injection intradermally along with a single dose of saline solution of 0.9% NaCl administered intradermally and no Benlysta.
89052007|NCT00572208|Active Comparator|1|Gabapentin group
89052008|NCT00572208|No Intervention|2|placebo
89052009|NCT04611386||rivaroxaban group|20 rivaroxaban using patients
89052010|NCT04611386||apixaban group|20 apixaban using patients
89052011|NCT04611386||edoxaban group|20 edoxaban using patients
89052012|NCT04611386||control group|5 control group patients
89052013|NCT00572247|Experimental|1|Behavioral
89052014|NCT00572247|No Intervention|2|
89682777|NCT04398212|Experimental|Complaining group|the students in this group are complaining of CVS symptoms but will be examined to document their complains and correlate to clinical findings
89682778|NCT02301039|Experimental|Soft tissue sarcoma|Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
89052015|NCT04611620||Breast Cancer and Colorectal Cancer Survivors|The purpose of this study is to explore the factors related with cognitive concerns and other symptoms in breast and colorectal cancer survivors.
89052016|NCT00572286||1|heart transplant patient ( pre or post)
89052017|NCT04611659|Active Comparator|Information Only|Women in both the control and treatment conditions will complete a baseline survey that includes the Mini-International Neuropsychiatric Interview (MINI),34 a contraceptive use survey,35 and the WHO Quality of Life-Brief (WHO-QOL-B).36 Women in the control group will be provided a color brochure with easy-to-read information about the advantages of LARC. Via this brochure, control group women will be provided no-cost options and corresponding referral information for receiving LARC.
89052018|NCT04611659|Experimental|Motivational Interviewing and Educational Training (MIET)|Women randomized to the treatment group will complete the baseline survey and receive the same brochure; however, they also will receive structured education regarding unintended pregnancies among women using opioids, potential complications associated with opioid, alcohol, and other drug use, and education on contraceptive use (with an emphasis on LARC). This structured education will be coupled with a brief, initial MI conversation. The interventionist will receive respective patients' MINI for opioids,37 contraceptive survey, and WHO-QOL-B from the research coordinator, and the answers to the survey forms will expedite the conversation around each woman's contraceptive desires.
89052019|NCT00563693|Experimental|A|The patients use ASV
89052020|NCT00563693|Active Comparator|B|Patients without ASV
89052021|NCT00572325||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
89052022|NCT04582032|Active Comparator|Dexketoprofen group,|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in dexketoprofen group were administered intravenous dexketoprofen (50 mg/2ml) and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
89052023|NCT04582032|Other|Saline group|IV cannulation was performed on hand dorsum or brachial and canulation place was recorded. Patients allocated in control group were administered intravenous 2 ml of saline and 0,3 mg/kg midazolam 10 minutes prior to general anesthesia induction
89052024|NCT04581876|Experimental|raltitrexed for injection + nab-paclitaxel|Patients receive raltitrexed 2mg/m2 (iv, 15min) and nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
89052025|NCT00563888|Experimental|A|Narrative Exposure Therapy (NET)
89682779|NCT02301039|Experimental|Bone sarcoma|Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]. Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
89682780|NCT02301039|Experimental|Expansion|Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
89682781|NCT02984540|Experimental|LOW-CARBOHYDRATE DIET|The low-carbohydrate diet will consist of a meal plan of less than 20 grams of carbohydrates per day to be consumed over 6 weeks. Foods that provide high levels of healthy fats (preferably low in saturated fats) will be generously included in the diet plan. Various lean meats, fish, and nutrient rich foods that meet the requirement of less than 20 grams total carbohydrates per day will be included in the meal plans. Carbohydrates will be expected to make up less than 10% of total caloric intake. Participants in the low-carbohydrate diet group will receive a supply of extra virgin olive oil at study visits to incorporate into their individualized meal plans.
89682782|NCT02984540|Experimental|LOW-FAT DIET|The low-fat diet will consist of a low-fat, higher-carbohydrate meal plan to be consumed over 6 weeks. Participants will be encouraged to limit their amount of fat intake to less than 40 grams per day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Various lean meats and other sources of protein will be included in the diet plan. Carbohydrates will be expected to make up 50-60% of total caloric intake.
89682783|NCT00662675|Experimental|001|Pancrease MT 10.5 or MT 21 Pancrease MT capsules for maximum dose of 10 000 lipase units / Kg / day
89682784|NCT00662675|Experimental|002|Placebo for Pancrease MT 10.5 or MT 21 Capsules with Pancrease MT excipients without the active enzymes
89682785|NCT04760210|Active Comparator|Control Group|"Pre-physiotherapy session:~Tens~Infrared/Moist Heat heat for 10 minutes at the low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan with lumbar Sacral Support~Bed rest after the controlled treatment is recommended for this group."
89052026|NCT00563888|No Intervention|B|Waitinglist Control Group
89052027|NCT04579458||COVID-19 Positive|COVID-19 positive in nasopharyngeal swabs and tears or saliva.
89052028|NCT04611932|Experimental|Reference-Reference-Test|
89052029|NCT04611932|Experimental|Reference-Test-Reference|
89052030|NCT04611932|Experimental|Test-Reference-Reference|
89052031|NCT00572442||1|"Subjects without any cardiovascular risk factors:~Age ≥ 45 in men; Age ≥ 55 in women.~Hypertension: BP > 140/90 mmHg or on BP meds.~Diabetes Mellitus: Known fasting blood sugar >126 mg/dl or on DM meds.~Dyslipidemia: On lipid lowering medication or LDL ≥ 160 mg/dl in absence of other risk factors; ≥ 130 mg/dl if other non-diabetic risk factors; ≥ 100 mg/dl if diabetic. Known HDL < 40 mg/dl.~Cigarette smoking (past or present).~Family history of premature CAD in first degree relatives: Age < 55 in men; Age < 65 in women."
89052032|NCT00572442||2|Subjects with 1 cardiovascular risk factor (listed above)
89052033|NCT00572442||3|Subjects with 2 cardiovascular risk factors (listed above)
89052034|NCT00572442||4|Subjects with more than 2 cardiovascular risk factors (listed above)
89052035|NCT00572520|Active Comparator|1|Evidence-based behavioral weight loss treatment with health education counseling
89052036|NCT00572520|Experimental|2|Evidence-based behavioral weight loss treatment with brief behavior therapy for depression
89052037|NCT01150123|Experimental|5 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (5 µg) without any adjuvant
89052038|NCT01150123|Experimental|20 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (20 µg) without any adjuvant.
89216287|NCT04555226|Experimental|Experimental group|Open/minimally invasive pelvic and para-aortic lymph node dissection followed by chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy + brachytherapy).
89682786|NCT04760210|Active Comparator|Decompression|"Pre-physiotherapy session:~Tens~Infrared/Moist Heat heat for 10 minutes at the low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan~Decompression therapy session after the controlled treatment is recommended for this group."
89682787|NCT04760210|Active Comparator|ELDOA|"Pre-physiotherapy session:~Tens~Infrared/Moist Heat heat for 10 minutes at low back region.~Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~Postural Education~Home Plan~Segmental Spinal ELDOA Exercise after the controlled treatment is recommended for this group."
89682788|NCT01970787|Experimental|RFA|Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
89682789|NCT00591305|Experimental|PDL+DIM pill|once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
89682790|NCT00591305|Placebo Comparator|PDL+placebo pill|once-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects
89682791|NCT01988415|Other|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile in one eye (active comparator [i.e., control]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).
89682792|NCT01799603|Experimental|TMC435 in fasted then fed condition|Participants under fasting condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fed condition of second treatment period (after washout period of 9 days, between the two treatment periods).
89682793|NCT01799603|Experimental|TMC435 in fed then fasted condition|Participants under fed condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fasting condition of second treatment period (after washout period of 9 days, between the two treatment periods).
89682794|NCT01970943|No Intervention|No Intervention|PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.
89682795|NCT01970943|Placebo Comparator|Saline Injection (Placebo)|PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.
89682796|NCT00666029|Active Comparator|Atorvastatin|Active arm atorvastatin 40 mg. o.d.
89682797|NCT00666029|Placebo Comparator|Placebo|Placebo arm dummy pill
89682798|NCT03196778|Experimental|Low Dose Radiation|Subjects will receive low dose body radiation for 5 weeks.
89682799|NCT04372940|Experimental|Intervention Side: TXA Irrigation|2.5% tranexamic acid will be applied directly to the wound via bulb irrigation and left in place for 5 minutes in the wound bed
89682800|NCT04372940|Placebo Comparator|Control Side: Saline Irrigation|Contralateral side will serve as a control
89682801|NCT01971255|Experimental|High Titer (HAI > or = 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of ≥1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
89682802|NCT01971255|Experimental|Low Titer (HAI < 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of <1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
89682803|NCT04355312|Experimental|Kysindo|Group of 45 patients with short-term desire for pregnancy who will undergo laparoscopic ovarian cystectomy with use of indocyanine green. Evaluation of the ovarian reserve preoperatively and longitudinal cohort follow-up after surgery at 6 months and 12 months. Analysis by a new imaging technique.
89682804|NCT00592475|Experimental|Regimen 1 Conivaptan 12.5 mg|Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours
89682805|NCT00592475|Experimental|Regimen 2 Conivaptan 25 mg|Conivaptan intravenous loading dose (20 mg) + 5 mg continuous infusion over 6.5 hours
89682806|NCT00592475|Placebo Comparator|Regimen 3 Placebo|Placebo continuous intravenous infusion over 6.5 hours
89682807|NCT01989195|Experimental|CORONARY DISEASE SUBJECT|ALL SUBJECTS IN THIS STUDY HAVE PREVIOUSLY DOCUMENTED CORONARY ARTERY DISEASE BY ANGIOGRAPHY
89682808|NCT00592943|Active Comparator|Armodafinil (100mg)|
89682809|NCT00592943|Active Comparator|Armodafinil (250 mg)|
89682810|NCT01973205|Placebo Comparator|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
89682811|NCT01973205|Experimental|Acetaminophen 250 mg and aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg
89682812|NCT03220802|Experimental|Test group|participants receive a daily dose of OMNI-BiOTiC PPI for three months
89682813|NCT01990677|Active Comparator|25mg Eplerenone- Chronic CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58 day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
89682814|NCT01990677|Placebo Comparator|Placebo- Chronic CSCR Diagnosis|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 58 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
89682815|NCT01990677|Active Comparator|25mg Eplerenone- Acute CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28 day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
89052039|NCT01150123|Experimental|5 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
89052040|NCT01150123|Experimental|20 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
89052041|NCT01150123|Experimental|5 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 4.87 mg of MF59
89052042|NCT01150123|Experimental|20 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 4.87 mg of MF59
89052043|NCT01150123|Experimental|5 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 9.75 mg of MF59
89052044|NCT01150123|Experimental|20 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 9.75 mg of MF59
89052045|NCT01150123|Placebo Comparator|Placebo|Subjects received 2 injections of placebo administered 1 month apart
89052046|NCT00572559|Experimental|1|
89052047|NCT00572559|Experimental|2|
89052048|NCT04611464||Single-group cross-sectional cohort|"Patients who have previously received off-label prescriptions of misoprostol for lumbar spinal stenosis for any duration and who are willing to provide verbal and informed consent.~Once enrolled, patients will complete the Swiss Lumbar Spinal Stenosis Questionnaire (SSSQ) as well as the Oswestry Disability Index (ODI). The SSSQ will elicit patients' responses specifically related to their usage of misoprostol for lumbar spinal stenosis.~Then their walking tolerance will be assessed by having them walk along a measured walkway of up to 500 feet to determine the onset of their neurogenic claudication symptoms at a certain distance, their claudication distance.~Prescription information on dosage and frequency of misoprostol use, and any reported side effects with use of this medication, and any cessation or stoppage of use of this medication will all be recorded."
89052049|NCT04611347|Active Comparator|Start with CBD|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only ) for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
89052050|NCT04611347|Active Comparator|Start with control (Shea butter)|The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD)for 2 additional weeks. Patients will apply the cream at the thumb base twice daily for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
89052051|NCT04611776|Experimental|Arm A: Atezolizumab + platinum-doublet followed by atezolizumab maintenance|
89052052|NCT04611776|Placebo Comparator|Arm B: Placebo + platinum-doublet followed by placebo maintenance|
89052053|NCT04611308||cases|
89052054|NCT04611308||controls|
89052055|NCT01149655|Experimental|Phase 1|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
89052056|NCT01149655|Experimental|Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
89052057|NCT01149655|Placebo Comparator|Phase 3|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo
89052058|NCT00575406|Active Comparator|R-CHOP|Treatment with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone
89052059|NCT00575406|Experimental|R-COMP|Treatment with Rituximab, Cyclophosphamide, liposomal Doxorubicin, Vincristin and Prednisolone
89052060|NCT00572715||Observation|"Inclusion criteria - Families of infants (birthweight >1500g) be asked to participate in the study.~Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded"
89052061|NCT00564005|Experimental|1|constraint-induced therapy
89052062|NCT00564005|Experimental|2|bilateral arm training
89052063|NCT00564005|Experimental|3|combined therapy
89052064|NCT00564005|Active Comparator|Control intervention|
89052065|NCT01149538|Experimental|Choline Bitartrate|Choline Bitartrate supplementation
89052066|NCT01149538|Placebo Comparator|Placebo|Placebo for choline bitartrate supplementation
89052067|NCT00575445||1|Pediatric patients with previously diagnosed asthma
89682816|NCT01990677|Active Comparator|Placebo- Acute CSCR Diagnosis.|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 28 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
89682817|NCT02030366||TBI patients|
89682818|NCT02030366||Healthy Volunteers|
89682819|NCT00593645|Experimental|Arm 1: Non-myeloablative conditioning regimen|"Clofarabine 40mg/m2/day IV over two hours daily x 5 days on Days -6 thru -2~Cytarabine 1gm/m2/day IV over two hours daily x 5 days on Days -6 thru -2 after the START of Clofarabine.~Thymoglobulin 1.0mg/kg IV over 6 hours X 1 day on Day -4, then 2.5mg/kg/day x 2 days on Days -3 and -2.~Stem Cell Transplant - On day 0 a minimum of total CD34+ cell dose of 2 x10E6/kg (actual weight of recipient) will be infused."
89682820|NCT03219086|Active Comparator|Group M|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
89682821|NCT03219086|Active Comparator|Group P|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
89682822|NCT04398290|Experimental|iNOpulse Treatment Group|Participants in this group will receive iNO delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days.
89682823|NCT04398290|Active Comparator|Placebo Group|Participants in this group will receive nitrogen gas delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days
89682824|NCT04397510|Experimental|Nebulized Heparin|Heparin 5,000 units/mL Dose: 25,000 units Frequency: every 6 hours Duration: 10 days
89682825|NCT04397510|Placebo Comparator|Placebo|0.9% Sodium Chloride Dose: 5 mL Frequency: every 6 hours Duration: 10 days
89682826|NCT00704717||All Treated Patients|All patients participating in the study.
89682827|NCT03708224|Experimental|Atezolizumab Monotherapy|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery.
89682828|NCT03708224|Experimental|Atezolizumab (Adjuvant)|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery. The first 9 participants in Arm A (atezolizumab monotherapy) will also receive adjuvant atezolizumab 16 weeks after standard of care surgery and radiation, or chemoradiation therapy, at a fixed dose of 1200 mg IV every 3 weeks for an additional 12 cycles.
89682829|NCT03708224|Experimental|Atezolizumab + Tiragolumab|Participants will receive 840 mg of atezolizumab IV and 600 mg of Tiragolumab during the 15-day neoadjuvant period prior to definitive surgery.
89682830|NCT03708224|Experimental|Atezolizumab + Tocilizumab|Participants will receive 840 mg of atezolizumab IV and 6 mg/kg of Tocilizumab during the 15-day neoadjuvant period prior to definitive surgery.
89682831|NCT03632642|Active Comparator|Benzylpenicillin arm|Patients randomised to benzylpenicillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 1.8g Q4H IVI for uncomplicated BSIs and 2.4g Q4H for deep-seated or critical illness infections.
89682832|NCT03632642|Active Comparator|Flucloxacillin arm|Patients randomised to flucloxacillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 2g Q6H IVI or 2g Q4H for deep-seated or criticial illness infections.
89682833|NCT05038514|Experimental|music therapy|Music therapy intervention, bluetooth headphones will be applied in the intensive care unit and will be disinfected after the application. The intervention consists of a 30-minute, single-session, nature-based music concert. the music concert is calibrated by the audiologist (60 decibels). During nature-based music listening, patients will be asked to close their eyes, rest and follow the sound flow.
89682834|NCT05038514|No Intervention|control|The control group will be given the prone position and music therapy will not be applied.
89682835|NCT00594425|Experimental|1|PDT using MAL concentration A
89682836|NCT00594425|Experimental|2|PDT using MAL concentration B
89682837|NCT00594425|Placebo Comparator|3|PDT using Placebo cream
89682838|NCT03686384|Experimental|SVT-15652|1 vial twice daily
89682839|NCT03686384|Placebo Comparator|Placebo|1 vial twice daily
89682840|NCT04317404||Diabetic with Knee Osteoarthritis|HbA1c between 6.5% - 12.0% in the 3 months prior to Visit 1
89682841|NCT04317404||Pre-diabetic with Knee Osteoarthritis|HbA1c between 5.6% - 6.4% in the 3 months prior to Visit 1
89682842|NCT04317404||Non-diabetic with Knee Osteoarthritis|HbA1c < 5.6% in the 3 months prior to Visit 1
89682843|NCT04399070|Placebo Comparator|Propofol group|patients were treated with propofol 1 mg/kg and saline bolus infusion before ECT
89682844|NCT04399070|Active Comparator|Ketamine group|patients were treated with propofol 1 mg/kg and ketamine 0.5 mg/kg bolus infusion before ECT
89682845|NCT04399070|Experimental|S-ketamine group|patients were treated with propofol 1 mg/kg and S-ketamine 0.25 mg/kg bolus infusion before ECT
89682846|NCT00667511|Active Comparator|Home Short Daily Hemodialysis|Intervention: Patients perform short daily hemodialysis (2 to 4 hour treatments) in the home setting using the NxStage System One.
89682847|NCT00667511|Experimental|Home Nocturnal Hemodialysis|Intervention: Patients perform nocturnal hemodialysis (6 to 10 hour treatments) in the home setting using the NxStage System One.
89682848|NCT00667589|Experimental|urea 40% cream|
89682849|NCT00667589|Experimental|fluocinonide 0.05% cream|
89682850|NCT00667589|Experimental|tazarotene 0.1% cream|
89682851|NCT00667589|Experimental|bland emollient cream|
89682852|NCT00667745|Experimental|1|Participants received lithium plus optimized medication treatment, as needed.
89682853|NCT00667745|Active Comparator|2|Participants only received optimized medication treatment, as needed; lithium was not be used.
89682854|NCT03173612|Experimental|AML-CAMS-2016 trial|AML-CAMS-2016 regimen includes risk-stratified therapy and the use of Dasatinib in CBF-AML.The induction regimen includes MAE (etoposide 150mg/㎡/d d1-5, cytarabine 200mg/㎡/d d6-12 , mitoxantrone 5 mg/㎡/d d6-10), CAG (aclacinomycin 6mg/㎡/d d1-8, Ara-C 10mg/㎡ q12h d1-14 , G-CSF 200ug/㎡/d d1-14),IAE (idarubicin 8 mg/㎡/d d1-3, Ara-C 500mg/㎡/d d1-3 d8-10, VP-16 200mg/㎡/d d8-10).Consolidation regimen includes IA (Ara-C 1g/㎡ q12h d1-4, IDA 10mg/㎡/d d1), MA (Ara-C 1g/㎡ q12h d1-4, MTZ 5mg/㎡/d d1-3), IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5), MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6). Dasatinib (60-80mg/㎡) is used in CBF-AML as a part of consolidation therapy.
89682855|NCT02998775|Other|6 participants with mild renal impairment|Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)
89682856|NCT02998775|Other|6 participants with moderate renal impairment|Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min
89682857|NCT02998775|Other|6 participants with severe renal impairment|Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min
89682858|NCT02998775|Other|8 participants normal renal status|Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants
89682859|NCT02998775|Other|6 participants with mild hepatic impairment|Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6
89682860|NCT02998775|Other|6 participants with moderate hepatic impairment|Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9
89682861|NCT02998775|Other|6 participants with severe hepatic impairment|Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15
89682862|NCT02998775|Other|8 participants normal hepatic status|Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants
89682863|NCT02999711|Experimental|Cohort 1|REGN3500 low dose or placebo
89682864|NCT02999711|Experimental|Cohort 2|REGN3500 medium dose or placebo
89682865|NCT02999945|Active Comparator|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)
89682866|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
89682867|NCT02999945|Active Comparator|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
88997293|NCT02277301|Experimental|Mellow Babies|Mellow Babies is a group day programme, run one day a week over 14 weeks with a joint focus on maternal wellbeing and the parentinfant interaction: transport and crèche facilities are provided.The focus is to: (a) explicitly enhance close mother-infant attunement, using a combination of baby-massage, interaction coaching and infant focussed speech; and (b) offer mothers support for their own distress. Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
88997294|NCT02277301|No Intervention|Care as Usual|Routine care received by mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
88997295|NCT00548626|Active Comparator|A|Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
88997296|NCT00548626|Experimental|B|Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
88997297|NCT04953637|Experimental|Physiotherapy group|Participants assigned to the physiotherapy group will receive physiotherapy treatment at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks. They will begin to receive the physiotherapy treatment at 4 months following their surgery and once their DBS settings are optimized.
88997298|NCT04953637|No Intervention|Control group|Participants assigned to the control group will not receive any additional intervention and will be precluded from starting formal physiotherapy for the duration of the study. However, they will be encouraged to keep an active lifestyle. In order to stay active, they will be recommended to do simple home exercises following a home exercise video that will be presented to them. They will be asked to do it 3 times/week for 8 weeks and keep an exercise log to help them stay on track.
88997299|NCT00548665|Experimental|1|Carotid plaque screening and brief advice for smoking cessation: Smokers with at least one carotid plaque will receive pictures of their own plaques with a structured explanation on the general significance of plaques.
88997300|NCT00548665|Active Comparator|2|Brief advice for smoking cessation (without carotid ultrasound for plaque screening): to ensure equal contact conditions, smokers not undergoing ultrasound will receive a relevant explanation on the risks associated with tobacco smoking.
88997301|NCT00548743|Experimental|1|Intervention arm
88997302|NCT00548743|Placebo Comparator|2|Usual care
88997303|NCT00548782|Active Comparator|A|Subjects will be placed on Paleolithic diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. a paleolithic diet excludes dairy, grains, legumes and processed foods.
89682868|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
88997304|NCT00548782|Active Comparator|B|Subjects will be placed on ADA ( American Diabetes Association) recommended diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. An ADA diet is lower fat and more whole grains.
88997305|NCT00548821|Experimental|2|ARM 2: Weekly cisplatin 40mg/m2, concurrent with radiotherapy.
88997306|NCT00548821|Experimental|1|ARM 1: 5-day 3 weekly cisplatin 20mg/m2 for 5 days, concurrent with radiotherapy
88997307|NCT00548899|Other|Sorafenib|Single Arm: All patients receive sorafenib in addition to the established chemotherapy
89682869|NCT00595361|Active Comparator|Arg/Arg|Arg/Arg subjects on 2 week salmeterol treatment
89682870|NCT00595361|Active Comparator|Gly/Gly|Gly/Gly subjects on 2 week salmeterol treatment
89682871|NCT02998463|Experimental|Snuby® users|This group receives the Snuby® skin-to-skin facilitating garment to use in the first six weeks following birth with their baby. The use of the Snuby® garment is participant led, and used for as long and as often as they wish in the six week period.
89682872|NCT02998463|No Intervention|Conventional Care|This group does not receive any intervention, and collects data on the research outcomes when having conventionally facilitated skin-to-skin contact, using a towel, blanket, or clothing as preferred. Skin-to-skin contact frequency and duration is dictated by the participant.
88997308|NCT00549016|Experimental|1|
89682873|NCT02999867|Experimental|M1 triticale and mung bean|M1: triticale and mung bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
89682874|NCT02999867|Experimental|M2 adzuki bean|M2: adzuki bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
89682875|NCT00596453|Placebo Comparator|Placebo|
89682876|NCT00596453|Experimental|Ciprofloxacin hydrochloride|
89682877|NCT02998697|Experimental|Treated Group|Systolic heart failure patients received Ferrous Sulfate 200 mg t.i.d for 90 days
89682878|NCT02998697|Placebo Comparator|Control Group|Systolic heart failure patients received placebo oral capsule t.i.d for 90 days
89682879|NCT02998307|Experimental|Monthly|Receive bedside CPR training monthly
89682880|NCT02998307|Experimental|3 months|Receive bedside CPR training every 3 months
89682881|NCT02998307|Experimental|6 months|Receive bedside CPR training every 6 months
89682882|NCT02998307|No Intervention|Control|No additional training and only performance evaluation after 1 year
89682883|NCT00597545|Active Comparator|Conventional Shunt|"Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt only if it is indicated by EEG, by conventional management."
89682884|NCT00597545|Experimental|Prophylactic Shunt|Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt even when by standard criteria they would not need to receive one.
89682885|NCT00705107||All Treated Patients|All patients participating in the study
89682886|NCT00240331|Experimental|Rosuvastatin 10mg|
89682887|NCT00240331|Placebo Comparator|Placebo|matching Placebo
89682888|NCT00240097|Experimental|Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
89682889|NCT00240097|Experimental|Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) area under the concentration curve (AUC) 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
89682890|NCT00597935|Experimental|SSLF and PMT|Sacrospinous Ligament Fixation (SSLF) and Pelvic Muscle Training & Exercises (PMT)
89682891|NCT00597935|Experimental|ULS and PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) and Pelvic Muscle Training & Exercises (PMT)
89682892|NCT00597935|Experimental|SSLF without PMT|Sacrospinous Ligament Fixation (SSLF) without Pelvic Muscle Training & Exercises (PMT)
89682893|NCT00597935|Experimental|ULS without PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) without Pelvic Muscle Training & Exercises (PMT)
89682894|NCT00739765|Experimental|1 Interpersonal Psychotherapy (IPT)|Participants will receive interpersonal psychotherapy.
89682895|NCT00739765|Active Comparator|2 Prolonged Exposure (PE)|Participants will receive prolonged exposure therapy.
89682896|NCT00739765|Active Comparator|3 Relaxation therapy|Participants will receive relaxation therapy.
89682897|NCT04270721|Experimental|After intervention (sequence 1)|'After intervention' group receives the training immediately and data are only collected after the intervention.
89682898|NCT04270721|Experimental|Before and after intervention (sequence 2)|For the 'Before and after intervention' group, data are collected both before and after the training.
89682899|NCT04270721|No Intervention|Before intervention (sequence 3)|"The 'before intervention' group collects data only before the training.~*This arm will receive the educational intervention after data collection is completed."
89682900|NCT04270487|Experimental|IBS diet|The simple IBS diet is a diet based on the Low FODMAPs diet and the NICE (National Institute of Health and Care Excellence) IBS diet. Patients will be aid to follow the diet with a mobile app.
89682901|NCT04270487|Active Comparator|Otilonium bromide|Otilonium bromide is a a frequently used musculotropic spasmolytic. The dosis used will be 40 mg t.i.d.
89682902|NCT00705653|Experimental|PG-11047|
89682903|NCT02998073|Experimental|Conduct Disorder|Participants are justice-involved youth with conduct disorder. Participants will receive Stop, Now and Plan (SNAP) psychosocial intervention.
89682904|NCT02998073|No Intervention|Control|Participants are healthy males. Participants receive no intervention.
89682905|NCT00739999|Other|1|6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.
89682906|NCT00739999|Other|2|10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.
89682907|NCT02999555|Experimental|Aspirated follicular fluid|Follicular fluid aspirated by follicle size and tested for the novel markers after eggs were identified and separated for the purpose of fertilization
89682908|NCT02999321|Experimental|0% aspartame (water)|participants will not have any aspartame, this is a control.
89682909|NCT02999321|Experimental|5 mg aspartame|participants will receive 5 mg aspartame in a beverage.
89682910|NCT02999321|Experimental|15mg aspartame|participants will receive 5 mg aspartame in a beverage, and 10mg in capsules.
89052068|NCT02884063||NGS reading for Media Free DNA|Ability to read the DNA product available in embryo culture media using NGS to have valuable diagnostic image for genetic composition of embryo before implantation.
89052069|NCT02884063||NGS reading for blastomer DNA|DNA extracted from Blastomere used for aneuploidy screening.
89052070|NCT04601207|Experimental|Solutech™- TC10|10.0mg THC, 12.2 mg CBD liquid emulsion product given orally once in-clinic
89052071|NCT04601207|Active Comparator|MCT-diluted Cannabis Product|10.0mg THC, 12.2 mg CBD liquid MCT-diluted oil product given orally once in-clinic
89052072|NCT01149460|Experimental|Valacyclovir|Test 1000 mg Tablet
89052073|NCT01149460|Active Comparator|Valtrex|Reference Listed Valacyclovir 1000 mg Tablet
89052074|NCT00575484|Placebo Comparator|1|
89052075|NCT00575484|Active Comparator|2|
89052076|NCT04600739||AVD Patients|Patients suffering from aortic valve stenosis receiving replacement of the diseased valve using a TAVI procedure.
89052077|NCT04579614|Active Comparator|Organizational Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own, and with the organizational target. These updates and targets are sent bi-weekly."
89052078|NCT04579614|Experimental|Achievable Target|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a static and achievable target based on their previous year's flu vaccination success rate."
89052079|NCT04579614|Experimental|Variable|"Providers are shown the flu success performance rate of their team (a pod, or group of providers who practice together), in comparison to their own. They will receive a variable target that will fluctuate bi-weekly, based on their previous bi-weekly flu vaccination success rate."
89052080|NCT04600778|Placebo Comparator|placebo|twice daily
89052081|NCT04600778|Experimental|Cavosonstat 5 mg|twice daily
89052082|NCT04600778|Experimental|Cavosonstat 10 mg|twice daily
89052083|NCT04600778|Experimental|Cavosonstat 25 mg|twice daily
89052084|NCT00572871||Exercise after fasting|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions after a 10-hour fast
89052085|NCT00572871||No exercise|Will complete a ten-hour fast but do no exercise
89052086|NCT00572871||Exercise after snack|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions 2 hours following a 500 calorie nutritional supplement
89052087|NCT04600583|Active Comparator|Alignment according to Functional Alignment philosophy|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System aligned according to Functional Alignment philosophy. This method of implant alignment is defined by a patient's native joint line as well as the soft tissue envelope. Triathlon Total Knee System components will be positioned relative to intra-operative soft tissue laxity assessment. A mobile application (KneeBalancer) will be used to assist surgeon decision making during the dynamic joint balancing surgical step.
89052088|NCT04600583|Active Comparator|Alignment to the patient's natural Mechanical axis|Patients randomized to this group will undergo a TKA (total knee arthroplasty) to receive a Triathlon Total Knee System neutrally aligned to the Mechanical axis. More specifically, the femoral component and tibial component are aligned 0° to the mechanical axis of each respective limb. Femoral component rotation is fixed to the trans-epicondylar axis. Soft tissue releases are performed at the discretion of the surgeon to achieve balance and full range of motion.
89052089|NCT04600700||CDSS weaning group|This group will be exposed to the CDSS to inform inotrope weaning
89052090|NCT00575523|Active Comparator|1: Atropine|Atropine 0,5mg is administered intravenously immediately before starting percutaneous ethanol instillation.
89052091|NCT00575523|Placebo Comparator|2: Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
89052092|NCT04600661|Experimental|control group (Traditional therapy group)|control group (Traditional therapy group) (n=21): patients will receive traditional training exercises (high load resistance training
89052093|NCT04600661|Experimental|Experimental group I (BFR training group)|Experimental group I (BFR training group) (n=21): patients will receive LLRT with BFR.
89052094|NCT04600661|Experimental|Experimental group II (Neuromuscular training group)|Experimental group II (Neuromuscular training group) (n=21): patients will receive neuromuscular training exercises
89052095|NCT00572949||1|Patients with chest pain syndrome
89216288|NCT04525183|Experimental|Run In|"Recruit up to 5 patients who meet eligibility criteria to participate in the run-in period of the study~Participants will receive a 6-week Acceptance and Commitment Therapy (ACT) intervention (REVITALIZE)."
89216289|NCT04525183|Experimental|Enhanced Usual Care (EUC)|Participants randomized to EUC will receive educational materials developed by the National Comprehensive Cancer Network (NCCN) about fatigue and exercise during cancer treatment.
89682911|NCT01279525|Experimental|Multifactorial intervention|Multifactorial intervention to prevent falls
89682912|NCT00600743|Placebo Comparator|1 'Instructions to eat normally'|'Instructions to eat normally' Placebo 1 mg dose
89682913|NCT00600743|Active Comparator|2 'Instructions to eat normally'|'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'
89682914|NCT00600743|Placebo Comparator|3 'Instructions to eat normally'|'Instructions to eat normally' 2 mg placebo
89682915|NCT00600743|Active Comparator|4 'Instructions to eat normally'|'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'
89682916|NCT00600743|Placebo Comparator|5 'Instructions to eat normally'|'Instructions to eat normally' 4 mg placebo
89682917|NCT00600743|Active Comparator|6 'Instructions to eat normally'|'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'
89052096|NCT04600349|Experimental|Identity Oriented Psychotrauma Therapy (IOPT)|35 participants will be randomly allocated to the IOPT group. They will attend 10 groups of IOPT every two weeks and they will work 10 Intentions. The groups will be conducted by clinicians or psychotherapists specialized in IOPT. IOPT represents a group treatment developed by Franz Ruppert 20 years ago. It is an effective therapeutic intervention, offering access to less conscious aspects of our psyche, with the help of other persons, named 'representatives.' The method is based on the theory of multigenerational psychotraumatology developed by Ruppert. Although it is very often and widely used all over the world, it has not previously been the subject of randomized controlled trials (RCT), and therefore, its potential efficacy is unknown. In the current study, we want to test this new intervention model on autoimmune thyroiditis.
89052097|NCT04600349|Active Comparator|Treatment as Usual|35 participants will be randomized to this group. They will continue only the medical treatment for Hashimoto their doctor prescribed to them.
89052098|NCT01149421|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
89052099|NCT01149421|Experimental|0.75 milligram (mg) LY2189265|LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
89052100|NCT01149421|Placebo Comparator|Placebo|Placebo: subcutaneous (SC), once weekly (QW)
89052101|NCT04600310|Other|Study Arm 1 Conventional Prep/Control|The preoperative preparation for the control group will use ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) that will be applied to the skin using a sponge-on-a-stick method; this solution is widely recognized as optimal. After the alcohol-based solution has evaporated (no less than 3 minutes), the patient extremity is draped for surgery.
89052102|NCT04600310|Other|Study Arm 2 ULTRAPREP Group/Intervention Arm|ChloraPrep (2% chlorhexidine and 70% isopropyl alcohol) will be poured into the ULTRAPREP bag which will be placed on the patient's extremity while in the holding area; it will be removed only after scrub time of 3 minutes is complete and the patient has been transferred to the OR, anesthetized, and positioned. The patient is draped only after the solution has evaporated (no less than 3 minutes).
89052103|NCT04600232|Experimental|Diagnosis arm|Urine TB-LAM, sputum smear, Gene Xpert, mycobacterial culture
89052104|NCT03453879||1: Study population|Participants in this study are working staff (junior and senior doctors, midwifes and other health personal) in the maternity wards of two hospitals in Central Region Denmark: Horsens Regional Hospital and Aarhus University Hospital, Skejby.
89052105|NCT04600193|Experimental|Phosphate modified diet with organic phosphate|
89052106|NCT04600193|Experimental|Phosphate modified diet with inorganic phosphate|
89052107|NCT00575601|Active Comparator|A|
89052108|NCT00575601|Placebo Comparator|B|
89682918|NCT00600743|Placebo Comparator|7 Instructions to binge eat|Instructions to binge eat 4 mg placebo
89682919|NCT00600743|Active Comparator|8 Instructions to binge eat|Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'
89682920|NCT02997995|Experimental|Immune-attractant/lymphocyte activation|After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
89682921|NCT00601367|Experimental|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
89682922|NCT03620162|Active Comparator|Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™|Participants will receive a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
89682923|NCT03620162|Experimental|Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
89052109|NCT04600271||Study Group|Patients over the age of 18 and who undergone major elective non-cardiac abdominal surgery.
89052110|NCT00575640|Active Comparator|1|"The objective of this study is to determine the MTD for Hydralazine added to standard neoadjuvant chemotherapy for operable recta cancer. Four dose levels of hydralazine are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
89052111|NCT00575679|Experimental|1|Brief motivational interview
89052112|NCT00575679|No Intervention|2|No discussion
89052113|NCT04579887|Experimental|Brain changes triggered by PH induction in Parkinson's disease|Clinical and neuropsychological evaluations + Sensorimotor task for PH-induction
89052114|NCT04599959|Experimental|Overall (Swab/Saliva)|
89682924|NCT03620162|Experimental|Group 3: Prevnar 13™-Prevnar 13™-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
89052115|NCT04579731||Fecal Impaction (LUTD-FI)|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those with 50% of symptom improvement were assumed to have a significant improvement attributable to the development of Lower Urinary Tract Dysfunction- Fecal Impaction (LUTD-FI).
89052116|NCT04579731||Lower Urinary Tract Dysfunction Not Related to Fecal Impaction|Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks. Following eight weeks of treatment, patients were re-evaluated and those without symptom improvement place into lower urinary tract dysfunction not related to fecal impaction (LUTD-FI). They serve as a control group.
89052117|NCT00565487|Experimental|Single arm|This is a single arm dose escalation study with a cohort expansion.
89052118|NCT03453801|Experimental|MZ twins 2-5 yo|Monozygotic twins, 2-5 yo (annual return): In 2014-2015, individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an intramuscular (IM) injection annually following Advisory Committee on Immunization Practices (ACIP) recommendation against LAIV4.
89052119|NCT03453801|Experimental|Non-twins 6 mo-10 yo|Non-twins 6 mo-10 years (annual return): In 2014-2015, participants between 6-23 mo will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM then switch to FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally starting at age 24 months in annual follow-up. Participants aged 24 mo-8 yo will be given LAIV4 at enrollment and for annual follow-up. However, if LAIV4 is contraindicated, the child will continue with IIV4. Participants 9-10 yo will be given IIV4 annually. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first year then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016, all participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually following ACIP recommendation against LAIV4.
89052120|NCT03453801|Experimental|Non-twins 6-12 mo Flu/MMRV Naïve|Non-twins 6-12 mo Flu/MMRV Naïve (annual return): In 2014-2015, participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an IM injection. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.
89052121|NCT04600115|Experimental|MRI vs.PET with/without Cardiac disease|Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging
89052122|NCT03453762|Active Comparator|Recruitment maneuver group|After anesthetic induction, recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
89052123|NCT03453762|Experimental|Lung ultrasonography group|After anesthetic induction, recruitment maneuver is performed, being guided by ultrasonography.
89052124|NCT04599998||COVID-19 inpatients|Patients with laboratory and/or thoracic CT confirmed COVID-19 pneumonia ; older than18 years of age; treated as inpatients; evaluated at 6-12 months after hospital discharge in outpatient clinic
89052125|NCT04579419|Experimental|Sodium Bicarbonate|
89052126|NCT04579419|Placebo Comparator|Normal Saline|
89052127|NCT04600037|Active Comparator|Group 1|Patients received pregabalin (target dose 300 mg/day) and exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
89052128|NCT04600037|No Intervention|Group 2|Patients received exercise therapy alone (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
89052129|NCT04599842|No Intervention|GROUP SA|Group SA was categorized as the group which spinal anaesthesia alone (SA) was performed
89052130|NCT04599842|Active Comparator|GROUP SA+ESP|Group SA+ESP was categorized as group which SA+ESP block was performed.
89052131|NCT00575757||Primary|HIV infected with abnormal liver enzymes in the absence of HCV or HBV coinfections.
89052132|NCT04599881|Experimental|PTR-01 3 mg/kg|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg every other week for a total of 7 doses.
89052133|NCT00575796|Experimental|1|"Children will be treated with Vinblastine Sulphate chemotherapy via intravenous administration once a week over a period of 26 weeks. MRI disease evaluation should be performed at weeks 12 and 26 (+/- 1 week). If response on MRI at week 26 > stable (i.e. stable disease, objective or partial or complete response compared to the baseline MRI exam), continue weekly Vinblastine to the total duration of treatment (i.e. 70 weeks).~All children will be followed until they demonstrate clear signs tumour progression."
89052134|NCT04599530|Other|Biomechanical|All experimental tasks will be evaluated on biomechanical outcome measures
89052135|NCT04599530|Other|Psychological|All experimental tasks will be evaluated on psychological outcome measures
89052136|NCT04599530|Other|Physiological|All experimental tasks will be evaluated on biomechanical outcome measures
89682925|NCT03620162|Experimental|Group 4: Prevnar 13™-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
89052137|NCT04599530|Other|Performance|All experimental tasks will be evaluated on biomechanical outcome measures
89682926|NCT03620162|Experimental|Group 5: V114-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
89052138|NCT04599452|Experimental|10 patients with recurrent refractory elderly AML were treated|The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
89052139|NCT00575835|Active Comparator|1|
89052140|NCT00575835|Experimental|2|
89052141|NCT00565565|Experimental|BAY60-4552, 1 mg|Subjects were planned to receive 1 mg of BAY60-4552 as solution
89052142|NCT00565565|Experimental|BAY60-4552, 2.5 mg|Subjects were planned to receive 2.5 mg of BAY60-4552 as tablet
89682927|NCT02999165||CPAP group|25 infants undergoing treatment with continuous nCPAP who are making attempts at breast feeding and receiving nasogastric feeds.
89682928|NCT02999165||HHFNC group|25 infants undergoing treatment with continuous HHFNC oxygen who are making attempts at breast feeding and receiving nasogastric feeds.
89682929|NCT00742573|Active Comparator|1 Texas Medication Algorithm|Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
89682930|NCT00742573|Experimental|2 Patient Choice|Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
89682931|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Saline|IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours plus Saline infusion at a rate of 30 mL/hour
89682932|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Intralipid|IV Administration of 5% Dextrose in water /D5W (vehicle) 12 mg plus Intralipid infusion at a rate of 30 ml/hour
89682933|NCT02321111|Active Comparator|Eritoran + Intralipid|IV administration of Eritoran 12 mg every 12 hours plus Intralipid infusion at a rate of 30 ml/hour
89682934|NCT03809923|Experimental|Dexmedetomidine Combined With Lidocaine Infusion Affect PONV|
89682935|NCT03809923|Experimental|Effect of infusion saline on PONV|
89682936|NCT03809923|Experimental|Effect of infusion lidocaine on PONV|
89682937|NCT03809923|Experimental|Effect of infusion dexmedetomidine on PONV|
89682938|NCT02997917|Experimental|Education|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the real education group, solutions at suprathreshold concentration for detection will be given with a subsequent comment on the flavor and an explanation of the components and preparation of the soup (low temperature cooking to preserve flavors).
89682939|NCT02997917|Sham Comparator|Sham|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the sham education group solutions at subthreshold concentration for detection with no explanation will be provided.
89682940|NCT03802279||Rhabdomyolysis with myoblasts back up|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited from a diagnostically muscle biopsy and whose myoblasts are available.~Patients benefit from an effort test as part of their care."
89682941|NCT03802279||Rhabdomyolysis|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited or not from a diagnostically muscle biopsy but whose myoblasts are not available.~Patients benefit from an effort test as part of their care."
89682942|NCT03802279||Witness patients : effort test|10 patient-matched healthy controls for age and sex having performed an effort test and cardiac exploration as part of their care.
89682943|NCT03802279||Witness patients : myoblasts|6 healthy controls matched by age and sex having performed a muscle biopsy as part of their care and whose myoblasts are kept.
89682944|NCT02998931|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
89682945|NCT02998931|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
89682946|NCT02998619||Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
89682947|NCT00719329|Experimental|A|Chlorhexidine cleansing of the cord for seven days
89682948|NCT00719329|Experimental|B|Chlorhexidine cleansing of the cord for 1 day
89682949|NCT00719329|Placebo Comparator|C|Dry cord care, as recommended by WHO
89682950|NCT00602225|Experimental|Arm I|See Detailed Description
89682951|NCT04297748|Experimental|Cohort A|Patients (pts) will receive an initial trace (100 mg, IV) dose of zirconium-89 (1.8-2.5 mCi) labelled M7824 (89Zr-M7824) on day 1, sequential PET imaging over 1 week will be performed to determine the biodistribution 89Zr-M7824 into the tumour and normal tissues. All patients who remain on study after Day 14 will have a 1200 mg dose of M7824 q2w beginning on Cycle 1 Day 15. Pts will then receive a 2nd infusion of 100 mg of 89Zr-M7824 with cold M7824 making a total dose of 1200mg on Day 29. All patients will then receive a dose of cold 1200mg M7824 on Cycle 1 Day 43. Patients will continue to receive a therapeutic dose of 1200 mg q2w of M7824 until disease progression or unacceptable toxicity. Patients who do not achieve a CR after 3 doses of M7824 in Cycle 1, may then commence treatment with concurrent chemotherapy with carboplatin and pemetrexed at conventional doses.
89682952|NCT04297748|Experimental|Cohort B|Cohort A will determine whether or not high PD-L1 positive disease is required at study entry to Cohort B. All other assessments within cohort A will be undertaken.
89682953|NCT00602771|Experimental|Arm I|Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10.
89052143|NCT00565565|Experimental|BAY60-4552, 5 mg|Subjects were planned to receive 5.0 mg of BAY60-4552 as tablet
89052144|NCT00565565|Experimental|BAY60-4552, 7.5 mg|Subjects were planned to receive 7.5 mg of BAY60-4552 as tablet
89052145|NCT00565565|Experimental|BAY60-4552, 10 mg|Subjects were planned to receive 10 mg of BAY60-4552 as tablet
89052146|NCT00573105|Experimental|1|Laparoscopic Ventral hernia repair by heavy weight mesh
89052147|NCT00573105|Experimental|2|Laparoscopic Ventral hernia repair by lighter weight mesh
89052148|NCT04599374||high TSH and high FT4|patients with high TSH and high FT4
89052149|NCT04599374||high TSH and low FT4|patients with high TSH and low FT4
89052150|NCT04599374||high TSH and high FT3|patients with high TSH and high FT3
89052151|NCT04599374||high TSH and low FT3|patients with high TSH and low FT3
88997309|NCT00549367|Other|1|Clients in the control arm of the study will receive nutrition assessment only for the first 24 weeks and the be transferred to nutrition counselling group
88997310|NCT00549406|Experimental|1|computer-based visual-training program UFOV
88997311|NCT00549406|Experimental|2|video-game based visual training
88997312|NCT00549406|Placebo Comparator|3|computerized word puzzles
88997313|NCT03456232|Experimental|High-flux hemodialysis|High-flux hemodialysis lasting for 4 hours
88997314|NCT03456232|Active Comparator|Hemodiafiltration|Hemodiafiltration lasting for 4 hours
88997315|NCT03456154|Experimental|Botox|In this group patients will receive 3 injections of botox on each masseter (left and right), after randomization. This injection will be performed once, and the patient will be evaluated after 3 and 6 months after this day.
88997316|NCT03456154|Active Comparator|Occlusal splint|In this group patients will receive an occlusal splint, which will be manufactured after taking their full mouth impression. This appliance has to be worn everyday, for 6 months, at night.
88997317|NCT00161447|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3
88997318|NCT00161447|Active Comparator|2|Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 & at month 3) + Acyline (SQ) every two weeks for the first 12 weeks
88997319|NCT00549484||1|10 mL/kg platelet transfusion
88815836|NCT01116986|Experimental|13, Patch, No Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815837|NCT01116986|Experimental|14, Patch, No Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88997320|NCT00549484||2|15 mL / kg platelet transfusion
88997321|NCT00549523|Placebo Comparator|Placebo|Placebo (capsule filled with inert materials)
88997322|NCT00549523|Experimental|Low Dose|400 mg bid Lessertia Frutescens
88997323|NCT00549523|Experimental|Mid Dose|800 mg bid Lessertia Frutescens
88997324|NCT00549523|Experimental|High Dose|1200 bid Lessertia Frutescens
88997325|NCT00161486|Placebo Comparator|1|Placebo acyline injections every two weeks (2 doses) + placebo testosterone gel daily for 4 weeks
88997326|NCT00161486|Active Comparator|2|Acyline 300 μg/kg every two weeks (2 doses) + placebo Testosterone gel daily for 4 weeks
88997327|NCT00161486|Active Comparator|3|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks + Testosterone gel 100 mg daily for 4 weeks
89682954|NCT00602771|Experimental|Arm II (closed to accrual as of November 2008)|Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.
89682955|NCT04278482|Active Comparator|DHA supplement|Supplement rich in DHA form algae source
89682956|NCT04278482|Placebo Comparator|Placebo|Placebo supplement
89682957|NCT02997683|Experimental|3-month home based training on whole body vibration platform|This Group will receive a training device to perform their given exercises on
89682958|NCT02997683|Placebo Comparator|3-month home based training on floor|This Group will perform their given exercises at home on the floor
89682959|NCT00742963|Experimental|1|75 mg/m2 of Doxorubicin administered by bolus injection starting on Day 1 of a 21-day cycle.
89682960|NCT02997839|No Intervention|group 2|no intervention
89682961|NCT02997839|Other|group 1|sleep disruption
89682962|NCT01279603|Experimental|GO-203-2c|
89052152|NCT04599179||Group 1|Patients underwent placement of a self-expandable metal stent (SEMS)
89052153|NCT04599179||Group 2|Patients underwent to stomach-partitioning gastrojejunostomy
89052154|NCT00575874|Experimental|1|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
89052155|NCT00575874|Experimental|2|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
89052156|NCT00575874|Experimental|3|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
89052157|NCT00575874|Active Comparator|4|30 mg pioglitazone HCl capsules once daily for 12 weeks
89052158|NCT00575874|Placebo Comparator|5|Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
89052159|NCT03454217|Active Comparator|Oxycodone|Postoperative pain treatment with oxycodone
89052160|NCT03454217|Active Comparator|Tramadol|Postoperative pain treatment with tramadol
89052161|NCT04598945|Experimental|Adults|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
89052162|NCT04598945|Experimental|Children|The subject will be subjected to 2 functional MRI sessions spaced 3 days apart Each session will be composed of the same MRI sequences without injection, namely an anatomical exploration sequence followed by sequences of functional exploration of rest and activation (while the subject performs the task motor). The resting functional exploration sequences will frame (1 before, 1 after) the functional activation sequence.
89052163|NCT04579263|Experimental|Patient with diabetes mellitus type 1 (T1DM)|Treatment by transplantation of fecal microbiota
89052164|NCT04579263|Experimental|Patient with diabetes mellitus type 2 (T2DM)|Treatment by transplantation of fecal microbiota
89682963|NCT02997527|Experimental|Intraluminal impedance testing|"During the participant's clinical endoscopy the 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope.~The catheter (tiny tube) will be placed through the endoscope in your esophagus 1 cm above where your stomach and esophagus meet for 5 seconds.~At 2 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds~And at 3 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.~At 4 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.~At 5 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds."
89052165|NCT04598906|Experimental|Virtual environment rehabilitation - Paper-pencil rehabilitation|The participants in this arm completes Virtual environment rehabilitation as the first condition and then crossover to Paper-pencil rehabilitation.
89052166|NCT04598906|Experimental|Paper-pencil rehabilitation - Virtual environment rehabilitation|The participants in this arm completes Paper-pencil rehabilitation as the first condition and then crossover to Virtual environment rehabilitation.
89052167|NCT04579302|Experimental|serratus anterior block|serratus anterior block with 20 ml bupivacaine
89052168|NCT04579302|Experimental|erector spinae block|erector spinae block with 20 ml bupivacaine
89052169|NCT04579302|Sham Comparator|control group|sham block with 20 ml saline
89052170|NCT04598867|Experimental|CD-008-0045 40 mg/day|Patients assigned to the CD-008-0045 40 mg/day group will receive 1 capsule of CD-008-0045 (20 mg) before breakfast and before dinner for 32 weeks.
89052171|NCT04598867|Placebo Comparator|Placebo|Patients assigned to the Placebo group will receive 1 placebo capsule before breakfast, and dinner for 8 weeks.
89052172|NCT04598867|Active Comparator|Afobazol 30 mg/day|Patients assigned to the Afobazol 30 mg/day group will receive 1 tablet of Afobazol (10 mg) before breakfast, before lunch and before dinner for 8 weeks.
89052173|NCT00573300||Schizophrenia|Schizophrenia Patients
89052174|NCT00573300||Healthy Controls|Healthy Controls
89052175|NCT04578795|Experimental|Pt underwent single use flexible ureteroscopy|Patients with renal stones who will operated by single use flexible ureteroscopy
89052176|NCT00565682|Experimental|A|Etoricoxib 120 mg
89216290|NCT04525183|Experimental|REVITALIZE ACT Intervention|Participants randomized to the REVITALIZE acceptance and commitment therapy (ACT) will receive 6 weekly sessions lasting approximately 60-75-minutes over a 6-8 week period, delivered face-to-face using iPads, computers or tablets, and a HIPAA-compliant platform (Zoom for Healthcare). If participants have difficulty connecting to the platform, telephone sessions are permitted.
89682964|NCT03579602|Active Comparator|Arm 1 (no tozuleristide)|Subjects randomized to Arm 1 (~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
89682965|NCT03579602|Experimental|Arm 2 (tozuleristide treated)|Subjects randomized to Arm 2 (~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m^2 at least 1 hour and no more than 36 hours prior to surgery. They will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
89682966|NCT02990741||Usual screening group|ECG recordings at baseline plus at 1 and 2 year of follow-up; three ECG recordings in total.
89682967|NCT02990741||Intensive screening subgroup|ECG recordings at baseline plus quarterly during follow-up, at months 3, 6, 9 ,12, 15, 18, 21 and 24; 9 ECG recordings in total.
89682968|NCT02990741||More intensive screening subgroup|ECG recordings at baseline plus weekly during the first month of follow-up and quarterly afterwards, at weeks 1, 2, 3 and 4 and months 3, 6, 9, 12, 15, 18, 21 and 24; 13 ECG recordings in total.
89682969|NCT03190070|Experimental|Study group|All study participants are in the same group and will have their kidney function measured twice, before and after ingestion of protein, 1 g/(kg body weight). The protein will be given in the form of the protein drink Liquacel (Global Health Products, Rochester, NY).
89682970|NCT00744211|Placebo Comparator|Vehicle|Vehicle Group
89682971|NCT00744211|Experimental|ET-ARA 1mg/kg|ET-ARA 1 mg/kg
89682972|NCT00744211|Experimental|ET-ARA 2mg/kg|ET-ARA 2 mg/kg
89682973|NCT04274972||Pancreaticoduodenectomy patients|All patients, affected by a resectable PDAC of the head of the pancreas, visited at the Department of Pancreatic Surgery of Verona, will be enrolled. All the patients must be scheduled for an elective PD. The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated.
89682974|NCT02997371|Placebo Comparator|Placebo|Isotonic saline administered as an injection and infusion
89682975|NCT02997371|Experimental|1.5 g Kineret|Kineret provided as a 500 mg injection followed by a 1g infusion.
89682976|NCT02997371|Experimental|3.0 g Kineret|Kineret provided as a 500 mg injection followed by a 2.5g infusion.
89682977|NCT04248998|Experimental|Chemotherapy plus Fasting-Mimicking Diet (FMD)|"Experimental Arm A will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD.~Chemotherapy will consist of:~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~twelve consecutive cycles of weekly paclitaxel 80 mg/mq~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles."
88997328|NCT00549796|Active Comparator|1|PCI performed at a hospital with co-located (on-site) cardiac surgery
88997329|NCT00549796|Other|2|PCI performed at a hospitals without co-located (on-site) cardiac surgery
88997330|NCT02963571|Experimental|screw fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw internal fixation.
88997331|NCT00549835|Active Comparator|Real Acupuncture|Participants will have acupuncture performed at a rate of 3 times (Mon, Wed, Fri) / week for total of 2 weeks (total of 6 sessions). We will follow Saam Acupuncture methods, which have been the mainstream of acupuncture methodology in most Korean Oriental Medical Colleges and among clinical practitioners >400 years. Standardized acupuncture prescriptions for mucositis will be acupuncture points tonifying Spleen Meridian (R side) and Small Intestine Meridian (L side). In Oriental Medicine, the spleen has functions of promoting water metabolism, transporting nutrients, and controlling blood. Mouth belongs to the spleen system according to Five element theory. Small intestine is related with mucositis symptoms including thirst and tongue ulcers. We will use sterile, disposable, filiform needles, size 0.16 (40Gauge) - 0.30 mm (30Gauge) in diameter and 15-40 mm long. Total number of acupuncture needles will be 8 (4 needles each side) and needles will be retained for 20 minutes.
88997332|NCT00549835|Sham Comparator|Sham Acupuncture|Newly diagnosed leukemia patients will be recruited from the large patient population on the Leukemia Inpatient Services who will be receiving high dose preperative regimens such as Busulfan + Cytarabine for marrow transplantation.
88997333|NCT00549874|Experimental|1|
88997334|NCT00549874|Experimental|2|
88997335|NCT00549913|Experimental|1|10 subjects to receive lowest dose of NeoFuse (MPCs)
88997336|NCT00549913|Active Comparator|2|4 subjects standard posterolateral spinal fusion with instrumentation
88997337|NCT00549913|Experimental|3|10 subjects to receive middle dose of NeoFuse
88997338|NCT00549913|Active Comparator|4|3 subjects standard posterolateral spinal fusion with instrumentation
88997339|NCT00549913|Experimental|5|10 subjects to receive highest dose of NeoFuse
88997340|NCT00549913|Active Comparator|6|3 subjects with standard posterolateral spinal fusion with instrumentation
88997341|NCT00550030|Experimental|left/right|half-body comparison
88997342|NCT04904068||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease.
88997343|NCT04904068||Healthy|Healthy individuals with no known neurological disorders.
88997344|NCT00550108|No Intervention|A|Observation of pancreatic cysts
88997345|NCT00550108|Experimental|B|Ethanol lavage of pancreatic cysts
88997346|NCT00550186|Placebo Comparator|1|No preload
88997347|NCT00550186|Active Comparator|2|Preload with cristalloid infusion
88997348|NCT00550186|Active Comparator|3|Preload with collid infusion
88997349|NCT00550225|Experimental|Sequence 1|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
88997350|NCT00550225|Experimental|Sequence 2|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
88997351|NCT00550225|Experimental|Sequence 3|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
88997352|NCT00550225|Experimental|Sequence 4|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
88997353|NCT00550225|Experimental|Sequence 5|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
89216291|NCT04523168|Experimental|Chronic Refractory Angina|Subjects with chronic refractory angina will undergo implantation of the Neovasc Reducer™ System in the cardiac catheterization laboratory.
89216292|NCT04520451|Experimental|Rilzabrutinib + glucocorticoids|Rilzabrutinib tablets, 400 mg twice daily from Week 0 to Week 12 plus glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 2 weeks on study)
89216293|NCT04520451|Active Comparator|Glucocorticoids|Glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 12 weeks on study)
89682978|NCT04248998|Experimental|Fasting-mimicking diet plus metformin plus chemotherapy|"Experimental Arm B will consist of 6 months of standard anthracycline-taxane preoperative chemotherapy in combination with triweekly cycles of 5-day FMD and daily metformin~Chemotherapy will consist of:~four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~twelve consecutive cycles of weekly paclitaxel 80 mg/mq~The FMD will consist of a triweekly 5-day regimen of a plant-based, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles.~Metformin will be administered at an initial dosage of 850 mg/dya, and then escalated to the maximum dosage of 1700/day (two 850 mg tablets) if well tolerated. Metformin will be interrupted 7 days before surgery."
89682979|NCT00714233|Experimental|1|Metformin
89682980|NCT00714233|Experimental|2|Oral Contraceptive Pills
89216294|NCT04519541|Experimental|Neurolyser XR treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
89216295|NCT04507412|Experimental|arm A|• 9 mg of i.v. dexamethasone
89216296|NCT04507412|No Intervention|arm B|• no steroid supplementation
89216297|NCT04503096|Experimental|High-dose accelerated rTMS|
89682981|NCT00714233|Active Comparator|3|lifestyle modification program
89682982|NCT00714233|Placebo Comparator|4|placebo to active metformin arm
89682983|NCT00721357||Stroke|Stroke subjects
89682984|NCT00721357||Control|neurologically healthy subjects
89682985|NCT02984306|Experimental|Dietary supplement|
89682986|NCT03809845|Active Comparator|Motor neuron disease|
89682987|NCT03809845|Active Comparator|Benign fasciculation syndrome|
89682988|NCT00714311|Active Comparator|TFP|Transference-Focused Psychotherapy
89682989|NCT00714311|Active Comparator|ECP|treatment by experienced community psychotherapists
89682990|NCT04213118|Experimental|Group A|Administration anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.
89682991|NCT00746395|Active Comparator|lubiprostone 24mcg single dose|lubiprostone 24mcg single dose po prior to capsule endoscopy
89216298|NCT04500795|Experimental|Embolization Group|Patients with residual or recurrent haematoma (higher than 10mm thickness of haematoma at any dimension) following prior surgical evacuation of haematoma will be admitted to the Embolization Group and undergo embolization of MMA. Serial CT scans will be taken at times of presentation of the residual or recurrent haematoma, 1-day, 1-week, 1-month, 3-month, and 6-month following embolization. Size of haematoma will be measured for comparison to the Control Group. Clinical examinations will be done at the same setting.
89682992|NCT00746395|Placebo Comparator|Sugar pill|Placebo (sugar pill) - matched single dose po prior to capsule endoscopy
89682993|NCT04385615|Experimental|FMD Group|Participants will be requested to follow a Fasting Mimicking Diet, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
89682994|NCT04385615|No Intervention|Control Group|Participants will be requested to continue with their habitual eating habits, for three consecutive months. Before and after the intervention dietary intake and physical activity data, evaluation of beige/brown adipose tissue activation, anthropometric measures and body composition (DEXA scan), lipid profile and inflammatory markers.
89682995|NCT02997449||NSCLC, SABR, nodal staging|Patients with a clinical or pathological diagnosis of Non-Small Cell Lung Cancer (NSCLC), and who are medically inoperable or refuse surgery, are eligible if Stereotactic ablative radiotherapy (SABR) is recommended by a multi-disciplinary tumor board. All patients undergo complete mediastinal and hilar staging procedure (EBUS+EUS-B). Pre endoscopy imaging data will be compared with endosonography data.
89216299|NCT04500795|No Intervention|Control Group|All symptomatic patients (headache unresponsive to analgesic or neurological deficits including focal neurological deficits, deteriorated consciousness, headache, seizures, and other signs or symptoms suggestive of SDH as the cause) will undergo haematoma evacuation either by burr-hole drainage or craniotomy. Their response to treatment, neurological status, and CT scans will be monitored. Asymptomatic patients will be monitored radiologically (CT) every 2-4 weeks. The decision for surgical evacuation of haematoma will be based on CT findings (increasing haematoma size) and presentation of symptoms or neurological deficits. They remain in the control group should they refuse embolization of MMA. The size of haematoma will be measured continuously based on CT scans taken at times of presentation, 1-day, 1-week, 1-month, 3-month, and 6-month post-op. Size of haematoma, residual or recurrent will be measured for comparison to the Embolization Group.
89216300|NCT04497064||Athlete|those who identified as participating in athletic competitions at DI, intramural, club or competitive levels
89216301|NCT04497064||non-athletes|those who did not identify as participating in athletic competitions at DI, intramural, club or competitive levels
89216302|NCT04494672|Experimental|Intramedullary nailing with ADAPT system (arm-A)|A commercial product, namely ADAPT will be used as investigation product in arm-A
89216303|NCT04494672|Active Comparator|Intramedullary nailing without ADAPT system (arm-B)|No aid in performing intramedullary nailing for proximal femoral fractures will be implemented in arm-B
89216304|NCT04488926|Active Comparator|Group 1|Normast® MPS (mPEA and umPEA 300mg + 600mg) microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days
89682996|NCT03426644|Active Comparator|Group A|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.
89682997|NCT03426644|Experimental|Group B|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
89682998|NCT03426644|Experimental|Group C|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
89682999|NCT03426644|Experimental|Group D|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group D.
89683000|NCT01275989|Sham Comparator|21|sham acupuncture
89683001|NCT01275989|No Intervention|15|Control
89683002|NCT01275989|Active Comparator|20|intervention
89683003|NCT02997137|Active Comparator|BOT-01|Dietary supplement: specific amino acid composition with micronutrients
89052177|NCT00575952|Experimental|Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)|"Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
89052178|NCT00565799|Active Comparator|1. Omentectomy|LAGB & Omentectomy
89052179|NCT00565799|Placebo Comparator|2 No Omentectomy|LAGB Only
89052180|NCT00573417|Experimental|modafinil|modafinil 100mg, 200mg, or 300mg (dose escalation)
89052181|NCT00573417|Placebo Comparator|placebo|placebo
89052182|NCT00565838||2|G1 - Autologous Fascial Sling G2 - TVT
89052183|NCT00573456|Other|1|
89052184|NCT00565877|Experimental|1 - Neck Ultrasound|post-PICC insertion ultrasound inspection of the ipsilateral neck
89052185|NCT00565877|No Intervention|2 - Control|No post-PICC insertion ultrasound inspection of the ipsilateral neck
89052186|NCT00573495|Experimental|hTERT/Survivin Multi-Peptide Vaccine|
89052187|NCT00565955|Active Comparator|A1|Children Between 5-15 Years of Age Receiving Montelukast
89052188|NCT00565955|Placebo Comparator|A2|Children Between 5-15 Years of Age Receiving Placebo
89052189|NCT04598594|Experimental|Nicotine patch|
89052190|NCT04598594|Placebo Comparator|Placebo patch|
89052191|NCT01580774||Post-discharge phone call|All patients in this group will receive a phone call within 72-hours of being discharged from hospital.
89052192|NCT01580774||Usual care (no phone call)|
89052193|NCT00575991|Experimental|A|
89052194|NCT00575991|Placebo Comparator|B|
89052195|NCT04598243|Experimental|Treatment of CFS/FMS with the nutritional combination|
89052196|NCT00576030|Other|H|habitual coffee drinkers
89052197|NCT00576030|Other|N|non-habitual coffee drinkers
89052198|NCT04579341|Active Comparator|probiotics arm|probiotics administered in addition to insulin regimen
89052199|NCT04579341|No Intervention|control|regular insulin regimen
89052200|NCT04598126|Active Comparator|Traditional physical therapy|Traditional physical therapy
89052201|NCT04598126|Experimental|patient education manual +traditional physical therapy|Patient education manual +traditional physical therapy
89052202|NCT00573573|Other|1|
89052203|NCT00576108|Experimental|KD7040 topical gel|
89052204|NCT00576108|Placebo Comparator|Placebo gel|
89052205|NCT00565994||Hemodialysis patients|Male and female patients undergoing hemodialysis therapy as outpatients
89052206|NCT00565994||Control|Male and female healthy volunteers
89052207|NCT00565994||Pre-dialysis patients|Male and female patients with Stage 3, 4, or 5 chronic kidney disease, but not yet on dialysis
89052208|NCT00573612|Placebo Comparator|1|Telephone Call for the Attention Control Group Each AC call will follow the same format as the MI call. During the AC call, study subjects will receive health information on important topics relevant to their illness. Specifically, there will be one topic during each phone call that includes the following: (a) overview of FMS, (b) pain, (c) fatigue (d) sleep, (e) stress, and (f) living well with FMS. The AC calls will be an avenue to transfer relevant health information from the RA to the study subject. The scheduled topics during each contact will give the call face validity (i.e., establish a credible pretense for the contact) while being neutral with respect to encouragement of exercise.
89052209|NCT00573612|Active Comparator|2|Telephone-delivered Motivational Interviewing Participants will receive 6 telephone calls throughout the study. Harland et al reported that the most effective intervention for promoting exercise in the primary care setting was the most intensive treatment arm that included six MI sessions (208). Importantly, in our pilot study, participants who completed 5 to 6 phone calls achieved greater symptomatic benefits than participants who had ≤ 4 phone calls. The phone calls will be scheduled at week 3, 4, 6, 8, 10 and 12 of the study. Telephone sessions may run for 30 minutes on the average
89052210|NCT00566033|Experimental|1|
89052211|NCT00566033|No Intervention|2|Patients in this arm (arm 2) will undergo to standard care.
89052212|NCT00573651|Other|Group A pauciarticular JIA|Females age 9-26 with pauciarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for serum titres taken to measure antibody and RNA titers.
89052213|NCT00573651|Other|Group B polyarticular JIA|Females age 9-26 with polyarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for Serum Titers taken to measure antibody and RNA titers.
89052214|NCT00573651|Other|Group C seronegative arthritis|Females age 9-26 with seronegative arthritis (including ankylosing spondylitis and psoriatic arthritis). All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers.
89052215|NCT00566072|Experimental|1|instructions and coaching on the use and intake of ganciclovir
89052216|NCT00566072|No Intervention|2|
89052217|NCT04597970|Experimental|cTACE-HAIC(oxaliplatin and raltitrexed)|Patients receive cTACE+HAIC (oxaliplatin, raltitrexed) treatment, 6-8 weeks as a cycle
89683004|NCT02997137|Placebo Comparator|Placebo|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties
89683005|NCT01276067|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
89683006|NCT01276067|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
89683007|NCT04183868|Experimental|Empagliflozin|"Eligible patients (meeting all inclusion criteria) will be randomized to receive empagliflozin in addition to existing metformin background therapy (daily dose of ≥1.500 mg, which has to remain unchanged throughout the study) for 26 weeks.~At the end of 26 weeks of treatment, subjects belonging to empagliflozin arm will be shifted to glimepiride treatment."
89683008|NCT04183868|Active Comparator|Glimepiride|"Eligible patients will be randomized to receive glimepiride (starting dose: 2 mg daily) treatment arm, can undergo to up-titration of glimepiride to a maximum of 6 mg/day, if they experience fasting plasma glucose (FPG) levels > 112 mg/dl (6,2 mmol/l) at scheduled visit at 6th week or at any later scheduled visit.~Whereas, glimepiride-treated patients experiencing recurrent hypoglycemic episodes should down-titrate glimepiride to a dose, considered as appropriate by Investigator.~Hypoglycemic events are defined as symptoms suggestive of low blood glucose confirmed by self monitored blood glucose (SMBG) < 56 mg/dl (3,1 mmol/l).~Severe hypoglycemia is defined as any hypoglycemic episode requiring the assistance of another party for recovery.~At the end of 26 weeks of treatment, subjects belonging to glimepiride arm will be shifted to treatment with empagliflozin for 26 weeks."
89683009|NCT02997215|Experimental|intravenous lidocaine|intravenous lidocaine 1.5mg/kg during induction then infused at 2mg/kg/h until the end of procedure.
89683010|NCT02997215|Placebo Comparator|saline placebo|same amount volume saline infusion
89683011|NCT02990507|Experimental|AVEED|AVEED is composed of arm and leg cranks that can be used independently or together with a virtual exercise environment (VEE). Participants rotate arm and/or leg cranks under 4 conditions for 5 min each with a 5 min rest between: 1) Arm rotation with VEE, while sitting or standing (AVEED: Arm rotation, video display); 2) Arm rotation without VEE, while sitting or standing (AVEED: Arm rotation, without video display); 3) Leg rotation with arm-energy input to assist the legs with VEE, while sitting (AVEED: Leg rotation, arm-energy input, video display); 4) Leg rotation with arm-energy input to assist the legs without VEE, while sitting (AVEED: Leg rotation, arm-energy input, without video display). VEE controlled with voice commands, leaning, or keyboard buttons.
88997354|NCT00550225|Experimental|Sequence 6|In session 1, subjects will receive placebo followed by 900 micrograms of GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
88997355|NCT00550225|Experimental|Sequence 7|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
88997356|NCT00550225|Experimental|Sequence 8|In session 1, subjects will receive placebo followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
88997357|NCT00550264|Experimental|1|
88997358|NCT00550264|No Intervention|2|
88997359|NCT00550342|Experimental|Rituximab|Rituximab (375 mg/m2) will be administered intravenously as per current package label in a facility capable of handling infusion reactions. Subjects would be pre dosed with diphenhydramine and acetaminophen. Solu-Medrol, 1.5 mg/kg would be dosed 1 hour prior to the first dose of rituximab. Three subsequent doses of rituximab will be given at weekly intervals.
88997360|NCT00550381|Placebo Comparator|1|10mg
88997361|NCT00550381|Placebo Comparator|2|20mg
88997362|NCT00550381|Placebo Comparator|3|40mg
88997363|NCT00550381|Placebo Comparator|4|80mg
88997364|NCT00550381|Placebo Comparator|5|160mg
88997365|NCT00550381|Placebo Comparator|6|240mg
88997366|NCT00550381|Placebo Comparator|7|400mg
88997367|NCT00550381|Placebo Comparator|8|640mg
88997368|NCT00550381|Placebo Comparator|9|960mg
88997369|NCT00550381|Placebo Comparator|10|placebo
88997370|NCT02963454|Experimental|levosimendan 0.2 μg/kg/min|"Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus).~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
88997371|NCT02963454|Active Comparator|dobutamine 5 μg/kg/min|"Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period.~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
88997372|NCT00550498|Experimental|A|Behcet's Disease with ocular lesions
88997373|NCT00550576|Experimental|digibind|Injection of digibind and psychological tests
88997374|NCT00550693|Placebo Comparator|A|The patients in this arm continued with the local catheter care protocol.
88997375|NCT00550966|Active Comparator|1|"Randomized controlled trial with a 12-month follow-up involving two groups, one of which is the intervention group that includes patients receiving a psychoeducative program and the other is the control group formed by patients treated for FM in the usual way.~Setting. Three urban PC centers in the province of Barcelona (Spain) Sample. The total sample comprises 218 patients (over 18 years of age) suffering FM, selected from a database (Rheumatology service-Viladecans hospital) of patients with this illness. Only those patients introduced in the database between the years 2005 and 2007 are included in the selection. Selected patients are asked for written informed consent to participate in the study."
88997376|NCT00161720||All participants|Participants with severe congenital protein C deficiency who were treated under an emergency use IND.
88997377|NCT00551044|Active Comparator|Bicalutamide|Osteoporotic patients (T score ≤ -2.5) on bicalutamide
88997378|NCT00551083|Experimental|CDSS-D|Computer Decision Support System for Depression (CDSS-D) - This arm provided physicians with a computerized treatment algorithm and a decision support system to treat their patients suffering Major Depressive Disorder
88997379|NCT00551083|Active Comparator|UC|Usual Care (UC) - This group of physicians treated their patients suffering from Major Depressive Disorder with their standard treatment as usual, and received no algorithm support with regard to treatment decisions
89216305|NCT04488926|Placebo Comparator|Group 2|Placebo microgranules for sublingual use, 1800mg/die in 2 doses (morning and evening) for 90 days
89683012|NCT03422744|Experimental|patient with peripheral lung lesion|"Patient presenting a peripheral lung lesion seen at Ct-scan but invisible at simple endoscopy.~Intervention : trans bronchial biopsy guided by echo-endoscopic miniprobes.~Intervention: If first intervention doesn't give a diagnosis we get cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control"
89683013|NCT02990351||HCC patients|29 HCC patients who had loco regional therapies for HCC were analyzed. Twenty patients met the Milan criteria (68.97%) & 4 (13.8%) were beyond Milan but met UCSF criteria and 5 were exceeding UCSF criteria (17.2%).All patients underwent preoperative LRTs, The protocol of bridging/down staging, methods, duration of follow up, the number of the patients who were successfully down-staged before LT and their outcomes after LT were recorded.
89683014|NCT03381872|Active Comparator|Intravascular imaging arm|The choice of intravascular imaging devices such as IVUS or OCT during PCI will be left to the operator's discretion. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended. Use of intravascular imaging devices will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but intravascular imaging evaluation after stent implantation will be mandatory.
89683015|NCT03381872|Active Comparator|Angiography arm|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
89683016|NCT02990585|Active Comparator|One individual back school session|The 1 individual session will consist of a 60 min 1-on-1 education/exercise session with an athletic trainer. Information will be an abbreviated version of the 8-session school and fill focus on the strengthening, stretching, pain control and movement re-education most needed for the individual.
89683017|NCT02990585|Active Comparator|8 group session of back school|All sessions last 45-60 minutes. There will be up to 8 participants in each session which will be led by an athletic trainer or rehabilitation trainer. Pain management, prevention strategies, and active treatment will be covered in the 8 sessions. Active treatment includes strengthening, stretching, pain control, movement re-education, and walking.
89683018|NCT03084302||Pregnant women|Women in their first trimester of pregnancy, aged 18-45, who plan to receive their prenatal care from University of Pittsburgh Medical Center providers.
89683019|NCT03331484|Other|Ticagrelor and Rivaroxaban|All participants will be prescribed ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily for a year.
89683020|NCT00721513|Experimental|TPFChemotherapy + Concomitant Cetuximab & RT|Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab & Radiation Therapy
89683021|NCT03314558||COPD patients following a pulmonary rehabilitation program|COPD patients following a pulmonary rehabilitation program
89683022|NCT00706121|Experimental|Vitamin E + selenium placebo|Vitamin E and selenium placebo daily for 7 - 12 years
89683023|NCT00706121|Experimental|Selenium + vitamin E placebo|Selenium and vitamin E placebo daily for 7 - 12 years
89683024|NCT00706121|Experimental|Vitamin E + selenium|Vitamin E and selenium daily for 7 - 12 years
89683025|NCT00706121|Placebo Comparator|Vitamin E placebo + selenium placebo|Vitamin E placebo and selenium placebo daily for 7 - 12 years
89683026|NCT03251612|Other|Treatment|1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.
89683027|NCT00746863|Experimental|1|Patients randomized to this arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
89683028|NCT00746863|No Intervention|2|Patients assigned to this arm will have the mid-urethral sling placed via the suprapubic approach in the standard fashion with no injection of Marcaine into the retropubic space.
89683029|NCT04121156|Active Comparator|2 milli Amp dose of HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
89683030|NCT04121156|Sham Comparator|Sham (placebo) dose of HD-tDCS treatment|Sham (placebo) dose of HD-tDCS treatment for 20 minutes, for 5 consecutive twice daily sessions
89683031|NCT04385563|Experimental|TQ-B211 + docetaxel|Participants will be administered TQ-B211 plus docetaxel once every three weeks(Q3W) in cycles up to cycle 8.
89683032|NCT04385563|Active Comparator|Herceptin®+docetaxel|Participants will be administered Herceptin® plus docetaxel Q3W in cycles up to cycle 8.
89683033|NCT01279837|No Intervention|Usual care|Control (Usual care) group in which patients will receive swallowing and prescribed dietary intervention during the radiotherapy period prescribed by the attending physician.
89683034|NCT01279837|Experimental|High Intensity Pharyngocise|Patients receive twice daily swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises.
89683035|NCT01279837|Active Comparator|Low Intensity Pharyngocise|Patients will receive a one time only swallowing intervention session by a speech language pathologist, instructing them in the battery of isometric / isotonic exercises plus a home practice instruction digital video tape to support self directed practice of this program at home.
89683036|NCT03082898|Experimental|AIS A or B using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) A or B (non- ambulatory) will receive regular dosing of exoskeleton walking.
89683037|NCT03082898|Experimental|AIS C or D using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) C or D (Poorly ambulatory) will receive regular dosing of exoskeleton walking.
89683038|NCT01272271||Children|
89683039|NCT01272271||Adults|
89216306|NCT04485858|Experimental|CorNeat KPro|Intraocular implantation of the CorNeat KPro
89216307|NCT04483739|Experimental|Krd Induction|4 28 day cycles of Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
89216308|NCT04483739|Experimental|Isa-KRd induction|"Isatuximab= 10 mg/kg IV on day 1, 8, 15, and 22 during Cycle 1, followed by 10 mg/kg IV on days 1 and 15 during Cycles 2 to 4.~Carfilzomib = 20 mg/m2 IV on day 1 cycle 1 only, followed by 56 mg/m2 IV on days 8, 15 cycle 1 and on days 1, 8, 15 for cycles 2-4 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22"
89683040|NCT03568838|Experimental|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin.
89683041|NCT03568838|No Intervention|Standard Therapy|Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI.
89683042|NCT00726713|Experimental|1|Metanx
89683043|NCT00726713|Placebo Comparator|2|Placebo
89683044|NCT01272349|Experimental|Low oxygen|
89683045|NCT01272349|Sham Comparator|Room Air|
89683046|NCT03087344|Experimental|Chronic liver disease|patient who will undergo liver biopsy will undergo liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
89683047|NCT00759187|Placebo Comparator|A|
89683048|NCT00759187|Active Comparator|B|
89683049|NCT00759187|Active Comparator|C|
89683050|NCT04387175|Experimental|Carriere Motion 3D Class III Appliance|
89683051|NCT04387175|Active Comparator|Facial mask|
89683052|NCT03085940|Experimental|Hydroxychloroquine|
89683053|NCT03085940|Placebo Comparator|Placebo|
89683054|NCT00727337|Experimental|LACE-DVD|Participants will complete the LACE training, however, not in an interactive computer mode but through a static DVD mode
89683055|NCT00727337|Experimental|LACE-COMPUTER|Participants will complete a computer-based auditory training program (i.e., LACE)
89683056|NCT00727337|Active Comparator|PLACEBO-DIRECTED LISTENING|Participants will complete a directed listening to books on CD treatment
89683057|NCT00727337|Active Comparator|CONTROL|Participants will be provided with hearing aids
89683058|NCT01279915|Experimental|ASP group|ASP0456 receiving group
89683059|NCT01279915|Placebo Comparator|Placebo group|Placebo treatment
89683060|NCT03809455|Experimental|FAR Arm|
89683061|NCT03809455|Placebo Comparator|Placebo Arm|
89683062|NCT02990273|Active Comparator|TEG|Blood transfusion
89683063|NCT02990273|Active Comparator|Prothrombin Time (PT)/International normalized ratio (INR)|Blood transfusion
89683064|NCT01272427|Experimental|noncaloric beverage|noncaloric sweetened beverage administered 30 min prior to mealtime
89683065|NCT01272427|Experimental|noncaloric beverage (60 min)|noncaloric sweetened beverage administered 60 min prior to mealtime
89683066|NCT01272427|Experimental|glucose beverage|glucose beverage administered 30 min prior to mealtime
89683067|NCT01272427|Experimental|glucose beverage (60 min)|glucose beverage administered 60 min prior to mealtime
89683068|NCT01272427|Experimental|whey protein beverage|whey protein beverage administered 30 min prior to mealtime
89216309|NCT04483739|Experimental|KRd post ASCT consolidation|4 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
89216310|NCT04483739|Experimental|Isa-KRd post ASCT consolidation:|4 28 day cycles of Isatuximab= 10 mg/kg IV on days 1 and 15 on cycles 5-8 Carfilzomib = 56 mg/m2 IV on days 1, 8, 15 cycle 5-8 Lenalidomide= 25 mg orally daily on days 1-21 Dexamethasone = 40 mg orally/IV on days 1, 8, 15, 22
89683069|NCT01272427|Experimental|whey protein beverage (60 min)|whey protein beverage administered 60 min prior to mealtime
89683070|NCT04270097||Emirati Genetic T2D cohort|
89683071|NCT02997059|Experimental|Fluconazole|200mg per day for 6 months
89683072|NCT02997059|Placebo Comparator|Placebo|One capsule per day for 6 months
89683073|NCT01279993|Experimental|Kerato refractive Surgery|
89683074|NCT01271491||Cases|Children hospitalized in the ICU with bronchiolitis
89683075|NCT01271491||Controls|Children hospitalized in the general ward with bronchiolitis
89683076|NCT02990117||Asthmatic patient|Asthma patients aged >18 in out-patient clinic of the first affiliated hospital of Xi'an Jiaotong university from November 2016 to January 2018 were investigated. A two-stage study was applied which was non-assumptive deep dive qualitative scoping to investigate the determinants of poor compliance in stage 1 asthma patients, and developed new questionnaire for cross sectional survey in stage 2 to obtain more accurate information about the critical issues on asthma management.
89683077|NCT00759811|Experimental|Methotrexate|Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
89683078|NCT00759811|Placebo Comparator|Placebo|Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
89683079|NCT03085628|Experimental|Oxytocin|Oxytoxin nasal spray
89683080|NCT03085628|Placebo Comparator|Placebo|Placebo nasal spray
89683081|NCT00694577|Experimental|Irradiation using 32 Gy / 8 fractions|Study Participants 1-100 Partial Breast Irradiation using 32 Gy / 8 fractions BID in one week
89683082|NCT00694577|Experimental|Irradiation using 36 Gy / 9 fractions|Study Participants 101-200 Partial Breast Irradiation using 36 Gy / 9 fractions BID in one week
89683083|NCT00694577|Experimental|Irradiation using 40 Gy / 10 fractions|Study Participants 201-330 Partial Breast Irradiation using 40 Gy / 10 fractions BID in one week
89683084|NCT02996981||Cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2016 and September 2016 and discharged home with an indwelling urinary catheter following the surgery. This group of people had cranberry juice capsules prescribed.
89683085|NCT02996981||No cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2015 and September 2015. This group of people did not have cranberry juice capsules prescribed.
89683086|NCT02990039|Experimental|Counseling letter (intervention group)|Participants of the intervention group received a brief counseling letter intervention aiming to reduce sedentary time and to increase physical activity. The intervention comprised up to three tailored letters based on separate questionnaires.
89216311|NCT04483739|Experimental|KRd light consolidation|12 28 day cycles of Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
89216312|NCT04483739|Experimental|Isa-KRd light consolidation|Isatuximab= 10 mg/kg IV on day 1 Carfilzomib = 56 mg/m2 IV on days 1, 15 Lenalidomide = 10 mg orally on days 1-21 Dexamethasone = 20 mg orally/IV on days 1, 15
89216313|NCT04461535|Experimental|AVS with ACTH stimulation|Patients divided into AVS with ACTH stimulation group need to undergo stimulation with a continuous cosyntropin infusion.
89216314|NCT04461535|No Intervention|AVS without ACTH stimulation|Patients divided into AVS without ACTH stimulation group take the same procedure of AVS with a continuous saline infusion.
89216315|NCT04441099|Experimental|Dose-escalation Cohort (DEC)|Escalating doses of NBE-002 depending on cohort at enrollment.
89216316|NCT04441099|Experimental|Safety-expansion Cohort (SEC)|Dose to be determined based on DEC.
89216317|NCT04441099|Experimental|Expansion Cohort 1 (EC1)|Dose to be determined based on DEC and SEC.
89683087|NCT02990039|No Intervention|No counseling letter (control group)|Participants of the control group did not received the brief counseling letter intervention.
89683088|NCT02996669||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
89683089|NCT02996669||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
89683090|NCT04397666|Experimental|1|
89683091|NCT01276613|Experimental|Intraoperative Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal.
89683092|NCT01276613|Experimental|Intraoperative Gemcitabine + Losartan|"Losartan 50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.~Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal."
89683093|NCT03077594||Successfully ablated patients|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy.
89683094|NCT03077594||Successfully ablated patients - VLE|Mucosal impedance will be performed at the time of clinically indicated endoscopy. Research biopsies will be obtained during clinically indicated endoscopy. Volumetric laser endomicroscopy (VLE) will be done.
89683095|NCT01276691|Active Comparator|Acute, Aspirin|81 mg asprin provided 30 minutes prior to firefighting- Acute single dosage
89683096|NCT01276691|Placebo Comparator|Acute, Placebo|Acute single dosage of placebo provided 30 minutes prior to firefighting
89683097|NCT01276691|Active Comparator|Chronic, Aspirin|81 mg asprin provided prior to firefighting- 14 day dosage
89683098|NCT01276691|Placebo Comparator|Chronic, Placebo|14 day dosage of placebo provided prior to firefighting
89216318|NCT04441099|Experimental|Expansion Cohort 2 (EC2)|Dose to be determined based on DEC and SEC.
89216319|NCT04432012|Experimental|arm-A Intra-venous dexamethasone|9 mg of Intra-venous dexamethasone
89216320|NCT04432012|Experimental|arm-B intra-articular dexamethasone|9 mg of intra-articular dexamethasone
89216321|NCT04432012|No Intervention|arm-C routine|No steroid supplementation or other drugs will be added to the routinely performed anaesthesia protocol in the control group
89216322|NCT04420598|Experimental|Trastuzumab deruxtecan (DS-8201a)|"Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.);~Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM;~Cohort 3: HER2-positive BC with progressing BMs after local treatment;~Cohort 4: HER2-low expressing BC with progressing BMs after local treatment;~Cohort 5: HER2-positive or HER2-low expressing BC with LMC."
89216323|NCT04406103|Experimental|Sleepwell|Mailed information package includes 2 Sleepwell booklets (How to get your sleep back and How to stop sleeping pills)
89216324|NCT04406103|Active Comparator|Empower|Mailed information package includes 2 Empower booklets (You may be at risk AND How to get a good night's sleep without sleeping pills)
89216325|NCT04406103|No Intervention|TAU|Treatment-as-usual group: no mailed intervention package.
89216326|NCT04369937|Experimental|IMRT + Pembrolizumab + Cisplatin + ISA101b|"IMRT (Intensity Modulated Radiotherapy) of 70 Gy in 35 fractions over 7 weeks (5 fractions per week).~Pembrolizumab will be administered at 200 mg (fixed dose) IV every 3 weeks (+/- 3 days), beginning beginning one week (week -1) prior to concurrent cisplatin-IMRT.~Cisplatin will be administered at 100 mg/m2 IV on days 1(Week 0) and 22 (Week 3).~ISA101b will be administered as three rounds of vaccination 3-4 weeks apart via two SC injections per vaccination round at 100ug/peptide, before pembrolizumab treatment. Vaccination #1 will be administered 1 week before pembrolizumab."
89683099|NCT04398836|Active Comparator|Malnourished patients - EEN|patiens will receive EEN for 4 week prior surgery
89683100|NCT04398836|Other|Malnourished patients - enriched diet|patiens will receive an enriched high energy and protein diet.
89683101|NCT04398836|Other|Well nourished patients|Patient will receive a standard nutrition
89683102|NCT03081416|Experimental|Intranasal Ketamine arm|Intranasal ketamine administered to participant
89683103|NCT03081416|Active Comparator|Standard Therapy|Reglan 10 mg; Benadryl 25 mg administered to all participants Toradol 15-30 mg; dexamethasone 10 mg added at treating providers discretion.
89683104|NCT00706589|Experimental|1|Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
89683105|NCT00706589|Placebo Comparator|2|Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
89683106|NCT03080402|Experimental|High KAM|Mechanically-driven neuromuscular training. 2 times per week for 6 weeks for a total of 12 sessions. Perturbation training
89683107|NCT03080402|No Intervention|Normal KAM|No intervention
89683108|NCT01276769|Active Comparator|ET|The control arm receive the paclitaxel plus epirubicin
89052218|NCT00573690|Experimental|Group 1|Patients receive cisplatin IV over 1 hour on day 2 of courses 1 and 2 and on day 1 of all subsequent courses; etoposide IV over 30 minutes on days 1-3; and oral sorafenib tosylate once or twice daily on days 1-21. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
89052219|NCT00573690|Experimental|Group 2|Patients receive carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Patients also receive sorafenib tosylate as in group 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
89052220|NCT04597814||interstitial lung disease patients|interstitial lung disease patients who need lung transplantation
89052221|NCT04597814||non- interstitial lung disease patients|non- interstitial lung disease patients who need thoracic surgery to remove pneumatocele
89052222|NCT00576186||1|Patients being referred for the routine Equilibrium Radionuclide Angiocardiography (ERNA) for assessment of their left ventricular function will be asked to participate in the study. All patients will be asked to sign the consent form. Patients will be given a choice to participate in either or both studies (i.e. ERNA plus ACGBS or ERNA plus ACGBS and 3 DE).
89052223|NCT00576225|Experimental|Experimental|
89052224|NCT00576225|Active Comparator|Control|
89683109|NCT01276769|Experimental|PC|the experimental arm which receive the paclitaxel combined with carboplatin
89052225|NCT00573807|Other|1|
89052226|NCT04597931|Experimental|SC Romosozumab 210 mg/monthly|SC Romosozumab 210 mg/monthly
89052227|NCT04597931|Active Comparator|IV Zoledronic acid 5 mg|IV Zoledronic acid 5 mg
89052228|NCT00576459|Experimental|Fluocinolone acetonide 0.59 mg|0.59 mg fluocinolone acetonide intravitreal implant
89683110|NCT01279681|Active Comparator|Arm A [fluoropyrimidine + bevacizumab (BEV)]|Patients receive either 5FU/LV or Capecitabine, plus BEV. 5FU/LV + BEV is comprised of 5FU IV over 46-48 hours, LV calcium IV over 2 hours, and BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Capecitabine + BEV is comprised of capecitabine PO BID on days 1-14 and BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89683111|NCT01279681|Experimental|Arm B [fluoropyrimidine/oxaliplatin (OXAL) + BEV]|Patients receive either mFOLFOX7 plus BEV, or Capecitabine + OXAL (XELOX) plus BEV. mFOLFOX7 + BEV is comprised of OXAL IV over 2 hours, LV calcium IV over 2 hours, and 5FU IV over 46-48 hours on day 1. Patients also receive BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. XELOX + BEV is comprised of OXAL IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Patients also receive BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89683112|NCT01276925|Active Comparator|B3: Blockade of three nerves|Peripheral nerve blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with ropivacaine.
89683113|NCT01276925|Active Comparator|B2: Blockade of 2 nerves|"Peripheral nerve blockade of the anterior division of the obturator nerve and the lateral femoral cutaneous nerve with ropivacaine.~Sham blockade of the femoral nerve with saline."
89683114|NCT01276925|Sham Comparator|K: Control group|Sham blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with saline.
89683115|NCT01272505|Placebo Comparator|conventional SILC|Conventional method of single incision laparoscopic cholecystectomy
89683116|NCT01272505|Active Comparator|HS-SILC|
89683117|NCT00728507|Experimental|1|Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
89683118|NCT00728507|Active Comparator|2|Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
89683119|NCT01279057|Experimental|Test|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
89683120|NCT01279057|Active Comparator|Reference|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
89052229|NCT00576459|Experimental|Fluocinolone acetonide 2.1 mg|2.1 mg fluocinolone acetonide intravitreal implant
89052230|NCT00576459|Active Comparator|Laser photocoagulation|standard of care laser photocoagulation
89052231|NCT04597736|Experimental|cohort|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine
89052232|NCT04597775|Experimental|Arm 1 hydroxychloroquine 800mg day 1 and hydroxychloroquine 400mg day 2-5|hydroxychloroquine 800mg (400mg twice daily) given orally on day 1, (loading dose) hydroxychloroquine. Then 400mg (200mg 2 tablets) on day 2,3, 4 and 5.
89052233|NCT04597775|Active Comparator|Arm 2 hydroxychloroquine 400mg day 1 and hydroxychloroquine 200mg day 2-5|hydroxychloroquine 400mg (200mg twice daily) Given orally first day (loading dose), then 200mg once daily on day 2,3, 4 and 5.
89052234|NCT04597775|No Intervention|No Intervention|No Intervention- SARS-CoV-2 surveillance Standard control measures in the country of interest such as self isolation, good personal hygiene and good nutrition.
89052235|NCT00573885|Experimental|Arm I|Patients receive oral defined green tea catechin extract twice daily for 6 months.
89052236|NCT00573885|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
89052237|NCT00573924|Active Comparator|1|Oral PPI
89052238|NCT00573924|Active Comparator|2|Intravenous PPI
89052239|NCT04597229|Active Comparator|Instant multigrain|Oral instant multigrain supplement
89052240|NCT04597229|No Intervention|Standard care|Standard care without oral instant multigrain supplement
89052241|NCT04579809|Active Comparator|children below six years|children below sex years both genders
89052242|NCT04579809|Active Comparator|cooperative children|repair of the tendos by modified kessler
89052243|NCT04579770|Placebo Comparator|Placebo|Only carbohydrates will be provided
89052244|NCT04579770|Experimental|Ketone ester|Ketone ester with carbohydrates will be provided
89052245|NCT04579770|Experimental|Ketone ester + bicarbonate|Ketone ester with bicarbonate and carbohydrates will be provided
89052246|NCT04579770|Experimental|Bicarbonate|Bicarbonate and carbohydrates will be provided
89052247|NCT00576498|Experimental|1- Narrow Band Imaging|"NBI-AFI imaging - Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.~Autofluorescence Imaging (AFI)- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm)"
89052248|NCT00576498|Other|2-Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars
89052249|NCT04597463|Experimental|Endometrial injury|Endometrial injury before the embryo transfer of a frozen cycle
89052250|NCT04578990|Experimental|Walking intervention group|It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.
89052251|NCT04578990|Experimental|Strength intervention group|The training program consists of performing a training program with resistance exercises for 36-72 weeks.
89052252|NCT04578990|Experimental|Concurrent intervention group|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli.
89052253|NCT04578990|No Intervention|Control group|It will receive standard advice consisting of the recommendation to perform aerobic exercise at the lower limbs level.
89052254|NCT04597385||Long-term Follow-Up|No intervention.
89052255|NCT00573963|Active Comparator|1|Ropivacaine
89052256|NCT00573963|Placebo Comparator|2|Placebo
89052257|NCT04597034|Experimental|AN69 Oxiris|"To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.~To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.~To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.~To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
89052258|NCT04597034|Active Comparator|AN69 Standard|"To evaluate the safety in using the AN69-Oxiris membrane in contrast with the use of a conventional membrane in critically ill patients with COVID-19 associated AKI and CRRT requirements.~To examine the efficacy of the AN69-Oxiris membrane in reducing inflammatory interleukins compared with reduction using conventional membranes in this specific group of patients.~To exhibit the potential benefit of AN69-Oxiris in decreasing ICU length of stay versus the effect of using conventional membranes in COVID-19 associated AKI.~To investigate the effect of AN69-Oxiris in reducing 28-day mortality in contrast compared with the effect of a conventional membrane in this population."
89052259|NCT00574002||Group A|Patients that have their chest tube removed when drainage is 400mL or less in 24 hours.
89052260|NCT00574002||Group B.|Patients that have their chest tube removed when drainage is 200mL or less in 24 hours.
89683121|NCT01279057|Placebo Comparator|Placebo|Placebo nasal spray administered once daily for 14 days.
89683122|NCT01277003|Experimental|Aculife Magnetic Wave Therapist|patients with carpal tunnel syndrome treated with Aculife
89683123|NCT01277003|Active Comparator|TENS|patients with carpal tunnel syndrome treated by TENS
89683124|NCT05249738||Study Group|Patients followed up with a mechanical ventilator for 4 days or longer were included in the study group.
89683125|NCT05249738||Control Group|Patients followed up with mechanical ventilation for 3 days or less were included in the control group.
89683126|NCT04384783||GH group|GH group: Participants diagnosed POR according to POSEIDON criteria with low ovarian reserve undergo IVF in our center with long protocol or antagonist protocol and is adjuvant with GH 2IU/d from previous menstrual period for about six weeks.
89683127|NCT04384783||NGH group|NGH (non-GH) group: Participants diagnosed POR according to POSEIDON criteria with low reserve undergo IVF in our center with long protocol or antagonist protocol without GH adjuvant.
89683128|NCT03186326|Active Comparator|Arm A Chemotherapy (standard treatment)|FOLFOX or FOLFIRI +/- targeted therapy
89683129|NCT03186326|Experimental|Arm B - Immunotherapy (experimental arm)|Avelumab
89683130|NCT02999633|Experimental|Isatuximab|Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).
89683131|NCT02991599|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89683132|NCT02991599|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89683133|NCT00706823|Experimental|i-gel-SGA|Patients who received i-gel supraglottic device (i-gel airway) for intubation
89683134|NCT00706823|Active Comparator|LMA-Unique|Patients who received the Laryngeal Mask Airway-Unique (uLMA) for intubation
89683135|NCT04348058|No Intervention|Control group|Invitation letter and reminder letter to screening colonoscopy
89683136|NCT04348058|Experimental|Call Center|Telephone recruitment by motivational conversation and colonoscopy appointment
89683137|NCT04348058|Experimental|Combined|Non responders to invitation and reminder letter will be recruited by telephone conversation
89683138|NCT02996513|Experimental|Retinol Isotope dilution (RID)|A once-off dose of 0.4 mg 13C4-retinyl acetate will be administered to subjects as a capsule
89683139|NCT01270061|Active Comparator|HIV testing|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
89683140|NCT01270061|Experimental|General Health Screening|In Group 2 (Intervention), a theory-based video is used to obtain informed consent for a free general health screening that includes a blood pressure check, blood glucose measurement, and an HIV test.
89683141|NCT01277237|Active Comparator|Omacor|
89683142|NCT01277237|Placebo Comparator|Lactose tablet|
89683143|NCT04276688|Active Comparator|Study group|triple combination
89683144|NCT04276688|Active Comparator|Control group|single
88997380|NCT00551122|Experimental|Paclitaxel, gemcitabine, cisplatin, ifosfamide|"Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.~If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.~Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.~MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF."
88997381|NCT00551239|Active Comparator|Arm I (control)|Patients receive rituximab IV on day 1 and fludarabine phosphate IV on days 2-4. Treatment repeats every 28 days for up to 6 courses.
88997382|NCT00551239|Experimental|Arm II|Patients receive rituximab and fludarabine phosphate as in arm I. Patients also receive pixantrone IV on day 2. Treatment repeats every 28 days for up to 6 courses.
88997383|NCT00551278||1|Patients with previous diagnosis of breast cancer scheduled for sentinel lymph node dissection.
88997384|NCT00551356|Active Comparator|2|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
88997385|NCT00551356|Active Comparator|1|Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications.
88997386|NCT00551395|Experimental|SLT Early Completion (Arm 1)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degree on Day 2
88997387|NCT00551395|Active Comparator|SLT Late Completion (Arm 2)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degrees at 1 month follow up appointment.
88997388|NCT02963337||remifentanil PCA|The patients in the remifentanil group will receive remifentanil hydrochloride (Ultiva, GlaxoSmithKline, Oslo, Norway) diluted in physiologic saline to a concentration of 40µg/ml and administered using PCA pump with a bolus duration of 20 sec. A stepwise bolus doses from 15 to 30 µg, maximum 40 per 2 min will be applied with no background infusion.
88997389|NCT02963337||Combined spinal-epidural analgesia PCA|A 27-gauge needle will be placed via the shaft of the epidural needle inserted at the L2-3/L3-4 inter-space by the investigator. After confirming the CSF, 2,5 mg of bupivacaine with 20 µg of fentanyl will be injected. That will be followed by the placement of a 20-gauge multi-hole catheter into the epidural space which will be connected to the PCA pump with a possibility of injecting 6-10 ml 0,1% bupivacaine with 2 µg of fentanyl/ml every 20 min with no background infusion.
88997390|NCT00551434|Experimental|1|
88997391|NCT00551434|Experimental|2|
88997392|NCT00551434|Experimental|3|
88997393|NCT00551434|Placebo Comparator|4|
88997394|NCT03455881||NICU TED Genetic Cohort|This study involves one inpatient biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
88997395|NCT03455881||NICU TED MRI Cohort|This study involves up to three inpatient NICU MRI encounters. The first MRI may be done before surgical repair if the clinical team feels the infant is clinically stable. The second MRI may be completed post-surgical repair of TED. An additional 3rd MRI may be done prior to the time of discharge from the NICU. The pre repair, post-surgical, and pre discharge MRIs will provide valuable data for the understanding of tracheal esophageal malformation disorders and may provide clinical guidance for the participant's care.
88997396|NCT03455881||TED Genetic Cohort|This study involves one biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
88997397|NCT03455881||NICU Control MRI Cohort|This study involves two inpatient NICU MRI encounters. The first MRI will occur within the first month of life, and the second MRI will occur prior to discharge.
88997398|NCT00551512|Experimental|CBP501 and Cisplatin|Dose escalation study
88997399|NCT00551551|Experimental|Rééducation|Standardized pelvic floor muscle training program with a physiotherapist in 8 sessions (20-30 minutes each) between 24 and 36 weeks of gestation AND Written instructions about personal (Kegel) pelvic floor exercises
88997400|NCT00551551|Active Comparator|Control|Written instructions about personal (Kegel) pelvic floor exercises
88997401|NCT00551590|Placebo Comparator|1|placebo PO (placebo control for sitagliptin) for three days. Saline IV (placebo control for exendin(9-39) on two consecutive study days.
88997402|NCT00551590|Experimental|2|Sitagliptin 100 mg PO for three days. Saline IV (placebo control for exendin(9-39)) on two consecutive study days
89683145|NCT02996435|Experimental|Mobile Adherence Platform|Participant adherence will be monitored using a mobile application and platform which provides a real-time reminder that alerts the participant to take his or her medication. The application will also send an alert to the participant when a refill is needed based on calculated medication or pill supply. The intervention will focus only on daily adherence to rivaroxaban.
89683146|NCT02996435|Other|Control: Standard of Care|Participants will receive physician- or nurse-guided standard of care for their rivaroxaban adherence. No drug will be administered as part of this study.
89683147|NCT04275986|Experimental|Experimental arm|Endoscopic resection+ concurrent chemoradiotherapy
89683148|NCT01277393||Experimental Group|
89683149|NCT01277393||Control Group|
89683150|NCT02996357||Cases|Patients with IAD Category 2 (red skin with skin breakdown)
89683151|NCT02996357||Controls|Patients with IAD Cat. 0 (at risk, no redness and skin intact)
89683152|NCT02996279||group 1|maternal chorioamnionitis
89683153|NCT02996279||group 2|no maternal chorioamnionitis
89683154|NCT05246150||infants receiving nursing care|
89683155|NCT01277627|Active Comparator|Nevirapine|
89683156|NCT01277627|Active Comparator|Non-nevirapine|
89683157|NCT04397744|Experimental|Unidas por Vida y Salud prevention program|Unidas por Vida y Salud (United for Life and Health) prevention program
89683158|NCT04397744|No Intervention|No intervention control|The control arm will not receive the Unidas por Vida y Salud (United for Life and Health) prevention program during the study analysis period (though, the control arm will receive the intervention after study has been completed).
89052261|NCT00576615||1: placebo|placebo solution
89052262|NCT00576615||2: propofol|propofol
89052263|NCT00576771|Experimental|1|"ALI/ARDS patients~evaluated the effect of PSV, NAVA and assisted controlled mechanical ventilation by patient through a button"
89683159|NCT02996201|Experimental|Electronic reporting of PRO-CTCAE items|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
89683160|NCT02996201|No Intervention|Standard practice|
89683161|NCT03009890|Experimental|Open reduction internal fixation|Surgical open reduction internal fixation (ORIF)
89683162|NCT03009890|Active Comparator|Plaster immobilization|Standard local hospital protocol for cast treatment
89683163|NCT00728819|Active Comparator|1|Tapered PICC
89683164|NCT00728819|Active Comparator|2|Non-tapered PICC
89683165|NCT05245214||Patients with disc herniation|Having only disc degeneration and not having any other neurological or orthopedic disease. Patients who had previous spinal surgery, patients with lumbar scoliosis, spondylolisthesis or structural defect in the sacrum were excluded from the study.
89683166|NCT05245214||Patient in control group|Patients without disc herniation, severe disc degeneration and spondylolisthesis were included in the control group.
89683167|NCT01270217|Experimental|Brief motivational interview|
89683168|NCT01270217|No Intervention|No discussion|
89683169|NCT05245838|Experimental|Z-1018 Dose Level 1|100 mcg gE + 3000 mcg CpG 1018
89683170|NCT05245838|Experimental|Z-1018 Dose Level 1a|100 mcg gE + 3000 mcg CpG 1018 + alum
89683171|NCT05245838|Experimental|Z-1018 Dose Level 2|100 mcg gE + 6000 mcg CpG 1018
89683172|NCT05245838|Experimental|Z-1018 Dose Level 2a|100 mcg gE + 6000 mcg CpG 1018 + alum
89683173|NCT05245838|Active Comparator|Shingrix|
89683174|NCT02996123|Experimental|cad/cam maxillary dentures|single maxillary dentures fabricated by cad/cam method
89683175|NCT02996123|Active Comparator|conventional dentures|heat cured single maxillary dentures
89683176|NCT01270451|Other|Lifestyle group counseling|Included patients will be randomised into two groups: to the intervention group or to the control group.
89683177|NCT01270607|Experimental|Acupuncture|
89683178|NCT01270685||1|Veterans with spinal cord injuries and disorders
89683179|NCT01270685||2|Comparison group: general Veteran population (without spinal cord injuries or disorders)
89683180|NCT01270685||3|Health care providers with face-to-face contact with Veterans with SCI/D
89683181|NCT01270685||4|Infection control Chiefs/Officers
89683182|NCT01277939|Experimental|Therapeutic Education System (TES)|Experimental (E) condition, the Therapeutic Education System (TES) delivered via effective informational technologies and multimedia learning tools.
89683183|NCT01277939|Active Comparator|Standard Care|The Control (C) condition, Standard Care, consisting of psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
89683184|NCT00729053|Active Comparator|Previous treatment, 0.16mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
89052264|NCT04596761|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with Radio frequency (RF)-utilizing powered toothbrush
89052265|NCT04596761|Experimental|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
89052266|NCT00574041|Experimental|1|titrated dose of Avonex
89052267|NCT00574041|Active Comparator|2|full dose Avonex
89052268|NCT04596956|Experimental|sodium bicarbonate Ringer injection|
89052269|NCT04596956|Active Comparator|Ringer lactate solution|
89052270|NCT04597073|No Intervention|Healthy|included individuals with probing depth (PD) ≤3mm, no sites with attachment loss, and no radiographic evidence of alveolar bone resorption. They exhibited no sign of inflammation (GI=0).
89052271|NCT04597073|Experimental|Gingivitis|had varying degrees of gingival inflammation (GI≥1), PD≤3mm with no clinical attachment loss or with no alveolar bone destruction.
89052272|NCT04597073|Experimental|Chronic Periodontitis|was defined as those who were with PD ≥ 4mm, clinical attachment loss (CAL) ≥ 2mm, and who had bone loss affecting >30% of the existing teeth on clinical and radiographic examination.
89052273|NCT04596722|Active Comparator|Assigned Interventions|oral active pomella taken by mouth once per day
89052274|NCT04596722|Placebo Comparator|Placebo|oral placebo taken by mouth once per day
89683185|NCT00729053|Active Comparator|Previous treatment, 0.64mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
89683186|NCT00729053|Active Comparator|Treatment Naive, 0.16mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
89683187|NCT00729053|Active Comparator|Treatment Naive, 0.64mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
89683188|NCT00706979|Experimental|1|Practice Quit Attempt plus Nicotine Replacement Therapy
89683189|NCT00706979|Active Comparator|2|Practice Quit Attempt only
89683190|NCT01278017|Experimental|ceftriaxone|
89683191|NCT01278095|Experimental|GLPG0555 solid dispersion, fasting|50 mg as solid dispersion capsule, in fasting condition
89683192|NCT01278095|Experimental|GLPG0555 solid dispersion, fed|50 mg as solid dispersion capsule, after breakfast
89683193|NCT01278095|Experimental|GLPG0555 nanosuspension, fed|50 mg as nanosuspension, given after breakfast
89683194|NCT02995811||Observational Cohort|"On Days 1, 3, 7 and 10 of ICU admission, patients will undergo ultrasound assessment of the diaphragm, transverse and rectus abdominis, quadriceps rectus femoris, and tibialis anterior muscles. Imaging all four muscles together requires approximately 1 hour.~Physical activity monitoring: On Days 1-10 of ICU admission patients will wear an activity monitor. These devices use several inertial motion sensors to track the movement and acceleration of the limbs in horizontal and vertical directions.~Patients will also undergo daily assessment of global peripheral skeletal muscle strength assessed by the Medical Research Council Sum-score and global function measured by the Chelsea Critical Care Physical Assessment Scale"
89216327|NCT04364152|Experimental|PD patients with freezing of gait, internal strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
89683195|NCT00729521|No Intervention|Control|a control group receiving no special resources or guidance related to fall injury prevention or the community health improvement process;
89683196|NCT00729521|Active Comparator|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
89683197|NCT00729521|Experimental|Facilitative System|"a Facilitative System group receiving facilitative system support in addition to the resources provided the Standard Program group"
89683198|NCT01278251||Endobutton|
89683199|NCT01270763||The Look AHEAD Study|The Look AHEAD Study includes intensive lifestyle intervention treatment, focusing on caloric intake and physical activity, and a treatment arm focused on diabetes support and education.
89683200|NCT00716963|Active Comparator|1|Fluticasone propionate (Flovent Diskus) 250 mcg
89683201|NCT00716963|Active Comparator|2|budesonide 400mcg
89683202|NCT00716963|Placebo Comparator|3|placebo
89683203|NCT01270997|Experimental|HD203|Subcutaneous injection (SC) HD203 25mg twice a week for 48 weeks
89683204|NCT01270997|Active Comparator|Enbrel|Subcutaneous injection (SC) Enbrel® 25mg twice a week for 48 weeks.
89683205|NCT00717041||Presenting to the ED|Patients who present to the ED
89683206|NCT01271075|Active Comparator|Bilastine A|A: Crossover Bilastine 20 mg, Bilastine 40 mg, Placebo, Bilastine 80 mg
89683207|NCT01271075|Active Comparator|Bilastine B|B: Crossover Bilastine 80 mg, Placebo, Bilastine 40 mg, Bilastine 20 mg
89683208|NCT01278745|Experimental|Rituximab|Rituximab induction/conventional immunosuppression
89683209|NCT01278745|Placebo Comparator|Rituximab Placebo|Rituximab Placebo / conventional immunosuppression
89683210|NCT02995655|Experimental|CX-01 + Azacitidine|"CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.~Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.~Up to 6 cycles of treatment allowed"
89683211|NCT01271153|Active Comparator|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours
89683212|NCT01271153|Placebo Comparator|Placebo|An equivalent infusion of placebo will be infused for 2.5 h
89683213|NCT03809065|Experimental|group N|Patients in this group will receive Nitroglycerin infusion for deliberate hypotension at a rate of 0.5-2 μg /kg/min .
89683214|NCT03809065|Active Comparator|group L|Patients in this group will receive Labetalol infusion for deliberate hypotension at a rate of be 0.5-2 mg/kg/h .
89683215|NCT01271387|Experimental|Moderate Hepatic Impairment|
89683216|NCT01271387|Experimental|Mild Hepatic Impairment|
89683217|NCT01271387|Experimental|Healthy Volunteers|
89683218|NCT01272739|Experimental|Study Group|Subjects will take 500 mg of the investigational product 15 minutes prior to the 3 main meals of the day.
89683219|NCT01272739|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
89683220|NCT02995577||Feeding tolerant|Patients that are able to reach 80-100% of full enteral feeds (whether fed by mouth or through a nasogastric tube) 7 days after the initiation of feeds. Patients will be excluded from this group if they are ever diagnosed with NEC at any time during this hospitalization.
89683221|NCT02995577||Feeding intolerant|Patients with GI symptoms (vomiting, abdominal distention, diarrhea, hematemesis, and/or hematochezia) that persist for 48 hours or longer while needing to be NPO, this patient is retrospectively categorized into the feeding intolerance group. Patients with feeding intolerance may also include infants that are made NPO, placed on bowel rest, and are started on antibiotics to rule out NEC, but are never diagnosed with NEC. Exclusion criteria include patients that are continued on antibiotics for greater than 48 hours due to diagnosed bacterial sepsis or diagnosed NEC, and those that have a positive blood, urine, or sputum culture.
89683222|NCT02995577||Necrotizing enterocolitis|Any infant that is diagnosed (radiographically, by Bell's criteria) with and treated for NEC.
89683223|NCT05137418|Experimental|3-5 years old age group|500 participants aged 3-5 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.
89683224|NCT05137418|Experimental|6-11 years old age group|500 participants aged 6-11 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.
89683225|NCT04278209|Experimental|Breakfast 1 - Breakfast 2|Participants will receive Breakfast 1 then Breakfast 2.
89683226|NCT04278209|Experimental|Breakfast 1 - water|Participants will receive Breakfast 1, then water.
89216328|NCT04364152|Experimental|PD patients with freezing of gait, external strategies|Participants in this group will include PD patients with freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
89216329|NCT04364152|Experimental|PD patients without freezing of gait, internal strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
89683227|NCT04278209|Experimental|Breakfast 2 - water|Participants will receive Breakfast 2, then water.
89683228|NCT04278209|Experimental|Breakfast 2 - Breakfast 1|Participants will receive 2 servings, then 1 serving of the study product.
89683229|NCT04278209|Experimental|Water - Breakfast 1|Participants will receive water, then Breakfast 1.
89683230|NCT04278209|Experimental|Water - Breakfast 2|Participants will receive water, then Breakfast 2.
89683231|NCT05244434|Experimental|Prospective cohort (SOC treatment, biopsy, blood collection)|Patients receive SOC treatment consisting of ribociclib or palbociclib plus AI. Patients undergo biopsy of tumor tissue at baseline and post-treatment. Patients also undergo collection of blood samples at baseline, on day 1 of SOC treatment cycles 2, 4, and 6, every 6 cycles thereafter, and at post-treatment.
89216330|NCT04364152|Experimental|PD patients without freezing of gait, external strategies|Participants in this group will include PD patients without freezing of gait. During dual-task walking training, external attentional strategies will be given, aiming to improve their gait performance.
89683232|NCT05244434|Experimental|Retrospective cohort|Patients' tumor tissue collected during previous SOC treatment (ribociclib or palbociclib plus AI) is used for analysis.
89683233|NCT02995265|Experimental|Exoskeleton Program|Exoskeleton-based walking rehabilitation until discharge (or to a maximum of 8 weeks), 3 - 5 days a week for 30-60 minutes per session. Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke. The exoskeleton will allow standing and walking with full weight bearing from the first sessions in rehabilitation.
89683234|NCT02995265|Active Comparator|Usual Care Program|Standard physiotherapy stroke rehabilitation which includes training for regaining walking as well as other functional tasks, 3 - 5 days a week for 30-60 minutes per session until discharge (or to a maximum of 8 weeks). Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke.
89683235|NCT02995187|Experimental|Apatinib Mesylate tablet|Patients received oral apatinib 500 mg in tablet once daily, a treatment cycle was defined as 28 days (4 weeks).
89683236|NCT01278329|Experimental|Music|"Mothers in the music group were provided a pre-recorded Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India) with a running duration of approximately 50 minutes and a cassette player with headphones. They were asked to listen to the recorded music daily in the evening just before going to the bed with a minimum of ambient noise."
89683237|NCT01278329|No Intervention|Control|Standard routine ante-natal care.
89683238|NCT05246306||Healthy group|Healthy adolescents aged 14-24 who have not been diagnosed with any chronic disease
89683239|NCT05246306||Patient with PCOS group|Adolescents between the ages of 14-24 diagnosed with Polycystic Ovary Syndrome according to the Rotherdam criteria.
89683240|NCT01271621|Active Comparator|Macintoch group|Intubation with Macintoch Laryngoscope
89683241|NCT01271621|Experimental|Glidescope|Inubation by Glidescope
89683242|NCT02394704|Experimental|Graded sensory attention training|Sensory stimuli will begin at a maximal tolerable intensity and decrease in intensity throughout the training, to shift from involuntary to voluntary attentional focus.
89683243|NCT02394704|Active Comparator|Non-graded sensory attention training|Sensory stimuli will begin and be maintained at a minimal detectable intensity to maximize voluntary attentional training.
89683244|NCT02995109|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89683245|NCT03554330|Active Comparator|control group|Only graded balloon atrial septostomy is carried out, and no radiofrequency catheter ablation is performed.
89683246|NCT03554330|Experimental|single-RFA group|After graded balloon atrial septostomy procedure identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration.
89683247|NCT03554330|Experimental|double-RFA group|The first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (graded balloon atrial septostomy and radiofrequency catheter ablation around the rim of fenestration).
89683248|NCT02995031|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89683249|NCT01272089|Experimental|Pataday|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once daily for one week
89683250|NCT00748657|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89683251|NCT02994953|Experimental|Avelumab and M9241|
89683252|NCT02994953|Experimental|Avelumab (once weekly) + M9241 (MTD)|
89683253|NCT02994953|Experimental|Avelumab (once weekly) + M9241 (RP2D) (Expansion cohort)|
89683254|NCT05249660|Experimental|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
89683255|NCT05249660|Active Comparator|Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
89683256|NCT01272895|Experimental|GENOUS stent|
89683257|NCT05244902|Experimental|Obese pediatric patient|Obese children aged 6-14 years, over 95% percentile, fasted for the night before planned surgery.
89683258|NCT05244902|Active Comparator|Non-obese pediatric patient|Non-obese children aged 6-14 years, between 5-85% percentile, fasted for the night before planned surgery.
89683259|NCT01272973|Experimental|Oral 1|
89683260|NCT01272973|Experimental|Oral 2|
89683261|NCT01272973|Experimental|Oral 3|
89683262|NCT01272973|Active Comparator|S.c.|
89683263|NCT02924636|Experimental|Intervention|personalized and online intervention. The intervention website will provide secure communication with dietician and lifestyle coaches. Women will receive emails and monthly newsletters with new content and reminder.
89683264|NCT02924636|No Intervention|Control|standard care with oral information about the goal of nutritional needs during pregnancy and gestational weight gain guidelines according to BMI
89052275|NCT00576849|Experimental|A|Total balanced volume replacement regimen consisting of a balanced HES 130/0.42 plus a balanced crystalloid
89683265|NCT02994875|Placebo Comparator|Placebo First|Placebo - Participants will receive placebo for one week. Following a two-week washout period, they will receive NAC for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
89052276|NCT00576849|Active Comparator|B|Conventional volume replacement strategy consisting of 6% HES 130/0.4 prepared in saline solution plus Ringer's lactate
89683266|NCT02994875|Active Comparator|NAC First|N-acetylcysteine - Participants will receive NAC for one week. Following a two-week washout period, they will receive placebo for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
89683267|NCT03809143|Experimental|Depot buprenorphine arm|All participants will receive monthly injections of depot buprenorphine (RBP-6000, Sublocade)
89683268|NCT02390960|Active Comparator|Sildenafil|Sildenafil (SST-6006) is a preserved, white to off-white, topical cream. The active ingredient is 5% sildenafil citrate by weight. During the SST-6006 dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
89683269|NCT02390960|Placebo Comparator|Placebo|Placebo cream will be the same as SST-6006 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6006 topical sildenafil cream. During the placebo cream dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
89683270|NCT03808831|Experimental|Experimental groups|Subjects in the experimental group will wear the fall detection and prevention system on the lower back. The system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
89683271|NCT03808831|Sham Comparator|Sham group|In the sham group, subjects wear a sham system with record but no alert function.
89683272|NCT04270331|No Intervention|A Before group|No protocol assigned
89683273|NCT04270331|Experimental|An After group|PADS (pain, agitation, delirium, sleep deprivation assessment and management) protocol assigned
89052277|NCT00566189|Experimental|1|Roux-en-Y bypass gastroplasty
89052278|NCT00576888||Vascular Anomaly with Coagulopathy|All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) or with a vascular anomaly with coagulopathy
89052279|NCT00566267|Experimental|2|Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg
89052280|NCT00574314||Women|Women with varying backgrounds
89052281|NCT00566306|Experimental|A|PHMG will be introduced in three wards for hand hygiene and environmental disinfection in CDAD patients' rooms. The rooms for showers and toilets will be coated with biocide coating (PHMG) as well as bed frames in investigational wards.
89052282|NCT00566306|No Intervention|B|Three wards will be control wards and continue using alcohol based hand disinfectants and routine environmental cleaning and disinfection with quats/chloramines.
89052283|NCT00574353|Experimental|1|FMISO PET study.
89052284|NCT04596839|Experimental|Remdesivir with Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
89052285|NCT04596839|Other|Standard of Care Treatment for COVID-19 Infection|Participants will receive continued standard of care therapy.
89052286|NCT00574392||1|Multiwavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented lesions on skin in vivo
89052287|NCT00574431|Other|Observation|Observation
89052288|NCT00574431|Active Comparator|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
89052289|NCT04596683|Experimental|Interested in SDS NSM or SSM|Patients interested same day discharge after NSM or SSM that do not have conditions that would exclude them. Based on discharge outcome after surgery, will be split into SDS group and Admit group.
89052290|NCT00574470|Experimental|1|Treatment with daclizumab/infliximab
89052291|NCT04596527|Experimental|18F-FMPP PET MPI (following off-study 13N-ammonia PET MPI)|"Imaging Procedure: 18F-FMPP PET Day 1: All subjects will receive rest and stress IV boluses of 18F-FMPP injections in a large peripheral vein. The dosages of 18F-FMPP Injection administered at rest and during stress conditions are 2.5 mCi and 6.0 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor.~Imaging Procedure: 13N-Ammonia PET All subjects will receive 2 IV boluses of 13N-ammonia Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of 13N-ammonia Injection administered at rest and during stress conditions is 20mCi and 20 mCi for an individual subject. Rest or stress PET imaging will be acquired for 20 minutes. The pharmacological stress will utilize ATP as the stressor."
89052292|NCT00577161|Active Comparator|Comparator|fludarabine and rituximab
89052293|NCT00577161|Experimental|Experimental|fludarabine, rituximab, pixantrone
89052294|NCT04596332||Group A|Patients with the initial central venous pressure(CVP1) <8 mm Hg
89052295|NCT04596332||Group B|Patients with 8≤CVP1≤12mm Hg
89052296|NCT04596332||Group C|Patients with CVP1>12 mm Hg
89052297|NCT04579497|Experimental|38° C footbath|Footbath with warm water at a constant temperature of 38° C
89052298|NCT04579497|Experimental|40° C footbath|Footbath with warm water at a constant temperature of 40° C
89052299|NCT04579497|Experimental|42° C footbath|Footbath with warm water at a constant temperature of 42° C
89052300|NCT04579497|Experimental|Rising temperature footbath|Footbath with warm water rising from 38° C to 42° C
89052301|NCT04596605|Experimental|T2309|4 capsules daily for 12 weeks
89052302|NCT04596605|Active Comparator|Nutrof Total|2 capsules daily for 12 weeks
89216331|NCT04364152|Experimental|Healthy elders, internal strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
89216332|NCT04364152|Experimental|Healthy elders, external strategies|Participants in this group will include healthy elders. During dual-task walking training, internal attentional strategies will be given, aiming to improve their gait performance.
89522691|NCT03395249|Experimental|SPR994, FI, F2, F3, F4 Oral Tablets|"SPR994 is active against multidrug-resistant Gram-negative and Gram-positive pathogens that cause serious and life-threatening infections, including extended spectrum beta-lactamase (ESBL) producers as well as strains resistant to levofloxacin and trimethoprim/sulfamethoxazole. SPR994 is administered in tablet form orally. Up to five different time released formulations of SPR994 will be studied in this protocol at 100 mg, 300 mg, 600 mg and 900 mg dosages.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered twice daily (BID) over a period of 14 days or forty doses administered three times daily (TID) over period of 14 days"
89683274|NCT00759967|Active Comparator|Short daily hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of short daily hemodialysis(2 hours/day,6 days/week)B/P will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 month period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
89683275|NCT00759967|Active Comparator|Conventional hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of conventional hemodialysis 3 days/week 3.5-4 hours/ treatment. BP will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 moth period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
89683276|NCT00719615||Thyroid Cancer in Remission Group|Thyroid Cancer-Remission Group & use of Vitamin D
89683277|NCT00719615||Thyroid Cancer with Active Disease Group|Thyroid Cancer-Active Group & use of Vitamin D
89683278|NCT00719615||Thyroid nodule group (no cancer) & Vit D|Thyroid nodule group without cancer and use of Vitamin D
89683279|NCT02394548|Experimental|Contralateral Esophagus Sparing Technique (CEST)|IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
89683280|NCT04385953||Trauma patients|Subject experiencing major trauma
89683281|NCT04385953||Obstetric patients|Obstetric patient with postpartum hemorrhage
89683282|NCT02769806||GBM patients undergoing MRI|GBM patients undergoing standard-of-care post-operative combination chemoRT and clinically indicated MRI including standard DSC-PWI for follow-up.
89683283|NCT03808519|Experimental|n3 PUFA|n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
89683284|NCT03808519|Placebo Comparator|Placebo|Organic Sunflower Oil 5000mg per day
89683285|NCT03139838|Active Comparator|EHR-Based Intervention A|Intervention A (Prognostication) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
89683286|NCT03139838|Active Comparator|EHR-Based Intervention B|Intervention B (Accountable Justification) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
89683287|NCT03139838|Active Comparator|Combined EHR-Based Intervention (A+B)|Intervention A and B prompts will be combined and triggered for eligible patients simultaneously. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
89683288|NCT03139838|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 5 months of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the hospital. The length of the control phase will differ at each hospital, dependent on the sequence in which hospitals are assigned to switch to the intervention phase.
89683289|NCT00720473|Other|A: Other|Open Label Study
89683290|NCT00720473|No Intervention|B: Healthy Controls|
89683291|NCT00637832|Experimental|single group|
89683292|NCT01277887|Active Comparator|Cognitive-Behavioral Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
89683293|NCT01277887|Placebo Comparator|Smoking Cessation Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
89683294|NCT04276454|Experimental|Single arm|
89683295|NCT00720629|Experimental|First Study Stage: Study Treatment|Visilizumab, Tacrolimus and Methotrexate.
89683296|NCT00720629|Active Comparator|Second Study Stage: Standard Treatment|Second Stage: Antithymocyte-globulin (ATG), Tacrolimus and Methotrexate. The study was closed during first stage and did not proceed to the second stage comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
89683297|NCT04759820|Experimental|Nano carbon group|Injection of carbon nanoparticle
89683298|NCT04759820|Active Comparator|Indocyanine green group|Injection of indocyanine green
89683299|NCT01276327|Experimental|1 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
89683300|NCT01276327|Experimental|2 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
89683301|NCT01276327|Experimental|3 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
89683302|NCT01276327|Experimental|4 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
89683303|NCT03183830|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
89683304|NCT03183830|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
89683305|NCT00721175|Experimental|SEMS|self-expandable metal stent group
89683306|NCT00721175|Active Comparator|PS|plastic stent group
89683307|NCT05245760|Experimental|All patient|All patients receive Tislelizumab, q3week; chemotherapy with carboplatin and paclitaxel weekly concurrently for 5 weeks before surgery. Tislelizumab is continued q3week in all patients after surgery for a total of one year from the start of study.
89683308|NCT03808285||mandibular osteomylitis|description of mandibular osteomylitis due to denosumab
89683309|NCT03808363|Experimental|High Intensity Interval Training Group|Approximately eight individuals with spinal cord injuries will participate in high intensity interval training for 6 weeks
89683310|NCT01278641|Experimental|1|Intervention i arm 1 comprises graded strength resistance training, 75 minutes twice a week for 12 weeks.
89683311|NCT01278641|Experimental|2|Intervention in arm 2 comprises low intensive temperate pool exercise 50 minutes, twice a week for 12 weeks.
89683312|NCT01278641|No Intervention|3|Reference group, continues with normal activities during the study period of 12 weeks.
88997403|NCT00551590|Experimental|3|Sitagliptin 100 mg PO for three days. Exendin(9-39) IV on two consecutive study days.
88997404|NCT00551590|Placebo Comparator|4|placebo PO (placebo control for sitagliptin) for three days. Exendin(9-39)IV on two consecutive study days.
88997405|NCT00551629|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
88997406|NCT00551629|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
88997407|NCT00551629|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
88997408|NCT00551629|Experimental|PR51 (6, 15)|Participants were vaccinated with 0.5 ml of PR51 (6, 15) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
88997409|NCT00185172|Placebo Comparator|1|2 week placebo run-in
88997410|NCT00185172|Experimental|2|Olmesartan medoxomil tablets for 8 weeks
88997411|NCT00185172|Experimental|3|Olmesartan medoxomil tablets, or olmesartan medoxomil tablets + hydrochlorothiazide tablets for 4 weeks
88997412|NCT04836286|Experimental|single group repeated design|The Emotive Intelligent Spaces (EIS) leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
88997413|NCT00551668|Experimental|1|Operative
88997414|NCT00551668|Experimental|2|Nonoperative
88997415|NCT00551785||1|Women prescribed Intrinsa and estrogen therapy
88997416|NCT00551785||2|Women prescribed estrogen therapy
88997417|NCT00551824|Experimental|1|"First dilation session with topical mitomycin applied over esophageal mucosa after dilation.~Second dilation session (after 14 days): standard dilation without topical mitomycin."
89683313|NCT02674958|Active Comparator|Aspirin|Aspirin 325mg orally bolus followed by 162mg orally daily during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
89683314|NCT02674958|No Intervention|No aspirin|No aspirin allowed during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
89683315|NCT04385771|Experimental|vv-ECMO + cytokine adsorption|after indication of treatment with vv-ECMO in acute respiratory failure in COVID-19-disease, patients will additionally receive cytokine adsorption using a Cytosorb adsorber
89683316|NCT04385771|Other|vv-ECMO (no cytokine adsorption)|treatment with vv-ECMO in acute respiratory failure in COVID-19-disease (standard treatment without additional cytokine adsorption)
89683317|NCT00760435|Experimental|1|Infliximab plus Intravenous immunoglobulin (IVIG)
89683318|NCT00760435|Placebo Comparator|2|Placebo plus IVIG
89683319|NCT02144597|Active Comparator|2-week LCD and Roux-en-Y gastric bypass (RYGB)|A 2-week liquid formula low-calorie diet (LCD) will be administered for 2 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
89683320|NCT02144597|Active Comparator|6-week LCD|A 6-week liquid formula low-calorie diet (LCD) will be administered for 6 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
89683321|NCT02144597|Other|Control diet|1000 calorie diet
89683322|NCT03808129|Active Comparator|ESP Group: Bupivacaine and lidocaine|ESP Group: Bupivacaine and lidocaine: Erector Spinae Plane Block : (1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine) was administered.
89683323|NCT03808129|No Intervention|control group|Control Group:
89216333|NCT04313738|Experimental|Intervention group|Experimental: Intervention group Intervention group: Home visit, health education, telephone counseling At the intervention group; the researcher firstly made spirometry meausurement in hospital. After, the researcher made pretest (baseline measurement) before nursing interventions at the first home visit. At the first home visit, the researcher was offered education and guide smoking cessation. Second, Third and fourth home visit were made 15 days later, one and six months after visit first visit. During the second, third and fourth home visits, firstly the patient's stage of change was determined and then appropriate nursing intervention was performed in accordance with the guidelines.Between the third and fourth home visits, the participants were contacted through telephone calls once a month. At fourth home visit, the researcher made posttest. After the patient was invited to the hospital and spirometry measurements were repeated.
89216334|NCT04313738|No Intervention|Control Group|At the control group; No home visits were paid to the control group. The researcher made measurements twice at in the first and sixth months in the hospital. The researcher also given at the end of the sixth month, all of the nursing interventions, given to the intervention group, for the control group.
89216335|NCT04312360|Experimental|intervention track 1|"14 patient with right-sided colon cancer receive intervention before the hemicolectomi.~both arms of this study use the same intervention."
89216336|NCT04312360|Experimental|intervention track 2a|"14 patient with right-sided colon adenoma receive intervention before the endoscopic mucosa resection.~both arms of this study use the same intervention."
89683324|NCT00749125|Experimental|1 Lexapro|The depressed participants in this arm will be given Lexapro.
89683325|NCT00749125|No Intervention|2 Control|The nondepressed participants in this arm will not be given any intervention for depression.
89683326|NCT02144675|Experimental|Arm I (choline magnesium trisalicylate and chemotherapy)|Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
89683327|NCT02144675|Active Comparator|Arm II (chemotherapy)|Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
89216337|NCT04290663|Active Comparator|RAI group|
89683328|NCT01273363||1|Male and female over 18. Patients with asthma diagnosed in accordance with the Global Initiative for Asthma within 6 months before inclusion into the study and without changes in treatment for 2 months before inclusion
89683329|NCT00721253|Active Comparator|ReSTOR Aspheric +4|ACRYSOF ReSTOR Aspheric +4 Model SN6AD3
89683330|NCT00721253|Active Comparator|Tecnis MF|Abbott Medical Optics Tecnis Multifocal Intraocular Lens (IOL) Model ZM900
89683331|NCT00721253|Active Comparator|Acri.LISA|Meditec Acri.LISA Intraocular Lens (IOL) Model 366D
89216338|NCT04290663|Experimental|GUIDED FOLLOW-UP group|
89216339|NCT04289077||Patients with histopathological proven DTF|
89216340|NCT04272372||Group 1|Complete Decongestive Therapy
89216341|NCT04272372||Group 2|Complete Decongestive Therapy + PO Ketoprofen + Local ketoprofen gel
89216342|NCT04272372||Group 3|Complete Decongestive Therapy + Local Ketoprofen gel
89216343|NCT04270760|Active Comparator|Arm 1 Olpasiran Dose 1|
89216344|NCT04270760|Active Comparator|Arm 2 Olpasiran Dose 2|
89216345|NCT04270760|Active Comparator|Arm 3 Olpasiran Dose 3|
89683332|NCT00707447|Placebo Comparator|1/Control|Control group received written information about diabetes risks with instructions about healthy eating and increasing physical exercise
89683333|NCT00707447|Experimental|2/PREDIAS|Intervention consists of a group programme (PREDIAS) aiming at modification of lifestyle
89683334|NCT03807895|Experimental|REBT Career Intervention|High-school students in the experiment group attend to eight modules of career intervention with rational emotive behavioral therapy (REBT) techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive Restructuring, Exposure/behavior activation and problem solving, Planning, Goal Setting.
89683335|NCT03807895|Active Comparator|Regular Career Intervention|High-school students in the treatment as usual group attend to eight modules of career intervention with regular career intervention techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Problem solving, Planning, Goal Setting.
89683336|NCT00749671|Active Comparator|ICD testing BIS|Bispectral Index Monitoring will be used to assess adequacy of moderate sedation during DFT.
89683337|NCT00749671|Active Comparator|ICD testing Ramsey|Ramsey Sedation Scale will be used to assess adequacy of moderate sedation during DFT
89683338|NCT01272323||Placebo|Subjects previously randomised to receive placebo in study CP005
89216346|NCT04270760|Active Comparator|Arm 4 Olpasiran Dose 4|
89216347|NCT04270760|Placebo Comparator|Arm 5 Placebo Dose 5|
89216348|NCT04256473|Experimental|Intervention|"Bolus of IV alteplase (5 mg) followed by continuous infusion of HisproUK 40 mg/hr during 60 minutes.~Depending on results of interim analyses, the alternate dose may be revised to a lower dose (30mg/hr during 60 minutes) or a higher dose (50mg/hr during 60 minutes)."
89216349|NCT04256473|Active Comparator|Control|Usual care with alteplase 0.9 mg/kg in 60 minutes
89216350|NCT04253002|Experimental|Robinson's Culturally Adapted Coping with Stress Course|
89216351|NCT04253002|Active Comparator|Standard Care Control Condition|
89216352|NCT04217746|Experimental|High flow nasal cannula (HFNC) group|The HFNC group will receive heated (approximately 37 ⁰C) and humidified (100% relative humidity) oxygenated gas delivered at high flow at 50L/min. Flow could be decreased to as low as 30L/min and temperature to 31 ⁰C as per patient's tolerance.
89683339|NCT01272323||Cat-PAD Group 1|Subjects previously randomised to receive Cat-PAD dose 1 in study CP005
89683340|NCT01272323||Cat-PAD Group 2|Subjects previously randomised to receive Cat-PAD dose 2 in study CP005
89683341|NCT01272401||Breast cancer patients and survivors|
89683342|NCT01272557|Active Comparator|Sorafenib 400 mg bid (oral) continuously|Sorafenib 400 mg bid (oral) continuously until progression or unacceptable toxicity).
89683343|NCT01272557|Experimental|q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19|During trial therapy period in Arm-A treated patients will receive doxorubicin infusion with 60mg/m² on day 1 every 21 days for maximum of 18 weeks (or 6 cycles) until a maximal dose of 360mg/m² are reached. Sorafenib 400mg bid (oral) will be administered from day 3-19 every 21 days during the trial therapy period
89216353|NCT04217746|No Intervention|Conventional flow nasal oxygen (CFNO) group|The conventional flow nasal oxygen (CFNO) group is the control group which will receive ambient temperature and non-humidified oxygen delivered at flow rates of up to 8L/min (standard care).
89216354|NCT04198363|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
89216355|NCT04198363|Active Comparator|Esomeprazole 20 mg|Esomeprazole 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
89216356|NCT04195828|Experimental|Camrelizumab + Apatinib + nab-paclitaxel +S-1|Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
89216357|NCT04195828|Active Comparator|nab-paclitaxel +S-1|nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer
89216358|NCT04193371|Experimental|active acupuncture + lifestyle management|Participants in this group are treated by active acupuncture and lifestyle management for 4 months and follow up 4 months after the last treatment.
89216359|NCT04193371|Sham Comparator|control acupuncture + lifestyle management|Participants in this group are treated by control acupuncture and lifestyle management for four months and follow up 4 months after the last treatment.
89216360|NCT04192747|Experimental|Elixir Bioadaptor (ELX1805J)|The Elixir Bioadaptor (ELX1805J) 2.25 - 4.0 mm diameter and 14,15,18, 23, 28, 32 and 38 mm in length
89216361|NCT04192747|Active Comparator|Medtronic Resolute Onyx Stent|The Medtronic Resolute Onyx Stent 2.25 - 4.0 mm diameter and 15, 18, 22, 30, 34 and 38 mm in length
89683344|NCT01272713|Other|Oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol~Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~In-hospital oxygen as per hospital protocol"
89683345|NCT01272713|Other|No oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol~No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%."
89683346|NCT00762307|Experimental|Treatment Group 1|Cooling Intensity Factor = 33 Duration = 60 minutes
89683347|NCT00762307|Experimental|Treatment Group 2|Cooling Intensity Factor = 37 Duration = 30 minutes
89683348|NCT00762307|Experimental|Treatment Group 3|Cooling Intensity Factor = 37 Duration = 45 minutes
89683349|NCT00762307|Experimental|Treatment Group 4|Cooling Intensity Factor = 42 Cooling Duration = 30 minutes
89683350|NCT00639002|Experimental|Ruxolitinib then Ruxolitinib + Dexamethasone|Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
89683351|NCT00761137|Experimental|Tropicamide placebo|subject received (blinded) each of the 4 drug doses at different visits - 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
89683352|NCT00761137|Experimental|Tropicamide 0.3 mg|subject received (blinded) each of the 4 drug doses at different visits - 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide
89683353|NCT00761137|Experimental|Tropicamide 1 mg|subject received (blinded) each of the 4 drug doses at different visits - 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide
89683354|NCT00761137|Experimental|Tropicamide 3 mg|subject received (blinded) each of the 4 drug doses at different visits - 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide
89683355|NCT01273103|Experimental|Treatment|[14C]- GSK2248761 200 mg
89683356|NCT04386161|Experimental|Children with dyslexia|Children, aged between 8 and 11 years, with clinical dyslexia diagnosed by a child and adolescent psychiatrist
89683357|NCT02145247|Active Comparator|Normal adult women|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained at T = -0.5, 0, and +24 hours.~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
89683358|NCT02145247|Active Comparator|Women with PCOS|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained at T = -0.5, 0, and +24 hours.~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
89683359|NCT00722111|Experimental|Arm 1|lingual press (high-intensity, oral, non-swallowing)
89683360|NCT00722111|Experimental|Arm 2|effortful swallowing (high-intensity swallowing)
88997418|NCT00551824|Experimental|2|"First dilation session: standard dilation without topical mitomycin.~Second dilation session (after 14 days) with topical mitomycin applied over esophageal mucosa after dilation."
89216362|NCT04173247|Experimental|KeraStat Skin Cream Arm|Patients randomized to the KeraStat arm will be provided with KeraStat Skin Cream for application as often as needed but at least twice daily, morning and evening using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
89683361|NCT00722111|Experimental|Arm 3|natural swallowing (high frequency, low intensity swallowing)
89216363|NCT04173247|Active Comparator|Routine Skin Care Arm (RSC Arm)|Patients randomized to this arm will apply commercially available products from a list provided at least twice daily using the product on the start date of radiation and continue until returning for follow up approximately one month after last radiation treatment.
89216364|NCT04167891||Patients admitted in the intensive care unit|Patients with return of spontaneous circulation after cardiac arrest regardless of initial rhythm, and admitted in intensive care unit for post cardiac arrest care
89216365|NCT04149977|Experimental|blood flow restriction therapy (pressure cuff)|The cuff will be placed around the upper thigh of the injured leg and set at a pressure that will prevent approximately 80% arterial blood flow. The machine will determine what pressure is required to reach that 80%, when placed on the leg and turned on.
89216366|NCT04149977|Placebo Comparator|blood flow restriction therapy (placebo)|Patients with a placebo pressure will have a pressure setting, 50% lower than the effective setting as stated in the experimental arm
89216367|NCT04144036|Experimental|Neihulizumab Dose Escalation, 3 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
89216368|NCT04144036|Experimental|Neihulizumab Dose Escalation, 6 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
89216369|NCT04144036|Experimental|Neihulizumab Dose Escalation, 9 mg/kg|Initial dose will be 6 mg weekly and the highest dose administered will be 9 mg weekly. Patients will be entered sequentially to each dose level. If 0 of the first 3 patients at that level has a DLT, new patients may be entered at the next higher dose level. If 1 of 3 patients has a DLT, up to 3 more patients are to be treated at that same dose level. If 0 of the additional 3 patients at that dose level has a DLT, new patients may be entered at the next higher dose level. If 1 or more of the additional 3 patients experience a DLT, 0 patients are to be started at that dose level and the preceding dose is the MTD. If 2 of 3 of the dosed patients has a DLT on the first dose level, the drug will be administered at a lower dose, 3 mg weekly. If 0 of 3 patients has a DLT at the highest dose level, an additional 3 patients will be enrolled to ensure that 6 patients are treated at the MTD. The MTD is the highest dose level at which no more than 1 of 6 treated patients, experiences a DLT.
89216370|NCT04144036|Experimental|Neihulizumab Dose Expansion|Upon determination of the maximum-tolerated dose, an expansion cohort of 4-7 patients will be enrolled so that a total of 10 patients are enrolled at the potential Phase II dose. This will be done to preliminarily assess efficacy.
89216371|NCT04125355|Placebo Comparator|Placebo|Placebo control
89683362|NCT00722111|Sham Comparator|Arm 4|non-oral sham (control) exercise
89683363|NCT00638846|Experimental|senofilcon A toric|senofilcon A, daily wear, toric contact lens worn for two weeks
89683364|NCT00638846|Active Comparator|balafilcon A toric|balafilcon A, daily wear, toric contact lens worn for two weeks
89683365|NCT01273415||hormone receptor-positive breast cancer|postoperative hormone receptor-positive breast cancer
89683366|NCT01273493|Experimental|Trabectedin 1.3 mg/m^2 plus Dexamethasone|Control group Trabectedin 1.3 mg/m^2 i.v.will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
89683367|NCT01273493|Experimental|Trabectedin 0.58 mg/m^2 plus Dexamethasone|Hepatic dysfunction group Trabectedin 0.58 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
89683368|NCT00638456|Active Comparator|1|oral viscous budesonide plus Prevacid
89683369|NCT00638456|Placebo Comparator|2|placebo plus Prevacid
89683370|NCT01273571|Experimental|001|Canagliflozin/Metformin Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8 followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
89683371|NCT02147899|Experimental|SYM-1219 Low Dose|Administered orally
89683372|NCT02147899|Experimental|SYM-1219 High Dose|Administered orally
89683373|NCT02147899|Placebo Comparator|Placebo|Administered orally
88997419|NCT00185250|Experimental|Arm 1|
89683374|NCT01273649|Experimental|ice, rate of force development|to monitor the long term effect of cryotherapy in rate of force development.
89683375|NCT02565992|Experimental|CAVATAK and pembrolizumab|Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.
89683376|NCT03807583|No Intervention|Control group|
88997420|NCT00185250|Experimental|Arm 2|
88997421|NCT00185250|Placebo Comparator|Arm 3|
88997422|NCT00185250|Placebo Comparator|Arm 4|
88997423|NCT00551863|Active Comparator|IVPT|Intervention based on Motivational Interviewing and CBT
88997424|NCT00551902|Experimental|1|Trabeculectomy with anterior chamber infusion system
88997425|NCT00551902|Active Comparator|2|Trabeculectomy without anterior chamber infusion system
89216372|NCT04125355|Experimental|Reflexology|foot reflexology
89216373|NCT04093219|Experimental|IV Acetaminophen|1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
89216374|NCT04093219|Placebo Comparator|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
89216375|NCT04089917||Q Aspiration Catheter|mechanical thrombectomy for acute ischemic stroke
89216376|NCT04050072||Childhood Cancer Survivors (CCSS)|i. PRO-CTCAE-SCC ii.Quality of life assessment
89216377|NCT04050072||St. Jude Life (SJLIFE)|i. PRO-CTCAE-SCC ii. Quality of life assessment iii. Comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation
89216378|NCT04050072||Community non-cancer control|i. PRO-CTCAE-SCC ii.Quality of life assessment
89216379|NCT04046107|Experimental|Cohort 1: Cemiplimab (0.3 mg/kg)|Participants will receive cemiplimab 0.3 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
89683377|NCT03807583|Active Comparator|AMINOVEN® 10%|"The AMINOVEN® 10% comparative product is a drug in the form of a 130 mL intravenous infusion solution. This product is composed of amino acids.~The product is administered per os during the first hour of dialysis sessions for the duration of the study."
89683378|NCT03807583|Experimental|RENORAL®|"The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.~The product is a beverage packaged in 150 mL aluminum cans. It contains a liquid solution of native milk proteins and partially hydrolyzed whey proteins."
89216380|NCT04046107|Experimental|Cohort 2: Cemiplimab (1 mg/kg)|Participants will receive cemiplimab 1 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
89216381|NCT04046107|Experimental|Cohort 3: Cemiplimab (3 mg/kg)|Participants will receive cemiplimab 3 mg/kg dosed in two infusions, one infusion at Week 6 and Week 12.
89216382|NCT04039243|Experimental|Active Treatment|Up to 12 sessions of Parent-Child CBT using an adaptation of the Being Brave protocol
89216383|NCT04039243|Active Comparator|Parent Education|Parents receive educational materials about how to help young children overcome shyness and anxiety
89683379|NCT03802123|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.
89683380|NCT00733343|Active Comparator|Treatment Group|treatment with Adaptive Servoventilation (Europe: AutoSet CS (USA: VPAP (Variable Positive Airway Pressure) Adapt SV)) + standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
89683381|NCT00733343|No Intervention|Control Group|standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
89683382|NCT00638378|Experimental|Ruxolitinib|Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.
89683383|NCT03807661|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
89683384|NCT00762619|Placebo Comparator|A -|fluoride toothpaste (Ultrabrite)
89683385|NCT00762619|Active Comparator|B - Postive control|fluoride/triclosan/copolymer toothpaste
89683386|NCT05248568|Experimental|Swiss ball|Swiss ball practice can create an unstable environment and play an important role in promoting the development of muscle function and joint stability. It can effectively train the core muscles. Swiss ball practice will be involved in intermediate level training to develop participants' stability and muscle endurance。
89683387|NCT05248568|Experimental|Kettlebell|"Kettlebell training can strengthen the anti rotation ability of the trunk. For example, Kettlebell training has many actions like kettlebell swing. This movement is easy to cause imbalance in the human body, so they can further exercise the trunk stability and anti rotation ability required by athletes."
89683388|NCT05248568|Experimental|Barbell|Barbell is a commonly used and multifunctional strength training instrument. It is usually used as the main instrument to develop the maximum muscle strength and muscle explosiveness. Therefore, this study will involve barbell practice in upper intermediate training and advanced level training
89683389|NCT05248568|Experimental|Medicine balls|Medicine balls are often used to assist patients in injury recovery, rehabilitation and strength training, and play an important role in the field of sports medicine. Its special design and construction make training more functional and in line with the movement chain theory, such as throwing training, so the medicine ball is often used in explosive force and core training. Therefore, this study will involve medicine balls practice in upper intermediate training and advanced level training
89683390|NCT02521142||AMD: treatment-naive|
89683391|NCT02521142||AMD: active neovascular AMD|
89683392|NCT00734903|Experimental|A Woman's Path to Recovery (WPR)|A gender-focused approach to addiction recovery
89683393|NCT00734903|Active Comparator|12-Step Facilitation (TSF)|An evidence-based, non-gender-focused approach to addiction recovery
89683394|NCT01273753|Active Comparator|Exercise|After baseline measurements, all subjects will undergo a phase involving intradialytic exercise. Subjects will serve as their own controls.
88997426|NCT00551941|Active Comparator|2|non-union of diaphysary tibial fractures will be treated with allograft together with DBM
89216384|NCT04039243|No Intervention|Monitoring|
89216385|NCT04037917|Experimental|Synthetic Tissue Substitute|Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
89216386|NCT03993509|Experimental|1 Hz Arm|Subjects will receive a continuous train of 1 Hz stimulation until all 3000 pulses are delivered. Consistent with the 10 Hz condition, TMS will occur during the Sternberg WM paradigm.
89216387|NCT03993509|Experimental|10 Hz Arm|Subjects will receive 75, 4 second trains at 10 Hz, separated by a 36 second ITI. Stimulation will occur while subjects are doing the Sternberg WM paradigm. The timing of the Sternberg task will be jittered so that each rTMS train will be administered during the maintenance interval of a WM trial.
89216388|NCT03981263|Other|MEAVANTI + Standard protheses|The patients will benefit from the experimental prothesis (MEAVANTI), after a wash-out period of 15 days, they will benefit from the standard non-adherent prothesis.
88997427|NCT00551941|Experimental|1|non-union of diaphysary tibial fractures will be treated with BMP-7 in adjunct to fresh frozen allograft
89683395|NCT00735449|Active Comparator|Combigan ®|Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)
89683396|NCT00735449|Active Comparator|Timolol Maleate 0.5%|Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)
89683397|NCT04386343|Placebo Comparator|50% dose level arm - Phase I|4 healthy volunteer will use 50% dose level for Phase I in the left hand side and use placebo in the right hand side
89683398|NCT04386343|Placebo Comparator|100% dose level arm - Phase I|4 healthy volunteer will use 100% dose level for Phase I in the left hand side and use placebo in the right hand side
89683399|NCT04386343|Active Comparator|167% dose level arm - Phase I|4 healthy volunteer will use 167% dose level for Phase I in the left hand side and use placebo in the right hand side
89683400|NCT04386343|Placebo Comparator|Placebo arm - Phase II|20 Breast cancer patients will use Placebo in the radiation affected area right after radiation
89683401|NCT04386343|Placebo Comparator|50% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 50% of the expected dose level in the radiation affected area right after radiation
89683402|NCT04386343|Placebo Comparator|100% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 100% of the expected dose level in the radiation affected area right after radiation
89683403|NCT04386343|Placebo Comparator|167% dose level arm - Phase II|20 Breast cancer patients will use CH1701 with 167% of the expected dose level in the radiation affected area right after radiation
89683404|NCT01273831|Other|atracurium|Patients who underwent general anesthesia received atracurium
89683405|NCT01273831|Other|cisatracurium|Patients who underwent general anesthesia received cisatracurium
89683406|NCT00735839|Experimental|V710|V710 vaccination (60 mcg) single dose on Day 1
89683407|NCT00735839|Placebo Comparator|Placebo|Placebo single dose on Day 1
89683408|NCT00723073||Caspofungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an Absolute Neutrophil Count (ANC) < 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.
89683409|NCT00723073||Micafungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an Absolute Neutrophil Count (ANC) < 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent
89683410|NCT03805711|Experimental|Aortic Valve Replacement with HLT® Transcatheter System|Replacement of aortic valve using the HLT® Transcatheter System (HLT System) comprised of The Meridian® II Valve with TriVent™ Anticalcification Treatment and The Pathfinder® II Delivery System
89683411|NCT00735917|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89683412|NCT00779155|Placebo Comparator|Inactive Resonator Therapy|Inactive magnetic resonance therapy
89683413|NCT00779155|Active Comparator|Active Resonator Therapy|active magnetic resonance therapy
89683414|NCT00736073|Active Comparator|1|aprepitant
89683415|NCT00736073|Placebo Comparator|2|Placebo
89683416|NCT00736229|Experimental|Exenatide|0.05 µg/min liquid bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
89683417|NCT00737243|Experimental|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
89683418|NCT00737243|Other|Treatment determined by physician|Other treatment determined by physician based on molecular profiling assay
89683419|NCT00707759|Experimental|A: withdrawal steroids|"Arms A: TAC + MMF + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
89683420|NCT00707759|Active Comparator|B|"Arms B: TAC + MMF + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
89683421|NCT01273727|No Intervention|No Ozurdex|Arm 1(control) - Patients who have had epi-retinal membrane peeling and have macular edema at least 3 months (90 days) after surgery. These patients will followed without Ozurdex. The patients will be treated with current standard of care, including topical and intravitreal or subtenon's medication.
89683422|NCT01273727|Experimental|Ozurdex 3 months after surgery|Patients who have had epi-retinal membrane peeling and have residual macular edema 3 months after surgery. These patients will receive an Ozurdex implant
89683423|NCT01273727|Experimental|Ozurdex 6 months or longer after surgery|Patients who have had epiretinal membrane peeling and have residual macular edema at least 6 months after surgery
89683424|NCT00707915|Experimental|Dose reduction|The benzodiazepine dose will be discontinued in 4 weeks by a weekly 25% reduction. Participants will be observed for 8 weeks.
89683425|NCT04386083||COVID-19 patients with neurologic manifestations|Patients with confirmed COVID-19 disease who presented with neurological symptoms or new-onset neurological disorders/complications
89683426|NCT04386083||COVID-19 patients without neurologic manifestations|Patients with confirmed COVID-19 disease who did not present with neurological symptoms or new-onset neurological disorders/complications
89683427|NCT02994407|Experimental|N8-GP s.c.|
89683428|NCT00708071|Experimental|1|One side of the face is treated with FS VH S/D 4; the other side of the face is treated using standard of care.
89683429|NCT02994641||Adverse discharge disposition|Patients who were discharged to a skilled nursing facility or died in the hospital
89683430|NCT02994641||No adverse discharge disposition|Patients who were not discharged to a skilled nursing facility or did not die in the hospital
89683431|NCT02994485|Active Comparator|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks
89683432|NCT02994485|No Intervention|no treatment|no treatment
89683433|NCT02994173|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
89683434|NCT02994173|Active Comparator|Ketamine 0.25|Oxycodone 1 mg / ml + S-ketamine 0.25 mg / ml (ratio 1:0.25)
88997428|NCT00185289|Experimental|Arm 1|
88997429|NCT00551980|Experimental|Cognitive and physical program|Randomized group of workers of the same institution ( City of Turin, Italy).
88997430|NCT00551980|No Intervention|Control group|Randomized group of workers of the same institution ( City of Turin, Italy).
88997431|NCT00552214|Other|Human Blood Donor Plasma Specimens|
88997432|NCT00185328|Experimental|Arm 1|
88997433|NCT04766164||Males and Females ages 18-26|Participants between the ages of 18-26 will complete a survey
88997434|NCT04766164||Males and Females ages 27-45|Participants between the ages of 27-45 will complete a survey
89683435|NCT02994173|Active Comparator|Ketamine 0.5|Oxycodone 1 mg / ml + S-ketamine 0.5 mg / ml (ratio 1:0.5)
89683436|NCT02994173|Active Comparator|Ketamine 0.75|Oxycodone 1 mg / ml + S-ketamine 0.75 mg / ml (ratio 1:0.75)
89683437|NCT00723749||Suboxone|Patients for whom a drug dependence therapy with SUBOXONE® is planned and indicated, and who have already been pre-treated with SUBUTEX®, or another maintenance drug for at least 6 months.
89683438|NCT00723827||All Participants|Participants with newly diagnosed glioblastoma multiforme (treat with temozolomide & radiotherapy) or participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy (treat with temozolomide).
89683439|NCT02995343|Experimental|Hypogastric and/or uterine artery ligation|Patients who had been ligated hypogastric artery and or uterine artery for ceasing uterine bleeding during c-section
89683440|NCT02995343|No Intervention|Normal postpartum women|
88997435|NCT00552253|Experimental|1|under eltroxin
88997436|NCT00162110|Active Comparator|1|
88997437|NCT00552331|Active Comparator|LISS|Treatment of distal femur fracture with less invasive stabilization system
88997438|NCT00552331|Active Comparator|Standard Treatment|Treatment of distal femoral fractures using locking condylar plates or dynamic condylar screws
88997439|NCT00552487|Other|1|healthy people without Hashimoto disease receive a 1µg ACTH stimulation test
88997440|NCT00552487|Other|2|patients with Hashimoto disease with well being receive a 1 µg ACTH stimulation test
88997441|NCT00552487|Other|3|patients with Hashimoto disease an impaired well-being receive a 1 µg ACTH stimulation test
88997442|NCT00552487|Other|4|patients with Hashimoto disease and negative TPO antibodies receive a 1µg ACTH stimulation test
88997443|NCT00162149|No Intervention|A1|
88997444|NCT00162149|Experimental|A2|
88997445|NCT00162149|Experimental|A3|
89683441|NCT02993861||Levetiracetam|Children with epilepsy who are treated with levetiracetam per local standard of care
89683442|NCT02993861||Valproic Acid|Children with epilepsy who are treated with valproic acid per local standard of care
89683443|NCT02993861||Topiramate|Children with epilepsy who are treated with topiramate per local standard of care
89683444|NCT02993861||Oxcarbazepine|Children with epilepsy who are treated with oxcarbazepine per local standard of care
89683445|NCT00779311|Experimental|Experimenal|All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle. Sorafenib will be administered daily throughout treatment beginning on day 1
89683446|NCT01274039||Patient with a trabeculectomy planed|
89683447|NCT03802201|Experimental|PTG-300 Active|Drug: PTG-300 Subcutaneous
88997446|NCT00162149|No Intervention|B1|
88997447|NCT00552526|Active Comparator|Ketogenic diet|
88997448|NCT00552526|Active Comparator|AED|Most appropriate antiepileptic drug
88997449|NCT00552565|Placebo Comparator|1|
88997450|NCT00552565|Experimental|2|
88997451|NCT00552565|Experimental|Rezular 37.5mg|
89683448|NCT01274117|Placebo Comparator|One-stage transposition of the basilic vein|One-stage transposition of the basilic vein
89683449|NCT01274117|Experimental|Two-stage transposition of the basilic vein|Two-stage transposition of the basilic vein
89683450|NCT00725153|Other|PureVision/Acuvue 2|PureVision contact lenses worn first, with Acuvue 2 contact lenses worn second. Both products worn for 10 hours each.
88997452|NCT00552565|Experimental|Rezular - 75mg|
88997453|NCT00552604|Experimental|1|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
88997454|NCT00552604|Placebo Comparator|2|matching placebo capsules, twice daily
88997455|NCT00552643|Experimental|1|Treatment with Polyheal 1
88997456|NCT00552643|Active Comparator|2|Saline
88997457|NCT04755088|Experimental|Cohort 1|Subjects with Normal Renal Function: All patients to receive study drug (Surufatinib 300mg) on Day 1
88997458|NCT04755088|Experimental|Cohort 2|Subjects with Moderate Renal Impairment: All patients to receive study drug (Surufatinib 300mg) on Day 1
88997459|NCT04751890|Experimental|Structured home-based exercise|Program will include two 10-minute sessions/day (6 days/week) of intermittent walking (1-minute work and 1-minute rest while seated) at a prescribed speed converted into a walking cadence and followed at home using a metronome. The walking sessions will be preferably performed indoors at home or on a treadmill. During the study, 2 follow-up visits (at weeks 8 and 16) will be performed to evaluate patient adherence to the program and to update the exercise program with the duration of each session that remained constant. The walking intensity of each exercise regime will be progressively modified to increase the training load. The patients will be asked to fill out a daily training record indicating completion of the exercise and any associated symptoms. Patients will have the ability to contact the rehabilitation team, composed of a physician and a sports science expert, throughout the entire study period via phone.
88997460|NCT04751890|Active Comparator|Walking advice|Patients will receive advice to walk as suggested by the guidelines. In particular, a team member will recommend patients to gather almost 30 minutes of walking at least 3 times per week; when the patient will face claudication pain, he/she will be allowed to rest, and restart walking as soon as possible. A daily log to be compiled will be provided to each patients to record the amount of walk performed.
88997461|NCT04709926||Paramedics that were eligible to take part in the PRESTO study|Paramedics that are employed by one of the four Ambulance Services involved in the PRESTO study and were eligible to complete the training provided by Manchester University NHS Foundation Trust to take part in the PRESTO study.
89683451|NCT00725153|Other|Acuvue 2/PureVision|Acuvue 2 contact lenses worn first, with PureVision contact lenses worn second. Both products worn for 10 hours each.
89683452|NCT03807349|Other|N-Force Screws|N-Force Screws augmented with N-Force Blue in Intracapsular Femur Fractures.
89683453|NCT04387019||I|30 with uncontrolled type 2 DM patients
89683454|NCT04387019||II|30 controlled type 2 DM patients
89683455|NCT04387019||III|30 healthy subjects as a control group
89683456|NCT01274195|Experimental|Busulfan|
89683457|NCT00779701|Other|A|All subjects placed on insulin infusion.
89683458|NCT04345055|Experimental|Fascial treatment|Treatment the lumbar fasciae
89683459|NCT04345055|Placebo Comparator|Placebo group|Introduce in a machine off
89683460|NCT01279031|Experimental|Abbott WHITESTAR Signature System|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound
89683461|NCT01279031|Experimental|Alcon Infiniti|Alcon Infiniti with the OZIL Torsional Handpiece
89683462|NCT03802825|Active Comparator|Patient Navigation|Participants randomized to the patient navigation only arm will be referred to a KPNW patient navigator using a standard electronic health record-based referral process. Once the participant has completed the Your Current Life Situation (YCLS) assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 month period by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention. Participant will also receive monthly mailing of American Diabetes Association educational materials.
89683463|NCT03802825|Experimental|Patient Navigation+Diabetes Self-Management Support|"In addition to receiving patient navigation as described, participants in this arm will also be referred to Project Access NOW by study staff using REDCap. Project Access NOW will connect participants to a community-based organization based on their preference, previous experience with an agency, geography, and capacity.~The CHW will follow-up with the participant to conduct a home visit and follow-up on community-based referrals already placed by the KPNW patient navigator and assess for additional needs. The timing of the diabetes self-management training will be based on the needs of the participant."
89683464|NCT00738023|Active Comparator|Diabetics|Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours
89683465|NCT00738023|Active Comparator|Non-Diabetic|Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours
89683466|NCT03808909|Experimental|Doula|Participants will be assigned a doula.
89683467|NCT03808909|No Intervention|Control|Participants will not be assigned a doula.
89683468|NCT04385849|Experimental|Experimental Arm|N-803 Recombinant human super agonist interleukin-15 (IL-15) complex
89683469|NCT04385849|Placebo Comparator|Placebo Arm|Sterile saline solution
89683470|NCT00708851|Active Comparator|NB-UVB Light Device (311-315 nm)|the subject will receive full body NB-UVB light therapy
89683471|NCT00708851|Experimental|LCD Solution with NB-UVB Phototherapy|on half of the body will receive LCD while the full body receives NB-UVB therapy
89683472|NCT03809221|Experimental|early follicular phase down-regulation|Patients have a injection of 3.75mg long-acting Triptorelin acetate (Dipherelin®, IPSEN, France) on the 1st-4th day of menstrual cycle. If complete pituitary down-regulation is achieved after 28-42 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours after pre-ovulatory hCG injection transvaginally under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
89683473|NCT03809221|Active Comparator|luteal phase down-regulation|Patients have a injection 0.1mg short-acting Triptorelin acetate (Decapeptyl®, Ferring, Germany) every day, 10-12 days before the next menstrual cycle. If complete pituitary down-regulation is achieved after 14-21 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and the serum hormone level and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours later under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
89683474|NCT02993627|Experimental|Spirulina|daily intake of spirulina tablets weight reduction diet therapy
89683475|NCT02993627|Placebo Comparator|placebo|daily intake of placebo tablets weight reduction diet therapy
89683476|NCT02993315|Experimental|nDC vaccination arm|Patients in the nDC vaccination arm will receive a maximum of 3 cycles each consisting of 3 nDC injections intranodally (3-8x10^6 nDC).
89683477|NCT02993315|Placebo Comparator|placebo arm|Patients will receive a maximum of 3 cycles each consisting of 3 placebo injections intranodally.
89683478|NCT00739583|Active Comparator|1|Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)
89683479|NCT00739583|Active Comparator|2|Skin preparation for hip replacement with an Iodine based skin preparation solution, Duraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA.
89683480|NCT04385459||Patients without coronary artery disease|No prior coronary intervention and no significant stenosis noted during coronary angiography.
89683481|NCT04385459||Patients with coronary artery disease|"Our definition of coronary artery disease is:~Prior coronary artery bypass grafting or percutaneous coronary intervention~Significant stenosis or occlusion noted during coronary angiography"
89683482|NCT01274741|Active Comparator|Seeking Safety (SS)|17 sessions of present-focused therapy Seeking Safety
89683483|NCT01274741|Experimental|Creating Change (CC)|17 sessions of past-focused Creating Change
88997462|NCT04705012|Experimental|Test - increased frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
88997463|NCT04705012|Active Comparator|Control - conventional frequency of submucosal cleaning|At follow-up time points (3-, 6-, 9-, 16 weeks) following initial treatment), all implants receive supramucosal polishing, but only test-implants receive submucosal debridement 12 + 24 +36 weeks following baseline: all implants receive supramucosal polishing as well as submucosal debridement as described above
88997464|NCT04701580|Experimental|HD patients|At baseline and 2-year follow-up
88997465|NCT04701580|Active Comparator|Healthy controls|At baseline and 2-year follow-up
88815838|NCT01116986|Experimental|15, Patch, No Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815839|NCT01116986|Experimental|16, Patch, No Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815840|NCT01116986|Experimental|17, No Patch, Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88997466|NCT00552682|Experimental|A|Duloxetine 60 mg, 1 tablet/day
88997467|NCT00552682|No Intervention|B|To continue with the antidepressive treatment if exist
88997468|NCT02963142||SCAP requiring ECMO|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require extra-corporeal membrane oxygenation and a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
89683484|NCT02993237|Experimental|Group 1: DRV/COBI Placebo followed by D/C/F/TAF Placebo|Participants will receive fixed dose combination (FDC) of darunavir/cobicistat (DRV/COBI) matching placebo tablets (Intake 1) and FDC of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
89683485|NCT02993237|Experimental|Group 2: D/C/F/TAF Placebo followed by DRV/COBI Placebo|Participants will receive FDC of D/C/F/TAF matching placebo tablets (Intake 1) and FDC of DRV/COBI matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
89683486|NCT03808597|Experimental|Intervention group|The participants in this group will be exposed to digital health promotion. Please note that the participants are not randomly chosen, but stratified after the project villages. The participants in this group belong to the villages: Izazi and Migoli.
89683487|NCT03808597|No Intervention|Control group|"The participants in this group will be not be exposed to digital health promotion, but the villages will receive the intervention after one year. Please note that the participants are not randomly chosen, but stratified after the project villages.~The participants in this group belong to the villages: Kimande and Idodi."
89683488|NCT03808207|Experimental|Intervention group|Increase of the average intake of dietary DHA: dietary advices concerning the concentration of docosahexaenoic acid (DHA) in several foods; the recommended daily or weekly intake of different food options (animal, vegetal) in order to reach the average intake of 300-350 mg DHA/day
89683489|NCT03808207|No Intervention|Control group|No specific dietary advice; Only endorsement and promotion of breastfeeding.
89683490|NCT02993159|Experimental|Arm I (afimoxifene, placebo)|Patients apply afimoxifene gel to both breasts and receive placebo PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
89683491|NCT02993159|Active Comparator|Arm II (placebo, tamoxifen citrate)|Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
89683492|NCT03807505|Active Comparator|Interscalene nerve block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot interscalene brachial plexus nerve block or an interscalene brachial plexus nerve catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
89683493|NCT03807505|Active Comparator|Erector Spinae Plane block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot erector spinae plane block or receive erector spinae plane catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
89683494|NCT03802513|Other|Individualized Physiotherapy|This study has 1 health-related intervention. Veterans with somatosensory tinnitus will receive individualized physiotherapy.
89683495|NCT02993003|Other|Children between 7 months and 12 months|nasopharyngeal probe will be marked with indelible ink from 2-10 cm in 1-cm increments and inserted 10 cm
89683496|NCT02993003|Other|children between 1 and 5 years|nasopharyngeal probe will be marked with indelible ink from 2-15 cm in 1.5-cm increments and inserted 10 cm
89683497|NCT02993003|Other|children between 6 and 12 years|a nasopharyngeal probe will be marked with indelible ink from 2 to 20 cm at 2 cm increments from its tip, and inserted 20 cm
89683498|NCT01279421|Experimental|Social Network HIV Testing|Participants in this arm will be recruited through social networks and will receive an HIV test.
89052303|NCT04596488|Experimental|Efavirenz 400mg+TDF+3TC|Combined antiretroviral therapy(cART) consisting of three regimens such as efavirenz, tenofovir and lamivudine is an effective measure for the treatment of HIV-1 infection.Efavirenz 600mg daily was approved by the US Food and Drug Administration in 1998. In this single-arm research, patients were treated with a reduced 400mg dose of efavirenz combined with tenofovir 300mg and lamivudine 300mg once a day. This treatment had to be maintained indefinitely due to the existence of HIV reservoir.
89052304|NCT00574626|Experimental|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
89052305|NCT00574626|Active Comparator|Bone Marrow Transplantation|Bone Marrow Transplantation
89052306|NCT04596566|Other|CD-TDI|Therapeutic diet Intervention ( CD-TDI )Group : Patients receiving CD-TDI will be offered patient-centered counseling for 12 weeks by a Registered Dietitian (RD) trained in the CD-TDI protocol with the goals of (a) identification and treatment of malnutrition if present, (b) targeted treatment of macro- and micronutrient deficiencies using whole foods;(c) increasing adherence to CD-TDI (d) multivitamin adherence and (e) reduced exposure to dietary antigens (e.g., maltodextrin, carrageenan, other food additives). They will receive a5 face-to-face appointment every 3 weeks with the study RD, and all other weekly appointments, which are 8 in number will be completed by phone.
89052307|NCT04596566|No Intervention|Conventional management|Conventional Management (Control) Group: CM patients will meet with the RD at baseline, week 7 and week 13 to complete their 24HR food recall twice on different days of the week, followed by a phone few days after the visit to complete the second part of the recall. They will be advised to follow their habitual diet and will be offered the dietary intervention at 14 weeks if they are still experiencing a disease flare
89052308|NCT00574665|Experimental|1|
89052309|NCT04578717|Experimental|Air-abrasion + Etch & rinse adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by etch&rinse adhesive application using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
89683499|NCT01279421|Experimental|Peer Network Intervention|Eight (8) current or former crack users will be recruited to facilitate small networks of crack users in a three-day intervention. They will also facilitate monthly meetings open to all community members regarding HIV prevention and interpersonal violence.
89683500|NCT02992847||Dotarem|At least 5 injection with Dotarem exclusively
89683501|NCT02992847||Multihance|At least 5 injection with Multihance exclusively
89683502|NCT00723931||Participants with Chronic Hepatitis C|Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with Chronic Hepatitis C are generally treated.
89683503|NCT00740129|Experimental|Zoledronic Acid 5 mg|Participants received single re-treatment dose of zoledronic acid 5 mg intravenous (IV) infusion.
89683504|NCT00762853|Placebo Comparator|A|fluoride toothpaste from Thailand
89683505|NCT00762853|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
89052310|NCT04578717|Experimental|Air-abrasion + Self-etch adhesive|Air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 followed by self-etch adhesive application which was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
89683506|NCT00740207|Active Comparator|Isovue 250|
89683507|NCT00740207|Active Comparator|VISIPAQUE 270|
89683508|NCT00724009|Experimental|Clofarabine|Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days
89683509|NCT04384081|Experimental|Dose group 1|
89683510|NCT04384081|Experimental|Dose group 2|
89683511|NCT04384081|Experimental|Dose group 3|
89683512|NCT04384081|Placebo Comparator|Placebo group|
89683513|NCT01279499|Active Comparator|SEVO group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes.If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
89683514|NCT01279499|Active Comparator|SEVO-BIS group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target BIS of 40 - 50 .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes. If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
89683515|NCT01279499|Active Comparator|Propo- Remi group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR > 15% of baseline will be followed by a R bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of R to 1.0 μg/kg/min . If HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of stress responses that required intervention is recorded."
89683516|NCT01279499|Active Comparator|Propo-Remi-BIS group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (IBW).~The depth of anesthesia will be adjusted to accomplish a BIS score 40 -50. If BP or HR is > 15% of baseline will a bolus of R IV (1 μg/kg IBW) will be given and an the infusion rate of R will be increased to 1.0 μg/kg/min . If this response persists and HR < 70/ min, Nifedipine 10 mg will be given s.l. and if HR > 70/ min Diltiazem 10-20 mg IV will be given, followed by esmolol infusion if no response is observed."
89683517|NCT04384237|Experimental|Er,Cr:YSGG laser-aided CSF|Experimental: Er, Cr: YSGG laser-aided Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment of the orthodontic treatment by inserting the laser tip at an angle of 10-15º to the radicular surface
89683518|NCT04384237|Active Comparator|Conventional CSF|Fiberotomy comparator: this arm is going to receive a blade conventional Circumferential Supracrestal Fiberotomy in the lower arch, posterior leveling and alignment by inserting a surgical blade into the gingival sulcus at an angle like that in the laser-aided CSF.
89683519|NCT02992925|Experimental|Cohort 1: BK1310-High|
89683520|NCT02992925|Experimental|Cohort 1: BK1310-Low|
89683521|NCT02992925|Experimental|Cohort 2: BK1310-High or -Low|Either BK1310-High or -Low will be chosen based on the result of cohort 1
89052311|NCT04578717|Experimental|Etch & rinse adhesive|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light
89052312|NCT04578717|Experimental|Self-etch adhesive|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
89683522|NCT02992925|Active Comparator|Cohort 2: ActHIB® and Tetrabik|
89683523|NCT00762931|Experimental|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation, all subjects will receive active treatment
89683524|NCT01275209|Experimental|HCD122|
89683525|NCT00780715|Active Comparator|Gliclazide MR|
89683526|NCT00780715|Active Comparator|Sitagliptin|
89683527|NCT00780715|Active Comparator|Pioglitazone|
89683528|NCT00780715|Experimental|Metformin|
88815841|NCT01116986|Experimental|18, No Patch, Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
89683529|NCT03807193|Experimental|Fixed treatment, weekly support|Receives a predetermined treatment program and have weekly support.
88815842|NCT01116986|Experimental|19, No Patch, Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
89052313|NCT04595942|Active Comparator|Midodrine|10 mg midodrine three times a day
89052314|NCT04595942|Active Comparator|Fludrocortisone|0.1 mg fludrocortisone two times a day
89052315|NCT04595942|Other|Lifestyle modification|Education, salt and water intake, counter-pressure maneuvers
89052316|NCT00566384|Active Comparator|Arm 1|
89052317|NCT00566384|Placebo Comparator|Arm 2|
89052318|NCT00574743|No Intervention|2|
89052319|NCT00574743|Active Comparator|1|
89052320|NCT04596020|Experimental|Blood Flow Restriction Group|This group will perform 2 lower extremity exercises (sitting unilateral knee extension, standing unilateral knee curl) under occlusion (i.e., BFR) for 4 sets (30/15/15/15 reps) each followed by 2 shoulder exercises (scaption and sidelying external rotation) 3 sets x 15 reps each. Exercises will be performed at 30% of 1RM.
89052321|NCT04596020|Active Comparator|Non-Blood Flow Restriction Group|This group will perform the same exercises for the same volume without the use of BFR.
89052322|NCT04578366|Experimental|Shockwavetherapy Group/Experimental group|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
89052323|NCT04578366|Active Comparator|Conventional Group|Conventional therapy hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
89052324|NCT04596176|No Intervention|Business As Usual|Families who were involved in the child welfare services
89052325|NCT04596176|Active Comparator|Intensive Supportive Housing for Families|Families who were randomly assigned in this group
89052326|NCT04596176|Active Comparator|Program Supportive Housing for Families|Families who were randomly assigned in this group
89052327|NCT04596137|Experimental|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
89052328|NCT00574899||1|patients scheduled to receive standard of care with a Radical prostatectomy
89052329|NCT00574899||2|patients scheduled to receive standard of care with radiation therapy
89052330|NCT00574977|Experimental|A|Subjects who have been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection
89683530|NCT03807193|Experimental|Fixed treatment, support on demand|Receives a predetermined treatment program and have access to support on demand.
89683531|NCT03807193|Experimental|Selected treatment, weekly support|Select their own treatment material and have weekly support.
89683532|NCT03807193|Experimental|Selected treatment, support on demand|Select their own treatment material and have access to support on demand.
89683533|NCT03800485|Experimental|IMT-GE|the participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will increase from the 15% of the maximal inspiratory preassure until the 60% of the maximal inspiratory preassure.
89683534|NCT03800485|Placebo Comparator|IMT-GP|The participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will be the 10% of the maximal inspiratory preassure during all the 8 weeks
89683535|NCT01273987|Experimental|neobladder with round lig|ileal neobladder suspened with round ligament
89683536|NCT01273987|No Intervention|standard neobladder|conventional standard neobladder
89683537|NCT03806725||Liver transplant (LTx) candidates with eGFR>=60|Liver transplant candidates with renal function defined by eGFR above or equal to 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement.
89683538|NCT03806725||LTx candidates with eGFR<60|"Liver transplant candidates with decreased renal function.~Defined by eGFR less than 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement."
89683539|NCT01274143|Active Comparator|Telephone-delivered risk intervention|Participants in this arm receive a personalized telephone-risk assessment intervention provided by a trained cancer risk counselor.
89683540|NCT01274143|Active Comparator|Mailed pamphlet intervention group|Participants in this group receive a mailed pamphlet containing information about familial colorectal cancer risk and screening.
89683541|NCT00740831|Experimental|A (PGL4001 5 mg)|Drug: PGL4001 5mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
89683542|NCT00740831|Experimental|B (PGL4001 10mg)|Drug: PGL4001 10 mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
89683543|NCT00740831|Active Comparator|C (GnRH-agonist)|PGL4001 matching placebo (oral tablets) and leuprorelin 3.75 mg (intramuscular injection)
89683544|NCT03806569|Active Comparator|MAC-cbt group treatment for adult ADHD|"The patients will be treated with psychological group treatment for 8 sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process. This will be called Mindfulness, Acceptance and Commitment-Therapy for adult Patients with ADHD"
89683545|NCT03806569|Sham Comparator|Relaxation-group for adult ADHD|"The patients will be treated with a relaxation-treatment, long-time established as Jacobson muscle relaxing technique."
89683546|NCT01275287|Active Comparator|Standard of care|Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here.
89683547|NCT01275287|Experimental|Eculizumab arm|"Standard of care for ANCA vasculitis + eculizumab treatment~Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here."
89683548|NCT05744245|Experimental|Standard dose|"1 x 35 minute therapy session of Swallow Strength and Skill training per day, 5 days a week for 2 weeks. 10 sessions in total.~Plus usual care"
89216389|NCT03981263|Other|Standard + MEAVANTI protheses|The patients will benefit from the standard non-adherent prothesis, after a wash-out period of 15 days, they will benefit from the experimental prothesis (MEAVANTI).
89216390|NCT03951480|Experimental|Manual medicine|
89216391|NCT03951480|Active Comparator|Corticosteroids infiltration|
89216392|NCT03943446|Placebo Comparator|Placebo|TAK-018 placebo-matching tablets, orally, twice daily (BID) for up to 27.7 weeks.
89683549|NCT05744245|Experimental|High dose|"2 x 35 minute therapy therapy sessions of Swallow Strength and Skill training, per day, 5 days a week for 2 weeks. 20 sessions in total.~Plus usual care"
89683550|NCT05744245|No Intervention|Usual care|Usual care
89683551|NCT02992535|Experimental|Single arm|Intense pulse light therapy (E-Schwin)
89683552|NCT01275443|Experimental|300mg TMC278LA|Single gluteal intramuscular injection (300mg) at day 1
89683553|NCT01275443|Experimental|1200mg TMC278LA|Single gluteal intramuscular injection (1200mg) at day 1
89683554|NCT01275443|Experimental|600mg TMC278LA|Single gluteal intramuscular injection (600mg) at day 1
89683555|NCT01275443|Experimental|150mg TMC278LA|This arm was included in the adaptive design of the study, but was not recommended for use based on the review of results from 300mg and 600mg arms by the protocol steering committee
89683556|NCT01274221|Placebo Comparator|Placebo|
89683557|NCT01274221|Active Comparator|SPD489|
89683558|NCT03806023|Experimental|All subjects|All subjects undergo same full protocol, including PNS and TMS at rest and active hand movements (signals from thumb muscle) triggered PNS and TMS.
89683559|NCT00741455|Experimental|Study Treatment|Chemotherapy, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate
89683560|NCT01274299||Infants|Healthy 0-4 years of age both boys and girls
89683561|NCT01274377|Experimental|Recipients Using 3-5/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 Human Leukocyte Antigen (HLA) Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
89683562|NCT01274377|Experimental|Recipients Using 6/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 HLA Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
89683563|NCT00742313|Experimental|Arm A|Arm A has FloSeal Matrix applied to EVH wound bed.
89683564|NCT00742313|No Intervention|Arm B|Arm B does not have FloSeal Matrix applied to EVH wound bed.
89683565|NCT05744011|Experimental|Tango group|"Tango intervention 2 times/week~1 hour During 3 months Conducted by care staff who previously received training in therapeutic tango from the University of Burgundy."
89216393|NCT03943446|Experimental|TAK-018 0.30 g Low Dose|TAK-018 0.30 gram (g), tablets, orally, BID for up to 31.7 weeks.
89216394|NCT03943446|Experimental|TAK-018 1.5 g High Dose|TAK-018 1.5 g, tablets, orally, BID for up to 26.1 weeks.
89216395|NCT03940482|Experimental|Single Arm|Subjects will act as their own controls
89216396|NCT03896763|Experimental|Supine / CMV|Supine positioning and conventional mechanical ventilation
89216397|NCT03896763|Experimental|Prone / CMV|Prone positioning and conventional mechanical ventilation
89216398|NCT03896763|Experimental|Supine / HVOF|Supine positioning and high-frequency oscillatory ventilation
89216399|NCT03896763|Experimental|Prone / HFOV|Prone positioning and high-frequency oscillatory ventilation
89216400|NCT03896737|Experimental|Dara-VCd|"treatment period includes administration of four 28-day cycles of induction with Dara- VCd; then patients will undergo transplant and finally they will receive two 28-day cycles of Dara-VCd consolidation treatment.~The response will be assessed after each cycle. Patients in the first randomization will be stratified according to FISH (standard/missing vs high risk,defined as del17, t 4;14, t 14;16) and ISS (I vs II and III).~TREATMENT SCHEMA - INDUCTION Daratumumab: 16 mg/Kg given by IV infusion on days 1, 8, 15, 22, on cycles 1-2 and on days 1, 15 on cycles 3-4.~Bortezomib: 1.3 mg/m2 given SC injection on days 1, 8,15, 22; Cyclophosphamide: 300 mg/ m2 given orally or IV infusion on days 1, 8, 15, 22; Dexamethasone: 40 mg given orally or by IV infusion on days 1, 8, 15,22 Repeat for four 4-week induction cycles."
89216401|NCT03896737|Active Comparator|VTd|"treatment period includes administration of four 28-day cycles of induction with VTd; then patients will undergo transplant and finally they will receive two 28-day cycles of VTd consolidation treatment.~TREATMENT SCHEMA INDUCTION~ARM VTd:~Bortezomib: 1.3 mg/m2 given by SC injection on days 1, 4, 8, 11 of 28-day cycle; Thalidomide: 100 mg given orally on days 1-28. Dexamethasone: 20 mg given orally or by IV injection on days 1, 2, 3, 4, 8, 9, 10 and 11 of every 28-day cycle.~Repeat for four 4-week induction cycles."
89216402|NCT03896724|Experimental|Group 1|"n=150. Age 5-17 month-old. 5mcg R21/25mcg Matrix-M at Day 0, 28 and 56 and 1 year.~Following the initial booster, Group 1 will be randomised 2:1 into Groups1a and 1b for 5ug R21/50ug Matrix-M: control. Groups 1a and 1b will receive these second and third booster vaccinations each year prior to the malaria season"
89683566|NCT05744011|Active Comparator|Physical activity group|"Physical activity intervention 2 times/week~1 hour During 3 months No music Conducted by physical activity professor assisted by care staff"
89683567|NCT05743933||Study group|Accidental adrenal tumor with 1mg-DST cortisol >50nmol/L
89683568|NCT05743933||Control group|Accidental adrenal tumor with 1mg-DST cortisol ≤50nmol/L
89683569|NCT00742469|Active Comparator|1|Rifaximin
89683570|NCT00742469|Placebo Comparator|2|Placebo
89683571|NCT00763243|Experimental|Cogmed Working Memory Training|Cogmed Working Memory Training Program
89683572|NCT02992613|Experimental|Ultra-Congruent(UC) group|Ultra-Congruent(UC) insert will be used in total knee arthroplasty.
89683573|NCT02992613|Active Comparator|posterior-stabilized(PS) group|Posterior-stabilized(PS) insert will be used in total knee arthroplasty.
89683574|NCT01279577|Experimental|Low dose TSO|Low dose suspension of TSO
89683575|NCT01279577|Experimental|Medium dose TSO|Medium dose suspension of TSO
89683576|NCT01279577|Experimental|High dose TSO|High dose suspension of TSO
89683577|NCT01279577|Placebo Comparator|Placebo|Placebo solution
89683578|NCT01275599|Experimental|Open-Label Arm|"The treatment period will include 3 phases:~14 day run-in period~7 day co-administration period~31 day follow-up period"
88997469|NCT02963142||SCAP requiring ITU support|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require intensive care support and undergo a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
88997470|NCT02963142||Healthy controls|"Healthy volunteers who undergo bronchoscopy as part of a designated research bronchoscopy list.~Molecular laboratory techniques will be applied to bronchoalveolar lavage samples."
88997471|NCT00185367|Experimental|Arm 1|
88997472|NCT00185367|Active Comparator|Arm 2|
88997473|NCT04663633|Experimental|Core stability training|"The EG performed an 8-week core stability training, consisting in 30 min of core stability and plyometric exercises 3 days per week, 24 sessions in total.~The CST sessions were conducted in a gym suitable for RG practise and the safety of the participants will be maintained. The equipment necessary for the training was provided to the participants.~The coaches are RG professionals with national coach level in RG and volunteered to lead the specific CST designed by a RG national coach and an expert core stability physiotherapist.~Before each session EG and CG performed a 15 min warm up. The load of the session was calculated by the RPE (rate of perceived exertion). And was modulated in order to maintain 7-8 intensity."
88997474|NCT04663633|No Intervention|Traditional RG training|The CG performed the traditional training while the EG carried out the CST. The training load was calculated to be 7-8 RPE in order that both groups (EG and CG) undergo an equivalent intensity and training load.
88997475|NCT00407069||Active Atopic Dermatitis (AD)|Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
89683579|NCT01279655|Experimental|tDCS and training|Transcranial Direct current stimulation (tDCS) is applied together with a bimanual learning task. tDCS is delivered through two gel-sponge electrodes (eldith DC Stimulator, neuroConn GmbH, Ilmenau, Germany) embedded in a saline-soaked solution. tDCS will be applied for 20 min, with a current intensity of 1mA.
88997476|NCT00407069||Inactive Atopic Dermatitis (AD)|Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
88997477|NCT00407069||Psoriatics|Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
88997478|NCT00407069||Asthmatics (without a history of AD)|Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
88997479|NCT00407069||Eczema Herpeticum (EH|Pediatric and adult AD subjects with a history of EH.
88997480|NCT00407069||Healthy Volunteers|Healthy individuals with no history of skin or respiratory disease.
88997481|NCT04652089|Experimental|Experimental arm: Simvastatin|Simvastatin 20mg capsule once a day for 7 days
88997482|NCT04652089|Placebo Comparator|Control arm: Placebo|Placebo capsule once a day for 7 days
88997483|NCT00552721|Experimental|A|Physical therapy with strength training.
88997484|NCT00552721|Active Comparator|B|Physical therapy without strength training.
88997485|NCT04684303|Experimental|Lumbar medial branch RF neurotomy|Procedure lumbar medial branch RF neurotomy By raising the temperature of the tip of the electrode to 85 C for 120 seconds. RF generator. Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be > 4 )
88997486|NCT04684303|Experimental|Lumbar medial branch cryoablation|"Procedure lumbar medial branch cryoablation Decreasing the temperature of the electrode to - 85 C for 120 seconds in two cycles.~Follow-up: before procedure, 3 months, 6 months, 12 months and 24 months after procedure Repeated cryoablation ablation procedures is allowed (when VAS will be =/> 4 )"
88997487|NCT04609306|Experimental|Subjects getting 3% H2O2 applied to the incision|For the experimental cohort, a lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes. Following the 3 minutes, the sponge will be removed, the wound will be flushed with 100 mL of normal saline, and the exposed dermis will be swabbed and sent for culture.
88997488|NCT04609306|No Intervention|Subjects not getting 3% H2O2 applied to the incision|In the control cohort, the dermis will be swabbed and sent for culture immediately after the skin incision is made and the knife is removed from the field.
88997489|NCT00407147|No Intervention|Control|Standard treatment
88997490|NCT00407147|Experimental|PCT|PCT guided arm
88997491|NCT04597879||Severe traumatic brain injury|
88997492|NCT04597879||Severe trauma without brain trauma|
88997493|NCT04597879||Healthy controls|
88997494|NCT04710680||group A|
89683580|NCT01279655|No Intervention|Control|No intervention is applied
89683581|NCT01279655|Placebo Comparator|Sham tDCS + Training|The training consists of a bimanual training task. tDCS is only applied for a few seconds and will than be ramped-down.
89683582|NCT00782821|Active Comparator|Rabbit Antithymocyte Globulin (rATG)|Rabbit Antithymocyte Globulin (rATG) 1.5mg/kg per dose x 6 doses rATG was administered on post-op day 0, 2, 4, 6, 8 and 10.
88997495|NCT04710680||group I|
88997496|NCT04684498|Experimental|Tamiflu (Oseltamivir Phosphate Capsules)|Standardized STEMI treatment + oseltamivir phosphate capsule (75mg, 2 times/day, 7days, oral)
88997497|NCT04684498|Other|no intervention|Standardized STEMI treatment + no intervention
88997498|NCT04541602||Dysphagia-positive|"critically ill patients more than 17 years of age~matching study inclusion criteria~confirmed newly acquired swallowing dysfunction using FEES at study day 10 or later~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
88997499|NCT04541602||Dysphagia-negative|"critically ill patients more than 17 years of age~matching study inclusion criteria~newly acquired swallowing dysfunction ruled out using FEES at study day 10 or later~ICU-AW positive (MRC-ss <48) or ICU-AW negative (MRC-ss ≥48)"
88997500|NCT04541602||Controls|"healthy volunteers without any neuromuscular disease~swallowing dysfunction ruled out using FEES"
88997501|NCT00552799|Experimental|1|Penicillin VK 250 mg b.d.
88997502|NCT00552799|Placebo Comparator|2|placebo tablet b.d.
88997503|NCT00409071|Experimental|1|cocculine
88997504|NCT00409071|Placebo Comparator|2|placebo
88997505|NCT04524325|Active Comparator|Trans men|transgender men taking physiologic doses of testosterone for gender affirming hormone therapy
88997506|NCT04524325|No Intervention|control|cisgender women not receiving testosterone and with normal sex hormone levels
88997507|NCT00162305|Active Comparator|1|
88997508|NCT00162305|Active Comparator|2|
88997509|NCT00162305|Active Comparator|3|
88997510|NCT00162305|Placebo Comparator|4|
88997511|NCT04395625|Experimental|Group 1|Patients had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding.
88997512|NCT04395625|Experimental|Group 2|Patients had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
88997513|NCT00409149|Experimental|CALM BP|dietary approach, education on cooking and food consumption choices, walking physical exercise, Qi Gong - a form of Chinese slow movement exercise combined with relaxation breathing and imagery and group therapy coaching in stress management techniques and mind-body balancing techniques.
88997514|NCT00409149|Active Comparator|DASH|standard dietary DASH approach in hypertensive patients
88997515|NCT00162383|Experimental|Cocktail|
88997516|NCT04683874|Experimental|3D printed tray|3D printed tray
88997517|NCT00192270|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|All subjects were scheduled to receive 2 doses of CAIV-T.The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
88997518|NCT04355143|Experimental|Colchicine plus current care|Colchicine 0.6 mg po BID x 30 days plus current care per UCLA treating physicians
88997519|NCT04355143|Active Comparator|Current care alone|Current care per UCLA physicians alone (control arm)
88997520|NCT00185445|Experimental|Arm 1|
88997521|NCT00552838|No Intervention|A|Physicians in this arm did not have any intervention with the AUT. Antimicrobial prescriptions were based on hospital guidelines or on the physician's medical knowledge.
88997522|NCT00192309|Experimental|Cold-adapted influenza vaccine (CAIVT)|A single intranasal dose of 10^7 fluorescent focus units.
88997523|NCT00192309|Active Comparator|Trivalent inactivated vaccine (TIV)|A single dose of commercially available Flushield was administered intramuscularly.
88997524|NCT00192309|Placebo Comparator|Placebo|The 0.2 mL administered intranasally.
88997525|NCT04297111|Placebo Comparator|Placebo|Maltodextrin containing capsule
88997526|NCT04297111|Experimental|Probiotic|Probiotic containing capsule
88997527|NCT00552877|Active Comparator|1|Cypher Select plus stent
88997528|NCT00552877|Active Comparator|2|Xience V stent
88997529|NCT04233034|Active Comparator|HCL and placebo|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or a Medtronic HCL system (Medtronic 670G 4.0 AHCL (prior to protocol version 5.0) or Medtronic 780G (starting with protocol version 5.0)). This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
88997530|NCT04233034|Active Comparator|HCL and verapamil|"Participants assigned to HCL group will initially be randomly assigned 1:1 to use either the Tandem t:slim X2 with Control-IQ technology or a Medtronic HCL system (Medtronic 670G 4.0 AHCL (prior to protocol version 5.0) or Medtronic 780G (starting with protocol version 5.0)). This group will receive intensive diabetes management with frequent contacts by study staff with the goal of near-normalization of glucose concentrations.~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
89052331|NCT00574977|Experimental|B|Subjects will include those who have not been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection.
89683583|NCT00782821|Experimental|RATG/Rituxan|Rabbit Antithymocyte Globulin (rATG)/Rituxan 1.5mg/kg per dose x 5 doses of rATG. 375mg/m2 x 1 dose of rituxan. rATG was administered on post-op day 0, 2, 4, 6 and 8. Rituxan was given on post-op day 1.
89683584|NCT00782821|Experimental|RATG/Velcade|Rabbit Antithymocyte Globulin (rATG) /Velcade 1.5mg/kg per dose x 5 doses of rATG. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10.
89683585|NCT00782821|Experimental|RATG/Rituxan/Velcade|"Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade 1.5mg/kg per dose x 4 doses of rATG. 200mg/m2 for 1 dose of rituxan. 1.3mg/m2 per dose x 4 doses of velcade.~rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10. Rituxan was given on post-op day 1."
89683586|NCT00743093|Experimental|acetaminophen|acetaminophen, 4 grams/day (1 gram every 4 hours for 4 doses)
89683587|NCT00743093|Placebo Comparator|placebo|placebo for acetaminophen 4 grams/day (2 caplets every 4 hours for 4 doses)
89683588|NCT03805945|Experimental|dexmedetomidine group|After umbilical cord was cut, a loading dose of dexmedetomidine was pumped at 0.5ug/kg within 10min, followed by a further infusion of dexmedetomidine at 0.5ug /kg/h until the end of the surgery.Then connected with patient-controlled intravenous analgesia pump (dexmedetomidine 2ug/kg + sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
89683589|NCT03805945|Placebo Comparator|control group|Continuous infusion of saline after the umbilical cord was cut until the end of the operation.Then connected with patient-controlled intravenous analgesia pump (sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
89683590|NCT02992301|Experimental|Open Label|All enrolled patients will receive open label Praluent (Alirocumab).
89683591|NCT00743717|Experimental|1|
89683592|NCT00743717|Active Comparator|2|
89683593|NCT00744965|Active Comparator|Glyburide|Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
89683594|NCT00744965|Placebo Comparator|Placebo|Women with mild gestational diabetes will be started ADA diet and placebo.
89683595|NCT04385225|Other|Healthy controls|Age-matched controls with normal hearing or mild sensorineural hearing loss: 40 decibel or less in better hearing ear, and normal vestibular function
89683596|NCT04385225|Other|Moderate Sensorineural hearing loss|Moderate Sensorineural hearing loss: 41-60 decibel in the better hearing ear
89683597|NCT04385225|Other|Severe Sensorineural hearing loss|Severe Sensorineural hearing loss: 61-80 decibel in the better hearing ear
89683598|NCT04385225|Other|Bilateral Vestibulopathy|Bilateral vestibulopathy: half with normal hearing, half with severe to profound sensorineural hearing loss
89683599|NCT04385225|Other|Mild Cognitive Impairment|Mild Cognitive Impairment
89683600|NCT04385225|Other|Alzheimer's Disease|Alzheimer's Disease
89683601|NCT00763867|Placebo Comparator|Placebo|Placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
89683602|NCT00763867|Experimental|Sildenafil|Sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
89683603|NCT00749879|Experimental|25 mg AMCC fed|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose~Fed State"
89683604|NCT00749879|Experimental|25 mg AMCC fasting|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose~Fasting State"
89683605|NCT00749879|Experimental|50 mg AMCC fed|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose~Fed State"
89683606|NCT00749879|Experimental|50 mg AMCC fasting|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose~Fasting State"
89683607|NCT00749879|Experimental|50 mg SMCC fasting|"2, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose~Fasting State"
89683608|NCT04385147||ERCP|Patients who will have endoscopic retrograde cholangiopancreatography
89683609|NCT04385147||EUS|Patients who will have endoscopic ultrasound
89683610|NCT00711347|Active Comparator|DisCoVisc|Alcon's DisCoVisc Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
89683611|NCT00711347|Active Comparator|Healon5|Abbott Medical Optic's (AMO) Healon5 Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
89683612|NCT01276223|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week to allow for tapering of the steroid exposure.
89683613|NCT01276223|Placebo Comparator|Vehicle|Difluprednate vehicle, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week.
89683614|NCT01275833|Experimental|Device programming modifies AV timing|DDD-40-BiV
89683615|NCT01275833|No Intervention|Device programming allows intrinsic AV timing.|VVI-40-RV
89683616|NCT01279733||Microarray Analysis|
89683617|NCT01275755|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally every day (QD) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
89052332|NCT00574977|Experimental|C|Subjects will be those who have been vaccinated with vaccinia virus (small pox)and will be receiving the vvCD-CDSR via intravenous infusion
89052333|NCT04595708|Experimental|Intervention - Calls|Participants randomized to the intervention will receive a call of between 5 - 10 minutes in length each by a consistent caller, five times a week, Monday through Friday for 4 consecutive weeks to check in on them. After the first week of calls, subjects in the intervention arm will be asked if the frequency of calls is acceptable or if they would like to reduce the call frequency, potentially to a minimum of twice per week.
89052334|NCT04595708|No Intervention|Control - No calls|Participants randomized to a control group will not receive the intervention calls. The control group will receive calls from a member of the research team at the beginning of the study to collect baseline survey data and at the post-4-week period to collect post-study survey data.
89052335|NCT03453606|Active Comparator|home group|
89052336|NCT03453606|Active Comparator|center group|
89052337|NCT04595669|Experimental|Personalised advice|
89052338|NCT04595552|Experimental|Study group|Children with cochlear implant were given Auditory training and language therapy
89216403|NCT03896724|Experimental|Group 2|"n=150. Age 5-17 month-old. 5mcg R21/50mcg Matrix-M at Day 0, 28 and 56 and 1 year.~Following the initial booster, Group 2 will be randomised 2:1 into Groups 2a and 2b or 5ug R21/50ug Matrix-M:ccontrol. Groups 2a and 2b will receive these second and third booster vaccinations each year prior to the malaria season"
89216404|NCT03896724|Placebo Comparator|Group 3 (control group)|n=150. Age 5-17 month-old. Rabies Vaccine by the end of the trial.
89216405|NCT03894202||Ultra-early aneurysm treatment|Ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping within the initial twenty-four hours.
89216406|NCT03894202||Non-ultra-early aneurysm treatment|Non-ultra-early aneurysm treatment is defined as definitive cerebral aneurysm treatment such as coiling or clipping after the initial twenty-four hours.
89216407|NCT03884049|Experimental|Embolization group|Group undergoes transcatheter arterial embolization of neovessels around the knee.
89683618|NCT01275755|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally QD for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-milligrams (mg) ADL5945 capsule orally QD for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally QD for 1 week.
89683619|NCT00784225|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
89683620|NCT00784225|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
89683621|NCT00784225|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
89683622|NCT00784225|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamin E placebo and selenium placebo daily for 7-12 years
89683623|NCT02991989|Experimental|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening. They will also be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers.
89683624|NCT02991989|Other|Yogurt Only Group|For 28 days, this group will be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers. Apart from consuming the yogurt, this group will be asked to continue their normal lifestyle.
89683625|NCT02992145||Case group: This group will include forty (40) preeclampt|
89683626|NCT02992145||Control group: This group will include forty (40) normoten|
89683627|NCT02991911|Experimental|Arm A|MEDI3726 Post-Chemo
89683628|NCT02991911|Experimental|Arm B|MEDI3726 Pre-Chemo
89683629|NCT02991911|Experimental|Arm C|MEDI3726 & Enzalutamide Combo
89683630|NCT01275131|Active Comparator|Stage 1: Insulin aspart first, then insulin aspart-rHuPH20|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
89683631|NCT01275131|Active Comparator|Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
89683632|NCT01275131|Active Comparator|Stage 3: Insulin aspart first, then insulin aspart + rHuPH20|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp.~After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp."
89683633|NCT01275131|Active Comparator|Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp .~After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp."
89683634|NCT00749957|Experimental|1|Subjects at least 6 y/o treated with a lower dose of the vector by subretinal injection
89683635|NCT00749957|Experimental|2|Subjects at least 6 y/o treated with a higher dose of the vector by subretinal injection
89683636|NCT01274429|Experimental|Open label peanut flour|Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.
89683637|NCT04272671|Experimental|Educational Intervention Arm|The intervention arm will receive educational material that enhances the standard of care for deprescribing opioids and BZDs.
89683638|NCT04272671|No Intervention|Ususal Care (Control Arm)|Control group will receive standard of care
89683639|NCT01273883|Experimental|Magnesium first, then placebo|Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.
89216408|NCT03884049|Sham Comparator|Sham Embolization Group|Group undergoes sham embolization
89216409|NCT03880838|No Intervention|No contact control|Participants are not contacted.
89216410|NCT03880838|Experimental|Letter|Participants are only contacted through a letter with a personal testimonial.
89216411|NCT03880838|Experimental|Link and no nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and no nudges.
88997531|NCT04233034|Active Comparator|non-HCL and verapamil|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.~Verapamil will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
88997532|NCT04233034|Placebo Comparator|non-HCL and placebo|"Participants assigned to non-HCL will receive a Dexcom G6 CGM and diabetes management will follow usual care by their personal diabetes health care provider.~Placebo will be taken orally once per day by participants in Cohort A. A dosing scheme will be followed, using 120mg tablets or 60mg half tablets.~Whether drug is active or placebo is blinded to both participant and site.~[Cohort B participants will not receive study drug. Instead, they will be randomized 2:1 to HCL or non-HCL.]"
88997533|NCT00552916|Other|1|Participants will be randomized to either an intervention arm where they will receive 'true' FES and the other control arm where they will receive 'false' FES. The sham group will receive 'false' FES.
88997534|NCT00552916|Other|2|The intervention group will receive 'true' FES
88997535|NCT00185484|Experimental|Arm 1|
88997536|NCT04218721|Experimental|eHealth application|Participants get access to the eHealth application InvolveMe
88997537|NCT04710290|Experimental|Solid beverage powder|Whey portein solid beverage powder use 1 pack for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
88997538|NCT04710290|Experimental|Capsule|Capsules use 1 cap for every 10 kg of body weight.A total of 6 cap under 60 kg a day, an extra 1cap for each additional 10 kg over 60 kg. Use from the 7th day of the 2nd course of treatment for 5 months.
88997539|NCT04710290|Placebo Comparator|Placebo|placebo use 1 powder for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
88997540|NCT00185523||CML in first Chronic Phase or Accelerated Phase|Busulfan/cyclophosphamide Day -7: Busulfan 1.0 mg/kg IV q6 hrs** Day -6: Busulfan 1.0 mg/kg IV q6 hrs Day -5: Busulfan 1.0 mg/kg IV q6 hrs Day -4: Busulfan 1.0 mg/kg IV q6 hrs Day -3: Cyclophosphamide 60 mg/kg Day -2: Cyclophosphamide 60 mg/kg Day -1: rest Day 0: Allogeneic PBSC infusion
88997541|NCT00185523||AML and ALL in first or second remission|FTBI/VP-16 Day -7: FTBI 120 cGy x 3 fractions Day -6: FTBI 120 cGy x 2 fractions Day -5: FTBI 120 cGy x 3 fractions Day -4: FTBI 120 cGy x 3 fractions* Day -3: VP-16 at 60 mg/kg Day -2: rest Day -1: rest Day 0: Allogeneic PBSC infusion
88997542|NCT00162461|Experimental|Phenytoin|
88997543|NCT04167124|Experimental|multi-sensor lifestyle intervention|
88997544|NCT04684030|Experimental|CGMS group|Using continuous glucose monitoring system(CGMS) group
89683640|NCT01273883|Placebo Comparator|Placebo first, then magnesium|Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.
89683641|NCT01273805|Experimental|Hydroxychloroquine 400 mg b.i.d.|Patients received 400 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
88997545|NCT04684030|Active Comparator|SMBG group|Self-monitoring of blood glucose group (conventional fingerpricking method)
89683642|NCT01273805|Experimental|Hydroxychloroquine 600 mg b.i.d.|Patients received 600 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
89683643|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
89683644|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
89683645|NCT01273181|Experimental|Ph II:Anti-MAGE TCR PBL MTD+HD IL-2|"Phase II:Anti-MAGE A3/12 TCR PBL MTD + HD IL-2, Melanoma, RCC~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
88997546|NCT04114864|Experimental|Experimental|This arm will be receiving the 7 ME-WE sessions psycho-educational intervention. The experimental group will involve a blended approach with 'face to face' meetings in three European partner countries and online sessions (via a ME-WE mobile app) and a purely 'f2f' approach in a further three European partner countries.
89683646|NCT01273181|Experimental|Ph II:Anti-MAGE A3/12 TCR PBL MTD|"Phase II: Anti-MAGE A3/12 TCR PBL MTD + HD-IL2 Other Cancer~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
89683647|NCT01272947|Experimental|Diclofenac sodium topical gel 1%|
89683648|NCT01272947|Placebo Comparator|placebo|
89683649|NCT01279343|Experimental|Foley Bulb plus Misoprostol|
89683650|NCT01279343|No Intervention|Misoprostol|
89683651|NCT03830645|Experimental|Platelet rich plasma group|
89683652|NCT02991833|Experimental|Of A New Incontinence Care Product|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product ( the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
89683653|NCT02991833|Active Comparator|Diaper|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product (diaper ) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
89683654|NCT01278797|Active Comparator|Telmisartan/Amlodipine Fixed Dose|Telmisartan/Amlodipine medium fixed dose combination tablet once daily.
89683655|NCT01278797|Active Comparator|Amlodipine Monocomponent|Amlodipine Monocomponent 10mg tablet once daily
89683656|NCT04277273|Other|Patients treated in the MaxilloFacial Prosthesis consultation|Patients treated in the MaxilloFacial Prosthesis consultation (Dental Department, Pitié-Salpêtrière Hospital Group)
89683657|NCT01272869|Active Comparator|Sensura|SenSura is the reference product and the product is already commercially available
89683658|NCT01272869|Experimental|Morfeus|The test product is the product with the proposed new filter (Morfeus)
89683659|NCT01272635|Experimental|Azythromycin (APRIL) and Prednisolone (OCELOT)|
89683660|NCT01272635|Experimental|Azythromycin (APRIL) and Placebo (OCELOT)|
89683661|NCT01272635|Experimental|Placebo (APRIL) and Prednisolone (OCELOT)|
89683662|NCT01272635|Placebo Comparator|Placebo (APRIL) and Placebo (OCELOT)|
89683663|NCT01272011|Experimental|Phase 1 Arm (Pilot)|Individuals were exposed to intermittent hypoxia and locomotor training to establish our interventions (set up lab, train personnel, develop study protocols/interventions, etc)
89683664|NCT01272011|Experimental|Phase 2 Arm (LTF)|Individuals were exposed to 10 days of intermittent hypoxia to determine the effect of this intervention on ventilatory long-term facilitation, as measured by minute ventilation
88997547|NCT04114864|Placebo Comparator|Control|The control-group will be a wait-list, receiving relaxation exercises during waiting.
88997548|NCT00185601|Other|on-line self management intervention|
88997549|NCT00185601|No Intervention|usual care control group|
88997550|NCT00185601|Experimental|on-line self management intervention with email reinforcement|
88997551|NCT00162656|Active Comparator|Standard LMB B|
88997552|NCT00162656|Experimental|LMB B without COPADM3|
89683665|NCT01272011|Other|Phase 3 Arm (Ventilatory Loading)|Individuals were exposed to 10 days of intermittent hypoxia to determine changes in ventilatory loading.
89683666|NCT00750191|Active Comparator|Intradiscal Biacuplasty|"On the day of the procedure, patients were given midazolam for relaxation and, if needed, fentanyl IV during the procedure. For treatment subjects, two TransDiscal probes were positioned under fluoroscopic guidance in the posterior annulus of the intervertebral disc. The probes were attached to the Radiofrequency generator and Radiofrequency energy was delivered. Placement of the probes within the disc annulus was confirmed using oblique, lateral, and anterior-posterior fluoroscopic images.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure."
88997553|NCT00162656|Experimental|LMB B with half cyclophosphamide|
88997554|NCT00162656|Experimental|LMB B without COPADM3 and with half cyclophosphamide|
88997555|NCT00162656|Active Comparator|LMB C standard|
88997556|NCT00162656|Experimental|LMB C with mini CYVE and without 3 maintenance courses|
88997557|NCT00185757|Experimental|Cytokine-induced Killer Cells|The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.
88997558|NCT00192465|Experimental|1|MEDI-524 (Numax-TM)
88997559|NCT00192465|Experimental|2|MEDI-524 (Numax-TM)
88997560|NCT00192465|Experimental|3|MEDI-524 (Numax-TM)
88997561|NCT00192465|Experimental|4|MEDI-524 (Numax-TM)
88997562|NCT00192465|Experimental|5|MEDI-524 (Numax-TM)
88997563|NCT00185796|Experimental|TLI/ATG conditioning|Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).
88997564|NCT00162890||Patient with degenerative cervical disease|
88997565|NCT04025749|Experimental|Immediate intervention group|Thirty children with CP aged 8 to 12 years (or fifteen with neuroimage data) will participate in a computerized executive training program from home (12 weeks, 5 days a week, 30 min a day).
89052339|NCT03453450||Health TAPESTRY volunteers|Volunteers in a primary care setting connecting with Health TAPESTRY clients
89052340|NCT03453450||Health TAPESTRY Volunteer Coordinators|The coordinators of volunteers
89052341|NCT03453411||Non interventional study|
89052342|NCT04595318|Active Comparator|Standard clinical care|Four weeks of medication-assisted treatment (MAT) with standard clinical care (SCC). MAT includes individual counseling that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance abuse counselors.
89683667|NCT00750191|Placebo Comparator|Sham|"Sham procedures mimicked active treatment procedures, except that the probes were positioned just outside of the disc and no radiofrequency energy was delivered through the electrodes. Thus, sham patients were provided similar tactile, auditory and visual experiences as treatment patients, without receiving the active RF treatment.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure.~The study will be unblinded at 6 months. If the patients in the IDB group show significant improvement compared to placebo they will be offered IDB."
89683668|NCT04387097||gradual withdrawal following by drip-infusion of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated. Following by drip-infusion of remifentanil for 30 minutes was administered immediately after tracheal extubation.
89683669|NCT04387097||gradual withdrawal of remifentanil|In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated.
89683670|NCT01270841|Placebo Comparator|Placebo|Placebo
89683671|NCT01270841|Active Comparator|Testim (topical testosterone)|Testim (topical testosterone)
89683672|NCT01270841|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
89683673|NCT01270841|Experimental|Androxal 25 mg|Androxal 25 mg/day
89683674|NCT04345523|Experimental|Treatment Arm|Pathogen-reduced CP from patients recovered from COVID-19, whom, for the purpose of this trial, are herein designated as donors.
89683675|NCT04345523|Active Comparator|Control Arm|Standard of Care (SOC) for COVID-19
89683676|NCT01270139|Experimental|Nano group|60 patients in Nano group were treated with transplantation of nanoparticles (NP), particularly with a bioengineered patch that was grown with allogenous stem cells pre-cultivated in the medium with NP. After the admission, patients were examined with QCA, and allocated to the trial. The implantation of the patch onto the artery was undergone by the minimally invasive cardiac surgery (MICS CABG) with fixation of the graft to the epicardial myocardium. MICS CABG implies a beating-heart multi-vessel heart surgery performed through several small incisions under direct vision through an anterolateral mini-thoracotomy in the 4th-6th intercostal spaces. The patients can expect high quality of life resuming all everyday activities within a few weeks of their operation. NP were activated with NIR laser at 7 days after the intervention. Patients were treated with bolus of bivalirudin on the day of NP detonation.
89683677|NCT01270139|Active Comparator|Ferro group|60 patients in Ferro group were managed with transplantation of iron-bearing nanoparticles (NP), particularly with intracoronary infusion of allogenous stem cells or CD68 targeted micro-bubbles pre-cultivated in the medium with iron-bearing NP. Cells and/ or micro-bubbles were infused with QCA- and IVUS-guidance to the target coronary artery via micro-catheter on the day of admission. The destruction of CD68 targeted micro-bubbles was obtained by using a Sonos 5500 machine with an S3 transducer operating in ultraharmonic mode (transmit, 1.3MHz/ receive, 3.6 MHz) with a mechanical index of 1.5 and a depth of 4 cm. The AXIOM Artis dBC (Siemens) magnetic navigation system was used for precise delivery of NP to the atheroma through two permanent computer-controlled external magnets generating a navigational magnetic field of 0.08 Tesla in any direction. NP were detonated with NIR laser under the protection of anti-platelet therapy.
89683678|NCT01270139|Other|Stenting control|In case of control group (stenting control), XIENCE V stent was implanted to 60 patients. Patients with a single de novo native coronary stenosis of less than 12 mm lesion length, more than 50% stenosis and reference diameter of 3.0 mm as assessed by online QCA were stented by a single stent of 3.0 x 18 mm. The procedure of implantation had to be performed according to common interventional practices including the administration of intracoronary nitroglycerine 0.2 mg of glycerol trinitrate or isosorbide dinitrate and intra-arterial heparin (50-100 U/kg body weight). Predilation with a conventional balloon catheter was recommended before DES deployment according to the manufacturer's recommendation. The protocol recommended the study stent should cover 2 mm of non-diseased tissue on either side of the target lesion. Postdilatation was allowed with a balloon that was shorter than was the study device.
89683679|NCT01278407|Placebo Comparator|Placebo - Confirmatory Phase|Participants received donepezil matched placebo tablets orally, once daily for 12 weeks in the confirmatory phase.
89683680|NCT01278407|Experimental|Donepezil 5 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.
89683681|NCT01278407|Experimental|Donepezil 10 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.
89052343|NCT04595318|Active Comparator|Standard clinical care and varenicline|Four weeks of MAT with standard clinical care plus varenicline therapy (SCC and VT). Varenicline therapy included a one-month supply of standard doses: 0.5mg for the first three days, 0.5mg twice a day for the following four days, and 1 mg twice a day for the remaining 21 days. MAT includes individual counseling that uses motivational and cognitive behavioral strategies, may address cannabis or tobacco use, and is delivered by trained substance abuse counselors.
89052344|NCT03453333|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
89052345|NCT03453333|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
89052346|NCT00566423|Experimental|1|Patients with Pulmonary Arterial Hypertension
89216412|NCT03880838|Experimental|Link and commitment nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a commitment nudge.
89216413|NCT03880838|Experimental|Link and prevention nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a prevention nudge.
89683682|NCT01278407|Experimental|Placebo to Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
89683683|NCT01278407|Experimental|Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
89683684|NCT01278173|Other|Sabril|
89683685|NCT00784303|Experimental|DTC cohort|This arm will enroll participants with radioiodine (131 I)-refractory/resistant differentiated thyroid cancer.
89683686|NCT00784303|Experimental|MTC cohort|This arm will enroll participants with medullary thyroid cancer.
89683687|NCT00750815|Experimental|A. Phase I - Dose Escalation|"Dose of Cyclophosphamide to depend on how many patients we treated:~Dose Level 1: Cyclophosphamide 250 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 2: Cyclophosphamide 500 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 3: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 4: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.3 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12"
89683688|NCT00750815|Experimental|B. Phase II - Maximum Planned Dose (MPD)|Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.
89683689|NCT00784849|Experimental|1|One arm diagnostic
89683690|NCT04386707|Experimental|Experimental Vaccine-lot 1|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
89683691|NCT04386707|Experimental|Experimental Vaccine-lot 2|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
89683692|NCT04386707|Experimental|Experimental Vaccine-lot 3|sIPV manufactured by Sinovac Biotech Co., Ltd at commercial scale.
89683693|NCT04386707|Active Comparator|Control Vaccine|Wild strain IPV (wIPV）manufactured by Sanofi Pasteur S.A.
89683694|NCT01277861|Active Comparator|FENTANYL|FENTANYL
89683695|NCT01277861|Placebo Comparator|SALINE|SALINE
89683696|NCT00786487|Experimental|lipid trained|20% lipid infusion in trained subjects
89683697|NCT00786487|Active Comparator|glycerol trained|glycerol infusion into trained subjects
89683698|NCT00786487|Experimental|lipid untrained|lipid infusion into untrained subjects
89683699|NCT00786487|Active Comparator|glycerol untrained|glycerol infusion into untrained subjects
89683700|NCT02991443|Experimental|Mindfulness based stress reduction|Parents of children with IBD will undergo mindfulness based stress reduction (MBSR) intervention consisted of 8 group sessions. The effect on stress and anxiety will be assessed using 3 validated questionnaires which will be filled prior to intervention, at the end of intervention and 3 months following intervention.
89216414|NCT03880838|Experimental|Link and both nudges|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and both commitment and prevention nudges.
89683701|NCT01277549||Non-mobilized donors|In this arm the collection efficiency of mononuclear cells from non-mobilized donors will be studied.
89683702|NCT01277549||G-CSF mobilized donors|In this arm the collection efficiency of CD34+ cells will be studied.
89683703|NCT01274455|Experimental|Therapy|
89683704|NCT03805633||Sarcoidosis Patients|Patients referred to UAB Pulmonology who are diagnosed with sarcoidosis.
89683705|NCT03805633||Diabetes Patients|Patients followed by UAB Endocrinology with diabetes mellitus.
89216415|NCT03880838|Experimental|DVD and no nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and no behavioral nudges.
89683706|NCT03805633||Sarcoidosis and Diabetes patients|Patients followed by UAB Pulmonary and/or UAB Endocrinology with both sarcoidosis and diabetes mellitus.
89683707|NCT01274767||High risk cohort|Patients having history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have a negative test for H. pylori based on histology
89683708|NCT01274767||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
89683709|NCT01274845|Other|Heliox|
89683710|NCT01276847|Experimental|Ustekinumab|
89683711|NCT01276847|Active Comparator|Etanercept|
89683712|NCT01276847|No Intervention|No treatment|
89683713|NCT03830879||No treatment|This cohort study have any no treatment.
89683714|NCT03805555|Active Comparator|Radiofrequency ablation|Best radiofrequency ablation
89683715|NCT03805555|Experimental|Cryoballoon ablation|Best cryoballoon ablation
89216416|NCT03880838|Experimental|DVD and commitment nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a commitment nudge.
89216417|NCT03880838|Experimental|DVD and prevention nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a prevention nudge.
89683716|NCT00945269|Experimental|Treatment (cellular adoptive immunotherapy)|Patients receive autologous T-cell IV over 30-60 minutes on days 0 and 28 and low-dose aldesleukin SC twice daily on days 0 to 13 and 28 to 41. Beginning 4-6 days before second T-cell infusion, patients receive denileukin diftitox IV over 30 minutes on days 1-3.
89683717|NCT00765193|Other|Skin cancer screening|
89683718|NCT02991287||Chronic post-surgical pain patients|Patients scheduled for differents types of surgery (inguinal, hernia repair, abdominal hysterectomy, vaginal hysterectomy, and thoracotomy).
89683719|NCT01272791|Experimental|Gemcitabine, bavituximab|Gemcitabine will be administered on Days 1, 8, 15 of each 28-day (4 weeks) cycle until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will receive 3 mg/kg weekly (in addition to gemcitabine) until disease progression or unacceptable toxicities
89683720|NCT01272791|Active Comparator|Gemcitabine|Patients randomized to Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities.
89683721|NCT00765661|Experimental|LCP-Tacro|The initial dose starting at 0.14 mg/kg (the starting daily dose for African-American patients was 0.17 mg/kg), will be administered orally in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
89683722|NCT00765661|Active Comparator|Prograf (tacrolimus)|"Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
89683723|NCT01274923|Sham Comparator|shock wave treatment|
89683724|NCT01274923|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
89683725|NCT00765895|Active Comparator|Nortriptyline|Nortriptyline Hydrochloride dose escalation from 10 mg to 75 mg
89683726|NCT00765895|Placebo Comparator|Placebo (for nortriptyline)|No treatment
89683727|NCT03805087|Experimental|Coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
89683728|NCT05743309|Experimental|Telemedicine Practices|In this study, telemedicine practices stand for video call sessions used for contraceptive counseling services.
89683729|NCT05743309|No Intervention|Routine Contraceptive Counseling Services|Participants in the control group received only routine contraceptive counseling services provided by primary health care settings.
89683730|NCT01275157|Experimental|LY2452473|15 mg, containing 100 micro curies of 14C labeled LY2452473 taken once only
89683731|NCT05743231|Active Comparator|interpectoral area block + serratus anterior area block group (IPSA)|Interpectoral plane block + serratus anterior plane block will be performed randomly on the participants.
89683732|NCT05743231|Active Comparator|erector spinae group (ES)|Erector spinae block will be performed randomly on the participants
89683733|NCT01276457|Experimental|Upper everolimus blood target + very low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 8-12 ng/mL. Patients also received a very low dose of cyclosporine (150-300 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 200 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
89683734|NCT01276457|Active Comparator|Standard everolimus blood target + low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 3-8 ng/mL. Patients also received a low dose of cyclosporine (350-500 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 400 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
89683735|NCT03804931|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation
89683736|NCT03804931|Sham Comparator|placebo fecal microbiota transplantation|Infusion of Saline
89683737|NCT03804931|Other|Traditional treatments|Drug:5-Aminosalicylic acid(5-ASA) and/or Prednisone
89683738|NCT02991131||Tedizolid|Hospitalized ABSSSI patients treated with tedizolid
89683739|NCT02991131||Linezolid|Hospitalized ABSSSI patients treated with linezolid
89683740|NCT00748865|Experimental|Systane Ultra|Systane Ultra 1 drop each eye one time
89683741|NCT00748865|Active Comparator|Systane|Systane 1 drop each eye one time
89683742|NCT00766753|Experimental|Single|All consenting, eligible subjects receive the intervention
89683743|NCT03804775||case group|patients presenting with gallstone disease
89683744|NCT03804775||control group|inpatients with no history of gallstones
89683745|NCT03804697|Experimental|selective anticoagulation group|"Selective anticoagulation group used anticoagulant when thromboelastogram（TEG） indicated hypercoagulability.~TEG was performed 1 day before the surgery, 1 day after the surgery, 3 days after the surgery, and 5 days after the surgery.~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
89683746|NCT03804697|Active Comparator|conventional anticoagulation group|"The Intervention for conventional anticoagulation group was using anticoagulant until one month after surgery routinely.~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
89683747|NCT00767767|Placebo Comparator|Placebos|Saline Infusion
89683748|NCT00767767|Active Comparator|Propofol 0.45mcg/mL|Anesthetic Drug Infusion
89683749|NCT00767767|Active Comparator|Propofol 0.90mcg/mL|Anesthetic Drug Infusion
89683750|NCT00767767|Active Comparator|Thiopental 1.5mcg/mL|Anesthetic Drug Infusion
89683751|NCT00767767|Active Comparator|Thiopental 3mcg/mL|Anesthetic Drug Infusion
89683752|NCT00761345|Experimental|radiotherapy and chemotherapy|gemcitabine will be administered at 1000mg/m2 IV on days 1 and 8 of each 21 day cycle. erlotinib at either 100mg (cohort 1-3) or 150mg (cohort 4) PO daily. Low dose fractionated radiotherapy (LDRT) will be given BID on days 1 and 2 and 8 and 9 of each 21 day cycle
89683753|NCT01273337|Experimental|ALD-401|ALD-401 is derived from Autologous Bone Marrow of the Stroke Subject
89683754|NCT01273337|Sham Comparator|Sham Comparitor|Sham Bone Marrow harvest and sham dosing procedure.
89683755|NCT00761813|Experimental|Single Sliding Hip Screw|
89683756|NCT00761813|Experimental|Multiple Cancellous Screws|
89683757|NCT03803423|Experimental|The Donor App|Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant's name, contact info, and organ needed into the Donor App's secure management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link the participant will be allowed to use the Donor App indefinitely.
89683758|NCT03807791|Experimental|Patient living in the Unit of Long Term Care|Patient living in the Unit of Long Term Care without any limit time
89683759|NCT03807557|Experimental|Robotic mCIMT group|1 hour unilateral robotic therapy, followed by 30 minutes of functional practice of affected UE using shaping technique, 3/week for 8 weeks and restraint of the unaffected limb at home for 2 hrs per day
89683760|NCT03807557|Active Comparator|Control group|conventional upper extremity rehabilitation training 1.5 hours per session, 3/week for 8 weeks and home exercise 2 hrs per day
89683761|NCT01279889||Cesarean Delivery|Healthy pregnant women having an elective cesarean delivery
89683762|NCT03801083|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic biliary tract cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
89683763|NCT01279967|No Intervention|A|Arm A is control arm with best supportive care.
89683764|NCT01279967|Experimental|B|Arm B is the treatment arm with best supportive care plus ADI-PEG20.
89683765|NCT03807635|Experimental|simulation of skin pricking type 450|The evaluator simulated the capillary blood sampling with the safety lancet type 450
89683766|NCT03807635|Experimental|simulation of skin pricking type 610|The evaluator simulated the capillary blood sampling with the safety lancet type 610
89683767|NCT00762515|Placebo Comparator|A|commercially available Fluoride only toothpaste
89683768|NCT00762515|Active Comparator|B|Commercially available triclosan/copolymer/fluoride toothpaste
89683769|NCT00753935|Experimental|Enteric-coated aspirin|patients received enteric-coated aspirin 81 mg qd for 2 weeks
89683770|NCT00753935|Active Comparator|Chewable aspirin|Patients received chewable aspirin 81 mg qd for 2 weeks
89683771|NCT00779285|Experimental|Single-arm|Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles
89683772|NCT00786643|Experimental|Stratum 1|Patients in stratum 1 have not received prior chemotherapy in the metastatic setting.
89683773|NCT00786643|Experimental|Stratum 2|Patients in stratum 2 have received 1-2 prior chemotherapy regimens in the metastatic setting.
88997566|NCT04025749|Other|Wait-list delayed intervention|Thirty children with CP (or fifteen with neuroimage data) matched by age, sex, motor and cognitive impairment severity.
88997567|NCT04015414|Active Comparator|Varenicline (Champix)|Varenicline treatment will start one week prior to the patient's target quit date at 0.5 mg/day for days 1-3, 0.5 mg twice daily for days 4-7. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for day 8-week 12. Patients will receive weekly calls during the first 4 weeks and at weeks 8, 12, and 24 to inquire about medication adherence and smoking status, motivate the patient to take the medication, encourage them not to smoke, and ask about possible side effects or other issues.
88997568|NCT04015414|Active Comparator|Cytisine (Tabex)|Patients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25.
89683774|NCT01275469|Experimental|GFT505 80mg|
89683775|NCT01275469|Placebo Comparator|Matching placebo|
89683776|NCT05742997|Active Comparator|PartoSure|Use of PartoSure to determine the risk of preterm birth
89683777|NCT05742997|Active Comparator|Fetal Fibronectine (fFn)|Use of fFn to determine the risk of preterm birth
89683778|NCT03804463|Experimental|radical surgery group|Endometrial cancer radical surgery to be administered in this arm.
89683779|NCT03804463|Experimental|fertility preservation group|Fertility-sparing surgery to be administered in this arm.
89683780|NCT03804463|Experimental|ovarian preservation group|Ovarian preservation surgery to be administered in this arm.
89683781|NCT01276379|Experimental|FOLFIRI (m) or FOLFOX-6 (m) + cetuximab|FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.
89683782|NCT01275547|Experimental|S-ketamine & midazolam spray|all 20 minutes as a patient controlled analgesia alternating s-ketamine / midazolam
89683783|NCT01275547|Active Comparator|morphine, patient controlled analgesia|morphine as an active comparator as a patient controlled analgesia system
89683784|NCT03804385|Other|intercostal tube|insertion of intercostal tube is surgical operation used in pneumothorax
89683785|NCT04272697||Heterozygous Familial Hypercholesterolaemia|Adults and children with Heterozygous Familial Hypercholesterolaemia.
89683786|NCT04272697||Homozygous Familial Hypercholesterolaemia|Adults and children with Homozygous Familial Hypercholesterolaemia
89683787|NCT04272697||Unaffected (non-FH) relatives of FH individuals|Adults and children with unaffected (non-FH) relatives of FH individuals
89683788|NCT01275703||patients with PH undergoing exercise testing|
89683789|NCT03804307|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
89683790|NCT03804307|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
89683791|NCT03804151|Experimental|FitSpirit Intervention|FitSpirit physical activities and events are organized by participants' schools during the school year. Girl-only activities such as physical activity sessions, speaking engagements, turnkey running program and special events can be offered. The number, type and frequency of activities are decided by each school.
89683792|NCT00789685|Experimental|Interferon Beta|Interferon Beta
89683793|NCT03804073|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
89683794|NCT03804073|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
89683795|NCT05742529|Active Comparator|TIP|
89683796|NCT05742529|Active Comparator|stitch by stitch|
89683797|NCT03803917|Other|Treatment|Injection with freshly collected autologous adipose tissue
89683798|NCT04276987|Experimental|MSCs-derived Exosomes Treatment Group|Conventional treatment and aerosol inhalation of MSCs-derived exosomes treatment participants will receive conventional treatment and 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
89683799|NCT00769015|Experimental|BA-LVR|In BA-LVR, a low vision occupational therapist (OT) will deliver Behavior Activation (BA), a psychological treatment to prevent depression. This will be administered in the context of the standard of low vision care for OTs as defined by the American Occupational Therapy Association (AOTA). The OTs will collaborate with low vision optometrists, who will deliver the standard of low vision care as defined by the American Optometric Association. The optometrists will evaluate remaining vision and magnification needs, prescribe optical devices, and provide the OTs with initial care plans. The OTs will subsequently meet with subjects in their homes 6 times over 12 weeks to enhance device use, home modifications, and compensatory strategies.
89683800|NCT00769015|Placebo Comparator|ST-LVR|Subjects randomized to ST-LVR will receive clinic-based low vision optometry, in addition to 6 in-home Supportive Therapy (ST) sessions. ST is a placebo condition that controls for the attention that subjects in the active treatment arm will receive.
88997569|NCT03989050||Melanoma patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for melanoma
88997570|NCT03989050||Non-small cell lung cancer (NSCLC) patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for NSCLC
88997571|NCT03989050||other malignancy patients|Patients receiving therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent for other malignancy
88997572|NCT03985267|Experimental|Mindfulness Based Swinging Technique (MBST)|Standard guided imagery combined with Mindfulness and breathing technique will be applied. Additionally, the directives will be given to participants to imagine themselves swinging in a green peaceful environment where they will face no harm but healing and full of wellness. Every time they imagine their swing goes up, patient will be asked to physically take a deep breath (taking the breath will be physically (actually) done, not imagining), and when going down patient will be asked to physically release their breath (releasing breath will be physically (actually) done, not imagining).
88997573|NCT03985267|Active Comparator|Standard Treatment|Participants will receive a session of standard psycho-social care for anxiety (50 minutes length). The standard psycho-social care interventions involve the most well-known talking therapy approach of Cognitive Behavioural Therapy (CBT).
89683801|NCT04384549|Experimental|BCG Arm|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
89683802|NCT04384549|Placebo Comparator|PLACEBO Arm|One intradermal placebo injection.
89683803|NCT02149303||Dabigatran|
89683804|NCT03803527|Experimental|EST|"All subjects enrolled into the study will:~Complete a clinical history~Have vitals obtained~Complete Patient-reported outcomes~Have Esophageal mucosal biopsies collected as part of standard of care at the time of the most recent endoscopy to report the peak eosinophilia per hpf.~Complete the Esophageal String test"
89683805|NCT03803449|Active Comparator|Control group|Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam
89683806|NCT03803449|Experimental|Fentanyl group|Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.
89683807|NCT03803839|Active Comparator|Clodronate|1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
89683808|NCT03803839|Placebo Comparator|Saline|1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
89683809|NCT03803293|Other|Primary cohort|All eligible Biobank participants that receive the majority of their care at Mayo Clinic based on EHR length and depth had pharmacogenomic testing done.
88997574|NCT03979495|No Intervention|Standard of care|standard of care
88997575|NCT03979495|Active Comparator|IT platform|Access to an IT platform for visit-based reminders about overdue abnormal cancer screening test results
88997576|NCT03979495|Active Comparator|IT platform with reminders|Access to an IT platform that will deliver both visit based and between visit reminders about abnormal cancer screening test results.
88997577|NCT03979495|Active Comparator|IT platform and patient navigation|the IT platform available in Arm 3 and navigation to help with scheduling and to address social barriers to care.
89683810|NCT03803137|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients with thoracic surgery for carcinological resection
89683811|NCT00771277|Experimental|Arm 1|Use of volunteer support teams to provide services
89683812|NCT00789997|Experimental|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later prednisone placebo po daily for 10 days Levofloxacin 750 mg po daily for 10 days.
89683813|NCT00789997|Active Comparator|Prednisone|prednisone 40 mg daily for 10 days etanercept placebo subcutaneous given on the day of randomization and one week later Levofloxacin 750 mg daily for 10 days.
88997578|NCT00192543|Active Comparator|case|diet of fish and fruit addition compared to regular diet
88997579|NCT00192543|Placebo Comparator|control|regular diet
88997580|NCT03970603|Active Comparator|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
89052347|NCT01149343|Experimental|GSK2302025A Cohort 1|Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
89052348|NCT01149343|Experimental|GSK2302025A Cohort 2|Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
89052349|NCT01149343|Experimental|GSK2302025A Cohort 3|Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
89052350|NCT01149343|Experimental|GSK2302025A Cohort 4|In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.
89052351|NCT04578561||Prophylactic mesh|Patients who received a prophylactic mesh after emergency surgery due to high risk of incisional hernia.
89052352|NCT04578561||Suture|Patients who's laparotomies closure was using only suture without any abdominal wall reinforcement
89052353|NCT04595162|Experimental|CAR-T treatment group|The patients will receive one dose of GC019F.
89052354|NCT01149148|Active Comparator|Intervention INVOS Cerebral Oximetry Monitoring|Intervention will be initiated if rSO2 drops > 20% from baseline or rSO2 declines below 50%.
89052355|NCT01149148|Active Comparator|Standard of Care|Blinded cerebral oximetry monitoring with no intervention in surgical procedures and anesthesia without deviation from standard of care.
89052356|NCT00624988|Experimental|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
89052357|NCT04313101||Cases (ICUAW)|57 critically ill patients developing ICUAW during their stay in the intensive care unit will be included in the study as cases.
89052358|NCT04313101||Controls|A total of 57 Critically ill patients in the same period who did not develop ICU acquired weakness during their ICU stay will be included as controls.
89052359|NCT00577668|Experimental|VDT and Melphalan|To find out if three drugs, bortezomib, thalidomide, and dexamethasone in addition to high doses of melphalan (M-VTD) and autologous transplant can be given safely and effectively to subjects who have failed previous regimens with transplant(s).
89052360|NCT04313179|Experimental|Music group|"Deep Sleep music track from Bedtime Mozart: Classical Lullabies for Babies, played through smart phone speakers, at maximum sound up to 45 dB, starting 20 minutes before the heel prick procedure, continuing through the procedure and for 5 minutes after the procedure. Also given 0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure for baseline pain relief."
89052361|NCT04313179|Placebo Comparator|Placebo group|0.5 ml of 24% Sucrose given 2 minutes prior to heel prick procedure. No music played.
89052362|NCT00577746||surgery|Those subjects who went to surgery for treatment for their lung cancer.
89052363|NCT00577746||no surgery|The subjects who did not go to surgery for treatment of their lung cancer.
89052364|NCT04595084|Experimental|MBCT-R + CHA-MW|Mindfulness-Based Cognitive Therapy (MBCT) is an effective group intervention for depression and anxiety that combines mindfulness training with elements of cognitive therapy. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
89052365|NCT04595084|Active Comparator|iCBT (MoodGym) + CHA-MW|MoodGym is a form of iCBT, which an evidence-based online program for depression, anxiety, stress and general psychological well-being. This will be delivered with CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
89683814|NCT00771745|Active Comparator|rATG 4 doses|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
89683815|NCT00771745|Active Comparator|rATG 3 doses|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
88997581|NCT03970603|Active Comparator|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
88997582|NCT03970330|Experimental|Low-Dose Naltrexone|12-week intervention period of 4.5 mg daily naltrexone in combination with standard treatment of 5-15 mg daily norethindrone acetate
88997583|NCT03970330|Placebo Comparator|Placebo|12-week intervention period of daily placebo in combination with standard treatment of 5-15 mg daily norethindrone acetate
88997584|NCT04724408|Experimental|VieScope|intubation with the VieScope laryngoscope
88997585|NCT04724408|Active Comparator|Conventional|intubation with MacIntosh-type laryngoscope
88997586|NCT03788044|Experimental|Application-driven education (AF-EduApp substudy)|Education will be given via a newly developed application. Medication adherence (oral anticoagulation) will be measured using a special bottle cap that fits on a medication bottle. The patients in this group will receive feedback (notification and/or alarm) during the entire study period via this application when these patients have to take their medication.
88997587|NCT03788044|Experimental|In-person education (AF-EduCare study)|Education will be given on regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
89683816|NCT02148835|Active Comparator|Triomeg|Sausage: Triomeg
89683817|NCT02148835|Placebo Comparator|Control sausage|Sausage: Control
88997588|NCT03788044|Experimental|Online education (AF-EduCare study)|Education will be given on regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
88997589|NCT03788044|No Intervention|Standard care (AF-EduCare study and AF-EduAppsub study)|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
88997590|NCT04724174||Pancreaticogastrostomy (PG) group|Patients underwent pancreatoduodenectomy with the PG technique
88997591|NCT04724174||Pancreaticojejunostomy (PJ) group|Patients underwent pancreatoduodenectomy with the PJ technique
88997592|NCT00163046|Experimental|Gabapentin|
88997593|NCT00163046|Placebo Comparator|Placebo|
88997594|NCT00185952|Active Comparator|Nifedipine|Maintenance tocolysis with nifedipine.
88997595|NCT00185952|Placebo Comparator|Placebo|Maintenance tocolysis with placebo tablets.
88997596|NCT03541447|Experimental|Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
88997597|NCT03541447|Experimental|Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
88997598|NCT03516604|Experimental|PF-04995274|"PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days~+ 1 placebo capsule, once daily for 7-9 days"
88997599|NCT03516604|Active Comparator|Citalopram|"Citalopram, one x 20mg capsule, once daily for 7-9 days~+ 3 placebo tablets, once daily for 7-9 days"
88997600|NCT03516604|Placebo Comparator|Placebo|3 placebo tablets and 1 placebo capsule, once daily for 7-9 days
88997601|NCT00185991|Active Comparator|Once daily Gentamicin|
88997602|NCT00185991|Active Comparator|Every eight hour Gentamicin|
88997603|NCT03434158|Experimental|Olaparib|600 mg/day
88997604|NCT00552994|Active Comparator|1|Cypher Select plus stent
88997605|NCT00552994|Active Comparator|2|Xience V stent
88997606|NCT03318952|Experimental|lidocaine then articaine|For the first dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed. For the second dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
88997607|NCT03318952|Experimental|articaine then lidocaine|For the first dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered. For the second dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed.
88997608|NCT03455647|Experimental|ASF Promotion plus Girinka|Participants have received a cow from the government of Rwanda through the Girinka program and will receive an animal source food promotion intervention from the study.
89683818|NCT00790699|Active Comparator|I-PORT|Treatment group
89683819|NCT00790699|Active Comparator|standard injections|control group
89683820|NCT03803215||Theophylline group|Patients who have electrocardiographic documentation of asystolic syncope will be treated with oral theophylline at tailored dosage
89683821|NCT03803215||Control untreated group|A propensity-score matched control group is generated from the large database of patients who had received an implantable loop recorder
89683822|NCT00790855|Experimental|Bendamustine|Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.
89683823|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab Alone|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab.
89683824|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab + Tremelimumab|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab + Tremelimumab.
89216418|NCT03880838|Experimental|DVD and both nudges|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and both commitment and prevention nudges.
89216419|NCT03880838|Experimental|Link and DVD and no nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and no behavioral nudges.
89216420|NCT03880838|Experimental|Link and DVD and commitment nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a commitment nudge.
89216421|NCT03880838|Experimental|Link and DVD and prevention nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a prevention nudge.
89216422|NCT03880838|Experimental|Link and DVD and both nudges|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and both commitment and prevention nudges.
89683825|NCT00791089|Experimental|Fish Oil, Ablation, Sinus Rhythm|Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
89683826|NCT00791089|Placebo Comparator|placebo, Ablation, sinus rhythm|Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
89683827|NCT03802903|Experimental|Remo-Wax|Test product will be applied into ear canal for 20-60 minutes.
89683828|NCT03802669||caries free children aged between 3-6|
89683829|NCT03802669||caries active children aged between 3-6|
89683830|NCT03802669||caries free children aged between 6-12|
89683831|NCT03802669||caries active children aged between 6-12|
89683832|NCT03802669||caries free adult aged between 18-25|
89683833|NCT03802669||caries active adult aged between 18-25|
89683834|NCT04384315||EVRF|Patients that have undergone Endovenous Radio Frequency® (EVRF®) from F Care Systems (Belgian) for the treatment of primary great and short saphenous vein reflux.
89683835|NCT00791323|Active Comparator|1|Ketorolac 0.4%
89683836|NCT00791323|Active Comparator|2|Mineral Oil Emollient
89683837|NCT03802357|Experimental|High training intensity|Exercise Training with high intensities consists of a cycling Interval Training at 100% of the individual Peak work rate, resistance Training for 3 sets à 8 repetitions and squats on a Vibration plate.
89683838|NCT03802357|Active Comparator|moderate training intensity|Exercise Training with moderate intensities consists of a cycling endurance Training at 60% of the individual Peak work rate, resistance Training for 3 sets à 20 repetitions and squats on the floor.
89216423|NCT03828331||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-55 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
89216424|NCT03815929|Active Comparator|Standard replacement therapy regimen|100 mcg transdermal estradiol patch (or equivalent oral dose)
89216425|NCT03815929|Active Comparator|Titrated replacement therapy regimen|Transdermal estradiol patch (or equivalent oral dose) titrated to achieve pre-menopausal estradiol level
89216426|NCT03815929|No Intervention|Timed Control Group|Healthy age-matched subjects not on hormone therapy
89216427|NCT03810170|Active Comparator|control|control group receives 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
89216428|NCT03810170|Experimental|intervention|intervention group receives safe sex and HIV/STD prevention education via a website, and weekly emails on with positive psychology-based happiness and resilience boosting activities
89216429|NCT03809988|Experimental|Interventional Arm (Arm A)|Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).
89216430|NCT03809988|Active Comparator|Control Arm (Arm B)|Patients will receive endocrine therapy (letrozole or fulvestrant).
89216431|NCT03808987|Experimental|CHW+CPP brief prenatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
89683839|NCT00772915|Experimental|Lenalidomide with On-Demand Dexamethasone|"Lenalidmoide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Dexamethasone: 10-40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression."
89683840|NCT00774163|Experimental|1|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
89683841|NCT00774163|Placebo Comparator|2|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
89683842|NCT03801967|Experimental|AZD9977|Each participant will receive AZD9977 at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
89683843|NCT03801967|Placebo Comparator|Placebo|Each participant will receive placebo at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
89683844|NCT03801889|Experimental|Cohort 1|SP-420 initially at 28 mg/kg
89683845|NCT03801889|Experimental|Cohort 2|SP -20 initially at 56 mg/kg
89683846|NCT03801889|Experimental|Cohort 3|SP-420 initially at 84 mg/kg
89683847|NCT03801577|Experimental|Hepaxa|Subjects will receive Hepaxa according to standard use (4 capsules daily over a 6 month period)
89683848|NCT03801733|Experimental|Rosuvastatin, Vadadustat|Part 1: Subjects will receive rosuvastatin 20 mg alone, vadadustat 600 mg alone, followed by rosuvastatin 20 mg in combination with vadadustat 600 mg in a fixed-sequence dosing design.
89683849|NCT03801733|Experimental|Sulfasalazine. Pravastatin, Vadadustat|"Part 2, Arm 1: Subjects will receive sulfasalazine 500 mg alone followed by sulfasalazine 500 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.~Part 2, Arm 2: Subjects will receive pravastatin 40 mg alone followed by pravastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
89683850|NCT03801733|Experimental|Atorvastatin, Simvastatin, Vadadustat|"Part 3, Arm 1: Subjects will receive atorvastatin 40 mg alone followed by atorvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.~Part 3, Arm 2: 24 subjects will receive simvastatin 40 mg alone followed by simvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
89683851|NCT03801421|Experimental|Continous suture group|The surgical incision will be treated by mass continous suture with PDS.
89683852|NCT03801421|Active Comparator|Control group|The surgical incision will be treated by interrupted suture with thread.
89683853|NCT03801343|Experimental|Nutrakos®|12 female subjects aged 35-70, have taken during a meal, for the 1 month ,2 stick packs/die of the food supplement
89683854|NCT04383535|Experimental|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma, in addition to standard care.
89683855|NCT04383535|Placebo Comparator|Placebo|Single infusion of saline solution, in addition to standard care.
89052366|NCT04595084|Active Comparator|CHA-MW|Participants randomized to the CHA-MW arm will only receive CHAMindWell mental wellness monitoring with CAT-MH and telephone coaching as needed.
89052367|NCT00577785||cystectomy group|Subjects undergoing planned cystectomy who agree to provide bladder tissue from removed bladder post cystectomy and/or cystoscopic biopsy tissue prior to cystectomy
89052368|NCT01148017|Experimental|ACWY - 4|Subjects who had previously received 4 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their first year of life are administered one booster dose of the same vaccine at 60 months of age.
89052369|NCT01148017|Experimental|ACWY - 2|Subjects who had previously received 1 or 2 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their second year of life, are administered one booster dose of the same vaccine at 60 months of age.
89052370|NCT01148017|Other|Naïve - 40|Control subjects, age-matched with the intervention groups subjects (40 months of age), to receive 1 optional dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
89052371|NCT01148017|Active Comparator|Naïve - 60|Control subjects, age-matched with the intervention groups subjects (60 months of age), are administered one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
89052372|NCT04594928|Experimental|GLPG3667 Dose A|Daily doses of GLPG3667 for 4 weeks.
89052373|NCT04594928|Experimental|GLPG3667 Dose B|Daily doses of GLPG3667 for 4 weeks.
89052374|NCT04594928|Placebo Comparator|Placebo|Placebo to match will be administered as capsules for daily oral use.
89052375|NCT00577902||Observational|This is an observational study
89052376|NCT01147900|Experimental|Boostrix-REF Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
89052377|NCT01147900|Experimental|Boostrix-US Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
89052378|NCT01147900|Experimental|Boostrix-INV Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
89052379|NCT04594850|No Intervention|Placebo-Control group|Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.
89683856|NCT04383613|Experimental|PRONE POSITIONING|Patients in this arm will be instructed to lie on their stomach while they are in bed for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for >24 hours or study outcome.
89683857|NCT04383613|No Intervention|STANDARD OF CARE|Patients in this arm are not specifically instructed to lie on their stomach while they are in bed.
89052380|NCT04594850|Experimental|Injection group: Cellgram-ED|Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand.
89052381|NCT04594889|Experimental|Sirolimus|Sirolimus eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
89052382|NCT04594889|Active Comparator|Paclitaxel|Paclkitaxel eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes
89052383|NCT01147744|Experimental|GSK2190915 10mg and placebo|GSK2190915 10mg (1 x 10mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
89683858|NCT00775411|Experimental|700 µg dexamethasone and ranibizumab|700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
89683859|NCT03801655|Experimental|Bio-Kult|4 capsules/day
89683860|NCT03801655|Placebo Comparator|Placebo|4 capsules/day
89683861|NCT03801499|Experimental|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89216432|NCT03808987|Experimental|CHW+CPP brief postnatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning postnatally, in addition to services from a Community Health Worker (CHW)
89216433|NCT03808987|Experimental|CHW+CPP 12 months|Participants will receive Child-Parent Psychotherapy (CPP) for 12 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
89683862|NCT00808405|Active Comparator|acyclovir|
89683863|NCT00808405|Placebo Comparator|placebo|
89683864|NCT00775645|Experimental|Arm I|Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks.
89683865|NCT00775645|Placebo Comparator|Arm II|Patients receive oral placebo 3 times daily for 24 weeks.
89683866|NCT04902781|Experimental|Experimental: AT-007|AT-007 The starting dose in Part A will be 5 mg/kg for all age groups. For each age group, Part B of the study will not start until the optimum dose evaluated in Part A has been identified
89683867|NCT04902781|Placebo Comparator|Placebo|Placebo given orally
89683868|NCT01974687|Experimental|Group A: Healthy|Healthy participants will receive sequentially higher doses of uprifosbuvir (10 mg - 300 mg) capsules or matching placebo capsules once daily (QD) on Day 1 (Cohorts 1a-3a, 5a), Days 1 and 7 (Cohort 4a), or Day 1 - Day 7 (Cohort 6a). Dosing of next cohort will be based on review of available safety and PK data. Dosing will occur under fasted conditions with the exception of Cohort 4a, in which drug administration will occur under both fasted and fed conditions.
89683869|NCT01974687|Experimental|Group B: GT1 HCV-infected, treatment naive on Day 1|HCV GT1 participants with no prior direct-acting antiviral (DAA) exposure will receive a single dose of uprifosbuvir (10 mg - 300 mg) for 1 day across sequential dose cohorts. Dosing will commence following review of available safety and PK data from respective dose cohorts in Group A. All dosing will occur under fasted conditions.
89683870|NCT01974687|Experimental|Group C: GT1 HCV-infected on Days 1-7|HCV GT1 participants will receive uprifosbuvir (50 mg - 400 mg in capsules or 300 mg or 450 mg in tablets) or matching placebo capsules QD for 7 days. Dosing will commence following review of available safety and PK data of Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
89683871|NCT01974687|Experimental|Group D: GT2 through GT6 HCV-infected on Days 1-7|HCV GT2 - GT6 participants will receive uprifosbuvir (50 mg - 300 mg) capsules QD for 7 days. Dosing will commence following review of available safety and PK data from Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
89683872|NCT01974687|Experimental|Group E: GT1 HCV-infected on Days 1-7, mild hepatic impairment|HCV GT1 participants with mildly impaired hepatic function will receive uprifosbuvir (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.
89683873|NCT01974687|Experimental|Group F: GT1 HCV-infected on Days 1-7, + Itraconazole|HCV GT1 participants will receive itraconazole 200 mg twice daily (BID) on Day -5 and itraconazole 200 mg QD from Day -4 to Day 11. Participants will also be co-administered uprifosbuvir 300 mg from Day 1 to Day 7.
89683874|NCT00795145|Placebo Comparator|Cohort 1: Placebo|
89683875|NCT00795145|Experimental|Cohort 1: 900 mg linezolid|
89683876|NCT00795145|Experimental|Cohort 1: 1200 mg linezolid|
89683877|NCT00795145|Placebo Comparator|Cohort 2: Placebo|
89683878|NCT00795145|Experimental|Cohort 2: 600 mg linezolid|
89683879|NCT00795145|Experimental|Cohort 2: 1200 mg linezolid|
89683880|NCT00795145|Active Comparator|Cohort 2: 400 mg Moxifloxacin|
89683881|NCT03801187|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
89683882|NCT03801187|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
89683883|NCT03801187|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
89683884|NCT00809185|Experimental|RAD001 (everolimus)|RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis
89683885|NCT03800953|Experimental|Avelumab (Bavencio)|This is a single arm, and open label study. All the subjects recruited will receive Avelumab.
89683886|NCT03809663|Placebo Comparator|Part A: Placebo|"Matching placebo administered via SC injection Q2W for a maximum of 52 weeks.~Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
89683887|NCT03809663|Experimental|Part A: Tezepelumab 210 mg|"Tezepelumab 210 mg administered via SC injection once every 4 weeks (Q4W) from Week 4 for a maximum of 52 weeks.~All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive a placebo at Week 2 to maintain blinding.~Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
89216434|NCT03808987|Experimental|CHW only|Participants will receive services from a Community Health Worker (CHW) without Child-Parent Psychotherapy (CPP)
89216435|NCT03773107|Experimental|Phase I|Cohort 1) 5mg ruxolitinib, Cohort 2) 10mg ruxolitinib, Cohort 3) 15mg ruxolitinib
88997609|NCT03455647|No Intervention|Girinka only|Participants have received a cow from the government of Rwanda through the Girinka program and will not receive any intervention from the study.
88997610|NCT03455647|No Intervention|Girinka eligible|Participants are eligible to receive a cow through the government of Rwanda Girinka program, but have not yet received a cow. They will not receive any intervention from the study.
88997611|NCT04684069|Active Comparator|syringe free long axis in-plane|
88997612|NCT04684069|Sham Comparator|Short axis out-of-plane|
88997613|NCT00553033||A|
88997614|NCT03114397|Active Comparator|anodal stimulation|Patients will receive anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
88997615|NCT03114397|Placebo Comparator|sham stimulation|Patients will receive sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
88997616|NCT00163280|Experimental|1|ATL-104 50mg
88997617|NCT00163280|Experimental|2|ATL-104 100mg
88997618|NCT00163280|Experimental|3|ATL-104 150mg
88997619|NCT00163280|Placebo Comparator|4|Placebo
88997620|NCT02890693|Experimental|interdisciplinary lifestyle/psychosocial|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions.
88997621|NCT02890693|No Intervention|treatment as usual|Usual clinical follow-up and treatment is based on the current American Diabetes Association, the Endocrine Society guidelines, and the NICE guidelines.
88997623|NCT02789800|Active Comparator|Group A|Intervention group (n = 163) Intervention: Participates in DIMAC02 Program
88997624|NCT02789800|No Intervention|Group B|Control group (n = 163)
88997625|NCT02789800|No Intervention|Group C|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
88997626|NCT02556931|Experimental|PBSCT D90|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.
88997627|NCT02556931|Experimental|PBSCT D60|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.
88997628|NCT02316184|Placebo Comparator|Brief Advice|Participants in this arm will receive brief advice about alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
88997629|NCT02316184|Active Comparator|MI|Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
88997630|NCT04683952|Experimental|Rehabilitation with HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, and with Humified High Flow Nasal Cannula (HHFNC).~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
88997631|NCT04683952|Active Comparator|Control Group rehabilitation without HHFNC|"15 Chronic Obstructive Pulmonary Disease patients in nocturnal Non Invasive Ventilation (NIV) who will perform rehabilitation, with / without Oxygen Therapy according to prescription, without Humified High Flow Nasal Cannula (HHFNC).~The Rehabilitation program consists in 20 session of 40 minutes, thrice a week for three times with a washout period of 3 months."
88997632|NCT00186342|Experimental|CIK cell|The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.
88997633|NCT02171104|Experimental|IMD - Except Haplo-identical|"Inherited Metabolic Disease (IMD) - Except Haplo-Identical~See intervention descriptions."
88997634|NCT02171104|Experimental|OP - Except Haplo-Identical|"Severe Osteoperosis (OP) - Except Haplo-Identical~See intervention descriptions."
89683888|NCT03809663|Experimental|Part A: Tezepelumab 280 mg|"Tezepelumab 280 mg administered via SC injection Q2W from Week 2 for a maximum of 52 weeks.~All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive their randomized dose of 280 mg Q2W from Week 2.~Participants defined as non-responders (those who did not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose."
89683889|NCT03809663|Experimental|Part A: Tezepelumab 420 mg|Tezepelumab 420 mg administered via SC injection Q2W for a maximum of 52 weeks.
89216436|NCT03773107|Other|Phase II|Cohort A) non-responders to Phase I regimen, Cohort B) responders to Phase I regimen
89216437|NCT03755934|Experimental|Dose Level 1|MEDI7352
89216438|NCT03755934|Experimental|Dose Level 2|MEDI7352
89216439|NCT03755934|Experimental|Dose Level 3|MEDI7352
89216440|NCT03755934|Placebo Comparator|Placebo|Placebo
89216441|NCT03755934|Experimental|Dose Level 4|MEDI7352
89683890|NCT03809663|Experimental|Part B: Placebo and Topical Corticosteroids Regimen|Matching placebo administered via SC injection Q2W with topical corticosteroids (TCS) for a maximum of 52 weeks.
89683891|NCT03809663|Experimental|Part B: Tezepelumab 420 mg and Topical Corticosteroids Regimen|Tezepelumab 420 mg administered via SC injection Q2W with TCS for a maximum of 52 weeks.
89683892|NCT04349787||Colorectal polyp patients|Patients who have a colonoscopy in regular care as part of the Dutch colorectal screening program, in the context of complaints or in the context of the follow-up of previously diagnosed bowel diseases. And who have at least one colorectal polyp found and resected during the examination.
89683893|NCT00795769|Experimental|Ondansetron therapy|Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.
89683894|NCT00796627|Sham Comparator|Healthy volunteers|"Healthy volunteers with no burn wounds Volunteers donate blood that will be studied in comparison to patients who have sustained burns. The circulating bone marrow stem cells will be counted and compared to the levels in burn patients. Six 12 ml tubes will be taken for the study. You will not be compensated. But you will be helping to advance science if you join the study."
89683895|NCT00796627|Active Comparator|Burn volunteer|To recruit burn wound patients with defined clinical criteria for study. A second-degree burn of at least 10 cm2 to up to 95% BSA; age = 14-75 years; BP > 100 mm Hg systolic; heart rate < 100 beats/minute; urine output > 30 ml/hour; area of burn < 20% of BSA; body temperature = 98.5-101 degrees Fahrenheit; serum albumin > 3 mg/ml; and informed consent. We will also obtain a history regarding the presence or absence of risk factors that may affect CAC numbers: hypertension > 1 year; smoking > 2 pack-years or within the last year; diabetes mellitus; and family history of premature coronary artery disease (men < 55 and women < 65 years of age).Six 12 ml tubes will be taken at 5 time points
89683896|NCT01975935|Placebo Comparator|Placebo|Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
89683897|NCT01975935|Experimental|Amlexanox|Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
89683898|NCT04345679|Experimental|Hospitalized patients with SARS CoV-2 infection|
89683899|NCT02305017|Experimental|Period 1 OPC + Paracetamol; Period 2 OPC|Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
89683900|NCT02305017|Experimental|Period 1 OPC; Period 2 OPC+ Paracetamol|Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
89683901|NCT00249821|Experimental|Saizen® 0.057 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than [<] -2 SDS or greater than [>] -2 SDS)
89683902|NCT00249821|Experimental|Saizen® 0.035 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (< -2 SDS or > -2 SDS)
89683903|NCT01976871|Experimental|Oral Dopamine Agonist to Rotigotine|During the study, we will switch patients who are not satisfied with their current oral dopamine agonist to rotigotine. Cross-titration will allow determination of the lowest effective dose of rotigotine. We will use as initial guidance the equivalence determined from the Parkinson's Disease trials, in which 1 mg rotigotine was shown to be approximately equivalent to 1-1.5 mg ropinirole or 0.25 -0.375 mg pramipexole. Tolerability, adverse events, and RLS symptom control will be evaluated. These data will provide clinicians with practical guidance to optimize RLS treatment while minimizing adverse events.
89683904|NCT03602781|Placebo Comparator|Cohort 1: Placebo 99.999% Nitrogen|"Randomized Withdrawal Treatment Period Week 1-8:~Placebo at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
89216442|NCT03743766|Experimental|Relatlimab|"Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1).~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
89216443|NCT03743766|Experimental|Nivolumab|"Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks.~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
89216444|NCT03743766|Experimental|Relatlimab + Nivolumab|Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.
89683905|NCT03602781|Active Comparator|Cohort 2: iNO 75 mcg/kg IBW/hr|"Randomized Withdrawal Treatment Period Week 1-8:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
89216445|NCT03729817|Experimental|Submaximal balloon angioplasty plus intensive medical therapy|Endovascular intervention with submaximal balloon angioplasty
89216446|NCT03716817|Experimental|Tetric CAD Crown|Tetri CAD crowns will hand polished and cemented with a dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
89216447|NCT03716544|No Intervention|Waiting list control group|There will be no treatment for 12 months.
89683906|NCT02280239|Placebo Comparator|Control Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time dose of placebo via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
89683907|NCT02280239|Experimental|Acetaminophen Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time does of acetaminophen 650mg via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
89683908|NCT01993875|Experimental|Lubiprostone|
89683909|NCT01993875|Placebo Comparator|Placebo|
89683910|NCT03809741|Experimental|Preventing L&D Infections|Low-cost bundled L&D infection prevention interventions will be implemented, including education, visual reminders, feedback, and alcoholic hand rub supply. Infection control practices and child delivery outcomes will be assessed after implementation of these interventions.
89683911|NCT00796705|Experimental|Adalimumab / Adalimumab Placebo|1 sub-cutaneous (SQ) injection of adalimumab or 1 SQ injection of placebo will be given in a blinded and alternating fashion for a total of 12 weeks
89683912|NCT00796705|Experimental|Etanercept|Participants will receive 1 SQ injection of etanercept each week for 12 weeks
89683913|NCT03800875|Experimental|Insulin-Pramlintide Closed-Loop Strategy|Fast-acting insulin will be delivered using two separate infusion pumps. The pumps' infusion rates will then be changed manually based on the computer-generated recommendation. The computer-generated recommendations are based on a dosing algorithm. With no-meal announcement or carbohydrate counting, the dual-hormone closed-loop system will be fully reactive, and insulin and pramlintide dosages will be based solely on sensor readings
89683914|NCT03800875|Active Comparator|Insulin-alone Closed Loop Strategy|"Fast-acting insulin will be delivered by a subcutaneous insulin infusion pump based on an algorithm that automatically adjusts insulin rates based on a dosing algorithm. The carbohydrate content for every ingested meal will be entered into the algorithm to calculate the insulin prandial bolus based on each participant's insulin-to-carbohydrate ratio. The carbohydrate content will be entered at the onset of the meal.~Drug(s): Insulin (FiAsp)"
89683915|NCT02148523|Experimental|Weekly Adherence Report|Adherence report to subject every 7 days.
89683916|NCT02148523|Experimental|Weekly Adherence Peer-Comparison Report|Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.
89683917|NCT02148523|Other|Usual Care|Usual care with GlowCap.
89683918|NCT00809809|Active Comparator|Zinc gluconate|Oral swabs containing homeopathic Zinc gluconate
89683919|NCT00809809|Placebo Comparator|Placebo|placebo
88815843|NCT01116986|Experimental|20, No Patch, Gum, Prequit, Int In-Person, Int Phone, 16Wk|How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt
88815844|NCT01116986|Experimental|21, No Patch, Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815845|NCT01116986|Experimental|22, No Patch, Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815846|NCT01116986|Experimental|23, No Patch, Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815847|NCT01116986|Experimental|24, No Patch, Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815848|NCT01116986|Experimental|25, No Patch, No Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815849|NCT01116986|Experimental|26, No Patch, No Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88997635|NCT02171104|Experimental|OP and IMD -Haplo-Identical Only|"Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)~-Haplo-Identical Only~See intervention descriptions."
89683920|NCT04384471||People living with Type 1 Diabetes|People from all ages living with type 1 diabetes in the Province of Quebec
89683921|NCT03839797|Experimental|Cadet Healthy Personal Skills|Cadet Healthy Personal Skills
89683922|NCT03839797|Active Comparator|Standard Health Education|Standard Health Education
89683923|NCT00248651|Active Comparator|Amitriptyline|Amitriptyline capsule (50 mg) plus a placebo escitalopram tablet will be taken at night half an hour before bedtime. To maximize patient tolerability, in the first 2 weeks the dose of amitriptyline will be 25 mg and then the dose will be increased to 50 mg, but the 25 mg and 50 mg capsules will be indistinguishable to maintain blinding.
89683924|NCT00248651|Active Comparator|Escitalopram|Escitalopram tablet (10 mg) plus a placebo amitriptyline capsule will be taken by mouth at night half an hour before bedtime for 12 weeks.
89683925|NCT00248651|Placebo Comparator|Placebo|Placebo escitalopram tablets and placebo amitriptyline capsules will be taken by mouth half an hour before bedtime for 12 weeks.
89683926|NCT03839719|Experimental|Group OC|"Ocimum sanctum (OC) is a natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is also listed by the U.S. FDA as an herb Generally Recognized As Safe (GRAS) for its intended use as a therapeutic herb. Pharmacological constitutes present in the extract are eugenol, Urosolic acid, Carvacrol, linalool , limatrol, caryophyllene, and methyl carvicol. The literature showed that Ocimum sanctum extract has significant anti-gingivitis and anti-inflammatory effect as mouthrinse.~Other Names:~Tulsi Holy Basil"
89683927|NCT03839719|Active Comparator|Group CHX|"Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in a variety of oral disorders in various formulations.~As an antimicrobial agent, chlorhexidine is effective in vitro against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes and yeasts and fungi. The digluconate of chlorhexidine (1:6Di 4' chlorophenyl-diguani-dohexane) is a synthetic antimicrobial drug which has been widely used as a broad spectrum antiseptic.~Other Names:~Chlorhexidine"
89683928|NCT03839719|Placebo Comparator|Group PI|"Group PI: Placebo (Distilled water) as the mouthrinse.~Placebo (Distilled water) 10 ml is used as mouthrinse. Distilled water is commonly used as an excipient in a variety of drugs and it is also widely used as a placebo.~Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.~Treatment was carried out by placing 03 sterile agar plates uncovered at pre-designated sites to collect samples of aerosolized bacteria."
89683929|NCT03800251|Other|Fasting parturients at term|Fasting parturients at term, admitted for elective cesarean section, who consent to partake in the study
89683930|NCT05464381|Experimental|Verum|
89683931|NCT05464381|Placebo Comparator|Placebo|
89683932|NCT03800797|Experimental|LX-P group|loxoprofen sodium hydrogel patch (LX-P) 100 mg per day for 4 weeks
89683933|NCT03800797|Active Comparator|LX-T group|loxoprofen sodium tablet (LX-T) 60 mg t.i.d. for 4 weeks
89683934|NCT04383067|Experimental|Tumor Infiltrating Lymphocytes (TIL)|
88997636|NCT02171104|Experimental|cALD SR-A (Standard-Risk, Regimen A)|See intervention descriptions.
88997637|NCT02171104|Experimental|cALD SR-B (Standard-Risk, Regimen B)|See intervention descriptions.
88997638|NCT02171104|Experimental|cALD HR-C (High-Risk, Regimen C)|See intervention descriptions.
88997639|NCT02171104|Experimental|cALD HR-D (High-Risk, Regimen D)|See intervention descriptions.
88997640|NCT02086630|Experimental|Intervention|The Heart to Heart (HTH) intervention was a flexible and individualized intervention with the following components: 3 intervention sessions with video-components; patient navigation lasting up to 24 weeks; treatment initiation support groups (up to 5); and inclusion of a Support Partner. This is a behavioral intervention. The intervention uses Motivational Interviewing.
88997641|NCT02086630|No Intervention|Control|Treatment as usual
88997642|NCT01818661|Experimental|Tau positron emission tomography (PET)|All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.
88997643|NCT01626313|Active Comparator|Immediate intervention|Subjects are randomized to receive immediate intervention of the 8 session FOCUS IFRT
88997644|NCT01626313|Active Comparator|Waitlisted|Subjects are randomized to be waitlisted for 4 months, re-assessed and then receive intervention of the 8 session FOCUS IFRT
88997645|NCT00717652|Experimental|1|arbutin, tretinoin, triamcinolone
88997646|NCT00717652|Active Comparator|2|Triluma
88997647|NCT00461539|Active Comparator|2|Participants will receive treatment as usual
88997648|NCT00461539|Experimental|1|Participants will receive the behavioral health intervention
88997649|NCT05454826|Experimental|Cold application group|applied relaxation exercise+ cold pack
88997650|NCT05454826|Experimental|control group|applied relaxation exercise
88997651|NCT00163553|Experimental|P|Epidural pethidine group
88997652|NCT00163553|Placebo Comparator|N|placebo group
88997653|NCT05420818|Experimental|Active Group|Patients who underwent transversalis fascia inversion during TEP
88997654|NCT05420818|No Intervention|Control Group|Patients who did not undergo transversalis fascia inversion during TEP
88997655|NCT00192699||Group 1: Cemented Bi-Metric femoral stem|Cemented Bi-Metric femoral stem
88997656|NCT04683445||HR+/HER2- advanced breast cancer|Efficacy and Safety of Eribulin in the Treatment of HR+/HER2- Advanced Breast Cancer
88997657|NCT04683445||HER2+ advanced breast cancer|Efficacy and Safety of Eribulin and anti-HER2 Targeted therapy in the Treatment of HER2+ advanced breast cancer
88997658|NCT04683445||triple negative advanced breast cancer|Efficacy and Safety of Eribulin and Immunotherapy in the Treatment of triple negative advanced breast cancer
88997659|NCT00553072|Active Comparator|Magnesium sulphate, neurological outcome|Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
88997660|NCT00553072|Placebo Comparator|Placebo|Placebo every 24 hours for 3 doses starting from 6 hours after birth
88997661|NCT00163670||Motor vehicle accident|
88997662|NCT00163670||Control|
88997663|NCT05808842|Active Comparator|Group A CeraVe|Subjects will be given a skincare regimen consisting of CeraVe products to be applied to the face and neck following laser treatment.
88997664|NCT05808842|Sham Comparator|Group B Calecim|Subjects will be given a skincare regimen consisting of CeraVe products and Calecim products to be applied to the face and neck following laser treatment.
88997665|NCT05808829|Experimental|Experimental: Progressive Muscle Relaxation Exercise|Participants performed muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, the researcher exercised with the participants in online groups to control the research and to check whether the participants were doing the exercise correctly.
88997666|NCT05808829|No Intervention|No Intervention: Control Group|The participants continued their daily life.
88997667|NCT05808816|Experimental|Arm A|Patient with oral supplementation of Lactobacillus Crispatus M247
88997668|NCT05808816|No Intervention|Arm B|Patients without oral supplementation of Lactobacillus Crispatus M247
89683935|NCT01994109|Active Comparator|MYOBLOC 2500 U|Subjects will receive specified dose of MYOBLOC
89683936|NCT01994109|Active Comparator|MYOBLOC 3500 U|Subjects will receive specified dose of MYOBLOC
89683937|NCT01994109|Placebo Comparator|Placebo|Subjects will receive volume matched Placebo
89683938|NCT03800095|Experimental|Conventional haematological care|Patients with haematological malignancy Conventional haematological care
89683939|NCT03800095|Experimental|Conventional care associated with a monthly consultation|Patients with haematological malignancy Conventional care associated with a monthly consultation realized by a palliative and supportive care team
89683940|NCT01978509|Active Comparator|Low volume prep (Prepopik)|Low volume prep for colonoscopy (Prepopik)
89683941|NCT01978509|Active Comparator|Moderate volume prep (Moviprep)|Moderate volume prep for colonoscopy (Moviprep)
89683942|NCT01978509|Active Comparator|High volume prep (Golytely)|High volume prep for colonoscopy (Golytely)
89683943|NCT00248495|Experimental|Neoadjuvant chemotherapy|Patients receive pemetrexed disodium IV over 10 minutes followed by cisplatin IV over approximately 1 hour on day 1. Treatment repeats every 21 days for 3 courses
89683944|NCT03809767|Experimental|CS1003 monoclonal antibody|
89683945|NCT03806465||Feasibility survey|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age. For the midline household survey, this would be restricted to children aged 12-23 months of age.
89683946|NCT03806465||Sentinel hospital surveillance|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age who are hospitalized in the 18 sentinel hospitals.
89683947|NCT03806465||Community mortality surveillance|These will be children whose deaths are reported in the vaccinating and in non-vaccinating areas aged less than 5 years of age .
89683948|NCT02307123||HEMS treated patients|Patients whose airways were secured by the HEMS physician.
89683949|NCT03800641|Experimental|oral administration|oral administration of dexmedetomidine 4μg/kg
89683950|NCT03800641|Active Comparator|intravenous administration|intravenous administration of dexmedetomidine 0.8μg/kg
88997669|NCT05808790|Active Comparator|Minimally invasive pulmonary metastasectomy|Minimally invasive parenchymal sparing pulmonary metastasectomy Surgical approach by means of video-assisted thoracic surgery (VATS), robot-assisted (RATS), or uniportal VATS
88997670|NCT05808790|Experimental|Stereotactic ablative radiotherapy|Gross tumor volume = tumor visible on CT (+/- PET) No CTV margin will be added (Clinical target volume (CTV) = Gross target volume (GTV)) Planning Target Volume (PTV): GTV plus margins of 3-5mm (varying depending on site, motion, SABR delivery approach)
88997671|NCT05808777||ICH|"Patients were eligible for inclusion if they~were aged 20 years or older~had been admitted to a neurology, neurosurgery, or rehabilitation ward with a diagnosis of primary ICH~had a diagnosis of ICH confirmed by a brain CT~have written informed consent given by themselves or by their legal representative"
88997672|NCT05808712||Translation and validation design|"To translate the English version of The Supportive Care Needs Survey-short form (SCNS-SF34) questionnaire into Swedish and to test the reliability and validity.~Design: Translation and validation design~A multicenter national validation study, in three university hospital in Sweden. Consecutive sampling procedure during a one-year period (2023), to evaluate internal consistency and test-retest reliability of the SCNS-SF34 in Swedish. Number is calculated to be 300 patients, and test-rest (reliability) in 50 patients. Inclusion criteria = >18 years, cancer patients with different gastrointestinal cancer diagnosis. Exclusion criteria= not able to answer a questionnaire in Swedish.~Demographical and clinical data will be collected using a case report form. The survey will be distributed to patients via a web-based questionnaire or paper and pen questionnaire procedure."
88997673|NCT05808660||General population|
88997674|NCT05808647|Active Comparator|Energy balanced metabolic diet (5-days)|45 kcals/kg of fat free mass [FFM]/day; 28% fat, 15% protein, 57% carbohydrate
88997675|NCT05808647|Experimental|Low energy availability metabolic diet (5-days)|20 kcal/kg of FFM/day; 28% fat, 15% protein, 57% carbohydrate
88997676|NCT05808634|Experimental|BA3182|All Patients will receive BA3182
88997677|NCT05808569||Breast cancer patients undergoing radiotherapy in adjuvant setting|
89683951|NCT03800641|Experimental|nasal administration|nasal administration of dexmedetomidine 1μg/kg
89683952|NCT03807011|Active Comparator|fentanyl|A bolus dose of fentanyl 2 μg/kg was administered intravenously at anesthetic induction
88997678|NCT05808556|Experimental|Sticker pads containing lavender and ylang ylang oil|The subjects in the sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days
88997679|NCT05808556|Placebo Comparator|Placebo group|The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
88997680|NCT05808543|Experimental|Both EARS training package (BEARS) and Usual Care|BEARS is a compilation of virtual reality games designed specifically for young people with bilateral cochlear implants. The hardware is either: A Head Mounted Display Device or an iPad with headphones.
88997681|NCT05808543|Active Comparator|Usual Care|Usual care describes the routine rehabilitation received by participants via their implant centre.
89052384|NCT01147744|Experimental|GSK2190915 30mg and placebo|GSK2190915 30mg (1 x 30mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
89683953|NCT03807011|Active Comparator|remifentanil|Remifentanil was continuously infused at a rate of 0.2 μg/kg/min from anesthetic induction to the end of surgery
89683954|NCT02986503||Chemotherapy for Good responder|Doxorubicin + cisplatin + ifosfamide Pre-operative and post-operative chemotherapy for patients with good responder high grade osteosarcoma
89683955|NCT02986503||Chemotherapy for Poor responder|Doxorubicin+cisplatin+ifosfamide+methotrexate Pre-operative and post-operative chemotherapy for patients with poor responder high grade osteosarcoma
89683956|NCT04727983|No Intervention|Pelvic Floor Muscle Function|Pelvic floor muscle function will be evulated with the Modified Oxford Scale
89683957|NCT04727983|No Intervention|Bladder function|Bladder function will be evulated with the urinary diary for 3 days
89683958|NCT04727983|No Intervention|Incontinence Symptoms|Incontinence Symptoms will be evulated with The International Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) and the Coital Incontinence Score (CIS)
89683959|NCT04727983|No Intervention|Quality of Life|Quality of life will be evulated with the King Health Questionnaire (KHQ)
89683960|NCT04727983|No Intervention|Sexual Function|Sexual Function will be evaluated with Pelvic Organ Prolapse / Urinary Incontinence Sexual Questionnaire (PISQ-12).
89683961|NCT04727983|Experimental|NMES group|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS)
89683962|NCT04727983|Sham Comparator|SHAM ES group|The second group will be given sham NMES in addition to LSS
89683963|NCT04727983|No Intervention|End of Treatment Special Evaluations|Subjective perception of improvement and treatment satisfaction of the patients will be questioned
89683964|NCT02986191|Experimental|Mucograft|One side of the mouth will be subjected to Mucograft in this split-mouth study design.
89683965|NCT02986191|Active Comparator|Connective tissue graft|The opposite side of the mouth will be subjected to a connective tissue graft.
89683966|NCT03806699|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
89683967|NCT03806699|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
89683968|NCT03806699|Placebo Comparator|Control group|Participants will receive 0.5 mL (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
89683969|NCT01978743|Experimental|Raltegravir|Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
89683970|NCT00763061|Experimental|Travoprost 0.004%|Travoprost 0.004%
89052385|NCT01147744|Experimental|GSK2190915 100mg QD and placebo|GSK2190915 100mg (1 x 100mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
89052386|NCT01147744|Experimental|GSK2190915 300mg QD and placebo|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
89052387|NCT01147744|Active Comparator|Fluticasone propionate 100mcg and placebo|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS and two placebo tablets in the morning and one placebo capsule in the evening
89052388|NCT01147744|Active Comparator|Montelukast 10mg and placebo|Montelukast 10mg (1 x 10mg capsule) once daily in the evening and two placebo tablets in the morning and inhaled placebo twice daily via ACCUHALER/DISKUS
89052389|NCT01147744|Placebo Comparator|Placebo Comparator|Two GSK2190915 placebo tablets once daily in the morning, montelukast placebo capsule once daily in the evening and fluticasone propionate placebo twice daily via ACCUHALER/DISKUS
89052390|NCT04594460|Experimental|experimental Group|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
89052391|NCT04594460|Active Comparator|Control Group|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
89052392|NCT00625027||Group 1|Children presenting to the Emergency Department under the care of a parent or guardian, between 0600 and 2400 during the study period.
89052393|NCT04594577|Experimental|Fluispotter|Fluispotter automated blood sampling system
89683971|NCT00763061|Active Comparator|Timolol 0.5%|Timolol 0.5%
89683972|NCT03806335|Experimental|Infiltration|Patients will receive pre-incision infiltration of 2.5 ml local anesthesia mixture in each tonsil.
89683973|NCT03806335|Placebo Comparator|Placebo|Patients will receive pre-incision infiltration of 2.5 ml saline in each tonsil.
89683974|NCT03806777|Experimental|Intra-nasal dexmedetomidine|A single dose of dexmedetomidine, determined by a biased coin algorithm (min: 1 mcg/kg; max: 4 mcg/kg or 200mcg), will be delivered intranasally 45min before an MRI scan.
89683975|NCT03809689|Other|acute infarction|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
89683976|NCT03809689|Other|acute infarction requiring reperfusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
89683977|NCT03809689|Other|chronic ischemic occlusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT before and 2 months after reperfusion treatment
89683978|NCT01979133|Experimental|icariin|Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
89683979|NCT03800069||Arm 1|A finger stick sample is collected and tested on the study device.
89683980|NCT04675879|Experimental|Velpau bandage (Group 1)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with velpau bandage.
89683981|NCT04675879|Experimental|Shoulder arm sling (Group 2)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with shoulder arm sling.
89683982|NCT04675879|Experimental|Padded shoulder arm sling (Group 3)|Patients with neer type 2, 3 or 4 proximal humerus fractures under conservative follow-up with padded shoulder arm sling with 30 degree abduction.
89683983|NCT04645069|Experimental|ADG126 mono dose escalation|ADG126 monotherapy dose escalation will be traditional 3+3 cohort design.
89683984|NCT04645069|Experimental|ADG126 mono dose expansion|Monotherapy dose expansion is designed to evaluate the preliminary antitumor activity of ADG126 at RP2D or the doses approved by the SRC.
89683985|NCT04645069|Experimental|ADG126-anti PD1 drug dose escalation|Combination therapy will commence at a dose level lower than the cleared dose from the monotherapy dose escalation arms and approved by the SRC.
89683986|NCT04645069|Experimental|ADG126-anti PD1 drug dose expansion|Combination therapy expansion will commence at RP2D or the dose approved by the SRC.
89683987|NCT04645069|Experimental|ADG126-ADG106 dose escalation|Combination therapy will commence at a dose level lower than the cleared dose from the monotherapy dose escalation arms and approved by the SRC.
89683988|NCT04645069|Experimental|ADG126-ADG106 dose expansion|Combination therapy expansion will commence at RP2D or the dose approved by the SRC.
89683989|NCT05432713|Experimental|LP-168 tablet|After confirmation of inclusion, subjects will be randomized into the LP-168 tablet or LP-168 placebo tablet arm and receive single or multiple doses of LP-168 tablet or LP-168 placebo tablet.
89683990|NCT05432713|Placebo Comparator|LP-168 Placebo tablet|After confirmation of inclusion, subjects will be randomized into the LP-168 tablet or LP-168 placebo tablet arm and receive single or multiple doses of LP-168 tablet or LP-168 placebo tablet.
89683991|NCT00754247|Experimental|Regimen A|0.5% hydrocortisone, silicone, vitamin E lotion
89683992|NCT00754247|Experimental|Regimen B|Onion extract gel
89683993|NCT00754247|Placebo Comparator|Regimen C|Cetearyl alcohol lotion
89683994|NCT02305329|Experimental|Group 1 BIA 9-1067 25 mg|Period 1 - 5x5 mg OPC Period 2 - 1x25 mg OPC
89683995|NCT02305329|Experimental|Group 2 BIA 9-1067 25 mg|Period 1 - 1x25 mg OPC Period 2 - 5x5 mg OPC
89683996|NCT02305329|Experimental|Group 1 BIA 9-1067 50 mg|Period 1 - 2x25 mg OPC Period 2 - 1x50 mg OPC
89683997|NCT02305329|Experimental|Group 2 BIA 9-1067 50 mg|Period 1 - 1x50 mg OPC Period 2 - 2x25 mg OPC
89683998|NCT01979445|Experimental|Prasugrel 30 Min After Cangrelor|Prasugrel 60 milligram (mg) administered orally 30 min after the discontinuation of cangrelor infusion on Day 1 (2.5 hours [hrs] after initiation of cangrelor infusion).
89683999|NCT01979445|Experimental|Clopidogrel Within 5 Min After Cangrelor|Clopidogrel 600 mg administered orally within 5 min after the discontinuation of the cangrelor infusion on Day 1 (2 hrs after initiation of cangrelor infusion).
89684000|NCT01979445|Experimental|Clopidogrel 1.5 Hrs During Cangrelor|Clopidogrel 600 mg administered orally 1.5 hrs after the initiation of cangrelor infusion on Day 1.
89684001|NCT01979445|Experimental|Clopidogrel 1 Hr During Cangrelor|Clopidogrel 600 mg administered orally 1 hr after the initiation of cangrelor infusion on Day 1.
89684002|NCT03802565|Experimental|Tolperisone 50 mg|TID (150 mg/day)
89684003|NCT03802565|Experimental|Tolperisone 100 mg|TID (300 mg/day)
89684004|NCT03802565|Experimental|Tolperisone 150 mg|TID (450 mg/day)
89684005|NCT03802565|Experimental|Tolperisone 200 mg|TID (600 mg/day)
89684006|NCT03802565|Placebo Comparator|Placebo|TID
89052394|NCT04313374|Active Comparator|Morphine PCA 1 mg|The patient controlled analgesia device give 1mg morphine for each demand of the patient.
89052395|NCT04313374|Active Comparator|Morphine PCA 0,5 mg|The patient controlled analgesia device give 0,5 mg morphine for each demand of the patient.
89052396|NCT04313374|Placebo Comparator|Placebo|The patient controlled analgesia device give 2 mL serum physiologic for each demand of the patient.The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours. If the VAS skore more than 4 the Group 3 patients will take 1 g paracetamol every 6 hours.
89052397|NCT02883907||Healthy volunteers|
89052398|NCT02883907||Osteoarthritis patients|
89052399|NCT04594148|Experimental|Weight-shift training|The experimental group will receive a single session of 10x 2.5min of weight-shift training with the VR Wasp Game
89052400|NCT04594148|No Intervention|Passive control|The passive control group will not receive any form of training. Instead, they will relax for 25min (i.e. talking with the researcher and/or reading a magazine)
89052401|NCT00577980|Experimental|Testosterone|Testosterone 200 mg administered parenterally by intramuscular (IM) injection every 2 weeks
89052402|NCT05219578|Experimental|RTX-224 Dose Escalation|Phase 1: RTX-224 monotherapy dose escalation in Solid Tumors, administered intravenously on Day 1 of each cycle.
89052403|NCT05219578|Experimental|RTX-224 Dose Expansion|Phase 2: RTX-224 monotherapy dose expansion in Solid Tumors, administered intravenously on Day 1 of each cycle.
89684007|NCT02308371|Experimental|Prospective|Patients in this arm will have fluid given based on standard clinical data (blood pressure, heart rate, lactate level, urine output) in addition to information provided by automated pulse pressure variation (PPV). PPV will be followed for first 48 hours after recruitment to the study. Fluid (normal saline, albumin 5%, hetastarch per the clinician preference) will be given in 5cc/kg increments for PPV> 13 (in addition to standard clinical data) until PPV < 13.
89684008|NCT02308371|No Intervention|Retrospective|Patients in this arm were previously admitted to the PICU and were given fluid based on standard clinical data. PPV was not used to guide therapy in this group of patients.
89684009|NCT04382443|Experimental|Oral Colchicine +BMS implantation|This group will receive after BMS and Colchicine, at the time of PCI, 0,5 mg twice a day during the first three months after stent implantation
89684010|NCT04382443|No Intervention|Second generation Drug eluting stent (DES)|"This group will receive DES at the moment of randomization and will be treated as standard of care.~All second generation DES should be approved by ANMAT for clinical use."
89684011|NCT01980771|Experimental|BTWB intervention|Barbershops are assigned to either experimental or active control condition. Men recruited from experimental barbershops receive a single-session group intervention focused on HIV prevention.
89684012|NCT01980771|Active Comparator|Cancer prevention and screening|Barbershops are assigned to either experimental or control condition. Men recruited from control barbershops receive information on cancer prevention and control.
89684013|NCT04633213|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
89684014|NCT04633213|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
89684015|NCT01981863|Experimental|Epsilonaminocaproic acid|One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo
89684016|NCT01981863|Placebo Comparator|Placebo, Antifibrinolytic activity|Placebo: same IV volume as experimental arm
89684017|NCT00245765|Placebo Comparator|Placebo|Subcutaneous injections of Placebo every 2 weeks
89684018|NCT00245765|Experimental|Certolizumab Pegol 200 mg|Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter
89684019|NCT00245765|Experimental|Certolizumab Pegol 400 mg|Subcutaneous injections of 400 mg every 2 weeks
89684020|NCT01995045|Experimental|Bupivicaine & Triamcinolone|Retrobulbar anesthesia with Bupivicaine Hydrochloride and Triamcinolone Acetonide
89684021|NCT01995045|Active Comparator|Bupivicaine|Retrobulbar anesthesia with Bupivicaine Hydrochloride
89684022|NCT04937725||Patients without neurological pathologies|Patients with no history of neurological diseases
89684023|NCT04937725||Patients with neurological pathologies|
89216448|NCT03716544|Experimental|Hearing aid group|Participants will receive amplification with hearing aids. Bilateral open-fit hearing aids will be fitted. Participants will be required to use the hearing aids for at least 2 hours daily for 12 months.
89216449|NCT03716544|Active Comparator|Customized music group|Customized music according to participants hearing level will be made available in an iPod. The iPod will deliver ear-specific therapeutic sound for asymmetrical hearing profile. Participants will have to listen to the therapeutic sound at a comfortable volume for two hours daily for 12 months.
89216450|NCT03716180|Experimental|Paclitaxel+Trastuzumab+Pertuzumab|Paclitaxel is administered intravenously on days 1, 8, and 15 of each 21-day cycle Trastuzumab is administered intravenously on day 1 of each 21-day cycle Pertuzumab is administered intravenously on Day 1 of each 21-day cycle
89216451|NCT03696199|No Intervention|Traditional Pain Control Care|Standard of care post-operative pain control with oral narcotics
89216452|NCT03696199|Experimental|Regional Anesthesia|Single injection perioperative peripheral nerve block + followed by administration of oral narcotics on a need-based system
89216453|NCT03696199|Experimental|Long-Acting Local Anesthesia|Subcutaneous local cocktail injection + followed by administration of oral narcotics on a need-based system
89684024|NCT03806075|Experimental|Peutz-Jeghers patients|All Peutz-Jeghers patients meet the clinical criteria
89684025|NCT03806075|Placebo Comparator|Health persons|Those without Peutz-Jeghers syndrome
89684026|NCT04539457|No Intervention|Usual care|Neither the 'Desktop Helper (version 10)' will be integrated in the EMR system nor the 'e-learning' will be offered to GPs. However, to prevent attenuation of usual care, GPs will be free to adjust any medication on their own initiative or to use any other aid to decrease inappropriate prescribing in COPD patients.
89684027|NCT04539457|Active Comparator|Only desktop helper|Only the 'Desktop Helper (version 10)' will be integrated in the EMR system. Specifically, GPs will receive a notification about the 'Desktop Helper (version 10)'. This notification will inform general practitioners about the option in the Medicom Smart Module to identify COPD patients with comorbidities who have one or more 'medication-comorbidity clashes' (i.e. undesired interactions between medications for COPD and comorbid conditions).
89216454|NCT03684187|Experimental|Stress in Control for Healthy Liver (SynC-HL) Intervention:|This mindfulness based intervention to target healthy liver focuses on teaching skills of mindfulness, yoga and self-control to improve lifestyle choices and decision making.
89216455|NCT03674229|Active Comparator|Group I (information about weight management programs)|Participants receive information about commercially-available weight management programs and encouragement to participate in one of the programs for 6 months.
89216456|NCT03674229|Experimental|Group II (information, call from patient navigator)|Participants receive information about commercially-available weight management programs encouragement to participate in one of the programs for 6 months. Participants also receive 6 phone calls over 20-30 minutes each from an assigned patient navigator for 6 months.
89216457|NCT03651349|Placebo Comparator|Placebo control|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
89216458|NCT03651349|Experimental|50 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
89216459|NCT03651349|Experimental|100 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
89216460|NCT03651349|Experimental|150 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
89216461|NCT03651349|Experimental|225 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
89216462|NCT03651349|Experimental|300 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
89684028|NCT04539457|Active Comparator|Only E-learning|Only the 'e-learning' will be offered to GPs. Herein, GPs, will be invited to perform an e-learning module which provide information about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
89684029|NCT04539457|Active Comparator|Both dekstop helper and e-learning|Both 'Desktop Helper (version 10)' will be implemented in the EMR system. GPs will subsequently be notified about the possibility to detect COPD patients with 'medication-comorbidity clashes'. The implementation of the 'Desktop Helper (version 10), will be accompanied by e-learning offered to GPs. about COPD and their (co)morbidities and the 'medication-comorbidity clashes'.
89684030|NCT03805997|Experimental|Experimental Group|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
89684031|NCT03805997|Placebo Comparator|Control Group|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
89684032|NCT01995123|Experimental|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
89216463|NCT03651349|Experimental|400 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
89684033|NCT01995123|Active Comparator|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
89684034|NCT00781079|Experimental|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
89684035|NCT00781079|No Intervention|Care as Usual|Care as usual
89684036|NCT01982643|Experimental|naltrexone plus bupropion|extended-release depot naltrexone (XR-NTX; as Vivitrol®)plus extended-release bupropion tablets (BRP; as Wellbutrin XL®)
89216464|NCT03651349|Experimental|525 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
89052404|NCT01147471|Active Comparator|Operative rib fixation|"Randomized subjects will be operated upon within 72 hours of ventilation (early fixation) to stabilize the stove-in segment. Where all fractured ribs are accessible and the number of fractured ribs is few, stabilization of all fractured ribs would be the goal. However, where fractured ribs are in areas difficult to access, enough ribs, based on surgeon judgment, would be fixed to stabilize the stove-in segment. Post-operatively, the patients would receive the standard of care, similar to what is outlined for the non-operative arm.~Operative fixation will be accomplished utilizing the MatrixRIB Fixation System (Synthes CMF, West Chester, PA, USA) according to the device's instructions for use. Sites will obtain the product based on their medical center's normal purchasing practices."
89052405|NCT01147471|No Intervention|Non-operative arm|"Randomized subjects to receive standard of care therapy for blunt thoracic trauma (as per each participating institution's own protocols):~a. Ventilatory support b.Timing of extubation (removal from ventilator): c.Analgesia: institution should provide adequate analgesia utilizing available resources including oral, parenteral, epidural, local nerve blocks etc., d.Chest physical therapy, e.Postural drainage, f.Incentive spirometry - after extubation."
89052406|NCT04594343|Experimental|Disulfiram|
89052407|NCT04594343|Placebo Comparator|Placebo|
89052408|NCT00578019|Active Comparator|1, A|
89052409|NCT00578019|Experimental|2, B|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
89052410|NCT04594304|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports upon survey completion, and their PCP will receive automatic supports in the EMR to assess and treat the patient's alcohol and/or tobacco use. In cases where a patient does not have risky alcohol and tobacco use, a personalized eToolkit based on their physical activity levels will be administered, and their PCP will receive automatic supports in the EMR to facilitate physical activity discussions. Intervention arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and a 3 months follow-up e-survey following their appointment. Resources will be automatically produced for the patient and PCP following completion of the baseline e-survey.
89052411|NCT04594304|No Intervention|Usual care|The control arm will not receive intervention materials. Control arm patient participants will be asked to complete a baseline e-survey before their scheduled appointment, a process evaluation e-survey 3 days following their appointment, and 3 months follow-up e-survey following their appointment.
89052412|NCT04578483||PCA group|Patients receiving patient-controlled analgesia (PCA) will be allocated to PCA group.
89052413|NCT04578483||ERDS group|Patients receiving one dose of extended-release dinalbuphine sebacate (ERDS) by ultrasound-guided muscle injection will be allocated to ERDS group.
89684037|NCT01996839|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
89684038|NCT01996839|Active Comparator|Vehicle (BID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
89684039|NCT01996839|Experimental|Loteprednol Etabonate Gel (TID)|Loteprednol Gel 0.38% administered three times daily (TID).
89684040|NCT01996839|Active Comparator|Vehicle (TID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID).
89684041|NCT00797797|Experimental|Milnacipran Added|
89684042|NCT00797797|Experimental|No Treatment Added|
89684043|NCT01996917|Active Comparator|Prineo closure|One breast will have skin closure with Prineo.
89684044|NCT01996917|No Intervention|Standard Suture|One breast will be closed in the standard fashion with suture.
89684045|NCT03496233|Experimental|All patients included|All patients included will be treated with Elbasvir/grazoprevir for 8 weeks
89684046|NCT04482673|Experimental|COVID-19 Negative Active Treatment|Participants will be randomized to vitamin D3 (6000 IU) per day for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
89684047|NCT04482673|Placebo Comparator|COVID-19 Negative Placebo|Participants in this arm would receive placebo for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
89684048|NCT04482673|Experimental|COVID-19 Positive Active Treatment|Participants will be randomized to vitamin D3 as a bolus (20,000 IU) per day for 3 days followed by high dose vitamin D (6000 IU) per dayfor 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
89684049|NCT04482673|Placebo Comparator|COVID-19 Positive Placebo|Participants in this arm would receive placebo as a bolus followed by daily placebo for 12 months. All participants will receive a multivitamin containing 800 IU vitamin D3/day.
89684050|NCT01984515|Experimental|Team Red Primary Care|Eligible patients will receive the Referral Management System in primary care
89684051|NCT00245063|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89684052|NCT02151487||Ropivacaine|Ropivacaine 0.5% 25 ml alone for supraclavicular block
89684053|NCT02151487||Ropivacaine and dexamethasone|25 ml 0.5% ropivacaine + 4 mg dexamethasone
89684054|NCT02151487||Ropivacaine and clonidine|25 ml 0.5% ropivacaine + 100 mcg clonidine
89684055|NCT02151487||Ropivacaine, dexamethasone and clonidine|25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
89684056|NCT02148809|Experimental|Blood Volume Analysis, Fluid|Preop I-131 is given and the BVA is performed, 6 hours after surgery the same procedure will be done to compare the TBV at both points
89684057|NCT03805763|Experimental|Large extent of ILM Peeling|Extent of ILM peeling is 4DD and the ILM flap is inserted
89684058|NCT03805763|Experimental|Small extent of ILM Peeling|Extent of ILM peeling is 2DD and the ILM flap is inserted
89684059|NCT05318339|Experimental|Trastuzumab + Pyrotinib|"Patients receive a loading dose of trastuzumab IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes every three weeks.~Meanwhile, patients also receive pyrotinib 400mg PO daily. Treatment may continue till unacceptable toxicity or disease progression occurs."
88815850|NCT01116986|Experimental|27, No Patch, No Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
89684060|NCT00763919|Experimental|Customized Adherence Enhancement (CAE)|"Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles.~Treatment Modules:~Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module"
89684061|NCT04703335|Experimental|Non-inferiority and Persistence|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution).
89684062|NCT04382989||Mothers of extremely preterm infants|(gestational age < 28 weeks)
89684063|NCT04382989||Mothers of very preterm infants|(gestational age 28 - 31 weeks)
89684064|NCT04382989||Mothers of moderate and late preterm infants|(gestational age 32 - 36 weeks)
89684065|NCT04382989||Mothers of term infants|(gestational age ≥ 37 weeks)
89684066|NCT03806153|Active Comparator|Conventional morphology arm (reference method)|
89684067|NCT03806153|Experimental|Morphokinetic arm|
89684068|NCT04695301|Experimental|digital platform rehabilitation|Rehabilitation program through a digital platform for 3 months
89684069|NCT04695301|Experimental|control group|Patients without access to technology will do the exercises using booklets and will compose the control group
89684070|NCT04691635||Group 1|Patients with Progressive Supranuclear Palsy
89684071|NCT04691635||Group 2|Patients with Parkinson's disease
89684072|NCT04691635||Group 3|Healthy controls
89684073|NCT05352529|Experimental|Experimental condition|This condition implemented the assistive technology in question: the MapHabit System (MHS). The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application was made available to families through compatible tablets.
89684074|NCT05352529|Active Comparator|Control condition|The control condition acted as the active comparator to the experimental condition. This condition implemented educational videos focused on Alzheimer's disease, dementia care, and caregiver support. The videos were made available to caregivers through compatible tablets.
89684075|NCT00764309|Experimental|A1|
89684076|NCT02151877|Experimental|Nitric oxide on CPB|neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
89052414|NCT04578483||PRN group|Patients receiving analgesics other than ERDS and PCA will be allocated to PRN group.
89052415|NCT01147393|Experimental|All subjects|two weekly infusions of 90Y-epratuzumab tetraxetan in combination with four weekly infusions of 200 mg/m2 veltuzumab.
89052416|NCT00578058|Other|1|Counseling plus everyday noise type 1
89052417|NCT00578058|Other|2|Counseling plus static noise type 2
89052418|NCT00578058|Other|3|Counseling plus static noise type 3
89052419|NCT00578058|Other|4|Hearing aid and counseling plus everyday noise type 1
89052420|NCT00578058|Other|5|Hearing aid and counseling plus static noise type 2
89052421|NCT00578058|Other|6|Hearing aid and counseling plus static noise type 3
89052422|NCT02884024||lean|healthy subject undergoing routine screening colonoscopy, BMI< or = 25
89052423|NCT02884024||mildly obese|healthy subject undergoing routine screening colonoscopy, BMI 30-33.9
89052424|NCT02884024||moderate-to-severe obese|healthy subject undergoing routine screening colonoscopy, BMI 34+
89052425|NCT00566774|Experimental|1|
89052426|NCT00566774|Active Comparator|2|
89052427|NCT00578097|Experimental|A - 125 units|
89052428|NCT00578097|Experimental|B - 250 units|
89052429|NCT00578097|Experimental|C - 500 units|
89052430|NCT00578097|Placebo Comparator|D|
89052431|NCT04593797||Patients undergoing major upper abdominal surgery|major open upper abdominal surgery eg pancreatic, liver surgery
89052432|NCT00578370|Experimental|1|
89052433|NCT00578370|Experimental|2|
89052434|NCT00578370|Active Comparator|3|
89052435|NCT00578370|Active Comparator|4|
89052436|NCT00578370|Placebo Comparator|5|
89052437|NCT04593719|Experimental|Experiment|Lactation management model is applied to the experimental group.
89052438|NCT04593719|No Intervention|Control|Lactation management model is not applied to the control group.
89052439|NCT04593836|Experimental|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
89052440|NCT04593836|Placebo Comparator|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
89052441|NCT04578405|Active Comparator|Extracorporeal anastomosis|
89052442|NCT04578405|Experimental|Intracorporeal anastomosis|
89052443|NCT04593368|Experimental|FMT|
89052444|NCT04593524|Active Comparator|Treatment Group|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
89052445|NCT04593524|Active Comparator|Counseling Group|24 participants which only receives nutritional counseling for 28 days
89052446|NCT00578526|Active Comparator|Arm 1|SU011248 - 4 weeks on followed by 2 weeks rest period every 6 weeks
89052447|NCT00578526|Placebo Comparator|Arm 2|1 50 mg capsule OD PO for 4 weeks with 2 week rest until disease progression. Any patient with disease progression will be unblinded and patients on the placebo arm may then be considered for the open label Sutent treatment.
89684077|NCT02151877|Placebo Comparator|control|neonates not receiving inhaled NO into the cardiopulmonary bypass
89684078|NCT04382833|Experimental|HOT APPLICATION GROUP|Thermoforming, one of the dry hot application methods, was performed on the sacral (S1-S4) vertebrae region of pregnant women in the hot application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). Thermoforming was applied by wrapping it with a towel to protect pregnant women from the direct effect of its hot surface. The mean water temperature used in thermoforming was 50C. The water temperature was measured using a liquid thermometer. When 50°C water was subjected to hot application, the surface temperature reached around 40°C. The hot application was carried out continuously for 20 min.20 The body temperature of the pregnant women was evaluated before the application.
89684079|NCT04382833|Experimental|MASSAGE GROUP|Massage using effleurage and friction techniques was applied to the 4-5 cm right and left lateral parts of the midline on the sacral (S1-S4) vertebrae region of pregnant women in the massage application group while they were in sitting or left-side-lying position (during 4-5, 6-7, and 8-9 cm cervical dilation). The massage application was carried out continuously for only 10 min because it was thought to cause irritation to the area where it was practiced.
89684080|NCT04382833|No Intervention|CONTROL GROUP|
89684081|NCT00798577|Experimental|Vigamox|Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)
89684082|NCT00798577|Placebo Comparator|BSS Placebo|Balanced Salt Solution
89684083|NCT00799435|No Intervention|1|Participants will receive usual care for 12 weeks. The care will be dictated by the primary physician and/or diabetologist caring for the participant. Efforts will be made to ensure that all participants receive standard measures as indicated by guidelines, with a particular emphasis on blood pressure control and glucose control.
89684084|NCT00799435|Experimental|2|Participants will receive exenatide for 12 weeks.
89684085|NCT04329091|Experimental|Dexmedetomidine Arm|Dexmedetomidine: Administration of a 0.5 mcg/kg bolus followed by an infusion of 0.5-0.7 mcg/kg/hr, titrated up by 0.1 mcg every 1 minute until the subject spontaneously closes his or her eyes. When the subject spontaneously closes his or her eyes the infusion continues for 90 minutes from that point.
89684086|NCT00244751|Experimental|GI262570 0.5 mg|Participants received GI262570 0.5 milligrams (mg) tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
89684087|NCT00244751|Experimental|GI262570 1.0 mg|Participants received GI262570 1.0 mg tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
89684088|NCT00244751|Placebo Comparator|Placebo|Participants received matching placebo tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
89052448|NCT04593446|Experimental|Oral Sulfate Tablet(ORA·FANGⓇ)|Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery
89052449|NCT04593446|Active Comparator|Sodium Picosulfate Solution(PicosolutionⓇ)|Subjects who are randomized into experimental arm will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery
89052450|NCT00578604||Patients with a diabetic wound|Patients with a diabetic wound
89052451|NCT00578604||Control|Patients without a diabetic wound
89052452|NCT00566891|Active Comparator|A|Tirofiban
89052453|NCT00566891|Placebo Comparator|B|Clopidogrel
89052454|NCT00578682|Experimental|1|Single IV dose of 0.3 mg/kg MEDI-557
89052455|NCT00578682|Experimental|2|Single IV dose of 3 mg/kg MEDI-557
89052456|NCT00578682|Experimental|3|Single IV dose of 15 mg/kg MEDI-557
89052457|NCT00578682|Experimental|4|Single IV dose of 30 mg/kg MEDI-557
89052458|NCT04593485|Experimental|Cohort 1|patients with postoperative recurrence of malignant melanoma of the female genital tract requiring adjuvant therapy, Camrelizumab for injection
89052459|NCT04593485|Experimental|Cohort 2|patients with metastatic or unresectable malignant melanoma of the female genital tract, Camrelizumab for injection
89052460|NCT04592900|Experimental|the control group|the control group Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and balance training exercises and gait training in open environment.
89052461|NCT04592900|Experimental|the virtual reality group|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
89052462|NCT04592900|Experimental|the Biodex Balance Training group|Group 3 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min
89052463|NCT00578760|Placebo Comparator|2|placebo OD during course of chemotherapy
89052464|NCT00578760|Experimental|1|325mg ASA OD during course of chemotherapy
89052465|NCT00578799|Active Comparator|Kyo-Dophilus|Kyo-Dophilus (5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening)
89052466|NCT00578799|Placebo Comparator|Placebo|placebo capsules (potato starch)
89052467|NCT04592705|Experimental|Therapeutic plasma exchange|
89052468|NCT00578838||1|25 patients with metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
89052469|NCT00578838||2|25 patients with non-metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
89052470|NCT00578838||3|11 healthy volunteers, who will also undergo two scans 2-3 weeks apart.
89052471|NCT04592822|Experimental|Treatment T|30 minutes after the start of a standard breakfast, subjects will take one straw of WD-1602 Dabigatran Etexilate Mesylate Granules (150 mg) in 100 mL water as oral administration.
89052472|NCT04592822|Active Comparator|Treatment R|30 minutes after the start of a standard breakfast, subjects will receive a single Pradaxa® 150 mg capsule swallowed with 240 mL water as oral administration.
89052473|NCT00578916|Experimental|1|
89052474|NCT00567047|Experimental|1|Vildagliptin
89052475|NCT00578994||Oxford® Meniscal Unicompartmental Knee|Patients with PKA using the Oxford® Meniscal Unicompartmental Knee System
89052476|NCT03454178||Hypertensive patients|150 Chinese patients with a diagnosis of essential hypertension from a primary care clinic
89052477|NCT00579033|Sham Comparator|1|
89052478|NCT00579033|Active Comparator|2|
89052479|NCT04578171||Study population|Subjects with severe asthma treated with mepolizumab
89684089|NCT04382209|Active Comparator|Erector Spinae plane block group|Erector spinae plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively.
89684090|NCT04382209|Sham Comparator|Control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
89684091|NCT03417921|Experimental|ARM A|ABTL0812 (starting 1,300 mg tid orally) in combination with gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer
89684092|NCT03417921|Active Comparator|ARM B|Gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer as standard pattern
89684093|NCT03028935|Experimental|Prevention (exercise, nutrition education program)|Exercise Intervention & Nutritional Intervention. Participants undergo instructor-led exercise and nutrition education classes for 60 minutes twice a week for 12 weeks.
89684094|NCT00799981|Experimental|AABB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 7 cm then 10 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
89684095|NCT00799981|Experimental|ABAB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 7 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
89684096|NCT00799981|Experimental|ABBA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 10 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
89684097|NCT00799981|Experimental|BAAB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 7 cm then 7 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
89684098|NCT00799981|Experimental|BABA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then then 7 cm then 10 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
89052480|NCT03454139|Active Comparator|Subcostal TAP group|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,25 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia. After that, the patient is positioned to lithotomy position and the open-end catheter is inserted. After that the patient is turned to prone position and the percutaneous nephrolithotomy is performed. Tramadol 100 mg iv is administrated 20 minutes before the end of the surgery. Morphine patient controlled analgesia is planned for postoperative pain management.
89052481|NCT03454139|No Intervention|Non- TAP group|Percutaneous nephrolithotomy is performed under general anesthesia. No regional analgesia is administered to this patients. Paracetamol 1000 mg/100ml; iv and Tramadol 100mg iv is administered 20 minutes before the end of the surgery for postoperative analgesia. Morphine patient controlled analgesia is planned for postoperative pain management.
89052482|NCT00579150||Exenatide|Exposure to any form of exenatide during pregnancy for treatment of type 2 diabetes. Patients also taking Insulin may be included, though only as part of a combination treatment.
89052483|NCT00579150||Non-exenatide group|Exposure to non-insulin antidiabetic medication not including exenatide for treatment of pre-existing type 2 diabetes during pregnancy. Patients also taking Insulin may be included, though only as part of a combination treatment.
89052484|NCT03454100|Experimental|multi-sectoral package of activities|Villages in the experimental arm received the full multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
89052485|NCT03454100|No Intervention|Control|Villages in the control arm did not receive teh multi-sectoral package of village level activities.
89052486|NCT03454061|Experimental|Intervention|Physical activity intervention
89052487|NCT03454061|No Intervention|Control|Keep usual activities in kindergarten
89052488|NCT03453983|Experimental|Anodal tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
89052489|NCT03453983|Sham Comparator|Sham tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
89052490|NCT00579306||SPS3 patient cohort|All SPS3 patients who participate in Baseline and 1-Year F/U blood draw
89052491|NCT04593017|Experimental|Active Probiotic|Probiotic contain active microorganism
89052492|NCT04593017|Placebo Comparator|Placebo Probiotic|Probiotic with no active microorganism
89052493|NCT03453294|Experimental|Apnoeic oxygenation using THRIVE|Oxygenation by apnoea oxygenation using THRIVE
89052494|NCT03453294|Active Comparator|Endotracheal intubation and mechanical ventilation|Ventilation and oxygenation by an endotracheal tub and mechanical ventilation
89052495|NCT04592666|Experimental|Combinational therapy|
89052496|NCT04592666|Active Comparator|Single TKI|
89684099|NCT00799981|Experimental|BBAA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 10 cm then 7 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
89684100|NCT03378297|No Intervention|Feasibility study cohort|
89684101|NCT03378297|Experimental|Metformin|850 mg
89684102|NCT03378297|Experimental|Acetylsalicylic acid|160 mg
89684103|NCT03378297|Experimental|Olaparib|300 mg x 2
89684104|NCT03378297|Experimental|Letrozol|2.5 mg
89684105|NCT03933475|Experimental|Intendu Active Brain Trainer Telerehabilitation Games|Use of telerehabilitation Games within the home environment
89684106|NCT03367689|Experimental|Olaparib 300 mg|Patients whose tumours are identified as Homologous Recombination Deficient, will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.
89684107|NCT00813319|Experimental|1 - Girls OnGuard/HPV awareness|Adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses.
89684108|NCT00813319|No Intervention|2 - General health promotion|Adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. HPV awareness and vaccination will not be addressed.
89684109|NCT00243659|Experimental|A|
89684110|NCT00243659|Experimental|B|
89684111|NCT00814177|Experimental|No change|Intervention Drug warfarin no change in the dose is performed
89684112|NCT00814177|Active Comparator|Change|Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level
89684113|NCT05335681|Experimental|Experimental group;|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen, and groin areas will be applied
89684114|NCT05335681|No Intervention|Control group|No intervention will be made in the control group. In stages where the dilatation gap is 4 and 7 cm, the pain will be evaluated with the VAS scale at 0, 10, and 20 minutes.
89684115|NCT04332601|Experimental|ENERGY intervention|"ENERGY Intervention:~14 sessions of 1h CBT intervention (standardized fatigue treatment comprising six modules over 14 individual therapy sessions)~1 session per week~With a psychologist (different to the psychologist who will perform the assessments)~Individual sessions~and Treatment as usual"
89684116|NCT04332601|Other|Treatment as usual (TAU)|"Comparison group~TAU defined by antipsychotic medication coupled with day hospital care"
89684117|NCT00243269|Sham Comparator|1|Expectancy neutral handout and expectancy neutral tape
89684118|NCT00243269|Experimental|2|Expectancy enhancing handout and expectancy neutral tape
89684119|NCT00243269|Experimental|3|Expectancy neutral handout and expectancy enhancing tape
89684120|NCT00243269|Experimental|4|Expectancy enhancing handout and expectancy enhancing tape
89684121|NCT03364491|Experimental|Tranexamic Acid|Tranexamic Acid for intravenous administration
89684122|NCT03364491|Placebo Comparator|Placebo|Normal saline for intravenous administration
89684123|NCT04311307|Experimental|Patients|GSDIa patients
89684124|NCT04311307|Active Comparator|Controls|Healthy volunteers
89684125|NCT04294069|Active Comparator|Azithromycin 500mg|500mg azithromycin PO daily for seven days
89684126|NCT04294069|Active Comparator|Azithromycin 1000mg|1000mg azithromycin PO once at admission
89684127|NCT00782639|Active Comparator|Iopamiro-370|
89684128|NCT00782639|Active Comparator|Visipaque 320|
89684129|NCT03805295|Experimental|Spring 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Winter-Spring 2018. They will serve as the control group in Fall 2018.
89684130|NCT03805295|Experimental|Fall 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Fall 2018.
89684131|NCT05744219|Experimental|Iv Iron|Ferric Carboxymaltose, single dose, Intra venous 1000 mg in 100 ml 0.9% NaCl
89684132|NCT05744219|Placebo Comparator|Placebo|Placebo, single dose, Intra venous 0.9% NaCl 100 ml
89684133|NCT01997229|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction phase: 3 vials of study drug (equivalent to 900 mg of eculizumab) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (equivalent to 1200 mg of eculizumab) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (equivalent to 1200 mg of eculizumab) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
89684134|NCT01997229|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient; Induction phase: 3 vials of study drug (placebo) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (placebo) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (placebo) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
88997682|NCT05808517|Experimental|TC plus rTMS group|Participants received 12 one-hour sessions over 4 weeks (three times per week with a day between sessions). Each session of rTMS consisted of a sequence of three stimulation pulses per string with a string interval of 1 s (total 500 strings, total 1,500 stimulation pulses, and total stimulation time of 30 mins per session). After subjects finished each rTMS session, they immediately attended the TC class together with the participants in the TC-alone group.
88997683|NCT05808517|Active Comparator|TC-alone group|Participants underwent a 4-week intervention program consisting of simplified Yang style 12-Form Easy TC given as 1-hour sessions, three times per week. Each session included 5 to 10 minutes of warm-up exercise, 45 minutes of TC practice, and 5 to 10 minutes of cool-down exercise. The TC intervention was conducted in a small group format (i.e., 6-8) led by a trained TC instructor.
88997684|NCT05808517|No Intervention|Treat-as-usual control group|Participants in the TAU control group received treatments as usual for 4 weeks. No additional sleep intervention was provided. All participants were required to complete the subjective and objective assessments.
88997685|NCT05808504|Experimental|Patients with Parkinson disease|Patients with idiopathic PD. Will receive real or sham transcranial alternating current stimulation at the second visit according to the randomization order. The other stimulation condition will be applied at the third visit.
88997686|NCT05808504|Experimental|Healthy volunteers|Healthy volunteers with no major cognitive impairment. Will receive real or sham transcranial alternating current stimulation at the second visit according to the randomization order. The other stimulation condition will be applied at the third visit.
88997687|NCT05808491|No Intervention|control|provide usual care, which includes patient education sheets and medical treatment covered by National Health Insurance regulations
88997688|NCT05808491|Experimental|intervention|provide a resilience intervention by teaching participants how to assess their level of resilience and how to minimize their level of stress. Other objectives include to enhance coping, to control belief, and to manage skills through role-play, group discussion, and individual practice.
89052497|NCT04577937|Experimental|PSG in LAM patients|Patients affected by LAM underwent whole-night PSG
89052498|NCT04592939|Other|Group 1: immediate weight bearing|
89216465|NCT03632993|Active Comparator|Treatment I: CCH Shallow Injection, 3 Aliquots|"In Treatment I, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 milliliters (mL) aliquots (for a total injection volume of 0.3 mL).~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 milligrams (mg) of CCH (0.84 mg in each treatment area)."
89216466|NCT03632993|Active Comparator|Treatment II: CCH Shallow Injection, 1 Aliquot|"In Treatment II, CCH will be injected subcutaneously while the participant is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
89216467|NCT03632993|Active Comparator|Treatment III: CCH Deep Injection, 1 Aliquot|"In Treatment III, CCH will be injected subcutaneously while the participant is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
89216468|NCT03632993|Active Comparator|Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots|"In Treatment IV, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5 mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
89684135|NCT00800839|Experimental|Busulfan + Fludarabine + Cyclophosphamide|Busulfan starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
89684136|NCT02000583|Experimental|Aerobic Exercise Group|Exercise 150 minutes per week (over 3 to 5 days) for 52 weeks
89684137|NCT02000583|Other|Control Group|Standard of Care exercise recommendations
89684138|NCT00814255|Experimental|2|Conservative medical therapy plus adalimumab
89684139|NCT00814255|Active Comparator|1|Conservative medical therapy (lisinopril, losartan, atorvastatin)
89684140|NCT00814255|Experimental|conservative medical therapy plus galactose|drug: galactose 0.2 g /kg/dose (maximum dose 15g) po BID
89684141|NCT02000973|Placebo Comparator|Normal saline|General anesthesia combined with thoracic epidural 0.9% normal saline 8ml
89684142|NCT02000973|Experimental|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine 8ml
89684143|NCT02000973|Experimental|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine 8ml
89684144|NCT02000973|Experimental|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine 8ml
89684145|NCT02002767|Experimental|Participants with renal impairment|Participants with severe renal impairment will receive a single dose of velpatasvir.
89684146|NCT02002767|Active Comparator|Participants with normal renal function|Participants with normal renal function will receive a single dose of velpatasvir.
89684147|NCT00815035|Active Comparator|Peanut OIT|Subjects randomized to receive active treatment with peanut protein flour.
89684148|NCT00815035|Placebo Comparator|Placebo|Subjects randomized to receive placebo in the form of oat flour.
89684149|NCT01985685|Experimental|Thiamine|200mg intravenous thiamine in 50ml 5% dextrose, single dose
89684150|NCT01985685|Placebo Comparator|Placebo|50ml intravenous 5% dextrose, single dose
89684151|NCT00815347|Other|1 Crossover|
89684152|NCT01985763|Experimental|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.
89684153|NCT02061969|Active Comparator|Insulin glargine|Insulin glargine starting at 0.1 unit/kg/day added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
89684154|NCT02061969|Experimental|linagliptin|Oral linagliptin 5mg once daily added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
89684155|NCT02003625|Placebo Comparator|A. GCSF + Placebo|GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis [days -4, -3, -2, -1] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.
89684156|NCT02003625|Experimental|B. GCSF + meloxicam|"B. GCSF + meloxicam:~Patients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected."
89684157|NCT04037683||MOLI participants pre IOL|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) after recruitment to MOLI RCT but prior to the start of the induction of labour (IOL) process
89684158|NCT04037683||MOLI participants post IOL (misoprostol/misoprostol)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/misoprostol Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
89684159|NCT04037683||MOLI participants post IOL (misoprostol/oxytocin)|Semi-structured interviews with MOLI participants - estimated 12 patients (until data saturation) 12 women post IOL with misoprostol/oxytocin
89684160|NCT04037683||Staff focus group pre and during MOLI recruitment|"A focus group in each of the 2 recruitment sites before the start of the MOLI trial (n=2) A focus group in each of the 2 recruitment sites and with each cadre of staff during the MOLI trial (n=8)~Research assistants~Residents~Consultants~Midwives"
89684161|NCT04768413||Group A|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
89684162|NCT04768413||Group B|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
89684163|NCT04383301|Active Comparator|Intra corneal ring segment|Intra corneal ring segment implantation for moderate keratoconus patients
89684164|NCT04383301|Active Comparator|Corneal Wavefront-guided TPRK and ACXL|Combined Corneal Wavefront-guided Transepithelial Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-linking following intracorneal ring segment by at least three months
89684165|NCT03356431|Experimental|Supervised group exercise|The supervised exercise group will receive a lower extremity exercise treatment, under physiotherapist supervision for 60 min, two times a week (12 sessions).
89684166|NCT03356431|Experimental|Home-based exercise|"For the home-based exercise group, exercises will be demonstrated to the patient with the supervision and guidance of a physiotherapist in an exercise session. These patients will perform the same exercise protocol at home at least twice a week.~In addition to the initial session, subjects will perform further two supervised sessions (at one week and four weeks after the initial session).~The exercise program are the same as the supervised group exercise."
89684167|NCT03211221|Active Comparator|Active rTMS|Active stimulation parameters will be 1-Hz, 10 seconds per train, 10 pulses per train (3 seconds inter-train interval) for a total of 160 trains (1600 pulses/session) at 130% of resting motor threshold (MT) (using the lowest value of the dominant hemisphere), once a day, 5 day/week, for 3 weeks. The coil will be positioned over the pre-SMA, targeted using the International 10-20 EEG System. Pre-SMA is defined at 15% of the distance between inion and nasion anterior to Cz (vertex) on the sagittal midline. The coil will be placed with the handle along the sagittal midline, pointing towards the occiput to stimulate bilaterally and simultaneously the pre-SMA.
89684168|NCT03211221|Placebo Comparator|Sham rTMS|Sham TMS will be administered by tilting the coil 90° off the scalp, with one wing of the coil touching the scalp. This sham-TMS approach produces a clicking sound that is very similar to an active TMS pulse and induces a voltage in the brain that is more than 75% lower than active TMS.
89684169|NCT02395185|Experimental|Milk|Milk bottle administration
89684170|NCT02395185|Experimental|Water|Water bottle administration
89684171|NCT02395185|Experimental|Sucrose|Sucrose bottle administration
89684172|NCT02396511|Experimental|TRC105 and Bevacizumab|TRC105 weekly intravenous infusion bevacizumab every 2 weeks intravenous infusion
89684173|NCT02396745|Experimental|TECR & ECM|Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)
89684174|NCT00816829|Placebo Comparator|1|Fenofibrate-matching placebo tablet
89684175|NCT00816829|Experimental|2|145 mg NanoCrystal fenofibrate tablet
89684176|NCT02062359|Experimental|All Participants|Patients will receive the standard National Cancer Institute (NCI) Surgery Branch non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of the anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ engineered peripheral blood lymphocyte (PBL) and aldesleukin
89684177|NCT02397291|Placebo Comparator|Part 1: Measurements of maternal and fetal concentrations|"At the time of the elective cesarean section, a blood sample of 0.5 ml will be obtained from a maternal heated hand vein at the time the umbilical cord is clamped. Then, the umbilical cord will be doubly clamped to isolate a segment. The umbilical artery and vein will be sampled for 0.5 ml of blood. There are no stable isotopes infused. Heating the maternal hand vein allows it to be arterialized. These patients are separate from those required for the stable isotope studies listed below."
88997689|NCT05808478|Experimental|Experimental Group (EG)|The experimental group will undergo treatment with innovative high-tech tools, such as Eye Tracking, for communication purposes. The duration of the treatment will be six months, twice a week, with sessions of 45 minutes.
88997690|NCT05808478|Active Comparator|Control Group (CG)|"The control group will undergo conventional AAC treatment, with low-tech tools, such as PECS or sign language.~The duration of the treatment will be six months, twice a week, with sessions of 45 minutes."
88997691|NCT05808387|Experimental|Resveratrol|Trans-resveratrol, 1000mg daily for 90 days.
88997692|NCT05808387|Placebo Comparator|Control|Starch, 1000mg daily for 90 days.
88997693|NCT05808348||COVID-19 Group|Demographic and clinical information, Numerical Pain Rating Scale, Falls Efficacy Scale International, Baecke Physical Activity Questionnaire
88997694|NCT05808348||Healthy Group|Demographic and clinical information, Numerical Pain Rating Scale, Falls Efficacy Scale International, Baecke Physical Activity Questionnaire
88997695|NCT05808322|Experimental|Study Group|Treated with P1101 (Ropeginterferon alfa-2b) plus standard of care (SOC)
88997696|NCT05808322|Active Comparator|Control Group|Treated with SOC alone
88997697|NCT05808296|Experimental|Experiment|aromatherapy will be performed by dropping 2 drops of lavender oil on the shoulder with a sponge 20 minutes before bedtime every night for a week
88997698|NCT05808296|Sham Comparator|Control|Saline solution will be performed by dropping 2 drops of saline solution on the shoulder with a sponge 20 minutes before bedtime every night for a week
88997699|NCT05808244|Experimental|tgCBFI|
88997700|NCT05808244|Active Comparator|Usual psychiatric care|
88997701|NCT05808231|Other|Control Group|Standard of Care alone
88997702|NCT05808231|Other|Experimental Group|Standard of Care + Quinine Sulfate
88997703|NCT05808205||Open Non-comparative|In this study, it is planned to include about 70 patients each year, assuming two treatments per patient. Due to the post-market nature of the study, this sample size is not based on a formal statistical sample size calculation, but the size is considered appropriate for the study purposes and considering the enrollment rate estimated at the center.
89684178|NCT02397291|Active Comparator|Part 2: Stable Isotope Studies|Prior to the elective cesarean section, 2 samples from the patient's heated hand vein are obtained to establish a baseline for the compounds. Next, a primed constant infusion containing the stable isotopes of mannose and myoinositol is begun in a peripheral IV of the mother. This is continued approximately 2 hours until the Cesarean section is complete and the umbilical cord samples are obtained. An additional 3 samples are obtained from the patient's heated hand vein: 1 at the start of the cesarean section, 1 at the time the fetus is delivered, and 1 at the time the umbilical cord samples are obtained.
89684179|NCT00816907|Experimental|Metformin|Encapsulated metformin 1000-2000 mg/day
89684180|NCT00816907|Placebo Comparator|Placebo|Matching placebo capsules 2-4 daily
89684181|NCT00817219|Experimental|TACLONEX ointment|
89684182|NCT02007369|Experimental|WhatsApp|Provide peer support and deliver relapse prevention messages through WhatsApp for 8 weeks and telephone follow ups
89684183|NCT02007369|Experimental|Facebook|Provide peer support and deliver relapse prevention messages through Facebook for 8 weeks and telephone follow ups
89684184|NCT02007369|No Intervention|Control|Telephone follow ups and received a self-help book only
89052499|NCT04592939|Other|Group 2: 6 week toe touch weight bearing|
89052500|NCT00579462||1|Patients with advanced lung cancer.
89052501|NCT00579540|Active Comparator|1|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
89052502|NCT00579540|Active Comparator|2|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
89052503|NCT00579540|Active Comparator|3|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
89052504|NCT04592315|Experimental|1|Dose 5 mg
89052505|NCT04592315|Experimental|2|Dose 10 mg
89052506|NCT04592315|Experimental|3|Dose 20 mg
89052507|NCT04592315|Experimental|4|Dose 40 mg
89052508|NCT04592315|Experimental|5|Dose 60 mg
89684185|NCT00817843|Experimental|First Simva 80mg then Simvai/Eze10/10mg|First 6 weeks of Simvastatin 80mg, then 6 weeks of Simvastatin/Ezetimibe 10/10mg after 6 weeks of placebo washout
89684186|NCT00817843|Experimental|First Simva/Eze 10/10mg then Simva 80mg|First 6 weeks of Simvastatin/Ezetimibe 10/10mg, then 6 weeks of Simvastatin 80mg after 6 weeks of placebo washout
89684187|NCT02008149|No Intervention|Standard of care group|SCI individuals receiving conventional rehab
89684188|NCT02008149|Experimental|FES-rowing group|Individuals with SCI participating in an FES-rowing program
89052509|NCT04592315|Experimental|6|Dose 80 mg
89684189|NCT00817999|Experimental|Loading Dose|Participants received a 300 mg dose of clopidogrel with or without GFJ.
89684190|NCT00817999|Experimental|Maintenance Dose|Participants received clopidogrel 75 mg/day for 7 days with or without GFJ
89684191|NCT03839485|Active Comparator|Pasta Guedes-Pinto|Endodontic treatment using Guedes-Pinto Paste
89684192|NCT03839485|Experimental|Pasta Guedes-Pinto without antibiotic|Endodontic using Guedes-Pinto paste without antibiotic
89684193|NCT02008617|Active Comparator|Study Drug|Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000 (Study Drug)
89684194|NCT02008617|Sham Comparator|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
89684195|NCT03839251|Other|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
89684196|NCT00819403|Active Comparator|simvastatin|Simvastatin 40 mg daily
89684197|NCT00819403|Active Comparator|simvastatin/ezetimibe|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
89052510|NCT00579657|Placebo Comparator|1|"Intervention: 'control diet, supported by dietary supplement twice daily'~control diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement daily)]"
89052511|NCT00579657|Experimental|2|"Intervention: 'high cereal fiber diet, supported by dietary supplement twice daily'.~high cereal fiber diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber > 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber daily)]"
89684198|NCT02010021|No Intervention|No drug treatment|Post-menopausal women with stage I-III breast cancer will have surgical resection of tumor and tumor tissue will be used to study cell growth signaling pathways ex-vivo.
89684199|NCT02010021|Active Comparator|Letrozole-presurgical|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
89684200|NCT03272737|Active Comparator|Traditional strength exercise|"This group will be carried out to knee extension exercise without blood flow restriction.~Interventions:~Plethysmography;~Protocols of isometric exercise;~Pulse wave Velocity (PWV);~Flow-mediated dilatation (FMD);~Arterial pressure and blood pressure;~Quality of life (Euro Qol);~1RM test~Speed gait test~Anthropometric Assessment"
89684201|NCT03272737|Active Comparator|Strength exercise with KAATSU|"This group will be carried out to knee extension exercise with partial blood flow restriction.~Interventions:~Plethysmography;~Protocols of isometric exercise;~Pulse wave Velocity (PWV);~Flow-mediated dilatation (FMD);~Arterial pressure and blood pressure;~Quality of life (Euro Qol);~1RM test~Speed gait test~Anthropometric Assessment"
89684202|NCT02062905|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
89684203|NCT02062905|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
89684204|NCT00820573|Placebo Comparator|Placebo|Placebo to be provided for 6 weeks
89684205|NCT00820573|Experimental|Sitagliptin|Sitagliptin to be provided for 6 weeks
89684206|NCT00820573|Experimental|Metformin|Metformin to be provided for 6 weeks
89684207|NCT00820573|Experimental|Sitagliptin+Metfromin|Sitagliptin + Metformin combined will be provided for 6 weeks
89684208|NCT03113305||Gastric bypass patients|Patients planned to undergo Gastric bypass procedure. Patients will be assessed -1 month, 3-, 24-, 48- and 60 months post surgery.
89684209|NCT03113305||Healthy controls|Healthy controls with no planned weight loss/gain. Control participant assessments will be time-matched with patients.
89684210|NCT00821041|No Intervention|Waiting list control|
89684211|NCT00821041|Experimental|CBT|A 6 weeks online course. Each week participants log on to view videos and read information that focus on a variety of intervention techniques. These include relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training. Participants also monitor their sleep using an online sleep diary and respond to questions regarding their adherence to the program.
89684212|NCT00821119|Active Comparator|NCPAP|preterm infants with nasal positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome will be compared to preterm infants with nasal intermittent positive pressure ventilation
89684213|NCT00821119|Experimental|NIPPV|preterm with nasal intermittent positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome
89684214|NCT02959645||Cervical Dystonia|patients will have Cervical Dystonia
89684215|NCT02959645||Healthy control|Healthy Volunteers
89684216|NCT05217355|Experimental|MBA-P01|Experimental group, Dose: 20U
89684217|NCT05217355|Placebo Comparator|Placebo|Placebo gorup, Normal saline
89684218|NCT05236855||Intervention|Women seen at the colposcopy clinic at Nova Scotia Health in Gynaecology-Oncology because of an abnormal cervical screen lab report
89684219|NCT05236855||Control|Women seen at the General Gynaecology Clinic and the Izaak Walton Killam (IWK) Health Centre with a normal cervical screen lab report
89684220|NCT04382599|Experimental|Added sugar warning message|"Message displayed on warning labels is: WARNING: High in added sugar."
89684221|NCT04382599|Experimental|Weight gain warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to weight gain."
89684222|NCT04382599|Experimental|Type 2 diabetes warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to type 2 diabetes."
89684223|NCT04382599|Experimental|Heart damage warning message|"Message displayed on warning labels is: WARNING: Excess consumption of drinks with added sugar contributes to heart damage."
89684224|NCT04382599|Active Comparator|Neutral message|"Message displayed on control label is: Please refrain from littering."
89684225|NCT02010645|Experimental|Eltrombopag + Decitabine|"Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.~Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle."
89684226|NCT02944747|Experimental|Education & paper based calendar|"The participants will be counseled on importance of remembering LMP. In addition, a free calendar will be provided to the participant who will be asked to record menstrual bleeding and spotting dates in each month. The women will be asked to record no bleeding if she did not bleed for any particular month. Likewise, if anybody forgets to record, she will ask to keep a record of it in the subsequent month. Female counselors from the study team will conduct the group or individual education sessions."
88997704|NCT05808192||tolerant|patients who withdraw IS drugs after LT
88997705|NCT05808192||non tolerant|patients who couldn't wean IS drugs
88997706|NCT05808114|Experimental|Group cognitive behavioral therapy|Friends Program
88997707|NCT05808114|Experimental|Treatment as Usual|A TAU condition during which participants received routine care services tailored to each child individually.
88997708|NCT05808101||With Neuro-QoL Depression scale T-score > 55|"Collection of demographic and clinical data (age, gender, BMI, ethnicity, age of onset, number of relapses).~Administration of the Neuro-QoL depression scale~Neurological exam to evaluate disability and calculate the EDSS score (ranging from 0 to 10)~Neurological cognitive and functional assessments: a 9-hole Peg Test and 25-ft Timed Walk from the Multiple Sclerosis Functional Composite (MSFC); the Symbol Digit Modality Test (SDMT)~Administration of the Fatigue Severity Scale (FSS)~Collection of a 4-days food diary to evaluate diet composition of enrolled pwMS~Administration of the Stanford 7-day Physical Activity Recall Scale (PAR)~Evaluation of sleep quality by administration of the Neuro-QoL sleep disturbance scale~Collection of a stool sample for gut microbiome and metabolome analyses~Collection of a saliva sample for microbiome and metabolome analyses"
88997709|NCT05808101||With Neuro-QoL Depression scale T-score < 55|"Collection of demographic and clinical data (age, gender, BMI, ethnicity, age of onset, number of relapses).~Administration of the Neuro-QoL depression scale~Neurological exam to evaluate disability and calculate the EDSS score (ranging from 0 to 10)~Neurological cognitive and functional assessments: a 9-hole Peg Test and 25-ft Timed Walk from the Multiple Sclerosis Functional Composite (MSFC); the Symbol Digit Modality Test (SDMT)~Administration of the Fatigue Severity Scale (FSS)~Collection of a 4-days food diary to evaluate diet composition of enrolled pwMS~Administration of the Stanford 7-day Physical Activity Recall Scale (PAR)~Evaluation of sleep quality by administration of the Neuro-QoL sleep disturbance scale~Collection of a stool sample for gut microbiome and metabolome analyses~Collection of a saliva sample for microbiome and metabolome analyses"
88997710|NCT05808088|Experimental|Group 1, sound-files from inclusion|
88997711|NCT05808088|Active Comparator|Group 2, sound-files after 7 days|
88997712|NCT05808075|Experimental|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal Dental Composite will be selected , the tooth will be selectively etched with Phosphoric acid gel (37%) to enamel for 30 seconds .The etchant will be removed and the cavity will be rinsed with water spray for 30 seconds and air dried. A uniform thin layer of the adhesive will be applied on all the prepared surfaces then will be dispersed with a stream of air and then light cured. The restorative material will be applied using an incremental filling technique starting at the gingival wall. The restoration will be cured in 2 mm increments for 20 s. The proximal surfaces will be contoured with finishing strips following manufacturer's instructions. The occlusion will be checked with a thin articulating paper and will be adjusted by removing material with a fine diamond or stone. Finishing will be accomplished by finishing diamond stones then polished using rubber points
89684227|NCT02944747|Experimental|Education & SMS system|Cell-phones will be provided free of cost to participants who will be asked to text the bleeding dates of their menstruation and spotting every month within 3 days of the start of the bleeding. Study team will collaborate with a mobile phone company and the charge of SMS for reporting LMP dates will be free for the user. In situations, where the participant fails to text, she will be provided with several SMS reminders after the due date.
89684228|NCT02944747|Experimental|Education & smart-phone application|Smart phones with an application and an inbuilt reminder system will be provided free of cost to participants who will be asked for recording menstruation dates. Experienced programmer from icddr,b will be involved in developing the application. Again, participants will be asked to record bleeding dates each month and will upload the data in the central server via internet. If participants fail to record the dates and upload the data, an automatic reminder will be sent.
89684229|NCT02944747|No Intervention|Comparison|The participants will not receive any of the interventions that are focused in this study.
89684230|NCT02833207|Experimental|EDD Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
89684231|NCT02833207|Experimental|EDD Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
89684232|NCT02833207|Experimental|ROV Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
89684233|NCT02833207|Experimental|ROV Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
89684234|NCT02065479|Active Comparator|Ticagrelor|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
89684235|NCT02065479|Experimental|Prasugrel|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
89684236|NCT05236621|Experimental|Permadomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
89684237|NCT02066727|Active Comparator|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
89684238|NCT02066727|Placebo Comparator|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
89684239|NCT05235997|Experimental|Hydrolized Collagen Peptide|This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
89684240|NCT05235997|Placebo Comparator|Placebo|This arm will be allocated randomly and receive placebo throughout the study.
89684241|NCT04349241|Experimental|favipiravir|favipiravir in a regimen of 3200 mg (1600 mg 12 hourly) loading dose on day-1 followed by 1200 mg maintenance dose (600 mg 12 hourly daily) on day-2 to day-10
89684242|NCT04349241|Active Comparator|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10.
89684243|NCT05212129|Active Comparator|Treatment Arm A (hEDS)|(n=60) patients who meet criteria for hEDS or Hypermobile Spectrum Disorder (HSD) will receive aVNS (acoustic vagal nerve stimulation) therapy via filtered vocal music sound therapy using the Safe and Sound protocol (randomized 1:1 to active vs sham music; double blind study design)
89684244|NCT05212129|Experimental|Treatment Arm B (ANS Dysfunction)|(n=30) patients with concerns for ANS dysfunction (with or without hEDS) will receive auricular percutaneous vagal nerve stimulation (pVNS) therapy. Additional sub-study option: 15-20 subjects will undergo gastric MRI and (those who consent to it) will also participate in a biobank blood sample collection study.
89684245|NCT02012283|Experimental|Vegetable Intake with Spices Added|Subjects consuming vegetables with mixed-spices added.
89684246|NCT02012283|Active Comparator|Vegetable Intake without Spices Added|Subjects consuming vegetables without spice.
88997713|NCT05808075|Active Comparator|Tetric N-Ceram Nano-hybrid Dental Composite|The tooth will be selectively etched with N-Etch (IvoclarVivadent, Schaan, Liechtenstein) Phosphoric acid gel (37%) to enamel for 30 seconds. The etchant will be removed and the cavity will be rinsed with water spray for 30 seconds and dried with air syringe. A Uniform thin layer of the adhesive will be applied on all the prepared surface then dispersed with a stream of air and then light cured (Woodpecker Light Cure LED ,China).The restorative material Tetric N-Ceram Nano-hybrid will be applied using an incremental filling technique starting at the gingival wall. Each increment will be polymerized for 20 seconds., Occlusal adjustments will be made using articulating paper. Finishing will be accomplished by finishing diamond then polished using rubber points
88997714|NCT05808049|Experimental|MXP22 (Probiotic and antioxidant capsule)|Dose : NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
88997715|NCT05808049|Placebo Comparator|Placebo (Microcrystalline Cellulose )|Dose : NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once dailybafter lunch for 120 days
88997716|NCT05808036|Other|DOMINO app - DOMINO app|The patients start with the DOMINO diet (8 weeks). Patients that experienced symptom improvement, will continue with the DOMINO diet (6 weeks).
88997717|NCT05808036|Active Comparator|DOMINO app - low FODMAP diet|The patients start with the DOMINO diet (8 weeks). Patients that experienced no symptom improvement, will switch to the strict low FODMAP diet (6 weeks).
88997718|NCT05808023|Active Comparator|Mannitol|Mannitol belongs to the group of polyols within the FODMAPs.
88997719|NCT05808023|Active Comparator|Fructans|Fructans belong to the group of oligosaccharides, specifically the fructose-oligosaccharides (FOS), within the FODMAPs.
88997720|NCT05807984|Experimental|carbon ion therapy for unresectable local recurrent rectal cancer|
88997721|NCT05807958|Experimental|Skin Prick Automated Test|
89052512|NCT00579657|Experimental|3|"Intervention: 'high protein diet, supported by dietary supplement twice daily'~high protein diet [carbohydrates 40 - 45% , protein > 25 - 30%; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 25 g whey and plant protein daily)]"
89684247|NCT02812615|Experimental|Malnourished participants|After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months.
89684248|NCT02402127|Other|TruEye, MyDay, clariti 1day|Narafilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 1 day (16 hours).
89684249|NCT02402127|Other|TruEye, clariti 1day, MyDay|Narafilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
89684250|NCT02402127|Other|MyDay, TruEye, clariti 1day|Stenfilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
89684251|NCT02402127|Other|MyDay, clariti 1day, TruEye|Stenfilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
89684252|NCT02402127|Other|Clariti 1day, TruEye, MyDay|Somofilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
89684253|NCT02402127|Other|Clariti 1day, MyDay, TruEye|Somofilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
89684254|NCT05195749|Experimental|COVID-19 Patients|Moderate to severe COVID-19 patients receiving SOC and '005.
89684255|NCT05195749|Placebo Comparator|Control|Moderate to severe COVID-19 patients receiving SOC and placebo.
89684256|NCT02067039|Experimental|HIV self-testing|The intervention group of MSM (HIV negative or unaware of HIV status) will receive 4 rapid HIV test kits - 2 oral fluid tests (OraQuick), and 2 finger-stick blood tests (Sure Check). Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period, and men in the intervention arm will be allowed to order additional test kits to replenish the ones they use or give away. At month 12, all HIV-negative or those who are unaware of their HIV status participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a dried blood spot (DBS) specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
89052513|NCT00579657|Experimental|4|"Intervention: diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily.~high cereal fiber/high protein (MIX) moderately high cereal fiber/high protein diet (carbohydrates 45- 50)% , protein 20 - 25%; fat ca. 30% of energy content; dietary fiber 15 - 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber and 2 x 25 g whey and plant protein daily)"
88815851|NCT01116986|Experimental|28, No Patch, No Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815852|NCT01116986|Experimental|29, No Patch, No Gum, No Prequit, Min In-Person, Min Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815853|NCT01116986|Experimental|30, No Patch, No Gum, No Prequit, Min In-Person, Int Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815854|NCT01116986|Experimental|31, No Patch, No Gum, No Prequit, Int In-Person, Min Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
88815855|NCT01116986|Experimental|32, No Patch, No Gum, No Prequit, Int In-Person, Int Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
88815856|NCT01098422|Experimental|Yttrium-90 Radioactive Resin Microspheres|Yttrium-90 Radioactive Resin Microspheres
88815857|NCT01098500||Cancer patients|Adults (age ≥18 years) with at least two ICD-9 codes for a particular cancer within a 6 month timeframe and at least one code for a TKI drug that occurs on or after the first cancer diagnosis code
88815858|NCT01098578|Experimental|Floseal|Received 1 syringe of Floseal for treatment of posterior epistaxis.
88815859|NCT01099202|Experimental|Procrit|Starting dose 40,000 units subcutaneously once a week with chemotherapy.
88815860|NCT01099202|No Intervention|No Procrit|No intervention.
88815861|NCT02448303|Experimental|Arm 1|pembrolizumab
88815862|NCT02448303|Experimental|Arm 2|acalabrutinib plus pembrolizumab
88815863|NCT02449473|Experimental|Tralokinumab Dose Regimen|Tralokinumab Subcutaneous Injection
88815864|NCT02449473|Placebo Comparator|Placebo Dose Regimen|Placebo Subcutaneous Injection
88815865|NCT02450799|Experimental|AcrySof IOL|Acrylic IOL, prior implantation (1994-2000) in one or both eyes
88815866|NCT02450799|Active Comparator|Silicone IOL|Silicone IOL, prior implantation (1994-2000) in one or both eyes
88815867|NCT02450799|Active Comparator|PMMA IOL|PMMA IOL, prior implantation (1994-2000) in one or both eyes
89684257|NCT02067039|No Intervention|Information only|All comparison group of MSM (HIV negative or unaware of HIV status) will take a baseline survey. Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period. At month 12, all HIV-negative and unaware of their HIV status comparison arm participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a DBS specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
89684258|NCT02067273|Experimental|TMS Intervention for 5 days|Application of Transcranial Magnetic Stimulation (TMS) for up to 5 days
89684259|NCT02067273|Experimental|TMS Intervention for 1 day|Application of Transcranial Magnetic Stimulation (TMS) for 1 day
89684260|NCT02151253|Experimental|Armodafinil First, Then Placebo|"During double-blind treatment subjects took armodafinil for 4 weeks before crossing over to placebo for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
89684261|NCT02151253|Placebo Comparator|Placebo First, Then Armodafinil|"During double-blind treatment subjects took placebo for 4 weeks before crossing over to armodafinil for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
89684262|NCT02151331|Experimental|REP + EF|Replication Effective Programs (REP) augmented with External Facilitation (EF)
89684263|NCT02151331|Experimental|REP + EF/IF|Replicating Effective Programs (REP) augmented with External and Internal Facilitation (EF + IF)
89684264|NCT02067585|Experimental|LAGB|Standardized Lipid meals will be served to Laparoscopic adjustable gastric banding patients.
89684265|NCT02067585|Experimental|LRYGB|Standardized Lipid meals will be served to the Laparoscopic Rou-en-Y gastric bypass patients.
89684266|NCT02067585|Experimental|Non-surgical|Standardized Lipid meals will be served to the non-surgical obese patients
89684267|NCT02314689|Experimental|IV citrulline|IV citrulline 20 mg/kg bolus with dose escalation of 10 mg/kg to target citrulline concentration of 100 µmol/L with a maximum dose of 60 mg/kg.
89684268|NCT02403999|Experimental|Test shampoo|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
89684269|NCT02403999|Experimental|Test bath foam|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
89684270|NCT02403999|Experimental|Test head to toe Wash|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
89684271|NCT02405325|Experimental|Physical Activity|The program will be run by peer Leaders and senior center staff with the support of UCSD staff. Participants will work towards a 2000 increase in daily steps through self-paced incidental walking and peer led group walks.
89684272|NCT02405325|No Intervention|Usual Care|Measurement at baseline, 6, 12, 18 and 24 months only with a health related event at each time point.
89052514|NCT04592198|Experimental|A (Buccal 0.25 Mg)|Palonosetron HCl Buccal Film 0.25 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
89052515|NCT04592198|Experimental|B (Buccal 0.5 Mg)|Palonosetron HCl Buccal Film 0.5 Mg and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
89052516|NCT04592198|Active Comparator|C (IV Injection 0.25 Mg)|IV palonosetron 0.25 Mg (ALOXI®) and oral dexamethasone 12 Mg, both administered on Day 1, and dexamethasone 8 Mg PO on days 2 and 3
89052517|NCT04592432|Experimental|SIGN@L-A followed by SIGN@L-B|"Participants in this arm will have access to the prototype SIGN@L-A of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-B."
89052518|NCT04592432|Experimental|SIGN@L-B followed by SIGN@L-A|"Participants in this arm will have access to the prototype SIGN@L-B of the serious game for seven days. They will have access to this prototype from their personal computer and will be able to play with it whenever they want and for how long they wish during this period. After these seven days, they will have access the same way to the prototype SIGN@L-A."
89052519|NCT00579774|Experimental|1 - Low AGE Diet|Low Age Diet
89052520|NCT00579774|Active Comparator|2 - Regular Diet|Regular Diet
89052521|NCT04592354|Active Comparator|Oxaloacetate Therapeutic Arm|"Anhydrous Enol-Oxaloacetate~A 500 mg oxaloacetate capsule taken by mouth twice a day~Planned study duration is 6 weeks with an interim assessment at the end of 2 weeks and final assessment at 6 weeks"
89052522|NCT04592354|Placebo Comparator|Placebo Arm|"Rice Flour~A 500 mg rice flour capsule taken by mouth twice a day"
89052523|NCT04592081|Experimental|DEXTENZA placed within the upper canaliculus|Dextenza placed within the upper canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
89052524|NCT04592081|Active Comparator|DEXTENZA placed within the lower canaliculus|Dextenza placed within the lower canaliculus following bilateral cataract extraction surgery with posterior chamber intraocular lenses implantation.
89052525|NCT00579852||1|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day.
89052526|NCT04591964|Active Comparator|baseline|standard medical therapy + using of mobile application + improving therapy
89052527|NCT04591964|No Intervention|Control|standard medical therapy
89052528|NCT04592042|Experimental|Feel-Good-Group|Pre-post assessment of feasibility and putative efficacy of an emotion-oriented cognitive-behavioral group intervention over 8 sessions and four weeks.
89052529|NCT04591769|Experimental|Group T(Tapered- shaped)|Tracheal intubation using TaperedGuard Tracheal Tube
89684273|NCT02069847|Experimental|Esophageal stricture, Budesonide|Budesonide 1mg twice a day for a total of 8 weeks following endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR)
89684274|NCT02069847|No Intervention|Control group|Retrospective collect data for subjects who undergo endoscopic submucosal dissection or endoscopic mucosal resection
89684275|NCT02070237|Active Comparator|Enoxaparin Once Daily|This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.
89052530|NCT04591769|Active Comparator|Group C(Cylindrical-shaped)|Tracheal intubation using Hi-Contour Tracheal Tube
89052531|NCT04591847|Experimental|Vitamin D supplemented group|Vitamin D2 20000 IU 1 tab oral weekly start at GA 18 -22 weeks until delivery
89052532|NCT04591847|Experimental|Placebo group|Placebo drug (Appearance same as Vitamin D2) 1 tab oral weekly start at GA 18 -22 weeks until delivery
89052533|NCT00580086||1|
89052534|NCT04591535|Experimental|WD-1603 (tablet strength 1) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 1) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
89052535|NCT04591535|Experimental|WD-1603 (tablet strength 2) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 2) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
89052536|NCT04591535|Experimental|WD-1603 (tablet strength 3) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 3) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
89052537|NCT04591535|Experimental|WD-1603 (tablet strength 4) single dose|A single oral dose of carbidopa/levodopa extended release tablets (WD-1603 tablet strength 4) will be administered to each subject within 5 minutes at 30 minutes after serving standardized vegetarian breakfast under fed condition in each period as per randomization schedule.
89052538|NCT00580164||1|Splint
89052539|NCT00580164||2|No Splint
89052540|NCT00580242|Experimental|1|This is a Phase I dose escalation trial with three cohorts of 3-6 patients each plus 10 additional patients (up to a maximum total of 28 patients) treated at the candidate maximum tolerated dose.Cohorts will receive increasing doses of bortezomib at 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 in combination with lenalidomide at 10 mg a day for Days 1-21. Each cycle will be 28 days. Patients will receive up to 9 cycles of treatment, with efficacy assessed after 3, 6, and 9 cycles.
89052541|NCT04591496|Experimental|SmartFeeding4Kids|SmartFeeding4Kids: information about children's healthy diet and effective parental feeding practices, with a behavioral intervention (5 sessions plus 2 brief booster sessions online intervention)
89052542|NCT04591496|Active Comparator|SmartFeeding4Kids Health|Psychoeducational condition: information about children's healthy diet and effective parental feeding practices (5 sessions plus 2 brief booster sessions online intervention)
89052543|NCT00580281|Experimental|blood, urine, and dexa scan|This study will involve venipuncture for obtaining blood samples; a spot second void (whenever possible) urine sample will be obtained at the same time. A Dexa scan to evaluate bone density will be obtained at the beginning, middle and end of the study.
89052544|NCT04591457|Experimental|Insulin Glargine Sansulin|Drug product Insulin Glargine, Sansulin Log-G 100 IU/mL (PT. Sanbe Farma)
89052545|NCT04591457|Active Comparator|Insulin Glargine Lantus|Drug product Insulin Glargine, Pen Injector [Lantus] 100 IU/mL (PT. Sanofi-Aventis)
89052546|NCT00580320|Experimental|A|dacarbazine + bortezomib
89052547|NCT00567086|Placebo Comparator|A|
89052548|NCT00567086|Experimental|B|
89052549|NCT00567086|Experimental|C|
89052550|NCT00567086|Experimental|D|
89052551|NCT00580359|Active Comparator|A|S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
89684276|NCT02070237|Active Comparator|Enoxaparin Twice Daily|This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.
89052552|NCT00580359|Active Comparator|B|Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
89052553|NCT00567125||I|Patients with cholelithiasis operated on using standard laparoscopy method
89052554|NCT00567125||II|Patients with cholelithiasis operated on using low-pressure CO2 pneumoperitoneum laparoscopy
89052555|NCT04591340||test group|all the patients treated with HSCT are with nutrition risk, so they will be all included to accept nutrition therapy.
89052556|NCT04578132||Genitourinary cancer patients that suffered COVID-19|Patients diagnosed with genitourinary cancer (urothelial, kidney, prostate and germ) that suffered from COVID-19 infection prior to cancer treatment, during treatment, or after treatment.
89684277|NCT02406495|Experimental|filcon IV 1 and ocufilcon D|Habitual wearers of filcon IV 1 sphere lenses refitted with asphere ocufilcon D lenses.
89684278|NCT02071095|Experimental|Arm A: Poly-ICLC|Arm A (N=15): Patients will receive an injection of 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir) subcutaneously on day 1 and day 2.
89684279|NCT02071095|Placebo Comparator|Arm B: Normal Saline|Arm B: (N=5): Patients will receive an injection of normal saline subcutaneously on day 1 and day 2.
89052557|NCT04591418|Active Comparator|Rotary handpieces|
89052558|NCT04591418|Experimental|Er:YAG laser|
89052559|NCT00580593|Active Comparator|1|
89052560|NCT00580593|Sham Comparator|2|
89052561|NCT04591145||Observational group|Patients received bowel preparation and colonoscopy. The withdrawal phase video was saved and their lesions detection was record.
89052562|NCT00580749|Active Comparator|DJ|Naso disal jejunal(DJ) feedings randomized to 50% of subjects meeting criteria.
89052563|NCT00580749|Active Comparator|NG|Placement of naso gastric feeding tube through nare into stomach for enteral feeding.
89052564|NCT04591301|Experimental|HEC113995 PA•H2O 2.5mg|Healthy subjects are given HEC113995 PA•H2O 2.5 mg in a single dose.
89052565|NCT04591301|Active Comparator|HEC113995 PA•H2O 5mg|Healthy subjects are given HEC113995 PA•H2O 5 mg in a single dose.
89052566|NCT04591301|Active Comparator|HEC113995 PA•H2O 10mg|Healthy subjects are given HEC113995 PA•H2O 10 mg in a single dose.
89684280|NCT02406573|Experimental|Crest® Sensi-Stop™ Strips|Professionally Applied
89684281|NCT02071173|Experimental|Enrolled Patients|Subjects undergo an implant procedure to receive at least one investigational lead -- ACUITY X4 left ventricular (LV) CRT lead, RELIANCE 4-FRONT right ventricular (RV) ICD lead
89684282|NCT02348359|Experimental|50 mg of X-82 plus ivt anti-VEGF prn|Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
89684283|NCT02348359|Experimental|100 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
89052567|NCT04591301|Active Comparator|HEC113995 PA•H2O 20mg|Healthy subjects are given HEC113995 PA•H2O 20 mg in a single dose.
89684284|NCT02348359|Experimental|200 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
89684285|NCT02348359|Placebo Comparator|Placebo plus ivt anti-VEGF prn|Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
89684286|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in VSG|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing vertical sleeve gastrectomy
89684287|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in RYGB|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing Roux-en Y gastric bypass.
89684288|NCT02407041|Experimental|GR-MD-02|active arm
89684289|NCT05235841|Experimental|AG|The group that met the criteria of the study and applied acupressure protocol before Coronary Angiography
89684290|NCT05235841|No Intervention|CG|BEFORE CORONARY ANGIOGRAPHY, THE GROUP WITHOUT ANY INTERVENTION, CONTROL GROUP
89684291|NCT02206945|Experimental|neurofeedback|Two imaging sessions of neurofeedback.
89684292|NCT02206945|Placebo Comparator|control feedback|Two imaging sessions of feedback
89684293|NCT05235607|Experimental|Tumor antigen-sensitized vaccine and their sensitized T cells|"Tumor antigen-sensitized vaccine is administrated, 1- week interval, totally 2 times.~Then, Neo-antigen DC vaccine and their sensitized T cells are administrated, 2-week interval, totally 5 times."
89684294|NCT02093455|Active Comparator|Chardonnay Seed Flour (CSF)|Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.
89684295|NCT02093455|Placebo Comparator|Placebo|Pre-packaged capsules taken 3 times per day. For the first month, a total of 15 g/d. During months 2 - 4, a total of 30 g/d.
89052568|NCT04591301|Active Comparator|HEC113995 PA•H2O 40mg|Healthy subjects are given HEC113995 PA•H2O 40 mg in a single dose.
89052569|NCT04591301|Active Comparator|HEC113995 PA•H2O 60mg|Healthy subjects are given HEC113995 PA•H2O 60 mg in a single dose.
89052570|NCT04591301|Active Comparator|HEC113995 PA•H2O 80mg|Healthy subjects are given HEC113995 PA•H2O 80 mg in a single dose.
89052571|NCT04591301|Placebo Comparator|placebo|Healthy subjects are given placebo in a single dose.
89052572|NCT04577625|Active Comparator|L. reuteri Low Dose|L. reuteri will be delivered in a capsule at a low dose including Vitamin D3. Administration twice daily.
89052573|NCT04577625|Active Comparator|L. reuteri High Dose|L. reuteri will be delivered in a capsule at a high dose including Vitamin D3. Administration twice daily.
89052574|NCT04577625|Placebo Comparator|Placebo|The placebo product will be identical to the active product in taste and appearance and include Vitamin D3 but without the L. reuteri. Administration twice daily.
89052575|NCT00580827|Placebo Comparator|placebo disulfiram|placebo disulfiram (0 mg/day)
89052576|NCT00580827|Experimental|disulfiram 62.5|disulfiram at 62.5 mg/day
89052577|NCT00580827|Experimental|disulfiram 125|disulfiram at 125 mg/day
89052578|NCT00580827|Experimental|disulfiram 250|disulfiram at 250 mg/day
89052579|NCT00580905|Active Comparator|1|To compare the effects of adenosine at a dose of 80 mcg/kg/min for 30 minutes, Sodium nitroprusside will be used at a dose that produce similar systemic effects (5 mcg/kg/.min)
89052580|NCT00580905|Active Comparator|2|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
89052581|NCT00581022||1|Patients with Chronic Orthostatic Intolerance
89052582|NCT04577664|Active Comparator|TT group|
89052583|NCT04577664|Active Comparator|ST group|
89052584|NCT04591262|Experimental|PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV|PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.
89052585|NCT00567203|Experimental|1|
89052586|NCT00567203|Experimental|2|
89052587|NCT00567203|Placebo Comparator|3|
89684296|NCT05235529||Aortic valve replacement with surgery (SVAo)|This group of patients with severe aortic stenosis will be treated with aortic valve replacement with surgery.
89684297|NCT05235529||Transcatheter aortic valve implant (TAVI)|This group of patients with severe aortic stenosis will be treated with transcatheter aortic valve implant (TAVI).
89684298|NCT05164237|Experimental|group A|17 subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
89684299|NCT05164237|Experimental|group B|17 subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
89684300|NCT05164237|Experimental|group C|17 subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
89052588|NCT04590989|Experimental|Personalized Plan (PP)|"Each subject in the PP group will be allocated to one of five clusters based on their metabolic and genetic health biomarkers from samples of urine, plasma, serum, and saliva. 58 biomarkers will be included to characterize the 5 metabolic clusters/processes in the PREVENTOMICS platform: 1) oxidative stress; 2) inflammation; 3) carbohydrate metabolism; 4) lipid metabolism; 5) microbiota-generated metabolites. Eurecat Nutrition Team has prepared a list of recommended food items to increase and food to exclude/limit from the diet for each cluster. The list will be adopted by Simple Feast in creating five different menus that will encompass the 12 meals/week of breakfasts and dinners for the five different metabolic clusters. Additionally, subjects will receive personalized actionable Do's push notifications by ONMI. The messages are personalized based on user reports from the behavioral questionnaire at V2 in addition to inputs from the nutritional recommendations of food to increase."
89684301|NCT02341599|Experimental|Group A: Healthy|Healthy participants with normal renal function (Stage 1: eGFR ≥90 mL/min/1.73m^2).
89052589|NCT04590989|Placebo Comparator|Control Group|"Dietary intervention:~The second group of 50 subjects will receive meals from Simple Feast, after integrating their metabolic profile and other blood biomarkers by PREVENTOMICS, which are based on the national dietary guidelines.~Behavioral intervention:~Subjects will also receive nudges, after filling out ONMI's behavioral questionnaire at V2, but that will not be personalized (i.e. basic information that is available online from NHS and WHO)."
89052590|NCT04590638|Active Comparator|Tumescent with adrenaline|skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution containing adrenaline.
89052591|NCT04590638|Active Comparator|Tumescent without adrenaline|skin graft donor site of patients recurited in this group will be injected subcutaneously with tumescent solution not containing adrenaline.
89052592|NCT04590950||Single-group study|Severe haemophilia B patients substituted with eftrenonacog-alfa
89052593|NCT04590677||Group 1|Pregnant women at 36 weeks gestational age, who are not expected to have risk factors for preterm birth, n=150.
89052594|NCT04590677||Group 2|Pregnant women who have presented with signs and symptoms of threatened preterm labour (e.g. ruptured membranes, contractions, bleeding), at or after 24 weeks gestation, n=50.
89052595|NCT04590755|Experimental|Interactive father-child sessions and use of website|Intervention group will receive the Run Daddy Run intervention.
89052596|NCT04590755|No Intervention|No intervention (no interactive father-child sessions and use of website)|Intervention group will not receive the Run Daddy Run intervention.
89052597|NCT00567281|Experimental|1|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
89052598|NCT00567281|Active Comparator|2|Active rTMS to left/right Wernicke's region plus sham rTMS to opposite hemisphere middle temporal cortex
89052599|NCT00567437|Other|A|10 patients with no aortic stenosis
89052600|NCT00567437|Other|B|100 patients with asymptomatic AS
89052601|NCT00567515|Experimental|LAA Clip|AtriCure LAA Exclusion System
89052602|NCT04577703|Experimental|CT053PTSA (dose escalation)|"Patients were treated in 5 dose cohorts of 15 mg, 30 mg, 60 mg, 100 mg, and 150 mg QD capsules.~Patients receive treatment with CT053PTSA once on Cycle 0 Day 1 following a 7-day treatment-free withdrawal period to observe the safety and pharmacokinetic of CT053PTSA.~After that, Patients receive treatment with CT053PTSA per orally, beginning on Cycle 1 Day 1 for 28 day following a 7-day treatment-free withdrawal period to observe efficacy of CT053PTSA and determine to continue taking medicine or not. Each cycle had 28 days."
89052603|NCT04577586||Water|Patients who ingested only water as an oral contrast
89052604|NCT04577586||Milk|Patients who ingested milk as an oral contrast
89052605|NCT04577586||Mannitol|Patients who ingested mannitol as an oral contrast
89052606|NCT00567554|Experimental|1|EC-T
89052607|NCT00567554|Experimental|2|EC-T +/- B
89052608|NCT00567554|Experimental|3|Pw
89052609|NCT00567554|Experimental|4|Pw + RAD001
89052610|NCT00567554|Experimental|5|EC-T + H
89052611|NCT00567554|Experimental|6|EC-T + L
89052612|NCT04577469|Experimental|500 mg sulfadoxine / 25 mg pyrimethamine tablet|500 mg sulfadoxine / 25 mg pyrimethamine tablet will be administered once.
89052613|NCT04577469|Active Comparator|G-COSPE® tablets|G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) will be administered once.
89052614|NCT04590911|Experimental|CEP intervention|Cognitive Enrichment Program (CEP) : tailored for individuals who sustain a TBI in later adulthood. The CEP is a 12-week multimodal intervention structured into three modules designed to simultaneously address cognitive problems resulting from TBI, as well as age-related cognitive issues in the following domains: self-awareness, attention and memory, and executive functions.
89052615|NCT04590911|No Intervention|Usual care|Usual care : interventions within a holistic interdisciplinary rehabilitation program focused on resuming daily activities and social roles, if needed, as determined by treating physician; does not include any form of cognitive rehabilitation.
89052616|NCT04577508|Experimental|Functional Remediation|Functional Remediation
89052617|NCT04577508|Other|Control|Treatment as usual
89052618|NCT04590560|No Intervention|1-year screening interval|Women will follow the normal screening program (they will be invited to screen every year)
89052619|NCT04590560|Experimental|2-year screening interval|Women will be invited to screen every two years
89052620|NCT04590560|Experimental|3-tailored screening interval|the screening interval will be decided on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C)
88815868|NCT02416713|Placebo Comparator|Education Only (Control)|The Cellcontrol DriveID device will run completely in the background with no observable changes to cellphone functions while driving. During Week Four, participants will be presented educational materials on the dangers of distracted driving.
89052621|NCT04590287||Patients after ischemic stroke|The analysis included the presence of CVD risk factors in patients after ischemic stroke durning in the early rehabilitation.
89052622|NCT04590287||Patients after hemorrhagic stroke|The analysis included the presence of CVD risk factors in patients after hemorrhagic stroke durning in the early rehabilitation.
89684302|NCT02341599|Experimental|Group B: Mild RI|Participants with mild RI (Stage 2: eGFR ≥60 to <90 mL/min/1.73m^2).
89684303|NCT02341599|Experimental|Group C: Moderate RI|Participants with moderate RI (Stage 3: eGFR ≥30 to <60 mL/min/1.73m^2).
89684304|NCT02341599|Experimental|Group D: Severe RI|Participants with severe RI (Stage 4: eGFR <30 mL/min/1.73m^2) not receiving HD.
89684305|NCT02341599|Experimental|Group E: ESRD-HD|Participants with ESRD who are receiving HD for at least 3 months preceding the initial dose in this study (Stage 5).
89684306|NCT02408445|Experimental|Testosterone treatment|Testosterone cypionate (200 mg/ml) intramuscular injection
89684307|NCT02408445|No Intervention|No treatment|Subjects will not receive any testosterone during the study period.
89684308|NCT01889329|Experimental|RUTF-1|Made from local food ingredients
89684309|NCT01889329|Experimental|RUTF-2|Made from local food ingredients
89684310|NCT01889329|Active Comparator|Plumpynut|Made from peanut
89684311|NCT05235373||group A: (mild cases): with no progression of the respiratory symptoms.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
89684312|NCT05235373||group B: (moderate cases): who have worsened disease but not requiring ICU admission.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
89684313|NCT05235373||Group C: (sever cases): patient who needed ICU admission.|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
89684314|NCT05235373||Group D: (fatality cases): cases who died with or without ICU admission).|multislice CT finding,The CT finding were then compared to the short-term clinical outcome of the patients (1-3weeks), acquired from the hospital patient data archive.
89684315|NCT05235217|Experimental|Test product (T) 40 mg Hard Gelatin Capsules|Single oral dose of 40 mg capsule
89684316|NCT05235217|Active Comparator|Reference product (R) 40 mg Hard Gelatin Capsules (first dose)|Single oral dose of 40 mg capsule
89684317|NCT05235217|Active Comparator|Reference product (R) 40 mg Hard Gelatin Capsules (second dose)|Single oral dose of 40 mg capsule
89684318|NCT02016885|Experimental|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
89684319|NCT02016885|Experimental|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
88997722|NCT05807945|Experimental|Ropivacaine 7.5% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 7.5%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
88997723|NCT05807945|Active Comparator|Ropivacaine 2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
88997724|NCT05807893|Experimental|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
88997725|NCT05807880|Experimental|Intervention arm|"First, patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks for 4-6 cycles. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid from day 1 to day 21. Then a maintenance treatment will be run with penpulimab and capecitabine(the dose and the medication method remain the same) for every 3 weeks until PD or intolerance to drug toxicity.~Note: After using the penpulimab for 2 years, it is dependent on the researcher's judgement of the benefit evaluation whether to continue using it."
88997726|NCT05807828|Other|Control Group|This group will include medical students who will only watch instructional videos on basic THA skills on the cup and stem implantation before actual implantation on sawbones
88997727|NCT05807828|Other|VR Group|This group will include medical students who will watch instructional videos and perform three consecutive VR sessions on basic THA skills on the cup and stem implantation before actual implantation on sawbones
88997728|NCT05807815|No Intervention|Control group|Patients with oxygen saturation > 97% will only be observed. ORi values will be recorded blindly from the clinician. Adjustments to be made in FiO2 will be determined by the intensive care doctor independently of the study, and only observation will be made in this group.
88997729|NCT05807815|Active Comparator|ORi+SpO2 (oxygen saturation) group|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95<oxygen saturation≤%98
88997730|NCT05807776|Experimental|tislelizumab|Received tislelizumab for 2 cycles, 200mg, iv, d1,Q3W. Patients achieved PR or reduced SD were enrolled in arm 1 and accepted surgery. After surgery, patients in arm 1 would receive tislelizumab as adjuvant therapy for 3-6 months.
88997731|NCT05807776|Experimental|tislelizumab+lenvatinib|"Received tislelizumab for 2 cycles, 200mg, iv, d1,Q3W. Patients achieved PD or increased SD were enrolled in arm 2 and continued to accept treatment with tislelizumab and lenvatinib for 2 cycles.~After 2 cycles, patients would receive surgery according to their physical conditions.~After surgery, patients in arm 2 would receive tislelizumab and lenvatinib as adjuvant therapy for 3-6 months."
89684320|NCT02016885|Experimental|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
89684321|NCT02016885|Experimental|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
89684322|NCT02016885|Placebo Comparator|Vehicle|Vehicle Topical Wipes
89684323|NCT00802633|Active Comparator|Stapling device|Efficacy of stapling device during radical cystectomy
89684324|NCT00802633|Active Comparator|Ligasure Device|Efficacy of ligasure tissue sealing device during radical cystectomy
89684325|NCT02016963|Experimental|Raxibacumab arm|A maximum of 25 subjects (to include 3 evaluable female subjects) will receive a second dose of raxibacumab equal to that of the previous dose >= 4 months following the first dose.
89684326|NCT02018445|Other|Accell Evo3 DBM & Local Autograft|Accell Evo3 DBM (posterolateral gutter symptomatic side) and Local Autograft (posterolateral gutter contralateral non-symptomatic side)
89684327|NCT02342379|Experimental|Bevacizumab and TH-302|Patients will be treated with combination of bevacizumab and TH-302.
89684328|NCT02019069|Experimental|Liposomal cytarabine-daunorubicin CPX-351|"1st INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV at a dose of 65 units/m2/day over 90 minutes on days 1, 3, and 5.~2nd INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3.~CONSOLIDATION: Beginning on day 28, patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3."
89684329|NCT00821821|Experimental|MCI-186|
89684330|NCT00821821|Placebo Comparator|Placebo Group|
89684331|NCT03839875|Experimental|Active Treatment|
89684332|NCT02409459|Experimental|Injectafer|15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
89684333|NCT02409459|Placebo Comparator|Placebo|15 cc of Normal Saline IV push at 2 ml/minute
89684334|NCT05198167|Experimental|Hyperoxygenated Fatty Acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
89684335|NCT05198167|Experimental|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
89684336|NCT02409927|Other|Healthy participant|Each participant undergo 7 metabolic day, separate by at least 3 days, where they received a different dietary supplement on each day: control (no supplement), MCT oil 10g, MCT oil 20g, MCT oil 30g (provided from pure MCT oil), MCT homogenate 10g, MCT homogenate 20g, MCT homogenate 30g (provided by a 10% MCT homogenate emulsion)
89684337|NCT00816751|Active Comparator|1|
89684338|NCT00816751|Experimental|2|
89684339|NCT00822523|Experimental|Botulinum toxin type A, 20 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 20 units
89684340|NCT00822523|Experimental|Botulinum toxin, type A, 2 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 2 units
89684341|NCT00822523|Placebo Comparator|Placebo|Saline, Single dose, Intramuscular injection into right EDB
89684342|NCT02410707|Experimental|Nitrous Oxide Arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
89052623|NCT04590482|Experimental|letrozole then misoprostol|description:letrozole 2.5 mg each 12hours for 2 days at home followed by misoprostol 800mcg vaginally at hospital repeated after 4 hours if needed
89052624|NCT04590482|Placebo Comparator|placebo then misoprostol|Description:placebo each 12 hours for 2days at home followed by 800mcg misoprostol vaginally at hospital and repeat dose after 4 hours if needed
89684343|NCT00822757|Experimental|1|V710
89684344|NCT00822757|Placebo Comparator|2|Placebo
89684345|NCT02343081|Active Comparator|Temodal|Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
89684346|NCT02343081|Experimental|Dralitem|Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose
89684347|NCT03839329|Experimental|ACT Group Condition|The ACT group condition will receive two 90-minute group Acceptance and Commitment Training (ACT) workshops (scheduled approximately one week apart) and will complete assessments.
89684348|NCT03839329|No Intervention|Assessment-Only Condition|The Assessment-only condition will not receive any intervention and will only complete assessments.
89684349|NCT02343627|Experimental|NVXT Solution|NVXT Solution once daily for 60 days
89684350|NCT02343627|Placebo Comparator|Vehicle of test product|Vehicle of test product, once daily for 60 days
89684351|NCT00823069|Other|Perlane and Perlane-L|This is a split-face design injecting both Perlane and Perlane-L injectable gels, administered once. Each subject received Perlane-L on one side of the face, and Perlane on the other. Subjects were blinded to which side of their face receive Perlane or Perlane-L. The study was randomized and treatments successive.
89684352|NCT00823303|Experimental|Paricalcitol|titrated to achieve 40-60% PTH suppression
89684353|NCT00823303|Active Comparator|Calcitriol|titrated to achieve 40-60% PTH suppression
89684354|NCT02344251|Other|Group 1|Adherence measured by MEMS Cap
89684355|NCT02344251|Other|Group 2|Adherence measured by ID-Cap technology.
89684356|NCT02344407|Experimental|2|ChAd3-EBO Z
89052625|NCT00581217||Single arm study|Burn patients or patients with skin loss requiring split-thickness skin graft
89052626|NCT00581295||trauma|Diffuse optical spectroscopy measurment
89052627|NCT04589780||Posture Assessment|Posture will be assessed with New York Posture Rating Chart (NYPR) originally published in 1958
89052628|NCT04589780||Sagittal spinal alignment and mobility|Sagittal spinal alignment and mobility will be measured using the Spinal Mouse (IdiagAG Mülistrasse 18 CH-8320 Fehraltorf, Switzerland), a computer-aided, non-invasive device.
89684357|NCT02344407|Experimental|3|VSVG-ZEBOV
89684358|NCT02344407|Placebo Comparator|1|Placebo (Saline)
89684359|NCT00823459|Experimental|Single-Arm Everolimus|Single-arm study with patients receiving Everolimus orally once daily dosing of 10 mg continuously from Day 1 of study until progression of disease or unacceptable toxicity. In addition archival tissue will be analysed for markers of P13K/mTOR pathway activation.
89684360|NCT02411565|Active Comparator|Fermented Wheat Germ Extract (FWGE)|FWGE administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
89684361|NCT02411565|Placebo Comparator|Placebo Administration|Placebo administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
89684362|NCT03839407|Experimental|MUSE device Class 21|Participants will utilize the MUSE device for 12 weeks during the intervention period.
89684363|NCT03839407|No Intervention|No MUSE device Class 21|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
89684364|NCT03839407|Experimental|MUSE device Class 22|Participants will utilize the MUSE device for 12 weeks during the intervention period.
89052629|NCT04589780||Injury risk assessment|Injury risk will be evaluated with Functional Movement Screen (FMS) test battery. A previous systematic review has demonstrated acceptable reliability for the FMS
89052630|NCT04589858|Active Comparator|Group A|Received a supervised exercise protocol including both strengthening and stretching exercises for specific muscle groups.
89684365|NCT03839407|No Intervention|No MUSE device Class 22|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
89684366|NCT02020785|Active Comparator|Higher phosphorus period|Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks
89684367|NCT02020785|Placebo Comparator|Lower phosphorus period|Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks
89684368|NCT04974775||Critically Ill|Critically ill patients and patients in need of post-operative intensive care.
89684369|NCT04974775||Cardiac Arrest|Cardiac Arrest according to the ICD-10 I469 diagnosis.
89684370|NCT04974775||Sepsis|Sepsis according to the sepsis-3 criteria.
89684371|NCT04974775||Covid-19|Critically ill patients with a positive Covid-19 test.
89052631|NCT04589858|Experimental|Group B|Received manual therapies including both myofascial mobilization and manipulation technique in addition to a supervised exercise protocol.
89052632|NCT00567671|Experimental|Treatment|Corneal collagen cross-linking
89052633|NCT00567671|Sham Comparator|Control|Sham Treatment
89052634|NCT00581451|Experimental|A|bifeprunox 25 day
89052635|NCT00581451|Experimental|B|bifeprunox 14 day
89052636|NCT00581451|Experimental|C|bifeprunox 14 day
89052637|NCT00581451|Experimental|D|bifeprunox 9 day
89052638|NCT04589936|Experimental|COVID-19|Non-ventilated patients with COVID-19
89052639|NCT04589936|Active Comparator|Pneumonia control|Patients with pneumonia unrelated to COVID-19 requiring supplemental O2.
89052640|NCT04577196||Briefing supported by the trauma dashboard|During the entire chain of transmission (from the initial phone call to the end of the briefing to the trauma team) the trauma leader will be provided with a trauma dashboard to synthesize and disseminate the available information about the arriving patient.
89052641|NCT04577196||Briefing without the trauma dashboard|The transmission chain will not be supported by any specific tool.
89052642|NCT04590053|Experimental|COVID-19|Up to 24 subjects, male or female > 18 and < 80-year-old diagnosed with respiratory dysfunction and COVID-19, as defined in the Eligibility Criteria, and treated with a single intravenous dose of Allocetra-OTS investigational product as detailed in the Interventions section.
89052643|NCT00567710|Experimental|I|BL - 1020 lowdose
89052644|NCT00567710|Experimental|II|BL 1020 high dose
89052645|NCT00567710|Placebo Comparator|III|
89052646|NCT00567710|Active Comparator|IV|Risperidone
89052647|NCT04590131|Experimental|Hubrid revaskularization|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.
89684372|NCT04974775||Influenza|Critically ill patients with a positive influenza test.
89684373|NCT04974775||Trauma|Critically ill patients after a severe traumatic event.
89684374|NCT04974775||Healthy controls|Healthy at the time of blood sampling
89684375|NCT00825565|Experimental|Alwextin cream|8 subjects enrolled in this single study arm. All 8 subjects completed the study.
89684376|NCT02345031|Active Comparator|AUT00063 (600 mg capsules)|3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
89684377|NCT02345031|Placebo Comparator|(AUT00063 placebo capsules)|3 capsules of placebo, to take orally once daily with food for 4 weeks
89684378|NCT00803647|Experimental|treatment|mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab
89684379|NCT00827983|Experimental|Progesterone SC|
89052648|NCT04590131|Active Comparator|Endovascular treatment|Patients (n=50) with recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
89052649|NCT00581490||Idiopathic premature pubarche|Children with premature pubarche without precious puberty, adrenal hyperplasia or androgen secreting tumors
89052650|NCT04594863||cachexia|patients suffering from cachexia recently
89052651|NCT04594863||no cachexia|patients are not suffering from cachexia recently
89052652|NCT04589702||females with isolated patellofemoral arthritis|those with anterior knee pain
89052653|NCT04589702||healthy females|those without anterior knee pain
89052654|NCT04589429|Active Comparator|MN group|intrathecal morphine 300 micrograms+2mg nalbuphine
89052655|NCT04589429|Placebo Comparator|M group|intrathecal morphine 300 micrograms
89684380|NCT00827983|Active Comparator|Progesterone Vaginal gel|
89052657|NCT04589390|Other|Selexipag|Selexipag will be up titrated for a period that will last 12 weeks (Phase 2). The initial dose will be 200 mcg of selexipag every 12 hours, with weekly dose increases of 200 mcg, up to the maximum dose of 1600 mcg every 12 hours or until the classic side effects of the prostacyclin pathway drugs (headache, mandibular pain), among others) arise. The dose will then be reduced by 200 mcg per dose, and this will be the maximum dose considered for that particular patient, maintained in Phase 3 (16 weeks).
89052658|NCT04577040||1|Tadalafil in moderate puts
89052659|NCT04577040||2|Tadalafil in severe puts
89052660|NCT04577040||3|Tadalafil with sildosin in moderate luts
89052661|NCT04577040||4|Tadalafil with sildosin in severe luts
89052662|NCT04577235|Experimental|Survivors group|Lung ultrasound score and computed tomography score were evaluated in the surviving group
89684381|NCT02412501|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent
89684382|NCT02346903|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. The patients will be asked follow-up questions concerning their experiences with chest pain in the past and their tolerance of spicy foods. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion."
89684383|NCT00844051|No Intervention|No Intervention|No school-based influenza vaccination program
89684384|NCT00844051|Active Comparator|Intervention|School-based Influenza Vaccination Program
88815869|NCT02416713|Experimental|Opt-in Blocking|Participants will have to initiate Cellcontrol DriveID device when entering the vehicle; the blocking settings will be pre-set to block all calls and text messages when the car is in motion.
88815870|NCT02416713|Experimental|Opt-out Blocking|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion.
88815871|NCT02416713|Experimental|Opt-out Blocking with Notification|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion. If a participant overrides the blocking function, an email will be sent to a parent/guardian.
88815872|NCT02419521|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Stent System
88815873|NCT00363363|Experimental|1|
88815874|NCT00363363|Active Comparator|2|
88815875|NCT02423577|Experimental|FF-3 dry powder|FF-3
88997732|NCT05807763|No Intervention|Control Group|Fundoplication
88997733|NCT05807763|Experimental|Study Group|No Fundoplication
89052663|NCT04577235|Experimental|Non survivors group|Lung ultrasound score and computed tomography score were evaluated in the non surviving group
89684385|NCT02347605|Experimental|Nicotine lozenge 4 mg prior to cue exposure|Nicotine lozenge is used 15 minutes prior to smoking cue exposure
89684386|NCT02347605|Placebo Comparator|Placebo lozenge prior to cue exposure|Placebo lozenge is used 15 minutes prior to smoking cue exposure
88815876|NCT02423577|Placebo Comparator|Placebo|
88815877|NCT02424357|Experimental|5% povidone iodine ophthalmic solution|patient received 1 drop of 5% povidone-iodine instilled over the adjustable suture noose in addition to routine antibiotic/steroid ointment to operated eye at surgery completion
88815878|NCT02424357|Active Comparator|no povidone-iodine ophthalmic solution|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
88815879|NCT02425449|Experimental|01 mg/kg|Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
88815880|NCT02425449|Experimental|0.15 mg/kg|Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
88815881|NCT02425449|Experimental|0.2 mg/kg|Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
88815882|NCT02425449|Experimental|0.25 mg/kg|Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
88815883|NCT02425449|Experimental|0.3 mg/kg|Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable
89684387|NCT02347605|Other|Control condition: Lozenge after cue exposure|Lozenge is used immediately after smoking cue exposure
89684388|NCT02410161|Experimental|4 week ALA treatment|Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
89684389|NCT02348619|Active Comparator|75, 150, 300 mg of JZP-110|Once Daily Dosing
89684390|NCT02348619|Active Comparator|Placebo|Once Daily Dosing
89684391|NCT02153671|Experimental|Primed with H5N2|Subjects who received A(H5N1) inactivated influenza vaccine as well as primed with H5N2 live attenuated influenza vaccine approximately 1.5 years before
89684392|NCT02153671|Active Comparator|Did not receive A(H5N2)|Subjects who received A(H5N1) inactivated influenza vaccine and did not receive A(H5N2) live attenuated influenza vaccine in a previous study.
89684393|NCT02413203|Experimental|Celecoxib|Oral administration of a single pill of celecoxib (200 mg). Celecoxib pills will be over-encapsulated to match the placebo.
89684394|NCT02413203|Placebo Comparator|Placebo|Oral administration of a single placebo pill.
89684395|NCT04382365|Other|Internet-Based Insomnia Intervention|"2 weeks of online sleep diaries. Participants will also wear an Actiwatch at night, which records measurements of movements of a limb, providing an estimation of sleep duration, sleep pattern and disturbed sleep.~9 week interveition period, subjects complete the internet based CBT-I program, consisting of six Cores (Getting Ready, Sleep Scheduling, Sleep Practices, Thinking Differently, Sleep Hygiene, and Moving On).Each Core takes approximately 45-60 minutes to review online, and most participants spend an additional 30-45 minutes per week on recommended exercises.~Participant will then be instructed to complete a post-Assessment, consisting of one online questionnaire and two weeks of Daily Sleep Diaries. The Actiwatch is worn as before during this two week period."
89684396|NCT02021955|No Intervention|usual care|Primary care providers treat their patients discharged from hospital for a COPD exacerbation as usual.
89684397|NCT02021955|Experimental|guideline treatment recommendations|Primary care clinicians receive treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
89684398|NCT00848185||Antagonist-hCG for triggering|Protocol with antagonist and hCG to trigger oocyte maturation
89684399|NCT00848185||Antagonist-aGnRH for triggering|Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
89684400|NCT00848185||Long protocol-hCG for triggering|Long Protocol and hCG to trigger oocyte maturation
89684401|NCT02022111|Active Comparator|Intervention Program of Care|"Patient Education and Behavioral Activation by a Care Coordinator;~Supporting Self-Care;~Psychiatrist and Diabetologist Reviews; and~Decision-support Electronic Health Record System"
89684402|NCT02022111|Placebo Comparator|Control Arm|Participants randomized to the control arm will receive the existing standard of care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
89684403|NCT02022735|Experimental|Bilateral stimulation|Participants will receive Deep Brain Stimulation Bilaterally.
89684404|NCT02022735|Experimental|Left stimulation|Participants will receive Deep Brain Stimulation on the left side only
89684405|NCT02022735|Experimental|Right stimulation|Participants will receive Deep Brain Stimulation on the right side only
89684406|NCT02022735|No Intervention|Off stimulation|Participants will receive no brain stimulation
89684407|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Placebo|Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation
89684408|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Colchicine|Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation
89684409|NCT02153983|Experimental|Diet-controlled Type 2 Diabetes Adults Assigned to Colchicine|Participants with Diet-controlled Type 2 Diabetes who were assigned to Open-label treatment with colchicine. These participants were not randomized and were not part of the randomized controlled trial.
89684410|NCT02153983|No Intervention|Evaluation Only Non-obese Adults|Participants without obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
89684411|NCT02153983|No Intervention|Evaluation Only Obese Adults Not Randomized|Participants with obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort. These participants were found not eligible for randomization.
89684412|NCT02153983|No Intervention|Evaluation Only Adults with Type 2 Diabetes|Participants with Diet-controlled Type 2 Diabetes seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
89684413|NCT02348775|Experimental|GlyNAC|HIV infected subjects will be studied before and after taking oral glycine and n-acetylcysteine for 3 months
89684414|NCT00828061|Placebo Comparator|A|placebo
89684415|NCT00828061|Active Comparator|B|10 mg prednisone
89684416|NCT00828061|Active Comparator|C|25 mg prednisone
89684417|NCT00849121|Experimental|1|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then every 12 weeks until disease progression.
89684418|NCT00849121|Experimental|2|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then given every 2-week, 4-week, or 3-month intervals as dictated by cellular immune response measurement.
88815884|NCT02429115|Experimental|Face-to-face peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
88815885|NCT02429115|Experimental|Online peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
88815886|NCT02429115|No Intervention|Control|Will not receive peer mentoring.
88815887|NCT02454075|Experimental|Eligible patients|The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
88815888|NCT02454153|Active Comparator|REMStar Positive Airway Pressure|Positive pressure therapy is the standard of care for managing obstructive sleep apnea.
88815889|NCT02454153|Other|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
88815890|NCT04744233|Active Comparator|Freshly squeezed orange juice (FS)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juice assayed was freshly squeezed (FS). Six subjects consumed FS-orange juice.
88815891|NCT04744233|Active Comparator|Commercially available low pasteurized orange juice (LP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was commercially available low pasteurized juice (LP). All participants consumed the LP orange juices.
88815892|NCT04744233|Active Comparator|High-pressure processed orange juice(HPP)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was high-pressure processed (HPP). All participants consumed the HPP orange juices.
88815893|NCT04744233|Active Comparator|Pulsed electric fields treated orange juice (PEF)|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed was those treated with pulsed electric fields (PEF). Six participants consumed the PEF-orange juice.
88815894|NCT02455167|Experimental|HCV positive group|A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.
88815895|NCT02457897|Experimental|Patients with insulin receptor mutation|
88815896|NCT02431455|Active Comparator|Incentive Spirometry|Incentive spirometry 10 times per hour while awake
88815897|NCT02431455|Experimental|No Incentive Spirometry|No incentive spirometer provided
88815898|NCT04341753|Experimental|Pulmonary rehabilitation|"In addition to the usual evaluation, other tests will be carried out in addition and specifically for this study:~the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
88815899|NCT02458365|Experimental|Teen Choices|Teen Choices: A Program for Healthy Nonviolent Relationships
88815900|NCT02458365|Other|Comparison|Health In Motion
88815901|NCT02434497|Experimental|Single Arm|One treatment period for all patients (<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
88815902|NCT02435901|Experimental|Reduced Intensity Regimen|Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients <10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients > 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
89684419|NCT02023125|Experimental|Group 1: Treatment A first, then Treatment B|Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Each period will be separated by at least 10 days.
89684420|NCT02023125|Experimental|Group 1: Treatment B first, then Treatment A|Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Each period will be separated by at least 10 days.
89684421|NCT02023125|Experimental|Group 2: Alectinib Alone, Alectinib + Esomeprazole|Period 1 (Days 1 to 10): Following an overnight fast of at least 10 hours, participants will start a standardized meal and should consume the meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal on Day 1 of Period 1. Period 2 (Days 11 to 20): Participants will receive oral esomeprazole 40 mg once daily for 6 days (Days 11-16) in the morning after an overnight fast of at least 10 hours, and at least 1 hour before a regular breakfast; On Day 16, following an overnight fast of at least 10 hours, a single oral dose of 40 mg esomeprazole will be administered 1.5 hours prior to the start of a standardized meal. Following a standardized meal, a single oral 600 mg dose of alectinib will then be administered.
89684422|NCT00803959|Active Comparator|No UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation only.
89684423|NCT00803959|Active Comparator|UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation with preoperative urodynamic studies prior to surgery.
89684424|NCT02349477|Experimental|Gabapentin|Gabapentin up to 1200 mg per day in 3 divided doses
89684425|NCT02349477|Placebo Comparator|placebo|matching placebo
89684426|NCT00828295|Experimental|1 mcg/kg arm|Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
89684427|NCT00828295|Experimental|3 mcg/kg arm|Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
89684428|NCT00850603|Active Comparator|Group 1|0.5 mL Subcutaneous arm (Menomune® )
89684429|NCT00850603|Experimental|Group 2|0.1 mL Subcutaneous arm (Menomune®)
89684430|NCT00850603|Experimental|Group 3|0.05 mL Intradermal arm (Menomune®)
89684431|NCT00850603|Experimental|Group 4|0.1 mL Intradermal arm (Menomune®)
89684432|NCT00850603|Experimental|Group 5|0.15 mL Intradermal arm (Menomune®)
88815903|NCT02438826|Experimental|Galcanezumab 300 mg|"Double-Blind Treatment Phase: Participants received galcanezumab 300 mg once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
88815904|NCT02438826|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
88997734|NCT05807685|No Intervention|control group|"At the beginning of the study, Data collection tools such as Individual Identification Form, Expressed Guilt Scale and Burnout Scale Short Version will be applied to the control group.~No intervention will be made in the control group. In the post-test, the Expressed Guilt Scale and the Burnout Scale Short Version will be administered again."
89684433|NCT02350569|Experimental|LDV/SOF|Participants with genotype 1 or 4 HCV who are undergoing liver transplant will receive one dose of LDV/SOF prior to the transplant and then will receive LDV/SOF once daily for 4 weeks following the transplant.
89684434|NCT02023515|Experimental|Stress Management|Approximately half of the participants will be randomized to a stress management arm. Participants will undergo Emotional Brain Training during a 90 minute session once per week for ten weeks in order to rewire the brain and improve stress management techniques.
88815905|NCT05370066|Experimental|CS6BP and cuff|CS6BP watches will be used in the study with Commercially available FDA approved Blood pressure monitors:
88815906|NCT02438280|Experimental|Active Vibration|Use of Active Vibration (AcceleDent device) 20 minutes each day during treatment with aligners
88815907|NCT02438280|Active Comparator|Sham Vibration|Use of Sham Vibration (Sham AcceleDent device) 20 minutes each day during treatment with aligners
88815908|NCT02437383|Active Comparator|Propranolol ER|Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
88815909|NCT02437383|Placebo Comparator|Placebo|Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).
88815910|NCT02385708|Active Comparator|Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery
88815911|NCT02385708|Active Comparator|Treatment Arm|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
88815912|NCT01099358|Experimental|Cetuximab and Cisplatin (D)|"Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1.~100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1.~After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
89052664|NCT04589000|Experimental|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
89052665|NCT04589000|No Intervention|control|No accupressure will be applied. Milk will be expressed for a total of 15 minutes, 1 time on the post-op 0th day, 2 times on the post-op 1st day and once on the post-op 2nd day for a total of 15 minutes and will be recorded in the milk measurement table.
89052666|NCT04594668|No Intervention|Standard treatment|Standard intensive care
89052667|NCT04594668|Active Comparator|Senicapoc|Senicapoc
89052668|NCT04589234|Experimental|Saltikva with FOLFIRINOX|30 patients will be enrolled to receive standard of care FOLFIRINOX with oral Salmonella-IL2 (Dose 10-9) every 2 weeks for 2 years
89052669|NCT04589234|Experimental|Saltikva with Gemcitabine/Abraxane|30 patients will be enrolled to receive standard of care Gemcitabine/Abraxane with oral Salmonella-IL2 (Dose: 10-9) every 3 weeks for 2 years
89052670|NCT03453177|No Intervention|Standard of Care|ampicillin 50mg/kg twice daily and gentamicin [3mg/kg for babies <2kg or 5mg/kg for babies >2kg] once daily for 7 days, as per Kenyan guidelines).
89052671|NCT03453177|Experimental|Standard of Care plus Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
89052672|NCT04588961|Active Comparator|Control group|Patients undergoing trapeziectomy with suspensionplasty for primary basal thumb osteoarthritis
89052673|NCT04588961|Active Comparator|Study group|Patients undergoing joint alloplasty using prothesis for primary basal thumb osteoarthritis
89052674|NCT04594629|Sham Comparator|nitroglycerine group|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
89052675|NCT04594629|Active Comparator|PGI2 group|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres.
89052676|NCT04589078||Interficial Intelligence|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
89052677|NCT04588844|Experimental|Growth Hormone group|Growth Hormone pretreatment for 6 weeks before ovarian stimulation
89684435|NCT02023515|Active Comparator|standard behavioral weight loss|Half of participants will receive a standard behavioral weight loss program in 90 minute sessions once per week for 10 weeks
89684436|NCT02350647|Experimental|HEALICOIL Regenesorb|Suture anchor for rotator cuff repair
89684437|NCT02350647|Active Comparator|Twinfix Ultra HA|Suture anchor for rotator cuff repair
89684438|NCT02023983|Experimental|Early discharge|
89684439|NCT02023983|Active Comparator|Standard discharge|
89684440|NCT02351115|Experimental|Sequence BEADC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
89684441|NCT02351115|Experimental|Sequence CDAEB|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
89684442|NCT02351115|Experimental|Sequence DEBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
89684443|NCT02351115|Experimental|Sequence EDBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
89052678|NCT04588844|No Intervention|Control group|No pretreatment before ovarian stimulation
89052679|NCT04594395||Healthy volunteers|Any adult aged 18 to 65 years of age living in Phnom Penh that is sufficiently healthy and willing to undergo fingerstick by the mobile unit for SARS-CoV-2 ELISA assays.
89052680|NCT04594395||Household contacts|Adult relatives of the healthy volunteers.
89052681|NCT04588532|Experimental|doxepin|"Drug: Doxepin + BAM8-22 Doxepin will be applied for 1.5 hrs followed by the application of BAM8-22. 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Histamine Doxepin will be applied for 1.5 hrs followed by the application of Histamine. 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Cowhage Doxepin will be applied for 1.5 hrs followed by the application of cowhage. 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop~Drug: Doxepin + Placebo Doxepin will be applied for 1.5 hrs followed by the application of placebo. 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
89684444|NCT02351115|Experimental|Sequence CABED|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
89684445|NCT02351271|Experimental|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
89684446|NCT02351271|Active Comparator|Manual capsulorhexis&lens fragmentation|The Conventional group acts as a control group with conventional capsulorhexis and ultrasound phacoemulsification
89684447|NCT02025075|Experimental|Deep Neuromuscular Block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
89684448|NCT02025075|Active Comparator|Moderate Neuromuscular block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
89684449|NCT02351505|Experimental|Treatment (selinexor)|Patients receive selinexor PO twice weekly. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89684450|NCT00242567|Experimental|Early Group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing at Baseline.
89052682|NCT04588532|Experimental|itch|"Drug: BAM8-22 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Histamine 20 µl of histamine will be applied to a previously determined area on the volar forearm followed by a prick through the drop~Drug: Cowhage 25/35 spicules of cowhage will be inserted in the skin through a gentle rubbing on a previously determined area on the volar forearm followed by a prick through the drop~Drug: Placebo 20 µl of placebo will be applied to a previously determined area on the volar forearm followed by a prick through the drop"
89052683|NCT04594083|Experimental|Palm Stimulator|The Palm Stimulator was placed in the palm of the child's active hand 20 seconds before the injection. It ensured by researcher that the apparatus was held tightly in the child's palm throughout the procedure. The apparatus was taken back from the child after completing the injection process.
89052684|NCT04594083|Experimental|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
89052685|NCT04594083|No Intervention|Control|The routine IM injection was applied to the children in the control group.
89052686|NCT04588454|Experimental|18F-PSMA-1007 PET/CT|
89052687|NCT03453138|Experimental|LMA Protector Group|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
89052688|NCT03453138|Experimental|Tracheal Intubation Group|Patients will be intubated after standart anesthesia induction and we will record heamodynamic variables. including mean blood pressure and heart rate
89052689|NCT00567749||A, Observational|
89052690|NCT03453099||Study Cohort|Any ASA I or II patients scheduled for elective day case general anaesthesia at Chelsea & Westminster Hospital, involving a standard propofol-fentanyl induction regimen, aged between 18-65 years . See specific exclusion criteria below.
89052691|NCT04588415|Experimental|Virtual Support Group Arm|Those with severe symptoms (indicated by an ICG-r score >25) will be notified that their symptoms are considered to be severe, with a suggestion to attend the virtual support groups. A recent meta-analysis of psychological interventions for grief found higher effect sizes in studies of participants who were >6 months post-loss, and those with higher baseline symptom levels. However, no participant in our study will be randomized to any treatment assignment, and the decision to attend the VSG will be left to the family members.
89052692|NCT04588415|No Intervention|Non-Virtual Support Group Arm|Family members that choose not to participate in the Virtual Support Group will be part of this non-intervention arm
89684451|NCT00242567|Experimental|Delayed group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing no sooner than 12 months after their baseline visit, and not until they have had three rises in PSA level from Baseline, one of which must be a least 10 ng/mL greater than the baseline Serum Prostate-specific Antigen (PSA) level.
89684452|NCT00241631|Placebo Comparator|Placebo|Inhaled Theophylline placebo capsule, then placebo, then active Theophylline
89684453|NCT00241631|Active Comparator|Steroid|Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline
89684454|NCT05744141|Experimental|Intervention Group|Elderly individuals undergoing relaxation exercises before cataract surgery
89684455|NCT05744141|No Intervention|Control Group|Standard care
89684456|NCT02351739|Other|Pembrolizumab|Arm 1: pembrolizumab monotherapy
89684457|NCT02351739|Other|ACP-196 in combination with pembrolizumab|Arm 2: ACP-196 in combination with pembrolizumab
89684458|NCT00240071|Experimental|Avastin|The patient will continue the same hormonal therapy used prior to study enrollment but will combine it with Avastin.
89684459|NCT02352363|Experimental|CVT-301|Capsules of Levodopa Inhalational Powder (LIP) used up to 5 times per day for OFF episodes, for up to 54 weeks duration.
89684460|NCT02352363|Other|Observational Cohort|Standard of care. Patients in both the CVT-301 treatment group and the observational cohort will be managed with their standard PD treatment throughout the study.
89684461|NCT03805139|Experimental|Ajwa Dates group|55-65gms Ajwa dates 7 days a week for 6 weeks
89684462|NCT03805139|No Intervention|Control|No intervention
89684463|NCT00765947|Experimental|Aliskiren-based regimen|All pts starting on aliskiren 150 mg (uptitrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (uptitrated to 25 mg) and amlodipine 5 mg (uptitrated to 10 mg), as necessary to achieve the Blood Pressure goal.
89684464|NCT03805061|Active Comparator|Aerobic exercise group|Group 1 was 'aerobic exercise group'. Patients in this group were included in an aerobic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed for a period of ; 8 weeks, 3 days a week, 30-45 minutes each patient according to the progressive exercise method. 5-10 minutes warm-up exercise was performed before starting to work, 5-10 minutes stretching exercise at the end of the exercise.
89684465|NCT03805061|Active Comparator|Isokinetic exercise group|Group 2 was 'isokinetic exercise group'. Patients in this group were included in an isokinetic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low resistance for 5 minutes before starting to exercise, and exercise was applied for 5-10 minutes to cool down at the end of the study.
89684466|NCT00766649|Experimental|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
89052693|NCT04594044|Experimental|Individual HRT and ERP|Individual treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
89052694|NCT04594044|Experimental|Group HRT and ERP|Group treatment with habit reversal training (HRT) and exposure response prevention (ERP) according to a protocol
89684467|NCT02352831|Experimental|Phase I (tosedostat + capecitabine)|"The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion.~Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat.~Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle~Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain."
89684468|NCT02352831|Experimental|Phase II (tosedostat + capecitabine)|"Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle~Capecitabine by mouth BID Days 1-14 of each 21-day cycle"
89684469|NCT00766727|Experimental|GLYDe Dressing|Investigational Dressing
89684470|NCT00766727|No Intervention|Standard of Care|Standard of care comparator
89684471|NCT04275479||SDS - without Diabetes diagnosis|SDS - without Diabetes diagnosis
89684472|NCT04275479||SDS with Diabetes Diagnosis|SDS with Diabetes Diagnosis
89684473|NCT04275479||Cystic Fibrosis (CF) patients data & lab results|De-identified data from age matched population norms, CF patients associated pancreatic insufficiency known or treated diabetes
89684474|NCT02353299|Active Comparator|Silenor 6 mg (DXP-4H)|Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
89684475|NCT02353299|Placebo Comparator|Placebo (PBO-4H)|placebo single nightime dose -4 hour post dose arousability and cognitive assessments
89684476|NCT02353299|Active Comparator|Zolpidem 10 mg (ZOL-1.5H)|zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
89684477|NCT02353299|Placebo Comparator|Placebo (PBO-1.5H)|placebo single nightime dose -1.5 hour arousability and cognitive assessments
89684478|NCT00756977|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
89684479|NCT00756977|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
89684480|NCT02027883|Active Comparator|Nominal Parameter|Nominal T shock setting
89684481|NCT02027883|Experimental|Experimental Parameter|Educated T shock setting
89684482|NCT00783965|Experimental|Arm I|Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.
89684483|NCT00783965|Experimental|Arm II|Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.
89684484|NCT02354859|Active Comparator|5 day of infusion of gallium nitrate|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device () using an ambulatory infusion pump infused over 24 hours for 5 sequential days.
89684485|NCT02354859|Placebo Comparator|5 day of infusion of normal saline|Placebo with be dispensed as 1,000 milliliters of 0.9% sodium chloride to match the reconstitution volume of the IV Ga
89684486|NCT00421551|Experimental|1|
89684487|NCT00421551|Active Comparator|2|
89684488|NCT02356107|Experimental|Open label treatment with 5-HTP and Creatine|
89684489|NCT00767507|Experimental|Cangrelor|Cangrelor was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days.
89684490|NCT00767507|Placebo Comparator|Placebo|A placebo infusion was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days, to maintain the blind.
89684491|NCT02029755|Experimental|TAP block|postoperative analgesia with sono-guided transversus abdominis plane block and intravenous patient controlled analgesia (IV-PCA). Bilateral sono-guided TAP block will be performed after the induction of general anesthesia. 20 ml of 0.25% ropivacaine will be injected to the transversus abdominis plane under ultrasound guidance at each side (total 40 ml). IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
89684492|NCT02029755|Active Comparator|Local infiltration|postoperative analgesia with local anesthetics infiltration at surgical wound and intravenous patient controlled analgesia (IV-PCA). 20 ml of 0.5% ropivacaine will be injected at the surgical wound by the surgeon before the closure of wound. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
89052695|NCT04577430|Experimental|Loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 0.5 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the operation finished.
89052696|NCT04577430|Experimental|Loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 0.5 μg/kg per hour during the operation until 0.5 h before the surgery finished.
89052697|NCT04577430|Experimental|Loading dose with 1 μg/kg, maintenance dose with 1 μg/kg|10 min before induction of anesthesia,the loading dose of dexmedetomidine is 1 μg/kg, and completed in 10 minutes. The maintenance dose is 1 μg/kg per hour during the operation until 0.5 h before the surgery finished.
89052698|NCT04577430|Placebo Comparator|Normal saline|
89052699|NCT00567788|Active Comparator|1|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
89052700|NCT00567788|Active Comparator|2|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
89052701|NCT04588766||constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
89052702|NCT04588766||control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
89052703|NCT00581607|Active Comparator|Bosentan for 16 weeks|Active drug
89052704|NCT00581607|Placebo Comparator|Placebo|Placebo for 16 weeks
89052705|NCT04588571|Experimental|Endovascular treatment|Patients (n=55) with recanalization of the femoral-popliteal arterial segment (TASC II, type D) above the knee with a biomimetic braided nitinol stent.
89052706|NCT04588571|Active Comparator|Open surgery|Patients (n=55) with femoropopliteal proximal bypass with a prolonged atherosclerotic lesion of the femoropopliteal arterial segment (TASC II, type D).
89052707|NCT04594122|No Intervention|Control|No intervention in this group
89052708|NCT04594122|Experimental|Intervention|Hygiene package, training, branding, and certification
89052709|NCT04588805||Colorectal Cancer Patients|
89684493|NCT02029755|Active Comparator|PCA only|postoperative analgesia with intravenous patient controlled analgesia. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
89684494|NCT05743829||Cardiac Surgery|Patients undergoing cardiac surgery - left atrial appendage excision
89684495|NCT05743829||Thoracic Surgery|Patients undergoing lung resection - ostial pulmonary vein tissue
89684496|NCT03804749|Experimental|Group 1-1|The dose of suramin sodium is 10 mg/kg
89684497|NCT03804749|Placebo Comparator|Group 1-2|The placebo is 0.9% sodium chloride injection
89684498|NCT03804749|Experimental|Group 2-1|The dose of suramin sodium is 15mg/kg
89684499|NCT03804749|Placebo Comparator|Group 2-2|The placebo is 0.9% sodium chloride injection
89684500|NCT03804749|Experimental|Group 3-1|The dose of suramin sodium is 20mg/kg
89052710|NCT00581646||1|gynecologic cancer survivors
89684501|NCT03804749|Placebo Comparator|Group 3-2|The placebo is 0.9% sodium chloride injection
89684502|NCT03804515|Experimental|14C-labeled Poziotinib|
89052711|NCT00581646||2|survivors of any type of malignancy with history of BMT/SCT
89052712|NCT00581646||3|non-cancer infertile women awaiting third party reproduction
89052713|NCT04588376|Experimental|Clinician-level and clinic-level monthly feedback|Group of 22 clinics to receive clinician-level and clinic-level monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
89052714|NCT04588376|Active Comparator|Clinic-level only monthly feedback|Group of 17 clinics to receive clinic-level only monthly feedback on appropriate antibiotic use for three acute respiratory tract infections
89684503|NCT02029911|Experimental|Aurora Treatment Arm|Endometrial Ablation
89684504|NCT05621213|Experimental|Intervention|Patients who will be followed up by teleconsultation assisted by a physiotherapist or a nurse at home.
89684505|NCT05621213|No Intervention|Control group|Patients not wishing to be followed up by teleconsultation but agreeing to participate in the study and the collection of questionnaires. They will follow up as usual in person (no teleconsultation).
89684506|NCT02357043|Experimental|Dario Blood Glucose Monitoring System|Subject will be requested to follow the device instructions and perform his/her own finger-stick test using the Dario Glucose Monitoring System (BGMS).
89684507|NCT05743751|Active Comparator|Hypothermic machine perfusion|After organ acquisition, the donor kidney was trimmed, and then the donor kidney was connected to the cryoperfusion machine (lifeport, which has been used in routine clinical practice in our hospital) for continuous low temperature mechanical perfusion (<8 ℃). The perfusion solution was extracted for proteomic study at 10 min after perfusion and at the end of perfusion.
89684508|NCT05743751|Experimental|Normothermic machine perfusion|After conventional UW perfusion is obtained, the marginal donor kidney is immediately perfused without ischemia at normal temperature. The perfusion time is at least 4 hours (so as to repair the marginal donor kidney). The perfusion solution is as above, and the perfusion solution is loaded into the device authorized in Europe (XVIVO - KidneyAssist ®）， Connect the transplanted renal artery with the device. Take 5ml perfusion solution in advance before perfusion, 5ml perfusion solution every 30min after perfusion, take perfusion solution at the end of perfusion (blood gas analysis for each perfusion solution, and finally perfusion solution for culture), and measure urine volume every hour. After perfusion, the transplanted kidney was disconnected from the perfusion device, and the donor kidney was perfused again with 2L HTK solution, followed by routine transplantation.
89684509|NCT02031627|Experimental|pneumatic compression - 1 hour per day|Pneumatic compression device - 12 consecutive days undergoing a 1 hour treatment regimen.
89684510|NCT02031627|Experimental|pneumatic compression - 2 hours per day|Pneumatic compression device - 5 consecutive days undergoing 1 hour treatment in the am and 1 hour of treatment in the pm.
89052715|NCT00566670||Observation (all participants)|Stage 5 Chronic Kidney Disease and hemodialysis patients
89684511|NCT02031627|Experimental|pneumatic compression - 4 hours per day|Pneumatic compression device - 5 consecutive days undergoing treatment twice per day consisting of 2 consecutive 1 hour treatments in the am and the pm (4 hours total)
89684512|NCT04273295|No Intervention|the control group|This group receives senna-based laxatives.
89684513|NCT04273295|Experimental|the study group|This group managed by abdominal massage with senna-based laxatives.
89684514|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from primary care practitioners or dermatologists, just as they would in the real world.
89684515|NCT02358135|Experimental|CCH Model|The intervention arm will be the collaborative connected health (CCH) model, which purports to increase access to specialists and improve outcomes. Specifically, CCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. CCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
89052716|NCT00581685|Placebo Comparator|2|Prospective, single center, randomized, double-blinded, placebo controlled study
89052717|NCT04588220||preterm premature rupture of membranes|Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation.
89052718|NCT04588220||Control group|Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications will be accepted into the control group. Forty-four gestational age-matched healthy pregnant women who will be delivered at term will be included in the study as the control group.
89052719|NCT00581724||1|"First 50 breast cancer survivors and then after demonstrating feasibility of the study design in the first 50 participants, recruitment will be opened to the other services Colorectal, Genitourinary, Head and Neck, and Thoracic.~Participants will be recruited in allotments of 50 patients from each service."
89052720|NCT04588181|Experimental|CBT 6 sessions|
89052721|NCT04588181|Active Comparator|CBT 12 sessions|
89216469|NCT03632993|Active Comparator|Treatment V: CCH Shallow Injections, 4 Aliquots|"In Treatment V, CCH will be injected subcutaneously while the participant lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2 mL of CCH (4 aliquots of 0.3 mL each). Dose per participant per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
89216470|NCT03626402|Experimental|Intervention|"These patients will be exposed to the educational intervention, including viewing the video, Planning for the Care You Want, and meeting with a lay health advisor to discuss advance care planning and initiate plans, as patients wish."
89216471|NCT03626402|No Intervention|Control - Usual Care|These patients will not be exposed to the educational intervention and will receive usual care. All patients will be mailed an informational brochure about advance care planning with a reminder letter two weeks after completing their baseline survey.
89216472|NCT03580616|Experimental|L-Serine|L-Serine 15 grams orally twice a day as tolerated for 6 months
89684516|NCT02032641|Experimental|Laser Treatment Side|"Each patient was randomized to have one of two scars treated with Laser Genesis. The treatment was administered by manually scanning the rapidly pulsed laser in an even, painting motion throughout the entire treatment zone. The eyebrow hairs were covered with white tape to prevent inadvertent alopecia. The laser handpiece was oriented perpendicular to the skin at all times, at a distance of 1-2 cm. Patients were instructed throughout to give verbal feedback regarding if the area was too hot as an additional safeguard against epidermal damage."
89684517|NCT02032641|No Intervention|Control side|Each patient had a scar which was randomized to not undergo treatments with Laser Genesis, and was used as a control. Patients were not allowed to undergo laser or any other scar treatments with the exception of sun protection for the control scar for the duration of the study.
89684518|NCT02312739|Active Comparator|Vicodin, Lorazepam and Oxygen|"Patients in this group will receive the Standard Oral Pain Medications consisting of Vicodin and Lorazepam, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Oxygen via scented mask will also given.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
89684519|NCT02312739|Experimental|Placebo pills and Nitrous Oxide|"Patients in this group will receive two placebo pills, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Nitrous oxide will be administered during the procedure via scented mask.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
89684520|NCT05718765|Sham Comparator|Usual care with sham intervention|Patients in the control group received usual care with sham exercise.
89684521|NCT05718765|Experimental|PACES intervention|PACES includes an exercise perception intervention and an exercise intervention, which lasts for 12 weeks and is carried out simultaneously.
89684522|NCT02351037|Experimental|Ibrutinib Monotherapy Cohort|Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.
89684523|NCT02351037|Experimental|Ibrutinib + LD-AraC Combination Cohort|Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
89684524|NCT02351037|Experimental|Ibrutinib+Azacitidine Combination Cohort|Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).
89684525|NCT02358603|Experimental|Case group|At the beginning of the study, each subject of the case group will complete echo examination and related lab test for BNP. During the study, each subject will have a six minutes' walk test and 24 hour ambulatory monitoring while having an ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. The treadmill test is optional to patients per physicians' instruction and/or patients' own judgment. It would be performed at the end of the study if chosen.
89684526|NCT02358603|Placebo Comparator|Control group|Each subject of the control group will do the same test and examination with the subjects in the case group.
89684527|NCT05718609|Active Comparator|Amoxicillin- and Clarithromycin-based BQT|rabeprazole 10mg bid, amoxicillin 1g bid, clarithromycin 500mg bid, colloidal bismuth 200mg bid for 14 days
89684528|NCT05718609|Experimental|Clarithromycin medication history-based BQT|The clarithromycin medication history will be asked before the treatment and the therapy will be performed as follows: with clarithromycin medication history: rabeprazole 10mg bid, amoxicillin 1g bid, furazolidone 100mg bid, colloidal bismuth 200mg bid for 14 days; without clarithromycin medication history: rabeprazole 10mg bid, amoxicillin 1g bid, clarithromycin 500mg bid, colloidal bismuth 200mg bid for 14 days.
89684529|NCT05718609|Experimental|Antimicrobial susceptibility tests-based BQT|Fecal molecular biology antimicrobial susceptibility tests will be performed before the treatment. The susceptibility of clarithromycin will be evaluated. The treatment regimen will be chosen according to the results of the antimicrobial susceptibility tests as follows: clarithromycin-sensitive: rabeprazole 10mg bid, amoxicillin 1g bid, clarithromycin 500mg bid, colloidal bismuth 200mg bid for 14 days; clarithromycin-resistant: rabeprazole 10mg bid, amoxicillin 1g bid, furazolidone 100mg bid, colloidal bismuth 200mg bid for 14 days.
89684530|NCT02359305||IV Acetaminophen|Acetaminophen administered by intravenous infusion.
89684531|NCT02359305||Rectal Acetaminophen|Acetaminophen administered by rectal suppository.
89684532|NCT02360319|Active Comparator|Clinician's Choice|Prescribers are not limited in the choice of treatment they can administer to their clients to alleviate the symptoms of schizophrenia. Any FDA approved antipsychotic agent can be used. Clients in the study wil be followed for 2 years
89684533|NCT02360319|Experimental|Aripiprazole Once Monthly|Aripiprazole long acting injectable formulation, 400mg per dose is to be administered once monthly. Clients in the study will be followed for 2 years
89684534|NCT05718531|Active Comparator|acute coronary syndrome group1|50 patients will have triple therapy (Aspirin,75 mg once daily, clopidogrel 75 mg once daily, and Rivaroxaban 2.5mg BID) prescribed for 3 month, then clopidogrel and Rivaroxaban for the following 9 months.
89684535|NCT05718531|Active Comparator|acute coronary syndrome group 2|50 patients will be on Aspirin 75mg once daily, clopidogrel 75mg once daily for 1 year.
89684536|NCT05718531|Active Comparator|chronic coronary syndrome group 1|33 patients with prescribed aspirin 75 mg once daily and Rivaroxaban 2.5 mg BID N.B: Patients with stents placement within a year will be excluded from this group
89684537|NCT05718531|Active Comparator|chronic coronary syndrome group 2|33 patients with clopidogrel 75 mg once daily and Rivaroxaban 2.5mg BID
89684538|NCT05718531|Active Comparator|chronic coronary syndrome group 3|34 patients with aspirin 75 mg once daily and clopidogrel 75 mg once daily.
89684539|NCT05718453|Active Comparator|COPD patients|It is about 60 patients with Stable COPD
89684540|NCT05718453|Active Comparator|Acute exacerbation COPD|It is about 40 patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
89684541|NCT05718453|Placebo Comparator|healthy controls|It is about 40 healthy controls were included in the study
88997735|NCT05807685|Experimental|experimental group|"Arm Title: Experimental Group: Individual Identification Form, Expressed Guilt Scale and Burnout Scale Short Version will be administered to the mothers of children studying at Sinop Atatürk Primary School in the 2022-2023 spring semester before the laughter therapy. At the end of the laughter therapy, the Expressed Guilt Scale and the Short Version of the Burnout Scale will be administered as a post-test.~The Individual Identification Form, Expressed Guilt Scale and Burnout Scale Short Version will be used for all mothers of the students studying in Atatürk Primary School in the 2022-2023 academic year. All women whose Burnout Scale Short Form is above the average will be included in the study. Since all women whose Burnout Scale Short Form is above the average, who volunteered to participate in the study and who met the inclusion criteria will be included in the study, no additional sample selection will be made."
88997736|NCT05807659|Experimental|fractionated busulfan|fractionated busulfan-based ChiFAB conditioning regimen: busulfan 3.2mg/kg d-13, -12, 1.6mg/kg d-6~-3, fludarabine 35mg/m2 d-6~-2 cytarabine 1g/m2,d-6~-2 chidamide 30mg d-13,-10,-6,-3
88997737|NCT05807633||Novosyn®|Novosyn® used in patients undergoing uterus closure in cesarean section
88997738|NCT05807607|Experimental|Patients who underwent the lower limb amputation and have phantom pain syndrome|
88997739|NCT05807542|Experimental|Tislelizumab combined with chemotherapy|
88997740|NCT05807503||A with Cerebrolysin administration|Group of patients with TBI diagnosis, admitted to ICU for further treatment after or without neurosurgical craniotomy, treated with Cerebrolysin administration in addition to standard ICU protocols.
88997741|NCT05807503||B without Cerebrolysin administration|Group of patients with TBI diagnosis, admitted to ICU for further treatment after or without neurosurgical craniotomy, treated without Cerebrolysin administration according to standard ICU protocols.
88997742|NCT05807438|Active Comparator|Foam Roller group|Myofascial release with foam roller, hamstring and gastrocnemius muscle groups were trained with foam roller for 30 seconds with 2 repetitions
88997743|NCT05807438|Active Comparator|Manual myofascial release group(Hands on)|We used the following treatment protocol for all patients in the MFR group. The techniques were performed by a physiotherapist with experience in MFR.
88997744|NCT05807425|Experimental|Polidocanol foam sclerotherapy|A cohort of cirrhotic patients with hemorrhoidal disease will be treated with polidocanol foam sclerotherapy.
88997745|NCT05807373|Experimental|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to MDS criteria (Postuma et al., 2015)
88997746|NCT05807373|Experimental|Multiple system atrophy parkinsonian subtype (MSA-P)|Diagnosis of Multiple Atrophy System (MSA-P) Parkinsonian form possible or probable according to consensus criteria (Gilman et al., 2008)
88997747|NCT05807373|Experimental|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
88997748|NCT05807347|Experimental|VACAG（Venetoclax Combined with Azacitidine and CAG）regimen|Participants will receive induction as azacitidine on days 1-7, venetoclax aily on days 1-28, cytarabine q12h on days 1-7, aclacinomycin on days 1,3,5,7, and granulocyte colony-stimulating factor on days 0-8. Participants will receive second induction if not reach complete remission.
88997749|NCT05807334|Experimental|DASH eating plan with eggs|Participants will receive dietary guidance to follow the DASH eating plan with the addition of 2 whole eggs daily during this 8-week treatment period.
88997750|NCT05807334|Active Comparator|DASH eating plan without eggs|Participants will receive dietary guidance to follow the DASH eating plan while excluding eggs from their eating plan during this 8-week treatment period.
88997751|NCT05807308|Experimental|technology-based cognitive and artistic therapeutic activities|The group receiving technology-based cognitive and artistic therapeutic activities
88997752|NCT05807308|No Intervention|Control group|the group that did not receive any training
88997753|NCT05807295|Experimental|Intervention|caregivers receiving a relaxation program
88997754|NCT05807295|No Intervention|Control group|the group that did not receive any training
88997755|NCT05807243|Experimental|Group 1 (Traditional → Digital)|"Participants in both groups will be monitored for a month while following an hypocaloric diet for healthy weight-loss.~The first group (n=50) will start collecting data via questionnaires (traditional method) for the first two weeks, and switch to the digital data-collection method for the last two weeks."
88997756|NCT05807243|Experimental|Group 2 (Digital → Traditional)|"Participants in both groups will be monitored for a month while following an hypocaloric diet for healthy weight-loss.~The second group (n=50) will start with the digital data-collection method for the first two weeks and switch to the data collection via questionnaires (traditional method) for the last two weeks.~n=100)"
88997757|NCT05807243|No Intervention|Group 3 - Young healthy population|n=100) Descriptive part: Data capture (clinical, anthropometric, lifestyle, genetic, biochemical, metabolomic and lipidomic data, among others) and comparison with the other groups.
89052722|NCT04588064|Experimental|18F-FDG PET/CT scan|Each subject receives a single intravenous injection of 18F-FDG, and undergo PET/CT imaging within the specified time.
89216473|NCT03566667|Active Comparator|Metoprolol|Metoprolol at an aimed dose of 100 mg in addition to usual standard care
89684542|NCT02360631|Experimental|Chantix (varenicline)|Participants will receive 1mg pills to take twice a day for 12 weeks.
89684543|NCT02360631|Placebo Comparator|Placebo|Participants will receive a placebo pill to take twice a day for 12 weeks.
89684544|NCT02033499|No Intervention|No testing|No testing
89684545|NCT02033499|Other|standard messaging|SMBG standard messaging
89684546|NCT02033499|Other|enhanced messaging|SMBG enhanced messaging
89684547|NCT02362191|Experimental|Single Session tACS Across Menstrual Cycle|Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.
89684548|NCT05718375|Experimental|CU01-1001 (low dose)|1 Tab/3 times/day (CU01-1001 120 mg, Breakfast and Dinner; Placebo 120 mg, Lunch)
89684549|NCT05718375|Experimental|CU01-1001 (high dose)|1 Tab/3 times/day (CU01-1001 120 mg, Breakfast, Lunch, and Dinner)
89684550|NCT05718375|Placebo Comparator|Placebo|1 Tab/3 times/day (Placebo, Breakfast, Lunch, and Dinner)
89052723|NCT04587986|Experimental|Abdominal Toning and Reduction of Subcutaneous Fat|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of BTL-703 will be applied over the umbilicus. The active group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with heating of the subcutaneous fat.
89052724|NCT04587986|Sham Comparator|Sham control|The treatment administration phase will also consist of three (3) treatments, delivered once a week. The sham group will receive a treatment with the intensities of the magnetic field and radiofrequency energy set to 5% of the maximum device output.
89052725|NCT00581763||Observation|Those with a condition
89052726|NCT00581802||1|Intensively studied participants initiating potentially suppressive drug therapy. Group 1 participants may undergo optional leukapheresis. Group 1 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 1 participants will default to either Group 3 or Group 4.
89052727|NCT00581802||2|Intensively studied, well-suppressed participants on HAART. Participants in Group 2 may undergo optional leukapheresis. Group 2 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 2 participants will default to either Group 3 or Group 4.
89052728|NCT00581802||3|Nonintensively studied participants initiating potentially suppressive drug therapy
89052729|NCT00581802||4|Nonintensively studied well-suppressed participants on HAART
89052730|NCT00581802||5|Intensively studied participants who are currently participating in the Merck Expanded Access Program and receiving raltegravir. Participants in Group 5 may undergo optional leukapheresis. Group 5 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 5 participants will default to either Group 3 or Group 4.
89052731|NCT04587557|Experimental|ASD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for children with Autism Spectrum Disorder
89052732|NCT04587557|Active Comparator|ASD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for children with Autism Spectrum Disorder
89052733|NCT04587557|Experimental|TD Group 1 - storytelling with social contextual information|Storytelling with social contextual information for typically developed children
89052734|NCT04587557|Active Comparator|TD Group 2 - storytelling without social contextual information|Storytelling without social contextual information for typically developed children
89684551|NCT00355095|Active Comparator|1|erythropoietin
89684552|NCT00355095|No Intervention|2|Placebo
89684553|NCT02366871|Experimental|Oral apixaban|Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
89684554|NCT02366871|Active Comparator|Subcutaneous enoxaparin|Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
89684555|NCT05718219|Experimental|Part 1 (dose escalation and dose expansion)|Cohorts of at least 3 participants each will be treated with escalating doses of SIM0348. Dose expansion part will be decided based on the findings of dose escalation part.
89684556|NCT05718219|Experimental|Part 2 (cohort expansion)|Participants will be treated with SIM0348 at a recommended dose (RD) in the study.
89684557|NCT02036541|Experimental|AqueSys XEN 45 Glaucoma Implant|
89684558|NCT02368431|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
89052735|NCT00581841||1|Healthy adult participants with no history of knee injury or osteoarthritis.
89052736|NCT04587362||Psoriatic Arthritis|Subjects newly diagnosed with psoriatic arthritis (< 5 years), confirmed by a rheumatologist and fulfilling the CASPAR criteria.
89052737|NCT04587362||Psoriasis without musculoskeletal symptoms|Patients with dermatologist confirmed psoriasis, without any history of Psoriatic Arthritis, and musculoskeletal symptoms.
89052738|NCT04587362||Non-Inflammatory Rheumatic conditions|Patients with non-inflammatory rheumatic conditions such as osteoarthritis, non-specific back pain, soft tissue rheumatism, degenerative tendinopathy and fibromyalgia. Patients with present or past history of psoriasis, psoriatic arthritis, known or suspected rheumatic inflammatory conditions (e.g. rheumatoid arthritis, spondyloarthritis and gout), and/or inflammatory bowel disease will be excluded.
89052739|NCT04594317|Experimental|low level laser therapy|970 ± 15-nm diode laser (Biolase Epic X, Biolase, Irvine, California, USA)will be activated at 0.5 W and 10 Hz at a distance of approximately 10 mm to the tissue around the apex of the root. A circular movement will be performed during application. Pulse duration will be 0.5 s, and pulse pause will be 50%. Total application time will be30 s for the tooth. For this application, a 200-μm optical tip will be used.
89052740|NCT04594317|Active Comparator|Calcium hydroxide intracanal medication|calcium hydroxide paste (Metapaste, Meta Biomed Co., Ltd, Korea) will be inserted in the canal using disposable plastic tip and placed at a distance 1 or 2 mm less than the working length.
89052741|NCT04587596||Clinical staff|All clinical staff employed at one surgery in Middlesbrough, UK who wish to participate
89052742|NCT04587713|Experimental|Part A, Sequence 1|"Part A, Sequence 1 = Treatment (Tx) C, Tx A, Tx C, Tx A~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout between treatments"
89684559|NCT02368431|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
88997758|NCT05807243|No Intervention|Group 4 - Senior population|n=100) Descriptive part: Data capture (clinical, anthropometric, lifestyle, genetic, biochemical, metabolomic and lipidomic data, among others) and comparison with the other groups.
88997759|NCT05807243|No Intervention|Group 5 - Oncological population|(n=100) Descriptive part: Data capture (clinical, anthropometric, lifestyle, genetic, biochemical, metabolomic and lipidomic data, among others) and comparison with the other groups.
88997760|NCT05807243|No Intervention|Group 6 - COVID-19 population|(n=100) patients who developed severe forms of COVID-19 or persistent COVID-19. Descriptive part: Data capture (clinical, anthropometric, lifestyle, genetic, biochemical, metabolomic and lipidomic data, among others) and comparison with the other groups.
88997761|NCT05807230|No Intervention|Conventional therapy: three-level rehabilitation treatment, Chinese medicine and acupuncture|Patients received conventional three-level rehabilitation treatment, conventional Chinese medicine and acupuncture treatment.
88997762|NCT05807230|Experimental|Conventional therapy and three-level network rehabilitation services|Three months after received conventional three-level rehabilitation treatment, conventional Chinese medicine and acupuncture treatment, patients continued to receive three-level network rehabilitation services within the medical alliance.
88997763|NCT05807217||Group A|12 patients (receiving meropenem) without acute kidney injury
88997764|NCT05807217||Group B|12 patients (receiving meropenem) without renal replacement therapy for acute kidney injury
88997765|NCT05807217||Group C|12 patients (receiving meropenem) with intermittent renal replacement therapy for acute kidney injury
88997766|NCT05807217||Group D|4 patients (receiving meropenem) with continuous renal replacement therapy for acute kidney injury
88997767|NCT05807217||Group E|4 patients (receiving piperacillin) with intermittent renal replacement therapy for acute kidney injury
88997768|NCT05807191|Experimental|Intervention Group|Kangaroo care was applied for 65 minutes to premature infants by their mothers based on the kangaroo care guide.
88997769|NCT05807191|No Intervention|Control Group|Kangaroo care was routinely administered by the nurse for 65 minutes without using a kangaroo care guide.
88997770|NCT05807165||HF-SRT|RT techniques and the dose schemes in the cohort of Hypofractionated Stereotactic Radiotherapy (HF-SRT)
88997771|NCT05807165||HS-WBRT plus memantine|The course of hippocampus-sparing whole-brain radiotherapy (HS-WBRT) combined with the synergic use of the neuroprotective agent, memantine
88997772|NCT05807152|No Intervention|Control Group|Furosemide infusion (standard treatment)
88997773|NCT05807152|Experimental|RenalGuard group|Furosemide infusion with matched de-hydration
88997774|NCT05807113|Experimental|Atopi intensive care BNO 3731 for topical use|
88997775|NCT05807113|Active Comparator|Benchmark skin care product for topical use|
88997776|NCT05807100||Stage I|Stage I Alzheimer's Group (n=42): Individuals diagnosed with probable Alzheimer's disease with mild (early stage) dementia according to the Clinical Dementia Rating Scale.
88997777|NCT05807100||Stage II|Stage II Alzheimer's Group (n=29): Individuals diagnosed with probable Alzheimer's disease with moderate (moderate stage) dementia according to the Clinical Dementia Rating Scale.
88997778|NCT05807100||Stage III|Stage III Alzheimer's Group (n=19): Individuals diagnosed with probable Alzheimer's disease with severe (advanced stage) dementia according to the Clinical Dementia Rating Scale.
88997779|NCT05807087|Active Comparator|Mechanical Osteotomy|
88997780|NCT05807087|Experimental|Piezosurgery|
88997782|NCT05806502|Experimental|Type 1 diabetes|Endothelium-dependent and -independent vasodilatation before and after 120 min intra-arterial administration of arginase the inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA).
88997783|NCT05806502|Experimental|Type 2 diabetes|Endothelium-dependent and -independent vasodilatation before and after 120 min intra-arterial administration of arginase the inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA).
88997784|NCT05806281|Experimental|MIED group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems
88997785|NCT05806281|No Intervention|Waitlist control group|no intervention.
88997786|NCT05799677|Experimental|Reflexology|Additive treatment with reflexology
88997787|NCT05799677|No Intervention|Control|No treatment with reflexology
88997788|NCT05797675|Experimental|Test group|Implant therapy and closed sinus lifting with A-PRF
88997789|NCT05792098|Active Comparator|Standard procedure group|The standard procedure group will undergo PDTS by the attending physician in the standard manner based on clinical examination and anatomical landmarks using bronchoscopic control.
88997790|NCT05792098|Active Comparator|Ultrasound navigated group|Ultrasound navigated group, the attending physician will additionally use ultrasound navigation during the procedure.
88997791|NCT05781698|Active Comparator|Control Group|The control group ( Mesalamine group, n =35 ) will receive 1 g mesalamine three times daily for 6 months
88997792|NCT05781698|Active Comparator|Fenofibrate group|Patients will receive 1 g mesalamine three times daily plus Fenofibrate (160 mg/day) for 6 months
88997793|NCT05779436||Patients undergoing cholangioscopy for evaluation biliary stricture|
88997794|NCT05720650||Case subjects diagnosed with gestational hypertension or preeclampsia|This is a restrospective observational study and there is no intervention.
88997795|NCT05720650||Control subjects diagnosed without any hypertensive disorders|This is a restrospective observational study and there is no intervention.
88997796|NCT05718193|Experimental|The DeFrame Group|Subjects in the DeFrame group were treated with a real-time computer-aided polyp detection system named DeFrame during colonoscopy.
88997797|NCT05718193|Experimental|The Classified DeFrame Group|Subjects in the Classified DeFrame group were treated with a real-time computer-aided polyp detection and classification system named Classified DeFrame during colonoscopy.
88997798|NCT05718193|Experimental|The Control Group|Subjects in the control group underwent standard colonoscopy.
89684560|NCT00757601|Experimental|15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)|Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5.
89684561|NCT00757601|Experimental|Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)|Participants received placebo to MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
88997799|NCT05709509|Experimental|Late PCI + Colchicine|Subjects that undergo late PCI (12-48 hours after STEMI), received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate), and colchicine
88997800|NCT05709509|Experimental|Late PCI + Optimal Medical Treatment|Subjects that undergo late PCI (12-48 hours after STEMI) and received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate)
88997801|NCT05709509|Experimental|Optimal Medical Treatment + Colchicine|Subjects that received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate) and colchicine
88997802|NCT05709509|Placebo Comparator|Optimal Medical Treatment|Subjects that received optimal medical treatment (statin, aspirin, P2Y12 inhibitor, and nitrate)
88997803|NCT05706909||Genex with ABMC|Injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the Core decompression procedure
88997804|NCT05705193|Experimental|Computerized Cognitive Remediation|
88997805|NCT05693844|Experimental|CD40 ligand expressing MSLN-CAR T cells|"Enrolled participants will be given a preconditioning regimen before the infusion of CD40 ligand expressing MSLN-CAR T cells.~Patients enrolled in dose 1 will be assigned to cohort 1 and cohort 2 respectively. Three patients in cohort 1 will be given albumin-bound paclitaxel plus cyclophosphamide as conditioning treatment. Another three patients will be enrolled into cohort 2 to receive albumin-bound paclitaxel plus cyclophosphamide and fludarabine. The final preconditioning regimen in the following dose levels will be determined by investigators according to the results from cohort 1 and 2, including controllable safety, CAR T cell expansion levels and superior persistence in PB."
88997806|NCT05674513|Active Comparator|Active CYP3A5 Allele|Ulipristal acetate 30mg orally x 1 dose with pharmacokinetic and pharmacodynamics testing in individuals with active CYP3A5 alleles
88997807|NCT05674513|Active Comparator|Inactive CYP3A5 Allele|Ulipristal acetate 30mg orally x 1 dose with pharmacokinetic and pharmacodynamics testing in individuals without active CYP3A5 alleles
88997808|NCT05665296|Experimental|cervicothoracic mobilization|This group will receive cervicothoracic mobilization with comprehensive corrective exercise
88997809|NCT05665296|Active Comparator|control group: comprehensive corrective exercise (CCE).|This group will receive traditional treatment comprehensive corrective exercise (CCE).
88997810|NCT05665036|Experimental|SIG-005|SIG-005 is comprised of human native alpha-L-iduronidase enzyme (hIDUA) producing spheres
89684562|NCT00757601|Experimental|15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
89684563|NCT00757601|Experimental|15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
89684564|NCT00757601|Experimental|60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo|Participants received 60 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
89684565|NCT00757601|Experimental|Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5
89684566|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
89684567|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
89684568|NCT00757601|Experimental|140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo|Participants received 140 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
89684569|NCT00757601|Experimental|Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
89684570|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5
89684571|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
88997811|NCT05657964||Gokhale ARM|Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
89052743|NCT04587713|Experimental|Part A, Sequence 2|"Part A, Sequence 2: Tx D, Tx B, Tx D, Tx B~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
89684572|NCT03809975|Active Comparator|Control Arm|"Current model of care~Patients will undergo the current standard of care in the Orthopaedic Outpatient Clinic in Tan Tock Seng Hospital. Patients will undergo routine consultation with an orthopaedic surgeon and will be provided with standard treatment as necessitated based on the assessment of the orthopaedic surgeon. Subsequent follow up appointments will be scheduled at the discretion of the orthopaedic surgeon. Patients will be referred to the physiotherapists, dietitian and psychologists as necessary for regular or adhoc sessions at the discretion of the allied health professional."
89684573|NCT03809975|Experimental|Intervention Arm|"Multidisciplinary Community Program~Community based, personalized, structured, 12-week multidisciplinary program that includes Orthopaedics, Physiotherapy, Dietitics, Psychology interventions. This intervention involves the use of formal assessment such as BMI and psychological questionnaires to determine the need for dietetics or psychological intervention. In addition, there are educational sessions to improve patient's understanding of osteoarthritis and improve their activation level. An optional support group session will be arranged at approx. 3-4 months after completion of the 12-week intervention program to improve sustainability of treatment effect."
89684574|NCT03836651|Active Comparator|Control Group|Following completion of baseline data collection, participants will be randomized to one of two groups. The research assistant will open a pre-assigned envelope in which group assignment was determined by a random number/block generator. The intervention is designed to complement guideline directed medical management. Therefore, both the intervention and control group will continue to be medically managed by their health care provider as usual. In order to avoid introducing the confound of extra attention paid to the intervention group, the control group will have the same visit and call schedule as the intervention group.
89684575|NCT03836651|Experimental|Intervention Group|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants assigned to the intervention group will receive dietary antioxidants as V8® Low Sodium 100% vegetable juice.
89684576|NCT05743439|Experimental|Early Augmentative and Alternative Communication (AAC) Intervention|After a period of stable baseline performance (3 to 5 sessions) on parent and child outcomes, the interventionist will apply the early AAC intervention.
89684577|NCT02037555|Experimental|AT-III (Human)|"Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:~AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4"
89684578|NCT02037555|Placebo Comparator|Placebo|Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
89052744|NCT04587713|Experimental|Part A, Sequence 3|"Part A, Sequence 3: Tx C, Tx A, Tx D, Tx B~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
89052745|NCT04587713|Experimental|Part A, Sequence 4|"Part A, Sequence 4: Tx D, Tx B, Tx C, Tx A~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
89052746|NCT04587713|Experimental|Part A, Sequence 5|"Part A, Sequence 5: Tx A, Tx C, Tx A, Tx C~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
89052747|NCT04587713|Experimental|Part A, Sequence 6|"Part A, Sequence 6: Tx B, Tx D, Tx B, Tx D~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
89052748|NCT04587713|Experimental|Part A, Sequence 7|"Part A, Sequence 7: Tx A, Tx C, Tx B, Tx D~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
89052749|NCT04587713|Experimental|Part A, Sequence 8|"Part A, Sequence 8: Tx B, Tx D, Tx A, Tx C~Single oral dose of treatment on Day 1 of each period in a 4-way crossover design with a ≥10-day washout period between treatments"
89052750|NCT04587713|Experimental|Part B,Treatment A|Single oral dose of Treatment A on Day 1
89052751|NCT04587011|Experimental|T1|Tegoprazan A mg or placebo
89052752|NCT04587011|Experimental|T2|Tegoprazan B mg or placebo
89052753|NCT04587011|Experimental|T3|Tegoprazan C mg or placebo
89052754|NCT04587011|Experimental|T4|Tegoprazan D mg or placebo
89052755|NCT04587206|Experimental|Experimental: Sequence 1|"Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-348- A single oral dose of 1 tablet under fasting condition"
89052756|NCT04587206|Experimental|Experimental: Sequence2|"Period 1: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-348- A single oral dose of 1 tablet under fasting condition~Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition"
89052757|NCT00581880||1|Terminally Ill patients
89052758|NCT00581958||Patients undergoing HSCT|Research subjects will have blood and/or urine sampled at three time points in the Department of Radiation Oncology. Participating patients will have at least a total two samples collected at each time point. The first sampling will occur before the first TBI treatment is given. The second sampling will occur before the second TBI treatment, usually 3 to 8 hours after the first treatment (in the case of multifraction TBI). If a patient is being treated with single fraction TBI, then the second sampling will occur approximately 3-8 hours after the first TBI treatment. The third and final sampling will occur at the next morning blood draw, prior to the fourth TBI treatment (in the case of multifraction TBI), 24 hours after the first TBI treatment.
89052759|NCT04586816|Placebo Comparator|vehicle only-placebo|Vehicle cream base containing no maple leaf extract to be applied twice daily to the face
89052760|NCT04586816|Experimental|1% red maple leaf extract|lotion preparation with 1% red maple leaf extract to be applied twice daily to the face
89052761|NCT04586816|Experimental|5% red maple leaf extract|lotion preparation with 5% red maple leaf extract to be applied twice daily to the face
89052762|NCT04593966||Pediatric AVM|"AVM patients' age under 18-years-old who underwent intervention in investigators' institution.~Patients' lesions were located in eloquent and confirmed by image."
89052763|NCT04593966||Adult AVM|"AVM patients' age over 18-years-old who underwent intervention in investigators' institution.~Patients' lesions were located in eloquent and confirmed by image."
89216474|NCT03566667|Other|Standard care|Usual standard care
89052764|NCT04593849|Active Comparator|group A (Ru-Yih-Jin- Huang-Saan group)|Herbal medicine(Ru-Yih-Jin- Huang-Saan) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
89052765|NCT04593849|Experimental|group B (Wan-Yin-Gao-Jia-Jean-Wey group)|Herbal medicine (Wan-Yin-Gao-Jia-Jean-Wey) will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
89052766|NCT04593849|Placebo Comparator|placebo group( topical agent without therapeutic effects)|topical agent without therapeutic effects will be applied to injured site and covered with gauze for 6 hours per day. Each subject will receive persistent treatment for 1 week
89052767|NCT04593849|No Intervention|control group|only oral analgesics will be applied to patients
89052768|NCT04586543|Experimental|Selegiline+ Docetaxel|Selegiline and plus Docetaxel
89052769|NCT04586543|Active Comparator|Docetaxel|Docetaxel
89052770|NCT00582192||1|Participants with certain types of cancers that are eligible for studies at Memorial Sloan-Kettering Cancer Center.
89052771|NCT04586777|Experimental|Anodal tvDCS|20 minutes of anodal tvDCS will be applied over the spine at 2.5mA.
89052772|NCT04586777|Experimental|Cathodal tvDCS|20 minutes of cathodal tvDCS will be applied over the spine at 2.5mA.
89052773|NCT04586777|Sham Comparator|Sham tvDCS|20 minutes of sham tvDCS will be applied over the spine.
89052774|NCT04593576|Experimental|Structured physical activity/outdoor sports.|Out door sports and structured physical activity protocol will be administered on children with Autism.
89052775|NCT04593576|Active Comparator|Intensive table teaching control group|Control group will only be exposed to intensive table teaching instead of physical activity protocol.
89052776|NCT04587284||Patients with robot-assisted laparoscopic radical prostatectomy|
89052777|NCT04587284||Patients with open retropubic radical prostatectomy|
89052778|NCT04587284||Patients with laparoscopic radical prostatectomy|
89052779|NCT04586738|Other|Non-resorbable uveoscleral implant associated with absorbable collagen matrix|non-perforating deep sclerectomy surgery with non-resorbable uveoscleral implant associated with absorbable collagen matrix
89052780|NCT04586738|Other|Isolated absorbable collagen matrix implant|non-perforating deep sclerectomy surgery with isolated absorbable collagen matrix implant
89052781|NCT04593693|Other|Invia Motion Endure NPWT system|Use of Negative Pressure Wound Thearpy
89052782|NCT04586582||ST-segment resolution <40.15%|ST-segment resolution <40.15%
89052783|NCT04586582||ST-segment resolution >40.15%|ST-segment resolution >40.15%
89052784|NCT00581568|Experimental|Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
89052785|NCT00582270||1|Follicular Lymphoma
89052786|NCT00582270||2|Non-follicular Lymphoma
89522692|NCT03395249|Placebo Comparator|Placebo Oral Tablet|"Placebo tablets (100, 300, and 600 mg) are pressed from a single placebo blend consisting of the same inactive ingredients; the active pharmaceutical ingredient (API) is replaced by Mannitol 200SD.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered BID over a period of 14 days or forty doses administered TID over a period of 14 days"
89522693|NCT03395249|Other|Optional Orapenem Open-Label Control|"A single, optional, open-label, control cohort that may enroll, in which all 8 subjects receive Orapenem.~SAD Cohort: One dose under fasted conditions and one dose under fed conditions."
89522694|NCT03396055|Experimental|Treatment group|Specific rehabilitation exercise
89522695|NCT03396055|No Intervention|Control|No intervention
89522696|NCT03395171|Experimental|Treatment: Cholecalciferol (Vitamin D3)|Athletes with Vitamin D levels lower than 30ng/mL will be treated with the supplement for eight weeks.
89522697|NCT03395171|No Intervention|Prospective Control Group|Athletes with Vitamin D levels higher than 30ng/mL were enrolled and compared but not treated.
89522698|NCT03395977|Placebo Comparator|Placebos PO and IV|PO : per os IV : intraveinously
89522699|NCT03395977|Experimental|Febuxostat PO and Placebo IV|240 mg a day for 3 days
89522700|NCT03395977|Experimental|Febuxostat PO And Rasburicase IV|Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
89522701|NCT03395977|Experimental|Placebo PO And Rasburicase IV|Placebo : for 3 days. Uricase : 3 mg once.
89522702|NCT03126487|Experimental|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND
89522703|NCT03821519|Experimental|Relapsed after Haplo transplant|
89522704|NCT03125551|Active Comparator|Ginger|Ginger ( Zingiber officinale) 4 grams po dly for 14 days
89522705|NCT03125551|Active Comparator|Garlic|Garlic (Allium sativum) 4-12 mg alliin po dly for 14 days
89522706|NCT03125551|Active Comparator|Ginkgo Biloba|Ginkgo Biloba 40mg po tds for 14 days
89522707|NCT03125551|Active Comparator|Ginseng|Ginseng 400mg po dly for 14 days
89522708|NCT03125551|Placebo Comparator|Placebo|Placebo po dly for 14 days
89522709|NCT03391687||Amylase Test|gastric cancer patients receiving radical gastrectomy
89522710|NCT03399383|Other|Patient education (longitudinal analysis)|Patients with adrenal insufficiency complete a questionnaire before and 6 months after participation in a standardised patient education.
89522711|NCT05239325|Active Comparator|Intervention Group|"Participants having previously attended at least once in previous years the World Cancer Day Walk will be considered as the group exposed to the health education intervention (returning)."
89522712|NCT05239325|No Intervention|Control Group|"The control/non-exposed group will be the participants who are attending the World Cancer Day Walk for the first time in 2022 (first timers) and have not yet received health education information."
89532796|NCT05914324|Experimental|Phefumla|Phefumla arm participants will be managed by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the Phefumla device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. if planning to go to hospital, how is the healthcare worker is travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the Phefumla device and a reference device.
89532839|NCT05865262||treated transgender people|Transgender individuals consulting at the Endocrinology department of the Haut-Leveque hospital in Pessac (France), whether they are (one unique visit) or not (2 visits) already on GAHT (feminizing hormone treatment in transgender women and masculinizing treatment in transgender men, respectively). Men and women not already on GAHT will have two visits in total, one inclusion visit before GAHT start and one at least after one month of GAHT (and maximum within 2 years of start). Transgender individuals already on GAHT will have one unique inclusion visit without any planned follow-up visit.
89532840|NCT05858034|Other|Activity Intervention|Customized selection of exercise and other community and online activity options to improve activity.
89532841|NCT05858034|Other|Nutrition Intervention|Development of a customized nutrition plan to address nutritional needs.
89532842|NCT05854992||Cardiovascular Risk Group Treated with Triptans|Subjects with diagnosis of migraine and cardiovascular disease, cerebrovascular disease and/or two or more cardiovascular risk factors who received Triptans as part of clinical care.
89532843|NCT05854992||Cardiovascular Risk Control Group Treated with No Triptans|Subjects with who did not received Triptans as part of clinical care.
89532844|NCT05854992||Pregnant Women Group Treated with Triptans|Subjects diagnosed with migraine that received Triptans as part of clinical care during pregnancy.
89532845|NCT05854992||Pregnant Women Control Group Treated with No Triptans|Subjects that did not receive Triptans as part of clinical care during pregnancy.
89532846|NCT05854433||Myotonic dystrophy type 2|"Adults with myotonic dystrophy type 2 who meet all inclusion and exclusion criteria for the study.~To be assessed at the baseline visit: Medical history and a focused neurological examination, brain MRI, a comprehensive Clinical Assessment Battery (CAB) of cognitive and motor measures, self-reported questionnaires, strength and motor function evaluation, and blood drawn for biomarker analysis.~A subset of the participants who agree to have cerebrospinal fluid (CSF) collection for additional biomarker analysis will undergo lumbar puncture procedure."
89532847|NCT05854433||Controls|"Healthy individuals who meet all inclusion and exclusion criteria for healthy controls.~To be assessed at the baseline visit: Medical history and a focused neurological examination, brain MRI, a comprehensive Clinical Assessment Battery (CAB) of cognitive and motor measures, self-reported questionnaires, strength and motor function evaluation, and blood drawn for biomarker analysis.~A subset of the participants who agree to have cerebrospinal fluid (CSF) collection for additional biomarker analysis will undergo lumbar puncture procedure."
89532848|NCT05852717|Experimental|GDP + Epcoritamab + AutoSCT or CAR T-cell therapy|"Cycles 1-3 (Cycle = 21 days) Epcoritamab will be administered by subcutaneous injection Days 1, 8, and 15. Epcoritamab Day 1: 0.16mg, Day 8: 0.8mg, Day 15: 48mg except Cycle 2-Epcoritamab will administered at 48mg on Days 1, 8 and 15~Gemcitabine will be administered by IV infusion on Days 1 and 8. Gemcitabine Days 1,8: 1,000mg/m^2~Cisplatin will be administered by IV infusion on Day 1. Cisplatin Day 1: 75mg/m^2~Dexamethasone will be given by mouth on Days 1-4. Dexamethasone Days 1-4: 40mg~After completion of Cycle 3 Autologous stem cell transplant (AutoSCT) OR CAR T-cell therapy"
89532849|NCT05852717|Experimental|GDP + Epcoritamab + Epcoritamab Maintenance|"Cycles 1-3 (Cycle = 21 days) Epcoritamab will be administered by subcutaneous injection Days 1, 8, and 15 of each Cycle.~Epcoritamab Day 1: 0.16mg, Day 8: 0.8mg, Day 15: 48mg except Cycle 2-Epcoritabab will administered at 48mg on Days 1, 8 and 15~Gemcitabine will be administered by IV infusion on Days 1 and 8 of each Cycle. Gemcitabine Days 1,8: 1,000mg/m^2~Cisplatin will be administered by IV infusion on Day 1 of each Cycle. Cisplatin Day 1: 75mg/m^2~Dexamethasone will be given by mouth on Days 1-4 of Cycle 1 ONLY. Dexamethasone Days 1-4: 40mg~Cycles 4-9 (Cycle =28 Days) Epcoritamab will be administered by subcutaneous injection on Days 1, 8, and 15 of Cycles 4-9."
89532850|NCT05850663|Other|Ecological Momentary Assessments (EMAs)|Patients will receive one EMA (Ecologic Momentary Assessment) per day for approximately 75 days, through the provided smart phone application.
89532851|NCT05849480|Experimental|Phase I|Keytruda, oxaliplatin, capecitabine and escalating doses of CDX-1140
89532852|NCT05849480|Experimental|Phase II|Keytruda, oxaliplatin, capecitabine and estimated safe dose of CDX-1140
89532853|NCT05848700|Experimental|SEP-363856|
89532854|NCT05848700|Placebo Comparator|Placebo|
89532855|NCT05845398|Experimental|DCR-AUD|Multiple doses of DCR-AUD. Subcutaneous administration of of DCR-AUD.
89532856|NCT05845398|Placebo Comparator|DCR-AUD Placebo|Multiple doses of placebo comparator. Subcutaneous administration of Placebo for DCR-AUD, volume to match active single dose
89532857|NCT05843643|Experimental|Study 1- Upadacitinib Dose A|Participants will receive upadacitinib dose A once daily for 52 weeks.
89532858|NCT05843643|Placebo Comparator|Study 1- Placebo|Participants will receive upadacitinib matching placebo once daily for 52 weeks.
89532859|NCT05843643|Experimental|Study 2- Upadacitinib Dose A|Participants will receive upadacitinib dose A once daily for 52 weeks.
89532860|NCT05843643|Placebo Comparator|Study 2- Placebo|Participants will receive upadacitinib matching placebo once daily for 52 weeks.
89532861|NCT05843643|Experimental|Study 3- Low Disease Activity Upadacitinib (LDA) Dose A|Participants in the upadacitinib arms from Study 1 or Study 2 with LDA will receive upadacitinib dose A once daily for 52 weeks.
89532862|NCT05843643|Experimental|Study 3- Low Disease Activity Upadacitinib Dose B|Participants in the upadacitinib arms from Study 1 or Study 2 with LDA will receive upadacitinib dose B once daily for 52 weeks.
89532863|NCT05843643|Experimental|Study 3- No LDA Upadacitinib Dose A|Participants in the upadacitinib arms from Study 1 or Study 2 with no LDA will receive upadacitinib dose A once daily for 52 weeks.
89532864|NCT05843643|Experimental|Study 3- Upadacitininb Dose A|Participants in the placebo arms of Study 1 or Study 2 will receive upadacitinib Dose A once daily for 52 weeks.
89532865|NCT05843643|Experimental|Study 3- Open Label Upadacitinib Dose A|Participants who experience a suspected systemic lupus erythematosus (SLE) flare may receive open label upadacitinib Dose A once daily for the remainder of the study.
89532866|NCT05843643|Experimental|Study 3- Open Label Upadacitinib Dose B|Participants who reach >= 65 years of age and are still on study drug may receive open-label upadacitinib Dose B once daily, and participants who experience a suspected SLE flare while on upadacitinib Dose B may receive upadacitinib Dose A for the remainder of the study.
89532867|NCT05841277|Experimental|LY3819469 (Control)|LY3819469 administered subcutaneously (SC) to participants with normal renal function
89052787|NCT04586465|Experimental|Neoadjuvant ICI combination with chemotherapy for stage Ⅱ-Ⅲ NSCLC|Eligible patients with clinical stage Ⅱ-Ⅲ NSCLC will receive dynamic PET-CT before and after 3 cycles neoadjuvant pembrolizumab plus chemotherapy, then patients receive surgical resection. Changes in tumor size were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Net uptake rate constant of FDG-Ki value based on dynamic PET will be calculated to evaluate Ki changes before and after treatment. Pathological tumor response were evaluated according to IASLC recommendations. Dynamic PET will be compared with RECIST whether it can better predict the pathological tumor response and disease free survival.
89052788|NCT04586309|Experimental|Early TM Training|This group will receive training in Transcendental Meditation and will complete assessments at baseline, 1 month and 3 months.(3 assessments in total).
89052789|NCT04586309|Active Comparator|Delayed TM training|This arm will complete the baseline, 1 month and 3 month assessments and then will receive the TM training, followed by additional 1 month and 3 month post-training assessments (5 in total)
89052790|NCT04586192|Experimental|COMET|Participants receive modules focused on cognitive restructuring, gratitude, behavioral activation and self-compassion. Participants were randomized to receive 3 of the 4 possible modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.Participants in the intervention condition were randomized to receive descriptions of the four modules at the beginning of the intervention that were phrased to focus on building and improving strengths (positive) or reducing negative emotions and behaviors (negative).
89052791|NCT04586192|Sham Comparator|Self-Awareness Control|Participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
89052792|NCT04586192|No Intervention|Waitlist|Participants filled out all pre-test and post-test measures without having access to COMET of the active control exercises. Participants in this condition will receive access to COMET at the end of the study.
89052793|NCT00582387||nonmuscle invasive bladder cancer|This is a hospital-based cohort study in which subjects with non-muscle invasive bladder cancer diagnosed within the previous 12 months will be evaluated to determine whether candidate genetic variants in patients with superficial bladder cancer can predict the risk of disease recurrence and/or progression, with the goal of modifying surveillance schedules as a function of predicted risk of recurrence or progression. All patients will be treated according to the treatment plan as outlined by their attending physician. The study will not require any deviation from the planned usual treatment.
89052794|NCT04586114||Early corticosteroid|Corticosteroid treatment within first seven days after ICU admission
89052795|NCT04586114||Late corticosteroid|Corticosteroid treatment later than seventh day's after ICU admission
89052796|NCT04586114||No corticosteroid|No corticosteroid treatment during ICU stay
89052797|NCT00566865|Experimental|2|mitiglinide + gemfibrozil
89052798|NCT00566865|Placebo Comparator|1|mitiglinide + placebo for gemfibrozil
89052799|NCT04585997|Active Comparator|Mepolizumab|Mepolizumab
89052800|NCT04585997|Active Comparator|Omalizumab|Omalizumab
89532868|NCT05841277|Experimental|LY3819469 (Severe Renal Impairment)|LY3819469 administered SC to participants with severe renal impairment
89532869|NCT05841277|Experimental|LY3819469 (End-Stage Renal Disease)|LY3819469 administered SC to participants with end-stage renal disease (ESRD)
89532870|NCT05839626|Experimental|SAR445514 RRMM Dose escalation phase (Part 1a)|SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)
89532871|NCT05839626|Experimental|SAR445514 RRLCA Dose escalation phase (part 1b)|SAR445514 will be administered to participants with relapsed/refractory light chain amyloidosis (RRLCA)) using subcutaneous route (SC)
89532872|NCT05839626|Experimental|SAR445514 Dose level A (part 2)|SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)
89532873|NCT05839626|Experimental|SAR445514 Dose level B (part 2)|SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)
89532874|NCT05839626|Experimental|SAR445514 RRMM Dose expansion (part 3a)|SAR445514 will be administered to participants with relapsed/refractory multiple myeloma (RRMM) using subcutaneous route (SC)
89532875|NCT05839626|Experimental|SAR445514 RRLCA Dose expansion (part 3b)|SAR445514 will be administered to participants with relapsed/refractory light chain amyloidosis (RRLCA) using subcutaneous route (SC)
89532876|NCT05837923|Placebo Comparator|Placebo Control 1|Relief Product Form 1 - control
89532877|NCT05837923|Experimental|Active Product 1.1|Relief Product Form 1 - active product 1
89532878|NCT05837923|Experimental|Active Product 1.2|Relief Product Form 1 - active product 2
89532879|NCT05837923|Placebo Comparator|Placebo Control 2|Relief Product Form 2 - control
89532880|NCT05837923|Experimental|Active Product 2.1|Relief Product Form 2 - active product 1
89532881|NCT05837923|Placebo Comparator|Placebo Control 3|Relief Product Form 3 - control
89532882|NCT05837923|Experimental|Active Product 3.1|Relief Product Form 3 - active product 1
89532883|NCT05837923|Experimental|Active Product 3.2|Relief Product Form 3 - active product 2
89532884|NCT05837923|Experimental|Active Product 3.3|Relief Product Form 3 - active product 3
89532885|NCT05837104|Experimental|Magnesium vitamin B6|Magnesium vitamin B6 (MagnéVie B6®) composed of Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
89532886|NCT05837104|Placebo Comparator|Placebo|Placebo tablet will be taken three times daily for four weeks.
89532887|NCT05836857||Cannabis (Marijuana) and Cannabidiol (CBD)|This is a survey to determine the number of cancer pain patients who use and/or used Marijuana and/or CBD for pain or other symptom burdens.
89532888|NCT05835479|Experimental|Rezafungin Acetate /Co-trimoxazole|"Rezafungin: Weekly intravenous infusion with a loading dose of 400 mg over 1 hour (±10 minutes) on Day 1 followed by maintenance doses of 200 mg over 1 hour (±10 minutes) on Day 8 and Day 15.~From Day 1 to Day 7, co-trimoxazole will also be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day.~For participants with a creatinine clearance between 15 mL/min and 30 mL/min, the dose of co-trimoxazole should be reduced to trimethoprim 7.5-10 mg/kg/day and sulfamethoxazole 37.5-50 mg/kg/day"
89052801|NCT04576845||Study Group|The study will be performed on Caucasian origin children who are among 2 to 6 years of age. The study group will be composed of children (n=31) who had CMA (Ig E-mediated and/or non-Ig E-mediated and/or mixed type) proved with oral food challenge tests in their early childhood (in ages of 0-2). The inclusion criteria to the study group will be to undergo a Cow's milk elimination (CME) diet or took a hypoallergenic formula in 0-2 years of age for at least 3 months or longer due to CMA allergy and improved afterward, and/or to eliminate other nutrients (e.g., eggs, potatoes, wheat flour, soybean, etc.) other than cow's milk between the ages of 0-2 for at least 3 months or longer, and/or to add these nutrients back to their diet in the last 3 months, and/or not receiving hypoallergenic formula for the last 3 months, not to be on the CME diet at present. Thus, no children in the study and control groups will be on a dietary restriction during the study.
89052802|NCT04585880|Experimental|Virtual Collaborative Care Clinic|The Virtual Collaborative Care Clinic arm participants use a home blood pressure monitor and routine blood pressure measurements will be uploaded to a dashboard monitored by clinical pharmacists. Blood pressure will be managed aggressively by the clinical pharmacists in coordination with Primary Care Physicians.
89052803|NCT04585880|No Intervention|Control Intervention|The control intervention will consist of providing the participant with educational material and a home blood pressure monitor. The patients in the control group will not have support from Virtual Collaborative Care Clinic pharmacists. Routine blood pressure measures using their device will not be collected via the dashboard and will not be available for pharmacist review. Participants will continue to see their physicians for their usual care for blood pressure management.
89052804|NCT00582465||Observation|Lupus
89052805|NCT04586036|Experimental|young healthy adults|Gait measured by Vicon Nexus System
89052806|NCT04586036|Experimental|young adults with chronic ankle joint instability|Gait measured by Vicon Nexus System
89052807|NCT00582504|Experimental|Vaccination|VEE TC-83
89052808|NCT04593108||Letrozole misoprostol|"Group (A):~A participant will receive three tablets of letrozole (Letrozole®, Technopharma) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
89052809|NCT04593108||Misoprostol,placebo|"Group (B):~A participant will receive three tablets of placebo as a single dose on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start"
89052810|NCT04577391|Experimental|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the use of involved side as maximum as possible. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating). In case of activities requiring both hand use, such as stabilizing paper during the painting or holding the bricks of lego on the ground, the treating physiotherapist undertook the role of the child's dominant hand.
89052811|NCT04577391|Active Comparator|Bimanual training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
89052812|NCT04585412|Experimental|Palonosetron (Stothu®)|Stothu® Solution for Injection 0.25 mg/5 mL
89052813|NCT04585412|Active Comparator|Palonosetron (Aloxi®)|Aloxi® Solution for Injection 0.25 mg/5mL
89052814|NCT04592796||Nursing-home residents|Older adults in a nursing-home who report a self-perception of poor sleep quality
89684579|NCT03809819||Patients with MRKHS|Thirteen patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty
89052815|NCT04576884||Group 1|participants of less than 18 years old
89052816|NCT04576884||Group 2|participants aged from 18 years to 40 year
89052817|NCT04576884||Group 3|participants aged from 41 years to 60 years
89052818|NCT04576884||Group 4|participants over 60 years old
89052819|NCT00567866|Experimental|1|placebo -50 mg quetiapine- 100 mg quetiapine
89684580|NCT03809819||Control group|A control group of 13 age-matched, childless, sexually active women
89052820|NCT00567866|Experimental|2|50 mg quetiapine -100 mg quetiapine- placebo
89052821|NCT00567866|Experimental|3|50 mg quetiapine -placebo- 100 mg quetiapine
89052822|NCT00567905|Experimental|A|Green tea extract
89684581|NCT03804359|No Intervention|GEMRITUX protocol|6 months of symptomatic antihypertensive and antiproteinuric therapy, and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio (UPCR) remains > 3.5 g/g and albuminemia < 30 g/l), two 375 mg/m2 rituximab infusions at 1-week interval.
89684582|NCT03804359|Experimental|Personalized treatment|"restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive and antiproteinuric treatment (KDIGO)~restricted anti-CysR activity after 6 months of symptomatic treatment with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 375 mg/m2 rituximab infusions at 1-week interval;~Anti-CTLD1/7 activity at inclusion or after 6 months with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 1g rituximab infusions at 2-week interval at month 0 and/or month 6."
89684583|NCT05743361||Autoantibodies|Detection of: ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
89684584|NCT02369211|Experimental|Intravenous acetaminophen|Patient receives 1g intravenous acetaminophen after the incision
89684585|NCT02369211|Placebo Comparator|Placebo|Patient receives saline injection instead of the study drug
89684586|NCT03804281|Experimental|Test group|esthetic crown lengthening with microsurgical approach
89684587|NCT03804281|Active Comparator|Control group|esthetic crown lengthening with conventional approach.
89684588|NCT00759161|Active Comparator|1|AN2728 Ointment, 5%
89684589|NCT00759161|Placebo Comparator|2|AN2728 Ointment Vehicle
89052823|NCT00567905|Placebo Comparator|B|
89052824|NCT00582543|Experimental|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position.
89052825|NCT00567983|Active Comparator|1.|
89052826|NCT00567983|Placebo Comparator|2.|
89052827|NCT00582582|Experimental|A|Docetaxel plus doxercalciferol
89684590|NCT02038023|Other|IV iron|Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron.
89684591|NCT04384133|Other|COPD group|Impulse oscillometric pulmonary function tests and spirometric pulmonary function test will be performed.To evaluate the degree of disease inflammation and phenotype, nitric oxide measurements will be made in the breath air with fractional exhaled nitric oxide (FENO) device. Blood eosinophil values will be examined. Thorax computed tomography will be performed to evaluate small airway dysfunction. To assess symptom control in patients with COPD, a dyspnea scale of mMRC will be administered. The COPD assessment test (CAT) will be applied to measure the quality of life. All participants will be followed for 1 year to record the number of exacerbations requiring emergency and hospital admissions for COPD.
89684592|NCT04384133|Other|Healthy control group with a history of smoking|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
89684593|NCT04384133|Other|Healthy control group with no smoking history|Impulse oscillometric pulmonary function test, spirometric pulmonary function test and chest x ray will be performed.
89052828|NCT00582582|Placebo Comparator|B|Docetaxel plus placebo
89684594|NCT02038179|Experimental|Allopurinol, Then Placebo|Participants will be asked to take 4 weeks of allopurinol (300 mg oral per day), then will crossover (after 2-4 week washout period) and take placebo for an additional 4 weeks.
89684595|NCT02038179|Experimental|Placebo, Then Allopurinol|Participants will be asked to take 4 weeks of placebo, then will crossover (after 2-4 week washout period) and take allopurinol (300 mg oral per day) for an additional 4 weeks.
89684596|NCT00768287|Experimental|IB1001|
89684597|NCT00768287|Active Comparator|nonacog alfa|
89684598|NCT00768521|Experimental|1|Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo
89684599|NCT00768521|Experimental|2|Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd)
89684600|NCT00768521|Experimental|3|Part II, Sequence 1: study drug crossing over to placebo
89684601|NCT00768521|Experimental|4|Part II, Sequence 2: placebo crossing over to study drug
89684602|NCT02038569|Experimental|LEO 80185 gel|
89684603|NCT00768599|Active Comparator|1|Econazole Nitrate Cream 1%
89052829|NCT04585373|Experimental|(24 hours)|kinesio-tapping along with conventional therapy
89052830|NCT04585373|Experimental|(48hours)|kinesio-tapping along with conventional therapy
89052831|NCT04585373|Experimental|(72 hours)|kinesio-tapping along with conventional therapy
89052832|NCT04592601|Experimental|S.L.I.M.M.S. Procedure|Prospective collection of data on the safety and efficacy of the S.L.I.M.M.S. Procedure
89684604|NCT00768599|Experimental|2|Econazole Nitrate Foam 1%
89684605|NCT00768599|Placebo Comparator|3|Vehicle Foam
89684606|NCT03804203|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
89684607|NCT03804203|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
89684608|NCT03803891||Endoscopic full-thickness resection|Patients with neoplastic lesions less than 30mm unresectable en bloc by other less invasive endoscopic techniques, including lesions suggestive of T1 colorectal cancer, subepithelial tumors, lesions with diverticular involvement, lesions with no-lifting sign (recurrent, incomplete prior resection or untreated lesions).
89052833|NCT04584944||Healthy adult men|Healthy young men, 20- 44 years old
88997812|NCT05657964||Physical Therapy ARM|Participants randomized into the standard care/physical therapy (PT) arm will similarly receive a standardized PT prescription during a 6-12 weeks period, meeting 1-2 times per week, to include posture education and training, therapeutic exercise instructions and development of an independent home exercise program.
89052834|NCT04584944||Healthy adult women|Healthy young women, 20- 44 years old
89052835|NCT04592718|Experimental|Slow deep breathing plus breath counting|Participants in this group will do a daily 5-min slow deep breathing exercise (6 breaths/minute) and will also count their breaths
89052836|NCT04592718|Active Comparator|Normal-paced breathing plus breath counting|Participants in this group will do a daily 5-min normal-paced breathing (15 breaths/minute) and will also count their breaths
89052837|NCT04592718|No Intervention|Control|Participants in this group will serve as a control and will not do any breathing exercises or breath counting.
89052838|NCT00566904|Experimental|1|Participants will receive one of three different topical treatments on Days 8, 15, or 22.
89052839|NCT04584983|Active Comparator|usual prescribed intralipid (UL) regimen|
89052840|NCT04584983|Experimental|restricted prescribed intralipid (RL) regimen|
89052841|NCT00568100|Experimental|1|COPD patients
89052842|NCT04576611|Experimental|face-to-face|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using face-to-face modality guided by a health professional.
89684609|NCT02370693|Active Comparator|bortezomib plus mycophenolate mofetil|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
89684610|NCT02370693|Placebo Comparator|Placebo plus mycophenolate mofetil|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
89684611|NCT03809507||NC Clinicians|Qualtrics Survey of NC Clinicians with DEA registration
89684612|NCT02039115|Experimental|prednisone|Daily oral prednisone is taken for 6 weeks, at a dose of 40mg/day in week 1, 30mg/day in week 2, 20mg/day week 3 and 4, 10mg/day in week 5, and 5mg/day in week 6. Prednisone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage complete Barretts excision.
89684613|NCT02039115|Placebo Comparator|placebo|Placebo tablets will be taken in the same manner as the prednisone arm.
89684614|NCT00759473|Placebo Comparator|Placebo/Placebo/Placebo/Placebo|Participants were assigned to receive placebo for each of 3 cue exposure sessions and at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
89684615|NCT00759473|Experimental|DCS/DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 3 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
89684616|NCT00759473|Other|DCS/Placebo/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) at the first and third cue exposure sessions and a placebo at the second cue exposure and the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
89684617|NCT00759473|Experimental|DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
89684618|NCT00759473|Active Comparator|Placebo/Placebo/Placebo|Participants were assigned to placebo for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
89684619|NCT00759707|Experimental|1|ultrasound imaging of saphenous vein bypass graft following an ischemic stimulus, administration of sublingual nitroglycerin and intravenous administration of L-NMMA.
89684620|NCT02039817|Experimental|Healthy Volunteers|All subjects receive a single 50 mg oral dose of IDN-6556
89684621|NCT02039817|Experimental|Severe Renal Impairment|All subjects receive a single 50 mg oral dose of IDN-6556
89684622|NCT02371785|Experimental|CorPath 200 System|CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.
89684623|NCT03809273|Experimental|Yangxinshi|
89684624|NCT03809273|Active Comparator|Trimetazidine|
89684625|NCT04384991|Experimental|HU007 Eye drop|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
89684626|NCT04384991|Active Comparator|Restasis Eye drop 0.05% (Cyclosporine)|"Adminster twice a day(one drop would be administered to both eyes once a time). When being administered, the IP should be mixed by upside down.~Medication is recommended at 9AM(±1H) and 9PM(±1H)"
89684627|NCT00354627|Experimental|TMC125|TMC125 200 mg b.i.d. till commercially available.
89684628|NCT00770861|Active Comparator|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets, oral administration
89684629|NCT00770861|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
89684630|NCT03808805|Experimental|studied group|Aprepitant 80 mg daily - 14 days Plus placebo of Hydroxyzine - 14 days
89684631|NCT03808805|Active Comparator|comparative group|Hydroxyzine 25 mg/d - 14 days Plus placebo of Aprepitant - 14 days
89684632|NCT05717829|Experimental|modified hip capsular incision|make re -suturing of the capsule easier with multiple stitches.
89684633|NCT03803267|Active Comparator|Erector spinae plane block|Patients will receive bilateral ultrasound-guided erector spinae plane block as an adjuvant analgesic technique
89684634|NCT03803267|Active Comparator|Quadratus lumborum block|Patients will receive bilateral ultrasound-guided quadratus lumborum block as an adjuvant analgesic technique
89684635|NCT00787241||Mild preeclampsia|Preeclampsia without eclampsia or HELLP syndrome
89684636|NCT00787241||Severe preeclampsia|Severe preeclampsia with eclampsia and/or HELLP syndrome
89684637|NCT00787241||Mild preeclampsia superimposed on chronic hypertension|Mild preeclampsia in association with chronic hypertension
89684638|NCT02041221|Experimental|SPARC1316 Dose 1|Subjects will be administered with SPARC1316 dose 1
89684639|NCT02041221|Placebo Comparator|Placebo|The subjects will receive placebo.
89684640|NCT02041221|Experimental|SPARC1316 Dose 2|Subjects will be administered with SPARC1316 dose 2
89684641|NCT02041221|Experimental|SPARC1316 Dose 3|Subjects will be administered with SPARC1316 dose 3
89684642|NCT02041221|Experimental|SPARC1316 Dose 4|Subjects will be administered with SPARC1316 dose 4
89684643|NCT02041221|Experimental|SPARC1316 Dose 5|Subjects will be administered with SPARC1316 dose 5
89684644|NCT02041377|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes used the Karajishi TS Investigational Blood Glucose Monitoring System with no training. The criteria for the intended use population:~At least 60% of subjects will be younger than age 65~At least 10% of subjects will have type 1 diabetes"
89684645|NCT00787943|Experimental|Left side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to left side of the face.
89684646|NCT00787943|Experimental|Right side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to right side of the face.
89684647|NCT00354705||Colon Cancer Patients|Patients with colon cancer recently removed by surgery.
89684648|NCT03803033|Experimental|Intervention|The objective of the group was to introduce an experimental clinical pharmacy-based home medication review service in the outpatient clinic setting of the Jordan University Hospital in Amman, Jordan. The intervention under evaluation in the study is the pharmacy-based home medication review service.
89052843|NCT04576611|Experimental|self-managed|A 4-week intervention (8 sessions) will be carried out in a group of patients with non-specific chronic low back pain using self-managed modality through BackFit App.
89052844|NCT04584515|Experimental|IMP4297 40 mg|Sequential treatments of IMP4297 alone, followed by Itraconazole + IMP4297, with a washout period in between.
89052845|NCT04584515|Experimental|IMP4297 100 mg|Sequential treatments of IMP4297 alone, followed by Rifampin + IMP4297, with a washout period in between.
89052846|NCT04592679|Experimental|FES-C|
89052847|NCT04592679|Active Comparator|Standard|
89052848|NCT04592757|Experimental|Subacute stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
89052849|NCT04592757|Experimental|Chronic stroke patients|Training with new virtual mirror therapy application. During 12 sessions of approximately 30 minutes.
89684649|NCT03803033|No Intervention|Control|The objective of the control group was to identify changes in treatment and associated costs that take place in patients as part of the usual practice, as compared to the intervention arm, regardless of the clinical pharmacist service intervention.
89684650|NCT05717751||experimental group|locally advanced cervical cancer treated with surgical staging
89684651|NCT00771173|Active Comparator|Study Medication Group|Participants that are randomized to the phenazopyridine HCl group will receive the study medication (200 mg of phenzopyridine HCl orally) after leaving the operating room. We anticipate the first dose to be given after the patient has left the recovery area. We will continue use of study medication until it has been given up to 24 hours after the first VAS collection or catheter removal, whichever occurs first
89684652|NCT00771173|Placebo Comparator|Placebo tablet Group|For participants randomized to the placebo group will follow the same dosing schedule for the study medication, although they will receive an inert placebo tablet.
89684653|NCT02377947||Patients with cirrhosis (grade 3 & 4 per west haven cr.)|Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema
89684654|NCT05717595|Other|high fructose|high fructose (>100 gram fructose / day) for 4 weeks
89684655|NCT05717595|Other|low fructose|low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks
89684656|NCT02044419|Experimental|lomitapide sprinkled in applesauce|Contents of single 20 mg capsule of lomitapide sprinkled in applesauce
89684657|NCT02044419|Experimental|lomitapide sprinkled in mashed banana|Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana
89684658|NCT02044419|Experimental|lomitapide (intact)|Intact capsule of 20 mg lomitapide
89684659|NCT02045277|Experimental|IDP-118 Lotion|halobetasol propionate [HP], tazarotene [Taz]
89684660|NCT02045277|Active Comparator|IDP-118 Monad HP Lotion|HP
89684661|NCT02045277|Active Comparator|IDP-118 Monad Taz Lotion|Taz
89684662|NCT02045277|Active Comparator|IDP-118 Vehicle Lotion|Vehicle
89684663|NCT02045511|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
89684664|NCT02045511|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
89684665|NCT02378025|Experimental|Yoga Group|Postures, meditation, breathing exercises
89052850|NCT04584476|Experimental|SCR group|underwent superior capsular reconstruction
89052851|NCT04584476|Other|Partial group|underwent partial rotator cuff repair
89052852|NCT00582699||1|Patients with pancreatic cancer who meet DSMIV criteria for a current diagnosis of a Major Depressive Episode (N=25).
89052853|NCT00582699||2|Patients with pancreatic cancer who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25)
89052854|NCT00582699||3|Healthy controls who meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
89052855|NCT00582699||4|Healthy controls who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
89052856|NCT04584437|Other|Vitality Therapy|"i. 500 to 1000 cubic centimeters of micro-clustered, hydrogen rich alkaline Vital Water.~ii. Irradiation in infrared sauna for 60 minutes at high fever temperature. iii. Supplementation - Multivitamins and Minerals."
89052857|NCT00567021||1|patients with GERD or NSAID-related ulcers
89052858|NCT04584593|Other|SARV-Cov|Men will give semen, saliva, urine and blood specimens
89052859|NCT04584710|Experimental|10 mg daily RTB101|"RTB101~TORC1 inhibitor"
89052860|NCT04584710|Placebo Comparator|Placebo|Placebo
89052861|NCT00582777|Active Comparator|USUAL|USUAL treatment - The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
89684666|NCT02378025|Active Comparator|Pain Management Wellness Group|Behavioral medicine
89684667|NCT00771407|Active Comparator|Strattice fascial inlay|Strattice will be placed as a fascial inlay to support the ostomy site
89684668|NCT00771407|Other|Standard ostomy construction|Ostomy will be created in the standard fashion
89684669|NCT02379117||Crohn's Disease Patients|Patients with a diagnosis of Crohn's disease fitting the studies inclusion & exclusion criteria.
89684670|NCT02379117||Healthy Volunteers|For healthy volunteers the studies exclusion criteria apply.
89684671|NCT03808649|Active Comparator|Individualized group|Participants are given different volume of a preparation of mannitol based on BMI as oral contrast agent over an hour prior to the examination.
89684672|NCT03808649|Experimental|conventional group|Participants are given 1500ml of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
89684673|NCT03808571||Study group|Pregnancies complicated with intrauterine growth restricted fetuses
89684674|NCT03808571||Control group|Healthy pregnancies
89052862|NCT00582777|Experimental|HS Dosing|"HS DOSING - In this period, the patient's antihypertensive regimen at the baseline visit will be standardized for the once/day medications to be given at bedtime.~For those on monotherapy with a once/day antihypertensive regimen, the time of administration will be changed to bed time.~For those on multi-drug therapy, the time of administration of all once a day antihypertensive drugs will be changed to bed time."
89052863|NCT00582777|Experimental|ADD-ON DOSING|ADD-ON DOSING - This regimen will start with the USUAL regimen to which an additional agent will be added at bed time. An additional dose of ramipril, diltiazem, or hydralazine are three possible options for the add on medication. The intent of the ADD ON therapy is to lower nocturnal BP with minimal impact on daytime BP. Thus, agents with < 24 hr duration of action are preferred. The specific choice and dose of add-on therapy (of the three agents) will be up to the site investigator considering the clinical situation of each participant based on the guidelines below.
89052864|NCT04584398|Experimental|Intervention|The intervention group (A) will perform respiratory muscle training and steam inhalation with WellO2 device for 30 days.
89684675|NCT00788255||All participants|"For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows:~Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL~After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation."
89684676|NCT02379195|Experimental|A|"All patients receive the same treatment.~All patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy are administered on day 0 to day 5.~Interleukin-2 are administered in an i.v. continuous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days~Subcutaneous injections of peginterferon alpha 2b are administered three time (day -2, day 7 and day 14)"
89684677|NCT02379273|Experimental|Hybrid L24 pivotal study subjects|Subjects implanted with the Nucleus Hybrid L24 Implant as part of the pivotal IDE study and who still have the device implanted will continue to be followed for 5 years post activation
89684678|NCT05715567||Patients with COVID-19|
89684679|NCT05715567||Patients without COVID-19|
89684680|NCT00771875|Active Comparator|Rabbit Antithymocyte Globulin (RATG)|Rabbit Antithymocyte Globulin (RATG) All patients will receive RATG (Thymoglobulin) dosed based on CD3 count. Patients will be redosed when the cluster of differentiation 3 (CD3) count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily. 1.5mg/kg/day over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
89684681|NCT00771875|Experimental|RATG/Rituximab|Rabbit Antithymocyte Globulin (RATG) + Rituximab Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
89684682|NCT00771875|Experimental|RATG/Bortezomib|Rabbit Antithymocyte Globulin (RATG) + Bortezomib -Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3). Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Bortezomib will be given at a dose of 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Methylprednisolone will be administered prior to each bortezomib dose. On days 2 and 5, administer methylprednisolone 100 mg intravenous push (IVP). On days 9 and 12, administer methylprednisolone 50 mg intravenous push (IVP). If thymoglobulin is administered the same day as bortezomib, the order of administration is- methylprednisolone, then bortezomib, then thymoglobulin.
89684683|NCT02046525|Experimental|Auto fecal microbitoa therapy|autologous fecal microbiota therapy
89684684|NCT02046525|Placebo Comparator|Saline enema|Saline enema
89684685|NCT02047305|Experimental|Radiofrequency ablation|To study the safety and effectiveness of radiofrequency ablation (RFA) using the HALO ablation system in completely eradicating the diseased epithelium in patients with ESCN
89684686|NCT00760019|Active Comparator|Salsalate first, then Placebo|In this crossover study, this group was randomly allocated therapy with salsalate first, a 4 week washout, then 4 weeks of placebo therapy in a double-blinded fashion.
89684687|NCT00760019|Placebo Comparator|Placebo first, then Salsalate|In this crossover study, this group was randomly allocated therapy with placebo first, a 4 week washout, then 4 weeks of salsalate therapy in a double-blinded fashion.
89684688|NCT02383719|Experimental|Oro-nasal mask|All patients are included in this arm. Patients in this group receive the experimental oro-nasal mask during non-invasive ventilation
89684689|NCT00789113|Experimental|Extended Release Lamotrigine|Extended Release Lamotrigine
89052865|NCT04584398|No Intervention|Control|The control group (B) will continue on their conventional treatment without respiratory muscle training or steam inhalation with WellO2. After 30 days, the group B performs the same 30-day intervention with the WellO2 device (test) as the group A.
89052866|NCT04584671||Mild COVID-19 Infection Group|100 participants age ≥ 18 and <80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of mild COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
89052867|NCT04584671||Severe COVID-19 Infection Group|100 participants age ≥ 18 and <80 years who experienced a documented case (documented by positive COVID-19 test and/or clinical history) of severe COVID-19 infection, including at least 50 participants who were hospitalized with COVID-19 infection, all of whom are within 3 months post recovery and non-infectious.
89052868|NCT00582855|Experimental|1|
89052869|NCT00582855|Placebo Comparator|2|
89052870|NCT04584359|Experimental|HVLA techiniques (G1)|Performed with thrust (also known as HVLA) in the sacroiliac joint and T10-L2 level
89052871|NCT04584359|Experimental|Global osteopathic protocol (G2)|Several elements were emphasized - myofascial, bone, and visceral.
89052872|NCT04584359|Experimental|Pelvic floor muscle training (G3)|Muscle Training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes.
89052873|NCT04584359|No Intervention|Control group (G4)|No intervention and was simply evaluated and re-evaluated.
89052874|NCT03454074|Experimental|B-Fit intervention|Combines group education about brain health with individualized goal-setting and group problem-solving to help participants effectively integrate healthy behavioral changes into their everyday lives.
89052875|NCT03454074|Active Comparator|Education Only|Provide group education about healthy behavior changes without problem-solving component.
89052876|NCT03454074|No Intervention|Wait-list|No intervention administered. Will be offered intervention following a delay.
89052877|NCT04584242|Experimental|Pioglitazone|
89052878|NCT04584242|Experimental|Evogliptin|
89052879|NCT04592835|Experimental|Cohort 1 (288mg)|72 mg/0.3 mL x 4 injection sites
89052880|NCT04592835|Experimental|Cohort 2 (576 mg)|144 mg/0.6 mL x 4 injection sites
89052881|NCT04592835|Experimental|Cohort 3 (960 mg)|216 mg/1.0 mL x 4 injection sites
89052882|NCT04583696|Experimental|Walnut Consumption of Healthy Volunteers|
89052883|NCT04592211|Experimental|olaparib+pembrolizumab+paclitaxel|
89052884|NCT04583813|Active Comparator|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
89052885|NCT04583813|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 24 months
89052886|NCT04576143|Active Comparator|epirubicin/CTX × 4 - docetaxel × 4, every 3 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 21 days); Cycle 5-8: Docetaxel i.v. 100mg/m2 (One cycle = 21 days) .
89052887|NCT04576143|Experimental|epirubicin/CTX × 4 - paclitaxel × 4, every 2 weeks a cycle|Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 14 days); Cycle 5-8:Paclitaxel i.v. 175mg/m2 (One cycle = 14 days) .
89052888|NCT04583930||Patients with Haemophilia A|"Patients suffering from moderate to severe haemophilia A~Age ≥ 18-years~Treatment with FVIII prophylaxis~Submitted written informed consent"
89052889|NCT04576221|Experimental|stacked breathing group|experimental group received staked breathing exercise for 7 days , 3 sessions per day, 7-8 times per session
89052890|NCT04576221|Experimental|CPAP group|experimental group received NIV with CPAP mask
89052891|NCT04591899|Experimental|CAD/CAM SS|
89052892|NCT04591899|Active Comparator|Conventionally manufactured SS|
89052893|NCT04583657|Placebo Comparator|Control|"Consumption of two classical eggs per day during three months. The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%."
89052894|NCT04583657|Experimental|Test|Consumption of two test eggs per day during three months. These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%, total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)
89052895|NCT04583267|Experimental|PrEP|
89052896|NCT04583111|Experimental|Domperidone group|Patients in Domperidone group took 10mg of domperidone 30min before PEG.
89052897|NCT04583111|Experimental|Sulpiride group|Patients in Sulpiride group took 100mg of sulpiride 30min before PEG.
89052898|NCT04583111|No Intervention|Control group|Patients in Control group followed the regular routine of 3L split-dose of PEG.
89052899|NCT04583345||Hypertensive|Diagnosis of hypertension
89052900|NCT04583345||Healthy|Healthy blood pressure level and absence of any chronic disease
89052901|NCT00583167||A1|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count >200 cells/mm3. Group A1 will undergo continuous CSF ( cerebrospinal fluid) sampling via intrathecal catheter.
89052902|NCT00583167||A2|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count <200 cells/mm3. Group A2 will undergo continuous CSF sampling via intrathecal catheter.
89052903|NCT00583167||B|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. Group B will not undergo continuous CSF sampling, but will undergo sparse CSF sampling by lumbar punctures.
89052904|NCT04583228|Experimental|Sequence 1|Random allocation to HLX71 1 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
89052905|NCT04583228|Experimental|Sequence 2|Random allocation to HLX71 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
89052906|NCT04583228|Experimental|Sequence 3|Random allocation to HLX71 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
89052907|NCT04583228|Experimental|Sequence 4|Random allocation to HLX71 15 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 8 receive intravenous injections of the HLX71.
89052908|NCT00583245|Experimental|1|Gait training
89684690|NCT03808259|Experimental|Part 1: OTF Sublingual and IV|Participants will receive (S)-ketamine oral thin film (OTF) at a dose of 7 milligram (mg) [cohort 1], 14 mg [cohort 2], and 28 mg [cohort 3] via sublingual route or 14 mg (S)-ketamine intravenous (IV) infusion for 40 minutes or matching placebo in 1 of 3 serial cohorts. Dose escalation decisions to further cohorts of Part 1 will be made based on safety and tolerability profile of the preceding lower dose level.
89684691|NCT03808259|Experimental|Part 2: IV Different Infusion Duration|Participants will receive single dose (S)-ketamine less than or equal to (<=)14 mg IV at a different infusion duration or matching placebo at a different infusion duration. The infusion duration and dose will be chosen after completion of Part 1.
89684692|NCT05742659|Experimental|experimental group|
89684693|NCT05742659|No Intervention|control group|
89684694|NCT03808181|Other|Active treatment with ChloraSolv|Single arm
89684695|NCT02386605|Experimental|Treatment|Motivational Interviewing Treatment group
89684696|NCT02386605|Active Comparator|Control|Relaxation Skills Training group
89684697|NCT03807947|Experimental|Radial access|
89684698|NCT03807947|Active Comparator|Transfemoral Access|
89684699|NCT02387853|Experimental|LEO 90100|
89684700|NCT05742581||The rotator cuff tear group|
89684701|NCT05742581||Control group|
89052909|NCT04583189|Other|Test rapid antigenic and Test RT-PCR|
89057658|NCT02216084|Experimental|Recombinant ADAMTS13|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 3 subjects; Cohort 2: 3 subjects; Cohort 3: 8 subjects]. Subjects will be enrolled and dosed sequentially. Subjects will be recruited to the next dose level only after short-term safety has been demonstrated and reviewed by an independent Data Monitoring Committee (DMC) at the preceding dose level. The first 2 subjects in any cohort will be ≥ 18 years of age. The effects of the investigational product on vital signs, hematology, and clinical chemistry parameters (up to 96 ± 2 hrs blood sampling timepoint) will determine short-term safety. The DMC will recommend whether to proceed with the study or in case of a safety concern recommend remedial actions and/or to discontinue the study. Subject participation will continue until 28 ± 3 days after infusion of the investigational product. Subject participation in one Dose Cohort (1-3) is expected to be approximately 6-8 weeks.
89684702|NCT02145299|Experimental|TruePath CTO Device|"The TruePath™ CTO Device (Boston Scientific Corporation, Natick, MA) is a new solution for intraluminal treatment of chronic total occlusions (CTO). It is the longest available crossing device (165 cm), and has a diamond-coated distal tip that can rotate at 13,000 rpm. Its profile is similar to a 0.018 guidewire, and includes a shapeable distal tip allowing 1:1 torque response. In addition, it provides audio and visual navigation during CTO crossing."
89684703|NCT02145299|Active Comparator|CROSSER CTO Device|"The CrosserTM CTO Recanalization Catheter (Crosser system) (Bard Peripheral Vascular Inc. Tempe, AZ, USA), which serves as a control in this investigation, gained U.S. FDA approval for peripheral indications in 2011. The device is similar in both design and indications to the TruePath device, with the exception that the Crosser system uses vibrational angioplasty to achieve CTO crossing."
88997813|NCT05646173|Active Comparator|grup 1|"Grup 1: Participants will be treated with ultrasound (5 min), TENS with a hot pack for (20 minutes). Home exercises will be given. The home exercises will be given consist of isometric waist, hip flexor stretching, hamstring stretching, self-mobilization exercise, waist and abdominal concentric strength exercises.~1.5w/cm² continuous ultrasound wiil applied with Chattanooga Intelect Mobile Ultrasound device.TENS: It will be applied to the lumbar region with a COMPEX brand stim device, together with a hot pack.The current intensity was opened by questioning according to the sensory threshold of the people.~Home based exercise program:In the first week of the exercise program; isometric exercises, stretching and mobilization exercises were given. Second week; additional bridging exercise; In the third week, additional isotonic, active abdominal and back strengthening exercises were included in all exercises.~The application will be done in 15 sessions, 5 days a week"
88997814|NCT05646173|Experimental|grup 2|"Grup 2: Participants will be given auricular vagus stimulation (25 min). Home exercises will be given. The home exercises will be given consist of isometric waist, hip flexor stretching, hamstring stretching, self-mobilization exercise, waist and abdominal concentric strength exercises.~Vagus stimulation: A specially manufactured earphone that can be selected according to the size of the ear placed in the outer ear will be applied from the vagustim device (frequency 10 Hz, pulse duration less than 500 microseconds, in modulated TENS mode and biphasic asymmetric waveform) connected to it.~Home based exercise program: In the first week of the exercise program; isometric exercises, stretching and mobilization exercises were given. Second week; additional bridging exercise; In the third week, additional isotonic, active abdominal and back strengthening exercises were included in all exercises.~The application will be done in 15 sessions, 5 days a week."
88997815|NCT05644340|Active Comparator|Automated Gas Flow Group using speed 8 to reach targeted end-tidal sevoflurane concentration|Pediatric patients who are operated under general anesthesia using automated gas flow which is set to speed 8 to achieve targeted end-expiratory sevoflurane concentration (MAC 1.2) will be included in the study. Automated gas flow provides a gas mixture in different proportions which is automatically generated and consists of sevoflurane, oxygen and air. Inspired and end-tidal concentrations of sevoflurane, oxygen and air will be available on the anesthesia ventilator screen which will be recorded accordingly in15-minute intervals.
88997816|NCT05644340|Active Comparator|Automated Gas Flow Group using speed 4 to reach targeted sevoflurane concentration|Pediatric patients who are operated under general anesthesia using automated gas flow which is set to speed 4 to achieve targeted end-expiratory sevoflurane concentration (MAC 1.2) will be included in the study. Automated gas flow provides a gas mixture in different proportions which is automatically generated and consists of sevoflurane, oxygen and air. Inspired and end-tidal concentrations of sevoflurane, oxygen and air will be available on the anesthesia ventilator screen which will be recorded accordingly in15-minute intervals.
88997817|NCT05631977||POCUS acquisition|"Prospective noninterventional single arm study collection of cardiac POCUS examination according to prespecified acquisition protocol.~Alongside POCUS images the study will also collect demographic and clinical information from the study participants and some information from the healthcare personal performing the POCUS exam (experience in US image acquisition, physician specialty or sonographer).~Patient management will not be impacted, and usual care will follow the regular practices at the study site."
88997818|NCT05627947|Active Comparator|mitomycine-C Group|This is the First Group and consists of !9 Patients and received 0.02% topical mitomycine C , 4 times per day for five days after the surgery.
88997819|NCT05627947|Active Comparator|Cyclosporine Group|This is the Second Group and consists of !9 Patients and received topical 0.05% Cyclosporine, 4 times per day for three months after the surgery.
88997820|NCT05627947|Active Comparator|artificial eye drops Group|This is the Third Group and consists of !9 Patients and received artificial eye drops, 4 times per day for three months after the surgery.
88997821|NCT05617118||Baclofen|"A cohort of patients who have not previously received baclofen will be offered a course of the drug therapy at a dosage of 10 mg according to the scheme:~1-3 days - 1 tablet per day; 4-6 days - 2 tablets per day; 7-9 days - 3 tablets per day; 10 days and then 4 tablets per day (morning and evening)."
88997822|NCT05617118||BTA|"A cohort of patients who previously received baclofen and canceled the course due to the development of side effects and/or individual intolerance, or who have contraindications to the use of this drug, will receive several injections with a total volume of 100 units. botulinum toxin type A in dilution up to 20 ml, distributed at the trigger points of the pelvic floor muscles."
88997823|NCT05611281|Experimental|GS3-007 oral liquid|"78 subjects: Part 1 SAD 36 subjects: A total of 6 dose groups of 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg and 6.4 mg/kg are planned. Once a day, a total of one dose.~Part 2 MAD 30 subjects: Three dose groups of 0.8 mg/kg, 1.6 mg/kg and 3.2 mg/kg were planned，The drug was administered once a day for 7 days Part 3 Food effects 12 subjects: Planned in 1.6mg/kg dose group。Once a day, a total of one dose."
89057659|NCT01684332|Experimental|High Sugar (HS)|Study of the postprandial effects after consuming 60g of strawberry jam with high sugar content
89057660|NCT01684332|Experimental|Low Sugar (LS)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content
88997824|NCT05611281|Placebo Comparator|Placebo GS3-007 oral liquid|"Part 1 SAD: A total of 6 dose groups of 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg and 6.4 mg/kg are planned. Once a day, a total of one dose.~Part 2 MAD: Three dose groups of 0.8 mg/kg, 1.6 mg/kg and 3.2 mg/kg were planned，The drug was administered once a day for 7 days"
88997825|NCT05609422|Active Comparator|control group|Received the designed physical therapy program.
88997826|NCT05609422|Experimental|study group|Received a designed physical therapy program in addition to scooter bord activities.
88997827|NCT05597241|Experimental|Cohort 1, Apimostinel|Apimostinel, 25 mg IV single dose
88997828|NCT05597241|Placebo Comparator|Cohort 1, Placebo|Placebo, IV single Dose
88997829|NCT05597241|Experimental|Cohort 2, Apimostinel, 1 mg IV 8 consecutive daily doses|Apimostinel, 1 mg IV 8 consecutive daily doses
88997830|NCT05597241|Placebo Comparator|Cohort 2, Placebo IV 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
88997831|NCT05597241|Experimental|Cohort 3, Apimostinel, 5 mg IV 8 consecutive daily doses|Apimostinel, 5 mg IV 8 consecutive daily doses
88997832|NCT05597241|Placebo Comparator|Cohort 3, Placebo 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
88997833|NCT05597241|Experimental|Cohort 4, Apimostinel, 10 mg IV 8 consecutive daily doses|Apimostinel, 10 mg IV 8 consecutive daily doses
88997834|NCT05597241|Placebo Comparator|Cohort 4, Placebo 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
88997835|NCT05597241|Experimental|Cohort 5, Apimostinel, 25 mg IV, 8 consecutive daily doses|Apimostinel, 25 mg IV 8 consecutive daily doses
88997836|NCT05597241|Placebo Comparator|Cohort 5, Placebo IV 8 consecutive daily doses|Placebo IV 8 consecutive daily doses
88997837|NCT05596513|Active Comparator|control group|received intensive motor-learning approaches that focuses on training of the affected hand (motor-learning approaches such as - constraint-induced movement therapy (CIMT) and hand-arm bimanual intensive training (HABIT) provide an alternative).
88997838|NCT05596513|Experimental|study group|received the intensive motor-learning approaches of the control group but from a vertical surface
88997839|NCT05588687|No Intervention|Control group|Children in the control group will be received standard care. Control group children will not receive any distraction techniques.
88997840|NCT05588687|Experimental|Virtual reality group|The children in the VR groups will watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Rollercoaster Group, will watch Ice Age.
88997841|NCT05588687|Experimental|Tablet group|The children in the tablet groups will watch the video during the blood draw with tablet. They will watch Ice Age.
88997842|NCT05570734|Experimental|LUNA Group|The LUNA Group is a culturally appropriate, E-Health enhanced, patient-centered, team-care model that includes: 1) care coordination by a Care Coordinator (CC) trained in electronic health records (EHR) clinical decision support and health promotion methods; 2) visits with a specially trained Behavioral Health Provider (BHP) with knowledge of diabetes and psychosocial aspects of diabetes; 3) care integration with primary care provider (PCP) implemented using the clinical decision support dashboard and/or synchronous communication during visits; and 4) a video adapted, evidence-based diabetes self-management education and support curriculum delivered through a learning management system.
88997843|NCT05570734|No Intervention|Care Coordination|The Care Coordination group applies the current methods of the federally qualified health center (FHQC) Patient Centered Medical Home initiative. Participants assigned to the care coordination group will continue with their regular medical visits with their primary care provider. In addition, they will receive care coordination and brief targeted health education provided by a specially trained medical assistant/care coordinator. This will involve 1 or more brief sessions with a care coordinator to provide health education, assist with appointments and referrals, and review medications. The care coordinator will work closely with their primary care provider. The care coordinator will also assist with referrals to behavioral health that may be initiated by the primary care provider.
88997844|NCT05546658|Experimental|Immediate Psilocybin|This arm will receive two sessions of psilocybin first (20mg in first session and then, if well tolerated, 30mg).
89057661|NCT01684332|Experimental|Low Sugar + Antioxidant (LSA)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content and an antioxidant extract from strawberry pulp
89057662|NCT01684371||Blue Dotted Elmore Oil|Patients applied the above oil 3 times daily for four weeks and on the fifth week stopped the application completely for the flush out period before switching to Orange Dotted Elmore Oil
88997845|NCT05546658|Active Comparator|Delayed Psilocybin|Waitlist control. This arm will receive psilocybin after the waiting period is over (20mg in first session and then, if well tolerated, 30mg).
88997846|NCT05542277|Experimental|ClearPlasma|Investigational Group (A): one-time infusion (up to 12 hours after surgery) of unlimited plasminogen depleted plasma PDP units generated by ClearPlasma™ device.
88997847|NCT05542277|Placebo Comparator|Control|Control Group (B): one-time infusion (up to 12 hours) of unlimited regular plasma, Fresh frozen plasma (FFP) with mock ClearPlasma™ device.
88997848|NCT05541705|Experimental|TOW|Treadmill Oscillation Walking training
88997849|NCT05523479|Active Comparator|Online education about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive traditional online education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
89057663|NCT01684371||Orange Dotted Elmore Oil|Patients give this oil applied it three times daily on the affected knees for four weeks and on the fifth week, stopped the application totally for the flush out period before switching to the Blue Dotted Elmore Oil.
89057664|NCT04531397|Placebo Comparator|ACEI treatment|Drug: ACEI will be given once daily
89052910|NCT01146652|Experimental|Sarilumab + Disease Modifying Anti-Rheumatic Drugs (DMARD)|Participants who completed any of initial studies:Part A or B of EFC11072, ACT11575, EFC10832 or SFY13370 were enrolled in LTS11210 and received sarilumab 150 milligrams (mg) subcutaneously (SC) once weekly (qw). Dose could be reduced to 150 mg every 2 weeks (q2w) due to neutropenia, thrombocytopenia or increase in liver enzymes (alanine aminotransferase [ALT]). After dose regimens selection for Phase 3 studies (150 mg q2w and 200 mg q2w), participants already receiving 150 mg qw were switched to sarilumab 200 mg q2w. Treatment duration per participant was at least 264 weeks from first study drug administration in LTS11210. Participants continued to be treated beyond 264 weeks until sarilumab was commercially available in their respective countries or until 2020, at the latest (maximum duration: 523 weeks). Participants who were already taking concomitant non-biologic DMARDs in initial study continued stable dose of one or combination of conventional synthetic DMARDs they were taking.
89052911|NCT01146652|Experimental|Sarilumab monotherapy|Participants who completed study EFC13752 were enrolled in LTS11210 and received sarilumab 200 mg q2w. Dose could be reduced to 150 mg q2w due to neutropenia, thrombocytopenia or increase in liver enzymes (ALT). Treatment duration per participant was at least 264 weeks from first study drug administration in LTS11210. Participants continued to be treated beyond 264 weeks until sarilumab was commercially available in their respective countries or until 2020, at the latest (maximum duration: 523 weeks).
89052912|NCT04582877|Other|FFR Measurement in Intermediate-Grade Coronary Stenosis|Participants with intermediate-grade coronary stenosis undergo measurement of fractional flow reserve using the test article (Zurich Pressure Guidewire System) and predicate article (Abbott PressureWire System).
89052913|NCT04576026|Experimental|Ketone esters|Ketone esters will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
89052914|NCT04576026|Active Comparator|Placebo|Iso-caloric carbohydrate drink will be given to mentally fatigued individuals, prior to a 45 minute simulated soccer game in which cognitive function will be assessed.
89052915|NCT04582955|Experimental|Arm A|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
89052916|NCT04591938|Other|Single arm|Fantom Encore Bioresorbable scaffold implantation
89052917|NCT01146613|Active Comparator|Varenicline|Varenicline Tartrate
89052918|NCT01146613|Placebo Comparator|Sugar Pill|
89052919|NCT04591704||Diabetic groups|COVID-19 patients with diabetes mellitus
89052920|NCT04591704||Control groups|COVID-19 patients without diabetes mellitus
89052921|NCT04582838||Spontaneous breathing ICU non-COVID|"Spontaneously breathing non-COVID-19 critically ill patients with sinus rhythm.~Inclusion and exclusion criterion are listed elsewhere."
89052922|NCT04582838||Spontaneous breathing ICU COVID|"Spontaneously breathing COVID-19 critically ill patients with sinus rhythm.~Inclusion and exclusion criterion are listed elsewhere."
89052923|NCT01145755|Experimental|AZD2066|
89052924|NCT01145755|Placebo Comparator|Placebo|
89052925|NCT01145755|Active Comparator|Duloxetine|Duloxetine
89052926|NCT02883946||hairy-cell leukemia|Patients with hairy-cell leukemia.
89052927|NCT02884141||Patients|"Patients with documented fibromuscular dysplasia (see inclusion criteria).~Non-usual care added acts:~blood sampling~urine sampling~renal echography"
89052928|NCT00625105|Active Comparator|Biofeedback|HRV coherence biofeedback procedure
89052929|NCT00625105|Sham Comparator|Sham intervention|Passive monitor viewing
89052930|NCT00568217|Active Comparator|1 drug|diclofenac 15 mg/kg suppository once
89052931|NCT00568217|Placebo Comparator|2 drug|Placebo suppository once
89052932|NCT00568217|Active Comparator|3 drug|acetaminophen mixture 15 mg/kg up to four times a day
89052933|NCT00568217|Active Comparator|4 drug|ibuprofen mixture 10 mg/kg up to four times a day
89052934|NCT00568217|Placebo Comparator|5 drug|oral placebo mixture up to four times a day
89052935|NCT00568256|Experimental|Experimental|Mind/Body Course
89052936|NCT00568256|Other|Other|Mind/Body Course
89052937|NCT00583323|Experimental|1|Lomotil given
89052938|NCT00583323|Placebo Comparator|2|Normal Saline given
89052939|NCT04582604|Experimental|Ruxolitinib combined with Decitabine|Ruxolitinib and Decitabine conditioning regimen All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Decitabine. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), decitabine (20 mg/m2/day, days -15 to -10), cytarabine (4 g/m2/day, days -10 to -9 (for unrelated donors or haploidentical donors; and 4 g/m2/day, days -9 for sibling donors)), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4);carmustine(BCNU)(250mg/m2/day, day -3),
89052940|NCT04582760|Experimental|early mobilization Arm|In addition to conventional bedside physical therapy, the mobilization program will be administered for 30 mins per session, two sessions per day, 7 days per week, until the patients are discharged from the ICU.
89052941|NCT04582760|No Intervention|non-early mobilization Arm|Conventional bedside physical therapy will be administered for 30 mins per session, one session per day, 5 days per week (only on working days), until the patients are discharged from the ICU.
89052942|NCT04582721|Active Comparator|CON-SCS with subcutaneous stimulation|7 days Conventional Spinal Cord Stimulation with subcutaneous stimulation
89052943|NCT04582721|Active Comparator|HF-SCS|7 days High Frequency Spinal Cord Stimulation
89052944|NCT04582721|Active Comparator|Combination Therapy|7 days a combination of CON-SCS with subcutaneous stimulation and HF-SCS
89052945|NCT00590928|Active Comparator|1|patients with indication for stress ulcer prophylaxis and gastric pH < 4
89052946|NCT00590928|Active Comparator|2|patients with indication for stress ulcer prophylaxis and gastric pH < 4
89052947|NCT00583440|Experimental|1|
89052948|NCT00583440|Active Comparator|2|
89052949|NCT04582526|Experimental|Intervention arm|BMS program
89052950|NCT01145560|Experimental|1|AZD9773 250/50 units/kg
89052951|NCT01145560|Experimental|2|AZD9773 500/100 units/kg
89052952|NCT01145560|Placebo Comparator|3|
89052953|NCT04582175||group A|patients who received complete revascularization by angioplasty during the PPCI
89052954|NCT04582175||Group B|patients who underwent complete revascularization by angioplasty in a staged procedure
89052955|NCT00591045|Experimental|1|The patients will undergo neoadjuvant chemotherapy with mFOLFOX and then an operation and then individualized adjuvant chemotherapy.
89052956|NCT00591045|No Intervention|2|No neoadjuvant chemotherapy and surgery and then adjuvant chemotherapy.
89052957|NCT01145482|Experimental|insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
89052958|NCT01145482|Placebo Comparator|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
89052959|NCT00583479|Other|A|subjects who get one medication injection into the celiac ganglion during the EUS
89052960|NCT00583479|Other|B|subjects who get divided dose of the medication injected into two locations within the celiac ganglion during the EUS
89052961|NCT04313413|Experimental|Yoga@Work|Yoga sessions specifically designed for office workers were provided in work settings. participants were given handouts and encouraged to practice in their own time and space during work days.
89052962|NCT00568295|Experimental|Acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP
89052963|NCT00568295|Active Comparator|Refecoxib 12.5 mg|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A
89052964|NCT00568295|Active Comparator|Rofecoxib 12.5 x 2|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A
89052965|NCT00591084|Experimental|ginsenoside-Rd 10mg|both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
89052966|NCT00591084|Placebo Comparator|placebo|2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
89052967|NCT00591084|Experimental|ginsenoside-Rd 20mg|2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed
89052968|NCT01145053||Treatment|
89052969|NCT00591162|Active Comparator|1|Compare bone density of severly burned children to normal non-burned population
89052970|NCT00568373|Experimental|Treatement|All subjects that meet the requirement for gastric stimulator placement
89052971|NCT04582136|Experimental|Sirolimus plus SOC|Sirolimus plus standard therapy (SOC) for SLE; Generic name: sirolimus (0.5mg capsule); Dosage: 1.5mg/day; Administration route: Oral
89052972|NCT04582136|Placebo Comparator|Placebo plus SOC|Placebo plus standard therapy (SOC) for SLE; Drug: Placebo comparator plus SOC; Administration route: Oral
89052973|NCT04582331||COVID-19 positive|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 positive status is confirmed by diagnostic testing and clinical diagnosis.
89052974|NCT04582331||COVID-19 negative, symptomatic|Patients with suspected COVID-19 based on presence of at least one newly emerged relevant symptom that has emerged at most 10 days prior to enrollment. COVID-19 negative status is confirmed by diagnostic testing and clinical diagnosis.
89052975|NCT04582331||Normal Healthy Volunteers|Asymptomatic healthy participants recruited from hospital staff or co-living family members, or co-living family member of a COVID-19 positive study participant.
89052976|NCT04582253||Keratoconus|"Those with a clinical diagnosis of keratoconus such as:~a) the presence of a central protrusion of the cornea with Fleischer ring, Vogt striae, or both by slitlamp examination.(b) an irregular cornea determined by distorted keratometry mires and distortion of retinoscopic red reflex or both in addition to the following topographic findings as summarized by Pińero and colleagues: focal steepening located in a zone of protrusion surrounded by concentrically decreasing power zones, focal areas with dioptric (D) values >47.0D, inferior- superior(I-S) asymmetry measured to be > 1.4 D or angling of the hemimeridians in an asymmetric or broken bowtie pattern with skewing of the steepest radial axis (SRAX) 2."
89052977|NCT04582253||Subclinical keratoconus|Defined as subtle corneal tomographic changes as the aforementioned keratoconus abnormalities in the absence of slit- lamp or visual acuity changes typical of keratoconus (subclinical keratoconus).
89052978|NCT04582253||Normal|This group comprised refractive surgery candidates and subjects applying for a contact lens fitting with a refractive error of less than 8.0 D sphere with less than 3.0 D of astigmatism and without clinical, topographic or tomographic signs of keratoconus nor suspected keratoconus.
89052979|NCT00591201|Experimental|A|Infliximab
89052980|NCT00591201|Placebo Comparator|B|Placebo
89052981|NCT04582058|No Intervention|Control Group (CG)|Control Group (CG): Standard of care, normally follow up, without mobile health
89052982|NCT04582058|Experimental|Interventional Group (IG)|Interventional Group (IG): Mobile Health to patients with an orientation about daily activities and protocol of physical exercise
89216475|NCT03544489|Experimental|E-ICD Intervention|E-ICD Intervention over 3 months, consists of home walking to achieve the goal of 30 minutes on all or most of the days at moderate level intensity. E-ICD elements are: 1) exercise instructional DVD and manual, 2) exercise monitoring tools (Polar HR monitor, Digi-walker, Borg scale, and exercise logs), and 3) telephone coaching by clinic RNs. Each participant receives an exercise prescription based on the ICD information using HR cut-offs, a minimum of 4 walking sessions/week will be prescribed. Exercise maintenance: At the 3 month conclusion of the E-ICD intervention, each patient will receive an exercise prescription based on the level they were able to achieve, with guidelines about increasing exercise to reach the target of 30 minutes/walking on all or most days over the ensuing 3 months. Participants will record walking sessions each week in the exercise logs that will be collected again at 6 months.
89532889|NCT05835479|Active Comparator|Co-trimoxazole|"From Day 1 to Day 21, co-trimoxazole will be given with trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day.~For participants with a creatinine clearance between 15 mL/min and 30 mL/min, the dose of co-trimoxazole should be reduced to trimethoprim 7.5-10 mg/kg/day and sulfamethoxazole 37.5-50 mg/kg/day"
89532890|NCT05829564|Experimental|virtual reality+Exercise|"An exercise program consisting of stretching exercises, posture exercises and breathing exercises and lasting approximately 20-30 minutes will be applied to the individuals in all 3 groups.~The virtual reality group will performe virtual reality for an additional 20 minutes. (Oculus GO)"
89532891|NCT05829564|Experimental|cervical mobilization+Exercise|"An exercise program consisting of stretching exercises, posture exercises and breathing exercises and lasting approximately 20-30 minutes will be applied to the individuals in all 3 groups.~Mobilization techniques that will mobilize the cervical region will be applied to the cervical mobilization group for 20 minutes."
89532892|NCT05829564|Other|Control|Control group will only perform an exercise program.
89532893|NCT05828069|Experimental|Treatment (tovorafenib)|Patients receive tovorafenib PO QW on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO scans, and FDG-PET or CT throughout the trial, and collection of blood samples on study. Patients with suspicion of bone marrow and/or central nervous system involvement will also undergo bone marrow biopsy and aspiration and lumbar puncture on study and during follow up.
89532894|NCT05826431|Experimental|Participants using Cubii|Participants will use the Cubii exercise unit at their homes for two months as they choose. They will maintain a log regarding their use of the device. They will complete validated self-report questionnaires (demographics, MS disease-related variables (e.g., pain, fatigue, falls), activity, exercise, quality of life, and biopsychosocial symptom variables) before and after the use of the exercise unit.
89532895|NCT05824429|Experimental|Connective Tissue Manipulation Group|Urotheraphy Diaphragmatic Breathing Exercises Pelvic Floor Muscle Exercise Connective Tissue Manipülation
89532896|NCT05824429|Active Comparator|Control Group|Urotheraphy Diaphragmatic Breathing Exercises Pelvic Floor Muscle Exercise
89532897|NCT05821855|Experimental|XEN45|Participants will be implanted with the XEN45 glaucoma treatment system in the study eye on Day 1 and followed for 60 months.
89532898|NCT05821855|Active Comparator|Trabeculectomy|Participants will undergo trabeculectomy in the study eye on Day 1 and followed for 60 months.
89532899|NCT05820139|Other|control group (voids 2/3 of the volume backfilled)|control group
89532900|NCT05820139|Active Comparator|test group (voids ½ of the total volume backfilled)|test group)
89532901|NCT05819359|Experimental|BIA 28-6156 10 mg|Participants will be randomized to receive BIA 28-6156 10 mg during the Treatment Period.
89532902|NCT05819359|Experimental|BIA 28-6156 60 mg|Participants will be randomized to receive BIA 28-6156 60 mg during the Treatment Period.
89532903|NCT05819359|Placebo Comparator|Placebo|Placebo
89532904|NCT05815342|Experimental|Treatment|All subjects wearing the Omnipod 5 Automated Glucose Monitoring System
89532905|NCT05815186|Experimental|Advanced NSCLC Patients|Patients with KRASG12C mutant NSCLC will receive ladarixin and sotorasib in combination.
89532906|NCT05814627|Experimental|Upadacitinib+ Adalimumab matching Placebo|Participants will receive upadacitinib once a day along with matching placebo for adalimumab at eow (every other week) in Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1.
89532907|NCT05814627|Experimental|Adalimumab + Upadacitinib matching Placebo|Participants will receive adalimumab at eow (every other week) along with matching placebo for upadacitinib once a day in Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1.
89532908|NCT05814029|Experimental|The group which mobilization with movement technique applied by clinician|17 individuals in this group, after evaluations, mobilization with movement technique applied by clinician and after that same evaluations will be applied
89532909|NCT05814029|Experimental|The group which mobilization with movement technique applied by individual himself|17 individuals in this group, after evaluations, mobilization with movement technique applied by individual himself and after that same evaluations will be applied
89532910|NCT05814029|No Intervention|Control Group|16 individuals in this control group, Relevant Extremity will assume a lunge position on a firm mattress with the foot in a weight-bearing stance and the foot in a neutral position. The person will feel uncomfortable and/or the parts will suddenly lunge until the end of their range of motion. No mobilization technique will be applied
89532911|NCT05811013|Experimental|Transcranial static magnetic field stimulation (tSMS)|Transcranial static magnetic field stimulation (tSMS) will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 12 +12 months.
89532912|NCT05811013|Sham Comparator|Sham tSMS|Sham Transcranial static magnetic field stimulation (tSMS) Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain). Real and sham magnets will be held with an ergonomic helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
89532913|NCT05783960||External validation a questionnaire|Questionnaire will be administrated to patient with chronic kidney diseases ti evaluated the consumption of salt and potassium intake. A Bayesian network and a multiple regression will be used to validated the questionary of 27 items
89532914|NCT05777603|Experimental|Arm 1|Pembrolizumab + de-escalating doses of aztreonam and vancomycin
89684704|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
89684705|NCT02146001|Active Comparator|Moderate-to-vigorous activity group|This group will target achieving the current recommendations for physical activity in older adults. This is 150 minutes of moderate-to-vigorous activity per week.
89684706|NCT02146001|Experimental|Reducing sedentary behavior group|This group will target a 60 minute per day reduction in sedentary behavior using an objective activity monitor.
89684707|NCT02313597|Placebo Comparator|SETON|Silk suture will be used as SETON
89684708|NCT02313597|Experimental|VAAFT|Video assisted anal fistula treatment
89684709|NCT05742503||Depo-Provera group|This group will receive150 mg of injectable progesterone every 90 days or 3 months
89684710|NCT05742503||Implanon group|This group will receive 68 mg of etonogestrel implant formerly known as Implanon.
89684711|NCT05742503||Norgestrel group|This group will receive 0.075 mg of norgestrel (Ovrette®) once daily.
89684712|NCT05742503||Mirena group|This group will receive IUD (Mirena) containing 52 mg of levonorgestrel.
88997850|NCT05523479|Active Comparator|Interprofessional education about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive interprofessional education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
88997851|NCT05523479|Active Comparator|Clinical protocol about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers deploy a clinical protocol that supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
89684713|NCT02388321|Experimental|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
89684714|NCT02388321|Active Comparator|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
89684715|NCT05742425|Experimental|One-arm research group|
89684716|NCT02313675|Experimental|IV tylenol|One time intra-operative IV acetaminophen administration
89052983|NCT04575831|Experimental|Intervention|The intervention arm will receive a 12-week multimodal intervention featuring exercise, nutrition, and palliative symptom management.
89052984|NCT04582097|Experimental|Ramipril|Ramipril, 2.5 mg daily, administered orally for 16 weeks
89052985|NCT04582097|Placebo Comparator|Placebo|Placebo, matched for the interventional drug, administered orally, daily for 16 weeks
89052986|NCT04582019|Active Comparator|Patients with polyurethane DJ stent|Polyurethane DJ stent, 6Fr. The stent will be removed using flexible cystoscopy.
89052987|NCT04582019|Active Comparator|Patients with polyurethane DJ stent with magnet|Polyurethane DJ stent with magnet (Blackstar, Urotech), 7Fr. The stent will be removed under ultrasound control using a magnetic retriever
89052988|NCT04575714||Acute low back pain|Adult patients with acute low back pain
89052989|NCT04581707||Kyphoplasty Single Balloon Catheter Allevo|
89052990|NCT04581707||Quattroplasty Double Balloon Catheter Stop'n GO|
89052991|NCT00583635||1|Low Risk Pregnancy, Placebo
89052992|NCT00583635||2|Low Risk Pregnancy, Active Food Supplement
89052993|NCT00583635||3|High Risk Pregnancy, Placebo
89052994|NCT00583635||4|High Risk Pregnancy, Active Food Supplement
89052995|NCT00591357|Active Comparator|A|Loperamide
89052996|NCT00591357|Placebo Comparator|B|Placebo
89052997|NCT04581590|Active Comparator|Active group|In the group G1 will be administered: tDCS active + dual-task motor training + cognitive training.
89052998|NCT04581590|Sham Comparator|Sham group|In the group G2 will be administered: tDCS active + dual-task motor training
89052999|NCT00591396|Experimental|Single Arm|
89053000|NCT00591435||1|200 laparoscopic cholecystectomies will be included, consultant cases will be compared to resident cases
89053001|NCT00591435||2|200 laparoscopic pelviscopies will be included, consultant cases will be compared to resident cases
89053002|NCT00591435||3|200 transurethral resection of urinary bladder or prostate gland will be included, consultant cases will be compared to resident cases
89053003|NCT04580966|Experimental|Inquiry Based Stress Reduction (IBSR) workshop|Participants of this group received an IBSR intervention workshop.
89053004|NCT04580966|No Intervention|Control group|Participants of this group did not take a part in the workshop.
89053005|NCT04580849|Experimental|telerehabilitation with dance (Parkinson's)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
89053006|NCT04580849|Active Comparator|telerehabilitation with dance (Healthy controls)|This group will receive dance classes online during 60 minutes, twice a week for 8 weeks.
89053007|NCT00591474|Experimental|1|VRE positive patients
89053008|NCT00591474|Placebo Comparator|2|VRE positive patients
89053009|NCT04581239|Active Comparator|Active neural mobilization|Therapist supervised active neural mobilization of sciatic nerve in lumber radiculopathy patients
89053010|NCT04581239|Experimental|passive neural mobilization|Therapist done passicive neural mobilization of sciatic nerve in lumber radiculopathy patients
89053011|NCT04581083||Volunteer participants|Samples of volunteer participants will be collected after informed consent and classified as symptomatic, asymptomatic and negative.
89053012|NCT03452241|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
89053013|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use
89053014|NCT03452241|Experimental|Intervention Group 1|The medical staffs who received the training will use the manual of brief intervention twice to deliver it and other materials about the harm of substance use.
89053015|NCT04581005|Experimental|Supervised Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.~This group will receive a supervised, in-hospital training."
89053016|NCT04581005|Experimental|Home-based Prehabilitation|"Prehabilitation will include exercise, nutrition, and anxiety-coping intervention.~This group will receive a home-based training."
89053017|NCT04575675|Experimental|Dapagliflozin|Dapagliflozin with standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
89053018|NCT04575675|Placebo Comparator|Standard of care|Standard-of-care therapies for heart failure, including sacubitril/valsartan, beta-blocker, MRA, ICD and CRT
89053019|NCT00568412|Active Comparator|1|Zarzenda applied topically twice daily for three weeks
89053020|NCT00568412|Active Comparator|2|Elidel 1% cream, applied topically twice daily for three weeks
89053021|NCT03452163|Experimental|Anesthesia, General|Subjects under anesthesia that are expected to stay for at least 24 hours in the ICU/NICU will be monitored by the PMD-200 device. An EEG monitor device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
89053022|NCT00583089||1|Algorithm Test Set
89053023|NCT00583089||2|Algorithm Development Set
89053024|NCT00568529|Experimental|Combine Chemotherapy|XELOX(Xeloda and oxaliplatin combination)
89053025|NCT00568568|Experimental|Growth hormone|
89532915|NCT05775913|Experimental|Tubal Selective Delivery System|The same intervention will be used for all study subjects.
89532916|NCT05771428|Experimental|ABBV-552 Dose A|Participants will receive ABBV-552 Dose A once daily (QD) for 12 weeks.
89532917|NCT05771428|Experimental|ABBV-552 Dose B|Participants will receive ABBV-552 Dose B QD for 12 weeks.
89532918|NCT05771428|Experimental|ABBV-552 Dose C|Participants will receive ABBV-552 Dose C QD for 12 weeks.
89532919|NCT05771428|Placebo Comparator|Placebo for ABBV-552|Participants will receive placebo for ABBV-552 QD for 12 weeks.
89532920|NCT05767346|Experimental|Aficamten up to 20 mg plus placebo for metoprolol|Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of aficamten (CK-3773274) plus placebo for metoprolol succinate with dose levels guided by echocardiography assessments for up to 24 weeks.
89532921|NCT05767346|Active Comparator|Metoprolol succinate up to 200 mg plus placebo for aficamten|Patients will receive 50 mg, 100 mg, 150 mg or 200 mg of metoprolol succinate plus placebo for aficamten (CK-3773274) with dose levels guided by echocardiography and heart rate assessments for up to 24 weeks.
89532922|NCT05762679||Latent PSSP|Latent PSSP defined as focal palpable nodules that may be tender on palpation with pain rating of < 5/10 when combined with the hand-behind-neck (HBN) maneuver.
89532923|NCT05762679||Active PSSP|Active PSSP is defined as focal palpable nodules that are tender on palpation, reproducing the pain, and eliciting a pain rating of >= 5/10 when combined with the hand-behind-neck (HBN) maneuver.
89532924|NCT05759988|Experimental|Outpatient cervical ripening with Foley|Cervical ripening will begin with a Foley balloon in the outpatient setting
89532925|NCT05759988|No Intervention|Standard of care Inpatient cervical ripening|Cervical ripening will begin in the inpatient setting with Foley ballooon or other cervical ripening agent
89532926|NCT05757713|Experimental|teplizumab injection|teplizumab injection, sterile solution for intravenous use
89532927|NCT05755620|Experimental|Arm 1, Low Dose|10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 10 mcg of the H1ssF_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 10 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
89532928|NCT05755620|Experimental|Arm 2, Medium Dose|10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 25 mcg of the H1ssF_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 25 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
89532929|NCT05755620|Experimental|Arm 3, High Dose|10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 50 mcg of the H1ssF_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 50 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
89532930|NCT05755620|Experimental|Arm 4, Optimal Dose|10 healthy adult volunteer subjects from 18-49 years of age will receive the selected optimal dose of the H1ssF_3928 mRNA Vaccine, administered intramuscularly once. The optimal dosing group will be selected based on safety outcomes from the 10 mcg, 25 mcg, and 50 mcg dosing groups. For the optimal dose, the highest dose with no identified safety concerns as determined by the Safety Review Committee (SRC) will be selected. N =10
89532931|NCT05755620|Active Comparator|Arm 5, IIV4|10 healthy adult volunteer subjects from 18-49 years of age will receive licensed Quadrivalent Influenza Vaccine (IIV4), administered intramuscularly once. Subjects receiving IIV4 will be followed for safety, but only their immune responses will be compared to those of participants receiving H1ssF_3928 mRNA Vaccine. N=10
89532932|NCT05749302|Experimental|Al18F-NOTA-FAPI PET/CT|Al18F-NOTA-FAPI PET/CT will be performed on patients with suspected or clearly diagnosed FAP positive-expressing tumors. The patients were injected with Al18F-NOTA-FAPI and underwent PET/CT scan 20~40min after the injection.
89532933|NCT05749289|Experimental|Al18F-octreotide PET/CT|Al18F-octreotide PET/CT will be performed on patients with suspected or clearly diagnosed Neuroendocrine Tumor. The patients were injected with Al18F-octreotide and underwent PET/CT scan 20~40min after the injection.
89532934|NCT05748327|Experimental|Alcasite restorative material|
89532935|NCT05748327|Active Comparator|Bulk fill glass hybrid restorative material|
89532936|NCT05740735||Disorder of consciousness patients - Prospective group|DOC defined either by a coma (Glasgow Coma Scale <8), a vegetative state (VS) or a minimal state of consciousness (MCS) according to the Coma recovery scale-revised (CRS-r) after a primary brain injury: severe traumatic brain injury (TBI)), subarachnoid hemorrhage, stroke or cardiac arrest (CA)
89532937|NCT05740735||Disorder of consciousness patients - Retrospective group|
89532938|NCT05735184|Experimental|Dose Escalation: Ziftomenib/Venetoclax/Azacitidine in R/R NPM1-m (A-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
89684717|NCT02313675|Experimental|IV toradol|One time intra-operative IV ketorolac thromethamine administration
89684718|NCT02313675|Experimental|IV tylenol/toradol combination|One time intra-operative IV combination of acetaminophen/ketorolac administration
89684719|NCT02313675|Placebo Comparator|saline|One time intra-operative 50ml IV normal saline administration
89684720|NCT02388633||Plasmapharesis|Patients undergoing apheresis for elevated LDL. Patients will undergo contrast ultrasound perfusion imaging at rest and during forearm exercise at before and immediately after apheresis.
89684721|NCT02389101|Experimental|Lymphoma|Newly diagnosed lymphoma, all subtypes allowed
89684722|NCT02389725|Active Comparator|disposable elastic tourniquet|
89053026|NCT04575558|Experimental|Hydroxychloroquine + Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD, both for 7 days
89684723|NCT02389725|Active Comparator|manual blood pressure cuff|manual blood pressure cuff inflated to 150 milliliters mercury (mmHg)
89684724|NCT03801629|Experimental|High Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.07 mg/kg).
89053027|NCT04575558|Placebo Comparator|Hydroxychloroquine + Placebo tablets|Hydroxychloroquine 400mg PO BID 2 times a day + Placebo, both for 7 days
89684725|NCT03801629|Experimental|Low Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.04 mg/kg).
89684726|NCT03801551|Experimental|Patient|
89684727|NCT05741021|Experimental|F520+Chemotherapy|"Cohort 1:~Treatment period (3 weeks/cycle): On the first day of each cycle, F520 (200 mg), pemetrexed and carboplatin were administered sequentially by intravenous infusion (at least 30 min between doses).~Maintenance period (3 weeks/cycle): On the first day of each cycle, F520 (200 mg) and pemetrexed were administered sequentially by intravenous infusion (at least 30 min between doses).~Cohort 2:~Treatment period (3 weeks/cycle): On the first day of each cycle, F520 (200 mg), paclitaxel and carboplatin were administered sequentially by intravenous infusion (at least 30 min between doses).~Maintenance period (3 weeks/cycle): On the first day of each cycle, F520 (200 mg) was administered sequentially by intravenous infusion (at least 30 min between doses)."
89684728|NCT04383977|Experimental|Apatinib-Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
89684729|NCT04383977|Active Comparator|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
89684730|NCT03801239||patients with Overactive Bladder (OAB)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
89684731|NCT03801239||patients with Mixed Urinary incontinence (MUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
89053028|NCT04581161|Experimental|Life2000® Ventilator|Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device.
89053029|NCT04581161|No Intervention|Control Group|Subjects in the control group will be identified from the population of patients previously admitted to the study site with COVID-19 infection who required non-invasive oxygen therapy with HFNC but were not treated with NIV therapy. Subject data will be collected retrospectively from the medical record.
89053030|NCT03452124|Active Comparator|IQOS|I quit ordinary smoking (IQOS) assistes cessation program
89053031|NCT03452124|Active Comparator|Smoker control|Conventional cigarette smoking continuation
89053032|NCT00568607|Experimental|IFO, VP-16, DDP, DXM|
89684732|NCT03801239||patients with Stress Urinary Incontinence (SUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
89684733|NCT03801161|No Intervention|Healthy infants|
89684734|NCT03801161|Experimental|Infants with an inflammatory condition|Investigators will also use pentavalent (PENTA) vaccine as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
89684735|NCT02389881|Experimental|Cohort 1 Non-elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
89684736|NCT02389881|Experimental|Cohort 2 Non-elderly Healthy: TAK-058 75 mg|TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
89684737|NCT02389881|Experimental|Cohort 3 Non-elderly Healthy: TAK-058 150 mg|TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
89053033|NCT03452085|Active Comparator|artificial saliva spray (AS)|"The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.~After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment."
89053034|NCT03452085|Placebo Comparator|maritime throat spray (TT)|"The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.~After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment."
89053035|NCT00568646|Experimental|1|
89053036|NCT00568724||1|Children referred to surgical treatment of congenital hydronephrosis
89053037|NCT00568724||2|15 age- and sex-matched controls
89053038|NCT00568724||Children with healthy pelvic tissue|Children referred to nephrectomy due to nephrotic syndrome
89684738|NCT02389881|Experimental|Cohort 4 Elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.
89684739|NCT02389881|Placebo Comparator|Cohort 5 Non-elderly Healthy: TAK-058 300 mg|TAK-058 300 mg solution, orally, once daily on Day 1, in non-elderly healthy participants.
89684740|NCT02389881|Placebo Comparator|Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.
89684741|NCT02389881|Placebo Comparator|Cohort 4 Elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
89684742|NCT02389959|Experimental|Bevacizumab|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
89684743|NCT02389959|Placebo Comparator|Saline Control|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. The saline control placebo will be mixed by the Stanford Hospital Pharmacy to a total dose of 4mL in order to be identical in quantity and appearance to the mixed doses of bevacizumab, and 2mL will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
89684744|NCT00775931|Active Comparator|marrow graft transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan, Fludarabine monophosphate, and total lymphoid irradiation followed by unrelated or matched related donor marrow graft transplantation (both peripheral blood and marrow) and a second CD34 cell infusion on Day 42.
89684745|NCT00775931|Active Comparator|cord blood transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan and Cyclophosphamide followed by unrelated umbilical cord blood transplantation and a second smaller portion cord blood graft infusion on Day 42.
89684746|NCT02148107|Experimental|BI 691751 Dose 1|multiple dose given over 14 days
89684747|NCT02148107|Experimental|BI 691751 Dose 2|multiple dose given over 14 days
89684748|NCT02148107|Experimental|BI 691751 Dose 3|multiple dose given over 14 days
89684749|NCT02148107|Experimental|BI 691751 Dose 4|multiple dose given over 14 days
89684750|NCT02148107|Experimental|BI 691751 Dose 5|multiple dose given over 14 days
89684751|NCT02148107|Experimental|BI 691751 Dose 6|multiple dose given over 14 days
89684752|NCT02148107|Placebo Comparator|Placebo|Placebo
89684753|NCT02052141|Experimental|500/1000|500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
89684754|NCT02052141|Experimental|1000/500|1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks
89684755|NCT02391987|Active Comparator|Tele-Monitoring|Tele-monitoring and health coaching in addition to standard health care
89684756|NCT02391987|No Intervention|Standard Care|Standard care is defined as Heart Failure (HF) care based on current American College of Cardiology (ACC) and American Heart Association (AHA) HF guidelines implemented and orchestrated by a cardiologist and support staff at the participating institution.
89684757|NCT00777179|Experimental|Vandetanib|
89532939|NCT05735184|Experimental|Dose Escalation: Ziftomenib/7+3 in 1L NPM1-m (A-2)|Ziftomenib/7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
89684758|NCT00777179|Placebo Comparator|Placebo|
89684759|NCT05507177|Experimental|Group I|patients that are treated in group I receive a medication review from healthcare providers that have already received the communication training programme
89684760|NCT05507177|No Intervention|Group II|patients that are treated in group II receive a medication review from healthcare providers that have not yet received the communication training programme
89684761|NCT05734235|Experimental|Vitamin C & Vitamin E|After subjects undergo UVB treatment then they will be instructed to take two Vitamin C and one Vitamin E tablets daily for 8 days.
89684762|NCT02392767|Active Comparator|Verum|2 times 2 tablets a day for 4 weeks.
89684763|NCT02392767|Placebo Comparator|Placebo|2 times 2 tablets a day which cornstarch. Tablets look identical like verum tablets.
89684764|NCT04384289|No Intervention|''Standard Care''|''Standard Care'' group were given standard care services.
89684765|NCT04384289|Experimental|"Transitional Care Model"|"Transitional Care Model group were given care based on the Transitional Care Model until the post discharge 9th week starting from date of hospitalization."
89684766|NCT05732129|Experimental|Fluzoparib plus Irinotecan|Patients will receive Fluzoparib combined with Irinotecan treatment protocol, which included irinotecan asintravenous infusion at 180mg/m2 (on day 1) and Fluzoparib 150mg capsules given bid (days 1-7) every 2 weeks .
89532940|NCT05735184|Experimental|Dose Escalation: Ziftomenib/Venetoclax/Azacitidine in R/R KMT2A-r (B-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy
89532941|NCT05735184|Experimental|Dose Escalation: Ziftomenib/7+3 in 1L KMT2A-r (B-2)|Ziftomenib/7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
89532942|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in R/R NPM1-m (A-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
89532943|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/7+3 in 1L NPM1-m (A-2)|Ziftomenib/7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and meet the protocol definition of high-risk disease
89532944|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax in R/R NPM1-m (A-3)|Ziftomenib/Venetoclax in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
89684767|NCT04384601|Experimental|SOX Chemotherapy|"Three preoperative and three postoperative cycles of SOX chemotherapy~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
89684768|NCT04384601|Active Comparator|FLOT Chemotherapy|"Four preoperative and four postoperative cycles of FLOT chemotherapy~A cycle consist of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
89684769|NCT02394951|Experimental|Pregabalin|Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
89684770|NCT02394951|Placebo Comparator|Placebo|Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
89684771|NCT03838367|Experimental|Phase I-Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
89684772|NCT03838367|Experimental|Phase I-Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
89684773|NCT03838367|Experimental|Phase I-Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
89684774|NCT03838367|Experimental|Phase II- MTD to be established for the combination treatment|MTD PRO 140 SC + AUC 5 Carboplatin in 30 subjects
89684775|NCT04384211||Radiologists|A computer search of CT scans (2010.01.01-2018.09.30) was performed in Wan Fang Hospital. These CT images were retrospectively reviewed by an experienced radiologist who classified and marked with annotations of vertebral fractures by the Genant's semiquantitative method.
88997852|NCT05523479|Active Comparator|Interprofessional education plus clinical protocol about risk-stratified post-extubation NIV/HFNC|During this period, ICU providers receive interprofessional education and use a clinical protocol that supports the implementation of risk-stratified, preventive post-extubation NIV/HFNC.
88997853|NCT05523479|Active Comparator|Online education about post-extubation HFNC|During this period, ICU providers receive traditional online education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of preventive post-extubation HFNC for all eligible patients.
88997854|NCT05523479|Active Comparator|Interprofessional education about post-extubation HFNC|During this period, ICU providers receive interprofessional education that demonstrates the evidence supporting use of preventive post-extubation respiratory support (NIV or HFNC) over conventional post-extubation oxygen and supports the implementation of preventive post-extubation HFNC for all eligible patients.
88997855|NCT05523479|Active Comparator|Clinical protocol about post-extubation HFNC|During this period, ICU providers deploy a clinical protocol that supports the implementation of preventive post-extubation HFNC for all eligible patients.
88997856|NCT05523479|Active Comparator|Interprofessional education plus clinical protocol about post-extubation HFNC|During this period, ICU providers receive interprofessional education and use a clinical protocol that supports the implementation of preventive post-extubation HFNC for all eligible patients.
88997857|NCT05523479|No Intervention|Usual care|During this period, ICU providers receive no structured education about preventive, post-extubation respiratory support therapies
88997858|NCT05517018||single layer uterotomy|53 women with a single-layer uterotomy while closing the uterus during Ceserian
88997859|NCT05517018||double layer uterotomy|53 women with a double layer uterotomy while closing the uterus during Ceserian
88997860|NCT05517018||purse string uterotomy|53 women with a purse string uterotomy tecnique had used while closing the uterus during Ceserian
88997861|NCT05510882|Other|three groups of different treatment modalities for OSA|Group I: patients were treated with CPAP. Group II: patients were treated with digitally fabricated MAD. Group iII: patients were treated with oral myofunctional therapy.
88997862|NCT05494580|Experimental|Pamiparib + Surufatinib (Phase Ib/II)|"Phase Ib:~A dose de-escalation schedule is used in the phase Ib dose finding part. Dose Level 1 (starting dose): pamiparib 40 mg administered orally twice daily (fixed dose) and surufatinib 250 mg administered orally once daily on a 21-day treatment cycle. If ≥2/6 patients experience a dose limiting toxicity (DLT), we will de-escalate to Dose Level 2: pamiparib 40 mg administered orally twice daily (fixed dose) and surufatinib 200 mg administered orally once daily on a 21-day treatment cycle. Approximately 3-12 patients will be enrolled in phase Ib study.~Phase II:~The phase II part will begin once the recommended phase 2 dose (RP2D) of surufatinib have been determined in the Phase Ib in order to assess antitumor activity of pamiparib and surufatinib combination. In phase II study, pamiparib 40 mg orally twice daily and surufatinib PR2D will be administered."
88997863|NCT05491252|No Intervention|Control Group (CG)|The subjects in the Control Group (CG) will receive usual care as being received in study hospitals. Usual care at study hospitals involve consultaion with the physician which encompasses history taking, blood glucose measurement, prescription and provision of general education regarding lifestyle modification verbally or in the form of pamphelets.
89053039|NCT00568724||Adults with healthy pelvic tissue|Adults referred to nephrectomy due to another cause than hydronephrosis
89053040|NCT03452046||PS 10 mmHg, PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
89053041|NCT03452046||PS 10 mmHg PEEP 0 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
89684776|NCT04384211||Smart Bone|The same CT images were separately reviewed and processed by the artificial intelligence system (Smart Bone) by Quanta for compression fractures. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
89684777|NCT00354861|Experimental|A|IMP321
89684778|NCT00354861|Placebo Comparator|B|Saline
89684779|NCT00354861|Active Comparator|C|Engerix B
89684780|NCT04345445|Experimental|Tocilizumab|Tocilizumab is given at 8 mg/kg (body weight) once and administered as an intravenous infusion within no less than 60 minutes.
89684781|NCT04345445|Active Comparator|Methylprednisolone|Reconstituted methylprednisolone is infused over 30 minutes and administered at a dose of 120mg/day for 3 days
88997864|NCT05491252|Experimental|Intervention Group (IG)|The subjects in the Intervention Group (IG) will receive usual care as well as a nurse-led PAtient CEntered Self-Management Intervention (PACE-SMI). PACE-SMI will be delivered for eight weeks duration comprising eight face to face individual and group educational, couselling and behavioral (ECB) training sessions in addition to telephonic reminders and a home visit by Principal Investigator (PI) and Research Assistants (RA). Outcome variables will be measured at three points in time (at baseline, at completion of intervention and lastly, after three months follow-up).
88997865|NCT05480618|Experimental|Spinal Cord Injury Subjects|20 medically stable male and female subjects between 18 and 60 years old, BMI between 18.5-35 kg/m2, with a history of SCI and who use a wheelchair were included. Participants that did not speak English or with a history of renal, neurological, or coronary artery disease, cancer, diabetes, significant arrhythmia smoking, or using cardioactive medications were excluded.
88997866|NCT05465291|No Intervention|Conventional care|Control Group
88997867|NCT05465291|Experimental|Exercise Group|Passive/active range of motion exercises group
88997868|NCT05465291|Experimental|Neuromuscular Electrical Muscle Stimulation group|Neuromuscular Electrical Muscle Stimulation group
88997869|NCT05465291|Experimental|Combined therapy (Neuromuscular Electrical Muscle Stimulation pulse limb exercise)|Combined therapy (Neuromuscular Electrical Muscle Stimulation pulse limb exercise).
88997870|NCT05464654|Experimental|Polynucleotide vaginal suppositories|"In this arm 72 first-time participants of the peri-postmenopause and bone metabolism clinic of the Regional Hospital October 1st  of ISSSTE Mexico, were randomly enrolled to be treated with local salmon polydeoxyribonucleotide (PDRN) therapy."
88997871|NCT05464654|Active Comparator|Conjugated estrogens cream|"In this arm 64 first-time participants of the peri-postmenopause and bone metabolism clinic of the Regional Hospital October 1st  of ISSSTE Mexico, were randomly enrolled to be treated with the gold-standard treatment with local estrogen-based hormone therapy."
88997872|NCT05459480|Experimental|Intervention Group|"Online training was continued according to the jigsaw technique for a total of 6 weeks, two hours a week. In the first week, 6 subgroups of 6 people were created.~Sub-topics of the physical examination course were shared according to the systems to these groups, called the main group.~In the first week, it was aimed for the groups to get to know each other and the first lesson was used for that. In the second week, the students in the main group researched the sub-topics of the unit given to them and formed a new group by coming together with students who were researching the same subject. This group was called the expert group. In the third and fourth weeks, expert groups continued their studies to reinforce the subject.~In the fifth and sixth group the students returned to their main groups and explained the subjects they had learned in the expert groups to their main group. Students were expected to teach each other all parts of the unit in their main groups."
88997873|NCT05459480|No Intervention|Control Group|The subjects were explained by the instructor with the traditional e-teaching method and as in the intervention group, the lectures were conducted online for two hours a week for 6 weeks. At the end of each week, the relevant course documents were shared with the students. At the end of the sixth week, the post-tests of the learning motivation and self-confidence scales were applied in the control group simultaneously with the intervention group. In addition, an academic achievement test was applied.
88997874|NCT05456750|Experimental|treatment group|The treatment group receive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The laser power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days each week, for 2 weeks (total 10 times in one course)
88997875|NCT05456750|Sham Comparator|control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
88997876|NCT05443503|Other|Intervention|"Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH).~Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track."
88997877|NCT05434650||Treatment group|Single arm group to receive ablation
88997878|NCT05410600|Experimental|Arm Ergometer Smart Trainer Cycling|Participants will participate in an 8-week exercise training program using the smart trainer.
88997879|NCT05357573|Experimental|KRN23|KRN23 administered subcutaneously (SC) every 4 weeks for 48 weeks. The dose varies according to serum phosphorus level which include 0.3,0.6,1.0,1.4 and 2.0 mg/kg.
88997880|NCT05356793|Experimental|Treatment|Active treatment with SCH-1
88997881|NCT05356793|Placebo Comparator|Placebo|Vehicle minus active components
88997882|NCT05332873|Experimental|Rivet Shunt Therapy|
88997883|NCT05332678|Experimental|SLS-005 - Once Weekly|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion once a week over 60 ± 5 minutes for volumes <600 mL or 90 minutes +5 min for volumes >600 mL.~For 52 weeks."
88997884|NCT05332678|Experimental|SLS-005 - Twice Weekly|"SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion). SLS-005 will be administered as a weight-based dose of 0.75 g/kg by IV infusion twice a week over 60 ± 5 minutes for volumes <600 mL or 90 minutes +5 min for volumes >600 mL.~For 52 weeks."
88997885|NCT05323968|Other|Acute diverticulitis|Patients with clinical suspicion of acute diverticulitis
88997886|NCT05298553|Experimental|Group 1|"The order in which the wearable devices being investigated will be randomly assigned in a 1:1 fashion.~Simultaneous 12-lead ECG and single-lead ECG with the SkyLabs CART-I ring followed by the Apple Watch."
88997887|NCT05298553|Experimental|Group 2|"The order in which the wearable devices being investigated will be randomly assigned in a 1:1 fashion.~Simultaneous 12-lead ECG and single-lead ECG with the Apple Watch followed by the SkyLabs CART-I ring."
89053042|NCT03452046||PS 0 mmHg PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
89684782|NCT02056431|Experimental|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
89216476|NCT03544489|No Intervention|Usual Care|"Usual Care will receive treatment as usual from their health care clinicians with outcomes measured at baseline, 3 and 6 months. Participants will not be discouraged from physical activity, but will be asked not to change their current level of activity for 6 months while in the study. Usual care involves ICD interrogation and follow-up every 3 months, measured either in-person or with home telephonic transmissions. Because participants in usual care may choose to participate in another exercise program, we will monitor those who participate in exercise programs and use the StepWatch monitor to quantify the amount and timing of physical activity. To control for group differences in attention, investigators will telephone usual care participants requesting information about health care utilization twice during the study at 3 and 6 months."
89216477|NCT03514589|Active Comparator|Arm 1|250 mcg IV synacthen
89216478|NCT03514589|Experimental|Arm 2|Nasal Synacthen
89216479|NCT03497546|Experimental|Exercise|Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
89216480|NCT03497546|No Intervention|Control|Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.
89684783|NCT02056431|No Intervention|IVR Control Group|Participants will receive 3 non-interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) containing general messages regarding diabetic education.
89684784|NCT03800459|Experimental|Experimental: Intervention group|Experimental: Intervention group
89684785|NCT03800459|No Intervention|Control:no intervation group|Control:no intervation group
89684786|NCT04919031|Experimental|study|Inspiratory muscle trainer plus diaphragmatic release and traditional medications
89684787|NCT04919031|Active Comparator|control|inspiratory muscle trainer plus traditional medications
89684788|NCT05664945|Experimental|pulmonary tele-rehabilitation (PTR)|"Recieve supervised PTR 2/weekly, session duration of 60 min; 35 min of exercise and 25min of patient education for 10-weeks (primary endpoint).~Delivered from Hvidovre/Bispebjerg Hospital to groups of 4-6 patients who exercise at home and communicate via tablet-camera.~After 10-weeks of PTR, participants are offered once weekly PTR for 60minuttes in groups of 4-8 patients throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
89684789|NCT05664945|Experimental|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR program. Patient goal is to achieve at least 20 min of self-initiated muscle-endurance based exercise 3days/weekly for 10-weeks (primary endpoint).~The first session is a home visit by an experienced respiratory physiotherapist and with focus on establishment of exercise goals, formal exercise prescription and education.~The home visit is followed by 1/weekly session for 10-weeks.The sessions is delivered from Hvidovre/Bispebjerg Hospital via tablet-camera or telephone call.~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 patients throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
89684790|NCT05664945|Active Comparator|Control|Control group will receive usual care; medication, scheduled follow-up visit and possible phone contact with GP or the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.
89684791|NCT03800147|Active Comparator|High-fat diet|"Participants will follow a high-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).~Blood samples, stool samples and clinical information will be collected during the study."
89684792|NCT03800147|Active Comparator|Low-fat diet|"Participants will follow a low-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).~Blood samples, stool samples and clinical information will be collected during the study."
89684793|NCT03800303|Experimental|two-week family-based treatment|Active treatment includes a two-week family-based partial hospitalization treatment utilizing and integrated therapeutic design.
89684794|NCT03800225|Experimental|Repair|Anterior cruciate ligament repair with internal brace after anterior ligament rupture.
89684795|NCT03800225|Active Comparator|Patella tendon graft|The Patella tendon graft is harvested and used as a knew anterior cruciate ligament after rupture.
89684796|NCT00795275|Experimental|Impaired Fasting Glucose|Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)
89684797|NCT00795275|Experimental|Normal glucose tolerance|Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)
89684798|NCT05713565|Experimental|Digital Care Solution group|"Participants will be instructed to download the SKH mobile app to which the participants will have access for 12 months, and the participants will receive an access code to activate the SKH CAD program. The aim of the program is to empower self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.~Beyond this, all patients in the interventional arm will also receive standard of care as defined below for the control arm."
89216481|NCT03496805|Experimental|MGE group|Patients will be randomized to muscadine grape extract (MGE). The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
89216482|NCT03496805|Placebo Comparator|Placebo group|Patients will be randomized to placebo. The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of placebo.
89216483|NCT03495609|Experimental|Ovitrelle|
89216484|NCT03493282|Active Comparator|300 mg|High Dose CT1812
89216485|NCT03493282|Active Comparator|100 mg|Low Dose CT1812
89216486|NCT03493282|Placebo Comparator|Placebo|Matching Placebo
89216487|NCT03475810|Experimental|VR GROUP|Patients watches 3D documentary videos on virtual reality glasses
89216488|NCT03475810|Active Comparator|midazolam|Patients do not watch virtual reality videos but will be administered iv sedative drugs before spinal attempt.
89684799|NCT05713565|Active Comparator|Standard of Care - control group|The participants in the Standard of Care - control group will receive an information leaflet about relevant lifestyle modifications for CAD. After baseline measurements and data collection, follow-up and continuous care will be as usual in outpatient care (i.e., Standard of Care).
89684800|NCT00777335|Experimental|Panobinostat i.v.|
89684801|NCT00777335|Experimental|Panobinostat oral|
88997888|NCT05294705||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), Brief Observation of Symptoms of Autism (BOSA), Childhood Autism Rating Scale-2(CARS-2) and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
88997889|NCT05294705||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
88997890|NCT05287958||Healthy|While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
88997891|NCT05287958||ALS|While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
88997892|NCT05267873||Duke Health System Electronic Health Record|Patients who received Duloxetine or Vortioxetine
88997893|NCT05267873||Johns Hopkins Health System Electronic Health Record|Patients who received Duloxetine or Vortioxetine
88997894|NCT05267873||Randomized Controlled Trial 1 (NCT01153009)|Patients who received Duloxetine or Vortioxetine
88997895|NCT05267873||Randomized Controlled Trial 2 (NCT01140906)|Patients who received Duloxetine or Vortioxetine
88997896|NCT05267873||Randomized Controlled Trial 3 (NCT00672620)|Patients who received Duloxetine or Vortioxetine
88997897|NCT05267873||Randomized Controlled Trial 4 (NCT00635219)|Patients who received Duloxetine or Vortioxetine
88997898|NCT05259956|Experimental|"3 plus 1 multidimensional exercise therapy"|The intervention consists of a Schroth-based exercise session and a manipulative therapy of pelvic asymmetry.
88997899|NCT05259956|Active Comparator|Schroth based scoliosis specific exercise|The intervention consists of the Schroth-based exercise session.
88997900|NCT05238038||Healthy|EIT measurements will be performed on appendicular muscles (in the upper and lower extremities) depending on the condition, both at rest and with contraction. EIT measurements will be repeated on an intermittent basis to assess repeatability as well disease progression or improvement over time
88997901|NCT05238038||Neuromuscular disease patients and Central neurological disease patients|EIT measurements will be performed on appendicular muscles (in the upper and lower extremities) depending on the condition, both at rest and with contraction. EIT measurements will be repeated on an intermittent basis to assess repeatability as well disease progression or improvement over time
88997902|NCT05224037|Experimental|Study group|This is a single-arm study. All the participants will undergo examinations with 2 devices
88997903|NCT05222295|Experimental|Supervised Pulmonary Telerehabilitation Group|Three times a week for 8 weeks, a supervised and standardized pulmonary rehabilitation program will be applied in the form of telerehabilitation with simultaneous video conference method, accompanied by a specialist physiotherapist, while the patients are at home.
88997904|NCT05222295|Experimental|Cognitive Telerehabilitation Group|Motor imagery + action observation methods will be applied. In therapy, a video recording of each exercise in the supervised telerehabilitation group will be sent to the patients by the physiotherapist in accordance with the number of repetitions. At the end of the session, the cognitive telerehabilitation group will be asked to actively do the breathing exercises and active breathing techniques cycle in the supervised telerehabilitation group as well as to imagine with the instructions in the video recording, and commands will be given accordingly.
88997905|NCT05221281|Experimental|Intervention: Multimodal intervention consisting of four core components.|"Core Component 1: Individualized Assessment~Core Component 2: Transition Facilitation with a Navigator~Core Component 3: Participant Skills-building~Core Component 4: Structured Educational eLearning Curriculum"
88997906|NCT05221281|Other|Control: Standard of care|Routine Care
89684802|NCT00790673|Experimental|1|CF102 1 mg qd
88997907|NCT05215171||World Trade Center - Airway Hyperreactivity (WTC-AHR)|WTC-AHR cases are defined as having either a positive MCT (PC20<16) and/or positive BDR (by ATS/ERS guidelines with improvement of FEV1 by 12% and at least 200mL) post-9/11.
89684803|NCT00790673|Experimental|2|CF102 1 mg bid
89684804|NCT00790673|Experimental|3|CF102 1 mg bid; 16 weeks
89684805|NCT00790673|Placebo Comparator|5|
89684806|NCT05644587|Active Comparator|Traditional Induction Arm|In this arm, study participants will wait until they have significant opioid withdrawal (SOWS score >=17) prior to starting buprenorphine. Participants will then started with 2 mg sublingual and escalate to a maximum of 12 mg on the first day depending on withdrawal symptoms. On day 2, the participant will take same dose as the total dose taken on day 1, and continue that dose daily until reevaluation.
89684807|NCT05644587|Active Comparator|Microdosing Induction Arm|In this arm, study participants will not wait until they have significant opioid withdrawal. They will take 0.5 mg buprenorphine on day 1, 2 mg on day 2, 4 mg on day 3, 6 mg on day 4, 8 mg on day 5 and 12 mg starting on day 6.
89684808|NCT03837587||Patients group|Patients with temporomandibular disorders
89684809|NCT00355251|Experimental|A|4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
89684810|NCT00355251|No Intervention|B|4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento
89684811|NCT04890717||ASD and/or ADHD children (Case group)|Suspected or confirmed cases of ASD and/or ADHD children (Case group); no intervention(s) to be administered.
89684812|NCT04890717||Parent group|Parents of suspected or confirmed cases of ASD and/or ADHD children; no intervention(s) to be administered.
89684813|NCT04890717||Sibling group|Typically developed siblings of suspected or confirmed cases of ASD and/or ADHD children; no intervention(s) to be administered.
89684814|NCT04890717||Control group|Typically developed children not related to the case group ; no intervention(s) to be administered.
89684815|NCT03832127|Experimental|Fludatep|PET with 18F-Fludarabine
89684816|NCT04880265||Patients undergoing cardiac surgery|
89684817|NCT00791219|Experimental|Test|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
88820623|NCT05886764|Experimental|Arm 3 (Digital Intervention + Community Outreach)|"Patient participants in this arm will receive digital messages (email, text, etc.) which include general educational information about clinical trials and available resources. They will also be invited to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.~Provider participants will also receive digital messages with educational materials and will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys."
89053043|NCT03452046||t tube (PS 0 mmHg PEEP 0mmHg)|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
89053044|NCT04575480|Active Comparator|Group 1|Group 1 will undergo SWL with 3 days between each session.
89053045|NCT04575480|Active Comparator|Group 2|Group 2 will undergo SWL with 7 days between each session
89053046|NCT04575480|Active Comparator|Group 3|Group 3 will undergo SWL with 14 days between each session.
89053047|NCT00568841|Experimental|1|
89053048|NCT00583869|Placebo Comparator|1|Patient to receive placebo beginning on the day of surgery until discharge.
89053049|NCT00583869|Experimental|2|Patient to receive 75mg PO BID pregabalin beginning on the day of surgery until discharge.
89053050|NCT00583869|Experimental|3|Patient to receive 150mg PO BID pregabalin beginning on the day of surgery until discharge.
89053051|NCT00568880|Experimental|Hydroxychloroquine Added to Bortezomib|Dose escalated by cohorts Hydroxychloroquine 200-600 mg pill every other day. Bortezomib 1.0-1.3mg/m2 IV, days 1, 4, 8, and 11 of each 21 day cycle.
89053052|NCT03451968|Experimental|critically ill|"amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive).~it is a single bolus, no other elements or drug will be administered."
89053053|NCT03451968|Active Comparator|control|amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive) it is a single bolus, no other elements or drug will be administered.
89053054|NCT00569036|Experimental|BMS-754807|Single arm, multiple-ascending dose escalation study
89053055|NCT00569075||High Risk|High risk disease prone population
89053056|NCT00569075||Low Risk|Low risk disease population
89053057|NCT03453021||mepolizumab|Patients will receive a subcutaneous injection of mepolizumab 100 mg every 4 weeks for one year, for a total of 12 injections
89053058|NCT03453944|Experimental|VF03-K active stimulation|NMES applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
89053059|NCT03453944|Sham Comparator|VF03-K sham stimulation|Sham stimulation applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Sham stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
89053060|NCT03451890|Experimental|Cohort 1: E2730 40 mg|Participants will receive a single oral dose of E2730 40 milligrams (mg) under fasted conditions.
89053061|NCT03451890|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
89684818|NCT00791219|Active Comparator|Reference|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
89684819|NCT00791219|Placebo Comparator|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
89684820|NCT04822545|Other|Intervention Arm|"-Adult (≥ 18 years of age) hospitalized patients who have obesity (BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 if Asian/South Asian), as recorded in the medical chart, who have decision-making capacity and whose acute medical condition has been stabilized.~we will exclude patients who are enrolling in hospice/comfort care and the patients who are already enrolled in the CWM clinic. Non-English speaking patients. Patients who have opted out of research in their Epic EHR will be excluded from consideration for participation."
89684821|NCT00797459|Experimental|Restylane and Restylane with Lidocaine|This is a split-face design injecting both Restylane and Restylane-L injectable gels, administered once. Each subject received Restylane on one side of the face, and Restylane-L on the other. Subjects were blinded to which side of their face received Restylane or Restylane-L. The study was randomized and treatments successive.
89684822|NCT05614401||RIPC group|Patients underwent RIPC treatment after IV thrombolysis in the index stroke.
89684823|NCT05614401||Control group|The control group underwent no inflations or deflations in the index stroke.
89684824|NCT04817553||IgG4 pancreatobiliary|IgG4 patients with pancreatobiliary involvement
89684825|NCT04807101|No Intervention|midazolam and fentanyl|Patients in this arm will receive standard conscious sedation with midazolam and fentanyl
89684826|NCT04807101|Experimental|midazolam alone|Patients in this arm will receive conscious sedation with medazepam alone
89684827|NCT05452031|Experimental|In-Person Care2Sleep|In-person, manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
89684828|NCT05452031|Active Comparator|Telehealth Care2Sleep|Telehealth, manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
89684829|NCT05452031|Placebo Comparator|Sleep Education only|In-person, education on sleep, aging, and dementia but without specific or individualized recommendations
89684830|NCT05416073|Experimental|Esketamine-PCIA(patient controlled intravenous analgesia)|PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.
89684831|NCT05416073|Active Comparator|Sufentanil-PCIA(patient controlled intravenous analgesia)|PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.
89684832|NCT02979171|Active Comparator|LMA-Classic|airway management with LMA-Classic
89684833|NCT02979171|Active Comparator|LMA-Flexible|airway management with LMA-Flexible
89684834|NCT02979171|Active Comparator|LMA-Proseal|airway management with LMA-Proseal
89053062|NCT03451890|Experimental|Cohort 2: E2730 80 mg|Participants will receive a single oral dose of E2730 80 mg under fasted conditions.
89053063|NCT03451890|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
89053064|NCT03451890|Experimental|Cohort 3: E2730 120 mg|Participants will receive a single oral dose of E2730 120 mg under fasted conditions.
89053065|NCT03451890|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
89684835|NCT05481801||Vaccination adherence|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Covid-19, Influenza Vaccination status, Pneumococcal Vaccination status and Hepatitis B Virus (HBV) status.
89684836|NCT05601687|Active Comparator|Step-up Approach|Standard procedure where necrosectomy is only performed in the absence of clinical improvement 72 hours after placements of lumen-apposing metal stent.
89684837|NCT05601687|Experimental|Direct Endoscopic Necrosectomy|Necrosectomy will be performed in the same procedure as the placement of the lumen-apposing metal stent.
89684838|NCT05664971|Experimental|Cohort 1|NSCLC-squamous carcinoma third line;JS004 200mg + JS001 240mg Q3w, maintained until disease progression
88997908|NCT05215171||Control Group|Cohort Controls will be randomly selected 10% of the baseline cohort
88997909|NCT05205265|Experimental|Rivet Shunt Therapy|
88997910|NCT05183607|Experimental|Virtual nutritional Intervention|This arm will receive the virtual nutritional intervention consisting of 4 - 30 minute sessions to educate cardiac surgery patients before their date of surgery. Each session will provide a different theme such as: 1) nutritional assessment, 2) protein intake education, 3) nutritional adequacy prior to surgery, and 4) protein and nutrition intake post surgery
88997911|NCT05133141||Echelon Contour|This prospective study will include the participants who plan to have an elective colorectal surgical procedure and collect clinical data in a post-market setting. Investigators will perform each procedure using the device in compliance with their standard surgical approach and the Echelon Contour instruction for use (IFU).
88997912|NCT05129293|Experimental|Prospective Memory Intervention|Participants randomized to the PM intervention (active group) will meet with an interventionist twice a week for four weeks. The first four sessions will focus on visual imagery, while the last four sessions will focus on implementation intentions. Participants will be led through a manualized treatment.
88997913|NCT05129293|Active Comparator|Educational|The control group (Education) will meet with a research assistant for the same frequency of sessions and will receive psychoeducation on MS and cognitive functioning. The interventionists will be following a manual and accompanying PowerPoint slides.
88997914|NCT05117840||Lung Cancer Screening Cohort|Individuals at high-risk of lung cancer undergoing standard of care screening as per USPSTF guidelines. All subjects will undergo low-dose CT scanning as per guidelines and an investigational blood-draw will be taken from all enrolled subjects.
88997915|NCT05089864|Other|Early stent placement|Stent placement 5-7 weeks post-STAR procedure
88997916|NCT05089864|Other|Later stent placement|Stent placement 12-14 weeks post-STAR procedure
88997917|NCT05035589||TCZ|The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
88997918|NCT05035589||Control|50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab
88997919|NCT05031286|Experimental|Experimental Arm|
88997920|NCT05012917|Other|Patient/Proxy-SSPedi Administered First|"Parent/child dyads will complete self-report SSPedi/mini-SSPedi and proxy-SSPedi as the first period and then co-SSPedi as a second period."
88997921|NCT05012917|Other|Co-SSPedi Administered First|"Parent/child dyads will complete co-SSPedi as the first period and then self-report SSPedi/mini-SSPedi and proxy-SSPedi as a second period."
88997922|NCT05009875|Experimental|SBD111|
88997923|NCT05009875|Placebo Comparator|Placebo|
88997924|NCT05007288|Experimental|RET Treated Eye Plus INhance Group|Participants randomized to receive the restorative eye treatment (RET) intervention on either the left or right eyelid will administer the RET cream on the eyelid daily for 4 consecutive weeks prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.
88997925|NCT05007288|Experimental|RET Untreated eye Plus INhance Group|Participants randomized to not receive the RET intervention will not receive any intervention prior to scheduled standard of care (SOC) blepharoplasty. After surgery, participants will receive INhance with Trihex technology applied to both eyelids daily for 10 consecutive days post surgery.
88997926|NCT05000411|Experimental|Experimental group|
88997927|NCT05000411|Placebo Comparator|Control group|
88997928|NCT04995601|No Intervention|Standard of Care|Participants will receive DVT prophylaxis using standard intermittent pneumatic compression during postoperative care after total joint replacement.
88997929|NCT04995601|Experimental|Recovery Force MAC|Participants will receive DVT prophylaxis using the RF Health MAC during postoperative care after total joint replacement.
88997930|NCT04986475|Experimental|Music Therapy|Music therapy was applied during the non-stress test.
88997931|NCT04986475|No Intervention|Control|A routine non-stress test was performed.
88997932|NCT04962503|Experimental|Afamelanotide|
88997933|NCT04960566|Experimental|eCBT+|eCBT+ participants will be enrolled in 6, 45-minute sessions delivered via a secure video platform with a GI psychologist. To reinforce concepts reviewed in the sessions, participants will complete weekly home practice exercises. The targets are 1) improved maladaptive cognitive-affective processes associated with increased hypervigilance and symptom anxiety, 2) reduced behaviors associated with EHA including avoidance, increased medication/healthcare utilization and 3) reduced autonomic nervous system (ANS) arousal by increased HRV. Participants will learn to identify, question, and modify maladaptive thoughts, beliefs, and assumptions related to their symptoms (symptom anxiety). Systematic exposure to feared events are used to reduce maladaptive coping strategies (hypervigilance, PPI overuse, HCU). Specific, paced diaphragmatic breathing exercises (Resonance Frequency Breathing) designed to increase HRV are the last component (visceral hypersensitivity, reflux physiology).
89684839|NCT05664971|Experimental|Cohort 2|NSCLC-squamous carcinoma second line;JS004 200mg + JS001 240 mg + docetaxel Q3w, maintained until disease progression
89684840|NCT05664971|Experimental|Cohort 3|NSCLC-non-squamous carcinoma first line;JS004 200mg + JS001 240 mg + pemetrexed + carboplatin/cisplatin Q3w, for 4 cycles;JS004 200mg + JS001 240 mg + pemetrexed, maintained until disease progression
89684841|NCT05664971|Experimental|Cohort 4|NSCLC-squamous cell carcinoma first line;JS004 200mg + JS001 240 mg + paclitaxel + carboplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
88997934|NCT04960566|Sham Comparator|Sham-SOC Lifestyle Coaching|Patients randomized to the SOC condition will receive lifestyle guidance recommended for patients with GERD over a period of 6, 45-minute sessions with the GI psychologist to maintain consistency of delivery between the two intervention arms. Topics include maintaining a healthy weight, identifying triggering food and drink, making healthy food choices, eating behaviors, smoking and/or alcohol use, and timing of meals. The SOC condition will be carefully designed to not include any principles of the eCBT+ condition rather be based solely on patient education and encouragement to practice lifestyle changes on their own.
88997935|NCT04935424||Experimental：Leukoderma|Device: ApolloVue® S100 image system
88997936|NCT04916080|Experimental|after treatment|chronic kidney disease patients after receiving NAC for 3 months
88997937|NCT04855305|Active Comparator|Patients with Interstitial Lung Disease|
88997938|NCT04855305|Active Comparator|Healthy Volunteers|
88997939|NCT04842032|Experimental|KRN23|KRN23 0.8 mg/kg starting dose, administered Q2W by SC injection up to Week 64. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
88997940|NCT04842019|Experimental|KRN23|KRN23 1 mg/kg administered subcutaneously (SC) every 4 weeks for 48 weeks. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
88997941|NCT04838782|Experimental|Repeat Surgical Resection|Standard surgical operative management according to local practices.
88997942|NCT04838782|Active Comparator|Management Without Re-operation|Non-surgical management with standard care according to local practices.
88997943|NCT04833140|Active Comparator|Estradiol|"Estradiol in the form of a transdermal patch 100 mcg daily (Vivelle-Dot generic).~Women with an intact uterus will also receive progesterone (100 mg) in the form of a vaginal tablet (Endometrin, Ferring Pharmaceuticals, Inc.) inserted daily for endometrial protection"
88997944|NCT04833140|Placebo Comparator|Placebo|Placebo patch (containing no estradiol) Women with an intact uterus will also receive vaginal placebo capsules (containing no progesterone)
88997945|NCT04828070||Registry participant|Prospective collection of clinical information, completion of anxiety/depression, microaggressions, and quality of life questionnaires
88997946|NCT04778618|Experimental|Individual dose of Thymoglobulin|Individual dose of Thymoglobulin (r-ATG) : Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg)
88997947|NCT04775979|Experimental|Diphenylcyclopropenone (DPCP)|Applying DPCP topically
88997948|NCT04773457||Spine Surgery|Pediatric patients presenting for elective spine fusion surgery at Boston Children's Hospital
88997949|NCT04773457||Abdominal Surgery|Pediatric patients presenting for elective abdominal surgery at Boston Children's Hospital
88997950|NCT04767841|Experimental|Metformin|Metformin 1000 mg daily plus Celecoxib 200mg capsule
88997951|NCT04767841|Experimental|Placebo|Placebo tablet daily plus Celecoxib 200mg capsule
88997952|NCT04761861|Experimental|Vildagliptin|Vildagliptin 50 mg tablet daily
88997953|NCT04761861|Placebo Comparator|Placebo|Placebo tablet daily
89684842|NCT05664971|Experimental|Cohort 5|SCLC first line;JS004 200mg + JS001 240 mg + etoposide + carboplatin/cisplatin Q3w, for 4 cycles; JS004 200mg + JS001 240 mg, maintained until disease progression
89684843|NCT04848077|Experimental|Very high dose|Very large proportional increase in stepcount relative to baseline stepcount.
89684844|NCT04848077|Experimental|High dose|Large proportional increase in stepcount relative to baseline stepcount.
89684845|NCT04848077|Experimental|Intermediate dose|Medium proportional increase in stepcount relative to baseline stepcount.
89684846|NCT04848077|Active Comparator|Active controls|Small proportional increase in stepcount relative to baseline stepcount.
89684847|NCT05591313|Experimental|Low-intensity with longer duration (40-min) exercise (LI-40)|The participants were instructed to complete a volume-matched low-intensity with longer duration (40-min) exercise (LI-40) treatment.
89684848|NCT05591313|Experimental|Moderate-intensity with 30 min exercise (MI-30)|The participants were instructed to complete a volume-matched moderate-intensity with 30 min exercise (MI-30) treatment.
89684849|NCT05591313|Experimental|High-intensity with shorter duration (16-min) exercise (HI-16)|The participants were instructed to complete a volume-matched high-intensity with shorter duration (16-min) exercise (HI-16) treatment.
89684850|NCT05591313|No Intervention|Control treatment (CON)|The participants in the control treatment (CON) were instructed to complete book reading for 30-min.
89684851|NCT05590299|Active Comparator|Fish oral immunotherapy|Fish oral immunotherapy to be taken daily for 12 months.
89684852|NCT05590299|Placebo Comparator|Placebo|Placebo oral immunotherapy to be taken daily for 12 months.
89684853|NCT05458713|Experimental|PC6 High Energy group|The participants of this group will be irradiated with a 4mm probe for 60 seconds with an output power of 100mW on PC6 (acupoint Neiguan).
89684854|NCT05458713|Experimental|PC6 Low Energy group|The participants of this group will be irradiated with a 4mm probe for 20 seconds with an output power of 100mW on PC6 (acupoint Neiguan).
89684855|NCT05458713|Placebo Comparator|PC6 Placebo group|The participants of this group will be irradiated with a 4mm probe for 0 seconds with an output power of 100mW on PC6 (acupoint Neiguan).
89684856|NCT05458713|Active Comparator|BL65 High Energy group|The participants of this group will be irradiated with a 4mm probe for 60 seconds with an output power of 100mW on BL65 (acupoint Shugu).
89684857|NCT05458713|Active Comparator|BL65 Low Energy group|The participants of this group will be irradiated with a 4mm probe for 20 seconds with an output power of 100mW on BL65 (acupoint Shugu).
89684858|NCT05458713|Sham Comparator|BL65 Sham group|The participants of this group will be irradiated with a 4mm probe for 0 seconds with an output power of 100mW on BL65 (acupoint Shugu).
89684859|NCT00355485|Experimental|Microdermabrasion Treatment|Bilateral, split-face comparison in which one half of the face will be randomly assigned to receive the microdermabrasion treatment(s) while the other half of the face will not. Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart. In all cases, microdermabrasion treatment parameters will be within those accepted in cosmetic work.
89684860|NCT05660915|Experimental|The intermediate approach|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
89684861|NCT05660915|Other|The standard approach|The area between superior mesenteric artery and superior mesenteric vein was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
89053066|NCT03451890|Experimental|Cohort 4: E2730 160 mg|Participants will receive a single oral dose of E2730 160 mg under fasted conditions.
89053067|NCT03451890|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
89053068|NCT03451812||prostate cancer|The newly diagnostic number for the high-risk PCa patients in our hospital annually is ~70, it is clinically feasible to recruit 40 patients a year since the study begins. The study could be completed in 3 years with 120 cases.
89053069|NCT00569114|Other|1|
89053070|NCT03452904|Experimental|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
89053071|NCT03452904|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
89053072|NCT03451695|Experimental|Morphine group|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
89053073|NCT03451695|Placebo Comparator|Placebo group|Placebo group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1 ml).
89053074|NCT00569465|Placebo Comparator|A|
89053075|NCT00569465|Experimental|B|
89053076|NCT00569504||A, observatoin|inpatients and outpatients in Seoul National Hospital
89053077|NCT00583986|Experimental|1|Levalbuterol HFA MDI with top mounted actuation indicator
89053078|NCT00569621|Experimental|1|
89053079|NCT00569621|Placebo Comparator|2|
89053080|NCT03451617|Other|Xpedition stent delivery system|
89053081|NCT03451617|Other|Alpine stent delivery system|
89053082|NCT00569699|Experimental|1|S-1, Bevacizumab
89053083|NCT00569738||A|patients with neuroendocrine tumors
89053084|NCT00569816|Active Comparator|Group 1|Propofol as the primary anesthetic
89053085|NCT00569816|Experimental|Group 2|Sevoflurane administered continuously after induction of anesthesia until initiation of cardiopulmonary bypass.
89053086|NCT00569816|Experimental|Group 3|Sevoflurane administered repetitive up to 1 MAC from induction of anesthesia until initiation of cardiopulmonary bypass. Wash in and wash out performed twice.
89053087|NCT04580576||Female group|Pediatric female patients undergoing hematopoietic stem cell transplantation
89684862|NCT04812509|Experimental|MW032|MW032 injection(120mg) was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
89053088|NCT04580576||Male group|Pediatric male patients undergoing hematopoietic stem cell transplantation
89053089|NCT00569894||2|TIV
89053090|NCT00569894||1|FluMist
89053091|NCT00569894||3|Unvaccinated
89053092|NCT00569933|Other|A/B/C|Patients are randomized to voice/music/ or no CD
89053093|NCT04574661|Active Comparator|Static stretching|Static stretching to lower limb muscles
89053094|NCT04574661|Experimental|Intermittent occlusion|Intermittent occlusion to lower limb
89053095|NCT00570011|Experimental|1|
89053096|NCT00570011|Experimental|2|
89053097|NCT04574388|Active Comparator|open label placebo|participants will take open label placebo pills TID and in conjunction with other PRN analgesics
89053098|NCT04574388|No Intervention|treatment as usual|participants will take PRN analgesics as usual
89053099|NCT04581122|Experimental|Selective lymphadenectomy|
89053100|NCT04581122|No Intervention|Systematic lymph node dissection|
89053101|NCT00570050|Experimental|Intranasal Insulin nasal spray|
89053102|NCT00570050|Experimental|Placebo nasal spray (i.e., no active treatment)|
89053103|NCT00584103|Experimental|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
89053104|NCT00584103|Other|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
89053105|NCT00570167|Active Comparator|2|Total cementless hip arthroplasty with metal-on-metal bearings
89053106|NCT00570167|Active Comparator|1|Hip resurfacing
89053107|NCT00584142|Experimental|1|
89053108|NCT00584142|No Intervention|2|
89053109|NCT00570206|Experimental|1|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
89053110|NCT00570206|No Intervention|2|Probation officers who are interested in Motivational Interviewing, but have not yet been trained to use it while conducting meetings with probationers.
89053111|NCT00570206|No Intervention|3|Treatment as usual. Regular probation officers conduct standard meetings with probationers.
89053112|NCT00584181||Lung transplant recipients|Lung transplant recpients enrolled as study subjects will undergo pulmonary function tests (spirometry and lung volume measurements) and initial HRCT of chest. These subjects will receive nebulized ipratropium followed by pulmonary function tests (spirometry and lung volume measurements) and repeat HRCT.
89684863|NCT04812509|Active Comparator|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
89684864|NCT00810095|Experimental|Treatment Arm|
89684865|NCT05446623|Active Comparator|Opioid free anesthesia (OFA)|The patients included in the OFA group will receive a bolus of Dexmedetomidine at the beginning of the surgery.
89684866|NCT05446623|Sham Comparator|anesthesia with opioid (OA)|The one in the OA group will be given a bolus of Sufentanil before and during the surgery. When the specific sequence will be completed, the care of all the patient will return to usual.
89684867|NCT04383899||Case patient|Patients from the cohort with severe coronavirus infection necessitating intensive care (artificial ventilation) with ulterior recovery or fatal outcome.
89684868|NCT04383899||Control patient|All patients from the cohort with non-severe coronavirus infection, who were not admitted to hospital or who were admitted to hospital but without the need for intensive care, and who recovered.
89684869|NCT00792077|Experimental|Sleep time|"Assessment of patients with chronic lymphocytic leukemia (CLL) experience severe cancer related fatigue (CRF):~Lenalidomide + Actigraph + Questionnaire + Sleep Test"
89684870|NCT02979015|Experimental|Alirocumab|Subcutaneous injection of a single dose of alirocumab, dose level according to ascending dose design
89684871|NCT02979015|Placebo Comparator|Placebo|Subcutaneous injection of a single dose of matching placebo
89684872|NCT04693767||Patients with ischemic stroke|
89684873|NCT04693767||Patients with intracranial hematoma|
89684874|NCT05583123|Experimental|OPZAs group (OG)|one-piece zirconia abutments (OPZAs)
89053113|NCT00570245|No Intervention|A|Neither donors or recipients will receive NO
89053114|NCT00570245|Active Comparator|B|Donor will not receive NO, recipient will receive up to 48 hours of NO
89053115|NCT00570245|Active Comparator|C|The donor will receive NO for 3 hours and the recipient will receive NO for up to 48 hours
89053116|NCT04574544|Experimental|Zinc supplementation|The 25 supplemented children had received an oral dose of 10 mg of zinc sulphate per day for 14 days
89053117|NCT04574544|Experimental|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
89053118|NCT00570284|Experimental|LBH589|
89053119|NCT00570440|Experimental|A|
89053120|NCT00570440|Active Comparator|B|
89053121|NCT00570479|Active Comparator|1|50 mgs of anecortave acetate (0.5 ml of a 10% suspension)
89053122|NCT00570479|Active Comparator|2|Patients will receive 30 mgs of anecortave acetate (0.5 ml of a 6% suspension)
89053123|NCT00570479|Active Comparator|3|Patients will receive 24 mgs of anecortave acetate (0.4 ml of a 6% suspension)
89053124|NCT00570479|Active Comparator|4|Patients will receive 12 mgs of anecortave acetate (0.2 ml of a 6% suspension)
89053125|NCT00570518||1|randomly stopped drivers of motorised vehicles and bicycles
89053126|NCT00570518||2|drivers of motorised vehicles and bicycles injured or killed in road traffic accidents
89053127|NCT04574622|Experimental|Five true ESWT sessions|"A total of five sessions (1x/week) were conducted.~A total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
89053128|NCT04574622|Experimental|Three true ESWT sessions and two sham ESWT sessions|"A total of three true ESWT (week 1, 3 and 5) and two sham ESWTs in (week 2 and 4) were conducted.~For true ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars.~For sham ESWT sessions, a total of 1,500 pulses were delivered to each gastrocnemius muscle with a 1 cm gap between between the probe and subject's skin. The energy flux density was constant at 0.1 mJ/mm2 and the repetition frequency was at 4 Hz, with a pressure of 1.5 bars."
89053129|NCT00584298|Experimental|1|
89053130|NCT00584298|Placebo Comparator|2|
89053131|NCT00584337||1|
89053132|NCT00584337||2|
89053133|NCT00570557|No Intervention|Group A Nurses|Participants receive neither web-based refresher courses nor periodic feedback by SLP
89684875|NCT05583123|Active Comparator|TPZAs group (TG)|two-piece zirconia abutments (TPZAs) with friction-fitted titanium bases
89684876|NCT04382417||Covid-19|Patients with verified or highly suggestive Covid-19 diagnosis and Intensive Care treatment.
89684877|NCT00799643|Active Comparator|1|Salsalate, 3.5 g/d orally, divided dosing
89684878|NCT00799643|Placebo Comparator|2|Salsalate Placebo, orally, divided dosing
89684879|NCT03835013|Placebo Comparator|Part A - Infusion A|"60 minute intravenous infusion of 0.9% saline~Followed by:~60 minute intravenous infusion of 0.9% saline"
89684880|NCT03835013|Active Comparator|Part A - Infusion B|"60 minute intravenous infusion of glucagon 25ng/kg/min and 0.9% saline.~Followed by:~60 minute infusion of glucagon 50ng/kg/min and 0.9% saline"
89684881|NCT03835013|Active Comparator|Part B - Infusion A|A 60 minute intravenous infusion of 0.9% saline
89684882|NCT03835013|Active Comparator|Part B - Infusion B|A 60 minute intravenous infusion of exenatide (50ng/min for 30 minutes followed by 25ng/min) and 0.9% saline
89684883|NCT03835013|Active Comparator|Part B - Infusion C|A 60 minute intravenous infusion of glucagon (25ng/kg/min) and 0.9% saline
89684884|NCT03835013|Active Comparator|Part B - Infusion D|A 60 minute intravenous infusion of exenatide (50ng/min for 30 minutes then 25ng/min) and glucagon (25ng/kg/min)
89684885|NCT05568303|Experimental|study ( interventional ) group|this group received 8 sessions of CBT
89684886|NCT05568303|No Intervention|Control group|they will receive on intervention sessions or any education researchers makes meeting every month to answer any questions and to maintain continuity of relation with participants
89684887|NCT05553561|Active Comparator|IRPL Therapy|17 patients with moderate to severe evaporative dry eye disease will treated with 3 sessions of IRPL therapy.
89684888|NCT05553561|Active Comparator|Non IRPL Therapy|17 patients with moderate to severe evaporative dry eye disease will treated with traditional methods of MGD
89684889|NCT04499157|Experimental|MEMOPTIC added to the usual treatment of glaucoma|MEMOPTIC added to the usual treatment of glaucoma
89684890|NCT04499157|Active Comparator|usual treatment of glaucoma|usual treatment of glaucoma
89684891|NCT00800345|Experimental|Experimenal|Metronomic oral topotecan and oral pazopanib will be administered by mouth beginning on Cycle 1 Day 1. Patients will be enrolled and observed for dose limiting toxicity (DLT) for 1 cycle of treatment. Dose modification of the combination will depend on the number of patients experiencing DLT(s) at each dose level.
89684892|NCT04479111|Experimental|LISRH group|Following the principle of complete mesocolic excision(CME), Ileocecus-Sparing Right colectomy refers to the resection of the most portion of the ascending colon, hepatic flexure and mid to distal transverse colon. The extent of lymph node dissection and length of distal resection margin are similar to conventional right hemicolectomy. The length of proximal resection margin varies.
89684893|NCT04788797|Active Comparator|Prolyl Endopeptidase|Patients blinded-receive active AN-PEP at a dose of 2 capsules/breakfast, lunch and dinner during 8 weeks (study arm)
89684894|NCT04788797|Placebo Comparator|Placebo|Patients blinded-receive 2 capsules of a placebo (specially designed and prepared for the study) at breakfast, lunch and dinner during 8 weeks (Placebo arm).
89684895|NCT03806751|Experimental|[O-15]water PET/MRI|Volunteers will have two brain PET/MRI scans; first scan after injection of [O-15]water; second scan after injection of 1 gram of acetazolamide followed by injection of [O-15]water.
89684896|NCT04383353||Cancer arm|Participants with new diagnosis of cancer, from whom a blood sample and contemporaneous tissue samples will be collected.
89684897|NCT04383353||Benign disease arm|Participants with benign diseases corresponding to the tumor types in the cancer arm, from whom a blood sample and contemporaneous tissue samples will be collected.
89684898|NCT04383353||Non-tumor arm (Healthy)|Participants with no known presence of malignancies or benign diseases, from whom a blood sample will be collected.
89684899|NCT04383197|Experimental|Semaglutide treatment|3 months of therapeutic semaglutide treatment
89684900|NCT04383197|Experimental|Semaglutide and Endurance exercise|12 weeks of endurance exercise concomitant to semaglutide treatment
89684901|NCT04383197|Experimental|Endurance exercise|12 weeks of endurance exercise
89684902|NCT04445493||Device: MindRhythm Harmony|Passive recording of the head pulse
89053134|NCT00570557|Experimental|Group B Nurses|Participants receive web-based skill refresher courses but no periodic feedback by SLP
89053135|NCT04580264|Experimental|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
89053136|NCT00584376|Active Comparator|1|Pregabalin
89053137|NCT00584376|Placebo Comparator|2|Placebo
89053138|NCT00570830|Other|1|single armed case series in which all patients underwent the same treatment.
89053139|NCT00570869|Active Comparator|CPR Class|mothers who are currently certified in CPR (i.e., have taken the traditional CPR class, or have been recertified in CPR by classroom instruction, within the past two years).
89684903|NCT04009811|Experimental|Suersen obturator then membraneous obturator|
89684904|NCT04009811|Experimental|Membraneous obturator then Suersen obturator|
88820624|NCT05884099|Experimental|Intercostal cryoanalgesia AND single-injection paravertebral block|"Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery~Cryoanalgesia 5 cm lateral to the neuraxial, on the inferior costal border, CO2 at (-)50C to (-)70C for 2 minutes, repeated on 7 costal levels (T3-T9), after the lung resection and before chest closure."
89053140|NCT04574310||Frozen embryo transfer (FET)|Collect retrospectively data on embryo implantation rate
89684905|NCT03796065|Experimental|FSI-R Treatment|Families randomized into the FSI-R Treatment arm will receive the 10-module Family Strengthening Intervention in addition to any outside services or programs they are participating in.
89053141|NCT04574310||Intracytoplasmic sperm injection (ICSI)|Collect retrospectively data on embryo implantation rate
89053142|NCT04574310||oocyte donation|Collect retrospectively data on embryo implantation rate
89053143|NCT00570947|Active Comparator|Class|The control group will be advised to take a traditional CPR class and be offered a list of local classes.
89053144|NCT00571025|Experimental|1|AD risk assessment based on family history and APOE genotype
89053145|NCT00571025|Active Comparator|2|AD risk assessment based on family history alone
89053146|NCT04573959|Experimental|SV-3 Capsule Endoscopy|CapsoCam SV-3 Capsule Endoscopy system will perform in a manner consistent with the performance of the CapsoCam SV-3 capsule endoscopy systems.
89053147|NCT04580342|Experimental|Ivabradine group|
89053148|NCT04580342|Experimental|propranolol group|
89053149|NCT00571142|Active Comparator|1|Renal disease
89053150|NCT00571142|Active Comparator|2|Without renal disease
89053151|NCT03453905|Experimental|CTFEA|Decision on preventive surgery vs follow-up will be based on expert judgement, Mirels' score and CTFEA
89053152|NCT03453905|Other|Mirels|Decision on preventive surgery vs follow-up will be based on expert judgement and Mirels' score
89684906|NCT03796065|No Intervention|FSI-R Control|Families randomized into the FSI-R Control arm will not receive the FSI-R treatment. Instead, they will continue with their usual care, referred to as Treatment as Usual (TAU).
89684907|NCT03973229|Experimental|Cohort 1: PTSD Receiving Estradiol then Placebo|Participants with PTSD will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
89684908|NCT03973229|Experimental|Cohort 1: PTSD Receiving Placebo then Estradiol|Participants with PTSD will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
89684909|NCT03973229|Active Comparator|Cohort 1: Trauma without PTSD Receiving Estradiol then Placebo|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
89684910|NCT03973229|Active Comparator|Cohort 1: Trauma without PTSD Receiving Placebo then Estradiol|Participants with trauma exposure will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
89684911|NCT03973229|Active Comparator|Cohort 1: Healthy Controls Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will record their first cycle with the Clue app. They will receive the estradiol patch during the second cycle, and the placebo patch during the third cycle.
89684912|NCT03973229|Active Comparator|Cohort 1: Healthy Controls Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will will record their first cycle with the Clue app. They will receive the placebo patch during the second cycle, and the estradiol patch during the third cycle.
89532945|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in 1L NPM1-m (A-4)|Ziftomenib/Venetoclax/Azacitidine in newly diagnosed NPM1-m AML patients
89532946|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in R/R KMT2A-r (B-1)|Ziftomenib/Venetoclax/Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy
89532947|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/7+3 in 1L KMT2A-r (B-2)|Ziftomenib/7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy
89532948|NCT05735184|Experimental|Dose Validation/Expansion: Ziftomenib/Venetoclax/Azacitidine in 1L KMT2A-r (B-3)|Ziftomenib/Venetoclax/Azacitidine in newly diagnosed KMT2A-r AML patients
89532949|NCT05732779|Experimental|eMocha intervention|Adolescent patients randomized to the use of asynchronous mobile video directly observed therapy (DOT) intervention (eMocha DOT app)
89532950|NCT05732779|No Intervention|Standard of care|Adolescent patients who continue enhanced goal-setting standard of care
89532951|NCT05727904|Experimental|Arm A|Lifileucel plus Pembrolizumab
89532952|NCT05727904|Active Comparator|Arm B|Pembrolizumab alone with Optional Crossover Period
89532953|NCT05727735|Active Comparator|Medtronic Signia Stapler|Patients randomized to this arm will undergo RTS segmentectomy with the Medtronic Signia Stapler.
89532954|NCT05727735|Experimental|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|Patients randomized to this arm will undergo RTS segmentectomy with the Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling.
88997954|NCT04741919|Active Comparator|Superior LPI placement|Each participant will be randomized to receive an LPI placement superiorly in one eye.
88997955|NCT04741919|Active Comparator|Temporal LPI placement|Each participant will be randomized to receive an LPI placement temporally in one eye.
88997956|NCT04735627|Experimental|Levodopameter|During the single study visit, participants will receive either: 1) one doses of oral carbidopa/ levodopa. The Levodopameter sensor device will serially measure levodopa levels from either capillary blood, sweat, or interstitial fluid and blood will be simultaneously collected from an intravenous line for high-performance liquid chromotography analysis of plasma levodopa levels.
88997957|NCT04716699|Experimental|Health services research (lidocaine, surgery)|Patients receive bolus lidocaine IV per standard of care. After intubation, patients receive another infusion of lidocaine IV over 4 hours or until the end of surgery. Patients also undergo collection of blood and tumor samples at the start of surgery and hourly afterwards until a total of 4 samples are collected.
88997958|NCT04702191|Experimental|Triple P (Positive Parenting Program)|Triple P - level 4 group: All 600 participants will undergo screening and a baseline assessment before randomization. Once randomized, the Triple P group (n=200) will be provided with 8-week group/individual sessions.
88997959|NCT04702191|Experimental|Circle of Security Parenting|Circle of Security - Parenting (COS-P): Once randomized to the COSP group (n=200), caregivers will be provided with an 8-week group session.
88997960|NCT04702191|No Intervention|Treatment As Usual|Treatment as usual: Caregivers randomized to this arm (n=200) will receive either a different program, or brief services depending on the organization.
88997961|NCT04685980||Failed spinal anaesthesia group|Failed spinal anaesthesia: failure of anaesthetic level of blockade both sensory and motor blockage, and consequently receive general anaesthesia
88997962|NCT04685980||Control Group|Patient receiving spinal anaesthesia and successfully finish the cesarean section
88997963|NCT04632420||Women with child birth|Women attending chronic pain clinic who have previously experienced childbirth
88997964|NCT04632420||Women without childbirth|Women attending chronic pain clinic who have not previously experienced childbirth
88997965|NCT04627974||ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
88997966|NCT04626934|Active Comparator|control group|Patients in the control group will recieve conventional occupational therapy treatment: 3 weeks of all together 12 sessions, 45 minutes each.
88997967|NCT04626934|Experimental|Intervention group|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
88997968|NCT04603209||IORT|All participants who plan to undergo partial mastectomy for treatment of early stage breast cancer will be considered for eligibility for IORT. Patient with single breast cancer less than 3cm in disease span, clinical negative axillary node will be offered the option of having IORT. If IORT is delivered following surgical resection of the tumor they will be followed in this registry for short and long term outcomes.
88997971|NCT04577690|Experimental|PECS block|A PECS block of 0.25 % bupivacaine with epinephrine 1:200000 (below the toxic dose limit of 3 mg/kg) in divided doses to cover the fascial planes identified in PECS I and PECS II. At the completion of surgery, the wound will be infiltrated with up to 0.2 ml/kg of 0.25 % bupivacaine into the wound.
88997972|NCT04577690|Active Comparator|Infiltration|At the completion of surgery, the EP cardiologist will infiltrate the wound with up to 0.8 ml/kg of 0.25 % bupivacaine with epinephrine 1:200000.
88997973|NCT04549181|No Intervention|Phase I: Qualitative|Rural HF dyads will participate in a one-time telephone-based semi-structured interview to explore the types of HF-related problems that rural HF dyads experience and how these problems are managed.
88997974|NCT04549181|Experimental|Phase II: Problem-Solving for Rural HF Dyads|The dyadic problem-solving intervention will be provided by a HF specialist nurse. The nurse will conduct the initial telehealth (virtual, telephone) session and provide dyads with an intervention booklet containing examples of common HF-related problems experienced by rural dyads and suggested management strategies tailored to the rural sociocultural context. The nurse will lead dyads in a card sorting task intended to help dyads prioritize current HF-related problems and will guide dyads in developing management strategies for the highest priority problem. Dyads will utilize these strategies until the next session at which time the nurse will guide dyads in evaluating the effectiveness of chosen strategies. The iterative process then begins again. Dyads will receive 7 follow-up telephone sessions with the nurse. In the intervention, the nurse will focus on problems related to self-care, including those specific to the rural population.
88997975|NCT04547816|Experimental|biofeedback and tibial neuromodulation (BFB+TNM)|
89684913|NCT03973229|Experimental|Cohort 2: PTSD Receiving Estradiol then Placebo|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
89684914|NCT03973229|Experimental|Cohort 2: PTSD Receiving Placebo then Estradiol|Participants with PTSD will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
89684915|NCT03973229|Active Comparator|Cohort 2: Trauma Control Receiving Estradiol, then Placebo|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
89684916|NCT03973229|Active Comparator|Cohort 2: Trauma Control Receiving Placebo then Estradiol|Participants with trauma exposure will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
89684917|NCT03973229|Active Comparator|Cohort 2: Healthy Control Receiving Estradiol then Placebo|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the estradiol patch before getting the MRI. They will apply the placebo patch during the third cycle.
89684918|NCT03973229|Active Comparator|Cohort 2: Healthy Control Receiving Placebo then Estradiol|Participants without trauma history or psychiatric disorder will begin daily urine ovulation tests on Day 11 of their first cycle, and will record the results with the Clue app. During the second month of cycle monitoring, the MRI will be scheduled 5-7 days after they record a positive ovulation test (during luteal phase) and they will use the placebo patch before getting the MRI. They will apply the estradiol patch during the third cycle.
89684919|NCT03782103|Experimental|ZuraPrep (70% IPA)|Isopropyl alcohol (IPA) 70%
89053153|NCT00584571|Active Comparator|Sensory Adaptation training|a large compliant balloon is placed in the rectum attached to a barostat. The balloon is distended in 1 mm increments until patient reports moderate discomfort and then increased in 1 mm increments until maximum tolerable pressure. Gradually over 6 training sessions, administered biweekly, the maximum tolerable pressure is increased over 3 months, if treatment is successful.
89053154|NCT00584571|Experimental|Escitalopram Therapy|Patients randomized to this arm will receive daily 10 mg escitalopram for 3 months. If the medication is effective their bowel symptoms and pain thersholds will improve.
89053155|NCT03451500|Experimental|Carbidopa-levodopa 2 tablets daily|carbidopa-levodopa 25-100 mg 2 tablets daily hs
89053156|NCT03451500|Experimental|carbidopa-levodopa 6 tablets daily|carbidopa-levodopa 25-100 mg, 2 tablets, 3 times daily, with breakfast, with supper and hs
89053157|NCT03451500|Placebo Comparator|Placebo|Placebo, 2 tablets, 3 times daily, with breakfast, with supper and hs
89053158|NCT04580108||Patients with systemic lupus erythematosus|Patients with systemic lupus erythematosus enrolled in the PLUS cohort between 2007 and 2010
89053159|NCT00571181|Experimental|1|
89053160|NCT00571181|Active Comparator|2|
89053161|NCT00584610|Experimental|1|Levonorgestrel-containing intrauterine device insertion
89053162|NCT00584610|Active Comparator|2|Copper containing intrauterine device
89053163|NCT00571220||Gastric bypass surgery|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
89053164|NCT00571220||Diet induced weight loss|Diet group of obese patient with type 2 diabetes, matched with the surgical group for diabetes duration, diabetes control (HbA1C), BMI, age.
89684920|NCT03782103|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
89684921|NCT03782103|Placebo Comparator|ZuraPrep Vehicle|Zurex Prep without IPA
89053165|NCT00584649|Other|Single Group Assignment|electrophysiology study and radiofrequency ablation
89053166|NCT00571298|Experimental|Extrapleural pneumonectomy (EPP)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
89053167|NCT00571298|Experimental|Pleurectomy/Decortication (P/DC)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
89053168|NCT00571298|Experimental|Tumor Debulking (TD)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
89053169|NCT04574271|Experimental|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
89684922|NCT00810719|Experimental|Gemcitabine and Erlotinib|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.Erlotinib will be dosed at 150mg orally (tablets) on days 2-5, 9-12, and 16-26 of a 28 day cycle.
88997976|NCT04547816|Experimental|BFB+TNM + pelvic floor muscles training (PFMT)|
88997977|NCT04547816|Experimental|BFB+TNM+PFMT+diet modification|
88997978|NCT04531176|Experimental|Obesity-centric approach + AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately two years. After discussing with the study doctor, participants will receive one of the following listed 4 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) phentermine/topiramate extended-release, 3) naltrexone/bupropion extended-release and 4) liraglutide 3.0 mg
88997979|NCT04531176|Experimental|Obesity-centric approach without AOM|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately two years.
88997980|NCT04531176|Active Comparator|Usual care approach (Comorbidity-centric approach)|Participants will receive the traditional usual care/standard of care approach to T2D, hypertension, hypercholesterolemia management for approximately two years.
88997981|NCT04456946|Experimental|Group of Low Level Laser Therapy|
88997982|NCT04456946|Experimental|Group of Occlusal Splint Treatment|
88997983|NCT04409860|Active Comparator|control group|In this group, observation is given after CCRT.
88997984|NCT04409860|Experimental|trial group|In this group, adjuvant chemotherapy is given after CCRT.
88997985|NCT04391335||Group 1|Participants who meet the screening criteria for the development of bronchiolitis obliterans syndrome (BOS) according to the NIH criteria
88997986|NCT04391335||Group 2|Participants who may or may not have abnormal spirometry; however they do not fulfill the NIH criteria for the development of BOS
88997987|NCT04360746|Active Comparator|Clinical pharmacist intervention group|"all hip fractured patients admitted to D1 subunit in Beit rivka geriatric rehabilitation center. This group will get a clinical pharmacist review of their medication and a pharmaceutical counseling to the medical staff in the first few days of admission (1-5 days post admission)"
88997988|NCT04360746|Other|control group|"The control group will include all hip fractured patients admitted to D2 subunit in Beit rivka geriatric rehabilitation center. This group will not receive any pharmacist intervention during their rehabilitation."
88997989|NCT04312867|Experimental|Project STRONG|Project STRONG is an active skill-based intervention designed to prevent adolescent dating violence among middle school boys. Boys and a parent will complete the web-based program together focusing on improving communication and emotion regulation.
88997990|NCT04312867|Active Comparator|Health Promotion|Health Promotion is an information-based program designed to mimic content areas provided during middle-school health education. The content is provided via a web-based interface to mirror the content delivery in the active intervention (Project STRONG).
88997991|NCT04303559|Active Comparator|Eloctate|Arm A: Eloctate 65 IU/kg will be administered weekly by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued up to 48 weeks.
88997992|NCT04303559|Experimental|Emicizumab|Arm B: Emicizumab 1.5 mg/kg will be administered weekly by subcutaneous injection (following 3 mg/kg/wk x4 induction) in previously untreated children with severe hemophilia A beginning before the first bleed and continue up to 48 weeks.
88997993|NCT04303390|Active Comparator|24 hour Cefuroxime arm|25% of the entire study participants are assigned to 24 hours and second generation cephalosporin
88997994|NCT04303390|Active Comparator|24 hour Cefazolin arm|25% of the entire study participants are assigned to 24 hours and first generation cephalosporin
88997995|NCT04303390|Active Comparator|48 hour Cefuroxime arm|25% of the entire study participants are assigned to 48 hours and second generation cephalosporin
88997996|NCT04303390|Active Comparator|48 hour Cefazolin arm|25% of the entire study participants are assigned to 48 hours and first generation cephalosporin
88997997|NCT04282967|Experimental|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
88997998|NCT04234139||Retrospective Cohort|Early Liver Transplantation (ELT) for patients who presented with Severe Alcoholic Hepatitis (SAH)
88997999|NCT04234139||Prospective Cohort 1|Early Liver Transplantation (ELT) for patients who present with Severe Alcoholic Hepatitis (SAH)
88998000|NCT04234139||Prospective Cohort 2|Orthotopic Liver Transplantation (OLT) in patient who present with Alcoholic Liver Disease (ALD)
88998001|NCT04230785||AIS before EVT group|This group includes patients with acute ischemic stroke (AIS) before endovascular treatment (EVT)
88998002|NCT04230785||AIS after EVT group|This group includes patients with acute ischemic stroke (AIS) after endovascular treatment (EVT)
89684923|NCT03835845|Experimental|PICO7Y|PICO 7Y is a single-use NPWT System consisting of a small portable pump & pump clip, 2 AA batteries, 2 large multisite dressings, 2 extension tubes and secondary fixation strips.
89684924|NCT04369443|No Intervention|MANH|
89684925|NCT04369443|Experimental|LANH|
89684926|NCT03761277|Other|Intrathecal Therapy|Enrolled subjects who successfully wean from all systemic opioids and have a successful intrathecal trial, proceed to the intervention phase. This includes implantation with a SynchroMed™ II infusion system in the intrathecal space for targeted drug delivery of preservative-free morphine sulfate (PFMS).
89684927|NCT00810797|Experimental|Treatment (exemestane)|Patients receive oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89684928|NCT03955913||Participants with Urothelial Cancer,selected FGFR aberrations|Participants with urothelial cancer (UC) will be evaluated for the prevalence of positive results of selected fibroblast growth factor receptor (FGFR) aberrations and will be assessed for eligibility status for erdafitinib studies. The primary data source for this study will be the medical records of each participant.
89684929|NCT00355641|Experimental|Open Label|All subjects will receive ropinirole XR in this study. The total daily dose range of ropinirole XR will be 0.5mg to 6.0mg daily
89684930|NCT04624763|Experimental|LBBP group|In this arm, a left bundle branch pacing(LBBP) lead is attempted to be placed.
89684931|NCT04624763|Active Comparator|RVP group|In this arm, a right ventricular pacing(RVP) lead are placed.
89684932|NCT00356733|Experimental|EPO rise|EPO administration
89684933|NCT00356733|Experimental|EPO stable|EPO and stable Hemoglobin
88998003|NCT04185298|Active Comparator|Group 1 (No treatment)|Group 1: Participants will have continuous activity monitoring (via Fitbit)
88998004|NCT04185298|Experimental|Group 2 (Experimental)|Group 2: Participants will receive the mSIM treatment and have their activity monitored continuously (via Fitbit)
88998005|NCT04175691||AIS group|This group includes patients with acute ischemic stroke (AIS).
88998006|NCT04175691||HC group|This group includes healthy controls (HC).
88998007|NCT04165746|Experimental|Enhanced Institutional Care|"Caregivers at institutions will participate in a caregiving training, called Video Feedback Intervention to Promote Positive Parenting (VIPP). During VIPP a trained interventionist meets with a caregiver and child in the home environment.~The VIPP Interventionist will meet with caregivers and children for 5, 2-hours sessions over 6-8 weeks to discuss recordings of children and their caregivers. As described above, the sessions will focus on creating a positive atmosphere by reinforcing positive interactions."
88998008|NCT04165746|Experimental|Enhanced Foster Care|"Foster parents will be recruited, consented to background checks, and trained in Portuguese. Hired foster parents will supported and monitored by project social workers and psychologists from local Foster Care programs. Foster parents will received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Project social workers will consult weekly with US staff experienced in dealing with young children in foster care.~Additionally, foster parents will participate in the VIPP caregiving training, in the same format as that described in the Enhanced Institutional Care Arm: the VIPP Interventionist will meet with caregivers and children for 5, 2-hours sessions over 6-8 weeks to discuss recordings of children and their caregivers. As described above, the sessions will focus on creating a positive atmosphere by reinforcing positive interactions."
88998009|NCT04119713||Study Population|Adult patients with a diagnosis of cancer receiving checkpoint inhibitor therapy at the University of Pennsylvania's Abramson Cancer Center (ACC).
88998010|NCT04092946|Experimental|Patients with musculoskeletal disorders|Tailored digital programs for individuals working for organizations that enter into a commercial agreement with SWORD Health, which acts as a service provider.
89684934|NCT00356733|No Intervention|control|standard treatment
89684935|NCT04591925|Experimental|"Investigative Device - SteadiSet™ device with coil-reinforced soft polymer indwelling cannula"|Participants are randomized into the investigational device (SteadiSet™) insulin infusion set group and then switched to a Commercially available infusion set (using a soft Teflon indwelling cannula) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the investigational infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Control device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
89216489|NCT03445494|Experimental|Brace|After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night
88998011|NCT04091165||Study Group|"Participants will be identified for inclusion by leaders of the GI Clinic after GI surgery has been scheduled. Upon consenting, participants will be instructed how to download and use the mobile phone application My Plate Calorie Counter."
88998012|NCT04088149|Experimental|GXNPC1|"There are 2 dose levels Cohort 1: Low dose (1 ± 0.1 × 10^8 GXNPC1) of IPs will be administered in parallel.~Cohort 2: High dose (2 ± 0.2 × 10^8 GXNPC1) of IPs will be administered sequentially."
88998013|NCT04075110|Placebo Comparator|Control group|50 patients will receive metformin up to 2000mg/daily (Control group)
88998014|NCT04075110|Experimental|Montelukast group|50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).
88998015|NCT04067479|Experimental|Young|"21-30 year old men and women Inclusion/Exclusion Criteria~All subjects will be sedentary or recreationally active (sedentary: one day or less per week of aerobic or resistance exercise for at least a year or recreationally active: not training for competitive events).~Age: 21-30 years~Body mass index <35 kg•m-2,~Chronic users of medications such as acetaminophen, ibuprofen, or prescription cyclooxygenase inhibitors will be excluded as these medications have been shown to alter tendon physiology.~Individuals with diabetes will be excluded. Diabetes is thought to change the structure of tendon.~Individuals with a history of tendon pain will be excluded, as chronic tendon pain is associated with changes in the structure of tendon.~Persons with allergies/sentivitiy to amino acids or ingedianet of Cystal Light will be excluded."
89053170|NCT04574271|Active Comparator|Usual dietary advice and exercise prescription|Generalized dietary advice and exercise prescription in elder subjects.
89053171|NCT00571376||1|Those exposed to health information technology or health information exchange
89053172|NCT00571376||2|Those not exposed to health information technology or health information exchange
89216490|NCT03445494|Experimental|Normal sling|After surgery the patient must wear the normal sling for two weeks
89216491|NCT03443856|Other|chemotherapy arm|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
89216492|NCT03443856|Experimental|immunotherapy arm|Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.
89216493|NCT03418753||single|subjects with abnormal intracranial pressure
88998016|NCT04067479|Experimental|Older Adults|"Inclusion/Exclusion Criteria~All subjects will be sedentary or recreationally active (sedentary: one day or less per week of aerobic or resistance exercise for at least a year or recreationally active: not training for competitive events).~Age: 60-75 years~Body mass index <35 kg•m-2~Chronic users of medications such as acetaminophen, ibuprofen, or prescription cyclooxygenase inhibitors will be excluded as these medications have been shown to alter tendon physiology.~Individuals with diabetes will be excluded. Diabetes is thought to change the structure of tendon.~Individuals with a history of tendon pain will be excluded, as chronic tendon pain is associated with changes in the structure of tendon.~Persons with allergies/sentivitiy to amino acids or ingedianet of Cystal Light will be excluded."
88998017|NCT04063384|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
88998018|NCT04063384|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
88998019|NCT04055909|Experimental|nangibotide 1|Treatment with study drug at at dose of 0.3mg/kg/hr
88998020|NCT04055909|Experimental|nangibotide 2|Treatment with study drug at at dose of 1.0mg/kg/hr
88998021|NCT04055909|Placebo Comparator|Placebo|Treatment with a matched placebo infusion
88998022|NCT04013711|Experimental|Thermal Imaging|Patients will undergo non-invasive, thermal imaging of their whole breast or head and neck cancer site, during the course of the radiotherapy treatment, at weekly time intervals.
88998023|NCT03997708|Active Comparator|Group A|MED-LFD Diet (diet A) for 2 - 6 weeks. After this period there will be a reintroduction phase protocol that will last 6 - 8 weeks.
88998024|NCT03997708|Active Comparator|Group B|Diet according to guidelines from the National Institute for Health and Care Excellent (NICE) Managing IBS (diet B) for 4 weeks.
89532955|NCT05722210||Adults >= 18 years of age|undergoing evaluation for hematopoietic stem cell transplant at the NIH Clinical Center
89532956|NCT05722210||Children 3-17 years of age|undergoing evaluation for hematopoietic stem cell transplant at the NIH Clinical Center
89532957|NCT05713799|Active Comparator|MG+ALA|Participants take mirabegron + alpha lipoic acid daily for 4 weeks. There is testing pre- and post-treatment. Will evaluate the effects of MG+ALA on metabolic heath.
89532958|NCT05713799|Placebo Comparator|MG+Placebo|Participants take mirabegron + placebo daily for 4 weeks. There is testing pre- and post-treatment. Will evaluate the effects of MG+Placebo on metabolic heath.
89532959|NCT05712200|Experimental|Abelacimab (MAA868)|Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
89532960|NCT05712200|Placebo Comparator|Placebo|Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
89532961|NCT05711615|Experimental|Treatment (peposertib, liposomal doxorubicin)|Patients receive peposertib PO BID and pegylated liposomal doxorubicin hydrochloride IV QD during treatment cycles on study. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo CT or MRI throughout the trial. Patients also undergo blood sample collection and tissue biopsy during screening and on the trial.
89532962|NCT05711394|Experimental|Open-Label PK Substudy: Atogepant Dose A (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of atogepant Dose A to determine appropriate dose for the 6-11 year old group in double-blind treatment period.
89532963|NCT05711394|Experimental|Open-Label PK Substudy: Atogepant Dose B (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of atogepant Dose B to determine appropriate dose for the 6-11 year old group in double-blind treatment period.
89532964|NCT05711394|Experimental|Double-Blind Treatment Period: High Dose Atogepant (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of high dose atogepant once a day for 12 weeks.
89532965|NCT05711394|Experimental|Double-Blind Treatment Period: Placebo (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks.
89532966|NCT05711394|Experimental|Double-Blind Treatment Period: Low Dose Atogepant (12-17 yrs)|Participants aged 12 to 17 will receive oral tablets of low dose atogepant once a day for 12 weeks.
89532967|NCT05711394|Experimental|Double-Blind Treatment Period: High Dose Atogepant (6-11 yrs)|Participants aged 6-11 will receive oral tablets of high dose atogepant once a day for 12 weeks.
89532968|NCT05711394|Experimental|Double-Blind Treatment Period: Placebo (6-11 yrs)|Participants aged 6 to 11 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks.
89532969|NCT05711394|Experimental|Double-Blind Treatment Period: Low Dose Atogepant (6-11 yrs)|Participants aged 6-11 will receive oral tablets of low dose atogepant once a day for 12 weeks.
89532970|NCT05704361|Experimental|RO7121932: Dose Escalation Cohorts 1 to 6|Participants will receive a single IV dose of RO7121932 on treatment Day 1. The planned starting dose of RO7121932 is 7 milligrams (mg) and will be escalated up to 2000 mg. The maximum dose will not exceed 4000 mg. Doses may be repeated, adjusted downwards, or intermediate doses may be investigated based on emerging data.
89532971|NCT05698615|Experimental|Chess training group|group receiving additional chess training
89532972|NCT05698615|No Intervention|control group|group receiving standard therapy only
89532973|NCT05696093|Experimental|cotrimoxazole|Use of cotrimoxazole for enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.
89532974|NCT05696093|Active Comparator|standard antibiotic therapy|Use of standard antibiotic therapy enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.
89532975|NCT05695339|Experimental|Resiniferatoxin|Resiniferatoxin
89532976|NCT05694338||Major surgery for gastrointestinal cancer|Patients with gastrointestinal cancer who are scheduled for major surgery
89532977|NCT05692882|Experimental|Percutaneous transluminal angioplasty and stenting|All patients will be implanted with Drug-Eluting Stents (NOVA DES).
89053173|NCT04573803|Experimental|MAST DURATION - <3 months|TBI patients with early seizures (within first 7 days following trauma) will receive a short course of up to 3 months of either Phenytoin Sodium or Levetiracetam.
89684936|NCT04591925|Active Comparator|Commercially available Insulin Infusion device using a soft Teflon indwelling cannula|Participants are randomized into the Commercially available insulin infusion set (using a soft Teflon indwelling cannula) group and then switched to Investigative Device infusion set (SteadiSet™) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the Control infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Investigational Device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
89684937|NCT04542473|Active Comparator|Pancreatic Enzymes (PE)|"Pancreatic enzymes formulated as 5000 IE lipase, 3600 IE amylase and 200 IE protease per 100 mg of granules, packaged as sachets. The target dose is 3000 IU lipase/kg, twice daily (1440 IU/kg amylase/80 IU/kg protease), which is the dose used for children with cystic fibrosis and exocrine pancreas insufficiency. For oedematous malnutrition, weight for dosing is reduced by 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands to allow a lower range of 2000 IU/kg/day and upper range of 4000 IU/kg/day:~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)~---------------------------------------------------------------------------------------------------------- 2.50 4.99 2 10000 4000 2000 5.00 7.49 4 20000 4000 2670 7.50 9.99 6 30000 4000 3000 10.0 15.0 8 40000 4000 2667"
89684938|NCT04542473|Placebo Comparator|Placebo-PE|"Oral/enteral placebo matching active Pancreatic Enzymes (PE). Dose presentation in whole sachets of 100mg of granules. For oedematous malnutrition, weight for dosing is reduced by a pragmatic 10%. To be prescribed following enrolment and given just prior to or during a feed. Prescription will follow weight bands:~Weight from Weight to Dose Dose Upper range Lower range (Kg) (Kg) (sachets) (IU Lipase) (IU/kg/dose) (IU Lipase)~----------------------------------------------------------------------------------------------------------------------------------------- 2.50 4.99 2 Nil Nil Nil 5.00 7.49 4 Nil Nil Nil 7.50 9.99 6 Nil Nil Nil 10.0 15.0 8 Nil Nil Nil"
89684939|NCT04542473|Active Comparator|Ursodeoxycholic acid (UA)|The dose of ursodeoxycholic acid will be given at 10 mg/kg twice per day just prior to or during a feed, using a suspension of 50 mg/ml = 0.2 ml/kg. For oedematous malnutrition participants, weight is pragmatically reduced by 10%. To be prescribed and given following enrolment.
89684940|NCT04542473|Placebo Comparator|Placebo-UA|The dose of placebo will be given twice per day just prior to or during a feed at 0.2 ml/kg. To be prescribed and given following enrolment.
89684941|NCT05158595|Experimental|low intensity group|Will receive wobble board based Exergame balance training, game intensity will be low for this group (Size of goal will be kept large)
89684942|NCT05158595|Experimental|moderate intensity group|Will receive wobble board based Exergame balance training, game intensity will be low for this group (Size of goal will be kept large)
89053174|NCT04573803|Experimental|MAST DURATION - >6 months|TBI patients with early seizures (within first 7 days following trauma) will receive a longer course of at least 6 months of either Phenytoin Sodium or Levetiracetam.
89053175|NCT04573803|Experimental|MAST PROPHYLAXIS - Phenytoin Sodium|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Phenytoin Sodium as seizure prophylaxis.
89053176|NCT04573803|Experimental|MAST PROPHYLAXIS - Levetiracetam|TBI patients, without an acute symptomatic seizure, will receive a 7-day course of Levetiracetam as seizure prophylaxis. Dosing will be as prescribed clinically by the treating physician.
89053177|NCT04573803|No Intervention|MAST PROPHYLAXIS - no treatment|TBI patients, without an acute symptomatic seizure, will not receive any anti-epileptic drug.
89053178|NCT00571415||cervix cancer patients|
89053179|NCT04575441|Experimental|Pilates Ball Exercises|Various exercises are conducted with using pilates ball. Sensory feedbacks like proprioception and vestibulation are given. Many physical fitness parameters like balance, coordination, speed and agility are used in this exercise program. Children are taken to the program for 40 min, twice a week during 6 weeks.
89053180|NCT04575441|No Intervention|Without exercise|The children in this group are not included in any kind of exercise/sport program during 6 weeks.
89684943|NCT05158595|Experimental|high intensity group|Will receive wobble board-based Exergame balance training, game intensity will be high for this group (Size of goal will be kept small).
89684944|NCT05158595|Active Comparator|control group|Will receive Exer-game balance training with Wii Fit balance games
89684945|NCT04290689||Botulinum Toxin-A injection treatment|Toe walking Cerebral Palsy subject who are subject to Botulinum toxin-A injection treatment. The dosage will be determined by the Orthopaedic Consultant
89684946|NCT04290689||Serial casting stretching treatment|Toe walking Cerebral Palsy subject who are subject to serial casting stretching treatment.
89053181|NCT04573374|Active Comparator|Biodentine|Biodentine (BD; Septodont, St Maur-des-Fosses, France) is a calcium silicate capping material. Biodentine is mixed according to manufacturer's instructions and placed in a 2-3 mm layer above the pulp tissue using an amalgam carrier and gently packed using a condenser. Initial setting is achieved after 12 minutes.
89053182|NCT04573374|Active Comparator|Portland cement|Preparation of Portland cement: Industrial Portland cement is mixed with Bisthmus oxide or Barium sulphate radio-opacifier in a 3:1 ratio. The mix is sieved through silk sieve then sterilized in hot air oven at 135 ֯C for 2 hours. Portland cement is mixed in a 3:1 powder: distilled water ratio and placed in the pulp chamber and condensed against a moist cotton pellet. A small cotton pellet moistened with saline is placed in the pulp chamber against PC for 5 seconds to ensure water uptake then removed
89053183|NCT00571454|Experimental|1|Telephone depression care management + treatment as usual
89053184|NCT00571454|No Intervention|2|Treatment as usual
89057665|NCT04531397|Experimental|Dapagliflozin+ACEI treatment|Drug: ACEI, will be given once daily Drug: Dapagliflozin, will be given once daily
89684947|NCT00801827|Experimental|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET) scans of their brains using F-18 (fallypride), a dopamine type 2/3 (DA D2/3) receptor radioligand whose binding is sensitive to competition with endogenous dopamine, before and after the operation.
89684948|NCT00802685|Experimental|early ibuprofen|"Drug: Early ibuprofen~IBUPROFEN DOSING SCHEDULE: At the diagnosis of PDA, infants randomized to early treatment will receive blinded ibuprofen initial dose 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy will be blinded. This group will then be eligible to receive unblinded, open label ibuprofen for a hemodynamically significant PDA include: SIGNS OF PDA + Presence of significant pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (not due to something other than PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
89684949|NCT00802685|Other|Late Ibuprofen expectant group (placebo)|"Late ibuprofen expectant group (placebo): Ibuprofen schedule: At PDA diagnosis, infants randomized to late expectant group will receive blinded placebo. If hemo-dynamically significant PDA develops, infants now receive open label ibuprofen, initial dose of 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA: Signs of PDA + pulmonary hemorrhage alone or Signs of PDA + Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Infants who had received placebo will ibuprofen for the first time (thus, late ibuprofen or expectant)."
89684950|NCT00802919|Experimental|Varenicline|Varenciline 1-2 mg/day
89684951|NCT00802919|Placebo Comparator|Matched Placebo|placebo for varenicline
89684952|NCT00802997|Active Comparator|1|Treatment with Sinergy system
89684953|NCT00802997|Placebo Comparator|2|placebo controlled
89684954|NCT04383041||Patients with Type 2 Diabetes|Patients with Metformin containing prescription drugs will be eligible for participation and consecutively invited to study participation in their pharmacy.
89053185|NCT01144663|Experimental|Nimenrix 3 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 3 primary doses of Nimenrix™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 3, 4 and 12 months of age.
89053186|NCT01144663|Experimental|Nimenrix 2 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Nimenrix™ vaccine at 2 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
89053187|NCT01144663|Active Comparator|Menjugate Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Menjugate® vaccine at 2 and 4 months of age, followed by a booster dose of Menjugate® vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
89053188|NCT01144663|Active Comparator|NeisVac-C Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of NeisVac-C™ vaccine at 2 and 4 months of age, followed by a booster dose of NeisVac-C™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
89053189|NCT00571571|Experimental|TFP-A|Specific aspects of TFP-A involve the setting up of a treatment contract/collaboration between patient and therapist to deal with the likely threats both to the treatment and to the patient's well being that may occur in the course of the treatment. After the behavioral symptoms of identity pathology are contained through structure and limit setting, the psychological structure that is believed to be the core of identity pathology are analyzed. In particular, treatment would involve the family in setting up the contract parameters, provide a psychoeducational component to the family and patient, inclusion of school personnel as appropriate to reinforce contract parameters, place an emphasis on the technique of clarification to understand specific emotional states.
89053190|NCT00571571|Active Comparator|Control|The Control Group is treatment as usual in the outpatient clinic. Treatment in this arm will be carried out by therapists in the Outpatient Department. Treatment will be determined by the therapist(s) and carried out according to their particular orientation and their assessment of patient's needs. It is expected based on clinic data that the majority of patients will be seen at least one time per week.
89053191|NCT00571610|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
89053192|NCT00584766|Experimental|1|
89053193|NCT02883868||patients treated with CXL|
89053194|NCT05206708|Active Comparator|Standard care group|Standard psychodynamic therapy
89684955|NCT04480385|Experimental|Remote Automated Monitoring System|MultiSense® strip will be attached on patient's thorax. The monitoring will last 7 days through post-operative monitoring room (continuous comparison with reference monitor), general ward (comparison with spot-check monitoring) and patient's home
89684956|NCT04382729|Experimental|NMES Group|
89684957|NCT04382729|Active Comparator|Control Group|
89684958|NCT00803543|Active Comparator|Valacyclovir|This is the arm taking Valacyclovir
89684959|NCT00803543|Placebo Comparator|Placebo|This is the arm taking the placebo
89684960|NCT04099641|Experimental|bavituximab and pembrolizumab|Bavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks
89684961|NCT05051735|Experimental|Paracetamol|Paracetamol P.O. 500 mg 2 tablets four times a day for 7 days
89684962|NCT05051735|Placebo Comparator|Placebo|Placebo P.O. 2 tablets four times a day for 7 days
89684963|NCT00803777|Experimental|Intended Users of the Monitoring System|Subjects with type 1 diabetes and healthcare professionals (HCP) used a new blood glucose monitoring system (BGMS) with subject capillary blood. Any subject under age 18 was accompanied by a parent or guardian, who assisted subject if applicable.
89684964|NCT00356343|Experimental|NMES Strengthening Group|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
89216494|NCT03389750|Active Comparator|Intravenous Challenge Drug: Oxymorphone|Intravenous (IV) Dose Range: 1.8, 3.2, 5.6, 10 mg/70kg of the participant's body weight
89216495|NCT03389750|Active Comparator|Intravenous Challenge Drug: Oxycodone|IV Dose Range: 10, 18, 32, 56 mg/70kg of the participant's body weight
89684965|NCT00356343|No Intervention|Control Group|No Intervention Control Group
89684966|NCT00356343|Active Comparator|Volitional Strengthening|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
89216496|NCT03389750|Active Comparator|Intravenous Challenge Drug: Hydromorphone|IV Dose Range: 3.2, 5.6, 10, 18 mg/70kg of the participant's body weight
89684967|NCT03466125||Adult patients who underwent cardiac surgery in Massachusetts|No interventions. A retrospective cohort study of patients who underwent cardiac surgery in Massachusetts in calendar years 2012 - 2016.
89684968|NCT03839147|Experimental|Education and Counseling|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. This education consisted of the definition and the purpose of hysterosalpingography, when and how it was applied, in what cases it was applied, whether it was a painful procedure, possible side effects and additional benefits of infertility treatment
89216497|NCT03389750|Placebo Comparator|Intravenous Challenge Drug: Placebo|IV saline
89216498|NCT03385330|Active Comparator|LOWER oxygen saturation target group|Oxygen saturation target range 90--94%. The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
89684969|NCT03839147|No Intervention|Control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed. Both groups were re-evaluated using the same scales after the hysterosalpingography. Within 5 minutes of completing the hysterosalpingography procedure, participants were asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale .
89684970|NCT05205369|Experimental|Yi Jin Bang group|Participants in this group will perform a 10-week home-based Yi Jin Bang exercise program.
89684971|NCT05205369|Experimental|Usual exercise therapy group|Participants in this group will perform a 10-week home-based usual exercise therapy program.
89684972|NCT05205369|No Intervention|Waitlist control group|Participants in the waitlist control group will be informed that they will receive either Yi Jin Bang training or exercise therapy after ten weeks have passed. This will be done only for motivational reasons and not for evaluation.
89684973|NCT03454347|Experimental|Protein Supplementation Group|Participants in this group will complete two weeks of lower limb suspension and receive 75g/day of supplemental protein in addition to education aimed at increasing protein intake through their diet.
89216499|NCT03385330|Active Comparator|HIGHER oxygen saturation target group|Oxygen saturation target range greater than or equal to 96%.The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
89216500|NCT03344744||SAH with DCI|Aneurysmal subarachnoid haemorrhage patients with delayed cerebral infarction
89216501|NCT03344744||SAH nonDCI|Aneurysmal subarachnoid haemorrhage patients without delayed cerebral infarction
89684974|NCT03454347|Active Comparator|Non-Supplemental Group|Participants in this group will complete two weeks of lower limb suspension and will receive no supplementation or nutritional education.
89684975|NCT03867305|Experimental|MOBIDERM group|
89216502|NCT03344744||Control|Healthy volunteers
89216503|NCT03328884|Other|nal-IRI|This is a single arm study. After signing the informed consent form, patients will start treatment with nal-IRI. nal-IRI will be administered at a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy.
89216504|NCT03326804||Cohort 1 - Safety|"Cohort 1 will consist of the first 20 participants recruited into the study for H1 Hip Resurfacing Arthroplasty. These patients will receive additional CT scans preoperatively and then post-operatively at these time points: immediately postoperatively (2days), at 6 weeks, 3 months, 6 months, 1 year and 2 years. They will have metal-ion measurements for safety analysis. Blood samples will be taken preoperatively and postoperatively at 3 months, 6 months, 1 year and 2 years.~A safety analysis of Cohort 1 will be performed at the 6 week, 3 month and 6 month post-operative stage by independent assessors. Yearly clinical evaluations will be performed until 10 years, and radiographs at 3,5,10 years. If the investigation supports the safety of the implant, the study will proceed with recruitment into Cohort 2."
89684976|NCT03867305|No Intervention|Control group|
89684977|NCT05199831||Participants living with HIV|Clinical, functional and cognitive evaluations; questionnaires on disability, social participation, mental health and physical activity
89684978|NCT05199831||Controls not infected with HIV|Clinical, functional and cognitive evaluations; questionnaires on disability, social participation, mental health and physical activity
89684979|NCT04940897|Experimental|Intervention|Usual care plus ketone meter and fluid therapy for identified high risk DKA patients
89684980|NCT04938869|Experimental|Supportive care (CGM)|Prior to hospital discharge, patients receive CGM application and education on how to apply the CGM, and how to use the sensor and its associated smart phone app. Patients also receive basic diabetes mellitus education. After hospital discharge, patients use CGM for up to 28 days.
89684981|NCT03361371|Experimental|Interventional group|"Intervention Group: in addition to receiving the aforementioned bronchiolitis discharge instructions, this group will undergo nasal suctioning prior to each feeding as needed for 72 hours post discharge home, using exclusively the Zo-Li study device (see above under study device), with saline nose drops. Families in this group will be given the Zo-Li device at no cost and instructed in the appropriate technique and importance of using this tool.~We shall not reveal the identity of the study devices to the ED physicians in order to minimize contamination of the control group. The ED treating physicians will also be blinded to which device the infant had been randomized to. We shall also ask the ED treating physicians not to recommend specific suctioning devices to the study patients."
89684982|NCT03361371|Placebo Comparator|Control group|Control Group: this group will receive standardized routine discharge instructions describing information about bronchiolitis, expected course of illness, recommended management strategies such as fever control, augmented air humidification, need for frequent feeding and warning signs prompting return for care. This group will be suctioned prior to feeds via bulb suction (with saline drops) which is expected to provide minimal effect, due to non-sustained negative pressures generated during bulb release. Since the benefit of nasal suction in bronchiolitis is unknown, this design is ethically reasonable. However, the use of no suction would likely meet with parental resistance and enrollment would be difficult. Families in the control group will be given the bulb device at no cost and instructed in the appropriate technique of using this tool prior to feeds.
89684983|NCT03359733|Experimental|TAK-659 100 mg Fasted + TAK-659 100 mg Fed|TAK-659 100 milligram (mg), tablet, orally under fasted state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fed state, once on Day 8 of a 15-day food effect treatment period.
89053195|NCT05206708|Experimental|Personalized care|Psychodynamic therapy or interactive guidance therapy
89053196|NCT02883634|Experimental|specific manipulation|"Participants allocated to group specific manipulation, will have their lumbar spine manipulated according to the previous clinical examination."
89053197|NCT02883634|Experimental|non-specific manipulation|"Participants allocated to group non-specific manipulation will have their upper thoracic spine manipulated (also known as global manipulation) regardless of the previous clinical examination."
89053198|NCT04573257||normotensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
89053199|NCT04573257||Prehypertension group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
89053200|NCT04573257||hypertensive group|The medical history and basic examination and examination information were collected. Echocardiography including conventional cardiac ultrasound, tissue Doppler and two-dimensional speckle tracking to measure myocardial strain and noninvasive myocardial work were carried out , and the brachial-ankle pulse wave velocity was measured in parallel.
89053201|NCT01143337|Experimental|1|dose1
89053202|NCT01143337|Placebo Comparator|2|Placebo
89053203|NCT04313023|Experimental|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution given by nebulization on Study Days 1, 3, 6, and 10
89053204|NCT04313023|Placebo Comparator|Sterile saline for inhalation|Sterile saline for inhalation given by nebulization on Study Days 1, 3, 6, and 10
89053205|NCT02883595|Experimental|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
89053206|NCT02883595|Placebo Comparator|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
89053207|NCT00571766|Experimental|1|Oral L-Arginine 2 g twice a day for 14 weeks
89053208|NCT00571766|Placebo Comparator|2|Placebo 2 g, twice a day for 14 weeks
89053209|NCT01143259|Placebo Comparator|300 mg Polyethylene|
89053210|NCT01143259|Active Comparator|Alvimopan|
89053211|NCT04573608|Experimental|Papacarie-Duo|
89053212|NCT04573608|Active Comparator|Atraumatic Restorative Treatment|
89053213|NCT00571805|Active Comparator|1|Varenicline
89053214|NCT00571805|Placebo Comparator|2|placebo
89053215|NCT02883556|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
89053216|NCT04580069|Experimental|Lymphatic drainage|Patients subjected to manual lymphatic drainage
89053217|NCT04580069|Experimental|Connective tissue|Patients subjected to connective tissue massage
89053218|NCT04580069|Active Comparator|control group|Subjects hat followed standard rehabilitative treatment
89053219|NCT00584961||600 patients|Patients with diagnosis of Bipolar Disorder (DSM-IV TR)
89053220|NCT00571844|Experimental|DASH diet|
89053221|NCT00571844|Experimental|DASH diet plus Weight loss|
89053222|NCT00571844|No Intervention|Usual Care|Usual Care Control Group: Patients in the Usual Care control group will be asked to maintain their usual dietary and exercise habits for 4 months until they are re-evaluated. At biweekly intervals we will ask patients to describe any spontaneous changes in their eating habits or food preferences. To ensure patient safety, BPs will also be monitored biweekly by our staff.
89053223|NCT00585000|Experimental|1|
89053224|NCT00585117|Experimental|1 CNS|imaging with CuATSM
89053225|NCT00585117|Experimental|2. Head and Neck|Imaging with CuATSM
89053226|NCT00585117|Experimental|3. Lung|imaging with CuATSM
89053227|NCT00585117|Experimental|4. Prostate|PET imaging with CuATSM
89053228|NCT00585117|Experimental|5. Esophagus|PET imaging with CuATSM
89053229|NCT00572078|Experimental|Sorafenib, Bevacizumab & Paclitaxel|Paclitaxel is given as i.v infusion over 60 min on days 1, 8, 15 every 28 days. Sorafenib is given orally starting with cycle 1 day 2. Bevacizumab is given as i.v infusion on days 1 and 15 every 28 days.
89053230|NCT01142791|Other|ExAblate treatment|
89053231|NCT04573218|Placebo Comparator|Group A|Glucose.
89053232|NCT04573218|Active Comparator|Group B|250 mg Oil Palm Phenolics.
89684984|NCT03359733|Experimental|TAK-659 100 mg Fed + TAK-659 100 mg Fasted|TAK-659 100 mg, tablet, orally under fed state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fasted state, once on Day 8 of a 15-day food effect treatment period.
89684985|NCT03357627|Experimental|Dose Escalation: TAK-659 + Venetoclax|TAK-659 40, 60, 80, or 100 milligram (mg) (tablet, orally, once daily, up to 35 days in Cycle 1 or in different intermittent schedules [7 days dosing followed by 7 days off or 14 days dosing followed by 7 days off or other intermittent dosing schedules]) along with venetoclax 200, 400, 800 or 1200 mg (tablet, orally, once daily, up to 35 days in Cycle 1). After Cycle 1, TAK-659 and venetoclax will be administered once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant.
89684986|NCT03357627|Experimental|Safety Expansion: Diffuse Large B-cell Lymphoma (DLBCL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
89684987|NCT03357627|Experimental|Safety Expansion: Follicular Lymphoma (FL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
89684988|NCT03839225|Other|Children, Adolescents and Adults|children, adolescents and adults who have been victims of the armed conflict in the municipalities of Soacha-Cundimanarca (Colombia)
89684989|NCT04923113|Experimental|patients who meet the inclusion criteria|5 different methods will be performed to detect H. pylori infection in patients who meet the inclusion criteria，and patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.
89684990|NCT05143047|No Intervention|Control|Participants in the usual care group will receive standard-of-care discharge communications per unit routine, including counseling regarding prescribed medications and post-discharge instructions, return precautions, and follow-up appointments by the pediatric nursing staff.
89684991|NCT05143047|Experimental|Intervention|Participants in the intervention group will receive supplementary medication discharge instructions in addition to the standard communications. They will receive instructions on how to submit information and complete study surveys securely through their cellphones during their child's home treatment period.
89684992|NCT03923907|Experimental|EIM group|patients with Hypertension (HT) will be recruited by a trained nurse when the patient attends the yearly to bi-yearly complication screening program called the risk assessment and management program (RAMP) program. This program is provided to all patients with HT, who are seen in the Government-funded primary care clinics in Hong Kong. The nurse will encourage the patient by motivational interviewing techniques and prescribe exercise. Combined exercise skills will be taught in the 12-week weekly exercise classes by certified physical trainers. Peer support is encouraged during and after the 12-week program. Regular feedback, prompting and problem solving will be provided by the nurse at 3m, 6m, and 12m. Exercise level will be monitored by validated wrist trackers to feedback participants, nurse and physical trainer by mobile apps and website. Resources to exercise will be made known to patients by apps, website and healthcare professionals.
89684993|NCT03923907|No Intervention|usual care|There is no extra intervention to patients allocated in this arm, except that they receive information and advice on lifestyle changes including benefits from exercise from the nurse at recruitment as stated above. Participants in both arms will have no changes in medication within the first 12-week to determine the BP difference between the two groups. In Hong Kong, patients have unlimited access to emergency department and general outpatient services. All patients with HT receive RAMP program counselling and screening every 1-2 years. These are not limited by the current trial.
89684994|NCT02152085|Experimental|Narrow pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 0.4 ms.
89684995|NCT02152085|Experimental|Wide pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 1 ms.
89684996|NCT03855657||Inflammatory Bowel Disease Patient|Patient with confirmed diagnosis of Inflammatory Bowel Disease
89684997|NCT03855657||Healthy control|Controls (non-IBD) will comprise individuals undergoing colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms, and friends and spouses or partners of patients at Prince of Wales Hospital or Alice Ho Miu Ling Nethersole Hospital, or any individuals who are interested to participate in this study.
89684998|NCT03855657||Healthy relatives of Inflammatory Bowel Disease patient|Relatives or household members of both patients with IBD or other diseases and controls will be recruited.
89684999|NCT00805493|No Intervention|Medication Taper|All participants begin with gradual tapering to the point of discontinuing medication
89685000|NCT00805493|No Intervention|Random assignment to placebo|Once they are medication-free, 50% of participants are randomized to placebo
89685001|NCT00805493|Active Comparator|Random assignment to riluzole|One they are medication-free, 50% of participants are randomized to riluzole
89685002|NCT03236649|Experimental|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
88998025|NCT03991234|Experimental|Coordinated Reading and Math Intervention|Coordinated intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction addressing similar skills as those addressed in the reading intervention arm & similar skills as the math intervention arm.
88998026|NCT03991234|Active Comparator|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction designed to build skill on letter-sound associations, decoding, sight words, & contextualized reading.
88998027|NCT03991234|Active Comparator|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge, counting strategies, and arithmetic skill.
88998028|NCT03991234|No Intervention|Business-as-usual Control|Participation in the school's typical reading and math classroom instruction and, if designated by the school, its supplemental program.
89053233|NCT00585156|Experimental|Arm #1|Celebrex treatment group
89053234|NCT00572351|Active Comparator|Red Wine|
89053235|NCT00572351|Active Comparator|White Wine|
89685003|NCT03236649|Active Comparator|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
89685004|NCT00807209|Experimental|High Dose SKY0402|
89685005|NCT00807209|Active Comparator|Standard of Care|
89685006|NCT00807209|Experimental|Low Dose SKY0402|
89685007|NCT00807989|Active Comparator|Carbamazepine|Carbamazepine
89685008|NCT00807989|Experimental|Lamotrigine/Valproate|Lamotrigine and Valproate combination therapy
89685009|NCT05131191||patients with coronary metal stents implantation|
89685010|NCT00843479||Elderly NGT|Normoglycemic subjects 65-80 years old
89685011|NCT00843479||Middle-age NGT|Middle-age normoglycemic subjects 35 to 50 years old.
89685012|NCT05124327|Other|Intervention Group|Implementation of quality improvement initiative to utilize RPM in PP HDP. Patients will utilize remote monitoring technology and bluetooth enabled BP buff to self monitor BPs- autopopulate to provider portal, and then have a telemedicine appointment at 48 hours post hospital discharge.
89685013|NCT04744558|Experimental|Ketogenic|Low carb high fat ketogenic diet
89685014|NCT04744558|Active Comparator|Non-ketogenic|Low carb high fat non-ketogenic diet
89685015|NCT04745247|Experimental|RSS|Repetitive somatosensory stimulation (RSS)
89685016|NCT04745247|Placebo Comparator|Sham RSS|Sham Repetitive somatosensory stimulation (RSS)
89685017|NCT05111392|Placebo Comparator|Placebo|Water
89685018|NCT05111392|Experimental|Oral rehydration solution 1|Beverage with 2.5% glucose with 45 mmol sodium/L.
89685019|NCT05111392|Experimental|Oral rehydration solution 2|Beverage with 1.7% glucose with 60 mmol sodium/L.
89685020|NCT03210675|Other|Study group|Will have a PSG at home every 6 months (± 1 month) from the age of 6 months until the age of 3 years.
89685021|NCT03210675|Other|Standard Care Group|Will have a single PSG at home which will give a reference in the Down Syndrome population of 3 years old and will be used as reference to the study group
89685022|NCT04928872||Non-diabetic older adults|Non-diabetic older adults
89053236|NCT01142596|Experimental|Asenapine 5 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg BID at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
89053237|NCT01142596|Experimental|Asenapine 10 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg bid at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
89053238|NCT00572390|Placebo Comparator|1|No oestrogen treatment
89053239|NCT00572390|Experimental|2|Oestrogen treatment
89685023|NCT00357591|Active Comparator|Control|
89685024|NCT04905628||Dexcom CGM System|Dexcom CGM System
89685025|NCT03218891|Experimental|Clinical treatment physical training|"Patients with optimized clinical treatment group that will do physical training for 12 weeks. They will do the tests in moment 1 and after 3 mounths.~The intervention is the Cardiac Rehabilitation."
89685026|NCT03218891|No Intervention|Optimized clinical treatment|Patients with optimized clinical treatment group that will not do physical training.They will do the tests in moment 1 and after 3 mounths.
89685027|NCT03218891|No Intervention|Coronary insufficiency without angina|Group with coronary insufficiency without angina and will not do physical training. They will do the tests only one moment.
89685028|NCT03218891|No Intervention|Normal healthy subjects|Group normal healthy subjects, without coronary injuries, diabetes, hypertension and another chronic disease. These group have be sedentary and will not do physical training. They will do the tests only one moment.
89685029|NCT05722977|Experimental|Surufatinib+envafolimab|
89685030|NCT00843713|Placebo Comparator|Placebo|For subjects assigned to the placebo group, patients will take a matching placebo pill of 400 mg by mouth twice daily for 24 weeks in addition to taking their current HIV medication
89685031|NCT00843713|Active Comparator|Raltegravir|For subjects assigned to the active comparator group, they will receive raltegravir at 400 mg by mouth twice daily for 24 weeks in addition to continuing to take their current HIV medication
89685032|NCT04845490|Experimental|Drug group 1|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with Mitomycin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
89685033|NCT04845490|Experimental|Drug group 2|"hyperthermic intraperitoneal chemotherapy (HIPEC) (with lobaplatin): Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
89053240|NCT01142128|Active Comparator|Nexium alone|Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
89053241|NCT01142128|Placebo Comparator|Placebo to Nexium, alone|Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
89053242|NCT01142128|Active Comparator|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.
89053243|NCT01142128|Placebo Comparator|Viokase 16 + placebo to Nexium|Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone
89057666|NCT04531475|Experimental|X842 50 mg QD|X842 50 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
89685034|NCT04845490|No Intervention|Control group|"hyperthermic intraperitoneal therapy (HIPET) (no drug) : Temperature Setting : 43 ± 1.0 ℃. Perfusion time: 60 min. Amount of perfusate: The perfusion fluid is based on the principle of filling the abdominal cavity and unobstructed circulation.~Choice of perfusate: Normal saline. Drug selection and dose: no drug. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time)."
89053244|NCT04572867|Experimental|Aquapheresis|Per protocol, if randomized to Aquapheresis arm (AQ), all diuretics are discontinued and AQ will be administered as per established protocol. BMP and CBC will be checked prior to initiation and as needed, 7-10 days, 30, 60 and 90 days post discharge. Note, aquapheresis rate is to be decreased by 100 cc/hr if Hgb increases by 1gm/dL, and stopped if rate is decreased to 50 cc/hr or reaches euvolemia, whichever comes first.
89053245|NCT04572867|Active Comparator|IV Diuretics|Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR< 2.0, or 5mg PO if Cr > 2.0, if refractory to high dose loop diuretic. If a patient in IV arm is refractory to maximum 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
89053246|NCT00572429|Placebo Comparator|A|
89053247|NCT00585273||1|Incident users of antipsychotics.
89053248|NCT00585273||2|Non-users of antipsychotics
89053249|NCT00572507|Experimental|MonoMax|MonoMax is used for abdominal wall closure
89053250|NCT01142089|Placebo Comparator|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours)
89053251|NCT01142089|Experimental|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
89053252|NCT00585390|Experimental|Essential omega-3 fatty acid replacement|
89053253|NCT00585390|Placebo Comparator|Placebo|
89053254|NCT01141660|Experimental|Endotracheal Tube|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
89053255|NCT01141660|Experimental|Laryngeal Mask Airway|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
89053256|NCT02883790|Experimental|Somnage|Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.
89685035|NCT04819360|Active Comparator|Vesicare|Group 1: will be treated with an anticholinergic (Vesicare® 10 mg per day for 12 weeks)
89685036|NCT04819360|Active Comparator|Botox|Group 2: will receive an intra-detrusor injection of a low dose of botulinum toxin type A (100 U of BOTOX®).
89685037|NCT04585204|Active Comparator|50 gr-100 gr OGTT|patients are tested firstly by 50 gr OGTT after that if necessary by 100 gr OGTT
89685038|NCT04585204|Active Comparator|75 gr OGTT|patients are tested by 75 gr OGTT
89053257|NCT02883790|Placebo Comparator|Placebo|Oral administration o.d.
89053258|NCT04572672|Active Comparator|Purse lip breathing with number counting arm|"1) Position: The patient lies down in a semi-supine position, the bed is adjusted by 45-60 degrees, 2) Pursed-lip breathing and number counting one and two during inspiration, and 3) Number counting, one, two, three, and four during exhalation for the first 15 minutes (min) of each hour, total study time was 3 hours or until the patient was discharged from the ER."
89053259|NCT04572672|No Intervention|Control arm|The patients who were allocated to the control group received usual nursing care i.e. bed rest in a supine position in a quiet area. Patients were advised to limit their activity. The frequency of the vital signs monitoring and pharmacologic treatment were the same as the intervention group.
89053260|NCT01140880|Experimental|Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Increasingly valuable incentives will be provided for urine samples that lack metabolites of stimulant drugs.~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
89053261|NCT01140880|Sham Comparator|Yoked Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Incentives will be provided to participants independent of stimulant drug use and determined in the same rate and timing as a randomly selected participant in the active CM condition.~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
89053262|NCT00572702|Active Comparator|A|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with Amreich-Richter procedure; it will be set randomly
89685039|NCT05722899|Experimental|Football training|10-week football training program with small-sided games, 2x/week, 45min-1h
89685040|NCT05722899|No Intervention|Control|No intervention, no changes in lifestyle and diet
89685041|NCT04341220|Experimental|Anodal tDCS + Exercise|Anodal tDCS applied over primary motor cortex (M1) - Dose: 1mA, 20 minutes + ( concomitantly) protocol of specific exercises for balance
89685042|NCT04341220|Sham Comparator|Sham tDCS + Exercise|Sham tDCS applied over primary motor cortex (M1) - Dose: 1mA, 30 seconds ON, + (concomitantly) protocol of specific exercises for balance
88820625|NCT05884099|Active Comparator|Single-injection paravertebral block|-Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery
89053263|NCT00572702|Active Comparator|B|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with total Prolift procedure; it will be set randomly
89685043|NCT04436458|Experimental|Niclosamide|Continued SOC therapy together with Niclosamide tablets for 14 days
89685044|NCT04436458|Placebo Comparator|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide
89685045|NCT03834753|Experimental|bevacizumab|ONS-5010
89685046|NCT03834753|Active Comparator|ranibizumab|
89685047|NCT04271878|Other|All participants|All participants will receive the same interventions
89685048|NCT00845039|Active Comparator|Cetuximab + Irinotecan|Participants in Treatment Group 1 will receive intravenous infusions of Cetuximab 500 milligrams per square meter (mg/m²) and Irinotecan 180 mg/m².
89685049|NCT00845039|Experimental|Cetuximab + IMC-A12 + Irinotecan|Participants in Treatment Group 2 will receive intravenous infusions of Cetuximab 500 mg/m², IMC-A12 10 milligrams/kilogram (mg/kg) and Irinotecan 180 mg/m².
89685050|NCT05098821||Dupilumab treated Patients|Patients with atopic dermatitis with indication for dupilumab treatments will be observed
89685051|NCT04154878||Pacemaker Optimization|Participants were referred for pacemaker optimization following implantation of a device. All had an intact atrial contraction either intrinsic or by device stimulation. A standard baseline echo was performed prior to programming changes with a final echo scan completed after all programming complete. Device programming consisted of adjusting atrial ventricular and right to left ventricular stimulation delays.
89685052|NCT04154878||Healthy|A brief cardiac history questionnaire and complete echocardiogram will be performed.
89685053|NCT03879616|Experimental|An Enhanced Reminder|"Members randomized to this arm of the study will receive an enhanced reminder protocol, which will include multiple reminders, multiple modalities, and motivational messages. The timing of reminders will depend on the wait time between the date the appointment is made and the date of the appointment.~An email reminder will be sent to all members who have provided their personal email information.~Members will receive up to two text messages that roll over to an IVR automated phone call if the text cannot be delivered.~Members scheduled for colonoscopy will also receive a single IVR-T reminder to begin their bowel prep the morning of the calendar day prior to the procedure."
89685054|NCT03879616|Other|Control|"Members randomized to this arm of the study will receive a single text message that rolls over to an IVR automated phone call if the text cannot be delivered. This message will be delivered 7 business days prior to the appointment. This replicates the current protocol for GI procedures. Of note, members who schedule appointments within 7 days of the procedure currently receive no reminders."
89685055|NCT00845195|Experimental|Olopatadine HCl Nasal Spray, 0.6%|
89685056|NCT00845195|Active Comparator|Azelastine HCl Nasal Spray, 0.1%|
89685057|NCT00845507|Experimental|Exenatide Group|Exenatide dstarted at 5 mcg subcutaneously twice daily within one hour before the morning and evening meals, and increased (as tolerated) to 10 mcg.
89685058|NCT00845507|Placebo Comparator|Placebo Group|Placebo: Sterile solution in equivalent doses as Exenatide
89685059|NCT03782506|Experimental|Interactive Music Therapy|Ten 45-minute individual interactive music therapy sessions.
89685060|NCT03782506|Active Comparator|Verbal-based Support|Ten 45-minute individual verbal support sessions.
89685061|NCT05078541|Experimental|RFA Warthins Tumor Group|Group of patients who will under RFA for Warthin's tumor.
89685062|NCT03761914|Experimental|Colorectal Cancer (CRC)|"N=20;~Metastatic CRC priorly Rxed with ≥2 lines of ChemoRx (3rd/4th line); must have documented disease progression post last administration of or intolerance to standard therapies, which must have included a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and, if KRAS wild-type, cetuximab or panitumumab. Prior regorafenib or trifluridine/tipiracil is allowed, but not mandated;~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
89685063|NCT03761914|Experimental|Ovarian Cancer (OvC)|"N=20;~Metastatic OvC priorly Rxed with ≥1 line of platinum-containing ChemoRx (2nd/3rd line) with either relapse or disease refractoriness; interval surgery permitted, as long as subjects have measurable disease by imaging and concomitant CA-125 increase, and/or biopsy showing OvC; must have either received (or been offered) bevacizumab therapy; those with BRCA germline mutations (gBRCA mut) must have been offered therapy with poly-ADP ribose polymerase (PARP) inhibitors.~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
89685064|NCT03761914|Experimental|Small Cell Lung Cancer (SCLC)|"N=20;~Advanced SCLC priorly Rxed with 1 line of ChemoRx (2nd line); must have measurable disease by imaging after they progressed or were resistant to 1 prior systemic therapy; asymptomatic or treated brain metastases are allowed;~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
89685065|NCT03761914|Experimental|Triple Negative Breast Cancer (TNBC)|"N=15;~TNBC priorly Rxed with 1 line of ChemoRx with residual or recurrent disease (2nd line); estrogen (ER) and progesterone receptor (PgR) negative, and HER2(-) by IHC AND HER2 non-amplified by fluorescence in situ hybridization; weak IHC positivity for ER or PgR (i.e., < 5%) eligible; must have undergone 2nd line therapy after 1st line Rx could include: neoadjuvant Rx if macroscopic disease still present after surgery OR adjuvant Rx but only if relapse occurred > 6 months from the start of pembrolizumab (P);~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
89057667|NCT04531475|Experimental|X842 100 mg QD|X842 100 mg, capsule, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily up to 4 weeks.
89057668|NCT04531475|Experimental|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, orally, once daily and X842 placebo-matching capsule, orally, once daily up to 4 weeks.
89057669|NCT01684449|Experimental|Phase 2: Experimental Arm|Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
89057670|NCT01684527||Children Suffering From Bronchiolitis|Respiratory secretions obtained from children suffering from Bronchiolitis
89057671|NCT01684527||Healthy Children|Respiratory secretions obtained from children with no respiratory infection
89685066|NCT03761914|Experimental|Acute Myelogenous Leukemia (AML)|"N=15;~Pts with AML who are not eligible for allogeneic stem cell transplant and have been able to achieve morphological partial remission (PR) as their best ever response at the time of completion of their 4th cycle of upfront Rx with HMA; prior initial upfront hydroxyurea or leukapheresis Rx or history of induction early failure after up to 2 cycles of ChemoRx (7+3 or similar regimen) with seamless immediate transitioning to HMA Rx eligible; must remain on HMA therapy throughout the trial.~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
89685067|NCT03140475||Individuals with schizophrenia|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates)~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response)~Clinical variables:~Positive and Negative Syndrome Scale / Birchwood Insight Scale / Beck Cognitive Insight Scale / Personal and Social Performance Scale / Calgary Depression Scale / Chlorpromazine equivalents~Neuropsychological variables:~National Adult Reading Test (French) / Wechsler Adult Intelligence Scale version IV (WAIS-IV) subtests (matrix reasoning, vocabulary, letter-number sequencing)"
89685068|NCT03140475||Controls|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates) /~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response) /~Clinical variables:~Calgary Depression Scale~Neuropsychological variables:~National Adult Reading Test (French) / WAIS-IV subtests (matrix reasoning, vocabulary, letter-number sequencing)"
89685069|NCT00845663|Active Comparator|Pre-filled Syringe|pre-filled syringe (reference)
89685070|NCT00845663|Experimental|Auto-injection Device|Auto-injection device (test)
89685071|NCT03416998|Active Comparator|Phototherapy Active|Phototherapy active group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
89685072|NCT03416998|Placebo Comparator|Placebo Phototherapy|"Phototherapy placebo group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.~For placebo treatment, the same procedures and treatment times will be employed, but the equipment will be set in placebo mode. Only the researcher in charge of programming the device will have knowledge regarding which treatment is being used. However, the programmer will not participate in the execution of the treatment, evaluations or data analysis"
89685073|NCT03267238|Experimental|Fecal Microbial transplantation|Fecal Microbial Transplantation will be offered to patients eligible to be part of the study.
88998029|NCT03989986|Experimental|iPeer2Peer Mentorship|In addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
88998030|NCT03989986|No Intervention|Waitlist Control Group|The control group participants will receive standard care and will be on a waitlist to receive the iPeer2Peer program until 15 weeks after completing their baseline questionnaires.
88998031|NCT03978689|Experimental|CUE-101 dose escalation and expansion|Part A&B: CUE-101 Monotherapy IV infusion Q3W Dose Escalation (Part A) and Expansion (Part B)
88998032|NCT03978689|Other|Pembrolizumab and CUE-101|Part C&D: CUE-101 Dose Escalation in Combination with KEYTRUDA® (pembrolizumab) for injection, for IV use 200 mg Q3W (Part C). Expansion of pembrolizumab plus CUE-101 at the combination RP2D (Part D)
88998033|NCT03875768|Experimental|Intervention|Participants will track their daily dietary intake for six months using an app and will receive automated feedback daily via text message based on DASH nutrients. Participants in-need of coaching based on their adherence to the key nutrients in the DASH dietary pattern or engagement in the intervention will receive responsive digital coaching from Nourish registered dietitians.
88998034|NCT03875768|No Intervention|Control|Participants will receive information about the DASH dietary pattern and will track their daily dietary intake using an app for six months.
88998035|NCT03816553|Experimental|SHR-1210 + Apatinib|Participants receive SHR-1210 200mg (3mg/kg for underweight patients) intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
88998036|NCT03784820|Experimental|UNITE|UNITE is a manualized cognitive-behavioral couple therapy (CBCT) intervention that engages the couple to address the core psychopathology of BED.
88998037|NCT03784820|Active Comparator|CBT-E|CBT-E is a trans-diagnostic cognitive behavioral individual therapy treatment for eating disorders. It has been shown to be effective in numerous controlled and open trials.
88998038|NCT03769675|Experimental|Spinal Cord Stimulator Implant|Spinal Cord Stimulator implant
88998039|NCT03729245|Experimental|Combination of bempegaldesleukin + nivolumab|Patients in Arm A will receive bempegaldesleukin in combination with nivolumab.
88998040|NCT03729245|Active Comparator|sunitinib or cabozantinib|Patients in Arm B will receive the Investigator's choice of either one of two treatment options.
88998041|NCT03727737|No Intervention|Sham|Patients with mild and moderate TBI will be assigned randomly to this arm and will not receive treatment
89685074|NCT03006016|Experimental|Omega 3|The patient will take Omega 3 before intervention 4-week course of 1.500 Mg/ day without caloric restriction
89685075|NCT03006016|Placebo Comparator|Placebo|The patient will take placebo before intervention 4-week course of 1.500 Mg/ day without caloric restriction
89685076|NCT02876380||Prospective cohort|These are women who are currently pregnant and who have a LQTS mutation. This also includes women whose partner/father of the baby has a LQTS mutation. If the father of the child has the LQTS mutation, the father will also be enrolled.
89685077|NCT02876380||Retrospective cohort|In this cohort the investigators will collect information about previous pregnancies affected by the LQTS mutation. Parents may enroll in both retrospective and prospective cohorts
89685078|NCT04292561|Experimental|light general anesthesia|During anesthesia maintenance, patients were received with low concentration sevoflurane to maintain a target of 0.8 MAC.
89685079|NCT04292561|Experimental|deep general anesthesia|During anesthesia maintenance, patients were received with high concentration sevoflurane to maintain a target of 1.0 MAC.
89685080|NCT02871934|Experimental|PGx+|Patients in the PGx+ (intervention) arm will have their SLCO1B1 results reported to their ordering provider immediately.
89685081|NCT02871934|Experimental|PGx-|Patient in the PGx- (control) arm will have their SLCO1B1 results reported to their ordering provider at the end of the study (after 12 months).
89685082|NCT03123393|Experimental|Cohort A: TAK-659 100 mg|TAK-659 100 mg tablet, orally, once daily (QD), during each 28-days cycle (median exposure was 41 days).
89685083|NCT03123393|Experimental|Cohort B: TAK-659 Ramp-up Dosing|TAK-659 60-100 mg tablet, orally, QD, dose based on safety and tolerability during each 28-days cycle (median exposure was 28 days).
89685084|NCT04340830|Experimental|smoker|Those consuming at least 10 cigarette a day for ten years were included in smoker group.
89685085|NCT04340830|Active Comparator|non-smoker|Patients who never smoke were included in non-smoker group. Patients who quit smoking were not included in this group.
89685086|NCT04743076|Experimental|Intervention group|Standard medical treatment plus endovascular treatment
89685087|NCT04743076|Active Comparator|Control group|Standard medical treatment alone
89685088|NCT00848237|Experimental|Treatment|All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
89685089|NCT03115203|Other|Facial paralysis|
89685090|NCT03115203|Other|Healthy subject|
89685091|NCT04276181||Combined Nerve and Tendon Transfer (CNaTT) group|The surgical procedures are described in the section Detailed description
89685092|NCT04276181||Traditional transfer procedure group|The surgical procedures are described in the section Detailed description
89685093|NCT03092895|Experimental|SHR-1210+Apatinib(Arm A）|
89685094|NCT03092895|Experimental|SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）|
89685095|NCT03084731|Experimental|Goup 1:Children with moderate stunting and wasting|Test 3 prototype MDCFs and the current rice-lentil RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week 2x /day intervention, with a 2 week post-intervention phase to assess durability of MDCF-induced changes in the microbiota.
89685096|NCT03084731|Experimental|Goup 2:Children with moderate stunting and wasting|Select most efficacious MDCF from study 1 and compare with 2 additional MDCF prototypes using the same design used in study 1.
89685097|NCT03084731|Experimental|Goup3:Children with moderate stunting and wasting|Select lead MDCF from studies 1, 2 and conduct final 'bake-off' vs current RUSF and also examine the impact of 1x vs 2x per day administration with a 4 week post-intervention period to provide additional information on the durability of MDCF-sponsored changes in the microbiota.
89685098|NCT03084731|No Intervention|Healthy controls|In order to construct a library of gut microbiota of healthy growing children of the same community, one spot fecal sample (1-2 gm) and spot blood sample (2 mL) will be collected from 30 children each who would be aged 12-18 months of either sex, having WLZ and LAZ : >-1
89685099|NCT02589808|Experimental|Full TTE|Full echocardiogram.
89685100|NCT02589808|Experimental|VScan|Handheld echocardiogram.
89685101|NCT03839771|Placebo Comparator|Arm A: Placebo|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |~The dosage for Placebo for AG-120 (IDH1): 500 mg dose/day~The dosage for Placebo for AG-221 (IDH2): 100mg dose/day"
89685102|NCT03839771|Experimental|Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2)|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |~The dosage for AG-120 (IDH1): 500 mg dose/day~The dosage for AG-221 (IDH2): 100mg dose/day"
89685103|NCT02591056|Experimental|Erchonia Verju Laser + Green PRESS 8|All subjects receive 12 combination treatments over 6 weeks (two per week) with the Erchonia® Verju™ Laser and the Green PRESS 8 devices simultaneously.
89685104|NCT02997033||Total study cohort|
89685105|NCT02953587|Experimental|Vertical Sleeve Gastrectomy (VSG) NJ/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
89057672|NCT01684605|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
89057673|NCT01684605|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
89057674|NCT04531202||Patients with confirmed or suspected of coronavirus infe|Clinical and laboratory data will be collected throughout the acute illness period. Research data will be integrated with information available from hospital and regulatory files.
89057675|NCT04531319||Case Group|Covid 19 (+) patients
89057676|NCT04531319||Control Group|Healthy volunteers
89057677|NCT01580085||Pulmonary embolism|Patients who were diagnosed with pulmonary embolism
89057678|NCT01580085||control group|age and sex matched adults with osa and no thromboembolism
89057679|NCT04537442|Experimental|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
89685106|NCT02953587|Experimental|Roux-en-Y Gastric Bypass (RYGB) NJ/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed by administering glucose through a nasojejunal (NJ) feeding tube preoperatively and orally (PO) postoperatively.
89685107|NCT02953587|Experimental|Vertical Sleeve Gastrectomy (VSG) PO/PO|Patients that are undergoing routine VSG will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
89685108|NCT02953587|Experimental|Roux-en-Y Gastric Bypass (RYGB) PO/PO|Patients that are undergoing routine RYGB will be studied preoperatively, and at 1 month postoperatively. Each time point will have two study visits with a cross-over design. The first visit at each time point will be randomized to a human ghrelin or a saline infusion, with the alternate infusion at the second visit. At each study visit, an Oral Glucose Tolerance Test (OGTT) will be performed.
89685109|NCT00814697|Experimental|Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Coil Stimulation (rTMS) treatment in Alzheimer's disease. The Magstim Rapid2 stimulator with a peak magnetic field of 0.5-3.5 Tesla at 100% output was used over the right and left dorsolateral prefrontal cortex. Patients received 4 sessions of rTMS over 2 weeks, lasting approximately 30 minutes, 2 consecutive days a week for 2 weeks.
89685110|NCT02938611||The study population|Persons with stage >=4 chronic kidney disease.
89685111|NCT00814775|Active Comparator|Group 1|Fastrach Laryngeal Mask Airway intubation
89685112|NCT00814775|Active Comparator|Group 2|Intubation of difficult airway using CTrach Laryngeal Mask
89685113|NCT02593396|Placebo Comparator|placebo|Placebo BD
89685114|NCT02593396|Experimental|Active|Bupropion hydrochloride sustained-release 150mg BD
89685115|NCT02593630|Experimental|Unicirc circumcision|Unicirc circumcision under topical anaesthetic, wound sealing with cyanoacrylate tissue adhesive
89685116|NCT00848783|Experimental|A-with IP Floxuridine|"Induction treatment:~Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.~Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.~Randomization~Surgery.~Postoperative IP treatment:~Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once~Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral"
89685117|NCT00848783|Experimental|B-Without IP Floxuridine|Same as Arm A except no postoperative IP treatment.
88998042|NCT03727737|Active Comparator|ACTIVE|Patients with mild and moderate TBI will be assigned randomly to this arm and will receive treatment
88998043|NCT03712397|Experimental|nal-IRI in Head & Neck cancer|nal-IRI 80 mg/m2 for 90 minutes in sequence at day 1, every 14 days counted as one cycle
88998044|NCT03660423|Experimental|Dance Group|Dance group will participate in a 60 minute integrative dance class two times per week
88998045|NCT03660423|No Intervention|Control Group|The Control group will continue with normal activities, not participating in the dance intervention.
88998046|NCT03557918|Experimental|Tremelimumab|Tremelimumab 750 mg IV Day 1 of each 28 day cycle. Up to 7 cycles.
88998047|NCT03557463|Active Comparator|Soy protein|Low isoflavone soy protein powder: Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
88998048|NCT03557463|Experimental|Dairy protein|UV-C treated raw milk protein supplement (TruActiv MPC 85). Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
88998049|NCT03544099|Experimental|Pembrolizumab for NPC patients|Pembrolizumab 200 mg Q3W IV infusion, Day 1 of each 3 week cycle, for 35 cycles
88998050|NCT03528408|Experimental|Nivolumab and Ipilimumab|All patients enrolled to the study will be treated with nivolumab 240 mg IV every 2 weeks plus ipilimumab 1mg/kg IV every 6 weeks. 1 cycle = 6 weeks.
88998051|NCT03514602|Experimental|Multicomponent behavioral intervention|The multicomponent intervention group will receive education and counseling, monitoring and feedback, contingent financial incentives, and family support.
88998052|NCT03514602|Active Comparator|Control|The control group will receive smoking cessation education only.
88998053|NCT03501381|Active Comparator|High Dose Interleukin 2|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19
88998054|NCT03501381|Experimental|High Dose Interleukin 2 plus Entinostat|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19 plus Entinostat 5 mg orally every 2 weeks starting Day -14
88998055|NCT03478566|Experimental|Transcutaneous CO2 monitoring|
88998056|NCT03475264||Healthy|Healthy Participants
88998057|NCT03475264||BPD cohort|Participants born prematurely with a diagnosis of BPD
88998058|NCT03475264||Non-BPD cohort|Participants born prematurely without a diagnosis of BPD
88998059|NCT03465618|Experimental|surgical patients|Patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. The patient's PET/CT Brain scans may be acquired prior to surgery. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging.
89057680|NCT01684683|Experimental|Theophylline|Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks
89057681|NCT01684683|Placebo Comparator|placebo|Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks
89685118|NCT05372536|Experimental|parent-led home-administered low-dose Cytarabine|Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
89685119|NCT00849251|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89685120|NCT05371912|Active Comparator|left IPL stimulation|half of the subjects will receive TMS on the left inferior parietal lobule.
89685121|NCT05371912|Active Comparator|right IPL stimulation|half of the subjects will receive TMS on the right inferior parietal lobule.
89685122|NCT00850031|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
89685123|NCT05371678|Active Comparator|Therapeutic motor control interventions|Treatment duration will be 8 weeks. Therapeutic motor control intervention therapy sessions will be 2 days a week. Therapeutic motor control intervention will include education about defecation and physiology, dietary advices, core stabilization exercises, pelvic floor muscle training with surface Electromyographic-Biofeedback and breathing exercises. In the first session education and dietary advices will be given to patient. Dietary advices will be given by dietitian. Two surface electromyographic electrodes will be applied on external anal sphincter muscle position.
89685124|NCT05371678|Active Comparator|Conventional treatment|Treatment duration will be 8 weeks. Conventional treatment will include education about defecation and physiology, dietary advices and laxative therapy. In the first session education and dietary advices will be given to patient. Dietary advices will be given by dietitian. Laxative therapy will be given by pediatric surgery.
89685125|NCT05371522|Experimental|[18F]DPA-714|All individuals included will undergo a [18F]DPA-714 positron emission tomography (PET) scan, irrespective of the existence of post-COVID-19 complaints.
89685126|NCT02153099|Experimental|Cohort 1: TAK-058 15 mg|TAK-058 15 mg, 100 mL oral solution, once on Day 1.
89685127|NCT02153099|Experimental|Cohort 2: TAK-058 30 mg|TAK-058 30 mg, 100 mL oral solution, once on Day 1.
89685128|NCT02153099|Experimental|Cohort 3: TAK-058 45 mg|TAK-058 45 mg, 100 mL oral solution, once on Day 1.
89685129|NCT02153099|Experimental|Cohort 4: TAK-058 5 mg|TAK-058 5 mg, 100 mL oral solution, once on Day 1.
89685130|NCT02153099|Experimental|Cohort 5: TAK-058 75 mg|TAK-058 75 mg, 100 mL oral solution, once on Day 1.
89685131|NCT02153099|Experimental|Cohort 6: TAK-058 150 mg|TAK-058 150 mg, 100 mL oral solution, once on Day 1.
89685132|NCT02153099|Placebo Comparator|Cohort 1-6: Placebo|TAK-058 placebo-matching, 100 mL oral solution, once on Day 1.
89685133|NCT00850889|Active Comparator|1|Juvederm Ultra Injectable Gel with Lidocaine
89685134|NCT00850889|Active Comparator|2|Restylane Injectable Gel
89685135|NCT05254288|Experimental|Split-mouth Group A|Half of patients will be assigned to this group. Quadrants Q1/Q4 will receive ozone administration. Quadrants Q2/Q3 will receive chlorhexidine administration.
89685136|NCT05254288|Experimental|Split-mouth Group B|Half of patients will be assigned to this group Quadrants Q2/Q3 will receive ozone administration. Quadrants Q1/Q4 will receive chlorhexidine administration.
89685137|NCT00851279|Experimental|Magnetic irrigated ablation catheter|Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).
89685138|NCT04742764|Active Comparator|Group A|Patients randomized to standard medical therapy.
89685139|NCT04742764|Active Comparator|Group B|Patients randomized to cytokine removal therapy with Cytosorb, with the adsorber device changed in every 12 hours.
89685140|NCT04742764|Active Comparator|Group C|Patients randomized to cytokine removal therapy with Cytosorb, with the adsorber device changed in every 24 hours.
89685141|NCT00851357|Experimental|Active patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of nicotine patches
89685142|NCT00851357|Placebo Comparator|Placebo patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of placebo patches
89685143|NCT00851357|Active Comparator|Telephone counseling|Proactive Telephone Counseling
89685144|NCT00851357|Active Comparator|Active patches and materials|8-weeks of nicotine patches and materials
89685145|NCT00851357|Active Comparator|Placebo patches and materials|8-weeks placebo patches and materials
89685146|NCT00851357|Active Comparator|Materials|Self-help materials
89685147|NCT05105074|Active Comparator|Intrathecal Morphine|One group will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and fentanyl 15 mcg for spinal anesthesia.
89685148|NCT05105074|Placebo Comparator|Placebo|One group will receive normal saline 100 mcg in addition to the standard dose of bupivacaine and fentanyl 15 mcg for spinal anesthesia
89685149|NCT00815087|Experimental|Functional Electrical Stimulation (FES)|Functional electrical stimulation: Experimental
89053264|NCT01140646|Experimental|Arm I|The first week of the study is a baseline week where data are being collected but study agent is not being taken. Patients then receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
89053265|NCT00572741|Experimental|1|Nutritional supplementation
89053266|NCT00572741|Placebo Comparator|2|Placebo
89057682|NCT04537325|Active Comparator|RenalGuard group|
89057683|NCT04537325|No Intervention|Control group|
89685150|NCT00815087|Active Comparator|Home Rehabilitation Program (HRP)|Exercise home program
89216505|NCT03326804||Cohort 2 - Efficacy|Cohort 2 will consist of the remaining target size population of 230 patients for H1 Hip Resurfacing Arthroplasty. They will undergo the same intervention as previously described for Cohort 1, but will not undergo metal-ion testing and reduced frequency CT-scans.
89216506|NCT03303547|Experimental|MRI-Pathology N1c matching group|MRI mapping will be used to guide pathologists to sample areas of the mesorectum where tumour deposits are likely to be present.
89685151|NCT04978324|Experimental|Autogenous Growth Factors Left Side|5-8mm pockets on the left side of the mouth will receive insertion of small treatment after deep cleaning. The right side of the mouth will receive deep cleaning only, the standard of care.
89685152|NCT04978324|Experimental|Autogenous Growth Factors Right Side|5-8mm pockets on the right side of the mouth will receive insertion of small treatment after deep cleaning. The left side of the mouth will receive deep cleaning only, the standard of care.
89685153|NCT02856269|Active Comparator|45 mg daily|Participants in this arm will take a daily 45 mg dose of zinc gluconate.
89685154|NCT02856269|Active Comparator|90 mg daily|Participants in this arm will take a daily 90 mg dose of zinc gluconate.
89685155|NCT04839250|Experimental|cataract surgery performed by heads-up method|3D heads-up surgery was performed under the NGENUITY® 3D visualization system
89685156|NCT04839250|No Intervention|Traditional surgery|Traditional surgery was performed under a surgical microscope.
89685157|NCT04382573||CDK13|CDK13 intragenic pathogenic variant
89685158|NCT00852137|Experimental|PEP005 (ingenol mebutate) Gel, 0.05%|
89685159|NCT00852137|Placebo Comparator|Vehicle Gel|
89685160|NCT04765306|Active Comparator|Traditional Direct Fascial Closure|At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed under traditional direct visualization without laparoscopic guidance using a single interrupted suture of 0-vicryl.
89685161|NCT04765306|Active Comparator|Fascial Closure Device|At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed using direct laparscopic visualization with the Carter-Thomason fascial closure device with a single interrupted suture of 0-vicryl.
89685162|NCT00852527||Subjects with mild TBI|Presence of mild TBI defined by positive reference test
89685163|NCT00852527||Subjects without mild TBI|Absence of mild TBI defined by negative reference test
89685164|NCT04652362|Experimental|Growth Mindset Intervention|
89685165|NCT04652362|Active Comparator|Supportive Therapy Intervention|
89685166|NCT04742530|Experimental|Fasted Evening Exercise|Exercise will take place in the evening, following a 7 hour period of fasting.
89685167|NCT04742530|Active Comparator|Fed Evening Exercise|Exercise will take place in the evening, after having consumed a carbohydrate-containing meal 2 hours prior.
89685168|NCT04742530|Active Comparator|Fed Morning Exercise|Exercise will take place in the morning, after having consumed a carbohydrate-containing meal 2 hours prior.
89685169|NCT00852761|Experimental|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam
89685170|NCT00852761|Active Comparator|Clobex lotion|Clobex (clobetasol propionate 0.05%) lotion.
89685171|NCT04222751|Experimental|Stretch Group|Subjects assigned to this group will be instructed on how to wear the device to produce the appropriate amount of dorsiflexion (stretch). Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
89685172|NCT04222751|Placebo Comparator|No Stretch Group|Subjects assigned to this group will wear the splints but instructed to wear the device in a position that produces no stretch. Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
89685173|NCT04084756|Experimental|Couples Crisis Response Plan|
89685174|NCT04084756|Active Comparator|Mental Health Education|
89685175|NCT04082806|Experimental|healthy controls|
89685176|NCT04082806|Experimental|Major Depressive Disorder|
89053267|NCT01140568|Experimental|nilotinib|Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.
89053268|NCT00572780||CTE with CD|Crohn's disease patients who underwent a CT enteroclysis as part of their clinical evaluation for symptomatic Crohn's disease.
89053269|NCT04572945||1- Cases: Diabetic patients with CKD.|classified according to estimated GFR into 5 stages according to KIDGO 2012 classification.
89053270|NCT04572945||2- Controls: Diabetic patients without CKD.|defined as patients who have normal kidney function test, normal urine analysis and normal ultrasound findings.
89053271|NCT00572819|Active Comparator|Misoprostol|
89053272|NCT00572819|Placebo Comparator|Placebo|
89216507|NCT03301558|Active Comparator|Low dose sodium bicarbonate|Low dose 1500 mg sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take one capsule with breakfast, one with lunch and one with dinner (schedule 1-1-1).
89685177|NCT05656222|Experimental|VIA treatment Group|
89685178|NCT00854087|Active Comparator|Fuzheng Huayu|Pill with Fuzheng Huayu
89685179|NCT00854087|Placebo Comparator|Placebo|Pill without Fuzheng Huayu (sugar pill)
89685180|NCT05631496||Patients with Knee Disorders|Patients with knee disorders such as traumatic meniscal and ligament injuries,fractures,osteoarthritis,patellofemoral joint pain
89685181|NCT02487797|Experimental|High dose oxytocin regimen|The oxytocin solution will be prepared using 90 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 6 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 6 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
89216508|NCT03301558|Active Comparator|High Dose sodium bicarbonate|High dose 3000 mg of sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take two capsules with breakfast, two with lunch and two with dinner (schedule 2-2-2).
89685182|NCT02487797|Active Comparator|Low dose oxytocin regimen|The oxytocin solution will be prepared using 30 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 2 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 2 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
89685183|NCT01733693|Experimental|Buprenorphine|Oral sublingual tablet, 8-32 mg per day, administered daily for duration of 4 months
89685184|NCT01733693|Active Comparator|Methadone|Oral sublingual tablet, 60-100 mg per day, administered daily for duration of 4 months
89685185|NCT00855413|Other|Darunavir/Ritonavir and Etravirine|"Darunavir/Ritonavir 800 mg/100 mg orally once daily.~ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen."
89216509|NCT03301467|Experimental|Avacopan|Avacopan (formerly CCX168) 10 mg capsules x 3 administered twice daily during the blinded 26 week blinded treatment period
89216510|NCT03301467|Placebo Comparator|Avacopan Matching Placebo|Matching placebo capsules x 3 administered twice daily during the 26 week blinded treatment period period
89216511|NCT03274050||patient group|Surgery with robot - all patients operated in surgery department with indication of robot in the routine care (all specialities).
89216512|NCT03274050||control group|Retroperitoneal coelioscopy - patient operated for pyeloplasty - only for pediatry
89216513|NCT03255954|Experimental|Interpersonal Counseling-C|Interpersonal Counseling for University Counseling Centers is a psychotherapeutic intervention
89685186|NCT05599204|Experimental|schroth exercise|the patients will receive Schroth exercise twice a week for four weeks
89685187|NCT05599204|Active Comparator|postural correction exercise|the patients will receive postural correction exercise twice a week for four weeks
89685188|NCT00856739||Group 1|
89685189|NCT00816101|Experimental|PROCELLERA™Antimicrobial Dressing|Dressing changes every 3 days, more frequently if needed
89685190|NCT00816101|Active Comparator|Mepilex® Border Lite|Dressing changes every 2-3 days, more frequently if needed
89685191|NCT00816101|Active Comparator|Band-Aid® Adhesive Bandage|Dressing changes every 2-3 days, more frequently if needed.
89685192|NCT05452018|Experimental|First intervention group|Recordings of muscle activity during swallowing
89685193|NCT00818363|Experimental|Group 1: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
89685194|NCT00818363|Placebo Comparator|Group 2: SABER-Placebo|5.0 mL SABER-Placebo/Once
89685195|NCT00828841|Active Comparator|Paclitaxel, Carboplatin, Cetuximab (Arm A)|Patients with squamous or non-squamous histologies will receive carboplatin and paclitaxel for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion.
89685196|NCT00828841|Active Comparator|Platinum, Gemcitabine, Cetuximab (Arm B)|Patients with squamous or non-squamous histologies will receive gemcitabine with either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion.
89685197|NCT00828841|Active Comparator|Platinum, Pemetrexed, Cetuximab (Arm C)|Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
89216514|NCT03253978|Experimental|SABR to prostate / seminal vesicles with pelvic ENI|36.25Gy / 5 fractions to prostate and seminal vesicles with additional SABR (25Gy /5 fractions) delivered to the pelvic nodes.
89216515|NCT03253978|Active Comparator|SABR to prostate and seminal vesicles only|36.25Gy / 5 fractions to prostate and seminal vesicles.
89216516|NCT03238755||Statin group|HIV-infected individuals receiving statin therapy for the duration of the study
89216517|NCT03238755||Placebo group|HIV-infected individuals receiving placebo therapy for the duration of the study
89216518|NCT03225222||Low-risk PCa|No TRUS-guided biopsy
89216519|NCT03225222||Intermediate/high-risk PCa (Control)|TRUS-guided biopsy 'only' (current standard practice).
89216520|NCT03225222||Intermediate/high-risk PCa (Intervention 1)|TRUS-guided biopsy 'first'; if indicated followed by MRI and targeted biopsies.
89216521|NCT03225222||Intermediate/high-risk PCa (Intervention 2)|MRI-'first', followed by TRUS-guided and targeted biopsies.
89216522|NCT03223077||Acute Campylobacter|We will enroll 150 patients with acute Campylobacter infection. Our microbiology laboratory will inform us of a culture or PCR positive case of Campylobacter infection as soon as that test result is available.
89216523|NCT03156036|Experimental|MGMT hypermethylated Cohort A|MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
89216524|NCT03156036|Active Comparator|MGMT hypermethylated Cohort B|MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
89216525|NCT03156036|Active Comparator|MGMT unmethylated Cohort A|MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
89216526|NCT03156036|Active Comparator|MGMT unmethylated Cohort B|"MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.~(n=37)"
89685198|NCT05445310|Experimental|Furmonertinib|Patients will receive furmonertinib 80mg/d for 3 years or until disease recurrence or treatment cessation for other reasons.
89685199|NCT00858689|Experimental|minocyline 50 mg or 100 mg PO BID|open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks
89685200|NCT05415592||DePuy Synthes Radial Head Replacement System|Participants will undergo a radial head replacement or partial replacement of the elbow joint with the DePuy Synthes Radial Head Replacement System.
89685201|NCT00830791|Experimental|MK-0941 20 mg Mild Renal Insufficiency|MK-0941 20 mg administered to participants with mild renal insufficiency and type 2 diabetes.
89685202|NCT00830791|Experimental|MK-0941 20 mg Moderate Renal Insufficiency|MK-0941 20 mg administered to participants with moderate renal insufficiency and type 2 diabetes.
89685203|NCT00830791|Experimental|MK-0941 5 mg Severe Renal Insufficiency|MK-0941 5 mg administered to participants with severe renal insufficiency and type 2 diabetes.
89685204|NCT00830791|Experimental|MK-0941 20 mg Matched Controls|MK-0941 20 mg administered to age-, gender-, race-, body mass index (BMI)-, and hemoglobin A1C (HbAIc)-matched control subjects with normal renal function and type 2 diabetes.
89685205|NCT00830791|Experimental|MK-0941 5 mg Matched Controls|MK-0941 5 mg administered to age-, gender-, race-, body mass index (BMI)-, and HbAIc-matched control subjects with normal renal function and type 2 diabetes.
89685206|NCT04741360|Experimental|Modified Story Memory Technique|
89685207|NCT04741360|Other|Control|
89685208|NCT00820235|Experimental|A|
89685209|NCT00820235|Active Comparator|B|
89685210|NCT00820235|Active Comparator|C|
89685211|NCT05026099|Experimental|Boxing training program|The program will start with a warm-up session involving breathing and stretching of the trunk and limbs for 5 minutes. The program will include mitt hitting and sand bag hitting for 10 minutes, with a 2-minute rest period. Thereafter, stretching of the trunk and limbs will be performed for 5minutes, similar to the warm-up
89685212|NCT05026099|Active Comparator|Task Oriented Training Program|Upper limb Exercises: Sitting position: open covered pots of different sizes and transfer the flour to a cup with a spoon, then close the pot.Sitting position: pick up coins and cards on the table and put the coins in a pot and gather the cards.Sitting position: write and/or draw pictures on a piece of paper.Sitting position: open a safe box with a key, pick up small objects inside the box, and transfer them to a pot, then lock the safe box Sitting position: pick up and transfer jars, bottles, and glasses of different sizes and weights located on a table. Transfer the liquid contents from jars and bottles to glasses Sitting position: throw and catch balls (in pairs)
89685213|NCT00821795|Active Comparator|NPH/Regular 70/30 mix|transition insulin therapy with NPH/Regular 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
89685214|NCT00821795|Active Comparator|Aspart insulin analog biphasic mix|transition insulin therapy with Aspart insulin analog 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
89685215|NCT05322304|Experimental|almond|dietary intervention with almonds ()20% of energy)
89685216|NCT05322304|No Intervention|Control|usual diet and lifestyle
89685217|NCT04382131|Experimental|Hypertonic saline nasal irrigation and gargling|Participants in the intervention arm will be asked to perform hypertonic saline nasal irrigation and gargling up to 12 times daily for a maximum of 14 days or until they report that they feel well.
89053273|NCT00585429||1|ESLD subjects on active liver transplant waiting list
89053274|NCT00585429||2|Subjects post-liver transplant with good liver function
89053275|NCT00585429||3|Subjects without liver disease undergoing kidney biopsy for diagnostic purposes
89053276|NCT00572858||Premenopausal women|Female patients who have undergone coronary angiography and are under the age of 55
89053277|NCT04572594||Inflammatory myofibroblastic tumor|tissue of Inflammatory myofibroblastic tumor lession
89053278|NCT00572975|Experimental|1|
89685218|NCT04382131|No Intervention|Standard Care|Participants in the control arm will be given standard NHS guidance for the management of their symptoms and household hygiene.
89053279|NCT00585624|Experimental|1|Supplement: 3 servings/day of Impact Advanced Recovery in addition to regular food or any other supplements recommended or desired by patient or primary care/surgical team.
89053280|NCT00585624|Placebo Comparator|2|Standard Care: Food, beverages, or supplements as recommended or desired by patient or primary care/surgical team.
89053281|NCT04580030||hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure <90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
89053282|NCT04580030||no hypotension|"Basal hemodynamic parameters and hemodynamic values will be taken every two minutes after induction until surgical incision. Patients with systolic pressure <90 mmHg or 30% drop in baseline, and mean artery pressure below 60 mmHg will be considered to have hypotension. Patients will be divided into two groups as Hypotension and No Hypotension."
89053283|NCT04572555|Experimental|Heat Treatment Group|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak. The subjects were instructed on the application of the thermophores. Thermoforming was applied wrapped in towels in order to shield the subjects from the effects of direct heat. In a study, heat packs that had a temperature of 38.9 °C were used for treatment of dysmenorrhea. In this study, the temperature of the water used in the thermoforming process was 45 °C. Considering the risk of the thermophores cooling down and the shielding provided by the towels, the water temperature was kept higher compared to those in other studies. The temperature of the water was measured using a liquid thermometer. Heat treatment was applied for 20 minutes without interruptions.
89053284|NCT04572555|No Intervention|Control Group|No Intervention
89053285|NCT03451110|Experimental|Part 1: Lemborexant plus Loestrin|Healthy female participants will receive a single oral dose of Loestrin 1.5/30 (containing ethinyl estradiol [EE] 0.030 milligrams [mg] and norethindrone [NE] 1.5 mg) in the evening of Day 1 after a fast of at least 3 hours. After a washout period of at least 4 days, participants will receive 10 mg lemborexant orally for 10 days. Lemborexant will continue to be administered in the evening on Days 15 through 18, followed by a single oral dose of Loestrin on Day 15 when administered with lemborexant after fasting in the evening for at least 3 hours.
89216527|NCT03023215|Experimental|Guided Meditation Group (GM)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
89216528|NCT03023215|Active Comparator|Focused Breathing Group (FB)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.."
89216529|NCT03023215|Active Comparator|Standard of Care Group (SC)|"Participants listen to a 10 minute neutral-content audio clip from National Public Radio prior to stereotactic breast biopsy (SBB).~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
89216530|NCT03005925|Experimental|connected group|remote monitoring by smartphone in the care management of patients with rheumatoid arthritis
89216531|NCT03005925|Active Comparator|control group|standard outpatient follow-up by physical consultation
89216532|NCT03005327|Experimental|X4P-001|"Initial Treatment Phase: Participants will initiate treatment with mavorixafor at 50 milligrams (mg) once daily (QD) orally or a higher dose, with potential escalation based on area under the curve for absolute neutrophil count and absolute leukocyte count (AUCANC/ALC) values to a maximum total daily dose of 400 mg. Participants are expected to receive treatment for 24 weeks in the initial Treatment Period or until development of a treatment-limiting toxicity (TLT).~Extension Phase: All participants will receive mavorixafor; the dose will not exceed 400 mg. In the Extension Phase, treatment may continue until mavorixafor becomes available via an alternative mechanism (for example, drug is commercially available, an expanded access program, etc.) or until the study is terminated by the sponsor."
89216533|NCT02998203|No Intervention|Conventional phase|During the conventional phase, participants are asked to maintain their usual dietary choices for 40 days.
89216534|NCT02998203|Experimental|Organic phase|During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.
89216535|NCT02972060|Active Comparator|ADT|"The standard treatment for this stage of the disease is ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
89216536|NCT02972060|Experimental|ODM 201|"ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) bid for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food.~Subjects who have clinical benefit at week 24 may continue to receive ODM-201 at the discretion of the investigator until disease progression, objective or clinical, or occurrence of an unacceptable toxicity. This includes those that will receive external beam radiation therapy.~Any anti-cancer therapy other than the study drug given as single agent will not be considered part of the protocol treatment."
89216537|NCT02968654|Other|Restrictive Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 7 g/dL (as suggested by current guidelines in general ICU population)"
89216538|NCT02968654|Other|Liberal Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 9 g/dL"
89685219|NCT04382261|Placebo Comparator|Periodontitis quadrant|Patients undergo non surgical quadrant scaling and root planing
89685220|NCT04382261|Active Comparator|Periodontitis full mouth|Patients undergo non surgical full mouth scaling and root planing
89685221|NCT00833365|Active Comparator|Early treatment|Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old
89685222|NCT00833365|Active Comparator|Late treatment|Infants randomized to this group will receive their initial dose of ibuprofen after infant has reached 96 hrs old but before the infant reaches 10 days old.
89685223|NCT00821951|Experimental|Vorinostat and Radiotherapy|
89685224|NCT00860015|Experimental|Alimta/Gemcitabine|IV administration of drugs for 14 days for up to 4 cycles
89685225|NCT00853333|Active Comparator|Propofol|Administration via an IV
89685226|NCT00853333|Active Comparator|Midazolam|Administration via an IV
89685227|NCT00853333|Active Comparator|Dexmedetomidine|Administration via an IV
89685228|NCT00853645|Experimental|Subcutaneous implantable cardioverter defibrillator (S-ICD) System|Single-arm with 6 patients implanted with an S-ICD System
89685229|NCT00822107|Experimental|Thiazide Response|Hydrochlorothiazide 50 mg will be administered by mouth once.
89685230|NCT05218408|Experimental|Phase 1Surgical rGBM CYNK-001 infusion ( IV and IC) in combination with IL-2|Phase 1 dose escalation will utilize a 3+3 dose escalation design and will evaluate safety, feasibility, and preliminary efficacy of four cohort dose levels of CYNK-001 administered after a 6M IU subcutaneous dose of rhIL-2 for both IV and IC cycles. Up to 21 patients will be enrolled over 4 dosing cohorts in Phase 1.
89685231|NCT05218408|Experimental|Phase IIa Surgical rGBM CYNK-001 at MPD IV and IC|To evaluate efficacy and safety of CYNK-001 administrations in recurrent GBM at maximum tolerated dose for IV and IC per Phase 1 outcome. No patients staggering will be implemented in phase 2a. DMC will review the phase 2a entirely
89685232|NCT05236907|Placebo Comparator|Control Group|Patients in this group received nothing for sedation.
89216539|NCT02873338|Active Comparator|Control (idarubicin+cytarabine)|"Induction:~Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, and 3)~Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 7)~Re-induction:~Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1 and 2)~Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 5)~Consolidation:~• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, and 5)"
89216540|NCT02873338|Experimental|Dociparstat 0.125 mg/kg|"Induction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/hr continuous 24-hour intravenous (IV) infusion (Days 1 to 7)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, and 3)~Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 7)~Re-induction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/hr continuous 24-hour IV infusion (Days 1 to 5)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1 and 2)~Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 5)~Consolidation:~Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/hr continuous 24-hour IV infusion on (Days 1 to 5; total 120 hours)~Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, and 5)"
89216541|NCT02873338|Experimental|Dociparstat 0.25 mg/kg|"Induction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/hr continuous 24-hour intravenous (IV) infusion (Days 1 to 7)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, and 3)~Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 7)~Re-induction:~Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/hr continuous 24-hour IV infusion (Days 1 to 5)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1 and 2)~Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1 to 5)~Consolidation:~Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/hr continuous 24-hour IV infusion (Days 1 to 5; total 120 hours)~Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, and 5)"
89216542|NCT02864147|Experimental|imiquimod + 9-valent HPV vaccine|Participants randomized to the imiquimod + 9-valent HPV vaccine group will receive instruction on imiquimod self application (16 week course) at the baseline visit. In addition, all women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
89216543|NCT02864147|Active Comparator|imiquimod only|Participants randomized to the imiquimod only group will receive instruction on imiquimod self application (16 week course) at the baseline visit.
89216544|NCT02864147|No Intervention|observation only (control)|Participants randomized to the control group will only be observed and will receive no intervention.
89216545|NCT02863055|Experimental|Nintedanib|200 mg twice a day per os
89685233|NCT05236907|Active Comparator|Midazolam group|7.5 mg of Midazolam were given orally the night before operation. Another dose 90 min. preoperatively.
89685234|NCT05236907|Experimental|Melatonin group|5 mg of Melatonin were given orally the night before operation. Another dose 90 min. preoperatively
89685235|NCT05217706|Experimental|Treatment|This group will be given ketamine 0.2mg/kg
89685236|NCT05217706|Placebo Comparator|Placebo|This group will be given normal saline in matched syringe
89685237|NCT00833443|Active Comparator|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days.
89685238|NCT00833443|Placebo Comparator|Sugar Pill|
89685239|NCT00822185|Experimental|vatreptacog alfa, 5 mcg/kg|
89685240|NCT00822185|Experimental|vatreptacog alfa, 10 mcg/kg|
89685241|NCT00822185|Experimental|vatreptacog alfa, 20 mcg/kg|
89216546|NCT02863055|Placebo Comparator|Placebo|Placebo match twice a day per os
89216547|NCT02809690|Experimental|Diagnostic (18F-FMAU PET/CT)|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.
89685242|NCT00822185|Experimental|vatreptacog alfa, 30 mcg/kg|
89685243|NCT00835003|Active Comparator|1|Elective caesarean section at 38 weeks and 3 days of gestation
89685244|NCT00835003|Active Comparator|2|Elective caesarean section at 39 weeks and 3 days of gestation
89685245|NCT05207722|Experimental|Phase I Dose Escalation|Up to two dosing cohorts of CYNK-101 in combination with rhIL2 will be evaluated following an initial induction and lymphodepletion regimen.
89685246|NCT05207722|Experimental|Phase IIa Expansion|Once the Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is determined in Phase I, the Phase IIa portion of the study will commence.
89685247|NCT00860171|Experimental|Treatment (iodine I 131 monoclonal antibody B, autologous HCT)|Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
89685248|NCT05206240||Study group|The patients considered eligible will form the study group and will start the conventional physical therapy program and radial extracorporeal shock wave therapy delivery (rESWT).
89685249|NCT03839303|Experimental|Mini Implant Supported Appliance|this group will receive an Infra-zygomatic Mini Implant Supported Appliance after leveling and alignment of the four upper incisors for 8 months or till class I canine or incisors realation is reached with follow up every month
89685250|NCT03839303|Active Comparator|Headgear|this group will receive a high pull headgear appliance attached to a removable acrylic maxillary splint for 8 months or till class I canine or incisors realation is reached with follow up every month
89216548|NCT02777385|Experimental|Arm 1|Cisplatin, Radiation, and Pembrolizumab started 3 weeks after completion of cisplating and radiation.
89216549|NCT02777385|Experimental|Arm 2|Cisplatin and Radiation and Pembrolizumab given 1 week prior to the start of cisp/radiation and given every 3 weeks
89216550|NCT02725567|Experimental|Part A: 3 to <24 months|Participants weighing 5 to less than (<) 7 kilogram (kg) received 25 milligram (mg) IVA, 7 to <14 kg received 50 mg IVA, and those weighing 14 to <25 kg received 75 mg IVA administered every 12 hours (q12h) on Days 1 through 3 and 1 morning dose on Day 4.
89216551|NCT02725567|Experimental|Part B + A/B:1 to < 24 months|Participants 4 to <6 months of age and weighing greater than or equal to (≥) 5 kg received 25 mg IVA q12h. At 6 months of age and older, participants weighing 5 to <7 kg received 25 mg IVA, 7 to <14 kg received 50 mg IVA, and those weighing 14 to <25 kg received 75 mg IVA q12h for 24 weeks on Part B. For Part A/B, participants 1 to <4 months weighing 3 kg to <5 kg received an initial low dose of 5.7 mg q12h IVA and those weighing ≥5 kg received 11.4 mg q12h IVA for the first 15 days of IVA treatment. Doses were maintained or adjusted upward at Day 15 and based on weight and/or age once they reached 4 months of age.
89216552|NCT02674217|Experimental|Multiple sclerosis autografted patients|Individuals with a relapsing-remitting (RRMS) course, secondary progressive (SPMS) or primary progressive (PPMS) were included. Patients should have a Karnofsky performance status (18) above 70% and a EDSS score (1) of 6 or below. The study is approved by the Etichs Committee of the Clinica RUIZ and all patients signed a consent form after being fully informed about procedure an possible complications. Patients included will de treated with Hematopoietic stem cell transplantation
89216553|NCT02639702|Experimental|Switch group|Participants will receive clozapine once daily at evening or bedtime throughout the study period. If a participant takes ≥200 mg of clozapine at a time other than evening/bedtime, half of this dose will be switched to an evening/bedtime regimen on day 0 (baseline), then another half dose will be switched on day 7 (week 1). Participants will receive placebo in place of the clozapine dose that was switched to evening/bedtime.
89216554|NCT02639702|No Intervention|Maintenance group|Participants will continue to take clozapine twice daily throughout the study period.
89216555|NCT02615275|Experimental|Supportive Care (bioelectrical impedance analysis, RT)|Patients undergo bioelectrical impedance analysis with seca mBCA and CT or PET at baseline, weekly for 6-7 weeks during standard of care RT, and at 10-12 weeks after completion of RT.
89216556|NCT02555579|Experimental|Dietary Protein Counting & Free Fruits & Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
89216557|NCT02431130|Experimental|Low-fidelty instructor driven simulation training|participants receive simulation training
89216558|NCT02431130|No Intervention|No simulation training|
89216559|NCT02290951|Experimental|Part A|DLBCL post CAR-T
89216560|NCT02290951|Experimental|1N Part B|FL
89216561|NCT02290951|Experimental|2N Part B|DLBCL
89685251|NCT05184088|Experimental|Patients with suspected cardiac amyloidosis|After enrolment, patients will be subjected to diagnostic procedures according to standard of care to resolve diagnostic uncertainties and to clarify possible cardiac involvement. The results of the clinical work-up will be used a standard of truth, i.e. patients with initially suspected cardiac amyloidosis that where subsequently clinically diagnosed with cardiac AL Amyloidosis, cardiac ATTR Amyloidosis, other cardiac Amyloidosis or non cardiac amyloidosis.
89685252|NCT00860795|Active Comparator|Echinacea|
89685253|NCT00860795|Placebo Comparator|placebo|
89685254|NCT00823043||Timolol hemihydrate|Subjects currently prescribed timolol hemihydrate 0.5% solution.
89685255|NCT00823043||Timolol maleate|Subjects currently prescribed timolol maleate in sorbate.
89685256|NCT05115760|Experimental|Supportive care (pea protein oral nutrition supplement)|Patients receive Kate Farms pea protein oral nutrition supplement PO during their mealtimes as directed by their clinical dietitian during and up to 1 month following chemoradiation in the absence of unacceptable toxicity.
89685257|NCT05103514||Cohort 1|Participants in this group started their recovery process < 1 year ago
89685258|NCT05103514||Cohort 2|Participants in this group started their recovery process 1 to <2 years ago
89685259|NCT05103514||Cohort 3|Participants in this group started their recovery process 2 to <3 years ago
89685260|NCT00861263|Other|spiral overtube|Any subject that has been referred for spiral enteroscopy will be asked to participate in this study. The purpose is to gather data about the technical aspects of the procedure,diagnostic capability and treatment as well as long term follow up.
89685261|NCT00862745|Experimental|Active|fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.
89685262|NCT00862745|Placebo Comparator|Control|placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.
89216564|NCT02209545|Experimental|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
89216565|NCT02209545|Placebo Comparator|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
89685263|NCT02150759|Experimental|Dexmedetomidine-ketamine|Dexmedetomidine-ketamine group
89685264|NCT02150759|Active Comparator|Dexmedetomidine-fentanyl|Dexmedetomidine-fentanyl group
89685265|NCT02150837||5 & 2 & 2 Plan|MWCC members who used the Medifast 5 & 2 & 2 Meal Replacement Plan for weight loss.
89685266|NCT02150837||4 & 2 & 1 Plan|MWCC members who used the Medifast 4 & 2 & 1 Meal Replacement Plan for weight loss.
89685267|NCT04991350|Active Comparator|Ranibizumab Group|Patients will receive monthly ranibizumab injections for 3 months.
89685268|NCT04991350|Active Comparator|Bevacizumab Group|Patients will receive monthly bevacizumab injections for 3 months.
89685269|NCT00857545|Experimental|Arm I (vaccine therapy and adjuvant)|Patients receive polyvalent antigen-KLH conjugate vaccine and immunological adjuvant OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 11, 23, 35, 47, 59, 71, and 83 in the absence of disease progression or unacceptable toxicity.
89685270|NCT00857545|Experimental|Arm II (adjuvant)|Patients receive immunological adjuvant OPT-821 SC as in arm I.
89216566|NCT02186509|Experimental|Alisertib, fractionated stereotactic radiosurgery|"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.~MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity."
89216567|NCT02108964|Experimental|Phase I part|Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations will be administered escalated doses of EGF816 orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study. The starting dose for the Phase I part first cohort of patients will be 75 mg once per day capsule.
89216568|NCT02108964|Experimental|Phase II part|Treatment naïve participants with locally advanced or metastatic NSCLC harboring EGFR mutations will be administered with EGF816 at RP2D during Phase II part of the study.
89216569|NCT02086045|Other|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|DESolve Scaffold
89216570|NCT02086006|Other|DESolve scaffold|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold. test arm, intervention
89216571|NCT01976065|Other|Mineral Trioxide Aggregate (MTA)|Standard Treatment group consisting of placement of Mineral Trioxide Aggregate (MTA), an FDA approved dental material at the end of an immature root followed by a composite restoration (crown).
89216572|NCT01976065|Experimental|Revascularization Treatment (REVASC)|Consists of standard treatment procedure PLUS disinfection of the canal space with Triple Antibiotic Paste study medication followed by placement of Collaplug, an FDA approved material to help promote clotting. A composite restoration in then placed.
89216573|NCT01976065|Experimental|Regeneration Treatment (REGENDO)|Consists of standard treatment procedure PLUS Triple Antibiotic Paste study medication PLUS use of Emdogain, an FDA approved medication used in an FDA approved manner, that is a growth factor to help surrounding tissues to grow together and heal.
89216574|NCT01970332|No Intervention|No Exercise Therapy or Revascularization operation|The patient is evaluated but no intervention
89216575|NCT01970332|Experimental|Revascularization Surgery|The patient undergoes surgery to revascularize the ischemic, symptomatic limb(s)
89216576|NCT01970332|Experimental|Exercise Therapy|The patient undergoes supervised exercise therapy for 6 months
89532978|NCT05691361|Experimental|PART A - Active ADX-324 administered to HV|For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
89685271|NCT04952194|Experimental|Stalevo group|Stalevo is taken five times a day, three hours apart. Compare the incidence of dyskinesia.
89685272|NCT04952194|Active Comparator|Control group|Carbidopa and Levodopa Sustained-release Tablets is taken five times a day, three hours apart. Compare the incidence of dyskinesia.
89685273|NCT04137965||Testicular torsion group|Men having undergone surgery for testicular torsion between 01.01.2003 and 12.31.2012
89685274|NCT04137965||Control group|Men without knowledge of their fertility status and who have never had their semen analyzed
89685275|NCT04930354|Experimental|Single arm|Single arm dose escalation study; ECP1014 oral capsule of10mg, 20mg, 40mg, 80mg and 160mg given once daily for 28 days
89685276|NCT00835159|Experimental|Rivastigmine Patch|Group receiving Rivastigmine Patch
89685277|NCT00835159|Placebo Comparator|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
89685278|NCT04927156||BALT medical devices|
89685279|NCT04860856|Experimental|Hematoma block|Fracture site injection of 20 mL of 0.5% ropivacaine with an 18-gauge needle (150 mm length).
89685280|NCT04860856|Placebo Comparator|Normal saline injection|Fracture site injection of 20ml of normal saline.
89685281|NCT02617888|Active Comparator|CCTA Breast Shields|Within female subset, randomization to wearing bismuth breast shield.
89685282|NCT02617888|No Intervention|CCTA No Breast Shields|Within female subset, randomization to wearing no bismuth breast shield (standard of care).
89685283|NCT02617888|No Intervention|Observational Arm|Non-females undergoing CTA and subjects undergoing cardiac catheterization and nuclear medicine testing.
89685284|NCT02618512|Experimental|SBC-103|Patients were administered 1 mg/kg by IV infusion once every other week (qow) for at least 12 weeks. After evaluation of 12-week safety, tolerability, and pharmacodynamic data in individual patients, the dose was increased to 3 mg/kg qow. Infusions were to be at least 10 days apart and were administered every 14 days ±5 days.
89685285|NCT00857857|Experimental|13 day repeat dose|
89685286|NCT02622178|Experimental|Healthy Subjects|42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal appearing optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
89685287|NCT02622178|Experimental|Glaucoma Suspects|45 Glaucoma suspects with glaucomatous appearance optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
89685288|NCT02622178|Experimental|Glaucoma Patients|49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc appearance (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
89685289|NCT02623348|Experimental|pedometer|Patients will be given pedometers and instructions to increase physical activity based on pedometer output
89685290|NCT02623348|No Intervention|usual care|No intervention
89685291|NCT02625298|Experimental|ProRoot MTA|Traumatized permanent teeth obturated with ProRoot MTA after root canal treatment
89685292|NCT02625298|Experimental|MTA+ Cercamed|Traumatized permanent teeth obturated with MTA+ Cerkamed after root canal treatment
88998060|NCT03465618|Experimental|non-surgical patients|Before the patient's PET Brain scans patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging
88998061|NCT03451786|Experimental|Treatment group|
89057684|NCT01684761|Experimental|Tcelna|30-45 x 10E6 total cells in 2 ml. Subjects receive two annual courses of 5 subcutaneous doses each year (at 0, 4, 8, 12 and 24 weeks).
89057685|NCT01684761|Placebo Comparator|Placebo|Tcelna inactive ingredients (without cells) totaling 2 ml per dose. Administered subcutaneously with same two year treatment regimen as experimental treatment arm.
89057686|NCT04537091|Experimental|ESWT group: rESWT|rESWT treatment was applied to patients
89057687|NCT04537091|Experimental|PRP group: PRP injection|PRP treatment was applied to patients
89057688|NCT01684800|Active Comparator|A. Desmopressin 10 microgram|
89057689|NCT01684800|Active Comparator|B. Desmopressin 25 microgram|
89057690|NCT01684800|Placebo Comparator|C. Placebo|
89057691|NCT04531163|Experimental|Interventional|"First arm is experimental, given (NAC) for 2 months in 1200mg/day dosing.~Both arms are assigned to pre-treatment analytical tests and post treatment all test analysis are repeated to compare drug effect with placebo group."
89057692|NCT04531163|No Intervention|Non-interventional|Second arm has no intervention. It is only used to compare results of analytical tests with the first interventional arm.
89057693|NCT04537169||Mild congenital ptosis|children with mild congenital ptosis
89057694|NCT04537169||Moderate congenital ptosis|children with moderate congenital ptosis
89057695|NCT04537169||Severe congenital ptosis|children with severe congenital ptosis
89057696|NCT01684995|Active Comparator|Minimal|Brief physician advice to quit smoking plus nicotine patch
89057697|NCT01684995|Experimental|Tailored|
89057698|NCT04530851|No Intervention|Conventional care|This group is conventional care of pregnant women after Cesarean section
89057699|NCT04530851|Experimental|ERAS protocol|This protocol for improve outcome of pregnant women after Cesarean section
89057700|NCT01685112||Conventional Group|Patients who developed refractory shock, but didn't received ECMO as salvage treatment
89057701|NCT01685112||ECMO group|Patient who have septic shock, and progreseed to have ECMO as salvage therapy
89057702|NCT04536896|Active Comparator|Traditional face-to-face teaching method|In this arm, participants underwent a 6-hour traditional face-to-face lecture on breastfeeding education in a classroom at a university. Course was divided into 4 1.5-hour sessions during a time span of two weeks.
89057703|NCT04536896|Experimental|Breastfeeding smartphone app|In this group, participants downloaded a smartphone application which contained an online breastfeeding education course. Participants freely navigated through the smartphone app during a time span of two weeks.
89057704|NCT01685190|Active Comparator|Prostate Alone IMRT|Participants will receive standard prostate Intensity Modulated Radiotherapy (IMRT) of 74Gy in 37 fractions delivered over 7.5 weeks.
89057705|NCT01685190|Experimental|Prostate & Pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
89057706|NCT01685346|Experimental|Biofeedback|biofeedback-mediated stress management (BFSM)
89057707|NCT04531124||control group without an integrated management|
89057708|NCT04531124||observational group with an integrated management|
89057709|NCT01685385|Active Comparator|Diagnostic intervention group A|Patients who will receive the BNP test
89057710|NCT01685385|No Intervention|Group B|Patients who will not receive the BNP test.
89057711|NCT04530968||Emerged from Minimally Conscious State (EMCS)|Emerged from Minimally Conscious State (EMCS): recovery of functional object uses or communication from chronic
89057712|NCT04530968||Minimally conscious state (MCS)|Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
89057713|NCT04530968||Vegetative state (VS)|Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
89057714|NCT04530968||Healthy controls (HCs)|Healthy controls (HCs)
89057715|NCT01200394|Experimental|PF-00489791|
89057716|NCT01200394|Placebo Comparator|Placebo|
89057717|NCT04527354|Experimental|Treamid 50 mg|1 tablet of Treamid 50 mg once a day during 4 weeks of treatment period.
89057718|NCT04527354|Placebo Comparator|Placebo|1 tablet of Placebo once a day during 4 weeks of treatment period
89057719|NCT04531280|Experimental|Home hospital care|Patients receive hospital-level care in their home, as a substitute to traditional hospital care.
89057720|NCT01685502||Group 1|Patients treated with Glucobay OD under practical manner
89057721|NCT04537130|Experimental|Experimental|The investigational medical product, the IN01 vaccine, will be administered in two phases to those patients in the experimental arm: the induction phase and the maintenance phase. During the induction phase IN01 vaccine will be administered on day 1 and will be repeated on Day 14, Day 28, Day 42 and day 56. During the maintenance phase, the vaccination will be administered every 2 months with the same dosage and administration mode as during induction.
89057722|NCT04537130|No Intervention|Control|The patients enrolled in the control arm of the study will receive standard of care.
89057723|NCT04527276|Active Comparator|Chlorhexidine|5 ml of 0,12 % Chlorhexidine (CHX) solution is applied to the intervention group for oral care
89685293|NCT02625844||Monopegylated Epoetin Beta|Health care personnel performing anemia management tasks for patients using monopegylated epoetin beta.
89685294|NCT02625844||Other Erythropoiesis Stimulating Agents (ESAs)|Health care personnel performing anemia management tasks for patients using other ESAs.
89685295|NCT00858013|Active Comparator|Nateglinide|Nateglinide 90~120mg three times a day
89685296|NCT00858013|Active Comparator|Glimepiride|Glimepiride 1~2mg once a day
89685297|NCT02626156|Experimental|Cooling gel pack|A cooling pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
89685298|NCT02626156|Active Comparator|Cooling cotton pack|A cooling cotton pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
89685299|NCT00835861|Experimental|Metformin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
89685300|NCT00835861|Active Comparator|Insulin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
89685301|NCT04339660|Experimental|UC-MSCs treatment group|Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.
89685302|NCT04339660|Placebo Comparator|Control group|Participants will receive conventional treatment and Placebo intravenously.
89685303|NCT02627794|Experimental|Silastic Silicone & Restora™ Steroid eluting spacer|"Silastic Silicone spacers are actively being used as the standard of care.~Restora™ Steroid eluting spacer (experimental).~Each nostril will receive one each of above spacers."
89685304|NCT00804973|Experimental|1|
89685305|NCT00804973|Placebo Comparator|2|
89685306|NCT00804973|Active Comparator|3|
89685307|NCT02628106|Experimental|Lipo-prostaglandin E1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days.
89685308|NCT02628964|Active Comparator|4.5% e-cig|e-cigarettes with nicotine cartridges
89685309|NCT02628964|Placebo Comparator|0 mg e-cig|e-cigarettes with placebo cartridges (0mg).
89685310|NCT00836017||BOTOX®|Patients received BOTOX® (onabotulinumtoxinA) treatment as standard of care in clinical practice as prescribed by the physician. No intervention was administered as part of the study.
89685311|NCT02629354|Experimental|Ibuprofen and Caffeine|
89685312|NCT02629354|Active Comparator|Ibuprofen|
89057724|NCT04527276|No Intervention|Placebo Group|Group of patients who received standard oral care
89057725|NCT04537052|Experimental|Onl Femoral vein|Ultrasound-guided controlled injection begins, and the venous diameter and gap between valves are reduced
89057726|NCT01200355|Experimental|micafungin|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
89057727|NCT01200355|Experimental|posaconazole|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
89057728|NCT04527705|Active Comparator|1-vist endodontic retreatment|Non-surgical root canal retreatment performed in one visit
89057729|NCT04527705|Active Comparator|2-vist endodontic retreatment|Non-surgical root canal retreatment performed in two visits
89057730|NCT04530929|Active Comparator|Group PROBIOTIC|The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies). Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
89057731|NCT04530929|Placebo Comparator|Group PLACEBO|Placebo created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.. Competitors used placebo for three months at a dose of 2x2 capsules daily.
89057732|NCT04536818||Time to surgery ≤12 hours|Waiting time to surgery ≤12 hours from hospital presentation.
89057733|NCT04536818||Time to surgery >12 hours|Waiting time to surgery >12 hours from hospital presentation.
89057734|NCT04527666||Anticoagulation group|Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.
89057735|NCT04527666||Control group|Patients with JAK2 mutation and gastroesophageal varices who didn't receive anticoagulation agents.
89057736|NCT04530500||Arm 1|Males first tested positive for SARS-CoV-2 at the site (medical center) with CAG length <24 (based on the CoVAST Test)
89057737|NCT04530500||Arm 2|Males first tested for SARS-CoV-2 at the site (medical center) with CAG length >=24 (based on the CoVAST Test)
89057738|NCT01685580|Experimental|Manufacturer VPAP ST|7 days minimum non-invasive ventilation at 2 levels of pressure (BPAP) to the intervention.
89057739|NCT01685580|No Intervention|No intervention|usual advice
89057740|NCT01685658|Active Comparator|Ketaprofen|"Patients randomized to this arm will receive intravenous ketaprofen when treating renal colic.~Intervention: intravenous ketaprofen"
89057741|NCT01685658|Experimental|Paracetamol|"Patients randomized to this arm will receive intravenous paracetamol when treating renal colic.~Intervention: intravenous paracetamol"
89216577|NCT01921335|Active Comparator|ARRY-380 Twice Daily Dosage|ARRY-380 will be 450mg orally twice-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg.ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
89216578|NCT01921335|Active Comparator|ARRY-380 Once Daily|ARRY-380 will be 750mg orally once-daily. Trastuzumab will be given at the standard full dose with a loading dose of 8 mg/kg on Day 1, cycle 1, followed by 6 mg/kg in subsequent cycles. Participants who are within 5 weeks of a 6 mg/kg dose or within 2 weeks of a 2 mg/kg dose of trastuzumab at the time of initial study dosing will not be required to have a re-loading dose but will begin treatment at 6 mg/kg. ARRY-380 will be escalated until MTD is defined or the maximum planned dose has been evaluated. The dose for subsequent dose levels will be determined according to the treatment-related AE observed during the cycle 1 (21 days) in the previous dose level
89216579|NCT01882803|Experimental|Duvelisib|
89216580|NCT01855633|Experimental|Tradtional Theta burst stimulation (TBS) rTMS|Participants will receive continuous theta burst stimulation (cTBS) rTMS to contralesional hemisphere based on a previous study (Huang et al., 2005)
89216581|NCT01855633|Active Comparator|Modified TBS rTMS|Participants will receive modified cTBS rTMS to contralesional hemisphere based on a previous study (Nyffeler et al., 2006)
89685313|NCT02834247|Experimental|Part 1: Advanced Solid Tumors|TAK-659 60 milligram (mg), tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 milligram per kilogram (mg/kg), infusion over 60 minutes, intravenously (IV), on Days 1 and 15 in each 28 day treatment cycle until PD or unacceptable toxicity. Dose escalation of TAK-659 to 100 mg may be done using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or RP2D.
89685314|NCT02834247|Experimental|Nivolumab Fixed Dose Cohort|After RP2D of TAK-659 has been identified, based on evaluation of combination with weight-based dose of nivolumab (3 mg/kg), RP2D may be evaluated in combination with a fixed dose of 240 mg IV nivolumab after discussion between investigator and sponsor for all types of advanced solid tumors. For single-agent nivolumab, fixed dose is expected to have equal exposure, safety, and efficacy as weight-based (3 mg/kg) dose. If nivolumab fixed dose is evaluated with TAK-659 RP2D, 3 participants will be initially enrolled into cohort. Following evaluation of safety, efficacy, and any available PK data, along with discussions between investigator and sponsor, 3 additional participants may be enrolled into cohort for a total of 3 to 6 participants. If >=1 out of 6 participants experiences dose-limiting toxicity (DLT) in Cycle 1, or significant safety issues are seen in Cycle 2 and beyond, re-evaluation of TAK-659 RP2D when administered with a fixed dose of nivolumab is permitted.
89685315|NCT02834247|Experimental|Part 2: Metastatic Triple-negative Breast Cancer (TNBC)|Participants with metastatic TNBC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
89685316|NCT02834247|Experimental|Part 2: Metastatic Non-small Cell Lung Cancer (NSCLC)|Participants with metastatic NSCLC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1.disease or unacceptable toxicity. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
89685317|NCT02834247|Experimental|Part 2: Metastatic HNSCC|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
89685318|NCT00859027|Experimental|Risedronate|35 mg by mouth every week as directed
89685319|NCT00859027|Placebo Comparator|risedronate placebo tablet|Calcium and vitamin D
89216582|NCT01855633|Sham Comparator|Sham rTMS|Participants will receive sham cTBS rTMS to contralesional hemisphere.
89216583|NCT01797523|Experimental|Letrozole + Metformin + RAD001|"Patients have a 7-10 day lead in period where they take Metformin alone. The starting dose of Metformin 500 mg by mouth daily for 4 days and then increased to 500 mg by mouth twice a day. Everolimus and Letrozole added and considered the start of Cycle #1.~Everolimus administered by mouth as once daily dose of 10 mg. Letrozole 2.5 mg tablet by mouth once daily. The oral dose of Everolimus should be taken together with the daily dose of Letrozole 2.5mg."
89216584|NCT01669824||Group 1|
89216585|NCT01472562|Experimental|all patients|"Induction Phase (week 1 - 48):~Lenalidomide will be given at 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance Phase (week 49 - progression of disease):~Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.~Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
89216586|NCT01266044|Experimental|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
89216587|NCT01266044|Active Comparator|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
89685320|NCT02630992|Experimental|amoxicillin-clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)
89685321|NCT00836407|Experimental|Arm 1: Ipilimumab Alone|Ipilimumab alone
89685322|NCT00836407|Experimental|Arm 2: Ipilimumab + Pancreatic Cancer Vaccine|Ipilimumab + Pancreatic Cancer Vaccine
89685323|NCT02631772|Experimental|Late Cohort, Arm 1|Ledispasvir (LDV) and Sofosbuvir (SOF) monotherapy x 12 weeks
89685324|NCT02631772|Active Comparator|Late Cohort, Arm 2|Ledispasvir (LDV) and Sofosbuvir (SOF) +ribavirin x 12 weeks
89685325|NCT05039463||PRP + HA|two injections of PRP (plasma rich in platelets ), in combination with HA (hyaluronic acid)
89685326|NCT05039463||HA alone|HA (hyaluronic acid)
89685327|NCT02633488|Placebo Comparator|Placebo|12 weeks of Placebo tablet 3 x daily
89685328|NCT02633488|Experimental|Metformin|12 weeks of Metformin tablet 850 mg 3 x daily
89685329|NCT00859339|Experimental|Experimental Treatment|Neoadjuvant cisplatin, gemcitabine and sunitinib malate followed by radical cystectomy
89685330|NCT05032599|Experimental|CD5 CART|All patients who receive CD5 CART cell infusion
89685331|NCT00859495|Experimental|Multimodal lung sparing regimen|"Intrapleural chemotherapy plus systemic chemotherapy:~Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy."
89685332|NCT05722041||Customized Abutment|Customized abutment will be placed after molar immediate implant placement.
89685333|NCT05722041||Conventional Abutment|Conventional abutment will be placed after molar immediate implant placement.
89685334|NCT05029635|Active Comparator|treatment arm|Eligible subjects will be treated with planned dose of 300 mg HMPL-523 once daily for 24 weeks
89685335|NCT05029635|Placebo Comparator|placebo arm|Drug: Placebo HMPL-523 matching placebo will be oral administrated once daily for 24 weeks.
89685336|NCT00355719|Experimental|Nevirapine-atazanavir|Atazanavir/ritonavir 300/100 mg once daily for ≥2 weeks. Nevirapine was added at a dose of 200 mg once daily from days 0 to 14, and 200 mg twice daily from days 14 to 28.
89685337|NCT00859651|Active Comparator|20,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.~Cholecalciferol 20,000 IU (2 active capsules + 1 matching placebo capsule)"
89685338|NCT00859651|Active Comparator|30,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.~Cholecalciferol 30,000 IU (3 active capsules)"
89685339|NCT02811705||PFAPA group|Life quality for PFAPA patient report by themselves or parent
89685340|NCT02811705||FMF group|Life quality for FMF patient report by themselves or parent
89685341|NCT02633956|Experimental|5 mg Obeticholic Acid|5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
89685342|NCT02633956|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
89685343|NCT02633956|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
89685344|NCT02633956|Placebo Comparator|Placebo|One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
89685345|NCT02800161|Active Comparator|Trehalose|Trehalose 70g/die
89685346|NCT02800161|Placebo Comparator|Placebo|Maltose 70g/die
89685347|NCT00836641|Active Comparator|pneumococcal immunization (2 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 2 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
89685348|NCT00836641|Active Comparator|pneumococcal immunization (10 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 10 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
89685349|NCT05721963||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.
89685350|NCT02693067|Experimental|PV-10|Intralesional rose bengal disodium (PV-10) to one or more neuroendocrine tumor metastases to the liver
89685351|NCT00806221|Experimental|Emollient|Skin barrier protection from birth
89216588|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
89216589|NCT01202851|Experimental|Relaxation Group 1|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
89216590|NCT01202851|Experimental|Relaxation Group 2|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
89216591|NCT01202851|Other|Waitlist Control Group (WLC)|Participants in this group given the option to take part in one of the two forms of relaxation (off study) after they finish their last questionnaire packet. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
89216592|NCT01196390|Experimental|Arm I (radiotherapy, chemotherapy, trastuzumab)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, 22, 29, 36, and 57 and paclitaxel intravenously IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Beginning 21-56 days after surgery, patients receive trastuzumab IV over 30-90 minutes. Treatment repeats every 21 days for 13 courses in the absence of disease progression or unacceptable toxicity.
89216593|NCT01196390|Experimental|Arm II (radiotherapy and chemotherapy)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive paclitaxel IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
89685352|NCT02634814|Experimental|TENS and Therapeutic Exercise|Patients assigned to the TENS+Therapeutic Exercise (TE) group will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN), and 8 hours of TENS per day (150 pulses per second, 150 msec phase duration at a patient-perceived strong sensory intensity). Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
89685353|NCT02634814|Sham Comparator|Sham TENS and Therapeutic Exercise|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program."
89685354|NCT02634814|Active Comparator|Therapeutic Exercise Only|The role of the comparison group is to provide data on how traditional TE affects the outcome measures. The TE only group will allow us to assess how the addition of TENS to traditional TE will augment the effects of traditional TE. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
89685355|NCT02978937||Metabolically healthy and abnormal obese|Obese patients divided into two groups according to their metabolic profile (healthy vs unhealthy)
89685356|NCT04345029|Experimental|Experimental group (Lippia citriodora + sabdariffa)|"Consumption for 60 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days."
89685357|NCT04345029|Placebo Comparator|control group Placebo (sucrose)|Two capsules per day will be consumed thirty minutes before breakfast orally for 60 days.
89685358|NCT02635828|Experimental|Triple therapy PONV prophylaxis|At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
89685359|NCT00836719|Experimental|Polyphenon E|Standarized green tea extract containing 50% EGCG
89685360|NCT05721885|Other|Peri-radiotherapy nutrition management group|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score > 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
89685361|NCT02638168|Active Comparator|Immediate Release Methylphenidate|With-in subjects trial. Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
89685362|NCT02638168|Placebo Comparator|Placebo|inert placebo ingredient
88820626|NCT05879198|Experimental|Single-Arm|All participants in this phase of the project will receive the active working memory training intervention (15, 20-30-minute computer-based training sessions over the course of 5 to 7 weeks). Additionally, key stakeholders will be asked to participate in a qualitative interview following the intervention to refine future models of intervention delivery in traditionally underserved communities.
89216594|NCT01164995|Experimental|MK-1775 and carboplatin|MK-1775: oral capsules. Carboplatin: intravenous infusion in 30 minutes
89216595|NCT01156129|Active Comparator|Arm A: Standard therapy (use of medications)|stool softener
89216596|NCT01156129|Experimental|Arm B: Acupressure bracelets|device - Biobands
89216597|NCT01156129|Experimental|Arm C|Sugar free gum
89216598|NCT00956007|Active Comparator|Arm I: Intensity-Modulated Radiotherapy|Patients undergo intensity-modulated radiotherapy (IMRT) once daily 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
89216599|NCT00956007|Experimental|Arm II: IMRT plus cetuximab|Patients undergo IMRT as in arm I. Patients also receive cetuximab IV over 1-2 hours once weekly beginning at least 5 days prior to the start of IMRT and continuing for 4 weeks after the completion of IMRT (for a total of 11 doses) in the absence of disease progression or unacceptable toxicity.
89216600|NCT00905515|Active Comparator|Control Group Cyclosporine|Maintain on Cyclosporine (CsA) at target trough level of 50-250 ng/mL.
89216601|NCT00905515|Active Comparator|Low Trough Level Prograf Group|Convert to Prograf (TAC) at target trough levels of 3.0-5.9 ng/mL.
89685363|NCT00837031|Experimental|Intervention|"The study began with a lead-in portion to confirm the tolerability of lenalidomide (25mg PO days 1-21) in combination with gemcitabine (1000mg/m2 IV days 1, 8, and 15).~After completion of the lead-in phase, all subsequent patients received lenalidomide 25mg PO on days 1-21 and gemcitabine 1000mg/m2 IV days 1, 8, and 15 of 28-day treatment cycles. Patients were instructed to take lenalidomide at approximately the same time each morning. Patients were permitted to continue treatment until disease progression or intolerable toxicity occurred."
89685364|NCT02973880|Experimental|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
89685365|NCT02973880|Active Comparator|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
89685366|NCT04344483|Active Comparator|Group A ( Lidocaine + Adrenaline)|Group A patients will receive 2% Lidocaine and 1:100,000 adrenaline soaked gauze over skin graft donor site of thigh per operatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site.
89685367|NCT04344483|Placebo Comparator|Group B ( Normal Saline)|Group B patients will receive normal saline soaked gauze over skin graft donor site of thigh intraoperatively for 10 minutes. After 10 minutes this dressing will be removed and sufratul dressing will be applied over donor site
89216602|NCT00905515|Active Comparator|High Trough Level Prograf Group|Convert to TAC at target trough levels of 6.0-8.9 ng/mL.
89216603|NCT00898365||Ancillary-correlative (renal tumor classification, biology)|Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)
89685368|NCT02639494|Experimental|Self-Centering Guide Catheter|Subjects who provided written informed consent and an attempt is made to insert the Self-Centering Guide Catheter into the subject's femoral artery.
89685369|NCT02154763|Placebo Comparator|Intraperitoneal Normal Saline|Intraperitoneal Normal Saline: 100mL (Milliliter) normal saline administered as in intervention arm
89216604|NCT00871637||Group One|Healthy non-smoking controls
89685370|NCT02154763|Experimental|Intraperitoneal ropivacaine|The abdomen will be entered and trocars placed in the usual manner. Using a standard suction/irrigation device and tubing, 200mg of Ropivacaine (0.2% Ropivacaine in 100mL Normal Saline) will be instilled into the abdomen at the start of the case, prior to dissection as follows. Under direct visualization, 50mL (Milliliter) (of the 100mL) will be infused over the esophageal hiatus. The remaining 50mL will be infused throughout the abdomen. The infusion line will then be flushed with 30mL (Milliliter) of Normal Saline to ensure the entire treatment dose is delivered, and no Ropivacaine remains in the tubing. The remainder of the surgery will proceed as usual.
89685371|NCT05721807|Experimental|functional magnetic stimulation|functional magnetic stimulation for stress urinary incontinence
89685372|NCT05721807|Experimental|pelvic floor muscle training program|exercise program for pelvic floor muscle
89685373|NCT02629731|Experimental|ankle OA|inclusion criteria: 1) diagnosis of ankle OA or PTTD [non-control subjects only], 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m) with the primary impediment to pain-free ambulation being ankle OA or PTTD
89685374|NCT02629731|Experimental|flat foot|inclusion criteria: 1) diagnosis of flat foot, 2) undergoing conservative care (i.e., prescribed a foot orthosis) and deemed not to be a surgical candidate, 3) between 18 and 80 years of age, and 4) ambulatory (able to walk at least 15 m)
89216605|NCT00871637||Group Two|Smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
89216606|NCT00871637||Group Three|Non-smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
89216607|NCT00659126|Experimental|Diagnostic (Gd, ferumoxytol, 3T or 7T MRI)|Patients receive gadolinium IV on day 1 and ferumoxytol non-stoichiometric magnetite IV on day 2. Patients undergo anatomical MRI sequences with 3T or 7T at baseline and on days 1-3. Patients also undergo DSC MRI and DCE MRI on days 1-2. Day 1 and day 2 imaging sessions may be separated by up to 7 days.
89685375|NCT02629731|No Intervention|control|inclusion criteria: 1) between 18 and 80 years of age, and 2) ambulatory (able to walk at least 15 m)
89685376|NCT02639884|Experimental|Evaluation Group|All subjects will be enrolled into the evaluation group and will receive SedLine EEG and RRa monitoring
89685377|NCT02641522|Experimental|Post-Infusion|Single infusion of siltuximab (11 mg/kg)
89685378|NCT02641834|Experimental|Veg Group|Group that starts with the Vegetarian diet
89685379|NCT02641834|Active Comparator|Med group|Group that starts with the Mediterranean diet
89216608|NCT00615082|Experimental|Mindfulness-Based Stress Reduction|"Behavioral: Mindfulness-Based Stress Reduction~Other Names:~MBSR An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching."
89216609|NCT00615082|Active Comparator|Caregiver Education & Social Support|"Behavioral: Caregiver Education & Social Support~Other Names:~CESS An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format."
89216610|NCT00581139|Active Comparator|1|
89216611|NCT00581139|Active Comparator|2|
89216612|NCT00581139|Active Comparator|3|
89216613|NCT00581139|Active Comparator|4|
89216614|NCT00572013|Experimental|Arm I Rituxan and BEAM post-autologous stem cell transplant|Rituxan and BEAM [Carmustine (BCNU), Etoposide, Cytarabine (Ara-C, cytosine arabinoside), Melphalan] will be a pre- and post-transplant agent to aid in the chemotherapy sensitization post-autologous stem cell transplant.
89216615|NCT00493831|Experimental|Nicotine replacement therapy (NRT)|any form of nicotine replacement would be allowed at subject discretion
89216616|NCT00482690|Experimental|Nicotine replacement therapy (NRT)|open label NRT self comparator design
89685380|NCT05721495|Experimental|Freeze all strategy embryo transfer|Three days after fecundation, the best embryo is criopreserved. It is transferred in a posterior cicle
89685381|NCT05721495|Active Comparator|Fresh embryo transfer strategy|Two or three days after fecundation, the best embryo is transferred.
89216617|NCT00177645|Experimental|sodium bicarbonate|inhaled sodium bicarbonate
89216618|NCT00152503|Experimental|Seletracetam|Escalating doses twice daily were to be administered.
89216619|NCT03865407|Active Comparator|Allopurinol|Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
89216620|NCT03865407|No Intervention|Standard of Care Control|The treatment arm will be compared to a standard of care arm.
89216621|NCT00487942|Active Comparator|50 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 50 mg/day armodafinil treatment arm for the double-blind treatment period of the study took one 50 mg armodafinil tablet plus three placebo tablets each morning.
89685382|NCT04964427|Experimental|anodal tDCS- sham tDCS- MPH|(A) anodal tDCS at t1 (B) sham tDCS at t2 (C) MPH at t3
89685383|NCT04964427|Experimental|anodal tDCS- MPH- sham tDCS|(A) anodal tDCS at t1 (C) MPH at t2 (B) sham tDCS at t3
89685384|NCT04964427|Experimental|sham tDCS- anodal tDCS- MPH|(B) sham tDCS at t1 (A) anodal tDCS at t2 (C) MPH at t3
89216622|NCT00487942|Active Comparator|100 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 100 mg/day armodafinil treatment arm for the double-blind treatment period of the study took two 50 mg armodafinil tablets plus two placebo tablets each morning. Subjects began taking 50 mg/day and then titrated to 100 mg/day on Day 2 of the first week of the double-blind treatment period.
89216623|NCT00487942|Active Comparator|200 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 200 mg/day armodafinil treatment arm for the double-blind treatment period of the study took four 50 mg armodafinil tablet and no placebo tablets each morning. Subjects were titrated to this dose by starting treatment at 50 mg/day (1 tablet) and increasing by 50 mg increments on days 2, 4, and 6 until they were taking 200 mg/day.
89216624|NCT00487942|Placebo Comparator|Placebo|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the placebo treatment arm for the double-blind treatment period of the study took four placebo tablets and no armodafinil tablets each morning.
89216625|NCT00132301|Active Comparator|Arm 1: Docetaxel and Prednisone|Chemotherapy after radical prostatectomy
89216626|NCT00132301|No Intervention|Arm 2: Standard of care|Standard of care
89216627|NCT00522873|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
89216628|NCT00522873|Active Comparator|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
89216629|NCT03684057|Experimental|TAU + App-Delivered Mindfulness Training (MT)|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
89216630|NCT03684057|Other|Treatment as Usual (TAU)|Individuals in the TAU group will complete the assessments without an intervention. (Note: participants will be transitioned to the Unwinding Anxiety program following the 2-month wait list control period)
89685385|NCT04964427|Experimental|sham tDCS- MPH- anodal tDCS|(B) sham tDCS at t1 (C) MPH at t2 (A) anodal tDCS at t3
89685386|NCT04964427|Experimental|MPH- anodal tDCS- sham tDCS|(C) MPH at t1 (A) anodal tDCS at t2 (B) sham tDCS at t3
89685387|NCT04964427|Experimental|MPH- sham tDCS- anodal tDCS|(C) MPH at t1 (B) sham tDCS at t2 (A) anodal tDCS at t3
89685388|NCT05721339|Experimental|Acceptance and commitment therapy|Intern nurses will participate in acceptance and commitment therapy through virtual group-based eight sessions twice weekly with homework assignments between sessions and skills demonstration.
89685389|NCT05721339|No Intervention|control group|Intern nurses who will not participate in acceptance and commitment therapy. And they are undergoing the pre-and post-tests and the post-test follow-up test.
89685390|NCT00357669|Placebo Comparator|Placebo|
89685391|NCT00357669|Experimental|Brivaracetam 50 mg/day|BRV 50 mg/day
89685392|NCT00357669|Experimental|Brivaracetam 150 mg/day|BRV 150 mg/day
89685393|NCT00861601|Experimental|low dose|eltrombopag 12.5 mg/day
89685394|NCT00861601|Experimental|middle dose|eltrombopag 25 mg/day
89685395|NCT00861601|Experimental|high dose|eltrombopag 37.5 mg/day
89216631|NCT03864627|Placebo Comparator|Placebo|Participants will receive MOR106 matching placebo via s.c. injection every other week on Day 1, 15, 29 and 43 given concomitantly with a medium potency TCS once daily until Day 57.
89216632|NCT03864627|Experimental|MOR106 320 mg|Participants will receive MOR106 320 milligrams (mg) via s.c. injection every other week on Day 15, 29 and 43 given concomitantly with a medium potency topical TCS once daily until Day 57. A loading dose of MOR106 2 x 320 mg via s.c. injection will be administered on Day 1.
89216633|NCT00519831|Experimental|Vinflunine + Cetuximab|Patients may receive more than 4 cycles of therapy if they continue to demonstrate response to therapy, have limited toxicity, and if the treating physician determines that they are deriving clinical benefit from the treatment. The decision of continuing therapy beyond 4 cycles must be discussed with the principal investigator.
89216634|NCT04303845|Experimental|Treatment with Erenumab|Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
89216635|NCT03964623||smokers|
89216636|NCT03964623||vapers|
89216637|NCT03964623||non smokers/non vapers|
89216638|NCT01634607||HIV uninfected|HIV negative patients
89685396|NCT05715723||The control group|Standard therapy
89685397|NCT05715723||The test group|Standard therapy + Reamberin
89216639|NCT01634607||HIV-infected, HAART naïve, high CD4 count|HIV positive patients with high CD4 and not on HIV treatment
89216640|NCT01634607||HIV-infected with planned to start HAART group|HIV positive patients who will start HIV treatment
89216641|NCT04269915|Experimental|Intervention|Volunteers will be exposed to escalating doses of female Schistosoma mansoni cercariae
89216642|NCT00131911|Experimental|Group A (patients with carcinoid tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
89216643|NCT00131911|Experimental|Group B (islet cell and other neuroendocrine tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
89216644|NCT01077037|Experimental|Decision Aid|Receives Decision Aid
89216645|NCT01077037|No Intervention|Control|Patient receives usual care.
89216646|NCT03968887||Case group|Patients with postoperative delirium.
89216647|NCT03968887||Control group|Patients who have not had postoperative delirium.
89216648|NCT01582633|Experimental|0.1 ml ID dose|Dose of 0.1 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
89685398|NCT02641912|Experimental|Experimental Mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
89685399|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
89685400|NCT00861913|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89216649|NCT01582633|Experimental|0.2 ml ID dose|Dose of 0.2 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
89216650|NCT01582633|Experimental|0.5 ml IM dose - needle-free|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
89685401|NCT00862537||Active Resonator magnetic field therapy|Administration of active magnetic fields with the Resonator Device
88998062|NCT03406299|Experimental|SLOG regimen|Arm 1 interventions : SLOG regimen: treatment for every 14 days as one cycle Tegafur (S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day) Leucovorin 30 mg/b.i.d., day 1-7; Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1; Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (FDR, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin
89216651|NCT01582633|Active Comparator|0.5 ml IM - needle and syringe|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by needle and syringe
89216652|NCT03968575|Experimental|Laser|
89216653|NCT00184093|Experimental|Gemcitabine weekly x 6 wks with concurrent external radiation|Gemcitabine 350 mg/m2 IV weekly x 6 weeks with concurrent external radiation
89216654|NCT01074619|Experimental|1|Memantine
89216655|NCT01074619|Placebo Comparator|2|Placebo
89216656|NCT00183625|Active Comparator|Risperidone Plus Supported Employment|
89216657|NCT00183625|Active Comparator|Olanzapine Plus Supported Employment|
89216658|NCT00183625|Active Comparator|Risperidone+Supported Employment+Skills|
89216659|NCT00183625|Active Comparator|Olanzapine+Supported Employment+Skills|
89216660|NCT00511875|Experimental|Doxycycline Monohydrate|stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months
89216661|NCT00511875|Placebo Comparator|Placebo|stratified equally to placebo taken once daily for 24 months
89685402|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
89685403|NCT00863551|Experimental|Trospium Chloride Extended Release, 60 mg|Trospium Chloride Extended Release, 60 mg
89685404|NCT03838575|Active Comparator|A - NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
89685405|NCT03838575|Active Comparator|B - SKIN PREP|"Mechanism: A broad-spectrum antiseptic to clean and prepare the skin prior to surgery.~Supplier: BD"
89685406|NCT03838575|Other|C - DRAPE|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~Mechanism: A thin impregnated plastic sheet applied to the prepared skin prior to incision to maintain sterility.~Supplier: 3M Infection Prevention"
89685407|NCT03838575|Active Comparator|D - SPONGE|"Mechanism: Small absorbable sponges placed into the wound at the time of closure which deliver high concentrations of antibiotic locally to kill pathogens present that may go on to cause SSI.~Supplier: SERB"
89685408|NCT03838575|Other|E - SKIN PREP and DRAPE|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~See descriptions in single arms (B & C)"
89685409|NCT03838575|Active Comparator|F - SKIN PREP and SPONGE|See descriptions in single arms (B & D)
89685410|NCT03838575|Other|G - DRAPE and SPONGE|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~See descriptions in single arms (C & D)"
89685411|NCT03838575|Other|H - SKIN PREP and DRAPE and SPONGE|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~See descriptions in single arms (B, C & D)"
89685412|NCT02642536|Active Comparator|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
89685413|NCT02642536|Active Comparator|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
89685414|NCT02620774|Experimental|Diabetic Wound Infection|Participants with a documented history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours.
89685415|NCT02620774|Active Comparator|Healthy Volunteer|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.
89685416|NCT03540355|Experimental|Cipros 20|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Cipros 20 association; and~1 tablet crestor placebo. Oral, once a day"
89685417|NCT03540355|Active Comparator|Crestor|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Crestor 20 mg; and~1 tablet cipros association placebo. Oral, once a day"
89053286|NCT03451110|Experimental|Part 2: Lemborexant plus Famotidine|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. On Day 15, participants will receive a single oral dose of 40 mg famotidine, followed at least 2 hours later by a single dose of 10 mg lemborexant. After a washout period of up to 14 days participants will receive 10 mg lemborexant orally for 10 days.
89053287|NCT03451110|Experimental|Part 3: Lemborexant plus Fluconazole|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. After a washout interval of approximately 10 days, on Day 11, participants will be administered 400 mg fluconazole followed by 200 mg fluconazole once daily from Days 12 to 26. During this time a single dose of 10 mg lemborexant will be administered following an overnight fast of at least 10 hours along with fluconazole on Day 15 only.
89053288|NCT03453827||PEX|Patients after Cataract surgery with PES
89053289|NCT03453827||Control|Patients after Cataract surgery without PES
89053290|NCT03453788|Experimental|Intervention group|Alternating follow-up visits by nurse and doctor. In the nurse-led consultations, the patients will be introduced to the smartphone LETSGOapp with access to information on cancer treatment and side effects, physical activity advice. Two-monthly assessment of 12 symptoms that may represent relapse through the app.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
89053291|NCT03453788|No Intervention|Reference group|Regular hospital follow-up.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
89053292|NCT00585702||1|Pregnant women with bipolar disorder
89053293|NCT00585702||2|Pregnant women without bipolar disorder
89053294|NCT03453749|Other|Salovum|Patients will be given Salovum 1g/kg body weight/24 hours, divided into 6 dosages and given during 5 consecutive days.
89053295|NCT03450993|Experimental|Immediate SMART Program Intervention|Subjects will receive the SMART-3RP intervention following study enrollment.
89053296|NCT03450993|Other|Delayed SMART Program Intervention|Subjects will record symptoms following enrollment and receive the SMART-3RP intervention approximately 3 months following study enrollment.
89053297|NCT03450954||Case(AMT patients)|patients who have undergone amniotic membrane transplant in our unit up till 2016.
89053298|NCT03450954||Control(Patients without AMT)|bullous keratopathy patients awaiting endothelial keratoplasty
89053299|NCT03453671|Experimental|Mindfulness|Participants will use the strategy of mindfulness, i.e., present moment awareness with nonjudgment and acceptance, while exercising.
89053300|NCT03453671|Experimental|Distraction|Participants will use the strategy of distraction, i.e., directing their attention to something other than exercise (specifically a podcast) while exercising.
89053301|NCT03453671|Active Comparator|Self-Monitoring|Participants will monitor their internal experience while exercising, without distraction and without being taught mindfulness skills of nonjudgment and acceptance.
89053302|NCT00585741|Experimental|2. Head and neck|Imaging with 18F-FLT PET
89053303|NCT00585741|Experimental|3. Lung|Imaging with 18F-FLT PET
89053304|NCT00585741|Experimental|4. prostate|Imaging with 18F-FLT PET
89053305|NCT00585741|Experimental|5. esophagus|Imaging with 18F-FLT PET
89053306|NCT00585741|Experimental|1.CNS|Imaging with 18F-FLT PET
89053307|NCT00573014||OBTP|Obtunded blunt trauma patients with normal CT C-spine
89053308|NCT00573053|Active Comparator|High|Arterial oxygen saturations in the range of 91-95%
89053309|NCT00573053|Experimental|Low|Arterial oxygen saturations in the range of 85-89%
89053310|NCT00585819|Experimental|2. Free breathing|Freebreathing in Body fix mold
89053311|NCT00585819|Experimental|1. breathing cycle|reproducing breathing cycles
89685418|NCT04339816|Experimental|HC-A group|"Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and 500 mg of Azithromycin once in 24 hours (with the first dose of hydrochloroquine)~Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval 250 mg of Azithromycin once in 24 hours (with the first daily dose of hydrochloroquine)"
89685419|NCT04339816|Active Comparator|HC group|"Day 1: Patients receive two doses 400 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)~Days 2-5: Patients receive two doses 200 mg of Hydrochloroquine in 12 hours interval and placebo once in 24 hours (with the first dose of hydrochloroquine)"
89685420|NCT04339816|Placebo Comparator|C group|• Day 1-5: Patients receive two doses of placebo in 12 hours interval and 1 extra dose of placebo once in 24 hours
89685421|NCT02643004|Active Comparator|Senofilcon A|Participants were randomized to wear senofilcon A lens pair for one week during the crossover study.
89685422|NCT02643004|Active Comparator|Stenfilcon A|Participants were randomized to wear stenfilcon A lens pair for one week during the crossover study.
89685423|NCT05588908|Experimental|SSGJ-613 100 mg (phase Ib)|Dose Arm 1 (phase Ib): SSGJ-613 100 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.
89685424|NCT05588908|Experimental|SSGJ-613 200 mg (phase Ib)|Dose Arm 2 (phase Ib): SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.
89685425|NCT05588908|Experimental|SSGJ-613 300 mg (phase Ib)|Dose Arm 3 (phase Ib): SSGJ-613 300 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.
89685426|NCT05588908|Experimental|SSGJ-613 200 mg (phase II)|Dose Arm 4 (phase II): SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.
89053312|NCT00573092||1|Data and specimens from three large population-based studies of heart attack, sudden death, and stroke in people treated for high blood pressure with one of the four major classes of high blood pressure drugs
89053313|NCT03450876||Healthy Control|Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort
89053314|NCT03450876||24 to < 36 months post-ipilimumab treatment|24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands
89053315|NCT03450876||≥ 36 to < 48 months post-ipilimumab treatment|36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands
89053316|NCT03450876||≥ 48 months post-ipilimumab treatment|Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands
89053317|NCT00573209|Other|1|
89053318|NCT01140451|Experimental|Ataluren/Ataluren|Participants who received double-blind ataluren during Study 009 will continue to receive open-label ataluren 3 times per day TID: 10 milligram (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
89053319|NCT01140451|Experimental|Placebo/Ataluren|Participants who received double-blind placebo during Study 009 will receive open-label ataluren TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
89053320|NCT03450837||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
89053321|NCT03450837||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
89053322|NCT03450837||Sedentary control|"This group were sedentary men without cardiovascular disease.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
89053323|NCT04579913||iTind subjects|Patient who participated previously in the MT-03 study in the iTind arm
89053324|NCT00585858||1|Subjects on mimimal or no immunosuppression and no rejection history
89053325|NCT00585858||2|Subjects who have had rejection on conventional immunosuppression
89053326|NCT00585858||3|Subjects who have not had acute or chronic rejection who are on conventional immunosuppression
89053327|NCT03450798|Active Comparator|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
89053328|NCT03450798|Sham Comparator|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
89053329|NCT00585897|Experimental|Behavioral counseling|Individual sessions which utilize motivational interviewing to assist participants to discontinue sugar sweetened beverages from their diet.
89053330|NCT04579796|Experimental|women with first trimester missed abortion|
89053331|NCT00585936||1|Normal controls without evidence of diabetes or islet specific autoimmunity
89053332|NCT00585936||2|Individuals within 6 months of diagnosis with type 1 diabetes
89053333|NCT00585936||3|Individuals at high risk for the development of type 1 diabetes
89053334|NCT00585936||4|Individuals with longstanding autoimmune diabetes
89053335|NCT00573326|Experimental|1|Imatinib 200 mg p.o. once a day for 6 months
89216662|NCT02576327|Experimental|Aprepitant Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）
89216663|NCT02576327|Active Comparator|Control Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）
89216664|NCT00183391|Active Comparator|Atomoxetine|Participants will receive treatment for ADHD with the non-stimulant atomoxetine
89216665|NCT00183391|Active Comparator|Methylphenidate|Participants will receive treatment for ADHD with the stimulant methylphenidate
89685427|NCT05588908|Experimental|SSGJ-613 300 mg (phase II)|Dose Arm 5 (phase II): SSGJ-613 300 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.
89685428|NCT05588908|Active Comparator|Compound Betamethasone Injection 1 mL (phase II)|Dose Arm 6 (phase II): Compound betamethasone injection 1 mL intramuscularly (i.m) once. The i.m. injection is recommended to be administered deeply into the gluteal muscle. Randomized patients will receive compound betamethasone injection 1 mL i.m. once and placebo matching SSGJ-613 s.c. once, on Day 1.
89685429|NCT05588830||Belimumab group|
89685430|NCT05588830||Telitacicept group|
89685431|NCT04740190|Experimental|interventional arm|Single fraction, low dose (2Gy) whole brain radiation therapy, followed by combination talazoparib and carboplatin
89685432|NCT00865969|Experimental|Belinostat|Belinostat 1000 mg/m^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.
89685433|NCT05588596|Experimental|Intervention group|Access to routine hospital care and outpatient services. Patients received relevant health counseling provided by the investigator. In addition, Patients received Trauma Resiliency Mindfulness-Informed Intervention, including Mindfulness awareness, body scanning, walking awareness, mindful breathing, etc.
89685434|NCT05588596|No Intervention|Waitlist group|Access to routine hospital care and outpatient services. In addition, the patient received relevant health counseling provided by the investigator, including AIDS related knowledge counseling, diet advice, etc. At the end of the study, patients in the waitlist group were provided with intervention.
89685435|NCT05588518|Experimental|test group-1- 10% propolis|10% propolis desensitizer, a pea-sized quantity was smeared over the test tooth. Subsequently, Iontophoresis was applied immediately. The desensitizing agent was administered at two intervals, immediately after oral prophylaxis and at the 14th-day visit.
89685436|NCT05588518|Active Comparator|test group -2- 2% sodium fluoride|2% sodium fluoride desensitizer, a pea-sized quantity was smeared over the test tooth. Subsequently, Iontophoresis was applied immediately. The desensitizing agent was administered at two intervals, immediately after oral prophylaxis and at the 14th-day visit.
89685437|NCT05588518|Active Comparator|test group-3- 1.23% acidulated phosphate fluoride|1.23% acidulated phosphate fluoride desensitizer, a pea-sized quantity was smeared over the test tooth. Subsequently, Iontophoresis was applied immediately. The desensitizing agent was administered at two intervals, immediately after oral prophylaxis and at the 14th-day visit.
89685438|NCT05588362|Experimental|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
89685439|NCT05588362|No Intervention|Traditional Glasses Procurement Group|(1) The control group will receive standard of care in which a prescription for glasses will be dispensed as a paper copy prescribed by the examiner before randomization. The research assistant will use a script (attached) that instructs families how to procure glasses traditionally through Masshealth. The participant/family will be instructed to bring the paper prescription to an optical shop that carries MassHealth frames. A printout of local optical shops that carry MassHealth frames will be provided to the patient.
89685440|NCT05588206|Experimental|Hypofractionated Stereotactic Radiotherapy for Brain Metastases|
89685441|NCT00866749|Experimental|Augmented BFM Therapy|Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
89216666|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)|Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
89216667|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 12.5 (mg/kg)|Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
89216668|NCT01021150|Experimental|Ombrabulin/cisplatin|AVE8062 combined with 75 mg/m2 of cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
89216669|NCT01021228||group1|continuous volatile anesthesia (sevoflurane) during the liver resection
89216670|NCT01021228||group2|continuous intravenous anesthesia (propofol) during the liver resection
89216671|NCT01021228||group3|preconditioning volatile anesthesia (sevoflurane) 30 minutes before ischemia (inflow occlusion)
89216672|NCT03997006|Active Comparator|Group A (n=30)|Aminophylline group
89216673|NCT03997006|Active Comparator|Group NA (n=30)|Neostigmine/Atropine group
89216674|NCT01015144||Atorvastatin|
89216675|NCT01015144||No statin|
89216676|NCT00511797|Experimental|DRSP 1 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
89216677|NCT00511797|Experimental|DRSP 2 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
89685442|NCT05587660|Experimental|Partially threaded cannulated screw fixation|In Group-A patients, cannulated screw fixation was done using partially threaded screws. In this procedure, first step was insertion of three guide wires under image. The 1st guide wire was inserted immediately above calcar and into femoral head. The second wire was placed posteriorly adjacent to posterior cortex of neck on lateral view. Finally, third guide wire was placed anteriorly and superiorly. Drilling of lateral cortex was done before insertion of screws. Then partially threaded screw fixation was done before removal of guide wires using washers.
89685443|NCT05587660|Experimental|Fully threaded cannulated screws fixation|The surgical approach in fully thread cannulated screws fixation group will remain same but instead of partially threaded screwsm fully threaded screws to be used in this group.
89685444|NCT00866905|Experimental|Ixabepilone/Cyclophosphamide|Systemic Therapy followed by surgery and possible radiation therapy
89685445|NCT05587426|Active Comparator|Glucose - Control|20 g of glucose mixed with 250 ml of cold water
89685446|NCT05587426|Experimental|SFF|20 g of SFF mixed with 250 ml of cold water
89685447|NCT05587426|Active Comparator|Regular chocolate chips - Control|50 g of regular chocolate chips
89685448|NCT05587426|Experimental|SFF chocolate chips|50 g of SFF chocolate chips
89685449|NCT00867139|Experimental|TCAD-Randomized Arm|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
89685450|NCT00867139|Active Comparator|Neuraminidase Monotherapy Arm|Zanamivir or Oseltamivir
89685451|NCT00867139|Other|TCAD Open Label Arm|TCAD for subjects who cannot tolerate or are ineligible to receive zanamivir
89685452|NCT05441878|Experimental|20% Albumin arm|20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h
89685453|NCT05441878|Active Comparator|Balanced salt solution arm|Fluid resuscitation protocol includes use of an immediate 500 ml bolus of crystalloid i.e., balanced salt solution (BSS) or 0.9% normal saline (Rescue phase), followed by 20 ml/kg fluid in the first 6 hours titrated to target MAP of > 65mmHg.The second phase of fluid resuscitation (Optimization phase) will be performed as per IVC targets, attainment of lactate clearance, and LUS score to prevent overload.
89685454|NCT05342818|Experimental|Group N|patients will receive an intravenous infusion of neostigmine in a dose of 2.5 mg in 100 ml of normal saline within 20 minutes once daily
89685455|NCT05342818|Experimental|Group O|patients will receive an intravenous infusion of 8 mg of ondansetron in 100 ml of normal saline once daily for 20 minutes
89685456|NCT05342818|Experimental|Group M|patients will receive metoclopramide in a dose of 10 mg in 100 ml of normal saline once daily for 20 minutes by infusion
89685457|NCT00867217|Experimental|High Dose Vitamin D|High Dose Vitamin D3 capsule (3 x 10,000 IU capsules weekly). All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
89685458|NCT00867217|Placebo Comparator|Placebo|Placebo matched for High Dose Vitamin D3 capsules. All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
89685459|NCT05337592|Experimental|SRD part: BI 1815368|
89685460|NCT05337592|Placebo Comparator|SRD part: Placebo|
89685461|NCT05337592|Experimental|BA part: T1-R-T2|R: BI 1815368 formulation 1, fasted condition T1: BI 1815368 formulation 2, fasted condition T2: BI 1815368 formulation 2, fed condition
89053336|NCT01140061|Experimental|Panel A - MK-0873 5.1 mg|In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
89053337|NCT01140061|Placebo Comparator|Panel A - Placebo|In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days.
89053338|NCT01140061|Experimental|Panel B - MK-0873 25 mg|In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days.
89053339|NCT01140061|Placebo Comparator|Panel B - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
89053340|NCT01140061|Experimental|Panel C - MK-0873 100 mg|In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days.
89053341|NCT01140061|Placebo Comparator|Panel C - Placebo|In Part II, healthy participants received skin application of placebo cream once daily for 10 days.
89053342|NCT01140061|Experimental|Panel D - MK-0873 200 mg|In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days.
89053343|NCT01140061|Placebo Comparator|Panel D - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
89053344|NCT01140061|Experimental|Panel E and Extension - MK-0873 200 mg|In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days.
89685462|NCT05337592|Experimental|BA part: R-T2-T1|
89685463|NCT05337592|Experimental|BA part: T2-T1-R|
89685464|NCT00867451|Experimental|Immediate Treatment|Children will receive behavioral sleep interventions and, if needed, melatonin, to improve sleep functions.
89685465|NCT00867451|Experimental|Delayed Treatment|Children will only receive sleep behavior interventions for the first four weeks of the trial. Treatment with study drug will be delayed to the 5th week.
89685466|NCT05302414|Experimental|board game-based learning|game-based learning
89685467|NCT05302414|Active Comparator|simulation-based learning|simulation education
89685468|NCT05302414|Placebo Comparator|lecture-based learning|lecture education
89685469|NCT05239156|Experimental|Janesse 15|Sixteen patients will be administered Janesse® 15 (Cross-linked Hyaluronic Acid) for the treatment of minor facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
89685470|NCT05239156|Experimental|Janesse 20|Sixteen patients will be administered Janesse® 20 (Cross-linked Hyaluronic Acid) for the treatment of medium-sized facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
89685471|NCT05239156|Experimental|Janesse 25|Sixteen patients will be administered Janesse® 25 (Cross-linked Hyaluronic Acid) for the treatment of major facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).
88998063|NCT03406299|Active Comparator|GC regimen|Arm 2 interventions : GC regimen: treatment for every 21 days as one cycle Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
88998064|NCT03396445|Experimental|Arm 1: Boserolimab|Participants receive escalating doses of boserolimab via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
88998065|NCT03396445|Experimental|Arm 2: Boserolimab + Pembrolizumab|Participants receive escalating doses of boserolimab via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
88998066|NCT03396445|Experimental|Arm 3: Boserolimab + Pembrolizumab + Pemetrexed + Carboplatin|Participants receive boserolimab at the selected dose via IV infusion PLUS pembrolizumab 200 mg via IV infusion PLUS pemetrexed 500 mg/m^2 via IV infusion PLUS carboplatin Area Under the Curve (AUC) 5 mg/mL/min via IV infusion, all given on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
88998067|NCT03396445|Experimental|Arm 4: Boserolimab + Pembrolizumab + Nab-paclitaxel|Participants receive boserolimab at the selected dose via IV infusion PLUS pembrolizumab via IV infusion PLUS nab-paclitaxel 100 mg/m^2 via IV infusion. Boserolimab and pembrolizumab will be given on Day 1 of each 6-week cycle (Q6W). Nab-paclitaxel will be given on a 3-week on (Days 1, 8 and 15)/ 1-week off schedule every 28 days. Boserolimab and pembrolizumab will be given for up to a total of 18 cycles (approximately 2 years).
88998068|NCT03355469|Placebo Comparator|LoEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
88998069|NCT03355469|Placebo Comparator|HiEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
88998070|NCT03355469|Active Comparator|LoEx+metformin|If subjects are assigned to this group they will participate in the same LoEx exercise program as outlined above. But, here they will be provided metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not be able to find out if you are on metformin until the study is done. If their doctor needs to know, the people doing this study can find out.
88998071|NCT03355469|Active Comparator|HiEx+metformin|If subjects are assigned to this group you will participate in the same HiEx exercise program and receive metformin as outlined above.
88998072|NCT03330028|Experimental|Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)|Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
88998073|NCT03313011||Progressive Apraxia of Speech|
88998074|NCT03311711|Experimental|SPIRIT-in person|Patients and surrogates who participate in the SPIRIT intervention in person.
88998075|NCT03311711|Experimental|SPIRIT-remote|Patients and surrogates who participate in the SPIRIT intervention remotely, via teleconference.
88998076|NCT03311711|Active Comparator|Usual care|Patients and surrogates who receive the standard information about advance directives that is provided at the time of diagnosis.
88998077|NCT03311555|Experimental|Recurrent PSA-only non-metastatic prostate cancer|Subjects with recurrent PSA-only prostate cancer within 4 years of prostatectomy, and a PSA of greater than 0.2 ng/mL and less than 4 ng/mL in the absence of metastatic disease on CT and bone scans.
88998078|NCT03278366|Experimental|Dancing students|Students will participate in dance activities from a video with their teacher in class.
88998079|NCT03278366|No Intervention|Non-Dancing Students|Students will continue with typical classroom activities in class and will not participate in dancing activities
88998080|NCT03271866|Other|metformin treatment|
88998081|NCT03271866|No Intervention|non-metformin treatment|
88998082|NCT03270891|Active Comparator|Delayed intervention (control arm)|Patients in this arm will have PGx test results made available to physicians 3 months after study enrollment
88998083|NCT03270891|Experimental|PGx Test|Patients in this arm will have PGx test results made available to physicians as soon available after enrollment.
88998084|NCT03217565|Experimental|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered intravenously (IV). For body weight <10 kg: 3 mg/kg; for body weight 10 to <30 kg: 2.5 mg/kg.
88998085|NCT03217565|Experimental|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension. For body weight <10 kg: 3 mg/kg; for body weight 10 to <30 kg: 2.5 mg/kg.
88998086|NCT03190382|Experimental|Received Decision Tool|Peripheral artery disease patients that received the decision support tool.
88998087|NCT02992743|Experimental|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
88998088|NCT02927912|Experimental|Treatment (IOERT boost)|Patients undergo standard of care lumpectomy and then undergo 1 fraction of IOERT boost to the lumpectomy cavity. Patients then undergo standard of care oncoplastic reconstruction and whole breast radiation therapy.
88998089|NCT02853344|Experimental|Cohort A: Clear Cell RCC|Participants with clear cell RCC receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
88998090|NCT02853344|Experimental|Cohort B: Non-clear Cell RCC|Participants with non-clear cell RCC receive pembrolizumab 200 mg IV Q3W for up to 35 doses (approximately 24 months).
88998091|NCT02739620|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
88998092|NCT02739620|No Intervention|Control|Control group
88998093|NCT02738229|Experimental|Valacyclovir|"Valacyclovir will be given twice a day with following doses according to weight:~10 to 13,9 kg : Valacyclovir 250 mg PO twice per day 14 to 19,9 kg : Valacyclovir 375 mg PO twice per day 20 to 28 kg : Valacyclovir 500 mg PO twice per day"
88998094|NCT02738229|Placebo Comparator|control|placebo pill
88998095|NCT02722486|Active Comparator|Standard Vestibular Rehabilitation|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions of an hour each). During these sessions, standard balance training exercises will be done at the discretion of the physical therapists.
89053345|NCT01140061|Placebo Comparator|Panel E and Extension - Placebo|In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days.
88998096|NCT02722486|Experimental|Vestibular Rehabilitation/Balance Belt|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions). They will undergo standard balance training exercises with the physical therapists like the control group, but will also undergo an additional 15 minutes of Balance Belt exercises during each session.
88998097|NCT02675426|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants continue to receive upadacitinib 15 mg once daily for an additional 248 weeks."
88998098|NCT02675426|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants continue to receive upadacitinib 30 mg once daily for an additional 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily."
88998099|NCT02675426|Experimental|Placebo / Upadacitinib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily for 248 weeks."
88998100|NCT02675426|Experimental|Placebo / Upadacitinib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily for 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily."
88998101|NCT02662270||Cases|Patients with a fibromyalgia diagnosis established according to the American College of Rheumatology current criteria by a trained physician.
88998102|NCT02662270||Controls|Healthy subjects paired by age and gender to the subjects in the cases group.
88998103|NCT02656433|Placebo Comparator|Placebo Group|Receive treatment with physiotherapy
88998104|NCT02656433|Experimental|Experimental or tRNS Group|Receive treatment with physiotherapy plus Transcranial Random Noise Stimulation (tRNS)
88998105|NCT02647294|Experimental|Polyunsaturated omega-3 fatty acids|Patients will receive n-3 fatty acids (Maxicor) 3,6 g/day.
88998106|NCT02647294|Placebo Comparator|Placebo|Patients will receive placebo (soya oil)
88998107|NCT02631837|Experimental|vNOTES hysterectomy|vaginal Natural Orifice Transluminal Endoscopic Surgery
88998108|NCT02631837|Active Comparator|LSC hysterectomy|Laparoscopic hysterectomy
88998109|NCT02579473|Experimental|Cohort 0|"Subjects in Cohort 0 will receive a single subcutaneous injection of 20 mg SER-214, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
88998110|NCT02579473|Experimental|Cohort 1|"Subjects in Cohort 1 will receive a single SC injection of 50 mg SER-214 at the beginning of each week for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
88998111|NCT02579473|Experimental|Cohort 2|"Subjects in Cohort 2 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a weekly SC injection of 100 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
88998112|NCT02579473|Experimental|Cohort 3|"Subjects in Cohort 3 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a single SC injection of 100 mg SER-214 at the beginning of week two, followed by a single SC injection of 200 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine PK and terminal wash-out PK of rotigotine and pro-drug SER-214."
88998113|NCT02526511|Experimental|Diagnostic (pMRI)|Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.
88998114|NCT02401035|Experimental|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.
88998115|NCT02313623||Patient Scheduled for Prostate Fusion Biopsies|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
88998116|NCT02153944|Experimental|Behavioral: Drug challenge with methylphenidate|Participant received methylphenidate 20 mg orally during study visit
88998117|NCT02153944|Placebo Comparator|Behavioral: Drug challenge with placebo|Participant received placebo orally during study visit
88998118|NCT02153944|Experimental|Behavioral: Drug challenge with propranolol|Participants received propranolol 40mg orally during study visit
88998119|NCT02153944|Experimental|fMRI: Drug challenge with methylphenidate|Participant received methylphenidate 20 mg orally during study visit
89216678|NCT00511797|Experimental|DRSP 3 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
89216679|NCT00511797|Placebo Comparator|Placebo|1 tablet per day placebo for 28 days in each 28-day cycle
89216680|NCT00487552|Experimental|1|palliative treatment of gastric outlet obstruction
89216681|NCT02272049|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI (less for children) to optimize acquisition of images for children and adults vs. proton MR imaging
89216682|NCT03996538|Experimental|Metformin Hydrochloride Extended Release Tablets|Patients will consume 3 tablets of 500mg metformin hydrochloride extended-release tablets daily (1500mg/day (after 3 week dose gradation)).
89216683|NCT03996538|Placebo Comparator|Placebo|Patients will consume 3 identical placebo tablets (after similar 3 week dose gradation).
89216684|NCT02576015|Experimental|Group L|Participants in group L will receive a single injection for femoral nerve block combined with continuous femoral nerve block intra-operatively. The femoral nerve block will be performed before the induction of anesthesia on the leg to be operated. Then the patients were given the 2% lidocaine 10 ml and 1% ropivacaine 10 ml as initial dose,then,the patients will receive a continuous infusion of 0.15% ropivacaine at 15 ml/h.Intra-operatively, bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 50-60.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
89216685|NCT02576015|Sham Comparator|Group D|Participants in group D will receive the placement of femoral nerve catheter preoperatively. The same dose of 0.9% saline was injected and infused as group L intra-operatively. Bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 30-40.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
89216686|NCT03998475|Experimental|Transition preparation program|Transition preparation intervention for young adults with type 1 diabetes (T1D)
89216687|NCT02577965|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
89216688|NCT02577965|Active Comparator|Male Arm|Male Gender with diagnose of ST segment Elevation Acute Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
89216689|NCT00182689|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89216690|NCT01326247|No Intervention|0.9% NaCl solution|
89216691|NCT03860259|Placebo Comparator|Auriculotherapy without nitrogen gas|Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with an empty cryopuncture with no nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
89216692|NCT03860259|Active Comparator|Auriculotherapy with nitrogen gas|Auriculotherapy will be performed by certified research staff using a cryopuncture device in the post-anesthesia recovery room with nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
89216693|NCT01078051|Active Comparator|Optimal medical therapy|optimal medical therapy
89216694|NCT01078051|Active Comparator|drug-eluting stent|Cypher, xience, Endeavor, Taxus
89685472|NCT00867529|Experimental|Treatment (rituximab pre- and post-transplant)|Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
89685473|NCT05199220||Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
89685474|NCT02417779|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89685475|NCT02417779|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89685476|NCT02417779|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89216695|NCT04071509|Experimental|Percutaneous Lung Biopsy|
89216696|NCT00131365|Experimental|ExAblate MRgFUS|Treatment with the ExAblate 2000 system Version 4.1
89216697|NCT02578121|Experimental|Ixazomib, Pomalidomide, Dexamethasone|Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
89216698|NCT00487240|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension twice daily
89216699|NCT00487240|Active Comparator|Detemir|Insulin Levemir (detemir) subcutaneous (SC) twice daily.
89216700|NCT01077115|Experimental|Laparoscopic cholecystectomy|
89216701|NCT01077115|Active Comparator|Open cholecystectomy|
89685477|NCT02417779|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89053346|NCT04312750|Experimental|Lidocaine Patch|All subjects received one lidocaine topical system, which was applied to a predetermined fixed area on subject's left side of the back or right side of the back (lower/mid back) according to randomization schedule and worn for 12 hours.
89053347|NCT00573365|Experimental|Treatment|LED treatment with Gentlewaves Select™ handheld high energy LED array 5 to 10 minutes before each radiation treatment and again 5-10 minutes after each radiation treatment
89053348|NCT00573365|Other|Control|Radiation only
89053349|NCT00586014|Experimental|I|High-dose sequential cyclophosphamide and VP-16 followed by myeloablation with high-dose BCNU and melphalan with autologous stem cell transplant
89053350|NCT01139164|Experimental|Single Arm, non-randomized study|
89053351|NCT00573404|Experimental|Therapeutic Intervention|
89053352|NCT01139125|Experimental|Cystagon, Cysteamine Bitartrate|We are examining the safety and efficacy of this medication on the treatment of schizophrenia patients.
89685478|NCT02417779|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89685479|NCT02417779|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89685480|NCT02417779|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89685481|NCT02417779|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89685482|NCT02417779|Experimental|Hypertrophic burn scar|"Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89685483|NCT02417779|Experimental|Hypertrophic burn scar (repetitive)|"Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89685484|NCT02417779|Experimental|Flap|"Group K (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89053353|NCT03450759|Experimental|Treatment sequence 1|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate)"
89053354|NCT03450759|Experimental|Treatment sequence 2|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 oral suspension (reference)"
89053355|NCT03450759|Experimental|Treatment sequence 3|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule"
89053356|NCT03450759|Experimental|Treatment sequence 4|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate)"
89053357|NCT01139047|Active Comparator|metronidazole 1% gel|
89053358|NCT01139047|Active Comparator|azelaic acid 15% gel|
89053359|NCT00573482|Active Comparator|control group|Control (only exposure to the food labels and the new lower ED foods).
89053360|NCT00573482|Experimental|intervention group|Education in REDE techniques plus exposure to the food labels and the new lower ED foods.
89685485|NCT02417779|Experimental|Flap (repetitive)|"Group L (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
89053361|NCT02883829|Experimental|Peer-Based Delivery|The Peer-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a peer will be the spokesperson delivering the intervention content.
89053362|NCT02883829|Experimental|Provider-Based Delivery|The Provider-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a healthcare provider will be the spokesperson delivering the intervention content.
89053363|NCT03450720|Experimental|GLPG2737 single dose.|Single dose of GLPG2737 oral suspension.
89053364|NCT01139008|Active Comparator|metronidazole 1% gel|
89053365|NCT01139008|Active Comparator|azelaic acid 15% gel|
89053366|NCT03450681|Placebo Comparator|No pulsed radiofrequency|Procedure consists of a mock incision at the pulsed radiofrequency needle insertion site and standard perioperative pain management by the pain clinic (femoral catheter and PCA)
89053367|NCT03450681|Experimental|Pulsed Radiofrequency|Procedure consists in pre-operative pulsed radiofrequency under ultrasound guidance of the saphenous nerve and standard postoperative pain management by the pain clinic (femoral catheter and PCA)
89053368|NCT03450642||Observation|Patients presenting with right Iliac Fosse pain
89053369|NCT00573599|Experimental|1|prochlorperazine and benadryl IV, saline subQ
89685486|NCT05028946|Experimental|Cohort 1: Foralumab Dose Level 1|Participants will receive foralumab enteric coated capsules at dose level 1, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
89685487|NCT05028946|Experimental|Cohort 2: Foralumab Dose Level 2|Participants will receive foralumab enteric coated capsules at dose level 2, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
89216702|NCT02577809|Active Comparator|Morphine100|1.8ml 0.5% hyperbaric bupivacaine with 0.1mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
89216703|NCT02577809|Active Comparator|Morphine50|1.8ml 0.5% hyperbaric bupivacaine with 0.05mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
89685488|NCT05028946|Experimental|Cohort 3: Foralumab Dose Level 3|Participants will receive foralumab enteric coated capsules at dose level 3, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
89685489|NCT05028946|Experimental|Cohort 4: Foralumab Dose Level 4|Participants will receive foralumab enteric coated capsules at dose level 4, administered orally once daily for 2 weeks (5 consecutive days in each week with a 2-day undosed safety assessment period after each 5 day treatment period).
89685490|NCT04814212|Experimental|Drug-coated balloon (DCB)|The coronary lesions fulfilling the inclusion criteria and randomized to the DCB group.
89685491|NCT04814212|Active Comparator|Drug-eluting stent (DES)|The coronary lesions fulfilling the inclusion criteria and randomized to the DES group.
89685492|NCT00889915|Active Comparator|1|Participants will receive methylphenidate transdermal system.
89685493|NCT00889915|Active Comparator|2|Participants will receive lisdexamfetamine dimesylate.
89685494|NCT00889915|Active Comparator|3|Participants will receive osmotic-release oral system methylphenidate (OROS MPH).
89053370|NCT00573599|Active Comparator|2|imitrex SubQ, saline IV
89053371|NCT04572516|Experimental|Topical group|Topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
89053372|NCT04572516|Experimental|Injection group|20 units of BTX_A (2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
89053373|NCT01138657|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses every other week (eow) starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
89053374|NCT01138657|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by eow dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
89053375|NCT00586053||1|485 patients,who have an average risk (asymptomatic and without colon screening in the last 5 years) or those who have a high risk for colon cancer (strong family history of colon cancer or polyps and/or personal history of colon cancer or polyps).
89053376|NCT00586053||2|160 patients, with a known colorectal lesion at or greater than 1 cm.
89053377|NCT00586053||3|610 patients, who are of average risk for colon cancer (asymptomatic and no colon cancer screening in the last 5 years).
89053378|NCT00573716||1|15 subjects who are taking aripiprazole monotherapy
89053379|NCT00573716||2|15 subjects who are taking Risperidone therapy
89053380|NCT00573716||3|30 healthy volunteers with an ethnicity, sex, and pubertal stage match of subjects taking aripiprazole monotherapy and Risperidone therapy
89053381|NCT04572282|Experimental|Mentora|Remote symptoms monitoring with mobile app
89053382|NCT01138501|Experimental|rFVIII|
89053383|NCT02883361|Experimental|Treatment|Receive 4 in-person motivational enhancement counseling sessions over the course of 12-months that specifically target medication adherence.
89053384|NCT02883361|Placebo Comparator|Control|Attend 4 in-person sessions to complete questionnaires and receive educational handouts.
89053385|NCT04572360|Experimental|Cardiorespiratory Exercise plus Chinese Herbal Medicines Group|"Includes:~1.12-week progressive & individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management & habit formation; access to a call center; & counselling sessions to enhance motivation to regularly engage in daily physical activities.~2.Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast & dinner, 7days/week for 12 weeks."
89053386|NCT04572360|Experimental|Cardiorespiratory Exercise Group|"Includes:~A 12-week progressive & individualized exercise, 60mins/session, 3 sessions/week, total 36 exercise sessions. Components: a set of home-based tele-exercise sessions with remote monitoring of vital signs; individualized action plan to perform various daily physical activities; educational sessions on self-management & habit formation; access to a call center; & counselling sessions to enhance motivation to regularly engage in daily physical activities."
89053387|NCT04572360|Experimental|Chinese Herbal Medicines Group|"Includes:~Chinese herbal formula of Modified Bai He Gu Jin Tang prescribed in granules, 10g/day (5g dissolved in 200ml of hot water, b.i.d), twice/day after breakfast & dinner, 7days/week for 12 weeks."
89053388|NCT04572360|No Intervention|Waiting List Group|The waiting list control sign will be adopted to conceal allocation results from the patients and further to reduce selection and confounding bias and increase their adherence to the study. Patients in the waiting list control group will receive no treatment in the study period (including a 12-week intervention period and a 12-week follow-up period). However, they will receive Chinese herbal medicines after the completion of the study (i.e., after the 3rd wave of measurements in the 25th weeks).
89053389|NCT01138150|Active Comparator|Treximet|"Fourteen participants randomized to receive Treximet (sumatriptan & naproxen) during an acute migraine attack. Blood drawn for immune & inflammatory markers (adipocytokines,cytokines, sex hormones) at different time points - on presentation with moderate to severe migraine pain; then 30 minutes, 1 hour and 2 hours after administration of study drug (Treximet).~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of Treximet if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
89685495|NCT00889915|Active Comparator|4|Participants will receive mixed amphetamine salts extended release.
89685496|NCT00841087|Experimental|SIBA|
89685497|NCT00841087|Active Comparator|Insulin Detemir|
89685498|NCT04642534||Postpartum women who had gestational diabetes mellitus|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
89685499|NCT04642534||Postpartum women after an uneventful pregnancy|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
89685500|NCT02685436|Other|omeprazole and domperidone|wheezy infants with GERD will receive 12 weeks of domperidone (0.2mg/kg/day t.d.s.) and omeprazole (10 mg/once/day).
89685501|NCT04338958|Experimental|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days
89685502|NCT00841555|Experimental|Hypofractionation Radiotherapy+Temozolomide|Patients will receive temozolomide PO daily for 5 weeks. Beginning week 1 after initiation of temozolomide therapy, patients undergo HIMRT times a week for a total of 15 fractions.
89685503|NCT02686138|Experimental|50mg BID|Tenapanor, 50mg BID (100mg total)
88998120|NCT02153944|Placebo Comparator|fMRI: Drug challenge with placebo|Participant received placebo orally during study visit
88998121|NCT02118805||Patients with ALS|No intervention is used in this study. The health of muscle is monitored over time.
88998122|NCT02118805||Patients with Myasthenia Gravis|No intervention is used in this study. The health of muscle is monitored over time.
88998123|NCT02118805||Patients with Muscle Disease|No intervention is used in this study. The health of muscle is monitored over time.
88998124|NCT02118805||Patients with Stroke|No intervention is used in this study. The health of muscle is monitored over time.
88998125|NCT02118805||Patients with Parkinson's Disease|No intervention is used in this study. The health of muscle is monitored over time.
88998126|NCT02118805||Healthy Volunteers|No intervention is used in this study. The health of muscle is monitored over time.
88998127|NCT02061111||Subclinical thyroid disease|26 pregnant women with subclinical hypothyroidism and/orTPO-antibodies, and their offspring.
88998128|NCT02061111||Healthy controls|51 pregnant women without thyroid disease or any other metabolic disorders, and their offspring.
88998129|NCT02060721|Experimental|Macitentan|Macitentan 10mg, oral tablet, once daily
88998130|NCT02060630|Other|Available vein, open surg. revasc.|Subjects with an available SSGSV cohort randomized to open surgical revascularization
88998131|NCT02060630|Other|Available vein, endovasc. revasc.|Subjects with an available SSGSV cohort randomized to endovascular revascularization
88998132|NCT02060630|Other|Alternative conduit, open surg. revasc.|Subjects with an alternative conduit cohort randomized to open surgical revascularization
88998133|NCT02060630|Other|Alternative conduit, endovasc. revasc.|Subjects with an alternative conduit cohort randomized to endovascular revascularization
88998134|NCT01782027|Experimental|3H-cholesterol|
88998135|NCT01565187||hand transplant candidates|Participants enrolled will be asked to complete behavioral questionnaires.
88998136|NCT01359956|Experimental|A1|combination chemotherapy without interferon
88998137|NCT01359956|Experimental|A2|combination chemotherapy with interferon
88998138|NCT01359956|Active Comparator|B1|single agent dacarbazine without interferon
88998139|NCT01359956|Experimental|B2|single agent dacarbazine plus interferon
88998140|NCT01306045|Active Comparator|A/ Erlotinib|Arm A - Erlotinib 150 mg by mouth (PO) every morning (QAM)
88998141|NCT01306045|Active Comparator|B/ AZD6244|AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
88998142|NCT01306045|Active Comparator|C/ MK-2206|MK-2206 200 mg by mouth (PO) every (Q) Week
88998143|NCT01306045|Active Comparator|D/ Lapatinib|Lapatinib 1500 mg by mouth (PO) every day (QD)
89216704|NCT02577809|Active Comparator|Fentanyl25|1.8ml 0.5% hyperbaric bupivacaine with 25μg fentanyl (2.3ml volume) administered into the intrathecal space
88998144|NCT01306045|Active Comparator|E/Sunitinib|Sunitinib 50 mg by mouth (PO) on days 1-28
88998145|NCT01306045|Other|F/ Not Otherwise Specified (NOS)|Participants who do not meet the eligibility criteria for enrollment
88998146|NCT01278303|Other|Treatment of Aortic Wall Injury|Repair of aortic wall injury with covered CP Stents
88998147|NCT01196936|Experimental|Arm I (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
88998148|NCT01196936|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
88998149|NCT01075971|Experimental|Buprenorphine hydrochloride|
88998150|NCT00775749|Experimental|1|The nicotine patch will be applied prior to surgery and remain on the right upper back for 24 hours.
88998151|NCT00775749|Placebo Comparator|2|The placebo patch has no active ingredients and the same inactive ingredients as the nicotine patch. It will be administered the same fashion as the nicotine patch.
88998152|NCT00567073||Pregnant women with confirmed diagnosis of pompe Disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Pompe disease that are participating in the Pompe Registry (NCT00231400) and consented to participate in the Pompe Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglusidase alfa) and irrespective of the commercial product with which she may be treated.
89216705|NCT03998085|Experimental|anlotinib|
89216706|NCT00579579||1|Patients Undergoing Surgery for Rectal Cancer
89685504|NCT02686138|Placebo Comparator|Placebo|Placebo
89685505|NCT00842023|Experimental|Nesiritide Infusion|Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.
89685506|NCT00842023|Active Comparator|Nitroglycerin Infusion|Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.
89685507|NCT00868309|Experimental|Anavip|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 30 minutes for Anavip
89685508|NCT00868309|Active Comparator|CroFab|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 60 minutes for CroFab, or as permitted by IV access.
89685509|NCT02693704|Experimental|Normal hearing|People showing no hearing loss (< 20 dB HL). Introduction of speech signal via the DAI of two hearing aids Phonak Naida IX SP.
89685510|NCT02693704|Experimental|Moderate hearing impaired|"Patients showing moderate hearing loss (40-60 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
89685511|NCT02693704|Experimental|Severe hearing impaired|"Patients showing severe hearing loss (60-80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
89685512|NCT02693704|Experimental|Profound hearing impaired|"Patients showing profound hearing loss (> 80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
89685513|NCT02696200|Experimental|Subjects Wearing the Q Collar|Subjects wearing the Q collar throughout the football season
89685514|NCT02696200|No Intervention|Subjects Not Wearing the Q Collar|Control group of subjects not wearing the q collar
89685515|NCT02697214|Active Comparator|Apple Watch|Apple Watch heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device .
89685516|NCT02697214|Active Comparator|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
89685517|NCT02697214|Active Comparator|Mio Fuse|Mio Fuse heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
89685518|NCT02697214|Active Comparator|Basis Peak|Basis Peak heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
89685519|NCT02697292|Placebo Comparator|Placebo/Normal Saline Group|Subjects will receive placebo for 4 infusions. After completion of the blinded phase, subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
89685520|NCT02697292|Active Comparator|Intravenous Immunoglobulin (IVIG) (Gamunex-C) Group|Subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
89685521|NCT00842335|Experimental|JI-101|
89685522|NCT02700334|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
89685523|NCT02700334|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
89685524|NCT00868699|Experimental|lurasidone low arm|
89685525|NCT00868699|Placebo Comparator|Placebo|
89685526|NCT00868699|Experimental|lurasidone high arm|
89685527|NCT02701270|Experimental|Experimental Dietary Fibre 1|
89685528|NCT02701270|Experimental|Experimental Dietary Fibre 2|
89685529|NCT02701270|Active Comparator|Polydextrose|
89685530|NCT02701270|Active Comparator|Dextrose control|
89685531|NCT02701582|Experimental|Goal Directed Therapy|Flotrack monitor is connected and based on what anesthesiologist sees and following study algorithm, anesthesiologist chooses: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
89685532|NCT02701582|Active Comparator|Control Group|FloTrac monitor is connected, but he anesthesiologist will not be able to see the monitor although the data will be collected and stored for analysis. Anesthesiologist will be given a study algorithm to follow for the duration of the surgery, and based on it will choose: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
89685533|NCT00869167|Experimental|1: Ramelteon|
89685534|NCT00869167|Placebo Comparator|2: Placebo|
89685535|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC|dietary phosphorus restriction (900 mg/day of phosphorus) + phosphorus binder (Lanthanum Carbonate)
89685536|NCT00843349|Active Comparator|Ad Libitum Diet-LC|no dietary intervention + phosphorus binder (Lanthanum Carbonate)
89685537|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC Placebo|dietary phosphorus restriction (900 mg/day of phosphorus) + placebo
89685538|NCT00843349|Placebo Comparator|Ad Libitum Diet-LC Placebo|no dietary intervention + placebo
89685539|NCT03839017|Experimental|Digital cognitive aid|The leader uses a digital cognitive aid designed as a smartphone app during advanced combat casualty care. Intervention: Device: SIMMAXMARCHERYAN2 Digital cognitive aid during the management of simulated war wounded.
89685540|NCT03839017|Experimental|Without digital cognitive aid|The leader practices advanced combat casualty care without the digital cognitive aid designed as a smartphone app. Intervention: Device: SIMMAXMARCHERYAN2 Without digital cognitive aid during the management of simulated war wounded.
89685541|NCT00869791|Other|Sequence 1|"Treatment Period 1:~IPX066 - 7 days; Washout Period - 7 days;~Treatment Period 2:~IR CD-LD- 7 days"
89685542|NCT00869791|Other|Sequence 2|"Treatment Period 1:~IR CD-LD - 7 days; Washout period - 7 days;~Treatment Period 2:~IPX066- 7 days"
89685543|NCT02704702|Other|Sequence 1 (ABC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)~There will be a washout of at least 7 days between the each period."
89685544|NCT02704702|Other|Sequence 2 (ACB)|"Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
89216707|NCT02224391|Experimental|Arm I (ABM training)|Patients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
89216708|NCT02224391|Sham Comparator|Arm II (sham training)|Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
89216709|NCT00487162|Experimental|intensive glycemic control|In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.
89216710|NCT00487162|Active Comparator|conventional glycemic control|In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL
89216711|NCT02219711|Experimental|MGCD516|MGCD516 oral capsule, administered in escalating doses in Phase 1, beginning with daily dosing and exploring other regimens as necessary, in 21 or 28 days cycles
89685545|NCT02704702|Other|Sequence 3 (BAC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)~There will be a washout of at least 7 days between the each period."
89685546|NCT02704702|Other|Sequence 4 (BCA)|"Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
89685547|NCT02704702|Other|Sequence 5 (CAB)|"Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
89685548|NCT02704702|Other|Sequence 6 (CBA)|"Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
89685549|NCT04382287|Experimental|REMIN paste|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
89685550|NCT04382287|Experimental|MI PASTE PLUS|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
89685551|NCT04382287|Active Comparator|COLGATE Total|The child's parents or caregivers were provided with printed instructions for applying the paste at home. The indicated procedure was as follows: application of the remineralisation agent was limited to the tooth's vestibular surface twice a day, after conventional toothbrushing (both in the morning and at night). The maximal amount of paste to be applied was equal to a pea-sized portion (one finger) per surface. The paste was applied using the parent or caregiver's finger across the WSL surface. After the application of the paste, patients were asked to avoid eating or drinking anything for the next hour.
89685552|NCT00869947|Experimental|Prosthesis|Powered ankle-foot prosthesis and passive-elastic prosthesis
89685553|NCT00869947|Experimental|Non-amputee|Non-amputee
89216712|NCT01021384|Other|Problem Solving Education|
89685554|NCT02707432|Experimental|Time 1 (T1) Intervention Group|"This group will be the first to receive the adapted intervention, Heart Matters (adapted from the PREMIER intervention). The intervention will be 12 months long."
89685555|NCT02707432|Experimental|Time 2 (T2) Intervention Group|"This delayed intervention group will receive the adapted intervention, Heart Matters, six months after the T1 Intervention group. The intervention will be 12 months long."
89685556|NCT03216655|Experimental|traditional group|phone call
89685557|NCT03216655|Experimental|new device group|wechat group
89685558|NCT02708212|Active Comparator|EGD-colonoscopy group|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to EGD and colonoscopy examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
89685559|NCT02708212|Active Comparator|Colonoscopy-EGD group|In this study group, patients receive a colonoscopy followed by an EGD during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to colonoscopy and EGD examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
89685560|NCT00871819|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
89216713|NCT03871959|Experimental|Pembrolizumab + Debio 1143|"Pembrolizumab : 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.~Debio 1143 : 3 escalating dose level (100 mg, 150 mg, 200 mg) administered daily for 14 days over a 21-day cycle period."
89216714|NCT00487084|Experimental|morphine - 2CP-saline (MCS)|morphine will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level; saline will be administered at skin incision
89216715|NCT00487084|Experimental|saline-2CP-morphine (SCM)|saline will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level;morphine will be administered at skin incision
89685561|NCT02708290||Test arm|The test group included participants who completed more than one thousand exercises and made no more than one error per exercise.
89685562|NCT02708290||Control arm|The control group included the rest of participants. The test group participants were matched to the control group by age, gender, expressive language, receptive language, sociability, cognitive awareness, and health at the 1st evaluation.
89685563|NCT00895531|Active Comparator|Peripheral Nerve group|Group will receive sciatic catheter placed before or after surgery by subgluteal approach with the use of ultrasound. The ischial tuberosity will be identified with the ultrasound probe and its midpoint marked. A catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
89685564|NCT00895531|Experimental|Depodur Group|patients will have an L2-L3 epidural placed while they are in the sitting position before or after femoral catheter placement. They will receive 7.5 mg Depodur via the epidural catheter. All of these patients will receive Singular 10 mg and Claritin 10 mg before the epidural Depodur is placed, as per our protocol of patients receiving EREM.
89685565|NCT00872833||age 18-29|People age groups 18-29 with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
88998153|NCT00567073||Pregnant women receiving no treatment for pompe disease|Pregnant women with pompe disease enrolled in the pompe disease registry (NCT00231400) who are not receiving treatment
88998154|NCT00567073||Infants born to mothers receiving treatment for pompe disease|The infants of mothers with pompe disease enrolled in the pompe disease registry (NCT00231400) where the mothers are receiving treatment of alglucosidase alpha (Myozyme)
88998155|NCT00567073||Infants born to mothers receiving no treatment for pompe disease|The infants of mothers with pompe disease enrolled in the Pompe Disease Registry (NCT00231400) where the mothers are not receiving Treatment
88998156|NCT00360646||Subjects with liver injury|
88998157|NCT00360646||Subjects without liver injury|
88998158|NCT00338065|Experimental|Subjects with autonomic dysfunction|"Subjects with known autonomic dysfunction diagnoses as defined by the General Clinical Research Center (GCRC) such as pure autonomic failure, Postural orthostatic tachycardia syndrome (POTS), and Multiple System Atrophy( MSA).~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
88998159|NCT00338065|Experimental|Primary open-angle glaucoma subjects|"Subjects diagnosed with primary open-angle glaucoma following a glaucoma specialist's examination.~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
88998160|NCT00338065|Experimental|Subjects with normal-pressure glaucoma|"Subjects with open-angle glaucoma damage following a glaucoma specialist's examination without ever an intraocular pressure recording greater than 21 mm Hg.~.1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
88998161|NCT00338065|Active Comparator|Normal subjects|"Subjects without evidence of glaucoma or autonomic dysfunction.~..1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
88998162|NCT00324922|Active Comparator|Trimethoprim-sulfamethoxazole|trimethoprim-sulfamethoxazole, double strength, 2-3 tabs twice a day by mouth for 6-12 weeks
88998163|NCT00324922|Active Comparator|Vancomycin|Vancomycin, dosage to be determined by serum levels, medication provided by vein and duration 6-12 weeks
88998164|NCT05380102||Single Arm Study (Cohort)|"All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device). Data from all devices will be measured simultaneously."
89685566|NCT00872833||age 30+|People age groups 30+ years with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
88998165|NCT05377879|Experimental|OPTIVF predicted drug dosage|In our study, we will be using the patient's age and day three serum day AMH and FSH levels to decide the starting dose for the patient's cycle. We will use the first two days of data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient with the help of the decision support tool OPTIVF for this intervention in the clinical trial.
88998166|NCT05377879|No Intervention|Traditional drug treatment|Patients where drug dosage is decided by the physician based on ultrasound and estrogen levels for each day of the cycle.
88998167|NCT05356975|Experimental|Superset|This group will perform three strength circuit training. Each circuit training consists of three exercises (lower, middle, and upper body exercises) performed in a supersets fashion. This order makes it less complex, which is important given the characteristics of the population.
88998168|NCT05356975|Active Comparator|Concurrent|This group will perform six resistance exercises in a traditional fashion (three exercises for the lower body, three exercises for the upper body) and three aerobic exercises (floor tap squat, jumping jacks, and skaters).
88998169|NCT00407186|Experimental|1chemoradiotherapy|5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.
88998170|NCT00407186|Active Comparator|2chemotherapy|3 adjuvant courses epirubicin, cisplatin, capecitabine.
88998171|NCT00553111|Experimental|1|pre survey, intervention, post test survey
88998172|NCT00553111|No Intervention|2|pre test survey and post test survey
88998173|NCT00553111|Experimental|3|video intervention and post test survey
88998174|NCT00553111|No Intervention|4|post test survey
88998175|NCT05335720|Active Comparator|Cohort 1|"EASYEF® + moist gauze EASYEF® is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.~Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage."
89216716|NCT00487084|Active Comparator|saline-lidocaine-morphine (SLM)|Saline will be administered 30 min prior to epidural anesthesia; lidocaine will be used to achieve a T4 level; morphine will be administered at skin incision
89216717|NCT04770675||Treatment group|Any subject who is scheduled to undergo bronchoscopy as per routine clinical practice
89216718|NCT03998787||Patients with Parkinson's disease|Patients with Parkinson's disease
89216719|NCT03998787||Healthy Subjects|Healthy subjects
89216720|NCT01721291|Experimental|COPD 1|COPD patients
89216721|NCT01721291|Experimental|Healthy|Healthy participants
89216722|NCT01721291|Experimental|COPD 2|Second group of COPD patients
89216723|NCT01721291|Active Comparator|Asthmatics|Asthmatics patients
89216724|NCT01021462|Experimental|Period 1 + Period 2|graded infusion of intravenous glucose
89216725|NCT01403350|No Intervention|Current Practice|Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
89216726|NCT01403350|Active Comparator|Intervention Arm|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
89216727|NCT04840511|Experimental|lidocaine group|The study group receives perioperative lidocaine infusion with general anesthesia for robot-assisted prostatectomy
89216728|NCT04840511|Placebo Comparator|control group|The control group receives normal saline infusion with with general anesthesia for robot-assisted prostatectomy
89216729|NCT04072133|Experimental|Meditative Movement Intervention|Participants will complete the following components of baseline (T1) data collection: demographics, biometric measurements, a heart rate variability assessment, and questionnaires. Participants will be asked to provide six saliva samples via passive drool to measure cortisol levels. Participants will be assigned into hour-long meditative movement (MM) classes for eight weeks total. Participants will be asked to practice their MM skills at home for at least 30 minutes most days per week. The study will distribute hard-copy movement manuals and DVD instruction videos for guidance. Participants will be asked to provide a log of all dates and lengths of their at-home practice. After the eighth class, participants will return for post-intervention (T2) data collection, consisting of biometric measurements, a heart rate variability assessment, and questionnaires. Participants will provide six more saliva samples via passive drool method.
89532979|NCT05691361|Placebo Comparator|PART A- Placebo administered to HV|For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
89532980|NCT05691361|Experimental|PART B - ADX-324 administered to HAE participants|This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs. The treatment of HAE participants is an open-label study.
89216730|NCT00486226||1 Endovascular|All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.
89216731|NCT02199665|Experimental|Selinexor, carfilzomib, dexamethasone|Patients receive selinexor PO, carfilzomib IV, and dexamethasone PO QD or IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89216732|NCT01021696|No Intervention|Treatment as usual|Control group
89216733|NCT01021696|Active Comparator|Paracetamol|Intervention group
89532981|NCT05690815||gbMSM|This study will enroll gay, bisexual men who have sex with men (gbMSM), transgender and gender non-binary participants.
89532982|NCT05687305|Active Comparator|Intervention Group|On the 0th and 1st postoperative days, patients in the intervention group will listen to white noise with a bluetooth headset for 30 minutes before going to sleep, and they will be kept under observation during this time.Patients in the control group will be monitored according to their routine clinical procedures. Since there are no procedures or interventions in clinical procedures, only patient monitoring will be performed. Patients in the control group will also be followed up at the same times and with the same forms.
89532983|NCT05687305|No Intervention|No Intervention Group|Patients in the control group will not receive any intervention other than their routine. Data collection forms will be applied to the participants in the control group at the same time as the intervention group.
89532984|NCT05687279|Experimental|RSVt Vaccine Group|2 intranasal administrations (56 days apart) of the RSVt vaccine at D01 and D57
89532985|NCT05687279|Placebo Comparator|Control Group|2 intranasal administrations (56 days apart) of the placebo at D01 and D57
89532986|NCT05686551|Experimental|Tominersen 60 mg|
89532987|NCT05686551|Placebo Comparator|Placebo|
89532988|NCT05686551|Experimental|Tominersen 100 mg|
89532989|NCT05686447||Multiple myeloma|Multiple myeloma (MM) is a hematologic malignant tumor characterized by abnormally cloned plasma cells in bone marrow, whose growth can lead to destructive bone injury, acute kidney injury, anemia, and hypercalcemia.
89532990|NCT05686447||Healthy control|Individuals in good health without obvious disease and with normal physical examination report; Avoid people who have not suffered from major chronic diseases in recent years, such as hypertension, diabetes, chronic kidney disease, etc; controls were appropriately selected that matched cases for age and sex.
89532991|NCT05682352|Experimental|LEO 158968 Single Ascending Dose (SAD) Cohorts|Participants will receive a single dose of LEO 158968 or matching placebo via an intravenous (IV) infusion or subcutaneous (SC) injection. The dose of LEO 158968 will be increased per cohort.
89532992|NCT05682352|Experimental|LEO 158968 Multiple Ascending Dose (MAD) Cohorts|Participants will receive 5 once weekly (QW) doses of LEO 158968 or matching placebo via a SC injection.
89532993|NCT05681715|Experimental|Rozanolixizumab Sequence 1: Syringe Driver - Manual Push|Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.
89532994|NCT05681715|Experimental|Rozanolixizumab Sequence 2: Manual Push - Syringe Driver|Study participants will receive predefined weekly doses of rozanolixizumab for 18 weeks.
89532995|NCT05677971|Experimental|Fazirsiran|Participants will receive fazirsiran 200 milligram per milliliter (mg/ml) subcutaneous (SC) injection on Day 1, at Week 4, and then every 12 weeks (Q12 W) thereafter up to Week 196.
89216734|NCT01021696|Active Comparator|Morphine|Intervention group, individual pain treatment
89216735|NCT01021696|Active Comparator|Buprenorphine plaster|Intervention group, individual pain treatment
89685567|NCT02710240|Experimental|ICG Arm|Subjects undergo indocyanine green injection within 72 hours prior to surgery. Permitting infusion time within 72 hours of operation is believed to be adequate for tissue glow/surgical visualization. Alternately, patients may receive 25 mg of indocyanine green during induction. Dose and time of administration will be determined by the neurosurgeon during surgical planning. This 25 mg dose of indocyanine green is similar to dosing for other intraoperative vascular visualization.
89685568|NCT01603225||Autism|Individuals with autism will have either Anodal, Cathodal, or Sham Transcranial Direct Current Stimulation (tDCS).
89216736|NCT01021696|Active Comparator|Pregabalin|Intervention group, individual pain treatment
89685569|NCT03215875|Experimental|Fed- 60mg ER Torsemide|Adult healthy subjects will be given standardized high-fat, high-calorie meal prior to dosing
89685570|NCT03215875|Experimental|Fasting- 60mg ER Torsemide|Adult healthy subjects will fast overnight (at least 10h) prior to dosing
89685571|NCT02710630|Active Comparator|Dabigatran etexilate capsule|
89685572|NCT02710630|Experimental|Dabigatran etexilate tablet A1|
89685573|NCT02710630|Experimental|Dabigatran etexilate tablet B1|
89685574|NCT02710630|Experimental|Dabigatran etexilate tablet C1|
89216737|NCT01018498|Experimental|Restricted FODMAPs diet|Restricted fermentable substrate diet for 1 week
89216738|NCT02577575|Experimental|Oxytocin|40 IU Oxytocin
89532996|NCT05677971|Placebo Comparator|Placebo|Participants will receive placebo on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
89685575|NCT02710630|Experimental|Dabigatran etexilate tablet D1|
89685576|NCT02710630|Experimental|Dabigatran etexilate tablet E1|
89216739|NCT02577575|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
89685577|NCT00342667||1|patients with preterm labor/contractions and preterm premature rupture of membranes
89685578|NCT00342277||Pregnant Women|Consecutive pregnant women admitted with either: Preterm labor/delivery/PROM. Termdelivery without labor/spontaneous labor /chorioamnionitis/failed labor leading to c-section
89685579|NCT02715076|Experimental|Ambient Temp 19°C & Passive Insulation|Ambient Temperature 19°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
89685580|NCT02715076|Experimental|Ambient Temp 19°C & Forced-air Warming|Ambient Temperature 19°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
89685581|NCT02715076|Experimental|Ambient Temp 21°C & Passive Insulation|Ambient Temperature 21°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
89685582|NCT02715076|Experimental|Ambient Temp 21°C & Forced-air Warming|Ambient Temperature 21°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
89685583|NCT02715076|Experimental|Ambient Temp 23°C & Passive Insulation|Ambient Temperature 23°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
89685584|NCT02715076|Experimental|Ambient Temp 23°C & Forced-air Warming|Ambient Temperature 23°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
89216740|NCT02577653|Other|subjects|participant undergoing posturographic evaluation
89216741|NCT04827407|Experimental|Basic therapy + Efferon LPS|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis plus extracorporeal hemoperfusion therapy (Efferon LPS)
89216742|NCT04827407|No Intervention|Baseline therapy|Basic therapy is the institution's routine practice for treating patients with septic shock against a background of abdominal sepsis.
89216743|NCT02578979|Experimental|ECG for 5 days|Patients will receive 12-lead electrocardiogram for 5 days during their hospitalization.
89216744|NCT02578979|Active Comparator|24-h Holter|Patients will receive a 24-h Holter during their hospitalization.
89532997|NCT05675436||1|i. Phase 3: Mitapivat 50 mg BID
89532998|NCT05675436||2|ii. Phase 3: Mitapivat 100 mg BID
89532999|NCT05675436||3|iii. Phase 3: Mitapivat Open-Label Extension Period
89533000|NCT05675423||25 subjects with a history of TBI but no history of TMI|25 subjects with a history of TBI but no history of TMI.
89533001|NCT05675423||25 subjects with a history of TMI|25 subjects with a history of TMI.
89533002|NCT05675423||35 healthy controls|35 healthy controls.
89533003|NCT05675410|Active Comparator|Arm A (ABVD)|Patients receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo blood sample collection on trial.
89685585|NCT00873457|Experimental|Perifosine|Perifosine 50 mg twice a day for a total of six 28-day cycles.
89685586|NCT02715700|Experimental|Maintenance Methadone and MK-1439|Participants maintained on a stable methadone regimen (20 to 200 mg once daily) for ≥14 days prior to Day 1 will continue to receive methadone maintenance once per day on Days 1 to 7. From Day 2 to 6, participants will also receive doravirine 100 mg once daily.
89685587|NCT00875329||Group 1|A convenience sample of 97VHA patients who served during the OEF or OIF era, who are targeted in CPRS as requiring the TBI Clinical reminder will be included. This includes all ages, both sexes, and all races and ethnicities.
89685588|NCT03215953|Active Comparator|Group A|cast shoe plus standard wound care
89685589|NCT03215953|Active Comparator|Group B|removable walker plus standard wound care
89685590|NCT02716324|Active Comparator|ADHD Portal|In this arm, the ADHD Portal was used alone as an electronic communication tool.The ADHD portal is considered standard of care at our institution for communicating information between clinicians, teachers, and parents.
89685591|NCT02716324|Experimental|ADHD Portal plus Care Manager (CM)|In this arm, the ADHD Portal was combined with the CM. Clinicians, teachers, and parents used the ADHD Portal as standard of care. In addition, clinicians, teachers, parents, and any external mental health providers interacted with a CM, who had access to information contained in the ADHD Portal.
89685592|NCT00875641||HRV cohort|HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).
89685593|NCT00875641||Concurrent Control cohort|Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).
89053390|NCT01138150|Placebo Comparator|Sugar Pill|"Fourteen participants randomized to receive placebo during an acute migraine attack. Blood is drawn for immune & inflammatory markers (adipocytokines,cytokines), sex hormones at different time points - on presentation with moderate to severe migraine pain, then 30 minutes, 1 hour and 2 hours after administration of placebo.~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of placebo if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
89053391|NCT01138111|Experimental|Arm 1|
89053392|NCT00586092|Other|1|This trial employs a phase I design with a dose escalation stage (stage I) and an expansion stage (stage 2) to better describe the tolerability of this combination and the effect of this combination on several biomarkers. In this second stage there will be two groups, each with ten patients, to better describe the tolerability of the bevacizumab/ABT-510 combination and the effect of this combination on several biomarkers. The primary objective of this study is to estimate the MTD/recommended phase II dose regimen. All other objectives are exploratory in nature.
89053393|NCT01137955|Experimental|Rifaximin 400mg|Antibiotic ,Rifaximin 400mg, given 3 times a day for 10 days.
89053394|NCT01137955|Placebo Comparator|Placebo|Placebo pills given 3 times a day for 10 days.
89053395|NCT00573950|Experimental|Cilostazol|cilostazol group
89053396|NCT00573950|Placebo Comparator|Placebo|placebo group
89053397|NCT03452748|Experimental|FTIR arm|all excised membranes are examined with FTIR spectroscopy
89053398|NCT03452670|Experimental|Active Group|Participants in this group will use a contemplative wellness application for 8 weeks.
89053399|NCT03452670|Other|Waitlist Group|The waitlist group will receive no intervention during the study but will be able to use the wellness application after completion of the study.
89053400|NCT00574106|Other|1|Infrared Radiation
89053401|NCT03450564|Experimental|Women Education|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
89053402|NCT03450564|Experimental|Male Involvement|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, model who allows his wife to use FP, religious leader, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
89053403|NCT03450564|Other|Control group|The third arm in this community-based intervention was following the community without provision of male and married women education. In this arm, there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
89053404|NCT00574223|Experimental|Arm 1|
89053405|NCT00574223|Placebo Comparator|Arm 2|
89053406|NCT00586131|Active Comparator|Low normal pH (arterial pH 7.36-7.38)|Ammonium chloride or sodium citrate/citrate acid as needed to achieve the target pH
89216745|NCT00485758|Other|1|Arm 1: One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study.
89053407|NCT00586131|Active Comparator|High Normal pH (arterial pH 7.44-7.46)|High Normal pH (7.44-7.46) with use of increasing doses of sodium bicarbonate up until the desired pH is achieved
89053408|NCT00574301|Experimental|1|
89053409|NCT00574379|Experimental|1|Bilastine 20mg once per day
89053410|NCT00574379|Experimental|2|Bilastine 20mg twice per day
89053411|NCT00574379|Experimental|3|Bilastine 10mg once per day
89053412|NCT00574379|Experimental|4|Bilastine 10mg twice per day
89053413|NCT00574379|Placebo Comparator|5|
89053414|NCT03450408|Active Comparator|Placement with gloved hand|The Foley bulb transcervical dilator will be placed blindly with a gloved hand.
89053415|NCT03450408|Active Comparator|Placement with sterile speculum|The cervix will be directly visualized using a sterile speculum, and an instrument will be used to advance the Foley bulb transcervical dilator into the cervical os.
89053416|NCT00574418|Other|1|
89053417|NCT00574457|Other|All subjects that meet the inclusion criteria invited|
89053418|NCT00586287|Experimental|A|Algorithm which uses serum albumin and weight to determine the loading dose of phenprocoumon within the first 5 days
89053419|NCT00586287|Experimental|B|Algorithm which uses serum age and weight to determine the loading dose of phenprocoumon within the first 5 days
89053420|NCT00586287|Active Comparator|C|The physician chooses the loading dose of phenprocoumon according to his/her experience
89053421|NCT03450330|Experimental|daily dose of AZD4205|daily dose of AZD4205
89053422|NCT00574574|Experimental|1|500mg/d of anthocyanin, contained in 4 X 250mg capsules (125mg anthocyanin/ capsule). 2 capsules to be taken with food, twice per day (n=4 in total).
89053423|NCT00574574|Placebo Comparator|2|500mg/d of placebo control containing no anthocyanin, 2 X 250mg capsules to be taken with food, twice per day (n=4, 250mg capsules in total / d).
89685594|NCT00875641||Recent Historical Control cohort|Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.
89685595|NCT04338724|Experimental|CS1002|
89685596|NCT00340171||Pregnant women and infants|pregnant women with singleton pregnancy and their newborns
89685597|NCT00339235||Non-pregnant women|Non-pregnant women aged 18 years and older
89685598|NCT00339235||Pregant women|Pregnant women aged 18 years and older
89685599|NCT00895921|Active Comparator|Aripiprazole|Participants will receive an injection of aripiprazole during the tracer-clamp study.
89685600|NCT00895921|Active Comparator|Olanzapine|Participants will receive an injection of olanzapine during the tracer-clamp study.
89685601|NCT02716714|Active Comparator|ingenol mebutate gel 0.015%|Applied on face and scalp for three days.
89685602|NCT02716714|Active Comparator|ingenol mebutate gel 0.05%|Applied on trunk and extremities for two days.
89685603|NCT02719366|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
89685604|NCT02719366|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
89685605|NCT00368212|Experimental|1|"Participants will receive psychoeducational counseling (termed health care counseling)"
89685606|NCT00368212|Active Comparator|2|Participants will receive relaxation response training
89685607|NCT05319457|Placebo Comparator|Print brochures|Participants assigned to the print brochure group will receive three educational print brochures about radon published by EPA via postal mails for three months (one per each month).
89685608|NCT05319457|Experimental|The radon app|Participants assigned to the radon app group will be asked to use the radon app for three months where they will be exposed to mobile friendly educational content that is repurposed from educational print brochures about radon published by EPA.
89685609|NCT03215329||CPAP30|Alveolar recruitment maneuver with a continuous positive airway pressure (CPAP) at 30 cmH2O during 30 seconds
89685610|NCT03215329||PEEPsteps|Alveolar recruitment maneuver with a stepwise increase and decrease in positive end expiratory pressure from 5 to 20 cmH2O.
89685611|NCT02720224|Experimental|Estetrol|A single oral dose of 15 mg carbon 14 labelled estetrol ([14C]-estetrol), containing approximately 2.8 MBq (76 µCi) 14C
89685612|NCT05312827|Experimental|Telehealth|The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
89685613|NCT02722330|Experimental|Baha 5 SuperPower on Baha Attract System|"The device involves the following parts:~The sound processor unit, an actuator unit and a cable, the Sound Processor Magnet (SP Magnet) of the Baha Attract System, the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant, a snap coupling."
89685614|NCT05314777|Experimental|Low dose ESWT application group|Exercise Training Low dose ESWT application
89685615|NCT05314777|Experimental|High dose ESWT group|Exercise Training High dose ESWT application
89685616|NCT05314777|Active Comparator|Control group|Exercise Training Sham ESWT
89685617|NCT00881647|Experimental|1|Participants will receive an 8-week course of cognitive behavioral therapy for insomnia.
89685618|NCT00881647|No Intervention|2|Participants will be placed on a waitlist for 8 weeks.
89685619|NCT00882661|Experimental|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
89685620|NCT00882661|Active Comparator|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
89685621|NCT00883675|Experimental|Treatment|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
89685622|NCT00884065|Experimental|Intervention Group|The intervention group was treated with a single session of DF following the procedure as described by the authors.
89685623|NCT00884065|Placebo Comparator|Control Group|The control group was treated with a single placebo session of DF.
89685624|NCT03215407|Experimental|Intra-articular Tocilizumab|Tocilizumab, solution, 80mg intra-articular.
89685625|NCT03215407|Active Comparator|Intra-articular Compound Betamethasone|Compound betamethasone, solution, 14mg intra-articular
89685626|NCT02722408|Experimental|Gemcabene|Participants with homozygous familial hypercholesterolemia (HoFH) on stable lipid lowering therapy received 300 milligram (mg) of Gemcabene, orally once daily from day 1 to 28 followed by 600 mg of Gemcabene, orally once daily from day 29 to 56 followed by 900 mg of Gemcabene, orally once daily from day 57 to 84. Participants were followed until Day 112.
89685627|NCT00884611|Experimental|Predictive Low Glucose Suspend|The pump suspension system consists of the Revel CGM device communicating with a laptop computer that contains the hypoglycemia prediction algorithm. During the 21 night study period, the laptop is placed at the bedside and turned on by the participant at bedtime and off on arising in the morning.The laptop contains a randomization schedule (2:1) that indicats whether the hypoglycemia prediction algorithm will be in operation that night (Predictive Low Glucose Suspend Algorithm ON) or will not be activated (Predictive Low Glucose Suspend Algorithm OFF), to which the participant is blinded.
89685628|NCT05310331|Experimental|Patients with recurrent cervical cancer|Eligible patients according to inclusion and exclusion criteria.
89685629|NCT00891319|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~Electrical stimulator~Stimulation to finger and thumb extensors only in response to, and with an intensity proportional to, opening of the contralateral unimpaired hand.~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity.~Therapy sessions are done with the subject being assisted by the CCFES system."
89685630|NCT00891319|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation~Electrical stimulator~Preprogrammed cycles of finger and thumb extensor stimulation repeatedly and automatically open the hand.~Subject instructed to not move the contralateral arm/hand during stimulation.~Therapy sessions are done without the stimulation system."
89685631|NCT00885079|Experimental|Rebamipide|Instillation,4 times/day for 4 weeks
89685632|NCT00885079|Active Comparator|Hyaluronate|Instillation,6 times/day for 4 weeks
89685633|NCT00896779|Other|ranibizumab Group 1|Group 1: 3 monthly injections of 0.5mg then prn
89685634|NCT00896779|Other|ranibizumab Group 2|Group 2: 6 monthly injections of 0.5 mg then prn
89685635|NCT03214939|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
89685636|NCT02726620|Experimental|Hypotension decision support|"The intervention period. Several decision support elements are implemented to notify anesthesia providers: attending anesthesiologists and in-room anesthesia providers of intraoperative hypotension (threshold of a mean arterial pressure below 60 mmHg). Two types of decision support will be implemented: near real-time decision support and feedback emails.~Near real-time decision support elements will notify the anesthesia providers of a blood pressure drop below the threshold and display the associated increased risk of acute kidney injury. The notification is presented through the pager system for attending anesthesiologists and through the anesthesia information management system for the in-room anesthesia provider.~All providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension that is associated with an increased risk of organ injury due to organ ischemia."
89685637|NCT02726620|Active Comparator|Usual care group|The 'before' period - or historic control group - during which no decision support for intraoperative hypotension was being used, also known as 'usual care'. This is the three year period prior to the intervention period (the 'Intraoperative hypotension decision support' arm).
89685638|NCT04381585|Experimental|Distraction osteogenesis using mini distractor|"A mini distractor will be used to move bone. Distraction osteogenesis originally developed for the severe craniofacial malformations has been adapted to correct vertical defects of the oral bone to improve bone volume for dental procedures.~However, the design of the distractor~has not evolved to adapt to a much smaller surgical site such as bone ridge in the oral cavity which necessitates a smaller screw.~are bulky, cumbersome to place, and cause significant discomfort to the patient.~has an extraoral component jutting out of the mouth to which a key (blue object) is attached to turn the screw to move bone fragments. Our Solution and the Innovation is to remove the extra-oral component by reducing the size and permitting an atraumatic placement of the screw under the gingiva (gum) thereby lessening irritation for the patient."
89685639|NCT00887575|Experimental|Dose Level I|"Neoadjuvant - Paclitaxel IV (70 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.~Maintenance - Sunitinib PO (25mg) daily"
89685640|NCT00887575|Experimental|Dose Level II|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
89685641|NCT00887575|Experimental|Dose Level III|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 6) day 1 of every cycle and Sunitinib PO (25mg) daily.
89685642|NCT03214783||Coronary artery disease (CAD) group|Patients enrolled with at least one coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
89685643|NCT03214783||No CAD group|Patients enrolled without coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
89685644|NCT03352843|Experimental|Single arm|
89685645|NCT03215173|Experimental|Fit After Baby Group|Fit After Baby mobile health lifestyle intervention to increase postpartum weight loss, increase postpartum physical activity, and improve postpartum diet.
89685646|NCT03215173|Active Comparator|Text4Baby Control Group|Receive text messages from the free Text4Baby program.
89685647|NCT03214549|Active Comparator|gull wing preparation veneers|intervention: gull wing preparation in laminates veneers proximal margin of the preparation is placed toward the lingual .The area of the proximal margin between the contact area and the gingival papilla is placed even further to the lingual. This preparation design helps to hide the margin when the restorations are viewed from an angle.
89685648|NCT03214549|Active Comparator|conventional preparation veneers|intervention: conventional preparation in laminates veneers preparation of veneers without lingual extension of preparation in mesial and distal areas
89685649|NCT03238027|Experimental|Ph1a D1: 1 mg/kg SNDX-6352|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
89685650|NCT03238027|Experimental|Ph1a D2: 3 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
89685651|NCT03238027|Experimental|Ph1a D3: 6 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
89216746|NCT00485758|Active Comparator|2|Arm 2: stable lipid-modifying regimen, adding Placebo ER niacin/laropiprant in week 4, for the duration of the study.
89216747|NCT04073459|Experimental|L dose of Hexavalent|Low dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
89216748|NCT04073459|Experimental|M dose of Hexavalent|Middle dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib)
89685652|NCT03238027|Experimental|Ph1a D4: 10 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 10 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
89685653|NCT03238027|Experimental|Ph1b D1: 1 mg/kg SNDX-6352+1500 mg durvalumab|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee. If 1 DLT is observed in 1 of 3 patients, then 3 additional patients will be treated at the 1 mg/kg SNDX-6352 dose level; if none of the 3 additional patients experience a DLT (i.e. 1 of 6), the dose will be escalated to an intermediate dose of 2 mg/kg. Escalation from 2 mg/kg to 3 mg/kg will follow the general dose escalation rules described above for both study phases.
89685654|NCT03238027|Experimental|Ph1b D2: 3 mg/kg SNDX-6352+1500 mg durvalumab|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
89685655|NCT03238027|Experimental|Ph1b D3: 6 mg/kg SNDX-6352+1500 mg durvalumab|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 every two weeks and 1500 mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
89685656|NCT00887653|Experimental|Raltegravir|This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
89685657|NCT00887965|Other|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
89685658|NCT05312749|Experimental|Experimental:|Experimental: will do progressive relaxation exercises
89685659|NCT05312749|No Intervention|Control|won't do progressive relaxation exercises
89685660|NCT02729038|Experimental|Part 1: Subjects with normal renal function (Group A)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
89685661|NCT02729038|Experimental|Part 1: subjects with moderate renal impairment (Group B)|Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
89685662|NCT02729038|Experimental|Part 1: subjects with severe renal impairment (Group C)|Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
89685663|NCT02729038|Experimental|Part 2: subjects with normal renal function (Group D)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
89685664|NCT02729038|Experimental|Part 2: subjects with mild renal impairment (Group E)|Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
89685665|NCT02729038|Experimental|Part 2: subjects with ESRD on hemodialysis (Group F)|Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).
89685666|NCT05311813|Placebo Comparator|Control group|The control group including 50 patients (n=50) receiving the conventional therapy of Covid-19 adopted by the Egyptian ministry of health for 15 days.
89685667|NCT05311813|Active Comparator|Enaxoprin group|The enoxaparin group (n=50) which received 40mg/day SC for 14 days (for patients with normal renal function and body weight between 50 and 100kg) plus the conventional therapy of Covid-19 adopted by the Egyptian ministry of health for 15 days.
89685668|NCT05311813|Active Comparator|Hydroxychloroquine group|The HCQ group which received 400 mg/day HCQ for five days plus the conventional therapy of Covid-19 adopted by the Egyptian ministry of health for 15 days(n=50).
89685669|NCT05311813|Active Comparator|Enoxaparin plus Hydroxychloroquine group|The HCQ plus Enoxaparin combination group including 50 patients receiving combined therapy of 400 mg/day HCQ for five days and 40mg/day enoxaparin for 14 days plus the conventional therapy of COVID-19 adopted by the Egyptian ministry of health for 15 days
88998176|NCT05335720|Active Comparator|Cohort 2|"EASYEF® + tulle gauze + moist gauze EASYEF® is applied directly on the wound surface then tulle gauze and moist gauze is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.~Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage."
89216749|NCT04073459|Experimental|H dose of Hexavalent|High dose of candidate hexavalent vaccine (DTwP-HepB-Sabin IPV-Hib).
89216750|NCT04073459|Active Comparator|Pentavalent+IPV|Co-administration of EupentaTM Inj and Imovax Polio
88998177|NCT05298241|Experimental|Hand-grip Strength Game|Participants will receive a hand-grip strength game for 5-20 minutes twice a day for consecutive three days.
89216751|NCT01018576|Experimental|Delayed cord clamping|
89216752|NCT02577341|Experimental|Nimotuzumab|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin, and concurrent weekly Nimotuzumab.
89685670|NCT03214627|Experimental|Anemia Control Model IV iron and ESA|"Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period"
89685671|NCT00888511|Experimental|1|
89685672|NCT05311111|Experimental|distal radial artery approach|Elective percutaneous coronary intervention by forearm radial artery through the distal radial artery in the dorsum of the hand or the anatomical snuff-box
89685673|NCT05311111|Active Comparator|conventional radial artery approach|Elective percutaneous coronary intervention through conventional radial artery access
89685674|NCT03214393||Pre-Eclampsia|pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler
89685675|NCT02730988|Experimental|Weight Loss Lifestyle Counseling|The high protein weight loss group follows the Medifast 4 & 2 & 1 Plan™, a 1200 calorie, high protein diet targeting ~10% weight loss over 24-weeks through a combination of meal replacement products (MRPs), meal plans, and individual nutrition/behavioral counseling. Participants are guided by the study RD on food purchasing and preparation and encouraged to consume only what is approved from the menu. Participants meet bi-weekly for RD-lead behavioral counseling group classes to provide support and introduce new topics in behavioral weight control. Weight is also measured at each session with progress feedback provided to increase motivation. Participants complete daily food logs to verify compliance to the diet.
89685676|NCT02730988|Active Comparator|Weight Stable Lifestyle Counseling|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
89685677|NCT03214315||Prostatectomy|Visceral adipose tissue specimen sample
89685678|NCT02731300|Active Comparator|Active tDCS|2 mA of cathodal tDCS placed over M1 for 20 mins
89685679|NCT02731300|Sham Comparator|Sham tDCS|0 mA of sham tDCS placed over M1 for 20 mins
89685680|NCT05315089|Experimental|Interventional Group|Virtual reality games +conventional exercises
89685681|NCT05315089|Active Comparator|control Group|Conventional exercises
89685682|NCT00368368|Experimental|1|
89685683|NCT00368368|Experimental|2|
89685684|NCT00368368|Experimental|3|
89685685|NCT00888979|Experimental|Nicotrol with Behavioral Counseling|Nicotrol Inhaler: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
89685686|NCT02734498|Active Comparator|Right unilateral (RUL) ECT|Right Unilateral placement of treatment electrodes in electroconvulsive treatment.
89685687|NCT02734498|Active Comparator|Bilateral (BL) ECT|Bilateral placement of treatment electrodes in electroconvulsive treatment.
89685688|NCT02734498|No Intervention|Control group|No ECT treatment for control group.
89685689|NCT03142867||Control|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The control group will be made of individuals who do not meet the qualifications for a liver biopsy."
89685690|NCT03142867||NAFLD|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD."
89685691|NCT03142867||NASH|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH."
89685692|NCT02734576|Experimental|Venous Sinus Stenting|Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. Under general anesthesia, a catheter will be inserted through a vein the upper part of the leg (groin area) and guided through the veins all the way to neck and the head. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed. After the procedure, the participants will stay in the intensive care unit for 24 hours for observation
89685693|NCT03214237||Participants|Older adult inpatients on elderly care wards in acute hospitals within the Northumbria Hospitals NHS Foundation trust area, aged 70 or over and able to consent to involvement in the study
89685694|NCT03214159|Experimental|group 1|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: Ritonavir tablet 100mg cylcle 2 Drug: NORVIR tablet 100mg cylcle 3 Drug: Ritonavir tablet 100mg cylcle 4 Drug: NORVIR tablet 100mg"
89685695|NCT03214159|Experimental|group 2|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: NORVIR tablet 100mg cylcle 2 Drug: Ritonavir tablet 100mg cylcle 3 Drug: NORVIR tablet 100mg cylcle 4 Drug: Ritonavir tablet 100mg"
89685696|NCT03213925|Experimental|RT|"After clinical response, breast magnetic resonance imaging (MRI) is performed and analyzed by two independent radiologists. Complete image response is defined by no enhanced tumor visible on any serial images.~Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region."
89685697|NCT03213847|Other|Participants with carpal tunnel syndrome|Participants diagnosed with carpal tunnel syndrome; will be evaluated with Doppler ultrasound and superb microvascular imaging (SMI) ultrasound. The results of these two evaluations will be compared between each other in according to severity of carpal tunnel syndrome (severity will be determined by electromyography studies)
89685698|NCT03838705|Other|bariatric surgery patients|patients aged 18-65 years with ASA status II-III, BMI>40 who were undergoing bariatric surgery operation
89685699|NCT03213613|Experimental|Adaptive Attention Training|The training group will engage in 15 hours of at-home training on a novel iPad-based adaptive attention training program ('Engage'). Individuals will complete thirty 30-minute sessions over six weeks. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely and analyzed over secure online servers to ensure that participants are completing training as scheduled and to deal with any unexpected road-blocks in training.
89685700|NCT03213613|Placebo Comparator|Active Control|The active control group will engage in 15 hours of at-home training on an iPad game ('Boing'). Individuals will complete game play for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with research personnel, and monetary rewards. Compliance will be monitored similarly to the adaptive attention training group.
89685701|NCT03213613|Placebo Comparator|Low-dose Adaptive Attention Training|The low-dose training group will engage in 1 hour of at-home training on 'Engage'. Individuals will complete two 30-minute sessions at the beginning and middle of a six-week period. Compliance will be monitored similarly to the adaptive attention training group.
89685702|NCT03838315|Experimental|Neural Mobilization with Soft Tissue Mobilization|"Neural Mobilization with Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization and Post Isometric Relaxation Techniques.~Frequency for Neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 40mints each session)"
89685703|NCT03838315|Active Comparator|Neural mobilization without Soft Tissue Mobilization|Neural Mobilization without Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural Mobilization Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 30mints each session)
89685704|NCT02737072|Experimental|20 mg LY2510924 + 1500 mg Durvalumab|20 milligrams (mg) LY2510924 given subcutaneously (SQ) once daily in combination with 1500 mg durvalumab given intravenously (IV) on Day 1 of each cycle (28 days).
89685705|NCT02737072|Experimental|30 mg LY2510924 + 1500 mg Durvalumab|30 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
89685706|NCT02737072|Experimental|40 mg LY2510924 + 1500 mg Durvalumab|40 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
89685707|NCT02834065|Active Comparator|Deep Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature ≤20 degrees Celsius
89685708|NCT02834065|Active Comparator|Low Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 20.1 - 24.0 degrees Celsius
89685709|NCT02834065|Active Comparator|Moderate Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 24.1 - 28 degrees Celsius
89685710|NCT05446558|Experimental|Intracorporeal anastomosis (IA)|Experimental: Intracorporeal anastomosis Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen is retrieved through a Pfannenstiel incision.
89685711|NCT05446558|Active Comparator|Extracorporeal anastomosis (EA)|A transverse incision in the right upper quadrant is performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Rel Stapler
89685712|NCT03213379|No Intervention|Referent group|"The patient of the referent group will have 2 measures of actimetry:~A first one at baseline before the apomorphim set-up:the report will be provided to the investigator and a second one before the 6 months follow-up visit but this report will not be provided to the investigator."
89685713|NCT03213379|Experimental|Actimetry group|"The patient of the Actimetry group will have at least 4 measures of actimetry and the reports will be all provided to the investigator:~One at baseline before the apomorphim set-up/ the second one 8 days after the hospitalisation/ the third one 28 days after the hospitalisation and the last one before the 6 months follow-up visit One optional measure can be performed 84 days after the hospitalisation."
89685714|NCT05446480|Experimental|Desloratadine|Desloratadine (Aerius) 10mg compounded to oral pill
89053424|NCT03450291|Experimental|Recovered from anorexia nervosa|Those who have a past diagnosis of AN (defined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria) but are currently recovered, as shown by BMI over 18.5 throughout the last 12 months (self-report and current weight measured). Defined as either 'fully recovered'and: score must be within the 'normal range' of the Eating Disorders Examination Questionnaire (EDE-Q) global mean scores for young women, below 20 on the EAT-26 and below 16 on the Clinical Impairment Assessment for Eating Disorders (CIA); or partially recovered where one or more of these scores may be above the above-mentioned cutoffs.
89053425|NCT03450291|Experimental|High scoring on the EAT-26|Those who score above 20 on the EAT-26, but who do not declare a former diagnosis of an eating disorder (though they may meet criteria for a current diagnosis during the Structured Clinical Interview for the DSM-5).
89053426|NCT03450291|Experimental|Healthy controls|No history of or current diagnosis of any psychiatric disorder (especially eating disorders) which could impact study results.
89053427|NCT04579562||COVID-19 positive AKI|
89053428|NCT04579562||COVID-19 positive no AKI|
89053429|NCT04579562||COVID negative AKI|
89053430|NCT04575168||Positive for COVID-19|Subjects positive for COVID-19 as indicated by the Standard of Care test.
89053431|NCT04575168||Negative for COVID-19|Subjects negative for COVID-19 as indicated by the Standard of Care test.
89053432|NCT00574613|Experimental|1|
89053433|NCT00574613|Placebo Comparator|2|
89053434|NCT00586365|Experimental|1|Will receive 500 mg Naproxen twice a day for two weeks
89053435|NCT00586365|No Intervention|2|Will not receive naproxen
89685715|NCT05446480|Experimental|Inert Placebo|Placebo 10mg compounded to oral pill
89685716|NCT05446480|Experimental|No Intervention|No intervention: neither drug nor placebo
89685717|NCT03213145|Experimental|Part 1|
89685718|NCT03213145|Experimental|Part 2|
89685719|NCT02722564|Experimental|all study participants|subject will self estimate breath alcohol content and their actual BrAC will be recorded as measured by the Alco Sensor IV after each beer ingested.
89685720|NCT05446246||Superobese patients|Patients with preoperative BMI > 50
89685721|NCT05446246||Morbidobese patients|Patients with preoperative BMI > 35 and <50
88998178|NCT05298241|No Intervention|routine care|The control group will not involve hand-grip strength game at night.
88998179|NCT05295199|Experimental|Experimental|Routine maintenance and Progressive relaxation exercise
88998180|NCT05295199|No Intervention|Control|Routine maintenance
88998181|NCT00163826||Trauma Patients|Major trauma patients
88998182|NCT05283343||Adults 20 years old or older|
88998183|NCT05277961|Experimental|UVR Dose 1x3SED|UVR Dose 1x3 standard erytheme dose (SED)
88998184|NCT05277961|Experimental|UVR dose 3x1SED|UVR dose 3x1 standard erythema dose (SED)
88998185|NCT00193011|Experimental|1|Docetaxel
88998186|NCT00193011|Experimental|2|Cyclophosphamide + Methotrexate + 5-fluorouracil
88998187|NCT05276791|Active Comparator|Endoscopic submucosal dissection|
88998188|NCT05276791|Active Comparator|Endoscopic mucosal resection|
88998189|NCT00163865||Clinical Group|clinical adolescent group
88998190|NCT00163865||Community Group|community adolescent group
88998191|NCT05272228|Active Comparator|Coenzyme Q10 (ubiquinone)|Synonyms: Co-Q10; Ubiquinone; Ubidecarenone; 2,5-Cyclohexadiene-1,4-dione, 2- [(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-,6,10,14,18,22,26,30,34,38- tetracontadecaenyl]-5,6-dimethoxy-3-methyl CAS number: 303-98-0 Molecular formula: C59H90O4 USP standard Content: Co-Q10 (ubiquinone), bulking agent (maltodextrin), capsule (HPCM- hydroxypropyl methyl cellulose), anti-adherents (magnesium stearate and anhydrous silica) Dosage: 2 capsules, total 100 mg Co-Q10
88998192|NCT05272228|Experimental|Q10 MICROENCAPSULATED|IP1:Q10 MICROENCAPSULATED. ENG: Ingredient BMT® Coenzyme Q10 Content Co-Q10 (ubiquinone), stabiliser (gum arabic), bulking agent (maltodextrin), capsule (HPCM- hydroxypropyl methyl cellulose), olive oil, corn starch, anti-adherents (magnesium stearate and anhydrous silica), acidity regulator (citric acid, acetic acid) HPMC capsules, size '0', 50 mg/capsule Dosage: 2 capsule, total 100 mg Co-Q10
89053436|NCT00574652|Other|1|it is a single arm study
89053437|NCT00586404||A|Patients with confirmed Barrett's Esophagus
89053438|NCT00574691|Other|1|Vascular Closure Device
89053439|NCT03450213|Active Comparator|Patients with keratoconus|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
89685722|NCT02598817||Standard Infant Formula|Standard Infant Formula containing High Sn-2
89685723|NCT05446090||Asthma Attack patients.|Patients admitted with Asthma Attacks.
89685724|NCT02547883|Experimental|Patients stopping statin|
89685725|NCT02547883|No Intervention|Patients continuing statin|
89685726|NCT05445700|Active Comparator|Non-frail|FRAIL scale= 0
89685727|NCT05445700|Active Comparator|Pre_frail|FRAIL scale= 1-2
89685728|NCT05445700|Active Comparator|Frail|FRAIL scale >2
89685729|NCT05445622|Experimental|Experimental|Subjects were able to practice spinal manipulation using the Activ5 device (Activbody, San Diego, CA, USA) for real-time objective visual feedback during in class lecture and lab. Activ5 device has a built-in force sensor that can provide realtime objective visual feedback via a Bluetooth connected mobile device.
89685730|NCT05445622|Active Comparator|Control|Subjects were taught spinal mobilization using the traditional approach.
89685731|NCT05312203|Other|the App first group (fAPP)|Participants assigned to fAPP group will use the App initially for 28 consecutive days (T1). After T1, during the next 28 consecutive days (T2) without washout period, fAPP will only maintain the usual treatment.
89685732|NCT05312203|Other|wait list crossover group (dAPP)|During T1, participants assigned to the dAPP arm will maintain the usual treatment. After T1, during the next 28 consecutive days (T2) without washout period, dAPP will use the APP.
89685733|NCT05445388|Experimental|OCT imaging|OCT imaging
89685734|NCT03213301|Experimental|Lurbinectedin|Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.
89685735|NCT05445154|Experimental|SKLB1028 Dose Escalation|"Part1:Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug SKLB1028.SKLB1028 capsules beginning at 100 mg bid.~Part2: Once the appropriate therapeutic schedule has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort."
89685736|NCT03213067||Mitochondrial Disease Patients|"Male and Females >18 years at the time of screening~Patients must have proven genetic disease (confirmed by assessment of heteroplasmy in blood and urine samples) of the m.3243 A>G mutation.~Capacity to provide informed consent taken before any study related activities.~Ability and willingness to adhere to the protocol, including all appointments.~Ability to read and converse in English."
89685737|NCT03213067||Healthy Control Group|"Male and Females >18 years at the time of screening~Capacity to provide informed consent taken before any study related activities.~Ability and willingness to adhere to the protocol, including all appointments.~Ability to read and converse in English."
89685738|NCT05444998|Experimental|Intuzumab + pyrrolidone + nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~postoperative adjuvant therapy:4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy."
89685739|NCT05444842|Experimental|insulin iontophoresis|the patients will receive insulin iontophoresis for thirty weeks
89685740|NCT05444842|Experimental|topical insulin|the patients will receive topical insulin for thirty weeks
89685741|NCT05444842|Active Comparator|conventional treatment|the patients will receive standard dressing and normal saline twice daily for thirty weeks
89685742|NCT04381741|Experimental|CD19-7×19 CAR-T plus PD1 monoclonal antibody|
89685743|NCT03838003|Experimental|Experimental: Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
89216753|NCT02577341|Active Comparator|Control|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin.
89685744|NCT03838003|No Intervention|No Intervention: Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
89053440|NCT03450213|Placebo Comparator|Normal people at the same age and sex|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
89053441|NCT03450174|Placebo Comparator|Control|this group, only placebo product will be given
89685745|NCT05444452|Experimental|GENOSS stent arm|Coronary lesions of the subjects this arm will be treated with GENOSS stent when in need of stent implantation
89685746|NCT05444452|Active Comparator|XIENCE stent arm|Coronary lesions of the subjects this arm will be treated with Xience stent when in need of stent implantation
89685747|NCT04380571|Experimental|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
89685748|NCT04380571|Experimental|Electrical Stimulation|Bilateral (TPTNS); was applied with an electrode above the medial malleolus A second electrode) was applied just below the same malleolus. Electrical stimulation with a low-frequency current (10 Hz), and adjustable intensity. The procedure was done for 20-30 minutes, three times per week for 3 months together with the conventional maneuvers applied in the control group.
89685749|NCT04380571|Active Comparator|Control group|were managed by conventional methods through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
89685750|NCT05444374|Experimental|Serplulimab plus Bevacizumab Combined With Chemotherapy|"Each cycle being 21 days, Cisplatin plus Paclitaxel up to 4-6 cycles, the maximum duration of treatment with Serplulimab is 2 years (up to 35 cycles).~Serplulimab, 300 mg IV, Day1 of each cycle~Bevacizumab, 7.5 mg/kg, IV, Day1 of each cycle~Cisplatin: 50 mg/m2, IV, Day1 of each cycle~Paclitaxel: 175 mg/m2, IV, Day1 of each cycle"
89685751|NCT05312359|No Intervention|Healthy control group|No intervention is conducted in the healthy control group.
89685752|NCT05312359|Experimental|Intervention group of amphetamine addiction|A 20-minute tACS intervention of real-stimulus is conducted twice a day for a total of 10 days in the intervention group of amphetamine addiction.
89685753|NCT05312359|Sham Comparator|Control group of amphetamine addiction|A 20-minute tACS intervention of sham-stimulus is conducted twice a day for a total of 10 days in the control group of amphetamine addiction.
89685754|NCT05312359|Experimental|Intervention group of alcohol addiction|A 20-minute tACS intervention of real-stimulus is conducted twice a day for a total of 10 days in the intervention group of alcohol addiction.
89685755|NCT05312359|Sham Comparator|Control group of alcohol addiction|A 20-minute tACS intervention of sham-stimulus is conducted twice a day for a total of 10 days in the control group of alcohol addiction.
89685756|NCT05312281|No Intervention|"Control group without lumbar belt"|"Control group without lumbar belt"
89685757|NCT05312281|Experimental|Device : Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo|Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo
89685758|NCT05444218|Placebo Comparator|Control|Open flap debridement + Er: YAG irradiation alone + systemic placebo of metronidazole and amoxicillin thrice a day (TID) for 14 days
89685759|NCT05444218|Experimental|Test|Open flap debridement + Er: YAG irradiation alone + systemic metronidazole (400mg) and amoxicillin (500mg) thrice a day (TID) for 14 days
89685760|NCT01830361|Experimental|midostaurin (PKC412), capsules|midostaurin 50 mg (two 25 mg capsules) is given in combination with the second of two induction cycles and in combination with three cycles of high-dose cytarabine (HiDAC) consolidation chemotherapies and maintenance treatment in patients with c-kit or FLT3-ITD positive t(8;21) AML in an open-label one-arm design. The first cycle of induction is not part of the study.
89685761|NCT05444140|Experimental|Experimental group|Health coaching
89685762|NCT01830439|Experimental|Fed PA-824 200mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
89685763|NCT01830439|Experimental|Fasted PA-824 200 mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
89053442|NCT03450174|Experimental|Formative messages|this group will be received only daily formative messages on diet diversity, healthy and best nutrition practices
89053443|NCT03450174|Experimental|Fortified product|this group will be received only fortified product on alternate day up to 6 months
89053444|NCT03450174|Experimental|Fortified product plus|this group will receive fortified product along with daily messages on diet diversity and healthy nutrition practices
89053445|NCT00574769|Experimental|1|
89053446|NCT00586443|Other|I|This is a Phase I safety study. There is only one arm.
89053447|NCT00574808|Experimental|intervention|Outreach Facilitation implementing elements of the Chronic Care Model. The facilitators will provide hands on support to practices and help to implement tools and processes designed to incorporate evidence-based practice into the routine delivery of cardiovascular care. Specifically, they will a) assist with practice performance assessment, feedback, and consensus building towards goal setting, b) offer clinical, technical, organizational resources and practical advice, and c) provide encouragement to face and overcome the challenges of implementing system change.
89053448|NCT00574808|No Intervention|control|Baseline data before implementation of the program will serve as the control. Comparisons will be made between baseline and post-intervention within each divisions of primary care practices as well as between divisions (ie. baseline information from one division will serve as the control for another).
89053449|NCT03450135||Mid-pubertal girls|Adolescent girls (ages 11-14) who are undergoing a healthy pubertal transition (Tanner developmental stage 3 or 4) will perform Trier Social Stress Test and Emotional go/no-go task.
89053450|NCT00586560|Experimental|1|Stratum 1 (~ 25 patients) will include patients with known bone marrow metastases or those who have had prior intensive myelosuppression therapy (including autologous or allogeneic stem cell rescue [SCR], total body irradiation [TBI], craniospinal irradiation [CSI], or hemipelvic radiation).
89053451|NCT00586560|Experimental|2|Stratum 2 (~ 25 patients) will include patients without previous intensive myelosuppressive therapy and bone marrow metastases.
89053452|NCT00574964|Experimental|1|
89053453|NCT00575003|Experimental|1|
89053454|NCT00575003|Placebo Comparator|2|
89053455|NCT00586599|Other|Control|Subjects who have no inflammatory disease who will be age/gender matched controls for the 2 other arms.
89053456|NCT00586599|Other|IBD and infliximab|Subjects who have IBD and will be receiving infliximab for the first time.
89053457|NCT00586599|Other|Newly Diagnosed IBD|Subjects who are newly diagnosed with IBD and given corticosteroid therapy.
89053458|NCT03453554|Experimental|DMN/Smart Home Partnership|Participants will learn how to use a digital memory notebook partnered with smart environment prompting technology to support everyday activities of daily living and reduce problems associated with memory deficits.
89053459|NCT03453554|Active Comparator|Digital Memory Notebook app|Participants will learn how to use a Digital Memory Notebook app to support everyday activities of daily living and reduce problems associated with memory deficits.
89053460|NCT00586638|Experimental|1|Video Game play with training strategy
89053461|NCT00586638|Active Comparator|2|Video game play without training strategy
89053462|NCT00586638|No Intervention|3|Minimal contact control
89053463|NCT00586677|Active Comparator|RF|Relationship focused where the primary goals are to strengthen the relationship between the parent and the child and to give the parent additional skills that can be used to manage the behavior of the child.
89053464|NCT00586677|Active Comparator|HS|The physical health and safety are the primary components of this parenting program where the parent is taught about basic healthcare and safety in the home.
89053465|NCT03453476|Experimental|SRP and Fotosan 630|Scaling and root planing, photodynamic therapy using Fotosan 630
89053466|NCT03453476|No Intervention|Control|Scaling and root planing only
89053467|NCT01137682|Experimental|Pasireotide LAR 40 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
89053468|NCT01137682|Experimental|Pasireotide LAR 60 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
89053469|NCT01137682|Active Comparator|Control arm (octreotide or lanreotide)|"If a patient is randomized to the open label arm the investigator will either:~be instructed to contact a Novartis delegate to initiate shipment of either octreotide LAR 30 mg or lanreotide ATG 120 mg from a Novartis or designee depot to the site, or~continue to dispense either octreotide LAR 30 mg or lanreotide ATG 120 mg available at the institution to the patient if permitted by local regulations."
89053470|NCT03453320|Experimental|Rapid - Slow|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.~First time rapid (30 minutes), second time slow (120 minutes). Albumin solution"
89053471|NCT03453320|Experimental|Slow - Rapid|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.~First time rapid (120 minutes), second time slow (30 minutes). Albumin solution"
89216754|NCT03998800|Experimental|L-arginine and L-citrulline|10 days of supplementation with 1.5 g of L-arginine and 1.5 g of L-citrulline per day
89685764|NCT01830439|Experimental|Fed PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
89685765|NCT01830439|Experimental|Fasted PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
89685766|NCT05443828|Active Comparator|Extruded puff with vitacel|The participants consumed a portion of extruded puff with added vitacel (cellulose) contained 11 g of fiber, in the context of a breakfast meal
89685767|NCT05443828|Experimental|AX bread|Participants consumed a portion of bread enriched with arabynoxylans (AX) contained 11 g of fiber, in the context of a breakfast meal
89685768|NCT05443828|Experimental|Wheat bran puff|Participants consumed a portion of wheat bran puff contained 11 g of fiber, in the context of a breakfast meal
89685769|NCT01830517|Experimental|amlodipine camsylate|amlodipine camsylate 5mg
89685770|NCT01830517|Active Comparator|losartan potassium|losartan potassium 50mg
89685771|NCT04380415|Active Comparator|Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist. ECG will be collected from a single lead ambulatory ECG patch worn on the chest. The data from both the commercial wrist-worn device and the ECG patch are not analyzed real-time.
89685772|NCT04380415|No Intervention|Non Detection Notification|Pulse rate data will be collected from a commercial device worn on the wrist.
89685773|NCT05443516||Systemic Lupus Erythematosus - Lupus Nephritis Cohort|Systemic Lupus Erythematosus - Lupus Nephritis Cohort
89685774|NCT03837457|Experimental|Cobomarsen|
89685775|NCT05443360|Experimental|amorphous calcium carbonate (ACC group)|oral use, 2 ACC tablets (1000 mg / tablet, 200 mg calcium element / tablet) twice daily given after breakfast and dinner.
89685776|NCT05443360|Active Comparator|crystalized calcium carbonate (CCC group)|oral use, 2 CCC tablets (1000 mg / tablet, 200 mg calcium element / tablet) twice daily given after breakfast and dinner.
89685777|NCT01830751|Experimental|Limit trunk flexion upon rising|Immediately upon rising particpants perform the Restrained Sitting Treatment intervention for one hour.
89685778|NCT01830751|Sham Comparator|Limit trunk flexion before going to bed|Immediately prior to going to bed, particpants perform the Restrained Sitting Treatment intervention for one hour.
89685779|NCT05443282||POI group (Study group)|"The study group included 68 women with POI.~The POI cases had been diagnosed as idiopathic POI.~The POI diagnosis was based on the presence of amenorrhea before the age of 40, increased serum FSH level higher than 40 mIU/ml, and decreased estradiol levels lesser than 50 pg/mL."
89685780|NCT05443282||Normally menstruating women (Control group)|"Control group consisted of 65 healthy, regularly menstruating women.~The women were at the age of lesser than 40 years old.~The women were recruited consecutively from those that applied to outpatient clinics to get counselling for family planning."
88998193|NCT05272228|Experimental|Final formulated product BQSM®|IP2: Final formulated product BQSM® Ingredients: Rosehip (Rosa canina) fruit extract standardised to min. 70 % of vitamin C (L-ascorbic acid), capsule (HPCM- hydroxypropyl methyl cellulose), BMT® Coenzyme Q10 (ubiquinone), vitamin E (D-alfa tocopheryl acetate), vitamin A (retinyl acetate), L-selenomethionine, bulking agent (maltodextrin), stabiliser (gum arabic), olive oil, corn starch, anti-adherents (magnesium stearate and anhydrous silica), acidity regulator (citric acid, acetic acid) HPMC capsule, size '0', 50 mg/capsule Dosage: 2 capsule, total 100 mg Co-Q10
88998194|NCT05260216|Experimental|Experimental subgroup of Cariostat|Use Cariostat as the caries risk assessment tool to divide the children into different risk levels. Based on the results, children with low risk of caries will receive twice fluoride foam each year and oral hygiene guidance, children with middle or high risk of caries will receive forth fluoride applications each year, oral hygiene guidance and professional caries treatment.
88998195|NCT05260216|Experimental|Experimental subgroup of Cariogram|Use Cariogram as the caries risk assessment tool to divide the children into different risk levels. Based on the results, children with low risk of caries will receive twice fluoride foam each year and oral hygiene guidance, children with middle or high risk of caries will receive forth fluoride applications each year, oral hygiene guidance and professional caries treatment.
88998196|NCT05260216|Placebo Comparator|Control group|Use Cariogram and as the caries risk assessment tool to divide the children into different risk levels. All children will receive routine prevention including wice fluoride foam each year and oral hygiene guidance.
88998197|NCT05256082|Active Comparator|with mask (FFP2 mask or surgical mask)|Patient is Walking with mouth/nose-mask for 6 Minutes.
88998198|NCT05256082|Placebo Comparator|without mask|Patient is Walking without mouth/nose-mask for 6 Minutes.
88998199|NCT05171296||abdominal trauma patients|blunt abdominal trauma patients planned for conservation.
88998200|NCT05167045||No Dementia|
89216755|NCT03998800|Experimental|L-arginine|10 days of supplementation with 3 g of L-arginine per day
89685781|NCT05443048|Experimental|Ivoclar Ivotion Denture System|
89685782|NCT00904345|Experimental|Treatment|
89685783|NCT05442892|Experimental|Physical exercise|The intervention will consist of a multicomponent exercise training programme, which will be composed of supervised progressive resistance exercise training, balance-training, strength-training and walking for 4 consecutive days. During the training period, patients will be trained in 30 min sessions daily.
89685784|NCT05442892|No Intervention|Without physical exercise|Participants randomly assigned to the usual care group will receive normal hospital care, which includes physical rehabilitation when needed
89685785|NCT05442736|Active Comparator|Free drug|Free drug incorporated in in situ gels
89685786|NCT05442736|Active Comparator|drug entrapped in nanoparticles|drug entrapped in nanoparticles then incorporated in in situ gels
89685787|NCT03212911|Active Comparator|3-standard dose HBV vaccination group|participants will receive 3 standard doses of HBV vaccination at 0, 1, 6 months
89685788|NCT03212911|Active Comparator|4-standard dose HBV vaccination group|participants will receive 4 standard doses of HBV vaccination at 0, 1, 2, 6 months
89685789|NCT05311657||Test Group|Severe COPD (GOLD 3 and 4).
89685790|NCT05311657||Control Group|Matched to Test Group regarding age, sex, smoking history and number of systemic diseases.
89685791|NCT05442502||The conventional overlap group|In conventional overlap group, after firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
88998201|NCT05149690|Experimental|monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
89685792|NCT05442502||The OGT-assisted group|In OGT group, the anvil fork was inserted into the esophageal mucosa canal by movement of the connection of fork-OGT-gastric tube.
89685793|NCT01830829|Experimental|Jaylyn|Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
89685794|NCT01830829|Placebo Comparator|Placebo|Placebo
88998202|NCT05149690|Active Comparator|Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
89216756|NCT03998800|Placebo Comparator|Placebo (corn-starch)|10 days of supplementation with corn-starch
88998203|NCT00164021||Cystic Fibrosis|Patients with cystic fibrosis
89685795|NCT03212755|Experimental|group 1|25 diabetic patients without diabetic nephropathy
89685796|NCT03212755|Experimental|group 2|25 type 2 diabetic patients with diabetic nephropathy
89685797|NCT03212755|Sham Comparator|group 3|25 healthy subjects
89685798|NCT05440084||Patients referred for CTO PCI|
89685799|NCT01831063|No Intervention|1|This group received the traditional seizure teaching. This consisted of verbal instruction from health care professionals on acute seizure management and administration of the rescue medication.
89685800|NCT01831063|Experimental|2|This group received the traditional seizure teaching as well as the supplemental simulation based seizure management teaching. The simulation based seizure teaching consisted of numerous opportunities to manage a simulated seizure with instructor guidance and feedback. This session was deemed complete when caregivers verbalized confidence with seizure management.
89685801|NCT05437822|Experimental|TXA group|Tranexamic acid, a topic dose of 2 g diluted in 50 mL saline solution infused in shoulder joint
89685802|NCT05437822|No Intervention|Control group|In the control group will not be administered TXA or any other drugs.
89685803|NCT05437042||Individuals with pronated foot|
89685804|NCT05448040|Experimental|Collagen|This group received a bone graft (xenograft) and had the socket covered with a collagen membrane, in order to protect the bone graft inserted and seal the socket.
89685805|NCT05448040|Experimental|Free gingival graft|This group received a bone graft (xenograft) biomaterial and had the socket covered with a free gingival graft material, in order to protect the bone graft inserted and seal the socket.
89685806|NCT03212443|Sham Comparator|Group A|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
89685807|NCT03212443|Active Comparator|Group B|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
89685808|NCT05447962|Experimental|Barbershop-Based Facilitation (BF)|Participants will receive the Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP) program manual and receive exposure to Barbershop-Based Facilitation (BF), which is designed to stimulate specific, actionable steps that community health workers (CHWs) can undertake to implement CLIP at the barbershop.
89685809|NCT05447962|Active Comparator|Self-Directed|Participants will receive the Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP) program manual.
89685810|NCT05311423||Non-TB Group|QuantiFERON-TB test (QFT) negative, continue assisted reproductive treatment
89685811|NCT05311423||Latent tuberculosis infection Group|QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, acid-fast bacilli (AFB) microscopy, Mycobacterium tuberculosis (Mtb) culture, or GeneXpert MTB/RIF Ultra test results. Then assisted reproductive treatment can be continued, but follow-up for tuberculosis-related symptoms is required
89685812|NCT05311423||Subclinical genital tuberculosis Group|QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, AFB microscopy, Mtb culture, but GeneXpert MTB/RIF Ultra positive test results. They are recommended to receive 6-month first-line standard anti-tuberculosis treatment (ATT) regimen
89685813|NCT05311423||Female genital tuberculosis Group|QFT positive. Excluded active pulmonary tuberculosis, regardless of GeneXpert MTB/RIF Ultra results, at least one of these test results, including endometrial histopathologiy, AFB microscopy, Mtb culture is positive, they will receive 6-month ATT
89685814|NCT03212053|Other|Patients with Essential Thrombocythemia|"patients who come in consultation at diagnosis or during the follow-up for an Essential Thrombocythemia.~They will have biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)"
89685815|NCT05447260|Experimental|Ruxolitinib|
89685816|NCT05447104|Active Comparator|ADA Clinically-Tested Reference Sugar-Free Gum|Peppermint flavored sugar-free chewing gum (1 piece = 2.2 grams)
89685817|NCT05447104|Experimental|Marketed Gum: Sugar-free gum|Orbit White, peppermint flavored sugar-free chewing gum Mars Wrigley Confectionary US, LLC (1 piece = 2.0 grams)
89685818|NCT05311267|Experimental|AOT|Participants who, in addiction to standard rehabilitation program after surgery (isometric exercises), underwent two training session of action observation therapy.
89685819|NCT05311267|No Intervention|Control group|Participants who received standard rehabilitation program after surgery. The control group, before performing the functional exercises watched two videos of different landscapes lasting 4 minutes each.
89685820|NCT05311189|Experimental|HLX10, Trastuzumab and Chemotherapy|HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
89685821|NCT01831297||syncope|
89685822|NCT01831375|Experimental|Speak Up|Participants will learn how to speak up to their medical doctors for improving their medical care.
89685823|NCT01831375|Other|Get Connected|Attention control group
89685824|NCT05446402|Experimental|Acne Treatment|
89685825|NCT01831453|Placebo Comparator|isopropylmyristate oil|placebo Soft gelatinous capsules filled with isopropylmyristate oil
88998204|NCT00164021||Control|
88998205|NCT04683523|Experimental|Anaerobic exercise training|
88998206|NCT04683523|Active Comparator|Aerobic exercise training|
88998207|NCT05093452|Experimental|Motivational interviewing|Educational session based on the motivational interviewing
89685826|NCT01831453|Active Comparator|experimental|omega-3 1 gram three times daily for 6 months
89685827|NCT03212209|Experimental|CPAP C- Flex-Plus by Philips Respironics|Four consecutive weeks with CPAP C- FLEX PLUS treatment. After these 4 weeks, patients will undergo full PSG with CPAP FLEX- PLUS. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
89685828|NCT03212209|Experimental|CPAP with Sensawake by Fisher and Paykel|Four consecutive weeks with CPAP Sensawake treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
88998208|NCT05093452|Other|Information flyer|Information flyer on childhood vaccines
88998209|NCT05077969|Experimental|Group 1 (Study Product)|Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.
88998210|NCT05077969|Placebo Comparator|Group 2 (Reference Therapy)|Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, participants will continue to receive matching famotidine placebo, QID, for an additional 9 days.
88998211|NCT00164138|Experimental|Pelvic Floor Training Group|Pelvic floor training, biofeedback.
88998212|NCT05062564|Experimental|LipiFlow group|Single preoperative treatment with the thermal pulsation system LipiFlow within two months before cataract surgery
88998213|NCT05062564|Active Comparator|Control group|Eyelid warm compresses plus eyelid massage twice a day for the preoperative month
88998214|NCT04722510|Experimental|Effect of repeated TMS on aggressive impulse behavior in patients with BPD.|A protocol of 15 sessions of repeated Transcranial Magnetic Stimulation at 1 Hz on right dorsolateral prefrontal cortex.
88998215|NCT05023642|Experimental|resistance training|"Participants will not be offered the exercise program in the three months before data collection.~From then on, participants will perform exercises during the resistance training protocol intervention."
89685829|NCT03212209|Active Comparator|CPAP fixed pressure|Four consecutive weeks with CPAP fixed pressure treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
89685830|NCT00369850|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomisation.
88998216|NCT05023642|No Intervention|control group|Individuals in the control group will not be offered the exercise program in the three months before data collection and during the entire period corresponding to the 12-week intervention.
88998217|NCT04683328|Experimental|SCTA01 Group|SCTA01+Best Supportive Care
88998218|NCT04683328|Placebo Comparator|Placebo Group|Placebo+Best Supportive Care
88998219|NCT04683016||Periodontitis patients|Patients with a diagnosis of periodontitis, irrespective of its stage and grade.
88998220|NCT04981405||Patients hospitalised to clinics of First Pavlov State Medical University of Saint - Petersburg|450 cases - patients hospitalised with COVID-19 450 control - patients hospitalised without COVID-19 in the same period (surgical, oncological, cardiological, ophthalmologic, gastroenterological departments)
88998221|NCT04981405||Patients referred to Medical Institute named after Berezin Sergey for computed tomography|Cases - patients with pneumonia confirmed after computed tomography. Controls - patients without pneumonia after computed tomography.
88998222|NCT00409695|Experimental|High Dose Thymoglobulin (ATG)|High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
88998223|NCT00409695|Experimental|Low Dose Thymoglobulin (ATG)|Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
89685831|NCT00369850|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomisation.
89685832|NCT00369850|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
89685833|NCT00369850|Experimental|Letrozole 2 years plus tamoxifen 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
89685834|NCT01831531|Experimental|S-1|"Patients will receive chemoradiation with S-1.~Interventions:~Drug: S-1 Radiation: Radiation therapy"
89685835|NCT03211897||Haloperidol 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
89685836|NCT03211897||Ziprasidone 20mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
89685837|NCT03211897||Olanzapine 10mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
89685838|NCT03211897||Midazolam 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
88998224|NCT04977232|Experimental|Escitalopram + game intervention|Escitalopram treatment and game intervention are given in combinations for 8 weeks.
88998225|NCT04977232|Active Comparator|Escitalopram|Escitalopram treatment for 8 weeks
89685839|NCT00422500||Chemotherapy Symptoms|Study participants with advanced-stage lung cancer.
89685840|NCT01831687|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
89685841|NCT01831687|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
88998226|NCT04974814|Placebo Comparator|control group|in this group patients will not receive statin before primary PCI
88998227|NCT04974814|Active Comparator|atorvastatin group|in this group patients will receive 80 mg atorvastatin single dose before primary PCI
88998228|NCT04974814|Active Comparator|rosuvastatin group|in this group patients will receive 40 mg rosuvastatin single dose before primary PCI
88998229|NCT00409734||Children with pyloric stenosis|Male or female children age two to nine weeks with history of vomiting and feeding intolerance, and abdominal sonogram showing presence of pyloric stenosis
88998230|NCT00409734||Children without pyloric stenosis|Male or female children age two to nine weeks without pyloric stenosis admitted to the hospital for other reasons
88998231|NCT04921345|Experimental|Cohort 1: Participants aged 7-11 years|Participants aged 7-11 years will receive nemolizumab for 52 weeks.
88998232|NCT04921345|Experimental|Cohort 1.1: Participants aged 7-11 years|Participants aged 7-11 years will receive nemolizumab for 52 weeks.
88998233|NCT04921345|Experimental|Cohort 2: Participants aged 2-6 years|Participants aged 2-6 years will receive nemolizumab for 52 weeks.
88998234|NCT00193635|Active Comparator|1|oral MMF
88998235|NCT04723979||Exposed to recombinant FVIIa (NovoSeven®)|all women exposed to NovoSeven® during sPPH
88998236|NCT04723979||Standard of Care|Women with postpartum hemorrhage not exposed to NovoSeven®.
89685842|NCT05444296|Experimental|Dry Needling|Experimental group
89685843|NCT05444296|Active Comparator|Upper Cervical Mobilizations|Active control
89685844|NCT05441254|Experimental|Experimental group|"Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;"
88998237|NCT00193674|Experimental|1|
88998238|NCT00193674|Placebo Comparator|2|
88998239|NCT04861246|Experimental|Experimental|Epidermal pigmented lesion
88998240|NCT04841356|Experimental|ICG|Immediate Compression Garment
88998241|NCT04835545|Experimental|Wet Perlite, 2L air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with 2L air pocket
88998242|NCT04835545|Experimental|Wet Perlite 2L air pocket with resistance compensation|Breathing in the simulated avalanche snow. Breathing into model of wet perlite 2L air pocket with resistance compensation
88998243|NCT04835545|Experimental|Wet Perlite, no air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet perlite with no air pocket
88998244|NCT00193791|No Intervention|Radiation (RT) Alone|Standard radical radiation therapy alone
88998245|NCT00193791|Experimental|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
88998246|NCT04832425|Experimental|PRAX-114|40 mg PRAX-114 once daily
88998247|NCT04832425|Placebo Comparator|Placebo|Placebo once daily
88998248|NCT04724135||Study group|Female health-care givers aged 45 to 64 years. The study participants will be recruited from UMC (Clinical Academic Department (CAD) of Women's Health, Pediatric Clinical Academic Department, Republic Diagnostic Center (RDC) and National Center for Children's Rehabilitation (NCCR)), Nur-Sultan, Kazakhstan.
88998249|NCT04825639||Sepsis|"Patients admitted to PICU who are selected from registry based on primary diagnoses with codes for the following search codes were selected:~Sepsis is defined as per the International Consensus Conference pediatric sepsis definition (2005) [citation 1].~In silico analysis will be carried out in the sepsis cohort comparing admissions with Acute Kidney Injury (AKI) and those without AKI to identify factors associated with AKI.~In those selected admissions to PICU, information on Renal Function, Chloride levels, clinical outcome and medication use as well as fluid resuscitation will be collected from hospital online resources such as discharge summaries, results portal and the PICANet database. In addition the Paediatric Index of Mortality 3 severity of illness scores will be reported for all admissions.~Sepsis will be defined based on the International Pediatric Consensus Conference definition of sepsis (2005)"
88998250|NCT04825639||Diabetic Ketoacidosis (DKA)|"This group is defined based on the British Society of Paediatric Endocrinology and Diabetes.case definition for Diabetic Ketoacidosis [citation 2].~The data collected will be similar to the sepsis cohort. In silico analysis will be carried comparing those with AKI and without AKI in the DKA cohort."
88998251|NCT04818658||Preformed Metal Crowns using Hall Technique|
88998252|NCT04818658||Compomer Restoration|
88998253|NCT04683484|Experimental|Low dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
88998254|NCT04683484|Experimental|Middle dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
88998255|NCT04683484|Experimental|High dose of Nanocovax|Intramuscular injection, two doses given 28 days apart
88998256|NCT04683484|Placebo Comparator|Placebo|Intramuscular injection, two doses given 28 days apart
89685845|NCT00904813|Active Comparator|1. Short-course RT (5x5 Gy) + surgery within 1 week (SRT)|RT=Preoperative radiotherapy Gy=Gray
89685846|NCT00904813|Active Comparator|2. Short-course RT (5x5 Gy) + surgery after 4-8 weeks (SRT-delay)|RT=Preoperative radiotherapy Gy= Gray
89685847|NCT00904813|Active Comparator|3. Long-course RT (25x2 Gy) + surgery after 4-8 weeks (LRT-delay)|RT= Preoperative radiotherapy Gy= Gray
89685848|NCT04016428|Experimental|OPTIMISM Intervention|Participants will receive online delivery of a mindfulness-based program for improving sleep in pregnancy, along with the usual care they would receive from their provider.
89685849|NCT04016428|Active Comparator|Sleep Education|Participants will receive online delivery of an education program on sleep in pregnancy, along with the usual care they would receive from their provider.
89685850|NCT04738864|Experimental|behcet's disease patient|patient who presented with manifestation of behcet disease
89685851|NCT04738864|Experimental|Healthy people|healthy control people
89685852|NCT01832077||rural doctor|examine patient's fundus by 90D fundus pre-set lens
89685853|NCT01832077||grader|grade fundus pictures in ZOC
89685854|NCT03777202|Experimental|High-flow nasal oxygen during sleep endoscopy|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
89685855|NCT03777202|Active Comparator|Low-flow nasal oxygen during sleep endoscopy|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
89685856|NCT01832233|Experimental|Renal Denervation|Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive Renal Denervation as a treatment
88998257|NCT04683367|Experimental|clinical hernia|developing clinical hernia
88998258|NCT04683289|Experimental|Visco-Circumferential-Suture-Trabeculotomy|Visco-Circumferential-Suture-Trabeculotomy
88998259|NCT04683289|Active Comparator|viscotrabeculotomy|Viscotrabeculotomy
88998260|NCT04683133|Other|Single arm|Optical coherence tomography evaluation of coronary arteries with intermediate to severe stenosis.
88998261|NCT00193908|Experimental|1|
88998262|NCT00193908|Experimental|2|
88998263|NCT00164723|Other|NSAID|patients taking NSAID will undergo capsule endoscopy
88998264|NCT00164723|Other|Aspirin|patients taking Aspirin will undergo capsule endoscopy
88998265|NCT00164723|Other|Non-user|patients didn't take NSAID or ASA will undergo capsule endoscopy
88998266|NCT04810117||COVID-19 PCR positive patients who are not yet vaccinated|Patients test positive with PCR and recovered from COVID-19
88998267|NCT04810117||COVID-19 patients with obvious symptoms who are not yet vaccinated|COVID-19 patients with obvious symptoms but PCR test was not conducted for them
88998268|NCT04810117||COVID-19 suspected patients with no symptoms who are not yet vaccinated|COVID-19 suspected patients with no symptoms but came in obvious contact with infected environmental/biological samples
88998269|NCT04810117||COVID-19 PCR positive patients who are vaccinated|COVID-19 suspected patients who have got either one or two doses of vaccine
88998270|NCT04810117||Healthy Individuals who are vaccinated|Control group
88998271|NCT04810117||Healthy Individuals who are not vaccinated|Control group
88998272|NCT02277340|Experimental|EAPA for Pilonidal Disease|The abbrevition EAPA is used to describe the study. The cohort of pilonidal disease patients treated who do not have an acute abscess or other problems like hydradenitis suppurativa, has been treated by endoscopy assisted fulguration of the inner surface and additional crystallized phenol application for further clean up of the remaining tissue as well as preventing bacterial growth.
88998273|NCT00193947||women initiating ARV therapy during pregnancy with neveripine|
88998274|NCT00176241|Experimental|1|
88998275|NCT04732897|No Intervention|Control arm|wearing made-to-measure soles with SHORE greater than or equal to 65 (standard of care)
88998276|NCT04732897|Experimental|Interventional arm|wearing made-to-measure soles with SHORE greater than or equal to 65 + dynamic dressing of the joint
88998277|NCT04727203|Experimental|Intervention|Partcipants in this group will receive the 8 week healthy lifestyle program
88998278|NCT04727203|No Intervention|Control|Participants in this group will not receive any intervention
88998279|NCT04719793|Experimental|Wharton's Jelly|Intraarticular injection of Umbilical Cord-derived Wharton's Jelly
88998280|NCT04723940|Active Comparator|Oral Antibiotics|Participant will receive 6 weeks of oral antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
88998281|NCT04723940|Active Comparator|Intravenous Antibiotics|Participant will receive 6 weeks of intravenous (IV) antibiotic therapy to treat their infection. The type of antibiotic given will be at the discretion of the infectious disease doctor.
88998282|NCT04684849||Healthy subjects|Subjects who are healthy without disease
88998283|NCT04684849||Gas and Bloating patients|Patients with symptoms of gas and bloating
88998284|NCT04680793|Other|EDS Patients|No intervention during the control period (9 weeks) and then experimental during the rehabilitation stage (9 weeks).
88998285|NCT04678570|Experimental|Intervention Group-1|White Noise intervention and standard care, procedures will be applied.
88998286|NCT04678570|Experimental|Intervention Group- 2|The swaddling method and standard care, procedures will be applied.
88998287|NCT04678570|Experimental|Intervention Group- 3|White Noise, swaddling method, and standard care, procedures will be applied.
88998288|NCT04678570|No Intervention|No Intervention Group|Standard care and procedures to be applied.
89685857|NCT01832467|Experimental|cetuximab-containing chemotherapy|"Cetuximab may be given at either one of the following schedules at the investigator's discretion:~2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.~Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.~Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.~Regimens to be combined with biweekly cetuximab:~Irinotecan at 2-weekly schedule.~FOLFIRI (as inpatient or via ambulatory pump).~FOLFOX (as inpatient or via ambulatory pump)."
89685858|NCT03211351|Experimental|Liposic|Liposic was applied to one eye of patients in this group
89685859|NCT03211351|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
89685860|NCT05442658||Food hypersensitivity, Food allergy|"younger children undergo complete screening of the fecal microbiota and determination of total serum IgE and specific IgE levels.~The specific IgE antibodies that were measured included those for the following food allergens: egg white, cow milk, wheat, peanut, soy, and gluten. Subjects with FH were defined as those with a total IgE level of over 100 IU/ml and a level of at least one specific IgE of greater than 0.35 IU/ml."
89685861|NCT05442658||Healthy control|The control children came from an age-matched cohort and did not exhibit allergic manifestations or increased total or specific IgE levels.
89685862|NCT01832623|Experimental|Exploration of Vitamin D roles|Various exams will be performed during two visits (the same day or within three months) in order to answer the objectives of the study.
89685863|NCT03708640|Placebo Comparator|Physical Activity Counseling|"Group receives baseline physical activity counseling.~Group does not receive personalized, health coaching via smart text messages."
89685864|NCT03708640|Experimental|Digital Activity Tracker/Smart Text Messaging|"Group receives baseline physical activity counseling.~Group receives personalized, health coaching via smart text messages informed by digital activity tracker."
89685865|NCT01832701|Experimental|coffee|4 cups of soluble coffee per day (2.5g per cup)
89685866|NCT01832701|Placebo Comparator|Maltodextrine with caffeine|4 cups per day containing 2.5 g of product each
89685867|NCT03617926|Experimental|Test product|Water-based lotion (internal code (X92001666)
89685868|NCT03617926|Active Comparator|Reference|Commercial, pyrethrin-based shampoo (RID shampoo)
89685869|NCT03837613||Group 1 (TT<4mm)|Patients with a preoperative tumor thickness less than 4 mm. Intervention: tumor resection and neck dissection
89685870|NCT03837613||Group 2 (TT >= 4mm)|Patients with a preoperative tumor thickness equal to or more than 4 mm Intervention: tumor resection and neck dissection
89685871|NCT03610984||Intensive structured education group|Regular outpatient visit in every 3 months to these patients. The glucose control and diabetes complication screening will be evaluated in visit. Patients will also be evaluated by specialized psychologists, dietitians and therapists. Diabetes self-management education will be regularly exposed to patients
89685872|NCT03610984||Conventional education group|Outpatients visit to endocrinologists when necessary in a conventional way.
89685873|NCT03837145||Liver transplant recipients|Adult patients requiring elective post-operative ventilation after a living donor liver transplant receiving intravenous propofol infusion for sedation titrated to Bi-Spectral Index (BIS) score of 60-80,as per our institutional protocol.
89685874|NCT03836911|Active Comparator|serious game|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a serious game
89685875|NCT03836911|Other|Classic program|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a classical exercise program in older subjects living in a nursing home
88998289|NCT04644133||Healthy|Subjects without bowel issues will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
88998290|NCT04644133||Constipation|Subjects diagnosed with constipation will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
88998291|NCT04644133||Fecal Incontinence|Subjects diagnosed with fecal incontinence will be asked to complete a 2 week electronic stool diary and a 2 week paper stool diary. They will complete feedback questionnaires for comparison between the two forms of diaries. The subjects will have the option to download the Stool Dairy App or if they do not have access to a smartphone they will be provided with a phone on which one the app has already been uploaded and instructed on its use. Subject's charts may be reviewed.
88998292|NCT04641247|Experimental|Participants receiving niraparib|Participants will receive niraparib once a day, continuously throughout each 90-day cycle until one of the following occurs: disease progression, unacceptable toxicity, initiation of new anticancer therapy that was not part of the parent study, withdrawal of consent, discontinuation at the discretion of the Investigator, noncompliance with protocol, death, or discontinuation for any other reason. The doses provided in this long-term treatment extension study will be those defined in the parent study for each enrolled participant. The starting dose of niraparib will be the same as the assigned dose and regimen that were given in the parent study.
88998293|NCT04635007|Experimental|Group 1: Tranexamic acid group|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
88998294|NCT04635007|Experimental|Group 2: Misoprostol group|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
88998295|NCT04590898||significant peri-device leakage after LAA occlusion|Peri-device leakage closure after left atrial appendage occlusion
88998296|NCT04546945||control cases|normal healthy person
88998297|NCT04546945||Patients|Patients with hematologic malignancies. Newly diagnosed.
88998298|NCT00194064|Experimental|Olanzapine|Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg
88998299|NCT04503343|Other|intervention group|subjects are randomly divided into the intervention group. and they will be given a one-time non-drug intervention(mindfulness training, relaxation training or electrical cerebellar stimulation).
88998300|NCT04503343|No Intervention|control group|subjects are randomly divided into the control group and regularly followed up.
88998301|NCT04485676||Dalbavancin|"Patients to be included in this study have been treated with Dalbavancin according to clinician's judgement and clinical practice according national or international guidelines.~Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Information about dosing treatment will be collected."
88998302|NCT04467970|Experimental|Unicompartmental Knee Replacement|
88998303|NCT04467970|Experimental|High Tibial Osteotomy|
88998304|NCT04427917|Experimental|PF-06835919|
88998305|NCT04427917|Placebo Comparator|Placebo|
88998306|NCT00194103|No Intervention|TAU|
88998307|NCT00194103|Active Comparator|Telephone Monitoring|
88998308|NCT00194103|Experimental|Telephone Monitoring and Counseling|
88998309|NCT04418557||Pregnant women without COVID-19 Infection|Women who are tested for COVID-19 at the time of admission for labor and delivery and test negative
88998310|NCT04418557||Pregnant women with a history of COVID-19 infection|Women who are tested for COVID-19 at any point during their pregnancy, including at the time of admission for labor and delivery, and test positive
88998311|NCT04418557||Pregnant women vaccinated for COVID-19|Women who are vaccinated against COVID-19 at any point during their pregnancy
88998312|NCT04682782|Experimental|Esketamine|Participants randomized to this arm will receive Esketamine (1 mg/ml) infused at 0.1 mg/kg/hour (0.1 ml/kg/h) throughout the operation
89685876|NCT05438446|Experimental|Renal Denervation Arm|Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)
89685877|NCT05438446|No Intervention|Control|The patient will not receive any interventional therapy
89685878|NCT02470312||CRT|Patients who are undergoing CRT implantation utilizing MediGuide system and tools
89685879|NCT02470312||EP|Patients who are undergoing ablation procedures for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia utilizing MediGuide system and tools
89685880|NCT03211195|Experimental|Sotagliflozin - Commerical|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Commercial formulation) by mouth under fasted conditions
89685881|NCT03211195|Active Comparator|Sotagliflozin -Development|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Development formulation) by mouth under fasted conditions - Type: Active Comparator
89685882|NCT02470390|Active Comparator|Nasal fentanyl|"nasal fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute.~Will be administered on either study day 1 or 3 per protocol and randomization."
89685883|NCT02470390|Active Comparator|Sub-Lingual fentanyl|"sublingual fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue.~Will be administered on either study day 1 or 3 per protocol and randomization."
89685884|NCT02470390|Active Comparator|IV fentanyl|"IV fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes.~Will be administered on study day 5 per protocol."
89685885|NCT05313685||Mayo Clinic hiccup educational materials|
89685886|NCT05313685||Mayo Clinic hiccup educational materials + updated supplementary content|
89685887|NCT05311501|Experimental|Immediate periodontal treatment|Right after the execution of a complete periodontal chart, non-surgical periodontal treatment (NST) was performed, according to the most recent clinical guidelines. NST was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments. Oral Hygiene Instructions (OHI) were provided throughout the experimental period.
89685888|NCT05311501|No Intervention|Delayed Periodontal treatment|Right after the execution of a complete periodontal chart, the patient is informed regarding their group allocation, according to which they are asked to delay NST for 10 weeks. 10 weeks after baseline examination, NST was performed according to the most recent clinical guidelines. NST was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments.
89685889|NCT05441566||Driver gene-positive|
89685890|NCT05441566||Driver gene-negative|
89685891|NCT03211273||Patient cohort|Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.
89685892|NCT03505996|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every three weeks
89685893|NCT01832857|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
89685894|NCT03837535||Patients undergoing surgery|Swedish patients, >18 years undergoing surgery 2007-2014
89685895|NCT03837301|Experimental|NESS-EFTR|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation (basin dissection)
89685896|NCT01832935|Active Comparator|insulin glargine|patients receiving variable doses of Insulin glargine.start with 0.2 to 0.6unit per kg
89685897|NCT01832935|Active Comparator|Insulin NPH|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
89685898|NCT02471326|Experimental|HIV Positive Subjects|VRC-HIVMAB060-00-AB (VRC01) given in HIV-infected Adults (age 18-65 years) on cART with suppressed viremia
89685899|NCT01833013|Other|endometriosis cohort|females suffer from endometriosis
89685900|NCT05406778|Other|TBD|
89685901|NCT01833091|Experimental|intervention|creat light period 12 hours with cover on incubator
89685902|NCT01833091|No Intervention|control|
89685903|NCT03411382|Experimental|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
89685904|NCT03411382|Experimental|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
89685905|NCT03411382|Experimental|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
89685906|NCT03411382|Placebo Comparator|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
89685907|NCT03210805|Experimental|Supplementation|Omega-3 Polyunsaturated Fatty Acids
89685908|NCT04380181||Dobutamine|Weaning from cardiopulmonary bypass using dobutamine as inotrope.
89685909|NCT04380181||Milrinone-epinephrine|Weaning from cardiopulmonary bypass using milrinone and epinephrine as inotropes.
89685910|NCT02472262|Experimental|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
89685911|NCT02472262|Experimental|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
89685912|NCT02472262|Active Comparator|Corn Soy Flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
89685913|NCT03210727|Other|single arm|This arm will be used to pilot test the Ready to CARE program (with the caregivers) and measure outcomes (in the patients).
89685914|NCT01833559|Other|Incidence of GDM|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
88998313|NCT04682782|Placebo Comparator|Saline|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the operation
88998314|NCT00165035|Experimental|1|CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES
88998315|NCT00165035|Active Comparator|2|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
88998316|NCT03455374|Experimental|Treatment with CSI atherectomy device|removal of the plaque from vessel wall by optical coherence tomography
88998317|NCT04330339|Experimental|Fasting|"Eligible participants will undergo baseline assessments prior to starting the intervention.~Baseline assessments include measurements of weight, height, quality of life, fatigue, mood, levels of physical activity, and blood markers.~Participants will fast for 13 hours nightly for 12 weeks.~Assessments will be repeated at the completion of the 12-week intervention."
88998318|NCT04322695|Experimental|Rehabilitation Education Care Program (RECP)|Cancer rehabilitation program and patients education can improve disability and promote return to work.
88998319|NCT04322695|Other|Usual care|Usual care
88998320|NCT04307953|Experimental|AZD0530|
88998321|NCT04307953|Experimental|Placebo/AZD0530|
88998322|NCT04306861||Treatment Naïve PDAC Patients|Patient presenting with treatment-naïve, biopsy-proven pancreatic ductal adenocarcinoma (PDAC) who qualifies for neoadjuvant chemo-radiation therapy.
88998323|NCT00165152|Active Comparator|Genetic Counseling|
88998324|NCT00165152|Active Comparator|Informed Consent Counseling|
88998325|NCT04297267|Experimental|GP group|Patients should receive four cycles of GP regimen (cisplatin at 75 mg/m2 iv infusion on day 1 plus gemcitabine at 1250 mg/m2 iv infusion over 30 min on day 1 and 8 every 3 weeks).
88998326|NCT00176475|Experimental|Therapeutic allogeneic lymphocytes with rituximab|
88998327|NCT04283968|Experimental|Treatment arm|All patients will receive 4 fecal microbial transplantations from healthy donors each 2 weeks apart
88998328|NCT04283968|Placebo Comparator|Placebo followed by treatment arm|All patients will receive 4 placebo fecal transplantations followed by 4 fecal microbial transplantations from healthy donors each 2 weeks apart
88998329|NCT04231357|Experimental|Platelet rich plasma (PRP)|3 mL of autologous platelet rich plasma with a moderate concentration of platelet (2x above peripheral blood) and no leukocytes will be injected under ultrasound guidance
88998330|NCT04231357|Active Comparator|control|needle tenotomy with lidocaine
88998331|NCT04166500|Experimental|Intervention|
88998332|NCT04166500|No Intervention|Control|
88998333|NCT04165369||Patients with extended surgical exposures|Patients with extended surgical exposures requiring postoperative observation.
88998334|NCT00165308|Experimental|Tamoxifen|Single arm: Tamoxifen 20mg daily
88998335|NCT00176748|Experimental|1|
89216757|NCT02577497|Experimental|Beclomethasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
89216758|NCT02577497|Experimental|fluticasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
89216759|NCT01021774|Active Comparator|Advancement flap surgery|
89216760|NCT01021774|Active Comparator|Collagen plug|
89216761|NCT01602263||Controls|Healthy Controls with no known cognitive impairment will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
88998336|NCT04118140|Experimental|True SA (Somatic Acupressure ) group|Receiving true somatic acupressure+usual care
88998337|NCT04118140|Sham Comparator|Sham SA group|Receiving sham somatic acupressure+usual care
89216762|NCT01602263||Individuals with schizophrenia|Individuals with schizophrenia and first-degree relatives will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
89685915|NCT01833559|Other|Gestational outcomes|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
89685916|NCT01833559|Other|Metabolic disorder|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
89685917|NCT03253120|Other|Patient|Patients will drink 5dl of water.
89685918|NCT03253120|Other|Healthy volunteer|Healthy volunteers will drink 5dl of water.
89685919|NCT03210649|Experimental|CKD-519 400mg(PartⅠ: 1day)|CKD-519 400mg(100mg x 4tabs) or placebo
89685920|NCT03210649|Experimental|CKD-519 400mg(PartⅡ: 14days)|CKD-519 400mg(100mg x 4tabs) or placebo
89685921|NCT01833637|No Intervention|Arm A: Control Group|Patients randomized to the control group will be asked to fill out a patient symptom questionnaire using an iPad at the time of registration and then every 24 hours until released from the hospital. It should take about 10 minutes to complete the questions each time. The survey will not interfere with the care the healthcare team will be providing. Patients will be asked to fill our a Patient Satisfaction Questionnaire at the time of discharge.
89685922|NCT01833637|Active Comparator|Arm B: APN Intervention Group|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
89685923|NCT03215485|Experimental|Intervention Group|"All intervention youth participants will receive three components:~Nutrition lessons~Virtual World learning environment~Newsletters"
89685924|NCT03215485|Active Comparator|Comparison|"All comparison youth participants will only receive one component:~1) Newsletters"
89685925|NCT05394142|Placebo Comparator|Arm 1 - Placebo|Placebo
89685926|NCT05394142|Experimental|Arm 1 - PIO|Pioglitazone
89685927|NCT05394142|Experimental|Arm 1 - SPIO|Spironolactone and Pioglitazone
88998338|NCT04118140|Other|Usual care group|Receiving usual care only (an education booklet regarding knowledge of BC and FSD symptom cluster management advice)
88998339|NCT00194415|Other|1|HSV-2 antepartum testing
88998340|NCT00194415|Other|2|Subjects will receive safer-sex counseling during pregnancy
88998341|NCT04082650|Experimental|Vitamin D|Participants in the intervention group will be treated with vitamin D 4000IU (800IU per pill, take five pills once each day) per day for around 12 weeks (till the triggering day).
88998342|NCT04082650|Placebo Comparator|Placebo|Participants in the control group will be treated with equal amount of placebo tablets per day for the same duration.
88998343|NCT00165542||All patients|A PROTEIN levels in all patients and with all tumor types.
88998344|NCT00194454|Experimental|1|Nine session psychosocial/behavioral counseling with homework
88998345|NCT00194454|Active Comparator|2|Usual clinic care with booklet describing depression following stroke
88998346|NCT04036942|Active Comparator|Hybrid argon plasma.|"After diagnostic endoscopy investigators will proceed to use argon plasma probe for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will use the jet included in the argon plasma probe with effect 20 to 40 system for the injection of the background submucosa in the marking area, applying 0.9% saline solution with methylene blue, to achieve adequate Submucosal elevation for application or argon plasma with high voltages (100 watts, 1.5 liters / min) using forced coagulation mode, applying plasma argon to 1cm above the Z line in the esophageal mucosa and 2cm below it towards the gastric mucosa, argon will be applied until a carbonization effect of the mucosa is achieved, once the application of the therapy is performed mucosal lavage and immersion technique to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications"
88998347|NCT04036942|Active Comparator|Band mucosectomy|After diagnostic endoscopy investigators will proceed to use the tip of a polypectomy snare for marking 270 grades around the esophagogastric junction preserving part of the mucosa towards the greater curvature, then investigators will perform submucosal elevation with the injection of 0.9% saline with carmine indigo and adrenaline 1:10000, after adequate submucosal elevation investigators will proceed with the help of a band ligation cap to suction and release the elastic band in the previously marked and elevated tissue, proceeding to resect the previously ligated tissue with polypectomy loop below the elastic band with forced coagulation (Effect 2, 40 W), until the marked mucosa is completely resected (average used of 5 elastic bands, reviewing the work area for complications like bleeding or perforation.
88998348|NCT03997201|Other|Ripple Mapping guided ischaemic VT ablation|Patients referred for ablation of ischaemic VT undergo Ripple Mapping guided procedure.
88998349|NCT03978208|Active Comparator|Placebo Comparator|ATB-346 150 mg overencapsulated tablet taken by mouth once daily for 14 days
89685928|NCT05394142|Experimental|Arm 1 - SPIOMET|Spironolactone, Pioglitazone and Metformin
89685929|NCT00901225|Experimental|G-CSF plus Plerixafor|Patients who were unable to mobilize a minimum number of cells (CD34+ cell count <20 cells/ul)following 5 days of G-CSF mobilization.
89685930|NCT02472730|Experimental|Cap Assisted Colonoscopy|The distal attachment cap is affixed to the colonoscope before every colonoscopy in this arm.
89685931|NCT02472730|No Intervention|Standard Colonoscopy|Standard colonoscopy without the distal attachment cap is performed in this arm.
88998350|NCT03978208|Active Comparator|ATB-346 mid-dose|ATB-346 200 mg overencapsulated tablet taken by mouth once daily for 14 days
88998351|NCT03978208|Active Comparator|ATB-346 standard dose|ATB-346 250 mg overencapsulated tablet taken by mouth once daily for 14 days
88998352|NCT03978208|Placebo Comparator|Active Comparator|Overencapsulated placebo tablet taken by mouth once daily for 14 days
88998353|NCT00194493|Experimental|1|Patient's clinician receives graphical report of patient-reported symptoms and quality of life issues.
89685932|NCT05393050|Active Comparator|Colquhounia Root Tablet plus methotrexate (MTX)|Colquhounia Root Tablet 0.9g tid and methotrexate (MTX) 10 mg oncea week for the first 12 weeks，Colquhounia Root Tablet 0.54g tid and methotrexate (MTX) 10 mg once a week for the after 12 weeks.
89685933|NCT05393050|Placebo Comparator|placedo of Colquhounia Root Tablet plus methotrexate (MTX)|placedo of Colquhounia Root Tablet 0.9g tid and methotrexate (MTX) 10 mg oncea week for the first 12 weeks，placedo of Colquhounia Root Tablet 0.54g tid and methotrexate (MTX) 10 mg once a week for the after 12 weeks.
89685934|NCT03210415||Study group|Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
89685935|NCT03210415||Control group|Pregnant women ≥35 years old would not have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
89685936|NCT03166228|Active Comparator|normal saline0.9%|0.9% saline distension media is used as long as diathermy is not in use
89685937|NCT03166228|Placebo Comparator|1.5% GLYCINE|1.5% GLYCINE DURING OPERATIVE HYSTEROSCOPY as long as diathermy is in use
89685938|NCT01833793||Group 1|
89685939|NCT01833949|Active Comparator|ULOD arm (N=49)|"Unilateral laparoscopic drilling~In the ULOD group, we treated the right ovary.The thermal dose of 60 J applied per one cubic centimeter of ovarian volume was calculated from the mean total energy applied on a 10 cm3 ovary (627 J) from three earlier ULOD reports. Ovarian volume had been measured by ultrasound at baseline to determine the total thermal dose to apply on the right ovary. The number of punctures (Np) was also calculated for each patient according to the following formula:~Np = 627 J / 30 W / 4 s Therefore, patients in the ULOD group differed in the number of punctures and energy received by the right ovary, depending on its volume."
89685940|NCT01833949|Active Comparator|BLOD arm (N=47)|"Bilateral laparoscopic drilling~In the comparator, BLOD group, all patients received 600 J per ovary (totaling 1200 J) through five punctures at 30 W for 4 s each (5 punctures x 4 s x 30 W = 600 J).~The ovaries in both groups were cooled after the drilling by irrigating the abdominal cavity with 200-300 mL of physiological saline."
89685941|NCT03154996|Experimental|Long term CED of Topotecan|An additional 5 patients will be treated with TPT by CED maintained for 32 days. TPT infusions will be carried out for 32 days using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in the short term studies.
89685942|NCT03219307|Experimental|NOVOCART 3D|Matrix associated autologous chondrocyte implant
89685943|NCT05389306|Experimental|MRI Scanning and CEUS for detection of small cervical lymph node metastases.|All patients enrolled will undergo an MRI Scanning and CEUS to evaluate their cervical lymph nodes. Ultrasound-guided lymph node aspiration and pathologic examination will be performed subsequently to obtain definitive diagnosis of the lymph nodes. The pathologic results of the lymph nodes will be adopted as gold standard to evaluate the diagnostic performance of MRI Scanning, CEUS, and the combined diagnostic criteria.
89685944|NCT04380259|Experimental|MBTR-R (Mindfulness-Based Trauma Recovery for Refugees)|Mindfulness-based group intervention consisting of nine 2.5-hour weekly sessions.
89685945|NCT04380259|No Intervention|Waitlist-Control|Following the 9-week waitlist period and 1-week post-intervention assessment, participants randomized to waitlist-control were offered an equivalent group intervention (i.e., 22.5 total hours, group instructor and cultural mediator, psychoeducation and low-intensity cognitive behavior therapy skill training, relaxation techniques).
89685946|NCT02475070|Active Comparator|Vildagliptin first|Treatment with vildagliptin 50mg twice daily for two weeks followed by four weeks washout and then treatment with dapagliflozin 10mg once daily for two weeks
89685947|NCT02475070|Active Comparator|Dapagliflozin first|Treatment with dapagliflozin 10 mg once daily for two weeks followed by four weeks washout and then treatment with vildagliptin 50 mg twice daily for two weeks
89685948|NCT05381506|Experimental|Orelabrutinib and Gemox|Orelabrutinib and Gemox for 6 cycles
89685949|NCT00902161|Experimental|Propanolol + Placebo > Propanolol + MK0893|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893-matched placebo was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893 on Day 21 (Visit 8).
89685950|NCT00902161|Placebo Comparator|Propanolol + MK0893 > Propanolol + Placebo|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893 was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893-matched placebo on Day 21 (Visit 8).
89685951|NCT01834105|Experimental|Liuwei Dihuang Pills|
89685952|NCT03095170|Experimental|Computerized brain fitness training|"Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Calendar Training and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue the computerized brain fitness for another 24 weeks.Participants are encouraged to do at least two hours per week."
89685953|NCT03095170|Experimental|Yoga|"Will receive a 10 day intervention program (over 2 weeks) consisting of Yoga, Calendar Training, and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue yoga for 24 weeks. Participants assigned to the yoga intervention will continue to meet with their group and their yoga instructor for one hour per week and will be expected to do at least an additional hour of yoga by themselves every week."
89685954|NCT03095170|Active Comparator|Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Wellness Education, Calendar Training and Support Group.
89685955|NCT01834183|Experimental|Tivozanib/Gemcitabine|Segment 1: Tivozanib, taken orally days 1-21 of each 28 day cycle. Segment 2: Tivozanib, taken orally days 1-21 of each 28 day cycle. Gemcitabine, taken intravenously, Days 1 and 8 of each 28 day cycle.
89685956|NCT04379947||FFR-CABG|Patients with at least one intermediate stenosis that received a preoperative FFR evaluation before being referred for CABG
89685957|NCT04379947||Angio-CABG|Patients with at least one intermediate stenosis that did not received a preoperative FFR evaluation before being referred for CABG
89685958|NCT02478580|Experimental|Nuvigil|A single oral dose of Nuvigil at 150mg dose in preoperative area
89685959|NCT02478580|Placebo Comparator|Placebo|A single oral placebo will be given in preoperative area
88998354|NCT00194493|No Intervention|2|
88998355|NCT04682899|Experimental|PCT-guided antibiotic therapy (PCT group)|Participants in the PCT group will complete a PCT test within 2 hours after randomization and the results will be sent back to the clinician by laboratory through the internal network of the hospital. The prescribing clinician will use the results of the PCT to help guide their antibiotic prescription decision. The detailed recommendations are as follows: if PCT<0.1ng/ml，strongly discouraged；if PCT (0.1-0.25ng/ml) and no sputum purulence, discouraged; if PCT (0.1-0.25ng/ml) and sputum purulence, Recommended; PCT>0.25 ng/ml, Strongly recommended.
88998356|NCT04682899|Active Comparator|Guideline-guided antibiotic therapy (guideline group)|Participants in the guideline group will also need to complete a PCT test within 2 hours after randomization, however, the laboratory will save the results and do not sent back to the clinician. The clinician will make an antibiotic prescribing decision on the basis of the recommendations of GOLD guideline. The guideline recommend the following patients to receive antibiotic therapy. Patients with exacerbations of COPD who have three cardinal symptoms: increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).
88998357|NCT03789916|Experimental|DAPT|"Dual antiplatelet therapy: acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die"
88998358|NCT03789916|Active Comparator|SAPT|"Single antiplatelet therapy: acetylsalicylic acid 100 mg/die"
88998359|NCT03768310|Experimental|CD19.CAR-multiVST for Group A|"Group A: Patients with no evidence of disease after having a bone marrow transplant.~T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
88998360|NCT03768310|Experimental|CD19.CAR-multiVST for Group B|"Group B: Patients with evidence of disease before bone marrow transplant OR have relapsed after bone marrow transplant.~Patients in Group B will receive the T cells at the earliest feasible time point after the detection of disease, but no earlier than day 30 after the transplant. The three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
88998361|NCT03729154|Experimental|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
88998362|NCT03729154|No Intervention|Treatment as Usual|Participants in the Treatment as Usual condition will receive behavioral and counseling services typically provided by their preschool.
88998363|NCT03697603|Experimental|Brexpiprazole 1mg|Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
88998364|NCT03697603|Experimental|Brexpiprazole 2mg|Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
88998365|NCT03697603|Placebo Comparator|Placebo|Tablets, Oral, once daily, 14 weeks
88998366|NCT03686644|Experimental|Children with Cerebral Palsy|Children with Cerebral Palsy (CP) will be included. They will have to wearing of night splint ankle foot orthoses (phase A) and then no wearing of night splint ankle foot orthoses (phase B). The phases A and B will be repeated twice. In more, they will have an ultrasound, isokinetic dynamometer and measure of quality of night sleeping.
88998367|NCT03413800|Experimental|Lenalidomide-Dexamethasone-DLI|"Patients will receive Len (10 mg in the presence of ≤ grade I acute GVHD or absence of chronic GVHD; 5 mg in presence of controlled mild or moderate chronic GVHD) daily x 21 days with Dex 40 mg once weekly for a total of 6 cycles of 28 days each~For grade ≥III non hematologic or grade IV hematologic toxicity, Len can be reduced to 5 mg~In absence of these toxicities, acute GVHD (using Glucksberg modified criteria) or severe chronic GVHD (using NIH criteria), Len dose can be increased by 5 mg per cycle to a maximum of 25 mg~If eligibility is confirmed, sibling and unrelated donor transplant recipients will both receive 3 donor lymphocyte infusions (DLIs) at the following doses: 5 x 106 CD3+/kg; 1 x 107 CD3+/kg; 5 x 107 CD3+/kg~Patient will be followed for 5 years post relapse."
88998368|NCT03303742|Experimental|feather edge finish line marginal design|intervention
88998369|NCT03303742|Active Comparator|deep chamfer finish line marginal design|comparator
88998370|NCT03207256|Experimental|TGR-1202|Oral TGR-1202 Daily
88998371|NCT03207256|Experimental|TGR-1202 + Ublituximab|Oral TGR-1202 in combination with Ublituximab intravenous administration
88998372|NCT00166010|Experimental|Nesiritide|
88998373|NCT00166049|Placebo Comparator|Usual Care Attention Control|Usual care with provision of supplemental printed educational material on HF self care
88998374|NCT00166049|Experimental|Group 2 Patient Family Education PFE|Patient Family Education PFE Heart Failure Patients and family member dyads were provided with an educational and counseling session, and attended a 2 hour patient-family education session on heart failure self management with emphasis on dietary sodium and medication taking behaviors.
88998375|NCT00166049|Experimental|Group 3 Family Partnership Intervention|Patient and family member received one individual dyadic education/counseling session, and two group sessions focused on developing family approaches to HF self management. the emphasis of the two group sessions was on developing autonomy supportive approaches to family support.
88998376|NCT04685395|Active Comparator|Benzydamine hydrochloride|"group I ( benzdymine HCL ); subject will be instructed to use Benzydamine hydrochloride gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).~dose :5 ml every time dosage form ; mouth wash"
88998377|NCT04685395|Active Comparator|Rebamipide|"group II ( rebamipide) :subject will be instructed to use Rebamipide gargle 6 times daily and not to eat or drink for the subsequent 10 min from first day of radiation therapy (4-6 week) until 2 weeks after the end of treatment(end of radiation ).~dosage form ; mouth wash"
88998378|NCT00537784|Active Comparator|1|Injection of autologous platelet concentrate into repair site
88998379|NCT00537784|Placebo Comparator|2|No injection
88998380|NCT00166088|Experimental|Mediterranean Diet Arm|
88998381|NCT00166088|Active Comparator|Mediterranean Dietary Supplement Arm|
88998382|NCT00166088|No Intervention|Control Arm|
88998383|NCT00194649|Experimental|1|100 mg Miglustat BID (twice daily) for six weeks
88998384|NCT05425147||Post-induction hypotension group|Post-induction hypotension is defined as systolic blood pressure (SBP) <90 mmHg, mean arterial pressure (MAP) <65 mmHg, or a decrease of more than 30% of baseline within 20 minutes after induction or before incision.
88998385|NCT05425147||Stable blood pressure group|All enrolled elderly patients will undergo surgery under general anesthesia after preoperative monitoring. Those patients whose blood pressure is relatively stable after induction and does not meet the PIH criteria is classified as the stable blood pressure group.
88998386|NCT05425069||Dexmedetomidine with minimal concentration of propofol (D-P)|"Intravenous infusion with Dexmedetomidine for 10 minutes at 0.8 ug/kg/hr and so on, then induction with Propofol TCI Target 2.0 ug/ml (Schnider model) and Remifentanil TCI 4.5 ng/ml. 3 minutes after LOC Propofol will be reduced to 0.5 ug/ml. intubate using Remifentanil 4.5 ng/ml and Rocuronio 0.5 mg/kg.~Anesthesia will be dynamically adjusted to maintain SEF95 remains at minimum values at 10 Hz for the rest of the surgery. Sedline will be maintained for up to 60 min post-op. in the recovery room. Data will be retrieved via pen drive stick from SEdline"
88998387|NCT05425069||Propofol TCI fine titrated (P)|"Basal frontal EEG with eyes opened and closed (90 sec each) The previous bolus of Lidocaine in a 20 mg intravenous dose, TCI Propofol Induction (Schnider Model) is initiated starting 8 mg/kg/h until clinical unconsciousness (LOC loss of response to the call and to moderate stimulus in the shoulder) and then it is passed to TCI to keep the Ce calculated to the LOC.~After LOC, we proceed to intubate using Remifentanil 4.5 ng/ml and Rocuronio. Anesthesia will be dynamically adjusted to maintain Sedline SEF 95 value of minimum at 10Hz. Sedline will be maintained for up to 60 min post LOC in the recovery room.~Data will be retrieved via pen drive stick."
88998388|NCT03455257|No Intervention|Control|Families assigned to this arm will be assessment only controls that do not receive the cash transfer.
88998389|NCT03455257|Experimental|Intervention|Families assigned to this arm will recieve a cash transfer following an in-depth conversation with the head of household and the signing of a contract stating they understand the purpose of the study.
88998390|NCT00166244|Active Comparator|Fixed Dose|1 g MMF twice-daily (bid) for adults or 600 mg/m2 bid for paediatric patients. Treatment to be given orally unless it is not possible, in which case it is administered via intravenous (iv) infusion.
88998391|NCT00166244|Active Comparator|Concentration Controlled|1 g MMF bid for adults or 600 mg/m2 bid for paediatric patients. Thereafter, MMF doses will be adjusted to MPA AUC0-12 between 30-60mg.h/L based on 3-point abbreviated AUCs (taken at timepoints: 0, 30 min and 120 min always in fasted patients, except for pediatric patients on concomitant tacrolimus) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine MPA levels in plasma.
88998392|NCT05311930|Experimental|2.5mg/d|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hetrabopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
88998393|NCT00177138|Active Comparator|Group 2|Tacrolimus/MMF/TMG
88998394|NCT00177138|Experimental|Group 1|Campath/MMF/TMG
88998395|NCT00166283|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
88998396|NCT00166283|Placebo Comparator|placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
88998397|NCT02427997|Experimental|Treadmill training with virtual reality|The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
88998398|NCT02427997|Active Comparator|Treadmill training alone|TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
88998399|NCT00177177|Experimental|1|L Carnosine
88998400|NCT00177177|Placebo Comparator|2|Placebo
88998401|NCT05311774|Experimental|•tramadol and duloxetine|patients will receive tramadol 50 mg twice daily, titration will be done every 3days until 2 weeks, maximum dose will be 400mg daily and will receive duloxetine 30mg daily fixed dose in combination with tramadol. Investigators will follow up the patients for 3 months
88998402|NCT05311774|Active Comparator|tramadol and placebo|patients will receive tramadol 50 mg twice daily, titration will be done every 3days until 2 weeks, maximum dose will be 400mg daily and will receive placebo drug once daily in combination with tramadol. Investigators will follow up the patients for 3 months
88998403|NCT05302102|Experimental|Paretic-limb-only plyometric training group|Participants in this group performed plyometric movements/exercises unilaterally using the paretic leg.
88998404|NCT05302102|Experimental|Doule-limb plyometric training|Participants in this group performed plyometric movements/exercises bilaterally through the paretic and non-paretic legs.
88998405|NCT05302102|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program.
88998406|NCT00194727|Experimental|1|Vinorelbine (20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle) and capecitabine (825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle). Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
88998407|NCT02042287|Experimental|1: Gynofit®|Vaginal lactic acid gel
88998408|NCT02042287|Active Comparator|2: metronidazole|Oral antibiotic
88998409|NCT05296213|Experimental|silver diamine fluoride-potassium iodide SDF-KI (riva star)|SDF-KI was applied once as a professional application over the early enamel lesions in cervical third of the buccal surface of molar teeth.
88998410|NCT05296213|Experimental|casein phosphopeptide amorphous calcium phosphate CPP-ACP(tooth mousse)|CPP-ACP cream was applied twice daily according to manufacturer's instructions over the early enamel lesions in cervical third of the buccal surface of molar teeth.
88998411|NCT05296213|Experimental|Experimental tricalcium silicate|Experimental tricalcium silicate paste was applied twice daily over the early enamel lesions in cervical third of the buccal surface of molar teeth
88998412|NCT05282875||kidney transplant patients returning to dialysis after graft loss|"This cohort contains kidney transplant patients returning to dialysis after graft loss in Lorraine between 1 January 2007 and 31 December 2019. They are identified by the REIN registry of the Lorraine region.~The REIN registry is a national database that contains multiple information on patients with chronic end-stage renal disease (type of nephropathy, type of replacement therapy, comorbidities)."
88998413|NCT00194766|Experimental|1|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
88998414|NCT05276089|Experimental|Intervention arm|A total of 50 practices who use System 1 will be in the intervention arm to send out the video to their eligible patients.
88998415|NCT05276089|No Intervention|Control arm|50 practices who use EMIS will be in the control arm to deliver care as usual
89685960|NCT03838081|Experimental|Group 1|Group 1: Patients who were given only basic information verbally
89685961|NCT03838081|Experimental|Group 2|Group 2: Patients with detailed written information about preoperative, intraoperative, and postoperative periods
89685962|NCT03838081|Experimental|Group 3|Group 3: Patients with previous experience and knowledge about third molar extraction
89685963|NCT03210181|Experimental|Block|Patients will receive superficial cervical plexus block
89685964|NCT03210181|Placebo Comparator|Placebo|Patients will receive normal saline
89685965|NCT05345470|Placebo Comparator|0 grams of chia seeds|3 cookies (30 grams)
89685966|NCT05345470|Experimental|3 grams of chia seeds|3 cookies (30 grams)
89685967|NCT05345470|Experimental|5 grams of chia seeds|3 cookies (30 grams)
89685968|NCT05345470|Experimental|7 grams of chia seeds|3 cookies (30 grams)
89685969|NCT03210493|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
89685970|NCT03210493|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
89685971|NCT03210025|Experimental|BF-Methyldopa Tablet 250mg|During the study session, healthy subjects will be administered a single dose of BF-Methyldopa Tablet 250mg after an overnight fast of approximately 10 hours
88998416|NCT00408096|Active Comparator|1|The Copeland uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
88998417|NCT00408096|Active Comparator|2|The Global Cap uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
88998418|NCT05259631|Experimental|Inhalational sedation|
88998419|NCT05259631|Active Comparator|Intravenous sedation|
88998420|NCT05220163|Experimental|CAD + POC Xpert|CAD followed by Xpert in CAD-positive participants (performed at POC) employing a low-cost panel van that is staffed by three health care workers. CAD-negative participants will be followed up, while CAD-positive participants will be offered POC Xpert. Xpert-positive participants will be referred for TB treatment initiation, while Xpert-negative (but CAD-positive) participants will undergo a clinical review. Thus, the active case finding (ACF) interventional package is one of CAD + POC Xpert (only in CAD positive participants).
88998421|NCT05220163|Active Comparator|POC Xpert only|Participants who are Xpert-positive will be referred for TB treatment initiation while Xpert-negative participants will be followed up. Thus, the active case finding (ACF) standard of care package is POC Xpert.
88998422|NCT05205304|Experimental|Treatment group|Subjects will be treated with liquid carbon dioxide (D'oxyva) administered transdermally on the thumb after the Aortic Cross Clamp is removed
88998423|NCT05205304|No Intervention|Control group|Subject will not be treated with liquid carbon dioxide (D'oxyva)
88998424|NCT00194805|Experimental|1|Subjects randomized into the treatment group received the computer treatment
88998425|NCT05181904||Critically ill children ready for extubation|Children admitted to a paediatric intensive care unit, invasively ventilated and intubated, enterally fed and presenting with a clinical condition allowing for extubation. 45 children will be included.
88998426|NCT05160376|Experimental|Guided Intervention Group|The participants in the guided intervention group will receive feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor, after each online self-help intervention session. The participants in the guided intervention group will also receive an email reminder and text message if the participants have not completed the required session of that week on the 5th, 6th, and 7th of the same week. Technical supports are available.
88998427|NCT05160376|Experimental|Unguided Intervention Group|The participants in the unguided intervention group will not receive the aforementioned feedback calls. The participants in the unguided intervention group will only receive an email reminder and text message if the participants have not completed the required session of that week on the 5th, 6th, and 7th of the same week. Technical supports are available.
88998428|NCT05160376|No Intervention|Wait-list Control Group|The waitlist control group will not receive any online self-help intervention. Unguided intervention will be provided to the waitlist control group after both the Post-treatment Assessment Phrase are finished.
88998429|NCT00194844|Experimental|1|Nurse Caring
88998430|NCT00194844|Experimental|2|Self Caring
88998431|NCT00194844|Experimental|3|Combined Caring
88998432|NCT00194844|No Intervention|4|This group is not treated and serves as control.
88998433|NCT05133622|Active Comparator|Covid-19 group|"Individuals between the ages of 20-30 Individuals who were diagnosed with COVID-19 positive in the last 3-10 months and were treated with home isolation and whose last PCR test was negative Individuals who had not to get vaccinated Individuals whose physical activity level is between 600-3000 MET min/week according to International Physical Activity Questionnaire-Short form (IPAQ-SF) (sedentary)"
88998434|NCT05133622|Active Comparator|Control group|Individuals between the ages of 20-30 Individuals who have not been diagnosed with COVID-19 positive Individuals who had not to get vaccinated Individuals whose physical activity level is between 600-3000 MET min/week according to the IPAQ-SF (sedentary)
88998435|NCT05124067|Experimental|Group A (DEXA)|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
88998436|NCT05124067|Experimental|Group B (ONDAN)|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
88998437|NCT05124067|Experimental|Group C (DEXMED)|Patients will receive dexmedetomidine (0.3 μg/kg)
88998438|NCT05124067|Placebo Comparator|Group D (CONTROL)|patients will receive normal saline
88998439|NCT05109286|Experimental|CrossFit training|CrossFit training twice a week.
88998440|NCT05109286|No Intervention|Control arm|Exercise according to their ideas.
88998441|NCT02277184|Experimental|Ficlatuzumab, Cisplatin and IMRT|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every two weeks beginning the week prior to cisplatin-IMRT (week -1), for a total of 4 doses.~Cisplatin will be administered as an IV infusion over 60 minutes on Monday, Tuesday, or Wednesday of each treatment week beginning concurrent with IMRT during week 1 of study treatment (and one week following the first dose of ficlatuzumab) for a total of 7 doses.~IMRT: Treatment will be delivered once daily, 5 fractions per week, 35 - 37 fractions, no weekends or holidays over 7 - 8 weeks. All targets will be treated sequentially."
88998442|NCT00194922|Placebo Comparator|A|
88998443|NCT00166868|Experimental|Neomycin prescribed|Interventions: 10 cases received Neomycin for 6 months
88998444|NCT00166868|Experimental|Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed|Interventions: 10 cases received Probiotics for 6 months
88998445|NCT00166868|No Intervention|control|10 cases without intervention were historical control.
88998446|NCT04943458||Cardiac surgery group|
88998447|NCT04943458||Glaucoma group|
88998448|NCT04943458||Control group|
88998449|NCT00177372|Experimental|1|Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
88998450|NCT04892914|Experimental|Embr thermal device|Use of the Embr thermal device
88998451|NCT04834765|Active Comparator|Mindfulness|Participants will be engaging in a mindfulness tasks twice per week for 5 weeks in which they will learn techniques through the use of yoga, meditation and breathwork.
88998452|NCT04834765|Active Comparator|Art Therapy|Participants will engage in art therapy with the use of clay twice per week through prompts.
88998453|NCT04834765|Active Comparator|Mindfulness based Art Therapy|Participants will engage in both mindfulness activities and art therapy twice per week and will learn techniques through the use of yoga, mediation, breathwork and art.
88998454|NCT04834765|No Intervention|Control Group|Participants will go about daily life as usual.
88998455|NCT04819399|Experimental|Catumaxomab|intravesical Catumaxomab instillation
88998456|NCT04800172|Active Comparator|Roflumilast arm|
88998457|NCT04800172|Placebo Comparator|Placebo arm|
88998458|NCT04769518|Active Comparator|Advanced Recovery Room Care (ARRC)|Patients are provided with high acuity care from arrival in Recovery (PACU) until the morning after surgery. This includes higher than normal nursing ratios (1:2), regular frequent rounds by specialist anaesthetic staff, and access to monitoring and medicines (eg vasopressor infusions) not available on normal postoperative surgical wards.
88998459|NCT04769518|Placebo Comparator|Usual care|Patients are managed in Recovery (PACU), then normal postoperative surgical wards, as per usual care.
88998460|NCT00177411|Experimental|PTHrP group|Subjects receiving PTHrP in varying doses.
88998461|NCT03457324|Experimental|JCM-16021 Group|JCM-16021 granules 8g/sachet, three times daily for 8 weeks.
88998462|NCT03457324|Placebo Comparator|Placebo Group|Placebo granules 8g/sachet, three times daily for 8 weeks
88998463|NCT00177489|Experimental|Treatment|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
88998464|NCT00177489|Other|Control|"Caregivers in the control group received 2 brief check-in telphone calls during the 6 month intervention."
88998465|NCT04716985|Active Comparator|TREATMENT GROUP|"Water saturated with molecular hydrogen at the rate of 2 times 250 mL / day for 21 days.~80 mg of Mg metal, and safe excipients (dextrose, malic acid, L-tartaric acid, adipic acid)."
88998466|NCT04716985|Placebo Comparator|PLACEBO GROUP|Water saturated with magnesium at the rate of 2 times 250 mL / day for 21 days. 80 mg of Mg, but in ionic form.
88998467|NCT04711174||movement,high Aldrete score group (MH group)|LMA removal be conducted when the child's spontaneous respiratory recovers with body movement spontaneously, and the child be transited from PACU when Aldrete score reaches 9
89685972|NCT03210025|Active Comparator|Metopa Tab 250mg|During the study session, healthy subjects administered a single dose of Metopa Tablet 250mg after an overnight fast of approximately 10 hours
89685973|NCT03219853|Experimental|Lower selenium-status|
89685974|NCT03219853|Experimental|higher selenium|
89685975|NCT04338412|Active Comparator|Group U|Performers' umbilicus
89685976|NCT04338412|Active Comparator|Group R|Performers' lowest rib margin
89685977|NCT04338412|Active Comparator|Group X|Performers' xiphoid process
89685978|NCT02480998|Experimental|IL-YANG Flu Vaccine QIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
89685979|NCT02480998|Active Comparator|IL-YANG Flu Vaccine TIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
89685980|NCT03218995|Experimental|Eteplirsen|Eteplirsen will be administered once every 7 days by intravenous (IV) infusion starting on Day 1 for up to 96 weeks. The starting dose will be 2 milligrams/kilogram (mg/kg) eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg for 10 weeks, and then participants will continue to receive eteplirsen at 30 mg/kg for the duration of the study.
89685981|NCT01834495|Experimental|Balloon expandable stent|study design is 1:1 randomization design. Patients will be randomized in a 1:1 manner according to different two (balloon expandable versus Self expandable)stents. Randomization procedure will be performed using a web-based program
89685982|NCT01834495|Active Comparator|Self expandable stent|same to Balloon expandable stent
89685983|NCT00905125|Experimental|Arm 2, Fluarix®|Single 0.5 mL intramuscular injection of Fluarix®.
89685984|NCT00905125|Experimental|Arm 1, Fluzone®|Single 0.5 mL intramuscular injection of Fluzone®.
89685985|NCT00905827|Experimental|Intervention 1: in person CAMS|In person Collaborative Assessment and Management of Suicidality (CAMS) training for providers
89685986|NCT00905827|Experimental|Intervention 2: e-learning CAMS|Online Collaborative Assessment and Management of Suicidality (CAMS) training for providers
89685987|NCT00905827|No Intervention|Control: no training|Control Group: no training
89685988|NCT03219541|Active Comparator|Interventional Automated mobile phone text|"Subjects will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention. During the intervention, participants will receive a text question at the end of every day asking you How many cigarettes have you smoked today?"
89685989|NCT03219541|Placebo Comparator|Control Texts|The intervention will consist of a 3-day pre-quit period and then a 4-week post-quit period. Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
89685990|NCT03219073|Sham Comparator|SHAM tDCS|SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.
89685991|NCT03219073|Active Comparator|Active tDCS with a tDCS device|Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.
89685992|NCT00894127|Experimental|CyPath Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from two cohorts, including (1) high-risk control group comprised of individuals not diagnosed but at high risk for lung cancer (n=102) and, (2) cancer group comprised of individuals with confirmed lung cancer diagnosis (n=26), was labeled in exact manner with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
89685993|NCT03216499|Experimental|Treatment (HIF-2 alpha inhibitor PT2385)|"Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis~Pharmacogenomic Study"
89685994|NCT03215797|Active Comparator|phenylephrine and norepinephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of perioperative hypotension.
89685995|NCT03215797|Other|Norepinephrine and phenylephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion in postoperative time in case of hypotension
89685996|NCT03219463|Experimental|Regular Exercise Group|at least 30 minutes of moderate to vigorous activity at least 3 times per week. Will recieve 3 grams of ginger for 8 weeks.
89685997|NCT03219463|Active Comparator|Non Regular Exercise Group|at least 30 minutes of moderate to vigorous activity 1-2 times per week. Will recieve 3 grams of ginger for 8 weeks.
89685998|NCT02484898||SEEQ™ MCT/ECM System|SEEQ™ MCT/ECM monitoring for the detection of non-lethal cardiac arrhythmias.
89685999|NCT01834573|Active Comparator|Intervention|Patients of the intervention arm receive a 10 week exercise program
89686000|NCT01834573|No Intervention|Control|Patients of the control arm do not participate in exercise
89686001|NCT03211507||Case|Males with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.
89686002|NCT03211507||Controls|Males with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.
89686003|NCT01830049||Group I|Older males with ED
89686004|NCT01830049||Group II|Older males with normal erectile function
89686005|NCT01830049||Gourp III|Young males with normal rectile function
89686006|NCT02485834|Active Comparator|Arm A - surgery, chemotherapy and radiation therapy|Patients undergo surgery within 42 days of completion of pre-registration chemotherapy. Beginning within 49 days of surgery, patients receive 5-FU IV continuously and capecitabine PO BID on days 1-7, and undergo 3D-CRT or IMRT QD on days 1-5. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.
89686007|NCT02485834|Experimental|Arm B - surgery, chemotherapy and FDG-PET|Beginning within 28 days of day 1 of pre-registration chemotherapy, patients receive docetaxel IV and irinotecan IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses. Beginning within 42 days of completion of docetaxel and irinotecan, patients undergo surgery. Patients also undergo FDG-PET within 14 days of planned surgery. Beginning within 60 days after surgery, patients receive 3 additional courses of docetaxel and irinotecan hydrochloride courses in the absence of disease progression or unacceptable toxicity.
89686008|NCT01830283|Active Comparator|1 dose varicella vaccine|The providers would get the 2nd dose since they had one dose varicella vaccine
89686009|NCT01830283|Experimental|2 dose varicella vaccine|The provider never get the varicella vaccine
89686010|NCT01834807||Cohort|
89686011|NCT01834885|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
89686012|NCT01834885|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
89686013|NCT01834963|Experimental|Interferon Alfa、Fluorouracil|"Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
89686014|NCT01834963|Experimental|Cisplatin、Fluorouracil|"Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
89686015|NCT03219385|Experimental|Treatment with the Mirabilis System|
89686016|NCT03219151|Experimental|eMAR game|Participants provided access to eMAR simulator game in advance of simulated return-demonstration; also receive normal education pre-work related to eMAR administration
89686017|NCT03219151|Active Comparator|Normal pre-work|Participants receive normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
89686018|NCT04380103|Experimental|XELOXIRI/Bevacizumab|drugs: Irinotecan, Oxaliplatin, Capecitabine, Bevacizumab bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7, administered every 2 week for 12 cycles, after 12 cycles, administer bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy.
89686019|NCT03219229||Prepubertal children|Healthy 7-11 year old girls and boys.
89686020|NCT01954966|Active Comparator|Progesterone 200 mg capsules|Subjects will be prescribed progesterone 200 mg capsules by the study Principal Investigator. Subjects will take 200 mg of progesterone daily for four days.
89686021|NCT01954966|Placebo Comparator|Progesterone 200 mg look-alike capsules|Subjects will be prescribed progesterone 200 mg look-alike placebo capsules by the study Principal Investigator. Subjects will take look-alike placebo capsules daily for four days.
89686022|NCT01835119|Experimental|chewing gum|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at least 5 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
89686023|NCT01835119|No Intervention|control group|no gum
89686024|NCT01839019|Placebo Comparator|Placebo|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
89686025|NCT01839019|Experimental|ODM-102|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
89686026|NCT01835275|Experimental|Music conditioning|Subjects are tested with music, sound, and silence, after conditioning to enhance music induced analgesia
89686027|NCT01835275|Active Comparator|Sound|Subjects are tested with music, sound, and silence, after conditioning to enhance sound induced analgesia
89686028|NCT01835275|No Intervention|Calibration|Subjects are tested with music, sound, and silence, with no enhanced audio received
89686029|NCT01835353|Experimental|Prasugrel 100mg loading dose|Prasugrel 100mg loading dose
89686030|NCT01835353|Active Comparator|Prasugrel 60mg loading dose|
89686031|NCT05210608|Experimental|Working Memory Training (Active Training) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
89686032|NCT05210608|Active Comparator|Control Training (CT) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Control Condition Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
89686033|NCT03836365|Active Comparator|Preoperative counseling office visit|Participants will present for an in-person preoperative counseling office visit (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
89686034|NCT03836365|Active Comparator|Preoperative counseling phone call|Participants will receive a preoperative counseling phone call (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
89686035|NCT01835509|Experimental|Intervention, Camp + Reunions|5 day , day camp plus 5 monthly reunions
89686036|NCT01835509|No Intervention|Control, Newsletters|
89686037|NCT02485912|Active Comparator|Group 1|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. Both vaccinations are administered in the same arm.
89686038|NCT02485912|Active Comparator|Group 2|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. The MVA-EBO Z is administered in the opposite arm to the ChAd3-EBO Z.
89686039|NCT03836599|Experimental|24 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol from Day -7 to Day -1. During the Treatment Period, participants will be administered 24 mg verinurad with 300 mg allopurinol once daily on Days 1 to 7.
89686040|NCT03836599|Experimental|12 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol once daily from Day -7 to Day -1. During Treatment Period, participants will receive a single dose of 12 mg verinurad and 300 mg allopurinol on Day 1. No dosing will be done on Day 2. Participants will continue dosing on Day 3 and will be dosed once daily until Day 9.
89053472|NCT00586755|Experimental|Intensive Induction-BMT|Patients will undergo induction regimen and stem cell mobilization with cyclophosphamide for bone marrow transplant (BMT). This will be immediately followed by high dose therapy with stem cell support.
89053473|NCT00575120|No Intervention|A|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI before 15 min. ischemia reperfusion of forearm
89053474|NCT00575120|Active Comparator|B|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI after 15 min. ischemia reperfusion
89053475|NCT03458442|Experimental|Intervention Arm|Standard surgical training + simulation-based surgical training
89053476|NCT03458442|Active Comparator|Control Arm|Standard surgical training
89053477|NCT03457506|Other|Patients undergo a digital PET/CT|Single arm prospective study of paired PET scans. Patients who are referred to the nuclear medicine department to undergo a PET scan, will undergo a PET/CT scan on the conventional scanner as well as the digital PET/CT scanner.
89053478|NCT00575198|Experimental|1|No drainage threshold
89053479|NCT00575198|Active Comparator|2|Drainage <2 mL/kg
89053480|NCT00586794|Active Comparator|A|
89053481|NCT00586794|Placebo Comparator|B|from the 26th weeks on open-label, all patients were treated with Sildenafil
89053482|NCT00575237|No Intervention|Control|In the control group, CO2 was removed by passive deflation of the abdominal cavity through the holes of the trocar.
89053483|NCT00575237|Experimental|Intervention|
89053484|NCT00575276||1|Females with acute cholecystitis
89053485|NCT00575276||2|Females with Chronic Cholecystitis
89053486|NCT00575276||3|Males with acute cholecystitis
89053487|NCT00575276||4|Males with Chronic Cholecystitis
89053488|NCT00586833||1|No CHF/HTN Never diagnosed with CHF and undergoing current treatment for HTN
89053489|NCT00586833||2|CHF with HFpEF HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.
89053490|NCT00586833||3 Healthy normal adults|No identifiable cardiac issues at time of exercise.
89053491|NCT03453255|Experimental|t(8;21)AML|chemotherapy 5-Aza-2'-deoxycytidine IV 20mg/m2 d8-12 homoharringtonine IV 2mg d1-5 chidamide P.O. 30mg twice/W cytarabine IV 1000mg/m2(<60 year old) 500mg/m2(>60 year old) IV q12h d1,3,5
89053492|NCT00575354|Active Comparator|1|Sevoflurane: induction 3-6%, maintenance 2-3%
89053493|NCT00575354|Active Comparator|2|Isoflurane: induction 3-6%, maintenance 2-3%
89053494|NCT00586911|Active Comparator|Cystadane|
89053495|NCT00586911|Placebo Comparator|Identical Placebo|
89053496|NCT00575471|Experimental|1|rivoglitazone HCl 0.5 mg tablets once daily for 12 weeks
89053497|NCT00575471|Experimental|2|rivoglitazone HCl 1 mg tablets once daily for 12 weeks
89053498|NCT00575471|Experimental|3|rivoglitazone HCl 1.5 mg tablets once daily for 12 weeks
89053499|NCT00575471|Placebo Comparator|4|Matching placebo tablets once daily for 12 weeks
89053500|NCT03454308|Experimental|SMASH|Automated reminder functions activated on pill monitoring device, motivational text messages, at home BP monitoring
89053501|NCT03454308|Other|Enhanced SC|No reminder functions on the pill monitoring device, attention control text messages
89053502|NCT04579601||ERAS group|We recruited 50 patients throughout 2018 and 2019, patients undergoing thoracic surgery within an ERAS program
89053503|NCT04579601||Standard group|A group of 50 patients selected randomly prior the implementation of the ERAS program, in 2016.
89053504|NCT03452397|Active Comparator|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
89053505|NCT03452397|Active Comparator|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
89053506|NCT03452397|Active Comparator|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
89053507|NCT03452397|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
89053508|NCT03453684|Experimental|Administration of Vancomycin|Administration of Vancomycin 15 mg/kg over 1 hour prior to surgical incision
89053509|NCT00575627|No Intervention|2|
89053510|NCT00575627|Experimental|1|Drug: peginterferon α-2a (40 kDa) plus ribavirin for 24-48 weeks
89053511|NCT04674878|Experimental|MET group|METs for accessory muscles of respiration including sternocleidomastoid, scalenes and trapezius given thrice a week for 8 weeks.
89053512|NCT04674878|Active Comparator|Breathing exercise group|Diaphragmatic breathing, pursed lip breathing and diaphragmatic breathing with resistance given thrice a week for 8 weeks.
89053513|NCT00586989||1|Patient with Barrett's Esophagus with a history of High grade dysplasia or early esophageal adenocarcinoma
89053514|NCT00587028||Oral Omnipaque MCA|Ten participant minimum: for stool tagging two days preceding the CT colonography, if applicable, with oral Omnipaque. This cohort at Scottsdale Mayo Clinic only.
89053515|NCT00587028||IV Iodine MCR|Ten participant minimum: for intravenous iodine contrast dye. This cohort at Rochester Mayo Clinic only.
89053516|NCT00587028||NO oral and no IV MCR|Five participant minimum for no oral or IV contrast.
89053517|NCT00587028||Replacement Group|Five participant minimum for either cohorts 1, 2, or 3 as above should there be poor imaging results. A like prepped participant will replace that who had poor quality imaging to meet 25 imaging data sets.
89053518|NCT00555815||1|Extended hygiene measures
89053519|NCT00555815||2|Standard hygiene measures
89053520|NCT04674839|Experimental|MS-20|8 ml/day for 8 weeks
89053521|NCT04674839|Other|Placebo|8 ml/day for 8 weeks
89053522|NCT03458130|Active Comparator|AG10 Low Dose|AG10 400mg tablets twice daily for 28 days
89053523|NCT03458130|Active Comparator|AG10 High Dose|AG10 800mg tablets twice daily for 28 days
89053524|NCT03458130|Placebo Comparator|Placebo|Placebo tablets twice daily for 28 days
89053525|NCT04674488|Experimental|TILs intervention|
89686041|NCT03836599|Placebo Comparator|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
89686042|NCT01839097|Experimental|Dose Finding Phase|"This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.~Enrollment will begin with the enrollment of patients into Cohort 3.~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen."
89053528|NCT04674605||ocular myasthenia gravis|
89053529|NCT04674605||generalized myasthenia gravis|
89053530|NCT00587106||1|One cohort group of patient with PNDS or suspected PNDS
89053531|NCT03456219|Experimental|Shift workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the normal protein diet.
89053532|NCT03456219|Experimental|Night workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the high-protein diet.
89053533|NCT02277483|Active Comparator|active treatment|LAIS® Mites Sublingual tablets + rescue medication
89053534|NCT02277483|No Intervention|control|Rescue medication
89053535|NCT04575129||Study Group|No intervention will be applied
89053536|NCT00555932|Active Comparator|1|The research head ultrasound (HUS) will be performed at the bedside in the Neonatal Unit. The ultrasound examination will be performed within 10 hours time window of the MR and or CT study.
89686043|NCT02488018|Experimental|Provision of experimental honeys|Eight experimental monofloral honeys and reference glucose
89686044|NCT01835665|Experimental|Nimodipine|
89686045|NCT01839175|Experimental|Group 1|
89686046|NCT01839175|Active Comparator|Group 2|
89686047|NCT01835821|Experimental|prosthesis|"NobelProcera™ Crown shaded zirconia:~The device is an individual, ceramic core (figure a) made of shaded zirconium with an anatomic contour providing homogenous veneering material thickness and a minimum core thickness of 0.4 or 0.7mm. The core is veneered with dental porcelain (IPS e.max Ceram) at the dental laboratory"
89686048|NCT01839253|Experimental|Atenolol|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
89686049|NCT01839253|Active Comparator|Enalapril|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
89053537|NCT04575402||CSMC prostate cancer patients receiving ADT|Prostate cancer patients recruited from oncology clinic at Cedars-Sinai Medical Center.
89053538|NCT04575402||Veterans with prostate cancer|Prostate cancer patients recruited from the Veteran Affairs Oncology Clinic (Durham, NC).
89053539|NCT04674332|Experimental|long acting insulin|
89053540|NCT04674332|Active Comparator|multiple dose regimen|
89053541|NCT04674449|Active Comparator|Intervention Group - Stratified Medicine|All randomised participants will receive stratified medicine. The subjects will undergo functional coronary angiography involving guidewire-based coronary function tests (interventional diagnostic procedure, IDP) as an adjunct to invasive coronary angiography. The IDP results will be disclosed to the catheter laboratory clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and IDP findings.
89053542|NCT04674449|Sham Comparator|Standard Care Group|All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also receive the IDP at time of the angiogram. The results of the IDP will be concealed from the catheter laboratory clinician who will be blinded. The cardiac physiologist / clinical scientist will remain unblinded for the purpose of data recording and quality assurance. The sham procedure is intended to be the same as in the Intervention Group. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and IDP findings.
89216763|NCT01602263||Individuals with aphasia|Individuals with aphasia will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
89686050|NCT01839253|Placebo Comparator|control|none of antihypertensive agents
89686051|NCT00404170|Experimental|B-CIT and SPECT imaging|To assess B-CIT injection and SPECT scanning. Optional ongoing B-CIT SPECT imaging scans at follow-up visits
89686052|NCT01839409|No Intervention|control|Control without vestibular stimulation
89686053|NCT01839409|No Intervention|Bilateral areflexia|Patient with vestibular bilateral areflexia
89686054|NCT01839409|No Intervention|Areflexia controls|Controls for patients with vestibular bilateral areflexia, matched in sex and age
88998468|NCT04711174||movement,low Aldrete score group (ML group)|LMA removal be conducted when the child's spontaneous respiratory recovers with body movement spontaneously, and the child be transited from PACU when Aldrete score reaches 7
88998469|NCT04711174||sedation,high Aldrete score group (SH group)|LMA removal be conducted when the child's spontaneous respiratory recovers but with no body movement, and the child be transited from PACU when Aldrete score reaches 9
88998470|NCT04711174||sedation,low Aldrete score group (SL group)|LMA removal be conducted when the child's spontaneous respiratory recovers but with no body movement, and the child be transited from PACU when Aldrete score reaches 7
88998471|NCT04693819||Hyperacusis|Abnormally reduced tolerance to sound
88998472|NCT00167141|Experimental|testosterone injections|injections of testosterone to normal men (arm 1) and two men with subnormal semen parameters (arm 2)
88998473|NCT04660045|Experimental|Acalabrutinib|Acalabrutinib 100 mg will be administered orally twice daily continuously in 28-day cycles until treatment is discontinued for any reason.
88998474|NCT04612387|Experimental|Mind-body Intervention arm|Online yoga, meditation and nutrition tips.
89686055|NCT01839409|Experimental|vestibular stimulation|Subjects submitted to vestibular stimulation in order to improve circadian rhythms
89686056|NCT01835977|Active Comparator|Focal ablation|Focal ablation of unilateral histopathologically confirmed, organ confined prostate cancer using IRE
89686057|NCT01835977|Active Comparator|Extended ablation|Extended ablation unilateral histopathologically confirmed, organ confined prostate cancer using IRE
89686058|NCT01839565||Patients|Patients undergoing osteosynthesis of acetabular fractures by using the Quadrilateral Surface Plate
89686059|NCT01836211|Experimental|Fast strategy|High sensitivity cardiac troponin T followed by computed coronary tomography angiography
89686060|NCT01836211|Active Comparator|Standard of care strategy|Standard of care strategy based on serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
89686061|NCT04379869|Experimental|NNZ-2591 Single dose Cohort 1|Single dose of oral NNZ-2591 in healthy volunteers
89686062|NCT04379869|Experimental|NNZ-2591 Single dose Cohort 2|Single dose of oral NNZ-2591 in healthy volunteers
89686063|NCT04379869|Experimental|NNZ-2591 MAD Cohort 1|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
89686064|NCT04379869|Experimental|NNZ-2591 MAD Cohort 2|Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
89686065|NCT01836289|Experimental|High-dose Cyclophosphamide|High-dose Cyclophosphamide
89686066|NCT03218839|Experimental|HIV+ PrePex|PrePex male circumcision device
89686067|NCT03218449||1/NC|noninfective complication
89686068|NCT03218449||2/IC|infective complication
89686069|NCT01839643|Experimental|2.4 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
89686070|NCT01839643|Experimental|3.0 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
89686071|NCT01839721|Active Comparator|Bifilact® probiotics standard dose|concentration of 1.3 billion of Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. one pill twice a day. Each capsule contained maltodextrin and magnesium stearate as excipient
89686072|NCT01839721|Active Comparator|Bifilact® probiotics high dose|containing 10 billion Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. One pill three times a day. Each capsule contained maltodextrin and magnesium stearate as excipient
89686073|NCT01839721|Placebo Comparator|placebo|Each capsule contained maltodextrin and magnesium stearate as excipient. One pill twice a day
89686074|NCT01836367|Experimental|Ingenol Mebutate 0.015%|two cycles of ingenol mebutate 0.015%
89686075|NCT04379557|Experimental|High power ablation|Ablation Index guided high power ablation (radio frequency energy: Left atrium anterior segment and roof: 40W, Left atrium inferior/posterior: 30W, near esophagus: 25W)
89686076|NCT04379557|Active Comparator|Conventional ablation|Conventional ablation applying 30-35W strategy for Left atrium anterior segments.
89686077|NCT04380025|Experimental|Mirtogenol|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) the experimental group will also take Mirtogenol. Mirtogenol is a dietary supplement composed of bilberry and pycnogenol which are botanical compounds with antioxidant properties. The active components of bilberry are flavonoid anthocyanosides (anthocyanins). Anthocyanosides are the only flavonoids able to reach the eye as a target organ in experimental animals. Unchanged anthocyanosides demonstrated after oral administration that it is absorbed and distributed into ocular tissues, showing its ability to pass through the blood-aqueous and blood retinal barriers.6
89686078|NCT04380025|Placebo Comparator|Lactose based Placebo|In addition of conventional treatment with glaucoma ophtalmic drop medication (bimatoprost) this control group will also take an identical placebo. This placebo is a inactive lactose based product of the same color and size capsule.
89686079|NCT00908791|Experimental|CLA|open-label, single-institution proof of principle study of oral CLA in patients with newly diagnosed adenocarcinoma of the breast.
89686080|NCT01836601|No Intervention|Pre-nighttime communication intervention arm|This arm is the pre-intervention arm of parents, nurses, and residents before the nighttime communication bundle has been enacted.
89686081|NCT01836601|Experimental|Post-nighttime communication intervention arm|This arm is the post-intervention arm of parents, nurses, and residents after the nighttime communication bundle has been enacted.
89686082|NCT03218371||study group (Indentation)|Eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed with scleral indentation. (Exposure)
89686083|NCT03218371||control group (Non-indentation)|eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed without scleral indentation.
89686084|NCT01836679|Experimental|Arm 1|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive Chidamide 20mg orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
89686085|NCT01836679|Placebo Comparator|Arm 2|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
89686086|NCT03218293|Experimental|RIPC|Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
89686087|NCT03218293|No Intervention|Blank control group(BC)|Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
89686088|NCT02489110|Experimental|Webnovela|Caregivers will watch the Webnovela and read related information. The Webnovela is a short online Telenovela in Spanish, specifically designed for Hispanic caregivers on how to cope with dementia caregiving. A DVD will be available to participants without Internet access.
89686089|NCT02489110|Active Comparator|Control|Caregivers will be directed to existing web sites, such as NIA Alzheimer's and Dementia Resources in Spanish. Participants will receive related materials in Spanish language.
89686090|NCT05452096|Active Comparator|Intervention group|"The intervention provided to the intervention group is based on evidence-based good standard of care and includes:~Healthy scheduling (fast forward-rotating shift schedules adapted to chronotype, adequate resting times, napping, bright-light therapy)~Education program for drivers (psychoeducation promoting sleep hygiene, cognitive-behavioral strategies, stress-management techniques, information on chronotherapy such as bright-light therapy and napping)"
89686091|NCT05452096|No Intervention|Control group|The control group will continue working according to the default shift schedules while being assigned to a waiting list in anticipation of the education program.
89686092|NCT00369538|Active Comparator|1|losartan, hydrochlorothiazide
89686093|NCT00369538|Active Comparator|2|hydrochlorothiazide, losartan
89686094|NCT02489734|Experimental|low concentration (LC)|low concentration group
89686095|NCT02489734|Experimental|high concentration (HC)|high concentration group
89686096|NCT05124262|Experimental|Low-FODMAPdiet group|Low-FODMAPdiet intervention as group treatment in three steps during 12 weeks, elimination, re-introduction and personalization of the diet. This group of participants starts immediate.
89686097|NCT05124262|Experimental|Delayed start of treatment low-FODMAPdiet group|Delayed start of treatment. This arm starts after three months
89686098|NCT02490670|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
89686099|NCT02490670|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods.
89686100|NCT00908947|Experimental|Overall Study|PTA plus stenting with the LifeStent® Vascular Stent System
89686101|NCT02492854|Active Comparator|Standard Sterile Gauze Dressings|In this arm, pts. will be randomized to receive standard sterile gauze dressing post-operatively.
89686102|NCT02492854|Experimental|PICO Negative Pressure Dressings|In this arm, pts. will be randomized to receive PICO single-use negative pressure dressings.
89686103|NCT05451706|Experimental|YouTube Intervention|Participants assigned to this task were asked to search YouTube for a 5-10 minutes' video promoting mental help-seeking among college students. Then, they were expected to provide the link to the video and describe the content of the video. Next, participants were guided to form rebuttals disapproving three statements that rationalize students' low intention to seek mental help.
89686104|NCT05451706|Active Comparator|Facebook Intervention|This task was to draft a Facebook message for the participants' fellow students. In their message, participants were expected to list three reasons for seeking mental help. The length of the message was not pre-determined.
89686105|NCT05451706|Placebo Comparator|YouTube Control Group|Participants in this group were assigned a YouTube task advocating social distancing during a pandemic. The question prompts were modified from the tasks for the experimental groups.
89686106|NCT05451706|Placebo Comparator|Facebook Control Group|Participants in this group were assigned a Facebook task advocating social distancing during a pandemic. The question prompts were modified from the tasks for the experimental groups.
89686107|NCT01836757|Experimental|MSM group|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
89686108|NCT01836757|Placebo Comparator|Placebo Group|Placebo 3 gr twice a day for 26 weeks (6 gr/day total)
89686109|NCT05451472|Experimental|pediatric group|
89686110|NCT01836835||Hyperemesis gravidarum|Women diagnosed with hyperemesis gravidarum admitted to hospital Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
89686111|NCT01836835||Healthy pregnant women|Women with presumed normal pregnancy Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
89686112|NCT01839877|Experimental|HIA DEBIRI + systemic FOLFOX|Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX
89686113|NCT05451394|Experimental|ROAF Arm|6 one-hour workshops working on enhancing postural awareness through the use of ROAF
89686114|NCT05451394|Active Comparator|Active control|6 one-hour workshops on higher cognitive processes (memory, attention...)
89686115|NCT01839955|Experimental|Arm I (Dose Escalation Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.
89686116|NCT01839955|Experimental|Arm II (Extension Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.
89686117|NCT02493088||Antisocial personality|Individuals Diagnosed with Antisocial Personality Disorder
89686118|NCT01831843|Placebo Comparator|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
89686119|NCT01831843|Experimental|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
89686120|NCT01831843|Experimental|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
89686121|NCT02494102|Placebo Comparator|Placebo|Administered Placebo day of surgery immediately prior to general anesthesia and surgery
89686122|NCT02494102|Active Comparator|Intervention|Administered Modafinil 200mg day of surgery prior to general anesthesia and surgery
89686123|NCT01836991|Other|D2 surgery|D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)
89686124|NCT01836991|Experimental|D2+ surgery|D2+ surgery(D2+8p、12b、13、14v lymph node)
89686125|NCT03219619|Experimental|Cap group: Cap-EGD|Undergoing cap-assisted esophagogastroduodenoscopy
89686126|NCT03219619|Active Comparator|Duo group: Duo|Undergoing side-viewing duodenoscope
89686127|NCT05451160|Experimental|Steep Pulse Therapy System|
89686128|NCT05451160|Active Comparator|RF Ablation System|
89686129|NCT05451082||Single Group Assignment|
89686130|NCT00894517|Experimental|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
89686131|NCT00894517|Placebo Comparator|Placebo (saline)|Placebo (saline) injected into the prostate on Day 1.
89686132|NCT01833871|Experimental|myometrial fibroid/adenomyoma|Patients scheduled for myomectomy or hysterectomy with preoperative diagnosis of uterine myoma, adenomyosis or both by ultrasound .Trans-vaginal 3D power Doppler and uterine artery doppler will be done for all participants prior to surgery.
89686133|NCT05059210|No Intervention|Control|Coach McLungs not yet implemented in practice
89686134|NCT05059210|Active Comparator|Intervention|Coach McLungs Implemented in Practice
89686135|NCT01838395|Experimental|BL-8040 + Ara-C|"Eligible subjects will receive subcutaneous (SC) injections of BL-8040 (monotherapy period) over two days (one injection per day) followed by concurrent administration of BL-8040 with standard salvage chemotherapy (combined period) over 5 days. During the combined period, BL-8040 will be administered 4 hours prior to chemotherapy. The chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age), administered intravenously (IV) over 3 hours, for 5 days and will not be escalated."
89686136|NCT01837147|Experimental|Web-based Tracking Group|Technology-Based Physical Activity Promotion
89686137|NCT01837147|Active Comparator|Pedometer Group|Participants assigned to this group will receive a pedometer.
89686138|NCT01837303||Liquid based cytology|All participants will undergo both manual and conventional automated liquid based cytology (pap smear, cervical cytology).
89686139|NCT05048056|Experimental|AK120 Regimen 1|AK120 Regimen 1- subcutaneous injection every 2 weeks for 30 weeks.
89686140|NCT05048056|Experimental|AK120 Regimen 2|AK120 Regimen 2- subcutaneous injection every 2 weeks for 30 weeks.
89686141|NCT05048056|Experimental|Placebo to AK120|Placebo subcutaneous injection every 2 weeks, then crossover to AK120 Regimen 1, subcutaneous injection at Week16, after primary endpoint evaluation
89686142|NCT03217981||2015|2015 - Individuals with a diagnosis of sepsis from June 2014 to May 2015
89686143|NCT03217981||2016|2016 -Individuals with a diagnosis of sepsis from June 2015 to May 2016
89686144|NCT02494180|Placebo Comparator|A: intravenous fentanyl, midazolam|group A will be given intravenous 0.1mg fentanyl and 5mg midazolam prior oocyte retrieval
89686145|NCT02494180|Placebo Comparator|B: intravenous pethidine, diazepam|group B will be given intravenous 25mg pethidine, 5mg diazepam prior oocyte retrieval
89686146|NCT05032690|Experimental|Treatment B: Bosutinib four 25 mg capsule after meal|Bosutinib four 25 mg capsule taken after a high-fat and high-calorie breakfast for comparison 1
89686147|NCT05032690|Active Comparator|Treatment A: Bosutinib 100 mg capsule after meal (active comparator)|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast for comparison 1
89686148|NCT05032690|Experimental|Treatment A: Bosutinib 100 mg capsule after meal (experimental)|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast for comparison 2
89686149|NCT05032690|Active Comparator|Treatment C: Bosutinib 100 mg capsule after fasting|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours for comparison 2
89686150|NCT02494336|Active Comparator|Trans-incisional rectus sheath block|rectus sheath block under direct visualization through the umbilical incision by the attending surgeon
89686151|NCT02494336|Active Comparator|Laparoscopic guided rectus sheath block|rectus sheath block under direct laparoscopic visualization by the attending surgeon
89686152|NCT01839331|Experimental|Ampion 4 mL Dose|4 mL Injection of Ampion
89686153|NCT01839331|Placebo Comparator|Placebo 4 mL Dose|4 mL Injection of Placebo
89686154|NCT01839331|Experimental|Ampion 10 mL Dose|10 mL Injection of Ampion
89686155|NCT01839331|Placebo Comparator|Placebo 10 mL Dose|10 mL Injection of Placebo
89686156|NCT01837381|Other|Transarterial Ethanol Ablation (TEA)|Two treatment sessions at 2 months apart were given and started within 4 weeks after randomization.
89686157|NCT02495038|No Intervention|Intubating dose, Group I|"combined ED95 rocuronium and ED95 cisatracurium~ED95, dose causing on average 95% suppression of neuromuscular response."
89686158|NCT02495038|Experimental|10% reduction of combination of Esmeron® and Nimbex®, Group S|This arm reduced 10% of combined ED95 rocuronium and ED95 cisatracurium
89686159|NCT02495038|Experimental|20% reduction of combination of Esmeron® and Nimbex®, Group L|This arm reduced 20% of combined ED95 rocuronium and ED95 cisatracurium
89686160|NCT01834339|Active Comparator|AlloDerm|The subject will be treated with the standard of care, AlloDerm, to cover the defect in the mouth.
89686161|NCT01834339|Experimental|EVPOME|An ex-vivo produced oral mucose equivalent (EVPOME) will be used to cover the defect in the top of the mouth.
89686162|NCT01830985|Experimental|Single Arm VX-509|
89686163|NCT05450614|Experimental|Thrive app|In the Thrive group, access to the application and information regarding its use will be made available to participants. Reassessments and data collection will be performed at 5 points including baseline, 4 weeks, 8 weeks, 12 weeks and 6 months. These five evaluations will be carried out through questionnaires sent to the participants.
89053543|NCT04674176|Experimental|Rifaxamin (R)|Patients in the experimental group will receive additional instructions to take 550 mg of Rifaximin 3 times a day for 12 days at the start of the diet. The experimental group will be provided the required doses of Rifaximin at the initial weigh-in and office visit.
89053544|NCT04674176|No Intervention|Control|Participants in the control group will undergo no intervention and will only be asked to follow an Intermittent fasting diet.
89216764|NCT01602263||Individuals with high-functioning autism|Individuals with high-functioning autism will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
89216765|NCT02577419|Experimental|Target Fortification|
89053545|NCT00199875|Experimental|Cohort 1 (0.2 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.2 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
89216766|NCT02577419|Experimental|Higher Initial Concentration|
89686164|NCT05450614|Active Comparator|TCCG|"Participants selected for the TCCG group will undergo a new randomization, which will select 50% of patients for immediate start of online sessions and the remainder for inclusion in a waiting list. Participants selected for immediate start will start the CBCT sessions at the time of the initial assessment and will be reassessed at the same points as the Thrive group, also through self-administered online questionnaires.~The waiting list will last for 12 weeks, with assessment through self-applicable online scales at the end of the period. Patients who present PHQ≥ 9 will then start online CBCT sessions, according to the protocol above."
89686165|NCT01837459||Obese-Normal|Obese with Apnea Hypopnea index (AHI) <1
89686166|NCT01837459||Obese-SDB|Obese and with AHI>1
89686167|NCT01837459||Lean-Normal|Non-obese with AHI<1
89686168|NCT01837459||Lean-SDB|Non-obese with AHI>1
89686169|NCT01837615|Experimental|Photopill treatment|
89686170|NCT02501590||study|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
89686171|NCT02501590||control|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
89686172|NCT01837693|No Intervention|one year follow up|A random sample of HPV positive women with negative cytology will be invited to repeat HPV DNA test and biomarkers after a year, as recommended by the current screening protocols based on HPV DNA
89686173|NCT01837693|Experimental|direct sending in colposcopy|Experimental: immediate colposcopy. A random sample of HPV positive women with negative cytology will be sent to immediate colposcopy
89686174|NCT04993144|Active Comparator|Active|"Participants received the real intervention of TBS (cTBS 600) over the left dorsolateral prefrontal cortex for 8 weeks (2 days/week).~*cTBS = continuous theta burst stimulation"
89686175|NCT04993144|Sham Comparator|Sham|Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the left dorsolateral prefrontal cortex for 8 weeks (2 days/week).
89686176|NCT04993144|No Intervention|Normal control|No intervention.
89686177|NCT03837769|Experimental|Aktiia SA PulseWatch|Aktiia OBPM PulseWatch wrist device
89686178|NCT04956484|Experimental|Belimumab 10 mg/kg plus standard of care|Standard of care and Belimumab: 10 mg per kilogram of body weight，days 1 (baseline), 15, and 29 and every 28 days thereafter to week 24
89686179|NCT03217435|Experimental|Cornea epithelial allograft|Femtosecond laser assisted corneal epithelial allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
89686180|NCT03217435|Active Comparator|Limbal conjunctival allograft|Diamond knife assisted limbus conjunctival allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
89686181|NCT05450458|Experimental|Hyaluronic Acid group|All overuse knee syndrome participants after both knee joint infiltration with two doses each of Synolis VA (2ml = 40 milligrams of hyaluronic acid with 80 milligrams of sorbitol).
89686182|NCT01837771|Active Comparator|Diaphragmatic stimulation|Diaphragmatic stimulation via electrode for 4 weeks
89686183|NCT01837771|No Intervention|No intervention|
89686184|NCT05449912||Patients registered in the RICO database|Patients hospitalized for myocardial infarction between 01/01/2002 and 31/12/2008
89686185|NCT01720615|No Intervention|Propofol or Sevoflurane|General anesthesia
89686186|NCT01837927|Experimental|NVA237|NVA237 inhaled via the Breezhaler® device once daily
89686187|NCT01837927|Active Comparator|Tiotropium|Tiotropium 5μg inhaled via the Respimat® device once daily
89686188|NCT02503852|Experimental|Fat + High Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
89686189|NCT02503852|Experimental|Fat + Low Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
89686190|NCT02503852|Active Comparator|Fat Alone|Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
89686191|NCT02503852|Placebo Comparator|No Fat Control|Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
89686192|NCT01838005|No Intervention|Standard of Care|"Routine implementation of the national PMTCT guidelines which are an adaptation of the WHO's Option A"
89686193|NCT01838005|Experimental|Conditional Cash Transfer|Financial incentive to attend regular clinic visits and receive PMTCT care
89686194|NCT01838083|Experimental|Insulin glargine new formulation (test T formulation)|Once daily for 6 days
89686195|NCT01838083|Experimental|Insulin glargine new formulation (reference R formulation)|Once daily for 6 days
89686196|NCT05441644|Placebo Comparator|frontal BIS|frontal BIS is a standard position
89686197|NCT05441644|Active Comparator|infraorbital BIS|Infraorbital BIS is a comparator to find agreement with standard location
89686198|NCT01838161|Active Comparator|Part I|Interview questions will focus on reticence to vaccinate children.
89686199|NCT01838161|Experimental|Part II|"We will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents.~a pretest survey~the video vignette~and a post-test survey measuring intention to receive appropriate adolescent vaccines"
89686200|NCT01838161|Experimental|Part III|"enhanced video educational intervention (video vignettes + standard of care vaccine event)~standard of care vaccination event"
89686201|NCT04943926|Active Comparator|Energy Restricted Diet|A nutritional complete formula diet for 3 months followed by an energy restricted diet for 12 months.
89216767|NCT02577419|Active Comparator|Portagen Growth Reference|
89216768|NCT02576171|Experimental|Group-therapy + ICBT|This is an open trial with only one study arm
89216769|NCT04071665|Experimental|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion for treatment of scoliosis
89216770|NCT04071665|Active Comparator|transforaminal lumbar interbody fusion|transforaminal lumbar interbody fusion
89686202|NCT04943926|Experimental|Continuous LCHF Diet|A very low-carbohydrate high-fat ketogenic diet (VLCHF) diet for 3 months, followed by a low-carbohydrate high-fat diet (LCHF) for 12 months.
89686203|NCT01838239|Experimental|Fish oil|
89686204|NCT01720693|Experimental|hypoperfusion|Hypoperfusion of the renal artery
89686205|NCT02504554|Experimental|Oral Group|This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
89686206|NCT02504554|Experimental|Rectal Group|This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
89686207|NCT01838473|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
89686208|NCT01838473|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
89686209|NCT01838473|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
89686210|NCT01838473|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
89686211|NCT03217123|Experimental|Deep Brain stimulation|After the surgery, a random sequence of contact activations (0 [Nacc],1,2 and 3), including sham (-), was generated for each patient. Each contact was activated using 130 Hz, 60 ms, and 4.5 V for three months (the sham activation was 0 V) following the patient's individual sequence, separated by one month of washout with the generator turned off
89686212|NCT04937452|Experimental|Rotigotine 4 mg|Rotigotine 4 mg/24 hours transdermal patch administration
89686213|NCT04937452|Experimental|Rotigotine 6 mg|Rotigotine 6 mg/24 hours transdermal patch administration
89686214|NCT04937452|Placebo Comparator|Placebo|Placebo transdermal patch administration
89686215|NCT03216811|Experimental|nutraceutical|after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones
89686216|NCT01720771|Active Comparator|Probiotic tablet|a tablet with three probiotic streptococci strains (S. uberis KJ2, S. oralis KJ3 and S. rattus JH145) at a concentration of 3x108 CFU
89686217|NCT01720771|Placebo Comparator|Sugar pill|The same tablet but without active probiotic bacteria
89686218|NCT01838629||thyroid nodule|
89686219|NCT01838707|Active Comparator|Bupivacaine|0.125% Bupivacaine HCL @ 4-5 ml/h
89686220|NCT01838707|Active Comparator|Bupivacaine, Morphine|0.125% Bupivacaine HCL , Morphine sulphate 3 mg @ 3-5 ml/h
89686221|NCT01838707|Active Comparator|Bupivacaine, Fentanyl|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
89686222|NCT01720849||Fampyra group|
89686223|NCT04379479|Experimental|Dialyzable Leukocyte Extract|"Oral administration 2 mg/5 mL every 24 hours for 14 days, following by 2 mg/5 mL twice a week for 3 weeks.~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
89686224|NCT04379479|Placebo Comparator|Placebo|"Oral administration 5 mL every 24 hours for 14 days, following by 5 mL twice a week for 3 weeks.~All patients will receive paracetamol as symptomatic treatment, 500 mg oral administration 3 times per day."
89686225|NCT00914485|Other|Provider Communication Skills Training|Provider clinical communication training intervention
89686226|NCT02506114|Experimental|Arm A: PROSTVAC-V/F|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.
89686227|NCT02506114|Experimental|Arm B: Ipilimumab Monotherapy|Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.
89686228|NCT02506114|Experimental|Arm C: Combined PROSTVAC-V/F + Ipilimumab|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
89686229|NCT00915031|Active Comparator|Hypothermia Only OR|Use of Hypothermia Cooling device only in the operating room. Intervention is Hypothermia Cooling Device.
89686230|NCT00915031|Active Comparator|Hypothermia in OR + Recovery|Use of hypothermia cooling device in the operating room and up to five hours after surgery is intervention.
89686231|NCT00370084|Placebo Comparator|Placebo|
89686232|NCT00370084|Experimental|Itopride|
89686233|NCT01720927||Acute Pharyngitis|Subjects presenting with acute pharyngitis
89686234|NCT04923256|Experimental|Experimental: Approach Bias Modification|Participants will complete 2 x 5-7 min training sessions of approach bias modification for the period of four weeks
89686235|NCT04923256|Active Comparator|Control: Minimal intervention|Participants will complete a standardised alcohol approach-avoidance training task (AAT) on a weekly basis for four weeks.
89686236|NCT01725685|Experimental|Treatment A - FF 400 microgram (mcg)|Subjects will be randomized to single dose of FF 400 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
89686237|NCT01725685|Experimental|Treatment B - UMEC 500 mcg|Subjects will be randomized to single dose of UMEC 125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
89686238|NCT01725685|Experimental|Treatment C - FF/UMEC 400/500 mcg|Subjects will be randomized to single dose of FF/UMEC 100/125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
89686239|NCT01721083|Experimental|Z-Track immunization|Subject receives Intramuscular injection by z-track method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
89686240|NCT01721083|Active Comparator|Bunch immunization|Subject receives Intramuscular injection by bunch method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
89686241|NCT05449054|Active Comparator|Continuous stitches for anterior colporrhaphy|Continuous stitches will be used for plication during anterior colporrhaphy. Sutures will be at a distance of no more than 0.5 cm. Trimming of the vagina will be performed if necessary. The anterior vaginal skin is closed with continuous 2/0 vicryl sutures.
89053546|NCT00199875|Experimental|Cohort 2 (0.3 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.3 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
89053547|NCT00199875|Experimental|Cohort 3 (0.4 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.4 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
89053548|NCT00199875|Experimental|Cohort 4 (0.45 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.45 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
89053549|NCT00199875|Experimental|Cohort 5 (0.55 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.55 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
89053550|NCT04674527|Experimental|experimental group|Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.And elemene injectable emulsion will be given for 80 -120 ml/day in each 14-day cycle or 21-day cycle.
89053551|NCT04674527|Experimental|contral group|Maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
89053552|NCT00587184||1|patients who were seen clinically indicated endoscopic surveillance and biopsies of BE and confocal microscopy was performed.
89686242|NCT05449054|Active Comparator|Interrupted stitches for anterior colporrhaphy|Interrupted stitches will be used for plication during anterior colporrhaphy. Sutures will be at a distance of no more than 0.5 cm. Trimming of the vagina will be performed if necessary. The anterior vaginal skin is closed with continuous 2/0 vicryl sutures.
89686243|NCT04920994|Active Comparator|Group A (M-TAPA )|Ultrasound-guided M-TAPA block will be performed under strict aseptic conditions with the patient in the supine position, and bupivacaine will be administered.
89686244|NCT04920994|Active Comparator|Group B (SCTAP)|Ultrasound-guided SCTAP block will be performed under strict aseptic conditions with the patient in the supine position, and bupivacaine will be administered.
89686245|NCT03409939|Experimental|Aromatic Amino Acid Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
89686246|NCT01721395|Placebo Comparator|Colored, Flavored water|The placebo will be colored to approximate the reddish amber color of the agave syrup. The placebo will use the same flavoring used in the agave syrup. The placebo will be created in a GMP facility
89686247|NCT01721395|Experimental|Agave Syrup|The formulation of pasteurized agave syrup consists of pasteurized agave syrup and natural flavoring.
89686248|NCT01721395|Sham Comparator|Air-filled oral syringe|Air-filled oral syringe to match experimental and placebo arm
89686249|NCT02506660|Active Comparator|Intravenous dexamethasone|Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
89686250|NCT02506660|Experimental|Perineural dexamethasone|Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
89686251|NCT04377607||Group OP|outpatients with asymptomatic or uncomplicated or mild pneumonia
89686252|NCT04377607||Group H|hospitalized patients
89686253|NCT04377607||Group IC|patients admitted to intensive care unit
89686254|NCT01725997|Active Comparator|Operative treatment|Operative treatment with hook plate.
89686255|NCT01725997|Active Comparator|Conservative treatment|Physiotherapy
89686256|NCT02509624|Experimental|Moderate hepatic impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
89686257|NCT02509624|Experimental|Severe hepatic impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
89686258|NCT02509624|Experimental|Mild hepatic impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
89686259|NCT01726075|Experimental|COLIRIOBCN070660|COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution. One drop/eye administered twice a day.
89686260|NCT01726075|Placebo Comparator|Placebo|Placebo Eye drops, solution. One drop/eye administered twice a day.
89686261|NCT01726075|Experimental|Brimonidine|Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.
89686262|NCT01726153|No Intervention|Web sites|Individuals assigned to this arm are given a list of websites where they can view additional information relating to condom use.
89686263|NCT01726153|Experimental|Condom-HIM|Individuals assigned to this arm must follow an on-line one session tailored intervention.
89686264|NCT04338334|Active Comparator|CONTROL GROUP|Control group includes physical therapy protocol composed of manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active arm therapeutic exercises.
89686265|NCT04338334|Experimental|COHESIVE BANDAGE GROUP|Cohesive bandage is a self-adherent lightweight bandage, made of a porous nonwoven polyester material. A single self-adherent inelastic bandage will be directly applied at full stretch on cleaned and dried skin (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States) in a spiral method around the limb, starting at the hand and a layer overlap of 50%, so that the greatest compression was located at the distal points, gradually decreasing toward the proximal shoulder part. Cohesive latex-free bandages will be available for those allergic women. Women will do progressive active arm therapeutic exercises with bandaging.
89216771|NCT02575937|Experimental|Diabetes group|During the trial period, the participants who are diagnosed of diabetes are instructed to consume low glycemic diet every day
89216772|NCT02575937|Experimental|Fatty group|During the trial period, the participants who are diagnosed of obesity are instructed to consume low glycemic diet every day
89053553|NCT00199836|Experimental|Patients with Cancer Expressing NY-ESO-1 or LAGE-1 Antigen.|NY-ESO-1b peptide, 100 μg mixed with 1 mg CpG 7909 and 0.5mL of Montanide® ISA-51 was administered to patients with cancer expressing NY-ESO-1 or LAGE-1 antigen. The injections were given subcutaneously beginning on week 1 and repeated every three weeks for 4 injections total. There was a 3 week follow-up period after the last injection. In the absence of toxicity and progressive disease (PD), a second cycle was offered to patients who received 4 vaccinations.
89053554|NCT00199797|Experimental|huA33 antibody plus chemotherapy|"huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.~Starting on day 15 and continuing every second week, oxaliplatin, 5-fluorouracil (5-FU) and leucovorin were also administered.~Oxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.~The doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as a bolus infusion and 600mg/m2 as a continuous infusion.~A complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression."
89053555|NCT04674215|Experimental|intervention group|"Data about sociodemographic and clinical characteristics of the patients in all groups were collected. Their mobility status and general anxiety levels were evaluated.~The patients in the intervention group were given a planned in-bed turning and mobilization training in the patient's room by the researcher one day before the surgery. This training included explaining the importance of postoperative mobility, demonstrating the correct in-bed turning and mobilization steps through pictures with the Illustrated In-Bed Turning and Mobilization Training Material, answering questions (if any), and finally, simulating postoperative in-bed turning and the first mobilization using the role-playing technique in collaboration with the patient."
89053556|NCT04674215|Other|control group|"Data about sociodemographic and clinical characteristics of the patients in all groups were collected. Their mobility status and general anxiety levels were evaluated.~Patients in the control group received routine clinical care. This care included the provision of verbal information to the patient at different times by the primary physician and/or nurse about postoperative in-bed turning and mobilization and answering questions if any."
89053557|NCT04572087|Experimental|Cognitive Control Training + Verum stimulation|This arm consists of the cognitive control training (six sessions) combined with 2mA anodal tDCS over the right dlPFC (F4) during the training for 20 minutes.
89053558|NCT04572087|Active Comparator|Cognitive Control Training + Sham stimulation|This arm consists of cognitive control training (six sessions) with sham-tDCS. 2 mA Sham-tDCS (40 seconds of tDCS) is applied to the right dlPFC (F4) before the trainings starts.
89053559|NCT04673903|Experimental|Intervention group|"The intervention group will be instructed to include the Copenhagen adduction exercise into their warm up before training session (3 times per week) during one season (6 months).~The Copenhagen adduction exercise is a body-weight exercise which mainly works the groin and hip adductor. It has a large eccentric component, meaning the muscles are working whilst lengthening."
89053560|NCT04673903|Active Comparator|Control group|The control group will practice their usual warm up. Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
89216773|NCT02575937|Experimental|Impaired glucose tolerance group|During the trial period, the participants who are diagnosed of impaired glucose tolerance are instructed to consume low glycemic diet every day
89053561|NCT01137604|Experimental|Cohort 1|"Cohort 1 assessed participants with recurrent Grade 4 malignant glioma (ie, glioblastoma [GBM]) who were bevacizumab-naive. Participants were planned to be accrued in Cohort 1 and randomized in a 1:1 ratio to receive lenvatinib (experimental) or bevacizumab (active comparator).~Cohort 1 - Bevacizumab~Cohort 1 - Lenvatinib"
89053562|NCT01137604|Experimental|Cohort 2|Cohort 2 assessed participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive. Participants in Cohort 2 were planned to be treated with lenvatinib.
89053563|NCT01137604|Experimental|Cohort 3|Cohort 3 assessed participants with recurrent GBM who had disease progression following prior bevacizumab treatment. Participants in Cohort 3 were planned to be treated with lenvatinib.
89053564|NCT00637351||Group A|Subjects with diagnosed pneumonia & positive culture of streptococcus pneumoniae
89053565|NCT00637351||Group B|Subjects with diagnosed pneumonia & positive culture of non-typable haemophilus influenzae
89686266|NCT01721629|Other|Sudden wean of nasal CPAP|The CPAP is taken off at the morning ward round. If the discontinuation of the CPAP fails according to prespecified failure criteria, CPAP is recommenced and continued for at least 24 hours. Then a new evaluation takes place and if the infant again meets the inclusion criteria another attempt of sudden wean can be undertaken. Infants are considered successfully weaned if they are off CPAP for three days.
89686267|NCT01721629|Other|Gradual wean of nasal CPAP pressure|The reduction of the CPAP pressure begins at the morning ward round and the pressure is reduced in steps with 1 cmH2O maximum once a day. Each time the pressure is to be reduced the infant needs to be evaluated according to the inclusion criteria and only if these are still met, will the pressure be reduced. When a CPAP pressure at 4 cmH2O is reached the infant is treated with this pressure for 24 hours and then the CPAP is discontinued. Infants are considered successfully weaned if they are off CPAP for three days.
89686268|NCT05448898|Experimental|Traditional Chinese Medicine with olfactory training|"Traditional Chinese Medicine therapy:~Oral Traditional Chinese Medicine CU Xiu Tang once a day for at least 3 months~Olfactory training:~repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months"
89686269|NCT05448898|Experimental|Olfactory training|repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
89686270|NCT00369616|Experimental|NicQb vaccine|
89686271|NCT00369616|Placebo Comparator|Placebo vaccine|
89686272|NCT00369694|Active Comparator|1|72 hours of Terlipressin
89686273|NCT00369694|Placebo Comparator|2|24 hours of Terlipressin & then next 48 hours of Dummy of Terlipressin
89686274|NCT01721707|Experimental|Latanoprost+Brinzolamide combination|Latanoprost 0.005%(50 mg/ml)+brinzolamide 1%(10mg/ml) eye drops
89686275|NCT01721707|Active Comparator|Latanoprost|Latanoprost 0.005% (50 mg / ml)
89686276|NCT03409783|Active Comparator|Active or ENSO Group|Active ENSO device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
89686277|NCT03409783|Sham Comparator|Sham Group|Sham device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
89686278|NCT03409705|Experimental|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
89686279|NCT03409705|Placebo Comparator|Control group|2,000 mg of placebo was orally administered per day for 12 weeks.
89686280|NCT05448586||Balanced anesthesia with opioids|Patients who had Major Surgery for gynecologic cancers (cervix, endometrium, ovarian and breast cancer) under balanced anesthesia including opioids between February 2019 and 2020 in Hospital La Paz.
89686281|NCT05448586||Opioid Free Anesthesia (OFA)|Patients who had Major Surgery for gynecologic cancers (cervix, endometrium, ovarian and breast cancer) under Opioid Free anesthesia between February 2019 and 2020 in Hospital La Paz.
89686282|NCT01726465|Experimental|N-acetylcysteine|Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.
89686283|NCT01726465|Experimental|Methylprednisolone|Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
89686284|NCT01726465|Placebo Comparator|Placebo|Patients were randomized to this arm will receive placebo (Ringer's acetate) in an hour after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
89686285|NCT02509936|Active Comparator|Standard of Care Arm|In this arm enrolled children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement.
89686286|NCT02509936|Experimental|Home-based Education|In the intervention arm, children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement. In addition, they will receive monthly home visits from a community health promoter who will provide detailed dietary assessments and individualized dietary coaching and education to parents.
89686287|NCT01720303|Experimental|Rep + NPH|
89686288|NCT01720303|Active Comparator|Premixed insulin/NPH|
89686289|NCT03216889|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6 weeks of CBT-I.
89686290|NCT03216889|Active Comparator|Control|6 weeks of stretching and thinking games.
89686291|NCT00912301|Experimental|NaCDC 500 mg|Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
89686292|NCT00912301|Experimental|NaCDC 1000 mg|Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
89686293|NCT00912301|Placebo Comparator|Placebo|Participants randomized to this arm received a placebo capsule each day for 4 days.
89686294|NCT04341766||Patient hospitalised with COVID-19 infection|Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan
89686295|NCT01726543|Active Comparator|Canaloplasty and phacoemulsification|
89686296|NCT01726543|Active Comparator|Non-penetrating deep sclerectomy and phacoemulsification|
89053566|NCT03454919|Other|Palbociclib|single arm
89053567|NCT00198822|Experimental|1|Weekly oral supplement with 7000 µg retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy
89686297|NCT03409627|Experimental|Group 1|Single infusion of INXN-4001, Dose 1
89686298|NCT03409627|Experimental|Group 2|Single infusion of INXN-4001, Dose 2
89686299|NCT04862416|Experimental|1A 30μg R0.6C Alhydrogel|3 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
89686300|NCT04862416|Experimental|1B 30μg R0.6C Alhydrogel + Matrix M1|3 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
89053568|NCT00198822|Experimental|2|Weekly oral supplement with 42 mg of beta-carotene from early pregnancy through 12 weeks following termination of pregnancy
89053569|NCT00198822|Placebo Comparator|3|Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy
89686301|NCT04862416|Experimental|2A 30μg R0.6C Alhydrogel|5 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
89686302|NCT04862416|Experimental|2B 30μg R0.6C Alhydrogel + Matrix M1|5 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
89686303|NCT04862416|Experimental|3A 100μg R0.6C Alhydrogel|3 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
89686304|NCT04862416|Experimental|3B 100μg R0.6C Alhydrogel + Matrix M1|3 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
89686305|NCT04862416|Experimental|4A 100μg R0.6C Alhydrogel|5 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
89686306|NCT04862416|Experimental|4B 100μg R0.6C Alhydrogel + Matrix M1|5 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
89686307|NCT01721863|Experimental|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
89686308|NCT01721863|No Intervention|control group|Control group conducted the usual care
89686309|NCT04850638|Experimental|SHR4640 tablets|
89686310|NCT01721941|Experimental|Phase I dose level -1|TH-302 25mg; Doxorubicin 50mg
89686311|NCT01721941|Experimental|Phase I Dose level 1|TH-302 50mg; doxorubicin 50mg
89686312|NCT01721941|Experimental|Phase I Dose level 2|TH-302 100mg; doxorubicin 50mg
89686313|NCT01721941|Experimental|Phase 1 Dose level 3|TH-302 150mg; Doxorubicin 50mg
89686314|NCT05448508|Experimental|Automatic Lancet|Manual lancet, needle tips and automatic lancets are used in the heel blood collection process. It has been reported that there may be complications arising from health professionals in the use of manual lancet or needle tip. In this study, an automatic lancet penetrating 2.4 mm-3 mm depth was used for safe puncture in term newborns.
89686315|NCT05448508|No Intervention|Control|No intervention, routine maintenance performed
89686316|NCT05448430|Experimental|predominant negative symptoms|iTBS for predominant negative symptoms
89686317|NCT05448430|No Intervention|positive symptoms|
89686318|NCT05448430|No Intervention|healthy control|
89686319|NCT01726387|Experimental|Psychosocial Counseling|A Counseling Assistant offers a low-threshold intervention (self-management support, counseling, active guidance). This nurse practitioner collaborates extensively with the general practitioner, re-adjusting the intervention in order to meet the patient's needs.
89686320|NCT01726387|Placebo Comparator|Usual Care|Depending on the conditions, patients get usual care of their general practitioner.
89686321|NCT01722175|Experimental|Arm I (ALPPS)|Patients undergo Associating Liver Partition with Portal Vein Ligation (ALPPS) step 1 surgery on day 0 and step 2 surgery 7-14 days later, based on patient's liver size.
89686322|NCT01722175|Active Comparator|Arm II (PVO)|Patients undergo portal vein occlusion (PVO) step 1 on day 0 and step 2 surgery 6-8 weeks later, based on patient's liver size.
89686323|NCT01726699||Cancer Diagnosis|
89686324|NCT04308096|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks (adult) or 2 weeks (pediatric) from Week 0 through Week 140.
89686325|NCT02512276|Experimental|Telepharmacist intervention|Patients diagnosed with diabetes, hypertension, or hyperlipidemia exhibiting sub-optimal adherence to their medications [defined as combined (average of averages) proportion of days covered (PDC) < 80%] who also have poor or worsening disease control.
89686326|NCT02512276|No Intervention|Usual care|Patients randomized to this arm will receive usual care.
89686327|NCT00915499|Active Comparator|ASV mode|
89053570|NCT05214976|Experimental|Single Group|
89686328|NCT00915499|Active Comparator|CPAP mode|
89686329|NCT01726777|Placebo Comparator|Control|30g normal cheddar cheese once per week
89686330|NCT01726777|Experimental|Vitamin D|30g cheddar cheese containing 28,000IU vitamin D once per week
89686331|NCT04833088|Other|Healthcare professionals|
89686332|NCT04833088|Other|Patients who suffer from spatial neglect|
89686333|NCT04833088|Other|Patients who have walking difficulties|
89686334|NCT04833088|Other|Patients who require long term use of an IV-stand|
89686335|NCT05532306|Experimental|Test product (T)|Subjects were served a standardized high caloric meal 30 minutes before the administration of a single film-coated tablet containing 400 mg Ribavirin (1*400mg) with approximately 240 ml of water
89686336|NCT05532306|Active Comparator|Reference product (R)|Subjects were served a standardized high caloric meal 30 minutes before the administration of two film-coated tablets each containing 200 mg Ribavirin (2*200mg) with approximately 240 ml of water
89686337|NCT01722253||placebo, electroacupuncture|"Electroacupuncture before and after surgery (40min and 60 min respectively) with frequency 2 Hz, and 'frequency scanning mode'.~Placebo electroacupuncture, in which the needles are secured (without penetrating the skin) and connected to the electrical device, which is not functional."
89686338|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 1 (12 to 14 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 12 to 14 years of age.
89686339|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 2 (15 to 17 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 15 to 17 years of age.
89686340|NCT01722409|No Intervention|sevoflurane and saline infusion|After induction of general anesthesia, Group S received a placebo infusion of normal saline.
89686341|NCT01722409|Experimental|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
89686342|NCT01722409|Experimental|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
89053571|NCT05204134|Experimental|Control-IQ Technology with Algorithm Derived Initial Profile Settings and Regular Updates|After CGM run-in, participants will begin use of Control-IQ technology with algorithm derived initial insulin delivery settings, then have regular settings updates from the algorithm through 13 weeks of use.
89053572|NCT00587262||1|Two pediatric participants with high frequency hearing loss post cochlear implant with either long or short electrode array.
89686343|NCT01726933|Experimental|LAS41008|up to 6 tablets/ day for 16 weeks double blind treatment period, randomized gastric resistant tablet
89686344|NCT01726933|Placebo Comparator|Placebo|up to 6 tablets/ day for 16 weeks randomized, double blind gastric resistant tablet
89686345|NCT01726933|Active Comparator|LASW1835|double blind, randomized gastric resistant tablet up to 6 tablets/ day for 16 weeks
89686346|NCT04707586|No Intervention|Control|No application will be made to patients in this group. Routine patient care will be provided. After the patients who develop pain are recorded, the application will be made with a cold application bandage.
89686347|NCT04707586|Experimental|experimental group|Patients in this group will be applied cold application with cold application bandage for 20 minutes as soon as the infusion begins.
89686348|NCT01722565|Experimental|Mesh Group|Patients receiving conventional sigmoid end colostomy plus a preperitoneal lightweight mesh Physiomesh® by laparoscopic procedure
89686349|NCT01722565|No Intervention|Control Group|Patients receiving conventional sigmoid end colostomy by laparoscopic procedure, without mesh
89686350|NCT04735198|Active Comparator|Experimental group|Patients with midgut neuroendocrine tumor who will undergo only primary tumor surgery.
89686351|NCT04735198|Experimental|Control group|Patients with midgut neuroendocrine tumor that will undergo through primary tumor surgery combined with prophylactic cholecystectomy.
89686352|NCT01727401|Experimental|Fondaparinux|Drug: fondaparinux once daily sc injections 2.5 mg if renal clearance of creatinine above 50 ml/min once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
89686353|NCT05532228||Obstructive sleep apnea|children with adenotonsillar hypertrophy and reports of nocturnal arousals/gasp/respiratory abnormalities
89686354|NCT05532228||No obstructive sleep apnea|children without adenotonsillar hypertrophy and no reports of nocturnal arousals/gasp/respiratory abnormalities
89686355|NCT05532228||Recurrent infections|Children with recurrent upper respiratory infections
89686356|NCT05532228||no recurrent infections|Children without recurrent upper respiratory infections
89686357|NCT02513212|Other|oxalate liquid, SnF2 paste, manual toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Manual toothbrush
89686358|NCT02513212|Other|oxalate liquid, SnF2 paste, power toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Power toothbrush
89686359|NCT05591508|Experimental|A, Intervention Arm|Ketogenic Diet +Standard care of Status epilepticus according to current guideline of management
89686360|NCT05591508|No Intervention|B, No Intervention Arm|Standard care of Status Epilepticus according to current guidelines of management
89686361|NCT02513446|Experimental|BI 1026706|Single dose
89686362|NCT02513446|Experimental|BI 1026706 + Itraconazole|7 days of itraconazole treatment combined with a single dose of 1026706 on day 4
89686363|NCT00363844|Experimental|E|
89686364|NCT04703062|Experimental|Experimental group 1|physical activity counseling group + exercise group
89053573|NCT00587262||2|Eight participants with high frequency hearing loss post cochlear implant with either short or long electrode array.
89686365|NCT04703062|Experimental|Experimental group 2|physical activity counseling group
89686366|NCT04687800|Experimental|Dextenza 0.4mg|Intracanalicular insert
89686367|NCT04687800|Active Comparator|Durezol 0.05%|difluprednate ophthalmic emulsion
89686368|NCT00864383|Placebo Comparator|Regimen 1 - 2EHRZ/4HR (control regimen)|"Eight weeks of chemotherapy with Ethambutol, Isoniazid, Rifampicin and Pyrazinamide plus the Moxifloxacin placebo, followed by~Nine weeks of Isoniazid and Rifampicin plus the Moxifloxacin placebo, followed by~Nine weeks of Isoniazid and Rifampicin only."
89686369|NCT00864383|Experimental|Regimen 2 - 2MHRZ/2MHR|"Eight weeks of chemotherapy with Moxifloxacin, Isoniazid, Rifampicin and Pyrazinamide plus the Ethambutol placebo, followed by~Nine weeks of Moxifloxacin, Isoniazid and Rifampicin, followed by~Nine weeks of the Isoniazid placebo and the Rifampicin placebo."
89686370|NCT00864383|Experimental|Regimen 3 - 2EMRZ/2MR|"Eight weeks of chemotherapy with Ethambutol, Moxifloxacin, Rifampicin and Pyrazinamide plus the Isoniazid placebo, followed by~Nine weeks of Moxifloxacin and Rifampicin plus the Isoniazid placebo, followed by~Nine weeks of the Isoniazid placebo and the Rifampicin placebo"
89686371|NCT05532072|Experimental|The group of Meprednone combined with Rapamycin|The specific dose of methylprednisolone pulse therapy is 500mg / week * 6 + 250mg / week * 6. RAPA has rich experience in the application of renal transplantation, and the recommended maintenance amount for renal transplant patients is 2 mg / day. The efficacy benefits of doses above 2 mg are unclear, and the overall safety of Rapa 2 mg is better than that of patients taking Rapa 5 mg daily. Therefore, based on the clinical experience and clinical research data of RAPA, we would select the dose of Rapamycin as 2mg / day. The experimental group received rapamycin 2 mg/day orally for 24 weeks on the basis of methylprednisolone pulse therapy, and monitor the blood concentration of Rapa at the end of the first week and the end of the 12th week.
89686372|NCT05532072|Other|The group of Meprednone alone|The specific dose of methylprednisolone pulse therapy is 500mg / week * 6 + 250mg / week * 6. The effect of methylprednisolone pulse therapy on moderate and severe active Tao has been widely verified in clinical work. EUGOGO will take methylprednisolone pulse therapy as the first-line treatment of moderate and severe active Tao in 2020.
89686373|NCT03216772|Experimental|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using the Olympus PK Morcellator in PneumoLiner containment device
89686374|NCT02514070|Experimental|EPA-rich fish oil arm then DHA-rich fish oil arm|Subjects randomized to the EPA-rich fish oil arm will take the equivalent to 3g of EPA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the DHA-rich capsule arm
89686375|NCT02514070|Experimental|DHA-rich fish oil arm then EPA-rich fish oil arm|Subjects randomized to the DHA-rich fish oil arm will take the equivalent to 3g of DHA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the EPA-rich capsule arm
89686376|NCT00864539|Experimental|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 mL
89686377|NCT00864539|Active Comparator|plain milk|daily intake of 200 mL plain milk
89686378|NCT00864539|Experimental|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium
89686379|NCT00864539|Active Comparator|plane juice|subjects receiving plain orange juice
89686380|NCT00864539|Experimental|vitamin D-Ca supplement|Subjects receiving daily supplement containing 500 mg + 200 IU vitamin D
89686381|NCT00864539|Placebo Comparator|Placebo|Subjects receiving daily placebo containing 1g starch
89686382|NCT03143920|Experimental|Hyperbaric Oxygen|Hyperbaric oxygen therapy-2.4 atmosphere absolute for 90 minutes with 2-five minute air breaks administered daily, 5 days per week for 8 weeks total treatment.
89686383|NCT00827255||Patients who received Restasis®|Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)
89686384|NCT02442102|Experimental|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
89686385|NCT05235503|Experimental|20mg Oxycodon (capsule) + 100 mg Bedrocan (vaporized)|As stated above
89686386|NCT05235503|Placebo Comparator|Placebo oxycodon (capsule) + 100 mg Bedrocan (vaporized)|As stated above
89686387|NCT02153489|Experimental|Aclidinium bromide|Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
89686388|NCT02153489|Placebo Comparator|Placebo|Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
89686389|NCT04634344|Experimental|DZD2269 as monotherapy|
89686390|NCT04600102||GROUP 1|Healthy able-bodied individuals with no history of lower extremity trauma.
89686391|NCT04600102||GROUP 2|Individuals with unilateral, below knee functional deficits that require an AFO for daily activities (e.g. fracture, muscle and/or nerve injury, ankle arthritis, or peripheral neurologic disease).
89686392|NCT00866879|Active Comparator|Control|Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.
89686393|NCT00866879|Experimental|Transition to Sirolimus Group|Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus
89686394|NCT00866879|Other|Donors|Data and blood samples from the donors are collected in this study to contribute to the general knowledge to be used in assessing the two donor recipient groups, which are the target of this study.
89686395|NCT02311920|Experimental|Arm I (temozolomide and ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and then beginning 3 months after course 4 once every 3 months for 4 courses in the absence unacceptable toxicity.
89686396|NCT02311920|Experimental|Arm II (temozolomide and nivolumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes once every 2 weeks for 16 weeks and then once every 2 weeks for 48 weeks in the absence unacceptable toxicity.
89686397|NCT02311920|Experimental|Arm III (temozolomide, nivolumab, ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and nivolumab IV over 60 minutes once every 2 weeks for 64 weeks in the absence unacceptable toxicity.
89686398|NCT02153723|Experimental|Copaxone|"Dose escalation:~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection."
89686399|NCT04388878|Experimental|PF-07054894|Participants will receive single or multiple ascending doses of oral PF-07054894
89686400|NCT04388878|Placebo Comparator|Placebo|Participants will receive matching placebo
89686401|NCT00828191|Experimental|Progesterone SC|
89053574|NCT00587262||3|Fifteen participants from the existing Cochlear Implant data base.
89053575|NCT04673747|Experimental|Group 1 (Total Hip Arthroplasty with intraoperative manual correction)|Patients will undergo total hip arthroplasty with intraoperative manual correction of Iliosacral displacement of the sacroiliac joint
89686402|NCT00828191|Active Comparator|Progesterone Tablets|
89686403|NCT04571320|Experimental|Summer STRIPES|Up to two weeks of daily high school orientation (four hours per day) immediately prior to the start of ninth grade, staffed by peer interventionists (2:1 ratio + extra interventionist in case of absences) and a school staff member. Two sessions of summer parent training. During the school year, ninth grade students will continue to meet weekly with their peer interventionists in a group setting under the supervision of the school staff sponsor. School year follow-up component of summer STRIPES will occur for 16 weeks and will include weekly 30 minute meetings between peer and target students. Parent components during the school year will include optional monthly group problem solving sessions with the school staff sponsor and school mental health liaison and a weekly phone call (up to five minutes) from the school staff sponsor to discuss home contingency management.
89686404|NCT04571320|Active Comparator|Enhanced School Services as Usual|Students who are assigned to the SSU plus group will be referred to their identified school counselor for referral to services available in the school setting. The counselor will be provided with a report from the student's intake assessment that summarizes the student's symptoms and presenting problems. The student will also receive new school supplies at the beginning of ninth grade. In our past trials, SSU plus students typically received subject-specific tutoring or after-school homework help. We will systematically track services received by students in the SSU plus condition.
89686405|NCT05531838|Other|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system for Fu Lishan instant sense hospital), on the basis of the original eating habits of patients, according to the guidelines and the training of MMC center, patients are guided to adjust the diet model according to the glucose map monitored by the dynamic glucose monitoring system and the log recorded, so as to implement therapeutic monitoring, control the blood glucose level within the target range as far as possible, and record the amount of various foods accordingly, After that, the eating method and amount remained basically unchanged.
89686406|NCT00867659|Experimental|Cetrotide acetate|oocyte donors will receive cetrotide acetate on the day of oocyte retrieval. The incidence of OHSS will be assessed.
89686407|NCT00912925|Placebo Comparator|Placebo|Patients in the placebo-control group were administered a solution of 100 millimolar (mM) sodium phosphate, 150 mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over approximately 4 hours once weekly for 26 weeks.
89686408|NCT00912925|Active Comparator|Aldurazyme treatment|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 Units/kg (approximately 0.58 mg/kg = labeled dose) administered intravenously over approximately 4 hours once weekly for 26 weeks.
89686409|NCT05531058|Experimental|AI-driven vaccine communicator intervention group|The intervention will include six modules web-based psychoeducation programme (two modules sessions weekly, each module lasts for 15-20 minutes) which includes educational materials, animations of vaccine research and development, and an MI communication skills-based AI, digital assistant.
89686410|NCT05531058|Active Comparator|Self-learning of COVID-19 vaccine knowledge control group|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge.
89686411|NCT04549870|Active Comparator|Roflumilast|Roflumilast 500 microgram daily (capsule)
89686412|NCT04549870|Placebo Comparator|Placebo|Placebo (capsule)
89686413|NCT00828347|Other|1.0 μg/day Alfacalcidol|Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months
89686414|NCT00828347|Other|0.25 μg/day Alfacalcidol|Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months
89686415|NCT05531760||DMEK-operated eyes without graft detachment|Eyes operated with DMEK without graft detachment
89686416|NCT05531760||DMEK-operated with graft detachment|Eyes operated with DMEK with graft detachment
89686417|NCT00829049|Active Comparator|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
89686418|NCT00829049|Active Comparator|Adapalene Gel 0.3%|1 pea-size amount, QD x 16 weeks
89686419|NCT03835429|Experimental|MyTAP oral appliance plus mouth shield|MyTAP plus mouth shield
89686420|NCT01727479|Experimental|Ribose|After each of the 3km time trial (3 in total), consumption of ribose incorporated in a sports drink.
89686421|NCT01727479|Placebo Comparator|Placebo|After each of the 3km time trial (3 in total), consumption of placebo incorporated in a sports drink.
89686422|NCT00868751|Experimental|Tocilizumab|Single arm study - treatment only
89686423|NCT01727557|Active Comparator|Local anesthesia|
89686424|NCT01727557|Active Comparator|regional anesthesia|
89686425|NCT04529044|Experimental|Treatment (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV over 30-40 minutes during weeks 1, 8, 16, and 24 in the absence of disease progression or unacceptable toxicity.
89686426|NCT01821144|Other|Control|No salt awareness education
89686427|NCT01821144|Experimental|Salt reduction|Salt reduction
89686428|NCT00913003|Placebo Comparator|Placebo|Group B using saline as a placebo.
89686429|NCT00913003|Active Comparator|Lidocaine|Group A lidocaine infusion and bolus.
89686430|NCT00869141|Experimental|Research arm (postop IOP>10)|Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
89686431|NCT00869141|Active Comparator|Standard of care arm (postop IOP>17)|Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
89686432|NCT05530902|Experimental|Patients with musculoskeletal pain|Patients with musculoskeletal pain
89686433|NCT01722799|Experimental|Drug elluting Balloon (DEB)|Is a coronary dilating device with Paclitaxel ® drug delivery, for dilatation and provisional spot bare metal stenting (BMS).
89686434|NCT01722799|Active Comparator|Drug elluting coronary stent (DES)|The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.20 mm.
89686435|NCT01727635|Experimental|counseling|body-mind-spirit group therapy
89686436|NCT03408925|Experimental|Intervention|The intervention consists of an exercise program developed by the medical team of the National Federation of Orienteering. Specifically, it consists of four exercises targeting strength, flexibility and coordination of the lower extremity. The orienteerers are asked to perform the exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function (online supplement). Each second week the exercises' difficulty level is increased.
89686437|NCT03408925|No Intervention|Control|Normal training, no intervention
89686438|NCT01722955|Experimental|Pre-warmed fluids|Pre-warmed fluids will be prepared for 8hous in 41℃ set hot cabinet.
89686439|NCT01722955|Experimental|Room temperature fluids|Room temperature fluids will be stored at ambient temperature.
89686440|NCT04216420|Experimental|MERM-observed self-administered therapy (SAT)|A participant in the intervention arm (n = 57) will receive a 15-day TB medication supply in the evriMED500 MERM device to self-administer. The participant returns every 15 days, where the healthcare provider counts any remaining tablets in the pillbox device, connects the MERM module with a computer and downloads the pill-taking data, reviews the event reports together with the participant and captures the data, underwent IsoScreen urine isoniazid test and refills the participant with a 15-day medication supply in the MERM device.
89053576|NCT04673747|Active Comparator|Group 2 (Total hip Arthroplasty: standard method)|Patients will undergo total hip arthroplasty according to the standard method
89053577|NCT05181436||Malaysian children aged ≥ 6 months to ≤ 36 months|The study population consists of Malaysian children aged ≥ 6 months to ≤ 36 months seen at Mother and Child Health Clinic (MCHC).
89053578|NCT04674098||Usual Care|Every patient who is admitted or transferred to the target unit during both the baseline and intervention phases of the study will be approached by a member of the research staff to be a subject in the study. The patient will be informed of the overall study objectives and be requested to provide informed consent to participate. The patient's involvement in the study will include having the research staff access and extract relevant outcome variables collected from their electronic health record (EHR) (AEs, admissions to the ICU, hospital length of stay and activation of the rapid response team) as a result of their hospital stay.
89053579|NCT04674098||Intervention|If the patient provides consent during the intervention phase, the BAS technology will passively monitor their vital signs generated by the Philips vital sign monitor by relaying their deidentified vital signs data to the CLU, proprietary Cloud server, and subsequently Lumori® on a study-issued cell phone of the RN who is primarily responsible for the patient's care. Patient's admitted or transferred to the targeted unit will NOT be excluded from being approached to participate in the study.
89053580|NCT01137292||Active Treatment|Patients who are eligible for voriconazole treatment according to their physician decision.
89053581|NCT00197496|Experimental|BWSTT|Body weight supported treadmill training
89053582|NCT00197496|No Intervention|Usual care|Usual care
89053583|NCT04312477|Experimental|Experimental group|Modified Gegen Qinlian Decoction, Oral, 7.2g per bag, 2 times / day, 30 minutes before breakfast and dinner
89053584|NCT04312477|Active Comparator|Control group|Bifico(Bifidobacterium triple viable capsule), orally，2 capsules/time, 2 days/time.
89053585|NCT05367154||Eyes with SMILE surgeries|Eyes with SMILE surgeries which were performed by three surgeons with different experiences.
89053586|NCT04673981|Experimental|patient treated for a oral cavity and oropharynx cancer|questionnaire and tests to evaluate neuropathic pain
89053587|NCT05176795||Experimental|Child under 10 years old newly diagnosed with JIA, IBD or T1DM
89053588|NCT05176795||Active Comparator: Healthy control|Brother/sister of child with pediatric onset inflammatory disease (same age category - same environment: food, living space)
89053589|NCT02883478|Active Comparator|Treatment group A|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 3 milliwatt/cm² (mW/cm²) for 30 minutes.~Device: UV-X 1000 irradiator (3 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
89053590|NCT02883478|Active Comparator|Treatment group B|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 9 mW/cm² for 10 minutes.~Device: UV-X 2000 irradiator (9 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
89686441|NCT04216420|No Intervention|Standard directly observed therapy (DOT)|"The provider handles a participant in the control arm (n = 57) according to the standard DOT, where the participant visits the healthcare facility each day throughout the intensive phase to swallow the daily dose with direct observation by the healthcare provider. The participant will undergo the urine isoniazid test every 15 days.~Both arms will be treated based on the WHO-recommended two-month fixed-dose-combination of first-line anti-TB drug (2RHZE) delivered as a single daily dose and followed throughout the intensive phase that lasts two months. In the end, participants will undergo a microbiological test to assess sputum smear conversion and trained study staff will complete several data tools, including a treatment outcome monitoring tool, adherence self-report, HRQoL, cost, treatment satisfaction, and MERM usability tools."
89686442|NCT00829985|Experimental|Glycerinated German Cockroach Allergenic Extract|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered concentrated (1:20 weight per volume [w/v]) daily doses of glycerinated German cockroach allergenic extract (50% glycerin) placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The extract was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
89686443|NCT00829985|Placebo Comparator|Placebo|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered daily doses of placebo placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The placebo was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 weight per volume [w/v]) was achieved.
89686444|NCT01606176|Experimental|GW-1000-02|Each 100 μl actuation contains 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose was 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
89686445|NCT01606176|Placebo Comparator|Placebo|Each 100 μl actuation contains the excipients only. The maximum permitted dose was 48 actuations in any 24 hour period
89686446|NCT00913081|Experimental|Quercetin 500 mg|Quercetin 500 mg once, administered one hour before 500 mg immediate-release niacin
89686447|NCT00913081|Experimental|Quercetin 1000 mg|Quercetin 1000 mg once, administered one hour before 500 mg immediate-release niacin
89686448|NCT00913081|Experimental|Quercetin 2000 mg|Quercetin 2000 mg once, administered one hour before 500 mg immediate-release niacin
89686449|NCT00913081|Placebo Comparator|Placebo|Placebo once, administered one hour before 500 mg immediate-release niacin
89686450|NCT04077424|Active Comparator|Fluzone-High Dose|FDA approved high dose inactivated influenza vaccine (HD-Fluzone)
89053591|NCT00197145|Experimental|GW873140|
89053592|NCT04674137|Experimental|XC8 100 mg|XC8 100 mg orally
89053593|NCT04674137|Placebo Comparator|Placebo|Placebo orally
89053594|NCT01136785|Active Comparator|Active CPAP therapy|7 days of treatment in the laboratory with active CPAP therapy.
89053595|NCT01136785|Sham Comparator|Sham CPAP therapy|7 days of sham CPAP therapy in the laboratory.
89053596|NCT04673864|Experimental|Sequence 1|"Period 1: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 2: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 3: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 4: CKD-386- A single oral dose of 1 tablet under fasting condition"
89053597|NCT04673864|Experimental|Sequence 2|"Period 1: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 2: D012, D326, D337- A single oral dose of 3 tablets under fasting condition~Period 3: CKD-386- A single oral dose of 1 tablet under fasting condition~Period 4: D012, D326, D337- A single oral dose of 3 tablets under fasting condition"
89053598|NCT04312321|No Intervention|CONTROL|CONTROL group: low urgency cases with routine operation of paramedic crew with optional consultation with a doctor over the phone.
89053599|NCT04312321|Experimental|PHONE|In the PHONE group, there will be a mandatory consultation of a doctor over the phone in all low urgency cases.
89053600|NCT04312321|Experimental|VIDEO|In the VIDEO group, there will be a mandatory consultation of a doctor over the audiovisual consultation in low urgency cases
89686451|NCT04077424|Active Comparator|Fluad|Adjuvanted (MF59) inactivated influenza vaccine (Fluad)
89686452|NCT04077424|Active Comparator|Recombinant Hemagglutinin vaccine (Flublok)|Recombinant hemagglutinin vaccine
89686453|NCT05597592|Experimental|Patients with neuromuscular or neurogenerative disease|
89686454|NCT00869375|Active Comparator|CLEARWAY GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous in situ thrombolysis (local thrombolytic plus low pressure balloon angioplasty) with Clearway balloon
89686455|NCT00869375|Active Comparator|ANGIOJET GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy with AngioJet Rheolytic Thrombectomy System
89686456|NCT01727869|Experimental|Cohort 1|Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
89686457|NCT01727869|Experimental|Cohort 2|Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
89686458|NCT01727869|Experimental|Cohort 3|Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
89686459|NCT04425330|Experimental|physiotherapy exercises + PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The irradiation will be with LED with a wavelength of 850 nm, energy per point of 25 J, 50 seconds per point and power of 200 mW.~Treatment will be performed in 24 sessions 2 times a week"
89686460|NCT04425330|Sham Comparator|physiotherapy exercises + SHAM PBM|"Physiotherapy exercises will be individualized and personalized for each child. It will take into account complaints and / or motor delay resulting from the injury. Circuit exercises will be performed involving muscle strengthening exercises, sensory stimulation and balance.~For irradiation, the subjects will be positioned comfortably in prone position on the examination table. Four points will be irradiated above the injury level. The level of the lesion will be located by palpation. The same LED device will be used in groups. However, in the placebo group (Sham), the device does not emit light.~Treatment will be performed in 24 sessions 2 times a week"
89686461|NCT02684266|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen
89686462|NCT01723033||EEG acquisition|15 PTSD patients and 15 OCD patients who will, while wearing a net of electrodes for EEG acquisition on their heads, perform three error detection tasks.
89686463|NCT01723033||Control|Previously collected healthy student's data
89686464|NCT00869609|Active Comparator|GLB Traditional Maintenance (TM)|Group Lifestyle Balance (GLB) program Traditional Maintenance: After completion of the GLB 12 core sessions, participants who are randomly assigned to GLB program Traditional Maintenance (TM) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions.
89686465|NCT00869609|Active Comparator|GLB-Carb-focused Maintenance (CF)|Group Lifestyle Balance (GLB) program Carb-focused Maintenance: After completion of the GLB 12 core sessions, participants randomly assigned to GLB Carb-focused Maintenance (CF) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information regarding healthy carbohydrate intake and hunger management.
89686466|NCT04379167|Experimental|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma.
89686467|NCT01603368|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938, 125 million bacteria/day
89686468|NCT01603368|Placebo Comparator|Placebo|The same oil drops as the active study product but without Lactobacillus reuteri
89686469|NCT00370942|Placebo Comparator|GW823093C A|A=45 mg
89686470|NCT00370942|Placebo Comparator|GW823093C B|B=30 mg
89686471|NCT00370942|Placebo Comparator|GW823093C C|C=15 mg
89686472|NCT01727947|Experimental|MSOME|Couples in which the sperm cells were analysed through MSOME
89686473|NCT01728103||No Treatment|
89053601|NCT04312438|Experimental|13 mo to 15 yo children diagnosed with Cow's Milk Allergy|oral food challenge with cow's milk proteins
89686474|NCT04476628|Other|Budesonide 5MR then 1MR|"All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.~st time period: Patients will undergo a 2 week washout period. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.~nd time period: 5MR administration method once daily for 8 weeks in duration.~rd time period: Patients will undergo a 2 week washout period of daily. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.~th time period: 1MR administration method once daily for 8 weeks in duration."
89053602|NCT04673474|Experimental|Arm A|Hemay022 Period 1, Fasted control → Period 2, Fed control
89053603|NCT04673474|Experimental|Arm B|Hemay022 Period 1, Fed control → Period 2, Fasted control
89053604|NCT00197106|Active Comparator|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg
89053605|NCT00197106|Other|fluticasone propionate 2 x 100 mcg|fluticasone propionate 2 x 100 mcg
89053606|NCT01136746|Active Comparator|Sliding scale regular insulin|
89053607|NCT01136746|Experimental|Basal-bolus therapy|
89053608|NCT02883751|Active Comparator|Control group|Control group - gold standard: Conventional ulcer treatment with Rayon® and essential fatty acids (Dersani®). Cleaning of the surgical wound will be performed with saline solution. The wound will then be covered with a sterile polyethylene film, over which the LED plate will be positioned for placebo treatment (emission of sound, but with the device switched off). After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
89053609|NCT02883751|Experimental|LED group|LED group: Cleaning of the surgical wound will be performed with saline solution and the wound will be covered with a sterile polyethylene film, over which the LED plate will be positioned for active treatment with the device switched on. After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
89053610|NCT04673435|Experimental|Permeaderm as temporary coverage|A: temporary coverage with PermeaDerm until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
89053611|NCT04673435|Active Comparator|FHCA as temporary coverage|B: temporary coverage with FHCA until autografting: After randomization of study site, study dressing will be applied as temporary coverage on freshly excised full-thickness burn wounds.
89053612|NCT04673435|Experimental|Permeaderm over widely meshed autograft|C: temporary coverage of widely meshed autograft with PermeaDerm until healing occurs and PermeaDerm can remove
89053613|NCT04673435|Active Comparator|FHCA over widely meshed autograft|D: temporary coverage of widely meshed autograft with FHCA until healing occurs
89686475|NCT04476628|Other|Budesonide 1MR then 5MR|"All participants will administer budesonide daily via Mucosal Atomization Device (MAD) with a minimum requirement of at least five days a week for the duration of the study in this arm.~st time period: Patients will undergo a 2 week washout period. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.~nd time period: 1MR administration method once daily for 8 weeks in duration.~rd time period: Patients will undergo a 2 week washout period of daily. The washout period will involve standard of care daily non-medicated intranasal saline irrigation.~th time period: 5MR administration method once daily for 8 weeks in duration."
89686476|NCT01728181|Experimental|Phase I|Will receive Tivozanib and Erlotinib treatment.
89686477|NCT01728181|Other|Phase II Group 1 (Standard of Care)|"Group 1: VeriStrat® predicts the chance of no benefit from erlotinib~• The patient will get standard-of- care"
89686478|NCT01728181|Active Comparator|Phase II Group 2 (arm 1)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 1: Patient will get the study drugs Erlotinib and Tivozanib"
89686479|NCT01728181|Placebo Comparator|Phase II Group 2 (arm 2)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 2: Patient will get the study drug erlotinib and placebo"
89686480|NCT01728493||Part 1|- newly diagnosed hypertensive patients in general practice
89686481|NCT01728493||Part 2:|"newly diagnosed hypertensive patients with primary aldosteronism~newly diagnosed hypertensive patients with essential hypertension"
89686482|NCT01728493||Part 3:|"newly diagnosed hypertensive patients with normokalemic primary aldosteronism~newly diagnosed hypertensive patients with essential hypertension"
89686483|NCT04378231|Experimental|high-dose group|patients take dry suspension of amoxicillin clavulanate potassium 45 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
89686484|NCT04378231|Experimental|standard dose group|patients take dry suspension of amoxicillin clavulanate potassium 30 mg/kg/ time (amoxicillin) orally twice a day, total daily dose not exceeding 2 g, and the course of treatment is two weeks.
89686485|NCT04475302|Experimental|Intervention arm|In the identified hotspots, BCG vaccine will be offered to all the elderly between 60 - 80 years of age. Those who get vaccinated will be followed for a period of 6-months.
89686486|NCT04475302|No Intervention|Control arm|"in the hotspots, those who do not agree for vaccination, will be considered as controls. They will have an entry and exit interview at baseline and end of study period~in situations where we are unable to enrol the required number of controls from the vaccination hotspot zones, then hotspots in the neighbouring area / wards where BCG is not offered will be taken as control sites. Elderly between 60-80 years in those areas would be considered as control sites for the study. The elderly participants will be approached for an entry and exit interview, if they agree. If they do not agree for an exit interview at the end of 6-months, then the status of those in the control group would be collected either from the corporation records / other medical database."
89686487|NCT04378309|Experimental|ePrep|The ePREP program is the online version of the Prevention and Relationship Enhancement Program. It consists of 6 self-directed online sessions and accompanying homework and brief coach calls.
89686488|NCT01728571|Active Comparator|Vitamin D3 + fish oil|Dietary Supplement: vitamin D3 Drug: omega-3 fatty acids (fish oil)
89053614|NCT00587340||1|15 subjects with subjective sleep disturbance based on the Pittsburgh Sleep Quality Index
89053615|NCT00587340||2|mild/moderate subjective sleep disturbance (insomnia) based on the Pittsburgh Sleep Quality Index
89686489|NCT01728571|Active Comparator|Vitamin D3 + fish oil placebo|Dietary Supplement: vitamin D3 Dietary Supplement: fish oil placebo
89686490|NCT01728571|Active Comparator|Vitamin D3 placebo + fish oil|Drug: omega-3 fatty acids (fish oil) Dietary Supplement: vitamin D3 placebo
89686491|NCT01728571|Placebo Comparator|Vitamin D3 placebo + fish oil placebo|Dietary Supplement: vitamin D3 placebo Dietary Supplement: fish oil placebo
89686492|NCT00832637|Experimental|Gemcitabine, Cisplatin, Erlotinib|A combination of Cisplatin at 40 mg/m2 + Gemcitabine at 1000 mg/m2, every 28 days + Erlotinib 100 mg daily, orally. Cycles will be repeated every four weeks.
89686493|NCT04338490|Experimental|Intervention|
89686494|NCT04338490|No Intervention|Control|
89686495|NCT05191901|Experimental|stress ball group|
89686496|NCT05191901|No Intervention|control group|
89053616|NCT00587340||3|severe subjective sleep disturbance (insomnia)based on the Pittsburgh Sleep Quality Index
89686497|NCT03408301||Tourniquet deflation|Tourniquet deflation after insertion of the prosthetic components during total knee replacement arthroplasty under spinal anesthesia
89686498|NCT05186285|Experimental|CM338 30mg, IV|30mg, single dose, IV
89053617|NCT02883322||Initial|Patients answering the initial translation
89053618|NCT02883322||Committee-only|Patients answering the translation modified by an expert committee
89053619|NCT02883322||BT-only|Patients answering the translation modified with the use of a back-translation
89053620|NCT02883322||Both|Patients answering the translation modified by an expert committee with the use of a back-translation
89053621|NCT01136356|Experimental|Morphine, then Buprenorphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day). Participants then underwent an 18-day period of spontaneous opioid withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
89053622|NCT01136356|Experimental|Buprenorphine, then Morphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day). Participants then underwent an 18-day period of spontaneous withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
89053623|NCT00587379|Active Comparator|1|Patients randomized to take 1 40mg Atorvastain pill per day for 6 week study period
89053624|NCT00587379|Placebo Comparator|2|Patients randomized to 1 40mg placebo pill per day for 6 week study
89053625|NCT04673396|Experimental|Tolerance test|The design is based on 3+3 dose escalation: three subjects were enrolled in each dose group, administered once a day for 2 weeks, and were observed for 7 days after withdrawal. If dose-limiting toxicity (DLT) was not observed, the dose was incresed to the next dose group. If dose-limiting toxicity (DLT) was found in 2 or more patients in a given dose group, the climbing test was terminated and the dose was reduced by 1 dose. If there were only three subjects, three more subjects were observed, so that the MTD dose group had at least six evaluable subjects.If DLT occurs in 1 patient in a given dose group, 3 more subjects should be added to that dose group. If DLT occurs in 1 or more of these 3 subjects, the climb will be stopped and the dose group will be reduced by 1 dose group. If there are only 3 subjects, 3 more subjects will be observed, so that at least 6 patients in the MTD dose group can be evaluated.
89686499|NCT05186285|Experimental|CM338 60mg, IV|60mg, single dose, IV
89053626|NCT04673396|Experimental|Pharmacokinetic studies|At the same time of tolerance test, blood PK sampling was performed. At the end of the tolerance test in each group, on the premise of good safety, and after evaluation by the researchers, additional cases were selected from the three dose groups (low, medium and high) for pharmacokinetic study, so as to ensure that at least 8 patients could be evaluated for PK in each group.
89053627|NCT04673396|Active Comparator|Comparative Study|It is planned to select the 20mg dose of norcantharidin sodium for injection to carry out pharmacokinetic study of 8 cases. The specific research design will be formulated after the tolerance and pharmacokinetic test of norcantharidin lipid microsphere injection is completed.
89053628|NCT00637390|Experimental|one|
89053629|NCT00637429||General Co-infection|Individuals with HIV infection and hepatitis B surface antigen positive results who are currently receiving or planning to commence HAART.
89053630|NCT00587418|Experimental|Arginine|
89053631|NCT00587418|Placebo Comparator|Placebo|
89053632|NCT04673669|Experimental|Single group|measuring the strength of the tendon of the posterior tibial muscle in healthy subjects with a hand-held dynamometer by two examiners and with an isometric dynamometer
89053633|NCT00196326|Experimental|DR-1011|Participants were instructed to take, by mouth, one tablet daily for four 91-day cycles.
89053634|NCT04673318|No Intervention|Control|Course of recovery with standard of care.
89053635|NCT04673318|Active Comparator|Exercise training|low resistance velocity based exercise training ~40 min, 3 times a week at home for 8 weeks
89053636|NCT04673318|Experimental|heat therapy|heat therapy (~40C skin temperature) with a leg garment 5 times a week for 40-55 min for 8 weeks
89053637|NCT00587496|Experimental|1|placebo, 6 capsules per day for 30 days
89053638|NCT00587496|Experimental|2|500 mg Valtrex one capsule per day plus 5 capsules of placebo per day for 30 days
89053639|NCT00587496|Experimental|3|500 mg Valtrex capsule one per day, Acetylsalicylic acid (aspirin) 325 mg capsules three per day, plus 2 placebo capsules per day for 30 days
89686500|NCT05186285|Experimental|CM338 120mg, IV|120mg, single dose, IV
89686501|NCT05186285|Experimental|CM338 240mg, IV|240mg, single dose, IV
89686502|NCT05186285|Experimental|CM338 240mg, SC|240mg, single dose, SC
89686503|NCT05186285|Experimental|CM338 480mg, IV|480mg, single dose, IV
89686504|NCT05186285|Experimental|CM338 600mg, IV|600mg, single dose, IV
89686505|NCT05186285|Experimental|CM338 600mg, SC|600mg, single dose, SC
89686506|NCT05186285|Placebo Comparator|Placebo|Placebo, single dose, IV or SC
89686507|NCT03408223|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
89686508|NCT03408223|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12-20 Gy on Days -8 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
89686509|NCT00918229|Other|balloon implantation|implantation of an absorbable perirectal spacer balloon
89686510|NCT00370240|Experimental|Ropivacaïne|
89686511|NCT00370240|Placebo Comparator|placebo|
89686512|NCT03408145|Placebo Comparator|Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml and 1ml of Saline) comprising a total volume of 8.5ml fluid during one procedure.
89686513|NCT03408145|Active Comparator|Hyaluronic Acid & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Saline) comprising a total of 8.5mL fluid during one procedure.
89686514|NCT03408145|Active Comparator|Amniotic Tissue & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Saline and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
89686515|NCT03408145|Experimental|Amniotic Tissue & Hyaluronic Acid|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
89686516|NCT01663896||Single or multi vessel disease|Pre- and post-PCI fractional flow reserve (FFR) and OCT were performed in participants.
89686517|NCT02475772|Experimental|Cisplatin and doxorubicin|Cisplatin and doxorubicin will be applied under pressure into the abdomen via laparoscopic trocars. The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
89686518|NCT04338256||Students enrolled in the Wellness Course|Students in this group are enrolled in the Wellness Course for the Spring 2020 or Fall 2020 semesters
89686519|NCT04338256||Controls|Students in this group are enrolled at study sites during the Spring 2020 or Fall 2020 semesters, but are not enrolled in the Wellness Course
89686520|NCT00915655|Experimental|DRV/rtv (darunavir/ritonavir)|Patients will receive darunavir tablets 2 x 400 mg in combination with ritonavir capsule 100 mg once daily for 48 weeks along with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) ie, either zidovudine/lamivudine or abacavir/lamivudine
89686521|NCT05531682|Experimental|Experimental: HB0017 dosing regimen 1|HB0017 low dose short intervals of subcutaneous injection
89686522|NCT05531682|Experimental|Experimental: HB0017 dosing regimen 2|HB0017 low dose long intervals of subcutaneous injection
89686523|NCT05531682|Experimental|Experimental: HB0017 dosing regimen 3|HB0017 high dose long intervals of subcutaneous injection
89686524|NCT05531682|Placebo Comparator|Placebo Comparator: placebo group|Placebo was subcutaneously injected into the 12 weeks turnover HB0017 subcutaneous injection
89686525|NCT03622138|Experimental|Naive EBP Providers|Naive Providers (providers with no prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
89686526|NCT03622138|Experimental|Experienced EBP Providers|Experienced EBP Providers (providers with prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
89686527|NCT04379323|Experimental|YuWell YE900 and mercury sphygmomanometer|Blood Pressure Measurement with the YuWell YE900 Electronic Sphygmomanometer (YuWell YE900) and with Desk Mercury Sphygmomanometer.
89686528|NCT01728649|No Intervention|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA approved devices. After which patient will be started on normothermia attempting to keep core body temp between 38 and 36.5 degrees centigrade. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
89686529|NCT01728649|Experimental|Mild Hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA cleared device. Patient will also have a Quattro catheter placed in the femoral vein and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours and then be rewarmed very slowly. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
89686530|NCT03835507|Placebo Comparator|Control group|Inject Normal saline 100ml * 12 times (1month apart)
89686531|NCT03835507|Experimental|Low dose group|Inject 500IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
89686532|NCT03835507|Experimental|High dose group|Inject 750IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
89686533|NCT05530746||Control|Volunteers with no significant abnormalities on colonoscopy were given informed consent to obtain colon tissue biopsies and fecal specimens.
89686534|NCT05530746||Non-advanced adenoma|Patients with non-advanced adenoma were given informed consent to obtain colon tissue biopsies and fecal specimens.
89686535|NCT05530746||Advanced adenoma|Patients with advanced adenoma were given informed consent to obtain colon tissue biopsies and fecal specimens.
89686536|NCT05530746||Inflammatory bowel disease|Patients with inflammatory bowel disease were given informed consent to obtain colon tissue biopsies and fecal specimens.
89686537|NCT05530746||Colorectal cancer|Patients with colorectal cancer were given informed consent to obtain cancer tissue biopsies and fecal specimens.
89686538|NCT03835195|Experimental|Diabetes Disease Management Program|Diabetes Disease Management Program
89686539|NCT03835195|Active Comparator|Usual Care Process|Usual care process
89686540|NCT03581656|Experimental|Arm|The ChordArt System is intended for chordal replacement in patients with mitral valve insufficiency due to leaflet prolapse or flail delivered through a catheter based technology for mitral chordal replacement via a small incision in the thorax.
89686541|NCT01723111||Peritoneal dialysis|start PD
89686542|NCT01723111||Hemodialysis|start HD
89686543|NCT02195440|Experimental|PRI-724|"3 cohorts (PRI-724: 10, 40, 160 mg/m2/day), 6 cycles (1 cycle: 1-week continuous i.v. administration+1-week observation period)~*Cycle 2 will not be started until plasma drug concentrations of PRI-724 and C-82 on Days 1 and 2 in Cycle 1 are confirmed.~Cohort 1: 10 mg/m2/day (6 subjects) Cohort 2: 40 mg/m2/day (6 subjects) Cohort 3: 160 mg/m2/day (6 subjects) One cycle consists of 1-week continuous i.v. administration of PRI-724 followed by a 1-week observation period. The tolerability and safety after 6 cycles will be confirmed."
89686544|NCT03834805|Experimental|Pregnant women with a normal pregnancy|Assesment of fetal lung and liver stiffness with 2D Ultrasounds Shear Wave Elastography
89686545|NCT05525052||Cohort|Patients having a history of spinal surgery such as laminectomy and/or classic surgical arthrodesis, and subsequent focal spinal, treated by transfacet arthrodesis under CT scan guidance
89686546|NCT03834259|Active Comparator|Group 1|12.5 mg 0.5% hyperbaric bupivacaine
89686547|NCT03834259|Active Comparator|Group 2|10 mg 0.5% hyperbaric bupivacaine
89686548|NCT03834259|Active Comparator|Group 3|12.5 mg 0.5% hyperbaric bupivacaine
89686549|NCT05524974|Experimental|Camrelizumab combined with Oxplatin and S-1 for Immune Genotypes|
89686550|NCT05524974|Active Comparator|Oxplatin and S-1 for Immune Genotypes|
89686551|NCT05524974|Experimental|Apatinib Mesylate combined with Oxplatin and S-1 for Mesenchymal Genotypes|
89686552|NCT05524974|Active Comparator|Oxplatin and S-1 for Mesenchymal Genotypes|
89686553|NCT05524974|Experimental|Nab-paclitaxel combined with Oxplatin and S-1 for Classic Genotypes|
89686554|NCT05524974|Active Comparator|Oxplatin and S-1 for Classic Genotypes|
89686555|NCT05524974|Active Comparator|Oxplatin and S-1 for Metabolic Genotypes|
89686556|NCT01723189||Central Apnoeas Patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of central apnoea (central apnoea index> 10 / h, or Cheyne-Stokes breathing for more than 30% of total sleep time or mixed apneas with central apnoeas> 50% of total apneas)
89686557|NCT01723189||Obstructive apnoea patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of obstructive sleep apnea (apnea-hypopnea index> 20 / h)
89686558|NCT01723189||No SDB patients|• 30 patients diagnosed with TIA / stroke within 7 days of admission and no evidence of sleep respiratory disorders at polysomnography
89686559|NCT01723189||Healthy controls|• 30 healthy controls matched for age, sex, race and BMI.
89686560|NCT03321682|Experimental|Functional Training|Patients in the functional training group, in addition to maintaining their usual care, will perform functional training including exercises for core strength, power training, knee dominance, hip dominance, horizontal pressure, vertical pressure, horizontal pull and vertical pull, using unstable surfaces.
89686561|NCT03321682|Active Comparator|Strength Training|These group, in addition to maintaining their usual care, will perform the exercise protocol as recommended by the American Heart Association.
89686562|NCT00870467|Placebo Comparator|DB Placebo|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
89686563|NCT00870467|Experimental|DB adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
89686564|NCT00870467|Experimental|DB Adalimumab/OL Adalimumab|Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
89686565|NCT00870467|Experimental|DB Placebo/OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
89686566|NCT00870467|Experimental|DB Adalimumab/RE OL Adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
89686567|NCT00870467|Experimental|DB Placebo/RE OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
89686568|NCT05209932|Experimental|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group NBP. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations. Units are highly interactive. Sessions began with a check-in in which parents responded to questions about use of the program skills and were provided with ways to address the challenges they experienced. The skill was then taught using modeling videos, interactive exercises, and testimonials from prior participants. The program then prompted parents to set times to use the skill, identify barriers to using it and select strategies to reduce these barriers. Parents were provided with tip sheets to address challenges in using the skill, downloadable sheets to record use of and competence in using the skill and a downloadable handbook that summarized what was covered in the unit.
89686569|NCT05209932|No Intervention|wait-list control condition|Parents in the waitlist-control condition were told that they would have access to the eNBP 12 weeks after they completed the pre-test. Twelve weeks after assignment to condition, parents and children were sent links to the posttest
89686570|NCT01728727|Active Comparator|conventional|conventional treatment & antiviral treatment
89686571|NCT01728727|Experimental|UC-MSC transplantation|Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit
89686572|NCT01723267|Active Comparator|3D follicles assessment|During IVF treatment all ultrasound examinations will use 3D- SonoAVC technology. Timing of hCG injection and oocyte collection will be based on follicle volume and 3D-volume based diameter.
89686573|NCT01723267|Active Comparator|2D follicles assessment|During IVF treatment all ultrasound examinations will use standard 2D ultrasound. Timing of hCG injection and oocyte collection will be based on follicle diameter.
89686574|NCT01723345|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
89686575|NCT01723345|No Intervention|control|just receive standard treatment
89686576|NCT04289116|Experimental|We Test|Each participant or couple will receive MI-CST + observation of ACT videos + CHTC. Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
89686577|NCT04289116|Active Comparator|Individual HIV Testing and Counseling|Individual HIV Testing and Counseling (IHTC). Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone.
89686578|NCT01728883||Diagnosed DR/DME requiring treatment|Patients diagnosed as diabetic retinopathy(DR) and/or diabetic macular edema (DME) and requiring treatment at the time they are recruited into the Study. Patients will be home vision monitoring using myVisionTrack®.
89686579|NCT04288336|Experimental|Prevention (intermittent fasting)|Beginning when patients' PSA is detectable up to 24 months after surgery, patients follow a daily intermittent fasting routine consisting of restricting the daily eating period to 8 hours (e.g. between 1PM-9PM) followed by 16 hours of prolonged nightly fasting for up to 1 year or until secondary therapy commences.
89686580|NCT01728961|Active Comparator|ARM A: AL + NVP -based ARV treatment|AL given to children who test positive for malaria and are already taking NVP as prescribed by their healthcare provider
89686581|NCT01728961|Active Comparator|ARM B: AL with No ARV treatment|AL given to children who do not meet national guidelines for beginning ARV treatment
89686582|NCT00870545|Experimental|Telephone support|12 telephone support group sessions based on the letters of the word BATTLEMIND
89686583|NCT05524896||Low FFR|Invasive FFR value <= 0.8
89686584|NCT05524896||High FFR|Invasive FFR value > 0.8
89686585|NCT01723501|Placebo Comparator|sterile water|sterile water wipes
89686586|NCT01723501|Experimental|0.25% chlorhexidine|0.44% chlorhexidine digluconate wipes which will release 0.25% free chlorhexidine
89686587|NCT05524818||Test-retest reliability group|All the participants received conventional rehabilitation (e.g., occupational therapy, physical therapy, or speech therapy) or other interventions (e.g., acupuncture) as usual during the research period.
89686588|NCT05524818||Responsiveness group|All the participants received conventional rehabilitation (e.g., occupational therapy, physical therapy, or speech therapy) or other interventions (e.g., acupuncture) as usual during the research period.
89686589|NCT01729117|Other|Meal Replacement|Meal Replacements will be provided to participants randomized to the MR group
89686590|NCT01729117|Other|Standard Care|Standard Care participants will receive standard care but no meal replacements
89686591|NCT00872027|Experimental|1|Participants will receive 8 weeks of escitalopram treatment.
89686592|NCT00872027|Placebo Comparator|2|Participants will receive 8 weeks of placebo pills.
89686593|NCT01950910||subjects w/ non-motor neurodegenerative disease|subjects with ALS or with non-motor neurodegenerative disease
89686594|NCT01950910||subjects w/out motorneuron degenerative dis|subjects without motorneuron degenerative disease
89686595|NCT01854814|Experimental|mycophenolate mofetil|mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan
89686596|NCT01854814|Active Comparator|losartan|maximus tolerated labeled dose of losartan
89686597|NCT01723657|Other|Risk-adapted postremission treatment.|Ara-C, G-CSF, Autologous peripheral blood stem cell transplantation, Allogeneic matched related or unrelated donor transplant, G-CSF Priming, CD34+ selection, Myeloablative or reduced intensity conditioning, Mylotarg purging before autologous PBSC transplantation.
89686598|NCT02576652|Other|Osteoarthritis Participants|Participants previously treated with denosumab and planning to undergo total hip replacement (THR) received one cycle of tetracycline administered at either 250 mg four times a day or 500 mg twice a day for 3 days and one cycle of demeclocycline administered at either 150 mg four times a day or 300 mg twice a day for 3 days, ten days after last dose of tetracycline in cycle 1. THR surgery was performed 5 to 42 days after the last dose of demeclocycline.
89686599|NCT00872339||transfusion-dependant|People with transfusion-dependant thalassemia who received at least 8 transfusions in the past year.
89686600|NCT00872339||non-transfusion-dependant|People with non-transfusion-dependant thalassemia who received no transfusions in the past year.
89686601|NCT00872339||intermittently transfused|Intermittently transfused patients- individuals who received at least one but fewer than eight transfusions in the last year
89686602|NCT01851382||Cohort 1|Healthy volunteers.
89053640|NCT04610606|Experimental|Multimodal intervention (MM)|Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization (diet + mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids) and relaxation strategies.
89053641|NCT04610606|No Intervention|Standard of care (SOC)|Education on benefits of physical activity and healthy diet, with no specific information.
89053642|NCT00587535||Hemochromatosis|Hemochromatosis
89053643|NCT00587535||Living-related liver donation|Living-related liver donation
89053644|NCT00564044|Active Comparator|2|
89053645|NCT00195663|Experimental|Adalimumab|Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.
89053646|NCT00195663|Experimental|Adalimumab + methotrexate|Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
89053647|NCT00195663|Experimental|Methotrexate|Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
89053648|NCT00564122||All subjects|
89053649|NCT01135498|Experimental|1|
89053650|NCT04610567|Experimental|MTX-LDE phase 1|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
89053651|NCT04610567|Experimental|MTX-LDE phase 2|Methotrexate carried by a lipid nanoparticle (MTX-LDE)
89053652|NCT04610567|Placebo Comparator|Placebo-LDE phase 2|Lipid nanoparticle (LDE)
89053653|NCT02883439|Experimental|Investigational product|MP29-02 137
89053654|NCT02883439|Active Comparator|Non-investigational product|fluticasone propionate
89053655|NCT02883283|Active Comparator|Epidural Catheter Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural catheter following catheter placement. (Current standard practice) Epidural loading dose via epidural catheter.
89053656|NCT02883283|Experimental|Epidural Needle Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural needle prior to catheter placement. Epidural loading dose via epidural needle.
89053657|NCT04610255|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
89053658|NCT04610255|Experimental|Dynamic myofascial release|Experimental group was given Dynamic myofascial release along with the cervical isometrics and muscle stretching
89053659|NCT04610333|Experimental|School teacher training|"Teacher training programme:~MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.~Four-day residental course~3 x 2 seminar days~Modified MBSR programme delivered to the students:~- 1hour group session once a week in 10 weeks taught by the educated teachers on class"
89053660|NCT04610333|No Intervention|Usual practice|
89053661|NCT01134562|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous (IV) injection after hemodialysis.
89053662|NCT01134562|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide by intravenous (IV) injection after hemodialysis.
89053663|NCT04610216||Bilateral users: two implant systems|For bilateral CI users two Naida CI M sound processors (one per ear) will be used during the study.
89053664|NCT04610216||Bimodal users: hearing aid contralateral|For bimodal subjects there will be one Naida CI M sound processor on the implanted ear as well as one hearing aid on the contralateral ear.
89053665|NCT00587574||I|Chronic graft-versus-host disease
89053666|NCT00587574||II|No chronic graft-versus-host disease
89053667|NCT02883166|Other|group 1|1000mg abiraterone fasted followed by 500 mg with breakfast
89053668|NCT02883166|Other|group 2|500 mg abiraterone with breakfast followed by 1000mg fasted
89053669|NCT04610489|Other|Study Population|All subjects will undergo bilateral mid-turbinate swabs for COVID Antigen (Quidel Sofia SARS Antigen Fluorescent Immunoassay (FIA)) as well as bilateral rt-PCR testing (Quest SARS-CoV-2 rRT-PCR).
89053670|NCT04610021|No Intervention|Control|Control group: autologous bone + bench bone
89053671|NCT04610021|Experimental|i-Factor|I-Factor group: autologous bone + bench bone + i-Factor™ bone graft
89053672|NCT00195351|Active Comparator|A|
89053673|NCT00195351|Active Comparator|B|
89053674|NCT04609982|Experimental|wearing ear plugs|
89053675|NCT04609982|No Intervention|Not wearing ear drops|
89053676|NCT04609748|Active Comparator|The group that received nimesulide|
89053677|NCT04609748|Experimental|The group that received CBD Oil|
89053678|NCT04574934|Experimental|the study group|study group received the traditional physical therapy program plus aquatic therapy
89053679|NCT04574934|No Intervention|the control group|control group received traditional physical therapy program only.
89053680|NCT04609631|Experimental|Tai Chi (5 times/week)|5 sessions of Tai Chi per week for 12 weeks
89053681|NCT04609631|Experimental|Tai Chi (3 times/week)|3 sessions of Tai Chi per week for 12 weeks
89686603|NCT03407911||Peri-implant microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
89686604|NCT03407911||Periodontal pocket microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
89686605|NCT03407911||healthy teeth|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
89053682|NCT04609631|Experimental|Tai Chi (1 time/week)|1 session of Tai Chi per week for 12 weeks
89053683|NCT04609631|Active Comparator|cognitive behavior therapy (CBT)|1 session of CBT per week for 12 weeks
89053684|NCT04609631|No Intervention|Waiting-list|Participants will maintain their routine treatment and life style for 12 weeks.
89053685|NCT00195273|Experimental|1|Sirolimus + Daclizumab + Mycophenolate + Corticosteroids
89053686|NCT00195273|Active Comparator|2|Cyclosporine + Mycophenolate + Corticosteroids
89053687|NCT00564161||1|
89053688|NCT00564161||2|
89686606|NCT01850758|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.
89686607|NCT01850758|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate knee strengthening exercises and given an instructional hand-out to take home.
89686608|NCT01812304|Experimental|hands-on training|probands perform predefined maneuvers to manage a vaginal breech hands-on after one instruction
89686609|NCT01812304|Active Comparator|frontal teaching|Probands perform predefined maneuvers to resolve a vaginal breech after forntal teaching
89053689|NCT00587652||1|Intermediate Segment Barrett's (2-4cm)
89053690|NCT00587652||2|Long segment Barrett's (>4 cm)
89053691|NCT00564239|Experimental|A|
89053692|NCT00564239|Active Comparator|B|
89053693|NCT00564239|No Intervention|C|
89053694|NCT00193479|Experimental|Cyclophosphamide/Vincristine/Rituximab +/- Mitoxantrone|All patients receive three courses of combination chemotherapy/rituximab followed by pegfilgrastim, administered at 21-day intervals. Treatment administered is as follows: cyclophosphamide 500mg/m2 IV day 1; mitoxantrone 10mg/m2 IV day 1; vincristine 1.0mg/m2 (maximum 2mg) IV day 1; prednisone 80mg PO days 1 - 5; rituximab 375mg/m2 IV day 1.
89053695|NCT00564317|Experimental|1 KIDNET|Narrative Exposure Therapy for Children
89053696|NCT00564317|Experimental|2 Meditation/Relaxation|mixed Meditation/Relaxation Protocol
89053697|NCT00564317|Experimental|3 KIDNET + Meditation/Relaxation|KIDNET according to protocol, waiting time of 5 months, then Meditation/Relaxation according to protocol
89053698|NCT00564317|Experimental|4 Meditation/Relaxation + KIDNET|Med/Relax according to protocol, 5 months waiting time, KIDNET according to protocol
89053699|NCT04609475|Experimental|Osseodensification technique|
89053700|NCT04609475|Active Comparator|Motor driven expanders' technique|
89053701|NCT00193206|Experimental|Intervention|Patients were treated with 6 doses of neoadjuvant gemcitabine 2000 mg/m2, epirubicin 50 mg/m2, and albumin-bound paclitaxel 175 mg/m2 intravenously administered at 14-day intervals. Following neoadjuvant chemotherapy, patients underwent either mastectomy or breast conservation surgery; pathologic response to treatment was assessed. Postoperatively, patients received 4 doses of gemcitabine 2000 mg/m2 with albumin-bound paclitaxel 220 mg/m2 at 14-day intervals. Pegfilgrastim 6 mg was administered subcutaneously on day 2 following each dose of chemotherapy.
89053702|NCT00587691|Experimental|Dose Level 1|6-9 million MRTC
89053703|NCT00587691|Experimental|Dose Level 2|30-45 million MRTC
89686610|NCT01729273|Experimental|Diet and Exercise Intervention|"Tests will include EndoPAT analysis to assess endothelial function, applanation tonometry to assess arterial stiffness, carotid artery imaging to assess the wall thickness of the carotid arteries, exercise testing to assess the physical exercise capacity of these children and blood work to evaluate the lipid profile and inflammation status (CRP).~The Home Exercise Program will be 3 days a week for 12 weeks and participants will connect with the trainer to perform 45-60 minutes of a combination of strength training and aerobic activity via Skype. The Dietary Approaches to Stop Hypertension(DASH) eating pattern will be prescribed to all participants in the treatment group and specific strategies to achieve goals will be discussed weekly by the participant over the phone."
89686611|NCT04645134||Inactive|Older adults who have a sedentary or under-active lifestyle.
89686612|NCT04645134||Highly Active|Older adults who have a highly active lifestyle.
89053704|NCT00587691|Experimental|Dose Level 3|60-90 million MRTC
89053705|NCT04609358|Experimental|Intervention group|The patients' nutrition were supported according the the algorithm of the enteral nutrition.
89053706|NCT04609358|No Intervention|Control group|The patients' nutrition were supported according the prescription of the physicians and dietician in our hospital.
89053707|NCT00193050|Experimental|Intervention|"In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles~Patients then had either mastectomy or breast conservation surgery and pathologic treatment responses were assessed.~After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21 day intervals.~After completion of chemotherapy, local regional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines."
89053708|NCT04609241|Experimental|Administration of CD79b CAR-T Cell|
89053709|NCT00587730|Active Comparator|Clinical SPECT|GE Hawkeye Attenuation Correction Camera is being compared to the approved clinical use SPECT camera.
89053710|NCT04608734|Experimental|Buccal midazolam|
89053711|NCT04608734|Active Comparator|Intranasal midazolam|
89053712|NCT00192504|Experimental|Motavizumab, 3 mg/kg as a single intravenous dose|Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0
89053713|NCT00192504|Experimental|Motavizumab, 15 mg/kg as a single intravenous dose|Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0
89053714|NCT00192504|Experimental|Motavizumab, 30 mg/kg as a single intravenous dose|Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0
89053715|NCT00192504|Placebo Comparator|Placebo, as a single intravenous dose|Placebo, as a single intravenous dose administered on Day 0
89053716|NCT00564356|Other|A|patients under coumadin and antiaggregants operated by phacoemulsification
89053717|NCT00192114|Experimental|Enzastaurin HCl|
89053718|NCT04608929|Experimental|Intervention|The arm where the Kegel exercise focused intervention is applied
89053719|NCT04608929|Experimental|Control|The arm where home follow-up and scale evaluations are made
89053720|NCT00192075|Experimental|A+FFG|Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid
89053721|NCT00192075|Active Comparator|A+FOLFOX 4|Avastin + Oxaliplatin + 5-Fluorouracil (5FU)/Folinic Acid
89053722|NCT00192036|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).~Cisplatin: 80 mg/m2, IV, every 21 days x 5 cycles.~Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."
89053723|NCT04609007|Active Comparator|Treatment as usual|The TAU condition consists of a single session of regular help-line telephone counselling
89053724|NCT04609007|Experimental|Cognitive behavioral therapy|The experimental condition consists of a single session of regular help-line telephone counselling plus four therapist guided online CBT sessions.
89053725|NCT04608461|Experimental|pumpkin seeds extract containing cream|Intervention-pumpkin seeds extract containing cream, dose-twice daily for 12 weeks
89053726|NCT00191724|Experimental|1|
89053727|NCT00191724|Experimental|2|
89053728|NCT00191724|Experimental|3|
89053729|NCT00191724|Experimental|4|
89053730|NCT00191724|Placebo Comparator|5|
88998475|NCT03457285|Experimental|Physiotherapy via the Salaso Apllication Intervention|"All participants' physiotherapy- prescribed exercise programmes will be monitored via the Salaso application. Telehealth appointments will occur monthly and modifications to exercises will be made as required.~This will continue for the 6-month duration of the intervention."
88998476|NCT00195117|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal.
89053731|NCT00564473||A|patients hospitalized in the Department of Internal Medicine of the Shaare Zedek Medical Center, Jerusalem, Israel.
89053732|NCT04608422|Experimental|Electrical stimulation|The patients will receive neuromuscular electrical stimulation on quadriceps muscle and sensory stimulation in the anatomical region of the kidneys.
89053733|NCT04608422|No Intervention|Control|The patients only will be evaluated and reassessed.
89216774|NCT02575859|Experimental|Adjuvant HIPEC|Adjuvant HIPEC will be performed simultaneously with primary tumor resection in patients undergoing curative surgery for primary colorectal cancer associated with risk factors for the development of metachronous peritoneal metastases.
89533004|NCT05675410|Experimental|Arm B (ABVD, brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV and nivolumab IV once during each treatment cycle. Each cycle lasts 21 days. Treatment continues for 4 cycles. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
89686613|NCT01743742|Experimental|Oral vitamin E, vitamin C|Single dose of vitamin E drops 200 IU within 6 hours of birth and vitamin C tablet 250 mg in pulverised form (2 doses at 24 hr interval) via infant feeding tube
89686614|NCT01723735|Experimental|Alirocumab + Ezetimibe Placebo|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe placebo
88998477|NCT00195117|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their participation in this study.
89686615|NCT01723735|Experimental|Alirocumab + Ezetimibe|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe
89686616|NCT01723735|Experimental|Alirocumab + Fenofibrate|Subcutaneous (SC) injections of alirocumab added to oral administration of fenofibrate
89686617|NCT00872729|Active Comparator|Cystagon®|Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg
89686618|NCT00872729|Experimental|RP103|Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg
89686619|NCT01729429|Active Comparator|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
89686620|NCT01729429|Experimental|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit~Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
89686621|NCT04640376|Experimental|Paracetamol UNIFLASH 125mg|1 sachet Paracetamol UNIFLASH 125mg + 2 placebo capsule
89686622|NCT04640376|Placebo Comparator|Placebo|1 Placebo sachet + 2 placebo capsule
89686623|NCT04640376|Active Comparator|Paracetamol 500mg|1 Placebo sachet + 1 placebo capsule + 1 capsule Panadol 500mg
89686624|NCT04640376|Active Comparator|Paracetamol 1000mg|1 Placebo sachet + 2 capsules Panadol 500mg
89686625|NCT03320200|Experimental|CNS-focused treatment|Group of subjects receiving a 10 week CNS (Central Nervous System) -focused treatment program for frozen shoulder in addition to 5 days per week home treatment program
89686626|NCT03320200|Experimental|Standard Care Treatment|Group of subjects receiving a 10 week standard care treatment program for frozen shoulder in addition to 5 days per week home treatment program based on conventional physiotherapy
89686627|NCT03407755|Active Comparator|Air|Intraocular 100% atmospheric air (anterior chamber).
89686628|NCT03407755|Experimental|SF6|Intraocular 20% sulphur hexaflouride (anterior chamber).
89686629|NCT00832871|Experimental|Mifepristone|200 mg RU-486 (Mifepristone) daily
89686630|NCT01723813|Experimental|Group 1 : peptides + GM-CT-01 IV|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections
89686631|NCT01723813|Experimental|Group 2 : peptides + GM-CT-01 IV+PT|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections and Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
89686632|NCT05081297|Experimental|Qigong practitioner group|This arm is the experimental group where qigong intervention is going to be applied to practitioners with experience
89686633|NCT05081297|No Intervention|No practice|This group has no intervention and acts as control
89686634|NCT05081297|Experimental|Beginner Qigong practitioner group|This arm is the experimental group where qigong intervention is going to be applied to practitioners with no experience.
89686635|NCT03307018|Experimental|Bronch|Postoperative systematic bronchial aspiration.
89686636|NCT03307018|No Intervention|Control|In this arm bronchial aspiration with bronchoscope will not be done.
89686637|NCT01729507|Active Comparator|Treatment with tDCS|This group will receive 7x verum treatment with tDSC. All participants receive standardised behavioural therapy ('The smoke-free programme')
89686638|NCT01729507|Placebo Comparator|7x sham treatment|This group will receive 7x sham treatment. All participants will receive standardised behavioural therapy ('The smoke-free programme')
89686639|NCT05530200|Experimental|Radiotherapy, PD-L1 inhibitors Sequential GM-CSF and IL-2|
89686640|NCT05044949|Active Comparator|Low dose L reuteri capsules|Subjects will be asked to consume 2 capsules with high dose L reuteri per day in 28 days.
89686641|NCT05044949|Active Comparator|High dose L reuteri capsules|Subjects will be asked to consume 2 capsules with a low dose L reuteri per day in 28 days.
89686642|NCT05044949|Placebo Comparator|Placebo capsules|Subjects will be asked to consume 2 capsules with placebo powder per day in 28 days.
89686643|NCT01729585|No Intervention|control group|control group
89686644|NCT01729585|Active Comparator|Massage therapy|Treatment group receives pre-determined massage therapy protocol x 5 over 10-12 weeks. massage therapy protocol includes a blend of Swedish strokes and myofascial trigger point therapy. Initially, dosing will be more frequent. Treatments will be spaced out to determine the ability of the body to maintain a more efficient musculoskeletal system, especially related to respiratory and postural efforts. Each session will end with resting hands and relaxation strokes to signal the end of the session. This protocol invites increased mobility in the musculoskeletal system. The ultimate goal is to return connective tissue (including muscles and fascia) to a more relaxed and neutral state, thus allowing expansion and ease of movement of the areas of the musculoskeletal system being worked.
89686645|NCT03301168|Experimental|BPX-501 T cells and Rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.~Rimiducid: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment."
89686646|NCT01723891|Active Comparator|Surfolase capsule & HT-002-01|
89686647|NCT01723891|Active Comparator|HT-002-01 & Surfolase capsule|
89686648|NCT04981301|Active Comparator|Group Q = QLB group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.
89686649|NCT04981301|No Intervention|Group C = Control group|"Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure.~Wound local anesthetic infiltration will be applied to the patients in the control group."
89686650|NCT01729663|Active Comparator|Interferon alpha 2 b|Interferon alpha 2b treatment will consist of s.c. injection of 10 MU (5 t/w) for four weeks and then 5 MU (3t/w) for 23 months.
89686651|NCT01729663|Experimental|CSF470 vaccine, BCG, Molgramostim|"CSF470 vaccine, BCG, Molgramostim~CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year.~Each vaccine consist of a mixture of 17,6.106 melanoma cells , from four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 µg prot) the first day and rhGM-CSF (Molgramostim 400 µg, fractionated in four days doses) will be used."
89686652|NCT03407677|Other|ROTO Track|The individual patient will serve as his/her own control before intervention with ROTO Track
89686653|NCT03070600|Active Comparator|Universal PrEP Counselling|All enrolled women receiving antenatal care at facilities assigned to Universal PrEP arm will receive standardized HIV risk counseling and then self-select whether they want to use PrEP.
89686654|NCT03070600|Experimental|Targeted PrEP Clinics|All enrolled women receiving antenatal care at facilities assigned to the Targeted PrEP arm will be assessed for HIV-risk prior to receiving targeted PrEP counseling.
89686655|NCT00873821|Experimental|1|MK-0941
89686656|NCT00873821|Placebo Comparator|2|Placebo Comparator
89686657|NCT01724047|Experimental|Playground Intervention|Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed 2) Waitlist treatment, where the training will begin the following school year. The initial delivery will occur for 30 minutes three times for a period of two to three weeks, then 30 minutes two times for a period of two weeks, then 30 minutes once a week for up to 16 sessions, within a period of 3 months, then a 30 minute follow up will occur 3 months later. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment, and 3-month follow-up. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
89686658|NCT01724047|Experimental|STAT Intervention|Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. The intervention will be over a period of 6 weeks, with baseline, treatment, and a follow up visit totaling 18 weeks at the school site. Each visit is approximately 30 minutes. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
89686659|NCT01724047|No Intervention|Playground Waitlist Control|Waitlist Control
89686660|NCT01724047|No Intervention|STAT Waitlist Control|Waitlist Control
89686661|NCT03407599|Experimental|Faster aspart followed by insulin aspart (NovoRapid®)|Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
89686662|NCT03407599|Experimental|Insulin aspart (NovoRapid®) followed by faster aspart|Participants will receive single dose of NovoRapid® followed by single dose of fast-acting insulin aspart on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
89686663|NCT04974359|Experimental|Lu AG06466|Participants will receive an oral titrated dose of Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.
89686664|NCT04974359|Placebo Comparator|Placebo|Participants will receive an oral dose of placebo matching to Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.
89686665|NCT01729975||18-28 years old Non-pathologic|
89686666|NCT01729975||29-80 years old Non-Pathologic|
89686667|NCT01729975||29-80 years old pathologic corneal disease|
89686668|NCT05529888|Active Comparator|Patient group|Patients were treated with Isotretinoin in a dose (from 20 to 40) for 3 months and serum homocysteine were assessed before and after treatment
89686669|NCT05529888|No Intervention|Control group|Assessment of serum YKL40 in healthy individuals
89686670|NCT01724125|Experimental|Case|Assigned a Personal Electronic Health Record
89686671|NCT01724125|Active Comparator|Control: Usual Care|Assigned to control arm, continued to receive care as usual in community. Was issued information on community health resources, but did not use research study personal health record.
89686672|NCT05524272|Experimental|THE EFFECTS OF COLOUR BY NUMBER MANDALA|This study was conducted to find out the effects of colour by number mandala in decreasing the stress of hospitalized children with chronic disease. A randomized controlled study.This study was conducted with 120 children between the ages of 8 and 11. 60 children formed the experimental group, while 60 children formed the control group. Descriptive Information Form and Perceived Stress Scale were used in data collection.
89686673|NCT04377841||Facial Demodicosis|"Clinical presentation of facial skin matches any of the followings:~Pityriasis folliculorum.~Papulopustular lesion.~Rosacea.~Demodex infestation detected by direct microscopic examination ≥ 5 mites/cm2."
89216775|NCT02575859|No Intervention|Matched control|"Comparable controls will be retrospectively selected from patients undergoing curative surgery for colorectal cancer at the National Cancer Institute (Milan, Italy) during the same period.~Every single control patient will be matched with a.patient in HIPEC group according to the following criteria: i) risk-factor for metachronous PM (minimal synchronous PM vs. ovarian metastases vs. pathological tumor [pT] stage (pT4a/b); ii) pathological node (pN) stage (pN0 vs. pN1/2); iii) grading (well/moderately vs. poorly differentiated); iv) histological subtype (adenocarcinoma vs. mucinous/signet ring cell carcinoma); v) sex; vi) age (+/-5 years). The investigators will be blinded to patient outcomes during the process."
89686674|NCT04377841||Ocular Demodicosis|"Clinical presentation of ocular region matches any of the followings:~Chronic blepharitis.~Eyelash abnormalities: trichiasis, distichiasis, madarosis.~Meibomian gland dysfunction.~Recurrent chalazion.~Ocular rosacea.~Demodex infestation detected by cilia epilation test ≥ 1 mite/eyelid."
89686675|NCT05524194|Experimental|Experimental: 6MW3511|Subjects will receive 6MW3511 by intravenous administration.
89686676|NCT03407365|Experimental|Home Exercises|Patients will be given a set of home exercises to perform as part of their rehabilitation home exercise program. They will be initially trained by a research team member and will be given a DVD home exercise video with instructions on how to perform the exercises.
89686677|NCT03407365|Active Comparator|DVD Program|Weeks 1-10, subjects will not be prescribed exercise at home. If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
89686678|NCT05518578|Experimental|Open-Label Treatment|0.25 mg to 4 mg SPN-817 taken orally twice daily
89686679|NCT05518500|Experimental|Healthy Older Adults|Will receive FDA-approved influenza vaccine (Fluzone HD Year 1, FLUAD Year 2, TBD Year 3)
89686680|NCT03838913||IPNB|intraductal papillary neoplasm of the bile duct
89686681|NCT05518344|Experimental|single arm|"Release ISL from Inserter~Remove Inserter.~Tack the haptics under the iris in 4 locations~Verify that ISL is centered~Remove lid speculum and drape from subject's eye and face.~Move the subject to a slit lamp and verify ISL centration."
89686682|NCT05518266|Active Comparator|US-guided post-incisional PIFB|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of the sternum after skin closure under ultrasound guidance
89686683|NCT05518266|Active Comparator|Surgeon-delivered post-incisional parasternal block|Just before wiring the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
89686684|NCT05523960|Experimental|NBP group|Patients allocated to NBP were instructed to not prepare the bowel.
89686685|NCT05523960|Other|MBP group|Patients allocated to MBP were instructed by the study nurse to prepare their bowel mechanically by drinking 3~4L of polyethylene glycol (Polyethylene Glycol Electrolytes Powder 68.56g; Shenzhen, China) with water before 6pm in the evening the day before the surgery.
89686686|NCT05529576|Experimental|Major depressive disorder|Outpatients in main-center and sub-centers; meet the DSM-IV diagnosis of Major Depressive Disorder (mental examination was conducted by at least two professional doctors); available relevant HIS system biochemical data; haven't been treated with physical therapy; age between 18-65 years old; gender is not limited.
89216776|NCT02576873||Hemodiafiltration|End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months
89686687|NCT05529576|Active Comparator|Bipolar disorder|Outpatients in main-center and sub-centers; meet the DSM-IV diagnosis of Bipolar disorder (mental examination was conducted by at least two professional doctors); available relevant HIS system biochemical data; haven't been treated with physical therapy; age between 18-65 years old; gender is not limited
89686688|NCT05529576|No Intervention|Healthy controls|Healthy controls in main-center and sub-centers; no history of psychiatric disease; age between 18-65 years old; gender is not limited.
89686689|NCT00212134|Active Comparator|aphakic contact lens|"Contact lens correction of aphakia~INTERVENTION: use of an external contact lens (CL) to correct the large hyperopic refractive error produced by surgically extracting the natural cataractous lens. As the eye grows, the refractive error changes and the power of the CL can be changed accordingly."
89686690|NCT00212134|Experimental|aphakic intraocular lens|"Intraocular lens implantation~INTERVENTION: At the time of surgery to remove the cataractous natural lens, an intraocular lens was implanted to correct the large hyperopic refractive error induced by the cataract surgery."
89686691|NCT05517954||Subjects with TBI and PTE|10 subjects with a history of TBI, diagnosed with PTE (post-traumatic epilepsy). PTE is defined as acquired epilepsy with seizures that developed within ten years of TBI with no other clear cause
89686692|NCT05517954||Subjects with TBI, no PTE|"10 subjects with a history of TBI, and absent epilepsy, but TBI in the past two years and any of the following:~Multifocal intracerebral hemorrhages (ICH)~depressed skull fracture~Subdural hematoma (SDH) requiring surgery~SDH and ICH~Penetrating wound"
89686693|NCT05517954||Healthy volunteers|10 healthy volunteers; absent epilepsy or TBI
89686694|NCT02575950|Experimental|LEO43204 0,018%|Experimental drug
89686695|NCT02575950|Placebo Comparator|Vehicle|Placebo
89686696|NCT02477878|Experimental|BPX-501 and Rimiducid|"All subjects will receive 3 cycles of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of Rimiducid ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
89686697|NCT00371098|Experimental|active vaccine|patients received active influenza vaccine for season 2004/2005
89686698|NCT00371098|Placebo Comparator|placebo vaccine|patients received placebo influenza vaccine for season 2004/2005 containing all vaccine compounds except viral antigens
89686699|NCT04114708|Other|ACLR|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
89686700|NCT04114708|Other|ACLR with lateral extra-articular tenodesis|All LETs will be performed in a standardized fashion using the modified Lameire technique.
89686701|NCT05523804||interval cytoreductive surgery|women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) cytoreductive surgery
89686702|NCT05523804||delayed cytoreductive surgery|women with stage III-IV ovarian cancer, undergoing delayed (>5 cycles of chemotherapy) cytoreductive surgery
89216777|NCT00469612|Experimental|A|NeuroVision's NVC treatment for low myopia
89216778|NCT00469612|No Intervention|B|The subjects in this group will serve as controls and will be the no intervention group.
89216779|NCT00469456|Active Comparator|1|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
89216780|NCT00469456|Placebo Comparator|2|Placebo oral administration twice daily for 12 weeks
89686703|NCT05523804||no surgery|women with stage III-IV ovarian cancer, undergoing >5 cycles of chemotherapy alone (no cytoreductive surgery)
89686704|NCT00913627|Experimental|1|1 x 600 mg ibuprofen IR/ER-roller compaction caplet
89686705|NCT00913627|Experimental|2|1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
89686706|NCT00913627|Active Comparator|3|1x 220 mg naproxen sodium (Aleve caplet)
89686707|NCT00913627|Placebo Comparator|4|1 x placebo caplet
89686708|NCT05454748||Healthy controls|
89686709|NCT05454748||Stroke patients|
89686710|NCT05517798|Active Comparator|Xenograft + resorbable collagen membrane|Bone grafting material (bovine origin) + resorbable collagen membrane (porcine origin)
89686711|NCT05517798|Active Comparator|Xenograft combined with EMD + resorbable collagen membrane|Bone grafting material (bovine origin) with enamel matrix derivative (porcine origin) + resorbable collagen membrane (porcine origin)
89686712|NCT05529498|Experimental|Experimental|High intensity interval gait training
89686713|NCT05529498|Active Comparator|Control|Moderate intesnity continuous gait training
89686714|NCT04297176|Experimental|Traditional monitoring method|Patients are dosed using two timed vancomycin serum concentrations
89686715|NCT04297176|Active Comparator|One concentration method|Patients are dosed based on one timed vancomycin serum level
89686716|NCT05529420||Pediatric patients rocuronium|In pediatric patients undergoing a planned general anesthesia with non-depolarizing muscle relaxants, induction of anesthesia will involve either standard intravenous (an opioid, anesthetic, muscle relaxant) or inhalational agents according to the preference of the anesthesiologist.
89686717|NCT05454592|Experimental|Peer-presented group|The online outreach program focused on four key areas of mental health resilience-building: dealing with stress, decreasing self-criticism, improving self-care and help-seeking behaviours, and enhancing social connections and social support. Using videos, interactive infographics, guided audio recordings, and podcasts, students were provided with clear descriptions of each area of mental health resilience as well as a variety of evidence-based strategies specifically targeting one or more of these areas. A first video was sent to students describing the online program, its overall focus, and how to access the skills-based strategies on the website's interactive resource library. Two subsequent videos then were sent to (a) help students with problem-solving for common challenges to strategy practice, and (b) maintain long-term strategy practice habits. To assess differences in terms of preference for deliverer, this video series was delivered by undergraduate students (i.e., peers).
89686718|NCT05454592|Experimental|Mental health service provider-presented group|The program focused on four areas of mental health resilience-building: dealing with stress, decreasing self-criticism, improving self-care and help-seeking behaviours, and enhancing social connections and social support. Using videos, infographics, guided audio recordings, and podcasts, students were provided with clear descriptions of each area of mental health resilience as well as a variety of evidence-based strategies specifically targeting one or more of these areas. A first video was sent to students describing the online program, its overall focus, and how to access the skills-based strategies on the website's interactive resource library. Two subsequent videos were then sent to (a) help students with problem-solving for common challenges to strategy practice, and (b) maintain long-term strategy practice habits. To assess differences in terms of preference for deliverer, this video series was delivered by mental health service providers.
89686719|NCT05454592|No Intervention|Wait-list comparison group|Participants in the wait-list comparison group did not receive any intervention throughout the duration of the study. However, they were asked to fill out the same baseline, post, and follow-up surveys as all other participants.
89686720|NCT04142034|Experimental|iAmHealthy Behavioral Intervention|This intervention will receive the American Academy of Pediatrics (AAP) newsletter, group and individual sessions with the iAmHealthy behavioral intervention team via an electronic tablet provided by the sponsor.
89686721|NCT04142034|Active Comparator|NewsLetter intervention|This intervention arm will only receive the American Academy of Pediatrics (AAP) newsletter for six months.
89686722|NCT04142034|Other|Consecutive Recruitment method|Using this recruitment method, clinics will identify potential eligible study participants through their medical records among those that have been seen in the clinic within the past year and those children with upcoming appointments and approach them and their caregivers about enrolling in the study.
89686723|NCT04142034|Other|Traditional Recruitment method|Flyers, advertisements, and other materials will be used to recruit potential participants to the study.
89686724|NCT05523648|Experimental|The control group|The control group was treated with silibinin meglumine tablets and tenofovir
89686725|NCT05523648|Active Comparator|The treatment group|The treatment group was treated with Ganshuang granules combined with silibinin meglumine tablets and tenofovir
89686726|NCT02115100|Active Comparator|pulmonary vein+renal artery denervation|Procedure: pulmonary vein and renal artery denervation
89686727|NCT02115100|Active Comparator|Pulmonary vein isolation|Procedure: Pulmonary vein isolation
89686728|NCT05529108|Placebo Comparator|Control biscuits group|Subjects are required to consume 90 g control biscuits as their breakfast everyday during 12-week intervention period.
89686729|NCT05529108|Experimental|autoclaved BSG-containing group|Subjects are required to consume 90 g autoclaved BSG-containing biscuits as their breakfast everyday during 12-week intervention period.
89686730|NCT05529108|Experimental|bio-transformed BSG-containing group|Subjects are required to consume 90 g fermented BSG-containing biscuits as their breakfast everyday during 12-week intervention period.
89216781|NCT00581555|Experimental|etanercept|Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
89686731|NCT05523258|Experimental|Intervention Group|Patients in this group will receive computerized cognition training, including processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning and problem solving. The training program and its difficulty are constantly adjusted with the patients' training performance.
89686732|NCT05523258|Sham Comparator|Control group|Patients in this group will receive basic training based on tablet computer, and the subjects will receive five training tasks of processing speed and attention, which are fixed in difficulty and scheme. The training methods and intensity are similar to the intervention group.
89686733|NCT04047160|Experimental|OP-724|"Dose: 140, 280, 380 mg/m2/4 hrs~Administration method:~[Level 1] 140 mg/m2/4 hours [Level 2] 280 mg/m2/4 hours (starting dose) [Level 3] 380 mg/m2/4 hours Continuous intravenous administration will be done for 4 hours twice a week. This procedure will be as one cycle and 12 cycles (12 weeks in total) will be conducted. On 7 days prior to the first cycle administration, a dose scheduled in the first cycle will be administered with continuous intravenous for 4 hours and the safety and pharmacokinetics on the day of administration to the next day after administration will be evaluated."
89686734|NCT05517720|Experimental|Aria Trio complete Facial System|Skincare system targetting wrinkles, pore size, sun spots, and overall skin quality.
89686735|NCT01724203|Active Comparator|Lactobacillus rhamnosus|Formula containing 1 million CFU/g Lactobacillus rhamnosus HN001 (trademarked DR20) at least three times daily for 12 weeks.
89686736|NCT01724203|Active Comparator|Bifidobacterium animalis subsp. lactis|Formula containing 1 million CFU/g Bifidobacterium animalis subsp. lactis HN019 (trademarked DR10) at least three times daily for 12 weeks.
89686737|NCT01724203|Placebo Comparator|Placebo|Placebo formula without probiotics at least three times daily for 12 weeks.
89686738|NCT02738086|Experimental|Early PABC Intervention|GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
89686739|NCT02738086|Experimental|Wait-List Control Intervention|GROUP 2 will participate in a non-exercise control phase during the first 3 months. GROUP 2 will then participate in the Physical Activity Behavior Change (PABC) intervention phase in the second 3 months.
89686740|NCT04054882|Experimental|Sabin-IPV and DTaP|234 subjects are simultaneously administrated with Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
89686741|NCT04054882|Active Comparator|Sabin-IPV only|234 subjects are administrated with Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
89686742|NCT04054882|Active Comparator|DTaP only|234 subjects are administrated with DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
89686743|NCT05523102|Experimental|Paracetamol|Paracetamol 15mg/kg 6 hourly for 48 hours post-operatively
89686744|NCT05523102|Active Comparator|Ketorolac|Ketorolac 0.5mg/kg 8 hourly for 48 hours post-operatively
89686745|NCT03407287||Cardiac Catheterization|
89686746|NCT03407287||Distributive shock|
89686747|NCT03407287||Vasoactive and inotropic agents|
89686748|NCT03407287||Congestive heart failure|
89686749|NCT03407287||Atrial fibrillation|Patients with atrial fibrillation undergoing elective direct current cardioversion
89686750|NCT03407287||Patients undergoing surgery|Patients undergoing surgery requiring positive pressure ventilation and arterial line placement
89686751|NCT05453890||A sample of adult egyptian population|
89686752|NCT05523024|Active Comparator|Probiotic|"Individuals receive Probiotics (9 strains: B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19, and Lactococcus lactis W58) in dose: 1x109 colony forming units (CFU), daily, for 12 weeks.~Intervention: Dietary Supplement: Probiotic"
89686753|NCT05523024|Active Comparator|Berberine|"Individuals receive Berberine (Berberine hydrochloride 97% extract of Berberis aristata) in dose: 1500 mg/day, for 12 weeks.~Intervention: Dietary Supplement: Berberine"
89686754|NCT05523024|Placebo Comparator|Placebo|Individuals receive placebo daily, for 3 months. Intervention: Dietary Supplement: Placebo
89686755|NCT05523024|Active Comparator|Probiotics and Berberine|"Individuals receive: Probiotics (9 strains: B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19, and Lactococcus lactis W58) in dose: 1x109 colony forming units (CFU), daily and Berberine (Berberine hydrochloride 97% extract of Berberis aristata) in dose: 1500 mg/day, for 12 weeks.~Intervention: Dietary Supplement: Probiotic and Berberine"
89686756|NCT00877877|Other|Cervarix Group|Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.
89686757|NCT01724281||pregnant women between 19-30 weeks gestational age|No intervention, only follow up
89686758|NCT02739100|Experimental|Triferic via Hemodialysate|"Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.~Intervention Drug: Triferic"
89686759|NCT02739100|Experimental|Triferic via IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via the unused heparin infusion line (pre-dialyzer).~Intervention: Drug: Triferic"
89686760|NCT02739100|Experimental|Triferic IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via an infusion port (post-dialyzer).~Intervention: Drug: Triferic"
89686761|NCT04378543|Experimental|ART252-L|local autologous bone graft will be treated ex vivo once with ART352-L prior to re-implantation into the site of spinal fusion
89686762|NCT03407209|Sham Comparator|PEIB - Use of local levobupivacaine anesthetics: 0.625 mg / ml|"automatic hourly bolus: 8ml (5mg) on 3 min~patient controlled bolus: 8ml (5mg) on 3 min~refractory period: 8min~continuous infusion: 0~maximum dose: 65mg/4h"
89686763|NCT03407209|Experimental|FREE programming - levobupivacaine anesthetics: 0.625 mg / ml|"Epidural analgesia totally controlled by the patient~automatic hourly bolus: 0~patient controlled bolus: 8ml (5mg) on 3 min~refractory period: 8min~continuous infusion: 0~maximum dose: 65mg/4h"
89053734|NCT00191646|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 milligrams per meter square (mg/m^2) Day 1 and Day 8, Carboplatin Area Under the Curve (AUC) 5 Day 1, six 21-day cycles
89053735|NCT00191646|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel 175 milligrams per meter square (mg/m^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles
89053736|NCT00191451|Experimental|HER2+|Human Epidermal growth factor Receptor 2 positive (HER2+): Gemcitabine + Carboplatin + Herceptin.
89053737|NCT00191451|Experimental|HER2- (Taxane-)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-naive patients).
89053738|NCT00191451|Experimental|HER2- (Taxane+)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-pretreated patients).
89053739|NCT04608071||M group|In M group, patients underwent modified post-pyloric feeding tube bedside placement
89053740|NCT04608071||C group|In C group, patients underwent conventional Corpak protocol
89053741|NCT04608071||EM group|In EM group, patients received standard electromagnetic guided tube placement.
89053742|NCT00191334|Experimental|A|
89053743|NCT00191139|Experimental|Gemcitabine|
89053744|NCT00191139|Experimental|Gemcitabine plus Docetaxel|
89053745|NCT00564512|Experimental|FCCAM|Fludarabine-Cyclophosphamide-Campath (FCCam) Oral Fludarabine: 40 mg/m2 per os, D1 to D3 Oral Cyclophosphamide: 250 mg/m2/day as one dose at noon, D1 to D3 Campath®: 30 mg sc, D1 to D3 without dose escalation
89053746|NCT00564512|Active Comparator|FCR|"Fludarabine-Cyclophosphamide-Rituximab (FCR)~First course:~Rituximab 375 mg/m2 on D1.~D2 to D4:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon~Subsequent courses (2 to 6)~Rituximab 500 mg/m2 on D1~D1 to D3:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon"
89053747|NCT04571853|Experimental|PNE-explained group|The participants in the PNE-explained group will be explained the fact sheets with an explanatory video (due to COVID-19 circumstances) conducted by the therapist M.S. The video will last one hour approximately and it contains a presentation by Mayte Serrat with a view of the fact sheets. This group will be given one week to watch the video and comprehend its content.
89053748|NCT04571853|Active Comparator|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
89053749|NCT04571853|Active Comparator|TAU group|Participants allocated into this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professional.
89053750|NCT00564551|Active Comparator|2|High dairy intake and calcium supplement. High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
89053751|NCT00564551|Placebo Comparator|1|Usual diet of low dairy and calcium intake. Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet.
89053752|NCT00190983|Experimental|Pemetrexed|
89053753|NCT04607759|Experimental|Experimental group (cucumber)|"Consumption for 90 days of cucumber extract (20mg/day)~Two capsules a day orally for 90 days."
89053754|NCT04607759|Placebo Comparator|control group Placebo (sucrose)|Two capsules a day orally for 90 days.
89053755|NCT04607798|Experimental|Vulvovaginal treatment|Internal vaginal treatment monthly for 3 treatments.
89053756|NCT00190749|Experimental|Olanzapine|
89053757|NCT00190749|Active Comparator|Risperidone|
89053758|NCT04607720|Experimental|the artificial-EUS-FNA group|the first two passes were made without the AI-assisted diagnosis system guidance during EUS-FNA, and then two passes were made under guidance from the AI-assisted diagnosis system
89053759|NCT04607720|Experimental|the AI-EUS-FNA group|the first two passes were made with the AI-assisted diagnosis system guidance and then another two manual passes without the AI-assisted diagnosis system guidance.
89053760|NCT04607447|Active Comparator|Atorvastatin plus Dexamethasone tablets|
89686764|NCT05453734|Experimental|Experimental Group: The group applied Progressive Muscle Relaxation Exercises|Introductory information form and EPDS were completed by the mothers before the PMR exercises. PMR exercises were applied and training was given to the mothers by the researcher in the milking room (a quiet room) located on the NICU floor (approximately 40 minutes). The application was continued until the mother was able to do the PMR exercises on her own. After the application and training, the mother was given guidance on PMR. The mother was asked to perform the exercises twice a day, in the morning and evening, and record them on the follow-up form. The researcher's contact number was given to the mother for counseling in case she had difficulty following the steps of the PMR exercises. During the follow-ups, the mother was called by the researcher and a message was sent to ensure her continuity in the exercises. At the end of the 1st and 2nd weeks of the follow-up, BSES, EPDS and patient follow-up forms were filled when the mother came for routine controls.
89686765|NCT05453734|No Intervention|Control group: The group without any ıntervention|Introductory information form, the BSES, and the EPDS were initially applied to the mothers. At the end of the 1st and 2nd weeks of the follow-up, the BSES and the EPDS were applied to the mothers. At the end of the 2nd week, it was told the mothers how to practice the PMR exercises and the guideline on the PMR exercises was given to them.
89686766|NCT01724515|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
89686767|NCT01724515|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
89686768|NCT01724515|Experimental|Healthy Control Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
89686769|NCT05528640|Experimental|Mental Health Literacy Educational Program|An educational program consisting of six 30-minutes online educational sessions and one 60-minutes face-to-face session.
89686770|NCT05528640|No Intervention|Control Group|No active intervention
89686771|NCT03407131|Experimental|Joint replacement|Intertrochanteric fracture patients were treated with joint replacement surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
89686772|NCT03407131|Active Comparator|Intramedullary nail fixation|Intertrochanteric fracture patients were treated with intramedullary nail fixation surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
89686773|NCT01724593||Observational Cohort|No Intervention
89686774|NCT01721239|No Intervention|Control group|No intervention
89686775|NCT01721239|Experimental|Standardized Followup program|Standardized written information, patient photos and three follow-up consultations.
89686776|NCT03999268|Experimental|Intervention|Participants assigned to the intervention group will receive insulin administration education according to standard procedures plus have access to the I-START app. Over the course of the study period, participants will be able to use I-START as much or as little as they prefer.
89686777|NCT03999268|Active Comparator|Usual Care|Participants in the usual care group will receive insulin administration education according to standard procedures. They will not have access to the I-START app.
89686778|NCT01724671||Cefatroline|Investigators will retrospectively capture patient cases that have been treated for MRSA with ceftaroline. Cases will only be included if the isolate was tested against vancomycin and ceftaroline
89686779|NCT01724671||Vancomycin|Investigators will retrospectively capture patient cases that were been treated for MRSA with Vancomycin.
89686780|NCT05522712|Experimental|Acapella user|this group will use acapella in addition to traditional chest physiotherapy , early mobility and sternal precautions.
89686781|NCT05522712|Experimental|Incentive spirometer user|this group will receive incentive spirometer in addition to traditional chest physiotherapy, early mobility and sternal precautions.
89686782|NCT05522712|Other|Control user|this group will receive traditional chest physiotherapy , early mobility and sternal precautions.
89686783|NCT01724749||Healthy control subjects|"Age: 21 - 80 years~No prior history or symptoms of cardiovascular disease~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80."
89686784|NCT01724749||Subjects with cardiovascular disease|"Age: 21 - 80 years~HeartSCORE > 0%~Symptoms of angina pectoris~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80. Also, the investigators aim to include patients in 3 strata of HeartSCORE risk: low risk (1-4%), mild risk (5-9%) and high risk (> 9%)"
89686785|NCT02740504||Subjects|All 20 subjects. Selected to have a range of ages (18 to less than 75) and BMI from 18.5 to 45
89686786|NCT04378465||ERP group|A prospective series of consecutive patients undergoing elective colorectal surgery completing a standardized Enhanced Recovery Program (ERP) protocol at the S. Anna University Hospital in Ferrara (Italy) in 2013-2015
89686787|NCT04378465||Non-ERP group|A retrospective series of consecutive patients operated at the same hospital (S. Anna University Hospital in Ferrara), in the same period of time (2013-2015), but with a traditional perioperative care protocol.
89686788|NCT05528406|Experimental|HLX208|
89686789|NCT05453422|Experimental|Self-Acupressure|Each application to the acupressure points (H17, L14, ST36, SP6) will be done in 2 minutes and right and left)
89686790|NCT05453422|No Intervention|Control group|Routine maintenance will be applied.
89686791|NCT01729897|Experimental|Etomidate & Fentanyl|"4 min before procedure: fentanyl 1 μg/kg (0.02 ml/kg), intravenous injection~After injection of fentanyl, etomidate was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~Additional dose of etomidate would be administrated separately when duration of procedure was prolonged."
89053761|NCT04607447|Experimental|drugs+low intracranial pressure strategy treatment|Drugs means treatment with Atorvastatin plus Dexamethasone tablets
89053762|NCT04607213|Active Comparator|Advancement-rotation approach|
89053763|NCT04607213|Experimental|Straight-line approach|
89053764|NCT00190671|Experimental|Pemetrexed 600 mg/m2|
89053765|NCT00190671|Experimental|Pemetrexed 1800 mg/m2|
89053766|NCT00199914|Experimental|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
89053767|NCT00199914|Sham Comparator|control|continuous sham shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
89053768|NCT04607525|Experimental|Group D|Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline
89053769|NCT04607525|Placebo Comparator|Group C|Patients received equal volume and rate of normal saline as Group D.
89053770|NCT00198276|Experimental|Bleomycin|Bleomycin 4.0 U/mL at dose of 1 U/cm^3 of treatment area; Medpulser EP
89053771|NCT04607642|Experimental|A BMX-001|Patients will receive standard of care radiation therapy plus Cisplatin. BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
89053772|NCT04607642|Placebo Comparator|B Placebo|Patients will receive standard of care radiation therapy plus Cisplatin. Placebo will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks.
89053773|NCT00587808||HFpEF|Patients with a history of HFpEF
89053774|NCT00587808||control|Patients with a without a history of CHF
89053775|NCT00587925|Experimental|1|Bone Mineral Density
89053776|NCT00588003|Experimental|1|This is an exploratory study utilizing micro-array technology and immunohistochemistry to test the hypothesis that changes in gene expression occur as an early event in response to endocrine therapy and that these changes can be correlated with changes in surrogate biological markers.
89053777|NCT00588003|Placebo Comparator|2|no medication before surgery
89053778|NCT00588042|Active Comparator|1|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
89053779|NCT00588042|Sham Comparator|2|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
89053780|NCT00588081|Other|1|Participants will receive a cover letter, questionnaire and invitation to participate in a post-operative interview.
89053781|NCT04607291|Experimental|Health services research (Witness CARES services) Intervention|Patients who are not prepared for a colonoscopy or stool test receive educational materials, messages, and videos electronically or by mail with information about colorectal screening and are followed up by phone within 2 weeks. Patients desiring colonoscopy, receive navigators assistance with obtaining the screening (e.g.,determining gastrointestinal doctor, scheduling appointment, prep materials and process, transportation, escort). Patients desiring a stool test, receive navigators assistance by facilitating fecal tests.
89053782|NCT00588120|Experimental|C-13 labeled oxalate|Hyperoxaluric patients
89053783|NCT04574973|Experimental|Anodal tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
89053784|NCT04574973|Experimental|Cathodal tDCS|Subjects will receive 20 minutes of active, excitatoryinhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
89053785|NCT04574973|Experimental|Dual tDCS|Subjects will receive 20 minutes of active, excitatory transcranial direct current stimulation of the ipsilesional hemisphere and inhibitory transcranial direct current stimulation of the contralesional hemisphere at 1.4mA, followed by 2 hours of intensive motor therapy of the affected upper extremity.
89053786|NCT04574973|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the affected upper extremity.
89053787|NCT04607057|Experimental|experimental group (Arm A)|"Preparation of parenteral nutrition (PN): Among winuf(1820cc for central vein, 1,450cc for peripheral vein), smofkabaven(986cc for central vein, 1206cc for peripheral vein), and nutriplex(1875cc for central vein, 1,250cc for peripheral vein) Amount of PN: Total energy expenditure (TEE) of the patients will be calculated with Harris-Benedict Equation, activity factor, and stress factor. The amount of calorie from oral intake will be subtracted from TEE then the remainder will be provided through PN.~Route of PN Injection: PICC (percutaneously-inserted central catheter) will be secured for PN for the central vein. PN for the peripheral vein will be injected directly through peripheral superficial vein.~Day0 : fasting(NPO) + crystalloid fluid~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~POD#2 : Semifluid diet (SFD) + crystalloid fluid~POD#3 : Semifluid diet (SFD) + PN~POD#4-7: Soft blended diet (SBD) + PN"
89053788|NCT04607057|No Intervention|control group (Arm B)|"Day0 : fasting(NPO) + crystalloid fluid~POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~POD#2 : Semifluid diet (SFD) + dextrose 5% water~POD#3 : Semifluid diet (SFD) + dextrose 5% water~POD#4-7: Soft blended diet (SBD)"
89053789|NCT04575012|Experimental|Deferred invasive strategy|
89053790|NCT04575012|Other|Early invasive strategy|
89053791|NCT00564590|Experimental|A|Melatonin treatment group
89053792|NCT00564590|Active Comparator|B|Omeprazole 20 mg once a day for 3 months
89053793|NCT00564590|Experimental|C|Placebo once a day for 3 months
89053794|NCT04574817|Experimental|HX008|Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)
89053795|NCT00564707|Active Comparator|1|Standard biofeedback therapy will be given for painful levator ani syndrome over a course of eight weeks.
89053796|NCT00564707|Active Comparator|2|Botulinum toxin type A will be injected under EMG guidance into spastic and painful levator ani muscles. This may be repeated only twice on separate visits.
89053797|NCT04607018|Active Comparator|Chronic intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product already before the study started (since 28 days before or even longer)
89053798|NCT04607018|Active Comparator|Naive intake group|healthy subjects (control group) receive PMA-zeolite as powder. They take the product only since the first day of the study
89053799|NCT04606862|Experimental|Investigational Arm|The patients enrolled into the investigational arm at each participating hospital will be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis.
89053800|NCT04606862|No Intervention|Control Arm|The patients enrolled into the control group of each participating hospital will not be monitored with the Morley Medical Sepsis (MMS) Software Device for the prediction and early identification of sepsis. These patients will be monitored according to each institution's standard sepsis screening practices.
89053801|NCT00588276|Experimental|1|Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).
89053802|NCT04606667|Experimental|Multi component program|"The intervention lasted 16 weeks, with the evaluations carried out at baseline, after 8 weeks and at the end.~The multi-component exercise program took place in day centers or collective residences. It was supervised by physiotherapists. The classes took place 3 times a week, at the same hour and on alternate days, for 45-60 minutes, for a total of 48 sessions. The program consisted on a warm-up (5 min) with exercises and walking, a balance and strength training (35-40 min) with exercises repeated 3 times and held for 15 seconds flexibility / relaxation (5 to 10 mins) periods. The strength training is performed with the resistance of the body weight or accessible and low cost equipment, with two series of 10 to 15 repetitions, after maximum resistance was calculated.~The flexibility and cooling training consists of 3 repetitions maintained for 15 seconds."
89053803|NCT03452592|Experimental|The way patients take Alflutinib|patients take Alflutinib orally once per day at dose of 80mg or160mg
89053804|NCT04606511|Other|Breast cancer patients with lymphedema|
89053805|NCT04606511|Other|Breast cancer patients without lymphedema|
89053806|NCT00564746|Experimental|6 subjects in a single cohort|Each subject will be administered a single 10 milligrams (50 microcurie) oral dose of [14C]SB-681323.
89053807|NCT03452514||Cohort 1 - Low Dose CT (LDCT) Scan|Individuals undergoing their first or subsequent annual LDCT screening study
89053808|NCT03452514||Cohort 2 - Diagnostic CT Scan|Individuals referred for a follow-up diagnostic chest CT scan due to a lung-RADS category 3 or 4 result on a previous LDCT scan
89053809|NCT04606277||Young Adult|
89053810|NCT04606043|Experimental|Sandblasting|The enamel surfaces will be subjected to sandblasting prior to acid etching
89053811|NCT04606043|Active Comparator|Acid Etching Alone|Acid etching will be applied alone before the rebounding procedures
89053812|NCT00588432||1|Hemiparesis as the result of an ischemic hemispheric stroke.
89053813|NCT00588432||2|Immobilization following severe Achilles tendon tear or rupture, ankle injury or plantar fascial pain.
89053814|NCT00588432||3|Myofascial trigger points in trapezius muscle.
89053815|NCT00588432||4|Hyperthyroid Myopathy
89053816|NCT00588510||Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible.
89053817|NCT04606082|Experimental|Group 1|Granulocyte Colony Stimulated Factor was intrauterine injected once at ovum pick up day
89053818|NCT04606082|Active Comparator|Group 2|500 IU Human Chorionic Gonadotropins was injected intrauterine once at ovum pick up day
89053819|NCT04605770|Experimental|pemetrexed+cisplatin|Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.
89053820|NCT00588588|Active Comparator|1|Bronchoscopy
89053821|NCT00588588|Active Comparator|2|CPIS
89053822|NCT00588627||1|Post Nasal Drip and chronic cough
89053823|NCT00588627||2|Post nasal drip and no cough
89053824|NCT04605887|Active Comparator|treatment group|Ang 1-7 subcutaneously 500 mcg/kg /day
89053825|NCT04605887|Placebo Comparator|control group|NaCl 0.9% subcutaneously 2.0 cc once a day
89053826|NCT00588705||focus group & questionaire|The group will discuss its views about how and when to talk about the risk of getting breast cancer. The focus group will be video recorded and the video recorded material will be later transcribed and carefully analyzed. In addition you will be asked to answer questions about yourself, such as education and marital status.
89053827|NCT04606004|Experimental|Experimental (standard of care + stool application)|In addition to standard of care, they will apply stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time.
89053828|NCT04606004|Active Comparator|Control group (standard of care)|Will follow standard of care for skin care pre-operatively. They will not be applying ostomy stool output to the skin but can apply an OTC skin barrier such as Aquaphor, Desitin, or Vitamin A&D if the patient is experiencing skin redness from urine incontinence.
89053829|NCT00588783||1|
89053830|NCT00588783||2|
89053831|NCT04605926|Experimental|EQ001|EQ001 administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
89053832|NCT04605926|Placebo Comparator|EQ001 Placebo|Placebo administered in a blinded fashion by intravenous infusion on Day 1 and Day 8 for a total of 2 doses.
89053833|NCT00588939||I|participants with symptoms of acid reflux disease (heartburn)
89053834|NCT04605419|Experimental|Calcium electroporation|Calcium chloride
89053835|NCT00588978|Active Comparator|1|Diet alone
89053836|NCT00588978|Active Comparator|2|Exercise alone
89053837|NCT00588978|Active Comparator|3|Diet and exercise (combined)
89053838|NCT00589095||1|
89053839|NCT04605575|Experimental|Pyrotinib plus vinorelbine|
89053840|NCT00589134|Experimental|1|type of beverage
89053841|NCT00589173|Experimental|Intervention|Patients referred to the IPHR
89053842|NCT00589173|Active Comparator|Control|"Patients receiving standard preventive care"
89053843|NCT00589212|Experimental|1|Patients with 1-3 brain metastases
89053844|NCT04605224||Culinary class (intervention group)|The culinary class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
89053845|NCT04605224||Social studies class (control group)|The social studies class is 55-70 minutes in duration and is offered daily, Monday to Friday, over an 18-week semester (September 2019 to January 2020).
89053846|NCT00589251|Other|penicillin skin test|Patients will have the skin test placed
89053847|NCT00589368||1|stroke group
89053848|NCT00589368||2|control group
89053849|NCT00564785|Placebo Comparator|Placebo|
89053850|NCT00564785|Experimental|Synera(TM)|
89053851|NCT00564824|Experimental|CAD patients|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
89053852|NCT00564824|Experimental|Placebo|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
89053853|NCT00589446|Experimental|1|Embryoscopy will be evaluated in women with at least two previous miscarriages, after confirmation of missed abortion by ultrasound. Embryoscopy will only be performed in patients in whom curettage is clinically indicated, and will only be added to the D&C if there is a possibility of visualizing embryonic tissue, i:e. from approximately 5½ weeks onwards when there is an embryonic pole detected on ultrasound.
89053854|NCT00564863|Other|CS19 expressing ETEC strain|Ascending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
89053855|NCT00589485||1|
89053856|NCT00589485||2|
89053857|NCT00564941|Experimental|Deferasirox|
89053858|NCT00589641|Experimental|CBT-RP + Enhanced TAU|CBT-RP augmenting relapse prevention intervention, in addition to enhanced treatment as usual, monthly check-ins, and monitoring
89053859|NCT00589641|Active Comparator|Enhanced TAU (Treatment as Usual)|Treatment as usual in the community, monthly monitoring regarding service use and needs, monitoring
89053860|NCT04605068|Active Comparator|Transverse preputial island flap (Duckett's technique)|72 patients (Group I) with penoscrotal hypospadias with chordee
89053861|NCT04605068|Active Comparator|Double-faced preputial flap (DFPF)|72 patients (Group II) with penoscrotal hypospadias with chordee
89053862|NCT04605107|Experimental|A test|Epifasi 5000 I.U. Ampoules
89053863|NCT04605107|Active Comparator|B reference|Pregnyl 5000 I.U. Ampoules
89053864|NCT04605341|Active Comparator|group one|patient with metacarpal fracture that will use minipate for fixation
89053865|NCT04605341|Active Comparator|gruop two|patient with metacarpal fracture that will use buried k wires for fixation
89053866|NCT04605653|Experimental|Weight Management Intervention|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
89053867|NCT00589719||2000,3000,4000|Children at risk for asthma were identified using a cross-sectional asthma screening survey.
89053868|NCT00589758||Acute Decompensated Heart Failure|"Admitted to Heart Failure ICU for acute decompensated heart failure. 2D and 3D echocardiography will be obtained at baseline, 24 -48 hours and 1-2 weeks post discharge.~Blood and urine will be collected for biomarker evaluation at each timepoint"
89053869|NCT00564980|Active Comparator|1|Wafer Procedure
89053870|NCT00564980|Active Comparator|2|Ulnar shortening osteotomy
89053871|NCT00589953|Placebo Comparator|EPO###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
89053872|NCT00589953|Experimental|EPO ###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
89053873|NCT04605029||Critically Ill patients|No Intervention
89053874|NCT00590070|Active Comparator|1|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
89053875|NCT00590070|Active Comparator|2|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
89053876|NCT00590070|Placebo Comparator|3|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered
89053877|NCT00565019|No Intervention|Control|
89053878|NCT00565019|Experimental|Steroid|
89053879|NCT00590304||EU, LV, MA, EL, DU|The population will consist of 120 English-speaking participants ages 4-17 years from four rural schools with physician-diagnosed asthma or symptoms of asthma in the previous 12 months. As of June 2008, an additional rural school has been added to the population criteria, making a total of five rural schools.
89053880|NCT00565097|Placebo Comparator|2|Placebo
89053881|NCT00565097|Experimental|1|Lanreotide
89053882|NCT04604756|Experimental|Losartan group|Drug: Losartan
89053883|NCT04604756|Placebo Comparator|Placebo group|Drug: Placebo Oral Tablet
89053884|NCT00590343|Experimental|1|Intervention=Patients will receive treatment with PTK787/ZK222584 daily. A treatment cycle will be defined as a 28-day period. Subjects will continue on their present treatment regimen of receiving Sandostatin LAR 30mg IM every 4 weeks.
89053885|NCT04604717|Experimental|Pulmonary rehabilitation|8 weeks of pulmonary rehabilitation (twice weekly training) Exercise and education sessions accompanied by home exercise program
89053886|NCT04604717|No Intervention|Control group|Usual medical treatment for 8 week period
89053887|NCT04574700|Experimental|knee joint mobilization and traction|Tibiofemoral, Tibiofibular joint anterioposterior mobilization, keltonborn knee traction Transcutaneous electrical nerve stimulation(TENS) and quadriceps strengthening
89053888|NCT04574700|Active Comparator|Post isometric relaxation|Post isometric relaxation on hamstring, TENS and quadriceps strengthening.
89053889|NCT04604600|Experimental|amyloid PET、T807 PET|PET/CT
89053890|NCT00590421||1|145 individuals treated by irradiation in their childhood
89053891|NCT00590421||2|150 matched control subjects with no history of irradiation
89053892|NCT04604678|Experimental|Treatment with Metformin and LDN|Patients will be treated with 1500 mg/day of metformin and 4.5 mg/day of LDN for a total of 4 weeks.
89053893|NCT04604678|No Intervention|Regular health care comparison group|Patients will receive regular health care and will serve as a control group.
89053894|NCT00590499||agitation group|The Riker sedation-agitated scale (SAS) levels 5-7.
89053895|NCT00590499||non-agitation group|The Riker sedation-agitated scale (SAS) levels 1-4.
89053896|NCT03452436||Testicular cancer patients|Forty testicular cancer patients included after orchiectomy but prior to any further treatment.
89053897|NCT03452436||Prostate cancer patients|Forty prostate cancer patients included prior to medical castration and radiotherapy.
89053898|NCT03452436||Healthy controls|Forty age- and education-matched healthy controls (20 matched to testicular cancer patients, 20 matched to prostate cancer patients).
89053899|NCT04604639||Out-of-hospital cardiac arrest|Patients suffering an out-of-hospital cardiac arrest to who the ambulance service was requested to attend.
89053900|NCT04604327|Active Comparator|Prophylactic bemiparin (3,500 IU/day)|Bemiparin 3,500 IU daily for 10 days
89053901|NCT04604327|Experimental|Full therapeutic bemiparin (weight adjusted)|Bemiparin at full therapeutic dose, adjusted to body weight, for 10 days
89053902|NCT00590616||1|
89053903|NCT00590655|Active Comparator|2|Treatment B includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). Treatment lasts 17 weeks and after that there will be one and two year control visits including weighing and questionnaires for eating behavior and quality of life.
89053904|NCT00590655|Experimental|1|Treatment includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). After that a maintenance programme starts with monthly sessions for one year. Weight loss, quality of life, and eating behavior will be assessed at the end of the maintenance program and one year later.
89053905|NCT04604171|Experimental|Action Observation Training|Conventional treatment for 60 mins plus Action Observation Training for 30 mins
89053906|NCT04604171|Active Comparator|Task Oriented Training|Conventional treatment for 60 mins plus Task Oriented Training for 30 mins
89053907|NCT00590694|Active Comparator|Group1|Will receive ranibizumab treatments until resolution of macular edema only and as macular edema recurs.
89053908|NCT00590694|Active Comparator|Group 2|Will receive ranibizumab treatments until resolution of both macular edema and PED, and as macular edema or PED recur.
89053909|NCT00565175|Experimental|famotidine|
89053910|NCT00565175|Placebo Comparator|Placebo|
89053911|NCT00590811||adolescents|3rd year high school girls (14-16 years old)
89053912|NCT00590811||young adults|1st year university young females (18 - 20 years old)
89053913|NCT00477165|Experimental|Citalopram|One 20mg capsule per day for 4 weeks, then 2 capsules per day (40mg) for 4 weeks
89053914|NCT00477165|Placebo Comparator|Placebo|Identical to citalopram 20mg capsule. One capsule per day for 4 weeks, then 2 capsules per day for 4 weeks
89053915|NCT04604054|Experimental|Group 1|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Granulocyte Colony Stimulating Factor as a treatment.
89053916|NCT04604054|Active Comparator|Group 2|Females With a History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection will receive Human Chorionic Gonadotropin as a treatment.
89053917|NCT00476229|Experimental|Radiation + Chemotherapy + BSCT|Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)
89053918|NCT04603976|Experimental|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI)
89053919|NCT00476151|Placebo Comparator|placebo cream|vehicle cream
89053920|NCT00476151|Active Comparator|amitriptyline 4% ketamine 2% cream|active topical cream
89053921|NCT04603703|Experimental|HVLAT Manipulation|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics, HVLAT
89053922|NCT04603703|Active Comparator|Conventional physical therapy|Ultrasound, moist hot pack, piriformis stretching, myofascial release, gluteal muscles strengthening, sciatic neurodynamics
89053923|NCT00475644|Experimental|Enzastaurin|Enzastaurin: 1125 milligram (mg) loading dose then 500 mg, oral daily, up to 3 years
89053924|NCT04603664||study group|blood sampling and measduring of serum NGAL and cystatin c on admission and after 48 hours and creatinine every day
89686792|NCT01729897|Placebo Comparator|Propofol & Fentanyl|"4 min before procedure: fentanyl 1 g/kg (0.02 ml/kg), intravenous injection~After injection of fentanyl, propofol was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~Additional dose of propofol would be administrated separately when duration of procedure was prolonged."
89686793|NCT01048177|Experimental|Treatment|
89686794|NCT05517096|Experimental|E-Health and monitoring|eHealth care and explorative observational home-monitoring
89686795|NCT05517096|No Intervention|regular care and monitoring|only explorative observational home-monitoring during regular care
89686796|NCT02740582|Experimental|Tolcapone First, then Placebo|Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID
89686797|NCT02740582|Placebo Comparator|Placebo First, then Tolcapone|Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID
89686798|NCT05453266|Active Comparator|TXA Group|Patients with rotator cuff tear, operated arthroscopically under intraarticularly applied tranexamic acid in arthroscopic irrigation solution.
89686799|NCT05453266|Placebo Comparator|Control group|Patients with rotator cuff tear, operated arthroscopically without intraarticularly applied tranexamic acid in arthroscopic irrigation solution.
89686800|NCT01724827|Active Comparator|ceramic|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
89686801|NCT01724827|Active Comparator|composite|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
89686802|NCT03406663|Experimental|Group 1|"In group 1, the dose of Gla-300 will be titrated by the patients by 1 unit per day until achieving a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (INSIGHT algorithm).~Titration algorithms:~Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose~> 4.4 and ≤ 5.6 mmol/L, no change~< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
89686803|NCT03406663|Active Comparator|Group 2|"In group 2, the dose of Gla-300 will be titrated by the patients based on the SMPG values of the last 3 days at least weekly, but no more often than every 3 days to achieve a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (EDITION algorithm).~Fasting SMPG (median of the last 3 days including current day) in the range of~≥ 7.8 mmol/L, increase 6 units of Gla-300 dose~> 5.6 and < 7.8 mmol/L, increase 3 units of Gla-300 dose~> 4.4 and ≤ 5.6 mmol/L, no change~≥ 3.3 and < 4.4 mmol/L, reduce 3 units of Gla-300 dose~< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
89686804|NCT05187702|Experimental|Functional exercise group and aerobic group|Along with functional exercises, aerobic exercises (walking) 3 per week were given.
89686805|NCT05187702|Active Comparator|Aerobic Exersize Group|aerobic exercises (walking) 3 per week were given.
89686806|NCT05187702|No Intervention|Control Group|They continued their daily routine
89686807|NCT01049581|Experimental|pediatric aquatic therapy|The children of the PAT group participated in a 1 hour/time, twice-per-week, 12-week, PAT program in addition to conventional rehabilitation programs
89686808|NCT01049581|No Intervention|conventional therapy|The children included in the control group continued with their original rehabilitation programs
89686809|NCT05522400|Experimental|intervention group|
89686810|NCT05522400|No Intervention|control group|
89686811|NCT01724905|Experimental|Modified Stop Light Diet|
89686812|NCT01724905|Active Comparator|Recommended Care for Weight Reduction|
89686813|NCT02740660|Experimental|Caffeine 100mg / Albuterol 4mg|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
89686814|NCT02740660|Placebo Comparator|Placebo|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
89686815|NCT03929068|Active Comparator|carbidopa-levodopa|Each tablet of carbidopa-levodopa in this study will be equivalent to half of a standard carbidopa-levodopa 25/100mg tablet. Participants will take one tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
89686816|NCT03929068|Placebo Comparator|Placebo|Participants will take one placebo tablet three times a day for the first week of the study period, increasing to two tablets three times a day for the remainder of the study period.
89686817|NCT03925636|Experimental|Dietary therapy for C. difficile colonization|Dietary therapy intervention for this arm is the Specific Carbohydrate Diet.
89053925|NCT04603235|Experimental|Intervention|This is a quasi-experimental study
89686818|NCT05516784|Active Comparator|Clopidogrel|The primary endpoint is the non-inferiority in platelet reactivity of clopidogrel versus ticagrelor among CYP2C19*2 or *3 allele carriers.
89686819|NCT05516784|Experimental|Ticagrelor|The primary endpoint is the non-inferiority in platelet reactivity of clopidogrel versus ticagrelor among CYP2C19 CYP2C19*2 or *3 allele carriers.
89686820|NCT04337788|Experimental|gerontological telemonitoring action|"Nurses answer a daily resident-reported questionnaire (e.g. temperature, dyspnea, pain), edited by French health authorities. From D0 to D20, data are transmitted to the NHSP. Warning algorithms specially developed for older persons identify signs that are monitored by the NHSP geriatrician coordinator. A feedback is provided to the general physician for specific actions required and appropriate support.~A last questionnaire is completed at D30 by the nurse in order to stop monitoring and know event occurred between D20 to D30."
89686821|NCT04337788|No Intervention|routine care without gerontological telemonitoring|routine care
89686822|NCT05528016|Active Comparator|Skin-Only Blepharoplasty|Only the skin excision was performed for upper eyelid dermatochalasis.
89686823|NCT05528016|Active Comparator|Skin+Muscle Blepharoplasty|Skin plus muscle excision was performed for upper eyelid dermatochalasis.
89216782|NCT00581555|Placebo Comparator|placebo|Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.
89216783|NCT00469144|Experimental|Fixed-Dose Busulfan + Fludarabine|Busulfan Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
89686824|NCT05522166|Active Comparator|Digital Storytelling Group|After the digital storytelling group teacher candidates are determined, forms and digital stories will be prepared to be used as pre-test, post-test and retention test. Afterwards, the skill assessment, in which the pre-test form will be applied, will be observed without intervention and evaluated by the researcher. Then, digital stories about TYD will be uploaded to social media for teacher candidates to watch. After watching these applications for two months, one-to-one applications will be made with teacher candidates in face-to-face education models. One month after the last test, the posttest and permanence test will be held in the same environment.
89686825|NCT05522166|No Intervention|Face to Face Applied Training Group|After the teacher candidates of the face-to-face application group are determined, the seminar training and program will be prepared. Then, the forms developed by the researcher will be applied as a pre-test. Pre-test skills of teacher candidates will be evaluated by the researcher with a skill evaluation form by making face-to-face observations on the model without any intervention. After the 8-week training of the teacher candidates is over, knowledge and skills will be given as a post-test. One month after the last test, retention tests will be done in a similar way.
89686826|NCT02571972|Experimental|Dorzolamide-timolol|"On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.~Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.~Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits~At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients"
89686827|NCT03694288|Active Comparator|Removal Group|The implant removal group will have surgery scheduled 6 months after their initial surgical fixation.
89686828|NCT03694288|No Intervention|Retention Group|The implant retention group will retain their implant for a minimum of 2 years from the time of their initial surgery.
89686829|NCT05435872|Experimental|The intervention group (Artificial intelligence Cloud Platform Auxiliary Group)|The patients in this group would be examined by endoscopists with the Artificial intelligence Cloud Platform Auxiliary Device launched with gastrointestinal endoscopy.
89686830|NCT05435872|No Intervention|The control group (Non-Auxiliary Group).|The patients in this group would be examined by endoscopists with the gastrointestinal endoscopy alone.
89686831|NCT04994496|Experimental|Web-based intervention group|Two-week web-based intervention group
89686832|NCT04994496|Sham Comparator|Web-based control group|Two-week web-based sham comparator
89686833|NCT05377840|Active Comparator|Cognitive Behavioral Therapy|Participants in this arm will participate in CBT to assess the impact it will have on anxiety or depression among patients with Crohn's disease
89686834|NCT05377840|Experimental|Sudarshan Kriya Yoga|Participants in this arm will participate in SKY to assess the impact it will have on anxiety or depression among patients with Crohn's disease
89686835|NCT05516550|Experimental|Treamid 25 mg|1 tablet of Treamid 25 mg + 1 tablet of Placebo in the morning and 2 tablets of Placebo in the evening daily during 4 weeks of treatment period.
89686836|NCT05516550|Experimental|Treamid 50 mg twice a day|1 tablet of Treamid 25 mg + 1 tablet of Placebo in the morning and 1 tablet of Treamid 25 mg + 1 tablet of Placebo in the evening daily during 4 weeks of treatment period.
89686837|NCT05516550|Experimental|Treamid 50 mg once a day|2 tablets of Treamid 25 mg in the morning and 2 tablets of Placebo in the evening daily during 4 weeks of treatment period.
89686838|NCT05516550|Placebo Comparator|Placebo|2 tablets of Placebo in the morning and 2 tablets of Placebo in the evening daily during 4 weeks of treatment period.
89686839|NCT04382339|Active Comparator|Treatment-naive|"Naive Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
89686840|NCT04382339|Active Comparator|Treatment-experienced|"Experienced Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)"
89686841|NCT00842075|Experimental|1 Symlin|Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin
89686842|NCT00842075|No Intervention|2 Usual Regimen|Usual bolus insulin dose at each meal
89686843|NCT04382105||Control|observation of salivary IL-6 levels
89686844|NCT04382105||Periodontitis|observation of salivary IL-6 levels
89686845|NCT05522010|Active Comparator|Group (1) (ACDF)|All patients on this group will undergo Anterior Cervical Discectomy And Fusion
89686846|NCT05522010|Active Comparator|Group (2) (DCI)|All patients on this group will undergo Dynamic Cervical Implant
89686847|NCT05521932||IUA organoid|Organoids were generated from endometrial specimens remaining from pathological testing following adhesiolysis surgery.
89686848|NCT05233150|Experimental|PriCARE/CARIÑO plus Usual Care|Caregiver-child dyads assigned to the PriCARE/CARIÑO plus usual care group will receive the PriCARE/CARIÑO intervention within 4 months of randomization plus usual care. The intervention will last 6 weeks. Each group, administered by 1-2 trained mental health professionals, will have approximately 4-10 caregiver participants and will meet weekly for 6 weeks. Each of the 6 sessions is approximately 80 minutes. Caregivers are expected to practice the skills they learn with their children between sessions.
89686849|NCT05233150|No Intervention|Usual care|Caregiver-child dyads assigned to the usual care group will receive usual care and will not be aware of being in a group of about 8-10 recently-enrolled subjects.
89686850|NCT00879359|Experimental|I|
89686851|NCT05160844||Diseased|young Egyptian patients with premature myocardial infarction
89686852|NCT05160844||Control|healthy young Egyptians
89686853|NCT00880919|Active Comparator|1|Seroquel XR 150mg oral tablets taken daily for 8 weeks.
89686854|NCT00880919|Active Comparator|2|Seroquel XR 300mg oral tablets taken daily for 8 weeks.
89686855|NCT00880919|Placebo Comparator|3|Equivalent number of placebo oral tablets taken daily for 8 weeks.
89686856|NCT02741284|Experimental|No Oxygen|Room air
88998478|NCT04566250|Active Comparator|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 20mg PO daily x 30 tabs (to be taken only while utilizing Naproxen). In the case of a Naproxen intolerance, a prescription for Meloxicam 15mg PO BID PRN x 60 tabs will be given.~A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
88998479|NCT04566250|Other|Standard of Care|The control group is standard of care, which typically includes a prescription for an opioid.
88998480|NCT04548583|Experimental|remestemcel-L (150 million cells)|"Targeted endoscopic delivery of remestemcel-L, at a dose of 150 million cells into the submucosal layer of the colon wall at baseline~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)"
88998481|NCT04548583|Experimental|remestemcel-L (300 million cells)|"Targeted endoscopic delivery of remestemcel-L, at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.~If at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial)."
88998482|NCT04548583|Placebo Comparator|Placebo|"Direct injection of normal saline into the submucosal layer of the colon wall. If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L, at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.~If at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
88998483|NCT00167297|Experimental|Atomoxetine|Atomoxetine (Strattera) 25mg peroral (PO) each day for seven days, then up to 40mb bid 40mg PO each day for three days, then 80mg PO bid.
88998484|NCT04687579|Experimental|Umbilical hernia repair|Patients with cirrhosis undergoing umbilical hernia repair with or without preoperative optimization. See the section about interventions.
88998485|NCT04687579|Other|Watchful waiting|Patients who do not agree for operation but consent for follow-up. Patients will be followed in the whole inclusion period and can at any time change their preference if they wish to undergo surgery.
88998486|NCT04519684|Experimental|Mesenchymal stem cells|Direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.
88998487|NCT04519684|Placebo Comparator|Placebo|Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into ileal pouch fistula(s).
88998488|NCT04441840|Active Comparator|Active Probiotic Culture|Active culture of Bacillus Coagulans Dose: 1 x 10^9 colony forming units (CFU)
88998489|NCT04441840|Active Comparator|Inactive Probiotic Culture|"Inactive culture of Bacillus Coagulans (GBI-30, 6086) - Marked as StaImune Dose: 1 x 10^9 colony forming units (CFU)"
88998490|NCT04369417|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
88998491|NCT04369417|Active Comparator|Active Comparator: Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
88998492|NCT00195195||1|Sirolimus
88998493|NCT00583804|Experimental|Stimulation ON|Individuals implanted with stimulator/sensor device. Stimulator is turned on and is active.
88998494|NCT00583804|Active Comparator|Stimulation OFF|Function with stimulation turned off.
88998495|NCT04282330|Other|CEST imaging performed|CEST imaging will be performed (15 min): Axial 3D volume acquisition at 3.5 mm isotropic voxel size, 20-30 offset frequencies, plus Axial 3D T1w and T2w map at same resolution for use in CEST quantification. A routine stroke MRI protocol will also be performed (10 min): Axial T2w; Axial DWI and ADC (apparent diffusion coefficient) using accelerated multi-band sequence; Axial T2w* or SWI (susceptibility weighted imaging); and dynamic susceptibility contrast-enhanced (DSC) perfusion imaging following contrast agent administration (5 min, provided Radiology Department protocols allow DSC (e.g. no renal impairment)).
88998496|NCT04248010|Active Comparator|standard tDCS|20 min of standard 2-electrode transcranial direct current stimulation (2 mA) at a previously reported scalp location.
88998497|NCT04248010|Active Comparator|HD-tDCS - anterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to anterior language areas of the brain.
88998498|NCT04248010|Active Comparator|HD-tDCS - posterior target|20 min of individualized high-density 5-electrode transcranial direct current stimulation to posterior language areas of the brain.
88998499|NCT04248010|Sham Comparator|sham tDCS|sham transcranial direct current stimulation using a brief pulse at the beginning and end of the 20 min intervention.
88998500|NCT04122898|Experimental|Intervention Group|Three months home-based PFM training program with weekly follow-up by a physiotherapist
88998501|NCT04122898|No Intervention|Control Group|No intervention
88998502|NCT04687657|Experimental|cord blood transfusion|The arm that will receive the target treatment.
88998503|NCT04064593|Experimental|Polygraphy|
89686857|NCT02741284|Active Comparator|Oxygen|10L oxygen by nonrebreather mask
89686858|NCT00880997|Experimental|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both groups were tapered off doxazosin or placebo over study weeks 14-17."
89686859|NCT00880997|Placebo Comparator|placebo|A sugar pill to mimic the experiment drug, doxazosin, will be administered in the same manner as the experimental drug through the study duration.
89686860|NCT05521620|Active Comparator|Father-friendly NICU|"Fathers have skin-to-skin contact with their infants~Fathers participate in important situations~Fathers receive information and guidance directly~Both parents participate in meaningful conversations~The department organize mother and father groups~The families have the opportunity to have a close family member to support them~Older siblings have the opportunity to stay overnight.~The department offer counseling by a social worker"
89686861|NCT05521620|No Intervention|No Father-friendly NICU (baseline)|Baseline - before implementation of the intervention
89686862|NCT00881465|Experimental|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks. The first session will be held face-to-face to foster rapport. Sessions 1-4 will be held twice weekly; thereafter sessions will be held weekly. Sessions 1-3 are devoted to psychoeducation, treatment discussion, and hierarchy development. Sessions 4-10 involve CBT exercises specific to each youth.
89686863|NCT00881465|Placebo Comparator|Waitlist|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
89686864|NCT00883103|Active Comparator|Lidocaine|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
89686865|NCT00883103|Placebo Comparator|Aqueous gel|Plain aqueous gel as placebo will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
89686866|NCT02742532|Experimental|Oxytocin|Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)
89686867|NCT02742532|Placebo Comparator|Placebo|Intra-nasal saline placebo (5 puffs in each nostril)
89686868|NCT05521386|Experimental|Caffeine|caffeine dose of 5 mg per kg of body mass administered orally via a gelatine capsule
89686869|NCT05521386|Placebo Comparator|Placebo|maltodextrin (placebo) dose of 5 mg per kg of body mass administered orally via a gelatine capsule
89686870|NCT05521230|Placebo Comparator|Placebo|Participants rinsed 10 ml of placebo mouthwash for a period of 60 seconds, three times a day with an interval of 7-9 hours in between, for 4 days (period 1)
89686871|NCT05521230|Experimental|Cymenol (test)|Participants applied a 10 ml rinse of 0.1% cymenol mouthwash for a period of 60 seconds, three times a day with a 7-9 hour interval in between, for 4 days (period 1) and 4 days more (period 2)
89686872|NCT04984980|Experimental|combined treatment group|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab Gemcitabine: 1000mg/m^2, iv, d1, d8, q3w Oxaliplatin: 100mg/m^2, iv, d1, q3w Sintilimab: 200mg, iv, d1, q3w Bevacizumab: 5mg/kg, d1, q3w
89686873|NCT00370786|Experimental|1|
89686874|NCT03437356|Active Comparator|ADT ON Group|'CLOSE'-guided PVI with continuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation.
89686875|NCT03437356|Active Comparator|ADT OFF Group|'CLOSE' guided PVI with discontinuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation
89686876|NCT05516160|Experimental|multifocal lens|examination of dysphotopsia
89686877|NCT05516160|Active Comparator|control group|examination of dysphotopsia
89686878|NCT03387670|Active Comparator|Simvastatin|
89686879|NCT03387670|Placebo Comparator|Placebo|
89686880|NCT04979832|Experimental|Local administration of GM-CSF, fosfomycin and metronidazole in the pouch|"Local administration of 50 micrograms GM-CSF, 400 milligrams fosfomycin and 100 milligrams metronidazole in the pouch.~In a Phase A of the trial, this will be applied as a single dose during endoscopy of the pouch. In Phase B of the trial, this will be applied as a first dose during endoscopy of the pouch, followed by 6 further daily doses for a total of 7 doses."
89686881|NCT02740114|Active Comparator|Bupivacaine Group|"Local wound infiltration with Bupivacaine immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
89686882|NCT02740114|Experimental|Liposomal Bupivacaine + Bupivacaine Group|"Local wound infiltration with Liposomal Bupivacaine and 0.25% Bupivacaine admixed immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
89686883|NCT05527158|Experimental|Yi Jin Jing exercise|Yi Jin Jing exercise three times per week for 12 weeks. Each exercise lasts an hour and consists of three fundamental Yijinjing exercises.
89686884|NCT05527158|No Intervention|Routine care|routine joint rehabilitation guidance, such as joint energy conservation and joint protection, basic daily activities without additional exercise.
89686885|NCT03356470||FLT/PET + biopsy|F-FDG and FLT PET/CT imaging will be obtained prior to anti-cancer treatment and 10-12 weeks after starting treatment with anti-PD-1 antibody.
89686886|NCT05520996|Experimental|one arm study|Memory test performed before and after cyberball task
89686887|NCT05515926|Experimental|Cranial OMT|The experimental group received the three cranial osteopathic manipulative techniques, occipital-atlantal decompression (OAD), occipital-mastoid decompression (OMD), and compression of the fourth ventricle (CV4), consecutively applied.
89686888|NCT05515926|Sham Comparator|Sham manipulation|The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
88998504|NCT00167531|Experimental|Treadmill walking|30 minutes per day of treadmill walking with body weight support and assistance from one therapist
88998505|NCT00167531|Active Comparator|Overground walking|30 minutes per day of overground walking with assistance from one therapist
88998506|NCT04030234|Experimental|Intensive treatment group|Participants randomized into the Intensive treatment group will have a goal of SBP <120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of <120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
88998507|NCT04030234|Active Comparator|Standard treatment group|Participants randomized into the Standard treatment group will have a goal of SBP <140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is <130 mmHg at a single visit or <135 mmHg at two consecutive visits.
88998508|NCT03962023||Patient cohort|Routine follow-up of patients in the Cardiological Functional Explorations department - Valve Disease Centre for their primary mitral insufficiency by prolapse
88998509|NCT00532090|Experimental|1|
88998510|NCT00532090|Experimental|2|
88998511|NCT00532090|Experimental|3|
88998512|NCT03920176|Active Comparator|Computed tomography coronary angiography|
88998513|NCT03920176|Sham Comparator|Assign Score only|
88998514|NCT03888079||Local anesthetic|Patients who chose local anesthesia for their surgery
88998515|NCT03888079||General anesthetic|Patients who chose general anesthesia for their surgery
89686889|NCT05515926|No Intervention|Non touch group|The control group whose members did not receive any manipulations.
89686890|NCT05527080||typically developing infants|recruitment at 5-8mos of age; infants are considered typically developing if they are born at term age with no neurologically significant medical history, and they are not medically followed up for a suspicion of such. The benchmark for this is taken from the nationally harmonized pre/postnatal screening practise.
88998516|NCT00167648|Active Comparator|A|Leuprolide 7.5 mg or Goserelin 3.6 mg
88998517|NCT00167648|Experimental|B|Transdermal estradiol 0.6 mg q 3 days
88998518|NCT03852706|Experimental|LORETA|In the first session, Low Resolution Brain Electromagnetic Tomography (LORETA) will be used in combination with Z-scores to identify participants' resting state EEG differences relative to a database of norms of their demographic. EEG abnormalities which are consistent with the research literature on neural changes associated with AVH will then be targeted for normalization using neurofeedback training using LORETA in combination with Z-scores.
88998519|NCT03852706|Other|Treatment as usual|Maintenance use of an atypical antipsychotic (e.g., clozapine) with support, when needed, of a community nurse.
88998520|NCT02907034|Experimental|Group 1|First,Virtual reality approach (VR), then classical narrative approach (CN)
88998521|NCT02907034|Active Comparator|Group 2|First, classical narrative approach (CN), then virtual reality approach
88998522|NCT02906722|Experimental|Experimental group|Patients receive simultaneously nebulized colimycin every 8 h and intravenous placebo administered once, twice or 3 times per day according to renal function
88998523|NCT02906722|Active Comparator|Control group|Patients receive simultaneously intravenous colimycin administered once, twice or 3 times per day according to function renal and nebulized placebo every 8 h
88998524|NCT00167687|Placebo Comparator|2|
88998525|NCT02906956|Experimental|Preferred Music Playlist|All participants will have this phase twice in the protocol. See description in intervention section.
88998526|NCT02906995|Experimental|Sublingual tablet 4 mg|The 24 study participants will be administered the sublingual 4 mg nicotine tablet on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
88998527|NCT02906995|Active Comparator|Nicorette lozenge 4 mg|The 24 study participants will be administered the Nicorette lozenge containing 4 mg of nicotine on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
88998528|NCT02906800|Experimental|DIGHANC|Patients meeting all inclusion /exclusion criteria, will be given 3 cycles of the following regimen: 1) digoxin (0.25 mg/day) for a 7-day period (digitalization time) from Day 1 to Day 7; 2) chemotherapy regimen TPF protocol from Day 8 to D12 (continuous perfusion of fluorouracil for 120h, Cisplatin at Day 10 and Docetaxel at Day 11) administered in combination with digoxin 0.25 mg/day from Day 8 to Day 9; 3) a 15-day period off treatment.
88998529|NCT02906683|Experimental|TAS-303 3mg|
88998530|NCT02906683|Experimental|TAS-303 6mg|
88998531|NCT02906683|Placebo Comparator|Placebo|
88998532|NCT02906605|Experimental|JNJ-809 plus Apalutamide (Group A)|JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.
88998533|NCT02906605|Experimental|Apalutamide (Group B)|Apalutamide 240 mg orally daily.
88998534|NCT02906527||Non-exposed group|Non-exposed group / Patients receiving VKA
88998535|NCT02906527||Exposed group|Exposed group / Patients receiving DOAC
88998536|NCT02906410|No Intervention|Control 1|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for numeric labeling conditions.
88998537|NCT02906410|Experimental|Numeric individual|Features Item-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices.
88998538|NCT02906410|Experimental|Numeric individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices. Additionally, an aggregated numeric calorie count for the entire meal will be dynamically updated as items are added or removed from the meal.
88998539|NCT02906410|No Intervention|Control 2|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for light labeling conditions.
88998540|NCT02906410|Experimental|Light individual|Features Item-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices.
88998541|NCT02906410|Experimental|Light individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices. Additionally, an aggregated traffic light label for the entire meal will be dynamically updated as items are added or removed from the meal.
88998542|NCT02906449|Experimental|Mindfulness Training|Daily Mindfulness Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
88998543|NCT02906449|Active Comparator|Relaxation Meditation Training|Daily Relaxation Meditation Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
88998544|NCT02906371|Active Comparator|Tocilizumab high tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
88998545|NCT02906371|Active Comparator|Tocilizumab low tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
88998546|NCT00167804|Other|1|Present Centered Therapy focuses on the veterans problems in the here and now. It uses a problem solving approach and avoids discussion of war related traumatic events.
88998547|NCT02906293||Healthy Participants|Potential participants will self-refer.
88998548|NCT02906254||ECIL-4 guidelines group|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st February 2014 to 30th November 2014, antibiotics were stopped when patients had been afebrile for more than 48 hours, as recommended by the ECIL-4 guidelines"
89053926|NCT00474903|Active Comparator|Arm I (placebo, esomeprazole magnesium)|Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
89053927|NCT00474903|Experimental|Arm II (low-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
89053928|NCT00474903|Experimental|Arm III (higher-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
89053929|NCT01134055|Experimental|investigational arm 1|5 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
89053930|NCT01134055|Experimental|investigational arm 2|5 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
89053931|NCT01134055|Experimental|investigational arm 3|10 mg/mL pazopanib eye drops BID with allowance for as-needed ranibizumab injection
89686891|NCT05527080||neurodevelopmental concern|recruitment at 5-8mos of age; infants are recruited from the outpatient clinic in the New Children's hospital (NCH). They have either a known perinatal risk factor (e.g.stroke, HIE, meningitis), or they are referred to pediatric neurologists at NCH due to a suspected delay or deviance in neurodevelopment.
89686892|NCT05527080||hip dysplasia concern|recruitment at 2-6 weeks of age after perinatal clinical suspicion of hip dysplacia. These infants may be left out of follow-up (mild), or treated by orthopedic clinic with a soft brace (moderate) or a stronger cast (sever)
89686893|NCT04745104|Experimental|SHR-1707 Dose level 1|SHR-1707 or placebo is administered intravenous to young healthy subjects
89686894|NCT04745104|Experimental|SHR-1707 Dose level 2|SHR-1707 or placebo is administered intravenous to young healthy subjects
89686895|NCT04745104|Experimental|SHR-1707 Dose level 3|SHR-1707 or placebo is administered intravenous to young healthy subjects
89686896|NCT04745104|Experimental|SHR-1707 Dose level 4|SHR-1707 or placebo is administered intravenous to young healthy subjects
89686897|NCT04745104|Experimental|SHR-1707 Dose level 5|SHR-1707 or placebo is administered intravenous to young healthy subjects
89053932|NCT01134055|Experimental|investigational arm 4|10 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
89053933|NCT01134055|Experimental|investigational arm 5|10 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
89053934|NCT01134055|Placebo Comparator|placebo control arm|Placebo eye drops QID with allowance for as-needed ranibizumab injection
89053935|NCT01134055|Active Comparator|active open-label control arm|Ranibizumab intravitreal injection every 4 weeks
89053936|NCT00474708|Experimental|1|1.Effexor XR Group
89053937|NCT00474708|Active Comparator|2|2.SSRI or Conventional Antidepressant Group
89053938|NCT04603040|Experimental|Experimental group|Experimental group:ToripalimabTreatment
89053939|NCT04603118|Other|The patients with Idiopathic intracranial hypertension (IIH)|33 patients who applied to the neurology clinic with the pre-diagnosis of IIH were performed lumbar puncture. 25 of them diagnosed with IIH. Optic nerve sheath diameter was measured by optic ultrasonography from both eyes before and after the LP.
89053940|NCT04603118|Other|Control group|In the control group, optic nerve sheath diameter was measured from both eyes by optic ultrasonography.
89053941|NCT02883127||The study group|Receives lifestyle intervention with motivational interviewing focusing on following the recommended diabetes diet and gestational weight gain recommendations in addition to routine care
89053942|NCT02883127||The control group|Was given the same routine care with the same treatment goals, but without motivational interviewing.
89053943|NCT04603586|Experimental|Arm A|SBRT with BED 60-70Gy combined with Gemcitabine + albumin-bound paclitaxel
89053944|NCT04603586|Experimental|Arm B|SBRT with BED >70Gy combined with Gemcitabine + albumin-bound paclitaxel
89053945|NCT00474240|Placebo Comparator|1|
89053946|NCT00474240|Active Comparator|2|
89053947|NCT00474240|Experimental|3|
89053948|NCT00474240|Experimental|4|
89053949|NCT00474240|Experimental|5|
89053950|NCT00474240|Experimental|6|
89053951|NCT02277561|Experimental|Diagnostic (VB-DTI, MRI)|Patients undergoing WBRT for a total of 10 fractions also undergo VB-DTI MRI at baseline, 1 week after WBRT initiation, and 7-11 days after completion of WBRT. Patients undergoing SRS without WBRT also undergo VB-DTI MRI at baseline and 7-11 days after completion of SRS.
89053952|NCT00473889|Experimental|1|vorinostat; IV paclitaxel; IV carboplatin
89053953|NCT00473889|Placebo Comparator|2|Placebo; IV paclitaxel; IV carboplatin
89053954|NCT04602416||Control (Health)|The control had two sessions: the Introduction and another on Health. The health sessions were based on topics used by United States Peace Corps medical officers training volunteers about how to stay healthy in Tanzania: nutrition, worms, HIV/AIDS, and first aid.
89053955|NCT04602416||Entrepreneurship|The sessions for this arm were six: the two sessions of the Control arm, plus Sources of Capital, Marketing, Saving and Investing Profit, and Writing a Business Plan. Each session lasted one day.
89053956|NCT04602416||Beekeeping|The Beekeeping arm had six sessions: the two sessions of the Control arm, plus Beginning Beekeeping, Environment-Forests-Bees, Building a Beehive, and Harvesting.
89053957|NCT04602416||All Interventions|This arm was 10 sessions, and included all sessions of the Control, Entrepreneurship, and Beekeeping
89686898|NCT04745104|Experimental|SHR-1707 Dose level 3 (Elderly subjects)|SHR-1707 or placebo is administered intravenous to Elderly subjects
89686899|NCT04296474|Active Comparator|Active ILIT treated|Patients that have received ILIT with birch and grass allergen 5-6 years previously
89686900|NCT04296474|Placebo Comparator|Non- AIT treated|Patients that have received placebo ILIT 5-6 years previously and patients with birch and grass pollen induced allergic rhinitis that have not previously been treated with allergen immunotherapy (AIT).
89686901|NCT04295850||Low Dose Aspirin|"Pregnant singletons at high risk for preeclampsia based on:~at least one high risk factor for preeclampsia: prior preeclampsia, chronic hypertension, pregestational diabetes, lupus, antiphospholipid antibody syndrome, or chronic kidney disease. OR~at least two of the following: BMI>30, black race, state insurance, IVF pregnancy, advanced maternal age, nulliparous or >10yr from last delivery, prior adverse pregnancy outcome~who are planning to, but have not yet started, aspirin therapy <16 weeks' gestation. Patients will take 81mg aspirin as prescribed."
89216784|NCT00469144|Experimental|Adjusted Dose Busulfan + Fludarabine|Busulfan Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
89216785|NCT01025050|Experimental|Group A|In this group the smallest ring diameter will be applied.
89216786|NCT01025050|Experimental|Group B|In this group the intermediate ring diameter will be applied.
89216787|NCT01025050|Experimental|Group C|In this group the biggest ring diameter will be applied.
89216788|NCT02576093|Experimental|0.1% WOL071-007|Formulation containing 0.1% WOL071-007 for topical application
89216789|NCT02576093|Experimental|0.3% WOL071-007|Formulation containing 0.3% WOL071-007 for topical application
89216790|NCT02576093|Experimental|1.0% WOL071-007|Formulation containing 1.0% WOL071-007 for topical application
89216791|NCT02576093|Placebo Comparator|WOL071-007 Placebo|Formulation containing Placebo of WOL071-007 for topical application
89686902|NCT05520918|Other|COVID-19 pneumonia patients|sequential LIT was performed to this patient group
89686903|NCT04738240|Experimental|Intra-operative endoscopy|The intervention arm will have an intra-operative endoscopy performed per rectum once the anastomosis has been performed. The anastomosis will be graded from 1 to 3 in the endoscopic group. Grade 1 is defined as circumferentially normal appearing peri-anastomotic mucosa. Grade 2 is defined as ischemia or congestion involving <30% of either the colon or rectal mucosa. Grade 3 is defined as ischemia or congestion involving >30% of the colon or rectal mucosa or ischemia/congestion involving both sides of the staple line. If appearances are grade 2 a suture re-inforcement or re-anastomosis will be performed; if appearances are grade 3 a re-anastomosis will be performed. Images will be obtained via the endoscopy stack during the assessment.
89053958|NCT04602455|Experimental|Heartfulness Group|Participants were asked to practice relaxation tools for 15 minutes a day using the calendar and HeartBot app, and participate in once a week webinar for 30 minutes during the four weeks. UCLA Loneliness scale was recorded prior to the start of the study and at its end after the duration of 4 weeks. The score was reviewed to see the changes in the loneliness scale.
89053959|NCT04602455|No Intervention|Control Group|The control group had no change in their daily routines.
89053960|NCT00565214|Active Comparator|Group 1|On Day 1, Group 1 will initiate in a double-blinded fashion, a once daily vitamin combination of selenomethionine(400 μg), vitamin E(400 IU), and vitamin C (1000 mg) orally for 30 days at home. After 30 days of treatment with Vitamin supplements, the gene expression of the airway epithelium will be compared to that of the Placebo group.
89053961|NCT00565214|Placebo Comparator|Group 2|On Day 1, Group 2 will initiate the placebo in a double-blinded fashion.
89053962|NCT00575172||U|Intensified insulin therapy with ultrarapid insulin-analogue (Insulin-Aspart)
89053963|NCT00575172||R|Intensified insulin therapy with human regular insulin
89053964|NCT04602689|Experimental|Fibrin glue group|Spread Fibrin glue(Greenplast Q™) at iatrogenic ulcer after gastric ESD
89053965|NCT04602689|No Intervention|Control group|No intervention after gastric ESD
89053966|NCT00575211||Cardiomyopathy|
89053967|NCT02277600|Experimental|Cohort 1, Treatment A, B|"Treatment A:~BMS-663068 orally twice daily (BID) on Days 1 through 4~Treatment B:~BMS-663068 orally BID plus DRV/COBI orally once daily (QD) on Days 5 through 14"
89053968|NCT02277600|Experimental|Cohort 2, Treatment C, D|"Treatment C:~BMS-663068 orally BID on Days 1 through 4~Treatment D:~BMS-663068 orally BID plus COBI QD on Days 5 through 14"
89053969|NCT00575250|Active Comparator|1|Osteoporosis Prevention and Self-Management Course (4 x 2 1/2 hours)
89053970|NCT00575250|Active Comparator|2|"One introductory osteoporosis education session (1 x 2 1/2 hours)"
89053971|NCT04602143|Experimental|Testosterone gel 4 weeks|Patients with low ovarian reserve received 4-week TTG application before controlled ovarian hyperstimulation.
89053972|NCT04602143|Experimental|Testosterone gel 6 weeks|Patients with low ovarian reserve received 6-week TTG application before controlled ovarian hyperstimulation.
89053973|NCT04602143|No Intervention|Control group|Patients with low ovarian reserve received no medication before controlled ovarian hyperstimulation.
89686904|NCT04738240|No Intervention|Standard air leak test|The control arm will receive an intra-operative leak test. This involves insufflation of air per rectum via bladder syringe while the anastomosis is bathed in sterile water. The presence of air bubbles from the anastomosis denotes a positive test.
89686905|NCT05520840|Experimental|Patient referred for screening colonoscopy or for endoscopic resection|Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
89686906|NCT02166905|Experimental|Arm I (CDX-1401, poly ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly ICLC as in Phase I.
89686907|NCT02166905|Experimental|Arm II (CDX-1401, poly ICLC, IDO1 inhibitor INCB024360)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, and IDO1 inhibitor INCB024360 as in Phase I.
89686908|NCT02743078|Experimental|Bevacizumab and TTFields Therapy|Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.
89686909|NCT04294368|Other|Control|Standard fortification of breast milk
89686910|NCT04294368|Experimental|Experimental|Targeted fortification of breast milk
89686911|NCT03323398|Experimental|Arm A: mRNA-2416 Alone|Participants will be administered mRNA-2416 through an intratumoral injection at the applicable dose on Days 1 and 15 for six 28-day cycles.
89686912|NCT03323398|Experimental|Arm B: mRNA-2416 in Combination with Durvalumab|Participants will be administered mRNA-2416 through an intratumoral injection at the applicable dose on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 6 in combination with durvalumab through an intravenous infusion at a fixed dose on Day 1 of Cycles 1 through 6. The duration for each cycle is 28 days.
89686913|NCT00890981|Other|Arm 1|Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.
89686914|NCT05515770|Experimental|Injectable Cabitegravir|Participants that are interested in Cab long action injectable
89686915|NCT05520684||positive for bacteriuria/ urinalysis abnormality|The patients who have any growth in urine culture or urinalysis abnormality at the initiation of SGLT2 inhibitor (dapagliflozin or empagliflozin)
89686916|NCT05520684||negative for bacteriuria/ urinalysis abnormality|The patients who do not have growth in urine culture or do not have abnormality in urinalysis at the initiation of SGLT2 inhibitor (dapagliflozin or empagliflozin)
89686917|NCT04480138|Experimental|Pegylated Interferon-α2b + Standard of care|"Test :- Pegylated Interferon-α2b + Standard of care (SOC)~Pegylated Interferon-α2b-Initial 1 mcg/kg will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered along with the recommended standard of care at the time of conduct of trial."
89686918|NCT04480138|Active Comparator|Standard of Care|"Control: Standard of care~Standard of care treatment will be provided as per regulatory recommendation and approval."
89053974|NCT02277678|Experimental|Oxycodone|Epidural oxycodone 3mg single dose as opioid administration
89053975|NCT02277678|Active Comparator|Morphine|Epidural morphine 3mg single dose as opioid administration
89053976|NCT04601636|Active Comparator|Active Prewarming group (PW group)|Group randomized to receive at least 30 minutes of active prewarming before induction of anesthesia, combined to active warming intraoperatively.
89053977|NCT04601636|Placebo Comparator|Control group (C group)|Group randomized to receive the standard care : passive prewarming before induction of anesthesia combined to active warming intraoperatively.
89053978|NCT04579536|Experimental|Study group|This is the study group; it will consist of 84 first permanent molars. These molars will be sealed using light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA). reapplication will be done after 3,6, 12, and 18 months.
89053979|NCT04579536|Other|Control group|This group will consist of 84 first permanent molars. These molars will receive 5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA). These molars will serve as a control group. reapplication will be done after 3,6, 12, and 18 months.
89686919|NCT00371488|Experimental|GW572016 in combination with trastuzumab|"Lapatinib:~A specified dose of lapatinib will be orally taken once daily, at least one hour before or one hour after the morning meal. Lapatinib should be taken at the same time of day wherever possible.~The starting dose of lapatinib should be 750 mg/day, which will be increased to 1000 mg/day (dose escalation group) according to the dose escalation criteria.~Trastuzumab:~Trastuzumab (4 mg/kg/day in the first week and 2 mg/kg/day for the 2nd and subsequent weeks) will be administered by intravenous infusion over at least 90 minutes immediately after administration of lapatinib. The fifth (Day 36) and subsequent doses may be administered up to 3 days after the scheduled date. In this case, however, the all following doses should be administered at one-week intervals."
89686920|NCT02743312|Experimental|Torso Weights then Sham Weights|"No weights worn for 4 weeks. Garment with torso weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with sham weights for 2-4 hours daily for 2 weeks.~Participants wear the Fitbit Flex throughout."
89686921|NCT02743312|Experimental|Sham Weights then Torso Weights|"No weights worn for 4 weeks. Garment with sham weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with torso weights for 2-4 hours daily for 2 weeks.~Participants wear the Fitbit Flex throughout."
89686922|NCT01501955|Active Comparator|Stanmore|25 patients will have the Stanmore prosthesis
89686923|NCT01501955|Experimental|Metaphyseal Hip Prosthesis|25 patients will have the Metaphyseal Hip Prosthesis (MHP) prosthesis
89686924|NCT02743702|Experimental|GROUP RECEIVING RESPIRATORY PHYSIOTHERAPY|Respiratory Physiotherapy sessions were held once a week by the physiotherapist, and four times more for the family at home, for one year. The sessions have a duration between 30 and 45 minutes, varying according to the level of patient cooperation. The exercise program should be repeated in three cycles, although younger children took longer than older in performing them.
89686925|NCT02743702|Experimental|GROUP RECEIVING THEIR USUAL THERAPIES|This group received no approach of their respiratory difficulties by Physiotherapy. Only continued their usual therapies.
89686926|NCT04335760||Patients with Coronary Artery Disease|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
89686927|NCT04335760||healthy subjects|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
89686928|NCT05520606||minimally invasive surgery|laparoscopic pancreatoduodenectomy.
89686929|NCT05520606||open surgery|open pancreatoduodenectomy
89686930|NCT02743936|Experimental|NIPPV with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula in place
89686931|NCT02743936|Active Comparator|NIPPV without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula
89686932|NCT00842231||Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
89686933|NCT04337632|Experimental|PP|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, day 1, intravenous drip, repeated every three weeks.
89686934|NCT04337632|Active Comparator|TP|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
89686935|NCT05526612|Active Comparator|Group 1|Motor imagery and Bobath Therapeutic Approach (BTA+MI)
89686936|NCT05526612|Experimental|Group 2|Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)
89686937|NCT05349058||ICI patients|Patients receiving an Immune Checkpoint Inhibitor as treatment for their malignancy
89686938|NCT05348980|Active Comparator|Phenylephrine 4mg|Inj Phenylephrine HCL 04 mg as Group P4.
89686939|NCT05348980|Active Comparator|Phenylephrine 8mg|Inj Phenylephrine HCL 08 mg as Group P8.
89686940|NCT00884585|Experimental|Cyclosporine Ophthalmic Solution (COS) followed by COS|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
89053980|NCT04601519||Patients-type 1 diabetes|Participants are recruited by e-mail, among the users of the libreview platform (Abbott), who are followed up for type 1 diabetes at the CHU Grenoble Alpes (France), to participate in an anonymous online questionnaire and to allow their glycemic data extracted from the libreview platform to be used for the research.
89053981|NCT04601675|Experimental|Diabetic ME: Ranibizumab and intravitreal Dexamethasone|Participants with diabetic macular edema will receive a combination of Ranibizumab and intravitreal Dexamethasone
89686941|NCT00884585|Other|Placebo followed by COS|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution 0.010% up to 9 additional months; at Month 9 the dose may be adjusted to 2 times a day.
89686942|NCT05520372|Experimental|autologous immune enhancement therapy (AIET) for treating cancer|A total of 60 cancer patients received one to seven sittings of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) infusions.
89053982|NCT04601675|Active Comparator|Diabetic ME: Ranibizumab|Participants with diabetic macular edema (ME) will receive Ranibizumab only.
89686943|NCT00884897|Experimental|Oxytocin|We will purchase OT from PharmaWorld, an international pharmacy located in Switzerland; the preparation of intranasal OT is manufactured by Novartis and sold under the trade name: Syntocinon. We have obtained an IND (number 78,246) for Syntocinon (intranasal oxytocin) manufactured by Novartis.
89686944|NCT00884897|Placebo Comparator|Placebo|We will be purchasing oxytocin placebo nasal spray through LABOSWISS located in Davos, Switzerland and distributed through PharmaWorld. LABOSWISS will manufacture the matching the placebo under GDP guidelines. The placebo will be in every way identical to the oxytocin formulation but will not contain OT.
89686945|NCT02753842|Experimental|Fitted, Then Thin, Then Standard Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
89686946|NCT02753842|Experimental|Fitted, Then Standard, Then Thin Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
89686947|NCT02753842|Experimental|Thin, Then Fitted, Then Standard Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
89686948|NCT02753842|Experimental|Thin, Then Standard, Then Fitted Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
89686949|NCT02753842|Experimental|Standard, Then Fitted, Then Thin Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
89686950|NCT02753842|Experimental|Standard, Then Thin, Then Fitted Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
89686951|NCT03216473|Experimental|Neuronox|Botulinum Toxin Type A for injection
89686952|NCT03216473|Active Comparator|Botox|Botulinum Toxin Type A for injection
89686953|NCT00886145|Other|Vibration and No Vibration|Vibration: Right Leg and No Vibration: Left Leg.
89686954|NCT02753920|Active Comparator|Retrograde fill voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~Catheter is removed~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~The patient will subjectively quantify their force of stream via visual analog scale (VAS) scale (however this information will only be used for research purposes).~If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids <200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial."
89686955|NCT02753920|Active Comparator|Force of Stream (FAST) voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~Catheter is removed~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~The patient will subjectively quantify their force of stream via VAS scale.~If VAS scale >/=50 (>/=50%) the catheter will remain out, patient is discharged home without measuring a PVR~If VAS scale is from 0-49 (=0-49%) a PVR will be checked via bladder scan. If PVR is <500cc, the patient will be discharged without a catheter; if PVR is >/=500cc, the patient will be discharged with a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days."
89686956|NCT00887471||Children who underwent PITA|Children who underwent partial intracapsular tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
89686957|NCT00887471||Children who underwent T&A|Children who underwent total tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
89686958|NCT05520216||asymptomatic individuals|The demographic information of the participants (gender, age, height, body weight, body mass index, occupation, dominant extremity, education level, marital status) will be questioned with the Demographic Data Form to be created by the researchers. Except for the demographic data form, the breath-holding capacity of the participants will be evaluated by measuring the breath-holding times, and the thoracic cage mobility will be evaluated by measuring the chest circumference during normal respiration, maximal inspiration and maximal expiration. The curvature of the spine, the presence of kyphosis and lordosis will be measured using the Spinal Mouse (IDIAG m360) device, which is an objective measurement method. The flexibility of the spine and indirectly the mobility of the rib cage will be checked with the sit and lie test. The results of the evaluations will be recorded.
89686959|NCT02754310|Active Comparator|Repeated scenarios|Participants in the repeated scenario group will learn the management of a pediatric asthma exacerbation on the same scenario repeated three times. The scenario is a pediatric moderate asthma exacerbation not responding to treatment, .
89686960|NCT02754310|Experimental|Varied scenarios|"Participants in the varied scenarios group will learn the management of a pediatric asthma exacerbation on three different scenarios: a moderate asthma exacerbation, a mild one, and a severe one, for the same length of time than the repeated scenarios group. In this group, there is a variation of scenarios."
89053983|NCT02277756|Experimental|high functioning Autism|Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with high functioning Autism
89053984|NCT02277756|Placebo Comparator|witness|Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with a witness
89053985|NCT04601597|Experimental|The catheter tip was placed in the subclavian vein.|The pre-placement catheter length measured through the body surface was greater than the actual length. Therefore, 2 cm was subtracted from the pre-puncture point to the ipsilateral sternoclavicular joint to calculate the effective catheter pre-placement length.
89053986|NCT04601597|Experimental|The tip of the catheter was placed in the axillary vein of the chest wall.|The pre-placement length of the catheter was measured by subtracting 3-4 cm from the distance between the puncture point and ipsilateral midclavicular line. This adjustment was intended to prevent the catheter tip from entering the subclavian vein.
89053987|NCT04601597|Experimental|the catheter tip was located distal to the axillary vein.|The measurement method of catheter pre-placement length was as follows: in cases where the catheter was punctured from the basilic and brachial veins, the distance from the pre-puncture point to the intermuscular sulcus of the ipsilateral deltoid muscle and pectoralis major muscle was measured (not surpassing the intermuscular sulcus and not reaching the axilla); however, the distance from the pre-puncture point to the ipsilateral sub shoulder or axilla was measured.
89686961|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-6 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89686962|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-6 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89053988|NCT01580865|Active Comparator|Mycophenolate Mofetil (MMF)|MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. .
89053989|NCT01580865|Experimental|Tacrolimus (TAC)|TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter
89053990|NCT04601441|Other|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
89053991|NCT00473694|Experimental|rocuronium+sugammadex|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 post-tetanic counts (PTC) and after the last dose of rocuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
89053992|NCT00473694|Active Comparator|rocuronium+neostigmine|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 PTC and after the last dose of rocuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
89053993|NCT00473694|Experimental|vecuronium+sugammadex|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
89053994|NCT00473694|Active Comparator|vecuronium+neostigmine|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
89053995|NCT04601792|Experimental|Individualized Decoction|"It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For subjects with lung and spleen qi deficiency syndrome, the investigators added Radix Codonopsis Pilosulae, Pericarpium Citri Reticulatae, and Atractylodes Macrocephala Koidz. The investigators can adjust the individualized decoction in accordance with the change in the patient's condition throughout the whole study duration.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
89053996|NCT04601792|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
89053997|NCT04601792|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
89053998|NCT02210013||Caucasian women|200 Caucasian infertile women undergoing their first or second IVF cycle
89686963|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 6-12 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89686964|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 6-12 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89686965|NCT03384563|Placebo Comparator|Placebo 6-12 months|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89686966|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-3 years|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89686967|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-3 years|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89686968|NCT03384563|Placebo Comparator|Placebo 1-3 years|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89686969|NCT03384563|Placebo Comparator|Placebo 1-6 months|Saline intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
89053999|NCT02210013||Indian women|200 Indian women undergoing their first or second IVF cycle.
89054000|NCT02210130||patients HIV+ CSVD+|patients with HIV and cerebral small vessel disease
89054001|NCT02210130||control HIV+ CSVD-|patients with HIV and without cerebral small vessel disease
89054002|NCT04601012||Patients with COVID19|The patients with previous diagnosis of COVID19
89054003|NCT04601012||Control subjects|Healthy subjects without actual and previous ocular diseases
89054004|NCT00565331|Active Comparator|1|Rituximab
89054005|NCT00565331|Placebo Comparator|2|Placebo
89054006|NCT04576481|Active Comparator|Group 1: Text Messaging|Consist of daily text messages on shared reading
89054007|NCT04576481|Experimental|Group 2: Text Messaging + Coaching|Will consist of Group 1 plus personalized coaching.
89054008|NCT04576481|Experimental|Group 3: Text Messaging + Coaching + Lottery|Will consist of Group 2 plus availability of a weekly lottery.
89054009|NCT00473382|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
89686970|NCT03375437|Experimental|NTRK, ROS and ALK molecular screening|"The molecular screening to detect NTRK1, 2, 3, ROS or ALK gene rearrangements will be a two step process, consisting of:~First, immunohistochemistry (IHC) assay to detect protein expression of TRKA/B/C (encoded by NRTK1,2,3), ROS1 or ALK.~Second, RNAseq analysis will be performed on positive IHC specimens to detect specific rearrangements in the NTRK1, NTRK2, NTRK3, ROS1 or ALK genes."
89054010|NCT00473382|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
89686971|NCT04946526|Active Comparator|Broccoli seed extract|A single dose dietary supplement made up of 385 mg broccoli seed extract delivering 50 mg GR (115 umol GR) and 100 mg vitamin C (as ascorbic acid).
89054011|NCT00473382|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
89054012|NCT00582959|Other|1|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
89054013|NCT02210325|Active Comparator|Ceftriaxone plus Azithromycin|A single intramuscular dose of 500 mg ceftriaxone plus a single oral dose of 1000 mg azithromycin
89054014|NCT02210325|Experimental|Solithromycin|A single oral dose of 1000 mg solithromycin
89054015|NCT00473265|Experimental|PTH(1-84)|100mcg of PTH1-84 every other day, every day, or every three days
89054016|NCT00583037|Experimental|NAVA|Implementation of NAVA for 24 hours
89054017|NCT04576286|Experimental|Holmium en bloc resection|Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency
89054018|NCT04576286|Active Comparator|bipolar en bloc resection|bipolar en bloc tumor resection of urinary bladder tumors
89054019|NCT00472641|Experimental|Ziprasidone/Geodon|Ziprasidone/Geodon up to 320 mg per day
89054020|NCT04576208|Experimental|Cohort 1|TAK-788 160 mg, capsules, orally, once daily (QD) with or without a low-fat meal until disease progression or as assessed by the investigator during every 3-week cycle.
89054021|NCT04576208|Experimental|Cohort 2|TAK-788 160 mg, capsules, orally, QD with or without a low-fat meal and antidiarrheal prophylaxis administered during the first 8 weeks of treatment until disease progression or as assessed by the investigator during every 3-week cycle.
89054022|NCT04571151|Active Comparator|Lexette + Sorilux|"Halobetasol Propionate Topical Foam (Lexette Foam) + Calcipotriol Foam (Sorilux Foam) for 2 weeks~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g."
89054023|NCT04571151|Placebo Comparator|Lexette + Vehicle|"Halobetasol Propionate Topical Foam (Lexette Foam) + Vehicle Foam for 2 weeks~Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks. Each gram of Halobetasol Propionate Topical Foam contains 0.5 mg of halobetasol propionate.~Vehicle Foam would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application."
89054024|NCT04571151|Active Comparator|Sorilux|"Calcipotriol Foam (Sorilux Foam) for 6 weeks~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.~Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 6 weeks. SORILUX Foam contains calcipotriene 50 mcg/g."
89054025|NCT04571151|Placebo Comparator|Vehicle|"Vehicle Foam for 6 weeks.~Participants from Groups A and B who are clear or almost clear at the end of 2 weeks will be re-randomized into Groups 1 and 2.~Vehicle Foam would be applied over the affected area twice daily for 6 weeks."
89054026|NCT04576169|Experimental|Central or Radial Tear: Arthroscopic debridement|Arthroscopic debridement
89054027|NCT04576169|Placebo Comparator|Central or Radial Tear: Sham surgery|Diagnostic arthroscopy only (placebo surgery).
89054028|NCT04576169|Experimental|Ulnar Tear: Arthroscopic or open repair|Arthroscopic or open repair
89054029|NCT04576169|Active Comparator|Ulnar Tear: Physiotherapy|Diagnostic arthroscopy and physiotherapy
89054030|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 1b)|Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine
89054031|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 2)|Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine
89054032|NCT01133977|Active Comparator|Dacarbazine (Phase 2)|Participants received dacarbazine
89054033|NCT04570917|Experimental|Intervention group (INT)|An online learning module targeted to reduce ageism will be delivered to the INT group.
89054034|NCT04570917|Active Comparator|Control group (CON)|An online learning module on diversity and cultural competence will be delivered to the CON group.
89054035|NCT00583193|Other|1|Open-label Study
89054036|NCT01133821|Placebo Comparator|Placebo|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus placebo (sugar pill). This condition will be called IPSRT-PLA.
89054037|NCT01133821|Experimental|IPSRT plus quetiapine|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus the FDA approved medication quetiapine (Seroquel). This condition will be called IPSRT-QUE.
89054038|NCT00472446|Experimental|cervical block before surgery|bilateral superficial cervical block, placed before surgery (just before skin incision)
89054039|NCT00472446|Placebo Comparator|placebo cervical block before surgery|placebo bilateral superficial cervical block with saline, placed before surgery (just before skin incision)
89686972|NCT04946526|Experimental|Broccoli seed extract with mustard seed powder|A single dose dietary supplement made up of a mixture of 385 mg broccoli seed extract delivering 50 mg GR (115 umol GR), 145 mg mustard seed powder containing enough active myrosinase (enzyme) to fully hydrolyze the GR in the capsule to SF post-ingestion (~30 units myrosinase activity) and 100 mg vitamin C (as ascorbic acid).
89054040|NCT00472446|Experimental|cervical block after surgery|bilateral superficial cervical block, placed after surgery (just after skin closure)
89054041|NCT00472446|Placebo Comparator|placebo cervical block after surgery|placebo bilateral superficial cervical block with saline, placed after surgery (just after skin closure)
89054042|NCT00583232|Active Comparator|Corticosteroid|Subjects receiving corticosteroid therapy (1-2 mg/kg/day up to 60mg/day) with taper.
89054043|NCT00583232|Active Comparator|infliximab|Subjects receiving infliximab therapy (5 mg/kg at 0, 2 and 6 weeks, followed by every 8 week therapy)
89054044|NCT00583271||1|subjects who are getting a celiac block for chronic pancreatitis
89054045|NCT00583271||2|subjects who are getting a celiac block for pancreatic cancer
89054046|NCT04570995|Active Comparator|fish oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing fish oil encapsulated in soft gel capsules.
89054047|NCT04570995|Placebo Comparator|safflower oil|participants will be asked to consume a daily (5 days per week) dietary supplement containing a placebo oil product (safflower oil) encapsulated in soft gel capsules.
89054048|NCT04576013|Experimental|Active PNS during training|Individuals in this group will receive active PNS while participating in 2 hours of motor training of the affected arm.
89054049|NCT04576013|Active Comparator|Active PNS before training|Individuals in this group will receive 2 hours of active PNS before participating in 2 hours of motor training of the affected arm.
89054050|NCT04576013|Sham Comparator|Sham PNS during training|Individuals in this group will receive 2 hours of sham PNS while participating in 2 hours of motor training of the affected arm.
89054051|NCT00472290|Experimental|Open Label Romiplostim (formerly AMG 531)|
89054052|NCT01133704|Active Comparator|sipuleucel-T (APC8015)|
89686973|NCT02748070|Experimental|Prednisone|Provided oral steroid and topical steroid
89686974|NCT02748070|Placebo Comparator|Placebo|Provided oral placebo and topical steroid
89686975|NCT03216629|Experimental|Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will say sorry repeatedly. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
89686976|NCT03216629|No Intervention|Not Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will remain silent. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
89686977|NCT05514756|Active Comparator|Active t-VNS|Active t-VNS at 8 Hz to the left cymba conchae, acutely for up to 60 minutes
89686978|NCT05514756|Sham Comparator|Sham t-VNS|Sham t-VNS at 8 Hz to the left earlobe, acutely for up to 60 minutes
89686979|NCT05514756|Placebo Comparator|Baseline assessments|Baseline assessments of neurocardiovascular stability, cognition and serum and plasma inflammatory markers per participant serve to act as their own control in this three-part crossover design
89686980|NCT05311709|Experimental|Sotorasib|Single arm trial. All patients will be included in this interventional arm.
89686981|NCT02748928|Experimental|UltraShape Power treatment to abdomen|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape Power device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
89686982|NCT05310383|Experimental|Patients with recurrent cervical cancer|Patients with recurrent, metastatic and persistent advanced cervical cancer
89686983|NCT02574312|Active Comparator|TKA with RUI|44 Subjects will receive TKA with RUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Reusable instruments (RUI).
89686984|NCT02574312|Experimental|TKA with SUI|44 Subjects will receive TKA with SUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Single Use Instruments (SUI).
89686985|NCT04424784|No Intervention|20% O2|In the control group, oocyte pickup will be performed in atmospheric oxygen environment (20% oxygen, 89% nitrogen, 6% carbon dioxide).
89686986|NCT04424784|Experimental|5% O2|In the experimental group, oocyte pickup will be performed in a low oxygen tension environment (5% oxygen, 89% nitrogen, 6% carbon dioxide). If time lapse embryo culture system is used, fertilization check and embryo grading will also be conducted under the low oxygen tension environment.
89054053|NCT01133704|Placebo Comparator|Placebo|
89054054|NCT02883088||LAD-group|Subjects over 18 years who are undergoing Frequency Domain - Optical Coherence Tomography (FD-OCT) evaluation of the native left anterior descending artery during clinically indicated coronary angiography regardless of the clinical syndrome (silent ischemia, effort angina or acute coronary syndrome).
89054055|NCT00583310|No Intervention|Control|Subjects receive standard written educational information at baseline, but do not receive the telephone-based intervention. Subjects may participate in the intervention following completion of the study.
89054056|NCT00583310|Experimental|Intervention|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
89054057|NCT05158582|Experimental|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|The modified exercise group will perform 12 exercises.
89054058|NCT05158582|Active Comparator|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercises program will perform conventional exercises.
89686987|NCT05519670|Experimental|Only Arm|niraparib + capecitabine treatment
89686988|NCT05519592|Experimental|Ropivacaine|Ropivacaine intramuscular injection
88998549|NCT02906254||short-course antibiotic therapy|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st December 2014 to 30th September 2015, antibiotics were stopped on day 5 in febrile or afebrile patients (short-course antibiotic therapy)."
88998550|NCT02906098|Experimental|Patient centered oral health education|The program is based on cognitive behavioral theory and principles. Hence, the intervention is adapted to each individual's problem, capacity and goals were the dental hygienist use motivational interviewing skills in communication and act as a guiding resource during the process of behavioral change. The program follows a specific structure including components such as formulation of personal goals, continuous self-monitoring by diary and planning of behavior. The initial intervention phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
88998551|NCT02906098|Active Comparator|Standard educational intervention|The subjects in the control group receive educational intervention by a dental hygienist in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
88998552|NCT02906059|Experimental|AZD1775 & Irinotecan|"Group AZD1775 (study drug); Irinotecan (chemotherapy)~1) 125 mg two times a day (BID) for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2A) 150 mg BID for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2B) 125 mg BID for 5 days every 2 weeks; 180mg/m2 every 2 weeks~3) 150 mg BID for 5 days every 2 weeks ; 180mg/m2 every 2 weeks"
88998553|NCT02906176|Experimental|SLCO2B1 wild type|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
88998554|NCT02906176|Experimental|SLCO2B1 variant|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
88998555|NCT02905942|Experimental|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.
88998556|NCT02905942|Active Comparator|rhG-CSF|Patients in control group received rhG-CSF day +1 after transplantation.
88998557|NCT02905864|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
88998558|NCT02905864|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
88998559|NCT00177840|Experimental|1|True acupuncture using true needles
88998560|NCT00177840|Sham Comparator|2|sham acupuncture using sham needles
88998561|NCT02905708|Active Comparator|Forced Air Warming Device|"Active Comparator: Forced Air Warming Device first group will have the warming devices started in the pre-operative area. You will receive a full body forced air warming. Device is non experimental and FDA approved, used within the hospital to keep patients warm.You will then have your temperature taken and documented by the staff at various prescribed times.~Warming in the operating room: You will receive the same or a similar warming device known as a Bair Hugger and warmed IV fluids once you are in the operating room. Bair Paws or Bair Hugger will also be used in the post-anesthesia care area."
88998562|NCT02905708|Active Comparator|Air-Activated heating packs|The second group will receive the study warming device which consists of a jacket, pants, gloves and socks with integrated Air-Activated heating packs. Device is supplied vacuum packed, heat packs of iron powder/activated charcoal activated by air. Device applied at least twenty minutes prior to surgery. The same device will be maintained in place throughout the surgery and the post-anesthesia period.
88998563|NCT02905747|Experimental|Medical Exercise Therapy|Medical Exercise Therapy (MET) developed by Oddvar Holten
88998564|NCT04681885|Experimental|Tapered bristles A|
88998565|NCT04681885|Active Comparator|Tapered bristles B|
88998566|NCT04681885|Active Comparator|End rounded bristles|
88998567|NCT04681924|Experimental|Low carb diet|Low carb diet (n=54)
88998568|NCT04681924|Experimental|Low fat diet|Low fat diet (n=40)
88998569|NCT02905630|Experimental|Exercise training|High intensity aerobic exercise training
88998570|NCT02905630|No Intervention|No training|No exercise training, only ordinary daily life activities.
88998571|NCT02905513|Experimental|Intervention|App plus the contraceptive instant messages
88998572|NCT02905513|Placebo Comparator|Control|App only
88998573|NCT02905552||Case group|Patient developing a first episode of infection since diagnosis of high-risk MDS (index case)
88998574|NCT02905552||Control group|"Patient with no infection since diagnosis of MDS~Patient will be paired to index case by:~Hospital site~Age~Sexe Control patient is eligible if he has been seen in consultation within 15days before or after date of first infection of index case If matching fails, control patient can be found in another site and/or within 30days before or after date of first infection of index case"
88998575|NCT00177996|Active Comparator|Sertaline high dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline high dose titration) are consistent with recommended FDA guidelines.
88998576|NCT00177996|Active Comparator|Sertaline low dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline low dose titration) are consistent with recommended FDA guidelines.
88998577|NCT02905474|Experimental|eKidneyCare|The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
89054059|NCT00583349|Experimental|Abraxane administration|Patients will restrict their fluid intakes the morning of treatments and will have emptied their bladders at each of their visits and have up to 100ml of Abraxane solution administered to their bladder via urinary catheter once weekly for six weeks.
88998578|NCT02905474|Active Comparator|My MedRec (Commercial App)|My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
89686989|NCT05519592|Placebo Comparator|Control|Sodium Chlorure intramuscular injection
89686990|NCT05519514|Active Comparator|Cortiment (Budesonide 9 mg prolonged release tablet)|
89686991|NCT05519514|Experimental|Budesonide 9 mg prolonged release tablet|
89686992|NCT02756572|Experimental|Treatment (chemotherapy, HCT)|See Detailed Description
89686993|NCT01049035|Experimental|Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months|Participants aged 2 months (at the time of enrollment) received Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein (MenACYW) Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.
89686994|NCT01049035|Experimental|Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.
89686995|NCT01049035|Experimental|Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.
89686996|NCT01049035|Experimental|Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months|Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.
89686997|NCT01049035|Experimental|Group 5: MenACYW Conjugate Vaccine: Month 12|Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.
89686998|NCT01049035|Other|Group 6: Control: 2, 4, 6, and 12 Months|Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.
89686999|NCT01049035|Other|Group 7: Control: 2, 4, 6, 12, and 15 Months|Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.
89687000|NCT05134272||mCIMT plus NMES|"Phase 1: Infants will receive therapy 1 hour/day, 1 day/week for 3 weeks while wearing a sock 1 hour/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks.~Phase 2:Infants will receive therapy 2 hours/day, 3 days/week for 3 weeks while wearing a splint 24 hours/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks.~Phase 3:Infants will receive therapy 1 hour/day, 1 day/week for 3 weeks while wearing a sock 1 hour/day. Parents will complete home program activities 1 hour/day, 6 days/week for 3 weeks."
89687001|NCT05131698|Experimental|Patients with advanced unresectable liver cancer|
89687002|NCT05519358||difficult airway|difficult laryngoscopy; Cormack-Lehane grades 3 or 4 or Difficult intubation; Intubation Difficulty Scale (IDS)> 5 .IDS based on parameters known to be associated with difficult intubation
89687003|NCT05519358||non difficult airway|not difficult intubation or laryngoscopy
89687004|NCT01724983|Experimental|ketamine|patients will receive ketamine at induction
89687005|NCT01724983|Active Comparator|fentanyl|patients will receive fentanyl at induction
89687006|NCT02973958|Active Comparator|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen post-operatively as needed.
89687007|NCT02973958|Experimental|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
89687008|NCT05519280|Experimental|the Biopsychosocial-Spiritual Group Intervention|The experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
89687009|NCT05519280|No Intervention|weekly general chatting activities|The Control group received weekly general chatting activities for 30 minutes.
89687010|NCT01048333|Experimental|Formoterol, then Salmeterol, then Placebo|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
89687011|NCT01048333|Experimental|Salmeterol, then Palcebo, then Formoterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
88998579|NCT02905279|Active Comparator|Biofeedback|Biofeedback Relaxation Training
88998580|NCT02905279|Active Comparator|Standard Exposure|Exposure Therapy
88998581|NCT02905279|Experimental|Exposure with Threat-Relevant OAs.|Exposure with Threat-Relevant Opposite Actions
88998582|NCT02905279|Experimental|Exposure with Threat-Irrelevant OAs|Exposure with Threat-Irrelevant Opposite Actions
88998583|NCT02905396|Experimental|Spinal cord stimulation|implantation of spinal cord stimulator
88998584|NCT02905123|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
88998585|NCT02905123|No Intervention|Control|No Intervention Control
88998586|NCT02905045|Active Comparator|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
88998587|NCT02905045|Placebo Comparator|Placebo|women will take one tablet placebo one hour before the procedure
88998588|NCT04723329|Experimental|web-based education group|Patients will be given a username and password to access the website. The change stage of the patients will be determined by the researcher with the Exercise Change Phase Short Question Form, and it will be ensured that they reach the educational content prepared according to the transtheoretic model. Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
88998589|NCT04723329|No Intervention|Control Group|In the first interview, the patients in the control group will be collected data and contact information will be obtained using the Patient Information Form, Exercise Change Phase Short Question Form, Change Processes Scale, Decision Making Balance Scale and Self-Efficacy Scale. Later, patients will be given their username and password so that they can log into the website where the scales are located in order to apply the final test. No intervention will be applied to the patients in the control group. At the end of the 6th month, the same scales will be applied on the website as a final test. At the end of the study, it is aimed to gain exercise behavior to the patients in the control group.
88998590|NCT02905162||HIV positive individuals incarcerated at Lusaka Central Prison|Cohort of individuals scheduled for release within 30 days will be followed for 6 months post release
88998591|NCT02905201||mCRPC participants|Participants will not receive any intervention as a part of this study. Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have adequate response to treatment (abiraterone Acetate + prednisone) will be observed to collect data for ECOG performance status, safety assessments (as described above), the collection of PROs (BPI-short form, Pain VAS, HCU questionnaire), the assessment of disease status and parameters, and the assessment of participant compliance to treatment.
88998592|NCT02904772|Other|alipogene tiparvovec with IS|Patients in the Immuno+ group will receive an immunosuppressant regimen to be initiated three days prior to alipogene tiparvovec administration. The regimen is to be continued for 12 weeks: Cyclosporins (3 mg/kg/day) and mycophenolate mofetil (2 x 1 g/day). Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
88998593|NCT02904772|Other|alipogene tiparvovec without IS|Patients in the Immuno- group will not receive an immunosuppressant regimen during 12 weeks. Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
88998594|NCT02904889|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
88998595|NCT02904889|Active Comparator|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
88998596|NCT02904850||group of patients|Plasma dosage of erlotinib and OSI-420
88998597|NCT02904733|Experimental|mHealth platform|Stable HIV-1 infected subjects will be followed-up using an mHealth platform. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to healthcare providers. The minimum length of follow-up will be 12 months and the maximum 35 months.
88998598|NCT02904616|Experimental|Healthy volunteers|"Healthy volunteers wash their hands with a traditional soap. Every healthy volunteers pose with palm of hand three times on the device in order to measure basal level of fluorescence of the skin.~Healthy volunteers repeated three times this procedure in order to assess the reproducibility of the measurement."
88998599|NCT02904538|Experimental|Perineural group|1cc (4mg) of dexamethasone will be administrated in perineural injection. 2.5cc of isotonic saline solution will be administrated in systemic injection.
88998600|NCT02904538|Experimental|systemic group|1cc of isotonic saline will be administrated in perineural injection. 2.5cc (10mg) of dexamethasone will be administrated in systemic injection.
88998601|NCT02904655|Active Comparator|healthy diet|Participants were provided all meals and snacks for four weeks. Menus were created to target a healthy diet high in unsaturated fats.
88998602|NCT02904655|No Intervention|control diet|Participants were instructed to consume their usual diet.
88998603|NCT02963103|Experimental|Tacrolimus group|oral
88998604|NCT02904499||VKA|First Initiators of VKA for non-valvular atrial fibrilation
88998605|NCT02904499||Dabigatran|First Initiators of Dabigatran for non-valvular atrial fibrilation
88998606|NCT02904421||Group 1|the placebo group
88998607|NCT02904421||Group 2|the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day
88998608|NCT02904421||Group 3|the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day
88998609|NCT02904343|Experimental|Group of domestic hemodialysis machine|
88998610|NCT02904343|Active Comparator|Group of imported hemodialysis machine|
88998611|NCT00553423|Experimental|1|Lactulose 30 ml q6h for 48 hrs
88998612|NCT00553423|Placebo Comparator|2|Placebo 30 ml q6 hrly for 48hrs
88998613|NCT02904148|Experimental|Shoulder mobilisation|The shoulder mobilisation is performed daily by a physiotherapist for 45 days.
88998614|NCT02904304|Experimental|Desloratadine+Phenylephrine+Ibuprofen|"It's a tablet manufactured by Aché S.A., composed of desloratadine 2,5mg, Phenylephrine hydrochloride 20mg and Ibuprofen 400mg.~Tablet will be dispensed in a cartridge containing 10 tablet to 75 participants."
88998615|NCT02904304|Placebo Comparator|Placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo will be dispensed in a cartridge containing 10 tablet to 75 participants. The participants shall administer the placebo tablets to enable the double-blind study.~The use of placebo comparator is important in this type of pathology because with this design will be able to evaluate the response of the pure treatment, rapid relief of symptoms, or 03 hours after the first administration of study drug."
88998616|NCT02904031|Experimental|FOLFOX plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1;~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
88998617|NCT02904031|Experimental|5FU/LV plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
88998618|NCT02904109|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo.
88998619|NCT02904109|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
88998620|NCT02904070|Experimental|Threat of premature delivery|"Perform detection test of Placental Alpha-Microglobulin-1, fetal Fibronectin and phosphorylated Insulin-like Growth Factor Binding Protein-1ph by vaginal swabbing;~Collection of clinical data, laboratory data and treatment of obstetric care in the delivery room during childbirth for all included subjects"
88998621|NCT04681495|Other|Usability of Bullying Prevention Online Application|This intervention has a single arm. It consists of conducting focus groups and usability testing of a bullying prevention online application for middle-school-aged students.
89687012|NCT01048333|Experimental|Placebo, then Formoterol, then Salmeterol|Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
89687013|NCT01048333|Experimental|Formoterol, then Placebo, then Salmeterol|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
89687014|NCT01048333|Experimental|Salmeterol, then Formoterol, then Placebo|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
89687015|NCT01048333|Experimental|Placebo, then Salmeterol, then Formoterol|Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
89687016|NCT05513976|Experimental|treatment group A|
89687017|NCT05513976|Experimental|treatment group B|
89687018|NCT05513976|Placebo Comparator|treatment group C|
89687019|NCT04335526|No Intervention|Metformin alone|
89687020|NCT04335526|Other|Metformin with cholestyramine|
89687021|NCT05525832|Experimental|Normal saline group|Patients that will receive normal saline 0.9% solution for nasopharyngeal wash
89687022|NCT05525832|No Intervention|control group|Patients that will not perform nasopharyngeal washes
89687023|NCT01725295|Experimental|NST|A form of physical therapy to relieve symptoms of fibromyalgia
89687024|NCT01725295|Active Comparator|Hydrotherapy|An alternate form of physical therapy to relieve symptoms of fibromyalgia
89687025|NCT05348434||patients with maxillofacial deformities|10 patients with maxillofacial deformities (trauma patients, war injuries, patients with pre-existing maxillofacial tumours, and meucrmycotic patients)
89687026|NCT05348278|No Intervention|standard of care|standard of care including hand and foot care, avoid friction
89687027|NCT05348278|Experimental|urea cream|use 10% urea cream apply at both hands and feet twice a day from time of starting capecitabine
89687028|NCT02323113|Experimental|Phase 1b: TAK-659|TAK-659 tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage of TAK-659 may increase in 20 mg increments using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
89687029|NCT02323113|Experimental|Phase 2: TAK-659|TAK-659, tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage for this phase will be determined from results of Phase 1b MTD/RP2D.
89687030|NCT05519202|Experimental|SOX and Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1) The treatment period of the above drugs was 3 weeks, and the duration of preoperative treatment was 3 cycles. After treatment, the patient underwent surgery after evaluation. Four cycles of adjuvant therapy with the original regimen (preoperative) were performed after surgery.
89687031|NCT05519124|Experimental|BTL-785-7 Treatment|
89687032|NCT05519046|Experimental|Cardiac Contractility Modulation Group - CCM Group|CCM implantation.
89687033|NCT05519046|Active Comparator|Cardiac Resynchronization Therapy Group - CRT Group|CRT implantation
89687034|NCT04934670|Experimental|T-Guard|Participants will be administered four doses of T-Guard intravenously for a 4-hour period every other day
89687035|NCT04934670|Active Comparator|Ruxolitinib|Participants will take ruxolitinib twice daily for continuous daily dosing
89687036|NCT02759146|Experimental|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
89687037|NCT02759146|Experimental|Meditative Practice|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
89687038|NCT02759146|No Intervention|Control|Control - no intervention
89687039|NCT02281383|Experimental|Bacillus Calmette-Guérin (BCG)|Patients will be treated with an induction course (6 intravesical instillations) of BCG followed by a second induction course (6 intravesical instillations), with a recovery period between the 2 treatment courses.
89687040|NCT01047553|Experimental|1|Formoterol 9 μg/dose
89687041|NCT05525442||patients with recurrence|Recurrence in the first year after percutaneous cholecystostomy catheter removal
89687042|NCT05525442||patients without recurrence|No recurrence within the first year after percutaneous cholecystostomy catheter removal
89687043|NCT05513820||Retrospective group|Retrospective group: 700 patients from the databases of the AP-HP, the Lyon University Hospital and the Lille University Hospital for training and validation of the algorithms.
89687044|NCT05513820||Prospective group|Prospective group: 550 patients (test-set) from AP-HP (CHU Pitié, Tenon, Bicêtre, Necker), CHU Lille, CHU Lyon, CHU Bordeaux and CHU Strasbourg to tes the performance of the algorithms.
89687045|NCT04337398|Experimental|Wearables|Adults with several mental illness
89687046|NCT04337398|Experimental|Wearables and exergames|Adults with several mental illness
89687047|NCT05120232|Active Comparator|Unified Protocol (UP)|The Unified Protocol (UP) is a transdiagnostic, cognitive-behavioral therapy that has been shown to be effective for treating emotional disorders. The UP targets negative emotions and helps people respond to their emotions in ways that are more helpful for them and in line with their goals. This will be delivered entirely on an online platform.
89687048|NCT05120232|Experimental|Modified Unified Protocol (UP+)|A modified version of the UP (called the UP+) delivered entirely on an online platform that will include exercises specifically designed to enhance positive emotions.
89687049|NCT03837717|Experimental|Holding First|Holding will occur on the second day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
89687050|NCT03837717|Experimental|No Holding First|Holding will occur on the third day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
89687051|NCT02760862|Active Comparator|Group (I) (N=25)|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours (Hydrocortisone as sodium succinate, vial, equivalent to hydrocortisone 100mg, Egyptian INT, Pharmaceutical Industries CO. ARE,EIPICO.EGYPT).
88998622|NCT04681378|Active Comparator|Classical double layer closure|a holding Vicryl 1-0 was placed in the in the left corner to stabilize and define the demarcation of the suture line. A continuous unlocked stitch beginning at the right corner was used, closing the whole thickness of the uterine wall, including the decidual layer. The second unlocked stitch was performed by Vicryl 1-0 in a lateral -lateral (horizontal) position, adapting the first layer. Up to three additional single sutures were added for hemostasis if required.
88998623|NCT04681378|Active Comparator|Turan technique|beginning in one corner, the incision is closed using Vicryl 1-0 stitch. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously in the form of a purse string closure. With this technique, the original string is returned to the starting point and tied with a knot. Following the double layered purse-string closure, the aperture left in the middle of the uterine incision is closed with one separate figure of eight suture
88998624|NCT04681378|Active Comparator|Double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
88998625|NCT04681573|Other|Single ARM|Only one arm
88998626|NCT00168233||1|No antiretroviral therapy for 12 months
88998627|NCT00168233||2|Initiating ARV therapy with an NNRTI based regimen
88998628|NCT00168233||3|Initiating ARV therapy with a PI based regimen
88998629|NCT04681612||MINOCA|Patients hospitalised with MINOCA according to the recently published consensus document of ESC after cardiac MRI confirmation.
88998630|NCT02904187|Other|Profound deaf patients|Profound deaf patients with bilateral cochlear implants: Cortical brain activation pattern obtained by PET and EEG
88998631|NCT02904187|Other|Healthy volunteers|Healthy volunteers: Cortical brain activation pattern obtained by PET and EEG
88998632|NCT02903875||laryngectomised patients since 1 month|laryngectomised patients since 1 month and their close relative
88998633|NCT02903875||laryngectomised patients since 3 months|laryngectomised patients since 3 months and their close relative
88998634|NCT02903875||laryngectomised patients since 6 months|laryngectomised patients since 6 months and their close relative
88998635|NCT02903875||laryngectomised patients since 12 months|laryngectomised patients since 12 months and their close relative
88998636|NCT00195858|Active Comparator|Diet and Aerobic Exercise|
88998637|NCT00195858|Active Comparator|Diet and Resistane Exercise|
88998638|NCT00195858|Active Comparator|Diet and Combined Aerobic and Resistance Exercise|
88998639|NCT00195858|Other|Diet-only control group|
88998640|NCT02903797||Endometrial Hyperplasia|The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
88998641|NCT02903797||Control group|The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms
88998642|NCT02903524|Active Comparator|control group|Pirarubicin combination with cyclophosphamide,4 cycles (each cycle is 21days) of chemotherapy
88998643|NCT02903524|Experimental|Experimental group|Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide, 4 cycles (each cycle is 21 days) of chemotherapy
88998644|NCT02903602|Experimental|CHW training method-Sharing Histories|"Experimental clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing the experimental teaching methodology, Sharing Histories.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
88998645|NCT02903602|Active Comparator|CHW training method-Standard|"Control clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing a standard CHW teaching methodology.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
88998646|NCT02903485|Experimental|nurses (intervention arm)|for patients without risk factors, the anesthetic team is not involved in patients' care
88998647|NCT02903485|Active Comparator|anesthetic team (control arm)|the anesthetic team is involved in every patient's care (with or without risk factors)
88998648|NCT05996081|No Intervention|Control|Individuals in the HIV clinics randomised to the control or intervention group will attend a consultation session as a usual HIV care based on the Indonesian guideline for HIV care and treatment (Ministry of Health Regulation No. 23/2022). Although it may slightly vary by clinic, for every visit they will collect their medications and receive general information from the HIV care provider on the prescribed ART regimens, including the dose, time of administration, potential side effects and how to deal with them, and the importance of adherence. They will be followed-up at the same time points as those in the intervention group.
89687052|NCT02760862|Active Comparator|Group (II) (N=25)|group (II), received mannitol 20% intravenous fluid (100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis for 48 hours) (Manufactured by Allmed Middle East, Egypt).
89687053|NCT05720559|Experimental|Conventional treatment group|Conventional treatment was performed according to the NCCN Guidelines for Colorectal Cancer 2023 Edition
88998649|NCT05996081|Experimental|Intervention|Individuals attending the HIV clinics that are randomised to the intervention group will receive an intervention over 12 months in addition to usual care. The intervention using an adherence toolkit will be delivered during regular clinic visits when they collect their medications.
88998650|NCT05996068|Active Comparator|trauma patients with arterial line insertion|the after phase, actively recruited patients who are eligible for arterial line insertion
88998651|NCT05996068|No Intervention|trauma patients without arterial line insertion|the before phase, retrospectively data collection from the past
89054060|NCT04571073|Experimental|Treatment arm|The only arm in the study was the intervention arm as this is a pilot study.
88998652|NCT05996055|Active Comparator|control group|initially using the Type A device (the NTUH version_support device)
88998653|NCT05996055|Experimental|experimental group|initially using the Type B device (improved version_support device)
88998654|NCT05996042|Other|Time-restricted diet group|Subjects in this group were given a limited diet every Tuesday, Thursday and Saturday. They were only allowed to eat from 7am to 3pm on the same day, and only allowed to drink purified water during other periods, namely an 8-hour eating window and a 16-hour fasting period
89054061|NCT00583388||A|42 healthy subjects aged 18 to 60 will be be randomly assigned to 6 different treatment sequences.
89054062|NCT01133665|Experimental|Sub Group 1|All Subjects Enrolled in the Trial
88998655|NCT05996042|Other|Multimode aerobics group|Subjects in this group performed multi-mode aerobic exercise from 6:00 PM to 7:00 PM on Monday, Wednesday and Friday under the unified guidance of the physical education teacher of the Health Science Center in the gymnasium and sports field of Peking University Health Science Center, including aerobics, yoga and comprehensive physical training
88998656|NCT05996042|Experimental|A combination of time-restricted diet and multimodal aerobic exercise|Subjects in this group received the same time-limited dietary intervention every Tuesday, Thursday and Saturday according to the above requirements of the single time-limited dietary group, and the same multi-mode aerobic exercise intervention every Monday, Wednesday and Friday according to the above requirements of the single multi-mode aerobic exercise group.
88998657|NCT05996029|Experimental|Intervention group|"Intensive intervention package Quit with Love (1 month)~Cognitive-behavioral (CBT) smoking cessation intervention~ACT cessation intervention with positive thinking~Online group smoking cessation intervention through live streaming~Quit Assistant intelligent support platform (3 months)~Quit smoking punch card toolkit~Machine learning algorithm-driven cessation assistance practice service"
88998658|NCT05996029|No Intervention|control group|Reduced functionality of the Love Quit applet Only a simple smoking punch card support function, mainly used to assist subjects to quit smoking on their own and collect follow-up information
88998659|NCT05995990|Experimental|Colorectal liver metatases|Liver tissue containing colorectal liver metastases
88998660|NCT05995977|Experimental|Intervention Group that applied nursing interventions|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging and motivating patients to maintain medication adherence and healthy lifestyle changes.
88998661|NCT05995977|No Intervention|Individuals who do not apply nursing interventions based on protection motivation theory|Control Group: Individuals who did not apply nursing interventions based on protection motivation theory in patients with hypertension
88998662|NCT05995951|Other|Deep Bran Stimulation (DBS) - Treatment group|"Treatment group will undergo Deep Bran Stimulation (DBS) for OCD (targeting the amSTN) for four months.~At the end of four months treatment, the groups will be crossed-over for another four months. Thus, the sham group will start active stimulation and the treatment group will start sham treatment for four months."
89054063|NCT04571346|Active Comparator|the classical TOT procedure|performing the trans-obturator procedure through the standard vertical incision
89054064|NCT04571346|Experimental|2 paramedian vertical incisions|performing the trans-obturator procedure through a new technique of 2 paramedian vertical incisions
89054065|NCT00583427|Experimental|Sulodexide|
89054066|NCT01133626|Placebo Comparator|Placebo|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
89054067|NCT01133626|Experimental|BDP HFA 320 µg/day|Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
89054068|NCT01133626|Active Comparator|Prednisone|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
89054069|NCT04575974||Adolescents 13-19 years|All adolescents between 13-19 years of age in North Trøndelag county were invited to participate in HUNT 3 and followed up after 11 years.
89054070|NCT01133392|Experimental|Insulin Lispro A|20 units (U) subcutaneously (SC)
89054071|NCT01133392|Active Comparator|Insulin lispro B|20 units (U) subcutaneously (SC)
89054072|NCT04575818|Experimental|GLPG4059 SAD|Single doses of GLPG4059 at up to 6 dose levels in ascending order
89054073|NCT04575818|Placebo Comparator|Placebo SAD|Single doses of placebo
89054074|NCT04575818|Experimental|GLPG4059 rBA/FE oral suspension fasted|Single dose of GLPG4059 in fasted state
89054075|NCT04575818|Experimental|GLPG4059 rBA/FE tablet fed|Single dose of GLPG4059 in fed state
89054076|NCT04575818|Experimental|GLPG4059 rBA/FE tablet fasted|Single dose of GLPG4059 in fasted state
89054077|NCT02882815|Other|IrisFIT PFO Occluder|Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.
89054078|NCT00471354|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD), by mouth (PO), starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
89054079|NCT04575701||Ulcerative Colitis (UC)|This Group includes all patients suffering from UC who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
89054080|NCT04575701||Crohn's disease (CD)|This Group includes all patients suffering from CD who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
89054081|NCT04575701||IBD unclassified|This Group includes all patients suffering from IBD unclassified who have been treated with a TNF Alpha antibody within the last 20 years at the IBD outpatient clinic at our Hospital.
89054082|NCT02882893|Experimental|DWP450|Single-dose
89054083|NCT02882893|Active Comparator|Botox|Single-dose
89054084|NCT00583544|Placebo Comparator|1|
89054085|NCT00583544|Experimental|2|
89054086|NCT02210364|Experimental|lurbinectedin (PM01183) and capecitabine|
89054087|NCT00471315|No Intervention|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
89054088|NCT00583739|Active Comparator|1|Yoga intervention
89054089|NCT00583739|No Intervention|2|Control. No Yoga for 8 weeks.
89054090|NCT04575623||Study group|It will consist of 120 patients suffering from migraine according to international classification of headache
89054091|NCT00471237|No Intervention|Placebo|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
89054092|NCT00471237|Active Comparator|Alendronate|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
89054093|NCT00471237|Active Comparator|Teriparatide|Open-label arm. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
89054094|NCT00471237|Experimental|Ronacaleret|4 arms, 100mg, 200mg, 300mg, 400mg. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study.
89054095|NCT04575545||HIV positive patients|
89054096|NCT04575545||Patients taking PrEP|
89054097|NCT00583895|Active Comparator|1|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
89054098|NCT00583895|Placebo Comparator|2|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
89054099|NCT04570683|Active Comparator|AFL monotherapy|Singe dose AFL as monotherapy, 100 mJ
89054100|NCT04570683|Active Comparator|AFL+nivolumab|Single dose AFL 100 mJ followed by immediate intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
89054101|NCT04570683|Active Comparator|nivolumab monotherapy|Intratumoral injection of nivolumab 10% 0.1 ml/cm2 tumor
89054102|NCT00583934||A|Those six months post treatment for head and neck cancer.
89054103|NCT00471081|Experimental|Group A|Single dose GSK134612.
89054104|NCT00471081|Experimental|Group B|Two doses of GSK134612.
89054105|NCT04570449|Experimental|Fluoxetine|"Participants instructed to take fluoxetine 20 mg capsule orally daily for 8 weeks in the following schedule:~Week 1 = 1 pill (20 mg), Week 2 = 2 pills (40 mg), Weeks 3-6 = 3 pills (60 mg), Week 7 = 2 pills (40 mg), Week 8 = pill (20 mg)"
89054106|NCT04570449|Placebo Comparator|Placebo|"Participants instructed to take fluoxetine placebo capsule matching fluoxetine orally daily for 8 weeks in the following schedule:~Week 1 = 1 pill, Week 2 = 2 pills, Weeks 3-6 = 3 pills, Week 7 = 2 pills, Week 8 = pill"
88998663|NCT05995951|Other|Sham-control|"sham stimulation for four months.~At the end of four months treatment, the groups will be crossed-over for another fourmonths. Thus, the sham group will start active stimulation and the treatment group will start sham treatment for four months."
88998664|NCT05995938|Experimental|Experimental|1
88998665|NCT05995938|No Intervention|Control|1
88998666|NCT05995912|Experimental|Etoricoxib-Tramadol|Etoricoxib-Tramadol 120mg/100mg tablet, once-daily, for 3 days
88998667|NCT05995912|Active Comparator|Naproxen + Tramadol|Naproxen 220 mg tablet + Tramadol 50 mg capsule, twice a day, for 3 days.
88998668|NCT05995821||Upper Aerodigestive Malignancies|Patients with cancer of the head and neck, thorax and upper gastrointestinal tract, who are receiving or may receive treatments known or hypothesized to have an immunomodulatory antitumor effect.
88998669|NCT05995808|Experimental|diagnostic group|
88998670|NCT05995782|Experimental|FB418|"Part A - Single ascending oral doses of FB418 in healthy adult subjects and healthy elderly subjects.~Part B - Multiple ascending oral doses FB418 in healthy adult subjects."
88998671|NCT05995782|Placebo Comparator|FB418-Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
88998672|NCT05995756||In pateint|
88998673|NCT05995756||Out pateint|
88998674|NCT05995730|Experimental|Experimental group|Lavender inhalation will be administered to this group.
88998675|NCT05995730|Placebo Comparator|Placebo group|Olive oil will be administered to the placebo group.
88998676|NCT05995691|Experimental|ABP 501|Participants will receive a single dose of ABP 501
88998677|NCT05995691|Active Comparator|Adalimumab|Participants will receive a single dose of adalimumab
88998678|NCT05995665|Experimental|EsoGLOVE with Trigno Biofeedback (EMG sensors) group|The EsoGLOVE + Trigno Biofeedback Group subjects will receive EsoGLOVE with Trigno Biofeedback (EMG sensors) training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day
88998679|NCT05995665|Active Comparator|Graded Repetitive Arm Supplementary Program (GRASP) Group|The GRASP group subjects will receive the Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day
88998680|NCT05995639|No Intervention|Control Group|Patients who will undergo an exercise treatment for the UT. The exercise therapy will focus on stretching exercises for the UT. Exercise therapy will undergo 2 weeks.
88998681|NCT05995639|Active Comparator|Dry Needling Group|Patients who will undergo DN treatment for the UT. A clinician with 5 years of DN experience will assess patients and apply DN treatment. The active trigger points will be diagnosed by the criteria described by Simons and Travell. 0.25x25mm acupuncture needles will be used. DN will be performed with fast in fast out technique and needling will continue until a local twitch response is elicited. Treatment will be applied 3 times, one week apart.
88998682|NCT05995639|Active Comparator|Ozone Group|Patients who will undergo ozone treatment for the UT. A clinician with 10 years of ozone experience will assess patients and apply ozone treatment. 12 gamma ozone will be used. Patients will be injected with ozone in UT with most sensitive parts. Treatment will be applied 3 times, one week apart.
88998683|NCT05995574|Experimental|chatbot training|Ten physician learners will train with the artificial intelligence communication training tool as a behavioral intervention. Before the training, the 10 learners will complete 5 sexual health clinical encounters with adolescent-mother dyads (50 total encounters) where encounters will be audio-recorded and post-encounter surveys competed by each triad member. After training with the tool, the same 10 learners will complete 5 more sexual health clinical encounters with adolescent-mother dyads (50 total encounters) that are audio-recorded and post-encounter surveys completed. The investigators will compare survey results pre and post to evaluate for improvement in communication interactions.
88998684|NCT05995561||atrial fibrillation|cases presenting with atrial fibrillation at the emegency department.
88998685|NCT05995522|Experimental|Supplementation arm|Vitamin K2
88998686|NCT05995522|Placebo Comparator|Placebo arm|Cornstarch
88998687|NCT05995509|Active Comparator|3 MOPs group|The subjects under a split mouth intervention on the experimental side will undergo 3 micro-osteo-perforations (creating small holes in the buccal cortical bone) to assess the rate of tooth movement.
88998688|NCT05995509|Experimental|1 MOP group|the subjects under the split mouth intervention on the control side will undergo 1 micro-osteo-perforation in comparison to the experimental side.
88998689|NCT05995483|Experimental|Have access to web based BSE training and notifications|Have the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
88998690|NCT05995483|No Intervention|Has no intervention during the study|Only has an powerpoint training og BSE, not knowing about the web base system
88998691|NCT05995431|Experimental|PERIODONTITIS STAGE 2 AND STAGE 3 WITH BRUXISM|All the participants will undergo scaling and root planing
88998692|NCT05995431|Active Comparator|AGE MATCHED PATIENTS WITH STAGE 2 AND STAGE 3 PERIODONTITIS WITHOUT BRUXISM|All the participants will undergo subgingival instrumentation
88998693|NCT05995418||amnestic mild cognitive impairment(aMCI）|"aMCI diagnostic criteria of National Institute of Aging and National Association of Alzheimer's Disease (NIA-AA).~The ClinicalDementiaRating scale (CDR) is 0.5.~Mini-MentalStateExamination (MMSE): MMSE≥17 for those with 0 years of education, ≥20 for those with less than 7 years, and ≥24 for those with more than 7 years.~Memory impairment is prominent, and it may also be accompanied by functional impairment of other cognitive domains.~The onset is insidious and the progress is slow.~Not up to the level of dementia"
88998694|NCT05995418||mild to moderate AD|Clinical dementia rating (CDR) was used to assess and determine the degree of cognitive impairment of the patients, according to the CDR score, where the mild AD group with a CDR score of 1, and the moderate to severe AD group with a score of 2 to 3.
88998695|NCT05995418||severe AD|Clinical dementia rating (CDR) was used to assess and determine the degree of cognitive impairment of the patients, according to the CDR score, where the mild AD group with a CDR score of 1, and the moderate to severe AD group with a score of 2 to 3.
88998696|NCT05995379||Derivation cohort|
88998697|NCT05995379||Validation cohort|
88998698|NCT05995262||HbA1c|Minimum of one HbA1c reading within 90 days prior to first visit AND one HgbA1c reading within 90 days after the last clinic encounter
88998699|NCT05995210|Experimental|Kinesio taping group|In addition to the standard exercise program, kinesio taping was applied to the knee for 6 weeks.
88998700|NCT05995210|Experimental|Orthosis group|In addition to the standard exercise program, they were asked to use a knee orthosis for 6 weeks.
88998701|NCT05995210|Active Comparator|Control group|A standard exercise program was applied for 6 weeks.
88998702|NCT05995197|Experimental|action observation therapy group|Children will watch the action observation therapy video on the computer screen placed 1 m in front of a chair in which they can sit comfortably, but they will not be allowed to move while watching the video. Children will watch the video of the exercise offered by the therapist and then practice the exercise. The watching time for each exercise is 3 minutes, and after watching 3 minutes, they will do the exercise in the video for 3 minutes.In order to increase the effectiveness of the action observation training. Children will be instructed to concentrate on the video at 1-minute intervals to allow children's attention span. The treatment program will be applied for 30 minutes, 5 days a week for 3 weeks. The first session of the exercise program will be held face-to-face and the other sessions will be followed online. Treatment will be started within the first 48 hours after the evaluation. After the applications, the evaluations at the beginning of the treatment will be repeated.
88998703|NCT05995197|No Intervention|control group|Children with CP will watch the video on the computer screen placed 1 m in front of a chair in which they can sit comfortably, but they will not be allowed to move while watching the video. The therapist will explain the exercises verbally. Children will practice the exercise after watching cartoons. The watching time for each exercise is 3 minutes, and after watching 3 minutes of cartoons, they will do the exercise for 3 minutes. Children will be instructed to concentrate on the video at 1-minute intervals to allow children's attention span. The treatment program will be applied for 30 minutes, 5 days a week for 3 weeks. The first session of the exercise program will be held face-to-face and the other sessions will be followed online. Treatment will be started within the first 48 hours after the evaluation. After the applications, pre-treatment evaluations will be repeated.
88998704|NCT05995158||Smokers ≥ 10 cigarettes/day|metagenomic testing of the subgingival plaque samples 16S rRNA metagenomic testing (sampling, extraction and sequencing of the oral microbiome in the samples)
88998705|NCT05995158||Smokers < 10 cigarettes/day|metagenomic testing of the subgingival plaque samples 16S rRNA metagenomic testing (sampling, extraction and sequencing of the oral microbiome in the samples)
88998706|NCT05995158||non-smokers|metagenomic testing of the subgingival plaque samples 16S rRNA metagenomic testing (sampling, extraction and sequencing of the oral microbiome in the samples)
88998707|NCT05995080|Experimental|chlorhexidine bathing group|Patients aged between 2 months and 18 years with temporary central venous catheter in the pediatric intensive care unit were recruited. Patients younger than 2 months of age, patients with a catheter use of less than 48 hours, patients with a history of allergic reaction with chlorhexidine, patients with a skin condition that interferes with skin cleansing with chlorhexidine, and immunocompromised patients were excluded from the study. Participants of the study were randomized with a ratio of 1:1. In study group, standard bathing will be applied on the first day of insertion of the central venous catheter, and in addition to that it is planned to clean the skin of the patient daily with cleaning pads impregnated with 2% Chlorhexidine gluconate.
88998708|NCT05995080|No Intervention|standart bathing group|Patients who are included in the study but not intervention group will be treated with standard bathing, which applied in every 72 hours in our facility.
88998709|NCT05995054|Experimental|Intervention (Obinutuzumab)|110 enrolled subjects: one infusion
88998710|NCT05995041|Experimental|Multiple universal CAR T cells to treat AML|
88998711|NCT05995015|Experimental|Universal 4SCAR19U cells to treat CD19-positive hematological malignancies|
88998712|NCT05994885|Other|Root surface debridement|Periodontal pockets with PPD of 4 to 6mm are treated with root surface debridement only and assessed after 3 months for success/failure of treatment.
88998713|NCT05994872|Sham Comparator|Traditional extraction drilling|A standard hamstring autograft procedure was performed using traditional extraction drilling to prepare bone tunnel (n = 108).
88998714|NCT05994872|Experimental|Reverse drilling technique|A standard hamstring autograft procedure was performed using reverse drilling technique to prepare bone tunnel (n = 108).
88998715|NCT05994846|Experimental|Experimental Treatment Arm|Participants will receive closed-loop transcutaneous spinal cord stimulation via the RISES-T System while completing repetitive task practice
88998716|NCT05994742|Active Comparator|Arm 1: Standard-of-care (control)|Children in the control arm will receive Ready to Use Therapeutic Food (RUTF) for at least 2 weeks, plus all standard care. Children with HIV will receive long-term Cotrimoxazole prophylaxis and antiretroviral therapy, as per current guidelines.
88998717|NCT05994742|Experimental|Arm 2: Antimicrobial package|Children will receive a bundle of azithromycin (3 days every month), isoniazid (daily), rifampicin (daily) and pyridoxine (daily) for 12 weeks.
88998718|NCT05994742|Experimental|Arm 3: Reformulated RUTF|Children will receive a reformulated RUTF, with increased medium-chain triglycerides (MCTs), higher hydrolysed protein content and a more bioavailable form of selenium (selenium yeast). Children will receive RUTF for at least 2 weeks.
88998719|NCT05994742|Experimental|Arm 4: Psychosocial package|"Caregiver-child pairs will receive a low-cost, co-designed intervention to strengthen caregiver support, enhance income generation and promote child play. This is delivered over 12 weeks and comprises:~i) The Friendship Bench, developed as a low-cost psychological intervention utilising problem-solving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders.~ii) Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities in a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards.~iii) Educational and behaviour-change messages around better nutrition; play for children with SAM; stigma, HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours."
88998720|NCT05994742|Experimental|Arm 5: Antimicrobial package + reformulated RUTF + psychosocial package|A combination of all interventions from arms 2, 3 and 4, plus standard care delivered for 12 weeks.
88998721|NCT05994690|Active Comparator|Standard arm Rc|3 consolidation courses (HAM + HA3E + FLA)
88998722|NCT05994690|Experimental|Investigational arm Rc|2 consolidation courses (HAM + FLA)
89054107|NCT00583973||1|Chronic hemodialysis patients
89054108|NCT00584051||1|
89054109|NCT00584051||2|
89054110|NCT00584051||3|
89054111|NCT00470847|Other|Lapatinib,Whole Brain Radiation,Herceptin|Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly
89054112|NCT00584090|Experimental|1|
89054113|NCT00584090|Placebo Comparator|2|
89054114|NCT04570527||Obesity|BMI>=25
89054115|NCT04570527||Non-Obesity|BMI<25
89054116|NCT00584129|Experimental|1|Patients will receive pre-treatment swallowing exercises.
89054117|NCT00584129|Active Comparator|2|Post-treatment swallowing exercises.
89054118|NCT04570566|Experimental|titanium mish|horizontal alveolar ridge augmentation with non-resorbable titanium mish .evaluation after 4 months
89054119|NCT04570566|Experimental|pericardium membrane|horizontal alveolar ridge augmentation with resorbable pericardium membrane then .evaluation after 4 month.
89054120|NCT00584168|Placebo Comparator|2|Patient will receive a placebo.
89054121|NCT00584168|Experimental|1|Patient will receive dexamethasone.
89054122|NCT00470535|Experimental|Arm 1 - Oral Erlotinib hydrochloride|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity
89054123|NCT00584324|Experimental|Bispectral Index (BIS) 40|Target BIS 40
89054124|NCT00584324|Experimental|Bispectral Index (BIS) 60|Target BIS 60
89054125|NCT00470418|Other|NIC5-15|Subjects with Alzheimer's Disease
89054126|NCT00470418|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease
89054127|NCT01133275|Experimental|Lenalidomide and Prednisone Therapy|All participants received lenalidomide and prednisone therapy for 6 cycles (24 weeks). Each cycle is 28 days (4 weeks).
89054128|NCT00584441||1|Women with pre-menstrual asthma (PMA): As defined by a 20% or more fall in PEFR and / or change by 20% or more of daily symptom score.
89054129|NCT00584441||2|Women without pre-menstrual asthma
89054130|NCT00584441||3|Women on oral contraceptives
89054131|NCT00470184|Experimental|Chemo|Oxaliplatin 85 mg/m2 will be administered IV on days 1, 15 and 29. Capecitabine 1250 mg/m2 will be administered in 2 divided daily doses P0 or via enteral tube, on radiation days only (Monday- Friday/ weekly). Capecitabine will be continued until the final dose of radiotherapy
89054132|NCT00584519||500 patients|Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2
89054133|NCT04570254|Experimental|Patients with septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.~With the following specifications:~Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.~Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.~Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.~N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.~The dose of pentoxifylline that all patients will receive is as follows:~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
89054134|NCT04570254|Experimental|Patients without septic shock|"Only one antioxidant will be administered, which the treating physician will decide following a previously established decision tree plus pentoxifylline via an oral or orogastric tube for five days.~With the following specifications:~Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours.~Vitamin E. 800 mg tablet. 800 mg dose every 24 hours.~Melatonin. Tablet 5 mg. A dose of 50 mg every 24 hours.~N-acetylcysteine. Tablet 600 mg. 600 mg dose every 12 hours.~The dose of pentoxifylline that all patients will receive is as follows:~a) Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours."
89054135|NCT00584597|Placebo Comparator|1|Saline
89054136|NCT00584597|Experimental|2|Traumeel S 1 mL
89054137|NCT00584597|Experimental|3|Traumeel S 2 mL
89054138|NCT00584597|Experimental|4|Traumeel S 3 mL
89054139|NCT00470067|Experimental|Doxorubicin and carboplatin|Patients receive doxorubicin hydrochloride liposome IV over 1 hour on day 1 and carboplatin IV over 30 minutes on day 1
89054140|NCT00584636|Experimental|Pulmicort Respules|using pulmicort respules
89054141|NCT04570137|Experimental|1|This arm received the arabinoxylan/ß-glucan mix first.
89054142|NCT04570137|Experimental|2|This arm received the inulin/oligofructose mix first.
89054143|NCT00479817|Experimental|Arm A|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 10 mg/kg IV QW
89054144|NCT00479817|Experimental|Arm B|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 3 mg/kg IV QW
89054145|NCT00479817|Active Comparator|Arm C|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 placebo
89054146|NCT04575506|No Intervention|Control group|
89054147|NCT04575506|Active Comparator|Obesity-Non-hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
89054148|NCT04575506|Experimental|Obesity-Hepatic steatosis|Healthy lifestyle education program focused on dietary and lifestyle guidelines for both children and parents (2 days/month, 60 min), and exercise program based on high-intensity interval training which combine aerobic and resistance training (at least 3 days/week, from 38 to 44 min).
89054149|NCT04575194|Active Comparator|Liraglutide 3 mg|Patients will be prescribed sc liraglutide 3 mg/day along with a dietary and physical activity intervention.
89054150|NCT04575194|Active Comparator|Naltrexone/bupropion 32/360 mg|Patients will be prescribed oral naltrexone/bupropion 32/360 mg/day along with a dietary and physical activity intervention.
89054151|NCT04570059|Experimental|Intervention program|Intervention group
89054152|NCT04570059|Active Comparator|Usual Care|Control group
89054153|NCT00584753|Other|1|Normal volunteers
89054154|NCT00584753|Active Comparator|2|Breast PET/CT scan
89054155|NCT00584753|Active Comparator|3|Whole body and breast PET/CT
89054156|NCT04569825|Active Comparator|Local Nasal Steroid|Application of Local Nasal Steroid for the COVID-19 patients with anosmia
89054157|NCT04569825|Placebo Comparator|Normal Saline|Application of Normal Saline for the COVID-19 patients with anosmia
89054158|NCT00584792||1|Controls (No prostate cancer)
89054159|NCT00584792||2|Cases (Prostate Cancer Diagnosed)
89054160|NCT00476931|Experimental|1|SB-509
89054161|NCT00476931|Placebo Comparator|2|
89054162|NCT04569669|Experimental|Patients diagnosed with Coronary Artery Disease（CAD）by CCTA|Patients admitted to hospital with the diagnosed of CAD by CCTA and who accept to participate to the study will undergo the invasive coronary angiography, fractional flow reserve (FFR) will be measured during the invasive coronary angiography.Outcome measures were comparing FFRct to FFR.
89054163|NCT00479427|Experimental|Overall study|overall study population
89054164|NCT00585143|Experimental|1|
89054165|NCT04569981|Active Comparator|Climbing Group (CG)|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
89054166|NCT04569981|Active Comparator|Unsupervised active group (UAG)|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
89054167|NCT00585260|Experimental|Exploratory Mannitol|This is an exploratory / ancillary study open to all participants in the BASALT trial [NCT00495157] who consented to undergo mannitol bronchoprovocation procedures during the 36 week treatment period
89054168|NCT04569474|Experimental|Dressing Group|use of sterile transparent dressing
89054169|NCT04569474|No Intervention|Standard Group|non-sterile transparente dressing
89054170|NCT00585299|Experimental|Low-fat diet|20% kcals from fat diet followed for 8 weeks then 8 weeks of maintenance diet with visits to dietitian every other week
89054171|NCT00585299|Active Comparator|Traditional|Traditional low-fat diet given and dietitian follows up in 16 weeks
89054172|NCT00585416|Experimental|1|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
89054173|NCT00475020|Experimental|Fludarabine + Busulfan + Thymoglobulin|Fludarabine 40 mg/m^2 by vein daily over 1 hour x 4 days. Busulfan test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days. Thymoglobulin 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor.
89054174|NCT00585455||A|Chronic heart failure patients with concomitant depression
89054175|NCT02484456|Experimental|AV 101 (4-chlorokynurenine), then Placebo|After a two-week drug-free period, participants received daily oral dose of AV 101 (4-chlorokynurenine) monotherapy 1,080mg/day for seven days, then dose increased to AV 101 1,440mg/day for next seven days followed by a two-week washout period; then crossover to placebo phase with daily dose of placebo pill for two weeks.
89054176|NCT02484456|Experimental|Placebo, then AV 101 (4-chlorokynurenine)|After a two-week drug-free period, participants received daily dose of placebo pill for two weeks followed by two-week washout period; then crossover to AV 101 treatment phase with daily oral dose of AV 101 (4-chlorokynurenine) monotherapy 1,080mg/day for seven days, then dose increased to AV 101 1,440mg/day for next seven days.
89054177|NCT00585728|Other|1|CT virtual proctoscopy
89054178|NCT00585767||1|Patients with two kidneys
89054179|NCT00585767||2|Patients with solitary kidney
89054180|NCT01084629||Surveillance Barrett's esophagus|Patients scheduled for endoscopic surveillance of Barrett's esophagus
89054181|NCT01084629||Barrett's esophagus post ablation|Patients scheduled for surveillance endoscopy who have undergone ablative therapies (PDT, RF ablation) for their Barrett's esophagus
89054182|NCT00585806||1|Subjects with Heart Failure and ejection fraction greater than or equal to 45%
89054183|NCT00585806||2|Healthy Volunteers
89054184|NCT01132807|Experimental|Treatment (chemotherapy and F-18 PET/CT)|See Detailed Description
89054185|NCT00585845|Experimental|CRS-207|
89216792|NCT03987022|Experimental|"ICE-T"|"Regimen #1 ICE-T Opioid Sparing Regimen At the end of surgery patients will receive 30mg of intravenous (IV) toradol. Once out of the post anesthesia care unit (PACU) patients will receive~ICE PACKS applied to the surgical sites every hour for 20 minutes Around the clock (ATC) until discharge.~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~Once out of the PACU will receive 1 gram of Tylenol per os (PO) every 6 hours for a total of 4 grams daily ATC until discharge~Patients will receive dilaudid 0.2mg IV every 3 hours as needed (PRN) for breakthrough pain.~Patients will be discharged home with (PO) Tylenol and PO toradol as needed (PRN)."
89216793|NCT03987022|Active Comparator|Standard of care|"Regimen #2 STANDARD Postoperative Regimen~Once out of the PACU patients will receive Standard postoperative regimen~Motrin 600mg PO every 4 hours PRN pain scale 1-3 pain~Percocet 1 tab PO every 4-6 hours PRN pain scale 4-6 pain~Percocet 2 tabs PO every 7-10 hours PRN pain scale 7-10 pain~Patients will receive dilaudid 0.2mg IV every 3 hours PRN for breakthrough pain.~Patients will be discharged home with Motrin and Percocet for pain PRN."
89216794|NCT02575781|Experimental|SAR428926-Escalating cohort|SAR428926 will be administered intravenously up to disease progression or dose limiting toxicities
89216795|NCT02575781|Experimental|SAR428926 in triple negative breast cancer-Expansion Cohort 1|SAR428926 will be administered intravenously at maximum tolerated dose (MTD) up to disease progression or unacceptable toxicity
89216796|NCT02575781|Experimental|SAR428926 in solid tumors-Expansion Cohort 2|SAR428926 will be administered intravenously at the MTD up to disease progression or unacceptable toxicity
89216797|NCT03789838||Before of sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, before introduction of sepsis response team in the Emergency Department.
89216798|NCT03789838||Sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, with sepsis response team in the Emergency Department.
89216799|NCT01025128|Active Comparator|group A low D|ultra-Orthodox clinics patients aged 18-39 with lowest vitamin D levels
89216800|NCT01025128|No Intervention|group A high D|ultra-Orthodox clinics patients aged 18-39 with highest vitamin D levels
89216801|NCT01025128|Active Comparator|group B low D|mixed population clinics patients aged 18-39 with lowest vitamin D levels
89687054|NCT05720559|Experimental|Quintuple method treatment group|SOX regimen chemotherapy, low dose cetuximab targeted therapy, and folic acid, vitamin A, metronidazole three-drug regimen were combined. Specific drug dosages were as follows: SOX regimen was administered every three weeks, d1 was given oxaliplatin intravenously, the dosage was 130mg/ m2 * patient's body surface area, d2-d15 was taken orally by S1, 20mg three times a day each time. Cetuximab combined with chemotherapy was administered intravenously, once every three weeks, before oxaliplatin, and the dosage was 250mg/ m2 * patient's body surface area. Metronidazole 0.4g/ time, once a day; Vitamin A 25,000 units/time, once a day; Folic acid 0.4mg/ time, once a day. The last three drugs were continued until the end of all chemotherapy cycles. These regimens last for 6 to 8 sessions.
89687055|NCT05720247|Experimental|Fibroscan|Screening and brief intervention with additional Fibroscan procedure and sharing of results with patient
89687056|NCT05720247|Active Comparator|Standard Care|Screening and brief intervention without Fibroscan
89687057|NCT02761252|Experimental|Bilastine+montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment
89687058|NCT02761252|Active Comparator|Bilastine+placebo montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.
89216802|NCT01025128|No Intervention|group B high D|mixed population clinics patients aged 18-39 with highest vitamin D levels
89216803|NCT04073381|Experimental|Prehabiliation Program|100 subjects between the ages of 18 and 90, who have GI cancer and will undergo surgery will be recruited for this study ad participate in the prescribed prehabilitation exercise and nutrition program.
89216804|NCT00468910|Experimental|Arm I|Patients receive oral acetylsalicylic acid (aspirin) once daily.
89216805|NCT00468910|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
89216806|NCT01025206|Experimental|BI-505|
89216807|NCT02577185|Experimental|botulinum toxin type A|Experimental drug
89216808|NCT02577185|Placebo Comparator|sodium chloride 9 mg/ml|Vehicle drug
89216809|NCT00519285|Placebo Comparator|Placebo|Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
89216810|NCT00519285|Experimental|Aflibercept|Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
89216811|NCT00464620|Experimental|Dasatinib, 70 mg, twice daily|Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
89216812|NCT05212857|Experimental|systemic treatment combined with radical treatment and radiotherapy|"All recruited participants would receive long-term and unified systemic treatment. Systemic treatment is defined as chemical castration plus new-generation anti-androgen therapy.~For the primary lesion:~The preferred local treatment for primary lesion is radical prostatectomy. Patients who refuse surgery or whose tumors cannot be surgically resected after 3 months' systemic treatment could receive radical radiotherapy.~For the metastatic lesion:~Radiotherapy for metastatic lesions would be performed between 4 weeks and 24 weeks after the local treatment for primary lesion. Stereotactic body radiation therapy (SBRT) is preferred, which could treat all the detected lesions at once or in stages."
89216813|NCT02099123|Experimental|Atorvastatin|40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily
89687059|NCT02761252|Active Comparator|Montelukast+placebo bilastine|Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.
88998723|NCT05994690|Active Comparator|Standard arm Ri|No addition om gemtuzumab ozogamicin (GO) to the first induction course of CD33-positive AML
89216814|NCT02099123|Placebo Comparator|Placebo|Placebo (2 x 20 mg placebo) taken orally once daily
89216815|NCT00464542|Other|Metronidazole|Observational before and after treatment Drug: Metronidazole 500 mg, taken by mouth, two times a day, 7 days
89216816|NCT00468676|Active Comparator|B|Treatment as usual
89216817|NCT00468676|Experimental|A|Case management intervention
89216818|NCT02578823|Experimental|TTM-36|"Participants assigned to TTM-36 Arm will be managed by Arcticgel™ and Arctic Sun® to maintain core temperatureTemperature at 36.0℃ for 72 hours.~After targeted temperature management(TTM), Fever will be controlled for remaining 7 days by conventional antipyretic treatment. (Treat core temperature ≥ 38.3℃).~A total of 40 participants will be enrolled."
89216819|NCT02578823|Active Comparator|Conventional treatment|"Participants who are assigned to this Arm will be treated with conventional antipyretic treatment regarding the occurrence fever for 7 days.(Treat core temperature ≥ 38.3℃).~A total of 20 participants will be enrolled."
89216820|NCT01969643|Experimental|LV Dose Escalation|
89216821|NCT01969643|Experimental|LV + Trastuzumab|
89216822|NCT01969643|Experimental|LV Monotherapy|LV will be given at the recommended dose (at or below the monotherapy MTD determined in the LV dose escalation arm).
89216823|NCT00464308|Active Comparator|001|Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
89216824|NCT00464308|Active Comparator|002|Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
89216825|NCT00464308|Active Comparator|003|Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
89216826|NCT00468286|Experimental|A|Treatment group A: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
89216827|NCT00468286|Experimental|B|Treatment group B: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
89216828|NCT00463840|Experimental|Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6|"Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;~Combined with :~5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):~Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours."
89216829|NCT00129389|Active Comparator|Arm A: FAC|FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.
89216830|NCT00129389|Experimental|Arm B: FAC-wP|FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)
89216831|NCT01025362|Experimental|Lactation counseling|"Intervention arm: The mother and child health centres will implement The Baby-Friendly Initiative to improve their lactation counseling.~Other Names: The Baby Friendly Community Health Service"
89216832|NCT01025362|Active Comparator|Standard care|The comparison group was mother and child health centres which continued offering standard care.
89216833|NCT01025440|Active Comparator|CPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
89216834|NCT01025440|Active Comparator|HFCPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: During HF CPAP 35 L/min wil be administered.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
89216835|NCT00468052|Active Comparator|fentanyl|fentanyl bolus 1ug.kg-1
89216836|NCT00468052|Experimental|dexmedetomidine|dexmedetomidine 2ug.kg-1 over 10 min followed by 0.7ug.kg-1.h-1
89216837|NCT04712981|Experimental|Intervention|HOPE intervention peer-led online community
89216838|NCT04712981|No Intervention|Control|Online community without HOPE intervention psychological components
89216839|NCT00453310|Experimental|sunitinib malate|The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)
89216840|NCT04071743|Active Comparator|Treatment|Treatment and Prevention with active gammacore device(vagus nerve stimulator)
89216841|NCT04071743|Sham Comparator|Sham|Treatment and Prevention with sham gammacore device(vagus nerve stimulator)
89216842|NCT02578667|No Intervention|Gorbly Compression not needed|
89216843|NCT02578667|Experimental|Gorbly Compression may benefit|the use of the Gorbly device with the consent of the patient
89216844|NCT00128843|Experimental|Exemestane|25mg/day per VO until progression disease, after this progression the patient could receive the another drug (comparator arm) ie Anastrozole by investigator decision
89216845|NCT00128843|Active Comparator|Anastrozole|1mg/day per VO until progression disease, after this progression the patient could receive the another drug (experimental arm) ie Exemestane by investigator decision
89216846|NCT02575703|Experimental|[¹⁴C]-LY3023414|Single oral dose of [¹⁴C]-LY3023414 administered on Day 1
89216847|NCT04609553|Active Comparator|Usual care including ROR|Literacy promotion is a pediatric standard of care. Participants in this group will receive usual care that includes ROR, a primary care literacy promotion intervention.
89216848|NCT04609553|Experimental|ROR plus text messages|In addition to ROR, participants will receive three text messages per week, plus one interactive follow-up message per month, for the study period with scheduled breaks.
89216849|NCT04609553|Experimental|ROR plus text messages plus connection to community resources|In addition to ROR and text messages, participants will be referred to a county-based single point of entry system for referrals to community resources. This system simplifies access to poverty-reducing resources by creating a centralized access point, maintaining an updated data base of resources with existing capacity to support families, and providing case management.
89216850|NCT04071431|No Intervention|Control|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.~The RFQ results of this group are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
89687060|NCT05714475||Pancreas resection for colorectal metastasis|"Patient underwent a pancreas resection (whipple, distal pancreasectomy ...) with inclusion criteria. Criteria~Inclusion Criteria:~Isolated pancreatic metastases from Colorectal cancer~Previous surgery for colorectal cancer~Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas~Other procedures:~total-pancreatectomy distal-pancreatectomy other metastases resection~R0 resection~no signs of peritoneal metastasis or tumor manifestations outside of the pancreas.~CT Scan before surgery~Exclusion Criteria:~metastases from different malignancies~other malignancies~surgically unmanageable lesions~Multiple synchronous colorectal metastasis"
89687061|NCT00357357|Placebo Comparator|Group1|4x 7 day rising dose
89687062|NCT00357357|Placebo Comparator|Group2|4x, 7 day rising dose
89687063|NCT00357357|Placebo Comparator|Group3|28 day fixed lower dose
89687064|NCT00357357|Placebo Comparator|Group4|28 day fixed upper dose
89687065|NCT05448742|Experimental|Main arm of the study|Six cadaveric lower limbs will have biplanar PSI slope-reducing MOWHTO performed on and accuracy of biplanar correction will be assessed.
89687066|NCT01046695|Active Comparator|TENS Unit|"This arm will be adding the use of the TENS unit for 48 hours in addition to standard care for their post operative pain control.~Patient's primary area of postoperative pain was determined by nursing personnel. Four electrodes were placed on or around the area of maximum pain. The TENS unit was turned on, 1 of 5 frequency patterns selected and the impulse turned up until the patient could feel the impulse. The location of the electrodes, the pattern, and/or the intensity of the TENS unit were adjusted until the patient achieved maximum comfort with the sensation."
89687067|NCT01046695|No Intervention|Control Arm|This arm will have standard care for their post operative pain control.
89687068|NCT05443984|Experimental|Experimental Group|JP-1366 20mg + Esomeprazole 40mg(placebo)
89687069|NCT05443984|Active Comparator|Active Comparative Group|JP-1366 20mg(placebo) + Esomeprazole 40mg
89687070|NCT01725373||Angioplasty of left main|"Patients with:~stable or unstable angina and/or documented ischemia~de novo ≥50% stenosis in the left main stem referred for angioplasty"
89687071|NCT01725607|No Intervention|the control group (Group C)|general anesthesia
89687072|NCT01725607|Experimental|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
89687073|NCT01725607|Experimental|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
89687074|NCT02763124|Experimental|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to perform one or two corneal arcuate incisions.
89216851|NCT04071431|Experimental|Risk shown|"During the application stage of endoscopy, the patients are required to complete a RFQ according to their own situations. The RFQs will soon uploaded to the core server of the quality control system and be analysed automatically immediately after finish. The results are sorted into four types including N/A, High-risk for esophageal cancer, High-risk for gastric cancer and High-risk for colorectal cancer, which will be shown during the endoscopy of the specific person.~The endoscopies are carried out by experienced endoscopists. All of the data of the endoscopy itself are collected and recorded in the quality control system.~The RFQ results of this group are known by the endoscopists before and during the endoscopy."
89216852|NCT04073927|Active Comparator|Sodium butyrate|3.6 g sodium butyrate. 6 capsules twice daily for 12 weeks.
89687075|NCT03304379|Experimental|Dosing regimen 1|
89687076|NCT03304379|Experimental|Dosing regimen 2|
89687077|NCT03304379|Experimental|Dosing regimen 3|
89687078|NCT03304379|Experimental|Dosing regimen 4|
89687079|NCT00915967|Experimental|Vancomycin|Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
89687080|NCT00915967|Placebo Comparator|Saline|Subjects in the saline group will receive a Saline injection directly into the wound pocket.
89687081|NCT05327842|Experimental|New training simulator|Participants received training with new simulator
89687082|NCT05327842|Active Comparator|Traditional method|Participants received traditional training
89687083|NCT02763826|Experimental|Determine the Optimal tDCS current|We will invesitigate the optimal curent in range of 1 mA to 4 mA. We hypothesize that 4 mA is tolerable, safe and can induce the highest level of cortical excitability in the lesional motor cortex.
89054186|NCT01132651|Experimental|Chillow cooling pillow|This group of subjects will follow their current eczema regimen with the addition of using the cooling pillow at night to sleep on.
89054187|NCT01132651|Placebo Comparator|Standard of care (regular pillow at night)|This group of subjects will serve as the control group following a their current eczema care regimen, including sleeping on their normal pillow.
89054188|NCT01089543|Experimental|Rabeprazole 10 mg|
89054189|NCT01089543|Experimental|Rabeprazole 20 mg|
89054190|NCT01089543|Experimental|Rabeprazole 40 mg|
89054191|NCT01089543|Placebo Comparator|Placebo|
89687084|NCT02763826|Experimental|Determine the optimal tDCS electrode montage|We hypothesize that the bi-hemispheric stimulation with anodal stimulation on the lesional hemisphere and simultaneous cathodal stimulation on the non-lesional hemisphere induces more cortical excitability in the lesional hemisphere than either anodal stimulation on the affected hemisphere or cathodal stimulation on non-lesional hemisphere alone.
89054192|NCT04569396||Non-Alcoholic Fatty Liver Disease|A total of 72 severely or morbidly obese patients with non-alcoholic fatty liver disease and associated co-morbidities like diabetes and hypertension were enrolled into the study.
89054193|NCT00586040|Experimental|1|superficial closure with PTB
89054194|NCT00586040|Active Comparator|2|superficial sutures
89054195|NCT04569630|Experimental|Intervention group|
89054196|NCT00586079|Experimental|A|Ten patients who have had deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
89054197|NCT00586079|Experimental|B|Ten patients who are scheduled to have deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
89054198|NCT04569318|Experimental|Treatment Arm|Treatment with treatment beam.
89054199|NCT03452852|Other|NPWT (PICO device)|In this arm, investigators will use the PICO system (Smith and Nephew) for compression therapy after split thickness skin graft of leg ulcers.
89054200|NCT03452852|Other|Compression bandaging (Coban 2 lite)|In this arm, investigators will use the Coban 2 lite compression bandaging for compression therapy after split thickness skin graft of leg ulcers.
89687085|NCT05525364||Screening of diabetes|"Our investigations included patients receiving treatment protocols conferring a diabetogenic risk. These included total body, cranial and abdominal irradiation (respectively TBI, CI and AI), steroids and L-asparaginase. Our cohort was therefore composed of patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).~The patients were stratified according to the presence or absence of hyperglycemia during the treatment protocol and during clinical follow-up, which ended in August 2020. The groups were called the hyperglycaemia-positive ALL, NHL or HL and the hyperglycaemia-free ALL, NHL or HL."
89687086|NCT05032560|Experimental|25 mg single dose|Subject will receive a single oral dose of ABX464 25 mg or its matching placebo
89687087|NCT05032560|Experimental|50 mg single dose|Subject will receive a single oral dose of ABX464 50 mg or its matching placebo
89687088|NCT05032560|Experimental|25 mg multiple dose|Subject will receive a daily oral dose of ABX464 25 mg or its matching placebo for 28 days
89687089|NCT05032560|Experimental|50 mg mulptiple dose|Subject will receive a daily oral dose of ABX464 50 mg or its matching placebo for 28 days
89687090|NCT02766244|Experimental|ICG/SPY|Daily wound care with antibiotic ointments after cleansing plus evaluation using ICG/SPY fluorescence.
89054201|NCT03452735||patients diagnosed before age 40|Patient between 18 and 50 years-old with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism who will answer to a questionnaire about fertility
89054202|NCT03452735||Control Group|Patient between the ages of 18 and 50 years, not diagnosed with Chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology, presenting no chronic pathology, having no chemo or radiotherapy or immunosuppressive therapy, or pelvic surgery before age 40 years who will answer to a questionnaire about fertility
89054203|NCT01089504|Active Comparator|Phenobarbital|Phenobarbital, 4-5 mg/kg/day, for 4 months
89054204|NCT01089504|Placebo Comparator|Placebo|Placebo in a volume equivalent to active drug for 4 months
89054205|NCT03452696|Experimental|Calcium supplement 10/90|Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.
89054206|NCT03452696|Experimental|Calcium supplement 5/95|Microencapsulated calcium1316 mg orally (5% protein and 95% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 shots of 1,316 mg each orally, to make a total contribution of 1,000 mg. calcium element
89054207|NCT03452696|Active Comparator|Calcium carbonate supplement|1,250 mg orally (500 mg of calcium element). There will be 2 doses of 1,250 mg. each orally, to make a total contribution of 1,000 mg. of calcium element.
89054208|NCT03452696|Active Comparator|Calcium citrate supplement|1,500 mg orally (315 mg of calcium element). There will be 2 taken orally, to make a total contribution of 945 mg. calcium element
89054209|NCT01088997|Experimental|High Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
89054210|NCT01088997|Experimental|Low Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
89054211|NCT00586118||1-Sevo|Sevoflurane/ACD group (n=60)
89054212|NCT00586118||2-Propofol|Propofol group (n=60)
89054213|NCT00586235||1|patients with indeterminate kidney or liver lesions
89054214|NCT01088529|Experimental|AA+LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) and 1,000 mg abiraterone acetate (AA) plus 5 mg of prednisone daily for 3 months prior to radical prostatectomy.
89054215|NCT01088529|Experimental|LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.
89054216|NCT00586274|Experimental|CD34 selected haploidentical PBSCT|CD34 selected haploidentical PBSCT
89054217|NCT00586352|Active Comparator|Normal|Subjects who have normal endoscopic findings
89687091|NCT03406117|Experimental|HAT1-EPBF2|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
89054218|NCT00586352|Active Comparator|Newly diagnosed Crohn's disease|Subjects who are newly diagnosed with Crohn's disease after endoscopy.
89054219|NCT00586352|Active Comparator|Newly diagnosed Ulcerative Colitis|Subjects diagnosed with Ulcerative Colitis after endoscopy
89054220|NCT01087944|Experimental|1|"Peginterferon via auto-injector device.~All participants will receive Peginterferon in a cross-over design."
89054221|NCT01087944|Active Comparator|2|"Peginterferon via pre-filled syringe.~All participants will receive Peginterferon in a cross-over design."
89054222|NCT00586430|Active Comparator|1|single 2 mg dose of lorazepam
89054223|NCT00586430|Placebo Comparator|2|single dose of placebo
89054224|NCT01132612|Experimental|Fixed-time interval regimen|Secukinumab 150 mg subcutaneous (sc) administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter
89054225|NCT01132612|Experimental|Treatment at start of relapse regimen|Placebo administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter. If relapse, then switch to secukinumab 150 mg sc administered every 4 weeks
89054226|NCT01132612|Experimental|Open-label|Secukinumab 150 mg sc administered every 4 weeks
89054227|NCT00586547|Experimental|Treatment|After patients have completed preparation to receive cells, they will be treated at one of five dose levels.
89054228|NCT04569279|Active Comparator|Warfarin arm|Patients randomly assigned to (W) group will receive an adjusted dose of warfarin with targeted INR of 2.0 to 3.0.
89054229|NCT04569279|Experimental|Rivaroxaban arm|Patients randomly assigned to (R) group will receive 20mg rivaroxaban daily if CrCl>50 mL/min using Cockcroft-Gault equation or 15mg rivaroxaban daily if CrCl 30-50 mL/min.
89216853|NCT04073927|Placebo Comparator|Placebo|Placebo. 6 capsules twice daily for 12 weeks.
89687092|NCT03406117|Experimental|HAT1-HMF3|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
89687093|NCT03406117|Active Comparator|Saline Solution: Sodium Chloride|Saline, Sodium Chlorine (NaCl; 0.9%), was used as the negative irritant control in the CIT portion of the study
89687094|NCT03216395|Experimental|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
89054230|NCT01132495|Other|Cohort A: PCI plus OMT|PCI plus optimal medical treatment
89054231|NCT01132495|Other|Cohort A: OMT alone|Optimal medical treatment alone
89054232|NCT01132495|Other|Cohort B|FFR > 0.80; treatment according to local practice
89054233|NCT00586586|Experimental|Group CBT|The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered in groups of 4 to 8. 10 weekly sessions plus 2 booster sessions.
89054234|NCT00586586|Experimental|Individual CBT|"The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered individually.~10 weekly sessions plus 2 booster sessions."
89054235|NCT00586586|No Intervention|Wait-list control|Wait-list control condition for 5 weeks after last child has been included.
89054236|NCT04312204|Experimental|Sintilimab+Gemcitabine+Carboplatin|
89054237|NCT04312282|Experimental|Cohort 1, Sequence 1A: Fed then fasted|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fed conditions~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions"
89054238|NCT04312282|Experimental|Cohort 1, Sequence 1B: Fasted then fed|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle under fasted conditions~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle under fed conditions"
89054239|NCT04312282|Experimental|Cohort 2: Tesetaxel plus itraconazole|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and itraconazole on Day -3 through Day 14 of a 21-day cycle"
89054240|NCT04312282|Experimental|Cohort 3: Tesetaxel plus rifampin|"Cycle 1: Tesetaxel on Day 1 of a 21-day cycle~Cycle 2: Tesetaxel on Day 1 of a 21-day cycle and rifampin on Day -6 through Day 14 of a 21-day cycle"
89054243|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
89054244|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
89054245|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
88998724|NCT05994690|Experimental|Investigational arm Ri|Addition om gemtuzumab ozogamicin (GO) to the first induction course of CD33-positive AML
88998725|NCT05994599|Experimental|EVE119 vaginal ring|EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
88998726|NCT05994599|Active Comparator|Nuvaring vaginal ring|Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
88998727|NCT05994586|Experimental|AP029 mix - type II diabetes|Patients with type II diabetes receiving metformin for up to 5 months
88998728|NCT05994586|Experimental|AP029 mix - prediabetes|Patients with pre-diabetic
88998729|NCT05994586|Placebo Comparator|Placebo - type II diabetes|Patients with type II diabetes receiving metformin for up to 5 months
88998730|NCT05994586|Placebo Comparator|Placebo - prediabetes|Patients with pre-diabetic
88998731|NCT05994560|Other|without temporary occlusion|Without temporary occlusion: No occlusion of uterine or útero-ovarian ligaments during laparoscopy myomectomy
88998732|NCT05994560|Active Comparator|With temporary occlusion|Temporary occlusion of the uterine arteries and utero-ovarian ligaments during laparoscopic myomectomy
88998733|NCT05994547|Experimental|Midazolam|"Patients aged <60 years or weighing >50 kg were randomly assigned to receive 3 mg intravenous midazolam. In contrast, those aged ≥60 years or with a body weight of <50 kg were assigned 2 mg intravenous.~If adequate sedation was not achieved after the initial sedative administration, additional midazolam (0.5 mg) was administered at intervals of 3-4 min, at the discretion of the physician."
88998734|NCT05994547|Active Comparator|Remimazolam|"Patients aged <60 years or weighing >50 kg were randomly assigned to receive 5 mg remimazolam. In contrast, those aged ≥60 years or with a body weight of <50 kg were assigned intravenous 3 mg remimazolam.~If adequate sedation was not achieved after the initial sedative administration, additional remimazolam (2.5 mg) was administered at intervals of 3-4 min, at the discretion of the physician."
88998735|NCT05994508|Experimental|Participants|A single group of participants with Parkinson disease will participate in a 6-week pickleball program with pre-test, post-test, and one month follow-up testing.
88998736|NCT05994469|Experimental|Copenhagen Adduction Exercise Group|there is no control group, all teams can implement the intervention protocol that better fits their normal schedule, the intervention can consist of 1 or 2 Copenhagen Adduction Exercise sessions per week
88998737|NCT05994456|Experimental|PD-1 inhibitor|Neoadjuvant therapy with PD-1 inhibitor (Toripalimab)
88998738|NCT05994443||Pregnant women exposed to threatened preterm labor and exposed to antenatal corticosteroids|Pregnant women with threatened preterm labor (TPTL) who received antenatal corticosteroids (ACS) between 22 and 34 weeks and 6 days of gestation at our hospital.
88998739|NCT05994443||Non-exposed pregnant women|Pregnant women with normal pregnancies.
88998740|NCT05994430|Experimental|Training Group|"The End-of-Life Care Awareness Training Program in Intensive Care prepared by the researchers in line with the End-of-Life Nursing Education-Intensive Care (ELNEC-Critical Care) program was applied to the intensive care nurses in the training group. The program was implemented online by determining a common day and time interval suitable for the working hours of the nurses. Half an hour before the training, nurses were reminded of the training topics of the relevant week, time, and Zoom link address via text message.~40-60 minutes one day a week for 4 weeks in the training program; Week 1: Introduction of the training program and palliative care nursing in intensive care Week 2: Pain management and management of other symptoms (respiratory, gastrointestinal, etc.) Week 3 Communication, cultural and spiritual issues Week 4: Loss, grief, mourning, and ethics were covered."
88998741|NCT05994430|No Intervention|Control Group|"Intensive care nurses in the control group did not receive any intervention during the study. The nurses in this group continued to participate in routine in-service trainings. Similar to the training group, the post-test forms/scales End-of-Life Care Knowledge Test and the Scale of Attitudes and Behaviors of Intensive Care Nurses Towards End-of-Life Care were administered to the intensive care nurses in the control group in order to determine the changes in the levels of knowledge, attitudes and behaviors towards end-of-life care over time and to compare them with the training group."
88998742|NCT05994417||Non-Hispanic Black|Infants born to mothers identifying as Non-Hispanic Black
88998743|NCT05994417||Non-Hispanic White|Infants born to mothers identifying as Non-Hispanic White
88998744|NCT05994417||Infants across the spectrum of melanin index and ITA-based skin color classification|
88998745|NCT05994404||Anterior Cervical Discectomy and Fusion|Ventral decompression and fusion was performed using multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft was used at each disc space and all compressive osteophytes were removed using the operating microscope. Plate fixation was done with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
88998746|NCT05994404||Posterior Instrumented Cervical Fusion|Dorsal decompression and instrumented fusion was performed using midline cervical laminoectom with the application of lateral mass screws and rods for rigid fixation. Local bone was used along with allograft to promote a lateral mass fusion.
88998747|NCT05994404||Laminoplasty|Laminoplasty was performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) were used with titanium plates and screws to expand the spinal canal diameter.
88998748|NCT05994391|Experimental|LasoperinTM|"Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin~2 capsules per day~Take twice per day with food and water, once in the morning and once in the evening.~If a dose is missed the participant can consume it as soon as they remember within the day. This means that the participant may consume 2 capsules at once. If both capsules are missed for the day the participant should not consume 4 capsules the next day and should return to the normal dosage of one capsule in the morning and evening"
88998749|NCT05994391|Placebo Comparator|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose~2 capsules per day~Take twice per day with food and water, once in the morning and once in the evening.~If a dose is missed the participant can consume it as soon as they remember within the day. This means that the participant may consume 2 capsules at once. If both capsules are missed for the day the participant should not consume 4 capsules the next day and should return to the normal dosage of one capsule in the morning and evening"
88998750|NCT05994365||Anlotinib group|Anlotinib hydrochloride capsules: 12 mg once daily for 2 weeks, followed by a discontinuation of 1 week (21 days as a cycle)
88998751|NCT05994365||Observation group|Observation: prospectively and retrospectively collect data of patients who did not receive anlotinib hydrochloride capsules or similar small-molecule antivascular inhibitors.
88998752|NCT05994352|No Intervention|control group|no intervention will be applied to the students in the control group
88998753|NCT05994352|Experimental|experimental group|virtual reality simulation will be applied to the experimental group
88998754|NCT05994300|Experimental|Moderately Hypofractionated Adaptive Radiotherapy|
88998755|NCT05994274||HTx|Patients after heart transplantation.
88998756|NCT05994209|No Intervention|Control Group|Nationwide resource referral and intervention waitlist
88998757|NCT05994209|Experimental|Experimental Group A: Mobile App Intervention|quitSTART Mobile Application Adapted for Vaping Cessation Among Young Adults
88998758|NCT05994209|Experimental|Experimental Group B: Mobile App Intervention with Embedded Chatbot Feature|quitSTART Mobile Application Adapted for Vaping Cessation Among Young Adults Including Embedded Chatbot Feature
88998759|NCT05994196|Experimental|Optimum|the secondary prioritization software of patients
88998760|NCT05994196|No Intervention|Control|the standard dashboard of patients
88998761|NCT05994170|Experimental|Reduction CTVp1|CTVp1=GTVp+5mm
88998762|NCT05994170|Placebo Comparator|Non-reduction CTVp1|CTVp1=GTVp+5mm+whole nasopharynx
88998763|NCT05994144|No Intervention|CONTROL|The control group, traditional DOTS is the group who will be attending daily to their respective PR-1/PR-2 throughout intensive phase.
88998764|NCT05994144|Active Comparator|INTERVENTION ARM (VOT)|The intervention group, video observed therapy (VOT) is the group who will be teleconferencing daily with their respective PR-1/PR-2 TB team via WhatsApp throughout the intensive phase.
88998765|NCT05994131|Experimental|Experimental Group in cohort 1, cohort 2, and cohort 3|IN10018+Furmonertinib
88998766|NCT05994131|Active Comparator|Control Group in cohort 3|Furmonertinib
88998767|NCT05994118|Placebo Comparator|Normal Saline|0.5 milliliter of NACL 0.9% subcutaneous saline injection
88998768|NCT05994118|Active Comparator|Magnetized Normal Saline|0.5 milliliter of magnetized NACL 0.9% subcutaneous saline injection
88998769|NCT05994105|No Intervention|Control Group|individuals who will not receive the management plan
88998770|NCT05994105|Experimental|Experimental Group|Individuals who will receive therapy
88998771|NCT05994079|Experimental|high intensity focused ultrasound group|This group includes 43 patients who have abdominal skin laxity post sleeve gastrectomy and who will receive high intensity focused ultrasound. patients will receive one session; time of session is 40 minutes.
88998772|NCT05994079|Active Comparator|medical topical firming creams group|This group includes 43 patients who have abdominal skin laxity post sleeve gastrectomy and who will receive medical topical firming creams.
88998773|NCT05994053|Active Comparator|Active HD-tACS|HD-tACS of OFC
88998774|NCT05994053|Sham Comparator|Sham HD-tACS|HD-tACS of OFC
88998775|NCT05994014|Other|Main group|All patients undergo both, experimental and standard, tests
88998776|NCT05994001|Experimental|Group 1|6 mg/kg cardonilizumab, 14 days for 1 course.
88998777|NCT05994001|Experimental|Group 2|1.8mg /mg LM-302 was treated for 1 course for 14 days.
88998778|NCT05994001|Experimental|Group 3|6 mg/kg cardonilizumab for 14 days was a course of treatment; RP2D LM-302 is 1 course of treatment for 14 days
88998779|NCT05993988|No Intervention|control group|The participants in the control group did not receive any intervention.
88998780|NCT05993988|Experimental|Exercise group|The participants in the exercise group performed Jacobson muscle relaxation exercises with a specialist physiotherapist through the Zoom program (https://zoom.us). The exercises were applied 4 days a week for 4 weeks.
88998781|NCT05993520||Interstitial Lung Disease|Between June 2020 and June 2023, a total of 36 voluntary participants, aged 18 and above, who were receiving treatment at the Department of Chest Diseases, Istanbul Faculty of Medicine, Istanbul University, and met the inclusion criteria, were included in the study.
88998782|NCT05992909||Lymphovenous bypass procedure (LBP)|A surgical procedure for treating lymphedema called lymphovenous bypass procedure (LBP), but it is usually only done after a patient develops lymphedema
88998783|NCT05992337||Women with breast cancer treated with chemotherapeutics without signs of cardiotoxicity|
88998784|NCT05992337||Women with breast cancer treated with chemotherapeutics with signs of cardiotoxicity|
88998785|NCT05991921|Experimental|"Transcutaneous Electrical Nerve Stimulation"|TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each.Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort. All participants in the TENS, received all other routine obstetric care provided by hospital healthcare professionals.
88998786|NCT05991921|Sham Comparator|Plasebo|Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
88998787|NCT05991921|No Intervention|Control|Participants in the control group were not dependent on TENS. All participants in the control group received all other routine obstetric care provided by hospital healthcare professionals.
88998788|NCT05991557|Experimental|treatment arm|peroneus longus autograft
88998789|NCT05991154|Experimental|Usual Practice + JoyPop|Participants will be monitored through the existing wait-list practices, which involve regular phone calls to check in and assess functioning, and will receive access to the JoyPop app for 4 weeks.
88998790|NCT05991154|No Intervention|Usual Practice|Participants will be monitored through existing wait-list practices which involve regular phone calls to check in and assess functioning. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
88998791|NCT05991050|Active Comparator|Diet regimen group|an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E.
88998792|NCT05991050|Active Comparator|whole body vibration group|"For 8 weeks, WBV participants completed 3 supervised training sessions a week. The exercises were consisted of dynamic squats starting from upright position into the assigned degree of knee ﬂexion squats with 90° knee angle, semi-squats with 120° knee angle and heel elevation (calf-raise), each exercise was performed for 3 sets and each set consisted of 5 repetitions."
88998793|NCT05991024||The primary group|"Patients diagnosed with incisional hernia in our hospital's electronic medical record system were divided into two groups: primary group and recurrent group based on whether the incisional hernia recurred after incisional hernia repair,who were screened out with abdominal wall incisional hernia."
88998794|NCT05991024||The recurrent group|"Patients diagnosed with incisional hernia in our hospital's electronic medical record system were divided into two groups: primary group and recurrent group based on whether the incisional hernia recurred after incisional hernia repair,who were screened out with abdominal wall incisional hernia."
88998795|NCT05990049|Active Comparator|Hyaluronic acid|During the surgery, the hyaluronic acid will be administered on donor site wound and on recipient site before suturing.
88998796|NCT05990049|No Intervention|Control|"After the harvesting of the graft from the donor site, the wound will be sutured using only saline to clean the wound.~On the recipient site, before positioning the graft, only saline will be used."
88998797|NCT05990036|Experimental|Sports vision participants|Women softball team participating in a sports vision training program
88998798|NCT05988502|Experimental|auricular acupressure (AA) group|the auricular acupressure (AA) group was given auricular acupressure for two weeks
88998799|NCT05988502|No Intervention|control group|all participants received the same routine care which was general heart failure care and medications for constipation therapy provided by the study hospital professionals. Prior to the study, every participant was assessed by the cardiologist and identified as being appropriate and safe.
88998800|NCT05988294|Experimental|Group A (Pilates Group)|Participants will receive Pilates exercises for 60 minutes followed by conventional physical therapy program for 45 minutes, 3 days/ week for 12 weeks.
89216854|NCT00124657|Experimental|Patients with High-Grade/Low-Grade Glioma|Patients with newly diagnosed high-grade glioma (excluding those originating in the brain stem) and unfavorable low-grade glioma who are ≥ 3 years and <26 years of age. Patients receiving enzyme-inducing anticonvulsants (EIACs) are not eligible for this study. Patients with spinal cord tumors will be eligible for the Phase I and Phase II component of this study, but they will not be taken into consideration to estimate PFS in the Phase II component of this trial because of their notoriously worse prognosis. Patients receive erlotinib hydrochloride.
89216855|NCT00581945|Experimental|Canakinumab|Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.
89216856|NCT00581945|Placebo Comparator|Placebo|Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.
89216857|NCT02578589|Active Comparator|surgery|
89216858|NCT02578589|Active Comparator|Conservative treatment|
89216859|NCT01079845|Experimental|Low-glycemic Load Diet|
89216860|NCT01079845|Active Comparator|Low-fat Diet|
89216861|NCT02578277|Experimental|Single sequence, 3-period DDI (drug-drug interaction)|Single sequence
89216862|NCT04071197|Experimental|Gastrostomy-biliary tube|The study group will be subjected to gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
89687095|NCT03216395|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clips or pulse
89687096|NCT03401125||Sickle cell disease patients (SS genotype)|Sickle cell disease patients with a SS genotype having an history of blood transfusions within the CHU Brugmann and the Queen Fabiola Children's Hospitals.
89216863|NCT04071197|Experimental|Other biliary diversion modalities|The control group will include those cases with other modalities of therapy as external biliary diversion, internal biliary diversion, and nasobiliary tube
89216864|NCT00555906|Experimental|1|
89216865|NCT03817879|Experimental|VivaSight double-lumen tube|
89216866|NCT03817879|Active Comparator|Conventional double-lumen tube|
89216867|NCT04071353||Interferon combined with ribavirin group|Interferon combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) in patients with chronic hepatitis C, collect basic data before antiviral therapy, and during the PR antiretroviral treatment period, Follow-up was performed every 3-6 months in March, June, September, December, DAAs antiviral treatment during January, March, and withdrawal follow-up, and clinical biochemistry, HCV RNA, and serological markers were used during follow-up ( anti-HCV), AFP and liver imaging (liver ultrasound) examination.
89216868|NCT04071353||DAAs treatment group|Patients with chronic hepatitis C treated with direct acting antivirals (DAAs), collect basic data before antiviral therapy, and during the period of PR antiviral treatment, January, March, June, September, December Follow-up was performed every 3-6 months during January, March, and withdrawal follow-up during DAAs antiviral therapy. Clinical biochemistry, HCV RNA and serological markers (anti-HCV), AFP, and liver imaging were performed at follow-up. Liver ultrasound) check.
89216869|NCT03968497|Other|Postoperative pain assessment|Postoperative pain evaluation by a female and a male investigator, respectively at approximately 15-minute intervals.
89687097|NCT04337086|Experimental|T4k|
89687098|NCT04337086|Active Comparator|Twin block|
89687099|NCT03405961||Manual PAR score|Patient will receive upper and lower impressions, which will be cast to produce plaster models. A calibrated individual will PAR score the casts in the traditional manner (regular care pathway)
89687100|NCT03405961||Direct digital PAR score|Patient will receive upper and lower intra-oral scans which will be PAR scored directly by the computer
89687101|NCT03405961||Indirect digital PAR score|Patient will receive upper and lower impressions which will be cast to produce plater models (regular care pathway). The casts will be scanned with Carestream 3600 intra oral scanner and scored digitally by the computer.
89687102|NCT03838835|Experimental|Equine-facilitated group therapy|
89687103|NCT03838835|Experimental|Augmented equine-facilitated CBT group program|
89687104|NCT03838835|Other|Wait List Control (WLC)|
89216870|NCT01078129|Active Comparator|behavior therapy - CRT|behavior program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions) by means REHACOM® software
89216871|NCT01078129|Sham Comparator|non-CRT|no intervention
89216872|NCT04071899||Patients|patients with RBD
89216873|NCT04071899||Bedpartners|Subjects which are the bedpartners of patients with RBD
89216874|NCT01078285||Control|
89216875|NCT01078285||Intervention Arm|
89687105|NCT02767492|Experimental|BioDRestore™|BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint.
89687106|NCT02767492|Active Comparator|Corticosteroid|Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.
89687107|NCT05525208|Experimental|Primary dose of inactivated (Sinovac®) vaccine (1)|Subject who had received a complete primary dose of inactivated (Sinovac®) vaccine
89687108|NCT05525208|Experimental|Primary dose of mRNA (Pfizer®) vaccine (1)|Subject who had received a complete primary dose of mRNA (Pfizer®) vaccine
89687109|NCT05525208|Experimental|Primary dose of Viral Vector (AstraZeneca®) vaccine (1)|Subject who had received a complete primary dose of viral vector (AstraZeneca®) vaccine
89687110|NCT05525208|Experimental|Primary dose of inactivated (Sinovac®) vaccine (2)|Subject who had received a complete primary dose of inactivated (Sinovac®) vaccine
89687111|NCT05525208|Experimental|Primary dose of mRNA (Pfizer®) vaccine (2)|Subject who had received a complete primary dose of mRNA (Pfizer®) vaccine
89687112|NCT05525208|Experimental|Primary dose of Viral Vector (AstraZeneca®) vaccine (2)|Subject who had received a complete primary dose of viral vector (AstraZeneca®) vaccine
89054246|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
89054247|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
89054248|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
89054249|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
89054250|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
89054251|NCT00586742|Active Comparator|1|Labral repair with suture anchors
89054252|NCT00586742|Active Comparator|2|Biceps tenodesis with suture anchor
89054253|NCT00586742|Sham Comparator|3|only a diagnostic arthroscopy performed
89054254|NCT04311736|Active Comparator|Exergame|Moderate intensity cycling only 3 times per week for 12 weeks + concurrent virtual reality cognitive training, supervised by an exercise specialist
89054255|NCT04311736|Active Comparator|Cycling|Moderate intensity cycling only 3 times per week for 12 weeks, supervised by an exercise specialist
89054256|NCT04311736|Sham Comparator|Stretching|Stretching 3 times per week for 12 weeks, supervised by a therapist
89054257|NCT00586781|Experimental|3|The S.T.A.R. ankle system is the study device. The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants. Both ankles of every subject will be treated with the STAR ankle.
89054258|NCT00586859|Experimental|A|NDO Full-thickness Plicator Procedure
89054259|NCT01087788|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
89216876|NCT02576561|Experimental|TVGV-1 (cohort 1)|Antigen + Adjuvant - 0.6 mg lyophilized PEK fusion protein + 0.6 ml* GPI- 0100 (1:1 ratio)
89054260|NCT01087788|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
89216877|NCT02576561|Active Comparator|GPI-0100 (cohort 1)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml* GPI- 0100 (1:1 ratio)
89216878|NCT02576561|Placebo Comparator|Placebo (cohort 1)|Placebo- 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml placebo-diluent (1:1 ratio)
89216879|NCT02576561|Experimental|TVGV-1 (cohort 2)|Antigen + Adjuvant - 0.9 mg lyophilized PEK fusion protein + 0.9 ml* GPI- 0100 (1:1 ratio)
89216880|NCT02576561|Active Comparator|GPI-0100 (cohort 2)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml* GPI- 0100 (1:1 ratio)
89216881|NCT02576561|Placebo Comparator|Placebo (cohort 2)|Placebo - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml placebo diluent (1:1 ratio)
89216882|NCT02576561|Experimental|TVGV-1 (cohort 3)|Antigen + Adjuvant - 1.2 mg lyophilized PEK fusion protein + 1.2 ml* GPI- 0100 (1:1 ratio)
89216883|NCT02576561|Active Comparator|GPI-0100 (cohort 3)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein + 1.2 mg lyophilized placebo cake 1.2 ml* GPI- 0100 (1:1 ratio)
89216884|NCT02576561|Placebo Comparator|Placebo (cohort 3)|Placebo - 0 mg lyophilized PEK fusion protein. 1.2 mg lyophilized placebo cake + 1.2 ml placebo-diluent (1:1 ratio)
89216885|NCT04071275|Active Comparator|Mirror therapy|Subjects will be asked to perform specific movements (using the unaffected limb while watching its mirrored reflection for 20 minutes per day, for 10 treatment days, completed during two weeks (every weekday, excluding weekends)
89216886|NCT04071275|Sham Comparator|Mirror therapy + sham tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, a sham tDCS treatment will be applied.
89216887|NCT04071275|Experimental|Mirror therapy + active tDCS|Subject will undergo the mirror therapy treatment, as in the first study arm. In addition, at the same time, an active tDCS treatment will be applied.
89216888|NCT00709475||A|
89687113|NCT05310149|Experimental|obturator group(unilalateral maxillary defect)|Prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. Followings are the objectives of maxillary obturator Restoration of esthetics or cosmetic appearance of the patient, Restoration of function, Protection of tissues, Therapeutic or healing effect and psychological therapy.
89687114|NCT05310149|No Intervention|Control group|intact side of the same patient
89687115|NCT01044433|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.
89687116|NCT04336774|Experimental|Echocardiogram patients|Patients scheduled to have an echocardiogram (echo) and who are also being evaluated for, or are positive for COVID-19.
89687117|NCT03216239||Colectomy Group|Mean age 52.3 years (range:20-85), 82% females, and a mean duration of symptoms of 79.9 months in the colectomy group. The indication for colectomy was constipation (36%), diverticular disease (8%), bowel obstruction (8%), colorectal carcinoma (8%), colon polyps (6%), and other (34%).
89687118|NCT03216239||Control Group|Mean age of 49.9 years (range 18-88), 76% females, and mean duration of symptoms 77.6 months,
89687119|NCT04336930||Cardiac Arrest group|Patients remaining comatose after a cardiac arrest
89687120|NCT03400969|Active Comparator|Glycerol 17 %|Oral moisturizer
89687121|NCT03400969|Active Comparator|Aequasyal (OGT)|Oral moisturizer
89687122|NCT03400969|Active Comparator|Salient (new product)|Oral moisturizer
89687123|NCT04381871|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose
89687124|NCT04381871|Placebo Comparator|Control group|This group will be provided with pectin powder provided as one-gram-dose
89687125|NCT04337008|Active Comparator|Positive COVID 19 patient with no respiratory distress|
89687126|NCT04337008|Experimental|Positive COVID 19 patient with respiratory distress|
89687127|NCT03400813|No Intervention|Control|Patients in this group continue their usual care without intervention.
89216889|NCT04071041|Experimental|Standard care plus albumin|"Patients will receive human albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.~Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team."
89216890|NCT04071041|No Intervention|Standard care alone|Patients will receive empirical antibiotic therapy according to guidelines as soon as CAP is confirmed. All microbiological assessments and additional treatment (e.g. oxygen, bronchodilators, corticosteroids, analgesic drugs, vasoactive agents, fluid resuscitation, and mechanical ventilation) will be at the discretion of the treating physicians (not the study investigators). The time of discharge and duration of antibiotics will not be determined by the study investigators, but by the treating physician team.
89216891|NCT02575625|Experimental|Fibroscan exam|"Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD).~Experimental procedures consist in:~Fibroscan measure, preceded by tracking sonography.~liver MRI (for substudy about MRI comparison, in step 2)~a blood test for biological assessment of liver functions"
89216892|NCT00555672|Experimental|A|
89216893|NCT02575547||NC+CCRT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin)
89687128|NCT03400813|Experimental|R-TEP EMDR|Patients in R-TEP EMDR group will receive the intervention.
89687129|NCT03262415||Study Cohort|30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
89687130|NCT05518890|Experimental|Diet Only|Reduced calorie intake by 5000kcals per week over a 4 week period
89687131|NCT05518890|Experimental|Diet plus Exercise|Reduced calorie intake by 5000kcals per week over 4 weeks with the addition of five 30 minute exercise sessions per week on a cycle ergometer. The exercise in intensity will be progressive and perceptually based and monitored by the investigators.
89687132|NCT04336696|Active Comparator|Comparison between the studied groups regarding management.|The postoperative RAI scan after 1 month, showed a positive residual tumour in lateral LN in 70 patients in the controlled group and 13 patients in Group II, 8 patients in group III. In group I, Patients with residuals were submitted to RAI ablation.
89054261|NCT01087788|Placebo Comparator|Placebo|"Matching Placebo to Certolizumab Pegol (CZP) injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group and were re-randomized to either CZP 200 mg Q2W or CZP 400 mg Q4W arm on Week 16.~After 24 weeks, all subjects were re-randomized to active treatment with CZP 200 mg every two weeks (Q2W) or CZP 400 mg every four weeks (Q4W)."
89054262|NCT01087788|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
89054263|NCT01087788|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
89054264|NCT01087788|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
89054265|NCT01087788|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
89054266|NCT00586937||1|Lung Cancer Survivors
89054267|NCT00586976|Experimental|1|Ropivicaine infusion into the sternal wound
89054268|NCT00586976|Placebo Comparator|2|Normal saline infusion into the sternal wound
89054269|NCT02277834||pancreatic adenocarcinoma|15 patients receiving Endoscopic Retrograde Cholangiopancreatography with suspected pancreatic adenocarcinoma (localized or metastatic).
89054270|NCT02277834||chronic pancreatitis|15 patients with a history of chronic pancreatitis that are having Endoscopic Retrograde Cholangiopancreatography .
89054271|NCT02277834||non-pancreatic, non-neoplastic disorders|15 patients undergoing an Endoscopic Retrograde Cholangiopancreatography for non-pancreatic, non-neoplastic indications.
89054272|NCT00587015|Active Comparator|1|CAT-8015
89054273|NCT01086969|Experimental|Study Group|Participants in three age cohorts - Children: 2 - 11 years of age; Adolescents: 12 - 17 years of age, and Adults: 18 - 55 years of age will be enrolled.
89054274|NCT00587093|Other|1|CT scan and CA-125
89054275|NCT04568772|Active Comparator|Atovaquone/Proguanil 250/100 mg|A single oral administration of atovaquone/proguanil 250/100 mg
89054276|NCT04568772|Experimental|Tegoprazan 50 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of tegoprazan 50 mg once daily for 6 days and then co-administration of tegoprazan 50 mg and atovaquone/proguanil 250/100 mg at 7 day
89054277|NCT04568772|Experimental|Esomeprazole 40 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of esomeprazole 40 mg once daily for 6 days and then co-administration of esomeprazole 40 mg and atovaquone/proguanil 250/100 mg at 7 day
89054278|NCT04568772|Experimental|Vonoprazan 20 mg + Atovaquone/Proguanil 250/100 mg|Oral administration of vonoprazan 20 mg once daily for 6 days and then co-administration of vonoprazan 20 mg and atovaquone/proguanil 250/100 mg at 7 day
89054279|NCT04575272|Experimental|Continuous Deep Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately deep to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
89054280|NCT04575272|Active Comparator|Continuous Superficial Serratus Anterior Plane Block group|at the level of the fifth rib in the mid-axillary line. After anaesthetizing the skin with 2 mL of lidocaine 2%, an 18-gauge Touhy needle was introduced in-plane, under direct visualization, to the plane immediately superficial to the serratus anterior muscle. After negative aspiration, 35 mL of bupivacaine 0.25% will be injected. Afterwards, a 20-gauge peripheral nerve catheter will be threaded into the space. then bupivacaine 0.125% infusion at a rate of 5 ml/h by an Infusion Syringe Pump will be started.
89054281|NCT04575350||Cohort|no intervention.
89054282|NCT01086423|Experimental|INFANRIX-IPV+HIB 1 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.
89054283|NCT01086423|Experimental|INFANRIX-IPV+HIB 2 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.
89054284|NCT01086423|Active Comparator|INFANRIX-HIB+POLIORIX GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.
89054285|NCT04575116|Experimental|Tafamidis Free acid tablet then tafamidis meglumine capsule|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
89054286|NCT04575116|Experimental|Tafamidis meglumine capsule then Tafamidis Free acid tablet|On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
89687133|NCT04336696|Other|Recurrence free survival|patients with total thyroidectomy only had shorter recurrence free survival
89687134|NCT02758210|Experimental|Participants with MICRA Device|Participants that received the MICRA device prior to study enrollment will have monitored use of Smart Phone and Tablet at one study visit. Electrogram printing will take place during use of each device to see if there is any pacing inhibition or asynchronous pacing.
89687135|NCT05513430||controlled hypertension|Controlled hypertension was defined as systolic blood pressure (SBP) ≤139 mmHg and/or diastolic blood pressure (DBP)≤89 mmHg for non-diabetic patients, and as SBP ≤139 mmHg and/or DBP ≤84 mmHg for diabetic patients, based on the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) guidelines. observational study
89687136|NCT05513430||uncontrolled hypertensive patients.|Individuals who had blood pressure levels above these values were defined as uncontrolled hypertensive patients.
89687137|NCT01043185|Experimental|A|AZD3355 30 mg
89687138|NCT01043185|Experimental|B|AZD3355 90 mg
89687139|NCT01043185|Experimental|C|AZD3355 120 mg
89687140|NCT01043185|Experimental|D|AZD3355 240 mg
89687141|NCT01043185|Placebo Comparator|E|Placebo
89687142|NCT05207254||difficult airway|C-L≥3 grade
89687143|NCT05207254||none difficult airway|C-L<3 grade
89687144|NCT02769442|Experimental|Terumo SurFlash Plus catheter|Patients randomized to the Terumo catheter
89687145|NCT02769442|Active Comparator|BD Insyte Autoguard catheter|Patients randomized to the BD catheter
89687146|NCT01042093|Active Comparator|ROP/EPI/TOR/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
89687147|NCT01042093|Active Comparator|ROP/EPI/TOR|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)
89687148|NCT01042093|Active Comparator|ROP/EPI/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
89687149|NCT01042093|Active Comparator|ROP/EPI|Ropivacaine 5mg/ml (49.25ml) Epinephrine 1 mg/ml (0.5 ml)
89054287|NCT01086150|Other|Healthy control patients|Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
89054288|NCT01086150|Other|Type I or Type II diabetes with painful diabetic neuropathy|18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
89054289|NCT01086150|Other|patients with non-painful diabetic peripheral neuropathy|18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
89054290|NCT00587210||Suspected or known Crohn Disease|Suspected or known Crohn Disease
89054291|NCT02278107|Experimental|Tidal Assist Ventilator System|Lightweight, portable, positive pressure ventilator system with proprietary nasal interface. Ventilator is powered by compressed oxygen delivered by cylinder, concentrator, or wall source.
89054292|NCT02278107|Active Comparator|Nasal Cannula Oxygen|Nasal Cannula Oxygen Standard nasal cannula oxygen at 2-5 liters per minute (LPM) based on patient requirement. Oxygen sources includes cylinder, concentrator, or wall source.
89054293|NCT00587249|Experimental|3|50 mcg of ICC-1132 with alhydrogel adjuvant.
89054294|NCT00587249|Experimental|2|20 mcg of ICC-1132 with alhydrogel adjuvant.
89687150|NCT03400735|Experimental|Cefdinir/clavulanic acide 300/125 mg Film Coated Tablets|
89687151|NCT03400735|Active Comparator|Cefdinir 300 mg Capsules|
89687152|NCT03400657||fully implemented to the MDT decision|group of patients fully implemented to the MDT decision
89687153|NCT03400657||not completly implemented to the MDT-decision|group of patients not completly implemented to the MDT decision
89687154|NCT03400657||not implemented to the MDT decision|group of patients not implemented to the MDT decision
89687155|NCT02770846|Experimental|Immediate loading|Immediate loading of single dental implant in the anterior maxilla with temporary crown in central occlusion
89687156|NCT02770846|Active Comparator|Delayed loading|Delayed loading. 2-stage procedure with a 4 months healing period before fabrication of temporary crown.
89687157|NCT04737928|Experimental|latanoprost switch to tafluprost|POAG and OH patients prescribed latanoprost(QID) at least 3 months (IOP>20). At least one eye must have a score above 1 on the NEI scale. Switch to latanoprost (QID) for 3 months.
89054295|NCT00587249|Experimental|1|10 mcg of ICC-1132 with alhydrogel adjuvant.
89054296|NCT01086033||Humira|Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.
89687158|NCT04336540|Experimental|Energy labelling|Energy labelling provided on restaurant menus
89687159|NCT04336540|No Intervention|No energy labelling|No energy labelling provided on restaurant menus
89054297|NCT00587327|Experimental|Barusiban|
89054298|NCT00587327|Experimental|Atosiban|
89687160|NCT04336540|Experimental|Increased availability of lower energy meals|Higher proportion of meals are 600kcals or less
89687161|NCT04336540|No Intervention|Baseline availability of lower energy meals|Proportion of meals that are 600kcals or less at baseline level
89054299|NCT00587327|Placebo Comparator|Placebo|
89054300|NCT00587405|Active Comparator|1|Cryotherapy
89054301|NCT00587405|Active Comparator|2|Argon Plasma Coagulation
89054302|NCT01085682|Active Comparator|Lifestyle counseling|
89054303|NCT01085682|Active Comparator|Standard care|
89054304|NCT00587444|Other|1|control standard dose heparin dose
89054305|NCT00587444|Active Comparator|2|high dose heparin dose
89054306|NCT00587444|Active Comparator|3|hepcon guided therapy
89054307|NCT00587522|Experimental|A|NDO Full-thickness Plicator Procedure
89054308|NCT02278302|Experimental|Aggrenox®|treatment alone or in combination with Ethanol
89054309|NCT02278302|Placebo Comparator|Placebo|treatment alone or in combination with Ethanol
89054310|NCT00587600|Active Comparator|Photodynamic therapy|will have photodynamic therapy
89054311|NCT00587600|Active Comparator|radiofrequency ablation of barretts esophagus|radiofrequency ablation of barretts esophagus
89054312|NCT01085214|Experimental|AZD6244 (Selumetinib) Treatment|Participants receive AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89054313|NCT00587756||1|Prospective cohort of consecutive patients who undergo surgery for colorectal cancer liver metastases
89054314|NCT01085136|Active Comparator|Investigator's choice of chemotherapy|Patients will be treated with investigator's choice of chemotherapy
89054315|NCT01085136|Experimental|BIBW 2992 and Paclitaxel|Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2
89054316|NCT00587873|Experimental|1|MTX, 6-TG, and Leucovorin combination
89054317|NCT02210481||GLUC-MAC-COHORT|post vitrectomy for retinal detachment or epimacular membrane patients
89054318|NCT00587951||A|Candidates for epilepsy surgery, undergoing pre-surgical evaluation at Mayo Clinic, and in whom SISCOM was ordered by the treating physician as part of that evaluation
89054319|NCT04574804|Experimental|online training program|online training program Participants receive access to online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis, which they will be instructed to and encourage to complete over the 6 intervention period.
89054320|NCT04574804|No Intervention|control group|control group Participants do NOT receive access to the online training program consisting of 6 e-learning modules on topics of weight management in osteoarthritis during the intervention period.
89054321|NCT01084707|Experimental|Oral Nicotine 24-SA|2 Self-administrations of Experimental Nicotine once every hour
89054322|NCT01084707|Experimental|Oral Nicotine 24|2 administrations of Experimental Nicotine by study personnel once every hour
89054323|NCT01084707|Experimental|Oral Nicotine 48|2 administrations of Experimental Nicotine by study personnel once every 30 minutes
89054324|NCT01084707|Active Comparator|NiQuitin™ Lozenge 4 mg|1 NiQuitin™ lozenge, administered by study personnel once every hour
89054325|NCT01084707|Active Comparator|Nicorette® Gum 4 mg|1 piece Nicorette® gum, chewed for 30 minutes once every hour
89054326|NCT00588107|Experimental|Web site access|Web intervention- and access to pharmacotherapy
89054327|NCT00588107|Active Comparator|print materials|Receives tailored print materials and access to pharmacotherapy (Materials condition)
89687162|NCT04336462|Experimental|oxyhydrogen|conventional treatment + hydrogen/ oxygen inhaled
89054328|NCT02210520|Experimental|laser|3 J/cm², 2 minutes in 6 points around the back spine
89054329|NCT02210520|Experimental|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine
89054330|NCT02210520|Experimental|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
89054331|NCT02210520|No Intervention|control|no treatment.
89054332|NCT04574726|Experimental|virtual environment|Balance test in virtual environment with a virtual reality software executed in a 6DOF Occulus Quest helmet and a motion capture software with a Kinect Azure DK camera.
89054333|NCT04574726|Active Comparator|reel environment|Balance test in real environment with a motion capture software and a Kinect Azure DK camera.
89054334|NCT02210598|Active Comparator|inpatient Foley balloon induction|"Inpatient Foley induction participants will be placed in the dorsal lithotomy position, a Foley catheter will be placed transcervically and its balloon filled with 60mL of sterile saline. One of two methods will be used to place the transcervical foley based on provider preference and determination of which method will offer the greatest chance for successful placement. Method A is placement of the foley blindly by palpation of the cervix. Method B utilizes direct visualization with sterile speculum placement. Method will be documented in the data collection forms. The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded."
89054335|NCT02210598|Experimental|outpatient Foley balloon induction|Patients randomized to the experimental group will undergo outpatient Foley induction of labor. Either of the above two described methods will be used to place an 18 French Foley catheter transcervically and its balloon filled with 60mL of sterile saline. The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours. When the patient returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.
89687163|NCT04336462|Experimental|oxygen|conventional treatment + oxygen inhaled
89687164|NCT00372502|Active Comparator|1|
89687165|NCT00372502|Experimental|2|
89687166|NCT01041859|Experimental|Tapentadol Extended Release (ER)|
89687167|NCT01041859|Placebo Comparator|Placebo|
89054336|NCT01084668||Adalimumab|Participants with moderate to severe chronic plaque psoriasis treated with adalimumab after biologic disease modifying anti-rheumatic drug (BDMARD) failure
89054337|NCT02210637||Retrospective Cohort|Retrospective Cohort of scheduled outpatient appointment
89054338|NCT00588224||1|adults
89054339|NCT00588224||2|adolescents
89687168|NCT04827550||STUDY GROUP|diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
89054340|NCT01084551|Experimental|SPM 962 4.5|started at 2.25 mg/day to 4.5 mg/day for 13 weeks
89054341|NCT01084551|Experimental|SPM 962 6.75|started at 2.25 mg/day to 6.75 mg/day for 13 weeks
89054342|NCT01084551|Placebo Comparator|placebo|for 13 weeks
89054343|NCT03452657|Experimental|Ranibizumab|Participants received 0.5mg intravitreal ranibizumab injection
89054344|NCT03452657|Sham Comparator|Sham-injection|No drug involved in the sham procedure; patient's eye is anesthetized and a syringe without needle gently pressed on the conjunctival surface to simulate the force of an actual injection
89054345|NCT02210676|Experimental|Patients with Mallet Finger|All enrolled patients
89054346|NCT03452618|Experimental|patients with a NIV equipment|Determination of diagnosis variables in a group of patient who benefit of the Non Invasive ventilation equipment one year after the diagnostic
89054347|NCT03452618|Active Comparator|patients without a NIV equipment|Determination of diagnosis variables in a group of patient who not benefit of the Non Invasive ventilation equipment one year after the diagnostic
89054348|NCT03452501||Naïve group|Newly diagnosed patients
89054349|NCT03452501||Switched group|Patients who received at least one dose of Infliximab reference medicinal product (RMP) before the first infusion of Remsima®
89054350|NCT00588302|Experimental|A, 1|All patients received an open-label moexipril during the study period.
89054351|NCT00588419||1|Patients who have undergone mastectomy Patients who have undergone immediate, twostage expander/implant breast reconstruction; Patients who have undergone immediate, autogenous tissue flap reconstruction including: pedicled and/or free TRAM flap or DIEP flap reconstruction
89054352|NCT04568655||COVID-19 patients need noninvasive ventilation|
89054353|NCT00588458|Experimental|single arm|All patients with PSC in will have CT cholangiography.
89054354|NCT01084005|Experimental|linagliptin|patients receive linagliptin 5 mg tablets once daily
89054355|NCT01084005|Placebo Comparator|placebo|patients receive placebo tablets matching linagliptin 5 mg once daily
89054356|NCT00588497||Study Group|Twenty-five subjects for this study will be recruited from patients who have requested a form of permanent sterilization, and who, after considering all the options, choose the trans-cervical hysteroscopic sterilization for this end. Any subject who is deemed suitable for the micro-insert hysteroscopic sterilization system (Essure micro-insert system, Conceptus Incorporated, Mountain View, California) placement will be offered the opportunity to participate in the study.
89054357|NCT04568577|Experimental|tensioned tape|The tensioned tape group will apply weekly with gradual tension calculated by measuring the initial length of the tape. From the first week of application, there will be a 5% increase in tension up to the fifth week.
89054358|NCT04568577|Active Comparator|tape without tension|The tensionless tape group will receive the application of the tape weekly without tensioning during the five weeks.
89054359|NCT00588653|Active Comparator|1|All patients were to undergo all 4 diagnostic modalities, and each of these was compared to the consensus clinical diagnosis. Readers of each modality were blinded to the results of the other 3.
89054360|NCT00588887||1|
89054361|NCT00588887||2|
89054362|NCT01083810||therapy-naive|Patients who had not received prior antiretroviral drug therapy
89054363|NCT01083810||pre-treated|Patients that had previously received antiretroviral therapy, but are protease inhibitor naive
89054364|NCT01083810||non-B|Patients infected with non-B subtypes of HIV-1
89054365|NCT00588926|Experimental|A|The patients get a period of sedation with remifentanil, before, during and after which, the changes in the electrical activity of the Basal Ganglia is recorded.
89054366|NCT01083771|Experimental|Olive Oil|At least 3 tablespoons of olive oil each day
89054367|NCT00589082|Active Comparator|1|standard 3+7
89054368|NCT00589082|Experimental|2|DNX 3+7
89054369|NCT00589199|Experimental|1|Functional Electrical Stimulation for Production of Artificial Cough
89054370|NCT01083693||Rheumatoid, Psoriatic Arthritis, Ankylosing Spondylitis|Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, patients with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.
89054371|NCT00589238|Other|Arm 1 (Standard Arm)|Arm 1 (Standard Arm) Preoperative (primary/ neoadjuvant) intravenous weekly paclitaxel 80 mg/m2 for 12 weeks followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
89054372|NCT00589238|Experimental|Arm 2 (Experimental Arm)|Arm 2 (Experimental Arm) Preoperative intravenous weekly paclitaxel 80 mg/m2 in combination with carboplatin AUC 2 on D1, D8 and D15 every 28 days for 4 cycles followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
89054373|NCT00589355||1|postmenopausal women with glucose intolerance (either pre-diabetes or diet-controlled diabetes)
89054374|NCT00589355||2|postmenopausal women with normal glucose tolerance
89054375|NCT04568070|Experimental|Stroke|Stroke patients who applied to the Physical Medicine and Rehabilitation outpatient clinic, met the inclusion criteria and volunteered to participate in the study
89054376|NCT00589394|Other|pneumococcal vaccination (Pneumovax)|"Intervention:~Patients receive one dose of the Pneumovax vaccine. The 23 pneumococcal serotypes are measured before and after vaccination in order to measure response in a healthy population."
89054377|NCT01083576|Active Comparator|Paromomycin Alone Treatment|Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days
89216894|NCT01037387|Active Comparator|Control|Conventional treatment for COPD
89054378|NCT01083576|Active Comparator|WR 279,396|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days
89054379|NCT00589433||1|
89054380|NCT04568265|Experimental|APG-1387 12 mg combined with entecavir 0.5 mg|
89054381|NCT04568265|Experimental|APG-1387 20 mg combined with entecavir 0.5 mg|
89054382|NCT04568265|Experimental|APG-1387 30 mg combined with entecavir 0.5 mg|
89054383|NCT04568265|Experimental|entecavir 0.5 mg|
89054384|NCT00589589|Active Comparator|A|
89054385|NCT04568343|Experimental|small bowel bleeding patient|with suspicious small bowel bleeding,patient will recieve Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule later for evaluations
89054386|NCT00589706|Experimental|A|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections. The purpose of this protocol is to allow you to receive course(s) of 1251-MAB 425 until your brain tumor begins to grow, you develop side effects to the treatment, or your medical condition changes (ie: become affected with human immunodeficiency virus (HIV) or develop another cancer).
89054387|NCT01083186||Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism|Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)
89054388|NCT00589745|Other|Subjects being evaluated for CF|Subjects will be referred from physicians who are clinically concerned about the possibility of Cystic Fibrosis. Nasal potential difference measurement will be obtained to potentially help aid in diagnosis.
89054389|NCT04568304|Experimental|Toripalimab Injection + chemotherapy group|
89054390|NCT04568304|Placebo Comparator|Placebo + chemotherapy group|
89054391|NCT01082640|Placebo Comparator|Placebo|Placebo-matching capsules, orally, twice daily for up to 12 months.
89054392|NCT01082640|Experimental|Febuxostat 30 mg BID|Febuxostat 30 mg, capsules, orally, twice daily (BID) for up to 12 months.
89054393|NCT01082640|Experimental|Febuxostat 40/80 mg QD|Participants initially received febuxostat 40 mg, capsules, once daily (QD) and one placebo-matching capsule QD and remained on this dose for up to 12 months if their serum urate (sUA) was <6.0 mg/dL at the Day 14 visit. Participants whose sUA was ≥6.0 mg/dL at the Day 14 visit received febuxostat 80 mg, capsule, QD, and one placebo-matching capsule QD at the Month 1 visit, and for the remainder of the study.
89054394|NCT00589862|Experimental|1|
89054395|NCT00589901|Experimental|A|phase II trial of capecitabine and cyclophosphamide in the management of metastatic breast cancer
89054396|NCT04568187|Active Comparator|cryolipolysis machine on Left inner thigh|Zeltiq machine as intervention procedure was carried out on left inner thigh (treated side) for 1 hour through cool sculpting procedure with CIF (Cooling Intensity Factor: -73 mW/cm2).
89054397|NCT04568187|Sham Comparator|radiofrequency on right thigh|The radio frequency method was applied on right thigh (control side) as sham procedure for 30 minutes through 3000 Hz- amplitude modulated frequency at once.
89054398|NCT00590174|Experimental|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
89054399|NCT00590174|Active Comparator|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
89054400|NCT01082367|Experimental|TOBI (tobramycin inhaled solution)/Placebo|Participants randomized to TOBI received the investigational treatment for 28 days twice daily (bi)d in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the open label (OL) phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received placebo for 28 days bid (second treatment cycle).
89054401|NCT01082367|Placebo Comparator|Placebo/TOBI|Participants randomized to placebo group received 0.9 % saline (NaCl) for 28 days bid in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the OL phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received TOBI for 28 days bid (second treatment cycle).
89054402|NCT04567797|Experimental|Exoskeleton|To compare the efficacy of four different exoskeleton devices, all participants will be asked to finish simulated construction tasks with each exoskeleton. Additionally, all participants will be asked to finish the same tasks without wearing an exoskeleton for reference.
89054403|NCT00590252||Scheduled for an MRI|Clinically Indicated Adults
89054404|NCT01082211|Experimental|Partial Breast Re-Irradiation|Partial Breast Re-Irradiation (PBrI) 3D-Conformal External Beam 1.5 Gy x 15 (BID) to 45 Gy Total
89054405|NCT00590291||Cases|premature CAD and MI, AVM
89054406|NCT00590291||Controls|No CAD, MI, AVM
89054407|NCT04567758|Experimental|Telerehabilitation (TR) Group|The TR group will be followed up through the video-based exercise software within the 8-week home exercise program.
89054408|NCT04567758|Active Comparator|Conventional Rehabilitation (CR) Group|The CR group will be trained face-to-face with conventional methods before the 8-week home exercise program, and an exercise program will be prescribed with a visual information form.
89054409|NCT00590408|Active Comparator|1|
89054410|NCT00590408|Placebo Comparator|2|
89054411|NCT01081665||Chronic Kidney Disease|All eligible patients treated with IV Paricalcitol (Zemplar)
89054412|NCT04574648|Experimental|ADE information transmitted to PharmaNet|Patients in the experimental arm will have standardized information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database. The information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile. Community pharmacy software will import the non-adherence information such that community pharmacists can view the information prior to dispensing medications.
89054413|NCT04574648|No Intervention|Standard care (ADE information retained locally)|Patients in the control arm will have their information recorded in ActionADE, and their information will be retained locally, as is the current standard of care. This means that their information will not be visible to other providers via PharmaNet.
89054414|NCT04567875||CRPC patients|CRPC patients without evidence of distant metastasis are eligible
89054415|NCT00590447|Experimental|A|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.
89054416|NCT00590447|Experimental|B|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.
89054417|NCT04567953|Experimental|Saliva and NP paired specimen collection|
89054418|NCT00590525||1|
89054419|NCT01081626|Experimental|Group I: Chronic Low dose Protocol|Gonal-f will be injected on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 International Units (IU) for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 millimeter (mm) diameter, stimulation will be continued with the same dose for further 7 days. On Day 14 of stimulation, if no ovarian response is seen, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation would be made, depending on ovarian response.
89054420|NCT01081626|Experimental|Group II: Low dose Protocol|Gonal-f will be administered on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 IU for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 mm diameter, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation will be made, depending on ovarian response.
89054421|NCT03452423|Experimental|ACRFP|Patient suffering from osteoarthritis of knee joints, and planning to receive ACRFP, are enrolled into this study. Gait pattern is obtained preoperatively, 3 months, and 6 months postoperatively.
89054422|NCT03452384|Experimental|acupucture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface.
89054423|NCT03452384|Sham Comparator|control|For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998). The needles will be affixed with plastic O-rings and adhesive tapes. The needles with blunt tips will be quickly put onto the same acupoints used in real acupuncture without inserting into the skin.
89054424|NCT01080768|Experimental|Aliskiren/amlodipine + Placebo to amlodipine|"During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
89054425|NCT01080768|Active Comparator|Amlodipine + Placebo to aliskiren/amlodipine|"During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
89054426|NCT03452345|Experimental|MEDITOXIN|
89054427|NCT03452345|Placebo Comparator|Placebo|
89054428|NCT03452306|Experimental|Metformin|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
89054429|NCT03452306|Active Comparator|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fed condition"
89054430|NCT04567641||Enteral Nutrition|
89054431|NCT04567641||Parenteral nutrition|
89054432|NCT04568109|Experimental|Exposure-based cognitive-behavior therapy|Patients are treated in accordance with a manualized protocol (Gloster et al., 2011)
89687169|NCT04827550||CONTROL GROUP|90 healthy volunteers
89687170|NCT03405805||3+1|Healthy infants will receive 4 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4,6 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
89687171|NCT03405805||3+0|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 6 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
89687172|NCT03405805||2+1|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
89687173|NCT04336072|Experimental|Reminder Focused Positive Psychiatry (RFPP)|RFPP aims to enhance contextual discrimination and emotional regulation, and promote the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
89687174|NCT04336072|Active Comparator|Trauma Focused Cognitive Behavioral Therapy (TFCBT)|TFCBT is inclusive of the trauma narrative (TN) & processing components facilitated the child talking about memories individually and in groups, the last sessions focused on grief-specific elements.
89687175|NCT04377139||Prophylaxis|Those LTR receiving prophylaxis against CMV
89687176|NCT04377139||Preemptive therapy|Those LTR receiving preemptive therapy against CMV
89687177|NCT03405727|No Intervention|Standard treatment|
89687178|NCT03405727|Experimental|Oral dietary supplements|
89687179|NCT05349994|No Intervention|Control|Standard amount of physical therapy at surgical wards in an urban hospital, corresponding to 1.75 physiotherapy employment on weekdays divided on four wards with a total of approx. 40-48 patients.
89687180|NCT05349994|Experimental|Intervention|Extended physiotherapy with an extra 0.5 employment on weekdays, leading to 1-2 physiotherapy session per day for the study participants in the intervention group.
88998801|NCT05988294|Other|Group B (Control Group)|Participants will receive conventional physical therapy program (diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs) for 45 minutes, 3 days/ week for 12 weeks.
89216895|NCT01037387|Experimental|NIMV group|NIMV: Conventional treatment plus noninvasive mechanical ventilation
89687181|NCT01040845|Experimental|Oral Contraceptive with Colchicine then Placebo|
89687182|NCT01040845|Placebo Comparator|Oral Contraceptive with Placebo then Colchicine|
89687183|NCT05349916|Experimental|Control|
89687184|NCT05349916|Experimental|Isomaltodextrin Low Dose|
89687185|NCT05349916|Experimental|Isomaltodextrin High Dose|
89687186|NCT05349916|Experimental|GPC partially digestible maltodextrin|
89687187|NCT05349916|Experimental|Resistant Starch Type 4|
89687188|NCT00371956|Active Comparator|1|raloxifene
89687189|NCT00371956|Placebo Comparator|2|placebo arm
88998802|NCT05985863|Placebo Comparator|Group Control|standard medical treatment+Placebo(5% human serum albumin in 0.9% saline, at week0, week1 and week2)
88998803|NCT05985863|Experimental|Group MSC-1|Patients received standard medical treatment and infusions of hUC-MSC(1.5×10^8) via peripheral veins once a week for 3 timess(at week0, week1, and week2).
88998804|NCT05985863|Experimental|Group MSC-2|Patients in Group MSC-1 received standard medical treatment and infusions of hUC-MSC(1.5×10^8) via peripheral veins once a week for another 2 timess(at week4 and week5).
88998805|NCT05985239||Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
88998806|NCT05985239||Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
88998807|NCT05984121|Active Comparator|Local ozon injections|Local ozone therapy consists of 95-99% oxygen, 1-5% medical ozone mixture and is obtained from medical ozone generators. Medical ozone therapy contains at least 95% oxygen and at most 5% ozone. (Bocci, Velio Alvaro. 2006)
88998808|NCT05984121|Active Comparator|Local dextroz prolotherapy injections|"Hypertonic dextrose prolotherapy stimulates the cells at the injection site dehydrates, causing local tissue trauma, and increases macrophage and attracts granulocytes to that area and provides tissue healing. (Hauser, Ross and et al, 2016). Kesikburun Serdar et al. in 2022 with plantar fasciitis prolotherapy injection 3 times at 2 weeks intervals in their study They used a 15% dextrose prolotherapy solution."
88998809|NCT05984121|Other|Exercise Group (Control Group)|"Patients in the exercise group were treated as in the other groups during the treatment period.~plantar fascia stretching exercises, gastrocsoleus stretching exercises, foot intrinsic muscle strengthening exercises will be taught 2 times a day 10 times each will be asked to do so. In a systematic review by Siriphorn et al. fascia stretching exercises and gastrocsoleus stretching exercises in plantar fasciitis There is evidence that it is effective. The control group was given exercise therapy We aimed to ensure that the control group was not left untreated. in case of cold application and NSAIDs other than paracetamol will be asked not to take medication."
88998810|NCT05983224|Experimental|Quercetin|The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.
88998811|NCT05983224|Placebo Comparator|Placebo|The Placebogroup will receive Placebo tablets daily, after breakfast and lunch, for twelve weeks.
88998812|NCT05958056|Experimental|Low load resistance exercises with Practical blood flow restriction (PBFR)|Participants in the experimental group performed one session of 30% 1RM with Practical blood flow restriction training. The number of repetitions in every set was 15 times with PBFR.19 Participants in the experimental group used the elite band (occlusion training bands) for both thighs during the training session. The width of the thigh band was 5cm, which would produce a pressure between 160-240 mmHg. This pressure range is appropriate for most of the individuals who used PBFR.27 The perceived pressure scale (PPS) was used to estimate the appropriate pressure (7 out of 10) in training before performing the exercises.28,29 The blood flow restriction bands booklet was used30 along with previous studies to design the training session. Participants removed the BFR band immediately after the end of the training session.
88998813|NCT05958056|Active Comparator|High resistance exercises|Participants in the control group performed one session of 80% 1RM without PBFR. The number of repetitions in every set was 10 times.
88998814|NCT05953246|Active Comparator|Neutral labels|Labels shown will be QR codes with and without neutral text (i.e., not mentioning environmental impacts)
88998815|NCT05953246|Experimental|Numeric text-only sustainability labels|Labels shown will contain numeric text depicting the greenhouse gas emissions associated with production of the menu item
88998816|NCT05953246|Experimental|Endorsement text-only sustainability labels|Labels shown will contain text endorsing menu items as having low environmental impact
88998817|NCT05953246|Experimental|Endorsement icon-only sustainability labels|Labels shown will contain icons endorsing menu items as having low environmental impact
88998818|NCT05953246|Experimental|Endorsement text-plus-icon sustainability labels|Labels shown will contain both text and icons endorsing menu items as having low environmental impact
88998819|NCT05942430|Experimental|The costa group|Autologous costal osteochondral transplantation
88998820|NCT05942430|Active Comparator|The ilium group|Autologous iliac osteoperiosteal transplantation
88998821|NCT05939024|Active Comparator|Conventional Physical Therapy (CPT) Group|Patients in this group will receive Conventional Physical therapy only, which includes hot pack, TENS, Ultrasonic, stretching and strengthening exercises.
88998822|NCT05939024|Experimental|Muscle Energy Technique plus Conventional Physical Therapy Group|In this group, Post Isometric Relaxation of the Muscle Energy Techniques will be applied to the Spinal Stabilizers and Mechanoreceptors in addition to Conventional Physical Therapy.
88998823|NCT05922527|Experimental|Combined regenerative technique|Open flap debridement combined with Amnion Chorion Membrane and DFDBA
89687190|NCT04334200|Experimental|Cultivate yourself: support for caregivers of dementia persons|There will be six sessions (1 or 2 session per week). The duration of each session will be 1.5-2 hours per session. The contents include: introduction on dementia, caregivers' role, how to communicate with dementia persons, tips on caregiving, stress and emotional management. The training content has been verified by one social worker, family caregivers of individuals living with dementia and a teacher who teach Chinese, Chinese history and culture in the secondary school in Hong Kong. No adverse comments are received from them.
89054433|NCT04568109|No Intervention|Wait-List control condition|Patients are assessed prior to and after a 12-week waiting period. Patients are treated after this 12-week delay.
89687191|NCT05349604|Experimental|Garlic extracts|Take 450mg of Garlic extracts(Food Item Making Report Product Name: Vegetable Extract Powder No. 1905, Item Report No.: 202004980275)
88998824|NCT05922527|Active Comparator|Open flap debridement|Open flap debridement
88998825|NCT05911217|Experimental|anti-claudin18.2 chimeric antigen receptor T-cell therapy|Experimental: anti-claudin18.2 chimeric antigen receptor T-cell therapy Phase 1b: Evaluate the efficacy and safety of CT041
88998826|NCT05895058|Experimental|2D 4K laparoscopic imaging system|Performing gastric bypass surgery intervention using a 2D 4K laparoscopic imaging system.
88998827|NCT05895058|Active Comparator|3D HD laparoscopic imaging system|Performing gastric bypass surgery intervention using a 3D HD laparoscopic imaging system.
88998828|NCT05885594|Other|AUD-Alcohol Use Disorder|60 adult men and women who have alcohol use disorder will undergo up to 2 PET/CT scans each approximately 60 minutes of dynamic scanning starting at the time of injection of [18F]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of [18F]NOS.
88998829|NCT05885594|Other|HV-Healthy Volunteer|30 adult men and women between the ages of 18-65 who do not have alcohol use disorder and are a healthy volunteer will be enrolled in this study.
88998830|NCT05880459|Active Comparator|propofol and nalbuphine group|
88998831|NCT05880459|Active Comparator|Propofol and magnesium sulfate group|
88998832|NCT05877222|Experimental|Treatment A (5 × 10 mg daridorexant)|Participants will receive a single oral dose of 5 × 10 mg daridorexant.
88998833|NCT05877222|Experimental|Treatment B (5 × 25 mg daridorexant)|Participants will receive a single oral dose of 2 × 25 mg daridorexant.
88998834|NCT05869552|Experimental|Suicidal Teens Accessing Treatment - Primary Care (STAT-PC)|This group will participate in a brief, suicide prevention intervention based on motivational interviewing that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management that has been adapted.
88998835|NCT05869552|Experimental|Youth-Nominated Support Team (YST-III)|This group will participate in a brief, suicide prevention intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation that has been adapted.
88998836|NCT05864417|Experimental|Sunscreen|Participants will choose one facial sunscreen (SPF 70) out of the two (one with a light tone [Color 2.0] and another with a medium tone [Color 3.0]) based on the tone that best suits their skin color. At home, they will apply a generous amount of facial sunscreen to the face twice daily and will reapply when they feel the need up to 84 + (-) 2 days.
88998837|NCT05856136|Experimental|Ultrasound Shear Wave Elastography Examination - Lower|Subjects identified as being administered low dose opioids during an elective lower extremity orthopedic surgery per standard of care will undergo an ultrasound shear wave elastography examination while performing different breathing techniques.
88998838|NCT05856136|Experimental|Ultrasound Shear Wave Elastography Examination - Mid|Subjects identified as being administered mid dose opioids during an elective lower extremity orthopedic surgery per standard of care will undergo an ultrasound shear wave elastography examination while performing different breathing techniques.
88998839|NCT05856136|Experimental|Ultrasound Shear Wave Elastography Examination - Higher|Subjects identified as being administered higher dose opioids during an elective lower extremity orthopedic surgery per standard of care will undergo an ultrasound shear wave elastography examination while performing different breathing techniques.
88998840|NCT05853029|Experimental|Group A|Group (1): Twenty patients will receive 2000 pulses of Focused shock wave therapy with (4 Hz; 0.2 millijoule (mJ)/mm2) in addition to conventional therapy including eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007). Each patient will have 3 treatment sessions held at weekly basis(Król et al., 2015).
88998841|NCT05853029|Experimental|Group B|Group (2): Twenty patients will receive both 2000 pulses of (Focused shockwave therapy with (4 Hz; 0.2 mJ/mm2) and 2000 pulses of Radial shockwave therapy with (8 Hz, 2.5 bars) )= combined shockwave therapy in addition to conventional therapy including eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007). Each patient will have 3 treatment sessions held at weekly basis(Król et al., 2015).
88998842|NCT05853029|Experimental|Group C|Group (3): Control group of twenty patients that will only receive conventional therapy including eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007).
88998843|NCT05850390||Diagnosed asthma patients|Adults aged 18 and above who have been diagnosed with persistent asthma or allergy with asthma as a co-morbidity and are prescribed a controller medication.
88998844|NCT05845632||Short time to treatment (<30 days)|Patients with high-risk HNcSCC with a time to treatment (date of pathological diagnosis to date of start treatment) of less than 30 days.
88998845|NCT05845632||Long time to treatment (30 days or more)|Patients with high-risk HNcSCC with a time to treatment (date of pathological diagnosis to date of start treatment) of 30 days or more.
88998846|NCT05812300|Experimental|HA35 local injection of Periodontal Pocket group|The tissue-permeable 35 kDa low molecular hyaluronan fragment HA35 was freshly manufactured using pharmaceutical grade hyaluronidase PH20 injection (State Drug Administration H31022111) and joint cavity HA injection (State Drug Administration H20174089) mixed at room temperature for 20 min.
88998847|NCT05806996|Experimental|Magnesium Group|Subjects having urology surgery per standard of care will receive intravenous magnesium during the surgery.
88998848|NCT05806996|Placebo Comparator|Placebo Group|Subjects having urology surgery per standard of care will receive intravenous placebo during the surgery.
88998849|NCT05788016|Experimental|Pharmacist-led opioid taper intervention|The participant will attempt to taper their opioid dose by ~50% during the 4-6 week preoperative period. Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
88998850|NCT05755048|Experimental|FS-1502|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
89054434|NCT01080300|Experimental|Gabapentin Extended Release|Active treatment
89054435|NCT01080300|Other|Placebo|Placebo
89054436|NCT00590603|Experimental|1|Dose escalation study with two cohorts. A standard dose of Arsenic Trioxide will be given with escalating dose of Bortezomib.
89054437|NCT01085097|Placebo Comparator|Placebo|Participants will receive 2 capsules of placebo matching to laquinimod orally once daily (QD) for 24 weeks, MMF 500 mg tablet orally twice daily (BID) for the first week then 1 gram (g) BID from Week 2 to Week 28, and MP 500 mg/day intravenously (IV) from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
89054438|NCT01085097|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 mg and 1 capsule of placebo matching to laquinimod orally QD for 24 weeks, MMF 500 mg tablet orally BID for the first week then 1 g BID from Week 2 to Week 28, and MP 500 mg/day IV from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
89054439|NCT01085097|Experimental|Laquinimod 1 mg|Participants will receive 2 capsules of laquinimod 0.5 mg orally QD for 24 weeks, MMF 500 mg tablet orally BID for the first week then 1 g BID from Week 2 to Week 28, and MP 500 mg/day IV from Days 1 through 3, followed by oral prednisolone/prednisone (initial dose 40 mg/day which is tapered to 10 mg/day or less by the end of Week 20, on a fixed steroid-tapering regimen) from Day 4 through Week 28.
89054440|NCT00590642||1|
89054441|NCT00590798|Experimental|1|Patients are asked to walk within 30 minutes after implantation of the Star- Close vascular closure system.
89054442|NCT04567446||Patients who will start cancer treatment|"Collection of biological samples (stool, blood, saliva) and data from patients included in the study will be performed:~By identifying the patients who will start treatment anticancer (chemotherapy, hormone therapy, immunotherapy).~Collection of biological resources (all samples will be collected in fresh):~Stool: collected at diagnosis, before initiating anticancer treatment, during treatment~Blood: 40 mL collection before, 3 and 6 months of treatment cancer~Saliva: 5 mL collection before initiation of treatment cancer~Collection of clinical data corresponding to each patient included in the study by a clinical research assistant"
89054443|NCT00590837|Experimental|1|Patients will be treated by adding lomustine to chemotherapy
89054444|NCT00590837|No Intervention|2|Patients will be treated without adding lomustine to chemotherapy
89054445|NCT01086267|Experimental|BMS-908662 (A1)|Phase 1
89054446|NCT01086267|Experimental|Cetuximab (A1)|Phase 1
89054447|NCT01086267|Experimental|BMS-908662 (B1)|Phase 2
89054448|NCT01086267|Experimental|BMS-908662 + Cetuximab (B2)|Phase 2
89054449|NCT04567563|Active Comparator|Remote Ischemic Condition|
89054450|NCT04567563|No Intervention|Standard of Care|
89054451|NCT00590876||1|T1DM patients with a history of severe hypoglycemia and/or hypoglycemia unawareness who have been selected based upon this history to undergo islet cell transplantation at the University of Minnesota.
89054452|NCT00590876||2|T1DM patients (C-peptide negative) who are matched for age, gender, and duration of diabetes, who also have a history of severe hypoglycemia and/or hypoglycemia unawareness meeting the criteria for islet cell transplantation. The hemoglobin A1c for each of these subjects will fall within 1% of the islet transplant recipient to whom they are matched.
89054453|NCT00590876||3|Nondiabetic subjects (fasting plasma glucose < 110 mg/dl) who are matched for age and gender to the islet transplant recipient to whom they are matched.
89054454|NCT04574687|Active Comparator|Neurodevelopmental Techniques|Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
89054455|NCT04574687|Experimental|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
89054456|NCT02277873||No Treatment|Defined population (pregnant women) compared on a environmental moon luminosity influence
89054457|NCT04574570|Other|interventional patient|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
89054458|NCT04571892|Experimental|ScTIL210|This trial is designed single arm. All the subjects enrolled will receive the experimental intervention, ScTIL210(Super circulating tumor infiltrating lymphocytes).
89054459|NCT04567290|Experimental|Chewed ticagrelor|"Ticagrelor pills. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement and after signed informed consent. Patients will be asked to chew, but not to swallow, during at least 40 seconds in presence of investigation staff.~Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed"
89054460|NCT04567290|Active Comparator|Swallowed ticagrelor|"Ticagrelor integral tablet. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement is drawn. Patients will swallow the loading dose followed by 25-40 ml of water.~Drug: ticagrelor (Brilinta) 90 mg tableta, 2 tablets swallowed"
89054461|NCT04567329|Experimental|NOV03|100% perfluorohexyloctane 4 times daily (QID)
89216896|NCT02574533|Experimental|Vigil™ + Pembrolizumab|"Biological: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens.~Drug: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter"
89216897|NCT00709553|Experimental|1|midazolam, one single dose of 705mg
89216898|NCT00709553|Experimental|2|ZD4054(Zibotentan)- 10mg od, 7 days + midazolam (one single dose of 7.5 mg on day 6 )
89216899|NCT02575391|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
89216900|NCT03958656|Experimental|1/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Dose Escalation|Patients will receive escalating doses (up to 4 planned) of Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)-CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^22 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
89216901|NCT03958656|Experimental|2/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Expansion Phase|Maximum tolerated dose (MTD) dose of Anti-Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)- CAR T Cells + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
89216902|NCT00950274|Active Comparator|CD133+ autologous bone marrow stem cells|
89216903|NCT00950274|Placebo Comparator|Placebo|
89687192|NCT05349604|Placebo Comparator|placebo|As a food ingredient that does not affect blood pressure and is harmless to the human body, it is made almost identical in weight and appearance to garlic extract.
89687193|NCT04335838||Polytrauma Patients|Patients with an ISS >16 points, an AIS >3 in one body region and at least 2 different body regions affected were included.
89687194|NCT01040689|Placebo Comparator|Placebo|olodaterol placebo and/or Tiotropium placebo inhaled once daily
89687195|NCT01040689|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
89687196|NCT01040689|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
89687197|NCT01040689|Active Comparator|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
89687198|NCT04133584|Experimental|Group 1 EV71 +SIV|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV) simultaneously with 28 days apart
89687199|NCT04133584|Active Comparator|Group 2 EV71|Give 2 doses of Inactivated Enterovirus 71 Vaccine (EV71) with 28 days apart
89687200|NCT04133584|Active Comparator|Group 3 SIV|Give 2 doses of seasonal influenza vaccine(SIV) simultaneously with 28 days apart
89687201|NCT01048255|Experimental|VX-765|
89687202|NCT03400189|Other|Single arm|"Single oral dose of sulthiame (Ospolot® tablets)~Period I: 50 mg~Period II: 100 mg~Period III: 200 mg given 3 weeks apart"
89687203|NCT04429048|Experimental|acupressure group|The participants received modern routing standard therapy accompanied with the round plastic studs of sea-band were placed just on the skin surface of bilateral PC6 acupoints , and then keep the persistent compressive state for 3 minutes per time and three times a day.
89687204|NCT04429048|Sham Comparator|control group|The participants received modern routing standard therapy only with general elastic band without bud over PC6 acupoints.
89687205|NCT01043263|Experimental|EN3324 (axomadol)|
89687206|NCT01043263|Placebo Comparator|Placebo|
89687207|NCT04334434|Experimental|Study Group|The group to which the exercise protocol consisting of aerobic and strengthening exercises will be applied.
89687208|NCT04334434|No Intervention|Control Group|Control group where evaluations will be made.
89687209|NCT04087174|Experimental|Part A1: Capivasertib + enzalutamide|From day 1 to day 28 of this study treatment, patients will continuously enroll on a starting dose of capivasertib in combination with 160 mg enzalutamide.
89687210|NCT04087174|Experimental|Part A1: Capivasertib dose level 1 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+1 along with 160 mg enzalutamide.
89687211|NCT04087174|Experimental|Part A1: Capivasertib dose level 2 + enzalutamide|On day 29 of the treatment, patients will escalate the capivasertib dose to dose level+2 along with 160 mg enzalutamide.
89687212|NCT04087174|Experimental|Part A2: Capivasertib + abiraterone|Patients will continuously enroll on a starting dose of capivasertib in combination with 1000 mg abiraterone.
89687213|NCT04087174|Experimental|Part B1: Capivasertib + enzalutamide|This optional expansion will treat patients at the recommended dose regimen of capivasertib and enzalutamide.
89687214|NCT04087174|Experimental|Part B2: Capivasertib + abiraterone|This optional expansion will treat patients at the recommended dose regimen of capivasertib and abiraterone.
89687215|NCT01043029|Experimental|aleglitazar|
89687216|NCT01043029|Active Comparator|pioglitazone|
89687217|NCT04065958|Experimental|Yoga-mindfulness|Yoga-mindfulness program consisting of movements/postures (asanas), breathing practices, relaxation practices and meditation practices, together with brief talks on yoga-based coping strategies. The intervention starts with a introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks, with home assignments for about 30 minutes per day, four days per week.
89687218|NCT04065958|Active Comparator|Patient education and physiotherapy|Patient education program consisting of lectures on topics related to inflammatory arthritis and pain together with mild physiotherapy. The interventions starts with an introductory lecture and is then followed by one session per week, á 90 minutes, for 15 weeks. Each session consists of a lecture and a program of instructed physiotherapy. Besides the weekly sessions, home assignments consisting of 30 minutes of walking, are performed four days per week.
89687219|NCT04294342|Active Comparator|Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program which consists of three blocks. All sessions include: Balance, Strength, power and break fall exercises. The intervention group i tested before and after the 10 week exercise.
89687220|NCT04294342|No Intervention|Control Group|The subjects in the control group go about their normal life for 10 weeks without any intervention. The control group is tested before and after the 10 week period.
89687221|NCT04282954|Experimental|Group 1|JP-1366 A mg
89216904|NCT00561912|Experimental|Decitabine + Interferon Alfa-2b|Decitabine 15 mg/m^2 intravenous (IV) daily over one hour for 5 days + Interferon Alfa-2b 0.5 million Units Subcutaneously Twice Daily Continuously, as of Cycle 3, Day 1.
89216905|NCT00561678|Experimental|Precedex|Precedex (Dexmedetomidine)
89216906|NCT00561678|Placebo Comparator|Placebo|Placebo - normal saline
89216907|NCT00946608|Experimental|1|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
89216908|NCT00946608|Experimental|2|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
89216909|NCT00946608|Active Comparator|3|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
89216910|NCT00463684|Experimental|All subjects|Healthy infants 9 months of age (plus or minus 2 weeks) that met the eligibility criteria. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV) and one dose of live, attenuated measles vaccine.
89216911|NCT00463606|Experimental|ABT-335 and Rosuvastatin Calcium|ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
89687222|NCT04282954|Experimental|Group 2|JP-1366 B mg
89687223|NCT04282954|Experimental|Group 3|JP-1366 C mg
89216912|NCT00463606|Active Comparator|ABT-335|ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
89216913|NCT00463606|Active Comparator|Rosuvastatin Calcium|Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks
89216914|NCT03996070|Active Comparator|Treatment arm|Therapeutic dose regime
89216915|NCT03996070|Placebo Comparator|Sham arm|Sub-therapeutic dose regime
89216916|NCT03961308|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
89216917|NCT03961308|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
89687224|NCT04282954|Active Comparator|Goup 4|Esomeprazole 40 mg
89687225|NCT05337436||All patients receive conventional dialysis treatment at enrollment|All patients receive conventional dialysis treatment at enrollment
89687226|NCT04755712|Experimental|ropivacaine in quadratum lumburum block 2|Ropivacaine will be administrated in perineural in quadratum lumburum block 2 after the caesarian.
89687227|NCT04755712|Active Comparator|Intrathecal morphine|Morphine will be administrated in intrathecal
89687228|NCT04746274|Experimental|Online large-group one-session multicomponent positive psychological intervention|
89687229|NCT04746274|Active Comparator|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|
89687230|NCT04746274|No Intervention|Waitlist Control Group|
89687231|NCT04733638||Pre-Viz ICH VOLUME|Patient data collected prior to Viz ICH VOLUME implementation, utilized as a control data set
89687232|NCT04733638||Post-Viz ICH VOLUME|Patient data collected post-Viz ICH VOLUME implementation
89216918|NCT00956436|Experimental|Sorafenib Monotherapy|Sorafenib Monotherapy
89216919|NCT00956436|Experimental|Sorafenib with BIIB022|Sorafenib with BIIB022
89216920|NCT00956514|Experimental|Transcranial Magenetic Stimulation|All subjects will be assigned to active, open-label treatment with the NeuroStar TMS System for 6 weeks (30 treatment sessions).
89216921|NCT00950508|Active Comparator|High volume plasma exchange|3 successive plasma exchanges over 3 days
89216922|NCT00950508|Placebo Comparator|Standard medical treatment|
89216923|NCT00950586|Experimental|Cohort 1|14 days dosing
89216924|NCT00950586|Experimental|Cohort 2|Single dose followed by 14 days repeat dosing
89216925|NCT00950586|Experimental|Cohort 3|Up to 28 days repeat dosing with drug interaction
89216926|NCT00174187|Experimental|Somatropin|
89687233|NCT05330026|Experimental|Yoga practitioner|"The RUSI protocol for taking measurements with ultrasound for physiotherapists will be followed. Three measurements of each of the explorations will be made with the average of the three, pausing for 30 seconds between each repetition.~Three variables will be analyzed: diaphragm thickness, its rate of contraction, and diaphragmatic excursion, all of them at rest, ujjayi breathing, and pursed-lip breathing."
89687234|NCT05330026|Active Comparator|Non yoga practitioner|"Each subject will have previously received (one week before taking the measurements) the instructions where the main researcher will have shown him what calm diaphragmatic breathing is like, as well as forced breathing at maximum inspired volume with neutral breathing, yoga breathing (ujjayi ) and pursed-lip breathing. During that week prior to taking measurements, the subjects should practice each breath for 20 minutes a day in order to have a good awareness of how to perform them correctly.~The RUSI protocol for taking measurements with ultrasound for physiotherapists will be followed. Three measurements of each of the explorations will be made with the average of the three, pausing for 30 seconds between each repetition.~Three variables will be analyzed: diaphragm thickness, its rate of contraction, and diaphragmatic excursion, all of them at rest, ujjayi breathing, and pursed-lip breathing."
89687235|NCT05285488|Experimental|"focused attention group"|adult subjects practicing focused attention meditation
89687236|NCT05285488|Active Comparator|"Contemplation group"|adult subjects practicing contemplation meditation
89687237|NCT04334044|Experimental|Ruxolitinib|Ruxolitinib 5 mg BID since the beginning of dyspnea or increment of work of breathing with pneumonia changes in chest CT-scan
89687238|NCT03576976|Active Comparator|Clinic-based Cognitive Remediation|Clinic-based cognitive remediation is the current standard of care in NY State outpatient programs. It consists of twice weekly group-based and clinician-led sessions.
89687239|NCT03576976|Experimental|Hybrid Cognitive Remediation|Hybrid cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
89216927|NCT01011335|Experimental|Active Vaccine|Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT
89216928|NCT01011335|Placebo Comparator|Placebo with Alum|
89216929|NCT01011335|Placebo Comparator|Saline Placebo|
89216930|NCT00467896|Experimental|Iloprost|The study enrolled patients who were already using iloprost (10 µg/mL) standard dose (5 µg) delivered by I-neb® Adaptive Aerosol Delivery (AAD) System with Power Disc-6 (PD-6) without any safety or tolerability concerns, thereby facilitating a direct comparison with the Power Disc-15 (PD-15). The single arm design allowed each patient to serve as his/her own control.
89216931|NCT00946686|Experimental|1|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
89054462|NCT04567329|Placebo Comparator|Saline solution|0.6% sodium chloride solution 4 times daily (QID)
89054463|NCT00591071|Active Comparator|B|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
89054464|NCT00591071|Experimental|A|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
89054465|NCT01084161|Experimental|N1539 5 mg|
89054466|NCT01084161|Experimental|N1539 7.5 mg|
89054467|NCT01084161|Experimental|N1539 15 mg|
89054468|NCT01084161|Experimental|N1539 30 mg|
89054469|NCT01084161|Experimental|N1539 60 mg|
89054470|NCT01084161|Placebo Comparator|Placebo|
89054471|NCT01084161|Active Comparator|morphine|
89054472|NCT00591110|Active Comparator|1|Educational intervention communicating practical information about vision, eye conditions and eye care.
89054473|NCT00591110|Sham Comparator|2|
89054474|NCT01083615|Experimental|Custirsen|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of custirsen will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly custirsen infusions (640 mg total dose) on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
89054475|NCT01083615|Placebo Comparator|Placebo|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of placebo (isotonic, 0.9% sodium chloride) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly placebo infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
89054476|NCT00591188|Experimental|1|All patients will receive capecitabine and interferon-alpha.
89054477|NCT00591383|Experimental|Single Arm|Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.
89054478|NCT01081782|Experimental|E1|
89054479|NCT01081782|Experimental|E2|
89054480|NCT01081782|Experimental|E3|
89054481|NCT01081782|Placebo Comparator|P|
89054482|NCT00591422|Experimental|Single Arm|
89054483|NCT04567212||Male-group|in this group we will enroll only male with asthma
89054484|NCT04567212||Female-group|in this group we will enroll only female with asthma
89054485|NCT00591461||1|Study participants must be older than 18 years of age who are having an endoscopy performed to evaluate symptoms of GERD such as heartburn, acid taste in the mouth, dysphagia, dyspepsia, or those who are having a screening/surveillance exam for BE.
89054486|NCT01080222|Experimental|Treatment Arm A|Treatment Arm A was discontinued as a result of patients meeting a pre-defined stopping rule related to viral breakthrough during the first four weeks of dosing.
89054487|NCT01080222|Experimental|Treatment Arm B|Treatment Arm B was discontinued as a result of patients meeting a pre-defined stopping rule relating to viral breakthrough.
89054488|NCT01080222|Experimental|Treatment Arm C|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~Enrollment for this arm is complete. No additional subjects will be recruited."
89054489|NCT01080222|Experimental|Treatment Arm D|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~Enrollment for this arm is complete. No additional subjects will be recruited."
89054490|NCT01080222|Experimental|Treatment Arm E|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
89054491|NCT01080222|Experimental|Treatment Arm F|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
89054492|NCT03452267|Experimental|Metformin|
89054493|NCT03452267|Experimental|Pioglitazone|
89054494|NCT03452267|Placebo Comparator|Placebo|
89054495|NCT03451994||Body odor|individuals self-reporting idiopathic body odor with or without bad breath
89054496|NCT03451994||Breath odor|individuals self-reporting idiopathic bad breath but no body odor
89216932|NCT00946686|Active Comparator|2|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
89216933|NCT00579059|Other|1|Maxim® Pop-Top® Tibia
89216934|NCT00579059|Other|2|Maxim® Regular Tibia
89054497|NCT01088802|Experimental|Dose de-escalating radiation therapy with chemotherapy|This protocol combines selective radiation therapy dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks) in patients with HPV-associated cancers of the oropharynx
89054498|NCT03451877|Active Comparator|Study group|Children with cycloplegia refractive error more than -6 D TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
89054499|NCT03451877|Other|Control group|Emmetropic children TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
89054500|NCT04999683|Experimental|ITIS diet|anti-inflammatory (ITIS) diet for 14 days
89054501|NCT03451838||Diabetes mellitus|Pregnant women with diabetes mellitus will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
89054502|NCT03451838||control group|Pregnant women with no medical disorders will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
89054503|NCT03451682|Experimental|procyanidine group|
89054504|NCT03451682|No Intervention|Control group|
89054505|NCT04566822|Experimental|High-touch intervention|"6 live video coaching sessions~Coaching/feedback is tailored to the individual and adaptive to their progress~Member can send the Coach messages between sessions, but the Coach will not respond until the live session"
89054506|NCT04566822|Experimental|medium-touch intervention|"3 live video coaching sessions~2 live videos are optional (recommended for end of Weeks 3 and 5, but member can take advantage of them anytime)~2-4 pre-recorded video sessions at end of the week. Pre-recorded videos provided in the absence of live sessions~Chat messaging between sessions with 24-48 hour response time"
89054507|NCT04566822|Experimental|low-touch intervention|"1 Live video coaching session (week 1)~Chat messaging with 24-48 hour response time"
89054508|NCT04566822|Sham Comparator|Sleep education control|"Weekly sleep education for six weeks~No interaction with coach"
89054509|NCT03451643|Experimental|Endoscopic Expandable Stent|Procedure/Surgery. Endeosocpically a self-expandable metal stent will be placed in the colon rectum. Chemotherapy will be added
89054510|NCT03451643|Active Comparator|Colorectal Resection|Procedure/Surgery. A standard open or laparoscopic surgery will be performed to remove the colorectal cancer. Chemotherapy will be added
89054511|NCT04566744|Experimental|Physical tool use, tool making and construction|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a physical tool, making a physical tool or building a construction. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools as well as when we build constructions.
89054512|NCT04566744|Experimental|Use of modern physical tools and stone tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when solving mechanical problems in using either a modern physical tool or a stone tool. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use or make physical tools irrespective of whether they are modern or old (i.e., stone tools).
89054513|NCT04566744|Experimental|Use of modern physical, arbitrary and digital tools|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when watching video clips of individuals using either a modern physical tool, an arbitrary tool (e.g., a washing machine) or a digital tool (e.g., a touchscreen). Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we observe others using different kinds of tools, which have appeared progressively over technological evolution.
89054514|NCT04566744|Experimental|Physical tool use and Internet|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when estimating the capacity to solve a mechanical problem with modern physical tools either alone or with the help of a Internet Tutorial. Only the fMRI experimental session is necessary. These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we imagine and estimate solving a mechanical problem alone or with the help of the Internet;
89054515|NCT04574453|Experimental|Iracross|1 course of IRACROSS (crosslinked 2% Hyaluronic Acid) at baseline, consisting of a mono-dose intra-articular administration (2ml).
89054516|NCT04574453|Active Comparator|Iraline|1 course of IRALINE (linear 2% Hyaluronic Acid); each course consists of 3-5 intra-articular administrations (2ml) at weekly intervals (from week 1 to 3, 4 or 5, depending on each patient's need)
89216935|NCT02531737|Experimental|traitment|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1
89687240|NCT04335448||Arterial Switch Operation - Transposition of Great Arteries|Patients with previous arterial switch operation for the treatment of a transposition of great arteries will constitute the sole group of the cohort.
89687241|NCT05220670|Experimental|HIIT Group|This group receives a training in which intervals of intense work and periods of active rest are combined using a cycle ergometer with an intensity of 85-95% of the maximum heart rate [MHR], followed by intervals of active rest of 3 minutes duration. at 50-70% MCF.
89687242|NCT05220670|Experimental|MICT Group|The participants will perform a training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be controlled individually.
89687243|NCT05220670|No Intervention|Control Group|The participants will receive advice on the general positive effects of the regular practice of physical activity, and will be given the guide of recommendations for the promotion of physical activity.
89687244|NCT04334122|Experimental|Control group|"All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~As a traditional treatment, patients received hot packs, conventional transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound and exercise.~Hot packs used as superficial heat were wrapped in a towel and applied to the waist area for 20 minutes.~Conventional TENS used as analgesic current were applied to the waist region for 20 minutes with 4 electrodes with 2 outputs, with a current time of 180 ms at a frequency of 80 Hz.~It was applied with a dose of 1Mhz for 5 minutes with ultrasan (Chattanooga Intelect Mobile Combo model device) used to heat deep tissues.~Waist exercises were asked to be done during the treatment, with 10 repetitions, each exercise twice a day (morning and evening)."
89687245|NCT04334122|Experimental|Experiment group|"In addition to the traditional physiotherapy program, tool-assisted soft tissue mobilization was performed 3 times a week (12 sessions with 1 day interval) in the experimental group.~Instrument Assisted Soft Tissue Mobilization (IASTM) treatment was applied to ilicostalis lumborum, priformism, gluteus medius, erector spinas, quadratus lumborum muscles, superficial and deep fascia. Before applying the application, petroleum jelly was applied to the area and the tool was slipped.~IASTM treatment was applied to the treated muscle fibers for 6 minutes, each technique (SWEEP-FAN-BRUSH-SWEEP techniques) with 8-10 repetitions.~Sweep: Applied in all directions at 30 or 60 degree angle. Fan: It was applied by moving one side fixed arm at 30 degree angle. Brush: It was applied in straight steps at 30 degrees angle. Each stage of IASTM treatment was done by the physiotherapist."
89687246|NCT00372814|Experimental|Multisystemic Therapy (MST)|Adolescents receiving MST will receive Intensive Home-Based Family Therapy which will consist of home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their daily diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
89687247|NCT00372814|Active Comparator|Telephone Support Calls|Adolescents receiving Supportive Telephone Calls (TS) will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
89687248|NCT04521088||visitors of the outpatient clinic for COVID-19|visitors of the outpatient clinic for COVID-19
89687249|NCT03223714|Experimental|Conbercept|Conbercept
89687250|NCT03223714|Sham Comparator|Conbercept or sham|Conbercept or sham
89687251|NCT00372268|Active Comparator|B|Administration of ropivacaïne 0,2% by direct intra-abdominal administration at the end of the surgery
89687252|NCT00372268|Active Comparator|C|Administration of ropivacaïne 0,75% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
89687253|NCT00372268|Placebo Comparator|A|Administration of Nacl 0,9% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
89687254|NCT00372268|Placebo Comparator|D|Administration of Nacl 0,9% by direct intra-abdominal administration at the end of the surgery
89687255|NCT05113498|Experimental|(-)-Epicatechin|(-)-Epicatechin supplementation
89687256|NCT04501822||Covid19 pneumonia patients|The study includes men and women ≥18 years old with documented COVID-19 pneumonia
89687257|NCT05457088|Experimental|intervention group|Dietary intervention with protein intake 1.5 gr/kg/day
89687258|NCT05457088|Experimental|control group|Dietary intervention with protein intake 0.8 gr/kg/day
89687259|NCT02420470||healthy control group|fasting plasma glucose(FPG)<6.11mmol/L，and 2-h plasma glucose(2hPG)<7.77mmol/L；
89687260|NCT02420470||prodromal diabetes group|IFG：fasting plasma glucose(FPG) ≥5.6mmol/L (100mg/dl)，and<7.0mmol/L (126mg/dl)，oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) <7.8 mmol/L ；IGT：oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) ≥7.8mmol/L (140mg/dl)，and<11.1mmol/L (200mg/dl)，fasting plasma glucose(FPG)< 5.6mmol/L
89054517|NCT04566471||PPP and GPP|Palmoplantar pustulosis (PPP) and Generalized pustular psoriasis (GPP) are rare chronic inflammatory skin diseases, characterized by repeated episodes of sterile pustules in several months or years, associated with erythrokeratodermia generally. Both two diseases are easy to cause skin rupture, leading to bleeding and pain.
89054518|NCT03451526||Surgeries+adjuvant chemotherapies|Patients who received radical resection of lung cancer + adjuvant chemotherapies
89054519|NCT03451526||Perioperative chemotherapies|Patients who received perioperative chemotherapies
89054520|NCT04996602|Experimental|2.0 GBq of 177Lu-EB-PSMA|The patients were intravenously injected with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
89216936|NCT00467818|Active Comparator|Omega 3 fatty Acids, drug|Omega 3 Fatty acids will be dispensed to subjects in the active experimental group of the study.
89216937|NCT00467818|Placebo Comparator|Placebo|The placebo will be dispensed to subjects in the control group
89687261|NCT02420470||diabetes group|fasting plasma glucose(FPG)>7.0mmol/L, or 2-h plasma glucose(2hPG)>11.1mmol/L
89687262|NCT04485754|Experimental|Telemedicine FU|Telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
89687263|NCT04485754|Active Comparator|Office FU|Office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
89687264|NCT05441098||Neoadjuvant therapy|Patients with breast cancer treated with neoadjuvant therapy attending each center from 2010-2020.
89687265|NCT05456698|Experimental|Inotuzumab Ozogamicin|Each subject will be treated with Inotuzumab Ozogamicin
89687266|NCT04383340|Experimental|Mother-Infant Transaction Program|Four sessions were delivered to the mothers one-on-one based on a manualized protocol while the infants were still in the neonatal intensive care units. These coaching sessions included psychological care for the mother and topics on recognizing premature infant's characteristics, understanding and recognizing signs of infant stress and infant's engagement and disengagement cues, principles of graded stimulation, and how to optimize interactions and avoid over-stimulating the infant.
89687267|NCT04383340|Active Comparator|Treatment as usual|For this group, infants and mothers received standard hospital care following the initial baseline assessment; these mothers were invited to ask questions about recommended ways to take care of their infants, but no specific knowledge or skills targeted by the adapted MITP program were taught
89687268|NCT02973724|Experimental|Remifentanil|Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
89687269|NCT05456464|Experimental|Reiki|The researcher, a second-degree Reiki therapist, performed the Reiki therapy. Patients were told to lie comfortably on their backs after they were informed about the therapy. Each of the 7 Reiki hand positions was applied sequentially. Each of the hand positions took 2-3 minutes, requiring 30-40 minutes in total.
89687270|NCT05456464|No Intervention|Control group|Routine maintenance will be applied
89687271|NCT03216005|Experimental|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
89687272|NCT01719484||Healthy|Subjects deemed to be medically healthy
89687273|NCT01719484||Obese|Subjects deemed to be medically obese
89054521|NCT04997694|Experimental|Active Heating Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form Vital Signs Follow-up Form, Temperature Comfort Perception Scale- The form was recorded in the Shivering Level Diagnosis Form Filling.Before anesthesia was given, heating was performed with the 3M Bair Hugger Model 775 Heating Unit, which has an active heating system, for 20 minutes. The participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form Vital Signs Follow-up Form Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
89054522|NCT04997694|Experimental|Pasive Heating Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form ,Vital Signs Follow-up Form, Temperature Comfort Perception Scale. The form was recorded in the Shivering Level Diagnosis Form . Before anesthesia was given, heating was performed with a wool blanket, which is a passive heating method, for 20 minutes. The participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form Vital Signs Follow-up Form , Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
89054523|NCT04997694|No Intervention|Control Group|When the participants comes to the preoperative unit before the operation, vital signs, temperature comfort perception scale and shivering level, temperature and humidity measurements of the room are measured by the investigator and Personal Information Form Vital Signs Follow-up Form , Temperature Comfort Perception Scale The form was recorded in the Shivering Level Diagnosis Form the participants, whose surgery was completed, was taken to the postoperative recovery unit, where the vital signs, tremor level, temperature and humidity of the room were measured by the investigator and the Personal Information Form , Vital Signs Follow-up Form , Shivering Level Diagnosis Form was recorded. One participant was followed every 15 minutes until the body temperature reached 36 0C.
89054524|NCT04574414||Children with Attention Deficit Hyperactivity Disorder|Cases
89054525|NCT04574414||Children without Attention Deficit Hyperactivity Disorder|Population controls
89054526|NCT04566549|Placebo Comparator|Placebo group|Shampoo base without probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance.
89054527|NCT04566549|Active Comparator|Test group|Shampoo base with probiotics inculding Aqua、Sodium Lauryl Ether Sulphate、Cocamidopropyl Betaine、Cocoamide DEA、Sodium、Polyquaternium-10 、Disodium EDTA、Acrylates Copolymer、Citric Acid、Phenoxyethanol、Fragrance、Heat-killed Lactobacillus paracasei powders (5x10^8 cells/ g-shampoo).
89054528|NCT04566705||Women with uterine rupture|Women with uterine rupture
89054529|NCT04566705||Women without uterine rupture|Women without uterine rupture
89054530|NCT04566588|Experimental|Early apical release holmium enucleation of the prostate|Early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
89054531|NCT04566588|Active Comparator|Classic holmium enucleation of the prostate|Classic holmium enucleation of the prostate (HoLEP), as a surgical treatment for benign prostatic hyperplasia
89054532|NCT04992858|Experimental|CT053PTSA|60 mg/d, starting on the first day
89054533|NCT02210754|Experimental|E-cigarette 1|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
89054534|NCT02210754|Experimental|E-cigarette 2|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/propylene glycol (PG) vehicle)
89054535|NCT02210754|Experimental|E-cigarette 3|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
89054536|NCT02210754|Experimental|E-cigarette 4|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
89054537|NCT02210754|Experimental|E-cigarette 5|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
89054538|NCT02210754|Active Comparator|Combustible Cigarette|Marlboro Cigarette
89054539|NCT02210793|Active Comparator|Transepithelial PRK|20 eyes to undergo a no touch , all-laser advanced surface ablation technique termed transepithelial PRK using the Amaris laser platform (Schwind eye-tech solutions Gmbh, Germany)
89054540|NCT02210793|Active Comparator|Conventional LASIK|20 eyes to undergo LASIK using a mechanical microkeratome (M2, Moria Surgical, Antony, France) and the Mel 80 excimer laser system(Carl Zeiss Meditec)
89054541|NCT03451214|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 11 mg/d and 25 mg supplemental zinc/d
89054542|NCT04996056|Experimental|TNX-1300|TNX-1300 Intravenous injection 200 mg once over 2 mins
89054543|NCT04996056|Other|Usual Care|Usual Care per the Emergency Department protocol for treating Cocaine Intoxication
89054544|NCT04992078|Experimental|Robotic-Unicompartmental Knee Replacement (R-UKR)|NAVIO/CORI Surgical System
89054545|NCT04992078|Active Comparator|Conventional-Unicompartmental Knee Replacement (C-UKR)|Non-robotic conventional instrumentation
89054546|NCT02210871|Experimental|Normal hepatic function|
89054547|NCT02210871|Experimental|Mild hepatic impairment|
89054548|NCT02210871|Experimental|Moderate hepatic impairment|
89054549|NCT02210871|Experimental|Severe hepatic impairment|
89054550|NCT04574141|Experimental|spray before tablet|
89054551|NCT04574141|Experimental|tablet before spray|
89054552|NCT04573907|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
89054553|NCT04573907|Active Comparator|Reference formulation of Levothyroxine|Eutirox 100 mcg Single dose of 600 mcg administered in dosing period 1 or 2
89054554|NCT02277912|Experimental|Transcranial Magnetic Stimulation I|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the motor cortex
89054555|NCT02277912|Experimental|Transcranial Magnetic Stimulation II|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the secondary somatosensory cortex
89054556|NCT02277912|Sham Comparator|Sham Stimulation|Intervention: Repetitive sham Transcranial Magnetic Stimulation with SHAM block of the motor cortex
89054557|NCT02277951||Participants|The Bonfils Intubation Fibrescope the Video Rigid Flexing Laryngoscope the C-MAC® S Video Laryngoscope the Macintosh Laryngoscope
89054558|NCT02278029||Concussed|those subjects with a concussion
89054559|NCT02278029||Controls|those subjects without a concussion
89054560|NCT04573790||Trained in eFONA|Trained participants completed our eFONA workshop within the last six month prior to participating in this study
89054561|NCT04573790||Untrained in eFONA|Untrained participants had never taken part in our institutional eFONA workshop
89054562|NCT02278068|Experimental|Metabolic Neuromodulation System (MNS)|Hepatic sympathetic denervation therapy to aid in glycemic control
89054563|NCT04566627|Experimental|YSLQQ group|"Schools in this group implemented Yo Sé Lo Que Quiero program. This is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
89054564|NCT04566627|No Intervention|Control Group|Schools in this group implemented the usual preventive actions to reduce substance use. Usually, these actions are not manualized.
89054565|NCT04573361|No Intervention|Group Control|Patients having no access to chiropractic treatment during the trial
89054566|NCT04573361|Experimental|Group Chiropractic Care one session|Patients having access to in-person chiropractic treatment once during the trial
89054567|NCT04573361|Experimental|Group Chiropractic Care multiple sessions|Patients having access to in-person chiropractic treatment more than once during the trial
89054568|NCT04566354|Other|Sprint exercise|Three bouts of 30-s sprint exercise with 20 min rest in between. Three fat biopsies obtained ar rest before first sprint, 15 min after and 120 min after third sprint Blood samples from stomach vein and arteria during the whole experiment
89054569|NCT04998981|Experimental|K-877 0.1 mg BID|K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily
89054570|NCT04998981|Experimental|K-877 0.2 mg BID|K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily
89054571|NCT04998981|Active Comparator|Fenofibrate 200 mg QD|Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily
89054572|NCT04998981|Placebo Comparator|Placebo|Placcebo tablet x 2 twice daily, Placebo capsule once daily
89054573|NCT04573088|Experimental|ABICOL|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
89054574|NCT04573088|No Intervention|CONTROL|No acceptance-based intervention or other discussion related to the patients' fears and worries will be applied.
89054575|NCT04573049|Experimental|Levosimendan|Levosimendan 0.1µg/kg/min will last for 24h after the valve is released.
89054576|NCT04573049|Placebo Comparator|Placebo|5% glucose 0.1µg/kg/min administration will continue for 24h after the valve is released.
89054577|NCT04572932|Active Comparator|group 1:Probiotic arm|first group was prescribed probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl 50mg three times daily for 4 weeks
89054578|NCT04572932|Active Comparator|Group 2:Placcebo arm|the second group received only itopridehcl 50mg by the same dose for four weeks.
89054579|NCT04572698|Experimental|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
89054580|NCT04572698|Active Comparator|EYLEA|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
89054581|NCT02210910|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
89054582|NCT02210910|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair, and placement of the InSpace™ system.
89054583|NCT04572542|Experimental|Camrelizumab + Apatinib + nab-paclitaxel|Camrelizumab combined with Apatinib mesylate tablets and nab-paclitaxel in the second-line treatment of advanced gastric cancer
89054584|NCT04565964|Other|Health behaviors|Health behavior intervention for one month will be provided to every participant. We will teach children's guardians (care-giver) how to change the health behaviors to clean indoor environment, including the health behaviors in bedroom, kitchen room, restroom, refrigerator, washing machine, and incense burning hall.
89054585|NCT04572386|Active Comparator|Light cure universal bond|light cured 3m single bond universal
89054586|NCT04572386|Active Comparator|self cure universal bond|self-cure universal bond (Palfique, Tokuyama, Japan)
89054587|NCT04572464|Experimental|Experimental|Mindfulness Based Guided Meditation
89054588|NCT04572620||group 1(rituximab)|
89054589|NCT04572620||group 2 (abatacept)|
89054590|NCT04994691|Placebo Comparator|No message|No message sent
89054591|NCT04994691|Active Comparator|Standard message|2 MyChart reminders that child is overdue for well child check visit
89054592|NCT04994691|Active Comparator|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
89054593|NCT03451019|Active Comparator|sevelamer hydrochloride|the subject receive a single dose of 2,4 g
89054594|NCT03451019|Active Comparator|lanthanum carbonate|the subject receive a single dose of 1.0 g
89054595|NCT03450902|Experimental|Chinese herb & acupuncture|Participants will take Yiqi Suoquan granule and receive acupuncture.
89054596|NCT03450902|Active Comparator|Chinese herb & sham acupuncture|Participants will take Yiqi Suoquan granule and receive sham acupuncture.
89054597|NCT03450902|Active Comparator|Placebo & acupuncture|Participants will take placebo granule and receive acupuncture.
89054598|NCT03450902|Placebo Comparator|Placebo & sham acupuncture|Participants will take placebo granule and receive sham acupuncture.
89054599|NCT04565652|Experimental|ICD Defibrillation|Detection of ICD shock during elective ICD implant using the investigational device
89054600|NCT03450863||Fast-acting insulin aspart|Participants will receive fast-acting insulin aspart at the treating physician's discretion as part of the usual clinical practice. The prescription and use of fast-acting insulin aspart is completely independent of this study. Total study duration for the individual patient will be approximately 24 weeks.
89054601|NCT02211027|Experimental|Vaccine|The vaccine is composed of lethally irradiated semi-allogenic human fibroblasts (MRC-5) transfected with genomic tumor DNA from the patients own tumor.
89054602|NCT02211066|Active Comparator|Clopidogrel|Clopidogrel 75 mg will be administered daily for 1 year
89054603|NCT02211066|Experimental|Ticagrelor|Ticagrelor 90 mg will be administered daily for 1 year
89054604|NCT03450746||Healthy patients for orthopaedic surgery|Standard general anaesthesia and ventilation with FiO2 0.50 for at least 45 minutes following the standard settings in our department.
89054605|NCT04572113||No collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are not wearing a cervical collar
89054606|NCT04572113||DJO collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a DJO cervical collar
89054607|NCT04572113||Miami J collar|Cervical range of motion and tissue interface pressure measurements are recorded while subject are wearing a Miami J cervical collar
89054608|NCT04998864||Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2.0 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
89054609|NCT04995042|Experimental|SHR7280 Does Escalation and Expansion|
89054610|NCT03450551|Experimental|Twin Block|61 patients will receive the Twin Block appliance (one of the three appliances being studied)
89054611|NCT03450551|Active Comparator|Herbst|61 patients will receive the Herbst appliance (one of the three appliances being studied)
89054612|NCT03450551|Active Comparator|Frog distalising appliance|61 patients will receive the Frog distalising appliance (one of the three appliances being studied)
89054613|NCT03450395|Placebo Comparator|Cereal - Cream of Rice|40 g cream of rice
89054614|NCT03450395|Experimental|Cereal - Oats containing beta-glucan|40 g oats
89054615|NCT03450317|Experimental|Aspirin|Aspirin 80mg once daily
89054616|NCT03450317|No Intervention|Non-treatment group|No intervention
89687274|NCT05315687|Experimental|Arm I (systemic therapy, Y90 radioembolization)|Patients receive systemic therapy. Beginning 1-6 weeks after starting systemic therapy, patients also undergo Y90 radioembolization.
89687275|NCT05315687|Active Comparator|Arm II (systemic therapy)|Patients receive systemic therapy.
89687276|NCT03215615|Active Comparator|Group NF + TE|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with nanofilled resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
89687277|NCT03215615|Active Comparator|Group NF + UA|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with nanofilled resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
89054617|NCT04996563|Experimental|Video|A brief educational video on POP will be sent electronically to participants randomized to the video group. Participants will view the video within one week prior to their consultation visit.
89054618|NCT04996563|No Intervention|No video|Participants assigned to this group will not be sent the educational video to view.
89054619|NCT03450278|No Intervention|control|canine retraction without any means of acceleration.
89054620|NCT03450278|Experimental|micro-osteoperforation|canine retraction accelerated with micro-osteoperforation
89054621|NCT04565496|Experimental|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
89054622|NCT03450239|Experimental|Recovered from anorexia nervosa|Women who have recovered from Anorexia Nervosa for over a year. BMI over 18.5, aged 18-40, scores on Eating Disorder Examination (EDE) within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
89054623|NCT03450239|Experimental|Healthy controls|Healthy control women. BMI over 18.5, aged 18-40, scores on EDE within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
89054624|NCT04992117||Unplanned-extubation in the ICU|Patients with unplanned extubation in the ICU
89054625|NCT04572425|Active Comparator|Guided imagery|10 minutes of guided imagery (using Apple iPad and headphones, subject watches 10 minute video of a guided-imagery session depicting a peaceful walk through a forest with instrumental background music and 2-dimensional imagery)
89054626|NCT04572425|Experimental|Virtual reality|10 minutes of virtual reality (using study-administered Facebook Oculus Go VR headset with headphones, subject engages with VR application Forest of Serenity (Holosphere VR®, Birmingham, UK) that features a forest environment with voice narration that can be played in a seated or fixed position.
89054627|NCT04565340||Induction of labor with Foley catheter|Induction of labor with Foley catheter
89054628|NCT04565340||Induction of labor with Propess|Induction of labor with Propess
89216938|NCT01326559|Experimental|Experimental 1|Induction chemotherapy using Docetaxel, Cisplatin and 5-FU for week 1 to week 9 and followed by concurrent chemoradiation plus cetuximab from week 10 to week 16
89054629|NCT03450200|Experimental|Exercises Group|three times daily exercises of hands and fingers exercises and foot exercises which last for 10 minutes in eight weeks, and health education about diabetic foot care
89054630|NCT03450200|Other|Control Group|health education about diabetic foot care
89054631|NCT03450161|Experimental|High-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 20 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
89054632|NCT03450161|Experimental|Low-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 3 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
89054633|NCT03450161|Experimental|Continuous Dose of Fentanyl|"5 minutes prior to sternotomy, patients will receive a NaCl 0.9% bolus (placebo) and a perfusion pump with fentanyl (verum) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
89054634|NCT04996212|Experimental|Walking APP Group|
89054635|NCT04996212|Experimental|Functional APP Group|
89054636|NCT03458039|Experimental|In-person CETA|This is the in-person delivery method of the Common Elements Treatment Approach (CETA).
89054637|NCT03458039|Experimental|Telephone CETA (T-CETA)|This is the technology-based delivery method for the Common Elements Treatment Approach (CETA).
89054638|NCT03458039|Active Comparator|Treatment As Usual|This is the treatment as usual control condition who will engage with their usual care in the community and will receive CETA, if desired, following completion of the study.
89054639|NCT04565184|Experimental|Artesunate-amodiaquine (Arm A)|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
89687278|NCT03215615|Active Comparator|Group MH + TE|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with micro-hybrid resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
89687279|NCT03215615|Active Comparator|Group MH + UA|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with micro-hybrid resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
89687280|NCT04264000|Experimental|platelet-rich plasma|The perineural injection with PRP is a potential treatment for peripheral entrapment neuropathy
89687281|NCT04264000|Active Comparator|5% dextrose|The perineural injection of 5% dextrose is a novel management for peripheral entrapment neuropathy
89687282|NCT05455996|Experimental|MDMA-assisted therapy|Participants will receive 2-dosing model of MDMA-assisted therapy (includes 9 non-drug therapy sessions)
89687283|NCT05455918|Experimental|TIP treatment arm|
89687284|NCT04334902||Abnormal|The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism
89054640|NCT04565184|Active Comparator|Artemether-lumefantrine (Arm B)|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
89054641|NCT03455192|Experimental|Synbiotic supplements|One synbiotic tablet, per day, during 30 days
89054642|NCT03455192|Placebo Comparator|Placebo Oral Tablet|One placebo tablet , per day, during 30 days
89054643|NCT04565262|Experimental|NAs+IFN-α|NAs+IFN-α/ 96w
89054644|NCT04565262|Other|NAs+(IFN-α+ NAs )|NAs/48w+(IFN-α+ NAs)/96w
89054645|NCT04564950||Control|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
89054646|NCT04564950||Periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
89054647|NCT04564950||Coronary heart disease|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
89054648|NCT04564950||Coronary heart disease + periodontitis|Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease
89054649|NCT03454022|Active Comparator|Usual care|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure."
89054650|NCT03454022|Experimental|DART|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure. They also receive a link to access the web-based decision-aid program, Decision-Aid for Renal Therapy (DART). Participants may access this program using a computer at home throughout the duration of the trial. Those who do not have a computer with web access at home are assisted in watching the program in the clinic."
89054651|NCT03452579|Active Comparator|Nivolumab + Standard Dose Bevacizumab|"nivolumab 240 mg IV and standard dose bevacizumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.~Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion"
89054652|NCT03452579|Experimental|Nivolumab + Low Dose Bevacizumab|"nivolumab 240 mg IV and low dose bevacizumab 3mg/kg every 2 weeks until disease progression or unacceptable toxicity~Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion"
89054653|NCT04565223|Experimental|Cognitive behavioral therapy (CBT)|"5 sessions of Cognitive behavioral therapy for insmonia and an extra session for benzodiazepine withdrawal (if necessary).~The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal"
89054654|NCT04565223|No Intervention|Usual care|Usual care from GPs or nurses
89054655|NCT04997850|Experimental|TACE + lenvastinib + sindilimab/carrelizumab|The patients with body weight ≥ 60kg were treated with oral lenvastinib within 3 days (the initial dose was 12mg QD for patients with body weight < 60kg, the initial dose was 8mg QD for patients with body weight < 60kg). After 1-2 weeks of treatment, the patients received the first TACE treatment (3 days before TACE), and continued to take oral lunvastinib 3 days after TACE. Within one week after TACE treatment, 200 mg of sindilimab was given intravenously once every three weeks (every 21 days as a cycle) or 200 mg of carrelizumab was given intravenously once every three weeks (every 21 days as a cycle).
89054656|NCT04997850|Active Comparator|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
89054657|NCT03450629|Experimental|PDP-716|
89054658|NCT03450629|Active Comparator|Brimonidine Tartrate Ophthalmic Solution|
89054659|NCT04572347||Nurses working in PUTH|Participants will be recruited from Peking University Third Hospital through cluster sampling. Female registered nurses, licensed practical nurses and/or midwives with informed consent are included in this study. The exclusion criteria are student nurses and training nurses.
89054660|NCT04997772||1|Gaucher disease patients > 18 years old.
89054661|NCT03459014|Experimental|Stimulus rich VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the experimental group will walk in a stimulus rich VE such as walking in a park.
89687285|NCT04334902||Normal|The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism
89687286|NCT02958748||ARDS|Patients admitted to ICU with diagnosis of ARDS,which happened in 48hours.
89687287|NCT02958748||Control|Heathy vonlunteers
89687288|NCT05455762|Experimental|Exercise group|patients in this group will participate in an 8 week program of exercise. The exercise program includes both aerobic and resistance exercise. The patients will exercise 6 days a week,3 days aerobic exercise and 3 days resistance ones. The aerobic exercise consists of 20 minutes walking. Patients will walk slowly in the first five minutes to warm up, then they walk faster and with the intensity prescribed by the physiotherapist. In the last 5 minutes the patient will walk like the first 5 minutes. The middle 10 minutes may be increased or not based on patients' weekly self-report. The resistance training include hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
89687289|NCT05455762|No Intervention|Control group|The patients in this group will continue their routine life and treatment prescribed by the gastroenterologist for their condition
89687290|NCT00889187|Experimental|Phase 1 Cohort 1: Photon Rad (30 Gy/12 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 1, a total dose of 30 Gy in 10 fractions (3 Gy/day) was prescribed to the 95% isodose and administered 5 days per week over 12 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
89054662|NCT03459014|Active Comparator|Stimulus poor VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the control group will walk in a stimulus poor VE, such as walking through an endless hallway.
89054663|NCT03456947|No Intervention|control group|the patients receive routine preoperative preparation without having Pregabalin
89054664|NCT03456947|Experimental|Pregabalin150mg group|the patients receive 150mg pregabalin 60 minutes prior to the surgery
89054665|NCT03456947|Experimental|Pregabalin300mg group|the patients receive 300mg pregabalin 60 minutes prior to the surgery
89054666|NCT04999527|Experimental|Healthy Volunteer: Single Ascending Dose of DISC-0974|Single Intravenous (IV) or Subcutaneous (SC) ascending dose in healthy volunteers
89054667|NCT04999527|Experimental|Healthy Volunteer: Single Ascending Dose of Placebo|Single Intravenous (IV) or Subcutaneous (SC) ascending dose in healthy volunteers
89054668|NCT04995861|Active Comparator|Group A (adductor canal only)|Will recieve adductor canal block only
89054669|NCT04995861|Active Comparator|Group AB (adductor canal + IPACK)|Will recieve both adductor canal block and IPACK
89054670|NCT03456791||endometrial carcinoma( cases)|42 patients with abnormal uterine bleeding and diagnosed endometrial cancer at prior endometrial biopsy, underwent staging laparotomy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
89054671|NCT03456791||benign diseases(control)|42 patients with abnormal uterine bleeding and diagnosed benign endometrial pathology by endometrial biopsy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
89054672|NCT02277431|Experimental|Probiotic dietary supplement|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
89054673|NCT02277431|Placebo Comparator|Placebo|The placebo capsules utilized in this study will be indistinguishable from the probiotic dietary supplement capsules as they will be identical in appearance, odor, weight, and taste. Furthermore, the same sunflower oil matrix will be in both the probiotic dietary supplement and placebo. The only difference between the dietary supplement and placebo capsules will be the probiotic bacteria.
89054674|NCT02277509|Experimental|Chinese DPP|Our Chinese DPP intervention includes: 1) skills development core adapted from the DPP core curriculum, 2) stress reduction counseling and activities, 3) physical activity sessions, 4) self-monitoring tools for diet and physical activity, 5) barriers assessment linked to tool box, and 6) post-core support intervention.
89054675|NCT02277509|Active Comparator|Minimal Intervention Control|The minimal control intervention will consist of providing patients with publically available materials on diabetes prevention, which are produced in Chinese.
89054676|NCT04571268||Healthy validation subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for the purpose of developing and validating the biomechanical models used to track scapular motion
89054677|NCT04571268||Healthy comparison subjects|Healthy subjects who meet the inclusion criteria and participate in data collection for comparison of shoulder motion and muscle activation patterns with RCT subjects
89054678|NCT04571268||RCT subjects|Subjects who have sustained a major rotator cuff tear
89054679|NCT01580852|Active Comparator|Dead Sea Water|
89054680|NCT01580852|Sham Comparator|Pool Water|
89054681|NCT04564326|Active Comparator|Group C|Patients will be assigned to receive opioids analgesia before spinal anesthesia in the form of intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between before positioning the patient for spinal anesthesia.
89054682|NCT04564326|Experimental|Group P|Patients will be assigned to receive Pericapsular Nerve Group Block (PENG Block) before positioning the patient for spinal anesthesia.
89054683|NCT04564326|Experimental|Group F|Patients will be assigned to receive Fascia Iliaca Block (F.I Block) before positioning for spinal anesthesia.
89054684|NCT03453164|Experimental|Radiotherapy + Nivolumab|Localized short-term radiotherapy (22.5 Gy/5 fractions/5 days, Day 1-5) + nivolumab (starting on Day 15-22, a dose of 3 mg/kg (body weight), every 2 weeks to a total of 6 courses)
89054685|NCT03450434|Experimental|XC8 2 mg|XC8 2mg orally
89054686|NCT03450434|Experimental|XC8 10 mg|XC8 10 mg orally
89054687|NCT03450434|Experimental|XC8 100 mg|XC8 100 mg orally
89054688|NCT03450434|Placebo Comparator|Placebo|Placebo 2 mg, 10 mg or 100 mg orally
89054689|NCT04564716|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
89054690|NCT04564716|Placebo Comparator|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
89054691|NCT00198029|Experimental|Pilot Study of Hylan G-F 20|32 Subjects have received Synvisc Injections and followed for 6 months.
89054692|NCT00197054|Experimental|VACC 1 (RTS, S/AS01B)|RTS, S/AS01B: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
89054693|NCT00197054|Experimental|VACC 2 (RTS, S/AS02A)|RTS, S/AS02A: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
89054694|NCT00197054|Active Comparator|Rabipur (Rabies) Vaccine|Rabipur (Rabies) Vaccine: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
89054695|NCT04564131|Experimental|reflexology practice|"Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism.~Experimental group participants will be given 10 sessions of reflexology massage twice a week for 5 weeks. A total of three follow-ups will be performed in the 1st session, the 5th session and the 10th session. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied."
89687291|NCT00889187|Experimental|Phase I Cohort 2: Photon Rad (25 Gy/11 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 2, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 11 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
89687292|NCT00889187|Experimental|Phase I Cohort 3: Photon Rad (25 Gy/5 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 3, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 5 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
89687293|NCT00889187|Experimental|All Phase I: Photon Rad+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~All Phase I participants received the radiation regimen according to the established dose escalation schedule.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
89687294|NCT00889187|Experimental|Phase II: Photon Rad (MTD)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~Phase II participants received the radiation regimen established in the Phase I study (MTD).~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
89687295|NCT04334824||Hydrochlorothiazide|Patients who received a new prescription for hydrochlorothiazide (alone or in combination with non-ACE inhibitor antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
89687296|NCT04334824||Angiotensin-converting enzyme (ACE) inhibitors|Patients who received a new prescription for an ACE inhibitor (alone or in combination with non-hydrochlorothiazide antihypertensive drugs) at cohort entry, and did not have a previous prescription for any antihypertensive drug any time before cohort entry.
89687297|NCT03215537|No Intervention|observation|No Intervention
89687298|NCT03215537|Active Comparator|comprehensive intervention|preoperative: exercise counseling postoperative : symptoms counseling and pulmonary rehabilitation
89687299|NCT05314127|Experimental|Tazarotene|20 patients of verruca plana receiving daily topical Tazarotene 0.1% gel at night
89687300|NCT05314127|Active Comparator|Imiquimod|20 patients with verruca plana will be treated with imiquimod cream 5% applied once daily at night
89687301|NCT05314127|Experimental|5- fluorouracil|20 patients with verruca plana will be treated with topical 5- fluorouracil 5% cream applied once daily at night
89687302|NCT05314127|Placebo Comparator|Petrolatum|20 patients with verruca plana will be treated with petroleum jelly once daily at night.
89054696|NCT04564131|Experimental|Control|Blood glucose measurement with a glucometer to be provided by the researcher, blood pressure measurement with a digital blood pressure device, and foot temperature measurement with an infrared thermometer will be made. Turkey podiatry foot care guide will be trained under the guidance of the Society of Endocrinology and Metabolism. 1. 3. 5. A total of three follow-ups will be done once in the week. In the follow-up sessions; VAS, DN4, LANSS, NePIQol scales will be applied, foot assessment and SWMI test will be applied.
89054697|NCT04998435|Active Comparator|ESPB group|Erector Spinae Plain Block
89054698|NCT04998435|Active Comparator|PV group|Paravertebral Block
89054699|NCT00197015|Active Comparator|HAV Group|Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)
89054700|NCT00197015|Experimental|HAV+MMR+V Group|Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9
89054701|NCT00197015|Active Comparator|MMR+V→HAV Group|Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)
89054702|NCT04564248|Experimental|website access for families|
89054703|NCT04564248|No Intervention|standard care|
89054704|NCT04563897||HBV/HCV|
89054705|NCT04563897||Fatty liver disease|
89054706|NCT04563897||Liver background after systematic treatment|
89054707|NCT04563897||normal hepatic background|
89054708|NCT02215122|Experimental|MGR001|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via CRC749 inhaler.
89054709|NCT02215122|Experimental|Advair® Diskus®|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Diskus® inhaler.
89054710|NCT02215122|Experimental|Seretide™ Accuhaler™|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Accuhaler™ inhaler.
89216939|NCT02575313|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
89216940|NCT00709709|Experimental|1|Scan
89216941|NCT00709787||Hypertensive Subjects undergoing primary prevention|
89216942|NCT04069949|Experimental|sorafenib plus toripalimab|"Stage I：Subjects (n=3) in cohort A received oral sorafenib (400 mg qd), in combination with intravenous toripalimab (240 mg d1, q3w). Subjects (n=3) in cohort B received oral sorafenib (400 mg bid) and the administration of toripalimab is consistent with cohort A. If dose-limiting toxicity (DLT) does not occur within 42 days of the first administration, the dose is escalated.~Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39."
89216943|NCT00714467|Active Comparator|1|Expert system (stage-based manual and 3 individualized tailored feedback reports) only for smokers, paired-supporters (family or friend participant) do not receive any study intervention
89216944|NCT00714467|Experimental|2|Expert system (stage-based manual and 3 individualized tailored feedback report) to all the smoker participants; a family assisted intervention in a form of a self-help booklet that discusses specific strategies to work with smokers at each stage of change to the paired-supporters
89216945|NCT02574767|Experimental|Lifestyle counseling + PUFA supplement|Home-based Diet and Physical activity plus n3LC-PUFAs supplementation
89216946|NCT02574767|Experimental|Routine diet & PA + PUFA Supplementation|Routine Diet & Physical Activity counseling care plus n3LC-PUFAs supplementation.
89216947|NCT02574767|Experimental|Lifestyle counseling + PUFA placebo|Home-based Diet and Physical Activity plus placebo for n3LC-PUFAs supplementation.
89216948|NCT02574767|Placebo Comparator|Routine diet & PA + PUFA placebo|Routine Diet & Physical Activity counseling plus placebo for n3LC-PUFAs supplementation.
89216949|NCT02575235|Experimental|1.5mg Cetylpyridinium Chloride (CPC)|1.5mg CPC will be taken daily for four weeks.
89687303|NCT04932850|Experimental|Active|"3 active cohorts are involved into study: Cohort 1 (48 mg), Cohort 2 (100 mg) and Cohort 3 (400 mg).~Each cohort is composed of two groups. The subjects enrolled in the first group of each cohort (groups 1, 3 and 5 for Cohorts 1, 2 and 3, respectively) will be sentinel subjects and will be treated one at the time at 48 h intervals in order to evaluate possible treatment-related adverse events."
89687304|NCT04932850|Placebo Comparator|Placebo|Placebo will be administered to 2 subjects for each cohort.
89687305|NCT05455528||renal insufficiency group|"Surgical population currently on dialysis~Surgical population with estimated GFR < 60 ml/min per 1.73 square meter within 90days before the index surgery. The estimated GFR"
89687306|NCT05455528||Non-renal insufficiency group|Defined as the study subjects with eGFR > 90 60 ml/min per 1.73 square meter within 90 days before the index surgery
89687307|NCT03215459||Cardiopulmonary Exercise Test|A cardiopulmonary exercise bike test will be administered prior to palliative chemotherapy treatment.
89687308|NCT04225078|Experimental|Treatment Sequence 1: Treatment ADBC|Participants will receive treatment A (Loperamide therapeutic dose) on Day 1 on treatment period 1, followed by Treatment D (Moxifloxacin) on Day 1 of treatment period 2 followed by Treatment B (Loperamide supratherapeutic dose) on Day 1 of treatment period 3 followed by Treatment C (placebo) on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
89687309|NCT04225078|Experimental|Treatment Sequence 2: Treatment BACD|Participants will receive Treatment B on Day 1 of treatment period 1 followed by Treatment A on Day 1 of treatment period 2 then Treatment C on Day 1 of treatment period 3 and then Treatment D on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
89687310|NCT04225078|Experimental|Treatment Sequence 3: Treatment CBDA|Participants will receive Treatment C on Day 1 of treatment period 1 followed by Treatment B on Day 1 of treatment period 2 then Treatment D on Day 1 of treatment period 3 and then Treatment A on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
89687311|NCT04225078|Experimental|Treatment Sequence 1: Treatment DCAB|Participants will receive Treatment D on Day 1 of treatment period 1 followed by Treatment C on Day 1 of treatment period 2 then Treatment A on Day 1 of treatment period 3 and then Treatment B on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
89687312|NCT04380935|Experimental|convalescent plasma and standard of care|
89687313|NCT04380935|Active Comparator|standard of care|
89687314|NCT00373048|Placebo Comparator|Placebo, tablet|
89216950|NCT02575235|Experimental|4.5mg Cetylpyridinium Chloride (CPC)|4.5mg CPC will be taken daily for four weeks.
89216951|NCT02575235|Placebo Comparator|Control|Placebo will be taken daily for four weeks
89216952|NCT02575157|No Intervention|Discontinuing usage|Patients will discontinue use of bisphosphonates. Bone markers and BMD will be monitored until a need for reinitiation of treatment within 2-years is identified or needed.
89216953|NCT04070963||Cohort|We propose a prospective, observational single-centre pilot study in the PAC (SGH), on participants aged 21 years and above. A HbA1c test will be added to their routine preoperative blood tests. The incidence of newly-diagnosed DM/pre-diabetes (HbA1c ≥6.1%) and poorly controlled DM (HbA1c ≥ 8%), demographic details and presence of significant comorbidities will be analysed.
89216954|NCT00710099|Experimental|1|
89216955|NCT00710099|Active Comparator|2|SNP iontophoresis
89216956|NCT02574689|Experimental|HIPP Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes regular mailings (three mailings in month 1, two mailings in months 2 and 3, one mailing in months 4, 5, 6, 8, and 10) of physical activity manuals that are matched to the participant's current level of motivational readiness and individually-tailored computer expert system feedback reports.
89216957|NCT02574689|Active Comparator|Wellness Contact Control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the ACS website (www.cancer.org) will be mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
89216958|NCT00714545|No Intervention|prospective study|This study is a prospective study of patients treated at Scripps Clinic with intracoronary brachytherapy for recurrent restenosis within drug-eluting stents. Beta irradiation with a 40-mm strontium/yttrium-90 source. No placebo will be used in this trial.
89216959|NCT03944044|Other|Subcutaneous route first|The first route of administration is designated by randomization. In the subcutaneous group, patients received intravenous route in a second time.
89054711|NCT00196976|Experimental|GSK134612A Form1 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
89054712|NCT00196976|Experimental|GSK134612A Form2 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
89054713|NCT00196976|Experimental|GSK134612A Form3 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
89687315|NCT00373048|Experimental|mefloquine, tablet|
89687316|NCT05455372|No Intervention|oral H. pylori negative and gastric H. pylori negative group|These people are tested negative for C13-urea breath test (C13-UBT) and negative for H. pylori Saliva Test Cassette (HPS).
89054714|NCT00196976|Experimental|GSK134612A Form4 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
89054715|NCT00196976|Active Comparator|Control (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer's Meningitec™ conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
89054716|NCT00196976|Experimental|GSK134612A Form1 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
89054717|NCT00196976|Experimental|GSK134612A Form2 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
89054718|NCT00196976|Experimental|GSK134612A Form3 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
89054719|NCT00196976|Experimental|GSK134612A Form4 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
89216960|NCT03944044|Other|Intravenous route first|The first route of administration is designated by randomization. In the intravenous group, patients received subcutaneous route in a second time.
89216961|NCT00553254|Experimental|1|
89216962|NCT01022476|Experimental|Raltegravir potassium|raltegravir 400 mg twice a day
89687317|NCT05455372|No Intervention|oral H. pylori positive and gastric H. pylori negative group|These people are tested negative for C13-urea breath test (C13-UBT) and positive for H. pylori Saliva Test Cassette (HPS).
89687318|NCT05455372|Experimental|oral H. pylori negative and gastric H. pylori positive group|These patients are tested positive for C13-urea breath test (C13-UBT) and negative for H. pylori Saliva Test Cassette (HPS),they are given PPI quadruple therapy for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT will be performed to confirm the results of gastric H. pylori eradication.At the same time, Patients with successful eradication will be instructed to conduct 13C-UBT examination after 1year to confirm whether the recurrence of gastric H. pylori.
89687319|NCT05455372|Experimental|oral H. pylori positive and gastric H. pylori positive group|These patients are tested positive for C13-urea breath test (C13-UBT) and positive for H. pylori Saliva Test Cassette (HPS),they are given PPI quadruple therapy for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT will be performed to confirm the results of gastric H. pylori eradication, and the oral H. pylori infection will be re-detected by HPS.At the same time, Patients with successful eradication will be instructed to conduct 13C-UBT examination after 1year to confirm whether the recurrence of gastric H. pylori.
89687320|NCT00372892|Active Comparator|A|Rituximab
89687321|NCT00372892|Placebo Comparator|B|Saline placebo iv infusion
89687322|NCT04127656|Experimental|Amino Acid-Based Experimental Study Formula|Single-Arm Study
89687323|NCT00895817|Active Comparator|Swallowed fluticasone|
89687324|NCT00895817|Active Comparator|Esomeprazole|
89687325|NCT03020303|Placebo Comparator|Placebo Oral Tablet|A tablet with no active medication that will be an exact match of the active spironolactone in taste and appearance
89687326|NCT03020303|Active Comparator|Spironolactone 25 MG Tablet|25 mg of active spironolactone in tablet form
89687327|NCT04825522|No Intervention|Control|Participants will not be receiving vancomycin.
89687328|NCT04825522|Active Comparator|Vancomycin|For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.
89687329|NCT00373204|Experimental|Xcytrin® (motexafin gadolinium)|
89054720|NCT00196976|Active Comparator|Control (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).
89054721|NCT00196976|Experimental|GSK134612A Form1 (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
89054722|NCT00196976|Active Comparator|Control (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
89054723|NCT00196976|Experimental|GSK134612A Form1 (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.
89687330|NCT01047319|Experimental|Experimental: Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
89687331|NCT00373438|No Intervention|A|
89687332|NCT00373438|Experimental|B|Fetoscopic tracheal occlusion
89687333|NCT03838679||Cohort 1|80 participants with neovascular AMD and a minimum history of 12 months of anti- VEGF therapy will be included in cohort 1 and examined only once (1 study visit).
89054724|NCT00196976|Active Comparator|Control (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, did not receive any booster vaccination.
89054725|NCT04563936|Experimental|LY01005 3.6 mg|Intramuscular injections of LY01005 3.6 mg every 28 days for a maximum of 3 consecutive doses.
89054726|NCT04563936|Active Comparator|ZOLADEX® 3.6 mg|Subcutaneous injections of ZOLADEX® 3.6 mg every 28 days for a maximum of 3 consecutive doses.
89054727|NCT04572308|Experimental|CD7 CAR-T|Patients will be treated with CD7 CAR-T cells
89054728|NCT04563975|Experimental|Chemotherapy and programmed death 1 inhibitor|Docetaxel /nab-paclitaxel in combination with Toripalimabs
89054729|NCT00196313|Experimental|1 levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablet|
89054730|NCT00196313|Placebo Comparator|2|
89054731|NCT04563819||Newborns with DDH|Newborns (born 1988-90) with sonographic hip dysplasia (DDH)
89054732|NCT04563819||Newborns without DDH|Newborns (born 1988-90) without sonographic hip dysplasia (DDH)
89054733|NCT04563819||Hip dysplasia at skeletal maturity|Subjects that show signs of acetabular dysplasia at skeletal maturity (age 17-19 years), in 2007-09, when hip radiographs and salivary samples were collected.
89054734|NCT04561440||molecular karyotyping|
89054735|NCT04561440||cytogenic karyotyping|
89054736|NCT04561479|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training, inspiratory muscle training and progressive resistance training
89054737|NCT04561479|Sham Comparator|Control Group|Control group will receive alternative upper extremity exercises and breathing exercises.
89054738|NCT04563663|Experimental|One session|One session of talus posteriorization.
89054739|NCT04563663|Experimental|Two sessions|Two sessions of talus posteriorization.
89054740|NCT04563663|Experimental|Three sessions|Three sessions of talus posteriorization.
89054741|NCT04563663|Experimental|Four sessions|Four sessions of talus posteriorization.
89054742|NCT04563585||Muscle strength|Maximal voluntary isometric (MVIC) knee flexion and extension strength were measured using a handheld dynamometer (HDD) (Lafayette Instrument Company, Lafayette, IN).
89054743|NCT04563585||Lower Extremity Vertical Power|Lower extremity vertical power was identified through the use of the VertiMetric (Lafayette Instrument Company, Lafayette, IN) according to protocols suggested by Ambegaonkar et al.
89687334|NCT03838679||Cohort 2|40 participants with treatment-naive neovascular AMD receiving standardized anti- VEGF therapy will be included in cohort 2 and followed for 12 months (6 study visits).
89687335|NCT02911805|Active Comparator|Aerobic Exercise|Exercise 3 times a week
89687336|NCT02911805|Placebo Comparator|Balance Training|Group balance training 3 times a week
89687337|NCT03215225||Root canal treatment|
89687338|NCT01123018||Older Adults|Persons over age 60 Participants will complete the Memtrax memory screening test
89687339|NCT03405649|Experimental|Group A|Participants train 60 min per session for 10 weeks on non-consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and weights, elastic bands and balls will be used. Babies less than 20 weeks of age will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
89687340|NCT03405649|Experimental|Group B|Participants train 60 min per session for 10 weeks on non consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and different equipment such as weights, elastic bands and balls will be used. Babies older than 20 weeks will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
89687341|NCT02884414|Experimental|Cutaneous Stimulation|Cutaneous stimulation and/or feedback. This stimulation and/or feedback may be visual, auditory, tactile (e.g. vibratory, temperature), or haptic and is completely external.
89687342|NCT04382027|Experimental|Monoacylglycerol|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in monoacylglycerol form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
89687343|NCT04382027|Active Comparator|Ethyl ester|The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in ethyl ester form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
89687344|NCT01044901||Subjects with Sickle Cell Disease (SCD)|38 clinically stable black patients with Sickle Cell Disease (SCD) (including individuals with hemoglobin SS, SC, and β-thalassemia demonstrated by high-performance liquid chromatographic separation or gel electrophoresis).
89687345|NCT01044901||Healthy Volunteers|13 healthy control subjects were frequency matched to patients with SCD on age, sex, and race.
89687346|NCT02884492|Experimental|Cognitive impairment|Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
89687347|NCT02884492|Active Comparator|No cognitive impairment|Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).
89054744|NCT04563585||Trunk Extension Endurance|Trunk extension endurance was measured using the Biering-Sorensen test as previously described
89054745|NCT04563585||Upper Limb Performance|The Davies test (DT) was used to assess upper body agility and stabilization.The Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST) was utilized to assess shoulder performance function and stability according to protocol suggested by Goldbeck and Davies.
89054746|NCT04563585||Lower Limb Performance|The Shark Skill Test (SST) was developed in order to assess lower extremity agility and neuromuscular control.
89054747|NCT00195650|Experimental|Adalimumab|Open-label adalimumab 40 mg
89054748|NCT04571957||Donors with NASH|Donors with NASH underwent donor optimization protocol
89054749|NCT04571957||Donors without NASH|Donors without NASH
89054750|NCT04560465|Experimental|group A: Cases that had tranexamic acid infusion|Group A had perioperative tranexamic acid infusion at the rate of 100mls per hour
89054751|NCT04560465|Placebo Comparator|Group B: Control|control were given perioperative placebo at the rate of 100mls per hour
89054752|NCT02211105||Laparoscopic Nissen Fundoplication|Patients whose GERD is being treated surgically through Laparoscopic Nissen Fundoplication.
89054753|NCT02211105||Transoral Incisionless Fundoplication|Patients whose GERD is being treated surgically through Transoral Incisionless Fundoplication.
89054754|NCT00195494|Active Comparator|1a|Etanercept + Methorexate for Period 1 (first 12 months) and Period 2 (Second 12 months)
89054755|NCT00195494|Active Comparator|1b|Etanercept + Methotrexate for Period 1 (First 12 months) and Etanercept alone for Period 2 (Second 12 months)
89054756|NCT00195494|Active Comparator|2a|Methotrexate alone in Period 1 (First 12 months) and etanercept + Methotrexate in Period 2 (Second 12 months)
89054757|NCT00195494|Active Comparator|2b|Methotrexate alone in Period 1 (First 12 months) and Methotrexate alone in Period 2 (Second 12 months)
89054758|NCT02211144|Experimental|BIRB 796 BS|in escalating doses
89054759|NCT02211144|Placebo Comparator|Placebo|
89054760|NCT00194987|Experimental|IVIG x 2|IVIG 2 g/kg/wk divided into 2 infusions per week for women with a fetus affected by FNAIT
89054761|NCT00194987|Experimental|IVIG x 1 + prednisone|IVIG 1 g/kg/wk in 1 infusion per week + prednisone 0.5 mg po daily for women with a fetus affected by FNAIT
89054762|NCT04560855||Covid19 Patients|Patients diagnosed as COVID-19 positive and managed on an outpatient basis.
89054763|NCT00194792|Experimental|Treatment (hormone therapy and chemotherapy)|See detailed description
89054764|NCT02486367|Active Comparator|Standard care/clopidogrel|300mg load followed by 75mg daily.
89054765|NCT02486367|Experimental|Ticagrelor|180mg load followed by 90mg twice daily for 30 days.
89054766|NCT02211183|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
89054767|NCT02211183|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
89054768|NCT00194675|Active Comparator|Testosterone gel + oral placebo|Testosterone 1% gel 7.5 topical daily + placebo dutasteride orally daily
89054769|NCT00194675|Active Comparator|Testosterone gel + oral dutasteride|Testosterone 1% gel 7.5 topical daily + dutasteride 0.5 mg orally daily
89687348|NCT00896441|Experimental|Depressed patients|Depressed patients assigned in an open-label study of citalopram
89687349|NCT00896441|No Intervention|Controls|Healthy controls used as a comparison (no intervention) group for change in resting-state fMRI over time
89687350|NCT02885350|Active Comparator|Spinal fentanyl|20 micrograms of intrathecally administered fentanyl in single dose. Total volume of intrathecal injection 2 ml.
89687351|NCT02885350|Experimental|Epidural fentanyl|100 micrograms of epidurally administered fentanyl in a single dose. Total volume of epidural injection 7 ml.
89687352|NCT02885350|Active Comparator|Spinal sufentanil|5 micrograms of intrathecally administered sufentanil in a single dose. Total volume of intrathecal injection 2 ml.
89687353|NCT02885350|Experimental|Epidural sufentanil|20 micrograms of epidurally administered sufentanil in a single dose. Total volume of epidural injection 7 ml.
89687354|NCT03400111|Experimental|Low-level laser therapy|Patients upper and lower jaws will be irradiated with low-level laser therapy at specific points on the alveolus around the teeth from the vestibular and lingual sides. This group of patients will be followed up till the end of treatment.
89216963|NCT05673239|Experimental|Test group|The patients in the test group were injected with levocarnitine on each dialysis day, and other conventional treatment drugs such as hemodialysis drugs were maintained in the original scheme and recorded in detail on the CRF form.
89216964|NCT05673239|No Intervention|Control group|The patients in the control group were the same as those in the test group, except that they were not treated with L-carnitine.
89216965|NCT00714701||High Risk Group 1|familial Peutz-Jeghers syndrome
89216966|NCT00714701||High Risk Group 2|familial pancreatic cancer relatives
89216967|NCT00714701||High Risk Group 3|germline mutation carriers BRCA1, BRCA2, PRSS, PALB2, p16
89216968|NCT00714701||High Risk Group 4|young-onset pancreatic cancer relative
89216969|NCT00714701||High Risk Group 5|both parents affected
89216970|NCT00714701||Control 1|negative controls
89216971|NCT00714701||Control 2|chronic pancreatitis
89216972|NCT00714701||Control 3|pancreatic cancer
89216973|NCT00714701||Control 4|intraductal papillary mucinous neoplasm (IPMN)
89687355|NCT03400111|Experimental|Panadol-extra|Patients will be given Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine) at specific time points to control pain and discomfort during orthodontic treatment. This group of patients will be followed up till the end of treatment.
89687356|NCT03400111|No Intervention|Traditional Treatment|Patients will not undergo any actual irradiation therapy or take any active tablets during orthodontic treatment.
89687357|NCT03404791|Experimental|Participants Ineligible for Radical Cystectomy|Participants will receive the TAR-200 transuretherally on Day 0 in to the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed on Day 21 via flexible or rigid cystoscopy. Participants will undergo an 84-day induction period comprised of four consecutive 21-day dosing cycles. Participants may undergo 21 day cycle every 3 months for a maximum of 3 cycles as maintenance (Up to 14 months). Each TAR-200 system will be removed at 21 days after insertion.
89687358|NCT03215381|Other|[11C]AZD1390 Microdose|[11C]AZD1390 single dose not exceeding 10 ug by IV bolus
89687359|NCT03406039|Experimental|Integrated Online CBT and MI|Participants in this arm will be given access to the online integrated treatment.
89687360|NCT03406039|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about alcohol and mental illness.
89687361|NCT03839069|Experimental|Minor Salivary Gland Transplantation|Cicatrizing conjunctivitis patients that received minor salivary gland transplantation for dry eye treatment.
89687362|NCT03834415|Experimental|Lactobacillus reuteri DSM17038|Lactobacillus reuteri DSM17038, 1x108 CFU once a day for 30 days
89687363|NCT03834415|Placebo Comparator|Placebo probiotics|Placebo for probiotics, pols drops similar in consistency and flavor as experimental product
89687364|NCT03834649|Active Comparator|Mucograft|Soft tissue augmentation of the defective alveolar ridge using Mucograft inside the prepared vestibular pouch leaving part of the mucograft exposed at the crestal area and will be sutured using 5/0 suture material around the defect margin and secured in the vestibular pouch.
89687365|NCT03834649|Experimental|Partially de-epithelialized connective tissue graft|Soft tissue augmentation of the defective alveolar ridge using Partially de-epithelialized connective tissue graft by preparing vestibular pouch at the defect site and place the de-epithelialized part inside the pouch leaving the epithelialized part sutured and exposed at the crestal area
89687366|NCT04380623|Experimental|Mobile Phone-Based Web-Page: HPV vaccine|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit, tailored education information on the HPV vaccine via a text message with a website link.
89687367|NCT04380623|Active Comparator|Mobile Phone-Based Web-Page: Healthy Lifestyles|Parents who have already declined the HPV vaccine for their adolescent will receive pre-visit education information on an unrelated topic (e.g., healthy eating and physical activity) via a text message with a website link.
89687368|NCT00918931|Experimental|Obatoclax Mesylate|30 mg by vein over 3 hours Days 1-3, 14-day cycle
89687369|NCT04381715||YY1|YY1 intragenic pathogenic variant
89687370|NCT03405493|Experimental|Wake and Light Therapy|This consists of (a) Total Sleep Deprivation with group support on days one and two; (b) Phase Advance of Sleep over 5 days and daily Light Therapy. (c) Light Therapy is given daily
89216974|NCT01025518|Experimental|resistance training and dietary supplement|
89216975|NCT01025518|Placebo Comparator|Resistance training and placebo ingestion|12 weeks of resistance training and placebo ingestion
89687371|NCT03405493|Active Comparator|Sleep and Light Therapy|Participants will be given information on sleep hygiene and getting a good night's sleep. They are then given Light Therapy daily for 1 week.
89687372|NCT02885506|Experimental|Cohort 1|Oral administration of P218 capsules 10 mg
89216976|NCT02575001||Type 1 diabetes|"Children with Type 1 diabetes, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Cortisol release test, Procedure/Surgery: Saliva cortisol measurement."
89216977|NCT02575001||Healthy control|"Healthy primary school pupils, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Saliva cortisol measurement."
89216978|NCT01021930|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
89216979|NCT01021930|Active Comparator|Group B: Non-DM|Coronary artery disease without diabetes mellitus
89216980|NCT00946764|Experimental|1|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
89216981|NCT00946764|Active Comparator|2|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
89216982|NCT01022008|Experimental|Osteodistraction techniques|Osteodistraction techniques
89216983|NCT00950820|Experimental|Panitumumab + XELOX|KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)
89687373|NCT02885506|Experimental|Cohort 2|Oral administration of P218 capsules 30 mg
89216984|NCT00950820|Other|XELOX (KRAS mutational status wt)|KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)
89216985|NCT00950820|Other|XELOX (KRAS mutational status mutant)|KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)
89216986|NCT02574923|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
89054770|NCT04560387|Experimental|Interventional|"Physician-lead complex program of weight-reducing interventions including education, diet counselling and regular physical activity aimed at achieving and maintaining a 10% reduction of baseline body weight.~Bariatric surgery - sleeve gastrectomy in a subgroup of subjects with BMI > 35 kg/m2, i.e. standard indication of bariatric surgery (patients with BMI > 35 kg/m2 and a presence of metabolic or other complications)."
89054771|NCT04560387|No Intervention|Conservative|Routine treatment of obesity
89054772|NCT04560348|Experimental|Adventure-based cognitive behavioral intervention|An adventure-based cognitive behavioral intervention program An 13-session adventure-based cognitive behavioral intervention program, including 6 lectures, 5 workshops and adventure games, and one adventure day camp (2 sessions). One session per week, 3 hours for each session. A variety of cognitive behavioral skills are taught in lectures and these skills are practiced in two groups (with appropriately 20 students in each group) in workshop to help students to apply these skills to cope with their own daily life stress. The adventure training includes a day adventure camp and five 40-minute adventure games in the beginning of each workshop. Skill briefing, case demonstration and debriefing, group sharing and discussion, in-class exercise and homework are used in the intervention program.
89054773|NCT00194012|Active Comparator|Aripiprazole-Randomized Phase|Patients randomly assigned to aripiprazole received medication in pill form with dosing at 2mg, 5mg, 7mg, 10mg, 12mg or 15mg depending on their response.
89054774|NCT00194012|Placebo Comparator|Placebo-Randomized Phase|Patients randomly assigned to placebo received pills/dosing made to look identical to the aripiprazole.
89054775|NCT04563351|Active Comparator|conventional inferior alveolar nerve block (IANB)|37 patients received Inferior Alveolar Nerve Block (IANB) for dental treatment of mandibular posterior teeth.
89054776|NCT04563351|Experimental|Intraligamentary Anesthesia (ILA)|35 patients received Intraligamentary Anesthesia (ILA) for dental treatment of mandibular posterior teeth.
89054777|NCT00192647|Experimental|PEG-IFN alfa-2a+Ribavirin - Induction Treatment|Participants will receive 12 weeks of induction therapy with PEG-IFN alfa-2a (Pegasys), 360 micrograms (mcg) subcutaneous (SC) once weekly, along with ribavirin, 1000 or 1200 milligrams (mg) orally daily in divided doses. Thereafter, the dose of PEG-IFN alfa-2a will be reduced to 180 mcg SC once weekly and the ribavirin dose maintained for the remaining 36 weeks of treatment.
89054778|NCT00192647|Experimental|PEG-IFN alfa-2a+Ribavirin - Standard Treatment|Participants will receive 48 weeks of standard therapy with PEG-IFN alfa-2a, 180 mcg SC once weekly, along with ribavirin, 1000 or 1200 mg orally daily in divided doses.
89054779|NCT04563312|No Intervention|Balance Assessment|The Flamingo Balance Test and Y Balance Test were used to evaluate static and dynamic balance, respectively.
89054780|NCT04563312|No Intervention|Coordination Assessment|Coordination was assessed using the Hexagon Test.
89054781|NCT04563312|No Intervention|Lower Extremity Functional Performance Assessment|Lower extremity functional performance was evaluated using the Single Leg Hop Test.
89054782|NCT04563312|Experimental|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
89054783|NCT00192296|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
89687374|NCT02885506|Experimental|Cohort 3|Oral administration of P218 capsules 100 mg
89687375|NCT02885506|Experimental|Cohort 4|Oral administration of P218 capsules 250 mg
89687376|NCT02885506|Experimental|Cohort 5|Oral administration of P218 capsules 500 mg
89687377|NCT02885506|Experimental|Cohort 6|Oral administration of P218 capsules 750 mg
89687378|NCT02885506|Experimental|Cohort 7|Oral administration of P218 capsules 1000 mg
89687379|NCT02885506|Placebo Comparator|Cohort 8 - Pooled Placebo|Oral administration of P218 matching placebo
89687380|NCT02885506|Experimental|Fed - Fasted|Oral administration of P218 capsules 250 mg Under fed then fasted conditions.
89687381|NCT02885506|Experimental|Fasted - Fed|Oral administration of P218 capsules 250 mg Under fasted then fed conditions.
89687382|NCT03214913|Other|EGDT Group|Early Goal Directed Therapy ：30ml/kg in the first bolus to have a CVP（central venous pressure） 8-12 mmHg and MAP（mean artery pressure ） 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenaline，red blood cell transfusion if necessary.
89687383|NCT03214913|Other|Ruijin Group|"Ruijin Strategy therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR（heart rate） <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT（hematocrit） 25%~35%."
89054784|NCT00192296|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
89687384|NCT03404011|Experimental|Propylene glycol and Glycerol intake|One gram intake of a Propylene glycol/Glycerol mix (50:50)
89687385|NCT03404011|Placebo Comparator|Mimicking intake|Mimicking Propylene glycol/Glycerol intake with the device turns off
89687386|NCT04381949|No Intervention|Standard extubation Arm|
89687387|NCT04381949|Experimental|Positive pressure extubation arm|
89687388|NCT03840382|Experimental|Tele-PrEP Intervention|The telemedicine intervention will allow participants to discuss HIV prevention and PrEP with PrEP specialists at an academic medical center via videoconference from their local community based organization (CBO). During the intervention, participants will gain information related to HIV and PrEP, view a video to improve motivation for engagement in PrEP related care, and receive resources to address barriers to care.
89054785|NCT00192296|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
89054786|NCT00192296|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
89054787|NCT04563429|Experimental|Treatment Group|
89054788|NCT04563429|No Intervention|Control Group|
89054789|NCT00192023|Experimental|Atomoxetine|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO) for 1 week, 1.2 mg/kg/day QD, PO for 7 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
89054790|NCT00192023|Placebo Comparator|Placebo|placebo, daily (QD), by mouth (PO) for 8 weeks, then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
89054791|NCT04563624|Experimental|ceramic cad cam blocks|
89054792|NCT04563624|Active Comparator|composite cad cam blocks|
89054793|NCT00191984|Experimental|Pemetrexed + Irinotecan|
89054794|NCT04560426|Experimental|Naked eyes & Instrument assistance|Identify the parathyroid glands through the experience of surgeons and assistance of instrument.
89054795|NCT04560426|No Intervention|Naked eyes only|Identify the parathyroid glands only through the experience of surgeons.
89054796|NCT04560270|Experimental|Only arm|Blood samples to analyze ctDNA
89054797|NCT00191906|Experimental|Atomoxetine first, then Placebo|Atomoxetine, 1.2 mg/kg/day, by mouth (PO) for 4 weeks, 2 week washout period and cross-over to placebo, every day (QD), PO for 4 weeks
89054798|NCT00191906|Experimental|Placebo first, then Atomoxetine|Placebo, every day (QD), by mouth (PO) for 4 weeks, 2 week washout period and cross-over to atomoxetine 1.2 mg/kg/day, PO for 4 weeks
89054799|NCT00191906|No Intervention|Normal Control|Normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population.
89054800|NCT00191906|No Intervention|Reading Disordered Control|The reading disordered control group is comprised of children with reading disorder who receive standard remedial teaching therapy.
89054801|NCT04562922|Experimental|Lifemel|"LifeMel is bee-honey obtained using Zuf Globus Ltd technology: it is produced in Israel and distributed by VitalMel in Italy. In Italy Ministry of Health has listed it as a food supplement.~Two tea spoons (5 g each) of honey were administered to subjects on each day of the chemotherapy treatment."
89054802|NCT00191789|Experimental|Gemcitabine+Doxorubicin+Cisplatin+Surgery|"Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).~Doxorubicin: 60 mg/m^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision."
89054803|NCT00191282|Experimental|1|Postprandial: Premeal insulin lispro +/- bedtime NPH
89687389|NCT02132741||Treated hypertension|Patients on treatment for hypertension
89687390|NCT02132741||CKD-ESRD|Pre- & post haemodialysis
89687391|NCT02132741||Healthy individuals|Healthy volunteers
89687392|NCT02132741||Chronic kidney disease|Pre-dialysis CKD & those with a functional renal transplant
89687393|NCT02132741||Hypertension|Untreated
89687394|NCT03214835|Experimental|Brush biopsy for laryngeal lesion|Brush biopsy of the larynx - in addition to the standard biopsy
89687395|NCT03214835|Experimental|Brush biopsy for LPR|Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
89687396|NCT05312099||Case group|Women who have entered early menopause (before the age of 40), have chronic systemic diseases (diabetes, heart disease, hypertension, thyroid, rheumatic disease, psychiatric disease history), and use psychiatric drugs were not included in the study.
89687397|NCT05312099||Control group|Women under the age of 45, over the age of 55 with chronic systemic diseases (diabetes, heart disease, hypertension, thyroid, rheumatic disease, psychiatric disease history) and using psychiatric drugs were not included in the study.
89687398|NCT03214757||group with dilated cardiomyopathy without anemia|
89687399|NCT03214757||group with dilated cardiomyopathy with anemia|
89687400|NCT05311865|Experimental|participating to the event|
89687401|NCT05311865|No Intervention|Non partipating to the event|
89687402|NCT05311787|Other|Early oral feeding|The part of our investigation was prostective randomised trial which compared the result of patients with early oral feeding (since first day) and traditional group (oral feeding since 5th day)
89687403|NCT02895100|Experimental|PTG-100 (150 mg QD)|Low dose
89687404|NCT02895100|Experimental|PTG-100 (300 mg QD)|Medium dose
89687405|NCT02895100|Experimental|PTG-100 (900 mg QD)|High dose
89687406|NCT02895100|Placebo Comparator|Placebo group|Placebo control
89687407|NCT01830413||Stenting|cerebral artery stenting for systematic Intracranial artery stenosis
89687408|NCT01830491|Experimental|Clopidogrel napadisilate|aspirin 100mg
89687409|NCT01830491|Active Comparator|clopidogrel bisulfate|aspirin 100mg
89687410|NCT03837275|Experimental|humsfe|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique)
89687411|NCT03837275|Active Comparator|closed sinus lift|transcrestal maxilllary sinus floor elevation
89687412|NCT00904007|Experimental|SE Game Cohort|Will receive ISE intervention.
89054804|NCT00191282|Active Comparator|2|Fasting: NPH/insulin glargine or human insulin 30/70
89054805|NCT04563156||Severe Covid-19 Survivors|Severe Covid-19 survivors previously admitted in the hospital
89054806|NCT04559958||non-dialysis CKD group|Participants with estimated glomerular ﬁltration rate (eGFR) <60 mL/min/1.73 m2 more than three months and without regular dialysis will be enrolled in non-dialysis CKD group.
89054807|NCT04559958||ESRD group|Participants with eGFR ≤15 mL/min/1.73 m2 and underwent regular dialysis will be recruited in ESRD group.
89054808|NCT04559958||control group|Participants with eGFR ≧60 mL/min/1.73 m2 and without evidence of kidney damage such as albuminuria or abnormal findings on renal imaging will be enrolled in control group.
89216987|NCT00168805|Experimental|dabigatran etexilate 220 mg|220 mg once daily
89687413|NCT00904007|No Intervention|Control Cohort|The control cohort will receive identical content online (with no ISE)
89687414|NCT02777944|Experimental|Intervention|Access to Motivate: a web-based intervention, in addition to Usual Care
89687415|NCT02777944|No Intervention|Control|Usual Care
89687416|NCT01830569|Experimental|EBMeDS group|The regular Evidence Linker and the EBMeDS system will be available in this group.
89687417|NCT01830569|Other|Control group|The regular Evidence Linker will be available in this group.
89687418|NCT01830647||Cohort|
89687419|NCT01830725||Gout/Hyperuricemia|Subjects with a diagnosis of hyperuricemia (defined as a uric acid of > 7.2 mg/dl) and/or gout.
89687420|NCT01830725||Control|Approximate age and gender matched controls without hyperuricemia or gout
89687421|NCT02778880|Experimental|Ketamine|Ketamine 1.5 mg/kg intranasally for one dose
89687422|NCT02778880|Active Comparator|Fentanyl|Fentanyl 2 mcg/kg intranasally for one dose
88998851|NCT05755048|Active Comparator|Trastuzumab Emtansine (T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
89216988|NCT00168805|Experimental|dabigatran etexilate 150 mg|150 mg once daily
89216989|NCT00168805|Active Comparator|enoxaparin|40 mg once daily
89216990|NCT00950976|Experimental|Citrulline|
89216991|NCT00950976|Placebo Comparator|lemonade|Equal volume and flavor to citrulline.
89687423|NCT05311319|Experimental|HAIC+Anlotinib (4 Cycles) +TQB2450 (4 Cycles)|HAIC treatment was performed one month after surgery, and Anlotinib and TQB2450 for 4 cycles.
89687424|NCT05311319|Experimental|HAIC+Anlotinib (8 Cycles) +TQB2450 (4 Cycles)|HAIC treatment was performed one month after surgery, and Anlotinib for 8 cycles and TQB2450 for 4 cycles.
89687425|NCT05310929|Experimental|Group N ( nitroglycerine group )|Group N received nitroglycerin intravenous infusion in a concentration of 1 mg/ml, thus 1µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient. The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point) by adjusting the infusion rate as required either by maintaining the same infusion rate or by changing its infusion rate by 1 ml/hr up or down according to the clinical condition every 10 minutes.
89687426|NCT05310929|Experimental|Group L (labetalol group)|. Group L received labetalol intravenous infusion in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication was 5 ml/hr. The infusion rate was titrated to stabilize systolic blood pressure (SBP) at 130-140 mmHg and diastolic blood pressure (DBP) at 80-90 mmHg (study end point) by adjusting the infusion rate as required either by maintaining the same infusion rate or by changing its infusion rate by 1 ml/hr up or down according to the clinical condition every 10 minutes.
89687427|NCT03214133|Experimental|Epicatechin Dose Response|This arm will investigate varying doses of epicatechin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.
89687428|NCT03214133|Placebo Comparator|Epicatechin-rich cocoa on performance|Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.
89687429|NCT00891995|Experimental|Intensive Treatment|closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
89687430|NCT00891995|Active Comparator|Standard Treatment|home glucose monitoring (2 years)
89687431|NCT02781454|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 4 weeks.
89687432|NCT02781454|Active Comparator|Mexiletine, 600 milligrams|Mexiletine, 600 milligrams by mouth per day for 4 weeks.
89687433|NCT02781454|Placebo Comparator|Placebo|Placebo, by mouth per day for 4 weeks.
89687434|NCT00892697|Experimental|Arm|15 subjects will receive Telaprevir in combination with pegylated interferon alfa-2a and ribavirin
89687435|NCT04381403|Experimental|Bio-descaling D-Tart toothpaste|Bio-descaling D -Tart is a bio-descaler toothpaste that is manufactured at Du-Var laboratories (1460 Graham Bell, Boucherville, Québec, Canada J4B 6H5)
89687436|NCT04381403|Active Comparator|Crest®|anti-tartar toothpaste, Complete Whitening plus Scope, tartar control produced by Procter & Gamble, Cincinnati, OH),
89687437|NCT04381793|Experimental|Assessing clinical efficacy|Subjects will receive four tablets twice a day (three times a day for five day loading dose), taking the treatment for 5 - 6 weeks. The treatment is a unique nutritional peptide mix derived from porcine serum. Pre-and post FIQ-R and VA symptom score will be assessed as well as overall well-being. In a subgroup, pre-and post antibody levels will also be checked. Phase 1 will be a group of 60 subjects
89687438|NCT01830959|Experimental|Roflumilast|Roflumilast
89687439|NCT01830959|Placebo Comparator|Placebo|Placebo
89687440|NCT02155465|Experimental|Ruxolitinib and Erlotinib|"Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.~Phase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion. The patient take their previous dose of erlotinib if it is less than 150mg daily."
89687441|NCT01831193|Active Comparator|Diabetic|
89687442|NCT01831193|Active Comparator|Non-diabetic|
88998852|NCT05752994|Active Comparator|Home program group|The guardians will receive the education about autistic spectrum disorder and home program training.
89687443|NCT03402919||Normal healthy elderly|participants with no subjective or objective cognitive deficits or decline.
89687444|NCT03402919||Subjective Cognitive Decline|Participants with a complaint of subjective cognitive impairment, but no objective evidence of such.
89687445|NCT03402919||Mild Cognitive Impairment (MCI)|Participants with objective evidence of cognitive impairment, but it does not impact on daily function.
89687446|NCT03402919||Vascular MCI|Participants meeting criteria of MCI who also show signs of cerebrovascular disease on imaging but have no history of stroke.
89687447|NCT03402919||Alzheimer's Disease|Participants with dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association criteria
89687448|NCT03402919||Dementia of Mixed Etiology|Participants with dementia and evidence of more than one etiology.
89687449|NCT03402919||Lewy Body/Parkinson's spectrum|Participants with Parkinson's disease who show mild or moderate cognitive impairment and/or dementia.
89687450|NCT03402919||Frontotemporal dementia (FTD) spectrum|Participants with behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, or corticobasal syndrome
89687451|NCT01831505|Experimental|Multiple drug microinjection|Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin, bendamustine, prednisolone, or a combination of them
89687452|NCT02781610|Other|ERR-10|ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
89054809|NCT04559997|Experimental|Exercise+FU|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 6 years.
89054810|NCT04559997|Active Comparator|Exercise|After 3 weeks of intensive treatment, no special exercises are performed as a control.
89054811|NCT04559997|No Intervention|Controll|No intervention.
89054812|NCT00191165|Experimental|1|Doubled dosage
89054813|NCT00191165|Active Comparator|2|In-label dosage
89054814|NCT04560231|Experimental|Group intervene with Remdesivir|Review effect of Remdesivir as clinical trial among hospitalized patients with COVID-19 infection. 200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
89054815|NCT04560153|Experimental|patient living with HIV|
89054816|NCT00190775|Experimental|Atomoxetine|Atomoxetine 40 milligrams (mg) once daily (QD) for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
89054817|NCT00190775|Placebo Comparator|Placebo|Placebo is administered once daily (QD), orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
89054818|NCT04563117||Automatic registration|
89054819|NCT04563117||Point-based registration|
89054820|NCT02211924|Experimental|BI 44847|single rising dose
89054821|NCT02211924|Placebo Comparator|Placebo|
89054822|NCT00199901|Active Comparator|Vaccine|NY-ESO-1 ISCOMATRIX® vaccine
89054823|NCT00199901|Placebo Comparator|Adjuvant Alone|ISCOMATRIX® adjuvant alone
89054824|NCT00198263|Experimental|Bleomycin|Bleomycin 4 USP Units/mL; intratumorally at dose of 0.25mL/cm^3
89054825|NCT04562844|Experimental|Social cognition|
89054826|NCT00198107|Placebo Comparator|1 Placebo|Participants will take placebo
89054827|NCT00198107|Active Comparator|2 Aripiprazole|Participants will take aripiprazole
89054828|NCT00198107|Active Comparator|3 Aripiprazole + D-cycloserine|Participants first will take aripiprazole then will also take D-cycloserine
89054829|NCT04563000|Experimental|Vitamin C|Group of patients that will receive vitamin C (ascorbic acid 1,5 g mixed with 0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
89054830|NCT04563000|Placebo Comparator|Placebo|Group of patients that will receive placebo (0,9 % solution of sodium chloride 100 ml every 12 hours for 4 days intravenously).
89054831|NCT04562961|Experimental|Schizophrenia caregiver (relative)|
89054832|NCT00179660|Experimental|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
89054833|NCT00178256|Experimental|1st dose cohort 15mg/m2 taxol plus RT|"15 mg/m2 Paclitaxel On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.~On Monday, Tuesday, Wednesday, Thursday, Friday Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible"
89054834|NCT00178256|Experimental|2nd dose cohort20 mg/m2 taxol plus daily RT|
89054835|NCT00178256|Experimental|3rd Dose Cohort --25mg/m2 taxol plus RT|
89054836|NCT00178256|Experimental|Phase II Arm --20mg/m2 taxol plus RT|
89054837|NCT04560192|Active Comparator|Intervention group|Treatment with the mindfulness based emotion regulation therapy (MBERT) in block 1, no study-treatment in block 2 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy).
89054838|NCT04560192|Other|Treatment as usual (TAU)|No study-treatment in block 1 (but patients receive their possibly already started treatment as usual including pharmacotherapy and psychotherapy), treatment with the mindfulness based emotion regulation therapy (MBERT) in block 2.
89054839|NCT04560192|No Intervention|Control condition|Healthy subjects will get a single TSST session.
89054840|NCT00177164|Active Comparator|1|Oral Risperidone followed by Long acting Risperidone injections (Consta)
89054841|NCT00177164|Active Comparator|2|Oral second generation antipsychotic agents other than clozapine or risperidone (olanzapine, quetiapine, ziprasidone, aripiprazole)
89216992|NCT00467584|Active Comparator|High Dose Aspirin|High Dose Aspirin; 1300 milligrams of aspirin per day, taken by mouth as two tablets, twice per day for 8 weeks
89216993|NCT00467584|Active Comparator|Low Dose Aspirin|Low Dose Aspirin; 162 milligrams of aspirin per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
89216994|NCT00467584|Placebo Comparator|Placebo|Placebo tablets, matching the active aspirin tablets in appearance, taken by mouth twice per day for 8 weeks
89216995|NCT04521725|No Intervention|Group1: ECG+SpO2 only|Traditional ECG (heart rate) and SpO2 (pulse oximetry) monitoring for resuscitation only.
89216996|NCT04521725|Active Comparator|Group 2: ECG+SpO2+RFM|Addition of Respiratory Function Monitor to ECG and SpO2 during resuscitation.
89216997|NCT04521725|Active Comparator|Group 3: ECG+SpO2+RFM+NIRS|Addition of cerebral NIRS and Respiratory Function Monitor to ECG and SpO2 during resuscitation.
89216998|NCT00956670|Experimental|Supportive care (lymphedema assessment)|"Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)~Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.~Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.~Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months."
89216999|NCT02574611|Experimental|SCI observational|"Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
89217000|NCT02574611|Experimental|Able-bodied observational|"Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
89217001|NCT02574611|Active Comparator|SCI drug group|Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.
89217002|NCT02574611|Placebo Comparator|SCI placebo group|Individuals with SCI will undergo a second day of observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo).
89217003|NCT01025596|Experimental|CYT107|
89217004|NCT00710255||Asthmatics|Asthmatics with exercise induced bronchospasm
89217005|NCT01025674|Experimental|7 Treatment Schools|The Positive Action program was implemented over 6 years, starting with Grade 3, then continuing through Grade 8.
89217006|NCT01025674|No Intervention|7 Control Schools|Standard educational practice
88998853|NCT05752994|Experimental|Multisensory room group|The guardians in this group will receiver the educational program the same as the home program group plus the training in multisensory room.
89217007|NCT00714779|Active Comparator|1|Fluoxetine
89054842|NCT04559841|Active Comparator|bone substitute; NanoBone® (group 1, control group)|a synthetic bone substitute consisting of nanocrystalline hydroxyapatite and silica fabricated in a sol-gel process.
89054843|NCT04559841|Experimental|simvastatin + NanoBone (group 2, test group)|medications used to treat hypercholesterolemia
88820627|NCT05878990|Active Comparator|Culturally-tailored Tobacco Treatment Intervention|Upon consent, participants will complete a baseline survey, receive the home Carbon monoxide monitor and instructions on how to use, and be scheduled for weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences. Participants will also receive weekly Culturally-tailored Content Newsletters emailed after their weekly cessation counseling session.
89054844|NCT02487251|Experimental|Experimental: Phase 1 Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
89054845|NCT02487251|Experimental|Experimental: Phase 1 Mealtime support activities|Participants will engage in mealtime support activities such as healthy eating classes, cooking demonstrations, provision of cookware, receipt of mealtime ingredients, receipt of prepared meals, make and eat meals).
89054846|NCT02487251|Experimental|Experimental: Phase 2- Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
89054847|NCT02487251|Experimental|Experimental: Phase 2- Meal Delivery and Receipt of Cookware|Participants will receive two prepared meals weekly for 12 weeks and will receive a comprehensive set of cookware
89054848|NCT02489942||Jardiance|Patients with T2DM to receive Jardiance tablets 10 mg, 25 mg
89054849|NCT04562493|Active Comparator|Magnesium sulphate group|Effect of transforaminal Magnesium sulphate on oxidative stress markers and radicular pain
89054850|NCT04562493|Experimental|Ozone Group|Effect of transforaminal Ozone on oxidative stress markers and radicular pain
89054851|NCT04562493|Other|Steroid group|Effect of transforaminal steroids on oxidative stress markers and radicular pain
88998854|NCT05750199|Experimental|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
88998855|NCT05750199|Experimental|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course.
88998856|NCT05731999|Experimental|Single application of phenethylamines (D1)|Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of phenethylamines.
88998857|NCT05731999|Experimental|Single application of benzodiazepines (D2)|Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of benzodiazepines.
88998858|NCT05731999|Experimental|Single application of cannabinoids (D3)|Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of cannabinoids.
88998859|NCT05731999|Experimental|Single application of opioids (D4)|Evaluation of Previct Drugs' function to measure pupils and eye movements and to evaluate if there are any changes in the pupillometric parameters before and after intake of opioids.
88998860|NCT05711849|Experimental|Treatment arm|Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.
88998861|NCT05711849|Sham Comparator|Sham arm|Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).
88998862|NCT05706779|Experimental|Encorafenib + Cetuximab|
88998863|NCT05706623|Experimental|Moderate hepatic impairment|Child-Pugh B
88998864|NCT05706623|Experimental|Normal hepatic function|
88998865|NCT05706623|Experimental|Mild hepatic impairment|Child-Pugh A
88998866|NCT05694559|Experimental|Genetic Testing and Counseling|Participants will be given a saliva collection kit to collect a saliva sample for hereditary cancer and genetic testing.
88998867|NCT05694559|Experimental|Screening Form|"Participants will complete a screening form to assess your risk of hereditary breast and colorectal cancers. You will be asked to provide your:~Name and contact information (including your address, phone number, and email)~Demographic information (including your age, race, and ethnicity)~Health insurance status~Annual household income~Personal and family history of cancer, including diagnosis and age at diagnosis"
88998868|NCT05658393|Experimental|ReLiver-N App Group|"The ReLiver-N App will be introduced to the participants with liver cirrhosis during face-to-face interviews. The ReLiver-N App group will have access to all the contents of the ReLiver-N App, which includes the about us, patient education information about liver cirrhosis , patient activity skills, and measuring tools. During the follow-up period, the participants in the ReLiver-N App group will take WhatsApp messages once a week and be reminded to use the education program. The ReLiver-N App will be asked to use it for three months on daily and weekly inputs their results. During the follow-up period, the participants can contact researcher via the 24/7 on the ReLiver-N App. The clinical researchers of the team will answer the participant' questions via WhatsApp. Participants in the ReLiver-N group will also receive routine patient education and routine hospital follow-ups given by the Gastroenterology team."
88998869|NCT05658393|Active Comparator|Active Control Group|"The ReLiver-N App will be introduced to the participants with liver cirrhosis in the active control group during face-to-face interviews. The active control group will have access to only these fields about us, patient activity skills, and measuring tools. Participants in the active control group will also receive routine patient education and routine hospital follow-ups given by the Gastroenterology team during the three-month follow-up period."
88998870|NCT05645640|Active Comparator|Intervention|Subjects in the intervention group will receive village doctor-led tailored health management which includes five main components (marking of individual risk factor profiles, tailored targets for risk factor modification, individualized health education based on Smart Phones, health monitoring and feedback based on Smart Bands, and incentive based on gamification).
88998871|NCT05645640|No Intervention|Control|Subjects in the control group will receive usual care (advice on lifestyle change, medication, and rehabilitation).
88998872|NCT05641532|Experimental|Capability-Opportunity-Motivation-Behavior (COM-B) based physical activity behavioral intervention|This is a 1-arm study with an intervention condition based on the COM-B model
88998873|NCT05631834|Active Comparator|Continuous Peri operative Thoracic epidural catheters analgesia|"Epidural catheter insertion will be performed at level T9 with catheter tip at level T7 After negative test dose with Lidocaine 2%, loading dose using Ropivacaine 0.5% (see table).~Patient height (cm) Volume of LA (mL) 140-149 8 150-159 10 160-169 12 170-180 14 >180 16 Evaluation of sensory block should be at level T4 to T10 by cold test and pinprick. If extension needed, bolus of ropivacaine 0.5% 2 mL may be added.~In post operative period▪ analgesia with intermitent automatic bolus UAB of ropivacaine 0.2% will be connected and started at 10 min after arrival in post operative care unit~▪ Pump preparation and settings: Patient 140 - 149 cm = 8 mL Patient 150 - 159 cm = 10 mL Patient 160 - 169 cm = 12 mL Patient 170 - 180 cm = 14 mL Patient >180 cm = 16 mL IAB every 4h reduced to 3h if needed Catheter will be removed 72h after end of surgery"
89054852|NCT04562571|Experimental|Charter & patient information leaflets|A public commitment charter promoting antibiotic stewardship, signed by the general practitioner (GP) and displayed in the practice waiting room; a non-prescription pad, to be distributed to patients when an antibiotic is not needed; and a patient information leaflet to be used when antibiotics were prescribed
89054853|NCT04562571|No Intervention|Control|No intervention, eligible general practitioners randomised in the control group not informed of the intervention
89054854|NCT04559568|Experimental|LY3522348 (Part A)|LY3522348 administered orally.
89054855|NCT04559568|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
89054856|NCT04559568|Experimental|LY3522348 (Part B)|LY3522348 administered orally. Some participants will also receive midazolam.
89054857|NCT04559568|Placebo Comparator|Placebo (Part B)|Placebo administered orally. Some participants will also receive midazolam.
89054858|NCT02211300|Experimental|Optiscanner values vs YSI|Matched samples up to 12 times per 24 hour period
89687453|NCT02781610|Other|ERR-14|ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
89687454|NCT02781610|Other|NERR-14|NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
89687455|NCT02781610|Other|NERR-21|NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
89687456|NCT01831583|Experimental|Measurement of PPG waveforms|Collection of photoplethysmograph(PPG)waveform data from patients with obstructive sleep apnea for 4-8 hours
89687457|NCT01831583|Experimental|Measurement of Pulse Arrival Time (PAT)|Collection of PAT waveform data from patients with obstructive sleep apnea for 4-8 hours
89687458|NCT02155543|Experimental|Cohort 1: AGN-223575 Form A/Vehicle|One drop of AGN-223575 Formulation A in the study eye and one drop of AGN-223575 vehicle in the other eye on day 1, followed by one drop of AGN-223575 Formulation A twice daily in the study eye and 1 drop of AGN-223575 vehicle in the other eye twice daily for 6 days.
89687459|NCT02155543|Experimental|Cohort 2: AGN-223575 Formulation A BID|One drop of AGN-223575 Formulation A in both eyes on day 1, followed by one drop of AGN-223575 Formulation A twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation A in both eyes on day 15.
89687460|NCT02155543|Experimental|Cohort 3: AGN-223575 Formulation B BID|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
89687461|NCT02155543|Experimental|Cohort 4: AGN-223575 Formulation C BID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
89687462|NCT02155543|Placebo Comparator|AGN-223575 Vehicle BID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle twice daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
89687463|NCT02155543|Experimental|Cohort 5: AGN-223575 Formulation C TID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C three times daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
89687464|NCT02155543|Placebo Comparator|AGN-223575 Vehicle TID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle three times daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
89687465|NCT03405337||FVIII products (prospective)|"Qualitative patient/caregiver study:~Hemophilia A patients/caregivers (N=30) having initiated a FVIII products with improved half-life"
89687466|NCT03405337||Conventional FVIII replacement therapies|"Qualitative patient/caregiver study:~Hemophilia A patients/caregivers (N=30) receiving conventional FVIII replacement therapy for at least 6 months who are considering switching to a FVIII product with improved half-life within the next 1 year"
89687467|NCT03405337||FVIII products (retrospective)|"Quantitative physician interview/ chart review study:~Hemophilia A patients (N=100) who have switched from conventional FVIII replacement therapy to FVIII products with improved half-life."
89687468|NCT01831661|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA
89687469|NCT01831661|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
89054859|NCT02211339|Experimental|Peer-led intervention group|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
89054860|NCT02211339|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
89054861|NCT00176462|Experimental|Arm 1 Standard Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin
89054862|NCT00176462|Experimental|Arm 2 High Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C
89054863|NCT04559295|Experimental|Stem Cells (BMC)|Subjects in the BMC arm received an injection of bone marrow concentrate
89054864|NCT04559295|No Intervention|Control|Subjects in the control arm received no treatment for their condition
89054865|NCT02211378|Experimental|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
89054866|NCT02211378|Active Comparator|Hotseat|Trainees are in the 'hotseat' actively participating during all 3 simulation sessions
89687470|NCT03403387|Experimental|GlutenShield|3 capsules of GlutenShield supplement/day for 28 days
89687471|NCT03403387|Placebo Comparator|Placebo|3 capsules of the placebo (Avicel and bentonite powder (for color))/ day for 28 days
89054867|NCT00175019|Experimental|Febuxostat 80 mg QD|
89054868|NCT00175019|Experimental|Febuxostat 120 mg QD|
89054869|NCT00175019|Active Comparator|Allopurinol QD|
89054870|NCT04559763||Healthy Adult Volunteers|
89054871|NCT00174941|Experimental|1|
89054872|NCT00174941|Experimental|2|
89054873|NCT00174941|Experimental|3|
89217008|NCT00714779|Active Comparator|2|Short-term psychodynamic psychotherapy
89687472|NCT03799432|Experimental|TF-CBT Learning collaborative + COAST-IS|In addition to participating in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls, organizations will receive additional training and tailored implementation support.
89687473|NCT03799432|Active Comparator|TF-CBT Learning collaborative|Organizations will participate in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls.
89687474|NCT03405181|Experimental|Training with additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet with an additional weight characterized by 20% of the total mass of the upper limb placed on both wrists. This training will be adopted for the adequate weight intervention group and low weight intervention group.
89687475|NCT03405181|Placebo Comparator|Training without additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet without additional weight, placed on both wrists. This training will be adopted for the adequate weight placebo group and low weight placebo group.
89687476|NCT01831739||Multi-organ|Non-acute presentation, any Scadding stage, evidence of 5 or more organ systems involved, chronic or uncertain clinical course.
89687477|NCT01831739||Non-acute, Stage I, untreated|Non-acute presentation, Scadding stage I, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
89687478|NCT01831739||Stage II-III, treated|Non-acute presentation, Scadding stages II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treated for at least 3 months.
89687479|NCT01831739||Stage II-III, untreated|Non-acute presentation, Scadding stage II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
89687480|NCT01831739||Stage IV treated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treatment current and for at least 3 months.
89687481|NCT01831739||Stage IV untreated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
89687482|NCT01831739||Acute Sarcoidosis, untreated|Acute presentation, Scadding stages I, II, or III, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
89687483|NCT01831739||Remitting, untreated|Remitting clinical course, no treatment for at least 3 months.
89687484|NCT01831739||Cardiac defining therapy|Chronic or uncertain clinical course, no multi-organ involvement, cardiac manifestations defining need for systemic corticosteroid and/or immunomodulatory therapy.
89687485|NCT04375501||COVID-19 positive|All patients admitted with fractured neck of femur during specified time period testing POSITIVE for COVID-19
89687486|NCT04375501||COVID-19 negative|All patients admitted with fractured neck of femur during specified time period testing NEGATIVE for COVID-19
89687487|NCT03796468|Other|Best Medical Therapy (BMT)|Best treatment medical probably associated to the rescue endovascular treatment in case of neurological deterioration
89687488|NCT03796468|Other|Mechanical Thrombectomy (MT)|Endovascular treatment (thrombectomy) associated with the best treatment medical
89687489|NCT04375423|Experimental|Intervention|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. In response to the behaviors they report, they receive messages on their smartphones supporting ongoing healthy behaviors or suggesting alternative behaviors to limit risks. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
88998874|NCT05631834|Experimental|Continuous Peri operative Bilateral erector spinae catheters analgesia|"The ESP will be performed Right side level The tip of the catheter should be on t T7.~Left side level The tip of the catheter should be on T8.~Induction with ropivacaine 0.5% with loading dose as follows:~Patient height (cm) Volume of LA (mL) LEFT RIGHT 140-149 8 6 150-159 10 8 160-169 12 10 170-180 14 12 >180 16 14~For post operative analgesia:~Pumps with intermittent automatic bolus (IAB) of ropivacaine 0.2% started at 10 min after arrival in PACU~Patient 140 - 149 cm = 6 mL / left side - 8 mL / right side~Patient 150 - 159 cm = 8 mL / left side - 10 mL / right side~Patient 160 - 169 cm = 10 mL / left side - 12 mL / right side~Patient 170 - 179 = 12 mL / left side - 14 mL / right side~Patient > 180 kg = 14 mL / side - 16 mL / right side The bolus on the second catheter will be delayed by 1 hour IAB every 6h Catheter will be removed 72h after end of surgery"
88998875|NCT05625516||Patients with acute syndesmotic injuries|The patients undergo a bilateral external torque CT.
88998876|NCT05625516||Patients with asymptomatic chronic syndesmotic injuries|The patients undergo a bilateral external torque CT.
88998877|NCT05625516||Patients with symptomatic chronic syndesmotic injuries|The patients undergo a bilateral external torque CT.
88998878|NCT05622201|Experimental|Rituximab|Rituximab 1000 mg, infusion
88998879|NCT05622201|Placebo Comparator|Placebo|Saline infusion
88998880|NCT05615376|Experimental|ECG App arm|Participants will be provided with a wearable device on Day 1 and Day 4 whilst admitted in hospital.
89217009|NCT03839212|Experimental|Happy Older Latinos are Active (HOLA)|A 16-week multi-component, health promotion intervention
89687490|NCT04375423|Active Comparator|Control|On smartphones, participants in this arm will receive twice daily and weekly prompts to report on behaviors under study and be able to send self-initiated event-contingent reports on behaviors under study. They will complete in-person assessments at enrollment, 30-days and study exit at 90-days.
89687491|NCT03709732||Spinal cord injury|Persons with a spinal cord injury. No intervention
89687492|NCT03709732||Caregivers spinal cord injury|Caregivers for persons with a spinal cord injury. No intervention
89687493|NCT03709732||Controls for patients|Control group for patient cohort. No intervention
89687494|NCT03405103|Experimental|Striving|Striving vs Boning-up & Personal Choice
88998881|NCT05610293||5mm surgical margin|Patients treated with a 5mm surgical margin for a T1 SCC of the lip.
88998882|NCT05610293||10mm surgical margin|Patients treated with a 10mm surgical margin for a T1 SCC of the lip.
89217010|NCT00168103|Experimental|C1-INH 10 U/kg bw|10 Units (U)/kg body weight (bw) dose
89687495|NCT03405103|Active Comparator|Boning-up Standard Education|Boning-up vs Striving and Personal Choice
89687496|NCT03405103|Sham Comparator|Personal Choice|Personal Choice vs Striving & Boning-up
89687497|NCT03400267|Active Comparator|paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
88998883|NCT05583708|Experimental|Experimental: Pembrolizumab + Lutetium Lu177|"All patients will receive pembrolizumab once every 6 weeks + Lutetium Lu177 dotatate once every 2 months~Pembrolizumab Cycle=6 weeks (for up to 2 years) Lutetium Lu177 dotatate Cycle=2 months (4 doses total)"
89687498|NCT03400267|Active Comparator|fentanyl|
88998884|NCT05579314|Active Comparator|SAD Cohort A - XW014|Single oral XW014 administration
88998885|NCT05579314|Placebo Comparator|SAD Cohort A - Placebo|Single oral placebo administration
88998886|NCT05579314|Active Comparator|MAD Cohort B - XW014|MAD in Healthy Subjects with Elevated BMI
88998887|NCT05579314|Placebo Comparator|MAD Cohort B - Placebo|MAD in Healthy Subjects with Elevated BMI
88998888|NCT05579314|Active Comparator|MAD Cohort C - XW014|MAD in Patients with T2DM
88998889|NCT05579314|Placebo Comparator|MAD Cohort C - Placebo|MAD in Patients with T2DM
88998890|NCT05557162|Experimental|Notification of the AI ECG algorithm and the A3E scores|Provider-facing recommendation report that alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders
88998891|NCT05557162|No Intervention|Usual Care|No alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders
88998892|NCT05542251|Experimental|Parent Educational Program|Caregivers of children with gross motor delays who are randomized to receive an educational intervention delivered through social media.
88998893|NCT05542251|No Intervention|Control Group|Caregivers of children with gross motor delays who are randomized to the waitlist control group who will receive an educational intervention delivered through social media after a 9 week waiting period.
88998894|NCT05517408|Experimental|Ciprofol group|
88998895|NCT05514431||Dural puncture epidural (DPE)|Subjects that received neuraxial labor analgesia of dural puncture epidural for intrapartum cesarean delivery
88998896|NCT05514431||Combined spinal epidural (CSE)|Subjects that received neuraxial labor analgesia of combined spinal epidural for intrapartum cesarean delivery
88998897|NCT05514431||Traditional Epidural|Subjects that received neuraxial labor analgesia of epidural for intrapartum cesarean delivery
88998898|NCT05511480|Experimental|Interference on sequence 1|The interference intervention (session six) will be applied to one of the two previously learned sequences (temporal).
88998899|NCT05511480|Experimental|Interference on sequence 2|The interference intervention (session six) will be applied to one of the two previously learned sequences (spatial).
88998900|NCT05511480|Experimental|Interference on sequences 1 and 2|The interference intervention (session six) will be applied to both of the two previously learned sequences (temporal and spatial).
88998901|NCT05511480|Sham Comparator|No interference|The interference intervention (session six) will be applied.
88998902|NCT05504837|Experimental|Cohort 1 (open label)|A single administration of KB407
88998903|NCT05504837|Experimental|Cohort 2 (open label)|Two administrations of KB407
88998904|NCT05504837|Experimental|Cohort 3 (open label)|Four administrations of KB407
89687499|NCT01831973|Experimental|Lipotecan, injection for chemotherapy|Patients receive TLC388 (50 mg/m2) given as a 30-minute IV infusion, on Days 1, 8, and 15 of a 28-day cycle.
88998905|NCT05473637||Genetic group|Patients who have positive DNA results by NGS screening of the following 5 genes: NOTCH3 (19q13.12), HTRA1 (10q26.13), GLA (Xq22.1), TREX1 (3p1.31) and COL4A1 (13q34).
88998906|NCT05473637||Nongenetic group|Patients who have negative DNA results by NGS screening .
88998907|NCT05473312|Experimental|Intervention|"Community Sensitization~28-day behaviour practice (Positive Deviance (PD) /Hearth sessions plus home practice)~Supplemental Print Information"
88998908|NCT05473312|No Intervention|Control|Control households will continue with usual practices.
88998909|NCT05470699|Experimental|Diagnostic ([18F]-DCFPyL PET-CT, X1 RMRS PET-CT)|Patients receive [18F]-DCFPyL IV and undergo [18F]-DCFPyL PET-CT over 30 minutes per SOC. Patients with PET avid lesions then undergo a X1 RMRS PET-CT imaging-only session within 120 minutes of injection over 20-35 minutes.
88998910|NCT05458453|Experimental|Esketamine arm|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ e sketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
88998911|NCT05458453|No Intervention|Sufentanil arm|Continuous pumping with self-controlled intravenous analgesia pump. According to sufentanil 1.5ug/ml+16mg ondansetron. At the end of the operation, connect the analgesic pump, and pump it with sufentanil at 0.1ug/kg/h for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
88998912|NCT05450549|Experimental|DNL919 (Healthy Participant)|
88998913|NCT05450549|Placebo Comparator|Placebo (Healthy Participant)|
88998914|NCT05438979|Placebo Comparator|Placebo|The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.
88998915|NCT05438979|Active Comparator|Calcium Fructoborate|Calcium Fructoborate (CFB), is a proprietary, safe generally-recognized-as-safe (GRAS) supplement. The only content of the supplement is CFB - there are no excipients, binders, or flow agents, nor are there any other materials. 216mg of CFB will be administered daily for 90 days.
88998916|NCT05390385|Placebo Comparator|Control placebo|
88998917|NCT05390385|Experimental|KE1 5g|
88998918|NCT05390385|Experimental|KE1 10g|
88998919|NCT05390385|Experimental|KE4 5g|
89687500|NCT02785354||NOAC|New oral anticoagulant groups
89687501|NCT02785354||VKA|VKA group
89687502|NCT03213821|Experimental|high protein intake|Study participants will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg Ideal Body Weight)
89687503|NCT03213821|Active Comparator|GFR based protein intake|Study participants will receive GFR based protein diet to preserve renal function.
89217011|NCT00168103|Experimental|C1-INH 20 U/kg bw|20 U/kg bw dose
89217012|NCT00168103|Placebo Comparator|Placebo|
89687504|NCT01832051|Experimental|HER2-PET|Injection of 89Zr-trastuzumab followed by PET scan
89687505|NCT02785432|Sham Comparator|Sham low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 0 watts for a total of 0 joules based on body surface area treated. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Area for administration will include 6 minutes of application along spine (C2-S1), and 4 minutes of application either to bilateral upper extremity or bilateral lower extremity based on areas of primary pain complaint. The contact head applicator will be used if soft tissue contact is tolerable. Otherwise, the non-contact head will be utilized.
89687506|NCT02785432|Active Comparator|Active low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 15-25 watts for a total of 9,000-15,000 joules based on body surface area treated. This equates to standard acceptable dosing of 6-10 j/cm2 over the larger area of treatment. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Areas for administration and contact will otherwise be consistent with the sham group.
89687507|NCT01832129|Active Comparator|i.m. injection of Vitamin B12|Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks.
89687508|NCT01832129|Experimental|Oral administration of vitamin B12|High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring.
89687509|NCT02786134|Experimental|low-dose methotrexate (LDM)|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
89687510|NCT02786134|Experimental|placebo|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
88998920|NCT05390385|Experimental|KE4 10g|
88998921|NCT05379803|Experimental|Furmonertinib|furmonertinib 160 mg orally QD
88998922|NCT05368844|Experimental|Active iTBS|rTMS treatments will employ the Brainsway stimulator (Brainsway Ltd, Israel). Prior to the first treatment (no more than 5 days prior), each subject's motor threshold (MT) will first be determined according to published methods (Schutter, van Honk, 2006; Julkunen et al, 2009). This location, as well as the stimulation target spot, will be marked at the first session on the scalp and standard methods will be used to target this spot during treatment sessions. The modified BeamF3 scalp heuristic will be used to localize the treatment site over the left DLPFC (Mir-Moghtadaei et al., 2015). Subjects will complete 5 treatments days. A treatment day will consist of 10 treatment sessions with the start of each session timed to be at least 50 minutes from the previous session.
88998923|NCT05368844|Sham Comparator|Sham iTBS|The BrainsWay Model 104 with H4 coil has an integrated sham coil. The sham condition will start with the same clicking noise as the active TMS condition. Every helmet has a corresponding sham H-coil encased in the same helmet. The sham coil induces only a negligible sub-threshold field in the brain while making an identical noise and inducing some scalp sensation. Subjects will complete 5 treatments days. A treatment day will consist of 10 treatment sessions with the start of each session timed to be at least 50 minutes from the previous session. Subjects in this arm will have the option of receiving the Active iTBS protocol after they complete the 5 days of 10 daily treatment sessions.
88998924|NCT05365451|Experimental|Arm 1A: metformin alone (baseline)|Arm 1A will consist of administration of a single dose of metformin (50 mg) by mouth as a liquid to 16 subjects (8 males, 8 females). Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 2A and 2B. A washout of at least 7 days will occur between Arm 1A and Arm 1B.
88998925|NCT05365451|Experimental|Arm 1B: metformin + cimetidine|Arm 1B will consist of administration of a single oral dose of cimetidine (400 mg) with water by mouth. One hour later, metformin (50 mg) will be administered by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 2A and 2B. A washout of at least 7 days will occur between Arm 1B and Arm 2A.
88998926|NCT05365451|Experimental|Arm 2A: furosemide alone (baseline)|Arm 2A will consist of administration of a single dose of furosemide (5 mg) by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. A washout of at least 7 days will occur between Arm 2A and Arm 2B.
88998927|NCT05365451|Experimental|Arm 2B: furosemide + probenecid|Arm 2B will consist of administration of a single oral dose of probenecid (1,000 mg) with water by mouth. One hour later, furosemide (5 mg) will be administered by mouth as a liquid. Plasma and urine will be collected from 0-24 hours. Participants may or may not elect to participate in Arms 1A and 1B. A washout of at least 7 days will occur between Arm 2B and Arm 1A.
88998928|NCT05364671|Experimental|Raphamin|Tablet for oral use.
88998929|NCT05364671|Placebo Comparator|Placebo|Tablet for oral use.
88998930|NCT05342064|No Intervention|Standard of care|No intervention will be administered. Observational data regarding TPT uptake and adherence will be captured on all participants presenting for care
88998931|NCT05342064|Experimental|TB screening and evaluation followed by TPT via a decentralized delivery system|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
88998932|NCT05309603|Active Comparator|Unloaded Walking|Walking on a treadmill without wearing a pack
88998933|NCT05309603|Experimental|Loaded Walking High|Walking on a treadmill while wearing a 30% body mass load with the weight placed at the high-back
89054874|NCT04558944|No Intervention|Control group|This group received pain and pruritus medication as needed, received the usual physical therapy as per the protocol of our burn unit, as well as compression garments, silicone sheets and gels and moisturizing cream twice a day. Additionally, the patients were advice on reducing sun exposure and applying +50SPF sunblock on a daily basis.
89054875|NCT04558944|Experimental|Extracorporeal Shock Wave Therapy group|This group received the same treatment as the control group plus Extracorporeal Shock Wave Therapy (The DermaPACE® System, SANUWAVE Health Inc., USA) with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
89054876|NCT04562727|Experimental|Only MWA|Only preform MWA, chemotherapy isn't necessary
89054877|NCT04562727|Active Comparator|MWA combined with perioperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed before MWA and after MWA
89054878|NCT04562727|Experimental|MWA combined with postoperative chemotherapy|MWA combined with perioperative chemotherapy. Chemotherapy was preformed after MWA
89054879|NCT00171704|Experimental|Letrozole|2.5 mg once daily (q.d.)orally for 5 years
89054880|NCT00171704|Experimental|Tam-Let|20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.
89054881|NCT02211963|Experimental|BI 44847|
89054882|NCT02211963|Placebo Comparator|Placebo|
89054883|NCT00171314|Experimental|Upfront Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
89054884|NCT00171314|Experimental|Delayed Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
89054885|NCT04562259||patients with Kimmerle's anomaly|patients who have a complete or incomplete bony bridge over the posterior arch of the first cervical vertebra
89054886|NCT04571918|Experimental|Group A: Biodegradable spacer|Intervention group
89054887|NCT04571918|Active Comparator|Group B: control group|Control group
89054888|NCT04562454|Experimental|Normal group|Specific diet with CGM for 5days
89054889|NCT04562454|Experimental|T1DM group|Specific diet with CGM for 5days
89054890|NCT04562454|Experimental|T2DM group|Specific diet with CGM for 5days
89054891|NCT04562454|Experimental|other type of diabetes group|Specific diet with CGM for 5days
89054892|NCT04562337|Experimental|SHR1316+Chemotherapy +Radiotherapy|Paiticipant receive SHR-1316 、Chemotherapy and Radiotherapy
89054893|NCT00171158|Experimental|Imatinib Mesylate (STI571)|Participants initially received STI571 capsules or tablets, orally, initially once daily (400 mg) or (600 mg). The dosage was escalated from 400 mg to 600 mg and from 600 mg to 800 mg, on an individual basis as per the investigator's judgement. Treatment continued until death, or the development of intolerable toxicity, or the participant was considered not to benefit from treatment, whichever came first.
89054894|NCT04562415|Active Comparator|Active rTMS group|chronic ischemic stroke patients receiving active low frequency repetitive transcranial magnetic stimulation therapy and physical therapy
89054895|NCT04562415|Active Comparator|Active cTBS group|chronic ischemic stroke patients receiving active continuous theta burst stimulation therapy and physical therapy
89054896|NCT04562415|Sham Comparator|Sham cTBS group|chronic ischemic stroke patients receiving sham continuous theta burst stimulation therapy and physical therapy
89054897|NCT00170846|Active Comparator|Group A: No RAD|Calcineurin Inhibitors (CNI) ± Mycophenolate Acid (MPA)/Azathioprine (AZA) ± Steroids
89054898|NCT00170846|Experimental|Group B : CNI Withdrawal|Initiation of everolimus (8-12 ng/mL) with discontinuation of CNI. Everolimus(RAD001) 4 mg initial daily dose.
89054899|NCT00170846|Experimental|Group C: CNI Reduction|Initiation of everolimus (3-8 ng/mL) with reduction by 70-90% in CNI blood levels. Everolimus (RAD001) 3 mg initial daily dose.
89054900|NCT04562025|Experimental|UC-MSCs treatment group|"Conventional treatment plus UC-MSCs:~Participants will receive conventional treatment plus 3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL intravenously at week 1, week 2，week3)."
89054901|NCT04562025|Placebo Comparator|Placebo control group|"Conventional treatment plus Placebo:~Without UC-MSCs therapy but conventional treatment should be received. Participants will receive conventional treatment plus 3 times of Placebo intravenously at week 1, week 2，week3."
89054902|NCT04562103|Experimental|Epinephrine QLB|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
89217013|NCT04011228||Type 2 diabetic patients|
89687511|NCT02903446|Active Comparator|Intervention|Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care
89687512|NCT02903446|No Intervention|Control|Standard urate lowering therapy
89687513|NCT01832285|Experimental|Fluvoxamine|Tablets of Fluvoxamine in dosage 100mg/day will be added to the treatment regimen and continued for 6 weeks
89687514|NCT01832363|Experimental|HXe MRI guided treatment sequence for BT|Patients in this arm will undergo bronchial thermoplasty treatment where the first session of the procedure will target the six most problematic airways as determined with HXe imaging. Patients will have the remaining of the airways treated in the two subsequent sessions.
89687515|NCT01832363|Active Comparator|Standard treatment sequence for BT (control)|Patients in this arm will undergo standard treatment sequence of bronchial thermoplasty. To preserve the blind of the procedure to the subjects, the same timeline and clinical measures will be followed as for HXe guided patients.
89687516|NCT02903836|Experimental|Nafithromycin 800 mg 3 days|PO q24h for 3 days; subjects will receive matching placebo , to maintain the blind
89687517|NCT02903836|Experimental|Nafithromycin 800 mg 5 days|PO q24h for 5 days; subjects will receive matching placebo, to maintain the blind
89687518|NCT02903836|Active Comparator|Moxifloxacin 400 mg|PO q24h for 7 days;subjects will also receive two nafithromycin placebo tablets PO q24h on Days 1 through Day 7 to maintain the blind
89687519|NCT01832441|Other|Transfer of autologous MNC intrathecally|single arm Intra thecal transplantation of autologous MNC
89687520|NCT01832519||CF group|Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
89054903|NCT04562103|Active Comparator|Plane QLB|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
89054904|NCT02278380|Other|Arm 1|"To compare the Glycemic Index value of seven test foods:~Low GI standard Breakfast Medium GI standard Breakfast Nutritional pregnant milk supplement Nutritional product for diabetics Pregnant and lactation women milk powder Nutritional drinks for diabetics Test product"
89054905|NCT04561635|Experimental|Intervention group|The intervention group was supplemented with three sachets of MMS each week for every other day for a period of 12 months. Each sachet containing 1 g consisting of ten vitamins and five minerals. It was to be sprinkled over a cooked meal or dissolved in a drink for the child. Written instruction for using and storing the MMS in simple language with visuals was given prior to the supplementation. The intervention group also received health and nutrition advice at 3, 6 and 9 months after supplementation begins.
89054906|NCT04561635|No Intervention|Control group|The control group received health and nutrition advice that were similar to intervention group and delivered by the investigator at 3, 6 and 9 months after the study began.
89054907|NCT00471302||1|Healthy adults in a malaria endemic area in Mali
89054908|NCT04561674|Experimental|Experimental Group|"The patients in the experimental group participated in Web-Based Patient Education with Colostomy and Ileostomy on computer between the third and seventh days after surgery.~The cards with the website address, username and the website QR code were given to the patients in order to be able to receive education after discharge.The patient and her family received the training from any computer or smartphone connected to the internet."
89054909|NCT04561674|No Intervention|Control group|The clinical routine was applied to the control group.
89054910|NCT00479882|Experimental|Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg|After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.
89054911|NCT00479882|Experimental|Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.
89054912|NCT00479882|Experimental|Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg|After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.
89054913|NCT00479882|Experimental|Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.
89054914|NCT00479765|Experimental|1|OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
89054915|NCT04558242|Active Comparator|Genix LLLT Therapeutic Cap|This is a low-level light device containing 150, 650 nanometer LEDs and 50, 940 nanometer LEDs of equal energy output, fixed at 10 milliwatts in a low profile helmet.
89054916|NCT04558242|Sham Comparator|Sham Non-therapeutic Placebo Cap|Sham Placebo Cap low profile helmet containing no low-level light.
89054917|NCT00479687|Active Comparator|Supartz|SUPARTZ® 3 injections over 2 weeks
89054918|NCT00479687|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline 3 injections over 2 weeks
89054919|NCT02212002||Control|Control group: infants born to GBS-negative mothers, who thus did not receive any antibiotic treatment before/at delivery.
89054920|NCT02212002||IAP|IAP group: infants born to GBS-positive mothers who have received adequate intrapartum antibiotic prophylaxis (IAP). According to the Institutional treatment protocol for GBS prophylaxis (derived from CDC guidelines), intravenous ampicillin is given every 4 hours until delivery (first dose 2 g, following doses 1 g each). IAP is considered adequate when the mother received at least two doses of ampicillin before delivery.
89054921|NCT02212080|Experimental|BAY1214784|Dose 1 to 7 of BAY1214784
89054922|NCT02212080|Placebo Comparator|Placebo|Placebo Dose 1 to 7 of BAY1214784
89054923|NCT00479336|Placebo Comparator|1|
89054924|NCT00479336|Experimental|2|
89054925|NCT00479336|Experimental|3|
89054926|NCT00479336|Experimental|4|
89054927|NCT02212158|Experimental|motivational interviewing group|"Motivational Group Intervention:~Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies."
89054928|NCT00478244|Experimental|Epidermolysis Bullosa (EB) Patients|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant.
89054929|NCT02212236|Experimental|Psychological preparation + TAU|TAU=treatment as usual
89054930|NCT02212236|No Intervention|Treatment as usual|Usual care including medication, nursing, and psychologist support.
89054931|NCT00478205|Experimental|1|
89054932|NCT00478205|Experimental|2|
89217014|NCT04011228||Prediabetic patients|
89217015|NCT04011228||Women with gestational diabetes|
89054933|NCT00477971|Active Comparator|Arm A|"Patients receive low-dose melphalan IV over 15-30 minutes on day~1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses.~Study treatment beyond one year is not allowed."
89217016|NCT04011228||Healthy control subjects|
89217017|NCT04011228||Pregnant women without gestational diabetes|
89217018|NCT00463060|Experimental|Treatment|Participants treated with chemotherapy and radiotherapy
89217019|NCT00956748|Active Comparator|Ciprodex otic solution|ciprofloxacin 0.3% / dexamethasone 0.1% otic solution
89217020|NCT00956748|Experimental|Ciprodex with 2% NAC|Ciprodex otic solution (ciprofloxacin 0.3% / dexamethasone 0.1%) augmented with 2% N-acetylcysteine
89217021|NCT00710333|Placebo Comparator|1|500ng dose
89217022|NCT00710333|Experimental|2|
89217023|NCT01079923|Active Comparator|Single High Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects .
89217024|NCT01079923|Active Comparator|Daily Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects.
89217025|NCT00947076|Experimental|1|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
89217026|NCT00947076|Active Comparator|2|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
89217027|NCT00462982|Experimental|Sunitinib|Patients will be treated with 50 mg daily for four out of every six weeks.
89217028|NCT02573597|Active Comparator|Part A Group 1|CEI bupivacaine and CEI sufentanil
89217029|NCT02573597|Active Comparator|Part A Group 2|PIEB bupivacaine and PIEB sufentanil
89217030|NCT02573597|Active Comparator|Part B Group 3|CEI bupivacaine and PIEB sufentanil
89217031|NCT02573597|Active Comparator|Part B Group 4|PIEB bupivacaine and CEI sufentanil
89217032|NCT05300958|Experimental|Treatment arm|Deferoxamine：50mg/kg+500ml normal saline (NS) plus chemotherapy
89217033|NCT00951210|Experimental|PLX-PAD low dose|IM injection Single treatment; multiple injections
89217034|NCT00951210|Experimental|PLX-PAD high dose|IM injection Double treatment; multiple injections
89217035|NCT04070729|Placebo Comparator|Negative control|Placebo gel
89217036|NCT04070729|Experimental|Test group 1|Hyaluronic acid gel
89217037|NCT04070729|Experimental|Test group 2|injectable prf
89217038|NCT00951288|Active Comparator|Saffron|Crocus Sativus extract
89217039|NCT00951288|Placebo Comparator|Placebo|Placebo comparator
89217040|NCT00462904|Experimental|BPI infusion group|BPI will be infused by bolus for 30 minutes followed by continuous infusion for 47.5 hours
89217041|NCT00710411||A, 2|Polytraumatized patients with ISS > 18 and healthy controls
89217042|NCT00956826|Experimental|Electrode added to device|With an electrode and a regular vacuum device
89217043|NCT00709397||Observation|antiretroviral-experienced patients requiring raltegravir to construct an adequately potent antiretroviral regimen.
89217044|NCT00467272|Experimental|Daptomycin|Daptomycin 6 mg/kg intravenous (IV) every 24 hours for at least 7-14 days, depending on the type of bacteria.
89217045|NCT00956904|Experimental|3-D TRUS navigation software during T-RALP|
89687521|NCT01832519||Non-CF Control|1 chest MRI with contrast and blood for proteomics and metabolomics
89687522|NCT03213431||IQ of <90 and ≥40|Patient-Reported Outcomes (PRO) will be evaluated in a group of 30 childhood cancer survivors with global neurocognitive impairment classified by IQ of <90 and ≥40 and 30 of their parents.
89687523|NCT03213431||IQ of ≥90|Patient-Reported Outcomes (PRO) will be evaluated in a group of 10 childhood cancer survivors with global neurocognitive unimpairment classified by IQ of ≥90 and 10 of their parents.
89687524|NCT00014911|Experimental|Islet Transplantation|All study participants
89687525|NCT01832675|Active Comparator|Bupivacaine lozenge|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
89687526|NCT01832675|Active Comparator|Xylocain, cutaneous spray, solution|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
89687527|NCT03213587|Experimental|apatinib|
89687528|NCT03219983|Active Comparator|Interscalene Block|Ultrasound guided interscalene catheter will be placed and a 30 ml .5% ropivacaine will be given pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
89687529|NCT03219983|Active Comparator|Deep soft tissue/surgical site injection|A total volume of 100ml will be comprised of 60ml of 0.9% normal saline + 20ml 0.5% bupivacaine + 20ml liposomal bupivacaine will be injected into the deep soft tissue using an 18 or 20 gauge needle prior to or after prosthesis insertion
89687530|NCT03219905|Experimental|Kinesio-taping Group|Therapeutic Kinesio-taping
89687531|NCT03219905|Sham Comparator|Control Group|Sham Kinesio-taping
89687532|NCT03219749|Experimental|Exercise Intervention|Exercise training will take place three times per week for six weeks and involve both aerobic and resistance exercise.
89687533|NCT02240017|Active Comparator|Carboplatin/Gemcitabine|
89687534|NCT02240017|Experimental|Fractionated Cisplatin/Gemcitabine|
89687535|NCT00899717|Experimental|A|
89687536|NCT00899717|Placebo Comparator|B|
89687537|NCT04374955|Experimental|İnfantile colic|Mothers of babies diagnosed with infantile colic in the intervention group will receive routine care and start taking probiotic products after the first stool of the babies and blood is taken for intestinal permeability and will continue for 15 days.
89687538|NCT04374955|Other|Control|Mothers of babies diagnosed with infantile colic in the control group will receive routine care for 15 days after blood is taken for the first stool and intestinal permeability of the babies.
89217046|NCT00714857|Experimental|1|Patients receiving dexmedetomidine sedation
89217047|NCT00957060|Experimental|glimepiride|The initial dose is 2 mg once a day. At week 2, the dose can be increased to 4 mg once a day according to the titration. At week 4 and 12, the dose can be increased from 2 mg to 4 mg or from 4 mg to 6 mg according to the titration.
89217048|NCT00957060|Active Comparator|sitagliptin|100 mg once a day. The dose will not be titrated.
89687539|NCT03219593|Experimental|Apatinib Group|take apatinib orally (500mg/d, once a day, continuously)
89687540|NCT02240095|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, students will be offered all 3 online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
89687541|NCT02240095|Experimental|Interventions A + B|"See Interventions Description. In this arm, students will be offered the 2 following interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach"
89687542|NCT02240095|Experimental|Interventions A + C|"In this arm, students will be offered the 2 following online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention C - Online Audit and Feedback"
89687543|NCT02240095|Experimental|Interventions B + C|"See Interventions Description. In this arm, students will be offered the 2 following online interventions combined:~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
89687544|NCT02240095|Experimental|Intervention A alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention A - Online Clinical Questions Recorder"
89687545|NCT02240095|Experimental|Intervention B alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention B - Online Evidence Retrieval Coach"
89687546|NCT02240095|Experimental|Intervention C alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention C - Online Audit and Feedback"
89687547|NCT02240095|No Intervention|No intervention|In this arm, students will be offered none of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
89687548|NCT03836807|Experimental|Ketoprofen|Single oral administration of Ketoprofen lysine salt 40 mg granules
89687549|NCT03836807|Placebo Comparator|Placebo|Single oral administration of placebo granules
89687550|NCT03404713|Active Comparator|Standard Behavioral Weight Loss (BWL) Treatment|All participants will participate in 4 weeks of group based behavioral weight lost treatment in the intervention called Pathways to Health. Based on early treatment response (improvement in binge eating), participants will be assigned to either continue in this arm for the remaining 12 weeks of treatment (early strong responders) or be assigned to the 2nd arm of this study.
89687551|NCT03404713|Experimental|Acceptance-Based Binge Eating Treatment|After 4 weeks of standard BWL treatment, early weak responders will be assigned to individual acceptance-based treatment for the remaining 12 weeks of treatment.
89687552|NCT03213197|Experimental|CPR video|Patient watches a short CPR video
89687553|NCT01832831||Continent Men|
89687554|NCT01832831||Incontinent Men|
89687555|NCT02240173|Experimental|Jobelyn + Haloperidol|Combination of the conventional drugs and Jobelyn
89687556|NCT02240173|Active Comparator|Haloperidol + Placebo|Combination of the conventional drug + Placebo
89687557|NCT01832909|Experimental|Walnut Diet first, then Control Diet|Controlled diet with 1.5 oz/d of walnuts, followed by controlled diet without walnuts.
89687558|NCT01832909|Experimental|Control Diet first, then Walnut Diet|Controlled diet without almonds first (control), then controlled diet with 1.5 oz/d of almonds.
89687559|NCT02240641||hypertension treatment strategies|
89687560|NCT03219671|Experimental|nivolumab plus ipilimumab|nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
89687561|NCT03404635||Apixaban for VTE|
89687562|NCT03404635||Rivaroxaban for VTE|
89687563|NCT03404557||Crohn's Disease patients group|44 patients
89687564|NCT03404557||Ulcerative Colitis patients group|22 patients
89687565|NCT03404557||Healthy volunteers group|22 patients
89687566|NCT01832987|Experimental|co-trimoxazole|On 4, 5 or 6 consecutive days, 960 mg co-trimoxazole (oral) will be added to the normal treatment of tuberculosis.
89687567|NCT03404479|Experimental|Co-administration group|Co-administration of Diacerein 50mg, Celecoxib 100mg.
89687568|NCT03404479|Active Comparator|Single administration group 1|Single administration of Diacerein 50mg and placebo.
89687569|NCT03404479|Active Comparator|Single administration group 2|Single administration of Celecoxib 100mg and placebo.
89687570|NCT03837665|Experimental|PRP Treatment|Participants receive platelet rich plasma treatment. Participants will be asked to make up to 5 trips to the clinic (one for eligibility, one for the PRP, three follow-up visits). Participation is expected to last up to about 6 weeks. After the second visit and application of PRP, patients will be monitored closely for any complications or concerns. This will include a follow up phone call 3-5 days after the initial application of PRP. Patients will also be followed closely in 2 week intervals or sooner should any problems or concerns arise.
89687571|NCT03219203|Experimental|Arm A: Single dose hepatitis B vaccine|Single dose of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at entry
89687572|NCT03219203|Active Comparator|Arm B: 3-dose series of hepatitis B vaccine|3-dose series of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at month 0, 1, and 6
89687573|NCT04374643||Confined patients|General population
89687574|NCT04374487|Experimental|Test Arm|50 subjects will be randomized in this arm. Patients in the test group will receive convalescent plasma.
89687575|NCT04374487|Other|Control Arm|50 subjects will be randomized in this arm and will be treated according to the standard care. The Ministry of Health and Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity. For the management of ARDS or sepsis, the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented.
89687576|NCT04380467|Experimental|Vitamin D Group|Six doses of cholecalciferol 100,000units (5x aviticol 20,000units capsules) administered monthly over 20 weeks.
89687577|NCT04380467|No Intervention|Control|No vitamin D given
89687578|NCT03218735|Experimental|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
89687579|NCT03218735|Active Comparator|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
89687580|NCT04374409|Experimental|High-flavanol Cocoa powder|Dietary supplement: single serving of a high-flavanol cocoa powder containing 150 mg of (-)-epicatechin and 35.5 mg of (+)-catechin
89687581|NCT04374409|Active Comparator|Low-flavanol Cocoa powder|Dietary supplement: single serving of a low-flavanol cocoa powder intervention containing < 4 mg of (-)-epicatechin and (+)-catechin and matched as best as possible for macronutrients and micronutrients, such as caffeine and theobromine.
89054934|NCT00477971|Experimental|Arm B|Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
89687582|NCT03218579|No Intervention|No intervention|No intervention after antibiotic treatment.
89687583|NCT03218579|Active Comparator|Probiotic microbiome rehabilitation|Probiotic treatment after antibiotic treatment.
89054935|NCT04558086|Experimental|Reduce pain and fear|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
89054936|NCT04558086|Experimental|control group|To develop the intervention strategies of hospitalized school-age children with IV placement, using photo book to further examine the effectiveness of reducing IV pain and fear.
89054937|NCT00477464|Experimental|Lapatinib+capecitabine|Lapatinib 1250mg once daily +capecitabine 2000mg/m^2 twice daily (14 days out of 21 days)
89054938|NCT02212275|Experimental|Dextromethorphan in ASD|8-12 years old: > 30 boys will be recruited who have a known or suspected diagnosis of ASD confirmed by DSM-5 checklist and the ADOS-2 at screening. They will have the cortical metric measured 20 min prior to receiving DXM and 2 hours after receiving a single age and weight appropriate dose of DXM. The outcome reported is the difference in the cortical metric after the DXM dose and before the DXM dose.
89054939|NCT02212275|Active Comparator|Dextromethorphan in controls|30 typically developing boys 8-12 years old who have the cortical metric measured 20 min before receiving a single age and weight appropriate dose of DXM and 2 hours after the single dose of DXM. The reported value will be the difference between the cortical metric 2hrs after the single dose of DXM and the cortical metric 20 minutes prior to the single dose of DXM.
89054940|NCT04558008|Experimental|Online MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
89054941|NCT04558008|No Intervention|Wait-list control|Usual practice
89054942|NCT04557774||Liver cirrhosis group|All included patients were asymptomatic at the baseline with no evidence of neurological impairment. Patients with a history of moderate alcohol drinking plus hepatitis B/C virus infection, medication for sedation, MELD (Model for End-stage Liver Disease) score of more than 20, OHE, seizure, head trauma, stroke, dementia, Parkinson's disease, or any kind of focal neurologic deficits were excluded. Any patients who were suspected of alcohol induced direct neurologic damages such as Wernicke's encephalopathy, alcohol induced spinal cord disease, or alcohol induced peripheral nerve disease were excluded. After evaluating the data including the laboratory findings, image findings, endoscopic findings, and medical records of all these patients, as well as liver biopsy findings for some patients, we sub-classified these 88 patients into two groups: alcoholic LC and viral LC. Finally, 80 patients (viral: 37; alcohol: 43) with compensated LC were prospectively considered in this study.
89054943|NCT00477386|Experimental|Carboplatin combined with Decitabine|Decitabine at escalating dose levels will be given X 5 days followed by Carboplatin given on Day 8.
89054944|NCT02212314|Experimental|Response Inhibition Training|Treatment group will receive immediate treatment after pre-test.
89687584|NCT03218579|Active Comparator|Bacteriotherapy microbiome rehabilitation|Bacteriotherapy after antibiotic treatment.
89054945|NCT02212314|No Intervention|Waitlist Crossover|Waitlist group will not receive intervention while treatment group is active, but waitlist group will be offered treatment after post-test is completed.
89054946|NCT00477269|Experimental|STI571|STI571
89054947|NCT00477269|Placebo Comparator|Placebo|Placebo
89054948|NCT00477269|Experimental|All Patients|Open label extension
89054949|NCT04557852||Anterior transvaginal mesh group|Women received anterior transvaginal mesh surgery without concomitant mid-urethral sling surgery.
89054950|NCT00477152|Experimental|HYLENEX-augmented subcutaneous (SC ) rehydration|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
89687585|NCT04374331|Experimental|Video-Assisted Training Group|The patients in the VAT group watch a training video in the patient rooms before RCR in addition to the routine treatment and care in the unit.
89687586|NCT04374331|No Intervention|control group|The control group received the routine treatment and care in the unit. The routine treatment and care of the unit includes verbal briefing by physicians and nurses about the surgical procedure before RCR, cold application and analgesic application for pain control after RCR, using arm sling, verbal discharge training (e.g., drug use, exercises, follow-up time, etc.) and discharge on the first post-operative day in the absence of complications. In addition, patients are invited to weekly controls to explain how to do the exercises and, if necessary, they are referred to physiotherapy.
89687587|NCT03218657|Experimental|experimental group|the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
89054951|NCT04557345||Biological prostheses INC|"Prosthetic valve manufactured in the National Institute of Cardiology Ignacio Chávez."
89054952|NCT04557345||Imported Biological aortic prostheses|St Jude EPIC and Carpentier-Edwards Perimount
89054953|NCT04557345||Mechanical prostheses|St Jude Masters HP, Carbomedics Standart, ON-X Life Technologies, Edwards Mira, Carbomedics Orbis, Medtronic Hall and Medtronic ATS.
89054954|NCT04557345||Control|In subjects who come to donate blood products altruistically, in the blood bank service of the INC, with prior informed consent, the subjects will be matched with PO patients of CVA by age and gender.
89054955|NCT04557657|Experimental|Control Group Resin cement|Control group Using resin cement
89687588|NCT03218657|Other|control group|the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
89687589|NCT02240719|Experimental|Everolimus + Bendamustine|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89687590|NCT01833299|Active Comparator|TACE group|Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
88998934|NCT05309603|Experimental|Loaded Walking Mid|Walking on a treadmill while wearing a 30% body mass load with the weight placed at the mid-back
89687591|NCT01833299|Experimental|TACE+sorafinib|TACE+sorafinib
88998935|NCT05296070|Experimental|Loncastuximab tesirine Cycles 1-6|Patients will be treated with loncastuximab tesirine for a total of 6 cycles on Day 1 (+/-3) of each 21 day (3 week) cycle. The total duration of treatment is approximately 18 weeks (4.5 months)
88998936|NCT05294146|Experimental|Loading dose Clofazimine|All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine (CFZ) once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.
88998937|NCT05293522|Experimental|NTX-001|Solution #1, Solution #2 Active, Solution #3
88998938|NCT05293522|No Intervention|Standard of Care|Standard neurorrhaphy
88998939|NCT05284591||DRd with daratumumab iv de novo|Patients either continue DRd with daratumumab iv, switch to daratumumab sc or switch multiple times iv/sc
88998940|NCT05284591||DRd with daratumumab sc de novo|Patients either continue DRd with daratumumab sc, switch to daratumumab iv or switch multiple times sc/iv
88998941|NCT05265611|Experimental|Young Adult Community Mental Health Worker|Syrian refugee young adults will be trained to implement Problem Management Plus (PM+): a WHO evidence-based low intensity mental health intervention to Syrian refugee adults in their community. They will complete 4 surveys to measure outcomes and mechanisms.
88998942|NCT05265611|Active Comparator|Young Adult Tutors|Syrian refugee young adults will be trained to tutor elementary school students in their community.They will complete 4 surveys to measure outcomes and mechanisms.
88998943|NCT05265611|No Intervention|Young Adut Control Group|Syrian refugee young adults in the control group will only complete the surveys. They will complete 4 surveys to measure outcomes and mechanisms.
88998944|NCT05263973|Experimental|Music group|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination.
88998945|NCT05263973|No Intervention|No intervention|The infants in the control group will not be subjected to any intervention other than their clinical routines, only observation will be made.
88998946|NCT05263154|Experimental|Goal directed low oxygen|Oxygen given at low concentrations following goals of oxygen saturation during and after anesthesia
88998947|NCT05263154|Active Comparator|High oxygen|Oxygen given as traditionally including high concentrations
88998948|NCT05245201|Active Comparator|Arm 1 - Standard of care|Standard of care
88998949|NCT05245201|Active Comparator|Arm 2 - Clinical decision support for PrEP|EHR-based decision support tools to support PrEP discussions and prescribing for patients who have increased predicted HIV risk
88998950|NCT05227638|Active Comparator|Schroth group|The Schroth group performed Schroth exercises
88998951|NCT05227638|Active Comparator|PNF group|"PNF group (PG) performed chop and lift exercises"
88998952|NCT05206734||Cases|All incident cases of Inflammatory Bowel Disease (IBD); comprising of Ulcerative Colitis, Crohn's Disease and IBD Unclassified in children, adolescents and young adults up to their 25th birthday. Cases will be defined based on an algorithm using diagnostic codes from the electronic medical record (EMR).
88998953|NCT05206734||Controls|People without a diagnosis in their electronic medical record (ERM) of Inflammatory Bowel Disease, matched on age group, sex, ethnicity (consistent with UK census categories: White, Asian, Black, Mixed, Other), index of multiple deprivation based on postcode, and by practice where numbers allow.
88998954|NCT05195073|Active Comparator|3 D laparoscopy group|salpingectomy will be performed by using Storz image 1 S 3D laparoscopy system (Karl Storz, Tuttlingen, Germany) which is comprised of a 10 mm scope with 2 full HD sensors at the tip of the scope and a 3 D control unit plus a 3 D display
88998955|NCT05195073|Active Comparator|2 D laparoscopy group|salpingectomy will be performed by using a conventional 2 D laparoscopy system.
88998956|NCT05174572|Other|IMR|IMR evaluation before and after Reducer implantation
88998957|NCT05152927|Experimental|Parathyroid Eye (PTeye)|For patients assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
88998958|NCT05152927|No Intervention|Usual Standard of Care|The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
89687592|NCT02240797||Anorexia Nervosa - Recovered (AN-REC)|Anorexia Nervosa - Recovered (AN-REC)
88998960|NCT05131204|Experimental|Pozelimab and Cemdisiran|Randomized 1:1
88998961|NCT05131204|Experimental|Anti-C5 standard-of-care|Randomized 1:1
88998962|NCT05128474|Experimental|Group 1|Neuromuscular Control-Based Exercise Training Group
88998963|NCT05128474|Active Comparator|Group 2|Conventional Exercise Training Group
89054956|NCT04557657|Active Comparator|Intervention Group Active Cement|Intervention Group Using active cement bio activa
89687593|NCT02240797||Healthy Control (HC)|Healthy Control (HC)
89687594|NCT01833377|Experimental|caraway sample|caraway sample
89687595|NCT01833377|Active Comparator|Placebo|
89687596|NCT03213041|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30-60 minutes on day 1 beginning with course 3. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
89687597|NCT02240875|Experimental|Group 1|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly
89687598|NCT02240875|Experimental|Group 1b|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
89687599|NCT02240875|Experimental|Group 1c|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
89687600|NCT02240875|Experimental|Group 2|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly
89687601|NCT02240875|Experimental|Group 2b|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
89687602|NCT02240875|Experimental|Group 2c|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
89687603|NCT02240875|Experimental|Group 3|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly
89054957|NCT00476996|Experimental|Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
88998964|NCT05121480|Experimental|Cohort 1|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 2 capsules (1.6 x 10^11 total cells) once daily for 16 weeks
88998965|NCT05121480|Experimental|Cohort 2|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 2 capsules (6.4 x 10^11 total cells) once daily for 16 weeks
88998966|NCT05121480|Experimental|Cohort 3|100 participants with mild, moderate or severe Atopic Dermatitis 75 participants on EDP1815 and 25 participants on matching placebo administered as 1 capsule (3.2 x 10^11 cells) twice daily (6.4 x 10^11 total cells) for 16 weeks
88998967|NCT05121480|Experimental|Cohort 4|105 participants with mild, moderate or severe Atopic Dermatitis 70 participants on EDP1815 and 35 participants on matching placebo administered at 1 capsule (8.0x10^10 total cells) once daily for 16 weeks
88998968|NCT05111756||Unit A|Staff at first phase units, receiving Braining, physical exercise
88998969|NCT05111756||Unit B|Staff at second phase units, receiving Braining, physical exercise
88998970|NCT05109819|No Intervention|Arm A: standard radiotherapy treatment|Patients in arm A will receive standard radiotherapy treatment for metastatic spinal cord compression.
88998971|NCT05109819|Experimental|Arm B: esophagus sparring radiotherapy treatment|Patients in arm B will receive esophagus sparring radiotherapy treatment.
88998972|NCT05106335|Experimental|Treatment Arm A|camrelizumab + famitinib
88998973|NCT05106335|Experimental|Treatment Arm C|famitinib
88998974|NCT05106335|Active Comparator|Treatment Arm B|docetaxel
88998975|NCT05102565|Experimental|Treatment group|6 weekly sleep education program
88998976|NCT05089825|Active Comparator|Receive routine instructions|Participants will receive routine instructions included in the myLAB Box Clinical Laboratory Improvement Amendments (CLIA) certified collection kit
88998977|NCT05089825|Active Comparator|Telehealth Visit|Participants will have a telehealth-based instructional visit and receive routine instructions included in the myLAB Box commercially available, CLIA certified collection kit
88998978|NCT05088317||Obese group|Volunteer female and male individuals aged 20-65 years, followed in an Internal Diseases unit of a state hospital in Turkey, diagnosed with obesity (BMI> 30 kg/m^2), who met the inclusion criteria of the study.
88998979|NCT05088317||Healthy group|Healthy male and female individuals between the ages of 20-65 who were not diagnosed with obesity and volunteered to participate in the study.
88998980|NCT05073705|No Intervention|Control Group|Control condition: The control condition will be standard of care. This will include regular review in the clinic for medical refills and adherence counseling that will be given in the clinic as required and determined by the attending clinicians and the counselors in the HIV clinic. The clinic visits will be guided by the clinical status, availability of school programs, distance from the clinic, and ability to afford transport fare to the clinic.
89054958|NCT00476996|Experimental|Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
88998981|NCT05073705|Experimental|Empowerment and personal transformation intervention|Intervention/Treatment: The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
88998982|NCT05073679|Experimental|Intervention|Oral naltrexone, to start as 25mg for three days then 50mg a day for 6 weeks. Oral naltrexone generic tabs will be blinded in opaque gelatin capsules with methylcellulose filler
88998983|NCT05073679|Placebo Comparator|Control|Opaque gelatin capsules with methylcellulose filler, taken by mouth once a day for six weeks
88998984|NCT05071976||Participants undergoing a pelvic or abdominal wall reconstruction procedure|Women undergoing a pelvic or abdominal wall reconstruction procedure after radical gynecologic surgery for any indication at Memorial Sloan Kettering Cancer Center
88998985|NCT05056506|Active Comparator|Endoscopic papillary large balloon dilation group|Endoscopic papillary large balloon dilation to extract bile duct stones
88998986|NCT05056506|Experimental|Endoscopic papillary Large balloon dilation combined with limited endoscopic sphincterotomy group|Endoscopic papillary large balloon dilation combined with limited endoscopic sphincterotomy to extract bile duct stones
88998987|NCT05036733|Experimental|Dupilumab|
88998988|NCT05031429|No Intervention|Control - Standard Care|"includes a minimum 12-hour feeding window for 7 days per week~no caloric restriction will be used~will wear a continuous glucose monitor"
88998989|NCT05031429|Experimental|Intervention - Time Limited Eating|"includes an 8-hour feed/16-hour fast for 7 days per week~will be instructed to consume all of their calories in the afternoon/evening period~can consume non-caloric beverages (water, tea, coffee) during the fasting period~will wear a continuous glucose monitor~no caloric restriction will be used"
88998990|NCT05027867|Experimental|Arm 1|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
88998991|NCT05027867|Experimental|Arm 2|KRT-232 180 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
88998992|NCT05025748|Experimental|Health services research (ASQ brochure)|Patients receive ASQ brochure and complete questionnaires over 30 minutes at baseline, over 10 minutes pre-clinic visit, and over 30 minutes post-clinic visit.
88998993|NCT05005234|Experimental|GFH925|"Phase Ia Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design.~Phase Ia Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently.~Phase Ib Subjects with KRAS G12C mutant advanced colorectal cancer or other tumors will be enrolled and treated at the monotherapy RP2D to evaluate the efficacy.~Phase 2 Subjects with KRAS G12C mutant advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy."
88998994|NCT04979793|Active Comparator|Placebo|Oral placebo, 3 grams milk powder sachet, taken once daily
88998995|NCT04979793|Experimental|Daily L-citrulline|L-citrulline, 3 grams L-citrulline sachet, taken once daily
88998996|NCT04969653||Cases|All adults with an episode of active atopic dermatitis at any point between 1st Jan 2010 to 1st Jan 2015 will be included for analysis.
88998997|NCT04969653||Controls|Adults without atopic dermatitis or other skin conditions matched to cases by age, gender, and duration of practice registration.
88998998|NCT04969419||Cases|Patients with a confirmed diagnosis of Vitiligo within the study period will be included as cases for analysis.
88998999|NCT04969419||Controls|The controls will be defined by matching cases with people who have never been diagnosed with vitiligo either prior to or during the study period, by age and sex, at General Practice level.
88999000|NCT04964986|Experimental|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
88999001|NCT04957251|Experimental|Anterior approach|Patient's undergoing an anterior approach to the hip
88999002|NCT04957251|Active Comparator|Posterior Approach|Patient's undergoing an posterior approach to the hip
88999003|NCT04956094||First Trimester Prenatal Visit|Women attending an initial first trimester prenatal visit who will be undergoing a standard blood draw.
88999004|NCT04929392|Experimental|Treatment (chemoradiation, pembrolizumab, lenvatinib)|"CHEMORADIATION PHASE: Patients receive carboplatin IV and paclitaxel IV QW for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT over 6 weeks and receive pembrolizumab IV over 30 minutes on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity.~WINDOW PERIOD: Patients receive pembrolizumab IV over 30 minutes on day 1 of week 3 and lenvatinib mesylate PO QD at weeks 3-6 in the absence of disease progression or unacceptable toxicity.~SURGERY/SURVEILLANCE: Patients without complete response undergo standard of care surgical resection. Patients with complete response/pursue non-operative management undergo surveillance via periodic endoscopic biopsy."
88999005|NCT04918771|Experimental|Raphamin|Tablet for oral use.
88999006|NCT04918771|Placebo Comparator|Placebo|Tablet for oral use.
88999007|NCT04876742|Experimental|0.5 liters of alcoholic beer|
88999008|NCT04876742|Placebo Comparator|0.5 liters of water|
88999009|NCT04876742|No Intervention|non-interventional cohort control group|
89687604|NCT02240875|Experimental|Group 3b|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
89687605|NCT02240875|Experimental|Group 3c|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
89687606|NCT02240875|Experimental|Group 4|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 7
89687607|NCT02240875|Experimental|Group 5|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 14
89687608|NCT02240875|Experimental|Group 6|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 7
89687609|NCT02240875|Experimental|Group 7|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 14
89687610|NCT01833611|Experimental|ETV group|Entecavir 0.5mg at first year; then open with entecavir 0.5mg qd for 2nd, 3rd year
89687611|NCT01833611|Placebo Comparator|Placebo group|Placebo at first year, then opne with entecavir 0.5mg qd for 2nd, 3rd year
89687612|NCT02240953|Active Comparator|Warfarin|In the first arm only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
89687613|NCT02240953|Active Comparator|Warfarin + ASA 100 mg + PPI|In the second arm 100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
89687614|NCT02240953|Active Comparator|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
89687615|NCT02240953|Active Comparator|Observational Warfarin|This arm is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
89687616|NCT03218813|No Intervention|Control cohort ('before' group)|Control cohort ('before' group): eligible patients will receive treatment as usual (TAU) and will complete all outcome measures.
88999010|NCT04867278|Experimental|External Beam Radiation (XRT) with Debridement|Patients will receive gluteus minimus debridement in the OR, which is the standard of care at Shock Trauma. If randomized to the treatment group, patients that undergo surgical fixation of an acetabular fracture via a posterior or combined anterior and posterior approach will undergo a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery. This treatment is currently the standard procedure performed for all patients who undergo a posterior or combined approach at our institution.
88999011|NCT04867278|Active Comparator|Debridement Alone (Control)|The control treatment arm will only include gluteus minimus debridement in the OR and will not receive XRT.
88999012|NCT04834505||Derivation sample|The patients conclusively diagnosed as FAIP or PC are retrospectively collected.
88999013|NCT04834505||Validation sample|The patients with difficulty in distinguishing between FAIP and PC are prospectively enrolled.
88999014|NCT04831294|Experimental|Cannabidiol (CBD)|A tincture containing 125mg broad spectrum CBD oil (6.7%), 24mg sunflower lecithin (1.3%), 56mg peppermint oil (3.0%), and 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
88999015|NCT04831294|Placebo Comparator|Placebo|A tincture containing 149mg sunflower lecithin (8.0%), 56mg peppermint oil (3.0%), 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
88999016|NCT04828694|Experimental|BICX104|BICX104 is an eroding implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously. It will be administered once for 84 days.
88999017|NCT04828694|Active Comparator|Vivitrol|Vivitrol intramuscular injection containing 380 mg of naltrexone. Three consecutive doses will be administered once every 28 days for 84 days.
88999018|NCT04820309|Experimental|KarXT|
88999019|NCT04810299|Experimental|Aromatherapy Massage Group|According to this Tisserand Institute guide chart, for a 2% dilution process, dilution will be provided with a total of 12 drops by adding 4:4:4 drops of lavender, Roman chamomile and ginger essential oils in 20 ml of sweet almond oil. Expert opinion was obtained from a phytotherapy and aromatherapy specialist physician that the oils and dilution rates used were appropriate. Foot massage will be applied on the 1st, 2nd and 3rd postoperative days. State Anxiety Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and after the application.Richard-Campbell Sleep Quality Scale will be applied before application Foot massage will be applied for 20 minutes.
88999020|NCT04810299|Experimental|Classical Foot Massage Group|Baby oil will be applied as massage oil to patients who are assigned to the classical foot massage group before the surgery. Foot massage will be applied for 20 minutes on the 1st,2nd and 3rd days. State Anxiety Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and after the application.Richard-Campbell Sleep Quality Scale will be applied before application
88999021|NCT04810299|No Intervention|Control Group|Except for routine care practices, no attempt will be made to the patients assigned to the pre-operative control group. State Anxiety Scale, Richard-Campbell Sleep Quality Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied on postoperative 1st, 2nd and 3rd days. The same scales will be re-evaluated 60 minutes after the first measurement. Richard-Campbell Sleep Quality Scale will be applied once
89687617|NCT03218813|Experimental|Intervention cohort ('after' group)|Eligible patients will receive the pharmacist-led intervention and will complete all outcome measures.
89687618|NCT03212729|Active Comparator|Control Group|CONVENTIONAL ENDODONTIC TREATMENT
89687619|NCT03212729|Experimental|Test Group|CONVENTIONAL ENDODONTIC TREATMENT ASSOCIATED WITH ANTIMICROBIAL PHOTODYNAMIC THERAPY
89687620|NCT03218501|Active Comparator|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
89687621|NCT03218501|Active Comparator|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
89687622|NCT03218501|Placebo Comparator|Placebo|Placebo is to be administered orally once daily for 2 weeks
89687623|NCT02241031|Experimental|MPs|MPs will be intravenously infused within 48 hours after chemotherapy. During the study period, patients can receive platelet infusion but can not receive platelet stimulating factors.
89054959|NCT00476996|Placebo Comparator|Placebo x 2 IV + Non-Biologic DMARD Therapy|Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
89054960|NCT04557267|Experimental|Group A (dosage A)|The lower dose of the active drug
89054961|NCT04557267|Experimental|Group B (dosage 2)|The middle dose of the active drug
89054962|NCT04557267|Experimental|Group C (dosage 3)|The higher dose of the active drug
89054963|NCT04557267|Placebo Comparator|Group D (placebo)|Placebo
89054964|NCT04557579||Bifocal group|Patients in bifocal group implanted with Restor +2.5D IOL (Alcon, Fort Worth, TX, USA) in bilateral eyes
89054965|NCT04557579||Extended depth of focus group|Patients in extended depth of focus group implanted with EDOF Symfony IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
89054966|NCT04557579||Monofocal group|Patients in monofocal group implanted with Sensar AR40e IOL (AMO, Santa Ana, CA, USA) in bilateral eyes
89054967|NCT02212353||Site 1 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 1 in delivering to care to neck of femur patients.
89054968|NCT02212353||Site 2 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 2 in delivering to care to neck of femur patients.
89054969|NCT02212353||Site 3 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 3 in delivering to care to neck of femur patients.
89054970|NCT00476957|Active Comparator|1|Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
89054971|NCT00476957|Active Comparator|2|Cordis Cypher® Sirolimus-eluting Coronary Stent
89054972|NCT04556955|Placebo Comparator|post isometric relaxation and exercises|Group A included Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier and conventional exercise program ; this program included Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions).This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the End of treatment, i.e. ROM, pain intensity by NPRS and PPT , functional disability.
89054973|NCT04556955|Experimental|Graston technique and exercises|Group B included Graston Technique to Upper Trapezius and Levator Scapulae.This instrumented-assisted soft tissue massage applied with deeper pressure to the area of concern.The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min Hot pack placed over the painful area in cervical region before the treatment ( 20 minutes).Strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior due to weak muscles (2 sets of 10 repetitions once a day) Stretching exercises for pectoralis muscles (20-second hold, 5 repetitions). This exercise protocol was for 4 weeks and 3 sessions per week. Measurements taken at baseline level and at the END of treatment , i.e. ROM, pain intensity by NPRS and PPT , functional disability.
89054974|NCT00475865|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate (GA) for 24 weeks
89054975|NCT00475865|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
89054976|NCT00475865|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
89054977|NCT04556877||Intraabdominal pressure under 12 mmHg|Patients with intraabdominal pressure under 12 mmHg
89054978|NCT04556877||Intraabdominal pressure between 12-20 mmHg|Patients with intraabdominal pressure between 12-20 mmHg
89054979|NCT04556877||Intraabdominal pressure over 20 mmHg|Patients with intraabdominal pressure over 20 mmHg
89054980|NCT00475709|Experimental|Trifecta Aortic Heart Valve|All subjects enrolled into the study are implanted with the Trifecta Aortic Heart Valve.
89054981|NCT04556994|Active Comparator|Phase 1 Cardiac Rehabilitation|Phase 1 Cardiac Rehabilitation
89054982|NCT04556994|Experimental|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Phase 1 Cardiac Rehabilitation with lower limb paddling
89054983|NCT04556721|Experimental|Sugammadex|After surgery and general anesthesia, a clinically-appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade. Either 2 mg/kg or 4 mg/kg dosing will be used based on the level of neuromuscular blockade at the time of reversal. Administer as single IV bolus injection infused over 10 seconds into existing IV line. Dose is based on actual body weight (mg/kg).
89054984|NCT00475670|Active Comparator|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.
89054985|NCT00475670|Experimental|Trastuzumab, Taxane|Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator.
89054986|NCT04557072||The selective alpha-blockade group|Patients treated with selective alpha-blockade before pheochromocytoma surgery
89054987|NCT04557072||The non-selective alpha-blockade group|Patients treated with non-selective alpha-blockade before pheochromocytoma surgery
89054988|NCT04556760|Experimental|Cohort 1|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (72 mg AZD9567 followed by 40 mg prednisolone [AB sequence group] or 40 mg prednisolone followed by 72 mg AZD9567 [BA sequence group]).
89054989|NCT04556760|Experimental|Cohort 2|Participants will be randomised in a ratio of 1:1 to receive AZD9567 and prednisolone over two 72 hour periods in a cross over design (40 mg AZD9567 followed by 20 mg prednisolone [AB sequence group] or 20 mg prednisolone followed by 40 mg AZD9567 [BA sequence group]).
89054990|NCT04556760|Active Comparator|Cohort 3|Participants will be randomised in a ratio of 1:1 to receive placebo and prednisolone over two 72 hour periods in a cross over design (placebo followed by 5 mg prednisolone [AB sequence group] or 5 mg prednisolone followed by placebo [BA sequence group]).
89054991|NCT00474968||Arm 1 - Experimental|e2 Cell Collector [SoftPAP(R)]
89054992|NCT00474968||Arm 2 - Control|Brush/spatula
89054993|NCT04556799|Experimental|Study group|3D osteotomy template for derotation osteotomy with the aid of computer-assisted simulated surgery technique
89054994|NCT04556799|Experimental|Control group|traditional osteotomy technique
89054995|NCT00474929|Experimental|Multiple Myeloma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
89054996|NCT00474929|Experimental|Lymphoma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
89054997|NCT04556604||1|First cycle of the audit on consenting practice pre intervention
89054998|NCT04556604||2|Second cycle of the audit on consenting practice to assess change following intervention
89054999|NCT04556604||3|Third cycle of the audit on consenting practice to assess long term compliance
89055000|NCT04556409|Experimental|low intensity pulsed ultrasound|20 women were treated by low intensity pulsed ultrasound (5 min, 0.5 w/cm2, 1MHZ with 20% duty cycle, 3 times/ week for 4 weeks plus static abdominal and pelvic floor exercises.
89055001|NCT04556409|Experimental|low level laser therapy|20 women were treated by low level laser therapy (Gallium Aluminum Arsenide Laser), 808nm, 4J/cm2, pulsating signal, 60 seconds for each point, 30 Mw/cm2, 3 times/week for 4 weeks plus static abdominal and pelvic floor exercises.
89055002|NCT04556409|Placebo Comparator|static abdominal and pelvic floor exercises|20 women were the control group who received only static abdominal and pelvic floor exercises. , 3 times/week for 4 weeks.
89055003|NCT00474812|Experimental|Dasatinib Treatment|Patients receive oral dasatinib twice daily on days 1-28.
89055004|NCT04556643|Experimental|Intervention Group|Two sessions will be given to pregnant women in Intervention group. One session breathing exercises training will be given during first stage of labor by the investigator. During training all participants in Intervention group will be instructed to perform breathing exercises during the second stage of labor.
89055005|NCT04556643|No Intervention|Control Group|Usual hospital delivery protocol will be followed.
89055006|NCT00474383|Experimental|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) tablet or capsule will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study, along with prednisone/prednisolone 5 mg tablet orally twice daily or dexamethasone 0.5 mg tablet orally once daily.
89055007|NCT04556448|Experimental|Aligners|Invisalign treatment
89055008|NCT04556448|Active Comparator|Traditional braces|Clear braces
89055009|NCT00474266|Experimental|Nimenrix + Priorix-Tetra Group|Subjects received 1 dose of Nimenrix vaccine and 1 dose of Priorix-Tetra vaccine on Day 0 and a second dose of Priorix-Tetra vaccine on Day 84.
89055010|NCT00474266|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
89055011|NCT00474266|Active Comparator|Priorix-Tetra Group|Subjects received 1 dose of Priorix-Tetra vaccine on Day 0, 1 dose of Meningitec vaccine on Day 42 and a second dose of Priorix-Tetra vaccine on Day 84.
89055012|NCT00474266|Active Comparator|Meningitec Group|Subjects received 1 dose of Meningitec vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
89055013|NCT02277821|Experimental|Stendo pulsating suit System|One 20 minutes Stendo pulsating suit session will be applied to the patient.
89055014|NCT00473564|Experimental|TORS Candidates|Participants who consented to undergo transoral robotic-assisted surgery using the da Vinci® Robotic System
89687624|NCT02241031|Active Comparator|Non-MPs|Patients can receive platelet infusion but can not receive platelet stimulating factors.
89687625|NCT02156167|Experimental|CP810 and Codacs™Test System|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
89687626|NCT03212807|Experimental|Investigational|Durvalumab + Lenalidomide
89055015|NCT00472199|Experimental|Pramipexole|4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
89055016|NCT00472199|Placebo Comparator|Placebo|4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.
89055017|NCT00472082|Experimental|1|The study drug Efalizumab will be given as part of a triple drug regimen including mycophenolate mofetil and prednisone. A test dose of Efalizumab 0.7mg/kg will be given at the enrollment visit. Beginning with study visit 2, Efalizumab 1mg/kg will be administered subcutaneously by injection on a weekly basis for 1 year. Mycophenolate mofetil will be given at a dose of 2gm/day which is the same as the standard of care dose. If patient experiences drug toxicity with mycophenolate mofetil they may be reduced and resume a minimum of at least 1gram daily to continue in the study. Patients will be maintained at 10mg of prednisone daily, same as standard of care.
89055018|NCT04556292|Experimental|SC10914 group|
89055019|NCT00471887|Experimental|Treatment-Single Arm|See intervention descriptions
89055020|NCT04556058|Experimental|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
89055021|NCT04556058|Active Comparator|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
89055022|NCT00471536|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89055023|NCT04556253|Experimental|treatment arm|Subjects will receive AK104 by intravenous administration.
89055024|NCT00470834|Experimental|Arm 1|50 mg bicalutamide and 3.5 mg Dutasteride (IP)
89055025|NCT00470834|Placebo Comparator|Arm 2|50 mg bicalutamide and placebo
89055026|NCT04555746|Experimental|Physical activity|Physical activity
89055027|NCT04555746|No Intervention|Control|Waiting list
89055028|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 1 group|Two subjects in this group will receive NL005 for 0.05ug/kg respective in D1.
89055029|NCT04555824|Experimental|Dose 2 groupRecombinant Human Thymosin β4|Two subjects in this group will receive NL005 for 0.25ug/kg respective in D1.
89055030|NCT04555824|Experimental|Dose 3 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 0.5ug/kg respective in D1.
89055031|NCT04555824|Experimental|Dose 4 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 2ug/kg respective in D1.
89055032|NCT04555824|Experimental|Dose 5 groupRecombinant Human Thymosin β4|Eight subjects in this group will receive NL005 for 5ug/kg respective in D1.
89055033|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 6 group|Eight subjects in this group will receive NL005 for 12.5ug/kg respective in D1.
89055034|NCT04555824|Experimental|Recombinant Human Thymosin β4 Dose 7 group|Eight subjects in this group will receive NL005 for 25ug/kg respective in D1.
89055035|NCT04555824|Placebo Comparator|Placebo|Two subjects in each dose group（0.5/2/5/12.5/25ug/kg）were given placebo respective in D1. A total of 10 subjects were given placebos.
89687627|NCT03212417|Other|Interventional trial without phases-supportive care.|This is a feasibility pilot study project assessing the presence of compassion fatigue in clinical research nurses (cohort 1) and bone marrow transplant nurses (cohort 2). A survey will be completed by participants prior to and after an educational presentation. The intervention includes the risk factors, signs and symptoms, and interventions on compassion fatigue. The survey will be completed prior to the education, immediately following the education, one month following the education and two months following the education. A final survey will be implemented for the cohort 2 only. The objective of this concluding analysis is to gather data relative to CF and coping mechanisms.
89687628|NCT01833767|Experimental|Cyclophosphamide and Interleukin-2|Cytoxan IV on day 1, IL2 IV on days 1-5
89687629|NCT01833923|Experimental|anlotinib|dosage form:capsule dosage:5mg,10mg,16mg,12mg frequency:once one day duration:Continuous two weeks then stop a week
89687630|NCT01834079|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
89687631|NCT03213353|Experimental|Treatment sequence AB|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
89687632|NCT03213353|Experimental|Treatment sequence BA|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
89687633|NCT01834157||methotrexate|methotrexate with or without low-dose corticosteroids
89687634|NCT01834157||other DMARDs|other DMARDs (leflunomide, azathioprine, mycophenolate mofetil) with or without low-dose corticosteroids
89687635|NCT01834157||low-dose corticosteroids|low-dose corticosteroids without DMARDs
89687636|NCT01834157||No DMARD or corticosteroids|No DMARD or corticosteroid treatment
89687637|NCT01834157||CPH/CSA - Exploratory cohort|cyclophosphamide or cyclosporine-A with or without other DMARDs or low-dose corticosteroids
89687638|NCT01834157||Biologics - Exploratory cohort|Biologic therapy with or without other DMARDs or low-dose corticosteroids
89055036|NCT00470366|Experimental|Paclitaxel, Ifosfamide, and Cisplatin|-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.
89055037|NCT02212431|Experimental|Cysteamine|"Dosing will be in accordance with licensed use of cysteamine for cystinosis, i.e. 450mg qds.~Dose will be escalated:~450mg od for one week 450mg bd for one week 450mg tds for one week 450mg qds for two weeks"
89055038|NCT00470093|Experimental|Interleukin-6 and Interferon-α|Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.
89055039|NCT02212548|Experimental|Hydrogel|The patient will be in the dorsal lithotomy position and prepared and draped. A transrectal ultrasound (TRUS) will be used for alignment of the needle and to ensure safe delivery. The hydrogel precursor and accelerator solutions will be mixed and connected to the Y connector that has been flushed with saline and to a syringe holder that ensures both syringe barrels are injected at the same time. After aspirating to ensure the tip of the needle is not intravascular, the perirectal space will be adequately dissected from the apex to midgland by injecting saline into the space between denonvilliers fascia and the anterior rectal space under TRUS guidance. Maintaining the needle position and angulation, the saline syringe is disconnected and the hydrogel system connected. After aspirating to ensure the needle tip is not in a blood vessel and under TRUS guidance, the 'PEG Hydrogel (SpaceOAR) is injected in a smooth, continuous technique.
89055040|NCT00470054|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89055041|NCT04555668|Experimental|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch
89055042|NCT04555668|Active Comparator|Hamstring Stretch Program|Hamstring Stretch Program and Knee -flexor eccentric training
89055043|NCT00478595|Experimental|Rimonabant|Rimonabant 20 mg once daily
89055044|NCT00478595|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily
89055045|NCT04555707|Experimental|Otezla + Enstilar|
89055046|NCT04555980|Experimental|Warm patch|the injection site was covered with warm patch.
89055047|NCT04555980|Placebo Comparator|Cotton patch|the injection site was covered with cotton patch.
89055048|NCT02212626|Experimental|Rotarex|After assessment of the lesion by angiography the occlusion is intraluminally crossed with the wire according to physician's discretion. The device is introduced and the catheter is activated while its tip is still proximal to the occlusion to allow lubrication of the spiral inside the catheter with the aspirated blood. The catheter is advanced into the occlusion with occasional retraction into the already recanalized lumen. Care must be taken to achieve sufficient cooling of the catheter tip and evacuation of the debris to get an appropriate blood flow along the catheter. In order to minimize peripheral embolization of clot the distal end of the occlusion should not be passed too fast before all loose material has been sucked back into the catheter. Several passages of the occlusion may be needed to clean out all wall-adherent thrombotic material. If residual underlying stenosis of >30% persist further endovascular treatment can be performed according to the physician's discretion.
89055049|NCT04673201|Active Comparator|Viscotrabeculotomy group|Management of medically uncontrolled steroid induced glaucoma by viscotrabeculomy technique
89055050|NCT04673201|Active Comparator|"Trabeculectomy with MMC group"|Management of medically uncontrolled steroid induced glaucoma by trabeculotomy with MMC
89055051|NCT04555629|Experimental|Advanced Cognitive Stimulation Therapy Hong Kong|"Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. It has also been translated and adapted for the Hong Kong Chinese population.~ACST-HK will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee, or care home staff."
89055052|NCT04555629|No Intervention|Treatment as usual|Standard care in care homes
89055053|NCT00478088|Experimental|1|NeoDisc
89055054|NCT00478088|Active Comparator|2|ACDF
89055055|NCT00474188|Experimental|Single Arm|
89055056|NCT04555083||CAI group|Case group is CAI group that recruit patients complain of ankle insatiability and giving way mainly
89055057|NCT04555083||control group|control group recruits participants with non injured ankle, matched with case group in gender and dominant limb
89055058|NCT04555395||gonadal|
89055059|NCT04555395||extra-gonadal|
89055060|NCT04555395||chemotherapy|
89055061|NCT04555395||without chemotherapy|
89055062|NCT00475982|Experimental|Arm 1: Weight Loss|Weight Loss Group
89055063|NCT00475982|Active Comparator|Arm 2: No Weight Loss|No Weight Loss Group
89055064|NCT01089647|Active Comparator|budesonide and montelukast|treatment arm
89055065|NCT01089647|Placebo Comparator|placebo|sugar pill, salt water nasal spray
89055066|NCT04555434|Experimental|Probiotics group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
89055067|NCT04555434|Placebo Comparator|Placebo group|The selected test subjects were randomly assigned to test group 1, test group 2, test group 3, or control group according to the order registered at visit 2 (week 0) after a 2-week run-in period, and for 8 weeks, the study drug or study After taking the treaty, analyze the results of the observations.
89055068|NCT04555005|Other|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
89055069|NCT01089608|Placebo Comparator|Unifluid|Eye drops in Single Dose Unit
89055070|NCT01089608|Experimental|Azithromycin|Eye drops Single dose unit
89055071|NCT04672694|Active Comparator|VNB (vagus nerve block)|Vagus nerve block
89055072|NCT04672694|Placebo Comparator|Control|No vagus nerve block
89055073|NCT04554654||frozen embryo transfer cycles|patients undergoing frozen embryo transfer with artificial hormone replacement
89055074|NCT04554615|Active Comparator|Conventional Insulin Therapy|CIT was provided as a continuous infusion of 50 IU of Actrapid HM in 50 ml of 0.9% sodium chloride using a pump, Infusion was adjusted to achieve BG level in range of 180-200 mg/dl.
89055075|NCT04554615|Active Comparator|Intensive Insulin Therapy|IIT was provided as an insulin infu-sion at rate of 1 mU/kg/min and was adjusted to achieve target BG level in range of 80-110 mg/dl.
89055076|NCT01089413||Cohort|
89055077|NCT04554810|Active Comparator|Intervention group|Intervention group participants are the refugees who received the medication management review service and pharmacist's counselling. They have been assessed at baseline and at follow-up after 3 months) home visits.
89055078|NCT04554810|No Intervention|Control group|Control group participants are the refugees who did not received the medication management review service and no pharmacist's counselling wsa provided to them during the study period. They have been assessed at baseline and at follow-up (after 3 months) home visits.
89055079|NCT02212665|Experimental|High intense interval training (HIIT)|3 x 20 sec, 3 x week
89055080|NCT02212665|Experimental|Increased daily activity detected by the pedometer|10.000 steps a day
89055081|NCT02212665|Experimental|Increased daily activity detected by te pedometer+HIIT|10.000 steps + 3 x 20 sec, 3 x week
89055082|NCT02212665|Experimental|Increased daily activity (pedometer)+group intervention|10.000 steps + group intervention
89055083|NCT02212665|No Intervention|Control group|
89055084|NCT01089023|Experimental|1|
89055085|NCT02212704|Experimental|Vestibular stimulation|This is the experimental paradigm applied in all participants
89055086|NCT02212782|Experimental|A Group|1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg
89055087|NCT02212782|Experimental|B Group|1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg
89055088|NCT01088984|Experimental|Bendamustine|Bendamustine 90 or 120 mg/m^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.
89055089|NCT02212821|Placebo Comparator|Placebo|intravenous infusion
89055090|NCT02212821|Experimental|Erythromycin|intravenous infusion
89055091|NCT01088438|Experimental|Contextualization workshop|A four-hour course on contextualization.
89055092|NCT01088438|No Intervention|Control|No intervention
89055093|NCT04554537|Placebo Comparator|Brain Health Workshop|The BHW training has been used in multiple prior studies as a comparison training program in cognitive training trials It consists of sessions of fact-based information about the brain but does not train cognitive strategies. Topics include neuroanatomy, neuroplasticity, and effects of TBI on cognitive functioning. Other sessions focus on diet, exercise, sleep, and social functioning and their relationships to brain health. Participants are encouraged to share how the topics impact their lives. Participants are given take-home reading materials on related topics that were then discussed at the last session. At home, they were instructed to watch assigned videos but had no other homework.
89055094|NCT04554537|Experimental|SMART|"SMART emphasizes top-down processing by targeting focused attention, assimilation of information, and mental flexibility and innovation, all higher-order cognitive functions driven by the frontal lobes. SMART was delivered in small groups (n = 2 to 8) consisting of two 3-hour sessions over two days, followed by one 3-hour session a month later. Overall, sessions focused on strategic attention, integrative reasoning, and cognitive control functions (Chapman, 2014). Training consists of initial sessions of skills training with the one-month follow-up session being a booster session consisting of review. We modified the training such that all sessions included skills training with briefer review. The first two sessions consisted of strategic attention and integrated reasoning and the final session discussed innovation."
89055095|NCT04554186|Experimental|Serratus anterior plane block|20 patients will receive SAP block with 0.4 ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
89055096|NCT04554186|Active Comparator|Thoracic Paravertebral block|20 patients will receive TPVB 0.4ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%
89055097|NCT04554186|Placebo Comparator|Control group|20 patients will receive Fentanyl patch 50 microgram
89055098|NCT01088243|Experimental|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
89055099|NCT01088243|Placebo Comparator|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
89055100|NCT04554342|Experimental|healthy participants starting with candy V01|healthy participants testing a candy in 5 different variations by (unstimulated and stimulated) salivary flow rate (before and after comparison)
89055101|NCT04554342|Experimental|healthy participants starting with candy V02|
89055102|NCT04554342|Experimental|healthy participants starting with candy V03|
89055103|NCT04554342|Experimental|healthy participants starting with candy V04|
89055104|NCT04554342|Experimental|healthy participants starting with candy V05|
89055105|NCT04672499|Experimental|Cohort 1: Miricorilant 900 mg (Regimen A1)|Participants will receive a single oral dose of miricorilant 900 mg (3 X 300 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.
89055106|NCT04672499|Experimental|Cohort 1: Miricorilant 300 mg (Regimen A2)|Participants will receive a single oral dose of miricorilant 300 mg (2 X 150 mg) after breakfast on Day 1. Cohort 1 treatment will be randomized and open label.
89055107|NCT04672499|Experimental|Cohort 2: Miricorilant (Regimen B1 and B2)|Participants will receive a single oral dose of miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.
89055108|NCT04672499|Placebo Comparator|Cohort 2: Placebo (Regimen B1 and B2)|Participants will receive a single oral dose of placebo matching miricorilant 900 mg (6 X 150 mg) after breakfast on Day 1 (Regimen B1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 900 mg (6 X 150 mg) qd for 14 days (Regimen B2). Day 1 treatment in Regimen B2 will be in the fasted state; the remaining doses will follow breakfast. Cohort 2 treatments will be randomized and blinded.
89055109|NCT04672499|Experimental|Cohort 3: Miricorilant (Regimen C1 and C2)|Participants will receive two oral doses (morning and evening) of miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
88999022|NCT04801589|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of either 4 mcg/mL or 8 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr."
89055110|NCT04672499|Placebo Comparator|Cohort 3: Placebo (Regimen C1 and C2)|Participants will receive two oral doses (morning and evening) of placebo matching miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and placebo matching miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
89055111|NCT04554108|Active Comparator|Intravenous antibiotic treatment|Intravenous antibiotic treatment started during an initial hospitalization of 3 days, with continuation of oral antibiotic therapy at home for a total duration of antibiotic therapy of 3 weeks
89055112|NCT04554108|Experimental|oral antibiotic treatment|Oral antibiotic treatment started in hospital then continued at home for a total duration of 3 weeks of antibiotic therapy
89055113|NCT04554303||S-amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
89055114|NCT04554303||Amlodipine treatment group|Patients with essential hypertension, who satisfies all criteria listed in eligibility section are randomly assigned, after a wash-out period of at least two weeks.
89217049|NCT02573519|Active Comparator|Diabetic patient|"The study consists of four different parts:~11C Donepezil PET/CT scan~3D-Transit~3D-Transit during treatment with pyridostigmine~3D-Transit after Malone appendicostomy (only diabetic patients who had a Malone-surgery for severe obstipation ordered during standard clinical practice)"
89217050|NCT02573519|Active Comparator|Healthy subjects|"The study consists of two different parts:~11C Donepezil PET/CT scan~3D-Transit"
89687639|NCT01834157||Combinations - Exploratory cohort|Combination of two or more DMARDs with or without low-dose corticosteroids
89687640|NCT04381013|Experimental|Phase 1: Routine surgery|As part of routine cardio-thoracic surgery, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 1 minute.
89687641|NCT04381013|Experimental|Phase 2: ECHO treatment|During care with Extracorporeal Membrane Oxygenation (ECMO) for non-SARS-CoV-2, endotracheal tubes split from ventilator delivering oxygen independently to each lung for up to 24 hours.
89687642|NCT04381013|Experimental|Phase 3: COVID-19 treatment|Endotracheal tubes split from ventilator delivering oxygen independently to two patients with COVID-19 disease for up to 1 hour.
89687643|NCT03218267|Experimental|Individuals after total hip replacement|Individuals after total hip replacement. Patients treated at the Out-Patient Ward of W. Dega Orthopaedic-Rehabilitation Clinical Hospital of Karol Marcinkowski University of Medical Sciences in Poznań. The examination of participants included the static posturography and one-leg standing test.
89687644|NCT03218267|Active Comparator|control group|The group with healthy individuals; without total hip replacement. The examination of participants included the static posturography and one-leg standing test.
89687645|NCT03218111|Other|Healthy Normal Subjects|Healthy normal subjects 20-80 years old. All subjects will undergo the same procedures: intrathecal injection, using CT-guidance, with an MRI contrast. After injection subjects will undergo six sessions of MR imaging over a 10-12 hour period
89687646|NCT03212573|Experimental|ERAS protocol|ERAS protocol includes early oral intake (6 hours after surgery), early deambulation (6h after surgery) and multimodal analgesia (port-sites infiltration with Bupivacain 0.5% combined with postoperative intravenous analgesia)
89687647|NCT03212573|Active Comparator|Standard care|Oral intake and early deambulation begins 24h after surgery and analgesia consists in only intravenous drugs
89687648|NCT03218033|No Intervention|Control|Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules for 8 weeks. At the end of each module there were questions pertaining to the subject of each module. The control group answered the questions in provided journals and these were sent back to the investigator. All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies.
89687649|NCT03218033|Active Comparator|Social Media (SM)|"The intervention phase was 8 weeks in duration. Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules. 8 The SM group answered the questions at the end of each module on a blogging site with other SM participants. SM participants were encouraged to provide feedback or questions about the material or personal questions that arose in response to each module.~All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies."
89687650|NCT03217955|Experimental|CBT-SA|"Group sessions for 4 weeks, two sessions per week, 60 minutes per session, two trainers (a CBT therapist and a CBT assistant); eight participants, and;~Individual sessions (crystallizing learned skills, focus on individual needs) during 6-8 weeks, one session per week, 45 minutes per session"
89687651|NCT03217955|Active Comparator|Standard Treatment|Participants in both study conditions will receive ST. Participants are hospitalized or attending day-treatment at the Department of Early Psychosis, Amsterdam, the psychosis department of the ABC team, Utrecht, Parnassia Den Haag and collaborating (local community) mental health centers.
89687652|NCT01834235|Active Comparator|Abraxane, gemcitabine|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
89687653|NCT01834235|Experimental|Abraxane, gemcitabine, NPC-1C|"Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.~Patients on arm B will receive NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 4-week cycle. This will be administered 30minutes after completion of the gemcitabine infusion."
89687654|NCT03212339|Experimental|Mothers with children <3 years of age|Dyads of mothers with children up to 3 years of age will be attending modified Group Attachment Based Intervention (mGABI) sessions at the SPARK Center that will include a small group of other mother-child pairs and approximately two therapists. Dyads will be offered the 10 session therapeutic intervention.
89687655|NCT03212339|Experimental|Mothers with children 3-5 years of age|Dyads of mothers with children between the ages of 3 and 5 years will be attending Brief Dyadic Intervention (BDI) sessions at Child Witness to Violence and/or the SPARK Center with their child and an individual therapist. Dyads will be offered the 10 session therapeutic intervention.
89687656|NCT03212027||Patients with low-risk thymomas|low-risk thymomas include types A, AB, and B1 thymomas
89687657|NCT03212027||Patients with high-risk thymomas|high-risk thymomas include types B2 and B3 thymomas
89687658|NCT03212027||Patients with thymic carcinomas|thymic carcinomas also called types C thymomas
89687659|NCT01834391||Geriatric Traumatic Injury|Geriatric trauma pateints being admitted to Saint Marys Hosptial.
89687660|NCT03211871|Active Comparator|Group D|Group D received dexmedetomidine infusion 0,5 mcg/kg/h from induction in anesthesia to extubation
89687661|NCT03211871|Placebo Comparator|Croup C|group C (control) received normal saline infusion
89687662|NCT01834469|Other|ICG NIR imaging|see Summary and description iv injection of ICG
89687663|NCT03217487|Experimental|Corneal epithelial autograft|Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD
89687664|NCT03217487|Active Comparator|Limbal conjunctival autograft|Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD
89687665|NCT03838133|Experimental|TLC590 dose 1 (152 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
89055115|NCT01088048|Experimental|Idelalisib + Rituximab|"Participants with chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL) will receive treatments as follows:~Cohort 1a: Idelalisib (IDELA) 100 mg orally twice daily (BID) on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 intravenously (IV) on Days 1, 8, 15 & 22, Cycles 1 & 2~Cohort 2a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2~Cohort 3e: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2~Cohort 4a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle, starting Cycle 2 Day 1 with the 5th dose of rituximab + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2"
89055116|NCT01088048|Experimental|Idelalisib + Rituximab + Bendamustine|"Participants with CLL, iNHL and mantle cell lymphoma (MCL) will receive treatments as follows:~Cohort 3a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 70 mg/m^2 IV on Days 1 & 2 of each 28-day cycle from Cycles 1 - 6~Cohort 5c: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6"
89217051|NCT00947232|Experimental|Motivational interviewing|Motivational interviewing for people aging with multiple sclerosis or spinal cord injury to increase physical activity and decrease depression.
89217052|NCT00947232|Active Comparator|Education|Education about physical activity for people aging with multiple sclerosis or spinal cord injury to decrease depression.
89217053|NCT02572661|Other|Squamous Head and Neck Cancer|radiation
89687666|NCT03838133|Experimental|TLC590 dose 2 (190 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
89687667|NCT03838133|Experimental|TLC590 dose 3 (228 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
89687668|NCT03838133|Active Comparator|Naropin®|Naronpin injection contains ropivacaine HCl 50 mg (0.5%, 10 mL)
89687669|NCT03838133|Placebo Comparator|Placebo|Normal Saline (0.9% sodium chloride, 10 mL)
89687670|NCT03838133|Active Comparator|Bupivacaine|Bupivacaine HCl 50 mg (0.5%, 10 mL)
89687671|NCT03217409|Experimental|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week
89687672|NCT03217409|Active Comparator|Rosuvastatin|Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week
89687673|NCT00895193|Active Comparator|Apple-pectin 2000mg|Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
89687674|NCT00895193|Active Comparator|Regular Non-enteric coated aspirin 325mg|Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
89687675|NCT00895193|Active Comparator|Apple pectin + aspirin|Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
89687676|NCT00895193|Placebo Comparator|Placebo Comparator|Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
89687677|NCT01834547|Experimental|Methylphenidate|Methylphenidate
89687678|NCT01834547|Experimental|modafinil|modafinil
89687679|NCT01834547|Experimental|caffeine|caffeine
89687680|NCT01834547|Placebo Comparator|placebo|placebo
89687681|NCT03211637|Experimental|INTERVENTION GROUP|This group comprises 6 healthcare units equipped with a Family Health Strategy, where patients are seen by coordinating nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
89687682|NCT03211637|Active Comparator|CONTROL GROUP|This group comprising 5 healthcare units equipped with a Family Health Strategy. Patients were seen by coordinating nurses who used techniques and supplies with which they were already familiar. They had no protocol in place.
89687683|NCT03217253|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89687684|NCT03212105|Active Comparator|60 Second Video|The mindfulness intervention is a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
89687685|NCT03212105|Other|Educational Pamphlet|The educational pamphlet contains information about pain and stress, which patients will be able to read within 60 seconds.
89687686|NCT01834703|Active Comparator|UAE treatment|After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment
89687687|NCT01834703|Active Comparator|HIFU|After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment
89687688|NCT03211559|Active Comparator|AEROBİC EXERCİSE (walking on treadmill)|Patients walked on treadmill for 8 weeks, 3 days in a week,30-40 minutes each.
89687689|NCT03211559|Experimental|Aerobic Exercise+Clinical Pilates|Patients walked on treamill for 8 weeks, 3 days in a week, 30-40 minutes each. Additionally they did clinical pilates exercise for 8 weeks, 3 days in a week.
89687690|NCT01834781|Active Comparator|Pulsed electromagnetic fields|Pulsed electromagnetic fields is applied transcranially 30 minutes twice a day for 7 days a week over 6 consecutive weeks
89687691|NCT01834781|Placebo Comparator|Wearing the inactive device|The inactive device is worn on the head for 30 minutes twice a day for 7 days a week over 6 consecutive weeks
89687692|NCT03217331|Experimental|CRD-102 Treatment|CRD102 Treatment
89687693|NCT03216863|Experimental|8 weeks Respiratory rehabilitation|
89687694|NCT03211169|Experimental|Pediatric Biopsy Forceps directed biopsies|Biopsies of the stricture will be taken with Pediatric Biopsy Forceps after bile duct brushings have been obtained.
89687695|NCT03211169|Active Comparator|Cholangioscopy-directed biopsies|Biopsies of the stricture will be taken under cholangioscopic guidance after bile duct brushings have been obtained.
89687696|NCT04380389|Other|profound hypoxia|
89687697|NCT03217019|Experimental|Guidewire|"Radial artery puncture with direct radial pulse palpation.~24G angiocatheter insertion with guidewire-assist. (Catheter over guidewire)"
89217054|NCT02572583|Experimental|Liugan Shuangjie Heji Group|Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
89217055|NCT02572583|Active Comparator|Shufeng Jiedu Capsule Group|Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
89217056|NCT02572583|Active Comparator|Oseltamivir Phosphate Capsule Group|Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
89217057|NCT04011306|Experimental|Lumina24 BLU|Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site.
89217058|NCT00714935|Experimental|3|Decision Counseling Program(DCP) combined with Coronary Artery Disease Decision Aid (CAD-DA) described in Arm 2
89217059|NCT00714935|No Intervention|1|
89217060|NCT00714935|Experimental|2|"Behavioral: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
89217061|NCT00951444|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and MK-0646 IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients with stable disease or partial or complete response may then receive MK-0646 alone on days 1 and 15. Treatment with MK-0646 repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89217062|NCT00951444|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride and carboplatin as in arm I. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients may crossover to arm upon disease progression.
89217063|NCT00462826|Experimental|Treatment (aflibercept)|Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89217064|NCT00718601|Experimental|1|3+3 cohort dose escalation
89217065|NCT00951522|Experimental|1|GS-9411 2.4 mg
89217066|NCT00951522|Experimental|2|GS-9411 4.8 mg
89217067|NCT00951522|Experimental|3|GS-9411 7.2 mg
89217068|NCT00951522|Experimental|4|GS-9411 9.6 mg
89217069|NCT00951522|Placebo Comparator|5|Placebo
89687698|NCT03217019|Active Comparator|Direct|"Radial artery puncture with direct radial pulse palpation.~24G angiocatheter insertion without guidewire-assist. (Catheter over needle)"
89687699|NCT03211403|Experimental|SHR4640 2.5mg|6 subjects assigned to 2.5mg SHR4640 and 2 subjects assigned to placebo
89687700|NCT03211403|Experimental|SHR4640 10mg|6 subjects assigned to 10mg SHR4640 and 2 subjects assigned to placebo
89687701|NCT03211403|Experimental|SHR4640 20mg|6 subjects assigned to 20mg SHR4640 and 2 subjects assigned to placebo
89687702|NCT03211247|Experimental|Viaskin Peanut 250 mcg|
89687703|NCT03211247|Experimental|Viaskin Peanut 100 mcg|
89687704|NCT03211247|Placebo Comparator|Placebo|
89687705|NCT03216941|Active Comparator|ketamine|assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)
89687706|NCT03216941|Active Comparator|olanzapine|assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)
89687707|NCT03216707|Sham Comparator|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
89687708|NCT03216707|Active Comparator|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
89217070|NCT00718679|Experimental|1|Study drug
89217071|NCT00718679|Placebo Comparator|2|Placebo
89217072|NCT00947388|Experimental|Bendamustine plus Alemtuzumab|
89217073|NCT00710645||Arm I|50 subjects with multiple sclerosis will be tested one time on the Lido Workset. The test will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
89687709|NCT03216707|Active Comparator|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
89687710|NCT01835093|Experimental|A single-arm study|
89687711|NCT01835249|Experimental|Intensive BP Arm|"Participants randomized into the Intensive BP arm will have a goal of SBP <120mmHg. Drugs will be added and/or titrated at each visit (monthly) to achieve SBP <120 mmHg. At periodic milepost visits, addition of another drug will be required if not at goal."
89055117|NCT01088048|Experimental|Idelalisib + Bendamustine|"Participants with CLL and iNHL will receive treatments as follows:~Cohort 1b: IDELA 100 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 2b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3f: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3g: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 70 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 4b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle starting Cycle 2, Day 3 (after the Cycle 2 bendamustine dosing) + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6"
89055118|NCT01088048|Experimental|Idelalisib + Ofatumumab|"Participants with CLL will receive treatments as follows:~Cohort 3c: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + ofatumumab 12 doses (300 mg (Day 1 or Day 2, Dose 1), followed 1 week later by 1,000 mg weekly for 7 doses (Doses 2 - 8), followed 5 weeks later by 1,000 mg every 4 weeks for 4 doses (Doses 9 - 12))"
89055119|NCT01088048|Experimental|Idelalisib + Fludarabine|"Participants with CLL will receive treatments as follows:~Cohort 3d: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + fludarabine 40 mg/m^2 orally on Days 1 - 5 of each 28-day cycle, Cycles 1 - 6"
89055120|NCT01088048|Experimental|Idelalisib + Everolimus|"Participants with MCL will receive treatments as follows:~Cohort 5a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + everolimus 10 mg orally once daily on Days 1 - 28 of each 28-day cycle"
89055121|NCT01088048|Experimental|Idelalisib + Bortezomib|"Participants with MCL will receive treatments as follows:~Cohort 5b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bortezomib 1.3 mg/m^2 subcutaneously on Days 1, 8 & 15 of each 28-day cycle"
89055122|NCT01088048|Experimental|Idelalisib + Chlorambucil|"Participants with CLL will receive treatments as follows:~Cohort 6a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + chlorambucil 10 mg/m^2 orally once daily for 7 days every 28 days, Cycles 1 - 12"
89055123|NCT01088048|Experimental|Idelalisib + Rituximab + Chlorambucil|"Participants with CLL will receive treatments as follows:~Cohort 6b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + chlorambucil 10 mg/m^2 orally once daily for 7 days every 28 days, Cycles 1 - 12"
89055124|NCT01088048|Experimental|Idelalisib + Rituximab + Lenalidomide|"Participants with CLL and iNHL will receive treatments as follows:~Cohort 7a: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 5 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles~Cohort 7b: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 10 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles~Cohort 7c: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 20 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles"
89055125|NCT04554498|Experimental|Hemodiafiltration with ATA filter|patients with clinical history of hypersensitivity to polisulfone/poliethersulfone dialysis filters or hypersensitivity to drugs or generic allergens.
89055126|NCT04554498|Active Comparator|Hemodiafiltration with Helixone filter|no history of hypersensitivity to polisulfone/poliethersulfone dialysis filters is assessed; no history of hypersensitivity to drugs or generic allergens is assessed.
89055127|NCT04554381|Experimental|JL1|JL1 on acute leukemia
89055128|NCT04554381|Experimental|JL1 and acute leukemia|Assesment of JL1 expression on acute leukemia
89055129|NCT04553952||Gummy smile (GS(+))|
89055130|NCT04553952||Gumms smile(GS(-))|
89055131|NCT04672577||Arboviral infection or malaria positive cohort|
89055132|NCT04553796||diabetic participants|HBA1C : 6.5% or higher Fasting Plasma Glucose : 126 mg/dl or higher Oral Glucose Tolerance Test : 200 mg/dl or higher Random Plasma Glucose Test : greater than or equal to 200 mg/dl
89055133|NCT04553796||prediabetic participants|HBA1C : 5.7% to 6.4% Fasting Plasma Glucose : 100 mg/dl to 125 mg/dl Oral Glucose Tolerance Test : 140 mg/dl to 199 mg/dl
89055134|NCT04553796||non diabetic participants|HBA1C : less than 5.7% Fasting Plasma Glucose : less than 100 mg/dl Oral Glucose Tolerance Test : less than 140 mg/dl
89687712|NCT01835249|Active Comparator|Standard BP Arm|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mmHg @ 1 visit; ≥140 mmHg @ 2 consecutive visits; Down-titration if SBP <130 mmHg @ 1 visit; <135 mmHg @ 2 consecutive visits.
89687713|NCT01838993|Active Comparator|Lidocaine|Inhalation of lidocaine before intubation
89687714|NCT01838993|Placebo Comparator|Control|Normal saline inhalation before intubation
89687715|NCT03211013|Experimental|Immediate Oxytocin|Participants randomly assigned to this arm will receive OT nasal spray (24 IU) at laboratory visit 1 and placebo nasal spray at visit 2. The order will be masked for participants and study staff.
89687716|NCT03211013|Placebo Comparator|Delayed Oxytocin|Participants randomly assigned to this arm will receive placebo nasal spray at laboratory visit 1 and OT nasal spray (24 IU) at visit 2. The order will be masked for participants and study staff.
89687717|NCT03836495|Experimental|White bread unfortified (WB)|bread with no lysine no phosphorus
89687718|NCT03836495|Experimental|White bread fortified with lysine (WB-L)|Bread with lysine
89687719|NCT03836495|Experimental|White bread fortified with phosphorus (WB-P)|bread with phosphorus
89687720|NCT03836495|Experimental|White bread fortified with lysine and phosphorus (WB-LP)|Bread with phosphorus and lysine
89687721|NCT03836573|Experimental|E-cigarette only decision aid|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of information on e-cigarettes only. Patients will only be enrolled in this group in phase II if they self-identify as 'uninterested in quitting cigarettes'. During the physician encounter will be given harm-reduction guidance.
89217074|NCT00710645||Arm II|25 normal subjects will be tested on the Lido workset. The testing will be performed one time for each patient and will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected control subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
89217075|NCT00951600|Experimental|1|Oxcarbazepine oral suspension 300 mg/5mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
89217076|NCT00951600|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5mL of Novartis
89217077|NCT00710723|Experimental|1|vitrification
89217078|NCT00710723|No Intervention|2|Slow freezing
89217079|NCT00951678||ER patients|"Subjects must be 18 yrs or older, male or female, and must have the anatomy that we will be examining. Patients will be given the option of enrolling in the study whilst being cared for in Tampa General Hospital Emergency Room.~We anticipate enrolling normal, healthy volunteers, elderly persons (>65) not cognitively impaired, persons with social, economic or educational disadvantages , and persons who do not understand English fluently."
89217080|NCT00957216|Placebo Comparator|sugar pill|
89217081|NCT00957216|Active Comparator|Coenzyme Q10|The CoQ10 arm will be compared with the placebo arm to determine if high-dose CoQ10 is safe and well tolerated in subjects with sporadic adult-onset spinocerebellar ataxias
89217082|NCT00710957||CHS All Stars|CHS All Stars is an ancillary study of the Cardiovascular Health Study (CHS), a longitudinal, observational, population-based study of the onset, progression, and course of heart disease and stroke in the elderly which began in 1988. The All Stars study reexamined the survivors of CHS to determine the likelihood of maintaining function later in life. A focus was to determine whether age-related biological factors are long-term predicators of functional aging which was assessed through a follow-up exam (Yr 18 visit conducted in 2005-06, n=1674 older adults, mean age =84 years) and 3 yrs of subsequent 6 month interval phone contacts. Vitamin D status (serum 25(OH)D and PTH) is being assessed in all CHS All Stars participants who provided a blood sample at the Yr 18 visit (n~1100).
89217083|NCT00957294||Schizophrenia|Patients with first-episode schizophrenia age 18-45 years
89217084|NCT00957294||Depression|First-time hospitalized patients with depression age 18-45 years
89217085|NCT00957294||healthy controls|Healthy controls matched on age and gender (18-45 years)
89217086|NCT00718757|Experimental|1|
89217087|NCT00947466|Experimental|Patch|
89217088|NCT04069013|Active Comparator|Standard PCNL|Patients receive a standard PCNL procedure using a 24 fr tract
89217089|NCT04069013|Active Comparator|Mini-PCNL|Patients receive a mini-PCNL procedure using a 16 fr tract
89687722|NCT03836573|Experimental|E-cigarette and Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. Patients will only be enrolled in this group in phase II if they self identify as 'interested in quitting and using e-cigarettes'. During the physician encounter will be given e-cigarette cessation guidance.
89687723|NCT03836573|Experimental|Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. All patients in phase I will be enrolled in this group. In addition, patients in phase II who self-identify as 'interested in quitting but do not use e-cigarettes' will also be enrolled in this group. During the physician encounter will be given standard smoking cessation guidance.
89687724|NCT01835405|Active Comparator|LiquiBand Flex|LiquiBand® Flex skin adhesive is indicated for topical application only, to hold closed easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed trauma-induced lacerations. It may be used in conjunction with, but not in place of deep dermal sutures.
89217090|NCT00951756|Other|High Fat Low Fiber Diet|
89217091|NCT00951756|Other|Low Fat High Fiber Diet|
89217092|NCT00718835|Active Comparator|Contingent Voucher condition|Subjects in this condition will receive a brief education intervention plus voucher-based incentives contingent on demonstrating objective evidence of recent smoking abstinence.
89217093|NCT00718835|Placebo Comparator|Noncontingent control condition|Subjects assigned to this control condition will receive the brief education and vouchers delivered independent of smoking status and yoked to the schedule of voucher earnings in the Contingent Voucher condition.
89217094|NCT00946842|Experimental|Panel A: Treatment Sequence ABC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ABC with food and subsequent treatments will be separated by 4 weeks.
89217095|NCT00946842|Experimental|Panel A: Treatment Sequence ACB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ACB with food and subsequent treatments will be separated by 4 weeks.
89217096|NCT00946842|Experimental|Panel A: Treatment Sequence BAC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BAC with food and subsequent treatments will be separated by 4 weeks.
89217097|NCT00946842|Experimental|Panel A: Treatment Sequence BCA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BCA with food and subsequent treatments will be separated by 4 weeks.
89217098|NCT00946842|Experimental|Panel A: Treatment Sequence CBA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CBA with food and subsequent treatments will be separated by 4 weeks.
89217099|NCT00946842|Experimental|Panel A: Treatment Sequence CAB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CAB with food and subsequent treatments will be separated by 4 weeks.
89217100|NCT00946842|Experimental|Panel B: Treatment Sequence DEF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DEF with food and subsequent treatments will be separated by 4 weeks.
89217101|NCT00946842|Experimental|Panel B: Treatment Sequence DFE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DFE with food and subsequent treatments will be separated by 4 weeks..
89217102|NCT00946842|Experimental|Panel B: Treatment Sequence EDF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EDF with food and subsequent treatments will be separated by 4 weeks.
89217103|NCT00946842|Experimental|Panel B: Treatment Sequence EFD|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EFD with food and subsequent treatments will be separated by 4 weeks.
89217104|NCT00946842|Experimental|Panel B: Treatment Sequence FDE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FDE with food and subsequent treatments will be separated by 4 weeks.
89217105|NCT00946842|Experimental|Panel B: Treatment Sequence FED|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FED with food and subsequent treatments will be separated by 4 weeks.
89217106|NCT00951834|Experimental|Epigallocatechin-Gallate|"Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)~add-on to Donepezil."
89217107|NCT00951834|Placebo Comparator|Placebo|add-on to Donepezil.
89217108|NCT00715091|Experimental|1|continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily
89217109|NCT00715091|Active Comparator|2|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.
89217110|NCT00947622|Placebo Comparator|Placebo stimulation|Placebo stimulation at the occipital head area for 1800 seconds at 0 mA, three times a week, during one week (with seconds of stimulation to get onset tingling sensation)
89217111|NCT00947622|Experimental|Effective transcranial stimulation|Effective stimulation at the occipital head are for 1800 seconds at 2 mA, 3 times a week for 1 week
89217112|NCT00957762||Body Composition|120 subjects will help create the regression models. The remaining 50 subjects will be recruited to determine if the equations work for the population.
89217113|NCT00718913|Experimental|1|TCX ->RT -> TCX
89217114|NCT04011930|Active Comparator|Experimental study|"vitamin D Generic name -cholecalciferol (40,000IU)Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks.~Drug cholecalciferol- ingredients -cholecalciferol (40,000 IU) Microcrystalline cellulose(58.1 gm),hydroxy toluene (.2mg),magnesium stearate(3mg0,gelatin capsule shell(1mg)~other name D-rise"
89217115|NCT04011930|Placebo Comparator|Experimental control|"Placebo oral capsule Dose-80,000 Dosage -2capsule/week for consecutive 26 weeks~placebo oral capsule-ingredients-microcrystalline cellulose,butylated hydroxy toluene~,magnesium stearate~other name D-rise"
89217116|NCT04068857|Experimental|rTMS|
89217117|NCT04068857|Sham Comparator|Sham|
89217118|NCT00957840|Other|Omaya reservoir group- observational|These infants have been identified with severe enough post hemorrhagic ventricular dilation (PHVD) that they require a reservoir placed for serial cerebro-spinal fluid (CSF) removal. There is no randomization, and infants are compared to a baseline. Observational data will be collected to include NIRS and aEEg which will be done twice weekly, and CSF will be analyzed with each reservoir tap for protein biomarkers.
89687725|NCT01835405|Active Comparator|Dermabond Advanced|Dermabond Advanced™ adhesive is intended for topical application only, to hold closed easily approximated skin edges of wounds from surgical incisions, including incisions from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Dermabond Advanced ™ adhesive may be used in conjunction with, but not in place of, deep dermal stitches.
89687726|NCT01835405|Active Comparator|Sutures (Prolene)|Prolene™ Suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
89217119|NCT00715169|Active Comparator|1|
89217120|NCT00715169|Placebo Comparator|2|
89217121|NCT00718991|Experimental|1|CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions
88999023|NCT04801589|Active Comparator|Midazolam|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of either 0.5 mg/mL or 1 mg/mL midazolam. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr."
89217122|NCT00947700|No Intervention|Assessment & Monitoring|No Intervention. Parent-Child participants in assessment and monitoring visits but does not receive any study provided treatment.
89217123|NCT00947700|Experimental|Assessment, Monitoring + Intervention|Parent-Child participants in assessment and monitoring visits but also the Promoting First Relationships PFR intervention (http://pfrprogram. Org). PFR is a 10 weekly 60-85 minute in-home visits by a masters level mental health provider trained in the PFR curriculum. The PFR curriculum focuses on increasing parenting sensitivity using attachment theory-informed, strength-based consultation strategies. The curriculum is fully manualized and fidelity was assessed according to the manual.
89217124|NCT02574377|Experimental|A: myDC vaccination|intranodal injection with tumor peptide-loaded myeloid dendritic cells
89217125|NCT02574377|Experimental|B: pDC vaccination|intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells
89217126|NCT02574377|Experimental|C: combined myDC/pDC vaccination|intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells
89217127|NCT00715247||Affected Population|Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
89217128|NCT00715247||Healthy Female Controls|Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
89217129|NCT00551616|Experimental|CDB-2914|
89217130|NCT00551616|Active Comparator|Levonorgestrel|
89217131|NCT00715325|Experimental|A|
89217132|NCT02574221|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
89217133|NCT02574221|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
89217134|NCT00719147||1|
89217135|NCT02572349|Experimental|IW-1701|Single Dose
89217136|NCT02572349|Placebo Comparator|Matching Placebo for IW-1701|Single Dose
89217137|NCT00719303|Experimental|Group I (lifestyle intervention)|Participants receive a dietary intervention designed to promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of micronutrient intake. Participants also undergo a physical activity intervention comprising a moderately low aerobic regimen to raise the usual activity level. Participants also undergo face-to-face counseling, receive educational materials and counseling focused on how to read food labels to estimate grams of fat per serving and serving size, and undergo telephone counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2 weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every other month for 12 months. Participants complete daily fat gram and step diaries at least three times per week.
89217138|NCT00719303|Active Comparator|Group II (observation)|Participants receive a study notebook containing general study-related information. Participants are not asked to record diet or physical activity but are provided a single sample diary in their study notebook. Participants receive telephone contact on a sliding scale similar to the intervention group, but at less frequent intervals (22 versus 33 calls over the course of the intervention).
89217139|NCT00452530|Experimental|Apixaban, 2.5 mg BID + Placebo|Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
89217140|NCT00452530|Active Comparator|Enoxaparin, 40 mg QD + Placebo|Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
89217141|NCT00549198|Experimental|ABC/3TC + EFV|
89217142|NCT00549198|Active Comparator|TDF/FTC + EFV|
89217143|NCT00607724|Experimental|Stage 1: GDC-0449 (150 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 milligram (mg) on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 150 mg, orally, continuing until disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0), maximum benefit, or intolerability.
89217144|NCT00607724|Experimental|Stage 1: GDC-0449 (270 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
89217145|NCT00607724|Experimental|Stage 1: GDC-0449 (540 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 540 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 540 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
89217146|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (150 mg)]|Participants with basal cell carcinoma (BCC) received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
89217147|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (270 mg)]|Participants with BCC received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
89217148|NCT00607724|Experimental|Stage 2:Safety Expansion Cohort [GDC-0449 (150 mg)]|Participants received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
89217149|NCT00607724|Experimental|Stage 2: New Formulation [GDC-0449 (150 mg )]|Participants received a daily oral dose of GDC-0449 Phase II drug product hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
89217150|NCT00506415|Experimental|Open label: Rivastigmine (5 cm^2 / 10 cm^2)|Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
89217151|NCT00506415|Experimental|Double blind: Rivastigmine (10 cm^2)|Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.
89687727|NCT03210857|Experimental|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
89687728|NCT01835561|Experimental|Part 1: Severe liver disease and healthy volunteer match|Subjects with severe liver disease (Group 2) and healthy volunteer subjects (Group 1) matched to the subjects with liver disease
89687729|NCT01835561|Experimental|Part 2: Mild and moderate Liver disease|Subjects with moderate (Group 3) and/or mild (Group 4) liver disease
89687730|NCT01835639|Experimental|Vitamin D Supplementation|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
89687731|NCT01839071|Other|biopsy of fat tissue|
89687732|NCT03210623|Experimental|group A|subjects applying the stent retriever(TonbridgeMT)
89687733|NCT03210623|Active Comparator|group B|subjects applying Solitaire™
89687734|NCT01839149|Experimental|TI-001 (intranasal oxytocin)|TI-001 is intranasal oxytocin
89687735|NCT01839149|Placebo Comparator|Placebo|Placebo for TI-001 is the same intranasal formulation without oxytocin
89687736|NCT01839383|Active Comparator|DCa1.25|using dialysate calcium concentration 1.25 mmol/L(DCa1.25)
89687737|NCT01839383|Active Comparator|DCa1.5|using dialysate calcium concentration 1.5mmol/L
89687738|NCT01839383|Active Comparator|DCa1.75|using dialysate calcium concentration 1.75mmol/L
89687739|NCT01835795|Active Comparator|Radial Extracorporeal Shock Wave|Swiss DolorClast® CLASSIC applicator
89217152|NCT00506415|Experimental|Double blind: Rivastigmine (15 cm^2)|Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.
89217153|NCT00506415|Experimental|Extended open label Rivastigmine (10 cm^2)|Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.
89217154|NCT04036526|Experimental|Group 1 Drop method|Group 1 will receive vaccine/placebo by drop method.
89217155|NCT04036526|Experimental|Group 2 Nasal actuator|Group 2 will receive vaccine/placebo with nasal actuator.
89217156|NCT00893360|Experimental|Cardiac Stem Cell Treatment - Group 1|Autologous stem cell infusion of 12.5 MIL CDCs via intracoronary infusion.
89217157|NCT00893360|Experimental|Cardiac Stem Cell Treatment -Group 2|Autologous stem cell infusion of 25 MIL CDCs via intracoronary infusion.
89217158|NCT00893360|No Intervention|Observation (Control Group)|Observation of myocardial recovery after usual medical management.
89217159|NCT04036604|Experimental|Group of pelvic floor exercise|Group of pelvic floor exercise include 47 elderly people which contains contraction and repetition of pelvic floor muscle exercises during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.
89217160|NCT04036604|No Intervention|Group of pelvic floor education|Group of pelvic floor education include 47 elderly people which contains anatomy of pelvic floor and dysfunction during once a week for 8 weeks performed by an expert pelvic health physiotherapist.
89217161|NCT00947778|Active Comparator|session of training 1|Arm from which members will perform their training session after the first session of evaluation
89687740|NCT01835795|Placebo Comparator|Placebo|Swiss DolorClast® CLASSIC placebo applicator
89687741|NCT00906425|Active Comparator|Submerged healing|The Straumann Bone Level Implant(s) will be placed using a submerged healing treatment
89687742|NCT00906425|Active Comparator|Trans-mucosal healing|The Straumann Bone Level Implant(s) will be placed using a trans-mucosal healing treatment
89687743|NCT01835873|Active Comparator|Lactated Ringer's|Crystalloid solution - 1000 ml preload
89687744|NCT01835873|Active Comparator|HES 130/0.42|Hydroxyethyl starch (HES 130/0.42) - 500 ml preload
89687745|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
89687746|NCT01835951|Other|Grouped Debriefing|Grouped debriefing consists in the analysis of the management of the anaesthesia crisis simulated in the presence of all the subject included in the Grouped Debriefing group.
89687747|NCT01839539|No Intervention|B|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up.
89687748|NCT01839539|Experimental|A|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks).
89687749|NCT00901199|Experimental|Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects received Deferasirox (Exjade) and Deferoxamine (DFO) dosing based on the iron overload at baseline.
89687750|NCT01839617|Active Comparator|Early parenteral nutrition|Parenteral nutrition starts at 2nd postoperative day.
89687751|NCT01839617|Active Comparator|Late parenteral nutrition|Parenteral nutrition starts at 7th postoperative day.
89687752|NCT03210935||Merkel cell carcinoma|
89687753|NCT03210935||Advanced basal cell carcinoma|
89687754|NCT03210935||Cutaneous adnexal carcinomas|
89687755|NCT01836341|Experimental|Afatinib w Cisplatin Pemetrexed Chemoradiation|"induction afatinib 40mg daily x 28days Cisplatin or Carboplatin (can be used if patient is not eligible for cisplatin) + Pemetrexed + 50Gy to pretreatment field boost to 60Gy to residual tumor + afatinib dose escalation*~*afatinib dose levels: 20mg daily, 30mg daily & 40mg daily (3+3 design) Then adjuvant afatinib x 2 years"
89687756|NCT01836419|Experimental|young adult group|young adult patients undergoing minor urologic surgery or lower extremity surgery
89687757|NCT01836419|Active Comparator|elderly group|elderly patients undergoing minor urologic surgery or lower extremity surgery
89217162|NCT00947778|Active Comparator|Session of training 2|Arm from which members will perform their training session after the second session of evaluation
89217163|NCT02572115|Active Comparator|Intervention arm - jumped the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who choose to use the intervention."
89217164|NCT02572115|Active Comparator|Intervention arm - did not jump the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who got the option to use the intervention but DID NOT."
89217165|NCT02572115|No Intervention|Control|This arm does not get the intervention.
89217166|NCT00893438|Experimental|FitNet treatment|FitNet treatment: web-based cognitive behaviour therapy
89217167|NCT00893438|Active Comparator|Usual care|waiting list for FitNet intervention (usual care allowed)
89217168|NCT00952146|Experimental|Transgastric peritoneoscopy|Only one arm, feasibility study
89217169|NCT00452452|Experimental|A|
89217170|NCT01009437|Active Comparator|Control Arm - No Ritonavir|Five ER+, HER2- breast cancer patients meeting all study eligibility will be enrolled prior to the start of phase I recruitment to act as controls (no ritonavir will be given-will receive therapeutic conventional surgery) to confirm that anesthesia does not affect EET levels. Core biopsies, surgical tumor/normal tissue and pre- and post- surgery blood samples will be collected for comparison with the treatment group.
89217171|NCT01009437|Experimental|Ritonavir - Escalating Doses (I)|"Standard phase I dose escalation (with therapeutic conventional surgery) will be used with 3 levels of ritonavir given - 200 mg bid, 400 mg bid, and 600 mg bid for the following groups:~ER+, HER2-~ER+, HER2+~ER-, HER2+~ER-, PR+, HER2-~ER-, PR-, HER2-"
89687758|NCT00906503|Experimental|PET/Computed Tomography (CT)|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan; Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
89055135|NCT01087970|Experimental|Triplet Combination Therapy|"Cycle 1:~Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1"
89055136|NCT01087814|Active Comparator|efavirenz|
89055137|NCT01087814|Experimental|over-encapsulated efavirenz|
89055138|NCT02212938|Experimental|BI 14332 CL fasted|
89055139|NCT02212938|Experimental|BI 14332 CL fed|
89055140|NCT04672421|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after laparoscopic surgery
89055141|NCT04672421|Sham Comparator|Placebo|laparoscopic surgery
89055142|NCT04553991|Active Comparator|QL block group|For the ultrasound-guided quadratus lumborum block group, the patient was placed in lateral position . QL was identified medial to the aponeurosis of transversus abdominis muscle. Then the needle was inserted from supero-anterior to postero-inferior and advanced using in plane technique till the needle tip reached the anterolateral border of the QL at its junction with transversalis fascia.An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
89055143|NCT04553991|Active Comparator|TAP block group|For the ultrasound-guided TAP block,The probe was placed in the mid-axillary line above the level of the anterior superior iliac spine, then slided cranially till the three abdominal wall muscles identified (External oblique muscle (EAO), internal oblique muscle (IOM) and transverse abdominis muscle (TAM)). The needle was advanced using in-plane technique till it reached the transvers abdominis plane. An injection of 20 mL of 0.25% bupivacaine was applied bilaterally
89055144|NCT01087775|Experimental|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
89055145|NCT02213172|Experimental|Bifidobacterium longum R0175|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
89055146|NCT02213172|Experimental|Lactobacillus paracasei HA-196|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
89055147|NCT02213172|Placebo Comparator|Placebo|1 capsule daily for 8 weeks
89055148|NCT01087502|Experimental|Linagliptin|52 weeks treatment
89055149|NCT01087502|Placebo Comparator|Placebo|First 12 weeks of treatment
89055150|NCT01087502|Active Comparator|Glimepiride|Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)
89055151|NCT02213211|Experimental|Diagnosis and treatment of malaria|"School-based diagnosis and treatment of uncomplicated malaria using malaria RDTs and Artemether lumefantrine as part of Learner Treatment Kits (LTK) used by teachers.~Drug: Artemether lumefantrine (artemisinin-based combination therapy [ACT], Coartem). Three-day doses of 20mg/120mg, 40mg/240mg, 60mg/360mg and 80mg/480mg Coartem are provided, according to weight, upon a positive rapid diagnostic test (RDT) result."
89055152|NCT02213211|No Intervention|No intervention|No intervention provided
89055153|NCT02213367|Active Comparator|20 mg Bilastin|20mg Bilastine once daily
89055154|NCT02213367|Active Comparator|Bilastin 40mg|40 mg Bilastine once daily, intake of two tablets 20mg Bilastine
89055155|NCT02213367|Active Comparator|Bilastin 80mg|80 mg Bilastine once daily, intake of four tablets 20mg Bilastine
89055156|NCT01086410|Active Comparator|FF/444 Dose B|Fluticasone furoate/GW642444 Dose B inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
89055157|NCT01086410|Active Comparator|FF/444 Dose A|Fluticasone furoate/GW642444 Dose A inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
89055158|NCT01086410|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
89055159|NCT01086410|Active Comparator|Prednisolone|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral prednisolone 10mg capsule each day on the last 7 days of the study
89687759|NCT01836575|Experimental|Arm B|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle] + Antiemetic therapy at investigator's discretion.
89687760|NCT01836575|Active Comparator|Arm A:|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Antiemetic therapy at investigator's discretion.
89687761|NCT01836653|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
89687762|NCT01836653|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
89687763|NCT01836731|Experimental|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
89687764|NCT01836731|Experimental|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
89687765|NCT01836731|No Intervention|Control|"The control group is not enrolled in the CBEHPP.~Because of the government's commitment for the national roll out to the CBEHPP, the control population will receive the intervention as soon as possible following the conclusion of the trial phase. Nevertheless, we will continue to evaluate the sustained impact of the intervention for two additional years by monitoring various behavioural outcomes and indicators and their impact on exposure outcomes (drinking water, hand hygiene, consumption, schooling and labour market participation etc.). We will use data from the RCT phase and clinical records to estimate the effect of any sustained impact on health. Long term impacts can be inferred by using data from the trial as well as data on long term behavioural outcomes."
89687766|NCT03836885|Experimental|Apremilast|Oral tablet
89687767|NCT03836885|Placebo Comparator|Placebo|Oral tablet
89055160|NCT04553679||Stroke survivors|Participants who have had a stroke
89055161|NCT04553679||Caregivers|Participants who are caring for someone who have had a stroke
89055162|NCT04553601|Experimental|8F-FDG PET/CT and PET/CT-guide targeted biopsy|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time.
89055163|NCT01086215||Limb Ischemia|Patients presenting with limb ischemia for treatment
89055164|NCT01086215||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
89055165|NCT01086215||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
89055166|NCT01086215||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment
89055167|NCT04553250|Active Comparator|Conventional technique|"In this group, double-staple colorectal anastomosis will be performed following the technique described by Lee et al: Prior to firing the endostapler, a suture will be placed on the rectal stump that includes both dog ears. After the punch comes out of the endostapler, the point will be tied, which will invaginate the two corners of the staple line on the same punch. Subsequently, the endostapler will be closed and fired, including the dog ears in the anastomotic rims"
89055168|NCT04553250|Active Comparator|Lateral invagination technique|In this group, the circular endostapler will be fired in a conventional way, that is, without having invaginated the two corners of the staple line.
89055169|NCT04553328|Active Comparator|Group T|Group (T) received ultrasound guided (US) combined ipsilateral transverse abdominis plane (TAB) and ilioinguinal- iliohypogastric (ILIH) nerve block
89055170|NCT04553328|Active Comparator|Group I|Group (I) received US guided ipsilateral illioinguinal- illiohypogastric nerve block only.
89055171|NCT01085591|Experimental|CB-183,315, 125 mg|125 milligrams (mg) CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
89055172|NCT01085591|Experimental|CB-183,315, 250 mg|250 mg CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
89055173|NCT01085591|Active Comparator|Vancomycin, 125 mg|125 mg vancomycin administered orally four times a day for 10 days.
89055174|NCT04553172||Affected family members|Affected family members
89055175|NCT04553172||Affected PM|Affected PM
89055176|NCT04672265|Experimental|Mother tongue and Norwegian|Written material related to screening sent to the invitee in two languages.
89055177|NCT04672265|No Intervention|Norwegian|Written material related to screening sent to the invitee in Norwegian only.
89055178|NCT04553055||community pharmacists|
89055179|NCT02213406|Experimental|intervention group|Fat detection threshold test, intake of high and low fat yogurt, fMRI-measurements
89055180|NCT04552977|Experimental|fluzoparil+temozolomide|Participants receive fluzoparil and temozolomide
89217172|NCT01009437|Experimental|Ritonavir - Maximum Tolerated Dose (II)|Phase II: Once the maximum tolerated dose (MTD) of ritonavir is established, 19 ER+, HER2- patients will be enrolled at MTD during the phase II component along with therapeutic conventional surgery.
89217173|NCT04322435|Other|Adrenal insufficiency|Patients followed in the paediatric endocrinology department of the Necker Hospital, with primary and secondary adrenal insufficiency, aged from 6 months to 6 years.
89217174|NCT02540408||presence of COPD|COPD patients are defined according to the results of a spirometry
89217175|NCT00947934|Experimental|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation.
89217176|NCT00719381|Active Comparator|1|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
89217177|NCT00719381|No Intervention|2|Patients in this arm will receive no intervention
89217178|NCT01022086||early stage/adjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
89217179|NCT01022086||locally advanced/neoadjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
89217180|NCT01022086||metastatic|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
89217181|NCT01022086||anthracycline-containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
89217182|NCT01022086||non-anthracycline containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
89217183|NCT05673161||anemia, treatment|anemic patients who had iron therapy
89217184|NCT05673161||anemia, no treatment|anemic patients who had no therapy
88999024|NCT04801238|Active Comparator|LCBDE + LC|Laparoscopic common bile duct exploration with laparoscopic cholecystectomy
89217185|NCT00952224||Acute myocardial infarction patients|Patients undergoing primary percutaneous coronary intervention in ST-elevation myocardial infarction plus magnetic resonance imaging
89217186|NCT00510783|Active Comparator|Phenytoin/Fosphenytoin|Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).
89217187|NCT00510783|Active Comparator|Levetiracetam|Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).
89217188|NCT00952302|Placebo Comparator|CMS - placebo first|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
89217189|NCT00952302|Experimental|CMS - iron|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
89687768|NCT03837119||Heterozygous Hemoglobinopathy|pregnancy outcome in women with heterozygous hemoglobinopathy
89687769|NCT03837119||No Heterozygous Hemoglobinopathy|pregnancy outcome in women without heterozygous hemoglobinopathy
89687770|NCT00920647|Other|Control|Untreated Patients
89687771|NCT00920647|Experimental|Idursulfase -IT (1 mg)|monthly using an intrathecal drug delivery device (IDDD)
89687772|NCT00920647|Experimental|Idursulfase-IT (10 mg)|monthly using an intrathecal drug delivery device (IDDD)
89687773|NCT00920647|Experimental|Idursulfase -IT (30 mg)|monthly using an intrathecal drug delivery device (IDDD)
89687774|NCT01836887|Placebo Comparator|Intervention 1|Very low polyphenol fruit based drink (control)
89687775|NCT01836887|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - low
89687776|NCT01836887|Active Comparator|Invervention 3|Polyphenol-enriched fruit-based drink - high
89687777|NCT01836965|Experimental|Social Skills Intervention|The intervention is a 12-week social skills training program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session (in the form of a photography class with typically developing peers) meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the photography class. During the group therapy session adolescents will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with a typically developing peer for the photography class.
89217190|NCT00952302|Placebo Comparator|SLR - placebo|Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
89217191|NCT00952302|Experimental|SLR - iron|Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.
89217192|NCT00897650||Lung cancer|Patients with a diagnosis of invasive lung cancer.
89687778|NCT04373395|Experimental|D-CLAG|Administration of D-CLAG regimen (Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor)
89687779|NCT01837043|Experimental|Belatacept|Subjects will be converted from standard of care CNI therapy to Belatacept 10 mg/kg IV on post renal transplant Day 7 (+/- 3 days). As suggested in the package insert for de novo dosing, further dosing of belatacept will be given as 10 mg/kg IV at weeks 2, 4, 8 and 12 then 5 mg/kg at week 16 and then every 4 weeks (+/- 5 days) through week 52. CNI will be stopped during the first belatacept infusion.
89687780|NCT01837043|Active Comparator|Calcineurin Inhibitor|Patients randomized to this arm will remain on the current CNI as prescribed by post-transplant standard of care therapy.
88999025|NCT04801238|Active Comparator|ERC + LC|Endoscopic retrograde cholangiography with laparoscopic cholecystectomy
88999026|NCT04796948|Experimental|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|"irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion.~oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial.~5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.~LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution."
88999027|NCT04772755|No Intervention|Usual Care|Participants received usual care that followed administration of a vaccine and a 20 minute post vaccination observation period.
88999028|NCT04772755|Experimental|Buzzy ® and Electronic Game|Buzzy® was applied to the arm receiving vaccination for 30-60 seconds prior to vaccination and removed following vaccination. For the electronic game, participants were instructed to select a game from a prepopulated list of games on a tablet provided by the study team and then played that game for a specified amount of time before, during and after the vaccination administration.
88999029|NCT04765865||Wave 1|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey, 24-hour and spot urine assessments, blood sample collection for fatty acid estimation, and four (4) 24-hour dietary recalls (n=450).
88999030|NCT04765865||Wave 2|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey and 24-hour and spot urine assessments (n=450).
88999031|NCT04765865||Wave 3|Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey, 24-hour and spot urine assessments, and four (4) 24-hour dietary recalls (n=450).
88999032|NCT04699617|Experimental|Active arm|The active arm will include 3 days a week of training with the Dolphin 2.0 for 12 consecutive weeks. Each session will have the duration of 60 minutes.
88999033|NCT04699617|Active Comparator|Delayed-start control arm|The delayed-start control arm will have six-weeks of physiotherapy specialized for PD (3 times/week, 60 minutes/session) and six-weeks of 3 days a week of training with the Dolphin 2.0, with sessions of 60 minutes.
88999034|NCT04692467|Experimental|Intervention (Early hypertension)|Participants randomized to the early HTN treatment arm will initiate 5mg daily of amlodipine immediately, increasing to 10 mg if SBP >130 mmHg after 1 month.
88999035|NCT04692467|No Intervention|Standard of Care|Participants randomized to the SOC arm will not be initiated on any medications initially. They may be initiated on amlodipine only if they develop HTN (SBP ≥140 or DBP ≥90 mm Hg).
88999036|NCT04692077|Experimental|CAB LA|In Step 1, participants will receive one CAB tablet orally every day for 5 weeks. In Step 2, participants will receive an intramuscular (IM) injection of CAB LA at Weeks 5, 9, 17, 25, and 33. In Step 3, participants will receive a TDF/FTC tablet orally every day for 48 weeks or may be offered the opportunity to join an open label CAB study instead, if such a study is being implemented in their area at the time.
88999037|NCT04662099|Experimental|Conditioning chemotherapy plus CAR T cells infusion|
88999038|NCT04661163|Experimental|Virtual reality avatar therapy|Patients will be offered seven individual sessions of virtual reality therapy and two booster sessions conducted by a skilled therapist. In the initial phase of treatment, the participants create a virtual avatar that corresponds to their visual perception of the source of their voice. The therapist initiates, encourages and supports a dialogue between the participant and the avatar by alternating between talking as the avatar and as a supportive therapist. The therapy sessions last 50 minutes of which around 15 minutes is spent in dialogue with the avatar. The remaining 30 minutes will be used on preparing the patient for the confrontation with the avatar, evaluating on the interaction with the avatar, and use general cognitive behavioral techniques to reduce the auditory hallucination. The treatment is conducted with the use of virtual reality, so the participant will wear VR headset during treatment and watch and talk with the avatar shown in front of him or her.
88999039|NCT04661163|No Intervention|Supportive counselling (comparison group)|The control group is offered seven session with health professionals providing supportive counselling. This can (but does not necessarily) involve psychotherapy targeting auditory hallucinations.
88999040|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 1|Randomised participants will receive oral inhalation of AZD1402 Dose 1 via DPI.
88999041|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 2|Randomised participants will receive oral inhalation of AZD1402 Dose 2 via DPI.
88999042|NCT04643158|Experimental|Part 1: AZD1402 Dose 3|Randomised participants will receive oral inhalation of AZD1402 Dose 3 via DPI.
88999043|NCT04643158|Placebo Comparator|Part 1 and Part 2: Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
88999044|NCT04627025|Experimental|Apraglutide SC injections, once weekly|Peptide analogue of GLP-2
88999045|NCT04627025|Placebo Comparator|Placebo|Placebo for apraglutide, SC injection once weekly
88999046|NCT04597593||ADR Group|ISTH bleeding scale Major Bleeding
88999047|NCT04597593||Control Group|No ADR, No Treatment Failure
88999048|NCT04597593||Treatment Failure Group|Recurrent MI, Ischemic stroke, Other thromboembolic disorders
88999049|NCT04590040|Active Comparator|Toothpaste 1|Toothpaste 3 containing 5% potassium nitrate (KNO3) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
89687781|NCT01839773|Experimental|DHP107 (oral paclitaxel)|DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
88999050|NCT04590040|Active Comparator|Toothpaste 2|Toothpaste 2 containing 15% nano-HAP will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
88999051|NCT04590040|Placebo Comparator|Toothpaste 3|Toothpaste 1 containing 0% nano-hydroxyapatite (HAP) will be used by subjects to brush their teeth twice daily for 3 minutes in the morning and before bed each night using a 1 inch strip of toothpaste on a soft-bristled toothbrush.
88999052|NCT04586296|Experimental|Telemedicine Group|Group that will be receiving the telemedicine intervention in addition to the standard of care post-op.
88999053|NCT04586296|No Intervention|Standard Treatment|Patients will be receiving the standard of care, post op visits at 2, 6, and 12 weeks.
88999054|NCT04583098||carbapenem-resistant Enterobacteriaceae|FMT using frozen or capsulized stool
88999055|NCT04583098||vancomycin-resistant Enterococci|FMT using frozen or capsulized stool
88999056|NCT04581993|Experimental|Intervention|Pregnant and lactating women (PLW) will receive Super Cereal - wheat soya blend with sugar and children aged 6-23 months will receive lipid-based nutrient supplement-medium quantity (LNS-MQ). Social and behavior change communication (SBCC), community mobilization, referrals, identification of model families, food demonstrations, local recipe) ration/beneficiary entitlement cards will be provided for easy verification and tracking during delivery of intervention.
88999057|NCT04581993|No Intervention|Control|Control districts will receive routine health care services available in the study area.
88999058|NCT04557488|Experimental|Music therapy|The treatment group will receive social skill intervention using music therapy in groups of eight. A certified music therapist with prior experience with children with ASD and ID will be the trainer for the treatment group. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to facilitate the group activities, manage unexpected situations, and ensure the safety of the participants.
88999059|NCT04557488|Experimental|Behavioral-based social skill training|The control group will receive behavioral-based social skill training in groups of eight. The trainer will be a registered social worker with experience in providing social skill training for children with ASD and ID. Parents or the primary caregivers will be invited to attend the intervention sessions and to observe the training. An assistant trainer will also be present in all sessions to provide support.
88999060|NCT04542083||COVID-19 period|Admissions from January to December 2020
89687782|NCT01839773|Active Comparator|Taxol® (IV paclitaxel)|Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
89687783|NCT04373239||Women in BC conceiving by ART|All women in BC registered in the Perinatal Services BC database having undergone Assisted Reproductive Technology. Assisted Reproductive Technology will consist of in vitro fertilization (+/-ICSI). Data from April 1, 2008 to March 31 2018 will be analyzed for live birth rate.
89687784|NCT04373239||Women in BC conceiving spontaneously|he comparison group will be all women in BC registered in the Perinatal Services BC database with spontaneously conceived pregnancies between April 1, 2008 to March 31 2018.
89687785|NCT04373161|Experimental|Suspected COVID-19 patients being discharged to home|Patients will be given a portable, fingertip pulse oximeter to take home. Patients will monitor their resting home oxygen saturation three times per day.
89687786|NCT00909155|Active Comparator|Depressed; Venlafaxine treatment|Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.
89687787|NCT00909155|Active Comparator|Depressed; Fluoxetine treatment|Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
89687788|NCT00909155|No Intervention|Control|Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication
89687789|NCT01839851||Asthma|Treatment with any inhaled corticosteroid
89687790|NCT01839851||Allergic rhinitis|Treatment with any intranasal glucocorticoid
89687791|NCT01839851||Asthma and allergic rhinitis|Inhaled corticosteroid + intranasal glucocorticoid
89687792|NCT01839929|Experimental|Prograf/Advagraf|conversion from Prograf to Advagraf
88999061|NCT04542083||Control period|Admissions from January 2018 to December 2019
88999062|NCT04542018|Experimental|Study patients with IBS-D|Patients with diarrhea-predominant IBS who will undergo a low FODMAP diet for 4 weeks
88999063|NCT04540874|Experimental|BI 894416 25mg|1 tablet of 25 milligrams (mg) BI 894416 was administered orally as single dose with 240 milliliters of water after an overnight fast of at least 10 hours on day 1, followed by at least 48 hours close medical surveillance, followed by 2 weeks of follow-up period.
88999064|NCT04540874|Placebo Comparator|Placebo group|Matching placebo was administered orally as single dose with 240 milliliters of water after an overnight fast of at least 10 hours on day 1, followed by at least 48 hours close medical surveillance, followed by 2 weeks of follow-up period.
88999065|NCT04531982|Experimental|Drug - Pimavanserin|Pimavanserin 34 mg taken as two tablets + background antipsychotic, once daily by mouth
88999066|NCT04531982|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
88999067|NCT04505618|Other|Controls|Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.
88999068|NCT04505618|Other|Diabetics with and without Diabetic Retinopathy Only|Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.
89217193|NCT05300646|Experimental|Intervention|The prenatal MBSR program is an adaptation of MBSR. Details on the adaptation process is described in Skovbjerg S et al. Pilot and feasibility studies, 2021 Jun 3; 7 (1):118. Prenatal MBSR include nine weekly two-hour classes and is delivered in a combination between physical attendance and live-online teaching. The recommended time for daily mindfulness training between sessions is 15 minutes a day with options for longer practice. Audio recordings with guided meditations and a video with yoga programs for pregnancy is provided for home practice.
89217194|NCT05300646|No Intervention|Treatment as usual|Standard clinical practice, usual care (TAU), consists of an average of six routine pregnancy visits to the outpatient antenatal clinic at Copenhagen University Hospital, Hvidovre and to a General Practitioner. Routine pregnancy visits involves primarily preventive counselling by midwifes, and in some cases consultations with a physician or social worker throughout pregnancy and the early post-partum period. In some cases, usual care may include consultations with a psychologist, although usually limited to a few sessions, and in more severe cases referral to psychiatric treatment.
89217195|NCT00518973|Placebo Comparator|Placebo|The primary outcome was to determine the effect of quetiapine compared with placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorder Inventory-2 (EDI-2).
89217196|NCT00518973|Experimental|Quetiapine|Secondary outcomes were to determine if quetiapine is superior to placebo in reducing anxiety, depression and obsessionality assessed with the State Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM D) and Yale-Brown Obsessive Compulsive Scale, respectively. In addition, another secondary goal was to determine if quetiapine is superior to placebo in terms of weight gain. Adverse events were also determined.
89217197|NCT00897806||Genetic Markers|
89217198|NCT00958152|Experimental|Cohort 1|
89217199|NCT00958152|Experimental|Cohort 2|
89217200|NCT00958152|Experimental|Cohort 3|
89217201|NCT00897884|Experimental|Metformin|Patients will take metformin three times a day for two to three weeks prior surgery.
89217202|NCT00958230|Experimental|dCell Vascular Patch|This Xenograft device is manufactured from Porcine Pericardium Tissue which has been decellularised leaving a scaffold style structure for ingrowth of human endothelial cells after placement into the operative site.
89217203|NCT01022164|Other|fibrin glue|
89217204|NCT01012401|Experimental|CHESS with Clinician Report + Internet access|An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
89217205|NCT01012401|Active Comparator|Usual care with Internet access|Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites
89217206|NCT00897962||Metastatic Breast Cancer|Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
89217207|NCT00897962||Non-cancer medical illness|Patients with non-cancer medical condition
89217208|NCT00897962||Healthy Controls|Healthy patients being seen for an annual exam
89217209|NCT05300178||multiple vessel disease|patients with coronary artery disease will be revascularized by using different bypass configuration.
89217210|NCT01012479|Experimental|Candesartan QD + Hydrochlorothiazide QD|
89217211|NCT04317287|Experimental|Cardio formulation|Tomato-based formulation with dietary supplement
89217212|NCT04317287|Placebo Comparator|Placebo|Placebo softgels
89217213|NCT02541734|Experimental|gelofusine and 111In-exendin 4 SPECT/CT|subjects will receive a gelofusine injection before the injection of the radiopharmaceutical (111In-exendin 4)
89217214|NCT02541734|Placebo Comparator|saline and 111In-exendin 4 SPECT/CT|As a control, subjects will receive an injection of saline before the injection of the radiopharmaceutical (111In-exendin 4)
89217215|NCT00952458|Experimental|BIS monitoring|Dosing of sedatives with BIS monitoring
89217216|NCT00952458|No Intervention|Standard monitoring|Dosing of sedatives without BIS monitoring
89217217|NCT00948012||Patients without pulmonary hypertension|Patients with sickle cell with normal response of pulmonary artery pressure to exercise
89217218|NCT00948012||Exercise-induced pulmonary hypertension|Patients with sickle-cell anemia with exercise-induced pulmonary hypertension.
89217219|NCT00462670|Placebo Comparator|1|0mg
89217220|NCT00462670|Experimental|2|15mg OPC-41061
89217221|NCT01009593|Experimental|ABT-869|
89217222|NCT01009593|Active Comparator|Sorafenib|
88999069|NCT04505618|Other|Hypertension Only|Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
89217223|NCT00719459|Experimental|1|Hospira Iron Sucrose
89217224|NCT00719459|Active Comparator|2|Venofer
89217225|NCT00952536|Active Comparator|Triple therapy|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule (test group 1)
89217226|NCT00952536|Active Comparator|Dual Therapy|Juice Plus+ with 2 vegetable & 2 fruit & 2 placebo capsule (test group 2)
89217227|NCT00952536|Placebo Comparator|Control|Daily Placebo in the form of 6 capsules (control group)
89217228|NCT01022320|Experimental|Surgical outcome|20 consecutive cases of patients who underwent the lateral pharyngoplasty
89217229|NCT00711503|Placebo Comparator|2|The patients are instructed to administer placebo by subcutaneous injection
89217230|NCT00711503|Experimental|1|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
89217231|NCT00888212|Experimental|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
89217232|NCT00958386|Experimental|1|Panitumumab+irinotecan
89217233|NCT00711581|Experimental|A|Subjects will undergo a laparoscopic cholecystectomy. The gallbladder will be retracted using the Endograb retractor.
89217234|NCT04035512|Experimental|Expressive writing|The expressive writing group will perform the writing task, for 3 consecutive days, 20 minutes each day
89217235|NCT04035512|No Intervention|Control group|Any intervention
89055181|NCT04552860|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
89055182|NCT01085357|Experimental|CyPass Micro-Stent + Cataract Surgery|Subjects receive the CyPass Micro-Stent at the conclusion of their cataract surgery
89055183|NCT01085357|Active Comparator|Cataract Surgery Only|Subjects do not receive the CyPass Micro-Stent at the conclusion of their cataract surgery
89055184|NCT04552938||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA between June 2018 and May 2019.
89055185|NCT02277860|Experimental|Exercise|Aerobic and strength training using the Wii Fit Plus for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
89055186|NCT02213484||Marfan syndrome|Individuals with a clinical diagnosis of Marfan syndrome
89055187|NCT02213484||Aortopathy syndrome|Individuals with one of the following clinical diagnoses: Loeys-Dietz syndrome, Turner syndrome, Ehlers-Danlos type IV syndrome, Thoracic Aortic Aneurysm and Dissection syndromes.
89055188|NCT02213523|Experimental|Plant concentrate A|Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)
89055189|NCT02213523|Experimental|Plant concentrate B|Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)
89055190|NCT02213523|Experimental|Plant concentrate C|Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)
89055191|NCT02213523|Experimental|Plant concentrate D|Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)
89055192|NCT01085201|Experimental|Stage 1|12-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
89055193|NCT01085201|Experimental|Stage 2|24-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
89055194|NCT01085201|Experimental|Stage 3|24-hour infusion to adults with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
89055195|NCT01085201|Experimental|Stage 4|24-hour infusion to children with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
89055196|NCT01085201|Experimental|Stage 2B|48-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
89055197|NCT02213562|Experimental|200 mg CFO|200 mg of chrysanthemum flower oil
89055198|NCT02213562|Experimental|300 mg CFO|300 mg of chrysanthemum flower oil
89055199|NCT02213562|Experimental|400 mg CFO|400 mg of chrysanthemum flower oil
89055200|NCT04671992|Active Comparator|Ultrasound Guided Out of-Plane Technique|Ultrasound Guided Out of plane technique (probe applied by holding horizontal)
89055201|NCT04671992|Active Comparator|Ultrasound Guided In-Plane Technique|Ultrasound Guided Out of plane technique (probe applied by holding vbertical)
89055202|NCT02213679|Experimental|Guanidinoacetic acid|Supplementation with dietary guanidinoacetic acid
89055203|NCT02213679|Placebo Comparator|Placebo|Supplementation with cellulose
89055204|NCT04671758||AR TAVI|The population consists in patients with severe symptomatic AR on native aortic valve who are candidates for surgical aortic valve replacement but who are deemed inoperable by the heart team due to technical issues (i.e., porcelain aorta, previous coronary artery bypass grafting,…), extreme left ventricular dysfunction or comorbidities (liver cirrhosis, severe chronic obstructive pulmonary disease…).
89055205|NCT02213718|Experimental|Desflurane|desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)
89055206|NCT02213718|Active Comparator|propofol|intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).
89055207|NCT01085084|Placebo Comparator|Placebo|Participants will receive 2 capsules of placebo matched to laquinimod orally once daily for 12 weeks.
89055208|NCT01085084|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 mg and 1 capsule of placebo matched to laquinimod orally once daily for 12 weeks.
89055209|NCT01085084|Experimental|Laquinimod 1 mg|Participants will receive 2 capsules of laquinimod 0.5 mg orally once daily for 12 weeks.
89055210|NCT01085045|Experimental|Inhaled PT003 (Dose 1)|PT003 MDI Dose 1
89055211|NCT01085045|Experimental|Inhaled PT003 (Dose 2)|PT003 MDI Dose 2
89055212|NCT01085045|Experimental|Inhaled PT005 (Dose 1)|PT005 MDI Dose 1
89055213|NCT01085045|Experimental|Inhaled PT005 (Dose 2)|PT005 MDI Dose 2
89055214|NCT01085045|Placebo Comparator|Inhaled Placebo|Placebo MDI
89055215|NCT01085045|Active Comparator|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Tiotropium Bromide inhalation powder
89055216|NCT01085045|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
89055217|NCT01085045|Experimental|Inhaled PT001 (Dose 1)|PT001 MDI Dose 1
89055218|NCT02213796|Other|1h infusion of 1 g meropenem|
89055219|NCT04552626|Experimental|Prolonged sitting (social breaks)|
89055220|NCT04552626|Experimental|Prolonged sitting with step-up exercise break|
89055221|NCT04552626|Experimental|Prolonged sitting with simple resistance activity breaks|
89055222|NCT01084772|Other|VISIONAIRE Instrumentation|TKA with VISIONAIRE instrumentation
89055223|NCT01084772|Other|Standard Instrumentation|TKA with standard instrumentation
89055224|NCT04552158|No Intervention|controlled group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management only
89055225|NCT04552158|Experimental|experimental group|patients with IBD who will be assessed for their nutritional status at day 0 and after 3 months of medical management and nutritional management in the form of the Mediterranean diet
89217236|NCT05352438|Experimental|Manual Therapy Group|Manual Therapy combined with education and home exercises
88999070|NCT04505618|Other|Diabetics w/ or w/o Diabetic Retinopathy & Hypertension|Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
88999071|NCT04497961|Experimental|Lenalidomide maintenance|"Those randomized to lenalidomide maintenance will receive a maintenance dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.~ARM A1: The first 15 patients on each arm interested in this sub study will be enrolled during C10D1 visit to initiate whole food plant based diet (WFPBD) meals and nutrition counseling on C13D1 for 12 weeks followed by additional 12 weeks of counseling alone from C16D1. They will continue on their lenalidomide maintenance schedule per study calendar.~ARM A2: The patients who do not go on the nutrition sub study will continue on their lenalidomide maintenance schedule per study calendar."
88999072|NCT04497961|Experimental|Daratumumab maintenance|"Those randomized to receive daratumumab maintenance will receive 1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36. HRQoL with EORTC QLQ-C30, EORTC QLQ-MY20 and PRO-CTCAE questionnaires will be collected: prior to therapy initiation (baseline); day 1 of cycle 2 and every cycle day 1 thereafter; at therapy discontinuation, and at 1-month post therapy follow-up.~ARM B1: The first 15 patients on each arm interested in this sub study will be enrolled during C10D1 visit to initiate whole food plant based diet (WFPBD) meals and nutrition counseling on C13D1 for 12 weeks followed by additional 12 weeks of counseling alone from C16D1. They will continue on their daratumumab maintenance schedule per study calendar.~ARM B2: The patients who do not go on the nutrition sub study will continue on their daratumumab maintenance schedule per study calendar."
88999073|NCT04464629|Experimental|Intracanalicular Sustained Release Dexamethasone, 0.4 mg|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of post-surgical inflammation and pain associated with ocular surgery.
88999074|NCT04464629|Active Comparator|topical prednisolone acetate 1%.|
88999075|NCT04459416|Experimental|Usual Care plus Acupuncture|Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. to prevent severe pain. If acupuncture does not prevent severe pain, the participant will receive opioid medication as backup pain relief.
88999076|NCT04459416|Active Comparator|Usual Care|Will receive only the usual pain management approach, which includes opioid medication when needed for severe pain, according to the routine guidelines for their care.
88999077|NCT04456647||Parenteral nutrition|
88999078|NCT04438551|Active Comparator|Standard dietary counseling|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection.
88999079|NCT04438551|Experimental|Standard dietary counseling plus mobile app|Subjects will be given the standard low sodium diet handout with counseling, complete a validated low sodium questionnaire, and a 24-hr urine collection. Subjects will use a mobile app to build their shopping lists prior to grocery shopping.
88999080|NCT04433442||Moderate to Severe Plaque Psoriasis or Psoriatic Arthritis|Participants will receive risankizumab as prescribed by the physician in routine clinical practice.
88999081|NCT04432935|Experimental|Bovine Lactoferrin|Intervention group will receive bovine lactoferrin supplementation daily once a day from day 0 of birth to 6 weeks of life.
88999082|NCT04432935|Placebo Comparator|Glucon D|Control group will receive Glucon-D supplementation daily once a day from day 0 of birth to 6 weeks of life.
88999083|NCT04430335|Other|Telephone-Based Cognitive Behavioral Therapy|Participants with moderate or severe anxiety and/or depressive symptoms will participate in the telephone-based intervention that consists of the CBT workbook (15 minutes daily to complete exercises), plus psychotherapy delivered by telephone with a licensed bilingual mental health provider (45-50 minute sessions weekly).
88999084|NCT04429568|Other|Smoked Cannabis, Vaped Cannabis, or Tobacco Cigarette|"Abstinence from any product night before hospital admission~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~6-hr abstinence and blood draws (PK)~2 hr Free use session w/ video monitoring~Free use of assigned product~12-hr cardiovascular (CV) monitoring~Circadian blood draws~12-hr urine collection"
88999085|NCT04429568|Other|Either of the 2 remaining products|"Abstinence from any product night before hospital admission~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~6-hr abstinence and blood draws (PK)~2 hr Free use session w/ video monitoring~Free use of assigned product~12-hr CV monitoring~Circadian blood draws~12-hr urine collection"
88999086|NCT04429568|Other|Remaining product|"Abstinence from any product night before hospital admission~Standardized Session of assigned product: smoked cannabis, vaped cannabis, or tobacco cigarette~6-hr abstinence and blood draws (PK)~2 hr Free use session w/ video monitoring~Free use of assigned product~12-hr CV monitoring~Circadian blood draws~12-hr urine collection"
88999087|NCT04414722|Placebo Comparator|Concurrent control yogurt and amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
88999088|NCT04414722|Placebo Comparator|Control yogurt taken 4 hours after amoxicillin-clavulanate|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
88999089|NCT04414722|Active Comparator|Concurrent BB-12 yogurt and amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt and amoxicillin-clavulanate 875 mg-125 mg oral tablet, taken at the same time
88999090|NCT04414722|Active Comparator|BB-12 yogurt taken 4 hours after amoxicillin-clavulanate|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt taken 4 hours after amoxicillin-clavulanate 875 mg-125 mg oral tablet
89055226|NCT00179673|Experimental|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
89055227|NCT01084655|Experimental|Phase 1: Orteronel 200 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 200 milligram (mg), tablets, orally, twice daily (BID) starting from Day 1 along with docetaxel 75 milligram per square meter (mg/m^2), infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
89055228|NCT01084655|Experimental|Phase 1: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Day 1 along with docetaxel 75 mg/m^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
89055229|NCT01084655|Experimental|Phase 2: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Cycle 1 Day 15 along with docetaxel 75 mg/m^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets, orally, twice daily from Day 1 up to Day 21 of each 21-day treatment cycle until disease progression or end of treatment (EOT).
89055230|NCT04552431|Placebo Comparator|Placebo|Men assigned to placebo
89055231|NCT04552431|Experimental|Ciprofloxacin alone|Men assigned to Ciprofloxacin alone
89055232|NCT04552431|Experimental|Tamsulosin alone|Men assigned to Tamsulosin alone
89055233|NCT04552431|Experimental|Combination of ciprofloxacin and tamsulosin|Men assigned to a combination of ciprofloxacin and tamsulosin
89055234|NCT01084538||End stage chronic kidney disease|Secondary hyperparathyroidism defined as intact PTH > 300 pg/mL
89055235|NCT01083680||Participants with Crohn's Disease (CD)|Participants with Crohn's Disease treated with adalimumab (HUMIRA®) in routine clinical practice.
89055236|NCT00179517|Experimental|depotestosterone plus anastrozole (T-A)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes an oral tablet of anastrozole 1 mg daily for the duration of the study. This group is referred to as the depotestosterone plus anastrozole (T-A) group.
89055237|NCT00179517|Placebo Comparator|depotestosterone plus placebo (T-P)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes 1 matching placebo oral tablet daily for the duration of the study. This group is referred to as the depotestosterone plus placebo (T-P) group.
89055238|NCT01083641|Experimental|Estrogen Therapy|Estrogen therapy
89055239|NCT00179010|Experimental|Adenosine then Adenosine Mono Phosphate (AMP)|Intrarterial infusion of adenosine then same subject switch to AMP one month apart.
89055240|NCT00179010|Experimental|Adenosine Mono Phosphate (AMP) then adenosine|Intrarterial infusion of AMP then same subject switch to Adenosine one month apart.
89055241|NCT01083602|Experimental|panobinostat + bortezomib & dexamethasone|panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
89055242|NCT04552002|Experimental|Synbiotic group|"Intervention group:~Will receive synbiotic supplements: one capsule/day. Each capsule contains 20 billion CFU multi-strain probiotics + prebiotics (inulin and oligosaccharides) for a duration of 6 months."
89055243|NCT04552002|No Intervention|Placebo group|Will receive a placebo. The placebo will be similar to the synbiotic supplements in appearance.
89055244|NCT00178464|Experimental|Aspirin|One-arm study
89055245|NCT04671914|Active Comparator|Hyaluronic acid gel after D&C|After abortion in the II trimester, we provide D&C and after the procedure, we apply in uterine cavity Hyaluronic acid gel.
89055246|NCT04671914|Active Comparator|Only D&C|After abortion, in the II trimester, we provide only D&C.
89055247|NCT01083485|Experimental|Tablets Oxycodone Naloxone (OXN)|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)
89687793|NCT03403855|Experimental|Rocket® IPC- Long External Length|"Intervention Rocket® IPC- Long External Length: a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate their product."
89687794|NCT03403855|Experimental|Rocket® IPC- Short External Length|"Intervention Rocket® IPC- Short External Length : a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate Rocket's product."
89687795|NCT04373083|Experimental|Concomitant treatment|Treatment Group A
89687796|NCT04373083|Experimental|Sequential treatment|Treatment Group B
89687797|NCT03210545|Active Comparator|betamethasone - physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated physiological dose during one treatment period.
89687798|NCT03210545|Active Comparator|betamethasone - supra physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated supra physiological dose during one treatment period.
89687799|NCT04372849|Active Comparator|Nasal insulin spray|
89687800|NCT04372849|Placebo Comparator|Placebo spray|
89687801|NCT03210389|Experimental|lobaplatin+5-FU|Patients enrolled in this trial would get 4-6 cycles of lobaplatin + 5-FU chemotherapy.
89217237|NCT05352438|Experimental|Splint Therapy Group|Splint Therapy combined with education and home exercises
89217238|NCT04069871|Active Comparator|TENS|
89217239|NCT04069871|Sham Comparator|Control|
89217240|NCT04035746||Single-group study|Assessment of microcirculation, brain plasticity and clinical function
89217241|NCT00948324|Active Comparator|CSII|CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.
89217242|NCT00948324|Active Comparator|ALA|ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.
89217243|NCT00948324|Active Comparator|RSG|RSG:CSII combined with three months rosiglitazoneor 4mg QD.
89217244|NCT00948324|Active Comparator|MET|MET:CSII combined with metformin 500mg BID-TID.
89217245|NCT01012635||Neurofeedback, tDCS (2 levels), Self-hypnosis, Meditation|
89217246|NCT04068701|Experimental|MaNMT Biofeedback|A group that will receive a neuromuscular training intervention that incorporates biofeedback training
89217247|NCT04068701|Sham Comparator|Sham|a group that will receive the same neuromuscular training intervention with sham feedback training.
89217248|NCT05352360|Experimental|Pilates Exercises with kinesiotaping|
89217249|NCT05352360|Experimental|Muscle energy technique with kinesiotaping|
89217250|NCT02573285|Active Comparator|Simple Aspiration|Subjects in this arm will undergo initial management of their pneumothorax with a simple aspiration procedure. The procedure will involve placement of a small catheter into the chest cavity and applying negative pressure to manually aspirate the air out of the chest cavity, which will allow the lung to re-expand.
89217251|NCT02573285|Active Comparator|Surgeon Preference|Subjects that choose the surgeon preference arm of the study are enrolling for prospective data collection only. These subjects will not have any portion their care directed by the study protocol. The decision to proceed with any treatment or intervention will be made jointly by the surgeon and the patient and his or her legal guardian. Any standard treatment option may be utilized, including simple aspiration, chest tube placement, or an operation (VATS).
89217252|NCT01009671|Experimental|ART 44|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
89217253|NCT01009671|Active Comparator|ART 50|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
89217254|NCT04199988||Athletes with shoulder pain|Overhead athletes with shoulder pain
89217255|NCT04199988||Athletes without shoulder pain|Overhead athletes without shoulder pain
89217256|NCT01009749|Experimental|MESA|
89217257|NCT01009749|Active Comparator|MESH|
89217258|NCT00719693|Experimental|A|ABT-143 under low-fat meal condition
89217259|NCT00719693|Experimental|B|ABT-143 under fasting meal condition
89217260|NCT00952770|Experimental|Atorvastatin|Group receiving atorvastatin 20mg/day
89217261|NCT00952770|Active Comparator|Simvastatin/Ezetimibe|Group receiving simvastatin/ezetimibe 10/10mg
89217262|NCT01009827||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at the 15 sites and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
89217263|NCT00719771|Other|Global® AP™ Shoulder|Global® AP™ Shoulder
89217264|NCT00948402|Experimental|metformin|
89217265|NCT00948402|Active Comparator|oral contraceptive|
89217266|NCT04068467|Experimental|Active|Instructed to download the app and use the app daily for 30 days.
89217267|NCT04068467|Active Comparator|Waitlist Control|Waitlist control.
89217268|NCT05352126|Experimental|Puressentiel Purifying spray|"Puressentiel Air Purifying Spray with 41 essential oils~Capacity: 200 ml~BIOCIDE Product type 2: Disinfectants used in the private and public health sector~Composition: Ethanol (CAS no. 64-17-5) 75% m/m and 41 essential oils"
89217269|NCT05352126|Placebo Comparator|Placebo|Saline spray in the similar device as Puressentiel Purifying spray
89217270|NCT00719927|Experimental|1|Comadre Treatment
89217271|NCT00719927|Active Comparator|2|Non Support Partner Treatment
89217272|NCT00711659||1|all third year medical students starting their pediatric clerkship rotation
89217273|NCT05351970||Monofilament closure|Patients with midline emergency laparotomy, which closure was performed with monofilament suture
89687802|NCT03403777|Experimental|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks. Courses will be repeated every 14 days until progression or unacceptable toxicity. AVELUMAB will be administered as a 1-hour (-10 minutes / +20 minutes, i.e., 50-80 minutes) intravenous (i.v.) infusion. The dose of AVELUMAB will be calculated based on the weight of the subject determined on the day prior to or the day of each drug administration.
89687803|NCT01837121|Other|the SMS group|the diabetic retinopathy patient in the SMS group will receive a SMS reminder message about the revisit time,address 1 week and 3 day before the appointment.
89687804|NCT01837121|No Intervention|the control group|the diabetic retinopathy patient in the control group won't get any reminder message before the appointment.
89687805|NCT02241421|Placebo Comparator|Placebo|No intervention: Placebo 3x2 capsules per day during 7 consecutive days.
89687806|NCT02241421|Experimental|Treatment Antibiotics: Amoxicillin|Experimental: Amoxicillin (broad spectrum antibiotics) 1500 mg/day (3x2 capsules of 250 mg) during 7 consecutive days.
89687807|NCT02241421|Experimental|Treatment Antibiotics: Vancomycin|Experimental: Vancomycin (small spectrum antibiotics) 1500mg/day (3x2 capsules of 250 mg) during 7 consecutive days
89687808|NCT01837199|Experimental|Smoking|Metronidazole plus Amoxicillin
89687809|NCT01837199|Experimental|Non-Smoking|Metronidazole plus Amoxicillin
89687810|NCT03210233|Experimental|Naive controls|Never received teicoplanin. Blood test, skin testing and challenge testing.
89687811|NCT03210233|Experimental|High Risk|Received teicoplanin and suffered suspected IgE mediated anaphylaxis. Blood test, skin testing and challenge testing.
89687812|NCT03210233|Experimental|Low Risk|Received teicoplanin previously with no adverse reaction Blood test, skin testing and challenge testing.
89687813|NCT01837355|Placebo Comparator|Placebo|placebo once daily for 12 weeks
89687814|NCT01837355|Experimental|Lactobacillus rhamnosus|lactobacillus rhamnosus once daily for 12 weeks
89687815|NCT03210311|No Intervention|control group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~Perform skin care~Perform twice a day upper limb exercises at home. They are advised to use the arm as normal as possible."
89687816|NCT03210311|Active Comparator|intervention group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~Perform skin care~Perform upper limb exercises at home twice a day. They are advised to use the arm as normal as possible~Wear a compression sleeve"
89687817|NCT00926185|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
89687818|NCT00926185|Experimental|0.1% Lifitegrast|Lifitegrast
89687819|NCT00926185|Experimental|1.0% Lifitegrast|Lifitegrast
89687820|NCT00926185|Experimental|5.0% Lifitegrast|Lifitegrast
89687821|NCT03210467||experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
89687822|NCT03210467||control group|patients who were untreated ever in immune-active phase took entecavir(ETV) for maintenance treatment.
89687823|NCT01837511||Cancer Group|Patients with pathologically proven stage I, II and III NSCLC.
89217274|NCT05351970||Barbed closure|Patients with midline emergency laparotomy, which closure was performed with barbed suture
89217275|NCT05351814|Active Comparator|Control group|Control group; traditional patellofemoral pain syndrome exercises; isometric exercises 3 sets of 10 repetitions in one session, balance exercise 30/45 sec, one leg balance exercise 45/60 sec , stretching exercises 4 sets 5 repetitions 20 sec duration, off kinetic chain (CHC) AND open kinetic chain (ACZ) exercises were planned as 3 sets for 4 weeks and 3 days a week.
89687824|NCT00921895|Experimental|Device Testing|Patients with conjunctivitis will be tested with the RPS Adeno Detector IV
89687825|NCT03210077||Entropy Group|General Anesthesia using Entropy Monitoring
89687826|NCT03210077||Control Group|General Anesthesia without Entropy (Control Group)
89687827|NCT04372771|No Intervention|Control|No diet or exercise intervention
89687828|NCT04372771|Experimental|Curves Program|The Curves group will follow the high protein/low fat diet (30% carbohydrate, 45% protein, 25% fat) for 7-days at 1,200 kcals/day and then 1,500 kcals/day for the remaining 21-days of the 30-day diet period. The participants will then consume a normal maintenance diet (2,200 kcals/d; 45% carbohydrate, 30% protein, 25% fat) for 30-days. During the maintenance period, participants will diet for 2-days at 1,200 kcals/day if they gain 3 pounds of weight.
89687829|NCT04372771|Experimental|Weight Watchers Momentum Program|"This program is based on the Weight Watchers four pillar approach (food, exercise, behavior and support). The Momentum Program uses POINTS values to help keep track of what you eat. A POINTS budget will be personalized for you at the weekly meetings."
89687830|NCT01837589|Other|QCT and DXA|All the patients will have both QCT and DXA
89687831|NCT02241499|Experimental|Radiotherapy and chemotherapy (oxaliplatin and fluorouracil).|Radiotherapy (5 x 4 Gy) will be given. After completion of radiotherapy, 4 cycles of chemotherapy will be administered, cycle length 14 days. Each patient will receive oxaliplatin as infusion at a dose of 85 mg/m2, followed by a bolus injection of fluorouracil at a dose of 400 mg/m2, and a long time infusion (44 hours) of fluorouracil at a dose of 2 400 mg/m2.
89687832|NCT01837667|Experimental|LB-100 for Injection and Docetaxel|Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.
89687833|NCT02241577|Experimental|Surgical treatment|Surgical access for scaling and disinfection of dental implant
89687834|NCT02241577|Experimental|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of dental implant
89687835|NCT04372303|Experimental|Short-term Compassion Fatigue Resiliency Program|Experimental I received a short-term program (five hours per day for two days, ten hours in total).
89687836|NCT04372303|Experimental|Long-term Compassion Fatigue Resiliency Program|Experimental II received a long-term program (five weeks, two hours per week, ten hours in total).
89687837|NCT04372303|No Intervention|Control|No intervention was applied to the control group.
89055248|NCT01083485|Active Comparator|Oxycodone|Oxycodone PR 20mg or 10mg (twice a day) BID for 2.5 days (total 5 dosages)
89055249|NCT02213835|Experimental|Specific Carbohydrate diet (SCD)|"The treatment for this study will be the Specific Carbohydrate diet (SCD). Intervention will be based upon standard dietary therapy as well as a nutritional handbook developed in the Gastroenterology division. Patients will receive one-on-one guidance by a Seattle Children's Dietician trained in the SCD during each visit. Prior to each visit patient will fill out a 3 day nutrition log which will be reviewed by the dietician during the clinic visit. Each patient will receive books on the SCD therapy which will include recipes and information about the diet The two books given will include Breaking the Vicious Cycle by Elaine Gottschall and Recipes for the Specific Carbohydrate Diet by Raman Prasad."
89055250|NCT04551924|Experimental|dose 1|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
89055251|NCT04551924|Experimental|dose 2|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
89055252|NCT04551924|Experimental|dose 3|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
89055253|NCT04551924|Experimental|dose 4|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
89055254|NCT04551924|Active Comparator|Naropin|Naronpin injection contains ropivacaine HCl. Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
89055255|NCT04671836|Experimental|Lorazepam first|This arm comprises of participants who were randomized to receive lorazepam 1 mg prior to the first MRI scan and then placebo on the second MRI scan a week later.
89055256|NCT04671836|Placebo Comparator|Placebo first|This arm comprises of participants who were randomized to receive placebo prior to the first MRI scan and then lorazepam 1 mg orally prior to the second MRI scan a week later.
89055257|NCT04552353|Experimental|Vaway Lyo-Injection|Voriconazole, 200 mg/vial
89055258|NCT04552353|Active Comparator|Vfend Lyo-Injection|Voriconazole, 200 mg/vial
89055259|NCT00556088|Experimental|Part 1|"Part I Phase I dose escalation trial. LBH589 will be administered orally on Monday and Thursday or Tuesday and Friday each week (twice weekly). Paclitaxel and carboplatin will be administered intravenously every 21 days.~Part II LBH589, paclitaxel, and carboplatin dosing will be determined in the first phase of this study (Phase I). The drug dosages to be administered will be reduced one level from the determined Maximum Tolerated Dose (MTD). In addition, bevacizumab 15 mg/kg will be added to the second portion of this trial."
89055260|NCT01083173||Participants with HIV-1 infection|Participants treated with Kaletra (lopinavir/ritonavir 200 mg/50 mg and 100 mg/25 mg) tablet
89055261|NCT00177294|Experimental|1|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly interpersonal psychotherapy (IPT)
89055262|NCT00177294|Active Comparator|2|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly depression care management(DCM) without interpersonal psychotherapy (IPT)
89055263|NCT01082081|Experimental|Paracetamol 1000 mg|Paracetamol 1000 mg
89055264|NCT01082081|Experimental|Paracetamol 500 mg|Paracetamol 500 mg
89055265|NCT01082081|Placebo Comparator|Placebo|Placebo
89055266|NCT00177216|Experimental|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
89055267|NCT00177216|Experimental|Excitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
89055268|NCT00177216|Placebo Comparator|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
89055269|NCT01081886|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
89055270|NCT01081886|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
89055271|NCT02213952|Experimental|Platelet-Rich Plasma|Our goal is to evaluate the efficacy of the autologous Platelet-Rich Plasma (PRP) in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous ulcer.
89687838|NCT03217877|Active Comparator|No Routine stress testing after PCI|
89687839|NCT03217877|Experimental|Routine stress testing at 9~15 months after PCI|
89687840|NCT03403543||1|This cohort study only set up a group. We will follow up and observe the pregnant women's lifestyle during pregnancy in order to find the risk factors of adverse pregnancy outcomes. We will divide the participants into more than one group according to the variables（e.g. age, smoking status, drinking status, sleep pattern .etc.）
89687841|NCT04379531|Active Comparator|Standard Chest CT|
89687842|NCT04379531|Experimental|Low-dose Chest CT|
89687843|NCT03833947|Experimental|lignocaine with bicarbonate|Endotracheal tube cuff was filled with mixture of 7.5% sodium bicarbonate with 2% lignocaine in a ratio of 0.5:9.5 ml
89687844|NCT03833947|Active Comparator|lignocaine with dexamethasone|Endotracheal tube cuff was filled with mixture of dexamethasone with 2% lignocaine in a ratio of 0.5:9.5 ml
89687845|NCT03219437|Active Comparator|Methotrexate|Participants to receive double-blind methotrexate.
89687846|NCT03219437|Experimental|Risankizumab|Participants to receive double-blind risankizumab.
89687847|NCT00920023|Experimental|SPIO MRI|
89687848|NCT03212963|Experimental|Halobetasol lotion treatment arm|All subjects will receive Halobetasol Topical Lotion, 0.05%.
89687849|NCT03403309|Experimental|Inosine 5'-monophosphate arm|Subjects are treated with inosine 5'-monophosphate to increase serum uric acid level.
89687850|NCT03403309|Placebo Comparator|Placebo arm|Subjects are treated with placebo not to increase serum uric acid level.
89687851|NCT04347499|Experimental|Intervention|This group will receive CaCBT based guided selfhelp using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual
89687852|NCT04347499|No Intervention|Control|This group will receive treatment as usual
89055272|NCT02213952|Active Comparator|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
89687853|NCT03218969|Experimental|Study period 1|"Ecopipam or matching placebo 25 mg by mouth for 7 days (week 1), followed by~Ecopipam or matching placebo 50 mg by mouth for 7 days (week 2), followed by~Ecopipam or matching placebo 100 mg by mouth for 23 days (weeks 3)."
89687854|NCT03218969|Experimental|Study period 2|"Matching placebo or ecopipam 25 mg by mouth for 7 days (week 7), followed by~Matching placebo or ecopipam 50 mg by mouth for 7 days (week 8), followed by~Matching placebo or ecopipam 100 mg by mouth for 23 days (week 9)."
89687855|NCT02982499||control group|Healthy participants will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
89687856|NCT02982499||optic neuropathy group|Participants with optic neuropathy will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
89687857|NCT03214523|Experimental|Sleep Education|The intervention will be a brief education of the importance of sleep and healthy sleep habits. Subjects will also receive a standard sleep brochure on healthy sleep (which will also be given to the other arm).
89687858|NCT03214523|No Intervention|Sleep Brochure|Subjects will receive a one page hand out on healthy sleep habits.
89687859|NCT01838291||Patients on Ferriprox therapy <1 month|
89687860|NCT04372537|Experimental|Hypnosis|"Patients will benefit from formal hypnosis (trance induction, hypno analgesia, comfort suggestions) and/or conversational hypnosis (confusion, distraction, use of chosen words, goodwill using verbal and non verbal languages).~They will also get to be informed of the proceedings of the performed examination as the standard procedure group."
89687861|NCT04372537|Active Comparator|Standard procedure group.|"Patients will be informed of the proceedings of the performed examination, without using any hypnosis technique.~This corresponds to the standard clinical procedures used while performing an electroneuromyogram."
89687862|NCT04372225||477 patients|the biological tests of 477 patients undergoing total thyroidectomy were analyzed
89687863|NCT03214289|Experimental|Fecal Microbiota Transplantation (FMT)|"Participants will receive a single dose of oral FMT, which is 15 capsules per day for 2 consecutive days (total of 30 capsules). All capsules administered to a participant are from the same unrelated donor. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Participants will be asked to drink at least 360cc of water during administration.~Treatment will be administered on an inpatient basis. In patients with no/partial response, the FMT may be repeated from the same or a different donor.~Subjects receiving any amount of the FMT capsules will be followed for at least 6 months.Stool and blood samples will be serially collected."
89687864|NCT01830023||cardiac ultrasound examination|
89055273|NCT01081769|Experimental|Paliperidone Palmitate|paliperidone palmitate injection with 150 mg equivalent on Day 1 100 mg equivalent on Day 8 75 mg equivalent on Day 38 and flexible dosing with 25 50 75 100 or 150 mg equivalent once monthly thereafter
89055274|NCT01081769|Active Comparator|Oral Antipsychotics|oral antipsychotics daily treatment according to local label for maximally 24 months
89687865|NCT01830101|Experimental|TMZ plus concurrent re-irradiation|TMZ plus concurrent re-irradiation
89687866|NCT01830101|Experimental|TMZ alone|TMZ alone
89687867|NCT01838603||Interventional pain management patients|Patients passed through interventional pain management program
89687868|NCT01830257|Experimental|sending message|The investigators would send the tip to the children's guardian
89687869|NCT01834625||Florbetapir +ve NPH patients|Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
89055275|NCT04551768|Experimental|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
89055276|NCT04551768|Experimental|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
89687870|NCT01834625||Florbetapir -ve patients|Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
89687871|NCT01838759||Hypovolemic hyponatremia|"Negative values of Overhydration measured by Bioimpedance spectroscopy"
89687872|NCT01838759||Hypervolemic hyponatremia|"Positive values of Overhydration measured by Bioimpedance spectroscopy"
89687873|NCT01830335|Experimental|Drug|Indomethacin 1.2 mg kg 1 dose
89687874|NCT01830335|Placebo Comparator|Placebo|flour capsule
89055277|NCT04671407|Active Comparator|CONTROL|40ml of hypersal saline (3% NaCl) will be administered to bladder the after the surgery
89055278|NCT04671407|Placebo Comparator|PLACEBO|40ml of normal saline (0.9% NaCl) will be administered to bladder the after the surgery
89055279|NCT02213991|Experimental|Intraoperative Radiotherapy|"Intervention:~Intraoperative Radiotherapy~* Operation day~Breast conservative surgery + Intraoperative radiotherapy 20 Gy~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity. Purse string suture pulles up tissues and wraps up the applicator. IORT with 20Gy is followed. After IORT, applicator was out of the operative field, and usual wound closure will be done.~* Postoperative period~± Chemotherapy~WBRT (46 Gy) for 4~5 weeks~± Endocrine therapy or target therapy"
89055280|NCT04671641|Experimental|Endovenous Radiofrequency Ablation Closure System|
89055281|NCT04671641|Active Comparator|ClosureFast™ Radiofrequency Ablation System|
89687875|NCT00926263|Experimental|10 mg/kg cohort|
89687876|NCT00926263|Experimental|20 mg/kg cohort|
89687877|NCT00926263|Experimental|20/20 mg/kg cohort|
89687878|NCT01838915|Experimental|Dietary Supplement: Prebiotics+Glutamine|
89687879|NCT01838915|Placebo Comparator|Placebo|
89687880|NCT01725659|Experimental|Motor Learning|subjects are provided with intensive motor learning training of the upper limb
89687881|NCT01725659|Experimental|Robotics and Motor Learning|subject are provided with intensive motor learning and robotics training of the upper limb
89687882|NCT01725659|Experimental|Motor learning and FES|subjects are provided with intensive motor learning and surface FES (Functional Electrical Stimulation) of the upper limb
89687883|NCT00926497|Experimental|Procalcitonin group|Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
89687884|NCT00926497|No Intervention|Standard group|Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters
89687885|NCT00916643|Experimental|H.E.L.P. Secura|"The H.E.L.P. System is a device composed of multiple modules and their associated disposables which can selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient. Procedure steps:~Flushing the system with normal saline.~Filtering whole blood through a 0.2 micron plasma filter for continuous plasma removal.~Mixing the plasma with an equal volume of acetate buffer containing heparin.~Precipitation of LDL as a complex with heparin.~Removing the LDL-heparin precipitate by continuous circulation through a filter.~Removing heparin with use of a heparin adsorber.~Bicarbonate dialysis and ultrafiltration to produce an LDL-free plasma without excess heparin.~Re-mixing the LDL-free plasma with blood coming from the plasma filter and returning the reconstituted blood to the patient."
89687886|NCT04372147|Experimental|intervention group|MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
89687887|NCT04372147|No Intervention|control group|standard medical care
89687888|NCT03409913||GCA cases|In a cohort of patients suspected of GCA based on the following inclusion criteria were 1) age ≥50 years, 2) CRP>15mg/l or ESR>40mm/h, 3) either a) cranial symptoms, b) new-onset extremity claudication or c) weight loss >5 kilograms or fever>38oC for >3 weeks, patients with a clinical diagnosis of GCA is identified.
89217276|NCT05351814|Experimental|Core Stability group|Core stability group; In addition to traditional patellofemoral pain syndrome exercises; hip muscle strengthening exercises are 3 sets of 10 repetitions in each session, and (core) stabilization exercises are 1st and 2nd weeks 2 sets 15 repetitions 3rd and 4th weeks 2 sets 5 repetition was planned for 4 weeks and 3 days a week.
89217277|NCT03911999||Non-prostate cancer subjects|No clinical evidence of prostate cancer
89217278|NCT03911999||Subjects with pathologically insignificant prostate cancer|Insignificant prostate cancers were organ confined with tumor volumes less than 0.5 cc and Gleason score < 7.
89687889|NCT03409913||controls|Age-(+/- 3 years) and sex-matched malignant melanoma (MM) patients who had a follow-up metastatic-disease-free FDG PET/CT ≥6 months after MM resection
89687890|NCT03403075|Active Comparator|Usual Care|"Control Group will be offered usual care (UC), plus two sessions of therapeutic education delivered in small groups. In these educational sessions, patients are provided with useful information on communication strategies, problem solving strategies, recognition and management of symptoms and the management of any aids/orthoses provided in everyday life, etc. In the meetings, it will be emphasized the importance of maintaining an active lifestyle as much as possible by encouraging involvement in physical activity even during the cancer treatment period.~Written information material that summarizes the concepts addressed during group meetings will be provided."
89687891|NCT03403075|Experimental|ETAF: Therapeutic Education Physical Activity|"Intervention group will perform UC, and the two sessions of therapeutic education delivered in small group, as for the Control Group. The Intervention group will also provided for 6 individual sessions of therapeutic education and physical activity held by physiotherapists dedicated to the study, according to the patients' needs and objectives.~In these sessions, the topics discussed in group will be deepened, personalizing them according to the patient's characteristics. Furthermore, personalized physical activity is planned, taking into account the context of execution, the clinical condition and the patient's preferences. The patient will be trained to build an action plan aimed at self-plan physical activities and a diary will be provided to monitor the physical activity carried out autonomously.~Written information material that summarizes the concepts addressed during group and individual sessions will be provided."
89687892|NCT03833869|Experimental|Assisted hatching|Five-day frozen embryos will undergo assisted hatching prior to embryo transfer
89687893|NCT03833869|No Intervention|Control|Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer
89687894|NCT01725737|Placebo Comparator|Placebo|
89687895|NCT01725737|Active Comparator|GlyTI-M|GlyTI-M: 0.03gm/kg/day
89687896|NCT04371991||Group 1|Ectopic pregnancy
89687897|NCT04371991||Group 2|Early viable pregnancy
89687898|NCT04371991||Group 3|incomplete miscarriage
89687899|NCT04371991||Group 4|Healthy women
89687900|NCT02242279|Experimental|BEA 2180 - low dose|
89687901|NCT02242279|Experimental|BEA 2180 - medium dose|
89687902|NCT02242279|Experimental|BEA 2180 - high dose|
89687903|NCT02242279|Active Comparator|Tiotropium|
89687904|NCT02242279|Placebo Comparator|Placebo|
89687905|NCT04371757|Experimental|Aerobic exercise session|The aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end.
89687906|NCT04371757|Experimental|Resistance exercise session|The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise.
89687907|NCT04371757|Experimental|Combined exercise session|The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises.
89687908|NCT00917735|Experimental|Green tea extract|Green tea extract capsules containing 80.7 % total catechins (51.7 % EGCG)
89687909|NCT00917735|Placebo Comparator|Sugar pill|Placebo capsules containing 50% maltodextrin, 49.5 % cellulose, and 0.5 % magnesium stearate
89055282|NCT04551534|Experimental|DNL201|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
89687910|NCT04371601|Active Comparator|Control group|conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies
89687911|NCT04371601|Experimental|Experimental group|On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106/Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission
89055283|NCT04551534|Placebo Comparator|Placebo|Part 1: Single-ascending dose cohorts; Part 2: Multiple-ascending dose cohorts (10 days); Part 3: Additional multiple-dose cohort (10 days)
89055284|NCT04551456|Placebo Comparator|Placebo Infusion PBS|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to have standard of care plus placebo. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Assigned Interventions:~Biological/Vaccine: Biological/Vaccine: WJMSCs Vs.placebo"
89055285|NCT04551456|Experimental|Single dose Infusion WJMSCs|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to standard of care plus one time or three times in doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Biological/Vaccine:~WJMSCs Vs.placebo"
89055286|NCT04551456|Experimental|Infusion WJMSCs multiple doses|"The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to one time or three times at 30-day intervals for equal doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.~Biological/Vaccine:~WJMSCs Vs.placebo"
89055287|NCT01081301|Experimental|Living with Hope Program|Receive Living with Hope Program
89055288|NCT00174954||1|Volumes/measurements of tophi determined by serial MRIs
89055289|NCT04671563|Experimental|Viproof Film Coated Tablets 300mg|Dosage form：Film-coated tablet Strength： 300 mg/tablet Dose：300 mg (one tablet, single oral dose)
89055290|NCT04671563|Active Comparator|Viread Tablets|Dosage form：Film-coated tablet Strength： 300 mg/tablet Dose：300 mg (one tablet, single oral dose)
89055291|NCT04551573|Experimental|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
89055292|NCT04551573|Experimental|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
89055293|NCT01081145|Experimental|Extended-release Guanfacine HCl|
89055294|NCT01081145|Placebo Comparator|Placebo|
89055295|NCT00174915|Experimental|Febuxostat 80 mg QD|
89055296|NCT00174915|Experimental|Febuxostat 120 mg QD|
89055297|NCT00174915|Experimental|Febuxostat 240 mg QD|
89055298|NCT00174915|Active Comparator|Allopurinol QD|
89055299|NCT00174915|Placebo Comparator|Placebo QD|
89055300|NCT04671368|Experimental|Artificial Intelligence|A deep learning based artificial intelligence diagnostic system(DOI:10.1093/neuonc/noaa163)
89055301|NCT04671368|Active Comparator|Practicing Pathologists|One pathologist who has at least 5 years of experience
89055302|NCT04671368|Other|Gold Standard|A committee composed of two expert pathologists who has at least 10 years of experience and one expert pathologist who has at least 15 years of experience
89055303|NCT01080716|Experimental|Part 1/Arm 1 of Study: WRSS1 vaccine|WRSS1 is a live attenuated S. sonnei vaccine candidate derived from the Mosely strain of S.sonnei
89687912|NCT01832207|Active Comparator|MTS|Motor threshold of stimulation
89687913|NCT01832207|Active Comparator|STS|Sensorial threshold of stimulation
89687914|NCT01832207|Sham Comparator|Placebo|
89687915|NCT04371523|Experimental|Intervention - Hydroxychloroquine|
89055304|NCT01080716|Placebo Comparator|Part 1/Arm 2 of Study: Placebo vaccine|Placebo
89055305|NCT01080716|Experimental|Part 2/Arm 1 of Study: S. sonnei 53G|10 volunteers from Study Arm 1/Part 1 (WRSS1 vaccine) plus 4 alternates from Arm 1/Part 1 are given 53G S. sonnei
89055306|NCT01080716|Active Comparator|Part 2/Arm 2 of Study: S sonnei 53G|10 subjects (naïve controls) plus 4 alternates are give 53G S sonnei
89055307|NCT04551339|Active Comparator|High dose Zinc (PreserVision AREDS formulation soft gels or tablets)|Subjects will have a high dose Zinc supplementation in combination with Copper, Vitamin C/E and beta-carotene
89055308|NCT04551339|Active Comparator|Multivitamin with 11mg of zinc|Subjects in this arm will have a multivitamin supplement with 11mg of zinc
89055309|NCT04671446||Severe eosinophilic asthma and/or EGPA|
89055310|NCT04671446||Other respiratory conditions|Milder asthma, other vasculitides, eosinophilic COPD, and/or eosinophilic oesophagitis
89055311|NCT04671446||Healthy controls|
89055312|NCT04671134|Experimental|Biomimetic remineralizing agent|
89055313|NCT04671134|Active Comparator|Resin modified glass ionomer varnish|
89055314|NCT04571489|Experimental|Gimatecan group|All patients will receive gimatecan (0.8mg/m2, on days 1 to 5, PO, every 4 weeks) until progressive disease (PD).
89055315|NCT04571489|Placebo Comparator|placebo group|All patients will receive tegafur, gimeracil and oteracil potassium (40-60mg, twice daily, on days 1 to 14 , PO, every 3 weeks) or gemcitabine (1000mg/m2, on days 1、8, IV, every 3 weeks) until progressive disease (PD).
89055316|NCT00172185|Experimental|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d teduglutide subcutaneous injection
89055317|NCT00172185|Experimental|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d teduglutide subcutaneous injection
89055318|NCT01080326|Experimental|Endoscopic Translumenal Omental Patch|Patients with the clinical diagnosis of a perforated viscus who are scheduled to undergo surgical exploration will be recruited. The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix the Endoscopic Translumenal Omental Patch in place.
89687916|NCT04371523|Placebo Comparator|Control|
89687917|NCT03402997||Resistivity measurements|The resistivity measurements will be done by introducing the needle-probe into fresh healthy, peritumoral, and tumoral ex vivo tissues
89687918|NCT01837979||DBS screening test|cell-free fetal DNA for Dried blood spots samples in high risk pregnant women.
89687919|NCT01837979||maternal serum screening test|cell-free fetal DNA for maternal serum screening test samples in high risk pregnant women.
89687920|NCT02242357||Patients with hypertension|
89687921|NCT03409835|Experimental|Ramosetron|
89687922|NCT03409835|Placebo Comparator|Control|
89687923|NCT02242513|Active Comparator|pulsed mode radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. One dose of PRF was given in tibial nerve behine the medial ankle in intervention group.
89055319|NCT00171951|Experimental|Pasireotide 600 μg BID SC or Ramp up Dose 900 μg BID SC|Participants received pasireotide 600 micrograms (μg) twice daily (BID) subcutaneously (SC) to achieve or maintain urinary free cortisol (UFC) normalization. If UFC levels were increased at any time, participants received 900 μg BID SC, until no safety or tolerability concerns were observed as per investigators assessment. If the participant was unable to tolerate the 900 μg BID, dosing of 600 μg three times a day was given.
89055320|NCT01080131|Experimental|Canakinumab 150 mg|"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to receive open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year, for a total duration of 18 months."
89055321|NCT01080131|Active Comparator|Triamcinolone acetonide 40 mg|"Participants received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to switch to open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year. Triamcinolone acetonide was not to be administered in the second extension study."
89055322|NCT04551612||Patients with cholesteatoma|Patients with cholesteatoma in one ear that will compared with the other healthy one.
89055323|NCT00171873|Experimental|Octreotide LAR (Long Acting Release)|Octreotide LAR 30 mg intramuscularly every 28 days
89055324|NCT00171873|Placebo Comparator|Placebo|Placebo - Sodium chloride intramuscularly every 28 days
89055325|NCT01087151|Active Comparator|A|
89055326|NCT01087151|Experimental|B|
89055327|NCT01087151|Experimental|C|
89055328|NCT04551027|Experimental|compensatory cognitive treatment|compensatory cognitive treatment intervention, focusing on learning cognitive strategies to overcome cognitive deficits.
89055329|NCT04551027|No Intervention|control group|standard ambulatory treatment
89055330|NCT04571528|Experimental|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
89055331|NCT04571528|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
89055332|NCT04571528|Active Comparator|Physiotherapy part of VIRTUA FIBROWALK|The physiotherapy part of the VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE) and therapeutic exercise.
89055333|NCT02214030|Active Comparator|Assiut Femoral Compression Device|the sheaths were removed 2 hours after PCI instead of conventional 6hours. To standardize compression times, AFCD were applied to patient and complete femoral artery compression were applied for 5 minutes, followed by a gradual release of pressure over the ensuing 8 minutes. Therefore each patient received a minimum of 13 minutes of compression, with further compression applied only if full hemostasis had not been achieved at that point with maximum of 30 minutes.
89055334|NCT02214030|Placebo Comparator|Manual compression|The intra-arterial sheaths were removed 6 hours after PCI in the MC group according to the standard local protocols.
89055335|NCT04571996|Experimental|ODM-104 and Panadol Zapp|
89055336|NCT00171249|Experimental|Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 400 mg|Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
89217279|NCT03911999||Subjects with pathologically significant prostate cancer|Significant cancers are those with either Gleason score > 7, evidences of extra-prostatic extension with positive margins, or seminal vesicles / lymph nodes involvement.
89687924|NCT02242513|Placebo Comparator|Xylocaine|2 c.c xylocaine was given in tibial nerve behind the medial ankle in control group.
89687925|NCT03409757||hemodialysis patients with hyperphosphatemia|"dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool~Velphoro® medication"
89687926|NCT03409757||control group|- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
89687927|NCT03402763|No Intervention|Control Arm|Participants receive a short informational handout on the process and choices involved in advance care planning.
89687928|NCT03402763|Experimental|Intervention|Participants are shown a 6-minute video that describe CPR, breathing tube placement, and mechanical breathing support in addition to the general process of advance care planning.
89687929|NCT03409679|Experimental|Murepavadin|Murepavadin IV + one anti-pseudomonal antibiotic
89055337|NCT00171249|Experimental|Lymphoid Blast Crisis 400 mg|Participants with lymphoid blast crisis received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
89055338|NCT00171249|Experimental|Acute Lymphoblastic Leukemia 400 mg|Participants with acute lymphoblastic leukemia received STI571 400 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
89055339|NCT00171249|Experimental|Accelerated Phase Chronic Myeloid/Myelogenous Leukemia 600 mg|Participants with accelerated phase chronic myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
89055340|NCT00171249|Experimental|Lymphoid Blast Crisis 600 mg|Participants with lymphoid blast crisis received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
89055341|NCT00171249|Experimental|Acute Lymphoblastic Leukemia 600 mg|Participants with acute lymphoblastic leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
89055342|NCT00171249|Experimental|Acute Myeloid/Myelogenous Leukemia 600 mg|Participants with acute myeloid/myelogenous leukemia received STI571 600 mg, orally, once daily, until death, the development of intolerable toxicity, or the investigator felt it was no longer in the participant's best interest to continue therapy, whichever came first.
89055343|NCT04671056|Experimental|MGL-3196 100 mg tablet plus Pioglitazone 15 mg tablet|MGL-3196 administered orally plus Pioglitazone administered orally on 2 separate days
89055344|NCT01082549|Active Comparator|gemcitabine/carboplatin|
89055345|NCT01082549|Experimental|gemcitabine/carboplatin plus Iniparib|
89055346|NCT02214069||Patients with Atrial Fibrillation|Patients with Atrial Fibrillation admitted to the hospital for drug loading with Dofetilide or Sotalol willing to record and transmit heart rhythm using AliveCor.
89055347|NCT04550949|Experimental|QL1206|QL1206 injection(120mg)was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
89055348|NCT04550949|Active Comparator|Xgeva®|Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
89055349|NCT01085630|Experimental|Arm I|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89055350|NCT01085630|Active Comparator|Arm II|Patients undergo observation until disease progression.
89055351|NCT00171210|Experimental|Deferasirox|All participants received Deferasirox (ICL670) orally once a day. Dosage based on body weight.
89055352|NCT04670861|Experimental|experimental group|Upper extremity Biodex balance training program three times/week for eight weeks in addition to regular weightlifting training exercises
89055353|NCT04670861|Active Comparator|control group|regular weightlifting training exercises
89055354|NCT00171054|Experimental|Valsartan 320 mg|
89055355|NCT00171054|Experimental|Amlodipine 10 mg|
89055356|NCT00174837|Experimental|Tirapazamine + Cisplatin|
89055357|NCT00174837|Active Comparator|Cisplatin|
89055358|NCT00179400|Active Comparator|Pioglitazone|
89055359|NCT00179400|Placebo Comparator|Placebo|
89217280|NCT00606086|Experimental|1|GI-5005 monotherapy continuing on to triple therapy
89217281|NCT00606086|Active Comparator|2|Standard of care alone
89055360|NCT04991090|Experimental|escalation|The gross tumor volume (GTV) was defined as gross disease determined on MRI scans. The clinical target volume (CTV) was defined as the GTV plus areas considered at significant risk of harboring microscopic area. The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost. The planning target volume (PTV) was generated by adding an 8-mm margin around the GTV, GTVnd, and CTV in all directions. Doses of 58 Gy, 50 Gy, and 45 Gy were delivered to PTV-GTVnd, PTV-GTV, and PTV-CTV at 25 fractions, respectively. The dose of the normal organs at risk was constrained to the following criteria: bowel bag, V50 ≤ 5%; bladder, V50 ≤ 50%; femoral heads, V50 ≤ 5% .
89055361|NCT04550793||Intervention|The stroke patients who receive botulinum toxin injection at affected brachialis and/or biceps brachials.
89055362|NCT04550793||Control|The stroke patients who do not receive botulinum toxin injection at affected brachialis and/or biceps brachials in the past 3 months.
89055363|NCT04550910|Other|Arm A|40 Gy /15 fx / 3 weeks, 5 days per week, is a dose prescribed (after randomization ) for Breast Cancer patients indicated for adjuvant RTH after mastectomy
89055364|NCT04550910|Experimental|Arm B|28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy is a dose prescribed (after randomization )for Breast Cancer patients indicated for adjuvant RTH after mastectomy
89055365|NCT00479856|Experimental|Lapatinib plus Chemotherapy|Lapatinib is administered in combination with one of the following chemotherapies based on the discretion of the investigator : capecitabine, docetaxel or nab-paclitaxel.
89055366|NCT04997759|Experimental|Neostigmine group|This group will administered neostigmine for reverse the efficacy of neuromuscular blocking agent and stabilize the patient's vital signs.
89055367|NCT04997759|Experimental|Sugammadex group|This group will administered Sugammadex for reverse the efficacy of neuromuscular blocking agent and stabilize the patient's vital signs.
89055368|NCT00479466|Experimental|MK0893 80 mg|MK0893 tablets totaling 80 mg once daily.
89055369|NCT00479466|Experimental|MK0893 60 mg|MK0893 tablets totaling 60 mg once daily.
89055370|NCT00479466|Experimental|MK0893 40 mg|MK0893 40 mg tablet once daily.
89055371|NCT00479466|Experimental|MK0893 20 mg|MK0893 20 mg tablet once daily.
89055372|NCT00479466|Active Comparator|Metformin|Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
89055373|NCT00479466|Placebo Comparator|Placebo|PLA tablets. 12 week treatment period.
89055374|NCT04991948|Experimental|CYAD-101 with FOLFOX Infusion administered concurrently followed by pembrolizumab|
89055375|NCT04550286|Experimental|Intervention Group|"Intervention points in time include:~Baseline measure~Installation of the study app~Advice on general enhancements regarding study environment and behavior (BCT 4.1)~Students are to develop up to three action plans (BCT 1.4) and coping plans (BCT 1.2) to reduce smartphone interference during exam preparation periods by putting the smartphone away~Students receive weekly questionnaire (t1-t3) and one questionnaire after their first exam (t4). All these questionnaires concern their academic performance and well-being. A short questionnaire (t5) asks for the participants' exam grades approx. 2 months after their exam. A time period of 2 months has been chosen to ensure that universities have enough time to announce the grades.~During the whole period of the study, the mobile application tracks the students' smartphone behavior (i.e., daily smartphone use, daily screen activations, and specific app usage)."
89055376|NCT04550286|Active Comparator|Control Group|Control points in time include all parts except for number 4. Here students in the control group will receive questionnaires on general health behavior in order to achieve an equal questionnaire completion time compared to the intervention group.
89055377|NCT04990778|Experimental|Treatment (eprenetapopt, venetoclax)|Patients receive eprenetapopt IV over 6 hours on days 1-4 and venetoclax PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89055378|NCT04993703|Experimental|Kinesiotaping|"A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.~Additionally for this group, kinesiotaping will be applied by using carpal tunnel technique including button hole and I band technique of space correction; and with 25-50% tension in center of tape over dorsal carpal tunnel at the end of the each session. Patients will request to keep kinesiotaping at nights throughout the study."
89055379|NCT04993703|Experimental|Night splinting|"A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.~Additionally, night splinting will be advised. Patients will request to keep their splints at nights throughout the study."
89055380|NCT04993703|Experimental|Control group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3sets of ten repetitions) will be applied.
89055381|NCT00479388|Other|1|One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
89055382|NCT00479388|Active Comparator|2|Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.
89055383|NCT04670939|Experimental|SPT|
89055384|NCT04670276|Experimental|Experimental arm|Patients treated by endoscopic injection of emulsified adipose tissue stromal vascular fraction
89055385|NCT00479232|Experimental|Cohort 1: Vorinostat (sequential)|"Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment.~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
89055386|NCT00479232|Experimental|Cohort 2: Vorinostat (concurrent)|"Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles.~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
89055387|NCT00478881|Experimental|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
89055388|NCT00478881|Placebo Comparator|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
89687930|NCT03409679|Active Comparator|Two anti-pseudomonal antibiotics|Association of 2 anti-pseudomonal antibiotics
89687931|NCT00926887|Sham Comparator|Placebo Laser|Placebo Laser is an inactive light
89687932|NCT00926887|Active Comparator|Erchonia EML Laser|Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.
89687933|NCT04371367|Experimental|avdoralimab|"Biological/Vaccine: avdoralimab intravenous administration of avdoralimab~Other Names:~• IPH5401"
89687934|NCT04371367|Placebo Comparator|Placebo|intravenous administration of Placebo
89687935|NCT01725971||Control group|Group of nonsmokers individuals without respiratory disease.
89687936|NCT01725971||normal exam|subjects with silicosis , but with normal spirometric data
89687937|NCT01725971||mild obstruction|subjects with silicosis with mild obstruction in spirometric data
89687938|NCT01725971||moderate to severe obstruction|subjects with silicosis with moderate to severe obstruction in spirometric data
89217282|NCT02573363|Experimental|selinexor, cytarabine, and mitoxantrone|"INDUCTION CHEMOTHERAPY: Patients receive high-dose cytarabine and mitoxantrone hydrochloride per standard of care on days 1 and 5, and selinexor PO on days 2, 4, 9, and 11.~CONSOLIDATION CHEMOTHERAPY: Patients receive high-dose cytarabine per standard of care on days 1, 3, and 5, and selinexor PO on days 2, 4, 9, and 11. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Patients achieving at least stable disease after consolidation chemotherapy may receive selinexor PO on days 1, 8, 15, and 22 at the discretion of principal investigator."
89217283|NCT03727113||Control cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
89217284|NCT03727113||Optimization cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
89217285|NCT00715637|Experimental|Arm A|Amonafide in Combination with Cytarabine
89217286|NCT00715637|Active Comparator|Arm B|Daunorubicin in Combination with Cytarabine
89217287|NCT01012791|Experimental|Zumba exercise group|
89217288|NCT01012791|No Intervention|Non-Zumba exercise group|
89217289|NCT00953004|Experimental|fiber drink|
89217290|NCT00953004|Experimental|fiber bread|
89217291|NCT00953004|Experimental|placebo|
89217292|NCT00953316||at-risk infants|Includes all children born at less than 37 weeks gestation and other high risk newborns such as those with a history of breathing problems and/or low tone.
89217293|NCT00898274||High risk for developing prostate cancer|Male subjects age 45-65 at high risk for developing prostate cancer.
89217294|NCT00898274||Healthy participants|Aged matched healthy participants
89217295|NCT02541656|Experimental|preloaddependence indice after volume expansion in laparoscopy|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
89217296|NCT00720005||Aspheric Acrysof ResTOR Lens|Implantation of Aspheric Acrysof ResTOR
89217297|NCT00898430||Head and neck squamous cell carcinoma patients (HNSCC)|
89217298|NCT00948636||Related Donors|Related Hematopoietic Stem Cell Donors
88999091|NCT04414722|Other|Amoxicillin-clavulanate|Amoxicillin-clavulanate 875 mg-125 mg oral tablet
89217299|NCT00893594|Placebo Comparator|1|Placebo taken at onset of aura associated with migraine.
89217300|NCT00893594|Active Comparator|2|Sumatriptan with naprosyn taken at onset of aura associated with migraine.
89217301|NCT00715715|No Intervention|1|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients not treated with steroids: The patients will receive 6 weeks of sugar pills (placebo) before taking Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
88999092|NCT04410146|Experimental|SQUID|Embolization of the Middle Meningeal Artery (MMA)
88999093|NCT04410146|Active Comparator|No Embolization|Standard Management
88999094|NCT04404114||Normal renal function|Normal renal function
88999095|NCT04404114||Acute kidney injury in normal kidney|Acute kidney injury in normal kidney
88999096|NCT04404114||Acute kidney injury in chronic kidney disease|Acute kidney injury in chronic kidney disease
88999097|NCT04404114||Chronic kidney disease|Chronic kidney disease
88999098|NCT04392037|Experimental|Iberdomide plus low-dose cyclophosphamide and dexamethasone|"Iberdomide 1.6mg on days 1-21~Low-dose Cyclophosphamide 50 mg on days 1-28 of each 28 day cycle~Dexamethasone 40 mg once weekly (20 mg in patients aged > 75 years)"
88999099|NCT04333485|Active Comparator|Home-based Active Case Finding (HACF)|
88999100|NCT04333485|Active Comparator|Telephonic Active Case Finding (TACF)|
88999101|NCT04289753|Active Comparator|Brief clinician education|Clinicians attributed to clinics in the brief clinician education arm will receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
88999102|NCT04289753|Experimental|Clinical decision support nudges and brief clinician education|Clinicians attributed to clinics randomized to the clinical decision support nudges and brief clinician decision support arm will receive clinical decision support within the EHR when conditions meet alert triggering criteria. These clinicians will also receive invitation to view an online educational module and be recruited to complete an online survey at baseline and 18 months.
88999103|NCT04287062|Placebo Comparator|Placebo|Placebo sleep medication (2 placebo oral capsules)
88999104|NCT04287062|Active Comparator|Suvorexant|Sleep medication (20mg suvorexant; 2 10mg capsules; patients can self-titrate to 1 10mg capsule)
88999105|NCT04249141||ICU providers|Surveys and a concept mapping exercise will be administered to ICU providers who participated in the ICU Liberation Collaborative
88999106|NCT04249141||Secondary Data Analysis|Secondary data analysis will used information on patients and providers who participated in the ICU Liberation Collaborative
88999107|NCT04238520|Other|Control|10 PWD/CG dyads
88999108|NCT04238520|Experimental|Interventional|30 PWD/CG dyads
88999109|NCT04229368|Active Comparator|Low Vitamin D3 Supplementation|Subjects enrolled into Group 1 (low-dose Vitamin D3 supplementation) will receive 800 IU of oral Vitamin D3 (Cholecalciferol) daily for 4 weeks prior to surgery, followed by 800 IU of oral Vitamin D3 daily for 3 months after surgery. Vitamin D3 supplementation will be given for a total of 4 months. Supplementing Vitamin D-deficient patients with a minimum of 800 IU of Vitamin D3 daily is supported by the IOM.
88999110|NCT04229368|Active Comparator|High Vitamin D3 Supplementation|Subjects enrolled into Group 2 (high-dose Vitamin D3 supplementation) will receive 50,000 IU of oral Vitamin D3 (Cholecalciferol) twice per week for 1 weeks followed by 50,000 IU once per week for 3 weeks prior to surgery. After surgery they will receive 50,000 IU of oral Vitamin D3 once per week for 4 weeks followed by 800 IU daily for 8 weeks. Vitamin D3 supplementation will be given for a total of 4 months.
88999111|NCT04229368|No Intervention|No supplementation|Subjects with serum 25(OH)D level ≥30ng/mL will not receive any Vitamin D supplementation both pre- and postoperatively, as these are considered sufficient. These control patients will be asked to take any supplements containing Vitamin D for the duration of their participation in the trial. All patients in group 3 will have their serum 25(OH)D checked at 3 months after the surgery.
88999112|NCT04148664|Active Comparator|Standard Catheter Settings|Group 1 - Standard RF ablation settings
88999113|NCT04148664|Experimental|High Power Short Duration (HPSD)|Group 2 - High power short duration RF
88999114|NCT04106544|Other|Acid Sphingomyelinase Deficiency (ASMD) Cohort|Patients across the full spectrum of chronic ASMD who have fulfilled the eligibility criteria and who have performed the inclusion visit
88999115|NCT04095052|Experimental|Methyl Folate|Participants will receive a capsule containing 1,000 mcg methyl folate and microcrystalline cellulose orally once per day for 15 days.
88999116|NCT04095052|Placebo Comparator|Placebo|Participants will receive a microcrystalline cellulose capsule orally once per day for 15 days.
88999117|NCT04082533|Active Comparator|Stiffness Intravenous Hydrocortisone|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
88999118|NCT04082533|Placebo Comparator|Stiffness Intravenous Placebo|Total knee replacement patients with preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
89217302|NCT00715715|Experimental|2|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
89217303|NCT00953394|Experimental|treatment arm|continuous 5 fluouracil infusion plus long-acting octreotide
89217304|NCT00720161|Active Comparator|A|Metformin during 12 months and then 6 months Placebo
89217305|NCT00720161|Placebo Comparator|B|Placebo during 6 months, afterwards 12 months metformin
89217306|NCT00888368|Experimental|Transpatellar Approach|
89217307|NCT00888368|Active Comparator|Suprapatellar Approach|
89687939|NCT02242591|Active Comparator|ACB_active/placebo|"Patients will receive the first ACB with a active drug, 30 ml bolus Ropivacaine 7,5 mg/ml at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60 (60 minutes after T0), patients will receive their second ACB with the placebo drug, 30 ml bolus Saline and outcome measures performed again at T120(120 minutes after T0).~The measurements for baseline and outcome will be made in following order:~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
89687940|NCT02242591|Placebo Comparator|ACB_placebo/active|"Patients will receive the first ACB with placebo, 30 ml isotonic saline at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60(60 minutes after T0), patients will receive their second ACB with the ropivacaine 7,5 mg/ml 30 ml and outcome measures performed again at T120(120 minutes after T0).~The measurements for baseline and outcome will be made in following order:~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
89687941|NCT03409601|Experimental|100% Portion Size|Test meal consists of baseline (100%) portion size of meal.
89217308|NCT04068077||Experimental|Patients with amyloidosis and other indistinguishable diseases
89217309|NCT04010916|Active Comparator|Group Pre = preoperatively before inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
89217310|NCT04010916|Active Comparator|Group Pre-T = preoperatively after inflation of the tourniquet|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
89217311|NCT04010916|Active Comparator|Group Post = Postoperatively group|ACB will be performed under general anesthesia in the supine position. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
89217312|NCT00893672||1|Routine strategy of chest radiograph prescription
89217313|NCT00893672||2|On-demand strategy of chest radiograph prescription
89687942|NCT03409601|Experimental|125% Portion Size|Test meal consists of food portion size that is 125% the size of baseline portion.
89687943|NCT03409601|Experimental|150% Portion Size|Test meal consists of food portion size that is 150% the size of baseline portion.
89687944|NCT03409601|Experimental|175% Portion Size|Test meal consists of food portion size that is 175% the size of baseline portion.
89687945|NCT02242669||AIM 1|200 current DBSA participants.
89687946|NCT02242669||AIM 2|60 new DBSA attendees with mood disorders who have attended their first meeting in the past month.
89687947|NCT02242669||AIM 3|100 matched control group individuals with mood disorders with no current or prior exposure to DBSA.
89687948|NCT01726127|Experimental|Broccoli and Brussels Sprouts|Subjects will consume broccoli or Brussels sprouts (40g daily) for 8 weeks.
89687949|NCT01726127|Experimental|Cruciferous Complete|Subjects will take Cruciferous CompleteTM supplements (2 capsules, 3 times daily) for 8 weeks.
89687950|NCT01726127|Placebo Comparator|Placebo|Subjects will take placebo capsules (2 capsules, 3 times daily) for 8 weeks.
89687951|NCT02982577|Experimental|Pilocarpine|Spray with Pilocarpine
89687952|NCT02982577|Placebo Comparator|Placebo|Spray without Pilocarpine
89687953|NCT02242747|Other|ingenol mebutate|Patients assigned to ingenol mebutate gel received an application a day for three consecutive days in a pre-determined area
89687954|NCT02242747|Other|5% 5-FU|Patients assigned to 5% 5-FU received two applications a day for four weeks in a pre-determined area
89687955|NCT04371133||Endometrioma|Endometrioma (n=23)
89217314|NCT00711815||UA|HPV positive
89217315|NCT00948714|Experimental|Case|
89217316|NCT00948714|Active Comparator|Control|
89217317|NCT00898508||Normal benign breast disease or ductal carcinoma in situ|
89687956|NCT04371133||Healthy controls|Healthy controls Healthy volunteers n=25
89687957|NCT01726205|Active Comparator|pregabalin|perioperative pregabalin starting the evening before surgery, and for five days postoperatively
89217318|NCT00898508||Invasive breast cancer|
89217319|NCT00711893||ICD and CRT-D|Patients indicated for an implantable defibrillator or cardiac resynchronization defibrillator
89217320|NCT00720239|No Intervention|0|
89217321|NCT00720239|Experimental|1|Experimental Group 1 (n = 10) will receive TalidermR to the wound once during the treatment phase.
89687958|NCT01726205|Active Comparator|pregabalin and continuous wound infusion|Pregabalin as previous group and continuous infusion of ropivacaine 0.2% via a wound catheter
89687959|NCT01726205|Placebo Comparator|placebo|Placebo drug and normal saline infusion
89687960|NCT02242825||Patients with hypertension and diabetes mellitus|
89217322|NCT00720239|Experimental|2|Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
89217323|NCT00720239|Experimental|3|Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
89217324|NCT00609986|Experimental|Intensive|The experimental group will receive the intravenous regular insulin infusion protocol for the maintenance of blood sugar levels 70-110 mg/dL while hospitalized up to 7 am post operative day #3 and after hospitalization will receive subcutaneous insulin to maintain blood sugar levels 70-140 mg/dL.
89217325|NCT00609986|Active Comparator|Control|The control group will receive subcutaneous insulin injections (NPH or glargine and aspartame) to maintain a blood sugar level between 70-180 mg/dL while hospitalized and after hospitalization subcutaneous insulin to maintain blood sugar levels 90-180 mg/dL.
89687961|NCT00918125||White educational video|Patients will view an educational video that contains White physicians and patients.
89687962|NCT00918125||African-American educational video|Patients will view an educational video that contains African-American physicians and patients.
89687963|NCT00918125||Usual care|Patients will receive counseling about their condition and treatment options.
89687964|NCT04370743||Group 1|
89217326|NCT00715871|Experimental|Active Smokers|Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.
89217327|NCT02572193|Experimental|Active case|POEM procedure
89217328|NCT00888446|Experimental|Group A|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0 + 6"
89217329|NCT00888446|Experimental|Group B|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0+12"
89217330|NCT00888446|Experimental|Group C|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+6"
89217331|NCT00888446|Experimental|Group D|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+12"
89217332|NCT00888446|Experimental|Group E|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+6"
89217333|NCT00888446|Experimental|Group F|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+12"
89217334|NCT00888446|Experimental|Group G|"Number of Vaccine Recipients: 10~Preselected for baseline AAV neutralization titers of <1/8~Dosage level 3 x 10^12 DRP~Month 0+6"
89687965|NCT04370977|Active Comparator|Artemether-Lumefantrine|4 sites, namely Massinga, Mopeia, Moatize and Montepuez
89687966|NCT04370977|Active Comparator|Amodiaquine-Artesunate|3 sites, namely Massinga, Mopeia and Montepuez
89687967|NCT01726283||low risk subjects for developing post-operative ectasia|Patients undergoing vision correction surgery who are not at a higher risk for developing post-op ectasia
89687968|NCT01726283||Subjects at Risk for Ectasia|Patients undergoing vision correction surgery who are at a higher risk for developing post-operative ectasia
89687969|NCT02243683|Experimental|Cohort A|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
89687970|NCT02243683|Experimental|Cohort B|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
89687971|NCT03409211|Active Comparator|Pso|with or without PsA
89687972|NCT03409211|Active Comparator|Healthy Subjects|Without PsA
89687973|NCT04370899||Familial hypercholesterolaemia children|FH diagnostic criteria were as follows: a positive genetic test or, if no genetic test results were available, LDL-C >160 mg/dL and one parent with a DLCN score >8.
89687974|NCT04370899||Unaffected children|The children evaluated for suspected FH who did not meet the FH criteria were included in the non-FH control group
89687975|NCT01720121|No Intervention|Control group|The control group received the guidelines orientation provide by nursing team
89687976|NCT01720121|Experimental|Guidelines printed group|The patient received the informative material in details about the cardiac catheterization provide by the researchers
89687977|NCT01720121|Experimental|Guidelines digital video disc group|Guidelines digital video disc group: The patient received the informative provide by digital video disc in details about the cardiac catheterization
89687978|NCT04370431|Experimental|PartA: TTYP01 single ascending doses|In Part A: a single-ascending-dose (SAD) escalation study with four consecutive cohorts, single ascending doses of TTYP01 (60, 120, 180 and 240 mg) will be orally administrated.
89687979|NCT04370431|Placebo Comparator|Part A: Placebo|Placebo control for Part A of the study
89687980|NCT04370431|Experimental|Part B: TTYP01 (oral edaravone) first then IV edaravone|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 60 mg oral edaravone tablet (TTYP01); Period 2: 30 mg IV edaravone (Radicut® ampoule), Period 3: 120 mg oral edaravone tablet (TTYP01); Period 4: 60 mg IV edaravone (Radicut® bag). Each dose will be spearated by a minimum of 7 days washout period.
89687981|NCT04370431|Experimental|Part B: IV edaravone first then TTYP01 (oral edaravone)|Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 30 mg IV edaravone (Radicut® ampoule); Period 2: 60 mg oral edaravone tablet (TTYP01); Period 3: 60 mg IV edaravone (Radicut® bag); Period 4: 120 mg oral edaravone tablet (TTYP01). Each dose will be spearated by a minimum of 7 days washout period.
89687982|NCT04370431|Experimental|Part C: TTYP01: fasted dosing first then fed dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fasted condition; Period 2: under fed condition. Each dose will be spearated by a minimum of 7 days washout period.
89687983|NCT04370431|Experimental|Part C: TTYP01: fed dosing first then fasted dosing|Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fed condition; Period 2: under fasted condition. Each dose will be spearated by a minimum of 7 days washout period.
89687984|NCT01726361|Experimental|MTFC|Out of home placement in MTFC family program
89687985|NCT01726361|Active Comparator|TAU|Other kind of out of home placement
89217335|NCT00888446|Placebo Comparator|Placebo|3 volunteers will receive placebo matched to each experimental group.
89217336|NCT00720395||1|Women with bipolar disorder who are preconception or pregnant. Primary focus on predictors of postpartum bipolar disorder relapse and burden of illness through first six months postpartum
89217337|NCT02540174|Experimental|Arm A|integrated addiction treatment program
89217338|NCT02540174|Other|Arm B|standard of care
89217339|NCT02572271|Active Comparator|Rubins Mastopexy|Patients are allocated to a mastopexy using Rubins technique
89217340|NCT02572271|Active Comparator|LOPOSAM|Patients are allocated to a mastopexy using the LOPOSAM technique
89217341|NCT04035824|Active Comparator|Gastrodia and Uncaria granule|Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
89687986|NCT04370353|Placebo Comparator|Placebo|Placebo supplement, each capsule containing: 0mg total flavanols, matched for caffeine and theobromine content as experimental supplement (2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM & 2PM after mixed meal for 7 days.
89687987|NCT04370353|Experimental|Cocoa Flavanols|Experimental supplement, each capsule containing: 316 mg CocoActiv (Naturex, Netherlands: 100mg total cocoa flavanols, 2.9 mg caffeine and 22.5 mg theobromine) and microcrystalline cellulose volume filler. Participants consume 4x capsules daily (2AM & 2PM) for 7 days.
89687988|NCT01726439||CHB patients who are naive to NUC treatment|CHB patients who are naive to NUC at enrollment and be treated at hospitals at tier 2 cities in China
89687989|NCT03409055||Group 0|patients without pleural effusion
89687990|NCT03409055||Group 1|patients with pleural effusion
89687991|NCT03409055||Group 2|patients with pleural Effusion and need of drainage
89687992|NCT02245165|Experimental|Nitric oxide synthase (NOS) inhibition|After a control period of 4 hours, intervention with L-NMMA (10 mg/kg IV) is done and recording continued for 4 hours.
89687993|NCT02245165|Sham Comparator|Saline|After a control period of 4 hours, intervention with saline is done and recording continued for 4 hours.
89687994|NCT03408977|Experimental|Men|
89687995|NCT03408977|Experimental|Women|
89687996|NCT03835871|Experimental|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 12 weeks
89055389|NCT02214108|Experimental|Phisical activity with Nintendo Wii|3 hours of weekly of physical activity, divided in 1 hour interday with Nintendo WII. games applied: Wii Boxing, Wii Tennis; Wii Bowling
89055390|NCT02214108|No Intervention|phisical activity with phisiotherapist|3 hours of weekly physical activity, divided in 1 hour interday. applying cardiovascular and muscular endurance static exercises.
89055391|NCT04571775|Active Comparator|Qi-Shield user group|
89055392|NCT04571775|Sham Comparator|Sham Qi-Shield user group|
89055393|NCT04571775|No Intervention|No Qi-Shield device group|
89055394|NCT04670120|Experimental|First group|Pyfazimine 100mg group, 12 cases.
89055395|NCT04670120|Experimental|Second group|Pyfazimine 200mg group, 12 cases.
89055396|NCT04670120|Experimental|Third group|Pyfazimine 300mg group, 12 cases.
89055397|NCT04670120|Active Comparator|Forth group|Pyrazinamide 1500mg group, 10 cases.
89055398|NCT04670120|Active Comparator|Fifth group|Pyfazimine 200mg + Pyrazinamide 1500mg group, 10 cases.
89055399|NCT00556127|Experimental|1|
89055400|NCT00478647|Experimental|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
89055401|NCT04990934||Video Telemedicine|20 participants will have used video telemedicine for appointments with their treating oncologist.
89055402|NCT04990934||Telephone Telemedicine|10 participants will have used telephone telemedicine for appointments with their treating oncologist.
89055403|NCT04550325|Experimental|Immune gamma globulin (IgG)|Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion
89055404|NCT00556205|Active Comparator|1|Bevacizumab monotherapy 10 mg/kg IV q2 weeks
89055405|NCT00556205|Active Comparator|2|Combination Sunitinib & Bevacizumab Bevacizumab 10 mg/kg IV q2 weeks Sunitinib 50 mg PO QD on 4/2 schedule
89055406|NCT00556244|Active Comparator|2|
89055407|NCT04550559|Active Comparator|Group 1|The patients in group 1 were instructed to masturbate at least 3-4 times a week
89055408|NCT04550559|Other|Group 2|The patients in group 2 were prescribed oral tamsulosin 0.4 mg once daily
89055409|NCT04550559|No Intervention|Group 3|The patients in group 3 acted as controls and received only standard medical therapy
89055410|NCT00556283|Experimental|1|STARR
89055411|NCT00556283|Active Comparator|2|Biofeedback
89055412|NCT00478257|Active Comparator|1 Active Bright White Light Treatment|Intervention: Bright white light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
89055413|NCT00478257|Active Comparator|2 Comparator Red Light Treatment|Intervention: Dim red light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
89055414|NCT00478140|Experimental|Trastuzumab|Participants receive trastuzumab loading dose 8 mg/kg intravenous (IV) over 30-90 minutes on day 1 and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89055415|NCT04990739|Experimental|Part A Dose-Escalation and Part B RP2D Dose-Expansion|"Study has two parts:~Part A Dose-Escalation will evaluate MTB-9655 monotherapy administered in 21 days cycle,and will be conducted in 2 stages (accelerated titration and dose-escalation).~The first stage will consist of accelerated titration in single-patient cohorts for the initial two dose levels.~In the second stage, a conventional 3+3 schema using a modified Fibonacci dose titration strategy will be implemented. The first dose at every dose level and in every patient will be administered under close medical supervision, and the patients will be hospitalized for approximately 24 hours.~Up to 30 participants will participate in this dose escalation arm.~Part B dose-expansion will further explore the safety, PK and preliminary efficacy of MTB-9655 at the RP2D. The RP2D level will be no higher than the MTD identified in Part A."
89055416|NCT00478023|Active Comparator|Morphine|
89055417|NCT00478023|Experimental|Tapentadol 50 mg immediate release|
89055418|NCT00478023|Experimental|Tapentadol 75 mg immediate release|
89055419|NCT00478023|Experimental|Tapentadol 100 mg immediate release|
89055420|NCT00478023|Placebo Comparator|Matched placebo|
89055421|NCT04993001|Active Comparator|Emergence from general anesthesia with an open lung extubation strategy|
89055422|NCT04993001|Placebo Comparator|Emergence from general anesthesia with a conventional extubation strategy|
89055423|NCT04995107|Experimental|Electro-Press Needle group|Body acupoints of Yintang (GV29), Dazhui (GV14), Guanyuan (CV4), bilateral Zigong (EX-CA1), and bilateral Sanyinjiao (SP6) and auricular acupoints of Heart (CO15), Chuiqian (LO4) and Shenmen (TF4) will be selected for treatment. Auricular acupoints on right and left ear will be stimulated alternatively, one side on each time.The treatment will last 40mins for each session, 3 sessions a week (ideally every other day) for a succession of 6 weeks.
89055424|NCT04995107|No Intervention|Waiting-list group|Participants in the waiting-list group will receive no intervention for 6 weeks and be followed up till weeks 30.
89055425|NCT00477750|Experimental|Treatment (Lenalidomide, Melphalan, Prednisone)|"Intervention: Drug: lenalidomide Dose determined by Phase I treatment schedule. Taken orally days 1-21 every 28 days until progression~Intervention: Drug: melphalan Dose determined by Phase I treatment schedule. Taken orally days 1-4 every 28 days until progression~Intervention: Drug: prednisone 60mg/m^2, orally days 1-4 every 28 days until progression"
89055426|NCT04670003||users|users of web-application
89055427|NCT00477672|Experimental|2|Pimavanserin tartrate (ACP-103), 10 mg, tablet, once daily by mouth, 6 weeks
89055428|NCT00477672|Experimental|3|Pimavanserin tartrate (ACP-103), 40 mg, tablet, once daily by mouth, 6 weeks
89055429|NCT00477672|Placebo Comparator|1|Placebo tablet, once daily by mouth, 6 weeks
89055430|NCT04549935|Active Comparator|Group A Dextenza|Drug: Dextenza 0.4mg Opthalmic Insert The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion, The attributes of the insert reduce risks for improper corticosteriod tapering and unwanted peaks and troughs in drug concentration.
89055431|NCT04549935|Active Comparator|Group B Topical Prednisolone|Drug: Topical Prednisolone Standard of care topical drop treatment
89055432|NCT00477633|Experimental|Norethindrone/ethinyl estradiol|1 tablet per day
89055433|NCT04999787|Experimental|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
89055434|NCT04999787|Placebo Comparator|Placebo|
89055435|NCT04992767|Active Comparator|Sunnyside|An online intervention to better manage mood during and after pregnancy.
89055436|NCT04992767|Experimental|SunnysideFlex|An online intervention to treat symptoms of PTSD and better manage mood during and after pregnancy.
89055437|NCT04992767|No Intervention|Treatment as Usual|A control condition consisting of standard prenatal medical care, without provision of the SunnysideFlex or Sunnyside intervention
89055438|NCT04669847|Experimental|Study Group|Patients who performed Trunk-oriented exercise program and conventional exercise program
89055439|NCT04669847|Experimental|Control Group|Patients who performed a conventional exercise program
89055440|NCT04541901|Experimental|Massage|12 minutes of effleurage and petrissage on the upper limbs administered after fatiguing exercise in the swimming pool
89055441|NCT04541901|Experimental|Cold-water immersion|12 minutes of cold-water immersion at the shoulder level with water temperature between 11 to 15°C
89055442|NCT04541901|No Intervention|Control|12 minutes of rest. The athletes are free to sit or walk around the place but are advised to refrain from exercise in and out of the pool.
89055443|NCT04669730|Placebo Comparator|Arm A: usual care|Routine usual care
89055444|NCT04669730|Active Comparator|Arm B: walk|Walk 30mins per day, 5 days per week.
89055445|NCT04669730|Active Comparator|Arm C: Baduanjin|Baduanjin 12 mins per day, 5 days per week.
89055446|NCT04669730|Experimental|Arm D: Baduanjin plus walk|Walk 30mins then Baduanjin 12 mins per day, 5 days per week.
89055447|NCT04992338|Experimental|Intervention group - CarpeDiem app|Participants will receive at their home the activity tracker of Fitbit brand, model Inspire HR 2, as well as instructions to download and use the CarpeDiem application and the Fitbit application in their mobile phones and synchronize the bracelet. The intervention consists of detecting unhealthy user behaviors and, through contextualized and personalized recommendations and strategies based on gamification, modifying said behaviors and motivating individuals to maintain this modification over time in order to prevent illnesses associated with bad habits. The intervention is performed through the CarpeDiem application, participants will be able to answer follow-up questionnaires, carry out missions designed to improve their eating habits, monitor their physical activity and sleep.
89055448|NCT04992338|No Intervention|Control group - Activity tracker + general recommendations|"Participants will receive the Fitbit activity tracker, model Inspire HR 2. They will also receive instructions to download the Fitbit application from their mobile phone and synchronize the bracelet. Additionally, this group will receive general recommendations on healthy lifestyle habits through standardized documents that contain general guidelines, such as: Get in the habit of going to sleep and always waking up at the same time, even on weekends."
89055449|NCT04541823|Experimental|Desflurane|Patients allocated to this arm will receive desflurane during the maintenance of anesthesia.
89055450|NCT04541823|Placebo Comparator|Propofol|Patients allocated to this arm will receive propofol during the maintenance of anesthesia
89055451|NCT04996043|Placebo Comparator|Placebo drink|
89055452|NCT04996043|Experimental|Collagen Peptide Drink|
89055453|NCT04541862||Critically ill patients|
89055454|NCT04549584||metaplastic breast cancer|Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.
89055455|NCT04549584||non-metaplastic breast cancer|Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer
89055456|NCT04994093||COLON CANCER|This cohort will consist of 100 patients with Colon Cancer.
89217342|NCT04035824|Placebo Comparator|Placebo|Placebo of Gastrodia and Uncaria granule, Chengdu Jiuzhitang Jinding Pharmaceutical Co., Ltd
89217343|NCT00901004||1|Reflux esophageal minimal change in the endoscopic finding
89217344|NCT02572037||Group I|Penile sensory hyperexcitability: Latencies of GPSEP and/or DNSEP of them are abnormal. They will receive treatment of Compound Lidocaine Cream-a kind of local anaesthetics that is widely used to treat PE.
89217345|NCT02572037||Group II|Sympathetic hyperexcitability: Latency of PSSR are abnormal.They will be treated with Dapoxetine(Priligy)-a kind of selective serotonin reuptake inhibitor(SSRI) which has been shown effective to PE.
89217346|NCT02572037||Group III|Mixed type: Both Latencies of GPSEP and/or DNSEP and Latency of PSSR are abnormal.They will receive both Compound Lidocaine Cream and Dapoxetine.
89217347|NCT02572037||Group IV|Others: Both Latencies of GPSEP, DNSEP and Latency of PSSR are normal.They will receive further tests. (This group is not the main objects to be observed in this study.)
89217348|NCT00893750|Experimental|NET Truth Education|
89217349|NCT00893750|Experimental|Conflict Resolution Trainings|
89217350|NCT00893750|Experimental|Traditional Methods|
89217351|NCT00712049|Active Comparator|1|Nicotinic acid + Simvastatin
89217352|NCT00712049|Active Comparator|2|Simvastatin
89217353|NCT00712127|Experimental|Diet and Exercise|Diet and Exercise for Class II and Class III Obesity
89217354|NCT00712127|Experimental|Diet and Exercise-Delayed|Diet and Exercise-Delayed for 6 months for Class II and Class III Obesity
89217355|NCT00712127|No Intervention|Control|Normal weight, overweight and Class I obesity
89217356|NCT00898742||head and neck cancer patients|
89217357|NCT00716027|Active Comparator|1|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
89217358|NCT00716027|Experimental|2|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
89217359|NCT00712205|Placebo Comparator|A|20 Patients with asthma in a crossover design
89217360|NCT00712205|Active Comparator|B|20 Patients with asthma in a crossover design
89217361|NCT02574299|No Intervention|1: Normal hearing children without SLI, transversal group|Normal hearing children without Specific Language Impairment (SLI),Transversal group for test-retest measures
89217362|NCT02574299|No Intervention|2: Normal hearing children without SLI, longitudinal group|Normal hearing children without Specific Language Impairment (SLI), longitudinal group without training
89217363|NCT02574299|Other|3: Normal hearing children with SLI, longitudinal group|Normal hearing children with Specific Language Impairment (SLI), longitudinal group with training
89217364|NCT02574299|No Intervention|4: Normal hearing adults without SLI, transversal group|Normal hearing adults without Specific Language Impairment (SLI), transversal group for test-retest measures
89217365|NCT02574299|No Intervention|5: Normal hearing adults without SLI, longitudinal group|Normal hearing adults without Specific Language Impairment (SLI), longitudinal group without hearing aids (HA)
89217366|NCT02574299|Other|6: Hearing Impaired candidates for HA, longitudinal group|Hearing Impaired adult candidates for hearing aids (HA), longitudinal group with hearing aids (HA)
89217367|NCT00451906|Experimental|Bevacizumab + Chemotherapy|Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chemotherapy in line with the licensed national prescribing information, during the treatment period. The initial dose of bevacizumab will be administered following chemotherapy; all subsequent doses could be given before or after chemotherapy.
89217368|NCT04162691||Malignant thymoma|
89217369|NCT04162691||Benign thymoma|
89217370|NCT00712283|Placebo Comparator|D|healthy volunteers
89217371|NCT00712283|Active Comparator|C|healthy volunteers
89217372|NCT00712283|Active Comparator|B|healthy volunteers
89217373|NCT00712283|Active Comparator|A|healthy volunteers
89217374|NCT04070495|Experimental|Clarithromycin|
89217375|NCT04070495|Experimental|Rifampicin|
89217376|NCT00712361|Experimental|Group A|The group A incorporates three subgroups of individuals at various ages. A.1 Age: 16 - 30 A.2 Age: 31 - 60 A.3 Age > 60 All subgroups will be randomly distributed according to the following factors: BMI, gender, race and hematocrit.
89217377|NCT00720707|Experimental|(CAF+ADM+EMD)|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
89217378|NCT00720707|Active Comparator|(CAF + ADM)|root coverage procedure by using a coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM)
89217379|NCT00716105|Placebo Comparator|Control|Standard Infant Formula
89217380|NCT00716105|Experimental|Test Product|Infant formula with different level of proteins
89217381|NCT00716105|No Intervention|Breast Milk|Breastfeeding reference group
89217382|NCT02573129|Experimental|Red Meat Restricted|Following a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is restricted in lean, minimally processed red meat for 5 weeks.
89217383|NCT02573129|Experimental|Red Meat Rich|Following a 4-wk wash out period and a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is rich in lean, minimally processed red meat for 5 weeks.
89217384|NCT00712439|Experimental|1|
89217385|NCT00712439|Placebo Comparator|2|
89217386|NCT00451282|Experimental|Stepped Preventive Care|Receiving Stepped Preventive Care intervention - at least 2 brief assessments with nurse and/or social worker (1) during hospital admission , and (2) approximately 2 weeks post-discharge. Additional interventions provided as needed, based on manual.
89217387|NCT00451282|No Intervention|Treatment as usual|Medical and psychosocial care per usual hospital protocols, which may include social work support.
89217388|NCT00716183|Experimental|Probiotic 1|Women receiving Lactobacillus salivarius HN6
89217389|NCT00716183|Experimental|Probiotic 2|Women receiving Lactobacillus reuteri CR20
89217390|NCT00716183|Experimental|Probiotic 3|Women receiving Lactobacillus fermentum LC40
89217391|NCT00716183|Active Comparator|beta-lactam|The evolution of the women ascribed to the other three arms will be compared with that of 100 women suffering lactational mastitis that will follow a conventional antibiotic treatment as prescribed by the pediatrician/gynecologist
89217392|NCT03995446|Experimental|low-level laser therapy|808nM wavelength, power density of 300mW
89217393|NCT03995446|Sham Comparator|Sham laser acupuncture treatment|received the same manner except for joule.
89217394|NCT04069559|Experimental|Intervention Group|Intervention contain education and application about refugees health.
89217395|NCT04069559|No Intervention|Control Group|Students of control group performed routine public health nursing practices.
89217396|NCT04070417|Experimental|Treatment Group|Lifestyle Medicine Group
89217397|NCT04070417|No Intervention|CAU Group|Care-As-Usual Group
88999119|NCT04082533|Active Comparator|Non-stiff Intravenous Hydrocortisone|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of 100mg intravenous hydrocortisone every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
89217398|NCT03996226|Experimental|E7386: Fed + Fast|Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
89217399|NCT03996226|Experimental|E7386: Fast + Fed|Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
89217400|NCT00712517|Active Comparator|1|Patients will receive propofol anesthesia during varicose vein stripping surgery.
89217401|NCT00712517|Active Comparator|2|Patients will receive sevoflurane anesthesia during varicose vein stripping surgery.
89217402|NCT03838198|Other|Safety plan + booster text messages + booster call (Group A)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group A: Participants will receive the in-person MI-enhanced safety plan (individual meeting with the adolescent and a family meeting) during hospitalization -- focused on developing a personalized list of coping strategies and enhancing adolescents' motivation and self-efficacy to utilize these strategies-- which will be followed by 4 weeks of daily post-discharge booster text messages and a phone booster call.
89217403|NCT03838198|Other|Safety plan + booster text messages (Group B)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group B: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by 4 weeks of daily booster text messages post discharge.
89217404|NCT03838198|Other|Safety plan + booster call (Group C)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group C: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by a post-discharge booster call.
89055457|NCT04669496|Experimental|Neoadjuvant treatment|"Gemox chemotherapy D1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.~Lenvatinib (8mg/d) for 9 weeks of continuous use.~Toripalimab (240 mg, once every 3 weeks), used 3 times in a row. All patients undergoing resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses."
89055458|NCT04669496|No Intervention|Traditional group|No anti-tumor drug treatment before surgery. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, a total of 8 courses.
89055459|NCT04669769||shaving|patients with DIE and shaving
89055460|NCT04669769||disc resection|patients with DIE and Disc resection
89055461|NCT04669769||segmental resection|patients with DIE and segmental resection
89055462|NCT04669769||multifocal|patients with multifocal DIE having more than one bowel procedure
89055463|NCT04571450|Experimental|Experimental group|All participants will receive access to the same web-based lifestyle intervention (exercise and nutritional education)
89055464|NCT04541784|Active Comparator|3 counselling sessions with gynaecology-oncology nurses|Patients randomized to the control group will receive standardized care, 3 counselling sessions with a gynaecology-oncology nurse and written information at three points in time during 6 months after diagnosis/surgery.
89055465|NCT04541784|Experimental|Mobile app and 3 counselling sessions (WOMAN-PROIII)|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III. Counselling sessions will take place at 3 points in time during 6 months after diagnosis/surgery. Additionally, the gynaecology-oncology nurse will instruct the patient to use the mobile app. It includes a diary for symptom assessment and gives graphical feedback. Further, the app includes disease and treatment related information. If a symptom occurs the app will give an evidence-based recommendation (Kobleder et al., 2016). The patients can use the app whenever they want for a period of six months."
89055466|NCT04999319|Active Comparator|PVB Group|Paravertebral block administered group
89055467|NCT04999319|Active Comparator|ESPB group|Erector spinae plane block administered group
89055468|NCT04549818|Experimental|sacral neuromodulation|Sacral neuromodulation group, will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
89055469|NCT04549818|No Intervention|medical therapy|this group will be treated with sustained release morphine tablets for pain control
89055470|NCT04541550|Experimental|Low Dose AMP-001|12.5 mg AMP-001 in 3 ml Saline
89055471|NCT04541550|Experimental|Medium Dose AMP-001|25 mg AMP-001in 3 ml Saline
89055472|NCT04541550|Experimental|High Dose AMP-001|50 mg AMP-001 in 3 ml Saline
89055473|NCT00556361|Placebo Comparator|1|
89055474|NCT00556361|Experimental|2|
89055475|NCT04671290||Control|Carbapenem (imipenem, or meropenem, or ertapenem) as first-line therapy or after receiving up to 72 hours of other antibiotics (including aminoglycosides).
89055476|NCT04671290||Cases|Temocillin above 50% of the time of effective antibiotic therapy duration. Temocillin had to be given as first-line therapy or after receiving a maximum of 5 days of other antibiotics (including carbapenems and aminoglycosides).
89055477|NCT04571606|Active Comparator|Liposomal Bupivacaine|Pre-operative ultrasound guided interscalene nerve block with 10 mL 1.3% liposomal bupivacaine (Exparel) and 10 mL 0.5% bupivacaine
89055478|NCT04571606|Active Comparator|Peripheral Nerve Catheter|Pre-operative ultrasound guided interscalene nerve block with 20 mL of 0.25% bupivacaine and placement of peripheral nerve catheter with 10 mL/hr 0.2% bupivacaine infusion via OnQ pump.
89055479|NCT04669613|Experimental|Patients|
89055480|NCT04541160||Suspected community-acquired pneumonia patients|Suspected community-acquired pneumonia patients that will be evaluated by an imaging method
89055481|NCT04549506||ASD group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. All ASD participants were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders 5th Edition's (DSM-5) diagnostic criteria (APA, 2013) and conﬁrmed by clinical consensus. ASD individuals were recruited from a community autism program and referred to children's health doctors and child psychiatrists. Exclusion criteria for all participants were neurological abnormalities, a history of epilepsy or seizures, head trauma and IQ <75. The subjects did not participate in any intervention or drug programs during the experimental period.
89055482|NCT04549506||Control group|There is no intervention to be administered in this study. Here, this fMRI study used the backwardly masked paradigm to elucidate how perceiving emotional expressions affects amygdala engagement and its related functional connectivity across two participant groups: ASD with and controls. The participants in the age- and sex-matched control group were recruited from the local community, and screened for major psychiatric illnesses by conducting structured interviews.
89055483|NCT04571372||Patients with severe aortic stenosis or severe aortic regurgitation|Patients with severe aortic stenosis or severe aortic regurgitation
89217405|NCT03838198|Other|Safety plan (Group D)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group D: Participants will receive the in-person MI-enhanced safety plan during hospitalization.
89055484|NCT04541277|Experimental|Tislelizumab with DAN hypmethylation agent +/- chemotherapy|"Decitabine, 20 mg/m2/d, IV, on days 1-5; or Azacitidine, 75 mg/m2/d,SC, on days 1-7.~Aclamycin hydrochloride, 20 mg/d, IV, on day 1, 3, and 5 (For relapse/resistance AML, on days 1-5.); or idarubicin hydrochloride,10 mg/d, IV, on day 1, 3, and 5.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cytarabine,100 mg, IV, q12h/d. For patients with one of the following conditions, cytarabine,10 mg, SC, q12h/d: (1) There are obvious heart, lung, and kidney complications; (2) Bone marrow is hypoproliferative; (3) Age> 75 years old; (4) Age> 60 years old who are unfit for standard-dose chemotherapy.~Recombinant human granulocyte colony stimulating factor injection, 5 μg/kg, SC, from day 0 to stop of chemotherapy after the WBC count exceeds 10.0×10^9/L; or Pegylated recombinant human granulocyte stimulating factor injection Liquid, 100 μg/kg, SC, on day 0.~Tislelizumab,200 mg, IV, on the next day after chemotherapy was stopped."
89055485|NCT04541394|Experimental|MolecuLight group|Patients with infected wounds received MolecuLight photography during debridement operation to evaluate the adequacy of remission of infected biofilm and facilitate wound healing
89055486|NCT04541394|No Intervention|Control group|Patients with infected wounds received debridement operation by surgeon's clinical experiences to decide the extension of wounds
89055487|NCT02210234|Active Comparator|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat brand cereal during the day for 3 weeks.
89055488|NCT02210234|Active Comparator|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat brand cereal the day for 3 weeks.
89055489|NCT02214264|Experimental|Loving-Kindness training|Participants receive Loving-Kindness meditation training for approximately 12 minutes.
89055490|NCT02214264|Experimental|Breath Awareness training|Participants receive Breath Awareness meditation training for approximately 12 minutes.
89055491|NCT02214264|Experimental|Gratitude training|Participants will receive Gratitude training for approximately 12 minutes.
89055492|NCT02214264|Other|Control|Participants write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
89055493|NCT04571294|Experimental|group A|PALN removal
89055494|NCT04571294|No Intervention|group B|No PALN removal
89055495|NCT04541316||Short term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-5 weeks post implantation
89055496|NCT04541316||Mid term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 3-4 months post implantation
89055497|NCT04541316||Long term post inguinal hernia repair with ProFlor|Determining presence and level of maturation of vascular structures in the inguinal hernia implant named ProFlor at 6-8 months post implantation
89055498|NCT04541238||Novel template report|"The last 100 consecutive and anonymized MRI investigations for primary perianal fistula reported according to standard practice by dedicated radiologists (the last 10 reports from each of 10 international centers) are reviewed blindly and independently by two experienced radiologists (based on case load, years of experience and publications on anal fistula) using a novel template incorporating 8 key descriptors.~A third independent experienced radiologist will resolve any disagreement and assess the presence of descriptors in the original report compared to the novel template."
89055499|NCT04997408|Active Comparator|Study Arm|Mobile device-assisted rehabilitation
89055500|NCT04997408|Active Comparator|Control Arm|In-person therapist-supervised rehabilitation
89055501|NCT04541199|Active Comparator|Conventional|
89055502|NCT04541199|Experimental|Closed-loop|
89055503|NCT02210351|Experimental|MRI test|
89217406|NCT00712595|Experimental|1|Mifepristone 10 mg daily for three months
89217407|NCT00712595|Experimental|2|Mifepristone 5 mg daily for three months
89217408|NCT00115765|Active Comparator|Oxaliplatin and bevacizumab without panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.
89217409|NCT00115765|Experimental|Irinotecan and bevacizumab plus panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
89217410|NCT00115765|Active Comparator|Irinotecan and bevacizumab without panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W alone
89217411|NCT00115765|Experimental|Oxaliplatin and bevacizumab plus panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
89217412|NCT00606008|Experimental|Sutent Treatment|Sutent was administered daily for 4 weeks at a dose of 50 mg followed by a 2 week study drug free break.
89217413|NCT00721019|Experimental|5-hour bedtime|
89217414|NCT00721019|Experimental|8.5-hour bedtime|
89217415|NCT03837184|Experimental|Onasemnogene Abeparvovec-xioi|Participants will receive a single dose of onasemnogene abeparvovec-xioi, administered intravenously.
89217416|NCT00898898||Arm I|Tissue samples from protocol NCCTG-N9831 are obtained for immunohistochemistry and fluorescence in situ hybridization analysis of MYC, IGF- 1R, PTEN, and TOP2A genes. Exons 9 and 20 of PIK3CA gene are amplified via polymerase chain reaction; mutations in exons 9 and 20 of PIK3CA gene are identified.
89217417|NCT04068233|Experimental|Eligible patients - pacing mode sequence 1|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-synchronous pacing mode first, then AV-dyssynchronous pacing mode.
89217418|NCT04068233|Experimental|Eligible patients - pacing mode sequence 2|Echo assessment of parameters of diastolic function, systolic function, and atrial function. Then, the stroke volume and cardiac output are measured during AV-asynchronous and AV-synchronous pacemaker stimulation: AV-dyssynchronous pacing mode first, then AV-synchronous pacing mode.
89217419|NCT04035122|Experimental|Robotic Treatment|The Lokomat is a robotic device. For treatment with the robotic system, the amount of body weight supported will initially set at 70% of every patient's weight, then decreasing in accordance with load tolerance, although not providing less than 20% support. The selected speed will be adapted to the patient's working comfort under the supervision of a trained physiotherapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
89217420|NCT04035122|Active Comparator|Conventional Treatment|The CG will perform traditional overgroung gait rehabilitation. Exercises in this program are designed with gradual increments to meet each patient's abilities and were supervised by a physical therapist. The rehabilitation protocol consists of 40 training sessions (3 sessions per week lasting 45 minutes).
89217421|NCT00461812|Experimental|Mometasone|
89217422|NCT00461812|Experimental|Advair|
89217423|NCT02539862|Experimental|cognitive behavioral therapy online|patients receive cognitive behavioral therapy via an online program
89217424|NCT02539862|Other|no cognitive behavioral therapy online|patients receive psychoeducation by a doctor
89217425|NCT00721331|Experimental|CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine)|
89055504|NCT02214342|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
89055505|NCT02214342|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
89055506|NCT04549389|Active Comparator|Group A|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (1/week) by using Dornier Aries 2 shockwave machine (energy level 7)
89055507|NCT04549389|Active Comparator|Group B|Patients will receive 6 Low-intensity shockwave therapy (LiST) sessions (2/week) by using Dornier Aries 2 shockwave machine (energy level 7)
89055508|NCT04549623|Experimental|Group ETCO2|Novel end-tidal carbon dioxide monitoring device is used for sedation.
89055509|NCT04549623|Experimental|Group Reg|Peripheral oxygen saturation (SpO2) and respiratory motion are regularly monitored during sedation.
89055510|NCT04570982||Convalescent Plasma with SOC|All patients will receive CPT and SOC
89055511|NCT04548843|Experimental|Cohort 1 & Cohort 2|"3 patients will be administrated with Dose 1 (0.88 mitochondria unit (mU) citrate synthase (CS) activity per million cells).~3 patients will be administrated with Dose 2 (4.4mU mitochondria unit (mU) citrate synthase (CS) activity per million cells)."
89055512|NCT04993586|Experimental|Group A|
89055513|NCT04993586|Experimental|Group B|
89055514|NCT04993586|Experimental|Group C|
89055515|NCT04993586|Experimental|Group D|
89055516|NCT04993586|Experimental|Group E|
89055517|NCT04548765|Active Comparator|Standard Letter|The standard letter describes the importance of getting screened and instructs recipients how to use the FIT kit for screening at home.
89055518|NCT04548765|Experimental|Letter with Risks|The standard letter is enhanced with language that further emphasizes the risks but also clearly describes how early detection with a test can reduce those risks; it also explains why test kits are being sent to disarm skepticism about the program.
89055519|NCT04548765|Experimental|Letter with Risks and Options|In addition to the enhancements added by the letter with risks, the letter also includes a table comparing FIT kit and colonoscopy. Presenting different screening options allows recipients to make the choice that best suits them. In addition, presenting multiple options increases the chance that recipients get screened in one way or another.
89055520|NCT04548765|Experimental|Letter with Risks, Options, and Consequences for Inaction|In addition to the enhancements added by the letter with risk, the comparison table includes comparisons of the consequences of getting screened vs. waiting for symptoms to appear.
89055521|NCT04540926|Experimental|COVID-19 Pneumonia control group|COVID-19 pneumonia patients with standar treatment: enoxaparin 0.5 mg/kg S.C. once, Clarithromycin 500 mg twice an metylprednisolone 0.5 mg/kg once endovenous.
89055522|NCT04540809||Psoriatic arthritis group (PsAG)|The evaluation was made using dynamometer, goniometer, mobile application, and Purdue pegboard test.
89055523|NCT04540965|Experimental|Telaglenastat and Famotidine|Famotidine
89055524|NCT04540965|Placebo Comparator|Telaglenastat and Placebo for Famotidine|Placebo for famotidine
89055525|NCT04548687|Active Comparator|carbon dioxide insufflation|patients with planned minimally invasive or repeated cardiac surgery using standard methods of deaeration of cardiac cavities, supplemented with carbon dioxide insufflation during surgery + standard methods of deaeration of cardiac cavities
89055526|NCT04548687|Other|no carbon dioxide|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
89055527|NCT02215356|Active Comparator|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5, cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles, while chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times). Progressive patients will be administered oral icotinib 125 mg three times daily.
89055528|NCT02215356|Experimental|Icotinib with concurrent radiotherapy|Chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times), while icotinib 125mg three times daily (375 mg per day) by mouth. Maintenance icotinib will be administered after radiotherapy. Progressive patients will receive chemotherapy, using the platinum-based two-drug chemotherapy regimen.
89055529|NCT04540653|Other|Standard vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, aged ≥50 years old, using a standard vaccination schedule (three doses of 20 μg, in months 0, 1, 6).
89055530|NCT04540653|Experimental|Reinforced vaccination schedule|To evaluate the immunogenicity of the monovalent hepatitis B vaccine, expressed in Hansenula polymorpha, in individuals aged ≥50 years, using a reinforced vaccination schedule (three doses of 40 μg, in months 0, 1, 6).
89055531|NCT04999514|Experimental|Mindful Parenting Program|The Mindful Parenting program as developed by Bögels and Restifo (2013), is selected as one of the parenting intervention programs in this study. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in parenting context.
89055532|NCT04999514|Experimental|Tuning in to Kids Program|The Tuning in to Kids program as developed by Havighurst and colleagues (2010), is selected as one of the parenting intervention programs in this study. It will be extended to 8-week program that aims at equipping parents with emotion coaching skills.
89055533|NCT04999514|No Intervention|Waitlist Control Group|The waitlist control group will not receive any intervention until the intervention arms complete their training. Depending on the availability of the program instructor, either the Mindful Parenting or Tuning in to Kids program will be offered to this group.
89055534|NCT04548960|Other|cancer patients|cancer patients To explore the phenomena of resistance during the therapeutic response and/or the progression of the pathology, the investigatorswill used a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq) from blood and tumor samples and immunological profil by ELISA
89055535|NCT04570865|Experimental|Dapagliglozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
89055536|NCT04540731||NAFLD and diabetes/NASH and fibrosis|Patients with NAFLD and type 2 diabetes (or insulin-resistance) or with any stage of fibrosis in the inclusion visit will be followed over time in a prospective cohort study with scheduled visits. Patients without diabetes/insulin-resistance or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study.
89055537|NCT04540731||NAFLD without diabetes/NASH without fibrosis|Patients without diabetes (or insulin-resistance) or any stage of fibrosis will participle in a single visit (inclusion) and will be part of a cross-sectional study
89055538|NCT04570748|Experimental|Group A|Direct anterior hip arthroplasty with capsule repair.
89055539|NCT04570748|Active Comparator|Group B|Surgery that the surgeon will not perform capsule repair after performing an initial capsulectomy during total hip arthroplasty
89055540|NCT04548726||Sapien 3|Patients with aortic stenosis treated with Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) TAVI
89055541|NCT04548726||Myval|Patients with aortic stenosis treated with Myval (Meril Life Sciences Pvt. Ltd., India) TAVI
89055542|NCT04540419|Experimental|Ad5-nCoV single dose|375 subjects, Ad5-nCoV containing 5E10 vp, single dose
89055543|NCT04540419|Placebo Comparator|Placebo single dose|125 subjects, Placebo containing 0 vp, single dose
89055544|NCT04570826|Experimental|Meditation program|The experimental group participated in the Meditation program during one month, eight sessions with a total of sixteen hours.
89055545|NCT04570826|Active Comparator|Scientific descriptions about meditation|The control group received scientific descriptions about meditation.
89055546|NCT04540614|Experimental|Intervention|70 participants receiving active comparator treatment plus experimental
89055547|NCT04540614|Active Comparator|Control|70 participants receiving active comparator treatment
89055548|NCT04561427||Pediatric Patients with narcolepsy|"Patients between 0 and 18 years old~Patients diagnosed with primary or secondary narcolepsy~From both gender"
89055549|NCT04548531|No Intervention|Usual Care Arm|This arm will be a usual care arm. Patients may call to schedule a colonoscopy or other tests as desired.
89055550|NCT04548531|Experimental|Shared Decision Making Arm|This is the intervention arm. Patients will receive a shared decision making information sheet in the mail and will be able to receive decision coaching from study staff to support selection of an option if desired.
89055551|NCT04570592|Placebo Comparator|Granisetron|Granisetron 1 mg (1ml) + Normal saline 1ml
89055552|NCT04570592|Experimental|Granisetron and Dexamethasone|Granisetron 1mg (1ml) + Dexamethasone 4mg (1ml)
89055553|NCT04540263||Sleeve Gastrectomy|Patients who underwent Sleeve gastrectomy operation
89055554|NCT04540263||Gastric Bypass|Patients who underwent Gastric Bypass operation
89055555|NCT04570514||Obesity|Patients with Obesity. BMI>=25
89055556|NCT04570514||Non-Obesity|Patients without Obesity. BMI<25
89055557|NCT04548414||Sepsis group|The patients in this group are diagnosed sepsis with the sepsis 3.0 definition.
89055558|NCT04548414||Control group|The recruited volunteers in this group are healthy.
89055559|NCT04560959|Experimental|tACS arm|The patient would receive strings of tACS stimulations in 77.5 HZ, each string would last for 1 second, followed by an interval of 5 seconds. A total of 600 strings would be sent out to the patients.
89055560|NCT04548336|Experimental|Motor Imagery|
89055561|NCT04548336|Experimental|Action Observation|
89055562|NCT04548336|Placebo Comparator|Placebo group|
89055563|NCT02211872|Experimental|Treatment A|BI 2536 BS single rising dose
89055564|NCT02211872|Experimental|Treatment B|BI 2536 BS multiple rising doses on three consecutive days (d1-3 schedule)
89055565|NCT02214459|Experimental|mhealth counseling|DASH Mobile mhealth enhanced coaching
89055566|NCT04561037|Active Comparator|Control Group|Control group patients received traditional physical therapy treatment. The traditional physical therapy treatment program consisted of TMJ mobilization techniques include distraction, anterior glide, anterior glide with pre-positioned mouth opening, medial/lateral glides, caudal-anterior-medial (CAM) glide, and CAM glide with pre-positioned mouth opening and isometric exercises against resistance for muscles of mastication.
89055567|NCT04561037|Experimental|Study Group|Study group patients received PEMFT, using EMG 8400 PEMF device (made in Italy, by EME) in addition to physical therapy treatment program.
89055568|NCT04548453|Experimental|Uterine EMG during labor|Multichannel uterine electromyography will be recorded on patients receiving oxytocin for induction or augmenation of labor.
89055569|NCT02215395|Experimental|CVR treatment cycle|Women who meet all inclusion and no exclusion criteria will be randomized to the first treatment cycle with the CVR alone followed by the second treatment cycle with the CVR and miconazole (one of three dosing regimens) or the first treatment cycle with the CVR and miconazole followed by the second treatment cycle with the CVR alone.
89055570|NCT04561310|Experimental|Post facilitation stretch|Post facilitation stretch with Maitland mobilization
89055571|NCT04561310|Active Comparator|Active release technique|Active release technique with Maitland mobilization
89055572|NCT02215434|Placebo Comparator|Biolipid B2 (blanked/placebo)|"The study is a single-center, single-blind, placebo-controlled, parallel group trial.~It consists of a 4-week screening period plus a 12-week treatment phase. At the screening visit, all participants underwent a physical examination including vital signs and breast and pelvic examination.~They were randomly assigned in a 1:1 ratio to receive a transdermal vehicle biolipid B2 (identical placebo) provided by Evidence Pharmaceuticals Inc, SP,BRAZIL.~The testosterone and placebo emulsion were alcohol-free matrixes that were applied topically to the forearm daily for the period of 12 weeks."
89055573|NCT02215434|Active Comparator|Testosterone, Transdermal, Behavior|Testosterone 0.5%, daily, 3 months
89055574|NCT04561076|Experimental|Sequence 1|Random allocation to HLX70 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
89055575|NCT04561076|Experimental|Sequence 2|Random allocation to HLX70 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
89055576|NCT04561076|Experimental|Sequence 3|Random allocation to HLX70 30 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
89055577|NCT02215473|Experimental|gingivitis mouth rinse|
89055578|NCT02215473|Experimental|periodontitis mouth rinse|
89055579|NCT02215473|Active Comparator|gingivitis no mouth rinse|
89055580|NCT02215473|Active Comparator|periodontitis no mouth rinse|
89055581|NCT04560842|Experimental|Conventional oxygen devise|Chose devise to keep patient's SpO2 > 92%
89055582|NCT04560842|Active Comparator|High flow nasal cannula|High flow oxygen device
89055583|NCT04548102|Experimental|Fetal Movement Counting|Fetal movement counting
89055584|NCT04548102|No Intervention|standard antenatal follow up care|Women in the control group received the antenatal hospital standard care.
89055585|NCT04560764|Experimental|Virtual Reality + Action Observation Therapy|Participants will see a video demonstrating the exercise they will be later asked to perform. The same procedure is performed for each of the four different exercises.
89055586|NCT04560764|Sham Comparator|Virtual Reality + Landscape video|Participants will see a video demonstrating a natural landscape and later they will perform an exercise. The same procedure is performed for each of the four different exercises.
89055587|NCT04570241|Active Comparator|Group A-Malaria toolkit|School children shall be trained on key malaria messages with a malaria toolkit. From the training received, the pupils will carry out awareness-raising in communities with key messages learnt.
89055588|NCT04570241|No Intervention|Group B-No malaria toolkit|"School children shall not be trained on key malaria messages with a malaria toolkit. Pupils will not carry out awareness-raising in communities with key messages.~."
89055589|NCT02215512|Experimental|RRx-001 + WBRT|RRx-001 administered intravenously twice a week (10, 17, 33, 55 mg) in subjects with brain metastases receiving whole brain radiation therapy (WBRT).
89055590|NCT04548258|Experimental|electric welded metal framework|using electric welding device to intraorally join metal framework where the study aim to save time and cost and eliminate lab errors
89055591|NCT04548258|Experimental|conventional cast metal technique|using the conventional casting technique to join metal framework and compare it with the electric welding technique
89055592|NCT02215590|Experimental|Re-Step|"The system consists of a pair of special shoes which sole height and angles change in a specific given order, thereby facilitating motor learning and problem solving in real time.~This unpredictable change will introduce a situation of necessary adaptation to keep balance."
89055593|NCT04547829|Experimental|PEG-rhG-CSF|pegylated recombinant human granulocyte-colony stimulating factor subcutaneous injection
89055594|NCT02211911|Experimental|Bisacodyl|
89055595|NCT02211911|Experimental|Sodium picosulfate|
89055596|NCT04540146||Case|End Stage Colorectal Cancer patients with intraabdominal ascites
89055597|NCT04540146||Control|Congestive heart failure and liver cirrhosis patient who had intraabdominal ascites
89055598|NCT04560491||Frozen section|Patients underwent intraoperative sentinel node examination by frozen section
89055599|NCT04560491||Scrape cytology|Patients underwent intraoperative sentinel node examination by scrape cytology
89055600|NCT01131676|Experimental|BI 10773 low dose|BI 10773 tablets once daily
89055601|NCT01131676|Experimental|BI 10773 high dose|BI 10773 tablets once daily
89055602|NCT01131676|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
89055603|NCT04560569|Experimental|Group A|ABT weekly and 3BNC117 bi-weekly
89055604|NCT04560569|Experimental|Group B|both ABT and 3BNC117 treatment bi-weekly
89055605|NCT04547322|Experimental|VR application group|The experimental group received VR application in the preoperative period for 10 minutes.
89055606|NCT04547322|No Intervention|Control group|The control group received the routine procedure in the unit clinic where the study was conducted. The routine procedure of the unit includes patients are taken to the operating room on a stretcher and wait on the stretcher in the surgery waiting room until the operation room is prepared.
89055607|NCT04539990|Experimental|Behavioral Sleep Treatment|"Parents of children with autism will come to two group meetings (up to 5 families in each group) where they will be receive information regarding sleep hygiene and behavioral techniques for reducing sleep onset delays and night awakenings. The program will last 8 weeks. Meetings will be held on week 1 and week 3. In addition parents will receive a weekly phone call where they will be asked about their ability to implement the behavioral techniques.~Sleep of the children will be measured using questionnaires, sleep diaries and with a Fitbit sensor before and after the program."
89055608|NCT04540029||COVID-19 Exposed Pregnancy (CEP)|Women who were pregnant and delivered during the outbreak of COVID-19 pandemic in Italy, and their infants.
89055609|NCT04540029||Non-Exposed Pregnancy (NEP)|Women who were pregnant and delivered during an anticipated COVID-19 free period in Italy, and their infants.
89055610|NCT04560374|Experimental|Experimental Group|Crochet octopus was delivered to the hands of the neonates in the experimental group 10 minutes before heel lance process and they were contacted with the crochet octopus up to 10 minutes after the procedure.
89055611|NCT04560374|No Intervention|Control Group|Control group neonates were performed all the process without delivering them any crochet octopus.
89055612|NCT04539912|Experimental|angulated screw-retained group(AG)|
89055613|NCT04539912|Active Comparator|cemented group (CG)|
89055614|NCT04560257|Experimental|Group intervene with HFNC|Review effect of HFNC as clinical trial among hospitalized patients with COVID-19 infection.
89055615|NCT04547361|Experimental|Cohort 1: Dose 1 E2511 or Placebo|Participants will receive Dose 1 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
89055616|NCT04547361|Experimental|Cohort 2: Dose 2 E2511 or Placebo|Participants will receive Dose 2 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
89217426|NCT00721331|Experimental|CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine)|
89217427|NCT00721331|Experimental|0.1% nortriptyline HCl|
89217428|NCT00721331|Active Comparator|0.1% mometasone furoate|
89217429|NCT00721331|Placebo Comparator|Active ingredient free vehicle cream of CRx-197|
89217430|NCT01025908|Experimental|Cognitive Behavioral Therapy|25 panic disorder patients
89217431|NCT01025908|Active Comparator|Supportive psychotherapy|25 panic disorder agoraphobia
89217432|NCT02540096|Experimental|Intervention (Mental Practice)|Participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups). They will also participate in a structured mental practice session (lasting 30 minutes and three times a week), totaling 12 sessions at the end of this intervention.
89217433|NCT02540096|Placebo Comparator|Control group|Participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes. They will also participate in a cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions.
89217434|NCT00123955|Experimental|1|Spironolactone
89217435|NCT00123955|Placebo Comparator|2|Placebo
89217436|NCT04372121|Experimental|Linzagolix 75 mg|
89217437|NCT04372121|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
89217438|NCT03837028||HPV 16/18 (+), cytology normal|"Women who have HPV 16/18 positivity and normal cytology results in their cervical cancer screening test (co-test) results.~The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later."
89217439|NCT03837028||HPV 16/18 (+), cytology abnormal|Women who have HPV 16/18 positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
89217440|NCT03837028||non-16/18 HPV (+), cytology abnormal|Women who have non- 16/18 high-risk HPV positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
89217441|NCT03837028||non-16/18 HPV (+), cytology normal|Women who have non- 16/18 high-risk HPV positivity and normal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
89217442|NCT02539784|Experimental|Spinal Cord Stimulation|
89217443|NCT04069481|Experimental|Dance intervention|Participants will receive a 1-hour group dance class twice a week for 12 weeks. Classes will include a seated warm up, dance exercises in standing, dance activities moving across the floor, throughout the space and conclude with a bow exercise. Music and dance styles will vary and personal preference of participants will also be taken into account.
89687997|NCT03835871|Experimental|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg per day Daily dose of Beclomethasone 200 µg 1 inhalation 100 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
89687998|NCT03835871|Experimental|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg per day Daily dose of Beclomethasone 100 µg 1 inhalation 50 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
89687999|NCT03835871|Placebo Comparator|placebo|Intervention: Drug: placebo 2 inhalations 2 times a day for 12 weeks
89688000|NCT03402373|Experimental|Lycoderm|soft gel contains nutritional supplement
89688001|NCT03402373|Placebo Comparator|Placebo|Soft gel without active ingredients
89688002|NCT03402295|Active Comparator|Vcd- (Bortezomibe, cyclophosphamide and dexamethasone)|"Intervention - Bortezomib 1.3mg/m2 Intra venous or Subcutaneous once a week (D1-8-15-22) 35days cycle Intervention- Dexamethasone 40mg once a week for four weeks orally or Intravenously- total dose per cycle was 160mg.~Intervention- Cyclophosphamide 900-2000mg- intravenously or orally- total dose monthly Total of four cycles"
89688003|NCT03402295|Active Comparator|Ctd- Cyclophosphamide, thalidomide and dexamethasone|"Intervention- Cyclophosphamide 900-2000mg intravenously or orally total dose monthly Intervention- Thalidomide 100-200mg orally- daily dose Intervention -Dexamethasone 40mg once a week for four weeks each month- total dose per cycle was 160mg Total of four cycles (cycles of 28 each one)~28 days each cycles- total of four cycles"
89688004|NCT03836183|Other|ultrasound|"ultrasound is the only study group for all the patients~pleuropulmonary ultrasound~clinical examination~fibroscopy."
89688005|NCT02243761|Experimental|DBT Based Skills Groups for Families|Family members of youth with concurrent disorder participate in a 12-week DBT based skills group led by therapists and/or peer facilitators.
89688006|NCT02243839|Active Comparator|Thrombolytic therapy|In the first arm, thrombolytic therapy (TT) is performed to the patients with obstructive prosthetic valve thrombosis. The TT regimen depends on the functional status of the patient. In patients with NYHA class III-IV dyspnea low dose, relatively faster TT regimen (25 mg tPA/6 hours) is performed. In patients with NYHA class I-II dyspnea TT with low dose and ultra-slow infusion of tPA (25 mg tPA/25 hours) is performed. During TT, patients are followed up with transesophageal echocardiography in every 24 hours.
89688007|NCT02243839|Active Comparator|Surgery|In the second arm, redo valve surgery is performed for obstructive valve thrombosis. Intraoperative and postoperative results are recorded
89688008|NCT03402061||Community living seniors|Approximately 50 seniors will taste test each nutrient enhanced recipe and determine acceptability and palatability.
89688009|NCT03402061||LTC cognitively well|Approximately 15 seniors living in long term care who do not have cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
89688010|NCT03402061||LTC persons living with dementia|Approximately 15 seniors living in long term care with cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
89688011|NCT04369495||Cyclophosphamide|Patients with induction therapy for lupus nephritis with cyclophosphamide
89688012|NCT04369495||Mycophenolate|Patients with induction therapy for lupus nephritis with mycophenolate
89688013|NCT02243917|Experimental|Dose Escalation Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles; subjects who have completed at least one cycle may optionally participate in a food effect week, wherein CB-5083 will be orally administered once daily, on days 1 and 4, and thereafter return to the original dosing schedule
89688014|NCT02243917|Experimental|Dose Expansion Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles
89055617|NCT04547361|Experimental|Cohort 3: Dose 3 E2511 or Placebo|Participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 (Treatment Period 1) under fasted condition followed by Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 7 (Treatment Period 2) under fed condition. A washout period of 6 days will be maintained between the doses.
89055618|NCT04547361|Experimental|Cohort 4: Dose 4 E2511 or Placebo|Participants will receive Dose 4 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
89055619|NCT04547361|Experimental|Cohort 5: Dose 5 E2511 or Placebo|Participants will receive Dose 5 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
89055620|NCT04547361|Experimental|Cohort 6: Dose 6 E2511 or Placebo|Participants will receive Dose 6 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
89055621|NCT04547361|Experimental|Cohort 7: Dose 3 E2511 (Elderly Participants) or Placebo|Elderly participants will receive Dose 3 of E2511 or E2511 matched placebo, tablets, orally, once on Day 1 under fasted condition.
89055622|NCT02210312||elective non-cardiac surgery and non-neurosurgical procedures|300 Patients aged 60 years and older undergoing elective non-cardiac surgery and non-neurosurgical procedures in general anaesthesia or combined general/regional anaesthesia with a duration of operation of 120 minutes or longer. 80 age-, gender- and education-matched healthy controls.
89055623|NCT02215629|Experimental|Experimental VS4718|Oral VS-4718 administered BID during a 28 day cycle.
89055624|NCT01131520|Experimental|Computerized Brief Intervention|Computerized one-session brief intervention for drug use
89055625|NCT01131520|Active Comparator|Counselor delivered brief intervention|This is a brief intervention focused on drug use delivered by a behavioral health counselor and based on motivational interviewing
89055626|NCT01131325|Experimental|Nilotinib|
89055627|NCT04547244||T2DM patients with CRTd with automatic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an automatic optimization of CRTd.
89055628|NCT04547244||T2DM patients with CRTd with echocardiographic optimization|In this cohort the T2DM patients with CRTd will receive at follow-up an echocardiography guided optimization of CRTd.
89055629|NCT04560062||Population in Quito|576 randomly chosen patients with diabetes in District 17D06, Quito (Ecuador)
89055630|NCT04560062||Population in Esmeraldas|576 randomly chosen patients with diabetes in Eloy Alfaro District, Esmeraldas (Ecuador)
89055631|NCT01131130|Experimental|Investigational contact lens|Bausch & Lomb
89055632|NCT01131130|Active Comparator|Acuvue Oasys Contact Lens|Johnson & Johnson Lens
89055633|NCT01131130|Active Comparator|Air Optix Aqua|Ciba Vision
89055634|NCT01130974|Experimental|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
89055635|NCT01130974|Active Comparator|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
89055636|NCT02214498|Active Comparator|Enalapril/hydrochlorothiazide|This arm will start with six weeks of administration of enalapril/hydrochlorothiazide in the evening and placebo in the morning, followed by six weeks of active treatment in the morning and placebo in the evening
88999120|NCT04082533|Placebo Comparator|Non-stiff Intravenous placebo|Total knee replacement patients without preoperative knee stiffness (defined as flexion < 100 degrees or extension lag > 10 degrees) receive 3 doses of matched volume diluent every 8 hours. The first dose is given in the holding area approximately 2 hours prior to first incision.
88999121|NCT04074356|Active Comparator|Healthy Controls|Healthy volunteers with no known gastrointestinal complications will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
88999122|NCT04074356|Active Comparator|Achalasia subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of achalasia will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
88999123|NCT04074356|Active Comparator|Hypercontractile/spastic disorder subjects|Subjects who have undergone standard of care high resolution manometry that results in a diagnosis of hypercontractile/spastic disorder will be given questionnaires and testing by electroesophagogram (EESG) and magnetoesophagogram (MESG).
88999124|NCT04027426|Active Comparator|FBT (family-based behavioral treatment)|This condition will be prescribed the Traffic Light Diet (1000-1500 kcal/day, < 2 servings/day of RED [non-nutrient-dense, energy-dense] foods) and a > 60 min/day of MVPA prescription for children and > 30 min/day of MVPA for adults at least 5 days/week. FBT will receive a family-based, behavioral intervention to assist the targeted child and a participating adult caregiver with making changes in energy balance behaviors.
88999125|NCT04027426|Experimental|FBT+Variety|The FBT+Variety condition will receive FBT along with a limited variety prescription. In this prescription families will identify two RED foods, a dinner entree and snack food, and develop meal plans that reduce variety of RED foods by regularly consuming these foods and limiting consumption of other RED entrees and snack foods.
88999126|NCT03991182|Experimental|Community-based parenting group|The community-based parenting group will include 39 health zones and 585 caregiver-child dyads
88999127|NCT03991182|Active Comparator|Control group|The control group will include 39 health zones and 585 caregiver-child dyads
88999128|NCT03989271|Active Comparator|Quercetin|Quercetin 2000 mg/day Quercetin is provided as orange flavored soft chews and each chew will have 250 mg of quercetin Quercetin will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months.
88999129|NCT03989271|Placebo Comparator|Placebo|"Placebo is also provided as soft chews that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews.~Placebo will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months."
88999130|NCT03989206|Experimental|Nemolizumab|Nemolizumab administered via subcutaneous injection
88999131|NCT03961334|Experimental|DOACs|Direct oral anticoagulants
88999132|NCT03961334|Active Comparator|Antiplatelets|SOC therapy with antiplatelets until study completion or until detection of AF. After detection of AF treatment with DOAC becomes SOC.
88999133|NCT03897218|Placebo Comparator|Group 1|Patients consuming placebo (millet flakes) each day
88999134|NCT03897218|Experimental|Group 2|Patients consuming oatmeal flakes with a low dosage of prebiotic food supplements
88999135|NCT03897218|Experimental|Group 3|Patients consuming oatmeal flakes with a high dosage of prebiotic food supplements
88999136|NCT03854370|Experimental|Baby shampoo|Baby shampoo used for surgical site prep
88999137|NCT03854370|Active Comparator|Peridex (Chlorhexidine)|Peridex used for surgical site prep
88999138|NCT03854370|Active Comparator|TechniCare (chloroxynel)|TechniCare used for surgical site prep
88999139|NCT03854370|Active Comparator|Betadine (Povidone- iodine)|Betadine used for surgical site prep
88999140|NCT03809377||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
88999141|NCT03757533|Experimental|Health Coaching|Participants in the Health Coaching (HC) arm will be assigned to a health coach for a period of 5 months along with receiving usual care (UC). An initial telephone call with the coach will include a discussion about the participant's self-assessment of health perceptions and goals. This self-assessment creates the foundation for the personalization of the behavioral intervention. From this point, the participant schedules the remaining 9 biweekly sessions (30-45 minute in length), for a total of 10 coaching calls over 5 months. Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record.
88999142|NCT03757533|Other|Control|Participants in the control arm will receive usual care (UC). Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record. To enhance recruitment, those subjects randomized to the usual care control group will be offered to participate in the health coaching arm of the study as well after a period of 6 months. If they refuse, they will continue in the usual care control group.
88999143|NCT03729349||Participants with Diagnosis of Rheumatoid Arthritis|Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.
88999144|NCT03723226|Active Comparator|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Their contralateral leg will serve as within subject control.
88999145|NCT03723226|Experimental|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise plus blood flow restriction. Their contralateral leg will serve as within subject control.
88999146|NCT03710746|Experimental|Mixed Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the food-focused response and attention training intervention.
88999147|NCT03710746|Experimental|Mixed Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the generic response and attention training intervention.
88999148|NCT03710746|Experimental|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
88999149|NCT03710746|Experimental|Female Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the generic response and attention training intervention.
88999150|NCT03710746|Experimental|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
88999151|NCT03710746|Experimental|Male Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the generic response and attention training intervention.
88999152|NCT03690427|Experimental|Traditional Charcoal-Heated Hookah followed by Electronic Hookah|"Participants were invited to smoke a 30-minute traditional charcoal-heated hookah-smoking session, followed by a 30-minute electronic hookah vaping session.~To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days."
88999153|NCT03690427|Experimental|Electronic followed by Traditional Charcoal-Heated Hookah|"Participants were invited to vape a 30-minute electronic hookah session, followed by a 30-minute traditional charcoal-heated hookah smoking session.~To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days."
88999154|NCT03679962|Experimental|Triple Chronotherapy|Four-day intervention, with 24-hour total sleep deprivation, 3-days of sleep phase advancement and daily bright light therapy.
88999155|NCT03679962|Active Comparator|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
88999156|NCT03658668|Experimental|active tDCS+PA|
88999157|NCT03658668|Sham Comparator|sham tDCS+PA|
88999158|NCT03584945|Experimental|Obsessive Compulsive Disorder|
88999159|NCT03584945|Other|Subclinical Obsessive-Compulsive symptoms (OCS)|
88999160|NCT03584945|No Intervention|Healthy Control|
88999161|NCT03536897||IORT|All patients will undergo a partial mastectomy with sentinel lymph node biopsy with the goal of achieving a margin-negative resection while maintaining good cosmetic outcome. Immediately following partial mastectomy and frozen section evaluation of the sentinel lymph nodes, IORT is to be delivered. Intraoperative radiation therapy will involve 50 kV xrays to a dose of 20 Gy during breast conserving surgery. After surgery, patients are followed based on the standard schedule determined by their surgeon for 5 years.
88999162|NCT03535298|Experimental|EHT: Early Highly-effective|"Participants randomized to the EHT: Early Highly-effective arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab, Kesimpta) as their initial disease modifying treatment.~Interventions: one of the highly effective MS therapies~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
88999163|NCT03535298|Experimental|ESC: Escalation|"Participants randomized to the ESC: Escalation arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment.~Interventions: one of the MS therapies NOT in the highly effective group~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
88999164|NCT03535298|No Intervention|OBS: Observational|"Participants will not be restricted to a group of MS therapies.~Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm."
88999165|NCT03513705|Experimental|Best practice|Enhanced implementation of best practices in pancreatic cancer care
88999166|NCT03513705|No Intervention|Current practice|Pancreatic cancer care according to current practice
89055637|NCT02214498|Placebo Comparator|Placebo|This arm will start with six weeks of morning administration of enalapril/hydrochlorothiazide in the morning and placebo in the evening, followed by six weeks of placebo in the morning and active treatment in the evening
89055638|NCT04311775||video laryngoscopy|video laryngoscope is a camera laryngoscope system used to see the larynx with camera
89055639|NCT04311775||laryngoscopy|laryngoscopy is a method used to see the larynx.
89055640|NCT04560218|Experimental|Uterotonic agents group A|Misoprostol sublingually 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab
89055641|NCT04560218|Experimental|Uterotonic agents group B|Misoprostol Intrauterine 2 tab (400 mcg) + Oxytocin 20 IU Intravenous + Placebo sublingually 2 tab
89055642|NCT04560218|No Intervention|Uterotonic agents group C|Oxytocin 20 IU Intravenous + Placebo Intrauterine 2 tab + Placebo sublingually 2 tab
89055643|NCT04559828|Active Comparator|Pomace olive oil|50 g of pomace olive oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
89055644|NCT04559828|Active Comparator|High-oleic sunflower oil|50 g of high-sunflower oil will be administered in a single dose together with a breakfast composed of 3 slices of whole-grain bread, 5 g of tomato pureé and 200 ml of milk.
89055645|NCT04579718||Eclipse|
89055646|NCT04579718||Zeus Cloud TPS V1.0|
89055647|NCT04540185|Experimental|Standard dose bivalent oral polio vaccine|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
89055648|NCT04540185|Placebo Comparator|Comparable Placebo- 0.10 mg/kg|Saline administered orally on a sugar lump
89055649|NCT04540185|Experimental|Standard dose of NA-831|Drug: neuroprotection NA-831 30 mg of NA-831in a capsule administered orally
89055650|NCT04540185|Placebo Comparator|Comparable Placebo- 30mg|30 mg of placebo in a capsule administered orally
89055651|NCT04540185|Experimental|Standard dose of bivalent OPV and NA-831|Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump Plus 30 mg of neuroprotection drug NA-831 in a capsule administered orally
89055652|NCT04540185|Placebo Comparator|Comparable Placebo|Placebo of a vaccine administered orally on a sugar lump Plus 30 mg of a placebo in a capsule administered orally
89055653|NCT00575744|No Intervention|1|
89055654|NCT02214537|Experimental|MACS|Patients with MACS Selection
89055655|NCT01130272|Experimental|Eluxadoline 5 mg|Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks.
89055656|NCT01130272|Experimental|Eluxadoline 25 mg|Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. .
89055657|NCT01130272|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks.
89055658|NCT01130272|Experimental|Eluxadoline 200 mg|Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks.
89055659|NCT01130272|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks.
89055660|NCT04559789|Experimental|Digital Lifestyle Intervention|Participants randomized to the intervention arm will receive access to a digital intervention consisting of the MindMate cognitive health app and Neurotrack's personalized health coaching platform.
89055661|NCT04559789|Active Comparator|Health Education|Participants randomized to the control arm will receive digital health education materials that mirror the content in the app.
89055662|NCT00575783||1A, 1B|"Type 1 diabetic subjects with a history of severe hypoglycemia and hypoglycemia unawareness who:~1A) meet criteria for islet cell transplantation and are referred by a participating islet cell transplantation center~1B) meet similar criteria but are not currently planning islet cell transplantation"
89055663|NCT00575783||2|Type 1 diabetics who are not optimally controlled (>8% HbA1c) and rarely experience hypoglycemia
89055664|NCT00575783||3|Healthy non-diabetics
89055665|NCT04539600|Experimental|induction chemotherapy + anti-PD-1 antibody|Camrelizumab (200 mg, Q3w, 2 cycles in total) combined with induction chemotherapy (taxane-containing regimen, Q3w, 2 cycles in total) followed by concurrent radiotherapy and chemotherapy.
89055666|NCT00575822|Active Comparator|1|NDO Endoscopic Full-thickness Plicator procedure
89055667|NCT00575822|Sham Comparator|2|Sham control procedure
89055668|NCT04546815||Gram-positive cocci infection|No intervention. The clinical data of patients (including demographic information, details of anti-infective therapy, imaging and laboratory testings) will be collected and analyzed.
89055669|NCT01129960|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
89055670|NCT01129960|Experimental|Eslicarbazepine acetate 1200 mg QD|
89055671|NCT01129960|Experimental|Eslicarbazepine acetate 1600 mg QD|
89055672|NCT01129960|Placebo Comparator|Placebo|
89055673|NCT04539756|Active Comparator|Active control condition|Participants in the active control condition will receive the same number of text message reminders and will complete the same number of writing activities as the intervention group. The writing activity for the active control condition will ask them to list their activities for that day.
89055674|NCT04539756|Experimental|Positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
89055675|NCT01129921|Active Comparator|Decompression with mild® Device Kit|Fluoroscopically guided percutaneous lumbar decompression using the Vertos mild® Device Kit for bone and tissue removal to decompress the targeted stenosed level(s).
89055676|NCT01129921|Sham Comparator|Sham lumbar decompression|Sham procedure of fluoroscopically guided percutaneous placement of mild® Device Kit instrumentation with no removal of bone or tissue.
89055677|NCT04559672||Laminoplasty Group|Patients who underwent cervical laminoplasty surgery due to myelopathy.
89055678|NCT04559672||Laminectomy and Fusion Group|Patients who underwent cervical laminectomy and fusion surgery due to myelopathy.
89055679|NCT04312087|Experimental|MLND|Modified lateral neck dissection (compartment II-V) is performed in all patients.
89055680|NCT04312087|Experimental|SLNB|Sentinel lymph node biopsy in the lateral neck is performed. The decision of neck dissection is based on the result of sentinel lymph node biopsy.
89055681|NCT04311814|Other|v-MUCP value|All patients referred for urodynamics explorations will have a measure of the MUCP during a Valsalva manoeuver
89055682|NCT04559165|Experimental|sericin and chitosan cream|Apply sericin and chitosan cream on pressure ulcer 2 times/day for 21 days.
89055683|NCT04559165|Active Comparator|Cavilon cream|Apply cavilon cream on pressure ulcer 2 times/day for 21 days.
89055684|NCT04312048|Experimental|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
89055685|NCT04312048|Placebo Comparator|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
89055686|NCT04547127|Experimental|Convalescent anti-SARS-CoV-2 MBT Plasma + SMT|Participants will receive 2 consecutive transfusions of 200 to 250 milliliters (ml) of ABO-compatible convalescent plasma with each unit of plasma, obtained from the same convalescent donor, which will be administered on Day 1 using standard procedures for administration of fresh frozen plasma. Participants weighing less than 45 kilograms (kg) will receive two transfusions of 10 ml of convalescent plasma per kilogram of body weight with each unit of plasma obtained from the same convalescent donor. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.
89055687|NCT04547127|Active Comparator|Standard Medical Treatment|Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29.
89055688|NCT00625222|Experimental|1|
89055689|NCT04311697|Experimental|Aviptadil IV in escalating doses + standard of care|Patients will be administered Aviptadil IV in escalating doses of 50 pmol, 100 pmol, 150 pmol/kg/hr
89055690|NCT04311697|Experimental|Placebo + standard of care|Patients will first be treated with placebo infusion + maximal intensive care
89055691|NCT00575861|Active Comparator|1|Advair 250/50 (baseline) fluticasone/salmeterol 250/50
89055692|NCT04547088|Experimental|Camrelizumab+Apatinib|Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy. Every patient will receive Apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.
89688015|NCT02243917|Experimental|Food Effect Stage - CB-5083|CB-5083 will be orally administered once daily, on days 1 and 4 of week 1, cycle 1, and orally administered daily, 4 days on and 3 days off, for the remaining 3 weeks of cycle 1; for subsequent 28 day cycles, CB-5083 will be orally administered daily, 4 days on and 3 days off
89688016|NCT03401983|Experimental|PFMT + AT|Pelvic Floor Muscle Training and Abdominal Training
89688017|NCT03401983|Active Comparator|PFMT|Pelvic Floor Muscle Training
89688018|NCT02243995|Experimental|Physical training|
89688019|NCT03401905|Experimental|Low frequency|Percutaneous electrical nerve stimulation with frequency of 2 Hz and 120 microseconds of pulse width will be applied.
89688020|NCT03401905|Active Comparator|High frequency|Percutaneous electrical nerve stimulation with frequency of 120 Hz and 200 microseconds of pulse width will be applied.
89688021|NCT02244073|Experimental|Individualized blood glucose target|Maintain blood glucose in individualized target based on glycated hemoglobin level (A1c); Blood glucose level is maintained bellow 1.59 × A1c - 1.59 (mmol/l).
89688022|NCT02244073|Active Comparator|Conventional blood glucose target|Maintain blood glucose bellow 10 mmol/l.
89688023|NCT02244151|Experimental|DECAPEPTYL® diario|Group 1: DECAPEPTYL® diario,OPU 24 hours after GnRHa administration.
89688024|NCT02244151|Experimental|Decapeptyl® diaro|Group 2:Decapeptyl® diario OPU 30 hours after GnRHa administration.
89055693|NCT04559360|Active Comparator|Active group - PRESTOapp users|Once users are recruited, an independent researcher will randomize the participants using a 1:1 sequential method in two groups of 76 individuals and will assign a 6-digit identification code (IC) to each participant. The IC will be given to the participant on a reminder card and will be used to access the app guaranteeing its confidentiality. The name of the subjects and their respective code will be stored in independent servers for methodological, security and legal reasons. The intervention group will be asked to use the app for a period of 2 months. The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
89055694|NCT04559360|No Intervention|Control group|The control group will receive the usual follow-up and treatment during the same time by the PCMHSP team.
89055695|NCT01129882|Experimental|Aripiprazole IM depot|Active treatment of monthly doses of aripiprazole IM depot (300 mg or 400 mg)
89055696|NCT04546854|Experimental|Conservative - Binding Appeal|
89055697|NCT04546854|Experimental|Liberal - Individulizing Appeal|
89055698|NCT00575900|Experimental|1|Low carbohydrate and low fat.
89055699|NCT00575900|Experimental|2|Low carbohydrate fat rich diet
89055700|NCT00575900|Active Comparator|3|A balanced low fat diet
89055701|NCT02278419|Experimental|Group A1|Participants without cirrhosis will receive simeprevir 150 milligram (mg) capsule along with sofosbuvir 400 mg tablet, orally, once daily for 8 weeks.
89055702|NCT02278419|Experimental|Group A2|Participants without cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
89055703|NCT02278419|Experimental|Group B|Participants with cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
89055704|NCT04559321|Active Comparator|Holmium laser|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser.
89055705|NCT04559321|Experimental|Trilogy|General anesthesia, Valdivia-Galdakao position, cystoscopy will be performed, ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with LithoClast Trilogy EMS and 1.5 mm x 440 mm probe
89055706|NCT02882737|Experimental|Exercise and glucagon before exercise|"120 minutes after breakfast; a single subcutaneous bolus of 200µg glucagon is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.~When exercise is ended a single subcutaneous bolus of 0.2 ml saline is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
89055707|NCT02882737|Active Comparator|Exercise and glucagon after exercise|"120 minutes after breakfast; a single subcutaneous bolus of 0.2 ml saline is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.~Low-dose glucagon phase: When exercise is ended or when hypoglycemia occurs (≤3.9 mmol/l); a single subcutaneous bolus of 200μg glucagon is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
89055708|NCT02882737|Active Comparator|Resting and glucagon after resting|"120 minutes after breakfast; a single subcutaneous bolus of 200μg placebo is administered.~Resting: After placebo injection the patient will be resting on a hospital bed for 45 minutes. The patient do not know if placebo or glucagon is administered.~Low-dose glucagon phase: After 45 minutes of resting or when hypoglycemia occurs, a single subcutaneous bolus of 200μg glucagon is administered.~Safety issues: If plasma glucose drops < 2.5 mmol/l at two consecutive measurements with 5 min interval or the patient experiences unbearable symptoms of hypoglycemia even after glucagon administration, 20 g carbohydrate is given orally. If plasma glucose drops< 2.3 mmol/l or doesn't raise sufficient after oral glucose, we will give intravenøs glucose to the patient. The study will then end and a new study day will be planned."
89055709|NCT04539171|Experimental|Intervention|Pain neuroscience education (Health education) and Physical exercise program: 6 weekly sessions (2 hours each), and a reminder session one month later
89055710|NCT04539171|No Intervention|Control|Standard of care.
89055711|NCT02882698|Experimental|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
89055712|NCT02882698|Experimental|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
89055713|NCT02882698|Active Comparator|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
89055714|NCT02882698|Active Comparator|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
89055715|NCT02883010|Experimental|PICO|Single use NPWT (PICO Softport V1.6)
89055716|NCT02883010|Other|Standard care|Gauze dressing, Film dressing, foam dressing, skin glue, no dressing
89055717|NCT02211950|Experimental|Treatment A|single dose BI 44847 administered to white subjects
89055718|NCT02211950|Experimental|Treatment B|100 mg acarbose for 2 days, on the second day a single dose BI 44847 administered to white subjects
89688025|NCT02244151|Experimental|Decapeptyl® diario.|Group 3: Decapeptyl® diario, OPU 40 hours after GnRHa administration.
89688026|NCT02244151|Active Comparator|Decapeptyl® daily|Group 4: Decapeptyl® daily OPU 36 hrs after GnRH administration
89688027|NCT03401827|Experimental|Gemcitabine + nab-paclitaxel|Case with chemotherapy (Gemcitabine + nab-paclitaxel)
89688028|NCT03833791|Active Comparator|Control Group (CON)|education and modifying diet
89688029|NCT03833791|Experimental|Moderate physical activity Group (PAM)|education, modifying diet and physical activity prescription
89688030|NCT03833791|Experimental|Intensity physical activity Group (PAI)|education, modifying diet and physical activity prescription
89688031|NCT03833401|Sham Comparator|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation. This will serve as control group.
89688032|NCT03833401|Experimental|Autologous tissue transplantation|Root canal disinfection will be performed and revascularization will be induced with autologous tissue transplantation.
89688033|NCT03833635|Experimental|OMT|
89688034|NCT03833635|Placebo Comparator|Control|
89688035|NCT04376671||temporal lobe epilepsy|Group of patients with temporal lobe epilepsy
89688036|NCT04376671||Extra-temporal lobe epilepsy|Group of patients with extra-temporal lobe epilepsy
89688037|NCT00909545|Active Comparator|Isradipine CR 5mg|Isradipine CR 5mg/day
89688038|NCT00909545|Active Comparator|Isradipine CR 10mg|Isradipine CR 10mg/day
89688039|NCT00909545|Active Comparator|Isradipine CR 20mg|Isradipine CR 20mg/day
89688040|NCT00909545|Placebo Comparator|Placebo|Placebo
89688041|NCT02244229|Experimental|Tamsulosin|
89688042|NCT02244229|Active Comparator|Finasteride|
89688043|NCT04369027||preload responders|patients who increase their delta VTI by more than 10% during PLR
89688044|NCT04369027||preload unresponders|patients who do not increase their delta VTI by more than 10% during PLR
89688045|NCT04368793||Discharged COVID-19 patient cohort|All enrolled participants will be given 8 weeks (online 2 weeks + offline 6 weeks) pulmonary rehabilitation intervention, and will be followed up for at least one year, to assess their adherence and efficacy of the rehabilitation program.
89688046|NCT04369339|Experimental|Other High Risk HPV Positivity|Colposcopy performed to women with High risk HPV positive ,negative for intraepithelial lesions or malignancy cytology
89688047|NCT04369339|Active Comparator|HPV16/18|Colposcopy performed to women with HPV 16/18 positive ,negative for intraepithelial lesions or malignancy cytology
89688048|NCT02157103|Experimental|Bevacizumab|Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
89688049|NCT00924001|Experimental|Metastatic Melanoma|Melanoma that has invaded deep into the skin, lymph nodes, or other parts of the body.
89688050|NCT01726595||severe sepsis|Patients with severe sepsis or septic shock
89688051|NCT01726595||non-infected critically ill|Patients with severe non-infectious systemic inflammatory response syndrome
89688052|NCT01726595||healthy|healthy volunteers
89688053|NCT02244307||Patients with BPH treated with alpha-andrenergic blockade|
89688054|NCT00910481|Experimental|Elective IABP Insertion|
89688055|NCT00910481|No Intervention|No Planned IABP Insertion|
89688056|NCT03401593|Active Comparator|ablation|Patients in this group are treated with radio-frequency catheter ablation.
89055719|NCT02211950|Experimental|Treatment C|single dose BI 44847 after a Japanese diet of 6 days administered to white subjects
89055720|NCT02211950|Experimental|Treatment D|single dose BI 44847 administered to asian subjects
89055721|NCT02211950|Experimental|Treatment E|single dose BI 44847 administered to african subjects
89055722|NCT02882776|Other|Ginger drink once daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water once a day for continuous 5 days.
89055723|NCT02882776|Other|Ginger drink twice daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water twice a day for continuous 5 days.
89055724|NCT04539210|Experimental|Electric Welded Metal Framework|A preexisting or prepared flat surface area of the welding abutment of implant at central incisor position at one side (right or left) will serve as the welding point. A titanium bar will be shaped following the curvature of the implants positioned. At this point, temporary titanium implant abutments will be welded with the titanium bar in the oral cavity, using the Syncrystallization Unit. Finally, the prosthetic framework, created by welding the titanium bar to the implant abutments, will be removed and opaque will be applied in order to avoid metal shining through the acrylic resin. The framework is picked up to denture with hard liner, and screwed to the denture.
89055725|NCT04539210|Experimental|cast metal framework|On a verified analogue model, occlusion blocks will be constructed for adjustment of vertical dimension and bite registration. Afterwards, CCM abutments will be fastened over the analogues of the placed implants, followed by waxing, spruing and casting. The resultant cast metal framework will be inserted inside the patient's mouth on the right or left installed implants to insure passivity of fit. In case of framework misfit, separation will be performed using a disc, followed by intraoral splinting and soldering. After framework soldering, another try-in will be done to insure framework fit.
89055726|NCT02882659|Experimental|Dendritic Killer Cell (DKC)|All enrolled patients received one treatment cycle of DKC cell therapy, which consists of 5 infusion cycles approximately 23 days apart. There were 3 dose levels: 5 x 10^6, 1 x 10^7, and 5 x 10^7 cells, and the protocol followed a traditional 3+3 dose escalation design.
89055727|NCT04579055|Experimental|1-min STS test: chair seat height adjusted to 90° knee flexion|In this experimental condition, the patient performs the 1-minute sit to stand test on an individually adjusted seat height of 90° knee joint flexion.
89055728|NCT04579055|Active Comparator|1-min STS test: chair seat height standardized of 46cm|In this experimental condition, the patient performs the 1-minute sit to stand test on a standard height chair of 46cm.
89055729|NCT04539288||Gestational diabetes mellitus|Women who were diagnosed GDM in 24-28 gestation weeks.
89055730|NCT04559087|Experimental|Natural Orifice Specimen Extraction Surgery|
89055731|NCT04559087|Sham Comparator|Conventional laparoscopy|
89055732|NCT04546893|Experimental|1904B CAR-T|Patients will be treated with CD19 CAR-T cells
89055733|NCT04579328|Experimental|Lessons with Growth Mats|Participants, clustered by neighbor groups, will be given lessons on stunting. During the lessons the trainers will use the growth mats to demonstrate their points. In these villages, village-wide events will expose the full community to the messages in combination to the mats.
89055734|NCT04579328|No Intervention|Lessons without Mats|Participants, clustered by neighbor groups, will be given lessons on stunting without the aid of the growth mats. In these villages, village-wide events will expose the full community to the messages without the aid of the mats.
89055735|NCT04546932|Experimental|Lung-protective mechanical ventilation|Vt=7 ml/kg IBW; an intraoperative 10 cmH2O in PEEP, recruitment maneuvers applying a stepwise increase in PEEP.
89055736|NCT04546932|No Intervention|Conventional mechanical ventilation|the tidal volume was set at 10 ml/kg IBW without PEEP and (recruitment maneuvers) RM
89055737|NCT04578860|Active Comparator|Treatment as usual|Usual treatment of sleep disorders consist of adequate sleep hygiene entails the behaviors, practices, rituals, and habits.
89055738|NCT04578860|Experimental|Music Intervention|Using the app Music Care
89055739|NCT04578860|Placebo Comparator|White Noise|Using an app producing white noise (like rain, storm, fan, wind...)
89055740|NCT00575939||HIV positive|HIV infected treatment naive with CD4 cell count of at least 400
89055741|NCT00575939||Healthy controls|Healthy controls
89055742|NCT04546503|Active Comparator|Continuous Regional Analgesia group|Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score <4 and Ramsay Score > 4 + perinerval block catheter from 0 to 24h after admission in intensive care unit using ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H
89055743|NCT04546503|Experimental|Control Group|group with general anesthesia and without locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score <4 and Ramsay Score > 4
89055744|NCT04558853|Experimental|Autologous NK cells|"The investigation product is a cell suspension based on ex vivo expanded NK cells from patients with MM. The treatment is strictly autologous. The IP is given as three infusions with escalating doses.~Mode of administration Intravenous infusions. Dose levels~First infusion; 5x10^6 cells/kg body weight~Second infusion; 50x10^6 cells/kg body weight~Third infusion; 100x10^6 cells/kg body weight"
89055745|NCT04546659|Experimental|Group A|Osteoarthritic patient receiving Conventional therapy and Retrowalking
89055746|NCT04546659|Active Comparator|Group B|Osteoarthritic patient receiving Conventional therapy
89055747|NCT04558814|Other|Systemic lupus erythematosus patients|Evaluation of serum galectin-9 level
89055748|NCT04558814|Other|Control group|Evaluation of serum galectin-9 level
89055749|NCT04546464|Experimental|Experimental Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
89055750|NCT04546464|No Intervention|Standard care|
89055751|NCT01129102|Experimental|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
89055752|NCT01129102|Active Comparator|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
89055753|NCT01129102|Placebo Comparator|Placebo|Placebo for NPC-01
89055754|NCT04539132|Experimental|Intervention Group|"The intervention group will participate in the 6-month interdisciplinary comprehensive rehabilitation program. The ABI Wellness (ABIW) program aimed at this population would be 7 hours a week (2 days per week will be scheduled for the intervention group), consisting of around 4 hours of cognitive training (through specified drills, cognitive exercises focused on executive functioning), 1 hour of physical exercise, 1 hour of mindfulness sessions (meditation) and scheduled break times."
89055755|NCT04539132|No Intervention|Control Group|"The non-intervention group or control group will have all the same pre-tests administered as the intervention group, however, will not participate in the cognitive program. The control group will be required to complete the assessment periods only, however, keep a record of their daily activities in a log format which is presented in the materials included herein. No other intervention or programming will be provided."
89055756|NCT04538820|Active Comparator|control|patients with BMI=18.5-24.9 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
89055757|NCT04538820|Active Comparator|4 mg|patients with BMI>30 kg/m2 will be received 4 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
89055758|NCT04538820|Active Comparator|8 mg|patients with BMI>30 kg/m2 will be received 8 mg dexamethasone at induction of anesthesia for postoperative nausea and vomiting prophylaxis.
89055759|NCT00575978|Experimental|Hydralazine|"The objective of this study is to determine the MTD for hydrazaline added to standard neoadjuvant chemotherapy for operable breast cancer. Four dose levels of hydrazalline are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
89055760|NCT01129024|Experimental|Lusutrombopag|Participants received lusutrombopag 0.5 mg administered orally once a day for up to 3 years or until study termination. The dose was adjusted based on platelet counts. If a subject's platelet count remained < 50,000/μL, the dose could have been increased by 0.25 mg up to a maximum dose of 2.0 mg.
89055761|NCT04546347|Experimental|14CAZD9833 Infusion NMT 22.8 kBq/5mL|Dose 1 14CAZD9833 Solution for Infusion
89055762|NCT04546347|Experimental|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet type A
89055763|NCT04546347|Experimental|AZD9833 Oral Solution|Dose 1 AZD9833 oral solution
89055764|NCT04546347|Experimental|AZD9833 film-coated tablet B Dose 1|Dose 1 AZD9833 film-coated tablet type B
89055765|NCT04546347|Experimental|AZD9833 film-coated tablet A Dose 2|Dose 2 AZD9833 film-coated tablet type A
89055766|NCT04546347|Experimental|AZD9833 film-coated tablet B Dose 2|Dose 2 AZD9833 film-coated tablet type B
89055767|NCT02882932|Other|Super Oxidized Solution|Procedure/Surgery: Super Oxidized Solution(SOS) in group I - SOS with normal saline solution was used
89055768|NCT02882932|Other|normal saline|"Procedure/Surgery: normal saline~In group II - patients underwent normal saline wash and bacterial load was noted."
89055769|NCT04559477|Experimental|Static extension endurance exercise|static back extension endurance exercise
89055770|NCT04559477|Active Comparator|Dynamic extension endurance exercise|dynamic back extension endurance exercise
89055771|NCT04539054|Experimental|Pre-Workout Condition|This condition consisted of the ingestion of one serving of the pre-workout supplement.
89055772|NCT04539054|Experimental|Caffeine Condition|This condition consisted of the ingestion of 6 mg of caffeine per kg of body mass.
89055773|NCT04539054|Placebo Comparator|Placebo condition|This condition consisted of the ingestion of a placebo.
89055774|NCT04558697|Experimental|Shepherd's Purse extractum oleosum vagitories|Vagitories containing Calendulae extractum oleosum 5,5% (w/w), Bursae pastoris extractum oleosum 5,5% (w/w), Matricariae extractum oleosum 5,5% (w/w), Hyperici extractum oleosum 5,5% (w/w) and Millefolii extractum oleosum 5,5% (w/w) as active component
89055775|NCT04558697|Experimental|Tea tree oil vagitories|Vagitories containing tea tree oil, 200 mg per each vagitorie as active component
89055776|NCT04558697|Experimental|Hyperici extractum oleosum vagitories|Vagitories containing Hyperici extractum oleosum 32% (w/w) as active component
89055777|NCT04558697|Active Comparator|Vagitories - Probiotic|Commercially available vagitories with probiotic
89055778|NCT04546269|Experimental|Fully-guided|Single-tooth implant placed using a fully computer-guided approach
89055779|NCT04546269|Active Comparator|Conventionally guided|Single-tooth implant placed using a conventionally guided approach
89055780|NCT02215707|Experimental|Group 1|"Group 1: 5 doses of 2.7x10^5 PfSPZ Vaccine; homologous 3D7 CHMI~Grp 1 (n=15) gets 5 doses of 270,000 PfSPZ per dose (4 doses at 4 wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 and 2 start immunizations together.~1 subj in each of Grps 1 and 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/Grp 2 pilot subjects: 1st subject will be immunized, observed on site for minimum 1 hr; the 2nd subject may be immunized, will also be observed for minimum 1 hr. If no safety concerns are identified after 24 hrs that trigger the stopping rules, then rest of subjects in Grps 1 and 2 will be immunized.~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (Pf3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
89055781|NCT02215707|Experimental|Group 2|"Grp 2: 5 doses of 2.7x10^5 PfSPZ Vaccine; heterologous 7G8 CHMI~Grp 2 (n=15) gets 5 doses of 270,000 PfSPZ/dose (4 doses at 4wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 / 2 start immunizations together.~1 subj in each of Grps 1 / 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/ 2 pilot subj: 1st subj will be immunized, observed on site for min 1 hr; 2nd subj may be immunized, will also be observed for min 1 hr. If no safety concerns after 24 hrs that trigger stopping rules, then rest of Grps 1 / 2 will be immunized.~Approx 3 wks after final dose, Grps 1/3 have homologous CHMI; 2-3 days later, Grp 2 will undergo heterologous CHMI (Pf7G8) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1/3 have 2nd homologous CHMI; 2-3 days later, Grp 2 will undergo 2nd heterologous CHMI (7G8 strain) with 6 Infectivity Controls. Subj will be followed for 8 wks after last CHMI for safety purposes."
89217444|NCT04069481|Active Comparator|Exercise and mindfulness meditation|Participants will receive a 1-hour group exercise class twice a week for 12 weeks. Classes will include resistance training exercises with resistance bands, stretching and range of motion exercises in seated and standing positions. Classes will also include mindfulness exercises. During active exercises music will be played and personal preference of participant will be taken into account.
89688057|NCT03401593|No Intervention|non-ablation|Patients in this group are treated with rate control medications (e.g., beta blocker, calcium channel blocker, and digitalis) and anti-arrhythmic drugs. They also can be treated with DC cardio-version.
89688058|NCT03408821|Experimental|Problem Solving Therapy|All participants will attend 8 weekly sessions of Case Manager delivered Problem Solving Therapy.
89688059|NCT04376359|Experimental|hyperbaric oxygen therapy|Patients with stroke will receive the hyperbaric oxygen therapy (HBOT) for 40 times, which were completed on 40 business days over a 2-month period and each session lasted 90 minutes at 100% oxygen concentration and 2 atmospheres.
89688060|NCT04376359|No Intervention|Control|Stroke patients were not treated with HBOT except for the same routine treatment as the experimental group.
89688061|NCT03408743|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
89688062|NCT03408743|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
89688063|NCT03408743|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks. *Also referred to as 'benefits' in other arm descriptions**
89688064|NCT03408743|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus perceived benefits and self-efficacy modules for a period up to 3 weeks.
89688065|NCT03408743|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
89688066|NCT03408743|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus injunctive norms and self-efficacy modules for a period up to 3 weeks.
89688067|NCT03408743|Experimental|Injunctive norms and benefits|Participants will have access to the knowledge module plus injunctive norms and perceived benefits modules for a period up to 3 weeks.
89688068|NCT03408743|Experimental|Injunctive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89688069|NCT03408743|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms modules for a period up to 3 weeks.
89055782|NCT02215707|Experimental|Group 3|"Grp 3 (n=15) will receive 3 doses by DVI of 450,000 PfSPZ/dose (of PfSPZ Vaccine) at 8 wk intervals (starting approx. 4 wks after Grps 1 and 2 get 1st immunization).~3 subjects in Grp 3 will be immunized approx 24 hrs prior to rest of grp (pilot subjects). The 3 subjects will be immunized sequentially with min 2 hr observation period between subjects (and a 2 hr observation of 3rd subject as well). If no safety concerns identified in pilot subjects after 24 hours that trigger the stopping rules, the rest of subjects in Grp 3 will be immunized as scheduled.~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
89055783|NCT02215707|No Intervention|CHMI Controls.1|n = 6, infectivity controls for 1st homologous CHMI (3D7) occurring approximately 3 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
89055784|NCT02215707|No Intervention|CHMI Controls.2|n = 6, infectivity controls for 1st heterologous CHMI (7G8) occurring approximately 3 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
89055785|NCT02215707|No Intervention|CHMI Controls.3|n = 6, infectivity controls for 2nd homologous CHMI (3D7) occurring approximately 24 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
89055786|NCT02215707|No Intervention|CHMI Controls.4|n = 6, infectivity controls for 2nd heterologous CHMI (7G8) occurring approximately 24 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
89055787|NCT01128946|Experimental|Fluoride Toothpaste 1|Fluoride toothpaste containing sodium fluoride (NaF)
89055788|NCT01128946|Experimental|Fluoride Toothpaste 2|Fluoride toothpaste containing stannous fluoride (SnF) and NaF.
89055789|NCT01128946|Experimental|Fluoride Toothpaste 3|Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.
89055790|NCT01128946|Active Comparator|Reference Dentifrice|Low fluoride toothpaste containing NaF
89055791|NCT04558580|No Intervention|Standard of Care|
89055792|NCT04558580|Experimental|Rufinamide|
89055793|NCT04546035|Experimental|500 pulses|In this group, patients received one single rESWT session consisting of 500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
89055794|NCT04546035|Experimental|1,000 pulses|In this group, patients received one single rESWT session consisting of 1,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
89055795|NCT04546035|Experimental|1,500 pulses|In this group, patients received one single rESWT session consisting of 1,500 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
89055796|NCT04546035|Experimental|2,000 pulses|In this group, patients received one single rESWT session consisting of 2,000 pulses on hamstring muscle with energy flux density at 0.1 mJ/mm2, repetition frequency was at 4 Hz, and a pressure of 1.5 bars.
89055797|NCT00625261|Experimental|1|The mothers of the two-years old children in the intervention group took part at the Heidelberg Parent-based Language Intervention HPLI
89055798|NCT00625261|No Intervention|2|Waiting group, no intervention until children were three years of age
89055799|NCT00576095||PMD|Patients diagnosed with major depression with psychotic features
89055800|NCT00576095||NPMD|Patients diagnosed with major depression without psychotic features
89055801|NCT00576095||Controls|Participants with no psychiatric or depression history
89055802|NCT00625300|Active Comparator|1|Active treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
89055803|NCT00625300|Sham Comparator|Placebo|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (sham) over the motor cortex and the prefrontal cortex.
89055804|NCT02215746|Experimental|Treatment A|BI 44370 TA drinking solution 100 mg fasted
89055805|NCT02215746|Experimental|Treatment B|BI 44370 TA drinking solution 100 mg fed
89055806|NCT02215746|Experimental|Treatment C|BI 44370 TA drinking solution 200 mg fasted
89055807|NCT02215746|Experimental|Treatment D|BI 44370 TA drinking solution 200 mg fed
89055808|NCT02215746|Experimental|Treatment E|100 mg BI 44370 BS as two tablets 50 mg fasted
89055809|NCT02215746|Experimental|Treatment F|100 mg BI 44370 BS as two tablets 50 mg fed
89055810|NCT02278458|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
89055811|NCT02215785|Experimental|kiwifruit cohort|Patients that presented at Primary Care Centres with registered -Roma III criteria based- constipation and who accepted to participate in the study were followed-up for two weeks before intervention and three weeks under 3-daily kiwifruit intake.
89055812|NCT02215824|Experimental|BIWH 3|in escalating doses
89055813|NCT02215824|Placebo Comparator|Placebo|
89055814|NCT01128595|Active Comparator|ICS|
89055815|NCT01128595|Active Comparator|ICS/LABA|
89055816|NCT01128595|Active Comparator|LABA|
89055817|NCT01128595|Placebo Comparator|Placebo|
89055818|NCT01129336|Experimental|Patients without bone metastases|Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.
89055819|NCT01129336|Experimental|Patients with bone metastases|Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy)
89055820|NCT01128400||rs1761667- AA genotype|subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.
89055821|NCT01128400||rs1761667-GG genotype|subjects who are homozygous of CD36 genotype rs1761667-G allele.
89055822|NCT01128400||rs1761667-AG genotype|Heterozygous of CD36 gene rs1761667-A genotype.
89055823|NCT02882386|Placebo Comparator|Milk 1%|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
89055824|NCT02882386|Experimental|Whey protein concentrate 80 (WPC-80)|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
89055825|NCT02882386|Experimental|Microparticulated whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
89055826|NCT02882386|Experimental|Hydrolyzed whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
89055827|NCT02882386|Experimental|Native whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
89055828|NCT01128361|Experimental|Aerobic Exercise|
89055829|NCT01128361|Active Comparator|Stretching|
89055830|NCT01128244|Experimental|Vitamin B6 Effects in OC Users|"All subjects will be given an infusion of labeled serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.~The results from analysis of vitamin B6 and these amino acids in blood will provide us with specific measurements of the rates of two aspects of metabolism (Primary Outcomes 1 and 2) and specific measurements of vitamin B6 nutritional status (Primary Outcomes 3 and 4)."
89055831|NCT04545996|Active Comparator|Cervical Rang of Motion Exercises.|Cervical exercises for mechanical neck pain.
89055832|NCT04545996|Experimental|Cervical Exercises.|Cervical exercises for the management of mechanical neck pain.
89055833|NCT01127893|Experimental|Tanezumab 10 mg|
89055834|NCT01127893|Experimental|Tanezumab 5 mg|
89055835|NCT01127893|Experimental|Tanezumab 2.5 mg|
89055836|NCT00625339|Experimental|A|entecavir 0.5 mg QD
89055837|NCT00625339|Active Comparator|B|lamivudine 100 mg QD
89055838|NCT02215863|Active Comparator|PCV13 and Fluad|437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0
89055839|NCT02215863|Active Comparator|Fluad alone|437 Fluad recipients: one vaccine injection administered on Day 0
89055840|NCT02215863|Active Comparator|PCV13 alone|437 PCV13 recipients: one vaccine injection administered on Day 0
89055841|NCT04558463|Experimental|Favipiravir|The favipiravir group received loading dose and maintenance dose of Favipiravir for 2 up to 7 days in addition to standard therapy
89055842|NCT04558463|Active Comparator|Oseltamivir|The oseltamivir group was given oseltamivir for 7 days.
89055843|NCT04311385||Diverticulitis|"Patients admitted as an emergency with acute diverticulitis diagnosed by CT scan.~Inclusion criteria~Patients over 18 years old~Informed consent form signed~Diagnosed of acute diverticulitis~CT scan reported as 1-2 pericolic bubbles with or without free fluid~Exclusion criteria~o CT scan showing free distant bubbles in the abdomen"
89055844|NCT01126879|Experimental|Arm I|Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
89055845|NCT01126879|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
89055846|NCT02214654||ticagrelor，clopidogrel，antiplatelet drugs|
89055847|NCT00576212|Experimental|A|Subjects in the intervention group will receive supportive telephone calls biweekly for 6 months.
89055848|NCT00576212|No Intervention|B|Subjects in the control group will receive no intervention.
89055849|NCT04311658|Experimental|Isosorbide Mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG-IUD insertion
89055850|NCT04311658|Placebo Comparator|placebo|one tablet of placebo vaginally 3 hours prior to LNG- IUD insertion
89055851|NCT02882308|Experimental|Monotherapy with olaparib|Patients in the monotherapy arm will be treated with olaparib until the 21st -28th day depending on the day of surgery, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
89055852|NCT02882308|Experimental|Combination of cisplatin and olaparib|Patients in the cisplatin - olaparib combination arm will receive treatment until the 5th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day.
89055853|NCT02882308|No Intervention|No treatment arm|"Patients in the no treatment arm will wait to be operated or have a second biopsy on the 23rd - 29th day.Optionally, patients who have a baseline FDG-PET/CT scan may be re-examined on the 22nd -28th day by the same modality to assess metabolic response."
89055854|NCT02882308|Experimental|Combination of durvalumab and olaparib|Patients in the durvalumab - olaparib combination arm will receive treatment until the 21th-28th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
89055855|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
89055856|NCT02211989|Experimental|BI 14332 CL|single rising dose
89055857|NCT02211989|Placebo Comparator|Placebo|
89055858|NCT00625456|Experimental|Single Arm, dose escalation|dose escalation starting dose 1e5 pfu/kg bw to 3e7 pfu/kg bw; Recombinant Vaccinia GM-CSF (JX-594)
89055859|NCT04539444|Experimental|CD19/22 CART cells combined with PD-1 inhibitors|Patients will receive PD-1 inhibitor on the first day after CART cell infusion
89055860|NCT00576329|Placebo Comparator|A|
89055861|NCT00576329|Experimental|B|
89055862|NCT02882464|Experimental|2PRF+CAF|"Two tubes of blood samples were centrifuged by PC-02 Centrifuged device. This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France). PRF were prepared for patients in 2 layer platelet rich fibrin membrane with coronally advanced flap group (2PRF+CAF).~Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 2PRF+CAF group: two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flpa is positioned coronally."
89055863|NCT02882464|Experimental|4PRF+CAF|Four tubes of blood samples were centrifuged by PC-02 Centrifuged device,four layers of PRF membranes were prepared for patients in 4 layer platelet rich fibrin membrane with coronally advanced flap.(4PRF+CAF). This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France) Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 4PRF+CAF group: four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flap is coronally positioned.
89055864|NCT02882464|Active Comparator|CTG+CAF|"The surgical technique in coronally advanced flap with subepithelial connective tissue graft (CTG+CAF) group was envelope technique as described by Raetzke. The papillae were dis epithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. The connective tissue graft was harvested from the palate using trap-door technique described by Edel. Epithelial layer was elevated with a horizontal and two vertical incisions. The connective tissue graft was harvested as 1 mm by using a standard caliper, then epithelial layer was sutured by resorbable suture. The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ."
89055865|NCT02882581|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
89055866|NCT02882347|Experimental|somatostatin group|The investigators administrate somatostatin at a rate of 3.5ug/kg/hour to PHLF patients (prothrombin time < 50% and serum total bilirubin > 2.9mg/dl after liver resection) until recovery from liver failure.
89055867|NCT00576368|Experimental|1|
89055868|NCT02278536||Multiple high risk gestation pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
89055869|NCT02278536||Multiple low risk gestation pregnancies|women pregnant with twins or triplets at low risk for aneuploidy
89055870|NCT00637468|Experimental|1|Local intra-arterial fibrinolysis (LIF)
89055871|NCT00637468|Active Comparator|2|Conservative standard therapy
89055872|NCT00637507|No Intervention|2|Patients treated solely with a pressure- and volume-limited ventilatory strategy (target plateau pressure of 30 cm H2O) aimed at minimizing lung stress and strain, and thus, ventilator-induced lung injury.
89055873|NCT00637507|Experimental|1|Intermittent application of High-frequency Oscillation (HFO) and Tracheal Gas Insufflation (TGI) according to pre-specified criteria described in the Detailed Description. HFO-TGI sessions are interspersed with lung protective conventional mechanical ventilation until the PaO2/FiO2 ratio stabilizes at >150 mm Hg.
89055874|NCT00637546|Experimental|A,1|Physiotherapy
89055875|NCT02212067|Experimental|Semaglutide|Total of 12 visits
89055876|NCT02212067|Placebo Comparator|Placebo|Total of 12 visits
89055877|NCT02212067|No Intervention|Healthy subjects|Total of 2 visits
89055878|NCT02278575|Other|Consisting of treatment with Atenativ|During two weeks antithrombin concentrate(Atenativ) will be administered in order to maintain normal levels of antithrombin
89055879|NCT01126060|Active Comparator|Fibrin sealant|usage of fibrin sealant after surgery
89055880|NCT01126060|No Intervention|Control|No usage of fibrin sealant
89055881|NCT02882542|Experimental|Visible light exposure Orange 30 lux|The participants will be exposed to orange LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89688070|NCT03408743|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
88999167|NCT03493178|Active Comparator|MCI-active|30 Subjects with MCI will receive N-acetylcysteine and glycine for 12-weeks. ll subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks.
89688071|NCT03408743|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
89688072|NCT03408743|Experimental|Descriptive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89688073|NCT03408743|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
89688074|NCT03408743|Experimental|Descriptive and injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
89217445|NCT00898976||Group I|Immunohistochemistry is performed on tumor samples to analyze the following molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2, Bax, cyclin D-1, and insulin-like growth factor-1R. PROJECTED ACCRUAL: A total of 300 tissue samples (150 from Native American women and 150 from Caucasian women) will be accrued for this study.
89217446|NCT01027546|Placebo Comparator|placebo, tranexamic acid|
89217447|NCT00901082|Active Comparator|information and relaxation|will receive the intervention that consist of information and relaxation
89217448|NCT00901082|No Intervention|No intervention|No specific intervention before the medial branch block.
89217449|NCT05667545|Active Comparator|Negative control group (A1)|A1: cavities will be sealed directly by restorative material (conventional glass ionomer) without any treatment.
89217450|NCT05667545|Active Comparator|Treatment group (A2)|A2: cavities will be treated by Self-Assembling peptide P11-4 then sealed by conventional glass ionomer.
89217451|NCT01025986||Noninfectious Uveitis|
89217452|NCT00115063|Experimental|1|"Intensive Medical Intervention including Low Calorie Liquid Diet, Weight loss medications, Group Behavioral Therapy and a Tool Box approach"
89217453|NCT00115063|Active Comparator|2|Access to Weight Loss Informational Website sponsored by the Mayo Clinic
89217454|NCT01026064|Experimental|Part C- Azithromycin|2 x 250 mg once daily over 3 days
89217455|NCT01026064|Placebo Comparator|Part C- Placebo|Once daily over 3 days
89217456|NCT00899054|Experimental|P276-00 plus Radiation|"P276-00:~Level 1:100 mg/m2/day x 5 q 3 weeks, level 2:140 mg/m2/day x 5 q 3 weeks, level 3: 185 mg/m2/day x 5 q 3 weeks.~External beam radiotherapy (EBRT):~2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 2 cycles (6 weeks)followed by upto 10 additional Gy if required"
89217457|NCT05659745|Placebo Comparator|Vaginal Suppository Capsule|In the VM-02 Vaginal Suppository Capsule Placebo Arm, participants will take the test vaginal suppository capsule placebo as directed.
89217458|NCT05659745|Experimental|Vaginal Suppository Capsule Active|In the VM-02 Vaginal Suppository Capsule Active Arm, participants will take a test vaginal suppository capsule as directed.
89217459|NCT05659745|Experimental|Vaginal Suppository Tablet Active|In the VM-02 Vaginal Suppository Tablet Active Arm, participants will take a test vaginal suppository tablet as directed.
89217460|NCT05659745|Experimental|Oral Capsule Active|In the VM-02 Oral Capsule Active Arm, participants will take a test oral capsule as directed.
89217461|NCT05659745|Other|Commercial Oral Vaginal Probiotic Competitor|In the Commercial Over-The-Counter (OTC) Oral Probiotic Competitor Arm, participants will take an over-the-counter competitor product as directed.
89217462|NCT02571959|Experimental|amoxicillin and clavulanic acid|All volunteers receive a dose of amoxicillin and clavulanic acid
89217463|NCT00893906|Experimental|TIV|Children living in villages randomized to influenza vaccine
89217464|NCT00893906|Experimental|IPV|Children living in villages randomized to polio vaccine
89217465|NCT00721487||Fluconazole|30 evaluable patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy.
89217466|NCT00167245|Experimental|Topiramate|topiramate capsules dose titrated up to 300 mg daily
89055882|NCT02882542|Experimental|Visible light exposure Orange 120 lux|The participants will be exposed to orange LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89055883|NCT02882542|Experimental|Visible light exposure Cyan 30 lux|The participants will be exposed to cyan LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89055884|NCT02882542|Experimental|Visible light exposure Cyan 120 lux|The participants will be exposed to Cyan LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89055885|NCT02882542|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89055886|NCT02882542|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89055887|NCT02212184|Sham Comparator|Control Group|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
89055888|NCT02212184|Experimental|Intevention Group|"All patients will receive the Manual Diaphragm Release Technique, during 6 days of treatment. They will undertake four evaluations throughout treatment: before and immediately after the Day 1 (Baseline 1 and Post 1) and before and after Day 6 (Baseline 6 and Post 6).~In the other Days (2nd to 5th) patients will only receive the intervention and won't be evaluated."
89055889|NCT01125748|Experimental|Omalizumab|Participants received omalizumab subcutaneously at the same dose and dosing interval as administered prior to enrollment in this study. The dose of omalizumab was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
89055890|NCT01125748|Placebo Comparator|Placebo|Participants received placebo subcutaneously at the same dosing interval as omalizumab was administered prior to enrollment in this study.
89055891|NCT04558268|Experimental|treatment group|
89055892|NCT04558268|Placebo Comparator|placebo group|
89055893|NCT04545918||Infertile Female|90 female patients with infertility undergoing an ovarian stimulation with use of exogenous gonadotropins.
89217467|NCT00167245|Placebo Comparator|Placebo|placebo capsules identical in appearance to the topiramate capsules
89055894|NCT01125514|Experimental|Furosemide 60 mg|Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.
89055895|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 150 mg|Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.
89055896|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 300 mg|Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.
89217468|NCT00901160||Surgical patients|Blood will be taken from patients who are on anti-platelet medication and are having surgery that requires an overnight stay. This is a pilot study to see if Thromboelastography® and Platelet Mapping Assay™ will be able to predict if a patient is at risk for a bleeding or a clotting problem after surgery.
89055897|NCT04538547|Experimental|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
89055898|NCT04538547|Active Comparator|Non Accelerated Radiotherapy|Concurrent Chemoradiotherapy followed by 3 cycles adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday.
89055899|NCT00576446|Experimental|1|
89055900|NCT04545879|Experimental|Raw garlic juice|Raw garlic juice treatment group
89055901|NCT04578782|Experimental|BOTOX|155 UI of Botox were injected according to the approved PREEMPT protocol (the only FDA-approved injection pattern for chronic migraine), in 31 sites. From visit 5, the PREEMPT 'follow-the-pain' paradigm was applied in patients falling in the 'non-responder' or 'partial responder' classes after the first BoNT-A injection, with the possibility to increase the doses up to 195 UI in maximum 39 sites. The injections were every 3 months for 4 cycles
89055902|NCT00576485|Experimental|1|Cataract surgery and implantation of a spherical intraocular lens
89055903|NCT00576485|Experimental|2|Cataract surgery and implantation of a spherical intraocular lens
89055904|NCT04539015||Group-I|Patients randomized to the Group-I will receive PREVENA Plus, which is currently being used at our institution (Prevena, KCI) and it is FDA-approved device. Dressings will be applied under sterile conditions at the end of the surgery while still in the operating room and will continuously apply for 5 days.
89055905|NCT04539015||Group-II|"Subjects randomized to SOC surgical incision dressing arm will receive SOC dressing for 4 days immediately following surgery. The closed incision will be covered with materials which may include sterile gauze pieces, surgical tape and tegaderm.~Any material used for the SOC dressing will be documented."
89055906|NCT00576563|Other|FDG PET CT|To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy.
89055907|NCT04538391|Active Comparator|bupivacaine group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with 20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca) diluted in 20 ml of 0.9% saline.
89055908|NCT04538391|Active Comparator|meloxicam group|included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals). diluted in 20 ml of 0.9% saline.
89055909|NCT04538391|Active Comparator|placebo group|included 35 patients in which skin and subcutaneous tissue was infiltrated with 20 ml 0.9% saline.
89055910|NCT04558307||Observational Intervention|Rapid SARS-CoV-2 testing strategy
89055911|NCT04558307||Behavioral Intervention|Community-driven messages to promote COVID-19 testing
89055912|NCT04545801|Active Comparator|Ketamine Group|Patients recieving 0.25 mg/kg of ketamine 5 minutes after spinal anesthesia
89055913|NCT04545801|Placebo Comparator|Placebo Group|
89055914|NCT04558424|Experimental|Intervention group|This group will consist of 50 patients who will be treated with zinc and vitamin C at a dose of 220 mg and 1 gram orally daily for 10 days in addition to their standard treatment
89055915|NCT04558424|Placebo Comparator|Placebo group|This group will consist of 50 patients who will receive placebo at a dose same dose for 10 days in addition to their standard treatment.
89055916|NCT02214693|Experimental|Group 1(Severe decrease in GFR)|Severe decrease in GFR
89055917|NCT02214693|Experimental|Group 2(Moderate decrease in GFR)|Moderate decrease in GFR
89055918|NCT02214693|Experimental|Group 3(Mild decrease in GFR)|Mild decrease in GFR
89055919|NCT02214693|Experimental|Group 4(Normal GFR)|Normal GFR
89055920|NCT00576602|Experimental|1|
89055921|NCT00576602|Active Comparator|2|
89055922|NCT01125358|Experimental|10 milligrams (mg) LY2140023|
89055923|NCT01125358|Experimental|80 mg LY2140023|
89055924|NCT01125358|Experimental|160 mg LY2140023|
89055925|NCT01125358|Placebo Comparator|Placebo|
89055926|NCT02214732|Experimental|MBCT + Treatment as Usual (TAU)|"Behavioural: Mindfulness Based Cognitive Therapy~Participants in the MBCT group attend an 8 week course of a modified MBCT program for pregnant women, delivered by a licensed clinical psychologist."
89055927|NCT02214732|No Intervention|Treatment as Usual (TAU)|Participants in the TAU group access community resources for pregnant women experiencing psychological distress.
89055928|NCT02212223|Experimental|Group 1: Somali immigrant group, 10 µg (400 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months
89055929|NCT02212223|Experimental|Group 2: Somali immigrant group, 20 µg (800 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months
89055930|NCT02212223|Placebo Comparator|Group 3: Somali immigrant group, 0 µg vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months
89055931|NCT02212223|Experimental|Group 4: Original Finnish group, 10 µg (400 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months.
89055932|NCT02212223|Experimental|Group 5: Original Finnish group, 20 µg (800 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months.
89055933|NCT02212223|Placebo Comparator|Group 6: Original Finnish group, 0 µg vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months.
89055934|NCT00576641|Experimental|Vaccine|
89055935|NCT02214810|Active Comparator|Control- Marcain|Group 1 will receive non-liposomal bupivacaine introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
89055936|NCT02214810|Experimental|Experimental- Exparel|Group 2 will receive a mixture of non-liposomal bupivacaine and Exparel introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
89055937|NCT02214849|Experimental|LATCH Intervention|Women enrolled in the WIC program and receiving breastfeeding peer counseling services will receive text messages to support them with their breastfeeding intentions. They will start receiving automated text messages starting in pregnancy and continuing throughout the first 6 months after giving birth. Messaging during pregnancy will emphasize what to expect in the hospital, the onset of lactation, skin-to-skin contact with baby, early and often breastfeeding in post-partum period, milk transfer (suck & swallow), positioning (with links), common breastfeeding problems and how to seek help. Throughout the study, participants will be able to respond to automated text messages with specific questions that will be received and answered by their WIC program peer counselors. Texting will also have prompts to respond occasionally (at minimum once every two weeks) to ensure that phone is still in service and that the participant in the intervention arm are receiving intervention.
89055938|NCT02214888|Experimental|BIRB 796 BS, low dose|
89055939|NCT02214888|Experimental|BIRB 796 BS, high dose|
89055940|NCT02214888|Placebo Comparator|Placebo|
89055941|NCT04558034|Active Comparator|Interventioncryotherapy/control|Subjects will have one mitt/one slipper and serve as their own control
89055942|NCT04558034|No Intervention|standard of care|Subjects will have two mitts/slippers
89055943|NCT04538508|Experimental|Diathermy|Participants that receive 10 sessions of radiofrequency diathermy of 12 minutes of duration
89055944|NCT04538508|Active Comparator|Control|Participants that perform supervised exercises for three weeks
89055945|NCT04545684|Experimental|Mental practice|
89055946|NCT04545684|Placebo Comparator|Placebo group|
89055947|NCT00576719|Experimental|1|Participants will receive intensive cognitive behavioral therapy treatment without parent involvement
89055948|NCT00576719|Experimental|2|Participants will receive intensive cognitive behavioral therapy treatment with parent involvement
89055949|NCT00576719|Placebo Comparator|3|Waitlist control group
89217469|NCT00716339|Active Comparator|1|motivated
88999168|NCT03493178|Placebo Comparator|MCI-placebo|30 subjects will received alanine for 12-weeks. All subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks
88999169|NCT03469934|Experimental|Etokimab|Participants received a single dose of 300 milligrams (mg) etokimab administered on Day 1 by intravenous (IV) infusion over 1 hour. After completing the Day 1 assessments, all participants were followed up for 18 weeks.
88999170|NCT03469934|Placebo Comparator|Placebo|Participants received a single dose of placebo (0.9% sodium chloride) administered on Day 1 by IV infusion over 1 hour. After completing the Day 1 assessments, all participants were followed up for 18 weeks.
88999171|NCT03424278|Active Comparator|Motor Control|
88999172|NCT03424278|Experimental|Resistance Training|
88999173|NCT03422770|Other|Mild aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. All undergoing 1 year control.
88999174|NCT03422770|Other|Moderate aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. All undergoing 1 year control.
88999175|NCT03422770|Other|Severe aortic stenosis|50 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG. All undergoing 1 year control.
88999176|NCT03422770|Other|Controls|31 subjects, all undergoing echocardiography and blood test and MRI.
88999177|NCT03406650|Experimental|Durvalumab in combination with standard therapy|Combination of standard therapy consisting (4 cycles cisplatin/ gemcitabin followed by surgery) with 4 cycles of neoadjuvant durvalumab and 10 cycles of adjuvant durvalumab
88999178|NCT03377725|Experimental|Experimental group|MDS patients of the experimental group will be treated with decitabine and arsenic trioxide.
88999179|NCT03377725|Active Comparator|Controlled group|MDS patients of the controlled group will be treated with decitabine alone.
88999180|NCT03375853|Active Comparator|Control Condition|Participants will complete computer based response training tasks that will incorporate pictures of birds, flowers, and mammals. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the experimental condition, only the appearance and context of the stimuli will be different (i.e., non-food versus food items). The computer tasks described above comprise the Generic Response Training Control Intervention.
88999181|NCT03375853|Experimental|Experimental Condition|"Participants will complete computer-based response training tasks that will incorporate pictures of healthy food, unhealthy food, and glasses of water. As part of the computer-based training, participants will be instructed to respond or inhibit responses to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the control condition, only the appearance and context of the stimuli will be different (i.e., food versus non-food items). The computer tasks described above comprise the Computer Based Response Training Weight Loss Intervention. To optimize the intervention, we narrowed the low-calorie food stimulus set to make a better distinction between high-calorie and low-calorie foods and we changed the filler images (water and furry mammals) in the go/no-go task from 100% go to 50% go and 50% no-go to measure learning of stimulus-specific respond associations."
88999182|NCT03346135|Experimental|Treatment (ASCT, melphalan, daratumumab)|Patients undergo standard of care ASCT with a conditioning regimen of melphalan. Beginning 60-120 days after ASCT, patients receive daratumumab IV every week for 8 weeks, every 2 weeks for 16 weeks, and then every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
88999183|NCT03282916|Active Comparator|Valacyclovir|The oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day.
88999184|NCT03282916|Placebo Comparator|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day.
88999185|NCT03267524|Experimental|Supportive Care (Walking for Recovery from Surgery)|Patients and caregivers receive Walking for Recovery from Surgery prehabilitation intervention in 4 sessions 3-7 days before surgery, before discharge, and at 2 and 7 days post-discharge.
88999186|NCT03229382|Experimental|Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22|Patients with evidence of MCL molecular relapse defined as an increasing copy number in quantitative real-time polymerase chain reaction (RQ-PCR) of clone-specific immunoglobulin heavy chain (IGH) gene rearrangements or BCL1-IGH fusion genes according to BIOMED-2 methodology and protocols in peripheral blood or/and bone marrow without evidence of clinical relapse/progression after auto-HCT procedure with all inclusion and no exclusion clinical trial criteria will receive 4 weekly infusions of obinutuzumab.
88999187|NCT03215693|Experimental|X-396 capsule|225mg once daily
88999188|NCT03187106|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for a total of 6 doses; 500 mg metronidazole per oral every 8 hours for a total of 6 doses
88999189|NCT03187106|Placebo Comparator|Placebo / standard of care|Placebo pills per oral every 8 hours for a total of 6 doses
89217470|NCT00716339|No Intervention|2|control
89217471|NCT01027624||Hyperchlesterolaemia|Participants undertreated with hypercholesterolaemia
88999190|NCT03159702|Experimental|MEL/FLU and Total-Body Irradiation (TBI)|"For patients who are < 60 years.~Melphalan: 140 mg/m2/day IV on Day: -6~Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].)~TBI: 200 cGy Day: -1.~For patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of >3 (at the discretion of treating physician will have an option to receive):~Melphalan: 70 mg/m2/day IV on Day -6.~Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.~TBI: 200 cGy; Days -1."
88999191|NCT03143621|Experimental|Coffee|100 cc's of coffee administered three times per day until return to bowel function has been established.
89055950|NCT01125046|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
89055951|NCT04538937||Subjects with eosinophilia and respiratory manifestation|
89055952|NCT04538937||Healthy subjects|
88999192|NCT03143621|Placebo Comparator|Water|100 cc's of warm water administered three times per day until return to bowel function has been established.
88999193|NCT03096197|Experimental|EAW + TLS|The EAW+TLS training group will receive 60 minutes of exoskeleton-assisted walking overground per session, for a total of 80 sessions (3x/week, 28 wks.) with simultaneous transcutaneous lumbosacral stimulation (TLS) intervention followed by 15 minutes of over ground training without the exoskeleton. component is added to the exoskeleton assisted walking component in this group. TLS will involve placing self-adhesive stimulating electrodes bilaterally over the T11/T12 lumbar region. Correct placement will be confirmed by the elicitation of posterior root muscle reflexes in the lower limb muscles. A constant-voltage stimulator (RT 50 Sage stimulator) will deliver pulses of 2 ms width. TLS will be applied while the participant walks in the Exo-skeleton-assisted walking (EAW).
88999194|NCT03096197|Experimental|EAW without TLS|EAW, exoskeleton-assisted walking, an activity based therapy is a training which involves using the same exoskeleton device for all the participants. Each participant will undergo, 60 minutes of EAW as above. Each participant will undergo a stand evaluation and be instructed in proper use of the device. During the initial 3 sessions of training, the exoskeleton device will be tethered to an overhead pulley system during training to allow subjects to safely adapt to trunk, balance gait activities while walking in the exoskeleton. EAW overground walking will follow each training session with the 6-minute walk test, 10 meter walk test .
88999195|NCT03073122||TGA Case|Brain MRI, Neurocognitive and psychological testing
88999196|NCT03073122||Control|Brain MRI, Neurocognitive and psychological testing
88999197|NCT03054961||Epilepsy patients|Near-infrared spectroscopy for subjects with partial (focal) epilepsy seizures being studied in the EMU.
88999198|NCT03044977|Experimental|Cohort 1|"This is the initial treatment arm. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)"
88999199|NCT03044977|Experimental|Cohort 2|"This treatment arm is opened if Cohort 1 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
88999200|NCT03044977|Experimental|Cohort 3|"This treatment arm is opened if Cohort 2 is successful. 131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)"
88999201|NCT03044977|Experimental|Cohort -1 (alternative cohort)|"This treatment arm is opened if Cohort 1 is not tolerated.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
88999202|NCT03044977|Experimental|Cohort 2.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 200 centiGray (cGy) Radiation exposure to the kidneys is limited to 1500 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
88999203|NCT03044977|Experimental|Cohort 2.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 100 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
88999204|NCT03044977|Experimental|Cohort 3.1 (renal alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 3.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 250 centiGray (cGy) Radiation exposure to the kidneys is limited to 1900 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
88999205|NCT03044977|Experimental|Cohort 3.2 (bone marrow alternative)|"This treatment arm is opened if the kidney radiation exposure was not tolerated in cohort 2.~131I-MIBG and 90Y-DOTATOC are administered once per cycle, for up to 2 cycles 12 weeks apart.~Radiation exposure to the bone marrow is limited to 150 centiGray (cGy) Radiation exposure to the kidneys is limited to 2300 centiGray (cGy)~No further dose evaluations are done after this cohort is completed."
88999206|NCT03009201|Experimental|Treatment (ribociclib, doxorubicin hydrochloride)|"Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89055953|NCT04311346||Cardiac transplant|Patients exposed to cardiac transplantation
89055954|NCT04538313|Experimental|High dose group|10^10 TIL
89055955|NCT04538313|Experimental|Low dose group|10^9 TIL
89055956|NCT04538313|Experimental|Extension set|The number of TIL is decided by dose escalation experiment.
89055957|NCT04538469||Group 1|Admitted prior to COVID visitation restrictions introduced
89055958|NCT04538469||Group 2|Admitted following the introductions of visitation restrictions due to COVID 19 pandemic
89055959|NCT01124734|Experimental|Course 1 Cycle 1 and Cycle 2|"Course 1 Cycle 1: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.~Course 1 Cycle 2: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days."
89055960|NCT04538781||Same Day Discharge|Patients undergoing a-fib ablation procedures who were closed with VASCADE MVP and were discharged the same day.
89055961|NCT04557839|Active Comparator|Traditional physical therapy balance exercise|Traditional physical therapy including balance exercise on mate and swiss ball.
89055962|NCT04557839|Experimental|proprioception based balance training|proprioception based balance training with eye open and close on soft , firm and foam surface.
89055963|NCT00576875||Depressed|Older individuals with major depression
89055964|NCT00576875||Non-depressed|Older individuals without major depression
89055965|NCT04545450|Active Comparator|Testosterone Undecanoate plus dutasteride|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + dutasteride 5 mg/day
89055966|NCT04545450|Placebo Comparator|Testosterone Undecanoate plus placebo|Testosterone Undecanoate (TU) 1000 mg i.m. at weeks zero, six, 18, 30, 42 + a daily oral placebo pill
89055967|NCT04579133|Experimental|durvalumab plus olaparib|Durvalumab 1500 mg IV week 0, 3, 6 plus Olaparib tablets will be given orally on a continuous dosing schedule 300 mg BID OR 200 mg BID (if glomerular filtration rate [GFR] 31 to 50 mL/min) to complete 9 weeks of treatment.
89055968|NCT04579133|Experimental|durvalumab alone|Durvalumab 1500 mg IV week 0, 3, 6 to complete 9 weeks of treatment
89055969|NCT04545372|Experimental|the study group|the study group (GA) was treated only by the disease modifying drug (interferon beta-1a) in addition to aerobic exercise.
89055970|NCT04545372|No Intervention|the control group|control group (GB)was treated only by the disease modifying drug (interferon beta-1a)
89055971|NCT00576914|Active Comparator|A|vinorelbine plus cisplatin plus recombinant human endostatin
89055972|NCT00576914|No Intervention|B|vinorelbine plus cisplatin
89055973|NCT04545645|Active Comparator|Neural Stress Provoked by the Median Nerve|
89055974|NCT04545645|Experimental|Neural stress provocation with cognitive auditory distraction|
89055975|NCT04545645|Experimental|Providing neural stress with a motor distraction|
89055976|NCT04545645|Experimental|Neural stress provocation with both distractions|
89055977|NCT02212340|Experimental|TIVA group|Anesthesia is maintained with fresofol and remifentanil
89055978|NCT02212340|Active Comparator|Des group|Anesthesia is maintained with desflurane and remifentanil
89055979|NCT01124617|Experimental|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
89055980|NCT01124617|Placebo Comparator|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
89217472|NCT00894062|Active Comparator|1|ZES resolute (Endeavor® resolute)
89217473|NCT00894062|Active Comparator|2|EES (Xience®)
89055981|NCT00576992||GI observation|Patients presenting for an upper endoscopy procedure with gastrointestinal symptoms or complaints.
89217474|NCT00721565|Experimental|1|behavior change intervention
89217475|NCT00721565|No Intervention|2|written materials
89055982|NCT04205890|Experimental|Ketamine|The present study is designed as a prospective data analysis of patient response to the use of ketamine to treat treatment-resistant depression. For Phase I trail, 10 patients of any gender with an age range of 18 to 70 who have undergone the outlined procedure will be recruited for inclusion. A week before the scheduled ketamine treatment, the patients will have fMRI scans, including structural T1, Arterial Spin Labeling, and Resting BOLD. The scans take around 30 minutes at no charge to the patients. The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage will vary (see below) depending on every individual's unique treatment plan. The same scans will be taken two days after treatment.
89055983|NCT00577070|Active Comparator|H1|"Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS,20 minutes each session, to the left prefrontal cortex using H1 coil, in frequency of 20 HZ, with intensity of 120 % of motor threshold. H1-coil is an extracorporeal device positioned on the patient's scalp, designed to stimulate deep prefrontal brain regions, preferentially in the left hemisphere. The effective part of the coil, which has contact with the patient's scalp, includes 14 strips of 7-12 cm length. These strips are oriented in an anterior-posterior axis.This coil stimulates neuronal fibers in anterior-posterior orientation.~During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas."
89055984|NCT00577070|Experimental|H2|Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS, 20 minutes each session, to the prefrontal cortex bilateraly using H2 coil, in frequency of 0.1 HZ, with intensity of 120 % of motor threshold. H2-coil is designed to stimulate deep prefrontal brain regions bilaterally (without any preferencefor either hemisphere). The effective part of the coil, which has contact with the patient's scalp, includes 10 strips of 14-22 cm length.These strips are oriented in a right-left direction (lateral-medial axis).This coil is destined to stimulate lateral-medial neuronal fibers. During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas.
89055985|NCT00577109|Experimental|1|
89055986|NCT04538001|Experimental|Balloon implantation|Arthroscopic implantation of this sub-acromial balloon
89055987|NCT04538001|Active Comparator|Rotator cuff repair|Partial rotator cuff repair
89055988|NCT01124422|Experimental|fluticasone propionate/salmeterol DISKUS 250/50 + tiotropium|This is the active DISKUS (that is, containing fluticasone propionate/salmeterol combination) + open-label tiotropium
89055989|NCT01124422|Placebo Comparator|placebo DISKUS + tiotropium|This is the DISKUS and excipient minus the active ingredient (which is fluticasone propionate/salmeterol combination) + open-label tiotropium
89055990|NCT04544982|Active Comparator|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
89055991|NCT04544982|Placebo Comparator|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
89055992|NCT04538196|Experimental|R Education|Invervention: Resident who receives education on documentation and coding at the beginning of the surgical rotation
89055993|NCT04538196|No Intervention|R no Education|Resident who does not receive information on documentation and coding at the beginning of the surgical rotation
89055994|NCT00577226||1 Shilla Technique|The patients whose data is observed are those who have undergone the shilla surgical technique.
89055995|NCT00625495|Experimental|1|IV Nexium
89055996|NCT00625495|Experimental|2|Oral Nexium
89055997|NCT00625534|Experimental|1|Laparoscopic repair
89055998|NCT00625534|Active Comparator|2|Open tension free inguinal hernia mesh repair
89217476|NCT00894140|Other|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
89055999|NCT02882425|Experimental|Intravenous selexipag (Pilot phase)|Subjects received a 20-minute intravenous (i.v.) infusion of 50 µg selexipag
89056000|NCT02882425|Experimental|Sequence A-B (Main phase)|Subjects received a 80-minute i.v. infusion of 200 µg selexipag during Period 1, and 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 2. A washout period of 7 to 10 days separated the i.v. infusion from the oral administration.
89056001|NCT02882425|Experimental|Sequence B-A (Main phase)|Subjects received 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 1, and a 80-minute i.v. infusion of 200 µg selexipag during Period 2. A washout period of 7 to 10 days separated the oral administration from the i.v. infusion.
89056002|NCT04538235||Bi-block (Serratus and erector spinae block) group|"The Bi-block consisted in performing an ESP block followed by a SAP block on the side ipsilateral to the thoracic surgery. For the ESP block, 40 ml of Ropivacaine 2mg/ml were injected under the erector spinae muscle plane, at the level of the 4th thoracic vertebra. For the SAP block, 40 ml of Ropivacaine 2 mg/ml were injected under the serratus anterior muscle plane. The cumulative dose of Ropivacaine did not exceed 3 mg/kg.~Regional anesthesia was performed before surgery."
89056003|NCT04538235||Thoracic Epidural Analgesia (TEA) group|"The thoracic epidural was performed according to a standardized protocol, with a Tuohy needle via the median puncture technique, at the level of T4-T5 intervertebral space. After a test dose of 2 to 3 ml of Lidocaine, 5 to 10 ml of a mixture of Ropivacaine 2 mg/ml and Sufentanil 0.5 µg / mL were injected. Epidural continuous administration was performed with the same mixture of anesthetic connected to a CADD Solis ™ pump set according to a PCEA protocol adapted to the patient's weight (continuous flow rate from 3 to 6 ml/h, self-administered bolus dose from 3 to 5 ml, refractory period 30 min).~Regional anesthesia was performed before surgery."
89056004|NCT00577304|Other|2|Placebo - Topical AmphiMatrix
89056005|NCT00577304|Active Comparator|1|Topical AmphiMatrix with Nitroglycerin
89056006|NCT01124149|Experimental|MMX mesalamine/ mesalazine|
89056007|NCT04538118||Patient with a shoulder problem|Patients with shoulder problems between 18-65 years of age and being volunteered
89056008|NCT04545099|Experimental|Sugammadex|Administration of Sugammadex
89056009|NCT04545099|Active Comparator|Neostigmine|Administration of Neostigmine
89056010|NCT02882269|Active Comparator|Postoperative chemotherapy|Patients receive 6 months of chemotherapy after surgery.
89056011|NCT02882269|Experimental|Neoadjuvant chemotherapy|Patients receive 3-4 cycles of chemotherapy before surgery. Preoperative and postoperative chemotherapy will be given for a total of 6 months.
89056012|NCT04545294|Experimental|Active theta (6Hz) in-phase tACS|θ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany), via 10 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), at 6 Hz frequency, 2 mA current intensity without DC offset, with 100 cycles ramp-up/ramp-down and a 0° relative phase, for 20 min, twice-daily on 5 consecutive weekdays.
89056013|NCT04545294|Sham Comparator|Sham tACS|During sham sessions, tACS will be applied in the synchronous condition for 30 s of 2 mA normal-like stimulation at the beginning of each dual n-back task. After that, only a tiny current pulse (110 μA over 15 ms) for impedance control took place every 550 ms during the remaining time.
89056014|NCT04578899|Active Comparator|Transvertebral magnetic stimulation (Experimental group)|Experimental intervention will receive non-invasive transvertebral magnetic stimulation of the sacral spine roots (level S2-S3).
89056015|NCT04578899|Placebo Comparator|Transvertebral magnetic stimulation (Control group)|"Control group will receive an equivalent number of stimulation sessions using the placebo option."
89056016|NCT01123642||Group 1|Operation Enduring Freedom and Operation Iraqi Freedom Veterans
89056017|NCT02882503|Experimental|EUS-RFA|monopolar radiofrequency probe (1.2 mm Habib endoscopic ultrasound - radiofrequency ablation (EUS-RFA) catheter) and 19 or 22 gauge fine needle aspiration (FNA) needle
88999207|NCT03004404|Experimental|SRD part-Dose group 1: BI 730357 PfOS 2 mg Fasted|"Participants were administered on Day 1 a single oral dose of 2 milligram (mg) of BI 730357 powder for reconstitution of an oral solution (PfoS) reconstituted in solvent for oral solution 2 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) together with about 240 milliliter (mL) of water in fasted state.~One authorized employee of the trial site was witness of the administration of the trial medication."
88999208|NCT03004404|Placebo Comparator|Placebo|This arm comprises all placebo treated participants in trial part SRD, regardless of the dose group in which they were treated. Participants of the first cohort of each dose group (DG) were not randomized. In the second cohort of each DG participants were assigned to active treatment or placebo in a 3:1 allocation ratio.
89056018|NCT04578704|Experimental|Vacuum formed retainer group|It will be constructed following manufacturer's instructions for the thickness.
89056019|NCT04578704|Experimental|Fixed bonded retainer group|fixed bonded wire will be bonded on individual tooth extended distal to extraction space that were previously closed by fixed appliances treatment.
89056020|NCT04578704|Experimental|Vacuum formed retainer and fixed bonded retainer|Double regime retainer that will be consisted of bonded retainer and vacuum formed retainer for upper and lower arch.
89056021|NCT01122862|Active Comparator|0.12% Chlorhexidine Mouthrinse|Commercially available 0.12% Chlorhexidine mouthrinse
89056022|NCT01122862|Active Comparator|Cosmetic mouthrinse|Commercially available cosmetic mouthrinse
89056023|NCT01122862|Placebo Comparator|Sterile Water|Sterile Water
89056024|NCT04538274|Experimental|Patient researcher intervention|Intervention conducted by trained patient researchers to restart CPAP in addition to usual care
89056025|NCT04538274|No Intervention|Usual care|Usual care
89056026|NCT04537767|Experimental|ES group|Patients randomly assigned to the ES group were treated with esmolol to control the heart rate to the target range.
89056027|NCT04537767|Placebo Comparator|control group|Patients randomly assigned to the control group were treated with placebo.
89056028|NCT01122394|Experimental|Tailored Intervention (TI)|Tailored intervention based on the transtheoretical model
89056029|NCT01122394|Placebo Comparator|Attention Placebo (AP)|Attention Placebo
89056030|NCT01121926|Experimental|Trazodone HCl OAD|OAD: Once A Day
89688075|NCT03408743|Experimental|Descriptive and injunctive norms, and benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
89056031|NCT01121926|Active Comparator|Trazodone HCl (Apotex Corp.)|
89056032|NCT04578626|Experimental|dry needling group|Dry needling treatment on right or left side of the face (depending on randomization)
89056033|NCT04578626|No Intervention|control group|No treatment on left or right side of the face (depending on randomization)
89056034|NCT04544826|Experimental|Cohort 1: JNJ-77474462 (Low Dose) or Placebo|Participants will receive single low dose of JNJ-77474462 or matching placebo as subcutaneous (SC) injection.
89056035|NCT04544826|Experimental|Cohort 2: JNJ-77474462 (Medium Dose) or Placebo|Participants will receive single medium dose of JNJ-77474462 or matching placebo as SC injection.
89056036|NCT04544826|Experimental|Cohort 3: JNJ-77474462 (High Dose) or Placebo|Participants will receive single high dose of JNJ-77474462 or matching placebo as SC injection.
89056037|NCT02216019||study cohort|Patient undergoing planned heart surgery with cardiopulmonary bypass
89056038|NCT04578587|Active Comparator|Rater 1|Rater 1
89056039|NCT04578587|Active Comparator|Rater 2|Rater 2
89056040|NCT00577421|Experimental|1|5 mg/day risedronate
89056041|NCT04537611|Experimental|dHb contrast compared to gadolinium contrast imaging|Subjects will be referred for a clinical gadolinium contrast perfusion exam. Gas manipulation will be supplied by a programmable computer-controlled gas delivery system while subjects are in the MRI scanner. In addition to their prescribed clinical scans, two additional scans will be obtained: 1) a structural sequence (, followed by 2) a BOLD-EPI sequence while inducing changes of PO2. PO2 will be held at a baseline of 45-50 mmHg for 60s. For 10 s, the lung PO2 will be transiently raised to peak PO2 of 90-120 mmHg (normoxia) within 2 s transition, and then returned to baseline. Alternatively, the baseline may be at normoxia and the gas challenges will target PO2 of 45-50 mmHg. A total of 4 such ventilatory challenges will be applied over 6 min while maintaining normocapnia.
89056042|NCT00577499||Only group|adult cystic fibrosis patients who are not at goal body mass index and have started lubiprostone therapy within one month of study enrollment
89688076|NCT03408743|Experimental|Descriptive & injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89688077|NCT03408743|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
89688078|NCT03408743|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
89688079|NCT03408743|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
89688080|NCT03408743|Experimental|Expectancies, benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89688081|NCT03408743|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
89688082|NCT03408743|Experimental|Expectancies, injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
89688083|NCT03408743|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
89688084|NCT03408743|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89688085|NCT03408743|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
89688086|NCT03408743|Experimental|Expectancies, descriptive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
89688087|NCT03408743|Experimental|Expectancies, descriptive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
89688088|NCT03408743|Experimental|Expectancies, descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89688089|NCT03408743|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies , descriptive norms, and injunctive norms modules for a period up to 3 weeks.
89688090|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, efficacy|Participants will have access to the knowledge module plus the expectancies , descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
89688091|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
89056043|NCT04537494|Active Comparator|Prevention|Oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks
89056044|NCT04537494|Other|Treatment-as-needed|Supplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age
89056045|NCT00577538||1|
89056046|NCT00577538||2|
89056047|NCT04545255|Active Comparator|active|A shockwave device with a probe that conveys shockwave energy
89056048|NCT04545255|Sham Comparator|sham|A shockwave device with specially designed probe which has the shockwave energy blocked
89056049|NCT00577616|Other|1|Endovascular repair
89056050|NCT00577616|Other|2|conventional surgery repair
89056051|NCT04537572|Other|Sample Collection Method|All subjects will provide samples via traditional phlebotomy, finger-stick, and saliva collection.
89056052|NCT00577694|Other|single arm study|1
89056053|NCT04537533|Experimental|first group|1st group (A) will include 30 patients: each one will receive 15mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 10mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
89056054|NCT04537533|Active Comparator|second group|2nd group (B) will include 30 patients: : each one will receive 5mg/kg of I.V tranexemic acid as a bolus over 10 minutes (loading dose) then 1mg/kg/hour of I.V tranexemic acid as infusion all through the operation.
89056055|NCT04537533|Placebo Comparator|Third group|3rd group (C){controlled group} will include 30 patients: each one will receive saline (placebo) injection and infusion all through the operation.
89056056|NCT00577733||obese|obese
89056057|NCT00577733||healthy volunteers|healthy volunteers
89056058|NCT02214927|Experimental|BI 11634 single rising dose|tablet
89056059|NCT02214927|Experimental|BI 11634 cross-over|sequence: 1. tablet 2. drinking solution
89056060|NCT00577811||1|Patients from 6 different Special Need Plans
89056061|NCT00577811||2|
89056062|NCT04544553|Other|SMS reminder|This arm receive SMS reminder for the follow-up of DR Screening
89056063|NCT04544553|Other|No SMS reminder|This arm did not receive SMS reminder for the follow-up of DR Screening
89056064|NCT02216058|Experimental|NOYA|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
89056065|NCT00577850|Experimental|1|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks
89056066|NCT00577850|Active Comparator|2|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 70 mg of alendronate once a week for 52 weeks
89056067|NCT04544631|Experimental|Active VR|"Participants in the active VR group played a virtual reality game entitled Virtual River Cruise. In this game, an otter floats down a river on a boat and players activate snow-blowing statues along the shore by focusing on them. The statues will emit snow if they are correctly aimed at by the child, and a thermometer placed in the front of the boat shows decreased temperatures as more snowflakes are blown. As feedback to reinforce continued engagement, a scoreboard placed beside the thermometer will show children the number of statues he/she has activated. Additionally, as the temperature drops, snow and ice will start piling up on the boat and its surroundings, providing an enhanced cooling experience for pediatric burn patients. Children interact with the immersive virtual reality environment by tilting their head, minimizing potential interference with the dressing change procedure."
89056068|NCT04544631|Experimental|Passive VR|Participants in the passive VR group were immersed in the same virtual reality environment as the active VR group, without any interactions with the VR game.
89056069|NCT04544631|No Intervention|Standard Care Control|Participants in the standard group received routinely used distraction tools provided in the clinical setting, such as iPads, music, books, and/or talking.
89056070|NCT00577928||1|
89056071|NCT00577928||2|
89056072|NCT04537338||Active / Recovered Cases|"Active Cases:~Diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.~Most of the cases of Covid-19 are treated at CCSS hospitals or clnics.~Recovered cases:~Are subjects previously diagnosed with Covid-19 via a positive PCR test who were considered recovered because they had two consecutive negative PCR tests."
89056073|NCT04537338||Community control group|The community control group will be frequency-matched on age, sex and area of residence. Two controls per case will be selected as follows
89217477|NCT00443560||Instrumental Vaginal Delivery (IVD)|Instrumental vaginal delivery (IVD) is attempted to prevent fetal hypoxia if the second stage of labor is prolonged. It includes forceps and vacuum extractions.
89056074|NCT04537338||Household survey|"Are a household contact of a person diagnosed with Covid-19 disease by a positive PCR test in Costa Rica since March 2020.~A household will be defined as a group of persons living together who share a kitchen. To be considered eligible for inclusion a contact must have spent at least one night per week in the living area since onset in the index case."
89056075|NCT00578006|Experimental|A|If you are in group A, the investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
89056076|NCT00578006|Experimental|B|If you are in group B, the investigators will provide you with access to the STAR website using a computer in the waiting area, into which you can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy. The investigators may also provide you with a website address so that you can access STAR from home (or any other location) to report your symptoms at any time.
89056077|NCT04537455|Experimental|Abnormal cardiac conduction|patients with abnormal cardiac conduction will undergo an ultra-high frequency electrocardiogram
89056078|NCT00578045|Experimental|1|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
89056079|NCT00578084||surgery|those subjects who went to surgery to treat their lung cancer
89056080|NCT00578084||no surgery|those subjects who did not go to surgery for their lung cancer
89056081|NCT00578084||NSCLC|subjects with NSCLC
89056082|NCT00578084||Small cell lung cancer|those with small cell lung cancer
89056083|NCT04537221||No transfusions|Patients receiving no perioperative blood transfusions (PBT)
89056084|NCT04537221||Transfusions|Patients receiving perioperative blood transfusions (PBT)
89056085|NCT00578162||1|Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory.
89056086|NCT00578201|Experimental|1|radiochemotherapy,combination Cetuximab-FOLFOX
89056087|NCT04537143||Control|Non-AMD eyes
89056088|NCT04537143||AMD|AMD eyes
89056089|NCT00578357|Experimental|1|immediate intervention
89056090|NCT00578357|No Intervention|2|note: participants in this arm will receive the intervention after the 6-month follow-up (serving as control during the trial)
89056091|NCT04544319|Experimental|Arm I|Firstly, administrating each component Gemigliptin 50mg and dapagliflozin 10mg and after resting period administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg
89056092|NCT04544319|Experimental|Arm II|Firstly, administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and after resting period administrating each component Gemigliptin 50mg and dapagliflozin 10mg
89056093|NCT00578396|Active Comparator|Dose Level 1|1 lb/day fresh red grapes
89056094|NCT00578396|Active Comparator|Dose Level 2|2/3 lb/day fresh red grapes
89056095|NCT00578396|Active Comparator|Dose Level 3|1/3 lb/day fresh red grapes
89056096|NCT04544085|No Intervention|control group|Patients in the control group will not receive any noise management intervention
89056097|NCT04544085|Experimental|experimental group|Patients in the experimental group will receive noise management. The intervention measures mainly include the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.We will strengthen the education of medical staff to ensure the effective implementation of the noise management.
89056098|NCT04557410|Experimental|Receiving Supplement|Participants receive supplement PolyMVA. Dose is 2 teaspoons twice a day.
89217478|NCT00443560||Spontaneous Vaginal Delivery (SVD)|The control group consisted of parturients who had a spontaneous vaginal delivery (SVD)in the same 24 hour period who were case-matched for gravidity and parity.
89056099|NCT04537182|Experimental|LVRS treatment group|A bilateral lung volume reduction surgery (LVRS) by video-assisted thoracoscopic surgery (VATS) is performed under general anesthesia with double lumen endobronchial intubation. Unilateral treatment is accepted in cases with severe adhesions or intraoperative instability making a bilateral procedure unsafe.
89056100|NCT04537182|Active Comparator|BLVR study group|Unilateral bronchoscopic lung volume reduction with endobronchial valves (EBV) is performed using a flexible bronchoscope under general anesthesia and under full attendance of an anesthesiologist. Valves are placed unilaterally in segmental or subsegmental bronchi in the target lobe with the goal of complete atelectasis.
89056101|NCT04578470|No Intervention|Group C|Patients with replete VitaminD levels (≥30ng/ml) will be serving as a control in group C. Group C will not receive any Vitamin D intervention for the entire 12- month study period but will receive dietary interventions.
89056102|NCT04578470|Experimental|Group A|Group A will be prescribed Vitamin D supplementation in the form of daily 2000 IU cholecalciferol (two tablets)for 13 weeks, and daily1000 IU cholecalciferol(1tablet) for another 13 weeks and then treatment will be discontinued but dietary interventions will continue across the 12-month study period.
89056103|NCT04578470|Placebo Comparator|Group B|Group B will be prescribed placebo of Vitamin D with two tablets daily for 13 weeks then 1 tablet daily for13 weeks then no treatment for 26 weeks but dietary interventions will continue across the 12-month study period.
89056104|NCT04537065||preterm infants without ROP|
89056105|NCT04537065||preterm infants with regressed ROP|
89056106|NCT04537065||preterm infants with threshold ROP|
89056107|NCT04537065||full-term infants|
89056108|NCT04578821|Experimental|Deney group|"Education Program:The education program consists of theoretical didactic education, case discussion, film and video screening in class, Web-based laboratory work, SSI practice, poster preparation and awareness activities for a total of 12 weeks and 2 hours per week (24 hours per week).~Theoretical didactic education, film screening, video screening, Web-based laboratory work, Social Security Institution study, poster preparation, poster presentation at University Campus."
89056109|NCT04578821|No Intervention|Kontrol group|The control group participated in the courses and practices included in the routine curriculum.
89056110|NCT04543929|Active Comparator|exercise|exercise prescription + standard of care
89056111|NCT04543929|No Intervention|no exercise|no exercise prescription + standard of care
89056112|NCT04537260|No Intervention|Control Arm (Standard of Care)|The control group took the knowledge-based survey about induction of labor prior to meeting their provider (midwife or obstetrician) on the day of scheduled induction. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction with the labor and delivery process.
89217479|NCT04098341|Other|Screening|All eligible migrants will be offered opt-out IGRA blood test to screen for for latent Tuberculosis infection
89217480|NCT00922454|Experimental|Talent Stent-Graft|
89217481|NCT00922454|Experimental|Cook Zenith Stent-Graft|
89217482|NCT00721643|Experimental|1|Healthy control, 5g dry power of angel's plant (Angelica keiskei)
89217483|NCT00721643|Experimental|2|Metabolic syndrome, 5g dry powder of angel's plant (Angelica keiskei)
89217484|NCT00721721|Experimental|1|Participants will follow a low sodium diet for Days 1 through 7, a high sodium diet for Days 7 through 14, and a high sodium diet plus potassium supplement regimen for Days 14 through 21.
89217485|NCT01022632|Active Comparator|Fluoxetine|Fluoxetine : 20 mg Once a day in morning after taking food for 6 weeks
89217486|NCT01022632|Experimental|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
89217487|NCT01022632|Experimental|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
89217488|NCT00899288|Experimental|tamoxifen and no bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
89217489|NCT00899288|Experimental|Letrozole and no bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
89217490|NCT00899288|Experimental|Tamoxifen and bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
89217491|NCT00899288|Experimental|Letrozole and bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.
89217492|NCT01022710||Group 1|Veterans with sensorineural hearing loss
89217493|NCT03716999||Palliative Care Patients|Palliative care Patients meeting criteria will receive Starlight Therapy
89217494|NCT01026298|No Intervention|Control Group|8 weeks, no intervention for OSA
89217495|NCT01026298|Active Comparator|CPAP group|8-week randomized-controlled period of CPAP treatment
89217496|NCT03683381|Experimental|intervention|Patients in the intervention group will receive a 6-week app-based intervention to treat insomnia
89217497|NCT03683381|Experimental|patient education|Participants in the patient education group will receive weekly information on insomnia symptoms
89217498|NCT00712829|Experimental|1|123-I-MIP-1072 administration followed by 123-I-MIP-1095 administration two weeks later.
89217499|NCT00712829|Experimental|2|123-I-MIP-1095 administration followed by 123-I-MIP-1072 administration two weeks later.
89217500|NCT00712907|Active Comparator|1|vitamin C (Mayrhofer)
89217501|NCT00712907|Placebo Comparator|2|Placebo
89217502|NCT03734224|Active Comparator|Group1: Adhesix|This group gets the Adhesix mesh in a normal open hernia operation.
89217503|NCT03734224|Active Comparator|Group 2: Progrip|This group gets the Progrip mesh in a normal open hernia operation.
89217504|NCT05003141|Experimental|Single-arm, escalating dose levels|3 + 3 Phase 1 dose escalation design; sequential ascending dose levels.
89217505|NCT00899834||Tumor Samples|fresh-frozen and fixed tumor samples and correspondent normal tissue from patients affected with this tumor.(peripheral blood is applicable only to patients with focal brainstem gliomas and patients who undergo biopsy of a diffuse brainstem glioma at diagnosis)
89217506|NCT00716573|Experimental|1|Introduction of everolimus associated with CNI (ciclosporin or tacrolimus) reduction (50%) to the current immunosuppression schedule
89217507|NCT00716573|No Intervention|2|Maintain of their current immunosuppressive therapy
89056113|NCT04537260|Experimental|Intervention Arm (Educational video)|The intervention group had the opportunity to watch the 3-minute educational video. The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8. After watching the video, the participant was asked to take the knowledge-based survey. Twenty-four to forty-eight hours after delivery, at a time convenient to the participant during the postpartum stay at GW, a research team member asked the participant to fill out a second survey, focused on satisfaction.
89056114|NCT04557332|Experimental|Mobile app|In this arm, participants received a mobile app to support ART medication adherence.
89056115|NCT04557332|No Intervention|Control|In this arm, participants received care as usual.
89056116|NCT04544163|Experimental|Magnesium sulphate- Fentanyl|30 mg per kg MgSo4 infusion in 100 ml saline over 10 minutes
89056117|NCT04544163|Experimental|Fentanyl 4 mic|4 mic per kg fentanyl i.v
89056118|NCT04544163|Active Comparator|Fentanyl|2 mic per kg fentanyl i.v
89056119|NCT04544163|Experimental|Lidocaine- Fentanyl|Lidocaine 1.5 mg/kg
89056120|NCT04579016|Active Comparator|Standard care|Standard care
89056121|NCT04579016|Experimental|PAIGE2 intervention|One hour education session during pregnancy. Postnatally provision of activity tracker, 3/6 month referral to a commercial weight management organization, text and phone support.
89056122|NCT04543851|Experimental|CARA positioning|Planning and Treatment using the CARA Device
89056123|NCT00578591|Experimental|Patient|Four Rituximab doses administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT)
89056124|NCT04536987|Experimental|low-dosage robot therapy|12 sessions of robotic therapy over 4-5 weeks
89056125|NCT04536987|Experimental|hi-dosage robot therapy|24 sessions of robotic therapy over 8-10 weeks
89056126|NCT04536948|Experimental|Group 1|Cooling gel application
89056127|NCT04536948|Active Comparator|Group 2|Cold pack was applied
89056128|NCT04543890|Active Comparator|Hyperfrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
89056129|NCT04543890|Experimental|Hypofrationated Arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/15 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
89056130|NCT04536831|Experimental|Vitamin D group|Consisted of 48 patients selected on admission via lottery method those will be given Vitamin D mega dose
89056131|NCT04536831|Placebo Comparator|Normal Saline group|Consisted of 48 patients selected on admission via lottery method those will be given Normal saline
89056132|NCT02214966|Experimental|Telmisartan/Ramipril, fed|
89056133|NCT02214966|Active Comparator|Telmisartan/Ramipril, fasted|
89056134|NCT00578630||1|All Pediatric Oncology and Bone Marrow Transplantation Service patients with a histologically proven tumor for whom there is an intent to treat with chemotherapy
89056135|NCT04536558|Experimental|olanzapine plus fosaprepitant-based triple regimen|Olanzapine（5mg p.o. d1-d5）plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
89056136|NCT04536558|Placebo Comparator|Placebo plus fosaprepitant-based triple regimen|Placebo plus fosaprepitant（150mg i.v. d1-d3） plus ondansetron（8mg i.v. d1-d3）and dexamethasone（6mg p.o. d1-d5） before undergoing chemotherapy.
89056137|NCT00578708|Experimental|1|
89056138|NCT04543656|Experimental|AI-Based Lifestyle Recommendations Group|Participants in this group receive AI-based, personalized lifestyle recommendations based on analysis of their activity tracker and blood pressure data.
89056139|NCT04543656|Active Comparator|Control Group|Participants in this group do not receive the lifestyle recommendations, but are provided with an identical activity tracker and blood pressure monitor.
89056140|NCT04557605|Active Comparator|No face mask|Progressive step-exercise cycling test to exhaustion wearing no face mask
89217508|NCT02539706|Experimental|Follıcular group|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
89217509|NCT02539706|Active Comparator|Luteal group|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
89217510|NCT00451204|Active Comparator|Estriol plus Copaxone injections QD|Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
89217511|NCT00451204|Placebo Comparator|Placebo plus Copaxone injections QD|Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.
89217512|NCT00901472||Stable type 2 Diabetes (ST2D)|Adults with Type 2 diabetes who receive medical care at the University of Chicago
89217513|NCT04067999||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
89217514|NCT00721877|Experimental|Arm I|Participants receive oral resveratrol once daily for 4 weeks.
89217515|NCT00605540||Study COPD population|Patients with diagnosis of mild to very severe chronic obstructive pulmonary disease
89217516|NCT03742570||CBBDQ|A Questionnaire
89217517|NCT01026532||Segmental antigen challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
89217518|NCT01022788|Experimental|Home-based counselling visits by volunteers|Home-based counselling in pregnancy and the first few days of life to encourage women and families to adopt key newborn care behaviours
89217519|NCT01022788|No Intervention|Standard care through existing health system|
89217520|NCT00900458|Active Comparator|1|formerly preeclamptic women with low plasma volume
89217521|NCT00900458|Active Comparator|2|formerly preeclamptic women with normal plasma volume
89217522|NCT00900458|Other|3|Healthy controls
89217523|NCT02571803|Experimental|Dietary And Lifestyle Counseling|Patients receiving strict dietary counseling (implementation of the DASH diet) and lifestyle changes support atop of optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
89217524|NCT02571803|Active Comparator|Optimal Medical Treatment|Patients receiving optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
89217525|NCT03537586|Experimental|Non-Obstructive CAD|After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells.
89217526|NCT00894218|Active Comparator|Conventional arthroplasty|Total hip or knee conventional arthroplasty
89217527|NCT00894218|Experimental|Mini-invasive arthroplasty|Total hip or knee mini-invasive arthroplasty
89217528|NCT00894218|Experimental|Mini-invasive and computer-assisted arthroplasty|Mini-invasive and computer-assisted total hip or knee arthroplasty
89217529|NCT00722033|Other|A|< 30 weeks of gestation
89217530|NCT00894296||1|schizophrenia patients
89217531|NCT00894296||2|healthy control
89217532|NCT01027936||Normal Healthy Volunteers|
89217533|NCT00894374|Experimental|Artesunate (Pfizer)|
89217534|NCT00894374|Active Comparator|Artesunate (Arsuamoon® Tablets Guilin-China)|
89056141|NCT04557605|Experimental|Disposable face mask|Progressive step-exercise cycling test to exhaustion wearing a 3-ply disposable face mask
89056142|NCT04557605|Experimental|Cloth face mask|Progressive step-exercise cycling test to exhaustion wearing a cloth face mask
89056143|NCT04536753||Suspected large for gestational age (LGA)|Women with pregnancies suspected to be complicated by fetuses weighing more than the 90th centile on customised growth chart and induced for this reason prior to 287 days as the main indication without diabetes.
89056144|NCT04536753||Women with diabetes (DM)|Women with diabetes in pregnancy induced at between 259 and 266 days if on treatment and 273 days if gestational diabetes managed with diet alone.
89056145|NCT04536753||Control|All other women induced at or after 280 days of gestation
89056146|NCT04557137||NET|"Study A:~A cross-sectional study that investigates 250 patients (Cohort A) with neuroendocrine neoplasia, encompassing both patients with neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC).~Study B:"
89056147|NCT04557137||Newly diagnosed NET|A prospective study that investigates 30 newly diagnosed NET patients over three months (Cohort B) who are offered palliative treatment with somatostatin analogues.
89056148|NCT04536675|Experimental|VI/UME|Anoro (Vilanterol 25mcg/Umeclinidium 62.5mcg) in Ellipta device Inhaled through mouth once daily
89056149|NCT04536675|Placebo Comparator|Control|Placebo (including lactose monohydrate) in Ellipta device Inhaled through mouth once daily
89056150|NCT04556942|Experimental|Group 1 (Immediate Group)|"Group 1:~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:~Flow mediated dilation measurement~Blood pressure, pulse, blood oxygenation saturation measurement~Fit bit tracker counting steps and distance during 7 days~SGRQ (St Georg Respiratory Questionnaire)~Withdrawal of a blood sample for preservation for later examinations~This group will receive endobronchial valve placement (EVP) within 1-2 weeks after T0.~At T1 which will be 4-6 weeks after EVP the measurements done at T0 will be repeated."
89056151|NCT04556942|Other|Group 2 (Delayed Group)|"Group 2:~Will receive at time T0 the baseline study specific measurements of the primary and secondary endpoints:~Flow mediated dilation measurement~Blood pressure, pulse, blood oxygenation saturation~Fit bit tracker counting steps and distance during 7 days~SGRQ (St Georg Respiratory Questionnaire)~Withdrawal of a blood sample for preservation for later examinations~This group will receive endobronchial valve placement (EVP) 6-8 weeks after T0. A few days before that the investigators repeat the measurement taken at T0."
89056152|NCT04536441|Experimental|Treatment|Ultra Brief Online Mindfulness-based Intervention
89056153|NCT04536441|Placebo Comparator|Control|This arm requires participants to answer questions about themselves.
89056154|NCT04543578||Patients unfit for Surgery with mild-moderate acute cholecyst|Conservative treatment (antibiotics, etc). EUS-guided gallbladder drainage will be considered in recurrent acute cholecystitis and in patients with no improvement in 48-72h after admission.
89056155|NCT04543578||Patients unfit for Surgery with severe acute cholecystitis|Percutaneous cholecystostomy or Endoscopic Ultrasound (EUS)-guided cholecystostomy (the latter is not 24/7 available). Palliative care may also be considered in patients with very serious conditions and low life expectancy.
89056156|NCT04543578||Patients suitable for Surgery with high and intermediate risk|"Admission in Gastroenterology Department. antibiotic treatment. Close follow-up of posible AC complications. Once choledocholithiasis is solved or ruled our, the patient will be considered for same-admission cholecystectomy or programmed cholecystectomy.~High risk: Endoscopic Retrograde Cholangiopancreatography (ERCP) will be performed.~Intermediate risk: EUS or Magnetic Resonance Cholangiopancreatography prior to consider ERCP."
89217535|NCT04920149|Experimental|Mesalamine|Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
89217536|NCT04920149|Placebo Comparator|Placebo|Placebo for Mesalamine (Mesalazine, Pentasa sachet, 5-ASA) 2 g once daily for 2 years.
89217537|NCT01026610|Experimental|LB80380 90 mg|LB80380 90 mg (90 mg + placebo), once daily oral dose
89217538|NCT01026610|Experimental|LB80380 150 mg|LB80380 150 mg (60 mg + 90 mg), once daily oral dose
89217539|NCT01026610|Active Comparator|entecavir 0.5 mg|entecavir 0.5 mg, once daily oral dose
89217540|NCT00713063|Experimental|1|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
89217541|NCT00713063|Active Comparator|2|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
89217542|NCT03530254|Other|PGT-A without ERA|Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
89217543|NCT03530254|Other|PGT-A and test ERA|"Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive)."
89217544|NCT00901550|Active Comparator|Methotrexate|A drug for RA patient
89217545|NCT00901550|Active Comparator|Infliximab|for RA treatment
89056157|NCT04543578||Patients suitable for Surgery with low risk|"Admission in Surgery Department. According to the AC severity:~Mild-moderate AC: check de ASA/Charlson comorbidity index.~ASA I-II/Charlson <6: laparoscopic cholecystectomy~ASA > =III/Charlson >=6: close follow-up 24-48h. Consider laparoscopic cholecystostomy (if no improvement is achieved)~Severe AC: consider Intensive Care Unit admission. Percutaneous cholecystectomy."
89056158|NCT04557293|Experimental|CPAP Treatment|Patients with OSA will undergo cognitive assessment before starting CPAP treatment and after six months of CPAP use.
89056159|NCT04557293|No Intervention|Control Group|We will enrol a control group of subjects without sleep disorders and comparable to OSA patients for age and schooling. Control group will undergo cognitive assessment.
89056160|NCT04536597|Experimental|Quince seed jelly group|
89056161|NCT04536597|Experimental|Breast milk group|
89056162|NCT04536597|Other|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
89056163|NCT04556903|Experimental|Bilateral Arm Training|Bilateral Arm Training
89056164|NCT04556903|Active Comparator|modified constrained induce movement therapy|modified constrained induce movement therapy
89056165|NCT04536636|Active Comparator|Control|The patients on this arm received usual medical care
89056166|NCT04536636|Active Comparator|DHA supplementation|The patients on this arm received DHA supplementation (650 mg DHA/3 times/wk/post-HD session)
89056167|NCT04556747|Other|VR - Distraction|
89056168|NCT04556747|Other|VR - Biofeedback|
89056169|NCT02278653||Study group|The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).
89056170|NCT04536129|Experimental|Group A: glaucoma|OSD patients with glaucoma
89056171|NCT04536129|Active Comparator|Group B: no glaucoma|OSD patients without glaucoma
89056172|NCT00578981|Experimental|Arm 1|
89056173|NCT00578981|No Intervention|Arm 2|
89056174|NCT04556786|Experimental|Transitions of care|The study participants in this aim received usual care plus medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist.
89056175|NCT04556786|No Intervention|Usual care|The study participants in this arm received usual care.
89056176|NCT04556825|Experimental|Study group|Arthroscopic treatment with PRP injection
89056177|NCT04556825|Placebo Comparator|Control group|Arthroscopic treatment with normal saline injection
89056178|NCT04536246|Active Comparator|BQT Group|Procedure on this arm = bone quadriceps tendon reconstruction
89217546|NCT02573051|Active Comparator|Misoprostol plus isosorbide mononitrate|this group will receive 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries) plus 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company) will be inserted into the posterior vaginal fornix
89217547|NCT02573051|Active Comparator|Misoprostol plus placebo|This group will receive misoprostol 800 µg plus placebo in the same site.
89056179|NCT04536246|Other|SBHT Group|Procedure on this arm = single-bundle hamstring tendon reconstruction
89217548|NCT02539940||Patients with critical limb ischemia|Patients undergoing endovascular intervention of below-the-knee arteries with ELUTAX SV DEB (drug-eluting balloon).
89056180|NCT04556864||Description Group|"For each patient included in the study, the secondary variables will be noted in the patient's data collection logbook.~This is followed by radial artery cannulation (if absent), and connection to the HemoSphere/EV1000 platform~After the daily visit, the PI/collaborating investigators (CI) will measure the clinical, treatment, and mechanical ventilation parameters of the patient during the last 24 hours.~Daily arterial analysis will be requested~This information collection process will be followed for 5 days. At the end of the information collection period, the IP will perform two downloads, the engineering download, and the standard download in which the values are monitored every 20 seconds.~These will be noted in the secondary variables of the data collection logbook, along with the patients' ICU discharge date.~In-hospital mortality will be monitored during admission to a conventional hospital ward.~Records will be closed upon discharge of the patient."
89056181|NCT04556708|Active Comparator|saline control group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
89056182|NCT04556708|Active Comparator|ozone group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozoned water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
89056183|NCT04556708|Active Comparator|chlorhexidine group|"Periodontal clinical parameters and gingival crevicular fluid (GCF) samples were evaluated at baseline and 8 weeks after periodontal treatment in patients with periodontal disease.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination."
89056184|NCT04535973||study group|female postmenopausal women with burning mouth syndrome
89056185|NCT04535973||control group|female postmenopausal women without burning mouth syndrome
89056186|NCT04536090|Experimental|Isoquercetin (IQC-950AN)|1000 mg Isoquercetin b.i.d. on day 1, then 500 mg Isoquercetin b.i.d. for 27 more days, plus standard of care (as defined below)
89056187|NCT04536090|No Intervention|Standard of care|This arm will receive standard of care based on national guidelines. This may change as new information regarding best practice emerges.
89056188|NCT04536051|Experimental|Group 1a: single dose ChAdOx & paracetamol|Participants will receive a single standard dose of ChAdOx1 nCOV19 vaccine plus paracetamol
89056189|NCT04536051|Active Comparator|Group 1b: single dose MenACWY & paracetamol|Participants will receive a single dose of MenACWY plus paracetamol
89056190|NCT04536051|Experimental|Group 1c: two dose ChAdOx & paracetamol|Participants will receive two standard doses of ChAdOx1 nCoV-19 vaccine, 4-12 weeks apart, plus paracetamol
89056191|NCT04536051|Active Comparator|Group 1d: two dose MenACWy/saline & paracetamol|Participants will receive MenACWY prime, and Saline Placebo boost (0.5mL) plus paracetamol
89056192|NCT04543422|Experimental|Green tea extracts|Patients in this arm received green tea extract capsules
89056193|NCT04543422|Placebo Comparator|Placebo|Patients in this arm received placebo treatment
89056194|NCT00579215|Experimental|1|Enhance Care (EC) will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits.
89217549|NCT01028092|Active Comparator|Control|anti R-IL2 induction + Mycophenolate Mofetil + cyclosporine A + corticosteroids
89217550|NCT01028092|Experimental|CNI-free|Thymoglobulin + Mycophenolate Mofetil + everolimus + corticosteroids
89217551|NCT01028092|Experimental|Switch|anti R-IL2 + Mycophenolate Mofetil + (Cyclosporine then Everolimus) + corticosteroids
89217552|NCT00716729||Pateints with longstanding hip and/groin pain|
89056195|NCT00579215|Other|2|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
89056196|NCT04556669|Experimental|CD22（aPD-L1）CAR-T cells|
89056197|NCT02215005|Experimental|Telmisartan + Ramipril|5 days qd
89056198|NCT02215005|Active Comparator|Telmisartan|5 days qd
89056199|NCT02215005|Active Comparator|Ramipril|5 days qd
89056200|NCT04536714|Experimental|Intervention group|34 participants. Received Pythagorean Self-Awareness program
89056201|NCT04536714|No Intervention|Control group|35 participants. Received usual care
89056202|NCT02215044|Experimental|BI 2536 in combination with gemcitabine|
89056203|NCT02215083|Experimental|L-Glutamine|All patients will receive 20-30 grams of l-glutamine daily for 9 weeks (+/- 1 week)
89056204|NCT04556279||hyperaldosteronism surgical treatment|Hypertensive patients with primary hypersldosteronism, treated with surgery
89056205|NCT04556279||hyperaldosteronism medical treatment|Hypertensive patients with primary hypersldosteronism, treated with aldosterone blockade.
89056206|NCT04556279||hypertensive control|Hypertensive patients shown not to have primary hyperaldosteronism
89056207|NCT04535856|Experimental|Low-dose group|"Low-dose group (5 x 10^7cells):~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 2 vials for low-dose group"
89056208|NCT04535856|Experimental|High-dose group|"High-dose group (1 x 10^8 cells):~Drug substance and the amount: 2.5 × 107 cells/1 mL/vial, 4 vials for High-dose group"
89056209|NCT04535856|Placebo Comparator|Control group (placebo)|"Control group (placebo):~No Drug substance: 4 vials for Place group"
89056210|NCT00579332|Placebo Comparator|1|one a day placebo
89056211|NCT00579332|Experimental|2|Brassica intake
89056212|NCT00579332|Experimental|3|indole-3-carbinol supplement
89056213|NCT04535622|Experimental|Exercise group|A structured exercise instruction for facedown posture-related pain will be provided to the patients, and patients will go through three times of self-exercise sessions everyday according to the training provided.
89056214|NCT04535622|No Intervention|Control group|Patients are going to maintain face-down posture but no specific exercise instruction will be provided.
89056215|NCT02216253|Active Comparator|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|The combination of L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract will be administered in tablet twice a day 7 days before and after surgery
89056216|NCT02216253|Placebo Comparator|Placebo|Placebo tablet twice a day 7 days before and after surgery
89056217|NCT02216292||Preterm Single Donor Milk Group|The prospective study group = preterm single donor milk group (PSDM-Group) from June 2012 - April 2013
89056218|NCT02216292||Control Group|Retrospective control group receiving no donor milk = control group from March 2011 - May 2012
89056219|NCT00579410||A|Patients with Barrett's Esophagus
89056220|NCT00579410||B|Patients with reflux symptoms but no Barrett's Esophagus
89217553|NCT00713141||1|Early breast cancer
89056221|NCT00579410||C|Patients without reflux symptoms and a normal endoscopy
89056222|NCT02216331|Experimental|Group 1 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
89056223|NCT02216331|Experimental|Group 1 TMC207 and rifapentine|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifapentine administered as 4 tablets of 150 mg per tablet on each of Study Days 20-41.
89056224|NCT02216331|Experimental|Group 2 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
89056225|NCT02216331|Experimental|Group 2 TMC207 and rifampicin|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifampicin administered as 4 capsules of 150 mg per capsule on each of Study Days 20-41.
89056226|NCT02212418|Experimental|Abdominal hypopressive technique|
89056227|NCT04535817|Experimental|Treatment Group|Subjects will receive subcutaneous treatment of 300mg of omalizumab during the 24-week treatment period. One injection will be administered every 4 weeks.
89056228|NCT04577924||Road traffic injury victims|"All RTI patients presenting to ED within 24 hours of injury is included in the study..~Individual's not consenting to be part of the study or withdrawing consent later on would be excluded. We also would exclude cases where pre-hospital care provider could not be traced or where reliable data patient could not be collected even after repeated interview."
89056229|NCT04543149||Case|Patients with idiopathic granulomatous mastitis
89056230|NCT04543149||Control|Healthy volunteers
89056231|NCT04555889|Experimental|lung recruitment maneuver (LRM) group|The lung recruitment maneuver (LRM) will be done by increasing of PEEP 0,2 cm H2O every 3 minutes, until reach the opening pressure. After that PEEP decrease gradually until get the closing pressure. Than the investigators will back to the opening pressure for 3 minutes, and the final PEEP will be put backo 0,2 above closing pressure.
89056232|NCT04555889|No Intervention|without lung recruitment maneuver (LRM) group|Another group get standart protocol only.
89056233|NCT04543266||Patients with Progressive Disease|Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease
89056234|NCT04543266||Patients without Progressive Disease|Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease
89056235|NCT02215239|Experimental|Working type A & Workplace intervention|Participants: Workers tend to be seated during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
89056236|NCT02215239|No Intervention|Working type A & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
89056237|NCT02215239|Experimental|Working type B & Workplace intervention|Participants: Workers tend to be standing during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
89217554|NCT00900692|Experimental|Dynasplint Group|Along with the standard of care Botox and manual therapy, patients will use the Supination Dynasplint every day
89217555|NCT00900692|No Intervention|Standard of care|Patients in the standard of care group will have the standard Botox treatments and manual therapy with no additional interventions.
89217556|NCT00900770||PIB+ NC|PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
89217557|NCT00900770||PIB- NC|PIB negative, cognitively normal individuals without amyloid deposition
89217558|NCT00901706|Experimental|CGA plus APS Usual Care|Comprehensive geriatric assessment coupled with Adult Protective Services (APS) usual care for elders with self-neglect.
89217559|NCT00901706|Active Comparator|APS Usual Care|APS usual care consisting of social, medical, and legal interventions.
89217560|NCT00900848||8|8 patients
89217561|NCT00605306|Experimental|indacaterol maleate/mometasone furoate|Participants received 2 inhalations of indacaterol maleate / mometasone furoate 250/400 μg once daily in the evening (full dose 500/800 μg) delivered via the Twisthaler device for 14 days.
89217562|NCT00605306|Placebo Comparator|Placebo|Participants received 2 inhalations of placebo to indacaterol maleate / mometasone furoate once daily in the evening delivered via the Twisthaler device for 14 days.
89217563|NCT00905918|No Intervention|Arm I|Patients receive no intervention before undergoing planned surgery.
89217564|NCT00905918|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
89217565|NCT00905918|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
89217566|NCT00894608|Experimental|letrozole protocol|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
89217567|NCT00894608|Experimental|long GnRHa protocol|patients in long GnRHa protocol for ovarian stimulation with Gnrha and gonadotropins
89217568|NCT00901784|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
89217569|NCT00901784|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
89217570|NCT00716885||CHF|"Informed consented participants are recruited among all patients admitted to the OLVG hospital.~Inclusion criteria:~Chronic congestive heart failure patients of all ages selected for biventricular pacemaker implantation for resynchronization therapy~Dyspnoe NYHA class III and IV~Optimal and constant heart failure treatment according to the ESC guidelines~Exclusion criteria:~Renal failure (creatinine >1.70 mg/dl)~Signs of infection or inflammation"
89217571|NCT00716885||Control|The control group consists of ten age-matched volunteers with a normal left ventricular ejection fraction and without signs or symptoms of heart failure.
89217572|NCT00607022|Active Comparator|immediate load|immediate load of dental implant based on the bone quality determined by the insertion torque value
89217573|NCT00607022|Active Comparator|Loading at 6 weeks|delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
89217574|NCT00607022|Active Comparator|Loading at 12 weeks|traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
89217575|NCT00722345|Placebo Comparator|1|
89217576|NCT00722345|Experimental|2|
89217577|NCT00905996|Active Comparator|Endoscopic Cyanoacrylate injection|Endoscopic injection of cyanoacrylate in the gastric varix until obturation
89217578|NCT00905996|No Intervention|No Intervention|No treatment offered for gastric varix
89217579|NCT00905996|Other|Beta-blocker (propranolol)|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
89056238|NCT02215239|No Intervention|Working type B & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
89056239|NCT04578236|Experimental|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
89056240|NCT04578236|Sham Comparator|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
89056241|NCT04555772||Healthy Group|Patients who had been treated and recovered physically and gained cognitive functions completely.
89056242|NCT04555772||Sequel Group|Patients who could not gain their physical and cognitive functions.
89056243|NCT04555772||Exitus Group|Patients who did not respond to the treatments and lost their lives within 28 days of admission.
89056244|NCT02215278|Experimental|low phytic acid bean (lpa variety)|
89056245|NCT02215278|Experimental|high iron biofortified bean variety|
89056246|NCT02215278|Experimental|normal iron, normal phytic acid bean|
89056247|NCT04578119|No Intervention|Conventional Intubating Technique|'Conventional technique' means that endotracheal intubation is performed with the videolayngoscope blade lifting up the epiglottis.
89056248|NCT04578119|Experimental|Sliding Intubating Technique|'Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
89056249|NCT04542876|Experimental|Ayurveda|Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.
89056250|NCT00579449|Active Comparator|HF 36|For those randomly assigned to the 3-year HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, when possible, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. The 3-year HFD group will receive services to the child's third birthday.
89056251|NCT00579449|Active Comparator|HF 18|For those randomly assigned to the 18-month HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. Services for this group are terminated when the child is 18 months old, with clinically necessary referrals made for ongoing psychosocial and health needs.
89056252|NCT00579449|Active Comparator|YC|For those assigned to the Yearly Checkup group, a clinically-trained member of the HFD team will make yearly home visits to conduct the evaluation assessment. Information about community services and assistance with referrals are provided based on needs identified.
89056253|NCT00579449|No Intervention|MCC|Women placed in the community services as usual (Maternity Care Coordination only) group will receive no additional services or assessments as a part of this study.
89056254|NCT04542915||U.S. licensed dental hygienists|Dental hygienists licensed in the United States. No intervention will be administered.
89056255|NCT04542759|Active Comparator|Besifloxacin|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
89056256|NCT04542759|Placebo Comparator|Hydroxypropyl methylcellulose|1 DROP 4 TIMES A DAY FOR 3 DAYS PRIOR SURGERY
89056257|NCT04556006|No Intervention|Control|The patients in the control group received only the standard care provided by the clinicians. After the collection of post-test data, the content of the training was also explained to these patients and the study was completed by giving them the training guide.
89056258|NCT04556006|Active Comparator|İntervention|The training program was applied by the researcher who also work as an academic nurse. The contact information of the patients was obtained and the contact information of the researcher was also given to the patients. In order to consolidate the information given, the training guide was given to the patients in the intervention group. After the training, the patients in the intervention group were contacted again in the 2nd week by using face-to-face interview and in the 4th-8th and 12th weeks by phone calls. During these interviews, the questions of the patients, if any, were answered and the problems they faced regarding the disease management were tried to be solved. In the last interview, an appointment day was determined to meet face-to-face at home, workplaces or hospital according to the preferences of the patients.
89056259|NCT04542798|Experimental|NPPG (neuropatic pain group) PRF|Pulsed radiofrequency neuromodulation of dorsal root ganglia
89056260|NCT04542798|Active Comparator|NPPG (neuropatic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
89056261|NCT04542798|Experimental|NMPG (nociceptive/mechanic pain group) WCRF|Water cooled radiofrequency of the medial branch of the dorsal nerve
89056262|NCT04542798|Active Comparator|NMPG (nociceptive/mechanic pain group) CRF|Conventional radiofrequency ablation of the medial branch of the dorsal nerve
89056263|NCT04555850|Experimental|Recombinant Human Thymosin β4 0.5ug/kg|10 subjects in this group will receive NL005 for 0.5ug/kg respective.Continuous administration for 10 days.
89056264|NCT04555850|Experimental|Recombinant Human Thymosin β4 2.0ug/kg|10 subjects in this group will receive NL005 for 2.0ug/kg respective.Continuous administration for 10 days.
89056265|NCT04555850|Experimental|Recombinant Human Thymosin β4 5.0ug/kg|10 subjects in this group will receive NL005 for 5.0ug/kg respective.Continuous administration for 10 days.
89056266|NCT04555850|Other|Placebo|Two subjects in each dose group (0.5/2/5ug/kg) were given placebo for 10 days.A total of six participants were given a placebo.
89056267|NCT04542447|Active Comparator|Nuvastatic + standard treatment|5 patients, dosage: 3000 mg of Nuvastatic™ (C5OSEW5050ESA) each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
89056268|NCT04542447|Placebo Comparator|Placebo|5 patients, dosage: 3000 mg of placebo each day plus standard of care thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14 days in Covid-19 patients.
89056269|NCT02212496||Cancer-associated stroke|Cryptogenic embolic stroke with active cancer
89056270|NCT02212496||Cryptogenic embolic stroke|Cryptogenic embolic stroke without active cancer
89056271|NCT04542213|Experimental|DPP4 inhibitor + insulin|Patients assigned to this group of treatment will receive Linagliptin 5mg orally once daily plus a basal-bolo insulin scheme
89056272|NCT04542213|Active Comparator|Insulin scheme alone|Patients assigned to this group will receive only a basal-bolus insulin scheme
89056273|NCT02278406|Experimental|Parkinson's patients with DBS|Patients with Parkinson's Disease who are at least 3-months post subthalamic deep brain stimulator surgery
89056274|NCT04542252|Experimental|Group 1|SyB V-1901 alone, Simultaneous administration of SyB V-1901 and cyclosporine, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
89056275|NCT04542252|Experimental|Group 2|Simultaneous administration of SyB V-1901 and cyclosporine, SyB V-1901 alone, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion
89056276|NCT04532775|Other|group C|"This study was conducted on 100 patients. Patients were divided according to the injected drugs into two equal groups (50 patients each):~1- Group (C): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of normal saline (0.9 %) with a total volume of 4 ml."
89056277|NCT04532775|Other|group M|2- Group (M): where all patients received through the transforaminal epidural approach 2 ml of bupivacaine (0.5%), 1ml of methylprednisolone (40 mg) and 1 ml of preservative free magnesium (200 mg) with a total volume of 4 ml. Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol). Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
89056278|NCT04532580||AI- Aided performances|
89056279|NCT04532580||AI- Unaided performances|
89056280|NCT04578158|Active Comparator|Standard of care|This arm will receive the standard COVID-19 care as per the hospital physician guidelines.
89056281|NCT04578158|Experimental|Quercetin Phytosome|This arm will receive standard COVID-19 care + Quercetin Phytosome
89056282|NCT04532736|Experimental|Methotrexate|10 mg Emthexate, PO, once a week during 8 weeks
89056283|NCT04532736|Active Comparator|Methylprednisolone|8 mg/day Prednol, PO, for 8 weeks
89056284|NCT04532736|Active Comparator|Control|200 mcg/day, intranasal mometasone furoate, for 8 weeks
89056285|NCT00579683||1|This is a protocol to study tissue specimens to identify changes in tumor DNA in NSCLC patients who have previously responded to therapy and who have subsequently experienced disease progression.
89056286|NCT04555733|Experimental|Cohort 1: Lemborexant 5 mg|Participants will receive a single dose of lemborexant 5 milligram (mg) tablet, orally on Day 1.
89056287|NCT04555733|Experimental|Cohort 2: Lemborexant 10 mg|Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1 followed by a washout period of approximately 14 days further followed by multiple doses of lemborexant 10 mg tablets, orally, once daily from Day 15 through Day 28.
89056288|NCT04555733|Experimental|Cohort 3: Lemborexant 25 mg|Participants will receive a single dose of lemborexant 25 mg (1*5 mg tablet and 2*10 mg tablet), orally on Day 1.
89056289|NCT02216994|Other|surgery treatment|The patients with a predicting score of more than 5 are diagnosed with HD, and are performed surgery to remove the aganglionic bowel. The patients with a score less than 5 are mostly indicative of HAD, and receive conservative treatments that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments. one stage pull through procedure to remove the dysganglionic bowel segments.
89056290|NCT02217033|Placebo Comparator|Purified Water|"In this arm, eligible subjects will begin to consume purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume the placebo through their chemotherapy and then for an additional 12 weeks after completing chemotherapy.~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume placebo for a minimum of 168 days."
89056291|NCT02217033|Experimental|'R' (Electro-kinetically altered beverage)|"Patients randomized to this arm will begin to consume R (Electro-kinetically altered beverage) just prior to the 1st cycle of chemotherapy and continue it through their chemotherapy cycles and then for an additional 12 weeks after completing chemotherapy.~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume R for a minimum of 168 days."
89056292|NCT04555538||Atrial Fibrillation Group|
89056293|NCT04555538||Non-Atrial Fibrillation Group|
89056294|NCT02217072|No Intervention|Control|Control
89056295|NCT02217072|Experimental|Parents as Tutors|Educational support intervention
89056296|NCT02217072|Experimental|school intervention|Educational support intervention
89056297|NCT02217111|Experimental|voice therapy|
89056298|NCT04532697|Active Comparator|Chinese Medicine|Uncaria Rhynchophylla (Gou-Teng)
89056299|NCT04532697|Placebo Comparator|Placebo treatment|Placebo
89056300|NCT02212613|Experimental|Brexpiprazole|Brexpiprazole - Up to 2 mg/day, once daily dose, tablets, orally
89056301|NCT04532385|Experimental|GTE|Green tea extract, 400 mg every 12 hours for 12 weeks
89056302|NCT04532385|Placebo Comparator|Placebo|Calcined magnesia, 400 mg every 12 hours for 12 weeks
89217580|NCT02574065|Experimental|L. reuteri DSM 17938 group|"L. reuteri DSM 17938 will be given at a dose of 100000000 colony forming units (CFU) per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.~Each day, at about the same time, the infants will be given 5 drops (1x100000000 CFU) of the study product in connection with feeding."
89217581|NCT02574065|Placebo Comparator|Placebo group|The placebo consists of an identical formulation without L. reuteri. Each day, at about the same time, the infants will be given 5 drops placebo in connection with feeding.
89217582|NCT02539628|Experimental|Intermittent bolus|ropivacaine 0.2%, 21 ml every 3 hours
89217583|NCT02539628|Active Comparator|Continuous infusion|ropivacaine 0.2%, 7ml/h
89217584|NCT00906152||Subacute low back pain; chronic low back pain|Patients with subacute or chronic low back pain seen in the Primary Care Centers participating in the study.
89217585|NCT00717119||1|Patients with sprain of ankle treated with NSAID
89217586|NCT00894764||Routine Follow Up|Monthly nasopharyngeal swab for infant. Seen during acute illness.
89217587|NCT00894764||Immunology|Monthly nasopharyngeal swab for mother and infant. Serum sample taken from Infant. Seen during acute illness.
89217588|NCT00713297||Observation|Those who will use the new CPOE system
89217589|NCT00901862|Active Comparator|1 Active PEFs|The pulsed electromagnetic fields were directed to the wrist. The model used has the form of a bracelet called Quantum MH-2MR which uses, as a source of power, an alkaline battery of 1.5 volts connected to an electronic circuit formed by two hybrid circuits of magnetic oscillation and a control system of all the generating frequency system.
89217590|NCT00901862|Sham Comparator|2 Sham|The sham machines were identical to the machines in actual operation in both phases of the study. The only difference was that the hybrid circuits crucial for the generation of the electromagnetic field had been removed.
89217591|NCT02573987|Active Comparator|Oxygen/nitrous oxide equimolar mix|96 participants undergoing chorionic villi sampling. self administered inhalation of equimolar mixture of oxygen and nitrous oxide (MEOPA)
89217592|NCT02573987|Active Comparator|Lidocaine|96 participants undergoing chorionic villi sampling infiltrative local anaesthesia of 1% lidocaine
89217593|NCT00901940|Active Comparator|MenACWY Plain Polysaccharide (ACWY Vax)|The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY).
89217594|NCT00901940|Active Comparator|MenACWY conjugate|The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine.
89217595|NCT00906308|Placebo Comparator|Placebo|
89217596|NCT00906308|Experimental|MF101 5 g/day|
89217597|NCT00906308|Experimental|MF101 10 g/day|
89217598|NCT00906386|Experimental|1|
89217599|NCT00906386|Placebo Comparator|placebo|
89217600|NCT00722501|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1,4, 15, 45, 90, 180, and 300 mg
89217601|NCT00722501|Placebo Comparator|placebo|2 placebo subjects per group
89217602|NCT00902096||Prenatal factors|Prenatal factors to predict cord blood IgE
89217603|NCT00722579|Experimental|A|The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
89217604|NCT00906542||Acute ischemic stroke patients|Acute ischemic stroke patients admitted to the neurological intensive care unit or stroke unit within 24 hours after stroke onset in whom ischemic brain lesion was clearly assessed on CT and/or MRI
89217605|NCT04067687|No Intervention|Control|No palliative home visit intervention
89217606|NCT04067687|Experimental|Intervention|Palliative home visit intervention
89217607|NCT04035902|Experimental|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered during surgery
89217608|NCT04035902|Active Comparator|control|Ferric carboxymaltose is not administered
89217609|NCT00894842|Active Comparator|Pregnenolone|
89217610|NCT00894842|Placebo Comparator|Sugar pill|
89217611|NCT02571569|Experimental|Without inhibitors|Dose escalation steps for participants without inhibitors - intravenous infusion and subcutaneous injection
89217612|NCT02571569|Experimental|With inhibitors|Dose escalation steps for participants with inhibitors - intravenous infusion and subcutaneous injection
89217613|NCT02571569|Experimental|Without inhibitors_multiple dose|Multiple dose cohort for participants without inhibitors - a single subcutaneous injection once a week for 6 weeks
89056303|NCT04555460|Active Comparator|Decompressive surgery|Decompressive surgery was performed with a large hemicraniectomy that removed, ipsilateral to the stroke, a bone flap as large as possible including temporal, frontal, parietal, and some occipital squama.
89056304|NCT04555460|Active Comparator|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke. Administration of intravenous mannitol (0.25 to 0.5 g/kg) or furosemide was given only in patients whose condition was rapidly worsening because of brain edema, without additional recommendations on loading doses.
89056305|NCT00579800|Experimental|women undergoing routine breast MRI|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
89056306|NCT04532268|Experimental|Administration of Humanized CD19 CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89056307|NCT00579839|Experimental|A|Delayed Cord Clamping
89056308|NCT00579839|Active Comparator|B|Immediate cord clamping
89056309|NCT04532112|Experimental|Intubated Subjects with the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by anesthesiologists trained in device use.
89056310|NCT04532112|Placebo Comparator|Intubated Subjects without the Biocontainment Device|Subjects undergoing scheduled airway procedures under general anesthesia with the Biocontainment Device by same cohort of anesthesiologists trained in device use.
89056311|NCT04555499||Suspected stroke|Patients with suspected stroke who are evaluated by paramedics
89056312|NCT04532073|Experimental|Eurythmy therapy exercises|As part of the ENTAiER trial: In group sessions á 5 patients with a qualified therapist: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by an eurythmy manual and an exercise video. This supplements the regular care.
89056313|NCT04532073|Experimental|Tai Chi exercises|As part of the ENTAiER trial:In group sessions of 5 patients each with a qualified teacher: In the first 3 months twice a week, in the second 3 months once a week. Recommendation to practice at home on at least 3 days per week (optimal, practice daily). They are supported by a Tai Chi Manual and an exercise video. This complements the regular care
89056314|NCT04532073|Active Comparator|Standard Care Only|"As part of the ENTAiER trial:Brochure with detailed description of various evidence-based measures for fall prevention, prepared for the specific age group (https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf)~- Recommendation to visit the family doctor and discuss fall prophylaxis with her"
89056315|NCT00579917||1 Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT) involves one-on-one counseling
89056316|NCT00579917||2 Usual Care|Usual Care
88999209|NCT03004404|Experimental|SRD part-Dose group 2: BI 730357 PfOS 8 mg Fasted|"Participants were administered on Day 1 a single oral dose of 8 milligram (mg) of BI 730357 powder for reconstitution of an oral solution (PfoS) reconstituted in solvent for oral solution 8 milliliter (mL) (Macrogol 400 (Polyethylene glycol 400) together with about 240 milliliter (mL) of water in fasted state.~One authorized employee of the trial site was witness of the administration of the trial medication."
88999210|NCT03004404|Experimental|SRD part-Dose group 3: BI 730357 tablet 25 mg Fasted|Participants were administered on Day 1 a single oral dose of 25 milligram (mg) of BI 730357 film-coated tablet together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
88999211|NCT03004404|Experimental|SRD part-Dose group 4: BI 730357 tablet 50 mg Fasted|Participants were administered on Day 1 a single oral dose of 50 milligram (mg) of BI 730357 film-coated tablet together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
89056317|NCT02217150||Metastatic Lesions to the spine|Patients over the age of 18 receiving treatment using the DFINE Inc. STAR tumor ablation system for palliation of painful metastases of the spine.
89056318|NCT02217189|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
89056319|NCT02217189|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
89056320|NCT00579956|Experimental|Meropenem|Meropenem
89056321|NCT00579956|Active Comparator|Ceftazidime|Ceftazidime
89056322|NCT02217306||Contrast Sensitivity|Determine changes in contrast sensitivity frequences and visual function (visual acuity) after one month of treatment photocoagulation in macular edema
89056323|NCT04555304|Experimental|KH903 + Paclitaxel|IV KH903 4 mg/kg IV paclitaxel 80 mg/m²
89056324|NCT04555304|Active Comparator|Placebo + Paclitaxel|IV Placebo IV paclitaxel 80 mg/m²
89056325|NCT04531800|Experimental|Study Group|The necrotic bone was removed with rotating burs, curettage was performed, and the surface of the bone was smoothened. CGF was then applied to the surgical area in the study group (n=14), and the area was primarily closed after additional releasing incisions were made to the periosteum to assure tension-free soft tissue closure.
89056326|NCT04531800|Experimental|Control Group|The surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy, in the control group (n=14).
89056327|NCT00579995|Active Comparator|N-Acetylcysteine|Oral N-Acetylcysteine 600 mg
89056328|NCT00579995|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate 3 milliliter per kilogram per hour (3 mL/kg/hr) infused at 1 mL/kg/hr for 6 hours post-procedure
89056329|NCT04531683|Experimental|electroacupuncture|patients will receive electroacupuncture at 3 acupoints (Bladder meridian of foot-taiyang 33 and 35（BL33 and BL35), and Spleen meridian of foot-taiyin 33(SP6)) 3 times/week for 8 weeks(24 times in total), followed with 24-weeks follow up. Disposable acupuncture needles with size of 0.30 × 75 mm will be used at BL 33 and BL 35, and needles with size of 0.30 × 40 mm at SP 6. Standardised electroacupuncture apparatuses will be used, and the stimulation will last for 30 minutes with a continuous wave of 20 Hz, and a current intensity of 2 to 6.5 mA at BL33 and BL 35, and 1 to 3.5 mA at SP6. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
89056330|NCT04531683|Sham Comparator|sham electroacupuncture|patient will receive sham electroacupuncture with the same frequency and amount as applied in the electroacupuncture group, as well as the follow-up period. Disposable acupuncture needles with size of 0.30 × 40 mm will be applied and penetrate the skin of patients for 2 to 3mm at sham acupoints to the 3 acupoints mentioned above. The stimulation will only last for 30-second with a very weak currency intensity and a continuous wave of 20 Hz. Life style counselling will be provided to all patients and contents are as same as the life style counselling group.
89056331|NCT04531683|Other|life style counselling group|patients randomised to this group will receive a one-time life style counselling at the enrolment to improve their daily behaviour to expedite the recovery of their mixed urinary incontinence. Then the patients will be followed up for 20 weeks.
89056332|NCT04555421|Experimental|Lumen device usage and diet guidelines|
89056333|NCT04531371|Experimental|dexemedetomidine|dexemedetomidine was administered intravenously after induction of general anesthesia.
89056334|NCT04531371|Active Comparator|magnesium sulphage|magnesium sulphate was infused through out the surgery after induction of general anaesthesia.
89056335|NCT04531371|Placebo Comparator|saline|nothing was given just saline during the operation.
89056336|NCT04555109||COVID-19 Convalescents|The cohort will include up to 1000 persons recovered from COVID-19, ages 17 - 65, that will provide a written consent form to participate in the study, complete questionnaires and provide a blood sample.
89056337|NCT04531605|Experimental|Intervention|"12-week program of combined life-skills training and financial incentives (YBank program) described in more detail below.~Life-skills training: Every 4 weeks through the 12 week program, life-skills training sessions will be delivered during peer-group sessions at the clinic. Topics include economic empowerment, financial literacy, healthy relationships, and anti-retroviral therapy (ART) adherence.~Financial incentives: The incentives program combines an immediate financial reward with a long-term savings opportunity. For clinic attendance, 500 RWF (~$0.50) will be deposited into participants' mobile money short-term account, where funds will be immediately accessible, and 1500 RWF (~$1.50) will be deposited into their savings account upon completing the program. If participants demonstrate a suppressed viral load at a clinic appointment, an additional 1000 RWF (~$1) will be deposited to their short-term account and 3000 RWF (~$3) into their saving account."
89056338|NCT04555382||AKI group|this group are included patients who have not occured acute kidney injury at first, however acute kidney injury are occured soon afterwards during the observation period.
89056339|NCT04555382||non-AKI group|this group are included patients who have not occured acute kidney injury during the observation period.
89057742|NCT04530578|Experimental|NEBULIZED HEPARIN|"Nebulized Heparin (UNF)5000 IU in Saline Solution1 ml every 8 hours plus Enoxaparine 40mg /d or 60mg/d, adjusted by BMI and calculated creatinine clearance .~Device to nebulize without producing aerosolization:~To nebulized heparin we have a modified a fullface snorkel mask, in which instead of the discharge valve a connector for the Venturi has been placed, and in the air outlet / inlet of the snorkel it has been adapted a connector made with 3D printing for the insertion of a disposable antiviral filter (filters commonly used in Mechanical Respiratory Assistance devices).~The mask is made of materials that allow its sterilization with the STERRAT Hydrogen Peroxide plasma system, available at the institution."
89057743|NCT04530578|Active Comparator|Enoxaparine|Enoxaparin 40mg/d or 60mg/d adjusted by BMI and calculated creatinine clearance
88999212|NCT03004404|Experimental|SRD part-Dose group 5: BI 730357 tablet(s) 100 mg Fasted|Participants were administered on Day 1 a single oral dose of 100 milligram (mg) of BI 730357 film-coated tablets (2x50mg) together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
88999213|NCT03004404|Experimental|SRD part-Dose group 6: BI 730357 tablet(s) 200 mg Fasted|Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (4x50mg) together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
89057744|NCT01200238|Experimental|STA-9090: Cohort A|"Cohort A participants received STA-9090 200 mg/m2 given intravenously (IV) over 1 hour once weekly (d1, 8, 15 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
89057745|NCT01200238|Experimental|STA-9090: Cohort B|"Cohort B participants received STA-9090 150 mg/m2 given intravenously over 1 hour (IV) twice weekly (d1, 4, 8, 11, 15, 18 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
89057746|NCT01685853|Active Comparator|PEG 4 litres split|Polyethylene glycol with electrolytes (PEG)
89688092|NCT03408743|Experimental|Expectancies, descriptive & injunctive, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
89688093|NCT03401515|Active Comparator|Intervention|Adminstration of propranolol hydrochloride ( 1 MG /ml) 1 mg every 6 hrs .
89688094|NCT03401515|Placebo Comparator|Control|Adminstration of normal saline 1 mg every 6 hrs
89688095|NCT04368715|Experimental|2780 nm Er:Cr;YSGG laser treated group|Patients treated with Er:Cr;YSGG laser for labial frenectomy
89688096|NCT04368715|Experimental|940 nm Diode laser treated group|Patients treated with 940 nm Diode laser for labial frenectomy
89688097|NCT01726829|Experimental|MD-Logic Artificial Pancreas (MDLAP) system|four consecutive outpatients overnight sessions at home under closed loop MD-Logic Artificial Pancreas (MDLAP) system
89688098|NCT01726829|Active Comparator|Standard treatment with sensor augmented pump therapy|four consecutive outpatients overnight sessions at home under standard treatment with sensor augmented pump therapy
89688099|NCT02244385||Observation|No intervention
89688100|NCT03408509|Experimental|Cognitive training|
89688101|NCT02244541|Experimental|Anavex2-73 oral then the Anavex2-73 intravenous formulation|Participants first receive Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days. After a washout period of 11 days they then receive the Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days.
89688102|NCT02244541|Experimental|Anavex2-73 intravenous then the Anavex2-73 oral formulation|Participants first receive Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days. After a washout period of 11 days then they receive the Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days.
89688103|NCT02244541|Experimental|Anavex2-73 30 mg oral formulation|Participants will receive the 30 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
89688104|NCT02244541|Experimental|Anavex2-73 50 mg oral formulation|Participants will receive the 50 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
89688105|NCT01720433|Experimental|intervention|In the intervention group, in addition to the above, the patient was placed in the Trendelenburg position (30°) and a pulmonary recruitment maneuver utilized, consisting of two manual inflations to a maximum pressure of 60 cm H2O. This was performed by the Anaesthetist, who held each positive pressure inflation for five seconds, with the valves on the operative ports fully open.
89688106|NCT01720433|No Intervention|control arm|In the control group residual carbon dioxide pneumo-peritoneum was evacuated at the end of the procedure by passively allowing the abdomen to decompress by opening the operative ports.
89688107|NCT04368325||Study group|Total of 46 patients with low serum creatinine levels whose values were obtained from the central laboratory with inclusion criteria (< 40mmol/L)
89688108|NCT04368325||Control group|A total of 61 consecutive patients were obtained who were treated in ICU CHC Osijek, according to the date of admission.
89688109|NCT01720511|Experimental|Purple Rice|Twice a day given purple rice with 5mg of resveratrol.
89688110|NCT01720511|Active Comparator|Brown RIce|Plain Purple rice given twice a day
89688111|NCT01720589|Experimental|Melt (test oil)|Participants will consume a muffin containing 20 g of dietary fat provided by the test oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the test oil and their food intake at an ad libitum meal will be measured 1 hour later.
89688112|NCT01720589|Active Comparator|Corn oil (control)|Participants will consume a muffin containing 20 g of dietary fat provided by the control oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the control oil and their food intake at an ad libitum meal will be measured 1 hour later.
89688113|NCT02244697||Experimental: laryngeal ultrasound stridor|Children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre.
89688114|NCT02244697||Other: laryngeal ultrasound -control|Infants matched for age referred for ANL for reasons other than stridor will undergo US of the larynx.
89688115|NCT01726907|Experimental|Robotic SMG resection|Robot-assisted SMG resection
89688116|NCT01726907|Active Comparator|Endoscopic SMG resection|Endoscope-assisted SMG resection
89688117|NCT01720745||EUS FNA|Patients undergoing endoscopic ultrasound for solid mass lesions with a 22 G needle at University of Minnesota Medical center and Aurora St.Luke's Medical Center, Milwaukee, WI
89688118|NCT03401281|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
89688119|NCT03401281|Active Comparator|Butter|50g Butter to be consumed daily for four weeks
89688120|NCT03401281|Active Comparator|Olive oil|50g extra virgin olive oil to be consumed daily for four weeks
89688121|NCT03408431|Experimental|Group E|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neck extension positioning.
89688122|NCT03408431|Active Comparator|Group C|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neutral head and neck position.
89688123|NCT04368169|Experimental|Aromatic Extract|Participants receive the aromatic botanical extract orally every 4-6 waking hours for 3 days.
89688124|NCT04368169|Placebo Comparator|Placebo|Participants receive the placebo matching the botanical extract orally every 4-6 waking hours for 3 days.
89688125|NCT03408275||Pregnant women|Pregnant women enrolled in ALSPAC
89217614|NCT00906620|Experimental|QPR intervention|"QPR intervention (Question, Persuade & Refer): The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
89217615|NCT00906620|Experimental|Awareness program|The awareness programme is comprised of a leaflet, six posters and four seminars. The seminars are made up of one introductory lesson, and two interactive follow-up lessons with role play and one final meeting as a closing/debriefing lesson.
89217616|NCT00906620|Experimental|ProfScreen|The program's primary objective is to help young people and their parents through the early identification of mental health problems, such as anxiety, depression, substance abuse, and suicide. Screening strategies are based on the valid premise that suicidal adolescents are under-identified, suffer from an active, often treatable mental illness such as depression and exhibit identifiable risk factors (Gould et al. 2003). A potential shortcoming of screening programs is that asking about suicide could increase suicidal ideation and behaviour. About this issue a recent study (Gould et al . 2005) on over 2300 students reported no evidence of iatrogenic effects of suicide screening and that screening in high schools is a safe component of youth suicide prevention efforts.
89217617|NCT00906620|Experimental|Control group|The control group will comprise 250 subjects. After the baseline assessment, subjects will be randomized in one of the three intervention arms or in the control group. Individuals in the control group will undergo the same baseline and follow-up evaluations as subjects in the intervention arms and will receive the same leaflet about healthy lifestyles with information about the possibility to seek help for unhealthy, suicidal behaviour and mental health problems. In this arm, no additional intervention will be performed although the possibility of seeking help from mental health resources will be available.
89217618|NCT02539472|Experimental|investigation|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
89217619|NCT00902252|Experimental|Usual/Natura®/Vitala™|All subjects will wear usual product for 21 days, followed by Natura® for 14 days and followed by Vitala™ for 159 days.
89217620|NCT00717353||1|Lung cancer
89217621|NCT00902408|Experimental|Lutein|Lutein enriched eggs
89217622|NCT00902408|Placebo Comparator|Placebo|Non enriched
89056340|NCT00580112|Experimental|Group A|Participants with triple negative phenotype: estrogen receptor, progesterone receptor and human estrogen receptor-2 (HER-2) negative status for breast cancer (abnormal tissue that grows and spreads in the body until it kills) will receive trabectedin 1.3 milligram per meter square (mg/m^2) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 3-hours (hrs) every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72hrs after the start of study drug infusion from Day 1 to 3.
89056341|NCT00580112|Experimental|Group B|Participants with overexpressing HER-2 breast cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
89056342|NCT00580112|Experimental|Group C|Participants with familial breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2) mutation carriers cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 mg orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
89056343|NCT04531332|Experimental|Continuous infusion|Patients will be received linezolid 600 mg intravenous Loading dose over 30 to 60 minutes followed by 1200 mg/ day by Continuous infusion (50 mg /hr)
89056344|NCT04531332|Active Comparator|Intermittent dosing|Patients will be received Linezolid 600 mg intravenous twice daily over 30 to 60 minutes
89056345|NCT04555148|Placebo Comparator|Placebo|Saline
89056346|NCT04555148|Experimental|Low dose Treatment|Low dose treatment
89056347|NCT04555148|Experimental|Medium dose Treatment|Medium dose Treatment
89056348|NCT04555148|Experimental|High dose Treatment|High dose Treatment
89056349|NCT04530864|Experimental|DEXTENZA Insert|This prospective study will use a self controlled design for 35 eyes. Patients scheduled to undergo routine cataract surgery in at least one of their eyes will have their pre-surgical measurements performed, IOL calculated and surgery planned. Then they will receive insertion of an intracanalicular dexamethasone insert into the inferior punctum. At 2 weeks (+/- 2 days) post-insertion, patients will return for an identical set of measurements. The IOL will be calculated and the surgery planned based on post-insert data. The insert will be removed if present (manually or via saline irrigation). This self controlled design allows for greater control of potential confounders tied to participants' systemic and ocular health.
89056350|NCT04554875||Cohort 1|Derivation Cohort of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
89056351|NCT04554875||Cohort 2|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
89056352|NCT04554875||Cohort 3|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
89056353|NCT04554875||Cohort 4|One of Validation Cohorts of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules
89056354|NCT04531488|Experimental|Powered Mobility Training Simulator|Powered mobility simulator- the McGill Immersive Wheelchair Simulator (MiWe) was developed for adults. In a previous study the simulator was found valid for use with children. Participants were provided a laptop, joystick and the software program- MiWe- to practice at home or school
89056355|NCT04531488|Active Comparator|Training with Powered Wheel Chair|Participants were provided with a powered wheelchair to practice at home or school
89056356|NCT00580190|Active Comparator|1|
89056357|NCT00580190|Placebo Comparator|2|
89056358|NCT00580190|Experimental|3|
89056359|NCT04531137|Experimental|CLA-fortified milk powder|Respondents will receive CLA-fortified milk powder containing 3.4 gram for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
89056360|NCT04531137|Other|Placebo|Respondents will receive a placebo milk powder for one a day for 12 weeks. They will also receive individualized nutrition counseling and nutrition module at weeks 0, 4, and 8.
89056361|NCT00580268||H|Pregnant women with bipolar disorder
89217623|NCT00713687|Experimental|1|Treatment by combination of photodynamic therapy and chemotherapy
89056362|NCT04530903|Experimental|Group Clonidine|Group Clonidine will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine and 75 µg of clonidine per side.
89056363|NCT04530903|Placebo Comparator|Control|Group Control will benefit from the pudendal block realised with 10 ml of 0.25% levobupivacaine per side; 0.5 ml of 0.9% NaCl will be added to each syringe to homogenise the volume in order to remain blind.
89056364|NCT00580307|Placebo Comparator|Septoplasty|Septoplasty only
89056365|NCT00580307|Experimental|Septoplasty and correction|Septoplasty and endoscopic contact point correction
89056366|NCT04530474|Experimental|Ivermectin|Single dose of 0.15-2 mg/kg/dose to a maximum of 12 mg
89056367|NCT04530474|Placebo Comparator|Placebo|Single dose of 2-4 placebo pills
89056368|NCT04554641|Experimental|BioKult Advanced|This is a single arm study, all participants will take Bio-kult Advanced for 56 days (+/- 2days). Participants will be required to take 4 capsules daily.
89057747|NCT01685853|Experimental|Bisacodyl plus PEG-CS|Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)
89056369|NCT04530669|Experimental|study group|"in the active arm patients will receive high tone power therapy in addition to the physical therapy conventional selected exercise program"
89056370|NCT04530669|Sham Comparator|control group|"the sham arm will receive the same physical exercise program with sham high tone power therapy."
89056371|NCT04554680|Experimental|Treatment Group|Patients with progressive, metastatic or locally advanced, unresectable radioiodine (RAI)-refractory thyroid cancer of follicular cell origin with mutation involving MAPK signalling pathway, including BRAFV600E mutation or RAS mutation.
89056372|NCT04530396|Experimental|Primary Group|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
89056373|NCT04530396|Placebo Comparator|Control Group|placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21
89056374|NCT04554992|Experimental|Treatment|All subjects recruited will be transfused with COVID 19 convalescent plasma. A prospective comparison with matched historical controls receiving standard care will be employed.
89056375|NCT04530786||Vaccine, Post-transplant|Cohort consist of individuals who have received lung transplants Inactivated influenza vaccine will be administered intramuscularly annually.
89056376|NCT04530786||Vaccine, Healthy Control|Cohort consists of healthy individuals who received the influenza vaccine Inactivated influenza vaccine will be administered intramuscularly annually.
89056377|NCT01121575|Experimental|Arm 1|PF-02341066 AND PF-00299804: Patients will be treated with combined cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
89057748|NCT04317976|Active Comparator|Centrally located oesophagus post GA|Oesophagus remained central after general anaesthesia, cricoid pressure applied by fingertips under ultrasound guidance
88815306|NCT02161484|Experimental|Continuous Lumbar Plexus Block with Parasacral Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected."
89056378|NCT01121575|Experimental|Arm 2|PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804: Patients will be treated with single agent panHER inhibitor (PF-00299804) until disease progression and then with the maximum tolerated combined dose of cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
89056379|NCT04554797|Experimental|Regional Hypothermia group|
89056380|NCT04554797|No Intervention|Control group|
89056381|NCT04530591||Patient Participants|"This group of participants will complete a survey about their opioid use history and their preferences for a device-based intervention. They will then participate in a semi-structured interview to provide feedback on non-functional, looks-like prototypes of such a device."
89056382|NCT04530708|No Intervention|A: Standard of care|Normal standard of care and follow-up.
89056383|NCT04530708|Experimental|B: Thoracic radiotherapy|Addition of thoracic radiotherapy to 36 Gy after medical treatment.
89056384|NCT04205851|Experimental|KIN-1901|Single or repeat (once weekly for 4 weeks) KIN-1901 subcutaneous injection
89056385|NCT04205851|Placebo Comparator|Placebo|Single or repeat (once weekly for 4 weeks) placebo subcutaneous injection
89056386|NCT04530240||ERA-1 Group|Before the introduction of the MELD≥30 allocation scheme August 2010 - July 2014
89056387|NCT04530240||ERA-2 Group|After the introduction of the MELD≥30 allocation scheme August 2014 - July 2018
89056388|NCT04554758|Experimental|Sleeve gastrectomy|200 obesity patients who undergo laparoscopic sleeve gastrectomy
89056389|NCT04554758|Experimental|Roux-en-Y gastric bypass|200 obesity patients who undergo laparoscopic Roux-en-Y gastric bypass
89056390|NCT02882113|Experimental|Expressor|CYP3A5 expressor; containing CYP3A5*1 wild-type allele(*1/*1 type & *1/*3 type) intervention: Advagraf conversion
89056391|NCT02882113|Active Comparator|Non-expressor|CYP3A5 non-expressor: without CYP3A5*1 allele( *3/*3 type) intervention: Advagraf conversion
89056392|NCT04311190|Experimental|ICU A|Family members' involvement in the care of their beloved one
89056393|NCT04311190|No Intervention|ICU B|Standard care
89057749|NCT04317976|Experimental|Eccentric located oesophagus post GA|Oesophagus eccentric located after general anaesthesia, paralaryngeal pressure and cricoid pressure applied by fingertips under ultrasound guidance
89217624|NCT02539550|Placebo Comparator|Placebo|Placebo
89056394|NCT04311229|Experimental|Negative-Pressure Wound Therapy group|NPWT was applied three times for Class III and pressure ulcers. An initial pre-treatment measurement was used as a baseline, followed by three post-treatment measurements after each round to evaluate wound healing. A total of four measurements were performed for each subject. Wound healing was measured using the PUSH Tool and the 3DWM device in both groups.
89056395|NCT04311229|Other|CONTROL GROUP|wet to dry dressing group
89056396|NCT04530357|Experimental|Phase 1 Adult-vaccine (A Sample, blind study)|Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89056397|NCT04530357|Placebo Comparator|Phase 1 Adult-Placebo (A Sample, blind study)|Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89056398|NCT04530357|Experimental|Phase 2 Adult-Vaccine, twice vaccination (An Open study)|Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89056399|NCT04530357|Experimental|Phase 2 Elderly-Vaccine, twice vaccination (An Open study)|Group 4 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89056400|NCT04530357|Experimental|Phase 2 Adult-Vaccine, single vaccination (An Open study)|Group 5 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml volunteers from 18 years old and elder
89056401|NCT04530357|Experimental|Phase 2 Elderly-Vaccine, single vaccination (An Open study)|Group 6 (phase 2): 50 vvolunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml
89056402|NCT04554563|Experimental|Training group|4-week core stability training
89056403|NCT04554563|No Intervention|Control group|Standard physical therapy
89056404|NCT04530045||critically ill patients|Critically ill patients receiving continuous infusion of piperacillin/tazbactam or cefepim and dosage of plasma concentration of the B lactam administered
89056405|NCT01121536|Experimental|Armodafinil 150-200 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. At the discretion of the investigator, the dosage of armodafinil may be increased to 200 mg/day on day 6 or thereafter, and reduced to 150mg/day if the higher dose is not well tolerated. Treatment was administered for six months.
89056406|NCT02217423|Experimental|Obstructive increased AC|"Patient with obstructive respiratory disease with increased abdominal circumference.~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
89057750|NCT04530422|Experimental|• Group I (Sofosbuvir plus Ledipasvir)|Patients assigned to this group (125 patients) were received Sofosbuvir plus Ledipasvir, once daily for 15 to 21 days as minimum and maximum duration of therapy, respectively.
89217625|NCT02539550|Experimental|PF-06266047|PF-06266047
89688126|NCT04368247||Nevi undergoing biopsy per SOC|Subjects with Nevi who will as part of their standard of care, will undergo biopsy.
89688127|NCT00911495|Experimental|GMI-1070|
89688128|NCT03834103|Other|Arm 1: Self-rehabilitation arm|Self-rehabilitation arm
89688129|NCT03408197|Experimental|EasyWarm|
89688130|NCT03408197|Active Comparator|BairHugger|
89688131|NCT01726985||Patients hospitalized with CHF|Patients hospitalized with CHF Parameter Based Clinical Disposition
89688132|NCT04367701||Thalassemia group|"16 pediatric patients with thalassemia major undergoing surgery for repair of congenital heart disease.~Authors measure hemolysis by free plasma hemoglobin concentration."
89688133|NCT04367701||Control group|"25 pediatric patients with demographic data related to those in thalassemia group, undergoing surgery for repair of congenital heart disease.~Authors measure hemolysis by free plasma hemoglobin concentration"
89688134|NCT01727063|Experimental|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
89688135|NCT01727063|No Intervention|Placebo|Saline injection
89688136|NCT02244931|Experimental|Phase 1: Performance evaluation on ergometer|"The 3 devices are experimented in random order to compare them on performance using an ergometer wheelchair:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
89688137|NCT02244931|Experimental|Phase 2: Comparison of maneuverability|"The 3 devices are experimented in random order to compare them on maneuverability:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
89688138|NCT02244931|Experimental|Phase 3: Comparison of the autonomy|"The 3 devices are experimented in random order to compare them on the autonomy they afford to patients:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
89688139|NCT00918671||Medication-overuse headache|Chronic daily headache combined with medication overuse
89688140|NCT04366297|Experimental|Standard of Care (Intravenous Cannula)|obtaining intravascular access using a ready standard intravenous cannula
89688141|NCT04366297|Experimental|IO access using NIO® set|receive an IO line in the proximal tibia localization. IO lines are placed using an FDA-approved device called an NIO®.
89688142|NCT03408041||Alzheimer Disease|Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
89688143|NCT04366375||TLH+BSO|Total Laparoscopic Hysterectomy + Bilateral Salpingo-Oophorectomy N=20
89688144|NCT04366375||TAH + BSO|Total Abdominal Hysterectomy + BSO N=20
89688145|NCT01720823|Experimental|home polysomnography and standard polysomnography|home polysomnography (GETEMED) and standard polysomnography (BRAINNETII) are both carried out in children during 1 night.
89688146|NCT02245009||Pacemaker patients|Patients with pacemaker, presenting for cardioversion.
89688147|NCT02245009||ICD patients|Patients with ICD, presenting for cardioversion.
89688148|NCT02245009||CRT patients|Patients with CRT device, presenting for cardioversion.
89688149|NCT04379453|Experimental|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses
89056407|NCT02217423|Experimental|Obstructive disfunction with normal AC|"Patients with obstructive respiratory disease with normal abdominal circumference.~Patient with obstructive respiratory disease with increased abdominal circumference.~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
89056408|NCT02217423|Experimental|Restrictive increased AC|"Patients with restrictive respiratory disease with increased abdominal circumference. chest physiotherapy chest wall expansion.~The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
89056409|NCT02217423|Experimental|Restrictive disfunction with normal AC|"Patients with restrictive respiratory disease with normal abdominal circumference.~Chest physiotherapy chest wall expansion. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
89056410|NCT04311151|Experimental|self seizures visualization group|Visualization of the own epileptic seizures occured during hospital admission.
89056411|NCT04311151|No Intervention|usual management|Usual way management
89056412|NCT02217462||Pregnant women|
89056413|NCT00580619|Experimental|1 (markers of sympathetic activity)|To evaluate if the various indices of sympathetic activity (Autonomic Function Testing) differ between patients with chronic fatigue syndrome and postural tachycardia syndrome (CFS-P), and CFS without POTS.
89056414|NCT00580619|Experimental|2 (saline)|To test the null hypothesis that there is no difference between two saline therapies (pulse saline vs. sham saline) in improving both the fatigue score and postural tachycardia syndrome.Saline infusions
89056415|NCT00580619|Experimental|3 (NO inhibition/ autonomic blockade)|Response to nitric oxide inhibition in the presence and absence of an intact autonomic nervous system will be evaluated. L-NMMA trimethaphan will be used for NO inhibition and autonomic blockade, respectively.
89056416|NCT00580619|Active Comparator|4 (methyldopa)|The effects of chronic autonomic withdrawal on improving symptoms of chronic fatigue and postural tachycardia syndrome will be evaluated
89056417|NCT02217579|Placebo Comparator|Control|Isocaloric food without the test protein and prebiotic fiber.
89056418|NCT02217579|Experimental|Protein|Dietary protein consumed as two daily servings of 5 grams protein/serving.
89056419|NCT02217579|Experimental|Fiber|Prebiotic fiber consumed as two daily servings of 8 grams protein/serving.
89056420|NCT02217579|Experimental|Protein plus prebiotic fiber|Protein and prebiotic fiber consumed as two daily servings of 5 grams protein/serving plus 8 grams fiber/serving.
89056421|NCT04554524|Experimental|Chemotherapy+Pembrolizumab|Chemotherapy combined with pembrolizumab.
89056422|NCT01121263||Angiogram Review Group|All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period
89056423|NCT01121263||Therapeutic Intervention Group|"Cohort 2 Therapeutic Intervention Group - HCR Patients (including those from the angiogram review group) who undergo Hybrid coronary revascularization (HCR) with minimally invasive LIMA-LAD CABG, OR~Cohort 2 Therapeutic Intervention Group - PCI Patients (including those from the angiogram review group) who meet the proposed anatomic and clinical eligibility criteria and undergo multivessel Percutaneous Coronary Intervention with Drug Eluting Stents"
89056424|NCT04530084|Experimental|Diagnosed with open angle glaucoma|
89056425|NCT02212652|Active Comparator|Standard of Care plus Vitamin D|If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
89056426|NCT02212652|Placebo Comparator|Standard of Care plus Placebo|If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
89056427|NCT02217657|Active Comparator|operator informed to contact force|Thermocool Smart Touch Catheter, operator informed to contact force (Biosense Webster)
89056428|NCT02217657|Experimental|operator blinded to contact force|Thermocool Smart Touch catheter, operator blinded to contact force information (Biosense Webster)
89056429|NCT02212769|Experimental|A Group|1st oral administration of Losartan 50mg and 2nd oral administration of Losartan 50mg and DW1029M 1200mg
89056430|NCT02212769|Experimental|B Group|1st oral administration of DW1029M 1200mg and Losartan 50mg and 2nd oral administration of Losartan 50mg
89056431|NCT02217696|Experimental|Computerized reading training first|Cross-over design: group first receives the intervention
89056432|NCT02217696|Experimental|Waiting Control First|Cross-over design: group first serves as waiting control
89056433|NCT02212808|Experimental|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario.
89056434|NCT02212808|Experimental|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacists will review a list of patients receiving the targeted antibiotics on a daily basis to identify patients who have received one or more targeted antibiotics for 72 hours (± 24 hours). The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations.
89056435|NCT02217774|Experimental|MGUIDE assisted implant placement|Implant placement, using MGUIDE MORE system for implant planning and placement
89056436|NCT02217852|Experimental|A1 nitrendipine|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and nitrendipine will be added (dose range 10mg-20mg bid).
89056437|NCT02217852|Experimental|A2 hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and hydrochlorothiazide will be added (dose range 12.5mg-25mg)
89056438|NCT02217852|Experimental|B1 captopril plus Hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and captopril plus Hydrochlorothiazide will be added (dose range：captopril 25mg-50mg tid, Hydrochlorothiazide 12.5mg-25mg qd).
89056439|NCT02217852|Experimental|B2 Beijing hypotensive No.0|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and Beijing hypotensive will be added (dose range：Beijing hypotensive No.0 one pile qd or less ).
89056440|NCT02217930|Placebo Comparator|Placebo|"Placebo matched to WCK 2349, oral tablet(s)~Placebo matched to moxifloxacin overencapsulated tablet"
89056441|NCT02217930|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg positive control (overencapsulated tablet)
89056442|NCT02217930|Experimental|WCK 2349|WCK 2349 supratherapeutic dose determined in Part 1, oral tablet(s)
89056443|NCT01121185|Experimental|MBL-HCV1|
89056444|NCT01121185|Placebo Comparator|0.9% sodium chloride|
89056445|NCT01121146|Active Comparator|Crosslinked Marathon polyethylene|
89056446|NCT01121146|Active Comparator|Standard Enduron polyethylene|
89056447|NCT01120756|Experimental|Goal-oriented attentional self-regulation training|Goal-oriented attentional self-regulation training (GOALS).
89056448|NCT01120756|Active Comparator|Brain Health Education|Brain Health Education (EDU)
89056449|NCT01120717|Experimental|QVA149|110µg/50µg capsule for oral inhalation, once daily, delivered by a single dose dry powder inhaler (SDDPI)
89056450|NCT01120717|Placebo Comparator|Placebo|Placebo to match QVA149, capsules for inhalation once daily, delivered by an SDDPI
89056451|NCT04577846|Active Comparator|Intervention Arm|The intervention arm will be administered, either Cefazolin iv every 8 hours while NPO or cefalexin 500 mg q8 hours per oral if tolerating a diet.
89056452|NCT04577846|Placebo Comparator|Control|Controls will be provided with initially IV placebo while NPO and then with a placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
89056453|NCT04529811|Experimental|Formulation 1 - Low Dose|Rifaximin Formulation 1 Capsules
89056454|NCT04529811|Experimental|Formulation 1 Capsules - Mid Dose|Rifaximin Formulation 1 Capsules
89056455|NCT04529811|Experimental|Formulation 1 Capsules - High Dose|Rifaximin Formulation 1 Capsules
89056456|NCT04529811|Experimental|Formulation 1 Capsules - Max Dose|Rifaximin Formulation 1 Capsules
89056457|NCT04529811|Placebo Comparator|Formulation 1 Capsules - Placebo|Placebo Formulation 1 Capsules
89056458|NCT04529811|Experimental|Formulation 2 - Low Dose|Rifaximin Formulation 2 Capsules
89056459|NCT04529811|Experimental|Formulation 2- Mid Dose|Rifaximin Formulation 2 Capsules
89056460|NCT04529811|Experimental|Formulation 2 - High Dose|Rifaximin Formulation 2 Capsules
89056461|NCT04529811|Experimental|Formulation 2 - Max Dose|Rifaximin Formulation 2 Capsules
89056462|NCT04529811|Placebo Comparator|Formulation 2 - Placebo|Placebo Formulation 2 Capsules
89056463|NCT04529811|Experimental|Formulation 3 - Low dose|Rifaximin Formulation 3 Capsules
89056464|NCT04529811|Experimental|Formulation 3 - Mid dose|Rifaximin Formulation 3 Capsules
89056465|NCT04529811|Experimental|Formulation 3 - High dose|Rifaximin Formulation 3 Capsules
89056466|NCT04529811|Experimental|Formulation 3 - Max dose|Rifaximin Formulation 3 Capsules
89056467|NCT04529811|Placebo Comparator|Formulation 3 - Placebo|Placebo Formulation 3 Capsules
89056468|NCT04554407|Experimental|Treatment Group|All participants receive the SOMAVAC® 100 Sustained Vacuum System
89217626|NCT00717431|Experimental|Hippocampal Stimulation|Hippocampal Stimulation (Stimulator is turned ON) Surgical Intervention
89217627|NCT00717431|Sham Comparator|Hippocampal Implantation|Hippocampal Implantation (Stimulator is turned OFF)Surgical Intervention
88999214|NCT03004404|Experimental|SRD part-Dose group 7: BI 730357 tablet(s) 400 mg Fasted|Participants were administered on Day 1 a single oral dose of 200 milligram (mg) of BI 730357 film-coated tablets (8x50mg) together with about 240 milliliter (mL) of water in fasted state. One authorized employee of the trial site was witness of the administration of the trial medication.
89056469|NCT02217969|Experimental|Electronic alert to SLUScore increase|Patients whose anesthesia care team members are receiving alerts to increments in their SLUScore (progressive hypotensive exposures) are anticipated to be given interventions aimed at minimizing further hypotensive exposures. The decision of whether or not to intervene as well as the type(s) of interventions will be at the sole discretion of the patient's anesthesia care team
89056470|NCT02217969|No Intervention|Control (no alert)|Routine anesthesia care at the discretion of the anesthesia care team
89056471|NCT00580775||Placebo|Observing heart rate variability in placebo and active estrogen preparations
89056472|NCT00580775||Active estogen|Observing heart rate variability in placebo and active estrogen preparations
89056473|NCT02218047|Active Comparator|Best available therapy (BAT)|Best available therapy, as chosen by the investigator for patients who had been on HU in the 1 Year PROUD-PV study
89056474|NCT02218047|Experimental|Pegylated-Proline-interferon alpha-2b|AOP2014 for those patients who had been on AOP2014 in the PROUD-PV study
89056475|NCT01120600|Experimental|Odanacatib 50 mg once weekly|Participants will receive one Odanacatib 50 mg tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
89056476|NCT01120600|Placebo Comparator|Placebo once weekly|Participants will receive one Placebo tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
89056477|NCT04529694|Active Comparator|Cognitive-only Intervention|This condition includes cognitive interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
89056478|NCT04529694|Active Comparator|Behavioral-only Intervention|The condition includes behavioral interventions drawn from cognitive therapy as described in Beck, Rush, Shaw, & Emery (1979).
89056479|NCT04577885|Experimental|experimental group|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
89056480|NCT02218086|Experimental|professionals|balancing on the slackline / wobbling board 3 times by 30 seconds balancing on the slackline with a fix visual anchor / moving visual anchor 3 times by 30 seconds
89056481|NCT02218086|Experimental|beginners|balancing on the slackline / wobbling board 3 times by 30 seconds pre-training compared to post-training
89056482|NCT01120210|Experimental|Part 1 (Main Study)|3 consecutive 1-hour infusions of JNJ-39588146 5, 15, or 30 ng/kg/min or matching placebo
89056483|NCT01120210|Experimental|Part 2 (Extended Infusion Sub-Study)|1 18-hr infusion of JNJ-39588146 of the highest tolerated dose from Part 1 of the study or matching placebo
89056484|NCT04554329|Active Comparator|bandage contact lens|A bandage contact lens was applied on the eye at the end of the surgery, and the eye was not covered with a patch.
89056485|NCT04554329|Active Comparator|eye patching|Antibiotic eye ointment was applied on the eye, and the eye was covered with a patch at the end of the surgery.
89056486|NCT02218125|Experimental|Group 1- MVA Mosaic|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
89056487|NCT02218125|Placebo Comparator|Group 2 - Placebo|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
89056488|NCT02218125|Experimental|Group 3 - MVA Mosaic|Healthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
89056489|NCT02218125|Placebo Comparator|Group 4- Placebo|Participants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
89056490|NCT00580931|Experimental|1|Subjects will receive experimental drug in a blinded fashion.
89056491|NCT00580931|Placebo Comparator|2|Identical in size, shape and color to experimental drug.
89056492|NCT02218281|Experimental|C2Q-Teen app|Smoking cessation treatment delivered through a smartphone app via mindfulness training.
89056493|NCT02218281|Active Comparator|NCI's QuitSTART app|Smoking cessation treatment delivered through a smartphone app by NCI, without mindfulness training.
89056494|NCT02218281|Active Comparator|Written smoking cessation materials only|Receipt of written smoking cessation materials.
89056495|NCT01120093|Experimental|Aclidinium bromide 100 μg bid|Aclidininum bromide 100 μg twice daily by inhalation
89056496|NCT01120093|Experimental|Aclidininum bromide 200 μg bid|Aclidininum bromide 200 μg twice daily by inhalation
89056497|NCT01120093|Experimental|Aclidininum bromide 400 μg bid|Aclidininum bromide 400 μg twice daily by inhalation
89056498|NCT01120093|Placebo Comparator|Placebo|Placebo twice-daily by inhalation
89056499|NCT01120093|Active Comparator|Formoterol 12 μg bid|Formoterol 12 μg twice daily by inhalation
89056500|NCT00581009|Experimental|1|chronobiological augmentation group
89056501|NCT00581009|Experimental|2|medication only group
89056502|NCT00581009|Experimental|MDD Mechanism|
89056503|NCT02218359|Experimental|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin to be administered by aerosol via the AFIS Inline System.
89056504|NCT02218359|Placebo Comparator|Aerosolized Placebo|Aerosolized placebo to be administered by aerosol using the AFIS Inline System.
89056505|NCT02882191|Experimental|LevoCept IUD|LevoCept IUD placement
89217628|NCT02540876|Experimental|Treatment (ilorasertib)|Patients receive ilorasertib PO BID on days 1, 8, 15, 29, and 36. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89217629|NCT04353791|Active Comparator|Experimental arm OST-122|24 subjects will be randomized to receive OST-122 orally daily for 28 days
89056506|NCT02882035|Experimental|OFA (opioid free anesthesia)|"All drugs were given IV. Induction in the opioid free group began with a loading dose of clonidine (0.2 mcg kg-1), a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).~General anesthesia was maintained with sevoflurane (MAC: 1) (adapted according to hemodynamic stability).~Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups. A bolus of ketamine (0.2mg kg -1) was given if necessary in the opioid free group (up to three bolus max. were permitted).~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
89056507|NCT02882035|No Intervention|OA (opioid anesthesia)|"All drugs were given IV. Induction in the opioid group began with remifentanil TCI, a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).~General anesthesia was maintained with sevoflurane (MAC: 1). Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups.~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
89056508|NCT02212847|Experimental|vestibular stimulation|
89056509|NCT02218398|Experimental|Bronchodilator|Albuterol 3-4 times per day, steroids when necessary.
89056510|NCT02218398|No Intervention|No drug|No drug
89056511|NCT02218437|Experimental|MSC+ATG|The first agent MSC injection, began two weeks after ATG application; Each patient was injected three times, one time per week; Study on single dose tolerance and efficacy index; Each subjects received three dose groups of treatment.
89056512|NCT04577768|Experimental|HD-tDCS 2 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 2 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
89056513|NCT04577768|Experimental|HD-tDCS 1.5 mA|Single session of 20-min HD-tDCS to the right primary motor cortex with an intensity of 1.5 mA. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
89056514|NCT04577768|Sham Comparator|Control|Single session of 20-min of sham HD-tDCS. The session lasted approximately one hour. The participants returned after 24 hours to perform a retention test.
89056515|NCT02218515|Other|Open Flap Debridement|Open Flap Debridement (Control Group)
89056516|NCT02218515|Experimental|Enamel Matrix Derivative|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)
89056517|NCT02218515|Experimental|Enamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
89056518|NCT02218554|Experimental|Study Group|Subject has been diagnosed with BRONJ
89056519|NCT02218554|No Intervention|Control Group|Subject has not developed any signs or symptoms of BRONJ
89056520|NCT04577612|Experimental|Group 1|150 mg CBD
89056521|NCT04577612|Experimental|Group 2|300 mg CBD
89056522|NCT04577612|Experimental|Group 3|600 mg CBD
89056523|NCT04577612|Placebo Comparator|Group 4|Placebo MCT oil
89056524|NCT02218671|Experimental|WE 941 OD under deglutition|
89056525|NCT02218671|Experimental|WE 941 OD under non-deglutition|
89056526|NCT01119937|Experimental|NVA237|50µg once daily
89056527|NCT01119937|Experimental|Tiotropium|18µg once daily
89056528|NCT02278731|No Intervention|Control Group|The elderly in Control Group suffered no intervention and continued with their daily activities.
89056529|NCT02278731|Active Comparator|Pilates Group|Pilates group (PG), which underwent one-month (three times per week) training program with the Pilates method. This protocol consisted of Pilates exercises on the ground.Stretches were performed on upper trunk and lower limbs before the exercises. Subsequently, exercises that included the range of motion and strength of the upper limbs, trunk and lower limbs were performed, always associated with breathing and contraction of transversus abdominis muscles, in different positions, increasing repetitions and resistance in the weeks of the study, using the Swiss ball, thera-band and the magic circle.
89056530|NCT02278731|Active Comparator|PNF Group|PNF group that underwent one-month (three times per week) training program using the propriocptive neuromuscular facilitation method.The selected PNF diagonal patterns were chosen with all the basic procedures to the facilitation and according to three specific principles of PNF: rhythmic initiation, sustain and relax and reversal of antagonists. During the first week, one set of ten repetitions for each diagonal was performed; in the second week, two sets of ten repetitions and in the third and fourth weeks, three sets of ten repetitions were performed.
89056531|NCT01119898|Experimental|PENNSAID Gel|Diclofenac sodium 2.0% w/w
89056532|NCT01119898|Placebo Comparator|Vehicle|The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
89056533|NCT04577534|Experimental|Tocilizumab (TCZ)|Participants will receive one infusion of iv TCZ (according to weight of patient)
89056534|NCT04577534|No Intervention|standard of care (no TCZ)|Participants will receive standard of care
89056535|NCT02278809|No Intervention|waitlist control group|The waitlist control group parents received the online videos when the intervention period was over.
89056536|NCT02278809|Experimental|intervention group|
89056537|NCT01119859|Experimental|Tocilizumab 8 mg/kg|Patients received 6 infusions of tocilizumab 8 mg/kg intravenously every 4 weeks and 12 injections of placebo to adalimumab subcutaneously every 2 weeks.
89217630|NCT04353791|Placebo Comparator|Control arm Placebo|8 subjects will be randomized to receive placebo orally daily for 28 days
89217631|NCT00894920|Placebo Comparator|placebo|
89217632|NCT00894920|Active Comparator|biotin|
89217633|NCT00722735|Experimental|1|Group I: Finafloxacin tablets + Ciprofloxacin placebo capsule
89217634|NCT00722735|Active Comparator|2|Group II: Ciprofloxacin capsule + Finafloxacin placebo tablets
89217635|NCT00902642|No Intervention|control group|
89217636|NCT00902642|Active Comparator|Course on psychosocial factors|an eight day university training course for physical therapists designed to integrating psychosocial factors in clinical practice on a patient level
89217637|NCT00717509||clozapine group|"chronic schizophrenia~have been taking clozapine at leaset one year~without diabetes, pulmonary tuberculosis"
89217638|NCT04067531|Other|treatment of BV|all patients be treated with first Deqularum then with clindamycin Cream,
89217639|NCT00606632|Other|124-Iodine-cG250 (124I-cG250)|Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.
89217640|NCT00713765|Experimental|A|AZD3480 + Donepezil
89217641|NCT00713843|Experimental|1 Manual Therapy Utrecht|"Manual Therapy Utrecht (MTU) During the first consultation the manual therapist enquires about the complaints of the patient. The manual therapist conducts a number of measurements according to protocol. During treatment preferred movements are executed by the manual therapist in the patient's joints. The treatment techniques used by the manual therapist are very gentle mobilizations, without high velocity thrust techniques and are in general painless. In Manual Therapy Utrecht (MTU) it is common to give advices and recommend exercises.~A treatment session lasts between 30 and 60 minutes (repeated after one or two weeks). The maximum number of sessions is six.~The manual therapist has a minimum of five years of working experience."
89217642|NCT00713843|Active Comparator|2 Physical Therapy - Exercise Therapy|"The physical therapist conducts a complaint related function examination. Treatment consist of active exercises, manual traction or stretching and massage. The aims of active exercises are improvement of strength, mobility and movement coordination. Specific mobilization techniques are not a part of physiotherapeutic treatment. Treatment sessions take place no more than twice a week with a maximum of nine sessions (approximately 30 minutes) with a minimum of twenty minutes on active exercise therapy combined with instruction.~To prevent overlap with MTU (experimental arm), physical therapists are selected who are not (also) trained as manual therapists or have started this education.~The physical therapist has at least five years of working experience."
89217643|NCT00894998|Experimental|1|Heparin sodium 5.000 UI - Cristália
89217644|NCT00894998|Active Comparator|2|Heparin Sodium 5.000 USP - APP
89056538|NCT01119859|Active Comparator|Adalimumab 40 mg|Patients received 12 injections of adalimumab 40 mg subcutaneously every 2 weeks and 6 infusions of placebo to tocilizumab intravenously every 4 weeks.
89056539|NCT02278926||Patients ultrasound lypo-hypertrophy identification|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
89056540|NCT02278926||Control group|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
89056541|NCT01119703||Arm 1: Healthy, elderly participants|Healthy participants 65 years old and older.
89056542|NCT01119703||Arm 2: Healthy, young, participants|Healthy participants 25 to 40 years old.
89056543|NCT04554446|Experimental|T-MSAT(Motion style acupuncture treatment using Traction)|T-MSAT group receives 3 sessions of T-MSAT; on 2nd, 3rd, 4th day after hospitalization. A trained doctor of Korean medicine with clinical experience conducted the T-MSAT. And T-MSAT group is also treated with other Korean integrative medicine treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
89056544|NCT04554446|Active Comparator|Korean medicine treatment|The control group is received Korean integrative medicine treatment everyday; acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
89056545|NCT02218710||Growth hormone deficiency|
89056546|NCT02218710||healthy controls|
89056547|NCT02218749|Experimental|Initially triaged to physiotherapist|Initially triaged to physiotherapist
89056548|NCT02218749|Active Comparator|Initially triaged to physician|Initially triaged to physician
89056549|NCT02882230||exposition to the drugs|patients treated with at least one of the following drugs: dolutegravir, elvitegravir and rilpivirine
89056550|NCT02882230||patients non exposed to the drugs|
89056551|NCT00581087|Experimental|1|DHEA
89056552|NCT00581087|Placebo Comparator|2|Placebo
89056553|NCT01119625|Experimental|Synflorix™ Commercial-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of commercial lot of Synflorix™ co-administered with Rotarix™ and Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
89056554|NCT01119625|Active Comparator|Synflorix™ Clinical-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of clinical lot of Synflorix™ + Rotarix™ co-administered with Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (clinical and commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
89056555|NCT02218827|Experimental|dry eye patients|Loteprednol Etabonate (FML) topical treatment 1 drop 4 times daily for 1 month then Loteprednol Etabonate (FML) 1 drop 2 times daily for 1 month
89056556|NCT00581126|Experimental|1|Patients will receive Benefix IV according to blood amount
89056557|NCT02218866||Group 1|All participants will be examined by a neurologist to test sensation, reflexes, and strength and complete a few questionnaires. Tests will be performed to measure nerve function and small punch skin biopsies will be taken to assess nerve fiber density. Blood and urine tests will measure various markers of interest. Participants will be seen before and after their bariatric surgery.
89056558|NCT02218866||Group 2|"In addition to the procedures described for Group 1, participants in Group 2 will have the following procedures:~During bariatric surgery, a small biopsy from the liver and abdominal fat will be taken to examine how fat is processed within the body.~At the first visit, after a skin biopsy is taken, a small capsaicin patch will be placed on the lower thigh. The patch will remain in place for 48 hours and will cause the nerves in the immediate area to pull back from the skin. A biopsy will be taken from the patch area 48 hours, 1 month, and 3 months after the initial biopsy. This procedure will be repeated after surgery.~MRIs may be performed before and after bariatic surgery.~Participants may be asked to complete additional tests to evaluate nerve function"
89056559|NCT02218866||Group 3|Group 3 will comprise of individuals who are not overweight. Participants in this group will undergo a similar evaluation to Group 2.
89056560|NCT04553978|Experimental|Treatment A|"After an overnight fasting of at least 10 hours, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.~Subjects will be in sitting posture or ambulatory posture for the first 04 hours post-dose unless medically necessary."
89056561|NCT04553978|Experimental|Treatment B|"At least 03 hours after taking dinner, a single oral dose of WD-1603 Extended-Release Carbidopa/Levodopa Tablets will be administered to the subjects at ambient temperature by the trained study personnel.~Subjects will be in supine/lateral recumbent positions post-dose till morning when they will wake up unless medically necessary."
89056562|NCT04307719||Mexican Jewish Community|Sample of Patients from the Mexican Jewish Community to be subjected to genetic testing
89056563|NCT02881918||squamous cell carcinoma|Patients affected by Head & Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment
89056564|NCT02881762|Active Comparator|Immediate start maraviroc|To start maraviroc immediately after randomization.
89056565|NCT02881762|Active Comparator|Delayed start maraviroc|To start maraviroc 8 weeks after enrollment.
89056566|NCT02218905|Experimental|Sit to stand test|One minute sit to stand in 40 inches armless chair. Fatigue, breathlessness and failure to maintain tempo will lead to decease the test
89056567|NCT04554017|Experimental|Intervention arm - All participant (Single arm)|Participants received education or health talks on dietary and physical activity behaviours linked to hypertension
89056568|NCT04561947|Active Comparator|TT+CTG|The combined connective tissue graft (CTG) with tunnel technique (TT)
89056569|NCT04561947|Experimental|TT+CGF|The combined concentrated growth factor (CGF) membrane with tunnel technique (TT)
89056570|NCT01119118|Experimental|1|ZD4054 + multimodal PET/MRI imaging
89056571|NCT04577339||Adult patients with acute abdominal conditions|"All adult patients >=16years of age on all general adult wards (excluding maternity) between 2013 and 2020 with the following inclusion and exclusion criteria:~Inclusion criteria:~Must have an acute intestinal condition, based on their ICD-10 codes and OPSC-4 codes~Must be >= 16 years of age at the time of admission~Have at least one full set of vital signs recorded on the day of admission~Have at least one full set of routine blood tests recorded on the day of admission~Exclusion criteria:~Maternity admissions during/after pregnancy~Patients admitted or undergoing abdominal surgery for a second time or more"
89056572|NCT01119001|Experimental|P300 Brain Computer Interface for people with ALS|
89056573|NCT02212925|Experimental|BI 14332 CL|
89056574|NCT02212925|Placebo Comparator|Placebo|
89056575|NCT01118962|Experimental|Lacosamide|"Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949).~Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses."
89056576|NCT04561830|Active Comparator|group 1|underwent laparoscopic-assisted excision of mesorectum
89056577|NCT04561830|Active Comparator|group 2|open excision of mesorectum
89056578|NCT05362006|Active Comparator|Active|Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
89056579|NCT05362006|Sham Comparator|Sham|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
89056580|NCT05092984|Experimental|Spironolactone|
89056581|NCT05092984|Placebo Comparator|Placebo|
89056582|NCT02218944|Experimental|Response Inhibition Training: A|In the experimental condition, 20% of responses are no-go, with the majority of no-go responses paired with smoking images.
89056583|NCT02218944|Active Comparator|Response Inhibition Training: B|In the active comparator condition, 20% of responses are no-go trials, with no-go responses spread evenly across the various images.
89056584|NCT02218944|Placebo Comparator|Benign|A benign condition has also been added to control for the possibility that response inhibition training, regardless of target, increases behavioral control and hence decreases relapse likelihood. The benign condition has 50% no-go trials, with no-go responses spread evenly across images.
89056585|NCT01118728|Experimental|Sarilumab|Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.
89056586|NCT02218983|Experimental|Limited transthoracic echocardiogram (LTTE)|LTTE (SonoSite Ultrasound), which will be performed every 10 - 30 minutes, after each fluid challenge or transfusion, until two consecutive equivalent measurements are reached without fluid challenge or transfusion
89056587|NCT02218983|Active Comparator|Usual care|measurements on :blood pressure, heart rate, urine output, lactate, lactate clearance (after 6 hrs), base deficit, creatinine
89056588|NCT02213120||Dizziness|Patients with Dizziness
89056589|NCT02219022|Active Comparator|Control group|Patient remain with their usual clinical treatment.
89056590|NCT02219022|Experimental|Experimental group|"Patients in experimental group participated in a 12-week progressive resistance training using a maximum repetition exercise in which patients performed 1 Maximum Repetition with the maximum bearable weight. Once the 1 Maximum Repetitionwas determined, training was divided into the following regimen: 2 series of 8 repetitions, the first with 50% and the second with 70% of 1 Maximum Repetition.~The exercises were knee extension and flexion and hip abduction and adduction, elbow extension and flexion, wrist extension and flexion and shoulder abduction and adduction and spine extension and flexion all performed in machines. The 1 Maximum Repetition load was reevaluated every 6 weeks.~Patient remain with their usual clinical treatment."
89056591|NCT02213159|Active Comparator|Dexmedetomidine|prior to anticipated end of surgery bolus of 1 microgram/kg Dexmedetomidine intravenously over 10 minutes followed by 0.5 micrograms/kilogram/hour intravenous infusion until removal of laparoscopes
89056592|NCT02213159|Active Comparator|Morphine|prior to anticipated completion of surgery morphine 0.08 mg/kilogram intravenous bolus over 10 minutes followed by a saline infusion until removal of the laparoscopes
89056593|NCT02219061||GMT|
89056594|NCT00581282||1|Cocaine abstinent group
89056595|NCT00581282||2|Normal healthy control group
89056596|NCT01118455|Experimental|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
89056597|NCT01118455|Experimental|Anti-Epileptic Drug (AED)|This arm will supply a comparison between VNS and new AEDs which is necessary to determine an overall treatment regimen for the 30% to 40% of patients who fail to respond to 2 AEDs.
89056598|NCT02219100|Experimental|Home administration of mifepristone|This arm consisted of women who chose home administration of 200 mg mifepristone.
89056599|NCT02219100|No Intervention|Clinic administration of mifepristone|This arm consisted of women who underwent clinic administration of 200 mg mifepristone.
89056600|NCT04553861||Healthy subjects|Healthy subjects without blood pressure difference on both arm
89056601|NCT02219139|Other|ESTA abutment Roxolid|"One study abutment per patient will be placed. After healing for 6 to 7 weeks, patients will be asked to stop oral hygiene at the study site for 2 weeks.~Sulcus fluid and plaque samples will be taken at the abutment site at several visits before and during abdication of oral hygiene.~The study finishes with biopsy visit. Afterwards a regular abutment will be placed and the patients will be treated according to the standard protocol of the clinic to obtain their final restoration."
89056602|NCT04561752|Experimental|Treatment Sequence A-B|Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
89056603|NCT04561752|Experimental|Treatment Sequence B-A|Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.
89056604|NCT00581438||1|
89056605|NCT01118377|Experimental|Capecitabine + radiation therapy|Participants received 9 weeks of capecitabine 650 mg/m^2 orally (po) twice daily (bid) plus radiation therapy (180 cGy/day 5 days a week, total target dose of 56 Gy) followed by a 2-week rest period. Participants then received 3 cycles of capecitabine 1250 mg/m^2 po bid for 14 days followed by a 7-day rest period without radiation therapy.
89056606|NCT04577222|Experimental|Adipose Flap|Covering neurovascular bundle with fat
89056607|NCT04577222|No Intervention|Control|No adipose flap
89688150|NCT04376047|Experimental|Reverse Trendelenburg position group|Obese critically ill patients who are positioned in reverse Trendelenburg position
89688151|NCT04376047|Active Comparator|Semi-recumbent position group|Obese critically ill patients who are positioned in semi-recumbent position which is the routine ICU position
89056608|NCT02219178|Experimental|RsqVD|Oral lenalidomide 25mg days 1 - 14 of 21 day schedule Subcutaneous bortezomib 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule Oral dexamethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
89056609|NCT02213315|Experimental|100mg arm|100mg dose
89056610|NCT02213315|Experimental|150mg arm|150mg dose
89056611|NCT02213315|Placebo Comparator|Placebo|Placebo
89688152|NCT04379609||Employees and students|The control group was selected from among the employees and students of the faculty of dentistry to represent the general population without any temporomandibular disorder (TMD).
89688153|NCT04379609||Patients|Patients who were referred to the Ondokuz Mayıs University Faculty of Dentistry Department of Prosthodontics with a complaint of pain in the chewing muscles were enrolled in this study.
89688154|NCT04366141|Experimental|COVID-19 barrier box intervention group|Attending anesthesiologists will use a COVID-19 barrier box for intubating the patient participants of this group.
89688155|NCT04366141|No Intervention|Control group|Attending anesthesiologists will use standard intubation procedures.
89688156|NCT04379375|Active Comparator|Inertia|"Participants simply receive and subsequently have default access (i.e., readily and immediately available) to handwashing (HW) materials. This condition will functionally serve as a control comparison. As the term implies, inertia capitalizes on minimizing effort necessary (e.g., going to the grocery store) to engage in HW behavior in one's personal environment."
89688157|NCT04379375|Experimental|Anchoring|"Involves once again providing default access to HW materials as above, but adds an explicit written cue to wash hands at a rate of (15) times per day, which is placed directly on the soap dispenser. The stimulus is intended to deliberately prime participant thinking (and subsequent behavior) towards a higher reference point that overshoots a desired target rate of 10+ daily HWs."
89688158|NCT03834233|Experimental|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
89688159|NCT04367389|Experimental|Intervention|Participants receive a physical activity promotion intervention as well as an individualized exercise plan.
89688160|NCT04367389|No Intervention|Control|
89688161|NCT01727375|No Intervention|Standard light|In this arm patients receive standard lightening conditions
89688162|NCT01727375|Experimental|Ciradian light|In this arm patients receive artificial ceiling light (circadian light) at the bedside.
89688163|NCT04367545|Experimental|Patient with COVID-19 infection suspicion|Patient with COVID-19 infection suspicion are tested using standard diagnosis method
89688164|NCT03407963|Experimental|Prostate cancer patients|
89688165|NCT04367155|Active Comparator|tranexamic acid local|tranexamic acid inside the irrigation fluid
89688166|NCT04367155|Active Comparator|tranexamic acid IV|tranexamic acid injection
89688167|NCT01727453|Active Comparator|Bemiparin|Group 1 (low molecular weight heparin: bemiparin), which is the study group: after passing the bleeding episode, will receive low molecular weight heparin (bemiparin) in anticoagulant dose. Check should be made by measurement of anti-factor Xa.
89056612|NCT02219217|Experimental|No arms|All participants will be administered Tivicay® (dolutegravir 50 mg once daily) for 10 days, then will undergo a nine-day wash out period and then take Stribild® (245 mg of tenofovir disoproxil, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days.
89056613|NCT02213393|Experimental|Protein enriched products|The intervention group receives protein enriched products (CwC products) in the hospital and receives these also after discharge during 12 weeks.
89056614|NCT02213393|Active Comparator|Usual menu|The control group receives the usual protein and energy rich menu in the hospital and receives regular products, no protein enrichment, after discharge during 12 weeks.
89056615|NCT04577378|Active Comparator|13 cis retinoic acid doses orally|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
89056616|NCT04577378|Sham Comparator|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconzaole powder: single dose of 5mg/kg/day for 14 days
89056617|NCT04577378|No Intervention|control|No intervention
89056618|NCT02211573|No Intervention|Control group|Patients of this group don't performed physical training
89056619|NCT02211573|Experimental|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
89056620|NCT04553627|Experimental|Interventional cohort|Zeltiq system is a thermoelectric device that applies controlled cooling ot skin. The CoolAdvantage applicators use gentle vacuum pressure to draw tissue into the cup shaped applicator. A gelpad is applied to skin to improve thermal coupling between participant and the applicator cooling surface.
89056621|NCT02219412|Experimental|ticagrelor mono-therapy|Take ticagrelor 90 mg Bid for 2 weeks.
89056622|NCT02219412|Active Comparator|aspirin/ticagrelor dual-therapy|Take ticagrelor 90mg Bid plus Aspirin 100mg Qd and treated for 2 weeks.
89056623|NCT04577027|Experimental|vitiligo patients|Thirty Patients complaining of generalized non segmental vitiligo will be recruited in this study. They will be chosen from the attendants of the out-patient clinics of Dermatology, Assiut university hospital. six patches will be selected in each patient.
89056624|NCT02211612|Experimental|Saturated fatty acids (SFA)-group|Weight gain created by addition of muffins baked on saturated fat
89056625|NCT02211612|Experimental|Polyunsaturated fatty acids (PUFA)-group|Weight gain created by addition of muffins baked on polyunsaturated fat
89056626|NCT04553315|Experimental|intervention group|Intervention group was received Chest mobility exercises with Incentive spirometer and segmental breathing exercise and breath stacking technique . The patient in the intervention group was instructed to perform the exercises 3 times per day, 7-8 times per session for one week. Ensure that the patient fully hydrated by maintaining normal daily water requirement in the form of (30-35ml/kg/day) with restriction of intravenous fluids.
89056627|NCT04553315|Experimental|control group|control group will receive only routine hospital care
89056628|NCT02211690|Experimental|dolutegravir 50mg with co-formulated emtricitabine-tenofovir|One-hundred eligible participants will receive dolutegravir (1 x 50mg tablet) with co-formulated emtricitabine-tenofovir (1 tablet) once daily for 28 days
89056629|NCT04553393|Active Comparator|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem dual Specificity targeting CD19 and CD20 decitabine-primed CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 and improve the possibility of killing lymphoma tumor cells.
89056630|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
89056631|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
89056632|NCT04553393|Experimental|Decitabine-primed Tandem CAR19/20 engineered T cells plus chidamide+decitabine|The combination of chidamide and decitabine can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function, induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance
89056633|NCT02219451|Experimental|exercise training|We studied twenty-six chronic heart failure outpatients and they were assigned to 2 groups: Untrained (n=13) and trained (n=13).
89056634|NCT04553588|Active Comparator|Opioid Disposal Pouch|an opioid disposal pouch to inactivate and dispose of unused opioid medication within the first 30 days after surgery
89056635|NCT04553588|No Intervention|Usual Care|usual medication disposal includes multiple options as desired by patient; for example, flushing down toilet, giving to local pharmacist, giving to police department etc.
89056636|NCT02211807||Patients initiating an Efavirenz|Patients initiating an Efavirenz-containing antiretroviral regimen
89056637|NCT02211807||Patients initiating an Efavirenz-free regimen|
89056638|NCT02211846|Experimental|Mirabegron|Administered under fed and fasted conditions
89056639|NCT02219568|Experimental|obscure gastrointestinal bleeding|Those patients who developed obscure gastrointestinal bleeding either overt or occult bleeding who will then undergo video capsule endoscopy and CT enterography.
89056640|NCT02219607||epidural|
89056641|NCT02219607||general anesthesia|
89217645|NCT02572895|Active Comparator|Optimal dose|One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.
89217646|NCT02572895|Placebo Comparator|Control dose|One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
89056642|NCT02219646|Experimental|Vardenafil|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Study Group were treated with vardenafil 10 mg twice/daily.
89056643|NCT02219646|Placebo Comparator|Control|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Control Group were treated with tablets twice/daily identical to the Study Group, but containing placebo.
89056644|NCT04553510|Experimental|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
89056645|NCT04553510|Active Comparator|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
89056646|NCT02219724|Experimental|MOXR0916: Dose Escalation Stage|Participants in different cohorts (according to MOXR0916 dose received) will receive escalating doses of MOXR0916 to determine the MTD or maximum administered dose (MAD) for 21 to 42 days.
89056647|NCT02219724|Experimental|MOXR0916: Expansion Stage|Participants in different cohorts (according to different cancer types, prior therapy and mandatory procedures on study) will receive MOXR0916 at the highest dose level that has already been deemed to be tolerable in the dose escalation stage until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (approximately up to 3 years).
89056648|NCT01642017|Experimental|Pazopanib|Pazopanib : 3 dose levels are defined : 400, 600 and 800 mg per day.
89056649|NCT00581594|Other|1|Posterior repair with graft augmentation.
89056650|NCT00581594|Other|2|Posterior repair without graft augmentation.
89056651|NCT01642095||Basic science (FAK expression)|Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
89056652|NCT03453281|Experimental|Aflibercept Injection [Eylea]|Intravitreal injection of 2 mg in 0.05 ml Aflibercept. Frequency: once Duration: 10-15 minutes
89056653|NCT02219841||No intervention group|Receive general life-style advice and information on heart healthy diet Undergo catheter ablation for AFib
89056654|NCT02219841||Life-style intervention|patients will receive personilized low-calorie diet menu and undergo supervised exercise in the cardiac rehabilitation facility for 3 months before ablation with an aim of loosing >10% of body weight. They will continue diet and exercise for 1 year following ablation procedure Will receive catheter ablation for AFib
89056655|NCT04553159|Experimental|Adipose Derived Stem Cell(ADSC) arm|"Participants allocated to this arm will have tumescent liposuction performed on them to obtain lipoaspirate. The lipoaspirate will then be processed to obtain the stromal vascular fraction. This Adipose derived stromal vascular fraction which contains stem cells will then be infiltrated into the keloid tissue as a single dose infiltration.~This will be harvested and infiltrated as the whole cell pellet (stromal vascular fraction) comprising of an estimate total of 9 million ADSCs (range: 8.4-9.72; SD ± 6.6)."
89217647|NCT00906854||Group I|practice of weight training exercises
89217648|NCT00906854||Group II|aerobic exercises as part of lessons jump, step and dance classes
89056656|NCT04553159|Active Comparator|Triamcinolone Acetanoide (TAC) arm|Participants in this arm will receive a single dose Triamcinolone acetanoide infiltration into the keloid. This will be a single dose infiltration of 40mg/cubic centimetres of keloids.
89056657|NCT01642134|Active Comparator|Duoplavin|Both active substances in DuoPlavin: clopidogrel and acetylsalicylic acid, are inhibitors of platelet aggregation. Clopidogrel stops the platelets aggregating by blocking ADP. Acetylsalicylic acid the platelets aggregating by blocking the prostaglandin cyclo oxygenase.
89056658|NCT01642134|Sham Comparator|acenocumarol|
89056659|NCT04552964|Other|Single arm|This will be a single centre, single-arm, prospective pilot study.
89056660|NCT03453086|Active Comparator|Group I:|These patients will receive single ipsilateral Ultrasound TPVB which performed with the patient in the sitting position at the level of the T4 with the probe in a vertical position 2.5-3 cm lateral to the midline. The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes which visualized with the superior costo-transverse ligament and the pleura visible in between . After this, 15-20 cc of bupivacaine 0.25% will be injected
89056661|NCT03453086|Active Comparator|Group II :|These patients will receive serratus anterior plane block. The block will be performed while the patient is in the supine position by using a linear Ultrasound probe of high frequency (6-13 MHz) after sheathing. The probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted inferiorly and laterally, until the 5th rib is identified in the midaxillary line. The latissimus dorsi (superficial and posterior) , teres major (superior) and serratus muscles (deep and inferior) will be then easily identifiable by U/S overlying the fifth rib.
89057751|NCT04530422|Active Comparator|Group II (Oseltamivir plus HCQ & Azithromycin)|"Patients in this group (125 patients) were received the local medical committee of Almaza Fever Hospital guided standard treatment protocol for COVID-19:~Oseltamivir 150 mg q 12 hours for 10 days ;~HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.~Additional conservative medications were also given. Patients were evaluated as scheduled on day 0, 5 & 11 clinically"
89217649|NCT00906854||Group III|swimming (crawl mode)
89217650|NCT00717665|Experimental|A, 1, I|
89217651|NCT00717665|Active Comparator|A, 2, I|
89217652|NCT04067453||Patients undergoing fatiguing protocol|patient consulting for anorectal manometry in order to explore anorectal disorders with a voluntary command on external anal sphincter
89217653|NCT00717743||1|Patients diagnosed with RCC.
89056662|NCT03453047||1|Healthy volunteers. Liver donor groups; Course of the research: Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
89056663|NCT03453047||2|Liver transplant groups;Course of the research Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
89056664|NCT02219880|Placebo Comparator|Placebo|Inert tablets matched for colour, size and consistency to active arm treatment. Both treatment arm tablets will match in appearance, and neither participants nor the trial clinicians will know what they are taking.
89056665|NCT02219880|Experimental|Kava - standardised 240mg kavalactones|Standardised 240mg kavalactones per day - fixed dose regime of two tablets of kava twice per day
89056666|NCT04553042|Experimental|Treatment Sequence ABC|Participants will receive a single dose of seltorexant as formulation (Test 1) (Treatment A) in Treatment Period 1, followed by a single dose of seltorexant as formulation (Test 2) (Treatment B) in Treatment Period 2, followed by a single dose of seltorexant as formulation (Reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
89056667|NCT04553042|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
89056668|NCT04553042|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
89056669|NCT04553042|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
89056670|NCT04553042|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
89056671|NCT04553042|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.
89056672|NCT01642173|Other|OCT at baseline|"Subjects enrolled in the NIH funded and IRB approved (08-008161) protocol Lp-PLA2 and Coronary Atherosclerosis in Humans with a positive diagnosis of coronary artery endothelial dysfunction will be studied using Optical Coherence Tomography during the angiogram at baseline."
89056673|NCT01642173|Other|OCT following 6 month Lp-PLa2 inhibition|"Subjects who are enrolled in IRB 10-000044 Lp-PLA2 and Coronary Atherosclerosis in Humans Aim III a study in which the investigators are examining the impact of long-term inhibition of Lp-PLA2, with a specific novel inhibitor or placebo, on Lp-PLA2 activity and improvement in coronary endothelial function will be studied using Optical Coherence Tomography during the 6 month return angiogram."
89056674|NCT02213432|Experimental|Day 1 vaccination|"Different timing of influenza vaccination: Day 1~Day 1 vaccination group: patients will be vaccinated against influenza at the day (Day 1) when chemotherapy starts."
89056675|NCT02213432|Active Comparator|Day 11 vaccination|"Different timing of influenza vaccination: Day 11~Day 11 vaccination group: patients will be vaccinated against influenza at the 11th days after chemotherapy starts"
89056676|NCT02219919|Experimental|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
89056677|NCT02219919|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
89056678|NCT02213471||Elevated risk for melanoma|Individuals at increased risk for melanoma due to past history of melanoma, family history of melanoma, the presence of many moles, the presence of a genetic mutation known to increase the risk of melanoma.
89056679|NCT01118299|Experimental|Device|AMPLATZER Cardiac Plug
89056680|NCT01118299|Active Comparator|Optimal Medical Therapy (control)|Warfarin Dabigatran
89056681|NCT02219958||RAMP-HT and Non-RAMP-HT|
89056682|NCT04552574|Experimental|Intervention group|All subjects will intake HMR(Home meal replacement)-type omega-3-balanced-diet for 4 weeks.
89056683|NCT04552574|No Intervention|Control group|No intervention for 4 weeks.
89056684|NCT01118143|Experimental|intervention group|Tailored oral health literacy instruction
89056685|NCT01118143|No Intervention|control group|Oral health instruction not tailored to oral health literacy level
89056686|NCT00581711|No Intervention|Control|Usual Care
89056687|NCT00581711|Experimental|HIT Intervention without feedback|3-Part Intervention: Training, Otitis Media Episode Grouper, Clinical Decision Support
89056688|NCT00581711|Experimental|HIT Intervention with feedback|4-Part Intervention: Training, Episode Grouper, Clinical Decision Support, and Physician Feedback.
89056689|NCT00581711|Experimental|Feedback only|1 part intervention: Physician Feedback
89056690|NCT00581750||LCIS diagnosis|Patient with LCIS diagnosis
89056691|NCT00581789|Experimental|1|Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
89056692|NCT01642368|Placebo Comparator|Regular Diet|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
89056693|NCT01642368|Active Comparator|Medium Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
89056694|NCT01642368|Active Comparator|High Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
89056695|NCT02213549|Placebo Comparator|Placebo|3 placebo capsules/day for 12 weeks
89056696|NCT02213549|Experimental|Ume paste and ginger powder|3 experimental capsules/day for 12 weeks.
89056697|NCT01642446|Experimental|surgery|Precise hepatectomy
89056698|NCT01642446|Active Comparator|combined intervention|transcatheter hepatic arterial chemoembolization and/or ablation
89056699|NCT02213588|Active Comparator|AOX blend|Rosemary:Quercetin:Turmeric (300 mg total)
89056700|NCT02213588|Placebo Comparator|Placebo|Maltodextrin
89056701|NCT01642524|Experimental|hypertonic saline mixed Dextran|hypertonic saline mixed Dextran
89056702|NCT01642524|Placebo Comparator|Placebo controlled|Saline solution
89056703|NCT02213705|Experimental|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide
89056704|NCT02217228|Experimental|Sebacia microparticles and laser|Gold microparticle suspension + laser treatment x 3 over the course of two weeks
89056705|NCT02217228|Experimental|Vehicle suspension and laser|Vehicle suspension + laser treatment x 3 over the course of two weeks
89056706|NCT02217228|Experimental|Sebacia microparticles without laser|Gold microparticle suspension treatment x 3 over the course of two weeks
89056707|NCT02213783|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 2-5 days
89056708|NCT02213783|Experimental|Extended infusion arm|Infusion of 0.5 g of imipenem for 4 hr every 6 hr for 2-5 days
89056709|NCT01642563|Experimental|Pathogen reduced platelets|Transfusion
89056710|NCT01642563|Active Comparator|Standard platelets|Transfusion
89056711|NCT01642680|Experimental|Physical activity during chemotherapy|This group will start with a physical activity program 3 months before the end of their chemotherapeutic regimen. After chemotherapy they will continue the PA program for another 3 months.
89056712|NCT01642680|Active Comparator|Physical activity after chemotherapy|This group will start with a physical activity program after the end of their chemotherapeutic regimen. The physical activity program wil take 6 months to complete.
89056713|NCT00582101|Experimental|Family-based HIV|
89056714|NCT00582101|Active Comparator|Family-based HP|
89056715|NCT01642719|Placebo Comparator|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline
89056716|NCT01642719|Experimental|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks. For example, if they spend 9 hr TIB during baseline, they will reduce their TIB to 8 hr.
89056717|NCT00582140|Experimental|Cohort Level 1|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
89056718|NCT00582140|Experimental|Cohort Level 2|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
89056719|NCT00582140|Experimental|Cohort Level 3|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
89056720|NCT01642758|Experimental|Sodium 2,2 dimethylbutyrate|A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
89056721|NCT00582179|Active Comparator|1, A|Group A patients will be treated with a pressure dressing and observation.
89056722|NCT00582179|Active Comparator|2, B|Group B patients will be treated with a Vacuum Assisted Closure device (VAC).
89056723|NCT01642797|Experimental|CLE-TB|Confocal laser endomicroscopy with Targeted Biopsy
89056724|NCT01642797|Experimental|WLE-SB|Standard White-light endoscopy with Standard Biopsy
89056725|NCT04552379|Active Comparator|Interferon|Peginterferon beta-1alfa will be made available from Biogen Inc. Switzerland. 125 micrograms of pegylated IFNß1alfa (PLEGRIDY, Biogen) administered on Study Days 1, 6 and 11 (i.e. for a total of 3 doses) via subcutaneous injection.
89056726|NCT04552379|No Intervention|Standard of Care|Standard of Care; following national guidelines regarding self-isolation and infection prevention
89056727|NCT02215668|No Intervention|No physical exercise|Women are never subjected to any exercise prior to mammography.
89056728|NCT02215668|Experimental|Physical exercise (Upper limb)|Women will be subjected to physical exercise on upper limb prior to mammography.
89056729|NCT02215668|Active Comparator|Group 2|Women are subjected to physical exercise in the lower limbs prior to mammography
89056730|NCT01642836|Experimental|multi-component, multi-level, multi-setting (MMM)|"a theory-based community team sports program designed specifically for overweight and obese children,~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~a primary care provider behavioral counseling intervention linked to the community and home interventions."
89217654|NCT02571335|Experimental|Intensive Training|Treatment consists of endurance training in both groups of physiologically defined heart rate controlled cycling at 50-60 rounds per minutes (rpm) and progressive resistance training. Training groups differ in the applied intensities and frequencies.The IT will train less frequent but training sessions will be more intensive in its effects. Training will be performed daily in six sessions (three morning and three afternoon sessions), synchronized and individually matched to a ratio of active versus passive sessions of 2:1.
89217655|NCT02571335|Active Comparator|Normal Training|The NT is the normal training performed out of the daily routine and outlines the usual care of the Valens clinic. Training will be performed in up to eight training sessions that will not be synchronized and not individually matched to a ratio of active versus passive sessions.
89217656|NCT04067375||Pregnant women, HPA-1a positive|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a positive.
89217657|NCT04067375||Pregnant women, HPA-1a negative with HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and have formed anti-HPA-1a alloantibodies.
89217658|NCT04067375||Pregnant women, HPA-1a negative without HPA-1a alloantibodies|RhD or Rhc negative women, identified through prenatal screening for red cell alloimmunization, that are typed as HPA-1a negative and did not have formed anti-HPA-1a alloantibodies.
89217659|NCT02571413|Other|oral presentation|"Scoring the correct use of INC before, immediate after and 3 months after oral presentation without demonstration how to use INCS"
89217660|NCT02571413|Other|animated cartoon-aided VDO|"Scoring the correct use of INC before, immediate after and 3 months after animated cartoon-aided teaching how to use INCS"
89217661|NCT00713999|Experimental|STI/PZQ 1|Baseline and post-treatment follow-up (anti-STI and praziquantel Rx)
89217662|NCT04072601|Experimental|Atorvastatin|Atorvastatin 10-20 mg for 18 months of treatment. Start dose is 10 mg, adjusted to 20 mg after 15-30 days if no sideeffects occurs.
89217663|NCT04072601|Placebo Comparator|Control|Placebo of atorvastatin 10 mg, 1-2 tablets for 18 months of treatment. Start dose is 1 tablet (10 mg placebo), adjusted to 2 tablets (20 mg placebo) after 15-30 days if no side effects occurs.
89217664|NCT00717821|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
89217665|NCT00717821|Active Comparator|Epoetin Beta or Darbepoetin Alfa|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will continue to receive the same treatment (epoetin beta or darbepoetin alfa at the same dose, same administration intervals, and the same route of administration). When necessary, dose adjustments will be performed according to Summary of Product Characteristics (SmPC). Total duration of treatment will be up to 48 weeks.
89217666|NCT00714077||adjuvant capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
89217667|NCT00714077||adjuvant oxaliplatin and capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
89217668|NCT00722891|Active Comparator|Purevision Lens with ReNu|Purevision Lenses with ReNu Multiplus Solution
89217669|NCT00722891|Active Comparator|Purevision Lenses with RepleniSH|Purevision Lenses with Optifree RepleniSH Solution
89217670|NCT00717899|Active Comparator|1|School children from Haifa bay region, Israel.
89217671|NCT02571257|Placebo Comparator|Placebo|Placebo treatment on stable background statin therapy
89217672|NCT02571257|Experimental|Gemcabene 300 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
89217673|NCT02571257|Experimental|Gemcabene 900 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
89217674|NCT00714155||1|Physical examination, questionnaires, retrospective chart review
89217675|NCT00714155||2|Questionnaires, retrospective chart review
89217676|NCT00714155||3|Retrospective chart review
89056731|NCT01642836|Active Comparator|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~notification of primary care providers about metabolic measures and blood pressure~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
89056732|NCT01117987|Experimental|Core imatinib|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
89056733|NCT01117987|Experimental|Core placebo|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
89056734|NCT02215902|Experimental|Hemopurifier|Affinity plasmapheresis
89056735|NCT02213822||Pts with Solid Tumors/ Hematological Cancer|Patients on this study must have either a suspected or confirmed solid tumor or hematological cancer. The intervention performed in this study is the molecular analysis of cancer. The samples will be taken at the time of the patient's planned diagnostic or staging procedure. If the patient is scheduled for surgery a sample of tissue not required for their diagnosis will be obtained and used for this research study. If the patient has undergone a previous diagnostic procedure, some of the stored tissue from that procedure will be submitted for molecular analysis as well.
89056736|NCT01117870|Placebo Comparator|Placebo|The needle will be continuously stimulated at a low voltage to give a sensation of PRF treatment.
89056737|NCT01117870|Experimental|Pulsed Radiofrequency|PRF will be applied for 120 seconds at 42 degrees celsius.
89056738|NCT01642875|Experimental|EN|early enteral nutrition with standard enteral formulas administered through a nasojejunal tube
89056739|NCT01642875|Active Comparator|PerOs|early oral nutrition with hospital diets and oral formulas
89056740|NCT01117792|Experimental|S-ICD System|
89056741|NCT04552184|Active Comparator|GPOEM|
89056742|NCT04552184|Sham Comparator|SHAM|
89056743|NCT02219490|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.
89056744|NCT01117480||Moderate-to-severe rheumatoid arthritis|Participants with moderate-to-severe rheumatoid arthritis treated with adalimumab in routine clinical practice
89056745|NCT04310722||Gram-negative bacilli and MRSA infections in ICU|Carbapenem-resistant Gram-negative bacilli [Carbapenem-resistant Acinetobacter baumannii (CRAB), Carbapenem-resistant Klebsiella pneumoniae (CRKP), and Carbapenem-resistant Pseudomonas aeruginosa (CRPsA) ] and methicillin-resistant Staphylococcus aureus (MRSA) is prevalent around the world, and the isolation rate and resistance rate has increasing in China, especially in ICU. So, investigators aim to study transmission mechanism, resistance mechanism and horizontal transfer mechanism of these pathogens.
89056746|NCT00582374||A|Pregnant Women
89056747|NCT04310605||Step 1 only|Participants in the study who only receive Step 1 of specialised CBT
89056748|NCT04310605||Step 1 and 2|Participants who receive both Step 1 and Step 2 of speciliased CBT for tinnitus.
89056749|NCT01117051|Placebo Comparator|placebo|placebo
89056750|NCT01117051|Active Comparator|Resolor|prucalopride
89056751|NCT01642953|Experimental|Early recovery|"Patients who enroll in this arm are supplied a liquid diet one day before surgery without bowel preparation.~After gastric cancer surgery, they start sips of water on postoperative first day, and they are discharged once they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination."
89056752|NCT05360173|Experimental|Experimental group|The experimental group not only have the routine treatment, but have acupressure when they back to the ward with the following 3 days . The effectiveness evaluation was carried out by the same researcher before and after intervention. There are three assessments in this study: primary outcome including postoperative pain and bowel movement. The short-form McGill Pain Questionnaire is used to measure the quality of pain, Visual Analog Scale is used to the pain intensity and stethoscope is used to listen to the bowel sound. The study, also, will be recorded postoperative exhaust time, the postoperative date of Indwelling drainage tube and postoperative length of stay.
89056753|NCT05360173|Sham Comparator|Control group|The control group will have the same treatment and the evaluation, except received sham acupoint.
89056754|NCT01642992||Coronary bifurcation lesion|
89056755|NCT04577105||Suspected, probable, or confirmed COVID-19 case|Patients who come to the emergency room with symptoms compatible with a suspected, probable, or confirmed case of SARS-CoV2 infection, in which a chest computed tomography (CT) scan was requested for suspected COVID-19 pneumonia, will be evaluated. On April 1 and August 28, 2020.
89056756|NCT02211417|Experimental|Oral DS107 2g|Oral DS1072g, 4 x 500mg capsules administered orally once a day
89056757|NCT02211417|Placebo Comparator|Placebo|Placebo capsules matching Oral DS107 capsules
89056758|NCT00582413||1|Patients who have been diagnosed with Carcinoma of the oral cavity
89056759|NCT00582452||2|Affected patients who are at high risk for metachronous colorectal tumors due to mutation status.
89056760|NCT00582452||1|Unaffected patients who are at high risk for developing colon cancer based on family history and/or mutation status.
89056761|NCT02279121|Experimental|TauroLock|solution of taurolidine-citrate
89056762|NCT02279121|Other|Control|saline solution
89056763|NCT04576520|Experimental|pharmacopuncture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
89056764|NCT04576520|Active Comparator|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
89056765|NCT02218164|Experimental|Capecitabine or 5-FU with Pegylated Interferon alpha-2b|"Participants will start the Capecitabine pills on day 1 thru day 14 and be off for 7 days (day 15-day 21).~Participants will receive 5-FU days 1-4 of each 21 day cycle.~Participants will receive the Interferon alpha-2b injection weekly every week. The three week period is referred to as one cycle.~After three cycles, new imaging studies will be performed that will measure how the disease is responding to treatment. Participants whose disease is stable or improved will undergo an additional 3 cycles of therapy and the imaging studies will be repeated. Again, participants whose disease is stable or improved will undergo a final 3 cycles of treatment (a total 27 weeks of treatment)."
89056766|NCT01643109|Experimental|CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
89056767|NCT01643109|No Intervention|Comparison|Standard therapy.
89056768|NCT04552106|Active Comparator|Group 1|10 subjects
89056769|NCT04552106|Active Comparator|Group 2|10 subjects
89056770|NCT04552106|Active Comparator|Group 3|10 subjects
89056771|NCT04552106|Active Comparator|Group 4|10 subjects
89056772|NCT04552106|Active Comparator|Group 5|10 subjects
89056773|NCT04552067|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
89056774|NCT04552067|Active Comparator|Enoxamed|patients are given a curative dose of Enoxaparin (ENOXA)
89056775|NCT01643187|Experimental|Fortified beverage|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
89056776|NCT01643187|Active Comparator|Group receiving lactose-free milk|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
89056777|NCT01643265|Active Comparator|Whey Milk Protein|
89056778|NCT01643265|Experimental|Bovine Albumin Concentrate|
89056779|NCT04551833|Experimental|Group (T) : 30 patients (Tramadol group)|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 1.5 mg/kg Tramadol.
89056780|NCT04551833|Experimental|Group (D) : 30 patients (Dexamethasone group):|Patient will receive 0.4 mL/kg of 0.5% Levobupivacaine plus 8mg of Dexamethasone
89056781|NCT01643304||Group 1|
89533005|NCT05675410|Experimental|Arm C (ABVD, eBEACOPP, ISRT)|Patients receive eBEACOPP regimen (doxorubicin hydrochloride IV on day 1, cyclophosphamide IV on day 1, etoposide or etoposide phosphate IV on days 1-3, prednisone or prednisolone orally [PO] daily for the first 14 days of each treatment cycle, procarbazine hydrochloride PO on days 1-7, bleomycin sulfate IV on day 8, and vincristine sulfate IV) on day 8 of each treatment cycle. Treatment continues for 2 cycles. Each cycle lasts 21 days. Subsequently, patients undergo ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
89056782|NCT00582686|Active Comparator|ORIF with Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group A will be made up of patients that undergo ORIF and Tricortical iliac crest bone grafting.
89056783|NCT00582686|Active Comparator|ORIF without Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group B will consist of patients that undergo open reduction with internal fixation without bone grafting
89056784|NCT04551755|Active Comparator|Ivermectin plus Doxycycline plus standard care|Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours 2) Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes 3) Standard symptomatic and supportive treatment; Tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements
89056785|NCT04551755|Placebo Comparator|Placebo plus standard care|"1) Standard symptomatic and supportive treatment with placebo; Standard treatment includes tab paracetamol, tab antihistamine, tab montelukast will be mostly used as symptomatic treatment, vitamin C and vitamin D as supplements.~Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days"
89056786|NCT01643343||Typically Developing|Typically developing toddler volunteers between the ages of 8 months and 3 years
89056787|NCT01643343||Autism|Children between the ages of 8 months and 6 years with a diagnosis of an autism spectrum disorder
89056788|NCT02213939||CPB + Cytosorb|On pump myocardial revascularization with the use of the cytokine adsorbing circuit (Cytosorb)
89056789|NCT02213939||CPB / Control|Controll group; on pump myocardial revascularization
89056790|NCT02213939||OPCAB / Control|Controll Group; off-pump myocardial revascularization
89056791|NCT01640106|Experimental|Omega-3|Treatment arm, using the omega-3 product (fish oil/paste)
89056792|NCT01640106|Placebo Comparator|Control|Placebo is a paste of non-omega-3 (plant based) oil with a taste/flavour identical to intervention paste
89522713|NCT02678143|Experimental|Recipients|"The recipient of one antigen mismatch unrelated HSCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 300 cGy of total body irradiation (TBI) on Day -2.~The recipient of haplo-SCT will begin the preparative regimen on Day -7. Alemtuzumab on Days -7, -6, -5, -4, and -3, fludarabine on Days -7, -6, -5, -4, and -3, cyclophosphamide on Days -4 and -3, and 400 cGy of TBI on Day -2.~For both types of HSCT, the frozen peripheral blood stem cells will be thawed and infused on Day 0 per institutional guidelines. GVHD prophylaxis will consist of cyclophosphamide on Days +3 and + 4, mycophenolate mofetil (MMF) three times a day on Days +5 through +35 then tapered off over 1 week provided there is no evidence of GVHD, and sirolimus starting on Day +5 and continuing for one year. Sirolimus can be tapered at one year only if donor T-cell chimerism reaches more than 50% in the absence of GVHD."
89522714|NCT03399227||Liver transplantation recipients|Venipuncture (6x) Bone mineral density measurement: lumbar spine, hip region (3x) high resolution peripheral quantitative CT: radius, tibia (3x)
89522715|NCT03399227||Control group|Venipuncture (1x) Bone mineral density measurement: lumbar spine, hip region (1x) high resolution peripheral quantitative CT: radius, tibia (1x)
89056793|NCT01643421|Experimental|Deep inspiration and expiratory positive airway pressure|The protocol of deep inspiration combined to expiratory positive airway pressure will be applied in asthmatic subjects.
89056794|NCT01643421|No Intervention|Control|
89056795|NCT01643499|Experimental|Treatment (mFOLFIRINOX)|Patients receive oxaliplatin IV over 2 hours on, irinotecan hydrochloride IV over 1.5 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89056796|NCT00582725|Experimental|R-CHOP + GM-CSF|R-CHOP therapy (6-8 cycles) with GM-CSF
89056797|NCT01643538|Active Comparator|Control Arm|"Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or charity donations in this group."
89056798|NCT01643538|Experimental|Personal Financial Incentives Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will receive $20. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
89056799|NCT01643538|Experimental|Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week participants will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity. Charity donation is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
89057752|NCT02887573|Experimental|Free-residue nutrients+PEG|"Diet: Free-residue nutrients Free-residue nutrient will be given when the patients are hungry before the two days of the capsule day.There are no other diet in this arm.~Drug: PEG 2L PEG are used at 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.~Procedure: Colonoscopy On the following day of the test.All participants will undergo therapeutic colonoscopy."
89056800|NCT01643538|Experimental|Combined Financial Incentives & Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will receive money and/or be notified that a donation of the selected amount has been sent to the charity, depending on their selected preference. Incentives are terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
89056801|NCT00582764||1|Any patient undergoing MRI guided preoperative needle localization or MRI guided biopsy of the breast.
89056802|NCT01640145|Placebo Comparator|Carbohydrate|
89056803|NCT01640145|Active Comparator|Protein continous boluses|
89056804|NCT01640145|Active Comparator|Protein 2 boluses|
89056805|NCT01640223|Experimental|D-3 sensor|patients will be equiped with 2 Dexcom sensors 3 days before hospitalization
89056806|NCT01640223|Experimental|D-1 sensor|patients will be equiped with 2 Dexcom sensors one day before hospitalization
89056807|NCT04551794|Experimental|Online self-help program with additional peer support|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
89056808|NCT04551794|No Intervention|No intervention: waitlist-control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 9 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
89057753|NCT02887573|Experimental|Low fiber diet+PEG|"Diet: Low fiber diet Before the two days of the capsule day,when the patients hungry,low fiber diet wiil be given.~Drug: PEG 4L PEG are used at 21:00-23:00 the night before the test and 05:00-07:00 the morning of the test.~Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.~Procedure: Colonoscopy On the following day of the test,All participants will undergo therapeutic colonoscopy."
89217677|NCT02572973|Active Comparator|Active Treatment|The Acoustic Neuromodulation (ANM) active treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The level of sound during Sound Stimuli (SS) presentation is relatively low (20-40 decibels), and the volume level can be adjusted downward if the subject requests it. The active intervention sounds used in the trial couple sequential frequencies to the base frequency in a nonlinear (exponential) manner following a special algorithm developed by Dr. Izvarina. This algorithm varies both the rate of change and duration of the overlaying modulation that is presented to the brain.
89217678|NCT02572973|Placebo Comparator|Non-Active Placebo|The Acoustic Neuromodulation (ANM) treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The placebo sounds used in this trial mimic the active sounds, but instead of using nonlinear modulation, they are coupled to the base frequency in a linear manner. Both the sequence used as well as the rate of change and duration of this overlaying modulation are the same as that used for the active sounds. The only difference is use of a linear algorithm for the placebo sounds and a nonlinear (exponential) algorithm for the active sounds.
89217679|NCT00722969|Experimental|A|
89217680|NCT04069325|Experimental|simiaowan 6g + febuxostat 40mg|
89217681|NCT04069325|Placebo Comparator|placebo 6g + febuxostat 40mg|
89217682|NCT00723047|Experimental|1|
89217683|NCT03444779|Active Comparator|Control group|The patients will be treated with an open technique: cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope. The reduction will be performed using a spatula, a bone tamp or open reduction internal fixation. The osteosynthesis and filling of the cavity will be performed by the same surgical access.
89217684|NCT03444779|Experimental|Experimental group|"The patients will be treated with the Tibial Tuberoplasty technique under fluoroscopic guidance with or without arthroscopy. The reduction will be performed by an anterior approach using a kyphoplasty balloon. The combined osteosynthesis including cannulated screws and cementoplasty will both be performed by a percutaneous technique."
89217685|NCT00726791|Experimental|1|high frequency rTMS applied to the motor cortex
89217686|NCT04069403|Experimental|Intervention Arm- Automated Reports|Receives automated reports on prescription patterns monthly
89217687|NCT04069403|No Intervention|Control Arm: Usual clinical education and feedback|Receive no reports
89217688|NCT05373797||experimental and control group|experimental: 26 control group:26
89217689|NCT05373251|Experimental|Whole genomic DNA/RNA tumour sequencing|All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.
89217690|NCT04066985|Experimental|Growth Mindset Intervention|"Includes one online, single-session program, the Growth Mindset Program. The 30-minute, self-administered youth program includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change."
89217691|NCT04066985|Experimental|Self-Kindness Intervention|Includes one online, single-session program, the Self-Kindness Program. The 30-minute, self-administered youth program includes: An introduction to the science behind why adolescents might think disliking themselves is necessary for success and thus fear self-compassion; Scientific evidence and testimonials from other teens that being self-compassionate actually predicts being more successful socially and academically; Evidence-based tips for overcoming common, fear of self-compassion based obstacles to self-compassion in day to day life; And an exercise in which youths write notes to younger students, using scientific information to explain the benefits of using self-kindness.
89217692|NCT04066985|Active Comparator|Supportive Therapy Intervention|Includes one online, single-session active comparator program, the Supportive Therapy Intervention. The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. The 30-minute, self-administered control group program includes: vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family; the same number of reading and writing activities as the web-based growth mindset intervention. However, the only goals of the ST intervention are to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs.
89217693|NCT00723359|Experimental|BT062|BT062 single agent dose escalation
89217694|NCT00450814|Experimental|Stage 1 (MV-NIS alone)|Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)
89217695|NCT00450814|Experimental|Stage 2 (MV-NIS and cyclophosphamide)|Patients receive cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)
89522716|NCT03389269||Obese patients treated with AspireAssist|Healthy, obese with BMI > 27, treated with AspireAssist for weight management, the postprandial glucose metabolism will be tested with a meal test
89522717|NCT03389269||Matched controls|Healthy, obese with BMI > 27, the postprandial glucose metabolism will be tested with a meal test
89056809|NCT04551794|Experimental|Online self-help program with therapeutic guidance|The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences and difficulties concerning the program on a weekly basis with a therapeutic guide on the phone.
89056810|NCT01643577|Active Comparator|Acupuncture protocol for gastroparesis|Patients randomized to this arm will receive an acupuncture protocol that with points designed to treat gastroparesis
89688168|NCT01727453|Active Comparator|Warfarin|which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.
89688169|NCT04376125|Experimental|Suboccipital inhibition in tension headache|"Two groups of patients suffering from tension headache associated with cervicalgia are selected.~The control group performs conventional therapy. The experimental group performs conventional therapy plus the technique of suboccipital inhibition"
89688170|NCT04376125|Active Comparator|study of results|We compared data from both groups
89688171|NCT04377347||Confirmed spontaneous subarachnoid haemorrhage|"Patients, minimum 18 years of age, identified with the diagnosis in the Danish National Patient Register. The diagnosis is verified by medical record review.~All patients were initially admitted to a hospital in the Capital Region of Denmark.~In a national labour marked register and the civil registration register the patients are then followed for four years."
89056811|NCT01643577|Placebo Comparator|Acupuncture for musculoskeletal pain|Patients randomized to this arm will receive acupuncture therapy consisting of points designed to treat musculoskeletal pain.
89056812|NCT01117012|Experimental|VX-770|VX-770 (ivacaftor) 150 milligram (mg) tablet orally twice daily (q12h).
89056813|NCT01640262||localized prostate cancer|Danish men with localized prostate cancer
89056814|NCT04551209|Experimental|Apical patency group|Patients in which apical patency is maintained.
89056815|NCT04551209|No Intervention|Non- apical patency group|Patients in which apical patency is not maintained
89056816|NCT01640418|Experimental|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
89056817|NCT01640418|No Intervention|Standard Care|Standard Care
89056818|NCT01116739|Experimental|COHS administered fluoride varnish and oral health education|Paraprofessionals, called community oral health specialists (COHS), will be trained to administer fluoride varnish and oral health education to head start children quarterly for 2 years.
89056819|NCT01116739|Active Comparator|Usual care|Usual care will include regular dental services provided by the Indian Health Service.
89056820|NCT04541966||Nuchal translucency> = 99th percentile and <3.5mm|Nuchal translucency> = 99th percentile and <3.5mm
89688172|NCT04375969|Experimental|whole body cryostimulation treatment|WBC will be performed at the Pomeranian Rheumatologic Centre in Sopot. The centre is equipped with an electric cryochamber Zimmer Medicine System, Cryochamber ELECPOL, located in a temperature- and humidity-controlled room. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
89688173|NCT04375969|Experimental|Connection WBC treatment and HIIT training|This group will perform HIIT protocol and WBC sessions . HIIT will be performed after 1h WBC.
89688174|NCT04375969|Active Comparator|Control Group|Control group who will be investigated (meanwhile at baseline and after the interventions)
89688175|NCT04375969|Experimental|HIIT training group|This group will perform only HIIT protocol without cryo-sessions
89688176|NCT04377425||Patients with acute neurological symptoms|Consecutive patients with acute neurological disease admitted at the Neurology departments will be tested with a nasopharyngeal swap for SARS-COVID-19 RNA according to standard operating procedures at the department (if estimated hospital stay is >24hours). Medical and clinical characteristics will be collected
89688177|NCT04377425||Stroke patients|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
89688178|NCT04377425||Seizure/epilepsy|"COVID-19 positive patients will be asked to participate in the extended study together with matched COVID-19 negative controls.~Extended study: Collection of cerebrospinal fluid and blood-samples, clinical and cognitive assessment at baseline and at 3-month follow-up"
89688179|NCT04376203||Control|any patient with indications for thyroidectomy other than confirmed preoperative cancer
89688180|NCT04376203||Thyroid microcarcinoma|either preoperative detection or random finding after thyroidectomy of another indication.
89688181|NCT01720901|Experimental|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
89688182|NCT01720979||Patients with traumatic injuries|Children that were admitted to the hospital after traumatic injuries to body parts below the clavicles (traumatic control injury) and children that were admitted to the hospital after traumatic brain injury as diagnosed by a physician (TBI).
89688183|NCT04357561|Experimental|Exercise group (Schroth best practice)|Exercise program will consists of scoliosis-specific exercises (schroth best practice), which is a pattern specific scoliosis rehabilitation concept and provide three dimensional improvements and include patient education for maintaining corrected posture in daily life. In addition, these exercises provide improvements in neuromuscular control and the endurance of the postural muscles.
89688184|NCT04357561|No Intervention|Control group|Due to there is not a standard preoperative exercise protocol, additional exercise program will not be applied in control group. The patients will wait for the surgery in their routine daily life. Measurements will be performed at the same time frame in experimental group.
89688185|NCT01727531|Experimental|CQ Arm|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks.
88815307|NCT02161484|Active Comparator|Lumbar Plexus Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~No sham/placebo parasacral (sciatic) blocks will be performed in this group."
89056821|NCT04541966||Nuchal translucency> = 3.5 mm|Nuchal translucency> = 3.5 mm
89056822|NCT01116544|Experimental|AMES therapy with EMG biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of EMG activity the subject is able to generate in the hand. This study will examine whether AMES therapy combined with EMG biofeedback can restore hand opening to plegic stroke subjects.
89522718|NCT03395093|Experimental|FB with fentanyl|In the Bispectral Index monitoring,our study will use midazolam, propofol and fentanyl in the conscious sedation of FB
89522719|NCT03395093|Active Comparator|FB without fentanyl|In the Bispectral Index monitoring, our study will use midazolam, propofol in the conscious sedation of FB
88815308|NCT00988832||Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
88815309|NCT01023776|Other|live monovalent H1N1 vaccine|A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart
88815310|NCT00989612|Experimental|GSK2340274A GROUP|Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89056823|NCT01116544|Experimental|AMES therapy with Torque biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of torque (force) the subject is able to generate in the hand during the movement. This study will examine whether AMES therapy combined with Torque biofeedback can restore hand opening to plegic stroke subjects.
89056824|NCT01640496|Active Comparator|Vitamin D|Subjects will take 1 pill per day for 8 weeks.
89056825|NCT01640496|Placebo Comparator|Placebo|Subjects will be asked to take 1 pill per day for 8 weeks.
89056826|NCT04551443|Placebo Comparator|Placebo PBS|Standard therapy+Intravenous infusion PBS in patients with AMI
89056827|NCT04551443|Active Comparator|WJMScs|Standard therapy+Intravenous infusion WJMSCs in patients with AMI
89056828|NCT01643655|Experimental|Autologous Adipose Tissue Derived MSCs|
89056829|NCT04551248||PCV13 recipients (children)|Children < 5 years who had received PCV10 or PCV13 from May, 2014 to December, 2018 under the national childhood immunization program in South Korea.
89056830|NCT04551248||PPSV23 recipients (elderly adults)|Persons 65 years or older who had received at least one dose of PPSV23 between January, 2014 and December, 2018 under the national immunization program in South Korea.
89056831|NCT04551248||Influenza vaccine recipients (elderly adults)|Persons 65 years or older who had received at least one dose of influenza vaccine (as comparator) between January, 2014 and December, 2018 under the national immunization program in South Korea.
89056832|NCT01643733|Experimental|Transonics Arm|Intervention will be guided by flow through the fistula as guided by Transonics flow measurements
89056833|NCT01643733|No Intervention|Control arm|Patient will undergo normal fistula intervention guided only by angiographic assessment
89056834|NCT02214056||The study population|"There is only one group in this study. Please see the inclusion/exclusion criteria.~Intervention: Patient recruitment Intervention: Mobile team exam"
89056835|NCT04529382||Cohort 1: Unanticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 1 will be FNAIT cases that were not antenatally treated with by maternal IVIg administration (or other forms of fetal therapy).
89056836|NCT04529382||Cohort 2: Anticipated FNAIT cases|All children born between 2002 and 2017 and diagnosed with FNAIT are eligible for this study. Children in cohort 2 will be FNAIT cases which were anticipated antenatally by maternal IVIg administration according to our local protocol.
89056837|NCT04550819|Experimental|IEBSs in malignant extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with malignant extrahepatic biliary stricture
89056838|NCT04550819|Active Comparator|CPBSs in malignant extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with malignant extrahepatic biliary stricture
89056839|NCT04550819|Experimental|IEBSs in benign extrahepatic biliary stricture|Intraintestinal extended biliary stents(IEBSs) in patients with benign extrahepatic biliary stricture
89056840|NCT04550819|Active Comparator|CPBSs in benign extrahepatic biliary stricture|Conventional plastic biliary stents(CPBSs) in patients with benign extrahepatic biliary stricture
89056841|NCT01640535|Experimental|Test arm|Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg
89056842|NCT01640535|Active Comparator|Comparator arm I|Matching placebo of Montelukast sodium 10mg + Levocetirizine dihydrochloride 5 mg
89056843|NCT01640535|Active Comparator|Comparator arm II|Montelukast sodium 10mg + matching placebo of Levocetirizine dihydrochloride 5mg
89056844|NCT01640574|Experimental|DHA-P 7 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
89056845|NCT01640574|Experimental|DHA-P 14 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
89056846|NCT01640574|Active Comparator|Chloroquine 7 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
89056847|NCT01640574|Active Comparator|Chloroquine 14 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
89056848|NCT04550975|Experimental|Advanced Cognitive Stimulation Therapy|Advanced Cognitive Stimulation Therapy (ACST), a psychosocial intervention, is the modified version of CST for people with moderate and severe dementia. Activities consist of more multisensory stimulation elements than the original CST. ACST will be prescribed to participants 45-minutes per week, biweekly for 7 weeks. The intervention will be delivered by two facilitators, such as a research staff, clinical psychologist trainee or care home staff.
89056849|NCT04550975|No Intervention|Treatment as usual|Standard care in care homes
89056850|NCT01643811||Gastrectomy|Patients who underwent gastrectomy for early gastric cancer
89056851|NCT01643811||Endoscopic submucosal dissection|Patients who underwent endoscopic submucosal dissection for early gastric cancer
89056852|NCT01116427|Experimental|Abatacept|Receives abatacept during first course of treatment, switching to placebo during extension phase.
89056853|NCT01116427|Placebo Comparator|Placebo, followed by abatacept|Receives a placebo for first course of treatment, switching to abatacept in the extension phase.
89056854|NCT04550897|Experimental|BM7PE treatment|"The BM7PE treatment will be administered as a 20-minute i.v. infusion. The treatment is repeated after 2 weeks (day 15). The patients will be treated as in-patients and will stay at the hospital until toxicity have decreased to grade 2 and or plasma AST and or ALT levels has started to decrease. For at least a minimum of 3 days.~The dose administered to the patient will be 2.5, 5.0, 7.5, 10.0, 15.0 and 20.0 μg/kg body weight."
89056855|NCT04529226|Experimental|Clozapine|Pharmaceutical Form: Tablet Anatomical Therapeutic Chemical classification system (ATC Code): N: nervous system, N05: psycholeptic, N05A: antipsychotic, N05AH02: clozapine (N05AH02)
89056856|NCT04529226|Active Comparator|Control|Usual antipsychotic medication used in the treatment of treatment-resistant psychosis.
89056857|NCT04310683|Other|natural cycle for endometrium preparation|patients will have ovulation before embryo transfer
89056858|NCT04310683|Experimental|hormone replaced cycle for endometrium preparation|patients will do not have ovulation before embryo transfer
89217696|NCT02571491|Experimental|Ketamine Hydrochloride|"Received a combination of ketamine, remifentanil and morphine hydrochloride established by the following dosage regimen:~KETAMINE HYDROCHLORIDE 0,5mg/Kg Intravenous bolus administered during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~during surgery remifentanil 0,3 mcg / kg / min.~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
89522720|NCT03389191|Experimental|Patients with Viral Uveitis|Oral acyclovir 100 mg three times a day (TID).
88815311|NCT00989768|Experimental|Botulinum toxin type - A|Dysport® compared to Botox®
88815312|NCT00990236|Active Comparator|Enoxaparin 30 mg BID|standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
88815313|NCT00990236|Experimental|Enoxaparin dose adjusted based on TEG|enoxaparin dose modified based on TEG results
89056859|NCT04550702||Women received Mirabegron|Women with overactive bladder syndrome received Mirabegron
89056860|NCT01116232|Experimental|anti-thymocyte globulin, rituximab, sirolimus, tacrolimus,|"anti-thymocyte globulin: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter~Rituximab: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour;~For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).~Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose."
89522721|NCT04330183|Placebo Comparator|Normal Saline|Patients here will be administered 3cc of normal saline as placebo
89522722|NCT04330183|Experimental|Ketamine Interventions|Patients will be administered weight based 0.3mg/kg of ketamine
89522723|NCT05097053|Experimental|MVC-COV1901 vaccine (3-month Interval)|There will be approximately 100 participants (Group A) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 1
89522724|NCT05097053|Experimental|MVC-COV1901 vaccine (6-month Interval)|There will be approximately 100 participants (Group B) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 85.
89522725|NCT04323475|Active Comparator|Standard of Care|Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
89522726|NCT04323475|Experimental|Cocktail-SPK and standard of care|The experimental drug consists of Cocktail-SPK used as an adjunct to the standard of care. Standard of care consists of Xeroform primary dressing, a Melolin interface and a crepe. Kenacomb will be used for participants with diagnosed or suspected local infections.
89217697|NCT02571491|Placebo Comparator|Placebo|"Received a combination of physiological serum, remifentanil and morphine hydrochloride established by the following dosage regimen:~0,9 % physiological serum 0,5mg/Kg administered by an intravenous (IV) line during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~during surgery remifentanil 0.3 mcg / kg / min.~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
89217698|NCT01026688|Experimental|Intervention|
89217699|NCT01026688|Other|Control|
89217700|NCT00723515|Active Comparator|G1|NaF (sodium fluoride varnish) with 2.26% of fluoride
89217701|NCT00723515|Experimental|G2|NaF (sodium fluoride)2.71% of fluoride plus CaF2 (calcium fluoride)
89217702|NCT01022944|Other|Group 2 :|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
89217703|NCT01022944|Other|Group 1|Children with chronic middle ear effusion having adenoidectomy.
89217704|NCT01028170|Experimental|Furosemide with Hypertonic Saline|Furosemide with 150 mL of 2.4% NaCl
89217705|NCT01028170|Active Comparator|Pulse Furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
89217706|NCT00723671|Experimental|metabolic peaks|
89217707|NCT04067219|Experimental|Single arm|HIV-1 infected patients
89217708|NCT02570867||normal control group|Normal control group: healthy volunteers will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
89217709|NCT02570867||POAG group|POAG: The primary open angle glaucoma cases were will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
89217710|NCT00723983|Active Comparator|Period 1|Subject dosed with oral sumatriptan succinate during an acute migraine attack.
89217711|NCT00723983|Active Comparator|Period 2|Subject dosed with oral sumatriptan during a non-migraine period.
89217712|NCT00723983|Experimental|Period 3 and Period 6|Subject dosed with NP101 during an acute migraine attack.
89217713|NCT00723983|Experimental|Period 4 and Period 5|Subject dosed with NP101 study patch during a non-migraine period.
89217714|NCT00450658|Experimental|1|HZT-501: Ibuprofen 800mg/Famotidine 26.6mg
89217715|NCT00450658|Active Comparator|2|Ibuprofen 800mg
89217716|NCT02572505|Experimental|HIV-Discordant Couple|A couple in which the man is HIV-seropositive and the woman is HIV-seronegative who wish to have a biologically related child. Couple will use condoms for all sexual acts except one act of unprotected intercourse during the fertile period when the woman will be taking the drug Truvada.
89217717|NCT03720574|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
89217718|NCT03720574|Placebo Comparator|Matching Placebo BID|Matching Placebo tablet each morning and evening
89217719|NCT00724139|Experimental|1|patients (aged 50-75) with Symptomatic knee OA for at least 6 months, fulfilled American College of Rheumatology clinical criteria for OA of the knee and radiographically assessed osteoarthritis of the knee graded 1-2 according to the Kellgren & Lawrence scale.
89217720|NCT00718133|Experimental|1|Children at school age from Haifa bay region
89217721|NCT03720418|Experimental|OXB-102 Dose Level 1|OXB-102 Dose Level 1 Single Administration (Part A: open-label)
89217722|NCT03720418|Experimental|OXB-102 Dose Level 2|OXB-102 Dose Level 2 Single Administration (Part A: open-label)
89217723|NCT03720418|Experimental|OXB-102 Dose Level 3|OXB-102 Dose Level 3 Single Administration (Part A: open-label)
89217724|NCT03720418|Experimental|OXB-102 Selected Dose|Selected Dose of OXB-102 Single Administration (Part B: double-blind)
89217725|NCT03720418|Sham Comparator|Imitation Surgical Procedure|General anesthesia with bilateral skin incisions (Part B: double-blind)
89217726|NCT00517881|Experimental|C.E.R.A.|
89217727|NCT02572739||haemodynamics measuring|those with already implemented PICCO device get impedance device (NICCOMO) attached
89217728|NCT01009905||A|
89217729|NCT05372081||Patients who will receive digital assistant|Patients will receive digital assistance (in a few words text format) for any symptoms/adverse events they will include in their profile in the digital platform.
89217730|NCT05372081||Patients who will not receive digital assistant|Patients will just include any symptoms/adverse events in their profile in the digital platform.
89217731|NCT01565577|Experimental|Bras A|
89217732|NCT00724217|Experimental|Normal weight|BMI < 26
89217733|NCT00724217|Experimental|Overweight|BMI >= 26
89217734|NCT00724295||Arm 1|Overall study population
89217735|NCT00718289|Experimental|Citrate|Citrate dialysate for haemodialysis
89217736|NCT00718289|Active Comparator|Acetate|Acetate dialysate
89217737|NCT02571101|Experimental|Test 1|Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
89217738|NCT02571101|Experimental|Test 2|Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
89217739|NCT02571101|Placebo Comparator|Comparator|Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks.
89217740|NCT03525886|Experimental|Cohort 1 (50 mg QHS)|NBI-74788 50 mg once daily at bedtime (QHS) administered orally for 14 consecutive days.
89217741|NCT03525886|Experimental|Cohort 2 (100 mg QHS)|NBI-74788 100 mg once daily at bedtime (QHS) administered orally for 14 consecutive days.
89217742|NCT03525886|Experimental|Cohort 3 (100 mg QPM)|NBI-74788 100 mg once daily in the evening (QPM) administered orally for 14 consecutive days.
89217743|NCT03525886|Experimental|Cohort 4 (100 mg BID)|NBI-74788 100 mg twice daily (BID) administered orally for 14 consecutive days.
89217744|NCT00517413|Experimental|C.E.R.A|Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta [Mircera]). The initial dose of C.E.R.A. was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA); 120, 200, or 360 micrograms (mcg) C.E.R.A., IV or SC, every 4 weeks for 48 weeks.
89688186|NCT02982343|Experimental|Falls management plus exercise training|Falls management and education session. Home proximal lower limb strength training and multi-sensory balance training.
89688187|NCT02982343|Active Comparator|Falls management only|Falls management and education session only.
89688188|NCT01721135|Experimental|GSK2190915 100mg|GSK2190915 100mg on days 1-5; moxifloxacin placebo on day 5
89688189|NCT01721135|Experimental|GSK2190915 1000mg|GSK2190915 1000mg on days 1-5; moxifloxacin placebo on day 5
89217745|NCT00724529||Serious Active Crohns Disease|Patients with severe active Crohns Disease who do not show any response to treatment with corticosteroids or immunosuppressive agents, and have no drug tolerance or contraindications to such treatments.
89217746|NCT00724529||Fistula-Type Active Crohns Disease|Patients with fistula-type Crohns Disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant.
89688190|NCT01721135|Active Comparator|moxifloxacin 400mg|placebo tablet on days 1-5; moxifloxacin 400mg on day 5
89688191|NCT01721135|Placebo Comparator|placebo|placebo tablet on days 1-5; moxifloxacin placebo on day 5
89688192|NCT02982421|Experimental|Research|Group Art Therapy
89688193|NCT02982421|Sham Comparator|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
89688194|NCT03407885|Experimental|Experimental|Bundled payments for knee and hip replacement
89688195|NCT03407885|No Intervention|Control|No intervention
89688196|NCT00929071|Experimental|Pain assessment for Evolence/topical anesthetic|Assess injection pain severity for a one time 1.0 mL injection of Evolence with 0.2 ml of topical anesthetic, applied 30 minutes prior to injection, to the left nasolabial fold of each participant .
89688197|NCT00929071|Experimental|Pain assessment for Evolence/Lidocaine|Assess injection pain severity for a one time 1.0 mL injection of Evolence mixed with 0.18 mL of 2% lidocaine (0.3% final lidocaine-HCl) in the right nasolabial fold of each participant.
89688198|NCT04378205|Experimental|0.014/0.018 NiTi arch wire|0.014-inch NiTi on one side /0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
89688199|NCT04378205|Experimental|0.016/0.018 NiTi arch wire|0.016-inch NiTi on one side / 0.018-inch NiTi on the other side (Nitinol SuperElastic 3M, Unitek) for initial alignment. This group included 20 patients
89688200|NCT00929305|Placebo Comparator|Placebo laser|inactive laser light
89688201|NCT00929305|Active Comparator|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 milliWatt (mW) of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
89688202|NCT01727687|Experimental|Patients with Parkinson's disease|Using simulated traffic scene system to help patients with Parkinson's disease improve crossing road behaviors.
89688203|NCT04347265|Experimental|NMP in level 1|Participants in this group received NMP of the sciatic nerve in the gluteus region
89688204|NCT04347265|Experimental|NMP in level 2|Participants in this group received NMP of the sciatic nerve in the middle of the thigh
89688205|NCT04347265|Experimental|NMP in level 3|Participants in this group received NMP of the sciatic nerve before popliteus region
89688206|NCT01721525|Experimental|afatinib, ribavirin, and weekly carboplatin/paclitaxel|This will be a single institution phase I study with an expansion cohort. Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.
89688207|NCT04366063|Experimental|Two MSC infusion|Intervention Group1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) intravenously plus Conventional treatment.
89688208|NCT04366063|Experimental|Two MSC infusion Plus two EVs infusion|Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100×10e6 (±10%), intravenously plus two doses of EVs plus Conventional treatment
89688209|NCT04366063|No Intervention|Control|Control (n=20). Patients will conventional therapy for virus treatment and supportive care for ARDS will be used as control.
89688210|NCT01727843|Experimental|tranexamic acid|3000mg/mL tranexamic acid in saline applied directly to the wound at the end of the surgical procedure.
89688211|NCT01727843|Placebo Comparator|saline|3000mg/mL saline applied directly to the wound at the end of the surgical procedure
89688212|NCT04365751|Experimental|Percutaneous microwave ablation group|MWA (Microwave) is an ultrasound-guided, minimally invasive technique that implants ablation electrodes into target tissue to rapidly generate high temperatures and rapidly develop coagulative necrosis in tumor tissue, thereby achieving the goal of local tumor treatment.
89688213|NCT04365751|Other|Laparoscopic hepatectomy|Laparoscopic hepatectomy is a widely used surgical technique in the treatment of benign (malignant) liver diseases
89688214|NCT01727921|Active Comparator|22 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 22 gauge ProCore biopsy needle.
89217747|NCT00724529||Ankylosing Spondylitis|Patients with Ankylosing Spondylitis who do not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation.
89217748|NCT03714178|Experimental|FARAPULSE Endocardial Ablation|Subjects who are treated with the FARAPULSE Endocardial Ablation System for paroxysmal atrial fibrillation.
89217749|NCT01012869|Experimental|everolimus-eluting stent|patients undergoing treatment of a coronary chronic total occlusion (at least 3-months old) using everolimus-eluting stents (Xience, Abbott Vascular) or Promus (Boston Scientific)
89217750|NCT00718445||MND|"Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine~Patients seen in the Department of Neurology at Drexel University College of Medicine"
89217751|NCT03690999|Placebo Comparator|Placebo group|Placebo product
89217752|NCT03690999|Experimental|Prebiotic Supplement, low dose|
89217753|NCT03690999|Experimental|Prebiotic Supplement, high dose|
89217754|NCT05361785|Active Comparator|FMT form healthy donor|FMT from healthy donor
89217755|NCT05361785|Placebo Comparator|FMT plasebo|FMT plasebo
89217756|NCT03709342|Experimental|All Patients|
89217757|NCT01010295|Experimental|doxycycline|doxycycline 100 mg twice daily for 3 weeks
89217758|NCT03632291|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
89217759|NCT03632291|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
89217760|NCT03632291|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
89217761|NCT03632291|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
89217762|NCT03632291|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
89217763|NCT01010373|Experimental|AS101 infusions|In addition to induction chemotherapy AS101 will be given intravenously. The patient will also receive AS101 infusions during the time break till the next chemotherapy course, as long as the patient does not achieve complete remission and the platelet count is <20,000/μl; ANC <1000. AS101 will be administered likewise up to two consolidation or equivalent chemotherapy courses (re-induction or salvage in the event that no CR is achieved following first induction chemotherapy), i.e., total of three chemotherapy courses.
89217764|NCT02570945|Experimental|Intervention|Pharmacist-physician medication review
89056861|NCT04310527|Experimental|Treatment A: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib reference formulation will be given under fasted condition.
89056862|NCT04310527|Experimental|Treatment B: Administration of enasidenib fasted|A single oral 100 mg dose of enasidenib test formulation will be given under fasted condition.
89056863|NCT04310527|Experimental|Treatment C: Administration of ensidenib fed|A single oral 100 mg dose of enasidenib test formulation will be given under fed condition.
89056864|NCT04550663|Experimental|KD-025 CAR-T cells|NKG2D-based CAR-T cells infusion
89056865|NCT01115998|Experimental|Power wheelchair|
89056866|NCT01115998|Other|Control group|
89056867|NCT04528914|Experimental|Low-FODMAP diet|37 participants.
89056868|NCT04528914|No Intervention|Regular diet|"37 participants. The regular diet will reflect the habitual FODMAP intake in a normal diet.~Diets in both groups will be matched in terms of total energy, fat, protein, carbohydrates and dietary fiber with the usual participant's diet."
89056869|NCT02214095|Active Comparator|glucosamine sulphate capsules|500 mg Glucosamine Compound, three times daily for 3 months following initial cause related therapy.
89217765|NCT02570945|No Intervention|Control|
89056870|NCT02214095|Placebo Comparator|lactose capsules|lactose capsules three times daily for 3 months
89056871|NCT04550351|Experimental|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
89056872|NCT04550351|Experimental|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
89056873|NCT04550351|Placebo Comparator|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
89056874|NCT02214173|Experimental|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
89056875|NCT02214173|Placebo Comparator|placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
89056876|NCT01640691|Experimental|Study vaccine (AdimFlu-W)|0.5 mL/dose, a total of 2 doses, 21 days apart
89056877|NCT01205230|Experimental|Pazonib+ketoconazole|Administration of oral pazopanib 400mg (2 200-mg tablets) once-daily each morning for at least 7 consecutive doses during Period 1. Then administration of oral ketoconazole 400 mg (2 - 200 mg tablets) followed immediately by pazopanib 400 mg (2 -200 mg tablets) once-daily each morning for a total of 5 consecutive doses during Period 2.
89056878|NCT01205230|Experimental|Pazonib+esomeprazole|Subjects will receive orally administered pazopanib 800mg (4 - 200mg tablets) once-daily each morning for at least 7 consecutive doses in Period 1. In the evening on the last day of Period 1, subjects will take their initial dose of esomeprazole 40 mg (1 - 40 mg capsule) approximately 3 hours after the evening meal. Subjects will continue to receive pazopanib (each morning) and esomeprazole each evening once-daily for a total of 5 consecutive doses.
89056879|NCT04549961||patients admitted to intensive care units|all patients that are present on an intensive care unit on nutritionday
89056880|NCT01643889|Experimental|Sequence group ADBC|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
89056881|NCT01643889|Experimental|Sequence group BACD|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
89056882|NCT01643889|Experimental|Sequence group CBDA|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
89056883|NCT01643889|Experimental|Sequence group DCAB|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
89056884|NCT04550078|Active Comparator|Calcium Carbonate|800 mg calcium as calcium carbonate in capsules consumed orally once with a standardized meal.
89056885|NCT04550078|Experimental|Calcium-enriched permeate|800 mg calcium as calcium permeate in capsules consumed orally once with a standardized meal.
89056886|NCT04550078|Placebo Comparator|Maltodextrin|0 mg calcium as placebo capsules with maltodextrin consumed orally once with a standardized meal.
89056887|NCT01640730|Experimental|Kanglaite injection|
89056888|NCT02214251|Experimental|PK-16CH EXG system|PK-16CH EXG is a wireless physiological signal acquisition system for monitoring the bio-signals, such as EEG, ECG, and EMG. The system can concomitant EEG and EMG recording during ambulation.
89056889|NCT01643967|Experimental|Ozone therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
89056890|NCT01643967|Active Comparator|sunflower oil|"The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.~Other Names:~Sunflower oil"
89056891|NCT04549805||Patients without myocardial injury|Patients without myocardial injury will be recruited in a 2:1 fashion stratified by peak high-sensitivity cardiac troponin I concentration above and below a threshold of 5 ng/L.
89217766|NCT01010451|Experimental|Antimicrobial pulpotomy|Pulpotomy of primary molars with pulp inflammation or necrosis due to carious lesions using an antimicrobial paste
89217767|NCT01010451|Active Comparator|Calcium hydroxide pulpectomy|Pulpectomy of primary molars with pulp inflammation or necrosis due to carious lesions using a calcium hydroxide paste as intracanal medication
89217768|NCT02570789|Experimental|patients with sunitinib or pazopanib|This will be a non-randomized, proof-of-concept, prospective, longitudinal, multi-center study in patients with metastatic clear cell renal cell carcinoma with good or intermediate risk (based on MSKCC criteria) treated with sunitinib or pazopanib in first line.
89217769|NCT00604214|Experimental|Drotrecogin alfa (activated)|
89217770|NCT00604214|Placebo Comparator|Placebo|
89217771|NCT01010529|Experimental|occupational therapy|
89217772|NCT01010529|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (3 months).
89217773|NCT00450580|Experimental|Arm A|Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
89217774|NCT00450580|Active Comparator|Arm B|Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
89217775|NCT00724685|Placebo Comparator|Placebo|
89217776|NCT00724685|Experimental|Active|
89217777|NCT00123487|Experimental|dasatinib Twice a Day (BID)|70 mg dasatinib twice a day (BID)
89217778|NCT00123487|Experimental|dasatinib Once a Day (QD)|140 mg dasatinib once a day (QD)
89217779|NCT00509925|Experimental|Treatment period 1|Insulin detemir for 16 weeks (treatment period 1) followed by insulin NPH treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
89217780|NCT00509925|Experimental|Treatment period 2|Insulin NPH for 16 weeks (treatment period 1) followed by insulin detemir treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
89217781|NCT00724763|Experimental|1|Treatment group.
89217782|NCT00724763|Sham Comparator|2|control group
89217783|NCT05277974|Active Comparator|Group B.|group B will receive Inj Bupivicain only in Erector Spinae Plane Block.
89217784|NCT05277974|Active Comparator|Group D|group D will receive Inj Bupivicain plus Dexamethasone in Erector Spinae Plane Block.
89217785|NCT00504777|Experimental|1|
89217786|NCT00902798|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
89217787|NCT00902798|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
89217788|NCT00724919||1|
89217789|NCT03968263|Active Comparator|Hycon device(Routine protocol)|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions.
89217790|NCT03968263|Active Comparator|Hycon device(Modified protocol)|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise.
89217791|NCT03968263|Active Comparator|Hycon device(Routine protocol) and Vibration|The hycon device in this group will be activeted into half turn every 3 days in accordance with the manufacturer's instructions. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
89217792|NCT03968263|Active Comparator|Hycon device(Modified protocol) and Vibration|The activation period of the hycon device in this group will be modified. The first day will be clockwise half a turn, the second day will be half-turn clockwise and the third day will be turned half a turn counterclockwise. In addition, patients in this group twice a day for 10 minutes with acceledent device vibration will be applied.
89217793|NCT00895076|Experimental|1|dexamethasone iontophoretic patch
89217794|NCT00895076|Active Comparator|2|dexamethasone intramuscular injection
89217795|NCT00906932||Trachview videoscope, direct laryngoscopy|Each subject served as their own control - the Trachview videoscope and direct laryngoscopy was performed on by all subjects in a sequential fashion.
89217796|NCT00906932||See above|See above
89217797|NCT01078519|No Intervention|Massages baths|doulas, massages and baths
89217798|NCT01078519|Active Comparator|Combined spinal-epidural anesthesia|local anesthetics in low doses with opioids
89217799|NCT02539316|Active Comparator|Médialipides|parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)
89217800|NCT02539316|Experimental|SmofLIPID|parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)
89217801|NCT00724997|Other|cohort I|dose level I: 6.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
89217802|NCT00724997|Other|cohort II|dose level II: 6.7 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
89217803|NCT00724997|Other|cohort III|dose level III: 7.0 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
89217804|NCT00724997|Other|cohort IV|dose level IV: 7.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
89217805|NCT00724997|Other|cohort V|dose level V: 7.7 log10 TCID50/volunteer, 16 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
89688215|NCT01727921|Active Comparator|25 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 25 gauge ProCore biopsy needle.
89688216|NCT04365907|Experimental|Omarigliptin 12.5 mg|Drug: Omarigliptin 12.5 mg Once weekly new anti-diabetic drug approved only in Japan Other Name: Zafatek tablets
89688217|NCT04357639||Protease inhibitor exposed|HIV patients treated with antiretroviral drugs including a protease inhibitor
89217806|NCT03968185||Interfascial infiltration|Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.
89217807|NCT03968185||Standard medical treatment|Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.
89217808|NCT00509769|Experimental|Trastuzumab emtansine 3.6 mg/kg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.
89688218|NCT04357639||Protease inhibitor non exposed|HIV patients treated with antiretroviral drugs without a protease inhibitor
89688219|NCT00937105|Active Comparator|ReNu Multiplus and lotrafilcon A lenses|ReNu Multiplus contact lens care solution
89688220|NCT00937105|Active Comparator|Clear Care solution and lotrafilcon A lenses|Clear Care Contact Lens Care Solution
89688221|NCT04367077|Experimental|MultiStem|
89688222|NCT04367077|Placebo Comparator|Placebo|
89688223|NCT01721915|Experimental|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
89688224|NCT01721915|Placebo Comparator|Placebo|the placebo group will receive oily drops without vitD
89688225|NCT04357483|Experimental|Collastat|Patients who were applied flowable thrombin containing collagen hemostat matrix after pancreatectomy
89217809|NCT02531503||Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of asthma medication during the past 12 months.
89217810|NCT00902876|Experimental|Mucograft + CAF|Mucograft in combination with coronally advanced flap (CAF)
89217811|NCT00902876|Experimental|CAF|Coronally advanced flap (CAF) alone
89217812|NCT02977715|Experimental|Intervention (Liquid Formulation)|Up to 1000 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for monkeypox will receive two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL). A subset of participants will receive a booster dose.
89217813|NCT02977715|Experimental|Intervention (Lyophilized Formulation)|Up to 600 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for monkeypox will receive two doses of attenuated live virus smallpox vaccine (IMVAMUNE lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL). A subset of participants will receive a booster dose.
89217814|NCT01074697|Active Comparator|Fosaprepitant dimeglumine|
89217815|NCT01074697|Placebo Comparator|Saline water|
89217816|NCT00907010||Group I|11 to 18 years - composed of 12 adolescent with six women and six men
89217817|NCT00907010||Group II|20 to 26 years - composed of 12 young with six women and six men
89217818|NCT00907010||Group III|45 to 60 years - composed of 12 adult with six women and six men
89688226|NCT04357483|Active Comparator|Collaseal|Patients who were applied thrombin coated L-dopa contained collagen patch after pancreatectomy
89688227|NCT01721993|Experimental|T121E01F|
89688228|NCT01721993|Active Comparator|zoledronic acid IV|
89688229|NCT04366609||ADHD patients|Treatment of young ADHD patients with methylphenidate following The Danish guidelines, which are similar to The NICE guidelines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until no further effect is measured on a standard ADHD rating scale, or the appearance of intolerable ARs, or a maximum dose of 2.1 mg/kg/day.
89688230|NCT03407339|Active Comparator|Shared Oral Care Intervention|
89688231|NCT03407339|No Intervention|Control|
89688232|NCT04366843|Experimental|The chair massage group|chair massage 15 min,, 2 x week; measurement before and after each treatment
89688233|NCT04366843|Experimental|The exercise program group|excercises 15 min., 2 x week; measurement before and after each treatment
89688234|NCT04366843|No Intervention|The control group|control 2 measurements, 4 weeks apart
89056892|NCT01640769|Active Comparator|Image guided delivery of pacing leads|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm) versus standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
89056893|NCT01640769|Placebo Comparator|Standard delivery of pacing leads|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
89056894|NCT04550273|Experimental|study group|The study group (n=20) will receive three sessions of aerobic walking exercise per week for 3 months in addition to the traditional medical treatment
89056895|NCT04550273|No Intervention|control group|The control group (n=20) will receive no training
89057754|NCT01685892|Experimental|Dose-Finding: Schedule A: Relapsed/Refractory CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
89217819|NCT00907010||Group IV|66 - 82 years - composed of 12 aged with six women and six men
89217820|NCT02539082|Placebo Comparator|placebo injection|placebo, normal saline, injection in the plantar facia through randomization
89217821|NCT02539082|Experimental|Regenseal injection|Regenseal, collagen, injection in the plantar facia through randomization
89217822|NCT03997695|Active Comparator|Core stabilization exercise group|"Core stabilization exercise (CSE):~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional."
89217823|NCT03997695|Experimental|Core stabilization exercise plus kinesio taping group|"Core stabilization exercise (CSE):~The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.~Kinesio Taping:~The Kinesio Taping was carried out 2 days a week for 6 weeks (12 sessions) by experienced and certificated physiotherapist. Kinesio taping was applied to spinal region."
89217824|NCT01074775|Experimental|Challenge group|Recipients of three challenge infections with oral M bovis
89217825|NCT01080079|Active Comparator|Group A -Terbinafine HCl|Terbinafine HCl
89217826|NCT01080079|Active Comparator|Group B - Terbinafine HCl|Terbinafine HCl
89217827|NCT01080079|Active Comparator|Group C - Terbinafine HCl|Terbinafine HCl
89217828|NCT01080079|Active Comparator|Group D Terbinafine HCl|Terbinafine HCl
89217829|NCT01080079|Active Comparator|Group E|Terbinafine HCl
89217830|NCT01080079|Placebo Comparator|Group F - Placebo|Placebo application
89217831|NCT02538536|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
89217832|NCT00725231|Active Comparator|Arm A|Chemotherapy with dose dense CHOP-14, 6 cycles
89217833|NCT00725231|Experimental|Arm B|Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles
89217834|NCT02539238|Active Comparator|control|Annual BLS training
89217835|NCT02539238|Experimental|intervention|Brief CPR training dispersed over a year period of time with real-time feedback during working hour
89217836|NCT03381521|Experimental|Group A|Ultrasound-guided nerve hydrodissection with 10cc normal saline
89217837|NCT03381521|Active Comparator|Group B|Ultrasound-guided nerve hydrodissection with 5cc normal saline
89217838|NCT00114127|Placebo Comparator|Duloxetine 60mg + Placebo for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
89217839|NCT00114127|Active Comparator|Duloxetine 120mg for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
89217840|NCT00114127|Active Comparator|Duloxetine 60mg/day for 6 Weeks|In Phase 1 all participants entered an open trial.
89217841|NCT05158179|Experimental|Spasmodic Dysphonia Patients|"Following appropriate nasal local anesthetic, the channeled laryngoscope was inserted through the nose. The 6-0 monofilament was pressed against the posterior nasopharyngeal wall and swiftly removed to establish a perceptual strength of 1, as an internal anchor. The lateral pyriform sinus (LPS) was presented with the planned stimulus, followed by the aryepiglottic fold (AEF) and the false vocal folds (FVF). Participants were instructed to raise their hand when the stimulus was detected, and then were asked by the study team to report a perceptual strength score, in comparison to the nasopharyngeal anchor strength of 1. LAR response was recorded by the study team. A negative response was defined as a lack of LAR to two appropriate stimuli. The LPS and AEF were tested in order of increasing stimulus: 6-0, 5-0, 4.5-0 and 4-0 monofilaments. The false vocal folds (FVF) were tested last. Testing of FVF terminated after the first observed LAR."
89217842|NCT00902954|Experimental|A|anastrozole/letrozole 2-3 years switching to exemestane 3-2 years
89217843|NCT00902954|Active Comparator|B|anastrozole/letrozole 5 years
89217844|NCT02570009|Active Comparator|TEAMS|
89217845|NCT02570009|Active Comparator|TEAMS+|
89217846|NCT04034966|Active Comparator|Claria|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) with the telemedicine module. The telemedicine module is the platform for storing patient information directly from the PD machine. Handling will be done according to the basic operating instructions established by the manufacturer.
89217847|NCT04034966|No Intervention|Control|The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) without the telemedicine device. the device is used for automated peritoneal dialysis. Handling will be done according to the basic operating instructions established by the manufacturer.
89217848|NCT05077553|Placebo Comparator|Placebo sachet|
89217849|NCT05077553|Experimental|TCI999 probiotic sachet|
89217850|NCT00572624|Experimental|Diet|Participants who received counseling and instruction about weight loss through diet and exercise
89217851|NCT00572624|Experimental|Gastric bypass surgery|Participants who received gastric bypass surgery
89217852|NCT02540720|Experimental|group 1|Dexamethasone 0.5mg/kg.d i.v.
89217853|NCT02540720|Experimental|group 2|Dexamethasone & gamma globulin Dexamethasone 0.5mg/kg.d i.v. & gamma globulin i.v. qd*3d, and the total dose is 2g/kg
89217854|NCT02540720|Experimental|group 3|Dexamethasone & hemoperfusion Dexamethasone 0.5mg/kg.d i.v & hemoperfusion should be given at least three times in five days
89217855|NCT00725465||LAP surgery with CO2 colonoscopy|30 surgical patients, male and female undergoing laparoscopic surgical treatment for colorectal conditions such as neoplasm or rectal prolapse managed with intra-operative carbon dioxide (co2)colonoscopy for standard care of their medical condition.
89217856|NCT02540642|Active Comparator|Vitamin B12 and Antidiabetics|Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
89217857|NCT02540642|No Intervention|antidiabetics|Only regular antidiabetic drugs will be given
89057755|NCT01685892|Experimental|Dose-Finding: Schedule B: Relapsed/Refractory CLL|In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
89057756|NCT01685892|Experimental|Dose-Finding: Schedule A: Previously Untreated CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
89217858|NCT00122317|Experimental|Eculizumab|600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
89217859|NCT03964675|Experimental|Respiratory rate measurement|Simultaneous measurement of respiratory rate using SenseGuard and Capnography
89217860|NCT03870555|Experimental|Sequence 1|"Period 1: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 2: TAK-954 0.1 milligram (mg), infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
89217861|NCT03870555|Experimental|Sequence 2|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
89217862|NCT03870555|Experimental|Sequence 3|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg, infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2. A washout period of at least 16 days will be maintained between each Treatment Period."
89217863|NCT02569931|Experimental|study group|"36 participants recruited aged between 18 to 50 years of age~Participants will be considered eligible for the study group if they have had two or more episodes of patellar dislocation or multiple episodes of subluxation with at least one of the following:~i. Positive patellar apprehension test ii. Tenderness along the medial retinaculum iii. Abnormal patellar tracking or position.~The study group will undergo gait analysis and electromyography before surgery and 6 months after surgery.~During surgery the study group will undergo intra-operative tracking and pressure measurements."
89217864|NCT02569931|Other|control group|"36 participants recruited aged between 18 to 50 years of age, matched for age and gender with the study group. Control participants should be healthy subjects with no history of knee injury or surgery.~The control group will undergo gait analysis and electromyography."
89217865|NCT00908336|Experimental|Docetaxel and Erlotinib|"Patients in the experimental arm will receive sequential treatment of intermittent erlotinib and docetaxel up to 4 cycles in the absence of disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.~After 4 cycles, participants will receive 150 mg of erlotinib per day until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment."
89217866|NCT00908336|Active Comparator|Erlotinib|Erlotinib (Tarceva®) 150 mg/day po daily until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
89217867|NCT03964519|Experimental|20% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 20% less compared to the first repetition.
89217868|NCT03964519|Experimental|40% velocity loss|This group will train with a variable number of repetitions during each set. The group will stop the set once the mean propulsive velocity will be 40% less compared to the first repetition.
89217869|NCT03964519|Placebo Comparator|Control group|This group will be just tested as a control group.
89217870|NCT00908414|Experimental|Panel 1: Single Dose Escalation|Panel 1 will receive doses of 40 milligram (mg) (Session Ia), 100 mg (Session IIa), 200 mg (Session IIIa) and 400 mg (Session IVa) of TMC589337 or placebo.
89217871|NCT00908414|Experimental|Panel 2: Single Dose Escalation|Panel 2 will receive doses of 40 mg (Session Ib), 100 mg (Session IIb), 200 mg (Session IIIb) and 400 mg (Session IVb) of TMC589354 or placebo.
89056896|NCT01644006|Experimental|Device: Teleconsultation|"In cases of suspected acute coronary syndrome (including STEMI), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
89056897|NCT01644006|No Intervention|Historical Matched Pairs|Historical matched pairs were searched from local protocols. During this phase no teleconsultation system was existent.
89056898|NCT01205152|Experimental|asfotase alfa|An initial single intravenous (IV) infusion of 2 mg/kg asfotase alfa, followed by subcutaneous (SC) injections of 1 mg/kg asfotase alfa 3 times per week
89056899|NCT01640847|Experimental|Arm RT: HIFU plus ThermoDox|Index lesion has been treated with EBRT and is currently painful, but these subjects have already received their maximum cumulative EBRT dose.
89056900|NCT01640847|Experimental|Arm NRT: HIFU plus ThermoDox|Subjects have no yet received any radiation to the index lesion.
89056901|NCT04549727||infants with surgical NEC|Infants who undergo surgery for NEC disease
89056902|NCT04549727||Infants with GI surgical diseases other than NEC|Infants who undergo surgery for other GI diseases than NEC
89056903|NCT01205035|No Intervention|Observation|Observation; No treatment given
89056904|NCT01205035|Experimental|Intravitreal ranibizumab 2.0mg|Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
89056905|NCT01644045|Experimental|Device: Teleconsultation|"In cases of acute obstructive, respiratory emergencies if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
89056906|NCT04549844|Active Comparator|the intervention group (G A)|Group general anaesthesia plus peribulbar block : Total 35 cases who will receive general anesthesia with peribulbar block (bupivacaine 0.5 % xylocaine 2% hyaluronidase with total volume 0.06 mg \kg (bupivacaine : (xylocaine :hyaluronidase ) 1:1) Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery.
89056907|NCT04549844|Placebo Comparator|the control group (G B )|"General group: Total 35 cases who will receive general anesthesia only, i.e., without peribulbar block. (Fentanyl 1µg\kg, atracurium 0.5 mg\kg and propofol 2mg \kg.~After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane."
89056908|NCT01640886||Standard of Care|"Comparison of S. aureus to the reference methods for S. aureus (tube coagulase and Staphaurex.)~Comparison to the reference method (30 ug cefoxitin disc diffusion)."
89056909|NCT01640886||KeyPath Test Group|All specimens collected that meet the inclusion criteria will be tested using the KeyPath BTA Test.
89056910|NCT01644084|Experimental|HA (priming)-HES (up to 15 ml/kg after CPB)|
89056911|NCT01644084|Active Comparator|HES (priming)-HES (up to 15 ml/kg after CPB)|
89056912|NCT01644084|Active Comparator|HA (priming)-nonHES (only crystalloids after CPB)|
89056913|NCT04549883|Experimental|Performing after session|LB control during hip extension after intervention
89056914|NCT01204918|Experimental|Riluzole addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 8 weeks
89056915|NCT01204918|Placebo Comparator|Placebo addition to standard SSRI antidepressant|Placebo will be added to ongoing SSRI or SNRI antidepressant treatment for 8 weeks
89056916|NCT01204918|Experimental|Riluzole/Placebo addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 4 weeks and placebo will added to ongoing SSRI or SNRI antidepressant treatment for 4 weeks
89056917|NCT04528797|Experimental|Levothyroxine|Levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
89056918|NCT04528797|Experimental|Methylprednisolone|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later.
89056919|NCT04528797|Experimental|Combination|Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later plus levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.
89056920|NCT04528797|No Intervention|Control|No levothyroxine or methylprednisolone administered.
89056921|NCT00624481|Active Comparator|1|
89056922|NCT00624481|Experimental|2|
89056923|NCT00624481|Experimental|3|
89056924|NCT00624481|Experimental|4|
89056925|NCT00624481|Experimental|5|
89056926|NCT04318054|Experimental|Immediate intervention group|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, in the 2 months following the randomization, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
89056927|NCT04318054|Other|Deferred intervention group|Deferred intervention group : fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, one year after the inclusion, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
89056928|NCT01641003||Fresh tumor specimen|Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab.
89056929|NCT01644162|Other|iVAPS ventilation|3 months of ventilator use in iVAPS mode with data monitoring
89056930|NCT04549649|Experimental|Group A (Experimental oocyte triggering approach)|0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) associated with two ampoules of Ovitrelle (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be administered subcutaneously simultaneously for final oocyte triggering.
89533006|NCT05675410|Experimental|Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)|Patients receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
89056931|NCT04549649|No Intervention|Group B (Routine oocyte triggering approach)|Two ampoules of Ovitrelle® (Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) will be injected subcutaneously for final oocyte triggering.
89056932|NCT01644201|Active Comparator|High viscosity non-starch polysaccharide, PolyGlycopleX®-PGX®|
89056933|NCT01644201|Placebo Comparator|Placebo (Rice Flour)|
89056934|NCT02214329|Experimental|Sensor-based exercise training|The intervention group receives sensor-based balance training with real-time joint feedback through an interactive interface on LC monitor screen.
89056935|NCT02214329|Active Comparator|In-home balance training|The control group performs similar exercise as intervention group at home without use of sensor or any joint feedback from sensor data.
89056936|NCT04529187|Active Comparator|DEX group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a dexmedetomidine infusion in a rate of of 0.7 ug.kg-1.hr-1will be initiated. After 5 minutes of dexmedetomidine therapy a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
89056937|NCT04529187|Active Comparator|MID group|Participants allocated into this arm will undergo a baseline cardiac MRI. Then a single dose of midazolam (2 mg intravenously) will be given to each participant in this arm. After 5 minutes of midazolam administration a control cardiac MRI will be performed to detect changes in heart function following sedation administration.
89056938|NCT04549415|Active Comparator|metformin|Metformin, 1000 mg b.i.d, 12 months
89056939|NCT04549415|Active Comparator|lifestyle modification|Lifestyle modification Standard Principles
89056940|NCT01644279||Young|Young (age 20-35 years old)
89217872|NCT00908414|Experimental|Panel 3: Multiple dosing|AA mg (Final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. (twice daily) during 7 days (Session Va) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIa).
89217873|NCT00908414|Experimental|Panel 4: Multiple dosing|BB mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session Vb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIb).
89217874|NCT00908414|Experimental|Panel 5: Multiple dosing|CC mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. during 7 days (Session VIa) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXa).
89217875|NCT00908414|Experimental|Panel 6: Multiple dosing|DD mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session VIb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXb).
89217876|NCT00908414|Experimental|Panel 7: Multiple dosing|EE mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) or YY mg TMC589354 (n=6) b.i.d. or q.d. during 7 days (Session VII) ) plus a single oral dose of 300 mg or 600mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg or 600 mg TMC310911, single dose (Session X).
89217877|NCT01074853|Experimental|Propranolol|Chronic dose escalation of propranolol over period of 6 to 8 weeks.
89217878|NCT01074853|Placebo Comparator|Placebo|Matched placebo used for dose escalation period of 6 to 8 weeks
89217879|NCT03870477|Other|THP Hip Fracture Plating System|THP Hip Fracture Plating System in Intracapsular and Intertrochanteric Femur Fractures
89217880|NCT02570633|Experimental|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
89217881|NCT02570633|Placebo Comparator|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
89217882|NCT00908492|Active Comparator|Education Control|
89217883|NCT00908492|Experimental|Environmental Skill Building|
89217884|NCT01078597||Patients with early Rheumatoid Arthritis|Patients , aged 18 years or over, diagnosed with Rheumatoid Arthritis, with evidence of disease activity within the last year.
89217885|NCT04880291|Active Comparator|GFB-024 SAD Active|Single ascending dose arm of GFB-024 treatment
89217886|NCT04880291|Placebo Comparator|SAD Placebo|Single ascending dose arm of placebo treatment
89217887|NCT04880291|Active Comparator|GFB-024 Repeat-dose Active|Repeat-dose arm of GFB-024 treatment
89217888|NCT04880291|Placebo Comparator|Repeat-dose Placebo|Repeat-dose arm of placebo treatment
89217889|NCT00908570|Experimental|1Topical estriol cream|
89217890|NCT00908570|Placebo Comparator|2Placebo cream|
89217891|NCT01010607|Experimental|Vibraton Mirror (VM)|subjects will receive tendon vibration AND mirror therapy
89217892|NCT01010607|Active Comparator|Mirror (M)|Subjects will receive treatment only with Mirror, together with sham vibration (over bone instead of tendon)
89217893|NCT01010607|Sham Comparator|Sham (S)|Opaque board instead of mirror, bone vibration instead of tendon vibration
89217894|NCT00725777|Experimental|A|
89217895|NCT00165841|Placebo Comparator|Placebo|
89217896|NCT00165841|Experimental|Rabeprazole 20 mg|
89217897|NCT00907166|Experimental|Phase I, Arm A|CPI-613 + Gemcitabine
89217898|NCT00907166|Experimental|Phase II, Arm A|CPI-613 + Gemcitabine
89217899|NCT00907166|Active Comparator|Phase II, Arm B|Gemcitabine
89217900|NCT00725855|Experimental|1|1 mg dose
89217901|NCT00725855|Experimental|2|5 mg dose
89217902|NCT00725855|Experimental|3|15 mg dose
89217903|NCT00725855|Experimental|4|50 mg dose
89056941|NCT01644279||Old high-functioning|Old high-functioning (age 70-99 years old)
89056942|NCT01644279||Old low-functioning|Old low-functioning (age 70-99 years old)
89688235|NCT03407261|Experimental|Micro-osteoperforations|Minimally invasive micro-osteoperforations procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice
89688236|NCT03407261|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (sliding mechanics)
89688237|NCT04366687|Active Comparator|PAT-AU|Parents randomized to this arm (i.e., group) receive Parents as Teachers (PAT) services as usual (AU).
89688238|NCT04366687|Experimental|PAT+CSA|Parents randomized to this arm (i.e., group) receive the added CSA-focused session (Smart Parents - Safe and Healthy Kids) added to typical Parents as Teachers (PAT).
89688239|NCT03407183||spastic neurogenic bladder|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) in patients with spastic neurogenic bladder is 200 U of onabotulinumtoxinA once, then follow up after three months.
89688240|NCT03407105|Experimental|Arm 2|Specified dose on specified days
89217904|NCT00725855|Placebo Comparator|5|Placebo dose
89217905|NCT01326637|Experimental|intervention|Received the intervention: previsit planning phone call with filled out patient overview document & clinician huddle
89688241|NCT01728233|Experimental|Dacomitinib (PF-00299804)|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
89688242|NCT01722149|Experimental|Adoptive Transfer of re-directed T cells|Adoptive Transfer of re-directed FAP specific T cells in the pleural effusion
89688243|NCT01722227|Active Comparator|Liraglutide 0.6mg|Daily Injection
89688244|NCT01722227|Placebo Comparator|Placebo|Daily Injection
89688245|NCT01722305|Experimental|Treatment (pomalidomide, dexamethasone)|Patients receive pomalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89688246|NCT04365595||SARS-CoV-2 associated respiratory failure|Participants will receive a daily HrQoL questionnaire on their personal smartphone using the docdok health application during 3 months. A selection of participants will furthermore receive a custom-built home disease monitoring device during 1 month. Both procedures start at least 4 weeks after hospital discharge.
89688247|NCT04365517|Active Comparator|Treatment group|patients will be treated with sitagliptin add on to nutritional therapy with o without insulin treatment. The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
89688248|NCT04365517|No Intervention|Control group|Patients who will be prescribed nutritional therapy with or without insulin treatment
89688249|NCT03406871|Experimental|Nivolumab + Regorafenib|Nivolumab and Regorafenib
89688250|NCT04365439|Experimental|Convalescent plasma|Convalescent plasma from patients after COVID-19
89688251|NCT04365283|Experimental|New Bioactive Restorative Material|ACTIVA Presto restorative material
89688252|NCT04365283|Active Comparator|High Viscosity Glass Hybrid Reinforced Glass Ionomer|EQUIA Forte restorative material
89688253|NCT01728311|Experimental|Arm 1|
89688254|NCT04357093|Experimental|Grape seed extract mouthwash|Grape seed extract mouth wash 15% concentration
89688255|NCT04357093|Active Comparator|Sodium fluoride mouthwash|Sodium fluoride mouthwash 1000 ppm
89688256|NCT03406793|Experimental|1. Standard MNP|
89688257|NCT03406793|Experimental|2. High zinc, low iron MNP|
89688258|NCT03406793|Experimental|3. High zinc, low/no iron|
89688259|NCT03406793|Active Comparator|4. Dispersible zinc supplement|
89688260|NCT03406793|Experimental|5. Intermittent zinc supplement|
89688261|NCT03406793|Placebo Comparator|6. Placebo powder|
89688262|NCT04365127|Experimental|Progesterone plus SOC|Progesterone 100 mg will be administered subcutaneously twice daily for 5 days in addition to institutional standard of care
89688263|NCT04365127|No Intervention|SOC only|Subjects will receive institutional standard of care only
89688264|NCT01728467|Experimental|RVX000222, 200 mg daily|
89688265|NCT01728467|Placebo Comparator|Placebo|
89688266|NCT01722383||Chronic kidney disease|Stages 3-5 chronic kidney disease (pre-dialysis)
89688267|NCT03406559|Other|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
89688268|NCT01722461|Experimental|Active treatment|Ulthera System treatment
89688269|NCT01722461|Sham Comparator|Sham treatment|Ulthera System delivering no ultrasound energy
89688270|NCT00929773|Active Comparator|Erchonia PL2000 Laser|Low level laser light energy comprised of 1 milliWatts (mW) of red light (635 nm).
89688271|NCT00929773|Placebo Comparator|Placebo laser|inactive light
89688272|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine|"Sulfadoxine-Pyrimethamine every Four months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
89056943|NCT04549064||Patients with pancreatic cancer|Patients with pancreatic cancer did not receive any anti-cancer treatment and had no history of other malignant tumors.The diagnosis of pancreatic cancer patients is based on the final pathological diagnosis; the cancer staging is based on AJCC staging manual.
89056944|NCT04549064||Healthy Control|healthy controls had no history of benign pancreatic diseases and other benign and malignant tumors.
89056945|NCT04549220||Delivery (Birth) Cohort|All women greater than or equal (≥) to 18 years of age and emancipated minors aged between 14 and 17 years of age delivering a live infant or stillbirth at Kawempe Referral Hospital over a 6-month pilot phase will be invited to participate in the study until a sample size of at least 5000-6000 women is achieved.
89056946|NCT04549220||Active Surveillance Cohort|This is expected to improve capacity for managing and investigating infants <3 months of age presenting with suspected sepsis at Kawempe Neonatal Intensive Care Unit (NICU), Postnatal Ward, and Acute Paediatric Wards and Mulago Hospital Paediatric Acute Care Unit, through provision of supplies for blood culture, CSF culture and nasopharyngeal swabs. Mothers/caretakers of Neonates that are diagnosed with GBS through this active case surveillance will be invited to participate in the study and will be enrolled following written informed consent.
89056947|NCT02214368|Experimental|NIV bundle group|early use of NIV, and combination fiberoptic bronchoscopy and sedation
89056948|NCT02214368|Other|Conventional treatment group|standard supplemental oxygen, and conventional application of noninvasive ventilation.
89056949|NCT04529148|Experimental|The treatment group|Ginkgo biloba dropping pills (63mg / pill), oral, 5 pills each time, three times a day,12 weeks totally. ( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
89056950|NCT04529148|Placebo Comparator|The control group|Mimetic drug of ginkgo biloba dropping pills (63mg / pill),oral, 5 pills each time, three times a day,12 weeks totally.( Continued to receive the best western medicine treatment for stable angina pectoris of coronary heart disease during the observation period.)
89056951|NCT04548635|Experimental|VR-PAT|Virtual Reality administered during burn dressing changes
89056952|NCT04548635|No Intervention|Control|Dressing changes performed without Virtual Reality (other distraction methods available in the home allowed).
89056953|NCT01204294|Experimental|Bigu+Lina|biguanide plus linagliptin
89056954|NCT01204294|Experimental|Glin+Lina|glinide plus linagliptin
89056955|NCT01204294|Experimental|Glit+Lina|glitazone plus linagliptin
89056956|NCT01204294|Experimental|SU+Lina|sulfonylurea plus linagliptin
89056957|NCT01204294|Experimental|A-GI+Lina|alpha-glucosidase inhibitor plus linagliptin
89056958|NCT01204294|Active Comparator|SU+Met|sulfonylurea plus metformin
89056959|NCT01204294|Active Comparator|A-GI+Met|alpha-glucosidase inhibitor plus metformin
89056960|NCT01641276|Experimental|hepatitis|hepatitis B carriers patients
89056961|NCT01641276|Experimental|hepatocellular carcinoma patients|hepatites B carriers patients with associated hepatocellular carcinoma
89056962|NCT01182181|Experimental|Investigational Test Product|Anastrozole Tablets, 1 mg
89056963|NCT01182181|Active Comparator|Reference Listed Drug|Arimidex® Tablets, 1 mg
89056964|NCT04548674|Placebo Comparator|Positive Control Group|Whiteness HP 35%
89056965|NCT04548674|Experimental|Laser Group|Whiteness HP 35% + Laser
89056966|NCT04548674|Experimental|CPP Group|Whiteness HP 35% + CPP
89056967|NCT04548674|Experimental|Nano Group|Whiteness HP 35% + NANO
89056968|NCT04548674|No Intervention|Negative Control|Without intervention
89056969|NCT01181986|Experimental|Exenatide SC (Sub-study 1)|Study groups will be individuals with recent onset (<3 years) or established (>5 years) T2D. The plan is to achieve 40 complete studies of subcutaneous injection of exenatide BID (Byetta®, 5 or 10 µg) or identically looking Placebo SC for 10 days, separated by 14-day washout period. On the next day after each treatment phase, a single dose of the assigned medication will be injected just before a fat-enriched breakfast meal. A lunch meal of similar caloric and nutrient content will be administered 4 hours following the breakfast meal. Endothelial function will be measured just prior to the injection and every 2 hours during 8-hour post-breakfast period.
89057757|NCT01685892|Experimental|Dose-Finding: Schedule B: Previously Untreated CLL|In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
89688273|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine+Piperaquine|"Sulfadoxine-Pyrimethamine every 4 months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Piperaquine every four months Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.~Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
89688274|NCT01722539|Active Comparator|Control|"Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
89688275|NCT01722617|No Intervention|DAS 28|Patients in this group will be asked to fill basic questionnaires, but without the FLARE questionnaires.
89688276|NCT01722617|Active Comparator|DAS 28 + FLARE questionnaires|Patients in this group will be asked to fill basic questionnaires and FLARE questionnaires.
89688277|NCT01722617|Active Comparator|DAS 28+FLARE + information to doctor|Patients in this group will fill basic and FLARE questionnaires which then will be transmitted to physician.
89688278|NCT03406403|Active Comparator|Laryngeal mask airway group|20 slips of papers will be taken and labeled as group L (LMA) These slips will be placed in an envelope and one slip will be raised for each patient.
89056970|NCT01181986|Experimental|Exenatide IV (Sub-study 2)|Study group will be individuals with recent onset (<1 year) T2D on diet and impaired glucose tolerance. The plan is to achieve 35 complete studies. The intervention will include 3 randomly ordered visits with intravenous infusion of exenatide in the presence (v1) or absence (v2) of GLP-1 receptor inhibitor exendin-9, and a control test with Placebo IV without exendin-9 (v3). Endothelial function will be measured at baseline and 2 hours later during the final 15 minutes of the infusion cocktails. Study participants will remain fasting during the test visit (3 hours total).
89056971|NCT01644435|Other|Study arm A|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
89056972|NCT01644435|Other|Study arm B|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring.
89056973|NCT04315909|Experimental|Intervention group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus vitamin supplements (E (200 IU/ 2day) and C (250 mg/ 2day) ) for 8 weeks.
89056974|NCT04315909|Experimental|Control group|Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus placebo for 8 weeks.
89056975|NCT01644513||Positive Responders|Have received at least one injection with no evidence of residual subretinal or intra-retinal fluid present on Spectral Domain Optical Coherence Tomography (SDOCT) one month (+/- 1 week) following most recent injection.
89056976|NCT01644513||Suboptimal Responders|Have received three or more injections in last six months with residual subretinal or intra-retinal fluid present on SDOCT one month (+/- 1 week) following most recent injection; Have not demonstrated complete resolution of fluid following any of the injections in the last 6 months Show leakage on Fluorescein Angiography (FA) or Indocyanine Green (ICG) imaging at some time during last 12 months
89056977|NCT04548362|Experimental|Meat meals|This arm contains a 4-way cross-over intervention study with meats
89056978|NCT04548362|Experimental|Starchy meals|This arm contains a 4-way cross-over intervention study with
89056979|NCT01181167|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
89056980|NCT01181167|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
89056981|NCT01644552||eye examinations|
89056982|NCT02214446||primary caregivers of children newly diagnosed with cancer|Explore Factors related to Truth Telling in Primary Caregivers of Children Newly Diagnosed with Cancer
89217906|NCT01326637|No Intervention|observation|Received usual care
89056983|NCT04550507|Experimental|Group A: Mindful Sensory Awareness|Group A: Mindful Sensory Awareness receives the mindful sensory awareness intervention during the first 8-week period, and receives no active intervention delivery during the second 8-week period.
89056984|NCT04550507|Other|Group B: Mindful Sensory and Body Awareness|Group B: Mindful Sensory and Body Awareness receives no active intervention delivery during the first 8-week period, and during the second 8-week period receives an intervention combining the mindful sensory awareness content received by Group A with the mindful body awareness check-in approach.
89056985|NCT01644630|Active Comparator|Cemented single crowns|Cemented single crown: zirconia abutment (Straumann Cares abutment) with an all-ceramic lithium disilicate crown
89056986|NCT01644630|Active Comparator|Screw-retained single crown|Screw-retained single crown: zirconia abutment (Straumann Cares abutment), directly veneered with veneering ceramic
89056987|NCT04548557|No Intervention|Control|They will not receive any intervention
89056988|NCT04548557|Experimental|IVIG group|They will reveive intravenous immunoglobulin therapy
89056989|NCT04548323||Motor Imagery in Sedentary subjects|
89056990|NCT04548323||Motor Imagery active subjects|
89056991|NCT01181128|Experimental|Individualized (Tailored) Prophylaxis|"On rFVIIIFc Day 0, all participants underwent pharmacokinetic (PK) analysis with 50 IU/kg rFVIIIFc to estimate their PK parameters and guide the appropriate dose or interval of dosing. A subset of participants (Sequential PK subgroup) also had PK analyses performed with a single dose of 50 IU/kg Advate (Advate Day 0) within 8 weeks prior to rFVIIIFc Day 0. A >= 96 hour washout was performed before the PK dose of Advate or rFVIIIFc was administered. Repeat PK profiling with a single dose of 50 IU/kg rFVIIIFc was conducted at Week 14 or after 12 to 24 weeks of prophylaxis with rFVIIIFc.~After PK assessments, all participants started twice weekly treatment with 25 IU/kg of rFVIIIFc via intravenous (IV) injection on Day 1 and 50 IU/kg on Day 4, followed by individualized dose and interval modification within the range of 25 to 65 IU/kg every 3 to 5 days, as determined by rFVIIIFc PK analysis, to maintain a trough level of 1% to 3% (or higher, as clinically indicated) FVIII activity."
89056992|NCT01181128|Experimental|Weekly Prophylaxis|65 IU/kg of rFVIIIFc via IV injection every 7 days
89056993|NCT01181128|Experimental|Episodic (On-Demand) Dosing|10 to 50 IU/kg rFVIIIFc via IV injection, as required to treat a bleeding episode
89056994|NCT04548401||Antiplatelet-N group|Patients with ruptured aneurysm underwent coiling alone, without post-treatment antiplatelet therapy
89056995|NCT04548401||Antiplatelet-Y group|Patients with ruptured aneurysm underwent stent assisted coiling, with post-treatment antiplatelet therapy (aspirin and/or clopidogrel or ticagrelor)
89056996|NCT04548284|Experimental|Periorbitally Injected Glucocorticoids|Glucocorticoids periorbital injection. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
89056997|NCT04548284|No Intervention|Observe|Observe and wait.
89056998|NCT04547894|Experimental|ASC09F|ASC09F one tablet at a time, once per day, up to 7 days.
89056999|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,28 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 28 with equine rabies immunoglobulin 40 IU/Kg on day 0.
89057000|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,14 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 14 with equine rabies immunoglobulin 40 IU/Kg on day 0.
89057001|NCT01641315|Active Comparator|Rabies vaccine, IM Day 0,3,7,14,28 with RIG|Rabies exposed victims receive rabies vaccination intramuscularly on Day 0,3,7,14,28 with equine rabies immunoglobulin 40 IU/Kg on day 0
89057002|NCT04548011|Experimental|Three times a week group|Twenty participants in three times a week group will receive acupuncture treatment 3 times per week (every other day) for 4 weeks, 12 sessions totally. The acupuncture operation as above. Participants will not be not allowed to take any other medication or accept any treatment for FD. should not be accepted during the study. In case of unbearable symptoms, the assistant researchers will detailly document.
89057003|NCT04548011|Experimental|Once a week group|Twenty participants in once a week group will receive acupuncture treatment 1 time per week for 4 weeks (Weekly fixed day), 4 sessions totally. Other inventions will be same as the Three times a week group.
89057004|NCT04548011|No Intervention|Waiting for treatment group|After the health education（such as dietary adjustment for FD patients）, the participants will be followed up for 4 weeks. At the end of the follow-up, the patients could be given free acupuncture treatment (the invention will be similar with that of the Three times a week group) for 4 weeks at will.
89057005|NCT01641393|Experimental|EUR-1008 then Kreon|"EUR-1008 during Treatment Period 1 (29 days ±2 days) and~Kreon during Treatment Period 2 (29 days ±2 days)."
89057006|NCT01641393|Experimental|Kreon then EUR-1008|"Kreon during Treatment Period 1 (29 days ±2 days) and~EUR-1008 during Treatment Period 2 (29 days ±2 days)."
89217907|NCT02538458|Active Comparator|Test group|3 % hypertonic saline up to 72H.
89217908|NCT02538458|Placebo Comparator|Placebo control group|"3 % hypertonic saline up to 24H.~Followed by 48 hours of placebo (nebulized 0.9% normal saline)."
89217909|NCT00509223|Experimental|Group 1|Lifestyle counseling with Positive Airway Pressure (PAP) therapy
89217910|NCT00509223|Active Comparator|Group 2|Lifestyle counseling without Positive Airway Pressure (PAP) therapy
89217911|NCT01582867|Experimental|HD and HDF|During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
89217912|NCT01582867|Experimental|HDF and HD|patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
89217913|NCT02538380|Experimental|EUS-B-FNA for LAG analysis|All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
89217914|NCT05277662|Experimental|Precision diagnostics profiling|The study will involve subjects with endoscopically, laboratory and clinically confirmed diagnoses of organic and functional intestinal pathology or none of the above (healthy volunteers). All diagnoses are defined in accordance with the validated criteria presented in the clinical guidelines for the diagnosis and treatment of functional bowel pathology (Irritable Bowel Syndrome), 2020, Crohn's Disease (approved by the Ministry of Health of the Russian Federation, 2020), Ulcerative Colitis (approved by the Ministry of Health of the Russian Federation, 2020), in accordance with international criteria of ECCO-ESGAR Guidelines, 2018, 2019. After the initial screening and inclusion in the study, intestinal biopsy samples are taken in accordance with the applied endoscopic examination technique during the endoscopic examination. These biopsy samples will be further used for molecular and immunological diagnostics.
89217915|NCT04067063||Milpa Alta inhabitants|Population among 15 and 70 years old
89217916|NCT00460798||Non-Interventional Study|
89217917|NCT03965455||conventional group|
89217918|NCT03965455||diode laser group|
89217919|NCT02570399|Experimental|Lymph nodal metastatic lesions|Oligometastatic patients with abdominal-pelvic lymph nodes
89217920|NCT01075165|Experimental|Silicone Spray|Apply spray silicone
89217921|NCT01075165|Placebo Comparator|Saline Spray|Apply Saline Spray
89217922|NCT00726869|Experimental|Cohort 1|2.5 mg/kg
89217923|NCT00726869|Experimental|Cohort 2|5.0 mg/kg
89217924|NCT00726869|Experimental|Cohort 3|10.0 mg/kg
89217925|NCT00726869|Experimental|Cohort 4|20.0 mg/kg
89217926|NCT01028248|Active Comparator|2.0 mg Ranibizumab|
89217927|NCT01028248|Active Comparator|0.5 mg Ranibizumab|
89217928|NCT00726011|Experimental|Tetrodotoxin|There is only one arm; active treatment with TTX
89217929|NCT01028326|Experimental|Group A|Group A of children will receive 2 doses of PCV10 vaccine, one at the time of enrolment and one 2 months later, followed by a dose of DTaP vaccine 4 months later
89217930|NCT01028326|Experimental|Group B|Group B of children will receive PCV10 vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of PCV10 4 months later.
89217931|NCT01028326|Active Comparator|Group C|Group C of children will receive a dose of hepatitis A vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of hepatitis A 4 months later, along with a dose of PCV10.
89217932|NCT00603980|Other|Treatment sequence 1|Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217933|NCT00603980|Other|Treatment sequence 2|Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217934|NCT00603980|Other|Treatment sequence 3|Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217935|NCT00603980|Other|Treatment sequence 4|Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89057007|NCT04547933||OAB-wet|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency and urinary incontinence (UI) were allocated to the overactive bladder syndrome (OAB) -wet group.
89057008|NCT04547933||OAB-dry|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of urgency but without incontinence were allocated to the OAB-dry group.
89057009|NCT04547933||UI|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with at least one episode of UI but without urgency were allocated to the UI group.
89057010|NCT04547933||Nocturia|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 2 episodes of nocturia but without urgency and UI were allocated to the nocturia group.
89057011|NCT04547933||Frequency|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women with more or equal to 8 episodes of daytime frequency but without urgency, UI and nocturia were allocated to the frequency group.
89057012|NCT04547933||Normal|The bladder diaries and the King's Health Questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. Based on bladder diaries, women without urgency, UI, nocturia nor frequency were allocated to the normal group.
89057013|NCT01641432|Experimental|TAPAT|Computerized Tonic and Phasic Attention training consisting of visual, auditory, and spatial stimuli that requires sustained attention (24 minutes). Training is followed by a computerized cognitive exercise (12 minutes).
89057014|NCT01641432|Active Comparator|Active Comparator|Computerized conventional board-games that lack the therapeutic effect of the TAPAT exercises. Active control has stimulus parameters similar to the TAPAT exercises (eg. stimuli is presented on the computer, participant responses are collected, session time and improvement is measured).
89057015|NCT04547972|Active Comparator|Higher-load limbs|This treatment arm will have participants performing resistance training with loads of ~80% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
89057016|NCT04547972|Active Comparator|Lower-load limbs|This treatment arm will have participants performing resistance training with loads of ~30% of an individuals one-repetition maximum. Each participant will have one arm and one leg assigned to this condition.
89057017|NCT01644825|Experimental|paclitaxel and pazopanib|
89057018|NCT01644825|Active Comparator|paclitaxel|
89057019|NCT04547660|Experimental|Convalescent Plasma|Transfusion of 2 aliquots of 300 ml of frozen convalescent plasma, 2 days apart, thawed at 37 degrees Celsius before infusion. Best supportive care except for investigational interventions.
89057020|NCT04547660|Active Comparator|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
89057021|NCT01644864|Placebo Comparator|Placebo|saline injection
89057022|NCT01644864|Experimental|Experimental|0.375% ROPIVACAINE
89057023|NCT04547855|Experimental|experimental group|anlotinib combined with dose-dense temozolomide
89057024|NCT01641510|Experimental|Prasugrel|Loading and maintenance dose of prasugrel
89057025|NCT01641510|Active Comparator|Clopidogrel|Loading and maintenance dose of clopidogrel
89057026|NCT01644942|Other|Insulin sensitive patients|
89057027|NCT01644942|Other|Insulin resistant patients|
89057028|NCT04547621|Experimental|HSRT+IMRT+Temozolomide|"Intensity-modulated radiotherapy 20Gy/10fx, 5 days a week for 2 weeks.~Hypofractionated stereotactic radiotherapy 30Gy/5fx, 5 days a week for 1 week.~Temozolomide once daily (75mg/m2/d) orally administered concurrently with radiotherapy."
89057029|NCT01644981||VLBW infants|
89057030|NCT01641549|Experimental|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
89057031|NCT01641549|Active Comparator|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent
89057032|NCT04547348|Experimental|Denosumab treated group|Participants will receive a 60 mg subcutaneous injection of Prolia upon randomization and on week 28 after the first injection provided remission of the Charcot foot has not been achieved by then
89057033|NCT04547348|Placebo Comparator|Placebo treated group|Participants will receive an injection of placebo produced by the same provider as the prolia drug of equivalent volume at the same time points as the treated group
89057034|NCT04547426|Active Comparator|red wine and snuff|regular red wine and moist snuff
89057035|NCT04547426|Active Comparator|red wine and nicotine-free snuff|regular red wine and nicotine-free snuff
89057036|NCT04547426|Active Comparator|non alcoholic red wine and regular moist snuff|non alcoholic red wine and regular moist snuff with nicotine
89057037|NCT04547426|Placebo Comparator|non-alcoholic red wine and nicotine-free snuff|Non-alcoholic red wine and nicotine-free snuff
89057038|NCT04547387||Carotid Artery Stenting|Consecutive patients with symptoms or signs of ischemic cerebral injury eligible for endovascular carotid artery revascularization using direct carotid artery access and MicroNET covered carotid stent plaque exclusion under cerebral protection by temporary flow reversal
89057039|NCT01641627|Experimental|vibration|proprioceptive stimulation of the lower limb using vibration and plantar pressure boots
89057040|NCT04547231||Deferral of PCI group|Patients with a vessel determined to defer revascularization after FFR measurement who undergo CCTA within 90 days before FFR measurement will be included.
89057041|NCT04547231||PCI group|Patients with a vessel that undergo stent implantation and FFR measurement both before and after revascularization (pre-PCI FFR and post-PCI FFR) with available coronary CT angiography within 90 days before FFR measurement will be included.
89057042|NCT01641666|Experimental|Peg2b + Ribavirin + Boceprevir|Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
89057043|NCT02214485|Experimental|integrated care (IC)|Subjects will receive such care twice weekly for 12 weeks.
89057044|NCT02214485|Experimental|lower extremity strength training (LEST)|Subjects will receive training twice weekly for 12 weeks
89057045|NCT01645215|Experimental|Fruquintinib capsule|cohort 1: fruquintinb continuous oral dosing (1mg once a day) cohort 2: fruquintinb continuous oral dosing (2mg once a day) cohort 3: fruquintinb continuous oral dosing (4mg once a day) cohort 4: fruquintinb continuous oral dosing (6mg once a day) cohort 5: fruquintinb continuous oral dosing (5mg once a day) cohort 6: fruquintinb oral dosing, 3 weeks on/1 week off (5mg once a day) cohort 7: fruquintinb oral dosing, 3 weeks on/1 week off (6mg once a day)
89057046|NCT01203787|Active Comparator|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24
89057047|NCT01203787|Experimental|Sorafenib Ramp-Up Regimen|200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24
89057048|NCT01641744|Experimental|Group Attachment Based Intervention (GABI)|
89057049|NCT01641744|Active Comparator|Systematic Training for Effective Parenting (STEP)|
89057050|NCT02887768|Experimental|Treatment|Epicardial Infarct Repair with CorMatrix-ECM in addition to coronary artery bypass grafting
89057051|NCT04547504|Active Comparator|Pembrolizumab|Pembrolizumab
89057052|NCT04547504|Active Comparator|Chemotherapy-Pembrolizumab|Chemotherapy and Pembrolizumab
89057053|NCT01645254|Experimental|Argemone mexicana|"Argemone mexicana is traditional medicinal plant known as having an antimalarial activity.~The aerial part of this plant is used. The decoction of the powder of the plant will be used."
89057054|NCT01181011|Experimental|amlodipine/telmisartan/combination|all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order
89057055|NCT04528602|Experimental|Control (Extended leg position) Group|In the control (Extended leg position) group of the study, diaper change will be performed after the legs of the babies are brought to extension.
89057056|NCT04528602|Experimental|Experimental (Legs are flexed toward abdomen) Group|In the experimental (Legs are flexed toward abdomen) group, the diaper change will be performed after the legs of the babies are brought closer to the abdomen while maintaining their flexion leg position.
89057057|NCT04546997||Patients with ocular blunt trauma|Patients with previous ocular blunt trauma in one eye.
89057058|NCT04546997||Control Group|Healthy fellow eyes without actual and previous ocular trauma
89057059|NCT01180777|Other|etafilcon A (A)/etafilcon A (B)/etafilcon A (C)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
89057060|NCT01180777|Other|etafilcon A (A)/etafilcon A (C)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
89057061|NCT01180777|Other|etafilcon A (C)/etafilcon A (A)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
89057062|NCT01180777|Other|etafilcon A (B)/etafilcon A (C)/etafilcon A (A)|Printed etafilcon A Lens with PVP (B) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
89057063|NCT01180777|Other|etafilcon A (C)/etafilcon A (B)/etafilcon A (A)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
89057064|NCT01180777|Other|etafilcon A (B)/etafilcon A (A)/etafilcon A (C)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
89057065|NCT01641783|Experimental|nanoparticle Albumin-bound paclitaxel|evaluate one dose level of nab-paclitaxel:125mg/m2
89057066|NCT02214524|Experimental|Bair hugger forced air warming therapy|Use of Bair Hugger forced-air warming system perioperatively to keep patient normothermia
89057067|NCT02214524|No Intervention|conventional warming care|conventional warming care
89057068|NCT02214602|Experimental|Study group(Epirubicin)|in this arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor
89057069|NCT02214602|No Intervention|Control group|in this arm -control group- : patients will not receive immediate intravesical instillation of of epirubicin after compete transurethral resection of bladder tumor.
89057070|NCT01646580|Experimental|ciclopirox|
89057071|NCT04546802|Active Comparator|Immediate treatment|This group will undergo immediate treatment of the HCV once HCC complete response (CR) has been confirmed
89057072|NCT04546802|Active Comparator|Delayed treatment|This group will delay commencement of the HCV treatment until 6 months after HCC complete response (CR) has been confirmed
89057073|NCT04546880|Experimental|Group 1:Breathing and Stabilization Exercise Group|Breathing exercises combined with stabilization exercises
89057074|NCT04546880|Active Comparator|Group 2: Stabilization Exercise Group|Only Stabilization exercises therapy
89057075|NCT01645293|Experimental|Genetically modified T cells #1138|
89057076|NCT01648023|Experimental|Randomization to LC OR ONCOZENE Bead with Gem-Cis or Gem-Carbo|Transarterial Chemoembolization (LC or ONCOZENE Bead) with Gem-Cis or Gem-Carbo
89057077|NCT01648023|Active Comparator|Randomization to Gem-Cis or Gem-Carbo|Gem-Cis or Gem-Carbo alone
89057078|NCT04547114||SARS-CoV-2- infected|Detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
89057079|NCT04547114||non infected|Lack of detection of SARS-CoV-2 RNA by PCR in nasopharyngeal/oropharyngeal swabs
89057080|NCT01580033|Experimental|A+C+hib Conjugate Vaccine|600 infants aged 3-5 months, will be vaccinated on day0, 28, 56
89057081|NCT01580033|Active Comparator|Walvax AC vaccine, Pasteur Hib vaccine|300 infants aged 3-5 months, will be vaccinated on day0, 28, 56
89057082|NCT04547036||Endothelial cell count measurment|
89057083|NCT01645332|Placebo Comparator|Treatment I (control)|Placebo of DLBS3233 once daily for 12 weeks + lifestyle modification
89057084|NCT01645332|Experimental|Treatment II|100 mg DLBS3233 once daily for 12 weeks + lifestyle modification
89057085|NCT04546763||Paroxysmal Atrial Fibrillation Patients|This will be a single arm study of patients with paroxysmal atrial fibrillation. Subjects will be wearing the Study Watch and Zio XT Patch concurrently for up to 14 days.
89057086|NCT02757222|Active Comparator|Standard dose|Patients receive a radiation dose of 66Gy in 30 fractions to the planning target volume 1 (PTV1) and 54 Gy in 30 fractions to the PTV2 concurrent with platinum chemotherapy weekly
89057087|NCT02757222|Experimental|Escalated dose|Patients receive a radiation dose of 73.5 Gy in 30 fractions to the boost target volume (BTV), 63Gy in 30 fractions to PTV1 and 54 Gy in 30 fractions to PTV2 concurrent with platinum chemotherapy weekly
89057088|NCT04546490|Experimental|Pressure release|It will be applied with the patient in a supine position. The therapist will clamp his first and second fingers over the Myofascial Trigger Point located on the upper trapezium, it will be marked previously. The pressure will increase as the therapist perceives a reduction in the resistance offered by the soft tissue under his finger within a period of 90 seconds.
89057089|NCT04546490|Experimental|Ischemic pressure|Patient in supine position, the therapist performs pressure with first and second finger in PGM marked previously, this is performed until the patient tolerance, when the patient refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier. Repeat the process for 90 seconds.
89057090|NCT04546490|No Intervention|Control Group|Patient in supine position on the stretcher, the therapist performs a clamp with the first and second finger on the upper trapezius muscle without making any pressure on it during 90 seconds
89057091|NCT01645371||Subjects with opioid induced constipation|
89057092|NCT01645410|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
89057093|NCT01645410|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
89057094|NCT04546334|Experimental|Group A|Patients will be subjected to the routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector spinae plane block
89057095|NCT04546334|Experimental|Group B|Patients will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical treatment.
89057096|NCT04546334|Experimental|Group C|Patients that will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg)) together with medical treatment.
89057097|NCT04546256|Experimental|Test Product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89057098|NCT04546256|Active Comparator|Reference Product|ADVAIR DISKUS® 500/50
89057099|NCT01645449|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
89688279|NCT03406403|Active Comparator|Magensium sulphate group|20 slips of papers will be taken and labeled as group M (Mgso4) These slips will be placed in an envelope and one slip will be raised for each patient
89688280|NCT03406403|Active Comparator|Control group (closure of anesthetics)|20 slips of papers will be taken and labeled as group C (Control) These slips will be placed in an envelope and one slip will be raised for each patient.
89688281|NCT04378517|Other|ADHD FAM-SOTC support: A Pilot Study|"Phase-I, a pilot study to evaluate the feasibility of offering a 5-week intervention for families of adolescents diagnosed with ADHD at BUGL. The outcome helps to determining the feasibility of subjecting the intervention to a more rigour and a more expensive and time-consuming RCT.~Phase-II and III are an RCTs to determine the benefit of a FAM-SOTC intervention: Is there a significant difference in the impact of FAM-SOTC intervention:~From caregiver's perspective (phase II) on the experience of support for, family functioning, believes, coping patterns, general well-being, parental adaptation and parental assessment of ADHD symptoms and adolescent developmental disruptive behaviour, compared to caregivers receiving delayed treatment?~From adolescents' perspective (Phase-III) in the assessment of adolescents own self-awareness and self-esteem, after their parents receive FAM-SOTC intervention, compared to a group of adolescents where caregivers receive delayed treatment?"
89688282|NCT04357171|Active Comparator|Ileostomy|Loop protective ileostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
89688283|NCT04357171|Active Comparator|Colostomy|Loop protective transverse colostomy as a defunction mean after low anterior resection with D3 lymphnode dissection
89688284|NCT03406169|Active Comparator|Sildenafil 25mg Oral Tablet|25mg sildenafil citrate twice daily
89688285|NCT03406169|Active Comparator|Pentoxifylline|400mg pentoxifylline twice daily
89057100|NCT01645449|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
89057101|NCT04546100|Experimental|Maternal-Infant Exercise Program|"In the postpartum period, give the intervention group Maternal-Infant Exercise Program and encourage them to do exercise. The Parent-Child Exercise Program can be divided into three stages. Videos will be provided in each stage. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
89057102|NCT04546100|Placebo Comparator|Regular postpartum exercise guidance|"Another group will receive Regular postpartum exercise guidance. The guidance includes chest exercises, neck exercises, leg exercises, hip exercises, abdominal exercises, vagina contraction exercises, and uterine contraction exercises, starting from the third day after delivery to one month after delivery. The detail information will refer to the General Hospital of Tri-Services Provided the postpartum health education manual-postpartum exercise (p.8-10)"
89057103|NCT01645761|Experimental|PPI-based triple therapy with endonase|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week) plus 20,000 units of endonase twice daily for one week.
89057104|NCT01645761|No Intervention|PPI-based triple therapy|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week)
89688286|NCT03406169|Placebo Comparator|Placebo|placebo twice daily
89688287|NCT04346875|Experimental|Regularly changing group|Participants will undergo dressing every 3 days by the senior wound care nurse
89688288|NCT04346875|Active Comparator|Non-changing group|Participants will not be subject to dressing change.
89688289|NCT01722695|Other|Revaclear followed by FX|
89057105|NCT04546646|Experimental|GROUP A (Elastic Band Exercises)|Warm up: for 10 min, Exercise: Lower limb exercises using elastic band for 30 min. Cool down: Self-stretches 5 min.
89057106|NCT04546646|No Intervention|GROUP - B (No Intervention)|Routine activities of daily living
89057107|NCT02759640|Experimental|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
89057108|NCT04546529|Active Comparator|TsMS active|Patients undergoing real Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
89688290|NCT01722695|Other|FX followed by Revaclear|
89688291|NCT04357327|Experimental|Symptomatic patients|Patients with symptoms associated with COVID-19, i.e., dyspnea, cough, fever, etc.
89057109|NCT04546529|Sham Comparator|TsMS sham|Patients undergoing placebo Trans-spinal Magnetic Stimulation (TsMS) for 8 weeks
89057110|NCT04546022|Other|GSP measurement|For the GSP measurement, subjects will be Intravenous administered with 1.25 ml/kg G.S.P. solution (400 mg/ml of galactose) to subjects after I.V. G.SP. solution within 3 to 5 minutes. Sixty minutes after- G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of GSP value.
89057111|NCT01645800|Experimental|Lysozyme hydrochloride|
89057112|NCT01645800|Placebo Comparator|Placebo|
89057113|NCT01645878|Experimental|Hands on|breast feeding instructed by direct help of instructor
89688292|NCT04357327|Active Comparator|Asymptomatic subjects|Asymptomatic patients with low risk phenotype, that means patients with a previous negative swab, no relatives affected by COVID-19 and with reduced social interaction within the last two weeks.
89688293|NCT03835793||Early-RRSO|"RRSO before the age of 45 years~RRSO was done 10 or more years ago"
89688294|NCT03835793||Late-/non-RRSO group|"Natural menopause ≥ 50 years of age~No RRSO ≤ age of 55~No treatment-induced menopause ≤ 50 years of age"
89688295|NCT02982109||Postop pain level 1|Minor postoperative pain anticipated
89688296|NCT02982109||Postop pain level 2|Might experience postoperative pain
89688297|NCT02982109||Postop pain level 3|Moderate pain/substantial surgery performed
89688298|NCT02982109||Postop pain level 4|Severe postoperative pain expected/major surgery
89688299|NCT04357015|Experimental|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
89057114|NCT01645878|Experimental|hands off|
89057115|NCT01645878|Other|Control|Routin breast feeding education
89057116|NCT04546607|Experimental|Nuvastatic TM|Nuvastatic TM (C5OSEW5050ESA) capsule 1000 mg administered orally 3 times a day for 9 weeks.
89057117|NCT04546607|Placebo Comparator|Placebo|Excipient, without Nuvastatic TM (C5OSEW5050ESA) capsule administered orally 3 times a day for 9 weeks.
89057118|NCT01645917|Experimental|Ablation|Ablation with Arctic Front Advance Cardiac CryoAblation system
89057119|NCT02278445|Experimental|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
89057120|NCT02278523|Experimental|Inspiratory muscle training group|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
89057121|NCT02278523|Active Comparator|control group|normal volunteers use Inspiratory muscle trainer(Threshold IMT®)
89057122|NCT01645956||Single group|
89057758|NCT01685892|Experimental|Safety Expansion: Relapsed/Refractory CLL|In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
89217936|NCT00603980|Other|Treatment sequence 5|Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89688300|NCT04357015|Active Comparator|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
89688301|NCT04357015|Placebo Comparator|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
89688302|NCT03835637|Experimental|Regimen A|
89688303|NCT03835637|Experimental|Regimen B|
89688304|NCT03835637|Experimental|Regimen C|
89688305|NCT03835637|Experimental|Regimen D|
89688306|NCT03835637|Experimental|Regimen F|
89688307|NCT03835637|Experimental|Regimen H|
89688308|NCT03835637|Experimental|Regimen I|
89688309|NCT04364893|Other|Group 1|Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
89688310|NCT04364893|Other|Group 2|Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
89688311|NCT01722773|Active Comparator|Bipap|Bipap
89688312|NCT01722773|No Intervention|Standard of care|No intervention
89688313|NCT04356703||Children submitted to fetoscopic surgery|Children submitted to fetoscopic in utero myelomeningocele repair using the SAFER (Skin-over-biocellulose for Anternatal FEtoscopic Repair) technique will evaluate the neuropsicomotor development at 30 months of chronological age or older
89688314|NCT04364815|Experimental|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine oral loading dose of 400mg two times per day on Day 1 then 400 mg once a day for Day 2-10 plus standard preventive measures as defined by PGH Hospital Infection Control Unit (HICU)
89688315|NCT04364815|Placebo Comparator|Placebo plus standard preventive measure|Placebo tablet plus standard preventive measures as defined by PGH-HICU
89688316|NCT03406013|Active Comparator|Group I|Written Information
89688317|NCT03406013|Experimental|Group II|Written Information Prescription
89688318|NCT03406013|Experimental|Group III|Written Information Prescription Technology
89688319|NCT03406013|Experimental|Group IV|Written Information Prescription Technology Coaching
89688320|NCT01728701|Experimental|Grp 1: 75,000 PfSPZ Challenge, 3 immunizations|Grp 1 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 1 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 1 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
89688321|NCT01728701|Placebo Comparator|Grp 2: Normal Saline (NS)|Grp 2 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 2 gets ID injections of normal saline, on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 2 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
89688322|NCT01728701|Experimental|Grp 3: 75,000 PfSPZ Challenge, 3/4 immunizations|Grp 3 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 3 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 3 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will receive 1 additional immunization (immunization 4), consisting of 6 ID injections on the same day of 75,000 PfSPZ Challenge, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 3 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
89688323|NCT01728701|Placebo Comparator|Grp 4: Normal Saline (NS)|Grp 4 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 wks(98 days). In this time, Grp 4 gets ID injections of NS, on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 4 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will receive 1 additional immunization (immunization 4), consisting of ID injections of NS, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 4 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
89688324|NCT03405857|Experimental|Group 1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
89688325|NCT03405857|No Intervention|Group 2|No intervention will be administered
89688326|NCT04356625|Other|MEPic|"Ready for extubation (pass SBT)~Measurement of maximum expiratory pressure during the induced cough (MEPic)"
89688327|NCT04377269|Experimental|Taping Group|33 participants, received ankle taping
89688328|NCT04377269|Experimental|Bandaging|33 participants, received ankle bandaging
89688329|NCT04377269|Placebo Comparator|Placebo Taping (Control) Group|34 participants, received ankle placebo taping
89688330|NCT04652713|Experimental|High protein breakfast|Participants will be served a dairy-based protein-rich breakfast meal.
89688331|NCT04652713|Experimental|High carbohydrate breakfast|Participants will be served a carbohydrate-rich breakfast meal
89688332|NCT04652713|Experimental|No breakfast|Participants will be served no breakfast
89688333|NCT04377191|Experimental|VR 1 Group|In this group, participants received standard exercise and exergame training with Microsoft Xbox 360 Kinect for 2 days per week for 6 weeks.
89688334|NCT04377191|Experimental|VR 2 Group|In this group, participants received standard exercise and exergame training with ALDA balance gear for 2 days per week for 6 weeks.
89688335|NCT04377191|Active Comparator|Control Group|In this group, participants received only standard exercise for 2 days per week for 6 weeks.
89688336|NCT01728857|Experimental|Fat Reduction|
89688337|NCT02245243|Experimental|Delafloxacin|Single Dose 300 mg IV
89688338|NCT03405701|Active Comparator|IVM (in vitro maturation)|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
89057123|NCT02214680|Experimental|Combination of Brimonidine and Timolol|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
89057124|NCT02214875|Experimental|CQI/BTS|"Experimental: CQI/BTS~CQI/BTS interventions will be applied through rapid structured cycles of data collection, testing of solutions and review of changes will be done. At each site, Quality Improvement Teams (QIT) will be established among facility staff. Local Government/State QI teams will provide oversight function of facility based QI initiatives. Break Through Collaborative Series (BTS) will hold quarterly in each study state at a central location with participants from intervention sites. Sessions will provide opportunity for teams to learn from each other; adapt and implement changes using the Plan-Do-Study-Act (PDSA) model. Process indicators will be used to measure quality improvement from the intervention sites and collaboratives."
89057125|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
89057126|NCT02756208|Experimental|300 ug FLSC vaccine|Subjects will be vaccinated with 300 ug FLSC vaccine (highest vaccine dose) on study days 0, 28, 56 and 168.
89057127|NCT02756208|Experimental|150 ug FLSC vaccine|Subjects will be vaccinated with 150 ug FLSC vaccine (middle vaccine dose) on study days 0, 28, 56 and 168.
89057128|NCT02756208|Experimental|75 ug FLSC vaccine|Subjects will be vaccinated with 75 ug FLSC vaccine (lowest vaccine dose) on study days 0, 28, 56 and 168.
89057129|NCT02756208|Placebo Comparator|Placebo|Subjects will be vaccinated with placebo (control group) on study days 0, 28, 56 and 168.
89057130|NCT04545788|Active Comparator|A|4-6 INH EMB PZA Pto AM Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, AM: Amikacin, Cfz: Clofazimine, Mfx: Moxifloxacin) A group is the control group which includes injectable drugs (AM).
89057131|NCT04545788|Experimental|B|4-6 INH EMB PZA Pto LZD Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, LZD: Linezolid, Cfz: Clofazimine, Mfx: Moxifloxacin) B group is the experimental groups which is total oral short-term therapy.
89057132|NCT04545788|Experimental|C|4-6 BDQ LZD MFX CS CFZ / 5MFX CS CFZ (BDQ: Bedaquiline, LZD: Linezolid, Mfx: Moxifloxacin, CS: Cycloserine, Cfz: Clofazimine) C group is another experimental groups which is also total oral short-term therapy, and includes new anti-TB drugs: BDQ.
89057133|NCT02756013|Experimental|Paclitaxel + Carboplatin|Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.
89057134|NCT01680003|Experimental|Hepar-P|Hepar-P: Two capsules (250mg x 2), three times daily, orally
89217937|NCT00603980|Other|Treatment sequence 6|Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217938|NCT00603980|Other|Treatment sequence 7|Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217939|NCT00603980|Other|Treatment sequence 8|Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217940|NCT00603980|Other|Treatment sequence 9|Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217941|NCT00603980|Other|Treatment sequence 10|Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217942|NCT00603980|Other|Treatment sequence 11|Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217943|NCT00603980|Other|Treatment sequence 12|Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217944|NCT00603980|Other|Treatment sequence 13|Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217945|NCT00603980|Other|Treatment sequence 14|Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
89217946|NCT01026766||Non obese/ Warming blankets|
89217947|NCT01026766||Non obese/ Warming intravenous fluids|
89217948|NCT01026766||Obese/ Warming intravenous fluids|
89217949|NCT01026766||Obese/ Warming blankets|
89217950|NCT04880603|Active Comparator|A - Standard of Care|
89217951|NCT04880603|Experimental|B - Restrata Graft|
89217952|NCT01028404|Experimental|Trial part 1|
89217953|NCT01028404|Experimental|Trial part 2|
89217954|NCT00726947|Experimental|1|Ultrasound imaging of Acute DVT (deep vein thrombosis)
89217955|NCT00726947|Experimental|2|Ultrasound imaging of Chronic DVT (deep vein thrombosis)
89217956|NCT00450190|Experimental|Saizen® E-Device|
89217957|NCT01028482|Experimental|sertraline, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
89533007|NCT05675410|Experimental|Arm E (ABVD, AVD)|Patients receive AVD regimen (doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV) on days 1 and 15 of each treatment cycle. Each cycle lasts 28 days. Treatment continues for 4 cycles. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
89057135|NCT01680003|Placebo Comparator|Placebo for Hepar-P|Placebo: Two capsules, three times daily, orally
88815314|NCT01024010|Experimental|Arm A (PCO, closed to accrual as of 8/23/2011)|Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89057136|NCT01680042|Active Comparator|phenytoin paste|this group receives phenytoin paste after oral biopsy
89057137|NCT01680042|Placebo Comparator|usual mucoadhesive paste|this group receives the usual mucoadhesive paste without phenytoin after oral biopsy
89057138|NCT01646229|Active Comparator|Polymyxin-B hemoperfusion|In the HEMOPERFUSION group, a veno-venous dialysis catheter type GamCath 12 F, 3 lumen will be inserted instead of a regular double or triple-lumen central venous catheter, and connected to the Toraymyxin® (PMX-20-R) device for endotoxin adsorption by hemoperfusion with the DECAPSMART pump. The length of the hemoperfusion will be a minimum of 120 min and started just before the beginning of the surgical intervention in the OR and stopped at the end of surgery.
89057139|NCT01646229|Active Comparator|Control|"In the CONTROL group, the administration of fluids (250 to 500ml crystalloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP between > 8 and 12 < mmHg, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mMol/L, normalisation of the BE.~At the discretion of the attending anaesthesiologist with the FMH level, a PiCCO monitoring, a transoesophageal echography, or a pulmonary artery catheter, will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
89057140|NCT01680081|Experimental|CT perfusion group|
89057141|NCT04545203|Experimental|Slow-Stroke Back Massage Group|
89057142|NCT04545203|No Intervention|Control group|
89217958|NCT01028482|Placebo Comparator|placebo, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
89217959|NCT00907322|Experimental|Dimbeon 20 mg|
89217960|NCT00907322|Experimental|Dimebon 40 mg|
89217961|NCT00907322|Experimental|Dimebon 60 mg|
89217962|NCT00907322|Experimental|Placebo|
89217963|NCT00903188|Active Comparator|Cyclosporine|Simulect + cyclosporine + Myfortic + steroid stop at 3 months
89217964|NCT00903188|Active Comparator|Everolimus|Simulect + cyclosporine (decrease dose in one week at month 3 and replace by Everolimus (Certican)) + Myfortic + steroid maintenance
89217965|NCT00726245|Experimental|1|PRGF
89217966|NCT00726245|Placebo Comparator|2|physiological saline
89217967|NCT00727181|Other|Trifecta Valve|The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.
89217968|NCT00908726|Experimental|Microemulsion propofol|
89217969|NCT00908726|Active Comparator|Lipid emulsion propofol|
89217970|NCT02948309|Experimental|Mistletoe extract (Iscador Qu)|Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg
89217971|NCT02948309|Placebo Comparator|Placebo|isotonic saline solution, subcutaneous use 3 injections/week
88815315|NCT01024010|Experimental|Arm B (PCO with ofatumumab consolidation)|Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88815316|NCT00990782|Experimental|Single Arm|PillCam ESO Capsule Endoscope - all patients receive capsule endoscopy before and after RFA procedure.
89217972|NCT00726401|Active Comparator|1|
89217973|NCT00726401|Placebo Comparator|2|
89217974|NCT00903266|Experimental|MIT|Melodic Intonation Therapy
89217975|NCT00903266|Active Comparator|SRT|Speech-Repetition-Therapy
89217976|NCT00903266|No Intervention|NTC|No-Therapy Control; Patients in this arm will be re-randomized to the two active arms at the end of the NTC period.
89217977|NCT02569775|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
89217978|NCT00449956|Experimental|1|combination of dorzolamide hydrochloride and timolol maleate
89217979|NCT00449956|Active Comparator|2|Concomitant use of dorzolamide hydrochloride and timolol maleate
89217980|NCT00449956|Active Comparator|3|timolol maleate
89217981|NCT00908804|Active Comparator|open appendectomy|
89217982|NCT00908804|Active Comparator|laparoscopic appendectomy|
89217983|NCT00903422|Active Comparator|Eltrombopag|Eltrombopag
89217984|NCT00903422|Placebo Comparator|Placebo|Placebo
89217985|NCT01323088|Other|Control|Standard care control (no-exercise)
89217986|NCT01323088|Active Comparator|Aerobic Exercise|
89217987|NCT01323088|Active Comparator|Resistance Exercise|
89217988|NCT00907400|Experimental|1|PN400
89217989|NCT00907400|Active Comparator|2|Naprosyn E
89217990|NCT00726635|Active Comparator|1|Women in this arm will not receive a psychological intervention but rather will have a conversation with a nurse for one hour (attention control).
89217991|NCT00726635|Experimental|2|Cognitive intervention: Women in this arm will receive a cognitive psychological intervention(cognitive technique:self-talk)
89217992|NCT00726635|Experimental|3|Psycho-physiological intervention: Women in this arm will receive a psycho-physiological intervention (relaxation and guided imagery)
89217993|NCT01026922||SmartPill Participants|It is a single-center study, children aged 8-17 years with severe upper GI symptoms (ie, nausea, vomiting, retching, abdominal pain) referred for antroduodenal manometry (ADM) studies underwent a wireless motility capsule (smartpill) test. The scintigraphic gastric emptying study was done when clinically indicated either at the time of the ADM or at a different time within 1 year of the wireless motility capsule test. In summary, we studied symptomatic adolescents using scintigraphic gastric emptying studies, ADM, and the wireless motility capsule test, with the goal of identifying the diagnostic yield of each test and exploring how they compare in detecting motor abnormalities in the GI tract.
88815317|NCT02484690|Active Comparator|Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)|Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
88815318|NCT02484690|Experimental|Arm B: Faricimab, 1.5 mg Q4W|Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
89057143|NCT04545086|Experimental|VBE Group|Video Based Education was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
89057144|NCT04545086|Experimental|MT Group|Music Therapy was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation and Opinion regarding intervention was done.
89057145|NCT04545086|No Intervention|Control Group|Routine Information was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation was done.
89057146|NCT01646307|Placebo Comparator|standard care group|patients receive atorvastatin 20 mg/d
89057147|NCT01646307|Active Comparator|intensive rosuvastatin|administrated with rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d for 30 days after PCI
89057148|NCT01646307|Active Comparator|intensive atorvastatin|patients will be administrated with atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days after PCI;
89057149|NCT04548089|Experimental|Immediate Intervention Group|Participants assigned to the immediate intervention group will engage in a 4-week 2.5-hour Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) with intervention elements of brief psycho-education, weekly mindfulness meditation, facilitated creative art making, reflective writing, group sharing and discussion.
89057150|NCT04548089|Experimental|Waitlist Control Group|Participants assigned to the wait-list control group will not receive Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) until one month after baseline assessment.
89057151|NCT04545359|Experimental|Neurofeedback Group|Participants from this group perform actual neurofeedback training, i.e they are instructed to control -- decrease -- in real-time a sound that is inversely related to the amplitude of their own alpha activity, obtained from Melomind EEG signals.
89057152|NCT04545359|Sham Comparator|Control Group|Participants from this group perform sham neurofeedback based on the feedback sounds generated by the participants from the Neurofeedback Group at the same step of the training program.
89057153|NCT01680276|Experimental|PBS based staff training|"The training, which will be supported by a treatment manual will comprise the following sections:~Functional Behavioural Assessment and formulation skills~• Brief Behavioural Assessment Tool for brief functional analyses~Primary Prevention~Secondary Prevention and Reactive Strategies~Periodic Service Review and Problem Solving~Developing individualised periodic service reviews~Trouble shooting"
89057154|NCT01680276|Other|Treatment as usual|Most community intellectual disability services provide a range of health interventions that include but are not limited to psychiatric assessment and management, nursing support, psychology, speech and language therapy, occupational therapy and counselling. There may be some variation in resources but service users with challenging behaviour are likely to receive a range of broadly defined behavioural management and pharmacological interventions. Staff is routinely supervised by their clinical managers weekly.
89057155|NCT02214914|Experimental|BI 11634 drinking solution|single rising dose
89057156|NCT02214914|Placebo Comparator|Placebo|
89057157|NCT02214914|Experimental|BI 11634 tablet|
89057158|NCT04544969||Chemotherapy|Patients treated with palliative chemotherapy
89057159|NCT01646463|Experimental|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills is the standard CenteringPregnancy prenatal healthcare intervention combined with mindfulness meditation and mindful movement/yoga applied to pregnancy, childbirth, and parenting.
89057160|NCT01646463|Active Comparator|CenteringPregnancy|CenteringPregnancy is group-based prenatal healthcare delivered according to the guidelines of the American College of Obstetrics and Gynecology. It includes assessment, support, and health education delivered in a healthcare empowerment framework.
89057161|NCT01680354|Active Comparator|ReLEx|One eye is treated with ReLEx the other with LASIK
89057162|NCT01680354|Active Comparator|LASIK|One eye is treated with ReLEx the other with LASIK
89057163|NCT04544696||Patients with chronic non cancer pain|Patients with chronic non cancer pain, treated with opioids and having completed the POMi questionnaire
89057164|NCT04544657||stroke group|
89057165|NCT04544657||normal group|
89057166|NCT01646502|Experimental|Esp-supplemented standard wound care|500 pmol Esp protein will be added to the standard wound care protocol.
89057167|NCT01646502|Active Comparator|Standard wound care|"The standard treatment protocol established at the Vancouver Wound Healing Clinic is based on the Best Clinical Practice Guidelines for Venous Leg Ulcers from the Canadian Association of Wound Care."
89057168|NCT01680393|Experimental|Sequential compression device|During arthroscopic shoulder surgery, an SCD device will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
89057169|NCT01680393|Experimental|TED stockings|During arthroscopic shoulder surgery, TED stockings will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
89057170|NCT01680393|No Intervention|Control|no stockings will be applied to the patients legs
89057171|NCT04544579||Ascending aortic dissection patients|Ascending aortic dissection patients
89057172|NCT04541732|Experimental|Thoracic epidural block|Patients will receive thoracic epidural block following induction of general anaesthesia
89057173|NCT04541732|Active Comparator|Bilateral quadratus lumborum block|Patients will receive Ultrasound-guided bilateral quadratus lumborum block following induction of general anaesthesia
89057174|NCT04544774||Allergic rhinitis patients|Patients with persistent or intermittent allergic rhinitis complaints, confirmed by skin prick tests and/or immunocap for specific IgEs, that start with AIT treatment.
89057175|NCT01680432|Experimental|Probiotic cheese|The group received, for 30 days, was instructed to eat 30 g/day of probiotic fresh cheese enriched with Bifidobacterium lactis Bi-07.
89057176|NCT01680432|Placebo Comparator|Regular Cheese|The group placebo received, for 30 days, was instructed to consume 30g/day of regular fresh cheese.
89057177|NCT04541927||BCL11B|BCL11B intragenic pathogenic variant
89057178|NCT01646541||Asymptomatic|No dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class I]
89057179|NCT01646541||Symptomatic|Dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class II, III, or IV]
89057180|NCT02279277|No Intervention|No physical therapy|No prescribed, supervised physical therapy prior to total knee replacement
89057181|NCT02279277|Active Comparator|Physical Therapy|Prescribed, supervised physical therapy prior to total knee replacement
89057182|NCT01680471|Experimental|Midazolam 0.03mg/kg|This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
89057183|NCT01680471|Experimental|Midazolam 0.05mg/kg|This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
89057184|NCT01680471|Placebo Comparator|Placebo|This group will be injected intravenous normal saline five minutes before the end of surgery.
89057185|NCT02215304|Active Comparator|Bifidobacterium longum R0033|Bifidobacterium longum ssp infantis R0033, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
89057186|NCT02215304|Active Comparator|Lactobacillus helveticus R0052|Lactobacillus helveticus R0052, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
89057187|NCT02215304|Active Comparator|Bifidobacterium bifidum R0071|Bifidobacterium bifidum R0071, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
89057188|NCT02215304|Placebo Comparator|Placebo|potato starch 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
89057189|NCT02279316|Experimental|Jaques-Dalcroze eurhythmics|Jaques-Dalcroze eurhythmics (60min/wk) + 800 IU Vitamin D3
89057190|NCT02279316|Experimental|Home exercise program|Home exercise strength program (3x30min/wk) + 800 IU vitamin D
89057191|NCT02279316|Other|Vitamin D only|800 IU Vi-De 3
89057192|NCT04544306|No Intervention|Control arm|Standard of Care (intravenous antimicrobial therapy according to the American Heart Association Guideline 2015)
89057193|NCT04544306|Experimental|Partial oral treatment arm|The mode of antimicrobial delivery is switched to oral therapy after at least 10 days of IV therapy, guided by antimicrobial susceptibility
89057194|NCT01680588|Experimental|[18F]NAV4694|Single intravenous injection of 8.1 millicuries of [18F]NAV4694
89057195|NCT04544228|Experimental|ketamine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml ketamine
89057196|NCT04544228|Experimental|Neostigmine|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml neostigmine
89057197|NCT04544228|Active Comparator|Control|Patients will receive Ultrasound guided Serratus Anterior Plane Block preoperative with injection of 30 ml bupivacaine 0.25% + 1 ml normal saline.
89057198|NCT02279355||pressure ulcer group|Patient who developing pressure ulcer categorized as stage more than II after surgery
89057199|NCT02279355||Control group|Patients has identical values on the matching factors such as age, sex and surgical procedures of control group
89057200|NCT04544540|Experimental|One-Unit|Patients will be randomized to receive 1-unit of red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 1-unit
89057201|NCT04544540|Experimental|Two-Unit|Patients will be randomized to receive 2-unit sof red blood cell transfusions as an outpatient a period of one-year. At each outpatient transfusion episode, the patient will receive a transfusion of 2-units
89057202|NCT02279433|Experimental|DS-6051b|DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
89057203|NCT04544345|Experimental|His bundle pacing, AV optimized|Pacemaker programmed to DDD mode with ventricular lead placed on the bundle of His and echocardiographically optimized AV delay.
89057204|NCT04544345|Sham Comparator|Backup VVI pacing|Pacemaker programmed to ventricular only pacing with low base rate (40/min) to allow intrinsic rhythm.
89057205|NCT01680627||ADOLESCENT|
89057206|NCT01680744|Experimental|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
89057207|NCT01680744|No Intervention|Standard Treatment|
89057208|NCT01646697|Experimental|Diagnostic (cytopathologic evaluation)|Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.
89057209|NCT04541771|Experimental|drug group|The trial group will receive their usual feeds plus daily probiotic (Lactobacillus Reuteri DSM 17938) addition 1 drop/kg/dose(. minimum of 20 million live Lactobacillus Reuteri are present in One drop) twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
89057210|NCT04541771|Placebo Comparator|control group|this group is control group and will receive normal saline drops as 1 drop/kg/ dose mixed in enteral feed
89057211|NCT01646736|Placebo Comparator|GC+CYC|Patients were treated with Glucocorticosteroid and Cyclophosphamide.
89057212|NCT01646736|Experimental|GC+T2|Patients were treated with Glucocorticosteroid and oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
89057213|NCT04542005|Experimental|q3h albuterol|Using q3h as discharge criteria from hospital
89057214|NCT04542005|No Intervention|q4h albuterol|Using q4h as discharge criteria from hospital
89057215|NCT01646775|Experimental|Epidural bupivacaine|
89057216|NCT01646775|Active Comparator|Epidural bupivacaine and fentanyl|
89057217|NCT01680978|Experimental|Aleglitazar|
89057218|NCT01680978|Placebo Comparator|Placebo|
89057219|NCT04541576|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
89057220|NCT01646853|Experimental|Concurrent radiochemotherapy|
89057221|NCT04541459|Sham Comparator|Sham Qi-Shield user group|
89057222|NCT04541459|Active Comparator|Qi-Shield user group|
89057223|NCT01681056|Experimental|Autosuggestion|
89057224|NCT01681056|No Intervention|Standard medical theraphy|
89057225|NCT01681134|Experimental|Advagraf followed by Prograf|
89057226|NCT01681134|Experimental|Prograf followed by Advagraf|
89057227|NCT04543916|Experimental|Dose Level 1|Venetoclax 50mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
89057228|NCT04543916|Experimental|Dose Level 2|Venetoclax 100mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
89057229|NCT04543916|Experimental|Dose Level 3|Venetoclax 200mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
89057230|NCT04543916|Experimental|Dose Level 4|Venetoclax 400mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
89057231|NCT04543916|Experimental|Dose Level 5|Venetoclax 600mg by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
89057232|NCT04543916|Experimental|Phase 2 Expansion Cohort|Venetoclax recommended phase 2 dose (RP2D) by mouth once daily and Irinotecan 60 mg/m2 intravenously (IV) on days 1, 8, and 15
89057233|NCT01681173|Experimental|Drink enriched in fibers|7,5g enriched fiber drinks, BID
89057234|NCT01681173|Experimental|Placebo drink|Placebo drink, BID
89057235|NCT02214953|Experimental|BI 11634 ER formulation A|
89057236|NCT02214953|Experimental|BI 11634 ER formulation B|
89057237|NCT02214953|Experimental|BI 11634 ER formulation M|
89057238|NCT02214953|Experimental|BI 11634 ER formulation C|
89057239|NCT02214953|Active Comparator|BI 11634 IR tablet|
89057240|NCT01647204|No Intervention|usual mealtime care|patients admitted to the control ward receiving no intervention but usual mealtime help from ward staff
89057241|NCT01647204|Experimental|mealtime assistance|Additional lunchtime help from trained volunteer mealtime assistants to supplement help from the ward staff
89057242|NCT04541303|Experimental|Intervention|Topical application of tranexamic acid to granulating wound defect status post Mohs micrographic surgery.
89057243|NCT04541303|Placebo Comparator|Placebo|Topical application of normal saline to granulating wound defect status post Mohs micrographic surgery.
89057244|NCT01647243|Experimental|Preoperative strength training|Progressive strength training on group basis four weeks before the operation and progressive strength training on group basis four weeks after the operation
89057245|NCT01647243|No Intervention|Living as usual|The patients are living as usual the last 4 weeks before operation
89057246|NCT02214992|Experimental|Telmisartan/Ramipril|Fixed dose combination tablet
89057247|NCT02214992|Active Comparator|Telmisartan + Ramipril capsule|
89057248|NCT02214992|Active Comparator|Telmisartan + Ramipril tablet|
89057249|NCT01647321|Active Comparator|Active cycling|Individuals will receive functional electrical stimulation while on the stationary bike and instructed to actively pedal.
89057250|NCT01647321|Sham Comparator|Passive cycling|Individuals will receive active functional electrical stimulation (FES) while on the stationary bike and instructed to relax their legs, allowing the FES to move their legs on the stationary bike.
89057251|NCT01681290|Experimental|CBX129801 High Dose|Solution for injection, 2.4 mg, weekly for 52 weeks
89057252|NCT01681290|Experimental|CBX129801 Low Dose|Solution for injection, 0.8 mg, weekly for 52 weeks
89057253|NCT01681290|Placebo Comparator|Placebo|Solution for injection, vehicle with no active, weekly for 52 weeks
89057254|NCT04543721||24-h-ABPM|
89057255|NCT04528095|Experimental|Clozapine|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml
89057256|NCT04528095|Experimental|Clozapine+Amisulpride|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Amisulpride 200-800mg/d
89057257|NCT04528095|Experimental|Clozapine+Gingke biloba|Clozapine 400 ~ 600mg/d or plasma concentration >350ng/ml Gingke biloba 120-360mg/d
89057258|NCT04528095|Experimental|MECT|MECT:The treatment lasted for 4 months,16 times in total
89057259|NCT04528095|Experimental|MST|MST:The treatment lasted for 4 months,16 times in total
89057990|NCT04534868|Other|Patient Acceptance and satisfaction for teledermoscopy|"The aim of the first part of the study is to evaluate patients' skin monitoring habits, their knowledge of skin cancer, and their preconceptions about new telemedicine tools such as teledermoscopy. This is a written quantitative questionnaire with answers to tick.~An explanatory folder will be given to patients and they will be asked to read it beforehand in order to allow a good understanding of the terms used and the goal of the project. This part will include 70 to 100 patients.~The second part of the study is a qualitative study and the aim of it is to evaluate the satisfaction, acceptance and future expectations of those who have benefited from teledermoscopy. Individual and anonymous interviews, lasting 15 to 20 minutes, intended for patients who have benefit of teledermoscopy at the office. An explanatory folder will also be given to the patients concerned in order to explain to them the procedure of the interview. This part will include 8 to 10 patients."
89057991|NCT02216487|Experimental|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan.
89057992|NCT01198600|Other|Phase 1: Habitual no Replacement, then Habitual Replacement|Contact lenses per participant's habitual prescription worn for 30 days with no replacement, followed by contact lenses per habitual prescription worn for 30 days with a replacement pair dispensed at Day 28.
89057993|NCT01198600|Other|Phase 1: Habitual Replacement, then Habitual no Replacement|Contact lenses per participant's habitual prescription worn for 30 days with replacement pair dispensed at Day 28, followed by contact lenses per habitual prescription worn for 30 days with no replacement.
89057994|NCT01198600|Other|Phase 2: Lotrafilcon B Replacement|Contact lenses worn for 56 days with replacement pair dispensed at Day 28.
89057995|NCT01198600|Other|Phase 3: Lotrafilcon B Replacement Replacement|Contact lenses worn for 43 days with replacement pair dispensed at Day 1 and Day 28.
89057996|NCT02218814|Experimental|Adductor Canal Block:|Adductor Canal Nerve Block: The patient is placed in a supine position with the extremity to be blocked slightly externally rotated. On the medial thigh, at the midpoint between the inguinal crease and the medial condyle, 13-6-MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) is placed in a transverse orientation to visualize the femoral artery in short axis deep to the sartorius muscle. Sterile field and patient sedation achieved. A 21-gauge,100 mm, short-bevel needle (Stimuplex; B Braun) is inserted under ultrasound guidance in in-plane technique to position the needle tip anterolateral to the artery and just deep to the posterior fascia of the sartorius muscle. Once in position, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
89057997|NCT02218814|Active Comparator|Femoral Nerve Block|Femoral Nerve Block. The procedure is conducted with the patient in a supine position with a 13-6 MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) applied to the skin at the level of the inguinal crease. The femoral artery, fascia iliac, and femoral nerve are visualized. Sterile field and patient sedation achieved. A 22-gauge, 50-mm, short-bevel stimulating needle (Stimuplex; B Braun, Bethlehem, Pennsylvania) connected to twitch monitor B/Braun Stimuplex DIG RC is inserted under ultrasound guidance using an in-plane technique from lateral to medial until a quadriceps motor response is elicited at a current between 0.5 and 0.2 mA with a pulse width of 0.1millisecond from a twitch monitor . After negative aspiration, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral nerve and deep to the fascia iliac, with intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
89057998|NCT04317898|Active Comparator|serratus plane block|20 ml of Bupivacine 0.25% +80mg triamcinlone will be injected in serratus plane under ultrasound.
89218031|NCT00907946|Experimental|NT prior to PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one week prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
89218032|NCT00907946|No Intervention|NT at the surgery|A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.
89218033|NCT02569619|Experimental|Activity Intervention|The activity intervention is MoVo-LISA (Göhner & Fuchs, 2007). A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through physical activity and make detailed plans, how to implement activity in their everyday routine. Difficulties and barriers are discussed.
89218034|NCT02569619|Active Comparator|Healthy Diet Intervention|The healthy diet intervention is a modification of MoVo-LISA. A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through a healthy diet and make detailed plans, how to implement a healthy diet in their everyday routine. Difficulties and barriers are discussed.
89218035|NCT00909272||US-guided lumbar medial branch block|Patients who have low back pain and/or leg pain due to possible lumbar facet joint disease .
89218036|NCT00909272||Cadavers for Ultrasound landmarks|Cadavers donated to the Department of Anatomy in McMaster University will be used to determine the landmarks for ultrasound.
89218037|NCT00509067|Experimental|A|Participants assigned to receive galantamine and CDP-choline
89218038|NCT00509067|Placebo Comparator|B|Participants assigned to receive placebo
89218039|NCT04504487|Experimental|Early drain removal - POD3|Drain removal on POD3 if drain bilirubin is less than 3mg/dl and serous in nature.
89218040|NCT04504487|Placebo Comparator|Routine Drain Removal|Drain removed routinely when the output is less than 100ml and serous in nature
89218041|NCT02538146|Experimental|Treatment|Acetyl-L-carnitine 1000mg 2X per day for 3 months
89218042|NCT00909350||No treatment|genetic research project; to meet inclusion criteria, participants must have normal upper GI tract upon upper endoscopy, for study biopsies to be taken
89218043|NCT00504309|Experimental|4g P-OM3, then 1g P-OM3, then Placebo|4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
89218044|NCT00504309|Experimental|1g P-OM3, then 4g P-OM3, then Placebo|1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
89218045|NCT00504309|Experimental|Placebo, then 4g P-OM3, then 1g P-OM3|Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
89218046|NCT00504309|Experimental|4g P-OM3, then Placebo, then 1g P-OM3|4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
89218047|NCT00504309|Experimental|1g P-OM3, then Placebo, then 4g P-OM3|1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
89218048|NCT00504309|Experimental|Placebo, then 1g P-OM3, then 4g P-OM3|Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
89218049|NCT00730145|Experimental|PD-0332334|
89218050|NCT00908024|Experimental|BMS-754807 + cetuximab|Combination
89218051|NCT00508755|Experimental|Arm 1|stroke
89218052|NCT04065815|Experimental|Resistance Training (RT)|Individualized, protein-rich nutritional therapy combined with resistance training
89218053|NCT04065815|Experimental|WB-EMS|Individualized, protein-rich nutritional therapy combined with whole-body electromyostimulation (WB-EMS)
89218054|NCT04065815|Experimental|High-intensity interval training (HIIT)|Individualized, protein-rich nutritional therapy combined with high-intensity interval training (HIIT)
89218055|NCT04065815|Experimental|Combined HIIT and Resistance Training (Combi)|Individualized, protein-rich nutritional therapy combined with a combined high-intensity interval training (HIIT) and resistance training
89218056|NCT00908102|Active Comparator|BB|"Subjects received the back book booklet, which is an self-information booklet about managing low back symptoms.~Included in the Mild and Mild vs. NC interventions."
89523253|NCT03389971|Active Comparator|multi-sidehole catheter|
89218057|NCT00908102|Experimental|BB+A|"Subjects received a back book booklet and also oral advice based on the back book by the occupational health professional (OH Nurse or OH Physician in mild or moderate intervention, respectively).~Included in the Mild and Mild vs. NC interventions. Arm was also used as a control at the Moderate and Moderate vs. NC interventions."
89218058|NCT00908102|Experimental|DBC|A graded activity back school program was carried out in a physiotherapy out-patient clinic that consisted of one-hour session twice or three times per week, lasting for 12 weeks, supervised by a specially trained physiotherapist. Arm is included in the MOderate and Moderate vs. NC interventions.
89218059|NCT00908102|Experimental|PMU|An intensive, multidisciplinary LBP rehabilitation program was carried out in a physical medicine out-patient unit at the local Central Hospital. The program included a 3-week pre-course of 1,5 hour session at 3 days per week, closely followed by a 3-week intensive rehabilitation course of 6.5 hours per day for 5 days per week. A personal graded activity training program was made for each subject and patients were later called for follow-up visit within 1 year of the initial course. Arm is included in the MOderate and Moderate vs. NC interventions.
89218060|NCT00908102|Placebo Comparator|NC|Natural course of low back pain
89218061|NCT02538068|Experimental|Daily Surveys|Participants complete a daily survey regarding their daily life meaning, mood, physical activity, and other activities for 4 weeks.
89218062|NCT02538068|Active Comparator|Random Surveys (8)|Participants complete 8 random surveys over the first 4 weeks.
89218063|NCT00904124|Placebo Comparator|Control|No regular flour replaced
89218064|NCT00904124|Experimental|5% Cellulose|5% regular flour is replaced by cellulose
89218065|NCT00904124|Experimental|2.5% Alginate|2.5% regular flour is replaced by Alginate
89218066|NCT00904124|Experimental|5% Alginate|5% regular flour is replaced by Alginate
89218067|NCT00904124|Experimental|2.5% Guar gum|2.5% regular flour is replaced by Guar gum
89218068|NCT00904124|Experimental|1.25% Guar gum|1.25% regular flour is replaced by Guar gum
89218069|NCT00504231|Experimental|0.3 mL Influenza Vaccine ID|60% dose - 0.3 mL delivered intradermally with needle and syringe
89218070|NCT00504231|Experimental|0.15 mL twice Influenza Vaccine ID|60% dose - 0.15 mL delivered twice intradermally with needle and syringe
89218071|NCT00504231|Active Comparator|0.5 mL Influenza Vaccine by IM|100% dose - 0.5mL delivered intramuscularly with needle and syringe
89218072|NCT00504231|Experimental|0.3 mL Influenza Vaccine IM|60% dose - 0.3 mL delivered intramuscularly with needle and syringe
89218073|NCT00909506|Placebo Comparator|Placebo|Placebo
89218074|NCT00909506|Active Comparator|Metformin 500 mg/d|Metformin 500 mg/d
89218075|NCT00909506|Active Comparator|Metformin 1000 mg/d|Metformin 1000 mg/d
89218076|NCT03997539|Experimental|pyrotinib 320mg + vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
89218077|NCT03997539|Experimental|pyrotinib 400mg + vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
89218078|NCT03997539|Experimental|Pyrotinib + vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered OV on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
89218079|NCT03997539|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
89218080|NCT04422899|Experimental|AIV007 Treatment Dose 1|Intravitreal, Dose 1
89218081|NCT04422899|Experimental|AIV007 Treatment Dose 2|Intravitreal, Dose 2
89218082|NCT04422899|Experimental|AIV007 Treatment Dose 3|Intravitreal, Dose 3
89218083|NCT04034108|Experimental|Experiment group|All the patients were classified as AIS-A at the time of admission to the clinical center. The MRI was performed in all cases prior to and after the surgery. Surgeries were performed between 12 hours to 30 days after trauma. At 15 days after surgery, with protection of a tailored chest-waist cast made of polyurethane 8 foam for thoracic/lumbar injuries or a neck support for cervical injuries, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers.
89218084|NCT00728117|Experimental|ibuprofen-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
89218085|NCT00728117|Experimental|ibuprofen-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
89218086|NCT00728117|Experimental|indomethacin-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
89523254|NCT03389971|Experimental|USAT catheter|
89057999|NCT04317898|Active Comparator|paravertebral block|10 ml of bubivacine 0.25% +80 mg triamcinlone will be injected at T2 level (paravertebral) under ultrasound.
89058000|NCT02218853||Bipolar I disorder, with psychosis|Individuals diagnosed with Bipolar I disorder, with psychotic features
89058001|NCT02218853||Bipolar I disorder, without psychosis|Individuals diagnosed with Bipolar I disorder, without psychotic features
89058002|NCT02218853||Healthy Controls|Must have no personal history of any psychotic or mood disorder, or a family history of psychotic or recurrent mood disorder among their first-degree relatives
89058003|NCT02216565|Other|Medical treatment|Conventional medical non-interventional treatment
89058004|NCT02216565|Other|Endovascular treatment|Conventional medical treatment plus endovascular treatment
89058005|NCT02218931|Experimental|Targeted ESTEEM diet|"The ESTEEM dietary pattern is similar to that in a Mediterranean diet associated with reduced risk of pre-eclampsia.~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
89058006|NCT02218931|No Intervention|Current clinical practice|The control group will be provided the usual antenatal dietary advice. This includes advice on healthy and physical activity in women with normal weight and obesity and overweight. Folic acid and vit D supplementation are provided as per national recommendations. Participants will provide outcome data at point of delivery and food frequency questionnaire at baseline and 36 weeks or delivery depending on which is sooner.
89058007|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
89058008|NCT04534790|No Intervention|Not radiotherapy|control group
89058009|NCT04534790|Experimental|Radiotherapy|patientis with treatment with radiotherapy 1 Gy to Whole lung.
89058010|NCT02216630|Experimental|Adipose-Derived Stem Cell (ADSC) Therapy|This arm, as the sole arm, will consist of the ADSC treatment procedure. Intervention will consist of Adipose Derived Stem Cell (ADSC) Therapy
89058011|NCT02218970|Experimental|strength training|Strength training for leg muscles during10 weeks, 3 times a week: hack squat and plantar flexion, standing upright in a hack squat machine and lying down in a calf rise machine. Exercises will be carried out at 85% of 1-RM intensity under supervision at the institution where participants are having their SUD treatment.
89058012|NCT02218970|Other|control|patients treated for substance-related disorder but not participating in strength training intervention (no training control group)
89058013|NCT04534803|Experimental|BCG Vaccine|Participants randomized to the BCG arm will receive BCG vaccine. The vaccination site is about halfway down the outer aspect of the upper arm.
89058014|NCT04534803|Placebo Comparator|Placebo Arm|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm.
89058015|NCT02219126|Experimental|Homogenized and pasteurized milk|Milk that has undergone homogenization ans pasteurization treatment
89058016|NCT02219126|Experimental|Nonhomogenized and nonpasteurized milk|Unhomogenized and unpasteurized milk (raw milk)
89058017|NCT04534634|Experimental|Experimental group|IFN-α combined with CAR T-cells therapy
89058018|NCT04534634|No Intervention|Control group|CAR T-cells therapy
89058019|NCT01198132|Experimental|Cholecalciferol|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 3 times a week.
89058020|NCT01198132|Placebo Comparator|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks along with subcutaneous injection of Rebif 3 times weekly.
89058021|NCT02219165|Experimental|IVIG 2 g/kg|Intravenous human immunoglobulin Day 1: As soon as there is suspicion of TSS, randomisation will be performed in order for the study treatment to be administered within the 12h following PICU admission (or following the manifestation of the first signs of shock). Concurrently, the TSS antibiotherapy following Surviving Sepsis Campaign recommendations is given
89058022|NCT02219165|Placebo Comparator|Albumin 4%|Same study scheduling as the first arm. Only the study treatment given is different (albumin instead of IGIV)
89058023|NCT02887690|Experimental|Modular Prosthetic Limb|The Defense Advanced Research Projects Agency's (DARPA) advanced upper limb prosthesis, the Modular Prosthetic Limb (MPL)
89058024|NCT02216604|Experimental|Intervention group|Multimodal Exercise intervention (console-based training, age-specific resistance training and body awareness)
89058025|NCT02216604|No Intervention|Control|age, disease and gender matched
89058026|NCT04534608||Asymptomatic children w/out an underlying condition|
89058027|NCT04534608||Asymptomatic children with underlying condition(s)|
89058028|NCT04534608||Children with COVID-19 symptoms w/out an underlying condition|
89058029|NCT04534608||Children with COVID-19 symptoms with underlying condition(s)|
89058030|NCT04534439|Experimental|APX-115|Oral administration of APX-115 400mg, daily
89058031|NCT04534439|Placebo Comparator|Placebo|Oral administration of APX-115-matching placebo 400mg, daily
89058032|NCT04534478|Active Comparator|Control Group|Prednisone 0.75mg / Kg / d 4 weeks; 0.5mg / Kg / d 4 weeks; 20mg / d 4 weeks; 10mg / d 6 weeks; 5mg / d 6 weeks (6m)
89058033|NCT04534478|Active Comparator|Experimental group|Prednisone 0.5mg / Kg / d 3 weeks, 20mg / day 3 weeks; 15mg / day 2 weeks; 10mg / day 2 weeks, 5mg / day 2 weeks and discontinue.
89058034|NCT02216669|Experimental|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
89058035|NCT03881748|Experimental|Manual acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points.
89058036|NCT03881748|Experimental|Electro-acupuncture|Insertion of very thin, solid, sterile, stainless steel needles into the skin at specific points with additional application of weak electrical stimulation
89058037|NCT02219204|Active Comparator|Acupuncture treatment|"This will be performed twice weekly for 30 days. There will be 8 sessions of acupuncture treatments in total.~The needles to be use around the eyes will have the dimensions of 0.25 (diameter) x 13mm (length), while 0.25 x 25mm needles will be used behind the ear (feng chi) and 0.30 X 25mm needles on the upper and lower limbs. These needles will remain in the points for 20 minutes. The depth of penetration will be about 1-2 mm."
89058038|NCT02219204|Active Comparator|Herbal treatment|"This formulation is called qi ju gan lu yin or Lycium berry, a chrysanthemum beverage. This is a modified version of qi ju di huang wan published previously. The senior TCM collaborator, Prof Wei QP has made this modification in order to treat the dry eye patients with lung-kidney yin deficiency."
89058039|NCT02219204|No Intervention|Eye drops|
89058040|NCT03772158|Experimental|Treatment A|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
89058041|NCT03772158|Experimental|Treatment B|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast without water. Subjects will be instructed to chew the tablet completely before swallowing.
89058042|NCT03772158|Experimental|Treatment C|Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and 30 minutes after the start of the standard high-fat breakfast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.
89058043|NCT03772158|Active Comparator|Treatment D|Single dose of currently marketed US 10 mg cetirizine as immediate release tablet (ZYRTEC®), administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
89058044|NCT03772158|Active Comparator|Treatment E|Single dose of currently marketed EU/Australian 10 mg cetirizine film coated tablet (REACTINE®) administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
89058045|NCT03653988|Active Comparator|PEC I/II block - pre-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction case. The intervention administered to Group I will having the block performed by the anesthesiologist after induction of general anesthesia and prior to surgical incision.
89058046|NCT03653988|Experimental|PEC I/II block - intra-operative|The current standard of care at the University of Iowa is to receive a pectoralis nerve block (PEC I/II) prior to surgery for mastectomy and reconstruction cases. Group II will have the block administered by the surgeon after mastectomy is performed and before reconstruction.
89058047|NCT01197508|Experimental|0.1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.1 mg BID
89058048|NCT01197508|Experimental|1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1 mg BID
89058049|NCT01197508|Experimental|4 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
89058050|NCT01197508|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
89218087|NCT00728117|Experimental|indomethacin-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
89218088|NCT00909584|Experimental|1|4-Week dose equilibration period with Telintra followed by 4 month treatment period
89218089|NCT00909584|No Intervention|2|4 Month observation period with standard of care treatment and option to crossover to Telintra treatment for 4 week dose equilibration followed by 4 week treatment period
89218090|NCT02570243|Active Comparator|Standard dose of Heparin|50IU/Kg heparin intravenously
89218091|NCT02570243|Experimental|High dose of Heparin|100IU/Kg heparin intravenously
89218092|NCT00927212|Experimental|Group 1|2% AS101 ointment
89218093|NCT00927212|Experimental|Group 2|4% AS101 ointment
89218094|NCT00730379|Experimental|1|ridaforolimus (MK8669) + dalotuzumab (MK0646)
89218095|NCT04015466||Cases|Patients with high diagnostic suspicion of advanced GC diagnosis
89218096|NCT04015466||Control|Patients with confirmed absent of GC
89218097|NCT00730457|Experimental|A|Intramuscular (i.m.) vaccination of a single dose of 0.1 µg, 0.3 µg, 1 µg, 2 µg, 3 µg, 5 µg and 8 µg of STF2.HA1 (SI) (VAX125).
89218098|NCT00927290|Active Comparator|1|Pioglitazone, 16 weeks before and during antiviral combination therapy
89218099|NCT00927290|Placebo Comparator|2|Pioglitazone placebo, 16 weeks before and during antiviral combination therapy
89218100|NCT00728195|Placebo Comparator|Placebo First, Then Olanzapine|Participants will receive 2 matching placebo capsules orally twice daily for 6 consecutive weeks, then 2 matching placebo capsules orally in the morning and olanzapine 10 milligram (mg) capsule along with matching placebo capsule orally in the evening for next 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 5 weeks.
89218101|NCT00728195|Experimental|JNJ-37822681 10 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 10 mg capsule orally twice a day for 12 consecutive weeks.
89218102|NCT00728195|Experimental|JNJ-37822681 20 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 20 mg capsule orally twice a day for 12 consecutive weeks.
89218103|NCT00728195|Experimental|JNJ-37822681 30 mg|Participants will receive JNJ-37822681 30 mg (one 10 mg capsule along with JNJ-37822681 20 mg capsule) orally twice a day for 12 consecutive weeks.
89218104|NCT00728195|Active Comparator|Olanzapine|Participants will receive 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with matching placebo capsule orally in the evening for 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 11 consecutive weeks.
89218105|NCT00927446||Endoscopy screening|Patients with tissue diagnosis of head and neck cancer undergo endoscopy screening with conventional white light system first. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy.
89218106|NCT00927524|Active Comparator|Apidra (insulin glulisine)|Administration of Apidra at three meals during a 24 hour period.
89218107|NCT00927524|Active Comparator|70/30 insulin|Administration of 73/30 insulin at three meals during a 24 hour period.
89218108|NCT00728273|Experimental|MMF|multi-micronutrient-fortified biscuit plus placebo deworming-treatment
89218109|NCT00728273|Experimental|Alb|placebo biscuit plus deworming treatment with Albendazole
89218110|NCT00728273|Experimental|MMF + Alb|multiple micronutrient-fortified biscuits with deworming treatment with Albendazole
89218111|NCT00728273|Placebo Comparator|placebo|placebo biscuit (non-fortified) and placebo deworming treatment
89218112|NCT00927602|Experimental|fondaparinux|
89218113|NCT04286867|Experimental|Alcohol Moderation Group 1|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
89218114|NCT04286867|Active Comparator|Alcohol Moderation Group 2|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
89218115|NCT00927680||Colorectal cancer cases|
89218116|NCT00927680||Controls|
89058051|NCT02219243|No Intervention|Waitlist Control|This is a 1-month waitlist control to be compared with the active online interpretation training interventions. This is a no intervention control group
89058052|NCT02219243|Experimental|Active Interpretation Training|Online Interpretation Training Condition 2 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
89058053|NCT02219243|Experimental|Placebo Interpretation Training|Online Interpretation Training Condition 1 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
89058054|NCT04534764|Experimental|TEST/CONTROL|Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Test/Control)
89058055|NCT04534764|Experimental|CONTROL/TEST|Eligible subjects that are habitual soft contact lens wearers will be randomized into lens wear sequence (Control/Test)
89058056|NCT04534062|Experimental|Group A|Participants in Group A will perform PNF D2 flexion and extension with free weights (PNF D2 FW) The intensity of exercise will be determined for each individual by using maximum repetition test (1 repetition maximum 1-RM). The intensity will be kept 50 % of the maximal load. 3 sets of PNF D2 FW Flexion (flexion-abduction and external rotation) and PNF D2 FW Extension (extension-adduction-internal rotation) respectively will be performed on each upper limb with 10 repetitions per set. All exercises will be performed with a rest interval of 30 seconds to 1 minute between the sets.
89058057|NCT04534062|Experimental|Group B|Participants in this group will perform 3 sets of PNF D2 flexion (flexion-abduction and external rotation) and extension (extension-adduction-internal rotation) respectively with elastic bands after assessing the 1-RM test starting with a lightest resistance and gradually progressing to the higher level. Subsequently, 71% to 86% of 1-RM will be taken as a target range of the resistance for the training that will be applied through Elastic Resistance Band in accordance with values that are provided on the Thera-Band website. Moreover, each set will consist of 10 repetitions for both D2 flexion and Extension and a resting interval of 60 seconds between two consecutive sets. The procedure will be repeated for both limbs.
89058058|NCT04534062|Experimental|Group C|The participants in the Group C or control group will perform the PNF D2 flexion and extension without any resistance. Three sets consist of 10 repetitions of each pattern for both upper limbs will be performed with an interval of 60 seconds between two consecutive sets.
89058059|NCT02219399|Experimental|300 mg DHA|300 mg DHA
89058060|NCT02219399|Placebo Comparator|Placebo|olive oil or high oleic acid sunflower oil placebo
89058061|NCT02219399|Experimental|600 mg DHA|600 mg DHA
89058062|NCT02887378|Experimental|hot clamps|reusable hot biopsy forceps
89058063|NCT02887378|Active Comparator|normal clamps|normal clamps
89058064|NCT04534244|No Intervention|Control group|Treatment of the tributary veins by phlebectomy
89058065|NCT04534244|Experimental|Experimental group|Endovenous steam treatment of the tributary veins
89058066|NCT04534140|Experimental|HBKB Capsule|Experimental group participants will take one capsule of the HBKB botanical dietary supplement orally, once daily
89058067|NCT04534140|Placebo Comparator|HBKB Capsule Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
89058068|NCT03596697|Experimental|CRV431|Either single or multiple doses of varying dose levels
89058069|NCT03596697|Placebo Comparator|Placebo|
89058070|NCT03596697|Experimental|TDF|300 mg TDF
89058071|NCT01196416|Experimental|Treatment (RO4929097, cisplatin, vinblastine, temozolomide)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21, cisplatin IV over 30 minutes and vinblastine IV over 30 minutes on days 1-3, and temozolomide PO QD on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without progressive disease continue to receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temozolomide as above in the absence of disease progression or unacceptable toxicity.
89058072|NCT02219555||Non-surgical treatment|When clinically indicated, subjects will receive a standard of care carpal tunnel injection whose volume and specific steroid drug will be based on the recommendation of the treating clinician
89058073|NCT02219555||Surgical treatment|When clinically indicated, subjects will receive standard of care carpel tunnel release surgery as recommended by treating clinician
89058074|NCT03272178||Triathlon knee total knee arthroplasty|50 Patients who are assigned to Triathlon knee, half cemented/half cementless
89058075|NCT03272178||Depuy knee total knee arthroplasty|50 Patients who are assigned to Depuy knee, half cemented/half cementless
89058076|NCT04534088|Active Comparator|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|The VR tool was an attention control and was not weight related.
89058077|NCT04534088|Experimental|Standard Behavioral Weight Loss plus Weight-Related VR app|The Intervention's VR tool was designed to enable practice of behavioral skills taught in weekly group meetings, including managing social and home environmental cues for eating and activity.
89058078|NCT01196104|Experimental|Technosphere® Insulin Inhalation Powder (TI)|Insulin Glargine and Technosphere® Insulin Inhalation Powder
89058079|NCT01196104|Active Comparator|Comparator|Insulin Glargine and Insulin Aspart
89058080|NCT04534179|Experimental|Vacuum myofascial therapy and physical activity|The protocol would last 5 weeks, group received fifteen 30-minute sessions of vacuum myofascial therapy and fifteen sessions physical activity program similar to the control group per week.
89218117|NCT00909662||Patients|Female patients with operable breast cancer intending to undergo adjuvant chemotherapy
89218118|NCT00909662||Participants|Female control subjects will be recruited, consisting predominantly of age-matched (i.e.+/- 10 years of age) friends or family members of the patients.
89058081|NCT04534179|Active Comparator|Physical activity Program|The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 30 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
89058082|NCT02219594|Experimental|Gemstone CT|Gemstone CT ：Discovery CT750 HD（high definition） ，GE（General Electric Co.） Healthcare, Milwaukee； CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient
89058083|NCT02219594|Active Comparator|320-detector row spiral CT|320-detector row spiral CT：Aquilion One, Toshiba, Nasu, Japan. CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient .
89058084|NCT02219633|Experimental|LEO 39652 cream|Topical application
89058085|NCT02219633|Placebo Comparator|LEO 39652 cream vehicle|Topical application
89058086|NCT02219672|Experimental|Triptolide group|cART for 6 months, and the experimental group will take Triplitode 2 tabs tid po for another 12 months
89058087|NCT02219672|Active Comparator|Comparator group|combined antiretroviral therapy (cART): TDF+3TC+LPV/r+RAL for 18 months
89058088|NCT03113955|Experimental|single -arm|A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
89058089|NCT04533971|Experimental|WBC group|"Criteria~documented diagnosis of MS,~functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3~no contraindications for WBC treatments found in the medical examination~no other serious chronic diseases identified that may affect the results of the tests carried out~readiness to participate in daily WBC~a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
89058090|NCT04533971|No Intervention|Control Group|"Criteria~documented diagnosis of MS,~functional status classified according to the Expanded Disability Status Scale (EDSS) to a level lower or equal to 0-3~no contraindications for WBC treatments found in the medical examination~no other serious chronic diseases identified that may affect the results of the tests carried out~readiness to participate in daily WBC~a written statement of volunteers about not using WBC treatments in the last 2 years, and not using other forms of physiotherapeutic and complementary therapies (other than planned in the procedures) for the period of this study"
89058091|NCT02219750|Active Comparator|Preprandial premix therapy|switch twice-daily insulin Preprandial premix therapy mean that transition of advance insulin based on the basal insulin daily total dose at study entry divided into two equal dose of preprandial NovoMix 30. Patient discontinued all pre-study oral antidiabetic drug(OAD), including sulfonylureas, glinides, Thiazolidinedione(TZD) and Dipeptidyl peptidase-4(DPP-4) inhibitor but left metformin alone
89058092|NCT02219750|Active Comparator|Basal-plus insulin|switch twice-daily insulin Basal-plus insulin consisted of continued previous basal insulin and add-on once-daily insulin aspart(NovoRapid) before breakfast. The starting dose of insulin aspart was 4 unit(U) before breakfast and continued under previous basal insulin dose.
89058093|NCT04534374|Experimental|Resistance exercise|The experimental intervention is a session of resistance exercise described in the intervention section.
89058094|NCT04534374|Active Comparator|Stretching exercise|The active control intervention is a session of stretching exercise described in the intervention section.
89058095|NCT04534452|Experimental|Phenylephrine HCl|Subjects have a documented and/or self-reported history of allergic rhinitis with nasal congestion for at least 2 years.
89058096|NCT04533789|Experimental|the control group|Group 1 the control group received selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
89058097|NCT04533789|Experimental|virtual reality|Group 2 the study group received the same physical therapy program 30 min. plus virtual reality for 30 min.
89058098|NCT04533789|Experimental|Task oriented|Group 3 the study group received the same physical therapy program 30 min. plus task oriented training for 30 min.
89218119|NCT00730535|Experimental|Tolterodine 1|
89218120|NCT00730535|Experimental|Toterodine 3|
89218121|NCT00730535|Experimental|Tolterodine 6|
89218122|NCT00909818|Active Comparator|standard fractionated radiotherapy|50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
89218123|NCT00909818|Experimental|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
89218124|NCT00728429|No Intervention|standard of care|normal anthracycline therapy
89218125|NCT00728429|Experimental|exercise program|
89218126|NCT04066595|Experimental|Experimental (cohorts 1 and 2)|Cohort 1 will consist of patients who have been pre-treated with checkpoint inhibitors only (2nd line setting for cabozantinib). Cohort 2 will consist of patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (3rd line setting for cabozantinib). Both cohorts receive the same treatment.
89218127|NCT00927836|Experimental|AX200|
89218128|NCT00927836|Placebo Comparator|Placebo|
89218129|NCT02570321|Experimental|Bacterial ulcer cross-linking|Standard of care topical treatment for bacterial ulcer plus cross-linking
89218130|NCT02570321|Active Comparator|Bacterial ulcer control|Standard of care topical treatment for bacterial ulcer
89218131|NCT02570321|Experimental|Fungal ulcer cross-linking plus natamycin|Standard of care topical treatment for fungal ulcer with natamycin plus cross-linking
89218132|NCT02570321|Active Comparator|Fungal ulcer control with natamycin|Standard of care topical treatment for fungal ulcer with natamycin
89218133|NCT02570321|Experimental|Fungal ulcer cross-linking plus amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin plus cross-linking
89218134|NCT02570321|Active Comparator|Fungal ulcer control with amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin
89218135|NCT00904280|Experimental|Oxymorphone ER|
89218136|NCT04015310||PSC patients attending outpatient|Primary sclerosing cholangitis, as defined by EASL and AASLD guidelines.
89218137|NCT00904358||cross sectional area|internal jugular cross sectional area measured by ultrasound
89218138|NCT00730613|Experimental|Treatment (therapeutic autologous lymphocytes)|Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity.
89218139|NCT00928148|Experimental|SPD465 (50 or 75 mg)|
89218140|NCT00928148|Active Comparator|Immediate Release Amphetamine salt (25 mg)|
89218141|NCT00928148|Placebo Comparator|Placebo|
89218142|NCT02430077|Experimental|Active capsule of Obeticholic acid|Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.
89218143|NCT02430077|Placebo Comparator|Pacebo for Obeticholic acid|Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.
89218144|NCT00904436|Experimental|1|Spinal Cord Injury: subjects who have cervical spinal cord injury and complaints of dyspnea
89218145|NCT00904436|No Intervention|2|Controls
89218146|NCT00728585|Experimental|Arm I (palifermin)|Patients receive palifermin IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive palifermin IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
89218147|NCT00728585|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
89218148|NCT02422433|Experimental|OFDI Capsule Marking and Imaging|Subject will swallow the OFDI capsule, marking will be performed by making superficial cautery marks on the tissue. This will be followed by imaging using the OFDI Imaging system.
89218149|NCT00730769|Experimental|Single arm|Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
89218150|NCT04200287|Experimental|Young adult female (YA-F) cancer survivors|YA-F cancer survivors will complete a baseline survey (T1) of sociodemographic and patient reported outcomes (PRO) and then will be sent a link to access the decision aid tool (website) with instructions to review the website before their upcoming visit. A follow-up survey (T2) will be emailed 4-weeks post-baseline, prior to their clinic visit, to evaluate website access and PROs. A post-visit survey (T3) will be emailed 6- weeks post-baseline (after their survivorship care visit) to assess PROs.
89218151|NCT00728663|Experimental|Arm: Cetuximab and Docetaxel|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8 and Docetaxel: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
89523255|NCT03383939|Experimental|group A|"10 patients randomly allocated received nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month.~Intervention: nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month"
89058099|NCT04533776|Experimental|PEER-INTERACTION GROUP SUPPORT|"All the sessions of the research took place in a classroom in the hospital. The sessions lasted an average of 90 minutes with two 45-minute sections. During the break, which lasted about 20 minutes, gluten-free products were offered. During the break, adolescents were given the opportunity to chat and interact with each other.~Peer interactive group support was implemented for 3 months with an interval of one week. A total of 6 sessions were held with the study group. Adolescents in the study group were contacted by phone before each session. The day before the session, a text message was sent to all participants informing the location and time of the meeting. The contents of the first and second sessions in relation to the study were created beforehand. However, contents of the third, fourth, fifth and sixth sessions were prepared after the first two sessions."
89058100|NCT04533776|Experimental|routine health care- control group|Peer interactive group support was not provided to the control group.
89058101|NCT04533828|Experimental|68Ga-FAPI-04 PET/CT scanning|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
89058102|NCT02219789|Experimental|Treatment (alisertib, fulvestrant)|Patients receive fulvestrant IM on day 1 (days 1 and 15 of course 1 only) and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89058103|NCT04533932||Elastography|
89058104|NCT02216721||Non primary aldosteronism|Non primary aldosteronism patients undergoing usual anti hypertensive treatment
89058105|NCT02216721||Primary Aldosteronism|Patients with confirmed primary aldosteronism undergoing treatment
89058106|NCT02219828|Placebo Comparator|Placebo|placebo sc
89058107|NCT02219828|Active Comparator|Anakinra|Anakinra 2mg/Kg up to 100mg (maximum dose)
89058108|NCT04533867||Ondansetron|In Group B (n = 50): Intravenous injection of ondansetron 0.1 mg/kg diluted up to 5 mL with normal saline solution in a maximum dose of 8 mg is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
89058109|NCT04533867||Palonosetron|The antiemetics used are palonosetron in Group A (n = 50): Intravenous injection of Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution is performed at the end of bariatric surgery while patients are in anesthesia. The drug is injected once.
89058110|NCT01196026|Experimental|Fluarix 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
89058111|NCT01196026|Experimental|Fluarix 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
89058112|NCT01196026|Experimental|Fluarix 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
89058113|NCT01196026|Active Comparator|Havrix Junior 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
89058114|NCT01196026|Active Comparator|Havrix Junior 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
89058115|NCT01196026|Active Comparator|Havrix Junior 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
89058116|NCT02216708|Experimental|intravenous fluid for rehydration rapidly over 6 hours|intravenous fluid for rehydration rapidly over 6 hours
89058117|NCT02216708|Experimental|receive slow rehydration recommended by WHO (12 hours)|receive intravenous fluid followed by ORS (slow rehydration recommended by WHO) over 12 hours
89058118|NCT02219867|Experimental|Ketamine|Active Comparator
89058119|NCT04533906|Experimental|Carrageenan|Subjects sucking carageenan containing lozenge
89058120|NCT02219906|Placebo Comparator|Placebo|Placebo capsule given three times daily X 3 weeks
89218152|NCT00728897|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= 4x25 milligrams GSK598809 capsule given in fasted state, B= 100 milligrams GSK598809 capsule in given fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
89218153|NCT00728897|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= 4x25 milligrams GSK598809 capsule given in fasted state, C= 100 milligrams GSK598809 capsule given in fed state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
89218154|NCT00728897|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= 100 milligrams GSK598809 capsule in given fasted state, A= 4x25 milligrams GSK598809 capsule given in fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
89218155|NCT00728897|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= 100 milligrams GSK598809 capsule in given fasted state, C= 100 milligrams GSK598809 capsule given in fed state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
89218156|NCT00728897|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= 100 milligrams GSK598809 capsule given in fed state, A= 4x25 milligrams GSK598809 capsule given in fasted state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
89218157|NCT00728897|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= 100 milligrams GSK598809 capsule given in fed state, B= 100 milligrams GSK598809 capsule in given fasted state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
89218158|NCT04124705|Experimental|Armour® Thyroid|Participants were randomized to receive Armour Thyroid at a dose corresponding to their pre-randomized dose of synthetic T4. During the first 18 to 36 weeks (titration period) the dose of Armour Thyroid could be titrated based on levels of thyroid stimulating hormone (TSH), in order to achieve TSH levels within the normal reference range (0.45 - 4.12 mIU/L, inclusive). Once TSH levels were within the normal reference range, participants continued to receive a stable dose of Armour Thyroid for an additional 12 weeks (stabilization period).
89218159|NCT04124705|Active Comparator|Levothyroxine|Participants were randomized to receive levothyroxine at their pre-randomized dose. During the first 18 to 36 weeks (titration period) the dose of levothyroxine could be titrated based on levels of TSH in order to achieve TSH levels within the normal reference range (0.45-4.12 mIU/L, inclusive). Once TSH levels were within the normal reference range, participants continued to receive a stable dose of levothyroxine for an additional 12 weeks (stabilization period).
89218160|NCT00731003|Experimental|I|ATD procedure
89218161|NCT00731003|Experimental|II|Oxitriptan
89218162|NCT00731003|Placebo Comparator|III|Amino acid mixture with tryptophan
89218163|NCT00731003|Placebo Comparator|IV|Placebo capsule
89218164|NCT00728975||1|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Centre,
89218165|NCT00728975||2|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Centre for Southern Interior
89218166|NCT00728975||3|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Fraser Valley Centre
89218167|NCT00728975||4|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Island Centre
89218168|NCT00728975||5|Vancouver Coastal Cottage Hospice inpatients
89218169|NCT00728975||6|Vancouver Coastal Richmond Palliative Care Program patients
89218170|NCT00728975||7|Vancouver Coastal Lions Gate Palliative Care Unit inpatients
89218171|NCT00728975||8|Providence Health St Paul's Hospital Palliative Care Unit inpatients
89218172|NCT00728975||9|Providence Health Marion Hospice inpatients
89218173|NCT00728975||10|Vancouver Island Health Authority Victoria Hospice inpatients
89218174|NCT00728975||11|Fraser Health Burnaby Hospital Tertiary Palliative Care Unit inpatients
89218175|NCT00728975||12|Fraser Health Mission Hospice inpatients
89218176|NCT00728975||13|Fraser Health Langley Hospice inpatients
89218177|NCT00729131||A|Control group: subjects are homozygotic for major allele for TNF-308 promoter polymorphism.
89218178|NCT00729131||B|Case Group: subjects are homozygotic or heterozygotic for minor allele of TNF-308 promoter polymorphism.
89218179|NCT02569385||spontaneous breathing trials|spontaneous breathing trials in patients with prolonged weaning
89218180|NCT00731159||A|"Sperm capacitation:~Sperm capacitation is measured in a sample of the same ejaculated sperm unit given for fertilizing human oocytes in an IVF treatment cycle"
89218181|NCT00731237||1|The procedures undergone by this group will be evaluated for: Acute performance, deliverability and resource utilization during the procedure in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience.
89218182|NCT04095611|Experimental|SPAIRE|hemiarthroplasty surgery, the muscle-sparing modification of the posterior approach (SPAIRE).
89218183|NCT04095611|Active Comparator|LATERAL|hemiarthroplasty surgery, the standard lateral approach
89218184|NCT00729209|Experimental|ARRY-371797 (Schedule 1)|
89218185|NCT00729209|Experimental|ARRY-371797 (Schedule 2)|
89218186|NCT00729209|Placebo Comparator|Placebo|
89218187|NCT04026347|Experimental|Vesair|Subjects are treated with Vesair Balloon at enrollment (day 0)
89218188|NCT04026347|Sham Comparator|Sham|Subjects are treated with sham at enrollment (day 0) and treated with balloon (if desired) after six month visit.
89058121|NCT02219906|Experimental|Resveratrol|Resveratrol 1 gram three times daily X 3 weeks
89058122|NCT02729844||Neolifes Heart|All premature infants, admitted at the neonatal intensive care unit (NICU) of the University Medical Centre Groningen, born <30 weeks or birth weight < 1000 gram, who participate in NeolifeS
89058123|NCT04533893||BLS Training Group (Students without prior BLS Training)|"After completing training mode of the serious game module, participants were asked to choose the self-test mode of the serious game module.~the participants were asked to practice their hands-on skills in simulation center under the supervision of educators. After familiarization with the system using self-training mode, the participants were asked to proceed the BLS Hands-on training app with the simulator under the supervision of the educator.~Conventional OSCE score of each participant was obtained by watching the recorded sessions of BLS trainings."
89058124|NCT02219945|Experimental|Group 1 - 20 PTB patients aged >18yrs|Group 1 - 20 TB patients aged > 18 yrs 5 min exhaled breath sampling with nose clamp
89058125|NCT02219945|Experimental|Group 2 - 20 TB suspects > 18 yrs|Group 2 - 20 non-TB patients > 18 yrs (screened for TB - but appear to test negative for TB, and diagnosed with other conditions including bronchiectasis, etc) 5 min exhaled breath sampling with nose clamp
89058126|NCT02219945|Experimental|group 3 - 20 lung patients, non-TB|Group 3 - 20 patients with a lung disease - no TB suspects (recruited from Lung Clinics in Yogyakarta; lung cancer, COPD, etc) 5 min exhaled breath sampling with nose clamp
89058127|NCT02219945|Experimental|Group 4 - 20 healthy controls|Group 4 - 20 apparently healthy matched controls 5 min exhaled breath sampling with nose clamp
89058128|NCT02219945|Experimental|Group 5 - 7 newly diagnosedMDR PTB pts|Group 5 - 7 newly diagnosed MDRTB patients enrolled before start of treatment, to be followed 8 months, until after end of treatment 5 min exhaled breath sampling with nose clamp
89058129|NCT02219945|Experimental|group 6 - cohort of TB suspects|300 more individuals, suspected to have TB - final diagnosis by standard procedures plus sputum culture plus follow-up for >2 years 5 min exhaled breath sampling with nose clamp
89058130|NCT01620918|Experimental|2 types of healing abutment|Patients who are in need of minimal 2 dental implants, who will receive both types of healing abutments.
89058131|NCT04533516|Experimental|Manual Therapy additional over Inspiratory muscle training|Participants receive manual therapy protocol session three times a week for 12 weeks. The manual therapy protocol session lasts 30 minutes and included of the following manual therapy techniques: suboccipital decompression, gliding of the cervical vertebral articulations in the anterior/posterior direction, myofascial release of sternocleidomastoid and trapezius muscles, gliding of sternoclavicular joint in the anterior/posterior direction, myofascial release of intercostal muscles and paravertebral muscles, diaphragmatic release, rib raising, mobilization of scapulothoracic joint, and gliding of the thoracic vertebral articulations in the anterior/posterior direction. And all participants receive inspiratory muscle training.
89058132|NCT04533516|Active Comparator|Inspiratory Muscle Training|Participants receive only inspiratory muscle training by using Threshold Inspiratory Muscle Training device. Training load is 40% of the measured maximum inspiratory pressure, weekly. Participants receive inspiratory muscle training session for 30 min-per day, 7 days per week, for 12 weeks.
89058133|NCT04533243|Experimental|2.5ug/h transdermal fentanyl|
89058134|NCT04533243|Active Comparator|Oral immediate-released morphine|
89058135|NCT04533620|Active Comparator|Standardized CIRT|Patients will receive standardized CIRT with a dose of 63 GyE/21 fx.
89058136|NCT04533620|Experimental|Individualized CIRT|A previously predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
89058137|NCT02210585|Active Comparator|Kneehab|5 sessions per week
89058138|NCT02210585|Placebo Comparator|Placebo|5 sessions per week
89058139|NCT04533321|Other|Patients genotyped positive for MET-N375S polymorphism|will be treated with orally administered daily dose of afatinib (Gilotrif®) in a fasting state (1 hour before or 2 hours after meals).
89218189|NCT00731315|Experimental|Treatment Group 1 - uncomplicated UTI|Would receive computer-assisted treatment for a uncomplicated UTI.
89218190|NCT00731315|Active Comparator|Control Group 1|Qualified for expedited treatment for uncomplicated cystitis but would receive usual care in the Emergency Department of Community Health Center.
89218191|NCT00731315|Experimental|Treatment Group 2 - Complicated Cystitis|Would receive expedited treatment for complicated cystitis with longer antibiotic course than the simple UTI patients.
89218192|NCT00731315|Active Comparator|Control Group 2|Qualified for expedited treatment for complicated cystitis treatment but would receive usual care in the clinic or emergency department.
89218193|NCT00729287|Placebo Comparator|Arm I|Patients receive oral placebo daily in addition to standard care.
89218194|NCT00729287|Experimental|Arm II|Patients receive oral selenium daily in addition to standard care.
89218195|NCT02570087|Active Comparator|Successful CTO PCI|Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
89218196|NCT02570087|No Intervention|Unsuccessful CTO PCI|Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
89218197|NCT02569697|Other|HEC Placebo Gel|The placebo gel will come in pre-filled individual applicators (4mL). Placebo gel is clear in color and contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
89218198|NCT02569697|Other|Placebo Vaginal Insert|The placebo vaginal inserts will be supplied in white plastic bottles. The placebo inserts are white to off-white in color, uncoated and bullet-shaped. The inserts are composed of ingredients generally recognized as safe including isomalt, xylitol, polyvinylpyrrolidone K 30, hydroxypropyl methylcellulose, poloxamer, and sodium stearyl fumarate. The inserts are approximately ½ to 1 inch long and approximately ¼ to ½ inch thick, similar in size to vaginal tablets that are currently available.
89218199|NCT02569697|Other|Placebo Vaginal Film|The placebo vaginal films will be individually wrapped. The placebo vaginal film is a thin, clear to translucent sheet with dimensions of 2 in x 2 in. The ingredients include hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC, E5), sodium carboxymethyl cellulose (NaCMC), and glycerin.
89218200|NCT02569697|Other|Placebo Intravaginal ring (IVR)|The placebo IVRs will be supplied in individual foil pouches. Each ring has a longer white to off-white segment and a shorter transparent/translucent segment, and ingredients include polyurethane, glycerin, water and modified starch.
89218201|NCT03095417|Experimental|Physical Exercise and Cognitive Training|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory."
89523256|NCT03383939|Placebo Comparator|group B|"9 patients randomly allocated received 10ml 0.9%NaCl saline solution nebulised once daily during 1 month.~intervention: 10ml 0.9% Sodium Chloride saline solution nebulised once daily during 1 month."
89058140|NCT01004367|Experimental|1|Environmental- and individual based components carried out in the school.
89058141|NCT01004367|No Intervention|2|No intervention
89058142|NCT02211599|Experimental|15% protein meal and sweetened beverage|Breakfast and lunch will each contain 15% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
89058143|NCT02211599|Experimental|30% protein meal and sweetened beverage|Breakfast and lunch will each contain 30% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
89058144|NCT00734019||P.F.C. Sigma Knee System|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
89058145|NCT01195948|Experimental|B27PD 1 mg|Participants randomly assigned to the B27PD 1 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
89058146|NCT01195948|Experimental|B27PD 4 mg|Participants randomly assigned to the B27PD 4 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
89058147|NCT01195948|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
89058148|NCT02213354|Experimental|Group 2|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
89058149|NCT02213354|Experimental|Group 6|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
89058150|NCT02213354|Experimental|Group 5|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
89058151|NCT02213354|Experimental|Group 4|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
89058152|NCT02213354|Experimental|Group I|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant intramuscularly (IM) on Day 1, Day 29 and Day 169
89058153|NCT02213354|Experimental|Group 3|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
89058154|NCT04533048|Experimental|MW33|
89058155|NCT04533048|Experimental|Placebo|
89058156|NCT01195831|Experimental|Xamiol® gel|Calcipotriol (as hydrate) 50mcg/g plus betamethasone 0.5mg/g (dipropionate)
89058157|NCT01195831|Active Comparator|Calcipotriol scalp solution|Calcipotriol (as hydrate) 50 mcg/ml
89058158|NCT02210273|Experimental|Treatment|Subjects undergoing treatment with the Solace Bladder Control (Vesair) Balloon on day 0
89058159|NCT02210273|Sham Comparator|Solace Sham Treatment|Subjects undergoing sham treatment on day 0, and treatment with the Solace Bladder Control (Vesair) Balloon at 3 months
89058160|NCT01195675|Experimental|BI 10773|single oral (high and low) dose per subject
89058161|NCT01195675|Placebo Comparator|Placebo|2 single oral doses per subject
89058162|NCT01195675|Active Comparator|Moxifloxacin|single oral dose per subject
89058163|NCT04532931|Placebo Comparator|Arm A|Paracetamol (SOC)
89058164|NCT04532931|Experimental|Arm B|SOC plus Artesunate-Amodiaquine
89058165|NCT04532931|Experimental|Arm C|SOC plus Pyronaridine-Artesunate
89058166|NCT04532931|Experimental|Arm D|SOC plus Favipiravir plus Nitazoxanide
89058167|NCT04532931|Experimental|Arm E|SOC plus Sofosbuvir/daclatasvir
89058168|NCT02210975|Experimental|Electrical Stimulation Therapy|
89058169|NCT01195636|Experimental|XPF-002|
89058170|NCT01195636|Placebo Comparator|Placebo|
89058171|NCT04533113|Experimental|VitreBond LC|VitreBond LC used as a liner after selective carious tissue removal.
89058172|NCT04533113|Experimental|Biodentine|Biodentine used as a liner after selective carious tissue removal.
89058173|NCT04533113|Experimental|Theracal|Theracal used as a liner after selective carious tissue removal.
89058174|NCT01195363|Active Comparator|quetiapine SR|quetiapine SR, 200-600mg, po, qd
89058175|NCT01195363|Placebo Comparator|quetiapine sr Placebo|quetiapine SR placebo, 200-600mg, po qd
89058176|NCT04317625|Experimental|participants|All of the participants tested serum PSA, some of them conducted mpMRI with/without prostate biopsy under instruction.
89058177|NCT04525443||Patients with active SARS-CoV-2 infection.|Patients admitted for COVID-19 at Hospital Clínico San Carlos with positive SARS-CoV-2 polymerase chain reaction (PCR).
89058178|NCT04525443||Patients with past, not active, SARS-CoV-2 infection.|Patients with past infection (not active), demonstrated by serology and PCR.
89058179|NCT04525443||People without concurrent or past SARS-CoV-2 infection|Health personnel from the Cardiology Service of Hospital Clínico San Carlos who demonstrate by serology that they have not had SARS-CoV-2 infection.
89058180|NCT04533269|Experimental|Active|Arnica montana and Ledum palustre infused Pad
89058181|NCT04533269|Placebo Comparator|Placebo|Pad (Matching appearance with Active)
89058182|NCT01195090|Active Comparator|sitagliptin|add sitagliptin100mg/d to pre-study OADs
89058183|NCT01195090|Active Comparator|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
89058184|NCT04533282||Acute IHD with STEMI and PCI|"Acute ischemia in IHD is represented by the recruitment of patients presenting with ST-elevation myocardial infarction (STEMI patients) to the Meilahti Cardiac Care Unit (CCU) and admitted for Percutaneous Coronary Intervention (PCI) revascularization. The informed consent and blood samples from these patients will be collected during the first 72 hours after PCI, during their stay either in CCU or medical ward.~Inclusion of this cohort to the IHD-EPITRAN opens the possibility to identify novel circulative epitranscriptomic biomarkers representing acute ischemic myocardial damage as well as particularly insightful comparison of acute and chronic states of IHD when compared against the second study cohort."
89058185|NCT04533282||Chronic IHD and elective CABG|"The second study cohort composes of patients with stable IHD phenotype with angina pectoris or exertional dyspnea provoked by either moderate or severe physical exertion, corresponding either NYHA or CCS classes II to IV, respectively, destined to undergo an elective coronary artery bypass grafting (CABG) operation as method for revascularization. The duration of stable symptoms must exceed a month in order to exclude acute events.~The obtained blood samples from this main cohort of the IHD-EPITRAN project provides insightful overview into the circulation-borne RNAs' epitranscriptomic landscape for identification of novel biomarkers for stable IHD. Furthermore, availability of right atrial appendage tissue pieces following CABG surgery from this patient cohort gives invaluable organ-specific information in its own right as well as a crucial reference point, against of which the alterations observed in circulation can be compared."
89058186|NCT04533282||Elective aortic valve stenosis (AVS) replacement therapy|"The third study cohort consists of patients admitted for surgical (open heart surgery) valve replacement due to aortic valve calcification and critical stenosis with no IHD as a comorbidity. As to elective CABG patients, here patients are also required to be either moderately or severely symptomatic equaling NYHA or CCS II to IV classes, respectively.~This cohort will provide insights into how the pathological pressure overloaded left ventricular remodelling is reflected to the epitranscriptomes of the supposedly relatively spared right atrial appendage tissue and blood RNA. Comparison of this data to the data of the first two IHD study cohorts opens the window to assess the possible differences for these differing pathologies, thus functioning as an active control cohort."
89058187|NCT04533282||IHD-negative healthy controls verified by coronary CT|The fourth study cohort shall consist of patients referred to Meilahti Heart Unit's Coronary Artery Computerised Tomography (CT) Angiogram imaging in order to investigate the possibility of atherosclerotic coronary artery disease (i.e. IHD) behind symptoms such as pressing chest pain (i.e. angina pectoris) or abnormal dyspnea provoked by exertion. Based on the results from CT angiogram, only those patients' blood samples are selected for further study that show negative results for IHD (no visualisation of either atherosclerotic strands or plaques in coronary arteries). This patient cohort functions as a critical IHD-healthy control group in the IHD-EPITRAN project (i.e. negative control).
89058188|NCT02211287|Experimental|Intervention|The intervention will include five key elements: a Project Nurse - ACP facilitator; family education on comfort care at the end of life for individuals with dementia using the 'Comfort Care at the end of life for persons with dementia' booklet; a family meeting with follow-up telephone call; documentation of ACP decisions, and orientation and education directed towards General Practitioners (GPs) and nursing home staff about the intervention.
89058189|NCT02211287|No Intervention|Usual care|Care will continue as usual for the nursing home residents
89058190|NCT04525287||Severe COVID-19|Patients who have one of the following conditions during treatment: 1. Respiratory distress, RR≥30 beats/min; 2. In resting state, mean oxygen saturation≤93%; 3. Arterial oxygen partial pressure ( PaO2)/Inhalation Oxygen Concentration (FiO2) ≤300mmHg (1mmHg=0.133kPa); 4. Respiratory failure occurs and mechanical ventilation is required; 5. Shock occurs; 6. ICU monitoring and treatment is required for combined other organ failure.
89058191|NCT04525287||Mild COVID-19|The patient only showed symptoms such as fever and respiratory tract in general, and no severe symptoms occurred during the visit and follow-up.
89058192|NCT02212145||Screened group|Screened group is defined as those individuals who were willing to participate in the cardiovascular prevention program and all the individuals who lived in Sollentuna during the intervention.
89058193|NCT02212145||Relatives to the screened group|Relatives to individuals included in the screened group, who lived in Stockholm County at least during one year at the time of the intervention.
89058194|NCT02212145||Control group|"Matched controls is going to be selected randomly from the population of Stockholm County minus Sollentuna Municipality with relevant background factors. The whole population will be used as a comparison group when evaluating the result from all the municipality of Sollentuna during 1988-1993."
89523257|NCT03383939|No Intervention|Control|10 patients without bronchiectasis were initially compared wiht bronchiectasis patients (group A + B) to define baseline levels of A1-AT and neutrophil elastase in BAL
89218202|NCT03095417|Active Comparator|Physical Exercise and Cognitive Control|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
89218203|NCT03095417|Active Comparator|Cognitive Training and Stretching Control|"Stretching Control: This consists of up to 10 minutes of gentle stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory. ly directing one session per week and available as needed for rest of the sessions."
89218204|NCT03095417|Sham Comparator|Cognitive Control and Stretching Control|"Stretching Control: This consists of up to 10 minutes of stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
89218205|NCT00731393|Experimental|Group A|Subjects aged between 6 months and 3 years.
89218206|NCT00731393|Experimental|Group B|Subjects aged 3 to 6 years.
89218207|NCT00731393|Active Comparator|Group C|Subjects aged between 6 months and 3 years.
89218208|NCT00731393|Active Comparator|Group D|Subjects aged 3 to 6 years.
89218209|NCT00731471|Experimental|1|12 Healthy adults infected with HIV
89218210|NCT00731471|Experimental|2|12 HIV+ adults on antiretroviral therapy
89218211|NCT04390217|Experimental|LB1148|LB1148 contains 7.5 g TXA, polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Active will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Active is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
89218212|NCT04390217|Placebo Comparator|Placebo|Placebo contains polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 Placebo will be administered daily as a split dose (350 mL, every 12 hours) for up to 7 days. LB1148 Placebo is given as a single bolus, to be delivered orally or enterally via NG/OG tube, and should be fully consumed or delivered within 2 hours of the start of administration.
89218213|NCT02569463|Experimental|Low-does rhIL-2 therapy|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks
89218214|NCT00729443|Experimental|1|
89218215|NCT00729443|Placebo Comparator|2|
89218216|NCT00731627|Placebo Comparator|1|placebo
89218217|NCT00731627|Active Comparator|11|simvastatin
89218218|NCT00731705||1|Patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants OR First-degree relatives of patients evaluated for stem cell transplantation
89218219|NCT03050489||On-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed with cardiopulmonary bypass.
89218220|NCT03050489||Off-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass.
89218221|NCT03050489||BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation.
89218222|NCT00568178|Experimental|Losartan Double-Blind Base Study (12-weeks)|"Normotensive participants received losartan.~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo)."
89218223|NCT00568178|Active Comparator|Amlodipine Double-Blind Base Study (12-weeks)|Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
89218224|NCT00568178|Experimental|Losartan Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
89218225|NCT00568178|Active Comparator|Enalapril Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
89218226|NCT00924248||Group 1|
89218227|NCT00928460||Regular preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to current protocol, including routine preoperative ECG.
89218228|NCT00928460||New preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to a new protocol, in which a routine preoperative ECG is no longer provided.
89218229|NCT00577889|Experimental|Arm I (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on day 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
89218230|NCT00577889|Experimental|Arm II (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 2 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
89218231|NCT00577889|Experimental|Arm III (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on day 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 1 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
89058195|NCT02213081|Experimental|Ulipristal|25 patients with chronic, endometriosis-related pelvic pain refractory to medical and/or surgical therapies will receive 15mg ulipristal every other day (three times a week- Monday, Thursday, Saturday) for three months.
89058196|NCT02216760|Active Comparator|Ripple Mapping guided VT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to identify conduction channels within the ventricular scar substrate to guide ablation lesions in patients with monomorphic VT.
89058197|NCT02216760|Active Comparator|Conventional VT Ablation|Standard substrate ablation as per local operator preference will be used to guide ablation in the ventricular scar in patients with monomorphic VT.
89058198|NCT02213627|Experimental|Corifollitropin alfa|From day 2-3 of mense, a single 100 microgram dose of corifollitropin alfa is administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
89058199|NCT02213627|Experimental|Recombinant FSH|From day 2-3 of mense, daily injections of 150 IU of recombinant FSH will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
89058200|NCT02213627|Experimental|HP-hMG|From day 2-3 of mense, daily doses of 225 IU of HP-hMG will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
89058201|NCT02216799|Active Comparator|Regular Insulin incorporated in parenteral nutrition|Regular insulin ( Actrapid, 100 unit/mL0 Solution for injection, Insulin Human (rDNA), Novo Nordisk, will be added to parenteral nutrition to run over 24 hours as 80% of the total insulin requirement of the preceding day administered via subcutaneous sliding scale
89058202|NCT02216799|Active Comparator|Insulin glargine|Insulin glargine adminstred at daily night, calculated as 80% of the total insulin requirement of the preceding day from the insulin administered via subcutaneous sliding scale
89058203|NCT04532996|Experimental|Trauma-focused psychodynamic psychotherapy|Twice-weekly psychotherapy for 20-24 sessions.
89058204|NCT02216877|Placebo Comparator|Placebo|Oral placebo twice daily for 8 weeks. 12 subjects.
89058205|NCT02216877|Experimental|Mablet 360 mg once daily|Oral Mablet 360 mg once daily and oral placebo once daily for 8 weeks. 12 subjects.
89058206|NCT02216877|Experimental|Mablet 360 mg twice daily|Oral Mablet 360 mg twice daily for 8 weeks. 12 subjects.
89058207|NCT02214563|Active Comparator|Thrice-weekly cholecalciferol|Capsule containing 3,000 IU of cholecalciferol will be given at the end of each hemodialysis session. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
89058208|NCT02214563|Active Comparator|Monthly cholecalciferol|Capsules containing a dose equivalent to 9,000 IU/week will be given at the end of the first hemodialysis session in the 3rd week of each month. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
89058209|NCT02214563|Placebo Comparator|Thrice-weekly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
89058210|NCT02214563|Placebo Comparator|Monthly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
89058211|NCT01194973|Experimental|Eculizumab|
89058212|NCT04532853||COPD patients|
89058213|NCT02218619|Experimental|Taurourodeoxycholic Acid (TUDCA)|TUDCA 1750 mg/day x 12 months
89058214|NCT02218619|Placebo Comparator|Sugar pill (placebo)|Placebo at same dose, frequency, and duration as experimental treatment
89058215|NCT02218697|Experimental|Co-Ad Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28.
89058216|NCT02218697|Experimental|Control Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28.
89058217|NCT04524117||Group A(vulnerable plaque group)|Lipid plaques with fibrous cap thickness less than 65um, erosion and coronary artery dissection detected by OCT are defined as vulnerable plaque.
89058218|NCT04524117||Group B(stable plaque group)|Lipid plaques with fibrous cap thickness more than 65um detected by OCT are defined as vulnerable plaque.
89058219|NCT02216916|Experimental|HM781-36B|
89058220|NCT02279069|Active Comparator|4-point canne|Stroke patients walk with 4-point canne
89058221|NCT02279069|Experimental|4-roll canne|Stroke patients walk with 4-roll canne
89058222|NCT04533035||Single cohort|30 patients undergoing hallux valgus surgery
89058223|NCT02216747|Active Comparator|prednisone 60 mg/meter square Body Surface Aera|A - 60 mg Prednisone/meter square Boby Surface Area( 30 twice)/day until there are 3 days of undetected protein in urine and tapering down to 40 mg ,30 mg, 20 mg ,10 mg and 5 mg and end.
89058224|NCT02216747|Active Comparator|prednisone 45 mg/meter square BSA|B- 45 mg prednisone / day until there are 3 days of undetected protein in urine and then 30 mg / day for two weeks and to 30,20,10,5 mg until treatment is ended.
89058225|NCT02216747|Active Comparator|prednisone 30 mg/meter squer BSA|C- treatment of twice daily prednisone 30 mg per day until there are 3 days of undetectible protein in urine and then tapering down to 20 ,10 ,5 until treatment is ended.
89058226|NCT02216786|Experimental|Fulvestrant and AZD2014 (continuous)|Experimental arm
89058227|NCT02216786|Active Comparator|Everolimus and Fulvestrant|Comparator arm
89058228|NCT02216786|Active Comparator|Fulvestrant|Control 1
89058229|NCT02216786|Experimental|Fulvestrant +AZD2014 (intermittent)|Experimental arm
89058230|NCT02279147|Experimental|raceanisodamine & neostigmine|Patients receive immediately raceanisodamine（10mg）by intramuscular injection after operation.Then the patients will be receive 50mg raceanisodamine and 0.15mg neostigmine within 24hs by slow injection into vein for three consecutive days.
89058231|NCT02279147|No Intervention|blank|Patients do not receive special treatment after operation.
89058232|NCT04472754||A(healthy control group)|patients who did not have ischemic stroke and whose TCM constitution was dialectically peaceful;
89058233|NCT04472754||B|Patients with no ischemic stroke and whose TCM constitution was dialectical with damp phlegm constitution
89058234|NCT04472754||C|patients with ischemic stroke diagnosed with phlegm dampness syndrome
89058235|NCT04472754||D|patients with ischemic stroke diagnosed as non-phlegm dampness syndrome
89058236|NCT04472325||Atypical Parkinson's Disease patients|This group consists of patients includes 35 patients with Progressive Supranuclear Paralysis (PSP), 35 patients with Multiple System Atrophy (MSA), and 35 patients with Cortico-Basal Degeneration (CBD).
89058237|NCT04472325||Idiopathic Parkinson's Disease patients|This group consists of patients starting from 2012 to 2013 and includes 87 patients with typical Parkinson's Disease (PD)
89058238|NCT04472325||Healthy volunteers|"The 96 healthy volunteers should meet the following criteria:~Between 50-80 years old~Right-handed~MMSE score greater than or equal to 26~Able to understand study requirements and give informed consent"
89058239|NCT02216825|Experimental|Delayed release capsule, L. reuteri NCIMB 30242|
89058240|NCT02216825|Experimental|Standard vegetarian capsule, L. reuteri NCIMB 30242|
89058241|NCT02279186|Active Comparator|group A|receiving tranexamic acid
89058242|NCT02279186|No Intervention|group B|does not receive tranexamic acid
89058243|NCT02212691||Sickle cell disease|Patients diagnosed with sickle cell disease
89058244|NCT02212691||Healthy control|Healthy individuals recruited through fliers and have no history of cognitive disorders
89058245|NCT01600560||Social media|
89058246|NCT01177540|Experimental|Arm A|
89058247|NCT01177540|Experimental|Arm B|
89058248|NCT02216903||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
89058249|NCT04317469||ARDS group ,|
89058250|NCT04317469||non ARDS group|
89058251|NCT01177384|Experimental|Sitagliptin|Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily [t.i.d.])
89058252|NCT01177384|Placebo Comparator|Placebo|Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)
89058253|NCT04315714|Experimental|IBS Yoga Intervention (delivered online/virtually via Zoom)|Ten participants with IBS will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
89058254|NCT04315714|Experimental|IBS Waitlist Control Condition|Ten participants with IBS will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
89058255|NCT04315714|Experimental|HC Yoga Intervention (delivered online/virtually via Zoom)|Ten participants serving as HC will be randomized to the 6-week yoga intervention at the beginning of the trial, followed by the 6-week control condition (observation/active monitoring).
89058256|NCT04315714|Experimental|HC Waitlist Control Condition|Ten participants serving as HC will be randomized to the 6-week waitlist control condition (observation/active monitoring) at the beginning of the trial, followed by the 6-week yoga intervention.
89058257|NCT01640015|Experimental|low frequency diet|Participants will be assigned to a low frequency diet (fixed energy intake)
89058258|NCT01640015|Experimental|High frequency diet|
89058259|NCT04315519|Experimental|Blood Flow Restricted Aerobic (BFRA)|Low intensity Aerobic exercise with Blood Flow Restriction
89058260|NCT04315519|Experimental|Moderate Aerobic Exercise (MAE)|moderate intensity aerobic exercise
89058261|NCT01641887||GERD patients|Patients who have GERD will be recruited for this study.
89058262|NCT04514016||HIV positive participants with positive COVID-19 results|Participants in this group will have a RT-PCR and Coronavirus Disease (COVID) -19 specific antibody testing at baseline, 1 month and 3 month visits.
89058263|NCT04514016||HIV positive participants with negative COVID-19 results|Participants in this group will have a RT-PCR and COVID-19 specific antibody testing at baseline only.
89058264|NCT01640093|Experimental|Treatment B|Abiraterone acetate (500 mg), 2 coated, reformulated tablets.
89218232|NCT00928538|No Intervention|Usual NFP Care|Usual NFP care includes pregnancy planning and contraceptive advice during nurse home visits, with the prescription and dispensing of contraceptives provided through the women's primary care settings.
89218233|NCT00928538|Experimental|Enhanced NFP Care|Enhanced NFP intervention includes usual NFP care plus the intervention that includes contraceptive administration and distribution in the home
89218234|NCT00928616|Experimental|plant sterol esters|Participants consume plant sterol ester supplemented margarine (3 g/day)
89218235|NCT00928616|Placebo Comparator|Placebo|Placebo is a non-sterol ester supplemented margarine
89218236|NCT00460564|Active Comparator|High-Dose BTX|
89218237|NCT00460564|Placebo Comparator|High-Dose Placebo|
89218238|NCT00460564|Active Comparator|Low-Dose BTX|
89218239|NCT00460564|Active Comparator|Low-Dose Placebo|
89218240|NCT00729599|Experimental|1|Cetylpyridinium chloride during 21 consecutive days.
89218241|NCT04015076|Experimental|Single Ascending Dose|Inzomelid or Placebo
89218242|NCT04015076|Experimental|Multiple Ascending Dose|Inzomelid or Placebo
89218243|NCT04015076|Experimental|Patients with CAPS|Inzomelid Open Label
89218244|NCT03743480|No Intervention|standard care|Patients in this arm will receive standard hematological care and palliative care on demand
89218245|NCT03743480|Experimental|early palliative care|early palliative care: patients in this arm will receive integrated palliative care
89218246|NCT02538926|Experimental|Treatment (DA-EPOCH-A)|Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89218247|NCT01323400|Experimental|Pazopanib|"Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.~Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopanib may be continued (if the investigator wishes so) if a clinical benefit (pain reduction, 1 point increase in performance status) is observed."
89218248|NCT01323400|Other|Best supportive care|Best supportive care according to the investigator's judgment. Upon progression, compassionate treatment by pazopanib is possible according to eligibility criteria.
89218249|NCT00904592|Experimental|Qi ming granula|"Study group(combined therapy with Intervention of TCM): Basic therapy ＆ treating both on deficiency and stasis of blood.~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education.~Qi ming granula, Usage: 4.5g，po，tid."
89218250|NCT00904592|Placebo Comparator|placebo comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
89218251|NCT00928850|Active Comparator|urethral irrigation but no fascial suturing, QOL forms|The anterior two-thirds of the urethra is divided exposing a Foley catheter that was placed at the beginning of the procedure. Irrigation of the urethra may prevent spread of prostate cancer cells to tissue that is not removed during surgery. The urethra is irrigated with 60 cc of sterile water as it is withdrawn from the patient to 'wash' the urethra.
89218252|NCT00928850|Active Comparator|fascial suturing but no urethral irrigation, QOL forms|For patients undergoing fascial suturing only, after the initial placement of the suture through the urethra a second bite is taken deeply into the fascia of the lateral pelvic fascia.
89218253|NCT00928850|Active Comparator|both urethral irrigation and fascial suturing, QOL forms|
89218254|NCT00928850|Active Comparator|neither urethral irrigation nor fascial suturing, QOL forms|
89218255|NCT03745313|Experimental|Treatment|Treatment with the Edwards PASCAL Transcatheter Valve Repair System
89218256|NCT00904904|Experimental|Indomethacin|Indomethacin ophthalmic solution 0.1% for post-surgical inflammation
89218257|NCT00904904|Active Comparator|Ketorolac|Ketorolac ophthalmic solution 0.5% for post-surgical inflammation
89218258|NCT00731861|Experimental|1|Paclitaxel plus PTK787
89218259|NCT00928928|Active Comparator|Open group|Group of patients operated with open approach for colorectal cancer
89218260|NCT00928928|Active Comparator|laparoscopic group|Group of patients operated with laparoscopic approach for colorectal cancer
89218261|NCT03905993||Experimental: unique group.|At V0: 1238 subjects were screened At V1: 1012 subjects (12 later withdrew) gave the following samples: blood, nasal swab,stool. 323 subjects among 1000 gave one additional sample (Skin Biopsy) At V2: 504 subjects came at V2 to perform blood, nasal swab and stool samples
89218262|NCT00729755|Experimental|Creatine|The subjects with major depressive disorder, treated with creatine in addition to escitalopram
89218263|NCT00729755|Placebo Comparator|Placebo|The subjects with major depressive disorder, treated with placebo in addition to escitalopram
89218264|NCT00567476|Active Comparator|Omalizumab + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
89218265|NCT00567476|Active Comparator|Conventional Therapy|Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
89218266|NCT04065737|Experimental|Sintilimab|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W; duration: 8cycles (6 months) or randomization to the date of the first documented oral cancer incidence
89218267|NCT00729911|Active Comparator|AF ablation|"Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting."
89218268|NCT00729911|Active Comparator|Amiodarone|Amiodarone is taken orally on a daily basis.
89218269|NCT04018703|Experimental|Dexmedetomidine|Dexmedetomidine will be used for perioperative sedation.
89218270|NCT04018703|Experimental|Midazolam|Midazolam will be used for perioperative sedation.
89218271|NCT04629872|Experimental|endovascular treatment with fingolimod|
89218272|NCT04629872|No Intervention|endovascular treatment without fingolimod|
89218273|NCT04065581|Experimental|Treatment A-washout-treatment B|Subject will receive a single oral dose of acarbose/metformin FDC (Treatment A, 50 mg acarbose/500 mg metformin) in period 1, followed by a single oral dose of 50mg acarbose and 500mg metformin as loose combination (Treatment B) in period 2. Washout interval between 2 treatment periods was at least 7 days.
89218274|NCT04065581|Experimental|Treatment B-washout-treatment A|Subject will receive a single oral dose of 50 mg acarbose and 500 mg metformin as loose combination (Treatment B) in period 1, followed by a single oral dose of acarbose/metformin FDC (Treatment A, 50mg acarbose/500 mg metformin) in period 2. Washout interval between 2 treatment periods was at least 7 days.
89218275|NCT00929084|Other|Survivor Stories Arm|Women in the Survivor Stories intervention arm will be given the Survivor Stories Tablet to take home for two weeks at three different time points over a two year period.
89218276|NCT00929084|Other|Control Arm|Women in the Control Arm will receive standard care.
89218277|NCT05585645|Experimental|Stimus|"NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously) at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~Study drug will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
89218278|NCT05585645|Active Comparator|Aranesp|"Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously) at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~Study drug will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
89218279|NCT00732017|Experimental|HVPC-|This group received standard physical therapy treatment and HVPC with negative polarity.
89218280|NCT00732017|Active Comparator|CG|The control group received only standard physical therapy treatment.
89218281|NCT00732017|Experimental|HVPC+|This group received standard physical therapy treatment and HVPC using active electrodes with positive polarity.
89218282|NCT00924794||Cohort A|Women aged 18 years and above, diagnosed with high grade lesions or microinvasive cervical carcinomas in primary conization performed and registered in the Cancer Registry of Norway, and presenting with recurrent conization with high grade lesions or microinvasive cervical carcinoma or invasive cervical carcinoma.
89218283|NCT00733889|Experimental|1|
89218284|NCT00738491||1|Patients with stable angina pectoris and documented coronary heart disease recruited in Edinburgh
89218285|NCT00738491||2|Patients with stable angina pectoris and documented coronary heart disease recruited in London
89218286|NCT05153655|Experimental|Ischemic post-conditioning group|The safety and tolerability of ischemic post-conditioning will be investigated using 3+3 dose-escalation trial design.
89218287|NCT00929318|Active Comparator|benign|patients after surgery because of a benign disease
89218288|NCT00929318|Active Comparator|DTC|Patients after thyroidectomy because of papillary carcinoma of the thyroid gland
89218289|NCT00733967|Placebo Comparator|Placebo|Matching oral placebo capsules as control.
89218290|NCT00733967|Active Comparator|Varenicline|See assigned interventions.
89218291|NCT01010841|Active Comparator|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
89218292|NCT01010841|Experimental|Low-glycemic-load diet + medical food|Modified Mediterranean-style, low-glycemic-load diet + medical food
89218293|NCT00732095|Experimental|Experimental|Immediate Ad
89218294|NCT00732173|Experimental|Arm I|"Patients receive a lifestyle intervention, Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED), on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact."
89218295|NCT00732173|Active Comparator|Arm II|Patients receive usual care informational brochures but no lifestyle counseling related to weight loss, physical activity, and nutrition.
89218296|NCT04650243|Experimental|ursodeoxycholic acid 250mg bid|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally twice a day.
89218297|NCT04650243|Experimental|ursodeoxycholic acid 250mg qd|Patients will receive a reduced dosage of ursodeoxycholic acid 250mg orally once a day.
89218298|NCT04650243|Active Comparator|ursodeoxycholic acid standard dosage|Patients will receive standard dosage of ursodeoxycholic acid 250mg orally three times a day.
89218299|NCT00738569|Experimental|Raltegravir|
89218300|NCT04646811|Experimental|Tricuspid valve|tricuspid valve percutaneous repair strategy with clip for the tricuspid valve
89218301|NCT04646811|Other|Best medical treatment|
89218302|NCT00732329|Experimental|A|"optimized home based occupational therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
89218303|NCT00732329|No Intervention|B|treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without optimized occupational therapy
89218304|NCT04644627|Experimental|Single arm|Each patient serves as its own control: one half is treated with the study treatment in addition to standard wound therapy, the other half receives standard wound therapy only.
89218305|NCT00734045||1|Subjects with diagnosed congestive heart failure
89218306|NCT00734045||2|Subjects not diagnosed with congestive heart failure
89523258|NCT03379103|Active Comparator|GP - sevoflurane|GP - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with 1 MAC sevoflurane for 15 minutes before the installation of ischemia by tourniquete
89058265|NCT01640093|Experimental|Treatment C|Abiraterone acetate (250 mg), 4 coated, reformulated tablets.
89058266|NCT01640093|Experimental|Treatment D|Abiraterone acetate (500 mg), 2 coated, reformulated tablets, showing slower in vitro dissolution.
89058267|NCT01640093|Active Comparator|Treatment A|Abiraterone acetate (250 mg), 4 uncoated, current commercial tablets.
89058268|NCT04466631||Observative longitudinal|The participants won't receive any support during the post surgery period.
89058269|NCT01641965|Active Comparator|early non invasive ventilation|Patients assigned to this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB)immediately after randomization (when their FVC reaches the threshold of the 75% of the predicted value)
89058270|NCT01641965|Active Comparator|standard|patients in this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB) when they fulfil at least one of the following criteria: (i) FVC < 50% predicted, (ii) orthopnea, and/or (iii) PaCO2 > 45 mmHg.
89058271|NCT01642121||Observational|Samples and controls are sorted and re-sorted for CD34, CD38, and CD55 subsets by single-cell PCR analysis, flow cytometry, and reverse-transcriptase PCR. Sorted cell subsets are then transplanted into NSG mice. Beginning 6 weeks after transplantation, peripheral blood samples are collected and analyzed for human lymphoid- and myeloid-lineage cells by FACS.
89058272|NCT01194154|Experimental|Mircera|
89058273|NCT01194154|Placebo Comparator|Placebo|
89058274|NCT01642160|Active Comparator|Standard of care|Participants randomized to this arm will have the usual follow up care without any additional information.
89058275|NCT01642160|Active Comparator|Additional Education|This arm will receive a weekly text message or e-mail asking participants to sign on to the web page that we will provide. Once they sign on, they will see additional educational materials and questions regarding their CPAP use. Based on their response, they will be directed to suggestion or sites to help improve their compliance with their CPAP.
89058276|NCT01640405|Active Comparator|Control|modified FOLFOX6 + bevacizumab
89058277|NCT01640405|Experimental|Experimental|FOLFOXIRI+bevacizumab
89058278|NCT02279225|Placebo Comparator|placebo (P)|Intervention without radiation
89058279|NCT02279225|Experimental|phototherapy (FT)|Intervention only with phototherapy radiation
89058280|NCT02279225|Experimental|phototherapy+Physical activity (FT+A)|Intervention associated
89058281|NCT02279225|Experimental|Physical activity (A)|Intervention with physical activity: the gold standard of treatment in fibromyalgia
89058282|NCT01640444|Experimental|A|FOLFIRI+bevacizumab
89058283|NCT01640444|Experimental|B|FOLFIRI + cetuximab
89058284|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|
89058285|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|
89058286|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss|
89058287|NCT01642316|Experimental|washback|students received 8 specific related formative test for that lesson plus a pre-test and post-test, Michigan English language proficiency test
89058288|NCT01642316|Other|control|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
89058289|NCT01642355|No Intervention|Usual Care|Usual care includes physician assistant and/or nurse based medical and lifestyle recommendations in consultation with cardiac catheterization attending or patient's clinical cardiologist to potentially improve the patient's medical and lifestyle regimen. Relevant educational material is routinely distributed to patients.
89058290|NCT01642355|Active Comparator|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
89058291|NCT01642355|Active Comparator|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
89058292|NCT04529330||fractures with blister appeared|tibial plateau fractures with blister observed
89058293|NCT04529330||fractures without blister appeared|tibial plateau fractures without blister observed
89058294|NCT01642433|Placebo Comparator|Sugar pills|
89058295|NCT01642433|Active Comparator|Prazosin pills|
89058296|NCT04529213|Experimental|Tooth tissue-borne (KBME) expander|In this tooth tissue-borne appliance, the occlusal surfaces of the molar and premolar teeth and half of the palatinal and buccal surfaces are covered with heat polymerized acrylic. Hyrax expansion screw is in the midline, as far as possible to the palate positioned close and parallel
89058297|NCT04529213|Experimental|Tooth-borne (Hyrax) expander|In this tooth-borne expansion appliance, orthodontic bands are placed on the right and left 1st premolar and 1st molar teeth of the patients and the bands are soldered to the Hyrax expansion screw. The expansion screw is in the midline, as far as possible to the palate positioned close and parallel
89058298|NCT04529213|Experimental|Bone-borne (MIDME) expander|This bone-borne expander includes 2 mini-screws with a diameter of 1.6 mm and a length of 10 mm on the right and left sides, coinciding between the roots of the 2nd premolar and 1st molar teeth in addition to the hyrax expansion screw.
89058299|NCT01642472|Experimental|Ulipristal Acetate (PGL4001) 10mg|Ulipristal Acetate (PGL4001)10mg daily administration
89058300|NCT01640600||Children exposed to SSRIs in utero|This group are comprised of children whose mothers used antidepressants during pregnancy and who were therefore exposed to antidepressants in utero.
89058301|NCT01640600||Children exposed to nicotine in utero|This group is comprised of children whose mothers smoked cigarettes during pregnancy and who were therefore exposed to nicotine in utero.
89058302|NCT01640600||Children exposed to neither nicotine nor SSRIs|This group is comprised of children who were exposed to neither nicotine nor SSRIs in utero.
89058303|NCT01640639|Active Comparator|Thalidomide|Thalidomide
89058304|NCT01640639|Placebo Comparator|Placebo|Placebo
89058305|NCT01640678|Experimental|ReCell epidermal cell suspension grafting|CO2 laser abrasion + ReCell epidermal cell suspension + UV-therapy
89058306|NCT01640678|Active Comparator|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
89058307|NCT01640678|No Intervention|No treatment + UV-therapy|
89058308|NCT01642628|Experimental|Body Image/Mirror Education|Participants in the mirror arm will receive a mirror and mirror viewing education from oncology nurse navigators.
89058309|NCT01642628|No Intervention|Standard Care|Patients allocated to the control group will receive the usual pre and post-op standard care that does not include the use or discussion of mirrors.
89058310|NCT01642667|Placebo Comparator|primary PCI|
89058311|NCT01642667|Active Comparator|prouk-PCI|
89058312|NCT01642706||RA patients|Patients affected by Rheumatoid arthritis.
89058313|NCT01642706||Control|"Subjects affected by either :~mechanical pathology~systemic auto-immune pathology~other inflammatory rheumatism"
89058314|NCT01640912|Experimental|RXI-109|
89058315|NCT01640912|Placebo Comparator|Placebo|
89058316|NCT01642745|Experimental|Methacholine (Provocholine) with deep inhalation|
89058317|NCT01642745|Experimental|Mannitol (Aridol)|
89058318|NCT01642745|Active Comparator|Methacholine (Provocholine) tidal breathing|
89058319|NCT04503408||cystic fibrosis with abnormal glucose tolerance|cystic fibrosis with abnormal glucose tolerance Cystic fibrosis patients with descripted that impaired glucose tolerance or cystic fibrosis related diabetes by oral glucose tolerance test
89058320|NCT04503408||cystic fibrosis with normal glucose tolerance|cystic fibrosis with normal glucose tolerance Cystic fibrosis patients with descripted that normal glucose tolerance by oral glucose tolerance test
89058321|NCT04502784||Chronic Kidney Disease|This group will consist of 10 patients who have previously been diagnosed with chronic kidney disease and are receiving intravenous iron due to anaemia.
89058322|NCT04502784||Intestinal failure|This group will consist of 10 patients who have previously been diagnosed with intestinal conditions and are receiving intravenous iron due to anaemia.
89058323|NCT04502784||Healthy Volunteers|This group will consist of 20 healthy volunteers. This group will act as a comparator for the CKD and intestinal failure groups.
89058324|NCT01642784||Culprit lesion IRA revascularization|Culprit lesion IRA revascularization
89058325|NCT01642784||Complete IRA revascularization|Complete IRA revascularization
89058326|NCT01640990|Experimental|Cohort 1|slow IV infusion over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5 hours (total dose of 12mcg), and 10 mcg/h GW328267X for 4 hours (total dose of 40 mcg)
89058327|NCT01640990|Experimental|Cohort 2|Dose to be determined after analysis of Cohort 1
89058328|NCT04501887||Matched therapy|Molecular profiling performed with actionable molecular alterations detected and target therapy was then conducted
89058329|NCT04501887||Unmatched therapy|Molecular profiling performed with actionable molecular alterations detected but therapy was conducted based on the guideline treatment
89058330|NCT04501887||No marker|Molecular profiling performed without any actionable molecular alterations detected, tranditional therapy based on the guideline was then conducted
89058331|NCT01641029||pyelonephritis|Patients > 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.
89058332|NCT04501497||NSCLC cohort (N=800)|Patients with locally advanced or metastatic non-small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
89058333|NCT04501497||ED-SCLC cohort (N=400)|Patients with extensive disease small cell lung cancer who are planning to provide Atezolizumab combination thearapy as the most ppropriate medical care
89058334|NCT01642823||retinablastoma tumor tissue|
89058335|NCT01641068|Experimental|Arm I (memory and thinking skills workshop)|Patients participate in a memory and thinking skills workshop once weekly for 7 weeks. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).
89058336|NCT01641068|Active Comparator|Arm II (Education Workshop)|Patients participate in 7 weekly 1-hour group workshops focusing on increasing knowledge and education on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3). Patients are then given the option to participate in the memory and thinking skills workshop.
89058337|NCT04529057|Experimental|Tooth-borne (Hyrax) expander|
89058338|NCT04529057|Experimental|Tooth tissue-borne (KBME) expander|
89058339|NCT04529057|Experimental|Bone-borne (MIDME) expander|
89058340|NCT01642862|Experimental|Liquid formulation of Simvastatin|
89058341|NCT01642862|Active Comparator|Tablet formulation of Simvastatin|
89058342|NCT04529369|Experimental|Prominent middle lobe BPH satisfactory channel after MLO PVP|
89058343|NCT04529369|Active Comparator|Prominent middle lobe BPH unsatisfactory channel after MLO PVP|
89523259|NCT03379103|Placebo Comparator|GC - control|GC - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with intravenous propofol for 15 minutes before the installation of ischemia by tourniquete.
89058344|NCT01641146|Experimental|Enhanced Sexual Health Intervention for Men|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
89058345|NCT01641146|Active Comparator|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
89058346|NCT01642940|Active Comparator|Prasugrel|
89058347|NCT01642940|Experimental|Ticagrelor|
89058348|NCT04499430||1|"Group 1: 29 weeks and six days of gestation and earlier~Group 1a: complementary feeding began chronologically in the sixth month~Group 1b: Complementary feeding corrected at sixth month"
89058349|NCT04499430||2|"Group 2: Those whose gestational age is between 30 weeks and 33 weeks and sixth days~Group 2a: complementary feeding began chronologically in the sixth month~Group 2b: complementary feeding started in the sixth month, corrected"
89058350|NCT04499430||3|"Group 3: Those whose gestational age is between 34 weeks and 37 weeks and sixth day~Group 3a: complementary feeding began chronologically in the sixth month~Group 3b: complementary feeding started in the sixth month, corrected"
89058351|NCT01643018|Experimental|laparoscopic surgery|-Laparoscopic surgery group describes the patients treated with laparoscopic surgery
89058352|NCT01643018|Active Comparator|Open Surgery|-open surgery group describes the patients treated with traditional open surgery
89058353|NCT04497753||Can't fell bitterness|"The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.~Record whether the subject feels bitterness, if there is no feeling, the test is over."
89058354|NCT04497753||Can fell bitterness|"The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood, the number of sprays should be the same as that of the sensitivity test.~Record whether the subject feels bitterness, If there is a sensation, put the adhesive strip on the upper edge of the subject's mask and put on the hood to carry out the above fitness test again.~Record whether the subject feels bitterness, if not, the test is over. If there is any sensation, ask the subject to change to a medical surgical mask, and put an adhesive strip on the upper edge of the mask, and put on the hood to carry out the above fitness test again."
89058355|NCT01641185|Experimental|protons|irradiation 20 x 3,3 GyE protons
89058356|NCT01641185|Experimental|carbon ions|irradiation 20 x 3,3 GyE carbon ions
89058357|NCT01641224|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
89058358|NCT01641224|Active Comparator|Pinaverium|
89058359|NCT01641224|Placebo Comparator|Placebo|Placebo is blindly given to patients
89058360|NCT04497675||Can't fell bitterness|"The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.~Record whether the subject feels bitterness, if not, let the subject puts on the hood, carry out the fitness test again and record the results."
89058361|NCT04497675||Can fell bitterness|"The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively, and the subject can stop the spray as soon as he/she smells bitterness.~If the subject feels bitterness, stick the adhesive strip on the upper edge of the subject's mask and perform the direct spray test again. Record whether the subject feels bitterness, if not, ask the subject to put on the hood, carry out the fitness test again and record it. If there is a feeling, ask the subject to change to a medical surgical mask and put an adhesive strip on the upper edge of the mask, then conduct the direct spray test again, and record the test results."
89058362|NCT01641263|Experimental|Cognitive Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
89058363|NCT01641263|Active Comparator|Sleep Seminar|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
89058364|NCT01643057||Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
89058365|NCT01643096|Other|sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
89058366|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
89058367|NCT04451460||Hyponatremia|Hyponatremic small cell cancer patients
89058368|NCT04451460||Normonatremia|Normonatremic small cell cancer patients
89058369|NCT01641302||Patients undergoing robot-assisted laparoscopic prostatectomy|Patients undergoing robot-assisted laparoscopic prostatectomy under general anesthesia
89058370|NCT04450719||Group 1: Patients with lung cancer|Exercise capacity [6-minute walk test (6-MWT)], pulmonary functions [spirometry], respiratory [maximal inspiratory and expiratory pressures (MIP-MEP), mouth pressure device] and peripheral muscle strength [dynamometer], physical activity level [metabolic holter], dyspnea [Modified Medical Research Council dyspnea scale (MMRC)] and quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] were evaluated in patients with lung cancer. Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
89058371|NCT04450719||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were performed in healthy individuals.
89058372|NCT01643135|Active Comparator|tranexamic acid|Tranexamic acid (15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will given before induction and the second dose(15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will be given at 3 hours after the first dose.
89058373|NCT01643135|Placebo Comparator|0.9% NaCl|0.9% NaCl 100 ml will be given as a placebo before induction and 3 hours after the first dose
89058374|NCT01643174||Surgical treatment|
89058375|NCT01641419|Placebo Comparator|Placebo|Ropivacaine 0.5% plus 2ml of normal saline used for nerve block
89058376|NCT01641419|Active Comparator|Dexamethasone 4 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 4 mg used for nerve block
89058377|NCT01641419|Active Comparator|Dexamethasone 8 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 8 mg used for nerve block
89058378|NCT01643252|Placebo Comparator|Placebo and UVA light exposure|
89058379|NCT01643252|Active Comparator|Riboflavin drops and UVA light exposure|
89058380|NCT04493814||Cohort|All the patients with type 2 diabetes followed at Universitary Hospital of Nancy who had undergone a DEXA and a Fibroscan between 2014 and 2019.
89058381|NCT01641458|Experimental|fluoropyrimidine-based chemotherapy|DPYD-genotype and TDM-driven dosing of 5FU/Capecitabine
89058382|NCT01600794||male/female, immunity or others factor infertility, IVF|
89058383|NCT01641497|Active Comparator|3D conformational radiotherapy|25 * 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation
89058384|NCT01641497|Experimental|Intensity-Modulated Radiation Therapy|25 * 1.8 Gy in 5 weeks (=45 Gy). IMRT
89058385|NCT01641536|Experimental|1mg of HB-110|The subjects in this group will be administered 1 mg of HB-110 according to the protocol.
89058386|NCT01641536|Experimental|2mg of HB-110|The subjects in this group will be administered 2 mg of HB-110 according to the protocol.
89058387|NCT01641536|Experimental|4mg of HB-110|The subjects in this group will be administered 4 mg of HB-110 according to the protocol.
89058388|NCT01641575|Experimental|CO-1.01 and Cisplatin|
89058389|NCT01643369|Experimental|Compassion Meditation Group|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
89058390|NCT01643369|Active Comparator|Health Education and Wellness Group|Eight week training in health and wellness, using a curriculum developed specifically for this study.
89058391|NCT01643369|Experimental|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
89058392|NCT01641731|Active Comparator|Cow's milk|
89058393|NCT01641731|No Intervention|Control group|
89058394|NCT01643447|Active Comparator|Diammonium glycyrrhizinate|Conventional drugs protect liver
89058395|NCT01643447|Experimental|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
89058396|NCT01600872||Gruop 1|
89058397|NCT01600872||Group 2|
89058398|NCT01643486|Experimental|iTouch phosphate counting program|All patients will have an iTouch that will help them to calculate the required number of phosphate binders to be taken with each meal
89058399|NCT01643486|Active Comparator|Usual Care|Participants in the active comparator group will document their meals in the iTouch but continue to take their phosphate binders as prescribed by their MD/dietician
89058400|NCT01641770|Experimental|Dietary Counseling + ONS|
89058401|NCT01641770|Active Comparator|Dietary Counseling|
89058402|NCT01643603|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. Patients who are day 100-180 post transplant will be eligible. The treatment will be started as close to day 100 as possible. The range of days is provided to ensure that patients have recovered from toxicities associated with ASCT and are not deemed ineligible if they were recovering from any toxicity associated with ASCT at day 100.The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months.
89058403|NCT02488863||Older Adults with Musculoskeletal Pain|Older adults (60+ years old) experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
89058404|NCT02488863||Older Adults without Musculoskeletal Pain|Older adults (60+ years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
89058405|NCT02488863||Young Controls|Healthy young adults (18-25 years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
89058406|NCT02755844|Experimental|Olaparib, metformin and metronomic cyclophosphamide|"Phase 1: Dose escalation scheme: a continual reassessment method (CRM) will be used to guide inclusion of patients in drug dose levels pre-specified based on observations of dose-limiting toxicity.~Phase 2 (expansion of cohort): once RP2D will be determined, additional patients will be enrolled, in order to obtain preliminary data about efficacy in a 2 stage Simon's design."
89058407|NCT04490928||complete revascularization|All patients who underwent complete myocardial revascularization
89058408|NCT04490928||incomplete revascularization|All patients who did not complete myocardial revascularization
89058409|NCT04490928||without revascularization|All patients who were not revascularized
89058410|NCT01643642|Experimental|Cognitive behavioral treatment/farmacotherapy intervention|Brief intervention; intake, cognitive behavioral treatment/farmacotherapy (SSRI) and ROM
89058411|NCT01643642|Other|Treatment As Usual|Control group, TAU
89058412|NCT01600989||Patients with severe sepsis / septic shock|30 Adult patients (age > 18years), with severe sepsis or septic shock as defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference guidelines at the time of admission to ICU.
89058413|NCT01600989||Healthy volunteers|Healthy volunteers
89058414|NCT01643681|Experimental|AdMSC|Autologous Adipose Tissue derived Mesenchymal Stem Cells
89058415|NCT01600209||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.
89058416|NCT01643720||Autism Spectrum Disorders|Children with Autism Disorders and their parents
89058417|NCT01643720||Typically Developing|Typically Developing children and their parents
89058418|NCT06032195|Experimental|Custodiol-N|organ will be perfused with Custodiol-N solution
89058419|NCT06032195|Active Comparator|Custodiol|organ will be perfused with Custodiol solution
89058420|NCT06032078|Experimental|Patients with keratosis pilaris|Patients treated with 3 sessions of 1064nm Nd: YAG laser at 4-weekly intervals. Results are compared with baseline.
89058421|NCT06032065|Experimental|Supervised treadmill exercise + nitrate rich beetroot juice|This group will be participating in Supervised Treadmill Exercise and drinking nitrate rich beetroot juice for 12 weeks.
89058422|NCT06032065|Placebo Comparator|Supervised treadmill exercise + placebo|This group will be participating in Supervised Treadmill Exercise and drinking placebo beetroot juice with nitrate removed for 12 weeks.
89218307|NCT02568761|Active Comparator|Injection snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate. 0.5 ml of the solution will be implemented in three different regions of the submucosal layer of the soft palate, one median and two paramedians.
89218308|NCT02568761|Active Comparator|Oropharyngeal Exercises|Weekly sessions of myofunctional exercises under the supervision of a qualified professional, lasting about 30 minutes each, combined with daily exercises without supervision for a period of three months.
89218309|NCT00460408||Observational study, no comparator|Observational study of patients with AMD treated with Macugen, no comparator
89218310|NCT00732407|Experimental|1|Patients with diabetes melittus treated with an ACE inhibitor will be treated with aliskiren
89218311|NCT00732407|Experimental|2|Patients with diabetes melittus treated with an ACE inhibitor will be given losartan
89218312|NCT00507819|Active Comparator|Sildenafil, then Placebo|Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
89218313|NCT00507819|Active Comparator|Placebo, then Sildenafil|Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks
89218314|NCT00738647|Active Comparator|Ceram X|Fillings made with a traditional composite material (Ceram X)
89218315|NCT00738647|Experimental|Filtek Silorane|Fillings made with a new composite material (Filtek silorane)
89218316|NCT01566058|Experimental|With BB Box|"The mothers in this arm of the study will have access to a BB Box video system to maintain contact with their premature baby."
89218317|NCT01566058|Active Comparator|Without BB Box|"The mothers in this arm of the study will not have access to a BB Box video system to maintain contact with their premature baby. (Standard care)"
89218318|NCT02569307|Active Comparator|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
89218319|NCT02569307|Active Comparator|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose
89218320|NCT02569307|Active Comparator|Placebo|Placebo added to TAU
89218321|NCT02569307|Active Comparator|Minocycline Plus Omega-3 fatty acids|Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose
89218322|NCT01013103|Other|Atorvastatin, Ischemic Heart Disease|
89218323|NCT01013103|Placebo Comparator|Atorvastatin vs Placebo Cardiac Surgery|
89218324|NCT00732485|Active Comparator|Fenofibrate|
89218325|NCT00732485|Placebo Comparator|Placebo|
89218326|NCT01566136|No Intervention|Usual care|Current routine rehab care for persons with a hip fracture and CI lacks a well integrated care system within the local hospital network. The usual approach to care at the two sites differ in one major way: patients presenting with a hip fracture to Site 1 receive surgery locally, while those presenting to Site 2 receive surgery at a different hospital because of the absence of an operating suite at this site. Within 2 to 10 days 95% of patients presenting to either site hospital's emergency room with a hip fracture, receive internal fixation or arthroplasty surgery. Patients, including some with mild and moderate CI, are then transferred to in-patient rehabilitation beds at Site 1 or Site 2. Screening of patients for dementia or delirium is not routinely done.
89218327|NCT01566136|Experimental|Rehabilitation Model of Care|Staff will be introduced to five components of the Patient-Centred Rehabilitation Model of Care (PCRM-CI) in a one-day workshop prior to implementing the PCRM-CI model. They will then be provided with eight additional educational sessions throughout the year. A manual detailing all aspects of training, including specifics on how to present the material, ideas for stimulating discussion, and case vignettes to illustrate training concepts was developed for our pilot study and will be used here. We also produced a short video on care of elderly with CI in rehabilitation which will be utilized in the training session. The model will be tested over a one year period with a sustainability plan in place developed by the local hospital network and the two study sites.
89218328|NCT02569073|Experimental|Dronabinol|Patients who receive Dronabinol 5 mg, every other night, orally.
89218329|NCT02569073|Placebo Comparator|Placebo|Patients who receive Placebo every other night, orally
89218330|NCT03490084||Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
89218331|NCT03490084||Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
89523260|NCT03387709|Experimental|Pistachio-enriched diet|Participants in this group will be individually counseled on a lower calorie diet, receive pistachios to be consumed daily for four months, and receive print materials on incorporating pistachios into their diet.
89523261|NCT03387709|Active Comparator|General dietary guidance diet|Participants in this group will receive general dietary guidance as part of a 4-month long group intervention.
89523262|NCT03383705|Experimental|Treatment arm|
89058423|NCT06032065|Experimental|Home-based walking exercise + nitrate rich beetroot juice|This group will be participating in Home-Based Exercise and drinking nitrate rich beetroot juice for 12 weeks.
89058424|NCT06032065|Placebo Comparator|Home-based walking exercise + placebo|This group will be participating in Home-Based Exercise and drinking placebo beetroot juice with nitrated removed for 12 weeks.
89058425|NCT06032039|Active Comparator|Corticosteroid Injection|This arm will receive a corticosteroid (Triamcinalone) injection.
89058426|NCT06032039|Active Comparator|Platelet Rich Plasma Injection (PRP)|This arm will receive a PRP injection.
89058427|NCT06031987|Active Comparator|SMBG arm|Self Monitoring of Blood Glucose group
89058428|NCT06031987|Experimental|CGMS arm|Continuous glucose monitoring system, CGM
89058429|NCT06031961|Active Comparator|1st group: Melatonin group|All children in this group have to receive 0.5 mg/kg of melatonin(maximum dose 20 mg) which will be administered orally on the night before surgery ( at 12 am) and immediately before 30 minutes before entering the catheterization room.
89058430|NCT06031961|Placebo Comparator|2nd group: Placebo group|All children in this group have to receive a placebo which will be administered orally on the night before surgery and immediately before 30 minutes before entering the catheterization room.
89058431|NCT06031948|Experimental|DLPFC group|Active iTBS will be delivered to the left DLPFC.
89058432|NCT06031948|Experimental|DMPFC group|Active iTBS will be delivered to the left DMPFC.
89058433|NCT06031948|Sham Comparator|Sham to DLPFC group|Sham iTBS will be delivered to the left DLPFC.
89058434|NCT06031948|Sham Comparator|Sham to DMPFC group|Sham iTBS will be delivered to the left DMPFC.
89058435|NCT06031935|Experimental|Yoga study group|This is the only arm of the study. The patients will be given yoga videos to do at home for 8 weeks as a treatment for anterior knee pain.
89058436|NCT06031909||Stroke patients|Stroke patients admitted to the certified stroke-unit of the Department of Neurology, University Hospital Giessen, Germany.
89058437|NCT06031870|Active Comparator|Standard care|
89058438|NCT06031870|Active Comparator|Pelvic floor muscle training|
89058439|NCT06031870|Experimental|Vaginal pessary|
89058440|NCT06031857|Experimental|Group A|. Group A was given kinesio tape.Total six sessions of each intervention were given to each patient at a rate of two sessions per week along with the 10 minutes of interferential therapy and 10 minutes of moist packs to each patient
89058441|NCT06031857|Active Comparator|Group B|. Group A was given dry needling. Total six sessions of each intervention were given to each patient at a rate of two sessions per week along with the 10 minutes of interferential therapy and 10 minutes of moist packs to each patient
89058442|NCT06031792|Experimental|Piezo endodontic surgery|Experimental: Piezo endodontic surgery The osteotomy will be applied under magnification with a surgical operating microscope (at the apical third of the root .Osteotomy will be done with the Piezosurgery touch
89058443|NCT06031792|Experimental|Conventional endodontic surgery|Active Comparator: Conventional endodontic surgery The osteotomy will be applied under magnification with a surgical operating microscope at the apical third of the root .Osteotomy will be done with air motor high speed hand-piece and round bur with copious irrigation
89058444|NCT06031753|Experimental|TRE|Only time restricted eating was carried on by this arm, having the first meal of the day at 12:00hrs and last meal of the day at 18:00hrs. No other medication was allowed during the study for this group.
89058445|NCT06031753|Experimental|TRE-HT|They carried on Time Restricted eating, in combination with the oral contraceptives used for the standard hormonal treatment. First meal of the day at 12:00hrs and last meal of the day at 18:00hrs. Other than oral contraceptives, no medication was allowed during the 3 months of the study.
89058446|NCT06031753|No Intervention|HT|No time restricted eating was practiced by this group, only oral contraceptives were taken, serving as the control group by having the standard hormonal treatment. No modification to their daily habits and routine was made.
89058447|NCT06031714|Other|Patients|Patients who have had at least one pregnancy and have a venous ulcer, diabetic ulcer or sickle cell ulcer
89058448|NCT06031714|Other|"Patient Controls group "|Post-partum women of the same age but without wounds.
89058449|NCT06031714|Other|Children|
89058450|NCT06031675||intervention group|The intervention measures encompass the implementation of simulated vigorous intermittent lifestyle physical activity for all participants. The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
89218332|NCT03449667|Active Comparator|Cryoneurolysis first, then optional sham crossover treatment|"Initial treatment: Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.~Optional sham crossover treatment: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis."
89218333|NCT03449667|Sham Comparator|Sham Comparator first, then optional cryoneurolysis treatment|"Initial treatment: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.~Optional cryoneurolysis treatment: Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis."
89218334|NCT00734123|Experimental|1|Participants assigned to the intensive arm (1) will be targeted to specified therapeutic aims (concerning lipids, blood pressure and antiplatelets)according to the results of carotid ultrasound and ankle-brachial index.
89218335|NCT00734123|Active Comparator|2|Participants assigned to control group (2) will be followed according to the clinical standard of care.
89218336|NCT00734201|Experimental|1|Randomised to a parallel group comparison of either one of four doses of study drug (1mg, 2mg, 5mg, 25mg) or placebo. Dosed once daily for 28 days
89218337|NCT00734279|Experimental|1|Girls with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
89218338|NCT00734279|Experimental|2|Girls with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
89218339|NCT00734279|Experimental|3|Boys with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
89218340|NCT00734279|Experimental|4|Boys with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
89218341|NCT00442936|Experimental|Telcagepant 150 mg|Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
89058451|NCT06031649||Group A|30 mother underwent cesarean section
89058452|NCT06031649||Group B|30 healthy females who were in the control group
89058453|NCT06049147|Experimental|MBF-015 4mg oral single dose|Drug: MBF-015 oral single dose. MBF-015 4 mg strength hard gelatin capsules
89058454|NCT06049147|Experimental|MBF-015 8 mg oral single dose|Drug: MBF-015 oral single dose. Two 4 mg strength hard gelatin capsules
89058455|NCT06049147|Experimental|MBF-015 16 mg oral single dose|Drug: MBF-015 oral single dose. One 16 mg strength hard gelatin capsules
89058456|NCT06049147|Experimental|MBF-015 32 mg oral single dose|Drug: MBF-015 oral single dose. Two 16 mg strength hard gelatin capsules
89058457|NCT06049147|Experimental|MBF-015 64 mg oral single dose|Drug: MBF-015 oral single dose. Four 16 mg strength hard gelatin capsules
89058458|NCT06049147|Experimental|MBF-015 8 mg oral multiple dose|Drug: MBF-015 oral single daily dose during five days. Two 4 mg strength hard gelatin capsules
89058459|NCT06049147|Experimental|MBF-015 16 mg oral multiple dose|Drug: MBF-015 oral single daily dose during five days. One 16 mg strength hard gelatin capsules
89058460|NCT06049147|Experimental|MBF-015 32 mg oral multiple dose|Drug: MBF-015 oral single daily dose during five days. Two 16 mg strength hard gelatin capsules
89058461|NCT06049147|Experimental|MBF-015 64 mg oral multiple dose|Drug: MBF-015 oral single daily dose during five days. Four 16 mg strength hard gelatin capsules
89058462|NCT06049147|Placebo Comparator|Placebo single dose|Placebo Hard gelatin capsules filled with cellulose microcrystalline. One single administration
89058463|NCT06049147|Placebo Comparator|Placebo multiple dose|Placebo Hard gelatin capsules filled with cellulose microcrystalline. Single daily dose during five days
89058464|NCT06049030|Experimental|Phase Ia dose escalation|Participants will be assigned to pre-specified dose level to identify the MTD/MAD of HS-10516.
89058465|NCT06049030|Experimental|Phase Ib dose expansion arm|Participants will be assigned to the recommended dose level determined in Phase Ia to evaluate the safety, pharmacokinetics and antitumor efficacy of HS-10516
89058466|NCT06048939|Experimental|aerobic and resistance training|moderate intensity aerobic and body weight resistance training on female adolescents.
89058467|NCT06048939|Active Comparator|aerobic training|moderate intensity aerobic and body weight resistance training on female adolescents.
89058468|NCT06048926|Experimental|Experimental group: carrelizumab in combination with concurrent chemoradiotherapy|Study drugs were administered intravenously on the first day of each cycle. Administered sequentially: carrelizumab, 200mg/time, paclitaxel, 50mg/m2, cisplatin, 25mg/m2, chemotherapy once a week, a total of 5 doses, carrelizumab every three weeks until PD or intolerable, up to 2 years, simultaneous radiotherapy at the first dose, the total dose of radiotherapy is 50.4Gy, completed in 28 divided doses, 1.8Gy each time, 5 times a week.
89058469|NCT06048926|Placebo Comparator|Control group: placebo-resistant in combination with chemoradiotherapy|"Placebo: 200 mg intravenously given with Q3W until PD or intolerable, carrelizumab/placebo for up to 2 years.~Paclitaxel: 50mg/m2, iv, D1, 8, 15, 22, 29, once a week, a total of 5 times. cisplatin: 25mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 doses. Radiotherapy: total dose of 50.4 Gy, completed in 28 divided doses of 1.8 Gy each time, 5 times a week."
89058470|NCT06048913|Experimental|Nimotuzumab combined with concurrent chemoradiotherapy|Treatment options Nimotuzumab （400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses）combined with chemoradiotherapy (Oral chemotherapy with the tigio regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral tigio course from Monday to Friday is synchronized with radiation therapy) for the treatment of locally advanced elderly esophageal cancer patients, in which the tigio regimen with good clinical tolerability was selected for chemotherapy to evaluate the short-term efficacy and toxic side effects
89058471|NCT06048900|Other|Optic nerve sheath diameter measurements|A total of 7 measurements were planned to be made at specified times.
89058472|NCT06048887|Experimental|Single Ascending Dose (Part 1)|
89058473|NCT06048887|Experimental|Multiple Ascending Dose (Part 2)|
89058474|NCT06048861|Experimental|Individuals with Carpal Tunnel Syndrome|
89058475|NCT06048861|Experimental|Healthy Controls|
89058476|NCT06048835||MBC|Patients diagnosed with metastatic breast cancer
89058477|NCT06048835||EBC|Patients diagnosed with primary early-breast cancer candidate for surgery
89218342|NCT00442936|Experimental|Telcagepant 300 mg|Participants receive telcagepant 300 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 300 mg or placebo) or one dose of non-study rescue medication.
89218343|NCT00442936|Active Comparator|Zolmitriptan 5 mg|Participants receive zolmitriptan 5 mg tablets, one tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
89218344|NCT00442936|Placebo Comparator|Placebo|Participants receive placebo matching capsules or tablets, one capsule or tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
89218345|NCT00734357|Experimental|Isovue Arm|Subjects with a clinically scheduled CT examination will be given the contrast Isovue. The investigators of this study will determine which contrast medication subjects will receive using randomization.
89218346|NCT00734357|Experimental|Omnipaque Arm|Subjects with a clinically scheduled CT examination will be given the contrast Omnipaque. The investigators of this study will determine which contrast medication subjects will receive using randomization
89218347|NCT00738725||1|Survey only
89218348|NCT00738725||2|Imaging group
89218349|NCT00738725||3|Non-imaging group
89218350|NCT04065503|Experimental|Healthy Adults|Healthy adults will be given probiotic strains to evaluate the detection and persistence of the strains in the participant's feces.
89218351|NCT00732719|Placebo Comparator|Profile A|Device worn; no pressure given (placebo)
89218352|NCT00732719|Active Comparator|Profile B|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 30 mm Hg and upper cuff at 20mm Hg
89218353|NCT00732719|Active Comparator|Profile C|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 20 mm Hg and upper cuff at 10mm Hg
89218354|NCT00732719|Active Comparator|Profile D|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 10 mm Hg and upper cuff at 0mm Hg
89218355|NCT00732719|Active Comparator|Profile E|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 40 mm Hg and upper cuff at 40mm Hg
89218356|NCT00732719|Active Comparator|Profile F|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 30 mm Hg and upper cuff at 30mm Hg
89218357|NCT00732719|Active Comparator|Profile G|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 20 mm Hg and upper cuff at 20mm Hg
89218358|NCT01010997||Dry AMD|Intermediate AMD subjects
89218359|NCT01010997||Wet - treated AMD|AMD subjects under treatments
89218360|NCT00738803|Experimental|1|Leg Length and offset measurement arm
89058478|NCT06048835||HC|Control group of sex and age matched healthy volunteers, not affected by any neoplastic disease
89058479|NCT06048796|Experimental|Early cessation of sedation and TTM|Early cessation of sedation and targeted temperature management (TTM), with subsequent weaning from mechanical ventilation if appropriate (intervention group).
89058480|NCT06048796|No Intervention|Standard Care|Standard care, including sedation and targeted temperature management (TTM) for at least 24-48 hours (control group).
89058481|NCT06048705|Experimental|GSK3901961|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive high dose of GSK3901961 after completing lymphodepleting chemotherapy. The first study participant receiving GSK3901961 will receive the total assigned dose as 2 separate infusions 7 days apart, in aliquots of 30% (first infusion) and 70% (second infusion) of the total target dose, respectively. Based on the dose limiting toxicities reported in the first participant, then all subsequent participants treated with GSK3901961 will receive the full dose as a single, i.e., one-time, infusion.
89058482|NCT06048692|Experimental|Cefepime Group|Pregnant women (n=100) received IV cefepime (CEF) (maxipime®1000mg) 30 minutes before cesarean delivery (CD) and 12 hours after CD
89058483|NCT06048692|Active Comparator|Ampicillin/Sulbactam|Pregnant women (n=100) received IV Ampicillin/Sulbactam (AMS) (Unictam® 1500 mg) 30 minutes before CD and 12 hours after CD
89058484|NCT06048679|Other|main|
89058485|NCT06048666|Experimental|Intra ovarian by platelet rich plasma|intra-ovarian injection of autologous platelet rich plasma 3 months after the PRP injection,they will undergo assisted reproductive therapy with antagonist protocol followed by a dose of 450 units of FSH (Gonal F)
89058486|NCT06048666|No Intervention|control|they will undergo ICSI trial with antagonist protocol followed by a dose of 450 units of FSH (Gonal F)
89058487|NCT06048653|Experimental|control group|The control group (GI) will receive a computer based cognitive rehabilitation program (Rehacom system)
89058488|NCT06048653|Experimental|study group|The study group (GII) will receive a computer based cognitive rehabilitation program (Rehacom system) in addition to Vagus nerve stimulation.
89058489|NCT06048601|Experimental|two diagnostic approaches to the diagnosis of AL-CA in patients with a monoclonal protein|traditional invasive approach vs. non-invasive approach using the visual assessment of 18F-florbetaben PET/TC
89058490|NCT06048575||Number of patients with early therapy|Patients with early surgery (<72 hours of admission).
89058491|NCT06048575||Number of patients with subacute therapy|Patients with surgery for three days or more.
89058492|NCT06048575||Number of patients with late therapy|Patients with surgery beyond ten days.
89058493|NCT06048575||Number of patients with no therapy|Patients discharged with no surgical therapy.
89058494|NCT06048562|Experimental|idm|evaluation idm for cardiomyopathy
89058495|NCT06048536|Experimental|Norelgestromin low dose 2.43mg 28/0 regimen non-Obese|
89058496|NCT06048536|Experimental|Norelgestromin mid dose 3.64mg 28/0 regimen non-Obese|
89058497|NCT06048536|Experimental|Norelgestromin high dose 4.86mg 28/0 regimen non-Obese|
89058498|NCT06048536|Experimental|Norelgestromin high dose 4.86mg 21/7 regimen non-Obese|
89058499|NCT06048536|Experimental|Norelgestromin mid dose 3.64mg 28/0 regimen Obese|
89058500|NCT06048536|Experimental|Norelgestromin high dose 4.86mg 28/0 regimen Obese|
89058501|NCT06048536|Experimental|Norelgestromin high dose 4.86mg 21/7 regimen Obese|
89218361|NCT01013259|Placebo Comparator|Placebo|
89218362|NCT01013259|Experimental|Mutaflor|
89058502|NCT06048523|Other|Patient cohort|Patients with a molecularly identified NGD (80 patients in total of which 15 with LP (Lumbar Puncture) and of which 30 with cutaneous biopsy)
89058503|NCT06048523|Other|Control cohort|Patients control: 10 controls with lumbar puncture and 10 controls without LP (Lumbar Puncture)
89058504|NCT06048458||Cohort 1|Stable patients with gastrointestinal malignancies will be recruited to this 3 timepoint study prior to initiation of fluoropyrimidine chemotherapy. All investigations will be performed at baseline, at the end of cycle 1 and 4-6 weeks post completion of treatment.
89058505|NCT06048458||Cohort 2|Patients with gastrointestinal malignancies presenting to hospital with acute symptoms of fluoropyrimidine cardiotoxicity. All investigations will be performed during the acute presentation and the second visit will be performed 4-6 weeks post completion of treatment.
89058506|NCT06048445||Biliary Drainage Stent group|placement of Biliary Drainage Stent in pediatric liver transplantation
89058507|NCT06048445||no Biliary Drainage Stent group|no placement of Biliary Drainage Stent in pediatric liver transplantation
89058508|NCT06048432|Experimental|Intervention|Conventional phyisiotherapy + telecare
89058509|NCT06048432|Active Comparator|Control|Conventional physiotherapy
89058510|NCT06048393|Experimental|Group1|Single-dose:1 spray per side per time, 1ml/time Single-dose: 2 sprays per side per time, 2ml/time Multi-dose:1 spray per side per time, 1ml/time Multi-dose: 2 sprays per side per time, 2ml/time
89058511|NCT06048393|Placebo Comparator|Group2|Single-dose: 1 spray per side per time Multi-dose: 2 sprays per side per time
89058512|NCT06048380|Experimental|Treatment|Participants in this group will be asked to instill Glanatec Ophthalmic Solution (containing Ripasadil 0.4%) 4 times a day for 3 months following cataract removal surgery.
89058513|NCT06048380|Placebo Comparator|Placebo|Participants in this group will be asked to instill saline solution 4 times a day for 3 months following cataract removal surgery.
89058514|NCT06048367|Experimental|CNSI-Fe(II) 30 mg|30 mg
89058515|NCT06048367|Experimental|CNSI-Fe(II) 60 mg|60 mg
89058516|NCT06048367|Experimental|CNSI-Fe(II) 90 mg|90 mg
89058517|NCT06048354|Experimental|Wheat Polar Lipid Complex Oil|Dietary supplement - Wheat Polar Lipid Complex (Oil)
89058518|NCT06048354|Experimental|Wheat Polar Lipid Complex Powder|Dietary supplement - Wheat Polar Lipid Complex (Powder)
89058519|NCT06048354|Placebo Comparator|Placebo|Dietary supplement - Placebo
89058520|NCT06048224|Experimental|HS628|Subjects will receive 8mg/kg intravenous(IV) HS628 at Week 0,Week 4, Week 8, Week 12, Week 16, Week 20,Week 24
89058521|NCT06048224|Active Comparator|Actemra|Subjects will receive 8mg/kg intravenous(IV) ACTEMRA® at Week 0,Week 4, Week 8, Week 12, Week 16, Week 20,Week 24
89058522|NCT06048172|No Intervention|Waiting control group|The patients in the treatment-as-usual control group remain on the waiting list for 14 weeks after the baseline measurement. After 14 weeks, they participate in the study diagnostics post-treatment at time point.
89058523|NCT06048172|Experimental|Intervention group|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
89058524|NCT06048068|Experimental|Informational Intervention Arm|Participants in this arm will receive access to the informational intervention program, via a website link that they will access through their own person phone/tablet/computer.
89058525|NCT06048068|No Intervention|Control Arm|Participants in this arm will receive usual care and no access to the informational intervention program.
89058526|NCT06048055|Active Comparator|Group 1 (GA)|Twenty Egyptian male stroke patients will receive 30 minutes of transcutaneous vagal nerve stimulation at tragus of left ear immediately after a 30 minutes session of selected physical therapy program.
89058527|NCT06048055|Sham Comparator|Group 2 (GB)|Twenty Egyptian male stroke patients will receive 30 minutes of sham vagal nerve stimulation at tragus of left ear immediately after a 30 minutes session of selected physical therapy program.
89058528|NCT06048029|Other|Laparoscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for laparoscopic cholecystectomy compared to open cholecystetcomy
89058529|NCT06048029|Other|Open Cholecystectomy in children|Evaluate preoperative and operative risk factors for open cholecystectomy compared to laparoscopic cholecystetcomy
89058530|NCT06048016|Experimental|periodontitis patients|Periodontitis Patients participate to test level of ALP in saliva and GCF.
89058531|NCT06047990|Experimental|Cryobiopsy|In randomised patients in experimental arm was initially performed cryobiopsy (3 samples) and cosequently forceps biopsy (6 samples) with 5.2F or 7.5F forceps. Both sampling techniques were performed during one procedure of percutaneous transhepatic drainage under fluoroscopic control.
89058532|NCT06047990|Active Comparator|Forceps biopsy|In randomised patients in control arm was initially performed forceps biopsy (6 samples) with 5.2F or 7.5F forceps and cosequently cryobiopsy (3 samples). Both sampling techniques were performed during one procedure of percutaneous transhepatic drainage under fluoroscopic control.
89058533|NCT06047964|Experimental|De-novo DCB group|Patients with de-novo symptomatic intracranial atherosclerotic stenosis and treated with DCB
89218363|NCT00732953|Active Comparator|1|Genous stent implantation with paclitaxel-eluting balloon therapy
89058534|NCT06047964|Active Comparator|De-novo POBA group|Patients with de-novo symptomatic intracranial atherosclerotic stenosis and treated with POBA
89058535|NCT06047964|Experimental|Restenosis group|Patients with symptomatic intracranial atherosclerotic re-stenosis after interventional therapy and treated with DCB
89058536|NCT06047925|Experimental|group A|First permanant molar will be prepared to receive 3D printed crown
89058537|NCT06047925|Active Comparator|group B|First permanant molar will be prepared to receive SSC
89058538|NCT06047873|Experimental|cases|
89058539|NCT06047860|Experimental|Intervention group|"M-CSF 200 μg administered subcutaneously daily for 7 days on the first day of treatment; IL-2 2 million IU administered subcutaneously daily for 7 days the day after GM-CSF; PD-1/PD-L1 inhibitor within one week of radiotherapy; Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h starting on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.~Maintenance treatment phase:~Maintenance with PD-1/PD-L1 inhibitor in combination with recombinant human vascular endothelial inhibitor (Endo) until progression or intolerable side effects."
89058540|NCT06047808|Experimental|Storytelling Through Music|"Participants will be randomized to either the Storytelling Through Music (STM) experimental arm or the waitlist control arm. STM is a six-week intervention that utilizes storytelling, reflective writing, self-care skills (i.e., breathing exercises, meditation, self-compassion, body scans), and songwriting. The intervention is delivered online and in a group setting. Online delivery provides convenience to participants, and the group setting provides an environment of people with shared experiences, which has been shown to decrease social isolation and feelings of being alone in their emotional experience. By the end of the intervention, participants will have written a short story and a song based on their story."
89058541|NCT06047808|No Intervention|Waitlist Control|"Participants will receive the same Storytelling Through Music intervention once data collection from the experimental arm is complete."
89058542|NCT06047795|Experimental|Interventional|Aerobic and respiratory endurance exercises with patient education
89058543|NCT06047795|Placebo Comparator|Control|Usual care (Patient Education, Home Plan)
89058544|NCT06047769|Experimental|Interventional Group|Participants will receive cognitive training in board games including Ludo, Chutes & Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
89058545|NCT06047769|No Intervention|Control group|Participants will receive no intervention and will be observed for 8 weeks.
89058546|NCT06047730||multi-port laparoscopic surgery|
89058547|NCT06047730||transumbilical laparoendoscopic single-site surgery|
89058548|NCT06047730||vaginal natural orifice transluminal endoscopic surgery|
89218364|NCT00732953|Active Comparator|2|Genous stent implantation
89218365|NCT00577655|Experimental|Albuterol|Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.
89218366|NCT00577655|Placebo Comparator|Placebo|"A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as Placebo-HFA-MDI.)"
89218367|NCT01013337|Experimental|Arm I (Acupuncture)|Patients undergo 10, 20-minute sessions of acupuncture over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments).
89218368|NCT01013337|Sham Comparator|Arm II (Placebo)|Patients undergo 10, 20-minute sessions of sham acupuncture treatments over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments) via Streitberger needles at non-acupuncture points.
89218369|NCT01013337|No Intervention|Arm III (Control)|Wait-list control patients are contacted by phone at the same frequency as real and placebo acupuncture groups for data collection at weeks 1, 4, and 8.
89218370|NCT04514679||Healthy Lifestyles Program|Usual care in the Healthy Lifestyles Program.
89218371|NCT04514679||Obesity Medicine Program|Usual care in the Obesity Medicine program.
89218372|NCT00733031|Experimental|gemcitabine|gemcitabine administered in combination with AZD6918
89218373|NCT00733031|Experimental|pemetrexed|pemetrexed administered in combination with AZD6918
89218374|NCT00733031|Experimental|AZD6918|AZD6918 administered alone
89218375|NCT00734669||1|Type 2 diabetic patients on glibenclamide at individual dosage up to 7 mg/day for more than one year prone to hypoglycemic events
89218376|NCT00738959|Experimental|1|
89218377|NCT00113269|Experimental|Alemtuzumab High-Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
89058549|NCT06047652|Experimental|Intervention group|The e-CPD device will be given to the participant group according to the criteria. Each participant is given access rights for 1 week to try all the features in e-CPD.
89058550|NCT06047600|No Intervention|Control Group|The control group is based on the pre-existing organization, with no digital patient follow-up tools.
89058551|NCT06047600|Experimental|Uroconnect Follow Up Group|"The UroConnect device has a patient interface for presenting self-questionnaires and access to a library of educational content and a caregiver interface to rationalize and optimize the nurse's activity of perioperative coordination in his task"
89110983|NCT02737787|Experimental|WT1 Vaccine and Nivolumab|Patients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab every two weeks over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.This cohort has completed recruitment.
89218378|NCT00113269|Active Comparator|Conventional High-Risk Patients|Rabbit anti-thymocyte globulin, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
89218379|NCT00113269|Experimental|Alemtuzumab Low- Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
89218380|NCT00113269|Active Comparator|Conventional Low-Risk Patients|Basiliximab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
89058552|NCT06047587|Experimental|VR-TrAC|Participants assigned to the VR-TrAC group will follow the training: Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each. The treatment protocol used in this training is based on the Virtual Reality Aggression Prevention Training (VRAPT), developed by Klein Tuente et al. (2020). The first four sessions focus on the early stages of information processing (what is happening and what does it mean). Session five through eight focus on the late information processing stages (what goals am I trying to achieve, what options do I have to react, what am I going to do, and what is the reaction or behavior). Session 10 through 15 combines the early and late stages, as all newly learned behavior will be incorporated in the interactive scenarios. To train the aforementioned stages, different aggressive-inducing situations are practiced in VR.
89058553|NCT06047587|Other|Care as Usual|Participants receive Care As Usual (CAU) when necessary. CAU in prison consists of treatment with the main focus to stabilize a disrupted psychological state (such as pharmacological treatment, supportive contact or a transfer to a Penitentiary Psychiatric Centre where necessary interventions are applied to stabilize the disorder).
89058554|NCT06047561||Aortic Stenosis|Participants with Aortic Stenosis across the spectrum of disease severity
89058555|NCT06047561||Aortic Valve Replacement|Participants who have previously undergone aortic valve replacement
89058556|NCT06047561||Healthy Volunteers|Healthy Volunteers for the purposes of case-control analysis
89058557|NCT06047522|Experimental|Intervention|The participant will benefit from three immersion sessions with the virtual reality headset, either individually or in a group session, accompanied by a team member trained in the use of the headset (psychomotrician, occupational therapist, doctor, psychologist, facilitator). At each session, the scale of observed emotions and the cybermalaise questionnaire will be completed (T1, T2, T3). At sessions 1 (T1) and 3 (T3), the investigator will administer the ECPAI behavior scale.
89058558|NCT06047483|Experimental|HRF2105 patch|
89058559|NCT06047483|Active Comparator|Loxoprofen patch|
89058560|NCT06047483|Placebo Comparator|placebo|
89058561|NCT06047431|Experimental|QL1706H|"Part 1 (Dose escalation): QL1706H will be administered in sequential cohorts each receiving 1 dose of QL1706H by subcutaneous injection on day 1 and QL1706 by IV infusion on day 22, from then on will recieve QL1706 on day 1 of every 21-day cycle (3 weeks). Dose escalation will continue until the projected cohorts has been finished.~Part 2 (Dose Exploration): The PK parameters of QL1706H will be tested at different administration intervals."
89058562|NCT06047340|Experimental|Early AD|"10 participants with early AD~Intervention: Game"
89058563|NCT06047340|Experimental|MCI|"10 participants with mild cognitive impairment~Intervention: Game"
89058564|NCT06047340|Active Comparator|Health Control|"10 healthy control participants~Intervention: Game"
89058565|NCT06047327|Experimental|EUS Guided Liver Biopsy|Procedure will be done by 19G Franseen needle in EUS guided liver biopsy.
89058566|NCT06047327|Active Comparator|Percutaneous Liver Biopsy|Procedure will be done by 18G BioPince Needle in percutaneous liver biopsy.
89058567|NCT06047275||Test|Hep C positive
89058568|NCT06047275||Control|Hep C negative
89058569|NCT06047249|No Intervention|Coronary heart disease group|16SrDNA sequencing and ELISA test were carried out for patients over 50 years old who reported coronary atherosclerosis after coronary angiography or coronary angiography with CT examination to detect the abundance of Prevotella in their intestines, the concentration of 5-hydroxytryptamine, branched chain amino acids and lipopolysaccharide in their blood
89058570|NCT06047249|No Intervention|Non coronary heart disease group|For patients over 50 years old who reported no coronary atherosclerosis after coronary angiography or CTA examination, 16SrDNA sequencing and ELISA tests were carried out to detect the abundance of Prevotella in the intestinal tract, the concentration of 5-hydroxytryptamine, branched chain amino acids and lipopolysaccharide in the blood
89058571|NCT06047249|Experimental|KAP group|Conduct a survey on the relationship between coronary heart disease and dietary patterns among hospitalized patients in the form of KAP Popular Science Research. After the survey, conduct scientific popularization of relevant knowledge, conduct a satisfaction questionnaire survey after surgery, and collect data on preoperative and postoperative examinations and laboratory tests
89058572|NCT06047249|Sham Comparator|Non KAP group|Investigators will not conduct a survey on the relationship between coronary heart disease and dietary patterns among hospitalized patients, conduct science popularization, and conduct a satisfaction questionnaire survey after surgery
89058573|NCT06047210||A-HLH Patients|Patients diagnosed with A-HLH. The diagnosis of A-HLH was established by the treating physician.
89058574|NCT06047210||Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) Patients|Patients diagnosed with HLH in the context of a malignancy. The diagnosis of M-HLH was established by the treating physician.
89058575|NCT06047197|Experimental|First dose group|The initial dose is (0.5 ± 0.1) × 10^6/kg, with 1 participant enrolled
89058576|NCT06047197|Experimental|Second dose group|The second dose is (1.0 ± 0.2) × 10^6/kg, with 3-6 study participants enrolled
89058577|NCT06047197|Experimental|Third dose group|The third dose is (2.5± 0.5) × 10^6/kg, with 3-6 study participants enrolled
89058578|NCT06047197|Experimental|Fourth dose group|The fourth dose is (5± 1) × 10^6/kg, with 3-6 study participants enrolled
89058579|NCT06047184|Experimental|Monotherapy group 1|BEBT-209 capsules, 25mg once daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
89058580|NCT06047184|Experimental|Monotherapy group 2|BEBT-209 capsules, 25mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
89058581|NCT06047184|Experimental|Monotherapy group 3|BEBT-209 capsules, 50mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
89058582|NCT06047184|Experimental|Monotherapy group 4|BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
89058583|NCT06047184|Experimental|Monotherapy group 5|BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
89058584|NCT06047184|Experimental|Monotherapy group 6|BEBT-209 capsules, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
89058585|NCT06047184|Experimental|BEBT-209 combined with the letrozole group 1|"BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.~Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle."
89058586|NCT06047184|Experimental|BEBT-209 combined with the letrozole group 2|"BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.~Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle."
89058587|NCT06047184|Experimental|BEBT-209 combined with the Fulvestrant Group 1|"BEBT-209 capsules, 75mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.~Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle"
89058588|NCT06047184|Experimental|BEBT-209 combined with the Fulvestrant Group 2|"BEBT-209 capsules, 100mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.~Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle"
89058589|NCT06047158||Fish oil group|"The patients in this group were treated with omega-3 fish oil fat emulsion at a dose of 100ml/ per person per day for 5 days and added to a three-liter bag (containing water, glucose, amino acids, sodium chloride, vitamins, etc.) except fish oil.~Drug introduction:~Full name: omega-3 fish oil fat emulsion. Common name: Juventus. Specification: 100ml / 10g"
89058590|NCT06047158||Non-fish oil group|Do not use omega-3 fish oil fat emulsion (no omega-3 fish oil fat emulsion is added to the three-liter bag, other substances are the same)
89058591|NCT06047015|Experimental|IRE plus Checkpoint Inhibitor|"Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.~IRE is performed in the CT scanner. Patients will receive a general anesthetic, and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
89058592|NCT06047015|Experimental|IRE plus Checkpoint Inhibitor plus CpG Oligodeoxynucleotides (CpG-ODN)|"Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG-ODN solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
89522734|NCT05063123|Other|Single arm - Flotetuzumab|1 - 3 cycles of Flotetuzumab. Flotetuzumab will be administered intravenously via continuous (pump) administration. At least for the first 7 days of cycle 1, the drug will be administered in an inpatient hospital setting, but afterwards may be administered in an outpatient setting using an ambulatory pump configuration. Flotetuzumab will be dosed using multi-step increments in dosing over the first week as follows: 30, 60, 100, 200, 300, and 400 ng/kg/day each for 24 hours. On day 7, the dose will be increased to 500 ng/kg/day and administered as a continuous infusion for the remainder of cycle 1. After 1 cycle of flotetuzumab patients will proceed with alloHCT. However if there is a delay in access to transplantation, patients are allowed to receive up to 2 additional cycles flotetuzumab provided all non-hematologic toxicities have resolved to Grade <2.
89058595|NCT06046963|Experimental|Immunotherapy combined with intravenous and intraperitoneal chemotherapy|advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma patients with malignant ascites who have agreed to receive Immunotherapy combined with intravenous and intraperitoneal chemotherapy
89110984|NCT02737787|Experimental|ESO-1 Vaccine and Nivolumab|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
89110985|NCT02494570|Experimental|nab-Sirolimus|Patients with malignant PEComa received nab-sirolimus on Days 1 and 8 of every 21-day cycle, as a 30-minute IV infusion.
89058596|NCT06046924|Experimental|Fruits and vegetables (F+V)|51 participants with hypertension, normal estimated glomerular filtration rate (eGFR) (>90 ml/min/m2) and macroalbuminuria (albumin [mg] to creatinine [g] ratio > 200 mg/g) will receive a prescribed amount of base-producing fruits and vegetables (F+V) designed to reduce their dietary acid intake by half. Depending on the particular foods used, this amounts to 2-4 cups daily of fruits and vegetables given in weekly allotments. They will otherwise receive standard care for their medical concerns including angiotensin converting enzyme inhibitor therapy for albuminuria and followed annually for 5 years.
89058597|NCT06046924|Experimental|NaHCO3 (HCO3)|51 participants with hypertension, normal estimated glomerular filtration rate (eGFR) (>90 ml/min/m2) and macroalbuminuria (albumin [mg] to creatinine [g] ratio > 200 mg/g) will receive 0.4 mEq/kg/bw oral tablet dose of sodium bicarbonate (NaHCO3) designed to match the alkali intake of F+V. They will otherwise receive standard care for their medical concerns including angiotensin converting enzyme inhibitor therapy for albuminuria and followed annually for 5 years.
89058598|NCT06046924|Active Comparator|Usual Care (UC)|51 participants with hypertension, normal estimated glomerular filtration rate (eGFR) (>90 ml/min/m2) and macroalbuminuria (albumin [mg] to creatinine [g] ratio > 200 mg/g) will receive no additional alkali (neither F+V or NaHCO3) and will receive standard care for their medical concerns, including angiotensin converting enzyme inhibitor therapy for albuminuria and followed annually for 5 years.
89058599|NCT06046911|Experimental|Tai Chi group|The intervention was 12 weeks of Yang-style Tai Chi, three times a week.
89058600|NCT06046911|Experimental|Daily activity group|The daily activity group mainly maintained daily activities, such as walking and stretching, three times a week for 12 weeks.
89058601|NCT06046885|Experimental|Electricalstimulation|
89058602|NCT06046872|Other|Report-back training program|Researchers participate in a training program on sharing personal results. Pre-and post-tests are administered to evaluate shifts in perspectives and wiliness to report-back before and after the training program. There is no control group.
89058603|NCT06046846|Experimental|Asensei app intervention group|Participants randomised to the intervention group will be introduced to the mHealth prehabilitation programme delivered via a mobile app. Within this intervention group, participants will have access to a mHealth prehabilitation programme delivered and monitored via an app which will consist of a multimodal prehabilitation programme consisting of nutritional guidelines, improving well being and physical functioning prior to surgery.
89058604|NCT06046846|No Intervention|Standard Pre-Operative Care group|The control group will receive standard pre-operative care within NHS Lothian for patients undergoing surgery for oesophago-gastric cancer which includes the enhanced recovery after surgery pathway. This pathway includes a pre-assessment, verbal advice only on prehabilitation interventions surrounding nutrition, well being and physical activity as well as a follow up post treatment.
89058605|NCT06046807||35mmHg ECS|Subjects with first proximal DVT allocated to wear 35 mmHg elastic compression stockings (ECS) for 2 years during the CELEST RCT
89058606|NCT06046807||25mmHg ECS|Subjects with first proximal DVT allocated to wear 25 mmHg elastic compression stockings (ECS) for 2 years during the CELEST RCT
89058607|NCT06046781|Other|Control group|One group served as the control and was advised not to participate in any postoperative exercise.
89058608|NCT06046781|Experimental|Second week walking group|Postoperative walking initiated 2 weeks following surgery.
89058609|NCT06046781|Experimental|One month walking group|Postoperative walking initiated one month following surgery.
89058610|NCT06046781|Experimental|Second week waist exercise group|Postoperative waist exercise initiated 2 weeks following surgery.
89058611|NCT06046781|Experimental|One month waist exercise group|Postoperative waist exercise 1 month following surgery.
89058612|NCT06046768|Experimental|Child with oral feeding disorder(s)|Child (boy or girl) with oral feeding disorder(s) diagnosed by a speech therapist as part of a speech therapy assessment.
89058613|NCT06046755|Experimental|Energy restriction-ketogenic intervention (VLCKD)-breast cancer arm|Breast cancer patients with obesity will follow an energy-restricted-ketogenic dietary five steps program, which includes lifestyle and behavioral modification support. The first three steps consist of a VLCKD (600 -800 kcal/day), low in carbohydrates (< 50 g daily from vegetables) and lipids (only 10 g of olive oil per day). Throughout these ketogenic phases, supplements of vitamins and minerals supplements, such as K, Na, Mg, Ca, and omega-3 fatty acids will be administered. These three steps will be maintained until the patient lost the target amount of weight, ideally 80%. In steps 4 and 5, the patient started a low-calorie diet (800 -1500 kcal/day) and followed by a maintenance diet that will consist of an eating plan balanced in carbohydrates, protein, and fat (1500 and 2000 kcal/day).
89058614|NCT06046755|Experimental|Group educational intervention program (IGOBE)-breast cancer arm|Breast cancer patients with obesity will follow structured program of change of habits that will consist of a balanced hypocaloric diet, following the criteria of both the recommendations from Spanish Society of Study of Obesity (SEEDO) 2007, the American Dietetic Guidelines 2010, the Consensus SEEDO 2012 and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Guideline for the Management of Overweight and Obesity in Adults 2014. Coinciding all in pointing out that the hypocaloric diet should represent a deficit of about 500 to 1000 kcal / day with respect to the habitual intake of the patient in question. The intervention group will be included in a structured program of habits change and exercise. In the intensive phase of the intervention patients will assist to 6 additional weekly visits, with 15 patients per group and a duration of 60 minutes each.
89058615|NCT06046755|Experimental|Energy restriction-ketogenic intervention (VLCKD)-tumor free arm|Tumor-free patients with obesity will follow an energy-restricted-ketogenic dietary five steps program, which includes lifestyle and behavioral modification support. The first three steps consist of a VLCKD (600 -800 kcal/day), low in carbohydrates (< 50 g daily from vegetables) and lipids (only 10 g of olive oil per day). Throughout these ketogenic phases, supplements of vitamins and minerals supplements, such as K, Na, Mg, Ca, and omega-3 fatty acids will be administered. These three steps will be maintained until the patient lost the target amount of weight, ideally 80%. In steps 4 and 5, the patient started a low-calorie diet (800 -1500 kcal/day) and followed by a maintenance diet that will consist of an eating plan balanced in carbohydrates, protein, and fat (1500 and 2000 kcal/day).
89058616|NCT06046755|Experimental|Group educational intervention program (IGOBE)-tumor free arm|Tumor-free patients with obesity will follow structured program of change of habits that will consist of a balanced hypocaloric diet, following the criteria of both the recommendations from Spanish Society of Study of Obesity (SEEDO) 2007, the American Dietetic Guidelines 2010, the Consensus SEEDO 2012 and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Guideline for the Management of Overweight and Obesity in Adults 2014. Coinciding all in pointing out that the hypocaloric diet should represent a deficit of about 500 to 1000 kcal / day with respect to the habitual intake of the patient in question. The intervention group will be included in a structured program of habits change and exercise. In the intensive phase of the intervention patients will assist to 6 additional weekly visits, with 15 patients per group and a duration of 60 minutes each.
89058617|NCT06046755|No Intervention|Non intervention arm-breast cancer arm|This arm will include patients with obesity and normal weight women with breast cancer that will follow the normal clinical practice in their oncological therapy without intervention to lose weight in the group of patients with excess body weight.
89058618|NCT06046716|Experimental|Experimental mindful compassion group|Experimental randomised controlled waitlist study The experimental group (n=28) will receive mindful compassion intervention at week 1 and intervention terminates at week 4
89058619|NCT06046716|Other|Waitlist mindful compassion control group|Experimental randomised controlled waitlist study The delayed group (n=24) will receive mindful compassion intervention at week 4 and intervention terminates at week 8
89058620|NCT06046677||Sepsis cohort|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection."
89058621|NCT06046677||Elective cohort|Elective pre-operative upper GI surgical patients or elective stem cell transplant patients will be consented and enrolled at baseline, immediately prior to these procedures. If they go on to develop sepsis within 60 days of their surgery, they will go on to be sampled as per the sepsis cohort
89058622|NCT06046664|Other|DCIS Test|
89058623|NCT06046638|Experimental|Cyclopofol|For patients in the cyclopofol group, cyclopofol will be given as induction of anesthesia (0.4 mg/kg) followed by a continuous infusion (0.8 mg/kg/h) until the end of surgery.
89058624|NCT06046638|Active Comparator|Propofol|For patients in the propofol group, propofol will be given as induction of anesthesia (2 mg/kg) followed by a continuous infusion (5 mg/kg/h) until the end of surgery.
89058625|NCT06046612|Experimental|heart failure with preserved ejection fraction|Empagliflozin 10mg, tablet, once daily
89058626|NCT06046599||Patients living with amyotrophic lateral sclerosis|Individuals with a known diagnosis of amyotrophic lateral sclerosis will be recruited from King's College Hospital's Motor Nerve Clinic. The cohort will contain 20 individuals and their study partners and will be part of the study for one year.
89058627|NCT06046560|Experimental|Medication & Education-First|Patient will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm.
89058628|NCT06046560|Active Comparator|Education-First|Patient will first receive curated patient education, an alert to providers, and provider education, and then after 2 months begin participation in the remote clinic.
89058629|NCT06046508||Sigle arm study|Patients with migraine headache with aura (MHA), patent foramen ovale (PFO) and previous neurological event (transient ischemic attack -TIA- or stroke) with clinical indication for percutaneous correction of the defect according to guidelines will be enrolled
89058630|NCT06046469|Active Comparator|CT group|this group of patient is doing CT abdomen and plevis with IV contrast then they undergo TURBT and compare the radiological staging to histopathological staging.
89058631|NCT06046469|Active Comparator|MRI group|this group of patient is doing MRI pelvis with contrast then they undergo TURBT and compare the radiological staging to histopathological staging.
89058632|NCT06046404|Active Comparator|closed reduction followed by plaster casting|
89058633|NCT06046404|Experimental|only plaster casting|no closed reduction will be performed
89058634|NCT06046391|Experimental|LP-003 dose 1|Eligible patients randomized to this arm received LP-003 subcutaneously for 8 weeks
89058635|NCT06046391|Experimental|LP-003 dose 2|Eligible patients randomized to this arm received LP-003 subcutaneously for 8 weeks
89058636|NCT06046391|Placebo Comparator|Placebo|Eligible patients randomized to this arm received placebo subcutaneously for 8 weeks
89058637|NCT06046378|Active Comparator|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to."
89058638|NCT06046378|Active Comparator|Control|The students in the control group will listen to the Normal Birth and Postpartum term course face-to-face with the classical education approach. The knowledge level of the students will be measured with the knowledge tests.
89058639|NCT06046365||mastectomy|Expected to include female patients who are undergoing breast cancer resection surgery or those who have already undergone breast resection surgery for breast cancer.
89058640|NCT06046352||Cohort|Non-documented, clinically-suspected PSVT
89058641|NCT06046339||Patients|Patients hospitalized at Necker Hospital for an extra-hospital cardiac arrest between January 1, 2015 and October 31, 2019.
89058642|NCT06046326|Experimental|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
89058643|NCT06046326|No Intervention|control group|The control group will receive individual, content-focused education through a web platform that will cover the same topics as the VCoP but will be self-administered and without social interaction within theplatform.
89058644|NCT06046196|Experimental|Sarpogrelate SR 300mg, QD|Sarpogrelate SR 300mg, QD
89058645|NCT06046196|Active Comparator|Sarpogrelate 100mg, TID|Sarpogrelate 100mg, TID
89058646|NCT06046183|Experimental|Process Group|Medical students enrolled in the small process group, led by psychiatrist.
89058647|NCT06046183|No Intervention|Control Group|Medical students from the same cohorts, not enrolled in the small process group.
89058648|NCT06046144||Patients with a pigmented skin lesion|Patients with a pigmented skin lesion of more than 3mm diameter which have benefited systematically of all 3 imaging techniques at the same time, followed by either a surgical excision or annual imaging monitoring.
89058649|NCT06046131|Other|Patients prostate cancer|Patient with a confirmed diagnosis of prostate cancer will be included before starting any treatment. Recruitment will be carried out by urologists from the urology departments of the CHU of Guadeloupe and the CHU of Rennes.
89058650|NCT06046118|Experimental|Treatment group|"Two cycles of treatment using continuous and pulsed yellow light followed by continuous and pulsed red light.~Cycle 1 consists of 8 sessions (two sessions per week for 4 weeks) and cycle 2 consists of 6 sessions (two sessions per week for 3 weeks)."
89058651|NCT06046118|Sham Comparator|Sham group|"Sham treatment will occur using a sham mask, designed to release a very low level of light, in this way the patient will not be able to distinguish if he is receiving the treatment or not.~Cycle 1 consists of 8 sessions (two sessions per week for 4 weeks) and cycle 2 consists of 6 sessions (two sessions per week for 3 weeks)."
89058652|NCT06046105|Sham Comparator|Bupivacaine group (Group B) (control group)|Patients will receive 50 ml of Bupivacaine 0.25% (125mg) diluted in 100 ml of normal saline. The drug will be injected intraperitoneally through trocars at the end of the surgery.
89058653|NCT06046105|Experimental|Bupivacaine/Ibuprofen group (Group BI)|Patients will receive 50 ml of Bupivacaine 0.25% (125 mg) + 400 mg Ibuprofen diluted in 100 ml normal saline. The drug will be injected intraperitoneally through trocars at the end of the surgery.
89058654|NCT06046105|Active Comparator|Bupivacaine/Dexmedetomidine group (Group BD):|Patients will receive 20 ml of bupivacaine 0.25% (125 mg) + 1 µq/kg dexmedetomidine diluted in 100 ml normal saline. The drug will be injected intraperitoneally through trocars at the end of the surgery.
89058655|NCT06046027|Experimental|Accupressure Group|Patient in Accupressure Group applied an acupressure band (ACU-STRAPTM) on bilateral hands with a plastic bead at P6 acupoint, which is situated at the wrist between the tendons of the palmaris longus and flexor carpi radialis, 2 cun proximal from the distal palmar crease as shown in Figure 1, half an hour prior to surgery at the operation theatre reception
89058656|NCT06046027|Placebo Comparator|Placebo Group|Patients in Placebo Group will receive a standard elastic band without acuppresure bead, which will be applied to the patient's wrist.
89058657|NCT06045975|Experimental|Durvalumab/Tremelimumab|Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
89058658|NCT06045949||living donor liver transplantation in children|
89058659|NCT06045936|Experimental|Lidocaine Group|Subjects will receive a lidocaine injection in the back of their residual limb.
89058660|NCT06045936|Placebo Comparator|Sham Group|Subjects will receive a placebo injection in the back of their residual limb.
89058661|NCT06045923||Outpatient|15 outpatients will be recruited from a single pre-determined clinical site (Columbia University)
89058662|NCT06045923||Inpatient|Up to 85 hospitalized patients will be recruited from other participating clinical sites
89058663|NCT06045897|Experimental|Major depressive disorder|Major depressive disorder as defined by DSM-5 classification
89058664|NCT06045897|Experimental|Autism spectrum disorder|Autism spectrum disorder as defined by DSM-5 classification
89058665|NCT06045897|Experimental|At risk mental state|At risk mental state as defined in the CAARMS
89058666|NCT06045897|Experimental|First episode psychosis|Any DSM-5 category associated with psychotic symptoms
89058667|NCT06045897|Experimental|Schizophrenia|Schizophrenia as defined by DSM-5 classification
89058668|NCT06045897|Experimental|Healthy controls|Healthy controls with no history of neurodevelopmental disorder or psychotic disorder in a first degree relative
89058669|NCT06045871|Other|Patients with anterior vertical maxillary excess (gummy smile)|
89058670|NCT06045858|Active Comparator|Warfarin|Warfarin (Coumadine): INR target [2.0-3.0]
89058671|NCT06045858|Experimental|Apixaban|Apixaban (Eliquis) at 2.5mg, per os, twice a day
89058672|NCT06045832|Placebo Comparator|Control group|At the beginning of the study, the demographic characteristics of the study participants are recorded in detail, including sex, age, history of smoking, alcohol consumption, presence of bad breath and GI symptoms. The patients who are randomized into control group receive water gargle treatment (Gargle 3 times a day for 2 min each time for 7 days) Then, all patients were retested for oral H. pylori using H. pylori saliva test.
89110986|NCT02437071|Experimental|Pembrolizumab Plus Radiotherapy|pembrolizumab plus RT in subjects with metastatic CRC who are undergoing RT as standard therapy
89058673|NCT06045832|Active Comparator|MAXPOWER Biological Antibacterial Liquid group|At the beginning of the study, the demographic characteristics of the study participants are recorded in detail, including sex, age, history of smoking, alcohol consumption, presence of bad breath and GI symptoms. The patients who are randomized into MAXPOWER Biological Antibacterial Liquid group receive MAXPOWER Biological Antibacterial Liquid gargle treatment (Gargle 3 times a day for 2 min each time for 7 days) Then, all patients were retested for oral H. pylori using H. pylori saliva test.
89058674|NCT06045780||Sepsis|disease
89058675|NCT06045780||Healthy controls|healthy
89058676|NCT06045728|Active Comparator|group 1 telerehabilitation group|subjects in this group will receive telerehabilitation sessions through online video programs (including Pilates exercise and diet) 3 times per week for 12 weeks. Outcome measures will be evaluated at baseline and after 12 weeks
89058677|NCT06045728|Other|group 2 control group|subjects in this group will be informed about the importance of Pilates exercise and diet for one session only. subjects will be asked to apply the exercise at home 3 times per week for 12 weeks and diet. Outcome measures will be evaluated at baseline and after 12 weeks
89058678|NCT06045715||follow-up|patients were follow-up with different time intervals
89058679|NCT06045624|Experimental|Part A|"Drug- OR-101~Dosage level: SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.~Dosage form: Solution~Route of administration- Oral"
89058680|NCT06045624|Experimental|Part B|"Drug- OR101~Dosage level: Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group.~Dosage form: Solution~Route of administration- Oral"
89058681|NCT06045624|Experimental|Part C|"Drug- OR-101~Dosage level: MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days.~Dosage form: Solution~Route of administration- Oral"
89058682|NCT06045624|Placebo Comparator|Placebo|Placebo comparators taken by participants randomised to the placebo arm across Part A and C of the study.
89058683|NCT06045585|Experimental|infusion of JY231 injection|Infusion of JY231 Injection by dose of 1-10 x10^6 TU/kg、 1-5 x10^7 TU/kg、 5-10 x10^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
89058684|NCT06045546|Experimental|5-5-5-8 group|In this group, the new 5-5-5-8 technique of laparoscopic cholecystectomy will be done.
89058685|NCT06045546|Active Comparator|Control|In this group, the 10-10-5-5 technique of laparoscopic cholecystectomy will be done.
89058686|NCT06045429|Experimental|Hydrogen Peroxide|Intervention group: daily oral care will be provided according to the local standard, with 3% hydrogen peroxide, oral assessment and teeth brushing will be completed twice daily (morning and evening).
89058687|NCT06045429|Active Comparator|Chlorhexidine|Control group: daily oral care will be provided according to the local standard, with 0,2% chlorhexidine, oral assessment and teeth brushing will be completed twice daily (morning and evening).
89058688|NCT06045403||The Monitoring Group|The exposure temperature, electrocardiography(ECG), and blood pressure indicators will be monitored every day during the study period in the monitoring group.
89058689|NCT06045403||The Blank Control Group|The blank control group will only monitor the exposure temperature every day.
89058690|NCT06045377|Experimental|Armolipid|"One tablet of Armolipid (Rottapharm S.p.A., Monza, Italia), containing 200 mg red yeast rice, 10 mg policosanols, 0.2 mg folic acid, 2.0 mg coenzyme Q10 and 0.5 mg astaxanthin was administered once-daily with lunch.~Clinical and laboratory evaluation took place before and 6 (IQR: 5-8) and 16 (IQR: 11-19.7) months after treatment."
89058691|NCT06045338|Experimental|Mind Body Intervention #1|
89058692|NCT06045338|Active Comparator|Mind Body Intervention #2|
89058693|NCT06045338|No Intervention|Usual Care|
89058694|NCT06045312|Experimental|peer education|peer-trained group
89058695|NCT06045312|Experimental|adult education|adult-trained group
89058696|NCT06045312|No Intervention|control|no education
89058697|NCT06045286|Experimental|High- and Low-dose radiotherapy combined with immunotherapy.|All eligible patients will receive high-dose radiotherapy, followed by low-dose radiotherapy combined with PD-1 inhibitor therapy starting within 7 days after completion. The single dose of high-dose radiotherapy will be 6-8 Gy for 3-7 consecutive exposures, and the single dose of low-dose radiotherapy will be 0.5-1.4 Gy for 3-7 consecutive exposures.The PD-1 inhibitor (Zimberelimab) will be administered at the dose recommended in the specification every 3 weeks until disease progression, unacceptable toxicity, and withdrawal of informed consent by the patient.
89058698|NCT06045260|Experimental|7.4 Gbq Dose|"Patients with less than 2 risk factors out of the following will receive a dose equal to 7.4 GBq of the experimental radiopharmaceutical 177Lutetium-DOTATOC:~Pre-existing renal impairment (Creatinine > 1.5 mg/dl and/or eGFR or creatinine clearance >50 and < 60 ml/min) or(chemotherapy, local external radiotherapy);~Patients who have received earlier nephrotoxic treatment modalities (chemotherapy, local external field radiation);~Relevant renal morphological abnormalities;~Previously major (G3-4) iatrogenic toxicities;~ECOG = 2;~Any previous Peptide Receptor Radionuclide Therapy;~Type 1 or 2 diabetes not controlled with therapy;~Arterial hypertension not controlled with therapy;~Extension of disease = 4 according to tumor burden Krenning scale (9);~Age (>80 years)."
89058699|NCT06045260|Experimental|5.5 Gbq Dose|"Patients with al least 2 risk factors out of the following will receive a dose equal to 5.5 GBq of the experimental radiopharmaceutical 177Lutetium-DOTATOC:~Pre-existing renal impairment (Creatinine > 1.5 mg/dl and/or eGFR or creatinine clearance >50 and < 60 ml/min) or(chemotherapy, local external radiotherapy);~Patients who have received earlier nephrotoxic treatment modalities (chemotherapy, local external field radiation);~Relevant renal morphological abnormalities;~Previously major (G3-4) iatrogenic toxicities;~ECOG = 2;~Any previous Peptide Receptor Radionuclide Therapy;~Type 1 or 2 diabetes not controlled with therapy;~Arterial hypertension not controlled with therapy;~Extension of disease = 4 according to tumor burden Krenning scale (9);~Age (>80 years)."
89058700|NCT06045208|Active Comparator|Foot Exercise Group (FEG)|
89058701|NCT06045208|Active Comparator|Lower Extremity Exercise Group (LEEG)|
89058702|NCT06045208|No Intervention|Control Group (CG)|
89058703|NCT06045182|Active Comparator|Group A (Maitland mobalizations )|Patients in this group will receive Maitland mobilizations along with hot pack and TENS for pain and disability. A total of 3 sessions would be conducted over a period of 1 week.
89058704|NCT06045182|Experimental|Group B (Maitland Moblizations along with piriformis stretch)|Patients will receive Maitland mobilizations along with hot pack and TENs and additional stretch of piriformis muscle is given. A total of 3 sessions would be conducted over a period of 1 week.
89058705|NCT06045169|Other|Single Group|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
89058706|NCT06045091|Experimental|Human BCMA Targeted CAR-NK Cells Injection|Two doses on Day 0 and Day 7. 1.5×10^8 CAR+NK cells/dose, 3.0×10^8 CAR+NK cells/dose or 6.0×10^8 CAR+NK cells/dose
89058707|NCT06045065||patients with primitive tumor|Patient samples will be collected during routine care neurosurgical resection.
89058708|NCT06045065||patients with brain metastasis|Patient samples will be collected during routine care neurosurgical resection.
89058709|NCT06045052|Experimental|Eltrombopag|Eltrombopag will be administered orally once daily for 24 weeks (6 months) and the dose will be adjusted according to race, age and weight. Patients who achieve at least partial remission may continue treatment for up to one year.
89058710|NCT06045013|Active Comparator|5% dextrose injection|Ultrasound-guided 4 ml single injection of 5% dextrose
89058711|NCT06045013|Active Comparator|5% dextrose injections with methylprednisolone acetate|Ultrasound-guided single injection of 3 ml 5% dextrose plus 1 ml 40 mg/ml methylprednisolone acetate
89058712|NCT06045000|Experimental|[14C]-DC-806|Participants will receive a single oral dose of unlabeled DC-806 tablets followed by DC-806 capsule containing 3.7 MBq (100 μCi) of [14C]-DC-806 on Day 1.
89058713|NCT06044987|Active Comparator|Group I (TOT alone)|49 Female Patients diagnosed with Stress urinary incontinence and cystocele and offered repair by Trans obturator tape procedure
89058714|NCT06044987|Experimental|Group II (TOT+ Cystocele Repair)|49 Female Patients diagnosed with Stress urinary incontinence and cystocele and offered repair by Trans obturator tape procedure concurrently with cystocele repair.
89058715|NCT06044974|Active Comparator|Group I (n=15): combined therapy sessions using 1064 nm Nd-YAG laser (once/week)|"Each treatment session will include: a first pass, which will be performed using cold Piano Level Laser Therapy PLLT settings for photo biomodulation - MSP pulse (100 µs), P = 2W, 10 Hz, with 1 minute treatment duration per spot. A second pass, higher warm PLLT settings that causes mild heating of the tissue, aimed at pain relief - MSP pulses 5 W, 60 Hz, where the handpiece will be held at each spot from 30 seconds to 1 minute, depending on patient heat tolerance~. Both the masseter and temporalis muscles will be divided into 3 spots: insertion, body, and origin for the masseter muscle and anterior, middle, and posterior for temporalis muscle. A stamping technique will be carried out for both passes."
89058716|NCT06044974|Active Comparator|Group II (n=15): Epidermal Growth factor (EGF) injection|"Epidermal Growth factor (EGF) injection into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle~For masseter muscle injection, 3-point injection technique will be followed: 1 injection point in each zone. For temporalis muscle injection, 3-point injection technique will be followed: 1 in each zone~Each point will receive 0.1 ml of EGF"
89058717|NCT06044883|Experimental|Men suffering from erectile dysfunction not responsive to phosphodiesterase-5 inhibitors (PDEI5Is)|"Our study involves male participants aged 18-70 years old suffering from erectile dysfunction and not responding to oral PDE5Is All patients are sexually active. They had no history of pelvic or spinal surgeries or trauma. Patients will be recruited from the Andrology department and outpatient clinics - Kasr Alainy- Cairo University hospitals.~The study will be conducted in the ultrasound unit in the Radiology department- Kasr Alainy- Cairo University hospitals."
89058718|NCT06044870|Experimental|Modified laterally stretched technique with a connective tissue graft.|"After the administration of local anesthesia, root planing of the exposed root surfaces will be performed by means of hand instruments.~A partial thickness envelope is performed with tunneling instruments involving one or two teeth adjacent to the tooth, in case of a very thin biotype a complete thickness envelope could be done.~Two horizontal incisions are done at the base of the papillae, allowing to place the graft in a more coronal position and improving access and visibility."
89058719|NCT06044870|Active Comparator|Tunneling technique with connective tissue graft.|Immediately before surgery, contact point composite stops were placed to prevent the collapse of the suspended sutures in the inter-proximal spaces.• The entire gingival papillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva. The anchorage in the lingual gingiva will be placed far apically. The suture must capture the buccal flap and graft to avail optimal stabilization (Aroca et al., 2010, 2013; Azzi et al, 2002).
89058720|NCT06044844|Experimental|efficacy of tofacitinib in early diffuse cutaneous systemic sclerosis|tab tofacitinib 5mg twice daily will be given by oral route for 6month
89058721|NCT06044844|Experimental|efficacy of Cyclophosphamide in early diffuse cutaneous systemic sclerosis|injection cyclophosphamide 500mg/m2 body surface area/monthly by intravenous infusion.total 6cycle will be given
89058722|NCT06044792||DRM negative|"The cohort of patients, who will meet inclusion criteria, with HIV infections and no drug resistance mutations detected.~Epidemiological (age, sex, origin, sexual preferences) and clinical data (HIV viral load, CD4+ cell count, presence of AIDS-defining diseases, co-infection with HBV and HCV) will be collected at the time of diagnosis.~Subsequent controls of HIV viral load, level of CD4 and CD4/CD8 ratio will be carried out in accordance with the standard of care for an HIV-infected patient (usually every 6-12 months)."
89058723|NCT06044792||DRM positive|"The cohort of patients, who will meet inclusion criteria, with HIV infections and detected primary drug resistance mutations.~Epidemiological (age, sex, origin, sexual preferences) and clinical data (HIV viral load, CD4+ cell count, presence of AIDS-defining diseases, co-infection with HBV and HCV) will be collected at the time of diagnosis.~Subsequent controls of HIV viral load, level of CD4 and CD4/CD8 ratio will be carried out in accordance with the standard of care for an HIV-infected patient (usually every 6-12 months)."
89058724|NCT06044766|Other|Surgical exatrction of impacted lower third molars|Clinical intervention: Surgical exatrction of impacted lower third molar to examine and classify the roots, then to compare it with radiographic classification
89058725|NCT06044753|No Intervention|Control Arm( Arm1)|"Arm1 which is standard care/control group (as per usual practice). May use the distraction, Parental presence, or with musics, soft prep talks, distractions with toys, as per anaesthetist's usual practice.~Patients will receive 100% oxygen of 6 L/min flow for 30 seconds. Nitrous oxide of 2 L/min will be added with ratio oxygen and nitrous oxide of 3:1. Sevoflurane inhalation will be initiated with 4% concentration for 30 seconds, followed by 8%. The induction will be proceeded in usual manner"
89058726|NCT06044753|Experimental|VR ( Virtual Reality) ( Arm2)|"Group 2 patients will choose one of the three YouTube videos, either Frozen theme song, SpongeBob or Minions according to their preference. The selected video will be played on the doctor's handphone and slotted into the VR headset.A handphone playing YouTube videos (either Frozen or SpongeBob or Minions VR cartoons) will be slotted into the VR headset prior to applying on the patient. They will have mask on first followed by the VR headset.~Patients will receive 100% oxygen of 6 L/min flow for 30 seconds. Nitrous oxide of 2 L/min will be added with ratio oxygen and nitrous oxide of 3:1. Sevoflurane inhalation will be initiated with 4% concentration for 30 seconds, followed by 8%. The induction will be proceeded in usual manner"
89058727|NCT06044701|Active Comparator|Hologram fan|Hologram fan application during blood collection process
89058728|NCT06044701|Active Comparator|Bubble machine|Bubble machine application during blood collection
89058729|NCT06044701|No Intervention|Control Group|Performing routine application during the blood collection process
89058730|NCT06044688|Experimental|Phoropter|Refraction performed by an eye care professional using a phoropter.
89058731|NCT06044688|Active Comparator|VisionCheck|Self-administered refraction performed using the EyeQue VisionCheck device.
89058732|NCT06044675|Experimental|MDMA-Assisted CBCT Condition|Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered in two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.
89058733|NCT06044675|Active Comparator|CBCT-Only Condition|Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD. Dyads who have undergone the CBCT-Only condition will have the option to do a crossover and have the two MDMA sessions after follow-up.
89058734|NCT06044597|Experimental|SyncAV plus group|Patients implanted with a CRT-D programmed with SyncAV plus function ON.
89058735|NCT06044597|No Intervention|Biv Trad|Patients implanted with a CRT-D programmed with fixed AV delay.
89058736|NCT06044584||Pain|Patients suffering from acute/chronic nociceptive and neuropathic pain
89058737|NCT06044584||Control|Healthy controls
89058738|NCT06044545|Experimental|Web Based Pregnancy Preparation Education Group|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors
89058739|NCT06044545|No Intervention|Control Group|No action will be taken.
89058740|NCT06044532|Experimental|Skin characterization|
89058741|NCT06044519|Experimental|alginate|
89058742|NCT06044519|Experimental|film|
89058743|NCT06044519|Experimental|guaze|
89058744|NCT06044519|Experimental|hydrocolloid|
89058745|NCT06044519|Experimental|hydrofiber|
89058746|NCT06044519|Experimental|silicon|
89058747|NCT06044506|Experimental|Autologous Natural Killer Cell|"Dosage Form: Autologous Natural Killer (NK) Cells. These cells will be harvested from the patient's body and infused back into the patient.~Dosage: The specific dose quantity will be determined based on the patient's medical condition and response to the treatment. Customized dosages will be calculated for each individual.~Frequency: The treatment will be given through an intravenous method.~Duration: The length of the treatment will vary depending on how the patient responds and their medical assessment. It may take several weeks to evaluate its effectiveness and potential impacts thoroughly."
89058748|NCT06044480|Active Comparator|dexamethasone|This group of participans will be submitted to a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
89058749|NCT06044480|Placebo Comparator|placebo|This group of patients will be submitted to a same amount of saline solution.
89058750|NCT06044467|Experimental|Anti-human CCL24 monoclonal antibody (CM-101) - study Part One|"Anti-human CCL24 monoclonal antibody (CM-101)~NAFLD subjects that have normal liver functions - (Cohort 1: 2.5 mg/kg intravenously and Cohort 2: 5.0 mg/kg subcutaneously)"
89058751|NCT06044467|Placebo Comparator|Placebo - Study Part One|Placebo Comparator
89058752|NCT06044467|Experimental|Anti-human CCL24 monoclonal antibody (CM-101) - Study Part Two|"Anti-human CCL24 monoclonal antibody (CM-101)~NAFLD/NASH patients with NAS < 3 that are in general good health and have normal liver functions - 2.5 mg/kg intravenous infusion"
89058753|NCT06044467|Placebo Comparator|Placebo - Study Part Two|Placebo Comparator
89058754|NCT06044415|Experimental|JWH-018 condition|
89058755|NCT06044415|Placebo Comparator|Placebo condition|
89058756|NCT06044402|Placebo Comparator|group L|Ventilation was subsequently changed to individualized positive end-expiratory pressure and recruitment maneuvers during trendelenburg pneumoperitoneum, and the tidal volume was set to 6 ml/kg.
89058757|NCT06044402|Experimental|group I|Ventilation was subsequently changed to individualized positive end-expiratory pressure and recruitment maneuvers during trendelenburg pneumoperitoneum, and the tidal volume was set to 8 ml/kg.
89058758|NCT06044389||People suffering from fructose intolerance|
89058759|NCT06044376|Active Comparator|Probiotic Group|"During the baseline period, all participants consumed milk formula without any addition of probiotics three servings per day for 14 days. One serving of milk formula consists of 36 gram that is diluted in 180 mL lukewarm water.~The participants in the probiotic group consumed milk formula added with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10^7 CFU/serving). The milk formula is consumed three servings per day for 90 days during the intervention period. One serving of milk formula consists of 36 gram that is diluted in 180 mL lukewarm water."
89058760|NCT06044376|Placebo Comparator|Placebo Group|During the research period (both baseline and intervention period), all participants consumed milk formula without any addition of probiotics three servings per day for 104 days. One serving of milk formula consists of 36 gram that is diluted in 180 mL lukewarm water.
89058761|NCT06044350|Experimental|Experimental group：BAT4406F|RCP：Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP：Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times
89058762|NCT06044350|Active Comparator|Control group：BAT4406F Placebos|RCP：Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP：Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times
89058763|NCT06044272||Escherichia coli producing ESBL|Ceftazidime or cefotaxime resistance.
89058764|NCT06044272||Klebsiella pneumoniae producing ESBL|Ceftazidime or cefotaxime resistance.
89058765|NCT06044272||Klebsiella pneumoniae resistant to carbapenem|Ertapenem resistance.
89058766|NCT06044272||Pseudomonas aeruginosa resistant to carbapenems|Imipenem or meropenem resistance.
89058767|NCT06044272||Staphylococcus aureus resistant to methicillin|Methicillin resistance.
89058768|NCT06044259|Active Comparator|Hemiarch-AMDS|Patient with acute DeBakey I aortic dissection will be put on GA and conventional CPB. During circulatory arrest, the aorta will be trimmed to the level of the distal ascending or proximal arch The AMDS device will be implanted into the aortic arch and descending thoracic aorta. The distal anastomosis will be done between a vascular graft and the distal ascending aorta/aortic arch including the AMDS device sewing cuff. After the distal anastomosis is completed, visceral and cerebral systemic perfusion and rewarming will be started. Proximal anastomosis will be performed and the patient will be weaned from cardiopulmonary bypass and decannulated.
89058769|NCT06044259|Active Comparator|Hemiarch-C|Patient with acute DeBakey I aortic dissection will be put on GA and conventional CPB. During circulatory arrest, the aorta will be trimmed to the level of the distal ascending or proximal arch The AMDS device will be implanted into the aortic arch and descending thoracic aorta. The distal anastomosis will be done between a vascular graft and the distal ascending aorta/aortic arch as per routine. After the distal anastomosis is completed, visceral and cerebral systemic perfusion and rewarming will be started. Proximal anastomosis will be performed and the patient will be weaned from cardiopulmonary bypass and decannulated.
89058770|NCT06044207||Patients with perioperative neurocognitive dysfunction|
89058771|NCT06044207||Patients without perioperative neurocognitive dysfunction|
89058772|NCT06044194|Placebo Comparator|Treatment group|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group)
89058773|NCT06044194|No Intervention|Control group|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of Placebo for 3 months (control group)
89058774|NCT06044181|No Intervention|Peripheral avascular retina of ROP with no leakage.|If there is no active leakage detected by FFA, patients would be observed. The follow-up period: FFA will be done at the age of 18 months we will repeat FFA every 6 months and fundus examination with color photography every 3 months till the age of 3 years of children.
89058775|NCT06044181|Active Comparator|Peripheral avascular retina of ROP with active leakage.|If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route.
89058776|NCT06044129||Vaginal trial labor group|
89058777|NCT06044103|No Intervention|Control|Clinical routine
89058778|NCT06044103|Experimental|Patient-controlled sedation with propofol|PCS group
89058779|NCT06044090|Experimental|Placebo followed by Minocycline|In this arm, participants will take a 5-day course of placebo-control pills and then a 5-day course of 200 mg of minocycline. Sessions will be separated by a minimum washout period of 14 days.
89058780|NCT06044090|Experimental|Minocycline followed by Placebo|In this arm, participants will take a 5-day course of 200 mg of minocycline and then a 5-day course of placebo-control pills. Sessions will be separated by a minimum washout period of 14 days.
89058781|NCT06044077|Experimental|Experimental Group|1 dose vaccination of study vaccine
89058782|NCT06044077|Other|Control Group|1 dose vaccination of control vaccine
89058783|NCT06044051|Other|All patients|All patients included will be followed for 1 year, every 3 months
89058784|NCT06044038|Experimental|Physical activity group|Participation in supervised activities such as walking or Nordic walking groups, gentle gymnastics, soccer, swimming, and volleyball. Each activity was scheduled twice a week.
89058785|NCT06044038|Other|Usual care group|Participants in the control group attended weekly 90-minute cognitive rehabilitation sessions according to the usual care procedure in this type of population.
89058786|NCT06044012|Experimental|Patients with large Oro-antral Fistula|closure of oro-antral fistula by myomucosal flap and buccal pad of fat
89058787|NCT06043999|Experimental|Salvage adjuvant chemoradiotherapy group|"Patitents under local radical resection of rectal adenocarcinoma received:~Concurrent adjuvant chemotherapy~Adjuvant radiotherapy: long-course radiotherapy was planned in this study."
89058788|NCT06043999|Active Comparator|Radical TME group|"Patitents under local radical resection of rectal adenocarcinoma received:~Standard TME surgery was performed 3-4 weeks after local resection."
89058789|NCT06043973|Experimental|almonertinib plus anlotinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
89058790|NCT06043934|Experimental|Neural Mobilization with Intermittent Cervical Traction|Patients in this experimental group will receive neural mobilization with intermittent cervical traction and routine physical therapy.
89058791|NCT06043934|Active Comparator|Neural Mobilization|Patients in this control group will receive neural mobilization and routine physical therapy.
89058792|NCT06043921||Unresectable Pancreatic Cancer|
89058793|NCT06043921||Resectable Pancreatic Cancer|
89058794|NCT06043908|Experimental|0.05% cyclosporine eyedrops combined with artificial tear eyedrops|0.05% cyclosporine eyedrops combined with artificial tear eyedrops
89058795|NCT06043908|Active Comparator|artificial tear eyedrops|artificial tear eyedrops
89058796|NCT06043843|Active Comparator|Focused structured tele-education, medication adjustment and remote monitoring|
89058797|NCT06043843|No Intervention|Control|Standard Care
89058798|NCT06043804||healthy pregnant woman|healthy pregnant woman
89058799|NCT06043804||Pregnant women with recurrent pregnancy loss|Spontaneous abortion of three or more consecutive sexual partners
89058800|NCT06043778|Experimental|COPSI plus mindLAMP|Participants allocated to this arm will be enrolled in COPSI and also have access to the mindLAMP mobile application. mindLAMP's materials will be available on demand for participants use.
89058801|NCT06043778|Active Comparator|COPSI|Participants allocated to this arm will be enrolled in COPSI alone. COPSI is delivered in three phases: 1) intensive engagement (0-3 months), including six to eight home visits by Community Health Officers; 2) stabilization phase (4-7 months) with sessions delivered once every 15 days; 3) and maintenance phase (8-12) with sessions delivered once a month.
89058802|NCT06043765|Experimental|Cognitive strategy training + real rTMS|Verum rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total)
89058803|NCT06043765|Sham Comparator|Cognitive strategy training + sham rTMS|Sham rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total).
89058804|NCT06043752|Experimental|Remsima|
89058805|NCT06043726||Suspected PE|Patients with suspected pulmonary embolism
89110987|NCT02437071|Experimental|Pembrolizumab Plus Ablation|pembrolizumab plus ablation in subjects with metastatic CRC who are undergoing ablation as standard therapy
89218381|NCT04065269|Experimental|1A: AZD6738|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with single agent AZD6738.
89218382|NCT04065269|Experimental|1B: AZD6738 + olaparib|"In second stage of trial, opening of this cohort depends on response rate in cohort 1A during first stage of trial.~Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with loss of ARID1A expression treated with AZD6738 in combination with olaparib."
89218383|NCT04065269|Experimental|2: AZD6738 + olaparib|Women with relapsed ovarian (fallopian tube / primary peritoneal) and endometrial (uterus) clear cell carcinomas with NO loss of ARID1A expression treated with AZD6738 in combination with olaparib.
89218384|NCT04065269|Experimental|3: AZD6738 + olaparib|Women with other rare relapsed gynaecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status, treated with AZD6738 in combination with olaparib.
89218385|NCT00515619|Experimental|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing
89218386|NCT00733109|Active Comparator|excision of the lesion|
89218387|NCT00733109|No Intervention|espontaneous regression|
89218388|NCT00733187|Experimental|1|
89218389|NCT00449644|Experimental|TMC207 Stage 1|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
89218390|NCT00449644|Placebo Comparator|Placebo Stage 1|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
89218391|NCT00449644|Experimental|TMC207 Stage 2|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
89218392|NCT00449644|Placebo Comparator|Placebo Stage 2|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.
89218393|NCT00515541|Active Comparator|A|Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.
89218394|NCT00515541|Active Comparator|B|Patient is on regular dose of Aspirin ( < or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza
89218395|NCT00515541|Active Comparator|C|Patient is taking regularly 75mg of clopidogrel daily and Aspirin (< or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza
89218396|NCT00515541|Active Comparator|D|Patient is regularly taking Warfarin daily and Aspirin (< or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza
89218397|NCT00733265|Experimental|AZD6140|
89218398|NCT03462628|Experimental|Study Group|PVI with additional low-voltage substrate modification
89218399|NCT03462628|Active Comparator|Control Group|PVI only
89218400|NCT00112489|Experimental|Taxol-Carbo|Paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC = 6 IV over 30 minutes every 21 days until disease progression or adverse effects prohibit further therapy
89218401|NCT03666598|No Intervention|No tourniquet|No use of tourniquet during surgery
89218402|NCT03666598|Experimental|Tourniquet|Use of tourniquet during surgery. The cuff will be inflated to 300mmHg
89218403|NCT01023100|Experimental|Open label|
89218404|NCT00711971|Active Comparator|EPA-rich fish oil supplement|EPA-rich fish oil supplement
89218405|NCT00711971|Active Comparator|DHA-rich fish oil supplement|DHA-rich fish oil supplement
89218406|NCT00711971|Placebo Comparator|Soy Oil placebo|Soy oil
89218407|NCT01078831||ARDS / ALI patients|
89218408|NCT02531269||Patients treated with DCV (NPP)+Sofosbuvir +/- Ribavirin (RBV)|
89218409|NCT02531269||Patients treated with DCV (NPP) + Simeprevir +/- RBV|
89218410|NCT02531269||Patients treated with DCV(post-marketing) + Sofosbuvir +/- RBV|
89218411|NCT02531269||Patients treated with DCV(post-marketing) + Simeprevir +/- RBV|
89218412|NCT00515463|Experimental|Denosumab - Vial|Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.
89218413|NCT00515463|Experimental|Denosumab - Prefilled syringe|Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.
89218414|NCT00739037|Placebo Comparator|A|
89218415|NCT00739037|Experimental|B|
89218416|NCT01080157||Volunteers 18+, at risk for diabetes|
89218417|NCT01080235|Active Comparator|1|Control. Forty-two residency programs randomly assigned and stratified according to size, affiliation, geographic location, and presence of geriatrics fellowship. Twenty-one in the control arm. This group will use PIM as a data collection tool during baseline and follow-up time (i.e. audit of 50-75 charts, survey from 50-75 patients, and one system survey). They will not see the summary results of the data collected; they will not be required to complete a quality improvement plan based on the summary data. Local researchers will collect the data. Individual trainees will not do data collection or audits. At both baseline and follow-up, trainees will complete pre and post test surveys of 1) geriatric and 2) quality improvement knowledge, skills, and attitudes.
89218418|NCT01080235|Other|2|There are 21 residency programs in intervention arm who will 1) use PIM as a data collection tool (local researchers will audit 50-75 charts, survey 50-75 patients, and complete one system survey); 2) Each trainee will audit of up to five patient charts; collect 5 patient surveys; and complete the system survey as a group; 3) Summary data from these data streams will be reviewed by group; then they will design and implement a quality improvement plan; 4) At follow-up, local researchers will re-audit same 50-75 charts, collect surveys from same 50-75 patients, and complete one system survey. At baseline and follow-up, trainees and faculty will complete surveys of geriatric and quality improvement knowledge, skills, and attitudes.
89218419|NCT00734825|Active Comparator|1|IV contrast
89218420|NCT00734825|Active Comparator|2|IV contrast and oral contrast
89218421|NCT01080313||Patients with head and neck cancer|
89218422|NCT00739115|Experimental|1|Heliox gas added to nasal CPAP for the first 72 hours of life
89218423|NCT00739115|No Intervention|2|Conventional nasal CPAP for the first 72 hours of life
89218424|NCT01082731|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
89218425|NCT01082731|Active Comparator|Artemether- Lumefantrine|Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
89218426|NCT00739193|Placebo Comparator|Placebo|Placebo Control
89218427|NCT00739193|Experimental|PM101|PM101
89218428|NCT00739193|Active Comparator|Amiodarone IV|Amiodarone IV
89218429|NCT01011543|Active Comparator|Endoscopic approach|CT thorax is done in all patients to localize the exact anatomical site of the disease. This evaluation is followed by fluoroscopy-guided bronchoscopy for BAL (bronchoalveolar lavage) and TBB (transbronchial biopsies). A sputum sample immediately after the endoscopy will be collected if possible.
89218430|NCT01011543|Active Comparator|Induced sputum|Sputum induction after administration of 6-8 mL 3% NaCl aerosol by an ultrasonic nebulizer; sputum will be collected 15-30 minutes after administration of the aerosol. This process will be done twice in every patient.
89218431|NCT00733577|Experimental|Cohort 1|15 mg SB756050 or placebo
89218432|NCT00733577|Experimental|Cohort 2|Planned dose for Cohorts 2 50mg SB756050 or placebo
89218433|NCT00733577|Experimental|Cohort 3|Planned dose for Cohort 3 150mg SB756050 or placebo
89218434|NCT00733577|Experimental|Cohort 4|Planned dose for Cohort 4 600mg SB756050 or placebo
89218435|NCT03997461|Experimental|BPro vs Oscar 2|Blood pressure measurement with BPro and Oscar 2 simultaneously during 24 hours under ambulatory conditions
89218436|NCT00739271|Active Comparator|Study arm|Early enteral feed 48 hours after abdominal surgery
89218437|NCT00739271|Active Comparator|Control arm|Traditional treatment where patient is kept on a nasogastric drainage for a few days after abdominal surgery, wait for bowel sounds to appear and then start enteral feeds.
89218438|NCT04513977|No Intervention|Usual care|For older adults with cancer with G8 score 14 or less. Randomized to usual oncology care.
89218439|NCT04513977|Experimental|Geriatric Oncology Supportive Clinic|For older adults with cancer with G8 score 14 or less. Randomized to attend Geriatric Oncology Supportive Clinic
89218440|NCT01013493||myopic|
89218441|NCT01013493||non myope-healthy|
89218442|NCT00735059|Experimental|1|treatment with dialyzer ELISIO 170H
89218443|NCT00735059|Active Comparator|2|treatment with dialyzer PES-170DS
89218444|NCT00735137|No Intervention|A|Expectant management in twin pregnancy
89218445|NCT00735137|Experimental|B|Vaginal pessary treatment in twin pregnancy
89218446|NCT00735137|No Intervention|C|Expectant management in singleton pregnancy with short cervix; Women with cervix <15 mm will be commenced on vaginal progesterone
89218447|NCT00735137|Experimental|D|Vaginal pessary treatment in singleton pregnancy with short cervix; Women with cervix <15 mm will be commenced on vaginal progesterone
89218448|NCT04064255|Active Comparator|Case: Practical Body Image + Treatment as Usual|"The Case arm involves Practical Body Image + treatment as usual.~Practical Body Image is based on a cognitive behavioural model of body image addressing thoughts, feelings, behaviours and misperceptions. PBI is designed to be administered over 10 weeks (6 weekly sessions over 6 weeks, followed by 8 twice weekly sessions over 4 weeks).~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
89218449|NCT04064255|No Intervention|Control: Treatment as Usual Only|"Control arm involves treatment as usual only.~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist."
89218450|NCT00733733|Active Comparator|ATG|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
89218451|NCT00733733|No Intervention|Control|Standard immunosuppressive treatment for renal transplantation including tacrolimus/MMF/prednisolone without ATG treatment.
89218452|NCT00733811|Experimental|1|Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
89218453|NCT00733811|Active Comparator|2|Deferiprone alone at 75 mg/kg divided into three oral daily doses
89218454|NCT00739505|Experimental|Cohort 1|3 HPP patients are to be enrolled in Cohort 1 and receive a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 1 is at 8 weeks.
89218455|NCT00739505|Experimental|Cohort 2|Cohort 2 will begin when the safety and PK data for Cohort 1 weeks 1-4 has been reviewed by the DSMB. Cohort 2 will enroll 3 HPP patients and will receive a higher dose level than Cohort 1. Cohort 2 patients will have a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 2 is at 8 weeks.
89218456|NCT00920777|Experimental|8 weeks CBT|
89218457|NCT00920777|Active Comparator|Control group|
89218458|NCT00920777|Experimental|16 weeks CBT|
89218459|NCT00507507|Experimental|Tenofovir DF|Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
89218460|NCT00507507|Experimental|FTC+Tenofovir DF|Participants were randomized to receive FTC plus tenofovir DF once daily.
89218461|NCT00540761|Experimental|OFDI imaging|OFDI catheter advanced to the distal coronary artery
89218462|NCT00540761|Experimental|Intravenous Ultrasound|Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
89218463|NCT00459706|Experimental|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
89218464|NCT00459706|Experimental|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
89218465|NCT00735293|Other|Treatment|There is only one arm to this study. All patients will receive treatment with the VASER for their axillary hyperhidrosis/bromidrosis
89218466|NCT02568527|Experimental|PLGA Scaffold|Poly Lactide-co-Glycolic Acid (PLGA) 50:50
89218467|NCT00735527|Experimental|1|Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
89218468|NCT00735527|Active Comparator|2|Intra-venous lorazepam 0.1 mg/kg (max 4 mg)
89218469|NCT00735605|Active Comparator|1:BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
89218470|NCT00735605|Active Comparator|2 BTX A|Injected with BTX-A in the left lateral position; anesthesia was not required
89218471|NCT00735605|Active Comparator|3: PDPR|Inner half of puborectalis sling was divided on each side by using a scalpel NO
89058806|NCT06043687|Experimental|Dentifrice containing Jasmate formulation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Jasmate formulation toothpaste onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 24 weeks for assessment of the efficacy and safety in periodontitis patients.
89058807|NCT06043687|Active Comparator|Dentifrice containing Biomin formulation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Biomin formulation toothpaste onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 24 weeks for assessment of the efficacy and safety in periodontitis patients.
89058808|NCT06043687|Placebo Comparator|Dentifrice containing placebo formulation|Patients will be instructed to brush twice daily. Patients will be instructed to apply at least a 1-inch strip of the Placebo formulation toothpaste onto a soft toothbrush and to brush thoroughly for 2 minutes and expectorate. All patients will be instructed to use only the assigned products and refrain from other dentifrice or mouth-rinse during the trial but will be allowed to continue their normal oral hygiene practices. Patients will use the assigned product for a period of 24 weeks for assessment of the efficacy and safety in periodontitis patients.
89058809|NCT06043661||BI-RADS score 1 or 2 or 3 (Cohort A)|Subjects with a standard risk of breast cancer aged 40 years and above at the time of mammography with the BI-RADS score 1 or 2 or 3
89058810|NCT06043661||BI-RADS score 4 or 5 (Cohort B)|Subjects aged 40 years and above at the time of mammography with the BI-RADS score 4 or 5
89058811|NCT06043648||Constant monitoring|Intracuff pressure was monitored continuously throughout the surgery using the transducer of the invasive pressure monitoring device in patients undergoing elective non-head-neck surgical procedures under general anesthesia and orally intubated with a cuffed endotracheal tube.
89058812|NCT06043648||Intermittent monitoring|Intracuff pressure was monitored intermittently throughout the surgery using an analogue manometer in patients undergoing elective non-head-neck surgical procedures under general anesthesia and orally intubated with a cuffed endotracheal tube.
89110988|NCT02389387||Control|Two hundred twenty (220) dialysis facilities will follow standard of care practices in their management of ESRD patients. They will not receive interventions, but they will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
89218472|NCT05741255|Experimental|STUDY GROUP|After random sampling and dividing patients into two groups of study and control. Patients from the study and control groups will be interviewed individually by the researcher to apply the study tools. Acceptance and Commitment Therapy will be carried out for patients in the study group
89218473|NCT05741255|Active Comparator|Control group|Those in the control group will be left without any intervention to undergo the usual unit routine care.
89218474|NCT05741177||bronchiolitis|children with bronchiolitis
89218475|NCT05741099|Experimental|MSCs group|Patient in Mscs group will receive MSCs implantation by intravenous injection Within 10-15 days of infection
89218476|NCT05741099|Placebo Comparator|comparator|Patients in comparator group will receive placebo treatment Within 10-15 days of infection
89218477|NCT04063475|Experimental|cyanoacrylate beside sutures for FGG fixation|butyl cyanoacrylate
89218478|NCT00735683|Placebo Comparator|1|
89218479|NCT00735683|Experimental|2|
89218480|NCT00735683|Experimental|3|
89218481|NCT00735683|Experimental|4|
89218482|NCT00735683|Experimental|5|
89218483|NCT00735683|Experimental|6|
89218484|NCT03663322|Experimental|OMT Protocol|Subjects assigned to this arm will have selected osteopathic manipulative treatment techniques administered during the treatment sessions
89218485|NCT03663322|Sham Comparator|OMT-Sham Protocol|Subjects assigned to this arm will have sham-osteopathic manipulative treatment techniques administered during the treatment sessions
89218486|NCT00735761|Experimental|1|ME-609 (5% acyclovir and 1% hydrocortisone)
89218487|NCT00735761|Active Comparator|2|Acyclovir in ME-609 vehicle (5% acyclovir)
89218488|NCT03454438|Experimental|Algorithm|Use of electronic structured referral sheets using the algorithms for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
89218489|NCT03454438|Experimental|Triage|Triage by rheumatologist in a primary care setting.
89218490|NCT03454438|No Intervention|Usual care|Control group consisting of usual care.
89218491|NCT00740285|Experimental|1|
89218492|NCT00740285|Placebo Comparator|2|
89218493|NCT00507429|Experimental|Arm 1: CA4P + Carboplatin + paclitaxel|Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
89218494|NCT00507429|Active Comparator|Arm 2: Carboplatin + Paclitaxel|Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
89218495|NCT01011621|Experimental|0.5% prednisolone acetate cream|
89218496|NCT01011621|Active Comparator|0.1% betamethasone valerate cream|
89218497|NCT00449176|Experimental|001|tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
89218498|NCT00449176|Active Comparator|002|oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
89218499|NCT00449176|Placebo Comparator|003|placebo matching placebo twice daily for 15 weeks
89218500|NCT00515073|Experimental|Paclitaxel (Taxol) + Pelvic Radiation|"Paclitaxel (Taxol) 50 mg/m^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost."
89218501|NCT00710021|Experimental|vitamin D3 2000 IU|Participants in this arm take a vitamin D3 dose of 2000 international units (IU) daily by mouth for a duration of 12 weeks.
89218502|NCT00710021|Experimental|vitamin D3 4000 IU|Participants in this arm take a vitamin D3 dose of 4000 international units (IU) daily by mouth for a duration of 12 weeks.
89218503|NCT00710021|Placebo Comparator|vitamin D3 placebo|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks.
89218504|NCT00504153|Experimental|Treatment (tyrosine Kinase Inhibitor)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89218505|NCT05740787||Patient|No intervention
89218506|NCT00739895||Athletes|high performing athletes
89218507|NCT00735995|Experimental|A|Individual CBT
89218508|NCT00735995|Experimental|B|Group CBT
89218509|NCT00735995|No Intervention|C|Waiting-list control
89218510|NCT04064177||Babies (24-42 weeks)|All babies born between 24 and 42 weeks
89218511|NCT04064177||Preterm infants|Preterm infants with fetal growth restriction
89218512|NCT05740631|Experimental|Obeticholic acid|"FXR agonist, orally administration (10 mg)~Assignment of treatment (placebo and obeticholic acid) will be randomized before study visit 1. Either placebo or obeticholic acid will be administered orally in a single-blind fashion for 21 days. After a washout period of 28 days, either placebo or obeticholic acid will be administered as appropriate for an additional 21 days."
89218513|NCT05740631|Placebo Comparator|Placebo|Assignment of treatment (placebo and obeticholic acid) will be randomized before study visit 1. Either placebo or obeticholic acid will be administered orally in a single-blind fashion for 21 days. After a washout period of 28 days, either placebo or obeticholic acid will be administered as appropriate for an additional 21 days.
89218514|NCT00740363|Experimental|A|Patients will receive 4 weeks of treatment with sitagliptin once daily
89218515|NCT00740363|Placebo Comparator|B|No treatment for 4 weeks
89218516|NCT04065035|Active Comparator|Topical Firming Body Moisturizer|Oil-in-water emulsion base containing emollients, botanical extracts, peptides, antioxidants, prebiotics, and modified theophylline ingredients.
89218517|NCT04065035|Placebo Comparator|Placebo Moisturizer|Oil-in-water emulsion base containing emollients.
89218518|NCT00442702|Experimental|Mircera|Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
89058813|NCT06043648||None monitoring|After endotracheal intubation with a cuffed endotracheal tube, the cuff was inflated by the anesthesia provider using sealing pressure technique which involves slow inflation of the cuff until there is no audible gas leak while holding continuous positive airway pressure of 20 cmH2O with the head and neck in the neutral position. No other intracuff pressure monitoring or measurement was performed throughout the operation.
89058814|NCT06043622|Experimental|healthy subject vascular density|
89058815|NCT06043583|Active Comparator|Intrauterine device|
89058816|NCT06043583|Active Comparator|Uterine artery embolization|
89058817|NCT06043570|Experimental|Remote Monitoring follow up|
89058818|NCT06043570|No Intervention|Conventional Follow up|
89058819|NCT06043544|Experimental|Treatment group|patients shoulder treated with Hymovis® 24mg/3ml.
89058820|NCT06043544|Active Comparator|Control group|patients shoulder treated with Corticosteroid.
89058821|NCT06043518||Patients with congenital amputation|
89058822|NCT06043518||Healthy subjects|
89058823|NCT06043479|Experimental|Intervention group|The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
89058824|NCT06043479|No Intervention|Control group|Routine practices continued for the mothers for three days without providing any training.
89058825|NCT06043466|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 2-10x10^6 cells/kg
89058826|NCT06043453||with AP|
89058827|NCT06043453||without AP|
89058828|NCT06043401||healthy volunteers|Age and sex-matched healthy individuals will also be recruited as a control group. They will be scanned three times (baseline, 3-week, and 6-week time points).
89058829|NCT06043401||volunteers with Major Depressive Disorder|20 patients with MDD receiving standard-of-care depression treatment (TMS) at twill be recruited to participate in this observational neuroimaging study. They will be scanned three times (baseline, 3-week, and 6-week time points).
89058830|NCT06043375|Experimental|Licorice Root Powder Capsule|PCOS diagnosed patients in this group will receive licorice root powder capsules, once per day for 12 weeks.
89058831|NCT06043375|No Intervention|Control Group|PCOS diagnosed patients in this group will not receive licorice root powder capsules or any treatment for 12 weeks.
89058832|NCT06043349|Experimental|Intervention Group|The first group, called the intervention group, will receive a combination therapy of platelet-rich plasma injection (PRP) with topical 5% minoxidil for three months. PRP injection will be given every 4 weeks with a total of three injections. Respondents will be instructed to apply topical minoxidil twice daily for three months.
89058833|NCT06043349|Active Comparator|Control Group|The second group (control group) will receive topical 5% minoxidil as standard therapy. Respondents will be instructed to apply topical minoxidil twice daily for three months.
89058834|NCT06043336|Active Comparator|Group B|Group B received intravenous (IV) dexamethasone 4 mg after intubation & IV granisetron 1 mg at the end of surgery
89058835|NCT06043336|Experimental|Group A|Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation.
89058836|NCT06043310||AMAB + continuous estrogen|Identify as assigned male at birth (AMAB) who have had continuous estrogen treatment for a minimum of 1 year.
89058837|NCT06043310||AMAB - continuous estrogen|Identify as assigned male at birth (AMAB) who have not had continuous estrogen treatment for a minimum of 1 year.
89058838|NCT06043284||HBO Treatment Group|Children diagnosed with autism spectrum disorder received applied behavior therapy and hyperbaric oxygen therapy
89058839|NCT06043284||Control Group|Children diagnosed with autism spectrum disorder received applied behavioral therapy
89058840|NCT06043258|Experimental|(Group I) study group|eight patients with missing anterior or premolar tooth with insufficient horizontal (bucco/labio palatal) bone width were treated with dental implants and Bond Apatite (AugmaBio, United States of America) as a bone graft material to fill the defect.
89058841|NCT06043258|Active Comparator|(Group II) positive control group|eight patients with missing anterior or premolar tooth with insufficient horizontal (bucco/labio palatal) bone width were treated with dental implants and Bio-Oss (Bio-Oss, GeistlichPharmaAG, Wolhusen, Switzerland) as a bone graft material to fill the defect and pericardium resorbable membrane.
89058842|NCT06043245|Active Comparator|Duodenal switch|The restrictive portion of the surgery involves removing approximately 70% of the stomach (along the greater curvature) and most of the duodenum. The malabsorptive portion of the surgery reroutes a lengthy portion of the small intestine, creating two separate pathways and one common channel.The common channel is 200 cm and 100m the alimentary limb.
89058843|NCT06043245|Active Comparator|SADI-S|Creation of a sleeve gastrectomy (SG) and a duodenal-ileal anastomosis with preservation of the pylorus, jejunal exclusion and a total common-alimentary limb, originally measuring 200 cm and later standardized to 300 cm to reduce the risk of nutritional deficiencies.
89058844|NCT06043245|Active Comparator|Minigastric bypass|Creation of a gastric pouch similar to Sleeve gastrectomy and the small bowel is run to 200 cm distal to Treitz' ligament and then anastomosed antecolic end-to-side to the gastric pouch.
89058845|NCT06043232||glioma patients with routine surgery|surgery
89058846|NCT06043232||glioma patients with DC vaccine|surgery and DC vaccine
89058847|NCT06043219|Active Comparator|Traditional Teaching|Traditional anatomical teaching provided by a powerpoint lecture.
89058848|NCT06043219|Experimental|Action Observational|Traditional anatomical teaching via a recorded powerpoint and additionally receiving practice of the task via action observation.
89058849|NCT06043219|Experimental|Action Observational and Motor Imagery|Traditional anatomical teaching via a recorded powerpoint and additionally receiving practice of the task via action observation and at the same time imagine themselves executing the same action
89058850|NCT06043206||Cases Obesity and schizophrenia|Patients with schizophrenia and obesity undergoing bariatric surgery
89058851|NCT06043206||Controls|Patients without psychiatric pathology matched by age, sex, BMI and type of surgery and in a 4:1 ratio to cases.
89058852|NCT06043180||Severe aortic stenosis|Aortic valve area <1.0 cm2/<0.6cm2/m2 or mean gradient >40mmHg or jet velocity >4.0 m/s.
89058853|NCT06043115||covid-19 survival cohort|consists of surviving patients
89058854|NCT06043115||covid-19 mortality cohort|consists of deceased patients
89058855|NCT06043102|Other|TheraClearX treatment|TheraClearX treatment of the facial area weekly for 6 sessions.
89058856|NCT06043076|Experimental|Active then sham stimulation|Active iTBS over the left M1 hand region, followed after 1 week washout period by sham iTBS over the left M1 hand region
89058857|NCT06043076|Experimental|Sham then active stimulation|Sham iTBS over the left M1 hand region, followed after 1 week washout period by active iTBS over the left M1 hand region
89058858|NCT06043050||Neonates with severe thrombocytopenia|Neonates with a gestational age <34 weeks and a platelet count <50x10^9/L admitted to a NICU between January 1st, 2017 and January 1st, 2022.
89058859|NCT06043024|Experimental|TMD pain group|The arm includes patients with TMP pain screening scores ≥ 3 and with diagnosis of myalgia, arthralgia, headache attributed to TMP and painful disc displacement (with and without reduction) according to Axis I diagnostic criteria for temporomandibular disorders (DK/TMP). Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance.
89058860|NCT06042998|Experimental|Robotic group|Robotic gastrectomy
89058861|NCT06042998|Active Comparator|Laparoscopic group|Laparoscopic gastrectomy
89058862|NCT06042985|Active Comparator|RYGB arm: calcium citrate and calcium carbonate|The absorption effect between calcium citrate and calcium carbonate in patients with a RYGB
89058863|NCT06042985|Active Comparator|LSG arm: calcium citrate and calcium carbonate|The absorption effect between calcium citrate and calcium carbonate in patients with a LSG
89058864|NCT06042985|Active Comparator|OAGB arm: calcium citrate and calcium carbonate|The absorption effect between calcium citrate and calcium carbonate in patients with a OAGB
89058865|NCT06042959|No Intervention|Control|
89058866|NCT06042959|Experimental|Intervention|
89058867|NCT06042829|Experimental|Intubation with aerosol box|Aerosol box group where patient will be intubated using aerosol box
89058868|NCT06042829|Active Comparator|Intubation without Aerosol box|Without aerosol box group whereby patients will be intubated without aerosol box.
89058869|NCT06042816|Experimental|Free-opioid anesthesia|49 patients were injected bolus doses of lidocaine 1 mg/kg and ketamine 0.5 mg/kg before induction. Then intravenous propofol 1% 2-2.5 mg/kg, rocuronium 0.6 mg/kg were utilized for induction. For anesthesia maintenance, patients received intraoperative multimodal analgesia, in which an epidural bolus of 3 - 5 ml of levobupivacaine 0.1% was followed by a continuous infusion of 3 - 5 ml/h epidurally; in addition, intravenous infusion of lidocaine 1 mg/kg/hour and ketamine 0.25 mg/kg/h were maintained until the end of surgery. Patients were given a bolus of 3-5 ml levobupivacaine 0.1% epidurally and ketamine 0.25 mg/kg intravenously if SPI > 50, 40 < SE < 60, TOF = 0 and hemodynamics was stable. Postoperative pain management was implemented with patient-controlled epidural levobupivacaine 0.1% for 72 hours, and pain rescue with fentanyl 0.5 μg/kg.
89058870|NCT06042816|Active Comparator|Opioid anesthesia|49 patients received a bolus dose of fentanyl 2 µg/kg before induction of anesthesia. For anesthesia maintenance, in group OA, a bolus dose of fentanyl 3 µg/kg was given 5 minutes before skin incision, and then a continuous infusion of fentanyl 2 µg/kg/h was maintained for intraoperative pain management; fentanyl 0.5 μg/kg was bolused when SPI (Surgical Pleth Index) > 50, 40 < State Entropy (SE) < 60, Train of four (TOF) = 0 and the patient was hemodynamically stable. Propofol and fentanyl were discontinued at the start of skin closure. Postoperative pain management was implemented with patient-controlled epidural levobupivacaine 0.1% for 72 hours, and pain rescue with fentanyl 0.5 μg/kg.
89058871|NCT06042790||Covid-19 ICU patients|Patients with confirmed Covid-19 admitted to ICU care
89058872|NCT06042790||non-Covid-19 patients|Non Coivd-19 patients admitted to ICU before 2020
89058873|NCT06042777|Experimental|Acupuncture|This is an 8-week (two 50-min sessions per week) treatment of acupuncture on the following fixed acupoints: bilateral Touwei (ST8), Sishencong (EX-HN1), Taiyang (EX-HN5), Shuaigu (GB8), Toulinqi (GB15), and unilateral Yintang (EX-HN3), Baihui (GV20). The treatment will be performed by registered acupuncturists. based on acupuncturists' clinical judgement, acupuncture can be performed on any of the following additional acupoints, including unilateral Shenting (GV24), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), Neiguan (PC6), AND Anmian (EX-HN22).
89058874|NCT06042777|Experimental|TCM-based lifestyle management|This is an integrated TCM-based training program with components of dantian breathing, Baduanjin, and self-acupressure [Yintang (EX-HN3), Shenting (GV24), Taiyang (EX-HN5), Fengchi (GB20), Neiguan (PC6), Shenmen (HT7), and Sanyinjiao (SP6)]. The treatment will last for 8 weeks (two 50-min sessions per week), and it will include health education and workshops to be delivered by trained research assistants.
89058875|NCT06042777|Experimental|Acupuncture + TCM-based lifestyle management|This is a combination of the above two arms. The participants who randomly assigned to this arm will received two acupuncture sessions and two sessions on lifestyle management every week, and the intervention duration is 8 weeks.
89058876|NCT06042777|No Intervention|Wait-list control|Participants will receive no intervention during the whole assessment period.
89058877|NCT06042764|Experimental|SA55 Injection|Group 1: 300 mg Group 2: 600 mg
89058878|NCT06042764|Placebo Comparator|Placebo|Group 1: 0 mg Group 2: 0 mg
89058879|NCT06042738|Active Comparator|Group 1|group receiving antioxidant support
89058880|NCT06042738|No Intervention|Group 2|group that did not receive antioxidant support
89058881|NCT06042634|Experimental|Online psychoeducation|The online psychoeducation was presented virtually via Zoom videoconferencing for synchronous group meeting. It has two core components: didactic teaching and active participation. The didactic teaching provided information support about dementia caregiving which was delivered via Powerpoint presentations. The programme allowed: (1) hands-on skill training opportunities to rehearse caregiving skills through simulation and written assignments; (2) sharing of caregiving experiences and learning vicariously from other participants through group discussion; (3) reflection on own caregiving approach; and (4) addressing negative emotions through practicing relaxation technique. Participants went through six-weekly psychoeducation sessions in a small group of five to eight. Each psychoeducation session consisted of didactic teaching and active participation which lasted for 120 minutes. Participants went through discussion, simulation and was given home assignment weekly.
89058882|NCT06042634|Active Comparator|Face-to-face psychoeducation|Face-to-face psychoeducation had the same content and flow of presentation as online psychoeducation. The only difference was the mode of delivery which was presented physically in the community center.
89058883|NCT06042530||Post-COVID condition|Patients experiencing persisting cognitive dysfunction and fatigue after a SARS-CoV-2 infection, three months or more after the infections
89058884|NCT06042530||Non-symptomatic controls|Persons experiencing no symptoms after the SARS-CoV-2 infection or have not been subject for at SARS-CoV-2 infection
89058885|NCT06042439|Experimental|Morning (AM)|Exercise starting before 10:01 AM
89058886|NCT06042439|Experimental|Evening (PM)|Exercise starting after 3:59 PM
89058887|NCT06042283|Experimental|Intervention Group|Participants in this group will have Metacognitive Training-Silver program. Metacognitive Training-Silver program is an eight-module training that focuses on common cognitive problems and dysfunctional attitudes, beliefs and prejudices in solving problems seen in depression. The purpose of the sessions is to convey information about false beliefs and cognitive distortions, and to help sick individuals think critically, convey their thoughts, and acquire new problem-solving strategies through exercises.
89058888|NCT06042283|No Intervention|Control group|All participants in the control group will continue the treatment process determined in the routine. In this process, the patient participates in counseling and/or psychotherapy, ECT (electroconvulsive therapy) sessions, and psychopharmacological drugs. The control group will not participate in the Metacognitive Training-Silver program, an interview consisting of one session is planned considering for the placebo effect. At the end of the study, the Metacognitive Training-Silver program will be carried out with the voluntary participants in the control group, taking into account the ethics.
89058889|NCT06041958|Active Comparator|General rehabilitation therapy|Conducting a general rehabilitation program for lymphedema, three times a week, continuing until the end of the experiment.
89058890|NCT06041958|Experimental|ESWT therapy group|Participants are randomly assigned to receive either shockwave therapy or electromagnetic pulse therapy. Once assigned, the treatment method is fixed and continues for 12 weeks. From week 1 to week 12, participants receive either extracorporeal shockwave therapy or electromagnetic pulse therapy three times a week, totaling 36 sessions. After the completion of the 12-week treatment, the general rehabilitation program for lymphedema continues, conducted three times a week.
89058891|NCT06041958|Experimental|PEMFT therapy group|Participants are randomly assigned to receive either shockwave therapy or electromagnetic pulse therapy. Once assigned, the treatment method is fixed and continues for 12 weeks. From week 1 to week 12, participants receive either extracorporeal shockwave therapy or electromagnetic pulse therapy three times a week, totaling 36 sessions. After the completion of the 12-week treatment, the general rehabilitation program for lymphedema continues, conducted three times a week.
89058892|NCT06041854|Experimental|freeze-dried bone allograft combined with enamel matrix derivative|The intrabony defects will be treated by surgical treatment and the defects filled by freeze-dried bone allograft mixed with enamel matrix derivative.
89058893|NCT06041854|Active Comparator|freeze-dried bone allograft|The intrabony defects will be treated by surgical treatment and the defects filled by freeze-dried bone allograft.
89058894|NCT06041685|No Intervention|Non-warming group (C)|After induction, the baseline artery ultrasonography images are collected for the internal diameter and cross-sectional area of the artery. In the non-warming group (C), local warming is not applied on the catheterization site. Before catheterization, the artery ultrasonography images are collected. Then, arterial catheterization is applied.
89058895|NCT06041685|Experimental|Warming group (W)|In the warming group (W), local warming is applied on the catheterization site. Before catheterization, the artery ultrasonography images are collected. Then, arterial catheterization is done.
89058896|NCT06041074||Adults|Patients with adenoid vegetations, 14 years old and older
89058897|NCT06041074||Children|Patients with adenoid vegetations, 13 years old and younger
89218519|NCT00442702|Active Comparator|Darbepoetin alfa|Participants continued to receive the same dose of darbepoetin alfa as before screening by subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling during the dose titration (7 months) and the evaluation period (2 months).
89218520|NCT04065191|Experimental|High-intensity interval training|High-intensity interval training
89058898|NCT06040749|Experimental|Virtual group-based handcycling|Virtual group-based handcycling, twice per week for 12 weeks. Each 60-minute session of the intervention will begin with maximum 15 minutes of physiotherapist-led warm-up exercises. Next, a peer-facilitated handcycling session, lasting maximum 45 minutes, will proceed. The handcycling component involves the upper extremities cycling in tandem on a stationary exercise bike. The peer facilitator will be an individual with SCI aged >50 years, who will co-lead participants alongside the physiotherapist through brief group discussion, maximum 40 minutes of moderate-vigorous handcycling, and maximum 5 minutes of cool-down.
89058899|NCT06040736||Patients with acute kidney injury|Emergency department patients presenting with acute kidney injury, regardless of their complaint for ED admission. AKI is defined based on increase in serum creatinine (SCr) levels according to Kdigo criteria Patients will undergo both a bedside point of care ultrasonography and a central radiology imaging evaluation of hydronephrosis as part of routine care
89058900|NCT06040645|Experimental|Electronic Consult (E-consult)|In Arm 1, the investigators will implement an electronic referral system (electronic co-management), in which specialists will electronically review referrals and make additional recommendations if appropriate primary UI care was not provided.
89058901|NCT06040645|Experimental|Advanced Practice Provider (APP) Co-management|In Arm 2, Advanced Practice Provider (APP) co-management will reduce the burden of care on the PCPs by providing UI care, patient education, and assisting with patient self-management through dedicated televisits (APP co-management).
89058902|NCT06040242|Experimental|Patients Group|All patients will perform all exercises. Arrhythmogenic activity will compared with that assessed during treadmill walking.
89058903|NCT06040203|Experimental|Leukocyte-rich Platelet rich plasma (LR-PRP)|This group of patients will be treated with single injection of autologous leukocyte rich platelet rich plasma.At the 6-month follow-up visit, the patient will be informed about the treatment received.
89058904|NCT06040203|Experimental|Leukocyte-poor Platelet rich plasma (LP-PRP)|This group of patients will be treated withsSingle injection of autologous leukocyte poor platelet rich plasma.At the 6-month follow-up visit, the patient will be informed about the treatment received.
89058905|NCT06040203|Placebo Comparator|Saline solution|This group of patients will be treated with single intra-articular injection of saline solution (placebo). At the 6-month follow-up visit, patients will be informed about the treatment received. Patients of this group can cross-over to the treatment arm after 6 months following a dedicated randomization list.
89058906|NCT06038799|Active Comparator|Remote staff training|Staff will receive 15 hours of remote training followed by 12 weeks of remote supervision (one hour per week).
89058907|NCT06038799|Active Comparator|Face to face staff training|Staff will receive 15 hours of face to face training followed by 12 weeks of face to face supervision (one hour per week).
89058908|NCT06038669||People with diabetes|Patients who have diabetes will be asked to use a home collection kit to collect a dried blood spot sample which will be compared to the HbA1C result.
89058909|NCT06038669||Health care professionals|Health care professionals who work with diabetic patients will be interviewed and asked about diabetes monitoring in the healthcare setting, comments on current laboratory service, patient engagement, comments on service improvement
89058910|NCT06038656|Experimental|Experimental|Participants will receive 10 g of GOS daily for 6 weeks. Fractional iron absorption will be determined pre- and post the 6-week intervention from 3 conditions: 1) after a period of rest; 2) three hours after an acute resistance exercise bout without GOS and 3) three hours after an acute resistance exercise bout, co-administered with 10 g GOS.
89218521|NCT03444844|Experimental|Biochemical recurrent prostate cancer|"IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by whole body PET/CT scanning (pelvis to shoulders) for ~ 60 min (~150 min for first 10 patients/dosimetry) starting immediately after injection.~A contrast CT scan follows PET scan."
89218522|NCT03444844|Experimental|Intermediate/High Risk primary prostate cancer|IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by list mode PET/CT scanning using a fixed FOV including the pelvis area for ~ 50 min.
89218523|NCT00740441|Experimental|A|AS1411 treatment
89218524|NCT00740519||A|
89218525|NCT00740675|Experimental|1|"At post-discharge follow-up visit with PCP, PCP views:~Discharge medication reconciliation screen.~Prompts to perform post-discharge reconciliation at the first post-discharge visit."
89218526|NCT00740675|No Intervention|Uusual care|PCPs manage the patient's medications after hospital discharge as they normally would.
89218527|NCT03385486|Experimental|TBX-3400|TBX-3400 by intravenous infusion
89218528|NCT00736151|Experimental|1|Ralfinamide administered orally at rising doses of 80 - 320 mg/day
89218529|NCT00736151|Active Comparator|2|Placebo controlled with randomization of 2:1
89218530|NCT00514917|Experimental|Docetaxel+Leuprolide+Bicalutamide|Participants received docetaxel 75 milligram per square meter (mg/m^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
89218531|NCT00514917|Active Comparator|Leuprolide+Bicalutamide|Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
89218532|NCT00711425|Experimental|A|
89218533|NCT05740397|Other|Standard MAP|Control group: MAP values between 50-60 mmHg
89218534|NCT05740397|Other|High MAP|First Comparator group: MAP values between 70-80 mmHg
89218535|NCT05740397|Other|Patient-tailored MAP|"Second Comparator group: MAP comparable to the patient's pre-operative MAP. This one will be calculated by performing 3 blood pressure measurement in three different moments of the day before surgery (at 8 am, at 3 pm, and at 9 pm), and will be calculated using the standard formula Diastolic AP + 0,33 x (systolic AP - Diastolic AP). The preoperative MAP value obtained will be target during CPB, within a range of ± 10 mmHg"
89218536|NCT01011699|Active Comparator|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
89218537|NCT01011699|Active Comparator|nicotinamide|"Titration phase with nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of nicotinamide dose up to 4 tablets, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
89218538|NCT00740909|No Intervention|MAC|Minimal Attention Control
89218539|NCT00740909|Experimental|CBT|Cognitive Behavioral Therapy
89218540|NCT05740319|Experimental|FMT|Participants will be given FMT through oral capsules or nasojejunal tube once a month for three months.
89218541|NCT01011777|Experimental|Autologous Muscle Derived Cells|Surgeon will endoscopically inject previously harvested autologous muscle derived cells (MDC) into the same bladder exstrophy patient's urinary sphincter to improve outflow resistance and rhabdosphincter contractility. We will assess tolerability and induction of continence.
89218542|NCT00740987|No Intervention|1|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
89218543|NCT00740987|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
89218544|NCT04064645|Experimental|Respiratory rate accuracy measurement|
89218545|NCT00736307|Experimental|1|Cultured limbal stem cells Transplantation
89218546|NCT00504075|Experimental|Gammaplex (intravenous immunoglobulin)|
89218547|NCT00503997|Experimental|drug therapy|
89218548|NCT00741143|Experimental|1|Group that receives NaFeEDTA fortified wheat flour
89218549|NCT00741143|Placebo Comparator|2|Unfortified wheat flour
89218550|NCT01011855|Active Comparator|Radiant warmer bed sequence 1|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
89218551|NCT01011855|Active Comparator|Radiant warmer bed sequence 2|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
89218552|NCT01011855|Active Comparator|Radiant warmer bed sequence 3|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
89218553|NCT01011855|Active Comparator|Radiant warmer bed sequence 4|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
89218554|NCT01011855|Experimental|Radiant warmer bed sequence 5|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
89218555|NCT01011855|Experimental|Radiant warmer bed sequence 6|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
89218556|NCT04063319|Experimental|High-fidelity simulation|The participants in the intervention group will receive an high-fidelity simulation intervention
89218557|NCT04063319|No Intervention|Control|The participants in the control group will not receive any instructional intervention
89218558|NCT00736463|Active Comparator|1|Aimvastatin 80 mg
89218559|NCT00736463|Active Comparator|2|Atorvastatin 80 mg
89218560|NCT00736541|Experimental|2|
89218561|NCT00096265|Active Comparator|Arm I|Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery.
89218562|NCT00096265|Experimental|Arm II|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89218563|NCT00096265|Experimental|Arm III|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months.
89218564|NCT01082809|No Intervention|Sunitinib|Sunitinib, 37.5 mg orally once daily continuously, comprising a 4-week cycle
89218565|NCT01078987|Active Comparator|Group 1|One to three 5-day course of plasma exchange (plasmapheresis)
89218566|NCT01078987|Active Comparator|Group 2|One to three 5-day course of plasma exchange (plasmapheresis)
89218567|NCT01078987|No Intervention|Group 3|No intervention taken
89218568|NCT01078987|Active Comparator|Group 4|One to three 5-day course of plasma exchange (plasmapheresis)
89218569|NCT01080469|Active Comparator|Prograf® Capsule 1 mg|
89218570|NCT01080469|Experimental|Tacrolimus Capsule 1 mg|
89218571|NCT01079065|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
89218572|NCT01079065|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
89218573|NCT01079221|Experimental|Knee extensor exercise training|High intensity aerobic knee-extensor exercise training
89218574|NCT00711191|Experimental|single arm|
89218575|NCT00741221|Experimental|1|Pemetrexed/Bevacizumab
89218576|NCT00736619|Experimental|1|"Cetuximab loading dose, 400 mg/m2 intravenously (IV) IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days~Cetuximab 250 mg/m2 weekly IV X 7 weeks~Albumin-bound paclitaxel (Abraxane®) weekly IV X 7 weeks, according to dose escalation scheme"
89218577|NCT04557761|Experimental|Closure with microMend® Arm|The microMend® wound closure product will be used to close the Subject's laceration. The wound will be covered with a non-stick dressing.
89218578|NCT04557761|Active Comparator|Closure with Sutures Arm|The Subject's laceration will be closed with sutures. The standard method for suture closed wounds will be followed in accordance with regular institutional policies and procedures.
89688794|NCT05147389||Non-neoplastic bile duct lesions|This group is confirmed by DSOC videos from patients with DSOC-confirmed non-neoplastic bile duct lesions, coming from each participating group. Each DSOC video corresponds to a complete DSOC procedure in a single patient. The non-neoplastic bile duct criteria are in accordance with the two following tools: the Robles-Medranda et al and the Mendoza classification. A further follow will be necessary to confirm non-neoplastic bile duct lesion and the type, when available: acute or chronic cholangitis secondary to stones or parasite's location, autoimmune cholestatic liver diseases as autoimmune sclerosant cholangitis, and primary biliary cholangitis. Based on follow-up, videos from patients with confirmed neoplastic bile duct lesions will be re-assessed and re-classified or finally excluded by an expert blinded to clinical records and who do not participate in videos classification.
89218579|NCT00741377|Experimental|BHQ880 + zoledronic acid|BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle.
89218580|NCT02567903|Active Comparator|No Tourniquet|Knee arthroscopy without the use of a thigh tourniquet.
89688795|NCT03033667|Experimental|Glucose group (G group)|patients received 500 cc of glucose 10% that containing 50 g of glucose and provides patients with 200 Kcal with 556 mosmoles/L.
89688796|NCT03033667|Experimental|Lipid Group (L group)|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid and provides patients with 200 Kcal with osmolarity of 380 mosmoles /L.
89218581|NCT02567903|Experimental|Tourniquet|Knee arthroscopy with the use of a thigh tourniquet.
89218582|NCT00706511|Experimental|Group with OSA|Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
89218583|NCT00706511|No Intervention|Group without OSA|Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol
89218584|NCT00448864|Experimental|Ecallantide - Low Dose Regimen|Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 milliliters per hour (mL/hr) for 4 hours.
89218585|NCT00448864|Experimental|Ecallantide - High Dose Regimen|Participants received a maximum of 91 mg ecallantide in stages. IV infusion of 0.6 mg/mL ecallantide was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, an infusion of normal saline was started at 38 milliliters per hour (mL/hr) for 4 hours.
89218586|NCT00448864|Placebo Comparator|Placebo|Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours.
89218587|NCT00567398|Active Comparator|non glucose sparing|Dianeal only
89218588|NCT00567398|Experimental|Glucose sparing|Physioneal, Extraneal, Nutrineal
89218589|NCT02538848|Experimental|50mg in SAD|single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
89218590|NCT02538848|Experimental|100mg in SAD|single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
89218591|NCT02538848|Experimental|200mg in SAD|single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
89218592|NCT02538848|Experimental|300mg in SAD|single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
89218593|NCT00448708|Experimental|Vascular Wrap and Graft|Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access. The Vascular WrapTM Paclitaxel-Eluting Mesh is positioned on the vein and placed around the venous anastomosis to include both the toe and the heel of the anastomosis, and is sutured in place.
89218594|NCT00448708|No Intervention|Lifespan® ePTFE Vascular Graft|Lifespan® ePTFE Vascular Graft Only: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access.
89218595|NCT00929396|Experimental|Latent TB infection group|The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
89218596|NCT00929396|Experimental|BCG vaccinated group|The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart
89218597|NCT00929552|Experimental|Fish oil|Daily dose = 6g fish oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day. The fish oil was micro-incapsulated.
89218598|NCT00929552|Active Comparator|Vegetable oil (Mix of canola, palm and soy oil)|Daily dose = 6g vegetable oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day.
89218599|NCT00924872|Experimental|intervention|receive wheelchair skills training
89218600|NCT00924872|No Intervention|control|no formalized wheelchair skills training provided
89218601|NCT00925028|Experimental|Group A|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. After four months the groups will switch to the alternate management strategy.
89218602|NCT00925028|Experimental|Group B|Patients of group B will continue to be managed by their physician. After four months the groups will switch to the alternate management strategy.
89218603|NCT00905138|Experimental|1|single ascending doses
89218604|NCT00905138|Placebo Comparator|2|single dose placebo
89218605|NCT00905138|Experimental|3|multiple dose, 5 days, oral solution
89218606|NCT00905138|Placebo Comparator|4|multiple dose, 5 days, oral solution
89218607|NCT00905216|Experimental|Test|Heparin sodium - Bergamo
89218608|NCT00905216|Active Comparator|Comparator|Heparin APP
89218609|NCT00929630|Experimental|glue (Tissucol ) treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
89218610|NCT00929630|Active Comparator|Seton treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
89218611|NCT00905294||coronary artery disease|Subjects with coronary artery disease undergoing percutaneous coronary intervention
89218612|NCT00929786||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
89218613|NCT00925106|Active Comparator|Celebrex capsule|Commercial capsule
89218614|NCT00925106|Experimental|D1|Test formulation D1
89218615|NCT00925106|Experimental|D2|Test formulation D2
89218616|NCT00925106|Experimental|D3|Test formulation D3
89218617|NCT00925184||medical students, graduate year,|medical students at graduate year will be invited to participate in this study.
89218618|NCT02538692|Experimental|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
89218619|NCT02538692|Placebo Comparator|Placebo|It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
89218620|NCT00706355|Experimental|1|
89218621|NCT00905528||A|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
89218622|NCT00905528||B|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
89218623|NCT00925262|Experimental|Cognitive Processing Therapy|An adaptation of cognitive behavioral therapy, focusing on treatment for persons suffering mental health effects of trauma
89218624|NCT00925262|Experimental|Behavioral Activation|A form of counseling therapy that emphasizes enhancing pleasurable behaviors and minimizing negative behaviors as a means to reducing depression symptomatology.
89218625|NCT00925262|Experimental|non-specific counseling|a collection of counseling skills suitable for a broad range of mental health and psychosocial problems and not designed for specific disorders. This particular version was developed by a collaborator -Heartland Alliance - for use with torture survivors.
89218626|NCT00925262|No Intervention|wait control|persons in this study arm will not receive active treatment as part of the study but will be monitored during the study and offered treatment after 3-5 months of waiting.
89218627|NCT04063553|Other|Intervention arm|Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.
89218628|NCT04063553|Other|Control arm|The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given
89218629|NCT00925340|Experimental|1 - Family Check Up|Brief family intervention that employs Motivational Interviewing.
89218630|NCT00925340|Active Comparator|2 - Psychoeducation|
89218631|NCT00736697|Experimental|1|
89523263|NCT03383549|Experimental|Tele-rehabilitation|Tele-rehabilitation arm undergo a home-based rehabilitation combined protocol, made up of cognitive and physical exercises
89058911|NCT06038500|Experimental|Multicomponent Intervention in only one group of women at Risk of Sarcopenia|Quasi-experimental Pre-test/Post-test design - pilot
89058912|NCT06038448|Active Comparator|Effect of normal 10ml balloon volume on postoperative CRBD in non-LUTS patients|Efficacy of normal 10ml balloon volume for prevention of postoperative catheter-related bladder discomfort in patients undergoing non-lower urinary tract surgery
89058913|NCT06038448|Active Comparator|Effect of reduction of 5ml balloon volume for postoperative CRBD in patients undergoing non-LUTS|Efficacy of reduction of 5ml the balloon volume for prevention of postoperative catheter-related bladder discomfort in patients undergoing non-lower urinary tract surgery
89058914|NCT06037993|Experimental|PEA arm|Palmitoylethanolamide (PEA)-treated patients
89058915|NCT06037408|Experimental|20mM sodium pyruvate nasal spray treatment|
89058916|NCT06037408|Placebo Comparator|Saline placebo control|
89058917|NCT06037369|Experimental|intervention|At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object
89058918|NCT06037369|No Intervention|comparison|Routine care
89058919|NCT06036563||Multicenter prospective cancer-screening cohort|The cohort, including cancer patients and non-cancer patients, will be prospectively enrolled in from different departments and centers. The focused cancers include lung cancer, gastric cancer, colorectal cancer, liver cancer, esophagus cancer, breast cancer and pancreas cancer.
89058920|NCT06036303|Experimental|Nasr Fascial Closure Device|
89058921|NCT06036303|Active Comparator|Berci Fascial Closure Device|
89058922|NCT06035302|Experimental|Madany closure|the novel port site closure technique is to be done for this group
89058923|NCT06035302|Active Comparator|Control|external closure of the port site
89058924|NCT06034899|Experimental|Part 1: BMS-986196 Dose 1 (Treatment A)|
89058925|NCT06034899|Experimental|Part 1: BMS-986196 Dose 1 (Treatment B)|
89058926|NCT06034899|Experimental|Part 2: BMS-986196 Dose 2 (Treatment A)|
89058927|NCT06034899|Experimental|Part 2: BMS-986196 Dose 2 (Treatment B)|
89058928|NCT06034873|Active Comparator|Group A|In the IVAS group, the patients intravenous propofol combined with fentanyl. The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
89058929|NCT06034873|Active Comparator|Group B|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
89058930|NCT06034535|Experimental|Treatment|CD62L depleted donor lymphocyte infusion
89058931|NCT06034379|Experimental|Clinical prototype (CP1) device|15 subjects will be randomly assigned to use the eSpectacle Clinical Prototype (CP1) device 2 hours per day, at least 6 days per week. Standard single vision correction will be used during other waking hours. The eSpectacle clinical prototype (CP1) device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights onto the peripheral retina.
89218632|NCT00929942|Experimental|DV Stent|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
89218633|NCT00711113|Experimental|A|
89218634|NCT02568995|Experimental|LIA|Local infiltration analgesia using a combination of ropivacaine 300 mg + ketorolac 30 mg + adrenaline 0.5 mg
89218635|NCT02568995|Active Comparator|Femoral nerve block|Ultrasound guided 3-in-1 block using 30 ml of 0.75% ropivacaine
89218636|NCT03784898|Other|Participants Diagnosed With ITP|Participants with RMS who developed ITP after Lemtrada treatment were included in this study and provided blood samples for future genetic testing and biomarker analysis.
89218637|NCT00930020|Placebo Comparator|matching placebo pill|matching placebo
89218638|NCT00930020|Active Comparator|Oral minocycline|Minocycline 200mg
89218639|NCT00710879|Experimental|Multipurpose Solution|Multi-purpose solution administered to adapted FDA group I soft contact lens wearers and FDA group IV soft contact lens wearers.
89218640|NCT00905684||Group 1|
89218641|NCT00905684||Group 2|
89218642|NCT00925418|No Intervention|Without Glove|Patients do not use frozen glove during chemotherapy with Taxotere®
89218643|NCT00925418|Experimental|With Glove|Patients use frozen glove during chemotherapy with Taxotere®
89218644|NCT05742191||Established Clinic Patients at OSF INI with Episodic Migraine diagnosis.|Study subjects will be established clinic patients at OSF HealthCare INI neurological institute with a diagnosis of Episodic Migraine.
89218645|NCT03979274|Experimental|Reference Eutirox®, then Test Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (mcg) (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
89218646|NCT03979274|Experimental|Test Eutirox®, then Reference Eutirox®|Participants received single oral dose of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Reference Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
89218647|NCT00930254|Experimental|Ultrasound|Vascular puncture guided by vascular ultrasound
89218648|NCT00905762|Experimental|Besifloxacin|Besifloxacin one drop instilled into study eye.
89218649|NCT00905762|Active Comparator|Gatifloxacin|Gatifloxacin one drop instilled into study eye.
89218650|NCT00905762|Active Comparator|Moxifloxacin|Moxifloxacin one drop instilled into study eye.
89218651|NCT02568137|Experimental|Behavioral|Nurse-directed mobile health technology using smart phones to promote adherence to antihypertensive medication.
89218652|NCT02568137|No Intervention|Usual background care|Standard care
89218653|NCT02568059|Experimental|100 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 100 mg.
89218654|NCT02568059|Experimental|200 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 200 mg.
89218655|NCT00925496||Standard PROMOS prosthesis|Patients receiving a standard PROMOS prosthesis
89218656|NCT00925496||Reverse PROMOS prosthesis|Patients receiving a reverse PROMOS prosthesis
89218657|NCT00459316|Experimental|Group 1|Participants ≤11 to <25 years of age with CD4% at screening ≥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.
89688797|NCT03033667|Experimental|Control Group (C group)|patients was fasting overnight from 11 pm till 9 am except for clear fluids that was allowed till 5 am.
89688798|NCT03033433|Experimental|DCB-DM101, 500 mg tablet, determination of optimal dose|Stage 1:Dose level 1(1 tablet of DCB-DM101 q.d. for 7 days orally);Dose level 2(2 tablets of DCB-DM101 q.d. for 7 days orally);Dose level 3(4 tablets of DCB-DM101 q.d. for 7 days orally) Stage 2:Optimum dose of DCB-DM101 determined in Stage 1 as add-on treatment in T2DM patients for 14 days, q.d., orally
89688799|NCT00947167|Experimental|Pertuzumab and Erlotinib|
89688800|NCT04360759|Experimental|Arm 1: Chloroquine or hydroxychloroquine|Loading dose of 4 tablets (150 mg chloroquine base per chloroquine salt tablet; 155 mg chloroquine base per hydroxychloroquine tablet) at time 0 and 6 hours, followed by a maintenance dose of 2 tablets at time 12 hours, and then twice daily for a total of 7 days.
89688801|NCT04360759|No Intervention|Arm 2: Standard of care|This does not include specific therapy under current guidelines.
89688802|NCT04360993||Patients underwent PET/CT & PET/MRI|Patients with head and neck cancer were underwent PET/CT and PET/MRI for staging, assessment and follow up
89688803|NCT00940771|Experimental|boosted Atazanavir|Boosted Atazanavir was switched for the PI or NNRTI in the patients regimen
89688804|NCT04360603|Experimental|27 gauge system|study group, using 27G vitrectomy system
89688805|NCT04360603|Active Comparator|25 gauge system|control group, using 25G vitrectomy system
89688806|NCT03033277|Placebo Comparator|Control group|Hormone replacement therapy, placebo transplantation.
89688807|NCT03033277|Experimental|Experimental group|Hormone replacement therapy,HUC-MSCs transplantation.
89688808|NCT03033355||Pre- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction prior to receiving intradetrusor injection of Botulinum Toxin-A.
89688809|NCT03033355||Post- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction who receive intradetrusor Botulinum Toxin-A.
89688810|NCT03033121|Active Comparator|group A|Sixteen growth hormone (GH) deficiency children were assigned to receive daily growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
89688811|NCT03033121|Active Comparator|group B|Sixteen growth hormone (GH) deficiency children were assigned to receive three time weekly growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
89688812|NCT03033199|Active Comparator|Probiotic Agent Combining HD-DXM|"probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.~Dexamethasone 40mg per day, 4 consecutive day"
89688813|NCT03033199|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days
89688814|NCT02245711|Experimental|Stem Cell|
89688815|NCT04360525||Elderly patients|Elderly patients (60≤ age) with sigmoid volvulus
89688816|NCT04360525||Young patients|Young patients (<60 age) with sigmoid volvulus
89688817|NCT04360291||Healthy volunteers|Healthy volunteers
89688818|NCT04360291||Retinopathy pigment|Patients with retinopathy pigment
89688819|NCT00934141|Experimental|Interest Circle Call + Website|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach.
89058932|NCT06034379|Experimental|CP1 and 0.01% atropine|15 subjects will be randomly assigned to use the eSpectacle Clinical Prototype (CP1) device 2 hours per day, at least 6 days per week, in addition to nightly instillation of one drop of 0.01% atropine. Standard single vision correction will be used during other waking hours. The eSpectacle clinical prototype (CP1) device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights onto the peripheral retina. Atropine is an anticholinergic medication which can be used for dilation and cycloplegia and has been evaluated for slowing the progression of myopia.
89058933|NCT06034379|Experimental|0.01% atropine|15 subjects will be randomly assigned to nightly instillation of one drop of 0.01% atropine without use of the eSpectacle clinical prototype (CP1) device. Standard single vision correction will be used during waking hours. Atropine is an anticholinergic medication which can be used for dilation and cycloplegia and has been evaluated for slowing the progression of myopia.
89058934|NCT06034249|Experimental|Experimental Group: Mindfulness-Based VR group|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
89058935|NCT06034249|Placebo Comparator|Control Group: Mindfulness-based Audio Files|The control group will only be given the mindfulness-based audio files for six weeks.
89058936|NCT06034158|Other|madopar-propranolol-placebo|In a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions.
89058937|NCT06034158|Other|madopar-placebo-propranolol|In a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions.
89058938|NCT06034158|Other|propranolol-madopar-placebo|In a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions.
89058939|NCT06034158|Other|propranolol-placebo-madopar|In a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions.
89058940|NCT06034158|Other|placebo-propranolol-madopar|In a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions.
89058941|NCT06034158|Other|placebo-madopar-propranolol|In a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions.
89058942|NCT06033950|Experimental|Finerenone|
89058943|NCT06033950|Placebo Comparator|Placebo|
89058944|NCT06033625||Cd-TKR|Bicompartmental cemented cruciate retaining Total knee replacement
89058945|NCT06033625||Cs-TKR|Bicompartmental cementless cruciate retaining Total knee replacement
89058946|NCT06033495||Patients with refractory angina undergoing coronary sinus reduction stent implantation|
89058947|NCT06032650|Experimental|Study group A (Calisthenics exercise)|Group (A) (n =30) will receive calisthenics exercise three times /week for eight weeks, patients in this group will receive four forms of calisthenics exercise (squats, curl up, push up, blank) starting free and upgrading intensity according to ability of the patients.
89218658|NCT00459316|Experimental|Group 2|Participants ≤11 to <25 years of age with CD4% at screening <15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
89218659|NCT00459316|Experimental|Group 3|Participants >=2 to <11 years of age with CD4% at screening ≥ 25%; All received Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
89218660|NCT02568839|Active Comparator|A standard treatment|"docetaxel + trastuzumab sc + pertuzumab. Treatment with all three drugs is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm B.~Postoperatively, patients receive 2 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
89218661|NCT02568839|Experimental|B experimental treatment|"trastuzumab emtansine. Treatment is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm A.~Postoperatively, patients receive 4 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
89218662|NCT00930410|Experimental|endomicroscopy|Utilisation of an intra-ductal confocal endomicroscopy during the endoscopic Retrograde Cholangio-Pancreatography
89218663|NCT02538770|Experimental|Rapid Anyplex TMII RV16 Detection|Intervention is the rapid performance of Anyplex TMII RV16 detection
89218664|NCT02538770|Active Comparator|Delayed Anyplex TMII RV16 Detection|Comprative intervention is the delayed performance of Anyplex TMII RV16 detection
89218665|NCT05742035|Experimental|Hereditary hemochromatosis|Individual with ferritin >500 ng/mL and documented homozygous or compound heterozygous HFE-gen mutation.
89218666|NCT05742035|Experimental|secondary hyperferritinemia|Individual with ferritin >500 ng/mL, not fulfilling the criteria for hereditary hemochromatosis.
89218667|NCT05742035|Other|healthy blood donor with normal ferritin value.|Healthy comparator.
89218668|NCT06140875|Experimental|Experimental|"Radiochemotherapy (RCT) and maintenance chemotherapy (CT) according to Stupp et al. 2005 combined with radiofrequency electromagnetic field treatment.~The standard therapy involves gross- or subtotal tumor resection if feasible (alternatively biopsy only) followed by RCT (60 Gy over six weeks) with concomitant CT (temozolomide 75mg/m2) on all days, followed by maintenance CT (temozolomide150-200 mg/m2) on d1-5 for six cycles every 28 days.~The trial intervention includes radiofrequency electromagnetic field treatment for 60 minutes three times a week during RCT and twice a week during d1-5 of maintenance CT, resulting in a total number of 30 radiofrequency electromagnetic field treatment therapy sessions."
89218669|NCT06140862|Experimental|calf muscle exercise|the initial treatment plane was open and closed chain strengthening exercises for the calf muscle. The strengthening exercises include; double leg calf raise (i.e., straight and bent knees), single leg calf raise (i.e., straight and bent knee), seated calf raise, and wall sit calf raise. Calf stretching exercises were added to maintain the flexibility of the muscle and its Achilles tendon. Gait training protocol was also performed for correction of chronically adapted abnormal gait pattern especially at the mid stance and terminal stance sub-phases of GC
89218670|NCT06140862|Other|lower back exercise|lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
89218671|NCT06140797|Experimental|PRACTICE group|Pre-operative risk assessment combined with targeted intervention Including anti-frailty management, malnutrition management, depression management, cognitive impairment management, and prevention of postoperative delirium.
89218672|NCT06140797|No Intervention|Control group|The control group will receive standard of care that is provided as part of the perioperative surgical procedure and subsequent rehabilitation
89218673|NCT06140771|Sham Comparator|0.76% Sodium Monofluorophosphate Dentifrice|
89218674|NCT06140771|Sham Comparator|1.15% Sodium Monofluorophosphate Dentifrice|
89218675|NCT06140771|Active Comparator|Marketed 0.454% Stannous Fluoride Dentifrice|
89218676|NCT06140771|Active Comparator|0.454% Stannous Fluoride Dentifrice|
89218677|NCT06140745|Placebo Comparator|0 ppm Fluoride Dentifrice 1|
89218678|NCT06140745|Active Comparator|1100 ppm NaF Fluoride Dentifrice|
89218679|NCT06140745|Active Comparator|1500 ppm NaMFP Fluoride Dentifrice|
89218680|NCT06140745|Sham Comparator|0 ppm Fluoride Dentifrice 2|
89218681|NCT06140745|Sham Comparator|0 ppm Fluoride Dentifrice 3|
89218682|NCT06140732|Experimental|camrelizumab combined with apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
89218683|NCT06140706|Experimental|tSCS plus home tele-video support|Cervical transcutaneous spinal stimulation during home tele-video visits
89218684|NCT06140680|Experimental|LifelongU|"Four modules that performed face-to-face physical education lessons:~health-related fitness knowledge~fitness test and training~motor skill training~behavior change techniques (habit formation and implementation intention)"
89218685|NCT06140680|Active Comparator|Physical education|Classic physical education lessons: physical fitness training and skill training
89218686|NCT06140654||Non-dental group|"62 non-seeking dental treatment subjects, aged 30-65 years, previously recruited within the general population from december 2017 to january 2018. Declared painful conditions including temporo-mandibular disorder, cephalalgia, oral or dental pain were initially considered as excluding conditions. Exclusion criteria also included diagnosis of acute orofacial disease (i.e. rhinitis) or sensory trouble (i.e. anosmia, dysgeusia) neither at the time of the experiment nor in the recent past, pregnancy, head and neck irradiation, eating disorders, enteral or parenteral feeding, and cognitive impairment or impaired communication.~They took part in an individual session with a dental practitioner of about 30-min during which food selectivity, medical history, and oral health status were assessed."
89522735|NCT03391609|Placebo Comparator|control group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
89058948|NCT06032650|Experimental|Study group B (High intensity interval training)|Group (B) (n =30) will receive high intensity interval training three times /week for eight weeks, A motorized treadmill device (KETTLER, laufband alpha run 600, German) with a minimum speed of 0.5km/hr and capability to display the distance in kilometer per hour will be used in this study. Intensity of HIIT will be measured using Bruce protocol to calculate target heart rate of each patient.
89058949|NCT06032455||Families receiving standard MST|Families in which the adolescent and/or parent(s) has/have an ID receiving standard MST treatment
89058950|NCT06032455||Families receiving MST-ID|Families in which the adolescent and/or parent(s) has/have an ID receiving MST-ID treatment
89058951|NCT06031558|Experimental|SY-5007|SY-5007 will be given orally 160 mg twice daily in 28-day cycle continuously until disease progression, death, unacceptable toxicity, or withdraw consent in this study.
89058952|NCT06031337||Oral Cancer Group|23 patients with oral cancer
89058953|NCT06031337||Control Group|23 age-and-sex-matched healthy individuals, as normal controls
89058954|NCT06030466|Other|With physical standardized patients|Medical students practice consultation with physical standardized patients.
89058955|NCT06030466|Experimental|With virtual standardized patients|Medical students practice consultation with virtual standardized patients.
89058956|NCT06027788|Active Comparator|CardioGard Embolic Protection Cannula|In patients assigned to the embolic protection device group, the CardioGard Embolic Protection Cannula is used instead, according to the manufacturer's instructions for use (IFU).
89058957|NCT06027788|Placebo Comparator|Standard Aortic Cannula|In patients assigned to the standard cannula group, standard cannulation techniques are performed using any standard aortic cannula of the surgeon's choice
89058958|NCT06027190|Sham Comparator|Sham group|Intervention Name and Specification: Placebo coil (Magstim Company, Whitland, UK): looks and sounds consistent with true coil but does not produce current stimulation.
89058959|NCT06027190|Experimental|rTMS group|"5Hz-rTMS group~10Hz-rTMS group~30Hz-rTMS group~Intervention Name and Specification:~Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China)~70 mm diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China).~Each group received acute and chronic stimulation, respectively. In the acute stimulation stage, patients only needed to do rTMS once, and HREM and HRV were administered before and after rTMS; in the chronic stimulation stage, patients received 25 minutes of rTMS true stimulation each time a day for 20 times, which was completed within 30 days, and the true stimulation parameters were the same as those of acute stimulation."
89218687|NCT06140654||Dental group|"63 patients recruited from September 2019 to December 2020 among patients seeking/pending dental treatment within the university dental clinic of the Rothschild hospital (AP-HP Sorbonne University, Paris, France). Inclusion criteria were: age between 35 and 65 years, literate French speakers, willing and able to complete the survey in a single setting. Patients suffering from cognitive impairment or impaired communication were excluded.~They took part in an individual session with a dental practitioner of about 30-min during which food selectivity, medical history, and oral health status were assessed."
89218688|NCT06140641|Placebo Comparator|Placebo group|Daily administration of placebo for 8 weeks.
89058960|NCT06021444|Experimental|DKM420|Injecting to one side knee.
89058961|NCT06021444|Active Comparator|Conjuran|Injecting to one side knee.
89058962|NCT06018688|Experimental|osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals.The participants will undergo a two-month combination therapy, unless there is tumor progression (worsening) or intolerable toxic reactions that necessitate early termination of the drug treatment. Aspirin will be discontinued one week prior to the surgery.
89058963|NCT06018480|Experimental|Creatine Monohydrate Supplementation|Participants will be provided with 20 grams of creatine monohydrate per day (100 grams total) in sealed and unopened packages (5 grams in each package). Participants will be asked to complete their supplementation protocol (20 grams/day) by mixing 5 grams of creatine monohydrate powder into water 4 times a day or 10 grams of creatine monohydrate powder into water twice a day. This supplementation will occur after a baseline visit in which participants consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial. Following the 5 days of supplementation participants will come back and consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial.
89058964|NCT06018480|Placebo Comparator|Placebo (Maltodextrin)|Participants will be provided with 20 grams of maltodextrin (placebo) per day (100 grams total) in sealed and unopened packages (5 grams in each package). Participants will be asked to complete their supplementation protocol (20 grams/day) by mixing 5 grams of maltodextrin (placebo) into water 4 times a day or 10 grams of maltodextrin (placebo) powder into water twice a day. This supplementation will occur after a baseline visit in which participants consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial. Following the 5 days of supplementation participants will come back and consume a high-carb meal and have their vascular function studied before the meal and four hours post-prandial.
89058965|NCT06016322|Experimental|Before and after study in 6 patients with UC and 6 patients wiht CD|This is a 4-week before-after pilot study to explore the effectiveness of a WholeFiber Trademark (TM) intervention (a dried vegetable rich in prebiotic intrinsic fibers) on inflammation, fecal gut microbiota and metabolites, IBD-complaints and QoL and assesses its feasibility. In this before-after study, 12 patients with IBD will receive WholeFiberTM; of which 6 patients with CD and 6 patients with UC to assess if there is a difference in effect between these groups of patients.
89058966|NCT06016023||Group 1: 30 periodontally healthy individuals.|Group 1 comprises of 30 periodontally healthy individuals who have never been clinically diagnosed with periodontitis.
89058967|NCT06016023||Group 2: 30 individuals with generalized gingivitis|Group 2 comprises of 30 participants diagnosed with generalized gingivitis according to the WWP 2017 classification.
89058968|NCT06016023||Group 3: 30 participants with generalised mild/moderate (STAGE I/II) periodontitis|Group 3 comprises of 30 participants, diagnosed with generalized mild/moderate (STAGE I/II) periodontitis, according to the WWP 2017 classification of periodontal disease.
89058969|NCT06016023||Group 4: 30 participants with generalized severe/very severe (STAGE III/IV) periodontitis|Group 4 comprises of 30 participants, diagnosed with generalized severe/very severe (STAGE III/IV) periodontitis, according to WWP 2017 classification of periodontal disease.
89058970|NCT06012058|Experimental|Retinal nerve fiber layer optical texture analysis (ROTA)|The RNFL is imaged with OCT for ROTA.
89058971|NCT06012058|Active Comparator|Optic disc photography|The optic disc is imaged with color fundus camera.
89058972|NCT06011226||Phase 1: development of the questionnaire|"development of the patient reported outcome: The strategy consists of four phases:~structured litterature review~Group of experts: identification of the main areas to be covered by the questionnaire in order to draw up the focus group moderation guide~focus groups: A discussion session will explore patient symptomatology, the functional impact of the disease, quality of life and the problems faced by patients from their point of view."
89058973|NCT06011226||Phase 2: pilot phase|Once the initial version of the self-questionnaire has been developed, it will be tested on a group of 40 patients with either Chiari malformation with syringomyelia (n = 20), isolated Chiari malformation (n = 10) or isolated syringomyelia (n = 10), managed by the CRMR C-MAVEM at Bicêtre Hospital.
89058974|NCT06011226||Phase 3: national testing of the questionnaire|the 3rd phase will be submitted to the Human Subjects Protection Review Board according to the progression of the first two phases.
89058975|NCT06010810|Experimental|3 % Topical Tranexamic Acid|Patients will receive 3% Topical Tranexamic Acid, on half of the face, twice a day for a total duration of 2 months
89058976|NCT06010810|Experimental|4 % Topical Hydroquinone|Patients will receive 4% Topical Hydroquinone, on half of the face, twice a day for a total duration of 2 months.
89058977|NCT06009653|Active Comparator|Standard Care|In this arm, participants will receive the standard care intervention from community health workers.
89058978|NCT06009653|Experimental|Intensive lifestyle intervention plus placebo|In this arm, participants will receive a culturally-tailored dietary and behavioral intensive lifestyle intervention from community health workers, and will receive placebo subcutaneous injections weekly during the 52-week intervention.
89058979|NCT06009653|Experimental|Intensive lifestyle intervention plus tirzepatide|In this arm, participants will receive the behavioral plant-based intervention from community health workers, and will receive subcutaneous injections of tirzepatide weekly during the 52-week intervention
89218689|NCT06140641|Experimental|Probiotics group|Daily administration of Bifidobacterium Longum BL21 for 8 weeks.
89523264|NCT03383549|No Intervention|Control group|Control group receives only verbal instructions to train cognitive and physical conditions. Instructions will aim to promote daily and leisure activities.
89058980|NCT06009302|Experimental|US block of mandibular nerve|"Extraoral ultrasound-guided block of the mandibular nerve will be performed iusing an ultrasound device. After visualisation of the pterygomandibular space, of the maxillary artery and the mandibular nerve next to it, at a depth of 2-4 cm, the detection of the maxillary artery is confirmed by Color Doppler. A needle enters between the coronoid and condylar processes, using the out of plane technique, near the maxillary artery, and after negative aspiration, local anesthetic ropivacaine (0.75%, 2.5 mL) will be applied."
89058981|NCT06009302|Active Comparator|intraoral block of lower alveolar nerve|During the intraoral block of the inferior alveolar nerve, the patient will lie with his mouth wide open, and the inferior alveolar, lingual and buccal nerves will be anesthetized using two injections. The anesthetic used will be 40 mg/mL articaine chloride+0.01 mg/mL epinephrine: the planned amount of anesthetic is 2×1.7 mL, and if anesthesia is not achieved, an additional volume of anesthetic will be added as needed, until anesthesia
89058982|NCT06007846|Experimental|Arm 1|
89058983|NCT06006611||Azvudine group|Azvudine group included COVID-19 patients treated with azvudine antiviral therapy;
89058984|NCT06006611||No antiviral group|No antiviral group included COVID-19 patients treated with no antiviral therapy;
89058985|NCT06006611||Monotamivir|Monotamivir group included COVID-19 patients treated with monotamivir antiviral therapy
89058986|NCT06006338|Experimental|Experimental arm|
89058987|NCT06005129|Experimental|Personality-based treatment 2 week baseline|Participants will receive treatment tailored to 1 of 3 personality dimensions after a 2 week baseline assessment
89058988|NCT06005129|Experimental|Personality-based treatment 4 week baseline|Participants will receive treatment tailored to 1 of 3 personality dimensions after a 4 week baseline assessment
89058989|NCT06001333|Experimental|FMT group|fecal microbiota transplantation using frozen or capsulized stool
89058990|NCT06001333|No Intervention|non-FMT group|Simple observation without intervention
89058991|NCT05998759|Experimental|Telitacicept plus standard therapy|Telitacicept (160mg ih qw for 24 weeks) combined with standard therapy. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.).
89058992|NCT05998759|Placebo Comparator|Placebo plus standard therapy|Placebo combined with standard therapy. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.).
89058993|NCT05992844|Experimental|KB Exercises plus Conventional Rehabilitation Group|"While the participants in the study group will continue the conventional rehabilitation program described below for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
89058994|NCT05992844|Other|Conventional Rehabilitation Group|Control Group; Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
89058995|NCT05992688|Active Comparator|Sucrose sweetened beverage|Sucrose (i.e. sugar): 25 g sugar (100 Kcal per serving). Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
89058996|NCT05992688|Experimental|Stevia sweetened beverage|The stevia-sweetened beverage contains 30.1 mg of steviol equivalents. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
89058997|NCT05992688|Active Comparator|Calorie free flavored water beverage|Flavored water. Participants will be asked to consume the study product once a day for 8 to 14 weeks if they have normal weight or excessive weight, respectively.
89058998|NCT05992597|Experimental|rituximab, lenalidomide, and zebutinib,RDHAP|
89058999|NCT05992038|Experimental|Putty|The osteotomy gap will be filled with a synthetic ceramic material, Putty
89059000|NCT05992038|Placebo Comparator|Conventional|Osteotomy performed according to the conventional method, without gap filler
89059001|NCT05991310|Experimental|Telemedicine Assessment by Remote Neurologist|Following the initial assessment, the stroke nurse will activate the telemedicine video conference call and review the patient with the telemedicine neurologist. The telemedicine neurologist will perform a NIHSS with assistance from the stroke nurse, and this will be documented on the clinical records. Imaging will be evaluated remotely by the telemedicine neurologist. If there is a decision to administer thrombolysis, the stroke neurologist and nurse will discuss treatment with the patient or next of kin, where appropriate and able, to acquire assent in a timely manner.
89059002|NCT05991310|Active Comparator|In-Person Assessment by an Onboard Neurologist|Upon arrival on-scene, the MSU stroke nurse, neurologist, and paramedic will liaise with local ambulance services to obtain initial clinical details and perform an initial assessment. The NIHSS will be performed by the neurologist, and this will be documented on standardized clinical records. Imaging will be assessed at the console available within the ambulance. If there is a decision to administer thrombolysis, the stroke neurologist and nurse will discuss treatment with the patient or next of kin, where appropriate and able, to acquire assent in a timely manner.
89059003|NCT05986331|Experimental|BCD-201 group|BCD-201 200 mg as a 30-minute intravenous infusion once every 3 weeks
89059004|NCT05986331|Active Comparator|Keytruda|Keytruda 200 mg as a 30-minute intravenous infusion once every 3 weeks
89059005|NCT05984446|Experimental|real-rTMS|4 daily 25-minutes high-frequency rTMS sessions over one week
89059006|NCT05984446|Sham Comparator|sham-rTMS|4 daily 25-minutes sham-rTMS sessions over one week
89059007|NCT05984238|Active Comparator|ReCET procedure|"Patients receive ReCET (Re-Cellularization via Electroporation Therapy), which is performed using the ReCET device.~After which a 2 week isocaloric diet is followed, and then semaglutide, a GLP-1 receptor agonist is started."
89059008|NCT05984238|Sham Comparator|Sham procedure|"Patients receive sham procedure, this consists of placing an Endogenex catheter, or a catheter with a similar circumference at the endoscopists discretion in the stomach and leaving it in place for 30 minutes.~After which a 2 week isocaloric diet is followed, and then semaglutide, a GLP-1 receptor agonist is started"
89059009|NCT05983705|Experimental|Experiment group|The experiment group will receive written psychoeducation about children with externalizing behaviors, and start their parental program AFFEKT approximately one week from the information meeting (baseline).
89523265|NCT03387397||Lower Medications (LM) cohort|Patients will be assigned to the Lower Medications (LM) cohort group (N=85) if they received a drug regimen of less than five different medications/day during the study period.
89059010|NCT05983705|Active Comparator|Control group|The control group will receive written psychoeducation about children with externalizing behaviors, and start their parental program AFFEKT approximately seven weeks from the information meeting (when the experiment group has finished their AFFEKT program).
89059011|NCT05982964||back pain group|
89059012|NCT05982964||Healthy volunteers|
89059013|NCT05982600||Cancer Pathway referred patient|Patient referred for assessment and excision of their skin lesion, because of a suspicion of melanoma by the referring doctor.
89059014|NCT05979064|Experimental|Laparoscopically harvested omental tissue autograft|Use of laparoscopically harvested omental autografts into the resection cavity of recurrent glioblastoma multiforme (rGBM) patients.
89059015|NCT05978895|Experimental|Intervention group|22 adults with autism spectrum disorder (grade 1-2 or 3), admitted to the daycare service of Sacra Famiglia Onlus Foundation in Cesano Boscone (Milan, Italy)
89059016|NCT05976685|Experimental|LAAO and DOAC therapy|Left atrial appendage occlusion and therapy with direct oral anticoagulants
89059017|NCT05976685|Other|DOAC therapy only|Therapy with direct oral anticoagulants alone
89059018|NCT05975684|Active Comparator|Baclofen|Baclofen 0.5 mg/kg/day up to 15 mg/day divided three times a day in liquid formulation for 4 weeks.
89059019|NCT05975684|Placebo Comparator|Placebo|Matching placebo three times a day in liquid formulation for 4 weeks.
89059020|NCT05975151|Experimental|Pseudomonas aeruginosa Group|
89059021|NCT05971784|Experimental|Telerehabilitation group|In addition to the exercise program consisting of balance and walking activities, the group will receive task-oriented upper extremity training via telerehabilitation accompanied by a physiotherapist.
89059022|NCT05971784|Experimental|Control group|The group that will receive a home exercise program consisting of only balance and walking activities
89059023|NCT05968469|Experimental|High Intensity Interval Training (HIIT) protocol|Patients who underwent cycling ergometry program including high-intensity interval (HIIT) in the cardiopulmonary rehabilitation unit and stretching exercises for the cervical, thoracic and lumbar regions under the guidance of a physiotherapist
89059024|NCT05968469|Active Comparator|Exercise program only:|Patients undergoing cervical, thoracic and lumbar stretching exercises in the hospital with a physiotherapist
89059025|NCT05966935|Experimental|fenugreek cumin powder|Overweight and Obese adults in this group will receive fenugreek cumin powder daily twice a day before morning and evening meals for 8 weeks
89059026|NCT05966935|No Intervention|Control group|Overweight and obese participants in this group will not receive fenugreek and cumin powder or any intervention for 8 weeks
89110989|NCT02389387||Intensive Intervention|Two hundred twenty (220) dialysis facilities will follow standard of care practices and the intensive intervention in their management of ESRD patients. The intensive intervention will consist of 1) A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX) to enhance coordination between dialysis and transplant staff and track ESRD patients through the seven primary steps to transplant , 2) educational webinars/seminars for staff, 3) facility-specific performance feedback reports, 4) assistance with and review of center-specific action plans to increase transplant referral, 5) scheduled bi-annual phone calls with an SETC member to monitor progress, 6) patient education on transplant via creation of an Education Station in facility lobby, and 7) development of a Peer Mentor program.
89218690|NCT06140589||effective group|The tumor size of each diameter of the tumor before and after treatment was measured on magnetic resonance imaging or CT. According to Recist 1.1 criteria, patients who were evaluated as complete remission, partial remission and stable disease were included in the effective group. Patients assessed as having progressive disease were included in the treatment-refractory group.
89218691|NCT06140589||ineffective group|The tumor size of each diameter of the tumor before and after treatment was measured on magnetic resonance imaging or CT. According to Recist 1.1 criteria. Patients assessed as having progressive disease were included in the ineffective group.
89218692|NCT06140576|Experimental|Lenvatinib combined with Sindilimab and Nab-paclitaxel|The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
89218693|NCT06140550|Experimental|Experimental group|
89218694|NCT06140550|Experimental|Control group|
89218695|NCT06140498|Experimental|Intervention|Digital Self-Efficacy Training with 3 trainings daily and Ecological Momentary Assessment
89218696|NCT06140498|Active Comparator|Control|Ecological Momentary Assessment
89218697|NCT06140472|Active Comparator|Phoenix application|Specific individualized nurse follow-up using the PHOENIX application.
89218698|NCT06140472|Sham Comparator|Journal de bord|Regular nursing follow-up, with the use of an electronic journal.
89218699|NCT06140433|Other|VSC-MEDlib|SaMD: Data collection study. Software to be applied after data collection.
89218700|NCT06140381|Active Comparator|CTG|In conventional therapy, the treatment plan is determined based on medical opinion. After admission, each patient undergoes several multidisciplinary assessments aimed at objectively determining the care based on their needs. In this group, patients received only conventional rehabilitation. This will carry out in the same manner as a regular practice of the clinic. 3 sessions per week
89218701|NCT06140381|Experimental|ETG|In the absence of a standardized eccentric isokinetic training protocol established for hemiparetic subjects on the plantar flexor muscles, the protocol designed for this study drew inspiration from the one established by Clark and Patten. (2013) and by Harris-Love et al. (2017).This protocol allows the introduction of an eccentric stimulus for individuals who are new to this type of training and progressively advances their program to include workload levels sufficiently to stimulate muscle plasticity optimally, thereby inducing skeletal muscle adaptations. 3 sessions per week
89218702|NCT06140368|Experimental|Experimental group|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
89218703|NCT06140368|No Intervention|Control group|Patients will not use virtual reality glasses during trigger point injection.
89218704|NCT06138093|Experimental|Sealed / closed tracheostomy|Sealing of the tracheostomy wound using a sealing device.
89218705|NCT06138080|Other|VUR diagnostics|
89218706|NCT06138041|Experimental|lidocaine group|At the same time of induction of general anesthesia, an intravenous lidocaine bolus of 2mg/kg will be administered, followed by a continuous infusion of intravenous lidocaine at 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
89218707|NCT06138041|Placebo Comparator|control group|The control group will receive the same volume of normal saline in bolus and continuous infusion.
89218708|NCT06138028|Experimental|Combined chemo-immuno-irradiation|TP regimen plus PD-1 inhibitor for 4 cycles then irradiation and PD-1 inhibitor maintenance therapy for 13 cycles.
89218709|NCT06138015|Experimental|Exercise and Time-Restricted Eating|
89218710|NCT06138015|Active Comparator|Exercise only|
89218711|NCT06137989|Active Comparator|Fill-Up|Bulk-fill resin composite type
89218712|NCT06137989|Active Comparator|QuiXfil|Bulk-fill resin composite type
89218713|NCT06137989|Active Comparator|Tetric N-Ceram Bulk Fill|Bulk-fill resin composite type
89218714|NCT06137950|Active Comparator|Control|Interferon α2b gel treatment for 30 days.
89218715|NCT06137950|Experimental|Treatment|"Interferon α2b gel treatment for 30 days~+ Interferon α2b 3 MIU rectal suppository for 10 days"
89218716|NCT06137937|Experimental|Interventional Group|subjects in the treatment group underwent routine hemodialysis by committing to an intradialysis aerobic exercise program
89218717|NCT06137937|No Intervention|Control Group|subjects in the control group underwent routine hemodialysis without a physical exercise program
89218718|NCT06137924|Active Comparator|ANB with 0.5% bupivacaine plus dexamethasone 8 mg|ANB will be performed using 5% bupivacaine 20 cc plus dexamethasone 8 mg as the local anesthetic.
89218719|NCT06137924|Experimental|ANB with 0.5% bupivacaine plus dexamethasone and a colloid|ANB will be performed in this group using 0.5% bupivacaine 20 ccs plus dexamethasone 8 mg and a plasma volume substitute (succinylated gel).
89218720|NCT06137924|Experimental|0.5% bupivacaine plus clonidine 0.145 mcg|ANB with will be performed in this group using 0.5% bupivacaine 20 ccs plus clonidine 0.145 mcg.
89218721|NCT06137885||PCI group|Patients who received percutaneous coronary intervention (PCI) at the Department of cardiology of Peking University Third Hospital will be included in the PCI group.
89218722|NCT06137885||Heart failure group|Patients with heart failure who hospitalized at the Department of cardiology of Peking University Third Hospital will be included in the heart failure group.
89218723|NCT06137885||Cardiometabolic syndrome group|Patients with cardiometabolic syndrome who hospitalized at the Department of cardiology of Peking University Third Hospital will be included in the cardiometabolic syndrome group.
89218724|NCT06137885||Structural heart disease group|Patients with structural heart disease who hospitalized at the Department of cardiology of Peking University Third Hospital will be included in the structural heart disease group.
89218725|NCT06137859|Experimental|Intervention|Participants will receive PLBI intervention treatment including weekly-based functional fitness training, mastering physical literacy class, daily based reflective writing, buddy peers support group.
89218726|NCT06137859|No Intervention|Control|Participants will not receive PLBI intervention treatment. However, participants in the control group will be given the same treatment (program and activities) after all data has been collected.
89218727|NCT06137833|Experimental|APPORTAL®|APPORTAL® sachet, 1 sachet per day dissolved in a glass of water. To be consumed in the morning, about 10 minutes after breakfast. Dosage form: powder Route: Oral Treatment duration: 8 weeks
89218728|NCT06137833|Placebo Comparator|PLACEBO|PLACEBO sachet, 1 sachet per day dissolved in a glass of water To be consumed in the morning, about 10 minutes after breakfast. Dosage form: powder Route: Oral Treatment duration: 8 weeks
89218729|NCT06137820|Experimental|Treatment group (Cetilar®)|Participants received Cetilar® topical cream twice daily for 30 days. An average amount of 5 g per day
89218730|NCT06137820|Placebo Comparator|Control group (Placebo)|Participants received Cetilar Placebo topical cream twice daily for 30 days. An average amount of 5 g per day
89688820|NCT00934141|Experimental|Coaching + Website|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
89688821|NCT00934141|Experimental|Full: LS, Coaching, ICC, Website|Learning Session, Coaching, Interest Circle Calls, Website, see descriptions above
89688822|NCT00934141|Experimental|Learning Session + Website|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
89688823|NCT00941005|Experimental|Electroacustimulation|Received electroacustimulation at the wrist using a small, battery-powered electroacustimulation device.
89110990|NCT02341274|Active Comparator|Fresh Brand Name Tacrolimus (Prograf®)|Oral administration of 5 mg capsule of fresh brand name tacrolimus (Prograf®) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
89688824|NCT00941005|Sham Comparator|Control|Received a device that was not turned on.
89688825|NCT00934375|Experimental|1|
89688826|NCT00934375|Placebo Comparator|2|
89688827|NCT05105425|Active Comparator|NUTRIOSE®|1 sachet to be taken at breakfast during 4 weeks
89688828|NCT05105425|Placebo Comparator|GLUCIDEX® IT21|1 sachet to be taken at breakfast during 4 weeks
89688829|NCT03002974|Experimental|Anakinra 100 mg|1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
89688830|NCT03002974|Experimental|Anakinra 200 mg|2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
89688831|NCT03002974|Active Comparator|Triamcinolone 40 mg|2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg
89688832|NCT02245477||Obstetric Ultrasoud|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
89688833|NCT02245477||Serum Vascular Endothelial Growth Factor|Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat. No. DVEOO) manufactured by R & D Systems, Inc , (Minneapolis, MN, USA).
89688834|NCT03833557|Active Comparator|Nanohydroxyapatite Pulpotomy|"Biphasic calcium phosphate. Straumann BoneCeramic Regenerative Pulpotomy of 24 mandibular second primary molars using Nanohydroxyapatite~In Group 1: 24 mandibular second primary molars Caries removal and deroofing of pulp chamber Following the manufacturer's instructions, Nanohydroxyapatite was mixed with distilled water to homogeneous consistency then introduced into the pulp chamber and condensed properly against the pulp orifices.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy"
89688835|NCT03833557|Active Comparator|MTA Pulpotomy|"Angelus Grey MTA , Regenerative Pulpotomy Pulpotomy of 24 mandibular second primary molars using MTA Caries removal and deroofing of pulp chamber The MTA powder was mixed with sterile water in a 3:1 powder/water ratio according to the manufacturer's instructions to obtain a thick creamy paste, then placed on the floor of the pulp chamber using a messing gun and compacted against the pulp orifices with a condenser over a moist cotton pellet.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation at one, three ,six & 12 months after pulpotomy."
89688836|NCT03833557|Active Comparator|Formocresl Pulpotomy|"Buckley' s Formocresol , Fixation pulpotomy Pulpotomy of 24 mandibular second primary molars using Formocresol Caries removal and deroofing of pulp chamber~A cotton pellet with formocresol was placed on the pulp stumps then removed and ZO/E dressing was condensed against the pulp stumps.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy for clinical and radiographic evaluation. Independently, two examiners evaluated the teeth clinically and radiographically."
89688837|NCT04360447|Experimental|Reformer pilates group|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
89688838|NCT04360447|Active Comparator|Home exercise group|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
89688839|NCT04360057|Other|Hand Hygiene education|
89688840|NCT03032887|Experimental|voice prompts|Agitation (education, reminders and optimising materials) plus voice prompts
89688841|NCT03032887|Other|no voice prompts|only Agitation (education, reminders and optimising materials); no voice prompts
89688842|NCT02825212|Experimental|Participant with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia|"Participants treated with either Harvoni or Epclusa~Harvoni 90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.~Epclusa 400mg/100mg 400mg/100mg FDC once daily"
89688843|NCT03032809||Intracranial vasculopathy|Patients diagnosed intracranial vasculopathy will be imaged further by high resolution vessel wall MR imaging on a 3Tesla MR scanner.
89688844|NCT04986085||GEP NET|GEP NET patients in Spain
89688845|NCT02825680|Active Comparator|Enhanced NCP Support|Teams at facilities who expressed interest in being in the trial but who are not randomly assigned to the experimental arm will be in the active comparator arm. These facilities will receive enhanced support from NCP.
89218731|NCT06137794|Experimental|SDM group|"The anticoagulation therapy of AF patients will be determined by clinicians with the use of I-Anticoagulation, and AF patients will be managed using I-Anticoagulation during their anticoagulation therapy."
89059027|NCT05966376|Experimental|Modified Terumo Radial Band|"A standard hemostatic device used for proximal radial approach. The hard plastic component is removed to achieve better attachment in the distal radial approach.~Clean and dry the puncture site.~The introducer is withdrawn 2 cm.~Place the device on the patient's hand depending on the approach side.~Terumo logo is positioned toward the little finger side.~The green mark is positioned 1 cm proximal to the puncture site.~The bands are adjusted and fixed around the wrist.~The Terumo syringe is filled with 15 ml of air.~The balloon of the device is slowly inflated through the valve while the introducer is slowly withdrawn simultaneously.~Once the introducer is completely withdrawn, the balloon continues to be inflated until the absence of bleeding is verified.~Once hemostasis is achieved, the patient must be able to move his fingers and wrist without bleeding. If bleeding is observed, the balloon is inflated to achieve adequate hemostasis."
89218732|NCT06137794|No Intervention|Control group|AF patients in the control group will receive standard care.
89218733|NCT06137781|Experimental|Six weeks of digital prehabilitation|The digital prehabilitation programme comprises three 35-minute exercise sessions per week, including a warm-up, vigorous intensity aerobic and resistance exercises, and breathing exercises. The digital prehabilitation programme will be tailored to the participant's mobility level and fitness level, which will be assessed via in-platform questionnaires and functional assessments. Functional assessments will be repeated every two weeks to adapt the prehabilitation programme according to changes in fitness level. Within PreActiv's website, participants will be enrolled into a managed community forum of patients and healthcare professionals where they can post their achievements and questions. Alongside access to PreActiv's digital prehabilitation, patients will be given educational materials that summarise the benefits of prehabilitation and how to realise them.
89218734|NCT06137768|Experimental|Treatment group A: HRS-5965; high dose|
89218735|NCT06137768|Experimental|Treatment group B: HRS-5965; medium dose|
89218736|NCT06137768|Experimental|Treatment group C: HRS-5965; low dose|
89218737|NCT06137768|Placebo Comparator|Treatment group D: Placebo.|
89218738|NCT06137729|Experimental|PF-07899895|Participants will receive single or multiple ascending oral doses of PF-07899895.
89218739|NCT06137729|Placebo Comparator|Placebo|Participants will receive matching placebo.
89218740|NCT06137716|Experimental|Participant Group/Arm|Participants will rehabilitation with a robotic hand exoskeleton.
89218741|NCT06137703|Experimental|Sequence 1|Period 1 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 2 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 4 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D).
89218742|NCT06137703|Experimental|Sequence 2|Period 1 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 2 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg immediate release tablet (Treatment B).
89218743|NCT06137703|Experimental|Sequence 3|Period 1 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 3 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 4 - Two zavegepant 100mg immediate release tablets (Treatment C).
89523266|NCT03387397||Higher Medications (HM) cohort|Patients will be assigned to the Higher Medications (HM) cohort group (N=85) if they received a drug regimen of more than 5 different chronic medications/day during the study period.
89059028|NCT05966376|Active Comparator|PreludeSYNC distal|"A specific hemostatic device, designed for distal radial approach.~Clean and dry the puncture site.~Selection and preparation of the PreludeSYNC distal device according to the approach side.~The introducer is withdrawn 2cm.~The hemostasis device is placed on the patient's hand.~Bands position: 1) little finger side; 2) thumb side; 3) between the thumb and the index finger.~The circular mark of the balloon is positioned 1cm proximal to the puncture site.~Bands are adjusted and fixed.~The syringe is filled with 10 ml of air.~The balloon of the device is slowly inflated while the introducer is slowly withdrawn simultaneously.~Once the introducer is completely withdrawn, the balloon continues to be inflated until the absence of bleeding is verified.~Once hemostasis is achieved, the patient must be able to move his fingers and wrist without bleeding. If bleeding is observed, the balloon should be inflated to achieve adequate hemostasis."
89059029|NCT05958615|Experimental|Intervention Condition|Participants will receive 8 weeks of ReConnect followed by 8 weeks check-in surveys/follow-ups, as well as 3 assessments (baseline, 8 weeks, 16 weeks).
89059030|NCT05958615|Other|Waitlist Control Condition|Participants will receive 8 weeks of check-in surveys/follow-ups followed by 8 weeks of ReConnect, as well as 3 assessments (baseline, 8 weeks, 16 weeks).
89059031|NCT05956340|Experimental|Recording Session During Hospitalization|While inpatient, participants will undergo a research interview with recorded audio.
89059032|NCT05953597|Experimental|Nutrition Education Group|Participants in this study arm will receive nutrition education once a month for 12 months.
89059033|NCT05953415|Active Comparator|active iTBS group|active iTBS coupled with conventional cognitive therapy
89059034|NCT05953415|Sham Comparator|sham iTBS group|sham iTBS coupled with conventional cognitive therapy
89059035|NCT05944510|Experimental|Add-on Dextromethorphan|Dextromethorphan 30mg once daily will be administered along with clozapine (as standard of care) in Treatment-resistant schizophrenia.
89059036|NCT05944510|Placebo Comparator|Add-on Placebo|Matched Placebo will be administered along with clozapine (as standard of care) in Treatment resistant schizophrenia.
89059037|NCT05940675|Experimental|Generation Healthy Kids intervention|The intervention focuses on food and nutrition, physical activity, sleep and screen media habits, and engagement of the local stakeholders.
89059038|NCT05940675|No Intervention|Control|The schools will continue with their regular school schedules.
89059039|NCT05940493|Experimental|Active Treatment (Abemaciclib)|Administered twice daily on days 1-28 of each 28-day cycle.
89059040|NCT05940493|Placebo Comparator|Placebo|Administered twice daily on days 1-28 of each 28-day cycle.
89059041|NCT05938907|No Intervention|only apical surgery group|which will undergo only apical surgery (including apicoectomy, inflammation debridement, and retrofilling of the root apex)
89059042|NCT05938907|Experimental|bone substitute group|which will undergo apical surgery plus bone substitute
89059043|NCT05938907|Experimental|concentrated growth factors group|which will undergo apical surgery plus CGF (concentrated growth factors)
89059044|NCT05938907|Experimental|bone substitute and CGF group|which will undergo apical surgery plus bone substitute and CGF gel
89059045|NCT05935982|Experimental|Virtual reality exercise program in special physical education|During normal special physical education hours, participants will be provided with a virtual reality headset and exercise games and be prescribed to exercise at a moderate intensity.
89059046|NCT05934253|Experimental|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
89059047|NCT05934253|Active Comparator|Tetracaine ophthalmic solution 0.5%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
89059048|NCT05932888|Experimental|QLM3003|QLM3003 Single dose
89059049|NCT05932888|Placebo Comparator|QLM3003 Placebo|QLM3003 vehicle Single dose
89059050|NCT05925959|No Intervention|Upfront Surgery|
89059051|NCT05925959|Active Comparator|Preoperative Weight Management Program|
89059052|NCT05925400|No Intervention|ET on D5 without RV|Patients who will be randomized to the control group will be waiting for the embryo transfer procedure according to the usual service protocol.
89059053|NCT05925400|Experimental|ET on D5 with RV|"The transfer and preparation in the transfer room will be done according to the usual service protocol.~Exposure to virtual reality environment exposure"
89110991|NCT02341274|Active Comparator|Fresh Generic Tacrolimus|Oral administration of 5 mg capsule of fresh generic tacrolimus to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
89523267|NCT03383471|Experimental|Invossa K Inj.|Invossa K Inj.
89523268|NCT03383471|Placebo Comparator|Placebo|Placebo control
89218744|NCT06137703|Experimental|Sequence 4|Period 1 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 3 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A).
89218745|NCT06137677|Experimental|Sweet Snack|A sweet food will be served as the snack
89218746|NCT06137677|Experimental|Savory Snack|A savory food will be served as the snack
89218747|NCT06137664|Experimental|Adults: High-dose (HD) nOPV1 + HD nOPV2 + HD nOPV3|Adults will receive nOPV1 (10^6.5 Cell Culture Infectious Dose 50% [CCID₅₀]) plus nOPV2 (10^5.6 CCID₅₀) plus nOPV3 (10^6.5 CCID₅₀) on Day 1 and Day 29.
89218748|NCT06137664|Active Comparator|Adults:bOPV|Adults will receive bivalent OPV (types 1 and 3) on Day 1 and Day 29. Each dose (2 drops = 0.1 mL) contains >10^6.0 infective units of type 1 and >10^5.8 of type 3.
89218749|NCT06137664|Experimental|Young Children: Middle-dose (MD) nOPV1 + Low-dose (LD) nOPV2 + MD nOPV3|Children aged ≥ 1 to < 5 years old will receive nOPV1 (10^6.0 CCID₅₀) plus nOPV2 (10^5.3 CCID₅₀) plus nOPV3 (10^6.0 CCID₅₀) on Day 1 and Day 29.
89218750|NCT06137664|Experimental|Young Children: HD nOPV1 + HD nOPV2 + HD nOPV3|Children aged ≥ 1 to < 5 years old will receive nOPV1 (10^6.5 CCID₅₀) plus nOPV2 (10^5.6 CCID₅₀) plus nOPV3 (10^6.5 CCID₅₀) on Day 1 and Day 29.
89218751|NCT06137664|Active Comparator|Young Children: Low-dose (LD) nOPV2|Children aged ≥ 1 to < 5 years old will receive nOPV2 (10^5.3 CCID₅₀) on Day 1 and Day 29.
89218752|NCT06137664|Active Comparator|Young Children: bOPV|Children aged ≥ 1 to < 5 years old will receive bivalent OPV (types 1 and 3) on Day 1 and Day 29. Each dose (2 drops = 0.1 mL) contains > 10^6.0 infective units of type 1 and > 10^5.8 of type 3.
89218753|NCT06137664|Experimental|Neonates: MD nOPV1 + LD nOPV2 + MD nOPV3|Newborns will receive nOPV1 (10^6.0 CCID₅₀) plus nOPV2 (10^5.3 CCID₅₀) plus nOPV3 (10^6.0 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
89218754|NCT06137664|Experimental|Neonates: HD nOPV1 + LD nOPV2 + HD nOPV3|Newborns will receive nOPV1 (10^6.5 CCID₅₀) plus nOPV2 (10^5.3 CCID₅₀) plus nOPV3 (10^6.5 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
89218755|NCT06137664|Experimental|Neonates: MD nOPV1 + LD nOPV2 + HD nOPV3|Newborns will receive nOPV1 (10^6.0 CCID₅₀) plus nOPV2 (10^5.3 CCID₅₀) plus nOPV3 (10^6.5 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
89218756|NCT06137664|Experimental|Neonates: HD nOPV1+ LD nOPV2+ MD nOPV3|Newborns will receive nOPV1 (10^6.5 CCID₅₀) plus nOPV2 (10^5.3 CCID₅₀) plus nOPV3 (10^6.0 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
89218757|NCT06137664|Experimental|Neonates: HD nOPV1 + HD nOPV2 + HD nOPV3|Newborns will receive nOPV1 (10^6.5 CCID₅₀) plus nOPV2 (10^5.6 CCID₅₀) plus nOPV3 (10^6.5 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
89218758|NCT06137664|Active Comparator|Neonates: bOPV|Newborns will receive bivalent OPV (types 1 and 3) at birth, week 6, week 10 and week 14 of life. Each dose (2 drops = 0.1 mL) contains >10^6.0 infective units of type 1 and >10^5.8 of type 3.
89218759|NCT06137664|Experimental|Neonates: MD nOPV1 + LD nOPV2|Newborns will receive nOPV1 (10^6.0 CCID₅₀) plus nOPV2 (10^5.3 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
89218760|NCT06137664|Active Comparator|Neonates: LD nOPV2|Newborns will receive nOPV2 (10^5.3 CCID₅₀) at birth, week 6, week 10 and week 14 of life.
89218761|NCT06137651|Experimental|Cohort I (radiation therapy, trotabresib, vinorelbine)|Patients CNS metastases or LMD undergo radiation therapy over 7 days in the absence of disease progression or unacceptable toxicity. Patients then receive trotabresib PO QD on days 1-4 and vinorelbine IV over 6-10 minutes on days 4, 11, and 18 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT, and collection of blood samples throughout the trial.
89218762|NCT06137651|Experimental|Cohort S (surgery, trotabresib, vinorelbine)|Patients who undergo tumor resection receive trotabresib PO QD on days 1-4 and vinorelbine IV on day 4. Patients then undergo standard of care surgery. Patients may undergo radiation therapy after surgery per standard of care. Patients may then receive trotabresib PO QD on days 1-4 and vinorelbine IV over 6-10 minutes on days 4, 11, and 18 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT, and collection of blood samples throughout the trial.
89218763|NCT06137625|Experimental|Cerebral Palsy|Children with Cerebral Palsy
89218764|NCT06137625|Active Comparator|Typical developing|Typical developing children
89218765|NCT06137612||Patients with SMA|Patients with SMA type II and III
89218766|NCT06137612||Healthy controls|Age- and sex-matched HC
89218767|NCT06137573|Experimental|[14C]TNP-2198|Participants will take a single dose of 600mg 150μCi of [14C]TNP-2198.
89218768|NCT06137547|Experimental|HPI-guided|The arterial line of patients in HPI-guided arm will be connected to HemoSphere advanced monitoring platform (EV1000), which will provide HPI value calculated with Acumen Hypotension Prediction Index software.
89218769|NCT06137547|No Intervention|non-HPI-guided|The arterial line of patients in non-HPI-guided arm will also be connected to HemoSphere advanced monitoring platform (EV1000) and all hemodynamic parameters will be calculated and showed as HPI-guided arm EXCEPT that the HPI value will not be shown on screen.
89218770|NCT06137521||Patients with good coronary collaterals|Coronary collateral circulation development was graded according to the Rentrop score, grade 2 (partial filling of the epicardial segment by collateral vessels); grade 3 (complete filling of the epicardial artery by collateral vessels) were defined as good coronary collateral circulation.
89218771|NCT06137521||Patients with poor coronary collaterals|Coronary collateral circulation development was graded according to the Rentrop score, grade 0 (no filling of any collateral vessels) and grade 1 (filling of side branches of the artery to be perfused by collateral vessels without visualization of the epicardial segment) were defined as poor coronary collateral circulation.
89218772|NCT06137456|Experimental|Study group|Participants were involved in exoskeletal robotic therapy three days a week and conventional therapy five days a week for a maximum of eight weeks.
89218773|NCT06137456|Active Comparator|Control group|Participants were involved in conventional therapy five days a week for a maximum of eight weeks.
89218774|NCT06137443|Experimental|Balance Training|The study included five participants who were over 18 years of age and had experienced a spinal injury within the past year. These participants were classified as AIS D (American Spinal Injury Association Impairment Scale). Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
89218775|NCT06137430||Diabetic patients with chronic heart failure|
89218776|NCT06137430||Non_diabetic patients with chronic heart failure|
89218777|NCT06137404|Active Comparator|Splint M|Metacarpophalangeal joint blocking splint
89218778|NCT06137404|Experimental|Splint R|Relative motion extension splint
89218779|NCT06137352||Adolescent females who received their first dose of HPV vaccine at 13-14 years|Adolescent females who completed their last dose of domestic bivalent HPV vaccine or imported HPV vaccine and were between 13 and 14 years of age at the time of the first dose. Two follow-up visits were conducted 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of vaccination.
89218780|NCT06137339|Experimental|Avocado Group|Participants will consume 1 avocado per day and receive education to maintain usual caloric intake for 12 weeks and participate in 4 study visits.
89218781|NCT06137339|No Intervention|No Diet Modification Group|Participants will continue their normal dietary pattern for 12 weeks and participate in 4 study visits.
89218782|NCT06137326|Experimental|Pulsed Electromagnetic Field Therapy|
89218783|NCT06137326|Active Comparator|Laser Acupuncture|
89218784|NCT06137235|Experimental|test formula|infant formula and follow-on formula with bioactive ingredients
89218785|NCT06137235|Active Comparator|control formula|standard infant formula and follow-on formula
89218786|NCT06137222|Experimental|SOC plus TXB MicroTip Ultrasound|Sharp debridement of the outer margins of the index DFU using standard technique (curettage or sharp blade debridement) plus a single additional percutaneous debridement of bone and surrounding tissue via the TXB MicroTip for the first treatment session only plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed.
89218787|NCT06137222|Placebo Comparator|SOC|Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
89218788|NCT06137209|Active Comparator|Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)|Group A: Probiotic Micrococcus luteus Q24 serum (dose: 1e7 colony forming units per application)
89218789|NCT06137209|Active Comparator|Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)|Group B: Probiotic Micrococcus luteus Q24 serum (dose: 1e6 colony forming units per application)
89218790|NCT06137157|Experimental|Internal controlled arm|ATR12-351 on left side of body, vehicle on right side of body in one group; vehicle on left side of body, ATR12-351 on right side of body.
89218791|NCT06137092|Experimental|AryoGen Pharmed Co. rFVIII-Fc/Elocta® (Sobi Co. rFVIII-Fc)|AryoGen Pharmed Co. rFVIII-Fc, IV, 50 units/kg, single dose, then Elocta® (Sobi Co. rFVIII-Fc), IV, 50 units/kg, single dose (cross-over)
89218792|NCT06137092|Experimental|Elocta® (Sobi Co. rFVIII-Fc)/AryoGen Pharmed Co. rFVIII-Fc|Elocta® (Sobi Co. rFVIII-Fc), IV, 50 units/kg, single dose, then AryoGen Pharmed Co. rFVIII-Fc, IV, 50 units/kg, single dose (cross-over)
89218793|NCT06137027|Active Comparator|Cannabidiol Oil|Cannabidiol oil 5.5mg, equivalent to 10 drops
89218794|NCT06137027|Placebo Comparator|Placebo|Peppermint oil, 10 drops
89218795|NCT06137014|Experimental|Amino acid-fortified oral rehydration therapy|"Participants will consume the amino acid-fortified oral rehydration therapy (fORT) according to the WHO Treatment Plan A for ORT administration:~Child under 24 months: 50 to 100 ml ORT after each loose stool (approximately 500 ml daily)~Child from 2 to 10 years: 100 to 200 ml ORT after each loose stool (approximately 1000 ml daily)"
89218796|NCT06137014|Placebo Comparator|Standard of care oral rehydration therapy|"Participants will consume the standard of care oral rehydration therapy according to the WHO Treatment Plan A for ORT administration:~Child under 24 months: 50 to 100 ml after each loose stool (approximately 500 ml daily)~Child from 2 to 10 years: 100 to 200 ml after each loose stool (approximately 1000 ml daily)"
89218797|NCT06136988|Experimental|HB1801 and SG001 in combination with cisplatin and simultaneous radiotherapy|SG001 360 mg, Intravenous infusion, D1, Q3W, up to approximately 2 years ; Docetaxel for Injection (Albumin-bound) (HB1801), Intravenous infusion, D1, Q3W, 60 or 75 mg/m^2, up to 2 cycles; cisplatin for injection 25 mg/m^2, D1-D3, Q3W, up to 2 cycles; radiotherapy (28×1.8Gy).All treatments will be administered until disease progression or intolerable toxicity.
89218798|NCT06136988|Active Comparator|Paclitaxel in combination with cisplatin and simultaneous radiotherapy|Paclitaxel 135 mg/m^2, Intravenous infusion, D1, Q3W; cisplatin for injection 25 mg/m^2, D1-D3, Q3W, radiotherapy (28×1.8Gy). No other systemic antineoplastic therapy is allowed until disease progression, optimal supportive care and local palliative care are allowed.
89218799|NCT06136975||genitourinary symptoms of menopause|Women with genitourinary symptoms of menopause (GSM). Menopause was defined as no spontaneous menstruation for at least one year. GSM defined as vulvovaginal dryness and related symptoms, such as irritation, dyspareunia, or lower urinary tract symptom (LUTS) including urinary urgency, dysuria and recurrent urinary tract infection after menopause .
89218800|NCT06136975||stress urinary incontinence|Women with stress urinary incontinence (SUI). SUI was defined as involuntary loss of urine on effort or physical exertion including sporting activities, or on sneezing or coughing.
89218801|NCT06136910|Experimental|H101 combined with tirilizumab and platinum-containing two-drug chemotherapy|"Recombinant human adenovirus type 5 injection(H101), intratumoural, administered for 4 cycles, 1 injection on day 1 (d1) of each cycle.The number of injections should be determined according to the patient's tolerance and the ease of manipulation of the injection site, and should be no less than 2 times.~Tirilizumab injection, 200 mg, IV, d1, Q21d, administered until disease progression or intolerable side effects occur~Platinum-containing two-agent chemotherapy Adenocarcinoma: pemetrexed plus carboplatin Non-adenocarcinoma: paclitaxel/gemcitabine combined with carboplatin"
89218802|NCT06136858||healthy volunteers|participants of the Airway management Course in Copenhagen Denmark 2023
89218803|NCT06136845||non anastomotic leak|Non anastomotic clinical leak'
89218804|NCT06136845||anastomotic clinical leak|anastomotic clinical leak'
89218805|NCT06136806||Multisite Artery Disease (MAD) Group|Participants in MAD group mean these patients are suspected with multisite artery disease, like coronary artery disease accompany with renal artery stenosis or lower extremity atherosclerosis.
89218806|NCT06136806||Venous Thromboembolism （VTE）Group|Participants in VTE group mean these patients are suspected with deep vein thrombosis or pulmonary embolism.
89218807|NCT06136780|Experimental|Experimental|Free reading glasses immediately after cataract surgery
89218808|NCT06136780|No Intervention|Control|Free reading glasses will be given 4 months after cataract surgery
89218809|NCT06136702|Active Comparator|Educational session and follow-up assessment|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake
89218810|NCT06136702|Experimental|Educational session, self-sampling and follow-up assessment|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. In addition, women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site. The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time.
89218811|NCT06136689||Severe Aortic Stenosis - High Flow, High Gradient|patients undergoing surgical aortic valve replacement for severe AS
89218812|NCT06136689||Severe Aortic Stenosis - classical Low Flow, Low Gradient|patients undergoing surgical aortic valve replacement for severe AS
89218813|NCT06136689||Severe Aortic Stenosis - paradoxical Low Flow, Low Gradient|patients undergoing surgical aortic valve replacement for severe AS
89218814|NCT06136689||Moderate Aortic Stenosis|patients undergoing aortic root replacement (Bentall procedure)
89218815|NCT06136689||Heart Transplant|patients undergoing orthotopic heart transplant for any reason
89218816|NCT06136676|Experimental|Heart-centred spiritual meditation|Intervention 1: Christian contemplation and Intervention 2: Islamic contemplation
89218817|NCT06136676|Active Comparator|Mindfulness Meditation (MBRS)|Intervention 3: Mindfulness Meditation (MBRS)
89523269|NCT03383393||adenosine|Intracoronary bolus of adenosine (adenocor)
89218818|NCT06136676|No Intervention|Waitlist control|No Intervention: Participants in this condition will not receive any intervention and the outcome measures will be only collected at time points T1 and T2. After T2 testing, they will be given access to either the Christian or Islamic intervention.
89218819|NCT06136663||Pain-free control subjects|Patients with no postoperative chronic pain after open reduction and internal fixation of lower limb fractures.
89218820|NCT06136663||Patients with chronic postsurgical pain|Patients with postsurgical chronic pain after open reduction and internal fixation of lower limb fractures.
89218821|NCT06136611|Experimental|Optune|Patients will apply TTFields (a treatment device referred to as Optune) before surgery and continue using this once the stitches are removed (approximately one to two weeks after surgery). Patients will wear the Optune application for 2 to 3 weeks before their standard-of-care (SoC) surgery and 3 to 4 weeks after the surgery (while awaiting their postoperative radiotherapy). Treatment with TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
89218822|NCT06136611|No Intervention|Non-Experimental Arm|Patients will follow the routine care pathway for glioblastoma and timings of the following will be determined by the clinical team.
89523270|NCT03383393||GP IIb/IIIa|Intracoronary bolus of Integrilin (eptifibatide)
89522736|NCT03391609|Active Comparator|Dex. group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
89522737|NCT05238077|Other|VL-UVA1 vs NB-UVB|Participants will be treated with both VL-UVA and NB-UVB on different areas
89522738|NCT03391531|Active Comparator|levobupivacaine|Echo-guided bilateral subcostalTAP block will be performed using levobupivacaine [Chirocaine®] 0.375% Epi 1/200000.
89218823|NCT06136520|Experimental|experimental group|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
89218824|NCT06136520|No Intervention|Control group|The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher.
89218825|NCT06136429|Experimental|TAVR Treatment Group|
89218826|NCT06136416|Experimental|Patients with Non-dystrophic myotonias|
89218827|NCT06136377|Experimental|RIV treatment with 177Lu-PSMA-617.|
89218828|NCT06136364|Experimental|CD 7 CAR-T|
89218829|NCT06136338|Experimental|Mindfulness intervention group|intervention + routine care
89218830|NCT06136338|No Intervention|Control group|routine care
89218831|NCT06136312|Experimental|Multi4 procedure|Complete TURBT procedure performed in local anesthesia with Multi4 instrument via flexible cystoscopy
89218832|NCT06136299|No Intervention|Control - Standard warm-up|This group performed a standard warm-up protocol during their soccer practice sessions.
89218833|NCT06136299|Experimental|Intervention - NMT|This group performed a specific Neuromuscular Training (NMT) warm-up program known as FIFA 11+ Kids during their soccer practice sessions
89218834|NCT06136286|No Intervention|Control|Standard of care postoperative rehabilitation. Subject will undergo standard rehab following surgery without BFR.
89218835|NCT06136286|Experimental|Intervention - Blood Flow Restriction Therapy (BFR)|Subjects will undergo standard postoperative rehabilitation that incorporates BFR during certain exercises.
89218836|NCT06136169|Experimental|StudyArm|Participants will receive reminder-cue scanning training in a driving simulator.
89218837|NCT06136143|Active Comparator|Group 1: Autogenous bone graft|The maxillary sinus will treated with autogenous bone graft.
89218838|NCT06136143|Experimental|Group 2: Plenum® Osshp|The maxillary sinus will treated with Plenum® Osshp.
89218839|NCT06136143|Experimental|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will treated with Plenum® Osshp associated with i-PRF (i-PR - injectable platelet-rich fibrin).
89218840|NCT06136143|Experimental|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will treated with Plenum® Osshp associated with autogenous bone graft.
89218841|NCT06136130|Experimental|Positioning Material|"Preterm infants in Intervention group were placed in the nest with positioning material and placed in lateral and prone positions~The positioning material and hand-face maneuver were applied together to the preterm infants in the intervention group, and they were given lateral and prone positions in this way in the second day"
89218842|NCT06136130|No Intervention|Standard Care|Standard care was used
89218843|NCT06136104|Experimental|Mixhers HERTIME|1 daily powder stick packet (3.0-3.3 g) of Mixhers HERTIME herbal supplement mixed into water
89218844|NCT06136104|Placebo Comparator|Placebo|1 daily powder stick packet (3 g) of a matching placebo powder supplement mixed into water
89218845|NCT06136065|Experimental|Arm 1|50 patients with solid tumor and 18-Fluorine-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose Positron emission tomography / Computerized tomography scan dubious
89218846|NCT06136039|Experimental|Sarcopenia|Patients were categorized into preoperative sarcopenia
89218847|NCT06136039|No Intervention|normal|normal groups according to the AWGS 2019 criteria.
89218848|NCT06136026||Rectal cancer cohort|20,000 patients with rectal cancer will be included in this cohort and followed for five years.
89218849|NCT06136026||Colon cancer cohort|20,000 patients with colon cancer will be included in this cohort and followed for five years.
89218850|NCT06136026||Colorectal adenoma cohort|10,000 patients with colorectal adenomas will be enrolled in this cohort and followed for five years.
89218851|NCT06136013|Experimental|Morning HIIT 30-min following breakfast between 9:00 to 10:00 am.|The exercise prescription will be standardized according to body weight and based on physical activity guidelines to achieve a weekly target of 10 kcal/kg. The duration of the exercise sessions will be based on the weekly target for energy expenditure, considering weight and individual VO2peak and will be updated at the beginning of each intervention block.
89218852|NCT06136013|Experimental|Afternoon HIIT 30-min following lunch between 2:00 to 3:00 pm.|The exercise prescription will be standardized according to body weight and based on physical activity guidelines to achieve a weekly target of 10 kcal/kg. The duration of the exercise sessions will be based on the weekly target for energy expenditure, considering weight and individual VO2peak and will be updated at the beginning of each intervention block.
89218853|NCT06136013|Experimental|Evening HIIT 30-min following dinner between 7:00 to 8:00 pm.|The exercise prescription will be standardized according to body weight and based on physical activity guidelines to achieve a weekly target of 10 kcal/kg. The duration of the exercise sessions will be based on the weekly target for energy expenditure, considering weight and individual VO2peak and will be updated at the beginning of each intervention block.
89218854|NCT06135974|Placebo Comparator|Placebo|Vaginal placebo tablet administered daily for 7 days starting after antibiotic treatment
89218855|NCT06135974|Experimental|LC106 7 days|Vaginal live biotherapeutic product with 6 strains of L. crispatus, administered daily for 7 days after antibiotic treatment
89218856|NCT06135974|Experimental|LC106 3 days|Vaginal live biotherapeutic product with 6 strains of L. crispatus, administered daily for 3 days after antibiotic treatment and packaged with 4 tablets of placebo to maintain masking (so a total of 7 tablets)
89218857|NCT06135974|Experimental|LC106 7 days, early start|Vaginal live biotherapeutic product with 6 strains of L. crispatus, administered daily for 7 days starting on the 3rd day of antibiotic treatment
89218858|NCT06135974|Experimental|LC115|Vaginal live biotherapeutic product with 15 strains of L. crispatus, administered daily for 7 days after antibiotic treatment
89218859|NCT06135935|Experimental|No-added-sugar ice cream|KDD is developing a new line of no-added-sugar products in line with its metabolic reengineering initiative and its metabolic matrix. Four new flavored milks and four new ice creams all have no added sugar. Flavors include chocolate, vanilla, strawberry, and banana. The recipes fundamentally do not alter total saturated fat or protein levels and mainly offer the benefit of no added sugar and a significant reduction in net carbohydrates as well glycemic index.
89218860|NCT06135935|Active Comparator|conventional products|KDD has been a leading manufacturer of food and beverages with added sugar (conventional products). The majority of people with type 2 diabetes consume their food products.
89218861|NCT06135922|Experimental|Experimental: EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10^6/kg to 1×10^8/kg EBV-TCR-T cells per dose
89218862|NCT06135896|Experimental|Treatment Group|"Premedication: depending on the center (Ondansetron 8 mg +Dextrose 5% 50 mL, MIV, Dexamethason 10 mg IV, and Atropine sulfate 0.25 mg [0.5 amp] SC)~Onivyde 70 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 90 min~Leucovorin 400 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 30 min~5-FU (2400 mg/m2) + Dextrose 5% 500 mL (bag) and MIV for 46 h~Tripegfilgrastim 6 mg SC administered 24 h after completing 5-FU infusion The above chemotherapy will be administered every two weeks"
89218863|NCT06135896|No Intervention|Control Group|"Premedication: depending on center (Ondansetron 8 mg+Dextrose 5% 50 mL, MIV, Dexamethason 10 mg IV, and Atropine sulfate 0.25 mg [0.5 amp] SC)~Onivyde 70 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 90 min~Leucovorin 400 mg/m2 + Dextrose 5% 500 mL (bag), and MIV for 30 min~5-FU (2400 mg/m2) + Dextrose 5% 500 mL (bag), and MIV for 46 h The following medication will be provided in the event that the patient develops febrile neutropenia after the above chemotherapy~Tripegfilgrastim 6 mg SC administered 24 h after stopping 5-FU. In the event of neutropenia, chemotherapy will be paused until the patient recovers, and then restarted after recovery.~The above chemotherapy will be administered every two weeks."
89218864|NCT06135883||Case|Singleton pregnant women over the age of 18 and under the age of 45 who have at least one of the risk factors for neural tube defects (family history, MTHFR gene mutation, birth history with aneuploidy, history of GDM or known DM).
89218865|NCT06135883||Control|Singleton pregnant women over 18 years of age and under 45 years of age who do not have any risk factors for neural tube defects
89218866|NCT06135857|Experimental|Intervention group|
89218867|NCT06135857|No Intervention|Control group|
89218868|NCT06135844|Experimental|Treatment Group (Hand Sanitizer)|Participants with an early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom), with the visible manifestation of a lesion will be invited to participate in the study. Participants will apply a large drop of hand sanitizer in an unmarked container to a Q-tip and will hold the Q-tip on the lesion for 10 seconds. The hand sanitizer will be administered every waking hour in the same manner.
89218869|NCT06135844|Placebo Comparator|Control Group (Medical Grade Mineral Oil)|Participants with an early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom), with the visible manifestation of a lesion will be invited to participate in the study. Participants will apply a large drop of Medical Grade Mineral Oil in an unmarked container to a Q-tip and will hold the Q-tip on the HSV-1 lesion for 10 seconds. The medical grade mineral oil will be administered every waking hour in the same manner.
89218870|NCT06135818|Experimental|Patients with suspected extrapulmonary tuberculosis|Patients with pleural, pericardial, or peritoneal effusions due to suspected extrapulmonary tuberculosis and those with suspected TB meningitis.
89218871|NCT06135805|Experimental|Active Comparator: Fluocinonide 0,,05% oral gel|Patients were treated with a topical gel of Fluocinonide 0.05%, applied to oral lesions twice daily for 1 month.
89218872|NCT06135805|Placebo Comparator|Placebo Comparator: Placebo|Patients were treated with a topical gel of placebo, applied to oral lesions twice daily for 1 month.
89059054|NCT05924854|Experimental|Electroacupuncture group (E group)|When the patient's vital signs are stable, the blind researcher (acupuncturist) checks the electroacupuncture device, (SDZ-Ⅱ, Suzhou Medical Supplies Factory),after the check is been done, acupuncturist uses Huatuo brand copper milli-needle needles to pierce Baihui point（DU20）, Shenting point (DU24), bilateral Zulinqi (GB41) and bilateral Taichong (LR3) , and fixed and connection them to SDZ-Ⅱ..At first, sets the device output to zero ,then .the acupuncturist turns on the power of the treatment instrument with the output frequency from 50 to 100hz on a weak to strong wave mode continuously , 20 min after the intervention, stops the machine, the acupuncturist turns off the device and pulls out the needles.
89059055|NCT05924854|No Intervention|sevoflurane general anesthesia group（S group）|Anesthesia induction, anesthesia maintenance and anesthesia monitoring will carry out exactly the same in both groups,only difference is that S group has no electroacupuncture intervention.
89059056|NCT05921916|Experimental|MBF-118 100mg oral single dose|Drug: MBF-118 100mg oral capsules single dose Hard gelatin capsules
89059057|NCT05921916|Experimental|MBF-118 200 mg oral single dose|Drug: MBF-118 200mg oral capsules single dose Hard gelatin capsules
89059058|NCT05921916|Experimental|MBF-118 400 mg oral single dose|Drug: MBF-118 400mg oral capsules single dose Hard gelatin capsules
89059059|NCT05921916|Experimental|MBF-118 100 mg oral multiple dose|"Drug: MBF-118 100mg oral capsules multiple dose. One single daily dose during five days.~Hard gelatin capsules"
89059060|NCT05921916|Experimental|MBF-118 200 mg oral multiple dose|"Drug: MBF-118 200mg oral capsules multiple dose. One single daily dose during five days.~Hard gelatin capsules"
89059061|NCT05921916|Experimental|MBF-118 400 mg oral multiple dose|"Drug: MBF-118 400mg oral capsules multiple dose. One single daily dose during five days.~Hard gelatin capsules"
89059062|NCT05921916|Placebo Comparator|Placebo oral single dose|Placebo: Hard gelatin capsules single dose
89059063|NCT05921916|Placebo Comparator|Placebo oral multiple dose|Placebo: Hard gelatin capsules. One single daily dose during five days.
89059064|NCT05921916|Experimental|MBF-118 600 mg oral single dose|Drug: MBF-118 600mg oral capsules single dose Hard gelatin capsules
89059065|NCT05918822|Experimental|Part 1, Sequence 1: Treatment A + Treatment B + Treatment C|Participants will receive maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 1 under fasting condition (Treatment A), followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 2 under fasting condition (Treatment B), and further followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal (Treatment C). There will be a washout period of a minimum of 72 hours between each treatment.
89059066|NCT05918822|Experimental|Part 1, Sequence 2: Treatment A + Treatment C + Treatment B|Participants will receive maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 1 under fasting condition (Treatment A), followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal (Treatment C), and further followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 3 under fasting condition (Treatment B). There will be a washout period of a minimum of 72 hours between each treatment.
89059067|NCT05918822|Experimental|Part 1, Sequence 3: Treatment B + Treatment A + Treatment C|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 under fasting condition (Treatment B), followed by maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 2 under fasting condition (Treatment A), and further followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal (Treatment C). There will be a washout period of a minimum of 72 hours between each treatment.
89522739|NCT03391531|Placebo Comparator|Saline|Echo-guided bilateral subcostal TAP block will be performed with saline Epi 1/200000 in the control group.
89059068|NCT05918822|Experimental|Part 1, Sequence 4: Treatment B + Treatment C + Treatment A|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 under fasting condition (Treatment B), followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal (Treatment C), and further followed by maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 3 under fasting condition (Treatment A). There will be a washout period of a minimum of 72 hours between each treatment.
89059069|NCT05918822|Experimental|Part 1, Sequence 5: Treatment C + Treatment A + Treatment B|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 2 under fasting condition (Treatment A), and further followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 3 under fasting condition (Treatment B). There will be a washout period of a minimum of 72 hours between each treatment.
89059070|NCT05918822|Experimental|Part 1, Sequence 6: Treatment C + Treatment B+ Treatment A|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 2 under fasting condition (Treatment B), and further followed by maribavir single 200 mg commercial tablet, on Day 1 of Treatment Period 3 under fasting condition as (Treatment A). There will be a washout period of a minimum of 72 hours between each treatment.
89059071|NCT05918822|Experimental|Part 2: Treatment D: maribavir 200 mg|Participants will receive maribavir 200 mg pediatric powder-for-oral suspension, single oral dose on Day 1 of Treatment Period 1 under fasting condition (Treatment D).
89059072|NCT05918822|Experimental|Part 2, Treatment E: rabeprazole 20 mg + maribavir 200 mg|Participants will receive rabeprazole single 20 mg tablet, once daily on Days 1 to 5 of Treatment Period 2 under fasting condition followed by maribavir 200 mg pediatric powder-for-oral suspension, single oral dose, 2 hours after rabeprazole dosing on morning of Day 5 of Treatment Period 2 under fasting condition (Treatment E). There will be a washout period of a minimum of 72 hours between maribavir dosing in Treatment Period 1 and first dose of rabeprazole in Treatment Period 2.
89059073|NCT05916300||Standard physiotherapy group|Patients will be treated with standard physiotherapy according to the recommendation of the referring physician without modification of the treatment based on the output of the diagnostic ultrasonography examination.
89059074|NCT05916300||Diagnostic ultrasonography-guided physiotherapy group|Patients will undergo modified treatment techniques, the application of which will be indicated based on the initial diagnostic ultrasonographic examination.
89059075|NCT05899582|Experimental|Surgery|The patients in the surgical group will be treated with direct extracranial to intracranial bypass surgery plus best medical treatment.
89059076|NCT05899582|Active Comparator|Medical treatment|The patients will receive medical treatment alone according to the AHA/ASA Stroke and Transient Ischemic Attack (TIA) Stroke Prevention Guidelines (2021 edition).
89059077|NCT05895838|Experimental|Dexamethasone intervention, active|"As soon as possible after hospital admittance 20 mg of dexamethasonephosphate (Dexavit, Vital Pharma Nordic ApS, Denmark) will be given intravenously (i.v.) over 15 minutes - followed by 20 mg dexamethasonephosphate (or placebo) i.v. administered daily at 0600 (or at least 8 hours after initial dose) for two days, for a total of 3 doses.~For this arm the dexamethasonephosphate solution is provided in the DANOHCA trial kit in the form of Dexavit at a concentration of 4mg/mL stored in glass vials of 5mL; three vials are provided in total."
89059078|NCT05895838|Placebo Comparator|Dexamethasone intervention, placebo|"As soon as possible after hospital admittance placebo (isotonic saline) will be given intravenously (i.v.) over 15 minutes - followed by placebo solution administered i.v. daily at 0600 (or at least 8 hours after initial dose) for two days, for a total of 3 doses.~For this arm the placebo solution is provided in the DANOHCA trial kit in the form of isotonic sodium chloride stored in glass vials of 5mL; three vials are provided in total."
89059079|NCT05895838|Experimental|Backrest elevation intervention, elevation to 35 degrees|As soon as possible after hospital admittance the patients will have their headrest positioned at 35 degrees straight elevation of backrest in Semi-Fowler's position (elevated lower limp position). This position will be maintained during the initial 72 hours or until extubated. Adherence to assigned stratum will be checked every 8 hours and cuff pressure will be assessed and corrected if needed at the same time during the intervention period. The backrest position intervention may be temporarily canceled by the treating physician if needed for procedures or mobilization but will return to the assigned position if invasive ventilator treatment with orotracheal intubation is continued. The intervention will be terminated if the patient is extubated, or a tracheostomy is performed, during the intervention period of 72 hours.
89059080|NCT05895838|Active Comparator|Backrest elevation intervention, elevation to 5 degrees|As soon as possible after hospital admittance the patients will have their headrest positioned at 5 degrees straight elevation of backrest in Semi-Fowler's position. This position will be maintained during the initial 72 hours or until extubated. Adherence to assigned stratum will be checked every 8 hours and cuff pressure will be assessed and corrected if needed at the same time during the intervention period. The backrest position intervention may be temporarily canceled by the treating physician if needed for procedures or mobilization but will return to the assigned position if invasive ventilator treatment with orotracheal intubation is continued. The intervention will be terminated if the patient is extubated, or a tracheostomy is performed, during the intervention period of 72 hours.
89059081|NCT05895838|Experimental|Early wake-up intervention, wake-up ≤6 hours after ICU admission|"Patients will be subjected to a wakeup call and potential extubation after ≤6 hours after admission to the ICU. Definition for ready for extubation will be: GCS≥12, RASS 0- -1, able to raise arm or voluntary hand shake on command, spontaneous breathing trial and low ventilator settings (pressure support≤14, PEEP≤8 (10 if obese), and FiO2≤40%). A wakeup call may be aborted for the following reasons: seizures, respiratory distress, shock, or other cause with specification. Sedation prior to the scheduled wakeup calls is permitted in this early wakeup call group as needed for clinical care, while it is mandatory for the late wakeup call group. For both groups sedation as needed for clinical care will be permitted after the scheduled wakeup calls.~For this arm, information on the assigned time for wakeup call is provided in the DANOHCA trial kit. The assigned time for wakeup will be noted in the electronic patient file."
89059082|NCT05895838|Active Comparator|Early wake-up intervention, wake-up 28-36 hours after ICU admission|"Patients will be subjected to a wakeup call and potential extubation after 28-36 hours after admission to the ICU. Definition for ready for extubation will be: GCS≥12, RASS 0- -1, able to raise arm or voluntary hand shake on command, spontaneous breathing trial and low ventilator settings (pressure support≤14, PEEP≤8 (10 if obese), and FiO2≤40%). A wakeup call may be aborted for the following reasons: seizures, respiratory distress, shock, or other cause with specification. Sedation prior to the scheduled wakeup calls is mandatory for this late wakeup call group. For both groups sedation as needed for clinical care will be permitted after the scheduled wakeup calls.~For this arm, information on the assigned time for wakeup call is provided in the DANOHCA trial kit. The assigned time for wakeup will be noted in the electronic patient file."
89059083|NCT05895838|Experimental|Olanzapine intervention, active|"As soon as possible after arriving at the ICU olanzapine 10mg (dissolved tablet) is administered by feeding tube. Thereafter 10 mg olanzapine is administered by feeding tube (or orally in awake patients) the following two evenings at 1800 (with a minimum of 12 hours between the initial doses) for a total of 3 doses. Due to the potential QT-prolonging effect, and concern for arrythmia, patients will be excluded prior to randomization if Long QT Syndrome (LQTS) is suspected, and telemetry of heart rhythm is mandatory for 96 hours or until life sustaining therapies are withdrawn. In case of delirium patients are treated according to standard care most often including dexmedetomidine, haloperidol or midazolam.~For this arm the olanzapine tablets are provided in the DANOHCA trial kit in the form of olanzapin 10mg tablets (Accord Healthcare B.V., The Netherlands); three tablets are provided in total. Prior to administration by feeding tube the tablets are dissolved in water."
89059084|NCT05895838|Placebo Comparator|Olanzapine intervention, placebo|"As soon as possible after arriving at the ICU a placebo tablet (dissolved) is administered by feeding tube. Thereafter placebo will be administered by feeding tube (or orally in awake patients) the following two evenings at 1800 (with a minimum of 12 hours between the initial doses) for a total of 3 doses. Due to the potential QT-prolonging effect of olanzapine, and accompanying concern for arrythmia, patients will be excluded prior to randomization if LQTS is suspected, and telemetry of heart rhythm is mandatory for 96 hours or until life sustaining therapies are withdrawn. In case of delirium patients are treated according to standard care most often including dexmedetomidine, haloperidol or midazolam.~For this arm the placebo tablets are provided in the DANOHCA trial kit in the form of placebo tablets manufactured by the Pharmacy of the Capital Region; three tablets are provided in total. Prior to administration by feeding tube the tablets are dissolved in water."
89059085|NCT05894291|Experimental|Swimmer Prone Position|
89059086|NCT05894291|Active Comparator|Prone position with arms alongside the body|
89059087|NCT05888896|Experimental|anti-hypertensive drugs|Methyldopa tablets 250 mg will be used oral to reduce hypertension
89059088|NCT05888896|Experimental|anti-hypertensive drugs+foot reflexology|Methyldopa tablets 250 mg and foot reflexology sessions for 8 weeks ( 30 min 2 times per week) will be used to reduce hypertension
89059089|NCT05886582|Experimental|Active Rotigotine (RTG)|Participants who are randomized to the active RTG arm will receive Neupro® RTG patches
89059090|NCT05886582|Placebo Comparator|Placebo|Participants who are randomized to placebo will receive transdermal patches that match the size and color of active Neupro®.
89059091|NCT05885932|Experimental|Drug-eluting stenting group|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus best medical treatment including Aspirin 100mg per day + Clopidogrel 75mg per day or Ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
89059092|NCT05885932|Active Comparator|Medical group|All the participants in this group will be given medical therapy including Aspirin 100mg per day + Clopidogrel 75mg per day or Ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
89059093|NCT05885763|Experimental|1-week, single arm, open label treatment phase|
89059094|NCT05884684|No Intervention|Post-Procedural Images Not Discussed with Participants|"During a lumbar epidural steroid injection under fluoroscopic guidance, images are taken as part of the procedure. Following the procedure, the surgeon who performed it will not discuss the images with the participants in this arm.~If participants request an explanation of the images, they will not be included in the analysis."
89059095|NCT05884684|Other|Post-Procedural Images Discussed with Participants|During a lumbar epidural steroid injection under fluoroscopic guidance, images are taken as part of the procedure. Following the procedure, the surgeon who performed it will discuss the images with the participants in this arm.
89059096|NCT05884671|Active Comparator|Sulpiride|All study participants receive both placebo and the active medication (sulpiride 400mg), in a within-subjects , double-blind, randomized design.
89059097|NCT05884671|Placebo Comparator|Placebo|All study participants receive both placebo and the active medication (sulpiride 400mg), in a within-subjects , double-blind, randomized design.
89059098|NCT05880667|Experimental|Adaptive Stereotactic Body Radiation|Simulation and treatment to be performed over 3-4 weeks per dose escalation
89059099|NCT05876286|Experimental|Attention Deficit Disorder With Hyperactivity|Patients with Attention Deficit Disorder With Hyperactivity. Same examinations than control group
89059100|NCT05876286|Active Comparator|Control|Healthy volunteers Same examinations than Attention Deficit Disorder With Hyperactivity group
89059101|NCT05873179||Role-playing for learning the clinical interview|
89059102|NCT05872581|Experimental|Hand scanner instant feedback|Hand scanner results only but no training videos will be provided.
89059103|NCT05872581|Experimental|Video training|A training video only but no hand scanner results will be provided.
89059104|NCT05872581|Experimental|Hand scanner and Video training|Both hand scanner results and a training video will be provided.
89059105|NCT05872581|No Intervention|Control group without intervention|No hand scanner results or training videos will be provided.
89059106|NCT05871151|Experimental|active taVNS + exercise|Participants who are randomized into the active taVNS + exercise group will receive 15 minutes of active taVNS prior to exercise sessions.
89059107|NCT05871151|Sham Comparator|sham taVNS + exercise|Participants who are randomized into the sham taVNS + exercise group will receive 0 mA of current for 15 minutes prior to exercise sessions.
89059108|NCT05868876|Experimental|The dose escalation stage, dose expansion stage of AK127 combination with AK104|The dose escalation stage： 5 dose groups were set up, which were 0.3mg/kg、1 mg/kg, 3 mg/kg, 7.5 mg/kg, 15 mg/kg Q3W in dose escalation stage; The dose expansion stage： 8 cohorts with different indications were included in each group with 10-20 subjects in dose expansion stage.
89059109|NCT05867316|Experimental|Unified Protocol|Unified Protocol-based treatment, with three sessions
89059110|NCT05866341|Active Comparator|Nitrate-rich Diet|Daily consumption of 200 mg nitrate via the consumption of 300 mL of a nitrate-rich lettuce juice beverage.
89059111|NCT05866341|Placebo Comparator|Nitrate-depleted Diet|Daily consumption of 300 mL of a nitrate-depleted lettuce juice beverage.
89059112|NCT05863702|No Intervention|Usual Care|
89059113|NCT05863702|Experimental|Penny text-messaging program|
89059114|NCT05855161|Experimental|Rebound therapy|The group that will perform exercises on a trampoline.
89059115|NCT05855161|Experimental|Control group|The group that will perform exercises on a stable surface.
89059116|NCT05854303||Opioid Cessation|Subjects able to complete opioid cessation.
89059117|NCT05854303||Non-Opioid Cessation|Subjects unable to complete opioid cessation.
89059118|NCT05848739|Experimental|Dose Escalation Phase|The dose cohorts will be 0.5, 1, 2, 4, and 8 mg/kg IV once weekly (QW)
89059119|NCT05848739|Experimental|Triple Negative Breast Cancer - Expansion phase|Triple Negative Breast Cancer Expansion phase n=30
89059120|NCT05848739|Experimental|Colon Rectal Cancer (CRC) Expansion phase|Expansion phase n=30
89059121|NCT05848739|Experimental|Cholangiocarcinoma - Expansion phase|cholangiocarcinoma Expansion phase n=30
89059122|NCT05848739|Experimental|Ovarian Carcinoma|Ovarian Carcinoma - Expansion phase n=30
89059123|NCT05846568|Experimental|Experimental Group: GR1801+Rabies vaccine(CHENGDA PHARMACEUTICALS)|"GR1801 injections are administered by wound infiltration injection or by intramuscular injection.GR1801 injections are a bispecific monoclonal antibody that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.~Dosage form:2mg/1mL/vial, liquid, Dosage: 0.05mg/kg of GR1801 Frequency/duration: at Day 0.~Rabies vaccine should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, 0.5 mL after reconstitution, Frequency/duration: at Day 0, 3, 7, 14, 28."
89218873|NCT06135792|Experimental|Arginine solution|Arginine treatment is performed outside the oral cavity (ex vivo) by immersing one side of a splint into a solution of arginine 1.5% (w/v). Treatment is performed 3 times a day for 30 min.
89059124|NCT05846568|Active Comparator|Control Group:HRIG（BOYA-BIO）+Rabies vaccine(CHENGDA PHARMACEUTICALS)|"HRIG is administered by wound infiltration injection or by intramuscular injection. Dosage form: 200 IU/2mL/vial, liquid, Dosage: 20 IU/kg, Frequency/duration: at Day 0.~Rabies vaccine should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, 0.5 mL after reconstitution, Frequency/duration: at Day 0, 3, 7, 14, 28."
89059125|NCT05845450|Experimental|Cohort 1: HER2 positive|"Patients selected for the presence of pMMR/MSS status and HER2 overexpression/amplification defined as HER2 IHC 3+ or IHC 2+/ISH+ will receive the HER2 directed ADC trastuzumab deruxtecan 5.4 mg/kg IV on day 1.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
89218874|NCT06135792|Placebo Comparator|Placebo|Placebo treatment is performed outside the oral cavity (ex vivo) by immersing one side of a splint into distilled water. Treatment is performed 3 times a day for 30 min.
89218875|NCT06135753|Experimental|Experimental: psychosomatic intervention based on cognitive restructuring followed by Museum Therapy|"A psychosomatic intervention based on cognitive restructuring will be used as the non-pharmacological therapeutic strategy and 4 sessions will be delivered every other week with a duration of 120 minutes each in a group format with 10 participants.~The museum therapy will include 4 sessions, directed by the clinical psychologist and a museum educator, aimed at facilitating emotional expressions and participants' behavioral activation. The sessions will be delivered starting 2 weeks after the last session of the psychosomatic intervention as part of the Benessere al Museo Project by Uffizi Galleries.~A final additional session will be proposed."
89218876|NCT06135753|Placebo Comparator|Placebo Comparator: Control condition followed by Museum Therapy|"The control condition will include 4 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) Guidelines (https://www.nice.org.uk/guidance/lifestyleandwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.~The museum therapy will include 4 sessions, directed by the clinical psychologist and a museum educator, aimed at facilitating emotional expressions and participants' behavioral activation. The sessions will be delivered starting 2 weeks after the last control group's session as part of the Benessere al Museo Project by Uffizi Galleries.~A final additional session will be proposed."
89218877|NCT06135727|Other|Pathology (glaucoma) arm|
89218878|NCT06135727|Other|Normal arm|
89218879|NCT06135675|Experimental|TNP-2092 capsules 100mg Twice daily(BID)|
89218880|NCT06135675|Experimental|TNP-2092 capsules 300mg BID|
89218881|NCT06135675|Experimental|TNP-2092 capsules 600mg BID|
89218882|NCT06135675|Placebo Comparator|TNP-2092 placebo capsules|
89218883|NCT06135636|No Intervention|Usual Care|No up-front education, routine counseling as per their primary provider's standard practice, and written education on cocooning and recommendation for partner Tdap vaccination provided upon completion of the postpartum survey
89218884|NCT06135636|Experimental|Upfront Education Only|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
89218885|NCT06135636|Experimental|Upfront Education and Vaccination Administration:|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery plus the option to receive Tdap at their convenience at the WIH obstetric care clinic.
89218886|NCT06135623||COVID-19 Group|Having a history of COVID-19 infection
89218887|NCT06135623||Non-COVID-19 Group|No history of COVID-19 infection
89218888|NCT06135610||Pre-COVID|Patients identified in Kern County who presented to the emergency department with a gunshot wound (GSW), stab wound, or assault between March 2019 and February 2020 The group was further sub-classified based on the incident zip code. Kern County zip codes were combined into urban regions as NW (zip codes:93312, 93314), NE (93301, 93305, 93306, 93308), SW (93311, 93313), and SE (93304, 93307, 93309, 93241), with a separate category defined as rural (outside Bakersfield city limits).
89218889|NCT06135610||COVID|Patients identified in Kern County who presented to the emergency department with a gunshot wound (GSW), stab wound, or assault between March 2020 - February 2021. The group was then further sub-classified based on the incident zip code. Kern County zip codes were combined into urban regions as NW (zip codes:93312, 93314), NE (93301, 93305, 93306, 93308), SW (93311, 93313), and SE (93304, 93307, 93309, 93241), with a separate category defined as rural (outside Bakersfield city limits).
89218890|NCT06135597||Aspergillosis|Patients with aspergillosis
89218891|NCT06135597||COVID|Patients with history of COVID infection and without aspergillosis
89218892|NCT06135597||Control|Patients without history of COVID infection and without aspergillosis
89218893|NCT06135584|Experimental|Pioglitazone metformin tablets|Pioglitazone metformin tablets 15mg/500mg (To control the fasting blood glucose below 7.0mmol/l, adjust the dose and dosage according to the blood glucose)
89218894|NCT06135584|Active Comparator|Other drug|Chinese patent medicine or Hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin and GLP1 ((To control the fasting blood glucose below 7.0mmol/l)
89218895|NCT06135584|Other|Drug-free|Drug-free
89218896|NCT06135571||Cohort of left-sided colorectal cancer|Patients underwent curative surgery with dissection of No.253 Lymph node
89218897|NCT06135558||T3|patient staged T3 without marginal acute inflammation
89218898|NCT06135558||MAI|patient with marginal acute inflammation
89218899|NCT06135558||T4|patient staged T4 without marginal acute inflammation
89218900|NCT06135532|No Intervention|Non-Periodontitis|Only received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.
89218901|NCT06135532|No Intervention|Non-Peridontitis with T2DM|Only received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.
89218902|NCT06135532|Active Comparator|Periodontitis|"The patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.~The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks."
89218903|NCT06135532|Active Comparator|Periodontitis with well-controlled T2DM|"The patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.~The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks."
89218904|NCT06135532|Active Comparator|Periodontitis with poorly-controlled T2DM|"The patients received instructions in proper self-performed plaque control measures, including brushing and interproximal cleaning with dental floss and interdental brushes.~The patients underwent quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment was completed in a total of 4 sessions in four weeks."
89218905|NCT06135480|Active Comparator|combined subcision with platelet-rich plasma and microneedling group|
89218906|NCT06135480|Active Comparator|combined subcision with saline and microneedling group|
89218907|NCT06135415|Experimental|Tirbanibulin 10 mg/g|Participants will apply tirbanibulin 10 mg/g ointment once daily for 5 consecutive days beginning on Day 1. All participants will be evaluated for efficacy, safety, and tolerability at Day 8, 15, 29, and 57. Participants who do not achieve complete clearance (CC) at Day 57 will receive a second 5-day course of the treatment. Participants receiving a second treatment course will also be evaluated for efficacy, safety, and tolerability at Day 64, 71, and 85.
89218908|NCT06135415|Placebo Comparator|Vehicle ointment|Participants will apply vehicle ointment once daily for 5 consecutive days beginning on Day 1. All participants will be evaluated for efficacy, safety, and tolerability at Day 8, 15, 29, and 57. Participants who do not achieve CC at Day 57 will receive a second 5-day course of the treatment. Participants receiving a second treatment course will also be evaluated for efficacy, safety, and tolerability at Day 64, 71, and 85.
89218909|NCT06135402|Experimental|Laser group|3 monthly fractional laser treatment according to the user manual (correct applicator, vulvar and vaginal preset). In between daily local skin care with a drug free product of patients' choice.
89218910|NCT06135402|Active Comparator|Clobetasol group|Maintenance treatment with vulvar TCS (clobetasol) application 2x/week. Instruction given at trial start and monthly check up for treatment control Daily local skin care with a drug free product of patients' choice.
89218911|NCT06135376|Active Comparator|Control groups with single intervention|The control groups will each receive a single intervention which will be selected at random.
89218912|NCT06135376|Experimental|Experimental group with 4 interventions|"2 Primary Health Care Centers (PHCCs) will receive the comprehensive multi-component intervention, which consists of four elements:~Option for deferred prescription fulfilment.~Education of staff regarding appropriate uses of antibiotics.~algorithm-driven decision support tool.~Feedback on individual and group performance. The training will be repeated at monthly intervals over the 6-month intervention period."
89523271|NCT03383393||Nitroglycerine|Intracoronary bolus of nitroglycerine (nitronal)
89218913|NCT06135363|Experimental|Multiple doses SC1011 300mg（A1）|Drug: SC1011 tablet, SC1011-matching placebo tablet; Treatment: Food intake prior to dosing
89218914|NCT06135363|Experimental|Multiple doses SC1011 400mg（A2）|Drug: SC1011 tablet; Treatment: Food intake prior to dosing
89218915|NCT06135350|Experimental|Treatment arm|
89218916|NCT06135350|Placebo Comparator|Placebo arm|
89218917|NCT06135285|Experimental|Control subjects|The subject will lie down on the Korus smart mattress. Korus will detect when the subject is in a prone (face-down) position and reposition the subject into a recovery (sideways) position.
89218918|NCT06135272|Active Comparator|Group A|Resin infiltration
89218919|NCT06135272|Experimental|Group B|Resin modified glass ionomer varnish
89218920|NCT06135272|Experimental|Group C|Light cured giomer varnish
89218921|NCT06135246|Active Comparator|Standard Care group|Participants will receive standard compression bandaging and wound care alone without high-intensity laser therapy. Bandaging will be applied weekly and wound care will be performed as per institutional protocols.
89218922|NCT06135246|Experimental|High Intensity laser therapy + Standard care group|Participants will receive high-intensity laser therapy 3 times per week for 8 weeks or until ulcer closure in addition to standard care.
89218923|NCT06135207||COVID-19 Group|Patients with a history of COVID-19 infection and experiencing symptoms of dysphagia.
89218924|NCT06135207||Non-COVID-19 Group|Patients who do not have a history of COVID-19 infection but experience symptoms of dysphagia.
89218925|NCT06135181|Experimental|0.03 mmol Gd/kg BAY1747846 and matching placebo|12 healthy male participants were planned to be enrolled into this arm, 9 on BAY1747846 and 3 on placebo
89218926|NCT06135181|Experimental|0.1 mmol Gd/kg BAY1747846 and matching placebo|12 healthy male participants were planned to be enrolled into this arm, 9 on BAY1747846 and 3 on placebo
89218927|NCT06135168|Experimental|PEG-rhGH with new preparation|
89218928|NCT06135168|Experimental|PEG-rhGH with present preparation|
89218929|NCT06135155|Experimental|PEG-rhGH with new preparation|
89218930|NCT06135155|Experimental|PEG-rhGH with present preparation|
89218931|NCT06135090|Experimental|Trauma Recovery Program (official title TBD)|The trauma recovery program (TRP) is a seven-session, peer-led, group program for family members/significant others of people with borderline personality disorder (BPD) and emotion dysregulation. It draws on principles of cognitive processing therapy for PTSD and cognitive behavioural conjoint therapy for PTSD to target PTSD symptoms in these individuals that are related to having a loved one with BPD or emotion dysregulation. As a peer-support model, it is not a psychotherapy. The TRP involves learning about common reactions to trauma and learning methods of challenging trauma-related beliefs that inhibit trauma recovery. Group members are asked to practice exercises outside of sessions that focus on challenging beliefs that fall into several key trauma-related themes.
89218932|NCT06135077|Experimental|T-PRF|
89218933|NCT06135077|Active Comparator|T-PRF/xenograft|
89218934|NCT06135064|Experimental|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets affected by PTSD.
89218935|NCT06135064|Sham Comparator|Sham stimulation|Sham stimulation that applies the device in the same way as verum but only delivers auditory sounds correspoding to the ultrasonic pulses.
89218936|NCT06135051|Experimental|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets affected by Alzheimer's disease.
89218937|NCT06135051|Sham Comparator|Sham stimulation|Sham stimulation that applies the device in the same way as verum but only delivers auditory sounds correspoding to the ultrasonic pulses.
89218938|NCT06135038|Active Comparator|Suprascapular nerve block with physical therapy|"Suprascapular Nerve Block was applied to Group I before physical therapy program.~After the nerve block, a physical therapy program including standard procedure was applied to the patients in Group 1."
89218939|NCT06135038|Active Comparator|Only physical therapy|Patients in group 2 were applied only a physical therapy program that included the same standard procedure as group 1.
89522740|NCT03394937|Experimental|Cohort 1 600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 600 µg ECI-006
89522741|NCT03394937|Experimental|Cohort 1 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 1800 µg ECI-006
89522742|NCT03394937|Experimental|Cohort 2 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 1800 µg ECI-006
89059126|NCT05845450|Experimental|Cohort 2: POLE/D1 mutated with ultra-mutated status (>100 Mut/Megabase)|"Patients selected for the presence of a proof-read domain pathogenic mutation of POLE/D1 associated with ultra-mutated status will receive a short-course preoperative immunotherapy treatment with the anti-PDL-1 monoclonal antibody durvalumab 1500 mg IV on day 1.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
89059127|NCT05845450|Experimental|Cohort 3: EGFR-dependent|"Patients selected for the presence of pMMR/MSS status, RAS and BRAF wild type status, PRESSING negative status and left-sided primary cancer will receive treatment with the anti-EGFR agent panitumumab 6 mg/kg IV on days 1 and 15.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
89059128|NCT05845450|Experimental|Cohort 4: pMMR/MSS status|"Patients selected for the presence of pMMR/MSS status and absence of HER2 overexpression/amplification, absence of POLE/D1 proof-read domain pathogenic mutation associated with ultra-mutated status will receive a short-course preoperative treatment with the anti-CTLA4 antibody botensilimab 1 mg/kg on day 1.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
89059129|NCT05845450|Experimental|Cohort 5: pMMR/MSS status|"Patients selected for the presence of pMMR/MSS status and absence of HER2 overexpression/amplification, absence of POLE/D1 proof-read domain pathogenic mutation associated with ultra-mutated status will receive a short-course preoperative treatment with the anti-CTLA4 antibody botensilimab 1 mg/kg on day 1 plus the anti-PD-1 balstilimab 3 mg/kg on days 1 and 15~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
89059130|NCT05845450|Experimental|Cohort 6: dMMR/MSI-H status|"Patients selected for the presence of dMMR/MSI-H status and absence of POLE/D1 proof-read domain pathogenic mutation associated with ultra-mutated status will receive a short-course preoperative treatment with the anti-CTLA4 antibody botensilimab 1 mg/kg on day 1.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
89059131|NCT05845450|Experimental|Cohort 7: dMMR/MSI-H status|"Patients selected for the presence of dMMR/MSI-H status and absence of POLE/D1 proof-read domain pathogenic mutation associated with ultra-mutated status will receive a short-course preoperative treatment with the anti-CTLA4 antibody botensilimab 1 mg/kg on day 1 plus the anti-PD-1 balstilimab 3 mg/Kg on days 1 and 15.~After receiving the short-course preoperative treatment, patients will undergo standard radical surgery. After surgery, patients will receive adjuvant chemotherapy as per national and international guidelines and according to the suggestion of a central multidisciplinary team. Then, standard follow up will be started as per local guidelines."
89059132|NCT05845450|Experimental|Cohort 8: KRAS G12C mutated|Patients selected for the presence of pMMR/MSS status and KRAS G12C mutation will receive a short-course preoperative targeted treatment with the KRAS G12C inhibitor sotorasib 960 mg orally once daily from day 1 to 28 plus the EGFR inhibitor panitumumab 6 mg/kg IV on days 1 and 15.
89059133|NCT05842213|Experimental|AVT05|"AVT05 is the proposed biosimilar to Simponi. Subjects in this arm will receive AVT05 50mg s.c. every 4 weeks until week 48.~Intervention: Biological: Golimumab"
89059134|NCT05842213|Active Comparator|Simponi|"Subjects in this arm will receive EU Simponi 50mg s.c. every 4 weeks until week 12. At week 16 responders will be re-randomized in a 1:1 ratio to receive either:~AVT05 50mg s.c. every 4 weeks until week 48 Simponi 50mg s.c. every 4 weeks until week 48 Intervention: Biological: Golimumab"
89059135|NCT05830942|Active Comparator|Walking Exercise plus active tDCS|The walking exercise will focus on use of complex walking tasks such as obstacle crossing, accurate foot placement, and walking on compliant surfaces. Each session will consist of 30 minutes of walking. Active tDCS will be delivered over prefrontal cortex.
89059136|NCT05830942|Sham Comparator|Walking Exercise plus sham tDCS|The walking exercise will focus on use of complex walking tasks such as obstacle crossing, accurate foot placement, and walking on compliant surfaces. Each session will consist of 30 minutes of walking. Sham tDCS will be delivered over prefrontal cortex.
89059137|NCT05826418|Experimental|MEND diet|patients being treated with FMT
89059138|NCT05826418|Active Comparator|mNICE (modified NICE) diet|patients being treated with FMT
89059139|NCT05821842|Experimental|Sonu Treatment Group|Patients will receive acoustic resonance therapy for 15 minutes, twice a day, for two weeks using Sonu.
89059140|NCT05821842|Sham Comparator|Sham Control Group|Patients will receive non-resonant acoustic energy for 15 minutes, twice a day, for two weeks using Sonu.
89059141|NCT05816083|Experimental|Virtual Reality|All participants will receive the same intervention
89522743|NCT03394937|Experimental|Cohort 2 3600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 3600 µg ECI-006
89522744|NCT04177381|Active Comparator|interrupted closure of subcutaneous tissue with dra|consist of 75 patients that will be allocated for interrupted closure of subcutaneous tissue with drain
89059142|NCT05811377|Experimental|ICE-MRI|Participants will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50 milliliter (mL) solution containing Gadobutrol (302mg) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.
89059143|NCT05809427|Experimental|Patient with periodental Disease|Imaging/Scanning and recording by Ultrasonic periodontal probing per operator Manual probing per operator with the OMS probe (part of the routine of care)
89059144|NCT05802225|Experimental|BCD-178 group|Neoadjuvant therapy stage (6 cycles, 18 weeks): BCD-178, Trastuzumab, Docetaxel, Carboplatin; Surgical treatment; Adjuvant therapy stage (up to 12 months of HER2-targeted therapy in total): BCD-178, Trastuzumab
89059145|NCT05802225|Active Comparator|Perjeta Group|Neoadjuvant therapy stage (6 cycles, 18 weeks): Perjeta, Trastuzumab, Docetaxel, Carboplatin; Surgical treatment; Adjuvant therapy stage (up to 12 months of HER2-targeted therapy in total): BCD-178, Trastuzumab
89059146|NCT05801835|Experimental|Sequence A (T-R)|(cytarabine: daunorubicin) liposome for injection followed by Vyxeos
89059147|NCT05801835|Experimental|Sequence B (R-T)|Vyxeos followed by (cytarabine: daunorubicin) liposome for injection
89059148|NCT05799482||Retrospective cross-sectional arm|One-to-one semi-structured interviews will be conducted with patients who have received care in the UHS COVID follow-up clinics in no more than 12 months prior to study enrolment. Interviews will be conducted at one time point
89059149|NCT05799482||Prospective, longitudinal arm|One-to-one semi-structured interviews will be conducted with patients with confirmed prior COVID-19 infection who are scheduled to receive care in the UHS COVID follow-up clinics. Interviews will be conducted before attending the first clinic appointment (baseline) and after discharge from the clinic (at 12 weeks).
89059150|NCT05797545|Experimental|Abbreviated Breast MRI for Breast Cancer Detection|Women are classified and randomly assigned into MRI sequence groups(1st round screening/2nd round screening : AB (abbreviated)-MRI / FP (full protocol)-MRI application group and FP (full protocol)-MRI / AB (abbreviated)). MRI (either AB-MRI or FP-MRI) assigned as the 1st round screening (baseline), mammography, and ultrasound are performed on the same day. For the 2nd round screening one year after the 1st round screening, a different MRI (i.e., FP-MRI if AB-MRI was performed in the previous year, AB-MRI if FP-MRI was performed in the previous year), mammography, and ultrasound were performed on the same day as the 1st round screening.
89059151|NCT05797545|Experimental|Full Protocol MRI for Breast Cancer Detection|Women are classified and randomly assigned into MRI sequence groups(1st round screening/2nd round screening : AB (abbreviated)-MRI / FP (full protocol)-MRI application group and FP (full protocol)-MRI / AB (abbreviated)). MRI (either AB-MRI or FP-MRI) assigned as the 1st round screening (baseline), mammography, and ultrasound are performed on the same day. For the 2nd round screening one year after the 1st round screening, a different MRI (i.e., FP-MRI if AB-MRI was performed in the previous year, AB-MRI if FP-MRI was performed in the previous year), mammography, and ultrasound were performed on the same day as the 1st round screening.
89059152|NCT05790681|Experimental|Participants with Type 2 Diabetes|Participants will receive single subcutaneous (s.c.) fixed dose of insulin icodec (700 units per milliliter [U/mL]) that is 5.6 units per kilogram (U/kg) bodyweight. Subjects will be followed up for 5 weeks after dosing.
89059153|NCT05781386|Experimental|SIM1811-03 monotherapy or SIM1811-03 in combination with Sintilimab injection|All participants receive SIM1811-03 or SIM1811-03 in combination with Sintilimab injection
89059154|NCT05780216|Experimental|DMT and harmine|"This arm comprises the following interventions:~Mindfulness Intervention in the course of the meditation group retreat~Administration of DMT + harmine (moderate-high dose)"
89059155|NCT05780216|Placebo Comparator|Placebo|"This arm comprises the following interventions:~Mindfulness Intervention in the course of the meditation group retreat~Administration of Placebo"
89059156|NCT05775627|Experimental|Sleep Restriction First|"Equivalent to obtaining 5.5.h of sleep per 24h; n=10. Participants live on a 20h-day and will experience 15.33h wake episodes followed by sleep episodes of 4.67h long.~Ad libitum food is provided during this time and participants will be fed ~130-150% of their daily caloric needs across three meals a day."
89059157|NCT05775627|No Intervention|Controlled Condition First|"Equivalent to obtaining 8h sleep per 24h; n=10. Participants live on a 20h-day and will experience 13.33h wake episodes followed by 6.67h sleep opportunities.~Ad libitum food is provided during this time and participants will be fed ~130-150% of their daily caloric needs across three meals a day."
89059158|NCT05770570|Experimental|ROADmAP schema|Participants will be randomly assigned to one of eight study groups which will be one or a combination of 4 conditions: (1) in person individualized diet and exercise counseling (2) diet and exercise text messages (3) weekly telephone support and (4) self-monitoring tools for diet and weight. For the first part of the study, Survey, approximately 64 drivers and 36 management staff will take pate in the feedback questionnaire. For the second part of the study, Interview, approximately 8 drivers and 12 management staff may be invited to take part in an interview via phone, in person, or teleconference (Zoom).
89522745|NCT04177381|Active Comparator|interrupted closure of subcutaneous tissue without dra|consist of 75 patients that will be allocated for interrupted closure of subcutaneous tissue without drain
89059159|NCT05770570|Other|Consumo de Opciones Mas Ideales De Alimento (COMIDA)|Participants will be placed in either individual or group interventions by convenience. Recruitment will be consecutive and participants will be placed in either intervention depending on what resource is available on a given day at the VDS, individual counselor or a group educator.
89059160|NCT05770570|Other|SANOS|Conducting SANOS Focus Groups. We will conduct 3-5 focus groups (in Spanish) with 6-10 participants each, until saturation. Bilingual study staff will approach individuals visiting the VDS and VDS Mobile for potential participation. A brief screening questionnaire will be administered, and a BMI assessment conducted, to ascertain eligibility. Focus groups will be scheduled at the VDS Mobile unit at times convenient to participants. Participants will be verbally consented in Spanish, and will be apprised that their participation is purely voluntary and that their names will not be included in the final narrative. The 6-month follow-up and my plate dietary surveys can be done over phone. Study staff will access step counts (or obtain it through phone via the pedometer manual provided to the participant) and upload data onto the REDCap tracking tool. Staff may ask participants to report step counts captured by their personal devices (i.e., phone or smartwatch).
89059161|NCT05768529|Experimental|U16|"Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to U16 infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
89059162|NCT05766631|Active Comparator|Methadone Treatment-as-Usual|Participants randomized to the Methadone Treatment-as-Usual (TAU) Condition will receive treatment-as-usual at the community methadone clinics, which will include daily medication, individual and group addiction counseling, and outpatient or intensive outpatient behavioral health services, depending on the clinic and the needs of the patient. After randomization into the TAU arm, participants will complete the program's psychosocial and medical intake, methadone dose induction and adjustment, and provide urine tests and receive medication take-homes per the program's policies and methadone treatment regulations.
89059163|NCT05766631|Experimental|DynamiCare Plus Methadone Treatment-as-Usual|DynamiCare Plus Methadone Treatment-as-Usual (DCM+TAU) participants will receive the same services as TAU participants, plus access to the DynamiCare Health smartphone app for 48 weeks. After randomization, the research assistant (RA) will download the DynamiCare Health app onto their smart phone (or provide them with a smartphone with the app already installed). Participants will get oral fluid testing kits and a Next Step debit card. Participants will be trained in use of the app and oral fluid test kits and will practice until they can produce two valid tests in a row without aid of the research staff. Participants will earn $40 for successful completion of the orientation and training. DCM+TAU participants will then use the app to complete remote random drug screenings, prove attendance to appointments and medication pickups, interact with modules designed to improve substance use reductions, and other treatment-related activities.
89059164|NCT05761847|No Intervention|Usual Care|The usual care group will receive standard-of-care medication management practices delivered during the course of a routine clinical visit.
89059165|NCT05761847|Experimental|Intervention|The intervention group will receive the pMTM study intervention before a routine clinical visit.
89059166|NCT05759078|Experimental|Active|an i.v. 15-minute infusion of 20 mL Ferinject (containing 1000 mg of FCM) diluted in 50 mL of NaCl 0.9%
89059167|NCT05759078|Placebo Comparator|Placebo|70 mL of i.v. NaCl 0.9% infusion
89059168|NCT05757882|Active Comparator|4H|Participants who are following the standard fasting time (4 hours).
89688846|NCT02825680|Experimental|LEAP Intervention|Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.
89688847|NCT00373672|Active Comparator|1|armodafinil (Nuvigil) 150 mg
89059169|NCT05757882|Experimental|2H|Participants who are following minimized fasting time (2 hours)
89059170|NCT05755776||ETV group|Participants in this group will continue ETV daily until the end of the study.
89059171|NCT05755776||TMF group|Participants in this group will switch to TMF 25 mg, daily until the end of the study.
89059172|NCT05753306|Experimental|Treatment (gastrectomy, HIPEC)|Patients undergo collection of stool and blood sample before and after surgery. Patients also undergo robotic gastrectomy and HIPEC with docetaxel and cisplatin on study. Patients undergo CT, MRI, or PET/CT scans throughout the trial.
89059173|NCT05752734||Group D|Patients who used/applied dexamethasone before bariatric surgery were included in this group.
89059174|NCT05752734||Group C|Patients who did not use dexamethasone or steroid-derived drugs were included in this group.
89059175|NCT05748522|Other|Shoulder Mobility|It is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands. This type of reach test has been described as a tool for measuring glenohumeral joint (GH) mobility through functional shoulder movements.
89059176|NCT05748522|Experimental|Diaphragmatic Breathing|The participant lies on his back. He places his hands horizontally on the lowest part of the ribs. While inhaling, he is asked to inflate his stomach towards the bottom of his hands. It is taught that during breathing, the abdomen should swell rather than the rib cage, and the ribs should open outwards. Breath is taken through the nose, blown slowly through the mouth.
89688848|NCT00373672|Placebo Comparator|2|identical in appearance to active comparator
89688849|NCT03032731|Experimental|Website and pedometer Intervention|Participants allocated to this group will be given a one-off set-up session in which a researcher will show them the intervention website, create a user profile for them and provide guidance on how to use the site to gain health information, set personal behavioural goals and record and monitor their behaviour in relation to their goals. The researcher will also provide the participant with a pedometer and instruct them how to use this and where they can record their daily steps on the website. For 6 weeks, participants will be asked to use the website and be sent weekly email reminders to do so and log their goal progress. After 6 weeks, no further emails will be sent but participants will still be able to access the website and use the pedometer if they wish.
89059177|NCT05744661|Experimental|Group A (Mechanical Method)|In Group A, Calcium Hydroxide Intracanal Medicament will be removed by using Mechanical Method in which Rotary Master Apical File will be used .
89059178|NCT05744661|Experimental|Group B ( Chemomechanical Method)|In Group B, Calcium Hydroxide Intracanal Medicament will be removed by using Chemomechanical Method which involves Sonic Agitation of Endodontic irrigants.
89059179|NCT05741905|Experimental|Levofloxacin group|Levofloxacin 200mg twice per day is administrated.
89059180|NCT05741905|Placebo Comparator|Levofloxacin simulant group|Levofloxacin simulant 200mg twice per day is administrated.
89059181|NCT05736445||Students at the University of Michigan|Students enrolled in the Winter 2023 academic semester at the University of Michigan
89059182|NCT05733832|No Intervention|Control group|Patients in the usual care arm will receive standard follow-up care from their usual providers based on recommendations made by inpatient providers at the time of discharge from the hospital.
89059183|NCT05733832|Active Comparator|Transitional Liver Clinic (TLC)|Enrolled patients discharged during the experimental TLC intervention implementation period will receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit with a hepatology APP within 14 days of discharge. TLC staff will provide additional care based on individual patient needs during the 30-day transitional period.
89059184|NCT05733585||Patients with abdominal aortic pathology|Patients with abdominal aortic pathology (aneurysmal or steno occlusive disease) candidate to open repair with PuraBond haemostatic agent.
89059185|NCT05732974||Resected early stage non small cell lung cancer|Early stage (IA-IIIA) resectable non small cell lung cancer patients receiving surgery
89059186|NCT05728866|Experimental|Virtual reality (VR) therapy|
89059187|NCT05728034|Experimental|Injectable PrEP information|A mock Google search results page with five search results that reflect five messaging strategies about injectable PrEP (response efficacy, social norms, exemplar, celebrity, and basic information), displayed in random order.
89059188|NCT05728034|Experimental|Oral PrEP information (Study 1 only)|A mock Google search results page with five search results that reflect five messaging strategies about oral PrEP (response efficacy, social norms, exemplar, celebrity, and basic information), displayed in random order.
89059189|NCT05726656|Experimental|wii console based exercise group|the patient will recieve wii console based exercise in addition to traditional physical therapy session
89059190|NCT05726656|Other|control group|the patient will recieve only the traditional physical therapy session
89059191|NCT05725018|Experimental|EB-101 Surgical application of RDEB wounds|New or Previously Treated RDEB Patients
89059192|NCT05724160|Other|NSLBP treated with Physiotherapy|32 patients with non-specific low back pain receiving routine protocol-based physiotherapy care by an expert.
89059193|NCT05724160|Other|NSLBP treated with Physiotherapy + Sitting ellipticals|32 patients with non-specific low back pain receiving routine protocol-based physiotherapy care by an expert together with planned training using sitting ellipticals
89059194|NCT05723471|Experimental|Adaptative Physical Activity|
89059195|NCT05723471|No Intervention|Standard Exercise|
89059196|NCT05722496|Experimental|High Intensity Interval Training Group (Group A)|"Each training session consist of three parts of 30 minutes:~Warm up (5 minutes) free active exercise of the lower extremities,~Training continued with three exercise intervals lasting 3 min each, at an exercise intensity of 85%-95% of HRpeak equalling 15-17 on the Borg scale. Each interval was separated by 4 min of active breaks at an intensity of 60%-70% of HRpeak.~Cool down (5 minutes) free exercise of lower extremities. Training program will last for 8 weeks with frequency 3times / week."
89059197|NCT05722496|Experimental|Moderate intensity continous training group (Group B)|"Each training session consist of three parts of 30 minutes:~Warm up (5 minutes) free active exercise of the lower extremities,~Training continued with cycling at low-to-moderate exercise intensity of 50%-60% of HRpeak, representing 11-13 on the Borg scale.~Cool down (5 minutes) free exercise of lower extremities. Training program will last for 8 weeks with frequency 3times / week."
89059198|NCT05717491||Main group|Cross-sectional study
89059199|NCT05717491||Sub group|Case control study
89059200|NCT05717049|Experimental|Treatment|12 week oral treatment (theophylline)
89059201|NCT05714033|Experimental|Group 1|Group 1, Participants will receive VESAP during the bronchoscopy. Ventilatory Strategy To Prevent Atelectasis versus a Lateral Decubitus Strategy During Robotic Bronchoscopy
89059202|NCT05714033|Experimental|Group 2|Group 2, Participants will receive LADS Lateral Decubitus Strategy During Robotic Bronchoscopy during the bronchoscopy.
89059203|NCT05711888|Experimental|Semantic information in Alzheimer Disease|To observe the semantic information processing in early stages of Alzheimer Disease is the main aim of the study. A paper-pencil neuropsychological assessment battery will be used. For memory testing FCSRT (free and cued selective reminding test) will be used. The patients are going to be assessed while in clinical diagnosis routine.
89059204|NCT05711056|Experimental|Sociobehavioral program Group|A novel sociobehavioral collaborative program that will improve the health of individuals in rural areas by expanding access to MOUD through an ED- based telemedicine strategy. Researchers will prospectively study a poison center OUD consultation and peer recovery coach (PRC) intervention as it is rolled out at each site, collecting participant-level data at baseline, one week post intervention and 30 days post intervention.
89059205|NCT05711056|No Intervention|Control Group|Patients who are seen at a participating hospital prior to the initiation of the intervention will be considered controls.
89059206|NCT05704387|Active Comparator|restrictive fluid therapy group|Patients in this group will have a restrictive fluid therapy (1 ml/kh/h) from anesthesia induction until end of liver resection.
89059207|NCT05704387|Experimental|individualized GDFT group|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommendation of the AFM software in order to optimize patient's stroke volume (SV)
89218940|NCT06135025|Active Comparator|TLM_group|the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned at the pneumology clinic which also unifies the criteria for monitoring and treatment of respiratory disease. Whenever patients came to the emergency room (ER), they were evaluated by the Pneumologist in charge, ergo maintaining a similar approach in the assessment of ERs and deciding whether the patient should be admitted or discharged, independently of their group assignment.
89218941|NCT06135025|No Intervention|STD_group|Patients in this group receive usual monitoring and treatment regimen is left to the discretion of the treating physicians. At inclusion, patients receive a phone call to collect data.at 1 month a Face to Face visit is planned at the pneumology clinic which also unifies the criteria for monitoring and treatment of respiratory disease. Whenever patients came to the emergency room (ER), they were evaluated by the Pneumologist in charge, ergo maintaining a similar approach in the assessment of ERs and deciding whether the patient should be admitted or discharged, independently of their group assignment.
89218942|NCT06135012|Experimental|Transection with CUSA|Transection of pancreatic tissue using cavitron ultrasonic surgical aspirator (CUSA) and using metal clips for closing small intraparenchymal blood vessels and pancreatic branch ducts.
89218943|NCT06135012|Sham Comparator|Transection with scalpel/stapler|Standard transection of pancreatic tissue with a surgical scalpel without selective closure of small blood vessels and branch pancreatic ducts (in pancreaticoduodenectomy).
89218944|NCT06134960|Experimental|KD-496 cell infusion|
89218945|NCT06134947||Group A|group A=75 patients as case group (children with Chronic Respiratory Disease)
89218946|NCT06134947||Group B|group B=75 children as control group (children with no Chronic Respiratory Disease).
89218947|NCT06134908|Experimental|Multifaceted Intervention|Group in the intervention arm will receive a multicomponent intervention at the clinician- and patient-level, with a shared decision-making booklet as well as a mobile application to promote osteoporosis management and fracture practice.
89218948|NCT06134908|No Intervention|Usual-care Control|Group in the control arm will receive a leaflet and routine medical care per their existing health care providers.
89218949|NCT06134895|Experimental|Tramadol with Ketamine|Tramadol 0.25mg/Kg with Ketamine 0.25 mg/Kg
89218950|NCT06134895|Active Comparator|Tramadol|Tramadol 0.5mg/kg
89218951|NCT06134882|Experimental|Abstinence reinforcement|Participants earn incentives for submission of salivary drug toxicology video selfies that show test results consistent with the goals of treatment. Goals are abstinence-based (i.e., relate to which tested substances should be negative on the test given the medications that the particular participant has been prescribed). Incentives are also provided for attendance at treatment-related appointments and for completion of self-paced cognitive behavior therapy modules available via the smartphone app.
89218952|NCT06134882|Sham Comparator|Sample-contingent control|Identical to the experimental group except that incentives are available only for submission of selfie-videos that show test results, without regard to the results of the salivary drug toxicology test. Similarly, incentives are not provided for appointments or completion of wellness modules, and instead are based only on use of the app.
89218953|NCT06134869|Other|Patients requiring horizontal bone augmentation in the posterior mandible|
89218954|NCT06134856|Experimental|Intervention|"Subjects assigned to the intervention group will then receive a talocrural joint high velocity, low amplitude thrush mobilization/manipulation. Standardized technique for this procedure involves the subject long-sitting with their back supported on the treatment table. The provider will then passively dorsiflex and evert the ankle to the point at which a joint tension end-feel is obtained.~A small amplitude of movement is rapidly provided by the provider in a caudal direction. The provider may attempt up to three treatment thrust impulses, or until an audible cavitation is heard, indicating joint movement. Even without an audible cavitation, no more than three impulses will be provided. Some research in other body regions indicates that treatment effect is present even in those with whom audible joint cavitation is not noted."
89218955|NCT06134856|Sham Comparator|Control|Subjects in the control group will receive 1 minute of passive ankle movement into ankle dorsiflexion. The researcher will not move the subjects ankle into a point where tissue stretch/tension is perceived. This will serve as an appropriate sham treatment since it still involves the subjects perception of treatment and includes the hands-on element of manual therapy, without the use of any tissue intervention which would theoretically effect change.
89218956|NCT06134843|Experimental|DERMASEAL|"DERMASEAL will be placed to completely cover the donor site wound. The entire site will then be covered with a transparent film dressing (TegadermTM, 3M) with at least 3 cm margin of normal skin under the film dressing before securing it with kerlix gauze and an ace wrap bandage placed circumferentially around the extremity.~The dressing will be left on the donor site wound until the wound is completely closed or changed at the discretion of the treating team."
89218957|NCT06134843|No Intervention|Standard of Care|"The donor site wound is covered with a transparent film dressing (TegadermTM, 3M) with at least 3 cm margin of normal skin under the film dressing. The dressing is then secured with kerlix gauze and ace wrap bandage placed circumferentially around the extremity.~The dressing will be left on the donor site wound until the wound is completely closed or changed at the discretion of the treating team."
89218958|NCT06134817|Experimental|Patients with Post TKA Knee Pain|Patients with persistent knee pain resistant to conservative management for at least 9 months after total knee arthroplasty (TKA) will receive geniculate artery embolization (GAE) using Embozene Color-Advanced Microspheres. Treatment will be completed during one interventional session.
89218959|NCT06134791||Cervicogenic headache with positive flexion-rotation test|Diagnosis of cervicogenic headache according to the ICHD-3 criteria. Age: 18+ years Headache for at least 1 day/week for at least 3 months Limited mobility of the neck Positive flexion-rotation test (<32 degrees on the left/right side or a difference of 10 degrees or more between left and right side) NPRS > 3/10
89218960|NCT06134791||Cervicogenic headache without positive flexion-rotation test|Diagnosis of cervicogenic headache according to the ICHD-3 criteria Age: 18+ years Headache for at least 1 day/week for at least 3 months Limited mobility of the neck Negative flexion-rotation test (>32 degrees on the left/right side or a difference of less than 10 degrees between left and right side) NPRS > 3/10
89218961|NCT06134778|Experimental|IMT group|Inspiratory muscle training group
89218962|NCT06134765|Experimental|Bemalenograstim alfa for the prevention of reduced ANC in patients with colorectal/pancreatic cancer|Patients with colorectal cancer and pancreatic cancer（N=32）receive FOLFOXIRI or mFOLFIRINOX with or without targeted therapy. Subcutaneous injection of Bemalenograstim alfa 20mg/ time 24-48h after each cycle of chemotherapy.
89218963|NCT06134765|Experimental|Bemalenograstim alfa for the prevention of reduced ANC in patients with colorectal cancer|Patients with colorectal cancer(N=57)receiving FOLFIRI with or without targeted therapy.Subcutaneous injection of Bemalenograstim alfa, 20mg/ time, 24-48h after each cycle of chemotherapy.
89218964|NCT06134739||Patients with embolism after ablation for atrial fibrillation (or left atrial flutter).|"The EMBOL-AF is a multicenter, international, observational study designed as a retrospective registry that will investigate the characteristics of systemic arterial embolic events after treatment of atrial fibrillation by catheter ablation. Due to the retrospective nature of the study, the registry is specially focused on cerebral embolism (stroke and TIA) because these are not only the most frequent and clinically relevant but also the most susceptible to underreporting. However, all embolism associated to AFAbl will be included.~This study will gather all clinically relevant aspects and data of all cases of arterial embolism that have occurred over the last 5 years in the centers that will participate in the registry. Based on these reported cases, the incidence, management and outcomes of embolic events (particularly stroke and TIA) will be studied."
89218965|NCT06134713|Experimental|Root canal treatment cryotherapy group|Conventional root canal treatment with final irrigation using sterile saline at 2.5ºC
89218966|NCT06134713|Experimental|Root canal RE-treatment cryotherapy group|Conventional root canal RE-treatment with final irrigation using sterile saline at 2.5ºC
89218967|NCT06134713|Active Comparator|Root canal treatment control group|Conventional root canal treatment with final irrigation using sterile saline at room temperature
89218968|NCT06134713|Active Comparator|Root canal RE-treatment control group|Conventional root canal RE-treatment with final irrigation using sterile saline at room temperature
89218969|NCT06134700|Experimental|Low pressure pneumoperitoneum laparoscopic nephrectomy|Pneumoperitonuem Pressure of 8 - 10 mmHg
89218970|NCT06134700|Active Comparator|Standard pressure pneumoperitoneum laparoscopic nephrectomy|Pneumoperitonuem Pressure of 12 - 15 mmHg
89218971|NCT06134674||Early Enteral Nutrition|Patients who received enteral nutrition within the first 48 hours following intubation were included in the Early Enteral Nutrition (EEN) group.
89218972|NCT06134674||Late Enteral Nutrition|Patients who received enteral nutrition 48 hours or later following intubation were included in the late Enteral Nutrition (LEN) group.
89218973|NCT06134661|Experimental|Single Arm: Treatment with cTBS|This is a single-arm study. All participants will receive the treatment with cTBS.
89218974|NCT06134635||Statin-alone group|The participants in statin-alone group receive statins alone for lipid reduction.
89218975|NCT06134635||PCSK9-i group|The participants in PCSK9-i group receive statins and evolocumab for lipid reduction.
89218976|NCT06134622|Experimental|Intravenous thrombolysis plus tirofiban administration|Patients will receive Intravenous thrombolysis and tirofiban administration
89218977|NCT06134622|Active Comparator|Intravenous thrombolysis plus placebo administration|Patients will receive Intravenous thrombolysis and placebo (saline) administration
89218978|NCT06134583|Active Comparator|Superior cervical ganglion block group (CSB)|standardized protocol + CSB
89218979|NCT06134583|Active Comparator|Stellate ganglion block group (SGB)|standardized protocol + SGB
89218980|NCT06134531|Experimental|MR001|The investigational product is MR001 which will be supplied in glass vials containing 50 mg of Freeze-dried powder. MR001 could be diluted in saline for intravenous (IV) administration.
89218981|NCT06134518|Experimental|intervention|The intervention group will receive the competency-based education program for 1 month at each PHC, after baseline data collection. The education program will be conducted weekly. This education session will be conducted for 4 hours per session, with 20 health cadres in a group per PHC .The competency level is measured by the researcher developing a competency questionnaire which consists of a knowledge test, skill, and attitude checklist score at the 2nd post-assessment (2 months after being given the education program).
89218982|NCT06134518|Experimental|control|Health cadres in the control group have received the initial orientation from the PHCs. In this study, they take only the competency questionnaires including skill check will be collected following the data collection timeline. After completing the research, the control group will receive the education program material used for the intervention group if they require.
89218983|NCT06134479|Active Comparator|150μg CFA at SD 1 following by rFSH 200IU daily from SD 8|
89218984|NCT06134479|Experimental|150μg CFA at stimulation day (SD) 1 and 100μg CFA at SD 5|
89218985|NCT06134427|Other|basic combat training|Pre experimental design, only one group with intervention basic combat training
89218986|NCT06134401|Experimental|Treatment|Nebulised 6% Hypertonic saline
89218987|NCT06134401|Placebo Comparator|Control|Nebulised 0.9% normal saline
89218988|NCT06134388|No Intervention|Control Group|This group will include 25 patients who will be scheduled to receive 6 cycles of 5-Fluorouracil and Oxaliplatin- based regimens every 2 weeks for 3 months.
89218989|NCT06134388|Active Comparator|Sulfasalazine Group|This group will include 25 patients who will be scheduled to receive 6 cycles of 5-Fluorouracil and Oxaliplatin- based regimens every 2 weeks plus sulfasalazine (1 gram orally twice daily) for 3 months.
89218990|NCT06134310|Active Comparator|Manual Therapy based Fascial Distortion Model|All participants were given manual therapy based on the Fascial Distortion Model in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Manual Therapy was conducted for forty-five minutes once a week in a clinical setting.
89218991|NCT06134310|Active Comparator|Core Stabilization Training|All participants were given manual therapy based on the Core Stabilization Training in addition to conventional therapy (Rocabado's 6x6 Exercises and Patient Education). Conventional therapy was implemented as a home program for 8 weeks, while Core Stabilization Training was conducted for forty-five minutes once a week in a clinical setting.
89218992|NCT06134310|No Intervention|Control|No participant was given any therapy during the study.
89218993|NCT06134297|Experimental|Aerobic Exercise Group|Aerobic exercise using a cycle ergometer lasting 15 consecutive minutes with load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age).
89218994|NCT06134297|Experimental|Anaerobic Exercise Group|Muscle strength training using shin guards and elastic bands to promote muscle overload, generating maximum force production, where the contraction time should not exceed 20 seconds.
89218995|NCT06134297|Experimental|Mixed Exercise Group|Exercises through alternation between aerobic and anaerobic overload (performing the exercises from the previously mentioned groups on alternate days), in a 1:1 ratio until the end of the physical rehabilitation program.
89218996|NCT06134271|Experimental|Rezvilutamide cohort|Rezvilutamide 240 mg orally once a day. Patients should also receive androgen deprivation therapy, which includes both gonadotropin releasing hormone analogue (GnRHa) castration treatment or bilateral orchiectomy.
89218997|NCT06134271|Experimental|Rezvilutamide plus abiraterone cohort|Rezvilutamide 240 mg orally once a day. Simultaneously, take orally 1000 mg of Abiraterone tablets and 5 mg of prednisone once a day. Patients should also receive androgen deprivation therapy simultaneously, that is, they should also receive gonadotropin releasing hormone analogue (GnRHa) castration treatment or have undergone bilateral orchiectomy.
89218998|NCT06134271|Experimental|Continue previous treatment cohort|Continue using the previous treatment regimen for treatment.
89218999|NCT06134232|Experimental|Booster Arm|"Experimental: Treatment Group: Single Infusion of Sipuleucel-T (Booster) Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion.~Subjects randomized to sipuleucel-T arm will receive 1 infusion of sipuleucel-T 6-9 months after receiving commercial Provenge. These subjects will be followed as described in the schedule of events."
89219000|NCT06134232|No Intervention|No Booster|No Intervention: Control Arm Subjects randomized to the control arm after receiving commercial Provenge will be followed as described in the schedule of events.
89219001|NCT06134206|Experimental|Burr hole sonography|Patients within this arm (only arm of the study) undergo burr hole sonography
89219002|NCT06134193|Experimental|HAIC, surufatinib and tislelizumab|
89219003|NCT06134128|Experimental|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|Motivationally Enhanced Compensatory Cognitive Training for Addictions (ME-CCT-A) is a manualized group-based behavioral intervention (8 weeks, 2 hour per week) designed to improve cognitive functioning in Veterans with substance use disorders (SUDs) and cognitive complaints.
89219004|NCT06134115|Experimental|Treatment group (Lipocet®)|Participants received Lipocet® (food supplement) 1 sachet orally once a day for 60 days
89219005|NCT06134115|Placebo Comparator|Control group (Placebo)|Participants received Placebo 1 sachet orally once a day for 60 days
89219006|NCT06134076|Experimental|Unfermented Chickpea|
89219007|NCT06134076|Experimental|Fermented Chickpea|
89219008|NCT06134063|Experimental|Experimental group|
89219009|NCT06134063|Placebo Comparator|Control group|
89219010|NCT06134050|Experimental|55% correction|HTO using PSI targeted at 55% correction axis
89219011|NCT06134050|Active Comparator|62% correction|HTO using PSI targeted at 62% correction axis
89059208|NCT05703568|Experimental|Group- based virtual reality training|Individuals in this arm will be received intervention protocol of group- based virtual reality training program in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
89059209|NCT05703568|Experimental|Individual virtual reality training|Individuals in this arm will be received intervention protocol of individual virtual reality training program in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
89059210|NCT05703568|No Intervention|Control group|Individuals in this arm will continue their routine daily activities.
89059211|NCT05700708||Cirrhosis with Refractory Ascites|
89059212|NCT05698888|Experimental|VP301 (Dose Escalation)|Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
89059213|NCT05698888|Experimental|VP301 (Dose Expansion)|Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will receive the maximum tolerated dose or recommended phase 2 dose during the Dose Expansion period of the study.
89059214|NCT05698368|Active Comparator|Active comparator group|A series of educational videos and reflective questions of the same duration and required attention as the mindset intervention program. The videos are sourced videos from YouTube that educate about osteoarthritis. The content consists of information about osteoarthritis that patients would typically receive if looking for more information about the disease, including disease pathology, risks, symptoms, and treatment strategies. The included videos contain factual content with a similar format to the mindset intervention videos, including live experts sharing information with animations and supplementary b-roll footage.
89059215|NCT05698368|Experimental|Mindset intervention group|Four modules, each with a series of videos and reflective questions. Each module takes approximately 20-60 minutes to complete, with a total of about two hours to complete the entire program. Participants have one week to complete the program at their own pace. Participants are suggested to complete one module per day but are encouraged to go at the pace that works best for them.
89059216|NCT05698368|No Intervention|Waitlist control group|This group will take the same surveys as the other groups at the same time points but will not receive any additional content.
89059217|NCT05698147|Experimental|X-MTX-Ritu|"Escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively respectively on day 1,8,15,22 for 28-days cycle.and the phase 2 expansion at the recommended dose level based on phase 1b trial. And，~Methotrexate 3.5 g/m2, d1 and Rituximab 375 mg/m2, d0, 28-days cycle.The total 6 cycles, 28 days per cycle."
89059218|NCT05696236|Experimental|Monitor (TEWL) and stopping rules|Wears the monitor, and the food challenge will be done using the new stopping rules to end the test.
89059219|NCT05696236|Active Comparator|Monitor (TWLG) without stopping rules|Wears the monitor, but the stopping rules will not be used to end the food challenge. The food challenge will be done following standard oral food challenge procedures.
89059220|NCT05693818||PersonaIQ|Patients indicated for a PersonaIQ total knee arthroplasty
89059221|NCT05689333|Experimental|27 GA Vista Ophthalmics vitrector|The vitrectomy will be performed through the pars plana using the 27 GA Vista Ophthalmics vitrector.
89059222|NCT05689268|Other|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
89059223|NCT05685251|Experimental|Health Coaching|
89059224|NCT05685251|No Intervention|Standard of Care|
89059225|NCT05684653|Experimental|Orelabrutinib Tablets|Subjects take Single dose of 50 mg orelabrutinib tablet under fasting state
89059226|NCT05684510|Experimental|Experimental : clear aligners with class II elastics technique|clear aligners technique A group of patients in which participants will be undergo to clear aligners treatment with class II elastics ( clear aligners will be applied to the upper and lower arch, then a class II elastics 1\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
89219012|NCT06134024|Experimental|LAMS with Double Pigtail Plastic Stents|The group of participants with post-inflammatory pancreatic and peripancreatic fluid collections with double pigtail plastic stents introduced through the LAMS during endoscopic transmural drainage.
89219013|NCT06134024|Active Comparator|LAMS without Double Pigtail Plastic Stents|The group of participants with post-inflammatory pancreatic and peripancreatic fluid collections without double pigtail plastic stents introduced through the LAMS during endoscopic transmural drainage.
89219014|NCT06134011||Cancer tissues|
89219015|NCT06134011||Normal adjacent tissues|
89219016|NCT06133998|Experimental|incentive spirometry with aerobic exercises|"Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~In sitting position, for the relaxation of body, patient will take a deep breath.~In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~We will check the dyspnea of the patient by the borage scale~We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~We will check the quality of life by the questionnaire."
89219017|NCT06133998|Active Comparator|incentive spirometry without aerobic exercises|"Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~In aerobic exercise following treatment protocol will be involve~In sitting position, for the relaxation of body, patient will take a deep breath.~In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~We will check the dyspnea of the patient by the borage scale~We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~We will check the quality of life by the questionnaire.~We will check the chest expansion by measuring tap."
89219018|NCT06133972|Experimental|Ianalumab monthly|Ianalumab s.c. monthly
89219019|NCT06133972|Experimental|Ianalumab quarterly|Ianalumab s.c. quarterly
89219020|NCT06133972|Placebo Comparator|Placebo monthly|Placebo s.c. monthly
89219021|NCT06133946||Combined screening|All newborns underwent combined hearing and genetic screening.
89219022|NCT06133933||Study Cohort|Patients will have their preoperative pain threshold measured and complete postoperative pain journal, pill count, VAS, SF-12, SANE, and Satisfaction Survey in addition to the routine standard of care following perioperative management of total shoulder arthroplasty patients.
89219023|NCT06133920||Immobilization Group|"The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery."
89219024|NCT06133920||Early ROM|The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
89219025|NCT06133894|Experimental|Experimental group|The experimental group was educated and instructed and agaged in a 12-week exercise program - 15 minutes 6 times per week of complex daily routines delivered via on-line platform.
89219026|NCT06133894|No Intervention|Contol group|The control group continued in regular daily activities and was offered the same intervention as the experimental group after the research trial.
89219027|NCT06133868|Active Comparator|Group I (Experimental group) Chamomile|"- · Describing the method for the child to become familiar with~· The patient will inhale natural chamomile oil in a separate room prior to the intervention. Three drops (0.1 cc per drop) will be poured on a cotton roll, and patients will inhale the oil without skin contact for 3 min."
89522746|NCT04177381|Active Comparator|non closure of subcutaneous tissue with drain|In the drain group,a closed non vacuum drain will be inserted in the tissue and exit from the skin through a separate opening and stitch to the skin
89219028|NCT06133868|Active Comparator|- Group II (Experimental group) Lavender|"Describing the method for the child to become familiar with.~The patient will inhale natural lavender oil (100% pure Lavandula) in a separate room prior to the intervention. Three drops (0.1 cc per drop) of lavender oil will be poured on a cotton roll, and patients will inhale the oil without skin contact for 3 min"
89059227|NCT05684510|Experimental|: traditional treatment Fixed appliances with class II elastics.|A group of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
89059228|NCT05682677|Experimental|PACT+iTBS|Personalized, Augmented Cognitive Training (PACT; 6 sessions over 4 weeks) + intermittent theta burst stimulation (iTBS; 20 sessions over 4 weeks)
89059229|NCT05682677|Sham Comparator|PACT+sham iTBS|Personalized, Augmented Cognitive Training (PACT; 6 sessions over 4 weeks) + sham intermittent theta burst stimulation (sham iTBS; 20 sessions over 4 weeks)
89059230|NCT05676736||Study group (S) Obese group|Patients with body mass index (BMI) range from (≥30 kg/m2)
89059231|NCT05676736||Control group (C) Normal weight group|Patients with body mass index (BMI) range from (18.5-24.9 kg/m2)
89059232|NCT05672550|Experimental|Bayesian based dose adjustment|"Optimization of the enoxaparin dose using a bayesian program in order to prevent patients from complications due to the renal transplantation.~A first recommended dose of enoxaparin (50 IU/kg) is administered subcutaneously during transplantation or within the first 24 hours.~Then, in the experimental group, the dose is adjusted following a bayesian program integrated in the electronic Case Report Form which is based on each patient's data as the Anti-Xa activity"
89059233|NCT05672550|Active Comparator|Treatment as usual (empirical dose adjustment)|Anti-Xa activity is measured and twice-daily enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers
89059234|NCT05672407|Experimental|Tranexamic Acid Group|Participants undergoing standard of care periorbital procedures will be randomized to receive tranexamic acid with lidocaine/epinephrine on one of their eyelids at the beginning of the scheduled operation before incision.
89059235|NCT05672407|Placebo Comparator|Placebo Group|Participants undergoing standard of care periorbital procedures will be randomized to receive balanced salt solution with lidocaine/epinephrine on one of their eyelids at the beginning of the scheduled operation before incision.
89059236|NCT05659394|Other|Standard Wound Care Alone|Patients receiving gold standard compression therapy for venous or mixed etiology ulcers
89059237|NCT05659394|Other|Standard Wound Care plus IPC|Patients receiving gold standard compression therapy plus IPC (WoundExpress)
89059238|NCT05654805|Active Comparator|Supplementation with insoluble cereal fiber|Drinking powder supplement providing 7,5 grams of insoluble fiber per sachet, taken twice daily over a period of 12 weeks without any changes in dietary behavior, caloric intake or physical activity
89059239|NCT05654805|Placebo Comparator|Supplementation with placebo|Drinking powder supplement providing no insoluble fiber, but maltodextrin, taken twice daily over a period of 12 weeks without any changes in dietary behavior, caloric intake or physical activity
89059240|NCT05654623|Experimental|ARV-471|
89059241|NCT05654623|Active Comparator|Fulvestrant|
89059242|NCT05654363||Intrathecal morphine|Adult women American Society of Anaesthesiologists (ASA) physical status <= 3, scheduled for elective laparoscopic/laparotomic hysterectomy under general anesthesia between January 1st 2019 and December 31st 2021, who consented to the execution of a preoperative spinal analgesia with intrathecal morphine (as part of our standard practice) and who did not present any contraindications to lumbar puncture.
89059243|NCT05654363||Intravenous morphine|Adult women American Society of Anaesthesiologists (ASA) physical status <= 3, scheduled for elective laparoscopic/laparotomic hysterectomy under general anesthesia between January 1st 2019 and December 31st 2021, who did not consent to the execution of a preoperative spinal analgesia or presented contraindications to lumbar puncture (coagulopathy or incorrect discontinuation of anticoagulant drugs, increased intracranial pressure, infection at the site of injection, major spinal deformities).
89059244|NCT05653401|Active Comparator|Magnesium Sulfate|Intravenous Magnesium Sulfate combined to Diclofenac
89059245|NCT05653401|Active Comparator|Lidocaine|Intravenous lidocaine combined to Diclofenac
89059246|NCT05653401|Active Comparator|Diclofenac|Intramuscular Diclofenac alone
89059247|NCT05648162|Experimental|Electrical acupuncture+ tDCS + NDT-Bobath Rehabilitation|Electrical acupuncture, tDCS, and NDT-BOBATH rehabilitation were performed for 30 minutes per time, respectively. The number of intervention was held for about a month, five times a week(a total of 20 times).
89059248|NCT05648162|Active Comparator|Acupuncture + sham tDCS + NDT-Bobath Rehabilitation|Acupuncture, tDCS, and NDT-BOBATH rehabilitation were performed for 30 minutes per time, respectively. The number of intervention was held for about a month, five times a week(a total of 20 times).
89059249|NCT05645276|Experimental|The dose escalation stage, pharmacodynamic confirmation stage and dose expansion stage of AK129|7 dose groups were set up, which were 0.03mg/kg,0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg and 25 mg/kg in dose escalation stage; 2-3 dose levels that do not exceed maximum tolerated dose(MTD) may be selected for pharmacodynamic confirmation cohort extension in pharmacodynamic confirmation stage;Five cohorts with different indications were included in each group with 10-20 subjects in dose expansion stage.
89059250|NCT05634538|Active Comparator|Robotic-assisted PCI with Corpath GRX® System|Percutaneous coronary intervention (PCI) using the Corpath GRX System.
89059251|NCT05634538|Active Comparator|Standard PCI|Percutaneous coronary intervention (PCI) using manual techniques. This arm will be completed without robotic assistance.
89059252|NCT05630404|Active Comparator|Group IE= Surgical Injection ESPB|Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
89059253|NCT05630404|Active Comparator|Group UE= US guided ESPB|Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.
89059254|NCT05630404|No Intervention|Group C = Control group|"Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia.~Patients will be administered tenoxicam 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit."
89059255|NCT05621161|Active Comparator|GroupFICB= fascia iliaca compartment block|ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and then for correction of the needle 2 ml saline will be injected deep into the erector spinae muscle fascia. Following confirmation of the correct position of the needle 30 ml 0.25% bupivacaine will be administered for the block.
89219029|NCT06133868|Placebo Comparator|- Group III (Control group) Cotton with saline|"Describing the method for the child to become familiar with~The patient will inhale a clear cotton roll with saline."
89522747|NCT04177381|Active Comparator|non closure of subcutaneous tissue and no drain|75 women without subcutanous sutures and without drain
89059256|NCT05621161|Active Comparator|Group ESPB = erector spina plan block|FIC block will be performed in the supine position. The linear probe is placed transversely to identify the femoral artery, iliopsoas muscle, and fascia iliaca at the inguinal crease. The probe will be tilted cranially and caudally until optimal images of the fascia iliaca are obtained. Block needle (50 mm, 22G) will be passed through the iliac fascia via the in-plane method. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected.
89059257|NCT05620849|Experimental|Intervention only|This group will complete 4 weeks of the brief online program along with 5 weeks of check-in surveys.
89059258|NCT05620849|No Intervention|Assessment only|This group will complete 5 weeks of check-in surveys.
89059259|NCT05619653|Active Comparator|Verum|Prednisolone and Losartan
89059260|NCT05619653|Placebo Comparator|Placebo|Placebo 1 and Placebo 2
89059261|NCT05615701|Other|EOSedge imaging|Single arm study : All subjects include in the study underwent micro-dose EOS x-ray and digital radiography for radiographic evaluation of hip implant
89059262|NCT05614882|Active Comparator|Written Stroke Education|Participants in this arm will be given the current written standard of care for stroke education. Assessments will be completed during the participants inpatient stay.
89059263|NCT05614882|Experimental|Verbal Stroke Education|Participants in this arm will be given the experimental verbal stroke education. Assessments will be completed during the participants inpatient stay.
89059264|NCT05611073||Distance with Minimal Intermediate Visual Acuity Group|Patients with bilateral implantation of Eyhance IOLs. And defined by BCDVA of 0.1 logMAR or better but a DCIVA of 0.4 logMAR or worse.
89059265|NCT05611073||Distance with Enhanced Intermediate/Near Visual Acuity Group|Patients with bilateral implantation of Eyhance IOLS. And defined by BCDVA of 0.1 logMAR or better and a DCIVA of 0.3 logMAR or better.
89059266|NCT05610657|Experimental|Mitapivat|Mitapivat tablet as a single oral dose, under fasted conditions on Day 1 to compare participants with normal hepatic function to participants with moderate hepatic function (Child-Pugh [C-P] Score B, score of 7 to 9).
89522748|NCT03126305||OC-Go|Approximately 10-20 9-17 year-olds receiving exposure based cognitive behavior therapy for OCD through the UCLA Division of Child and Adolescent Psychiatry OCD treatment programs
89522749|NCT03391375|Experimental|DNA-Protein|Co-administration of DNA-HIV-PT123 and AIDSVAX B/E at week 0, 4 and 24
89059267|NCT05607537|Experimental|Part 1: E7386 40 mg Tablet + (14C)E7386|Participants will be administered a single oral dose of E7386 40 mg tablet on Day 1 followed by an intravenous infusion containing a microdose solution of [14C]E7386 (100 mcg) with not more than (NMT) 7.4 kilobecquerel (kBq) (0.20 microcurie [mcCi]), starting approximately 25 minutes post oral dose administered as 5 milliliter (mL) over 5 minutes to coincide with the time at which the highest drug concentration occurs (tmax) for E7386 after an oral dose.
89059268|NCT05607537|Experimental|Part 2: (14C)E7386 40 mg Capsule|Participants will be administered a single oral dose of E7386 40 mg capsule radiolabeled with approximately 2.96 megabecquerel (MBq) (80 mcCi) (14C)E7386 (final dose to depend on the specific activity of [14C]E7386) in the morning on Day 1 after an overnight fasting.
89059269|NCT05602506|Active Comparator|BETAF OD arm|one tablet taken orally once daily
89059270|NCT05602506|Experimental|BETAF 3W arm|one tablet taken orally 3 days per week : Mondays, Wednesdays, and Fridays
89059271|NCT05602506|Experimental|BETAF 2W arm|one tablet taken orally 2 days per week : Mondays, and Thursdays
89059272|NCT05602506|Experimental|BETAF 1W arm|one tablet taken orally 1 days per week : Mondays
89059273|NCT05600114|Experimental|Cannabidiol (CBD) Oral Solution 300 mg/day|
89059274|NCT05600114|Experimental|Cannabidiol (CBD) Oral Solution 600 mg/day|
89059275|NCT05600114|Placebo Comparator|Placebo Oral Solution|
89059276|NCT05599841|Active Comparator|Povidone Iodine Solution|The group whom PI solution will be used at surgery
89059277|NCT05599841|Placebo Comparator|Saline Solution|The group whom only saline solution will be used at surgery
89059278|NCT05593276|No Intervention|Waitlist|
89059279|NCT05593276|Experimental|Internet-based program|
89059280|NCT05589220|Experimental|Music intervention and NRT|The rhythm of the music sessions will be 2 per week in the first month, 1 per week in the second month and 1 every 15 days in the third month. In this group, music intervention will be associated to NRT.
89059281|NCT05589220|Active Comparator|NRT group|Nicotine Patch, Nicotine Gum As in the intervention group, the physician will adapt the type of NRT according to the patient's smoking profile.
89059282|NCT05588960||Term/Near-Term Group|Cohort of term/near-term infants undergoing therapeutic hypothermia for moderate to severe HIE. Data collected from NIRS monitoring and other assessments/investigations that are part of routine clinical care. There are no additional study specific interventions or exposures for this group.
89059283|NCT05588960||Preterm Group (Sub-study 1, First 72 hours after birth)|Cohort of infants born at less than 28 weeks gestational age. Data collected from NIRS monitoring, other physiological monitoring, cranial ultrasound scans and neurodevelopmental follow up assessments that are part of routine clinical care. This data will be analysed to fulfil secondary study objectives. There are no additional study specific interventions or exposures for this group.
89059284|NCT05588960||Preterm Group (Sub-study 2, Skin-to-skin care)|Cohort of infants born at less than 28 weeks gestational age who are considered by clinical team to be suitable to undergo period of skin-to-skin care. Participants will undergo additional research-specific period(s) of NIRS monitoring before, during and after period(s) of skin-to-skin care. Participants with and without severe brain injury on cranial ultrasound will be recruited to allow comparison.
89059285|NCT05588960||Preterm Group (Sub-study 3, Bronchopulmonary dysplasia)|Cohort of infants born at less than 28 weeks gestational age who will undergo an additional research-specific period of NIRS monitoring at 36 weeks corrected gestational age. Participants with and without bronchopulmonary dysplasia (BPD) will be recruited to allow comparison.
89059286|NCT05581186|Active Comparator|PEMT + exercise|A total of 15 sessions of pulse electromagnetic field therapy using an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057, Italia),five times a week and once a day for three weeks, were applied to the patients. The patients were then given a daily exercise program once a day by a physiotherapist.
89059287|NCT05581186|Sham Comparator|Sham PEMT + exercise|Sham therapy was applied in five sessions a week for three weeks, with a total of 15 sessions, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
89059288|NCT05581186|Other|Exercise only|Exercise program was applied in five sessions a week for three weeks, with a total of 15 sessions a day with the physiotherapist.
89059289|NCT05580679|Experimental|Abdominal massage group|Abdominal massage using for evaluation of constipation.
89059290|NCT05580679|No Intervention|Standart care group|No intervention palliative care patient
89059291|NCT05569811|Active Comparator|CHEMOTHERAPY|
89059292|NCT05569811|Experimental|HER3-DXd + Endocrine therapy (ET)|
89059293|NCT05569811|Experimental|HER3-DXd|
89059294|NCT05566899|Experimental|EGD at time of routine screening colonoscopy|This happens on Day 0. Screening for EGD, biopsy samples from esophagus, stomach, gastrointestinal junction, and duodenum AE's.
89059295|NCT05560789|Experimental|Participants with Post-bariatric Hypoglycemia Performing Structured Physical Activity|Individuals with a confirmed diagnosis of post-bariatric hypoglycemia will perform structured physical activity by cycling on a stationary bicycle ergometer or on a treadmill.
89059296|NCT05556876|Active Comparator|Intervention|the intervention group will be provided with oral nutritional supplements for 12 weeks after discharge
89059297|NCT05556876|No Intervention|Control|the control group will receive usual care after discharge
89059298|NCT05546528|Experimental|photobiomodulation|photobiomodulation application with the Laser Therapy XT device
89059299|NCT05546528|Sham Comparator|photbiomodulation-sham|photobiomodulation application with the Laser Therapy XT device off
89522750|NCT03398915||Robot-Guided Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of a robotic guidance system (SpineAssist or Renaissance, Mazor Robotics, Ltd., Caesarea, Israel or ROSA Spine, Medtech, Montpellier, France).
89219030|NCT06133842||Enrolled Participants|"Patients above the age of 60 undergoing major non-cardiac surgery requiring invasive MAP monitoring as standard of care. They will be monitored intra-op using non-invasive EEG and CO monitors, which will be correlated with MAP.~They will also undergo baseline and followup assessment for post-operative delirium using the standardised CAM and MoCA tools administered by study staff."
89219031|NCT06133803|Experimental|Treatment Arm|"Patients randomized to receive aspirin and Lovenox will begin taking one low dose 81mg aspirin and one 40mg injection of Lovenox daily, on the day of progesterone start."
89219032|NCT06133803|Active Comparator|Control Arm|This arm receives neither medication.
89219033|NCT06133712|Active Comparator|Dexmedetomidine|Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve
89219034|NCT06133712|Active Comparator|Ozone|Participants will receive a single local injection of 4 ml ozone (10 micrograms/dl) plus to 1 ml lidocaine (1%) using a 25 G needle.
89219035|NCT06133712|Active Comparator|Dexamethasone|Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL [8 mg] dexamethasone) via the same technique.
89219036|NCT06133504|Active Comparator|Early arm|Early multimodal therapy is characterized by a comprehensive set of therapeutic interventions executed by the physiotherapy, speech therapy, respiratory therapy, and occupational therapy teams precisely at the moment of study inclusion. This tailored approach ensures that patients receive a coordinated and multidisciplinary therapeutic regimen right from the outset of their participation in the study
89219037|NCT06133504|Active Comparator|Late arm|While late multimodal therapy is characterized by the same type of maneuvers carried out by the same disciplinary team but initiated once indicated by the attending physician.
89219038|NCT06133465||Pleomorphic Lobular Carcinoma in Situ (PLCIS) of the breast|Patients with diagnosis of pure pleomorphic lobular carcinoma in situ of the breast
89219039|NCT06133465||Florid Lobular Carcinoma in Situ (FLCIS) of the breast|Patients with diagnosis of pure florid lobular carcinoma in situ of the breast
89219040|NCT06133309|Experimental|Depressive patients|Patients suffering from depressive disorder and treated with Esketamine between 2 days and 3 months prior to the study.
89219041|NCT06132828|Experimental|DR30206|Subjects receive DR30206 monotherapy intravenously(IV) until no more benefits from treatment.
89219042|NCT06132178|Experimental|Full dose COMP360 with active aiTBS rTMS|25mg of COMP360 with the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) delivered over 10 sessions daily for 5 consecutive days.
89219043|NCT06132178|Active Comparator|Full dose COMP360 with sham aiTBS rTMS|25mg of COMP360 with sham iTBS delivered over 10 sessions daily for 5 consecutive days.
89219044|NCT06132178|Active Comparator|Low dose comparator with active aiTBS rTMS|1mg of COMP360 with the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) delivered over 10 sessions daily for 5 consecutive days.
89219045|NCT06132178|Sham Comparator|Low dose comparator with sham aiTBS rTMS|1mg of COMP360 with with sham iTBS delivered over 10 sessions daily for 5 consecutive days.
89219046|NCT06131944|Experimental|Rested & Ready to Learn|All participants will receive the four-week Rested & Ready to Learn sleep promotion program which includes text messaging to parents, home activities for parents and children to complete together, and brief classroom lessons.
89219047|NCT06131892||Successful defibrillation during extra corporeal life support (ECLS) rewarming|
89219048|NCT06131892||Non Successful defibrillation during extra corporeal life support (ECLS) rewarming|
89219049|NCT06131892||Successful defibrillation before rewarming or during non-ECLS rewarming|non- ECLS: non- extra corporeal life support
89219050|NCT06131892||Non- successful defibrillation before rewarming or during non-ECLS rewarming|non- ECLS: non- extra corporeal life support
89219051|NCT06131723|No Intervention|Arm 1: Standard tickler email|"Eligible, assigned participants will receive the current standard email notification (i.e., control tickler) from UCLA Health, informing patients that they have received a new message in their MyChart patient portal account, and containing links to their portal account."
89219052|NCT06131723|Experimental|Arm 2: Enhanced tickler email|"Eligible, assigned participants will receive a behaviorally informed email notification (i.e., enhanced tickler), coming from their PCP's office, informing patients that they are due for an important medical exam, and containing a direct link to the MAP Letter on their patient portal account."
89219053|NCT06131528|Experimental|Relaxation Breathing Exercises Group|This group preformed Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing on alternative pattern for 10 minutes to 30 minutes. These exercises are performed daily with 6 breaths per min. The minimum duration was 3 min for one session.
89522751|NCT03398915||Navigated Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of navigation (computer assistance using CT, O-arm or 3D-fluoroscopic imaging).
89059300|NCT05539326||PIQ Patients|"Patient is scheduled for or has undergone primary total knee arthroplasty (TKA) using a Persona Personalized Knee System with Canary Tibial Extension (PIQ) TKA implant according to the appropriate surgical technique and IFU. If you decide to take part in this research study, the general procedures include one follow-up visit where you will be asked to complete two performance-based tests that are used to assess your physical function following Total Knee Arthroplasty (TKA). As part of your standard of care, you will receive a Zimmer Persona® Personalized Knee System with Canary canturioTM (CTE) tibial extension. As part of this study, subjects will be asked to perform two performance based tests called the 4 meter walk test and the timed up and go test. Subjects will also be asked to complete a series of patient questionnaires that will assess their post-operative function."
89059301|NCT05538962|Experimental|Healthy controls|Healthy controls will receive the sensors
89059302|NCT05538962|Experimental|Outpatients with cirrhosis|Outpatients with cirrhosis will receive the sensors
89059303|NCT05538962|Experimental|Inpatients with cirrhosis|Inpatients with cirrhosis will receive the sensors
89059304|NCT05525546|Experimental|Group A: Full-Strength Formulation|Individuals receive one dose of full-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
89059305|NCT05525546|Experimental|Group B: Half-Strength Formulation|Individuals receive one dose of half-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
89059306|NCT05525546|Experimental|Group C: Dilutional Half-Strength Formulation|Individuals receive one dose of dilutional half-strength Trivalent Salmonella Conjugate Vaccine (TSCV). Subsequent blood samples are taken for safety and immunological testing.
89059307|NCT05525546|Placebo Comparator|Group D: Placebo|Individuals receive one dose of placebo. Subsequent blood samples are taken for safety and immunological testing.
89059308|NCT05525247|Experimental|Monotherapy|SLC-3010 Intravenous infusion over 30 minutes on day 1 of each 21-day cycle
89059309|NCT05525247|Experimental|Gemcitabine combination|"SLC-3010 Intravenous infusion over 30 minutes on day 1 of each 21-day cycle~Gemcitabine 1000 ㎎/㎡ Intravenous infusion over 30 minutes on day 1 and 8 of each 21-day cycle"
89059310|NCT05520814|Experimental|metastatic nasopharyngeal carcinoma|
89059311|NCT05518045|Experimental|LM-108 Dose Escalation|
89059312|NCT05518045|Experimental|LM-108 Dose Expansion|
89059313|NCT05518045|Experimental|LM-108 combination dose escalation|
89059314|NCT05518045|Experimental|LM-108 combination dose expansion|
89059315|NCT05516329|Experimental|18F-Thretide Injection|7±1 mCi (259±37 MBq) IV injection of 18F-Thretide
89059316|NCT05515796|Experimental|Gastric cancer:CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative)|"CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative):~Cycle 1 up to Cycle 3 CapeOX + Terelizumab (aka Tislelizumab) therapy Cycle: Day 1 through Day 21"
89059317|NCT05515796|Experimental|Gastric cancer:CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive )|"CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive ):~Cycle 1 up to Cycle 3 CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) Cycle: Day 1 through Day 21"
89059318|NCT05515796|Experimental|Rectal cancer:Radiotherapy with CapeOx+ Terelizumab (aka Tislelizumab)|"Rectal cancer:~Cycle 1:25 Gy/5 fractions (Day 1 through Day 7) Cycle 2 up to Cycle 3 CapeOX + Terelizumab (aka Tislelizumab) therapy(Day 1 through Day 21)"
89059319|NCT05515783|Experimental|Part I: safety, tolerability, biodistribution and dosimetry|PET imaging will begin at 30s (30s/bed), 15min (1min/bed), 30min (2 min/bed), 60min (2 min/bed) and 120min (2 min/bed) after injection
89059320|NCT05515783|Experimental|Part II: diagnostic efficacy|Participants with various types of cancer will have PET imaging 50-100 minutes after injection of 68Ga-FAP-RGD and another agent (68Ga-FAPI-02 or 18F-FDG).
89059321|NCT05514366|Experimental|End inspiratory pause under tOLA|"Application of four different end inspiratory pauses (EIP) corresponding to 10, 20, 30 and 40% of inspiratory time.~Phase 1) before the application of pneumoperitoneum and forced trendelenburg. Phase 2) during the application of pneumoperitoneum and forced trendelenburg. During both phases, all patients will be ventilated under a tOLA strategy (see Study Description section)."
89059322|NCT05513846||Meditation|This is the group that will have learned at least Shamhbavi Mahamudra Kriya before they are enrolled in the study.
89059323|NCT05513846||Control|This is the group that will not have learned Shambhavi Mahamudra Kriya before they are enrolled in the study. They will be invited to the study by the Meditation group.
89059324|NCT05513209|Active Comparator|opioid based multimodal anesthesia|One hundred and twenty pediatric patients will do elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
89059325|NCT05513209|Active Comparator|opioid free pterygopalatine ganglion block based multimodal anesthesia|One hundred and twenty pediatric patients will do elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
89059326|NCT05511610|Experimental|MAAS method trial|Accuracy of sevoflurane and desflurane vaporizers to guarantee the ettHA%, based on the MAAS method.
89059327|NCT05511584|Experimental|VO2 and SEVOup|Estimation of VO2 and SEVOup (ml/min) followed by estimation of O2 and sevoflurane supply (DO2 and SEVOsuppl, respectively) through a closed-circuit anesthesia administration system.
89059328|NCT05510531|Experimental|Treatment Diabetes Survival Skills (DSS)Training|Participants in the treatment group received a 6-session 1-hour weekly literacy tailored DSS education intervention.
89059329|NCT05510531|No Intervention|Control No intervention|Participants in the Control facility received the intervention upon completion of week twelve measurements.
89059330|NCT05509569||Icatibant|Participants will be recieved Icatibant 10 to 30 mg injection subcutaneously.
89059331|NCT05506605|Experimental|Switch from Etravirine to Doravirine|Switch from etravirine to Doravirine (Pifeltro) 100 mg each day
89059332|NCT05506566|Experimental|Part I: safety, tolerability, biodistribution and dosimetry|PET imaging will begin at 30s (30s/bed), 15min (1 min/bed), 30min (2 min/bed), 60min (2 min/bed) and 120min (2 min/bed) after injection, and whole-body low-dose CT needed to be re-acquired at 120 minutes
89059333|NCT05506566|Experimental|Part II: diagnostic efficacy|Participants with various types of cancer will have PET imaging 50-100 minutes after injection of 68Ga-FAP-CHX and another agent (68Ga-FAPI-04 or 18F-FDG).
89059334|NCT05503732|Experimental|Energy drink first, then placebo drink|Subjects will consume two 16-oz energy drinks before sleep for the first study visit, then consume two 16-oz identical looking placebo drink before sleep at the second study visit.
89059335|NCT05503732|Experimental|Placebo drink first, than energy drink|Subjects will consume two 16-oz identical looking placebo drink before sleep at the fist study visit, then consume two 16-oz energy drinks before sleep for the second study visit.
89059336|NCT05500482|Experimental|Vaccinated arm|Typhoid Conjugate Vaccine (TyphiBEV) 0.5 ml as a single dose given intramuscularly to consenting, eligible residents of vaccine clusters
89059337|NCT05500482|No Intervention|Control arm|No vaccination in the control clusters
89059338|NCT05500170|Experimental|Intervention|Participants in the intervention group will receive 500mg of NR twice daily
89059339|NCT05500170|Placebo Comparator|Placebo|Participants in the intervention group will receive 500mg of sham placebo twice daily
89059340|NCT05499390|Experimental|AK112|Subjects receive AK112 monotherapy intravenously (IV), selected dose.
89059341|NCT05499390|Active Comparator|Pembrolizumab|Subjects receive Pembrolizumab monotherapy intravenously (IV), 200mg q3w.
89059342|NCT05497908|Experimental|Transversus abdominis plane (TAP) block via lateral approach|This group receives a Transversus abdominis plane (TAP) block via lateral approach
89059343|NCT05497908|Experimental|Transversus abdominis plane (TAP) block via posterior approach|This group receives a Transversus abdominis plane (TAP) block via posterior approach
89059344|NCT05497908|No Intervention|Control group|The control group receives no TAP block.
89059345|NCT05492162|Other|paramedic students|para-experimental arm
89059346|NCT05490615|Experimental|Mindfulness Intervention (Group-A)|"Total length of study for participants in Group-A:15 Week~Six weekly sessions (each 60 minutes in length) of group based virtual mindfulness instruction, co-led by a mindfulness teacher and two autistic adults, following a workbook designed for autistic adults. In between sessions, participants are encouraged to complete homework and keep a record of when they practice formal and informal mindfulness practices. In addition, participants are provided with a link to autism informed mental health resources (https://www.yorku.ca/health/lab/ddmh/am-help/)"
89059347|NCT05490615|No Intervention|Waitlist Control (Group-B)|"Total length of study for participants in Group-B: 30 Week~A waitlist control group is an ethical alternative to no-treatment control groups when studying psychological and behavioral interventions. This group will have access to intervention at the end of the study as well. All waitlist participants are provided with a link to autism informed mental health resources (https://www.yorku.ca/health/lab/ddmh/am-help/)"
89059348|NCT05486559|Experimental|The ECMO-free Protocol group|For patients assigned to the ECMO-free protocol group, the study personnel will perform the ECMO-free protocol daily from enrollment until the first of death or ECMO decannulation; results will be recorded and shared with the treatment team. Final decisions regarding decannulation will be made by treating clinicians who are aware of the results of daily ECMO-free protocolized assessments.
89059349|NCT05486559|Active Comparator|The Usual Care Group|For patients assigned to the usual care group, ECMO weaning and assessments of readiness for ECMO decannulation will be at the discretion of treating clinicians.
89059350|NCT05486520|Active Comparator|BREAST MRI IMAGES FROM HEALTHY VOLUNTEERS|"All participants will be recruited prior to their scheduled diagnostic imaging or diagnostic procedures.~The expected time to complete the study is a maximum of 1.5 hours with approximately 30-60 minutes of scan time, depending on the specific MRI software being tested."
89059351|NCT05486520|Experimental|BREAST MRI IMAGES FROM PERSONS WITH KNOWN BREAST PATHOLOGIES BENIGN AND MALIGNANT|"All participants will be recruited prior to their scheduled diagnostic imaging or diagnostic procedures.~The expected time to complete the study is a maximum of 1.5 hours with approximately 30-60 minutes of scan time, depending on the specific MRI software being tested."
89059352|NCT05464147|Experimental|DynamX Drug-Eluting Coronary Bioadaptor System|
89059353|NCT05463263|Experimental|Phase 1 (Part 1, Dose Escalation)|Up to 5 dose levels with STP938 administered as oral monotherapy
89059354|NCT05463263|Experimental|Phase 2 (Part 2; expansion)|At defined dose level(s) with STP938 administered as oral monotherapy
89059355|NCT05462951|Other|Radiochemotherapy followed by brachytherapy|Standard daily radiotherapy plus weekly cisplatin followed by brachytherapy
89059356|NCT05461729||Coronary Artery Disease|Patients with Coronary Artery Disease
89059357|NCT05452564|Experimental|Baricitinib|"Potential participants will be pre-screened through review of the electronic medical record from Emory or Grady. Or if a potential participant receives care elsewhere, a release of medical information form will be signed and sent to the medical center that the individual goes to. The study team will enroll individuals who have well controlled HIV. Participants will then be randomized to either baricitinib or placebo.~Patients randomized to Baricitinib group will receive Baricitinib at dose of 2 mg oral for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10."
89059358|NCT05452564|Placebo Comparator|Placebo|"Potential participants will be pre-screened through review of the electronic medical record from Emory or Grady. Or if a potential participant receives care elsewhere, a release of medical information form will be signed and sent to the medical center that the individual goes to. The study team will enroll individuals who have well controlled HIV. Participants will then be randomized to either baricitinib or placebo.~Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10."
89059359|NCT05448274|Placebo Comparator|Placebo|The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
89059360|NCT05448274|Experimental|Ruminococcus torques|10^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline
89059361|NCT05447091|Active Comparator|Active high dose treatment|Active LOH game training- high dose
89059362|NCT05447091|Active Comparator|Active low dose treatment|Acrive LOH game training - low dose
89059363|NCT05447091|Sham Comparator|Sham treatment|Sham LOH game- high dose
89059364|NCT05445167|Experimental|KLH-2109|
89522752|NCT03398915||Freehand Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of the conventional freehand technique.
89059365|NCT05445167|Placebo Comparator|Placebo|
89059366|NCT05443945|Experimental|Advanced Water -100 ionized nasal spray|3 sprays in each nostril, 3 times a day during 14 days
89059367|NCT05443945|Placebo Comparator|Nasal spray with purified water|3 sprays in each nostril, 3 times a day during 14 days
89059368|NCT05440383|Experimental|KLH-2109|Oral administration
89059369|NCT05440383|Active Comparator|Leuprorelin|Subcutaneous administration
89059370|NCT05432297|Experimental|Physical exercise intervention|The physical activity intervention is based on national guidelines of physical activity in cancer rehabilitation. A physiotherapist together with each patient will develop individual adaptations to the exercise protocol, with suggestions on which type of exercise the participant is able to perform depending on their daily condition. Suggestions on physical activity for good, bad and in-between-days will be listed in collaboration with the participant, and the participant will report number of minutes/day in each of the 3 physical activity levels stated.
89059371|NCT05432297|No Intervention|Control|The control group will receive general advice on the importance of physical activity during oncologic treatment, according to local clinical standard.
89059372|NCT05431920|Experimental|Experimental|Vitamin D3: single 50,000 IU loading dose + 4,000 IU daily dose for three months
89059373|NCT05431920|Active Comparator|Active control|Vitamin D3: 2,000 IU daily dose for three months
89059374|NCT05431478|Other|LID022821, then AOHP|Serafilcon A contact lenses worn during Period 1, with senofilcon A contact lenses worn during Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection. The serafilcon A contact lenses will be replaced with a fresh pair at the Week 1 follow-up visit.
89219054|NCT06131528|Active Comparator|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management and include weight reduction, following the DASH eating plan with sodium restrictions, daily physical activity, and moderate alcohol consumption. In addition, all patients should be advised to stop smoking to reduce the risk of cardiovascular diseases.
89219055|NCT06131502|Active Comparator|Real FUS|The treatment volume and plan will be defined by the neurosurgeon. The ExAblate MRgFUS system will automatically compute the number of sonications, and the (per sonication spot) phase and amplitude corrections necessary for the system to produce a focal spot at each of the desired locations. The target selected for this study is the anterior limb of the internal capsule (ALIC). The target will be approximately 7-10mm rostral to the anterior edge of the anterior commissure, in the ventral part of the ALIC. A central point in the targeted area will be targeted with a low dose, sub-lethal energy level sonication to confirm the targeting accuracy on the MR images. Focal point position and/or transducer location will be adjusted as necessary.
89219056|NCT06131502|Sham Comparator|Sham FUS|The sham procedure will be identical in planning and execution to the ExAblate procedure with the only exception being that the energy output will be 0 for the sham-treated subjects. To perform the sham treatment, the sonication will be performed with energy output disabled. For sham subjects, the physician will interact with a subject in a similar manner and for a similar duration to simulate an actual procedure. When possible, the treating physician may determine a sonication (treatment) time for sham subjects to be similar to that which is occurring in the ExAblate procedure to maintain consistency between treatment arms. It should be noted that all treatment times of both treatment arms will be captured in the study CRF.
89219057|NCT06131463|Experimental|ECG function is enabled|Electrocardiogram (ECG) feature on the smartwatch is enabled
89219058|NCT06131463|No Intervention|ECG function is not enabled|Electrocardiogram (ECG) feature on the smartwatch is not enabled
89219059|NCT06131242||According to age, the group was divided into 18-45, 45-65, and > 65 years old.|
89219060|NCT06131164|Experimental|Diaphragmatic Breathing Exercise Group|This group will perform baseline treatment along with balloon breathing exercises also known as diaphragmatic breathing exercise for pulmonary function improvement and FHP Diaphragmatic breathing is done slowly and deeply through nose with minimum usage of chest movement. Only diaphragm is used for breathing in supine lying position with one hand placed on chest and other hand is placed on abdomen. Focus should be on the contraction of diaphragm that can be checked by hand placed on abdomen while there is as little movement in chest as possible which is also checked by hand placed on chest. Inhalation and exhalation should be for 6 second approximately. Each exercise session consist of 4 sets and each set has 4 complete breathing breaks. Will be done 2 times a day and 3 times per week for total of 8 weeks.
89219061|NCT06131164|Active Comparator|Thoracic Extension Exercise Group|This group along with baseline treatment will do Thoracic Extension Exercises (TEE) for FHP and Pulmonary function improvements. This is done in 3 steps. The restricted upper thoracic area is placed on foam roller with subject lying supine with knees flexed, buttock slightly lifted up from the floor and crossed hands on the chest. Roll the foam roller slightly up and down. Swiss ball is place in front of the subject who is sitting with knees flexed and then the ball is pushed slightly forward with both hands placed on it. While lying prone lift up and then pushing down the upper body while the upper body is supported by elbows places just below shoulders. All these steps will be followed by 2 sets of 15 repetitions and holding 10 sec for each repetition.
89219062|NCT06131112||Group A|22 patients with clinically suspected cardiac sarcoidosis
89219063|NCT06131112||Group B|22 patients with known cardiac sarcoidosis
89219064|NCT06131112||Group C|Up to 10 patients with clinically suspected or confirmed acute lymphocytic myocarditis
89219065|NCT06131112||Group D|22 patients with NET without known inflammatory heart disease who have previously been scanned with 64Cu-DOTATATE PET/CT as part of their routine diagnostic work-up or follow-up (control group)
89522753|NCT03391297|Experimental|60-minute Prolonged Exposure Therapy|This condition is a modified version of Prolonged Exposure Therapy for PTSD. It consists of weekly 60-minute sessions, with at least 20 minutes imaginal exposure.
89522754|NCT03391297|Active Comparator|90-minute Prolonged Exposure Therapy|This condition is standard Prolonged Exposure Therapy. It consists of 10 to 15 weekly sessions, each lasting about 90 minutes, with 40-60 minutes imaginal exposure.
89523272|NCT03394807|Experimental|LaGRA|regional anaesthesia of the right upper quadrant by injection of levobupivacaine 0.25% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
89059375|NCT05431478|Other|AOHP, then LID022821|Senofilcon A contact lenses worn during Period 1, with serafilcon A contact lenses worn during Period 2, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for approximately 14 days. CLEAR CARE will be used for daily cleaning and disinfection. The serafilcon A contact lenses will be replaced with a fresh pair at the Week 1 follow-up visit.
89059376|NCT05428618|Experimental|e-BariS app Group|"Self-Monitoring Module and Patient Education Module"
89059377|NCT05428618|Sham Comparator|Self-Monitoring Group|"Self-Monitoring Module"
89059378|NCT05427890|Active Comparator|Usual Care|
89059379|NCT05427890|Experimental|Relative Risk|
89059380|NCT05427890|Experimental|Metabolic Age|
89059381|NCT05427760|Experimental|Oxygen Group|"After the baby's diaper is changed, an oxygen hose placed inside the diaper will provide free oxygen flow to the diaper area.~Oxygen will be applied for 1 hour at each diaper change at a flow rate of 5L/min and at a concentration of 21% FiO2 which is equivalent to room air."
89059382|NCT05427760|No Intervention|Control Group|"This group will only receive routine care: Diaper will be changed using disposable wet wipes and disposable baby diaper.~A barrier cream containing 40% zinc oxide will be applied to the cleaned diaper area as a thin layer to cover the skin.~Baby's diaper change will be done 8 times a day, every three hours."
89059383|NCT05421793|Experimental|Gut barrier function treatments|Stressor, fibre, combination of treatments.
89059384|NCT05420233|Other|Patients diagnosed with Crohn´s disease within the past 12 months|All patients will undergo MRE in year 1, and this test may not be recommended in all patients. Year 1 MRE is the only procedure that may be performed outside of clinical practice.
89059385|NCT05418244|Experimental|Inhaled Isopropyl Alcohol|If the subject is assigned to receive the isopropyl alcohol pad group, an isopropyl alcohol pad (Covidien Webcol 2 ply prep pad, saturated with 70% isopropyl alcohol) will be given to the subject, or the legal guardian. The alcohol pad will be held 1-2 cm under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed during the Emergency Department (ED) stay.
89059386|NCT05418244|Active Comparator|Oral Ondansetron|If the subject is assigned to receive ondansetron treatment, subject will be provided with 4 mg ondansetron oral disintegrating tablet (ODT) for treatment.
89059387|NCT05418244|Placebo Comparator|Inhaled Placebo|If the subject is assigned to receive the inhaled placebo, a normal saline pad (Hygea sterile saline wipe) will be given to the subject or the legal guardian. The saline wipe will be held under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed.
89059388|NCT05415670||[Training set, N=80] Benign/Malignant Pulmonary Nodule|This is a prospective training-set cohort study. A stratified case-cohort design will be used to select patients with malignant pulmonary nodules and patients with benign pulmonary nodules for analysis. All participants will receive chest CT or low-dose computed tomography (LD-CT) scanning and detection of serum tumor markers, and receive Whole-genome methylation sequencing at baseline. GM-seq will perform methylation analysis to build a prediction model for benign and malignant classification.
89059389|NCT05415670||[Verification set, N=40] Benign/Malignant Pulmonary Nodule|This is a prospective validation-set cohort study. A stratified case-cohort design was used to select patients with malignant pulmonary nodules and patients with benign pulmonary nodules for analysis. All participants will verify the benign and malignant differentiation model based on GM-seq methylation analysis, and compare the results with histopathological benign and malignant results, so as to develop a clinical benign and malignant differentiation model.
89059390|NCT05411991|Experimental|Intervention arm|"Application of a standardized diuretic schedule with following key components:~UNa assessment in spot urine sample after every bolus of loop diuretics with continuation of intravenous diuretics until absence of clinical signs of fluid overload AND UNa <80 mmol/L~Loop diuretic dosing according to estimated glomerular filtration rate (eGFR) with higher dose for lower eGFR~Upfront use of intravenous acetazolamide 500 mg OD unless hypernatremia or metabolic acidosis~Upfront use of oral chlorthalidone 50 mg OD if eGFR <30 mL/min/1.73m² OR hypernatremia~Full nephron blockade with intravenous acetazolamide 500 mg OD, intravenous bumetanide 4 mg TID, oral chlorthalidone 100 mg OD, and intravenous canrenoate 200 mg OD in case of diuretic resistance, defined as UNa <80 mmol/L and persistent clinical signs of fluid overload~Provision of 500 mL intravenous Dextrose 5% with 3 g MgSO4 and 40 mmol KCl daily during intravenous diuretics"
89059391|NCT05411991|Active Comparator|Control arm|Usual care for AHF. It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines. Urine electrolyte assessment in the control arm is not allowed as it is a key component of the studied intervention.
89059392|NCT05411263|Experimental|Patients with advanced heart failure undergoing clinically indicated right heart catheterisation|Patients with advanced heart failure undergoing right heart catheterisation as clinically indicated, irrespectively of their ejection fraction.
89059393|NCT05410860|Experimental|Etripamil NS 70 mg with Optional Second Dose|Dosing regimen that permits a second dose of Etripamil NS 70 mg
89059394|NCT05410860|Experimental|Placebo with Optional Second Dose|Dosing regimen that permits a second dose of placebo
89059395|NCT05409612|Active Comparator|Supemtek® arm|"Patients recieving a quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
89059396|NCT05409612|Active Comparator|Vaxigriptetra® arm|Patients receiving a quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
89059397|NCT05408507|Experimental|Older patients with advanced cancer|Patients over 60 years old with advanced, incurable cancer.
89059398|NCT05407662||Survey on users of sMRA therapies|sMRA stands for steroidal mineralocorticoid receptor antagonist.
89059399|NCT05403385|Experimental|Part 1, open label|Inupadenant will be given at one or more dose levels to determine the recommended Phase 2 dose (RP2D).
89059400|NCT05403385|Experimental|Part 2, active treatment|Treatment with inupadenant combined with carboplatin and pemetrexed
89059401|NCT05403385|Placebo Comparator|Part 2, placebo|Treatment with matched placebo combined with carboplatin and pemetrexed
89059402|NCT05402280|No Intervention|Qualitative study|15 nurses (direct care nurses, nurse managers) and 5 patients, to investigate experiences and compare attitudes and opinions concerning the need for and quality of sleep in hospitalized patients.
89059403|NCT05402280|No Intervention|Prospective quantitative study|diagnosing predisposition to sleep disturbances: 400 inpatients staying in gene-ral wards: Patients will undergo a serial of structured and standardized questi-onnaires during scheduled: FIRST: on the day of admission and RCSQ during their hospital stay (record length of up to 7 days).
89059404|NCT05402280|No Intervention|Retrospective quantitative study|subjective assessment of factors affecting sleep: 600 hospitalized patients (360 patients in general wards, 240 patients in intensive care wards). On the day of discharge, patients will retrospectively assess disruptive factors that could in-fluence the quality of their sleep during their hospital stay by standardized que-stionnaire.
89059405|NCT05402280|Other|Interventional study|(subjective and objective assessment of sleep, quality of sleep with respect to delirium, baseline - routine care: PRE phase) implementation of sleep protocol and assess effectiveness (POST phase: determining the effectiveness of imple-mented sleep measures): overal: 2240 patients (1480 general ward, 760 inten-sive care wards.
89059406|NCT05401084|Active Comparator|Carbohydrate|Counseling, education, and implementation of low carbohydrate diet.
89059407|NCT05401084|Active Comparator|Low gluten|Counseling, education, and implementation of low gluten diet.
89059408|NCT05401084|No Intervention|Standard|No change/intervention in diet. Continuation of standard diet.
89059409|NCT05400863|Experimental|Avoid Sugary Drinks and Artificially Sweetened Drinks ( plus Metformin)|Counseling on Beverage Intake to avoid sugary sweetened and NNS (non-nutritive sweetened) drinks plus Metformin therapy (subjects will be given 12-week Metformin (500mg BID) as standard of care therapy).
89059410|NCT05400863|Active Comparator|Avoid sugary drinks only, allowed water and drinks with NNS (plus Metformin)|Counseling on Beverage Intake to avoid sugary drinks (allowed water and drinks sweetened with NNS) plus Metformin therapy (subjects will be given 12-week Metformin (500mg BID) as standard of care therapy).
89059411|NCT05400720|Experimental|Mentee|Participants will be approached by a mentor, exchange experiences and invite the prospective mentee to the program. Those interested to continue will undergo matching based on their desired criteria.
89059412|NCT05398198|Experimental|GSK3923868|All participants in this arm will receive GSK3923868
89059413|NCT05398198|Placebo Comparator|Placebo|All participants in this arm will receive matching placebo
89059414|NCT05395052|Experimental|Cohort A/A2/AA/AA2: FT536 Monotherapy|FT536 monotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer (BC), ovarian cancer, or pancreatic cancer.
89059415|NCT05395052|Experimental|Cohort B/B2/BB/BB2: FT536 + Avelumab|FT536 + avelumab combination therapy in participants with locally advanced or metastatic solid tumor indications with documented PD-L1 expression.
89059416|NCT05395052|Experimental|Cohort C/C2/CC/CC2: FT536 + Pembrolizumab, Nivolumab, or Atezolizumab|FT536 + pembrolizumab, nivolumab, or atezolizumab in participants with locally advanced or metastatic solid tumor indications with documented PD-L1 expression.
89059417|NCT05395052|Experimental|Cohort D/D2/DD/DD2: FT536 + Trastuzumab|FT536 + trastuzumab in participants with locally advanced or metastatic documented human epidermal growth factor receptor 2 (HER2+) expressing tumors
89059418|NCT05395052|Experimental|Cohort E/E2/EE/EE2: FT536 + Cetuximab|FT536 + cetuximab in participants with locally advanced or metastatic squamous NSCLC, CRC, or head and neck cancer.
89059419|NCT05395052|Experimental|Cohort F/F2/FF/FF2: FT536 + Amivantamab|FT536 + amivantamab in participants with locally advanced or metastatic NSCLC.
89059420|NCT05389657|Experimental|Web-based training|Web-based training will provide online training primarily focused on family-based treatment and appropriate adaptations to the treatment model.
89059421|NCT05389657|Active Comparator|Live training|Live training will include two days of expert-led live training (via zoom). The content of the training will be similar to that provided in web-based training, primarily focused on family-based treatment and appropriate adaptations to the treatment model.
89059422|NCT05387382||Patients pending bariatric surgery|A continuous cohort of patients pending bariatric surgery
89059423|NCT05384704|Experimental|Internet-based program|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
89059424|NCT05383092|Experimental|Adapted physical activity Strong|
89059425|NCT05383092|Active Comparator|Adapted physical activity Soft|
89059426|NCT05376488|Active Comparator|Meal type A|Meal type A: equicaloric meal as meal type B and C with differing constituents
89059427|NCT05376488|Active Comparator|Meal type B|Meal type B: equicaloric meal as meal type A and C with differing constituents
89059428|NCT05376488|Experimental|Meal type C|Meal type C: equicaloric meal as meal type B and A with differing constituents
89059429|NCT05376176|Experimental|STN1010904 ophthalmic suspension 0.03% BID|
89059430|NCT05376176|Experimental|STN1010904 ophthalmic suspension 0.1% BID|
89059431|NCT05376176|Placebo Comparator|Placebo Vehicle BID|
89059432|NCT05370339||Adolescents|Adolescents with type 1 diabetes between the ages of 11 and 17 years.
89059433|NCT05370235|Experimental|Afamelanotide|
89059434|NCT05364541|Other|MyoVista wavECG|Single arm - subjects meeting the inclusion, exclusion and screening criteria will receive a MyoVista wavECG and a trans-thoracic echocardiogram.
89059435|NCT05362071|Experimental|Remote Exercise Group|Participants will practice physical exercises twice a week, remotely and under the supervision of an exercise professional, for 12 weeks.
89059436|NCT05362071|Other|Group control|Participants will receive a booklet with recommendations for physical activity from the physical activity guide for the Brazilian population.
89059437|NCT05361720|Experimental|Arm I (ipilimumab, nivolumab)|"INDUCTION: Patients receive ipilimumab and nivolumab IV on day 1. Cycles repeat every 21 days for 4 cycles.~MAINTENANCE: Patients receive nivolumab IV on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
89059438|NCT05361720|Experimental|Arm II (nivolumab, cabozantinib)|Patients receive nivolumab IV on day 1 and cabozantinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89059439|NCT05361590|Experimental|Study group|Subjects in the study group will use the Lumoral device once a day according to the verbal and written instructions provided to them. In addition, they will brush their teeth twice daily in their customary manner while using the provided sonic toothbrush and regular toothpaste.
89059440|NCT05361590|Active Comparator|Control group|Subjects in the control group will brush their teeth in their customary manner twice daily while using the provided sonic toothbrush and regular toothpaste. They will not receive any additional intervention.
89059441|NCT05359653|Experimental|Clemastine 8 mg, then Placebo|Group 1 will receive the treatment (clemastine 8mg/day) for the first 90 days and then switch to the placebo (a sugar pill) for the remaining 90 days
89059442|NCT05359653|Experimental|Placebo, then Clemastine 8 mg|Group 2 will receive the placebo (a sugar pill) for the first 90 days and then switch to the treatment (clemastine 8mg/day) for the remaining 90 days
89059443|NCT05358704|Experimental|Combination of drugs prior to surgery|Receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
89059444|NCT05350826|Experimental|Ambulatory medical assistance|Patient benefiting from the ambulatory medical assistance nurse program in addition to conventional care for patients chronic lymphoid leukemia under targeted therapy
89219066|NCT06130813|Experimental|Increased perioperative communication program|The sample of the research is; it was determined as 70 patients by G. Power analysis based on the correlation coefficients in a sample study. 35 of the patients will be assigned to the intervention group (IG) and 35 to the control group (CG). Patients in the CG will receive routine perioperative care, while patients in the IG will be included in the IPCP. All patients will be followed for one month after discharge. IPCP consists of 8 informative contents such as preoperative preparations, surgical procedure, pain management, first mobilization, knee joint movements, exercise, discharge process, wound care, showering, nutrition, daily living activities, driving, sexual life, postoperative routine control, unexpected situations and etc. These informative contents will send to patients on days 7th, 4t and 1th days before the surgery and on days 1th, 2th, 3th, 5th an 7th days after surgery via whatsapp. Additionally, all participants will follow postoperative one month.
89219067|NCT06130813|No Intervention|Standart of care|Patients in the control group will receive routine perioperative care and will follow postoperative for one month.
89219068|NCT06130579|Experimental|IFN-α application in TP53+ myeloid malignancy|
89219069|NCT06130358|Experimental|Well-Being Museum intervention|The well-being intervention comprises six weeks of weekly museum visits, performed in groups of 10 participants. The well-being approach is based on the support of a museum mediator. His role is to help visitors to develop a more personal and sensitive understanding of artworks. To do this, he encourages the expression of feelings, impressions, and interpretations of the artwork, and supports exchanges within the group of visitors. With the mediator's support, the participants should be able to adopt a more subjective approach to the artwork, favoring their engagement when contemplating it.
89219070|NCT06130358|Active Comparator|Classic Museum intervention|The classic intervention comprises six weeks of weekly museum visits, performed in groups of 10 participants. The classic museum session will be performed according to what is typically provided to visitors as part of a guided visit to the museum. Each visit will be accompanied by a volunteer guide trained in art history. He will guide participants across artworks and provide information about art pieces, the artist, and the historical context. The volunteer guide will provide context and informative content about the artwork without intending to influence the discussions and the visitor's apprehension of the artwork.
89219071|NCT06130280|Experimental|MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)|Participants will undergo simulation including Gd-EOB-DTPAenhanced MR and planning using minimal margins. Ten days later (+/- 3 days) participants will receive 40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance and on-line adaptive replanning.
89219072|NCT06128616|Experimental|ESWT Group|Patients treated by BoNT-A, intermittent SC and ESWT, whom received either PT or OT
89059445|NCT05350826|No Intervention|Conventional care|Patient benefiting from conventional care for patients chronic lymphoid leukemia under targeted therapy
89059446|NCT05349968|Experimental|Dose 5 mg|Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
89059447|NCT05349968|Experimental|Dose 20 mg|Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
89059448|NCT05349968|Experimental|Dose 40 mg|Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
89059449|NCT05339776|Active Comparator|One of groups: amputees group|"We planned to enroll two groups to the study. One group is named amputees the other one is control. Both groups will enroll hand lateralization for at least 10 days. Before and after comparisons will be analyzed."
89059450|NCT05339776|Active Comparator|One of groups: control group|Control group will be matched in terms of age and gender with the amputees group.
89059451|NCT05336760||ALS Patients|Patients with confirmed amyotrophic lateral sclerosis.
89059452|NCT05336760||Relatives|Close relatives of the patients included in the study.
89059453|NCT05331755||Severe T2 high asthma|"Included patients will have severe type 2 high asthma, are eligible for dupilumab conform EU label, minimally treated with high dose ICS and LABA and have:~blood eosinophils 150 - 1500/mm2 OR~FeNO >20 ppb OR~clinical significant inhalation allergy (+ sIgE positive) OR~OCS dependency"
89059454|NCT05327946|Experimental|Monotherapy dose escalation|
89059455|NCT05327946|Experimental|Combination therapy dose escalation|
89059456|NCT05319184|Experimental|Myofascial Release Group|The application will be made with the patient in the prone position. By applying a few grams of constant force to the lumbar paravertebral muscles bilaterally with the hand of the physiotherapist in the direction of restriction for 3-5 minutes, the fascia will be stretched and allow the tissue to relax on its own. Thus, it is aimed to decrease the tone and stiffness of the paravertebral muscles.
89059457|NCT05319184|Experimental|Kinesiology Taping Group|During the application, the participants will be positioned standing and facing backwards due to the ease of application. While taping the lumbar region, the kinesiology tape cut as a long strip (I tape) will be applied paravertebrally to the right and left sides of the spine. Rounded corners will be created to prevent premature loosening and unwanted bends in the belt. The patient will be asked to perform maximum trunk flexion and 2 I-shaped pieces will be taped with 10-15% tension from the lumbar region to the thoracic region. The tape will remain on the patient's skin for 30 minutes.
89059458|NCT05319184|No Intervention|Control Group|No intervention.
89059459|NCT05318417|Other|Children and adults with unilateral hearing loss/single-sided deafness|
89059460|NCT05316168|Active Comparator|isolated adductor canal block (ACB)|Adductor Canal Block with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone.
89059461|NCT05316168|Active Comparator|isolated adductor canal block (ACB) + IPACK|ACB with 20cc 0.5% bupivacaine HCl + 2mg dexamethasone, and iPACK with 20cc 0.5% bupivacaine + 2mg dexamethasone.
89059462|NCT05306964|Active Comparator|Restrictive UFnet Strategy|Fluid removal will be titrated to keep net ultrafiltration rate between 0.5-1.5 mL/kg/h
89688850|NCT03032731|Other|Control|Participants allocated to this group will be given a one-off session in which a researcher shows them publicly available web-based resources for health behaviour change (provided by the National Health Service (NHS)). Like those participants in the intervention group, they will be assessed again after 6 and 12 weeks. Participants in the control arm will be offered the intervention (access to the study website and a pedometer) after 12 weeks.
89688851|NCT03032653|Active Comparator|Late WB|Intervention: Patients receive a plaster splint in the operating room. They are not permitted to WB or ROM on the affected limb at this stage. At the first follow-up appointment (two weeks post-op), the splint is removed and a removable pre-fabricated walking boot applied. At this stage the patient is permitted to WB as tolerated while wearing the boot, and to perform ROM exercises with the boot removed. At six weeks post-op, the boot is discontinued and full unrestricted and unprotected weightbearing and ROM is permitted.
89059463|NCT05306964|Active Comparator|Liberal UFnet Strategy|Fluid removal will be titrated to keep net ultrafiltration rate between 2.0-5.0 mL/kg/h
89059464|NCT05304728||Primary Objective: Severe Sepsis|The primary endpoint for this study is defined as the presence of sufficient data for SOWS training and algorithm development to proceed with subsequent validation. To provide sufficient data subsets (severe sepsis EHR encounters) for training and validation of the Sepsis Onset Warning System algorithm. There will not be any interventions administered.
89059465|NCT05300191||Peritoneal dialysis patients|Patients undergoing peritoneal dialysis. Patients may be using either Continuous Ambulatory Peritoneal Dialysis (CAPD), Continuous Cycling Peritoneal Dialysis (CCPD) or Intermittent Peritoneal Dialysis (IPD).
89059466|NCT05297487|Experimental|standard care associated with daily and early use of (IPPB) intermittent positive pressure breathing|
89059467|NCT05297487|No Intervention|standard care alone|
89059468|NCT05293509|Experimental|Phase I: Sequential Pharmacological PTIS|
89059469|NCT05293509|Experimental|Phase II: RTC Regimen and GVHD Prophylaxis Based on Post-Cy|
89059470|NCT05288790|Experimental|Study Supplement|Probiotic
89059471|NCT05288790|Placebo Comparator|Study placebo|Placebo
89059472|NCT05286892|Active Comparator|Control|Participants randomized to the control group will receive enhanced pre-release diabetes education with registered or licensed practical nurse-delivered diabetes education about medications and insulin administration supplemented with the literacy tailored diabetes education packets used in the principal investigator's prior research.
89219073|NCT06128616|Active Comparator|Control Group|Patients treated by BoNT-A, and intermittent SC, whom received either PT or OT
89688852|NCT03032653|Experimental|Immediate unprotected WB and ROM|Patient do NOT receive a brace or splint of any kind. They are permitted to weightbear and range of motion as tolerated within the limitations of their own comfort. Use of ambulatory aids of any kind is permitted as needed without restrictions.
89688853|NCT03004534|Experimental|Presurgical Molecular Assessment|Oral 300 mg darolutamide tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.
89059473|NCT05286892|Experimental|Intervention|Because eight avatars plus the educator avatar are allowed in the VE classroom at one time, we will cap enrollment for the feasibility study to allow for CHW and CDE training and the opportunity to work together during LIVE JustICE sessions. The DSMES will consist of six synchronous 1-hour education sessions and an hour support session for participants living in supervised community housing in the experimental group. We will run the six-week series sequentially a total of eleven times over 18 months. LIVE JustICE sessions will be held conveniently for participants, and days/times rotated if needed.
89059474|NCT05284643|Experimental|Cohort A: sMRI-Guided RT at 35 Gy in 10 fractions|"Participants will receive a total dose of 3500 centigrays (cGY) (35Gy) of Spectroscopic Magnetic Resonance Imaging (sMRI)-guided radiation therapy delivered in 10 fractions, 350 cGy (3.5 Gy) to the Clinical Target Volume (CTV) by Intensity Modulated Proton Therapy (IMPT) simultaneous integrated boost technique.~Participants will also receive Bevacizumab per standard of care, at treating physician's discretion. Initial dose will begin prior to first dose of radiation therapy (RT)."
89059475|NCT05284643|Experimental|Cohort B: sMRI-Guided RT at 40 Gy in 10 fractions|"Participants will receive a total dose of 4000 cGY (40Gy) of Spectroscopic Magnetic Resonance Imaging (sMRI)-guided radiation therapy delivered in 10 fractions, 400 cGy (4 Gy) to the Clinical Target Volume (CTV) by Intensity Modulated Proton Therapy (IMPT) simultaneous integrated boost technique.~Participants will also receive Bevacizumab per standard of care, at treating physician's discretion. Initial dose will begin prior to first dose of radiation therapy (RT)."
89059476|NCT05273736|Experimental|Intervention|Dose-finding study with 14 groups of 3 participants each. To identify the minimum effective dose (MED) to increase medication adherence by 20% between run-in and follow-up periods, the first group of 3 participants will receive a 5-week dose of the multi-BCT intervention. For the next subjects, the doses to administrate will vary between 1 and 10 weeks in length and will be determined by the modified Time-to-Event Continual Reassessment Method (TiTE-CRM) according to the observed responses in the previous subjects.
89059477|NCT05270369|Experimental|digital cognitive behavioural therapy for insomnia (CBTI)|The digital CBTI group will receive 6-session on their smartphone application
89059478|NCT05270369|Experimental|group cognitive behavioural therapy for insomnia (CBTI)|The group CBTI will receive 6-session CBTI in group
89059479|NCT05270369|No Intervention|waitlist|The waitlist group will receive treatment sessions after about 10 weeks' time
89059480|NCT05266911|Experimental|High-intensity strength training (HIFST) program|Home-based high-intensity strength training program
89059481|NCT05266911|Active Comparator|Lower extremity stretching program|Lower extremity stretching program
89059482|NCT05265000|Experimental|tSpinalStim|Individuals in this arm will receive spinal cord stimulation
89059483|NCT05263362||STARLINGS study population|The study population consists of breast cancer patients who were treated with breast conserving therapy (BCT) at one of the four participating hospitals (Erasmus MC, Albert Schweitzer hospital, Maasstad hospital and Franciscus hospital Gasthuis and Vlietland), for non-metastatic, histological proven invasive breast cancer or DCIS between 2016 and 2020 (at time of inclusion in 2022 respectively 6 to 2 years after treatment), and subsequently received adjuvant (whole breast) irradiation (WBI), with or without boost, at the Erasmus MC as part of their BCT.
89059484|NCT05256472|Experimental|AK104 monotherapy cohort (Part 1)|Subjects in this cohort will randomly receive three different dosage of AK104 monotherapy administered intravenously.
89059485|NCT05256472|Experimental|combination treatment cohort (Part 2)|Subjects in this cohort will receive AK104 (RP2D, administered intravenously) plus Axitinib 5 mg bid, administered orally.
89059486|NCT05240014|Experimental|Exoskeleton|Participants in this arm of the study will perform various tasks while wearing the modular powered orthosis
89059487|NCT05238558|Experimental|FMPV-1 vaccination|"GM-CSF (0.03 mg) + FMPV-1 (0.15 mg/injection: low dose) administered as 2 separate intradermal injections.~Total of 8 administrations intradermally; GM-CSF + FMPV-1 on 5 separate occasions and FMPV-1 (without GM-CSF) on 3 occasions for the DTH skin reactivity assessment."
89059488|NCT05236192|Experimental|Take Root Home Visitation (TRHV)|TRHV is an evidence-informed, manualized home-visiting curriculum.
89059489|NCT05236192|Active Comparator|Services as Usual (SAU)|SAU involves the current standard of care implemented at the participating Navy and Marine Corps installations.
89059490|NCT05235880|Experimental|study group|1 hour physiotherapy session for 3 times a week and 8 weeks in total.
89059491|NCT05235880|Active Comparator|control group|1 hour physiotherapy session for 3 times a week and 8 weeks in total.
89059492|NCT05227937||Single Dose Amikacin|Patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients >120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
89059493|NCT05227144|Experimental|Dose Escalation|ORIC-533 dosed orally, once per day of each consecutive 28-day cycle.
89059494|NCT05227144|Experimental|Dose Expansion|RP2D dose
89059495|NCT05219968|Experimental|LYR-210|Single administration of LYR-210 drug matrix (7500 μg)
89059496|NCT05219968|Sham Comparator|Sham procedure control|Single mock administration procedure
89059497|NCT05209750|Experimental|FAPI PET/CT|"Colon cancer patients: one FAPI PET/CT scan early after standard diagnostic imaging and prior to planned surgery.~Rectal cancer patients: two FAPI PET/CT scans, one for initial staging (pre neoadjuvant therapy) and one for restaging (post neoadjuvant therapy)."
89059498|NCT05208879||Case group.|"Patients with genetically proven familial hypocholesterolemia, who will accept to participate in this study and have been treated for this pathology since 1990 in the Department of Gastroenterology and Paediatric Nutrition (Pr Peretti) and continue their follow-up into adulthood at the GHE (Groupement Hospitalier Est) in Lyon in the endocrinology-nutrition service (Pr Moulin).~They may be girl/woman or boy/man over 6 years of age and over 12 kg at the time of inclusion (age required for cooperation on macular pigment measurement), agreeing to participate in the study with clear and informed consent. These patients are covered by social security."
89219074|NCT06127771|No Intervention|Standard of Care programming|Individuals' DBS will be programmed using SOC programming parameters.
89219075|NCT06127771|Experimental|Percept PC programming|Individuals' DBS will be programmed using the full capacity of Percept PC IPG.
89219076|NCT06127069|Experimental|chitosan group|debridement of residual periodontal pockets with ultrasonic scaler and the chitosan brush
89219077|NCT06127069|Active Comparator|control group|debridement of residual periodontal pockets with ultrasonic scaler only
89219078|NCT06126770|Experimental|The social norm intervention|The married adolescent girls (MAGs) and their spouses, and community members from the intervention clusters will receive the social norm intervention.
89219079|NCT06126770|No Intervention|Pure Control|Participants, including married adolescent girls (MAGs), their spouses, and community members from the control clusters, will not receive any intervention.
89219080|NCT06126614|Experimental|Povidone-Iodine 0.35% Lavage Solution|"The study lavage solution (povidone-iodine) is the final lavage and is to be poured in and left for 3 minutes then removed by suction.~The study lavage solution will be a total volume of 1 litre, made with sterile isotonic saline."
89219081|NCT06126614|Experimental|Povidone-Iodine 0.35% Lavage Solution and Vancomycin|"The study lavage solution (povidone-iodine) is the final lavage and is to be poured in and left for 3 minutes then removed by suction. Two grams of vancomycin is applied to the deep joint (to arthrotomy in knee and deep to fascia in hip) following removal of the study lavage solution and immediately prior to closure.~The study lavage solution will be a total volume of 1 litre, made with sterile isotonic saline."
89219082|NCT06126614|Experimental|Chlorhexidine Gluconate 0.05% Lavage Solution|"The study lavage solution (chlorhexidine-gluconate) is the final lavage and is to be poured in and left for 3 minutes then removed by suction.~The study lavage solution will be a total volume of 1 litre, made with sterile isotonic saline."
89219083|NCT06126614|Experimental|Chlorhexidine Gluconate 0.05% Lavage Solution and Vancomycin|"The study lavage solution (chlorhexidine gluconate) is the final lavage and is to be poured in and left for 3 minutes then removed by suction. Two grams of vancomycin is applied to the deep joint (to arthrotomy in knee and deep to fascia in hip) following removal of the study lavage solution and immediately prior to closure.~The study lavage solution will be a total volume of 1 litre, made with sterile isotonic saline."
89219084|NCT06126614|Active Comparator|Saline Lavage Solution|"The study lavage solution (saline) is the final lavage and is to be poured in and left for 3 minutes then removed by suction.~The study lavage solution will be a total volume of 1 litre."
89219085|NCT06126614|Experimental|Saline Lavage Solution and Vancomycin|"The study lavage solution (saline) is the final lavage and is to be poured in and left for 3 minutes then removed by suction.~Two grams of vancomycin is applied to the deep joint (to arthrotomy in knee and deep to fascia in hip) following removal of the study lavage solution and immediately prior to closure."
89219086|NCT06125977||Type-1 MNV|No intervention
89219087|NCT06125548|Experimental|Lactation Management Model-Experimental|The women in the experimental group were told about the care technique in accordance with the Lactation Management Model and were asked to apply it regularly for 3 days.The content of the Lactation Management Model includes skin-to-skin contact, hot application to the breast, relaxation and breast massage, and process monitoring.In this regard, the mother should apply skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes manual milking, 2 minutes . nipple stimulation, stroking for 3 minutes).
89219088|NCT06125548|No Intervention|Non-application group- Control|No treatment was performed on women in the control group.
89219089|NCT06125132|Active Comparator|OMNICHROMA one shade composite|a one-shade composite resin as experimental group
89219090|NCT06125132|Active Comparator|Zen Chroma one shade composite|a one-shade composite resin as experimental group
89219091|NCT06125132|Active Comparator|Filtek Z250 multi shade composite|a multi-shade composite resin as control group
89219092|NCT06124794|Experimental|PROTOXIN 100U (Clostridium botulinum toxin type A)|PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL)
89219093|NCT06124534|Experimental|Blistim System|Occipital Nerve Stimulation using the BliStim Occipital Nerve Stimulator
89219094|NCT06123208|Experimental|Whole cooked pinto bean meal|Participants will consume a meal comprised of 100 grams of whole cooked pinto beans
89219095|NCT06123208|Experimental|Pinto bean flour meal|Participants will consume a meal comprised of pinto bean flour equivalent to 100 grams of whole cooked pinto beans
89219096|NCT06123208|Active Comparator|Control meal|Participants will consume a control meal
89219097|NCT06121479|Experimental|branched-chain amino acid|Oral branched-chain amino acid (BCAA) is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
89219098|NCT06121440|No Intervention|Control Group|Routine tracheostomy care will be applied to the control group. No action will be taken.
89219099|NCT06121440|Experimental|Experimental Group|During the tracheostomy care process, the experimental group will listen to audiobook and play with musical-moving toy.
89059499|NCT05208879||Control group.|The control group consists of children over 6 years old or adult patients, followed routinely in the ophthalmology department of the Edouard Herriot Hospital, Lyon (Pr Kodjikian) not suffering from genetic hypocholesterolemia and requiring a fundus examination as part of the usual follow-up of their ocular pathology, if this pathology does not interfere with the macular pigment density. An additional measurement of the macular pigment density will be made during this examination. The control group is only needed for the macular pigment analysis. No control group is considered for the characterization of plasma lutein and zeaxanthin deficiency and for the analysis of oxidative stress, so there will be no additional blood sampling for control patients.
89059500|NCT05201313|Experimental|lidocaine spray|nebulization 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
89059501|NCT05201313|Active Comparator|mepivacaine infiltration|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
89059502|NCT05199766|Experimental|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks, in case of discontinuation due to patient's wishes and/or adverse event above grade 2 : 1000mg during 14 days then complete discontinuation if no resolution. In case of sudden discontinuation a therapeutic phlebotomy will be authorized.
89059503|NCT05199753|Experimental|LM-108 Dose Escalation|
89059504|NCT05199753|Experimental|LM-108 Dose Expansion|
89059505|NCT05199753|Experimental|LM-108 combination dose escalation|
89059506|NCT05199753|Experimental|LM-108 combination dose expansion|
89059509|NCT05188872|Experimental|68Ga-Pentixafor|Each subject receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT imaging within the specificed time
89059510|NCT05184348|Active Comparator|Narrow band Ultraviolet B phototherapy group|Patients will be treated with Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose of 1400 mJ/cm2.
89059511|NCT05184348|Active Comparator|Acitretin group|Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally for 3 months
89059512|NCT05184348|Active Comparator|Acitretin plus Narrow band Ultraviolet B phototherapy group|Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally plus NB-UVB phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
89059513|NCT05184348|No Intervention|Control group|30 healthy individuals un related , age, sex , BMI matched with volunteers.
89059514|NCT05184270|Experimental|Sleep Measurements|LFP recording from STN using externalized wires or implanted neurostimulator, while simultaneously recording clinical surface EEG and applying AS during deep sleep.
89059515|NCT05183412|Active Comparator|Ultrasound-guided regional nerve block and hand surgery without VR glasses|Patients will not receive the VR glasses during the ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery.
89059516|NCT05183412|Experimental|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Patients will receive the VR glasses during the ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery.
89059517|NCT05182125|Experimental|Part A, Group 1: AdC6-HIVgp140|Participants will receive 1 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
89059518|NCT05182125|Experimental|Part A, Group 2: AdC7-HIVgp140|Participants will receive 1 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
89059519|NCT05182125|Placebo Comparator|Part A, Group 3: Placebo|Participants will receive placebo for AdC6-HIVgp140 or AdC7-HIVgp140 (labeled as Sodium Chloride for Injection, 0.9%) to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.
89219100|NCT06121089|Active Comparator|Laparoscopy ileocecal resection with extended D3 lymphadenectomy.|Ileocecal resection with extended D3 lymphadenectomy.
89219101|NCT06121089|Experimental|Laparoscopy right hemicolectomy with D3 lymphadenectomy.|Right hemicolectomy with D3 lymphadenectomy
89059520|NCT05182125|Experimental|Part B, Group 4: AdC6-HIVgp140 + AdC7-HIVgp140 + 400 mcg CH505TF gp120/GLA-SE|"Participants will receive 5 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.~Then~5 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 3.~Then~400 mcg CH505TF gp120 admixed with 10 mcg GLA-SE administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6."
89059521|NCT05182125|Experimental|Part B, Group 5: AdC7-HIVgp140 + AdC6-HIVgp140 + 400 mcg CH505TF gp120/GLA-SE|"Participants will receive 5 x 10^10 vp AdC7-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0.~Then~5 x 10^10 vp AdC6-HIVgp140 to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 3.~Then~400 mcg CH505TF gp120 admixed with 10 mcg GLA-SE administered as a 1mL IM injection into either thigh unless medically contraindicated at month 6."
89059522|NCT05182125|Placebo Comparator|Part B, Group 6: Placebo + Placebo + Placebo|Participants will receive placebo for AdC6-HIVgp140and AdC7-HIVgp140 (labeled as Sodium Chloride for Injection, 0.9%) to be administered as two separate 1 mL IM injections into the deltoid of the non-dominant arm unless medically contraindicated at month 0 and 3. Placebo for CH505TF/GLA-SE (labeled as Sodium Chloride for Injection, 0.9% ) to be administered as 1 mL IM injection into either thigh at month 6.
89059523|NCT05181371|Active Comparator|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB)|After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive programmed intermittent bolus of local anaesthetic: 20mls 0.125% levobupivacaine every two hours.
89059524|NCT05181371|Active Comparator|Ultrasound Guided ESP Block with Continuous Infusion (CI)|After induction of general anaesthesia, an ESP catheter will be inserted at the level of T5. A bolus dose of 20 ml 0.25% Levobupicaine will be administered into the ESP space. Two hours post bolus administration, patients will receive a continuous infusion local anaesthetic: 0.125% levobupivacaine at an infusion rate of 10 ml/hr.
89059525|NCT05174988|Experimental|Angle stitch|"If the allocation corresponds to Angle stitch, surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) apexes. Knot tying technique (intra-corporeal vs extracorporeal) will be up to surgeon preference. After this is completed, barbed suture will be used to re-approximate the remainder of the vaginal cuff from right to left, backtracking once at the end for reinforcement."
89059526|NCT05174988|No Intervention|control|"If the subject's group corresponds to Control group, the surgeon will re-approximate the cuff in a standard fashion, using a running-barbed suture (2-0 V-LOC 90 with tapered needle), starting at the right apex, moving towards the left, and then back-tracking once to further reinforce the closure."
89059527|NCT05172648|Active Comparator|control group|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength
89059528|NCT05172648|Other|contrast group|Moisten the mouth with sterile distilled water with an oral cotton swab.
89059529|NCT05166629|Other|Usual Care|Usual care in the POWER Kids weight management program includes a nutrition assessment and education by a registered dietician nutritionist (RD). This includes taking a detailed dietary history, and providing individualized counseling, motivational interviewing, and nutrition education handouts/ web-based resources.
89059530|NCT05166629|Experimental|Eatable Alphabet|The intervention group will receive usual care, as described above, plus a set of Eatable Alphabet cards, which will be utilized during the visit for counseling and education, and given to the family to take home and use as they wish.
89059531|NCT05165238|Experimental|Coaching program|Participants will complete a 4-week coaching program in an on-line group setting. The purpose of the program will be to help participants change dietary behaviors via a small changes approach.
89059532|NCT05161884||Preclinical Study group|n=10 Landrace pigs The aim of the pre-clinical study was to assess the accuracy of BOLD-T2 MRI in acute systemic hyper- and hypoxemia in a porcine model in contrast to cardiac catheterization.
89059533|NCT05161884||Validation Study group|"n=25 The patients have an indication for a right heart catheter examination. This is a routine diagnostic examination that is performed on these patients.~Compared to the clinical routine, an additional MRI measurement will be performed. The measurement will be performed before the cardiac catheterization.~For the MRI examination, the patient/subject is placed in a magnetic resonance imaging machine. The MRI examination initially includes approximately 15 minutes of standard images for orientation and determination of function, morphology, and tissue characteristics. This is followed by images to determine oxygen saturation in the ventricles (approximately 5 minutes).~If a CMR examination is already planned for a patient for other reasons, this will only be extended by the recordings for the determination of oxygen saturation (approx. 5 minutes) at the time of study inclusion.~During the MRI measurements, patients will also perform a stepper stress test."
89059534|NCT05161884||Pulmonary Hypertension group|n=25 patients with pulmonary hypertension (definition: pulmonary arterial pressure (PAP) above 25 mmHg)
89059535|NCT05161884||Valvular heart disease group|n=25 patients with valvular heart disease (at least moderate)
89059536|NCT05161884||Ischemic cardiomyopathy group|n=25 patients with ischemic cardiomyopathy
89059537|NCT05161884||HFpEF group|n=25 patients with HFpEF (heart failure with preserved ejection fraction, definition: EF over 50%, heart failure symptoms, elevated NT-proBNP over 400pg/ml)
89059538|NCT05159908|Placebo Comparator|Placebo schedule|Participant follows Placebo schedule (13 weeks)
89059539|NCT05159908|Experimental|Dose schedule A|Participant follows Dose schedule A (13 weeks)
89059540|NCT05159908|Experimental|Dose schedule B|Participant follows Dose schedule B (13 weeks)
89059541|NCT05159908|Experimental|Dose schedule C|Participant follows Dose schedule C (13 weeks)
89059544|NCT05156944|Experimental|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including two exercises for daily self-guided therapy.
89059545|NCT05156944|No Intervention|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
89059546|NCT05147675|Experimental|Treatment Group (AlloRx)|Intravenous infusion and intraarticular injection (total dose of 100 million cells)
89059547|NCT05147376|Experimental|Curcumin mouthwash|The curcumin mouthwash contains the final concentration of 1 μM curcumin, water, xylitol, and food coloring agent.
89059548|NCT05147376|Sham Comparator|Placebo mouthwash|The placebo mouthwash contains water, xylitol, and food coloring agent.
89059549|NCT05140083|Experimental|68Ga-NOTA Evans Blue PET/CT in Patients with Lymphatic System Related Diseases|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA Evans Blue will be injected subcutaneously. PET/CT imaging will be performed at 5-30 min post- injection. Visual and quantitative method will be used to assess the PET/CT images.
89059550|NCT05135169||Contrast administration|
89059551|NCT05131100||Participants receiving Somavert|
89059552|NCT05127174|Experimental|Phase 1: Dose Level 1|Participants will take 200 mg fedratinib once daily by mouth.
89059553|NCT05127174|Experimental|Phase 1: Dose Level 2|Participants will take 300 mg fedratinib once daily by mouth.
89059554|NCT05127174|Experimental|Phase 1: Dose Level 3|Participants will take 400 mg fedratinib once daily by mouth.
89059555|NCT05127174|Experimental|Phase 2: Treatment at Recommended Phase 2 Dose (RP2D)|Participants will take fedratinib at the dose determined in the phase 1 portion of this study, once daily by mouth.
89059556|NCT05126563|Active Comparator|Treatment|HB-ad MSC's allogeneic
89059557|NCT05126563|Placebo Comparator|Placebo|Sterile Normal Saline
89059558|NCT05126472|Experimental|anti-CD40 antibody 2141-V11|Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses.
89059559|NCT05118854|Experimental|Sotorasib in Combination with Cisplatin/Carboplatin and Pemetrexed|4 cycles of at least one dose of sotorasib plus cisplatin (or carboplatin) and pemetrexed can be administered safely
89059560|NCT05116007|Experimental|Experimental|Subjects receive AK112 plus Etoposide and Carboplatin every 3- week cycle (Q3W) for 4 cycles followed by AK112 until progression.
89059561|NCT05114005|Experimental|Tango|The intervention will consist of 16 Argentine Tango (Tango) sessions, adapted for neurorehabilitation per Hackney and Earhart (2010). Delivered over 8 weeks at a frequency of 2x per week and duration of 1 hour per session, this program teaches the basics steps of partnered Tango dance.
89059562|NCT05114005|Active Comparator|Home Exercise (HEX)|The control group will consist of an evidence-based, structured home exercise program (HEX) based on the 8 week intervention described by Zimmer et al (2018) and recommended by physical therapists specializing in BC within our organization. This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hr training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
89059563|NCT05112289|Other|Migraine cohort|Women with migraine and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
89059564|NCT05112289|Other|Small vessel ischemic (SVI) disease cohort|Women diagnosed with SVI disease and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
89059565|NCT05112289|Other|Multiple sclerosis (MS) cohort|Women diagnosed with MS and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.
89059566|NCT05107726|Experimental|TRE Group|In the TRE group, study staff will instruct the family unit on limiting the eating window to 10-12 hours per day, during which they can eat ad libitum. Notably, in the TRE group, participants (children and adults) will be instructed to brush their teeth with a WIFI-enabled toothbrush in the morning and specifically within ½ hour after their evening meal. This will serve as a cue to stop evening eating, and information from the WIFI-enabled toothbrush will be accessed by study staff to approximate the eating window. The adult from each family unit will receive a daily REDCap-administered email to indicate the timing of the first meal of the day and the last meal of the day for the parent and child, which will also serve as an estimate of the eating window.
89059567|NCT05107726|No Intervention|Standard of Care Group|The standard of care control group will receive dietary instruction that is based on a 1200-1500 calorie diet, as is typical of family-based interventions. Calorie counting will not be encouraged. However, families will be encouraged to follow appropriate portion sizes; increase vegetable, fruit and lean protein consumption; as well as decrease consumption of energy-dense but low-quality items (e.g., sugar sweetened beverages). Families in this group will also receive a WIFI-enabled toothbrush and daily REDCap surveys but will not be instructed on when to brush teeth or to shorten their eating window
89059568|NCT05104476|Experimental|Lu AF82422|Participants in the DBP will receive Lu AF82422 intravenous (IV) infusion every 4 weeks (Q4W) from Baseline for a minimum 48 weeks up to a maximum 72 weeks. In the optional OLE, all participants will receive Lu AF82422 IV infusion starting on Day 1 of the OLE up to week 44.
89059569|NCT05104476|Experimental|Placebo|Participants in the DBP will receive Lu AF82422 matching placebo IV infusion Q4W from Baseline for a minimum 48 weeks up to a maximum 72 weeks.
89059570|NCT05095376|Active Comparator|Arm I (radiation therapy, temozolomide)|Patients undergo radiation therapy 5 days per week and receive temozolomide PO QD for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89059571|NCT05095376|Experimental|ARM II (radiation therapy, temozolomide, lomustine)|Patients undergo radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive lomustine PO on day 1 and temozolomide PO QD on days 2-6. Treatment repeats every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89059572|NCT05090696||One group only|Participants recruited from patients hospitalized in intensive care units and pulmonary unit of the University Hospital of Clermont-Ferrand, France.
89059573|NCT05087888||Observational (MRI, questionnaire, blood collection)|Patients undergo multiparametric MRI with contrast at baseline, 3 weeks during radiotherapy, and at 1, 3, 6, 12, and 24 months post-radiotherapy. Patients undergo multiparametric MRI without contrast at 1, 2, 4, 5, and 6 weeks during radiotherapy. Patients may undergo functional MRI at baseline and 6 months post-radiotherapy. Patients also complete questionnaires and undergo collection of blood samples at baseline, weekly through week 6 during radiotherapy, and at 1, 3, 6, 12, and 24 months post radiotherapy.
89059574|NCT05084560|Experimental|AWZ1066S|"AWZ1066S~Part A Cohort A1- 100mg single dose Cohort A2- 200mg single dose Cohort A3- 400mg single dose Cohort A4- 800mg fasted single dose and 800mg fed single dose Cohort A5- 1200mg single dose Cohort A6- 1600mg single dose~The doses for part B will be selected following review of data from Part A. Cohort B1- AWZ1066S once daily for 7 days Cohort B2- AWZ1066S once daily for 7 days Cohort B3- AWZ1066S once daily for 7 days Cohort B4- AWZ1066S once daily for 7 days"
89059575|NCT05084560|Placebo Comparator|Placebo|"Placebo~Cohort A1- equivalent placebo single dose Cohort A2- equivalent placebo single dose Cohort A3- equivalent placebo single dose Cohort A4- equivalent placebo fasted single dose and equivalent placebo fed single dose Cohort A5- equivalent placebo single dose Cohort A6- equivalent placebo single dose~The doses for part B will be selected following review of data from Part A. Cohort B1- equivalent placebo once daily for 7 days Cohort B2- equivalent placebo once daily for 7 days Cohort B3- equivalent placebo once daily for 7 days Cohort B4- equivalent placebo once daily for 7 days"
89059576|NCT05083546|Experimental|Intervention|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
89059577|NCT05083546|Placebo Comparator|Control|sugar pill
89059578|NCT05083312|Experimental|APT-1011|APT-1011 3 mg HS
89059579|NCT05083312|Placebo Comparator|Placebo|HS
89059580|NCT05080920|Experimental|Rosmalip®|Participants receive Rosmalip® (diterpene phenols 11,25 mg) 1 capsule orally once daily for 16 weeks
89059581|NCT05080920|Placebo Comparator|Placebo|Participants receive Placebo 1 capsule matching Rosmalip® orally once daily for 16 weeks
89059582|NCT05079698|Experimental|Stereotactic Body Radiotherapy and 177Lu-PSMA-617|
89059583|NCT05078905||Individuals Receiving Vaccine|Individuals receiving a vaccination for an emerging infection, like SARS-CoV-2
89059584|NCT05078138|Experimental|Exogenous Erythropoietin|Recombinant human Erythropoietin subcutaneous injection of 50 IU/kg body mass 3 times per week for 4 week
89059585|NCT05073874|Other|Functional Near-Infrared Spectroscopy (fNIRS)|"Subjects will be guided to walk at a normal pace while maintaining the required attentional focus:~no instructions about the attentional focus~internal focus on their feet movements,~external focus on two lines drawn on the floor,~divided attention (walking while performing an arithmetic task).~A fNIRS system will be used for the prefrontal cortex activation evaluation and connected soles for gait analyses."
89059586|NCT05072210|Experimental|Mobile Intervention Group|One half of the participants will receive personalized automated alerts throughout their involvement.
89059587|NCT05072210|No Intervention|Control Group|For 4 weeks, the other half of the participants will not receive personalized automated alerts. After 4 weeks, these alerts will be enabled.
89059588|NCT05069935|Experimental|Dose Escalation|"Cohort A: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved~Cohort B: FT538 plus trastuzumab in subjects with advanced documented HER2+ tumors~Cohort C: FT538 plus cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell carcinoma (HNSCC)"
89059589|NCT05069935|Experimental|Dose Expansion|"Cohort A, Arm 1: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved (except urothelial carcinoma (UC))~Cohort A, Arm 2: FT538 plus an anti-PD-1 antibody (nivolumab or pembrolizumab) in subjects with solid tumor malignancies where anti-PD-1/PD-L1 antibodies are approved (except UC)~Cohort B, Arm 1: FT538 plus trastuzumab in subjects with HER2+ tumors~Cohort C, Arm 1: FT538 plus cetuximab in subjects with advanced CRC or HNSCC~Subjects with UC may be enrolled in the randomized expansion cohorts as follows:~Cohort A, Arm R1: FT538 plus avelumab~Cohort A, Arm R2: FT538 plus atezolizumab"
89059590|NCT05067478||Cohort A Vibegron|Participants with previous anticholinergic therapy experience will receive vibegron as per the United States (U.S.) label.
89059591|NCT05067478||Cohort B Vibegron|Participants with previous mirabegron monotherapy or mirabegron plus solifenacin or combination therapy experience will receive vibegron as per the U.S. label.
89059592|NCT05064696|Active Comparator|Group 1 (Control group)|Surgical wound will be covered with the standard non-stick gauze dressing.
89059593|NCT05064696|Experimental|Group 2 (Treatment group)|Surgical wound will be covered with the PICO dressing.
89059594|NCT05064592||Patients|Medical records of minor patients hospitalized between 2015 and 2020 in PICU and having been under sedation and prolonged invasive mechanical ventilation (> 72h).
89059595|NCT05062902|Active Comparator|Template Injection|For the standard template injection, 200 units of BoNT diluted in 6mL of preservative saline will be prepared. 1/4 of the prepared BoNT solution will be administered to each of the pubococcygeus and puborectalis muscle at 5 and 7 o'clock position, respectively. The index finger will be used for palpation as the 20-gauge spinal needle with a trumpet guide (i.e. paracervical block kit) piercing through the vaginal mucosa to the intended muscle groups. The syringe will be withdrawn before each injection to avoid intravascular injection.
89059596|NCT05062902|Experimental|Guided Injection|For the guided injection, pelvic floor injections (total of 4) will be made to the pubococcygeus and puborectalis muscles each, at NMJ locations (1.5 ml per site), at patient-specific locations and depths identified from vaginal HD-sEMG recordings. NMJ mappings will be generated for each participant. The channel locations will provide angle measurements for each NMJ. The device will calculate these parameters based on acquired HD-sEMG. The index finger will be used for palpation and guidance of injection needle through the vaginal mucosa to the defined injection sites. The BoNT dosage with respect to the total 200 units administered to each site will be patient specific, determined as the ratio of the resting average resting root-mean square (RMS) value of a specific region divided by the total average resting RMS.
89059597|NCT05059678|Experimental|Group I (education material, videoconference session)|Participants receive education materials (brochure and a video) and attend 2 weekly videoconference intervention sessions over 45 minutes each. Caregivers attend 2 additional weekly intervention sessions over 45 minutes each.
89059598|NCT05059678|Active Comparator|Group II (waitlist control)|Participants receive standard of care.
89059599|NCT05058950||Phenotyped in Research Objectively: Cognitively Normal|"Participants with age ≥50 years and with a label of cognitively normal or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
89059600|NCT05058950||Phenotyped in Research Objectively: MCI|"Participants with age ≥50 years, with a label of MCI or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
89059601|NCT05058950||Phenotyped in Research Objectively: Exploratory Biomarker|"Participants with age ≥50 years, with documented positive result for an Alzheimer's disease biomarker, and with a label of subjective cognitive complaints or cognitively normal or its equivalent based on a clinical or research evaluation in the past 24 months will be enrolled virtually."
89059602|NCT05058950||Aging Across Adulthood: MCI|Participants with age ≥50 years, with a diagnosis of MCI, mild neurocognitive disorder (MND), or cognitively impaired, not demented (CIND) will be enrolled virtually from the community.
89059603|NCT05058950||Aging Across Adulthood: Subjective Cognitive Complaint|Participants with age ≥50 years and positive screen result from Cognitive Function Instrument (CFI) will be enrolled virtually from the community.
89059604|NCT05058950||Aging Across Adulthood: Cognitively Normal With Risk Factor For Dementia|Participants with age ≥60 years and self-reported history of a minimum of 2-4 risk factors for cognitive decline will be enrolled virtually from the community.
89219102|NCT06120998||Patients with rotator cuff tears pending for arthroscopic rotator cuff repair|"This is a Longitudinal Study. Patients were evaluated by orthopedic surgeons as having a rotator cuff tear, confirmed by magnetic resonance imaging (MRI) or ultrasound. If the patients required surgery and were willing to participate in the trial, the research assistant provided informed consent. The exclusion criteria were as follows.~Acromioclavicular arthritis requiring distal clavicular resection.~Severe glenohumeral arthritis (Hamada classification grade 3 or higher)15.~History of shoulder fracture.~Absolute contraindications to MRI, such as claustrophobia, pacemakers, neurostimulators, drug infusion pumps, artificial inner ear implants, and metallic implants."
89219103|NCT06118385|Experimental|Part A Dose 1|Part A Dose 1 Single dose of 2 mg BEN8744
89219104|NCT06118385|Experimental|Part A Dose 2|Part A Dose 2 Single dose of 6 mg BEN8744
89219105|NCT06118385|Experimental|Part A Dose 3|Part A Dose 3 Single dose of 20 mg BEN8744
89219106|NCT06118385|Experimental|Part A Dose 4|Part A Dose 4 Single dose of 40 mg BEN8744
89219107|NCT06118385|Experimental|Part A Dose 5|Part A Dose 5 Single dose of 80 mg BEN8744
89219108|NCT06118385|Experimental|Part A Dose 6|Part A Dose 6 Single dose of 140 mg BEN8744
89219109|NCT06118385|Experimental|Part A Dose 7|Part A Dose 7 Single dose of BEN8744 (Optional) (Dose To Be Determined (TBD))
89219110|NCT06118385|Experimental|Part A Dose 8|Part A Dose 8 Single dose of BEN8744 (Optional) (Dose TBD)
89219111|NCT06118385|Experimental|Part A placebo|Part A placebo Single dose of placebo
89219112|NCT06118385|Experimental|Part B Dose 1 fed|Part B Dose 1 Fed Single dose of BEN8744 after high-fat meal (Dose TBD)
89219113|NCT06118385|Experimental|Part B Dose 1 Fasted|Part B Dose 1 Fasted Single dose of BEN8744 after 10 hours fasting (Dose TBD)
89219114|NCT06118385|Experimental|Part B Dose 2 Fed|Part B Dose 2 Fed Single dose of BEN8744 after high-fat meal (Optional) (Dose TBD)
89219115|NCT06118385|Experimental|Part B Dose 2 Fasted|Part B Dose 2 Fasted Single dose of BEN8744 after 10 hours fasting (Optional) (Dose TBD)
89219116|NCT06118385|Experimental|Part C Dose 1|Part C Dose 1 14 daily doses of BEN8744 (Dose TBD)
89219117|NCT06118385|Experimental|Part C Dose 2|Part C Dose 2 14 daily doses of BEN8744 (Dose TBD)
89219118|NCT06118385|Experimental|Part C Dose 3|Part C Dose 3 14 daily doses of BEN8744 (Dose TBD)
89219119|NCT06118385|Experimental|Part C Dose 4|Part C Dose 4 14 daily doses of BEN8744 (Optional) (Dose TBD)
89219120|NCT06118385|Experimental|Part C placebo|Part C placebo 14 daily doses of placebo
89219121|NCT06116266|Experimental|Co-Care|Patient participants with providers will receive primary care treatment plus the full Co-Care intervention which includes: Nurse Care Manager (NCM) visits, Addiction specialist consultations through NCM if indicated, and Health coaching sessions.
89219122|NCT06116266|Active Comparator|Enhanced Usual Care (EUC)|Patient participants with providers will receive primary care treatment as usual plus educational materials.
89219123|NCT06113263||Anterior cervical decompression surgery|Individuals underwent anterior cervical decompression surgery due to cervical radiculopathy
89219124|NCT06113263||Posterior cervical decompression surgery|Individuals underwent posterior cervical decompression surgery due to cervical radiculopathy
89219125|NCT06111794|Experimental|REACH TBI|Participants will receive the REACH TBI psychoeducational intervention.
89219126|NCT06111794|Active Comparator|Waitlist Control|Participants will receive the REACH TBI psychoeducational intervention.
89522755|NCT04042285|Active Comparator|Extracorporeal shockwave therapy|The shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second (17). Participants will receive 3 sessions of shockwave therapy in a 7-day period. In addition to standard wound care (dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate).
89059605|NCT05058950||Aging Across Adulthood: Cognitively Normal Without Risk Factors For Dementia|Participants with age ≥60 years having missing descriptor of minimal risk factors for cognitive decline will be enrolled virtually from the community.
89059606|NCT05058950||Aging Across Adulthood: Cognitively Normal|Participants with age 21 to 59 years will be enrolled virtually from the community.
89059607|NCT05058859|Experimental|Study Drug|The study drug is Dapagliflozin
89059608|NCT05056818||Observational (medical records)|Patients' medical records and past imaging examinations are reviewed.
89059609|NCT05056779|Experimental|Nemolizumab|
89059610|NCT05056779|Experimental|Placebo|
89059611|NCT05050500|Experimental|Intervention Group|Dapagliflozin 10 mg every 24 hours for 6 months
89059612|NCT05050500|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 6 months
89059613|NCT05049590|Experimental|Intervention Group|Perform blood conservation in the operating room (OR).
89059614|NCT05049590|No Intervention|Control Group|Blood conservation will not be performed in the OR.
89059615|NCT05044026||Arm A: JAK inhibitor naive|JAK-inhibitor-naive patients, treatment start with ruxolitinib less than 14 days prior to the baseline visit
89059616|NCT05044026||Arm B: Pretreated patients|Patients pretreated with a JAK-inhibitor for more than 14 days prior to the baseline visit
89059617|NCT05043870|Experimental|infliximab and immunosuppressives therapy|the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
89059618|NCT05043870|Active Comparator|infliximab therapy|the infusion of infliximab (IFX) (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
89522756|NCT04042285|Placebo Comparator|Standard wound care|Patient with a diabetic foot wound who receive standard wound care, consisting of dressing changes, negative pressure wound therapy, debridement, offloading footwear, glycaemic control and antibiotics, where appropriate.
89059620|NCT05035654|Experimental|Treatment Arm A: LYR-220 Design 1|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
89059621|NCT05035654|Experimental|Treatment Arm B: LYR-220 Design 2|Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
89059622|NCT05035654|Sham Comparator|Treatment Arm C: Bilateral sham procedure control|Bilateral sham procedure control
89059623|NCT05034731|Other|Electric Only|
89059624|NCT05034731|Other|Aidable Residual Hearing|
89059625|NCT05033288||Observational (questionnaires, medical record review)|Patients complete quality of life questionnaires over 20 minutes at baseline (before any therapy), 2-4 and 5-9 months after completion of therapy, and then annually for up to 5 years. Patients' medical records are also reviewed.
89059626|NCT05030350|Experimental|PH94B 3.2 micrograms|100 microliter nasal spray to each nostril up to four times a day as needed for acute anxiety
89059627|NCT05029596|Active Comparator|Heparin Group|"Participants will receive the UTSW standard of of care for PICC line maintenance.~All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws."
89059628|NCT05029596|Experimental|Normal Saline Group|Participants will receive only Normal Saline for PICC line maintenance. All lumens of PICC line will be flushed every 24 hours with 10cc Normal Saline. PICC line will be flushed with 10cc Normal Saline after administration of medication, blood products, or blood draws.
89059629|NCT05027386|Experimental|Apatinib Mesylate combined with IT Regimen|"The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.~Combination therapy phase: Apatinib (orally once daily continuously in a 21-day cycle) was combined with IT regimen (repeated every 3 weeks) for up to 6 courses of treatment.~Apatinib:~<25Kg：0.25g，po，qd； 25Kg≤wight<40Kg：0.425g，po，qd； 40Kg≤wight<50Kg：0.5g，po，qd.~IT regimen:~Temozolomde：150mg/m2，iv 90min，d1-5，（1h before irinotecan）； Irinotecan: 50mg/m2，iv 90min，d1-5.~Monotherapy maintenance phase: Apatinib is administered as a monotherapy until tumor progression, patient withdrawal, or toxicity becomes intolerable."
89059630|NCT05026138||Biological relatives without HPV|Biological relatives without current HPV disease serving as controls to be compared with those from affected participants for evaluation of the differences between people with HPV and without.
89059631|NCT05026138||Participants with HPV|Patients with recurrent HPV related diseases refractory to standard-of-care medical or surgical interventions.
89059632|NCT05018767|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
89059633|NCT05016622|Experimental|Booster dose|
89522757|NCT03398837|Experimental|Cohort 1|Lenabasum 5 mg BID
89059634|NCT05015803|Experimental|CBTi with Application|Device-based intervention facilitation and clinician interfacing for Cognitive Behavioral Therapy for Insomnia (CBTi).
89059635|NCT05015803|Active Comparator|CBTi|Standard CBTi delivered via video conferencing [Zoom Health].
89059636|NCT05015803|Active Comparator|Sleep Hygiene|Treatment as usual: Sleep hygiene education and training.
89059637|NCT05013073|Experimental|Experimental Arm|All patients will be enrolled in a single arm and download the mobile application ASTHMAxcel ED to their smartphones.
89059638|NCT05010824|Experimental|Intervention group|The intervention will involve three consultation sessions and four follow-up phone calls with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
89059639|NCT05010824|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
89059640|NCT05010434|Experimental|Sintilimab and Bevacizumab Combined with Radiotherapy|
89059641|NCT05009381|Experimental|Treatment group|Treatment group will receive STYLAGE® XXL at enrollment with an optional touch up injection 30 days later
89059642|NCT05009381|Experimental|control group|Control group will not be treated at enrollment visit. Subjects will receive STYLAGE® XXL at visit 6 months after randomization, if they are still eligible for chin augmentation with an optional touch up injection 30 days later.
89059643|NCT05008315|Experimental|deep and superficial tissue mobilization group|include deep and superficial tissue mobilization
89059644|NCT05008315|Active Comparator|superficial tissue mobilization group|superficial tissue mobilization
89059645|NCT05008315|Placebo Comparator|control group|Sham (very light hand touch on the same location as the other two groups but without any treatment intention)
89059646|NCT05008315|Other|vaginal delivery group|education session
89059647|NCT05006807||Twitch Monitoring|Patients undergoing surgery with general anesthesia requiring neuromuscular blockade.
89059648|NCT04997265|Experimental|Low Intensity Anticoagulation|For patients assigned to the low intensity anticoagulation strategy, clinical teams will be instructed to initiate low intensity anticoagulation at doses and frequencies commonly used for deep vein thrombosis (DVT) prophylaxis. The choice of anticoagulant, dose, and frequency of administration will be deferred to treating clinicians.
89059649|NCT04997265|Active Comparator|Moderate Intensity Anticoagulation|For patients assigned to the moderate intensity anticoagulation group, clinical teams will be instructed to initiate a continuous infusion of moderate intensity anticoagulation targeting either a partial thromboplastin time (PTT) of 40-60 seconds or an Anti-Xa level of 0.2 to 0.3 IU/mL. The choice of anticoagulant and approach to dosing will be deferred to treating clinicians.
89059650|NCT04994639|Experimental|HPI group|Managing intraoperative hemodynamic condition under the HPI guidance
89059651|NCT04994639|No Intervention|Standard care group|Managing intraoperative hemodynamic condition with standard anesthesia care (blinding the HPI monitor screen)
89059652|NCT04986696|Experimental|Dose escalation of FLASH therapy in skin metastases of small volume (≤ 30 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
89059653|NCT04986696|Experimental|Dose escalation of FLASH therapy in skin metastases of large volume (> 30 and ≤ 100 cc)|7 dose levels (22 Gy; 24 Gy; 26 Gy; 28 Gy, 30 Gy, 32 Gy and 34 Gy)
89059654|NCT04985214||Oral therapy|Patients included in the PK-E3i clinical study or patients with hemopathies starting treatment with oral therapy.
89059655|NCT04984993|Experimental|MED3000|MED3000 gel formulation topically applied to the glans penis
89059656|NCT04984993|Experimental|Tadalafil|Tadalafil (5 mg) tablets to be taken orally
89059657|NCT04979611|Other|Patients will undergo 68Ga-NOTA-exendin-4 PET/CT imaging|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. PET/CT imaging will be performed at 30-60 min post-injection.Visual and semiquantitative method will be used to assess the PET/CT images.
89059658|NCT04975646|Experimental|Test group|Prescribed exercise program
89059659|NCT04975646|No Intervention|Control group|Exercising at patient's own discretion
89059660|NCT04971577|Placebo Comparator|Control arm|
89059661|NCT04971577|Experimental|Treatment arm|
89059662|NCT04970225|Experimental|Stable state|"45 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:~With severe cftr mutations~With or without PA chronic infection~Treated or not with Ivacaftor-Lumacaftor"
89059663|NCT04970225|Experimental|Starting Ivacaftor-Tezacaftor-Elexacaftor|"40 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France:~With at least one severe cftr mutation~With or without PA chronic infection~Initiating Ivacaftor-Tezacaftor-Elexacaftor"
89059664|NCT04970225|Experimental|Exacerbation|15 adult cystic fibrosis patients followed in the respiratory medicine department of Cochin hospital, paris, France and hospitalized for respiratory exacerbation
89059665|NCT04967248||alpelisib in combination with fulvestrant|Patients treated with alpelisib in combination with fulvestrant
89059666|NCT04952792|Experimental|Apixaban|Apixaban treatment, oral, 2.5 mg/12h, 28 days
89059667|NCT04950582||UTI-high risk patients|patients who are at high risk for developing a urinary tract infection (UTI).
89059668|NCT04947631|Experimental|DKF-313|Dutasteride 0.5mg + Tadalafil 5mg
89059669|NCT04947631|Active Comparator|Dutasteride|Dutasteride 0.5mg
89059670|NCT04947631|Active Comparator|Tadalafil|Tadalafil 5mg
89059671|NCT04940533||Participants receiving CFTR modulator therapy - Trikafta|This is a single arm study. Participants in this study are receiving CFTR modulator therapy.
89059672|NCT04931069|Experimental|Microbiota analysis|Mircobiota analysis on blood, stool and saliva and bile, pancreatic and intestinal mucosa samples
89059673|NCT04930822|Active Comparator|Table Top Visual Intervention|Interventions will include six, 20 minute sessions using pen and paper word search, scanning activities, and saccade visual training. All activities will be conducted with an occupational therapist/investigator.
89059674|NCT04930822|Experimental|Bioness Integrated Therapy System Visual Intervention|Intervention will includes six sessions using the Bioness Integrated Therapy System for 20 minutes using the programs of visual scanning, visual pursuits and/or visual motor.All activities will be conducted with an occupational therapist/investigator.
89059675|NCT04929951|Experimental|MFAT (Micro Fragmented Adipose Tissue)|Intra-articular shoulder injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's shoulder.
89059676|NCT04929951|Active Comparator|Conventional Therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg)
89059677|NCT04914910|Experimental|780G-780G|Participants will use MiniMed 780G system for 14 weeks + 14 weeks
89059678|NCT04914910|Placebo Comparator|Usual Care - 780G|Participants will continue with their usual insulin pump for 14 weeks. After completion of the first 14-week periode, they switch to 780G for another 14 weeks.
89059679|NCT04913610|Experimental|Part 1: Arm A|Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
89059680|NCT04913610|Experimental|Part 1: Arm B|Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by ABBV-4083 for 7 days.
89059681|NCT04913610|Experimental|Part 1: Arm C|Participants will receive ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
89059682|NCT04913610|Experimental|Part 1: Arm D|Participants will receive ABBV-4083 + albendazole for 3 days followed by ABBV-4083 + placebo for albendazole for 4 days followed by placebo for ABBV-4083 for 7 days.
89059683|NCT04913610|Experimental|Part 1: Arm E|Participants will receive placebo for ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.
89059684|NCT04913610|Experimental|Part 2: Arm K|Participants will receive active regimen from Part 1 followed by ivermectin at Month 6.
89059685|NCT04913610|Experimental|Part 2: Arm L|Participants will receive active regimen from Part 1 followed by placebo for ivermectin at Month 6.
89059686|NCT04913610|Experimental|Part 2: Arm M|Participants will receive active regimen from Part 1 followed by placebo for ivermectin or matching placebo at Month 6.
89059687|NCT04913610|Experimental|Part 2: Arm N|"Scenario 1: Participants will receive placebo for ABBV-4083 + placebo for albendazole followed by ivermectin at Month 6.~Scenario 2: Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for appropriate duration followed by ivermectin or matching placebo at Month 6."
89059688|NCT04910217|Experimental|Lokomat intervention|Patients randomized into the Lokomat arm will undergo therapy with Lokomat Pro FreeD for 20-50 minutes 5-times a week, a total of 15-times during the in-hospital stay in a total time of 1,800 minutes.
89059689|NCT04910217|Experimental|Conventional rehabilitation|Patients in this arm will undergo conventional rehabilitation ((ergotherapy and physiotherapy) for 60 min 5 times a week, a total of 15 times within 3 weeks (a total of 1200 min)
89059690|NCT04904835||Unselected blood donors|leftover samples from unselected blood donors from at least 2 donation centers. Leftover samples to be tested by Access HBV serological marker assays and CE-marked (european compliance marked) predicate assays
89059691|NCT04904835||Hospitalized patients|Leftover samples to be tested by Access HBV serological marker assays and CE-marked predicate assays
89059692|NCT04904835||Presumed HBsAg positive patients|"Leftover samples from patients at different stages of HBV infection (acute and chronic, minimum 10 per stage of infection), HBsAg positive by a Confirmatory testing of a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling), and minimum 20 high positive samples (>26 IU/mL) and minimum 20 samples in the cut-off range. If not enough samples in the cut-off range are obtained during the clinical trial, additional HBsAg specimens in the cut-off range will be tested by Research &Development to fit with Common Technical Specification requirements.~Leftover samples to be tested by Access HBsAg assays and CE-marked predicate assays"
89522758|NCT03398837|Experimental|Cohort 2|Lenabasum 20 mg BID
89522759|NCT03398837|Placebo Comparator|Cohort 3|Placebo BID
89219127|NCT06110572|Experimental|Treatment (carboplatin, atezolizumab, etoposide, TBI, H-RT)|"Description INDUCTION PHASE: Patients receive carboplatin IV and atezolizumab IV on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive TBI BID on day 18 or 19 of cycle 1 and beginning 2-3 days later, H-RT daily over 7 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive atezolizumab IV on day 1 of each cycle. Treatment repeats every 21 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo CT and MRI throughout the trial."
89219128|NCT06110156|Experimental|Patient-tailored deprescribing assessment and intervention (MCI and Dementia diagnosis)|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors, identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results with the primary care clinician (PCP). Once the PCP has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling and will follow-up with the patient at least once per month to assess side effects, adverse effects, and provide support. This arm specifically includes only patients with a diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment.
89219129|NCT06110156|No Intervention|Usual care (MCI and Dementia diagnosis)|Patients in the comparator arm will see their primary care clinician as needed. This arm specifically includes patients with a diagnoses of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment.
89219130|NCT06110156|Experimental|Patient-tailored deprescribing assessment and intervention (no MCI and Dementia diagnosis)|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors, identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results with the primary care clinician (PCP). Once the PCP has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling and will follow-up with the patient at least once per month to assess side effects, adverse effects, and provide support. This arm specifically includes only patients with NO diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment.
89219131|NCT06110156|No Intervention|Usual care (no MCI and Dementia diagnosis)|Patients in the comparator arm will see their primary care clinician as needed. This arm specifically includes patients with NO diagnoses of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment.
89219132|NCT06109480|Active Comparator|ECT combined with real stimulation tDCS group|Bifrontal short-pulse ECT was performed once a day for 3 consecutive days. Then,tDCS stimulates the dorsomedial prefrontal cortex. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. 2-mA (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes Twice a day over 10 consecutive sessions.
89219133|NCT06109480|Sham Comparator|ECT combined with sham stimulation tDCS group|Bifrontal short-pulse ECT was performed once a day for 3 consecutive days. Then,Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
89219134|NCT06109480|Other|ECT full course group|The ECT full corse group was used as a standard control.Bifrontal short-pulse ECT was performed once a day for 3 consecutive days,and then once every other day, for a total of 6 times.
89219135|NCT06108037|Other|Arm A|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm A receives AHN in Send 1, BAIC in Send 2, and CHH in Send 3"
89522760|NCT04038385|Experimental|Intervention|This group will receive routine services provided by WIC and an intervention that will combine behaviorally-focused nutrition education with 1) the establishment of a WIC-based farmers' market (implemented in 2019 during the WIC Farmers' Market Nutrition Program voucher issuance period [June 19 to August 19]), and 2) monthly trips to an area farmers' market (between September 1, 2019 and November 30, 2019 [the end of the local growing season]).
89219136|NCT06108037|Other|Arm B|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm B receives BHC in Send 1, CAIH in Send 2, and AAIN in Send 3"
89219137|NCT06108037|Other|Arm C|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm C receives CHC in Send 1, AHH in Send 2, and BAIN in Send 3"
89219138|NCT06108037|Other|Arm D|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm D receives AAIH in Send 1, BHN in Send 2, and CAIC in Send 3"
89219139|NCT06108037|Other|Arm E|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm E receives BAIH in Send 1, CHN in Send 2, and AHC in Send 3"
89219140|NCT06108037|Other|Arm F|"Each arm will receive 3 clinical scenarios spaced over time across 3 Sends. The 6 groups (Arms A-F) will be arranged with naming conventions as such:~First letter = A, B, or C where A = scenario 1, B = scenario 2, and C = scenario 3.~Second letter(s) = H or AI, where H = human response and AI = AI-written response to the patient question posed.~Third letter(s) = N, C, or H, where N = no disclosure, C = computer disclosure, and H = human disclosure. This refers to the disclosure at the bottom of the response message whereby the author is or is not disclosed.~Arm F receives CAIN in Send 1, AAIC in Send 2, and BHH in Send 3"
89219141|NCT06107907|Other|Group A|follow the sequence of oxygen mask, HFOT 40L, HFOT 50L, HFOT 60L, oxygen mask, CPAP 4cmH2O, CPAP 5cmH2O, and CPAP 6cmH2O.
89219142|NCT06107907|Other|Group B|follow the sequence of oxygen mask, CPAP 4cmH2O, CPAP 5cmH2O, CPAP 6cmH2O, oxygen mask, HFOT 40L, HFOT 50L, and HFOT 60L.
89219143|NCT06107725|No Intervention|Standard Stroke Care without Minocycline|560 Patients will receive standard stroke care.
89219144|NCT06107725|Experimental|Standard Stroke Care with Minocycline|560 patients in the Minocycline arm will receive Minocycline 200 mg every 24 hours for five days with standard stroke care
89219145|NCT06107218|Active Comparator|Diamond Stone group (Comparator)|Class I cavities will be finished using 20-30 μm grit extra fine (EF) yellow coded diamond stone with maximum rotational speed 300,000 min -1.
89219146|NCT06107218|Active Comparator|Bioactive Glass Air Abrasion group (Intervention)|Class I cavities will be finished by AquaCare Air Abrasion Device using bioactive glass air-abrasion particles (a mix of 30-60-90 μm particles). The nozzle of the air abrasion device will be 0.6 in diameter and angulated at 90° to the occlusal surface with a distance away from the tooth about 2-3 mm. The device will be used in a dynamic motion with 60 psi (4 Bar) adjusted pressure for 3 seconds.
89219147|NCT06107075|Experimental|Bioactive whey protein concentrate containing phospholipids|Bioactive whey protein concentrate containing phospholipids 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside their fattiest meal of the day.
89219148|NCT06107075|Placebo Comparator|Placebo|Placebo powder matched for macronutrient and caloric content containing pea protein around 40g powder mixed with 350ml water consumed once daily for 12 weeks alongside their fattiest meal of the day.
89219149|NCT06096922||AI frailty index establishment group|Individuals who undergo elective cardiac surgury
89219150|NCT06095492|Experimental|Empa group|
89219151|NCT06095492|Active Comparator|Lina group|
89219152|NCT06092749|Active Comparator|Transgrade technique (TG)|
89219153|NCT06092749|Active Comparator|Interlaminar technique (IL)|
89219154|NCT06091124|Experimental|Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin Followed by Radical Cystectomy|"The study population will include male and female patients over the age of 18 with invasive (cT1-cT4) neuroendocrine carcinoma of the bladder, with or without urothelial component (neuroendocrine component should be >50%). Patients with resectable N1-3 disease (judged by investigators) are eligible. Patients should be fit to undergo cystectomy with normal function of vital organs.~Participants will be intravenously treated with adebrelimab (1200mg, day 1) in combination with etoposide (0.1g, day 1-3) and cisplatin (35mg/m2, day 1-2) every 21 days for a maximum of 4 cycles. Radical cystectomy, lymph node dissection and urine diversion will be performed after the completion of therapy."
89219155|NCT06089915|Experimental|Occupational therapy + robot-assisted exercise|Standard occupational therapy five times per week for 90 minutes (tailored to the patient's needs and abilities) + five 30' sessions (2-3 per week) of robot-assisted exercise for fingers and hand using Amadeo device + five 30' sessions (2-3 per week) of robot-assisted exercise using Armeo Spring exoskeleton for facilitating gross movements of upper limbs
89219156|NCT06089915|Active Comparator|Occupational therapy only|Standard occupational therapy five times per week for 90 minutes (tailored to the patient's needs and abilities)
89219157|NCT06088641||Lower BNP|preoperative Lower BNP
89219158|NCT06088641||Higher BNP|preoperative higher BNP
89219159|NCT06088329|Experimental|Mindful Walking|All participants will belong to the experimental mindful walking arm for our single arm feasibility study.
89522761|NCT04038385|No Intervention|Control|This group will receive routine services provided by WIC only.
89522762|NCT03398759|Experimental|Butorphanol|Butorphanol 20ug/kg , anesthesia induction，Intravenous injection
89219160|NCT06087432|Active Comparator|Group 1|"Rocabado's 6 x 6 exercise program has been found to be beneficial in reducing pain and increasing masticatory muscle function, as well as improving forward head posture, correcting limited joint mobility, muscle length limitation, and postural and functional limitations.~Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique. Rocabado's 6x6 exercises will be shown to both groups and 6 sets and 6 repetitions will be performed per day for 8 weeks"
89219161|NCT06087432|Experimental|Group 2|"Addition to Rocabado's, Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques.~The patient will be placed supine on the treatment bed and asked to relax. The therapist's hands were placed according to PNF principles, depending on the applied technique and diagonality. Maximum resistance was provided to suit the needs of each individual First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement."
89219162|NCT06086184|Experimental|ACT group therapy|High-frequency inpatient ACT group therapy program for patients with psychosis spectrum disorder.
89219163|NCT06085755|Experimental|Trastuzumab deruxtecan + Afatinib|"The first part (PART A) will be in combination with T-DXd the starting dose of 20 mg afatinib MWF will be escalated to reach a maximum tolerated dose in patients with advanced gastric cancer patients with HER2-low, as defined by dose-limiting toxicity.~The second part (PART B) will be expansion cohort, in which Afatinib will be taken in combination with T-DXd according to the recommended Phase 2 dose(RP2D) confirmed through Part A from cycle 1."
89219164|NCT06085209|Experimental|Intervention|Bronchoscopic balloon dilation with radial cuts & truFreeze spray cryotherapy
89219165|NCT06085209|Active Comparator|Standard of care|Bronchoscopic balloon dilation with radial cuts
89522763|NCT03398759|Placebo Comparator|Placebo|Normal saline 5ml ， anesthesia induction，Intravenous injection
89522764|NCT03391219|Active Comparator|intravitreal Bevacizumab|
89059693|NCT04904835||Patients having recovered from natural HBV infection, presumed Anti-HBs positive|"Leftover samples from Patients positive for Anti-HBs and Anti-HBc Total by CE-marked assays. Target is to have at least ¾ of them recovered without HBV antiviral treatment.~Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays"
89059694|NCT04904835||Patients having received HBV vaccination, presumed Anti-HBs positive|Leftover samples Confirmed as vaccinated by testing at the time of enrollment (i.e. positive for Anti-HBs and negative for Anti-HBc by CE-marked assays).Leftover samples to be tested by Access anti-HBs assay and CE-marked predicate assays
89059695|NCT04904835||Presumed Anti-HBc Total positive patients|"Leftover samples from Patients at different stage of infection (acute, chronic or recovered, minimum 10 per stage of infection) positive for Anti-HBc Total by a CE-marked assay, including ≥ 25 same day fresh samples (tested ≤1 day after sampling).~Leftover samples to be tested by Access anti-HBc Total and CE-marked predicate assays"
89059696|NCT04904835||Presumed Anti-HBc IgM positive patients|"left over samples from Patients with acute/recent HBV infection, positive for Anti-HBc IgM by a CE-marked assay.~Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assays"
89059697|NCT04904835||Presumed HBeAg positive patients|"Leftover samples from Patients at different stages of infection (acute and chronic, minimum 5 per stage of infection), positive for HBeAg by a CE-marked assay.~Leftover samples to be tested by Access HBeAg assay and CE-marked predicate assays"
89059698|NCT04904835||Presumed Anti-HBe positive patients7|"Leftover samples from Patients at different stages of infection (chronic and recovered, minimum 5 per stage of infection), positive for Anti-HBe by a CE-marked assay.~Leftover samples to be tested by Access anti-HBe assay and CE-marked predicate assays"
89059699|NCT04904835||Patients with chronic HBV infection|Leftover samples to be tested by Access anti-HBc IgM assay and CE-marked predicate assay
89059700|NCT04898010|Experimental|Selective Cytopheretic Device|Subjects will be placed on Selective Cytopheretic Device (SCD) for planned daily 24 hour therapy for up to 7 consecutive days.
89059701|NCT04893161|Other|belimumab|All patients with SLE receive belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48. The patients who had SRI-4 response at week 48 were divided into response group and the patients without SRI-4 response at week 48 were divided into no response group.
89059702|NCT04891757|Experimental|FHD-286 Monotherapy|Closed to Enrollment
89059703|NCT04891757|Experimental|FHD-286 in Combination with LDAC|FHD-286 administered orally + LDAC administered subcutaneously
89059704|NCT04891757|Experimental|FHD-286 in Combination with Decitabine|FHD-286 administered orally + decitabine administered intravenously (IV)
89059705|NCT04890470|Experimental|oxytocin group|subjects with oxytocin treatment
89059706|NCT04890470|Experimental|vasopressin group|subjects with vasopressin treatment
89059707|NCT04890470|Placebo Comparator|placebo group|subjects with placebo treatment
89219166|NCT06085092|Experimental|Open weighing|The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
89219167|NCT06085092|Active Comparator|Blind weighing|The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or selfesteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight, but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
89219168|NCT06084793|Experimental|Music|All participants will listen to music throughout their time in the pre-transfer room and the designated embryo transfer room. The music will begin playing as soon as participants enter the room and will continue until their departure. Participants will curate a personalized playlist.
89219169|NCT06084793|No Intervention|No music|No music is played (usual care) in the embryo transfer room.
89219170|NCT06084312||This registry will not target any specific populations|
89219171|NCT06081920|Experimental|IBI363|
89219172|NCT06080451|Experimental|HEARTS implementation - Patients|A trial for 6 months will be carried out in 11 Ministry of Health primary care facilities starting in September 2023. This arm consists of the patients whose health markers will be monitored through the study.
89219173|NCT06080451|Experimental|HEARTS implementation - Providers|A trial for 6 months will be carried out in 11 Ministry of Health primary care facilities starting in September 2023. This arm consists of the health care providers who will be administering care to the patient participants.
89219174|NCT06079229||Patients over 70 undergoing pancreatic cancer surgery at the Édouard Herriot Hospital.|This is a non-comparative study, in which all subjects with histologically proven pancreatic cancer (all types) on biopsy or surgical specimen, operated on for this cancer (by cephalic duodenopancreatectomy or left pancreatectomy) at the Édouard Herriot Hospital since July 2021, aged 70 or older at the time of surgery, will be included in the same group.
89219175|NCT06078241|Active Comparator|Intravenous lidocaine infusion|
89219176|NCT06078241|Active Comparator|Erector spinae plane block (ESPB)|
89219177|NCT06078241|Placebo Comparator|Intravenous infusion of normal saline and ESPB with normal saline|
89219178|NCT06077656|Experimental|Group A|Participants will receive a single 0.5mL dose of IVT PCV-25 Formulation A administered by intramuscular injection on Day 1
89219179|NCT06077656|Experimental|Group B|Participants will receive a single 0.5mL dose of IVT PCV-25 Formulation B administered by intramuscular injection on Day 1
89219180|NCT06077656|Experimental|Group C|Participants will receive a single 0.5mL dose of IVT PCV-25 Formulation C administered by intramuscular injection on Day 1
89219181|NCT06077656|Active Comparator|Group D|Participants will receive a single 0.5mL dose of PCV 20 administered by intramuscular injection on Day 1
89219182|NCT06074614||Parkison's disease|Participants with clinically confirmed Parkinson's disease, Hoehn and Yahr stage 1 to 3.
89219183|NCT06074614||Healthy controls|Participants without Parkinson's disease.
89219184|NCT06069180|Experimental|Busulfan included group|The conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
89219185|NCT06069180|Other|Control group|The conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
89219186|NCT06067711|Experimental|Study group:|This group includes 30 burned patients who will receive resistance training program for 12 weeks (3times/week) using resistance band in addition to their traditional physical therapy program and medical treatment.
89219187|NCT06067711|No Intervention|Control group:|This group includes 30 burned patients who will receive only their traditional physical therapy program and medical treatment.
89219188|NCT06067217|Experimental|Tranexamic acid|Tranexamic acid 250 mg oral three times/day
89219189|NCT06067217|Experimental|Progynova|Progynova 1 mg oral three times/day
89219190|NCT06067009|Experimental|Group 1 - Communication|Participants in this group will complete one session of communication training and will have 1 follow up call a month after the session has been completed.
89522765|NCT03391219|Active Comparator|intravitreal Bavacizumab and Fasudil|
89522766|NCT04446923|Experimental|Hand antisepsis by scrub|Hand antisepsis by scrub using propan-ol-1 60%
89219191|NCT06067009|Experimental|Group 2 - Social Support Effectiveness|Participants in this group will complete 3 sessions of social support effectiveness training. All will complete 1 follow-up call after the 3 sessions have been completed.
89219192|NCT06067009|Experimental|Group 3 - Communication and Social Support Effectiveness|Participants assigned to this group will complete 4 sessions of communication and social support effectiveness training. One follow up call will be completed one month after the last session has been competed.
89219193|NCT06067009|Placebo Comparator|Group 4 - Wait-listed Control|Participants assigned to this group will receive no training sessions the first 12 weeks of enrollment. After 12 week data collection, they will be assigned to complete either communication (1 session) or social support effectiveness (3 sessions) training. One month after the completion of the training sessions a follow-up call will be made.
89219194|NCT06066723||Children with CF|All subjects to receive inhaled perfluoropropane during MRI procedures, including standard breath hold and free-breathing technique. Subjects will breathe the gas for 5 breath hold cycles (variable volumes as lung capacity/size varies per participant).
89219195|NCT06066723||Healthy Children|All subjects to receive inhaled perfluoropropane during MRI procedures, including standard breath hold and free-breathing technique. Subjects will breathe the gas for 5 breath hold cycles (variable volumes as lung capacity/size varies per participant).
89219196|NCT06062108||Patients with cirrhosis|Patients hospitalized during the inclusion period with cirrhosis medical history
89219197|NCT06061523|Experimental|Treatment Sequence ABC|"Participants will be administered sotorasib orally in the following order:~Treatment A - as 4 tablets under fasting conditions (test) Treatment B - as 8 tablets under fasting conditions (reference) Treatment C - as 4 tablets under fed conditions (test)"
89219198|NCT06061523|Experimental|Treatment Sequence BAC|"Participants will be administered sotorasib orally in the following order:~Treatment B - as 8 tablets under fasting conditions (reference) Treatment A - as 4 tablets under fasting conditions (test) Treatment C - as 4 tablets under fed conditions (test)"
89219199|NCT06060392|Experimental|Oral Semaglutide|Patient will receive oral semaglutide
89219200|NCT06060392|No Intervention|Standard of care|Patient will receive standard of care
89219201|NCT06059872|Experimental|Chronic Stroke with lower limb disability|The investigators will enroll 55 Veterans with chronic subcortical stroke in the 12-week HIIT intervention, with the expectation that 48 participants (85%) will complete the entire program. In our experience, 65% of participants will respond to the HIIT intervention, resulting in an estimated 31 responders and 17 resistors. Each chronic subcortical stroke participant will be asked to participate in the HIIT study protocol. Classification of resistor or responder: A responder to the 12-week HIIT intervention will be defined as a participant who increases their walking speed to greater than 0.6 m/s. A resistor to the intervention will be defined as a participant who does not increase their walking speed to greater than 0.6 m/s.
89219202|NCT06057597|Experimental|Experimental group|"This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery.~Laparoscopic OAGB will be performed with long and narrow gastric pouch (30cc) and 150 cm biliopancreatic limb"
89219203|NCT06057597|Active Comparator|Control Groupe|"This corresponds to patients with type 2 obesity (BMI 35-40) with comorbidities (high blood pressure, type 2 diabetes mellitus, obstructive sleep apnea, dyslipidemia, arthrosis) and type 3 obesity (BMI ≥ 40 kg/m²) and candidates for bariatric surgery.~Standard laparoscopic RYGB will be performed with a gastric pouch (30cc) and 150 cm antecolic Roux limb and a 50 cm biliopancreatic limb."
89522767|NCT04446923|Active Comparator|Hand antisepsis by rub|Hand antisepsis by rub using propan-ol-1 60%
89059708|NCT04888338||Observational (data collection)|Patients medical records are reviewed for details about CAR-T and RT treatment and acute and late toxicities, disease outcomes such as any events related to local or distant disease progression, survival, and cause of death if available. Patients' imaging scan data is collected at baseline, within 2 months of the first treatment of RT or CAR-T, and at 3, 6, 12 months, and then annually for 5 years after RT completion.
89059709|NCT04882137|No Intervention|Standard Education|Pediatric Providers in this arm will receive a continuing medical education on etonogestrel contractive implant but will not receive specialist coaching on how to manage side effects.
89059710|NCT04882137|Experimental|Standard Education plus Coaching|Pediatric Providers in this arm will receive a continuing medical education program on etonogestrel contraceptive implant. Providers in this arm will also receive a tip-sheet on how to manage side effects as well as a number to directly access a specialist who places them if needed.
89059711|NCT04881201|Other|Patients Charcot-Marie-Tooth|
89059712|NCT04881201|Other|Control subjects|
89059713|NCT04880161|Experimental|Active|Ampion
89059714|NCT04880161|Placebo Comparator|Control|Placebo
89059715|NCT04875221|Experimental|Experimental neurofeedback arm|The experimental arm will be able to view a feedback display that informs them of the strength of connectivity between the target regions. In both arms, feedback signals will be relayed back to the participant in the scanner through visualization software as a thermometer that increases or decreases as the extent to which the neural target model dominates (in other words, as the strength of directed connectivity between regions increases).
89059716|NCT04875221|Sham Comparator|Sham-control neurofeedback arm|Participants in the sham-control arm will receive yoked sham neurofeedback signal (or fake signal), corresponding to a replayed feedback signal from a successful participant in the experimental group in order to ensure similar motivational states and following standard methods.
89059717|NCT04873778|Experimental|Dynamic taping group|stabilize the Sacroiliac joints and stimulate muscle contraction
89059718|NCT04873778|Experimental|kinesio taping group|stabilize the Sacroiliac joints and stimulate muscle contraction
89059719|NCT04873778|Placebo Comparator|control group|use Kinesio taping for placebo effect
89059720|NCT04870788|Experimental|Group I (mindfulness program)|Patients and their partners participate in mindfulness program over 60 minutes consisting of meeting with a mindfulness coach to build awareness of thoughts, emotions, feelings, and sensations QW for 4 weeks.
89059721|NCT04870788|Active Comparator|Group II (mindfulness waitlist)|Patients and their partners participate in mindfulness program as in Group I beginning 12 weeks after starting the study
89059722|NCT04865159|Other|Single Group Assignment|Single Arm - Drug administered on Days 1-7 and Days 15-21 of a 28-day treatment cycle. Series of Pharmacokinetics and ECGs will be done during cycle 1.
89059723|NCT04864210|Experimental|Liposomal bupivacaine|The patient will receive an intercostal nerve block by the surgeon in the operating room after anesthetic has been administered. The surgeon will use thoracoscopic guidance to administer the intercostal nerve block. The medication used in this block will liposomal bupivacaine (Exparel).
89059724|NCT04864210|Active Comparator|Bupivacaine|The patient will receive a paravertebral block by the anesthesiologist staffing the pain service area within the hospital prior to surgery. This regional anesthesia will be done using ultrasound guidance. The medication used in this block will be plain bupivacaine with epinephrine.
89059725|NCT04853966|Experimental|Counseling group|
89059726|NCT04853966|No Intervention|Control Group|
89059727|NCT04843488|Active Comparator|Ridge Augmentation with a perforate PTFE mesh|Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
89059728|NCT04843488|Experimental|Ridge Augmentation with a perforate PTFE mesh covered with a collagen membrane|Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The mesh will be covered with a native collagen membrane. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
89059729|NCT04837625||Myasthenic Crisis Cohort|
89059732|NCT04835857||Experimental-Arm|"For the same subject,~ViTrack wrist cuff is applied on one of the wrist~Standard Oscillometric cuff is applied to the brachial artery / wrist of the same arm~Auscultatory cuff is applied to the brachial artery of the same arm"
89059733|NCT04831541|Experimental|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
89059734|NCT04831034|Experimental|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
89059735|NCT04830852||Recovery Group|Participants aged 21 years and younger and enrolled within 12 weeks after acute infection or positive test. These participants will attend study visits at baseline, every 3 months for the first 6 months, and subsequently every 6 months for a total of 3 years.
89059736|NCT04830852||Convalescent Group|Participants aged 21 years and younger and enrolled more than 12 weeks after acute infection or positive test. These participants will attend study visits at baseline and subsequently every 6 months for a total of 3 years.
89059737|NCT04830852||Healthy contacts|Individuals (aged ≤21 years) without a diagnosis of SARS-CoV-2 infection or current symptoms suggestive of COVID-19 will serve as a control group and will attend visits for evaluations and sample collection at baseline and every 12 months for a total of 3 years.
89059738|NCT04830852||Parents/guardians of participants|Parents or guardians of participants in all cohorts will also be enrolled for limited participation to complete questionnaires about how the family is impacted by the participant's health and SARS-CoV-2.
89059739|NCT04828863||Index subjects|25 young adults with MSUD who are 21 years and older.
89059740|NCT04828863||Control subjects|25 age-matched siblings or acquaintances who do not have MSUD and are 21 years and older
89059741|NCT04828031|Experimental|Vitamin D 50,000 IU PO every week|Vitamin D 50,000 IU PO every week for 12 weeks
89059742|NCT04826861|Other|Intervention for overweight pregnant women|Intervention will be delivered during antenatal visits in maternity care
89059743|NCT04825496|Experimental|ssCART-19 Cells|"Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to ssCART-19 cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
89059744|NCT04815239|Active Comparator|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) for at-risk offspring includes 8 sessions over 6 months delivered via secure telemedicine platform. The basis of the intervention is the treatment manual iteratively developed and tested in close consultation with content experts during our open pilot study and R34.The intervention focuses on education about BP risk, stabilizing sleep and daily routines and interpersonal relationships.
89110992|NCT02341274|Active Comparator|Low Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 10-30% crystallized generic tacrolimus (Low Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
89110993|NCT02341274|Active Comparator|High Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 40-60% crystallized generic tacrolimus (High Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
89110994|NCT02327481|Experimental|3D Laparoscopic Surgery|3D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
89110995|NCT02327481|Active Comparator|2D Laparoscopic Surgery|2D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
89110996|NCT02278055|Experimental|Radium-223|Radium Ra 223 dichloride will be administered as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles. The dosage of Radium Ra 223 dichloride after implementation of the new 2015 NIST standard is 55kBq/kg body weight.
89110997|NCT02231879|Active Comparator|Plerixafor first then G-CSF (PG)|Study drugs were both given subcutaneously twice daily for 14 months using unmarked prefilled glass syringes
89110998|NCT02231879|Active Comparator|G-CSF first then Plerixafor (GP)|Study drugs were both given subcutaneously twice daily for 14 months using unmarked prefilled glass syringes
89110999|NCT02118649|Experimental|Game|Participants will play a video game directing their gaze to on-screen targets.
89111000|NCT02111018|Active Comparator|CVVH|
89111001|NCT02111018|Experimental|CytoSorb Device|
89111002|NCT02041039||normal weight|non-smoking, right handed women age 18-40 years BMI between 18-25 kg/m2
89111003|NCT02041039||overweight/obese|non-smoking, right-handed women age 18-40 year BMI 30-50 kg/m2 (maximum weight 350 pounds, shoulder width no greater than 23/5 inches)
89111004|NCT01968460|Experimental|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.
89111005|NCT01968460|Experimental|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
89111006|NCT01968460|Placebo Comparator|Placebo|Placebo once daily for 12 weeks.
89111007|NCT01863056|Experimental|Sit-Stand Desk|Cross-over trial: so one group got the intervention in period 1 and didn't get the intervention in period 2 (serving as control for self in period 2) and the other group got the intervention in period 2 and didn't get the intervention in period 1 (serving as control for self in period 1).
89111008|NCT01863056|No Intervention|Control|Used normal work desk which only allows working sitting down
89111009|NCT01833806|Experimental|ExAblate Test Arm|Focused Ultrasound Surgery delivered by ExAblate MRgFUS
89111010|NCT01761929|Experimental|Stereotactic Body Radiation Therapy|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
89111011|NCT01532791||mtDNA mutation|m.3243 A>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included
89111012|NCT01532791||Control|controls (people not maternally related to mutation carriers) Preference is for married in relatives
89111013|NCT01527747|Placebo Comparator|Placebo|Placebo arm
89111014|NCT01527747|Experimental|Saxagliptin|Active drug arm
89111015|NCT01062581||Transplant Recipients and Living Donors|"All transplant recipients receiving transplants at the University of Minnesota (kidney, pancreas, liver, heart, lung, islet, intestine). All ages.~All living donors donating an organ at the University of Minnesota (kidney, pancreas, liver, lung) (by law, living donors are required to be at least 18 years old)"
89111016|NCT00932581||Full Exam|The first group will receive the full motor examination section in its original order.
89111017|NCT00932581||Subscale|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
89111018|NCT00646230|Experimental|Single arm of CIV infusion of emulsion 4-HPR|Single arm study of continuous intravenous infusion (CIV) of emulsion 4-HPR
89111019|NCT00261456||BRCA1/2 carriers|Carriers of a BRCA1 or BRCA2 mutation.
89111020|NCT00261456||BRCA1/2/non Carriers|Do not carry a mutation in either the BRCA1 or 2 genes that has been found in other members of the family.
89111021|NCT00816556|Active Comparator|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
89111022|NCT00816556|Active Comparator|Estradiol|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
89111023|NCT00816556|Placebo Comparator|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
89111024|NCT04100473|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.
89111025|NCT04100473|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection.
89111026|NCT02797197|Experimental|patient undergoing to chemotherapy during 6 months|
89059745|NCT04815239|Active Comparator|Healthy Lifestyle Intervention (HL)|HL is based on the treatment manual developed in a prior trial for adults and adolescents with BP. HL includes psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health. In HL, patients are taught to develop and maintain an individualized lifestyle plan and provided support and encouragement for making progress toward their goals. HL clinicians will deliver 8 sessions over 6 months via secure telehealth platform.
89059746|NCT04809220|Experimental|Dulaglutide 1.5 milligram (mg)|Participants received 1.5 mg of dulaglutide given weekly subcutaneously (SC) during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medication (OAM). Participants on dipeptidyl peptidase-4 inhibitors (DPP-4i) discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.
89059747|NCT04809220|Active Comparator|Dulaglutide 0.75 mg|Participants received 0.75 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.
89059748|NCT04804969||At Risk Echo Referrals|Study subjects will be drawn from patients who are at-risk for cardiac disease and who have been referred for 2D transthoracic echocardiogram as standard of care. All will receive a MyoVista wavECG test.
89059749|NCT04798755|Active Comparator|Adalimumab|
89059750|NCT04798755|Active Comparator|Methotrexate|
89059751|NCT04798755|Experimental|Adalimumab+Methotrexate|
89059752|NCT04794816||Observational (questionnaire administration)|Participants complete an online questionnaire over 5 minutes regarding information on patient demographics and preferences for receiving real-time appointment imaging results.
89059753|NCT04787783|Experimental|Web based assessment|Participants will be leaded through preoperative period on a web based application. Participants will be addressed to either virtual or traditional face to face outpatient consultation on the basis of the information registered in the web based preoperative questionnaire that the application incorporates. Virtual assessment will be the performed by evaluating both the filled web based questionnaire together with participants´ electronic records. Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records.
89059754|NCT04787783|No Intervention|Traditional face to face assessment|"Participants will be leaded through preoperative period following traditional institutional standards of care.~Face to face assessment will be performed in the traditional way by means of an interview with the participant together with the consultation of participant´s previous electronic records."
89059755|NCT04778371|Experimental|Almond supplement|Participants will consume 32 g dry roasted, unsalted almonds twice a day for 12 weeks
89059756|NCT04778371|Placebo Comparator|Placebo matched supplement|Participants will consume 100 g granola bar, calorie matched to Almond, twice a day for 12 weeks
89059757|NCT04775550|Experimental|Daratumumab, Bortezomib,Lenalidomide,Dexamethasone|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. Cycle Length is 28 days.~The names of the study drugs involved in this study are:~Daratumumab~Bortezomib~Lenalidomide~Dexamethasone"
89522768|NCT04447001|Experimental|Tai Chi Prime (TCP)-session 1|This arm will receive Tai chi prime as an intervention. TCP is a combination of two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
89059760|NCT04774991|Active Comparator|Azithro 1-59 fixed point|Azithromycin distribution to children 1-59 months of age using a fixed-point delivery approach via existing community health workers
89059761|NCT04774991|Active Comparator|Azithro 1-59 door-to-door|Azithromycin distribution to children 1-59 months of age using a door-to-door delivery approach via existing community health workers
89059762|NCT04773600|Active Comparator|Roflumilast (ARQ-151) cream 0.15%|Active comparator
89059763|NCT04773600|Placebo Comparator|Vehicle cream|Placebo comparator
89059764|NCT04769024|Active Comparator|LUMEEN intervention|Participants in the LUMEEN intervention group will participate in the 12 LUMEEN Virtual Reality sessions of 45 minutes taking place twice a week for 6 weeks, in groups of 6 participants. The content of these sessions is described in the Intervention Description part of this document.
89059765|NCT04769024|Sham Comparator|USUAL activities|Participants in the control group will participate in the 12 Control/non-digital stimulation sessions of 45 minutes taking place twice a week for 6 weeks, in groups of 6 participants instead of the LUMEEN Virtual Reality sessions. The content of these sessions is described in the Intervention Description part of this document.
89059766|NCT04768621|Experimental|Winter residents of Southern and Antartic French Lands,|people exposed to stressors over long periods including winter
89059767|NCT04768621|Active Comparator|Country people going to Southern and Antartic French Lands|people going to Southern and Antarctic French Lands who benefit from milder conditions and only make short stays
89059768|NCT04764162|Active Comparator|Choline supplementation|Participants will consume 1000 mg of choline per day for 4 weeks.
89059769|NCT04764162|Placebo Comparator|Placebo supplementation|Participants will consume 1000 mg of placebo per day for 4 weeks.
89059770|NCT04762290|Active Comparator|Active Group|This group will receive the intervention in the first 10 weeks of the study. The intervention is a dance intervention that consists of a series of expressive movements.
89059771|NCT04762290|Other|Waitlist Control|This group will receive the intervention in the second 10 weeks of the study (after the active group and after pre-post assessments in the first 10 weeks during the time of no intervention).
89219204|NCT06056804|Experimental|cCRT+tislelizumab+thymalfasin|A total of 20 pMMR/MSS locally advanced middle and low rectal cancer patients will receive long-course concurrent chemoradiotherapy combined with 3 cycles of tislelizumab and 11 weeks of thymalfasin therapy.
89219205|NCT06050889|Experimental|High Intensity Exercise|Participants will complete an upper body resistance exercise until they report a high fatigue level.
89219206|NCT06050889|Experimental|Low Intensity Exercise|Participants will complete an upper body resistance exercise until they report a low fatigue level.
89219207|NCT06050434||Trabectedin Rechallenge in Soft sarcoma patients|Adult GISAR participants with Trabectedin-pretreated soft tissue sarcomas and rechallenge with at least one cycle of Trabectedin in any line of therapy, with the interval between Trabectedin interruption and Trabectedin rechallenge being at least 3 months.
89219208|NCT06050265|Experimental|Intervention arm - CGM|Participants randomized to intervention arm will be given standard of care nutrition and exercise counseling to optimize weight, nutrition and glycemic status AND will be asked to wear a DEXCOM CGM for 90 days.
89219209|NCT06050265|No Intervention|Control arm|Participants randomized to control arm will ONLY be given standard of care nutrition and exercise counseling to optimize weight, nutrition and glycemic status.
89219210|NCT06049732||Nursing home residents with moderate to severe dementia|Simultaneous pain assessments using PainChek® and the Abbey Pain Scale undertaken by two independent pain assessors, blinded to each others results
89219211|NCT06047756|Experimental|Hippotherapy|Patients suffering with diplegic therapy will perform their exercise protocols on a stationary horse.The child is seat astride the horse wearing a helmet and was encouraged to perform various activities designed to emphasize movement in a forward and upward reaching direction to encourage active postural control, trunk strength, balance and trunk/pelvic dissociation.30 minutes to 1 hour with a frequency ranging from 4 sessions per week and the total duration of horseback riding 6 weeks.
89219212|NCT06047756|Active Comparator|Swiss Ball therapy|Children of second group will receive swiss ball therapy. Position the child to sit on the ball and giving extension rotation and flexion rotation to the child. This will facilitate trunk rotation by which the upper body is towards the weight bearing hip and away from the weight bearing hip.Training program 4 times per weeks with the treatment session of 30 minutes for 6 weeks duration
89059772|NCT04761120||Group 1: Primary mitral disease repair surgery with an Abbott annuloplasty ring implant|Group 1 will enroll 200 subjects undergoing surgical repair of primary mitral regurgitation that includes annuloplasty with an Abbott SJM Rigid Saddle Ring, Séguin Ring or full Tailor Ring without cut zone removal. Enrollment must include at least 50 subjects implanted with each ring model. In primary mitral regurgitation, backflow through the closed valve is caused by disease intrinsic to the mitral valve tissue itself.
89059773|NCT04761120||Group 2: Secondary mitral disease repair surgery with an Abbott annuloplasty ring implant|Group 2 will enroll 200 subjects undergoing surgical repair of secondary mitral regurgitation that includes annuloplasty with an Abbott SJM Rigid Saddle Ring, Séguin Ring or full Tailor Ring without cut zone removal. Enrollment must include at least 50 subjects implanted with each ring model. In secondary mitral regurgitation, backflow through the closed valve is secondary to diseases of the surrounding myocardium, rather than caused by disease of the valve tissue itself.
89059774|NCT04761120||Group 3: Primary tricuspid disease repair surgery with a full Tailor Ring implant|Group 3 will enroll up to 50 subjects undergoing surgical repair of primary tricuspid regurgitation that includes annuloplasty with a full Abbott SJM Tailor Ring without cut zone removal. In primary tricuspid regurgitation, backflow through the closed valve is caused by disease intrinsic to the tricuspid valve tissue itself.
89059775|NCT04761120||Group 4: Secondary tricuspid disease repair surgery with a full Tailor Ring implant|Group 4 will enroll up to 50 subjects undergoing surgical repair of secondary tricuspid regurgitation that includes annuloplasty with a full Abbott SJM Tailor Ring without cut zone removal. In secondary tricuspid regurgitation, backflow through the closed valve is secondary to diseases of the surrounding myocardium, rather than caused by disease of the valve tissue itself.
89059776|NCT04761120||Group 5: Primary tricuspid disease repair surgery with a partial Tailor Ring or Tailor Band implant|Group 4 will enroll up to 50 subjects undergoing surgical repair of secondary tricuspid regurgitation that includes posterior annuloplasty with either a partial Abbott SJM Tailor Ring with cut zone removed or an Abbott SJM Tailor Band. In primary tricuspid regurgitation, backflow through the closed valve is caused by disease intrinsic to the tricuspid valve tissue itself.
89059777|NCT04760652|Active Comparator|CBT Cognitive Behavioral Therapy|Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.
89059778|NCT04760652|Other|TAU Treatment As Usual|Participants will undergo Treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which many include physician visits and psychotherapy (except for formal CBT).
89059779|NCT04760613|Active Comparator|Cannabidiol (CBD)|
89059780|NCT04760613|Placebo Comparator|Placebo (PCB)|
89059781|NCT04740827|Placebo Comparator|Placebo|Participants received atogepant-matching placebo tablets, orally, once daily (QD) for up to 12 weeks in a double-blind (DB) treatment period.
89059782|NCT04740827|Active Comparator|Atogepant 60 mg|Participants received atogepant 60 mg, orally, QD for up to 12 weeks in a DB treatment period.
89059783|NCT04739124||Diabetic patients|Patients presenting type 1 or type 2 diabetes, eligible for the prescription of Freestyle Libre
89059784|NCT04739124||Caregivers|Caregiver caring for diabetic patients and practicing therapeutic education on a regular basis
89059785|NCT04732494|Experimental|Arm A: Tislelizumab plus Ociperlimab|Participants will receive tislelizumab (200 milligrams [mg]) plus ociperlimab (900 mg) intravenously once every 3 weeks.
89059786|NCT04732494|Placebo Comparator|Arm B: Tislelizumab plus Placebo|Participants will receive tislelizumab (200 mg) plus placebo intravenously once every 3 weeks.
89219213|NCT06045273|Experimental|Elders' Resilience Curriculum Recipients|Youth aged 9-14 who receive the Elders' Resilience Curriculum
89059787|NCT04725240|Experimental|Setmelanotide|Participants received setmelanotide once daily (QD) via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and dose escalated up to a maximum dose of 3.0 milligrams (mg) QD.
89059788|NCT04721132|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery during week 12.
89059789|NCT04721106||Vizimpro treatment group|This group is included the patients that Vizimpro are prescribed and administrated according to local label in the routine clinical practice
89059790|NCT04721067|Experimental|CBT-I|This arm will receive internet CBT-I using SHUTi, a validated and proven therapy provided via internet in the general population.
89059791|NCT04721067|Active Comparator|Sleep Education/Hygiene|This arm will receive best practices education on sleep hygiene.
89059792|NCT04717843|Experimental|Patients with embolic strokes of undetermined source.|Patients over 18 years old, with embolic strokes of undetermined source, fulfilling the TOAST criteria. The intervention consists of a 4D Flow MRI.
89059793|NCT04717843|Experimental|Patients with non-paroxysmal AF.|Patients over 18 years old, with non-paroxysmal AF. The intervention consists of a 4D Flow MRI.
89059794|NCT04717843|Active Comparator|Heathy volunteers|The control group will include volunteers over 45 years old with no history of cardio-vascular or neuro-vascular disease. The last will be certified by a pre inclusion protocol containing a medical consultation, a Holter ECG and a trans-thoracic echocardiography. The age of 45 was chosen to get comparable age group and set the analyses free of the age-related effect on the cardiac hemodynamic. The intervention consists of an ECG, holter ECG, Trans thoracic echocardiography ETT, Blood sample and 4D Flow MRI.
89059795|NCT04717843|Experimental|ESUS and non-paroxysmal AF patients with cardiac MRI|ESUS and non-paroxysmal AF patients (fulfilling the group 1 et 2 criteria) and who had had cardiac MRI, in a retrospective way. It corresponds to retrospective inclusion of patients which had MRI in the year before the beginning of the study.
89059796|NCT04715035|Active Comparator|Conventional treatment|Physical therapy: education, mobilizations, stretch, active exercises, home excercises.
89059797|NCT04715035|Experimental|Conventional treatment + eccentric exercises|Physical therapy: education, mobilizations, stretch, active exercises, home exercises, eccentric exercises.
89059798|NCT04713150||COVID-19 Positive During Pregnancy|Sixty mother-child dyads, who have or had a confirmed positive COVID-19 test during pregnancy, will be recruited and enrolled in this study. All women enrolled must be 18 years of age or older. Her child will go on to participate at 2-5 days of age, and again at 3-, 6-, 9-, 12- and 24-months of age.
89059799|NCT04713150||COVID-19 Negative During Pregnancy|Twenty-five mother-child dyads, who have a confirmed negative COVID-19 test during pregnancy will be recruited and enrolled in the study. Women without any SARS-CoV-2 positive test during pregnancy or any suspected COVID illness, even if not tested, will be enrolled. All women enrolled must be 18 years of age or older. Her child will go on to participate at 3-, 6-, 9-, 12- and 24-months of age.
89059800|NCT04713124|Experimental|R2C-M intervention|"R2C-M telephone intervention - Six approximately weekly sessions of R2C-M telephone-delivered intervention (50 minutes in duration), delivered by the same R2C-M Counsellor each session (a qualified clinical psychologist trained in the R2C protocol by the developer, Dr Kate Hall). Call duration will be recorded. Sessions will be digitally recorded, and an independent researcher will randomly select and rate fidelity of intervention sessions for 20% of participants.~R2C-M workbooks - Two workbooks to facilitate counsellor-delivered exercises within sessions, and between-session practice, will be mailed/emailed to participants.~Self-help booklet - (as in control group) R2C-M participants will also receive a booklet of information and self-help strategies for methamphetamine use problems."
89219214|NCT06042647|Active Comparator|0.01% Halobetasol and 0.045% Tazarotene Lotion|0.01% Halobetasol and 0.045% Tazarotene Lotion (Duobrii)Applied to designated target plaque at bedtime.
89219215|NCT06042647|Active Comparator|Clobetasol Propionate 0.05% Cream (generic)|Clobetasol Propionate 0.05% Cream (generic)Applied to designated target plaque at bedtime.
89219216|NCT06042062|Experimental|"Spacer group"|The subjects who are assigned to Articulating Spacers in two-stage exchange arthroplasty.
89219217|NCT06042062|Experimental|"Novel spacer group"|The subjects who are assigned to United Cellbrick Knee Spacer in two-stage exchange arthroplasty.
89219218|NCT06042049|Experimental|MEDI8897|Anti-RSV monoclonal antibody
89219219|NCT06042036||acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure transitioning to a spontaneous mode of mechanical ventilation ( PSV, APRV, NAVA, PAV+, CPAP)
89219220|NCT06041009||Patients with PDAC|
89219221|NCT06041009||Individuals at high risk for PDAC|
89219222|NCT06041009||Group of neuroendocrine neoplasm of pancreas|
89219223|NCT06041009||Group of solid pseudopapillary tumor of pancreas|
89219224|NCT06041009||Group of abnormally elevated CA19-9|
89219225|NCT06041009||Controls without pancreatic disease or elevated CA19-9|
89219226|NCT06037889|Experimental|Tirofiban group|Intravenous tirofiban will be administered immediately after randomization for a total duration of 48h with a loading dose of 0.4ug/kg/min*30min, followed by a maintenance dose of 0.1ug/kg/min*47.5h.
89219227|NCT06037889|Active Comparator|Standard antiplatelet therapy group|Standard antiplatelet therapy based on Chinese stroke guideline will be administered after randomization for a total duration of 48h, as the two following types: 1) aspirin 150-300 mg qd, or 2) aspirin 100 mg qd plus clopidogrel 75 mg qd. The time for administration of antiplatelet drugs will be determined by the doctor in conjunction with the participants' use of antiplatelet or anticoagulant medication in the 24h prior to randomization, but the drug should be given as soon as possible after randomization.
89219228|NCT06034340|Experimental|LET Gel after STAR Particle Application|Children, adolescents, and young adults will receive local anesthesia via different methods: STAR particles prior to lidocaine compared to topical lidocaine without the use of the STAR particles device.
89219229|NCT06033781|Experimental|Treatment Right-Away|Child will start the CBT-NC treatment right away.
89219230|NCT06033781|No Intervention|Waitlist Control|Waitlist control group will complete the assessments at the same time as the treatment group, without receiving any treatment. They will be offered treatment after finishing the waitlist.
89219231|NCT06019546||PEQUOD|Patients undergoing cardiac surgery with cardiopulmonary bypass whose parameters of interest will be registered during cardiopulmonary bypass by the Livanova BE-CAPTA monitor.
89219232|NCT06018974|Experimental|Yetitablet group|Older adults in the experimental group will participate in a 12-week, 3 times per week, 30-60 minutes per session (recommendation) gaming session with Yetitablet in their home facility. Games will be played in group of 3-5 people with participants taking turns. Gaming sessions are supervised by research assistant or facility personnel.
89219233|NCT06018974|No Intervention|Control group|Participants in control group will continue their normal daily activities in their home facility. No intervention is provided to control group (passive control group).
89219234|NCT06008028|Experimental|BR1015|
89219235|NCT06008028|Active Comparator|BR1015-1 + BR1015-2|
89219236|NCT06004570|Experimental|Complex product|18 volunteers
89219237|NCT06004570|Active Comparator|Polyphenol-rich extracts|18 volunteers
89219238|NCT06004570|Placebo Comparator|Placebo|18 volunteers
89219239|NCT06003790|Experimental|Intervention|Participants will receive MR-001 delivered to their home via mail. Participants will be asked to use the device for 24 sessions, 3 times a week for 8 weeks.
89219240|NCT06002178||Patients undergoing surgical procedure|"The following variables will be collected: age, weight, height, gender, previous neck surgery/radiotherapy, previous tracheostomy.~Subsequently, through ultrasound examination, the vascular anatomy of the neck will be studied by dividing it into twelve anatomical quadrants: Four medial quadrants (thyroid membrane, cricoid membrane, and cricothyroid membrane; first tracheal ring, from the beginning of the second tracheal ring to the end of the third tracheal ring), laterally on both right and left sides of each quadrant, the lateral quadrants will be identified. An ultrasound examination with a linear probe with doppler technique will be performed for each quadrant to identify the vascular structures.~For each quadrant, the presence of vessels, arterial or venous nature, and their diameter will be collected."
89219241|NCT05996770||Patients with COVID-19 packaged with Paxlovid|Treatment of patients with COVID-19 with Paxlovid
89219242|NCT05996770||Patients with COVID-19 packaged with Azvudine|Treatment of patients with COVID-19 with Azvudine
89219243|NCT05996770||Patients with COVID-19 packaged with Paxlovid and Azvudine|Treatment of patients with COVID-19 with Paxlovid and Azvudine
89219244|NCT05994976||Healthy volunteers|Healthy adults
89219245|NCT05994976||Acne|Adult subjects aged 18 to 45 years old with acne
89219246|NCT05994976||AD|Adult subjects with Atopic Dermatitis (AD)
89219247|NCT05994976||CHE|Adult subjects with Chronic Hand Eczema (CHE)
89219248|NCT05994976||HS|Adult subjects with Hidradenitis suppurativa (HS)
89219249|NCT05994976||PPP|Adult subjects with Palmoplantar pustulosis (PPP)
89219250|NCT05994976||Psoriasis|Adult subjects with Psoriasis
89219251|NCT05993845||Project population for total hip arthroplasty surgery recordings|We plan to record 60 total hip arthroplasty (THA) surgeries in the operating theatre performed by different surgeons of the hip team at Balgrist University Hospital or Kantonsspital Baden or Kantonsspital Winterthur, for data collection purposes.
89219252|NCT05991570|Other|case|Use of vedio assisted thoracoscopic surgery in exploration in diagnosis and treatment of chest trauma patients whos heamodynamically stable
89219253|NCT05991570|Other|control|exploratory thoracotomy inchest trauma patients in failure of vedio assisted thoracoscopic surgery or in haemodynamically instable patients
89059801|NCT04713124|Active Comparator|Control|"Self-help booklet - Control participants will receive (by mail/email) a booklet of information and self-help strategies for methamphetamine use problems.~Telephone check-ins + information on further support - (to control for frequency of contact across treatment arms) Participants in this group will receive 6 telephone calls from the research team (lasting maximum 5 minutes, call duration will be recorded). During these calls, participants will be asked about their use of the booklet. Whenever required, the researcher will provide participants with information on further support (e.g. DirectLine or other state/territory AOD helpline for advice or referral)."
89059802|NCT04701476|Experimental|colorectal cancer|metastatic colorectal cancer progressed on at least two lines of chemotherapy
89059803|NCT04701476|Experimental|NSCLC|Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
89059804|NCT04678427|Experimental|Supportive Care (TEAM Me)|Patients complete a 6-minute walk test and a timed get up and go test on the day of hospital admission, on days 0 (day of stem cell transplant) and 21, the day of discharge, and day 100. Patients also complete surveys over 10 minutes about quality of life and fatigue levels on the day of hospital admission, on days 0 (day of stem cell transplant) and 21, the day of discharge, and day 100. Patients who are able and allowed to, may also walk and participate in other intense physical activities to earn stickers. Patients who are unable to walk have tailored goals created by a physical/occupational therapist to earn stickers and participate in physical activity as prescribed by their therapist.
89059805|NCT04678271|Experimental|AFIX-OB Intervention Arm|Practices randomized to this arm will choose from a suite of quality improvement interventions that address patient, provider, and practice-level factors relating to maternal vaccination.
89059806|NCT04678271|No Intervention|Control Arm|Practices randomized to this arm will continue to provide their normal standard of care to pregnant patients at their practice.
89059807|NCT04672811|Experimental|App/Sensor Intervention|All subjects will be enrolled into the same experimental group for the duration of the study
89059808|NCT04663074||IVUS Group|Patients treated by BEVAR/CHEVAR/FEVAR due to a thoracoabdominal aneurysm.
89059809|NCT04651192||Soldiers|50 Israeli Defense Forces (IDF) infantry soldiers, all male, aged 18 years, with Hebrew as the dominant language and no condition excluding an MRI scan.
89059810|NCT04651192||Students|50 Reserve Officer Training Corps (ROTC) undergraduate students at Tel-Aviv University, all male, aged 18-19, with Hebrew as the dominant language and no condition excluding an MRI scan.
89059811|NCT04646434|Experimental|Supportive Care (brain and muscle monitoring, questionnaire)|Patients perform standard of care Kegel exercises while undergoing brain and muscle activity monitoring by EEG and EMG, respectively, before surgery, 6 weeks after surgery, and at 3, 6, and 12 months after surgery. Patients complete questionnaires over 5-10 minutes about urinary function
89059812|NCT04645420|Experimental|Apremilast|"15 PsA patients with active disease and naïve to conventional synthetic and biologic disease modifying anti-rheumatic drugs.~Treatment with apremilast orally in the whole group (n = 15). Escalating dose the first Week (10 mg once day1, 10 mg bid day2, 10 mg-20 mg day3, 20 mg bid day4, 20 mg-30 mg day5, 30 mg bid on day6), and 30 mg bid from day7 until week24."
89059813|NCT04638088||robot-assisted laparoscopy|radical prostatectomy performed by robot-assisted laparoscopy
89059814|NCT04638088||conventional laparoscopy|radical prostatectomy performed by conventional laparoscopy
89059815|NCT04638088||laparotomy|radical prostatectomy performed by laparotomy
89059816|NCT04636177|Experimental|Pain Rehabilitation Virtual Reality (PRVR)|Participants will complete VR in PT to engage participants in a series of immersive games customized to align with individual PT needs delivered over ~6-12 weeks or until clinician believes the patient is done with treatment. Patients in the PRVR arm will be given a structured HEP to practice prescribed exercises at home with integrated VR activities. PRVR participants will be allocated a VR headset for use in PT sessions and with HEP. VR will supplement treatment and be used in session (either in-person or telehealth) and at home as part of their prescribed treatment homework.
89059817|NCT04633551|Experimental|Intervention|Participants in this arm will receive a commercially available anti-inflammatory supplement.
89059818|NCT04633551|No Intervention|Control|Participants in this arm will not receive a commercially available anti-inflammatory supplement.
89219254|NCT05990764|Experimental|Probiotic, Prebiotic, Polyphenol-rich Extracts|18 patients with IBS
89219255|NCT05990764|Experimental|Probiotic, Prebiotic|18 patients with IBS
89219256|NCT05990764|Placebo Comparator|Placebo|18 patients with IBS
89219257|NCT05989919||study group|patients with antrochoanal polyps
89219258|NCT05989919||control group|patients with unilateral sinonasal disease other than antrochoanal polyps
89219259|NCT05989555||I/adjuvant|15 patients with thyroid carcinoma that are treated with radioacitive iodine in an adjuvant setting
89219260|NCT05989555||II/structutral disease|15 patients with thyroid carcinoma that are treated with radioactive iodine with the indication of persistent structural disease
89219261|NCT05989204|Experimental|NHL Dose Level 1|7x10(6) huCART19-IL18 cells administered as a single intravenous (IV) infusion
89219262|NCT05989204|Experimental|NHL Dose Level -1|3x10(6) huCART19-IL18 cells administered as a single intravenous (IV) infusion
89219263|NCT05989204|Experimental|NHL Dose Level 2|3x10(7) huCART19-IL18 cells administered as a single intravenous (IV) infusion
89219264|NCT05989204|Experimental|NHL Dose Level 3|7x10(7) huCART19-IL18 cells administered as a single intravenous (IV) infusion
89219265|NCT05985044|Experimental|Intervention|A patient-centered Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) intervention
89219266|NCT05984056|Experimental|Intervention|Multidisciplinary lifestyle interventions will be provided weekly for 12 weeks after enrollment.
89219267|NCT05984056|No Intervention|Control|No intervention. Periodic check-ups will be performed during the first 12 weeks, followed by monthly check-ins like the intervention arm.
89219268|NCT05978414|Experimental|2 subgroups with wisceral therapy|A group of women with endometriosis and reproductive organ prolapse will be randomly assigned to the intervention will have visceral therapy performed, and the group without the intervention will have a placebo.
89219269|NCT05978414|Placebo Comparator|2 subgroups with placebo (without intervention)|The group of women with endometriosis and reproduvtive organ prolapse without the intervention will have a placebo only hands held on the pelvis by a physiotherapist.
89219270|NCT05977348|No Intervention|Healthy Bodies Project Comparison (HBP)|All classrooms will receive the Eating the Alphabet curriculum, which includes 27 lessons that introduce children to a new fruit or vegetable from A-Z each week. Parents in comparison and intervention classrooms will receive access to web-based parent resources related to the Eating the Alphabet curriculum (e.g., food of the week fact sheets with recipes and suggestions for use, and coloring pages).
89219271|NCT05977348|Experimental|Healthy Bodies Project Plus (HBP+)|Intervention classrooms will receive the Eating the Alphabet curriculum described above for comparison classrooms, in addition to (1) the Healthy Eating curriculum, (2) classroom materials and teacher training designed to improve the classroom food and mealtime environment in ways that increase food acceptance, and (3) parent/caregiver education on responsive food parenting.
89219272|NCT05974969|Experimental|BCD-264|INN: daratumumab, single IV infusion at a dose of 8 mg/kg.
89219273|NCT05974969|Active Comparator|Darzalex|INN: daratumumab, single IV infusion at a dose of 8 mg/kg.
89219274|NCT05974293|Experimental|Nabiximols, then Placebo|During Period 1, participants receive daily nabiximols spray, delivered by a pump action oromucosal spray. The first 2 weeks of Period 1 are the titration period with participants following pre-specified uptitration schedule, until they reach their individualized optimum daily dosage, with a maximum of 12 daily sprays. Following these 2 weeks, they continue the optimum dose for 4 weeks. Then, they undergo a 2-week washout period, and then, enter Period 2 where they receive the matched placebo spray and again undergo a 2-week titration period, and a 4-week consistent daily dosage period.
89219275|NCT05974293|Experimental|Placebo, then Nabiximols|During Period 1, participants receive daily matched placebo spray, delivered by a pump action oromucosal spray. The first 2 weeks of Period 1 are the titration period with participants following pre-specified uptitration schedule, until they reach their individualized optimum daily dosage, with a maximum of 12 daily sprays. Following these 2 weeks, they continue the optimum dose for 4 weeks. Then, they undergo a 2-week washout period, and then, enter Period 2 where they receive the active nabiximols spray and again undergo a 2-week titration period, and a 4-week consistent daily dosage period.
89219276|NCT05972109|No Intervention|Control: No workplace SSB sales ban, no brief intervention|Participants receive no workplace SSB sales ban (environmental intervention) and no brief counseling intervention.
89219277|NCT05972109|Experimental|Workplace SSB sales ban only|Participants receive a workplace SSB sales ban (environmental intervention). This entails the removal of SSBs from all workplace sales outlets, replacing them with non-sugary beverage options.
89219278|NCT05972109|Experimental|Brief intervention only|Participants receive a 20-30 minute intervention by video call, with 2 booster telephone calls. One week and one month after the initial session, participants will have 10-minute check-in/booster phone calls.
89219279|NCT05972109|Experimental|Multilevel Intervention (workplace SSB sales ban + brief intervention)|"Sales ban: Participants receive a workplace SSB sales ban (environmental intervention). This entails the removal of SSBs from all workplace sales outlets, replacing them with non-sugary beverage options.~Brief Intervention: Participants receive a 20-30 minute intervention by video call, with 2 booster telephone calls. One week and one month after the initial session, participants will have 10-minute check-in/booster phone calls."
89219280|NCT05967962|Experimental|traumatic (scenes of injury and death during combat)|"In the experimental group participants will be exposed to a traumatic scene, to simulate combat exposure by watching 16 min traumatic combat scenes from the TV series When Heroes Fly."
89219281|NCT05967962|Active Comparator|non-traumatic (neutral) film|"In this active control group, participants will be watching 16 min. non-traumatic, neutral scene showing combatants as well (scenes from the YouTube series Warriors)."
89219282|NCT05966155|Experimental|Depression - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider
89219283|NCT05966155|Other|Depression - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period
89219284|NCT05966142|Experimental|Chronic Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
89219285|NCT05966142|Other|Chronic Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
89219286|NCT05966129|Experimental|Acute Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
89219287|NCT05966129|Other|Acute Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
89219288|NCT05965921||Barrett's oesophagus|Patients over 18 with known Barrett's oesophagus having gastroscopy for either surveillance or assessment of known Barrett's neoplasia
89219289|NCT05961527|Experimental|MDMA-assisted group therapy|Four Preparatory Sessions, two MDMA Sessions, and four Integrative Sessions following each MDMA Session.
89219290|NCT05960955|Experimental|Part 1 cohort 1|Subjects receive cadonilimab combination chemotherapy(SOX) neoadjuvant therapy 3 cycles.
89219291|NCT05960955|Experimental|Part 1 cohort 2|Subjects receive cadonilimab combination chemotherapy(SOX) and AK117 neoadjuvant therapy 3 cycles.
89219292|NCT05960955|Experimental|Part 2 cohort 1|Subjects receive cadonilimab combination chemotherapy(FLOT) neoadjuvant therapy 4 cycles.
89219293|NCT05960955|Experimental|Part 2 cohort 2|Subjects receive cadonilimab combination chemotherapy(FLOT) and AK117 neoadjuvant therapy 4 cycles.
89219294|NCT05960682||Questionnaire|Men will complete the French version of the Brief Index of Sexual Functioning for Men paper questionnaire.
89219295|NCT05960630|Experimental|MIRRORS Protocol|Diagnostic Laparoscopy proceed to either robotic or open Interval cytoreductive surgery with conversion to open at any point should this be required to remove all visible disease.
89219296|NCT05960630|Active Comparator|Standard Care|Standard Care - Open Interval Cytoreductive Surgery Surgery will proceed directly with standard open interval cytoreductive surgery through an extended midline incision
89219297|NCT05959499|Active Comparator|BR6002A+BR6002B|
89219298|NCT05959499|Experimental|BR6002|
89219299|NCT05956223|Other|Stage 1 Controls|Control participants - healthy volunteers without a known neurological disorder
89219300|NCT05956223|Experimental|Stage 2 Patients with Essential Tremor|Participants with moderately severe essential tremor
89219301|NCT05956223|Experimental|Stage 3 Patients with Essential Tremor of varying severities|Participants with essential tremor ranging from just detectable by neurologist to severe.
89219302|NCT05956223|Experimental|Stage 5|Participants with essential tremor and dystonia of the upper limbs, head and neck
89219303|NCT05953038|Experimental|LSD dose-ranging group|All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects.
89219304|NCT05952089|Experimental|Danicamtiv + Midazolam|
89219305|NCT05949983|Experimental|APA program Group|patients treated and monitored for breast cancer under the APA programme
89219306|NCT05949983|Active Comparator|Physical activity recommendation Group|patients treated and monitored for breast cancer who have received recommendations for physical activity
89219307|NCT05949281|Active Comparator|Colchicine|Colchicine tablet 0.5 mg once-daily
89219308|NCT05949281|Placebo Comparator|Placebo|Placebo tablet once-daily
89219309|NCT05949021|Experimental|Liposomal doxorubicin and Carboplatin|"Combination of liposomal doxorubicin 30milligrams per square meter (mg/m2) and carboplatin area under the curve 5 (AUC 5), administered every four weeks for four cycles.~Participants with triple-negative breast cancer (TNBC):~Completed breast surgery and sentinel lymph node biopsy~Tumor size less than2.5 and NO/ N1mi disease"
89219310|NCT05947656|Experimental|Cohort 1|Eligible patients in Cohort 1 will receive two (2) FUS treatments per week for two (2) weeks on Day 1, 4, 8 and 11, followed by three (3) safety follow-up visits on Day 36, 64 and 92.
89059819|NCT04633096|Experimental|tailored feedback|Using a randomized-controlled study design one third of the participants will receive individually tailored feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
89059820|NCT04633096|Experimental|standardized feedback|Using a randomized-controlled study design one third of the participants will receive a standard feedback after depression screening. The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
89059821|NCT04633096|No Intervention|no feedback|Using a randomized-controlled study design one third of the participants will not receive any feedback.
89059822|NCT04620746|Active Comparator|Skin Testing Arm|These subjects with reported PCN allergy and reported low risk responses will receive skin testing followed by oral challenge
89059823|NCT04620746|Active Comparator|Direct Oral Challenge|These subjects with reported PCN allergy and low risk responses will bypass skin testing and have direct oral challenge with amoxicillin
89059824|NCT04614987||Participants undergoing CAR T transfusion|Participants will undergo baseline examination followed by evaluations between Days 3 and 5 post-transfusion, on Day 30 post-transfusion date (PTD), PTD 90, and PTD 180. At baseline this will include plasma testing, lumbar puncture (voluntary), neuroimaging (voluntary) and neuropsychiatric performance testing (voluntary). Between post-transfusion Day 3 and day 5, participants will undergo repeat exam, plasma testing, lumbar puncture (voluntary), and neuroimaging (voluntary). Day 30 testing will again test all modalities, including serum, CSF/lumbar puncture (voluntary), brain imaging (voluntary), and formal neuropsychiatric performance testing (voluntary). Finally, Day 90 and 180 will repeat serum testing, brain imaging, and formal neuropsychological performance testing.
89059825|NCT04614909|Experimental|Arm A Newly diagnosed glioblastoma treated with pamiparib- ARM CLOSED|Participants undergoing resection for a presumed newly diagnosed glioblastoma (nGBM) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
89059826|NCT04614909|Experimental|Arm B Recurrent glioblastoma treated with pamiparib|Recurrent glioblastoma (rGBM) patients who are scheduled for surgery and expected to receive postoperative fractionated radiotherapy (RT) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
89059827|NCT04614909|Experimental|Arm C Recurrent glioblastoma treated with olaparib - ARM CLOSED|Arm C will be an exploratory arm in recurrent glioblastoma patients (rGBM) treated with Olaparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive olaparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
89059828|NCT04614636|Experimental|FT538 Monotherapy|FT538 monotherapy in subjects with r/r AML
89059829|NCT04614636|Experimental|FT538 in Combination with Daratumumab|FT538 in combination with daratumumab in subjects with r/r MM
89059830|NCT04614636|Experimental|FT538 in Combination with Elotuzumab|FT538 in combination with elotuzumab in subjects with r/r MM
89059831|NCT04609943|Experimental|BAY1211163|Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163.
89059832|NCT04609280|Experimental|Reduced C/L elective nodal volume|All patients will receive the reduced C/L elective nodal volume as described. Treatment will be delivered via IMRT/VMAT or PBPT.
89059833|NCT04588246|Experimental|Arm I (salvage SRS, memantine, HA-WBRT)|Patients undergo HA-WBRT daily (5 times weekly) for 2 weeks for a total of 10 fractions in the absence of disease progression or unacceptable toxicity. Within 1 week prior to or following HA-WBRT, patients undergo salvage SRS. Prior to HA-WBRT or no later than the 4th treatment, patients also receive memantine PO QD or BID for 24 weeks in the absence of disease progression or unacceptable toxicity.
89059834|NCT04588246|Active Comparator|Arm II (salvage SRS)|Patients undergo salvage SRS.
89059835|NCT04576676||Essential Tremor|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Essential Tremor~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
89059836|NCT04576676||Parkinson's Disease|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Parkinson's Disease~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
89059837|NCT04576676||Healthy Individuals|"Healthy individuals living within 3 hours of UTSW~Subjects must be 50 years of age or older~You are healthy and have not being diagnosed with any neurological disease~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
89059838|NCT04576676||Essential Tremor and Parkinson's Disease|"Subjects must be 50 years of age or older.~Subjects must have been diagnosed with Essential Tremor~Subjects must have been diagnosed with Parkinson's Disease preceded by at least 3 years of enrollment in study~Subjects must live within 3 hours of UTSW~Subjects will be screened for eligibility over the phone, and if eligible, will partake in a virtual video conference with a research assistant. Subjects will also travel to the Aston Building at UTSW for a blood draw."
89059839|NCT04568824|Experimental|GraphoLearn reading intervention|GraphoLearn is a research-based treatment, delivered as an engaging computer game. Players match auditory targets (e.g., phonemes, rimes) to visual targets (single letters, letter sequences, words). The complexity of the items within each level is ordered such that at each level, the most frequent and regular mappings are introduced first based on measures such as orthographic/phonological neighborhood size and morphological family size. GraphoLearn allows the children to practice and reinforce lessons at their own individual trial pace and provides a record of performance progress that can be used to guide analyses.
89059840|NCT04568824|Active Comparator|Vektor math control|We selected an active control to maximize the specificity of the treatment outcomes; to this end, math games are among the most commonly used. Game sessions support learning numerical mathematical skills and cognition related to mathematical skills. In addition to math, this game contains training tasks for visuospatial working memory, spatial visualization and visuospatial reasoning. The overall theme of the game and feedback style are similar to those in GraphoLearn.
89059841|NCT04557787|Active Comparator|Intermittent catheter; SpeediCath® Standard female|Participants underwent two catheterizations with standard of care intermittent catheter: The first was performed by a trained nurse, the second by the participant later the same day.
89059842|NCT04557787|Experimental|New intermittent catheter Variant 1 for females|Participants underwent two catheterizations with the new intermittent catheter variant 1 for females: The first was performed by a trained nurse, the second by the participant later the same day.
89059843|NCT04557787|Experimental|New intermittent catheter Variant 2 for females|Participants underwent two catheterizations with the new intermittent catheter variant 2 for females: The first was performed by a trained nurse, the second by the participant later the same day.
89059844|NCT04553666|Experimental|Intervention Group|Four 200mg EGCG pills and one 250mg Vitamin C pill taken one time each day
89059845|NCT04553666|No Intervention|Usual Care Group|No study pills
89059846|NCT04551885|Experimental|FT516 in combination with avelumab|
89059847|NCT04547998|Experimental|All Participants (within patient control)|Each participant will serve as their own Control, receiving both Control and Investigational Interventions randomly allocated to treatment of a portion of a depigmented vitiligo lesion.
89059848|NCT04545502||Gelsoft Plus - Straights and Bifurcated|Patients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards.
89059849|NCT04545502||Gelsoft Plus - Extra-Anatomical|Any patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards.
89059850|NCT04545502||Cardiovascular Patches - Gelseal, Gelsoft, Thin Wall|Patients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards.
89059851|NCT04545502||Gelweave - Abdominal, Thoracic, Thoracoabdominal|"Patients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards:~Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries.~Thoracic aorta or arteries arising from the thoracic aorta.~Abdominal and thoracic aorta requiring a thoracoabdominal repair"
89059852|NCT04545502||Gelweave - Valsalva|Patients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards.
89059853|NCT04538482|Experimental|DASH Diet|calorie-restricted DASH diet (25% fat; 57% carbohydrate; 18% protein; 34 g fiber)
89059854|NCT04538482|Active Comparator|standard American diet|calorie-restricted standard American diet (35% fat; 51% carbohydrate; %15 protein; 14 g fiber)
89059855|NCT04532970|Placebo Comparator|Standard|"Eligible patients will be randomized to one of the treatment arms, which will involve 5 phone-delivered counseling sessions over a 9 week treatment phase. SC will be based on the 2008 PHS Clinical Practice Guideline (Fiore et al., 2008) and on SC in our ongoing two-site trials (R01DA025078; R01CA165001) This intervention arm will begin with a pre-quit session designed to help participants prepare for their Target Quit Day (TDQ). The TQD session will occur at week 1. The SC arm will focus on self-monitoring, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, relapse prevention, and homework. The pre-quit session prepares participants for their TQD by reviewing their experience with quitting, beliefs about smoking/quitting, perceived barriers to cessation, and creating a quit plan to identify smoking triggers and implement alternative strategies to manage those triggers without smoking."
89059856|NCT04532970|Experimental|BAPS|Key components of BAPS include activity monitoring and rewarding activity scheduling, assessment of personal goals and values, assessment and altering of avoidance behavior and other maladaptive coping strategies, and contingency management. BAPS focuses on reducing stress pile-up and loss of pleasure that accompanies the cessation process and on identifying and establishing environmental/social changes to promote abstinence. BAPS addresses smoking as a behavior that prevents and restricts opportunities for contact with healthy rewarding behaviors. These changes are achieved through altering daily routines previously associated with smoking in ways that increase pleasure and mastery across life domains, reducing rumination, and increasing behavioral skills to prevent return to smoking as a means of avoiding stressors.
89059857|NCT04532047|Experimental|Experimental: in utero enzyme replacement therapy|ERT will be delivered in utero. Typically, the target of the procedure to administer in utero ERT will be the umbilical vein near the insertion of the umbilical cord into the placenta. The dose of the ERT will be dependent on the specific disease process and enzyme being replaced, and the estimated weight of the fetus. The dosage will be the same as the recommended weight-based postnatal dosing, adjusted for estimated fetal weight. IUERT will be repeated every 2-4 weeks, which is an interval consistent with the standard of care for IUTs (every 2-4 weeks) to avoid excessive access through the umbilical vein. This interval is also consistent with the half-life of each relevant enzyme.
89059858|NCT04531670|Experimental|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
89059859|NCT04531670|Active Comparator|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
89059860|NCT04524858|Experimental|ATI-450|Oral, small molecule MK2 inhibitor will be administered twice daily (BID) at a dose of 50 mg
89059861|NCT04521179|Experimental|KN026 combined with KN046|KN026 combination therapy
89059862|NCT04516447|Experimental|Combination with carboplatin|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles (± 3 days), and (2) carboplatin 5 mg/mL*min intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle (± 3 days)
89059863|NCT04516447|Experimental|Combination with PLD|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles (± 3 days), and (2) PLD 40 mg/m^2 intravenously over 60 minutes every 4 weeks, on Day 1 of each 28-day cycle
89219311|NCT05947656|Experimental|Cohort 2|Eligible patients in Cohort 2 will receive two (2) FUS treatments per week for three (3) weeks on Day 1, 4, 8, 11, 15 and 18, followed by three (3) safety follow-up visits on Day 43, 71 and 99.
89219312|NCT05946655|Experimental|Antibiotic therapy|Women with infertility diagnosed with CE undergoing empirical antibiotic therapy
89219313|NCT05946655|No Intervention|Control|Women with infertility diagnosed with CE not subjected to empirical antibiotic therapy
89219314|NCT05939726|Experimental|Moisturising Cream with Vitamin E and Urea Cream|Participants who are randomised in this arm will receive a moisturising cream containing palm-oil-derived vitamin E concentrate for external application on both palms and soles, in addition to urea-based cream as the standard of care for PPE management. They will be required to apply the investigational cream first, followed by the urea-based cream, at least two times a day.
89219315|NCT05939726|Experimental|Moisturising Cream without Vitamin E and Urea Cream|Participants who are randomised to this arm will receive a basic or plain moisturising cream without Vitamin E for external application on both palms and soles, in addition to urea-based cream as the standard of care for PPE management. They will be required to apply the investigational cream first, followed by the urea-based cream, at least two times a day.
89219316|NCT05939726|Active Comparator|Urea Cream Only|Participants who are randomised to this arm will receive urea-based cream only as the standard of care for PPE management. They will be required to use the urea cream at least twice a day.
89219317|NCT05939713||VSD subjects|Patients with a confirmed diagnosis of Ventricular Septal Defect (VSD) and implanted with the Cera VSD occluder as per IFU instructions
89522769|NCT04447001|No Intervention|Wait list control-session 2|Wait-list group will be receiving Tai-chi prime intervention after 8 weeks wait time. At week 7, pre-test measures from wait-list group will be used as a control and compared with the post intervention measures of the experimental group.
89219318|NCT05939193|Experimental|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if the urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of the surgery as needed, with a maximum cumulative dose not exceeding 250 mg. Intravenous hydration is performed to balance urine output and to maintain the SVV≤10%.
89219319|NCT05939193|Active Comparator|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher as per current medical practice. That is, furosemide is only administered when clinically necessary or at the discretion of attending anesthesiologists. Intravenous hydration is performed to maintain the SVV≤10%.
89219320|NCT05938933|Experimental|Cohort|Cohort
89219321|NCT05938439|Experimental|Interventional|The procedure consists in Medical Device (MAGUS) placement by endoscopy under general anesthesia with fluoroscopic control.
89219322|NCT05930964||Hemodialysis patients|They will fill 3 questionnaires and will do some functional tests.
89219323|NCT05929729|Experimental|Intravenous (IV) iron|This group will receive intravenous iron (Ferric Derisomaltose) in a single dose of 20 mg/kg (max individual dose of 1000 mg). The drug is administered as an infusion over 30 minutes. 3 months after the infusion, they will receive a 9-month supply of Novaferrum pill to be taken once a day.
89219324|NCT05929729|No Intervention|Standard of care iron|This group will be referred to their primary care provider for oral iron therapy. If a participant cannot obtain care from a physician
89219325|NCT05929729|No Intervention|Healthy Controls|This group will only be participating in the observational part of the study and serve as our controls.
89219326|NCT05926466|Active Comparator|Arm 1|Drug: Moxifloxacin Moxifloxacin will be dosed at the licensed dose of 400 mg orally once daily for 16 weeks Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks
89219327|NCT05926466|Experimental|Arm 2|Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 500 mg orally once daily for 16 weeks
89219328|NCT05926466|Experimental|Arm 3|Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 1000 mg orally once daily for 16 weeks
89219329|NCT05926466|Experimental|Arm 4|Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 1500 mg orally once daily for 16 weeks
89219330|NCT05925127|Experimental|Group-A Monovalent NVX-CoV2373 (5 μg)|The Monovalent NVX-CoV2601 of 5 μg of antigen with 50 μg of Matrix-M adjuvant
89219331|NCT05925127|Experimental|Group-B Monovalent NVX-CoV2601 (5 μg)|Monovalent NVX-CoV2601 (5 μg of antigen with 50 μg of Matrix-M adjuvant)
89219332|NCT05925127|Experimental|Group-C Monovalent NVX-CoV2601 (5 μg)|Monovalent NVX-CoV2601 (5 μg of antigen with 75 μg of Matrix-M adjuvant)
89219333|NCT05925127|Experimental|Group-D Monovalent NVX-CoV2601 (35 μg)|Monovalent NVX-CoV2373 (35 μg of antigen with 50 μg of Matrix-M adjuvant)
89219334|NCT05925127|Experimental|Group-E Monovalent NVX-CoV2601(35)|Monovalent NVX-CoV2601 (35 μg of each antigen with a 75 μg of Matrix-M adjuvant)
89219335|NCT05925127|Experimental|Group-F Monovalent NVX-CoV2601 (50 μg)|Monovalent NVX-CoV2601 (50 μg of each antigen with a 100 μg of Matrix-M adjuvant)
89219336|NCT05925127|Experimental|Group-G Bivalent XBB.1.5|Bivalent XBB.1.5 Omicron subvariant/prototype COVID-19 licensed mRNA vaccine
89522770|NCT03953053|Experimental|FLACS Group|Femto Laser treated (anterior Capsulotomy and Fragmentation of lens body before phaco emulification)
89219337|NCT05919888|No Intervention|No skin incision preparation|"All patients will receive standard pre-operative prophylactic antibiotics. Participants will all receive the same preoperative external skin preparation with Hibiclens (chlorhexidine) and ChloraPrep (2% chlorhexidine gluconate / 70% isopropyl alcohol solution) prior to draping. Intra-operative irrigation will be standardized with Irrisept (chlorhexidine gluconate 0.05% in sterile water).~The control group will receive no dermal layer skin preparation. At the time of the surgery, after the skin incision has been made with a skin knife, the dermal layer will not be prepped with an agent."
89219338|NCT05919888|Active Comparator|Povidone-iodine|"At the time of the surgery, after the skin incision has been made, the dermal layer be prepped with povidone-iodine.~Drug: povidone-iodine Dose: swabstick Administration: swab the incision Frequency: once"
89219339|NCT05919888|Experimental|SURGX Wound Gel|At the time of the surgery, after the skin incision has been made, the dermal layer be prepped with SURGX Wound Gel. SURGX wound gel is a topical antiseptic gel agent to be used on surgical incisions to prevent bacterial infection.
89219340|NCT05915533|Other|Before/after study|
89219341|NCT05914779|Experimental|Subject with antibiotics treatment|"Individuals with low risk of infection after OHCA will be randomized to either 1) early antibiotics, or 2) no antibiotics.~Experimental arm received antibiotics as per local hospital clinical care pathways and physician choice."
89219342|NCT05914779|Active Comparator|Subjects with no antibiotics treatment|"Individuals with low risk of infection after OHCA will be randomized to either 1) early antibiotics, or 2) no antibiotics.~Active comparator arm will receive no antibiotics,"
89219343|NCT05907720|Experimental|Intervention Arm|The intervention arm will receive a package of behavioral interventions in addition to usual care in health facilities.
89219344|NCT05907720|No Intervention|Control Arm|The control arm will not receive any intervention other than usual care.
89219345|NCT05906875|Experimental|Decrease fear of falling|
89219346|NCT05906875|Experimental|Decrease the number of fall risk factors|
89219347|NCT05906875|Experimental|Increase balance confidence|
89219348|NCT05906875|Experimental|prove feasible to integrate into an existing community group exercise program|
89219349|NCT05905276|Active Comparator|Standard of Care|Patients in the usual care arm of the trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
89219350|NCT05905276|Experimental|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
89219351|NCT05904717|Experimental|A (PXS-4728)|IP Name: PXS-4728 Dosage: 15 mg Mode: oral administration (PO)
89219352|NCT05904717|Placebo Comparator|B (Matching Placebo)|Matching placebo to PXS-4728
89219353|NCT05898100|Experimental|Virtual Reality Distraction|Use of virtual reality (VR) during dental procedure.
89219354|NCT05898100|Active Comparator|Standard Treatment|Dental Clinic's standard treatment during dental procedure.
89219355|NCT05897775|Experimental|upper extremity ET|participants with upper extremity ET who are scheduled to undergo DBS in the thalamus.
89219356|NCT05895409||PF|Patients with interstitial lung disease (ILD) of known or unknown etiology other than IPF who has radiological evidence of pulmonary fibrosis(PF).
89219357|NCT05893381|Experimental|Stereotactic Radiotherapy followed by Lu-PSMA (arm A)|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen. 177Lu-PSMA-I&T in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 Gigabecquerel (GBq)
89219358|NCT05893381|Active Comparator|Stereotactic Radiotherapy (arm B)|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen.
89219359|NCT05893277|Experimental|Intervention|Four sessions with husband containing standard primary care based Motivational Interviewing techniques to reduce AUD in community populations. Wife joins 4th session on relapse prevention and support. This is followed by six Behavioral Couples Therapy sessions - see intervention description for content. All sessions are weekly, 1 hour in duration, delivered in person by a trained study nurse and include role plays and assignments to practice between sessions. Comic strips and graphics reinforce lessons and skills taught throughout the sessions.
89522771|NCT03953053|Active Comparator|Manual Group|Gold Standard Method with manual rhexis with pinzette and phaco emulsification
89523273|NCT03394807|Placebo Comparator|Placebo|Sham regional anaesthesia of the right upper quadrant by injection of Saline 0.9% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
89219360|NCT05893277|No Intervention|Enhanced usual care|For ethical reasons, to ensure participants in the control arm receive care for IPV and AUD, a) trained staff will conduct initial safety assessments for all patients; b) for IPV, wives will be referred to a legal cell at NIMHANS, a one-stop IPV center, and given information re. their options and local resources such as contact information for local organizations that can provide legal advice, counseling, and shelters; c) for AUD, participants will receive a brief educational session based on the World Health Organization's (WHO) manual for managing AUD in PHCs and referral to NIMHANS, a tertiary care mental health and addictions treatment center that has a dedicated referral system with the PHCs.
89219361|NCT05888597|Experimental|Menthol|In the trial, 30 minutes prior to performing submaximal CPET, participants will be administered, L-menthol patch which will be attached to the inside of a facemask that is connected to the breathing circuit.
89219362|NCT05888597|Placebo Comparator|Placebo|For placebo, the patch will contain a similarly patch with strawberry scent.
89219363|NCT05885542|Experimental|cannabidiol 800 mg|Cannabidiol 800 mg will be administered orally once in the laboratory prior to a stress induction paradigm.
89219364|NCT05885542|Placebo Comparator|placebo|Placebo (formulated to appear identical to active condition) administered orally once in the laboratory prior to a stress induction paradigm.
89219365|NCT05884424|Experimental|PARO Therapy Robot|Participants allocated to the PARO Therapy Robot group will undergo three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.
89219366|NCT05884424|No Intervention|Control|Participants in the control group will maintain their standard care, participating in those activities previously assigned in their individual care plan.
89219367|NCT05882721|Experimental|Cellulite|
89523274|NCT03383315|Experimental|Group 1|Intravenous tramadol 50mg + intravenous metoclopramide 10mg
89523275|NCT03383315|Active Comparator|Group 2|Intravenous tramadol 50mg + placebo (normal saline)
89059864|NCT04516447|Experimental|Combination with paclitaxel|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles, and (2) paclitaxel 80 mg/m^2 administered intravenously over 60 minutes (± 10 minutes) on Days 1, 8, and 15 of each 28-day cycle
89059865|NCT04516447|Experimental|Combination with gemcitabine|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles, and (2) gemcitabine 1000 mg/m^2 intravenously over 30 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle. If the dose of 1000 mg/m2 is deemed to have unacceptable toxicity in combination with ZN-c3, lower doses may be assessed.
89059866|NCT04515459|Other|Patients treated for bone or soft-tissue sarcoma of the limbs|
89059867|NCT04502121|Experimental|Intervention group (IG)|
89059868|NCT04502121|No Intervention|Standard of Care (SOC)|
89059869|NCT04496479|Experimental|LYG-LIV0001|Open label group of subjects with end stage liver disease receiving increasing doses of the experimental therapy.
89059870|NCT04496323||LOW|Golf Skill level high, handicap below 11.5
89059871|NCT04496323||HIGH|Golf Skill level low, handicap 18.5 - 26.4
89059872|NCT04485559|Experimental|Treatment (trametinib, everolimus)|Patients receive dosing per their assigned dose level. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
89059873|NCT04474834||PRS|Providing polygenic risk score (PRS)
89059874|NCT04466345|Experimental|Semaglutide|Participants receive semaglutide once daily orally, initiated at 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks (i.e., duration of 16 weeks in total).
89059875|NCT04466345|Placebo Comparator|Placebo|Participants receive matching semaglutide placebo capsules once daily (duration of 16 weeks).
89059876|NCT04466150|Active Comparator|Ocrelizumab treated|Participants age 18-50 with a first clinical presentation of MS or high-risk CIS diagnosed within 90 days of screening will be treated with ocrelizumab (300 mg IV x 2 doses given 2 weeks apart) at disease origin and with maintenance ocrelizumab 600 mg every 6 months through 30 months with a final study visit at 3 years
89059877|NCT04466150|No Intervention|Observational study cohort|Subjects enrolled into an observational study matched for the same disease duration and who are either untreated or treated with alternate MS disease modifying therapies will serve as a parallel reference group
89059878|NCT04465721|Active Comparator|HABIT Group|Participants randomized to the HABIT group will maintain their habitual eating schedule (≥13-h).
89059879|NCT04465721|Experimental|TRE Group|Participants randomized to TRE will reduce their eating window to a self-selected eating window (≤10-h).
89059880|NCT04464265|Experimental|Functional Magnetic Resonance Imaging|"While music is played Noninvasive functional magnetic resonance (fMRI) imaging will be performed at the University of Michigan Health System, University Hospital, Department of Radiology.~The fMRI is done under anesthesia using propofol. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations of 1.2, 1.6, 2.0, and 2.4 μg/ml in a stepwise fashion."
89059881|NCT04462419||Diagnostic (18F-fluciclovine, PET/MRI imaging)|Patients receive fluciclovine IV and undergo brain dynamic PET/MRI imaging over 50 minutes.
89059882|NCT04461808|Experimental|Tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
89059883|NCT04461808|Active Comparator|Digital Mammography|"Women will be screened for digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
89059884|NCT04448184|No Intervention|Prophylactic Platelet Transfusion|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 109/L.
89059885|NCT04448184|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.
89059886|NCT04437888|Active Comparator|Racemic Ketamine|ketamine 0.5mg/kg bolus on induction of anesthesia and 10mcg/kg/min infusion initiated prior to incision and terminated at the completion of wound closure. Maximum ketamine dose will not exceed 500mg
89059887|NCT04437888|Placebo Comparator|Saline|saline in the same volume as the study drug, administered in the exact same format.
89059888|NCT04423302|Experimental|TOTUM-63 3 intakes per day|Experimental active diet supplement TOTUM-63 taken 3 times per day (blinded arm)
89059889|NCT04423302|Placebo Comparator|Placebo 3 intakes per day|Placebo comparator taken 3 times per day (blinded arm)
89059890|NCT04423302|Experimental|TOTUM-63 2 intakes per day|Experimental active diet supplement TOTUM-63 taken 2 times per day (open arm)
89059891|NCT04422600||Mothers who report use of THC with or without CBD|Mothers who report THC and CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
89219368|NCT05881850|Experimental|Intervention group|After the participants are given the necessary information about the research and written consent is obtained, the introductory information form, Osteoporosis Awareness Scale and Osteoporosis Health Belief Scale will be applied by the researcher to the women in the intervention group who meet the inclusion criteria in the study to collect pre-test data just before the education program begins. Twelve weeks after finishing the education program the Osteoporosis Awareness Scale and the Osteoporosis Health Belief Scale will be administered to collect the posttest data.
89219369|NCT05881850|No Intervention|Control group|After the participants were given the necessary information about the study and written consents were obtained, the Introductory Information Form, Osteoporosis Awareness Scale and Osteoporosis Health Belief Scale will be applied to the women in the control group who met the inclusion criteria in order to collect the pre-test data. Twelve weeks after finishing the education program, the Osteoporosis Awareness Scale and Osteoporosis Health Belief Scale will be applied to collect the post-test data.
89219370|NCT05880992|Other|Progress Check|This arm will include pre- and post-prehabilitation questionnaires as well as twice weekly progress checks by the research assistant to check on participant progress, answer questions and provide accountability and motivation.
89219371|NCT05880992|Other|No Progress Check|This arm will include only pre- and post-prehabilitation questionnaires.
89219372|NCT05876689||DREAM OCT|All 50 patients will have both eyes (if able) imaged, 3 times, on the same day during their clinic visit.
89219373|NCT05876312|Experimental|PART A - Active ADX-038 administered to HV|For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
89219374|NCT05876312|Placebo Comparator|PART A- Placebo administered to HV|For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
89219375|NCT05876312|Experimental|PART B - ADX-038 administered to PNH participants|This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs. The treatment of HAE participants is an open-label study.
89219376|NCT05872256|Other|Active Arm|0.045% Tazarotene/0.01% Habetasol Lotion apply once daily at bedtime to the scalp afflicted with psoriasis
89219377|NCT05871905|Experimental|TY-9591|TY-9591
89219378|NCT05871541|Experimental|Investigational Product|Participants randomized to this arm will be given the investigational product (JCXH-105).
89219379|NCT05871541|Active Comparator|Active Control|Participants randomized to this arm will be given the FDA approved Shingrix.
89219380|NCT05870995|Experimental|CLAGE-VEN-RIC-Conditioning|"Cladribine: 5mg/m2 day -21 to d -17 cytarabine: 1g/m2 day -21- to d -17 etoposide: 100mg/m2 day -17 to -15 venetoclax: 100mg day-21; 200mg day -20, 400mg day -19 to day-3 Fludarabine: 30mg/m2 day -7 to -3 Busulfan: 3.2mg/kg day -6 to -5 Melphalan: 50mg/m2 day -4 to -3. or Fludarabine 30mg/m2 day -7 to -3 Total marrow irradiation day-5 to -3 PBSC: day 0~Conditioning regimen cane delayed to in patients with ongoing active infection or work-up of donors after CLAGE-VEN chemotherapy based on clinicians' decision. Patients receiving all-HSCT in cytopenia are classified as sequential while patients with recovered CBC are considered as bridging transplantation."
89219381|NCT05869708|Experimental|Active Arm|Subjects randomized into the Active arm will receive RS-EFP-NF Prism training as an adjunct to standard of care.
89219382|NCT05869708|Sham Comparator|Control Arm|Subjects randomized into the Control arm will receive a Sham-EFP-NF training with the same schedule as the active arm, adjunct to standard of care.
89219383|NCT05868226|Experimental|PRE1 ALX148 (Evorpacept) + Fam-Trastuzumab Deruxtecan-Nxki (T-DXd, Enhertu®)|The combination of T-DXd and ALX148 aims to explore the anti-tumoral effects of trastuzumab, of the topoisomerase inhibitor DXd and of the CD47-blocking agent ALX148. The rationale for this combination is that ALX148 is hypothesized, based on preclinical data, to facilitate antibody-dependent cellular phagocytosis (ADCP) of HER2 expressing (>HER2 1+) breast cancer binding T-DXd while cancer cell intrinsic or bystander cytotoxicity of T-DXd will result in the release of neoantigens promoting immune mediated antitumor activity in the tumor microenvironment.
89523276|NCT03394729|Experimental|Propolis tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with propolis and xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
89523277|NCT03394729|Active Comparator|Xilytol tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
89523278|NCT05171621||Macular holes|
89059892|NCT04422600||Mothers who report use of CBD only|Mothers who report CBD usage during the trimester month of pregnancy, at a frequency of at least three time per week. Information will be collected from mothers receiving their obstetrical care at UAMS and will include data on the exact products used and the frequency of use.
89059893|NCT04422600||Control Mothers|Recruitment of pregnant women who do not use THC or CBD will be conducted using the Epic MyChart research participant recruitment tool
89219384|NCT05868226|Experimental|PRE2 Zanidatamab (ZW25, zani) + Tucatinib (TUKYSA®)|"Zanidatamab is a bispecific IgG1-like antibody directed against two distinct HER2 epitopes. It induces formation of receptor clusters and internalization resulting in downregulation. It also inhibits growth factor-dependent and -independent tumor cell proliferation as well as potently activating ADCC, ADCP, and CDC.~Tucatinib is a highly selective, small molecule tyrosine kinase inhibitor (TKI) of HER2 compared to other TKI's (i.e., EGFR). It is well tolerated, crosses the blood brain barrier and can treat CNS disease. It is FDA approved for HER2+ breast cancer.~Given the promising clinical data for each of these drugs which have different mechanisms, the effect of zanidatamab after T-DXd (Enhertu®) in breast cancer patients, and the favorable toxicity profile of both drugs, we hypothesize that the combination of tucatinib and zanidatamab will be well tolerated and more efficacious than either drug alone for the treatment of patients with HER2 positive breast cancer."
89219385|NCT05867615|Experimental|[177Lu]Lu-PSMA I&T|[177Lu]Lu-PSMA I&T, intravenous, dosage of 5.5 - 7.4 GBq every 8 weeks
89219386|NCT05864456|Experimental|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement with Prizvalve Pro™ transcatheter aortic valve system
89219387|NCT05859555|Other|Intervention: Thematic quality circles - Deprescription|
89219388|NCT05859555|No Intervention|No intervention|
89219389|NCT05858801|Experimental|PRIMUS|PRIMUS PNS System
89219390|NCT05855083|Experimental|Narsoplimab single arm-treatment|Narsoplimab 4 mg/kg
89219391|NCT05851976|Experimental|Naproxen + duloxetine|
89219392|NCT05851976|Placebo Comparator|Naproxen + placebo|
89219393|NCT05848674|Experimental|Intervention Group|CABIN will be delivered in a single session to each participant (one-to-one) of the intervention group by a Research Assistant who is a cardiac nurse with over 20 years of clinical experience in cardiac rehabilitation. A private space at a Coronary Care Unit (Royal Victoria Hospital or Ulster Hospital) will be used for intervention delivery before patient discharge. Intervention delivery should take approximately 20 minutes.
89219394|NCT05848674|Other|Control Group|A Research Fellow will deliver (one-to-one) a refined version of CABIN prior to patient discharge from a Coronary Care Unit (Royal Victoria Hospital or Ulster Hospital). A private space will be used, with delivery taking approximately 10 minutes.
89219395|NCT05848232|Experimental|coraFlex, coraForce, and/or coraCross Catheters|Single arm
89219396|NCT05846893|Experimental|SeQuent® Please NEO drug-coated balloon catheter|
89219397|NCT05846893|Experimental|Current-generation drug-eluting stent|
89219398|NCT05846815|Experimental|TD|Children of 8-13 years of age without any neuropsychiatric diagnose (typically developed)
89219399|NCT05846815|Experimental|ADHD|Children of 8-13 years of age with previously diagnosed ADHD symptoms
89219400|NCT05839574|Active Comparator|MTX in monotherapy|Combined treatment with MTX followed by hysteroscopic evacuation of POC
89219401|NCT05839574|Active Comparator|MTX + letrozole add-on|Combined treatment with MTX + letrozole add-on followed by hysteroscopic evacuation of POC
89219402|NCT05839561|Active Comparator|Tubal pregnancy treated with MTX|MTX in a single dose of 100 mg intravenously on day 0
89219403|NCT05839561|Active Comparator|Tubal pregnancy treated with letrozole|Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0
89219404|NCT05834959|Experimental|SOGH employees, taking part in the same education and training program.|Participants will be recruited from the Seven Oak General Hospital staff population and will complete a two-part education and practical program.
89219405|NCT05833204|Experimental|Colporrhaphy with barbed absorbable suture|The colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
89219406|NCT05833204|Active Comparator|Colporrhaphy with standard absorbable suture|The colporrhaphy will be performed using a standard 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
89219407|NCT05829317|Experimental|Magnesium Sulfate|4g Magnesium sulfate (100mL) BID, given intravenously over 2 hours, for a total of 10 doses
89219408|NCT05829317|Placebo Comparator|0.9% NaCl|100mL 0.9% NaCl BID, given intravenously over 2 hours, for a total of 10 doses
89219409|NCT05826886|Active Comparator|Control video|Video of a woman describing basic information about psychotherapy and how it is embedded in the insurance system in Germany. Personal experience with therapy are not provided. 'Emotional writing' is introduced as a type of intervention used in depression treatment and basic information about it is provided.
89219410|NCT05826886|Experimental|Testimonials|Video of a patient and a therapist, who both describe their personal experience of depression therapy in a positive but realistic way. Emphasis is on the personal experience protagonist. 'Emotional writing' is described as a helpful technique from a first person perspective.
89219411|NCT05825391|No Intervention|control group|Continue to use the center's original antiplatelet regimen: oral aspirin 100 mg and clopidogrel 75 mg daily
89523279|NCT05171621||Epiretinal membranes|
89059894|NCT04417062|Experimental|Olaparib-Ceralasertib|"Unresectable disease (can not be surgically removed) will be enrolled into Cohort 1 and Resectable disease (can be surgically removed) which is limited only to the lung parenchyma will be enrolled into Cohort 2.~Olaparib at a predetermined dose orally 2 times a day on days 1-28~Ceralasertib will be given at a predetermined dose orally 2 times a day on days 1-14 in 28-day study cycles.~Patients can remain on treatment for up to 2 years if disease progression has not occurred."
89059895|NCT04406389|Active Comparator|Intermediate Dose Prophylaxis|"Subjects will receive one of the following interventions, at their physician's discretion:~Enoxaparin 0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min~Enoxaparin 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 mL/min~If patient develops acute kidney injury: unfractionated heparin 7,500 units subcutaneously every 8 hours.~Fondaparinux (if history of heparin-inducted thrombocytopenia [HIT]) 2.5 mg daily subcutaneously"
89059896|NCT04406389|Experimental|Therapeutic Dose Anticoagulation|"Subjects will receive one of the following interventions, at their physician's discretion:~Unfractionated heparin (UFH) to target anti-Xa level 0.3 -0.7 IU/mL or activated partial thromboplastin time (aPTT) (according to institutional protocol).~Enoxaparin 1 mg/kg subcutaneously every 12 hours~Argatroban (if heparin-induced thrombocytopenia [HIT]), dosed according to institutional protocol.~Fondaparinux (if HIT and creatinine clearance greater than or equal to 50 ml/min) dosed by weight:~≥100 kg: 10 mg daily~<100 kg but ≥50 kg: 7.5 mg daily~<50 kg: 5 mg daily"
89059897|NCT04401462|Active Comparator|Operative group|tension band wiring or plate fixation
89059898|NCT04401462|Active Comparator|Non-operative group|conservative treatment
89059899|NCT04379544||COVID-19 Positive Patients Receiving CPUS|Adult patients (18 years) presenting to the ED or ICU with highly suspected diagnosis or confirmed diagnosis of COVID-19 in whom the clinician deems a CPUS (cardiopulmonary ultrasound) is indicated.
89059900|NCT04378751|Experimental|Decision aid video|Participants receiving the intervention will complete a pretest, watch the decision aid video, and complete posttest via tablet computer facilitated by Patient Navigators.
89059901|NCT04378751|Active Comparator|Genetic counseling informational brochure|Participants receiving the control will complete pretest, review a genetic counseling brochure with the Patient Navigators, and complete posttest via tablet computer facilitated by a Patient Navigator.
89059902|NCT04358458|Experimental|Monotherapy Arm|
89059903|NCT04358458|Experimental|Combination Arm|
89059904|NCT04356924|Experimental|Psychological treatment|The psychological treatment consists of 11 sessions (55 minutes per occasion), where the patient meets a psychologist face-to-face (either licensed or under training to be licensed) once a week. In between sessions, patients are supposed to complete homework exercises that are related to the contiguous sessions (2 x 45 minutes per week).
89523280|NCT04446949||Undocumented migrants|
89059905|NCT04356924|Active Comparator|Cognitive training|Like the experimental group, the active control group also consists of 11 sessions (55 minutes per occasion), once a week. At those occasions, the patient will meet a psychology student under training or a MSc in psychology that coaches the patients during the cognitive training. In between sessions, patients are supposed to take 2 walks (45 minutes per occasion to meaningfully match the home exercises in the experimental group).
89059906|NCT04356924|No Intervention|Treatment as usual|This group receives no intervention. They receive regular health information that is given after the extended cognitive examination at the Cognitive Centers. However, after the finalization of the post-intervention evaluations, this group will be randomized to participate in one of the active interventions. We will conduct additional post-intervention assessments also for those individuals in this group that accept this offer to increase the power of the intervention evaluation.
89059907|NCT04356729|Experimental|Atezolizumab and Bevacizumab|"The research study procedures include screening for eligibility, study treatment including evaluations, a biopsy, and follow up visits.~Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks~Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.~Treatment will be administered on an outpatient basis Study treatment will continue until study doctors decide to stop therapy due to criteria which may include disease progression, adverse events or changes in condition. Participants will be followed for survival health information following treatment until the study ends, which could be approximately 5 years from start of treatment"
89059908|NCT04345393|Experimental|Digital Transformation Network (DTN) Program|IBD patients at the 3 sites will be sent a message to their Smartphone
89059909|NCT04345393|Active Comparator|Control Arm|Patients will enter the control group once they initially complete the ePRO and online assessment tools. They will remain in the control group, and then at set intervals each site will transition these patients into the DTN intervention arm.
89059910|NCT04343716|Experimental|White women|White women aged 65-75 with knee OA
89059911|NCT04343716|Experimental|Black women|Black women aged 65-75 with knee OA
89059912|NCT04336826|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 24 weeks.
89059913|NCT04335721|Experimental|Voxelot|Voxelotor 1500mg once a day
89059914|NCT04335721|Other|Standard of Care (SOC)|Observational while receiving SOC
89059915|NCT04333810||Active IBD patients|Patients with active IBD, based on colonoscopic evaluation and biopsy results.
89059916|NCT04333810||IBD patients in remission|IBD patients in remission, with no recently colonoscopic evidence of disease, and only on maintenance therapy.
89059917|NCT04329650|Experimental|Siltuximab 11mg/Kg|
89059918|NCT04329650|Active Comparator|Dexamethasone 6mg/24h|
89059919|NCT04327310|Experimental|Meplazumab|The vial of meplazumab will be reconstituted with 1 mL of water for injection. The required amount of drug solution will be withdrawn and added to 100 mL sterile normal saline (0.9%) for IV infusion. A single dose of meplazumab will be infused over 60 minutes at a constant rate using an infusion pump.
89059920|NCT04327310|Placebo Comparator|Placebo|100ml placebo will be infused over 60 minutes at a constant rate using an infusion pump, single time.
89059921|NCT04326231|Experimental|Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
89059922|NCT04308499|Experimental|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions
89059923|NCT04308499|Active Comparator|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions
89059924|NCT04308135||vascular parkinsonism|the investigators will recruit 30 patients diagnosed as Vascular Parkisonism ,
89059925|NCT04308135||Parkinson's disease|50 patients diagnosed as Parkinson Disease
89059926|NCT04308135||Controls|30 healthy controls.
89219412|NCT05825391|Experimental|test group|Use a guided antiplatelet regimen based on LTA testing
89219413|NCT05824819|Active Comparator|Endometriosis|Women subjected to laparoscopy due to endometriosis. Before the procedure: collection of a stool sample for NGS testing (2 ml); During the procedure: collection of fluid/ washings from the peritoneal cavity (2 ml) and fluid from the endometrial cyst (2 ml), and collection of endometrial tissue by aspiration biopsy of the uterine cavity (1 ml) for NGS examination.
89219414|NCT05824819|Active Comparator|Idiopathic infertility|Women subjected to laparoscopy due to idiopathic infertility. Before the procedure: collection of a stool sample for NGS testing (2 ml); During the procedure: collection of fluid/ washings from the peritoneal cavity (2 ml) and collection of endometrial tissue by aspiration biopsy of the uterine cavity (1 ml) for NGS examination.
89219415|NCT05824507|Active Comparator|Endometriosis + empiric antibiotic therapy|Women undergoing laparoscopic removal of endometriotic foci due to pain/infertility and endometrial aspiration biopsy for diagnosis of CE followed by empirical antibiotic therapy of CE, if confirmed
89523281|NCT04446949||Immigrants with Norwegian ID|
89523282|NCT04446949||Norwegian residents|
89219416|NCT05824507|Active Comparator|Endometriosis + no empiric antibiotic therapy|Women undergoing laparoscopic removal of endometriotic foci due to pain/infertility and endometrial aspiration biopsy for diagnosis of CE without empirical antibiotic therapy of CE, if confirmed
89219417|NCT05823311|Experimental|GPLET (Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin)|Intravenous injection: gemcitabine and cisplatin (CG)+ tislelizumab； Oral administration: lenvatinib.
89219418|NCT05823311|Placebo Comparator|CG (Gemcitabine and Cisplatin)|Intravenous injection: gemcitabine and cisplatin (CG)+placebo； Oral administration: placebo.
89219419|NCT05822986||Individuals with stroke|Patients who were hospitalized in the Neurology Service of Pamukkale University Hospital and who had an acute stroke and who met the inclusion criteria
89219420|NCT05821205|Experimental|Narrative Persuasion (randomized weekly, 1 of 4 options)|Narrative persuasion will be youth or provider testimonial about violence in their community and/or how SafERteens helped their development and reduced violence. Randomized weekly.
89219421|NCT05821205|Experimental|Reciprocity (randomized weekly, 1 of 4 options)|The reciprocity engagement strategy (ES) will be operationalized as an unsolicited $5 gift card with the SafERteens Logo. Randomized weekly.
89219422|NCT05821205|Experimental|Commitment (randomized weekly, 1 of 4 options)|Commitment will be operationalized as a pledge committing to screening and/or delivering SafERteens (depending on role). Randomized weekly.
89219423|NCT05821205|No Intervention|Engagement Strategy Control (randomized weekly, 1 of 4 options)|The control condition will involve no ES for the weekly Engagement Strategies. Randomized weekly.
89219424|NCT05821205|No Intervention|Personalized feedback control (randomized monthly, 1 of 2 options)|The control condition will involve no personalized feedback. Randomized monthly
89523283|NCT04445285|Experimental|Treatment Arm|Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
89219425|NCT05821205|Experimental|Personalized feedback (randomized monthly, 1 of 2 options)|The feedback ES will be operationalized as a visual graphic of their personal performance screening and/or delivering SafERteens in relation to the mean of the provider group and/or towards a pre-set standard (i.e., screening 75% of adolescents; delivery rate of 75% of eligible youth). Personalized feedback or none will be randomized on a monthly basis.
89219426|NCT05819099||Training Set|
89219427|NCT05819099||Test Set|
89059927|NCT04300764|No Intervention|Control|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Control participants' steps will be passively monitored. Data will continue to be collected for 30 days after discharge.
89059928|NCT04300764|Experimental|Gamification Intervention|Participants will be recruited during an inpatient stay and given a Fitbit watch that will transmit data to the Way to Health study platform. Intervention patients will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Data will continue to be collected for 30 days after discharge.
89059929|NCT04296071||Group 1|patients who tend to have longer CPB
89059930|NCT04296071||Group 2|Patients who have shorter CPB
89059931|NCT04289415|Experimental|Individual Placement and Support|"The intervention used in this study will be a time-limited version of IPS. The employment specialist offers up until nine months job-search support and four months in-work support, giving a total of 13 months job-related support. If a participant succeeds in obtaining work before nine months has passed the remaining job-search support months may be transferred to in-work support time.~In the follow-up time while seeking employment, the employment specialists will work with the participants to identify skills and aspirations, establish contact with potential employers and ensure economic advice and help with benefits planning. The in-work support involves individual and regular contact with the participant and the employer.~All participants who receive this intervention will do so in addition to their clinical treatment. The treatment provider and the employment specialist should cooperate and clarify roles together with the patient."
89219428|NCT05819099||Verification Set|
89059932|NCT04289415|Active Comparator|Selv help kit and work shop|The participants in the control intervention will be offered a self-help tool kit and a following introduction course to help participants see what their opportunities are, and specific tips on how to get further help. The course will last three hours a session over four days, with the offer of an individual one hour follow up session with the course leader when the course is over. The goal of the control group intervention is to enable the participants to make use of the services offered at the ordinary labor and welfare service.
89059933|NCT04283370|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
89059934|NCT04283370|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
89059935|NCT04282187|Experimental|Treatment (decitabine, ruxolitinib, fedratinib, pacritinib)|Patients receive decitabine IV QD over 1 hour on days 1-10, and either ruxolitinib PO BID, fedratinib PO daily, or pacritinib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89059936|NCT04275336|Experimental|EMLA group|The specialist nurse who is to perform IV cannulation determine the puncture site. A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse performed IV cannulation for them.
89059937|NCT04275336|Experimental|Distraction group|The multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They are also taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
89059938|NCT04275336|Experimental|Combined group|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
89059939|NCT04269005|No Intervention|Treatment as usual|"phase 0: Treatment as usual in combination with baseline and follow-up Survey but without any screening procedures (facilitating the study as a run-in phase to establish study procedures).~phase 1: randomized and main control condition with TAU + collection of information on psychosocial distress in the baseline~Intervention effects will be estimated, using the distressed focus sample, contrasting Phase 2 vs. Phase 1.~We intend to conduct additional statistical analyses to compare data from phases 2 and 1 vs. phase 0 to estimate potential effects of introducing parts of the screening 1 without consequences."
89059940|NCT04269005|Experimental|Intervention condition|"phase 2: implementation of the SCCM~The intervention (SSCM) will be implemented step-wise in predefined sections at all three sites using a stepped-wedge cluster randomized trial design. Clusters will be randomized to different sequences that dictate the timing at which each cluster will switch from the control to the intervention condition."
89059941|NCT04266886|Active Comparator|Arm I (usual care)|Patients receive usual care including receipt of multi-modal analgesia and the injection of a local analgesic at the time of surgery on the ERAS pathway.
89059942|NCT04266886|Experimental|Arm II (usual care, self-hypnosis guided relaxation)|Patients receive usual care as in Arm I. Patients also receive self-hypnosis guided relaxation by listening to MP3 on the ERAS pathway.
89059943|NCT04266717|Experimental|Baby Play Parent Education Group|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
89219429|NCT05816122|Experimental|MSCopilot® Detect|Performance of digital tests and standard test in clinic at D0, M6, M12, M18 and M24 (if applicable) Use of MSCopilot® Detect at-home in between visits during 18 or 24 months (if applicable)
89219430|NCT05814055|Experimental|Full dose kava intervention|
89219431|NCT05814055|Experimental|Half dose kava intervention|
89219432|NCT05814055|Placebo Comparator|Placebo control|
89219433|NCT05813535|Other|Baseline|Patient on heparin locks when off venous nutrition
89219434|NCT05812287||Case|The case group includes high-grade intraepithelial neoplasia of the stomach, early gastric cancer, and advanced gastric cancer. According to the anatomical location of the tumors, they were divided into two groups: gastric cardia cancer and non-cardia gastric cancer.
89219435|NCT05812287||Control|Pathological findings in the control group showed no malignant changes in the stomach, including normal gastric mucosa, superficial gastritis, non atrophic gastritis, and gastric polyps, etc.
89219436|NCT05810116|Active Comparator|Levagen+|PEA in capsule form - 1 capsule with water upon pain onset, followed by another capsule with water after 2 hours if pain persists.
89219437|NCT05810116|Placebo Comparator|Microcrystalline cellulose|PEA in capsule form - 1 capsule with water upon pain onset, followed by another capsule with water after 2 hours if pain persists.
89219438|NCT05807932|Experimental|Venetoclax|Venetoclax treatment will be started orally once a day with food, one day before FLAMSA conditioning therapy and stopped the day before high-dose Treosulfan. The total duration of treatment with Venetoclax will be 6 days (day -11 to -6 before stem cell infusion). Patients with active disease at transplant will receive a 3-day ramp-up prephase of Ara-C (100mg total dose infused in 1h) with daily increasing doses of Venetoclax to prevent TLS during conditioning. Total treatment duration with Venetoclax in patients with active disease at transplant will be 8 days (day -13 to -6 before stem cell infusion).
89219439|NCT05806944|Experimental|Group A|Patients with BED not undergoing symptom provocation
89219440|NCT05806944|Experimental|Group B|Patients with BED not undergoing symptom provocation
89219441|NCT05806944|Experimental|Group C|Patients with BED undergoing symptom provocation
89219442|NCT05806944|Experimental|Group D|Patients with BED undergoing symptom provocation
89219443|NCT05803941|Other|Single arm|"Participants will be followed until death, lost to follow-up, or up to 10 years from first dose of AAA617, whichever occurs first.~There will be no study treatment administered to participants while participating in this study."
89219444|NCT05798078|Experimental|Cognitive Bias Modification for Interpretation (CBM-I)|Participants in this arm complete an initial introductory session of Cognitive Bias Modification for Interpretation (CBM-I) in the lab followed by 6 sessions scheduled to be completed over the subsequent week (1 per day). CBM-I will be administered via an online platform using an individual login account.
89219445|NCT05798078|Sham Comparator|Sham Training Control Condition|Participants in this arm complete an initial introductory session of the sham training control condition in the lab followed by 6 sessions scheduled to be completed over the subsequent week (1 per day). CBM-I will be administered via an online platform using an individual login account.
89219446|NCT05797376|Experimental|Rivaroxaban + Aspirin group|patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)
89219447|NCT05797376|No Intervention|Aspirin group|patients are prescribed aspirin at a daily dose of 100mg
89219448|NCT05797116||Anaesthesiologists in the Netherlands|The participants in this study are anesthesiologists in the Netherlands, preferably those in charge of preoperative screening. One anesthesiologist per anesthesiology department may be included.
89219449|NCT05794321|Experimental|IV TXA Group|Patients in the experimental group will receive a loading dose of IV tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction. Postoperative care will be standard and based on established UCSF guidelines.
89219450|NCT05794321|No Intervention|Control Group|Patients in the control group will not receive any IV TXA intraoperatively and will undergo a traditional gender affirming mastectomy following the established standard of care.
89219451|NCT05789407|Experimental|endometriosis|Women subjected to elective laparoscopy for pelvic endometriosis
89219452|NCT05789407|Active Comparator|idiopathic infertility|Women subjected to elective laparoscopy for idiopathic infertility
89219453|NCT05789056|Experimental|QRX003, 4%|Subjects will apply test article once daily in the morning (QAM) for 12 weeks
89219454|NCT05782582|Experimental|Package investigation|"Resting ECG,~Evaluation of risk according to PTP-table.~Echocardiography,~Exercise stress bicycle test (secondarily drug provocation) with injection of isotope for myocardial scintigraphy,~Scanning for myocardial perfusion~CAC-scoring with CT"
89219455|NCT05782582|Active Comparator|Standard investigation|"Resting ECG~Evaluation of risk according to PTP-table.~Echocardiography.~Exercise stress bicycle test.~If judged to be needed according to clinical indication sequentially completed by:~Echocardiography, Exercise stress bicycle test (secondarily drug provocation) with injection of isotope for myocardial scintigraphy and/or Coronary CTA. In addition, cardiac examinations done with other modalities chosen on clinical grounds will be examined in the study.~,"
89219456|NCT05776758|Experimental|NAC+RC|cisplatin-based neoadjuvant chemotherapy plus radical cystectomy
89219457|NCT05776758|Active Comparator|RC alone|radical cystectomy alone
89219458|NCT05763160|Experimental|RZL-012 50mg/ml|
89219459|NCT05757310|Experimental|Treatment (conditioning, haploHCT)|Patients receive cyclophosphamide PO and IV, pentostatin IV, anti-thymocyte globulin IV and undergo CD4+ T-cell depleted haploHCT on study. Patients also undergo bone marrow aspirate, bone marrow biopsy, and collection of blood samples at screening and follow-up.
89219460|NCT05748626|Experimental|Group #1: Anti-snoring appliance|Group #1: Anti-snoring appliance (Zyppah) that will be utilized during their procedure.
89219461|NCT05748626|Active Comparator|Group #2: Control group, that will not utilize anti-snoring appliance|Group #2: Control group, that will not utilize (Zyppah) anti-snoring appliance during their procedure.
89219462|NCT05745727|Experimental|PRX-115|Participants will receive a single dose of PRX-115 by IV infusion
89059944|NCT04266717|Active Comparator|Milestone Education Group|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
89059945|NCT04265625|No Intervention|blind tracheotomy|no endoscopic guidance tracheotomy
89059946|NCT04265625|Experimental|endoscopic guidance tracheotomy|With endoscopic guidance tracheotomy
89059947|NCT04256915|Experimental|CBT-I + Bright Light|n = 50
89059948|NCT04256915|Active Comparator|CBT-I + Placebo Light|n = 50
89059949|NCT04256915|No Intervention|Wait-list Control|n = 50
89059950|NCT04255745|No Intervention|Assessment-only control|30 Assessment-only control group will be mailed (standard or electronic) NIH/National Institutes on Aging (NIA) Go4Life® educational materials once a month for 3 months. Exercise logs documenting weekly exercise activities, duration, time and effort will be requested to be sent back.
89059951|NCT04255745|Experimental|Intervention|60 Intervention group will receive 12 weeks of supervised resistance training following the American Heart Association and American College of Sports Medicine guidelines for older adults. Exercises will include a mixture of upper-body and lower body strength exercises. Training load will be determined based on initial 1-repetition maximum tests (1-RM). Initial exercise load will start off at low resistance (40-50% 1RM) with more frequent repetitions per exercise, and will gradually increase weight load and intensity over the exercise training period.
89059952|NCT04254575||body dysmorphic disorder (BDD)|Adults with a current primary diagnosis of body dysmorphic disorder (BDD)
89059953|NCT04251910|Active Comparator|Cohort 1- 30 Micrograms|Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo
89059954|NCT04251910|Active Comparator|Cohort 2- 60 Micrograms|"Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo.~Additional 20 subjects receive 60 Micrograms or placebo."
89059955|NCT04251910|Active Comparator|Cohort 3- 90 Micrograms|Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo
89059956|NCT04251910|Active Comparator|Part B Cohort|Part B cohort consists 46 subjects receiving 40 Micrograms or placebo
89059957|NCT04248582|Experimental|Cryotherapy before chemoradiation|Patients receive 2 sessions of liquid nitrogen spray cryotherapy prior to chemoradiation
89059958|NCT04248582|Experimental|Cryotherapy before chemoradiation and during|Patients receive 2 sessions of liquid nitrogen spray cryotherapy prior to chemoradiation and one session during chemoradiation
89059959|NCT04248491|Active Comparator|Emsella Chair Active Treatment|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
89059960|NCT04248491|Sham Comparator|Emsella Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (<10% power).
89059961|NCT04248192|Experimental|Donor Derived HIV-Specific T-cells (DD HST-NEETs)|Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
89059962|NCT04246151|Experimental|Vancomycin & probiotic placebo|Vancomycin 125 mg orally every 12 hours plus probiotic placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
89059963|NCT04246151|Experimental|Probiotic & vancomycin placebo|Culturelle probiotic 20 billion active units orally every 12 hours plus vancomycin placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
89059964|NCT04246151|Placebo Comparator|Probiotic placebo & vancomycin placebo|Vancomycin placebo orally every 12 hours and Culturelle placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.
89059965|NCT04236882|Experimental|Focus group and interview (focus group, interview)|Participants attend either a focus group or interview about the sleep intervention and sleep-related problems over 90 minutes.
89059966|NCT04236882|Experimental|Group I (sleep intervention, health coaching session)|Participants receive a web-based sleep intervention weekly during weeks 1-4. Participants then receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out during weeks 5-9. Participants may optionally complete an interview over 1 hour at week 9.
89059967|NCT04236882|Experimental|Group II (health coaching session, sleep intervention)|Participants receive 2 web-based health coaching sessions over 30-45 minutes consisting of topics such as healthy shopping, increasing physical activity, identifying barriers, and eating out during weeks 1-4. Participants then receive a web-based sleep intervention weekly during weeks 5-9. Participants may optionally complete an interview over 1 hour at week 9.
89059968|NCT04236882|Active Comparator|Group III (health education material, counseling session)|Participants receive educational material on healthy homes. Participants also receive 2 web-based counseling sessions over 30-45 minutes consisting of topics such as indoor air quality, CPR and first aid, and emergency preparedness at weeks 1 and 3. Participants may optionally complete an interview over 1 hour at week 9.
89059969|NCT04236791|Experimental|Intervention group|
89059970|NCT04236791|Active Comparator|Control group|
89219463|NCT05745727|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion
89219464|NCT05745064|Active Comparator|TL-925 Arm|TL-925 will be administered OU BID
89219465|NCT05745064|Placebo Comparator|Placebo Arm|Placebo will be administered OU BID
89219466|NCT05741489|Experimental|ESKD with Burnt-out Diabetes|Participants with ESKD and burnt-out diabetes wearing a CGM for 10 days.
89219467|NCT05741489|Experimental|ESKD without Diabetes|Non-diabetic participants with ESKD wearing a CGM for 10 days.
89219468|NCT05738031||Group A|"Aim 1 (Part A). To utilize natural language processing (NLP) to identify all ED patients with incidentally detected lung nodules found on chest radiographs or chest or abdominal CT scans, and to develop a standardized referral and notification process~Aim 1.1) Utilization of NLP to screen radiologic reports and identify nodules meeting criteria for follow-up per Fleischner Society Guidelines~Aim 1.2) Creation of an electronic medical record-based notification system to alert patients and providers of the identification of an IPN that requires follow-up, tracked by a dedicated patient navigator~Aim 1.3) Establishment of a multidisciplinary lung nodule management team, hereafter referred to as the lung nodule clinic, to ensure guideline-directed management of nodules with emphasis on high risk nodules as identified in subsequent aims"
89219469|NCT05738031||Group B|"Aim 2 (Part B). To clinically risk stratify patients with IPNs utilizing artificial intelligence (AI) processing of known clinical risks factors for pulmonary malignancy, such as age, smoking history, and history of malignancy, along with radiographic risk classifiers including nodule location, size, and imaging features.~Aim 2.1) Development of an integrated classifier based on automated scanning and data retrieval from the electronic medical record (EMR) to stratify patients with IPNs as low, intermediate or high risk for malignancy, with factor analysis to assess contributions of individual factors to the model~Aim 2.2) Prospective evaluation of the integrated classifier and comparison of automated integrated classifier to established manual risk calculators"
89219470|NCT05738031||Group C|"Aim 3 (Part C). To investigate biologic risk classifiers that may aid in the risk stratification of pulmonary nodules~Aim 3.1) Evaluation of a blood-based gene expression assay for risk stratification of pulmonary nodules using biobanked specimens~Aim 3.2) Prospective collection of plasma from patients enrolled in lung nodule clinic and evaluation of gene expression to assess malignancy risk"
89219471|NCT05733611|Experimental|RP2 and atezolizumab plus bevacizumab in advanced MSS and pMMR CRC|RP2 will be injected by direct (including via colonoscope) or image-guided injection into injectable tumors (including subcutaneous, visceral, and nodal tumors).
89219472|NCT05733611|Experimental|RP3 and atezolizumab plus bevacizumab in advanced MSS and pMMR CRC|RP3 will be injected by direct (including via colonoscope) or image-guided injection into injectable tumors (including subcutaneous, visceral, and nodal tumors).
89219473|NCT05733598|Experimental|1L:RP3 w/atezolizumab + bevacizumab in advanced HCC not amenable to resection/locoregional therapies|RP3 will be injected by direct or image-guided injection into injectable tumors (eg,primary sitehepatic tumors, hepatic metastases, non-hepatic metastases, visceral, or nodal tumors).
89219474|NCT05733598|Experimental|2L:RP3 w/atezolizumab + bevacizumab in advanced HCC not amenable to locoregional thrpy after PD(L)1|RP3 will be injected by direct or image-guided injection into injectable tumors (eg,primary sitehepatic tumors, hepatic metastases, non-hepatic metastases, visceral, or nodal tumors).
89219475|NCT05730309|Experimental|Feasibility: Disclosure, customized discharge and expedited referral instructions|Participants enrolled in the Aim 1 cohort with LVH on POCUS will receive the study intervention consisting of disclosure, counseling with set discharge instructions and expedited referral (communication to existing primary care physician OR referral to follow-up clinic if no existing primary care)
89219476|NCT05723445|Experimental|Low Glycemic Load Diet|Feeding study with dietary composition (approximately) 50% fat, 20% protein, 30% carbohydrate.
89219477|NCT05719714|Experimental|Intervention group|Thirty individuals will be randomized to dapagliflozin 10mg to be taken daily for six months.
89219478|NCT05719714|No Intervention|Standard of Care group|Thirty individuals will be randomized to standard of care treatment.
89219479|NCT05719077|Experimental|Intervention Group|Clinicians in intervention group will watch a series educational and instructional videos and use caregiver burden assessment tool up to four times during regular home visits with family caregivers of home hospice patients living with dementia. Clinicians will be assessed for changes in knowledge regarding dementia caregiving (secondary outcome). Family caregivers will be assessed for changes in caregiver burden (primary outcome) and preparedness and self-efficacy (exploratory outcomes).
89219480|NCT05719077|Other|Control Group|Clinicians in control group will listen to a presentation on outcomes for home hospice patients living with dementia. Clinicians will be assessed for changes in knowledge regarding dementia caregiving (secondary outcome). Family caregivers will be assessed for changes in caregiver burden (primary outcome) and preparedness and self-efficacy (exploratory outcomes).
89219481|NCT05714566||IBD|
89219482|NCT05714566||IBD+CDI|
89219483|NCT05714566||Health control|
89219484|NCT05707858||Subject with suspected food allergy|
89219485|NCT05706402|Experimental|N-acetylcysteine|
89219486|NCT05706402|Placebo Comparator|Placebo|
89219487|NCT05704725|Experimental|ABP 938|Participants will be randomized in a ratio of 2:1 to receive either a single IVT injection of ABP 938 in a PFS or a single injection of aflibercept in a PFS.
89219488|NCT05704725|Experimental|Aflibercept|Participants will be randomized in a ratio of 2:1 to receive either a single IVT injection of ABP 938 in a PFS or a single injection of aflibercept in a PFS.
89219489|NCT05700903|Active Comparator|Prostate Cancer|Men undergoing androgen deprivation therapy via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for the treatment of prostate cancer
89219490|NCT05700903|Active Comparator|Healthy + ADT|Healthy men undergoing gonadal suppression via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for 9 weeks
89219491|NCT05700903|Placebo Comparator|Healthy + Placebo|Healthy men undergoing placebo for 9 weeks.
89219492|NCT05698901||Group A|"18 years or older~Male or female with Fabry disease diagnosed~Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.~ERT Treatment naïve Fabry patients"
89219493|NCT05698901||Group B|"18 years or older~Male or female with Fabry disease diagnosed~Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.~Agalsidase beta (ERT) exposed or treated Fabry patients"
89219494|NCT05697029|Experimental|tetrandrine group|Tetrandrine 60mg TID for 28 days
89219495|NCT05697029|Placebo Comparator|placebo group|placebo TID for 28 days
89219496|NCT05696197|Experimental|Experimental group|Practicing the Swipe Slide Pattern task in ST and DT conditions, offered in a random order over a period of 2 weeks, 5 days a week, approximately 10 minutes per training session. Training will be performed independently at home.
89219497|NCT05696197|No Intervention|Control group|Participants in the control group will receive no intervention during the study period. They are given the opportunity to perform the SSP-training after the study period to ensure motivation in this group.
89219498|NCT05695105|Experimental|Vibration Group|For primary and permanent teeth that will receive only toothbrush vibration treatment.
89219499|NCT05695105|Experimental|Vibration and Mini-implant Group|For permanent teeth that will receive mini-implant treatment followed by failed toothbrush vibration treatment.
89219500|NCT05693805|Experimental|Tai Chi Group|Participants randomized to this arm will receive a standardized Tai Chi protocol developed for veterans, adapted by the investigators, and administered by experienced VA Tai Chi instructors.
89219501|NCT05693805|Active Comparator|Wellness Group|Participants randomized to this arm will receive a wellness program that has been successfully used by the investigators in other studies of veterans with chronic pain.
89219502|NCT05689710|No Intervention|No intervention|
89219503|NCT05689710|Experimental|Experimental|Dietary Supplement with inositols and alpha-lactalbumin
89219504|NCT05689190||patients|Duplex ultrasound, angiogram, PTA intervention
89219505|NCT05687084|Experimental|Total hysterectomy with a uterine manipulator|Total hysterectomy with bilateral salpingo-oophorectomy performed with the use of a uterine manipulator during surgery.
89219506|NCT05687084|No Intervention|Total hysterectomy without a uterine manipulator|Total hysterectomy with bilateral salpingo-oophorectomy performed without the use of a uterine manipulator during surgery.
89219507|NCT05684549||stage I/II lung cancer patients|Patients with stage I/II lung cancer will receive radical surgery.
89219508|NCT05683990|Experimental|Arm 1|2 injections of Diamyd®
89219509|NCT05683990|Experimental|Arm 2|3 injections of Diamyd®
89219510|NCT05682859|Active Comparator|Roflumilast|20 of the participating patients are randomized to the active arm where systemic roflumilast 500 microgram tablets are received.
89219511|NCT05682859|Placebo Comparator|Placebo|20 of the participating patients are randomized to the active arm where systemic placebo tablets are received.
89219512|NCT05680272|Experimental|extrimental group|The experimental group will be given training on empathetic communication and the positive birth perception awareness scale will be applied to the experimental group.
89219513|NCT05680272|No Intervention|control group|No intervention will be made in the control group.
89219514|NCT05679245||Healthy Controls|Healthy controls without mental disorder in the general population of the Barcelona area of Catalonia, Spain to be assessed for exposure to traumatic life events, post-traumatic stress disorder, trauma symptoms, dissociative symptoms, affective symptoms, and psychosocial functioning.
89219515|NCT05669365|Experimental|Care Ecosystem|Patient and caregiver dyads receive the Care Ecosystem intervention
89219516|NCT05663541||Patient with multiple sclerosis|
89219517|NCT05659563|Experimental|Arm A|Giredestrant (GDC-9545): 30mg, orally (PO), daily (QD) during 15 days
89219518|NCT05659563|Active Comparator|Arm B|Tamoxifen: 20mg, orally (PO), daily (QD) during 15 days
89219519|NCT05652062|Experimental|Treatment|
89219520|NCT05647512|Experimental|LM-305 Dose Escalation|Administered intravenously
89219521|NCT05647512|Experimental|LM-305 Combination Expansion|LM-305 Administered intravenously Dexamethasone Orally
89219522|NCT05645042|Active Comparator|Transcendental Meditation (TM):|TM treatment for PTSD is designed to reduce stress, facilitate deep rest, and increase well-being. It was originally conceptualized as an effortless technique to enable physical relaxation. The treatment will be delivered by experienced, certified TM instructors receiving weekly supervision.
89523284|NCT04445285|Placebo Comparator|Placebo Arm 0.9% sodium chloride|Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
89523285|NCT03379025|Experimental|Early Intervention Group|JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
89219523|NCT05645042|Active Comparator|Present Centered Therapy (PCT):|PCT is a focused time-limited treatment for PTSD that focuses on increasing adaptive responses to current life stressors and difficulties that are directly or indirectly related to trauma or PTSD symptoms. PCT was originally designed as a treatment comparator in trials evaluating the effectiveness of trauma-focused cognitive-behavioral therapies such as PE and CPT. Several clinical trials have indicated that PCT may be an effective treatment option for PTSD and that patients may drop out of PCT at lower rates relative to trauma focused forms of CBT.
89219524|NCT05644002|Sham Comparator|Control|In this condition, participants are instructed to smoke as usual while attending to control stimuli presented to them on a computer monitor.
89219525|NCT05644002|Experimental|Puff Topography Biofeedback Training (PTBT)|In this condition, participants are provided instructions on how to puff their cigarette via a computer-assisted paradigm.
89219526|NCT05640245|Experimental|sonelokimab dose regimen 1|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 1
89219527|NCT05640245|Experimental|sonelokimab dose regimen 2|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 2
89219528|NCT05640245|Experimental|sonelokimab dose regimen 3|Subjects randomized to this arm will receive assigned sonelokimab dosage regimen 3
89059971|NCT04236479|Experimental|Bone marrow-derived mesenchymal stromal cell (BM-MSC)|The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10^6, 10x10^6, 20x10^6, 40x10^6, 80x10^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD.
89059972|NCT04235140|Experimental|LUM/IVA|Subjects will receive LUM/IVA for 96 weeks.
89059973|NCT04220684|Experimental|Conditioning Regimen|Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2g/ m2/day (days -6 to day -2)
89059974|NCT04220684|Experimental|Induction|Six doses of third-party-donor mbIL-21 expanded (KDS-1001) cells given thrice weekly for two weeks. Days may vary and KDS-1001 can be given from days 0 to 21
89059975|NCT04216589|Experimental|Semaglutide|All participants will receive a dose of 0.25 mg of semaglutide weekly starting at study entry, followed by 0.5 mg weekly starting at Week 2, and then 1.0 mg weekly from Weeks 4 through 24.
89219529|NCT05640245|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo
89219530|NCT05640245|Active Comparator|adalimumab|Subjects randomized to this arm will receive adalimumab
89219531|NCT05638568|Experimental|Intervention arm LS guided treatment|"all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.~The GAS will be analyzed immediately at the bedside by a LS-test POC device. For infants allocated to the interventional group the LS-result will be displayed as treat with surfactant or  do not treat with surfactant depending on wether the LS-ratio is under or above the cut-off ratio for treatment.~Those with LS-ratio above the cut-off ratio will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 > 0.30) - ie same as in control group."
89219532|NCT05638568|No Intervention|Control arm - routine surfactant treatment|"all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.~The GAS will be analyzed immediately at the bedside by a LS-test POC device, but result will remain blinded.~Infants allocated to the control group will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 > 0.30). The LS-ratio for those infants will remain blinded"
89219533|NCT05638412|Experimental|JASPER Intervention Group|"Caregivers receiving the JASPER intervention will undergo weekly virtual 60-minute sessions for 10 weeks conducted via Zoom.~The content of the intervention includes teaching and implementation of contingent responding and specific strategies to provide a high-quality response to children's communication, and play behaviors. Caregiver training is completed through review of pre-recorded videos of the caregiver-child dyad each week. The first half of each session will be dedicated to reviewing previous content and feedback on the play recording. The following half will consist of new material. The coaching support includes contingent responding, the parent is also taught to use specific strategies to provide a rich, high-quality response to children's communication, and play behaviors."
89219534|NCT05638412|Experimental|Psychoeducational Curriculum Group|"Caregivers receiving the 10 weekly psychoeducational curriculum modules will be provided with the resources via secure email and encouraged to engage with the material a self-directed manner.~The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The content of the modules will include information about developmental milestones in this age group for children with DS, behavior management strategy recommendations, positive parenting materials, and materials on increasing engagement through play."
89219535|NCT05633108||All Participants|Participants diagnosed with psychotic disorder at any time between 1 January 2014 and 31 December 2020 and have data available in French nationwide healthcare data system (SNDS) database during this period will be observed retrospectively.
89219536|NCT05631093|Active Comparator|ART + DOR/ISL|Participants with HIV-1 that has been virologically suppressed for ≥3 consecutive months on a stable oral ART are first treated with standard of care (SOC) ART for 48 weeks, followed by 48 weeks of treatment with DOR/ISL
89219537|NCT05631093|Experimental|DOR/ISL|Participants with HIV-1 that has been virologically suppressed for ≥3 consecutive months on a stable oral ART are treated with DOR/ISL for 96 weeks
89219538|NCT05629910|Experimental|Interventional period: Automated adjustment of FiO2 by O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
89219539|NCT05629910|No Intervention|Control period - manual adjustment of FiO2|During the control period, the bedside nurse will manually change FiO2 as per routine based on the reading from the Avant 9600 Nonin pulse oximeter connected to the central monitoring system), by changing oxygenflow from O2Matic as required to induce appropriate changes in SpO2:
89219540|NCT05629026|Experimental|primary lymphoedema|patients with primary lymphoedema
89219541|NCT05629026|Experimental|secondary lymphoedema|patients with secondary lymphoedema
89059976|NCT04206891||Group 1|Bilateral lobular invasive breast cancer
89059977|NCT04206891||Group 2|Invasive lobular breast cancer with age at onset <= 45 years
89059978|NCT04206891||Group 3|Invasive lobular breast cancer with family history for breast cancer
89059979|NCT04206891||Group 4|In situ lobular breast cancer with age at onset <= 45 years
89059980|NCT04206891||Group 5|In situ lobular breast cancer with family history for breast cancer
89059981|NCT04204915|Active Comparator|Group A: Aortic valve replacement|Participants randomised to AVR will be investigated and managed according to local protocols and standard practice. Participants will be placed on the waiting list with the aim that surgery will be performed within 3 months, dependent on local hospitals' waiting lists.
89059982|NCT04204915|No Intervention|Group B: Expectant management|Participants randomised to expectant management will continue to have regular monitoring of their condition in line with the procedures and standard practices of their hospital.
89059983|NCT04204798|Experimental|Dexmedetomidine group|Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.
89059984|NCT04204798|Placebo Comparator|Placebo group|Normal saline is infused for the same duration as in the dexmedetomidine group.
89059985|NCT04197869|Experimental|Experimental|The experimental group will take a pre-operative course of polyethylene glycol daily for seven days prior to procedure date.
89059986|NCT04197869|No Intervention|Control|The control group will not be given any intervention preoperatively.
89059987|NCT04193293|Experimental|Duvelisib + Pembrolizumab|"Stage 1: Duvelisib twice daily (BID) for 1 week followed by combination therapy with duvelisib BID + pembrolizumab every 3 weeks (q3w) (Cycle 1 was 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib; subsequent cycles were 3 weeks).~Stage 2: Duvelisib BID + pembrolizumab q3w in 3-week cycles."
89059988|NCT04191876|Experimental|Active|This study has only one arm. All patients enrolled will take part in the experimental arm.
89059989|NCT04188990|Active Comparator|Intervention arm|"The Intervention arm includes an intervention in the groups of patients who, after screening, are identified as having disease-related malnutrition (DRM) or at risk of DRM, and a follow-up of the rest of the patients"
89059990|NCT04188990|Placebo Comparator|By demand arm|"The By demand arm will include patients in whom the nutritional intervention, if given, is performed by demand by the medical staff responsible for each patient."
89059991|NCT04188990|Placebo Comparator|Usual care arm|"In the Usual care arm usual hospital practice is followed without any explicit nutritional intervention"
89059992|NCT04188457||Stroke - usual follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with regular follow-up
89059993|NCT04188457||Stroke - intensive follow-up|Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with intensive follow-up
89059994|NCT04188457||myocardial infarction - usual follow-up|Patient who has had a first or recurrent myocardial infarction with usual follow-up
89059995|NCT04188457||myocardial infarction -intensive follow-up|Patient who has had a first or recurrent myocardial infarction with intensive follow-up
89059996|NCT04187118||Lymphoma patients|Patients being in complete response after a first therapy for malignant lymphoma.
89059997|NCT04171843|Experimental|PBCAR269A at Dose Level 1 (Cohort A)|The starting dose of PBCAR269A will be 6 x 10^5 CAR T cells/kg body weight.
89059998|NCT04171843|Experimental|PBCAR269A at Dose Level 2|2 × 10^6 CAR T cells/kg body weight.
89059999|NCT04171843|Experimental|PBCAR269A at Dose Level 3|6 × 10^6 CAR T cells/kg body weight.
89060000|NCT04171843|Experimental|PBCAR269A at Dose Level 2 (Cohort B)|2 × 10^6 CAR T cells/kg body weight.
89060001|NCT04171843|Experimental|PBCAR269A at Dose Level 1 (Cohort B)|6 x 10^5 CAR T cells/kg body weight.
89060002|NCT04171843|Experimental|PBCAR269A at Dose Level 3 (Cohort B)|6 × 10^6 CAR T cells/kg body weight.
89060003|NCT04166552|Experimental|EHP-101 low dose once a day|
89060004|NCT04166552|Experimental|EHP-101 low dose twice a day|
89060005|NCT04166552|Experimental|EHP-101 high dose once a day|
89060006|NCT04166552|Experimental|EHP-101 high dose twice a day|
89060007|NCT04165993|Experimental|Concurrent chemotherapy and KN026|KN026 combined with docetaxol
89060008|NCT04165993|Experimental|KN026 monotherapy|KN026 monotherapy
89060009|NCT04165993|Experimental|A combination treatment of KN026 and KN046|KN026 combined with KN046
89060010|NCT04141501|Placebo Comparator|Control: Placebo|30 Patients will receive placebo
89060011|NCT04141501|Active Comparator|Intervention: Psilocybin|30 Patients will receive psilocybin
89060012|NCT04127604|Experimental|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|A combination of in-person and phone sessions along with significant other involvement over 6 months post-hospitalization.
89060013|NCT04127604|Active Comparator|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced symptom monitoring and safety evaluation over 6 months post-hospitalization.
89060014|NCT04126187||Panoptix|Bilateral implantation of the Panoptix trifocal IOL
89060015|NCT04106167||Treatment with Fate Therapeutics' FT500 Cellular Immunotherapy|Long Term follow-up of subjects who have received an allogeneic, iPSC-derived NK cell in a previous trial.
89060016|NCT04101318|Experimental|The non-Conformité Européene marked product, a Conformité Européene marked product|Participants first received the non-Conformité Européene marked investigational product for 42±3 days. Then there was a cross-over and the participants received one of the five Conformité Européene marked comparators products, which they used the following 42±3 days.
89060017|NCT04101318|Experimental|A Conformité Européene marked product, then the non-Conformité Européene marked product|Participants first received one of the five Conformité Européene marked comparators products for 42±3 days. Then there was a cross-over and the participants received the non-Conformité Européene marked investigational products, which they used the following 42±3 days.
89060018|NCT04091672|Experimental|All Participants (within patient control)|Each participant will serve as their own Control, receiving both Control and Investigational Interventions randomly allocated to treatment of a portion of a full-thickness skin defect.
89060019|NCT04091490|Experimental|Patients with relapsed/refractory Hodgkin's lymphoma|A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma
89060020|NCT04087057||Observational (interview, medical records review)|Patients complete questionnaires and participate in an interview to answer questions about information patients received before starting chemotherapy, any medical problems after surgery that could have been related to the start of the chemotherapy, how chemotherapy affected patients' life, and anything else patients may remember between the time when the breast surgery ended and the first dose of chemotherapy started. Patients' medical records are also reviewed.
89060021|NCT04084704|Other|Cingal injection|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
89060022|NCT04082780|Experimental|Rifamycin|Rifamycin-SV MMX 600 mg PO two times a day (1200 mg) for 30 days
89060023|NCT04082780|Placebo Comparator|Placebo|Placebo PO two times a day for 30 days
89060024|NCT04082117|Other|Open Label|Educational genetic counseling video
89060025|NCT04080284|Experimental|Niraparib|"Oral niraparib~-Cohort - Uterine serous carcinoma"
89060026|NCT04078373||Without urinary disorders|Subacute stroke patients without urinary disorders
89060027|NCT04078373||With urinary disorders|Subacute stroke patients with urinary disorders
89219542|NCT05628116|Experimental|XC243 50 mg single|Cohort 1 - 7 subjects will be randomized in a 5:2 ratio to be treated either XC243 50 mg (5 subjects) or placebo (2 subjects, see placebo single arm)
89219543|NCT05628116|Experimental|XC243 100 mg single|Cohort 2 - 7 subjects will be randomized in a 5:2 ratio to be treated either XC243 100 mg (5 subjects) or placebo (2 subjects, see placebo single arm)
89219544|NCT05628116|Placebo Comparator|Placebo single|Placebo comparator arm will consist of 4 subjects (1 subject each from Сohorts 1 and 2)
89219545|NCT05628116|Experimental|XC243 200 mg single-dose food effect|Cohort 3 - 14 subjects will be randomized in a 12:2 ratio to be treated either XC243 200 mg (12 subjects) or placebo (2 subjects, see placebo single arm) first on an empty stomach, and after the washing period after eating
89219546|NCT05628116|Placebo Comparator|Placebo single-dose food effect|Placebo comparator arm will consist of 2 subjects from Cohort 3
89219547|NCT05628116|Experimental|XC243 200 mg multiple|Cohort 4 - 10 subjects will be randomized in a 8:2 ratio to be treated either XC243 200 mg (8 subjects) or placebo (2 subjects, see placebo multiple arm)
89219548|NCT05628116|Placebo Comparator|Placebo multiple|Placebo comparator arm will consist of 2 subjects from cohort 4
89219549|NCT05619354||Individuals with headache|"Individuals with primary or secondary headache forms.~The Headache Disability Index will be applied:~In the translation phase:~Complete and assess the Dutch translation of the HDI questionnaire. The questionnaire and its evaluation can be completed online. If desired, the questionnaire can also be completed on paper, whereby the questions can be asked orally by a researcher.~OR~In the validation phase:~To complete the Dutch questionnaire, in combination with other questionnaires (RAND-36 questionnaire and HIT-6 questionnaire).The questionnaires can be completed online. If desired, the questionnaires can also be completed on paper. Afterwards participants will be asked to complete the HDI questionnaire again after 1 month."
89219550|NCT05619211|Experimental|Movement-to-Music|12 weeks of sprint-intensity interval training while following along with YouTube videos that include arm-based routines, with coaching through telecommunications. Participants are instructed to maintain their habitual diet and nutrition patterns
89219551|NCT05619211|No Intervention|Wait-list Control|12 weeks of maintaining habitual physical activity, diet, and nutrition patterns, until receiving 12 weeks of Movement-to-Music
89219552|NCT05615974|Experimental|LM101 Dose Escalation|
89219553|NCT05615974|Experimental|LM101 combination therapy exploratory|
89219554|NCT05615974|Experimental|LM101 combination expansion|
89219555|NCT05615818|Experimental|Experimental|Molecular targeted therapy matched to genetic alteration carried by the tumour
89219556|NCT05615818|Active Comparator|Control|Continued standard of care treatment for first-line biliary tract cancer
89219557|NCT05612880||Non-intervention controls|Men with advanced prostate cancer initiating androgen receptor signaling inhibitor treatment.
89219558|NCT05609682|Placebo Comparator|Placebo Arm|Standard ERAS protocol post-operative care with placebo
89219559|NCT05609682|Active Comparator|Gabapentin Arm|Standard ERAS protocol with scheduled postoperative gabapentin
89219560|NCT05600322|Experimental|Hexvix Blue light cystoscopy|In this study, enrolled patients will undergo standard White light cystoscopy and Blue light cystoscopy following Hexvix administration. Lesions detected during the cystoscopies will be resected or biopsied.
89219561|NCT05600062|Placebo Comparator|Placebo|Placebo tablet to be taken three times a day for three days
89219562|NCT05600062|Experimental|Racecadotril|Racecadotril 100 milligrams (mg) three times a day for three days
89219563|NCT05599932|Experimental|Group 1: Healthy Control|Each healthy participant will receive a single dose of HDM201
89219564|NCT05599932|Experimental|Group 2: Mild; Child-Pugh A|Each participant with mild Child-Pugh will receive a single dose of HDM201
89219565|NCT05599932|Experimental|Group 3: Moderate; Child-Pugh B|Each participant with moderate Child-Pugh will receive a single dose of HDM201
89219566|NCT05599932|Experimental|Group 4: Severe; Child-Pugh C|Each participant with severe Child-Pugh will receive a single dose of HDM201
89219567|NCT05597657|Other|Fluid administration (substudy 2)|
89219568|NCT05597475|Other|Patients|Patients with hypoglycemia
89219569|NCT05597475|Other|Controls|Patients without post-bariatric hypoglycemia
89219570|NCT05596630|Experimental|Stereotactic body radiation therapy|Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
89219571|NCT05596318|Experimental|Digital cognitive behavior therapy for insomnia (CBT-I)|
89060028|NCT04067115|Experimental|Trabectedin and Irinotecan|Trabectedin will be delivered by infusion on day 1 followed by 2 doses on irinotecan delivered by infusion for one hour on day 2 and day 4 of 21 day cycles. Some patients will receive an 18F-FLT Imaging scan prior to the first administration of trabectedin and once after administration of trabectedin.
89060029|NCT04065347||Group 1|A total of 150 participants taking tenofovir alafenamide will be enrolled in this cohort.
89060030|NCT04065347||Group 2|A total of 30 participants initiating/re-initiating tenofovir alafenamide will be enrolled in this cohort.
89060031|NCT04054375|Experimental|Weekly Steroid|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
89060032|NCT04051593|Experimental|Treatment|Exercise
89060033|NCT04048668|Active Comparator|Anodal tDCS|2mA for 20 minutes
89060034|NCT04048668|Sham Comparator|Sham tDCS|30 second ramp-up / ramp-down for 20 minutes
89060035|NCT04039386|Experimental|Cell Phone Based Cognitive Based Therapy|Young adults with hip pain
89060036|NCT04039386|Placebo Comparator|Placebo|Young adults with hip pain
89060037|NCT04034433|Experimental|Exercise|
89060038|NCT04034433|No Intervention|Control|
89060039|NCT04028830|Experimental|Arm 1|Medical representative presentation with the help internet tool for decision ANTIBIOCLIC
89060040|NCT04028830|Experimental|Arm 2|Medical representative presentation without presentation of the internet tool for decision support
89060041|NCT04028830|No Intervention|Arm 3|Usual practice without intervention regarding the prescription of antibiotics
89060042|NCT04023708||Cohort I: CYD-TDV exposed pregnant women and offspring|Pregnant women of any age and their offspring who were inadvertently exposed to CYD-TDV anytime during the pregnancy or in the 30 days preceding their LMP
89060043|NCT04023422|Active Comparator|Clinical intervention|Clinical health navigator, a community health worker, facilitates preparation for, attends, and confirms patients's understanding of an office visit.
89060044|NCT04023422|Experimental|Clinical intervention AND Home Visit|Patient receives Clinical intervention and Home visits. Care coordination activities occur taking into account the home environment, its social and physical characteristics.
89060045|NCT04023422|Experimental|Clinical intervention AND Feedback|
89060046|NCT04023422|Experimental|Clinical intervention AND Home Visit AND Feedback|
89060047|NCT04021641||Participants with Typical Hearing|From 5 age groups from their 6 years of age to adulthood
89060048|NCT04021641||Participants with Hearing Impairment|Participants with various degree of hearing impairment
89060049|NCT04017442|Experimental|Morphine|2mg preservative free morphine
89060050|NCT04017442|Placebo Comparator|Saline|4 mL preservative free saline
89060051|NCT04015622|Experimental|A: Biomarker directed Therapy (BT)|ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
89060052|NCT04015622|Active Comparator|B: Clinician's Choice (CC)|Enzalutamide or docetaxel until disease progression, then cross-over to the other therapy (e.g., enzalutamide to docetaxel, or docetaxel to enzalutamide).
89060053|NCT04010578|Experimental|MK-7 and vitamin D3 supplementation|Patients will receive a daily MK-7 and vitamin D3 supplementation for 3 months.
89060054|NCT04010578|Placebo Comparator|Placebo|Patients will receive a daily placebo for 3 months.
89060055|NCT04005521|Experimental|Preventive intervention|Patient will perform daily exercise: jaw and swallwing exercises, as well as are encouraged to eat and drink for as long as possible during treatment
89060056|NCT04005521|No Intervention|Control group|No intervention, only encouragement to eat and drink for as long as possible during treatment
89060057|NCT04003389|Experimental|Fezolinetant 30 mg|Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, once daily (QD) for a period of 52 Weeks.
89060058|NCT04003389|Experimental|Fezolinetant 45 mg|Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD for a period of 52 Weeks.
89060059|NCT04003389|Placebo Comparator|Placebo|Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, QD for a of period of 52 Weeks.
89060060|NCT04000282|Experimental|Part A: SAR442085 dose escalation|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
89060061|NCT04000282|Experimental|Part B: SAR442085 dose expansion|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
89060062|NCT03996018||group 1(HIV Uninfected)|Participant is HIV negative per antibody screen conducted on premises and participant is enrolled on HPTN 083 study
89060063|NCT03996018||group 2 (HIV Infected)|Participant has initiated ART therapy as a patient at St Jude Children's Research Hospital, newly diagnosed HIV and prolonged HIV
89060064|NCT03994055|Experimental|Anti-inflammatory Diet|"Dietary intervention providing:~Energy: 28-31 kcal/kg/day. Protein: 20-30%. Fat: 30-40%. Carbohydrates: 40-50%. The diet will be individualized according to the patients' comorbidities (obesity, type 2 diabetes, hypertension, renal insufficiency).~This group will include the consumption of foods that contain immune modulating nutrients:~Omega-3 fatty acids, antioxidants, soluble fiber, probiotics. The recommendation to include these foods will be made according to the patients' access to food in their home area."
89219572|NCT05596318|Active Comparator|Digital sleep hygiene education (SHE)|
89219573|NCT05594069|Experimental|Pre Group|intervention before and during radiotherapy
89219574|NCT05594069|Other|Re Group|intervention during radiotherapy only
89523286|NCT03379025|Other|Delayed Intervention Group|After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
89219575|NCT05593055|Active Comparator|Eplerenone|Participants be placed on enalapril 10 mg and weaned off their other anti-hypertensives prior to the Pre-Treatment Assessment. Amlodipine (5 to 10 mg) will be added if needed to control blood pressure. After the Pre-Treatment Assessment, participants randomized to this arm will receive 50 mg eplerenone . At 2 weeks, eplerenone will be increased to 100 mg. Amlodipine (5 to 10 mg) will be added at 6 weeks or later if needed to achieve the BP target of <135/85 mmHg.
89523287|NCT03252925|Experimental|Experimental Group|N-Acetylcysteine
89523288|NCT03252925|Placebo Comparator|Control Group|Placebo Oral Tablet
89060065|NCT03994055|Active Comparator|Low residue Diet|"Dietary intervention providing:~Energy: 28-31 kcal/kg/day. Protein: 20%. Fat: 20%. Carbohydrates: 60%. Diet will have lactose restriction, fiber restriction and fat restriction."
89060066|NCT03991104|Experimental|SOX-based Chemoradiotherapy|IMRT is delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy over 5 weeks. Concurrent Oxaliplatin (3 levels for phase I: 110mg/m², 120 mg/m² and 130 mg/m², d1) and fixed dose of S-1 (80mg/ m², d1-14) are administered concurrently with IMRT, every 4 weeks. The recommended dose of Oxaliplatin are then further evaluated in the Phase II setting.
89060067|NCT03989349|Placebo Comparator|Placebo|Placebo administered via subcutaneous injection
89060068|NCT03989349|Experimental|Nemolizumab|Nemolizumab administered via subcutaneous injection
89060069|NCT03985943|Placebo Comparator|Placebo|Placebo
89060070|NCT03985943|Experimental|Nemolizumab|Nemolizumab Active
89060071|NCT03983473|Other|Crohn's disease|Patients suffering from established Crohn 's disease without spondyloarthritis
89060072|NCT03983473|Other|Spondyloarthritis|Patients with established spondyloarthritis without Crohn 's disease
89060073|NCT03983473|Other|Crohn + spondyloarthritis|Patients suffering from both spondyloarthritis and Crohn 's disease
89060074|NCT03983473|Other|Healthy controls|Patients without spondyloarthritis and Crohn 's disease
89060075|NCT03968913|Placebo Comparator|Control|Subjects will receive two injections of sterile saline after ACL injury, prior to surgery
89060076|NCT03968913|Active Comparator|Two doses Anakinra|Subjects will receive two injections of anakinra after ACL injury, prior to surgery
89060077|NCT03968315|Experimental|Diagnostic (MRI, diaphragm fluoroscopy)|Patients undergo an MRI scan over 45-60 minutes and a diaphragm fluoroscopy 30 days before surgery.
89060078|NCT03962712||Low-Wage Workers from Minneapolis, MN|Low-wage workers from Minneapolis, MN, where the minimum wage will be increased to $15-an-hour over the study period.
89060079|NCT03962712||Low-Wage Workers from Raleigh, NC|Low-wage workers from Raleigh, NC, where the minimum wage will not be significantly changed over the study period.
89060080|NCT03960437|Other|Study Participant|Every study participant will receive etelcalcetide prescribed by their treating physician for the duration of the study.
89060081|NCT03959488|Experimental|MEDI8897|anti-RSV monoclonal antibody with an extended half-life
89060082|NCT03959488|Active Comparator|Palivizumab|anti-RSV monoclonal antibody
89060083|NCT03950817|Active Comparator|0.75 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 0.75 mg/kg sub-dissociative dose ketamine (SDK) to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
89060084|NCT03950817|Active Comparator|SDK: 1 mg/kg|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses 1 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
89060085|NCT03950817|Active Comparator|SDK: 1.5 mg/kg.|The on-duty ED pharmacist will prepare a breath-actuated nebulizer with doses of 1.5 mg/kg sub-dissociative dose ketamine (SDK), to give to ED pediatric patients with moderate to severe pain based on a score of 0 to 10 on a Visual Analog scale where 0 is no pain, 5 is moderate pain and 10 is very severe pain.
89060086|NCT03948984|Experimental|Therapeutic Music Session|
89060087|NCT03948100|Experimental|Group I (dyadic yoga)|Patients and caregivers undergo dyadic yoga intervention session involving physical exercises and relaxation techniques over 60 minutes each for up to 15 sessions.
89060088|NCT03948100|Active Comparator|Group II (dyadic education)|Patients and caregivers undergo dyadic education program session focusing on strategies of how to manage patient and caregiver symptoms over 60 minutes each for up to 15 sessions.
89060089|NCT03942250|Experimental|Treated|Patients who received REGE pro dressing on EB wounds lesion weekly for 10 weeks
89060090|NCT03936894|Experimental|Treatment|Canakinumab treatment
89060091|NCT03934268||infants with seizure with KCNQ2 gene mutation.|Infants who met the inclusion criteria were enrolled in this study. The infants will get their own DNA sequencing results by WES technology. The researchers found that some of them carried mutations in the KCNQ2 gene. so they wanted to compare whether there were differences with or without KCNQ2 gene mutations in the efficacy of anticonvulsants or long-term neurodevelopment in different exposure groups.
89060092|NCT03931707||Sick Neonatal Cohort, Sequencing|Infants and their parents enrolled through Neonatal Intensive Care Unit of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/physical exam, and the results of the genomic sequencing report.
89060093|NCT03926507|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo 4 PET/CT scans over 10 minutes paired with standard of care MRI within 14 days prior to initial maximal tumor resection, within 7 days prior to initiation of radiation therapy, 28 days after the completion of radiation therapy, and 6 months after the completion of radiation therapy.
89060094|NCT03913195|Experimental|Sentinel Group|Five (5) participants will receive two successive doses of 800mg ibalizumab administered in accordance with the prescribing information followed by five (5) successive 800mg doses on a schedule gradually increasing drug concentration and decreasing administration time.
89219576|NCT05593055|Active Comparator|Chlorthalidone + potassium|Participants be placed on enalapril 10 mg and weaned off their other anti-hypertensives prior to the Pre-Treatment Assessment. Amlodipine (5 to 10 mg) will be added if needed to control blood pressure. After the Pre-Treatment Assessment, participants randomized to this arm will receive 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium. Amlodipine (5 to 10 mg) will be added at 6 weeks or later if needed to achieve the BP target of <135/85 mmHg.
89219577|NCT05592054|Experimental|Intervention group|Balloon guide catheters (BGCs)
89060095|NCT03913195|Experimental|Core Group|HIV-infected Core Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds. Healthy Volunteer Core Group participants will receive a single 2000mg loading dose followed by three successive doses of 800mg in accordance with the prescribing information in order to reach steady state. Thereafter, Healthy Volunteers will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via undiluted IV Push over 30 seconds.
89060096|NCT03913195|Experimental|Intramuscular Injection Group|HIV-infected Intramuscular Injection Group participants will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via Intramuscular Injection. Healthy Volunteer Intramuscular Injection Group participants will receive a single 2000mg loading dose followed by three successive doses of 800mg in accordance with the prescribing information in order to reach steady state. Thereafter, Healthy Volunteers will receive two successive doses of 800mg ibalizumab (Trogarzo) administered in accordance with the prescribing information followed by four (4) successive 800mg doses via intramuscular injection.
89060097|NCT03912038||Null or low consumption|No-intervention. The group consists of women who have reported a null or low consumption of non-caloric sweeteners during late pregnancy.
89060098|NCT03912038||Moderate consumption|No-intervention. The group consists of women who have reported a moderate consumption of non-caloric sweeteners during late pregnancy.
89060099|NCT03912038||High consumption|No-intervention. The group consists of women who have reported a high consumption of non-caloric sweeteners during late pregnancy.
89060100|NCT03907124|Experimental|Genetically-guided treatment arm|The active arm - where patients will receive genetically-guided treatment
89060101|NCT03907124|No Intervention|Treatment as usual (TAU) control arm|TAU is the control arm - where patients will continue to receive their usual treatment as before.
89060102|NCT03894059||Retrospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period preceding the implementation of the educational intervention for ambulance telecommunicators.
89060103|NCT03894059||Prospective|Consecutive cases of out-of-hospital cardiac arrest occurring at participating sites, meeting the study eligibility criteria over a 12-month period following the implementation of the educational intervention for ambulance telecommunicators.
89522772|NCT05237843|Placebo Comparator|Group A (control group)|"35 women in this group will receive only the standard treatment in the form of :~low- dose aspirin (LDA) 81 mg/day orally (Jusprin® 81mg which manufactured by Future Pharmaceutical Company),~LMWH (Enoxaparin, Clexane® which manufactured by SANOFI company) with a dose ( .5 mg/kg) subcutaneously injected/24 hr .~LDA ought to be begun before origination, while LMWH ought to be begun after confirmation of pregnancy by detecting fetal viability by ultrasound till age of viability (20wks)~-PLUS Placebo specially manufactured tablets in Ain shams faculty of pharmacy will start once known she is pregnan"
89060106|NCT03884790|Experimental|Surgical repair of long bone defects|The Patients in the study group will be surgically treated and the GreenBone Bone Substitute will be implanted
89060107|NCT03884374|Experimental|African American Group|African Americans with knee osteoarthritis (OA).
89060108|NCT03884374|Experimental|Non-Hispanic White Group|Non-Hispanic whites with knee osteoarthritis (OA).
89060109|NCT03873818|Experimental|Treatment (ipilimumab, pembrolizumab)|Patients receive ipilimumab IV over 90 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles for ipilimumab and up to 35 cycles for pembrolizumab in the absence of disease progression or unacceptable toxicity.
89060110|NCT03847194|Experimental|PRISM Intervention Arm|"The goal of the intervention is to teach resilience resource skills for use in current or future stressful situations. The total intervention consists of two, 45-60 minute, one-on-one sessions approximately 2-4 weeks apart followed by a family meeting discussing the skills learned. Following the family session through week 12, participants receive bi-weekly booster contacts (1:1 check-in sessions with the interventionist) to practice/refresh skills and check-ins on how skills have been utilized. These boosters will then be delivered monthly in months 4-6. In addition, all PRISM participants have access to the digital PRISM app, which offers an interactive practice and tracking interface to continue enhancing skills."
89060111|NCT03847194|No Intervention|Usual Care|Families in both randomization arms will receive usual medical care for diabetes, including psychosocial care provided by the mental health professionals affiliated with the diabetes clinic if needed. At both sites, every diabetes patient is cared for by a team of diabetes specialists which includes a provider (MD, Physician Assistant and/or Nurse Practitioner), dietician, and social worker. Subspecialty referrals for additional mental health or other support are made at the discretion of the primary diabetes provider.
89060112|NCT03843294|Experimental|Nivolumab with TAA-T cell|Patients will receive doses of Nivolumab at a minimum of 8 weeks prior to first TAA-T cell infusion and additional dose(s) of Nivolumab will be given after 4 weeks following second TAA-T cell infusion starting at week 7 from first infusion of TAA-T.If patient meets eligibility criteria for TAA-T cell infusion, the patient will receive two TAA-T cell infusions given 2 weeks apart
89060113|NCT03828747|Experimental|Semorinemab|Semorinemab will be administered intravenously in the double-blind treatment period, and semorinemab will be administered intravenously in the optional open-label extension period.
89060114|NCT03828747|Placebo Comparator|Placebo|Placebo will be administered intravenously in the double-blind treatment period and semorinemab will be administered intravenously in the optional open-label extension.
89060115|NCT03825315|Experimental|DAXI 80 U|LOW Dose Group
89060116|NCT03825315|Experimental|DAXI 120 U|HIGH Dose Group
89060117|NCT03825315|Placebo Comparator|Placebo|Placebo Group.
89060118|NCT03821402|Experimental|DAXI 250 U|DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 250 U dose
89060119|NCT03821402|Experimental|DAXI 375 U|DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 375 U
89060120|NCT03821402|Experimental|DAXI 500 U|DAXI for injection for the treatment of Upper Limb Spasticity (ULS) in Adults with 500 U
89219578|NCT05592054|Active Comparator|Control group|Standard guide catheter
89060121|NCT03821402|Placebo Comparator|Placebo|Placebo group
89060122|NCT03804606|Experimental|High benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
89060123|NCT03804606|No Intervention|High benefit, no MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
89060124|NCT03804606|Active Comparator|Low benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
89060125|NCT03774758||Cohort 1A: Benign nodule on screening CT|"High-risk patients eligible for lung cancer screening but with negative radiographic findings on CT screening (Lung RADS ≤2).~≥30 pack-year history of cigarette smoking~≥55 years of age~Current smoker or quit within the past 15 years"
89060126|NCT03774758||Cohort 1B: Incidental benign nodule|"Patients with lung nodules ≥ 6 mm on routine (non-lung cancer screening) CT evaluation deemed suspicious for malignancy by initial physician judgment but not malignant by ≥2 years of radiographic stability and consensus clinical opinion.~1- Age ≥40 years."
89060127|NCT03774758||Cohort IC: Presumed lung cancer|"Patients with lung cancer (histologically proven or presumed by consensus opinion of tumor board); prior to definitive therapy.~1- Age ≥40 years."
89060128|NCT03774758||Cohort 2A: Suspicious nodule|"High-risk patients with newly diagnosed suspicious nodule of Lung RADS ≥3 on CT screening.~≥30 pack-year history of cigarette smoking~≥55 years of age~Current smoker or quit within the past 15 years"
89060129|NCT03774758||Cohort 2B: Suspicious incidental nodule|"Patients with newly diagnosed incidentally-found lung nodules ≥ 6 mm on routine CT evaluation deemed suspicious for malignancy by physician judgment.~1- Age ≥40 years."
89219579|NCT05589688|Experimental|acyclovir|Subjects take a single dose of 5 mg/kg infused over 1 hour.
89219580|NCT05584735||Participants with Inflammatory Bowel Disease (IBD)|Participants with IBD who are receiving a flu or COVID-19 vaccine
89219581|NCT05584514|Experimental|Arm 1|"The study is a within-subjects 2 x 3 factorial design. All participants are exposed to all experimental conditions or interventions"
89219582|NCT05582512||Clinical Characteristics of pediatric COVID-19 by the retrospective research group|Analyze all clinically visible data of hospitalized children with COVID-19 infection (different virus strains), and then find the cause of severe disease and related risk factors for disease
89219583|NCT05582512||acute case receiving group (including children with multisystem inflammatory syndrome)|"The correlation between the microbial flora of the respiratory tract and the central nervous system and the severity of SARS-CoV2 pneumonia and host immunity (host inflammatory biomarkers, antibody library/cell receptor library, chemokines, cytokines, cell-regulated immune responses, table Epitope mapping, host transcriptome studies)~To explore the correlation between the clinical manifestations of gastrointestinal tract and liver and SARS-CoV-2 infection and the analysis of gut microbiota~To analyze the host gene factors of COVID-19 patients.~To explore the changes of brain injury biomarkers (Biomarker) in acute and chronic phases, and to analyze the correlation with changes in brain structure and other clinical factors (e.g. severity of neurological symptoms)"
89219584|NCT05582512||children's long COVID-19 tracking group|"Clarify the incidence and persistent impact of COVID-19 symptoms in children through outpatient assessment, and further analyze the factors related to preventing the development of COVID-19. / Conduct long-term follow-up through brain MRI and neurophysiological examinations to explore the effects of COVID-19 infection on children brain structure and peripheral nerve function, and analyze the association of risk factors and other clinical symptoms. A psychiatric clinical diagnostic interview was also conducted to establish a psychiatric diagnosis. The emotional and behavioral assessment scale was used to fully evaluate the mental state and family social function.~To analyze the correlation between host genes and antibody repertoire/receptor repertoire, epitope mapping, microbial phase, and prognosis of severe COVID-19 patients"
89219585|NCT05582512||seroepidemiological research group|Through the antibody test and the content of the questionnaire, we can better understand the epidemiology of the COVID-19. Including the proportion of asymptomatic infections, the scale of infection, the speed of transmission, etc. Vaccinated people can also learn about the speed of antibody decline
89219586|NCT05582512||healthy control group|"Provide a sample of the normal population of the Acute Reception Unit. To carry out respiratory microbial flora, host inflammatory biomarkers, antibody library/receptor library, chemokines, cytokines, cell-mediated immune responses, epitope mapping, brain MRI, neurophysiological examinations (neurophysiological examinations) Conduction, brain waves, sleep watch checks, etc.), brain injury biomarkers (Biomarker), healthy control group studies of host transcriptome"
89219587|NCT05578326|Experimental|Trilaciclib and Lurbinectedin|Subjects with platinum refractory extensive stage small cell lung cancer receiving laciclib and Lurbinectedin
89219588|NCT05574868|Other|Experimental: Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis Group|Male subjects 21 years of age and older who are implanted with an Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis for erectile dysfunction.
89219589|NCT05566366|Other|population who lost a loved one during the COVID19 health crisis|"Analyze the grieving process of people who have lost a close first degree relative, understand the impact of death conditions on this process and model a theory of mourning in the context of the actual epidemic health crisis."
89219590|NCT05565729|Experimental|LY3471851 (Test formulation)|LY3471851 administered subcutaneously (SC).
89219591|NCT05565729|Experimental|LY3471851 (Test) + Levocetirizine|LY3471851 administered SC in combination with levocetirizine given orally.
89219592|NCT05565729|Active Comparator|LY3471851 (Reference formulation)|LY3471851 administered SC.
89219593|NCT05565729|Placebo Comparator|Placebo|Placebo administered SC.
89219594|NCT05562960|Other|ALS patients receiving plasmapheresis|Plasmapheresis in ALS patients with different titers of autoantibody against NRIP
89219595|NCT05561257|Placebo Comparator|Group 1 (control group)|300 ml NaCl infusion
89219596|NCT05561257|Experimental|Group 2 (750 mg Vitamin C)|295 ml NaCl + 5 ml (750 mg) Vitamin C
89219597|NCT05561257|Experimental|Group 3 (7.5 g Vitamin C)|250 ml NaCl + 1 x 50 ml (7.5 g) Vitamin C
89219598|NCT05561257|Experimental|Group 4 (15 g Vitamin C)|200 ml NaCl + 2 x 50 ml (2 x 7.5 g) Vitamin C
89219599|NCT05558995|Experimental|MDD patient|Male and female participants (N=10) with ages between 18 and 50 have a confirmed diagnosis of major depressive episode, are experiencing a current episode (following DSM-5 criteria),
89219600|NCT05558280|Experimental|Dinutuximab beta|The treatment phase foresees 5 cycles of Dinutuximab Beta. Dinutuximab Beta administration is restricted to hospital-use only and must be administered under the supervision of a physician experienced in the use of oncological therapies. It must be administered by a healthcare professional prepared to manage severe allergic reactions including anaphylaxis in an environment where full resuscitation services are immediately available. The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.
89219601|NCT05557955||Neoadjuvant chemoradiotherapy group|All patients will receive standard fractionation radiation therapy (RT) scheme: 40-50.4 Gy in 20-28 fractions over 4-6 weeks using intensity-modulated radiotherapy, concurrently with platinum- or taxane-based chemotherapy, with or without PD-1 inhibitors. All patients will undergo esophagectomy 6-8 weeks after the completion of neoadjuvant CRT. Dynamic breathing testing was performed before, during, and after radiotherapy.
89219602|NCT05557955||Definitive chemoradiotherapy group|All patients will receive standard fractionation radiation therapy (RT) scheme: 50-50.4 Gy in 25-28 fractions over 5-6 weeks using intensity-modulated radiotherapy, concurrently with platinum- or taxane-based chemotherapy, with or without PD-1 inhibitors. Dynamic breathing testing was performed before, during, and after radiotherapy.
89522773|NCT05237843|Experimental|Group B ( Hydroxychloroquine group )|This group included 35 women who will administered Hydroxychloroquine 200 mg (Hydroquine® 200mg which fabricated by MinaPharm Company) one tablets / day once known she is pregnant in addition to the standard therapy (LMWH + LDA )
89522774|NCT05237843|No Intervention|Study Director|Only those directing the study know the treatment that each participant receives Placebo OR Hydroxychloroquin
89060130|NCT03774758||Cohort 2C: Post-treatment lung cancer|"Patients with previously treated lung cancer (histologically proven or by consensus opinion); status-post completion of definitive therapy (resection +/- chemotherapy or SBRT with curative intent) within the previous year with no current evidence of disease.~1- Age ≥40 years."
89060131|NCT03765541|Experimental|Standard salvage therapy + dexamethasone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness in combination with dexamethasone
89060132|NCT03765541|Active Comparator|Standard salvage therapy alone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness
89060133|NCT03753334|Experimental|MAG-EPA group|5g/day of omega-3-rich fish oil capsules, which include 4g of purified EPA, to be taken once a day, for 12 months.
89060134|NCT03753334|Placebo Comparator|Placebo group|5g/day of high-oleic sunflower oil capsules, to be taken once a day, for 12 months.
89060135|NCT03752242|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.
89060136|NCT03748667||Patients with colorectal polyps|Patients with non-pedunculated type 0 lesions in Paris classification (not obvious cancers) larger than 10 mm
89060137|NCT03747887|Active Comparator|School as Usual|School as usual comparison condition.
89060138|NCT03747887|Experimental|Daily Report Card|A coach will establish a Daily Report Card based on IEP goals and objectives with the parents/teachers of the child in this arm.
89060139|NCT03738748|Experimental|Ultrasound-guided Percutaneous Neuromodulation|This group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L3 (1 times/ 4 weeks).
89060140|NCT03738748|Active Comparator|TENS therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region (1 times/ 4 weeks).
89060141|NCT03736590|Experimental|Intervention - Financial Coaching Plus Social Needs Screening|Families in this intervention arm will receive financial coaching at each well child visit, in addition to clinic-based social needs screening and referral.
89060142|NCT03736590|Active Comparator|Control - Social Needs Screening and Referral|Families in this active control arm will receive social needs screening and referral to community resources to address identified social needs.
89060143|NCT03712956|Experimental|Caelyx® for 8 courses|Caelyx® administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.
89060144|NCT03712098|Experimental|Smoking Cessation Counseling & Liraglutide|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of the medication liraglutide. Liraglutide comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which follows FDA guidelines and is documented to be safe and well-tolerated in prior clinical studies, will begin at 0.6 mg and increase weekly by 0.6 mg until the recommended dose of 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
89522775|NCT03389113|Experimental|Whole body vibration group|Whole body vibration group performed five sessions of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
89219603|NCT05551377|Experimental|Intervention group|At T0, in-clinic inclusion, we will record basic characteristics and several questionnaires, we will also perform a short tilt-table-test and standing blood pressure (BP) test. Intake is followed by one week of horizontal sleeping for baseline home-based BP measurements. Participants in the intervention group will then sleep in a head-up tilt position for two weeks each in angles 6°, 12° and 18°. At the second and final in-clinic meeting, at T1, measurements done at T0 will be repeated, complemented with an assessment of barriers and facilitators of HUTS. During HUTS daily BP measurements will be done, and data will be collected on orthostatic tolerance, nighttime urine production, subjective comfort of HUTS, falls.
89219604|NCT05551377|Other|Delayed intervention group|Follows the same structure as the intervention group, but starts with a HUTS placebo angle of 1° for two weeks, followed by two intervention angles of 6° and 12° for two weeks each. The 1°-angle serves as the control intervention.
89219605|NCT05542355|Experimental|Part A (Open-Label EXL01 Maintenance Therapy)|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
89219606|NCT05542355|Experimental|Part B (EXL01 Maintenance Therapy)|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
89219607|NCT05542355|Placebo Comparator|Part B (Placebo Maintenance Therapy)|Oral EXL01 matched placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
89219608|NCT05540314||Subjects that have undergone robotic bariatric surgery|Subjects that have undergone robotic bariatric surgery between January 2018 and December 2019
89219609|NCT05539560|Experimental|Intervention group|Olfactory training twice a day with essential oils
89219610|NCT05539560|Placebo Comparator|Control group|Olfactory training twice a day with fragrance-free oils
89219611|NCT05537259||Observation Group|Researchers will collect data on maternal mental health symptoms, as well as health and psychosocial factors, via short interviews (sessions 1 and 4) and via self-report questionnaires completed through REDCap at each session. Participating women will also provide one small hair sample (session 4) for measurement of the stress hormone cortisol and several finger stick blood spot samples (sessions 1,2, and 4) for measurement of immune markers.
89219612|NCT05536414|Experimental|Centanafadine + Placebo|
89219613|NCT05536414|Experimental|Centanafadine + Escitalopram|
89219614|NCT05536414|Active Comparator|Escitalopram + Placebo|
89219615|NCT05536414|Placebo Comparator|Placebo + Placebo|
89219616|NCT05536349|Experimental|Pirtobrutinib plus Venetoclax plus Obinutuzumab (combination)|Participants will receive the study drugs in cycles. Each cycle is 28 days.
89219617|NCT05535309||Occurrence of coagulation disorder|"All inpatients who used cefoperazone sulbactam sodium during hospitalization；~Hospital stay ≥ 48h;~Age ≥ 18 years old;~Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and platelet (PLT) were detected twice or more during hospitalization"
89219618|NCT05535309||No coagulation disorder|"Inpatients who did not use cefoperazone sulbactam sodium during hospitalization;~Hospital stay ≥ 48h;~Age ≥ 18 years old;~Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and platelet (PLT) were detected twice or more during hospitalization"
89219619|NCT05533944|Active Comparator|Simulation group|Trainees will undergo routine hands-on clinical ERCP training. In addition, trainees from Simulation Group have coached simulation training, by participating in three two-days intensive courses during the first three months of training, with a monthly basis.
89219620|NCT05533944|No Intervention|Control group|Trainees will undergo routine hands-on clinical ERCP training.
89219621|NCT05533619||AKI Group|
89219622|NCT05533619||Non-AKI Group|
89219623|NCT05533606||AKI Group|
89219624|NCT05533606||Non-AKI Group|
89219625|NCT05533593||AKI Group|
89219626|NCT05533593||Non-AKI Group|
89219627|NCT05532059|Experimental|GPLET|intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8; oral lenvatinib 8 mg/day (<60kg) or 12 mg/ d（≥60kg）from days 1 to 21; intravenous tislelizumab 200 mg on day 15
89060145|NCT03712098|Active Comparator|Smoking Cessation Counseling & Placebo|Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of placebo. The placebo comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which is the same as the liraglutide regimen, will begin at 0.6 mg and increase weekly by 0.6 mg until 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
89060146|NCT03706014|Experimental|SIBS Program|The program condition includes 12 weekly 90-minute afterschool group sessions for siblings. Sessions are structured as psycho-educational groups and include social interactional activities, role-playing, discussion, and didactic presentation. The focus is on sibling relationship skills, cognitions, and activities. During a total of 3 family nights, parents attend with their children. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children. Family Nights promote parents' understanding of sibling relationships, review concepts, provide strategies for parental support of siblings, and teach parents skills for dealing with sibling problems. Family Nights include dinner and last 2 hours.
89060147|NCT03706014|Placebo Comparator|Contact-Equivalent Attention Control|The Contact-Equivalent Attention Control condition includes 12 weekly 90-minute afterschool group sessions for siblings led by two co-leaders. Students work on educational games and activities. Groups begin with an icebreaker and continue with games and projects. This condition also includes 3 family nights, where parents attend with their children. Activities of the Family Nights include children showing their parents the activities they have been engaging in during the sessions. Family Nights include dinner and last 2 hours. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children; during this part, parents will break out with one group leader, and siblings will work with the other group leader.
89060148|NCT03704688|Experimental|Phase I: Dose Level -3|Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily
89060149|NCT03704688|Experimental|Phase I: Dose Level -2|Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily
89060150|NCT03704688|Experimental|Phase I: Dose Level -1|Trametinib 1.5 mg PO q daily 15mg PO q daily
89060151|NCT03704688|Experimental|Phase I: Dose Level 1|Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily
89060152|NCT03704688|Experimental|Phase I: Dose Level 2|Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily
89060153|NCT03704688|Experimental|Phase II|Maximum tolerated dose as established in Phase I portion
89060154|NCT03686332|Other|Arm A: Atezolizumab and Radiotherapy|"Patients in this group will concurrently be treated with locoregional radiotherapy and atezolizumab.~Drug: Arm A: Atezolizumab and Radiotherapy~Atezolizumab, 1200 mg, every 3 weeks, by IV infusion and receive 33 fractions of 1.5 or 1.8 Gy irradiation."
89060155|NCT03686332|Other|Arm B: Atezolizumab|Atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
89060156|NCT03684486|Experimental|rehabilitation by effort|8 sessions of rehabilitation by effort in sports medicine
89060157|NCT03683394|Active Comparator|SMARRT Intervention|The SMARRT intervention team will use a standardized procedure to develop an individualized Alzheimer's risk profile for each participant randomized to the SMARRT intervention arm. Participants will then meet in-person with an interventionist to review their risk profile and develop an initial personalized risk reduction action plan. For the few participants enrolled during COVID, initial interventionist visits were conducted by phone. Targeted areas will include: increasing physical, mental and social activities; quitting smoking; healthy diet; controlling cardiovascular risk factors (diabetes, hypertension), including avoiding hypoglycemia in people with diabetes; reducing depressive symptoms; improving sleep; and decreasing use of potentially harmful medications.
89060158|NCT03683394|Active Comparator|Health Education Intervention|Participants in the Health Education arm will be mailed general information that will address factors that will be targeted in the SMARRT intervention, including physical, mental and social engagement; management of cardiovascular risk factors; quitting smoking, healthy diet; depression; sleep; and contraindicated medications. HE participants will not be provided with personalized information about their risk of Alzheimer's and dementia.
89060159|NCT03671746|Placebo Comparator|Standard of Care without NSAID|Polytrauma participants will receive standard of care in addition to saline solution according to standard ATLS and standard ICU routine medical care.
89060160|NCT03671746|Experimental|Standard of Care with NSAID|Participants in the group will receive Ketorolac in addition to standard of care for the standard ATLS or ICU routine medical care.
89060161|NCT03667092|Experimental|Non-drug intervention type|"Exploration of gene transcript variation on seriate blood samples before treatment, before and after the 2nd and the 4th Lu-Dotatate injection and before and after the 6 month post treatment follow-up.~Measures of stability and reproducibility of selected gene transcripts and miRNA as radio sensitivity genes or progressive metastatic midgut neuroendocrine tumors genetic signatures before and during Lu-177 Dotatate internal vectorized therapy, as well as on the 6-month follow-up."
89219628|NCT05532059|Active Comparator|GP|intravenous gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8
89060162|NCT03658278|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
89060163|NCT03658278|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
89060164|NCT03656510|Experimental|High Dose: JNJ-53718678|Participants will be randomized to receive JNJ-53718678 2.5 milligram per kilogram (mg/kg) (Age Group 1: greater than or equal to [>=] 28 days and less than [<] 3 months of age), 3 mg/kg (Age Group 2: >=3 months and <6 months of age) and 4.5 mg/kg (Age Group 3: >=6 months and less than or equal to [<=3] years of age) orally twice daily for 7 days.
89060165|NCT03656510|Experimental|Low Dose: JNJ-53718678|Participants will be randomized to receive JNJ-53718678 0.85 mg/kg (Age Group 1: >=28 days and <3 months of age), 1 mg/kg (Age Group 2: >=3 months and <6 months of age) and 1.5 mg/kg (Age Group 3: >=6 months and 3 years of age) orally twice daily for 7 days.
89060166|NCT03656510|Placebo Comparator|Placebo|Participants will be randomized to receive matching placebo (i.e. high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose) orally twice daily for 7 days.
89060167|NCT03652545|Experimental|TAA-T|"Three different dosing schedules will be evaluated.~Dose Level One: 2 x 107 cells/m2 Dose Level Two: 4 x 107 cells/m2 Dose Level Three: 8 x 107 cells/m2~Group A patients (DIPG): The first TAA-T dose will be infused any time more than or equal to 14 days after completion of radiotherapy.~Group B patients (other recurrent/progressive/refractory CNS tumors): TAA-T will be infused any time more than or equal to 14 days after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.~Ideally, patients should not receive other systemic antineoplastic agents for at least 42 days after the infusion of TAA-T, although such treatment may be added if deemed critical for patient care by the attending physician."
89060168|NCT03646175|Experimental|Acute Choline Supplementation|Participants will consume 1000 mg (2x500 mg) of choline bitartrate the evening before each testing session.
89060169|NCT03646175|Placebo Comparator|Placebo Supplementation|Participants will consume 1000 mg (2x500 mg) of placebo the evening before each testing session.
89060170|NCT03642795||Patients with rheumatoid polyarthritis|
89060171|NCT03637816|Experimental|Arm I (anamorelin hydrochloride)|Patients receive anamorelin hydrochloride PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
89060172|NCT03637816|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 9 weeks in the absence of disease progression or unaccepted toxicity.
89060175|NCT03622528||Lung Cancer Screening Cohort|Patients who are seen in the UIHC lung cancer screening clinic will be asked to undergo an additional standard chest CT scan during their UIHC clinical lung cancer screening CT scan. Additionally, data from that clinical scan and all medical records associated with nodules that were discovered by the Lung Cancer Screening, will also be collected.
89060176|NCT03616886|Experimental|Phase I and Phase II Arm A|Patients are treated with paclitaxel, carboplatin, durvalumab and oleclumab.
89060177|NCT03616886|Active Comparator|Phase II Arm B|Patients are treated with paclitaxel, carboplatin and durvalumab.
89060178|NCT03609840||Pediatric Hematopoietic Stem Cell Transplant Recipients|Children undergoing hematopoietic stem cell transplant (HCT) at University of California, San Francisco Benioff Children's Hospital
89060179|NCT03601897|Experimental|Part 1 - Completed|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles.
89060180|NCT03601897|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with paclitaxel~Triple-negative and Stage IV inflammatory breast cancer~Ovarian cancer~Endometrial cancer~Gynecological Carcinosarcoma"
89060181|NCT03594981|Experimental|CMV/AdV /EBV/BKV specific T cells|CMV/AdV /EBV/BKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
89060182|NCT03586583||FBP (old processing)|Filtered back projection; old processing.
89060183|NCT03586583||ISR (new processing)|Iterative super resolution; new processing.
89060184|NCT03581461|Experimental|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
89060185|NCT03570177||all subject|the all population (described in eligibility criteria)
89060186|NCT03562507|Experimental|ESK981 Monotherapy|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
89060187|NCT03562507|Experimental|ESK981 and Nivolumab|"ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles~Nivolumab: 480 mg/dose IV, Day 1 of each 28-day cycle"
89060190|NCT03543371||Cardiac Arrest survivors|Cardiac arrest survivors at selected TTM2-sites only.
89060191|NCT03543371||Myocardial Infarction patients|A control group from a cohort of patients with myocardial infarction with performed coronary angiography but no occurrence of cardiac arrest will be recruited at 1:1 ratio.
89060192|NCT03539081|Experimental|Subjects with RLS|"Subjects with Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Subject will have received the standard of care intervention of epidural spinal cord stimulation for pain."
89060193|NCT03539081|Other|Subjects without RLS|"Subjects without Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Subject will have received the standard of care intervention of epidural spinal cord stimulation for pain."
89060194|NCT03539081|Other|Continous BP Monitoring|"This arm consists of subjects from arm Subjects with RLS, Subjects without RLS, and the rest of the qualifying subjects undergoing continuous blood pressure portion of the study only.~Subject will have received the standard of care intervention of epidural spinal cord stimulation for pain."
89060195|NCT03534713|Experimental|Neoadjuvant chemotherapy+standard therapy|neoadjuvant chemotherapy with carboplatin aera Under curve 5 and paclitaxel 175 mg/m² every 21 days during 3 cycles followed by standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
89060196|NCT03534713|Active Comparator|standard therapy alone|standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
89060197|NCT03518203|Experimental|Eculizumab|All patients will receive eculizumab based on their weight for 24 weeks.
89219629|NCT05531149|Experimental|Trimodulin|Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
89060198|NCT03507062|Experimental|Chloride-rich solution|Patients will receive two boluses of 10 and 20 ml/kg of the 0.9% saline in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
89060199|NCT03507062|Experimental|Low-chloride solution A|Patients will receive two boluses of 10 and 20 ml/kg of Ringer's lactate in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
89060200|NCT03507062|Experimental|Very low-chloride solution|Patients will receive two boluses of 10 and 20 ml/kg of a plasmalyte-like solution (namely soluzione elettrolitica reintegrante [SER]) in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
89060201|NCT03501693||DBT plus S-View|Breast images utilizing DBT plus S-View
89060202|NCT03501693||FFDM alone|FFDM alone images
89219630|NCT05531149|Placebo Comparator|Placebo|Human albumin 1%
89219631|NCT05529927|Experimental|Sustained-release Dexamphetamine|Tablets of 30 mg sustained-release dexamphetamine sulphate. Target dose: 90 mg/day, if tolerated. Tablets have to be taken daily, in the morning, per os for 24 weeks.
89219632|NCT05529927|Placebo Comparator|Placebo|Identical matched placebo, dispensed under the same conditions and with similar frequency as the investigational product (see above).
89219633|NCT05527444|Experimental|Randomized-SEC group|actived AS patients naïve to ADA and SEC
89219634|NCT05527444|Experimental|Randomized-ADA group|actived AS patients naïve to ADA and SEC
89219635|NCT05527444|Experimental|Non-Randomized-SEC group|AS patients who previously had inadequate response to ADA
89219636|NCT05527444|Experimental|Non-Randomized-ADA group|AS patients who previously had inadequate response to SEC
89219637|NCT05527054||AKI Group|
89219638|NCT05527054||Non-AKI Group|
89219639|NCT05525468|Experimental|SAD Cohorts 1-4 TDM-180935 topical ointment|Single dose administration of TDM-180935 topic ointment, 0.25% or 0.5% or 1.0% or 2.0%
89219640|NCT05525468|Placebo Comparator|SAD placebo for TDM-180935 topical ointment|Single dose administration of placebo for TDM-180935 topic ointment
89219641|NCT05525468|Experimental|MAD Cohorts 1-4 TDM-180935 topical ointment|Multiple dose administration of TDM-180935 topic ointment, 0.25% or 0.5% or 1.0% or 2.0%
89219642|NCT05525468|Placebo Comparator|MAD placebo for TDM-180935 topical ointment|Multiple dose administration of placebo for TDM-180935 topic ointment
89219643|NCT05524870|Experimental|Mobilization|Mobilization with movement plus exercise.
89219644|NCT05524870|Placebo Comparator|Sham mobilization|Sham mobilization with movement plus exercise
89219645|NCT05524870|Active Comparator|Control|Exercise alone
89219646|NCT05521438|Experimental|QRX003-2%|Subjects will apply test article once daily in the morning (QAM) for 12 weeks
89219647|NCT05521438|Experimental|QRX003-4%|Subjects will apply test article once daily in the morning (QAM) for 12 weeks
89219648|NCT05521438|Experimental|Vehicle Lotion|Subjects will apply test article once daily in the morning (QAM) for 12 weeks
89219649|NCT05521191|Experimental|RGLS8429|"The study will consist of three sequential cohorts of 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (36 subjects total).~Cohort 1: first dose level of RGLS8429 or placebo~Cohort 2: second dose level of RGLS8429 or placebo~Cohort 3: third dose level of RGLS8429 or placebo"
89219650|NCT05521191|Experimental|Placebo|"The study will consist of three sequential cohorts of 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (36 subjects total).~Cohort 1: first dose level of RGLS8429 or placebo~Cohort 2: second dose level of RGLS8429 or placebo~Cohort 3: third dose level of RGLS8429 or placebo"
89219651|NCT05520619|Experimental|Tislelizumab plus CRT with maintenance|Patients will receive 2 cycles of 3-weekly schedule of induction chemotherapy, consisting of paclitaxel 135-175 mg/m2, cisplatin 75 mg/m2, and tislelizumab 200mg on day 1 prior to CRT. Then all patients will receive standard fractionation radiation therapy scheme: 50.4 Gy in 28 fractions, concurrently with paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks and 2 cycles of tislelizumab. Patients in Arm A will receive 12 additional cycles of tislelizumab after the completion of radiotherapy.
89219652|NCT05520619|Experimental|Tislelizumab plus CRT without maintenance|Patients will receive 2 cycles of 3-weekly schedule of induction chemotherapy, consisting of paclitaxel 135-175 mg/m2, cisplatin 75 mg/m2, and tislelizumab 200mg on day 1 prior to CRT. Then all patients will receive standard fractionation radiation therapy scheme: 50.4 Gy in 28 fractions, concurrently with paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks and 2 cycles of tislelizumab. Patients in Arm B will receive 4 cycles of tislelizumab in total.
89219653|NCT05520008|Experimental|Active group (AG)|Active group (AG). The AG (n=15) will play game-based foot and ankle exercises via a mobile application on a tablet. They will be asked to wear a foot sensor that is connected to the tablet during the exercise. They will be asked to play the game for 5-minutes, daily. They will do this in conjunction with wearing a compression garment for a period of 4 weeks.
89219654|NCT05520008|No Intervention|Control group (CG)|Control Group (CG). The CG (n=15) will wear a compression garment for four weeks.
89219655|NCT05514990|Experimental|Cohort I (standard therapy)|Patients receive bortezomib SC) or IV and dexamethasone PO, IV, or IM on days 1, 8, and 15 of each cycle. Patients also receive pembrolizumab IV over 30 minutes on day 9 of each cycle. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
89219656|NCT05514990|Experimental|Cohort II (standard therapy, pelareorep)|Patients receive bortezomib SC or IV and dexamethasone either PO, IV, or IM on days 1, 8, and 15 of each cycle. Patients also receive pelareorep IV over 60 minutes on days 1, 2, 8, 9, 15, and 16 and pembrolizumab IV over 30 minutes on day 9 of each cycle. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
89522776|NCT03389113|Active Comparator|Exercise only group|The control group performed the same session without vibration.
89522777|NCT03391063|Experimental|reinforced polyamide denture base|metal reinforced polyamide denture base
89522778|NCT03391063|Active Comparator|conventional acrylic resin denture base|conventional heat cured acrylic resin denture base
89522779|NCT03394625|Experimental|immediate implant placement using socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
89522780|NCT03394625|Active Comparator|immediate implant placement using xenograft material|placing xenograft material in gap between implant and buccal bone
89522781|NCT04447105|Experimental|TIVA group|Patients receiving total intravenous anesthesia with propofol.
89522782|NCT04447105|Active Comparator|Desflurane group|Patients receiving inhalation anesthesia with desflurane.
89522783|NCT03398681|Active Comparator|Intravenous ferric carboxymaltose|Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.
89522784|NCT03398681|Placebo Comparator|Normal saline|Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.
89522785|NCT04447261|Experimental|BI 1356225|
89219657|NCT05512793|Active Comparator|Standard Technique followed by Combination|Back-to-back tandem colonoscopies by the same endoscopist. The first colonoscopy will be performed without PolyDeep (standard technique) followed immediately by another colonoscopy with PolyDeep (combination technique).
89219658|NCT05512793|Active Comparator|Combination followed by Standard Technique|Back-to-back tandem colonoscopies by the same endoscopist. In this arm, the first colonoscopy with be performed with PolyDeep (combination technique) followed immediately by another colonoscopy without PolyDeep (standard technique)
89219659|NCT05512520|Experimental|Concurrent Chemoradiotherapy group|After completion of 4 to 6 cycles of standard chemotherapy and anti-PD1, all patients will receive thoracic radiation therapy (RT) in the following scheme: 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks, and then followed by a maintenance treatment phase of anti-PD1 every 3 weeks.
89219660|NCT05512520|No Intervention|Control group|After completion of 4 to 6 cycles of standard chemotherapy and anti-PD1, patients will receive the maintenance treatment with anti-PD1 every 3 weeks.
89219661|NCT05505474||IVF with Neria™ Guard device|Patients undergoing IVF with the use of the Neria™ Guard subcutaneous catheter
89219662|NCT05505279|Active Comparator|30 L - 70 L|Initially, all patients will receive 3L/min of oxygen for 10 minutes. Than, patients in this arm will receive 30L/min of High Flow Nasal Oxygen for 15 minutes and subsequently 70 L/min for another 15 minutes.
89219663|NCT05505279|Active Comparator|70 L - 30 L|Initially, all patients will receive 3L/min of oxygen for 10 minutes. Than, patients in this arm will receive 70L/min of High Flow Nasal Oxygen for 15 minutes and subsequently 30 L/min for another 15 minutes.
89219664|NCT05494502|Experimental|Erector spinae plane block group|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
89219665|NCT05494502|Sham Comparator|Control group|General anesthesia alone.
89219666|NCT05492370|Experimental|EpiCor|500 mg EpiCor given as two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
89219667|NCT05492370|Placebo Comparator|Placebo|Two gummy supplements. Participants will be instructed to take two gummies per day in the morning, with or without food, for 84 days, starting on Day 1.
89219668|NCT05489341||Public Training and Development Set (1500 cases)|Available for all participants and researchers, to train and develop AI models. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021. All data is fully anonymized and made available under a non-commercial CC BY-NC 4.0 license. Includes 328 cases from the PROSTATEx challenge (prostatex.grand-challenge.org). Imaging data has been released via: zenodo.org/record/6624726 (DOI: 10.5281/zenodo.6624726). Lesion annotations of csPCa have been released and are maintained via: github.com/DIAGNijmegen/picai_labels.
89219669|NCT05489341||Private Training Set (7500-9500 cases)|Used exclusively by the organizers to retrain the top-ranking 5 AI algorithms, with large-scale data. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021.
89522786|NCT04447261|Placebo Comparator|Placebo|
89522787|NCT03394547|Active Comparator|Active Treatment|Treatment for 2 menstrual cycles using the pulsed shortwave therapy Allay® device (BioElectronics Corp, Frederick USA)
89060203|NCT03500172|Active Comparator|DTP, Continue DTP if Responsive|"DTP:~Standard of care (SoC), minus clinic referrals for antiretroviral therapy (ART) treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Continues with DTP intervention if virally suppressed at 6 months."
89060204|NCT03500172|Active Comparator|DTP, Standard of Care (SoC) if Responsive|"DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~SoC:~HIV counseling and testing (HTC)~Sexually transmitted infection (STI) screening and treatment~Tuberculosis (TB) screening and referral~Health education through peer educators and peer supported follow-up related to linkages to care~Referrals to Department of Health (DoH) primary healthcare clinics or TB HIV Care (THC) drop-in center for ART treatment initiation and management~Returns to SoC if virally suppressed at 6 months."
89060205|NCT03500172|Active Comparator|DTP, Continue DTP if Non-Responsive|"DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Continues with DTP intervention if not virally suppressed at 6 months."
89060206|NCT03500172|Active Comparator|DTP, DTP+ICM if Non-Responsive|"DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through female sex worker (FSW) initiated interaction~Receives both interventions at 6 months if non-virally suppressed."
89060207|NCT03500172|Active Comparator|ICM, Continue ICM if Responsive|"ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~Continues with ICM intervention at 6 months if virally suppressed."
89060208|NCT03500172|Active Comparator|ICM, SoC if Responsive|"ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~SoC:~HIV counseling and testing (HTC)~STI screening and treatment~TB screening and referral~Health education through peer educators and peer supported follow-up related to linkages to care~Referrals to DOH primary healthcare clinics or THC drop-in center for ART treatment initiation and management~Returns to SoC if virally suppressed at 6 months."
89060209|NCT03500172|Active Comparator|ICM, Continue ICM if Non-Responsive|"ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~Continues with ICM intervention at 6 months if non-virally suppressed."
89219670|NCT05489341||Hidden Validation and Tuning Cohort (100 cases)|Used for a live, public leaderboard that enables AI model selection and tuning throughout the open development phase of the challenge. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) prostate bpMRI cases from three Dutch centers (Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen), acquired between 2012-2021, that remain fully hidden throughout the course of the challenge.
89219671|NCT05489341||Hidden Testing Cohort (1000 cases)|Used to benchmark AI, radiologists, and test all hypotheses at the end of the PI-CAI challenge. A subset of 400 cases from this cohort is used to facilitate the PI-CAI: Reader Study. Includes multi-vendor (Siemens Healthineers, Philips Medical Systems) internal testing data (unseen prostate bpMRI cases from three seen Dutch centers {Radboud University Medical Center, Ziekenhuisgroep Twente, University Medical Center Groningen}) and external testing data (unseen prostate bpMRI cases from one unseen Norwegian center {Norwegian University of Science and Technology}), acquired between 2012-2021.
89219672|NCT05484115|Active Comparator|Standard endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|
89219673|NCT05484115|Active Comparator|Endosuture aneurysm repair (ESAR) with the Endurant II/IIs in conjunction with Endoanchors|
89219674|NCT05478512|Experimental|VenObi+Ven or VenObi+VenZan|Patients will receive VenObi combination followed by Venetoclax single agent or Venetoclax+zanubrutinib, according to MRD.
89219675|NCT05478031|Active Comparator|REM0046127 high dose: 1400mg (700mg bid) oral suspension|REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days
89219676|NCT05478031|Active Comparator|REM0046127 low dose: 350mg (175mg bid) oral suspension|REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days
89219677|NCT05478031|Placebo Comparator|Placebo|Placebo: placebo oral suspension bid for 28 days
89219678|NCT05472337|Experimental|Colchicine|Subjects allocated to the intervention group will receive colchicine + standard of care for 6 weeks.
89219679|NCT05472337|No Intervention|Standard of Care - Control|Subjects allocated to the control group will receive only standard of care for 6 weeks.
89219680|NCT05467046||AD-patients|
89219681|NCT05463133|Active Comparator|Arm 1 / Group 1 Standard Risk|Group 1 (Standard group) will receive tociluzumab at Day -10, Alemtuzumab on Day -9,-8,-7,-6,-5; Busulfan on Day -4, and -3, TBI, matched donor PBSC infusion, and Post transplant Cyclophosphamide.
89219682|NCT05463133|Experimental|Arm 2 / Group 2 High Risk.|Group 2 (High risk group will receive tociluzumab at day -24, a repeat dose at day -19, Alemtuzumab at day -9,-8,-7,-6,-5; Busulfan at day -4 and -3, Emapalumab at Day -1, matched donor PBSC infusion, and post transplant cyclophosphamide at Day +3 and +4
89219683|NCT05462496|Experimental|Participants who had Chemotherapy Following Pancreatic Adenocarcinoma|Participants to be given antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.
89219684|NCT05460741|Experimental|integrated exercise approach|an integrated exercise will be used which is the exercise plan that will be formulated using strengthening and endurance exercises.
89219685|NCT05460741|Experimental|eumenhorreic females|strength, postural stability and biomarkers of menstrual cycle in eumenhorreic females.
89219686|NCT05460676|Experimental|Active tDCS + Mindfulness|
89219687|NCT05460676|Sham Comparator|Sham tDCS + Mindfulness|
89219688|NCT05458284|Active Comparator|real acupuncture (RA)|Real Acupuncture weekly till taxane completion
89219689|NCT05458284|Placebo Comparator|sham acupuncture (SA)|Sham Acupuncture weekly till taxane completion
89219690|NCT05457010|Experimental|CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T Cell (ARC-T Cells)|Arm 1: Phase 1 Study of monovalent CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T cell (ARC-T Cells) for the Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
89219691|NCT05455138|Experimental|Arterial bypass procedures using autologous venous graft|Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using autologous venous graft
89219692|NCT05455138|Experimental|Arterial bypass procedures using allogeneic venous graft|Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic venous graft
89219693|NCT05455138|Experimental|Arterial bypass procedures using allogeneic arterial graft|Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using allogeneic arterial graft
89219694|NCT05455138|Experimental|Arterial bypass procedures using biologic bovine decellularized arterial graft|Patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease who undergo arterial bypass procedures using biologic bovine decellularized arterial graft
89219695|NCT05453630|Experimental|Patient Navigation Intervention|Patients randomized to this arm will receive language-concordant patient navigation from a trained navigator, over the phone and via text and email, to assist patients to complete colonoscopy to screen for colorectal cancer.
89219696|NCT05453630|Other|Usual Care Control|Participants randomized to this arm will receive an educational brochure about the importance of colonoscopy to screen for colorectal cancer.
89219697|NCT05447910|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD for 2-8 weeks prior to surgery in the absence of disease progression or unacceptable toxicity. Patients then undergo collection of blood and tissue samples.
89219698|NCT05445557|Active Comparator|RZL-012 50mg/ml|Subjects flanks treated with RZL-012 (in the double blind phase) will undergo a single treatment session with 50-55 injections. The maximal number of injections will be 55 with maximal doses 412.5 mg. Each injection point will be dosed with 7.5 mg for in a volume of 0.15 mL/injection site.
89219699|NCT05445557|Placebo Comparator|Placebo|Subjects flanks treated with placebo (in the double blind phase) will undergo a single treatment session with 50-55 injections. The maximal number of injections will be 55 with maximal volume of 8.25mL. Each injection point will be dosed with 0.15 mL/injection site.
89219700|NCT05439161|Active Comparator|XEN Glaucoma Gel Microstent (AbbVie) Device|Implantation of XEN Glaucoma Gel Microstent (Device, AbbVie) for the treatment of glaucoma will be performed in this arm. It is a newer filtering glaucoma surgery. XEN Glaucoma Gel Microstent implantation accounts to the filtering glaucoma surgeries.
89219701|NCT05439161|Active Comparator|Trabeculectomy|Trabeculectomy will be performed in this arm. Trabeculecomy is the classic filtering glaucoma surgery since more than 50 years for the treatment of glaucoma (gold standard within the filtering glaucoma surgery group).
89060210|NCT03500172|Active Comparator|ICM, ICM+DTP if Non-Responsive|"ICM:~Standard of Care~Assignment of peer case manager~Face-to-face meeting to tailor ICM approach to FSW preference~Self-efficacy building in face-to-face sessions and bi-weekly text messages~Relational support through monthly calls, face-to-face meetings every three months, and additional support through FSW initiated interaction~DTP:~Standard of care, minus clinic referrals for ART treatment initiation and management.~Nurse initiated and managed ART within the community on mobile van at sites served by the mobile van which already provides SoC services~Receives both interventions at 6 months if non-virally suppressed."
89060211|NCT03500172|No Intervention|Standard of Care (SoC)|"Standard of Care (SoC):~HIV counseling and testing (HTC)~Sexually transmitted infection (STI) screening and treatment~Tuberculosis (TB) screening and referral~Health education through peer educators and peer supported follow-up related to linkages to care~Referrals to Department of Health (DoH) primary healthcare clinics or TB HIV Care (THC) drop-in center for ART treatment initiation and management"
89060212|NCT03493932|Experimental|1|Recurrent Glioblastoma patients
89060213|NCT03487809||NTUH|National Taiwan University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
89060214|NCT03487809||FJUH|Fu Jen University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
89060215|NCT03487809||CGH|Cathay General Hospital, all participants receive Alvesco (Ciclesonide, 160mcg/puff)
89060216|NCT03485963|Experimental|Fixed dose HIV-1 specific T-cells (HST-NEETs)|Patients will be screened for eligibility in Step 1 and undergo a blood draw of 100-120mL to allow production of autologous HST-NEETS. patients will receive a fixed dose of 2x10e7/m2. For the first 3 recipients, the infusions will occur 4 weeks apart. If no adverse reactions occur that are attributable to the HST-NEETs, the recipients thereafter will receive the two infusions separated by 2 weeks.
89060217|NCT03470922|Experimental|Arm A: Relatlimab + Nivolumab|Combination
89060218|NCT03470922|Experimental|Arm B: Nivolumab|Monotherapy
89060219|NCT03469024|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
89060220|NCT03469024|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
89060223|NCT03451292|Experimental|Standard Medical Treatment + Albutein 20%|Standard Medical Treatment plus Albutein 20% administrations
89060224|NCT03451292|Active Comparator|Standard Medical Treatment|The sites will follow the Standard Medical Treatment as per their Standard of Care.
89060225|NCT03440814|Experimental|DCCR|75 - 450 mg DCCR
89060226|NCT03440814|Placebo Comparator|Placebo|75 - 450 mg placebo for DCCR
89060227|NCT03439228|Experimental|Brace|Lumbar brace wear prescribed for 3 months post-operation
89060228|NCT03439228|No Intervention|No brace|No lumbar brace prescribed
89060229|NCT03427814|Experimental|Pamiparib|Participants received pamiparib orally.
89060230|NCT03427814|Placebo Comparator|Placebo|Participants received placebo orally.
89060231|NCT03420651|Experimental|PEFR Guided Management|Peak Expiratory Flow Rate (PEFR) Patients in this group will perform PEFR testing every 30 minutes and this data along with the National Asthma Prevention and Education Program guidelines will be considered by primary ED medical providers in the management of this group.
89060232|NCT03420651|Experimental|Non-PEFR Guided Management|Standard Clinical Judgement Patients in this group will receive management based on primary medical provider's clinical judgement.
89060233|NCT03418493|Experimental|LY3316531 (Part A)|Participants received single doses of 3 milligrams (mg), 15 mg, 75 mg, 300 mg, 900 mg, or 2000 mg LY3316531 administered Intravenously (IV), or 300 mg LY3316531 administered Subcutaneously (SC).
89060234|NCT03418493|Placebo Comparator|Placebo (Part A)|Placebo matching LY3316531 administered IV.
89060235|NCT03418493|Experimental|LY3316531 (Part B)|Participants received 3 doses of 2000 mg LY3316531 administered IV (1 dose every 4 weeks).
89060236|NCT03418493|Placebo Comparator|Placebo (Part B)|Placebo matching LY3316531 administered IV.
89060237|NCT03418493|Experimental|LY3316531 (Part C)|Participants with psoriasis received single doses of 300 mg LY3316531 administered IV.
89060238|NCT03396731|No Intervention|Standard care alone (control)|Multilayer/multi component compression bandaging treatment
89060239|NCT03396731|Active Comparator|6 hours geko™ (no longer recruiting)|geko™ device 6 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
89060240|NCT03396731|Active Comparator|12 hours geko™|geko™ device 12 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
89060241|NCT03383016||Men at high-rik of prostate cancer|Lifestyle questionnaires such as diet questionnaire, physical activities questionnaires, quality of life , Follows up 1 year and 2 years after the enrollment, Anthropometric measures during the first visit , Blood withdrawal for laboratory biomarkers analysis After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
89688854|NCT04359589||Acute myocardial infarction (AMI) group|"700 patients with AMI;several demographics, clinical and analytical parameters were collected, and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cardiovascular disease of different severity. Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute ischemic cardiovascular diseases."
89688855|NCT04359589||Acute ischemic stroke group|"500 patients with acute ischemic; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cerebrovascular disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
89688856|NCT04359589||Acute lower limb ischemia group|"500 patients with acute lower limb ischemia; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in lower limb ischemia disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established circulatory integration diagnosis and treatment evaluation system of lower limb ischemia disease with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases."
89688857|NCT04359589||Control group|200 healthy volunteers were included as controls
89688858|NCT02826694|Other|Well infant, whole exome sequencing|Healthy infants and their parents enrolled in the study prenatally will participate. After the infant is born saliva sample will be collected for DNA extraction and whole exome sequencing will be done.
89688859|NCT02826694|Other|Diagnosed, whole exome sequencing|Infants and children with diagnosed conditions whose parents enroll in the study and consent to having their child sequenced will have saliva samples obtained and whole exome sequencing will be done on extracted DNA.
89688860|NCT02939170|Experimental|DT1 MF MM|Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours
89688861|NCT02939170|Active Comparator|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
89688862|NCT04346953|Experimental|Study Group|The group to which the exercise videos consisting of aerobic and strengthening exercises will be applied.
89688863|NCT04346953|No Intervention|Control Group|The control group where only the evaluations will be made and information about the benefits of exercise will be given.
89688864|NCT03004846|Experimental|Part A: GSK2981278 4%|Subjects will receive topical application of GSK2981278 4% ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
89688865|NCT03004846|Experimental|Part B: GSK2981278 4% and vehicle|In Part B, subjects will receive topical application of GSK2981278 4 % ointment or vehicle ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
89219702|NCT05428982|Experimental|Postoperative Modified Trendelenburg group|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours
89219703|NCT05428982|No Intervention|Control|Patients underwent the laparoscopic hysterectomy were positioned in a neutral position
89219704|NCT05428956|Active Comparator|Single breath technique|The technique of single maximal inhalation will be demonstrated to all the patients by a technician. In brief the patient will be asked to inhale slowly and maximally and hold the breath for at least 5 seconds. After the breath holding maneuver the patient will be asked to exhale. Salbutamol (100µg) be administered in a dose of 2 puffs, each after a one minute interval. The duration of the breath hold will be measured by a stop watch.
89219705|NCT05428956|Experimental|Tidal breath technique|The technique of 5 tidal breaths will be demonstrated to all the patients by a technician. In brief the patient will be asked to inhale 5 tidal breaths after administrating salbutamol in the spacer. After each breath patient will be asked to breathe out in the spacer. The spacer has a one way-valve and does not allow the exhaled air to enter in to the chamber, thus preventing rebreathing and dilution of the inhaled medicine. Salbutamol (100µg) be administered in a dose of 2 puffs, each after a one minute interval
89219706|NCT05415709|Active Comparator|Arm I (carboplatin, paclitaxel, CRS)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM I: No chemotherapy immediately before, during or after surgery. Carboplatin/paclitaxel is given 3-4 weeks prior to surgery and again 2-4 weeks after surgery."
89522788|NCT03394547|Placebo Comparator|Placebo|Treatment for 2 menstrual cycles using a placebo device which is identical in appearance to the active device but does not emit any pulsed shortwave therapy.
89522789|NCT03394547|No Intervention|No treatment|No intervention is given and a menstrual diary is completed for 2 cycles.
89522790|NCT03394469|Other|cohort|Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
89522791|NCT03398603||Group 1|25 women with age of 18-25 years
89522792|NCT03398603||Group 2|25 women with age of 26-40 years
89522793|NCT05237765|Experimental|midwife-controlled massage|
89219707|NCT05415709|Experimental|Arm II (carboplatin, paclitaxel, CRS, HIPEC, cisplatin)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM II: Patients undergo HIPEC and receive cisplatin IV over 90 minutes at the time of interval debulking surgery"
89219708|NCT05415709|Experimental|Arm III (carboplatin, paclitaxel, CRS, cisplatin)|"OUTLINE:~Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity. Within 3-4 weeks following the third or fourth neoadjuvant cycle, patients who achieve complete or partial response undergo interval debulking surgery~Patients are randomized to 1 of 3 arms.~ARM III: Patients receive cisplatin IV the day prior to interval debulking surgery"
89219709|NCT05409872|Experimental|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
89219710|NCT05409872|Placebo Comparator|Placebo|The subject takes the placebo twice a day for three months
89219711|NCT05404425|Experimental|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
89219712|NCT05404425|Other|Standard Procedure|Usual management of patients
89219713|NCT05404100||Severe aortic valve stenosis|Patients with severe AS planned to undergo AVR, either as surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).
89219714|NCT05401903|Experimental|Chiropractic Maintenance Care|The intervention group will receive weekly chiropractic care, in the form of high-velocity, low amplitude (HVLA) chiropractic adjustments delivered to restricted vertebrae of the cervical, thoracic and lumbar spinal segments. The intervention duration is 8 weeks. Subjects in the intervention group who do not attend at least four (4) scheduled chiropractic visits will be withdrawn from the study.
89219715|NCT05401903|No Intervention|Control|The control group will not receive any chiropractic care during study protocol.
89219716|NCT05390775|Experimental|Written Exposure Therapy|
89219717|NCT05390775|Placebo Comparator|Non-emotional Writing|
89219718|NCT05387655||BCG vaccination|People who received a BCG vaccination in the prior BCG-CORONA-ELDERLY or BCG-PRIME study
89219719|NCT05387655||Placebo vaccination|People who received a placebo vaccination in the prior BCG-CORONA-ELDERLY or BCG-PRIME study
89219720|NCT05385653|Experimental|patients with bulimia or binge eating disorder|patients with bulimia or binge eating disorder
89219721|NCT05385653|Other|control|paired healthy controls
89219722|NCT05383456||Study Participants|Waist and hip circumferences, CT Scan and FibroScan and Quality of Life questionnaire, vital signs, urine and blood testing in Adults with HIV on continuous Anti-Retroviral Therapy treatment.
89219723|NCT05378893|Experimental|Single-ascending dose：Part1：DR10624|Escalating doses of DR10624 for injection administered subcutaneously in healthy participants or obese but otherwise healthy participants
89219724|NCT05378893|Placebo Comparator|Single-ascending dose：Part1：placebo|Escalating doses of placebo for injection administered subcutaneously in in healthy participants or obese but otherwise healthy participants
89219725|NCT05378893|Experimental|Multiple-ascending dose：Part2：DR10624|Escalating doses of DR10624 for injection administered subcutaneously in obese adult subjects with moderate hypertriglyceridemia
89219726|NCT05378893|Placebo Comparator|Multiple-ascending dose：Part2：placebo|Escalating doses of placebo for injection administered subcutaneously in obese adult subjects with moderate hypertriglyceridemia
89219727|NCT05374590|Experimental|Efgartigimod or Efgartigimod PH20 SC|Patients receiving Efgartigimod IV treatment or Efgartigimod PH 20 SC treatment
89219728|NCT05367024|Experimental|Broccoli soup|The soup will be made with a commercially available dried vegetable soup supplemented with broccoli powder.
89219729|NCT05367024|Sham Comparator|Courgette soup|The soup will be made with a commercially available dried vegetable soup supplemented with courgette powder.
89219730|NCT05365490||Standard-risk patients requiring carotid intervention|Symptomatic or asymptomatic patients with a discrete lesion located in the internal carotid artery (ICA) with or without involvement of the contiguous common carotid artery (CCA), who require carotid artery revascularization.
89219731|NCT05364580|Experimental|PROTOXIN(Phase Ⅲ)|PROTOXIN will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL)
89219732|NCT05364580|Active Comparator|Botox® (Phase Ⅲ)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1mL, Total 20U/0.5mL).
89219733|NCT05363748||Observation group|sequential
89219734|NCT05361343|Other|Arm 1|"Nutrition: intermittent fasting;~Physical activity: medium-intensity or high-intensity physical activity;~Hypoxic training (at least three per visit to the center);~correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~Individual motivational counseling."
89219735|NCT05359081|Experimental|SEP-363856|SEP-363856 (50 or 75 mg/day, flexible dose)
89219736|NCT05358860|Experimental|Acne Scars|
89219737|NCT05358847|Experimental|Cellulite|
89060242|NCT03382249|Placebo Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2017 China Guidelines for the Diagnosis and Treatment of Carotid Artery Stenosis in order to promote best practices for risk factor management. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
89060243|NCT03382249|Experimental|OMC and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
89060244|NCT03380559|Experimental|Group A : Association (botulinum toxin + corticoid)|
89060245|NCT03380559|Placebo Comparator|Group C : placebo of toxin + corticoid :|
89060246|NCT03380559|Active Comparator|Group T : botulinum toxin + placebo corticoid|
89060247|NCT03379909|Experimental|Treatment arm|Metformin orally at doses up to 1500 mg twice daily for 3 months.
89060248|NCT03376984|Active Comparator|Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. For all the patients into the control arm of the study, the root canals will be filled with gutta percha (current standard of care), using the vertical condensation obturation technique (standard of care RCT technique).
89060249|NCT03376984|Experimental|ND and Amox modified Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, gutta percha modified with nanodiamonds and amoxicillin (NDGX) will be used for the middle and coronal thirds.
89060250|NCT03368664|Experimental|Alemtuzumab|- alemtuzumab - Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, prednisolone, H1 antagonist [antihistamine], H2 antagonist, paracetamol, acyclovir) will be administered prior alemtuzumab administration. - Type: Experimental
89060251|NCT03360422|Active Comparator|Survey group|Collect alcohol and sexual activity data via web survey from 683 young MSM to yield normative data for the alcohol and HIV preventive intervention in a follow-up study
89060252|NCT03360422|Active Comparator|Focus Group|30 young MSM who drink regularly to inform the content of the alcohol and HIV preventive intervention tested in the UH3 phase and ensure the intervention is culturally appropriate for MSM.
89060253|NCT03360422|Active Comparator|Usability Study|10 young adult MSM will test the mobile intervention in development for 30 days in order to establish usability, acceptability and correct any functionality issues.
89060254|NCT03345485|Experimental|Tinostamustine (EDO-S101)|"Phase 1:~Schedule A: Tinostamustine (EDO-S101), IV, 60mg/m2 up to 100mg/m2 Day 1 and 15 of each 28 day cycle~Phase 2:~The RP2D and selected schedule will be further investigated in patients with specific types of solid tumors: relapsed/refractory SCLC, soft tissue sarcoma, triple negative breast cancer, ovarian cancer and endometrial cancer."
89060255|NCT03343054|Experimental|talazoparib|0.75 mg/day or 1.0 mg/day
89060256|NCT03342144||Participants Receiving Venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
89060257|NCT03342144||Participants Receiving Venetoclax + Rituximab|Participants with CLL receiving venetoclax in combination with rituximab.
89060258|NCT03342144||Participants Receiving Venetoclax + Obinutuzumab|Participants with CLL receiving venetoclax in combination with obinutuzumab.
89060259|NCT03339596|Experimental|Erythropoietin|4 intravenous infusions of recombinant human erythropoietin (EPO)
89060260|NCT03339596|Placebo Comparator|Saline|4 intravenous infusions of saline (1 ml NaCl)
89060261|NCT03322358|No Intervention|Control|No changes to normal sleep habits.
89060262|NCT03322358|Experimental|Naps only|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
89219738|NCT05358327|Experimental|Upper Arm|
89219739|NCT05358145|Experimental|Tinkering|
89219740|NCT05358145|Active Comparator|Control Tinkering|
89219741|NCT05358145|Active Comparator|Board Games|
89060263|NCT03322358|Experimental|Home sleep aids only|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
89522794|NCT05237765|Experimental|self-controlled massage|
89522795|NCT05237765|No Intervention|control group|
89060264|NCT03322358|Experimental|Home sleep aids + Sleep incentives|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful. In addition, they will be given a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
89060265|NCT03322358|Experimental|Naps + Home sleep aids|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
89060266|NCT03322358|Experimental|Naps + Home sleep aids + Sleep incentives|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish, and 3) a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period. The sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
89060267|NCT03315975|Experimental|Influenza vaccination cohort|Subjects will receive one dose of seasonal quadrivalent inactivated influenza vaccine intramuscularly for standard of care for prevention of influenza infection.
89060268|NCT03309878|Experimental|Arm I (pembrolizumab, mogamulizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, then day 1 of subsequent courses. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89060269|NCT03309878|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89060270|NCT03303248|Experimental|Web-based Educational Intervention|This group of participants will be given access to a web-based educational resource in addition to the standard of care.
89060271|NCT03303248|No Intervention|Standard of Care|This group will be given only the standard of care during their clinic visit.
89060272|NCT03298295|Experimental|Insertion of Insulin Infusion Catheters|Non-diabetic patients scheduled for abdominoplasty will be inserted continuous subcutaneous insulin infusion (CSII) catheters of two different materials into the part of the abdomen which will be removed during surgery.
89060273|NCT03293264|Experimental|Exercise training group|The intervention group will be encouraged to perform 150 min of exercise training per week for 6 months. Subjects will be provided with individual feedback and exercise Training prescriptions. After month 6 subjects will be randomized to three different groups for follow-up observation.
89060274|NCT03293264|No Intervention|Waiting-control group|The control group will be provided with general informations on a healthy lifestyle. After 6 months wait-list-control months subjects will receive the guided exercise training intervention for 6 months.
89060275|NCT03291158|Experimental|Minocycline IV|Open label Minocin IV
89060276|NCT03282890|Experimental|CHRP-BB|Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
89219742|NCT05353569|Experimental|Children's Wisconsin Urgent Care Clinics|Subjects will receive a standard-of-care pneumatic otoscopy examination, followed by a research-only examination using an OCT device (PCT).
89219743|NCT05353569|No Intervention|Children's Wisconsin (Effusion in 0 or 1 ear)|Subjects will only receive a standard-of-care pneumatic otoscopy examination.
89219744|NCT05353569|Experimental|Children's Wisconsin (Effusion in 2 ears)|Subjects will receive standard-of-care ear and hearing examinations (pneumatic otoscopy and audiology/tympanometry), followed by research-only examinations using two OCT devices (UIUC OCT and PCT).
89523289|NCT05171543|Experimental|Periapical surgery with placement of an allograft and a membrane|Patients will undergo periapical surgery and an allograft and a membrane will be placed inside the bony crypt and over the denuded root surface respectively before closure of the flap.
89060277|NCT03282890|No Intervention|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
89060278|NCT03264989|Experimental|crizanlizumab 5 mg/kg|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.
89060279|NCT03264196|Active Comparator|Operative|Open Reduction and Internal Fixation of Condylar Head Fracture
89060280|NCT03264196|No Intervention|Conservative|Non-operatively managed Condylar Head Fracture
89060281|NCT03259867|Experimental|Advanced Hepatocellular carcinoma|"PD-1 inhibitor (Nivolumab 360 mg Q3W IV ) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
89060282|NCT03259867|Experimental|Metastatic Gastro-esophageal cancer|"PD-1 inhibitor (Nivolumab 360 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
89060283|NCT03256539|Experimental|Sleep Intervention|Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
89060284|NCT03256539|Placebo Comparator|Placebo intervention|Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
89060285|NCT03226691|Experimental|Single Cohort - Plerixafor|Plerixafor at a single dose of 240 microgram/kg
89060286|NCT03219502|Experimental|Group I (rTMS)|Patients undergo rTMS over 30 minutes for 10 sessions over 10 business days.
89060287|NCT03219502|Sham Comparator|Group II (sham rTMS)|Patients undergo sham rTMS over 30 minutes for 10 sessions over 10 business days.
89060288|NCT03219502|Active Comparator|Group III (standard of care)|Patients receive standard of care.
89060289|NCT03218761||POTS Patients|"Patients who self-identify as having Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
89060290|NCT03218761||Control Subjects|"Subjects who do not have Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
89060291|NCT03211624||Cushing syndrome|Male and female patients with Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
89060292|NCT03211624||Controls|Healthy controls matched for age, gender, and educational level
89060293|NCT03202628|Experimental|Treatment (ixazomib, pomalidomide, dexamethasone, ASCT)|"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.~CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89060294|NCT03200704|Experimental|IC2000/SPY-PHI|Per standard of care, each subject will receive an injection of Tc-99m radioactive colloid. Then the periareolar area of the breast(s) identified with breast cancer will be injected (intradermal) twice with 0.05 ml of a 2.5 mg/ml solution of IC2000. Following the injection lymph node mapping will occur based on intraoperative fluorescence visualization using IC2000 and SPY-PHI. Lymph nodes will be excised following identification with IC2000 and SPY-PHI. The Gamma Probe will then be used with Tc-99m for confirmation of the excised lymph nodes as well as in the area of LN excision to ensure all LNs have been identified and excised.
89060295|NCT03180216|Experimental|Prophylactic and treatment|"Virus Specific T cells (VSTs) for prophylactic and treatment of active viral infection(s) after HSCT.~3 different dose levels starting with 1 x 10E7 /m2 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 2 x 10E7/m2 and a final dose 5 x 10E7 VSTs/m2"
89060296|NCT03176472|Experimental|ricolinostat|Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)
89060297|NCT03176472|Placebo Comparator|placebo|Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth
89060298|NCT03141060|Experimental|Arm 1: Delamanid|Participants will receive delamanid (DLM) twice daily for 24 weeks. Participants will also receive non-study prescribed OBR for MDR-TB.
89060300|NCT03129828|Experimental|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
89060301|NCT03127631|Active Comparator|Randomized - Intervention|The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label statins, ACE-I, and other antihypertensive medications where appropriate.
89060302|NCT03127631|No Intervention|Randomized - Control|The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.
89060303|NCT03112200|Active Comparator|Subchondroplasty with Arthroscopy|After randomization to the study group, subjects assigned to the Subchondroplasty + Arthroscopy group will undergo the Subchondroplasty portion of the procedure before or after the Arthroscopy portion per the surgeon's discretion. All operative procedures are to be performed under aseptic conditions according to the institution's standards.
89060304|NCT03112200|Sham Comparator|Arthroscopy Alone|"After randomization, subjects assigned to the Arthroscopy control group will undergo arthroscopy of the study knee with one or more of the following procedures:~Partial meniscectomy~Lavage~Debridement~Loose body removal~Synovectomy~Removal of osteophytes in the notch or locations other than those adjacent to BML(s)~Superficial skin incision(s) should be created at the typical AccuPort® access point(s) as if the subject had undergone Subchondroplasty. The incisions should be closed in the typical fashion."
89060305|NCT03103139|Active Comparator|Transpapillary Stents|Stent placement across the Papilla (with a short plastic stent) for biliary leak
89060306|NCT03103139|Experimental|Stent across bile leak|Stent placement across the bile leak (with a longer stent) for biliary leak
89060307|NCT03100487|Experimental|Audio Record Guided Imagery (ARGI)|The audio recorded guided imagery sessions (treatment) will be delivered through a digital audio player (Apple iPod Shuffle).
89060308|NCT03100487|Experimental|Deep Breathing Exercises|The deep breathing exercises (control) will be delivered through a digital audio player (Apple iPod Shuffle).
89060309|NCT03067571|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 3.25-6.5 hours on days 1, 8, 15 and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and on day 1 of subsequent cycles. Cycles repeat every 28 days.
89060310|NCT06081062|Experimental|Fabagal® (Agalsidase beta)|1 mg/kg, administered every 2 weeks for 12 months
89060311|NCT06081062|Active Comparator|Active Comparator (Agalsidase beta)|1 mg/kg, administered every 2 weeks for 12 months
89060312|NCT06081023|No Intervention|Progressive Muscle Relaxation|This arm was provided with only a relaxing behavioral technique
89060313|NCT06081023|Experimental|Psycho-educational weight reduction program|This arm was provided with treatment of reducing emotional eating and obesity level
89060314|NCT06081010|Experimental|Intervention arm|Community Health Worker Intervention
89060315|NCT06081010|No Intervention|Control Group|Usual care that includes patients visit to health facility based on felt need
89060316|NCT06080984|Experimental|Treatment Cohort 1|"This arm includes 6 head and neck squamous cell carcinoma patients. Patients in the study receive intratumoral treatment with a novel oncolytic virus SDJ001 at two dose levels: 5x10^11 and 1x10^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter >2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters <0.5 cm, with a maximum of 4 mL)."
89060317|NCT06080984|Experimental|Treatment Cohort 2|This arm includes 9 melanoma patients. Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10^6 pfu/mL to 10^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
89523290|NCT05171543|No Intervention|Periapical surgery with no placement of any graft or membrane|Patients will undergo periapical surgery with no placement of any graft or membrane in the control group.
89060318|NCT06080984|Experimental|Treatment Cohort 3|This arm includes 9 sarcoma patients. Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10^6 pfu/mL to 10^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
89060319|NCT06080945|Experimental|Pharmacist-led care group|In addition to usual care, the patient in the intervention group received pharmacist-led multidisciplinary care. The multidisciplinary team consists of a physician, a pharmacist and a nurse. To ensure the uniformity of the material provided during counseling sessions, all professionals attended training before beginning to work with patients. Patients in the control group were given the hospital's standard of care discharge counseling on budesonide, whereas patients in the intervention group were given both the standard of care counseling and a pharmacist-driven discharge counseling on budesonide. A pharmacist first spoke with the parents to obtain comprehensive medical, familial, and social histories. After personalized pharmacogenetic testing, a pamphlet with instructions on how to take their medications was given to each parent.
89060320|NCT06080945|No Intervention|Usual care group|The control group will receive care as usual
89060321|NCT06080932|Experimental|Ketogenic Diet|The KD will follow general principles as we have described with the aim to achieve blood ketones >0.5 mM, which will require most participants to consume <50 g/day carbohydrate and ~1.5 g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
89060322|NCT06080854|Experimental|Concurrent radiochemotherapy combined with immunotherapy|Participants will receive toripalimab plus gemcitabine and nab-paclitaxel in cycles of 21 days. Non-progressors will plus concurrent radiotherapy during the 3rd cycle of chemotherapy. After 4-6 cycles treatment, Multiple disciplinary team (MDT) will evaluate whether to undergo radical surgery.
89060323|NCT06080841|Experimental|Group 1|1g of curcumin.
89060324|NCT06080841|Experimental|Group 2|1 g curcumin + 5 mg piperine.
89060325|NCT06080841|Experimental|Group 3|3 g of curcumin.
89060326|NCT06080841|Experimental|Group 4|3 g curcumin + 15 mg piperine.
89060327|NCT06080841|Experimental|Group 5|6 g of curcumin.
89060328|NCT06080841|Experimental|Group 6|6 g curcumin + 15 mg piperine.
89060329|NCT06080815|Active Comparator|Group I: patients receive maxillary complete denture opposed to conventional mandibular overdenture|
89060330|NCT06080815|Active Comparator|Group II: patients receive maxillary complete denture opposed CAD/CAM overdenture|
89060331|NCT06080802|No Intervention|control(SGLT2i/ARBs/MRA/ +/- diuretics).|Lifestyle counseling plus standard evidence-based therapy for HFpEF (SGLT2i/ARBs/MRA/ +/- diuretics).
89060332|NCT06080802|Experimental|intervention|Lifestyle counseling plus standard evidence-based therapy for HFpEF (SGLT2i/ARBs/MRA/ +/- diuretics)+ metformin
89060333|NCT06080776|Experimental|SH-1028 tablets|
89060334|NCT06080776|Placebo Comparator|Placebo SH-1028 tablets|
89060335|NCT06080750||healthy|as a control group
89060336|NCT06080750||mild to moderate covid-19|mild-moderate symptoms
89060337|NCT06080750||sever covid-19.|severe symptoms
89060338|NCT06080724|Other|Group A with intralesional injection of bleomycin with dexamethasone|Patients in the group A(n=57) were given intralesional bleomycin combined with dexamethasone and The intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose and similarly intralesional dexamethasone was given as 0.8-1.6 mg/kg/dose. The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=<50% decrease, 2=50-75%, 3=75-90%, 4=>90% but <100% and 5= 100% resolution. The data collection sheet included patent's age, sex, length, width, height, volume, site of haemangioma, dose of bleomycin, dexamethasone, clinical response being efficacious or non-efficacious as per operational definition and time taken to resolve for each patient.
89523291|NCT03383237|Experimental|Apatinib|Apatinib 500mg/d,q.d.,p.o.
89219745|NCT05352698||Non-Cardiac Surgery Patient|Our study population will be comprised of any patient undergoing non-cardiac surgery who meets standard of care criteria for BNP testing. This includes patients who are a) >65 years old, b) revised cardiac risk index (RCRI) ≥1 or c) >45 years old with significant cardiovascular disease (coronary artery disease, peripheral arterial disease, cerebral vascular disease, congestive heart failure, obstructive intracardiac disease such as severe aortic stenosis, severe mitral stenosis or severe hypertrophic obstructive cardiomyopathy)
89219746|NCT05351229|Placebo Comparator|Placebo|Intrathecal saline
89219747|NCT05351229|Active Comparator|Morphine|Intrathecal morphine
89219748|NCT05351164|Experimental|Patients with MSL|
89219749|NCT05349851||Renal failure patiens|Patients with advanced renal failure
89219750|NCT05346081||Patients with underlying lung disease|
89219751|NCT05346081||Healthy subjects|
89219752|NCT05343793|Experimental|Path 1|Enhanced Monitoring and Feedback
89219753|NCT05343793|Experimental|Path 2|Enhanced Monitoring and Feedback + NIATx/MAT Academy
89219754|NCT05343793|Experimental|Path 3|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx External Facilitation
89219755|NCT05343793|Experimental|Path 4|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx Internal Facilitation
89219756|NCT05343793|Experimental|Path 5|Enhanced Monitoring and Feedback + NIATx/MAT Academy + NIATx Internal Facilitation + NIATx External Facilitation
89219757|NCT05343585|Experimental|Experimental|"Training and use of Openfit~Using the app to estimate food intake from simulated meals in a laboratory at PBRC or LSU (participants will not eat food during the meals)~Rating the usability and satisfaction of the app"
89219758|NCT05339711|Experimental|Robotic Pet Therapy/Robot Cat Group|"In the robot cat group, the patients were given face-to-face personal information about the robot cat for about 15 minutes in the waiting room by the researcher, and the Robot Cat Information Brochure was given. Therefore, in this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher. After eight weeks of robotic pet therapy in the hemodialysis unit, this group of patients was followed up by the researcher with the same applications, without robotic pet therapy for eight more weeks. Data collection tools were applied to this group of patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
89219759|NCT05339711|Experimental|Pet Therapy/Betta Fish Group|"In the Betta fish group, the patients were given a 15-minute hands-on, face-to-face, individual information about Betta fish care in the waiting room by the researcher, and a Betta Fish Information Brochure was given to the patients. Then, the patients were asked to take care of the fish given to them at home for two months.This group of patients was given pet therapy for eight weeks, and then followed by the researcher with the same practices for another eight weeks without pet therapy. In order to observe or measure the positive effects of fish on patients, patients should spend at least 10 minutes with fish during the day (52). Data collection tools were applied to this group of patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
89219760|NCT05339711|No Intervention|Control Group|"This group of patients was only informed about the study and received routine hemodialysis treatment. The patients were followed for four months. Data collection tools were applied to the patients before the study. Again, in the last week of the 1st, 2nd, 3rd and 4th months of the study, all other data collection tools were applied, except the Structured Patient Information Form."
89219761|NCT05331443||participents who has the intention to fast Ramadan|subjects with at least two cardiovascular risk factors according to Framingham classification or with out any risk .
89219762|NCT05324098|Experimental|Health services research (STAND-T, text messages)|Patients review educational material and resources via online STAND-T platform. Patients also receive interactive text messages for 3 months.
89219763|NCT05319587|Experimental|Liposomal annamycin|
89219764|NCT05318755||transgender men|People whose sex assigned at birth is female but whose self-identified gender is male.
89219765|NCT05318755||transgender women|People whose sex assigned at birth is male but whose self-identified gender is female.
89219766|NCT05318755||Healthy cisgender people|People whose sex assigned at birth corresponds with their self-identified gender.
89219767|NCT05317429|Experimental|Treatment|Carbohydrate-rich meal
89219768|NCT05317429|Active Comparator|Control|Carbohydrate-rich meal
89219769|NCT05315258|Experimental|Cutaneous melanoma with molecular relapsed disease|tebentafusp weekly IV escalating in the first treatment cycle with dose 20 mcg on day 1, 30 mcg on day 8, 68 mcg on days 15 and 22. Thereafter weekly doses will be 68 mcg IV for 6 months.
89219770|NCT05315258|Experimental|Uveal melanoma with molecular relapsed disease|tebentafusp weekly IV escalating in the first treatment cycle with dose 20 mcg on day 1, 30 mcg on day 8, 68 mcg on days 15 and 22. Thereafter weekly doses will be 68 mcg IV for 6 months.
89219771|NCT05308472|Placebo Comparator|Placebo|
89219772|NCT05308472|Experimental|DISC-1459 oral dose level 1|
89219773|NCT05308472|Experimental|DISC-1459 oral dose level 2|
89219774|NCT05308472|Experimental|Open-Label Extension (optional)|
89219775|NCT05308186|Experimental|Auditory stimulation|Exposing the patient to an audio-based stimulus.
89219776|NCT05308186|Experimental|Auditory and tactile stimulations|Combination of tactual and audio-based stimuli.
89219777|NCT05306561|Experimental|Arm 1|Single arm trial
89219778|NCT05305053||high-risk noncardiac surgery patients for preoperative Multidisciplinary Team (MDT) discussion|observation of MDT in 11 hospitals
89219779|NCT05301933|Experimental|Intervention Group|
89060339|NCT06080724|Other|Group B WITH INTRALESIONAL INJECTION OF BLEOMYCIN|Patients in the group B(n=57) intralesional bleomycin alone after taking aseptic and antiseptic measuresThe intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose.The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=<50% decrease, 2=50-75%, 3=75-90%, 4=>90% but <100% and 5= 100% resolution. The data collection sheet included patent's age, sex, length, width, height, volume, site of haemangioma, dose of bleomycin, dexamethasone, clinical response being efficacious or non-efficacious as per operational definition and time taken to resolve for each patient.
89060340|NCT06080711|No Intervention|Workflow 1|Standard of care
89060341|NCT06080711|Experimental|Workflow 2|Consult with AI assistance
89060342|NCT06080711|Experimental|Workflow 3|First workflow 1, then workflow 2
89060343|NCT06080620|Experimental|Group A|Surgery+systematic treatment
89060344|NCT06080620|Active Comparator|Group B|Neoadjuvant therapy+surgery+systematic treatment
89060345|NCT06080438|Experimental|Botulinum toxin group|Participants will receive botulinum toxin eyes drop and be in this group for up to 40 minutes.
89060346|NCT06080438|Active Comparator|Saline solution group|Participants will receive saline eye drops and be in this group for up to 40 minutes.
89060347|NCT06080412||Blueprint Mixed Reality HOLOBLUEPRINT™ in Reversed Shoulder replacement|One single cohort of patients receiving a reversed shoulder arthroplasty with the use of Blueprint Mixed Reality HOLOBLUEPRINT™ as per standard of care.
89060348|NCT06080386||one group|Patients who had during their care UDFF ultrasound measurements and liver MRI over the study period may be included in this study
89060349|NCT06080373|Experimental|Formulated-based cognitive behavioral therapy|Participants randomized to the CBT group will receive a minimum of 13 and a maximum of 22 sessions of individual formulation-based CBT. It will be delivered by psychologists trained in CBT, according to a manual that will be available soon. Prior to intervention, a behavioral assessment is conducted to operationalize each case's clinically relevant behaviors, antecedents, and maintenance stimuli. Each case will be formulated and presented to the participant in simple and easy to understand language. To illustrate this, a schematic formulation of the typical case of an adult with ADHD is shown in Figure 2. Specific behavioral goals will then be agreed upon for each participant. To achieve these goals, various treatment strategies will be presented in the following sessions. The choice of strategies, the order in which they are applied, and the duration of each module will be customized for each participant according to the case formulation.
89219780|NCT05298995|Experimental|ARM A: MB/other embryonal tumor|After a lymphodepleting regimen, patients affected by relapsed/refractory MB/other embryonal tumor will receive 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
89219781|NCT05298995|Experimental|ARM B: Hemispheric HGG|After a lymphodepleting regimen, patients affected by relapsed/refractory hemispheric high grade glioma will receive 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
89060350|NCT06080373|Active Comparator|PROBECO and social therapeutic establishments|"The Spanish participants assigned to the active control group will receive the PROBECO. It is a group program designed by the Spanish Penitentiary Agency for its application with inmates convicted of different types of violent crimes . Its main goals are to eradicate criminal behavior and reduce recidivism, to modify the relevant dynamic risk factors related to general delinquency, and to introduce new social skills and prosocial values. It consists of four phases: (I) general intervention: aimed at the acquisition of social skills; (II) specific intervention: consists of four specific educational itineraries; (III) relapse prevention; (IV) follow-up.~Similarly, German participants will be assigned to a special type of prison known as a social therapeutic facility, where they will undergo compulsory psychotherapy focused primarily on relapse prevention."
89060351|NCT06080373|No Intervention|Waitlist|Participants in waitlist control group will receive no treatment while experimental groups are treated. They will be offered to receive CBT after the study.
89060352|NCT06080334|Experimental|Dry needling+eccentric exercises|Application of dry needling on the hyperalgesic trigger points of the gastrocnemius muscle and subsequent inclusion of eccentric exercises.
89060353|NCT06080334|Experimental|Electrolysis+eccentric exercises|Application of electrolysis to the Achilles tendon and subsequent inclusion of eccentric exercises.
89060354|NCT06080321|Experimental|WhatsApp messages|
89060355|NCT06080321|Experimental|Instagram messages|
89060356|NCT06080321|Experimental|Phone calls|
89060357|NCT06080321|Active Comparator|App alerts|
89060358|NCT06080321|No Intervention|No active reminders|
89060359|NCT06080269|Experimental|Intervention arm|The participants in the intervention arm will be receiving technology based training along with the conventional therapy
89060360|NCT06080269|Active Comparator|Control arm|The participants in the control arm will be receiving the regular conventional therapy program
89060361|NCT06080256|Experimental|Alirocumab added to statin therapy|Alirocumab (75 mg every 2 weeks for 6 months) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management.
89060362|NCT06080256|Active Comparator|Statin therapy|Atorvastatin 20-40mg. Anti-platelet aggregation and risk factor management in both arms.
89060363|NCT06080243|Active Comparator|Experimental-Standard Regime Malaria Vaccine Group1|Participants receiving three doses of R21/Matrix-M1 malaria vaccine at months 0, 1 and 2.
89060364|NCT06080243|Active Comparator|Experimental-Standard Regime Malaria Vaccine Group2|Participants receiving normal saline (placebo) at month 0 and two doses of R21/Matrix-M1 malaria vaccine at month 1 and 2
89060365|NCT06080243|Active Comparator|Experimental-Standard Regime Group3|Participants receiving three doses of normal saline (placebo) at months 0, 1 and 2
89060368|NCT06080152|Experimental|1|1. 12 patients get an A-linker 3 months before surgery (knee arthroplasty)
89060369|NCT06080152|No Intervention|2|2. 12 patients use a walker 3 months before surgery (knee arthroplasty)
89060370|NCT06080087|Experimental|Intervention|Intervention group will receive access to the I-TEAM
89060371|NCT06080087|No Intervention|Waitlist control|Waitlist control group will not receive access to the I-TEAM until the Intervention group has completed the 8-week intervention.
89060372|NCT06080035|Experimental|Topical Cetyl Tranexamate Mesylate|Product will be used on the face twice daily in the morning and in the evening for 2 weeks.
89060373|NCT06079996|Experimental|caffeine gum|The gum containing 200 mg of caffeine (CAF) were chewed for 10 minutes before test
89060374|NCT06079996|Placebo Comparator|placebo|The gum without caffeine (PLA) were chewed for 10 minutes before test
89060375|NCT06079983|Experimental|JSKN003|Administered intravenously according to protocol.
89060376|NCT06079983|Active Comparator|The chemotherapy chosen by the investigator|The mono-chemotherapy drugs selected by the investigators included capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The option should be determined before randomization.
89060377|NCT06079957|Experimental|Exercise and ergonomic intervention group|"Patients will be explained about the procedure and informed consent will be taken.~Individuals will be given a copy of ergonomic guidelines to follow which includes:~Organize workstation according to the primary , secondary and tertiary zones.~Place frequently used items within the reach of an arm.~Don't move head while reading documents instead raise or lower the eyes to read.~Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~Keep reference material upright at desk.~Avoid slouched postural habits, sit upright.~Adjust chair height in such a way that it shouldn't compress the thigh.~Arm rest should be at elbow flexion of 90 degrees.~Phone must be cradled between neck and shoulder to avoid forward head posture.~Neck exercises will be given"
89219782|NCT05298995|Experimental|ARM C: Thalamic HGG, DMG, DIPG and other rare CNS tumors not included in Arm A and B|After a lymphodepleting regimen, patients affected by relapsed/refractory thalamic HGG, DMG, DIPG and other rare CNS tumors not included in Arm A and B will receive 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
89219783|NCT05297045|Experimental|Dose Group A|
89219784|NCT05297045|Experimental|Dose Group B|
89219785|NCT05297045|Experimental|Dose Group C|
89219786|NCT05297045|Experimental|Dose Group D|
89219787|NCT05297045|Experimental|Dose Group E|
89219788|NCT05297045|Experimental|Dose Group F|
89219789|NCT05297045|Placebo Comparator|Placebo Group|
89219790|NCT05291403|Experimental|Experimental group (medical thoracoscopic cryotherapy)|
89219791|NCT05291403|Active Comparator|Cisplatin/erythromycin control group (sequential intrathoracic injection of cisplatin/erythromycin)|
89219792|NCT05291403|Other|Blank control group|Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.
89219793|NCT05288088||Tumor craniotomy patients|Patients undergoing elective brain tumor craniotomy
89219794|NCT05283239||Women with persistent HR-HPV infection|In the enrollment, women with persistent HR-HPV infection for more than 18 months will be included in this study. All participants will be followed up at 6th month, 12th month, 18th month and 24th month after baseline of recruitment.
89219795|NCT05283135|Experimental|risankizumab subcutaneous injection 600 mg (4x dosing) at Weeks 0, 4, and 16|
89219796|NCT05283135|Experimental|risankizumab subcutaneous injection 300 mg (2x dosing) at Weeks 0, 4, and 16|
89219797|NCT05282745||Women with high-grade squamous intraepithelial lesion (HSIL) in cervix|In the enrollment, women whose cervical histopathological results have been diagnosed as high-grade squamous intraepithelial lesion (HSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
89219798|NCT05282641|Experimental|Collagen hydrolysate|30 subjects will consume the protein hydrolysate daily for 4 weeks
89219799|NCT05282641|Placebo Comparator|Placebo|30 subjects will consume the placebo daily for 4 weeks
89219800|NCT05281939|Active Comparator|Artificial intelligence diagnostic group|Women who show abnormalities in cervical cancer screening and require referral for colposcopy. Colposcopy was performed with the aid of an Artificial intelligence (AI) system.
89219801|NCT05281939|No Intervention|Gynecologist diagnostic Group|Women who show abnormalities in cervical cancer screening and require referral for colposcopy. Colposcopy is performed independently by a gynecologist without any external assistance.
89219802|NCT05280756|Experimental|Active home-based transcranial direct current stimulation (tDCS)|The active home-based tDCS delivers a constant current intensity of 2mA on the subject's scalp, with electrodes positioned bilaterally (anodal-left and cathodal-right), on the dorsolateral prefrontal cortex (DLPFC), for 30 minutes.
89219803|NCT05280756|Sham Comparator|Sham home-based transcranial direct current stimulation (tDCS)|The sham home-based tDCS looks identical to a typical active home-based tDCS cap but delivers a 30-second ramp-up (0-2 mA) stimulation followed by a 30-second ramp-down (2-0 mA) at the beginning and end of the application.
89060378|NCT06079957|Active Comparator|Group B(Ergonomic intervention group)|"Patients will be explained about the procedure and informed consent will be taken.~Individuals will be given a copy of ergonomic guidelines to follow which includes:~Organize workstation according to the primary , secondary and tertiary zones.~Place frequently used items within the reach of an arm.~Don't move head while reading documents instead raise or lower the eyes to read.~Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~Keep reference material upright at desk.~Avoid slouched postural habits, sit upright.~Adjust chair height in such a way that it shouldn't compress the thigh.~Arm rest should be at elbow flexion of 90 degrees.~Phone must be cradled between neck and shoulder to avoid forward head posture."
89060379|NCT06079944|Active Comparator|Group A- Control group|"Group (A)/ control group Involves participants receiving~TENS+ hot pack (10mins)~Pendulum exercises and stretching exercises This group will not receive resistance training from 5 repetitions to 20 repetitions of door way stretch (maintained for 30seconds), pendulum exercises and foam roll strtech will be provided over the 6 weeks protocol"
89060380|NCT06079944|Experimental|Group B- Study Group|"Group (B)/ Experimental group involves participants receiving Traditional l physical therapy for shoulder impingement syndrome for 6 weeks.~TENS+ hot pack (10mins)~Pendulum exercises and stretching exercises 3-6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition: 25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks Speed of movement will be 2 seconds for both the eccentric and concentric phases.~To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation It is a combined treatment so study group will receive both study group and control group intervention"
89060381|NCT06079905||Frail elderly with limited life expectancy that fracture a hip|Frail elderly with limited life expectancy that fracture a hip
89060382|NCT06079853|Experimental|Experimental|Single arm pilot sample will receive intervention
89060383|NCT06079788|Experimental|Adrenocorticotrophic Hormone Group|"ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd"
89060384|NCT06079788|Active Comparator|Steroid Group|Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg （qod） or 0.125mg/kg （qd） every 4 weeks.
89060385|NCT06079762|Experimental|AGE SELF CARE group visit program|Participants will take part in 8 weekly 90-minute virtual group visit program sessions
89688866|NCT03032497|Experimental|EEG-based BCI analysis of fear avoidance|"All participants complete two experiments one after another-EEG patterns, skin conductance and pulse rate are recorded. The EEG cap is mounted on the participant's head, the GSR sensor secured on the fingers and the PPG sensor secured on the wrist using a Velcro strap. Exp 1-participants watch a series of 15, 1 min videos of people doing daily activities. Exp 2-participants do 15 movements (15 reps each in 1 min) as guided by a physiotherapist. 2 identical buzzers (labelled lesser pain and more pain) are available to press accordingly should participants experience 'lesser' or 'more' pain any time during the experiment. If 'more' pain experienced, participants' condition will be assessed and they can choose to continue the experiment at a lower intensity or stop."
89688867|NCT03032341||Patient group|20 patient in poor mobility group (MAT-sf < 51.38 in men and <45.61 in women), mid-mobility group (51.38< MAT-sf≤65.5 in men and 45.61≤MAT-sf<54.02) and high mobility group (MAT-sf>65.5 in men and MAT-sf>54.02 in women) for a total of 60 patients.
89688868|NCT03032341||Surrogate group|A family member/caregiver that attends visits with the patient and will be asked to answer the Mobility Assessment Test questionnaire on behalf of the patient at the initial visit and the follow up visit 1-14 days later.
89688869|NCT04359667||tocilizumab|one infusion of TCZ 8 mg/kg i.v., with a maximum dose of 800 mg, and SOC treatment according to local guidelines (hydroxychloroquine or/and lopinavir/ritonavir or/and remdesivir).
89688870|NCT00373750|Experimental|Family Spirit Intervention|The Family Spirit Intervention included 43 structured lessons and followed a culturally congruent format. Positive parenting lessons were focused on reducing behaviors (i.e., poor monitoring; coercive interactions;harsh, unresponsive, or rejecting parenting; and abuse/ neglect) associated with early childhood behavior problems, including externalizing, internalizing, and dysregulation problems.
89688871|NCT00373750|No Intervention|Optimized Standard Care Control Group|Optimized standard care consisted of transportation to recommended prenatal and well-baby clinic visits, pamphlets about child care and community resources, and referrals to local services. It also addressed access barriers to health care for young mothers and children, and it overcame concerns that home-visiting programs have operated in parallel, not in partnership, with pediatric care. Family health liaisons conducted the optimized standard care and were not trained in the Family Spirit intervention, to avoid contamination of the control condition.
89688872|NCT03017677||Group|
89688873|NCT03008590|Other|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
89688874|NCT03008590|Other|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
89688875|NCT04359511|Experimental|corticosteroid + Optimized Standard of Care|"prednisone 0.7 mg/kg/day for 10 days, administered orally, once a day, or~hydrocortisone hemisuccinate 3.5 mg/kg/day by continuous infusion for 10 days, administered by IV route if the patient cannot take drugs by oral route,~standard of care"
89688876|NCT04359511|No Intervention|Optimized Standard of Care|standard of care
89688877|NCT03032419|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
89688878|NCT03032419|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
89688879|NCT02981797||Radium 223 Standard of Care|Standard of Care and Blood Collection for Baseline Circulating Tumor Cells (CTCs) Numeration and H2AX Assay. Participants who have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Week 1 starts with the first Radium 223 treatment and week 24 ends 4 weeks after the last or sixth Radium 223 treatment. The circulating prostate cancer cell analysis will be performed within 24 hours of blood draw. Any unused blood samples for circulating prostate cancer cell analysis will be disposed per lab protocol.
89060386|NCT06079749||Simultaneous BTKA|Simultaneous BTKA
89060387|NCT06079749||Staged BTKA|Staged BTKA
89060388|NCT06079710||Emergence agitation group|
89060389|NCT06079710||Non emergence agitation group|
89219804|NCT05280379||Participants with non-medullary thyroid carcinoma|30 patients with non-medullary thyroid carcinoma, who are going to get surgery
89219805|NCT05280379||Participants with colon carcinoma|30 participants with colon carcinoma, who are going to get surgery
89219806|NCT05276024||iFuse Bedrock technique|Multilevel lumbar fusion procedure with additional sacroiliac joint stabilization using the iFuse-3D system
89060390|NCT06079684|Experimental|Vacuum Group|Vacuum Group with 32 patients: for 10 consecutive days, all patients performed the same program procedures: Intermittent vacuum therapy (for 30 minutes, with a Vacumed device -the lower body was positioned in the vacuum chamber, which was sealed around the participant's trunk with a cuff at the level of the umbilicus to allow application of negative pressure), general warm mud bath (20 minutes at 38 degrees Celsius), hydrokinetotherapy in saline water from Lake Techirghiol by a certified physical therapist (20 minutes at 35 degrees Celsius), massage therapy for paravertebral muscles, shoulder and pelvis girdle and kinesiotherapy with a standard program for peripheric joints for 30 minutes
89060391|NCT06079684|Active Comparator|Control Group|Control Group with 33 patients: for 10 consecutive days, all patients performed the same program procedures: general warm mud bath (20 minutes at 38 degrees Celsius), hydrokinetotherapy in saline water from Lake Techirghiol by a certified physical therapist (20 minutes at 35 degrees Celsius), massage therapy for paravertebral muscles, shoulder and pelvis girdle and kinesiotherapy with a standard program for peripheric joints for 30 minutes
89060392|NCT06079658|Experimental|Continuous Caloric Restriction (CCR) group:|Participants in this group will be placed on a diet that is prescribed a 25% reduction from maintenance calories (calories to maintain current body weight) with a dietary protein intake of 1.2 g of protein/kg body mass and remaining calories split evenly between fat and carbohydrate. In this group they will adhere to a 25% caloric reduction daily for 12 weeks.
89060393|NCT06079658|Experimental|Intermittent Caloric Restriction (ICR) group:|"Participants in this group will be placed on a diet that is prescribed a 25% reduction from maintenance calories (calories to maintain current body weight) with a dietary protein intake of 1.2 g of protein/kg body mass and remaining calories split evenly between fat and carbohydrate. Participants will adhere to a 25% caloric deficit daily and on every 7th day they will eat their maintenance calories known as a diet refeed and then on the 3rd week they will take a diet break of eating their Maintenance calories for 7 days."
89060394|NCT06079619||Group A: expert dermatologists|"Group A is composed of expert dermatologists. Group A doctors will have at their disposal 150 dermoscopic photos, x20 dermatoscopic photos according to the usual practice of pigmented genital tumors.~The dermatologists will characterize the dermatoscopy with a standardized reading grid to assess the different dermatoscopic patterns of genital tumors."
89060395|NCT06079619||Group B: non-dermatologists|"Group B is composed of gynecologists (Group B1) and general practitioners (B2) Group B physicians will only perform dermatoscopy x 400. They will have been given a maximum of 1 hour's training to identify melanosis-type pigmented tumors, which are the most frequent benign tumors in x 400 dermatoscopy.~Only three x400 dermatoscopy patterns will be presented to them to the exclusion of all others, which are sufficient to identify benign lesions."
89060396|NCT06079619||Group C: Artificial intelligence|Artificial intelligence: the skin Artificial intelligence software, a learning base will be provided, different from the evaluation base and the test base.
89060397|NCT06079606||Group A|Term children born with caesarean section (their mothers received intra-operative antibiotics)
89060398|NCT06079606||Group B|Term vaginally born children and their mothers received intra-partum antibiotics
89060399|NCT06079606||Group C|Term vaginally born children that received systemic antibiotics during the first week of life for at least 48 hours
89060400|NCT06079606||Group D (Control group)|Term vaginally born children that had not received systemic antibiotics at the time of recruitment
89060401|NCT06079554||the gastric cancer group|16 cases of intestinal type of gastric cancer under the background of atrophic gastritis
89060402|NCT06079554||the atrophic gastritis group|16 cases of atrophic gastritis without gastric cancer matched according to gender, age, and degree of gastric atrophy
89219807|NCT05275088|Experimental|Treatment|Transcatheter atrioventricular valve replacement with the Prizvalve® system
89219808|NCT05273749|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
89219809|NCT05273749|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
89219810|NCT05272579|Experimental|FFT treatment|Treatment with fecal filtrate transfer in saline solution administered by nasogastric tube
89219811|NCT05272579|Placebo Comparator|Placebo Treatment|Treatment with saline solution administered by nasogastric tube
89219812|NCT05269459|Experimental|Cannabidiol (CBD) as Nantheia ATL5|Cannabidiol (CBD) as Liquid Structure Formulation Nantheia ATL5 400mg BID. Administered in 100mg softgel capsules. Each 100mg softgel contains 10% CBD.
89219813|NCT05269459|Placebo Comparator|Placebo|Matching placebo
89219814|NCT05269459|No Intervention|Control Population|Control group for purposes of baseline data collection
89219815|NCT05267184|Experimental|Embolization of middle meningeal artery|Participants receive endovascular treatment with embolization of the middle meningeal artery ipsilaterally to the chronic subdural hematoma(s).
89219816|NCT05267184|Active Comparator|Standard neurosurgical hematoma evacuation and drainage|Participants receive standard neurosurgical hematoma evacuation via burr hole or mini craniotomy and post-operative subdural or subgaleal drainage.
89219817|NCT05261672|Active Comparator|Group QL1|quadratus lumborum block will be done. 20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
89219818|NCT05261672|Active Comparator|Group QL2|quadratus lumborum block will be done. ) 20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
89219819|NCT05257187|Active Comparator|6 hour foley catheter retention|Patients will have the foley catheter in place for up to 6 hours starting from insertion time to removal. If the catheter falls out earlier than the 6 hour mark, the patient will still be included for analysis.
89219820|NCT05257187|Placebo Comparator|12 hour foley balloon retention|Patients will have the foley catheter in place for up to 12 hours starting from insertion time to removal. If the catheter falls out earlier than the 12 hour mark, the patient will still be included for analysis.
89219821|NCT05255588||Cohort|Subjects who are at high-risk (Asia Pacific Colorectal Screening Score ≥4.0) of developing CRC aged ≥40
89219822|NCT05251207|Experimental|carnitine|2 grams of L-carnitine per day for 12 weeks
89219823|NCT05251207|Placebo Comparator|leucine|2 grams of L-leucine per day for 12 weeks
89219824|NCT05251207|Experimental|modified circadian cycle|no sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00).
89219825|NCT05251207|Active Comparator|normal circadian cycle|sleep at night for four consecutive days
89219826|NCT05240716|Experimental|FES program|
89219827|NCT05240547|Experimental|Spinal manipulation|Spinal manipulative therapy will be delivered to the cervical spine (segments including occiput-atlas to C7-D1) according to the chiropractors' evaluation during each visit. During each session, one or two segments will be manipulated using a high-velocity low-amplitude thrust manipulation (a joint cavitation will be expected, if not, the thrust can repeated once) applied to the segments with the highest motion restriction, as determined by the chiropractor by static and motion palpation of the cervical spine.
89219828|NCT05240547|Placebo Comparator|Placebo|Sham manipulation will be delivered to the cervical spine (segments including occiput-atlas to C7-D1) according to the chiropractors' evaluation during each visit. During each session, one or two segments will receive a sham manipulation applied to the segments with the highest motion restriction, as determined by the chiropractor by static and motion palpation of the cervical spine. The sham manipulation will consist in a identical contact to the real manipulation, except the thrust will be delivered towards the table, away from the target segment and with the intention to lower the cervical drop piece of the table, which will substitute the joint cavitation noise.
89219829|NCT05238896|Experimental|Baricitinib|Patients receiving baricitinib 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8
89219830|NCT05238896|Placebo Comparator|Placebo|Patients receiving placebo 4mg/day for 7 days, then open label study until day 42 with all patients receiving baricitinib during 5 weeks. 20 patients in this arm will have a MRI at day 0 and day 8
89219831|NCT05234879|Experimental|Frame Running intervention|Participants will be invited to 12 Frame Running training sessions
89688880|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel twice a day|drug
89688881|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel three times a day|drug
89688882|NCT00955513|Placebo Comparator|placebo|placebo
89688883|NCT02939326|Placebo Comparator|Placebo|"Intervention: Drug: Placebo~Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area."
89688884|NCT02939326|Active Comparator|EB-001 Dose 1 (1X)|"Intervention: Drug: EB-001~Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
89688885|NCT02939326|Active Comparator|EB-001 Dose 2 (3X)|"Intervention: Drug: EB-001, 3X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
89688886|NCT02939326|Active Comparator|EB-001 Dose 3 (9X)|"Intervention: Drug: EB-001, 9X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
89688887|NCT02939326|Active Comparator|EB-001 Dose 4 (12X)|"Intervention: Drug: EB-001, 12X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
89688888|NCT02939326|Active Comparator|EB-001 Dose 5 (16X)|"Intervention: Drug: EB-001, 16X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
89688889|NCT02939326|Active Comparator|EB-001 Dose 6 (21X)|Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
89688890|NCT02939326|Active Comparator|EB-001 Dose 7 (28X)|"Intervention: Drug: EB-001, 28X Dose 1~Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
89688891|NCT03032185|Active Comparator|Active TENS|Active TENS, 10 Hz/200 μs
89688892|NCT03032185|Sham Comparator|Not Active TENS|Sham TENS
89219832|NCT05232851|Experimental|Arm A (PDS0101)|Patients receive PDS0101 SC on day 1 of each cycle. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or FDG-PET/CT and blood sample collection throughout the trial. Patients may undergo a biopsy during screening and on the trial.
89219833|NCT05232851|Experimental|Arm B (PDS0101, pembrolizumab)|Patients receive PDS0101 SC on day 1 and pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or FDG-PET/CT and blood sample collection throughout the trial. Patients may undergo a biopsy during screening and on the trial.
89219834|NCT05231070|Experimental|TeleSPC|"Patients will be offered regular multidisciplinary video consultations with the SPC team and these patients and their informal caregiver will also be offered a dyadic psychological intervention.~Regular multidisciplinary video consultations with multidisciplinary team, involvering cooperation between the section og Palliative medicine and the Department of Oncology, District nurse and the general practitioner.~Operationel definition of informal caregiver: Patients will designated the closest person involved in their care (e.g., spouse, son/daughter, other relatives, and friends)."
89219835|NCT05231070|No Intervention|Control|Patients will follow the current practice in the healthcare system (standard care). Control patients will be offered information to clarify the options available in case of unmet palliative needs. Patients' informal caregiver will be invited to participate in the study, but no intervention will be offered.
89219836|NCT05230745|Experimental|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
89219837|NCT05227326|Experimental|Treatment (PCNA inhibitor AOH1996)|Patients receive PCNA inhibitor AOH1996 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89219838|NCT05226871|Other|Arm 1|Cetuximab
89219839|NCT05226871|Experimental|Arm 2|Palbociclib plus Cetuximab
89219840|NCT05226871|Other|Arm 3|Palbociclib plus Fulvestrant
89219841|NCT05226871|Other|Arm 4|Palbociclib plus Letrozole
89219842|NCT05225428|Experimental|QUALITATIVE ASSESSMENT|"This part of the research study involves watching a brief educational video about genetic testing for inherited cancer risk (about 8 minutes) before completing a short interview by video or telephone with trained researchers. This interview will be digitally recorded for later review.~It is expected that about 20 people will take part in this part of the research study.~In the larger part of the study that will happen after this part of the study, it is expected 1000 people will participate."
89219843|NCT05225428|Experimental|RCT-VERDI|A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling
89219844|NCT05225428|Experimental|RCT-Genetic Counseling|A randomized controlled trial (RCT) will evaluate the VERDI model vs. standard genetic counseling
89219845|NCT05222451|Experimental|Dietary Guidelines for Americans|7 days of a diet consistent with the Dietary Guidelines for Americans (DGA).
89219846|NCT05222451|Experimental|Medium Chain Triglyceride Supplemented DGA|7 days of a diet consistent with the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
89219847|NCT05222451|Experimental|Ketogenic Diet|7 days of a ketogenic diet (KETO).
89219848|NCT05218980|Experimental|Investigational|Yale Dining menu + 6 olives daily
89219849|NCT05218980|No Intervention|Standard|Yale Dining menu only
89688893|NCT02943226|Experimental|Becton Dickinson Nexiva Diffusics System|Intervention with the new Becton Dickinson Nexiva Diffusics System will be evaluated to see if it will improve image quality compared to the standard catheter.
89688894|NCT02943226|Active Comparator|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to novel 3 hole Becton Dickinson Nexiva Diffusics System to see which catheter provides the best image quality.
89688895|NCT00935311|Experimental|ABT-712|1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
89688896|NCT00935311|Active Comparator|Hydrocodone/Acetaminophen|2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
89219850|NCT05217849|Experimental|Tai Chi|Participants will engage in 60-minute Tai Chi classes twice a week for 12 weeks. The classes will be live-streamed over the internet. Tai Chi is an ancient Chinese system of gentle physical exercise and stretching. It involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
89688897|NCT00935311|Placebo Comparator|Placebo|2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
89688898|NCT03019744|Experimental|MeCFES|25 daily sessions (45 minutes each) of MeCFES-assisted task-oriented upper limb rehabilitation
89688899|NCT03019744|Active Comparator|Control|25 daily sessions (45 minutes each) of usual care task-oriented upper limb rehabilitation
89688900|NCT03031951|Experimental|Lifestyle Intervention Group|Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 90-120 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Participants will be instructed and motivated to make small but enduring reductions in caloric intake and to increase energy expenditure to induce a daily energy deficit of approximately 300 kcal. Weight will be monitored weekly.
89688901|NCT03031951|No Intervention|Control Group - Waiting List|"Participants assigned to the control group will have access to the intervention after the 12-month period - waiting list. Meanwhile, participants will receive multimedia health information fortnightly by e-mail over the first 4-month period. The health information covers healthy lifestyle topics.~During the 12 months of study participation, control group participants will be instructed to maintain their baseline level of physical activity. Individuals assigned to the control group will be asked to maintain their current nutritional practices and physical activity patterns."
89688902|NCT02946034|Experimental|Viekira Pak ± ribavirin or Mavyret|"12 week therapy with Viekira Pak ± ribavirin~8 or 12 week therapy with Mavyret"
89060403|NCT06079528|Experimental|Electromagnetic Stimulation combined with visceral manipulation|Consisted of 25 postmenopausal women with SUI received PEMS therapy augmented by VMT maneuvers in addition to supervised PFMT.
89060404|NCT06079528|Active Comparator|Electromagnetic Stimulation associated with general advice|Control group (B) performed the same PFMT associated with general advice with no medical treatment.
89060405|NCT06079515|Active Comparator|Ali Akdağ|All injections were performed by him under the guidance of a Clarius portable USG device (L7 HD Linear Ultrasound Scanner). A total of 10 ml of a mixture of 1 ml of 40 mg triamcinolone acetonide (Kenakort-A ampoule) and 9 ml of 0.5% bupivacaine hydrochloride (Marcaine) was used in each injection.
89060406|NCT06079515|Experimental|Muhammet Hüseyin Sarı|Blind observer to injections
89060407|NCT06079489|Active Comparator|Control Group|Participants were advised to repeat the brochure-based exercises 3 days a week for 8 weeks. Correct sitting and standing positions and ergonomic materials were also explained in detail. Participants' adherence to the exercise program was tracked by an exercise diary.
89060408|NCT06079489|Experimental|Experimental Group|Progressive physical fitness and posture exercises were given via telerehabilitation 3 days a week for 8 weeks. Specific exercises for upper extremities, lower extremities, neck, trunk and lower back were selected and progressed by changing the frequency, duration and variety within the program. All exercises were performed under the supervision of a physiotherapist during video conference calls lasting an average of 40 minutes. Correct sitting and standing positions and ergonomic materials were also explained in detail. Participants' adherence to the exercise program was tracked by an exercise diary.
89060409|NCT06079463|Experimental|Diabetic patients undergoing progressive relaxation exercise|"After the purpose of the study was explained and their verbal and written consents were obtained, a questionnaire including the Beck Anxiety Scale, which includes the socio-demographic characteristics, and the World Health Organization Quality of Life Scale, were applied to the patients in the experimental and control groups. will participate in the research, will be asked, and will be filled in face to face by the responsible researcher. After the progressive relaxation exercise training is given to the experimental group patients, the voice recording containing the commands for the application of the progressive relaxation exercise will be sent to the phone of the patient and/or their relatives. Patients in the experimental group spent an average of 25-30 minutes each day for four weeks. Ongoing exercises will be conducted and followed up. At the end of the fourth week, Beck Anxiety Scale and World Health Organization Quality of Life Scale will be applied."
89060410|NCT06079463|No Intervention|Diabetic patients not applied progressive relaxation exercise|After explaining the purpose of the study and obtaining their verbal and written consents, a questionnaire form including the Beck Anxiety Scale and the World Health Organization Quality of Life Scale, in which the socio-demographic characteristics of the experimental and control group patients who will participate in the research, are asked, will be filled in face to face by the principal researcher.Then, a voice recording containing the commands for the application of the progressive relaxation exercise will be sent to the phone of the volunteer patients in this group and/or their relatives, and they will be informed about how to apply it.
89060411|NCT06079450||experimental group|Artificial intelligence-based mobile application initiative was implemented for diabetes patients
89060412|NCT06079450||control group|no intervention was applied
89060413|NCT06079437|Experimental|experimental group|Heart rate, maximum isometric muscle strength, Soleus H-reflex, M-wave, and V-wave measurements were taken in three consecutive periods. First-period maximal isometric contraction; second-period maximal isometric contraction + cold pressure test; third-period maximal isometric contraction + Cheering
89060414|NCT06079424||Level of vascular aging|community-based prospective longitudinal cohort
89060415|NCT06079333|Experimental|neo-adjuvant and adjuvant braf/mek-inhibition|Participants will undergo neo-adjuvant treatment with dabrafenib/trametinib. After 6 weeks of BRAF/MEK inhibitors, participants will undergo an evaluation of resectability. If the tumor is resectable, patients undergo tumor resection. If not resectable, neo-adjuvant treatment continues for another 6 weeks followed by a new evaluation. All resected patients receive adjuvant dabrafenib/trametinib up to a total treatment duration of 52 weeks. If resection is not possible, patients will continue on dabrafenib/trametinib.
89060416|NCT06079255||IscAlert sensor in patient with risk of acute compartment syndrome|Patients admitted with leg injury at risk of acute compartment syndrome will receive IscAlert sensor(s) in the anterior compartment of the lower limb. A duration of maximum 10 days.
89060417|NCT06079151|Experimental|Nasal high-flow 30 L/min and then 50 L/min|The patient will be placed successively under nasal high-flow 30 L/min during 20 min and then 50 L/min during 20 min.
89060418|NCT06079151|Experimental|Nasal high-flow 50 L/min and then 30 L/min|The patient will be placed successively under nasal high-flow 50 L/min during 20 min and then 30 L/min during 20 min.
89688903|NCT00955747|Placebo Comparator|Sugar Substitute Splenda|1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 g dissolved in 125 ml of water tid if problems still persisted, until patients adapted to treatment.
89688904|NCT00955747|Experimental|Tagatose|15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ml of water tid, if needed due to gastrointestinal effects, until patients adapt to the treatment
89688905|NCT02946892|Experimental|Carvedilol|Study participants will receive carvedilol for 12 weeks
89688906|NCT02946892|Experimental|Placebo|Study participants will receive placebo (sugar pill) for 12 weeks
89688907|NCT03017521|Experimental|TAS-117|TAS-117, 16mg, orally, daily
89688908|NCT00935857|Experimental|Balloon Colonoscopy|Colonoscopy using the single balloon colonoscopy system (novel endoscope to facilitate difficult colonoscopy).
89688909|NCT00935857|Active Comparator|Standard Colonoscopy|Colonoscopy using a standard adult colonoscope
89688910|NCT03017599|Experimental|Intervention group|EUS-FNB using 20-gauge procore needle
89688911|NCT01045421|Experimental|MLN8237 (Alisertib)|MLN8237 administered as an enteric-coated tablet (ECT)
89688912|NCT00936481||Healthy controls|18 years or older with body mass index between 25-45
89688913|NCT00936481||Obstructive Sleep Apnea Group|Age 18 years or older with body mass index between 25 and 45
89688914|NCT02947984|Experimental|Standard Treatment|Standard radiation therapy: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week.
89219851|NCT05217849|Experimental|Gentle, Mindful Movement|Participants will engage in a gentle, mindful movement class twice a week for 12 weeks. The classes will be one hour long and will be live-streamed over the internet. The mindful movement classes will combine elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
89219852|NCT05217849|Active Comparator|Health and Wellness Education|Participants will engage in bi-weekly 60 minute sessions of Health and Wellness Education classes. The classes will be held on-line for 12 weeks.
89219853|NCT05215132|Other|Patient w/ Contrast|Patients will add 15 minutes to their SOC MRI for research purposes
89219854|NCT05215132|Other|Patient no contrast|Patients will add 15 minutes to their SOC MRI for research purposes
89219855|NCT05215132|Other|Volunteer w/ contrast|Volunteers undergo 1 research MRI for research purposes
89219856|NCT05215132|Other|Volunteer no contrast|Volunteers undergo 1 research MRI for research purposes
89219857|NCT05206617||Limb Girdle Muscular Dystrophy type 2L|At baseline, 1- and 3-year follow up will the outcome measures be assessed. There will be no intervention.
89219858|NCT05205486|Experimental|Cefazolin 3gm Injection|Study drug will be administrated as an infusion over 30 minutes starting approximately 0.5 hours before surgery begins and following institutional guidelines on Day 1 (day of surgery). All subjects will have five (5) individual whole blood samples (4 mL each) collected for the estimation of cefazolin concentration in plasma at the following times after the start of the infusion: 0.5 (+/-10 min) end of infusion, 1 h (+/-15 min), 2 h (+/-15 min), 4 h (+/-15 min), and 8 h (+/-15 min).
89219859|NCT05203159|Experimental|ocean sound|The group that will listen to the ocean sound
89219860|NCT05203159|Active Comparator|control group|The group that will not listen to sound
89688915|NCT02947984|Experimental|Higher Dose Treatment|63 CGE in 35 treatments of 1.8 CGE given once a day, for five days of each week.
89688916|NCT03031639||Endoscopic|This group is the patients who underwent endoscopic approaches thyroidectomy.
89688917|NCT03031639||Conventional|This group is the patients who underwent conventional approach thyroidectomy
89688918|NCT03402425|Experimental|All included patients|A 18F-FET PET scan is performed
89688919|NCT02981641|Experimental|Intraoperative radiotherapy (IORT) Group|Radiotherapy (Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1) + Sequential chemotherapy
89688920|NCT02981641|Experimental|Concurrent Chemoradiotherapy (CCRT) Group|Three dimensional conformal radiation therapy (3D-CRT) (Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30) + Concurrent chemotherapy (Gemcitabine(GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d) + Sequential chemotherapy
89688921|NCT04377737|Other|RT-PCR Covid-19|
89688922|NCT02981563|Experimental|Time Together|"Time Together as described under Interventions"
89688923|NCT03402347|Experimental|Laser irradiation regimes|Non-ionising radiation intervention will be applied to skin explants
89688924|NCT03017365|Active Comparator|M-SRT|Machine-based stable resistance training. Exercising 'traditional' machine-based resistance training.
89688925|NCT03017365|Experimental|F-URT|Free weight unstable resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
89688926|NCT03017365|Experimental|M-ART|Machine-based adductor/abductor resistance training. Exercising with 'traditional' adductor/abductor machines.
89688927|NCT03402191|Active Comparator|L-arginine|l-arginine for pulmonary hypertension in patients with thalassemia.
89688928|NCT03402191|Active Comparator|Sildenafil|Sildenafil for pulmonary hypertension in patients with thalassemia.
89688929|NCT03402191|No Intervention|Control|No pulmonary hypertension
89688930|NCT03031561|Experimental|Diagnostic (standard ultrasound, MicroPure, biopsy)|Patients undergo grayscale and MicroPure ultrasound imaging followed by sonographic or stereotactic guided core needle biopsy or surgical resection. Surgical specimens are then x-rayed.
89688931|NCT03402113|Experimental|Dexmedetomidine group|Dexmedetomidine consistent infusion as sedative.
89688932|NCT03402113|Active Comparator|Midazolam group|Midazolam consistent infusion as sedative.
89688933|NCT04359355||Artificial Intelligence|
89688934|NCT03017209|Experimental|Locally-prepared bar|The bar is similar to one tested recently in a pilot study and is a locally prepared bar designed to facilitate growth and cognitive development. It will provide 300 kcal/day and will have ≈20-30% of energy from protein (of which 25-50% is from an animal protein source), 20-35% from total carbohydrate and ≈40-60% from fat. The bar will be fortified with vitamins and minerals to meet USAID recommendations for moderate malnutrition and Dietary Reference Intake recommendations for at-risk and healthy children of the ages studied, and at the same time will not exceed Upper Level nutrient recommendations for any micronutrient. Ingredients in the bar will be a combination of local products and imported shelf-stable ingredients.
89688935|NCT03017209|Active Comparator|USAID Corn Soy Blend Plus|The usual-intervention condition will be 300 kcal/day of USAID Corn Soy Blend Plus cooked in the usual manner with fortified vegetable oil (10:3 ratio) and sugar. The community health workers or other designated villagers will prepare the supplement freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
89688936|NCT03017209|Placebo Comparator|Locally-purchased rice|The placebo condition will be 300 kcal/day of locally-purchased rice cooked with a small amount of oil (10:2 ratio), which mimics the usual breakfast of children in this region. The community health workers or other designated villagers will prepare the rice freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
89688937|NCT01725191|Experimental|Treatment (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89688938|NCT03017443|Experimental|Nutrisystem My Way|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem My Way plan.
89688939|NCT03017443|Experimental|Nutrisystem Turbo 10|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem Turbo 10 plan.
89060419|NCT06079138|Experimental|Active tDCS and telerehabilitation exercise program|Participants will receive active tDCS with an intensity 2 mA for 20 minutes and a telerehabilitation exercise program for 50 minutes. The program will be implemented over 12 sessions, occurring three times a week for four weeks).
89060420|NCT06079138|Sham Comparator|Sham tDCS and Telerehabilitation exercise|Participants will receive sham tDCS for 20 minutes. The program will be implemented over 12 sessions, occurring three times a week for four weeks.
89060421|NCT06079125|Experimental|Posterior fossa decompression with duraplasty|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened. Microsurgical dissection is performed and the dura is sewn closed.
89060422|NCT06079125|Experimental|PFDD with tonsillar resection/reduction|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened and herniated tonsil will be manipulated. Microsurgical dissection is performed and the dura is sewn closed.
89060423|NCT06079112|Experimental|9MW2821+Toripalimab|
89060424|NCT06079086|Active Comparator|Group A - group with textured envelope|Group A - group with textured envelope
89060425|NCT06079086|Active Comparator|Group B - group with velvet/silicone foam envelope|Group B - group with velvet/silicone foam envelope
89060426|NCT06079073|Experimental|Application plus treatment module|"The following exercises are pre-recorded and presented in the treatment module:~Tongue~Tongue brushing~Tongue sliding~Tongue suction~Tongue down Soft palate~1. Elevate soft palate and uvula 2. Balloon blow Facial~Put your finger in the oral cavity against your cheek. Pull against your finger with the cheek muscles.~Air pump Exercise adherence is registered in a study application"
89060427|NCT06079073|No Intervention|Application awaiting access to treatment module|Participants receiving a code not unlocking the treatment module will have full access to all other parts of the mobile app. After 90 days, during the outcome evaluation, all participants will receive a new code unlocking the treatment module in order to keep outcome evaluators blinded.
89060428|NCT06079034||Venovenous ECMO|
89060429|NCT06079034||Venoarterial ECMO|
89060430|NCT06079008||survival group|The patients who survived more than 1-year after amputation surgery.
89060431|NCT06079008||mortality group|The patients who were dead within 1-year after amputation surgery.
89060432|NCT06078995||Tenecteplase|acute ischemic stroke patients who receive intravenous thrombolysis with tenecteplase
89060433|NCT06078995||alteplase|acute ischemic stroke patients who receive intravenous thrombolysis with alteplase
89060434|NCT06078982|Experimental|Combination of Disitamab Vedotin and Toripalimab|Participants will receive Disitamab Vedotin + Toripalimab every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
89060435|NCT06078956|Active Comparator|Investigational Device|
89060436|NCT06078956|Other|Predicate device|
89060437|NCT06078943|Active Comparator|Investigational Device|The test device in this clinical study is the ABL90 FLEX PLUS running SW3.5 MR2 manufactured by Radiometer Medical ApS The analyzer provides results for 17 parameters in 35 seconds using 65 µL heparinized whole blood. However, in this investigation only the data concerning the parameters ctBil and FHbF will be evaluated.
89688940|NCT03017443|Experimental|Nutrisystem DASH|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem DASH plan.
89688941|NCT03017443|Active Comparator|Dieting on Your Own (DIY) - DASH|All subjects provided publically available information on the DASH diet and instructed to follow a reduced calorie DASH diet meal plan on their own.
89522796|NCT03398525|Active Comparator|Usual care|After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
89688942|NCT01725347||African American Girls|-25% of sample is African American Girls
89688943|NCT01725347||African American Boys|-25% of sample is African American Boys
89688944|NCT01725347||Hispanic American Girls|-25% of sample is Hispanic American Girls
89688945|NCT01725347||Hispanic American Boys|-25% of sample is Hispanic American Boys
89688946|NCT04359043|Experimental|Mediational Intervention for Sensitizing Caregivers|Half of the child participants and the careworkers in the Community-based Organization taking care of them, received the Mediational Intervention for Sensitizing Caregivers.
89688947|NCT04359043|Other|Treatment as Usual|The other half of child participants and the careworkers in the Community-based Organization taking care of them, received Treatment as Usual which consists of the usual services delivered to children at the CBO: food, help with homework, registrations for birth certificates.
89688948|NCT00914069|Experimental|RIVS vascular access|RIVS vascular access
89688949|NCT00914069|Active Comparator|Conventional vascular access|Conventional vascular access
89688950|NCT03031405|Experimental|Oxytocin and trauma film paradigm|
89688951|NCT03031405|Placebo Comparator|Placebo and trauma film paradigm|
89688952|NCT03031249|Active Comparator|High Dose of Cytarabine|Patients receive high dose of cytarabine.
89688953|NCT03031249|Experimental|HDAC + ATRA + ATO|Patients receive high dose of cytarabine plus ATRA and ATO treatment.
89688954|NCT02980315|Experimental|CAR-T cells|the group treat with CAR-T cells
89688955|NCT02980315|No Intervention|placebo|the group treat with CAR-T cells
89688956|NCT02980393|Experimental|Lifestyle intervention|Participants are guided by a fitness specialist who will help the participants to incorporate physical activity into their daily life. Based on the cardiologist assessment, an individual home-based exercise program will be developed. Participants are also guided and advised on nutrition with emphasis on low fat content and increased fiber. The nutrition counseling will focus on sustainable changes and will help participants to make healthy food choices.
89060438|NCT06078943|Sham Comparator|Predicate device|"The predicate device for this study is the unmodified device ABL90 FLEX PLUS (k160153) running software SW 3.1 MR7 including sensor casettes and solution packs versions corresponding to 2016.~ABL90 FLEX PLUS SW 3.1 MR7, has been selected as the predicate device because it has the appropriate 510(k) clearance, and the intended use matches the ABL90 FLEX PLUS SW. SW3.5 MR2 device."
89060439|NCT06078930||Patients with gastric cancer|
89060440|NCT06078930||Healthy participants|
89060441|NCT06078891|Experimental|BCG vaccinated patients|A single arm experiment to examine the effect of 3 standard intradermal vaccinations with BCG (at times 0, 1 month and 12 months) on plasma biomarkers.
89060442|NCT06078878|Experimental|Neurovascular Imaging|"Use of the Gentuity HF-OCT Imaging System with Vis-M Micro-Imaging Catheter (Gentuity Neurovascular Imaging System) as a diagnostic tool for intravascular imaging in the cerebrovasculature."
89060443|NCT06078865||Subjects|Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions
89060444|NCT06078839|Placebo Comparator|Placebo control group|
89060445|NCT06078839|Experimental|Nafamostat mesilate treatment group (experimental group)|
89060446|NCT06078826|Experimental|passive music therapy group|"Intubated patients on mechanical ventilator hospitalized in the 3rd Stage Intensive Care Unit will be included in the intervention group 48 hours after admission. The data of the individuals will be collected by face-to-face interview method in the Ramsey Sedation Scale, Patient Identification Form, Patient Follow-up Form, Behavioral Pain Scale to determine the level of pain, and Facial Anxiety Scale to determine the level of anxiety at the first interview.~Before the tracheal aspiration procedure, passive music therapy will be applied for 30 minutes and throughout the aspiration, and during this application, music will be continued for approximately two more minutes (15 seconds of first aspiration, 30 seconds of break, 15 seconds of second aspiration) during both aspirations. Patient Follow-up Form, Behavioral Pain Scale and Face Anxiety Scale will be filled again during and after tracheal aspiration (30 minutes later)."
89060447|NCT06078826|Experimental|foot massage group|"Intubated patients on mechanical ventilator hospitalized in the 3rd Stage Intensive Care Unit will be included in the intervention group 48 hours after admission. The data of the individuals will be collected by face-to-face interview method in the Ramsey Sedation Scale, Patient Identification Form, Patient Follow-up Form, Behavioral Pain Scale to determine the level of pain, and Facial Anxiety Scale to determine the level of anxiety at the first interview.~Foot massage will be applied for 30 minutes before the tracheal aspiration process and throughout the aspiration, and the music will be continued for approximately two more minutes (15 seconds of first aspiration, 30 seconds of break, 15 seconds of second aspiration) during both aspirations. Patient Follow-up Form, Behavioral Pain Scale and Face Anxiety Scale will be filled again during and after tracheal aspiration (30 minutes later)."
89060448|NCT06078826|No Intervention|control group|"No intervention will be made to the control group, and the routine care practice of the clinic will be applied. Ramsey Sedation Scale, Patient Identification Form, Patient Follow-up Form, Behavioral Pain Scale to determine pain level, Behavioral Pain Scale to determine the level of anxiety, at the first interview 48 hours after hospitalization in intubated patients hospitalized in the 3rd Stage Intensive Care Unit. Data will be collected by face-to-face interview method, Face Anxiety Scale. Hemodynamic parameters will be recorded. Patient Follow-up Form, Behavioral Pain Scale and Face Anxiety Scale will be filled again during and after tracheal aspiration (30 minutes later)."
89060449|NCT06078800|Experimental|YL-17231|YL-17231 will be administrated orally from 0.25mg QD, 0.5mg BID to 10mg BID in sequence during dose excalation part and selected doses in dose expansion part,for 21 consecutive days as a treatment cycle
89060450|NCT06078787|Experimental|Olaparb|
89060451|NCT06078735|Experimental|LockeT|These are the patients assigned for LockeT device arm to close the access site wound.
89060452|NCT06078735|No Intervention|Manual compression|These are the patients assigned for Manual Compression arm to close the access site wound.
89060453|NCT06078722||Study Cohort|Patients taking Carnitine-Orotate Complex and BDD regardless of study participation. The duration of observation for taking COCs and BDD is 6 months, and the duration of follow-up is 6 months.
89060454|NCT06078722||Control cohort|Patients who do not take Carnitine-Orotate Complex and BDD, regardless of study participation. Duration of patient observation - 12 months.
89060455|NCT06078696|Experimental|Siplizumab|Participants will receive 5 infusions of siplizumab. The first dose is given 14 days prior to the infusion of stem cells; the second dose is given 6 days before infusion; and doses 3, 4, and 5 are given on the day before, day of, and day after stem cell infusion.
89060456|NCT06078683|Experimental|Ketone Ester|This arm will provide a Keto Ester Beverage for consumption.
89060457|NCT06078683|Placebo Comparator|Placebo|This arm will provide a Placebo Beverage for consumption.
89688957|NCT03016663||Breast Lipofilling Technique|Preliminary MRI breast were performed for volumetric measurement. Fat harvesting performed by same surgeon using water-assisted liposuction (WAL) and subsequent washing with buffered lactate in a standardized technique. Fat transfer performed using Berlin autologous lipotransplantation technique according to the BEAULI protocol .Patient were followed up monthly and MRI breast were repeated at 1st and 6th months after lipofilling. Clinical assessment and MRI Volumetric measurement performed using OsiriX (v7.0.3, 64 bit, Pixmeo c) software by same radiologist based on predefined operational procedure
89688958|NCT01042535|Experimental|Treatment (vaccine therapy, 1-methyl-d-tryptophan)|Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89688959|NCT03031327|Experimental|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
89688960|NCT03031327|Experimental|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
89688961|NCT03031327|Active Comparator|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
89688962|NCT01725503|Experimental|Creatine and amino acid supplement|
89688963|NCT03031171|Experimental|Navigated: Screening patient navigation|Clinic patients who received navigation
89688964|NCT03031171|Active Comparator|Non-Navigated|Randomly matched sample of non-navigated clinic patients
89060458|NCT06078683|Experimental|Keto Ester Acute|This arm will provide a Keto Ester Beverage for consumption.
89060459|NCT06078683|Placebo Comparator|Placebo Acute|This arm will provide a Placebo Beverage for consumption.
89060460|NCT06078670|Experimental|Triple Negative Breast Cancer|CVL218+Toripalimab+Paclitaxel For Injection (Albumin Bound)
89060461|NCT06078670|Experimental|Stomach cancer|CVL218+Sintilimab+Paclitaxel Injection
89060462|NCT06078670|Experimental|Intestinal cancer|CVL218+Sintilimab+Fruquintinib
89060463|NCT06078657|Experimental|IBI110 combined with Sintilimab|
89060464|NCT06078618||cohort|Mothers and their newborn babies (live or stillborn) who were delivered between 32 and 36 weeks' gestation
89060465|NCT06078605|Experimental|Nicotinamide(Mitovita)|Group2 Baseline-6week: (Mitovita: 1.0 g/day, QD) 6-12week: (Mitovita: 2.0 g/day, BID) Crossover 12-18week: (Placebo: 1.0 g/day, QD) 18-24week: (Placebo: 2.0 g/day, BID)
89060466|NCT06078605|Placebo Comparator|Placebo|Group1 Baseline-6week: (Placebo: 1.0 g/day, QD) 6-12week: (Placebo: 2.0 g/day, BID) Crossover 12-18week: (Mitovita: 1.0 g/day, QD) 18-24week: (Mitovita: 2.0 g/day, BID)
89060467|NCT06078592|Experimental|BRIDIN-plus Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
89060468|NCT06078592|Active Comparator|Combigan Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
89060469|NCT06077942||Subjects|Subjects implanted with the shoulder replacement medical devices manufactured by FX Shoulder Solutions and distributed by FX Shoulder Solutions.
89060470|NCT06077123|Experimental|Telemonitoring Platform|Patients allocated to the active intervention group will receive a smartphone application called Contigo. This tool aims to detect signs and symptoms of oncology drug toxicity and delivering educational content that enables the patient to have tools to address common clinical situations associated with the diagnosis and treatment of their disease.
89060471|NCT06077123|No Intervention|Traditional Follow-Up|Those assigned to the traditional follow-up group will receive standard care and in-person check-ups as determined by their attending physician.
89060472|NCT06076980|Placebo Comparator|Placebo group|placebo group (100 ml normal saline over 15 minutes)
89060473|NCT06076980|Experimental|bolus group|bolus group (1000mg/100 ml paracetamol over 15 minutes)
89060474|NCT06076980|Experimental|Extended infusion group|Extended infusion (1000mg/100 ml paracetamol over 3 hours)
89060475|NCT06076733|Experimental|active group|Twenty 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes per session, twice daily over 10 consecutive days, and the stimulus frequency was set as 6Hz.
89060476|NCT06076733|Sham Comparator|sham group|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
89060477|NCT06075784|Experimental|Reiki|The intervention will be applied to the reiki group to be applied in the application laboratory of the midwifery department of the faculty of health sciences. Reiki therapy will be applied by a practitioner with a Reiki application certificate in the application laboratory for 30 minutes while the participants lie down with their eyes closed. 4 sessions of reiki application will be applied to the intervention group for a month. Reiki application will start from the time of menstruation, the first pain scores and comfort conditions will be recorded. Menstruation and general comfort after 4 sessions will be recorded. Any medication and side effects during menstruation with the last reiki application will be recorded by the research team member.
89060478|NCT06075784|Placebo Comparator|Placebo reiki|Placebo Reiki will be applied to the participants in the group in the application laboratory of the midwifery department of the faculty of health sciences. The practice will be carried out in the application laboratory for 30 minutes, with the participants sitting with their eyes closed. Reiki life energy will not be transferred to participants in the placebo reiki group. Since the participants' eyes are closed, they will not know that there is a transfer. Placebo Reiki application will be performed in the laboratory 4 times during a month. Placebo application will start from the time of menstruation, and the first pain scores and comfort conditions will be recorded. After 4 sessions, menstruation and general comfort will be recorded. Any medication and side effects during menstruation with the last application will be recorded by the research team member.
89522797|NCT03398525|Experimental|Musical intervention|"After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.~In addition, a U-shaped music program (MUSIC CARE, trade mark) will be delivered to the patient through headphones throughout the catheter insertion procedure beginning with the operator's hand washing and ending once the dressing is put on the catheter insertion site."
89060479|NCT06075394||psoriasis patients|Patients with psoriasis in the Department of Dermatology, Xijing Hospital of Air Force Medical University from December 2012 to December 2022 were consecutively collected. Inclusion criteria: (1) age ≥18 years; (2) Clear diagnosis of psoriasis. Exclusion criteria: (1) age <18; (2) Hypertension caused by conditions such as primary hypertension, hyperthyroidism, chronic renal insufficiency, or Cushing's syndrome, which are severe endocrine system diseases; (3) Patients with autoimmune diseases, severe cardiovascular, hepatic, renal, or other major organ disorders, as well as blood disorders and endocrine system diseases.
89060480|NCT06075394||Healthy individuals|Healthy individuals being randomly selected healthy individuals from a medical examination center.
89060481|NCT06075329|Experimental|Contemplative Practice|Maitribodh Sambodh (MSD) is a unique form of contemplative practice which combines breath watch, mantra or vibrational sound chant, focused meditation followed by loving kindness or a gratitude exercise at the end.
89060482|NCT06075329|Other|Waitlist Control|The arm will eventually get the intervention.
89060483|NCT06074653|Experimental|Experimental group A|Subjects will receive 8 sessions of Mulligan Bent Leg Raise technique on dominant side
89060484|NCT06074653|Experimental|Experimental group B|Subjects will receive 8 sessions of PNF Contract Relax technique on dominant side
89060485|NCT06074640|Experimental|interventional group 1(MET PIR with Dry needling)|Participants of this group will be treated with a MET protocol, and a dry needling session for Calf muscles MTrPs. Home regimen of self stretches for Calf muscles and plantar fascia will be given to patients
89688965|NCT01725581||Inexperienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
89688966|NCT01725581||Experienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
89688967|NCT01725581||Junior Doctors|Pre Royal College of Obstetric and Gynaecology registered junior doctors with experience in Obstetrics and Gynaecology
89688968|NCT03031015|Experimental|Cemented K-wire Fixation|The mean age of group A was 41 years (range, 18-63 years). There were 56 male and 11 female patients. The mean time from injury to operation was 5±4.53 days. Injured digits included index (n=24), long (n=19), ring (n=9), and little (n=15) fingers. Types of fractures were transversal (n=31), oblique or spiral (n=14), and comminuted (n=22) fractures. The patients were treated with Cemented K-wire Fixation.
89688969|NCT03031015|Active Comparator|Plating|The mean age of group A was 39 years (range, 19-61 years). There were 51 male and 13 female patients. The mean time from injury to operation was 6±5.53 days. Injured digits included index (n=21), long (n=17), ring (n=10), and little (n=16) fingers. Types of fractures were transversal (n=34), oblique or spiral (n=11), and comminuted (n=19) fractures.The patients were treated with Plating.
89688970|NCT03401957||RAS wild-type colorectal cancer|RAS mutation of patients who are pathologically diagnosed as metastatic colorectal cancer with RAS wild type genotyping will be evaluated using liquid biopsy during cetuximab treatment.
89688971|NCT04358965|Experimental|intravenous tranexamic acid|patients were given a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision plus one vaginal placebo tablet 1 hour before skin incision
89688972|NCT04358965|Active Comparator|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
89688973|NCT04358965|Placebo Comparator|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
89688974|NCT04358653|Experimental|fall prevention exercise program|The experimental group was designed to undergo supervised exercise 2 days a week for 8 consecutive weeks for 45-50 min/session. The intervention program was implemented at the nursing home facilities.
89688975|NCT04358653|No Intervention|Control Group|The control group did not receive any intervention during that period and were instructed to pursue their habitual daily life activities.
89688976|NCT01041287|Active Comparator|Nebivolol/ Metoprolol|"Subjects were randomized to nebivolol for 3 months. They crossed over to take 3 months of metoprolol succinate. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
89688977|NCT01041287|Active Comparator|Metoprolol/Nebivolol|"Subjects were randomized to metoprolol succinate for 3 months. They crossed over to take 3 months of nebivolol. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
89688978|NCT04358731|Experimental|NmCV-5|"A total of 1640 subjects 18 to 85 years of age will be accrued contemporaneously across three age groups - 18 to 29 years, 30 to 60 years, and 61 to 85 years.~Within each age group subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.~The NmCV-5 subjects in 18-29 year age group will be further randomized 1:1:1 into three different lots (Lot A, B & C) of NmCV-5.~Total 1230 subjects will be enrolled in NmCV-5 arm."
89688979|NCT04358731|Active Comparator|Menactra|"Subjects will be randomly assigned in a 3:1 ratio to receive either NmCV-5 or Menactra.~In Menactra arm, total 410 subjects will be enrolled."
89688980|NCT03401801|Active Comparator|4 ml of 1% lidocaine|Procedure: 4 ml of 1% lidocaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
89688981|NCT03401801|Active Comparator|6 ml of 1% lidocaine|Procedure: 6 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
89688982|NCT03401801|Active Comparator|8 ml of 1% lidocaine|Procedure: 8 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
89688983|NCT03401723|Other|Novices|"Any physician who has no experience of endoscopies or has done no more than 50 colonoscopies.~Each subject included are to perform on the Endoscopy Training System (ETS) during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
89060486|NCT06074640|Experimental|interventional group II (MET PIR without dry needling)|participants will follow the same MET PIR exercises but without adjunct dry needling for Calf muscles. Home regimen of self stretches for Calf muscles and plantar fascia will be given to patients
89060487|NCT06074393|Experimental|Care partners of patients with advanced Parkinsonian Syndromes|Care partners of patients with advanced Parkinsonian Syndromes will participate in a tailored support group
89060488|NCT06074289|Experimental|Family connections program|In each centre, caregivers are consecutively assigned to a group intervention including from 10 to 12 participants.
89060489|NCT06073002|Experimental|Home-based concurrent training|Combination of resistance training (5 exercises with bodyweight and/or resistance bands; 3 sets per exercise, 15-20 repetitions) and endurance training (mode of choice, light to moderate intensities which are monitored via heartrate zones, 20-40min per sessions); 3 weekly sessions on non-consecutive days
89060490|NCT06072456|Experimental|lateral suspension|Suspending the cervix to the bilateral abdominal wall through subperitoneal tunnels may properly mimic cardinal ligament and restore the normal vaginal axis. Preoperative and postoperative MRI results were evaluated
89060491|NCT06072456|Experimental|pectopexy|The cervix or vaginal cuff was suspended by the Cooper ligament.Preoperative and postoperative MRI results were evaluated
89060492|NCT06072456|Experimental|sacrospinous ligament fixation|vaginal cuff/uterus was sutured to the unilateral sacrospinous ligament.Preoperative and postoperative MRI results were evaluated
89060493|NCT06072456|No Intervention|hysterectomized patients|Vaginal axis MRI of women who have previously been hysterectomized and who do not have apical prolapse
89060494|NCT06072456|No Intervention|Nulliparous women|MRI of nulliparous women was evaluated for vaginal axis.
89060495|NCT06072287||Participants|Participants will answer two short questionnaires, 1 week apart.
89688984|NCT03401723|Other|Experienced|"Includes any physician who have succeeded more than 140 colonoscopies. Professional backgrounds include surgeons and gastroenterologists.~Each subject included are to perform on the ETS during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
89060496|NCT06072209|Experimental|Behavioral Activation|14 days of daily excercises
89060497|NCT06072209|Experimental|Mindfulness and Gratitude|14 days of daily excercises
89688985|NCT00955903|Experimental|Weight Loss|Participants receive Exercise and Reduced Calorie Diet Interventions
89060498|NCT06072209|Experimental|Combination: Behavioral Activation and Mindfulness and Gratitude|14 days of daily excercises
89060499|NCT06072209|No Intervention|Waitlist control group|Will receive the intervention (combination) after two weeks of intervention time of the other groups.
89060500|NCT06070961||Patients enrolled|Patient affected by advanced Follicular Lymphoma undergoing front-line immunochemotherapy and antiCD-20 maintenance in the FIL_FOLL19 trial
89060501|NCT06070350|Other|Group 1 (LTOWB+TXA)|Concurrent administration of LTOWB and TXA.
89060502|NCT06070350|Other|Group 2 (LTOWB+Placebo)|Concurrent administration of LTOWB and Placebo
89060503|NCT06070350|Other|Group 3 (TXA+CT)|Concurrent administration of TXA and CT
89688986|NCT00955903|Active Comparator|Control|Participants receive Exercise Intervention
89060504|NCT06070350|Other|Group 4 (CT+Placebo)|Concurrent administration of CT and Placebo
89060505|NCT06069596|Active Comparator|Study group|obstetric lubricant gel was applied to patients in the study groups, which had 47 nulliparous and 50 primiparous patients.
89060506|NCT06069596|No Intervention|Control group|obstetric lubricant gel was not applied to patients in the control groups, which had 55 nulliparous and 43 primiparous patients.
89688987|NCT00955903|Active Comparator|Weight Maintenance|Participants receive Exercise and a Weight Maintenance Diet Interventions
89688988|NCT04376879||Step 1: creation of the score|Cohort for the creation of clinical-biological score to predict the risk of intubation in COVID-19
89688989|NCT04376879||Step 2: validation of the score|Cohort for the validation of clinical-biological score to predict the risk of intubation in COVID-19
89688990|NCT03016585|Experimental|Tai Chi Training|Tai Chi exercises 3 times per wk for 12 weeks
89688991|NCT03016585|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 weeks.
89688992|NCT03401021||Crrent Male smokers|"Male smokers met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).~be aged 18 or above,~have a history of smoking at least one cigarette per day before their partners became pregnant,~be involved with partners whose pregnancies could be confirmed,~able to read Chinese and communicate in the Mandarin dialect."
89688993|NCT04358887|Experimental|periapical surgery with piezo.|After flap reflection bone and root end cutting are done with US6 piezoelectric surgical insert
89688994|NCT04358887|Active Comparator|Periapical surgery with bur.|After flap reflection bone and root end cutting are done with surgical bur.
89688995|NCT03400865|Experimental|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.
89688996|NCT03031093|Experimental|Healthy, non obese + HFNC|Healthy, non obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
89060507|NCT06068660|Experimental|The experimental group|The experimental group during hospitalization additionally received 40 minutes of one-on-one education three times a week for three weeks, as the Goal-Oriented Care program for 6 hours in total, followed by telephone sessions of 20 minutes every month for six months post-discharge.
89060508|NCT06068660|Active Comparator|The control group|The control group received routine health education
89060509|NCT06068582|Experimental|Strengthening the brain|Participants receive 30 minutes of 1-on-1 fitness training, dietary advice, and mental coaching, in addition to twice 20 minutes fitness at home, and 60 minutes of cognitive training each week for four months.
89060510|NCT06068582|Experimental|Strengthening the mind|Partiicpants receive biweekly 1-on-1 coaching by a trained work-coach who has MS to identify challenges at work and implement solutions. It is completed when satisfactory solutions have been implemented for all challenges or after four months.
89219865|NCT05195138|Experimental|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education (MBDE) will be delivered in-person in a group of 10-14 participants during 8 weekly sessions followed by 2 bimonthly individual sessions. Sessions integrate Mindfulness-Based Stress Reduction and Diabetes Self-Management Education. MBDE will introduce breath awareness meditation, body scan, walking meditation, mindful yoga, and applying mindfulness to daily activities, as well as core areas from DSME. MBDE will include incremental goal setting to build participants' self-efficacy for diabetes self-management behaviors, mindful attention to diabetes self-management, and on development of social support in the group. Participants will complete daily home mindfulness exercises and self-monitoring of diabetes self-management behaviors.
89219866|NCT05195138|Active Comparator|Standard Diabetes Self-Management Education|Standard DSME will be delivered in-person, in a group setting with 10-14 participants per group. Standard DSME will be delivered by a certified diabetes educator in eight weekly sessions of 2 hours duration. Sessions will cover seven core content areas - healthy eating, physical activity, medication usage, self-monitoring, preventing and treating acute and chronic complications, healthy coping, and problem solving.
89219867|NCT05193500|Active Comparator|Addressed|Children participate in an interaction with an experimenter who uses the word to be learned.
89219868|NCT05193500|Experimental|Overheard|Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.
89219869|NCT05193149|Experimental|4 wk IMT + 12 wk exercise|4 weeks of IMT, 3/week, 3 sets of 15 repetitions, intensity up to 70% of MIP using a pressure threshold device PLUS 12 weeks of aerobic exercise training including cycling, walking, elliptical, starting in week 5, 3/week, up to 50min per session, moderate intensity
89219870|NCT05193149|Sham Comparator|4 wk SHAM + 12 wk exercise|4 weeks of SHAM training, 3/week, 3 sets of 15 repetitions, intensity up of 10% of MIP using a pressure threshold device PLUS 12 weeks of aerobic exercise training including cycling, walking, elliptical, starting in week 5, 3/week, up to 50min per session, moderate intensity
89219871|NCT05192603|Experimental|Dietary intervention with Low FODMAP|The participants are given oral and written instructions on which diet that contains low contents of FODMAP.
89219872|NCT05192603|Experimental|Dietary intervention with SSRD|The participants are given oral and written instructions on which diet that contains SSRD.
89219873|NCT05188807|Experimental|The patient with cervical pathology|we will perform airway ultrasonography before the patients intubations and we will intubate the patients before cervical surgery
89219874|NCT05185115|Experimental|Intervention group (A)|Patients treated with 3 liters per minute oxygen delivered via nasal cannula duration hospitalization
89219875|NCT05185115|Other|Control group (B)|No oxygen therapy during hospitalization
89219876|NCT05184621|Active Comparator|efficacy|Including Primary outcome: changes in axial length of the eye. Secondary outcome: Equivalent spherical lens variation Other indicators: ① Changes in visual acuity with lenses, corrected visual acuity, and intraocular pressure.② Observation of changes in corneal thickness, anterior chamber depth, ciliary body thickness, and crystal thickness.Observation of fundus tissue structure of macula and peri-optic disc area. Observation of fundus choroidal/retinal thickness.Adherence index: frequency of device use.
89219877|NCT05184621|Active Comparator|safety|"Description of safety parameters: Adverse events, device defects during the test.~Method and time selection for evaluation, recording, and analysis of safety parameters. Adverse events and device defects were recorded from the beginning of each subject's enrollment to the end of the group for evaluation. Safety indicators:① Incidence of allergic reactions.② Posterior image time more than 5 minutes.③ The decrease of near vision.④ The grade of side effects such as self-induced photophobia and blurred vision.⑤ Elevated intraocular pressure, headache, nausea, and vomiting, etc."
89219878|NCT05183776|Experimental|Study patients|study patients will receive holmium radioembolization using a novel administration device.
89219879|NCT05178862|Experimental|IV echinocandin followed by oral ibrexafungerp (SCY-078)|
89219880|NCT05178862|Active Comparator|IV echinocandin followed by oral fluconazole|
89060511|NCT06068582|No Intervention|Enhanced usual care|Participants receiving general information about cognitive impairment in MS and following care as usual for four months.
89060512|NCT06066190|Experimental|Experimental: web based training|Web-Based Training will be given to midwives and nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
89060513|NCT06065007||Swedish cohort of persons with Systemic Mastocytosis|We aim to include all individuals with a diagnosis of SM in Sweden, by identification via either one the two centers of excellence of mastocytosis or by a regional representative for the mastocytosis group in Sweden.
89060514|NCT06064448|Active Comparator|Western Medicine Section (Sildenafil)|"Sildenafil is an effective and commonly used oral PDE5 inhibitor in the treatment of ED.~In this study, the subjects in the western medicine group will take sildenafil citrate orally, 25mg/capsule, once a night, one capsule each time for 4 weeks."
89060515|NCT06064448|Experimental|Traditional Chinese medicine group (Ningmitai capsule)|"Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of Urinary and reproductive system disease (eg. CP/CPPS, ED) in China for more than twenty years.~In this study, the subjects took Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd., Sinopharm Zhunzi Z20025442), 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals for 4 weeks."
89060516|NCT06064448|Experimental|Combined group (Ningmitai capsule + sildenafil)|In this study, the subjects will take Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd., Sinopharm Zhunzi Z20025442), 0.38 g/capsule, 4 capsules each time three times a day, after meals; Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
89060517|NCT06064032|Active Comparator|cognitive behvioral therapy|The subjects in the control group will be given a 10 minute session of Progressive Muscle Relaxation (PMR) 2 minutes deep breathing exercises and 3 minutes training for life style modification which includes the use of planners, setting alarms, breaking a difficult task into parts, positive reinforcement and communication. This would be taught for 15 days at one day interval.
89060518|NCT06064032|Experimental|motor learning techniques|"The subjects in the experimental group will be given a 10 minute session of Progressive Muscle Relaxation (PMR), 2 minutes deep breathing exercises,3 minutes training for life style modification which includes the use of planners, setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with a 3 minute session of drawing a specific pattern with installing pegs on pegboard, 2 minutes session of balance board training, 3 min session of solving jigsaw puzzles, 1 minute session of squeezing a ball with maximum repetition and 1 minute session of finding beads in puttey.~This would be taught for 15 days at one day interval."
89060519|NCT06061250|Experimental|Gum group|This group of patients will receive a piece of Xylitol gum (LOTTE WELLFOOD, Korea) 10 minutes before induction of anesthesia. Patients will chew it for 2 minutes and spit out. Other anesthetic care will follow routine protocol of the hospital.
89060520|NCT06061250|No Intervention|Control group|This group of patients will instructed to swallow their saliva twice 10 minutes before induction of anesthesia. Other anesthetic care will follow routine protocol of the hospital.
89060521|NCT06054893|Experimental|Part A - Cohort 1|Part A - Cohort 1 will contain patients ≥12 to <16 years of age. Patients will receive a single oral dose of 150 mg omaveloxolone.
89060522|NCT06054893|Experimental|Part A - Cohort 2|Part A - Cohort 2 will contain patients ≥12 to <16 years of age. Patients will receive a single oral dose of omaveloxolone at a dosage level determined by a Bayesian population pharmacokinetic (popPK) analysis using the data from Part A - Cohort 1 to select the dose.
89060523|NCT06054893|Experimental|Part B|Part B will contain patients ≥6 to <12 years of age and will initiate in parallel with Part A - Cohort 2. Patients will receive a single oral dose of omaveloxolone at a dosage level determined by a Bayesian population pharmacokinetic (popPK) analysis using the data from Part A - Cohort 1 to select the dose.
89060524|NCT06054893|Experimental|Part C|Part C will contain patients ≥2 to <6 years of age. Subjects will receive a single oral dose of omaveloxolone at a dosage level determined by a Bayesian population pharmacokinetic (popPK) analysis using the data from Part A and Part B to select the dose.
89060525|NCT06041269|Experimental|Rosnilimab SC Dose 1|This arm will receive treatment SC
89060526|NCT06041269|Experimental|Rosnilimab SC Dose 2|This arm will receive treatment SC
89060527|NCT06041269|Experimental|Rosnilimab SC Dose 3|This arm will receive treatment SC
89060528|NCT06041269|Placebo Comparator|Placebo|This arm will receive Placebo
89060529|NCT06040697||Usability Assessment Cohort|No interventions administered. Device usability assessment only.
89060530|NCT06028035|Experimental|BB01 Supplement Bars|Subjects will consume two BB01 supplement bars daily for 21 days.
89060531|NCT06026254|Experimental|Combination Therapy|IMSA101 + ICI
89060532|NCT06019676||Patients with mHSPC and treatment decision for apalutamide by clinician|
89060533|NCT06018818|Other|Amvia pacemaker or CRT-P implantation|
89060534|NCT06016478|Experimental|L-citrulline|6 grams/day
89060535|NCT06016478|Placebo Comparator|Placebo|Microcrystalline cellulose
89060536|NCT06006741|Experimental|Universal CART cells to treat MM|
89060537|NCT06000774|Experimental|Therapeutic Ketogenic Diet|A 2-week therapeutic ketogenic diet (TKD) induction will be implemented to establish nutritional ketosis (the goal are BHB blood levels of 0.5-3.0 millimoles per liter [mmol/L]). After establishing the ketotic state, study participants will continue TKD for 12 weeks.
89060538|NCT05997329|Experimental|MyFood (App for diet record)|Use of an App for diet record
89060539|NCT05997329|No Intervention|Usual care|Usual care
89060540|NCT05988697||Observation group|Primary IIIB-IV BRAF V600E mutated advanced non-small cell lung cancer in a population of patients with advanced lung cancer proposed to be treated with Trametinib， Dabrafenib and Asprin
89060541|NCT05978791||Hospitalized patients with suspected coronary artery disease|Take aspirin and ticagrelor maintenance dose ≥3 days, or loading dose of aspirin (300mg) and ticagrelor (180mg) ≥12 hours
89060542|NCT05978791||healthy volunteers|Age 18-75 years old, body weight ≥45kg, regardless of gender;
89060543|NCT05977192|Experimental|Standard MI|
89060544|NCT05977192|Experimental|Intensive MI|
89060545|NCT05977192|Experimental|MOTIVACC|
89060546|NCT05975450|Experimental|Abatacept|Participants will be assigned to a treatment regimen between 2 and 5 months after transplantation. The study drug will be administered until month 12 post-transplant; at that point, all participants will be transitioned to a physician-directed immunosuppressive regimen post-study.
89219881|NCT05174468||Screen-eligible Subjects|High-risk for lung cancer population who meet the USPSTF eligibility. One 10-L breath sample will be collected from each subject. During breath collection, subjects will be asked to exhale into a portable breath sampling device through a single use filter. Subjects will not be contacted to donate additional/serial breath specimens after the initial breath samples. Subjects will fill out a medical questionnaire and medical records will also be reviewed to extract low-dose CT scan (LDCT) screening results and any additional tumour-related information including histologic subtype, tumor stage, and sites of disease.
89219882|NCT05171153||IBD group|Subjects over 21 years old, with inflammatory bowel disease (both ulcerative colitis and Crohn's disease), diagnosed by clinical, biochemical, endoscopic and anatomo-pathological criteria.
89219883|NCT05171153||Control group|Subjects over 21 years old, without IBD or known metabolic bone disease, recruited voluntarily in the Endocrinology and Nutrition, Digestive System and Rheumatology departments of the Ruber Juan Bravo Hospital, during routine health control visits
89219884|NCT05170074||SRS implant|Surgical reconstruction of the anterior and apical compartment of the pelvic floor with an SRS implant
89219885|NCT05165888|Experimental|Communication and Bias Mitigation Training|This is a communication training session based on a culturally-based program developed with rural, southern Black patients and families and modified for an urban, northern population. A strategy of bias mitigation successfully used with medical students will be adapted for practicing clinicians using results of phase 1. This strategy is based on transformational learning theory and incorporates critical reflection, guided dialogue, perspective taking exercises, role plays and strategy development. If specific communication behaviors are found related to bias and stereotyping in phase 1, these will be discussed and targeted using these techniques. Otherwise, these techniques will be used to address racial bias generally. The intervention will be incorporated within the communication training session.
89219886|NCT05165888|Active Comparator|Communication Training Only|This is a communication training session based on standard palliative care techniques to listen empathically, share prognostic information and treatment options, elicit patient and family goals and values related to their treatment, and facilitate shared decision-making regarding end-of-life treatment.
89219887|NCT05163353|Experimental|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
89219888|NCT05163353|Other|Delayed treatment with diluted Radiesse|Delayed injection of Décolleté Wrinkles with diluted Radiesse
89219889|NCT05162664|Other|Healthy controls|Healthy controls
89219890|NCT05162664|Other|Patients with migraine|
89219891|NCT05157438|Experimental|Group I (virtual reality group)|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, the system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment.
89219892|NCT05157438|Active Comparator|Group II (screen program group).|the screens shows such as cartoons, animation movies or recorded video games are used for distraction during dental treatments. They could be seen on tablets, iPads or LCD screen.
89219893|NCT05155449|Active Comparator|Probiotics|Two capsules per day for 8 weeks
89219894|NCT05155449|Placebo Comparator|Placebo|Two capsules per day for 8 weeks
89219895|NCT05143567|Experimental|patients with COVID-19 without thrombotic complications|Group I: 50 patients with confirmed coronavirus infection without thrombotic complications
89219896|NCT05143567|Experimental|patients with COVID-19 and VTE who received pharmacological prophylaxis of VTE|Group II: 50 patients with confirmed coronavirus infection with thrombotic complications confirmed by ultrasonography with pharmacological prophylaxis of VTE
89219897|NCT05143567|Experimental|patients with COVID-19 and VTE who received pharmacomechanical prophylaxis of VTE|Group III: 50 patients with confirmed coronavirus infection with ultrasound-confirmed thrombosis of the deep and saphenous veins of the lower extremities using pharmacomechanical prophylaxis of VTE.
89219898|NCT05139563|Sham Comparator|Placebo injection|This group will first receive 3 mL intramuscular injections of a 20% fat emulsion (Intralipid 20%) every 2 months for 6 months.
89219899|NCT05139563|Experimental|Placebo implant|This group will first receive a single-use subdermal implant in the inner side of the upper arm for a duration of 6 months before removal.
89219900|NCT05138549|Placebo Comparator|Control: Placebo Group|Patients will receive a 6 week daily oral supply of placebo, identical in appearance to the astaxanthin supplement.
89219901|NCT05138549|Active Comparator|Experimental: Astaxanthin Supplementation Group|Patients will receive a 6 week daily oral supply of 12 mg astaxanthin supplement.
89219902|NCT05137743|Experimental|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia (CBT-I).
89219903|NCT05137743|Active Comparator|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
89219904|NCT05135377||Children with Anaphylaxis|Patients under 18 years of age presenting to the Emergency Department (ED) with an allergic reaction that matches diagnostic criteria for anaphylaxis.
89060547|NCT05974592|Experimental|Intervention Group|"To the participants in the intervention group; the Diabetic Foot Self-Management Training Program (DFSMTP) will be implemented. Printed, visual, and audio training materials will be used within this training program's scope. Training will be held in the Diabetes Education Room in line with the content of DFSMTP prepared by the researcher after determining the appropriate day and time with the participants. Written (training booklet) and visual (computer and PowerPoint presentation) training materials will be used during this training. The printed training booklet will be delivered to the participants at the end of the training. DFSMTP will be held in three sessions on the same day. In order to reinforce the learning of the participants in the intervention group, DFSMTP will also be video recorded with the presentation of the researcher and this recording will be transferred to the DFSMTP YouTube channel to be created by the researcher."
89060548|NCT05974592|No Intervention|Control Group|To the participants in the control group; General information about the anatomy and physiology of the pancreas will be explained with the verbal lecture technique. Participants in this group will receive the training only once. Following the completion of the research, the printed training booklet and YouTube channel link information will be shared with the participants.
89060549|NCT05949619|Experimental|Study treatment|Participants receive BL-M02D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89060550|NCT05945966|Experimental|experimental group|In this group stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side
89060551|NCT05945966|Active Comparator|control group|In this group stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
89060552|NCT05944471|No Intervention|Control group|The Inadequate Milk Perception Scale was administered to the mothers to determine the mothers who thought that their milk was inadequate by face-to-face interview method before discharge from the hospital after delivery. Mothers with low scale scores were randomly assigned to the control group as described in the intervention group. Then, Personal Information Form-1, Tendency to Discontinue Breastfeeding Scale and Breastfeeding Self-Efficacy Scale were applied to the mothers. The mothers determined as the control group were called by the investigators via telehealth application between the 2nd-5th days, 13th-17th days, 38th-40th days, 2nd-3rd months, 4th-5th months and at the end of the 6th month and the relevant forms were applied again. No intervention was made to the mothers in the control group.
89060553|NCT05944471|Experimental|Intervention Group|"Insufficient Milk Perception Scale, Personal Information Form, Tendency to Discontinue Breastfeeding Scale and Breastfeeding Self-Efficacy Scale were also administered to the mothers. After discharge, training videos and written documents were sent to the mothers individually via telehealth application once a week. Visualised messages explaining breastfeeding and that breastmilk is sufficient for the baby were also sent via telehealth application five days a week. Mothers were video-called between 10.00-17.00 on weekdays and live support was provided by the investigators. Mothers in the intervention group were called via telehealth application between the 2nd-5th days, 13th-17th days, 38th-40th days, 2nd-3rd months, 4th-5th months and at the end of the 6th month postpartum and the relevant forms were applied again. In addition, the qualitative questions in the Semi-structured Interview Form were asked at the end of the 6th month."
89060554|NCT05943821|Active Comparator|Allopurinol|The patients will receive allopurinol at an initial daily dose of 200 mg. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100 mg (up to 300 mg during V2). Similarly, the dose may be increased by another 100 mg at visit 3 and by another 100 mg at the visit 4 (up to 500 mg during V4).
89060555|NCT05943821|Placebo Comparator|Placebo|The patients will receive placebo at an initial daily dose of 200 mg. The dose may be increased by another 100 mg at visit 3 and by another 100 mg at the visit 4 (up to 500 mg during V4).
89060556|NCT05940610|Experimental|MSC-EV group|On the basis of standard medical treatment, an additional injection of MSC-EVs will be received by participants once a week for 4 weeks while hospitalized.
89060557|NCT05940610|No Intervention|Non-MSC-EV group|In the non-MSC-EV group, patients will receive standard medical treatment and 100ml saline as a control.
89060558|NCT05939362|Experimental|patient with early onset Alzheimer's disease|
89060559|NCT05938543|Experimental|Active cerebellum rTMS|Cerebellar targeted iTBS, once daily, one week
89060560|NCT05934708|Experimental|Low estrogen; low progesterone|Participants will come in while on their period. During this time estrogen and progesterone concentrations are low.
89060561|NCT05934708|Experimental|High estrogen; low progesterone|Participants will come in just before ovulation, when estrogen concentrations are high and progesterone concentrations remain low.
89060562|NCT05934708|Experimental|Medium estrogen; high progesterone|Participants will come in just after ovulation when estrogen concentrations are at a medium level, and progesterone concentrations are high.
89060563|NCT05911074||The SD Biosensor COVID-19 Ag test kit|This is one of the Investigational product or medical device(s) intended to be used with a study participant according to the study protocol
89060564|NCT05898412||Andexanet alfa|Hospitalized patients treated with andexanet alfa
89060565|NCT05891327|Experimental|Maca group|
89060566|NCT05891327|Placebo Comparator|Placebo group|
89060567|NCT05881668|Experimental|MSC-EV group|After liver transplantation, on the basis of postoperative standard treatment (anti-infection treatment, immunosuppressive treatment, nutritional support treatment, etc.), an additional injection of MSC-EV will be received between the 1st and 5th days after transplantation
89060568|NCT05881668|No Intervention|Non-MSC-EV group|After liver transplantation, patients will receive postoperative standard treatment (anti-infection treatment, immunosuppressive treatment, nutritional support treatment, etc.)
89060569|NCT05878951|Experimental|Intra-detrusor OnabotulinumtoxinA Injection|Injection of intra-detrusor OnabotulinumtoxinA into the bladder will be performed.
89060570|NCT05878951|No Intervention|No intra-detrusor OnabotulinumtoxinA Injection|Injection of intra-detrusor OnabotulinumtoxinA into the bladder will not be performed.
89060571|NCT05878080|Experimental|FPl-TMS|Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.
89060572|NCT05878080|Experimental|MFG-TMS|Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.
89060573|NCT05878080|Active Comparator|S1-TMS|Transcranial magnetic stimulation to the primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 2 seconds repeated every 10 seconds at 80% of active motor threshold.
89060574|NCT05870748|Experimental|Part 1: Luveltamab tazevibulin dose cohort A|5.2 mg/kg q3w with prophylactic pegfilgrastim for 2 cycles followed by 4.3 mg/kg q3w for cycle 3 onwards
89060575|NCT05870748|Experimental|Part 1: Luveltamab tazevibulin dose cohort B|4.3 mg/kg q3w
89060576|NCT05861115|Experimental|Software diagnosis|Software diagnosis with gold standard of echocardiography.
89060577|NCT05857592|Experimental|Experimental|Persons with Mild Intellectual Disability (MID) or Borderline Intellectual Functioning (BIF) complete the ABAS-3 in assisted form on two occasions: the original version the first time and an adapted version after a few weeks.
89060578|NCT05855369|Active Comparator|Combination Trigeminal Nerve Stimulation (TNS) and active Smell Training (ST)|30 minutes of once/day TNS and twice/day ST conducted 5 days/week for 12 weeks and a total of 60 stimulation and 120 smell training sessions
89060579|NCT05855369|Active Comparator|Active Smell Training (ST)|5 minutes of daily ST conducted twice/day, 5 days/week for 12 weeks and a total of 120 training session
89060580|NCT05855369|Placebo Comparator|Placebo Smell Training (PBO)|5 minutes of daily PBO conducted twice/day, 5 days/week for 12 weeks and a total of 120 training sessions
89060581|NCT05850533|Experimental|Tai Chi Easy Intervention|8-week/16-session virtual Tai Chi Easy (vTCE) intervention for adults with OUD, anxiety, and chronic pain
89060582|NCT05850312|Experimental|Round 1|Initially the aim is to recruit 5 clinicians to play the existing MoM game in a controlled environment. The goal is to congregate their collective feedback about the existing game as well as additional features that needs to be implemented to comprise Exposure Therapy to treat OCD with cleanliness. In addition, a feasibility analysis will be conducted to the proposed gameplay described in section 3.1.1. With these assessments, implementation process will be initiated.
89060583|NCT05850312|Experimental|Round 2|A second round of data collection will be conducted with a sample size of 10 subjects (5 clinicians and 5 non-clinician adults). In this second round it is intended to recruit both clinicians and non-clinicians as participants of the study. In the first phase of this study, the clinicians will play the game MoMG to carefully review the revised version of the game. In the second phase the non-clinicians will play the game in presence of clinicians with a goal to ensure that this game does not harm and the gameplay is enjoyable to the participants. While recruiting the non clinicians, it will be ensured via screening that none of the the participants have OCD or other germaphobia.
89060584|NCT05848180|Experimental|Iinterventional group|Ankle proprioceptive and balance training 3 days a week for 8 weeks.
89060585|NCT05848180|Active Comparator|control group|Balance training 3 days a week for 8 weeks.
89060586|NCT05838742|Experimental|GSK3858279 Dose 1|Participants will receive GSK3858279 dose 1.
89060587|NCT05838742|Experimental|GSK3858279 Dose 2|Participants will receive GSK3858279 dose 2.
89060588|NCT05838742|Experimental|GSK3858279 Dose 3|Participants will receive GSK3858279 dose 3.
89060589|NCT05838742|Experimental|GSK3858279 Dose 4|Participants will receive GSK3858279 dose 4.
89060590|NCT05838742|Placebo Comparator|Placebo|Participants will receive placebo.
89060591|NCT05837806|Experimental|tislelizumab+disitamab-vedotin|
89060592|NCT05828654|Other|Single Arm|Community representatives
89060593|NCT05827874|Experimental|Active Arm:|Participants will receive Nipocalimab loading dose intravenous (IV) infusion at Week 0 followed by tetanus, diphtheria, pertussis (Tdap) and pneumococcal polysaccharide vaccine (PPSV23) vaccine challenge as an intramuscular (IM) injection on Day 3 of Week 0 and additional doses of Nipocalimab IV at Week 2 and 4.
89060594|NCT05827874|Other|Control Arm:|Participants will receive PPSV23 and Tdap vaccine challenge as an IM injection on Day 3 of Week 0.
89060595|NCT05824728|Experimental|AGB101 first, then placebo|AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) once daily for 6 weeks, washout (4 weeks), then placebo capsule once daily for 6 weeks.
89060596|NCT05824728|Experimental|placebo first, then AGB101|Placebo capsule once daily for 6 weeks, washout (4 weeks), then AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) once daily for 6 weeks.
89060597|NCT05821959|Experimental|Cohort 1a and Cohort 1b|"Cohort 1a: Participants aged 7 to 17 years old (inclusive) to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device~Cohort 1b: Participants aged 2 to 17 years old (inclusive) at the time of AAVAnc80-hOTOF administration to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device"
89060598|NCT05821959|Experimental|Cohort 2|Cohort 2: Participants aged 2 to 17 years old (inclusive) at the time of AAVAnc80-hOTOF administration to receive intracochlear administration of AAVAnc80-hOTOF (dose level 2) in the study ear using a sterile, one-time use investigational medical device
89060600|NCT05813314|Active Comparator|BMN 111 injection with vial and syringe|Study treatment will be provided in glass vials. Each glass vial will be labeled as required per country requirement. Pre-filled Diluent Transfer Syringes will be provided for reconstitution.
89060601|NCT05813314|Experimental|BMN 111 injection with injector pen|Study treatment will be provided in a prefilled injector pen containing a dual chamber drug cartridge, for reconstitution and injection, after setting of the specified dose with the 2.0 mg/mL formulation.
89060602|NCT05773755|Experimental|Deep Brain Stimulation (DBS) for Treatment Resistant Depression|Open label active Deep Brain Stimulation (DBS)
89060603|NCT05773170||Pharmacological cardioversion with Refralon|"Refralon® 0.1% solution administration at a dose of 10 μg/kg of body weight intravenously (IV) for 2-3 minutes; It is allowed to divide the first Refralon® bolus into two consecutive injections: the first dose administration - 5 μg/kg of body weight, if the AF/AFL persists, administer the second dose - 5 μg/kg of body weight (total dose 10 μg/kg) in 15 minutes.~If no effect is registered (no sinus rhythm restoration), repeat IV administration of Refralon® 0.1% solution at a dose of 10 μg/kg of body weight (total dose: 20 μg/kg of body weight) in 15 minutes;~If no effect is registered, repeat IV administration of Refralon® 0.1% solution at a dose of 10 μg/kg of body weight (total dose: 30 μg/kg of body weight) in 15 minutes.~In case of AF/AFL recurrence after the sinus rhythm restoration (with no contraindications), it is possible to re-administer Refralon®, while the maximum total drug daily dose (from the first administration) should not exceed 30 μg/kg of body weight."
89060604|NCT05764785|Experimental|MentorPRO|Participants assigned to use MentorPRO
89060605|NCT05764785|No Intervention|Control|Participants in mentoring program as usual
89060606|NCT05763199|Experimental|Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®)|AHCC 3g PO Daily
89060607|NCT05763199|Placebo Comparator|Placebo|Placebo PO Daily
89060608|NCT05762276|Experimental|VXX-401 Cohort A|VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
89060609|NCT05762276|Experimental|VXX-401 Cohort B|VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
89060610|NCT05762276|Experimental|VXX-401 Cohort C|VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
89060611|NCT05762276|Experimental|VXX-401 Cohort D|VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
89060612|NCT05762276|Placebo Comparator|Placebo Cohort A and C|Placebo administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
89060613|NCT05762276|Placebo Comparator|Placebo Cohort B and D|Placebo administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
89060614|NCT05762276|Experimental|VXX-401 Cohort E|VXX-401 900mcg administered by intramuscular (IM) injection at Week 0. VXX-401 100 mcg administered by intramuscular (IM) injection at Week 4 and Week 12.
89060615|NCT05762276|Experimental|VXX-401 Cohort F|VXX-401 900mcg administered by intramuscular (IM) injection at Week 0. VXX-401 300 mcg administered by intramuscular (IM) injection at Week 4 and Week 12.
89060616|NCT05753774|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
89060617|NCT05749835|Experimental|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland et al
89060618|NCT05749835|Experimental|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\her head is cradled between your body and your right forearm (when you stand at his\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
89060619|NCT05743517|Experimental|Symptom burden-tailored goal setting app|The Fit4Treatment app is designed to encourage physical activity among older women with gynecologic cancer while they are undergoing cancer therapy. The app will contain the following features 1) education about safely increasing physical activity and steps; 2) tailored patient-specific push notifications to encourage physical activity 3) syncing of Fitbit steps and transmission of these data to study staff in real time; 4) daily, weekly and monthly step progress; and 5) goal setting that incorporates prior physical activity, patient desires, and daily symptom burden. The app will prompt patients to report their symptom burden on a scale of 1-5 each morning. Based on their symptom rating and the previous days step counts (measured directly by the Fitbit) patients will be provided with three different goal choices to select. Daily activity goals increase, decrease or stay the same depending on the previous day and the patient's own goals.
89060620|NCT05743517|Experimental|Exercise Partner|Participants assigned to the exercise partner component will be encouraged to discuss their step progress with their selected partner who will in turn support the participant and encourage them to stay active.
89060621|NCT05743517|Experimental|Provider/oncologist engagement|Participants assigned to the provider/oncologist engagement component will have their physical activity data recorded by the Fitbit shared with their oncology provider through the electronic medical record (EMR). For participants randomized to this condition, clinical staff will place an order into the EMR, allowing the patient to use the patient-facing portal MyChart to link their Fitbit to the health record. Prior to regularly scheduled clinic visits, the patient's oncology team will receive a message summarizing the participant's physical activity (average daily steps) for the prior three weeks.
89060622|NCT05743517|Experimental|Coaching|Participants assigned to the coaching intervention will receive weekly coaching calls. The study team will call them at a previously specified and mutually agreed upon time once per week to review topics related to physical activity and cancer treatment. Coaching calls will have an educational component and cover topics such as reducing sedentary behavior, benefits of increased physical activity, managing cancer treatment symptoms, social support, stress management, etc. During these calls, the topics as well as strategies and recommendations will be discussed. Barriers and facilitators will be reflected on and planned for to increased self-efficacy. Participants will engage in direct problem solving with their coach. Discussing these topics will enhance outcome expectation and increase motivation.
89060623|NCT05743387|Active Comparator|Intervention villages|"In the intervention villages, CC-VHWs will offer~a T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level according to clinical algorithms based on international guidelines for primary healthcare management of T2D and the updated Lesotho Standard Treatment Guidelines.~Direct guidance for treatment initiation, drug prescription, counselling and monitoring will be provided via the ComBaCaL app.~In case of complicated disease (i.e. if treatment targets are not reached with metformin alone), unclear diagnosis, relevant comorbidities or presence of clinical alarm signs or symptoms, participants will be referred to the closest health facility for further management."
89060624|NCT05743387|Active Comparator|Control villages|In control villages, CC-VHWs will refer participants to the responsible health facility for therapeutic management after enrolment and baseline assessment.
89060625|NCT05737160|Experimental|Telitacicept|Participants will receive subcutaneous Telitacicept 240 mg once a week for a total of 48 doses in addition to MG SoC.
89060626|NCT05737160|Placebo Comparator|Placebo|Participants will receive subcutaneous placebo once a week for a total of 24 doses (part A) and then weekly subcutaneous Telitacicept 240 mg for 24 doses (part B) in addition to MG SoC.
89060627|NCT05736497|Experimental|Intervention: Digital Care Plans with Accompanying Text Messages|Investigators will recruit families and patients diagnosed with a Cancer Predisposition Syndrome within 3 years. Participants will be provided with a digital care plan and optional accompanying text message reminders.
89060628|NCT05725733|Experimental|children with ASD group.|ASD groups will be randomly divided into 4 subgroups according to their age (4-7 years old, 7-10 years old, 10-13 years old and, 14-18 years old). Also, ASD group will be categorized according to the symptoms severity using the childhood autism rating scale (CARS).
89219905|NCT05130593||Nutrasorb bar evaluation|Participants in Phase 1 will taste test the bar for acceptability. Participants in Phase 2 will consume the bar and have blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2).
89219906|NCT05127603|Experimental|Individually tailored physiotherapy; cognitive behavioral intervention|The intervention is offered in accordance with the Neck Pain Guidelines, with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior.
89219907|NCT05122078|Experimental|ANI group|Investigator will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
89219908|NCT05122078|No Intervention|Control group|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. We will not monitor ANI in this group.
89219909|NCT05106595||Traditional Occupational Therapy|participants receiving traditional occupational therapy treatments and interventions provided in the inpatient rehabilitation setting. This includes, but is not limited to , therapeutic activity, therapeutic exercise, neuromuscular re-education. This group is retrospectively collected, and will not include participants who had access to the BAT.
89219910|NCT05106595||Bimanual Arm Trainer|Participants who are prospectively enrolled, who are appropriate for BAT use. Participants will receive additional traditional occupational therapy interventions, as deemed appropriate by treating therapists.
89219911|NCT05106387||REGN5459 in study R5459-RT-1944|Received a kidney transplant and were administered REGN5459 in study R5459-RT-1944.
89219912|NCT05106387||REGN5458 in study R5459-RT-1944|Received a kidney transplant and were administered REGN5458 in study R5459-RT-1944.
89219913|NCT05091190|Other|cancer patients|MADMAS will include 30 patients with metastatic NSCLC and 30 patients with metastatic head and neck cancers; patients will NSCLC will receive an immunotherapy-based treatment in first line metastatic setting; patients with head and neck cancers are included if they are planned to receive an immunotherapy-based treatment, whatever the line.
89219914|NCT05084378|Experimental|Povidone-iodine Lavage and Local Antibiotics|1 litre of 0.35% povidone-iodine lavage solution will be used. 2 grams of Vancomycin antibiotic powder will be applied to the deep joint (deep to fascia) following lavage solution and immediately prior to closure.
89219915|NCT05084378|Experimental|Chlorhexidine Lavage and Local Antibiotics|1 litre of 0.05% chlorhexidine lavage solution will be used. 2 grams of Vancomycin antibiotic powder will be applied to the deep joint (deep to fascia) following lavage solution and immediately prior to closure.
89060629|NCT05725733|Active Comparator|One hundred typically developed children or control group|They will be randomly divided into 4 subgroups according to their age (4-7 years old, 7-10 years old, 10-13 years old and, 14-18 years old)
89060630|NCT05724953|Experimental|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
89060631|NCT05721755|Experimental|Arm A (pembrolizumab and radiation)|Patients receive one cycle of pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV, and fluorouracil IV on study and then receive pembrolizumab IV with radiation therapy on study. Patients also undergo CT, PET/CT, and/or MRI throughout the trial.
89060632|NCT05721755|Active Comparator|Arm B (pembrolizumab monotherapy)|Patients receive one cycle of pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV, and fluorouracil IV on study and then receive pembrolizumab IV monotherapy on study. Patients also undergo CT, PET/CT, and/or MRI throughout the trial.
89060633|NCT05721755|No Intervention|Arm S (no intervention)|Patients proceed directly to Step II.
89060634|NCT05721755|Experimental|Arm T (pembrolizumab, chemotherapy)|Patients receive pembrolizumab IV with carboplatin IV and paclitaxel IV, or with cisplatin IV and fluorouracil IV, or with carboplatin IV and fluorouracil IV on study.
89060635|NCT05719805|Experimental|Mavacamten Dose 1|
89060636|NCT05719805|Experimental|Mavacamten Dose 2|
89060637|NCT05719623|Experimental|CUEVAS MEDEK EXERCISES|Experimental group will get conventional treatment along with Cuevas Medak Exercises
89060638|NCT05719623|Other|BALANCE AND POSTURAL|Controlled will get conventional treatment
89060639|NCT05717166|Active Comparator|Standard Arm (Arm 1)|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications.
89060640|NCT05717166|Experimental|Experimental Arm (Arm 2)|Consists of treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable (e.g. surgery, RFA, fractionated radiation, chemoradiation) if those are deemed to be preferable by the treating oncologists.
89060641|NCT05689099|Experimental|Sequence A|Participants will be administered a single subcutaneous (s.c.) dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 2.
89060642|NCT05689099|Experimental|Sequence B|Participants will be administered a single s.c. dose of 0.5 mg semaglutide B (0.68 mg/mL) in Period 1 followed by a single s.c. dose of 0.5 mg semaglutide B (1.34 mg/mL) in Period 2.
89111027|NCT04235127||Catalan population|The target population consists of the dynamic cohort of all Catalan residents during the 6-year period 2014-2019. Annual total population of Catalonia is between 7.5-7.6 million, with annual rates for immigration, emigration, birth and death being ~2.5%, ~1.9%, ~0.9%, and ~0.8%, respectively. Based on these figures, we expect a maximum of ~9.1 million individuals with Catalan residency status on at least one point in time over the 2014-2019 period. However, we expect SA in Catalonia to be extremely rare before the age of 10, in line with findings that self-injurious behaviour generally occurs as from the adolescent period. We will therefore exclude cases and controls that have not reached age 10 by the end of the 2014-2019 period (i.e., ~10.9%), lowering the total expected target population to ~8.1 million.
89060643|NCT05684055|Active Comparator|Intervention villages|CC-VHWs do screen, diagnosis, first-line aHT treatment for eligible participants, treatment monitoring at community-level (ComBaCaL app guides them to provide first-line antihypertensive SPCs to eligible individuals and treatment monitoring/ support to all individuals with aHT). CC- VHW offers lifestyle counselling, lipid -lowering treatment to participants with high CVD risk and antiplatelet treatment to participants with history of stroke/ myocardial infarction. Trained, supervised, mentored by chronic care nurses (CC nurses) and guided by the ComBaCaL app they follow-up persons with aHT to monitor adherence, life-style changes, treatment response, side-effects. TwiC 1: individuals with uncomplicated aHT (baseline BP above treatment targets) TwiC 2: individuals with uncomplicated pharmacologically controlled aHT. In case of complicated disease or presence of clinical alarm signs/ symptoms, participants are referred to the closest health facility for further investigation.
89060644|NCT05684055|Active Comparator|Control villages|"Control villages will follow the standard of care in the ComBaCaL cohort study. CC-VHWs will also receive tablets with the ComBaCaL app installed. They are trained, supervised and equipped to screen and diagnose aHT with subsequent referral to facility-based follow-up and care. In control villages the ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/ provision of antihypertensive or lipid-lowering medication.~TwiC 1: enrols individuals with uncomplicated aHT with baseline BP values above treatment targets.~TwiC 2: enrols individuals with uncomplicated pharmacologically controlled aHT.~In case of complicated hypertension or presence of clinical alarm signs or symptoms, participants will be immediately referred to the closest health facility for further investigation."
89060645|NCT05682612||Survivors|Survivors of COVID-19 induced respiratory failure
89060646|NCT05682612||Nonsurvivors|Nonsurvivors of COVID-19 induced respiratory failure
89060647|NCT05681559|Active Comparator|Medi for All|"Participants randomized to the USDA Mediterranean-style Food Pattern Arm (called Medi for all) will have access to a toolbox that includes education materials (e.g., food pattern tables according to daily caloric intake), recipes, grocery lists, group-based online dietary support, feedback, and reminders to encourage dietary change. Recipes and grocery lists can be individualized to a participant's food budget and preferences. Materials will be available in print and Web-based. This state-of-the art intervention will then use electronic feedback in the form of nudge messages designed to motivate participants to sustain or improve adherence to the Med-style Food Pattern."
89060648|NCT05681559|Active Comparator|Fiber Supplementation|Participants randomized to the High Fiber Diet Arm will be given commonly used patient education pamphlet,149 describing fiber and high-fiber foods, the rationale for increasing fiber intake, and ways patients can promote greater intake. Based on prior observational studies of incident diverticulitis, at least 25 grams/day of fiber will be recommended for participants.
89060649|NCT05680480|Experimental|Telitacicept 240 mg|Telitacicept 240 mg given SC weekly plus standard therapy through week 48.
89060650|NCT05680480|Experimental|Telitacicept 160 mg|Telitacicept 160 mg given SC weekly plus standard therapy through week 48.
89060651|NCT05680480|Placebo Comparator|Placebo|Placebo given SC weekly plus standard therapy through week 48.
89060652|NCT05675891|Experimental|Supplemental Feeding System Group|3 feeding between 08-16:00 are carried out with the supplemental feeding system. The remaining 5 feedings continue with the bottle.
89060653|NCT05675891|No Intervention|Bottle Feeding Group (Control)|All feedings are made from a bottle.
89060654|NCT05675085|Other|RIBBS arm|This clinical trial is a single-arm study in which asymptomatic 45-year-old women undergo a triple screening test: (1) two-view tomosynthesis of both breasts; (2) calculation of volumetric breast density (VBD); (3) assessment of breast cancer risk using the Tyrer-Cuzick model. Mean VBD and lifetime risk (LTR) are used to determine the type of imaging and frequency of subsequent screening cycles.
89060655|NCT05668897|Experimental|Single-dose ascending group|SAD study cotains at least 4 cohorts at dosage of 150mg, 300mg, 600mg and 900mg. Each cohort enrolls 6 subjects receive study drug.
89060656|NCT05668897|Placebo Comparator|SAD placebo comparator group|SAD study cotains at least 4 cohorts at dosage of 150mg, 300mg, 600mg and 900mg. Each cohort enrolls 2 subjects receive placebo.
89060657|NCT05668897|Experimental|Multi-dose ascending group|MAD study cotains 1-3 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 6 subjects receive study drug.
89060658|NCT05668897|Placebo Comparator|MAD placebo comparator group|MAD study cotains 1-3 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive placebo.
89060659|NCT05668897|Experimental|Food effect study|FE study cotains at least 1 cohort which were evaluated in SAD study to be tolerated . Each cohort enrolls 12 subjects receive study drug on fast or fed condition.
89060660|NCT05665166|Experimental|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|
89060661|NCT05664815|Experimental|Application of human amniotic membrane (hAM)|After conventional/standard treatment, hAM will be applied in a single layer against the bone defect before closure.
89060662|NCT05664815|Active Comparator|Conventional/standard treatment|Conventional/standard surgery.
89060663|NCT05657184|Experimental|REGEND001 autologous bronchial basal cells|Transplantation of autologous bronchial basal cells
89060664|NCT05656560|Other|Clinician education only|Online clinician education
89060665|NCT05656560|Experimental|Commitment nudge|The commitment nudge will be an EHR alert that is triggered when a clinician renews or orders a qualifying medication in any Epic encounter (including non-face-to-face encounters) for a patient aged 65 or greater who meets criteria for high-risk polypharmacy. When triggered, the commitment nudge will offer the clinician a choice option that sets a reminder to discuss polypharmacy at the patient's next visit date.
89060666|NCT05656560|Experimental|Justification nudge|The justification nudge will be an EHR alert triggered for patients with high-risk polypharmacy when a clinician begins to renew or newly prescribe a medication that causes a high-risk criterion to be fulfilled (i.e., a medication meeting causing 1 of the 7 high-risk polypharmacy criteria/primary study measures to be met). This alert will inform the clinician of the high-risk nature of the prescription and request a free-text justification for starting or renewing the medication. This written justification will appear in the EHR in a section of that encounter that other EHR users can see.
89060667|NCT05656560|Experimental|Commitment nudge + Justification nudge|This study arm will receive both the commitment nudge and the justification nudge.
89060668|NCT05656443|Experimental|GST-HG171/Ritonavir|
89060669|NCT05656443|Placebo Comparator|Placebo|
89060670|NCT05653323|Experimental|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-993.
89060671|NCT05653323|Experimental|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A.
89060672|NCT05653323|Placebo Comparator|Placebo Part A|Participants will be randomized to receive placebo matched to VX-993.
89060673|NCT05653323|Placebo Comparator|Placebo Part B|Participants will be randomized to receive multiple doses of placebo matched to VX-993.
89060674|NCT05650918|Experimental|MesoPher and mitazalimab combination therapy|"MesoPher. 25 million lysate loaded DCs administered in the form of 3 biweekly and 2 additional vaccinations (3 and 6 months after the third vaccination). 1/3 intradermal injection in the forearm and 2/3 via the intravenous route.~mitazalimab, 75µg/kg-150µg/kg-300µg/kg-600µg/kg or 1200µg/kg via intravenous route in the form of 3 biweekly and 2 additional infusions (3 and 6 months after the third vaccination)."
89060675|NCT05649410|Experimental|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
89111028|NCT02796807|Experimental|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
89219916|NCT05084378|Experimental|Normal Saline Lavage and Local Antibiotics|1 litre of sterile isotonic saline solution will be used. 2 grams of Vancomycin antibiotic powder will be applied to the deep joint (deep to fascia) following lavage solution and immediately prior to closure.
89219917|NCT05084378|Experimental|Povidone-iodine Lavage Solution with no Local Antibiotics|1 litre of 0.35% povidone-iodine lavage solution will be used immediately prior to closure.
89688997|NCT03031093|Active Comparator|Healthy, non obese|Healthy, non obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
89060676|NCT05649410|Experimental|sleeper stretch along with conventional therapy|IT will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
89060677|NCT05643755|Experimental|Intervention|Intervention group: educational material provided on the day of surgery containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
89060678|NCT05643755|No Intervention|Control|Control group: standard clinical care
89060679|NCT05643365||Hypothyroidism|decreased hormone levels (FT3 < 3.5 pmol/L, FT4 < 11.5 pmol/L, TSH > 4.78 μU/mL) and symptoms of hypothyroidism within 6 months' follow-up.
89060680|NCT05643365||Euthyroidism|normal hormone levels (FT3 3.5 to 6.5 pmol/L, FT4 11.5 to 22.7 pmol/L, TSH 0.55 to 4.78 μU/mL), and no symptoms of hyperthyroidism after 6 months' follow-up
89060681|NCT05643365||Hyperthyroidism|increased hormone levels (FT3 > 6.5 pmol/L, FT4 > 22.7 pmol/L, TSH < 0.55 μU/mL) and symptoms of hyperthyroidism after 6 months' follow-up
89060682|NCT05641701|Experimental|Deep Brain Simulation (DBS) System|The DBS device will be turned on to compare stutter to when the device was off (which would be the control).
89060683|NCT05630755|Experimental|DOR/ISL and Placebo to BIC/FTC/TAF|Participants will receive DOR/ISL 100 mg/0.25 mg and Placebo to BIC/FTC/TAF once daily (QD) orally from day 1 to week 96.
89060684|NCT05630755|Active Comparator|BIC/FTC/TAF and Placebo to DOR/ISL|Participants will receive BIC/FTC/TAF 50 mg/200 mg/25 mg and Placebo to DOR/ISL once daily (QD) orally from day 1 to week 96.
89060685|NCT05621486|Experimental|B4T2-001 CAR T cells|Single Arm and Open Label study consisting of dose escalation study design followed by dose expansion phase at determined MTD. Treatment follows a lymphodepleting chemotherapy regimen
89060686|NCT05621174|Other|Magisterial Dexamphetamine|Magisterial Dexamphetamine
89060687|NCT05621174|Other|Tentin|Tentin
89060688|NCT05617911|Experimental|Blood flow restriction and standard of care therapy|The experimental BFR therapy will be incorporated into the standard therapy sessions and will not elongate the treatment session, quantity of sessions or incur any additional cost. As the participant progresses over time in therapy sessions, the discretion of the PT will determine when they have graduated beyond receiving any benefit from BFRT as demonstrated by quad strength.
89060689|NCT05617911|Placebo Comparator|Sham and standard of care therapy|The sham comparator control group will also follow the Exercise Protocol in their physical therapy sessions with a non inflated blood flow restriction cuff attached in the same position as the experimental group. Similar to the intervention group, as participant's progress in therapy, the Physical Therapist will use their clinical decision making to advance the person through resistance and repetition increases.
89060690|NCT05610189|Experimental|Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg|"Participants will receive tavapadon 1x15 mg tablet, orally, once daily (QD) from Day 15 to 21.~Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 22 to 28."
89060691|NCT05610189|Experimental|Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg|"Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 15 to 21.~Participants will receive tavapadon 1x15 mg tablet, orally, QD from Day 22 to 28."
89060692|NCT05597696||1) Experimental Group: Transfemoral Amputee|Balance assessment in sitting
89060693|NCT05597696||2) Control Group: Healthy Subjects|Balance assessment in sitting
89060694|NCT05579977|Experimental|PF-07081532 20 mg T2DM|PF-07081532 20 mg daily in T2DM
89060695|NCT05579977|Experimental|PF-07081532 40 mg T2DM|PF-07081532 40 mg daily in T2DM
89060696|NCT05579977|Experimental|PF-07081532 80 mg T2DM|PF-07081532 80 mg daily in T2DM
89060697|NCT05579977|Experimental|PF-07081532 160 mg T2DM|PF-07081532 160 mg daily in T2DM
89060698|NCT05579977|Experimental|PF-07081532 260 mg T2DM|PF-07081532 260 mg daily in T2DM
89060699|NCT05579977|Placebo Comparator|Placebo T2DM|Placebo daily in T2DM
89060700|NCT05579977|Experimental|PF-07081532 80 mg Obesity|PF-07081532 80 mg daily in Obesity
89060701|NCT05579977|Experimental|PF-07081532 140 mg Obesity|PF-07081532 140 mg daily in Obesity
89060702|NCT05579977|Experimental|PF-07081532 200 mg Obesity (Option 1)|PF-07081532 200 mg daily in Obesity
89060703|NCT05579977|Experimental|PF-07081532 200 mg Obesity (Option 2)|PF-07081532 200 mg daily in Obesity
89060704|NCT05579977|Experimental|PF-07081532 260 mg Obesity|PF-07081532 260 mg daily in Obesity
89060705|NCT05579977|Active Comparator|Rybelsus 14 mg T2DM|Semaglutide 14 mg daily in T2DM
89688998|NCT03031093|Experimental|COPD, non obese + HFNC|non obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
89688999|NCT03031093|Active Comparator|COPD, non obese|non obese COPD participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
89689000|NCT03031093|Experimental|healthy, obese + HFNC|Healthy obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
89689001|NCT03031093|Active Comparator|healthy, obese|Healthy obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
89060706|NCT05579977|Placebo Comparator|Placebo Obesity|Placebo in Obesity
89060707|NCT05576584|Placebo Comparator|Single Ascending Dose|Five dose groups: 5mg (group I), 15mg (Group II), 30mg (Group III), 60mg (Group IV) and 100mg (Group V). According to the safety, tolerance and PK parameters of group V, higher dose group studies (150mg and 200mg alternatively) are not excluded. There were 10 subjects in each group, of which 8 received GST-HG121 tablets and 2 received placebo.
89060708|NCT05576584|Placebo Comparator|Multiple Ascending Dose|According to the results of single dose study, it is planned to select 1-3 dose groups within the range of single dose for oral administration for 7 consecutive days. There were 12 subjects in each group, of which 10 received GST-HG121 tablets and 2 received placebo. From D 1 to d 7, take GST-HG121 tablets or placebo orally on an empty stomach every day, tentatively once a day (the specific administration frequency may be adjusted based on the results of the single dose increase test)
89060709|NCT05576584|Placebo Comparator|food affects（A）|10 subjects (8 received GST-HG121 tablets and 2 received placebo)
89060710|NCT05576584|Active Comparator|food affects（B）|8 subjects (all received GST-HG121 tablets)
89060711|NCT05553145||Patients Seen by their Endocrinologist|Patients whose diabetes is managed by their Endocrinologist
89060712|NCT05553145||Patients Seen by their Primary Care Provider|Patients whose diabetes is managed by their Primary Care Provider
89060713|NCT05549648|Other|Self-controlled Study|Hong Kong citizens over 50 years old
89060714|NCT05537064|No Intervention|Control|Control arm exposed only to usual care, which consists of the passive decision support functionality Health Maintenance flag that is the current decision-support tool in the EMR.
89689002|NCT03031093|Experimental|COPD, obese + HFNC|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
89689003|NCT03031093|Active Comparator|COPD, obese|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
89689004|NCT01040351|Experimental|1: Hydrosalpinx needle aspiration|After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .
89689005|NCT01040351|No Intervention|2. no aspiration|IVF-ET is done without prior aspiration of hydrosalpingeal fluid
89689006|NCT03016741|Other|Arm I (abiraterone acetate, prednisone)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive abiraterone acetate PO and prednisone PO BID in the absence of disease progression or unacceptable toxicity. Patients then undergo cognitive assessment comprising of neuro-cognitive tests and assessments of overall quality of life, fatigue, pain, and symptoms at baseline, 3, 6, and 12 months. Patients also undergo MRI program for 40 minutes comprising of DTI, fMRI, ASL MRI, MPRAGE MRI, FLAIR MRI, and BOLD MRI at baseline and 3 months.
89219918|NCT05084378|Experimental|Chlorhexidine Lavage Solution with no Local Antibiotics|1 litre of 0.05% chlorhexidine lavage solution will be used immediately prior to closure.
89219919|NCT05084378|Active Comparator|Normal Saline Lavage with no Local Antibiotics|1 litre of sterile isotonic saline solution will be used immediately prior to closure.
89219920|NCT05077072|Experimental|ARM I (CHAT)|Patients participate in CHAT counseling intervention over 45-60 minutes twice a month for up to 12 weeks.
89219921|NCT05077072|Experimental|ARM II (NFB)|Patients undergo NFB intervention over 20-30 minutes twice a week for up to 10 weeks.
89219922|NCT05077072|Active Comparator|ARM III (SOC)|Patients receive 2-3 standard of care sessions per month over 45-60 minutes for up to 12 weeks.
89219923|NCT05074498|Experimental|Part 1: TB006|Participants will be randomized to 1 of 3 ascending dose groups to receive a total of 5 once-weekly doses of TB006, infused over 1 hour.
89219924|NCT05074498|Placebo Comparator|Part 1: Placebo|Participants will be randomized to receive 5 once-weekly doses of matching placebo.
89219925|NCT05074498|Experimental|Part 2: TB006|Participants will receive the highest safe and well-tolerated dose identified in Part 1, infused over 1 hour. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
89219926|NCT05074498|Placebo Comparator|Part 2: Placebo|Participants will be randomized to receive matching placebo. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
89219927|NCT05073926||Persons with latent tuberculosis treated with 4 months rifampicin|Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months
89219928|NCT05073926||Persons with latent tuberculosis treated with 6-9 months isoniazide|Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6-9 months
89219929|NCT05072821|Experimental|Botulinum Toxin type A injection side|The Botulinum Toxin type A will be injected into the dermal layer before skin closure in keloid excision surgery. The concentration of Botulinum Toxin type A is 100 units in 2 mL and dosage is 8 units/cm. The maximal dose is 100 units for each participant.
89219930|NCT05072821|Placebo Comparator|0.9% saline injection side|The 0.9% saline will be injected into the dermal layer before skin closure in keloid excision surgery. The dosage is 0.16 mL/cm.
89689007|NCT03016741|Other|Arm II (enzalutamide)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo cognitive assessment and MRI program as in Arm I.
89689008|NCT03401645|Experimental|Treatment (Alarm Active)|"Participants will be wearing the wrist device with an alarm timer that sends out signals every 5 minutes. The alarm is a buzzing noise and a vibration. Participants must turn off the alarm then perform a series of visuomotor tasks. This will be done for one hour, twice a day for two weeks.~Intervention: Device - Wrist Alarm; Behavioral - Home-based Arm and Hand Exercise"
89689009|NCT03401645|Sham Comparator|Control (Sham Control)|"Participants will perform the same tasks as the Alarm/Treatment group, but without the alarm timer. This is a series of visuomotor tasks for one hour, twice per day for two weeks.~Intervention: Behavioral - Home-based Arm and Hand Exercise"
89219931|NCT05067582|Placebo Comparator|Placebo Capsules|1 capsule twice daily
89219932|NCT05067582|Experimental|L1-79 200 mg or 300 mg Capsules|1 capsule twice daily
89219933|NCT05059535|Experimental|cryoneurolysis of the saphenous nerve|A cryoneurolysis of the saphenous nerve will be performed between 7 days and 5 days before the knee arthroplasty
89219934|NCT05059535|Experimental|cryoneurolysis of geniculate nerves|A cryoneurolysis of geniculate nerves will be performed between 7 days and 5 days before the knee arthroplasty
89219935|NCT05059535|Placebo Comparator|control|No cryoneurolysis will be performed before the knee arthroplasty
89219936|NCT05053867|Experimental|Group A: Inhaled tranexamic acid|will receive 500 mg/5ml nebulized tranexamic acid every 8 hours for at least 3 days, and up to 5 days
89219937|NCT05053867|Other|Group B: Usual Care|usual care
89219938|NCT05052268|Experimental|Phase 1 XTX202 Dose Escalation and Pharmacodynamics Expansion|"Part 1A Dose Escalation of XTX202 administered in ascending doses to patients with advanced or metastatic solid tumors to find the recommended phase 2 doses (RP2Ds).~Part 1B Evaluation of XTX202 in patients with selected advanced solid tumors to further characterize the pharmacodynamic profile of XTX202"
89689010|NCT04358809|Experimental|Suspension of Mw + Standard therapy of COVID-19|0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days + Standard therapy of COVID-19
89689011|NCT04358809|Placebo Comparator|Placebo|0.3 ml (0.1ml x 3 Injection) of intradermal Placebo for 3 consecutive days + Standard therapy of COVID-19
89689012|NCT01042925|Experimental|Arm 1|XL147 in combination with trastuzumab
89689013|NCT01042925|Experimental|Arm 2|XL147 in combination with trastuzumab and paclitaxel
89689014|NCT03017053|Experimental|Radiotherapy|Primary surgery & Radiotherapy
89689015|NCT03017053|Active Comparator|Elective neck dissection|Primary surgery & Elective neck dissection
89689016|NCT03401567|Experimental|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
89689017|NCT03401567|No Intervention|Control group|Control group will continue daily activities and a brochure on strengthening exercises and protection from injuries.
89689018|NCT03400709|Experimental|N-acetylcisteine group|
89689019|NCT03400709|Placebo Comparator|Control group|
89689020|NCT00956761|Experimental|1|
89689021|NCT01042769|Experimental|Aleglitazar|
89689022|NCT01042769|Placebo Comparator|Placebo|
89689023|NCT02049957|Experimental|Phase 1 (Part 1): Sapanisertib 5 mg + Exemestane|Sapanisertib 5 mg, unmilled active pharmaceutical ingredient (API) capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 12 cycles).
89689024|NCT02049957|Experimental|Phase 1 (Part 1): Sapanisertib 5 mg + Fulvestrant|Sapanisertib 5 mg, unmilled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection, intramuscularly (IM), once on Day 1 of each cycle (Up to 57 cycles).
89689025|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 3 mg + Exemestane|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 8 cycles).
89219939|NCT05052268|Experimental|Phase 2 XTX202 Dose Expansion|"Part 2A will enroll patients with metastatic renal cell carcinoma who have progressed following standard-of-care treatment.~Part 2B will enroll patients with melanoma who have progressed following standard-of-care treatment."
89219940|NCT05052216||NORM|healthy children
89219941|NCT05052216||OSA|children with obstructive sleep apnea
89219942|NCT05051852||Women with low-grade squamous intraepithelial lesion (LSIL) in cervix|In the enrollment, women whose cervical histopathological results have been diagnosed as low-grade squamous intraepithelial lesion (LSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
89219943|NCT05048407|Experimental|Gynaecological laparoscopic surgery|Eligible women aged 18 - 70 years, regardless of parity, who need laparoscopic gynaecological surgery and who provide informed consent prior to surgery
89219944|NCT05047822||Concurrent Controls|
89219945|NCT05047822||Vaccinated Cohort|
89219946|NCT05045963||Observational (medical record review)|Patients' medical charts are reviewed retrospectively.
89219947|NCT05035420|Experimental|Healthy Volunteer|Healthy Volunteer
89219948|NCT05031130|No Intervention|Control Group|For the control group, the researcher will provide routine care to pregnant adolescents.
89219949|NCT05031130|Experimental|Experimental group|For the experimental group, the researcher will provide the empowered program integrated with family support plus routine care.
89219950|NCT05029193|Experimental|Stroke survivors - Mindfulness intervention|Participants who have had a stroke who are receiving the mindfulness intervention immediately after enrollment (no wait period).
89219951|NCT05029193|No Intervention|Stroke survivors - Waitlist control|Participants who have had a stroke who are assigned to the waitlist.
89219952|NCT05029193|Experimental|Caregivers - Mindfulness intervention|Participants caring for someone who have had a stroke and receiving the mindfulness intervention immediately after enrollment (no wait period).
89219953|NCT05029193|No Intervention|Caregivers - Waitlist control|Participants caring for someone who have had a stroke assigned to the waitlist.
89219954|NCT05026723|Experimental|Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI)|The Medically Tailored Meal (MTM) + Intensive Lifestyle Intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
89219955|NCT05026723|Active Comparator|Standard MTM|The Standard Medically Tailored Meal (MTM) intervention (ILI) consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian.
89219956|NCT05022511|Experimental|Intervention group|"All women aged 50-69 years attending breast cancer screening in the intervention unit on an intervention day. They will all be offered to receive information on their screening status in cervical cancer og colorectal cancer screening.~Women aged 50-64 years, who have not had a cervical cytology sample taken within 5 years and 6 months will be offered to receive a self-sample device for high risk human papilloma virus (hrHPV) screening by mail, or reminded to see her general practitioner (GP) to have a conventional cervical cytology sample taken.~Women aged 50-69 years, who have not had a Faecal Immunochemical Test (FIT) within 2 years and 4.5 months will be offered to receive a new self-sampling kit for FIT."
89219957|NCT05022511|No Intervention|Control group|Women in the control group will receive standard screening offers according to the national screening programme.
89219958|NCT05021614|Experimental|Treatment|Transcatheter Mitral Valve Repair with Valveclip®
89219959|NCT05020574|Experimental|Cohort A: Standard antibiotics|Receive standard pre-incision antibiotics and 24-hour perioperative antibiotics - Prescribed standard postoperative antibiotics to take for at least 7 days post-operatively
89219960|NCT05020574|No Intervention|Cohort B: No antibiotics|Receive standard pre-incision antibiotics and 24-hour perioperative antibiotics - No antibiotics post-operatively, unless patient develops clinical evidence of infection
89219961|NCT05018169|Experimental|BA-A|Teens will participate in BA-A. BA-A is a 12-session manualized treatment that utilizes established BA strategies and incorporates common mental health treatment adaptations for young people with ASD.
89219962|NCT05017974|Experimental|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement (MBSR+PS)|The study intervention is standard mindfulness-based stress reduction (MBSR), which will be delivered through 8 weekly 2.5-hour sessions via video conferencing to groups of 20-30 pregnant and non-pregnant people. MBSR also consists of a 2.5-hour orientation session, a 30-minute private interview with the instructor, and an all-day retreat, all conducted via video conferencing. The supplemental prenatal sleep content will be delivered through 6-8 30-minute sessions via video conferencing either individually or to small groups, and draws material from mindfulness-based therapy for insomnia, mindfulness-based childbirth and parenting program, and cognitive behavior therapy for prenatal insomnia.
89219963|NCT05017974|Other|Treatment as Usual|The control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy, with the exception of asking participants to refrain from participating in non-study mindfulness practice. Use of non-study treatment will be tracked.
89219964|NCT05013710||Plan A Health|Founded in 2018, Plan A Health, Inc seeks to address health care disparities in rural communities by improving access to reproductive and sexual care. Beginning April 2021, the first Plan A mobile health clinic opened, serving five counties in the Mississippi Delta. The care team in the clinic includes a community health worker, nurse practitioner, volunteer providers, residents, and a collaborating physician.
89219965|NCT05013710||Just the Pill|Just The Pill offers telemedicine appointments by phone or online for sexual and reproductive health needs that is delivered to the patient's home. The organization is also opening a mobile health clinic that will deliver care directly to communities.
89689026|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 3 mg + Fulvestrant|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle up to 14 cycles plus fulvestrant 500 mg, injection, IM, once on Day 1 of each cycle (Up to 14 cycles).
89689027|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 4 mg + Exemestane|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 18 cycles).
89689028|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg + Exemestane (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 14 cycles) in everolimus sensitive participants.
89219966|NCT05013710||University of Florida Mobile Outreach Clinic|The mission of the Mobile Outreach Clinic is to reduce health disparities by providing best practice, flexible, low-barrier primary care at no cost to patients unable to access the healthcare system. They focus on addressing the social barriers that drive health inequities and educating health professions students in an environment that equips them to become the socially conscious medical providers of the future.
89219967|NCT05013632||Exposed pregnant women|Pregnant or recently pregnant women 18 years of age and older treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 at any time during pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
89219968|NCT05013632||Active comparator pregnant women|Pregnant women treated with another therapy for mild, moderate, or severe COVID-19
89219969|NCT05013632||Unexposed pregnant women|Pregnant women hospitalized but not treated with a medication specifically indicated for the treatment of mild, moderate, or severe COVID-19
89219970|NCT05009823||Stabilization phase|"The dietetic treatment is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
89219971|NCT05009823||Transition phase|The child is assigned to one the therapeutic regimen depending on the treatment received during the stabilization phase and the results of the appetite test.
89219972|NCT05008718|Active Comparator|38% SDF group|38% silver diamine fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
89219973|NCT05008718|Placebo Comparator|5% NaF group|5% sodium fluoride will be applied on caries lesions on deciduous teeth with a minimum score of 05 as defined by the International Caries Detection and Assessment System (ICDAS)
89219974|NCT05005845|Active Comparator|0.5% NFX-179 gel|Topical gel applied once daily to target cNFs
89219975|NCT05005845|Active Comparator|1.5% NFX-179 gel|Topical gel applied once daily to target cNFs
89219976|NCT05005845|Placebo Comparator|Vehicle gel|Topical gel applied once daily to target cNFs
89219977|NCT05004181|Experimental|Part A - Cohort 1: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
89219978|NCT05004181|Experimental|Part A - Cohort 2: 18 to 55 years of age|Participants will receive 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
89219979|NCT05004181|Experimental|Part A - Cohort 3: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7) of 30 µg.
89219980|NCT05004181|Experimental|Part A - Cohort 4: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
89219981|NCT05004181|Experimental|Part A - Cohort 5: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 of 30 µg.
89219982|NCT05004181|Experimental|Part A - Cohort 6: 18 to 55 years of age|Participants will receive 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
89219983|NCT05004181|Experimental|Part B - Cohort 1: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
89219984|NCT05004181|Experimental|Part B - Cohort 4: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
89219985|NCT05004181|Experimental|Part B - Cohort 6: 18 to 85 years of age|Participants will receive 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
89219986|NCT05004181|Experimental|Part C - Cohort 7: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.529.1) of 30 µg.
89219987|NCT05004181|Experimental|Part C - Cohort 8: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 of 30 µg.
89219988|NCT05004181|Other|Part C - Cohort 9: 18 to 85 years of age|Participants will receive no vaccination within 3 months after Visit 1.
89219989|NCT05004077|Active Comparator|Conventional amiodarone dosing regimen (CDR)|Initial amiodarone bolus of 150 mg IV over 10 minutes then a 24-hour amiodarone loading infusion (1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours), followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.
89219990|NCT05004077|Active Comparator|Repeated amiodarone bolus dosing regimen (RBDR)|Initial amiodarone bolus of 150 mg IV over 10 minutes, then 1.0 mg/min IV amiodarone infusion for 6 hours, then a 0.5 mg/min IV amiodarone infusion for 18 hours, followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. In addition, patients in the RBDR will receive an additional 150 mg IV amiodarone bolus whenever the patient develops tachycardia (Heart Rate (HR) = 110 beats per minute) lasting more than 10 minutes. This bolus may be repeated up to a total of 5 times (6 total boluses) over the first 24 hours. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.
89219991|NCT05003505||Women with cervical cytology (TCT) abnormalities|In the enrollment, women who have undergone cervical cytology (TCT) examination for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months, 12 months and 24 months.
89689029|NCT02049957|Experimental|Phase 2:Sapanisertib 4 mg+Fulvestrant (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 17 cycles) in everolimus sensitive participants.
89689030|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg+Exemestane (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus once daily in a 28-day cycle (Up to 12 cycles) in everolimus resistant participants.
89689031|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg+Fulvestrant (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 9 cycles) in everolimus resistant participants.
89689032|NCT03030937|Experimental|Irinotecan plus apatinib|"Irinotecan:160mg/m2, ivgtt,given on the eighth day; Apatinib:initial dose:250mg,oral,once a day, after meal ( try to take the medicine at the same time of the dauntoy ).~Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities."
89689033|NCT03030937|Active Comparator|Irinotecan|Irinotecan:180mg/m2, ivgtt,given on the eighth day. Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities.
89689034|NCT00950365|Active Comparator|Arm A (pemetrexed)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89689035|NCT00950365|Experimental|Arm B (pemetrexed disodium, erlotinib hydrochloride)|Patients receive pemetrexed disodium IV as in Arm A and erlotinib hydrochloride PO QD on days 2-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89689036|NCT01980147|Experimental|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT). This integrated model focuses on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The model and techniques are adapted to an age range of 9 to 17 years, with more visual material and child friendly language options for the younger part of the age range (9-12) and more teen-relevant and interpersonal content options for the older part of the age range (13-17). The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
89219992|NCT05003453|Experimental|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|Investigational product will be provided as a topical cream containing 1.5% PEA and participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
89219993|NCT05003453|Placebo Comparator|Placebo comparator|A comparator placebo moisturiser cream (an unscented moisturizing base cream) will be provided and applied in the same manner as the active ingredient group. Participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
89219994|NCT05001854|Experimental|Fludrocortisone|"100 μg every 6 hours of fludrocortisone per os~A pharmacokinetic study is performed in this arm"
89219995|NCT05001854|Placebo Comparator|Control|100 μg every 6 hours of placebo per os
89219996|NCT04998487|Experimental|LY3471851 (Abdomen)|LY3471851 administered subcutaneously (SC) into the abdomen.
89219997|NCT04998487|Experimental|LY3471851 (Thigh)|LY3471851 administered SC into the thigh.
89219998|NCT04997486|No Intervention|Control|Subjects will consume all meals/snacks during a ~15-h daily eating period (~9-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
89219999|NCT04997486|Experimental|TRE isocaloric|Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting). The prescribed energy intake will be monitored and adjusted as needed to achieve weight maintenance.
89220000|NCT04997486|Experimental|TRE ad libitum|Subjects will consume all meals/snacks during a ~9-h daily eating period (~15-h fasting) without any other dietary advice.
89220001|NCT04991493|Placebo Comparator|Placebo group|5ml normal saline was injected intravenously 15 minutes before anesthesia and 5ml normal saline was injected intravenously when the incision was washed and sutured.
89689037|NCT01980147|No Intervention|Comparison|Naturalistic comparison arm: No intervention offered, no intervention prohibited.
89689038|NCT01908465|Active Comparator|Ebastine|Ebastine
89689039|NCT01908465|Placebo Comparator|placebo|Placebo
89689040|NCT00950833|Active Comparator|AP-AP Group|subjects from the AP-AP group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015, receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
89689041|NCT00950833|Active Comparator|NAP-pre Group|subjects from the NAP-pre group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015 receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
89689042|NCT00950833|Active Comparator|Unprimed Group|Age-matched subjects from the unprimed group of the NCT00496015 study, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
89689043|NCT01763073||Medical Students|Fourth-year students in accredited US medical schools who have applied to, but not yet been matched with, residency programs in obstetrics and gynecology.
89689044|NCT05711745|Experimental|Myofascial induction in gastrocnemius|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
89689045|NCT02246023|Active Comparator|Fractionated propofol administration|"Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response.~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy"
89689046|NCT02246023|Experimental|Propofol-TCI|"Flexible bronchoscopy in moderate sedation with TCI propofol perfusor:~Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation.~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively."
89689047|NCT05720091|Experimental|ZX-7101A|
89689048|NCT05711277|Experimental|N-ICE CREAM|
89689049|NCT05711277|Active Comparator|Milkshake ONS|
89689050|NCT04358263|Experimental|rtCGM|Patients with use of the Guardian Connect Mobile system (real-time continuous glucose monitoring).
89689051|NCT04358263|Experimental|isCGM|Patients with use of the FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring).
89689052|NCT01041677|Experimental|001|R256918 10 mg capsule twice daily
89689053|NCT01041677|Experimental|002|R256918 15 mg capsule twice daily
89689054|NCT01041677|Placebo Comparator|003|placebo placebo capsule twice daily
89689055|NCT03401411|Experimental|Standard SCCMP|Health care provider completes triage survey of 15 fictional patient case scenarios using the standard SCCMP to prioritize each for admission.
89689056|NCT03401411|Experimental|SCCMP + Algorithm-based Triage Tool|Health care provider completes triage survey of 15 fictional patient case scenarios using SCCMP in addition to a newly designed flowchart-based triage guide to prioritize each for admission.
89689057|NCT03401333|Experimental|Text messaging and brief intervention|Brief motivational interview and 4-weeks of text messaging.
89689058|NCT01140789||Crohn's disease patients|Diagnosis of Crohn's disease by endoscopy, radiology and histology
89689059|NCT01140789||Ulcerative colitis patients|Diagnosis of ulcerative colitis defined by endoscopy, radiology and histology
89689060|NCT01140789||Non-IBD patients|Ethically, sex and aged-matched controls attending clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy.
89689061|NCT04375475|Experimental|Bright Changyou probiotic flavored yogurt|Bright Changyou probiotic flavored yogurt contains 5.0×10^8cfu/g of probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus plantarum ST-Ⅲ (7mg/kg), and 1.5% of inulin
89689062|NCT04375475|Active Comparator|Bright Changyou lactobacillus flavored yogurt|Bright Changyou flavored yogurt contains probiotics including Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus plantarum ST-Ⅲ (7mg/kg)
89220002|NCT04991493|Experimental|pre-tramadol group|5ml of tramadol containing 1mg / kg was injected intravenously 15 minutes before anesthesia and 5ml of normal saline was injected intravenously when the incision was washed and sutured.
89220003|NCT04991493|Active Comparator|post-tramadol group|5ml of normal saline was injected intravenously 15 minutes before anesthesia and 5ml of tramadol containing 1mg / kg was injected intravenously when the incision was washed and sutured.
89220004|NCT04989712|Experimental|20 minutes MVPA|20 minutes of moderate to vigorous exercise at 50-80% maximum heart rate to be performed on a cycle ergometer 40 minutes from the start of the testing session following consumption of a glucose solution at 0 mins. Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point.
89689063|NCT04375475|Active Comparator|Bright flavored yogurt|Bright flavored yogurt contains Lactobacillus bulgaricus, Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus casei LC2W (0.1 mg/kg)
89689064|NCT05719857|Experimental|Portal hypertension patients with TE ≤ 20 kPa.|All patients included will undergo HVPG measurement and US-guided percutaneous liver biopsy. The exams will be performed in sequence, in the laboratory of hepatic hemodynamics. Within 4 to 8 weeks, a multiparametric magnetic resonance imaging of the abdomen with elastography will be performed, concluding the protocol.
89689065|NCT00924053|Experimental|EGT0001474|
89689066|NCT00924053|Placebo Comparator|Placebo|
89689067|NCT05707845|Placebo Comparator|control group (A)|Group A: (control group): 20 participants Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs)
89689068|NCT05707845|Experimental|study group (B)|"Group B: (Study group): 20 participants~Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).~Physical therapy program weight reduction by diet program in the form of caloric restriction, in combination to aerobic exercise in the form of using treadmill 30 minutes /3 times a week for 12 weeks."
89689069|NCT04375319|Experimental|OCT guided 3-month follow-up group|OCT guided the operation, and OCT reexamined 3 months after the operation to evaluate the vascular repair
89689070|NCT04375319|No Intervention|3-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 3 months after operation to evaluate vascular repair
89689071|NCT04375319|No Intervention|6-month follow-up group under the guidance of angiography|Coronary angiography guides the operation, OCT reexamination 6 months after operation to evaluate vascular repair
89689072|NCT03400397||Intervention|Treatment with the Cool Kids programme. The Cool Kids programme is a manualised cognitive behavioural treatment programme for children with anxiety disorders.
89689073|NCT03834389|Experimental|Experimental Group|Experimental group: case-based teaching method applied
89689074|NCT03834389|No Intervention|Control Group|Control group: classical teaching method applied
89689075|NCT03400319||Thoracic Aortic Aneurysm|Patients with Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva ≥39mm, or ascending aorta ≥42mm. Men: at the level of the sinus of valsalva ≥44mm, or ascending aorta ≥46mm.
89689076|NCT03400319||No Thoracic Aortic Aneurysm|Patients without Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva <39mm, or ascending aorta <42mm. Men: at the level of the sinus of valsalva <44mm, or ascending aorta <46mm.
89689077|NCT03400241|Experimental|Tiotropium Easyhaler Product A|tiotropium bromide monohydrate 2 inhalations as a single dose
89689078|NCT03400241|Experimental|Tiotropium Easyhaler Product B|tiotropium bromide monohydrate 2 inhalations as a single dose
89689079|NCT03400241|Experimental|Tiotropium Easyhaler Product C|tiotropium bromide monohydrate 2 inhalations as a single dose
89689080|NCT03400241|Active Comparator|Spiriva HandiHaler|tiotropium bromide monohydrate 2 Spiriva capsules inhaled via HandiHaler
89689081|NCT05706987|Experimental|lidocaine infusion|intravenous lidocaine infusion 1.5mg/kg/hr (ideal body weight) during labiaplasty
89689082|NCT05706987|Placebo Comparator|normal saline infusion|equal volume of normal saline infusion during labiaplasty
89689083|NCT03400007||Prolapse surgery|
89689084|NCT00729573||1|Participants in MTN-003. Participants will remain a part of their assigned MTN-003 study groups.
89689085|NCT02951182|Placebo Comparator|Part 1: Placebo - Cohort 1A and 1B Combined|Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.
89689086|NCT02951182|Experimental|Part 1 Cohort 1A: Triple Combination (TC)|Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.
89689087|NCT02951182|Experimental|Part 1 Cohort 1B: TC Low Dose|Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.
89689088|NCT02951182|Experimental|Part 1 Cohort 1B: TC High Dose|Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.
89689089|NCT02951182|Active Comparator|Part 2: TEZ/IVA|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
89689090|NCT02951182|Experimental|Part 2: TC-2|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
89689091|NCT02959359|Other|DAA treatment arm|Active DAA treatment ('Ledipasvir 90mg/Sofosbuvir 400 mg plus Ribavirin' ) for HCV-HCC patients after curative resection or ablation.
89689092|NCT04375163|Experimental|Massage group (ME)|A sport massage was applied between the sets of an intense isokinetic exercise protocol for knee extensor muscles
89689093|NCT04375163|Active Comparator|Control|the break between the sets of an intense isokinetic exercise protocol for knee extensor muscles was passive
89689094|NCT04347551|Experimental|Eye movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
89689095|NCT04347551|Active Comparator|Head movement Fitts' task|High velocity/low amplitude cervical spine manipulation applied to chronic neck pain and asymptomatic participants.
89689096|NCT05705661|No Intervention|The control group (I)|The control group (I): The participants will follow the traditional pulmonary rehabilitation program including (active cycle of breathing technique, breathing control, deep breathing exercises, huffing). The session duration will be between 30 min twice/day for 15 days as guided by subject fatigue and comfort. (According to Borg scale of dyspnea for monitoring).
89689097|NCT05705661|Active Comparator|The study group (II)|The study group (II): The participants will receive active cycle of breathing technique, breathing control, deep breathing exercises (15 min) in addition to (HFCWO); the patient position will be in a semi-recline position, with wrapped vest around the chest. The (HFCWO) protocol included 3-5 cycles, with a pressure range of +10 to +40 IP cmH2O and will be adjusted according to the patient age, number of secretions, tolerance of patients, and chest auscultation every session. The numbers of total sets will be 3-5 with a duration of 15 min, daily, for two sessions / day , time range according to the ability of the patient. (Çelik et al., 2021).
89689098|NCT02829034|Active Comparator|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day
89689099|NCT02829034|Placebo Comparator|Placebo|Placebo by mouth twice per day
89689100|NCT00924209|Experimental|Stage IIIA lung cancer patients|Non-squamous cell non small cell lung cancer treated with 1250 mg/m^2 gemcitabine dose for two doses on day 1 and day 8 every 21 days,80 mg/m^2 cisplatin day 1 every 21 days for 3 cycles, 7.5 mg/kg bevacizumab on day 1 every 21 days for first 2 cycles only, and 100 mg/m^2 intravenous, and 100 mg/m^2 etoposide intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
89689101|NCT05719467|Active Comparator|Buscopan and bicarbonate|
89689102|NCT05719467|Active Comparator|Buscopan and placebo|
89689103|NCT05719467|Active Comparator|Placebo and bicarbonate|
89689104|NCT05719467|Placebo Comparator|Placebo and placebo|
89689105|NCT02830438|Experimental|Shear wave elastography group|Patients referred for kidney biopsy will then undergo shear wave elastography measurements.
89689106|NCT03408119|Experimental|Group A|100g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
89689107|NCT03408119|Experimental|Group B|50g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
89689108|NCT03408119|Placebo Comparator|Group C|800 IU vitamin D and 450 mg elemental calcium
89689109|NCT03837405|Active Comparator|Diet Education|All participants will receive instruction in the Carbohydrate-Restricted (CR) diet and basic behavioral strategies in weekly, in-person, group sessions for 3 months. The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat.
89689110|NCT03837405|Experimental|Diet Education + Mindfulness|In addition to the diet components described above, participants randomized to the Education + Mindfulness (Ed+MBI) group will receive MBI components using the Eat Right Now (ERN) platform. This will consist of two integrated components: 1) use of the ERN app at home, during the week, to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based discussions of how the mindful eating practices are going, trouble-shooting obstacles/pain points, and doing group exercises and reflecting on them.
89689111|NCT02832154|Experimental|Supportive Care|Patients complete an initial online questionnaire lasting about 25-30 minutes. Patients complete an internet-delivered PA program during weeks 3-8. Each week consists of didactic material and 20-30 minutes of daily online exercises.
89689112|NCT04374929|Active Comparator|Negative Pressure Wound Therapy|
89689113|NCT04374929|Active Comparator|Anti-Inflammatory Glucocorticoid|
89689114|NCT04374929|Active Comparator|Increased Electrode Spacing|
89689115|NCT04374929|Other|Control|
89689116|NCT05717361|Active Comparator|ketamine-lidocaine (KL) group combination of ketamine and lidocaine in one syringe|
89689117|NCT05717361|Active Comparator|: remifentanil group syringe of remifentanil|
89689118|NCT02951884|Experimental|Aspiration|Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.
89689119|NCT02951884|Experimental|Aspiration with injection|Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine
89689120|NCT02951884|No Intervention|Control|Participants assigned to this arm receive no injection or aspiration therapy.
89689121|NCT05701683|Experimental|ERADICATION of H-PYLORI INFECTION with ADDITION of LACTOBACILLUS REUTERI|In experimental group, patients receiving clarithromycin based sequential therapy with LACTOBACILLUS REUTERI
89689122|NCT05701683|No Intervention|ERADICATION of H-PYLORI INFECTION without LACTOBACILLUS REUTERI|control group included patients who received clarithromycin based sequential therapy alone
89689123|NCT05700591|Experimental|rhPro-UK|Recombinant Human Pro-urokinase (rhPro-UK)
89689124|NCT05700591|Active Comparator|rt-PA|Alteplase(rt-PA)
89689125|NCT03021538||Cardiopulmonary Bypass|There will be 40 patients placed on cardiopulmonary bypass during lung transplantation.
89689126|NCT03021538||Extracorporeal Membrane Oxygenation|There will be 40 patients placed on ECMO during lung transplantation.
89689127|NCT02834806|Experimental|BioNIR drug eluting stent system|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
89689128|NCT02835274|Experimental|Ring mode followed by Unrestricted mode|omni-directional stimulation followed by unrestricted Mode stimulation
89689129|NCT02835274|Active Comparator|Unrestricted mode followed by ring mode|Unrestricted Mode stimulation followed by omni-directional stimulation
89689130|NCT05577663|Other|Spontaneous healing|Routine treatment of the extraction socket. Extraction of the tooth and suturing of the extraction socket with resorbable suture PGA 5/0 (polygalactic acid 5/0 sutures; PGA, medipac, Greece).
89689131|NCT05577663|Active Comparator|Free gingival graft|Extraction of the tooth, placement of a Free Gingival Graft taken from the palate and adjusted to seal the socket opening and stabilize it by resorbable sutures PGA 5/0 (polygalactic acid 5/0 sutures; PGA, medipac, Greece).
89689132|NCT05577663|Experimental|Polylactic-Glycolic Acid membrane|Extraction of the tooth, adjustment of the Polylactic-Glycolic Acid membrane (PLGA,Tisseos®, Biomedical Tissues, Septodont, France) over the socket opening resting by 1 mm over the alveolar crest of the extraction socket. Tissues are sutured over the barrier by resorbable sutures PGA 5/0 (polygalactic acid 5/0 sutures; PGA, medipac, Greece).
89689133|NCT02836990|Active Comparator|Prevena|Prevena Incision Management System for vascular surgical groin wounds
89689134|NCT02836990|Active Comparator|Dermabond|Dermabond for vascular surgical groin wounds
89689135|NCT02841046|Other|group cardiac index|the treatment scheme of goal-directed fluid therapy(GDFT) use cardiac index（CI） as the primary judgment in group cardiac index,Patients in group cardiac index received a therapy with the goal of CI was no less than 2.5L•min-1•m-2 .
89689136|NCT02841046|Experimental|group Stroke Volume Variation|the treatment scheme of goal-directed fluid therapy(GDFT) use Stroke Volume Variation（SVV）and cardiac index（CI）as the primary judgment in group Stroke Volume Variation,Patients in group Stroke Volume Variation received a therapy with SVV was less than 12% and CI was no less than 2.5L•min-1•m-2 .
89689137|NCT05717127|Experimental|Intermittent fasting (time restricted feeding)|Intermittent fasting (IF) study arm consisting of time restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
89689138|NCT05717127|Active Comparator|Standard lifestyle|Standard lifestyle recommendation as per the Diabetes Canada guidelines, where participants are encouraged to maintain regularity in timing and spacing of means with no specific recommendations regarding the hours of fasting
89689139|NCT05694273||Ischemic stroke group|"Ischemic stroke secondary to patients receiving cardiac electronic implants~Ischemic stroke met the diagnostic criteria of the 2018 edition of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and was confirmed by cranial CT/MRI scan."
89689140|NCT05694273||Transient ischemic attack group|"Transient ischemic attack secondary to patients receiving cardiac electronic implants~Ischemic stroke met the diagnostic criteria of the 2018 edition of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and was confirmed negative of new onset of infarction by cranial CT/MRI scan."
89689141|NCT05694273||Cerebral hemorrhage group|"Cerebral hemorrhage secondary to patients receiving cardiac electronic implants~Cerebral hemorrhage met the diagnostic criteria of the 2021 Chinese Guidelines for the Diagnosis and Treatment of cerebral hemorrhage and was confirmed by head CT/MRI."
89689142|NCT05716971||RD: (study case group A)|Redetachment under Densiron
89689143|NCT05716971||RA : (control group B)|reattachment under Densiron
89689144|NCT03022396|Other|Group A: age 8-17 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
89689145|NCT03022396|Other|Group B: age 18-30 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
89689146|NCT03022396|Other|Group C: age 18-30 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
89689147|NCT03022396|Other|Group D: age 40 - 59 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
89689148|NCT03022396|Other|Group E: age 40 - 59 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
89689149|NCT03022396|Other|Group F: age 70 - 100 yo identical twins|Individual twins to receive Fluzone® (intramuscular) or High Dose Fluzone® (intramuscular)
89689150|NCT05694117|Experimental|self-determine sequence exercise program|The trial was divided into three cycles, and participants were allowed to choose any one of the a Taichi exercise program, a hybrid program of Taichi exercise and resistance training programs, and resistance training as their intervention content before the start of each cycle. Participants who chose Taichi exercise performed one hour of Taichi exercise for each session, while participants who chose a hybrid exercise program of Taichi exercise and resistance training completed Taichi exercise in the first half hour and resistance training for the second half hour. Participants who chose resistance training performed one hour of resistance training. One hour per training session, three times a week for 24 weeks
89689151|NCT05694117|Experimental|resistance training|Resistance strength training for resistance exercise and aimed at promoting the greatest hypertrophy response. Training is divided into three cycles, with progressive training load. Resistance exercise intervention three times a week for 24 weeks, one hour each time.
89689152|NCT05694117|No Intervention|control group|The participants in the control group were introduced by nurses to education about sarcopenia and various methods for preventing it, such as consuming more protein through their diet and participating in greater physical exercise.
89689153|NCT05694117|Experimental|Taichi exercise and resistance training|The trial was divided into three cycles, each lasting eight weeks. Participants performed a hybrid program of Taichi exercise and resistance training of varying duration and intensity in each cycle. Each session lasted one hour, three times a week for 24 weeks.
89689154|NCT05694117|Experimental|Randomly selected exercise program|The trial was divided into three cycles, and participants were allowed to choose any one of the a Yijinjing exercise program, a hybrid program of Yijinjing exercise and resistance training programs, and resistance training as their intervention content before the start of each cycle. Participants who chose Yijinjing exercise performed one hour of Yijinjing exercise for each session, while participants who chose a hybrid exercise program of Yijinjing exercise and resistance training completed Yijinjing exercise in the first half hour and resistance training for the second half hour. Participants who chose resistance training performed one hour of resistance training. One hour per training session, three times a week for 24 weeks
89689155|NCT03023176|Other|Healthy 1-8 year-old twins|Healthy 1-8 yr old identical and fraternal twin pairs given trivalent, inactivated influenza (Fluzone® standard IIV3 0.5ml or Fluzone® standard IIV3 Pediatric Dose) per participant age and standard of care.
89689156|NCT03839745|Other|Power level 10, 15, or 20 watts|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned battery power levels
89689157|NCT03839745|Other|1 of the other 2 remaining power levels|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 remaining power levels
89689158|NCT03839745|Other|Remaining power level|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining power level
89689159|NCT04366505|Experimental|NFB + (MBRP)|Neurofeedback (NFB) from target region or control region plus Mindfulness-based relapse prevention (for some)
89060715|NCT05537064|Experimental|Non-visit Based Intervention|In this arm the investigators will evaluate a non-visit-based nudge to refer patients eligible for but not prescribed high-intensity statins to centralized pharmacy services for initiation and/or titration of a statin. Practices will be randomized to usual care versus the non-visit-based nudge. The non-visit-based nudge will consist of an EPIC In-basket message sent to each provider that identifies their patients eligible for but not prescribed high- or moderate-intensity statins and notifies them that pended orders for a referral to centralized pharmacy services for statin management will be entered for these patients unless the provider opts out. At the time the in-basket message is sent out, PCPs will also have the opportunity to opt out of participating in the trial entirely.
89689160|NCT04366505|Active Comparator|TAU and sham NFB|TAU + Neurofeedback (NFB) from control region
89689161|NCT03023488|Experimental|Flexible ureteroscopy arm|the findings of patients undergoing flexible ureteroscopy + laser lithotripsy for renal stones according to EAU Guidelines Doppler Ultrasound examination has been performed in the pre-operative and post-operative periods
89689162|NCT04376645|Experimental|Group 1|Group 1: - Class III patients with increased vertical relationship These patients were scheduled for bimaxillary surgical procedures (Maxillary advancement and mandibular setback with posterior maxillary impaction) to correct the antero-posterior and vertical skeletal discrepancies.
89689163|NCT04376645|Experimental|Group 2|Group 2: - Class III subjects with normal vertical relationship These patients were scheduled for mandibular setback surgical procedure (with no posterior maxillary impaction) to correct the antero-posterior skeletal discrepancy.
89689164|NCT02977923|Active Comparator|Standard pharmacological treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
89689165|NCT02977923|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
89689166|NCT04374851|Experimental|New Device|The new Hearing aid is essentially the same as the current device (i.e., hardware, use) but with an improved digital signal processing (DSP).
89689167|NCT04374851|Active Comparator|Current Device|The current device is the Hearing aid that is currently sold on the market. It is used as a normal Hearing aid that is worn daily to amplify sounds for Hearing-impaired people.
89689168|NCT03024112|Experimental|Heated humidified high-flow nasal cannula (HHFNC) oxygen|The intervention group received HHFNC O2 at a set flow of 40L/min. FiO2 was titrated by respiratory therapists to maintain SpO2 ≥ 90%. The HHFNC O2 apparatus included: 1) Air-Oxygen blender - capable of delivering 21-100% FiO2 at flow rates up to 60L/min, 2) Heated Humidifier - providing active heating and humidification to the delivered air-O2 blend, 3) Nasal cannula - larger diameter, slightly elongated nasal cannula with single limb connection to humidifier
89689169|NCT03024112|Active Comparator|Standard oxygen Therapy|The standard O2 treatment group received usual nasal cannula or face mask oxygen titrated by nurses as necessary to maintain SpO2 ≥ 90%.
89689170|NCT04374383|Experimental|main treatment group|LASER assisted SRP followed by antimicrobial photodynamic therapy with a novel photosensitizer dye Phthalocyanine
89689171|NCT04374383|Placebo Comparator|control group|LASER assisted SRP
89689172|NCT02978001||Patients with Psoriasis|Patients with moderate to severe psoriasis (PASI>8)
89689173|NCT02978001||Healthy Control Subjects|Healthy subjects matching the patients with psoriasis regarding age, gender and BMI
89689174|NCT02978079|Experimental|Pupillometry in stroke patients|All eligible patients will undergo pupillometry test for the finding of Horner's syndrome
89689175|NCT04366427|Experimental|Low-pressure hyperbaric oxygenation (L-HBO)|Low-pressure hyperbaric oxygen administration at 1.45 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 sessions (3-4 per week).
89689176|NCT04366427|Experimental|Standard-pressure hyperbaric oxygenation (HBO)|Standard pressure hyperbaric oxygen administration at 2.5 ATA for 60 minutes, inclusive of compression and decompression times, and a 3-minute air pause at the midtime. For a total of 20 non-consecutive sessions (3-4 per week).
89689177|NCT04366427|No Intervention|Control|Control group of athletes, no intervention.
89689178|NCT04366427|Experimental|30% O2|Administration of air mixture with 30% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
89689179|NCT04366427|Experimental|50% O2|Administration of air mixture with 50% O2, subjects breathing this mixture for 60 minutes for a total of 20 non-consecutive sessions (3-4 per week).
89689180|NCT02842060|Experimental|myDEx Intervention|The proposed intervention will consist of a 6-session web-based program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, YMSM will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help YMSM consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
89689181|NCT02842060|Active Comparator|Non-tailored HIV Prevention|The investigators will create a 6-session web-based attention-control comparison to match myDEx in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites.
89689182|NCT02978313|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
89689183|NCT02978313|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
89689184|NCT00958477|Experimental|EMD 525797|
89689185|NCT02958826||No Smoke Evacuation|No Smoke Evacuation Group, anonymous questionnaire administered
89689186|NCT02958826||Smoke Evacuation|Smoke Evacuation Group, anonymous questionnaire administered
89689187|NCT05716737|Experimental|TMJ RT|Patients receiving irradiation to the TMJ
89689188|NCT05716659||Healthy subjects group|150 healthy subjects
89689189|NCT05716659||Metabolic syndrome group|100 patients with clinical diagnosis of metabolic syndrome.
89689190|NCT05716659||Heart failure group|100 patients with clinical diagnosis of heart failure.
89689191|NCT05716659||Heart failure with metabolic syndrome group|100 patients with clinical diagnosis of heart failure with metabolic syndrome.
89689192|NCT05716659||Severe aortic valve stenosis group|100 patients with clinical diagnosis of severe aortic valve stenosis.
89689193|NCT05716659||Ischemic stroke group|200 patients with clinical diagnosis of ischemic stroke.
89689194|NCT05620459|Experimental|Interventional arm (Ridge augmentation with simultaneous implant placement)|"Chin bone ring is harvested using surgical guide to augment~anterior maxillary defective recent extraction sockets OR~remaining roots that need extraction and are accompanied with labial bone loss Associated with simultaneous implant placement with the aid of surgical guides"
89689195|NCT00014495|Experimental|bismuth Bi 213 monoclonal antibody M195 & cytarabine|"Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14, patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days. Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are treated at the MTD.~Patients are followed twice weekly for 4 weeks and then monthly for 3 months"
89689196|NCT02978469|Experimental|Life style changing: reducing sedentary behavior|Meetings with social worker and physical therapist.
89689197|NCT02978469|Active Comparator|Physical exercise group|Physical therapy exercise training in group, strengthening and stretching muscles.
89689198|NCT03017287|Experimental|GlucoMe App|Self monitoring of glucose blood measurements using the GlucoMe glucose monitoring glucose device and App
89689199|NCT04366271|Experimental|Mesenchymal cells|Undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
89689200|NCT04366271|Active Comparator|Standard of care|Standard of care
89689201|NCT03030547|Experimental|Muscle Disease Group|Adult patients with muscle diseases diagnosed by neurologist, will wear SenseWear activity monitor for 5 days
89689202|NCT03030547|Active Comparator|Healthy Individuals Group|Healthy individuals with similar demographic characteristics as adult patients with muscle diseases, will wear SenseWear activity monitor for 5 days
89689203|NCT04374617||Venous thromboembolism|Patients at risk of venous thromboembolism (deep venous thrombosis and/or pulmonary embolism)
89689204|NCT04366037|Experimental|Control group|This group performed their routine training
89689205|NCT04366037|Experimental|Experimental 1|This group performed their routine training plus proprioceptive exercises in the warm-up.
89689206|NCT04366037|Experimental|Experimental 2|This group performed their routine training plus proprioceptive exercises in the cool-down
89689207|NCT04374227|Experimental|Treatment Group|The treatment group received three osteopathic manipulative treatments once a week for three weeks. The osteopathic manipulative treatment was a full body treatment based upon Dr. Zink's model of a common compensatory pattern.
89689208|NCT04374227|No Intervention|Control Group|This group received an osteopathic structural exam once a week for three weeks without any treatment performed.
89689209|NCT00960505|Experimental|Alternate day fasting (ADF)|Fast day diet: 25% energy intake, Feast day diet: Ad libitum energy intake (alternating days)
89689210|NCT00960505|Experimental|Calorie restriction (CR)|75% energy intake every day
89689211|NCT00960505|Active Comparator|Control|Usual diet
89689212|NCT04374071||Pre-Corticosteroid protocol|Patients with moderate or severe disease who presented to HFHS within the first week of the COVID epidemic in Detroit were initially treated with supportive care with or without a combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional guideline developed by Infectious Diseases Physicians and Pharmacists. The institutional guidelines were developed by consensus, and based on the available literature, experience from Wuhan, China and other centers around the world affected by COVID-19 before Michigan. Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically ventilated patients. On March 17, 2020 lopinavir-ritonavir with ribavirin was removed from the COVID-19 institutional protocol.
89689213|NCT04374071||Corticosteroid Protocol|"As a result of observed poor outcomes, clinical rationale based upon immunology, clinical course of COVID-19, and more recently best available evidence, the HFHS corticosteroid protocol was developed. We hypothesized that early corticosteroids would combat the inflammatory cascade leading to respiratory failure, ICU escalation of care, and mechanical ventilation. The corticosteroid protocol became the institutional standard on March 20, 2020. Patients with confirmed influenza infection were not recommended to receive corticosteroids.~Patients with moderate COVID-19 who required 4 liters or more of oxygen per minute on admission, or who had escalating oxygen requirements from baseline, were recommended to receive IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days. Patients who required ICU admission were recommended to receive the above regimen of hydroxychloroquine and IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 to 7 days."
89689214|NCT02958982|Experimental|RP3128|RP3128, A CRAC channel modulator
89689215|NCT02958982|Placebo Comparator|Placebo|Placebo
89689216|NCT02244749||skin specimen|skin specimen
89689217|NCT00357981|Experimental|ORTHO EVRA|"The approximate first two months of women's participation will be spent documenting baseline information about their health and well-being, work patterns and performance, and the economic impact of their menstruation. Subjects will then initiate two, two month intervals of continuous use of ORTHO EVRA.~Over this four month treatment period, subjects will document their health and well-being, work patterns and performance, and the economic impact of their menstruation while being treated with ORTHO EVRA. This will allow us to compare subjects' experiences pre- and post-treatment. The study's instruments will focus on eliciting information on the personal and economic costs of menstruation such as measuring time missed from work, changes in productivity and work satisfaction, and impact on quality of life."
89220005|NCT04989712|Experimental|4 x 5 mins MVPA|4 bouts of 5 minutes of moderate to vigorous exercise at 50-80% maximum heart rate to be performed on a cycle ergometer 30 minutes from the start of the testing session and repeated at 60 mins, 90 mins and 120 mins following consumption of a glucose solution at 0 mins. Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point.
89060716|NCT05537064|Experimental|Visit-Based Intervention|In this arm the investigators will evaluate a visit-based nudge to refer to centralized pharmacy services to refer patients eligible for but not prescribed high-intensity statins to centralized pharmacy services for initiation and/or titration of a statin. Physicians in a single practice will be randomized to usual care versus visit-based nudge. The visit-based nudge will consist of an interruptive Best Practice Advisory (BPA) in the EMR that will trigger during non-acute patient visits and will prompt the provider to refer the patient to a centralized pharmacy service for statin initiation and management.
89060717|NCT05531604||AN-Restricting (AN-R)|Meet Diagnostic and Statistical Manual (DSM-5) criteria for anorexia nervosa, restricting subtype
89060718|NCT05531604||Weight Restored AN-Restricting (WRAN-R)|"History of anorexia nervosa, restricting type - previously meeting full DSM-5 criteria.~Eating Disorder Examination Questionnaire (EDE-Q) ≤ 2 (within 1 standard deviation [SD] of community norms and lower than 1 standard deviation from clinical norms for female anorexia nervosa, restricting type populations)"
89060719|NCT05531604||Healthy controls|Healthy females from any racial or ethnic background, not meeting DSM-5 criteria for any psychiatric disorder.
89060720|NCT05524649|Experimental|Experimental 1|Probiotic single strain formulation comprising Bifidobacterium longum CECT7894 in liquid format suspended in sunflower oil. This probiotic strain has Qualified Presumption of Safety (QPS) status by European Food Safety Authority.
89060721|NCT05524649|Experimental|Experimental 2|Probiotic single strain formulation comprising Pediococcus pentosaceus CECT8330 in liquid format suspended in sunflower oil. This probiotic strain has Qualified Presumption of Safety (QPS) status by European Food Safety Authority.
89060722|NCT05524649|Placebo Comparator|Placebo|Sunflower oil
89060723|NCT05521074|Experimental|Active tDCS administered before extinction phase|The investigators will stimulate using 2mA of direct current during 20 min before the extinction phase of the fear conditioning and extinction paradigm.
89060724|NCT05521074|Experimental|Active tDCS administered during extinction phase|The investigators will stimulate using 2mA of direct current during 20 min during the extinction phase of the fear conditioning and extinction paradigm.
89060725|NCT05521074|Experimental|Active tDCS administered after extinction phase|The investigators will stimulate using 2mA of direct current during 20 min after the extinction phase of the fear conditioning and extinction paradigm.
89060726|NCT05521074|Sham Comparator|Sham tDCS|Sham will consist of a ramp up and down of activity (from 0 to 2mA and back to 0mA) in the first 30sec and again in the last 30 sec of the 20min stimulation period (which will occur before/during/after the extinction phase). No active tDCS will occur.
89060727|NCT05519475|Experimental|ALN-HSD|Randomized 1:1
89060728|NCT05519475|Placebo Comparator|Placebo|Randomized 1:1
89060729|NCT05509257|Experimental|Group A|All participants will receive both naltrexone and placebo, separated by a washout period, in a randomized, crossover fashion. Those randomized to group A will receive naltrexone then placebo. Those randomized to group B will receive placebo then naltrexone.
89060730|NCT05509257|Experimental|Group B|All participants will receive both naltrexone and placebo, separated by a washout period, in a randomized, crossover fashion. Those randomized to group A will receive naltrexone then placebo. Those randomized to group B will receive placebo then naltrexone.
89060731|NCT05507541|Experimental|Arm A (pembrolizumab, TTI-621)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle and TTI-621 IV over 60-120 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT scans or CT scans of the chest, abdomen, and pelvis prior to cycle 3 and every 4 cycles thereafter. If no disease progression after cycle 12, patients then receive pembrolizumab IV over 30 minutes on days 1 of each cycle and TTI-621 IV over 60-120 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.
89060732|NCT05507541|Experimental|Arm B (pembrolizumab, TTI-622)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle and TTI-622 IV over 60-90 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT scans or CT scans of the chest, abdomen, and pelvis prior to cycle 3 and every 4 cycles thereafter. If no disease progression after cycle 12, patients then receive pembrolizumab IV over 30 minutes on days 1 of each cycle and TTI-622 IV over 60-90 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.
89060733|NCT05489562|Other|Single Arm Mouthguard|Subjects wearing mouthguard to access tolerability and comfort of the device
89060734|NCT05463965|Experimental|Treatment Group|Single injection with QM1114-DP in glabellar lines
89060735|NCT05463965|Active Comparator|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
89060736|NCT05463965|Placebo Comparator|Placebo-Controlled Group|Single injection with placebo in glabellar lines
89060737|NCT05438680|Active Comparator|Group I: bovine colostrum group|
89060738|NCT05438680|Placebo Comparator|group II : control group|
89060739|NCT05436041|Experimental|Nutri|PCPs will receive an alert to use Nutri personalized diet goal setting software with enrolled patients
89060740|NCT05436041|No Intervention|Control|Usual care
89060741|NCT05434078|Experimental|Orthofeet Shoes|Participants will be given Orthofeet shoes to wear for 6 weeks
89060742|NCT05434078|No Intervention|No Orthofeet shoes|This group will not be wearing Orthofeet shoes for 6 weeks
89060743|NCT05417854|Experimental|Ultrasound Group|
89060744|NCT05414565||Vivity IOL|Subjects previously implanted with Vivity or Vivity toric IOL
89060745|NCT05414565||Aspheric Monofocal IOL|Subjects previously implanted with an aspheric monofocal or monofocal toric IOL
89060746|NCT05407012|Experimental|Intervention of the barrier enhancing preparation|Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.
89060747|NCT05407012|No Intervention|Absence of the barrier enhancing preparation|Dry skin or atopic dermatitis or healthy skin; application of the peanut protein extract +/- massage after extract application.
89060748|NCT05400707||patients admitted to emergency ward of the University Hospital Basel.|
89060749|NCT05395091|Experimental|AVT03|AVT03 is the proposed biosimilar for Prolia. Subjects in this arm will receive AVT03 60mg administered s.c. on Day 1 and Day 180/Month 6. At Month 12, subjects in the AVT03 arm will receive a third dose of AVT03 60 mg
89060750|NCT05395091|Active Comparator|Prolia|"Subjects will receive 60mg of commercially available Prolia, administered s.c. on Day 1 and Day 180/Month 6. At Month 12, subjects in the Prolia treatment group will be re-randomized in a 1:1 ratio to receive either:~Group 2a:Subjects will receive AVT03 60 mg administered s.c. on Day365.~Group 2b:Subjects will receive Prolia 60 mg administered s.c. on Day365."
89060751|NCT05388864|Experimental|Three-Tier Model|130 children with ACEs who received well-child care by a trained provider will be enrolled in this group.
89060752|NCT05388864|No Intervention|Comparison Group|80 children without ACEs who received usual well-child care will be enrolled in this group.
89060753|NCT05388864|No Intervention|Control Group|130 children with ACEs who received usual well-child care will be enrolled in this group.
89060754|NCT05387759|Experimental|Treatment Sequence 1|Healthy participants will receive single oral dose of Aticaprant (Dose 1) (Treatment A) in Treatment Period 1, followed by Moxifloxacin (Dose 2) (Treatment D) in Treatment Period 2, followed by Aticaprant (Dose 3) (Treatment B) in Treatment Period 3 and then placebo (Treatment C) in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
89060755|NCT05387759|Experimental|Treatment Sequence 2|Healthy participants will receive single oral dose of Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 and then Treatment D in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
89060756|NCT05387759|Experimental|Treatment Sequence 3|Healthy participants will receive single oral dose of Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3 and then Treatment A in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period.
89060757|NCT05387759|Experimental|Treatment Sequence 4|Healthy participants will receive single oral dose of Treatment D in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 and then Treatment B in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7 to 15 days between each treatment period.
89060758|NCT05380921|Experimental|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
89060759|NCT05380921|Experimental|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
89060760|NCT05380180|Experimental|OneClick Social Engagement Intervention Group|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8.
89060761|NCT05380180|Other|OneClick Social Engagement Waitlist Control Group|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension.
89060762|NCT05377827|Experimental|Part A Cohort A: Dose Escalation WU-CART-007 T-NHL|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the assigned dose level.
89060763|NCT05377827|Experimental|Part A Cohort B: Dose Escalation WU-CART-007 AML|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the assigned dose level.
89689218|NCT03030703|Experimental|350 mg phytic acid|350 mg phytic acid (inositol hexaphosphate) at week 0 (before supplementation) and at week 4 (after supplementation)
89689219|NCT02157623|Experimental|Red Light PDT and Blue Light PDT|The tumor clearance with one side treated with Levulan and Red light PDT, and the contralateral side treated with Blue light PDT.
89689220|NCT03030469|Experimental|10-pill default|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
89689221|NCT03030469|Experimental|5-pill default|New opioid analgesic prescriptions will automatically default to 5 pills.
89689222|NCT03030469|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
89689223|NCT03028324|Experimental|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
89689224|NCT00952081|Experimental|clevidipine,brain tumor,hypertension|21 or older, Clevidipine in brain tumor resection, epilepsy focus resection during acute hypertension under general anesthesia
89689225|NCT05716347|Experimental|the 5 μg recombinant SARS-CoV-2 S-Trimer vaccine booster group|
89689226|NCT05716347|Experimental|the 10 μg recombinant SARS-CoV-2 S-Trimer vaccine booster group|
89689227|NCT05716347|Experimental|the 30 μg recombinant SARS-CoV-2 S-Trimer vaccine booster group|
89689228|NCT05716347|Active Comparator|ICV booster group|
89689229|NCT02959840|No Intervention|Control|No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
89689230|NCT02959840|Active Comparator|Metoclopramide, Ondansetron|10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
89689231|NCT02959840|Experimental|Acupressure Point P6 stimulator|Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.
89689232|NCT04358341|Active Comparator|Irinotecan alone|150 mg/m2 iv drip d1; Repeat every 14 days.
89689233|NCT04358341|Experimental|Pegliposomal Doxorubicin and 5-FU|Pegliposomal Doxorubicin: 25mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h d1; Repeat every 14 days.
89689234|NCT02978547|Experimental|Metformin|All patients will receive metformin 500 mg per oral twice daily with food for at least 7 days, until 2 days prior to surgery. Metformin therapy should be discontinued 2 days before surgery to reduce the risk of lactic acidosis associated with fasting.
89689235|NCT00929357||1|DMARDs
89689236|NCT00929357||2|Biologics
89689237|NCT00961051|Experimental|Investigational MPS|Investigational multipurpose disinfecting solution (study MPS)
89689238|NCT00961051|Active Comparator|Predicate MPS|Opti-Free RepleniSH multipurpose disinfecting solution (predicate MPS)
89220006|NCT04989712|Experimental|Uninterrupted sitting - No exercise, sitting session (control).|A sitting only exposure, glucose solution to be consumed at 0 mins.Glucose readings from the FreeStyle Libre to be taken at 0 mins, 30 mins, 60 mins, 90 mins and 120 mins. Cognitive tests to be carried out before the glucose solution is administered at 0 mins and at the 120 min point
89220007|NCT04988516|Experimental|Virtual Reality Distraction|Use of Virtual Reality (VR) before the MRI.
89220008|NCT04988516|Active Comparator|Standard Treatment|Standard Treatment used at the radiology department.
89220009|NCT04986852|Experimental|Olinvacimab (TTAC-0001) 16 mg/kg and Pembrolizumab (Keytruda®) 200 mg|"Olinvacimab (TTAC-0001) 16 mg/kg on D1, D8 and D15~Pembrolizumab (Keytruda®) 200 mg on D1 Cycle: 3 weeks (21 days per cycle)"
89220010|NCT04982471||First relapsed/refractory diffuse large B-cell lymphoma|First relapsed/refractory diffuse large B-cell lymphoma (DLBCL) participants must have been diagnosed with relapsed/refractory (R/R) disease within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
89220011|NCT04982471||First relapsed/refractory follicular lymphoma|First relapsed/refractory (R/R) follicular lymphoma (FL) participants must have been diagnosed with R/R disease (grade 1 to 3B or transformed) within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
89220012|NCT04980612|Experimental|Group 1|4 cohorts of 10 participants to MBPR (First 3 groups single-arm, final group of 10 randomly assigned to MBPR)
89220013|NCT04980612|Active Comparator|Group 2|The last 20 participants will be randomly assigned to MBSR or MBPR, which will results in a control group with ~10 participants undergoing MBSR
89220014|NCT04978779|Experimental|Monotherapy of VIP152|Investigating VIP152 in a monotherapy cohort in patients with high-risk CLL and Richter Syndrome
89220015|NCT04978779|Experimental|VIP152 in combination with BTKi|Investigating VIP152 in combination with a BTKi in patients with CLL
89220016|NCT04976140|Experimental|Low dose group|The investigational product is intravenously administered according to the planned dose.
89220017|NCT04976140|Experimental|Intermediate dose group|The investigational product is intravenously administered according to the planned dose.
89220018|NCT04976140|Experimental|High dose group|The investigational product is intravenously administered according to the planned dose.
89220019|NCT04971993||Heart Failure NYHA Class II|Participants are diagnosed with NYHA Class II heart failure.
89220020|NCT04971993||Heart Failure NYHA Class III|Participants are diagnosed with NYHA Class III heart failure.
89220021|NCT04971993||At risk for arrythmias|Participants are indicated for an insertable cardiac monitor with no history of heart failure.
89060764|NCT05377827|Experimental|Part B Cohort A: Dose Expansion WU-CART-007 T-NHL|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the recommended phase II dose.
89060765|NCT05377827|Experimental|Part B Cohort B: Dose Expansion WU-CART-007 AML|Patients will receive preparative lymphodepletion in the week prior to WU-CART-007, after which WU-CART-007 will be infused 3 days following the last dose of chemotherapy at the recommended phase II dose.
89060766|NCT05373186|Experimental|BC Combo THDB0207|Single administration of BC Combo THDB0207
89060767|NCT05373186|Active Comparator|Humalog® Mix25|Single administration of Humalog® Mix25
89060768|NCT05373186|Active Comparator|Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus®
89060769|NCT05366010|Experimental|Intervention|Intervention time period, during which all subjects receive OLE therapy as their airway clearance intervention
89060770|NCT05361746|Experimental|SBU+ Treatment Group|Either 1 tooth (for Subjects with 2 eligible teeth) or 2 teeth (for Subjects with 4 eligible teeth) with Class-V NCCLs will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive .
89060771|NCT05361746|Active Comparator|SBU Control Group|Either 1 tooth (for Subjects with 2 eligible teeth) or 2 teeth (for Subjects with 4 eligible teeth) with Class-V NCCLs will undergo restoration(s) using the predicate device, Scotchbond Universal (SBU) Adhesive.
89060772|NCT05349227|Experimental|Intervention Group|In addition to standard of care services at the participant's respective health system, and study specific collection of clinical, PRO, and wearable data, as well as microbiome specimens, individuals randomized to the intervention group will receive immediate enrollment to a 6-month digital health coaching program followed by 6 months monitoring via PRO, wearable, and clinical data collection. They will collect fecal microbiome samples at baseline (study enrollment) and month 6 following enrollment.
89220022|NCT04970485|Experimental|Talking Matters intervention|Talking Matters is a group-level, two-pronged intervention for Black and African American 14 to 19 year old adolescents recruited from school- and community-based settings in Philadelphia, PA. Goals are to reduce teens' risk for unplanned pregnancy, sexually transmitted infections, and HIV, and to strengthen protective factors to improve health. The two prongs include (1) an adolescent-focused five-session, group-level intervention called We Get to Choose (WGTC) covering sexual and reproductive health (SRH) knowledge and skills, decision making and self-worth, healthy relationships, substance use and mental health; and (2) an adult-focused three-session, group-level training called Let's Talk Real Talk (LTRT) to build SRH knowledge and skills to communicate with teens about SRH. An opportunity to connect WGTC participants to trusted adults who completed LTRT is provided during one facilitated session conducted each quarter. LTRT participants are not human subjects of the study.
89220023|NCT04970485|No Intervention|Control Group|Business as usual
89220024|NCT04969094|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
89220025|NCT04969094|Active Comparator|MMBI|Participation in a multi-modality balance intervention
89220026|NCT04964076||COPD patients in the plateau|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Tibet Autonomous Region People's Hospital from January 2018 to December 2021.
89220027|NCT04964076||COPD patients in the plain|We consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Peking University Third Hospital from January 2018 to December 2021.
89220028|NCT04957329|Active Comparator|BAK-preserved|Xalatan eye drop
89220029|NCT04957329|Active Comparator|Preservative-free|Monoprost eye drop
89220030|NCT04953949|Experimental|NU-MAX®|Topical Hemostat
89220031|NCT04946279|Experimental|Arm I (conversation tool)|Patients receive the conversation tool.
89220032|NCT04946279|Active Comparator|Arm II (usual care)|Patients receive usual care.
89220033|NCT04943796||Part I: Participants with ADHD|Participants with psychiatric disorders undergoing ADHD diagnosis.
89220034|NCT04943796||Part II: Participants with ADHD|To collect pseudonymized data from participants who are underdiagnosed of ADHD with psychiatric disorders in daily clinical practice for up to 9 months from both Part I and II.
89220035|NCT04938596|Experimental|Respiratory Bundle Group|The intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.
89220036|NCT04938596|No Intervention|Standard of care|Under current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.
89220037|NCT04934826|Experimental|Hydrolized proteins|Group receiving hydrolyzed proteins in the postprandial metabolic test
89220038|NCT04934826|Active Comparator|Intact proteins|Group receiving intact proteins in the postprandial metabolic test
89220039|NCT04932096|Experimental|Melatonin|(melatonin doses of 3mg or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days)
89220040|NCT04932096|Placebo Comparator|Placebo|Placebo
89220041|NCT04931082|Active Comparator|Probiotics|One capsule per day for 12 weeks
89220042|NCT04931082|Placebo Comparator|Placebo|One capsule per day for 12 weeks
89220043|NCT04928586|Experimental|Pirfenidone group|CTD-ILD patients treated with DMARDs and pirfenidone
89220044|NCT04928586|Active Comparator|No-Pirfenidone group|CTD-ILD patients treated with DMARDs, without pirfenidone
89220045|NCT04928066|Experimental|Tofacitinib (TF)+Iguratimod (IGU)|"Drug: Iguratimod（IGU），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Tofacitinib（TF），5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone （Pred）： 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response."
89220046|NCT04928066|Other|Tofacitinib (TF)|"Drug: Tofacitinib（TF），5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Prednisone （Pred）： 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response."
89220047|NCT04927429||Affected participants|Participants with a clinically indicated referral for cardiac MRI
89220048|NCT04927429||Healthy participants|Healthy individuals of various ethnicities to serve as reference ranges
89220049|NCT04926376|Experimental|EYE90 Microspheres Treament|Radioembolization with Eye90 Microspheres
89220050|NCT04925700|Experimental|Probiotic Lozenge|
89220051|NCT04925700|Placebo Comparator|Placebo Lozenge|
89220052|NCT04918524||The Antiphospholipid syndrome (APS)|The cohort includes that patients who meet the proposed Sydney criteria.
89220053|NCT04918524||Undifferentiated connective tissue disease (UCTD)|The cohort includes the patients who are diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, antiphospholipid antibodies (aPL), and non-criteria aPL (NC-aPL), with at least one symptoms or signs suggesting CTD ,while not fulfilling any classification criteria of a defined CTD.
89220054|NCT04912115|Experimental|Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.1 mg/kg/hr to 0.30 mg/kg/hr. To maintain blinding, both active and placebo will be infused at similar infusion rates (mL/hr).
89220055|NCT04912115|Active Comparator|Midazolam|Midazolam will be administered as intravenous infusions with infusion rates ranging from 0.009 mg/kg/hr to 0.027 mg/kg/hr. To maintain blinding, both active and placebo will be infused at similar infusion rates (mL/hr).
89220056|NCT04908631|Other|tDCS during auditory training|Use of tDCS during completion of the auditory training program
89220057|NCT04906044|Experimental|Total Neoadjuvant Treatment combined with Sintilimab|
89220058|NCT04896645|Experimental|Patients 8 to <19 years of age with a diagnosis of asthma|Patients 8 to <19 years of age with a diagnosis of asthma as ICD-9 code 493 or ICD-10 code J45 seen in the allergy clinic at CHLA who have an albuterol rescue inhaler already prescribed and access to a personal smartphone will be eligible for recruitment.
89220059|NCT04894266|Other|Standard of Care|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital.
89220060|NCT04894266|Experimental|Standard of Care plus apabetalone|All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital. For the apabetalone cohort, treatment will be administered BID with meals.
89220061|NCT04877236|Experimental|Green Sun Medical Brace|This study only has one arm, administration of the Green Sun Medical Whisper Brace.
89220062|NCT04873752|Experimental|UDI-001|Four cycles with 8 administrations
89220063|NCT04871113|Experimental|Part 1: Participants receiving GSK3810109A 40 mg/kg (Cohort 1)|Participants will be administered GSK3810109A as a single IV infusion of 40 mg/kg dose in Part 1.
89220064|NCT04871113|Experimental|Part 1: Participants receiving GSK3810109A 280 mg (Cohort 2)|Participants will be administered GSK3810109A as a single IV infusion of 280 mg dose in Part 1.
89220065|NCT04871113|Experimental|Part 2: Participants receiving GSK3810109A (Cohort 3)|Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1.
89220066|NCT04871113|Experimental|Part 2: Participants receiving GSK3810109A (Cohort 4)|Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1
89220067|NCT04871113|Experimental|Part 2: Participants receiving GSK3810109A (Cohort 5)|Participants will be administered GSK3810109A as a single IV infusion or SC injection and will include dose level determined based on the data of Part 1.
89220068|NCT04871074|Active Comparator|Cognitively unimpaired|Results of most recent testing with the source cohort indicate the participant is cognitively unimpaired as judged by consensus or expert review.
89220069|NCT04871074|Active Comparator|Mild Cognitive Impairment|Abnormal cognitive status of MCI as judged by consensus or expert review using NIA-AA 2018 criteria.
89220070|NCT04871074|Active Comparator|Mild dementia|Abnormal cognitive status of dementia as judged by consensus or expert review using NIA-AA 2018 criteria.
89220071|NCT04870580|Other|Intervention arm|PET/CT with fluorodopa tracer
89220072|NCT04863352||Study group|Men who have been treated for localized or locally advanced prostate cancer with curative intent
89220073|NCT04863352||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019
89220074|NCT04861454||surgical|internal browbexy and brassier suture were done after blepharoplasty
89220075|NCT04856163|Experimental|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 24 weeks post-partum. Services will be available through mobile phone app.
89220076|NCT04856163|No Intervention|ebook|Participants in the control arm will receive care as usual. They will also receive a ebook with content on infant care.
89220077|NCT04854395|Active Comparator|Group A: Active FTB + Active PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml for IFCN + 10 ml Marcain 5 mg/ml is used for PPB
89220078|NCT04854395|Active Comparator|Group B: Active FTB + Sham PPB + Sham ACB|Single shot bolus of 10 ml Marcain 5 mg/ml is used for FTB, 5 ml Marcain 5 mg/ml is used for IFCN
89220079|NCT04854395|Active Comparator|Group C: Sham FTB + Sham PPB + Active ACB|Single shot bolus of 25 ml Marcain 5 mg/ml is used for ACB
89220080|NCT04852289||>=65 Female|Older Females
89220081|NCT04852289||>=65 Male|Older Males
89220082|NCT04852289||18-64 Female|Young Females
89220083|NCT04852289||18-64 Male|Young Males
89220084|NCT04852016|Experimental|Digital Educational Platform|Study participants randomized to the DEP+SVC group (intervention) will be presented with an iPad with a link to an interactive DEP module discussing the indications for LC, alternatives, risks, complications, expectations and anticipated recovery. They will be asked to review the DEP module at their own pace and will be required to confirm understanding of all of the material presented on the DEP. Upon completion of the module, a member of the surgery team will ask the patient if they have any additional questions or require further clarification regarding the LC procedure, indications for surgery, alternatives, risk, complications, expectations and anticipated recovery. Once all of participant's questions are answered, an informed paper-based consent form for LC will be signed.
89220085|NCT04852016|Active Comparator|Standard Verbal Consent|Study participants randomized to the SVC group (control) will discuss the LC procedure, indications for surgery, alternatives, risk, complications, expectations and anticipated recovery with a member of the surgery team. The study participant will be given the opportunity to ask questions and once all of the questions have been answered, an informed paper-based consent form for LC will be signed.
89220086|NCT04844294|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|
89220087|NCT04844294|Active Comparator|Present-Centered Therapy (PCT)|
89220088|NCT04841811|Active Comparator|Group A (almonertinib continuous treatment)|Subjects will be randomly assigned to groups A and B after radical therapy (surgery or radiothrapy) and will receive 110 mg of almonertinib once a day for 2 years or until disease recurrence or metastasis.
89220089|NCT04841811|Experimental|Group B (ctDNA monitoring guided the almonertinib treatment)|Subjects will be randomly assigned to group B after radical therapy (surgery or radiothrapy) and will receive almonertinib guided by ctDNA dynamic monitoring (every 3 months test ctDNA once, if it is positive, continue to receive almonertinib 110 mg once a day, if it is negative, stop almonertinib until ctDNA turns positive and receive almonertinib treatment again).
89220090|NCT04839991|Experimental|Multi center open label Dose Escalation followed by Cohort Expansion: Part 2A|Patients will receive CB307 IV infused every 7 days. Duration of treatment cycle is 21 days. Once the Dose Escalation phase (Part 1) is completed Cohort Expansion phase (Part 2) will begin. Part 2A arm will enrol patients with PSMA+ solid tumours. Treatment will continue until loss of clinical benefit, intolerable toxicity, withdrawal of consent or the study is stopped. Estimated study duration is 20 months.
89220091|NCT04839991|Experimental|Multi center open label Dose Escalation followed by Combination Cohort Expansion : Part 2B|Patients will receive CB307 IV infused every 7 days in combination with KEYTRUDA® (pembrolizumab) IV infused every 21 days . Duration of treatment cycle is 21 days. Once the Dose Escalation phase (Part 1) is completed Cohort Expansion phase (Part 2) will begin. Part 2B arm will enrol patients with PSMA+ metastatic castration-resistant prostate cancer. Treatment will continue until loss of clinical benefit, intolerable toxicity, withdrawal of consent or the study is stopped. Estimated study duration is 20 months.
89220092|NCT04839900|Active Comparator|Proactive iCCM|Community health workers (CHWs) will conduct weekly visits of all households in their communities to detect children < 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. Weekly household visits will be conducted year round. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
89220093|NCT04839900|No Intervention|Standard Passive iCCM|Community health workers (CHWs) will provide case management per national iCCM policy to all who are brought for consultation, but will not conduct household visits to provide active case detection. CHWs will be available for consultation throughout the week for sick visit consultations as per national iCCM policy (with malaria case management for all ages).
89220094|NCT04827537|Experimental|20-hydroxyecdysone group|water sports athletes with Giardia infection will receive 20-hydroxyecdysone (100 mg (one pill) x two times a day orally), 10 consecutive days
89220095|NCT04827537|Active Comparator|metronidazole group|"water sports athletes with Giardia infection will receive metronidazole, 500 mg (one pill) x two times a day orally, 10 consecutive days~, and placebo preparations, respectively"
89220096|NCT04827537|Placebo Comparator|placebo group|water sports athletes with Giardia infection will receive placebo preparation, 100 mg (one pill) x two times a day orally, 10 consecutive days
89220097|NCT04825288|Active Comparator|Arm 1|"XB2001 + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 1 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: XB2001 MTD as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-Fluorouracil 2400mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
89220098|NCT04825288|Placebo Comparator|Arm 2|"Placebo + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 2 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: Placebo as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
89220099|NCT04822740|Experimental|Novel strategy|"Inserting the CGMS device with use of the results of the device in real time by the health care team~Insulin infusion according to the same local guidelines for insulin therapy in ACS~Transmission of real-time data to the nurse and use of the alarms of the device~Adaptation of insulin according to blood glucose measured by the CGMS device and according to the same protocol as the conventional arm~Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
89220100|NCT04822740|Active Comparator|Conventional strategy|"Inserting the CGMS device without the use of the results by the health care team: blinded CGMS (use of these results only at the end of the participation to analyze the main criterion)~Insulin infusion according to the same local guidelines for insulin therapy in ACS~Adaptation of insulin according to the capillary blood glucose levels performed every hourly if insulin dose change, every 2 hours if stable insulin dose according to local recommendations~Glycemic range: maintain a blood glucose between 140 and 180 mg / dl"
89220101|NCT04820179|Experimental|Cabozantinib 40mg + Atezolizumab 1200mg|Cabozantinib 40 mg, tablets, oral administration, once daily, continuously. Atezolizumab 1200 mg, administered intravenously, on Day 1 of every 21 day cycle.
89220102|NCT04820036|Other|Patients with Obesity and NASH scheduled/recommended for P-ESG Procedure|We will perform a 12-month prospective, single-center, pilot observational study on patients with obesity and NASH with advanced fibrosis who are undergoing P-ESG. A total of 15 patients will undergo EUS-LB with EUS-PPG measurement in a single session prior to and at 12 months following P-ESG
89220103|NCT04817865||Standard Pre-Procedural Urine Culture|This is a control cohort that follows standard pre-procedural protocol by implementing antibiotic prophylaxis and treatment regimens based on dipstick urine analysis (UA) followed by reflexed traditional urine culture and sensitivity (C&S) methods performed before injection.
89220104|NCT04817865||Pre-Procedural M-PCR/P-AST|This is an experimental cohort that implements Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST) for pre-procedural UTI screening. The cohort follows an antibiotic treatment regimen based on the results of M-PCR/P-AST.
89220105|NCT04817124|Experimental|stimulation group|Anodal tDCS+ intensive cognitive Training
89220106|NCT04817124|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
89220107|NCT04815564|Experimental|Intervention|Subjects with a PAR score between 15 and 50 and fulfilling the other eligibility criteria will be offered participation in the trial.
89220108|NCT04815564|No Intervention|Natural History|Subjects with a PAR score outside of 15-50 will be offered the opportunity to remain on study for the Natural History arm.
89220109|NCT04808986|Other|serology COVID-19|Serology of COVID-19 will be proposed to all health professionels and household members included in the study
89220110|NCT04805918|Experimental|VIPP-SD (Video-feedback Intervention to Promote Positive Parenting and Sensitive Discipline).|The VIPP-SD includes seven sessions of 1½-2 hours each with an 2-4 weeks interval VIPP-SD is delivered by a VIPP-SD trained pedagogue and takes place in the family home and the targeted parent and child are videotaped during daily interactions. The intervener studies the video and prepares feedback. During the sessions, the intervener and parent review the video together and the intervener provides their feedback according to the VIPP-SD protocol.
89220111|NCT04805918|Active Comparator|Care as ususl|The existing standard practices for parents of 2-6 year old children identified to be at risk for developing externalizing problems in the participating municipalities will be the active control condition. These vary in content and duration in the municipalities. Likewise, CAU may change during the project period. The exact content and duration of CAU interventions as well as participants' adherence to treatment will be described as precisely as possible.
89220112|NCT04800692|Experimental|Tetrahydrobiopterin Dose 1 (Day 0 to 44)|All subjects will receive 3300mg l-Ascorbate , l-Arginine 3400mg and 10mg/kg of Tetrahydrobiopterin once a day.
89220113|NCT04800692|Experimental|Tetrahydrobiopterin Dose 2 (Day 45 to 90)|All subjects will receive 3300mg l-Ascorbate, l-Arginine 3400mg and 20mg/kg of Tetrahydrobiopterin once a day.
89220114|NCT04800055|Experimental|ATSB + VC intervention|Arm 1 will receive ATSBs for up to two years.
89220115|NCT04800055|No Intervention|VC only|Arm 2 will receive the standard of care of universal vector control coverage.
89220116|NCT04791709|Experimental|HOLA Group|Participants in this group will receive a multicomponent intervention for 16 weeks.
89220117|NCT04791306|Experimental|Exercise Training|All participants should increase their physical activity level to at least 150 min per week, guided with once a week supervised in-house training as well as an application for planning and documentation for home-based physical activity
89220118|NCT04786600|Experimental|ctDNA assay-guided intervention|Subjects on this arm will be tested with the Signatera ctDNA assay while receiving treatment on a pre-specified sequence of FDA-approved drugs and drug combinations. Subjects will move through this sequence based on the results of the ctDNA assay. Subjects will move to a new drug or drug combination in the sequence when the ctDNA assay indicates a significant increase in ctDNA level. Subjects will also have imaging scans every 12 weeks while on each drug or drug combination and subjects will move to a new drug or drug combination if these scans indicate disease progression.
89220119|NCT04786600|Active Comparator|Scan-guided Intervention|Subjects on this arm will be treated with the same pre-specified sequence of FDA-approved drugs and drug combinations as those on the ctDNA assay- guided intervention arm. Subjects will move through the sequence based on the results of imaging scans, moving to a new drug or drug combination if imaging shows progressive disease.
89220120|NCT04783454|Experimental|Intervention|"single (online) educational video on how the prevention program is designed and general advice on (how to adopt) a healthy lifestyle~12-week training program: 2 sessions of 60 minutes per week, with the focus of the first session on cardiovascular exercises, and the focus of the second session on mobility and strengthening exercises"
89220121|NCT04783454|No Intervention|control|no intervention (wait and see approach)
89220122|NCT04783415|Experimental|Treatment (ublituximab, acalabrutinib, umbralisib)|"Patients receive ublituximab IV over 90 minutes-4 hours on days 1, 8, and 15 of cycle 1 and days 1 of cycles 2-6. Patients also receive acalabrutinib PO BID and umbralisib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ublituximab IV on day 1 on cycles 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30. Patients also receive acalabrutinib Po BID and umbralisib PO QD on day 1-28. Treatment repeats every 28 days for 24 cycles in the absence of disease progression of unacceptable toxicity."
89220123|NCT04779736|Other|Pre-post design|The pilot intervention will be evaluated using a pre-post design.
89220124|NCT04779437|Experimental|Imagery Cognitive Bias Modification First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of imagery cognitive bias modification followed by two weeks of cognitive control training. Daily QIDS will be completed throughout the intervention phases.
89220125|NCT04779437|Experimental|Cognitive Control Training First|After completing two weeks of daily QIDS (baseline phase), participants randomly allocated to this arm will complete two weeks of cognitive control training followed by two weeks of imagery cognitive bias modification. Daily QIDS will be completed throughout the intervention phases.
89220126|NCT04761770|Experimental|Geriatric participants with various blood disorders|"Geriatric assessment (GA) pre-transplant~Risk-adapted allocation of conditioning intensity based on GA~GA-directed, longitudinal supportive care management"
89220127|NCT04758338|Experimental|CTS Program Arm|6-week intervention delivered via telehealth using the VUMC telehealth services.
89220128|NCT04758338|Active Comparator|Education Attention Control Arm|Receive educational materials either online, by email, or in print form.
89220129|NCT04752618|Experimental|P-STAIR|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. P-STAIR is a combination of STAIR and PCIT. STAIR focuses on reduction of PTSD symptoms through enhancement of emotion regulation skills. PCIT focuses on the reduction of negative parenting skills and the increase of positive parenting skills.
89220130|NCT04752618|Active Comparator|Supportive Counseling|Participants will receive 23 weekly individual treatment sessions. Each session will last one hour. Supportive counseling has been modified to permit non-trauma discussion of parenting problems. Each session is client-directed and clinicians take an unconditionally supportive role.
89220131|NCT04751773|No Intervention|Standard care alone (CON)|"Participants allocated to CON receive the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark.~Participants allocated to CON are allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise training program."
89220132|NCT04751773|Experimental|Postoperative exercise training and standard care (EX)|"Participants allocated to EX receive the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark, and postoperative exercise training.~The postoperative exercise training program consists of 8 weeks of supervised and home-based exercise 5 times/week. The intensity and duration are progressively increased during the postoperative period"
89220133|NCT04751279||Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (<5 years)|Patients with pulmonary sarcoidosis without signs of chest activity (Benamore score <2) and recent diagnosis (<5 years)
89220134|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (<5 years|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2) and recent diagnosis (<5 years)
89220135|NCT04751279||Patients with pulmonary sarcoidosis without signs of activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis without signs of activity (Benamore score <2), persistent form (>5 years)
89220136|NCT04751279||Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (>5 years)|Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2), persistent form (>5 years)
89220137|NCT04747626|Experimental|Treatment|Implantation of a physician-modified endovascular stentgraft(s) to treat the proximal aorta in subjects with aortic disease involving multiple segments.
89220138|NCT04745403|Experimental|mRNA HBV/TCR T-cells|Escalating regime from 1x10e5 to 5-10x10e6 cells/kg bodyweight (BW) every 2 weeks.
89220139|NCT04728334|Experimental|AK117 monotherapy|AK117 monotherapy intravenous (IV) infusion - Weekly doses
89220140|NCT04726566||Arthroscopic stabilization|Patient will have an anatomical surgery of chronic lateral ankle instability under arthroscopy
89220141|NCT04719663|Experimental|1. Congruent Rationale & Treatment: Biological/Pharmacol.|Participants receive a biological illness explanation and treatment rationale. During treatment they receive a placebo pill (Buscopan).
89220142|NCT04719663|Experimental|2. Incongruent Rationale & Treatment: Psychological/Pharmacol.|Participants receive a psychological illness explanation and treatment rationale. During treatment they receive a placebo pill (Buscopan).
89220143|NCT04719663|Experimental|3. Congruent Rationale & Treatment: Psychological/Psychol.|Participants receive a psychological illness explanation and treatment rationale. During treatment they receive a placebo psychological treatment (emotional writing).
89220144|NCT04719663|Experimental|4. Incongruent Rationale & Treatment: Biological/Psychol.|Participants receive a biological illness explanation and treatment rationale. During treatment they receive a placebo psychological treatment (emotional writing).
89220145|NCT04719663|No Intervention|5. Natural course control|Participants receive no intervention and remain on the psychotherapy waiting list. Participants who are recruited externally and are not on a waiting list, will be offered the option to join the waiting list.
89220146|NCT04716933|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
89220147|NCT04716933|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
89220148|NCT04715230|Experimental|IXT-m200|IXT-m200 is a high-affinity chimeric anti-METH monoclonal antibody that is well-tolerated in healthy volunteers and in non-intoxicated people with METH use disorder. The total dose will be given over 10 min for the 0.5-g dose and over 20 min for the 1-, 1.5-, and 2-g doses.
89220149|NCT04715230|Active Comparator|Treatment as Usual (TAU)|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting. Haloperidol is commonly used to treat agitation due to psychosis.
89220150|NCT04710368|Experimental|Treatment|Evolocumab subcutaneously administered 140 mg every 2 weeks for 26 weeks
89220151|NCT04709939||Patient Participants|Adults patients who are discharged from the hospital on outpatient parenteral antibiotic therapy.
89220152|NCT04709939||Physician Participants|Infectious disease physicians who prescribe OPAT to their patients but were not involved in the study.
89220153|NCT04708834|Experimental|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
89220154|NCT04708730|Experimental|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
89220155|NCT04708730|No Intervention|control group|
89220156|NCT04705116||Vaccinated pregnant women|Pregnant women who received at least one dose of a COVID-19 vaccine from 30 days prior to the first day of the LMP to end of pregnancy.
89220157|NCT04705116||Non-vaccinated pregnant women|Pregnant women who have not received a COVID-19 vaccine during pregnancy.
89220158|NCT04704375|Experimental|Bio Electro-Magnetic Regulation (BEMER) Therapy|Subjects in the BEMER group received treatment 5 times per week for a period of 3 weeks.
89220159|NCT04704375|Active Comparator|OMT (Osteopathic Manipulative Treatment)|Each subject in the OMT group received treatment 3 times per week for a period of 3 weeks.
89220160|NCT04704375|Experimental|BEMER + OMT|Each subject in the BEMER + OMT group received treatment 3 times per week for a period of 3 weeks.
89220161|NCT04704375|Sham Comparator|Control|Finally, subjects in the Placebo group will receive the light touch and BEMER sham treatments at same intervals as the corresponding experimental groups.
89220162|NCT04695340|Experimental|Familial amyloidosis patients|Familial amyloidosis patients with gastro-intestinal pain receiving Psyllium
89220163|NCT04692324||Basic science (biospecimen collection)|Patients undergo collection of CSF samples via lumbar puncture at least 2 times. Patients may undergo additional collection of additional CSF samples if they choose.
89220164|NCT04684641|Experimental|Phage therapy|Participants will be randomized to receive 3mL phage therapy, nebulized daily for 7 days.
89220165|NCT04684641|Active Comparator|Placebo|Participants will be randomized to receive the 3mL placebo, nebulized daily for 7 days.
89220166|NCT04676490|No Intervention|Usual Discharge Care|Usual ED discharge care
89220167|NCT04676490|Experimental|RECORD-ED Card|Usual care, plus a physical greeting card-style card with audio discharge instructions (English or Spanish) recorded on it
89220168|NCT04676490|Experimental|RECORD-ED Patient Portal|Usual care, plus access to audio-recorded discharge instructions (English or Spanish) through the patient portal
89220169|NCT04672005|Experimental|Treatment Regimen: mFOLFIRINOX + mGnabP|"All study participants will receive the following treatment:~mFOLFIRINOX (28-day cycle)~Day 1 and Day 15:~Oxaliplatin 85 mg/m2 2-hour intravenous infusion followed by leucovorin 400 mg/m2 2-hour infusions with the addition of irinotecan 150 mg/m2 as a 90 minute infusion. 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours will follow irinotecan.~Day 3 and Day 17:~Pegylated-Granulocyte Colony Stimulating Facotr (peg-GCSF) 6 mg subcutaneous injection following disconnection of 5-FU infusion, first cycle and then per investigator discretion.~Biweekly mGnabP (28-day cycle)~Day 1 and Day 15:~Nab-paclitaxel 125 mg/m2 infused over 30 minutes, immediately followed by Gemcitabine 1200 mg/m2 intravenously infused at the rate of 10mg/m2/min (over 120 minutes).~Patients will receive one month of each regimen, alternately monthly until progression of disease."
89220170|NCT04668651||diabetic|diabetic patients
89220171|NCT04668651||non diabetic|non-diabetic patients
89220172|NCT04658537|Active Comparator|Standard Arm|8 Gy / 1 Fraction
89220173|NCT04658537|Experimental|Single Fraction Dose Escalation|8Gy Planning Target Volume / 12Gy Clinical Target Volume +/- 14Gy Gross Tumour Volume / 1 fraction
89220174|NCT04652375|Experimental|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
89220175|NCT04652375|Experimental|Lactated Ringer's Solution|Participants will receive lactated Ringer's for fluid resuscitation post-surgery
89220176|NCT04649125|Active Comparator|standard|standard radiotherapy 5 fractions
89060773|NCT05349227|Other|Wait List Control Group|In addition to standard of care services, individuals in the wait list control will be monitored via the collection of PRO, clinical, and wearable data for the first 6 months, along with fecal microbiome collection at study enrollment baseline (study enrollment) and month 6. At month 6 these individuals will be enrolled into the 6-month digital health coaching program, during which clinical, PRO and wearable data will continue to be collected. At the completion of the 6-month coaching these individuals will come off study and will not receive additional follow-up.
89060774|NCT05349227|No Intervention|Household Healthy Participants|A cohort of consisting of adults without a cancer diagnosis residing in the same residence as participants, will be consented to collect fecal microbiome specimens to serve as a control for potential regional variation in microbiome dysbiosis. Up to 25 healthy controls will be enrolled per 100 participants at each study site. At sites enrolling fewer than 100 participants, an n up to 25% of the total patient enrollment sample will be approached for enrollment.
89060775|NCT05337007|Experimental|dietary intervention, high protein diet|commercially available high protein ultraprocessed food items (30% protein content), cross-over design, all subjects receive all interventions
89060776|NCT05337007|Active Comparator|dietary intervention, moderate protein diet|commercially available moderate protein ultraprocessed food items (13% protein content), cross-over design, all subjects receive all interventions
89060777|NCT05321758|Active Comparator|FMT group|Repeated and multiple FMTs plus PEN(80%) in the treatment of pediatric CD. Patients received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) and FMT intervention. In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
89060778|NCT05321758|Sham Comparator|Immunosuppressive group|Patients received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) combined with Immunosuppressants (hormones, azathioprine, thalidomide) treatment.
89060779|NCT05321745|Experimental|Repeated and multiple FMTs plus PEN|repeated and multiple FMTs plus PEN(50% of total calories as polymeric diet, Peptamen, Nestle, Vevey, Switzerland) in refractory pediatric CD
89060780|NCT05314933|Active Comparator|Study drug|"Each subject receives either a single dose (SAD) or a multiple dose (MAD) of a 3.5% 2-Deoxyglucose as nasal spray solution.~The starting dose for the first cohort is 3.5 mg/day up to a maximum of 84 mg/day at cohort 6."
89060781|NCT05314933|Placebo Comparator|Placebo|Each subject receives either a single (SAD) or multiple (MAD) dose of placebo. The dose for each cohort is corresponding the amount of solution needed in the verum group.
89060782|NCT05309187|Experimental|IO-202 Monotherapy (dose escalation)|
89060783|NCT05309187|Experimental|IO-202 dose escalation + pembrolizumab|Increasing dose levels of IO-202 with fixed dose of pembrolizumab
89060784|NCT05309187|Experimental|IO-202 + pembrolizumab combination therapy (dose expansion)|RP2D + pembrolizumab combination therapy in solid tumor cohorts
89060785|NCT05306743|Experimental|CONQUEST Intervention Arm|Intervention arm clusters will receive the CONQUEST quality improvement program.
89060786|NCT05306743|Other|Delayed Intervention Arm|The CONQUEST quality improvement program will be rolled-out to the delayed intervention practices at the end of the outcome evaluation period.
89060787|NCT05289544|Experimental|Phone-Based Walk With Ease Program|Telephone-based Walk With Ease Program adapted from the Arthritis Foundations program
89060788|NCT05289544|Other|Delayed Phone-Based Walk With Ease Program|Telephone-Based Walk With Ease Program starting after the 1 year assessment
89060789|NCT05276622||Subjects with newly diagnosed multiple myeloma|Forty subjects with newly diagnosed multiple myeloma.
89060790|NCT05276622||Care partners of the subjects with newly diagnosed multiple myeloma|Thirty care partners of the subjects with newly diagnosed multiple myeloma.
89060791|NCT05266222||People with respiratory infection|Persons with suspected or documented respiratory infection
89060792|NCT05262595|Experimental|Arm 1|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
89060793|NCT05262595|Experimental|Arm 2|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
89060794|NCT05262595|Experimental|Arm 3|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
89060795|NCT05262595|Active Comparator|Arm 4|A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over)
89060796|NCT05260424||non-invasive ventilation failure|babies who will be intubated in the first 72 hours
89060797|NCT05260424||non-invasive ventilation success|babies who will not intubated in the first 72 hours
89060798|NCT05260047|Active Comparator|IMANI BREAKTHROUGH|Participants will participate in 24-week IMANI weekly groups
89060799|NCT05260047|Experimental|IMANI BREAKTROUGH + church-based telehealth MAT option (IMANI + CTM)|Participants will participate in the 24-week Imani weekly group. During weeks 1-4 participants will received education on MAT. Those participants randomized will receive the IMANI weekly group as well as a church based telehealth Medication Assisted Treatment option. The church based telehealth MAT will consist of participants assigned to receive MAT from addiction treatment providers via telehealth. Telehealth sessions will be provided in the church.
89060800|NCT05260047|Experimental|IMANI BREAKTHROUGH + Traditional MAT plus Referral and Linkage|Participants will participate in the 24-week Imani weekly group. During weeks 1-4 participants will received education on MAT. Those participants randomized will receive the IMANI weekly group as well as Traditional MAT services with Referral and Linkage to services. Participants in this arm will be provided a list of referrals and links to community MAT providers. They will choose their providers.
89060801|NCT05250258||telephone peer support|Telephone peer support from experinenced father to father
89060802|NCT05250258||Routine care|Standard care as usual in child health care, one visit for fathers and nothing added
89060803|NCT05248659|Experimental|Sibeprenlimab 400 mg s.c. q 4 weeks|
89060804|NCT05248646|Active Comparator|Sibeprenlimab 400 mg s.c. q 4weeks|
89060805|NCT05248646|Placebo Comparator|Placebo|
89060806|NCT05248204|Experimental|Scotchbond Universal Plus Treatment|Study tooth with posterior Class I or Class II carious lesion randomized to undergo restoration using Scotchbond Universal Plus (SBU+) Adhesive (Treatment).
89060807|NCT05248204|Active Comparator|Scotchbond Universal Comparator|Study tooth with posterior Class I or Class II carious lesion randomized to undergo restoration using the predicate device, Scotchbond Universal (SBU) Adhesive (Control).
89060808|NCT05223010|Active Comparator|1|39 participant will receive melatonin 0.05 mg/kg
89060809|NCT05223010|Active Comparator|2|39 participant will receive melatonin 0.2 mg/kg
89060810|NCT05223010|Active Comparator|3|39 participant will receive melatonin 0.4 mg/kg
89060811|NCT05203471|No Intervention|Historical controls|Patients with diabetic foot ulcers cared for by a primary care provider participating in the study prior to launching the integrated care intervention.
89060812|NCT05203471|Active Comparator|Integrated care|Patients with diabetic foot ulcers cared for by a primary care provider participating in the study after launching the integrated care intervention. Only patients who provide informed consent and enroll in the study will be treated with our integrated care model. All other patients with a participating primary care provider will be treated using a standard care model and will not be considered study participants.
89060813|NCT05181592|Experimental|Luspatercept (single arm)|open-label, single-arm
89060814|NCT05178706||non-operative conservative treatment|"9 individuals diagnosed with FSHD who have not undergone unilateral or bilateral surgery who meet the inclusion criteria.~application of determined outcome scales and rehabilitation program on patients"
89060815|NCT05178706||scapulothoracic arthrodesis|"9 individuals diagnosed with FSHD who have undergone bilateral surgery who meet the inclusion criteria.~application of determined outcome scales and rehabilitation program on patients"
89060816|NCT05178706||healthy control|18 participants for measuring the normative datas; application of determined outcome scales
89060817|NCT05178589|No Intervention|Control|During the control condition cycle (no TENS), participants will refrain from using or taking other analgesics, besides ibuprofen.
89060818|NCT05178589|Experimental|One Unit TENS|Participants will use one-unit TENS set-up where the TENS unit has 2 channels.
89060819|NCT05178589|Experimental|Two Unit TENS|Participants will use a two-unit TENS set-up where the TENS unit has 4 channels.
89060820|NCT05169554|Active Comparator|RC8, Rifampicin plus Clarithromycin for 8 weeks|Rifampicin plus Clarithromycin (RC) therapy for 8 weeks
89060821|NCT05169554|Experimental|RCA4, Rifampicin plus Clarithromycin plus Amoxicillin/clavulanate for 4 weeks.|Rifampicin plus Clarithromycin (RC) plus Amoxicillin/clavulanate (A) for 4 weeks.
89060822|NCT05161390|Experimental|LM-302 Dose Escalation at different dose levels|LM-302 Dose Escalation. 6 dose levels were pre-defined, and the initial accelerated titration followed by the i3+3 design was adopted during phase I.
89060823|NCT05161390|Experimental|LM-302(RP2D) Dose Expansion|LM-302 Dose Expansion, RP2D will be selected for dose expansion, with the aim to further evaluate the preliminary anti-tumor activity, safety and tolerability, etc.
89060824|NCT05156320|Experimental|Main Efficacy Population (Apitegromab 10 mg/kg)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive apitegromab 10 mg/kg for up to 52 weeks.
89060825|NCT05156320|Experimental|Main Efficacy Population (Apitegromab 20 mg/kg)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
89060826|NCT05156320|Placebo Comparator|Main Efficacy Population (Placebo)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 2 through 12 years old at Screening. Participants will be randomized to receive placebo for up to 52 weeks.
89060827|NCT05156320|Experimental|Exploratory Subpopulation (Apitegromab)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 13 through 21 years old at Screening. Participants will be randomized to receive apitegromab 20 mg/kg for up to 52 weeks.
89060828|NCT05156320|Placebo Comparator|Exploratory Subpopulation (Placebo)|Type 2 SMA and Nonambulatory Type 3 SMA, ages 13 through 21 years old at Screening. Participants will be randomized to receive placebo for up to 52 weeks.
89060829|NCT05154994|Experimental|Treatment (durvalumab, belinostat)|Patients receive durvalumab IV over 60 minutes on day 1. Beginning cycle 2, patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 15 cycles in the absence of disease progression or unacceptable toxicity.
89060830|NCT05152342|Experimental|Staff intervention|Half day virtual training for staff focusing on stigma reduction strategies.
89060831|NCT05152342|Experimental|Client intervention|Three session virtual therapy group for clients focusing on behavioral strategies to cope with stigma.
89060832|NCT05138003|Other|Recreational cyclists performing the 'étape du tour (EDT) de France 2021|
89220177|NCT04649125|Experimental|single fraction dose escalation|8Gy to Planned Target Volume, 12Gy to Clinical Target Volume +/- 14Gy to Gross Target Volume
89220178|NCT04643379|Experimental|Olaparib + Pembrolizumab + Carboplatin AUC|"-Patients enrolled in this study will receive olaparib, pembrolizumab and carboplatin in three-week cycles for six cycles, followed by maintenance therapy with three-week cycles of olaparib and pembrolizumab. Treatment will continue until disease progression, intolerable toxicity, patient or physician decision to stop therapy, or after 35 cycles, whichever occurs first. Drug dosing for each cycle is as follows:~Olaparib 200 mg twice per day (bid) by mouth (po) Days 1-10 for the first six cycles (when given with carboplatin), followed by 400 mg bid po Days 1-21 of subsequent cycles.~Pembrolizumab 200 mg intravenous (IV) Day 1.~Carboplatin AUC 5 IV on Day 1 for up to six cycles."
89220179|NCT04642066|Experimental|Active Group|Healthy volunteers were followed during the 5-month CWI exposition under standard conditions (three times per week 7-10 min). Neoprene equipment was not allowed; volunteers with followed weight or muscle mass changes over 5% were excluded
89220180|NCT04642066|Sham Comparator|Sham control|Control without CWI exposition
89220181|NCT04638751||NSCLC|Stage 3 or stage 4 non-small cell lung cancer patients, being administered checkpoint inhibitor therapy for the first time. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89220182|NCT04638751||Triple-negative breast cancer|Stage 3 or stage 4 metastatic triple-negative breast cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89220183|NCT04638751||Colorectal cancer|Stage 3 or stage 4 colorectal cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89220184|NCT04638751||Pancreatic cancer|Stage 3 or stage 4 pancreatic cancer patients, being administered any type of treatment that the patient has not experienced before. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
89220185|NCT04638751||High risk for colorectal cancer|Subjects undergoing a standard-of-care colonoscopy for colorectal cancer (CRC) screening considered at high risk for CRC due to either 1) one or more first degree relatives with a history of CRC, or 2) a personal history of colorectal cancer, advanced adenoma as defined by USMSTF guidelines on colorectal cancer, or 3 or more non-advanced adenomas in a single screening or surveillance encounter (synchronous).
89220186|NCT04638751||Low risk for colorectal cancer|Subjects undergoing a standard-of-care colonoscopy for colorectal cancer (CRC) screening, who are not considered high risk for CRC based on family history or prior colonoscopy findings.
89220187|NCT04634916|Experimental|EndoAVF|
89220188|NCT04628507||Patients undergoing IVF|
89220189|NCT04616209|Experimental|PB103 (donor-derived NK cells) infusion|Cohort 1: 0.5×10^9，Cohort 2:1×10^9 or Cohort 3: 1.5×10^9 cells
89220190|NCT04614519|Active Comparator|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
89220191|NCT04614519|Experimental|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
89220192|NCT04608305|Experimental|phase I - Group Ia, prime, low dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0
89060833|NCT05130047|Experimental|Aldafermin (NGM282)|Aldafermin (NGM282) is an investigational medication. It is an engineered analog of FGF-19 which reduces synthesis of bile acids and diarrhea caused by elevated bile acids. Participants receive aldafermin (NGM282) 1 mg given by subcutaneous injection once daily for 28 days.
89060834|NCT05130047|Placebo Comparator|Placebo|A placebo looks exactly like the study drug but contains no active ingredients. It is used to learn if the effects seen are truly from the study drug. Participants receive placebo solution matching aldafermin (NGM282) given by subcutaneous injection once daily for 28 days.
89060835|NCT05127616|Experimental|Minimal Contact-Cognitive Behavior Therapy|CBT is a goal-focused, learning-based treatment that teaches practical self-management tools and strategies targeting biobehavioral factors that aggravate pelvic pain and urinary symptoms
89060836|NCT05127616|Active Comparator|Education/Support|EDU emphasizes the empowering therapeutic benefits that come from the common across empirically-validated drug or non-drug treatment such as being listened to, support, receipt of science-based information, mobilization of hope, and the establishment of a strong patient-doctor relationship working toward shared goals
89060837|NCT05121558|Experimental|Yoga|Participants will receive twice weekly yoga over the course of 8 weeks.
89060838|NCT05121558|Experimental|Education control (EC)|Participants will receive twice weekly education over the course of 8 weeks
89060839|NCT05121558|Active Comparator|Usual care (UC)|8 weeks of usual care
89060840|NCT05112952|Experimental|Part A: Group 1: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of lazertinib.
89060841|NCT05112952|Active Comparator|Part A: Group 2: Normal Hepatic Function|Participants with normal hepatic function who qualify for the control group will receive a single oral dose of lazertinib.
89220193|NCT04608305|Experimental|phase I - Group Ib, Prime, medium dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0
89220194|NCT04608305|Experimental|phase I - Group Ic, Prime, high dose|Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0
89220195|NCT04608305|Experimental|phase I - Group Id, prime-boost, low dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
89220196|NCT04608305|Experimental|phase II - Group IIa, prime, low dose*|"Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.~*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
89220197|NCT04608305|Experimental|Phase II - Group IIb, Prime, low dose, elderly subjects*|"Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E5 pfu/ml or saline placebo at day 0.~*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
89220198|NCT04608305|Experimental|phase II - Group IIc, Prime, medium dose*|"Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.~*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
89220199|NCT04608305|Experimental|phase II - Group IId, Prime, medium dose, elderly subjects*|"Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E6 pfu/ml or saline placebo at day 0.~*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
89220200|NCT04608305|Experimental|Phase II - Group IIe, prime, high dose*|"Male and female subjects (18-55 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.~*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
89220201|NCT04608305|Experimental|Phase II - Group IIf, Prime, high dose, elderly subjects*|"Male and female subjects (56-85 years old) administered with a single-dose of IIBR-100 1*10E7 pfu/ml or saline placebo at day 0.~*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
89220202|NCT04608305|Experimental|phase II - Group IIg, prime-boost, low dose*|"Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.~*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
89220203|NCT04608305|Experimental|phase II - Group IIh, prime-boost, low dose, elderly subjects*|"Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E5 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.~*Treatment arm was deactivated based on immunogenicity data and DSMB recommendations."
89220204|NCT04608305|Experimental|phase II - Group IIi, prime-boost, medium dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E6 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
89220205|NCT04608305|Experimental|phase II - Group IIj, prime-boost, medium dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E6 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
89220206|NCT04608305|Experimental|phase II - Group IIk, prime-boost, high dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E7 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
89220207|NCT04608305|Experimental|phase II - Group IIl, prime-boost, high dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E7 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
89220208|NCT04608305|Experimental|phase II - Group IIm, prime-boost, top dose|Male and female subjects (18-55 years old) administered twice with IIBR-100 1*10E8 pfu/ml or saline placebo, 4 weeks apart at days 0 and 28.
89220209|NCT04608305|Experimental|phase II - Group IIn, prime-boost, top dose, elderly subjects|Male and female subjects (56-85 years old) administered twice with IIBR-100 1*10E8 pfu/ml or saline placebo, 4 weeks apart, at days 0 and 28.
89220210|NCT04606446|Experimental|1A Monotherapy Dose Escalation|PF-07248144 Monotherapy Escalation
89220211|NCT04606446|Experimental|1B Combination Dose Escalation|PF-07248144 with Fulvestrant Combination Dose Escalation
89220212|NCT04606446|Experimental|1C Combination Dose Escalation|PF-07248144 with Letrozole + Palbociclib Combination Dose Escalation
89220213|NCT04606446|Experimental|2A Monotherapy Dose Expansion Arm|PF-07248144 Monotherapy Dose Expansion
89220214|NCT04606446|Experimental|2B Combination Dose Expansion Arm|PF-07248144 with Fulvestrant Dose Expansion
89220215|NCT04606446|Experimental|1D Combination Dose Escalation|PF-07248144 with PF-07220060 +Fulvestrant
89220216|NCT04606446|Experimental|2D Combination Dose Expansion Arm|PF-07248144 with PF-07220060 +Fulvestrant Dose Expansion
89220217|NCT04606446|Experimental|China Monotherapy Dose Expansion|PF-07248144 Monotherapy Dose Expansion
89220218|NCT04602117|Experimental|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|Single-arm, phase I trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel. The study contains 2 cohorts. Cohort A is the de-escalation cohort. Patients with certain HER-positive advanced solid tumors or HER2-low breast cancer will be enrolled in this cohort. Cohort B is the expansion cohort, in which only patients with HER2-positive or HER2-low breast cancer can be enrolled. Treatment will be administered on an outpatient basis.
89220219|NCT04599764|Active Comparator|Cognitive training|Participants will receive Cognitive training daily for two weeks
89220220|NCT04599764|Active Comparator|Anodal tDCS with Cognitive training|Participants will receive anoale tDCS daily and cognitive training for two weeks
89220221|NCT04596865||Pancreatic ductal adenocarcinoma|Patients who underwent pancreaticoduodenectomy for PDAC between 01/06/2010 and 31/05/2015
89220222|NCT04596865||Ampullary cancer|Patients who underwent pancreaticoduodenectomy for ampullary cancer between 01/06/2010 and 31/05/2015
89220223|NCT04596865||Distal extrahepatic cholangiocarcinoma|Patients who underwent pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma between 01/06/2010 and 31/05/2015
89689239|NCT02240303||Chronic Pain Group|Participants that experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
89689240|NCT02240303||No Chronic Pain Group|Participants that do not experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
89689241|NCT02959996|Placebo Comparator|Placebo|Normal saline will be infiltrated
89689242|NCT02959996|Active Comparator|Intervention|Liposomal bupivacaine will be infiltrated
89689243|NCT00929981||Oral Methylprednisolone|
89689244|NCT00961441|Experimental|Children 12-16 years old|
89689245|NCT00961441|Experimental|Adults 18-55 years old|
89689246|NCT02240381|Experimental|Diagnostic (OGTT, euglycemic hyperinsulinemic clamp)|Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
89689247|NCT05716113|Experimental|RD13-02 cell infusion|
89689248|NCT02961946|Active Comparator|Sublingual Nitroglycerin spray|Sublingual Nitroglycerin spray of 0.8 mg
89689249|NCT02961946|Active Comparator|Sublingual Nitroglycerin tablet|Sublingual Nitroglycerin tablet of 0.8 mg
89689250|NCT02961946|Active Comparator|Nitroglycerin skin patch|Nitroglycerin skin patch of 0.8 mg/h
89689251|NCT02240459|Experimental|Fesoterodine 4mg daily|fesoterodine 4mg oral
89689252|NCT02240459|Experimental|Fesoterodine 8mg|Fesoterodine 8mg in form of 2, 4mg tablets
89689253|NCT02240459|Active Comparator|oxybutynin|oxybutynin immediate release, encapsulated 2, 5mg capsules daily
89689254|NCT02240459|Placebo Comparator|placebo capsule|placebo capsule, 2 per day
89689255|NCT02978235|Experimental|TAS4464|
89689256|NCT02846740|Experimental|Adjunctive CES|CES 100µA for one hour daily, five to seven days per week. Rating scales will be administered at baseline (i.e., pre-treatment), twice a week and at the end of the study.
89689257|NCT02846740|Sham Comparator|Sham control CES|For the sham group the Alpha-Stim® will not emit electricity. All other procedures will be the same for both the sham group and the active CES group. The current intensity will be preset and locked by the manufacturer. The sham devices will appear identical to the active device.
89689258|NCT02240537|Experimental|Open Label Treatment Arm|BB-MPI-03 peptides plus montanide plus sargramostim
89689259|NCT02240615|Experimental|Sinopsys Lacrimal Stent|All enrolled patients will receive a Sinopsys Lacrimal Stent inserted from the caruncle to the ethmoid sinus. Discharge instructions will include administration of sterile saline and ophthalmic drops as well as assessments for device patency.
89689260|NCT05676333|Experimental|Secukinumab|
89689261|NCT02240771|Active Comparator|Transarterial chemotherapy|Doxorubicin 50mg, Cisplatin 100mg
89689262|NCT02240771|Placebo Comparator|Oral chemotherapy|Thalidomide---50-300mg once a day Capecitabine---- 500-1500mg once a day
89689263|NCT02848222|Experimental|Twice Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
89689264|NCT02848222|Experimental|Once Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the evening after lens removal
89689265|NCT02848222|Sham Comparator|Twice Daily Application of warm washcloth|Ten minute application of a hot-water warmed washcloth in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
89689266|NCT05715957||female carriers of DMD gene variants|
89689267|NCT05715957||patients with BMD|
89689268|NCT02240849|Experimental|Functional pillow|cervical pillow, designed functionally to decrease neck pain and help to ensure the right support of the cervical curve, was applied to patients' posterior neck area.
89689269|NCT02240849|Placebo Comparator|General pillow|Applicants Randomly allocated to this group were issued by placebo-general pillow. There is not any specific intervention for their neck discomfort except for that.
89689270|NCT00962065|Experimental|Low Dose|A low dose of LX4211; daily oral intake for 28 days
89689271|NCT00962065|Experimental|High Dose|A high dose of LX4211; daily oral intake for 28 days
89689272|NCT00962065|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 28 days
89689273|NCT02240927|Active Comparator|Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
89689274|NCT02240927|Active Comparator|Enoxaparine and 2.5 mg warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1.0). Full dose warfarin is continued after first trimester and dose is regulated according to INR (between 2.5-4)
89689275|NCT02240927|Active Comparator|Enoxaparine and 4 mg warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
89522798|NCT05237375||The MIDWIZE model|"Pregnant women giving birth during at Naguru maternity ward during the intervention period~It's only Sub/study 2 in this PhD project which is a clinical trial and which is described onwards.~Sub-study 2 will include all women above the age of 18 with uncomplicated full-term pregnancies and births (i.e. between weeks 37 + 0 - 42 + 0) giving birth at the delivery ward during the implementation phase.~Data will be collected during the implementation of the quality improvement components."
89522799|NCT05237375||The MIDWIZE model - postintervention|"Pregnant women giving birth at Naguru maternity ward 6 months post intervention period.~Sub-study 2 will include all women above the age of 18 with uncomplicated full-term pregnancies and births (i.e. between weeks 37 + 0 - 42 + 0) giving birth at the delivery ward 6months after the implementation phase.~Data will be collected after implementing the quality improvement components. The post-measurement data will be collected on the chosen components six months after project implementation to measure if the midwife-led quality improvement project has been sustained."
89522800|NCT03398369|Experimental|Intervention|CMR-Guided CRT
89060842|NCT05112952|Experimental|Part B: Group 3 (Optional): Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of lazertinib.
89060843|NCT05112952|Experimental|Part B: Group 4 (Optional): Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of lazertinib.
89060844|NCT05106426|Experimental|HC2 intervention Group|Participants in this group will receive the Healthy Caregivers-Healthy Children (HC2) intervention for 24 months
89522801|NCT03398369|No Intervention|Control|Standard CRT
89522802|NCT03398291|Active Comparator|Standard treatment|Patients continue to receive standard chemotherapy.
89060845|NCT05106426|Active Comparator|Jump Start Control Group|Participants in this group will receive the Jump Start intervention for 24 months
89060846|NCT05106426|No Intervention|Parents/Caregivers of Participants receiving HC2 intervention|Parents/caregivers of participants receiving the HC2 program will not be receiving any intervention.
89060847|NCT05106426|No Intervention|No Intervention: Parents/Caregivers of participants receiving Jump Start Intervention|Parents/caregivers of participants receiving the Jump Start program will not be receiving any intervention.
89060848|NCT05101356|Experimental|Phase 1 Treatment (sargramostim, LabVax 3(22)-23)|Patients receive sargramostim SC and LabVax 3(22)-23 ID on weeks 1, 2, 4, 8, and 12 in the absence of disease progression or unacceptable toxicity.
89060849|NCT05101356|Experimental|Phase 2 Treatment (sargramostim, LabVax 3(22)-23, pembrolizumab)|Pembrolizumab will be given intravenously every 3 weeks for up to 12 cycles on Day 1 of Weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, and 34. Participants will be given LabVax 3(22)-23 (intradermally) and adjuvant GM-CSF (subcutaneously) on weeks 7, 8, 10, 14, and 18.
89060850|NCT05074186|Experimental|neurological thrombectomy device|Revascularization device is an investigational device.
89060851|NCT05070767|Experimental|Neurolens|Our proprietary contoured prism lens design, commercially known as neurolens.
89060852|NCT05070767|Placebo Comparator|Control lens|A simple refractive error correction lens
89060853|NCT05059158||Alzheimer's Disease|Patients with a Alzheimer's Disease diagnosis
89060854|NCT05059158||Mild Cognitive Impairment|Patients with a mild cognitive impairment diagnosis
89060855|NCT05059158||Subjective Cognitive Decline|Patients with a subjective cognitive decline diagnosis
89060856|NCT05046431|Active Comparator|EU Simponi|
89060857|NCT05046431|Experimental|BAT2506|
89060858|NCT05039671|Experimental|Measurement-based care|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
89060859|NCT05039164|Active Comparator|Initial training|School personnel will implement CATS or CPP and CICO with students in the school setting. They will participate in an initial live remote training to learn about implementing the three EBPs (CC).
89060860|NCT05039164|Experimental|Initial training plus video|School personnel will implement CATS or CPP and CICO with students in the school setting. They will participate in an initial live remote training and receive access to asynchronous video training modules about the EBPs (RV).
89060861|NCT05039164|Experimental|Initial training plus video, plus coaching|School personnel will implement CATS or CPP and CICO with students in the school setting. They will participate in an initial live remote training, receive access to asynchronous video training modules about the EBPs, and receive coaching support by study staff (RV+). The coaching will be from a study consultant regarding the implementation of EBPs.
89060862|NCT05016908||Biofluid collection|Eligible volunteers will be asked to provide a single urine sample and undergo a single blood draw.
89060863|NCT05001347|Experimental|TJ004309 and Atezolizumab|TJ004309 20 mg/kg Q3W in combination with atezolizumab 1200 mg Q3W
89060864|NCT04996654|Experimental|Exergame|Participants will perform a twelve-week training intervention in addition to their usual care as provided by the memory clinics where the patients are recruited. The training intervention will be prescribed according to a newly developed exergame-based intervention concept that consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) perceptual-motor function.
89060865|NCT04996654|Active Comparator|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
89060866|NCT04996433|Experimental|Cognitive Behavioral Analysis System of Psychotherapy (CBASP)|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
89060867|NCT04996433|Active Comparator|Behavioral Activation (BA)|Behavioral Activation (BA) as acute treatment (5 wk. inpatient and 5 wk. either inpatient or dayclinic) followed by continuation treatment (6 wk. outpatient group therapy).
89060868|NCT04966169|Experimental|Sonendo GentleWave|Every participant will receive the same experimental treatment, which is root canal therapy using the Sonendo GentleWave System.
89060869|NCT04957082|Active Comparator|White Flint Registry: General|"White participants receive general consumption video information about SARS-CoV-2 antibody testing."
89060870|NCT04957082|Active Comparator|African American Registry: General|"African American participants receive general consumption video information about SARS-CoV-2 antibody testing."
89060871|NCT04957082|Experimental|African American Registry: Culturally Targeted|African American participants receive culturally targeted video information about SARS-CoV-2 antibody testing.
89060872|NCT04949958|Experimental|Experimental: Exercise Based Manual (Supervised)|Supervised Exercises with exercise based Manual (exercise & Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of different type of exercises including warm up and rest interval
89060873|NCT04949958|Experimental|Experimental: Exercise Based Manual (Home Based)|Experimental: Exercise Based Manual (Home Based) Home Based- Exercise Manual (Exercise & Educational Component) for 16 weeks. Subject will be asked to maintain a regular exercise.
89060874|NCT04949958|Placebo Comparator|Placebo Comparator: Control|Age matched Control Group followed for 16 weeks with General Advise to active
89060875|NCT04940650|Other|Recreational cyclists performing the 'étape du tour (EDT) de France 2021|
89060876|NCT04932421|Experimental|Experimental group (UP-C intervention)|UP-C intervention 15 weekly sessions, for children and parents
89060877|NCT04932421|Active Comparator|Control group (ABC of emotions intervention)|ABC of emotions - a psychoeducational intervention 5 sessions every 3 weeks for children
89060878|NCT04929236|Experimental|Panzyga High Dose|2.0g/kg of PANZYGA administered intravenously every four weeks over a period of sixteen weeks for a total of five treatment dosages.
89060879|NCT04929236|Experimental|Panzyga Low Dose|1.0g/kg of PANZYGA administered intravenously every four weeks over a period of sixteen weeks for a total of five treatment dosages.
89060880|NCT04928573||Group I|"All participants previously randomized in Brazil for the phase III study RTXM83-AC-01-11 already completed, which was conducted to support the registration of the new biosimilar of rituximab (Vivaxxia) in different countries.~The RTXM83-AC-01-11 study compared the efficacy and safety between biosimilar rituximab (RTXM83) and the reference rituximab (Mabthera®), both associated with CHOP chemotherapy (RTXM83-CHOP and R-CHOP, respectively) and included participants of the research with a diagnosis of lymphoma other than large B cell (LDGCB) CD20 positive."
89060881|NCT04921631|Experimental|Intervention|The intervention arm will receive early specialty palliative care integrated with standard critical care.
89060882|NCT04921631|No Intervention|No intervention|Usual ICU care; each study ICU has a policy for family meetings within 72 hours of admission and at least weekly thereafter.
89060883|NCT04914429|Experimental|Group 1: Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous (SC) injection at Weeks 0, 4, and then every 8 weeks (q8w) through Week 44. Participants will receive matching placebo at Week 16.
89060884|NCT04914429|Placebo Comparator|Group 2: Placebo|Participants will receive placebo SC injection for guselkumab at Weeks 0, 4, and 12, and then cross over at Week 16 to receive guselkumab 100 mg SC injection at Weeks 16 and 20 and q8w thereafter through Week 44.
89060885|NCT04910139|Experimental|Treatment|Treatment using acoustic energy
89060886|NCT04897945|Experimental|Shared decision-making with pharmacists|Participants randomized to the intervention arm will have an in-person visit to complete the baseline survey, record the participant's weight and receive a pharmacist-coordinated shared decision making intervention. Intervention participants will have follow-up research assessments visits at 6, 12 and 24 months.
89060887|NCT04897945|No Intervention|Usual Care|Participants randomized to the usual care control arm will have an in-person visit with the research study team to complete the baseline survey and record the participant's weight. These participants will then return to usual care with research assessments at 6, 12 and 24 months follow-up.
89060888|NCT04886856|Experimental|Mindful Moms|"Weekly Mindful Moms sessions"
89060889|NCT04886856|Active Comparator|Prenatal Education|Weekly prenatal education sessions
89060890|NCT04878757|Experimental|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
89060891|NCT04878757|No Intervention|Control - Business-As-Usual|Involves participation in the schools' typical math program
89060892|NCT04876599|Experimental|Intervention (IN FOCUS)|Participants will be randomly assigned and participate in eight weekly virtual group sessions to learn mind-body, cognitive behavioral, and positive psychology skills.
89060893|NCT04876599|Active Comparator|Usual Care|Participants will be randomly assigned and receive usual care, which is a referral for virtual group supportive services for cancer survivors provided in the community.
89522803|NCT03398291|Experimental|Surgical exploration|Patients receive surgical exploration and synchronous resection of primary pancreatic cancer and liver oligometastasis will be performed.
89522804|NCT05216315|Experimental|tDCS. Transcranial direct current stimulation|The stimulation time was 20 minutes, with an initial and final ramp of 30 seconds so that the participant could adapt to the sensation of the current. 10 sesions. Constant current intensity of 2 mA The anode was placed on position F7, coinciding with the dorsolateral prefrontal cortex, and the cathode was placed on Fp2, coinciding with the right supraorbital area (rSO).
89522805|NCT05216315|Sham Comparator|Sham stimulation|The sham group received direct current only on the ramps to generate a sensation of the effect.
89220224|NCT04592289|Experimental|Full bowel preparation (MBP+OA)|"Rifaximin 400 mg twice daily for three days prior to surgery~Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
89220225|NCT04592289|Active Comparator|Mechanical bowel preparation only|"Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
89220226|NCT04590963|Experimental|Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2|Participants will receive intravenous (IV) monalizumab 750 mg every two weeks (Q2W) and IV cetuximab 400 mg/m^2 initial dose followed by 250 mg/m^2 every one week (Q1W) until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
89220227|NCT04590963|Active Comparator|Placebo Q2W + Cetuximab 400 mg/m^2|Participants will receieve IV placebo matched to monalizumab Q2W and IV cetuximab 400 mg/m^2 initial dose followed by 250 mg/m^2 Q1W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.
89220228|NCT04583488|Experimental|Intraperitoneal docetaxel|Participants will receive intraperitoneal docetaxel combined with the standard of care. A standard 3 + 3 dose escalation design will be used according to the dose escalation plan.
89220229|NCT04580160|Experimental|Duo Venous Stent System Implantation|
89220230|NCT04579107|Other|Contrast Enhanced Mammography|All included women go through a Contrast Enhanced Mammography added to the standard of care examinations.
89220231|NCT04575051|Active Comparator|HearCARE (Consult+Engage)|Residents will be exposed to the Consult Model and the Engage Model.
89220232|NCT04575051|Other|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
89220233|NCT04573985|Experimental|Serious Game Eurekoi intervention|1 session in group using the serious game eurekoi
89689276|NCT02240927|Active Comparator|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
89689277|NCT03038308|Experimental|ROP Intervention|Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study
89689278|NCT04358497|Experimental|Interventional treatment plus best chronic medical treatment|Sandwich embolization ( 2% polidocanol + Coils) Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
89689279|NCT04358497|Active Comparator|Best chronic medical treatment alone|Diosmin hisperidin 1g twice a day for 6 months Ibuprofen 500mg 3 times a day for 6 months
89689280|NCT05545683|Experimental|VLA 2001|"One dose (0.5 mL) contains no less than 25 Antigen Units (AU) of inactivated SARS-CoV-2.~Highly purified whole virus SARS-CoV-2 antigen, inactivated and adjuvanted with CpG 1018 in combination with aluminum hydroxide."
89689281|NCT04373291|Active Comparator|BCG vaccine|"Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (BCG-Denmark, AJ Vaccines) in the skin covering the left upper deltoid muscle.~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units of the live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331."
89689282|NCT04373291|Placebo Comparator|Control|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine.
89689283|NCT02849938|No Intervention|Control Group|Usual care
89689284|NCT02849938|Experimental|Telemedicine Group|TytoCare Device
89060895|NCT04858230|Experimental|LymphoPilot|Patient will be implanted with the medical device under investigation, LymphoPilot, through a surgical procedure performed in loco-regional or general anesthesia. Lymphedema outcomes will be monitored for 8 weeks after implantation and compared to baseline values before device implantation. Safety data will be collected throughout the study.
89060896|NCT04852224||Androgen Deprivation Therapy (ADT+)|Men diagnosed with prostate cancer and scheduled to receive greater than or equal to 6-months of treatment with androgen deprivation therapy
89060897|NCT04852224||Prostate Cancer Surveillance (ADT-)|Men diagnosed with prostate cancer under active surveillance (i.e., not receiving active treatment for prostate cancer)
89060898|NCT04852224||Non-cancer Control (PCa-)|Age-matched men without a history of cancer
89060899|NCT04833114|Experimental|Experimental Arm: Pola-R-ICE|combination of standard chemotherapy with polatuzumab vedotin (Pola-R-ICE) Application
89060900|NCT04833114|Active Comparator|Standard Arm: R-ICE|conventional treatment with rituximab, ifosfamide, carboplatin and etoposide (R-ICE)
89060901|NCT04829045|Experimental|Acupuncture plus diabetic routine care|Subjects will receive acupuncture treatment using press needles
89060902|NCT04829045|Placebo Comparator|Placebo plus diabetic routine care|Subjects are given placebo
89060903|NCT04821440|Active Comparator|Lower Limb Lymphedema|Patients suffering from unilateral lower-limb lymphedema will receive volume measurements of their limb three times, once with the water displacement method, twice with the 3D sensor method
89060904|NCT04821440|Active Comparator|Upper Limb Lymphedema|Patients suffering from unilateral upper-limb lymphedema will receive volume measurements of their limb three times, once with the water displacement method, twice with the 3D sensor method
89060905|NCT04812535|Experimental|Arm A: IFX-1 monotherapy|IFX-1 monotherapy
89060906|NCT04812535|Experimental|Arm B: IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
89060907|NCT04806516|Experimental|Summit RC+S DBS Implant for OCD|All subjects will receive surgical implantation of RC+S DBS system with ECoG paddles
89060908|NCT04806516|Experimental|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
89060909|NCT04730947|Experimental|Dapagliflozin Group|Subjects with HFpEF will take the study drug dapagliflozin daily
89060910|NCT04730947|Placebo Comparator|Placebo Group|Subjects with HFpEF will take a placebo daily
89060911|NCT04725331|Experimental|Phase I, Part A - Dose escalation and safety of BT-001 alone|Dose escalation with repeated administrations of BT-001 directly into tumor as a single agent, in patients with metastatic or advanced solid tumors.
89060912|NCT04725331|Experimental|Phase I, Part B - Safety of BT-001 in combination with pembrolizumab|Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in patients with metastatic or advanced soft tissue sarcoma (STS), Merkel cell carcinoma (MCC), melanoma, triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC)..
89060913|NCT04725331|Experimental|Phase IIa - Expansion cohorts of BT-001 in combination with pembrolizumab|Repeated administrations of BT-001 directly into tumor in combination with infusions of pembrolizumab in several cohorts of patients with defined metastatic or advanced solid tumor conditions: soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple negative breast cancer, non-small cell lung cancer.
89060914|NCT04716725|Experimental|Experimental (68Ga-PSMA-11 PET)|Patients receive gallium 68Ga-PSMA-11 IV and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.
89060915|NCT04700488|Experimental|6D-MRI|Participants will undergo 6D-MRI imaging three times throughout the course of the study: once pre-NAT treatment, once during NAT treatment, and once post-NAT treatment.
89060916|NCT04688255|Experimental|Intervention group (MSTEP)|REHABILITATIVE EXERCISE: Participants will be asked to exercise at home daily for 6 weeks, meeting with an RA weekly via video conference to gradually increase the intensity and duration of exercise based on symptom tolerance. The eventual goal will be to achieve 60 minutes of MVPA daily (US Federal recommendations). They will wear a personal fitness device (Fitbit) to track whether they are achieving their HR goals.
89220234|NCT04573985|No Intervention|Control group|no intervention
89220235|NCT04573712|Experimental|Fatigue Severity Scale scores assessment|Fatigue Severity Scale scores assessment
89220236|NCT04563598||ILI/ Treatment group|This group includes Look AHEAD participants who were initially assigned to the intensive lifestyle intervention (ILI), consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
89220237|NCT04563598||DSE/Control group|This group includes Look AHEAD participants who were initially assigned to the diabetes support and education (DSE) control arm, consented to administrative data linkages, and were successfully linked to Social Security Administration databases.
89220238|NCT04562935||Pediatric intensive care|Children admitted to a pediatric intensive care unit before one year of age and admitted for to days or more and treated with mechanical ventilation and alive at follow
89220239|NCT04561778|Active Comparator|HOT-CRT|Subjects randomized to HOT-CRT will undergo CRT as described below. His bundle pacing lead will be placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and LV timing may be optimized to achieve maximal resynchronization. This will be at the discretion of the implanting physician. Only FDA approved leads and devices will be used.
89220240|NCT04561778|Active Comparator|Biventricular Pacing|Subjects randomized to biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.Only FDA approved leads and devices will be used.
89220241|NCT04559646||"Group A Haemoblock"|"100 patients. Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
89220242|NCT04559646||"Group B Control"|100 patients. Saline solution will be used after pocket formation during pacemaker implantation.
89220243|NCT04558515||Case|Symptomatic patients positive for malaria by PCR
89220244|NCT04558515||Control|Symptomatic patients negative for malaria by PCR
89220245|NCT04556656|Experimental|Pridopidine|45 mg pridopidine twice daily (BID)
89220246|NCT04556656|Placebo Comparator|Placebo|Matching placebo
89220247|NCT04556435||LC Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health). Information related to LC diagnosis (histologic sub-type, tumor stage) will be collected.
89220248|NCT04556435||Control Group|Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health).
89220249|NCT04550143||Septic Shock|
89220250|NCT04546776||Faecal and saliva sampling|A minimum of 4 and a maximum of 8 sample sets will be asked for over the study period
89220251|NCT04546750||Patients without Varicose Veins|Individuals who do not have varicose veins of lower legs: C0, C1 classes according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
89220252|NCT04546750||Patients with Varicose Veins|Individuals who have varicose veins of lower legs: C2 Ep class according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
89060917|NCT04688255|Active Comparator|Control group (Stretching)|STRETCHING: Participants will be asked to complete stretches daily. They will initially be given two stretches, primarily focused on the neck and upper back. Additional stretches will be added through weekly discussions with the study RA.
89060918|NCT04680468|Experimental|Belantamab mafodotin|Patients receive Belantamab mafodotin 2.5 mg/kg by intravenous infusion on day -42 relative to autologous stem cell infusion (day 0), on day +60, and every 90 days thereafter, for up to 2 years following ASCT.
89060919|NCT04673409||Suspected myocarditis of undefined aetiology|Patients with signs and symptoms of acute myocarditis (as defined by the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases).
89060920|NCT04673409||Suspected myocarditis with autoimmune rheumatic disease|Patients with suspected myocarditis due to an underlying AIRD.
89060921|NCT04660799|Active Comparator|Rituximab IV+CHOP|Participants will receive 8 cycles of IV rituximab in combination with 6 or 8 cycles of CHOP chemotherapy administered every 3 weeks.
89060922|NCT04660799|Experimental|Rituximab SC+CHOP|Participants will receive 1 cycle of IV plus 7 cycles of SC rituximab in combination with 6 or 8 cycles of CHOP chemotherapy administered every 3 weeks.
89060923|NCT04648033|Other|Atovaquone in Combination with concurrent CRT|"Atovaquone is taken during an initial run in period (2 weeks +/- 7 days), then continued during standard of care CRT. Atovaquone dose level is allocated to each patient by a TiTE-CRM statistical model which takes into account all toxicity data to date: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).~Two 21-day cycles of cisplatin and vinorelbine chemotherapy will be given concurrently during radiotherapy treatment. Patients will receive 80 mg/m2 cisplatin on days 1 & 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 & 29. Thoracic radiotherapy will be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday).~The last dose of atovaquone will be on the morning of the last fraction of radiotherapy. Total duration of atovaquone treatment will be 59 days (+/- 7 days), unless stopped earlier for toxicity or any other reason.~Patients will be followed up at 1, 3 and 6 months post-CRT."
89060924|NCT04640779|Experimental|Treatment (selinexor, choline salicylate)|Patients receive selinexor PO BIW on days 1, 3, 8, 10, 15, 17, 22, and 24, and choline salicylate PO TID on days 1-28. Patients undergoing pharmacokinetic analysis receive choline salicylate beginning on D3C1 and beginning on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patents who achieve >= stable disease continue treatment for an additional 6 cycles (maximum of 12 cycles) at the discretion of the treating physician and patient.
89060925|NCT04625517|Experimental|Breast cancer patients|Patients with ipsilateral intact biopsy-proven breast cancer
89060926|NCT04601987|Active Comparator|Counseling about the Maternal Benefits of Breastfeeding|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the maternal health benefits of breastfeeding.
89060927|NCT04601987|Active Comparator|Counseling about the benefits of Smoke-free Homes|Participants will review a slide deck while receiving scripted counseling designed to increase understanding of the health benefits of smoke free homes.
89060928|NCT04599192||Women Presenting with Cardiac Ischemia|Women presenting with cardiac ischemia as indicated by standard of care non-invasive stress testing with cardiac magnetic resonance (CMR), SPECT myocardial perfusion, and PET myocardial perfusion imaging. This cohort of women must also meet the clinical criteria to undergo coronary angiography. Women may be approached for consent either before or after their coronary angiography procedure.
89060929|NCT04598321|Experimental|Planned Therapy|Talazoparib monotherapy as 1 mg capsule orally on a daily basis for three cycles, defined as a 21-day period, prior to surgery. Volunteers will continue treatment to complete three cycles, unless disease progression or unacceptable toxicity occurs.Volunteers who complete neoadjuvant treatment with talazoparib should undergo surgical cytoreduction within three weeks of their last dose of talazoparib. All volunteers should then undergo standard of care adjuvant therapy using carboplatin and paclitaxel. For volunteers, who agree to continue talazoparib as maintenance therapy, treatment should begin three weeks (+/- 2 weeks) from the end of adjuvant chemotherapy or after cytoreductive surgery alone.
89060930|NCT04594616|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
89060931|NCT04594616|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
89060932|NCT04592523||All Participants|Participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) who initiate treatment for the first time with brigatinib in a routine clinical practical setting will be observed prospectively for up to 24 month-surveillance period.
89689285|NCT04373447|Active Comparator|fundus-calot laparoscopic cholecystectomy|use laparoscopic fundus first then calot dissection cholecystectomy
89689286|NCT04373447|Active Comparator|open cholecystectomy|open cholecystectomy
89689287|NCT05715801|Experimental|hyperbaric oxygen therapy|Ten sessions of hyperbaric oxygen therapy were completed within 4 weeks of enrollment.
89689288|NCT05715801|Active Comparator|conventional oxygen therapy|Ten sessions of conventional oxygen therapy were completed within 4 weeks after enrollment.
89689289|NCT04373213||Pleth variability index|Patients undergoing fluid management with Pleth variability index
89689290|NCT04373213||hemodynamic|Patients undergoing fluid management with hemodynamic findings
89689291|NCT04373135|Experimental|Experimental|Subjects will be provided a brief educational intervention prior to completing follow up survey about SRA attitudes and knowledge
89689292|NCT04373135|No Intervention|Control|Subjects will not be provided any prior to completing follow up survey about SRA attitudes and knowledge
89689293|NCT02851108|Experimental|AS-AQ-MB|Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
89689294|NCT02851108|Active Comparator|AS-AQ-PQ|Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
89689295|NCT04372667|Experimental|Post intervention|Community score card approach
89689296|NCT00358995|Active Comparator|1|Cognitive Behavior Therapy (CBT) may include keeping a diary of significant events and associated feelings, thoughts and behaviors; questioning and testing cognitions, assumptions, evaluations and beliefs that might be unhelpful and unrealistic; gradually facing activities which may have been avoided; and trying out new ways of behaving and reacting and using relaxation and distraction techniques.
89689297|NCT00358995|Active Comparator|2|Stress Management Therapy (SMT) includes relaxation, interaction, biofeedback, exercises, such as muscle stretching exercises, yoga, meditation, time management techniques, and many more.
89689298|NCT04347395|No Intervention|Group 1: Control Group|Current best practice for prevention of HAP
89689299|NCT04347395|Experimental|Group 2: Intervention|Respiratory Bundle Intervention
89689300|NCT02854540|Experimental|Hand A (iontophoresis) vs. Hand B (no treatment)|During the treatment period, participants will be asked to treat one hand with the hydrogel electrode-based iontophoresis device. Participants will also be asked to leave the other hand untreated.
89689301|NCT00930293|Experimental|Personalized Depression Care|Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.
89689302|NCT00930293|Active Comparator|Standard Depression Care|Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.
89689303|NCT02977767|Experimental|Conversational hypnosis|Use of conversational hypnosis during the tracheal cannula replacement
89689304|NCT02855086|Experimental|50 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a lower dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
89689305|NCT02855086|Experimental|100 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
89689306|NCT05368857|Experimental|Afamelanotide|
89689307|NCT02241005|Active Comparator|Theraworx™|Participants are randomized to use the Theraworx™ bath wipes.
89689308|NCT02241005|Active Comparator|Standard|Participants are randomized to use standard bath wipes.
89689309|NCT05541081|Other|Point-of-care STI testing|Provision of point-of-care testing for chlamydia, gonorrhoea, trichomoniasis, syphilis, HIV, and hepatitis B, with comprehensive case management including partner notification
89689310|NCT04347005|Experimental|AR882 (Dose A)|
89689311|NCT04347005|Experimental|AR882 (Dose B)|
89689312|NCT04347005|Experimental|AR882 (Dose C)|
89689313|NCT04347005|Experimental|AR882 (Dose D)|
89689314|NCT04347005|Experimental|AR882 (Dose E)|
89689315|NCT04347005|Experimental|AR882 (Dose B) Solid Oral Formulation|
89689316|NCT04347005|Placebo Comparator|Placebo|
89689317|NCT04347005|Active Comparator|Allopurinol|
89689318|NCT04347005|Active Comparator|Febuxostat|
89689319|NCT02856490|Active Comparator|vSculpt with Vibration Only|vSculpt genital device used in vibration mode only.
89689320|NCT02856490|Active Comparator|vSculpt with Vibration and Light|vSculpt genital device used in vibration and light mode.
89689321|NCT02856490|Active Comparator|InTone Device|InTone genital device using electric muscle stimulation only.
89689322|NCT02241083|Active Comparator|dopamine group|vasopressor dosage individually titred according to the mean arterial pressure
89689323|NCT02241083|Active Comparator|norepinephrine group|vasopressor dosage individually titred according to the mean arterial pressure
89689324|NCT02241083|Active Comparator|control group|no medication
89689325|NCT05367531|Experimental|Injection Scenario|"For each scenario participants will be asked to administer/inject the medication (likely saline or air) using various methods: 1) standard protocol , 2) Autoinjector 3) Pre-filled syringes. For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding)."
89689326|NCT04376723|Experimental|Assisted self-guidance|Participants will be asked to use the app for five weeks and will be contacted via telephone once a week by a researcher to provide a rationale for using the app, or to offer any information about the app itself. This will not be used to provide therapeutic intervention.
89689327|NCT04372901|Experimental|digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
89522806|NCT03394235|Experimental|Long-pulsed, 1064nm Nd-YAG laser|All participants will receive long-pulsed, 1064nm Nd-YAG laser treatments with three different parameters at the occipital area.
89220253|NCT04545151|Experimental|Verapamil SR|Eligible participants will be randomised into the Verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.
89522807|NCT03398057|Experimental|Health education group(intervention group)|Standardized heath education Program(SHEP) applied to this group participants .
89220254|NCT04545151|Placebo Comparator|Placebo|"Eligible participants will be randomised into the placebo arm and receive instructions on frequency of administration (daily intake).~40 participants on the control arm are expected to complete the trial."
89220255|NCT04544592|Experimental|I: Dose Escalation|First 3-21 subjects enrolled. Treated with escalating doses of therapy until the RP2D is determined.
89220256|NCT04544592|Experimental|II: Dose Expansion|22-40 additional subjects treated at the RP2D, including those treated within the phase 1 portion of the trial.
89220257|NCT04540822|Experimental|peripheral venous catheter with compress|Insertion of a peripheral venous catheter with a compress inserted below the catheter-extension tube junction
89220258|NCT04540822|Active Comparator|peripheral venous catheter without compress|Insertion of a peripheral venous catheter without any compress inserted below the catheter-extension tube junction.
89220259|NCT04538573|Experimental|Virtual Reality Distraction|Use of virtual reality (VR) during during burn treatment, dressing changes and hydrotherapy.
89220260|NCT04538573|Active Comparator|Standard Treatment|Standard treatment during burn treatment, dressing changes and hydrotherapy.
89220261|NCT04538092|No Intervention|Control|Standard post op complex spine orders placed for patients undergoing deformity correction
89220262|NCT04538092|Experimental|ERAS|Enhanced recovery after surgery protocol is applied to the patients undergoing deformity correction
89220263|NCT04516135|Experimental|Arm A (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.
89220264|NCT04516135|Active Comparator|Arm B (radiation therapy)|Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.
89220265|NCT04503577||Bladder cancer patients|
89220266|NCT04502849||"Group Bypass (A)"|50 patients with indications for bypass surgery (chronic lower limb ischemia, stage 2b-4 Fontaine).
89220267|NCT04502849||"Group Endovascular (B)"|50 patients with indications for endovascular angioplasty and stenting (chronic lower limb ischemia, stage 2b-4 Fontaine).
89220268|NCT04502849||"Group Hybrid (C)"|50 patients with indications for hybrid surgery (endovascular angioplasty/stenting and bypass surgery; chronic lower limb ischemia, stage 2b-4 Fontaine).
89220269|NCT04502849||"Group Conservative (D)"|50 patients without indications surgery (conservative treatment, chronic lower limb ischemia, stage 2b-4 Fontaine).
89220270|NCT04502849||"Group Healthy volunteers (E)"|50 healthy subjects.
89220271|NCT04502602|Experimental|Dose Level -1|Neratinib 160 mg and Niraparib 100 mg by mouth once daily for 28 day cycles.
89220272|NCT04502602|Experimental|Dose Level 1|Neratinib 160 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
89220273|NCT04502602|Experimental|Dose Level 2|Neratinib 200 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
89220274|NCT04502602|Experimental|Dose Level 3|Neratinib 240 mg and Niraparib 200 mg by mouth once daily for 28 day cycles.
89220275|NCT04502602|Experimental|Dose Level 4|Neratinib 240 mg and Niraparib 300 mg by mouth once daily for 28 day cycles.
89522808|NCT03398057|Placebo Comparator|Control group|Placebo health education.
89522809|NCT03126461|Experimental|SAbR plus ipilimumab plus nivolumab|SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
89220276|NCT04502602|Experimental|Phase 1b: Platinum Resistant Expansion Cohort|This portion of the study provides for cohort expansion to observe for 4 month or greater progression-free survival in patients with platinum resistant ovarian cancer treated at the recommended phase 2 dose (RP2D) determined in Phase I.
89220277|NCT04499612||"Group Single-chamber CIED (A1)"|50 patients with permanent atrial fibrillation and indications for cardiac implantable electronic device implantation (single-chamber system).
89220278|NCT04499612||"Group Dual-chamber CIED (A2)"|50 patients with atrioventricular block/sick sinus syndrome and indications for cardiac implantable electronic device implantation (dual-chamber system).
89220279|NCT04499612||"Group Dual-chamber CIED + Atrial fibrillation (A3)"|50 patients with atrioventricular block/sick sinus syndrome, paroxysmal or persistent atrial fibrillation and indications for cardiac implantable electronic device implantation (dual-chamber system).
89220280|NCT04499612||"Group CIED Replace (B)"|50 patients with cardiac implantable electronic device implantation 6-12 years ago (single- or dual-chamber system).
89220281|NCT04499612||"Group Conservative (C)"|50 patients with atrioventricular block/sick sinus syndrome/atrial fibrillation and without indications for cardiac implantable electronic device implantation (conservative group).
89220282|NCT04494386|Experimental|ULSC in Phase 1 Open Label|"Intravenous (IV) infusion of ULSC in 20 patients with COVID-19 ARDS:~In Phase 1, two separate cohorts per group will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The first cohort enrolled will receive the single dose; the next cohort enrolled will be administered the repeat dose regimen."
89220283|NCT04494386|Experimental|ULSC in Phase 2a Randomized|"Intravenous (IV) infusion of ULSC in 30 patients with COVID-19 ARDS:~In Phase 2a, 30 patients assigned ULSC will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The ULSC dosing regimen will be chosen based on Phase 1 data of safety and tolerability."
89220284|NCT04494386|Placebo Comparator|Placebo in Phase 2a Randomized|"Intravenous (IV) infusion of carrier control in 10 patients with COVID-19 ARDS:~In Phase 2a, 10 patients assigned Placebo will receive either single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval) of carrier control; the dosing regimen will correspond to that of the experimental arm."
89220285|NCT04493216|Experimental|Blinded GSK3640254 100 mg + GSK3640254 matching placebo + Open Label ABC/3TC or FTC/TAF|
89220286|NCT04493216|Experimental|Blinded GSK3640254 150 mg + Open Label ABC/3TC or FTC/TAF|
89220287|NCT04493216|Experimental|Blinded GSK3640254 200 mg + GSK3640254 matching placebo + Open Label ABC/3TC or FTC/TAF|
89220288|NCT04493216|Active Comparator|Open Label DTG + Open Label ABC/3TC or FTC/TAF|
89220289|NCT04488523|Experimental|Family-based Telehealth Treatment|A family-based telehealth intervention.
89220290|NCT04487314||Patients without Chronic Venous Disease|Individuals who do not have signs of chronic venous diseases of lower legs according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)
89220291|NCT04487314||Patients with Chronic Veinous Disease|Individuals who have signs of chronic venous diseases of lower legs according to CEAP classification (telangiectases, varicose veins, venous edema, skin hyperpigmentation, lipodermatosclerosis, venous ulcer).
89220292|NCT04486261|Experimental|High-intensity strength training|"16 weeks of high-intensity strength training two times per week.~Participants will receive the usual care in accordance to myositis (various DMARDs, different from patient to patient)~Interventions:~Other: high-intensity strength training Drug: Usual care"
89220293|NCT04486261|No Intervention|Control|"Participants receive the usual care in accordance to myositis (various DMARDs, different from patient to patient).~Intervention:~Drug: Usual care"
89689328|NCT04372901|Active Comparator|digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement
89689329|NCT02963974|Experimental|Cochlear Implant|Pediatric patients with single sided deafness will receive a cochlear implant in the ear of loss
89689330|NCT04372589|Experimental|Investigational arm|Participants randomized to the investigational arm will receive therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from supplemental oxygen >24 hours if previously required, whichever comes first) with heparin, with preference for subcutaneous low molecular weight heparin (enoxaparin preferred, although dalteparin or tinzaparin are also acceptable, as available) if no contraindication is present; alternatively, intravenous unfractionated heparin infusion may be used.
88821147|NCT05032820|Experimental|Lenalidomide and bb2121|Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m2 and fludarabine 30mg/m2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x106 cells. Maintenance lenalidomide, starting at 10mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.
89689331|NCT04372589|No Intervention|Control arm|Participants will receive usual care of thromboprophylactic dose anticoagulation according to local practice.
89689332|NCT05537493|Experimental|Telerehabilitation|Videos of the exercises they will do via whatsapp will be sent to the telerehabilitation group. Again, in telerehabilitation, whatapp application will be made in the form of videoconference. Rehabilitation program will be applied to the patients 4 times a week for 6 weeks.
89689333|NCT05537493|Active Comparator|Face to face|A rehabilitation program will be applied to the Face to Face rehabilitation group by a physiotherapist in the hospital for a total of 30 sessions per week for 6 weeks.
89689334|NCT04364399|Experimental|Experimental group|Mumps vaccine, one dose
89689335|NCT04364399|Active Comparator|Control group|measles, mumps and rubella combined vaccine, live, one dose
89220294|NCT04481399|Experimental|FSI-ECD|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. The FSI-ECD will be delivered in weekly 90-minute home visiting sessions for 12 consecutive weeks.
89220295|NCT04481399|Other|Control|The control is standard maternal and child health home visiting delivered by community health workers. Families will receive three 90-minute home visiting educational sessions focused on nutrition, hygiene, and post-natal care.
89220296|NCT04476901|Placebo Comparator|Genotype A administered with placebo Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.
89220297|NCT04476901|Experimental|Genotype A administered with hMSC Group|Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.
89220298|NCT04476901|Placebo Comparator|Genotype B administered with placebo Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.
89220299|NCT04476901|Experimental|Genotype B administered with hMSC Group|Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.
89220300|NCT04476901|Placebo Comparator|Genotype C administered with placebo Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.
89220301|NCT04476901|Experimental|Genotype C administered with hMSC Group|Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.
89220302|NCT04469790|No Intervention|SIT|Continuous sitting for 3 hours
89220303|NCT04469790|Experimental|SIT+WALK|Interrupt sitting with 3-minutes of moderate-intensity walking every 30 minutes for 3 hours
89220304|NCT04469790|Experimental|EX|Perform 18 consecutive minutes of moderate-intensity walking, then sit for the remaining time
89220305|NCT04462328|Experimental|Phase I Dose Level 1: Durvalumab + Acalabruitinib|"Acalabrutinib 100 mg twice per day by mouth on days 1-28~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
89220306|NCT04462328|Experimental|Phase I Dose Level 2: Durvalumab + Acalabruitinib|"Acalabrutinib 200 mg twice per day by mouth on days 1-28~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
89220307|NCT04462328|Experimental|Expansion Cohort: Durvalumab + Acalabrutinib|"Acalabrutinib 100 mg or 200 mg (depends on tolerable dose found in Phase I portion of study) twice per day by mouth on days 1-28~Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle"
89220308|NCT04458961|Active Comparator|One-stage|
89220309|NCT04458961|Active Comparator|Two-stage|
89220310|NCT04458506|Experimental|Rapid Maxillary Expander (RME)|36 patients will be treated with RME in order to correct their unilateral posterior cross bite
89220311|NCT04458506|Active Comparator|Quad Helix (QH)|36 patients will be treated with QH in order to correct their unilateral posterior cross bite
89220312|NCT04449432|Experimental|GROWell (Interactive Obesity Treatment Approach)|With Self-regulation Theory as the framework, the Interactive Obesity Treatment Approach Adapted for Pregnancy/Postpartum includes four components: (1) personalized goal setting, (2) daily support and educational messages, (3) self-monitoring of behavior with tailored feedback, and (4) skills training. Each component aligns with the self- regulatory processes shown in previous studies to be necessary for behavior change. All interactions with participants are via text using a cell phone.
89220313|NCT04449432|Active Comparator|Attention Support Control|The attention control will be delivered using text messaging to reduce the potential placebo effect that interacting with our mHealth system may have on pregnancy weight gain and postpartum weight loss. Information will be provided to control group participants that is specific to pregnancy, labor, delivery, and early infancy, but not to diet. Texts are specific to the participant's partner, pregnancy, employment, and breastfeeding plans/status.
89220314|NCT04445844|Experimental|Treatment (pelareorep, retifanlimab)|Patients receive pelareorep IV over 60 minutes on days 1, 2, 15, and 16. Patients also receive INCMGA00012 IV over 60 minutes on day 3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89220315|NCT04445792|Experimental|Acute Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
89220316|NCT04445792|Other|Acute Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
89220317|NCT04445792|Experimental|Chronic Pain - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
89220318|NCT04445792|Other|Chronic Pain - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period
89220319|NCT04445792|Experimental|Depression - Immediate PGx Testing|Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider
89220320|NCT04445792|Other|Depression - Delayed PGx Testing|Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period
89220321|NCT04433585|Experimental|LY3471851 High Dose|LY3471851 administered subcutaneously (SC).
89220322|NCT04433585|Experimental|LY3471851 Mid Dose|LY3471851 administered SC.
89220323|NCT04433585|Experimental|LY3471851 Low Dose|LY3471851 administered SC
89220324|NCT04433585|Placebo Comparator|Placebo|Placebo administered SC.
89220325|NCT04433338|Experimental|Intervention group|"Participants in the intervention group will follow a low-calorie diet during 14 days before undergoing surgery. The diet will consist of both meal replacements and regular foods.~For women, the diet provides ± 900 kcal, 50 grams of carbohydrates, 85 grams of protein, 30 grams of fat and 25 grams of fibres.~For men, the diet provides ± 1000 kcal, 55 grams of carbohydrates, 100 grams of protein, 30 grams of fat and 30 grams of fibres."
89220326|NCT04433338|No Intervention|Control group|Participants in the control group can eat according to the standard nutritional advices provided by their dietitian. These advices are intended to educate participants on the recommended eating pattern after surgery.
89220327|NCT04423783|Experimental|Spider gamification app|Participants play the spider gamification app twice a day for 7 days
89220328|NCT04423783|Experimental|Online exposure + spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play the spider gamification app twice a day for 7 days
89220329|NCT04423783|Active Comparator|Online exposure + non-spider gamification app|Participants receive a therapist-guided one-session online exposure therapy and play a non-spider gamification app twice a day for 7 days
89220330|NCT04413994|Active Comparator|Randomized study product group|"receiving study product (human milk fortifier Humavant) until a gestational age of 36 weeks"
89220331|NCT04413994|Active Comparator|Randomized control group|receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation
89220332|NCT04413994|No Intervention|Term control group|Term-born controls as a reference group for outcome parameters
89220333|NCT04409873|Placebo Comparator|Control (Distilled Water)|Over the counter: Distilled water
89220334|NCT04409873|Experimental|Oral-B Mouth Sore (H2O2) mouthwash|Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)
89220335|NCT04409873|Experimental|Crest Pro-Health Multi-Protection (C21H38ClN) mouthwash|Over the counter: Crest Pro-Health Multi-Protection (Crest, USA) contains cetylpyridinium chloride (C21H38ClN)
89220336|NCT04409873|Experimental|CloSYS (ClO2) mouthwash|Over the counter: CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA) contains stabilized chlorine dioxide (ClO2)
89220337|NCT04409873|Experimental|Listerine Mouthwash|Over the counter: Listerine Zero (Alcohol-Free)(Johnson and Johnson, USA) (C30H52O3)
89220338|NCT04409821|Experimental|Tele-delivered psychological intervention|Weekly tele-delivered psychological intervention
89220339|NCT04392297||Patients with CMV infection|
89220340|NCT04391348|Experimental|PET-TDM|PET-TDM with 18F-FDG and PET-TDM with 18F-fluorocholine
89220341|NCT04387734|Experimental|Ocrevus|
89220342|NCT04387734|Active Comparator|Other Disease Modifying Treatments|Other Disease Modifying Treatments will consist of FDA-approved injectable and oral medications for multiple sclerosis.
89220343|NCT04380324|Experimental|LY3471851|Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.
89220344|NCT04380324|Placebo Comparator|Placebo|Healthy participants in each cohort will receive the placebo comparator.
89220345|NCT04380077|Experimental|sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
89220346|NCT04380077|Active Comparator|balanced salt solution|vitreous substitution with balanced salt solution during vitrectomy
89220347|NCT04380064|Experimental|Study Group|Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment
89220348|NCT04380064|Active Comparator|Control Group|Subjects do not undergo ILM peeling during vitrectomy for the indication of tractional retinal detachment
89220349|NCT04371510|Other|Covid-19 patients with moderate symptoms|Whole blood, culture supernatant, serum
89220350|NCT04355533|Experimental|Hospitalized children or consulting at hospital|
89220351|NCT04355533|Experimental|Parents of one included child|
89220352|NCT04355533|Experimental|Children with potential COVID disease during the first wave|
89220353|NCT04355533|Experimental|Children SARS-coV2 positive|
89220354|NCT04355533|Experimental|Person living under the same roof as children included in the study|
89220355|NCT04345341|Active Comparator|Laparoscopic assisted TAP block|Laparoscopic assisted TAP block will be done by surgeon intra-operatively
89220356|NCT04345341|No Intervention|no TAP block|no TAP block would be done
89220357|NCT04332705||Patients with colon cancer|Patients with colon cancer of recent diagnosis will be recruited in consultation either in the surgical or gastroenterology departments
89220358|NCT04332705||Patients without colon cancer|Patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure will be recruited either in the surgical or gastroenterology departments
89220359|NCT04329949|Experimental|Relacorilant with nab-paclitaxel|Patients will be treated with relacorilant, administered orally, once daily in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
89220360|NCT04329065|Experimental|Treatment (WOKVAC, paclitaxel, trastuzumab, pertuzumab)|Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15, and trastuzumab IV and pertuzumab IV on day 1. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89220361|NCT04318925||1|Persons with diagnosed or suspected tick-borne disease age >=18 years
89220362|NCT04310891||Markerless|Markerless Tumour Tracking will be used to observe the radiation beam is accurately targeting the tumour.
89220363|NCT04300504||normal weight, not dynapenic|BMI 18.5 to 25kg/m2, waist circumference <= 88cm, healthy women aged 60-80 years, time to complete 5 chair stands <15 seconds
89220364|NCT04300504||normal weight, dynapenic|BMI 18.5 to 25kg/m2, waist circumference <= 88cm,healthy women aged 60-80 years, time to complete 5 chair stands >15 seconds
89220365|NCT04300504||obese, not dynapenic|BMI 30 to 40kg/m2, waist circumference > 88cm, healthy women aged 60-80 years, time to complete 5 chair stands <15 seconds
89220366|NCT04300504||obese, dynapenic|BMI 30 to 40kg/m2, waist circumference > 88cm, women aged 60-80 years, time to complete 5 chair stands >15 seconds
89220367|NCT04296617||Observational (medical chart review)|Patients' medical charts are reviewed.
89220368|NCT04293107||Phase 1: Content Validity Testing|Cohort of 6 parents/carers of children with cerebral palsy and GORD, who will be interviewed regarding the content validity of the PGSQ when used to assess symptoms of GORD in children with cerebral palsy.
89220369|NCT04293107||Phase 2: Reliability (test-retest) Testing|Cohort of 20 parents/carers of children with cerebral palsy and GORD, who will review and complete the adapted version of the PGSQ (post Phase 1) at two time points, two weeks apart.
89220370|NCT04290624|Experimental|Intervention Group|Participants will be instructed to use a dentifrice containing 0.454 percent (%) weight by weight (w/w) Stannous fluoride, COREGA denture foaming cleanser and mouth rinse containing 90 parts per million (ppm) sodium fluoride. Participants will brush with a strip of the dentifrice (full brush head) applied to the full length of the toothbrush head for 2 minutes followed by 2 pumps of denture cleanser foam brushed onto removable partial denture (RPD) for 90 seconds and 10 milliliter (ml) of mouth rinse for swished around the mouth for 1 minute. Participants will apply all these products twice daily (morning and evening) for 12 weeks.
89220371|NCT04290624|No Intervention|Reference Group|Participants will not be supplied any products and will continue with their existing dental/denture hygiene practices and should not make changes to either their established habits nor to the products they use following screening.
89220372|NCT04288115|Active Comparator|"Levothyroxine group (sham discontinuation)"|Continue the current dose of levothyroxine. The brand of levothyroxine to be used in this study will be Synthroid tablets of 25 mcg, 50 mcg, and 75 mcg (AbbVie Inc).
89220373|NCT04288115|Placebo Comparator|"Placebo group (real discontinuation)"|Stop the current dose of levothyroxine and take study placebo
89220374|NCT04287868|Experimental|Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies|"Triple Therapy: PDS0101 + NHS-IL12 + M7824 (MSB0011395C); The dose level of NHS-IL12 may decrease depending on dose limiting toxicity (DLT) events. The dose level of human papillomavirus vaccine (HPV) vaccine and M7824 will remain constant.~If more than 3 of 8 participants have an objective response then accrual will be expanded to 20 evaluable participants."
89220375|NCT04287868|Experimental|Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy|"Triple Therapy: PDS0101 + NHS-IL12 + M7824 (MSB0011395C); PDS0101 + NHS-IL12 + M7824; Reduced doses.~May enroll up to 12 participants for a safety evaluation and up to 12 additional participants for preliminary evaluation of efficacy and further evaluation of safety."
89220376|NCT04287738|Experimental|Navigated Care|Telephone-based collaborative dementia care navigation
89220377|NCT04287738|No Intervention|Survey of Care|Control group that will receive usual care and undergo the same regular assessments as patients enrolled in Navigated Care
89220378|NCT04276935||Health Services Research (cognitive interviews)|Participants take part in cognitive interviews in Spanish over 45-60 minutes.
88821148|NCT05027477|Active Comparator|Radical Prostatectomy|Patients in this group will undergo Radical prostatectomy. There will be about 67 people in this group.
88821149|NCT05027477|Experimental|TULSA Procedure|Patients in this group will undergo TULSA Procedure. There will be about 134 people in this group.
89220379|NCT04271813|Experimental|Anlotinib and Sintilimab|the combination of Anlotinib with Sintilimab as first-line treatment
89220380|NCT04269577|Experimental|SSP training - early PD|Practice of the Swipe Slide Pattern task alone for a group of patients with early Parkinson's disease (PD)
89220381|NCT04269577|Experimental|SSP training - mid PD|Practice of the Swipe Slide Pattern task alone for a group of patients with mid-stage Parkinson's disease (PD)
89220382|NCT04269577|Experimental|SSP training - HC|Practice of the Swipe Slide Pattern task alone for a group of healthy age-matched controls (HC)
89220383|NCT04263714|Experimental|Exercise|All subjects will perform both aerobic and resistance exercise
89220384|NCT04262193|Placebo Comparator|Suvorexant placebo|Placebo (inert) tablet
89220385|NCT04262193|Experimental|Suvorexant 20mg|Suvorexant 20mg tablet
89220386|NCT04261478|Active Comparator|Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be revascularized with a stent during the acute thrombectomy procedure.
89220387|NCT04261478|No Intervention|No Acute Stenting|All patients in this arm will receive standard of care with regards to intracranial thrombectomy and use of intravenous thrombolysis. In this arm, the cervical carotid artery stenosis will be not revascularized with a stent during the acute thrombectomy procedure.
89220388|NCT04251026|Experimental|Cohort A|Dose escalation followed by a consistent dose level in participants with neuronopathic MPS II
89220389|NCT04251026|Experimental|Cohort B|A consistent dose level in participants with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype followed by dose escalation in some participants.
89220390|NCT04251026|Experimental|Cohort C|A consistent dose level in participants with neuronopathic MPS II
89220391|NCT04251026|Experimental|Cohort D|A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II
89220392|NCT04251026|Experimental|Cohort E|A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II
89220393|NCT04248452|Experimental|Arm A (FOLXFOX)|Patients receive oxaliplatin IV over 1.5 hours, leucovorin IV over 1.5 hours, and 5-fluorouracil IV over 46-48 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89220394|NCT04248452|Experimental|Arm B (CAPOX)|Patients receive oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89220395|NCT04248452|Experimental|Arm C (radiation therapy, FOLFOX)|One week post induction of patients in ARM A, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
89220396|NCT04248452|Active Comparator|Arm D (FOLFOX)|Post induction of patients in ARM A, patients continue oxaliplatin, leucovorin, and 5-fluorouracil as in Arm A for 2 years in the absence of disease progression or unacceptable toxicity.
89220397|NCT04248452|Experimental|Arm E (radiation therapy, CAPOX)|One week post induction of patients in ARM B, patients undergo radiation therapy for up to 15 days. Within 2-4 weeks post radiation therapy, patients receive oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
89220398|NCT04248452|Active Comparator|Arm F (CAPOX)|Post induction of patients in ARM B, patients continue oxaliplatin and capecitabine as in Arm B for 2 years in the absence of disease progression or unacceptable toxicity.
89220399|NCT04238637|Experimental|Arm 1|Durvalumab
89220400|NCT04238637|Experimental|Arm 2|Durvalumab in combination with Tremelimumab
89220401|NCT04232670|Sham Comparator|EUS + SHAM|All subjects will undergo anesthesia administered sedation and endoscopic ultrasound (EUS). The endoscopist will assess the pancreas for parenchymal and ductal features of chronic pancreatitis and confirm the absence of exclusion criteria (such as the presence of an occult pancreatobiliary malignancy).
89220402|NCT04232670|Experimental|EUS + Pancreatic Endotherapy|If randomized to ERCP with pancreatic endotherapy, the endoscopist will proceed with this intervention immediately following the completion of EUS and treatment allocation (during the same anesthesia). Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement. Overall technical success will be defined by the ability to insert at least one pancreatic stent across the dominant main pancreatic duct obstruction. Technical success for pancreatic stone treatment will be defined by the ability to remove all fluoroscopically visible main pancreatic duct stones.
89220403|NCT04225182|Experimental|with instrumented Orthosis|patient will follow 8 weeks of muscular strengthening with the orthosis connected to the phone app associated
89220404|NCT04225182|Active Comparator|without instrumented Orthosis|patient will follow 8 weeks of traditional muscular strengthening without orthosis
89220405|NCT04221893|Experimental|Radiation therapy (RT)|Patients undergo radiation therapy for a total of 5 treatments over 5-9 calendar days in the absence of disease progression or unacceptable toxicity. Target prescription dose will be 30 Gy in 5 fractions and each treatment site (up to 5) will undergo standard Department-approved treatment planning, quality-assurance, and delivery protocols
89220406|NCT04217551|Experimental|6 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
89220407|NCT04217551|Experimental|12 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
89220408|NCT04217551|Experimental|18 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
89220409|NCT04217551|Experimental|24 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220410|NCT04217551|Experimental|30 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220411|NCT04217551|Experimental|36 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220412|NCT04217551|Experimental|42 Hours - shockable|Participants with shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220413|NCT04217551|Experimental|48 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220414|NCT04217551|Experimental|60 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220415|NCT04217551|Experimental|72 hours - shockable|Participants with shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220416|NCT04217551|Experimental|6 hours - non shockable|Participants with non-shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
89220417|NCT04217551|Experimental|12 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
89220418|NCT04217551|Experimental|18 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
89220419|NCT04217551|Experimental|24 hour - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220420|NCT04217551|Experimental|30 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220421|NCT04217551|Experimental|36 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220422|NCT04217551|Experimental|42 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220423|NCT04217551|Experimental|48 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220424|NCT04217551|Experimental|60 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220425|NCT04217551|Experimental|72 hours - non-shockable|Participants with non-shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
89220426|NCT04204473|Experimental|TY-9591|Find maximum tolerated dose of TY-9591 given orally. Escalating doses of TY-9591 starting at 20mg daily.
89220427|NCT04199195||Males and females aged at least 60 years.|"A longitudinal study of one cohort of 360 participants aged at least 60 years. Participants will be required to provide a stool sample, provide a blood sample and complete a health questionnaire every 6 months for 4 years. At alternate visits, participants will be required to under go cognitive assessments and physical measurements.~Participants will be required to under go an Optical Coherence Tomography Scan 3 times over 4 years.~Sub group 1 - During a routine care colonoscopy, at least 90 participants will have 6-8 colon tissue biopsies taken for research purposes.~Sub group 2 - Participants from cohort 3 only will be offered an optional brain MRI until the required number of 30 participants is achieved."
89220428|NCT04198623|Other|Montelukast (Singulair)|Montelukast(Singulair) 10mg to be taken in addition to standard institutional premedication
89522810|NCT03397979|Active Comparator|Infrequent soaking baths|Infrequent soaking baths, in this study, is defined as twice a week soaking baths for 10 minutes or less, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined above, and 2) Frequent soaking baths (defined as twice daily soaking baths for 15-20 minutes, over 2 weeks). All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
88821150|NCT05022862|Active Comparator|Usual Care|Participants will receive routine (non-study directed) medical care for latent tuberculosis infection according to published guidelines, including medication, nurse case management, Tuberculosis health education, and toxicity assessments.
89220429|NCT04191096|Experimental|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
89220430|NCT04191096|Placebo Comparator|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
89220431|NCT04187833|Experimental|Nivolumab + Talazoparib|Nivolumab 480mg intravenously every 4 weeks (28 days) + Talazoparib 1mg orally daily
89220432|NCT04178915||Patients with severe bacterial infections|
89220433|NCT04174963|Experimental|eToke + TPsy|All participants will receive the intervention (eToke+TPsy). The intervention consists of eToke (a brief computerized intervention that uses motivational enhancement therapy to improve readiness to decrease cannabis use and increase motivation to engage in substance use treatment) AND 6-8 interactive text messages regarding cannabis use reduction over 4 weeks . Text messages will contain written content, and queries, as well as links to publicly available websites and YouTube videos.
89220434|NCT04167748|Experimental|PGT-A transfer|Transfer of single chromosomally normal (euploid) blastocyst after PGT-A
89220435|NCT04167748|No Intervention|Untested blastocyst transfer|Transfer of single untested blastocyst based on embryo morphology criteria.
89220436|NCT04162418|Other|Intervention|Treatment with Temporary Spur Stent System and a commercially available, limus-base, drug coated balloon
89220437|NCT04160013|Experimental|Discipline education|Education about discipline using the Play Nicely program (www.playnicely.org).
89220438|NCT04160013|Placebo Comparator|Cavity prevention|Education about cavity prevention using a 2 page handout.
89220439|NCT04157335|Experimental|Benralizumab|Benralizumab administered subcutaneously
89220440|NCT04157335|Placebo Comparator|Placebo|Placebo administered subcutaneously
88821151|NCT05022862|Active Comparator|Video Directly Observed Therapy alone|Participants in this group will receive the same treatments and education provided to Usual Care Control participants, however treatment will be viewed by video directly observed therapy (video-DOT)
89220441|NCT04157127|Experimental|Autologous DC Vaccine Cohort 1|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 1:~st vaccine - 0.5 million cells~nd vaccine - 1 million cells~rd vaccine - 2 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
89522811|NCT03397979|Active Comparator|Frequent soaking baths|Frequent soaking baths, in this study, is defined as twice daily soaking baths for 15-20 minutes, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined in the first arm description above, and 2) Frequent soaking baths, as defined above in this arm description. All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
89220442|NCT04157127|Experimental|Autologous DC Vaccine Cohort 2|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 2:~st vaccine - 1 million cells~nd vaccine - 2 million cells~rd vaccine - 4 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
89220443|NCT04157127|Experimental|Autologous DC Vaccine Cohort 3|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 3:~st vaccine - 2 million cells~nd vaccine - 4 million cells~rd vaccine - 8 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
89522812|NCT03394157|Other|Diabetes Mellitus Type 2 in Obese patients|obese patients had metabolic surgery for the treatment for DMT2 .Preoperative data , which including SASI bypass , MGB and Sleeve gastrectomy
89689336|NCT02982551|Experimental|Hyperinsulinemic Clamp|Participants will complete two MRI scans approximately one hour apart - one under baseline conditions and the second during an insulin infusion. Each scan will include data collected during rest, and a taste task. The taste task involves receiving milkshake or a tasteless solution. After the first scan, an isoglycemic-hyperinsulinemic clamp will be implemented. An IV will be placed in the antecubital vein of of arm for infusion of insulin and dextrose. HumuLIN®-R regular insulin will be infused at 40 mU/m2/min. A second IV will be inserted in the back of the hand on the opposite arm to allow for frequent sampling of blood glucose levels. Dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline value. The study team will monitor blood glucose levels and adjust dextrose infusions as necessary. Thirty minutes after starting the insulin infusion, participants will be moved back into the bore of the MRI scanner for the repeat scans.
89689337|NCT02964910|Experimental|the chronic Hepatitis B patients|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
89689338|NCT02964910|Active Comparator|the healthy volunteer|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
89689339|NCT02156687|Active Comparator|Cololast, Inc. Restorell Y mesh|Y mesh
89689340|NCT02156687|Active Comparator|Coloplast, Inc. Restorelle Dual flat mesh|Dual flat mesh
89060935|NCT04571684|Experimental|Intervention Arm (HITSystem 2.1)|Participants enrolled at intervention sites will received HITSystem 2.1-supported PMTCT services through 6 months postpartum. Interventions received will include: text messages to patients to support medication adherence, appointment attendance, and hospital delivery and algorithm-driven alerts to notify providers when follow up services are missed.
89060936|NCT04571684|No Intervention|Control Arm (Standard of care)|Participants enrolled at control sites will receive standard of care PMTCT services, with no HITSystem 2.1 tracking or follow up.
89060937|NCT04553471|Experimental|SBRT|5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
89060938|NCT04542616|Active Comparator|Baerveldt 350|The patients in this arm will receive a Baerveldt 350 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
89689341|NCT02241239||participants|healthy adults without stroke and coronary heart disease
89689342|NCT02965144||HGG patients|single-group study- long term survivors
89689343|NCT04376411||patients with Behcet disease|Flow-cytometric assay Detailed 2 Di mention Echocardiographic analysis Two-Dimensional speckle tracking echocardiography
89689344|NCT04376411||Healthy control subjects|Flow-cytometric assay
89689345|NCT04364243|Experimental|Patients exercise|Low back pain patients Next to basic medical physical training therapy group A receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
89689346|NCT04364243|No Intervention|Patients control|Low back pain patients Group B will receive basic medical physical training therapy
89060939|NCT04542616|Active Comparator|Ahmed ClearPath 250|The patients in this arm will receive an Ahmed ClearPath 250 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
89060940|NCT04540068||Patients with Lumbar Disc Herniation|Patients with a lumbar disc herniation on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
89060941|NCT04540068||Patients with Lumbar Spinal Stenosis|Patients with a lumbar spinal stenosis on MRI and consistent with clinical findings are screened if they have an appointment at the pain clinic for treatment with a transforaminal epidural injection.
89060942|NCT04523701|Experimental|Experimental Intervention (treatment)|"Open bile ducts are identified by visual control of the liver resection surface combined with the direct injection in the cystic stump of 20-40ml of SMOFlipid 20% Fresenius Kabi Canada Ltd.; authorization number: 57231 (Swissmedic).~SMOFlipid is a white oily emulsion containing soya oil and medium chain triglycerides as main active components, normally used as parenteral nutrition as complement for essential fat acids supplementation. In this study the white test (= the administration of SMOFlipid retrograde through the cystic duct) is made by injection of one or two 20cc syringes full of lipidic solution (SMOFlipid 20%) in the cystic stump, directing the flow to the intrahepatic ducts. Residual fat emulsion is washed out from the biliary tract by a low pressure infusion of 20 to 50 ml of saline solution."
89060943|NCT04523701|No Intervention|Control Intervention|Open bile ducts are identified in the control group by visual control of the liver resection surface combined with the use of white gauzes (standard procedure)
89060944|NCT04491422|Active Comparator|Integrated Next Steps Counseling using poi|At quarterly visits, intervention arm participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine TFV levels <1000 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing.
89060945|NCT04491422|No Intervention|Standard adherence counseling|Control arm participants will receive standard adherence counseling.
89060946|NCT04490356|Experimental|Legacy Intervention|Older adults who have successfully completed a lifestyle intervention (lost at least 3% body weight and increased short physical performance battery (SPPB) score by 1 point or 6-minute walk test (6MWT) by 50 meters) will be enrolled in a tele-nutrition and tele-exercise intervention.
89060947|NCT04484831|Experimental|ABT Weight Loss Intervention|Adolescent participants will attend sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
89060948|NCT04484831|Placebo Comparator|Enhanced Care|Adolescent participants will receive handouts on elements of a healthy lifestyle and will participate in a midpoint one-on-one nutrition consultation with a registered dietitian.
89060949|NCT04477850|Experimental|Luspatercept Administration|
89060950|NCT04471233|Experimental|Multimodal analgesia regimen including pregabalin|For the pregabalin group, patient will be provided with an oral preoperative pregabalin dose of 150mg on the day of surgery. Patient will continue pregabalin 75mg two times a day, for two weeks postoperatively. For both the intervention and control groups, the operative technique and additional perioperative analgesic modalities will follow a standard protocol
89220444|NCT04157127|Experimental|Autologous DC Vaccine Cohort 4|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 4:~st vaccine - 6 million cells~nd vaccine - 6 million cells~rd vaccine - 6 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
89220445|NCT04157127|Experimental|Autologous DC Vaccine Cohort 5|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 5:~st vaccine - 7 million cells~nd vaccine - 7 million cells~rd vaccine - 7 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
89220446|NCT04157127|Experimental|Autologous DC Vaccine Cohort 6|"Vaccine made from autologous dendritic cells loaded with tumor cell lysate and RNA. Subject will get 3 doses of DC vaccine (one every 14 days) and be monitored (vital signs every 30 minutes) for 2 hours after each dose. During treatment, subjects get weekly peg-interferon a-2a at 180 mcg/week on the first day of vaccination up through 14 days after last vaccination.~DC Vaccine dose evaluated in Cohort 6:~st vaccine - 8 million cells~nd vaccine - 8 million cells~rd vaccine - 8 million cells~At each dose level, the 1st subject should get all 3 vaccinations before the 2nd and 3rd subjects at that level receive their 1st vaccination. The 3rd subject can begin vaccination regardless of the time since the 2nd subject began vaccinations. All 3 subjects in cohort should get all 3 vaccinations before any subjects are treated in the next higher cohort. Because of this, the study may not progress to every dose level before MTD is found."
89220447|NCT04147676||TB suspects|"Sputum specimens will be collected from TB suspects enrolled in the study.~The specimens will be tested with~Roche cobas MTB - for the detection of Mycobacterium tuberculosis complex~Roche cobas MTB-RIF/INH - all specimens that are Mycobacterium tuberculosis complex positive will be reflexed to the Roche cobas MTB-RIF/INH test for the detection of resistance to rifampicin and isoniazid~Hain FluoroType MTBDR - for the detection of Mycobacterium tuberculosis complex and the detection of resistance to rifampicin and isoniazid"
89220448|NCT04146493||Vascular surgery group|Patients which are given unfractionated heparin during their vascular surgery.
89220449|NCT04146493||Thromboprophylaxis group|Patients which are given low molecular heparins as a thrombosprofylax after major surgery
89220450|NCT04146493||Cardiothoracic surgery|Patients which are given high dose unfractionated heparin during their open heart surgey
89220451|NCT04145531|Experimental|JZP-458|"Part A (IM JZP-458) of the study will have 2 IM cohorts:~Cohort 1: a JZP-458 repeat dose/confirmatory cohort; a final IM JZP-458 dose level will be selected, and~Cohort 2: an expansion cohort to confirm the efficacy and safety of the final IM JZP-458 dose level and schedule~Part B (IV JZP-458 Dose Confirmation) will be conducted to define the optimal dose of the IV administration of JZP-458 for further study in ALL/LBL patients as a repeated dose.~Additional courses of JZP-458 (IM or IV depending on patient's allocation at study enrollment) will be administered based on each patient's original treatment plan for as long as the patient derives clinical benefit."
89220452|NCT04133116|Experimental|LY3471851|Participants received single doses of 450 microgram (μg), 900 μg or 1800 μg LY3471851 administered subcutaneously (SC).
89220453|NCT04133116|Placebo Comparator|Placebo|Placebo matching LY3471851 administered SC.
89220454|NCT04124692|No Intervention|Control Group: No-treatment|Participants will receive no treatment during the study.
89220455|NCT04124692|Experimental|Treatment Group: Sculptra Aesthetic|Participants will be injected with Sculptra Aesthetic by Treating Investigator at Day 1 until optimal correction achieved (up to 4 total treatment sessions)
89689347|NCT04364243|Experimental|Non-patients exercise|non-patients Groups C will receive a home exercising programme which involves 10 exercises for 2 minutes each with the Valedo training system.
89689348|NCT04364243|No Intervention|Non-patients control|non-patients Group D will receive no intervention
89689349|NCT02965534|Experimental|Night Spectacle Correction|Refraction for this glasses was obtained at low luminance.
89689350|NCT02965534|Active Comparator|Spectacle Correction for photopic light conditions|Refraction for this glasses was obtained at high luminance level.
89689351|NCT04372511|Experimental|Binaural Beats|Group A : use of stereo headphones that generate sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
89689352|NCT04372511|No Intervention|No sounds|Group B : use of stereo headphones with a white background noise
89689353|NCT02965924|Experimental|Phenylephrine|Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
89689354|NCT04364477|Active Comparator|Tap block Group|Tap Block group :(Group 1) After General anestehesia At the end of the operation, TAP blocks were placed to the 1st group patients.
89689355|NCT04364477|Placebo Comparator|Control Group|No block applied. only General anesthesia was applied.
89689356|NCT02241395|Experimental|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
89689357|NCT02967016|Experimental|normal spontaneous vaginal delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
89689358|NCT02967016|Experimental|Cesarean Delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
89689359|NCT04372277|Experimental|Enstilar|Enstilar foam
89689360|NCT04372355|Experimental|Chlorite-based drug WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five
89220459|NCT04119986|Experimental|drug coated balloon|A total of 110 patients with ISR are assigned to drug coated balloon treated group after randomization schedule.
89220460|NCT04119986|Other|drug eluted stent implantation|A total of 110 patients with ISR are assigned to drug eluted stent treated group after randomization schedule.
89220461|NCT04106128|Experimental|ultrasound examination|Assess the prevalence of acute diaphragmatic dysfunction by ultrasound
89220462|NCT04104854|Experimental|drug coated balloon|A total of 110 patients are assigned to drug coated balloon treated group after randomization schedule.
89220463|NCT04104854|No Intervention|drug eluted stent implantation|A total of 110 patients are assigned to drug eluted stent treated group after randomization schedule.
89220464|NCT04103970|No Intervention|Control group|"Usual care:~Before surgery all patients are invited to participate in a pre-surgery seminar, where they receive information and advice about the time before, during and after the LSF. The seminar will be guided by nurses, surgeons, anesthesiologist, occupational therapists and physiotherapist.~After the surgery the patient will be hospitalized on an average of 3-4 days. During hospitalization a physiotherapist consults the patients on a daily basis to provide information, guidance on mobilization and instructions in gradually progressing movement. The patients will have no restrictions on movement after surgery and should gradually return to normal activity level.~Three months post-operatively all patients will receive physical rehabilitation delivered by physiotherapists in a community care center."
89220465|NCT04103970|Experimental|Intervention group: Graded Activity and Pain Education (GAPE)|"Patients in the intervention-group will receive usual care and 9 sessions of GAPE, 4 sessions at the hospital, 2 sessions in the patient's home and 3 sessions by telephone.~Pain education in GAPE is viewed as an approach which target cognitive attitudes and beliefs about pain. The pain education will target 3 overall questions: 1. What is pain and is my pain normal? 2. What can affect my pain? 3. What can I do to relieve my pain? The education will be individually adjusted to each patient, so the patient's context and concerns regarding pain and movement are included.~The aim of Graded activity is to improve the patient's functional ability by positive reinforcement of health behaviors and activity levels. Graded activity will be based on which short-term activity-goals the patient evaluates as the most important for the treatment outcome. In close collaboration with the patient the physiotherapist will set quotas for the selected exercises/activities."
89220466|NCT04102423||CCUS|All participants meeting the criteria for CCUS
89689361|NCT05620667|Placebo Comparator|placebo|Placebo 25mL, without any ingredients of immature ponkan extract. Drink 25mL for once, and once a day.
89689362|NCT05620667|Experimental|immature ponkan (Citrus reticulate) extract|Immature ponkan (Citrus reticulate) extract 25 mL, drink 25mL for once, and once a day.
89220467|NCT04102423||CHIP|Subjects will be split into five cohorts depending on specific mutations
89220468|NCT04096664|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
89220469|NCT04096664|No Intervention|Control|Usual care
89220470|NCT04092894|Active Comparator|Suvorexant|Suvorexant 20 mg will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
89220471|NCT04092894|Placebo Comparator|Placebo|Placebo will be administered p.o. once a day between 9:00pm and 10:00pm for 7 days starting the night after extubation in the ICU.
89220472|NCT04088292|Active Comparator|USAT + low dose thrombolysis|UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization
89220473|NCT04088292|Active Comparator|Low dose thrombolysis|Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).
89689363|NCT05620667|Experimental|immature ponkan (Citrus reticulate) extract with time restricted feeding|Immature ponkan (Citrus reticulate) extract 25 mL, drink 25mL for once, and once a day, adding time restricted feeding.
89689364|NCT02968420|Active Comparator|Group 1|Group 1: girls who received 2 doses of Q-HPV vaccine at 0, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
89689365|NCT02968420|Active Comparator|Group 2|Group 2: girls who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
89689366|NCT02968420|Active Comparator|Group 3|Group 3: young women who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 16-26 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
89689367|NCT05529225||Boulder Care|People seeking buprenorphine for opioid use disorder via telehealth.
89689368|NCT05529225||OHSU|People seeking buprenorphine for opioid use disorder via treatment as usual.
89689369|NCT04364321|Experimental|Single dose Clonazepam|Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)
89689370|NCT04364321|Active Comparator|Intermittent oral diazepam|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.
89689371|NCT03039088||Fibromyalgia patients|
89689372|NCT03039088||Not fibromyalgia patients|
89689373|NCT05528913|Experimental|Benralizumab|Fasenra 60mg s.c. administration
89689374|NCT05528913|Placebo Comparator|Placebo|Placebo s.c. administration
89689375|NCT02241473|Experimental|CH training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion.
89689376|NCT02241473|Active Comparator|CN training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) condition in a single-blind fashion.
89689377|NCT05337345|Experimental|Part 1|
89689378|NCT05337345|Experimental|Part 2|
89060951|NCT04471233|Active Comparator|Multimodal analgesia regimen not including pregabalin|For the non-pregabalin group, patient will be undergo total knee arthroplasty with the same operative technique and additional perioperative analgesic modalities will follow a standard protocol
89060952|NCT04449510|Other|E-liquid pH 5, 7, or 9|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned e-liquid pH.
89060953|NCT04449510|Other|1 of the other 2 remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 assigned e-liquid pH.
89060954|NCT04449510|Other|Remaining e-liquid pH|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining assigned e-liquid pH.
89060955|NCT04445571|Active Comparator|INSURE|Surfactant administration by Intubation-surfactant-extubation to CPAP according to standard protocol including premedication with analgesia and sedation.
89060956|NCT04445571|Active Comparator|LISA|Surfactant administration by thin catheter during spontaneous breathing and continued CPAP according to set protocol including premedication with analgesia.
89060957|NCT04426019|Experimental|CLS intervention|Community health workers (CHWs) assess women's breast and/or cervical cancer screening needs and deliver behavioral education designed to increase breast and/or cervical cancer screening. After completing the education, CHWs provide women with clinic referrals to local and affordable screening services. Participants also are offered telephone-delivered navigation support, which focuses on helping women overcome logistic and personal barriers to accessing screening services.
89060958|NCT04426019|Active Comparator|No CLS intervention|Community health workers (CHWs) assess women's breast and/or cervical cancer screening needs and deliver print materials to women describing cancer screening guidelines.
89060959|NCT04421235|Other|Childbirth Support|Women who enroll in the intervention portion of this study will receive the childbirth support elements for which they are eligible in and elect to participate. Possible program elements include prenatal education classes, support group, lactation program, doula support, and parenting classes.
89060960|NCT04415281|Experimental|Active PBM|PBM has been used clinically in the treatment of musculoskeletal and other pain conditions for over 30 years. Despite the low quality of the existing evidence, PBM has been increasingly used in other countries for the treatment of TMD. However, in the US PBM is not widely used for the treatment of TMD pain. Due to the multifactorial nature of chronic TMD pain, we propose that a multimodal PBM protocol targeting multiple pathophysiological mechanisms will be the optimal approach for PBM implementation in patients with TMD.
89060961|NCT04415281|Sham Comparator|Sham PBM|When applying PBM therapy, there are some heating elements in the treatment device, and most of the sham treatment devices available do not offer this feature, which increases the likelihood of unblinding both the patient and the interventionist. The THOR® LX2.3 PBM machine includes this new feature, such that the sham condition mimics the heating activity of the active treatment.
89060962|NCT04401267|Experimental|Intensive Antihypertensive Therapy|Patients will begin Intensive antihypertensive therapy to achieve the targeted blood pressure (targeted to the 50-75th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
89060963|NCT04401267|Active Comparator|Conventional Antihypertensive Therapy|Patients will begin Conventional antihypertensive therapy to achieve the targeted blood pressure (targeted to the 90-95th percentile for age, sex, and height) on day 4 of Remission Induction on TOT17 and continue during steroid containing phases until the completion of reinduction II.
89060964|NCT04398966|Experimental|PAE Procedure|This will be a single arm, uncontrolled, non-blinded study of PAE using HydroPearl Beads in a small population of 30 subjects with benign prostate hyperplasia (BPH)
89060965|NCT04394676|Experimental|Reduction in Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
89060966|NCT04394676|Active Comparator|Standard Amount of Pressure|This group receives 15mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
89220474|NCT04088292|No Intervention|Heparin alone|UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)
89522813|NCT03389789|Experimental|Oral glucose solution + maternal holding|Infants will receive 2 mL of oral glucose solution two minutes before the heel-prick and will be held in the mothers' lap (maternal relationship) throughout the painful procedure.
89522814|NCT03389789|Experimental|Breastfeeding|Infants will be breastfed two minutes before the heel-prick and throughout the painful procedure.
88821186|NCT04960397|Experimental|Cohort 4|Once, there is sufficient evidence of safety and tolerability in Cohort 3 and enrollment has been completed for this cohort, and fifth cohorts (Cohorts 4 and 5) will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive two doses of the 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or two doses of placebo (N=10) at Day 1 and Day 29. N=25
89220475|NCT04083495|Experimental|ATLCAR.CD30 cells|The cellular product consisting of ATLCAR.CD30 cells will be administered via intravenous injection over 5 - 10 minutes through either a peripheral or a central line. The volume of infusion will depend upon the concentration of the cells when frozen and the size of the subject. Administration to eligible subjects will occur within 2 - 14 days after completing the lymphodepleting chemotherapy regimen
88821187|NCT04955639|Active Comparator|Control|A commercially available mobile phone app and program
88821188|NCT04955639|Active Comparator|Pivot|Pivot mobile phone app and program
88821189|NCT04945473|Experimental|Revision|"BMI≥30 or total weight loss (TBWL) < 10% and relaxation of gastric tubulisation at 6 months after ESG.~Additional stitches will be placed during the follow-up gastroscopy at 6 months."
89220476|NCT04080063|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
89220477|NCT04074642|No Intervention|Non compressive adenoma|Optical Coherence Tomography Angiography without surgery
89220478|NCT04074642|Experimental|Compressive adenoma|Optical Coherence Tomography Angiography before and after neurosurgery
89220479|NCT04066946|Experimental|Group 1 = Intervention group|Standard of care (hydration + silicone gel sheet) + Microcurrent
89220480|NCT04066946|Active Comparator|Group 2 = Control Group|Standard of care (hydration + silicone gel sheet)
89220481|NCT04066777|Other|Hypertrophic obstructive cardiomyopathy|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
89220482|NCT04059393|Experimental|Group I (web-based legacy intervention)|Patients participate in a web-based legacy intervention by answering questions about themselves and uploading videos, photographs, and music to create a digital story within 2 weeks.
89220483|NCT04059393|Active Comparator|Group II (standard of care)|Patients receive standard of care. Patients have the option to participate in the web-based legacy intervention after 2 months.
89220484|NCT04040530||Cryoablation|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with CT-guided cryoablation at Odense University Hospital in the period from 1/6-2019 to 1/6-2021.
89220485|NCT04040530||Partial nephrectomy|Consecutive patients diagnosed with biopsy proven renal cell carcinoma at stadium T1a or T1b, from the Region of Southern Denmark or Region Zealand, treated with partial nephrectomy at Odense University Hospital or Zealand University Hospital in the period from 1/6-2019 to 1/6-2021.
89220486|NCT04039750|Experimental|Antibiotic irrigation with suction|Group A: You will receive antibiotic irrigation with suction if a PA is found during surgery
89220487|NCT04039750|Active Comparator|suction only|Group B: You will receive suction alone if a PA is found during surgery
89220488|NCT04039061||ADPKD patients|Patients with a diagnosis, or suspected diagnosis, of ADPKD
89220489|NCT04038840|Experimental|Healthy Control (HC) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
89220490|NCT04038840|Experimental|Schizophrenia (SZ) Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer
89220491|NCT04029883|No Intervention|Control Group|The Control group will receive care as usual, as well as a MEMS-cap and a leaflet explaining the importance of pill-taking routines and how to establish them. The study coordinator will spend approximately ten minutes with them to go over the leaflet and answer questions. Control group participants also spend time with the study coordinator at each clinic visit where contact information is updated, and any MEMS-cap problems are resolved. These procedures, which we successfully applied in previous studies, minimize the possibility that results are confounded by differences in attention or other non-specific effects between groups.
89220492|NCT04029883|Active Comparator|Message Group|The Message group will receive the same brief information session as the Control group but also receive daily text messages reinforcing the information provided for 3 months. A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time. To keep the importance of routinizing pill- taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform. These messages will reinforce the information provided at recruitment, and remind participants of their personalized routinization strategy. Messages will be tailored and refreshed based on patient-specific factors including BP control, prior adherence, and current medication regimen.
89522815|NCT03389789|Active Comparator|Oral glucose solution|Infants will receive 2 mL of oral glucose solution given two minutes before the heel-prick on a changing table.
88821190|NCT04945473|No Intervention|Without revision|The control gastroscopy will be performed without any additional procedure (no additional stitches).
89522816|NCT03389789|Active Comparator|Oral expressed breastmilk|Infants will receive 2 mL of expressed breastmilk given two minutes before the heel-prick on a changing table.
89522817|NCT03394001|Active Comparator|Lidocaine Hydrochloride|Wound infiltration with Lidocaine
89220493|NCT04029883|Experimental|Incentive Group|The Incentive group will receive the same information and text messages, but in addition have a chance of winning small, intermittent rewards for taking their medication at the time coinciding with their anchoring strategy. In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits. When the participants return for their monthly visit, the study coordinator will download their MEMS-cap data and check whether this eligibility criteria was satisfied. MEMS software can be easily customized to display this information. If the patient qualifies, s/he is invited to draw one of three laminated cards with numbers 0, 25, and 50 out of a bag. The client receives the corresponding amount in USD in the form of a gift card immediately after the drawing.
89220494|NCT04028596|Active Comparator|Acetaminophen|Trade name: Paracetamol Pharmaceutical form: Tablet (oral use) Once 1000 mg 2h before the ECT-session. Total maximum of five times over the course of weeks
89220495|NCT04028596|Active Comparator|Nimodipine|Trade name: Nimotop Pharmaceutical form: Film-coated tablet (oral use) Once 60mg 2h before the ECT-session. Total maximum of five times over the course of weeks.
89220496|NCT04028596|No Intervention|Control|Glass of water (50cc) only. Once 2h before the ECT-session. Total maximum of five times over the course of weeks.
89220497|NCT04018066|Experimental|GP-SPI intervention|20 g of GP-SPI taken twice per day for 10 days
89220498|NCT04012645|Experimental|experimental group|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used during the surgeries.
89220499|NCT04012645|Active Comparator|control group|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
89220500|NCT04009330||Adults in the Intensive Care Setting|Adults in the Intensive Care Setting
89220501|NCT04008485|Experimental|Asymptomatic high-risk women|Women will be scheduled to attend for MIS measurement at 20-22 weeks, to be repeated at 26-28 weeks. This measurement will be taken at the same time as the routine examination which they receive when they attend the prematurity clinic. At each study visit the patient will undergo a vaginal examination. Triple high vaginal swabs will then be taken for bacteriology and fetal fibronectin. The sterile magnetic impedance probe will then be introduced, data being captured automatically by pressing the data capture button on the handle of the device. A transvaginal scan will also be performed to measure CL.
89522818|NCT03394001|Active Comparator|Ketorolac tromethamine|Wound infiltration with Ketorolac
89522819|NCT03389633|Experimental|Rehabilitation group|this group follows a 3 months rehab program
89522820|NCT03389633|No Intervention|No rehabilitation|This group does not follow a rehab program
89522821|NCT03393923|No Intervention|Control Group|Patient will undergo gait analysis
89522822|NCT03393923|Experimental|Experimental group|Patient will undergo gait analysis with use of anterior wedge
89522823|NCT03125681|Experimental|Remote ischemic conditioning|Applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times) before and after coronary anastomoses.
89522824|NCT03125681|Placebo Comparator|Control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
89522825|NCT03126149|Experimental|Cohort 1_Period 1_Active|Single ascending dose of PF-06667272
89522826|NCT03126149|Placebo Comparator|Cohort 1_Period 1_Placebo|Single dose of placebo
89522827|NCT03126149|Experimental|Cohort 1_Period 2_Active|Single ascending dose of PF-06667272
89522828|NCT03126149|Placebo Comparator|Cohort 1_Period 2_Placebo|Single dose of placebo
89522829|NCT03126149|Experimental|Cohort 1_Period 3_Active|Single ascending dose of PF-06667272
89522830|NCT03126149|Placebo Comparator|Cohort 1_Period 3_Placebo|Single dose of placebo
89522831|NCT03126149|Experimental|Cohrot 1_Period 4_Active|Single ascending dose of PF-06667272
89522832|NCT03126149|Placebo Comparator|Cohort 1_Period 4_Placebo|Single dose of placebo
89522833|NCT03126149|Experimental|Cohort 2_Period 1_Active|Single ascending dose of PF-06667272
89522834|NCT03126149|Placebo Comparator|Cohort 2_Period 1_Placebo|Single dose of placebo
89522835|NCT03126149|Experimental|Cohort 2_Period 2_Active|Single ascending dose of PF-06667272
89522836|NCT03126149|Placebo Comparator|Cohort 2_Period 2_Placebo|Single dose of placebo
89522837|NCT03126149|Experimental|Cohort 2_Period 3_Active|Single ascending dose of PF-06667272
89522838|NCT03126149|Placebo Comparator|Cohort 2_Period 3_Placebo|Single dose of placebo
89522839|NCT03126149|Experimental|Cohort 2_Period 4_Active|Single ascending dose of PF-06667272
89522840|NCT03126149|Placebo Comparator|Cohort 2_Period 4_Placebo|Single dose of placebo
89522841|NCT03393767|Other|prospective 1- Arm|OCT-guided high frequency intravitreal ranibizumab 0.5mg
89522842|NCT03393689|Experimental|Angiogenesis PET/MR|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/MR
89522843|NCT03393533|Other|Group I|Extraction third molar with pre and postoperative evaluation of edema, pain and trismus
89522844|NCT03393533|Active Comparator|Group II|Extraction third molar with therapeutic bandage pre and postoperative evaluation of edema, pain and trismus
89522845|NCT03389321|Experimental|Treatment A-B|All subjects will receive treatment A followed by treatment B. Treatment A consists of a single oral dose (1 mg) of riociguat (Adempas) on Day 1. Treatment B consists of a loading oral dose of 30 mg macitentan (Opsumit) (3 tablets of 10 mg) on Day 5, then 10 mg of macitentan once daily from Day 6 to Day 15, with a concomitant administration of riociguat (1 mg) on Day 10.
89522846|NCT03393377|Experimental|intervention group|received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days
89522847|NCT03393377|Placebo Comparator|control group|received placebo for 30 days
89522848|NCT02421263|Experimental|Immediate Participation Group|Participants will begin psilocybin intervention immediately after study enrollment.
89522849|NCT02421263|Active Comparator|Delayed Participation Group|Participants will begin the psilocybin intervention 6 months after study enrollment.
89220502|NCT04008485|Experimental|Symptomatic pregnant women|These women (≥ 16 years of age) will be approached when they attend the labour delivery room or triage with symptoms of preterm labour as detailed above. As a matter of clinical routine these women receive a speculum examination, triple vaginal swabs taken, and fetal fibronectin and cervical length scans as indicated. The study will be explained to them and study materials provided. They will be asked to contact research staff by telephone or through their clinical midwife if they wish to participate. They will be given time to decide. If they agree to take part, written informed consent will then be obtained by research staff who will also conduct the MIS study. If clinical assessments have not already been performed by the time of obtaining consent they will be carried out at the same time
89220503|NCT04006483||Stannous Fluoride Dentifrice|Twice daily brushing
89220504|NCT04006483||Positive control dentifrice|Twice daily brushing
89220505|NCT04006483||Negative control dentifrice|Twice daily brushing
89220506|NCT04003649|Experimental|Arm I (nivolumab, ipilimumab, IL13Ralpha2 CAR T cells)|Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14. Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/intracranital ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
89220507|NCT04003649|Experimental|Arm II (nivolumab, IL13Ra2 CAR T cells)|Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.
89220508|NCT04003649|Experimental|Arm III (IL13Ra2 CAR T cells)|Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week. Treatment repeats weekly for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After cycle 4, patients may receive additional CAR T cells weekly at the discretion of the principal investigator and oncologist.
89220509|NCT04002141|Experimental|Endometriosis Letrozole|Participants will be asked to take 5mg letrozole daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to letrozole. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
89689379|NCT04364009|Active Comparator|Optimized Standard of Care (oSOC)|The control group will receive optimized standard of care alone, including all treatments authorized for COVID-19 by the French Health Ministry and/or the center COVID-19 therapeutic committees at inclusion and during the follow-up.
89689380|NCT04364009|Experimental|Anakinra plus Optimized Standard of Care (oSOC)|The experimental group will receive Anakinra plus optimized Standard of Care. The patients will receive Intravenous injection (IV) of Anakinra 400mg/day (100mg IV every 6 hours) at Day 1, 2 and 3. From Day 4 to Day 10, the patient will receive IV injection of Anakinra 200mg/day (100mg every 12 hours). The total duration of Anakinra is 10 Days
89689381|NCT04344015|Other|Convalescent Plasma Donation|The goal of this study is to identify individuals who have previously been infected with COVID-19 and collect plasma from those who meet inclusion criteria for convalescent plasma donation. This protocol will allow for the collection, manufacturing, and storage of convalescent plasma that may be administered to patients with COVID-19 in the near future. In addition, it allows for testing of SARS-COV-2 antibody titers in the plasma that has been collected to inform studies assessing outcomes for patients currently infected with COVID-19 who have received convalescent plasma infusions.
89689382|NCT03040414|Active Comparator|PID Algorithm|Participants will receive insulin delivered by the Medtronic Minimed 670G 3.0 HCL system using a PID algorithm..
89689383|NCT03040414|Experimental|PID + Fuzzy Logic Algorithm|Participants will receive insulin delivered by the Medtronic advanced hybrid closed loop system (Minimed 670G 4.0 AHCL) with Guardian Sensor (3) continuous glucose monitoring sensor.
89689384|NCT02241629|Experimental|levo phencynonate hydrochloride 1mg|levo phencynonate hydrochloride tablet 1mg
89689385|NCT02241629|Placebo Comparator|placebo|Placebo
89689386|NCT02241629|Experimental|levo phencynonate hydrochloride 2mg|levo phencynonate hydrochloride 2mg
89689387|NCT04372043||Lebanese population|"The Sleep Hygiene Index with other demographic questions will be applied to the Lebanese population."
89689388|NCT02863198|Active Comparator|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
89689389|NCT02863198|No Intervention|non endometrial injury|non endometrial injury was done only for patient of the control group
89689390|NCT02959281|Experimental|Hemodynamic data available|Providing caring physicians with hemodynamic variables measured using the NICAS system.
89689391|NCT02959281|No Intervention|Hemodynamic data not available|Hemodynamic variables measured using the NICAS system will not be provided to the caring physicians.
89689392|NCT04371965|Experimental|Decolonization|1% Povidone iodine mouthwash (95 mL), gargle, and nasal spray (2,5 mL by nostril), and 10% nasal gel (one drop). All four time a day for five days.
89689393|NCT04371965|No Intervention|Control|Absence of local decolonization
89689394|NCT02959125|Experimental|Intervention|"Intervention~NutFish based supplementation for 60 days~Multiple micro nutrient for 60 days~Health education in pregnancy class"
89689395|NCT02959125|Active Comparator|Control|"Control~Government food supplementation for 60 days~Iron Folic acid for 60 days~Health education in pregnancy class"
89689396|NCT04347473|Experimental|Ilumya|Ilumya 100mg subcutaneous at weeks 0, 4 and 16.
89689397|NCT03040804|Experimental|Low Dose Radiotherapy|Patients will receive skin-directed radiotherapy, using a total prescription dose of 7.5 gy in five fractions of 1.5 gy over one week
89220510|NCT04002141|Placebo Comparator|Endometriosis Placebo|Participants will be asked to take one tablet placebo daily throughout their ovarian stimulation and for 2 weeks following retrieval. Participants will be blinded to their randomization to placebo. Participants will be asked to complete surveys during their stimulation and up to 12 weeks following retrieval to evaluate endometriosis associated symptoms. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
89220511|NCT04002141|No Intervention|No Endometriosis Control|Participants will be asked to complete surveys during their ovarian stimulation and up to 12 weeks following retrieval to evaluate symptoms of pelvic pain. Specifically, surveys will be administered at baseline ultrasound appointment for controlled ovarian hyperstimulation cycle, the day of trigger shot, 3 weeks following egg retrieval, 6 weeks following egg retrieval and 12 weeks following egg retrieval. There will be a total of 20 participants in this arm.
89220512|NCT03999710|Experimental|Non-Small Cell Lung Cancer|All participants have locally-advanced non-small cell lung cancer, Stage II-III. Treatment will consist of durvalumab administered concurrently with thoracic radiation consisting of 60 Gy in 30 fractions. Patients will be monitored weekly during on-treatment visits. Durvalumab will then be continued up to 1 year as maintenance or until disease progression or unacceptable toxicity. Optional Research MRIs (Does not apply to the Alliance Sites. Research MRIs will only be done at MSKCC)
89220513|NCT03991416|Experimental|Understanding Your Baby|Understanding Your Baby plus postnatal care as usual
89220514|NCT03991416|Active Comparator|Care As Usual|Postnatal care as usual
89220515|NCT03975660|Experimental|Part 1 Device Calibration|50 patients requesting epidural labor analgesia will have pain levels monitored during labor.
89220516|NCT03975660|Experimental|Part 2 Device Validation|60 patients requesting epidural labor analgesia will have pain levels monitored during labor.
89220517|NCT03970096|Experimental|Arm A1 (TBI, TnD)|Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 3 hours on days -6 and -5, fludarabine IV over 30 to 60 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
89220518|NCT03970096|Experimental|Arm A2 (busulfan, TnD)|Patients receive fludarabine IV over 30 to 60 minutes on days -6 to -2, busulfan IV over 180 minutes on days -5 to -2, and undergo TBI BID on day -1. Patients also receive tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
89220519|NCT03970096|Experimental|Arm C1 (TBI, PTCy, tacrolimus)|Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
89220520|NCT03970096|Experimental|Arm C2 (busulfan, PTCy, tacrolimus)|Patients receive fludarabine IV over 30 to 60 minutes on days -5 to -2, busulfan IV over 180 minutes on days -5 to -2, PBSC IV on day 0, cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
89689398|NCT00963157|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
89060967|NCT04370509|Experimental|Cohort A (Pembrolizumab monotherapy)|"Preoperative treatment consists of 200mg pembrolizumab IV on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles (9 weeks).~Within 14-21 days following the end of treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.~Within 21-42 days after surgery, patients with R0 resection or R1 resection receive 400 mg pembrolizumab every 42 days for up to 9 cycles (1 year) and patients with R2 resection receive pembrolizumab every 42 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
89060968|NCT04370509|Experimental|Cohort B (Pembrolizumab + VEGF-TKI)|"Preoperative treatment consists of 200 mg pembrolizumab IV on day 1 of each cycle, and 5mg axitinib (a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)) PO BID on days 1-42 of each cycle. Axitinib maybe titered in select patients after cycle 1. Treatment repeats every 21 days for up to 3 cycles (9 weeks).~Within 14-21 days following the end of pre-operative treatment, patients undergo standard of care CN or MET. Patients with PD may undergo CN or MET per physician discretion.~Within 21-42 days after surgery, patients with an R0 or R1 resection receive 400 mg pembrolizumab and 1, 3, 5, 7 or 10 mg axitinib PO BID every 42 days for up to 9 cycles (1 year), and patients with an R2 resection receive pembrolizumab IV and axitinib PO BID every 42 days for up to 18 cycles (2 years) in the absence of disease progression or unacceptable toxicity."
89060969|NCT04343417||Biorepository|Participants who contributed biospecimen samples (kidney tissue, blood, urine, DNA).
89060970|NCT04331444|Experimental|Group A, CGM|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group A (intervention) will, in similarity to the HCPs, receive a CGM-education and training session led by the study investigator and will be interactive and hands-on, using case studies. The training session will include spoken and written instructions on how to insert and wear the CGM device and how to interpret the CGM information to better understand the relation between participants blood glucose and their diabetes self-management."
89060971|NCT04331444|Experimental|Group B, CGM + peer-support|"Addition of a calibration free real-time CGM in 12 months in persons with type 2 diabetes treated with insulin plus 3 sessions of peer-support in groups of 6 participants.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly. Furthermore, participants in group B (intervention incl. peer-support) will, in similarity to group A, receive a CGM-education and training session. The training and CGM-course for participants in group B are similar to the course for group A with the addition of three peer-support sessions. The approach will be participatory and adaptable to allow flexibility in the content of the peer-support sessions and involving customized use of participatory methods i.e. dialogue tools and exercises."
89060972|NCT04331444|Active Comparator|Group C, SMBG|"Standard self-monitoring of blood glucose according to standard guidelines, in 12 months.~The participants will participate in a training course that will include the influence of different food items and exercise on glucose levels, how to measure SMBG correctly."
89060973|NCT04312659||Infliximab|Participants with pediatric Crohn's disease (CD) who were treated with Infliximab (IFX) and signed the Informed Consent Form (ICF) for the study will be enrolled case by case. Each participants will be followed up for at least 30 weeks. After 30 weeks, participants continuing IFX treatment will be followed up, with a maximum follow-up period of 102 weeks. The primary data source will be participants medical records for all data entered into the CRF.
89060974|NCT04308512|Experimental|Intervention Group (IG): Care coordination with Care4AD system|All participants will receive Care4AD device.All reminders will be activated in the intervention group (IG). Essential activity daily living (ADL) tasks will be pre-programmed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
89060975|NCT04308512|No Intervention|Control Group (CG): Standard of care|Participants in control group (CG) will also receive Care4AD device. However, all reminders and programming of activity daily living (ADL) tasks will be de-activated in the CG.
89060976|NCT04300894|No Intervention|Usual care group|Usual prenatal and postpartum care involves regular visits with one's health care provider while pregnant and after the baby is born.
89060977|NCT04300894|Experimental|Mamma Mia group|"Usual prenatal/postpartum care plus use of the Mamma Mia program"
89220521|NCT03970096|Experimental|Arm D1 (TBI, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]|Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
89220522|NCT03970096|Experimental|Arm D2 (busulfan, tacrolimus, methotrexate) [DISCONTINUED NOVEMBER 2021]|Patients receive busulfan IV over 180 minutes on days -8 to -5, cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
89220523|NCT03964454|Experimental|SC + BFI|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives contingent on observed breastfeeding.
89220524|NCT03964454|Active Comparator|SC|Participants randomized into Standard Care (SC) will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
89220525|NCT03957161|Experimental|ACEi/ARB continuation|Intervention group will continue or start to take ACEi and/or ARBs
89220526|NCT03957161|No Intervention|ACEi/ARB withdrawal|The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs
89220527|NCT03944954|Experimental|Excitatory TMS|Combinations of THC and excitatory TMS.
88821191|NCT04941157|Experimental|Prophylactic cerebrospinal fluid drain placement|Patients randomized to receive the experimental treatment will have a prophylactic cerebrospinal fluid drain placed prior to their endovascular aortic repair. All components of the endovascular aortic repair are standard of care treatments.
89060978|NCT04300894|Experimental|Mamma Mia Plus group|"Usual prenatal/postpartum care plus use of the Mamma Mia program plus occasional contacts from study staff"
89060979|NCT04287647|Active Comparator|Transpyloric stent|In this group, patient's will be randomized to receive a transpyloric stent for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
89060980|NCT04287647|Sham Comparator|Sham|In this group, patient's will be randomized to sham for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.
89060981|NCT04276701|Experimental|Systemic lupus erythematosus (SLE)|
89060982|NCT04274465||Control|Negative high risk (HR)-HPV, cytology co-test
89060983|NCT04274465||CIN 1|Biopsy with low grade dysplasia
89060984|NCT04274465||CIN 2-3|Biopsy with high grade dysplasia
89060985|NCT04258462|Experimental|Diagnostic (HP 13C pyruvate with MRI)|Participants receive HP 13C pyruvate IV and then undergo 13C MRI scan 1-2 minutes post HP 13C pyruvate injection. Participants may receive an optional second HP 13C pyruvate injection and undergo 13C pyruvate MRI scan 15 to 30 minutes following completion of the first scan or at a return visit 1-2 weeks from the first HP C13 MRI
89060986|NCT04258462|Experimental|Diagnostic (Combined (co-polarized) HP 13C pyruvate and 13C, 15N2 Urea with MRI)|Participants receive HP 13C pyruvate and 13C 15N2 urea IV and then undergo an MRI scan 1-2 minutes post injection. Participants may receive an optional second HP 13C pyruvate with 13C 15N2 urea injection and undergo a second MRI scan 15 to 30 minutes following completion of the first scan or at a return visit 1-2 weeks from the first HP C13 MRI
89060987|NCT04253977|Experimental|HEALTH-P2|Along with PAT National Center, parent educators affiliated with PAT sites in HEALTH-P2; with be trained to use the HEALTH-P2 training curriculum (implementation strategy).
89060988|NCT04253977|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual.
89060989|NCT04247100|Experimental|Active Stimulation (8)|"Participants will receive active auricular microstimulation via TENS unit for 8 weeks.~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks."
89060990|NCT04247100|Sham Comparator|Sham Stimulation (4), Active (4)|"Participants will receive sham therapy via inactive TENS unit for 4 weeks, followed by active auricular microstimulation via TENS for 4 weeks.~Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks (4 weeks of therapy with inactive TENS, 4 weeks with active TENS)."
89060991|NCT04245397|Experimental|Dose Escalation of SX-682|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
89060992|NCT04245397|Experimental|Expansion of SX-682 alone (lower risk patients, naive to hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in lower risk patients who have never received hypomethylating agents.
89060993|NCT04245397|Experimental|Expansion of SX-682 alone (lower risk patients, failed on hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in lower risk patients who failed on hypomethylating agents.
89060994|NCT04245397|Experimental|Expansion of SX-682 with decitabine (lower risk patients, naive to hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) with decitabine in lower risk patients who have never received hypomethylating agents.
89060995|NCT04245397|Experimental|Expansion of SX-682 with decitabine (lower risk patients, failed on hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) with decitabine in lower risk patients who failed on hypomethylating agents.
89060996|NCT04245397|Experimental|Expansion of SX-682 alone (higher risk patients, failed on hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in higher risk patients who failed on hypomethylating agents.
89220528|NCT03944954|Experimental|Inhibitory TMS|Combinations of THC and inhibitory TMS.
89220529|NCT03940313||Subjects|Participants >18 years old who meet inclusion and exclusion criteria, and have findings on physical exam and ultrasound that suggest potential benefit from prolotherapy.
89220530|NCT03940313||Controls|Participants >or =18 years old who do not complain of lower back pain, but consent to have physical examination testing and musculoskeletal ultrasound of the lower back to evaluate these areas.
89220531|NCT03932656||Females with borderline personality disorder|
89689399|NCT00963157|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
89689400|NCT00963157|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
89689401|NCT00963157|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
89689402|NCT00963157|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
89689403|NCT02972554|Experimental|Propanolol Hydrochloride|This is the experimental group given the beta-blocker
89689404|NCT02972554|Placebo Comparator|Placebo|This is the control group given a placebo.
89689405|NCT04371731|Experimental|Active Arm|Active cohort will use the Care4today platform to help manage their heart failure
89689406|NCT04371731|No Intervention|Control arm|Control arm will contain standard of care heart failure treatment
89689407|NCT05643807|Active Comparator|urinary catheter|Urinary cytology will be collected using a Ch.14 bladder catheter after the removal of the cystoscope. Catheter will be placed at the bladder neck level.
89689408|NCT05643807|Active Comparator|flexible cystoscope|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
89689409|NCT00921947|Experimental|VAX102 IM|VAX102 given as 1 µg intramuscular (i.m.)
89689410|NCT00921947|Experimental|VAX102 SC|VAX102 given as a 2 µg subcutaneous (s.c.) dose
89689411|NCT02241941|Experimental|Daptomycin|
89689412|NCT03041896||Decompression|Standard of care decompression for spinal stenosis, 1 or 2 levels.
89689413|NCT03041896||Fusion|Standard pedical and rod fixation with standard decompression, 1 or 2 levels.
89689414|NCT03041896||coflex®|Decompression surgery with the coflex® Interlaminar Technology, 1 or 2 levels.
89689415|NCT03041896||Hybrid|coflex and fusion at adjacent levels
89689416|NCT03834051|Experimental|Open Label|Fecal Microbiota Transplantation
89689417|NCT04363541|Experimental|Thermotherapy|"Electric heat pad applied in the thorax for 90 minutes, twice daily, for 5 days.~+ Usual in-hospital care"
89689418|NCT04363541|No Intervention|Control|Usual in-hospital care
89689419|NCT03043534|Experimental|Gel and Brush|The Experimental group of subjects will be given the study product Pre-Shave Gel and Brush. The gel and brush will be used prior to their normal shave routine. Subjects will shave at least 3 times weekly.
89689420|NCT03043534|No Intervention|Control|Subjects will use their normal razors and shave products during the six week study. Subjects must shave at least 3 times weekly. No change in normal shaving is done in this group
89689421|NCT04363775|Experimental|Regurgitation|intubation in regurgitation condition
89689422|NCT04363775|Experimental|Tongue edema|intubation in Tongue edema condition
89689423|NCT00359151|Experimental|Celecoxib|Celecoxib
89689424|NCT00359151|Placebo Comparator|Placebo|Placebo
89689425|NCT00359229|Experimental|1|For 3 weeks
89689426|NCT02979262|Experimental|Fathers for Change|Fathers for Change treatment begins with individual-focused sessions followed by co-parenting focused sessions and ending with restorative parenting sessions. The areas of focus for each of the three phases of Fathers for Change are: 1) abstinence from SA and violence; 2) co-parenting; 3) parenting/father-child relationship. Treatment begins with motivational enhancement by focusing the role of men as fathers to their young children, child development and the impact of violence and SA on parenting, and the father's own childhood experiences of SA and violence to highlight the multigenerational nature of these problems. The program then focuses on skills training in the following areas: reducing automatic hostile cognitions and increasing emotion regulation skills, 2) communication and problem solving around co-parenting, and 3) restorative parenting.
89689427|NCT02979262|Active Comparator|Parent Education (PE)|PE is an individual intervention.PE was developed to represent parent education and support that is typically available to parents with substance use problems who are at high risk for neglecting their children. Fathers enrolled in PE will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed for work with substance abusing parents. Sample pamphlet topics include routines and rituals, ages and milestones, alternatives to spanking, and nutrition and fitness.
89689428|NCT04363931|Experimental|Manual Therapy|Manual Therapy is a widely used physiotherapy modality which is known to be effective in the management of musculoskeletal problems . Manual Therapy is a passive, therapeutic approach used to target a variety of anatomical structures with the intent to create beneficial changes in the amount of pain a patient experiences. Manual Therapy includes joint mobilization, manipulation, or treatment of the soft tissues and is widely used to break fibrous adhesions, restore normal range of motion, reduce local ischemia, stimulate synovial fluid production, and reduce pain .
89689429|NCT04363931|Experimental|Kinesio Taping|Kinesio tape is a type of elastic therapeutic tape that was developed which is used in many different situations with various aims. Advocates of Kinesio Tape state that it may promote different therapeutic objectives such as; improved circulation and lymphatic drainage, pain inhibition, reduction of delayed onset of muscle soreness or improvement in performance and coordination .
89689430|NCT02980978|Experimental|Intervention|Individuals assigned to the intervention group will have supplemental care provided by a registered dietitian/certified diabetes educator which includes counseling on lifestyle to improve diabetes and overall health. Additionally, individuals in this group may be started on medications (or adjustments to current medications) for blood pressure, cholesterol or blood glucose to meet diabetes care goals
89689431|NCT02980978|No Intervention|Standard of Care|Individuals will be followed by their Primary Care Provider as standard of care and per usual clinical need
89689432|NCT05639517|Experimental|Group 1|Patients in this group will receive spinal stabilization training through augmented reality based telerehabilitation application.
89689433|NCT05639517|Active Comparator|Group 2|Patients in this group will receive spinal stabilization training face-to-face.
89689434|NCT04371341|Experimental|E1|will receive erector spinae block with 0.25% bupivacaine volume of 2.5 ml/segment
89689435|NCT04371341|Experimental|E2|will receive erector spinae block 0.25% bupivacaine with volume of 3.4ml/segment
89689436|NCT04371341|Experimental|E3|will erector spinae block receive 0.25% bupivacaine with volume of 6.6 ml/segment
89689437|NCT04371341|No Intervention|C|will not receive erector spinae block
89689438|NCT05297643|Experimental|Experimental Group|"A Complex decongestive treatment program consisting of manual lymphatic drainage, compression therapy, skin care and remedal exercise will be applied to the patients in this group. Exercise progame includes breathing exercises, joint range of motion exercise, pumping, stretching exercises and aerobic exercises( same with control grup).~In addition, ESWT will be applied as 2 sessions in the first two weeks and 1 session in the 3rd week. In ESWT, 2500 shocks will be applied per session with a frequency of 4 Hz at 2 bar pressure while the patient is in the supine position.~The distribution of this treatment is planned to be 750 shocks to the axillary lymph nodes and 250 shocks to the cubital lymph nodes.~The remaining 1500 shocks will be applied to the arm, forearm, and hand. While determining the dose and duration of ESWT to be applied in the study, it was arranged to be similar to the studies and reviews in the literature."
89689439|NCT05297643|Other|control group|A Complex decongestive treatment program consisting of manual lymphatic drainage, compression therapy, skin care and remedal exercise will be applied to the patients in this group. Exercise progame includes breathing exercises, joint range of motion exercise, pumping, stretching exercises and aerobic exercises
89689440|NCT04371185|Experimental|BAT2206 injection|45mg; subcutaneous injection
89689441|NCT04371185|Active Comparator|Stelara(US-licensed)|45mg; subcutaneous injection
89689442|NCT04371185|Active Comparator|Stelara(EU-licensed)|45mg; subcutaneous injection
89689443|NCT03834077|Experimental|Tissue flossing|Conventional physiotherapy consisted in electrotherapy and stretching in addition to tissue flossing.
89689444|NCT03834077|Placebo Comparator|Placebo comparator|Conventional physiotherapy consisted in electrotherapy and stretching in addition with tissue flossing without tension.
89689445|NCT03834155|Experimental|Hospital-based CR + Mobile Application|Traditional hospital-based cardiac rehabilitation with mobile application.
89689446|NCT03834155|Experimental|Choice CR + Mobile Application|Choice of hospital or home-based cardiac rehabilitation with mobile application.
89689447|NCT03834155|Experimental|Hospital-based CR + Mobile Application + Nudge|Hospital-based cardiac rehabilitation with mobile application and nudges.
89689448|NCT03834155|Experimental|Choice CR + Mobile Application + Nudges|Choice of Hospital or home-based cardiac rehabilitation with mobile application and nudges.
89689449|NCT01005355|Experimental|IMC-1121B|Participants receiving IMC-1121B intravenously
89689450|NCT02242175|Other|normal group|
89689451|NCT02242175|Other|irritable bowel syndrome group|
89689452|NCT05498649||Bilateral use of DT1fA contact lenses|DT1fA contact lenses
89689453|NCT04363151||Hydatid cyst patients|patients who underwent surgery for liver hydatid cyst from 2004 to 2018 in two major university-affiliated hospitals in Fars Province, southern Iran
89689454|NCT03030313|Experimental|Respiration rate monitoring|Reassure Non-Contact Respiration Monitor
89689455|NCT02981368|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
89689456|NCT02242253|Experimental|Tiotropium+salmeterol QD|free combination of tiotropium and salmeterol
89689457|NCT02242253|Active Comparator|Tiotropium+salmeterol BID|free combination of tiotropium and salmeterol
89689458|NCT02242253|Active Comparator|Tiotropium QD|
89689459|NCT02242253|Active Comparator|Salmeterol BID|
89689460|NCT05285943|Active Comparator|Betamethasone cream|Patients will apply Betamethasone Valerate 0.1% cream to the irradiated area twice a day.
89689461|NCT05285943|Active Comparator|Olive oil cream|Patients will apply prepared Olive Oil cream to the irradiated area twice a day.
89689462|NCT05285943|Placebo Comparator|Base cream|Patients will apply prepared base cream to the irradiated area twice a day.
89689463|NCT03030001|Experimental|PD-1 antibody expressing CAR-T cells|PD-1 antibody expressing mesothelin specific CAR-T cells
89689464|NCT02242331||essential hypertension patients|
89689465|NCT00963859|Experimental|Robotic-assisted laparoscopic surgery|Robotic-assisted laparoscopic extended pelvic lymph node dissection
89689466|NCT04370951|Active Comparator|Erector Spinae Plane Block|Patients will receive a ESP block with 20mls 0.25% Levobupivicaine bilaterally, pre incision plus standardised multimodal analgesia
89689467|NCT04370951|No Intervention|Control|no ESP block, standardised multimodal analgesia
89689468|NCT03030157|Experimental|Long-term Intravesical Instillation of pirarubicin(THP)|A single instillation of pirarubicin (THP) plus one year long-term intravesical instillation after nephroureterectomy was performed. The ﬁrst instillation was initiated within 72-168 hours after surgery, followed by four times weekly and 11 times monthly (16 times in total in one year time) . Every time, THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
89689469|NCT03030157|Active Comparator|Single Intravesical Instillation of pirarubicin|A single intravesical instillation of THP after nephroureterectomy was performed. This instillation was initiated within 72-168 hours after surgery . THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
89689470|NCT00359385|Active Comparator|Alendronate 70mg weekly|Alendronate 70mg weekly
89689471|NCT00359385|Placebo Comparator|placebo of alendronate 70mg weekly|placebo of Alendronate 70mg weekly
89689472|NCT04362683||High Power Atrial Fibrillation Ablation|"In our center, routine medical care for atrial fibrillation ablation includes:~Multidirectional high-density mapping~High power - short duration settings~Contact force sensing ablation catheter"
89220532|NCT03930199|Experimental|Not Meeting Mobility Goals|After the first three months of sensor monitoring, participants not meeting goals will receive an intervention (others will be removed from the study). The intervention assigned is not pre-determined, but will be assigned by an expert panel based on the individual needs determined from the assessment results and monitoring data. The intervention may include prosthetic care, physical therapy, motivational interviewing or other related psychological interventions, or a combination thereof. After three months of intervention, assessments are performed again and if improvement in prosthesis use is determined, participants are monitored for another three months to assess maintenance of prosthesis use (participants showing no improvement are removed from the study before these final three months of monitoring).
89220533|NCT03924219||Pediatric Solid Organ Transplant (SOT) Recipients|Pediatric patients (<18 years of age) undergoing or anticipated to undergo solid organ transplantation (heart, kidney, or liver) will be prospectively enrolled with serial blood collection for CMV T cell Immunity Assay performance.
89220534|NCT03916874||Pregnant females and her newborn.|A longitudinal study of one cohort of 250 pregnant females less than 22 weeks gestation and her newborn. Swabs and samples (low vaginal, skin, urine, blood and stool) will be requested at one time point during each trimester from the participant. In addition, there are three different questionnaires at trimester 2.
89220535|NCT03899805|Experimental|Liposarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
89220536|NCT03899805|Experimental|Leiomyosarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
89220537|NCT03899805|Experimental|Undifferentiated Pleomorphic sarcomas|"Participants will receive eribulin intravenously on Day 1 and Day 8~Pembrolizumab is administered intravenously Day 1, on a 21-day cycle"
89060997|NCT04245397|Experimental|Expansion of SX-682 with decitabine (higher risk patients, naive to hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) with decitabine in higher risk patients who have never received hypomethylating agents.
89060998|NCT04245397|Experimental|Expansion of SX-682 with decitabine (higher risk patients, failed on hypomethylating agents)|Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) with decitabine in higher risk patients who failed on hypomethylating agents.
89060999|NCT04166851|Experimental|Open contest messages|Participants will view the top PrEP-promotion messages developed via an open contest.
89061000|NCT04166851|Active Comparator|Social marketing messages|Participants will view the PrEP-promotion messages developed via social marketing.
89061001|NCT04153890|Experimental|FamPALcare|Standard Care plus FamPALcare
89061002|NCT04153890|No Intervention|Standard Care|The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines.
89061003|NCT04151342||Prospective|Living cancer patients with histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.
89061004|NCT04151342||Retrospective|Deceased cancer patients who had histologically confirmed rare molecular alterations in their tumours, such as in ALK, EGFR, ROS1, BRAF, and KRAS G12C from participating sites/cancer centres across Canada.
89061005|NCT04151342||Comparator group|All cancer patients without rare molecular alterations in their tumours. This group will be established in order to determine baseline characteristics and outcomes, including treatment outcomes, of more standard treatments such as systemic chemotherapy or immunotherapy.
89061006|NCT04136652|Placebo Comparator|Sham|The women are randomized, by a computer program, to a sham laser-treatment with the laser not active.
89061007|NCT04136652|Active Comparator|Laser|The women are randomized, by a computer program, to a vaginal CO2 laser-treatment with 30 w.
89061008|NCT04136626|Experimental|Perspectives OCD|12 week Smartphone-delivered CBT for OCD.
89061009|NCT04136626|Active Comparator|The Health and Well-Being Program|12 week health and well-being education
89061010|NCT04116112|Experimental|Higher Systolic Blood Pressure (SBP) Target|Lower systolic blood pressure to ≤180 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain ≥160 mmHg.
89061011|NCT04116112|Experimental|Lower SBP (<160 mmHg) Target|Lower systolic blood pressure to <160 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain >140 mmHg.
89061012|NCT04116112|Experimental|Lower SBP (<140mmHg) Target|Lower systolic blood pressure to <140 mmHg and maintain for 24 hours. If anti-hypertensive medication used, then maintain >110 mmHg.
89061013|NCT04077684|Placebo Comparator|Placebo|placebo s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
89061014|NCT04077684|Active Comparator|IL-2 at 0.2MIU|0.2 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
89061015|NCT04077684|Active Comparator|IL-2 at 0.5MIU|0.5 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
89689473|NCT04371029|Experimental|Experimental|A Polysomnography (PSG) will be performed in all patient the night before extubation, the day prior discharge and 3 month after. Recording will consist in EEG, EOG et EMG of the chin. We will record NIM EMG. We will also performed an actimetry during hospitalization in the post ICU ward. A quality of sleep questionnaire (Pittsburgh questionnaire) will be completed by the patients during the visit at 3 month.
89689474|NCT00966433|Experimental|Spontaneous ventilation|Pt's will be allowed to breathe spontaneously through the PLMA during surgery without the assistance of positive pressure ventilation.
89689475|NCT00966433|Experimental|Pressure support ventilation|Pt's will receive positive pressure assistance with each spontaneous breath through the PLMA.
89689476|NCT00966433|Active Comparator|Pressure control ventilation|Pt.'s will be placed on the ventilator and ventilated with pressure control. through the PLMA.
89689477|NCT05279547|Active Comparator|Arm 1 (First constant-load then interval bed-cycling protocol)|"During Day 1, patients will be familiarized with the constant-load and interval bed-cycling exercise against no resistance. Patients will be also randomized in the two arms of the study before the determination of the appropriate exercise intensities to be subsequently use during the constant-load and interval bed-cycling protocols on Day 2 and Day 3. Exercise intensities will be determined so that the volume of training during the two protocols will be equal.~During Day 2, patients randomized to arm 1 will perform the constant-load bed-cycling protocol. During Day 3, patients who executed the constant-load bed-cycling protocol on Day 1 (arm 1) will perform the interval bed-cycling protocol."
89689478|NCT05279547|Active Comparator|Arm 2 (First interval then constant-load bed-cycling protocol)|"During Day 1, patients will be familiarized with the constant-load and interval bed-cycling exercise against no resistance. Patients will be also randomized in the two arms of the study before the determination of the appropriate exercise intensities to be subsequently use during the constant-load and interval bed-cycling protocols on Day 2 and Day 3. Exercise intensities will be determined so that the volume of training during the two protocols will be equal.~During Day 2, patients randomized to arm 2 will perform the interval bed-cycling protocol. On Day 3 they will perform the constant-load bed-cycling protocol."
89689479|NCT05628129|Experimental|reminder intervention|On the basis of standard appointment, parents in intervention group will receive phone reminders at 4 days and 1 day before their scheduled appointments, and relevant scientific and educational knowledge will be relayed to them from the smartphone application at 1 week before appointments.
89689480|NCT05628129|No Intervention|standard appointment|Patients will be required to attend follow-up appointments at 1 week, 1 month, 3 months after surgery.
89689481|NCT03029455|Experimental|Part A: VX-659 or Matching Placebo|Part A includes single-dose escalation.
89689482|NCT03029455|Experimental|Part B: VX-659 or Matching Placebo|Part B includes multiple-dose escalation.
89689483|NCT03029455|Experimental|Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).
89689484|NCT03029455|Experimental|Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part D includes subjects with CF. Participants will receive TC or matching placebos.
89061016|NCT04077684|Active Comparator|IL-2 at 1.0MIU|1.0 MIU doses of IL-2 s.c. injection every other day for the first 12 weeks and then once a week for the second 12 weeks
89061017|NCT04063787|Experimental|Fist Assist device (all subjects)|"All study subjects will have Stage 4 or 5 Chronic Kidney Disease (CKD) that requires them to start hemodialysis. In preparation for hemodialysis, they will have an arteriovenous fistula (AVF) procedure which provides access to the veins for dialysis.~This study is testing a device called the Fist Assist to dilate the vein in preparation for dialysis. The device is similar to a blood pressure cuff (worn around the arm and applies pressure). All study participants will wear the Fist Assist twice a day up to three months before their AVF procedure."
89220538|NCT03897491|Experimental|Interstitial photodynamic therapy|20 mg 5-aminolevulinic acid per kg body weight orally four hours (range 3,5-4,5 hours) before the induction of general anaesthesia.
89220539|NCT03897127|Active Comparator|Standard arm|
89220540|NCT03897127|Experimental|Investigational arm|
89220541|NCT03896425|Experimental|right active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA right (AF4 anode - AF3 cathode) for 20 min, and then ramp-down for 30 seconds.
89220542|NCT03896425|Experimental|left active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA left (AF3 anode - AF4 cathode) for 20 min, and then ramp-down for 30 seconds.
89220543|NCT03896425|Sham Comparator|sham tDCS|Current will be turned off immediately after the initial 30-second ramp-up period.
89220544|NCT03895203|Experimental|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
89061018|NCT04051346|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the high oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
89061019|NCT04051346|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring at baseline and post diet. A ten day wash out period will follow, during which the subject will consume a self-selected diet. Subjects will then consume the low oxalate diet for the final four days, with blood and 24-hour urine collections once again occurring at baseline and post diet.
89061020|NCT04040400|Experimental|Treatment Arm|intraoperative radiotherapy (IORT) arm
89220545|NCT03895203|Active Comparator|Adalimumab dosage regimen|Subjects randomized to this arm will receive the assigned adalimumab dosage regimen during the Treatment Period.
89220546|NCT03895203|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be reallocated to receive bimekizumab dosage regimen during the Maintenance Period.
89220547|NCT03892915|Experimental|Depression Care|Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.
89220548|NCT03892915|No Intervention|Usual care|Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).
89220549|NCT03892200|Experimental|Daily Mouth Care|The intervention being tested is a standardized educational and skill-building program for use in assisted living communities, which highlights that mouth care is infection control (e.g., can reduce pneumonia); includes techniques and products to clean and protect the teeth, tongue, gums, and dentures (e.g., the jiggle-sweep approach to remove plaque, use of an interdental brush instead of floss); provides strategies for care provision in special situations (e.g., broken teeth); and includes a toolkit of dementia-sensitive approaches for people who are resistant (e.g., refuse to open the mouth). It also includes information about potential dental emergencies and issues that merit assessment.
89220550|NCT03892200|No Intervention|Standard Mouth Care|Assisted living communities will continue to provide standard mouth care to all residents. Assisted living staff will not receive training or supplies in the control condition.
89061021|NCT04027972|Experimental|Primary|6 Subjects will receive all 4 types of medication administration in random sequence
89061022|NCT04026009|Experimental|CDIFF Ag 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
89061023|NCT04026009|Placebo Comparator|Placebo 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
89061024|NCT04026009|Experimental|CDIFF Ag 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
89061025|NCT04026009|Experimental|CDIFF Ag + AS01B 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF Ag + AS01B adjuvant vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag + AS01B adjuvant vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
89061026|NCT04026009|Placebo Comparator|Placebo 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
89061027|NCT04013854|Active Comparator|Arm A: Adjuvant Nivolumab (Complete Pathological Response)|480 mg IV for up to one year
89061028|NCT04013854|Active Comparator|Arm B: Adjuvant Nivolumab (Less than Complete Response)|480 mg IV for up to one year
89220551|NCT03888404||Underlying Cohort|"The study will recruit and follow a prospective cohort of women at risk of pregnancy for one year."
89220552|NCT03888404||Pregnancy Match Cohort, Pregnant Group|Women from the Underlying Cohort who become pregnant will be transferred into the Pregnancy Match Cohort to be followed for two years.
89220553|NCT03888404||Pregnancy Match Cohort, Not Pregnant Group|The study will also follow a comparison cohort of non-pregnant women from the Underlying Cohort, frequency matched to the pregnant participants on Desire to Avoid Pregnancy score and time at risk of pregnancy.
89220554|NCT03878628|Experimental|Adipose tissue-derived mesenchymal stem cells|Approximately 11 million ASCs in a 0.5 ml suspension
89220555|NCT03871309||Tigertriever|Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.
89220556|NCT03868514||TiLOOP Bra Pocket|Medical Device
89220557|NCT03860142||full-term child born|use of a new scale to rate the severity of food disorders on full-term child born
89220558|NCT03860142||premature child born|use of a new scale to rate the severity of food disorders on premature child born
89689485|NCT02983552|Experimental|Binocular Computer Game Treatment|Binocular computer game treatment is defined as playing a Dig Rush application on an iPad® 1 hour per day, 5 days per week for 8 weeks in addition to continued spectacle correction (if required)
89689486|NCT02983552|Active Comparator|Continued Spectacle Correction|Continued spectacle correction is defined as wearing appropriate spectacle correction (if required) for all waking hours, 7 days per week for 8 weeks.
89689487|NCT04370405|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
89689488|NCT04370561|Active Comparator|1/3 tubular plate|"Standard care according to AO guidelines using the Implant 1/3 tubular plate"
89689489|NCT04370561|Active Comparator|Active ankle plate|"Actual care using the new implant using the Implant Active ankle plate"
89689490|NCT02245789|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope. All patients will received propofol and remifentanil anesthesia.
89689491|NCT02245789|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope. All patients will received propofol and remifentanil anesthesia.
89689492|NCT04370639|Experimental|AccuFlow Sensor|These 50 patients will wear the AccuFlow sensor device during their surgery, and will complete the post-procedural survey. The data will be reviewed after 25 patients, and the pilot study may be stopped at that point if it is felt that the device feasibility and tolerability have been adequately established.
89689493|NCT03029065||lung adenocarcinoma with brain (meningeal) metastasis|
89689494|NCT05484141|Experimental|With Blood Flow Restriction|
89689495|NCT05484141|Active Comparator|Without Blood Flow Restriction|
89689496|NCT04370171||Group TC: Diabetic patients followed by Teleconsultation|Teleconsultation group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist has been replaced by a teleconsultation due to the availability of diabetologists whose activity is focused on the management of Covid-19 negative patients.
89689497|NCT04370171||Group P: Diabetic patients with conventional follow-up|Conventional group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist was differed by 6 months due to the activity of some diabetologists entirely redirected towards the management of Covid-19 positive patients and not available
89689498|NCT04370015|Experimental|Treatment group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
89689499|NCT04370015|Placebo Comparator|Control group|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
89689500|NCT05482581||Questionnaires assessed adolescents and young adults|①14-35 years old; ②Being able to read and communicate in Chinese.
89689501|NCT04369781||Suspected critical limb ischemia|Patients referred for transcutaneous oxygen pressure measurements due to a clinical suspicion of critical limb ischemia
89689502|NCT01006369|Experimental|FOLFOX6 + Bevacizumab + Hydroxychloroquine|"Arm A: FOLFOX6 + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 5 mg/kg in 100 cc Normal Saline every 14 days on day one.~Drug: hydroxychloroquine hydroxychloroquine 200 mg po BID daily"
89689503|NCT01006369|Experimental|XELOX + Bevacizumab + Hydroxychloroquine|"Arm B: XELOX + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 7.5 mg/kg in 100 cc Normal Saline every 21 days.~Drug: hydroxychloroquine hydroxychloroquine 200 mg po BID daily"
89689504|NCT03046966|Other|Intervention Control: No Training|Does not receive hands-on intubation training in the Simulation Lab.
89689505|NCT03046966|Other|Intervention: Receives Training|Receives hands-on intubation training in the Simulation Lab.
89689506|NCT05260515|Experimental|Staying Sharp intervention|Staying Sharp is an online intervention to promote healthy behaviors through six health pillars (Be social, Engage your brain, Manage stress, Ongoing exercise, Restorative sleep, and Eat right).
89689507|NCT02242721||Intensive care unit patients needing renal replacement therapy|Male and female patients in the intensive care unit (ICU), needing renal replacement therapy due to renal dysfunction and are treated with antiinfective drugs.
89689508|NCT05476419|Experimental|Direct intra-oral scanning technique for the post space.|intervention will be the direct scanning of the prepared post space inside the patient mouth by using an intraoral scanner.
89689509|NCT05476419|Active Comparator|In-direct scanning of the conventional post space silicone impression.|The comparator will be extraoral scanning of the conventional sillicon impression of the prepared post space by using an extraoral scanner.
89689510|NCT02242877||Isolated systolic hypertension|
89689511|NCT02242877||Systolic and diastolic hypertension|
89689512|NCT01007071|Experimental|Growth hormone|Subjects randomized to growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Dose adjustments based on serum insulin-like growth factor-1 (IGF-1) levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 standard deviation (SD) to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
89689513|NCT01007071|Placebo Comparator|Placebo|Subjects randomized to placebo for 16 weeks. As noted above, placebo subjects will be initiated on a daily subcutaneous injection, with dose changes based on changes in active drug subjects.
89689514|NCT05475639|Experimental|"axillary diclophenac phonophoresis ( diclophen gel voltaren gel)"|the subject in the axillary diclophenac phonophoresis group will receive axillary diclophenac phonophoresis using ultrasound 1 MHz to increases the absorbtion. Diclofenac phonophoresis will be applied beside conventional therapy program ,Apply the diclophen gel (voltaren gel) on the head of the US in the axillary pouch of the capsule at 1.5 W\cm2 for 10 minutes as pulsed U.S. the group will be treated for 4weeks, 3 sessions per week and all patients will be assessed pre and post intervention.
89061029|NCT04013854|Experimental|Arm C: Adjuvant Combination (Less than Complete Response)|ipilimumab (1mg/kg) plus nivolumab (3mg/kg) for 4 doses and then nivolumab (480 mg) alone for a total of one year
89061030|NCT03995316|Other|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
89220559|NCT03855007|Experimental|Iguratimod|The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX), hydroxychloroquine (HCQ) , prednisone (Pred) step by step
89689515|NCT05475639|Experimental|Post isometric Facilitation Techniques.|the subject in the Post isometric Facilitation Techniques group will be treated by applying isometric contraction followed by isometric relaxation followed by stretching to the target muscle .when performing isometric facilitation with the shoulder in flexion , the patient was seated with his\her back supported and the therapist standing facing the patient's painful shoulder .the patient's shoulder joint was flexed to the maximum available range with the elbow completely flexed .the patient performed isometric contraction of the shoulder extensors against maximum resistance provided by the therapist .this contraction will last for 10 seconds followed by relaxation for 5 seconds .this contraction will allow the shortened shoulder extensors to relax and permit easier stretching.the group will be treated for 4weeks, 3 sessions per week and all patients will be assessed pre and post intervention.
89689516|NCT05475639|Active Comparator|traditional physiotherapy (infrared, supervised exercise program, home exercise program)|"The traditional physical therapy program, which includes Infrared (IR) lambs apply heat to deep joints such as shoulder joint. Avoid deltoid muscle; apply over thin, bony areas for maximum penetration.~supervised exercise program are self-exercise included: 1-Codmans or pendulum exercise (circumduction): It should be done 5 times daily in 5 to 10 minute sessions Passive stretching exercise (for shoulder extensors, abductors, and internal rotator) home exercise program includes the same exercise as in supervised exercise program. The participant will instruct to perform exercises1-2 times/day within pain -free ROM.~the group will be 4weeks, 3 sessions per week and all patients will be assessed pre and post intervention."
89689517|NCT02242955|Active Comparator|"AD = as-usual diazepam"|Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).
89689518|NCT02242955|Experimental|"PD = prolonged diazepam"|Diazepam will be slowly tapered to be stopped at day 30
89689519|NCT02984644|Active Comparator|Dapagliflozin|32 subjects will receive dapagliflozin 10mg
89689520|NCT02984644|Placebo Comparator|Placebo|16 subjects will receive placebo
89689521|NCT03026959|Experimental|Mindfulness Group|Participants assigned to the mindfulness group will attend four weekly sessions that are each 1.5 hours in length. The sessions will follow the structure described by Short, Mazmanian, Ozen, & Bédard (2015). The structure is designed to first enhance learners' foundation skills in mindfulness and progresses into teaching learners more advanced mindfulness skills.
89689522|NCT03026959|No Intervention|Social (control) Group|Participants assigned to the social group will also attend four weekly sessions that are each 1.5 hours in length. Each session will have participants focus on a creative tasks while permitting task related discussion. In this way the format is designed to parallel the mindfulness group, where participants engage in a new activity each week and have an opportunity to discuss the activities with the group without engaging in any formal intervention.
89689523|NCT02243111|Experimental|Doppler ultrasound|Recording Doppler signals from the lungs
89689524|NCT05621577|Other|mandibular advancing device|using mandibular advancement device for treatment of obstructive sleep apnea
89689525|NCT02243189|Experimental|JNJ-43260295 (Healthy Participants)|Participants will receive a single nasal dose of JNJ-43260295, 6400 microgram, equally spread over the two nostrils.
89689526|NCT02243189|Placebo Comparator|Placebo (Healthy Participants)|Participants will receive a single nasal dose of placebo matching to JNJ-43260295.
89689527|NCT02243189|Experimental|JNJ-43260295 (Asthmatic Participants)|Participants will participate in 3 consecutive treatment periods (Periods 1, 2, and 3). In Period 1, each participant will receive a single nasal dose of JNJ-43260295 without prior nasal allergen challenge. In Period 2, each participant will receive a single nasal dose of JNJ-43260295, preceded by a nasal allergen challenge approximately 15 hours prior to the dosing. In Period 3, each participant will receive single nasal allergen challenge without JNJ-43260295. There will be a washout period of at least 21 days between 3 consecutive treatment periods.
89689528|NCT00966823|Experimental|Detachable balloon|Intervention: Fetuses treated with endoscopic tracheal occlusion
89689529|NCT02977845|Experimental|Primary aim|The primary aim of this study is to assess the effect of Qigong on managing dyspnea, fatigue, and anxiety (as a cluster) in lung cancer patients.
89689530|NCT02977845|Experimental|Secondary aim|The secondary aim of this study is exploring the effect of Qigong on cough which is another common symptom linked with dyspnea, fatigue, and anxiety as a cluster, and QOL in lung cancer patients.
89689531|NCT02984878|Experimental|Revanesse Ultra|Revanesse Ultra open label retreatment
89689532|NCT05469867|Experimental|Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants|
89689533|NCT04370249||Patient with suspected COVID-19 infection|Patients admitted and managed in an emergency department under suspicion of COVID-19 infection who received a pleuro-pulmonary ultrasound on admission
89689534|NCT05260437|Experimental|CV2CoV Dose Cohort 1 (2µg or 4µg)|"Group 1a will receive CV2CoV dose level 2 µg~Group 1b will receive CV2CoV dose level 4 µg"
89689535|NCT05260437|Experimental|CV2CoV Dose Cohort 2 (8 µg)|"Cohort 2 will receive CV2CoV dose level 8 µg~Enrollment into Cohort 2 will begin after the Safety Review Team (SRT) has reviewed safety data from 2 sentinel participants from the previous dose cohort."
89689536|NCT05260437|Experimental|CV2CoV Dose Cohort 3 (12 µg)|"Cohort 3 will receive CV2CoV dose level 12 µg~Enrollment into Cohort 3 will begin after the SRT has reviewed safety data from 2 sentinel participants from the previous dose cohort."
89220560|NCT03850977||Patients and controls|Patients diagnosed with chronic pancreatitis or cirrhosis and healthy controls
89220561|NCT03828019|Active Comparator|Adalimumab (ADA)|"Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months.~Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents <30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks."
89220562|NCT03828019|Active Comparator|Conventional immunosuppression (CON)|"Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration.~Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID."
89220563|NCT03819322|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Liver recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
89689537|NCT05260437|Experimental|CV2CoV Dose Cohort 4 (16 µg)|"Cohort 4 will receive CV2CoV dose level 16 µg~Enrollment into Cohort 4 will begin after the SRT has reviewed safety data from all participants in the previous dose cohort."
89689538|NCT05260437|Experimental|CV2CoV Dose Cohort 5 (20 µg)|"Cohort 5 will receive CV2CoV dose level 20 µg~Enrollment into Cohort 5 will begin after the SRT has reviewed safety data from all participants in the previous dose cohort."
89689539|NCT02986282|Other|Single arm|Interventions - repeated ankle - brachial index measurement before and after electrical cardioversion in patients with atrial fibrillation
89689540|NCT04362605|Experimental|intervenional group|ENPT
89689541|NCT01008319|Active Comparator|Traditional Administration|The traditional approach to ovulation induction with clomiphene citrate involves administration of 50mg/day for five days (starting on cycle day 3, 4, or 5). If ovulation does not occur then a progestin is prescribed to induce menses (which occurs within one week of stopping the progestin) and then a higher dose of medication is used in the next cycle.
89689542|NCT01008319|Experimental|Stair-Step Administration|The stair-step protocol the dose of clomiphene citrate would be increased without administering progestin and inducing a period. This would eliminate the days of progestin (10 days) and the waiting for the period (usually 3 to 7 days) and finally waiting to start clomiphene citrate on cycle day 3 at the earliest (3 more days) for a total of up to 20 days difference for the 100 mg dose of clomid. If they did not ovulate on 100mg, then the process repeats and another 20 days before they start 150mg. Therefore, the time to ovulation and pregnancy may be reduced, and hopefully pregnancy, by using the stair-step protocol. This method utilizes ultrasound monitoring for follicle development before increasing the dose of clomiphene citrate.
89689543|NCT05252949|Active Comparator|Study Supplement: OEA|26 subjects will take the supplement (oleoylethanolamide) during the first phase of the study. 200mg will be taken twice a day for the 10-week period in phase one.
89689544|NCT05252949|Placebo Comparator|Control|26 subjects will take the placebo during the first phase of the study (10 weeks).
89689545|NCT04369391|Experimental|SEP363856 150 mg|SEP363856 tablet 150 mg
89689546|NCT04369391|Placebo Comparator|Placebo|matched placebo
89689547|NCT04369391|Active Comparator|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
89689548|NCT02873104|Active Comparator|Treatment|truSculpt rf device, therapeutic settings
89689549|NCT02873104|Sham Comparator|Sham|truSculpt rf device, non-therapeutic settings
89689550|NCT04369313|Experimental|delayed cord clamping|clamping the cord at least 30s at birth
89689551|NCT04369313|Other|early cord clamping|umbilical cord clamping before 15 seconds
89689552|NCT00967369|Experimental|Arm A (bortezomib, ifosfamide, carboplatin, etoposide)|ARM A: Patients receive bortezomib IV over 5 seconds on days 1 and 4, ifosfamide IV continuously over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on days 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89689553|NCT00967369|Active Comparator|Arm B (ifosfamide, carboplatin, etoposide)|Patients receive ifosfamide, carboplatin and etoposide as in Arm A. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89689554|NCT04361981||Cases|COVID-19 infection patients with a Deep Venous Disease event
89689555|NCT02876926|Experimental|"Enhanced home-based testing"|"These participants will download a study-specific smartphone app (eTEST), and receive home-based HIV test kits in the mail every 3 months. These kits will have been fit with sensors that enable remote detection of when the kit was opened. Qualified HIV test counselors (QHTC) will then follow up with these participants within 24 hours of receiving notification that the test has been opened to conduct routine counseling, offer referrals for other services, and connect those with reactive results with follow-up care."
89689556|NCT02876926|Active Comparator|Home-based testing alone|These participants will receive a typical home-based test for HIV in the mail every 3 months, but no phone-based follow-up will be provided.
89689557|NCT02876926|Sham Comparator|Reminders for clinic-based testing|Participants in this condition will receive a letter in the mail every 3 months reminding them to be tested at a local clinic for free.
89689558|NCT04369235|Experimental|tCES & upper extremity rehabilitation|The experiment group will receive tCES combined with upper extremity rehabilitation of affected side.
89689559|NCT04369235|Sham Comparator|Sham tCES & upper extremity rehabilitation|The sham control group will receive sham tCES combined with upper extremity rehabilitation of affected side.
89689560|NCT04369001|Experimental|Intervention Group|(Program ACTIVE n=20) Participants randomized into the Program ACTIVE group will receive a gym membership to a local, Detroit-based community recreation facility where they will complete 150 minutes of exercise per week for 12 weeks and will receive 10 sessions (once weekly) of CBT therapy sessions. Exercise per week will be documented using exercise logs. Exercise logs will be given to research staff at the end of the 12-week timeframe; all exercise logs will be kept organized respective to the participant identification number and related documents (questionnaires and surveys). To ensure treatment fidelity, three CBT and three physical activity sessions will be selected at random and recorded and rated for fidelity to the above content by our research team.
89220564|NCT03819322|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Post-operative day 1, liver recipients will be treated with 12-week oral course of sofosbuvir/ velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
89220565|NCT03817970|Experimental|Granisetron|Participants randomized to an antiemetic regimen containing granisetron 2 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
89220566|NCT03817970|Experimental|Ondansetron|Participants randomized to an antiemetic regimen containing ondansetron 8 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
89220567|NCT03817970|Experimental|Palonosetron|Participants randomized to an antiemetic regimen containing palonosetron 0.25 mg IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
89220568|NCT03815812|Experimental|IBI306|Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose
89220569|NCT03815812|Placebo Comparator|placebo|Participants received matching placebo dose regimen by subcutaneous injection.
89220570|NCT03815058|Experimental|Safety Run-in Period: Autogene Cevumeran + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by intravenous (IV) infusion followed by 200 mg pembrolizumab IV infusion every 3 weeks (Q3W) plus a recommended dose of autogene cevumeran.
89220571|NCT03815058|Active Comparator|Randomized Period: Arm A: Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with autogene cevumeran plus pembrolizumab (Arm B) after confirmed disease progression.
89220572|NCT03815058|Experimental|Randomized Period: Arm B: Autogene Cevumeran + Pembrolizumab|Participants will receive at least one cycle of 200 mg pembrolizumab monotherapy by IV infusion followed by 200 mg pembrolizumab IV infusion Q3W plus a recommended dose of autogene cevumeran.
89220573|NCT03814395||Exposure group|Group with environmental, nutritional or lifestyle exposures
89220574|NCT03814395||Non-exposed group|Group without any environmental, nutritional and lifestyle exposures
89220575|NCT03811249|Experimental|Implantation-Non-randomized|Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively for an additional 36 month period to measure long term safety and effectiveness outcomes.
89220576|NCT03810742|Experimental|Nanoliposomal Irinotecan + TAS-102|different dosage combination by Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
89220577|NCT03807531|Other|Treatment with TSS|This is a single-arm study. Participating subjects will be treated with the Temporary Spur Stent System (TSS)
89061031|NCT03995316|Other|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
89061032|NCT03927690|Experimental|LKA651|LKA651 Intravitreal injection
89061033|NCT03927690|Experimental|LKA651 + Lucentis|LKA651 + Lucentis Intravitreal injection
89061034|NCT03927690|Active Comparator|Lucentis|Lucentis Intravitreal injection
89061035|NCT03833921|Other|Abiraterone acetate + prednisone|All subjects will receive abiraterone acetate and prednisone, as per standard of care. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone twice per day. Subjects will continue to take abiraterone acetate and prednisone until confirmed disease progression.
89061036|NCT03821246|Experimental|Cohort A (atezolizumab)|Patients receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
89220578|NCT03790670|Experimental|Leukine Treatment|36 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
89220579|NCT03786536|Experimental|Treatment|All volunteers will receive the same treatment
89220580|NCT03783494|Experimental|Target-controlled infusion (TCI)|Target-controlled infusion (TCI) with propofol up to 5.5µg/ml during an anticipated average maximal time of 15 minutes
89220581|NCT03774472|Experimental|Treatment (hydroxychloroquine, palbociclib, letrozole)|"PHASE I: Patients with advanced, metastatic (stage IV) breast cancer receive hydroxychloroquine PO QD, palbociclib PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients with early stage (stage I-III) breast cancer receive hydroxychloroquine PO QD on days 15-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive palbociclib PO QD, and letrozole PO QD on days 1-28, followed by standard of care surgery at week 5. If there is a proliferative benefit with CCCA by biopsy at 4 weeks, cycles may repeat every 28 days for up to 20-24 weeks in the absence of disease progression or unacceptable toxicity, followed by standard of care surgery during weeks 20-24."
89220582|NCT03764592||VF BrS/ERS patients|Only patients that diagnosed with BrS or ERS based on ECG criteria
89220583|NCT03762291|Experimental|CVD908ssb-TXSVN|"3 different dosing schedules will be studied (3+3 design). At the beginning, patients will start on the lowest dose (1 of 3 different levels) of TXSVN. Once that dose schedule proves safe, the next group of patients will be started at a higher dose. This process will continue until all 3 dose levels are studied. If the side-effects are too severe, the dose will be lowered or the TXSVN administrations will be stopped. Each patient will receive 2 vaccinations at the same dose, 2 weeks apart, according to the following dosing schedules: The administration will be oral.~Dose Level 1~Day 0: 2 x 10^5 cfu~Day 14: 2 x 10^5 cfu~Dose Level 2~Day 0: 2 x 10^6 cfu~Day 14: 2 x 10^6 cfu~Dose Level 3~Day 0: 2 x 10^7 cfu~Day 14: 2 x 10^7 cfu"
89220584|NCT03753659|Experimental|Pembrolizumab with local ablation|"Pembrolizumab 200mg IV Q3W on day 1 of cycle 1 and 2~Radio Frequency Ablation (RFA) / Microwave Ablation (MWA) / brachytherapy or combination of TACE with RFA, MWA or brachytherapy will be performed on day 1 of cycle 3~Pembrolizumab 200mg IV administration 2 days after local ablation~Pembrolizumab 200mg IV Q3W for up to 12 months total treatment duration"
89220585|NCT03706417|Experimental|Telemedicine|Babies that received telemedicine consult intervention.
89220586|NCT03700034|Experimental|mHealth integrated model of hypertension, diabetes, anemia, and antenatal care|The mIRA trial intervention will consist of an electronic decision support system (EDSS), provided to healthcare providers at primary-level facilities in India and Nepal to deliver enhanced ANC with improved detection and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM) and anemia.
89220587|NCT03700034|No Intervention|Routine antenatal care|In the control clusters, pregnant women will receive the existing standard of care (usual care) from Frontline Health Workers (FHWs). Evidence-based guidelines in the form of posters/pamphlets on current national and state guidelines on screening and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM), anemia, and routine ANC procedures will be provided to all the control health facilities.
89220588|NCT03679676|Other|Cohort A: Omalizumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with placebo
89220589|NCT03679676|Other|Cohort B: Omalizumab/Dupilumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab.
89220590|NCT03679676|Other|Cohort C: Dupilumab|Participants will be treated with placebo for 8 weeks, followed by 24 weeks of treatment with dupilumab.
89220591|NCT03678688|Active Comparator|Stage 1: RHEZ|Participants received a single dose of RHEZ (each tablet containing 150 milligrams (mg) rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), orally, once daily (QD) from Day 1 through Day 20.
89220592|NCT03678688|Experimental|Stage 1: 10 mg OPC-167832|Participants received OPC-167832, 10 mg, orally, QD, from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
89220593|NCT03678688|Experimental|Stage 1: 30 mg OPC-167832|Participants received OPC-167832, 30 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
89220594|NCT03678688|Experimental|Stage 1: 90 mg OPC-167832|Participants received OPC-167832, 90 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
89220595|NCT03678688|Experimental|Stage 1: 3 mg OPC-167832|Participants received OPC-167832, 3 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
89220596|NCT03678688|Experimental|Stage 2: 30 mg OPC-167832 + 300 mg Delamanid|Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
89220597|NCT03678688|Experimental|Stage 2: 30 mg OPC-167832 + 400 mg Bedaquiline (BDQ)|Participants received OPC-167832, 30 mg, in combination with BDQ, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, QD, orally from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
89220598|NCT03678688|Experimental|Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ|Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg and BDQ, 400 mg, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, orally, QD from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
89220599|NCT03678688|Active Comparator|Stage 2: RHEZ|Participants received a single dose of RHEZ (each tablet containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), orally, QD, from Day 1 through Day 20.
89220600|NCT03667196||Observational|
89220601|NCT03666780||Subject|"All patients who signed informed consent and are implanted with a LAmbre occluder device will undergo follow-up (FU) evaluations as per local hospital standard and corresponding IFU which is expected to be at the following time points post implant:~At discharge (+/- 1 day)~1-3 months (+/- 1 week)~6 months (+/- 2 weeks)~12 months (+/- 1 month)~2 years (+/- 3 month)~3 years(+/- 3 month) Patients who have undergone a LAmbre explant should remain in the study and adhere to the above mentioned follow-up time point until completion of 3 years follow-up period.~After the patient has completed the 3 years follow-up assessments, the patient is considered to have completed the study. A study exit eCRF needs to be completed and the patient will receive routine care."
89220602|NCT03666000|Experimental|Dose Level 1|"PBCAR0191, 3 x 10^5 CAR T cells per kg body weight.~In this study, PBCAR0191, allogeneic anti-CD19 CAR T Cells, is used to treat patients with relapsed or refractory (r/r) Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia.~Route of Administration: Intravenous infusion.~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR0191 infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
89220603|NCT03666000|Experimental|Dose Level 2|PBCAR0191, 1 x 10^6 CAR T cells per kg body weight.
89220604|NCT03666000|Experimental|Dose Level 3a|PBCAR0191, 3 x 10^6 CAR T cells per kg body weight.
89220605|NCT03666000|Experimental|Dose Level 4|PBCAR0191, 6 x 10^6 CAR T cells per kg body weight as 2 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
89220606|NCT03666000|Experimental|Dose Level 4b|PBCAR0191, 500 x 10^6 CAR T cells (flat dose)
89220607|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications ON|Idiopathic Parkinson's patient's with Hoehn and Yahr score of 1.5- 2 i.e. in an early stage of the disease, under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
89220608|NCT03665493|Experimental|PD patients H&Y=3 Medications ON|Parkinson's patient's with Hoehn and Yahr score of 3, i.e. in moderate-to-advanced stages of the disease under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
89220609|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications OFF|Same as above described
89220610|NCT03665493|Experimental|PD patients H&Y=3 Medications OFF|Same as above described
89220611|NCT03665493|Experimental|Healthy age-matched controls|Healthy controls. Right-handed healthy subjects (it will be assessed by the Edinburgh handedness inventory) with normal or corrected-to-normal vision, without a history of neurological diseases. Age range: 40-70.
89220612|NCT03660280|Experimental|Probiotics|
89220613|NCT03660280|Placebo Comparator|Placebo|
89220614|NCT03648385|Experimental|DHEA|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks
89220615|NCT03648385|Placebo Comparator|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
89220616|NCT03641742||FAR-ILD Proband Participants|There will be no interventions administered to this group, only data collection.
89220617|NCT03641742||"FAR-ILD At-Risk Participants"|There will be no interventions administered to this group, only data collection
89220618|NCT03641209|Experimental|Paracetamol|Paracetamol 10 mg/mL infusion solution, intravenous loading dose 20 mg/kg, followed by maintenance dose 7.5 mg/kg every 6 h up to 9 days
89220619|NCT03641209|Placebo Comparator|Placebo|0.45% sodium chloride (NaCl) solution, equal amounts in mL as would have been given the experimental drug
89220620|NCT03637062|Experimental|pessary|the test group is pessary.The pregnant woman is assigned to the pessary group and after having excluded a vaginal infection the pessary will be inserted directly.
89220621|NCT03637062|Active Comparator|Progesterone|the control group is progesterone. Pregnant women in the control group were treated by 200 mg QN, it is used for 34 gestational weeks.
89220622|NCT03624036|Experimental|First Stage Cohort 1: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) will receive conditioning chemotherapy (fludarabine 30 mg/m^2/day over 30 minutes and cyclophosphamide 500 mg/m^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 1 x 10^6 anti-cluster of differentiate 19 (CD19) chimeric antigen receptor (CAR) T cells/kg on Day 0.
89220623|NCT03624036|Experimental|First Stage Cohort 2: 2 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r CLL will receive conditioning chemotherapy (fludarabine 30 mg/m^2/day over 30 minutes and cyclophosphamide 500 mg/m^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 2 x 10^6 anti-CD19 CAR T cells/kg on Day 0.
89220624|NCT03624036|Experimental|Second Stage Cohort 3: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r CLL and small lymphocytic lymphoma (SLL) with ≤1% malignant cells in peripheral blood or absolute lymphocyte count (ALC) < 5,000 cells/μL will receive conditioning chemotherapy (fludarabine 30 mg/m^2/day over 30 minutes and cyclophosphamide 500 mg/m^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 1 x 10^6 anti-CD19 CAR T cells/kg on Day 0.
89220625|NCT03624036|Experimental|Second Stage Cohort 4A: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r CLL who previously received two lines of therapy along with ibrutinib with or without anti CD20 antibodies, B-cell lymphoma 2 (BCL-2) and Phosphoinositide 3-kinase (PI3k) inhibitors will receive ibrutinib up to 30 hours prior to leukapheresis along with conditioning chemotherapy (fludarabine 30 mg/m^2/day over 30 minutes and cyclophosphamide 500 mg/m^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 1 x 10^6 anti-CD19 CAR T cells/kg on Day 0.
89220626|NCT03624036|Experimental|Second Stage Cohort 4B: 2 x 10^6 Anti-CD19 CAR T Cells/kg|"Participants with r/r CLL who previously received two lines of therapy along with ibrutinib with or without anti CD20 antibodies, BCL-2 and PI3k inhibitors will receive ibrutinib up to 30 hours prior to leukapheresis along with conditioning chemotherapy (fludarabine 30 mg/m^2/day over 30 minutes and cyclophosphamide 500 mg/m^2/day over 30-60 minutes) on Days -5 to -3 with 2 rest days, followed by single infusion of brexucabtagene autoleucel 2 x 10^6 anti-CD19 CAR T cells/kg on Day 0.~Upon completion of Cohort 4A, it was determined not to enroll participants in Cohort 4B."
89220627|NCT03621306||Men and women aged 18+|Men and women over the age of 18
89220628|NCT03618134|Experimental|Cohort I (SBRT, durvalumab, TORS, neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89220629|NCT03618134|Experimental|Cohort II (SBRT, durvalumab,tremelimumab,TORS,neck dissection)|Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive tremelimumab IV and durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery and modified radical neck dissection between weeks 6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89220630|NCT03609944|Sham Comparator|EUS + Sham|Subjects randomized to EUS + sham will undergo a diagnostic endoscopic ultrasound (EUS) under sedation. The physician investigator will not make any attempts to achieve minor papilla cannulation, but photo document the minor papilla using a duodenoscope. Diluted dye will be injected into the duodenum. A small caliber prophylactic pancreatic duct stent will be deposited into the duodenal lumen. These maneuvers are performed to minimize the risk of unmasking.
89220631|NCT03609944|Experimental|EUS + ERCP with miES|Subjects randomized to EUS + ERCP with miES will undergo the procedure at the same time as endoscopic ultrasound (EUS), under sedation. Indomethacin (100 mg) will be administered rectally at the onset of the ERCP procedure in patients with no known allergy to indomethacin. The techniques used to perform the endoscopic retrograde cholangiopancreatography (ERCP)with miES (minor papilla endoscopic sphincterotomy) will be left to the discretion of the study endoscopist. The extent of sphincterotomy will be per the discretion of the treating endoscopist. Unless methylene blue (or similar chromoendoscopy agent such as indigo carmine) has already been used to facilitate minor papilla cannulation, diluted dye will be injected into the duodenum.
89220632|NCT03607032|Experimental|RespinPad and usual treatment|
89220633|NCT03607032|Active Comparator|only usual treatment|
89220634|NCT03602612|Experimental|1/Conditioning chemotherapy plus chimeric antigen receptors (CARs) T-cells dose escalation|Patients will receive escalating doses (up to 5 planned) of CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
89220635|NCT03602612|Experimental|2/Conditioning chemotherapy plus chimeric antigen receptors (CARs) T-cells expansion phase|6.0x10^6 dose (maximum feasible dose) of CAR T Cells + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
89220636|NCT03585010|Experimental|Supportive Parenting for Anxious Childhood Emotions|Parent-based treatment for childhood anxiety disorders
89220637|NCT03585010|Active Comparator|Parent Educational Support or CBT|Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
89220638|NCT03584113|Active Comparator|IR guided chest tube insertion with fibrinolytics|Image guided chest tube insertion by interventional radiology along with MIST 2 trial fibrinolysis which includes intrapleural dornase (5mg) and Alteplase (10mg) every twelve hours for a total of six doses as primary intervention for empyema.
89220639|NCT03584113|Active Comparator|VATS Decortication|Video assisted thorascopic surgery decortication (VATS) as primary intervention for empyema.
89220640|NCT03583190|Experimental|Cervical-cranial dry needling|Patients randomized to this arm will receive cervical-cranial dry needling, thoracic manipulation, and exercise.
89220641|NCT03583190|Active Comparator|Orthopedic Manual Therapy|Patients randomized to this arm will receive orthopedic manual therapy to cervical spine, thoracic manipulation, and exercise.
89220642|NCT03582514|Experimental|Dose or volume radiation escalation|"Patients with a new radiological diagnosis of GBM (judged by the neuro-oncology multidisciplinary team) are to be considered for this study.~This study arm will use 5 radiotherapy doses (6 Gy, 8 Gy, 10 Gy, 12 Gy and 14 Gy) and three treatment volumes (<30 cm3, 30-60 cm3 and >60 cm3). The study will use 6 dosing levels based on a combination of radiotherapy dose and treatment volume. The stepwise inclusion process allows for variation in tumour volume and location. The study will commence with dosing level 1: 8 Gy to <30 cm3 and 6 Gy to 30-60 cm3. In collaboration with the Clinical Trials Unit, the Trial Management Group will enter outcome data for patients at a given dose level into the CRM model. The model output will then guide dose escalation to determine the next dose level. After the single fraction of radiotherapy, patients will receive the standard treatment."
89220643|NCT03576859|Other|cirrhotic patients with chronic liver failure|
89220644|NCT03576859|Other|cirrhotic patients without chronic liver failure|
89689561|NCT04369001|No Intervention|Enhanced Usual Care|(EUC n=20) Participants randomized to enhanced usual care will receive referrals to community mental health providers, pedometers, gym memberships to a community-based venue, and intervention patient manuals. Participants will not be required to report any use of resources offered or change their course of treatment in any way. Based on several years of experience in Detroit, providing all participants with referrals, pedometers, gym access and educational materials minimizes ethical concerns regarding assignment of underserved populations to receive a no-treatment control.
89689562|NCT03050320|Experimental|Exercise|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Five class times will be offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
89689563|NCT03050320|Other|No Exercise|The participants in this arm will be asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group will be offered the same exercise program following completion of the study. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
89689564|NCT05467605|Active Comparator|CASE, GROUP ONE|Group 1 (group who will receive probiotics): one sachet contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions), dissolved in 10 ml distilled water twice a day for 7days orally or through nasogastric/orogastric tube depending on clinical status of patients.
89689565|NCT05467605|Placebo Comparator|CONTROL, GROUP 2|GROUP 2 will receive only maltose dissolved in 10 ml of distilled water twice a day for 7 days orally or though nasogastric/orogastric tube depending on clinical status of patients.
89689566|NCT00967993||KRX-0502 (ferric citrate)|"KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate. All patients initiated on study drug will start with a fixed dose of KRX-0502 (ferric citrate) of 6 caplets per day.~Patients will be titrated at Visits 4, 5, and 6 based on serum phosphorus lab results. If serum phosphorus levels go below normal, there will be a decrease in pills; if serum phosphorus levels go above normal, there wil be an increase in pills. The maximum number of KRX-0502 (ferric citrate) caplets per day will be 12, or 12 g/day of ferric citrate.~Patients will take study drug orally with meals or snacks or within one hour after their meals or snacks."
89689567|NCT04369157||Elective surgery group|Patients undergoing hip/knee replacements or colorectal surgery will be recruited and tested on 3 occasions: pre-op, post-op and at follow-up. POCD status will be determined at post-op and follow up. Cognitive function, zinc status, POCD biomarkers and inflammatory markers will be measured on all 3 occasions.
89689568|NCT04362215||High AA group|Group 1 consisted of those having an AA level of 3.57-4.16 D (high AA group; those who had near clear vision between 24-28 cm). .
89689569|NCT04362215||Low AA group|Group 2 consisted of those having an AA level of 3.44-3.03 D (low AA group; those who had near clear vision between 29-33 cm)
89689570|NCT02878486|Experimental|Group 1|Subjects will have clinic visits, home visits, and telephone visits. Subjects will be asked to wear a wrist monitor (Jawbone Up) for duration of the study, will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
89689571|NCT02878486|Active Comparator|Group 2|Subjects will make clinic visits. At home visits, subjects will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
89689572|NCT02245295||EBUS-TBNA|EBUS-TBNA for enlarged mediastinal/hilar lymph nodes
89689573|NCT01009333|Experimental|Low InterStim rate setting at 5.2 Hz|
89689574|NCT01009333|Experimental|Medium InterStim rate setting at 14 Hz|
89689575|NCT01009333|Experimental|High InterStim rate setting at 25 Hz|
89689576|NCT04344093|Experimental|Connected patch validation|
89689577|NCT04362371|Experimental|Ainara|"Ainara is a class II medical device, already marketed in several EU countries. The product is a mucoadhesive moisturising gel for vulvovaginal use, indicated for the relief of symptoms of vaginal atrophy and dryness, and related discomfort. In each packaging there is a tube containing the gel (sterile and viscous with about 87% water) and a syringe-like plastic applicator with cannula and plunger.~Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration)."
89689578|NCT02981875|Experimental|experimental|oculomotor training
89689579|NCT02981875|Placebo Comparator|control|placebo vision training exercises
89689580|NCT04369079|Experimental|TREATMENT GROUP|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side. The exact sequence and number of procedures differed in each patient according to need as determined by prior functional examination. Before or after every of the treatment procedure treatment group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
89689581|NCT04369079|Other|CONTROL GROUP|Treatment duration was a mean of 4 weeks. Therapy was performed daily excluding weekends and consisted of 45 minutes of individual work with an oncological physiotherapist. The control group underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area. Before or after every of the treatment procedure control group patients underwent ten-minute manual lymphatic drainage in the limb on the mastectomy side.
89689582|NCT00359463|Active Comparator|Healthy subjects|Subjects will receive a single 50 mg oral dose of eltrombopag.
89689583|NCT00359463|Experimental|Subjects with hepatic impairment|Subjects with mild, moderate or severe hepatic impairment will receive a single 50 mg oral dose of eltrombopag.
89689584|NCT02880514|Experimental|PROPEL Mini Sinus Implant|Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation
89689585|NCT02880514|Active Comparator|Balloon Sinus Dilation Alone|In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement
89689586|NCT04361747|Experimental|nursing counseling intervention|The nursing counseling intervention was implemented by a maternity nursing instructor. During the 12-week prenatal genetic testing evaluation period, experimental-group participants received three nursing consultation sessions plus regular care, while their control-group peers received regular care only. The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
89689587|NCT04361747|No Intervention|control group|control group participants received regular care only
89689588|NCT05605431||COPD associated with OSA|
89689589|NCT05605431||COPD without OSA|
89689590|NCT00968071|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 intravenously (IV) over an hour and half daily for 5 days, Gemtuzumab Ozogamicin 3 mg/m^2 IV on day 5.
89689591|NCT04368923|Experimental|Oxygen Therapy Group|
89689592|NCT04368923|Experimental|Physical Therapy Group|
89689593|NCT02987374|Other|2011-2012 Fluzone IIV3 (IM)|Seasonal trivalent flu vaccine: NDC No 49281-011-50
89689594|NCT04368611|Active Comparator|fundus first cholecystectomy|start with fundus dissection then complete the dissection
89689595|NCT04368611|Active Comparator|Calot first dissection|start and complete the dissection by dissection of Calot triangle
89689596|NCT00968227|Experimental|Transfusion|
89689597|NCT04368767|No Intervention|Usual Care: Incubator|The infant will remain in the incubator and stress biomarkers will be collected per protocol
89689598|NCT04368767|Experimental|Intervention: Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, 30 minutes after feeding. SSC will usually occur in the afternoon between 11:30-12:30 pm or 14:30-15:30pm. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. The room will be monitored to maintain a temperature of 72-77 degrees Fahrenheit during SSC. Stress biomarkers will be collected per protocol.
89689599|NCT02988856|Experimental|Magnetic lid system|All participants will trial a commercially available device and an experimental magnetic device.
89689600|NCT04361903||Patients treated with ruxolutinib|SARS-CoV-2 COVID-19 patients with rapid worsening of respiratory parameters in the last 12 hours treated with ruxolutinib, dosage of at least 20 mg x 2 / day in the first 48 hours.
89689601|NCT02989246|Experimental|Intervention Arm|Ventilator management using the proposed protocol in both acute and weaning phases. Patients will be managed according the the Ventilator protocol using the esophageal catheter for the weaning phase
89689602|NCT00971737|Active Comparator|Cyclophosphamide and Vaccine only|Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
89689603|NCT00971737|Experimental|Cyclophosphamide, Vaccine and Trastuzumab|Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
89689604|NCT04368377|Experimental|Tirofiban|"Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0.15 microgram/kg/minute for 48 hours.~Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75 mg daily for 30 days.~Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75 mg daily for 30 days~Patents will receive concurrent fondaparinux 2.5 mg s/c per day for the duration of the hospital stay"
89689605|NCT02243345||Delayed|Time from surfacing to recompression >=48 hours
89689606|NCT02243345||Early|Time from surfacing to recompression <48 hours
89689607|NCT05223699|Experimental|Single dose MGTA-117|Dosing of MGTA-117 prepared and administered by IV infusion.
89689608|NCT04361513|Active Comparator|Nerve block group|3 point genicular nerve block under ultrasound guidance. half ml of Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) was injected in each point.
89689609|NCT04361513|Other|intra-articular steroid injection|1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) was injected intraarticular.
89689610|NCT05595993|Experimental|Cilostazol|Oral administration of 200 mg cilostazol.
89689611|NCT05595993|Placebo Comparator|Placebo|
89689612|NCT02243501|Experimental|Intervention Group|The Intervention Group receives access to the BNBD intervention, and can access alternative resources while enrolled in the study. The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
89689613|NCT02243501|No Intervention|Usual Care Group|The Usual Care Group will receive no treatment until after the 8 month follow-up assessment. The Usual Care Group can access alternative resources and additional programs and services while enrolled in the study.
89689614|NCT00972205|Experimental|Paclitaxel and CBT-1|
89689615|NCT00928421|Experimental|Varisolve 0.125%|
89689616|NCT00952315|Active Comparator|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
89689617|NCT00952315|Active Comparator|Lithoclast Select|Lithoclast Select will be used to breakup and remove kidney stone. Duration will be timed and documented.
89220645|NCT03557619|Experimental|Ethinyl estradiol/Levonorgestrel and Venetoclax|Ethinyl estradiol/levonorgestrel is administered on Period 1 Day 1 and then again on Period 3 Day 1. Venetoclax is administered on Period 2 Day 1 and then daily thereafter.
89220646|NCT03556007|Experimental|Cohort 1 - 3 μg/kg LY3471851|Participants received 3 microgram per kilogram (μg/kg) of LY3471851 or placebo on days 1, 15 and 29 by subcutaneous (SC) injection.
89220647|NCT03556007|Experimental|Cohort 1 - 6 μg/kg LY3471851|Participants received 6 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
89220648|NCT03556007|Experimental|Cohort 1 - 12 μg/kg LY3471851|Participants received 12 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
89220649|NCT03556007|Experimental|Cohort 1 - 24 μg/kg LY3471851|Participants received 24 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
89220650|NCT03524573|Experimental|Delayed Appendectomy|Patients will undergo appendectomy the morning following the decision to operate. This group will have an anticipated delay between 3 - 14 hours from the decision to operate, with a surgical start time between 0530 - 0900.
89220651|NCT03524573|Active Comparator|Immediate Appendectomy|Patients will undergo appendectomy within 6 hours of the decision to operate. Surgery will take place between 2000 - 0400.
89220652|NCT03518099|Experimental|Patient|Any patient admitted for acute abdomen condition with or without ischemic causes.
89220653|NCT03518099|Experimental|witness|
89220654|NCT03505229|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Prior to SBRT, fiducial markers will be placed to aid with image guidance during radiation delivery. Fiducials will be inserted endoscopically (preferable) or intraoperatively. After this procedure, patients will have radiotherapy planning. During treatment, the fiducials will be used for registration with the images acquired during treatment (including kV fluoroscopy, MV or optical). The acquired images may be processed to determine fiducial location using KIM or MATT software from University of Sydney. SBRT 30-45Gray in 5 fractions will be given over 2 weeks.~Four weeks after completion of SBRT participants will repeat a re-staging PET and CT scans. Those considered to be resectable will proceed to have surgery 6-10 weeks post SBRT."
89220655|NCT03503110|Experimental|dMRI and electrocorticography|Direct measurements of cortical electrical properties of patients operated on awake surgery for a brain tumor, using electrocorticography (ECoG), based on the dMRI tractography data previously acquired for each patient.
89220656|NCT03498521|Experimental|Molecularly-Guided Therapy|Participants will be assigned to molecularly-guided therapy based on genomic profile.
89220657|NCT03498521|Active Comparator|Platinum-Based Chemotherapy|Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).
89220658|NCT03489291|Experimental|Single infusion of AMT-061|Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After IMP administration (post IMP), subjects will be monitored for tolerance to the IMP and detection of potential immediate AEs at the clinical trial site for 24 hours (overnight stay).
89220659|NCT03483038|Experimental|Liposomal irinotecan with FOLFOX|Subjects will receive 8 cycles and each cycle is 14 days.
89220660|NCT03479515||Formerly-Premature Toddlers|Data will be used to create and evaluate predictive equation
89220661|NCT03457948|Experimental|Group I [pembrolizumab, 177Lu DOTATATE]|Patients will be treated with pembrolizumab and intravenous peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE, Lutathera®) for up to four (4) sessions. Patients with somatostatin receptor positive (SSTR+) tumors with Ki-67 index > 20% (well-differentiated grade 3) and any number of liver and/or extrahepatic lesions with liver parenchyma replacement by tumor < 75%. Patients who achieve progressive or stable disease response after cycle 4 may receive an additional 4 cycles of pembrolizumab and lutetium Lu-177 DOTATATE in the absence of disease progression or unacceptable toxicity and pembrolizumab for up to 35 cycles.
89689618|NCT00952315|Active Comparator|Cyberwand|The dual probe Cyberwand device will be used to fragment and remove the kidney stone. Duration will be timed and documented.
89689619|NCT00932321|Experimental|24 Day NA/EE|Norethindrone acetate 1 mg /ethinyl estradiol 20 mcg for 24 days of each 28 day cycle
89689620|NCT00932321|Active Comparator|21 Day NA/EE|Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg for 21 days of each 28 day cycle
89689621|NCT00952393|Other|Pharmacokinetic|This single arm examines the pharmaco-kinetics of the release of 3-2,4 dimethoxy-benzilidene anabaseine in a hypomellose sustained release formulation.
89689622|NCT00932399||Group 1|Underwent a procedure at a VA medical facility in VISN 20 for a lower limb amputation between 1997 and 2008
89689623|NCT00932399||Group 2|No history of lower limb amputation
89689624|NCT01011829|Active Comparator|Varenicline|"Varenicline:~0.5 mg daily for days 1-3~0.5 mg twice daily for days 4-7~1 mg twice daily from day 8 until end of week 8."
89689625|NCT01011829|Placebo Comparator|Placebo|8 weeks of daily matching oral placebo in tablet form
89689626|NCT05591157|Experimental|CSF-3 and ECG Holter|At least 40 healthy subjects with no relevant or cardiac medical history and negative cardiac symptoms. Subjects will perform an ECG spot-check measurement using the CSF-3 Device while simultaneously being connected to an ECG Holter. Recording duration for both ECG Holter and CSF-3 device will be at least 7 minutes.
89220662|NCT03457948|Experimental|Group II [pembrolizumab, TAE] (CLOSED)|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo Arterial Embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
89220663|NCT03457948|Experimental|Group III [pembrolizumab, yttrium-90 microsphere RE] (CLOSED)|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest measuring more than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo yttrium-90 microsphere Radio Embolization (RE) 3-15 days following the first dose of pembrolizumab.
89220664|NCT03444324|Experimental|BT524|Investigational Human Fibrinogen Concentrate
89220665|NCT03444324|Active Comparator|Fresh Frozen Plasma (FFP)/Cryoprecipitate (Cryo)|Standard of Care
89220666|NCT03442569|Experimental|Open-label, single arm, Phase II|Nivolumab and ipilimumab with panitumumab
89220667|NCT03422848|Active Comparator|Water intervention arm|The water intervention group will increase their habitual daily water intake with 1.5 L of tap water. Furthermore they will receive general life style advice (general oral and written advice on diet and physical activity).
89220668|NCT03422848|Other|Control arm|Control group that will receive general life style advice (general oral and written advice on diet and physical activity).
89220669|NCT03420963|Experimental|Treatment (cyclophosphamide, etoposide, NK cells)|Patients receive cyclophosphamide IV QD over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.
89220670|NCT03412227|Other|Principal Anxiety Disorder|Youth with a principal anxiety disorder
89220671|NCT03412227|Other|Principal Depressive Disorder|Youth with a principal unipolar depressive disorder
89220672|NCT03410498|Other|MS group|This group will perform walking trials in various conditions, i.e. normal walking, walking whilst performing an attention demanding task and walking while being physically tired.
89220673|NCT03409458|Experimental|PT-112 in combination with avelumab|"PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion~Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC are eligible for the dose confirmation phase of the study."
89689627|NCT00932477|Experimental|Artificial Tear Formulation 1|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
89689628|NCT00932477|Experimental|Artificial Tear Formulation 2|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
89220674|NCT03406897|Active Comparator|Omega-3 and Vitamin D Combination|The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
89220675|NCT03406897|Active Comparator|Vitamin D Only|The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
89220676|NCT03404895|Sham Comparator|Conventional Therapy|Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.
89220677|NCT03404895|Active Comparator|Conventional Therapy + venous stent(s)|Patients will receive a venous stent in addition to conventional therapy
89220678|NCT03386045|Active Comparator|Optimal SBRT|Participants in this group will be randomised to either SBRT ( 36 to 45 GY in 5 fractions) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the SBRT (5 treatments) and one third will get the standard fractions.
89220679|NCT03386045|Active Comparator|Optimal Booster|Participants in this group will be randomised to either standard radiotherapy plus SBRT (45 Gy in 20 fractions plus 20-30 Gy in 2 fractions-Booster) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the Booster arm and one third will get the standard fractions.
89220680|NCT03383458|Experimental|Arm A|
89220681|NCT03383458|Placebo Comparator|Arm B|
89220682|NCT03320122|Experimental|Telemedicine|Medical Direction will be provided by pediatric physiatrists using telemedicine.
89220683|NCT03320122|Active Comparator|In-Person Pediatric Physiatrist|Medical Direction will be provided by pediatric physiatrists in-person.
89220684|NCT03320122|Active Comparator|In-Person Non-Pediatric Physiatrist|Medical Direction will be provided by contracted physicians (i.e., non-pediatric physiatrists) in-person care.
89220685|NCT03319745|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. About 4 weeks after treatment, patients then undergo radical cystectomy per standard of care.
89220686|NCT03309150|Experimental|M6620 Monotherapy or Combination Therapy|
89220687|NCT03302663|Other|Patients attending for a clinical scan|Patients attending for a clinical scan will be offered 2-4 extra sequences. The additional sequences and compare them to the currently established ones.
89220688|NCT03302663|Other|Patients who have requested a TOP|Women who have requested a termination of pregnancy (TOP) will be asked if they are willing to have a fetal MRI at 3T performed prior to the TOP. The images obtained will be compared to either images done clinically at 1.5T before the TOP request (if done and with the patients consent) or to images obtained at 1.5T of a similar gestation and pathology that the investigators obtained in a previous research study.
89220689|NCT03302663|Other|Patients with fetal heart abnormality|The investigators plan to recruit patients with a fetus with heart abnormality on ultrasound and compare the MRI findings with the ultrasound findings and the clinical outcome.
89220690|NCT03302663|Other|Patient fetal bone abnormalities|The investigators would like to ask women who have a fetus with bone abnormalities if they would be willing to have a fetal MRI. The findings will be compared to the ultrasound findings and the clinical or pathological findings after delivery.
89220691|NCT03297060|Experimental|SSL Implementation Strategy|Science to Service Implementation Strategy for SBIRT adherence
89220692|NCT03297060|No Intervention|Standard Care|Standard Care SBIRT services
89220693|NCT03296709|Active Comparator|PPC m|
89220694|NCT03296709|Experimental|PPC z|
89220695|NCT03282292|Experimental|Jugular|CVC insertion in the left or right internal jugular vein
89220696|NCT03282292|Active Comparator|Femoral|CVC insertion in the right or left femoral vein
89220697|NCT03243058|Active Comparator|Treatment Arm|ILT-101 (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for two years.
89220698|NCT03243058|Experimental|Treatment-Placebo Arm|Participants in this group will receive study drug ILT-101 for one year, and then placebo for the second year.
89220699|NCT03243058|Placebo Comparator|Placebo|Participants in this group will receive a placebo injection for two years.
89220700|NCT03235544|Experimental|Cohort 1: Treatment A (Exposed to Ibrutinib)|"Participants received parsaclisib 20 mg tablets, orally, once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to 52 weeks.~Participants who were exposed to ibrutinib before enrollment were included in this group."
89220701|NCT03235544|Experimental|Cohort 1: Treatment B (Exposed to Ibrutinib)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to 116 weeks.~Participants who were exposed to ibrutinib before enrollment were included in this group."
89220702|NCT03235544|Experimental|Cohort 2: Treatment A (Bruton's Tyrosine Kinase Inhibitor Naïve)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 20 mg QW for up to approximately 145 weeks.~Participants who had not received a BTK inhibitor previously were included in this group."
89220703|NCT03235544|Experimental|Cohort 2: Treatment B (Bruton's Tyrosine Kinase Inhibitor Naïve)|"Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to approximately 136 weeks.~Participants who had not received a BTK inhibitor previously were included in this group."
89220704|NCT03228940|Experimental|treatment|RVX000222 (apabetalone) 100 mg to be administered orally BID 12 hours apart.
89220705|NCT03217305|Other|NAVA vs Pressure Support|Control (pressure support) - NAVA - Control (Pressure Support) Intervention is NAVA
89220706|NCT03196011|Active Comparator|TKR with mechanical alignment|TKR implanted using traditional alignment methods
89220707|NCT03196011|Experimental|TKR using alternative alignment method|TKR implanted using alternative alignment methods
89220708|NCT03191760|Experimental|Behavioral Activation and Social Engagement|Participants will attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
89220709|NCT03187353|Experimental|Lisdexamfetamine, then Placebo|Participants will have a 50% chance of first receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks. After a washout period of 2 weeks they will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
89220710|NCT03187353|Experimental|Placebo, then Lisdexamfetamine|Participants will have a 50% chance of first receiving the placebo, beginning with 1 sugar pill and increasing up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks. After a washout period of 2 weeks, they will begin active study medication at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks.
89220711|NCT03187080|Experimental|Group 1 Arm A|Breast reduction with Paravertebral block using local anesthetic.
89220712|NCT03187080|Sham Comparator|Group 1 Arm B|Breast reduction with Sham paravertebral block using saline.
89220713|NCT03187080|Experimental|Group 2 Arm A|Breast augmentation with Paravertebral block using local anesthetic.
89220714|NCT03187080|Sham Comparator|Group 2 Arm B|Breast augmentation with Sham paravertebral block using saline.
89220715|NCT03187080|Experimental|Group 3 Arm A|Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
89220716|NCT03187080|No Intervention|Group 3 Arm B|Breast reduction, standard perioperative management.
89689629|NCT00932477|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
89689630|NCT00972439|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
89689631|NCT00972439|Active Comparator|Ovcon Fe®|Ovcon Fe® is an oral contraceptive that contains less progestin.
89689632|NCT00358371|Experimental|Subjects receiving flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
89689633|NCT00358371|Experimental|Subjects receiving flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
89689634|NCT02989714|Experimental|HD IL2 and Nivolumab|
89689635|NCT02243657|Placebo Comparator|1: Placebo dose level|
89689636|NCT02243657|Experimental|2: ASP3652 lowest dose level twice daily|
89689637|NCT02243657|Experimental|3:ASP3652 low dose level twice daily|
89689638|NCT02243657|Experimental|4: ASP3652 medium dose level twice daily|
89689639|NCT02243657|Experimental|5: ASP3652 high dose level twice daily|
89689640|NCT02243657|Experimental|6: ASP3652 highest dose level once daily|
89689641|NCT05213013|Experimental|Experimental|All registered participants in the control group, will receive inhaler treatment with the toy-type nebulizer in the hospital. Both the parent and the child in the intervention group will be trained on the use of a nebulizer/mask.
89689642|NCT05213013|No Intervention|No intervention|No intervention. All registered participants in the control group, will receive inhaler treatment with the standard nebulizer in the hospital. Both the parent and the child in the intervention group will not be trained on the use of a nebulizer/mask.
89689643|NCT02991820|Experimental|Inexperienced users|Inexperienced users will include trainees (SRNAs, residents, fellows, and medical students) and nurses at NCH.
89689644|NCT02991820|Experimental|Experienced users|Experienced users will include faculty pediatric anesthesiologists CRNAs.
89689645|NCT04367753||Fulfilled contract|The contract before the epiphysiodesis has been fulfilled with the wanted limb length at the final analysis
89689646|NCT04367753||Failed contract|The contract before the epiphysiodesis hasn't been fulfilled with the wanted limb length at the final analysis
89689647|NCT02991898|Experimental|Treg Infusion|The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion
89689648|NCT00933491||Diabetic|Type II Diabetes
89689649|NCT00933491||Control|Non-diabetics
89220717|NCT03187080|Experimental|Group 4 Arm A|Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
89220718|NCT03187080|No Intervention|Group 4 Arm B|Breast augmentation, standard perioperative management.
89220719|NCT03179384|Experimental|ceftriaxone treatment|
89220720|NCT03176693|Active Comparator|Phenoxybenzamine|3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
89220721|NCT03176693|Experimental|Doxazosin|3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
89220722|NCT03175874|Other|osteoporosis and alzheimer|patient with osteoporosis and alzheimer hospitalized for total hip prosthesis.
89220723|NCT03175874|Other|osteoporosis without alzheimer|Patient with osteoporosis without alzheimer hospitalized for total hip prosthesis.
89220724|NCT03175874|Other|Patient with arthrosis without alzheimer|Patient with arthrosis without alzheimer hospitalized for total hip prosthesis.
89220725|NCT03143075|Active Comparator|Inflammation group|Subjects with CRP≥3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
89220726|NCT03143075|Active Comparator|Non-inflammation group|Subjects with CRP<3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
89220727|NCT03142919|Experimental|High CRP LPS Intervention|High CRP Individuals with Major Depressive Disorder receiving LPS intervention
89220728|NCT03142919|Active Comparator|Low CRP LPS Intervention|Low CRP Individuals with Major Depressive Disorder receiving LPS intervention
89220729|NCT03142919|Placebo Comparator|High CRP LPS Placebo|High CRP Individuals with Major Depressive Disorder receiving placebo
89220730|NCT03142919|Placebo Comparator|Low CRP LPS Placebo|Low CRP Individuals with Major Depressive Disorder receiving placebo
89220731|NCT03141034|Experimental|Irinotecan plus ramucirumab|-Patients will receive ramucirumab intravenously on an outpatient basis at a dose of 8 mg/kg over the course of 60 minutes on Day 1 of each 14-day cycle. They will then receive irinotecan intravenously at a dose of 180 mg/m2 over the course of 90 minutes on Day 1 of each 14-day cycle.
89220732|NCT03094052|Experimental|Treatment (Neratinib)|Patients will receive up to 240mg neratinib to be taken continuously in 21-day cycles once a day for up to 55 weeks on study with no rest between cycles unless related to toxicity. Patients will receive Neratinib and may also be prescribed standard of care maintenance adjuvant trastuzumab (duration of maintenance trastuzumab is at the discretion of the treating physician), for up to 55 weeks. If applicable, after the completion of trastuzumab maintenance therapy (determined by treating physician), neratinib may continue as monotherapy to complete a maximum of 55 weeks.
89220733|NCT03092323|Experimental|Treatment|Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.
89220734|NCT03092323|No Intervention|Standard of Care|Neoadjuvant radiotherapy followed by surgical resection.
89220735|NCT03083821|Experimental|Arm A|
89220736|NCT03073278|Other|Group 1|This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
89220737|NCT03073278|Other|Group 2|This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
89220738|NCT03073278|Other|group 3|This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
89220739|NCT03071393|Experimental|Acute Intermittent Hypoxia, then Sham Intermittent Hypoxia|Subjects with chronic spinal cord injury first received an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen). After a washout period of at least one week, they then received sham intermittent hypoxia with normal oxygen air (21% inspired oxygen).
89220740|NCT03071393|Experimental|Sham Intermittent Hypoxia, then Acute Intermittent Hypoxia|Subjects with chronic spinal cord injury first received a sham (placebo) intermittent hypoxia protocol with normal oxygen air (21% inspired oxygen). After a washout period of at least one week, they then received an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen).
89220741|NCT03056001|Experimental|Pembrolizumab + doxorubicin|Participants will receive pembrolizumab IV infusion and doxorubicin IV injection on Day 1 of every 21 (+/- 3) days
89220742|NCT03041987||Chronic Kidney Disease|"Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR <60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with nephrotic range proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR<60 ml/minute per 1.73m(2) is set for enrollment."
89220743|NCT03023449|Experimental|Healthy Controls|The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be called at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
89220744|NCT03023449|Experimental|Acute Ischemic Stroke|Patients will be enrolled in the study within 72 hours of stroke symptom onset. The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be undergo a final assessment at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
89220745|NCT03016130|Active Comparator|Liberalized Hospital Diet (Diet A)|Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.
89220746|NCT03016130|Active Comparator|Neutropenic Diet (Diet B)|Diet B is the hospital neutropenic diet.
89220747|NCT03009331|Experimental|Prone position|Intervention: Lungrecruitment in prone position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s.
89220748|NCT03009331|Active Comparator|Supine position|Intervention: Lungrecruitment in supine position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s. Clinical routine.
89220749|NCT02998918|Experimental|PolyResveratrol Supplementation|Participants take 500 mg of PolyResveratrol (100 mg curcumin phytosome, 100 mg quercetin phytosome, 100 mg green tea phytosome, 100 mg trans-resveratrol, 100 mg trans-pterostilbene; Thorne Research) twice daily for one week. Two blood Draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
89220750|NCT02998918|Experimental|Curcumin Supplementation|Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
89220751|NCT02990338|Active Comparator|Pd (pomalidomide + dexamethasone)|Participants received pomalidomide 4 milligrams (mg) Per os (PO) on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants greater than or equal to (>=) 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 241.6 weeks).
89220752|NCT02990338|Experimental|IPd (isatuximab + pomalidomide + dexamethasone)|Participants received isatuximab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants >= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 245.6 weeks).
89220755|NCT02950766|Experimental|Neovax in Combination with Ipilimumab|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20~Ipilimumab will be injected within 1 cm of each NeoVax administration"
89220756|NCT02950766|Experimental|NeoVax alone|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20)"
89220757|NCT02933918|Experimental|Probiotics|
89220758|NCT02907983|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivicaine
89220759|NCT02907983|Sham Comparator|Saline|Saline injection
89220760|NCT02898194||1/Patient Surrogates|Any eligible participant who have acted as a surrogate medical decision-maker.
89061037|NCT03821246|Experimental|Cohort B (atezolizumab, etrumadenant)|Patients will receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle and etrumadenant will be taken at a dose of 150mg PO, once daily, until 48 hours prior to RP, for at least 12 days. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
89220761|NCT02892487|Experimental|Early active swallowing therapy|
89220762|NCT02892487|No Intervention|Usual care|
89220763|NCT02877303|Experimental|Treatment (blinatumomab, inotuzumab, combination chemotherapy)|See detailed description.
89220764|NCT02875561|Active Comparator|Sonopet Ultrasonic Aspirator|Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
89220765|NCT02875561|Experimental|CO2 Laser Ablation|Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
89220766|NCT02850146|Experimental|18F-AV-1451|50 individuals who are cognitively normal, older, Aβ not elevated and enrolled in the LEARN study will undergo 18F-AV-1451 imaging procedures at 4 time points over a 4.5 year period.
89220767|NCT02846571|Other|Human Pancreatic Islet Transplantation|Islet transplantation into the anterior chamber of the eye single arm
89220768|NCT02837939|Experimental|Active|Drug: Human derived Transfer factor applied by subcutaneous injection in specified time points.
89220769|NCT02837939|Placebo Comparator|Control|Aqua pro injectione 4 mL ampules for subcutaneous administration in the same time points as in the active arm
89220770|NCT02822378|Experimental|Ca2+/VitD Control|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).
89220771|NCT02822378|Experimental|50g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
89220772|NCT02822378|Experimental|100g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).
89220773|NCT02813655|Experimental|Experimental arm|Tetracosactide (Synacthène®)
89220774|NCT02813655|Placebo Comparator|Control arm|placebo saline (0.9% NaCl)
89689650|NCT04361435|Other|NIOD first|In this arm, we will apply for NIOD first which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses. This arm of patients will receive standard CPT at least 3 hours after the NIOD intervention.
89689651|NCT04361435|Other|CPT first|In this arm, we will apply for CPT first which will be performed by physiotherapists. This arm of patients will receive NIOD procedures which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses at least 3 hours after the CPT intervention.
89689652|NCT05584995|Experimental|Control group|Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)
89689653|NCT05584995|Experimental|BUAL group|Cases will undergo Bilateral Uterine Artery Ligationafter Postpartum Hemorrhage after cesarean section resistant to medical treatment and did not need a hysterectomy.
89689654|NCT02881840|Experimental|14C-APD421|
89689655|NCT05583201|Experimental|KD-496 cell infusion|Each subject will receive KD-496 cell infusion
89689656|NCT04367597|Experimental|Active NMES|
89689657|NCT04367597|Sham Comparator|Modified NMES sham|
89689658|NCT02881996|Experimental|IV tylenol|Post-operatively, all patients will be placed on a standard patient/nurse controlled analgesia (PCA) according to our pain service protocol which included ketorolac. A 3 hours after first dose of ketorolac, patients in the acetaminophen arm will then receive scheduled 10mg/kg of IV acetaminophen every 6hrs for a total of 3 days in between doses of ketorolac. PCA Pumps will be discontinued with the return of bowel function and transition to oral intake in all patients as per the current protocol. If a patient in the acetaminophen arm is transitioned off of PCA prior to 3 days, IV acetaminophen will be stopped at that time as well. Patients in the control group only may receive oral/rectal acetaminophen as needed for treatment of fevers.
89689659|NCT02881996|Active Comparator|No IV tylenol|Same as above without IV tylenol.
89689660|NCT04367831|Experimental|Intervention arm: intermediate-dose anticoagulation|"If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily or unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1-0.3 U/mL.~If eGFR <30 mL/min or acute kidney injury or CRRT: Unfractionated heparin infusion at 10 units/kg/hour (minimum 500 units/hour if CRRT) with goal anti-Xa 0.1-0.3 U/mL"
89220775|NCT02742246|No Intervention|Standard treatment as usual (TAU)|This is the regular treatment a participant would normally receive at the clinic and generally includes individual and/or group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as teaching about the treatment program, teaching important ideas about recovery, increasing knowledge about specific problems participants may have with addiction and/or demonstrating new ways of coping with skills designed to fit their lifestyle. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
89220776|NCT02742246|Active Comparator|Individual clinician-provided CBT|This is individual treatment provided by a trained Cognitive Behavioral Therapy (CBT) clinician who will focus on teaching skills to understand and change participants behaviors to help them avoid alcohol use. Sessions with the clinician will generally last for 1 hour one time per week for 8 weeks. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
89220777|NCT02742246|Experimental|CBT4CBT|In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on. The CBT4CBT program will cover the same skills as the individual clinician-provided CBT, only here it will be done by a computer. Participants will be taught how to use the computer program by a staff member and will be asked to spend about 8 hours using the program (approximately one hour per week) at the clinic.Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
89220778|NCT02733042|Experimental|Arm A: Durvalumab + Lenalidomide ± Rituximab|"Participants assigned to Arm A will receive:~Durvalumab 1500 mg intravenous (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and~Lenalidomide orally at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 of:~Cycles 1 through 13 in indolent non-Hodgkin's lymphoma (NHL) or~All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL~Rituximab 375 mg/m² IV infusion every week in Cycle 1 (Days 2, 8, 15, 22) and on Day 1 of Cycles 2 through 5.~All treatment cycles were 28 days."
89220779|NCT02733042|Experimental|Arm B: Durvalumab + Ibrutinib|"Participants assigned to Arm B will receive:~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13~Ibrutinib orally at assigned dose levels (280 mg, 420 mg, or 560 mg) once daily until disease progression, unacceptable toxicity or discontinuation for any other reason.~All treatment cycles were 28 days."
89220780|NCT02733042|Experimental|Arm C: Durvalumab + Rituximab ± Bendamustine|"Participants assigned to Arm C will receive:~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13~Rituximab 375 mg/m² IV infusion on Day 2 of Cycles 1 through 6 (for CLL the rituximab dose will be 375 mg/m² Cycle 1 first dose and 500 mg/m² for each subsequent dose)~Bendamustine IV infusion at assigned dose levels (70 mg/m² or 90 mg/m²) on Days 1 and 2 of Cycles 1 through 6.~All treatment cycles were 28 days."
89220781|NCT02733042|Experimental|Arm D: Durvalumab Monotherapy|Participants assigned to Arm D will receive durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13. All treatment cycles were 28 days.
89220782|NCT02725619|Experimental|Cognitive-Behavioral Therapy (CBT)|CBT is dedicated to developing coping skills for managing anxiety such as emotion regulation and cognitive reappraisal. Children first learn and practice these skills during one-on-one, weekly sessions with experienced therapists and then apply this skills to navigate anxiety-producing situations as home, school and community. A key component of CBT involves exposure exercises, facing feared situations repeatedly while using the emotion regulation skills and remaining in the situations until anxiety is substantially reduced or become easy to tolerate. The feared situations are ordered from least to most distressing during therapy sessions in collaboration with the child and their parent. The unique combination of anxiety and ASD symptoms of social impairment and restricted/repetitive behavior is addressed in dedicated child and parent modules.
89220783|NCT02725619|Active Comparator|Psychoeducation and Supportive Therapy (PST)|"Psychoeducation and Supportive Therapy includes learning about and discussing issues of diagnosis, treatment and educational services can also benefit children with ASD and their families. Each PST session starts with a review of events of the past week and include queries of topics such as school, interests, and family with an overarching goal of enhancing subjective well-being. The clinician, through the use of supportive, empathic and nondirective actions, will provide the participant with a sounding-board so that they can voice their concerns regarding specific problems that may require discussion and assistance. A major objective is to provide a clinical contact that enables participants to think through and discuss their concerns with a sympathetic adult. Subjects randomized to PST will be offered CBT after completion of the endpoint assessments."
89220784|NCT02723721|Experimental|Picato gel|application on1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
89220785|NCT02709278|Other|Group 1A: low dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^3 cfu by the aerosol inhaled route, followed by bronchoscopy.
89220786|NCT02709278|Other|Group 1B: medium dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
89220787|NCT02709278|Experimental|Group 1C: standard dose aerosol BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
89220788|NCT02709278|Experimental|Group 1D: standard dose intradermal BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
89220789|NCT02709278|Other|Group 2A: lower than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
89220790|NCT02709278|Other|Group 2B: close to the standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^5 cfu by the aerosol route, followed by bronchoscopy.
89220791|NCT02709278|Other|Group 2C: higher than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^6 cfu by the aerosol inhaled route, followed by bronchoscopy.
89220792|NCT02709278|Experimental|Group 2D: close to or higher than standard aerosol BCG|3 volunteers receiving 1 x 10^7 cfu aerosol inhaled BCG Bulgaria (InterVax), followed by bronchoscopy 14 days later
89220793|NCT02709278|Experimental|Group 2E: close to or higher than standard intradermal BCG|9 volunteers receiving the optimal dose of aerosol inhaled BCG Bulgaria (InterVax) identified from preliminary results obtained from Groups 2C and 2D, and ID saline placebo, followed by bronchoscopy 14 days later
89220794|NCT02709278|Experimental|Group 2F: 1 log lower than Group 2E|12 volunteers will receive aerosol inhaled saline placebo and intradermal BCG Bulgaria (InterVax), at a dose a log lower than 2E then bronchoscopy and punch biopsy
89220795|NCT02704416|No Intervention|Control arm|Control arm - continued implanted cardioverter defibrillator therapy
89220796|NCT02704416|Active Comparator|Intervention Arm|ablation of areas of fragmented signal in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy
89220797|NCT02704416|Other|Single Cross Over Arm|these patients were initially assigned to the control arm of the study. When these patients met the primary outcome of the study it is allowed for these patients to be included in the intervention arm and/or to start quinidine
89220798|NCT02703545||Peutz-Jeghers syndrome|
89220799|NCT02703545||Familial pancreas cancer|"at least 2 close relatives affected with pancreas cancer on same side of family~first degree relative and 1 second degree relative(1st degree link) or~first degree relatives or~1 first degree relative and 2 or more second degree relatives"
89220800|NCT02703545||Germline mutation Carrier 10 % risk|BRCA2 mutation carrier with family history of pancreas cancer or, PALB2 mutation carrier or, FAMMM (p16/CDKN2A) mutation carrier
89220801|NCT02703545||Germline mutation carrier 5 % risk|BRCA1 mutation carrier with family history of pancreas cancer or, HNPCC (Lynch Syndrome) with family history of pancreas cancer or, ATM gene mutation
89220802|NCT02703545||Hereditary pancreatitis|PRSS1, PRSS2, CTRC gene mutations
89220803|NCT02690402|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
89220804|NCT02689427|Experimental|Treatment (enzalutamide, paclitaxel)|"Patients receive enzalutamide PO daily on days 1-7 and paclitaxel IV over 2 hours on day 1. Treatments repeat every 7 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: After 12 cycles of therapy, patients undergo surgical resection of primary tumor with or without lymph node biopsy or complete axillary dissection."
89220805|NCT02686528|Experimental|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
89220806|NCT02686528|Active Comparator|Hip Precautions|Patients will receive the following hip precautions: no hip flexion past 90º, no crossing the legs, and no twisting at the waist for the first six weeks after surgery.
89220807|NCT02673931|Experimental|GLP-1|"700 patients will be randomized to GLP-1, that will be administered as follows:~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes. A set dose of 17.4 microg will be given."
89220808|NCT02673931|Placebo Comparator|Placebo|"20% Human Albumin is given as placebo. 700 patients will be randomized to placebo, that will be administered as follows:~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin.~The placebo infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes at the same rate as the study drug."
89220809|NCT02673931|Experimental|Restrictive Oxygenation|"The intervention is FiO2 of 50%, given as 'Conoxia (AGA, oxygen)'. 700 patients will be randomized to a FiO2 of 50% as long as the arterial O2 saturation (Sa02) remains above 91% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after~a maximum of 1 hours of intervention or~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
89220810|NCT02673931|Active Comparator|Liberal Oxygenation|"The intervention is a FiO2 of 100%, given as 'Conoxia (AGA, oxygen)'. 700 patients will be randomized to a FiO2 of 100% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after~a maximum of 1 hours of intervention or~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
89220811|NCT02663297|Experimental|ATLCAR.CD30 cells|"Three dose levels of ATLCAR.CD30 cells will be evaluated. Using the modified continual reassessment method (CRM), initial cohort of size two will be enrolled at each dose level after that subjects are enrolled one at a time until a minimum of 12 patients is treated. Each patient will receive one injection according to the dosing schedules listed below. Investigators will start with the lowest cell dose (2X10^7 cells/m^2) given to patients in one of our previous trials employing CAR-T cells including the CD28 costimulatory endodomain, and investigators will escalate the cell dose to the highest cell dose (2X10^8/m^2) given in the same trial.~Note: Initially, only adults will be enrolled during the dose escalation phase of the study. Once a dose level has been tested in at least 2 adults without the occurrence of dose limiting toxicities (DLTs), children may then be enrolled on that dose level according to the CRM."
89220812|NCT02654561|Placebo Comparator|Saline|
89220813|NCT02654561|Experimental|Heparin|If severe sepsis with suspected DIC is diagnosed, the Heparin sodium(2ml:12500 units) will be administered intravenously continuously for 24 hours. The course of treatment will last 7 days or until the death or discharge.
89220814|NCT02614066|Experimental|Phase 1: 2 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with relapsed or refractory B-precursor acute lymphoblastic leukemia (r/r B-ALL) will receive conditioning chemotherapy (fludarabine 25 mg/m^2 intravenously [IV] over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel (KTE-X19) chimeric antigen receptor (CAR) transduced autologous T cells at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing > 100 kg, a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells/kg of body weight will be administered.
89220815|NCT02614066|Experimental|Phase 1: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 1 x 10^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing > 100 kg, a maximum flat dose of 1 x 10^8 anti-CD19 CAR T cells/kg of body weight will be administered.
89220816|NCT02614066|Experimental|Phase 1: 0.5 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 0.5 x 10^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing > 100 kg, a maximum flat dose of 0.5 x 10^8 anti-CD19 CAR T cells/kg of body weight will be administered.
89220817|NCT02614066|Experimental|Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 1 x 10^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing > 100 kg, a maximum flat dose of 1 x 10^8 anti-CD19 CAR T cells/kg of body weight will be administered.
89220818|NCT02600949|Experimental|Cohort A (personalized vaccine, imiquimod)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients then receive imiquimod cream topically in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.
89220819|NCT02600949|Experimental|Cohort B (personalized vaccine, imiquimod, pembrolizumab)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab IV over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.
89220820|NCT02600949|Experimental|Cohort C and D (vaccine, imiquimod, pembrolizumab, APX005M)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 9, 12, 15, 18, 21, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab IV over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Beginning about 1 hour after each vaccine, patients also receive sotigalimab IV over 60 minutes on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and weeks 6,12, and 24, then every 3 months, and at week 39.
89220821|NCT02599324|Experimental|Cohort 1: Renal Cell Carcinoma (RCC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of everolimus to determine the recommended phase 2 dose (RP2D) of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in phase 1b in combination with everolimus."
89220822|NCT02599324|Experimental|Cohort 2: Urothelial Carcinoma (UC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of paclitaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with paclitaxel."
89220823|NCT02599324|Experimental|Cohort 3: Gastric Adenocarcinoma (GA or GC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of docetaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel."
89220824|NCT02599324|Experimental|Cohort 4: Colorectal Adenocarcinoma (CRC)|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of cetuximab to determine RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab."
89220825|NCT02599324|Experimental|Cohort 5: Urothelial Carcinoma (UC) Ibrutinib|"Phase 1b: Participants receive ibrutinib at various dose levels to determine the RP2D of ibrutinib.(The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b."
89220826|NCT02599324|Experimental|Cohort 6: Urothelial Carcinoma (UC) With Pembrolizumab|"Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of pembrolizumab to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.)~Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab."
89220827|NCT02586831|Experimental|Arm A|"Participants in this group will receive Thymoglobulin, Aldesleukin, Adalimumab, and Exenatide over a period of 52 weeks.~Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg (2 infusions, 0.5 and 2mg/kg) Days 1 and 2~Adalimumab (Humira®) will be administered at a dose of 50 mg every month, for 1 year~Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®) will be administered 1 million IU/dose; 5 consecutive days (days 10-14), & then every 2 weeks, for 52 weeks~Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks."
89220828|NCT02586831|Placebo Comparator|Arm B|Participants in this group will receive the placebos for Thymoglobulin, Aldesleukin, Adalimumab, Exenatide, and Neulasta over a period of 52 weeks.
89220829|NCT02504866|Experimental|Aerobic Exercise Intervention (AET)|Participant with traumatic brain injury performed aerobic exercise on an elliptical trainer at a vigorous intensity for 30 minutes three times a week for 12 weeks
89220830|NCT02504866|Experimental|Rapid-Resistive Exercise Intervention (RET)|Participant with traumatic brain injury performed rapid reciprocal exercise on an elliptical trainer at light to moderate intensity for 30 minutes three times a week for 12 weeks
89220831|NCT02504866|No Intervention|Waitlist Control (CON)|Participant with traumatic brain injury were waitlisted and did not perform any exercise intervention in the first 12 weeks. They were randomized to either AET or RET after the initial 12 weeks
89220832|NCT02502162|Experimental|LDN|Naltrexone HCL, 4.5 mg, Once a day.
89220833|NCT02502162|Placebo Comparator|Placebo|Sugar pill
89220834|NCT02497677|Experimental|Circle of Security-Parenting|Circle of Security-Parenting (COS-P) is a brief educative group program for parents
89220835|NCT02497677|Active Comparator|Care as Usual (CAU)|Care as usual (CAU) i.e. the active control condition will be standard practices for infants and families at risk in Copenhagen.
89220836|NCT02494115|Experimental|subcutaneous drainage|This local treatment consists in inserting in lower limbs several catheters draining into enclosed bags in order to evacuate lymph fluid and to lower local pressure.
89220837|NCT02488720||Clinically normal older inviduals|500 clinically normal older individuals with florbetapir positron emission tomography (PET) scan that does not show evidence of brain amyloid pathology at screening.
89689661|NCT04367831|Active Comparator|Control arm: prophylaxis|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~BMI < 40 kg/m2: Enoxaparin 40 mg SC daily~BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~BMI > 50 kg/m2: Enoxaparin 60 mg SC q12h~If eGFR < 30 mL/min or acute kidney injury:~50-120 kg: Unfractionated heparin 5000 units SC q8h~>120 kg: Unfractionated heparin 7500 units SC q8h~If CRRT: Unfractionated heparin infusion pre-filter at 500 units/hour"
89220838|NCT02459769|Active Comparator|Dyadic Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed to both cancer survivors and their caregivers (daily walking and 3 times/week resistance prescription for 6 weeks). Cancer survivor and caregiver are also asked to discuss ways they can support one another in a) remaining adherent to exercise, and b) dealing with stress, including LGBT-specific minority stress.
89220839|NCT02459769|Other|Individual Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed solely to cancer survivors (daily walking and 3 times/week resistance prescription for 6 weeks). The caregiver is told not to change his/her exercise behavior in any way.
89220840|NCT02434744|Experimental|Cohort 1 100 mg KD026 BID|100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks
89220841|NCT02434744|Experimental|Cohort 2 150 mg KD026 BID|150 mg KD026 BID in combination with Metformin for 12 weeks
89220842|NCT02434744|Experimental|Cohort 3 200 mg KD026 BID|200 mg KD026 BID in combination with Metformin for 12 weeks
89220843|NCT02434744|Experimental|Cohort 4 100 mg KD026 TID|100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks
89220844|NCT02434744|Placebo Comparator|Cohort 1 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
89220845|NCT02434744|Placebo Comparator|Cohort 2 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
89220846|NCT02434744|Placebo Comparator|Cohort 3 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
89220847|NCT02434744|Placebo Comparator|Cohort 4 Placebo|Matched Placebo Dose TID in combination with Metformin for 12 weeks
89220848|NCT02432417|No Intervention|Standard|Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.
89689662|NCT02243891|Active Comparator|Control|Atrial fibrillation ablation only
89689663|NCT02243891|Experimental|ROX Coupler|Atrial fibrillation ablation with concurrent ROX Coupler insertion
89689664|NCT03051646|Experimental|Acetylsalicylic acid first, placebo second|Participant is administered acetylsalicylic acid one hour prior to exercise.
89689665|NCT03051646|Placebo Comparator|Placebo oral capsule first, ASA second|Participant is administered placebo one hour prior to exercise.
89689666|NCT02243969|Experimental|flaxseed oil (rich in α-linolenic acid )|
89689667|NCT02243969|Placebo Comparator|high oleic sunflower oil|
89689668|NCT05193981||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
89689669|NCT03110458|Experimental|SENS-111 100mg|SENS-111 100mg: 2 Oral Dispersible Tablets (1 SENS-111 100 mg and 1 placebo)
89689670|NCT03110458|Experimental|SENS-111 200mg|SENS-111 200mg: 2 Oral Dispersible Tablets (SENS-111 100 mg)
89689671|NCT03110458|Placebo Comparator|Placebo|Placebo: 2 placebo Oral Dispersible Tablets
89689672|NCT04361357|Experimental|Experimental group|whey protein powder was added on the basis of standardized enteral nutrition preparation.
89689673|NCT04361357|No Intervention|Control group|standardized enteral nutrition preparation only.
89689674|NCT04344405|Experimental|Vit D|
89689675|NCT04344405|Active Comparator|control|
89689676|NCT02993302|Active Comparator|PTU-Oral 1α-D3|patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
89689677|NCT02993302|Placebo Comparator|PTU-Placebos|patients were given placebo tablets for 8 weeks in addition topropylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
89689678|NCT03052972|Experimental|Amyloid Positive|Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan
89689679|NCT03052972|Experimental|Amyloid Negative|Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan
89220849|NCT02432417|Experimental|Experimental arm|"Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.~In addition this treatment will be combined with a daily intake of the recommended phase two dose (RPTD) of chloroquine (CQ)."
89220850|NCT02390895|Experimental|Minimally-invasive endoscopic repair|endoscopic repair of myelomeningocele before 26 SA
89220851|NCT02369016|Experimental|Copanlisib (BAY 80-6946)|patients with rituximab-refractory iNHL
89220852|NCT02363959|Experimental|Hyperbaric Oxygen, Airway Biopsy|"The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.~During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure."
89220853|NCT02363959|Other|No Hyperbaric Oxygen, Airway Biopsy|No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
89220854|NCT02317887|Experimental|Group 1|1e9 vg/eye
89220855|NCT02317887|Experimental|Group 2|1e10 vg/eye
89220856|NCT02317887|Experimental|Group 3|1e11 vg/eye
89220857|NCT02317887|Experimental|Group 4|1e11 vg/eye
89220858|NCT02317887|Experimental|Group 5|Not to exceed 3e11 vg/eye
89220859|NCT02317887|Experimental|Group 6|Not to exceed 6e11 vg/eye
89220860|NCT02316886|Experimental|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) +Optimal Medical Treatment
89220861|NCT02316886|Active Comparator|Optimal Medical Treatment|Optimal Medical Treatment
89220862|NCT02316314||Individuals diagnosed with FRDA|Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
89220863|NCT02316314||Healthy controls|Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
89220864|NCT02288221|Experimental|With non pharmacological therapeutic|Installation of ICT at patient's home
89220865|NCT02288221|Active Comparator|Without non pharmacological therapeutic|No change at patient's home
89220866|NCT02276573|Experimental|Oral lichen planus disease|buccal cavity sample
89220867|NCT02252237||Children with glucocorticoids|Children receiving Prednisone or Prednisolone or Methylprednisolone Pharmacokinetic
89220868|NCT02250352||Cohort I (newly diagnosed, surgery before systemic therapy)|Patients undergo baseline and, if applicable, follow-up core needle biopsies of breast cancer in the breast, regional nodes, and distant metastases. Patients who experience a recurrence or progression after therapy undergo additional core biopsies at the time of recurrence. Clinical and blood specimens will also be gathered.
89220869|NCT02250352||Cohort II (newly diagnosed, systemic therapy before surgery)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients also undergo biopsies at a specific time point following the initiation of standard systemic therapy.
89220870|NCT02250352||Cohort III (patients with suspicious breast mass)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients who have BIRADS 4b, 4c, and 5 lesions may undergo up to 6 additional 6 core biopsies.
89220871|NCT02250352||Cohort IV (breast cancer recurrence or progression)|Patients undergo core biopsy, clinical, and blood sample collection as in Cohort I. Patients may also undergo 1-3 extra core biopsies.
89220872|NCT02239783||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
89220873|NCT02238301|Other|"Patients test (pregnant women with a eutrophic fetus)"|Test the type of mask, oxygen flow and duration of oxygenation, adjustment of MRI machine Adjustment of MRI machine (choice of antenna calibration, verifying Settings of each sequence, adaptation of the number of cuts for the duration of each sequence, checking the correct execution of the succession of sequences, settings of total examination time)
89220874|NCT02238301|Active Comparator|Pregnant women with a diagnosis of IUGR fetuses|Measure of the BOLD effect in the feto-placental units of IUGR fetuses
89220875|NCT02238301|Active Comparator|Pregnant women with eutrophic fetuses|Measure of BOLD effects of fetal-placental unit eutrophic fetuses
89220876|NCT02231723|Experimental|A: BBI608 in combination with Gemcitabine and nab-Paclitaxel|
89220877|NCT02231723|Experimental|B: BBI608 in combination with modified FOLFIRINOX|
89220878|NCT02231723|Experimental|C: BBI608 in combination with FOLFIRI|
89220879|NCT02231723|Experimental|D: BBI608 in combination with MM-398, 5-FU and leucovorin|
89220880|NCT02199145|Other|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria /creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
89220881|NCT02198404|Experimental|sedation with propofol|propofol injection: induction with propofol at 20 mg/kg/h. When patient is sleeping, the dosage is deceased to 6 mg/kg/h
89220882|NCT02150889|No Intervention|Lean Trained|Metabolic control
89220883|NCT02150889|Experimental|Obese or Overweight|Running Program Yoga Program
89220884|NCT02131597|Experimental|Treatment (guadecitabine)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 4-8 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 3 courses are taken off therapy after 6 courses. Patients may continue to receive treatment after 24 courses if the investigator determines it is in the patient's best interest.
89220885|NCT02108054|Experimental|1|People with alcohol use disorder
89220886|NCT02108054|Experimental|2|People without alcohol use disorder
89220887|NCT02104349|Experimental|Mindfulness meditation|Subjects who are instructed on use of the mindfulness meditation technique
89220888|NCT02104349|No Intervention|Control|Subjects will receive standard surgery treatment without any mindfulness intervention.
89220889|NCT01969968|Other|sleeve bariatric surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy
89220890|NCT01969968|Other|morbidly obese adults with by pass surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass
89220891|NCT01969968|Other|non obese|non obese patients
89220892|NCT01965184|Experimental|Cognitive-Behavioral Therapy for Anger and Aggressive Behavior|CBT is a behavioral intervention that consists of 12 weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
89220893|NCT01965184|Active Comparator|Supportive Psychotherapy (SPT)|SPT consists of 12 sessions that are focused on discussing peer relationships and family functioning with a goal of enhancing subjective well-being
89220894|NCT01931709|Experimental|Diagnostic (FDG PET and DCE-MRI)|Patients undergo FDG PET and DCE-MRI 1-2 weeks prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery).
89220895|NCT01834755|Other|single arm|Evaluation of psychological phenotype with several questionnaire (Big Five, EPADV-16), physical activity with a self-administered questionnaire (Baecke) and several test ( SPPB, Handgrip Strengh test, MicroFET 2 Digital Dynamometer)
89220896|NCT01774240|No Intervention|before|no systematic approach
89220897|NCT01774240|Experimental|after|systematic screening and treatment of delirium
89220898|NCT01765218|Placebo Comparator|Placebo|Subjects will receive the standard of care intervention for HIE at our institution (whole body cooling for 72h followed by gradual rewarming)
89220899|NCT01765218|Active Comparator|Topiramate|In addition to whole body cooling, infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
89220900|NCT01756040|Other|Lactulose - rhamnose solution|Preterm Infants age 24-32 weeks gestation
89220901|NCT01701284|Experimental|Right-Sided Low-Frequency rTMS|Participants will have rTMS administered at 1Hz to the right dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
89220902|NCT01701284|Experimental|Left-Sided High-Frequency rTMS|Participants will have rTMS administered at 10Hz to the left dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
89220903|NCT01698892|Experimental|I.V. sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation
89220904|NCT01698892|Active Comparator|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
89220905|NCT01685541|Experimental|Maximum AVS Content|AVS includes patient name, visit date, chief complaining, allergies, immunizations, vital signs, medications, problem list, lab order, physician contact information, referrals, instructions
89220906|NCT01685541|Experimental|Intermediate AVS content|AVS includes patient name, visit date, vital signs, medications, diagnosis, problem list, physician contact information, referrals, instructions
89220907|NCT01685541|Experimental|Minimum AVS content|AVS contains patient name, visit date, medications, diagnosis, physician contact information, referrals, instructions
89220908|NCT01685541|Active Comparator|Control Group (Usual AVS)|Content differed by clinic site
89220909|NCT01631851|Experimental|Cognitive behavior therapy|
89220910|NCT01550861|Experimental|In vitro Maturation|in vitro maturation of immature oocytes
89220911|NCT01500473|Experimental|Females with CCHS > 16 years old on desogestrel|open label studied on drug.
89220912|NCT01459510|Experimental|multi media intervention|Play Nicely Program
89220913|NCT01459510|No Intervention|Routine primary care|Routine primary care
89220914|NCT01371929||ICU patients who become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected to develop sepsis, severe sepsis, or septic shock.
89220915|NCT01371929||ICU patients who do not become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected NOT to develop sepsis, severe sepsis, or septic shock.
89220916|NCT01326182|Experimental|MAADRE|Group-based intervention combining asthma education and cognitive behavioral treatment for depressive symptoms
89220917|NCT01326182|Active Comparator|MAAS|Group-based treatment combining asthma education and general information regarding child health
89220918|NCT01321216||Hospitalized Gastroenteritis|Children under 5 years of age hospitalized with gastroenteritis
89220919|NCT01306357||Zomacton® with Zomajet® needle-free device|Zomacton® 4 mg delivered by percutaneous transjection (needle-free) using the Zomajet® 2 Vision device or Zomacton® 10 mg delivered by percutaneous transjection (needle-free) using the Zomajet® Vision X needle-free device.
89220920|NCT01219075|Experimental|Arm I|Patients receive oral soy isoflavones supplement once daily for 12 months in the absence of disease progression.
89220921|NCT01219075|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 12 months in the absence of disease progression.
89220922|NCT00929214|Experimental|Standard Therapy + Local Therapy|Systemic Standard Therapy (chemotherapy and/or endocrine therapy) + Local Therapy (surgery and/or radiation)
89220923|NCT00871936|Experimental|1|SLx-4090 in combination with Metformin
89220924|NCT00871936|Other|2|Placebo
89220925|NCT00810979|Experimental|1|SLx-4090 dose #1 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
89220926|NCT00810979|Experimental|2|SLx-4090 dose #2 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
89220927|NCT00810979|Other|3|Placebo in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
89220928|NCT00741910|Experimental|1|Semapimod 60 mg IV q 6 - 10 weeks
89220929|NCT00567684|Experimental|CTU + IVU|CTU = Computed Tomography Urography + IVU = Intravenous Urography
89220930|NCT00563082||1|SLE participants positive for both APA and CHD
89220931|NCT00563082||2|Normal participants with a high titer of APA
89220932|NCT00562614|Experimental|1|SLx-2101
89220933|NCT00562614|Placebo Comparator|2|Comparative Placebo Dose
89220934|NCT00562575|Experimental|1|SLx-4090
89220935|NCT00562575|Placebo Comparator|2|Matching Placebo Dose
89220936|NCT00528242|Experimental|1|SLx-2101
89220937|NCT00528242|Placebo Comparator|2|Matching Placebo Dose
89220938|NCT00483249|Experimental|Interventional|Endovascular Branched Stent-Graft: The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents).
89220939|NCT00341679||Family Members|Family members need to be blood relatives of the proband with the diagnosis of an autoimmune disease
89220940|NCT00341679||IIM Patient|Adult and pediatric patients with diagnosis of myositis or a related autoimmune or rheumatic disorder (by Bohan and Peter criteria, American College of Rheumatology, or other criteria).
89220941|NCT00341679||Normal volunteers|gender and race-matched to a subset of autoimmune subjects as controls. Should be without any autoimmune disease.
89220942|NCT00931424|Experimental|reconstruction|patients in this group will have both valve reconstruction and superficial vein surgery
89220943|NCT00931424|No Intervention|unreconstruction|patients in this group will only have superficial vein surgery
89220944|NCT00930488||Group 1|
89220945|NCT04063943|Experimental|Sidus Stem-Free Total Shoulder|This arm will include all subjects who are implanted with the Sidus Stem-Free Total Shoulder Arthroplasty System
89220946|NCT00736931|Experimental|1|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
89220947|NCT00736931|Active Comparator|2|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
89220948|NCT00736931|Active Comparator|3|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
89220949|NCT00736931|Placebo Comparator|4|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
89220950|NCT00737087|Other|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
89220951|NCT04064099|Experimental|Rugby Players|Rugby player will be given custom-fitted mouthguards to be worn for 6-month
89220952|NCT00567164|Experimental|Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) intended treatment with one tablet daily of BAY86-5300 (SH T00186D) followed by a 4-day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred between days 25 to 120 of the treatment cycle, a 4-day tablet-free interval was advised. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment
89220953|NCT00567164|Experimental|Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) uninterrupted treatment with one tablet daily of BAY86-5300 (SH T00186D) and a 4-day tablet-free interval. Subjects were permitted to schedule their withdrawal bleeding (ie, 4-day tablet-free interval) at any time between days 25 to 120 of the cycle. Subjects had the option to follow the bleeding rules of the flexible (extended) regimen no. 1 of BAY86-5300. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
89220954|NCT00567164|Active Comparator|Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets of BAY86-5300 (YAZ, SH T00186D) followed by 4 days of tablets without active substance (together resulting in one cycle of 24+4 standard treatment). 13 withdrawal bleeding episodes during one year of treatment were expected.
89220955|NCT00920933|Experimental|AIN457|
89220956|NCT00920933|Placebo Comparator|Placebo|
89220957|NCT00920933|Active Comparator|oral corticosteroid|
89220958|NCT00930566|Experimental|Extracorporal Photopheresis|
89220959|NCT00737165|Experimental|Multimodal community intervention|Multimodal suicide prevention program
89220960|NCT00737165|Active Comparator|Community intervention as usual|Suicide prevention program as usual
89220961|NCT00925730|Experimental|Pimecrolimus cream 1%|Pimecrolimus
89220962|NCT00925808||Unsuspected VTE|Prevalence of unsuspected VTE in oncology patients on routine staging CT scans of the thorax, abdomen and pelvis
89220963|NCT00925886|Experimental|Acrysof Toric intraocular lens|A One piece, acrylic intraocular lens is implanted in the lens bag.
89220964|NCT00713219|Experimental|1|CHEMORADIATION
89220965|NCT03699644||Healthy Control|Healthy controls will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all healthy controls will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
89220966|NCT03699644||Alzheimer's Dementia|Subjects with Alzheimer's Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all subjects with Alzheimer's Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
89220967|NCT03699644||Frontotemporal Dementia|Subjects with Frontotemporal Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, subjects with Frontotemporal Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
89220968|NCT00931580|Placebo Comparator|Placebo|placebo tablet
89220969|NCT00931580|Experimental|400 IU|Vitamin D3 tablet, 400 IU
89220970|NCT00931580|Experimental|1,000 IU|Vitamin D3 tablet, 1,000 IU
89220971|NCT00931580|Experimental|2,000 IU|Vitamin D3 tablet, 2,000 IU
89220972|NCT00931580|Experimental|4,000 IU|Vitamin D3 tablet, 4,000 IU
89220973|NCT00930800|Other|Exercise|Dance Dance Revolution (DDR)
89220974|NCT00930878||Promus|Patients intended to be treated with a Promus™ stent system
89220975|NCT00930878||Endeavor|Patients intended to be treated with an Endeavor™ stent system (excluded the Endeavor™ Resolute™ stent)
89220976|NCT00930878||Cypher|Patients intended to be treated with a Cypher™ stent system
89220977|NCT00925964||Patients exposed|Patients with Systolic Pressure Index <0,9 ou >1,4.
89220978|NCT00925964||Patients not exposed|Patients with Systolic Pressure Index >0,9 ou <1,4.
89220979|NCT00931736|Active Comparator|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
89220980|NCT00931736|Active Comparator|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
89220981|NCT00926042||Healthy Control|Healthy control group for research on autoimmune diseases
89220982|NCT00930956|Active Comparator|Dextrose|30 g of carbohydrate via Sun-Dex OGTT beverage
89220983|NCT00930956|Experimental|RS Type 2|30g Resistant Starch Type 2 (Hi-Maize 260, National Starch)
89220984|NCT00930956|Experimental|RS Type 4 (cross linked)|30g of cross linked RS type 4 (Fibersym RW, MGP Ingredients, Inc.)
89220985|NCT00931034|Active Comparator|South Beach Diet with SBD Products|
89220986|NCT00931034|Active Comparator|ADA Diabetes meal plan|
89220987|NCT02567981|Experimental|21 micronutrient fortified supplement|21 micronutrient-fortified supplement
89220988|NCT02567981|Active Comparator|Current Standard of Nutritional Care|Cereal Fortificado (Fortified Cereal) Ferrous sulphate Vitamin A
89220989|NCT00931814|Other|exercise|
89220990|NCT05741567||transobturator cystocele repair by vaginal plastron|patients who underwent surgery using the transobturator repair by vaginal plastron for correction of anterior prolapse
89220991|NCT00931112|Other|exercise|
89220992|NCT00926120|Experimental|Mogroside sweetener|All subjects will received Mogroside. Mogroside sweetener administered at a dosage level of 5 g every 6 hours for 14 days.
89220993|NCT00737555|Experimental|1|Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
89220994|NCT00932048|No Intervention|Control|
89220995|NCT00932048|Experimental|Atorvastatin|
89220996|NCT04015778|Experimental|Nivolumab Mono|In arm A, 24 participants will be enrolled into this arm according to PD-L1 expressing level (≥50%).Arm A consists of 3 cycles of neoadjuvant nivolumab (240mg every 2 weeks), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
89220997|NCT04015778|Experimental|Nivolumab Plus Chemo|In arm B, up to 12 participants will be enrolled into each subgroup according to PD-L1 expressing level (<1% and 1%-49%).arm B consists of 3 cycles of neoadjuvant nivolumab (360mg every 3 weeks) with nab-paclitaxel and carboplatin(nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every three weeks ), and adjuvant nivolumab (240mg IV, over 30 min, every 2 weeks) up to 12 months
89220998|NCT02568293|Experimental|SBCV|SBCV is administered to the site immediately post balloon dilation.
89220999|NCT02568293|Placebo Comparator|Control|Saline is used as a control and is delivered immediately post balloon dilation.
89221000|NCT00926276|Active Comparator|Surgical Treatment Group-Fundoplication|Re-evaluated 1 month post-op Re-evaluated 2 months post-op
89221001|NCT00926276|Active Comparator|Medical Therapy|Treated by primary clinician for GERD Re-evaluated 1 month Proceed to Fundoplication if GERD persist by pH-MII Re-evaluated at 2 months (1 month post-op) Worsening BPD will be given option of immediate surgery
89221002|NCT05540873|Experimental|IL13Rα2 targeted CAR-T|
89221003|NCT00926354|Experimental|AS101 infusion|Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses.
89221004|NCT00926354|No Intervention|Control group|Twenty patients who developed thrombocytopenia during chemotherapy course will be treated according to standard of care and will not receive the investigational product. Their medical condition will be followed and a complete blood count will be performed routinely once weekly.
89221005|NCT00926432|Other|Healthy volunteers|Small group of aged healthy volunteers
89221006|NCT00926432|Other|Patients|Patients consulting for spine disorders that may or may not have postural troubles
89221007|NCT00921011||Perimenopausal women|Women at the beginning stages of menopause
89221008|NCT00712985|Experimental|Zometa (Zoledronic Acid) X 1 dose|Zometa (Zoledronic Acid) 5 mg IV X 1 dose
89221009|NCT00926510|Experimental|Language Toolkit|Language toolkit composed of simple tools that parents can use to interact with child and help language acquisition.
89221010|NCT00926510|Placebo Comparator|2|Safety counseling and smoke detector
89221011|NCT00737789|Experimental|Mesalazine once/day|Participants received 4g oral Mesalazine once a day (2 sachets of prolonged release granules) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral mesalazine 2g once daily (1 sachet/day) for an additional 4 weeks (maintenance period).
89221012|NCT00737789|Active Comparator|Mesalazine twice/day|Participants received oral mesalazine 4 g per day in two divided doses (1 sachet prolonged release granules twice a day) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral Mesalazine 2g (one sachet) once a day for an additional 4 weeks (maintenance period).
89221013|NCT00700115|Experimental|Kaletra + Isentress|Kaletra + Isentress
89221014|NCT00700115|Active Comparator|Standard HAART|Pre-study Antiretroviral regimen
89522850|NCT01889303|Active Comparator|Arm A|"chemotherapy regimen:Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles → 5-FU 400 mg/m2 IV and Leucovorin 20 mg/m2 IV on the first four and the last three days of radiotherapy + RT 45Gy (5weeks)→ Rest for 4 weeks →Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles.~Radiation: concurrent chemoradiotherapy with 5-FU/CF.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
89221015|NCT04062929||Intervention|The investigators included 32 patients who participated to a monocentric 4-day program for secondary prevention in cardiovascular disease, between January 2017 and October 2018. Participation to the program was on a voluntary basis and individuals were referred by their own physician, cardiac rehabilitation center or spontaneously. Eligibility criteria included age 18 years and older, stable coronary artery disease with appropriate medical certificate of fitness and no current medical conditions affecting sports participation. Patients unable to give written constent, with impaired cognitive functions, chronic motor deficiency or severe medical disorder (other than heart disease) significantly affecting functional abilities and individuals with insufficient information about medical history of documented coronary disease were excluded.
89221016|NCT04062773|Experimental|TRF|Eating restricted to between midday and 6pm.
89221017|NCT04062773|Placebo Comparator|Normal timing of food intake.|Eating between 8am and 11pm.
89221018|NCT02568917|Active Comparator|Conventional Restoration|Conventional Restoration - Composite Resin (Bulk Fill)
89221019|NCT02568917|Experimental|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment - Ketac Molar Easy Mix
89221020|NCT00566852|Experimental|WBRT+Memantine|Whole brain radiation therapy (WBRT) and memantine
89221021|NCT00566852|Active Comparator|WBRT+Placebo|Whole brain radiation therapy (WBRT) and placebo
89221022|NCT00931346|Experimental|FTC/TDF Daily|Daily dosing
89221023|NCT00931346|Experimental|FTC/TDF Intermittent|Dosed intermittently
89221024|NCT00931346|Placebo Comparator|Placebo Daily|Placebo dosed daily
89221025|NCT00931346|Placebo Comparator|Placebo Intermittent|Placebo dosed intermittently, orally.
89221026|NCT00936650|Experimental|cinacalcet|
89221027|NCT00936650|Placebo Comparator|placebo|
89221028|NCT00442546|Experimental|1|
89221029|NCT00442546|Experimental|2|
89221030|NCT00442546|Placebo Comparator|3|
89221031|NCT00936806||Unilateral intracranial tumor|Subjects with unilateral intracranial tumor
89221032|NCT00936806||Control group|Subjects without intracranial pathology
89221033|NCT03545594|Experimental|Patient-centered in home rehabilitation|Eight contacts of about 2 hours duration each delivered over a 4-month period (Six in home visits and two telephone contacts before the Corona pandemic and adjusted to eight contacts and up to six of them video based when necessary during the Corona pandemic) in three phases:
89221034|NCT03545594|Active Comparator|Control|Usual follow-up assessment and health care and rehabilitation services provided in the municipality
89221035|NCT00936962|Experimental|Group 1 NeisVac C vaccine - 0 doses|NeisVac C (Meningococcal C) vaccine - 0 doses
89221036|NCT00936962|Experimental|Group 2 NeiscVac C - 2 doses|2 priming doses of NeisVac C vaccine at 2 and 4 mths of age
89221037|NCT00936962|Experimental|Group 3 NeiscVac C - 1 dose|1 priming dose of NeisVac C vaccine at 2 mths of age
89221038|NCT00514683|Experimental|dose 1|low dose BIBF1120 once daily
89221039|NCT00514683|Experimental|dose 2|low dose BIBF 1120 twice daily
89221040|NCT00514683|Experimental|dose 3|intermediate dose BIBF 1120 twice daily
89221041|NCT00514683|Experimental|dose 4|high dose BIBF 1120 twice daily
89221042|NCT00514683|Placebo Comparator|placebo|placebo
89221043|NCT00566696|Experimental|High-Risk Hematologic Malignancies|"Participants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.~Grafts from suitable haploidentical donors are processed using the CliniMACS system."
89221044|NCT00937196|Active Comparator|Histaminum hydrochloricum globuli|To allow double-blind administration of the placebo pills going along with verbal suggestions of a blood-pressure-lowering effect
89221045|NCT00937196|Experimental|Placebo globuli|
89221046|NCT00937196|No Intervention|No treatment|
89221047|NCT00937274|Experimental|Test product|
89221048|NCT00937274|Active Comparator|Commercial product|
89221049|NCT00937274|Placebo Comparator|Standard care|
89221050|NCT00926744|Experimental|Intervention|Physically inactive participants receiving both physical activity and dietary counseling
89221051|NCT00926744|No Intervention|Active|Physically active participants receiving only dietary counseling
89221052|NCT00926744|No Intervention|Control|Physically inactive participants receiving only dietary counseling
89061038|NCT03821246|Experimental|Cohort C (atezolizumab, tocilizumab)|Patients will receive one (1) cycle of neoadjuvant atezolizumab and one (1) cycle of tocilizumab, 6mg/kg will be administered IV on day 1 of a 14 day IV prior to RP; atezolizumab will be administered in an identical fashion as Cohort A. RP will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
89061039|NCT03806985|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
89061040|NCT03806985|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
89061041|NCT03806985|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
89061042|NCT03806985|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
89061043|NCT03806985|Experimental|High Dose Psilocybin/Low Dose Psilocybin|Subjects in this arm receive high dose psilocybin in the first session and low dose psilocybin in the second session.
89061044|NCT03806985|Experimental|Low Dose Psilocybin/High Dose Psilocybin|Subjects in this arm receive low dose psilocybin in the first session and high dose psilocybin in the second session.
89061045|NCT03793842|Experimental|Usual care then PEEP titration by Electrical Impedance Tomography (EIT)|Patients in the usual care first group will continue to receive mechanical ventilation according to the University of Michigan Acute Respiratory Distress Syndrome (ARDS) protocol high-PEEP arm
89061046|NCT03793842|Experimental|PEEP titration by EIT then usual care|Patients in the high PEEP titration by EIT first will have receive ventilation with a PEEP determined by EIT titration procedure.
89061047|NCT03739411|Experimental|Cohort I (hyperpolarized C13, MRI)|Patients receive hyperpolarized carbon C 13 pyruvate intravenously IV and undergo MRI. The second hyperpolarized 13 C injection/imaging will be started approximately 15 to 60 minutes after the first injection for those who are willing to receive two 13 C injections
89061048|NCT03739411|Experimental|Cohort II (hyperpolarized C13, MRI, radiation, temozolomide)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRI before standard treatment with radiation therapy and temozolomide and 4 weeks after completion of radiation therapy.
89061049|NCT03721653|Active Comparator|FOLFOXIRI + Bevacizumab|"(to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
89061050|NCT03721653|Experimental|FOLFOXIRI + Bevacizumab + Atezolizumab|"Atezolizumab 840 mg iv over 30 minutes(60 minutes at the first infusion) day 1 followed by Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev plus atezolizumab, patients will receive maintenance 5-FU/LV plus bev plus atezolizumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev plus atezolizumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev and atezolizumab until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
89061051|NCT03709992|Active Comparator|Trospium|Patients will receive 30 mg of Trospium chloride tablet twice daily
89061052|NCT03709992|Active Comparator|Tamsulosin|Patients will receive 0.4 mg of Tamsulosin tablet once daily
89061053|NCT03699345||Edwards CENTERA THV|
89061054|NCT03696225|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
89061055|NCT03696225|Active Comparator|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
89061056|NCT03658694|Experimental|Conventional rTMS - study 1|In study 1 patients were randomly allocated to receive conventional repetitive transcranial magnetic stimulation (10Hz).
89061057|NCT03658694|Experimental|Sham rTMS - study 1|In study 1 patients were randomly allocated to receive sham repetitive transcranial magnetic stimulation.
89061058|NCT03658694|Experimental|Conventional rTMS - study 2|In study 2, after the end of the first trial will be allocated to receive conventional of repetitive transcranial magnetic stimulation (10Hz).
89061059|NCT03658694|Experimental|Patterned rTMS - study 2|In study 2, after the end of the first trial will be allocated to receive patterned of repetitive transcranial magnetic stimulation (Theta-burst).
89061060|NCT03606499||Inflammatory Bowel Disease (IBD) Participants with EIMs and/or IMIDs|IBD (Crohn's Disease [CD] or Ulcerative Colitis [UC]) participants with suspected extra-intestinal manifestations (EIMs) and/or one or more immune-mediated inflammatory diseases (IMIDs) will be enrolled into the study to assess effectiveness of ustekinumab on EIMs and/or IMIDs associated with IBD (both CD and UC). Participants will receive ustekinumab at study entry (Week 0) as treatment for IBD according to standard clinical practice and will be followed up to 24 weeks (+/- 3 weeks). Only data available per clinical practice will be collected within this study.
89061061|NCT03601286|Experimental|Lentiviral vector transduced CD34+ cells|Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system
89061062|NCT03597100|Experimental|Cala TWO|Two 40-minute stimulation sessions daily, separated by at least two hours
89061063|NCT03570632|No Intervention|Usual care|
89061064|NCT03570632|Experimental|Metformin|
89061065|NCT03555695|Experimental|Karate Class Participants|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD. Subjects will also complete an in-person pre-intervention focus group and post-intervention focus group, as well as a 6 month post-intervention follow up phone call.
89061066|NCT03538691|Experimental|Phase A: Brexpiprazole + ADT|Participants received brexpiprazole 2 or 3 milligrams per day (mg/day) along with protocol-specified antidepressant therapy (ADT), orally, for 6 to 8 weeks during Phase A. Participants were initially titrated to a target dose of brexpiprazole 2 mg over a 2 to 4-week period. Thereafter, participants who had not met response criteria as defined in the blinded addendum, did not have potentially dose-related adverse events (AEs), and had not achieved the maximum dose of medication had their dose increased up to 3 mg.
89061067|NCT03538691|Experimental|Phase B: Brexpiprazole + ADT|Eligible participants completing Phase A were enrolled in Phase B to receive brexpiprazole 2 or 3 mg/day along with protocol-specified ADT, orally, for 12 weeks.
89061068|NCT03538691|Experimental|Phase C: Brexpiprazole + ADT|Eligible participants completing Phase B received brexpiprazole 2 or 3 mg/day (dose of brexpiprazole that they were receiving at Week 20 of the Stabilization Phase) along with protocol-specified ADT, orally, for up to 26 weeks during Phase C.
89061069|NCT03538691|Experimental|Phase C: Placebo + ADT|Eligible participants completing Phase B received brexpiprazole-matching placebo along with protocol-specified ADT, orally, for up to 26 weeks during Phase C.
89061070|NCT03490760|Experimental|Durvalumab plus Radiation Therapy|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks plus 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
89061071|NCT03407417|Experimental|Fit Testing|Patients who self selected to receive FIT screening after interaction with the Application
89061072|NCT03407417|Active Comparator|Non-FIT testing|Patients who elected not to have FIT testing after interaction with the application
89061073|NCT03398135|Placebo Comparator|Substudy 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
89061074|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
89061075|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
89061076|NCT03398135|Experimental|Substudy 2: Open-label (OL) Clinical Assessment Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
89061077|NCT03398135|Experimental|Substudy 2: OL Therapeutic Drug Monitoring Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
89061078|NCT03398135|Experimental|Substudy 3: OL Extension Risankizumab|Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
89061079|NCT03398135|Experimental|OL Continuous Treatment Extension - Dose 1|Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 without receiving risankizumab rescue therapy in any sub-study will receive risankizumab Dose 1 administered by subcutaneous (SC) injection.
89061080|NCT03398135|Experimental|OL Continuous Treatment Extension - Dose 2|Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 and received risankizumab rescue therapy in any sub-study will receive risankizumab Dose 2 administered by subcutaneous (SC) injection.
89061081|NCT03383874|Placebo Comparator|Placebo|Participants will receive capsules containing placebo for 24-weeks.
89061082|NCT03383874|Experimental|Probiotic-Probio-Tec BG-VCap-6.5|Participants will receive capsules containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12 for 24-weeks.
89061083|NCT03370016|Experimental|Reduction in pressure|This group receives 8mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
89061084|NCT03370016|Active Comparator|Stand Amount of Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
89061085|NCT03364803||Participants with Cushing's Syndrome|
89061086|NCT03341689|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
89061087|NCT03341689|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
89061088|NCT03341689|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
89061089|NCT03341689|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
89061090|NCT03307746|Active Comparator|ARM A- Rituximab and Varlilumab|Patients in ARM A willl receive Cycle1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 2: varlilumab 3 mg/kg IV Cycles 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
89061091|NCT03307746|Active Comparator|ARM B - Rituximab and Varlilumab|Patients in ARM B will receive Cycle 1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 8: varlilumab 3 mg/kg IV Cycle 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
89061092|NCT03294954|Experimental|GINAKIT cells|GINAKIT cells will be administer to patients with Neuroblastomas on Day 0.
89061093|NCT03287908|Experimental|AMG 701|
89061094|NCT03287908|Experimental|AMG 701 + Pomalidomide|
89061095|NCT03287908|Experimental|AMG 701 + Pomalidomide + Dexamethasone|
89061096|NCT03286257|Experimental|Exercise Intervention|Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms. Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
89061097|NCT03266991|Experimental|RPT-INH|Participants treated with weekly rifapentine and isoniazid for twelve weeks.
89061098|NCT03266991|Active Comparator|control|Participants treated with daily isoniazid for six months
89061099|NCT03191266|Active Comparator|active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
89061100|NCT03191266|Sham Comparator|sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
89061101|NCT03180398|Experimental|Multi-parametric MRI for Prostate Cancer|MRI will be acquired for prostate cancer patients undergoing radiation treatment.
89061102|NCT03120949|Experimental|Treatment Arm 1: OKZ 64 mg q4w + MTX|Olokizumab 64 mg SC q4w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).
89061103|NCT03120949|Experimental|Treatment Arm 2: OKZ 64 mg q2w + MTX|Olokizumab 64 mg SC q2w + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular).
89061104|NCT03104855|Experimental|Single pharmacokinetics arm|
89061105|NCT03089905|Experimental|Sevoflurane/dexmedetomidine/remifentanil|"Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.~Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.~Sevoflurane: end tidal concentration of 0.6 -0.8% or less."
89061106|NCT03089905|Active Comparator|Sevoflurane|End tidal concentration of 2.5-3.0% or greater.
89061107|NCT03077347|Experimental|Experimental Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex
89061108|NCT03077347|Placebo Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
89061109|NCT03035448|Experimental|Video 1: Counselor Alone|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
89061110|NCT03035448|Experimental|Video 2: Doctor + Counselor|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
89061111|NCT02981329|Experimental|Group A: Hydroxyurea + Metformin|Subjects who are currently taking Hydroxyurea as part of standard of care and have sickle cell anemia.
89061112|NCT02981329|Experimental|Group B: Metformin (Group B has closed to enrollment)|Subjects who are not taking Hydroxyurea as part of standard of care and have sickle cell anemia.
89061113|NCT02939404||healthy volunteers|non-diabetic healthy volunteers at a stable weight
89061114|NCT02921256|Active Comparator|Arm I (mFOLFOX6, RT, capecitabine)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity. Participants assigned to Arm I concurrently with Arm II or with Arm III.
89061115|NCT02921256|Experimental|Arm II (mFOLFOX6, RT, capecitabine, veliparib)|Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID and veliparib PO BID Monday-Friday for 5 weeks in the absence of disease progression or unacceptable toxicity.
89061116|NCT02921256|Experimental|Arm III (mFOLFOX6, RT, capecitabine, pembrolizumab)|ARM III: Patients receive mFOLFOX6 regimen consisting of oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46-48 hours on days 1-2. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. 3-4 weeks after last does of mFOLFOX6 patient undergo RT and receive capecitabine PO BID Monday-Friday for 5 weeks. They also receive pembrolizumab IV over 30 minutes every 3 weeks beginning on day 1 of RT for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89061117|NCT02757885|Experimental|Bone Marrow Recipient|Single arm open label study: Participants with sickle cell disease (SCD) will receive bone marrow from a human leukocyte antigen (HLA) mismatched donor.
89061118|NCT02729480|Experimental|Continued Stimulation Group|Subjects randomized to this group will have the Halo Craniofacial Nerve Stimulator System activated immediately.
89061119|NCT02729480|Active Comparator|Delayed Continuation Group|Subjects randomized to this group with have the Halo Craniofacial Nerve Stimulator System activated after 90 days.
89061120|NCT02703623|Experimental|Arm 2A (abiraterone acetate, prednisone, apalutamide)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily in the absence of disease progression or unexpected toxicity.
89061121|NCT02703623|Experimental|Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
89061122|NCT02703623|Active Comparator|Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive cabazitaxel IV over 60 minutes and carboplatin IV, over 60 minutes on day 1 of courses 4-13. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
89061123|NCT02670811|Experimental|Intervention|Daily consumption of 150 mL of fermented milk with Lactococcus lactis for 8 weeks
89061124|NCT02670811|Placebo Comparator|Placebo|Daily consumption of 150 mL of artificially acidified milk
89061125|NCT02654119|Experimental|Treatment (cyclophosphamide, paclitaxel, trastuzumab)|"SYSTEMIC THERAPY: Patients receive cyclophosphamide IV over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.~Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard NCCN guidelines."
89061126|NCT02635867|Active Comparator|Indirect pulp capping therapy-Resin-modified calcium silicate - TheraCal|Resin modified calcium silicate-TheraCal (light curable)
89061127|NCT02635867|Active Comparator|Indirect pulp capping therapy- - Calcium hydroxide - Dycal|Calcium hydroxide - Dycal
89061128|NCT02635867|Active Comparator|Indirect pulp capping therapy-- Resin-based dentin bonding agent|Resin-based dentin bonding agent-Self etching adhesive
89061129|NCT02635867|Active Comparator|Direct pulp capping therapy-Resin-modified calcium silicate - TheraCal|Resin modified calcium silicate-TheraCal (Light curable)
89221053|NCT00932204|Experimental|Active stimulation|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d)."
89221054|NCT00932204|Sham Comparator|Sham stimulation|For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
89221055|NCT04014686|Sham Comparator|Control group|No exercise intervention
89221056|NCT04014686|Experimental|Exercise intervention group|Exercise intervention group (resistance band exercise training for 12 weeks, 3x per week, for 60 minutes per day).
89221057|NCT00926900|Active Comparator|D-cycloserine|
89221058|NCT00926900|Placebo Comparator|Placebo|
89221059|NCT00937430|Experimental|Bowel preparation group|Patients randomized to this arm will perform a bowel preparation prior to their pelvic organ prolapse surgery.
89221060|NCT00937430|No Intervention|No Bowel preparation group|Patients randomized to this group will not be performing a bowel preparation prior to their pelvic organ prolapse surgery.
89221061|NCT00503841|Experimental|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
89221062|NCT00937508|Placebo Comparator|Smoking counseling, Placebo|
89221063|NCT00937508|Experimental|Smoking counseling, Varenicline|
89221064|NCT00937664|Other|AZD7762 + gemcitabine|AZD7762 administered alone and in combination with gemcitabine
89221065|NCT03743324||BR group|Breast reconstruction without radiation therapy
89221066|NCT03743324||Immediate BR +post-op radiation|Immediate breast reconstruction followed by surgical site radiation therapy
89221067|NCT03743324||Radiation +delayed BR|previous post-mastectomy radiation followed by delayed breast reconstruction
89221068|NCT00937820|Experimental|YM150 group|
89221069|NCT00932516|Active Comparator|South Beach Diet™ with SBD™ Products|
89221070|NCT00932516|Active Comparator|South Beach Diet™ alone|
89221071|NCT00932516|Active Comparator|Calorie restricted diet w/ SBD™ Products|
89221072|NCT00932516|Active Comparator|Calorie Restricted Diet alone|
89221073|NCT00442468||All participants|This is a cross-sectional, non-interventional study. All enrolled subjects were asked to complete a questionnaire and pulmonary function test to assess the prevalence of airflow obstruction.
89221074|NCT00937976|Other|Control-delayed periodontal therapy|
89221075|NCT00937976|Other|Intensive Periodontal Therapy|
89221076|NCT00926978|Other|Radiopharmacokinetics|"1-2 mCi I-124 orally, once per day, twice total 0.9mg rhTSH intravenous injection, once per day, four total~After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
89221077|NCT00506883|Experimental|High Dose Colchicine|After confirmation of a gout flare, patients were to begin standard dosing of colchicine 4.8mg (two capsules (1.8mg) initially followed by additional one capsule doses (0.6mg) every hour for an additional 6 doses).
89221078|NCT00506883|Experimental|Low Dose Colchicine|Within 12 hours of a confirmed gout flare, patients were to begin the low dose colchicine regimen consisting of a total dose of 1.8 mg - two colchicine capsules initially (1.2 mg)followed an hour later by a single additional capsule of active drug(0.6 mg)then by 5 additional hourly doses of an identical looking placebo capsules
89221079|NCT00506883|Placebo Comparator|Placebo|
89221080|NCT00932594|Active Comparator|1.Arthrocentesis only|Patients only have Arthrocentesis, but without adjusting the pressure of the TMJ
89221081|NCT00932594|Active Comparator|3.Arthroscopic Treatment|Patient receives Arthroscopic treatments without adjusting the TMJ pressure
89221082|NCT00932594|Active Comparator|4.Arthroscopic with Adjust Pressure|Arthroscopic Treatment with Adjust TMJ Pressure Treatment, during the Arthroscopic treatment adjust the pressure of TMJ to normal value
89221083|NCT00932594|Active Comparator|5.The TMJ Orperation Treatment|The TMJ Operation Treatment without adjusting the pressure of TMJ
89221084|NCT00932594|Active Comparator|6.The TMJ Operation with Adjust Pressure|The TMJ Operation with Adjust TMJ Pressure Treatment, during the treatments to adjust the TMJ pressure to normal value
89221085|NCT00932594|Active Comparator|7.Bite Plate Treatment|Bite Plate Treatment for Temporomandibular Disorders without adjusting the pressure of TMJ
89221086|NCT00932594|Active Comparator|8.Bite Plate with Adjust pressure|Bite Plate and Adjust Pressure Treatment for Temporomandibular Disorders, during the treatments adjust the pressure of TMJ to normal value
89221087|NCT00932594|Active Comparator|2.Arthrocentesis with adjust pressure|Arthrocentesis with adjust pressure according to the pressure of TMJ
89221088|NCT01028638||Renal Cancer|Renal Cancer patients treated with everolimus
89221089|NCT00938132|Experimental|Fimasartan|
89221090|NCT01023334|Experimental|Intraocular lidocaine,topical anesthesia,MSICS|experimental group:manual small incision cataract surgery under topical anesthesia with intracameral lidocaine
89221091|NCT01023334|Experimental|intracameral balanced salt solution,topical anesthesia,MSICS|control group:manual small incision cataract surgery under topical anesthesia with intracameral balanced salt solution.
89221092|NCT04015388||Diabetes Mellitus / Hyperglycemia|iPro Continuous Glucose Monitoring on subjects with blood sugar value >140 mg/dL upon admission to the intensive care unit or who have been diagnosed with type 1 or type 2 diabetes or have glycosylated hemoglobin A1C (HbA1C) values > 6.5% prior to admission.
89221093|NCT00932672|Experimental|Atkins group|Men assigned to the Atkins diet will be asked to restrict carbohydrate intake to <20 grams/day. We will use an established clinical program directed by Dr. Eric Westman which implements this diet using a trained clinical nutritionist. No other dietary restrictions will be placed on the subjects. They will measure their urinary ketones at home weekly using urinary ketone strips. Subjects will meet with the nutritionist monthly during the 6 months of the study. Subjects in the Atkins arm will also be asked to walk at a brisk pace for 30 minutes a day, 5 days a week and will be provided a pedometer to measure the number of steps taken per day.
89221094|NCT00932672|No Intervention|Control group|Subjects assigned to the control group will be asked to make no changes in their dietary habits. At the completion of the study subjects will meet with the nutritionist and receive standard nutrition AHA recommendations.
89221095|NCT00927056|Active Comparator|Minimally Invasive Microdiscectomy|
89221096|NCT00927056|Active Comparator|Conventional Open Microdiscectomy|
89221097|NCT00938210|No Intervention|Laparoscopic surgery|Patients undergoing laparoscopic colonic surgery are compared with a historical cohort of patients undergoing similar open colonic surgery (right hemicolectomy and sigmoid resections).
89221098|NCT00932750|Placebo Comparator|MOS Weight maintenance|
89221099|NCT00932750|Placebo Comparator|MOS weight loss|
89221100|NCT00938288|Other|1|Single group
89221101|NCT00932906|Placebo Comparator|Instructor based training; <21 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
89221102|NCT00932906|Placebo Comparator|Instructor based training; 21-50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
89221103|NCT00932906|Placebo Comparator|Instructor based training; >50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
89221104|NCT00932906|Experimental|Video Skill Training; <21 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
89221105|NCT00932906|Experimental|Video Skill Training; 21-50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
89221106|NCT00932906|Experimental|Video Skill Training; >50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
89221107|NCT00932906|Experimental|Video scenario training; <21 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
89221108|NCT00932906|Experimental|Video scenario training; 21-50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
89221109|NCT00932906|Experimental|Video scenario training; >50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
89221110|NCT00932906|Experimental|Video demonstration training; <21 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
89221111|NCT00932906|Experimental|Video demonstration training; 21-50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
89221112|NCT00932906|Experimental|Video demonstration training; >50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
89221113|NCT00938444||Patients with moderate to severe RA|Patients with moderate to severe RA treated with Tocilizumab
89221114|NCT00938522|Experimental|Cilostazol loading|
89221115|NCT00938522|Placebo Comparator|Placebo|
89221116|NCT00938600|Experimental|A1 - non-pregnant single-dose|
89221117|NCT00938600|Experimental|A2 - non-pregnant; weekly dose|
89221118|NCT00938600|Experimental|B1 - pregnant; single-dose|
89221119|NCT00938600|Experimental|B2 - pregnant; weekly dose|
89221120|NCT00938600|Active Comparator|C1 - active control; pregnant women|
89221121|NCT00932984|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
89221122|NCT00938678|Experimental|Treatment Group 1|
89221123|NCT00938678|Active Comparator|Treatment Group 2|
89221124|NCT03743168|Experimental|Intermittent stretching protocol|Intermittent stretching protocol including five sets at 1 minute and 15 second rest.
89221125|NCT03743168|Experimental|Continuous stretch|2 minutes continuous stretch
89221126|NCT00933062|Active Comparator|SRT2104|Subjects will receive a dose of 2.0 g SRT2104 (administered as eight 250 mg capsules) on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
89221127|NCT00933062|Placebo Comparator|Placebo|Subjects will receive placebo on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
89221128|NCT00503685|Experimental|IMC-A12|Administered every 2 weeks
89221129|NCT00503685|Experimental|IMC-A12 + cetuximab|Administered every 2 weeks
89221130|NCT00503685|Experimental|IMC-A12 + cetuximab [Kirsten rat sarcoma (K-ras) wild-type]|Participants who have experienced confirmed partial response (PR) or stable disease (SD) ≥ 24 weeks on a prior anti-EGFR-containing therapy followed by disease progression are enrolled in this arm.
89221131|NCT00933140||HIV infected women|HIV infected women between ages 18 - 64 years of age due for cervical cancer screening were enrolled.
89221132|NCT00712673|Experimental|Lixisenatide (Morning Injection)|2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
89221133|NCT00712673|Experimental|Lixisenatide (Evening Injection)|2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
89221134|NCT00712673|Placebo Comparator|Placebo (Morning Injection)|2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
89221135|NCT00712673|Placebo Comparator|Placebo (Evening Injection)|2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
89221136|NCT01562990|Experimental|R-CMC544 and R-GEMOX|Treatment with R-CMC544 and R-GEMOX
89221137|NCT00939380|Experimental|P-SCIP|Arm I (Parent Social-Cognitive Intervention Program [P-SCIP]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
89221138|NCT00939380|Experimental|BPC|"Arm II (Best-recommended Psychosocial Care [BPC]): Participants undergo usual care and receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD, and 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks."
89221139|NCT00933218|Active Comparator|polyphenols (non-alcoholic beer)|
89221140|NCT00933218|Placebo Comparator|beverage without polyphenols|
89061130|NCT02635867|Active Comparator|Direct pulp capping therapy-Resin-modified calcium silicate - Calcium hydroxide - Dycal|- Calcium hydroxide - Dycal
89061131|NCT02565446|Experimental|Bariatric|Obese adult subjects who are scheduled to undergo bariatric surgery
89061132|NCT02565446|Experimental|Clinical|Subjects who received abdominal surgery for non-liver related indications (cholecystectomy, pancreatic cyst resection)
89061133|NCT02433054||CE-certified dedicated venous stents|Patients receiving self-expanding venous nitinol stents.
89061134|NCT02426658|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment and Laboratory Biomarker Analysis.
89061135|NCT02400242|Experimental|ACY-241, Pomalidomide, and dexamethasone|Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).
89061136|NCT02338687|Active Comparator|Education|Educational sessions
89061137|NCT02338687|Experimental|Education plus supplement|Educational sessions and 500 mg calcium per day
89061138|NCT02158091|Experimental|IPI-145|"Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation.~Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy.~Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing."
89061139|NCT02054429|Experimental|Insulin|IIT arm subjects will receive an insulin aspart infusion at a minimal rate of 2 units/hr while maintaining blood glucose between 90-120mg/dl for 48 hrs
89061140|NCT02054429|No Intervention|Standard glycemic control|standard of care if not randomized to Insulin
89061141|NCT01940757|Experimental|25 Necator americanus Hookworm Larvae|
89061142|NCT01940757|Experimental|50 Necator americanus Hookworm Larvae|
89061143|NCT01940757|Experimental|75 Necator americanus Hookworm Larvae|
89061144|NCT01728714||Adults over 18 years old|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months submitted to an educational programme during 1 year
89061145|NCT01728714||Adults with HbA1c <= 8,5%|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months followed according to normal clinical practice during 1 year
89061146|NCT01588054||adults, cervical deformity, surgical treatment|Adults 18years or older at time of enrollment, cervical deformity to include kyphosis (C2-7 greater than 10 degrees) or scoliosis (coronal cobb greater than 10 degrees), plans for surgical treatment of cervical deformity
89061147|NCT01460654|Placebo Comparator|Testosterone and Placebo Alendronate|
89061148|NCT01460654|Placebo Comparator|Alendronate and Placebo Testosterone|
89061149|NCT01460654|Experimental|Testosterone and Alendronate|
89061150|NCT01224275|Experimental|Group antenatal care|The first arm is midwife which allocated to group based antenatal care. They have education in this model of care and follow up meeting to secure the intervention
89061151|NCT01224275|No Intervention|Individual antenaal care|the second arm include midwife which allocated to traditional care as control group.
89061152|NCT01218776||Male, Female, Kidney Disease, Elderly|Non-interventional patient registry
89061153|NCT01093326|Experimental|Ponesimod 10 mg|Ponesimod 10 mg oral use
89061154|NCT01093326|Experimental|Ponesimod 20 mg|Ponesimod 20 mg oral use
89061155|NCT01093326|Experimental|Ponesimod 40 mg|Ponesimod 40 mg oral use
89061156|NCT01091038|Placebo Comparator|Routine Care|Usual care of patients in the ambulatory setting
89061157|NCT01091038|Experimental|Basic Clinical Decision Support|Providers use basic clinical decision support
89061158|NCT00912717||Pancreatic Cancer|individuals who have been diagnosed with pancreatic cancer
89061159|NCT00912717||Unaffected|individuals who have not been diagnosed with pancreatic cancer
89061160|NCT00752531|Experimental|HAT|
89061161|NCT00752531|No Intervention|Control|
89061162|NCT00497952|Experimental|Multiple Sclerosis Patients|Recipients treated with a hematopoetic stem cell infusion from a living donor
89061163|NCT03039439||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.
89061164|NCT03021460|Experimental|Treatment (ibrutinib, pembrolizumab)|Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89061165|NCT02996266|Experimental|Fever Prevention|Fever will be prevented using a surface targeted temperature management system
89061166|NCT02996266|Active Comparator|Standard Care|Standard care in which fever may spontaneously develop
89061167|NCT02954497|Experimental|Jarvik 2015 Device VAD|New, experimental continuous flow VAD
89061168|NCT02952248|Experimental|BI 754091|
89061169|NCT02939755|Experimental|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
89061170|NCT02939755|Active Comparator|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
89522851|NCT01889303|Experimental|Arm B|"chemotherapy regimen:Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles → Docetaxel 35mg iv D1,Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy (5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles~Radiation: concurrent chemoradiotherapy with DC.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
89061172|NCT02926859|Experimental|Cannabidiol|Cannabidiol as add-on to individualized pharmacological treatment
89061173|NCT02926859|Placebo Comparator|Placebo|Placebo as add-on to individualized pharmacological treatment
89061174|NCT02912312|Experimental|Arm I: Hypofractionated Regional Nodal Irradiation (RNI)|Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
89061175|NCT02912312|Active Comparator|Arm II: Standard Regional Nodal Irradiation (RNI)|Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
89061176|NCT02903420|Experimental|SAPIEN 3|Transcatheter Aortic Valve Implantation (TAVI) with the Edwards SAPIEN 3 Transcatheter Heart Valve and Delivery System
89061177|NCT02876107|Experimental|Group A (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 1 hour on day 1 of cycle 0 and over 30 minutes on days 1, 8, and 15 of cycles 1-4. Patients also receive paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1 of cycles 1-4. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
89061178|NCT02876107|Experimental|Group B (paclitaxel, carboplatin)|Patients receive paclitaxel, carboplatin, doxorubicin, and cyclophosphamide as in Group A. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
89061179|NCT02874885||Ancillary-Correlative (biospecimen collection)|Patients and healthy participants undergo collection of blood sample at baseline. Patients may also undergo collection of blood sample collections during tumor surgery, 4 weeks after surgery or after completion of treatment if you are not surgery, 8 weeks after the last dose of chemotherapy, 1 year after surgery or 1 year after completion of treatment if not having surgery, 2 years after surgery or 2 years after completion of treatment if not having surgery, and within 6 years after treatment or at the end of the 6 year follow-up if the disease gets worse with treatment or comes back.
89061180|NCT02872259|Experimental|BGB324 + pembrolizumab|"BGB324 capsules, 200 mg once daily + pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
89061181|NCT02872259|Experimental|BGB324 + dabrafenib and trametinib|"BGB324 capsules: Dose finding part of the study will determine if 100 mg once daily should be used for main part of the study or if 200 mg once daily once daily should be used.~Dabrafenib capsules: 150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
89061182|NCT02872259|Active Comparator|pembrolizumab|"Pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
89061183|NCT02872259|Active Comparator|dabrafenib and trametinib|"Dabrafenib capsules:150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
89061184|NCT02859467|Experimental|Kinesio Taping and Inhibitory Treatment Techniques|"During each session participants will receive the application kinesio taping in trapezius, infraspinatus and paravertebral muscles.~Inhibitory Treatment Techniques:~Release Technique of the trapezius muscle.~Release Technique for scalene muscles.~Technique suboccipital inhibition.~Technique hands crossed for induction dorsal superficial fascia."
89061185|NCT02859467|Active Comparator|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
89061186|NCT02831933|Experimental|Experimental|"ADV/HSV-tk (5 x 1011 viral particles) in a 2-mL total volume will be injected intratumorally on day 0 of the study.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days. Valacyclovir treatment will be administered 24 hours after the gene vector injection from day 1 to day 15 of the study.~SBRT of 30 gray (Gy; 6 Gy X 5 fractions) will be administered over 2 weeks from day 2 to day 16 of the study.~Nivolumab (480 mg) will be administered intravenously over 30 minutes every 4 weeks starting on day 17 of the study and continuing until disease progression, unacceptable toxicity, or up to 12 months in patients without disease progression."
89061189|NCT02813668|Experimental|Lifestyle Intervention Training Program|Participants at risk for developing diabetes or with unmedicated diabetes will participate in a lifestyle intervention training program. Individuals in the training program, as well as un-enrolled workers at the study sites, will be exposed to positive changes at the worksite to promote increased physical activity and healthier diets.
89061190|NCT02805803|Other|Quality of life questionary|"During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:~SF12~Beck~WOMAC"
89061191|NCT02792881|Experimental|Laparoscopic Completion Total Gastrectomy Group|Patients who underwent laparoscopic completion total gastrectomy with D2 lymphadenectomy will be assigned to this group.
89061192|NCT02789228|Experimental|Group A|"Group A includes patients who have undergone an allogeneic hematopoietic stem cell transplant (HSCT) as part of their prior therapy.~Group A patients (post allogeneic HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first."
89061193|NCT02789228|Experimental|Group B|"Group B includes patients who have undergone conventional (standard) therapy which does not include an allogeneic HSCT. Within group B, a cohort of patients with relapsed or refractory Wilms tumor will be enrolled and receive a lymphodepleting chemotherapy regimen followed by TAA-T.~Group B patients (no prior allogeneic HSCT): TAA-T will be infused any time >1 week after completing most recent course of conventional (non-investigational) therapy for their disease. Patients receiving lymphodepletion will be >2 weeks from most recent course of conventional therapy and have nadired and recovered before beginning protocol therapy."
89061196|NCT02760433|Experimental|Arm 1: Olokizumab q4w|"Olokizumab 64mg subcutaneous q4w + placebo + Methotrexate~Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)"
89061197|NCT02760433|Experimental|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
89061198|NCT02760433|Placebo Comparator|Arm 3: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)~Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group."
89061199|NCT02760407|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg subcutaneous q4w +placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
89061200|NCT02760407|Experimental|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
89061201|NCT02760407|Active Comparator|Arm 3: Adalimumab q2w|"Adalimumab 40mg q2w subcutaneous + Methotrexate~Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
89061202|NCT02760407|Placebo Comparator|Arm 4: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
89061203|NCT02760368|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
89061204|NCT02760368|Experimental|Arm 2: Olokizumab q2w|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
89061205|NCT02760368|Placebo Comparator|Arm 3: Placebo|Placebo Subcutaneous q2w + Methotrexate (oral)
89061209|NCT02752750||AD_GROUP|Patients with Alzheimer's disease
89061210|NCT02752750||HC_GROUP|Healthy controls
89061211|NCT02741570|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
89061212|NCT02741570|Active Comparator|Extreme Regimen|Specified dose on specified days
89061213|NCT02741180|Other|Patients with Arrhythmias|
89061214|NCT02741180|Other|Healthy Control|
89061215|NCT02730416|Experimental|A: Nintedanib|Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
89061216|NCT02730416|Placebo Comparator|B: Placebo|Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
89061217|NCT02723760|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of rheumatoid arthritis
89061218|NCT02706197|Experimental|IA No treatment except standard-of-care (SOC) surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IA, patients will not have any cancer therapy prior to removal of the OxyChip and duration of implantation is typically less than 4 weeks but may be up to 52 weeks.
89061219|NCT02706197|Experimental|IB SOC adjuvant therapy and SOC surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IB, patients will have standard of care neoadjuvant chemotherapy or pre-operative radiation therapy during the time that the OxyChip is within the tumor, which is typically 6 weeks but may be up to 52 weeks.
89061220|NCT02703610|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
89061221|NCT02703610|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/500 mg)
89061222|NCT02685566|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
89061223|NCT02685566|Active Comparator|Full-Field Digital Mammography|Breast Images with FFDM alone
89061224|NCT02683824|Experimental|pancreatic cancer patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
89061225|NCT02683824|Experimental|healthy patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
89061226|NCT02681185|Experimental|Interventional Group|The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.
89061227|NCT02681185|Active Comparator|Standard of Care|The recruited participants will receive the standard of diabetes care as offered by the services in their community.
89061228|NCT02661035|Experimental|Reduced Intensity Conditioning|Non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion
89061229|NCT02641483|Experimental|Colonic Motility|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
89061230|NCT02627846|Active Comparator|EndoVenous Laser Ablation|EndoVenous Laser Ablation (EVLA) involves the delivery of laser light through a glass fibre placed into the lumen of a refluxing vein. This energy is converted into heat inducing a permanent, non-thrombotic occlusion.
89221141|NCT00737867|Experimental|A|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
89221142|NCT00737867|Active Comparator|B|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Carboplatin infusion AUC = 5 (Calvert's formula) Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
89221143|NCT00737945||2|
89221144|NCT03976466|Experimental|Calcium sulfate Group|Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement
89221145|NCT03976466|Active Comparator|Control Group|Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement
89221146|NCT02536755|Experimental|Eliglustat|Participants who completed one of the Phase 2 (GZGD00304 [NCT00358150]) or Phase 3 studies (GZGD02507 [NCT00891202], GZGD02607 [NCT00943111], or GZGD03109 [NCT01074944]) were enrolled in this current (EFC13781) study. Participants who were cytochrome P450 (CYP) 2D6 intermediate metabolizer (IM), extensive metabolizer (EM) and ultra-rapid metabolizers (URM) received eliglustat 84 milligrams (mg) twice daily and participants who were CYP2D6 poor metabolizer (PM) received eliglustat 84 mg once daily, for duration of minimum 2 years (unless early discontinuation occurred) and up to 4 years, or until commercial eliglustat was available to participants through reimbursement or through the compassionate use (expanded access) program.
89221147|NCT02567279|Active Comparator|Denosumab subcutaneous injections|The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
89221148|NCT02567279|Placebo Comparator|Placebo subcutaneous injections|The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).
89221149|NCT00938834|Active Comparator|CFQ Qigong training group|"Qigong training con- sisted of an initial workshop conducted over three con- secutive half-days by a qualified CFQ instructor. Participants received training in level 1 CFQ; this con- sisted of instruction in seven key movements known as the hexagram and ancillary exercises. Hexagram move- ments consist of choreographed movements that emphasize softness, relaxation, downward releases and full body distribution of qi. Once initial training was complete, participants were asked to practice CFQ at home for 45 to 60 minutes per day for eight weeks; time could be broken up into shorter sessions during the day. Participants returned for a 60 minute weekly review/group practice sessions for these eight weeks."
89221150|NCT05460689|Experimental|Smartphone Application|mHealth App provided to caregivers of children undergoing tonsillectomy and/or adenoidectomy
89221151|NCT05460689|Sham Comparator|standard support|Information provided by nurses and physician orally or through printed booklets.
89221152|NCT00933296||A Patients with the Schnitzler syndrome|Patients with the Schnitzler syndrome
89221153|NCT00933296||B Control subjects:|B1 healthy B2 other diseases
89221154|NCT04013594|Experimental|carbohydrate group(CHO group)|
89221155|NCT04013594|No Intervention|control group|
89221156|NCT00933374|Experimental|Paclitaxel and RAD001|175 mg /m3 paclitaxel every 3 weeks and 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
89221157|NCT03303105|Experimental|TEV-48125 (225 mg/1 month) group|TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly [except for a loading dose of 675 mg in subjects with CM]).
89689680|NCT02994238|Experimental|Intervention|The intervention group will have the full Remote Health Management Sensor Platform. Research staff will review uploaded sensor data on a daily basis. If participants are enrolled into the control group, they will only receive Standard Asthma Education. The Standard Asthma Education follows the National Asthma Education and Prevention Program (NAEPP) guidelines for asthma management. This will include the following topics: 1. Explanation of symptoms; 2. Asthma triggers (description and how to avoid them); 3. Using medications (how to use prescribed asthma medications, the difference between controller medications and rescue inhalers, how to use a spacer, how to use a mask); and 4. Managing asthma control (purpose of asthma control test, asthma action plan, how to use a peak flow meter).
89689681|NCT02994238|No Intervention|Control|The control group will receive only standardized education.
89221158|NCT03303105|Experimental|TEV-48125 (675 mg/3 month) group|TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).
89221159|NCT00933452|Experimental|low dose group|single oral administer 15mg duloxetine
89221160|NCT00933452|Experimental|moderate dose group/multiple dose group|single oral duloxetine 30mg, after that repeat 7 oral duloxetine 30mg/d
89221161|NCT00933452|Experimental|high dose group/crossover group|single oral duloxetine 60mg, after that single oral innovator duloxetine 60mg
89221162|NCT03263325||AKI Group|Patients developing AKI after surgery
89689682|NCT02244203|Experimental|Single rising doses of BI 60732|
89689683|NCT02244203|Placebo Comparator|Placebo|
89689684|NCT05168709|Experimental|Approved COVID-19 vaccination|The approved COVID-19 vaccination arm will receive the COMIRNATY™ (tozinameran - BNT162b2 [mRNA]) COVID-19 VACCINE. The dose, strength of the dose unit, dosing interval and dosing period of tozinameran used in this trial will be as approved by the Therapeutic Goods Administration (TGA) and recommended by the Australian Technical Advisory Group on Immunisation (ATAGI) for children aged 5 to <12 years of age. The recommended dose of tozinameran for this age group is 10 µg (0.2 mL) and the recommended schedule is 2 doses, 8 weeks apart. Therefore two tozinameran doses of 10µg (0.2 mL) will be administered intramuscularly 8-weeks apart as part of this arm of the trial.
89689685|NCT03110692|No Intervention|Usual practice (control)|The usual practice group will rollover to the intervention arm after 3 months.
89689686|NCT03110692|Experimental|Intervention|Default initiation: Introduce a default prescription template in the palliative setting in order to reduce unnecessary daily image guided radiation.
89689687|NCT04367441|Experimental|608|8mg, 20mg, 40mg, 80mg, 120mg, 160mg, 200mg
89689688|NCT04367441|Placebo Comparator|Placebo|20mg, 40mg, 80mg, 120mg, 160mg, 200mg
89689689|NCT04367363||Community sample|We plan to recruit a representative sample of the Singapore population.
89689690|NCT03111316|Other|Foley Catheter & Dinoprostone Insert|transcervical Foley catheter and an intravaginal dinoprostone controlled release insert
89689691|NCT03111316|Other|Foley Catheter Alone|a Foley catheter alone
89689692|NCT04360733||asymptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR but no clinical symptoms
89689693|NCT04360733||symptomatic Covid-19|Patients with confirmed SARS-CoV2 PCR and light clinical symptoms
89689694|NCT04360733||severe Covid-19|Patients with confirmed SARS-CoV2 PCR and severe clinical symptoms with ICU admission
89689695|NCT04360733||healthy controls|Persons with negative SARS-CoV2 PCR
89689696|NCT03833687|Experimental|Profhilo®|"The 1st treatment was performed during the basal visit and repeated after 1 month.~3 mL of Profhilo® for each brachial zone, 1.5 mL for hemiabdomen was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 horizontal-levels for each tested areas (3-4-3 injection points respectively for the 1st, the 2nd and the 3rd horizontal-level). The amount of product to be injected was of 0.3 ml for each point."
89689697|NCT03054844|Experimental|PREMED|Patients will receive 0.25 mL of IN 4% lidocaine (10 mg) in each naris (total of 0.5 mL/20 mg for both nares) preceding adminstration of IN midazolam.
89689698|NCT03054844|Experimental|PREMIX|Patients will receive midazolam mixed with 0.5 mL of 4% lidocaine (20 mg).
89689699|NCT04360967|Experimental|Randomized Standard Formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
89689700|NCT04360967|Experimental|Randomized Nutrient-enriched formula-fed|Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
89689701|NCT04360967|No Intervention|Non-randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
89689702|NCT04360967|No Intervention|Non-Randomized HM-fed|Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
89689703|NCT03111550|Other|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Tecnis Model ZHR00
89689704|NCT03111550|Other|Investigational Lens Device #2|Investigational Intraocular Lens Device #2: Tecnis Model ZQR00
89689705|NCT03111550|Other|Control Device|Control TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00
89689706|NCT05447013|Experimental|For Phase II: Arm A|Standard of care (SOC) and Coronavirus-specific T cells (CoV-2-STs)
89689707|NCT05447013|Active Comparator|For Phase II: Arm B|Standard of care (SOC)
89689708|NCT03111628|Other|Omalizumab|Omalizumab 300mg every month for 3 doses
89689709|NCT03111940|Experimental|PCI optimisation|Post PCI FFR below 0.9
89689710|NCT03111940|No Intervention|No PCI optimisation|Post PCI FFR 0.9 or higher
89689711|NCT05120505|Experimental|Metformin group|The patients will be obtain Metformin starting from 50mg everyday to 1-2g per day for 6 months.
89689712|NCT05120505|Placebo Comparator|Placebo group|The patients will be obtain starch tablets starting from 50mg everyday to 1-2g per day for 6 months.
89689713|NCT03113656|Experimental|Weighted Blanket First|This group will receive the Weighted Blanket first and then the Non-weighted blanket
89689714|NCT03113656|Experimental|Non-weighted Blanket First|This group will receive the Non-weighted Blanket first and then the Weighted blanket
89689715|NCT05118711||COVID-19 (18 months post-infection)|Individuals with a positive Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) antigen-/polymerase chain reaction (PCR) test within the last 18 months that required hospitalisation. Symptoms typically worsened within a period of 5 to 10 days leading to e.g., prolonged fever, feeling of sickness and/or shortness of breath. This also includes individuals hospitalised in an intensive care ward. Individuals need to be hospitalised due to COVID-19 and not only with COVID-19.
89689716|NCT05118711||Control group|Age-, sex-, and comorbidity-matched (frequency matching), fully vaccinated individuals with no history of symptomatic SARS-CoV-2 infection.
89689717|NCT03114124|Active Comparator|Bipolar Ablation Catheter|Subjects will be randomized by random computer programming to receive standard ablation catheter for their procedure.
89689718|NCT03114124|Experimental|MIFI Ablation Catheter|Subjects will be randomized by random computer programming to receive an ablation with MIFI technology. MIFI Catheter contains tightly spaced multielectrode pattern
89689719|NCT02977533|Experimental|GZ402668|Dose 1 (up to a maximum optional Dose 2) will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
89689720|NCT02977533|Placebo Comparator|Placebo|A dose of matching placebo will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
89689721|NCT02997904|Experimental|Resultz Lice and Egg Elimination Kit|Resultz combing solution, head lice comb and instructions for use in a kit: apply liquid then comb out for 1 hour
89689722|NCT02997904|Placebo Comparator|Placebo Lice and Egg Elimination Kit|20% glycerin combing solution, comb and instructions for use in a kit: apply liquid then comb out for 1 hour
89689723|NCT05160753|Experimental|gastric function preserving surgery combined with resection of the anterior lymphatic drainage area.|"Steps of sentinel lymph node dissection Indocyanine green (ICG) tracing of anterior lymph nodes. ICG injection: A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method. 0.5 mL was injected at each site, and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.~Intraoperative and postoperative pathological examination Intraoperative histological examination of lymph nodes collected from the anterior lymph node pool was performed, If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed. After surgery, anterior lymph nodes that proved to be tumor-free on intraoperative frozen section examination were reevaluated."
89689724|NCT05160753|Active Comparator|Patients in the control group will undergo standard laparoscopic gastrectomy|Patients in the control group will undergo standard laparoscopic gastrectomy (laparoscopic distal gastrectomy with simultaneous D1+ lymph node dissection).
89689725|NCT04343625|Experimental|Modified sitting, gentle yoga class|Participants attended a modified sitting gentle yoga class,10 weekly classes, each 60 minutes in duration.
89221163|NCT03263325||No AKI Group|Patients who do not develop AKI after surgery
89221164|NCT03342716||Main cohort|Patients with a clinical or radiological diagnosis of acute pancreatitis (AP)
89221165|NCT03342716||Nested cohort|Subgroup of patients with a clinical or radiological diagnosis of acute pancreatitis (AP) who will undergo additional assessments and scans
89221166|NCT00933530|Experimental|Cohort 1 - Dose Level A (0.03g/day)|"0.03g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.03g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.03g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
89221167|NCT00933530|Experimental|Cohort 2 - Dose Level B (0.1g/day)|"0.1g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.1g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.1g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
89522852|NCT00783263|Experimental|Rosuvastatin 5 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
89522853|NCT00783263|Active Comparator|Rosuvastatin 10 mg|Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
89689726|NCT01012297|Experimental|Arm I Gem+Doce+Placebo|Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.
89689727|NCT01012297|Experimental|Arm II Gem+Doce+Bev|Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.
89689728|NCT02998684|Active Comparator|Active Transcranial Direct Current Stimulation|Participants will receive active Transcranial Direct Current Stimulation
89689729|NCT02998684|Sham Comparator|Sham Transcranial Direct Current Stimulation|Participants will receive sham Transcranial Direct Current Stimulation
89689730|NCT03000010|Active Comparator|Incisional Wound Vac|We will attach sponges and a suction tube to the incision after surgery. We will leave it on for 72 hours. From then on, patients will get the care that patients normally get after spinal fusion surgery.
89689731|NCT03000010|Active Comparator|Normal Gauze Bandage Group|We will cover patients incision with regular gauze bandages. These are the bandages that patients normally get after spinal fusion surgery. They will be left on for 72 hours.
89689732|NCT03000088||60° angle group|intubate using McGrath Videolaryngoscope with 60° angled stylet
89689733|NCT03000088||90°angle group|intubate using McGrath Videolaryngoscope with 90° angled stylet
89689734|NCT03000166|Experimental|Step-Up Intervention Group|Participants assigned to the Step-up intervention group will receive a 12-week physical activity intervention which includes components of education, negotiated collaboration to set individual physical activity goals during chemotherapy cycles, and tools for self-monitoring of physical activity.
89689735|NCT03000166|No Intervention|Attention Control Group|Participants assigned to the attention control group will receive usual guidance about maintaining physical activity during chemotherapy from their oncology providers.
89689736|NCT00923117|Experimental|Bevacizumab resistant patients|Patients who had tumor progression while treated with bevacizumab.
89689737|NCT00923117|Experimental|Bevacizumab naive patients|Patients with progressive tumor who have not been treated with bevacizumab.
89689738|NCT00953173||LapBand|Patients who have already consented to receive the LAP-BAND AP® Adjustable Gastric Banding System
89689739|NCT03054922|Active Comparator|Normal Saline|0.9% Sodium Chloride
89689740|NCT03054922|Active Comparator|Lactated Ringers|"Each 100 mL of Lactated Ringer's Injection USP contains:~Sodium Chloride USP 0.6 g; Sodium Lactate USP 0.31 g; Potassium Chloride USP 0.03 g; Calcium Chloride Dihydrate USP 0.02 g; Water for Injection USP qs"
89689741|NCT03054922|Active Comparator|Normosol-R|Each 100 mL of Normosol-R contains sodium chloride, 526 mg; sodium acetate, 222 mg; sodium gluconate, 502 mg; potassium chloride, 37 mg; magnesium chloride hexahydrate, 30 mg.
89689742|NCT02977611|Experimental|High Dose, Rapid Infusion Iron Sucrose|Patients will receive an infusion of 500 mg of iron sucrose over one hour and will be monitored for four hours.
89689743|NCT05405764|Experimental|Porcine protein group|The patients will receive protein supplements twice daily (2x22g) for a period of 6 weeks during breakfast and lunch. The supplement will be delivered in powdered form.
89689744|NCT05405764|Placebo Comparator|Carbohydrate group|The patients will receive isocaloric carbohydrate supplements twice daily (2x21g) for a period of 6 weeks during morning and afternoon. The supplement will be delivered in powdered form.
89689745|NCT04360655|Active Comparator|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
89689746|NCT04360655|Experimental|combined with bronchoscopic microwave intervention|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention
89689747|NCT04367207||Adult patients with COVID-19 referred to intensive care|Prospective observational cohort study of adult (≥18 years) patients referred to intensive care or high-care units in Africa with suspected or known COVID-19 infection in Africa
89689748|NCT03116230|Experimental|Experimental Treatment A then B|Subjects will receive two treatments: (1) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject and (2) a commercially-available knee sleeve, separated by a washout period.
89689749|NCT03116230|Experimental|Experimental Treatment B then A|Subjects will receive two treatments: (1) a commercially-available knee sleeve and (2) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject, separated by a washout period.
89689750|NCT04347317|Active Comparator|Low Intensity IMT|
89689751|NCT04347317|Experimental|High Intensity IMT|
89689752|NCT00975637|Experimental|140 mg SC|140 mg SC
89689753|NCT00975637|Experimental|70 mg SC|70 mg SC
89689754|NCT00975637|Experimental|280 mg SC|280 mg SC
89689755|NCT00975637|Placebo Comparator|210 mg SC|210 mg SC
89689756|NCT00975637|Experimental|Placebo|Placebo
89689757|NCT04376567|Active Comparator|One stage BBAVF|comparison
89689758|NCT04376567|Active Comparator|Two Stage BBAVF|comparison
89689759|NCT04360343|Experimental|LC51-0255 film-coated tablet|Drug: LC51-0255
89689760|NCT04360343|Active Comparator|LC51-0255 uncoated tablet|Drug: LC51-0255
89689761|NCT04343703|Experimental|Telephone-based management|Telephone-based management will consist of a three-phase intervention: 1) An initial 15-20 min call at 1 week of enrollment in which the cases manager introduces him/herself, and does a short assessment of the current suicide risk, 2) A 5-10 min telephone follow-up at 1, 3, 6, 9 and 12 months, 3) If suicide risk is detected, a 15-45 min crisis intervention call will be done, tailored to the participant's characteristics and context. If deemed necessary, an emergency face-to-face appointment will be scheduled. At each phone call information regarding the current treatment, adherence to mental health services, and current life stressors will be collected.
89221168|NCT00933530|Experimental|Cohort 3 - Dose Level C (0.25g/day)|"0.25g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.25g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.25g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
89221169|NCT00933530|Experimental|Cohort 4 - Dose Level D (0.5g/day)|"0.5g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.5g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.5g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
89221170|NCT00933530|Experimental|Cohort 5 - Dose Level E (1.0g/day)|"1.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 1.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 1.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
89221171|NCT00933530|Experimental|Cohort 6 - Dose Level F (2.0g/day)|"2.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 2.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 2.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
89522854|NCT00783263|Experimental|Rosuvastatin 10 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
89522855|NCT00783263|Active Comparator|Rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
89061231|NCT02627846|Active Comparator|MechanoChemical Ablation (ClariVein®)|Mechanochemical ablation (MOCA) is performed by a device called ClariVein® which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip.
89689762|NCT04343703|Experimental|iFightDepression for Suicide|The iFightDepression-Survive (iFD-S) program is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iFD tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. To that end, the expertise of a panel of mental health experts in suicide and cognitive-behavioral interventions will be asked. The iFD-S also provides telephone guidance (2h per participant) during the use of the program.
89689763|NCT04343703|Active Comparator|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual. TaU will consist of any routine procedures applied at each participating site.
89689764|NCT04343703|Experimental|Self Awareness of Mental Health|The Self Awareness of Mental Health (SAM) is an adaptation of the Youth Awareness of Mental Health program, originally developed for the Saving and Empowering Young Lives in Europe (SEYLE) study. The SAM aims to raise mental health awareness about risk and protective factors associated with suicide, provide knowledge about depression and anxiety, and enhance the skills needed to cope with adverse life events and suicidal behavior. The intervention is delivered by trained clinical psychologists in five, 45-60 minutes, face-to-face sessions.
89689765|NCT03024229|Other|LifePort® perfusion machine|Metabolomic analysis of the preservation fluid of the graft, donor and recipient urine by nuclear magnetic resonance spectroscopy, and if possible by liquid and gas chromatography coupled with mass spectrometry.
89689766|NCT02244437|Active Comparator|Ibuprofen|Ibuprofen has been shown to prevent AMS from previous studies.
89689767|NCT02244437|Experimental|Acetaminophen|Acetaminophen has not been tested yet in AMS prevention.
89689768|NCT03023839||Severe trauma patients|Severe Trauma patients (ISS >15) admitted to Intensive Care Unit (ICU)
89689769|NCT05448495|Experimental|Posterior TAP block|
89689770|NCT05448495|Active Comparator|ESPB|
89689771|NCT04346927|Experimental|Study Group|The group to which the exercise protocol consisting of breathing exercises, posture exercises, peripheral muscle training and light aerobic exercises will be applied.
89689772|NCT04346927|Active Comparator|Control Group|group to be given an exercise brochure
89689773|NCT03023527|Experimental|nivo-pom-dex|Nivolumab in combination with Pomalidomide and low dose dexamethasone
89689774|NCT03023527|Experimental|nivo-pom-dex-elo|Pomalidomide in combination with Nivolumab , dexamethasone and elotuzumab
89689775|NCT04359875|Experimental|Management by a student/general practitioner tandem|Patients will receive a phone call from the medical student who will inquire about their health. The medical student will then transmit this information to the general practitioner who will decide on the most suitable management for the patient.
89689776|NCT04359875|No Intervention|Usual care|"Usual care, i.e. patients will call their general practitioner when needed, up to 1 month, which corresponds to the estimated time for the intervention to be delivered to all patients in the intervention group.~At the end of the intervention at 1 month, patients in the usual care group will also receive a phone-call from the medical student/general practitioner tandem."
89689777|NCT04367285|Experimental|Sensor-based Training|
89689778|NCT04367285|Active Comparator|Upper limb motor training|
89689779|NCT02977689|Experimental|IDH305|IDH305 550 mg, oral, two times per day
89689780|NCT04366661|Experimental|screening|Participants undergo low dose CT of the chest
89689781|NCT02244515|Placebo Comparator|Group C|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered 10 ml NaCI 0.9%.
89689782|NCT02244515|Experimental|Group D|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
89689783|NCT03833375|No Intervention|Usual Care (n=20)|Control: general information about TBI from Center for Disease Control (CDC)/about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
89689784|NCT03833375|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
89689785|NCT05095935||Thoracic Adult|Use of Signia SDR for the transection of pulmonary arteries and veins in adult patients.
89689786|NCT05095935||Abdominal Adult|Use of Signia SDR for the transection of renal arteries and veins in adult patients.
89689787|NCT05095935||Abdominal Pediatric|Use of Signia SDR for the transection of the appendiceal stump and mesoappendix (simple acute appendicitis) in pediatric patients.
89689788|NCT04360031||Tacrolimus / Mycophenolate Mofetil|All patients receive maintenance immunosuppressive treatment of tacrolimus in combination with Mycophenolate Mofetil.
89689789|NCT00953719|Active Comparator|36 mm|36 mm ceramic head on ceramic acetabular liner
89689790|NCT00953719|Other|28 mm ceramic-on-polyethylene|28 mm ceramic-on-polyethylene historical control
89689791|NCT04366739|Experimental|CHLORPROMAZINE (CPZ)|Standard of Care (SOC) plus CHLORPROMAZINE (CPZ)
89689792|NCT04366739|Active Comparator|standard of care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparator arm"
89061232|NCT02603887|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89522856|NCT00664937|Placebo Comparator|I|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
89061236|NCT02576496|Experimental|Tinostamustine (EDO-S101)|EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2
89061237|NCT02573766|Experimental|Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
89061238|NCT02573766|Sham Comparator|Sham Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
89061239|NCT02573766|Other|Standard of Care|Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
89061240|NCT02554279|Experimental|menotropin|menotropins for injection
89061241|NCT02554279|Active Comparator|recombinant FSH|
89061242|NCT02535988|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of colorectal cancer receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy; Systemic agents are either capecitabine (Xeloda), paclitaxel or S-1;
89061243|NCT02515773|Experimental|MET and LIFE|Participants randomized to this group will receive both Metformin and lifestyle intervention.Participants randomized to treatment with MET will start at a dose of 500 mg orally at night and slowly titrated in 2-week intervals to ensure that each patient achieves maximum insulin-sensitizing effects of the drug while minimizing the chance of side effects. Investigators will also recommend that MET be taken with food to minimize side effects. If a participant's BMI percentile <5% (=underweight) his/her treatment with MET will be discontinued. Although the risk of low vitamin B12 while taking MET is associated with age > 50 years and having type II diabetes, Investigator will monitor B12 levels and a CBC throughout study participation.
89061244|NCT02515773|Experimental|Healthy lifestyle intervention (LIFE)|Participants randomized to this group will receive just lifestyle intervention alone.This healthy lifestyle intervention (LIFE) consists of counseling participants and families regarding a healthy eating plan, physical activity and sedentary activities. Prior to study initiation, clinical site staff will participate in a live (or taped) training session from a dietician to lean to administer LIFE. A trained site staff member (e.g. medical assistant or case manager) will meet with participants and their families for a 15-20 minute session at baseline that will focus on nutritional issues using the Traffic Light Plan (TLP).
89061245|NCT02511730|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
89061246|NCT02511730|Active Comparator|FFDM Alone|Breast Images with FFDM alone
89061247|NCT02510417|Experimental|VSTs against three viruses|Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team. If participants have a partial response (as defined by a 50% fall in viral load) they are eligible to receive up to 4 additional doses from day 28 after the initial infusion and at 2 weekly intervals thereafter.
89061248|NCT02484248|Active Comparator|cross-over of Ketotifen|Patients will begin the active ketotifen treatment first and cross over to placebo.
89061249|NCT02484248|Placebo Comparator|cross-over of Placebo|Patients will begin the placebo treatment first and cross over to the active ketotifen.
89061250|NCT02478788|Experimental|LR-MAS - Low-risk ADHD adolescents|ADHD adolescents without any first or second degree-relatives with bipolar disorder. Low-risk ADHD adolescents (n=60) will receive treatment with open-label mixed amphetamine salts-extended release (MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD.
89061251|NCT02478788|Experimental|HR-MAS - High-risk ADHD adolescents|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). The subjects in this group will receive mixed amphetamine salts-extended release( MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD."
89061252|NCT02478788|Placebo Comparator|HR-P - High-risk ADHD on Placebo|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). Following initiation of treatment, the ADHD adolescents will have regularly scheduled visits during which symptom and tolerability ratings will be performed."
89061253|NCT02478788|No Intervention|HC (Healthy Controls)|Healthy subjects (n=60) will be recruited from the community and will not receive medication but will undergo MR scans at the same intervals to assess normal variability in imaging parameters between time points as well as to adjust and interpret comparisons within patients (i.e., whether patient values are changing toward or away from those of healthy adolescents). Neuroimaging evaluations will be performed at baseline and Week 12 (or termination).
89061254|NCT02456194|Experimental|Calcium Sulfate + Antibiotics + Internal Fixation|
89522857|NCT00664937|Placebo Comparator|II|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
89061255|NCT02439450|Experimental|Arm 5: Viagenpumatucel-L + Nivolumab CPI Naive|Patients naïve to checkpoint inhibitor (CPI) therapy will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. After 18 weeks of treatment, patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
89061256|NCT02439450|Experimental|Arm 6: Viagenpumatucel-L + pembrolizumab|HS-110 dosing to be initiated at/before the start of the 3rd maintenance treatment cycle, or within 19 weeks of front-line pembrolizumab monotherapy. Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab every 3 weeks. Following the 13-week priming period, HS-110 injections will be administered for boosting every 3 weeks in combination with SOC pembrolizumab until confirmed disease progression or unacceptable toxicity, whichever occurs first.
89061257|NCT02439450|Experimental|Arm 5: Viagenpumatucel-L + Nivolumab CPI Progressor|Patients with prior checkpoint inhibitor (CPI) therapy will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. After 18 weeks of treatment, patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
89061258|NCT02439450|Experimental|Arm 6: Viagenpumatucel-L + pembrolizumab + pemetrexed|HS-110 dosing to be initiated at/before the start of the 3rd maintenance treatment cycle, or within 19 weeks of front-line pembrolizumab monotherapy. Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab + pemetrexed every 3 weeks. Following the 13-week priming period, HS-110 injections will be administered for boosting every 3 weeks in combination with SOC pembrolizumab + pemetrexed until confirmed disease progression or unacceptable toxicity, whichever occurs first.
89061259|NCT02437136|Experimental|Ph 2 NSCLC (squamous or adeno)|Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)
89061260|NCT02437136|Experimental|Ph 2 NSCLC pre-treated PD-1/LD-L1|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
89061261|NCT02437136|Experimental|Ph 2 Melanoma pre-treated PD-1/PD-L1|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
89061262|NCT02437136|Experimental|Ph 2 Mismatch Repair-Proficient CRC|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
89061263|NCT02435758|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
89061264|NCT02435758|No Intervention|Excision of Denonvilliers Fascia|Standard TME surgery (U-shaped excision of Denonvilliers fascia) in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
89061265|NCT02403778|Active Comparator|Ipilimumab|Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
89061266|NCT02403778|Experimental|VESANOID|Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.
89061267|NCT02386826|Experimental|INC280 + Bevacizumab|"Dose Escalation: 18 GBM patients received bevacizumab 10 mg/kg intravenously (IV) once every 2 weeks in combination with INC280 given by mouth (PO) starting at 100 mg twice daily and escalating on a 3+3 escalation pattern until the maximum tolerated dose (MTD) was determined.~Dose Expansion: Up to 45 GBM patients enrolled in 3 Cohorts:~Cohort A: 20 GBM patients - progressed during or after standard 1st-line therapy; Cohort B: 15 GBM patients - progressed during or after 2nd-line bevacizumab therapy; Cohort C: 10 unresectable GBM patients.~INC280: PO twice daily at the MTD. Bevacizumab: 10 mg/kg IV once every 2 weeks for Cohorts A and B; 15 mg/kg IV every 4 weeks for Cohort C Treatment cycles will be repeated every 28 days (4 weeks)."
89061268|NCT02378272|Experimental|Care manager for depression|A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression
89061269|NCT02378272|No Intervention|Treatment As Usual|Management of recruited patients with depression continued as usually applied at PCC
89061270|NCT02365454|Experimental|Thoracic Aortic Disease Single Arm Study|Thoracic Aortic Disease treated by Stent Graft Placement
89061271|NCT02312258|Placebo Comparator|Placebo|Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.
89221172|NCT00933530|Experimental|Cohort 7 - Dose Level G (3.0g/day)|"3.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 3.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 3.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period."
89221173|NCT00447694|Experimental|deferasirox every day for 77 weeks|Participants received Deferasirox 30 milligrams per kilogram per day (mg/kg/day) orally once daily (OD), 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 gram (g), tablets were dissolved in at least 100 milliliter (mL) of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed.
89221174|NCT00564278|Active Comparator|Standard antidepressant therapy|Participants will receive standard antidepressant therapy, including selecting among 9 FDA-approved antidepressants from several classes.
89221175|NCT00564278|Experimental|Motivational antidepressant therapy|Participants will receive motivational antidepressant therapy, including selecting among the same list of 9 FDA-approved antidepressants from several classes as in the control arm.
89221176|NCT04013906|Experimental|Rotational atherectomy|Patients will undergo rotational atherectomy
89221177|NCT04013906|Experimental|Intravascular lithotripsy|Patients will undergo intravascular lithotripsy
89221178|NCT00933842|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Dermacyd PH_DESILSTY_FL (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
89221179|NCT00565604|Experimental|Short Catheter Delviery|Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
89221180|NCT00933920|Active Comparator|Fed Group|
89221181|NCT00933920|Active Comparator|Fasted group|
89221182|NCT00938990|Active Comparator|Midazolam|
89221183|NCT00938990|Experimental|Etomidate|
89221184|NCT00933998|Experimental|Metanx|Metanx bid for 2 weeks then daily. Compare to non treated patient population
89221185|NCT00447226|Experimental|Lapatinib Oral Tablets|
89221186|NCT00447226|Placebo Comparator|Placebo Control|
89221187|NCT00446992|Experimental|Open Trial Group|The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.
89221188|NCT01028794|Experimental|autologous bone marrow mononuclear cell|On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
89221189|NCT01028794|Experimental|autologous bone marrow mononuclear cells|On day 7-10 after stroke, patient has 50ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
89221190|NCT00577031|Experimental|1|
89221191|NCT00565448|Experimental|Docetaxel/Cisplatin/5-FU (TCF)|"Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks~Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
89221192|NCT00565448|Active Comparator|Cisplatin/5-FU (CF)|"Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy.~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
89221193|NCT01012011||Group 1|
89221194|NCT00934076|Experimental|AT-101 plus Erlotinib|"Subjects will begin study treatment at 150 mg of erlotinib taken once daily in a continuous regimen expressed in 3 week cycles.~Subjects will begin treatment with oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
89221195|NCT04495803|Experimental|Experimental|After an initial assessment to confirm eligibility, the experimental group will receive 8 weekly sessions (2 hours long) of our augmented group CBT for perinatal anxiety during a global pandemic (n=6 per group). Participants will be re-assessed at post-treatment and at a 3-month follow-up to determine the effectiveness of the treatment and whether these effects are maintained in the long-term.
89221196|NCT00934154|Experimental|Thalidomide|MPT
89221197|NCT00934154|Active Comparator|Control|MP
89221198|NCT00446446|Experimental|Panitumumab|articipants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study.
89221199|NCT05078255|Placebo Comparator|placebo injections + placebo infusion|
89221200|NCT05078255|Experimental|Semaglutide 1.34 mg/ml injections + GIP infusion|
89221201|NCT05078255|Experimental|placebo injections + GIP infusion|
89221202|NCT05078255|Experimental|Semaglutide 1.34 mg/ml injections + placebo infusion|
89221203|NCT05077943|Active Comparator|No Breathing Exercise|Patients will do the second phase of cardiac rehabilitation for minimum 5 times per week, 30 minutes each time, in 3 months without being supervised
89221204|NCT05077943|Experimental|With Breathing Exercise|Patients will do the second phase of cardiac rehabilitation for minimum 5 times per week, 30 minutes each time and breathing and chest mobilization exercise for 3 times per week. They will be supervised through online meetings.
89221205|NCT04014608||Baseline Control|Standard Practice before the intervention was introduced
89221206|NCT04014608||Intervention initiative|Standard Practice plus Admission Surveillance for toxigenic C. difficile.
89221207|NCT02566967|Other|open label|open label use of tofacitinib at either 5 mg bid or 10 mg bid delending on treat to target goal
89221208|NCT00939068|Experimental|Telbivudine|Drug administration and follow up: the subjects in Telbivudine group start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continue to one month after delivery.And their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
89221209|NCT00939068|Other|Control|The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
89221210|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
89221211|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
89221212|NCT00934232|Experimental|Busulfan|Busulfex given to patients who are either ≥65 years or have renal insufficiency
89221213|NCT01013571|Experimental|1|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
89221214|NCT01013571|Experimental|2|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
89221215|NCT04061837|Experimental|MitralStitch repair system|Experimental group is allocated to use novel mitral valve repair system manufactured by Hangzhou Valgen Medtech Co., Ltd
89221216|NCT00934310||Ambulatory Surgical Patients 1|"The nature of the operating room time out for ambulatory surgical patients will be examined before implementation of the World Health Organization's Surgical Safety Checklist."
89061272|NCT02312258|Experimental|Ixazomib|Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.
89061273|NCT02276274|Experimental|Fasted dosing followed by fed dosing|Oral administration
89061274|NCT02276274|Experimental|Fed dosing followed by fasted dosing|Oral administration
89061275|NCT02221700|Experimental|Group I (leg massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks.
89061276|NCT02221700|Experimental|Group II (leg massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks.
89061277|NCT02221700|Experimental|Group III (head/neck/shoulder massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks.
89061278|NCT02221700|Experimental|Group IV (head/neck/shoulder massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks.
89061279|NCT02203903|Experimental|Tumor associated antigen lymphocytes (TAA-T)|"For Arm A Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first.~For Arm B Patients (pre-HSCT): TAA-T will be infused any time > 7 days after previous therapy for relapsed disease.~For Arm C Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first. All infusions will be within 5 months post-HSCT.~Five different dosing levels will be evaluated. Two to four patients will be evaluated on each dosing schedule (see below). This protocol is designed as a phase I dose-escalation study.~Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107 cells/m2 Dose Level Four: 4 x 107 cells/m2 Dose Level Five: 1 x 108 cells/m2 (ONLY applicable to Arm A patients)~Arm C patients will ONLY be enrolled at: Dose Level Four (4 x 107 cells/m2)"
89061280|NCT02203240|Experimental|Cocoa|3 servings of polyphenol-rich cocoa beverage consumed per day.
89061281|NCT02203240|Placebo Comparator|Placebo|3 servings of non-cocoa beverage consumed per day.
89061282|NCT02199184|Experimental|Treatment (DA-EPOCH and ofatumumab or rituximab)|Patients receive DA-EPOCH regimen comprising doxorubicin hydrochloride IV, vincristine sulfate IV, and etoposide IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 1-2 hours on day 5; and prednisone PO BID on days 1-5. Patients also receive ofatumumab IV over 2 hours on days 1, 2, and 11 of cycle 1; on days 1 and 8 of cycles 2 and 4; and on days 1 and 11 of cycle 3 for a total of 9 injections. Patients may receive rituximab instead of ofatumumab if their insurance provider does not cover the cost of ofatumumab. Patients receive rituximab IV over 2 hours on days 1 and 11 of cycles 1 and 3 and on days 2 and 8 of cycles 2 and 4. Treatment repeats every 21-28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89061283|NCT02196376||orthostatic tachycardia syndrome|participants with postural orthostatic tachycardia syndrome
89061284|NCT02196376||control subjects|participants not diagnosed with postural orthostatic tachycardia syndrome
89061285|NCT02185755|Active Comparator|Internet-Based Glucose Monitoring System|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and provide feedback limited to non-medicine related comments and suggestions.
89061286|NCT02185755|Other|Normal Medication Positive Control|The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
89061287|NCT02165007|Experimental|peripheral blood stem cell graft that are CD34+ selected|peripheral blood stem cell graft that are CD34+ selected. All patients will undergo reduced intensity conditioning regimen which followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device and Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year (see intervention).
89061288|NCT02164734|Active Comparator|Endotracheal intubation|Endotracheal intubation for surfactant administration, following remifentanil and atropine pre-medication
89061289|NCT02164734|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
89061290|NCT02131805|Experimental|Electronic Skin Surface Brachytherapy|The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.
89061291|NCT02110069|Active Comparator|Vincristine|"Induction phase: participants assigned to vincristine will receive vincristine weekly at a dose of 0.05mg/kg/dose IV (for participants less than 10kg) or a dose of 1.5 mg/m2/dose (for participants greater than 10kg) for 2 months.~Maintenance: if participants continue to receive vincristine weekly for 2 months, every 2 weeks for 5 months and every 3 weeks for 5 months."
89221217|NCT00934310||Ambulatory Surgical Patients 2|"The nature of the operating room time out for ambulatory surgical patients will be examined after implementation of the World Health Organization's Surgical Safety Checklist.Ambulatory surgical patients"
89061292|NCT02110069|Experimental|Sirolimus|"Sirolimus will be administered at a dose of 0.8mg/m2/dose twice a day on a continuous dosing schedule throughout the trial for participants randomized to Sirolimus or for participants who fail vincristine may cross-over to the sirolimus arm.~Sirolimus trough levels will be maintained between 10-15 ng/ml."
89061293|NCT02049515|Experimental|IPI-145|IPI-145 was administered orally and supplied as 5 mg and 25 mg formulated capsules.
89061294|NCT02049515|Active Comparator|Ofatumumab|Ofatumumab was administered as an intravenous (IV) infusion and was supplied in single-use vials at two strengths, 100 mg/5 milliliters (mL) and 1000 mg/50 mL.
89061295|NCT02046460|Active Comparator|Oral Anticoagulation|Vitamin K-Antagonists, target INR 2.0-3.0
89061296|NCT02046460|Experimental|Antiplatelets|Acetylsalicylic acid, 300mg o.p.d.
89061297|NCT02039401|Experimental|VM202|Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.
89061298|NCT02018497||Consecutive patients who consult a cardiologist|"Consecutive patients who consult a cardiologist - electrophysiologist since June 2006, regardless of the age or gender in the city of Medellin, Colombia. They could have consulted previously (considered as the enrollment date) if they had, at least, one measurement of their BP in supine position, and an immediate measurement of their BP in standing position that allows diagnosing their group of blood pressure. All patients have a record in paper and/or magnetic file and in OpenClinica.~No interventions."
89061299|NCT02004522|Experimental|Duvelisib|Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
89061300|NCT02004522|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.
89061301|NCT01956084|Experimental|LMP1/2 CTLs (Group A)|Patients receiving CTLs as adjunctive therapy following allogeneic stem transplant
89061302|NCT01956084|Experimental|LMP1/2 CTLs (Group B)|Patients receiving CTLs in relapse following allogeneic stem cell transplant
89061303|NCT01946503||Short bowel syndrome|Patients followed in a clinic for short bowel syndrome
89061304|NCT01946503||Healthy controls|Patients seen in a general pediatric clinic without chronic or acute diseases
89061305|NCT01945814|Experimental|CTL for CMV seropositive donors|CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
89061306|NCT01945814|Experimental|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
89061307|NCT01932697|Experimental|Treatment (docetaxel, hyperfractionated IMRT)|Patients receive docetaxel IV over 1 hour on days 1 and 8 and undergo hyperfractionated IMRT BID 5 days a week on days 1-12 for a total of 20 fractions.
89061308|NCT01820182|Experimental|capsocam capsula|capsocam capsula readings
89061309|NCT01816438||dysplasia or colorectal lesion|300 patients
89061310|NCT01803854||Gulf War Era Veterans|All Veterans who served in the uniformed services during 1990-1991 who signed consent forms, completed a survey, and provided a blood sample are included in the cohort.
89061311|NCT01752049|Active Comparator|Topical timolol maleate|"Drug: • Topical timolol maleate 0.5% drops~Topical timolol maleate 0.5% drops~Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~Study drops will be applied to 3 cutaneous telangiectasias per patient telangiectasia per patient)."
89061312|NCT01752049|Placebo Comparator|Placebo|"placebo saline drops~-Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient."
89061313|NCT01747447|Placebo Comparator|Vitamin D placebo + fish oil placebo|Daily vitamin D placebo and daily fish oil placebo
89061314|NCT01747447|Active Comparator|Vitamin D placebo + fish oil|Daily vitamin D placebo and daily fish oil capsule (1 g/d; EPA + DHA in a 1.2:1 ratio)
89061315|NCT01747447|Active Comparator|Vitamin D + fish oil placebo|Daily vitamin D (2,000 IU/d) and daily fish oil placebo
89061316|NCT01747447|Active Comparator|Vitamin D + fish oil|Daily vitamin D (2,000 IU/d) and daily fish oil capsule (1 g/d; EPA + DHA in a 1.2:1 ratio)
89061317|NCT01739309|Experimental|Abemaciclib|200 milligram (mg) abemaciclib administered orally every 12 hours on days 1 through 28 of a 28-day cycle
89061318|NCT01724346|Other|Arm A Post-Chlorambucil Therapy Followup|Patients randomized to Chlorambucil in the parent study(PCYC-1115-CA) who have not progressed at the time of parent study closure will be transferred to this Arm. Follow-up will continue until PD, unacceptable toxicity, or other reason for treatment discontinuation.
89221218|NCT00514449|Experimental|Valacyclovir|1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
89061319|NCT01724346|Experimental|Arm B Ibrutinib|Patients randomized to Ibrutinib in the parent study (PCYC-1115-CA) who have not experienced PD at the time of parent study closure will be transferred to this Arm to continue on Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
89061320|NCT01724346|Experimental|Arm C Second-line Ibrutinib|Patients who received Chlorambucil in the parent study (PCYC-1115-CA) and experienced PD are transferred to this Arm for Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
89061321|NCT01724346|Other|Arm D Alternative Anticancer Therapy|At the Investigator's discretion, alternative anticancer treatment is a therapeutic option for patients who experienced PD during Ibrutinib treatment or during or after Chlorambucil treatment. This Arm can also be considered if drug is discontinued for other reasons (e.g., intolerability or adverse event [AE]) or prior to experiencing PD).
89061322|NCT01659658|Experimental|Arm A: Ixazomib + Dexamethasone|Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 and dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15, and 22 of each 28-day cycle for up to a maximum of 95.2 months. Dexamethasone was increased up to 40 mg/day after 4 weeks, if tolerated.
89061323|NCT01659658|Active Comparator|Arm B: Dexamethasone + Melphalan|Participants received dexamethasone 20 mg, orally, and melphalan 0.22 mg/kg, orally once on Days 1 through 4 of each 28-day cycle, for up to a maximum of 72.4 months.
89061324|NCT01659658|Active Comparator|Arm B: Dexamethasone + Cyclophosphamide|Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15, and 22, and cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 of each 28-day cycle for up to a maximum of 72.4 months.
89061325|NCT01659658|Active Comparator|Arm B: Dexamethasone + Thalidomide|Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle, and thalidomide daily at a starting dose of 50 mg and increased, as tolerated, to a maximum of 200 mg, orally for up to a maximum of 72.4 months.
89061326|NCT01659658|Active Comparator|Arm B: Dexamethasone + Lenalidomide|Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle and lenalidomide 15 mg, orally, once on Days 1 through 21 every 28 days for up to a maximum of 72.4 months.
89061327|NCT01630421||affected, unaffected|Individuals with diagnosed ACC
89061328|NCT01619553||affected|individuals with keloids
89061329|NCT01619553||unaffected|unrelated unaffected controls or unaffected family members
89061330|NCT01586767|Active Comparator|Proton beam therapy|Subjects treated at Massachusetts General Hospital with proton beam therapy
89061331|NCT01586767|Active Comparator|IMRT|Intensity-modulated radiation therapy at institutions other than Massachusetts General Hospital
89061332|NCT01517243|Experimental|Alternating Sunitinib and Temsirolimus|"A cycle is defined as:~Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest"
89061333|NCT01407510|Experimental|Arm 1|
89061334|NCT01357161|Experimental|Part 1: adavosertib 225 mg + paclitaxel +carboplatin|During the open-label run-in, participants receive 225 mg adavosertib twice daily (BID) starting on Day 1 of Cycle 1 (cycle=21 days) for a total of 5 doses. Participants receive adavosertib in combination with paclitaxel (175 mg/m2) and carboplatin (area under the curve [AUC] 5).
89061335|NCT01357161|Experimental|Part 2: adavosertib 225 mg + paclitaxel +carboplatin|During Part 2, participants receive 225 mg adavosertib BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive adavosertib in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
89061336|NCT01357161|Placebo Comparator|Part 2: Placebo + paclitaxel +carboplatin|During Part 2, participants receive matched placebo to adavosertib BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive placebo in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
89061337|NCT01321073|Experimental|DelIVery for Pulmonary Arterial Hypertension Single Arm|All subjects were enrolled for implantation of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection.
89061338|NCT01308203|Experimental|Extended release niacin /laropiprant|The patients will be randomized to one of two arms. The intervention is with the extended release niacin laropiprant combination, that is an add on of the usual medication that the primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
89221219|NCT00514449|Placebo Comparator|Sugar pill|2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.
89061339|NCT01308203|Placebo Comparator|placebo|The patients will received placebo added to the usual therapy their primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
89061340|NCT01289171|Experimental|Glycolic acid|All who met the study criteria commenced once daily use of 15% glycolic acid lotion.
89061341|NCT01276704|Experimental|flaxseed lignan, SDG|Secoisolariciresinol diglycoside
89061342|NCT01276704|Placebo Comparator|Placebo|Matched Placebo
89061343|NCT01190930|Experimental|Arm A (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
89061344|NCT01190930|Experimental|Arm B (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
89061345|NCT01190930|Experimental|Arm B-LLy (4-week cycle maintenance)|See Detailed Description.
89061346|NCT01190930|Experimental|Arm C (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
89061347|NCT01190930|Experimental|Arm D (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
89061348|NCT01190930|Experimental|Arm LR-C (risk-adapted chemotherapy)|Patients receive consolidation, interim maintenance I, delayed intensification, interim maintenance II, and maintenance therapy. See detailed description.
89061349|NCT01190930|Experimental|Arm LR-M (risk-adapted chemotherapy)|Patients receive consolidation and maintenance therapy. See detailed description.
89061350|NCT01190930|Experimental|Arm SR DS (12-week cycle maintenance)|See Detailed Description
89061351|NCT01163682|Experimental|Electro-acupuncture|Subjects will receive 45 minute sessions scheduled once a week for 12 weeks with electro-acupuncture.
89061352|NCT01163682|Sham Comparator|Sham acupuncture|Subjects will receive 45 minute sessions scheduled once a week for 12 weeks with sham acupuncture.
89061353|NCT01047007|Experimental|Part 1: adavosertib 65 mg BID|Participants received 65 mg of adavosertib administered orally twice a day (BID) on Days 1-5 of a 21-day cycle.
89061354|NCT01047007|Experimental|Part 2 A1: adavosertib 20 mg BID+5-FU 1000 mg|Participants received 20 mg of adavosertib administered orally BID on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle.
89061355|NCT01047007|Experimental|Part 2 A2: adavosertib 20 mg QD+5-FU 1000 mg|Participants received 20 mg of adavosertib administered orally once a day (QD) on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle.
89061356|NCT01047007|Experimental|Parts 2B +3: adavosertib+5-FU+CDDP|Participants were to receive 20 mg or 65 mg of adavosertib administered either BID or QD on Days 1-5 of a 21-day cycle; 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle; and 60 mg/m^2 to 100 mg/m^2 of CDDP administered as an IV infusion on Day 1.
89061357|NCT01016613||Chronic Kidney Disease Cohort|chronic kidney disease patients with any type of kidney disease
89061358|NCT01016613||Matched Control Group|Healthy controls
89061359|NCT01016613||Trios|First degree relatives of pediatric chronic kidney disease cohort members
89061360|NCT01007578|Experimental|Paclitaxel treatment|Paclitaxel-coated balloon catheter angioplasty treated subjects
89061361|NCT01002872|Active Comparator|Lanthanum Carbonate (Fosrenol)|Subjects will receive the study drug Lanthanum Carbonate ( Fosrenol)
89061362|NCT01002872|Placebo Comparator|Placebo|Subject will receive placebo
89061363|NCT01000350|Experimental|Exercise Post Saline|Saline infusion 1L hours before exercise test
89061364|NCT01000350|Placebo Comparator|Placebo|Placebo given prior to exercise test
89061365|NCT00848588||1|Full and part-time 9-1-1 call takers employed at Ambulance Communication Centres in the Canadian provinces of Ontario, Nova Scotia, New Brunswick, as well as the city of Montreal, Quebec, Canada.
89061366|NCT00815815|Active Comparator|Continued inpatient treatment|Participants will undergo inpatient hospital treatment until they have gained enough weight to be discharged.
89061367|NCT00815815|Experimental|Sequenced treatment|Participants will begin with inpatient treatment, transition to day patient treatment, and then transition to outpatient treatment.
89061369|NCT00692471||1|Patients meeting the diagnostic criteria for the Postural Tachycardia Syndrome, a form of Orthostatic Intolerance
89061370|NCT00692471||2|Healthy control subjects who do not meet the criteria for the Postural Tachycardia Syndrome
89061371|NCT00648648|Experimental|adavosertib 325 mg Single Dose|Participants received adavosertib 325 mg, orally, on Day 1.
89061372|NCT00648648|Experimental|adavosertib 650 mg Single Dose|Participants received adavosertib 650 mg, orally, on Day 1.
89061373|NCT00648648|Experimental|adavosertib 1300 mg Single Dose|Participants received adavosertib 1300 mg, orally, on Day 1.
89061374|NCT00648648|Experimental|adavosertib 100 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an intravenous (IV) infusion on Days 1, 8, and 15 in each 4-week cycle plus adavosertib 100 mg single dose, orally, on Day 2 of each cycle.
89061375|NCT00648648|Experimental|adavosertib 200 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 in each 4-week cycle plus adavosertib 200 mg single dose, orally, on Day 2 of each cycle.
89061376|NCT00648648|Experimental|adavosertib 100 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 100 mg single dose orally, on Day 2 of each cycle.
89061377|NCT00648648|Experimental|adavosertib 200 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 200 mg single dose orally, on Day 2 of each cycle.
89061378|NCT00648648|Experimental|adavosertib 100 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin at an area under the time curve concentration of 5 mg/min/ml (AUC5) as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 100 mg single dose orally, on Day 2 of each cycle.
89061379|NCT00648648|Experimental|adavosertib 200 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 200 mg single dose orally, on Day 2 of each cycle.
89061380|NCT00648648|Experimental|adavosertib 325 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 325 mg single dose orally, on Day 2 of each cycle.
89061381|NCT00648648|Experimental|adavosertib 25 mg BID x2.5 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4-week cycle plus adavosertib 25 mg orally twice daily (BID) for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of adavosertib 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each cycle.
89061382|NCT00648648|Experimental|adavosertib 50/25 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 doses of adavosertib 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
89061383|NCT00648648|Experimental|adavosertib 50 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given once weekly for 3 consecutive weeks of a 4 week cycle plus adavosertib 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of adavosertib 50 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
89061384|NCT00648648|Experimental|adavosertib 100 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 100 mg orally once daily (QD) on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
89061385|NCT00648648|Experimental|adavosertib 125 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 125 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
89061386|NCT00648648|Experimental|adavosertib 150 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 150 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
89061387|NCT00648648|Experimental|adavosertib 175 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
89061388|NCT00648648|Experimental|adavosertib 200 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus adavosertib 200 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
89061389|NCT00648648|Experimental|adavosertib 50 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 50 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89061390|NCT00648648|Experimental|adavosertib 100 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 100 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89061391|NCT00648648|Experimental|adavosertib 125 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 125 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89061392|NCT00648648|Experimental|adavosertib 150 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 150 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89221220|NCT04061759|Active Comparator|Soft tissue mobilization&stabilization exercises|"The following manual therapy techniques will be applied:~Soft Tissue Mobilization;~Pretzel Maneuvers;~Pelvis Backward-Distraction;~Trunk Rotation;~Multifidus Mobilization; and~Piriformis Transverse Friction Massage"
89061393|NCT00648648|Experimental|adavosertib 200 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 200 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89221221|NCT04061759|Active Comparator|Kinesiotape&stabilization exercises|The Kinesio® Taping muscle technique, with 10-25% of the stretch of the tape, will be applied to the sacrospinalis, quadratus lumborum, gluteus medius/maximus and piriformis muscles, based on the the weakness that patient's muscles had. Factors interfering with tape adhesion, such as sweat or hair, will be removed before the application. The tape can stay in place for 3-5 days due to its water resistant and breathable properties
89061394|NCT00648648|Experimental|adavosertib 250 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 250 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89061395|NCT00648648|Experimental|adavosertib 75 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 75 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89061396|NCT00648648|Experimental|adavosertib 150 mg BID x 2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 150 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89061397|NCT00648648|Experimental|adavosertib 225 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 225 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89061398|NCT00648648|Experimental|adavosertib 325 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus adavosertib 325 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
89061399|NCT00625638|Experimental|Standard Care Only|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
89061400|NCT00625638|Experimental|Standard Care + IVR System|Standard Care + Interactive Voice Response (IVR) System Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes. Phone calls made once daily, each taking about 3-5 minutes to complete.
89061401|NCT00614172|Experimental|Proton Radiotherapy|Two week course of proton radiotherapy to the breast.
89061402|NCT00608725|Other|Patients|Patients with orthostatic intolerance
89061403|NCT00608725|Other|Healthy Control Subjects|"Healthy subjects to determine normal response"
89061404|NCT00581633|Experimental|1|saline infusion for sodium loading
89061405|NCT00581373|Experimental|1|water 16 oz
89061406|NCT00581321|Experimental|1|water ingestion
89061407|NCT00580996|Experimental|1|16 oz water in AM
89061408|NCT00580996|Active Comparator|2|water 1 oz in AM
89061409|NCT00546351|Experimental|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.
89061411|NCT00536172|Experimental|Escitalopram|Participants will receive treatment with escitalopram
89061412|NCT00536172|Placebo Comparator|Placebo|Participants will receive treatment with placebo
89061413|NCT00477100||Observational (biospecimen and medical data collection)|Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.
89061414|NCT00386906|Other|Sentinel Lymph Node (SLN) Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
89061415|NCT00345930||2|Individuals without drug induced liver disease
89061416|NCT00345930||1|Individuals with drug induced liver disease
89061417|NCT00003838|Other|Donor|The HLA matched donor will receive granulocyte colony-stimulating factor (G-CSF) with apheresis collections of PBPC on day 5 and day 6 if required. G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
89061418|NCT00003838|Experimental|Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality|Participants at high risk for transplant related complications and mortality will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver >5x10^6 CD34+ cells/kg.
89061419|NCT00003838|Experimental|Group B: Stem Cell Transplant in Debilitating Hematologic Diseases|Participants with hematologic diseases associated with reasonable longevity, shown to be curable by allogeneic Bone Marrow Transplant (BMT) but where concern for a high procedural mortality with conventional BMT will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m^2 intravenously daily x 5 days followed by a peripheral blood hematopoietic progenitor cell graft targeted to deliver >5x10^6 CD34+ cells/kg.
89061420|NCT06031636||Oncolytic adenovirus(H101) combined with PD-1 inhibitors|This study observed 2-4 treatment cycles. For the convenience of statistics, this project stipulated that the first combined medication (v1) after the patient was enrolled in this study was administered with oncolytic virus (recombinant human adenovirus type 5) by intratumoral injection or intrapleural injection on the 1-3 days. On the 4th or 5th day, PD-1 injection was administered once per cycle. The completion of two visits in this study is considered a completed case, and subsequent treatment is determined jointly by the researcher and the subject.
89061421|NCT06031610||Individuals accepted CAS|"Procedure: CAS and Standard medical treatment.~Other:~Neuropsychological testing.~Multimodal CT: included NCCT+CTP and reconstructed 4D-CTA.~Multimodal MRI included T1, T2-FLAIR, DWI, DTI, SWI, fMRI.~Optical coherence tomography angiography."
89061422|NCT06031610||Individuals accepted standard medical treatment alone.|"Procedure: Standard medical treatment alone.~Other:~Neuropsychological testing.~Multimodal CT: included NCCT+CTP and reconstructed 4D-CTA.~Multimodal MRI includedT1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI.~Optical coherence tomography angiography."
89061423|NCT06031545|Experimental|Long peripheral venous catheters|In the test group used LPCs during the perioperative period in obese patients
89061424|NCT06031545|Other|Midline catheters|In the control group used LPCs during the perioperative period in obese patients
89061425|NCT06031532||cases group|Non-alcoholic fatty liver patients
89061426|NCT06031532||control group|healthy persons
89061427|NCT06031519||Hypertrophic Obstructive Cardiomyopathy Patients underwent Liwen Procedure|
89061428|NCT06031506|Experimental|quad zygomatic hybrid maxillary prosthesis|All patients will be rehabilitated with immediate loaded hybrid prosthesis supported by 4 zygomatic implants.
89061429|NCT06031480|Experimental|anlotinib+TQB2450|
89061430|NCT06031389|Experimental|Henagliflozin|On the basis of basic treatment, the patients in the Hengglinide（tabuletta） intervention group were given Hengglinide once a day, 10mg or 5mg each time in the morning, and continued to intervene for 12 months.
89061431|NCT06031389|Placebo Comparator|Placebo|The blank control group was treated with placebo (starch tablets) once a day, 10mg or 5mg each time, taken in the morning for 12 months.
89061432|NCT06031376||Fruquintinib plus PD-1 inhibitors|In fruquintinib plus PD-1 inhibitors group,The patients were treated orally with Fruquintinib (5mg once daily for 14 days on/7 days off, over a 21-day cycle), combined with 1 of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
89061433|NCT06031376||TAS-102 plus bevacizumab|In TAS-102 plus BEV group, Patients received TAS-102 (35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days) and bevacizumab (5 mg /kg, intravenously, on days 1 and 15, every 28 days). Bevacizumab was approved to be a 30-minute intravenous infusion before TAS-102.
89061434|NCT06031350||Diseased eyes|The 30 diseased eyes of the patients were considered the case group.
89061435|NCT06031350||Fellow eyes|The 30 fellow eyes of the patients were considered the control group.
89061436|NCT06031298|Experimental|Alveolar ridge preservation using demineralized dentin graft at 12 weeks.|
89061437|NCT06031298|Active Comparator|Alveolar ridge preservation using demineralized dentin graft at 18 weeks|
89061438|NCT06031298|Active Comparator|Alveolar ridge preservation using demineralized dentin graft at 24 weeks|
89061439|NCT06031285|Experimental|Perioperative of Sinitilimab, bevacizumab biosimilar plus TACE-HAIC for PVTT-HCC|Perioperative of Sinitilimab, bevacizumab biosimilar and TACE-HAIC for HCC patients with PVTT
89061440|NCT06031246|Experimental|Selective Lymph Node Dissection|Selective Lymph Node Dissection is performed for cT1N0M0 Invasive Non-small Cell Lung Cancer With CTR>0.5 Located in the Apical Segment
89061441|NCT06031168|Experimental|Test group|
89061442|NCT06031168|Active Comparator|Control group|
89061443|NCT06031129|Experimental|Butorphanol|
89061444|NCT06031129|Placebo Comparator|normal saline|
89061445|NCT06031116|Experimental|ceramic soft tissue bur|Eight dental arches were treated by ceramic soft tissue bur
89061446|NCT06031116|Active Comparator|scalpel|Eight dental arches were treated by conventional scalpel technique
89061447|NCT06031103|Active Comparator|childhood urolithiasis treated with mini PCNL Procedure|pediatric patients with upper urinary tract calculus treated with mini-PCNL procedure
89061448|NCT06031103|Active Comparator|childhood urolithiasis treated with RIRS Procedure|pediatric patients with upper urinary tract calculus treated with mini-PCNL procedure
89061449|NCT06031090|Active Comparator|Group Cl (clonidine group)|will be given intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia
89061450|NCT06031090|Active Comparator|Group G (granisetron group)|will be given intravenous 1mg of granisetron 20 minutes before spinal anesthesia.
89061451|NCT06031090|Placebo Comparator|Group C (control group)|will be given intravenous10ml normal saline 20 minutes before spinal anesthesia
89061452|NCT06031064||Patients with chronic watery diarrhoea and clinical suspicion of MC|
89061453|NCT06031051|Other|Pillcam Crohn's Capsule Endoscopy and colonoscopy|All patients will be submitted to a Pillcam Crohn's Capsule Endoscopy (Medtronic) previous their colonoscopy
89061454|NCT06031038|No Intervention|control group|
89061455|NCT06031038|Active Comparator|TECCU group|
89061456|NCT06031012|Experimental|glutamine combined with thalidomide|"L-Glutamine: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take three times a day, two tablets each time; once in the morning, once in the afternoon, and once in the evening.~Thalidomide: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take orally at 100mg, once every evening."
89061457|NCT06031012|Active Comparator|glutamine alone|L-Glutamine: Start oral administration on the first day of radiation therapy, continuing until one week after radiation therapy ends. Take three times a day, two tablets each time; once in the morning, once in the afternoon, and once in the evening.
89061458|NCT06030973||Healthcare professionals involved in neuromodulation|
89061459|NCT06030960|Experimental|Group 1|Patients with Chronic Low Back Pain (CLBP) who will receive Virtual Reality (VR) stabilization exercises, regular stabilization exercises and patient instructions and education
89061460|NCT06030960|Active Comparator|Group 2|Patients with Chronic Low Back Pain (CLBP) who will receive regular stabilization exercises and patient instructions and education
89061461|NCT06030934|Experimental|Patients who have failed previous standard chemotherapy|
89061462|NCT06030934|Experimental|Patients with SD or above obtained by previous first-line PD-1 antibody therapy|
89061463|NCT06030869||Cohort-A: Patients with actionable targets|In the OncoKB(Precision Oncology Knowledge Base) database, the gene alteration has a variant of clinical evidence in this tumor or other tumor types and is considered to be an interventional variant. Cohort-A may include different observation subgroups. For example, substudy-A1: monotherapy/combination therapy for patients with A1-relative. Substudy-Ax: monotherapy/combination therapy for patients with Ax-relative.
89522858|NCT00664937|Placebo Comparator|III|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
89522859|NCT03389165|Experimental|Elderly adults|Stair climbing with and without a wearable hip assist robot
89061464|NCT06030869||Cohort-B: Patients with potential actionable targets|In cohort-B, the gene alteration that MTB combines with clinical practice and literature reports that can match targeted therapy is considered to be potential actionable targets. Cohort-B also includes different observation subgroups and clinical trials may conduct in each subgroup. For example, substudy-B1(TP53 as driver gene), substudy-B2(RAS as driver gene), substudy-B3(MAP2K1 as driver gene), substudy-B4(PTEN Loss as driver gene), substudy-B5(11q13 co-amplification as driver genes), Substudy-B6(concomitant actionable alterations), substudy-B7(other driver genes). MTB-guided therapy was defined as having a clinical benefit if the PFS ratio between the longest PFS on MTB-guided therapy and the PFS on the last therapy before MTB-guided therapy was ≥1.3 (i.e., using patients as their own controls) for each substudy. To meet the primary objective, at least 35% of participants had to achieve a PF2S/PFS1 ≥ 1.3 in a sample population of 25 evaluable patients.
89061465|NCT06030869||Cohort-C: Patients with non-actionable targets|MTB combined with clinical practice and literature reports can not match the gene alteration of targeted therapy, which is considered as an irreversible gene alteration.
89061466|NCT06030856|Experimental|STI test kits for home use coupled with self-administered behavioural risk assessment|The adolescent will receive STI test kits (NG, CT and TV) for home use coupled with self-administered behavioural risk assessment at the screening and enrolment visit.
89061467|NCT06030856|Active Comparator|Self-administered behavioural risk assessment only (standard of care)|The adolescent will receive a self-administered behavioural risk assessment at the screening and enrolment visit
89061468|NCT06030830|Experimental|Intervention|Participants will be instructed not to use the smartphone during breastfeeding for a week
89061469|NCT06030830|No Intervention|Control|Participants will not be instructed not to use the smartphone during breastfeeding for a week
89061470|NCT06030817|Experimental|99mTc-CNDG SPECT/CT|Inject 99mTc-CNDG and then perform SPECT/CT scan.
89061471|NCT06030791||Group 1|All examinees will undergo ACL reconstruction using BTB graft. MRI scans of operated knee will be conducted at two time points: 4 weeks and 1 year after ACL reconstruction surgery.
89061472|NCT06030791||Group 2|All examinees will undergo ACL reconstruction using BTB graft. MRI scans of operated knee will be conducted at two time points: 4 weeks and 1 year after ACL reconstruction surgery.
89061473|NCT06030752|Experimental|WMT|WMT with microbiota suspension Participants undergo repeated FMT with ~50ml microbiota suspension.
89061474|NCT06030674|Experimental|Exposure to secondhand cannabis smoke in public places|The research staff and participants will travel together to a public location by either ride share vehicles, taxis or public transit. The study will arrange and pay for the transit. Staff and participants will be exposed to ambient air in public places where cannabis products are being consumed by smoking, vaporizing or dabbing. Participants will remain in the company of the laboratory staff throughout the exposure. The exposures will last 0.5-4 hours, depending on the nature and duration of the event. Staff and participants will travel together back to the laboratory for the post-exposure study measures.
89061475|NCT06030648|Experimental|IV-MSC for cALD (Early Disease/Bridge Therapy)|Patients with active, cerebral adrenoleukodystrophy (cALD) as a bridge to hematopoietic stem cell transplant or gene therapy.
89061476|NCT06030648|Experimental|IV-MSC for cALD (Advanced Disease)|Patients with active, cerebral adrenoleukodystrophy (cALD) who are too advanced for gene therapy or HSCT.
89061477|NCT06030596||coronary artery disease|Suspected or known coronary artery disease
89061478|NCT06030570||Subjects with low back pain|Patients of University Hospitals Leuven participating in the interdisciplinary spine rehabilitation program (REVITA)
89061479|NCT06030544|Experimental|OA-enriched functional olive oil|Functional olive oil elaborated enriching the control olive oil with high purity (> 95 %) Oleanolic acid from olive leaf up to 600 mg OA/kg oil.
89061480|NCT06030544|Active Comparator|Control olive oil|Commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
89061481|NCT06030531||Inpatients|"Prospective participants who meet the study inclusion criteria will be identified by bi-weekly chart review of all new admissions to the acute inpatient spinal cord injury unit at the Shirley Ryan AbilityLab (SRAlab).~Eligible patients will be invited to participate by the clinical staff during their first week of admission."
89061482|NCT06030531||Control group|We will enroll non-injured healthy individuals to compare the level of biomarkers
89061483|NCT06030518|Experimental|Patient undergoing upper Gi endoscopy|"Children attending Sheffield Childrens' Hospital Gastroenterology out-patients departments between the ages of 11-16 years of age who require OGD to investigate abdominal pain or discomfort will be invited to take part in the study.~Interventions~The study will begin when capsule endoscopy is performed by a Clinical Research Fellow at the Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Trust."
89061484|NCT06030492|Experimental|hydrogen peroxide group|hydrogen peroxide group Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution.(
89061485|NCT06030492|Placebo Comparator|normal Saline solution|Packing the placental bed with a towel soaked with normal Saline solution
89061486|NCT06030479|Experimental|Topical Adrenaline Group|Topical adrenaline group
89061487|NCT06030479|Placebo Comparator|Warm saline Group|Warm saline Group
89061488|NCT06030453|Experimental|SMART HOME Care Gruop|"Experimental Group:SMART HOME refers to a set of interventions aimed at preventing delirium. Sleep hygiene.Multidisciplinary collaboration.Assessment of pain/anxiety/agitation.Release of tracheal tubes and restraints.Time and schedule.Home-like environment and Hearing.Orientation support.Medication review and adjustment.Early mobilization and nutrition."
89061489|NCT06030453|Active Comparator|Control Group|Control Group: The control group will receive traditional comprehensive care in the ICU based on the PADIS (pain, agitation, delirium, immobility, sleep disruption) assessment. This care will be administered by ICU nurses and will include pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions.
89061490|NCT06030375|Active Comparator|KAND567 in ascending doses|In each of the 3 cohorts, 6 subjects were planned to be randomised to receive KAND567. The dose levels were 33.8 mg/6 h (cohort 1), 67 mg/6 h (cohort 2), or 134 mg/6 h (cohort 3).
89061491|NCT06030375|Placebo Comparator|Placebo|In each of the 3 cohorts, 2 subjects were planned to be randomised to receive Placebo.
89061492|NCT06030310|Experimental|INPP Movement Program Group|The INPP Movement Program Group will consist on a group of children aged between 7 and 9 years old enrolled in the second grade class of a catalan school that will participate in the school motor program provided by the Institute of Neuro-Physiology Psychology (INPP). This program consists of exercises that replicate the developmental movements of babies. Each day, a set of specific exercises will be performed, it will be practiced for 6 weeks and replaced by another set of exercises. They will be conducted for 15 minutes daily throughout the entire academic year.
89061493|NCT06030310|No Intervention|Non Intervention Group|Children aged between 7 and 9 years old enrolled in the second grade at a catalan school. Students in the Non Intervention Group will continue with their regular academic school year without any additional intervention. If any student from the INPP Movement Program Group chooses not to participate in the study, they will join the class of the Non Intervention Group during the time when their peers are engaged in the school motor program.
89061494|NCT06029335||Diffuse cutaneous Systemic sclerosis|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
89061495|NCT06029335||Limited cutaneous Systemic sclerosis|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
89061496|NCT06029335||Primary Raynaud's|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
89061497|NCT06029335||Healthy|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
89061498|NCT06029335||Rheumatoid arthritis|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
89061499|NCT06029335||Inflammatory myopathies|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
89061500|NCT06029335||Systemic lupus erythematosus|Physical examination, routine blood, immunoserology, and special biomarker laboratory examination. General health, functional, and quality of life questionnaires, and neuropsychological measures are administered.
89061501|NCT06028490|Experimental|Interleukin-4 receptor responders 1|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
89061502|NCT06028490|Experimental|Interleukin-4 receptor responders 2|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
89061503|NCT06028490|Placebo Comparator|Placebo|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
89061504|NCT06028386|Active Comparator|Arm 1-AC5® Advanced Wound System|The intervention in this arm is the application of a synthetic self assembling peptide matrix (AC5) to UT Grade 1A diabetic foot ulcers
89061505|NCT06028386|Placebo Comparator|Arm2- Fibracol Plus Collagen dressing|The intervention in this arm is the application of collagen dressings to UT Grade 1A diabetic foot ulcers
89061506|NCT06028100|Active Comparator|espb group|The first group underwent sacral espb at the end of surgery. The lumbosacral region was sterilised with povidine iodine and then draped with the patient in prone position. The linear ultrasound probe was placed in the midline on the spinous process of the 5th lumbar vertebra after the sterile covering had been applied. After observation of the sacrum, the level of the 2nd median crest was determined and the ultrasound probe was moved 1.5-2 cm laterally and the 2nd intermediate crest and the erector spinae muscle between the two were observed. 22 G 50 mm needle was advanced from caudal to cranial direction to the sacral crest using in-plane technique, after confirming the needle position with 1-2 ml saline, 0.25% bupivacaine 20 ml was administered, local anaesthesia was observed to spread cauda-cranially separating the erector spinae muscle from the sacral crest, the same procedure was performed on the opposite side
89061507|NCT06028100|No Intervention|control group|The second group had no any block
89061508|NCT06027892|Experimental|Two-fraction stereotactic radiotherapy|Participants receive stereotactic ablative radiotherapy in two treatments to a dose of 27 Gy, with the options to boost a high-grade lesion to 30 Gy
89061509|NCT06027892|Active Comparator|Five-fraction stereotactic radiotherapy|Participants receive stereotactic ablative radiotherapy in five treatments to a dose of 40 Gy, with the options to boost a high-grade lesion to 45 Gy
89061510|NCT06027567|Experimental|Semaglutide|"Semaglutide up-titration to 2.4 mg for 10 months initially combined with a Very Low Calorie Diet (800 kcal/day) for 8 weeks.~Counselling by dietician Standard medical treatment of intracranial hypertension"
89061511|NCT06027567|Active Comparator|Standard care (dietician)|Standard weight loss intervention Counselling by dietician Standard medical treatment of intracranial hypertension
89061512|NCT06027528|Experimental|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket
89061513|NCT06027528|Active Comparator|dentin graft|extracted tooth will be grafted in the extracted socket
89061514|NCT06027099|Experimental|MI-Opioid Taper and tizanidine|
89061515|NCT06027099|Experimental|MI-Opioid Taper and placebo|
89061516|NCT06027099|Active Comparator|Enhanced Usual Care|
89061517|NCT06027021||Treatment group|Patients received radioembolization with hepatocellular cancer or colorectal cancer liver metastases
89061518|NCT06026800|Experimental|Personalized mRNA Vaccine iNeo-Vac-R01 with standard first-line treatment|Subjects will receive at least 4 cycles of standard first-line treatment according to Chinese Society of Clinical Oncology (CSCO) clinical guidelines. Then subjects will receive iNeo-Vac-R01 via IH injection on Day 1 of each 21-day cycle for up to 9 cycles at an applicable dose, identified during the dose escalation phase of the study.
89061519|NCT06026774|Experimental|iNeo-Vac-R01 in combination with standard adjuvant therapy|Subjects will receive at least 4 cycles of standard adjuvant therapy according to CSCO clinical guidelines after surgery. Then subjects will receive iNeo-Vac-R01 via IH injection on Day 1 of each 21-day cycle for up to 9 cycles at an applicable dose, identified during the dose escalation phase of the study.
89061520|NCT06026683|Active Comparator|CSP (Conduction system pacing)|Patients with pacemaker implanted with conduction system pacing.
89061521|NCT06026683|Active Comparator|RVAP (Right ventricular apical pacing)|Patients with pacemaker implanted with right ventricular apical pacing.
89061522|NCT06026358|Experimental|Tirbanibulin|Treatment
89061523|NCT06026358|Placebo Comparator|Placebo|Placebo
89061524|NCT06020001|Experimental|AP203 mixture (RESCOVIN®) in capsule form|Patients with an increased incidence of upper respiratory tract infection
89061525|NCT06020001|Experimental|AP203 mixture (RESCOVIN®) in syrup form|Patients with an increased incidence of upper respiratory tract infection
89061526|NCT06020001|Placebo Comparator|Placebo|Patients with an increased incidence of upper respiratory tract infection
89061527|NCT06019702|Experimental|Personalized mRNA Vaccine iNeo-Vac-R01|The traditional 3+3 design will be used in dose escalation. In dose escalation phase, subjects are expected to be enrolled at 50 μg, 100 μg and 150 μg (3-6 subjects in each group). The low dose group will be enrolled first. Subjects will receive iNeo-Vac-R01 administered via a hypodermic (IH) injection on Day 1 of each 21-day cycle for up to 9 cycles. The investigators will choose the optimal clinical dose for dose expansion phase.
89061528|NCT06016010|Experimental|Standard-dose USL group|2 tablets(1 USL, 1 placebo) b.i.d for 12 weeks
89061529|NCT06016010|Experimental|High-dose USL group|2 tablets(2 USL) b.i.d for 12 weeks
89061530|NCT06016010|Placebo Comparator|Placebo group|2 tablets(2 placebo) b.i.d for 12 weeks
89061531|NCT06014073|Experimental|Patients with refractory or relapsed B-cell NHL|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, TRAC and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T.
89061532|NCT06012110|Experimental|Transcutaneous electrical stimulation to reduce spasticity in PLS|Primary lateral sclerosis (PLS) is a progressive upper motor neuron neurodegenerative disorder. A hallmark of PLS is a presentation with lower extremity stiffness and spasticity as well as bulbar involvement. The investigators will be performing a preliminary study designed to assess transcutaneous electrical stimulation (tES), a non-pharmacological and non-invasive modality used in spinal cord injury and multiple sclerosis patients, as a treatment for reducing spasticity in the lower extremities and increasing mobility in patients with PLS.
89061533|NCT06007417|Experimental|GenSci004|
89061534|NCT06007417|Active Comparator|Genotropin|
89061535|NCT05990231|Experimental|Cadonilimab combined with anlotinib|
89061536|NCT05989906|Active Comparator|Usual Care|Participant will take part in the usual care during inpatient rehabilitation
89061537|NCT05989906|Experimental|Spring Interval Training (SIT)|Participant will take part in SIT approximately three times per week during inpatient rehabilitation.
89061538|NCT05989906|Experimental|SIT + ERGO|Participant will take part in SIT approximately three times per week during inpatient rehabilitation. In addition, participant will be provided with an consumer grade ergometer for home use.
89522860|NCT04951661|Experimental|All Participants|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
89061539|NCT05989906|Experimental|SIT + ERGO + MI|Participant will take part in SIT approximately three times per week during inpatient rehabilitation. In addition, participant will be provided with an consumer grade ergometer for home use. The participant will receive Motivational Interviewing sessions with a rehab psychologist one time per week (approximately 4 sessions) during inpatient rehabilitation and one time per month for six months after discharge from the hospital
89061540|NCT05985005|Experimental|online simulation of high alert medication safety training|
89061541|NCT05985005|No Intervention|classroom teaching regarding high alert medication|
89061542|NCT05980247|No Intervention|Control|No application and no thimble patch.
89061543|NCT05980247|Experimental|Use of the thimble application but not the thimble patch|Use of the thimble application but not the thimble patch
89061544|NCT05980247|Experimental|Use of the thimble patch but not the thimble application|Use of the thimble patch but not the thimble application
89061545|NCT05980247|Experimental|Use of both thimble application and thimble patch|Use of both thimble application and thimble patch
89061546|NCT05975060|Experimental|Group-A XBB.1.5 Vaccine (Booster)|The Monovalent [5 μg/50 μg] NVX-CoV2601 XBB.1.5 Vaccine (Booster)
89061547|NCT05975060|Active Comparator|Group-B The monovalent XBB.1.5 Vaccine (Single Dose).|Group-B The monovalent [5 μg/50 μg] NVX-CoV2601 XBB.1.5 Vaccine (Single Dose).
89061548|NCT05961306||antenatal period|Pregnant women between 20 and 24 weeks of pregnancy will be invited to participate
89061549|NCT05961306||postnatal period|Moms, 6 to 10 weeks after delivery will be invited to participate
89061550|NCT05951985|Experimental|HIFT Exercise|In this single group design, all participants will be provided with up to two years of twice weekly supervised group exercise.
89061551|NCT05931965|No Intervention|Antidepressant|Participants receive either escitalopram 10-20mg, sertraline 50-100mg, fluoxetine 20-40mg, duloxetine 30-60mg, mirtazapine 15-30mg, venlafaxine 75-150mg, trazodone 50-100mg, amitriptyline 25-75mg, or clomipramine 25-75mg orally daily for 4 weeks.
89061552|NCT05931965|Experimental|Antidepressant and L-methylfolate|Participants receive a combination of antidepressant and L-methylfolate 400µg twice daily orally for 4 weeks
89061553|NCT05931965|Experimental|Antidepressant and injectable mecobalamin|Participants receive a combination of antidepressant and mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
89061554|NCT05931965|Experimental|Antidepressant and Magnesium|Participants receive a combination of antidepressant and magnesium glycinate 400mg (Elemental: ≈120mg) twice daily orally for 4 weeks
89061555|NCT05921578|No Intervention|Routine diagnostic workup|
89061556|NCT05921578|Experimental|Routine diagnostic workup + pre-operative CBCT-based planning|
89061557|NCT05917964|Experimental|Cohort A (fasted-fed)|Cohort A was administered once in Cycle 1 Day1 under fasted condition and once in Cycle 2 Day1 (i.e., Day8 after Cycle 1 administration) under fed condition for a total of 2 doses.
89061558|NCT05917964|Experimental|Cohort B (fed-fasted)|Cohort B was administered once in Cycle 1 Day 1 under fed condition and once in Cycle 2 Day 1 (i.e., D8 after Cycle 1 administration) under fasted conditions for a total of 2 doses.
89061559|NCT05915806|Experimental|High-dose DHA|Enteral supplementation with high-dose DHA in the neonatal period.
89061560|NCT05915806|Placebo Comparator|Control|Control.
89061561|NCT05908955|Active Comparator|PVI|Participants in this group will receive pulmonary vein isolation.
89061562|NCT05908955|Experimental|PVI+SVCI|Participants in this group will receive superior vena cava isolation in addition to pulmonary vein isolation.
89061563|NCT05908487|Other|Clinician Trainees- Cluster 1|Within each participating institution, clinician clusters are randomized to 1 of 4 start date training times for the African American Communities Speak (AACS) Education Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
89061564|NCT05908487|Other|Clinician Trainees- Cluster 2|Within each participating institution, clinician clusters are randomized to 1 of 4 start date training times for the African American Communities Speak (AACS) Education Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period
89061565|NCT05908487|Other|Clinician Trainees- Cluster 3|Within each participating institution, clinician clusters are randomized to 1 of 4 start date training times for the African American Communities Speak (AACS) Education Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period
89061566|NCT05908487|Other|Clinician Trainees- Cluster 4|Within each participating institution, clinician clusters are randomized to 1 of 4 start date training times for the African American Communities Speak (AACS) Education Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period
89061567|NCT05898672|Active Comparator|Treatment A: rosuvastatin|Rosuvastatin tablets
89061568|NCT05898672|Experimental|Treatment B: rosuvastatin + nirmatrelvir/ritonavir|Rosuvastatin + nirmatrelvir/ritonavir tablets
89061569|NCT05897554|Experimental|Successful mechanical thrombectomy plus intra-arterial alteplase group|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed after intra-arterial thrombolysis.
89061570|NCT05897554|No Intervention|Successful mechanical thrombectomy only group|For patients in the successful MT only group, the choice of MT strategy will be made by the qualified neurointerventionalist, including stent retriever, aspiration and a combination technology. Patients who underwent more than 3 thrombectomy procedures were excluded from the study. Rescue therapy was performed at the discretion of the neurointerventionalist in case of the grade of stenosis at the occlusion site was presented to be more than 70% after MT.
89061571|NCT05883566|Experimental|behaviour|
89061572|NCT05883566|No Intervention|control|
89061573|NCT05864482|Experimental|Experimental|Brief Cognitive behavioral therapy intervention will be interviewed by the researcher as part of psychosocial care, with two sessions pre-operative and two post-operative sessions. In the postoperative period, an eye mask and ear plug will be applied to the patient by the researcher on the 3rd and 4th days of the short CBT post-op and between 23:00 and 07:00 at night. Visual Analogue Scale, State Anxiety Inventory, Richmond Agitation-Sedation Scale, Confusion Evaluation Scale in Intensive Care, Richard Campbell Sleep Quality Scale, Daily Follow-up Form will be applied after open heart surgery.
89061574|NCT05864482|No Intervention|Control|Patients who meet the research criteria and agree to participate in the study will be informed about the research process (purpose of the research, assignment to the intervention and control group, etc.), written informed consent and contact information of the patients will be obtained, and the contact information of the researcher will be given to the patient. Only routine nursing care will be given to the patient. will be applied by the researcher
89061575|NCT05856994|Experimental|Tacrolimus Ointment 0.03% with hydrocolloid dressing|Standard out-patient wound cleaning followed by application of tacrolimus ointment over the burn and hydrocolloid dressing on the treated area.
89061576|NCT05856994|No Intervention|Bacitracin ointment|Standard out-patient wound cleaning followed by application of bacitracin ointment over the burn and hydrocolloid dressing on the treated area.
89061577|NCT05856994|No Intervention|Hydrocolloid dressing|Standard out-patient wound cleaning followed by application of hydrocolloid dressing on the burned area.
89061578|NCT05846399|Placebo Comparator|Placebo (microcrystalline cellulose)|Placebo capsules by mouth twice daily x 5 days (5 days of placebo microcrystalline cellulose capsules)
89061579|NCT05846399|Active Comparator|Antibiotic x 1 day|"Amoxicillin-clavulanate 875-125mg capsules by mouth twice daily x 1 day (4 days of placebo capsules)~-Penicillin allergy: ciprofloxacin 500mg by mouth twice daily + clindamycin 300mg by mouth three times daily x 1 day"
89061580|NCT05846399|Active Comparator|Antibiotic x 5 days|"Amoxicillin-clavulanate 875-125mg capsules by mouth twice daily x 5 days (0 days of placebo capsules)~-Penicillin allergy: ciprofloxacin 500mg by mouth twice daily + clindamycin 300mg by mouth three times daily x 5 days"
89061581|NCT05842759|Other|Hypotension Avoidance Strategy|"After the patients' arrival in the induction area, routine anesthetic monitoring (electrocardiography and pulse oximetry) will be established. In all patients, the arterial catheter for continuous intraarterial blood pressure monitoring will be inserted before anesthetic induction (after the insertion site has been infiltrated with a local anesthetic). An uncalibrated pulse wave analysis monitor (MostCareUP, Vygon, Aachen, Germany) will be connected to the patient monitor for advanced hemodynamic monitoring of including cardiac output, systemic vascular resistance, stroke volume variation, and pulse pressure variation.~Besides continuous intraarterial blood pressure monitoring, the hypotension avoidance strategy will be applied."
89061582|NCT05794165|Experimental|Thrombate infusion|
89061583|NCT05794165|Placebo Comparator|Placebo|
89061584|NCT05784545|Placebo Comparator|Placebo|
89061585|NCT05784545|Experimental|Blueberry Supplementation|
89061586|NCT05779007||Pirfenidone initiators|Patients who initiated pirfenidone treatment
89061587|NCT05779007||Nintedanib initiators|Patients who initiated nintedanib treatment
89061588|NCT05764252|Other|BioEP|The EEG will be analysed using the BioEP algorithm
89061589|NCT05744856|No Intervention|Standard GDM care|"After being diagnosed with GDM, standard care includes counseling on nutrition and physical activity. All patients are referred to an endocrinologist at the General Hospital, yet this is not covered by insurance unless the patients have received a referral letter from a health station. The endocrinologist will perform blood glucose measurements (venous blood sample) once every four weeks at the General Hospital until gestational week 36, after which it will be monitored once a week until delivery. The cut-off for c-section is 3800g (no matter the mother's GDM status).~Treatment recommended by the endocrinologist may include home-monitoring of blood glucose and insulin treatment in the most severe cases. The home-monitoring requires that the women are able to buy the glucometer and test strips themselves."
89061590|NCT05744856|Experimental|Self-care with informal support|"Standard care + Self-care/informal support intervention~The detailed content of the self-care/informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
89061591|NCT05743153|Experimental|Patients with ulcerative colitis|Patients participate in multimodal intervention
89061592|NCT05732935|Experimental|Time Restricted Eating intervention|In the time restricted eating condition, participants will be instructed to fast for a target of 16 hours per day for a 24 week period.
89061593|NCT05732935|Active Comparator|Successful Aging Comparison Group (LEARN)|In the LEARN group, participants will be educated on health related topics similar to that of the TRE intervention for 24 weeks.
89061594|NCT05731323|Experimental|D-Cycloserine|"Prior to initiating TMS therapy, participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine.~During TMS therapy, participants will orally ingest a capsule containing a weight-based dose of the antibiotic d-cycloserine (dosed 25mg/17.5kg body weight) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions)."
89061595|NCT05700981|Experimental|Colon capsule endoscopy|Patients randomized to colon capsule endoscopy
89061596|NCT05700981|No Intervention|Colonoscopy|Patients randomized to colonoscopy
89061597|NCT05684159|Experimental|Cohort 1|6 subjects will receive an intravenous (IV) infusion of NM8074 at every two weeks for a total of 7 doses
89061598|NCT05684159|Experimental|Cohort 2|6 subjects will receive weekly doses of 10 mg/kg for a total of 4 doses followed by biweekly doses at 20 mg/kg for a total of 5 doses
89061599|NCT05658705|Experimental|experimental group(15-min supine group)|Participants in the experimental group will keep supine position for 15 minutes before AVS.
89061600|NCT05658705|Active Comparator|control group(2-hour supine group)|Participants in the control group will keep supine position for 2 hours before AVS.
89061601|NCT05636306|Experimental|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
89061602|NCT05636306|Placebo Comparator|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
89061603|NCT05629260||G-CSF/ATG group|Patients in the G-CSF/ATG group received a modified Bu/Cy plus ATG conditioning regimen as follows: cytarabine (4/g m2 per day IV.) on days -10 to -9; Bu (3.2 mg/kg per day IV.) on days -8 to -6; Cy (1.8 g/m2 per day IV.) on days -5 to -4; methyl chloride hexamethylene urea nitrate (Me-CCNU) (250 mg/m2 per day orally) once on day -3; and ATG (2.5 mg/kg per day IV; rabbit, Sang Stat, Lyon, France) on days -5 to -2.
89061604|NCT05629260||PT-Cy group|Patients in PT-Cy group received a Bu/Flu/Cy-based conditioning regimen as follows: Flu (40 mg/m2 or 1 mg/kg IV) on days -8 to -4; Bu (3.2 mg kg/ d-1 IV) on days -7 to -4; Cy (14.5-40 mg/kg IV) on days -3 to -2;±cytarabine (3 g/m2/d IV) on days -9 to -8; and ± IDA (15 mg/m2/d IV) on days -9 to -8. The addition of IDA and/or cytarabine depended on the performance status of the patients and whether the patients were in relapse status. High-dose PTCy (50 mg/kg/d IV) was administered on days +3 and +4.
89061605|NCT05621694|Experimental|Qigong/Tai Chi Intervention|"Tai chi and Qigong combined into a simplified, standard practice, Tai Chi Easy"
89061606|NCT05616208|Experimental|Implantation|This is a non-randomized, single group treatment study with a single arm and is not subject or investigator masked or blinded. BioSphincters will be implanted in every study subject.
89061610|NCT05609240|Active Comparator|Standard treatment|Cefuroxime 1.5 grams intravenous Administered in the hour before surgery and then 4 hourly intra-operatively.
89061611|NCT05609240|Active Comparator|Intervention treatment|"Cefuroxime loading dose of 2332mg intravenous Administered in the hour before surgery.~Following the loading dose a renal function based dosing will be given as a continuous intravenous infusion throughout surgery, as below. Continuous infusion will continue for up to 6 hours when it will return to 4 hourly dosing of cefuroxime at 1.5 grams intravenously, if required.~Creatinine clearance (ml/min) and Cefuroxime:Dose per hour (mg/hr) 40-50ml/min=723mg/hr 50-60ml/min=867mg/hr 60-70ml/min=1011mg/hr 70-80ml/min=1155mg/hr >80ml/min=1227mg/hr"
89061612|NCT05606198||COVID|641,407 patients with a SARS-CoV-2 infection in the year 2020.
89061613|NCT05606198||Non-COVID|Matched patients with no SARS-CoV-2 infection during the study period.
89061614|NCT05597033|Experimental|Morning (AM)|Before 10 A.M.
89061615|NCT05597033|Experimental|Evening (PM)|After 4 P.M.
89061616|NCT05588141|Experimental|1|Escalation/de-escalation dose levels of zotiraciclib given in 28 day cycles
89061617|NCT05588141|Experimental|2|Estimated RP2D of zotiraciclib given in 28 day cycles
89061618|NCT05588141|Experimental|3|One RP2D dose of zotiraciclib given on the day prior to brain tumor biopsy or resection, a continuation of treatment with estimated RP2D of zotiraciclib given in 28 days cycles following the recovery of the surgery
89061619|NCT05544526|Experimental|GD2 CAR T Cells|Treatment with the ATIMP: GD2 CAR T-cells
89061620|NCT05535439|Experimental|19 G EBUS-TBNA Needle|Mediastinal or Hilar Lymphadenopathy will be sampled by using 19 G EBUS-TBNA Needle
89061621|NCT05535439|Experimental|22 G EBUS-FNB Device|Mediastinal or Hilar Lymphadenopathy will be sampled by using 22 G EBUS-FNB Device
89061622|NCT05534763|Experimental|IERGD|I-ER GD is a 10-week intervention directed to the person with GD, provided via the internet with therapist-support. During treatment, participants have an assigned psychologist to interact with and be offered support by, either through feedback on assignments, asynchronous chats or, if needed, by telephone. I-ER GD will focus on increasing adaptive emotion regulation skills, healthy identity development, interpersonal effectiveness skills, coping and building a resilient lifestyle through psychoeducation on gender minority stress, practicing adaptive emotion regulation skills, and reducing emotional and behavioral avoidance.
89061623|NCT05534763|Other|IER SUPPORT|I-ER Support is a 5-week intervention directed to a support person, provided as an optional addition to I-ER GD. I-ER Support is administered in the same manner and in parallel to the I-ER GD intervention. Treatment content is based on the same principles as I-ER GD, but from the perspective of increasing emotional support and understanding of GD. The support person could benefit from increased coping and emotion regulation skills, as they may also be exposed to discrimination or stigma due to having a transgender child, sibling or loved one. In better understanding the processes of being stigmatized and with improved emotion regulation skills, the support person may offer better support and help alleviate burdening effects for the individual with GD. For this reason, I-ER support is primarily aimed at people without trans-experience.
89061624|NCT05531643|Experimental|Active TENS|TENS delivered for 20 minutes to the forehead via the active Cefaly (R) device; at least 3 times per week in-home; for 6 months.
89061625|NCT05531643|Sham Comparator|Sham TENS|Sham TENS delivered for 20 minutes to the forehead via the sham Cefaly (R) device; at least 3 times per week in-home; for 6 months.
89061626|NCT05529628||Control|Healthy volunteers with no known chronic or cancer disease
89061627|NCT05529628||Fournier's gangrene|Fournier's gangrene patients
89061628|NCT05529628||Perianal abscess|Perianal abscess patients
89061629|NCT05523973|Experimental|Lingual Endurance Training Only (Group 1)|Intervention group 1 will complete lingual endurance training only.
89061630|NCT05523973|Experimental|Lingual Endurance Training + Transference Exercise (Group 2)|Intervention Group 2 will complete lingual endurance exercise plus a transference exercise.
89061631|NCT05519397||No response|The breast cancer patients with no response to neoadjuvant therapy
89061632|NCT05519397||Moderate response|The breast cancer patients with moderate response to neoadjuvant therapy
89061633|NCT05519397||Good response|The breast cancer patients with good response to neoadjuvant therapy
89522861|NCT00540839|Experimental|Montelukast|Participants receive montelukast 4 mg oral granules (OG) or 4 mg chewable tablets (CT) once daily (QD) for 24 weeks and placebo to fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks. Participants aged >6 months to <2 years receive montelukast 4 mg packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive montelukast 4 mg CT QD for 24 weeks.
89061634|NCT05517382|Experimental|supportED group|Participants in this group will engage with the digital game for one session (~45min) and will receive NIDA and NIMH pamphlets on substance misuse and mental health for youth at the end of the session. Participants will use a dedicated device (e.g., tablet, laptop, or desktop) to access their digital experience on the web. The research staff and a school-based provider will be present to monitor gameplay, to provide support, if needed, and to field questions in person.
89061635|NCT05517382|Other|Control group|Participants in this group will engage with a non-health-related game for one session (~45min) and will receive NIDA and NIMH pamphlets on substance misuse and mental health for youth at the end of the session. Participants will use a dedicated device (e.g., tablet, laptop, or desktop) to access their digital experience on the web. The research staff and a school-based provider will be present to monitor gameplay, to provide support, if needed, and to field questions in person.
89061636|NCT05511623|Experimental|tislelizumab|The external radiation is administered at 45-50Gy/25f and brachytherapy is performed sequentially at 6Gy/time to a total doses of 30 Gy. The concomitant chemotherapy regimen is cisplatin 40mg/m2 on day 1 once every week for 5 weeks. In addition, patients also receive tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
89061637|NCT05511623|Active Comparator|concurrent chemoradiotherapy|The external radiation is administered at 45-50Gy/25f and brachytherapy is performed sequentially at 6Gy/time to a total doses of 30 Gy. The concomitant chemotherapy regimen is cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
89221222|NCT04061759|Active Comparator|Stabilization exercises|The core stabilization exercise treatment program consisted of the following exercises: a posterior pelvic tilt exercise, lower abdominal muscle isometric strengthening, hip adductor muscle isometric strengthening, lumbar stabilization exercises with a Swiss ball, upper and lower abdominal muscle strengthening exercises with a Swiss ball, oblique abdominal muscle strengthening exercises with a Swiss ball, quadratus lumborum muscle stretching with a Swiss ball, back extensor muscle strengthening exercises with a Swiss ball, a slump exercise (sciatic nerve stretching), lumbar lordosis exercises with a Swiss ball, bridge exercises with a Swiss ball, single leg bridge exercises on a Swiss ball, posture exercises, push-up exercises with a Swiss ball, and squat exercises with a Swiss ball
89221223|NCT04061759|Active Comparator|Reflex therapy&Stabilization exercises|Mobilization of each vertebra and pulls were applied from the medial side of the toe to the medial malleolus and to the heel by hand or with the help of an apparatus, including the cervical, thoracic and lumbar spine reflex zones. Finally, the procedure was finished by making a V-shaped maneuver with a thumb in the direction of spinal nerve exits.
89221224|NCT00565136|Experimental|TOPAS|TOPAS AMS Pelvic Floor Repair System
89221225|NCT00738179|Experimental|1|CPAP plus standard care of cardiovascular risk factors
89221226|NCT00738179|Active Comparator|2|Standard care alone
89221227|NCT00492921|Experimental|Cyclophosphamide 50|Treatment with cyclophosphamide 50 mg/kg/d x 1 days.
89221228|NCT00492921|Experimental|Cyclophosphamide 100|Treatment with cyclophosphamide 50 mg/kg/d x 2 days.
89221229|NCT00492921|Experimental|Cyclophosphamide 150|Treatment with cyclophosphamide 50 mg/kg/d x 3 days.
89221230|NCT00738257|Experimental|Parmidronate|
89221231|NCT00502671|Experimental|1|
89221232|NCT00738413|Active Comparator|Arm 1|Subjects will be treated for 6 days with deferoxamine.
89221233|NCT00738413|Active Comparator|Arm 2|Subjects will be treated for 6 days with deferasirox.
89221234|NCT00738413|Experimental|Arm 3|Subjects will be treated for 6 days with a combination of deferoxamine and deferasirox.
89221235|NCT00697463|Experimental|Women with Idiopathic osteoporosis (IOP)|Each subject will receive 20 micrograms of Teriparatide (PTH 1-34) subcutaneously daily for 18 -24 months
89061638|NCT05499650|Experimental|Exercise Group|Patients will be required to undergo an exercise program. Pre-intervention and post-intervention outcomes will be compared in each patient.
89061639|NCT05465538|Other|Cannabis using older adults|Subjects undergo a single PET scan using [11C]UCB-J
89061640|NCT05465538|Other|Healthy controls|Subjects undergo a single PET scan using [11C]UCB-J
89061641|NCT05465317||Patients with Type 2 Diabetes Mellitus (T2DM)|
89061642|NCT05457322|Experimental|Behavioral intervention one|
89061643|NCT05457322|Experimental|Behavioral intervention two|
89061644|NCT05451823|Experimental|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
89061645|NCT05450588||Sedentary|It will be obtained by open call for both students and administrative staff at the CES University.
89061646|NCT05450588||Physically active|Under the collaboration framework bet ween DBSS international SAS and Smart Fit Colombia, a sample of personal trainers who reside and work in Medellín, or its metropolitan area will be invited to participate.
89061647|NCT05450588||Athletes|Under the collaboration framework between DBSS international SAS and ARTHROS Physiotherapy and Exercise Center, a sample of professional athletes from different sports disciplines will be invited to participate.
89061648|NCT05446597|Experimental|Headache Treatment|Participants in the headache arm will be randomized to receive a peripheral, greater occipital nerve block with 0.5% Bupivacaine or the multimodal treatment protocol. Participants will complete a daily headache diary over the 6-week treatment period, following a link on their mobile device. Patients receiving a nerve block will have weekly over-the-phone or virtual check-ins by the study team to evaluate for any side effects, pain, as needed medications, and study compliance. These patients will be given supplemental HA education as needed. Participants receiving the block will be offered a second block at 6 weeks if they meet the following criteria: a. no side effects with the first block, b. participant received relief from the first block and prefers a second, and c. headache is still occurring at least once per week. Participants randomized to the multimodal treatment portion, will have up to 6 weeks of scheduled multimodal treatment sessions.
89061649|NCT05446597|Experimental|Dizziness and/or Neck Pain Treatment|Participants will be randomized to receive cervicovestibular physiotherapy (CV PT) or the multimodal treatment program. The CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings for six weeks. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, and dynamic balance.
89061650|NCT05446597|Experimental|Multimodal Treatment|The multimodal treatment consists of 6 treatment sessions that will combine basic physiotherapy exercises to address dizziness and balance problems, training in deep breathing, progressive muscle relaxation, visualization to address headache, sleep hygiene education to address insomnia, and cognitive-behavioral intervention and gratitude exercises to promote coping and resilience. The treatment is designed to be implemented by a variety of clinical health care professionals.
89061651|NCT05445869|Experimental|EVO Sleep and Snore Device|Participants will be provided with a custom EVO Sleep and Snore Device
89221236|NCT00492531|Experimental|Sildenafil|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo.
89221237|NCT00492531|Placebo Comparator|Placebo|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo
89221238|NCT04334603|Experimental|Home-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at home
89221239|NCT04334603|Active Comparator|Clinical-based exercise training|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital
89221240|NCT04334655||Clinic 1|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
89221241|NCT04334655||Clinic 2|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
89221242|NCT04334655||Clinic 3|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
89221243|NCT04334655||Clinic 4|Clinics will be identified using Clinic numbers: Clinic 1, Clinic 2, Clinic 3, Clinic 4. The interventions will be normal physical therapy interventions. The only addition is the monitoring of isometric neck retraction strength at the initial evaluation, progress reports, and discharge. The purpose of the study is not to administer new or specific interventions but to monitor neck strength changes over time during regular physical therapy care.
89221244|NCT00111475|Experimental|Part A: Romiplostim 0.2 µg/kg|Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
89221245|NCT00111475|Experimental|Part A: Romiplostim 0.5 µg/kg|Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
89221246|NCT00111475|Experimental|Part A: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
89221247|NCT00111475|Experimental|Part A: Romiplostim 3 µg/kg|Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
89221248|NCT00111475|Experimental|Part A: Romiplostim 6 µg/kg|Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
89221249|NCT00111475|Experimental|Part A: Romiplostim 10 µg/kg|Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
89221250|NCT00111475|Placebo Comparator|Part B: Placebo|Participants received placebo subcutaneously once a week for 6 weeks.
89221251|NCT00111475|Experimental|Part B: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
89221252|NCT00111475|Experimental|Part B: Romiplostim 3.0 µg/kg|Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
89221253|NCT00111475|Experimental|Part B: Romiplostim 6.0 µg/kg|Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.
89221254|NCT02566655|Experimental|Fucosylated MSC for Osteoporosis|Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.
89221255|NCT01015209|Active Comparator|Cohort 1: 18 healthy subjects|18 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3% (6 subjects per group)
89221256|NCT01015209|Active Comparator|Cohort 2: 12 healthy patients|12 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3%
89221257|NCT04948463|Experimental|Early Stopping|Stopping empiric FN antibiotics after resolution of fever for 48 hours, irrespective of absolute neutrophil count (ANC)
89221258|NCT04948463|Active Comparator|Standard of care|Continuing empiric FN antibiotics until resolution of fever for 48 hours and recovery of ANC as defined by the treating clinician but usually to ≥200-500/mm3
89221259|NCT04945421|Experimental|Sintilimab and IBI310 (single arm)|The test group will be treated with either (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
89221260|NCT01080547|Active Comparator|Conventional Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
89221261|NCT01080547|Active Comparator|FTMD Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.
89221262|NCT01080547|Active Comparator|Conventional Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
89221263|NCT01080547|Active Comparator|FTMD Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.
89221264|NCT02566811|Experimental|Abdominal surgery with lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)* with lymph node dissection to determine whether lymph nodes are positive or negative:~Positive: patients will receive systemic adjuvant treatment to include chemotherapy Negative: patients will receive vaginal brachytherapy only~Patients will then be followed up, to include assessment of adverse events and quality of life.~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, the lymph node dissection will be performed as a separate procedure."
89061652|NCT05443633|Experimental|Active therapy group|Participants will undergo individualized language treatment in which they will learn semantically- or phonologically based strategies to facilitate word finding difficulties, sentence formulation difficulties, or challenges in their narration and discourse. The level at which the treatment will be administered will depend on the participants' level of performance determined by the results of the language and cognitive testing done at baseline. Treatment will be administered twice a week for 10 weeks.
89061653|NCT05443633|Active Comparator|control group|control group will undergo standard speech-language intervention
89061654|NCT05428891|Other|Only pleural effusion|The patients with only pleural effusion on their CT scans.
89061655|NCT05428891|Other|Pleural effusion associated with pleural thickening or any other lesion like mass or nodules.|The patients with pleural effusion associated with pleural thickening or any other lesion-like mass or nodules on their CT scans.
89061656|NCT05405270||Primary cHSIL|Women with a first diagnosis of cHSIL (e.g. CIN 2 or CIN 3) who prefer treatment with imiquimod.
89061657|NCT05405270||Recurrent/residual cHSIL (rrcHSIL)|Women who were treated for cHSIL before, but who have a residual or recurrent lesion and prefer treatment with imiquimod.
89061658|NCT05405270||CIN 2 observational group|Women with primary CIN 2 who prefer expectant management to await the potential of spontaneous regression.
89061659|NCT05394376|Other|Inside private quiet1, Inside public loud, Inside public quiet, Inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside private quiet1, Inside public loud, Inside public quiet, Inside private quiet2"
89061660|NCT05394376|Other|Inside public loud, inside private quiet1, Inside public quiet, Inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside public loud, inside private quiet1, Inside public quiet, Inside private quiet2"
89061661|NCT05394376|Other|Inside public loud, inside public quiet, inside private quiet1, inside private quiet 2|"The order of noise/environment for participants randomized to this arm will be:~Inside public loud, inside public quiet, inside private quiet1, inside private quiet 2"
89061662|NCT05394376|Other|Inside public quiet, inside public loud, inside private quiet1, inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside public quiet, inside public loud, inside private quiet1, inside private quiet2"
89061663|NCT05394376|Other|Inside public quiet, inside private quiet1, inside public loud, inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside public quiet, inside private quiet1, inside public loud, inside private quiet2"
89061664|NCT05394376|Other|Inside private quiet1, Inside public quiet, Inside public loud, inside private quiet2|"The order of noise/environment for participants randomized to this arm will be:~Inside private quiet1, Inside public quiet, Inside public loud, inside private quiet2"
89061665|NCT05372328|Other|Desk1, Lap, Side, Desk2|"The order of arm positions for participants randomized to this arm will be:~Desk, Lap, Side, Desk"
89061666|NCT05372328|Other|Desk1, Side, Lap, Desk2|"The order of arm positions for participants randomized to this arm will be:~Desk, Side, Lap, Desk"
89061667|NCT05372328|Other|Lap, Desk1, Side, Desk2|"The order of arm positions for participants randomized to this arm will be:~Lap, Desk, Side, Desk"
89061668|NCT05372328|Other|Lap, Side, Desk1, Desk2|"The order of arm positions for participants randomized to this arm will be:~Lap, Side, Desk, Desk"
89061669|NCT05372328|Other|Side, Lap, Desk1, Desk2|"The order of arm positions for participants randomized to this arm will be:~Side, Lap, Desk, Desk"
89061670|NCT05372328|Other|Side, Desk1, Lap, Desk2|"The order of arm positions for participants randomized to this arm will be:~Side, Desk, Lap, Desk"
89061671|NCT05343650|Experimental|Study arm|"Stage 1 After shellfish allergy is confirmed through the skin prick test and IgE analysis, Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm. Participants will then be monitored for 1 hour, and any- reaction will be documented. In case of any symptoms of an allergic reaction, their study participation will be terminated.~Stage 2 If no allergic symptoms are observed in stage 1, the patient's nose will be anesthetized with topical lidocaine. A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes. After removal, the participant will be monitored in the clinic for an hour. Any allergic reaction will be documented, including increased nasal congestion, rhinorrhea, or pruritis."
89061672|NCT05338346|Experimental|ATG-018|"Dose Escalation Phase:~For Solid Tumors Group: A maximum of 44 subjects with solid tumors will be enrolled during the Dose Escalation Phase.~For Hematological Malignancies Group: Subjects with hematological malignancy will be enrolled.~Dose Expansion Phase:~The tumor types in Dose Expansion Phase may involve other tumor types based on the signals from the Dose Escalation Phase. Each tumor type is planned to enroll at least 12 subjects, and a further expansion (up to 40 subjects in each tumor type) may be triggered if 2 or more confirmed responses are observed in this cohort."
89061673|NCT05338190|Experimental|ARM A|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
89061674|NCT05338190|Placebo Comparator|ARM B|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
89061675|NCT05330637||Migratory old people with asthma from northern China in Sanya|Migratory old people with asthma from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
89061676|NCT05330637||Migratory old people with allergic rhinitis from northern China in Sanya|Migratory old people with allergic rhinitis from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
89061677|NCT05330637||Migratory old people with Chronic Obstructive Pulmonary Disease (COPD) from northern China in Sanya|Migratory old people with Chronic Obstructive Pulmonary Disease (COPD) from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
89061678|NCT05330637||Migratory old people with atopic dermatitis from northern China in Sanya|Migratory old people with atopic dermatitis from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
89061679|NCT05330637||Children with asthma in Sanya|Children with asthma have being exposure to tropical climate and environment in Sanya for years.
89061680|NCT05330637||Children with allergic rhinitis in Sanya|Children with allergic rhinitis have being exposure to tropical climate and environment in Sanya for years.
89061681|NCT05330637||Children with atopic dermatitis in Sanya|Children with atopic dermatitis have being exposure to tropical climate and environment in Sanya for years.
89061682|NCT05330637||Children with eczema in Sanya|Children with eczema have being exposure to tropical climate and environment in Sanya for years.
89061683|NCT05330637||Children with urticaria in Sanya|Children with urticaria have being exposure to tropical climate and environment in Sanya for years.
89061684|NCT05330637||Migratory old people with eczema from northern China in Sanya|Migratory old people with eczema from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
89061685|NCT05330637||Migratory old people with urticaria from northern China in Sanya|Migratory old people with urticaria from northern China to Sanya have being exposure to two different climate and environment from northern China to Sanya for months.
89061686|NCT05325840|Experimental|music therapy|"Experimental Group: Pre-test will be applied to pregnant women before the intervention. Since ST will be applied later, Nki will be applied to pregnant women, and their props will then be right lateral or lateral. NST registration form will be filled.~After the pregnancy is given, the type of music (Classical Turkish Music, Turkish Classical Music, Lullaby) is asked according to the preferences of the pregnant women and their music is given for 20 minutes. The NST process will be implemented from start to finish. In the application, music from pregnant women will be played on MP3 players. After the NST procedure is applied, the pregnant women will have a son."
89061687|NCT05325840|No Intervention|standard of care|"Control group: First of all, Personal Information Form, State Anxiety Scale and blood pressure measurement will be made to the pregnant women in the control group. In order to perform the NST procedure, the pregnant women will be given the left side or right side position to fix the probes. NST registration form will be filled.~20 minutes after positioning the pregnant women. During the routine NST procedure will be applied and no intervention will be made. After the NST procedure is completed, the State Anxiety Scale and blood pressure measurement will be repeated as the last test of the pregnant women."
89061688|NCT05319691|Active Comparator|Yoga Now (Treatment Group)|An initial 12-week Treatment Phase of weekly virtual yoga classes (Yoga Now) followed by a 12-week Follow-up Phase.
89061689|NCT05319691|No Intervention|Yoga Later (Wait List Control Group)|A wait-list control group (Yoga Later) will receive usual care. After the 24 week study period, participants in Yoga Later will be offered the yoga intervention in a non-study format.
89689793|NCT03023059|Experimental|Escalating dose of carbidopa-levodopa|The intervention is that patients will receive open label, commercially available Carbidopa-Levodopa 25 Mg-100 Mg oral tablet, once daily hs for one month, followed by one tablet dosed three times daily, in the morning, with supper and hs for one month, followed by two tablets dosed three times daily, in the morning, with supper and hs for one month (100-600 mg of levodopa daily). This is the equivalent of very low to moderate doses of carbidopa-levodopa in patients with Parkinson's disease (daily dose of levodopa 200-800 mg).
89061690|NCT05305586|Active Comparator|Packable Composite|Packable composite material was selected for splinting of luxated teeth
89061691|NCT05305586|Active Comparator|Bulkfill composite|Bulkfill composite material was selected for the splinting of luxated teeth
89061692|NCT05296109|Experimental|Imaging group|patients with parotid tumour being imaged
89061693|NCT05287503|Experimental|Ambroxol|"Ambroxol hydrochloride 200 mg tablets Dose: 1.2 g daily~Escalation scheme:~Day 1 - 5 200 mg 200 mg once a day Day 6 - 10 400 mg 200 mg twice a day Day 11 - 15 600 mg 200 mg three times a day Day 16 - 20 800 mg 400 mg twice a day Day 21 - 25 1000 mg 400 mg + 200 mg + 400 mg a day Day 26 - 365 1200 mg 400 mg three times a day"
89061694|NCT05287503|Placebo Comparator|Placebo|Excipients
89689794|NCT03022513|Active Comparator|NCWS patients|Fifty consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
89689795|NCT03022513|No Intervention|CD patients|Fifty sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as first control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
89689796|NCT03022513|No Intervention|IBS patients|Fifty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as second control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo.
89061695|NCT05271344|Placebo Comparator|Placebo Group|Placebo products for probiotics, prebiotics, omega 3 and vitamin D
89061696|NCT05271344|Experimental|Treated Group|Omega 3 fatty acids for 7 days (before starting conventional oral immunonutrition supplement), Probiotics for 14 days before and after the operation, Prebiotics for 14 days before and after the operation, Vitamin D for 6 days before the operation.
89061697|NCT05263908||PAXLOVID PACK|Subjects administered PAXLOVID PACK
89061698|NCT05259371|Experimental|Transcutaneous Pulsed Electrical Stimulation Treatment|Patients wear our clinical trial device 30mins once a day for 16weeks. Device: Nu eyne M02
89061699|NCT05227001|Experimental|PF-07852352 Influenza saRNA, low dose|
89061700|NCT05227001|Experimental|PF-07852352 Influenza saRNA, mid dose|
89061701|NCT05227001|Experimental|PF-07852352 Influenza saRNA, high dose|
89061702|NCT05227001|Experimental|PF-07836391 Influenza saRNA, low dose|
89061703|NCT05227001|Experimental|PF-07836391 Influenza saRNA, mid dose|
89061704|NCT05227001|Experimental|PF-07836391 Influenza saRNA, high dose|
89061705|NCT05227001|Experimental|PF-07836394 Influenza saRNA, low dose|
89061706|NCT05227001|Experimental|PF-07836394 Influenza saRNA, mid dose|
89061707|NCT05227001|Experimental|PF-07836394 Influenza saRNA, high dose|
89061708|NCT05227001|Experimental|PF-07836395 Influenza saRNA, low dose|
89061709|NCT05227001|Experimental|PF-07836395 Influenza saRNA, mid dose|
89061710|NCT05227001|Experimental|PF-07836395 Influenza saRNA, high dose|
89061711|NCT05227001|Experimental|PF-07836396 Influenza saRNA, low dose|
89061712|NCT05227001|Experimental|PF-07836396 Influenza saRNA, mid dose|
89061713|NCT05227001|Experimental|PF-07836396 Influenza saRNA, high dose|
89061714|NCT05227001|Experimental|PF-07867246 Influenza saRNA, mid dose|
89061715|NCT05227001|Experimental|PF-07867246 Influenza saRNA, low dose|
89061716|NCT05227001|Experimental|PF-07867246 Influenza saRNA, high dose|
89061717|NCT05227001|Placebo Comparator|Placebo|
89061718|NCT05227001|Active Comparator|Quadrivalent influenza vaccine (QIV)|
89061719|NCT05227001|Experimental|PF-07871987 Influenza saRNA, low dose|
89061720|NCT05227001|Experimental|PF-07871987 Influenza saRNA, mid dose|
89061721|NCT05227001|Experimental|PF-07871987 Influenza saRNA, high dose|
89061722|NCT05227001|Experimental|PF-07914705 Influenza saRNA mid dose|
89061723|NCT05227001|Experimental|PF-07914705 Influenza saRNA, high dose|
89061724|NCT05227001|Experimental|PF-07915048 Influenza saRNA, high dose|
89061725|NCT05212571|Experimental|Outpatient|The experimental intervention group visits the outpatient clinic to receive intravenous esketamine in day-care setting every 2 weeks for 3 months.
89061726|NCT05212571|Active Comparator|Inpatient|The standard treatment group receives intravenous esketamine for 6 consecutive days in hospital.
89061727|NCT05209763|Active Comparator|Standard rehabilitation|patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
89061728|NCT05209763|Experimental|More intensive rehabilitation|"patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.~patient daily exercises using the rehabilitation device MOTOmed Letto 2 for a minimum of 5 days, maximum duration not limited, minimum duration of exercise 20 minuts once daily~exercise duration will be recorded daily and total time (in hours) at the end of the hospital stay"
89061729|NCT05209763|Active Comparator|Standard nutrition|- nutrition determined by the attending physician according to recommendations for age, type of acute illness and comorbidities
89061730|NCT05209763|Experimental|More intensive nutrition|"determined by the attending physician according to recommendations for age, type of acute illness and comorbidity~- in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day and in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day for 5 days"
89061731|NCT05201001|Active Comparator|Standard of Care|"Carboplatin AUC = 5, IV day 1 and pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks~Total:6 cycles or until progressive disease or unacceptable toxicity."
89061732|NCT05201001|Experimental|APX005M|"Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 & 15 IV q4 wks x concomitant with chemotherapy~Total:6 cycles or until progressive disease or unacceptable toxicity."
89061733|NCT05201001|Experimental|APX005M+RT|"Carboplatin AUC = 5, IV day 1 combined with pegylated liposomal doxorubicin (PLD) 30 mg/m , IV day1 q4 wks APX005M 0.3 mg/kg, days 1 & 15 IV q4 wks x concomitant with chemotherapy External beam radiation therapy; a dose of 0.5 Gy per fraction, administered as single fractions prior to APX005M administration; days 1 & 15 q4 wks x 6 cycles. Maximum 24 wks of therapy; total dose 6 Gy.~Total:6 cycles or until progressive disease or unacceptable toxicity."
89061734|NCT05198050|Active Comparator|single dose letrozole tablets|starting from the first of January, patients will receive a single dose of letrozole (20 mg) two days, before starting misoprostol administration. Placebo tables with a similar appearance to letrozole will be administered the day before misoprostol administration and on the day of misoprostol administration.
89061735|NCT05198050|Active Comparator|multiple dose letrozole tablets|starting from the first of January, patients will receive 10 mg letrozole daily for two days before the day of misoprostol administration and on the day of misoprostol administration.
89061736|NCT05198050|Active Comparator|misoprostol tablets|starting from the first of January, patients will receive placebo tablets with a similar appearance to letrozole daily for two days before the day of misoprostol administration and on the day of misoprostol administration.
89061737|NCT05189223|Other|Open Pilot|In Phase 2, all Veterans will receive the active treatment.
89061738|NCT05189223|Experimental|Active Condition|In Phase 3 (Pilot RCT), half of Veterans will be randomly assigned to the active treatment.
89061739|NCT05189223|Active Comparator|Treatment as Usual|In Phase 3 (Pilot RCT), half of Veterans will be randomly assigned to treatment as usual.
89061740|NCT05176418|Active Comparator|delivery rate for nicotine dose 1mg/70kg|delivery rate 50,35, 16.6 and 12.5 ug per second
89061741|NCT05176418|Active Comparator|Delivery rate for nicotine dose 0.2mg/70kg|delivery rate 10,5, 3.3 and 2.5
89061742|NCT05171894|Experimental|Hemoporfin+A J/cm2 PDT|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
89061743|NCT05171894|Experimental|Hemoporfin+B J/cm2PDT|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
89061744|NCT05171894|Experimental|Hemoporfin+C J/cm2 PDT|Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
89061745|NCT05171894|Placebo Comparator|Placebo+A J/cm2 PDT|Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
89061746|NCT05171894|Placebo Comparator|Placebo+B J/cm2PDT|Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
89061747|NCT05171894|Placebo Comparator|Placebo+C J/cm2 PDT|Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
89061748|NCT05166642|Active Comparator|Bandgrip Micro-Anchor Skin Closure|
89061749|NCT05166642|Active Comparator|Standard of Care wound closure|Standard Monocryl suture closure
89689797|NCT02244827|Experimental|WCK 2349|Each subject will receive a single oral dose of WCK 2349 1000 mg (i.e., 2 tablets of 400 mg and 1 tablet of 200 mg) with 240 mL water on Day 1 in the morning. Study drug will be administered after a fast of at least 8 hours.
89689798|NCT02244905|Experimental|Positive Deviance Intervention Arm|Three hospital wards received Positive Deviance intervention.
89689799|NCT02244905|Other|Control Arm|Three hospital wards randomized to control arm received the Standard-of-Care Infection Control approach.
89061750|NCT05161780|Active Comparator|Normal Saline|This study will be a prospective double blinded randomized controlled trial. Fifteen patients will be randomly assigned to the normal saline group using a random number generator.
89061751|NCT05161780|Experimental|Lactated Ringer's Irrigation|This study will be a prospective double blinded randomized controlled trial. Fifteen patients will be randomly assigned to the lactated reinger group using a random number generator.
89061752|NCT05159414|Experimental|Glaucoma patients|Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).
89061753|NCT05133076|Active Comparator|Active arm|
89061754|NCT05133076|Placebo Comparator|Placebo arm|
89061755|NCT05130060|Experimental|Treatment (PolyPEPI1018, TAS-102)|Patients receive PolyPEPI1018 SC at 4 injection sites on days 1 and 15 and trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-15. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
89061756|NCT05121493|Active Comparator|Platelet Poor Plasma Tear|
89061757|NCT05121493|Experimental|Platelet Rich Plasma Tears|
89061758|NCT05120973||A|Tc-ICG in the prostate (SN procedure) and fluorescein unlilateral in leg or abdominal wall
89061759|NCT05120973||B|Free ICG bilateral in the abdominal wall
89061760|NCT05114486|Experimental|Pilocarpine 2% Ophthalmic Spray|2% pilocarpine ophthalmic spray administered with the Optejet dispenser
89061761|NCT05114486|Placebo Comparator|Placebo Spray|Placebo ophthalmic spray administered with the Optejet dispenser
89061762|NCT05108506|Experimental|No strict need to void following surgery before discharge|Participants randomized to this arm will have no strict need to void following surgery before they are discharged.
89061763|NCT05108506|Placebo Comparator|Strict need to void following surgery before discharge|Participants randomized to this arm will have a strict need to void following surgery before they are discharged.
89061764|NCT05105048|Experimental|mRNA-1647|CMV-seronegative or CMV-seropositive participants will receive mRNA-1647 vaccine by intramuscular (IM) injection in a 0-, 2-, and 6-month schedule.
89061765|NCT05105048|Placebo Comparator|Placebo|CMV-seronegative or CMV-seropositive participants will receive placebo matching to mRNA-1647 vaccine by IM injection in a 0-, 2-, and 6-month schedule.
89689800|NCT05088291||The new protection device|A total of 100 patients underwent continuous coronary angiography (CAG) or percutaneous coronary intervention (PCI). The first surgeon does not need to wear a lead dress to stand inside the new protective device (NPD) to perform all operations.
89689801|NCT05088291||The traditional lead clothing|A total of 100 patients underwent continuous coronary angiography (CAG) or percutaneous coronary intervention (PCI). The first surgeon wears the traditional lead clothing (TLC) to perform all operations.
89689802|NCT01012921|Active Comparator|Bio-Gide® membrane|Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
89689803|NCT01012921|Experimental|MembraGel|MembraGel The Straumann membrane is a synthetic degradable barrier membrane
89689804|NCT04360499|Experimental|Low-weight-high-repetitions training|Low-weight-high-repetitions (LWHR) refer to a specific form of resistance exercise which utilizes low weights and very high repetitions. Participants will be exercised 3 times per week for 3 months in small groups.
89689805|NCT04360499|Active Comparator|Pilates Training|Pilates exercises focused on breathing, concentration, control and precision. Participants will be exercised 3 times per week for 3 months in small groups
89689806|NCT04359485|Experimental|glycolic acid peel|
89689807|NCT04359485|Placebo Comparator|Saline|
89689808|NCT03055000|Experimental|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
89689809|NCT03055000|Experimental|AGS-v with adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
89689810|NCT03055000|Placebo Comparator|Placebo|WFI (0.5mL) on Day 0 and Day 21
89689811|NCT02245061|Experimental|paired pulses cortical electrical stimulation|
89689812|NCT04376099||Exercise oximetry|Patients complaining claudication and referred for exercise diagnostic oximetry. Exercise oximetry are performed on treadmill (3.2km/h, 10% slope)
89689813|NCT04376021|Experimental|Physical Contact|Baby carrier (and education) provided to mother to increase physical contact with baby
89689814|NCT04376021|No Intervention|Control|No intervention
89689815|NCT00922883|Experimental|Eltrombopag|Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.
88821192|NCT04941157|No Intervention|Selective cerebrospinal fluid drain placement|Patients randomized to the control arm of the study will not receive a prophylactic cerebrospinal fluid drain prior to their endovascular aortic repair. Patients will receive a CSF drain post-operative as needed to treat any symptoms of spinal cord ischemia. This arm of the study is current standard of care.
89061767|NCT05082675|Experimental|auto/RICallo treatment arm|Patients with an HLA-identical sibling donor were allocated to the auto-allo arm (n = 108)
89061768|NCT05082675|Active Comparator|auto arm|patients without a matched sibling donor were allocated to the auto arm (n = 249). Single (n = 145) or tandem (n = 104)
89061769|NCT05074953||Adults|145184 patients with COVID-19 over 17 years of age.
89061770|NCT05074953||Children and adolescents|11950 patients with COVID-19 under 18 years of age.
89061771|NCT05073419|Active Comparator|Control|Post-AMI patients in this arm will receive standard of care
89061772|NCT05073419|Experimental|ICM|Post-AMI patients in this arm will receive standard of care and an ICM
89061773|NCT05064839|Experimental|Bony scintigraphy|Bony scintigraphy within 1 to 4 months after inclusion
89061774|NCT05058976|Experimental|Romosozumab, then Zoledronic Acid|Monthly dose: 210 mg Romosozumab subcutaneous injections; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); all participants will receive 5 mg Zoledronic Acid IV infusion at the Month 12 visit.
89061775|NCT05058976|Placebo Comparator|Placebo, then Zoledronic Acid|Monthly dose: placebo saline subcutaneous injections; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); all participants will receive 5 mg Zoledronic Acid IV infusion at the Month 12 visit.
89061776|NCT05041647|Experimental|High CBD [25:1]|"1 dose (1 mL) of HIGH CBD~50 mg/ml CBD and 2 mg/ ml THC"
89061777|NCT05041647|Experimental|Low CBD [5:1]|"1 dose (1 mL) of LOW CBD~10 mg/ml CBD and 2 mg/ ml THC"
89061778|NCT05041647|Placebo Comparator|Placebo|"1 dose (1 mL) of PLACEBO~No active ingredients"
89061779|NCT05014815|Experimental|Arm A: Ociperlimab + tislelizumab histology-based chemotherapy|
89061780|NCT05014815|Placebo Comparator|Arm B: Placebo + tislelizumab + histology-based chemotherapy|
89061781|NCT05012384|Experimental|Vergence exercises|Orthoptic vergence exercises
89061782|NCT05012384|Placebo Comparator|Generic treatment|
89061783|NCT05003674|Experimental|Adults cochlear implant recipients receiving alternative stimulation strategy|ACE strategy, 8 maxima, alternative mode
89061784|NCT05003674|Active Comparator|Adults cochlear implant recipients receiving Standard-of-Care stimulation strategy.|ACE strategy, 8 maxima, monopolar mode.
89061785|NCT04983264|Experimental|Single-dose Period (Part A)|Refer to Study Description
89061786|NCT04983264|Experimental|Multiple Ascending-dose Period (Part B and Part C)|Refer to Study Description
89061787|NCT04953858|Other|Social Network Strategy|All study participants will receive social network strategy intervention as linkage method to receive HIV testing and care
89061788|NCT04943848|Experimental|"Lead In: rHSC-DIPGVax Monotherapy"|rHSC-DIPGVax for 8 total doses
89061789|NCT04943848|Experimental|Part A: rHSC-DIPGVax in Combination with BALSTILIMAB (Anti-PD1)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB (1 year of therapy or 27 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation completion. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to six patients will be enrolled on Part A. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB), the study will proceed to Part B."
89061790|NCT04943848|Experimental|Part B: Dose Escalation of ZALIFRELIMAB (Anti-CTLA4)|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (1 year of therapy or 9 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to 12 patients will be enrolled on Part B. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) plus anti-CTLA4 (ZALIFRELIMAB), the study will proceed to Part C."
89061791|NCT04943848|Experimental|Part C: Dose Expansion|"rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (at RP2D from Part B) (1 year of therapy or 9 cycles, whichever comes first)~Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. Up to 12 patients will be enrolled on Part C. All subjects in Part C will be monitored for DLT's for the duration of their participation in the study to monitor for excess toxicity."
89061792|NCT04942860|Active Comparator|Methotrexate 1% gel|1% methotrexate gel applied onto a predefined limb
89061793|NCT04942860|Active Comparator|Methotrexate 0.5% gel|0.5% methotrexate gel applied onto a predefined limb
89061794|NCT04942860|Placebo Comparator|Vehicle gel|Vehicle gel applied onto a predefined limb
89689816|NCT03055156|Experimental|Low rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
89689817|NCT03055156|Experimental|High rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
89689818|NCT04357613|Experimental|Expérimental ARM|800mg/d IMATINIB during 14days
89689819|NCT04357613|No Intervention|Comparator ARM|Standard of care
89689820|NCT02976987|Experimental|Cidofovir|Women receiving an aqueous gel containing 2% (w/w) cidofovir, administrated directly on cervix exhibiting high grade squamous intraepithelial lesion (CIN 2 and 3).
89689821|NCT02244281|Experimental|FLOMAX®|
89689822|NCT02244281|Placebo Comparator|Placebo|
89689823|NCT04376177||Patients with Thoracic outlet syndrome|Patients referred to the University Hospital of Angers for the diagnostis or follow-up of thoracic outlet syndrome
89689824|NCT00361413|Experimental|1|Alefacept
89689825|NCT00361413|Placebo Comparator|2|
89689826|NCT03062488|Active Comparator|opioid only|2 mcg/Kg of fentanyl
89689827|NCT03062488|Active Comparator|opioid plus PO analgesic|2 mcg/Kg of fentanyl plus PO acetaminophen 15 mg/Kg
89689828|NCT03062488|Active Comparator|opioid plus IV acetaminophen|2 mcg/Kg of fentanyl plus 15mg/Kg of IV acetaminophen
89689829|NCT00936299|Active Comparator|Bupropion + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.
89221265|NCT02566811|Active Comparator|Abdominal surgery, no lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)*. Patients will receive systemic adjuvant treatment to include chemotherapy.~Patients will then be followed up, to include assessment of adverse events and quality of life.~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, no further surgery will be given and the patient will proceed to receive systemic adjuvant treatment to include chemotherapy."
89221266|NCT02567747||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
89221267|NCT00492297|Experimental|Sorafenib + Dacarbazine|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
89221268|NCT02567513|No Intervention|Usual Care control group|Eligible, consented residents continue to receive usual care from nursing home staff and are independently monitored by trained research staff.
89221269|NCT02567513|Experimental|Supplement Intervention|Residents are offered a variety of supplement types and flavors consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
89221270|NCT02567513|Experimental|Snack Intervention|Residents are offered a variety of snack options (foods and fluids, including supplement) consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
89221271|NCT04608435||Male Group|
89221272|NCT04608435||Female Group|
89221273|NCT03997227|Active Comparator|Block group|
89221274|NCT03997227|No Intervention|control group|
89221275|NCT00565058|Experimental|Pilot|Pilot PD Study (Delayed GTI-2040) Group: In the Pilot PD Study Group, addition of GTI-2040 is delayed until 24 hours after initiation of HiDAC.
89221276|NCT00565058|Experimental|Phase II arm|Phase II PD Study (Early GTI-2040) Group: In the Phase II PD Study Group, GTI-2040 is given 24 hours prior to addition of HiDAC.
89221277|NCT04061681|Experimental|Behavioral Intervention (BIPAMS)|Participants will complete a 16-week behavioral intervention to increase physical activity levels.
89689830|NCT00936299|Placebo Comparator|Placebo + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.
89689831|NCT04375943||diabetic HF-pEF patients|It is composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (>45%).
89689832|NCT04375943||diabetic HF-rEF patients|It is composed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%).
89689833|NCT04375865|Experimental|Treatment A|Period1: Celecoxib 200mg Period2: Tramadol 150mg Period3: Celecoxib 200mg + Tramadol 150mg
89689834|NCT04375865|Experimental|Treatment B|Period1: Celecoxib 200mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Tramadol 150mg
89689835|NCT04375865|Experimental|Treatment C|Period1: Tramadol 150mg Period2: Celecoxib 200mg Period3: Celecoxib 200mg + Tramadol 150mg
89689836|NCT04375865|Experimental|Treatment D|Period1: Tramadol 150mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Celecoxib 200mg
88821193|NCT04932434|Experimental|Psilocybin therapy|Participants will receive one or two doses of psilocybin in a monitored setting approximately two weeks apart, with preparation sessions before and integration sessions after.
89221278|NCT04061681|No Intervention|Waitlist Control|Participants will have 16-weeks of no intervention or interaction.
89221279|NCT00934388|Experimental|Mesh placed in pre peritoneal plane|
89221280|NCT00934388|Active Comparator|No mesh placed|
89221281|NCT00939224||Cohort Phase 1|Cardiac Catheterization
89221282|NCT00564902|Placebo Comparator|Lutein|9 mg of Lutein for 12 months
89221283|NCT00564902|Active Comparator|Zeaxanthin and Lutein|3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
89221284|NCT00564902|Active Comparator|Zeaxanthin|3R 3'R Zeaxanthin 8 mg per day during 12 months
89221285|NCT04013516|No Intervention|Pure Control|Respondents received New Incentives' normal program.
89221286|NCT04013516|Placebo Comparator|Reminder Call|Respondents received a call from a New Incentives' staff member similar to the treatment arms, but weren't offered additional incentives.
89221287|NCT04013516|Experimental|Small Additional Incentive|Respondents were told they would receive 1000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
89221288|NCT04013516|Experimental|Large Additional Incentive|Respondents were told they would receive 3000 NGN more than originally promised by New Incentives' (either 2000 or 3000 NGN) when they brought their child for measles immunization.
89221289|NCT04014452|Experimental|Microwave ablation group|Microwave ablation is used for the treatment of Complicated Monochorionic Pregnancies
89221290|NCT04014452|Active Comparator|Radiofrequency ablation group|Radiofrequency ablation is used for the treatment of Complicated Monochorionic Pregnancies
89522862|NCT00540839|Active Comparator|Fluticasone|Participants receive fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks and placebo to montelukast 4 mg QD for 24 weeks. Participants aged >6 months to <2 years receive placebo packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive placebo CT QD for 24 weeks.
89522863|NCT03389087|Experimental|Apatinib and Etoposide Capsule|Apatinib and Etoposide Capsule
89522864|NCT03393299|Experimental|STOPP/START|Use of STOPP/START criteria during medication reconciliation
89522865|NCT03393299|No Intervention|CONTROL|Medication reconciliation done as usual, without the consideration of the STOPP/START criteria
89522866|NCT03389009||smartphone abusers|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
89221291|NCT04013750|Experimental|left hemiplegia|Patients in the left hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
89221292|NCT04013750|Experimental|right hemiplegia|Patients in the right hemiplegia group had 10 sessions of constraint induced movement therapy as groups of 4, 5 days a week. Each patient had modified constraint induced movement therapy 1 hour a day with professional support and performed home program by themselves 3 hours a day. Patients' less affected hands were limited by the help of a glove %50 of the time they were awake
89221293|NCT04013750|No Intervention|control|10 patients with right hemiplegia and 10 patients with left hemiplegia formed the control group and these patients were in line for inpatient rehabilitation programme.
89221294|NCT00446134|Experimental|Group 1: Drug|Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
89221295|NCT00446134|Experimental|Group 2: Drug|Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
89221296|NCT00446134|Experimental|Group 3: Drug|Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
89221297|NCT00446134|Active Comparator|Group 4: Drug|Oral ribavirin 800 mg/day (body weight <65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
89689837|NCT04375865|Experimental|Treatment E|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Celecoxib 200mg Period3: Tramadol 150mg
89221298|NCT00921089||Hemodialysis group|End stage renal disease patients aged lower than 70 years, treated for more than 6 months with hemodialysis
89221299|NCT00921089||Control group|Normotensive healthy controls
89221300|NCT00934466|Experimental|1|MK2637 120 mg
89221301|NCT00934466|Experimental|2|MK2637 50 mg
89221302|NCT00934466|Placebo Comparator|3|Placebo
89221303|NCT00934466|Active Comparator|4|Dextromethorphan 220 mg
89221304|NCT00934466|Active Comparator|5|Dextromethorphan 110 mg
89221305|NCT00921245||Group 1|
89221306|NCT00563186|Experimental|A|Admission to a novel hospital ward (e.g. abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
89689838|NCT04375865|Active Comparator|Treatment F|Period1: Celecoxib 200mg + Tramadol 150mg Period2: Tramadol 150mg Period3: Celecoxib 200mg
89689839|NCT01014091|Experimental|GSK2340272A F1 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
89689840|NCT01014091|Experimental|GSK2340272A F1 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
89689841|NCT01014091|Experimental|GSK2340272A F2 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
89689842|NCT01014091|Experimental|GSK2340272A F2 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
89689843|NCT01014091|Experimental|GSK2340272A F3 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
89689844|NCT01014091|Experimental|GSK2340272A F3 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
89689845|NCT03117634|Active Comparator|Fixed dosing group (2Q8)|Fixed Dosing with Aflibercept 2mg will be administered at a fixed regime at 8 week intervals through to week 52.
89689846|NCT03117634|Experimental|Treat and Extend group (T&E)|Reassessment at week 12 (month 3) by repeat examination for disease activity by OCT and indocyanine green angiography (ICGA). Subsequent treatment regime of Treat and Extend with Aflibercept 2mg will depend on disease activity at this point.
89689847|NCT05072847||ADAPT|The ADAPT system by Striker
89689848|NCT05071365|Experimental|Videos|"Single Arm study: All participants recruited to the study will be allocated to a single arm- videos in which participants will be able to access self help videos for plantar fasciitis"
89689849|NCT01014169|No Intervention|Usual care|Mothers in the control group will receive the nursing discharge newborn information from the nurse practitioner [sometimes via a Spanish interpreter, if required] according to current standard of care, which includes verbal information and written handouts.
89689850|NCT01014169|Experimental|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of the discharge envelope using their language of preference when receiving the standard newborn information.
89689851|NCT00937235|Experimental|Integrated Treatment|Prolonged Exposure + Varenicline + Medication Management Counseling
89689852|NCT00937235|Active Comparator|Varenicline|Varenicline + Medication Management Counseling
89689853|NCT01014403|Experimental|enoxaparin 30 mg SQ q12 hours|Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.
89689854|NCT01014403|Placebo Comparator|placebo|vehicle administered sq q 12 hours
89221307|NCT00563186|No Intervention|B|Hospital admission to a ward with traditional design features (eg. lack of sinks, predominance of 4-bed rooms [80%], shared bathrooms, curtains present)
89221308|NCT00699413|Active Comparator|1 - nutrition education plus active supplement|nutrition education plus active supplement
88821194|NCT04931017|Experimental|Cohort A (metformin ER)|Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity. Participants undergo bronchoscopy biopsy and blood sample collection at screening, and week 13.
89689855|NCT03120832|Experimental|PAN-301-1 (SNS-301) Vaccine|PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days
89689856|NCT00937859|Experimental|SER120|SER120
89061798|NCT04902820|Experimental|PrEPTECH intervention recipients|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine [200 mg]/tenofovir disoproxil fumarate [300 mg]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
89061799|NCT04902820|Active Comparator|Control resource-list only recipients|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
89061800|NCT04900740|Active Comparator|Standard care - catheter fixation with surgical stitch|In patients indicated for this type of treatment, as per the attending physician, the catheter will be fixed in the standard way, using a surgical stitch.
89061801|NCT04900740|Experimental|Experimental - catheter fixation with glue|In patients indicated for this type of treatment, as per the attending physician, the catheter will be fixed using the glue.
89689857|NCT00937859|Placebo Comparator|Placebo|
89061802|NCT04890262||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are currently ongoing vedolizumab intravenous (IV) treatment in line with current Summary of Product Characteristics (SmPC) or local prescribing information with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.
89061803|NCT04852055|No Intervention|Usual Care|Patients and proxies in assisted living centers randomized to the usual care arm have advance care planning discussions with a clinician at admission, annually, and sometimes with a hospitalization or other change in condition. There is no standardized decision- or conversation-support tools used to have these discussions.
89061804|NCT04852055|Experimental|Information|Patients and proxies in assisted living centers randomized to the information arm will receive a letter from their clinician with a link to an educational video describing the goals of care and how specific treatment decisions align with these goals. Patients and proxies will also continue to receive usual care advance care planning conversations.
89061805|NCT04836182|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRX by subcutaneous injection once-weekly
89061806|NCT04836182|Placebo Comparator|Placebo|Matching placebo by subcutaneous injection once-weekly
89061807|NCT04788511|Experimental|Semaglutide|All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
89061808|NCT04788511|Placebo Comparator|Placebo (semaglutide)|All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
89061809|NCT04781673|Active Comparator|Ketamine|"Infusion initiation: 0.1 mg/kg/hr Max: 0.3 mg/kg/hr Recommended titration: 0.1 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
89061810|NCT04781673|Active Comparator|Lidocaine|"Infusion initiation: 1 mg/kg/hr Max: 2 mg/kg/hr Recommended titration:0.25 mg/kg/hr* as needed every 4 hours based on pain scores ≥5 and physician order~Dosing will be based on patient actual body weight (ABW) recorded as dosing weight on time of hospital admission."
89061811|NCT04750642|Experimental|CI632D Investigational Medical Device (IMD)|
89061812|NCT04750642|Placebo Comparator|CI632 Comparator Device|
89061813|NCT04749667|Experimental|Arm A - Crossover with MSCs at baseline and placebo at 6 months|Receives mesenchymal stem cells at baseline and placebo at 6 months
89061814|NCT04749667|Experimental|Arm B - Crossover with placebo at baseline and MSCs at 6 months|Receives placebo at baseline and mesenchymal stem cells at 6 months
89061815|NCT04724291|Other|MAGNET + EGD|Capsule endoscopy followed by traditional endoscopy
89061816|NCT04713683|Active Comparator|Amplatzer PFO Occluder|Patients randomized in this arm will be implanted with Amplatzer PFO Occluder.
89061817|NCT04713683|Active Comparator|Gore Cardioform Septal|Patients randomized in this arm will be implanted with Gore Cardioform Septal Occluder.
89689858|NCT05405608||Group O|Ondansetron applied only, no tourniquet applied
89689859|NCT05405608||Group TO|Ondansetron and tourniquet applied,
89689860|NCT05405608||Group S|No ondansetron and tourniquet applied
89689861|NCT05405608||Group TS|Ondansetron not applied, only tourniquet applied
89689862|NCT01014871|Other|intra-individual comparison|
89689863|NCT04357769||Patients|Individuals aged 18-70 years with a diagnosis of severe mental disorder (schizophrenia or psychosis spectrum disorder; bipolar disorder; major depressive disorder) who were in a condition of psychopathological compensation, had their last clinical evaluation at the University of Naples Federico II outpatient unit of Psychiatry during January-February 2020, were not positive or suspected positive for COVID-19, and were under strict quarantine
89689864|NCT04357769||Controls (General Population)|Individuals aged 18-70 years who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine (e.g. not getting out for work)
89689865|NCT04357769||First-degree Relatives|Individuals aged 18-70 years who were first-degree relatives and caregivers of an individual included in the Patients group, who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine
89689866|NCT00375466|Experimental|Tranexamic Acid|
89061818|NCT04691323|Other|HU-Go app intervention arm|Participants will use the HU-Go app intervention arm for 12 months.
89061819|NCT04688411|Other|MED-Go app Intervention|Participants will use MED-Go app intervention for a total of 12 weeks
89061820|NCT04688411|No Intervention|Control Arm|Standard of care
89061821|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 2.0 ng/mL|"Each participant will receive study medication on three different occasions:~Session 1: remimazolam alone Session 2: remimazolam plus remifentanil 0.5 ng/mL Session 3 : remimazolam plus reminfentanil 2.0 ng/mL During each session remimazolam will be dosed in a step-up / step-down manner while the remifentanil target concentration will be kept constant."
89061822|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 4.0 ng/mL|"Each participant will receive study medication on three different occasions:~Session 1: remimazolam alone Session 2: remimazolam plus remifentanil 0.5 ng/mL Session 3 : remimazolam plus reminfentanil 4.0 ng/mL During each session remimazolam will be dosed in a step-up / step-down manner while the remifentanil target concentration will be kept constant."
89061823|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 0.1 ng/mL|"Each participant will receive study medication on three different occasions:~Session 1: remimazolam alone Session 2: remimazolam plus remifentanil 0.5 ng/mL Session 3 : remimazolam plus reminfentanil 0.1 ng/mL During each session remimazolam will be dosed in a step-up / step-down manner while the remifentanil target concentration will be kept constant."
89061824|NCT04670471|Experimental|Remimazolam + Remifentanil plasma concentration of 1.0 ng/ml|"Each participant will receive study medication on three different occasions:~Session 1: remimazolam alone Session 2: remimazolam plus remifentanil 0.5 ng/mL Session 3 : remimazolam plus reminfentanil 1.0 ng/mL During each session remimazolam will be dosed in a step-up / step-down manner while the remifentanil target concentration will be kept constant."
89061825|NCT04668898||LRRK2 Parkinson Disease|Individuals with LRRK2-related Parkinson Disease
89061826|NCT04668898||GBA Parkinson Disease|Individuals with GBA-related Parkinson Disease
89061827|NCT04668898||Idiopathic Parkinson Disease|Individuals with Idiopathic (without any known genetic cause) Parkinson Disease
89061828|NCT04668898||LRRK2 non-manifesting carriers|Individuals without Parkinson Disease who have a LRRK2 mutation
89061829|NCT04668898||GBA non-manifesting carriers|Individuals without Parkinson Disease who have a GBA mutation
89061830|NCT04668898||Healthy control|Individuals without a personal or family history (1st or 2nd degree) of a neurodegenerative disease
89061831|NCT04652804|Active Comparator|Arm 1: Low Intensity Intervention|4 weeks dispensation + standard adherence counseling
89061832|NCT04652804|Active Comparator|Arm 2: Medium Intensity Intervention|4 weeks dispensation + support from patient navigator
89061833|NCT04652804|Active Comparator|Arm 3: High Intensity Intervention|Directly Observed Therapy with flexible dispensing and support from patient navigator
89061834|NCT04620213|Experimental|Phentolamine Ophthalmic Solution 0.75%|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
89061835|NCT04620213|Placebo Comparator|Phentolamine Ophthalmic Solution Vehicle|2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis
89061836|NCT04615273|Experimental|Lonapegsomatropin|Lonapegsomatropin administered once-weekly by subcutaneous injection
89061837|NCT04615273|Placebo Comparator|Placebo|Placebo for Lonapegsomatropin administered once-weekly by subcutaneous injection
89061838|NCT04615273|Active Comparator|Somatropin|Somatropin administered once-daily by subcutaneous injection
89061839|NCT04608955|Experimental|Arm A: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.
89061840|NCT04608955|Experimental|Arm B: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 300mg orally once daily for 2 weeks.
89061841|NCT04608955|Experimental|Arm C: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 450mg orally once daily for 2 weeks.
89061842|NCT04608955|Active Comparator|Arm D: Standard treatment|Participants with newly-treated drug sensitivity tuberculosis receive standard treatment for two weeks.
89061843|NCT04608955|Experimental|Arm E: WX-081+MBT|Participants with drug-resistant tuberculosis receive WX-081 400mg orally once daily for 2 weeks, and then MBT+ WX-081 150mg orally once daily for 6 weeks.
89061844|NCT04608955|Active Comparator|Arm F: Bedaquiline+MBT|Participants with drug-resistant tuberculosis receive Bedaquiline 400mg orally once daily for 2 weeks, and then MBT+ Bedaquiline 200mg orally 3 times per week for 6 weeks.
89061845|NCT04595682|Experimental|Study Participants|Participants in this group will track their menstrual cycle, provide daily saliva samples, and undergo two rounds of alcohol sensitivity testing (with both placebo and alcohol).
89689867|NCT00375466|Placebo Comparator|placebo|
89689868|NCT04357691|Other|Healthy individuals (low-high-mod)|Participants will undergo the calibration phase beginning with low intensity training, followed by high, and moderate intensity training. Each training intensity will be performed 3 days a week for 2 weeks
89689869|NCT04357691|Other|Healthy individuals (mod-high-low)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by high, and low intensity training. Each training intensity will be performed 3 days a week for 2 weeks
89689870|NCT04357691|Other|Healthy individuals (mod-low-high)|Participants will undergo the calibration phase beginning with moderate intensity training, followed by low, and high intensity training. Each training intensity will be performed 3 days a week for 2 weeks.
89689871|NCT00976183|Experimental|Vorinostat|All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.
89689872|NCT04357535||Primary Cohort|"Patients enrolled in this study will have data collected from the beginning of their hospital stay until discharge.~Data collected will include:~Patient demographics (age, sex, weight, and height)~Indication for ACE-I, ARB therapy, duration and doses~Use of any a non ACE-I/ ARB sntihypertensive agents~Comorbidities, and COVID19 related markers: Including WBC, plateltes, ferritin, CRP, CK, and LD~CT scan reports~First positive COVID19 PCR~Admission to the intensive care unit (ICU) and data relating to ICU stay."
89689873|NCT03121144|Experimental|Masimo Centroid System|Single-arm study. All subjects are enrolled into the test group wherein the noninvasive positional monitoring device will be administered.
89689874|NCT01015807|Placebo Comparator|Placebo|Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
89061846|NCT04588116|Experimental|The web- based occupational therapy intervention SEE|The web-based intervention starts with eight educational modules focusing on engagement in activities and strategies to support an active life. The modules, that is delivered on a secure national health platform, include short education videos followed by self-reflections and digital assignments supporting the change process. The occupational therapist provides feedback after each assignment and, also, meet the patients for face- to- face online guiding sessions at three times during these first two- three weeks of the intervention. Thereafter, an individually tailored activity plan with goals and activity-based strategies are established. During the change process, the patients receive continued support from the occupational therapist until the goals are achieved.
89061847|NCT04587024|Other|mHealth intervention|mHealth intervention
89061848|NCT04587024|Placebo Comparator|standard of care|post-transplant standard of care
89061849|NCT04559893|Experimental|Collaborative Care|Intervention is administered to patients in this arm. Care to be delivered via collaborative care.
89061850|NCT04559893|No Intervention|Control|Patients in this arm will receive enhanced usual care.
89061851|NCT04546633|Experimental|Run-in - KAF156 and LUM-SDF QD for 2 days in fasted condition|KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
89061852|NCT04546633|Experimental|Run-in - KAF156 and LUM-SDF QD for 2 days in fed condition|KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
89061853|NCT04546633|Experimental|Cohort 1/2 - KAF156 and LUM-SDF QD (once daily) in either a 2-day or 3-day dose regimen|KAF156 and LUM-SDF QD (once daily) in either a 2-day or 3-day dose regimen. Food recommendation will be issued after the Run-in Cohort based on efficacy, safety, tolerability and PK data).
89061854|NCT04546633|Active Comparator|Cohort 1/2 - Coartem® BID (twice a day) for 3 days|Coartem® BID (twice a day) for 3 days (will be administered with food and doses will be based on patient's body weight as per product label).
89061855|NCT04512144|Experimental|Intervention|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. She will be provided a three month gift subscription. Headspace will be downloaded to her smartphone and she will be instructed on use. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. The number of Headspace sessions will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
89061856|NCT04512144|No Intervention|Control|Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. All patients in the control group may choose to practice calming or mindfulness exercises of their own accord but will not be specifically instructed to seek out such resources as is our standard practice. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
89061857|NCT04485221||Children with a TECPR2 mutation|"Children with a TECPR2 mutation, age 18 months to 12 years old.~Assessments will include collection of genetic mutation reports, functional assessments, and questionnaires. There will be a singular blood draw and skin biopsy."
89061858|NCT04476173|Experimental|Methoxyflurane|Patients treated with inhaled methoxyflurane (3 mg)
89061859|NCT04476173|Active Comparator|Morphine|Patients treated with intravenous morphine (5 mg)
89061860|NCT04475328|Experimental|AngongNiuhuang|Drugs : AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.
89061861|NCT04475328|Placebo Comparator|Placebo of AngongNiuhuang|Drugs : Placebo of AngongNiuhuang pill. The other treatments will provided according to guidelines for standard treatment of acute ischemic stroke.
89221309|NCT00699413|Placebo Comparator|2 - nutrition education plus inactive supplement|nutrition education plus inactive supplement
89061862|NCT04467723|Experimental|Treatment|"Atezolizumab (Tecentriq) intravenous (IV) 1200mg flat dose day 1 then every 3 weeks.~Pirfenidone (Esbriet) orally (PO) with food according to this schedule:~Days 1-14: 267 milligrams (mg) orally three times per day (PO TID) Days 15-29: 534 mg PO TID Days 30 onward until progression: 801 mg PO TID"
89061863|NCT04466579|Experimental|BIS monitoring|Study subjects randomized in this study arm will have the depth of anesthesia controlled with the BIS monitor.
89061864|NCT04466579|Active Comparator|Standard care|Study subjects randomized in this study arm will receive standard anesthesiology care according to the usual procedures used at the study centre.
89061865|NCT04464070|Experimental|niacin|"Blood (10 ml) will be drawn from the subject. Immediately before or after the blood draw the subject will collect a urine (3-10 ml) sample. After the baseline blood draw and the urine sample is collected the subject will take 500 mg of niacin. The niacin will not be an extended release formulation. Subjects will be encouraged to drink plenty of water during the study. Subjects are instructed to collect urine 1, 2, 4, 6, 8, and 10 hours after niacin administration. Subjects will collect their urine in separate plastic tubes that will be provided to them.~Approximately 1-2 h after niacin administration a second blood sample (10 ml) will be drawn from the subject."
89061866|NCT04464070|Experimental|niacin + low-dose aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of low-dose aspirin (81 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
89061867|NCT04464070|Experimental|niacin + regular-strength aspirin|Volunteers will provide a urine sample. They will receive 7 tablets of regular-strength aspirin (325 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
89061868|NCT04464070|Experimental|deuterated PGD2|"Volunteers will come to the clinical research center. Volunteers will provide a urine sample. The volunteers will be fitted to record an electrocardiogram (ECG) and blood pressure. ECG will be recorded continuously. Blood pressure will be taken at baseline and every 10 minutes thereafter for one hour. The solution with deuterated PGD2 (10 microgram) will be infused over the course of 30 min. Volunteers will be monitored for 1 h after the end of the infusion, and volunteers will start collecting urine in intervals up to 10 h.~Infusion of the deuterated PGD2 solution will be performed in the presence of a physician. The injection solution will be prepared by Vanderbilt University Medical Center (VUMC) Investigational Drug Services. The solution will be sterile and pyrogen free."
89061869|NCT04462536|Placebo Comparator|Placebo|Vehicle only
89061870|NCT04462536|Experimental|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
89061871|NCT04444479|Experimental|PICC catheter placement|Study subjects in whom placement of the PICC catheter is indicated
89061872|NCT04441138|Experimental|Concurrent, Split Course Chemoradiation Followed by Durvalumab|Concurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
89061873|NCT04440189|Placebo Comparator|Placebo|Subjects will receive an injection of Lactated Ringers in their index knee
89061874|NCT04440189|Experimental|Stromal Vascular Fraction (SVF)|Subjects will receive an injection of Stromal Vascular Fraction in their index knee
89061875|NCT04428177|Experimental|Intrvascular Lithotripsy|Calcified coronary lesions will be treated with intrvascular lithotripsy
89221310|NCT01028872|Sham Comparator|Sensar IOL|
89221311|NCT01028872|Active Comparator|Tecnis IOL|
89221312|NCT01028872|Active Comparator|AcrySof IQ|
89221313|NCT04061525||Patients with coronary bifurcation lesions|Patients from 18 to 90-years old with coronary bifurcation lesions with significant >50% diameter stenosis artery scheduled for intervention of the main vessel (Medina types: 1x1, x11, 111)
89221314|NCT04808609|Experimental|Intervention|The Intervention group receives standard smoking cessation counseling and nicotine replacement therapy AND access to the Lumme app that tracks smoking behaviors and provides cessation support.
89221315|NCT04808609|Other|Control|The Control group receives standard smoking cessation counseling and nicotine replacement therapy
89221316|NCT00940160|Active Comparator|QAX576 1 mg/kg|
89221317|NCT00940160|Active Comparator|QAX576 3 mg/kg|
89221318|NCT00940160|Active Comparator|QAX576 10 mg/kg|
89221319|NCT00940160|Placebo Comparator|Placebo|
89221320|NCT02565875|Experimental|SLL Presentation|"Intervention: Standardized Language of Laparoscopy (SLL) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation on the use of a SLL for communication between the primary and assistant surgeons during laparoscopy as previously determined by a national survey of Canadian experts and a modified delphi technique."
89221321|NCT02565875|Placebo Comparator|Control Presentation|"Intervention: Surgical Anatomy (SA) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation of similar duration as the intervention group on laparoscopy but not related to communication (laparoscopic anatomy). The simulated laparoscopic task will be identical to the SLL group."
89221322|NCT04013438|Experimental|FET cycle, discontinue estradiol after 6 gestational weeks|In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.
89221323|NCT04013438|Active Comparator|FET cycle, continue estradiol till 12 gestational weeks|Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.
89221324|NCT02565719|Experimental|REP 2139-Mg with Viread and Pegasys|REP 2139-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
89221325|NCT02565719|Experimental|REP 2165-Mg with Viread and Pegasys|REP 2165-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
89221326|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2139-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2139-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
89689875|NCT01015807|Active Comparator|TAP (Bupi)|2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
89689876|NCT01015807|Active Comparator|Clo-TAP (Bupi + Clon)|2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
89689877|NCT03067948|Experimental|Intervention - Positive Screen Shared|In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to the participant's next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to the next HIV primary care visit.
89689878|NCT04827225||PoPPY Group|Mother, Father and child born prematurely
89689879|NCT01575925|Experimental|4 mg Oral POM + 40 mg Oral DEX|Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
89689880|NCT01575925|Experimental|2 mg Oral POM + 40 mg Oral DEX|Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
89689881|NCT03121612|Experimental|Dolphin CPAP|CPAP machine with oxygen intake and an on-board air compressor, and integrated blender and humidifier, delivering heated humidified blended gases through a Fisher-Paykel nasal mask. [Also includes built-in Massimo pulse oximeter, though this is not used for this study, to prevent differential measurement error in SpO2 measurement]
89689882|NCT03121612|Active Comparator|Fisher-Paykel CPAP|Fisher-Paykel (F&P) CPAP machine with separate oxygen and medical air intakes, with third-party FP-compliant blender, and F&P blender, delivering heated humidified blended gases through a Fisher-Paykel nasal mask.
89689883|NCT00978445|Experimental|Home/Standard|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was at home first then in clinic INR and interaction with a care giver.
89689884|NCT00978445|Experimental|Standard/Home|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was an in clinic INR and interaction with a care giver, then the Home protocol was as described.
89689885|NCT04818645|Experimental|ASSERT insertable cardiac monitor|The ASSERT implantable cardiac monitor (ICM) is an FDA-approved device that can be injected into the subcutaneous tissue and can provide automatic as well as patient triggered electrocardiographic recordings of symptomatic episodes during long term follow-up. This Implantable cardiac monitor is paired with a remote monitoring smartphone application called My Merlin that capable of rapid remote review of electrograms to be utilized in this study for arrhythmia detection. The ASSERT ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.
89689886|NCT04818645|Active Comparator|Conventional Management|The conventional management arm will use arrhythmia signs and symptoms to determine occurrence of arrhythmias.
89689887|NCT00936377|Experimental|Dexmedetomidine, low dose|Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
89689888|NCT00936377|Experimental|Dexmedetomidine, high dose|Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
89689889|NCT00936377|Placebo Comparator|Placebo|Normal saline
89061876|NCT04428177|Active Comparator|Standard therapy|Standard treatment of calcified coronary lesions: cutting, scoring or non-compliant balloon predilatation or rotational atherectomy
89061877|NCT04311502|Experimental|Arm 1: Experimental 3-month, with CFZ loading dose|Participants will receive rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks.
89061878|NCT04311502|Active Comparator|Arm 2: Standard of care for drug-susceptible (DS) TB|Participants will receive rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks.
89061879|NCT04311502|Experimental|Arm C: PK only subgroup|Participants will receive PHZE + CFZ 100 mg once daily for 4 weeks; then on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks).
89061880|NCT04311073|Experimental|Tranexamic Acid|Patients will receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline 15 minutes prior to initial surgical incision time
89061881|NCT04311073|Placebo Comparator|Placebo|Patients will receive an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision
89061882|NCT04298827|Active Comparator|Unimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment.
89221327|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2165-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2165-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
89221328|NCT00934778|Experimental|Bronchoscopy|
89689890|NCT03123874|Experimental|Sterile pump set-up first|Participants will pump with sterile pump set-ups first. Approximately 3 hours later, participants will pump with their own pump set-ups.
89689891|NCT03123874|Experimental|Mother's Own pump set-up first|Participants will pump with their own pump set-ups first. Approximately 3 hours later, participants will pump with sterile pump set-ups.
89689892|NCT04472169||Severe haemophila A patients with or without inhibitors|
89689893|NCT00936455||Telemedicine|Telemedicine evaluated patients
89689894|NCT00936455||Telephone|Telephone evaluated patients
89689895|NCT03124342|Experimental|VANDERBILT ICU RECOVERY PROGRAM (VIP)|Patients assigned to the Vanderbilt ICU Recovery Program (VIP) group will receive the components of the ICU Recovery Program intervention.
89689896|NCT03124342|No Intervention|Usual care|Patients in the usual care group will receive care as dictated by their clinical team. In usual care in the study institution, patients frequently receive medication reconciliation by and ICU pharmacist at the time of transfer out of the ICU to the hospital ward, medication reconciliation by a physician at the time of hospital discharge, and follow up with their primary care physician within two weeks of hospital discharge. Usual care does not currently include an in-person assessment of the patient's cognitive and functional status or anticipated post-ICU needs by a nurse practitioner between ICU transfer and hospital discharge, access to a 24/7 contact line after hospital discharge, or assessment in a multi-disciplinary ICU Recovery Clinic.
89689897|NCT04359095|Active Comparator|I1 Emtricitabine + Tenofovir|Intervention 1: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days
89689898|NCT04359095|Active Comparator|I2 Colchicine + rosuvatatine|Intervention 2: Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
89689899|NCT04359095|Active Comparator|I3 Emtricitabine/ tenofobir + colchicine+ rosuvastatin|Intervention 3: Emtricitabine (200 mg) + tenofovir (300 mg): 500 mg once a day for 10 days + Colchicine: 0.5 mg every 12 hours for 14 days + Rosuvatatin: 40 mg / day for 14 days
89689900|NCT04359095|Other|I4 Standard Treatment|Intervention 4: Standard treatment. It is defined as treatment aimed to control symptoms including fever and pain, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient, might include Dexamethasone. No viral therapies are included.
89689901|NCT05402956|Experimental|Aerobic exercise|
89689902|NCT05402956|No Intervention|Control|
89689903|NCT05345080|Experimental|Exposure-Reduction Intervention Group|The exposure-reduction (intervention) group receives a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), a customized asthma self-management plan and support developed using motivational interviewing methods, and a customized selection of supplies to help reduce key exposures likely exacerbating asthma symptoms.
89689904|NCT05345080|No Intervention|Phone-Call-Only Control Group|The phone-call-only (control) group provides self-reported information about health and environmental exposures. They receive follow-up phone calls every 6 weeks to maintain contact only. After exit, the phone-call-only (control) group receives assessment for allergies (optional) and the exposure-reduction intervention.
89689905|NCT04359251|Experimental|Optimizing oxygenation|Best oxygenation during PEEP titration
89689906|NCT04359251|Experimental|Optimizing compliance|Best compliance during PEEP titration
89689907|NCT04359251|Experimental|ARDSnet|PEEP settings according to ARDSnet table
89689908|NCT02163421|Experimental|Vedolizumab SC 54 mg|Vedolizumab SC, once on Day 1.
89689909|NCT02163421|Experimental|Vedolizumab SC 108 mg|Vedolizumab SC, once on Day 1.
89689910|NCT02163421|Experimental|Vedolizumab SC 160 mg|Vedolizumab SC, once on Day 1.
89689911|NCT02163421|Active Comparator|Vedolizumab IV 300 mg|Vedolizumab IV, once on Day 1.
89689912|NCT05320510|Experimental|Se-yeast|Selenium-enriched yeast tablet (Se, 50 μg/d)
89689913|NCT05320510|Placebo Comparator|Placebo|placebo-yeast tablet
89221329|NCT00111007|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die [twice daily]) on Study Days 2 to 19 + Paclitaxel (225 mg/m^2 iv [Intravenous]) and Carboplatin (AUC [area under the curve] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
89221330|NCT00111007|Active Comparator|Carboplatin/Paclitaxel (C/P)|Placebo, 2 tablets bid on Study Days 2-19 + Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
89221331|NCT03975920|No Intervention|Usual Care (UC)|The study control is UC, which involves the dental assistant supporting the jaw during the extractions with concurrent use of a bite block.
89221332|NCT03975920|Experimental|Experimental Care (EC)|The study intervention for EC is use of the Restful Jaw version 2 (RJ2) device, which supports the jaw during the extractions, with concurrent use of a bite block.
89221333|NCT01082887|Experimental|TIL-Ad-INFg|
89221334|NCT03963037||Patients|The family members of our two kindreds who carry the truncating mutation in the Apolipoprotein B gene.
89221335|NCT03963037||Controls|The family members of our two kindreds who are no carriers of the truncating mutation in the Apolipoprotein B gene.
89221336|NCT00935168|Experimental|Hydroxy-ethyl starch|Intravenous fluid resuscitation with 6% Hydroxy-ethyl starch (130/0.4)
89221337|NCT00935168|Active Comparator|Saline|Intravenous fluid resuscitation with saline (0.9% sodium chloride)
89221338|NCT03962881|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89221339|NCT03962881|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
89221340|NCT03962881|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2,and 6
89221341|NCT00940394|Other|standard care|Families receive routine community and family mental health care services
89221342|NCT00940394|Experimental|mutual support group|bi-weekly, 12-session, family-led mutual support group
89221343|NCT00940394|Active Comparator|psychoeducation group|bi-weekly, 12-session, family psychoeducation group program
89221344|NCT01083043||Type 2 Diabetes Mellitus|
89221345|NCT00935246|Experimental|Antidepressant treated group|Antidepressant treated group: depressed patients treated with Escitalopram
89221346|NCT00935246|No Intervention|other antidepressant treated group|other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
89221347|NCT04013360|Active Comparator|Breath Stacking|Instrument composed of a one-way valve coupled to a face mask to promote the accumulation of successive inspiratory volumes.
89221348|NCT04013360|Active Comparator|Expiratory Positive Airway Pressure|Therapeutic technique consisting of a face mask, a one-way valve and an expiratory resistor, responsible for resistance to expiratory flow, which will determine the level of pressure in the airway.
89221349|NCT02793284|Experimental|Intervention 18F-DCFPyL PET/CT|18F-DCFPyL PET/CT scan obtained at the time of restaging for biochemical recurrence after primary radiotherapy
89221350|NCT00935324||Group A: patients following allo-SCT|Patients scheduled for allo-SCT fulfilling all inclusion criteria
89221351|NCT00935324||Group B - healthy controls|healthy voluntary blood donors
89221352|NCT00935402|Experimental|Short Sleep|Subjects are permitted to spend 4 hours in bed per night for 5 consecutive nights. Subjects are inpatients for a period of 6 days.
89221353|NCT00935402|Active Comparator|Regular Sleep|Subjects are permitted to spend 9 hours in bed per night for 5 nights. Subjects are inpatients for a period of 6 days.
89221354|NCT02667002|Experimental|Bilateral Abdominal Sacral Hysteropexy|Bilateral abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
89221355|NCT02667002|Experimental|Classic Abdominal Sacral Hysteropexy|Conventional abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
89221356|NCT02667002|Active Comparator|Women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
89221357|NCT00935480|Experimental|HAART+Raltegravir 12 months (+/-) Maraviroc|
89221358|NCT00935480|No Intervention|HAART|
89221359|NCT00939848|Experimental|B|The experimental arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with cediranib 20mg oral daily (continuous dosing).
89221360|NCT00939848|Placebo Comparator|Arm A|The control arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with a matching placebo 20mg oral daily (continuous dosing)
89221361|NCT04013048|Experimental|[14C]-Fluzoparib|Patients will receive single dose of [14C]- Fluzoparib.
89221362|NCT04014218|Experimental|Inhalation sedation|
89221363|NCT04014218|Active Comparator|Propofol|
89221364|NCT00935558|Experimental|Aromatase inhibitor and DC vaccination|the HLA-A2 positive patients will be treated with AI, DC vaccines, Zadaxin and IL-2
89221365|NCT00935558|Active Comparator|Aromatase inhibitor|the HLA-A2 negative patients will receive AI only
89221366|NCT05280236|Active Comparator|Propofol|Patients receiving general anesthesia with propofol-based total intravenous anesthesia
89221367|NCT05280236|Experimental|Remimazolam|Patients receiving general anesthesia with remimazolam-based total intravenous anesthesia
89221368|NCT00940472|Experimental|Experimental Drug|DMMET-01 + Diet
89221369|NCT00940472|Active Comparator|Metformin|Metformin + Diet
89221370|NCT04013204|Experimental|Intervention group|Intervention group: Before the patient returns to the doctor and the prescription is issued, the EDCM system will feed back the EndoPAT test results to the responsible doctor through the automatically generated information on the doctor's mobile phone, but will not let the patient know the endothelium test results (blinded to the patient).
89221371|NCT04013204|No Intervention|Control group|Control group: The EDCM system will not report the EndoPAT test results to the responsible doctor (the doctor cannot see the final EFT results), nor can the patients know the EFT results.
89221372|NCT00940550|Experimental|Prolonged-release melatonin 2 mg|
89221373|NCT00940550|Active Comparator|Temazepam 20 mg|
89221374|NCT00940550|Active Comparator|Zolpidem 10 mg|
89221375|NCT00940550|Placebo Comparator|Placebo|
89221376|NCT00935714|Active Comparator|Muscle Group|Exercise
89221377|NCT00935714|Active Comparator|Sequence|Exercise
89221378|NCT00935870||A|DEPRESSED LATERAL CONDYLE FRACTURE
89221379|NCT00935870||B|BENIGN BONE TUMOR
89221380|NCT00935870||C|SPINAL FUSION
89221381|NCT00935948|Active Comparator|Imescard ointment|
89221382|NCT00935948|Placebo Comparator|Placebo|
89221383|NCT00940628|Experimental|1|
89221384|NCT00940628|Other|2|
89221385|NCT00921323|Placebo Comparator|Control|The control group will be advised to continue to be physically active and record daily steps
89221386|NCT00921323|Active Comparator|Goal-setting group|This intervention group would be instructed to increase their daily step count by at least 20% above their baseline gradually over 3 months.
89221387|NCT00940004|Active Comparator|cytokine matured DC|vaccination with autologous dendritic cells matured with standard cytokine cocktail and electroporated with mRNA encoding tumor associated antigens
89061883|NCT04298827|Active Comparator|Trimodal|Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation, nutritional counseling and group therapy, prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment. Patient nutritional assessments will be obtained with Patient Generated Subjective Global Assessment questionnaires as well as targeted questioning by the dietician.
89061884|NCT04283669|Other|Open Label Continuous Treatment|Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles. Clinical response will be assessed by MRI (volumetrics, primary objective) and audiology at the end of every 3rd cycle. Subjects with volumetric tumor progression will be taken off protocol. Patients who complete 12 cycles of treatment without disease progression, but within the following 24 weeks show subsequent disease progression (defined as >20% increase in target tumor volume compared to off-treatment volume), will be eligible for re-treatment on study for up to 48 additional weeks, provided they still meet study eligibility criteria.
89061885|NCT04276883|Experimental|120 Micrograms|Sublingual film containing 120 Micrograms Dexmedetomidine
89061886|NCT04276883|Experimental|180 Micrograms|Sublingual film containing 180 Micrograms Dexmedetomidine
89061887|NCT04276883|Placebo Comparator|Placebo|Sublingual placebo film
89061888|NCT04271930|Experimental|Mindfulness Awareness Practices for Insomnia|Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with 5 minutes and increasing to 20 minutes over the course of the 6-week intervention - as is standard with the Mindfulness Awareness Practices (MAPs) course - with practice prior to bedtime. An intervention training manual is the cornerstone of standardized delivery of MAP-I. Participants are also provided with a book on mindfulness (Fully Present: The Science, Art, and Practice of Mindfulness, authored by the Mindfulness Awareness Research Center (MARC) leader and MAP-I instructor Diana Winston) as well as access to the University of California Los Angeles (UCLA) Mindful App courtesy of the MARC at UCLA (via personal iPhone or study-administered tablets per patient preference), which contains pre-recorded guided meditations for use in daily practice.
89061889|NCT04271930|Active Comparator|Sleep Health Education|Six individual 1-hour videos will be shown to participants at the same time points as, and with equal duration to, the MAP-I intervention. These videos will be recorded presentations that have been modified for HCT recipients based upon similar SHE interventions delivered in prior studies. Similar to the intervention group, patients in the SHE group will also participate in group Zoom chat sessions with equal frequency and duration lead by a study research coordinator. These sessions will allow for general patient interaction to discuss sleep and any questions or comments they may have, as lead by the group facilitator.
89061890|NCT04271085||Patients in the last phase of life|Patients in the last phase of life and their families
89061891|NCT04267107|Experimental|Managing Fatigue:The Individual Program|"Participants in the experimental group will receive the 6-week MFIP. Individuals in experimental group :~will participate in six one-to-one sessions (each takes 60 to 90 minutes)~will complete the Feasibility Questionnaire #1, after each session (10 questions) (Appendix 6)~will complete Feasibility Questionnaire #2 after completing all six-sessions (12 questions) (Appendix 7)~will complete the post-test measurement after completion of the program (approximately 60 minutes to complete)~will complete the follow-up measurement, three months after the completion of the program (approximately 60 minutes to complete)~will be advised to continue with their current healthcare services.~may participate in one focus group (one-hour session)"
89061892|NCT04267107|No Intervention|Control Group|"Participants in the control group will not receive the IMFP and they will be advised to continue with their current healthcare services.~Participants in the control group:~will complete post-test measurements after 6 weeks (approximately 60 minutes),~will complete the follow-up measurements three months later after completing the program (approximately 60 minutes).~will be advised to continue with their current healthcare services.~Following the study, participants in the control group will be offered the manual of the program and a three-hour training workshop after (three months after the baseline testing). In this workshop, they will learn about the about the program, including the pre-session activities, in-session activities, and homework. This workshop will be conducted by occupational therapists."
89221388|NCT00940004|Experimental|TLR ligand matured DC|vaccination with autologous TLR-ligand matured dendritic cells electroporated with mRNA encoding tumor associated antigens
89221389|NCT00936104||SP in PDAC|Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
89221390|NCT02565797|Experimental|DabirAIR overlay-ORICU|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room and in the post-op ICU.
89221391|NCT02565797|Experimental|DabirAIR overlay-OR|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room alone and on standard of care support surface in the post-op ICU.
89221392|NCT02565797|No Intervention|Control-SOC|Patients scheduled for neurosurgical procedures will be placed on standard of care support surface in the operating room and post-op ICU. Data will be abstracted through retrospective chart review.
89221393|NCT00936182|Experimental|Fluconazole|
89221394|NCT00936182|Placebo Comparator|Placebo|Placebo capsule daily for 30 days
89061893|NCT04261790|Other|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
89061894|NCT04238546|Experimental|Sirolimus-coated group|
89061895|NCT04238546|Active Comparator|Uncoated group|
89061896|NCT04212416|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD for days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may optionally continue leflunomide for an additional 6 cycles as long as response or stable disease is maintained.
89061897|NCT04193085||Spinal Muscular Atrophy (SMA)|ambulatory children and adults at least 5 years old by the time of enrollment with genetically confirmed SMA
89061898|NCT04193085||Duchenne / Becker Muscular Dystrophy (DMD/BMD)|ambulatory children and adults ages at least 5 years old by the time of enrollment with genetically confirmed Duchenne or Becker muscular dystrophy or evidence on muscle biopsy with a clinical presentation consistent with DMD /BMD.
89061899|NCT04193085||Healthy Control|The healthy control group will be age and gender-matched to the SMA and DMD groups as best as possible
89061900|NCT04108117||Robotic nipple sparing mastectomy group/RNSM|"Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.~The estimated sample size for this arm is 300 cases."
89061901|NCT04108117||Conventional nipple sparing mastectomy group/CNSM|"Cases or Patients who underwent conventional nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Conventional nipple-sparing mastectomy should not be performed using robotic or endoscopic surgical systems. Axillary or lateral incisions that are similar to incisions in robotic nipple-sparing mastectomy are not allowed. Other than axillary or lateral incisions can be performed for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with nipple-sparing mastectomy without immediate reconstruction are excluded.~The estimated sample size for this arm is 300 cases."
89061902|NCT04099992|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.
89061903|NCT04099992|Active Comparator|Health enhancement program (HEP)|Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions with a day-long retreat.
89061904|NCT04099992|Experimental|MBSR+tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD) ."
89221395|NCT00940082||youth control group|healthy people which ages from 30 to 59
89221396|NCT00940082||youth diabetes group|type 1 and type 2 diabetes patients which ages from 30 to 59
89221397|NCT00940082||the elderly diabetes group|type 1 and type 2 diabetes patients which ages from 60 to 90
89221398|NCT00940082||elderly control group|healthy people which ages from 60 to 90
89221399|NCT00936260|Experimental|alendronate 6 years|
89061905|NCT04099992|Active Comparator|MBSR+sham-tVNS|"Mindfulness-Based Stress Reduction (MBSR) tis designed to provide education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. MBSR is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session.~Sham stimulation will be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
89061906|NCT04099992|Experimental|HEP+tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator (a registered dietician) in a group setting for 8 weekly 2.5-hour sessions.~Transcutaneous vagus nerve stimulation (tVNS) is a simple, noninvasive, self-administered adjunctive therapy, that may enhance the sympatho-inhibitory effects of mindfulness meditation (MM) in chronic kidney disease (CKD)."
89061907|NCT04099992|Active Comparator|HEP+sham-tVNS|"Health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions.~Sham stimulation is be delivered using a sham device that is identical in appearance and function to tVNS, but programmed to produce a lower frequency (0.1 Hz) biphasic signal that can be felt by the participant without actually stimulating the vagus nerve."
89061908|NCT04099888|Experimental|PCI treatment in conjunction with Standard of Care (SoC)|Arm A: Fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by gemcitabine/cisplatin chemotherapy
89061909|NCT04099888|Active Comparator|Standard of Care (SoC)|Arm B: Gemcitabine/cisplatin chemotherapy
89061910|NCT04081389|Experimental|CKM weeks 1-3, doxorubicin, cyclophosphamide)|Patients receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
89061911|NCT04078854|Experimental|Foot amputation, sexual health|Group 1, Experimental arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations plus sexual health
89061912|NCT04078854|Active Comparator|Foot amputation, no sexual health|Group 2, Control arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations, with no mention about sexual health
89061913|NCT04033081|Experimental|CivaSheet Treatment|Implanted with CivaSheet during tumor removal
89061914|NCT04032080|Experimental|LY3023414 + prexasertib|Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression. Patients whose disease does not respond to the combination of LY3023414 and prexasertib may be treated with standard of care breast cancer therapies off study, at the recommendation of the treating physician.
89221400|NCT00936260|Experimental|alendronate 5 years|No treatment during year 6th
89221401|NCT00936260|Experimental|alendronate 5 years, not continued|No treatment during year 5th
89061915|NCT04022005|Experimental|Chidamide combined with R-GemOx|Chidamide, 20 mg,twice per week; Rituximab 375mg/m2, d1, intravenous drip; Gemcitabine 1000mg/m2, d2, intravenous drip; Oxaliplatin 100mg/m2, d2,intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive chidamide maintenance therapy.
89061916|NCT04020276|Experimental|MRI-Guided SBRT Dose Escalation|"Treatment on MRI Linac with SBRT in 5 fractions with adaptive planning, maximum dose 80 Gy~Dose Escalation Bowel Pathway, V34 < 0.5cc Dose Escalation Liver Pathway, 700 cc < 16 Gy~Subsequent Phase 1B: CRC only for Safety and Local Control, dosage informed by Phase 1A"
89061917|NCT04016142|Experimental|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients~will be registered in the first part of the study at diagnosis and will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage (no progression during Part 1 of the study and no medical contra-indication to the study treatment)."
89061918|NCT04004936|Active Comparator|Active Feedback|EQUIPPED with active provider feedback, implementing one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
89061919|NCT04004936|Active Comparator|Passive Feedback|EQUIPPED with passive provider feedback, implementing monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
89061920|NCT03970720|Experimental|T1DM - Unaware: Metoclopramide|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg metoclopramide four times a day during the four-week intervention period.
89061921|NCT03970720|Placebo Comparator|T1DM - Unaware: Placebo|T1DM participants with hypoglycemia unawareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
89061922|NCT03970720|Placebo Comparator|T1DM - Aware: Placebo|T1DM participants with hypoglycemia awareness determined by a hypoglycemic clamp study will receive 10 mg matching placebo capsules four times a day during the four-week intervention period.
89061923|NCT03943498|Experimental|Treatment (Fingolimod)|"Patients receive 0.5 mg dose of Fingolimod PO QD for 4 weeks.~Take your Fingolimod approximately every 24 hours"
89061924|NCT03912818|Experimental|Cohort II (durvalumab, cis-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Cisplatin 70 mg/m2 on Cycle Day 2, and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
89061925|NCT03912818|Experimental|Cohort III (Durvalumab, carbo-gem)|Durvalumab (MEDI4736), at 1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Carboplatin: AUC 5 on Cycle Day 1 and gemcitabine 1,000 mg/m2 on Cycle Day 1 and Day 8 in 21 day cycles (3 weeks). Patients undergo cystectomy within 6 weeks.
89061926|NCT03912818|Experimental|Cohort I (durvalumab, DD MVAC)|Durvalumab (MEDI4736), at1500 mg fixed dose, administered intravenously (IV) over 60 minutes. Standard chemotherapy will be administered as an IV infusion during each of the 4 cycles. Dose Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin (DD MVAC), in 14 day cycles (2 weeks), Methotrexate 30 mg/m2 on Cycle Day 1, Vinblastine 3 mg/m2 on Cycle Day 2, Doxorubicin 30 mg/m2 on Cycle Day 2 and Cisplatin 70 mg/m2 on Cycle Day 2. Patients undergo cystectomy within 6 weeks.
89061927|NCT03865277|Other|standard radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy
89061928|NCT03865277|Experimental|dose-escalated radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy
89061929|NCT03865277|Experimental|escalated radiochemoth., carbon boost, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)
89061930|NCT03865277|Other|standard radiochemotherapy, oxic|HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy
89061931|NCT03865277|Other|standard radiochemotherapy (70 Gy)|HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.
89221402|NCT00936260|Experimental|alendronate 4 years|No treatment during year 5th and 6th
89221403|NCT00936260|Experimental|alendronate 5 years, uncontinued|No treatment during year 4th
89061932|NCT03852498|Experimental|Lenti-D Drug Product|Participants received a single intravenous (IV) infusion of Lenti-D Drug Product at a dose of > or = 5.0*10^6 CD34+ cells/kilogram (kg) (autologous CD34+ cell-enriched population that contains cells transduced with lentiviral vector encoding ABCD1 cDNA for human adrenoleukodystrophy protein, suspended in a cryopreservative solution) following myeloablative conditioning with busulfan and fludarabine on Day 1.
89061933|NCT03781934|Experimental|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|Phase 2a expansion cohort HCC
89061934|NCT03781934|Experimental|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|Phase 2a expansion cohort HCC
89061935|NCT03781323|Experimental|mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
89061936|NCT03771261|Placebo Comparator|WL-Control|Weight loss intervention (WL-Control; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein~0.8g/g/d.
89061937|NCT03771261|Active Comparator|WL-Protein|High-protein weight loss intervention (WL-Protein; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein at each meal. Intakes of > 30g of protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal sources (high quality) and 60-70% of animal protein from eggs or egg protein powder that will be provided to WL-Protein participants.
89061938|NCT03742687|Experimental|A:Large target volume|The target volume for radiotherapy treatment volume is considered too large for a standard treatment of 66Gy in 33 fractions, considering the expected normal tissue toxicity with a standard treatment plan. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
89061939|NCT03742687|Experimental|B:Fragile patient|The patient is too fragile for standard long-course radiotherapy with 66 Gy. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
89061940|NCT03729362|Experimental|Cipaglucosidase Alfa/Miglustat|Participants received cipaglucosidase alfa co-administered with miglustat every 2 weeks (Q2W).
89061941|NCT03729362|Active Comparator|Alglucosidase Alfa/Placebo|Participants received alglucosidase alfa co-administered with placebo Q2W.
89061942|NCT03653884||Pregnancy with fetal intra-abdominal umbilical vein.|All women with a pregnancy with a partially intra-abdominal umbilical vein aneurysm isolated or associated with other abnormalities découvert lors d'une ultrasonic monitoring.
89061943|NCT03630211|Experimental|Autologous Stem Cell Transplantation|CD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
89061944|NCT03629106|Experimental|Contingent Reinforcement|The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level <20 ng/ml.
89061945|NCT03629106|Experimental|No Contingent Reinforcement|The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
89221404|NCT00936260|Experimental|alendronate 4 years, not continued|No treatment during year 4th and 6th
89061946|NCT03623984|Experimental|Gallium Dotatate|All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.
89061947|NCT03587961|Experimental|Symdeko|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern
89061948|NCT03587961|Experimental|Ivacaftor|Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.
89061949|NCT03587961|Experimental|Orkambi|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern
89061950|NCT03580772||Persona TKR|Patients will have undergone a medial congruent Persona total knee replacement
89061951|NCT03580772||Attune TKR|Patients will have undergone a Attune total knee replacement
89061952|NCT03580772||Control participants|Patients will not have recieved a primary TKR
89061953|NCT03551665|Experimental|Step training|This group will undergo a baseline control period, as well as an intervention period. As such, they will serve as their own control subjects.
89061954|NCT03534453|Experimental|Olaparib 300mg tablets|Taken orally twice daily
89061955|NCT03453385|No Intervention|Control|Participants will not receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
89061956|NCT03453385|Experimental|Sampling|Participants will receive an NJOY electronic cigarette to sample and will continue smoking their usual cigarettes as much or as little as they would like.
89061957|NCT03426293||Arterial procedure and ACT measurement|All patients undergoing an open or endovascular arterial procedure in which heparin is used peri-procedurally and the ACT is measured to determine effect of heparin
89061958|NCT03396718|Experimental|Interventional Arm A - HPV(+)|De-escalation Radio(chemo)therapy - Level 1
89061959|NCT03396718|Experimental|Interventional Arm B - HPV(+)|De-escalation Radio(chemo)therapy - Level 2
89061960|NCT03396718|Active Comparator|Observational Arm A - HPV(-)|Standard Radio(chemo)therapy
89061961|NCT03396718|Active Comparator|Observational Arm B - HPV(+)|Standard Radio(chemo)therapy
89061962|NCT03340766|Experimental|Cohort Ia: Blinatumomab 9/28 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion (CIVI) for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days then 28 µg/day for the remaining days of treatment.~Starting on Day 15 participants also received 200 mg pembrolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) until disease progression or for up to 35 cycles."
89061963|NCT03340766|Experimental|Cohort IIa: Blinatumomab 9/28/56 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days, 28 µg/day for 7 days then 56 µg/day for the remaining days of treatment.~Starting on Day 19 participants also received 200 mg pembrolizumab administered by IV infusion Q3W until disease progression or for up to 35 cycles."
89221405|NCT00936260|Experimental|alendronate 4 years, uncontinued|No treatment during year 4th and 5th
89221406|NCT00936260|Experimental|Alendronato 3 years|No treatment during the last 3 years
89221407|NCT00445978|Experimental|Sapropterin dihydrochloride|2.5, 5, 10, 20 mg/kg/day of sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks, with an optional extension phase at the highest tolerated dose for up to a total of 2 years.
89221408|NCT02566733|Experimental|Remiva|This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company.
89221409|NCT02566733|Active Comparator|Ultiva|This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company.
89221410|NCT00936338|Active Comparator|splint|
89221411|NCT00936338|Active Comparator|joint mobilization self exercise|
89221412|NCT05281991||Patients who had an epidural placed for labour|Patients who had an epidural placed for labour may take part. Study procedures will take place after delivery and prior to removal of the epidural catheter.
89221413|NCT00936416|Experimental|GFR and RBF followed by MRI|Subjects will undergo GFR and renal blood flow estimation by Inulin and PAH clearance method, followed by a MRI test. The MRI examination will be performed on the same day as the inulin/PAH procedure.
89221414|NCT02566421|Experimental|Treatment (precision medicine)|Patients receive treatment based on the results of their genomic sequencing analyses.
89221415|NCT00940706|Experimental|Physical activity in groups|Exercises of physical activity
89221416|NCT00940706|Experimental|Activity monitoring with accelerometers|Each subject will wear the accelerometer 24 hours a day for 4 days The activity will be recorded and analyzed
89221417|NCT00940706|Active Comparator|Treadmill|Treadmill with safety adaptations for handicapped persons
89221418|NCT01023412|Active Comparator|Nutritional product|Oral nutritional supplement containing immuno nutrients
89221419|NCT01023412|Placebo Comparator|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
89221420|NCT02566499|Experimental|Abnormal x-ray Mammography group|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
89221421|NCT00936494|No Intervention|Control|No inferior turbinate surgery.
89221422|NCT00936494|Other|Intervention|Intervention group: Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).
89221423|NCT01028950|Experimental|YM150 group|
89221424|NCT00940784|Experimental|Clopidogrel|Subjects will be randomized to clopidogrel (oral-75 mg per day) in addition to low dose aspirin and hydroxyurea
89221425|NCT00940784|Placebo Comparator|Placebo|Subjects will be randomized placebo in addition to low dose aspirin and hydroxyurea
89221426|NCT02566343||COPD cohort|confirmed COPD: 240 patients with COPD confirmed by spirometry undergoing high-risk noncardiac major surgery in the University Medical Center Hamburg-Eppendorf will be included in this group.
89221427|NCT02566343||Control cohort|disproved COPD: 80 patients without COPD (clinical risk factors but negative spirometry) undergoing high-risk noncardiac major surgery will be included as a control group.
89221428|NCT01023490|Placebo Comparator|Placebo|
89221429|NCT01023490|Active Comparator|Vitamin D|34,500 IU vitamin D per week
89221430|NCT00566228|Experimental|Immunologic autograft engineering|Patients' stem cells are collected according to modified Amicus settings (i.e., MNC OFFSET = 0.0 and RBC = 7.0). Patients undergo ASCT IV on the day of apheresis (lymphocyte enriched autograft).
89221431|NCT00566228|Active Comparator|Standard autograft collection|Patients' stem cells are collected according to standard Amicus settings (i.e., MNC OFFSET = 1.5 and RBC OFFSET = 5.0). Patients undergo ASCT IV on the day of apheresis.
89221432|NCT00698009|Experimental|Fludarabine + Cyclophosphamide + NK Cell Infusion|Fludarabine 25 mg/m^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.
89221433|NCT01027156|Experimental|High Intensity Exercise|
89221434|NCT00936572|Experimental|high dose|high dose of probiotics (109 cfu)
89221435|NCT00936572|Experimental|low dose|low dose of probiotics (107 cfu)
89221436|NCT00936572|Placebo Comparator|probiotics|Maltodoxtrin
89221437|NCT01529762||Osseotite Certain Tapered|Dental implant Osseotite Certain Tapered design
89221438|NCT04012658||Patients with the genetic diagnosis of Wilson's Disease|
89221439|NCT04012658||Asymptomatic Wilson's Disease carriers|
89221440|NCT04012658||Relatives of Wilson's Disease patients or carriers|
89221441|NCT04012658||Unrelated healthy controls|
89221442|NCT00944606|Active Comparator|Vitamin D|
89221443|NCT00944606|Placebo Comparator|Placebo|
89221444|NCT00941018|Experimental|SAD cohort 1|Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The starting dose will be 300 mg. Subsequent doses will be determined by the pk and safety data from previous cohorts.
89221445|NCT00941018|Experimental|SAD cohort 2|SAD cohort 2 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The doses to be administered will be determined by the pk and safety data from previous cohorts.
89221446|NCT00941018|Experimental|MAD cohort 1|Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.
89221447|NCT00941018|Experimental|MAD cohort 2|MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
89061964|NCT03340766|Experimental|Cohort IIIa: Blinatumomab 9/28/112 µg/day + Pembrolizumab|"Participants received blinatumomab administered as a continuous intravenous infusion for 8 weeks followed by a 28-day treatment-free interval. Participants with stable disease or better may have received a second 28-day consolidation cycle. The starting dose of each cycle was 9 µg/day for the first 7 days, 28 µg/day for 7 days then 112 µg/day for the remaining days of treatment.~Starting on Day 19 participants also received 200 mg pembrolizumab administered by IV infusion Q3W until disease progression or for up to 35 cycles."
89061965|NCT03340766|Experimental|Expansion Cohort|This cohort will test the maximum tolerated dose of blinatumomab in combination with pembrolizumab identified in Part 1 of the study.
89061966|NCT03334864||I Retrospective cohort|Diagnosis of advanced non-small cell lung cancer from 2012-2016
89061967|NCT03334864||II Prospective cohort|Advanced non-small cell lung cancer with driver gene mutations
89061968|NCT03334864||III Prospective cohort|Non-small cell lung cancer in immuno-therapy;
89061969|NCT03334864||IV Prospective cohort|Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;
89061970|NCT03334864||V Prospective cohort|Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.
89061971|NCT03302949|No Intervention|Control|Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
89061972|NCT03302949|Experimental|Intervention|Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090
89061973|NCT03290534|Experimental|CivaSheet Directional LDR Brachytherapy|FDA Cleared CivaSheet directional Pd-103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
89061974|NCT03267589|Experimental|Cohort A|Intervention: MEDI9447 (CD73) + durvalumab
89061975|NCT03267589|Experimental|Cohort B|Intervention: MEDI0562 (OX40) + durvalumab
89061976|NCT03267589|Experimental|Cohort C|Intervention: MEDI0562 (OX40) + tremelimumab combination
89061977|NCT03226106|Experimental|Physical Activity Behavior Intervention|A 12-week behavior change intervention that supplements conventional rehabilitation including: 10 telerehabilitation sessions, daily activity sensor use, education, self-monitoring, tailored feedback, barrier/facilitator identification, promotion of problem solving, action planning, and encouragement.
89061978|NCT03226106|Active Comparator|Attention Control|Conventional rehabilitation with 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
89061979|NCT03208452|Placebo Comparator|Normal saline(NS) group|loading 50mL of normal saline during 10minutes before starting of surgery, after starting of surgery, continuous infusion of normal saline as placebo by 0.15mg/kg/h until the end of surgery
89061980|NCT03208452|Active Comparator|Magnesium group|loading dose of 50mg/kg magnesium sulfate during 10minutes before starting of surgery, during the surgery, continuous infusion of magnesium sulfate by 15mg/kg/h
89061981|NCT03190265|Experimental|Arm A: CY, Nivolumab, Ipilimumab, GVAX, CRS-207|
89061982|NCT03190265|Experimental|Arm B: Nivolumab, Ipilimumab, CRS-207|
89061983|NCT03160612|Other|Case|Transfer Training Subjects will be randomized to receive the transfer training either after baseline measures are collected (case) during visit 1.
89061984|NCT03160612|Other|Control|Transfer Training Subjects will be randomized to receive the transfer training during the follow-up testing at visit 2.
89061985|NCT03124186|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
89061986|NCT03124186|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
89061987|NCT03109041|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
89061988|NCT03103880|Experimental|BreatheSmart|"104 subjects will be provided with the BreatheSmart platform, which consists of:~HeroTracker sensor that monitors real-time asthma medication adherence~Mobile spirometer that offer remote clinical-grade lung function monitoring~BreatheSmart mobile application that provides patients with real-time alerts, environmental information (weather, pollution, etc.), and the ability to complete questionnaires / surveys."
89061989|NCT03063216||Congenital cataract group|Cataract patients diagnosed with congenital cataract.
89061990|NCT03063216||Traumatic cataract group|Cataract patients diagnosed with traumatic cataract.
89061991|NCT03057119|Experimental|SBIRT Intervention|The interventionist will discuss substance use and misuse, HIV, and the interaction of aging and substance use; will give the patient feedback on their NM-ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change; motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues. Identifying and prioritizing need; problem-solving techniques to help patients identify which services may best help them work towards their goals; will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
89061992|NCT03057119|No Intervention|Treatment as Usual|Participants in the enhanced care treatment as usual group will receive the same illustrated handout depicting their substance use screening score and the same referral resource guide provided to those in the control group. These will be provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and to resemble the notification and referral strategy that would be standard care.
89061993|NCT02998983|Experimental|Racotumomab|Dosage form: intradermal injection. Dosage: 0.4 mg. Frequency: the first 5 doses: biweekly injections; the following 10 doses: monthly injections. Duration: 12 months
89061994|NCT02875158|Active Comparator|Diode laser using conventional settings|The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
89061995|NCT02875158|Experimental|Diode laser using modified settings|The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
89061996|NCT02843945|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a pancreatic cancer resection will receive a CivaSheet LDR directional brachytherapy implant at the time of surgery. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
89061997|NCT02816099|Experimental|Type-1 diabetes patients|
89061998|NCT02816099|Other|Controls|
89061999|NCT02814929||Demographic and Prenatal Characteristics|Gender, multiple pregnancy antenatal steroid therapy, invitro fertilisation, preeclampsia/eclampsia, infants of diabetic mother, chorioamnionitis will be compared among infants with and without ROP
89062000|NCT02814929||Neonatal Characteristics of infants|Neonatal characteristics: GA, BW, SGA, resuscitation in delivery room, RDS, duration of mechanical ventilation and oxygen therapy, intracranial hemorrhage, hemodynamically significant PDA, early/late sepsis, NEC, number of blood transfusions, BPD, breastfeeding and weight gain at postnatal 28th day will be compared among infants with and without ROP.
89062001|NCT02814929||Incidence of any ROP and severe ROP|Incidence of any ROP, severe ROP and its treatment in relation to BW and GA will be evaluated. The same parameters will also be evaluated in preterm babies of refugees.
89062002|NCT02711852|Experimental|Duvelisib|Participants received the same dose from their previous duvelisib study. All doses were taken twice daily. Two dose reductions were allowed per participant, but doses were not less than 10 milligrams (mg). Participants received duvelisib until disease progression or unacceptable toxicity.
89062003|NCT02703597|Experimental|ASPIRE Group|Participants engage in up to five 70-minute sessions of ASPIRE spread over a period of 5 weeks. Each session completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco. At baseline, after 3 sessions, following the last session of the intervention, and about one month after the intervention has ended, participants complete psychosocial surveys and social network surveys. Baseline survey again completed. About one month after assessment 4, this group receives a 5th assessment followed by a hybrid version of the GSA-ASPIRE-Network program (moderated by Kahoot!). The group receives additional assessments after 3 sessions, following the last session of the program, and about one month after the program has ended (assessment 8).
89062004|NCT02703597|Experimental|GSA-ASPIRE-Network Group|Participants engage in five 70-minute sessions of ASPIRE conducted over a period of 5 weeks, with 2 booster sessions. Each session completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources. ASPIRE use is coupled with game-based social activities (GSAs). ASPIRE use, participants watch videos and engage in activities on the same computer. Each session, participants will alternate between 10 minutes of ASPIRE use and 5-minute GSAs. Participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships. At baseline, after 3 sessions, following the last session of the intervention, and about one month after the intervention has ended (assessment 4), participants complete psychosocial surveys and social network surveys.
89062005|NCT02688114|Experimental|Barrett's Esophagus Treatment|All participants are in the treatment arm. Patients with Barrett's esophagus will undergo baseline surveillance endoscopy, be treated with radiofrequency ablation, and undergo follow up endoscopy 1, follow up endoscopy 2, and follow up endoscopy 3.
89062006|NCT02615691|Experimental|Previously untreated patients (PUPs)|"Part A (Main Study): Participants age <3 years and not experienced two joint bleeds will receive on- demand treatment of 10-80 international unit per kilogram (IU/kg) of BAX 855 intravenously depending on the severity of the bleeding episode and age <3 years or after a maximum of two joint bleeds will receive prophylaxis treatment with dose of 25-80 IU/kg of BAX855 IV (based on investigator discretion) once weekly for up to 100 EDs.~Part A (Surgery): In participants, the administration of BAX 855 will be individualized based on the participants IR and half-life. For major surgery to achieve the target level of 80-100% FVIII in plasma of normal FVIII level and for minor surgery >=30-60% FVIII levels for dental or other invasive surgery.~Part B (Immune tolerance induction [ITI]): Participants will receive prophylaxis treatment of 100-200 IU/kg BAX 855 IV daily or 50 IU/kg three time in a week and will be reduced to twice weekly to maintain FVIII trough level of 1% for further 3 months."
89062007|NCT02579460|Experimental|Barrett's esophagus patients|Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.
89062008|NCT02429570|Experimental|Meclofenamate|All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
89062009|NCT02342613|Experimental|MILs treatment|Patients treated with the activated PTCy-MILs
89062010|NCT02221934|Experimental|Test Treatment|Self-initiated high frequency bioelectric nerve block delivered to the nerve by Altius.
89062011|NCT02221934|Active Comparator|Active Sham Control Treatment|Self-initiated non-therapeutic electrical signal delivered to the nerve by Altius.
89062012|NCT02204072|Experimental|BI 836845 & Enzalutamide|
89062013|NCT02204072|Active Comparator|Enzalutamide|
89062014|NCT02163525|Active Comparator|Ablation vs Embolization|Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
89062015|NCT02163525|Active Comparator|Ablation vs Myomectomy|Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
89062016|NCT02143128|Experimental|Efficacy Safety Score|Patients assessed using the ESS
89062017|NCT02143128|Active Comparator|Verbal Numeric Rating Scale|Patients assessed using VNRS
89062018|NCT02143128|No Intervention|Control|Regular follow up
89062019|NCT01977417|Experimental|Salsalate|3.0 grams/day salsalate (1.5 g twice per day)
89062020|NCT01977417|Placebo Comparator|Placebo|Placebo capsule twice per day
89062021|NCT01969578|Active Comparator|Chemotherapy|"Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel~Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy"
89062022|NCT01969578|Experimental|Androgen Deprivation Therapy (ADT)|"ADT = bicalutamide + triptorelin~Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized."
89062023|NCT01951885|Active Comparator|Group A (tacrolimus, methotrexate)|Participants receive tacrolimus IV over 24 hours beginning on day -1 (or tacrolimus orally beginning on day -3) and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11.
89062024|NCT01951885|Experimental|Group B (tacrolimus, methotrexate, mycophenolate mofetil)|Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive oral mycophenolate mofetil BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD).
89062025|NCT01810588|Experimental|All Patients|"Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
89062026|NCT01627301|Experimental|Device-guided Breathing (DGB)|Participants randomized to the DGB group use a device to guide their breathing to a slow breathing rate.
89062027|NCT01627301|Sham Comparator|Sham DGB|Participants randomized to the sham DGB group use a device identical to the DGB device but respiratory rates are not guided lower than the physiological rate.
89062028|NCT01627301|Experimental|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants randomized to use a tVNS device to deliver mild electrical stimulation to the vagal nerve.
89062029|NCT01627301|Sham Comparator|Sham tVNS|Participants randomized to use the sham tVNS device which vibrates but does not stimulate the vagal nerve.
89062030|NCT01499888|Experimental|Allogeneic Non-Myeloablative Stem Cell Transplantation|The transplant regimen will consist of alemtuzumab 1mg/kg divided over five days, 300 cGy TBI, followed by sirolimus dosed for a target serum trough level of 10- 15 ng/mL.
89062031|NCT01409954||Spinal decompression|Spinal decompression with an instrumented posterolateral fusion
89062032|NCT00745316|Experimental|1|oral Dose 1
89062033|NCT00745316|Experimental|2|oral Dose 2
89062034|NCT00745316|Experimental|3|oral Dose 3
89062035|NCT00745316|Experimental|4|oral Dose 4
89062036|NCT00745316|Experimental|5|oral Dose 5
89062037|NCT00745316|Placebo Comparator|6|Placebo - 2 capsules bid
89062038|NCT00709865|Experimental|1|.03 mg/kg
89062039|NCT00709865|Experimental|2|.15 mg/kg
89062040|NCT00709865|Experimental|3|.3 mg/kg
89062041|NCT00709865|Placebo Comparator|4|Placebo
89062042|NCT00682318|Experimental|Fish oil|Omega-3 polyunsaturated fatty acids (n-3 PUFA)
89062043|NCT00682318|Active Comparator|Safflower Oil|Omega-6 polyunsaturated fatty acids (n-6 PUFA)
89062044|NCT00626990|Active Comparator|Radiotherapy (RT) alone|radiation therapy alone
89062045|NCT00626990|Active Comparator|RT & Concurrent CT|Radiotherapy and concurrent temozolomide chemotherapy
89062046|NCT00626990|Active Comparator|RT + Adjuvant CT|Radiotherapy plus adjuvant temozolomide chemotherapy
89062047|NCT00626990|Active Comparator|RT & Concurrent CT + adjuvant CT|Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy
89062048|NCT00107198|Experimental|Treatment (surgery, combination chemotherapy, radiotherapy)|"COMBINATION CHEMOTHERAPY: Patients receive doxorubicin hydrochloride IV over 10-30 minutes and cyclophosphamide IV over 1 hour on day 1, vincristine IV over 1 minute on days 1 and 8, and prednisone PO or IV two or three times daily on days 1-7. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve CR after 3 courses of therapy proceed to follow-up. Patients who do not achieve a CR proceed to involved-field radiotherapy.~IFRT: Beginning within 3 weeks after completion of combination chemotherapy, patients undergo IFRT once daily, 5 days a week for 2.8 weeks (14 treatments)."
89062049|NCT01601106|Active Comparator|Liposomal prednisolone|
89062050|NCT01601106|Placebo Comparator|Placebo control|
89062051|NCT04529018|Experimental|Healthy Volunteers|A group of 5 healthy volunteers will be tested with the PET radiotracer [18F]CETO to assess safety of tracer administration, and evaluate uptake by the normal adrenal glands.
89062052|NCT04529018|Experimental|Patients with primary aldosteronism|A group of 6 patients with Primary Aldosteronism (3 with unilateral and 3 with bilateral disease) will be tested with up to two administrations of the PET radiotracer [18F]CETO, to assess safety of tracer administration, evaluate the ability of [18F]CETO to distinguish between unilateral and bilateral cases of PA, and determine the effect of Dexamethasone in improving the quality of PET-CT images acquired following administration.
89062053|NCT01601145|Experimental|lozenges with Lactobacillus brevis CD2|Randomized group using lozenges for 6 weeks.
89062054|NCT01601145|Placebo Comparator|lozenges|Randomized group using lozenges for 6 weeks.
89062055|NCT01601184|Experimental|combination of vismodegib with temozolomide|"In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive~- Arm A: the combination of vismodegib (150 mg/day continuously) with temozolomide (150 mg/m2 during Cycle 1 [day 1 to day 5/ 28 day-cycle] and 200 mg/m2 during subsequent cycles) (6 patients)"
89062056|NCT01601184|Active Comparator|temozolomide alone|In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive Arm B: temozolomide alone (150 mg/m2 day1 to day 5/ 28 day-cycle during Cycle 1 and 200 mg/m2 day 1 to day 5/ 28 day-cycle during subsequent cycles) (3 patients).
89062057|NCT01601184|Other|vismodegib alone|Considering the rarity of the disease, the few therapeutic options available and the promising results reported with vismodegib in adult medulloblastoma : the Sponsor will consider (on case by case basis) the enrolment of patients previously treated by temozolomide in a 3rd independent and parallel study arm
89062058|NCT01643759|Experimental|buprenorphine transdermal system|buprenorphine transdermal system
89062059|NCT02754557|Experimental|Breath-Focused Meditation|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation.
89062060|NCT02754557|Experimental|Breath-Focused Meditation + Physiological Feedback|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation and physiological feedback.
89062061|NCT04528979|Experimental|Primary root canal treatment|Primary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
89062062|NCT04528979|Experimental|Secondary root canal treatment|Secondary root canal treatment sealed with guttapercha and AH Plus® or BioRoot RCS® root canal sealers
89062063|NCT01601262|Experimental|Open label|
89062064|NCT02279849|Experimental|Communications|These 6 stores received the communications intervention. Communications materials were developed for each program phase; 1) Healthier Drinks, 2) Healthier Essentials, and 3) Healthier Snacks. Each phase's materials included posters, recipe cards, educational handouts, shelf talkers, price tags, door signs, educational displays, and promotional giveaways (i.e., drink tumblers, re-usable shopping bags) to encourage healthy food purchasing and consumption. Stores receiving the communications intervention also received either a small refrigerator or freezer to help provide the environmental supports needed to stock perishable fruits and vegetables.
89062065|NCT02279849|No Intervention|Control|These 6 stores received no intervention.
89062066|NCT02279849|Experimental|Pricing|These 6 stores received a pricing intervention. 10-30% with discounts for specific foods contingent on price elasticity of demand, initial wholesale price, and projected store-level sales. Items were given the minimum discount needed to increase store supply and consumer demand. For example, brand name frozen vegetables were discounted 30% at the wholesaler, in order to provide the storeowner with enough incentive to stock the item. The % discount passed from the storeowner to the consumer was ultimately a decision made by the storeowner, but was suggested to be at least 50% in order to increase consumer demand. Discounts were automatically applied at wholesaler registers to stores receiving the pricing intervention.
89062067|NCT02279849|Experimental|Combined (Communications & Pricing)|These 6 stores received communications materials as well as pricing incentives as intervention (see Communications & Pricing Arms Descriptions).
89062068|NCT01680029|Experimental|PBASE-system 2.0|
89062069|NCT04528628|Experimental|MDD with melancholic features|
89062070|NCT04528628|Experimental|MDD with atypical features|
89062071|NCT04528628|Experimental|MDD with anxious distress|
89062072|NCT04528628|Experimental|MDD (overall)|
89062073|NCT04487379||Group with edentulous ridge|This group had edentulous ridge planning to receive a dental implant and had ultrasound and cone-beam computed tomography images of the ridge.
89062074|NCT01601340|Active Comparator|HQK-1001|
89062075|NCT01601340|Placebo Comparator|Placebo|
89062076|NCT04528862|Experimental|Nature|
89062077|NCT04528862|Sham Comparator|Urban|
89062078|NCT01600248|Other|Treatment arm|This is an open-label pilot study with no control group. Participants pre-treatment scores are compared to their post-treatment scores.
89062079|NCT01680068|Experimental|Pars plana vitrectomy and postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
89062080|NCT01641341|Placebo Comparator|Placebo capsule|Placebo capsule (sugar pill with no active medication)
89062081|NCT01641341|Active Comparator|Active treatment|"Active treatment will consist of the following interventions:~Bowel Dysbiosis - probiotics Bifidobacterium infantis,~Maldigestion/Malabsorption - Pancrelipase~Parasitic infection/presence - Nitazoxanide"
89062082|NCT01680107|Experimental|d-cycloserine|oral, capsule, 250 mg, once
89062083|NCT01680107|Placebo Comparator|sugar pill|oral, capsule, once
89062084|NCT01680146|Active Comparator|PRO|Subjects will ingest 20 g of intrinsically labeled casein dissolved in water
89062085|NCT01680146|Experimental|PRO+FAT|Subjects will ingest 20 g of intrinsically labeled casein plus 26.7 g of anhydrous milk fat dissolved in water
89062086|NCT01643915|Active Comparator|Control group|Patients with conventional treatment. No distraction method during the treatment visits.
89062087|NCT01643915|Experimental|Experimental group 1|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
89062088|NCT01643915|Experimental|Experimental group 2|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
89062089|NCT01680185|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
89062090|NCT01680185|Active Comparator|Basal insulin|NPH insulin titration regimen, as specified in the IPT-NODAT study
89062091|NCT01680185|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
89062092|NCT04484376||Other invasive candida infection|Patients with invasive candida infection due a Candida specie othr than Candida Auris.
89062093|NCT04484376||Candida Auris related invasive infection|Candida Auris related invasive candida infection.
89062094|NCT01680263|Experimental|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1 week interval"
89062095|NCT01680263|Active Comparator|NSAIDs/Physical therapy|treatment was done with NSAIDs and 10 sessions of daily physical therapy.
89062096|NCT01601574|Experimental|Modified Weight Watchers program|
89062097|NCT01601574|Active Comparator|Standard Diabetes Counseling group|
89062098|NCT01643993|Experimental|hCG at Time of Embryo Transfer|Patients will have hCG and media (for a total of 20 microliters) inserted during a mock embryo transfer immediately prior to actual embryo transfer.
89062099|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
89062100|NCT01601613|Experimental|rFVIIa|
89062101|NCT01601613|Placebo Comparator|placebo|
89062102|NCT01680380||At-Home|Overnight sleep at home
89062103|NCT01601730|Placebo Comparator|Placebo|
89062104|NCT01601730|Active Comparator|Modafinil 200 mg + Escitalopram 20 mg|
89062105|NCT01601730|Active Comparator|Modafinil 200 mg|
89062106|NCT01601730|Active Comparator|Escitalopram 20 mg|
89062107|NCT01644032|Experimental|Device_ Teleconsultation|"Six ambulances from five different Emergency Medical Service (EMS) districts are equipped with a portable telemedicine system. In cases of emergencies, where intravenous analgesia is necessary, if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team and can delegate the application of morphine and other analgesics. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The safety, efficacy and the quality of analgesia should be compared with regular EMS."
89062108|NCT01644032|No Intervention|Historical Control Period|After completion of the study arm, matched pairs from a historical phase (without the ability of teleconsultation) were searched. Local cases were always matched with comparable controls from the same location.
89062109|NCT04483518||HBV patients|HBV patients with HBsAg positive and/or HBV DNA positive
89062110|NCT01644071|Experimental|arm 1|application of three treatments and three masurements within 3 weeks
89062111|NCT04528589||Mothers|Women with adverse childhood experiences referred for treatment in gestational week 20-30
89062112|NCT04528589||Therapists|Clinicians with experience of providing psychotherapy to women with adverse childhood experiences referred for treatment during pregnancy
89062113|NCT01601769|Active Comparator|Colposcopy|a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.
89062114|NCT01601769|Experimental|Vitom|The VITOM system, consisting of the VITOM scope, xenon light source, HD camera system, AIDA HD documentation system, 1 monitor, and a mechanical support arm (all Karl Storz, Tuttlingen, Germany) is used for video exocolposcopy.
89062115|NCT01680536|Experimental|Maraviroc, darunavir, ritonavir|Single-arm,assessing cerebrospinal fluid inflammatory markers after addition of maraviroc to patients stable on monotherapy darunavir/ritonavir
89062116|NCT01601808|Placebo Comparator|Gemcitabine and Placebo|Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
89062117|NCT01601808|Experimental|Gemcitabine and vandetanib|Experimental arm. Vandetanib orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
89062118|NCT01680575||Training cohort|This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles.
89062119|NCT01680575||Validation cohort|"This is a retrospective cohort for validation of a risk prediction model developed using training cohort.~This is consisted with 600 patients with epithelial ovarian cancer who received adjuvant chemotherapy with paclitaxel/carboplatin after staging operation or debulking operation."
89062120|NCT01680614||At Risk Adult Drinkers|CASI
89062121|NCT01644305||Polycystic Ovary Syndrome|
89062122|NCT01644305||Idiopathic hirsutism|
89062123|NCT01644305||Control|
89062124|NCT01601886||Before SUPPORT|01/03-06/05
89062125|NCT01601886||During SUPPORT recruitment|07/05-02/09
89062126|NCT01601886||After SUPPORT|03/09-06/10
89062127|NCT01644383|Experimental|Treatment arm (logotherapy)|Participants in Arm I will attend the logotherapy group sessions by the trained psychologist for 4 visits (see Table II, III). The number of participants in group sessions will be 20 participants per group.
89062128|NCT01644383|No Intervention|Control arm (general health education)|Participants in Arm II will attend the routine health education by the nurse. The number of participants in group session will be 20 participants per group.
89062129|NCT01680692|Active Comparator|Continuous femoral and single shot sciatic nerve block|Will receive pre-operative continuous femoral catheter & post-operative single shot sciatic with both given an initial bolus of 30 mL (femoral) 0.5% Ropivicaine & 20mL (sciatic) 0.2% Ropivicaine. Following surgery the femoral infusion will be started, which will be running Ropivicaine 0.2 at 10cc/hr.
89062130|NCT01680692|Experimental|Continuous femoral and tibial peripheral nerve catheters|Patients will receive pre-operative continuous femoral catheter & post-operative continuous tibial catheter with an initial bolus of 30 mL 0.5% Ropivicaine (femoral) & 20mL 0.2% Ropivicaine (tibial), which will be followed by infusions post-operatively running at 10cc/hr.
89062131|NCT01601925|Experimental|neck extended group|We measured the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck.
89062132|NCT01644422|Other|Study arm A|Subjects will receive hair follicles transplants that are dipped in HPL before transplant
89062133|NCT01644422|Other|Study arm B|Subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection one week after transplant
89062134|NCT01644422|Other|Control arm C|Subject will receive Standard hair follicle transplant
89062135|NCT01601964||Follow-up or medical treatment.|medical treatment
89062136|NCT01601964||Surgical treatment|Surgical treatment
89062137|NCT01680731||Forceps assisted vaginal delivery|Forceps assisted vaginal delivery within 1-5 years without any interval delivery
89062138|NCT01680731||Vacuum assisted vaginal delivery|Vacuum assisted vaginal delivery within 1-5 years without any interval delivery
89062139|NCT01680731||Elective cesarean delivery|Elective cesarean vaginal delivery within 1-5 years without any interval delivery done prior to labor
89062140|NCT01680731||Spontaneous vaginal delivery|Spontaneous vaginal delivery within 1-5 years without any interval delivery
89062141|NCT01602003|Experimental|LC15-0444 25 mg bid|LC15-0444 25 mg bid(twice daily)added on Metformin therapy
89062142|NCT01602003|Experimental|LC15-0444 50 mg qd|LC15-0444 50 mg qd(once daily) added on Metformin therapy
89062143|NCT01602003|Active Comparator|Sitagliptin 100mg qd|Sitagliptin 100 mg qd (once daily) added on the Metformin therapy
89062144|NCT01680926|Experimental|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
89062145|NCT01644461|Other|Study Group|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
89062146|NCT01681043|No Intervention|24 hour PSG under ordinary conditions|24 hour PSG in 46 patients under ordinary (routine) conditions
89062147|NCT01681043|Active Comparator|24 hours PSG under protocol 'Quiet in the room'|24 hour PSG in the same 46 patients with protocol 'Quiet in the room' from 10 p.m. til 6 a.m.
89062148|NCT01644539|Other|Control|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion of 500 ml non caloric load consisting of water and thickening agent (guar gum), over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml non caloric load consisting of water and thickening agent (guar gum) in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
89062149|NCT01644539|Other|Oral ingestion|"Subjects participated in a 35 min fmri scan. Intervention: Oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk, over 5 min.~Time frame while scanning:~-5 - 0 min : baseline fmri scan 0 - 5 min: oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
89062150|NCT01644539|Other|Intra Gastric|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk, over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
89062151|NCT01602081||LIFT+Biodesign|
89062152|NCT01193920|Experimental|1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg|Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
89062153|NCT01193920|Placebo Comparator|2: Placebo - Sterile saline|Non-Pregnant Women who received two injection of saline solution.
89062154|NCT01193920|Experimental|3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg|Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
89062155|NCT01193920|Experimental|4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg|Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
89062156|NCT01193920|Experimental|5: GBS Trivalent Vaccine - 5/5/5 µg|Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
89062157|NCT01193920|Placebo Comparator|6: Placebo - Sterile saline|Pregnant Women who received one injection of saline solution.
89062158|NCT01681082|Experimental|Tai Chi Training|"Subjects will be recruited from the University of Wisconsin-Madison course, Introduction to Martial Arts: Tai Chi."
89062159|NCT01681082|No Intervention|Control|"Subjects will be recruited from the University of Wisconsin-Madison course Introduction to Psychology."
89062160|NCT04315480|Experimental|tocilizumab|
89062161|NCT01193686|Experimental|Peer Visitation Training (Peer Mentor)|Veteran Peer Visitors participated in a 2-day training program and then provide at 1-5 visits to at least 2 recipients.
89062162|NCT01193686|Experimental|Peer Visitation|Veterans who received at least one visit from a Veteran Peer Visitor.
89062163|NCT01681160|Experimental|MAGGOT THERAPY & conventional therapy T|Maggot therapy,ADMINISTERED TWO TIMES AS A NEW METHODS OF DRESSING in experimental group.conventional therapy ,administered two times in control group
89062164|NCT02886442|Experimental|Cohort 3|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.~There are two kinds of visits:~Visit 1:~Two adhesive strips (standard adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.~Visit 2:~Two adhesive strips (new adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.~Visit 2:"
89062165|NCT01644773|Experimental|Chemotherapy|Research participants with high grade glioma or diffuse intrinsic pontine glioma will receive crizotinib and dasatinib.
89062166|NCT01602159|Active Comparator|Open Bypass Surgery|Open Bypass Surgery
89062167|NCT01602159|Active Comparator|Angioplasty and Stenting|
89062168|NCT01681199|Experimental|Fluvastatin extended release tablet|Fluvastatin extended release tablet 80mg/day
89062169|NCT01681316|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
89062170|NCT01681316|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
89062171|NCT01602276|Experimental|Active Stimulation|Transcranial direct current stimulation using Anodal or Cathodal stimulation over the area of interest
89062172|NCT01602276|Sham Comparator|Sham Stimulation|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS.
89062173|NCT04528394|Experimental|Photon combined with Carbon ion|The participants received photon: 56 Gy/28 Fx for high-risk area(CTVhigh), 50.4 Gy/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
89062174|NCT04528394|Experimental|Proton combined with Carbon ion|The participants received proton: 56 GyE/28 Fx for high-risk area(CTVhigh), 50.4 GyE/28 Fx for lower neck low-risk area(CTVlow), plus carbon ion: 15-17.5 GyE/5 Fx for boost for visible tumors.
89062175|NCT04528316|Active Comparator|Control Group/Pilates Core Stability Exercises program Group|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~Stage I: Warm-up: consists of four Pilates motions:~Breathing:~Rolling back:~Coccyx-curl:~Hundred breathing:~Stage II: Work-out: consists of twelve Pilates motions:~Single leg stretch:~Straight leg raise:~Basic bridge:~Bridging variation:~Quadruped:~Clap with seal motion~Mermaid twist:~Swimming:~Double leg stretch:~Shoulder bridge:~Swan dive:~Leg full front:~Stage III: Cool-down: consists of three Pilates motions:~Rest position:~Cat with arm/leg extension:~Breathing:"
89062176|NCT04528316|Experimental|Balance Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Balance Program
89062177|NCT04528316|Experimental|Coordination Group|Twenty patients will receive the same selected Pilates core stability exercises program given to control group in addition to Coordination Exercises.
89062178|NCT01602354||Gram-negative Septic shock|Patients affected by Gram-negative septic shock
89062179|NCT01644812|Active Comparator|Aerobic exercise|The exercise intervention is a 12-week program involving 150 minutes of moderate intensity exercise (65-69% of participant's age-predicted [220-age] maximum heart rate) each week. Participants will complete one 50-minute supervised treadmill exercise session in the laboratory and 100 minutes of exercise on their own. These exercises may include walking, jogging, biking, or other forms of aerobic exercise. The at-home exercise regimen will be individualized for each participant.
89062180|NCT01644812|Sham Comparator|stretching|The exercise intervention is a 12-week program involving 150 minutes of stretching each week (one 50-minute stretching session in the laboratory and 100 minutes of stretching at home). Participants in the stretching condition will work with a facilitator to create a stretching regimen for 100 minutes of home stretching throughout the week. The facilitator will provide a list of potential stretches with descriptions on how to perform them.
89062181|NCT04479150||Pandemic Covid-positive cohort|All Covid-positive patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
89062182|NCT04479150||Pandemic Covid-negative cohort|All Covid-negative patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2020
89062183|NCT04479150||Control cohort|Pre-pandemic cohort: all patients operated on for emergency digestive pathology from March, 1st 2020 to June, 30th 2019.
89062184|NCT04528043||critically ill patients|critically ill patients admitted in one of the 5 ICUs of the university hospital of Nancy during the year 2016 with documented third group enterobacteriaceae infection and/or colonization with third group enterobacteriaceae
89062185|NCT01681355|Experimental|Intervention group|Healthy infants receiving standard cow's milk-based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition.
89062186|NCT01602588|Experimental|Arm B|Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.
89062187|NCT01602588|Active Comparator|Arm A: SCRT alone|Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy
89062188|NCT01681394|Active Comparator|Product 1|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
89062189|NCT01681394|Placebo Comparator|Control product|250 g of chocolate cream
89062190|NCT01681550|Other|Incretin theapy combined with insulin|
89062191|NCT01645085|Experimental|Treatment A|100mg MCC-based 13% drug-loaded tablets
89062192|NCT01645085|Experimental|Treatment B|100mg mannitol-based 38% drug-loaded tablets
89062193|NCT01645085|Experimental|Treatment C|150mg MCC-based 13% drug-loaded tablets
89062194|NCT01645085|Experimental|Treatment D|150mg mannitol-based 38% drug-loaded tablets
89062195|NCT01602627|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89062196|NCT01602783|Experimental|11C Acetate Imaging|11C acetate imaging
89062197|NCT01645124|Active Comparator|Cytoreduction for HCT < 45%|Patients will be treated with phlebotomy and/or HU more intensively, with the goal to reach and maintain the target of hematocrit(HCT)below 45%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
89062198|NCT01645124|Experimental|Cytoreduction for HCT between 45 and 50%|Patients will be treated with phlebotomy and/or HU less intensively, with the goal to reach and maintain the target of hematocrit(HCT)between 45% and 50%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
89062199|NCT01602861|Experimental|Spironolactone|
89062200|NCT01602861|Placebo Comparator|Placebo|
89062201|NCT01681667|Active Comparator|ibuprofen|liquid ibuprofen 400mg compared to tablet ibuprofen 400mg
89062202|NCT01681667|Placebo Comparator|sugar pill or liquid|
89062203|NCT01645163|Experimental|Mobile phone counselling|
89062204|NCT01600365|Active Comparator|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
89062205|NCT01600365|Placebo Comparator|Ophthalmic gel (placebo)|ophthalmic gel (placebo)in the study eye
89062206|NCT01602900|Experimental|GSK356278|Investigational drug
89062207|NCT01645202|Active Comparator|TAVI with Edwards Sapien XT valve|
89062208|NCT01645202|Active Comparator|TAVI with Medtronic CoreValve|
89062209|NCT01645241|Experimental|Lutheal phase ovarian stimulation|Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
89062210|NCT01602939|Experimental|2CDA+IFN|
89062211|NCT04528745||Patients with cancer receiving cytostatic treatment|Consecutive patients referred for cytostatic treatment or in treatment with cytostatic agents for colorectal or pancreatic cancer
89062212|NCT04528784|Experimental|Intervention|Transcutaneous tibial nerve stimulation will be applied as follows: 18 sessions of 30 minutes duration, delivered three times a week over a 6 week period using TENS device with 10 Hertz (Hz), and pulse width 200µs. The intensity of stimulation will be at the sensory and motor threshold by tingling sensation on sole of the foot with flexion of big toe and /or fanning of other toes.
89062213|NCT01600404||antimuscarinic treatment|antimuscarinic treatment
89062214|NCT01600404||no antimuscarinic treatment (control)|
89062215|NCT01600443|Experimental|LoFric - SC - SCCM|Study period 1: LoFric Study period 2: SpeediCath Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
89062216|NCT01600443|Experimental|LoFric - SCCM - SC|Study period 1: LoFric Study period 2: SpeediCath Compact Male Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
89062217|NCT01600443|Experimental|SC - SCCM - LoFric|Study period 1: SpeediCath Study period 2: SpeediCath Compact Male Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
89062218|NCT01600443|Experimental|SC - LoFric - SCCM|Study period 1: SpeediCath Study period 2: LoFric Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
89062219|NCT01600443|Experimental|SCCM - LoFric - SC|Study period 1: SpeediCath Compact Male Study period 2: LoFric Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
89062220|NCT01600443|Experimental|SCCM - SC - LoFric|Study period 1: SpeediCath Compact Male Study period 2: SpeediCath Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
89062221|NCT01681823|Experimental|PectaSol-C Modified Citrus Pectin (MCP)|Treatment with 4.8 grams PectaSol-C Modified Citrus Pectin three times a day, away from meals for six months.
89062222|NCT01603017|Placebo Comparator|Placebo - no therapy|Patients who were blinded but did not receive therapy
89062223|NCT01603017|Experimental|MRI therapy|Patients receiving MRI therapy but blinded to it
89062224|NCT01681862|Experimental|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
89062225|NCT01681901||Diagnostic (ultrasound)|Patients undergo breast ultrasound imaging.
89062226|NCT01603095||Growth measurements|Approximately 500 patients will be enrolled. Patients from birth to <= 17 years on the date of consent will be enrolled. Approximately equal numbers of boys and girls will be enrolled.
89062227|NCT01681940|Experimental|Lamazym|1 mg/kg body weight
89062228|NCT01603134|Experimental|Allopurinol 300 mg Tablets USP|Allopurinol 300 mg Tablets USP of M/s Ipca Laboratories Limited, India
89062229|NCT01603134|Active Comparator|Zyloprim®|Zyloprim® (Allopurinol) 300 mg Tablets manufactured by Catalytica Pharma Inc., USA for Prometheus Laboratories Inc., USA,
89062230|NCT01645319||White, non-hispanic - Medication Treatment Pathway|
89062231|NCT01645319||White, non-Hispanic - Laser Surgery Treatment Pathway|
89062232|NCT01645319||White, non-Hispanic - Incisional/Other Treatment Pathway|
89062233|NCT01645319||Hispanic - Medication Treatment Pathway|
89062234|NCT01645319||Hispanic - Laser Surgery Treatment Pathway|
89062235|NCT01645319||Hispanic - Incisional/Other Surgery Treatment Pathway|
89062236|NCT01645319||Asian - Medication Treatment Pathway|
89062237|NCT01645319||Asian - Laser Surgery Treatment Pathway|
89062238|NCT01645319||Asian - Incisional/Other Surgery Treatment Pathway|
89062239|NCT01645319||Black - Medication Treatment Pathway|
89062240|NCT01645319||Black - Laser Surgery Treatment Pathway|
89062241|NCT01645319||Black - Incisional/Other Surgery Treatment Pathway|
89062242|NCT01603173|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
89062243|NCT01603173|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
89062244|NCT01645358|Experimental|Helmet to deliver NIV|
89062245|NCT01645358|Active Comparator|Total Face to deliver NIV|
89062246|NCT01603212|Experimental|Vemurafenib + IL-2 + Interferon Alfa-2b|Starting dose of Vemurafenib 720 mg by mouth twice daily. Three dose levels of Vemurafenib evaluated in combination with interferon and IL-2. These doses are 480 mg, 720 mg and 960 mg. IL-2 given by continuous venous infusion at starting IL-2 dose of 7 million IU/m2 daily for 4 days (total of 96 hours, days 2-5) starting day 2. IL-2 dose levels are 5MU/m2/day, 7MU/m2/day and 9MU/m2 day. Doses of interferon remain constant at 5 MU/m2 subcutaneously daily for 5 days starting Day 1.
89062247|NCT01645397||Asthma, elevated exhaled NO|Children with asthma with elevated exhaled NO at initial evaluation (>25ppb)
89062248|NCT04474275||Study group 1|Primiparous women who gave birth with ceserean section
89062249|NCT04474275||Study group 2|Primiparous women who gave birth with vaginal route delivery without episiotomy
89062250|NCT04474275||Study group 3|Primiparous women who gave birth with vaginal route delivery with episiotomy
89062251|NCT04474275||Control group|Nulliparous women
89062252|NCT01645436|Experimental|treatment (exercise)|combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
89062253|NCT01645436|No Intervention|control (usual care)|Usual hospital care with no exercise
89062254|NCT04473612||Neuromuscular low physical status group|Patients diagnosed of Neuromuscular disease with low physical status
89062255|NCT04473612||Neuromuscular high physical status group|Patients diagnosed of Neuromuscular disease with high physical status
89062256|NCT04473612||Control group|Healthy subjects
89062257|NCT01645748|Experimental|S-1, induction chemotherapy|Cisplatin and 5-FU is the standard treatment for patients with head and neck cancer. Recently,docetaxel was used into CF, and it showed the prolongation of survival. Oral 5-FU showed similar or enhanced response rate, safety than intravenous 5-FU. S-1 showed promising preliminary result in combination with cisplatin in head and neck cancer. In patients with gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid, 60mg/m2 (D1) and 60mg/m2 (D1), respectively. And weekly docetaxel can reduce adverse events compared to 3 week regimen. The aim of this study was to evaluate the efficacy and safety of weekly docetaxel, cisplatin and S-1 combination chemotherapy
89062258|NCT02484924||Clopidogrel Group|Those patients treated with clopidogrel for ACS (before new guideline implementation)
89062259|NCT02484924||Ticagrelor Group|Those patients treated with ticagrelor for ACS (after new guideline implementation)
89062260|NCT01645826|Experimental|Diltiazem|The study agent will be Diltiazem and will start at 60 mg po BID then titrated up every two weeks until at a maximum dose of 180mg po BID.
89062261|NCT01645826|Placebo Comparator|Sugar Pill|The placebo group of patients will be treated with Drug A (sugar pill) PO bid and titrated up every two weeks for next titration dose (actually will be an unchanged concentration).
89062262|NCT01645865||Control|
89062263|NCT01645865||Intervention|
89062264|NCT01645904||Group 1|Patients participate in audiotaped focus group regarding web-based program, and fill out demographics questionnaire.
89062265|NCT01645904||Group 2|Patients come to Behavioral Research and Treatment Center (BRTC) at MD Anderson to use initial version of My Family Garden website. Completion of Website Analysis and MeasureMent Inventory (WAMMI), and demographics questionnaires.
89062266|NCT01645904||Group 3|Patients use final version of My Family Garden website, and are interviewed which will be audiotaped. Completion of Website Analysis and MeasureMent Inventory (WAMMI), questionnaire and demographics questionnaire.
89062267|NCT01645943|No Intervention|Conservative|Coronary angiogram only if recurrent ischemia or peristent heart failure or inducible ischemia in predischarge stress test if perfomed
89062268|NCT01645943|Active Comparator|Invasive|Routine coronary angiogram
89062269|NCT01600521|Active Comparator|Paeoniflorin + Polypeptides (PAE + CCPI)|Paeoniflorin (PAE), the extract from peony (Paeonia lactiflora), is an active ingredient with anti-inflammation properties. Polypeptides (3,000 - 10,000 dalton) in Cervus & Cucumis polypeptide injection (CCPI), the extract from Sika deer (Cervus nippon Temmick) bones and muskmelon (Cucumis melo L) seeds, are the active ingredients with bone healing, pain relieving, and anti-inflammation properties. PAE was administrated orally 600 mg twice a day for at least 12 months. CCPI was administered intravenously 8~12 mL daily with 250 mL 5% dextrose injection solution or 0.9% NaCl IV solution for 2 weeks, discontinued 1 week, and restarted for another 2 weeks.
89062270|NCT01600521|Active Comparator|Methotrexate (MTX) + Leflunomide (LEF)|DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months. MTX dose: 7.5 mg ~ 10mg / week, LEF dose: 10 mg ~ 20mg daily.
89062271|NCT01600521|Active Comparator|MTX + LEF + CCPI|The DMARDs and CCPI were administrated as in the above two groups.
89062272|NCT01646060|Experimental|Blood Draw|
89062273|NCT01607034|Experimental|Sequence 1 - tablet-fast|150 mg Dexpramipexole (intact tablet) single dose under fasted condition
89062274|NCT01607034|Experimental|Sequence 2 - tablet-fed|150 mg Dexpramipexole (intact tablet) single dose under fed condition
89062275|NCT01607034|Experimental|Sequence 3 - water-fast|150 mg Dexpramipexole single dose dispersed in water under fasted condition
89062276|NCT01607034|Experimental|Sequence 4 - apple-fast|150 mg Dexpramipexole single dose crushed and mixed in applesauce under fasted condition
89062277|NCT01646099|Experimental|Sun Protection Education|Distribution of the internet-based sun protection educational program.
89062278|NCT01646099|No Intervention|Control|Distribution of general skin care information.
89062279|NCT01603251|Active Comparator|Artemether-Lumefantrine|
89062280|NCT01603251|Experimental|Artemether-Lumefantrine + single dose Ivermectin|
89062281|NCT01603251|Experimental|Artemether-Lumefantrine + repeated dose Ivermectin|
89062282|NCT01603290||Hospitalized Leukemia Patients|leukemia patients with chemotherapy during hospitalization
89062283|NCT01646294|Experimental|OCAS-F|YM178 OCAS tablet (OCAS-Fast) taken orally under fasted and fed condition
89062284|NCT01646294|Experimental|OCAS-S|YM178 OCAS tablet (OCAS-Slow) taken orally under fasted and fed condition
89062285|NCT01646294|Experimental|OCAS-M|YM178 OCAS tablet (OCAS-Medium) taken orally under fasted and fed condition
89062286|NCT01603329|Experimental|Comprehensive incentives + comprehensive communication|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
89062287|NCT01603329|Experimental|Comp incentives + comp communication + non-white paper|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.
89062288|NCT01603329|Experimental|Focused incentives + focused com for oral diabetes medication|Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication.
89062289|NCT01603329|Experimental|Foc incentives + foc comm for Diabetes + non-white paper|Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.
89062290|NCT01603329|Experimental|Focused incentives + focused comm for hypertension meds|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.
89062291|NCT01603329|Experimental|Foc incentives + comm for hypertension meds + non-white paper|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.
89062292|NCT01603329|Experimental|Focused incentives + focused comm for cholesterol meds|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.
89062293|NCT01603329|Experimental|Foc incentives +comm for cholesterol meds + non-white paper|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.
89062294|NCT01603329|Experimental|Comprehensive communiation|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
89062295|NCT01603329|Experimental|Comprehensive communication + non-white paper|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.
89062296|NCT01603329|Experimental|Control Arm|Physicians and their patient adherence is tracked, but they receive no intervention.
89062297|NCT01193608|Experimental|0.5 mg/kg AAB-003|
89062298|NCT01193608|Experimental|1 mg/kg AAB-003|
89062299|NCT01193608|Experimental|2 mg/kg AAB-003|
89062300|NCT01193608|Experimental|4 mg/kg AAB-003|
89062301|NCT01193608|Experimental|8 mg/kg AAB-003|
89062302|NCT01193608|Placebo Comparator|Placebo|
89062303|NCT01646333|Active Comparator|Supportive Therapy|The supportive therapy offers patients and support persons the opportunity to discuss and reflect upon both Parkinson's Disease and non-Parkinson's Disease related problems.
89062304|NCT01646333|Experimental|Memory and Problem-Solving Intervention|The memory and problem solving training consists of a day calendar manual and note taking system and problem solving techniques. The neurocognitive memory intervention was adapted from a 6-week manualized day calendar and note taking system previously evaluated in an amnestic MCI sample and a brain tumor sample. The problem solving intervention was adapted from an originally 12-week intervention, which was later adapted into a 6-week brain tumor sample.
89062305|NCT01603446|Experimental|MELAS Patients|Three siblings with MELAS (A3243G) syndrome (1 male; 2 females) aged 17-23 years, followed or previously followed in the Neurometabolic Clinic at the Hospital for Sick Children will be studied.
89062306|NCT01603446|No Intervention|Control Group|Four age- and sex-matched controls and female controls will be matched according to phase in menstrual cycle corresponding with their age-matched MELAS subjects
89062307|NCT01607151|Active Comparator|Normothermia|Core temperature 36-37 C
89062308|NCT01607151|Experimental|Hypothermia|Core temperature 32-34 C
89062309|NCT01646372|Active Comparator|Control Group|This group gets a simulation based ACLS refresher as treatment, but no access to cognitive aids for any of the tests.
89062310|NCT01646372|Active Comparator|2nd Control Group|This group receives a standard Simulation based ACLS refresher as the intervention, like the control group. No mention is made of Cognitive Aids in the teaching, but they are available during the post-test and retention post-test.
89062311|NCT01646372|Experimental|Cognitive Aid Group|This group receives Cognitive Aid based teaching as the intervention. They also have access to cognitive aids for post-test and retention post-test
89062312|NCT01603563|Experimental|Stepped Care TF-CBT|Patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
89062313|NCT01603563|Active Comparator|Standard TF-CBT|Patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
89062314|NCT01646411||assorted acute infection|300 patients diagnosed with assorted acute infection.
89062315|NCT01607190||Patients with diabetic retinopathy.|
89062316|NCT01646450|Experimental|Icotinib|Icotinib: 125mg, oral administration, three times per day.
89062317|NCT01607229||otherwise healthy with various BMI|
89062318|NCT01646489|Experimental|Miravirsen sodium|
89062319|NCT01646489|Active Comparator|Telaprevir|
89062320|NCT01603719|No Intervention|Standard Formula|Standard formula with no supplementation
89062321|NCT01603719|Experimental|experimental formula|infant formula with higher beta-palmitate and supplemented GOS
89062322|NCT01646528||Consecutive patients for CLE examination|
89062323|NCT01603758|No Intervention|Observational Arm|Cholesterol metabolic parameters will be measured in 100 subjects in an observational study. Results will be related to circulating biomarkers and carotid intima-media thickness.
89062324|NCT01603758|Placebo Comparator|Ezetimibe Interventional Arm|Cholesterol metabolic parameters will be measured before and after ezetimibe or placebo intervention. Changes due to ezetimibe will be determined
89062325|NCT01603797|Experimental|Internet delivered ACT|Internet delivered acceptance and commitment therapy (ACT), 7 weeks treatment
89062326|NCT01603797|Active Comparator|Online discussion forum|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
89062327|NCT02279303|Experimental|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
89062328|NCT02279303|Active Comparator|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
89062329|NCT01177228|Placebo Comparator|Placebo|Vedolizumab-matching placebo, intravenous (IV), infusion on Days 1, 15, 29 and 85.
89062330|NCT01177228|Experimental|Vedolizumab 2 mg/kg|Vedolizumab, 2 mg/kg, IV infusion on Days 1, 15, 29 and 85.
89062331|NCT01177228|Experimental|Vedolizumab 6 mg/kg|Vedolizumab 6 mg/kg, IV infusion on Days 1, 15, 29 and 85.
89062332|NCT01177228|Experimental|Vedolizumab 10 mg/kg|Vedolizumab 10 mg/kg, IV infusion on Days 1, 15, 29 and 85.
89062333|NCT01607268||Pure Autonomic Failure|Pure autonomic failure is a type of primary autonomic failure characterized by peripheral autonomic nervous system impairment.
89221448|NCT00941018|Experimental|MAD cohort 3|MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.
89221449|NCT00941018|Experimental|MAD cohort 4|MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
89221450|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 1|Participants in the first cohort will receive the CCSH Interventions for Teams during the fall session (first intervention period).
89221451|NCT04060901|Experimental|CCSH Interventions for Teams in Cohort 2|Participants in the second cohort will receive the CCSH Interventions for Teams during the spring session (second intervention period).
89221452|NCT00944684|Experimental|A|PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels. Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia
89221453|NCT00944684|Active Comparator|B|PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day)
89221454|NCT04061057|Experimental|IV lidocaine|Perioperative IV lidocaine infusion
89221455|NCT04061057|Placebo Comparator|Normal saline|Perioperative IV normal saline infusion
89221456|NCT00921167|Experimental|Bevacizumab/Irinotecan|
89221457|NCT04061447|Experimental|susceptibility-guided therapy|In the group of the empirical triple therapy, patients received rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
89221458|NCT04061447|Active Comparator|empirical clarithromycin-based triple therapy|In the group of gastric juice susceptibility-guided therapy, the eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
89221459|NCT03968978|Experimental|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
89221460|NCT03968978|Experimental|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
89221461|NCT02567591|Experimental|A: physical activity program|at home physical activity program (during 12 weeks)
89221462|NCT02567591|No Intervention|B: conventional management|conventional management
89221463|NCT02565953|Experimental|Paclitaxel-releasing PTA balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter.
89221464|NCT02565953|Active Comparator|PTA Balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter.
89221465|NCT00562718|Experimental|Surgery and Chemotherapy|Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.
89221466|NCT05222165|Experimental|Infigratinib (BGJ398)|"Generic name: infigratinib. Dosage forms: 18mg and 25mg sprinkle capsules and 25mg, 75mg, 100mg capsules.~Phase 1b Three dose levels escalation until RP2D is determined.~Phase 2~Pediatric patients: dose defined in the phase 1b (RP2D);~Adults: 125 mg.~Frequency: once daily for 21 days in each 28-day treatment cycle.~Duration: Treatment duration will last up to 26 cycles unless progression, death or unacceptable toxicity occur."
89221467|NCT02567357|Active Comparator|Visual Scheduling|A caregiver training package on the use of a pictorial (visual) schedule to illustrate each day's expected activities to a child. Caregivers will be trained to ensure that activities occur as described in the schedule as far as possible, thus the expected mechanism of action is the reduction of (unexpected change) antecedents of children's temper outbursts.
89221468|NCT02567357|Experimental|Signalling change|A caregiver training package where parents are taught to present a distinctive visual-verbal cue to a child whenever they become aware that a change will take place in the child's usual/expected activities. Caregivers will be trained to only ever present to cue if they can be sure that a change to the child's routine or plan will occur, thus the expected mechanism of action is the child's learned association between the presentation of the cue and the subsequent occurrence of a change to their expectations. Signalled changes will therefore be more predictable for the child, and should therefore be easier for them to deal with.
89221469|NCT04555811|Experimental|FT596 + Rituximab Dose Level 1: 9x10^7 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
89221470|NCT04555811|Experimental|FT596 + Rituximab Dose Level 2: 3x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
89221471|NCT04555811|Experimental|FT596 + Rituximab Dose Level 3: 9x10^8 cells/dose|Up to three sequential FT596 dose levels are planned for Day 30 administration: (Dose Level 1: 9x10^7 cells/dose, Dose Level 2: 3x10^8 cells/dose, Dose Level 3: 9x10^8 cells/dose with a Dose Level -1: 3x10^7 cells/dose tested only if dose limiting toxicity events (DLT) occur at dose level 1).The maximum tolerated dose will be determined by using a modified continual reassessment method (CRM).
89689914|NCT02982317||Study group|All patients recruited will undergo the same protocol. An anesthesiologist will perform manual palpation of the patients lumbar spine and identification of the intervertebral spaces from L1-S1. A member of the UBC Department of Engineering will perform the US scanning and level identification using the novel US technology. In addition, freehand US will be used by two practitioners to determine the participant's lumbar level locations as per gold standard.
89062334|NCT01607268||Multiple System Atrophy|Multiple system atrophy is a type of primary autonomic failure characterized by central autonomic nervous system impairment.
89062335|NCT02279342|No Intervention|Non febuxostat treatment group|No febuxostat treatment
89062336|NCT02279342|Experimental|Febuxostat treatment group|once daily after breakfast
89062337|NCT01193530|Experimental|Bright Light Therapy|Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
89062338|NCT01193530|Placebo Comparator|Dim Red Light Therapy|Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.
89062339|NCT01607307|Active Comparator|Oral/enteral TJ-100 solution|Oral/enteral TJ-100 solution
89062340|NCT01607307|Placebo Comparator|Oral/enteral placebo solution|Oral/enteral placebo solution
89062341|NCT02279381|Experimental|Intervention group A|"Essential Neonatal Care~Kangaroo mother Care~Application of 4% Chlorhexidine~Education and counseling for mothers and care providers"
89062342|NCT02279381|Experimental|Intervention group B|"Essential Neonatal Care~Application of 4% Chlorhexidine~Education and counseling for mothers and care providers"
89062343|NCT02279381|Active Comparator|Control group|"Essential Neonatal Care~Education and counseling for mothers and care providers"
89062344|NCT02279459||Patient|Patients head and neck CT scans performed as standard of care done prior to radiation treatment and approximately 12 weeks following treatment, will be acquired in the dual-energy computed tomography (DECT) mode. Participants will have one additional scan, also in the DECT mode, 2 to 3 weeks after the start of their radiation treatment.
89062345|NCT01607385|Active Comparator|GSK2330672|
89062346|NCT01607385|Placebo Comparator|Placebo|
89062347|NCT01646567|Experimental|SHP-141C & Placebo & Calcipotriol & Betamethasone Valerate|A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses.
89062348|NCT01607424|Experimental|RECOS: 42 hours CR, 14 week-treatment.|RECOS(Cognitive Remediation for Schizophrenia) exercises were designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 5 main cognitive functions. RECOS modules focus on the relevant cognitive domains, which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS was determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participated in the module corresponding to his/her most altered cognitive area.
89062349|NCT01607424|Active Comparator|CRT: 42 hours CR, 14 week-treatment|CRT (Cognitive Remediation Therapy) exercises are the ones used by Wykes et al (1999). The CRT method consists of 3 modules: flexibility, memory (A and B) and planning (A and B). Each module involves a series of paper and pencil exercises with parallel forms providing with gradual difficulty.
89062350|NCT01646606|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be measured at a frequency determined by the responsible physician (as is current practice). The reading will be displayed on the bedside monitor in the participants' room.
89062351|NCT01646606|Experimental|Intermittent oxygen monitoring|
89062352|NCT01681979||Women with asthma during pregnancy|Women with asthma during pregnancy will be identified based on one of the following: 1) an asthma related medical code recorded anytime before the pregnancy start date and at least one prescription for an asthma medicine in the 6 months before the pregnancy start date or during pregnancy; 2) no asthma related medical code but at least 6 prescriptions for an asthma medicine in their record before the pregnancy start date, including one in the 6 months before the pregnancy start date or during pregnancy.
89062353|NCT01646684|Experimental|SOM230|
89062354|NCT01607580|Experimental|low-dose glucocorticoid|drug
89062355|NCT01607580|Other|no intervention after transplant|
89062356|NCT01646723|Experimental|VALID Intervention|Volunteers Adding Life in Dementia (VALID) Program
89062357|NCT01646801|Experimental|Experimental|NMB's Paclitaxel Drug ejecting balloon catheter
89062358|NCT01604070||Nextra fusion|group that has the nextra device
89062359|NCT01604070||k wire fixation|control group fixated with k wire
89062360|NCT01604148||HoLEP group|Holmium Laser Enucleation of Prostate Group
89062361|NCT01682018|Experimental|intervention group|Patients that underwent dingle lung transplantation due to emphysema and developed native lung overinflation as demonstrated by chest CT and decline in pulmonary lung function tests (FEV1 ) shall undergo valves placement to the native lung
89062362|NCT01607697|Experimental|Mindfulness Training|Group received Mindfulness Training
89062363|NCT01607697|No Intervention|Waitlist Control|Group received Usual Care
89062364|NCT01682057|Experimental|Group A|ROX Anastomic Coupler System (ACS) + continuing standard antihypertensive medications
89062365|NCT01604187|Active Comparator|Fentanyl|Ten minutes before the procedure fentanyl 100 mikrograms sublingual tablet will be given to the patient.
89062366|NCT01604187|Placebo Comparator|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
89062367|NCT01682096|Active Comparator|Computed coronary angiography (CTA)|Patients will undergo a MDCT as the initial diagnostic test to rule out Acute Coronary Syndrome
89062368|NCT01682096|Active Comparator|Exercise stress echocardiography|Patients will undergo exercise stress echocardiography as the initial diagnostic test to rule out acute coronary syndrome.
89062369|NCT01607736|No Intervention|Inactive Comparator|
89062370|NCT01607736|Experimental|Virtual Gait Training|
89062371|NCT01682174|Placebo Comparator|Control Test Drink|control drink
89062372|NCT01682174|Experimental|Experimental Test Drink|Experimental Drink
89062373|NCT01607814||Cirrhotic Patients|Patients affected by cirrhosis of any etiology and severity
89062374|NCT01607814||Control Group|Subjects age, sex and comorbidities matched
89062375|NCT01682252||musculoskeletal tumors|all patients undergoing surgery for musculoskeletal tumors
89062376|NCT01604226||Gynecologic surgery group|Those undergoing gynecologic laparoscopic surgery with TIVA
89062377|NCT01604226||Urologic surgery group|Those undergoing urologic surgery with TIVA
89062378|NCT01647191|Experimental|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
89062379|NCT01647191|Active Comparator|control group|The investigators will adopt previous treatment in the clinics to intervent the patients without any type of target intervention for this group.
89062380|NCT01604304|Active Comparator|Extracorporeal shockwave lithotripsy|stone treatment using electroconductive technology
89062381|NCT01604304|Active Comparator|Flexible ureteroscopy|intra renal retrograde surgery with or without laser and stone extraction
89062382|NCT01682291|Active Comparator|Life-style modifications|"Lifestyle modifications will include:~Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)"
89062383|NCT01682291|Active Comparator|Dietary supplements|Life-style modifications along with a novel combination of dietary supplements that includes: Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
89062384|NCT01607931|No Intervention|Resting Trial|a 1 hour period of rest immediately prior to OGTT or isoglycemic clamp
89062385|NCT01607931|Experimental|Exercise Trial|a 1 hour cycling exercise bout immediately prior to the OGTT or isoglycemic clamp
89062386|NCT01682330||Fitness|
89062387|NCT01682330||Whole-body vibration|
89062388|NCT01682330||Control|
89062389|NCT01604382|Experimental|treatment|Receives General Anesthesia as described above
89062390|NCT01604382|Placebo Comparator|Placebo|Patients receives neuraxial anesthesia as described above
89062391|NCT01604421|Sham Comparator|Thermoregulation-standard care|Standard thermoregulation without a plastic bag from one hour after birth until discharge or 24 hours after birth, whichever comes first.
89062392|NCT01604421|Active Comparator|Thermoregulation-with plastic bag|Thermoregulation with plastic bag covering torso and lower extremities from one hour after birth until discharge or 24 hours after birth to assist with thermoregulation. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
89062393|NCT01647269|Experimental|DBS Off first|
89062394|NCT01647269|Experimental|DBS On First|
89062395|NCT01682369|Other|Group 1 a - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
89062396|NCT01682369|Other|Group 1 b - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
89062397|NCT01682369|Other|Group 1 c - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Aggripal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Aggripal)~V3-(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
89062398|NCT01682369|Other|Group 2 a - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
88821195|NCT04931017|Active Comparator|Cohort B (metformin ER with waiting period)|Participants receive no intervention for 26 weeks, then cross-over to Cohort A. Participants undergo bronchoscopy biopsy and blood sample collection at screening, at week 26, and at 13 weeks after cross-over to Cohort A.
89062399|NCT01682369|Other|Group 2 b - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
89062400|NCT01682369|Other|Group 2 c - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
89062401|NCT01604460|Sham Comparator|Resuscitation-no plastic bag|Resuscitation per standard of care without a plastic bag
89689915|NCT02982395|Experimental|Nanoxel®M|75 mg in 100mL normal saline
89689916|NCT02982395|Active Comparator|Mitomycin|40 mg in 100mL normal saline
89689917|NCT00979069|Experimental|Aerobic Group|12 weeks of aerobic exercise 3 times a week
89689918|NCT00979069|No Intervention|Control Group|No contact control
89689919|NCT03124966|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all will receive the pulse oximeter sensor.
89689920|NCT02982005|Experimental|KHK4827|KHK4827 administered SC
89689921|NCT02982005|Placebo Comparator|Placebo|Placebo administered SC
89689922|NCT00979303|No Intervention|Control Group|Control Patients - Undergo ablation procedures with radiation/fluoroscopy only
89689923|NCT00979303|Experimental|Study Group|Study Group Patients - Undergo ablation procedures using intracardiac echocardiography and 3D navigational system in addition to radiation.
89689924|NCT04333264|Active Comparator|suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
89689925|NCT04333264|Active Comparator|no suction drainage|Patients will be dived with randomization in to two groups: with and without closed suction drainage after primary total hip arthroplasty
89689926|NCT04736836|Active Comparator|interventional|50 patient take rifaximin plus lactulose for 6 months
89689927|NCT04736836|Placebo Comparator|control|50 patient take lactulose for 6 months
89689928|NCT03021109|Experimental|Inferior vena cava diameteres|Measurement of inferior vena cava diameters with ultrasound
89221472|NCT04546217|Experimental|Treadmill training +Transfer package (TT+TP)|"The TT+TP group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist. In combination with the gait training, participants in this group will also receive a group of behavioral strategies called the Transfer Package (TP). Each intervention session will last 1.5h, 1h for the gait training and 30 minutes dedicated for the transfer package.~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
89221473|NCT04546217|Active Comparator|Treadmill training (TT)|"The TT group will receive 24 sessions (3x week for 8 weeks) of robotic treadmill gait training in a robotic device called KineAssist.~Participants will be assessed pre-, post-intervention, 3 and 6 months after the end of the intervention. Also, participants will be interviewed to investigate their perceptions about each element of the intervention, benefits, side effects and suggestion for change."
89221474|NCT00697619|Experimental|Test Group|Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
89221475|NCT00697619|No Intervention|Contorl Group|Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.
89221476|NCT02566187|Other|Group 1|Subjects of Group 1 take Fimasartan and Atorvastatin Individual Tablets at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 1 take a Fimasartan/Atorvastatin Combination Tablet at 8th day.
89221477|NCT02566187|Other|Group 2|Subjects of Group 2 take a Fimasartan/Atorvastatin Combination Tablet at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 2 take Fimasartan and Atorvastatin Individual Tablets at 8th day.
89221478|NCT05324891|Active Comparator|Fentanyl|Neonates received fentanyl infusion during postoperative phase.
89221479|NCT05324891|Active Comparator|Dexmedetomidine|Neonates received dexmedetomidine infusion during postoperative phase.
89221480|NCT00445432|Experimental|DB Adalimumab 40 mg eow|Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
89221481|NCT00445432|Placebo Comparator|Placebo eow|Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
89221482|NCT00445432|Experimental|OL Adalimumab 40 mg eow|Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
89221483|NCT00696137|Experimental|BEMA Fentanyl|BEMA Fentanyl
89221484|NCT02565641|Experimental|Capecitabine + Gemcitabine|Participants will receive oral capecitabine (830 milligrams per meter-squared [mg/m^2]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks [q4w]) along with IV infusion of gemcitabine (1000 mg/m^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period).
89062402|NCT01604460|Active Comparator|Resuscitation-torso bag|Use of plastic bag covering the torso and lower extremities for temperature regulation during and after resuscitation for the first hour after birth
89062403|NCT01682408|Active Comparator|Part A1|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), fed 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
89062404|NCT01682408|Active Comparator|Part A2|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed 150 mg ranitidine
89062405|NCT01682408|Active Comparator|Part B1|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
89062406|NCT01682408|Active Comparator|Part B2|1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
89062407|NCT01682408|Active Comparator|Part B3|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
89062408|NCT01607970|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
89062409|NCT01607970|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
89062410|NCT01608009|Experimental|Pazopanib and paclitaxel|
89062411|NCT01647347|Experimental|test treatment|"Test treatment:~1 min mouthwash with 10% PVP-iodine~1 min subgingival rinsing with 10% PVP-iodine~1 min ultrasonic debridement with 10% PVP-iodine as cooling liquid~blood sampling from the V.mediana cupidi"
89062412|NCT01647347|Placebo Comparator|Control group|"Control:~1 min mouthwash with water~1 min subgingival rinsing with water~1 min ultrasonic debridement with water as cooling liquid~blood sampling from the V.mediana cupidi"
89062413|NCT01604499|Experimental|Feedback only|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
89062414|NCT01604499|Experimental|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
89062415|NCT01604499|No Intervention|Control group|
89062416|NCT01682447|Experimental|Extensive Pulmonary Rehabilitation (ERP)|Participants in this group are measured on primary and secondary outcome measures before and after a 12 week extensive pulmonary rehabilitation program.
89062417|NCT01682447|No Intervention|Waiting List Control group|Participants in the waiting list control group are measured on primary and secondary outcome measures before and after waiting time for the extensive pulmonary rehabilitation program and start with this program after the second moment of measurement.
89062418|NCT01604577|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
89062419|NCT01604577|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
89062420|NCT01607463|Experimental|active TENS group|Two electrodes were attached to the radial side of dominant forearm. In the active TENS group, TENS was delivered via two electrodes on the venous cannulation site
89062421|NCT01607463|Placebo Comparator|Placebo group|"Two electrodes were attached to the radial side of dominant forearm. In the placebo group the TENS device had no current output although the power on indicator light remained active."
89062422|NCT01647386||MBT Revision Component|
89062423|NCT01604031|Experimental|B-CLL vaccine|Patients will receive doses of vaccine at 2 week intervals for 5 doses and at 4 week intervals for doses 6-16. The injection will be performed subcutaneously in the deltoid region of the upper arm.
89062424|NCT01682525|Experimental|Ovarian tissue cryopreservation|The ovarian tissue is cryopreserved and stored at Boston IVF, which is an FDA compliant and American Association of Tissue Banks accredited long term storage facility for reproductive tissue.
89062425|NCT02279927|Experimental|Low energy high frequency|Ureteroscopy with laser settings of low energy & high frequency with aim of stone dusting
89062426|NCT02279927|Active Comparator|High energy low frequency|Ureteroscopy with laser settings of low energy high frequency with aim of stone fragmentation and basket extraction of fragments
89062427|NCT01604616||PCFL GROUP|patients in this group had the PFCL for a period of 7-10 days before it was replaced by SF6 gas or silicone oil
89062428|NCT01604616||control group|in thos group no PFCL was left in the eye and either SF6 or silicone oil was the definitive treatment at the time of the retinal detachment surgery repair.
89062429|NCT01682564|Experimental|Candemore tablet|"Candemore tablet~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
89062430|NCT01682564|Active Comparator|Atacand tablet|"Atacand tablet~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
89062431|NCT01608048|No Intervention|control|
89062432|NCT01608048|Experimental|TEAS|
89062433|NCT01608048|Experimental|EA:electro-acupuncture|
89062434|NCT01647425||head and neck or lung cancer|patient with a first head and neck cancer or first lung cancer
89062435|NCT01604655|Active Comparator|Coronary CT Angiography|Patient admitted with chest pain is randomized to CCTA for assessment.
89062436|NCT01604655|Active Comparator|Stress Test|Patients admitted with chest pain are randomized to a stress test (stress SPECT or Echocardiography) for assessment.
89062437|NCT01647503||Tumor group|Parathyroid adenoma, hyperplasia and carcinoma
89062438|NCT01647503||Normal|Normal parathyroid samples
89062439|NCT01604694|Experimental|TAP Block with levobupivacaïne|
89062440|NCT01604694|Placebo Comparator|TAP Block with Placebo|
89062441|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 1) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
89062442|NCT01682798|Placebo Comparator|Placebo yoghurt|100g of placebo yoghurt (normal yoghurt) will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
89062443|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 2) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
89062444|NCT01608126|Active Comparator|Combined Cervical Block|
89062445|NCT01608126|Active Comparator|Median Cervical Block US guided|
89062446|NCT04528550|Experimental|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection in acute phase. Each included patient will receive a single dose of 100 million autologous bone marrow-derived mononuclear cells.
89062447|NCT04528550|Placebo Comparator|Control|Included patients will receive the same amount of saline through lumbar injection.
89062448|NCT04528472|Experimental|Acupuncture Treatment|Acupuncture Treatment: main point: DU20, DU24, MS7, LI4, ST40 Oral Medicine Rehabilitation Treatment
89062449|NCT04528472|Experimental|Regular Treatment|Acupuncture Treatment Oral Medicine Rehabilitation Treatment
89062450|NCT01647620|Active Comparator|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily
89062451|NCT01647620|Placebo Comparator|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
89062452|NCT01608243|Experimental|SLIT tablets of HDM allergen extracts|
89062453|NCT01608243|Placebo Comparator|Placebo|
89062454|NCT04527692||Child|Children/adolescents from 1 to 18 years of age with a serious illness requiring follow-up by a regional pediatric palliative care resource team and/or temporarily hospitalized.
89062455|NCT04527692||Parents|Adult person with parental authority over a child between the ages of 1 and 18 who is a carrier of a serious illness and requires follow-up by a regional pediatric palliative care resource team and/or is temporarily hospitalized.
89221485|NCT04036721|Experimental|ARM A - PROLONGED|induction dose 1-4mg/kg of prednisone, prednisone 60mg q24h for 2-4wks, tapering not faster than 10mg each 14d, maintenance dose 10mg q24h for 8wks, withdraw of treatment during 4wks, summary of treatment time not shorter than 12-24wks.
89221486|NCT04036721|Active Comparator|ARM B - FAST REDUCTION|induction dose 1-4mg/kg of prednisone, prednisone 30-60 mg q24h, tapering not faster than 10mg each 7d, summary of treatment time 6-12wks.
89221487|NCT00441142|Active Comparator|Phase II: Arm A (Control Group: RT + TMZ)|"The Induction Phase:~Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given]."
89062456|NCT01608282|Experimental|OPEN Intervention Group|Intervention group participants will receive an email prompt to access the OPEN website every two weeks for the first three months, with a short message about the ongoing projects at the Arthritis Research Centre of Canada. The OPEN website will remain accessible throughout the study, but no further prompting emails will be sent after Month 3. In addition, they will receive an education pamphlet produced by The Arthritis Society containing information about osteoarthritis, physical activity and other treatments.
89062457|NCT01608282|No Intervention|Control Group|Control group participants will receive, by email, the same Arthritis Society pamphlet as the Intervention group. Participants will also receive, by email, the same short message about the ongoing projects at the Arthritis Research Centre of Canada, every two weeks for the first three months (i.e. the same schedule as the intervention group receiving the prompting email so that the number of contacts is equal in both groups), but without the prompting to use the OPEN website.
89062458|NCT01682915||Group 1: ADHD+DAT1, Probands|30 ADHD probands with DAT1 variants
89062459|NCT01682915||Group 2: ADHD+DAT1, Unaffected sibling|30 same-sex unaffected siblings of Group 1
89062460|NCT01682915||Group 3: ADHD Drug-naïve, Probands|30 ADHD probands without DAT1 gene variants, who were age-, sex-, and IQ-matched to Group 1
89062461|NCT01682915||Group 4: ADHD Drug-naïve, unaffected sibling|30 same-sex unaffected siblings of Group 3
89062462|NCT01682915||Matched controls|30 age-, sex- and IQ-matched TD controls for each of 4 groups
89062463|NCT01608360|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
89062464|NCT01608360|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
89062465|NCT01647659|Experimental|GSK1120212 tablet|GSK1120212 tablet
89062466|NCT01647659|Experimental|GSK1120212 powder for oral solution|GSK1120212 powder for oral solution
89062467|NCT01608399|Experimental|Metacognitive therapy|
89062468|NCT01608399|No Intervention|Waiting list control|
89062469|NCT01682993|Active Comparator|Corneal Cross Linking|Patients will receive a standard corneal cross linking treatment
89062470|NCT01682993|Experimental|Corneal Cross Linking and Topo Laser|Patients will receive a topography guided laser treatment in combination with a standard corneal cross linking treatment in the same session.
89062471|NCT01604733||HYPERCHOLESTEROLEMIC PATIENTS|
89062472|NCT01604811|Experimental|Tested product|
89062473|NCT01604811|Active Comparator|Comparator|
89062474|NCT01683032|Experimental|Experimental: Healthy adults|Participants, aged 21-40 years, will be recruited through an advertisement posted at the University of Haifa (including the website of Haifa University).
89062475|NCT01604928|Experimental|YM178 Dose 1|low dose
89062476|NCT01604928|Experimental|YM178 Dose 2|high dose
89062477|NCT01604928|Active Comparator|Tolterodine|Oral
89062478|NCT01604928|Placebo Comparator|Placebo|Oral
89062479|NCT01647776||Individuals without colon polyps|
89062480|NCT01647776||Individuals with colon polyps|
89062481|NCT01608438|Experimental|SCI Static|SCI group that practices with a static body-machine map
89062482|NCT01608438|Experimental|SCI Machine Learning|Spinal Cord Injury patients who practice with a body-machine map that is adapted using machine learning
89062483|NCT01647815|Experimental|50 healthy volunteers|The study population consists of healthy volunteers aged 18 to 50 years and without previous surgery, trauma, or thrombosis of the axilla or the shoulder girdle.
89062484|NCT01605045|Experimental|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique)versus
89062485|NCT01605045|Active Comparator|Standard technique|Coronary anatomy visualized and documented using cinematography alone (standard technique)
89062486|NCT01683149|Experimental|Combination Chemotherapy|"Combination Chemotherapy: Topotecan and Sorafenib. Participants will receive the treatment in cycles. Every cycle is 28 days long. For the first cycle participants will get the chemotherapy drugs:~Topotecan PO (by mouth) once daily on days 1-5 and days 8-12~Sorafenib PO (by mouth) twice daily (BID), continuously on days 2-28 of cycle one and days 1-28 on each additional cycle.~Level -1: Topotecan 1.0 mg/m^2: Sorafenib 100 mg/m^2 BID~Level -2: Topotecan 0.8 mg/m^2: Sorafenib 100 mg/m^2 BID~Level 1: Topotecan 1.0 mg/m^2: Sorafenib 150 mg/m^2 BID~Level 2: Topotecan 1.4 mg/m^2: Sorafenib 150 mg/m^2 BID~Level 3: Topotecan 1.4 mg/m^2: Sorafenib 200 mg/m^2 BID~Level 4: Topotecan 1.8 mg/m^2: Sorafenib 200 mg/m^2 BID"
89062487|NCT01608555|Experimental|inhaled tobramycin once-a-day|Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.
89062488|NCT01647854|Experimental|Device: Teleconsultation|"If patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The safety and efficacy of the introduction and operation of this system should be evaluated."
89062489|NCT01683305||Subjects who have no mammographically detectable tumors|This group will be evaluated for marker presence in NAF. no drugs administered
89062490|NCT01683305||Subjects who have non-cancerous growths|This group will be evaluated to study whether marker(s) detected in NAF are also expressed in non-cancerous tumors. No drugs administered
89062491|NCT01683305||subjects who have cancerous growths|In this group, any markers detected in NAF could also be detected in tumor tissues. No drugs administered.
89062492|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.375mg/kg, single-dose|
89062493|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, single-dose|
89062494|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 1.5mg/kg, single-dose|
89062495|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, and dose escalation|
89062496|NCT01608633|Experimental|Spray and stretch|
89062497|NCT01608633|No Intervention|Control|
89062498|NCT01648010|Experimental|TC-3 gel|TC-3 gel group undergo intravesical instillation of the investigatory device
89062499|NCT01648010|Experimental|MMC- gel|MMC gel group undergo intravesical instillation of the reverse thermal gelation device mixed with MMC
89062500|NCT01605201|Experimental|Implantation of cartilage graft|
89062501|NCT01683461|Experimental|Enhanced Counseling|Women in the intervention arm receive: (1) a standardized health education video before HIV pre-test counseling; (2) HIV pre- and post-test counseling sessions that prepare women for decisions related to testing, serostatus disclosure and anti-retroviral (ARV) prophylaxis and help women plan strategies for sexual risk behavior change; (3) two additional post-test counseling sessions postpartum focused on legal education and referral, partner testing, sexual risk behavior change and family planning decisions and; (4) an active referral system to post-test support groups run by a clinically trained staff psychologist and (5) an active referral system to legal services run by a lawyer at the clinic.
89062502|NCT01683461|Active Comparator|Standard of Care|Women in the control arm receive the standard of care in terms of HIV counseling and testing during pregnancy. The standard of care for HIV counseling adheres to guidelines provided by the US Centers for Disease Control and the World Health Organization. Women receive one individual pre-test counseling session immediately before they are tested for HIV, and one individual post-test counseling session the same day that they are tested.
89062503|NCT01608711|Experimental|AGS-1C4D4 plus gemcitabine|Subjects will receive a maintenance dose of AGS-1C4D4 every 3 weeks (Q3W) in addition to the gemcitabine administration.
89062504|NCT01648049|Experimental|CBT|Cognitive behavior therapy for both insomnia and depression featuring stimulus control and cognitive therapy.
89062505|NCT01648049|Active Comparator|Treatment as Usual|No additional treatment besides regular care.
89062506|NCT02482623|Experimental|Intervention|Dyads in this arm will receive care provided by an interprofessional team trained through the DSM-H to provide patient/caregiver-centered dementia care through home healthcare.
89062507|NCT02482623|No Intervention|Control|Dyads in this arm will receive usual care provided in the home healthcare setting.
89062508|NCT01683500|Experimental|shock wave therapy|intervention: shock wave therapy with Modulith SLK (Storz)
89062509|NCT01605357|Active Comparator|Standard Care|Patients will be managed to maintain a goal serum sodium of > 135 mmol/L , a well recognized value in the management of severe traumatic brain injury.
88821196|NCT04926948|Experimental|Treatment (SBRT, immunotherapy)|Patients undergo 3-5 daily fractions of SBRT in the absence of disease progression or unacceptable toxicity. Patients also receive immunotherapy at the discretion of the treating medical oncologist.
89062510|NCT01605357|Experimental|Induced Hypernatremia|Patients will be treated with induced, sustained hypernatremia for 5 days following injury by using hypertonic saline to target a goal serum sodium of 150-160 mmol/L
89062511|NCT01648127|Experimental|Ceftaroline|Ceftaroline intravenous 600 mg single dose
89062512|NCT01605474|Active Comparator|Outpatient Cervical Ripening|Patients who are randomized to this arm will be allowed discharged home for 12 hours after fetal status is assessed and noted to be reassuring with the foley bulb in place. They will return sooner if they experience rupture of membranes or enter active labor or if the foley bulb falls out.
89062513|NCT01605474|No Intervention|Inpatient Cervical Ripening|In this arm, the fetus will be assessed and a foley bulb placed but these patients will be kept in the hospital.
89062514|NCT01683539|Experimental|The Thinking Skills for Work Program|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
89221488|NCT00441142|Experimental|Phase I + Phase II: Arm B (RT + TMZ + Vandetanib)|"The Induction Phase:~ZD6474 (Vandetanib) daily (to begin 5-7 days prior to starting participant's RT) Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given].~ZD6474 (Vandetanib) daily for the twelve (12) 28-day cycles of adjuvant temozolomide, with the option to continue until participant experiences an unacceptable toxicity or his/her tumor progresses."
89221489|NCT00921401|Experimental|Asthma Feedback|Each month and before all visits with their asthma care provider, participants will be encouraged to go online and answer a series of questions regarding the types of asthma medications they use and how often they use them, asthma symptoms they have experienced, emergency department visits in the past year, the care they have received for their asthma (e.g., specialist visits) in the past year, and the planned date of their next visit with their asthma care provider. Participants will receive tailored feedback about what questions they should ask their doctor during a subsequent visit, whether or not they should schedule a visit sooner, and links to read more about each recommendation.
89221490|NCT00921401|Active Comparator|Preventive Feedback|Each month and before all visits with their primary care provider, participants will be encouraged to go online and answer a series of questions regarding their preventive care. They will receive tailored feedback regarding preventive services, such as pap testing, cancer screenings, and flu shots. Participants will receive tailored feedback regarding preventive services (e.g., cancer screening) that they should discuss with their primary care provider.
89221491|NCT01029184|Active Comparator|complete non allergenic cereals|existing commercialized product
89221492|NCT01029184|Experimental|complete non allergenic cereals plus|commercialised product with the addition of a novel ingredient
89221493|NCT04025021|No Intervention|Control group (standard fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. As feedings are advanced to goal of 150 ml/kg/day, the TPN and SMOF lipids (Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil) will be decreased per standard management and NICU guidelines."
89221494|NCT04025021|Experimental|Intervention group (targeted fortification)|"Breast milk will be fortified standard with Similac Human Milk Fortifier 1 packet:~50 ml breast milk at 50ml/kg/day enteral feeds, then 1 packet:25 ml breast milk at 75 ml/kg/day. During this time, as the volume decreases, the TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day. Breast milk analysis will occur on a weekly basis immediately after birth for all infants enrolled in the study."
89221495|NCT03848416|Experimental|Ixekizumab (Reference)|Reference formulation ixekizumab 80 milligram (mg) administered as a subcutaneous (SC) injection in a prefilled syringe.
89221496|NCT03848416|Experimental|Ixekizumab (Test 1)|Test 1 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
89221497|NCT03848416|Experimental|Ixekizumab (Test 2)|Test 2 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
89221498|NCT01029418|Experimental|AZD6244 and sorafenib|AZD6244+ sorafenib
89221499|NCT04060979|Experimental|Group 1- NO treatment- dose 1|Will comprise of approximately 30 patients and will receive inhalations of dose 1 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
89221500|NCT04060979|Experimental|Group 2- NO treatment- dose 2|Will comprise of approximately 30 patients and will receive inhalations of dose 2 of NO combined with O2/air for 40 minutes, every 4.5 hours during the day four times a day for up to 5 days in addition to standard supportive treatment.
89221501|NCT04060979|Other|Group 3- Control treatment|Will comprise of approximately 30 patients and will receive O2/air using the same treatment schedule and equipment as groups 1 and 2, in addition to standard supportive treatment.
89221502|NCT00458302|Experimental|darunavir monotherapy|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
89221503|NCT00458302|Experimental|darunavir + 2 NRTI|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
89221504|NCT03851146|Experimental|LeY CAR T cells|"One arm study consisting of 3 + 3 dose escalation study design (see below) followed by dose expansion phase at determined MTD.~Dose level : Target Number LeY CART cells infused *~-1 (if needed): 1 x 10e8~2 x 10e8~5 x 10e8~1 x 10e9~5 x 10e9~Targeted number of LeY CAR T cells (minus 40% acceptance range) for manufacture according toTGA-approved standard protocols~Treatment follows a lymphodepleting, chemotherapy regimen that consists of Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 consecutive days prior to cell infusion, with chemotherapy completed at least 48 hours before the re-infusion of the LeY CAR T cells."
89221505|NCT01023646|Other|carbohydrate load|Food challenge - Carbohydrate load
89221506|NCT01023646|Other|Carbohydrate + Protein|Food challenge - carbohydrate + protein
89221507|NCT01023646|Other|Carbohydrate + Fat|Food challenge - carbohydrate + fat
89221508|NCT01023646|Other|Fiber|Food challenge - carbohydrate + fiber
89221509|NCT01023802||Neoadjuvant therapy for breast cancer|Women who present to the Internal Medicine Breast Cancer Clinic with breast cancer and who after discussion with the consulting surgeon and oncologist have agreed to undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy.
89221510|NCT00444106|Experimental|Artemether-lumefantrine (Coartem)|Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
89221511|NCT00444106|Active Comparator|Atovaquone-proguanil (Malarone)|Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
89221512|NCT00444106|Active Comparator|Artesunate-mefloquine|Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.
89221513|NCT00561470|Placebo Comparator|Placebo/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
89221514|NCT00561470|Experimental|Aflibercept/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
89221515|NCT00443872|Other|orally disintegrating selegiline|This is a one arm open label study of patients who are experiencing a dopamine agonist (DA) related adverse effects (AE) of either one or more of the following: excessive daytime sleepiness, hallucinations, pedal edema, impulse control disorder. All subjects received orally disintegrating selegiline.
89221516|NCT01323166||Excision of the levator muscle|The abdominal part of the operation is performed as an TME and the perineal part of the operation is performed with the intent to get a cylindrical specimen thus removing part of or the entire levator muscle with the specimen
89221517|NCT01323166||Traditional perineal operation|The abdominal part of the operation performed as a TME. The perineal operation performed with the intent of removing the tumour with CRM free of tumour and the levator left in place
89221518|NCT01323244|Experimental|TMC435|TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
89221519|NCT01027234|Experimental|1|
88821197|NCT04919564|Experimental|Furosemide group|Continuous furosemide 2 mg/hour for a period of 12 hours begins since anesthetic induction
89062515|NCT01683539|Active Comparator|The Cognitive Skills for Work Program|The Cognitive Skills for Work Program includes 4 components delivered by a Cognitive Specialist who works with the consumer's Employment Specialist: a) assessing the consumer's cognitive strengths and weaknesses their relation to job history b) teaching coping strategies for cognitive challenges associated with job search or maintenance c)job search planning, in which the consumer and the Cognitive and Employment Specialists help identify job leads based on the consumer's interests, and identify cognitive coping strategies and supports the consumer may need to succeed at the workplace; and d) job support consultation, in which the Cognitive and Employment Specialists consult with the consumer on additional cognitive coping strategies to enable the consumer to meet the demands of the job.
89062516|NCT01608750|Experimental|pantoprazole|
89062517|NCT01608750|Placebo Comparator|folic acid|
89062518|NCT01605513|Experimental|recombinant interferon|PEG-IFN-SA 1.0μg/kg for 12 times, Peginterferon alfa-2a 180 μg for 12 times, PEG-IFN-SA 1.5 μg/kg for 12 times, PEG-IFN-SA 2 μg/kg for 12 times, PEG-IFN-SA 3 μg/kg for 12 times, PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group for 12 times, Intergen 15μg/48hours for 7 times, ribavirin 0.45g/bid for 10 times
89062519|NCT04528277|Experimental|LGTB treatment group|The LGTB treatment group will receive the 1-month regimen of three times weekly rifapentine (150mg per capsule, 450mg po tiw) plus isoniazid (100mg per tablet, 400mg po tiw).
89062520|NCT04528277|No Intervention|LGTB no treatment group|The LGTB no treatment group will not take any medication related to preventive treatment of tuberculosis.
89062521|NCT04528277|No Intervention|non-LGTB group|The non-LGTB group will not take any medication related to preventive treatment of tuberculosis.
89062522|NCT01605591|Active Comparator|the DLT bending to the right|
89062523|NCT01605591|Active Comparator|the DLT bending to the left|
89062524|NCT01683617|Experimental|A treatment based on CBT and new technologies|Individuals will receive a treatment based on cognitive behavioral therapy and new technologies (virtual reality, virtual reality combined to biofeedback and mobile phones). Relaxation will be induced through the immersion in different virtual environments (e.g., lake) which will be customized with different pre-recorded audio narratives that describe the specific setting and that guide the execution of a series of relaxation exercises. During biofeedback exercises a wearable biosensor system will provide suggestions to the trainer based on the reactions of the participants, and the biosensor data will directly modify the virtual reality experience in real time.
89062525|NCT01683617|Active Comparator|Traditional treatment based on CBT|Participants will receive a treatment based on traditional cognitive behavioral therapy techniques for stress management, without the use of new technologies. Relaxation will be induced by guided imagery, through auditory narratives.
89062526|NCT01605630|Experimental|Family-based cancer literacy intervention|
89062527|NCT01605630|Active Comparator|Control|Standard of care
89062528|NCT01683656|Active Comparator|ER Niacin/laropipant|ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
89062529|NCT01683656|Placebo Comparator|ER Niacin/laropipant Placebo|ER niacin/laropiprant placebo p.m.
89062530|NCT01605747|Experimental|Culturelle|
89062531|NCT01605747|Placebo Comparator|Placebo|
89062532|NCT01605786|Experimental|PEBS Low dose|
89062533|NCT01605786|Experimental|PEBS High dose|
89062534|NCT01605786|Active Comparator|Control|
89062535|NCT01683695|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
89062536|NCT01683695|Placebo Comparator|AMG 557 Matching Placebo|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
89062537|NCT01648244|Experimental|Computer-Assisted Decision Support|These providers will use the CADS program to treat their enrolled patients.
89062538|NCT01608789|Experimental|Virtue® Male Sling|Patient implanted Virtue® Male Sling
89062539|NCT01683734||Renal Function Observation|
89062540|NCT01683773|Experimental|Group A|Two doses of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
89062541|NCT01683773|Experimental|Group B|One dose of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
89062542|NCT01683773|Experimental|Group C|Three doses of AERAS-402 (1x10^11 vp intramuscular injection)
89062543|NCT01648478|Experimental|Single Arm|
89062544|NCT01608945||steroid,liver function I/R|
89062545|NCT01683890||Simple hysterectomy group|Patients will undergo simple hysterectomy due to benign uterine disease.
89062546|NCT01608984|Active Comparator|RIPC-CABG|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery with blood cardioplegia for cardiac arrest (CABG) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 to 10 Minutes after aortic unclamping during reperfusion of the myocardium. Blood samples are taken up to 72 hours postoperatively.
89062547|NCT01608984|Placebo Comparator|Control-CABG|Control group: Coronary artery bypass grafting without RIPC protocol
89221520|NCT01027234|Placebo Comparator|2|
89221521|NCT01027312||Glaucoma Patients|Glaucoma patients covering the entire range of visual field loss from none to advanced.
89221522|NCT01027312||Control Group|Aged matched people with no eye diseases.
89221523|NCT01027390|Experimental|1 hr training 50% supervision|1 hr training 50% supervision
89062548|NCT01608984|Active Comparator|RIPC-OPCAB|Remote ischemic preconditioning (RIPC) protocol before Off-pump coronary artery bypass surgery (OPCAB) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before first coronary artery incision and 5 to 10 Minutes after completion of the coronary anastomoses. Blood samples are taken up to 72 hours postoperatively.
89062549|NCT01608984|Placebo Comparator|Control-OPCAB|Control group: Off-pump Coronary artery bypass surgery without RIPC protocol
89062550|NCT01648517|Experimental|Arm A|Genomic-driven dual agent chemotherapy Chemotherapy will consist of the assigned two drugs according to ERCC1 and RRM1 mRNA expression level A1: docetaxel + vinorelbine (DV) A2: gemcitabine + vinorelbine (GV) A3: docetaxel + carboplatin (DC) A4: gemcitabine + carboplatin (GC)
89062551|NCT01648517|Active Comparator|Arm B|standard of care All control arm patients received standard platinum-based doublet chemotherapy with docetaxel plus carboplatin
89062552|NCT01609101|Other|Coopdech® videolaryngoscope|
89062553|NCT01609101|Other|C-MAC® videolaryngoscope|
89062554|NCT01609101|Other|McGrath® Series 5 videolaryngoscope|
89062555|NCT01609101|Other|Glidescope® Cobalt videolaryngoscope|
89062556|NCT01609101|Other|King Vision® videolaryngoscope|
89062557|NCT01609101|Other|Venner® videolaryngoscope|
89062558|NCT01609101|Other|McGrath MAC® videolaryngoscope|
89062559|NCT01683929|Active Comparator|Oral glucose tolerance test|The participants will consume a beverage containing 75 gram glucose During the meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes. Also, they will record their macronutrient\caloric consumption during the 24 hour following the test.
89062560|NCT01683929|Placebo Comparator|Artificial sweetner|"participants will consume a beverage containing 0.42 gram artificial sweetener (Aspartame) During each meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes.~Also, they will record their macronutrient\caloric consumption during the 24 hour following the test."
89062561|NCT01609179|Experimental|IPI-926|
89062562|NCT01648556|Other|patients with a thrombopenia isolated|Patients of 60 years old and more presenting a thrombopenia isolated with a rate of platelet < 100 G/l Blood tests and bone marrow biopsy repeated
89062563|NCT01605981|Experimental|Nilotinib oral|Nilotinib oral dose of 400 mg BID (800 mg/day) continuous dosing for up to 24 months. Nilotinib oral dose of 300 mg BID (600 mg/day) continuous dosing in case of intolerance. Nilotinib oral dose of 400 mg QD (400 mg/day) continuous dosing in case of intolerance
89062564|NCT01648595|Experimental|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour. In control group was not intervention.
89062565|NCT01648595|No Intervention|Without Fentanyl|The control group did not receive Fentanyl.
89062566|NCT01606020|Active Comparator|Sleep deprivation First|"First night D7 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.~Second night D28 :~Overnight, the subjects stay in their homes. No intervention during this night."
89062567|NCT01606020|Active Comparator|sleep deprivation second|"First night D7 :~Overnight, the subjects stay in their homes. No intervention during this night.~Second night D28 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep."
89062568|NCT01648634|Experimental|Nebivolol|
89062569|NCT01648634|Placebo Comparator|Placebo|
89062570|NCT04527848|Experimental|small amount of undiluted C3F8|
89062571|NCT04527848|Active Comparator|large amount of diluted C3f8|
89062572|NCT04527848|Active Comparator|small amount of undiluted SF6|
89062573|NCT04527848|Active Comparator|large amount of diluted SF6|
89062574|NCT01606059|Active Comparator|DW-0919|
89062575|NCT01606059|Experimental|DW-0920|
89062576|NCT01606293||Carcinomas of the Cervix Survey|Women with small and large cell carcinomas of the cervix, who are members of the Facebook group found at the uniform resource locator https://www.facebook.com/SmallCellCC through an online link.
89062577|NCT04527809|Experimental|tDCS-active|tDCS-active will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area.
89062578|NCT04527809|Sham Comparator|tDCS-sham|tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. For the TDCS-sham the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
89062579|NCT01606332|No Intervention|Single in interscalene block|Single indwelling interscalene block with ropivacaine 0.5% 10ml
89062580|NCT01606332|Experimental|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
89062581|NCT01606371|Placebo Comparator|Healthy-Placebo|Placebo (capsule) administered once, orally
89062582|NCT01606371|Experimental|Healthy-2.5 mg LY2409021|2.5 mg LY2409021 administered once, orally
89062583|NCT01606371|Experimental|Healthy-10 mg LY2409021|10 mg LY2409021 administered once, orally
89062584|NCT01606371|Experimental|Healthy-30 mg LY2409021|30 mg LY2409021 administered once, orally
89062585|NCT01606371|Experimental|Healthy-100 mg LY2409021|100 mg LY2409021 administered once, orally
89062586|NCT01606371|Experimental|Healthy-250 mg LY2409021|250 mg LY2409021 administered once, orally
89062587|NCT01606371|Experimental|Healthy-500 mg LY2409021|500 mg LY2409021 administered once, orally
89221524|NCT01027390|Experimental|3 x 20 min training 50% supervision|3 x 20 min training 50% supervision
89221525|NCT01027390|Experimental|3 x 20 min training initial instructions|3 x 20 min training initial instructions
89221526|NCT01027390|Experimental|10 x 6 min training 50% supervision|10 x 6 min training 50% supervision
89221527|NCT01027390|No Intervention|reference|no training
89221528|NCT03034642|Experimental|Healthy Participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
89221529|NCT03034642|Experimental|COPD participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
89221530|NCT04839562|Experimental|solriamfetol|Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
89221531|NCT04839562|Placebo Comparator|placebo|Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
89221532|NCT04888624|Experimental|DrySee® dressing with moisture detection|DrySee® dressing with moisture detection
89221533|NCT04888624|Active Comparator|Tegaderm® + Pad transparent film dressing|Tegaderm® + Pad transparent film dressing
89221534|NCT01030978|Experimental|Family-based Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
89221535|NCT01030978|Active Comparator|Standard Diet & Activity Education (Control)|
89221536|NCT01029574|Experimental|Rotator cuff repair plus PRP|Conventional arthroscopic repair of rotator cuff with application of PRP.
89221537|NCT01029574|Placebo Comparator|Rotator cuff repair alone|Conventional arthroscopic repair of rotator cuff without application of PRP
89221538|NCT03316222|Experimental|Dose escalation|Dose escalation using 3+3 design with dose limiting toxicity (DLT) observation period of 28 days.
89221539|NCT03316222|Experimental|Dose Expansion|Additional patients will be enrolled into the recommended dose. These additional patients will undergo all of the same assessments as the patients enrolled in dose escalation with the exception of PK sampling.
89221540|NCT01024114||Positive MBI scan|Women who are previously enrolled in an MBI study that present with a positive MBI scan.
89221541|NCT03742492|Experimental|Canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
89221542|NCT03742492|Placebo Comparator|Canned tuna + soybean oil|Meal containing canned tuna + soybean oil
89221543|NCT00441064|Experimental|Diet Sequence Low/High Sodium|Patients on low sodium diet ( <= 100 mmol/day) for the first 4 weeks and high sodium (>= 200 mmol/day) diet for the next 4 weeks. [with Aliskiren 300 mg]
89221544|NCT00441064|Experimental|Diet Sequence High/Low Sodium|Patients on high sodium (>= 200 mmol/day) diet for the first 4 weeks and on low sodium diet ( <= 100 mmol/day) for the next 4 weeks. [with Aliskiren 300 mg]
89221545|NCT03962738|Experimental|50 milligram (mg) Lasmiditan|50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
89221546|NCT03962738|Experimental|100 mg Lasmiditan|100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
89221547|NCT03962738|Experimental|200 mg Lasmiditan|200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
89221548|NCT03962738|Placebo Comparator|Placebo|Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.
89221549|NCT05280002|Experimental|Adipose Tissue derived Total-Stromal-Cells (TOST)|Adipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cells plus standard conservative care.
89221550|NCT05280002|No Intervention|Control|Standard Conventional Treatment
89221551|NCT00561392|Experimental|Rivastigmine 5 and 10 cm^2 patch|For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm^2 patch, with adjustments as necessary for safety and tolerability.
89221552|NCT00694109|Experimental|Mipomersen|Mipomersen Sodium once a week for up to 4 years (depending on participant's consent). Participants were followed for additional 24 week post-treatment.
89221553|NCT03137693|Other|Change in Procedure Scheduling|Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
89221554|NCT03078491|Experimental|Intervention|The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.
88821198|NCT04919564|Placebo Comparator|Placebo group|Continuous NaCl 0.9% 2 cc/hour for a period of 12 hours begins since anesthetic induction
89062588|NCT01606371|Placebo Comparator|Diabetic-Placebo|Placebo (capsule) administered once, orally
89062589|NCT01606371|Experimental|Diabetic-75 mg LY2409021|75 mg LY2409021 administered once, orally
89062590|NCT01606371|Experimental|Diabetic-200 mg LY2409021|200 mg LY2409021 administered once, orally
89062591|NCT01606371|Experimental|Diabetic-500 mg LY2409021|500 mg LY2409021 administered once, orally
89062592|NCT04527653|Experimental|Tixel Treatment|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology
89062593|NCT01606410||young, sedentary|
89062594|NCT01606410||young, active|
89062595|NCT01606410||old, sedentary|
89062596|NCT01606410||old, active|
89062597|NCT01648712|Other|Balance Circuit|24 patients will be assigned to the Balance group , using a non -heparin extracorporeal pediatric device for operation . The intervention is to use the Balance circuit for this arm
89062598|NCT01648712|Other|Carmeda Circuit|"24 patients will be assigned to the Carmeda group, using a coated heparin extracorporeal pediatric device for operation.~The intervention is to use the Carmeda circuit for this arm. The intervention is the Carmeda circuit."
89062599|NCT01606449||Group 1|Group 1 = Patients with type II Hiatal Hernia submitted to surgical therapy
89062600|NCT01606449||Group 2|Group 2 = Patients with type III Hiatal Hernia submitted to surgical therapy
89062601|NCT01606449||Group 3|Group 3 = Patients with type IV Hiatal Hernia submitted to surgical therapy
89062602|NCT04527536||early-set BMJ group|Infants were admitted to our hospital at 4-7 days of age and were followed up to 28 days. Other pathological jaundice factors were excluded.Those who met the criteria were the early-onset BMJ group.
89062603|NCT04527536||late-onset BMJ group|Infants were admitted to our hospital after 7 days of age and were followed up to 28-42 days or until the jaundice disappeared. Other pathological jaundice factors were excluded..Those who met the criteria were late-onset BMJ
89062604|NCT04527536||healthy control|During the same period, the healthy newborns who were born in the obstetrics department of our hospital. These newborns were mainly breastfed or breastfed, and grew well. They were enrolled at 7-14 days of age and were followed up to 28-42 days without pathological jaundice.
89062605|NCT05140629|Placebo Comparator|Placebo (OGTT)|The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water.
89062606|NCT05140629|Experimental|Intervention (OGTT plus Baobab fruit extract)|The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW).
89062607|NCT01608165|Other|Partial nephrectomy|Patients randomised to this arm will undergo a partial nephrectomy
89062608|NCT01608165|Other|Radiofrequency ablation|Patients randomised to this arm will undergo radiofrequency ablation
89062609|NCT01608165|Other|cryoablation|Patients randomised to this arm will undergo cryoablation
89062610|NCT01688544|Experimental|Ilaprazole|"Before Ilaprazole dosing, 24 hours intragastric pH monitoring is performed as baseline value.~After 7 days dosing of Ilaprazole 10 mg, 24 hours intragastric pH monitoring, serum gastrin level check, and pharmacokinetic sampling is performed"
89062611|NCT01683968||Sickle cell|Patient who are admitted with sickle cell crises
89062612|NCT01688583||Fentanyl matrix|
89062613|NCT01648829|Active Comparator|Atorvastatin|os, 20 mg, once per day, for 30 days
89062614|NCT01648829|Active Comparator|Pitavastatin|os, 4 mg, once per day, for 30 days
89062615|NCT01688622|Other|Exercise|obese women who are volunteers for the 3 months exercise programs
89062616|NCT01648868|Experimental|Excitatory effects of rTMS|Study excitatory effects of rTMS applied to the STS in patients with autism
89062617|NCT01648868|Active Comparator|Inhibitory effects of rTMS|Study inhibitory effects of rTMS applied to the STS in healthy controls
89062618|NCT01688700|Experimental|Nimotuzumab plus chemotherapy|
89062619|NCT01684085|Placebo Comparator|Encouragement to sleep|Encouraging explanation to sleep, rest and receiving Lorazepam 1mg in the first night post trauma
89062620|NCT01684085|Experimental|Encouragement to deprived sleep|Encouraging explanation to deprived sleep in the first night post trauma
89062621|NCT01648985||Acute stroke and TIA patients|Cohort of acute stroke patients, admitted to the Stroke Unit Danderyd hospital 2010 - 2012
89062622|NCT01688817|Other|Physician's counseling|
89062623|NCT01688817|Active Comparator|Information leaflet|
89062624|NCT01684241|Experimental|RBL001/RBL002 intranodal administration|"All participants will be treated with RBL001/RBL002 after allocation to one of the four escalating dose cohorts:~Cohort-1 50 µg RBL001 and 50 µg RBL002~Cohort-2 100 µg RBL001 and 100 µg RBL002~Cohort-3 300 µg RBL001 and 300 µg RBL002~Cohort-4 600 µg RBL001 and 600 µg RBL002"
89062625|NCT01688934|Experimental|V116517 - 50 mg|V116517 50-mg tablets
89062626|NCT01688934|Experimental|V116517 - 30 mg|V116517 30-mg tablets
89062627|NCT01688934|Active Comparator|Naproxen 500 mg|Naproxen 500-mg capsules
89062628|NCT01688934|Placebo Comparator|Placebo|Placebo
89062629|NCT01684319|Placebo Comparator|Infant formula milk|Infant formula milk adapted to age of infant
89062630|NCT01684319|Active Comparator|Formula milk free of milk proteins|Milk-free formula milk adapted to age of infant
89062631|NCT02279576|Experimental|Pazopanib plus weekly paclitaxel|Pazopanib 800mg /day continuously administered plus paclitaxel 65 mg/m2 in weekly administration, 3 administrations (D1, D8 and D15) every 4 weeks period.
89062632|NCT02279615|Active Comparator|Treatment Group|(Mirabegron + Tamsulosin)
89062633|NCT02279615|Placebo Comparator|Control Group|(Placebo + Tamsulosin)
89062634|NCT01689051|Active Comparator|Healthy subjects|
89062635|NCT01689051|Active Comparator|Patients with type 2 diabetes|
89062636|NCT01684358|Experimental|Immediate implant|Sino-implant (II) inserted at enrollment visit
89062637|NCT01684358|Active Comparator|Delayed implant|Sino-implant (II) inserted at 3-month follow-up visit
89062638|NCT05140395|Experimental|Pre transfusion control|Pre control transfusion with the referent reagent and the in study reagent
89062639|NCT01684475|Experimental|Treatment with CJH1|
89062640|NCT05140356|Experimental|High amplitude repeated transcranial magnetic stimulation|Applied high amplitude repeated transcranial magnetic stimulation
89062641|NCT05140356|Experimental|Low amplitude repeated transcranial magnetic stimulation|Applied low amplitude repeated transcranial magnetic stimulation
89062642|NCT05140356|No Intervention|healthy control group|No intervention
89062643|NCT04528121|Experimental|study group|(CoDuSe) exercise inform of core stability, dual tasking, and sensory strategies the conventional selected exercise program inform of static and dynamic balance training exercises
89062644|NCT04528121|Experimental|control group|the conventional selected exercise program inform of static and dynamic balance training exercises
89062645|NCT01689090|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions at two examination days.
89062646|NCT01689090|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions at two examination days.
89062647|NCT01684553|Experimental|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
89062648|NCT01684553|Active Comparator|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
89062649|NCT01689129|Experimental|New formulation of insulin glargine|once daily in the evening on-top of mealtime insulin
89062650|NCT01689129|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of mealtime insulin
89062651|NCT01684631||Hip arthroplasty|Patients implanted with a PINNACLE® ULTAMET™ Metal-on-Metal implant for conventional total hip arthroplasty for the treatment of a severe hip disease or true femoral cervical fracture.
89062652|NCT01689168|Experimental|Counseling plus chiropractic adjustments|
89062653|NCT01689168|Active Comparator|Counseling alone|
89062654|NCT01689285|Active Comparator|valacyclovir tablet|Administration of 500 mg once daily on day 1 (group A) or on day 8 (group B)
89062655|NCT01689285|Experimental|valacyclovir oral solution|Administration of 500 mg once daily on day 1 (group B) or on day 8 (group A)
89062656|NCT01649063||the shape and frequency of uterine contractions in delivery|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
89062657|NCT01649063||the shape and frequency of uterine contractions in cesarean|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
89062658|NCT01649102|Experimental|Palindroom catheter|Insertion of Palindroom catheter
89062659|NCT01649102|Experimental|Hemoglide Bard Catheter|Insertion of Hemoglide Bard Catheter
89062660|NCT01606527|Experimental|Ibuprofen|Ibuprofen 600mg taken three times daily for four days.
89062661|NCT01606527|Placebo Comparator|placebo|Avicel placebo capsules three times daily for four days
89062662|NCT01684670|Experimental|Behavioral speech treatment|
88821199|NCT04913064|Experimental|Prevention (white button mushroom)|Participants receive white button mushroom PO daily for 3 months in the absence of disease progression or unacceptable toxicity.
89062663|NCT01609335|Other|Cognitively Normal Subjects|Study participation will consist of tests of memory and thinking, a MRI, and two PET scans. F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.
89062664|NCT01609374|Experimental|M6-C Artificial Cervical Disc|
89062665|NCT01609374|Active Comparator|Anterior Cervical Discectomy and Fusion|
89062666|NCT01606605||Diffuse large B-cell lymphoma|Patients diagnosed and treated at the Samsung Medical Center
89062667|NCT01684709|Experimental|Telemonitoring + self-management support|Automated assessment calls with follow-up by a Care Manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up.
89062668|NCT01684709|No Intervention|Usual Care|Usual Care
89062669|NCT01649141|Experimental|Treatment Group|Trauma-Focused Cognitive Behavioral Therapy
89062670|NCT01609413|Experimental|AlgaeCal|Calcium supplements derived from ocean algae. One dose equals 3 capsules containing 180 mg calcium each.
89062671|NCT01609413|Active Comparator|Caltrate 600|Proprietary calcium supplement. One dose contains 600 mg of calcium.
89062672|NCT02279966|Experimental|Vortioxetine 10 mg|daily, encapsulated, orally
89062673|NCT02279966|Other|Paroxetine 20 mg (active reference)|daily, encapsulated, orally
89062674|NCT02279966|Placebo Comparator|Placebo|capsules, orally
89062675|NCT01606644|Experimental|HBO|30 90-minute hyperbaric oxygen sessions at 2.4 atm.
89062676|NCT01606644|No Intervention|No HBO|No intervention. No hyperbaric oxygen is administered. Otherwise, the patient will follow the examination program.
89062677|NCT01684787|Experimental|1|Peginterferon alfa-2a + ribavirin in normal ALT
89062678|NCT01684787|Active Comparator|2|peginterferon alfa-2a + ribavirin in elevated ALT
89062679|NCT01606683|Experimental|GROUP 1|Infant formula supplemented with with functional ingredients (galacto-oligosaccharides, beta-palmitate, fermented milk). Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae.
89062680|NCT01606683|Other|GROUP 2|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
89062681|NCT01606683|Other|CONTROL GROUP|Breast milk
89062682|NCT01649219|Experimental|Exercise intervention|3-month supervised exercise intervention 3 times per week; 60min per time.
89062683|NCT01649219|No Intervention|No intervention|Standard couselling at baseline
89062684|NCT01609452|Experimental|Blisibimod|
89062685|NCT01609452|Placebo Comparator|Placebo|
89062686|NCT01649258|Experimental|Supportive care (antiemetics)|Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine IV over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.
89062687|NCT01649336|Experimental|MEK162 + paclitaxel|
89062688|NCT01609491|Active Comparator|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) will be used in the syringes
89062689|NCT01609491|Active Comparator|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
89062690|NCT04527341||cardiac surgery patients in ICU|
89062691|NCT01606917|Experimental|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity.
89062692|NCT01606917|No Intervention|Usual care|Usual care
89062693|NCT01684865||Non-Hodgkin's Lymphoma Participants|Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will receive rituximab for maximum two years or until disease progression. Participants will be followed for one year after last dose of rituximab administered as maintenance.
89062694|NCT01606956|Experimental|resting volume group|
89062695|NCT01606956|Active Comparator|half the maximum volume group|
89062696|NCT01685099||Group with tuberculous pleurisy|
89062697|NCT01685099||Group with non-tuberculous pleurisy|
89062698|NCT01609569||coronary complication|"patients with coronary complication and patients without coronary complications.~pro-calcitonin will be measured in both groups to see if any correlation."
89062699|NCT01649453||Cancer of uncertain primary|
89062700|NCT01580163|Experimental|JITAI combined therapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
89062701|NCT01580163|Experimental|Methadone combined herapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
89062702|NCT01580163|Experimental|JITAI therapy group|The investigator will adopt JITAI combined social support in Shanghai-related community and outside of Shanghai.
89062703|NCT01685177||SADI|Patients submitted to a second-step operation after a failed sleeve on which a single-anastomosis duodena-ileal bypass at 250 cm from the cecum is performed.
89062704|NCT01609647|Experimental|Prasugrel|Reloading with prasugrel 20mg & followed by administration of 5mg/day for 30 days
89062705|NCT01609647|Active Comparator|Clopidogrel|Reloading with clopidogrel 300mg and followed by administration of clopidogrel 75 mg/day for 30 days
89062706|NCT01649492|No Intervention|diclofenac without pineapple juice|single dose of diclofenac 25 mg without pre-exposure to pineapple juice
89062707|NCT01649492|Active Comparator|diclofenac with pineapple juice|single dose of diclofenac 25 mg with pre-exposure to pineapple juice
89062708|NCT01580202|Active Comparator|Lamivudine|LAM (100 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
89062709|NCT01580202|Experimental|Entecavir|ETV (0.5 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
89062710|NCT01649570|Experimental|Insulin aspart|
89062711|NCT01685294|No Intervention|Treatment as Usual (TAU)|Standard prison mental health treatment instead of the research groups, including individual therapy, medication, etc.
89062712|NCT01685294|Experimental|Group Interpersonal Psychotherapy (IPT) for Depression + TAU|Participants will receive Group IPT for Depression + TAU.
89062713|NCT01685450|Other|Intracranial pressure|
89062714|NCT01609764|Experimental|Exercise|Follows the fitness program as described in the intervention
89062715|NCT01609764|No Intervention|Control|Will not follow any regular fitness activity during one year
89062716|NCT01609803||Correlative studies|Formalin-fixed paraffin-embedded tissue samples are analyzed for 12q13-q14 frequency and protein overexpression by FISH and IHC.
89062717|NCT01649648|Experimental|Intervention|Autologous cord blood cells arm
89062718|NCT01609881|Other|Acuvail|Acuvail as preventive for inflammation and possible decrease or prevent diabetic retinopathy. The study has four arms - diabetic ketorolac, diabetic control, normal eyes ketorolac, normal eyes control. patients are randomized to ketorolac or control.
89062719|NCT01609881|Placebo Comparator|Placebo|Placebo using artificial tear drops
89062720|NCT01649687|Experimental|Mesenchymal stem cells(MSC) treatment|All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells
89062721|NCT01609920|Experimental|Gadofosveset MRL|
89062722|NCT04527458||Hospitalisations|All hospitalised COVID patients
89062723|NCT04527458||Critical care|All hospitalised COVID patients in critical care
89062724|NCT01609959|Active Comparator|Azilsartan group|
89062725|NCT01609959|Active Comparator|Valsartan group|
89062726|NCT01649726|Other|Standard strategy|Apnea test according to recommendations
89062727|NCT01649726|Experimental|CPAP strategy|Apnea test with CPAP connection
89062728|NCT01609998|Experimental|Group 1A (12-17yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
89062729|NCT01609998|Experimental|Group 1B (6-11yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
89062730|NCT01609998|Experimental|Group 2A (12-17yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
89062731|NCT01609998|Experimental|Group 2B (6-11yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
89062732|NCT01609998|Active Comparator|Group 3A: (12-17yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
89062733|NCT01609998|Active Comparator|Group 3B: (6-11yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
89062734|NCT04527263|Active Comparator|group A|subjected to institutional protocol of diagnosis of acute appendicitis
88821200|NCT04908800|Experimental|Part A single ascending dose (SAD) and Part B multiple ascending dose (MAD): KRP-A218|Administration Route: Oral
88821201|NCT04908800|Placebo Comparator|Part A (SAD) and Part B (MAD): Placebo|Administration Route: Oral
89062735|NCT04527263|Active Comparator|group B|subjected to institutional protocol of diagnosis of acute appendicitis plus measurement of urinary 5-HIAA
89062736|NCT01649882|Experimental|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
89062737|NCT01685528|Experimental|CBT|
89062738|NCT01685645|Experimental|Study population|"The study population consists of male and female patients admitted for programmed major knee surgery (arthroplasty) with a truncal analgesic block (femoral nerve block with a sciatic block) and operated under general anesthesia.~See inclusion and exclusion criteria.~Intervention: AlgiScan"
89062739|NCT01649921|Active Comparator|Interferon-gamma|
89062740|NCT01649921|Placebo Comparator|Saline 0.9%|
89062741|NCT01606566|Experimental|Amphinex induced PCI of bleomycin|"Drug: Amphinex induced PCI of bleomycin~Intervention:Intravenous administration of Amphinex (day 0) followed by intravenous administration of bleomycin and laser light application (day 4). Laser light application could be both interstitial and/or superficial depending on the tumour location."
89062742|NCT01644968|Experimental|KLH + anti-OX40|Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
89062743|NCT01644968|Experimental|Tetanus vaccine + anti-OX40|Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH
89062744|NCT01605708|Experimental|Cohort 1|
89062745|NCT01685723|Experimental|Counseling group|"Subjects in this group will receive a face-to-face individualized brief advice based on risk communication for 15-30 minutes from the nurse counselors and a booster intervention (10-15 minutes) at 1 week.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone.Ten subjects from the intervention group who have not quitted will be invited for a process evaluation in the form of face-to-face interviews by research assistants at 12-month follow-up."
89062746|NCT01685723|Sham Comparator|General supporting|"Subjects in this group will receive standard care without risk communication.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone."
89062747|NCT01605162|Experimental|E7016 plus TMZ|
89062748|NCT01649999|Experimental|ASP015K lowest dose|Oral
89062749|NCT01649999|Experimental|ASP015K low dose|Oral
89062750|NCT01649999|Experimental|ASP015K medium dose|Oral
89062751|NCT01649999|Experimental|ASP015K high dose|Oral
89062752|NCT01649999|Placebo Comparator|Placebo|Oral
89062753|NCT01604889|Experimental|Epacadostat 300 mg|300 mg twice daily (BID) in combination with ipilimumab
89062754|NCT01604889|Placebo Comparator|Placebo in combination with ipilimumab|
89062755|NCT01604889|Experimental|Epacadostat 25 mg|25 mg BID in combination with ipilimumab
89062756|NCT01604889|Experimental|Epacadostat 50 mg|50 mg BID in combination with ipilimumab
89062757|NCT01604889|Experimental|Epacadostat 75 mg|75 mg once a day (QD) in combination with ipilimumab
89062758|NCT01685762|Experimental|Metformin|Metformin once daily for 4 weeks (weeks 1-4) and then twice daily for 8 weeks (weeks 5-12).
89062759|NCT01600833||Obese women|BMI>25
89062760|NCT01600833||Non obese women|BMI<25
89062761|NCT01685879|Experimental|High Amylose Rice 1|Test rice with high dietary fiber content
89062762|NCT01685879|Experimental|High Amylose Rice 2|Test rice with high dietary fiber content
89062763|NCT01685879|Placebo Comparator|Control Rice|Rice portion that contains 50 g carbohydrate.
89062764|NCT01685879|Placebo Comparator|Glucose beverage|Glucose beverage with 50 g carbohydrate
89062765|NCT01602822|Other|Atazanavir, Ritonavir, Truvada|Open Label
89221555|NCT03078491|No Intervention|Attention Control|The attention control group will receive an android tablet pre-loaded with activity monitor devices, education material, and weblink to online education and surveys. However, the data will not be analyzed by CDS. An independent physician and a study staff member- only caring for the control group subjects will review the insulin and glucose data at in-person and remote study visits and make appropriate dosing adjustments based on self monitoring glucose levels
89221556|NCT00562484|Experimental|1|
89221557|NCT00562484|Other|2|
89221558|NCT00944762|Experimental|Ecosystem Focused Therapy (EFT)|Participants will receive EFT.
89221559|NCT00944762|Active Comparator|Education in stroke and depression|Participants will receive education in stroke and depression.
89221560|NCT04012892|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
89221561|NCT00940862|Experimental|adalimumab|A total of 20 patients will be randomized to adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
89221562|NCT00940862|Active Comparator|Non-systemic treatment.|A total of 10 patients will be randomized to non systemic therapy for psoriasis (topical treatments and/or UVB phototherapy).
89689929|NCT03126370|Experimental|TAF with a boosted PI and LDV/SOF|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for the next 12 weeks.~After taking TAF/FTC for 12 weeks, participants will then start taking ledipasvir 90mg/sofosbuvir 400mg (LDV/SOV, Harvoni) in combination with TAF/FTC and a boosted protease inhibitor for 4 weeks.~Participants will then return to taking TAF/FTC with a boosted protease inhibitor for the final 12 weeks of the study."
89689930|NCT00979459|Experimental|MK-1006 80 mg DFC|Participants received a single dose of four 20 mg dry filled capsules of MK-1006
89689931|NCT00979459|Experimental|MK-1006 80 mg FCT|Participants received a single dose of two 40 mg film coated tablets of MK-1006
89689932|NCT03126448|Other|Group 1: Closed Index Fractures|Group 1 is clean, closed fractures undergoing index open reduction internal fixation (ORIF), intramedullary nailing (IMN) where the fracture site is accessible, or staged treatment of a pilon or plateau that was initially treated by joint spanning external fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
89689933|NCT03126448|Other|Group 2: Hardware Removal from Healed Fractures|Group 2 will include patients having a plate removed from a healed fracture without clinical evidence of infection and excluding history of open fracture. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
89689934|NCT03126448|Other|Group 3: Index Treatment of Fracture Nonunions|Group 3 will be patients that are undergoing an index procedure for fracture nonunion at a site where prior surgery has been undertaken for the fracture. Exclusions include bone grafting of 'critical' defects, active clinical infection, or < 3 months from index fracture fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
89689935|NCT01019707|Placebo Comparator|Sugar pill|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
89689936|NCT01019707|Active Comparator|Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
89689937|NCT04457271|Experimental|Goal Management Training (GMT)|Participants in this arm will attend 9 weekly, 2-hour group GMT appointments.
89689938|NCT04457271|No Intervention|Wait List|Participants in this arm will receive no treatment for approximately 21 weeks (at which point, they will be offered the same, standard GMT treatment).
89689939|NCT00979615|Experimental|1|Olopatadine HCL Nasal Spray, 0.6%
89689940|NCT00979615|Active Comparator|2|Azelastine HCl Nasal Spray, 137 mcg
89689941|NCT03126682|Active Comparator|Wellbutrin during ECT 1|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 1
89689942|NCT03126682|Active Comparator|Wellbutrin during ECT 2|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 2.
89689943|NCT05236738|Experimental|Treatment Sequence Group 1|
89689944|NCT05236738|Experimental|Treatment Sequence Group 2|
89689945|NCT05236738|Experimental|Treatment Sequence Group 3|
89689946|NCT00980395|Experimental|VCR (Velcade, Cladribine and Rituximab)|"Rituximab 375 mg/m2 IV day1~Cladribine 4 mg/m2 IV over 2 hours days 1-5~Bortezomib 1.3 mg/m2 IV days 1 and 4~Repeat every 28 days for a maximum of 6 cycles"
89689947|NCT03072550|Experimental|Multi-center open label|Thirty Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
89689948|NCT01021111|Experimental|Activity Training with Feedback|Subject is tested prior to training and retested with feedback training designed to modify the mechanics of landing during jumping and running activities
89689949|NCT02976597|Active Comparator|Bupivacaine 0.25%|Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side on each side at end of the surgery.
89689950|NCT02976597|Active Comparator|Morphine 10mg|Morphine 10mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery.Patients will recieve 5mg morphine on each side
89689951|NCT02976597|Active Comparator|Morphine 15mg|Morphine 15mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery. Patients will recieve 7.5mg morphine on each side
89062766|NCT01644344|Active Comparator|X-ray|Control group: patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks. Each time radiographs are completed, the surgeon or resident will document if a change in fixation position is noted and if a change in patient management will be entertained (addition, modification or maintenance of cast or splint use, modification of or decision not to advance activity level, need for further surgery to adjust fixation or fracture reduction). The patients' time spent in clinic will be recorded upon arrival and upon completion of the patient-physician interaction.
89062767|NCT01644344|Active Comparator|No X-ray|
89062768|NCT02273154|Experimental|paroxetine and buspirone group|receive paroxetine (20-60mg/d) and buspirone(30mg/d)
89062769|NCT02273154|Active Comparator|paroxetine group|receive paroxetine (20-60mg/d)
89062770|NCT01644656|Experimental|acoustic radiation force impulse (ARFI)|Imaging of liver and spleen using modified ultrasound
89062771|NCT01607541|Experimental|Peer-driven intervention|"The PDI entails structured intervention sessions including a computerized CARE for Prevention tool and HIV pre-test and post-test counseling, the opportunity to educate three peers on core education messages, and navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and six months of navigation)"
89062772|NCT01607541|Active Comparator|Control|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
89062773|NCT02273193||Pregnant Women|Pregnant Women in the first trimester (<13 weeks) of pregnancy and the second trimester of pregnancy.
89062774|NCT01644851|Experimental|Executive function training|Executive function training
89062775|NCT01644851|Placebo Comparator|Word game training|Computer-based training in tasks related to verbal processing.
89062776|NCT01603836|Experimental|bone marrow concentrate|In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
89062777|NCT01645046|Active Comparator|Coenzyme A 200mg|Coenzyme A 200mg per day.
89062778|NCT01645046|Placebo Comparator|Placebo|Capsule without coenzyme A.
89062779|NCT01645046|Active Comparator|Coenzyme A 400mg|Coenzyme A 400mg per day.
89062780|NCT01605006|Other|NeuRx Diaphragm Pacing System (DPS)|Surgical implantation of the NeuRx DPS (on label use).
89062781|NCT01606215|Experimental|mesenchymal stem cells|1-2 x106 MSCs/kg administered at Week 0
89062782|NCT01606215|Sham Comparator|Placebo|Suspension media administered at Week 0
89062783|NCT01607775|Active Comparator|PEEK-cage|Patients will receive a PEEK-cage
89062784|NCT01607775|Experimental|PMMA-cage|
89062785|NCT01685957|Active Comparator|Standard dietary treatment (STD)|Dietary treatment - 6 individual sessions with a registered dietitian
89062786|NCT01685957|Experimental|"Ned i vaegt (NIV)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
89062787|NCT01685957|Experimental|"Verdens bedste kur (VBK)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
89062788|NCT01602393|Experimental|CHF 5074 1x|oral tablet, multidose
89062789|NCT01602393|Experimental|CHF 5074 2x|oral tablet, multidose
89062790|NCT01602393|Experimental|CHF 5074 3x|oral tablet, multidose
89062791|NCT01686074||Chronic fatigue syndrome|
89062792|NCT01686074||fibromyalgia|
89062793|NCT01686074||chronic fatigue syndrome + fibromyalgia|
89062794|NCT01686074||healthy sedentary control|
89062795|NCT01645787|Active Comparator|4-aminopyridine (Ampyra)|10 mg tab/ 1 tab twice daily
89062796|NCT01645787|Placebo Comparator|Sugar pill|Placebo 1 tab /twice daily
89221563|NCT04012580|Experimental|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the program, participants will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact provided on a weekly basis.
89221564|NCT04012580|No Intervention|Treatment as usual control|Participants will not receive access to the transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) program for 12-weeks. Participants will be permitted to access community resources (e.g., support groups). After 12-weeks, participants will be offered the program although their treatment data will not be included in the current study.
89221565|NCT03937661|Experimental|Group of participants receiving PRP treatment|Women presenting with POR, treated with autologous PRP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period.
89221566|NCT03937661|Placebo Comparator|Control Group: participants receiving Platelet Free Plasma|Women presenting with POR, treated with autologous PFP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period
89221567|NCT04012502|Active Comparator|conventional treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
89221568|NCT04012502|Experimental|Toxicities reduced treatment arm|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
89221569|NCT04062149|Active Comparator|Control Group|The control group will be the group where the participants receive only their normal physiotherapy treatment.
89221570|NCT04062149|Experimental|Experimental Group|The experimental group will be the group where participants receive physiotherapy aimed at improving their ability to stand on their weaker leg alongside their normal physiotherapy treatment.
89221571|NCT02565563|Active Comparator|Eye Movements|Eye Movement Desensitisation Reprocessing with eye movements (measuring Heart Rate Variability using HeartMath)
89221572|NCT02565563|Active Comparator|No Eye Movements|Eye Movement Desensitisation Reprocessing without eye movements (measuring Heart Rate Variability using HeartMath)
89221573|NCT00921479||Females|Norwegian females Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar.
89689952|NCT03020329|Experimental|Paclitaxel liposome, Cisplatin, 5-Fu,|Patients receive paclitaxel liposome(135mg/m2 on day 1), cisplatin (75mg/m2 on day 1,Separate injection on day 1 to 3) and fluorouracil (3750mg/m2 CIV 120h) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy(Intensive modulate radiotherapy,IMRT)and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
89221574|NCT00921479||Males|Norwegian males of Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar
89221575|NCT00561080|Experimental|Single Dose of Zostavax|Zostavax 0.65mL intramuscular injection administered on Day 0
89689953|NCT05395975||Group I|Preoxygenation with 100% oxygen for 3 minutes
89689954|NCT05395975||Group II|4 deep breaths with 100% oxygen in 30 seconds
89689955|NCT00980785|Placebo Comparator|Placebo|Matching Placebo
89689956|NCT00980785|Experimental|Active|Ramipril 5mg/day
89689957|NCT03019861|Active Comparator|Ayurvedic nutritional counseling|Patients will receive three Ayurvedic nutritional counselings (according to tradition) after 1, 3 and 8 weeks after Baseline.
89689958|NCT03019861|Active Comparator|Conventional nutritional counseling|Patients will receive three conventional nutritional counselings (according to German Nutrition Society - DGE) after 1, 3 and 8 weeks after Baseline.
89689959|NCT00981253|Experimental|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation with weekly stress management training for 12 weeks.
89689960|NCT00981253|Active Comparator|Standard Cardiac Rehabilitation|Standard cardiac rehabilitation consisting of supervised exercise for 12 weeks.
89689961|NCT03019705||Participants|Individuals with pathological health anxiety
89689962|NCT03126760|Experimental|Acthar Gel|Participants receive Acthar Gel under the skin once a day for 14 consecutive days
89689963|NCT03126760|Placebo Comparator|Placebo|Participants receive Placebo under the skin once a day for 14 consecutive days
89689964|NCT00982033|Active Comparator|Aliskiren|50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo.
89689965|NCT00982033|Placebo Comparator|Placebo|50% of subjects will be randomized to placebo.
89689966|NCT03127228|Other|Standard mechanical debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with dental scalers.
89689967|NCT03127228|Experimental|Er:YAG laser-assisted debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with the aid of the laser treatment.
89689968|NCT05026905|Other|GASL arm|"eligible patients will receive gemcitabine 800 mg/m2 on day 1, nab-paclitaxel 125 mg/m2 on day 1, S-1 orally 60-100 mg/day [depending on patient's baseline body surface area (BSA)] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~BSA < 1.25 m2: 60 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 80 mg/day~BSA ≥ 1.5 m2: 100 mg/day"
89689969|NCT05026905|Other|GAP arm|eligible patients will receive gemcitabine 800 mg/m2, nab-paclitaxel 125 mg/m2 and oxaliplatin 75mg/m2 on day 1 in a 2-week cycle.
89689970|NCT00982189|Experimental|Lisinopril|Lisinopril 10mg once daily
89689971|NCT00982189|Placebo Comparator|Lisinopril Placebo|Placebo pill (matched to lisinopril) once daily
89689972|NCT00982189|Experimental|Pravastatin|Pravastatin 20mg once daily
89689973|NCT00982189|Placebo Comparator|Pravastatin placebo|Placebo pill (matched to pravastatin) once daily
89689974|NCT03019471||Lung cancer|Isolate Tumor DNA from the patients blood.
89689975|NCT03019471||Breast cancer|Isolate Tumor DNA from the patients blood.
89689976|NCT03019471||Colorectal cancer|Isolate Tumor DNA from the patients blood.
89689977|NCT03019471||Glioma|Isolate Tumor DNA from the patients blood.
89062797|NCT02270034|Experimental|Cohort crizotinib|Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
89062798|NCT01686113|Experimental|NEFA|Participants swish and spit 5 mL of an oleic acid solution everyday for 10 days.
89062799|NCT01686113|Active Comparator|Control|Participants swish and spit 5 mL of sucrose solution everyday for 10 days.
89062800|NCT02270190|Other|tenesmus patients|Percutaneous Tibial Nerve Stimulation (PTNS) will be applied to all patients in the study
89062801|NCT01686230|Experimental|acupoints on specific meridian|Acupuncture plus foundation treatment。 We Select specific acpupoints on the heart and pericardium meridian.
89062802|NCT01686230|Active Comparator|acupoints on the other meridian|Acupuncture plus foundation treatment。We choose the acupoints on the other meridian。
89062803|NCT01686230|Sham Comparator|sham acupoints|Acupuncture plus foundation treatment。We use sham acupoints。
89062804|NCT01686230|Other|waiting-list|wait for the treatment，Only basic treatment, We will not treat the participants until they complete all the observations.
89062805|NCT02270229||Healthcare providers|
89062806|NCT02270229||PD patients|
89062807|NCT02270229||Primary caregivers of the PD patients|
89062808|NCT02270229||Laboratory personnel|
89062809|NCT02273271|Experimental|Imaging arm|18F-FLT-PET/CT and DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 4 cycles of chemotherapy
89062810|NCT01688414|Experimental|Diagnostic (fluorescence imaging, PAI)|Patients undergo fluorescence imaging and PAI during robot assisted laparoscopic surgery.
89062811|NCT02273349|Experimental|Treatment|Patients with Alpha-1-Antitrypsin deficiency treated with endoscopic lung volume reduction using Lung Volume Reduction Coils (PneumRx Inc.)
89062812|NCT01686308|Active Comparator|Conventional Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
89062813|NCT01686308|Experimental|Yellow Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
89062814|NCT02270268|Experimental|pectin|a kind of soluble dietary fiber
89062815|NCT02270268|Placebo Comparator|Placebo|maltodextrin
89062816|NCT01688531|Experimental|CD0271 0.1%/CD1579 2.5% gel|Split-face design, one application a day for 6 months
89062817|NCT01688531|Placebo Comparator|CD0271 0.1%/CD1579 2.5% gel vehicle|Split-face design, one application a day for 6 months
89062818|NCT02270307|Experimental|MSC+CY|Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery
89062819|NCT05140772|Active Comparator|group I|Patient were received 0.5gm/kg/day IV glutamine infusion (dipeptiven 100ml contains 20 g N(2)-L-alanyl-L-glutamine (= 8.20 g L-alanine, 13.46 g L-glutamine) Water for Injections).
89062820|NCT05140772|Placebo Comparator|group II|Patients received an equivalent volume of normal saline daily for 7 days.
89062821|NCT02270385|Experimental|Experimental group|The experimental group will be implemented a 16-week PU prevention programme. The PU prevention programme includes an intensive training on knowledge and skills ono PU prevention and also a PU prevention protocol. The purpose of the programme is to equip care staff with PU knowledge and skills and to guide especially health workers and personal care workers in PU prevention.
89062822|NCT02270385|Other|control group|The control group will be provided with the usual PU prevention care
89062823|NCT02270424|Experimental|Conventional medicine+ placebo TCM|Patients in this group will be given conventional medicine, Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three placebo TCM treatment, which are which are placebo Bufeijianpi granule, placebo Bufeiyishen granule and placebo Yiqizishen granule corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
89062824|NCT02270424|Experimental|conventional medicine+ TCM|Patients in this group will receive Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three types of TCM treatment, which are Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule. A herbal extract twice daily for 52 weeks for lower dosage. The three granules are corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
89062825|NCT01686347|Other|fetal cardiac rhythm abnormally|patient at term, in spontanous labor with fetal cardiac rythm abnormally which occurs 30 minutes after the epidural analgesia induction
89062826|NCT01686347|Other|control group|patient at term, spontaneous labor, without any fetal cardiac rhythm abnormalies during the 30 minutes after the epidural analgesia induction
89062827|NCT02270541|No Intervention|Control|Standard pre-hospital emergency care by the Paramedic Intervention Team, in accordance with their standing operating procedures.
89062828|NCT02270541|Experimental|Telemedicine|In-ambulance teleconsultation by a stroke expert aiming to support the Paramedic Intervention Team by focusing on patient identification, obtaining homeostasis (optimal control of blood pressure, blood oxygenation, temperature, heart rate and rhythm, glycemia), assessment of the patient's neurological status, stroke diagnosis, hospital notification, and patient selection for specific stroke treatment.
89062829|NCT01686425|Active Comparator|Percutaneous Transhepatic cholangiography|
89062830|NCT01686425|Active Comparator|Endoscopic Ultrasound guided biliary drainage|
89062831|NCT02270619|Placebo Comparator|Uninterrupted sleep & placebo|Uninterrupted sleep followed by placebo
89062832|NCT02270619|Experimental|Uninterrupted sleep & endotoxin|Uninterrupted sleep followed by endotoxin 0.8 ng/kg of body weight IV bolus
89062833|NCT02270619|Experimental|Partial sleep deprivation & placebo|Partial sleep deprivation followed by placebo
88821202|NCT04908800|Experimental|Part C drug-drug interaction (DDI): KRP-A218 and itraconazole|Administration Route: Oral
89062834|NCT02270619|Experimental|Partial sleep deprivation & endotoxin|Partial sleep deprivation followed by endotoxin 0.8 ng/kg of body weight IV bolus
89062835|NCT05140616|Experimental|Study of Chidamide in the Treatment of Steroid-resistant/Steroid-dependent Severe cGVHD|Subjects receive twice a week dose of 15mg of Chidamide tablets
89062836|NCT01688570|Active Comparator|Duloxetine|Neuromuscular fatigue testing with duloxetine dose
89062837|NCT01688570|Active Comparator|Cyproheptadine|Neuromuscular fatigue testing with cyproheptadine dose
89062838|NCT01688570|Placebo Comparator|Placebo|Neuromuscular fatigue testing with placebo dose
89062839|NCT02270697||Regular Diagnosis|Difficult in regular diagnosis specimens, assistance with array.
89062840|NCT01686464|Experimental|Magnetic - Oxygen|Magnetic and Oxygen Treatment for Bell's Palsy
89062841|NCT01686464|Active Comparator|prednisone - valacyclovir|prednisone and valacyclovir treatments for bell palsy
89062842|NCT02270775||Fibromyalgia Patients|"The central Sensitization questionnaire will be filled in by each patients included.~After One week, patients will filled it the questionnaire again to study the reliability."
89062843|NCT02270775||Ankle sprain Patients|The central Sensitization questionnaire will be filled in by each patients included.
89062844|NCT02270775||Healthy Volunteers|"The central Sensitization questionnaire will be filled in by each volunteer included.~After One week, volunteers will filled it the questionnaire again to study the reliability."
89062845|NCT01686542|Experimental|CPVI+RSM group|Circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification for atrial fibrillation ablation.
89062846|NCT01686542|Active Comparator|CPVI group|Circumferential pulmonary vein isolation is done alone for atrial fibrillation.
89062847|NCT02270970|Active Comparator|Responders to Belimumab|This Arm is defined as patients who complete 6 months of belimumab without and meet the primary endpoint
89062848|NCT02270970|Active Comparator|Non Responders to Belimumab|This Arm is defined as patients who complete 6 months of study and do not meet the primary endpoint
89062849|NCT01688648|Experimental|Lidocaine group|a bolus dose of lidocaine 1.5 mg/kg after anesthetic induction with following lidocaine infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
89062850|NCT01688648|Experimental|Dexmedetomidine group|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
89062851|NCT01688648|Experimental|Combined infusion group|Combined lidocaine and dexmedetomidine infusion with the dose specified in single infusion group
89062852|NCT01688648|No Intervention|Control group|The group without infusion of lidocaine or dexmedetomidine
89062853|NCT02271009|Placebo Comparator|Placebo without Al(OH)3|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
89062854|NCT02271009|Active Comparator|AllerT (10 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
89062855|NCT02271009|Active Comparator|AllerT (25 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
89062856|NCT02271009|Active Comparator|AllerT (50 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
89062857|NCT01686659|Experimental|SpHb Arm|These are the patients whose primary anesthesiologists have been allocated to treat them while having access to data from a continuous noninvasive hemoglobin monitoring device
89062858|NCT01686659|No Intervention|Control Arm|These are the patients whose primary anesthesiologists have been allocated to treat them without having access to data from a continuous noninvasive hemoglobin monitoring device
89062859|NCT02271048|Experimental|Group I|"The raters in this group one firstly review ultrasound images numbered from one to 50 using LCD monitor of ultrasound machine and after mandatory rests of 20 minutes, review the remaining ultrasound examinations numbered from 51 to 100 using iPhone display with CubeView at their first visit.(Remote ultrasonography interpretation using the smartphone)~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
89062860|NCT02271048|Experimental|Group II|"The raters in this group II firstly review the ultrasound images numbered from one to 50 using iPhone with CubeView (Remote ultrasonography interpretation using the smartphone) and 51 to 100 with the LCD monitor.~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
89221576|NCT00561080|Experimental|Zostavax - Day 0 and Month 1|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1
89221577|NCT00561080|Experimental|Zostavax - Day 0 and Month 3|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3
89221578|NCT01307306|Experimental|Metformin|
89221579|NCT01307306|Experimental|Insulin|
89221580|NCT01307306|No Intervention|Control|
89221581|NCT04012424|Experimental|Drug (400mg Curcumin) Curcumin is apice|"Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~patients will take 400mg capsule curcumin one hour before endodontic treatment and study its effect on post endodontic pain immediately and after 8,12,24,48 hours after completion of endodontic treatment"
89221582|NCT04012424|Placebo Comparator|Starch(400mg starch) starch is sometype of carbohydrates|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
89221583|NCT00562094||Pantoprazole|
89221584|NCT03817853|Experimental|Obinutuzumab+Chemotherapy|Participants received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone [CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone [CVP - 21-day cycle]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator is free to choose the chemotherapy for each patient. Obinutuzumab and chemotherapy is administered during induction phase and obinutuzumab monotherapy is administered during maintenance phase.
89221585|NCT02565251|Experimental|Sepsis grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
89221586|NCT02565251|Experimental|Sepsis grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
89221587|NCT02565251|Experimental|Soc septic grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
89221588|NCT02565251|Experimental|Soc septic grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours
89221589|NCT03890705||postpartum women|Women aged (15-49) and had given birth in the past 12 months
89221590|NCT02565095|Other|Carotid Baroreflex measurements|
89221591|NCT02567045|Experimental|Fecal occult blood testing|"Annual FIT and colonoscopy in case of a positive test. Fecal occult blood testing: annual FIT (two rounds) without diet restriction, one stool sample. Positive cut-off = 10 μg Hemoglobin/g feces.~Colonoscopy will be performed in case of a positive FIT."
89221592|NCT02567045|Active Comparator|one-time Colonoscopy|One-time Colonoscopy with sedation
89221593|NCT00944840|Active Comparator|SP and amodiaquine|Study subjects received intermittent preventive treatment with SP plus amodiaquine.
89221594|NCT00944840|Placebo Comparator|SP placebo plus amodiaquine placebo|Intermittent preventive treatment with SP placebo and amodiaquine placebo
89221595|NCT00439270|Active Comparator|Dasatinib, 50 mg + Docetaxel, 60 mg/m^2|Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m^2.
89221596|NCT00439270|Active Comparator|Dasatinib, 50 mg + Doxetaxel, 75 mg/m^2|Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
89221597|NCT00439270|Active Comparator|Dasatinib, 70 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
89221598|NCT00439270|Active Comparator|Dasatinib, 100 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
89221599|NCT00439270|Active Comparator|Dasatinib, 120 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
89221600|NCT00944918|Experimental|1|fulvestrant and anastrozole
89221601|NCT00944918|Experimental|2|fulvestrant and placebo
89221602|NCT00944918|Active Comparator|3|exemestane alone
89221603|NCT04012268|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs. They will also accept medication treatment by professional neurologists.
89221604|NCT04012268|Other|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists.
89221605|NCT03995134||Propofol and Remifentanil|Procedural sedation in Dentistry provided by a Target Controlled Infusion pump using propofol as the sedative/hypnotic agent and Remifentanil as the opioid analgesic agent.
89221606|NCT00553280|Experimental|pregabalin|
89221607|NCT01024192|Experimental|1|Zolpidem 12.5mg tablet at bed time during 12 weeks
89221608|NCT01024270|Experimental|sublingual, oral and vaginal administration of misoprostol|
89221609|NCT00944996|Active Comparator|antidepressant|
89221610|NCT00944996|No Intervention|Healthy volunteers|
89221611|NCT03266536|No Intervention|No western diet|Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.
89221612|NCT03266536|Experimental|Western diet|Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
89221613|NCT00950066|Placebo Comparator|Placebo|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with placebo once a day."
89221614|NCT00950066|Active Comparator|Irbesartan 150mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg once a day."
89221615|NCT00950066|Active Comparator|Irbesartan 150 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg / Amlodipine 5 mg once a day."
89221616|NCT00950066|Active Comparator|Amlodipine|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Amlodipine 5 mg once a day."
89221617|NCT00950066|Active Comparator|Irbesartan 300 mg|"Active Comparator: Irbesartan~Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg once a day."
89221618|NCT00950066|Active Comparator|Irbesartan 300 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg / Amlodipine 5 mg once a day."
89221619|NCT01024348|Active Comparator|Tramadex-OD|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid. 30 minutes prior to surgery and 24 hours afterwards, patients will take a tablet of 100 mg Tramadex-OD. Breakthrough pain will be managed with 1 gr paracetamol (per os) as needed.
89221620|NCT01024348|Active Comparator|Control group|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid.Postoperative pain will be managed throughout the study with 1 gr paracetamol (per os) every 6 hours as required.
89221621|NCT00945074|Experimental|Condition 1|"Condition 1:~Subjects receive Standard Acu/Moxa (fixed protocol)"
89221622|NCT00945074|Experimental|Condition 2: Individualized Acupuncture/Moxibustion|"Condition 2:~Subjects receive Individualized Acupuncture/Moxibustion (patient-oriented, based on traditional Chinese medicine diagnosis)."
89221623|NCT00945074|Sham Comparator|Condition 3: Control|"Condition 3:~Subjects receive Sham Acupuncture/Placebo Moxibustion (control group)"
89221624|NCT03994744|Experimental|Sintilimab and Metformin|"Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).~The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up."
89221625|NCT00950222|Experimental|1:Imipenem/Amikacin|"patients will receive as empirical therapy for VAP imipenem associated with amikacin.After primary outcome measure, antibiotic therapy will be left at the discretion of the physician in charge of the patient.~Imipenem: recommended usual dosage for VAP treatment, IV (in the vein), every 8 hours~Amikacin: recommended usual dosage for VAP treatment (20mg/kg), IV (in the vein), single dose (at H0) for the 48 first hours of treatment"
89221626|NCT01031290|Experimental|Group A|Active TMS
89221627|NCT01031290|Sham Comparator|Group B|Sham TMS
89221628|NCT05301530|Experimental|Faceptor + Docetacel|Patients received a loading dose of Faceptor 8 mg/kg IV + docetaxel 75 mg/m^2 IV on Cycle 1 followed by Faceptor 6 mg/kg IV + docetaxel 75 mg/m^2 IV on the next 5 cycles (each cycle is 21 days)
89221629|NCT05301530|Active Comparator|Herceptin + Docetacel|Patients received a loading dose of Herceptin 8 mg/kg IV + docetaxel 75 mg/m^2 IV on Cycle 1 followed by Herceptin 6 mg/kg IV + docetaxel 75 mg/m^2 IV on the next 5 cycles (each cycle is 21 days)
89221630|NCT03228160|Experimental|SGI irradiation|Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
89062861|NCT01686698|Active Comparator|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) sachets containing 450 x 109 bacteria, 1 sachet every 12 hours during 3 months (n=20).
89062862|NCT01686698|Placebo Comparator|Placebo|Placebo sachets, 1 sachet every 12 hours during 3 months (n=20).
89062863|NCT01688687||Superficial gastric neoplasia|Patients with superficial gastric neoplasia on diagnostic endoscopy, recieved both conventional endoscopic forcpes biopsies and pCLE. All patients were subject to endoscopic resection of the lesion.
89062864|NCT02271126|Experimental|TEG|TEG-driven anticoagulation group: Anticoagulation will be monitored by TEG. Target will be a range of R parameter at Kaolin activated-TEG (R K-TEG) is 16 - 24 seconds; frequency of TEG assays may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When TEG value falls well below the desired range an heparin bolus will be administered, when is too high infusion will be stopped for either 30 or 60 minutes.
89062865|NCT02271126|Active Comparator|APTT|APTT-driven anticoagulation group: anticoagulation will be monitored by aPTT. aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range an heparin bolus will be administered. When too high, infusion will be stopped for either 30 or 60 minutes.
89062866|NCT05140577||18-30 years old|Subjects in this group is aged between 18 ans 30 years old
89062867|NCT05140577||31-65 years old|Subjects in this group is aged between 31 ans 65 years old
89062868|NCT05140577||65+ years old|Subjects in this group is aged over 65 years old
89062869|NCT02271165|Active Comparator|IVIg naive|Patients naïve to IVIg who have active disease responding to corticosteroids or are corticosteroid-dependent, will be also included. Before these patients enter the study, they will receive 3 monthly infusions of IVIg starting with the standard dose of 2gram/kg/month and followed with monthly maintenance of 1 or 2gram/kg according to their response.
89062870|NCT02271165|Active Comparator|non-IVIg naive|Participants already on IVIg will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their muscle strength, skin changes, assessments of their daily activities and quality of life (QoL) every 4 weeks at scheduled visits for monthly maintenance IVIg infusions (weeks 0,4,8,12).
89062871|NCT01686737|Experimental|Yoga|"Iyengar Yoga~12 weeks of Iyengar yoga~2 weekly sessions of 60 minutes"
89062872|NCT01686737|Active Comparator|Aerobic exercise|"Walking~12 weeks of walking~2 weekly sessions of 60 minutes"
89062873|NCT01686737|No Intervention|Usual Care|
89062874|NCT05140460|Experimental|Intervention|
89062875|NCT05140460|Active Comparator|Control|
89221631|NCT03228160|Sham Comparator|Shame irradiation|Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
89221632|NCT00950378||CVI|Varicose veins, varicose veins with leg swelling, venous stasis skin color changes, no open ulcers
89221633|NCT00950378||No treatment|Subjects with no venous disease CEAP (clinical etiology antomy pathophysiology)Class 0
89221634|NCT04011956||Retrospective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures from 2002 to Feb 28th 2019 were recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
89221635|NCT04011956||Perspective Cohort of Aortic Coarctation|Patients diagnosed as aortic coarctation and undergone corrected procedures after Mar. 1st 2019 will be recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
89221636|NCT00941174|Active Comparator|Capsule: 400 microg 13C5-Calcium-L-Leucovorin|
89221637|NCT00941174|Active Comparator|IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin|
89221638|NCT00950456||H1N1 Pandemic Influenza Vaccine|Subjects will be enrolled and vaccinated according to national policy and standard practice.
89221639|NCT00440518|Placebo Comparator|Placebo|Placebo
89221640|NCT00440518|Experimental|Lacosamide 100mg|100mg lacosamide
89221641|NCT00440518|Experimental|Lacosamide 300mg|300mg lacosamide
89221642|NCT00945230|Experimental|Actigraphic Neurosurgical Outcomes|Actigraphic measurements that will be obtained by attaching the actigraphic watch device to the individual's non-dominant wrist and operationally defined repeated observational measurements. All measurements will continue through a baseline period and continue through the identified post surgical period. Actigraphic measurements will occur every 30 seconds with brief periods of non-measurement during the actual neurosurgical procedure and periods when the actigraphic device has reached storage capacity (approximately every 22 days) when data is retrieved and the device prepared resume measurements.
89221643|NCT00950534|Experimental|General Practitioner initiation with insulin glargine|Patients will be prescribed insulin glargine by their Investigator and they will be taught how to administer insulin glargine according to Australian guidelines. Patients will be treated for 24 weeks.
89221644|NCT00950534|Active Comparator|Usual standard of care|Patients will be treated by their Investigator with the usual standard of care for 24 weeks (e.g., OAD dose titration, addition of a second or third OAD, or referral to an endocrinologist)
89221645|NCT01029964|Active Comparator|6-9 years|Age at start of treatment
89221646|NCT01029964|Active Comparator|10-13 years|Age at start of treatment
89221647|NCT01029964|Active Comparator|14-16 years|Age at start of treatment
89221648|NCT01029964|No Intervention|Control 6-9 years|Untreated control group
89221649|NCT00941252|Active Comparator|Imiquimod|topical therapy for 16 weeks with imiquimod containing therapy
89221650|NCT00941252|Placebo Comparator|Placebo|topical therapy for 16 weeks with a placebo containing vaginal suppository
89221651|NCT01031368|Experimental|Treatment (chemotherapy, G-CSF, cord blood infusion)|"INDUCTION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients receive an infusion of non-HLA matched ex vivo expanded cord blood progenitors on day 6. G-CSF is administered SC on days 0-5 and from day 7 until blood counts recover. Treatment modifications may apply according to response.~CONSOLIDATION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients also receive G-CSF SC beginning on day 0 and continuing until blood counts recover."
89221652|NCT00945308|Active Comparator|Eptifibatide (intracoronary)|
89221653|NCT00945308|Active Comparator|Eptifibatide (intravenous)|
89221654|NCT00950768|Active Comparator|Mel100|
89221655|NCT00950768|Experimental|Mel200|
89062876|NCT02271282|Experimental|Oral Toremifene/Oral Placebo|"Oral toremifene will be given once on Day 1 and continue daily x10 days. A single combined IV injection of growth hormone releasing hormone (GHRH)/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.~After at least 3 weeks, subjects will return to receive oral placebo on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
89062877|NCT02271282|Experimental|Oral Placebo/Oral Toremifene|"Oral placebo will be given once on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.~After at least 3 weeks, subjects will return to receive oral toremifene on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
89062878|NCT01686815||Olanzapine|Olanzapine-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
89062879|NCT01686815||Risperidone|Risperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
89062880|NCT01686815||Iloperidone|Iloperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
89062881|NCT02271321|No Intervention|control group|The control group will receive usual care
89062882|NCT02271321|Experimental|experimental group|The experimental group will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
89062883|NCT01686893|Active Comparator|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
89062884|NCT01686893|Active Comparator|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
89062885|NCT01580111|Experimental|Short storage|Short storage arm: Will receive blood (Packed red blood cells) of 1 (one) to 10 (ten) days in storage.
89062886|NCT01580111|Active Comparator|Long storage arm|Will be transfused with blood ( packed red cells) of storage age 21- 35 days.
89062887|NCT01686971||questionaire|patients will receive a questionaire and speak to a nurse regarding their needs and/ or demands.
89062888|NCT01688804|Experimental|Behavioral intervention|Behavioral intervention to reduce sedentary time delivered via mobile smartphone
89062889|NCT01688960|Experimental|Cohort 1|
89062890|NCT01688960|Experimental|Cohort 2|
89062891|NCT01688960|Experimental|Cohort 3a|
89062892|NCT01688960|Experimental|Cohort 3b|
89062893|NCT01688960|Experimental|Cohort 4|
89062894|NCT02271360|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
89062895|NCT02271360|Active Comparator|group B|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be givenat day of HCG injection and for 8 days .
89062896|NCT01687049|Experimental|red yeast rice (RYR)|Two RYR capsules three times daily for a minimum of 6 months
89062897|NCT02271399|Active Comparator|acetylsalicylic acid|aspirin 300mg tablet by mouth, every 24 hours for postoperatively 10 days
89062898|NCT02271399|Experimental|rivaroxaban|xarelto 10mg tablet by mouth, every 24 hours for postoperatively 10 days
89062899|NCT01689038|Experimental|Tested product|
89062900|NCT02271438|Experimental|Part 1: Ibrutinib 840 milligram (mg)|Participants will receive ibrutinib 840 mg (6*140 mg capsules) + 6 placebo capsules on Day 1 of Part 1, Period 1.
89062901|NCT02271438|Experimental|Part 1: Ibrutinib 1680 mg|Participants will receive ibrutinib 1680 mg (12*140 mg capsules) on Day 1 of Part 1, Period 2.
89062902|NCT02271438|Experimental|Part 2: Treatment A|Participants will receive ibrutinib, 1680 mg (12*140 mg capsules) + 1 moxifloxacin-matching placebo capsule Day 1of Part 2.
89062903|NCT02271438|Experimental|Part 2: Treatment B|Participants will receive ibrutinib, 840 mg (6*140 mg capsules) + 6 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule.
89062904|NCT02271438|Experimental|Part 2: Treatment C|Participants will receive placebo (12 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule) Day 1 of Part 2.
89062905|NCT02271438|Experimental|Part 2: Treatment D|Participants will receive moxifloxacin 400 mg (1 capsule) + 12 ibrutinib-matching placebo capsules Day 1 of Part 2.
89062906|NCT02271516|Experimental|188Re-BMEDA-liposome|"Stage I:~188Re-BMEDA-liposomes, 14±1.4 mCi, single dose~Stage II:~188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)~0.42±0.04 mCi/kg~0.63±0.06 mCi/kg~0.84±0.08 mCi/kg~1.05±0.11 mCi/kg~1.26±0.13 mCi/kg~1.47±0.15 mCi/kg"
89062907|NCT02272595||Arm A - Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
89062908|NCT02272595||Arm B - Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
89062909|NCT02271555|Active Comparator|sevoflurane-remifentanil (Group SR)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
89062910|NCT02271555|Placebo Comparator|sevoflurane-saline (Group SS)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. Placebo is 0.9% saline. After the loss of consciousness saline will be administered to Group sevoflurane-saline in the form of intravenous bolus.
89062911|NCT02278211||Study Cohort|Patients hospitalised with myocardial infarction and angiographically proven multivessel coronary artery disease
89062912|NCT02271672|Experimental|XP1000 RF group|Subjects in the XP1000 RF group will be treated with the XP1000 RF device.
89062913|NCT02271672|Sham Comparator|Sham group|Subjects in the Sham group will be treated with the sham XP1000 RF device.
89062914|NCT01687205|Active Comparator|Group 1|Single Dose/1 hour before and 1 hour after sex (BAT) Cohort
89062915|NCT01687205|Active Comparator|Group 2|Multiple Dose Cohort
89062916|NCT02271711|Experimental|Treatment (autologous ex vivo-expanded NK cells)|Patients receive autologous expanded NK cells IV into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
89062917|NCT01687322||total hip replacement, quality of life, functioning|
89062918|NCT01689194|Experimental|genexolPM + cisplatin|
89062919|NCT02271750||Dementia|
89062920|NCT02271750||controls|
89062921|NCT01687361|Experimental|branched-chain amino acids (BCAA) supplementation|
89062922|NCT01687361|Placebo Comparator|PLACEBO|
89062923|NCT02271828|Active Comparator|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
89062924|NCT02271828|No Intervention|No sentinel lymph node procedure|No sentinel lymph node procedure
89062925|NCT01689272|Experimental|Kidney transplantation|Kidney transplantation from alive relative donor.
89062926|NCT02271867|Active Comparator|Levobupivacaine 0,5%|Levobupivacaine 0,5% 15 ml once
89062927|NCT02271867|Active Comparator|Levobupivacaine 0,5% with epinephrine|Levobupivacaine 0,5% with 1/200000 epinephrine 15 ml once
89062928|NCT02271867|Active Comparator|Ropivacaine 0,75%|Ropivacaine 0,75% 15 ml once
89062929|NCT01687439|Experimental|Treatment|Eligible patients receive one cycle of Endostar monotherapy, two cycles of Endostar combined with chemotherapy (vinorelbine plus cisplatin) treatment, followed by Endostar plus radiotherapy treatment.
89062930|NCT01588704|Experimental|Neoadjuvant Bevacizumab|Four cycles of neoadjuvant chemotherapy with pemetrexed, carboplatin and bevacizumab.
89062931|NCT01687634|Experimental|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
89062932|NCT01687634|Experimental|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
89062933|NCT01689311|Experimental|Treatment|All samples will undergo dose response treatment (increasing concentrations) of one of the four uterotonic drugs: oxytocin, ergonovine, prostaglandin F2alpha, or misoprostol.
89062934|NCT01588782|Experimental|Abiraterone acetate|All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14.
89062935|NCT01689389||Main study population|"All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age.~Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months."
89062936|NCT01689389||Schizophrenia SoC sample|Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
89062937|NCT01689389||Bipolar SoC sample|Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
89062938|NCT02272062|No Intervention|Preferences Not Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, but these preferences will NOT be shared with the treating clinicians.
89062939|NCT02272062|Experimental|Preferences Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, and these preferences WILL be shared with the treating clinicians.
89062940|NCT02276456|Experimental|early follow-up|Follow-up within 7 days after discharge from hospital after having an MI. This will be the early-follow-up or experimental arm.
89062941|NCT02276456|No Intervention|standard follow-up|Follow-up appointment within 14-18 days after discharge from hospital after having an MI
89062942|NCT02273427|Active Comparator|BIIL 284 BS fasted|
89062943|NCT02273427|Experimental|BIIL 284 BS with high fat meal|
89062944|NCT02273427|Experimental|BIIL 284 BS with low fat meal|
89062945|NCT02272101|Experimental|Vitamin D|Vitamin D 4,000 I.U. orally
89062946|NCT02272101|Placebo Comparator|Placebo|Placebo orally
89062947|NCT01689467|Experimental|Fermented Velvet Antler extract|
89062948|NCT01689467|Placebo Comparator|Placebo|
89062949|NCT01687829||ILM-on group|patients were scheduled to undergo macular hole surgery without internal limiting membrane (ILM) peeling
89062950|NCT01687829||ILM-off group|patients were scheduled to undergo macular hole surgery with internal limiting membrane (ILM) peeling
89062951|NCT02272218|Other|LAGB|There is only one arm for this study, since this study involves a single cohort receiving the same intervention, laparoscopic gastric banding (LAGB) surgery.
89062952|NCT02272335|Experimental|CB Stress Management|The Cognitive-Behavioral Stress Management (CBSM) intervention arm is a closed, structured group intervention that offers 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the Cancer Wellness and Education (CW) condition as well. i.e. Group Sessions
89062953|NCT02272335|Active Comparator|Cancer Wellness (CW)|Enhanced Breast Cancer Wellness and Education (CW). The CW condition consists of 10 weekly sessions that are roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain (e.g., National Cancer Institute, Susan G. Komen Foundation, American Cancer Society).i.e. Group Sessions
89062954|NCT02278133|Experimental|WNT974, LGX818 and cetuximab combo|Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab
89062955|NCT02277704|Placebo Comparator|Treatment A|"2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
89062956|NCT02277704|Active Comparator|Treatment B|"1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
89062957|NCT02277704|Active Comparator|Treatment C|"2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime."
89062958|NCT00107172|Active Comparator|Arm I|Patients undergo open or thoracoscopic sublobar resection comprising either a wedge resection or anatomical segmentectomy.
89062959|NCT00107172|Experimental|Arm II|Patients undergo surgery as in arm I. Patients also undergo intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
89062960|NCT01687868|Experimental|dexmedetomidine continuous infusion|
89062961|NCT01687907|Active Comparator|Fear of childbirth, music|Patients referred to the motherhood out-patient clinic because of fear of childbirth. Advised to active music listening. Followed up by weekly and monthly diaries and three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
89062962|NCT01687907|No Intervention|Fear of childbirth, control|Patients referred to the motherhood out-patient clinic because of fear of childbirth. No intervention. Followed up by three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
89062963|NCT01687907|Active Comparator|Nulliparous, music|300 nulliparous women recruited from the ultrasound screening. Advised to active music listening. Three questionnaires like the other arms, weekly and monthly diaries like the other music group. Screening questionnaires about fear of childbirth.
89062964|NCT01687907|No Intervention|Nulliparous, control|300 nulliparous women recruited from ultrasound screening. No intervention. 3 Questionnaires as all the other groups. Screening questionnaire about fear of childbirth.
89062965|NCT02272374|Experimental|e-AVF group|120 elderly with end stage renal disease will undergo AVF creation.
89062966|NCT02272374|Experimental|e-TCC group|120 elderly with end stage renal disease will undergo TCC placement.
89062967|NCT02272374|Experimental|e-AVG group|60 elderly with end stage renal disease will undergo AVG creation.
89062968|NCT02272374|Experimental|ve-AVF group|80 very elderly with end stage renal disease will undergo AVF creation.
89062969|NCT02272374|Experimental|ve-TCC group|80 very elderly with end stage renal disease will undergo TCC placement.
89062970|NCT02272374|Experimental|ve-AVG group|40 very elderly with end stage renal disease will undergo AVG creation.
89062971|NCT01687946||Pulmonary fibrosis in aged individuals|"Group A and B:~Patients with UIP (histologically and/or radiologically proven) providing informed consent. According to functional and radiological assessment, the disease may be either limited (Group A) or advanced (Group B). The patients are usually older than 55 years."
89062972|NCT01687946||Pulmonary fibrosis and inflammation|"Groups C and D:~Patients with HP (histologically and radiologically proven) providing informed consent. According to functional and radiological assessment, the disease will be either acute or chronic. The patients will be significantly younger (mean > 10 years) than in groups A and B."
89062973|NCT01687946||Regular wound healing in lung|Patients receiving lung biopsy or bronchoscopy for reasons other that the study and volunteers providing informed consent. The group will consist of young (18-40 years) and old individuals (older than 55 years).
89062974|NCT01688024|Experimental|Mitomycin C|Up to 10 mg administered during each standard of care endoscopic retrograde cholangiography. No more than five mitomycin C applications per every twelve months will be given.
89062975|NCT01688024|Placebo Comparator|Normal saline|Given during each standard of care endoscopic retrograde cholangiography. No more than five normal saline applications per every twelve months will be performed.
89062976|NCT01689506|Experimental|Volulyte|Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)
89062977|NCT01689506|Active Comparator|Human Serum Albumin|5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)
89062978|NCT01689545|Experimental|Individual level|
89062979|NCT01689545|Experimental|Structural level|
89062980|NCT01689545|Experimental|Combined individual & structural level|
89062981|NCT01689545|Active Comparator|Standard of Care|
89062982|NCT04059861|Other|ultrasound assisted resection|resection of tongue cancer will be done with assistance of ultrasound to visualise the deep margin.
89062983|NCT01689623|Experimental|Panel I|Each participant will be administered a single oral 40-mg atorvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
89221656|NCT03172936|Experimental|Dosing Schedule A|Patients were treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
89221657|NCT03172936|Experimental|Dosing Schedule B|Patients were treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
89221658|NCT00950924|Experimental|Bifocal Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
89221659|NCT00950924|Placebo Comparator|Single Vision Soft Contact Lenses|Subjects will be fitted with single vision soft contact lenses with goal of corrected emmetropia at a distance of 20 feet.
89221660|NCT01024426|Experimental|Health Facility intervention|In the clusters randomized to enhanced health facility-based care, the intervention is designed to address these barriers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
89221661|NCT01024426|Other|Standard of care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
89221662|NCT00951002||acellualr dermal matrix|patients treated with acellular dermal matrix plug
89221663|NCT01030042|Experimental|Cetuximab/Irinotecan|Cetuximab/irinotecan followed, after progression, by FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil)
89221664|NCT01030042|Active Comparator|FOLFOX 4|FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil) followed, after progression, by irinotecan/cetuximab
89221665|NCT00941408||Diagnostic tumor core biopsy|
89221666|NCT01024504|Experimental|XELOX/Avastin|Capecitabine Oxaliplatin Bevacizumab
89221667|NCT00945464||No treatment|Women over the age of 30 undergoing breast imaging at the Scripps Polster Breast Care Center.
89221668|NCT01030120|Active Comparator|etanercept|etanercept 50mg BIW
89221669|NCT01030120|Placebo Comparator|placebo|matching placebo
89221670|NCT04012112|Experimental|single-arm trials|longitudial study of the thoracolumbar brace in the neuromuscular scoliosis for 6 months
89221671|NCT01024582|Experimental|accelerated partial breast irradiation|pre-operative radiation of the in situ tumor in the breast
89221672|NCT00941564|Experimental|Commercially available infant formula A|Varying fat blend from comparator product
89221673|NCT00941564|Active Comparator|Commercially available infant formula B|
89221674|NCT00951158|Experimental|CLA|Open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. oral dose 7.5 g/day 28 day cycle
89221675|NCT00951236|Active Comparator|One injection|
89221676|NCT00951236|Active Comparator|Two Injections|
89221677|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
89221678|NCT00945542|Experimental|Preemptive transfusion|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. This corresponds to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
89221679|NCT00438256|Experimental|Group 1|10 Radiation Sessions over 2 weeks
89221680|NCT00438256|Experimental|Group 2|5 Radiation sessions: 3 in week 1 and 2 in week 2
89221681|NCT00438256|Experimental|Group 3|5 Radiation sessions: 4 in week 1 and 1 in week 2
89689978|NCT03128008|Experimental|Carboplatin/Paclitaxel with radiation therapy|Single arm, non randomized, open label study. Eligible subjects will receive standard of care Carboplatin IV once a week, Paclitaxel IV once a week given concurrently with daily hyperfractionated radiation therapy (RT). RT will be delivered as 6 fractions weekly.
89221682|NCT00438256|Experimental|Group 4|5 Radiation Sessions in one week
89221683|NCT00951392|Experimental|Problematic aging|
89221684|NCT00951392|Experimental|successful aging|
89221685|NCT00941642|Active Comparator|Lovaza|Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
89221686|NCT00941642|Placebo Comparator|Placebo|Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.
89221687|NCT01031524|Experimental|vaccine|30 µg of PfCS102 formulated in Montanide ISA 720
89221688|NCT01031524|Placebo Comparator|adjuvant|Montanide ISA 720
89221689|NCT00945620|Placebo Comparator|right side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
89221690|NCT00945620|Placebo Comparator|Left side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
89689979|NCT05017311|Active Comparator|Allocation by Predictive Biomarker Algorithm; Escitalopram + Brexpiprazole|Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted as non-responders to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.
89062984|NCT01689623|Experimental|Panel II|Each participant will be administered a single oral 40-mg simvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
89062985|NCT02272530||Healthy|100 healthy volunteers in age of 20-75 years
89062986|NCT02272530||Patients|100 patients with stable coronary artery disease and accordingly endothelial dysfunction
89062987|NCT04055142|Active Comparator|Electrocoagulation|This procedure will be implemented following the Standard of Care (SoC) on weeks: 0, 8 and 16 calculated since the day the patient is included into the trial.
89062988|NCT04055142|Experimental|Sinecatechins (10%)|Topical ointment wich contains 2 grams of active principle (sinecatechins 10%) at each administration. It will be taken three times per week during 8 weeks of treatment.
89062989|NCT04055142|Experimental|cidofovir (1%)|Topical ointment wich contains 2 grams of active principle (cidofovir 1%) at each administration. It will be taken three times per week during 8 weeks of treatment.
89062990|NCT02272569|Experimental|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant by an ab-externa technique with connection from the anterior chamber to the suprachoroidal space
89062991|NCT02272608||control|patients WHO do not have sleep apnea
89062992|NCT02272608||mild OSAS|mild apnea patients (AHI: 5-15)
89062993|NCT02272608||moderate OSAS|moderate apnea patients (AHI: 16-30)
89062994|NCT02272608||severe OSAS|severe OSAS patients (AHI: more than 30)
89062995|NCT01688297|Experimental|Low Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet formulation.
89062996|NCT01688297|Placebo Comparator|VXA Placebo Tablet|Oral tablets of the same size and number as the vaccine tablet doses. Placebo arms were included during enrollment of each of the experimental dose groups to maintain the double-blind study design.
89062997|NCT01688297|Experimental|Medium Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet
89062998|NCT01688297|Experimental|High Dose VXA-A1.1 Oral Vaccine|One dose of replication incompetent adenovirus given in an oral tablet dose. This dose was studied under protocol VXA02-003.
89062999|NCT04054323|Experimental|Patient Physical Activity Arm|Patients only receive physical activity intervention.
89063000|NCT04054323|Experimental|Dyadic Physical Activity Arm|Patients and caregivers both receive physical activity intervention.
89063001|NCT05138354|Active Comparator|Control group|Patients received a 4-week treatment program (12 treatment sessions, three times a week). Patients received the conservative treatment protocol comprised of ultrasound, hot pack application, and exercises.
89063002|NCT05138354|Experimental|Intervention group|Patients received a 4-week treatment program (12 treatment sessions, three times a week). Patients received LLLT and myofascial release combined with the control intervention. the conservative treatment protocol comprised of ultrasound, hot pack application, and exercises
89063003|NCT02272647|Experimental|IM Plac - Oral Plac - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
89063004|NCT02272647|Experimental|IM Plac - Oral Prog - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
89063005|NCT02272647|Experimental|IM E2 - Oral Plac - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Medroxyprogesterone (5 mg - for 10 days)
89063006|NCT02272647|Experimental|IM E2 - Oral Prog - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
89063007|NCT01689818|Experimental|exercise training|exercise training program which included aerobic exercise for 3 times per week.
89063008|NCT01689818|No Intervention|control|lifestyle counseling
89063009|NCT02272764|Other|Itraconazole|Itraconazole or placebo
89063010|NCT02272764|Experimental|ALKS 5461|ALKS 5461 or placebo Sublingual tablet
89063011|NCT01689896|Active Comparator|Testosterone Gel|Testosterone Gel
89063012|NCT01689896|Placebo Comparator|Placebo Gel|Placebo Gel
89063013|NCT01316094|Experimental|ASP group|oral
89063014|NCT01316094|Placebo Comparator|placebo group|oral
89063015|NCT01689935|No Intervention|Control|No drug, no treatment
89063016|NCT01689935|Active Comparator|ALA-PDT|Drug- topical 20% Aminolevulinic acid - ALA followed by red light irradiation - conventional photodynamic therapy -PDT
89063017|NCT01689935|Experimental|i-PDT|Drug - topical 20% Aminolevulinic acid - followed by inhibitory light during incubation time, then red light for photodynamic therapy
89063018|NCT01689935|Active Comparator|Red Light only|Red light only - no drug
89063019|NCT01689935|Active Comparator|Blue light only|Blue light only - no drug
89063020|NCT01316133|Experimental|Tacrolimus group|Oral
89063021|NCT01684826|Experimental|ClarityIQ|Angiographic run with new algorithm and low dose (50% dose)
89063022|NCT01684826|Experimental|AlluraXper|Angiographic run with predecessor algorithm and dose (100% dose)
89063023|NCT01316172|Experimental|5 Cs|Educational intervention
89063024|NCT01316172|No Intervention|Control|
89063025|NCT05654064|Active Comparator|Remifentanil-dexmedetomidine|
89063026|NCT05654064|Active Comparator|Dexmedetomidine- fentanyl|
89063027|NCT01689233|Experimental|TRx0237 200 mg/day|
89063028|NCT01689233|Placebo Comparator|Placebo|
89063029|NCT02272881|Experimental|immediate surgical intervention|immediate surgical reconstruction of the pressure ulcer via flap closure or comparable procedure
89063030|NCT02272881|Other|wound care|conservative wound management directed by certified wound care experts
89063031|NCT01687985|Experimental|BLI801 laxative - low dose|BLI801 laxative - oral solution
89063032|NCT01687985|Experimental|BLI801 laxative - high dose|BLI801 laxative - oral solution
89063033|NCT01686620|Experimental|BIOD-123|BIOD-123 used as prandial insulin
89063034|NCT01686620|Active Comparator|Lispro (Humalog)|Lispro (Humalog) used as prandial insulin
89063035|NCT01685255|Active Comparator|Epacadostat|Subjects randomized to Arm A (epacadostat) will take epacadostat tablets at a dose of 600 mg BID, beginning on Day 1.
89063036|NCT01685255|Active Comparator|Tamoxifen|Subjects randomized to Arm B (tamoxifen) will take tamoxifen tablets at a dose of 20 mg BID, beginning on Day 1.
89063037|NCT01684163|Placebo Comparator|Placebo injection|Normal saline
89063038|NCT01684163|Experimental|GLYX-13, 5 mg/kg|Low dose of GLYX-13
89063039|NCT01684163|Experimental|GLYX-13, 10 mg/kg|High dose of GLYX-13
89063040|NCT05653284|Experimental|AK130|Each subject will receive a single dose of AK130 every 3-week cycle (Q3W) or every 2-week cycle (Q2W). Participants may continue on study drug until unacceptable toxicity, or other withdrawal criteria is met.
89063041|NCT01680965|Experimental|Ofatumumab|"Phase I:~Escalating dose of ofatumumab~Phase II:~Maximum tolerated dose (MTD) of Ofatumumab"
89063042|NCT02272920|Experimental|Renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation: Medtronic Symplicity Flex, Medtronic Symplicity Spyral or St Jude EnligHTN.~Renal denervation is performed within seven days after PCI in patients with acute myocardial infarction and hypertension."
89063043|NCT02272920|No Intervention|Control: Standard of care|Standard-of-care follow-up after ACS. Including nurse and physician out-patient visits.
89063044|NCT02272959|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral stimuli.
89063045|NCT02272959|Placebo Comparator|Placebo Group|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns using only neutral stimuli.
89063046|NCT05140304|Other|A|
89063047|NCT01683188|Other|Cohort 1|Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2
89063048|NCT01683188|Other|Cohort 2|Patients who have receive >7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2
89063049|NCT04997135||Meibography Subjects|Eligible subjects will undergo testing to evaluate the Meibomian gland appearance
89063050|NCT01339923|Experimental|B_2h3h5_11|Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
89063051|NCT01339923|Experimental|B_3h5_11|Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
89063052|NCT01339923|Experimental|B_68_11|Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
89063053|NCT01339923|Experimental|B_02_2_5|Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
89063054|NCT01339923|Experimental|B_02_6_10|Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
89063055|NCT01339923|Experimental|BC_35_12|Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
89063056|NCT01339923|Experimental|C_35_12|Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
89063057|NCT04615832|Experimental|Toffee Full Face Mask|Toffee Full Face Mask: Full face mask for PAP therapy applied in a home environment for 2 weeks.
89063058|NCT05652036|Active Comparator|5 mL Group|100 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder in 5 separate injections of 1 mL. One injection will be at the trigone.
89063059|NCT05652036|Active Comparator|10 mL Group|100 units BTX-A reconstituted in 10 mL normal saline, injected into the bladder in 10 separate injections of 1 mL. One injection will be at the trigone
89063060|NCT05650905||subjects previously infected with COVID-19|subjects previously infected with COVID-19
89063061|NCT05650905||subjects with long COVID-19|subjects with long COVID-19 according to the WHO-guideline
89063062|NCT05650905||healthy age-and sex- matched control subjects with no history of COVID-19 infection|healthy age-and sex- matched control subjects with no history of COVID-19 infection
89063063|NCT05140109|Experimental|Cognitive-dissonance based program|Group program of 8 sessions of one hour and a half.
89063064|NCT05140109|Active Comparator|Mindfulness-based program|Group program of 8 sessions of one hour and a half.
89063065|NCT05140109|Active Comparator|Person-centered program|Group program of 8 sessions of one hour and a half.
89063066|NCT04195919|Experimental|Group1|Hemodialysis patients(MDRD-eGFR ≤ 15 mL/min/1.73m2)
89063067|NCT04195919|Experimental|Group2|Healthy control(MDRD-eGFR ≥ 90 mL/min/1.73m2)
89063068|NCT01380093|Placebo Comparator|Placebo|
89063069|NCT01380093|Active Comparator|MS Contin (morphine sulfate, controlled release)|
89063070|NCT01380093|Experimental|EMBEDA (morphine sulfate / naltrexone hydrochloride)|
89063071|NCT01686854|Experimental|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
89063072|NCT01686854|Active Comparator|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
89063073|NCT04083326|Experimental|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
89063074|NCT04083326|No Intervention|Conventional care group|Conventional care consists of specialist assessment in conjunction with pre-operative surgical visits and patient education. Patients in the conventional care group are provided with pre- and postoperative information face-to-face by paper-based method. Patients will be admitted and mobilised on the day of the surgery, and discharged one to three days after surgery. The follow-up visit, conducted by a physiotherapist, is conducted after 6 to 8 weeks post-discharge for patients with TKA and after 8 to 12 weeks for patients with THA.
89063075|NCT04059926||Patients with lumen metal apossing stent|
89063076|NCT04829084|Experimental|Intervention Arm|Health education
89063077|NCT04829084|No Intervention|Control Arm|No health education
89063078|NCT01379937|Experimental|GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
89063079|NCT01379937|Experimental|GSK1562902A Formulation 1 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
89063080|NCT01379937|Active Comparator|GSK1562902A Formulation 2 - Havrix / Havrix Jr Group|Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
89063081|NCT01379937|Active Comparator|Havrix / Havrix Jr Group|Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
89063082|NCT03720392|Experimental|FMT Capsules|"Two doses of FMT: one standard dose starting within four (4) days from the start of the conditioning regimen prior to HCT and one non-standard dose starting within 4 weeks after engraftment after HCT.~A standard dose of oral FMT is 15 capsules per day for two consecutive days,"
89063083|NCT03720392|Placebo Comparator|Placebo Capsules|"Two doses of placebo, instead of FMT: one starting within four (4) days from the start of the conditioning regimen prior to HCT and the second one starting within 4 weeks after engraftment after HCT.~A standard dose of oral Placebo is 15 capsules per day for two consecutive days,"
89063084|NCT01379781|Experimental|Behavioral Intervention for PPD|Behavioral Intervention for PPD delivered over 3 in-person sessions.
89063085|NCT01379781|No Intervention|Treatment As Usual|Referred to Treatment in the Community.
89063086|NCT04820972|Experimental|E-STAR group|
89063087|NCT04820972|No Intervention|traditional group|
89063088|NCT03558854|Active Comparator|ASA group|Pill containing 100 mg of acetylsalicylic acid, taken once daily for 04 weeks
89063089|NCT03558854|Placebo Comparator|Placebo oral capsule group|Identical pill containing placebo, taken once daily for 04 weeks
89063090|NCT01379703||Single patients group|Single HIV-1 infected patients group
89063091|NCT03545126||Progressive Supranuclear Palsy (PSP)|N=12 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
89063092|NCT03545126||Corticobasal Degeneration (CBD)|N=8 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
89221691|NCT01030276|Experimental|Bright light|
89221692|NCT01030276|Placebo Comparator|"Inactive placebo-light"|
89063093|NCT03545126||Frontotemporal Dementia: MAPT|N=12 Family members with or at-risk of tau mutations (e.g. P301L) Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.
89063094|NCT01335477|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
89063095|NCT01335477|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
89063096|NCT03389438|Experimental|Experimental arm|Participants who were treated with autologous Tcm cells immunotherapy.
89063097|NCT03389438|No Intervention|No intervention arm|Participants who were treated with no autologous Tcm cells immunotherapy.
89063098|NCT04829474||Women consulting for spouse abuse|The study focuses on women consulting a doctor as part of spouse abuse, whatever the context (at the request of the police or not) or their motivation (medical or social).
89063099|NCT04828850|Experimental|EBUS-TBNA procedure|Single arm protocol. Invasive mediastinal staging with EBUS-TBNA in clinical N0 NSCLC patients candidate to surgical resection with systematic lymphadenectomy.
89063100|NCT04825964||Patients|Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated at diagnosis and after 1-3 months.
89063101|NCT04825964||Healthy Controls|Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated one time.
89063102|NCT01371825|Experimental|Open-Label Sebelipase Alfa|Participants received intravenous (IV) infusions of sebelipase alfa during the open-label treatment. Participants initially received 0.35 milligrams (mg)/kilogram (kg) qw and escalated to 1 mg/kg qw after demonstrating acceptable safety and tolerability during at least 2 infusions. One participant initiated treatment under a Temporary Use Authorization prior to enrollment, wherein the participant's dose was gradually escalated from 0.2 to 1 mg/kg over 4 weeks; the participant started the study at this dose. Participants on treatment for 96 weeks and on stable qw dosing for 24 weeks could be switched to an every other week (qow) dosing schedule. In the event of protocol-defined disease progression at any time during treatment, a participant could receive a dose increase from 1 to 3 mg/kg qw and, if necessary, a dose increase to 5 mg/kg qw with Safety Committee approval. Participants dosed qow who met dose-escalation criteria were reverted to qw dosing or escalated to 1 or 3 mg/kg qow.
89063103|NCT01371747|Experimental|Stratum 1: 8.4 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L (milliequivalent)
89063104|NCT01371747|Experimental|Stratum 1: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
89063105|NCT01371747|Experimental|Stratum 1: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
89063106|NCT01371747|Experimental|Stratum 2: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
89063107|NCT01371747|Experimental|Stratum 2: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
89063108|NCT01371747|Experimental|Stratum 2: 33.6 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
89063109|NCT03321617|Experimental|POMA 40mg BID (80mg)|Subject will take 40mg pomaglumetad methionil (POMA) twice a day for 14 days.
89063110|NCT03321617|Experimental|POMA 80mg BID (160 mg)|Subject will take 80 mg pomaglumetad methionil (POMA) twice a day for 14 days
89063111|NCT03321617|Experimental|POMA 120mg BID (240mg)|Subject will take 120 mg pomaglumetad methionil (POMA) twice a day for 14 days
89063112|NCT03321617|Experimental|POMA 160 mg BID (320 mg)|Subject will take 160 mg pomaglumetad methionil (POMA) twice a day for 14 days
89063113|NCT01371708|Experimental|Desvenlafaxine Succinate Sustained-Release|
89063114|NCT01335399|Active Comparator|Lenalidomide + Dexamethasone|
89063115|NCT01335399|Experimental|Lenalidomide + Dexamethasone + Elotuzumab|
89063116|NCT03176615|Experimental|Group A (Cross-over Group 1)|Subjects randomly assigned to two experimental diets. This arm will receive high-fat meals first, followed by a washout period of two-seven days and then low-fat meals.
89063117|NCT03176615|Experimental|Group B (Cross-over Group 2)|Subjects randomly assigned to two experimental diets. This arm will receive low-fat meals first, followed by a washout period of two-seven days and then high-fat meals.
89063118|NCT01366521|Experimental|Mepolizumab 250 mg subcutaneous (SC)|250 mg subcutaneous (SC)
89063119|NCT01366521|Experimental|Mepolizumab 125 mg subcutaneous (SC)|125 mg subcutaneous (SC)
89063120|NCT01366521|Experimental|Mepolizumab 12.5 mg subcutaneous (SC)|12.5 mg subcutaneous (SC)
89063121|NCT01366521|Experimental|Mepolizimab 75 mg intravenously (I.V.)|75 mg intravenously (I.V.)
89063122|NCT04825262|Experimental|Intervention genotyping group|"Patients who are scheduled to receive renal transplant from a living donor between January 2021 to January 2023. They will be assigned to receive the initial CYP3A5 genotype-based tacrolimus (FK) dose as determined by their CYP3A5 genotype.~CYP3A5 expresser (extensive or intermediate metabolizer) - 0.20mg/kg CYP3A5 non-expresser (poor metabolizer) - 0.15mg/kg~The starting dose of the intervention arm will be reviewed for every 10 patients recruited based on the drug levels achieved."
89063123|NCT04825262|No Intervention|Historical Control Group|Patients who received renal transplant from a living donor between January 2016 - December 2020 and received standard weight-based dosing of tacrolimus
89063124|NCT04825145||Preeclamptic women|Pregnant women who is diagnosed with preeclampsia during anytime of pregnancy.
89063125|NCT04825145||Healthy pregnant women|Pregnant women without preeclampsia. Will be matched for body mass index, gestational age and age.
89063126|NCT01335009|Experimental|MORAb-004, 2 mg/kg|Biologic (monoclonal antibody)
89063127|NCT01335009|Experimental|MORAb-004, 4 mg/kg|Biologic (monoclonal antibody)
89063128|NCT04824365|Experimental|Treatment of COVID-19 infected patients with a sodium pyruvate nasal spray|In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days. This group will be compared to the placebo control group to determine if sodium pyruvate reduces the symptoms, duration and replication of COVID-19 infection.
89063129|NCT04824365|Placebo Comparator|Placebo control treatment of COVID-19 infected patients|In this arm, patients will be provided with a saline nasal spray as a placebo control. Patients will use the saline nasal spray 3x daily for 14 days, similar to the sodium pyruvate drug arm. This will serve as a control for the symptoms, duration and replication of COVID-19 infection.
89063130|NCT01366443||women pregnant|Healthy pregnant women between 15 or greater weeks gestation reporting with signs or symptoms of rupture of membranes.
89063131|NCT01332630|Experimental|TPI 287|TPI 287 administered at 160 mg/m2 by vein on Day 1 and repeated every three weeks. Day 1 of each subsequent cycle is equivalent of day 22 of the previous cycle; pre TPI 287: Dexamethasone 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, Dexamethasone 10 mgby vein may be given 30-60 minutes prior to treatment with TPI 287, Benadryl 12.5-25 mg IV push over 30-60 minutes, and Ranitidine 1mg/kg IV over 30-60 minutes.
89063132|NCT04822961|Experimental|Senaparib (IMP4297) 20 mg|During the treatment period, eligible patients will receive single agent of Senaparib at a dose of 100 mg once daily (QD), continuously on a 4-week cycle
89063133|NCT04822961|Placebo Comparator|Placebo|During the treatment period, eligible patients will receive placebo QD, continuously on a 4-week cycle
89063134|NCT01366209|Active Comparator|Active Arm|
89063135|NCT01366209|Placebo Comparator|Placebo Arm|
89063136|NCT01600001|Experimental|Drug:KWA-0711 dose 1|
89063137|NCT01600001|Experimental|Drug:KWA-0711 dose 2|
89063138|NCT01600001|Experimental|Drug:KWA-0711 dose 3|
89063139|NCT01600001|Experimental|Drug:KWA-0711 dose 4|
89063140|NCT01600001|Placebo Comparator|Drug: Placebo|
89063141|NCT01365546|Experimental|human VWF/FVIII concentrate|
89063142|NCT04828421|Experimental|Probiotic group|Participants will be treated with a daily capsule of a multi-species probiotic (3.3 billion Lactobacillus rhamnosus and Bifidobacterium lactis) during 10 weeks.
89063143|NCT04828421|Placebo Comparator|Placebo group|Participants will receive a harmless substance (potato starch) during 10 weeks.
89063144|NCT01600040|Other|Proton Radiation Therapy|This is a single arm study; all participants will receive proton radiation therapy.
89063145|NCT01365507|Experimental|IDegAsp Simple|
89063146|NCT01365507|Experimental|IDegAsp Step wise|
89063147|NCT02995694|Experimental|Test|Estradiol Vaginal Cream
89063148|NCT02995694|Active Comparator|Reference.|Estrace Vaginal Cream
89063149|NCT02995694|Placebo Comparator|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
89063150|NCT01365468|Experimental|Everolimus (RAD001)|enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.
89063151|NCT04827836|No Intervention|Cohort A - Room-temperature eye drops and povidone-iodine|Participants will receive a standardized topical anesthesia protocol of oxybuprocaine hydrogen chloride (HCl) 0.4% and lidocaine HCl 2% eye drops. Each drop will be instilled 3 times (one drop): At 10 minutes, 5 minutes, and just before the injection. Before the injection patients will receive cul-de-sac 5% povidone-iodine (3 drops) and the peri-ocular skin will be disinfected using a 10% povidone-iodine. A standard intravitreal injection of bevacizumab, 1.25 mg/0.05 ml will be performed through the pars plana with a 30-gauge needle, 3.5 mm from the corneal limbus, at the superior-temporal quadrant. Following the injection, a cotton swab absorbed with 5% povidone-iodine will be applied to the injection site.
89063152|NCT04827836|Experimental|Cohort B - Cooled eye drops and povidone-iodine|Participants will receive the same treatment as cohort A, using cooled eye drops and povidone-iodine (5 degree Celsius).
89063153|NCT01357980|Experimental|Dysport 750 U (15 injection sites)|
89063154|NCT01357980|Placebo Comparator|Placebo (15 injection sites)|
89063155|NCT01357980|Experimental|Dysport 750 U (30 injection sites)|
89063156|NCT01357980|Placebo Comparator|Placebo (30 injection sites)|
89063157|NCT01332318|Placebo Comparator|Placebo|XP13512 Placebo + Diphenhydramine Placebo
89063158|NCT01332318|Experimental|XP13512 1200 mg|XP13512 1200 mg/day + Diphenhydramine Placebo
89063159|NCT01332318|Experimental|XP13512 1800 mg|XP13512 1800 mg/day + Diphenhydramine Placebo
89063160|NCT01332318|Active Comparator|Placebo + Diphenhydramine|XP13512 Placebo + 50 mg Diphenhydramine
89063161|NCT02071901|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine by mouth (PO) daily (QD) until platelet counts reach >= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.
89063162|NCT01331109|Experimental|Milnacipran|oral administration, twice daily dosing
89063163|NCT01865396|Experimental|early palliative care|Interventional palliative care, after diagnosis and once a month.
89063164|NCT01865396|Active Comparator|Standard care|Patients will receive the standard oncologic care.
89063165|NCT01357551|Experimental|Maintenance intervention|Participants receive a theoretically-informed maintenance intervention for 42 weeks, followed by 14 weeks of no intervention contact to examine sustainability. The maintenance intervention involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
89063166|NCT01357551|No Intervention|Usual care|Participants receive usual care for 56 weeks
89063167|NCT01640483|Active Comparator|supportive|
89063168|NCT01640483|Active Comparator|interpretative|
89063169|NCT01640483|Active Comparator|mixed supportive/interpretative|
89063170|NCT01357239|Experimental|25 mg bid|
89063171|NCT01357239|Experimental|50 mg bid|
89063172|NCT01357239|Experimental|100 mg bid|
89063173|NCT01357239|Placebo Comparator|Placebo|
89063174|NCT04820582||Delphi Panel|A group of international experts comprising patients experts, gynecologists, radiologist, psychologists, nurses and researchers, were identified based on their expertise in the field or due to your active role in an endometriosis patient association that have accepted to participate to this study.
89063175|NCT00903500|Experimental|1|Daily physical activity
89063176|NCT00903500|No Intervention|2|Usual care
89063177|NCT00737321||2- Diabetics without wound (s)|These group of subject will be control arm, included who have good glycemic control diabetic with HbA1c 8.4 or lower and also without any open wounds. Samples will be collected.
89063178|NCT00737321||1-Subjects with diabetes with wound|This group of subjects will have wound and come for couple of follow up visits for saliva collection, biopsy collection and blood draw.
89063179|NCT01351350|Experimental|MLN0128P 30 mg QW|MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
89063180|NCT01351350|Experimental|MLN0128P 40 mg QW|MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
89063181|NCT01351350|Experimental|MLN0128P 6 mg QD×3d QW|MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
89063182|NCT01351350|Experimental|MLN0128P 7 mg QD×3d QW|MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
89063183|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
89063184|NCT01351350|Experimental|MLN0128P 9 mg QD×3d QW|MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
89063185|NCT01351350|Experimental|MLN0128P 10 mg QD×3d QW|MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
89063186|NCT01351350|Experimental|MLN0128P 7 mg QD×5d QW|MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
89063187|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW HER2-|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
89063188|NCT01351350|Experimental|MLN0128PH 8 mg QD×3d QW HER2+|MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on Day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
89063189|NCT02271503|Other|Sequence 1|Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
89221693|NCT03814252|Experimental|Lesion-targeted ablation with MRI-TULSA|Intervention: Targeted lesion based thermoablation of MRI-visible biopsy proven clinically significant prostate cancer. Ablative effect is aimed to cover lesion with 5 mm MRI based healthy tissue overlap wherever possible but not compromising viability of critical tissues, mainly the wall of rectum.
89221694|NCT02037620|Experimental|Epidural Stimulation|80 sessions each of epidural spinal cord stimulation for 1) cardiovascular function; 2) voluntary movement; and 3) standing.
89689980|NCT05017311|Placebo Comparator|Allocation by Predictive Biomarker Algorithm; Placebo|Patients are randomly assigned to the Allocation by Predictive Biomarker Algorithm group. Based on the outcome result from the personalized predictive biomarker algorithm, patients predicted to respond to escitalopram monotherapy will receive open-label escitalopram (10-20 mg/d) and blinded placebo for the first 8 weeks of the study. For the final 4 weeks of the study, responders will continue to receive open-label escitalopram without the placebo and non-responders will receive a combination of open-label escitalopram and open-label brexpiprazole.
89689981|NCT05017311|Active Comparator|Random Allocation; Escitalopram + Brexpiprazole|Patients are randomly assigned to the Random Allocation group and then randomly assigned to receive open-label escitalopram (10-20 mg/d) and blinded brexpiprazole (0.5-2 mg/d) for the first 8 weeks of the study. For the final 4 weeks of the study, patients will continue to receive both medications but the brexpiprazole will no longer be blinded.
89689982|NCT05017311|Placebo Comparator|Random Allocation; Placebo|Patients are randomly assigned to the Random Allocation group and then randomly assigned to receive open-label escitalopram (10-20 mg/d) and blinded placebo for the first 8 weeks of the study. For the final 4 weeks of the study, responders will continue to receive open-label escitalopram without the placebo and non-responders will receive a combination of open-label escitalopram and open-label brexpiprazole.
89689983|NCT03128086|Experimental|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation: performing a spontaneous breathing trial through a T-tube and after that to assess the patient's capacity to maintain airway. In case of reach a score the patient will extubated.
89689984|NCT03128086|No Intervention|Conventional weaning|A control group of weaning from mechanical ventilation according to the usual procedure: performing a spontaneous breathing trial through a T-tube and then extubation if the patient success this trial.
89689985|NCT05395273|Experimental|Cryocompression + standard therapy|Participants received daily crycompression by the patient to their comfort level beside the standard therapy.
89689986|NCT05395273|No Intervention|Standard therapy|The standard therapy include the common physical therapy interventions, which are normally used in the hospital.
89689987|NCT00982423|Experimental|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
89689988|NCT03073486|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
89689989|NCT03073486|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
89689990|NCT00983281||Hextend|Patients that received Hextend as part of their fluid resuscitation.
89221695|NCT01030354|Active Comparator|Dietary Intervention and Higher protein meal replacement|A higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass
89221696|NCT01030354|Active Comparator|Dietary Intervention and Standard Protein Meal Replacement|Standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
89221697|NCT00951470|Other|No CDT|CDT=complete decongestive therapy
89221698|NCT00951470|Other|Modified CDT Program|CDT=complete decongestive therapy
89221699|NCT00951470|Other|Full CDT Program|CDT=complete decongestive therapy
89221700|NCT01565746|Experimental|Radium-223 dichloride [50 kBq/kg]|
89221701|NCT01565746|Experimental|Radium-223 dichloride [100 kBq/kg]|
89221702|NCT01565746|Experimental|Radium-223 dichloride [expansion]|
89221703|NCT00951548|Experimental|VSL#3|Probiotic preparation VSL#3
89221704|NCT00951548|Placebo Comparator|placebo|Corn Starch
89221705|NCT01031602||Psych Needs Assessment|Female Sexual Function Index (FSFI), Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire given to underserved and minority women with a gynecologic cancer or premalignant condition.
89221706|NCT03994666|Experimental|simple dose|
89689991|NCT00983281||Standard of Care|Patients that received standard fluid resuscitation but no Hextend.
89689992|NCT03129178|Experimental|Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
89689993|NCT03129178|Experimental|Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
89689994|NCT03019393|Other|Beef|Beef topside fully cooked, 200g
89689995|NCT04741425|Experimental|REST intervention|There will be one session of online antenatal breastfeeding talk, 5 sessions of daily online postnatal individualized breastfeeding coaching, and 7 weekly postnatal telephone follow-ups.
89689996|NCT04741425|No Intervention|Usual care|"Standard antenatal and postnatal care provided by midwives and lactation consultants in the hospitals through by Zoom or by online self-learning through watching videos and reading pamphlets. Participants can also attend other breastfeeding talks or breastfeeding support groups provided by the non-governmental organizations for maternal care.~After delivery, mothers will be taught about baby care at bedside. Breastfeeding skills will also be taught and assessed by the midwives and lactation consultants individually or in group-based breastfeeding talk in the postnatal ward.~Upon discharge, a breastfeeding and postnatal hotline will be provided to all women for advices, and a telephone follow-up will be arranged for all the mothers within 3 to 4 days after delivery by midwives or lactation consultants. The mother-baby dyads will be suggested to follow up in MCHCs for baby growth and breastfeeding support."
89689997|NCT03129568|Experimental|CDC infusion|CDCs infusion by coronary intervention.
89063190|NCT02271503|Other|Sequence 2|Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.
89063191|NCT02271503|Other|Sequence 3|Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.
89063192|NCT01350999|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 52 weeks.
89063193|NCT01350999|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 52 weeks.
89063194|NCT01350999|Active Comparator|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.
89063195|NCT02275559|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
89063196|NCT02275559|Active Comparator|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
89063197|NCT01330914||Gastric Bypass Surgery Patients|Obese men and women undergoing gastric bypass surgery
89063198|NCT02270021|Experimental|Provider Mobile Application (ProvAPP)|Mobile phone application for providers.
89063199|NCT02270021|Experimental|ProvAPP + Patient Educational Tool (Tab)|Patient educational tool; plus the Mobile phone application for providers.
89063200|NCT02270021|No Intervention|ProvAPP Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
89063201|NCT02270021|No Intervention|ProvAPP+Tab Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
89063202|NCT01350804|Experimental|AIN457 10mg/kg - 75 mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
89063203|NCT01350804|Experimental|AIN457 10mg/kg - 150 mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
89063204|NCT01350804|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
89063205|NCT01350804|Active Comparator|Abatacept|Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).
89063206|NCT02274818|No Intervention|Standard Duty Hour Schedule|IM programs randomized to the currently mandated duty 16 hour standards (maximum work duration of 16 hours for interns and 28 hours for PGY2-3); this schedule may involve night float.
89063207|NCT02274818|Experimental|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~No more than 80 hours of work per week (when averaged over 4 weeks)~1 day off in 7 (when averaged over 4 weeks)~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
89063208|NCT04525781||1|
89063209|NCT04525508||Normal glucose tolerance (NGT)|Those of the study population with one normal Oral glucose tolerance test (OGTT)
89063210|NCT04525508||Dysglycemia|Those of the study population with one dysglycemia (IFG and/or IGT)
89063211|NCT04525508||Diabetic OGTT|Those of the study population with one Diabetic OGTT
89063212|NCT01350492|Experimental|Arm 1|Resistance exercise training
89063213|NCT01350492|No Intervention|Arm 2|Waitlist Control
89063214|NCT02270957|Active Comparator|Abatacept|Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.
89063215|NCT02270957|Placebo Comparator|Placebo|Patients receive placebo instead of Abatacept in a double blind fashion. Otherwise participation is the same, including that at the time of treatment failure they may elect any standard of care treatment and/or to begin taking open label abatacept but this rescue will define non-response in the primary endpoint at six months.
89063216|NCT01350414||Alair Group|Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)
89063217|NCT04525313||training set|58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2013.01 and 2017.12.
89063218|NCT04525313||validation set|another 58 unresectable simutaneous CRLM patients with ras mutation accepted Avastin plus chemotherapy treatment after primary tumor resection between 2018.01 and 2022.12.
89063219|NCT01350336|Experimental|Alair|Alair system
89063220|NCT04827290|Experimental|Normal-protein and low-AGE through raw or rare proteins diet|Normal-protein (0,8g/kg/day) and low-AGE through raw or rare proteins diet during 24 months
89063221|NCT04827290|Active Comparator|Normal-protein and AGE-rich diet|Normal-protein (0,8g/kg/day) and high-AGE through overcooked proteins diet during 24 months
89063222|NCT04826315|Experimental|Patient Caregiver Dyad|Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
89063223|NCT04523597||toracic hyperkyphosis|children with COBB angle ≥ 45˚
89063224|NCT04523597||control|children with kyphosis index < 13 measured using the flexicurve ruler
89221707|NCT03994666|Experimental|double dose|
89063225|NCT04823702|Experimental|Child-Pugh A (Mild Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
89063226|NCT04823702|Experimental|Child-Pugh B (Moderate Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
89063227|NCT04823702|Experimental|Child-Pugh C (Severe Hepatic Impairment) & Healthy Matched|Administered by subcutaneous injection
89063228|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397 (RP2D)|Subjects will be dosed at the recommended Phase 2 dose (RP2D)
89063229|NCT01349049|Experimental|oral dose of 800 mg/day of PLX3397|Level 0
89063230|NCT01349049|Experimental|oral dose of 1000 mg/day PLX3397|Level 1
89063231|NCT01349049|Experimental|oral dose of 1200 mg/day PLX3397|Level 2
89063232|NCT01349049|Experimental|oral dose of 1400 mg/day PLX3397|Level 3
89063233|NCT01349049|Experimental|oral dose of 2000 mg/day PLX3397|Level 4
89063234|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397|Level 5
89063235|NCT01349049|Experimental|oral dose of 4000 mg/day PLX3397|Level 6
89063236|NCT01349049|Experimental|oral dose of 5000 mg/day PLX3397|Level 7
89063237|NCT04829864|Experimental|STEP|Participants will participate, online or in-person, to the 8-9 sessions of the program addressing the psychological experience of pregnancy and supporting reflective capacities in relation to trauma and motherhood.
89063238|NCT04829864|No Intervention|Usual prenatal cares|Participants of the comparison group will receive usual prenatal cares (ex. prenatal classes)
89063239|NCT01348854|Experimental|Natural Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.
89063240|NCT01348854|Experimental|Post Cataract with Residual Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.
89063241|NCT01348776|Experimental|Hair2Go (Mē)|Subjects treated with Hair2Go (Mē) Device
89063242|NCT01348698||Adrenal Gland Neoplasm|To collect adrenal tumor tissue biopsy samples in order to study and evaluate new methods that may help identify cancerous or precancerous cells. Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor.
89063243|NCT01348542|Active Comparator|Trazodone|
89063244|NCT01348542|Active Comparator|Cognitive Behavioral Therapy|
89063245|NCT04827758|Other|Patients hospitalized in the follow-up care and rehabilitation units|
89063246|NCT04519307||Group 1|The newborns with covid 19 infection
89063247|NCT04519307||Group 2|The newborns with no covid 19 infection
89063248|NCT04826471|Experimental|DermoRelizema ecofoam|DermoReizema ecofoam for 42 days, 2 times per day
89063249|NCT01346709||In-patient Adult Non-obstetricSurgical|"Consecutive patients admitted to participating centres undergoing surgery Non-obstetric in-hospital surgical procedure, elective or emergent, under general anaesthesia (alone or in combination with regional/neuraxial anaesthesia), neuraxial anaesthesia or plexus block (with and without sedation).~All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible."
89063250|NCT04822766|Active Comparator|Chemotherapy|
89063251|NCT04822766|Experimental|Allogeneic Hematopoietic Cell Transplantation|Time of transplant procedure The best available treatments of AML
89063252|NCT04518839||Group with regional anaesthesia|
89063253|NCT04518839||Group with general anaesthesia|
89063254|NCT04828265|Experimental|Aldafermin 0.3mg|Subcutaneous injection of a single dose of aldafermin 0.3mg in healthy adult male Japanese or non-Japanese subjects
89063255|NCT04828265|Experimental|Aldafermin 1mg|Subcutaneous injection of a single dose of aldafermin 1mg in healthy adult male Japanese or non-Japanese subjects
89063256|NCT04828265|Experimental|Aldafermin 3mg|Subcutaneous injection of a single dose of aldafermin 3mg in healthy adult male Japanese or non-Japanese subjects
89063257|NCT01346592|Active Comparator|aTIV (6 to <72 months)|Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
89063258|NCT01346592|Active Comparator|Comparator TIV (6 to <72 months)|Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
89063259|NCT01346592|Active Comparator|TIV (6 to <72 months)|Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
89063260|NCT05139758|Experimental|hemiplegic cp|it will be classified into two subgroups according to body mass index to underweight and healthy weight .
89063261|NCT05139758|Experimental|diplegic cp|it will be classified into two subgroups according to body mass index to underweight and healthy weight .
89063262|NCT04822610|Experimental|Study group: interscalene block + IV PCA|preop usg guided interscalene block and IV PCA
89063263|NCT04822610|Experimental|Study group: suprascapular block + axillary block + IV PCA|preop usg guided suprascapular block + axillary block and IV PCA
89063264|NCT04822610|No Intervention|Control group: IV PCA|no block + IV PCA
89063265|NCT04515914||Decitabine therapy|The patients are treated with decitabine at least 1 cycles
89063266|NCT04515914||non-Decitabine therapy|The Patients are diagnosed as MDS and do not be treated with decitabine therapy
89063267|NCT01346514|Experimental|Arm 1: Addiction/Housing Case Management(AHCM)|The AHCM condition provided individual case management, delivered at the VA and in the community, designed to assist homeless Veterans with SUD issues who may be unable to take advantage of housing opportunities available in the VA due to difficulty navigating multiple services and maintaining stability with respect to SUD and co-occurring mental health conditions.
89063268|NCT01346514|Active Comparator|Arm 2: Housing Support Group(HSG)|The HSG condition involved a weekly drop-in housing support group.
89063269|NCT04825301||training cohort|data collection
89063270|NCT04825301||validation cohort|data collection
89063271|NCT01193335|Active Comparator|Group 1: Preterm infants|Infant born at < 37 weeks of gestation.
89063272|NCT01193335|Active Comparator|Group 2: Term infants|Infants born at ≥ 37 weeks of gestation
89063273|NCT02893995|Experimental|Slow Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 1.25 ng/kg/min of subcutaneous treprostinil with dose increases of approximately 1.25 ng/kg/min once every seven days for the first 4 weeks, then approximately 2.5 ng/kg/min every seven days thereafter according to clinical response and tolerability.
89063274|NCT02893995|Experimental|Rapid Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 2.0 ng/kg/min with dose increments of 1-2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate should be increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min has been achieved the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a dose rate of at least 10, 20, 30 and 40 ng/kg/min by the end of Weeks 1, 4, 8 and 12, respectively.
89063275|NCT04515485||Patients undergoing laparoscopy|The participants are patients that have undergone the laparoscopic surgery.
89063276|NCT01342887|Experimental|Treatment (immunosuppression, enzyme inhibitor, and chemo)|Patients receive cyclosporine IV continuously on days 5-9. Patients also receive pravastatin sodium PO every 6 hours on days 1-10, etoposide IV continuously on days 5-9, and mitoxantrone hydrochloride IV continuously on days 5-9. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/CRi may receive 2 additional courses in the absence of disease progression or unacceptable toxicity.
89063277|NCT04445610||A|mild
89063278|NCT04445610||B|moderate
89063279|NCT04445610||C|severe
89063280|NCT01342341|Experimental|Parafon Forte first, then Placebo|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).
89063281|NCT01342341|Placebo Comparator|Placebo first, then Parafon Forte|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).
89063282|NCT04444791||Cohort|This cohort study only set up one group. The habits and health status of mothers and their offspring will be followed up and observed. The participants will be divided into more than one group according to the variables (e.g. age, physical activity, dietary patterns, sleep quality.).
89063283|NCT04513847||Control|Psoriasis patients treated with non-biologic
89063284|NCT04513847||Non-Control|Psoriasis patients treated with biologic
89063285|NCT01340664|Experimental|Canagliflozin 50 mg bid|Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
89063286|NCT01340664|Experimental|Canagliflozin 150 mg bid|Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
89063287|NCT01340664|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 18 weeks
89063288|NCT01340625|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/35 mcg Chewable Tablets (Teva)
89063289|NCT01340625|Active Comparator|Reference Listed Drug|Ovcon® 35 Fe 0.4 mg/35 mcg Chewable Tablets (Warner Chilcott)
89063290|NCT04823468|Experimental|Experimental group|In addition to conventional dietary instruction and individualized nutritional counselling, patients were given additional ONS (Abbott®Ensure of 55.8 g tid) from the beginning to the end of radiotherapy.
89063291|NCT04823468|Other|Control group|Conventional dietary instruction and individualized nutritional counselling from the beginning to the end of radiotherapy.
89063292|NCT01340196|Experimental|sequence 1|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through day 22 (morning dose on day 22 only)
89063293|NCT04827212|No Intervention|Control|Control group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks
89063294|NCT04827212|Experimental|Treatment|Treatment group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks. In addition, the Companion will be deployed in the treatment group only.
89063295|NCT04826744||Adults with palpebral involvement of atopic dermatitis|
89063296|NCT02893332|Active Comparator|TKI without SBRT|"Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.~The oligometastatic disease will not receive SBRT"
89063297|NCT02893332|Experimental|TKI with SBRT|"experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.~SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions."
89221708|NCT03994666|Placebo Comparator|placebo|
89221709|NCT00951704||Cardiac arrest|
89063298|NCT04328493|No Intervention|Control arm|Patients randomized to the control arm will receive a standard of care therapy (a supportive care/treatment according to VN MoH's guideline).
89063299|NCT04328493|Experimental|Intervention arm|"In addition to standard of care therapy, patients randomized to the intervention arm receive chloroquine phosphate as below.~For adult ≥ 53kg: 1000mg (4 tablets) at initial dose (T=0), followed by 500mg (2 tablets) at 6 hours later (T=6), and 500mg (2 tablets) once daily for 9 days.~For adult from 45 - 52kg: 875mg (3.5 tablets) at T=0, followed by 500mg (2 tablets) at T=6 and 500mg (2 tablets) once daily thereafter.~For adult weighted 38 -<45 kg: 750mg (3 tablets) at T=0, followed by 375mg (1.5 tablets) at T = 6 and 375mg (1.5 tablets) once daily thereafter.~For adult weighted <38 kg: 625mg (2.5 tablets) at T=0, followed by 375mg (1.5 tablets) at T=6 and 375mg (1.5 tablets) once daily thereafter.~The total duration of treatment with chloroquine will be 10 days."
89063300|NCT04508465||OMEGA|Patients who have undergone major emergency abdominal surgery including the stomach, small or large bowel, or rectum for conditions such as perforation, ischemia, abdominal abscess, bleeding or obstruction.
89063301|NCT02893449|Other|SICRPPD group|(Specific Individual Cognitive Remediation Program in Parkinson's Disease). Group of patients profiting from a structured program of preoperative cognitive remediation
89063302|NCT02893449|Other|ICM group: Intensive Care Management|Group of patients profiting from a preoperative non structured support
89063303|NCT02893449|Other|CG group: Control Group|No supplementary support
89063304|NCT04396704||Botox|all eligible subjects, in a reverse consecutive order, initiated on onaBoNT-A from 01 March 2015 to 29 May 2017.
89063305|NCT04396704||Dysport|all subjects meeting inclusion/exclusion criteria and initiated on aboBoNT-A from 30 May 2017 to 30 March 2019.
89063306|NCT05139641|Placebo Comparator|control group|
89063307|NCT05139641|Experimental|counseling theraphy|
89063308|NCT05139641|No Intervention|Retrospective data|
89063309|NCT01600118|Active Comparator|ESWT|Extracorporeal shockwave therapy
89063310|NCT01600118|Placebo Comparator|ESWT Placebo|No extracorporeal shockwave therapy
89063311|NCT05139524||Health facility based cohort|Cohort of individuals with acute or reported fever enrolled at health facilities and followed up for upto 24 months.
89063312|NCT05139524||Community survey|Individuals enrolled in study as part of a cross sectional survey in the community.
89063313|NCT01327599|Experimental|DUOTRAV®|Travoprost 0.004%+Timolol 0.5% ophthalmic solution, 1 drop to the study eye(s) once a day at 8:00 PM for 12 weeks
89063314|NCT05139407|Experimental|Workshop|"The workshop is to discuss methods in various fields through activities, discussions, and lectures. It is an academic way to encourage participation, innovation, and predict solutions, suitable for people from different positions and ethnic groups to think, discuss, and communicate.~Each Intervention includes information relevant to how the Intervention was administered to participants in the associated Arm.~Workshop intervention for students: basketball training plan, basketball lesson plan, energy supply in muscle exercise, exercise prescription, track, and field mapping, basketball rules. All patients were intervened according to the frequency of 3 hours/once a week."
89063315|NCT05139407|Experimental|Oral examination|"The oral examination is a way of examination, which requires the examination to answer questions orally. Content intervention includes the comment, teacher's question and answer, proposition explanation, and proposition debate. In addition, each Intervention provides information relevant to how the Intervention was administered to students in the associated Arm.~Specific interventions for students: basketball training plan, basketball lesson plan, energy supply system, exercise prescription formulation, track and field venue planning, basketball game rules. All oral examinations take 90 minutes/once/week."
89063316|NCT04328415|Experimental|healthy volunteers|
89063317|NCT04328415|Experimental|patients with Chronic Kidney Disease|
89063318|NCT04329234||acute heart failure|Patients with acute heart failure
89063319|NCT04499768||control|the age-related cataract patients
89063320|NCT04499768||DR group|the cataract patients with mild/moderate NPDR
89063321|NCT02893215||Heart failure|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with heart failure, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
89063322|NCT02893215||Diabetes mellitus II|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with diabetes mellitus II, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
89689998|NCT04737759|Experimental|Taking Care of Us|Taking Care of Us involves seven sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. The program is a communication-based, relationship-focused intervention that is strengths-based and fosters new skills to support couples managing heart failure. The goals of the program are to 1) target the couple with heart failure as a team; 2) increase shared appraisal within the couple; 3) improve communication skills within the couple; 4) improve collaboration within the couple and dyadic management of heart failure; 5) improve confidence within the couple; and 6) improve both individual and dyadic health and well-being.
89689999|NCT04737759|Active Comparator|SUPPORT|The SUPPORT program involves three sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. This arm is an educational intervention to support management of heart failure.
89690000|NCT00983359|Experimental|Treatment (conformal stereotactic radiation therapy)|Patients undergo conformal stereotatic radiation
89690001|NCT04719819||Usual pratice|Assessment of usual practices
89690002|NCT02981719|Experimental|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment.
89690003|NCT02981719|Other|IRE group|percutaneous irreversible electroporation for locally advanced pancreatic cancer.
89690004|NCT03073876|Experimental|Drug|Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
89063323|NCT04498481||Breast cancer patients|HR+/HER2- advanced/metastatic breast cancer patients in the USA.
89063324|NCT04498559||Patients undergoing total hip replacement|Patients at HSS Main Campus undergoing primary total hip replacement surgery, age range between 18 and 80 years old, and English speaking
89063325|NCT05139329||Patients with symptoms of typical/atypical chest pain|Patients will be retrospectively included based on their presenting ICD codes or symptoms of typical/atypical chest pain, and those patients with positive ischemic workup will be excluded. The patients with negative ischemic workup will be included, and through chart review these patients will be followed to further assess their continued diagnostic workup.
89063326|NCT04393857||Oocyte donors|Healthy Oocyte donors fulfilling the criteria for oocyte donation are eligible. Patients may not have received any antibiotics or vaginal products (other than for menstrual hygiene - such as tampons) for the last 1 month. Informed consent is mandatory.
89063327|NCT04437927||Prospective patients|30 consecutive patients with cardiac FDG PET prescribed
89063328|NCT04437927||Control|30 patients referred for cardiac FDG PET in the nuclear medicine department of the Centre Hospitalier Princesse Grace
89063329|NCT01193257|Experimental|Orteronel + prednisone|
89063330|NCT01193257|Placebo Comparator|Placebo + prednisone|
89063331|NCT02886559|Experimental|DCCAG|Chidamide 30mg twice for one week decitabine 20mg/m^2 for 5 days
89063332|NCT05138978|Experimental|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
89063333|NCT05138978|Other|Colgate Cavity Protection|Toothpaste
89063334|NCT04493762||PSO/PSA|Patients diagnosed with psoriasis or psoriatic arthritis
89063335|NCT04493762||RA|Patients diagnosed with rheumatoid arthritis
89063336|NCT05138861|Experimental|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|TP-03, topical ocular administration in healthy adults. Single and multiple doses for 42 days.
89063337|NCT05138744|Experimental|Virtual reality treatment|Use of google maps with virtual reality to virtually situate the participants into scenarios that are motivating for them (i.e., the beach, a mountain, a park, etc.) at their choice.
89063338|NCT02893176|Placebo Comparator|Placebo|10mg will be administered one time daily
89063339|NCT02893176|Active Comparator|Active|10mg macitentan will be administered one time daily
89063340|NCT04435080||Non-rehabilitation|The patients hospitalised in ICU who were provided all the intensive care managements except for rehabilitation interventions (discharged from intensive care unit before April 14, 2020)
89063341|NCT04435080||Rehabilitation|The patients hospitalised in ICU who were provided rehabilitation interventions in addition to all the intensive care managements. (discharged from intensive care unit after April 14, 2020)
89063342|NCT05138627|Experimental|intervention|"Teaching of oral cryotherapy by the investigator in the hospital,~Implementation of oral cryotherapy accompanied by the investigator in the hospital~Individual application of oral cryotherapy at home by patients"
89063343|NCT05138627|No Intervention|control|Routine procedures in the clinic were performed on the first course (day 0) when the patients came to receive adjuvant chemotherapy and every 21 days thereafter, and oral cryotherapy was not applied to the patients. Before applying the first adjuvant chemotherapy, Nausea Vomiting Training and Guide was given to have equal conditions with the patients in the intervention groups.
89063344|NCT01193218|Experimental|BI 10773 low dose QD|BI 10773 tablets low dose once a day
89063345|NCT01193218|Experimental|BI 10773 mid-low dose QD|BI 10773 tablets mid-low dose once a day
89063346|NCT01193218|Experimental|BI 10773 mid-high dose QD|BI 10773 tablets mid-high dose once a day
89063347|NCT01193218|Experimental|BI 10773 high dose QD|BI 10773 tablets high dose once a day
89063348|NCT01193218|Placebo Comparator|Placebo|Placebo tablets once a day
89063349|NCT00592098|Experimental|1|2PX
89063350|NCT00592098|Placebo Comparator|2|Placebo
89063351|NCT04472663||Cohort 1|Retrospective Long-term Chart Review
89063352|NCT04472663||Cohort 2|Prospective-Retrospective Chart Review and Humanistic Burden
89063353|NCT01193101|Experimental|LCZ696 100 mg|LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
89063354|NCT01193101|Experimental|LCZ696 200 mg|LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
89063355|NCT01193101|Experimental|LCZ696 400 mg|LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.
89063356|NCT01193101|Placebo Comparator|Placebo|Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.
89063357|NCT02887846|Active Comparator|group 1|Heated humidified high-flow nasal cannula therapy device for post extubation
89063358|NCT02887846|Active Comparator|group 2|Nasal continuous positive airway pressure for post extubation
89063359|NCT04328805|Experimental|Ibuprofen|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
89063360|NCT04328805|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
89221710|NCT00951782|Active Comparator|High frequency TMS + smoking cue|
89221711|NCT00951782|Sham Comparator|Sham TMS + smoking cue|
89063361|NCT02886364|Other|Women delivered at AAC Hospital|The intervention is only being implemented at the Ángel Albino Corzo Hospital due to limited funding. The site was selected by the Ministry of Health in Chiapas as a hospital that would benefit from improved quality of care around childbirth. There are no other arms in this study.
89063362|NCT01192516|Experimental|Arm 1|Tailored activity pacing
89063363|NCT01192516|Experimental|Arm 2|General activity pacing and symptom management (Occupational therapy)
89063364|NCT01192516|No Intervention|Arm 3|Usual care group
89063365|NCT04329000|Experimental|On-demand PPI therapy|The patients in this group were advised to take PPI for 8 weeks continuously, followed by on-demand PPI therapy for the following 40 weeks.
89063366|NCT04329000|Active Comparator|Continuous PPI therapy|The patients in this group were advised to take PPI QD continuously for 48 weeks.
89063367|NCT01192399|Experimental|Eculizumab|Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses
89063368|NCT01600547||fall clinic population|women, aged + 65 years
89063369|NCT01600547||control fallers|randomly selected community aged matched female controls with a fall episode
89063370|NCT01600547||control non fallers|randomly selected community aged matched female controls, with out fall episodes
89063371|NCT01176916|Experimental|A|
89063372|NCT04328922|Active Comparator|Fecal microbial transplantation|FMT capsules fecal capsules on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will be matched to donors according to their CMV status (past exposure - CMV positive donors will be used for CMV positive patients, and CMV negative donors will be used for CMV negative patients).
89063373|NCT04328922|Placebo Comparator|Placebo|Placebo capsules placebo capsules- on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will receive placebo capsules.
89063374|NCT01192204|Active Comparator|10% FBR containing bioadhesive gel|Drug consisting of 10% FBR containing bioadhesive gel. Participants instructed to apply 0.5 gm of 10% FBR containing bioadhesive gel four times a day to lesional site
89063375|NCT01192204|Placebo Comparator|Placebo Gel|Color/consistency matched placebo (no black raspberry) gel
89063376|NCT01192126|Experimental|Bausch & Lomb new daily disposable|New daily disposable contact lenses
89063377|NCT01192126|Active Comparator|Johnson & Johnson Acuvue Moist|Contact lenses
89063378|NCT04469894||Niemann-Pick Type A|Also referred to as Infantile Neurovisceral ASMD
89063379|NCT04469894||Niemann-Pick Type A/B|Also referred to as Intermediate form or Chronic Neurovisceral ASMD
89063380|NCT04469894||Niemann-Pick Type B|Also referred to as Chronic Visceral ASMD
89063381|NCT04469894||Niemann-Pick Type C (Early Infantile)|Onset at less than 2 years of age
89063382|NCT04469894||Niemann-Pick Type C (Late Infantile)|Neurodegenerative form (late-infantile) onset at 2-6 years of age
89063383|NCT04469894||Niemann-Pick Type C (Juvenile)|Neurodegenerative form (juvenile) onset at 6-15 years of age
89063384|NCT04469894||Niemann-Pick Type C (Adult)|Psychiatric neurodegenerative form (adult) onset at greater than 15 years of age
89063385|NCT04469543||MTHFR polymorphism|
89063386|NCT02894268|Experimental|Regimen A|esomeprazole (E) 20 mg, doxycycline (D) 100mg, furazolidone (F) 100 mg, and colloidal bismuth subcitrate (B) 100 mg
89063387|NCT02894268|Active Comparator|Regimen B|two sensitivity antibiotics based on antibiotic sensitivity of helicobacter pylori culture, colloidal bismuth subcitrate (B) 100 mg, esomeprazole (E) 20 mg
89063388|NCT04467008||One group of patients|
89063389|NCT04466969||HF|"Patients with HF with reduced Ejection Fraction (HFrEF) is enrolled if patients meet following criteria within 6 months:~Ejection Fraction ratio（EF） ≤40%~New York Heart Association(NYHA) class II-IV"
89063390|NCT04466969||stages of CKD (stage 3b)|"CKD is diagnosed based on the following e Glomerular Filtration Rate (eGFR) categories:~Stage 3b: 30 mL/min/1.73m2 ≤ eGFR <45 mL/min/1.73m2"
89063391|NCT04466969||Stages of CKD (stage 4)|"CKD is diagnosed based on the following eGFR categories:~15 mL/min/1.73m2 ≤ eGFR <30 mL/min/1.73m2"
89063392|NCT04466969||stages of CKD (stage 5)|"CKD is diagnosed based on the following eGFR categories:~eGFR <15 mL/min/1.73m2"
89063393|NCT04466969||Treated by potassium binders|Patients who have been treated by Potassium Binders
89063394|NCT01600625|Experimental|Minocycline treatment group|
89063395|NCT01600664|Experimental|interactive computer game|"Participants will be using the interactive computer game- My Diabetic Friend, installed on Intel-powered convertible classmate PC."
89063396|NCT01600664|Active Comparator|Convertible PC|Participants will be using the convertible classmate PC without the interactive computer game
89063397|NCT02893839|Other|Prick to prick|
89063398|NCT01600742|Active Comparator|WBRT, placebo|
89063399|NCT01600742|Experimental|WBRT and concurrent vorinostat|
89063400|NCT04491227||Kidney disease in COVID-19|"Chronic Kidney Disease (CKD): Known diagnosis of chronic kidney disease; prior evidence of markers of kidney damage for 3 months (microalbuminuria, proteinuria >300mg/24 hrs or abnormalities in imaging tests) or the presence of glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for 3 months calculated with CKD-EPI equation, with or without other signs of kidney damage as described above.~ESKD: Patients that are dialysis dependent.~Suspected AKI: Oliguria (<200 mL/6 hours) and any AKI-related clinical signs or symptoms (see table 1) or urinalysis/dipstick abnormality. All suspected AKI cases must be confirmed prior to enrollment.~Confirmed AKI: Meeting of at least one of the modified KDIGO Criteria~Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours~Increase or decrease in serum creatinine > 50% from reference in 7 days~Urine output < 400 ml/day~Functioning Kidney transplant:"
89063401|NCT04386603||shoulder-tip pain group|The patients in this group have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
89063402|NCT04386603||non-shoulder-tip pain group|The patients in this group don't have postoperative phoulder-tip pain after laparoscopic surgery undergoing general anesthesia.
89063403|NCT01327482|Experimental|All|All patients were part of the intervention arm, as this was a pharmacokinetic study. All women took Raltegravir 400mg orally, twice daily for 3 weeks.
89063404|NCT04466189||Pancreatic Cancer Patients Treated With Proton Beam Therapy|Pancreatic Cancer Patients Treated With Proton Beam Therapy
89063405|NCT02893488|Experimental|SEQUENCE ABCDE|Participants will receive treatment A in period 1, treatment B in period 2, treatment C in period 3, treatment D in period 4 and treatment E in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with zero mineral content (ZMC) water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 milliliter (mL) stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 minutes(mins), re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
89221712|NCT00951782|Active Comparator|Low frequency TMS +smoking cue|
89221713|NCT00951782|Sham Comparator|Sham TMS - no cue|
89221714|NCT00951782|Active Comparator|High frequency TMS - no cue|
89221715|NCT00951782|Active Comparator|Low frequency - no cue|
89221716|NCT00945698|Other|ST-DI (Delayed intervention)|"1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
89063406|NCT02893488|Experimental|SEQUENCE BCDEA|Participants will receive treatment B in period 1, treatment C in period 2, treatment D in period 3, treatment E in period 4 and treatment A in period 5 (one treatment per period). Where A= EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
89063407|NCT02893488|Experimental|SEQUENCE CDEAB|Participants will receive treatment C in period 1, treatment D in period 2, treatment E in period 3, treatment A in period 4 and treatment B in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
89063408|NCT02893488|Experimental|SEQUENCE DEABC|Participants will receive treatment D in period 1, treatment E in period 2, treatment A in period 3, treatment B in period 4 and treatment C in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
89063409|NCT02893488|Experimental|SEQUENCE EABCD|Participants will receive treatment E in period 1, treatment A in period 2, treatment B in period 3, treatment C in period 4 and treatment D in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
89063410|NCT04328883|Active Comparator|162 mg Non-Enteric-Coated Chewable aspirin|Non-enteric coated aspirin (162mg, single dose)
89063411|NCT04328883|Experimental|50 mg ASA inhalation powder|Dry powder inhaled aspirin (50mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
89063412|NCT04328883|Experimental|100 mg ASA inhalation powder|Dry powder inhaled aspirin (100mg,1 dry powder inhalation capsule using dry powder inhaler, single dose)
89063413|NCT01600196|Experimental|Resection arm|Liver resection Plus Thrombectomy
89063414|NCT01600196|No Intervention|Best support care arm|Best supportive care
89063415|NCT00591669|Experimental|1|IBD patients
89063416|NCT00591669|Other|2|Control subjects
89063417|NCT01600235|Experimental|Phenylephrine|Phenylephrine induced-hypertension arm
89063418|NCT01600235|No Intervention|Conventional treatment|Control arm
89063419|NCT02893254|Experimental|IBI303|IBI303 40mg administered subcutaneously every other week, 12cycles
89063420|NCT02893254|Active Comparator|Adalimumab|Adalimumab 40mg administered subcutaneously every other week
89063421|NCT04429659||Group 1, patients with amblyopia and partially refractive ET|children with both amblyopia and partially refractive accommodative esotropia
89063422|NCT04429659||Group 2, patients with refractive ET|children with refractive esotropia
89063423|NCT02893137|Experimental|Craniectomy and Optune|Patients will receive best physician's choice chemotherapy along with Optune therapy and craniotomy surgery. Optune therapy will be administered in the standard configuration and in accordance with current guidelines with the exception of the surgical intervention.
89063424|NCT04464278||Case group: weight loss ≥ 5%|
89063425|NCT04464278||Control group: weight loss ≤ 5%|
89063426|NCT04428918||Cohort 1|Allogeneic HCT recipient or patient pending receipt of HCT
89063427|NCT04427748||congenital cataract group|children with congenital cataract who underwent lensectomy and anterior vitrectomy and IOL implantation are perfomed ERG
89063428|NCT04427748||age-matched normal children group|age-matched normal children are perfomed ERG
89063429|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Poor response|"If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction treatment, in many sites ifosfamide at high doses and MTP-PE (Muramyl tripeptide phosphatidylethanolamine), is incorporated in addition to adriamycin.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM (Adriamycin) 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)~All the product are used as commercial formulation~Other Names:~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
89063430|NCT04383288||Overexpression of ABCB1 / P-glycoprotein. Good response|"If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction treatment, in many centers the option of additional administration of methotrexate, CDDP (Cisplatinum) and adriamycin will be chosen.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)~All the product are used as commercial formulation~Other Names:~Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide"
89063431|NCT04383288||No overexpression of ABCB1 / P-glycoprotein|"If there is no overexpression of ABCB1 / P-glycoprotein, the administration of methotrexate, adriamycin and cisplatin will be chosen in many sites.~BEFORE SURGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~AFTER SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total length 34 weeks~All the product are used as commercial formulation~Other Names:~methotrexate cisplatin doxorubicine"
89063432|NCT04488302||Implant group|Patients with 1 or more implants with CBCT, ultrasound and open-bone images
89063433|NCT04487795||under 18 years old|
89063434|NCT04487795||18-40 years old|
89063435|NCT04487795||41-60 years old|
89063436|NCT04487795||over 60 years old|
89063437|NCT04487873||Bronchiectasis|Having been diagnosed with non-cystic fibrosis bronchiectasis
89063438|NCT04487873||Healthy individuals|Healthy individuals without chronic disease
89063439|NCT04482608||pMMR/MSS mCRC patients|The metastatic colorectal cancer patients with proficient mismatch repair or microsatellite stable status.
89063440|NCT04482608||dMMR/MSI-H mCRC patients|The metastatic colorectal cancer patients with deficient mismatch repair or microsatellite instability high status.
89063441|NCT04425213||Normal weight|BMI < 25 kg/m2
89063442|NCT04425213||Overweight|BMI : 25 - 29.9 kg/m2
89063443|NCT04425213||Moderate obesity|BMI : 30 - 39.9 kg/m2
89063444|NCT04425213||Severe obesity|BMI : > or = 40 kg/m2
89063445|NCT04328454||COVID-19 patients|Hospitalized patients with COVID-19
89063446|NCT04135248||IDF-DAR arm|Insulin management according to IDF-DAR guidelines (IDF-DAR arm) during the fasting period.
89063447|NCT04135248||DAFNE arm|Insulin management according to local experience (DAFNE arm) during the fasting period.
89063448|NCT00592137|Placebo Comparator|C|During one three week session of a controlled diet subjects will receive a smoothie based on soy protein two times per day that does not contain any additional calcium
89063449|NCT00592137|Active Comparator|B|During one three week period half of the participants will receive two smoothies per day based on soy protein that contain 650 mg Ca as calcium carbonate
89063450|NCT00592137|Active Comparator|A|During one three week session subjects will receive two smoothies per day based on dairy protein containing 650 mg calcium
89063451|NCT00592215|Experimental|A|Mifepristone followed by labor induction with misoprostol after 6-8 hours
89063452|NCT04479410||Drug resistant epilepsy patients|Patients with drug resistant epilepsy underwent epilepsy surgery
89063453|NCT04134507||Extended Depth of Focus IOL|Post-LASIK patients with implantation of a presbyopia-correcting IOL
89063454|NCT04134507||Monofocal IOL|Post-LASIK patients with implantation of a monofocal IOL
89063455|NCT00592332|Experimental|2|Hyperinsulinemic glucose clamp with Xanax given orally at beginning of each 2 hour clamp on day 1.
89063456|NCT00592332|Experimental|1|Hyperinsulinemic glucose clamp in group with no drug.
89063457|NCT04422873||in-centre|Currently dialysing in-centre
89063458|NCT04422873||home|Currently dialysing at home
89063459|NCT04454333||Hospitalized caused by COVID-19|A total of 466 patients hospitalized with the diagnosis of SARS-COV-2 at the University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital were retrospectively screened. 212 of these patients did not answer the calls, 34 of them could not be reached because they gave the wrong phone number beforehand. 4 of the patients called by the phone had communication problems due to language problems and 10 people did not want to fill the questionnaire. 206 of them were contacted by the phone and their pain and myalgia in the head, neck-back, waist, shoulder and hip regions before, during and after SARS-COV-2, their anxiety and depression levels after SARS-COV-2, and their quality of life were questioned.
89063460|NCT04476914||Family Member|Family members of ICU patients admitted with respiratory failure from COVID-19
89063461|NCT04420143||MLX - Medial Lateral Expandable Lumbar Interbody System|Patients who underwent lumbar interbody fusion with the MLX expandable interbody implant will be included in the MLX - Medial Lateral Expandable Lumbar Interbody System cohort.
89063462|NCT04420143||XLX ACR Interbody System|Patients who underwent lumbar interbody fusion with the XLX ACR expandable interbody implant will be included in the XLX ACR Interbody System cohort.
89063463|NCT01600274|Experimental|Diena|Dienogest-Ethinyl Estradiol (test product) tablet
89063464|NCT01600274|Active Comparator|Valette®|Dienogest-Ethinyl Estradiol (reference product) tablet
89063465|NCT01176565|Active Comparator|Standard SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the standard BP reduction group will be to reduce and maintain SBP < 180 mmHg for 24 hours from randomization. 160 mmHg is the target SBP for this arm.~For the standard group, SBP below the assigned treatment range is not artificially elevated to stay within the range if lower SBP occurs with nicardipine turned off (no fluid bolus given unless SBP falls below 110 mmHg with nicardipine off and there is risk for hypotension). Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
89063466|NCT01176565|Active Comparator|Intensive SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the intensive BP reduction group will be to reduce and maintain SBP < 140 mmHg for 24 hours from randomization. 125 mmHg is the target SBP for this arm.~For the intensive group, SBP falling below 110 mmHg (lower limit of the assigned treatment range) with nicardipine off is treated with normal saline fluid bolus to prevent or remedy hypotension. Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
89063467|NCT04451993||OSAS PATIENTS|mild, moderate and severe OSAS patients
89063468|NCT04451993||HEALTHY INDIVIDUALS|healthy individuals without chronic disease
89063469|NCT01600313|Experimental|treatment, control|
89063470|NCT01176292|Other|Rotating Platform High-Flex Cruciate Substituting TKA|
89063471|NCT01176292|Other|Rotating Platform Cruciate Substituting TKA|
89063472|NCT04315675|Experimental|Guided Imagery Intervention|Participants randomly assigned to this group will be provided with a MP3 Player which will have three guided imagery programs The Guided Imagery Programs include: 1.) Relaxation and Wellness; 2.) Immune System Imagery; and 3.) Healing Trauma.
89063473|NCT04315675|Experimental|Cognitive Power Intervention|The participant who is randomly assigned to this group completes The Power as Knowing Participation in Change Version II (PKPCT) to determine 1.) Freedom to Act Intentionally, 2.) Involvement in Creating Change, 3.) Freedom to Act Intentionally and 4.) My Involvement in Creating Change.
89063474|NCT04315675|Experimental|Cognitive Power Intervention and Guided Imagery|The participant is randomly assigned to this group completes both the Guided Imagery Intervention and the Cognitive Power Intervention.
89063475|NCT04315675|No Intervention|Control Group|The participant is randomized to the control group and completes all study measures twenty-one days after the baseline data are competed. .
89063476|NCT01600469|Experimental|DAOI-B|
89063477|NCT01600469|Placebo Comparator|Placebo|
89063478|NCT01113541|Experimental|Active treatment (switch to oral Ziprasidone)|
89063479|NCT01113502|Experimental|Phase 1 DL1|50 mg; Taken daily by mouth
89063480|NCT01113502|Experimental|Phase 1 DL 2|100 mg; Taken daily by mouth
89063481|NCT01113502|Experimental|Phase 1 DL3|200 mg; Taken daily by mouth
89063482|NCT01113502|Experimental|Phase 1 DL 4|300 mg; Taken daily by mouth
89063483|NCT01113502|Experimental|Phase 2|200 mg taken daily by mouth for 2 weeks; then 300 mg taken daily by mouth
89063484|NCT04474028||Hood group|The subject wears a mask and a hood, opens his/her mouth to breathe, and sticks out his/her tongue properly. Using the fitness test reagent to spray into the hood.
89063485|NCT04474028||Direct spray group|The subject wears a mask and his/her tongue sticks out properly. The suitability test reagent is used to spray directly to the subject from the top, bottom, left side and right side twice respectively.
89063486|NCT01113463|Experimental|TPI 287|TPI 287 Starting dose 160 mg/m^2 intravenous (IV) every 3 weeks
89063487|NCT02886403|Experimental|Cohort 02|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.~There are two visits:~The first visit:~Two adhesive strips (standard adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not.~The second visit:~Two adhesive strips (new adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not."
89063488|NCT01112917|Experimental|VenaTech Convertible Vena Cava Filter|Implantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.
89063489|NCT04473755||ADHD|This group will include participants who meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
89063490|NCT04473755||Non-ADHD|This group will include participants who do not meet DSM-5 diagnostic criteria for ADHD and meet all other study inclusion criteria.
89063491|NCT00591708|Experimental|B|Supplementation of a higher level of calcium (500-1300 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
89063492|NCT00591708|Experimental|A|Supplementation of a lower level of calcium (0-400 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
89063493|NCT01176058|Active Comparator|open label|
89063494|NCT04328766|Experimental|DWP14012 Cohort A|
89063495|NCT04328766|Experimental|DWP14012 Cohort B|
89063496|NCT04328766|Experimental|DWP14012 Cohort C|
89063497|NCT01600781|Active Comparator|NutriniDrink/Fortini group|this group will receive 2 bottles of NutriniDrink/Fortini MF unflavoured daily (200 ml each) and standard dietary counselling for a period of 6 weeks.
89063498|NCT01600781|No Intervention|control group|this control group will only receive standard dietary counselling
89063499|NCT04415502||Measuring of CTHRc1 , its correlation with RAdisease activity|Measuring of CTHRc1 levels and its correlation with RA disease activity
89063500|NCT01600820|Experimental|1 = Tested product 1|
89063501|NCT01600820|Experimental|2 = tested product 2|
89063502|NCT01600820|Placebo Comparator|3 = Control product|
89063503|NCT04371003||WNND|40 subject with West-Nile Neuroinvasive Disease will be recruited
89063504|NCT04371003||WNF|40 subject with West-Nile Fever will be recruited
89063505|NCT04371003||controls|20 control will be recruited. These controls will be aged matched to the cases.
89063506|NCT01600859|Experimental|E2609|
89063507|NCT01600859|Placebo Comparator|Placebo for E2609|
89063508|NCT01607021||Chinese children with HCV RNA positive|"A sample of 200 children with a recent confirmation of anti-HCV-antibody positive and HCV RNA positive. All the children were treated with antiviral therapy, and the course of treatment depend on HCV Viral genotyping(ie, genotype 1,2,3,4 subtypes).~Primary Outcome Measures:~Virologic response [ Time Frame: Weeks 2, 4, 6, 8, 10, and 12 ] Sustained virologic response (SVR, defined as plasma HCV RNA < lower limit of quantification [LLoQ] at 24 weeks after treatment cessation) following antiviral treatment.~Secondary Outcome Measures: Safety and tolerability of therapy. [ Time Frame: Up to 48 weeks ] measured by frequency of laboratory abnormalities , reported adverse events and discontinuations due to adverse events"
89063509|NCT04328142|Experimental|Qigong|The Qigong experimental group performed the 20 figures to improve health and longevity described by the master of Qigong 'Wang Ziping'. These are based on therapeutic exercises of Traditional Chinese Medicine. They work on breathing, flexibility and balance. Each figure was repeated 6 times. The sessions were administered twice a week during 45 minutes and were guided by a Doctor in Western Medicine who is also qualified as a Doctor of Traditional Chinese Medicine and Qigong teacher.
89063510|NCT04328142|Experimental|Physiotherapy|The physiotherapy experimental group completed an active exercises program guided by a qualified physiotherapist. The exercise programme was based on active shoulder, hips and spine kinesiotherapy. It included a warm up of 3-5 minutes walking, followed by 6 repetitions of shoulder and hip exercises in standing, cervical spine exercises in sitting or standing, according to the comfort of the patient, thoracic and lumbar spine exercises performed in supine on a mat and balance exercises in standing. Stretching exercises were also performed at the end of the session. The exercises were accompanied by gentle breathing coordinated with the movements. The sessions were administered twice a week during 45 minutes.
89063511|NCT04328142|No Intervention|Control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
89063512|NCT01607099|Experimental|Pico Prep|Arm in which sodium- picosulfate/magnesium citrate is used for bowel cleansing
89063513|NCT01607099|No Intervention|Standard|The standard drug macrogol is used for bowel cleansing
89063514|NCT02273765|Active Comparator|Raltegravir|Tenofovir 300mg QD + lamivudine 300mg QD + raltegravir 400mg BID
89063515|NCT02273765|Experimental|Efavirenz|Tenofovir 300mg QD + lamivudine 300mg QD + efavirenz 600mg QD
88821203|NCT04902911||Antigen testing in those who have history of COVID-19|Individuals must have had history of COVID-19. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
89063516|NCT01607138||Total laryngectomy|A group of patients who underwent total laryngectomy with trechea esophageal puncture (TEP)
89063517|NCT02277470||Golimumab|Patients who are eligible for golimumab therapy.
89063518|NCT00591747|Experimental|1|Progressive resistance training program 3 times a week for 12 months
89063519|NCT00591747|Active Comparator|2|Flexibility training 3 times a week for 12 months
89063520|NCT01607177|Experimental|Text message group|Patients randomised to this group will receive daily text message reminders used to motivate them to exercise in the preoperative period. They will also receive an exercise information sheet to complement the text messages.
89063521|NCT01607177|No Intervention|No text message group|Patients randomised to this group will receive standardised exercise advice but will not receive the text message reminders or the exercise information sheet.
89063522|NCT02279888||CardioMEMS HF System Group|Patients implanted with a CardioMEMS HF System.
89063523|NCT01607216||Premature Infant|Infants born 23 0/7 weeks gestation to 35 6/7 weeks gestation.
89063524|NCT01607216||Healthy Full Term Infants|Infants born between 37 0/7 weeks gestation to 41 6/7 weeks gestation.
89063525|NCT02489591|No Intervention|Control|No oral appliance (control) first, oral appliance (BluePro oral appliance or other device) second
89063526|NCT02489591|Experimental|Oral appliance|oral appliance (BluePro oral appliance or other device) first, no oral appliance (control) second
89063527|NCT01607333||Completed suicide|Patients who completed suicide
89063528|NCT01607333||Suicide attempt|Patients who have attempted suicide, or performed preparatory acts toward imminent suicidal behavior, suicidal ideation plus indeterminate or potentially suicidal events
89063529|NCT01607333||Not completed suicide|Patients who have not completed suicide
89063530|NCT02892981|Other|Pulmonary hypertension patients|All Pulmonary hypertension patients enrolled in the study underwent a cardiopulmonary exercise test and hypoxia and hypercapnia tests
89063531|NCT04413474||Study group|Unselected critically ill patients who met the inclusion criteria
89063532|NCT01601015|Experimental|Manual therapy|Manual therapy of Suboccipital soft tissue Inhibition treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
89063533|NCT01601015|Experimental|Occiput-atlas-axis joint manipulation|Is bilaterally administered. The aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction
89063534|NCT01601015|Experimental|Combined treatment|The group receiving combined treatment received the two previous techniques exactly with the same sequence.
89063535|NCT01601015|Placebo Comparator|Control group|Control group not receive treatment and stayed in this position for 10 minutes
89063536|NCT02893098|Experimental|Humia inj.|Participants with symptomatic Primary Osteoarthritis of Knee received a single injection of 3ml Humia inj.
89221717|NCT00945698|Experimental|LNS-10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
89221718|NCT00945698|Experimental|LNS-20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
89221719|NCT00945698|Experimental|LNS-20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
89221720|NCT00945698|Experimental|LNS-40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
89221721|NCT00945698|Experimental|LNS-40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
89221722|NCT01565824|Experimental|Web-based support|The subjects will get access to a website where they can store blood glucose levels, read specialized information concerning pregnancy and early motherhood, and access a discussion forum for peer support.
89221723|NCT01565824|No Intervention|Usual care|
89221724|NCT01030510|Active Comparator|group R|In group R, remifentanil was infused first before administrating propofol and rocuronium
89221725|NCT01030510|Active Comparator|group P|in group P, remifentanil was administered last after the propofol and rocuronium injection
89221726|NCT00941876|Experimental|A. Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
89221727|NCT04813822|Experimental|Miconazole Nitrate 2% + Domiphen Bromide Low Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
89221728|NCT04813822|Experimental|Miconazole Nitrate 2% + Domiphen Bromide High Dose Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
89221729|NCT04813822|Active Comparator|Gyno-Daktarin® Vaginal Cream|The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.
89221730|NCT00951860||Newborn|Every child born in the CHU of Saint-Étienne (inborn), any term of its birth, in the hospital neonatal unit at the time of registration (after 37 weeks corrected for prematurity) or in the maternity
89221731|NCT00945776|Active Comparator|Weekly phone calls|Will be called weekly to answer questions regarding usage.
89221732|NCT00945776|Active Comparator|Frequently asked questions|Providing written general answers to commonly asked questions.
89221733|NCT00945776|Active Comparator|Usual care|
88821204|NCT04902911||Antigen testing in those who do not have history of COVID-19 and COVID immunization|Individuals may not have history of COVID-19 and COVID immunizations in order to be eligible. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
89221734|NCT02917564|Sham Comparator|Control|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, a 3 ml syringe will be placed into the superotemporal conjunctival fornix but no needle is present and no drug injected."
89063537|NCT02893098|Active Comparator|High Hyal Plus inj.|Participants (Control Group) with symptomatic Primary Osteoarthritis of Knee received single injection of 2ml High Hyal Plus inj. given weekly for 3 weeks
89063538|NCT01601054|Active Comparator|Anterior lumbar interbody fusion|Anterior lumbar interbody fusion using a tantalum cage. Cage will be inserted through a left sided retroperitoneal approach.
89063539|NCT01601054|Active Comparator|Posterior instrumentation alone|Posterior pedicle screw instrumentation
89063540|NCT01607528|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day
89063541|NCT01607528|Placebo Comparator|Placebo|A similar looking and tasting powder
89063542|NCT04367610||Study Group|Kidney transplant recipients with biopsy-proven acute or chronic antibody-mediated rejection who were treated using 6 sessions of therapeutic plasma exchange, 2 g/kg of intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2 rituximab.
89063543|NCT01601093|Experimental|High dose|Ceftazidime 3g
89063544|NCT01601093|Experimental|Low dose|Ceftazidime 2g
89063545|NCT01601093|Active Comparator|CFP/SUB|Cefoperazone and sulbactam sodium for injection(2:1)
89063546|NCT04328571|Experimental|OLE enzymatically treated|Participants will receive 1 capsule of OLE enzymatically treated + 1 stick of maltodextrin each day in the morning for 21 days
89063547|NCT04328571|Experimental|OLE + probiotic|Participants will receive 1 capsule of OLE + 1 stick of probiotic each day in the morning for 21 days
89063548|NCT04328571|Active Comparator|OLE|Participants will receive 1 capsule of OLE + 1 stick of maltodextrin each day in the morning for 21 days
89063549|NCT01175824|Experimental|Insulin lispro low mixture (LM)|Two daily injections (breakfast and dinner) of insulin lispro mix 75/25
89063550|NCT01175824|Active Comparator|Insulin glargine+insulin lispro|Once-daily (bedtime) basal insulin glargine and once-daily (before the main meal with the highest average 2-hour postprandial blood glucose concentration) prandial insulin lispro
89063551|NCT02482532|Experimental|tvs-CTL Vaccine|Infusion of activated T-cells generated from a patient's own peripheral blood mononuclear cells.
89063552|NCT01607684|Other|Diabetes mellitus group|Subjects with Diabetes mellitus and symptoms of diabetic gastroparesis
89063553|NCT01607684|Other|Control group|Healthy volunteers as matched pairs according to gender and age
89063554|NCT01601210|Placebo Comparator|Placebo|
89063555|NCT01601210|Active Comparator|2 grams of creatine|
89063556|NCT01601210|Active Comparator|4 grams of creatine|
89063557|NCT01601210|Active Comparator|10 grams of creatine|
89063558|NCT01175707|Experimental|Daptomycin|500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted
89221735|NCT02917564|Active Comparator|Injection|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, 1mL of a 40 mg/ml suspension of triamcinolone acetonide is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down."
89221736|NCT00941954|Experimental|Lifestyle counseling|A group-based structured educational programme.
89221737|NCT00941954|Active Comparator|Control|Written Information (booklet).
89221738|NCT03079414||Unexplained Aborted Cardiac Arrest|Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
89221739|NCT00945932|Experimental|28 day repeat dose|
89221740|NCT01031758|Other|Group 1|Group 1 is comprised of 6 healthy subjects with HDL-C levels between the 25th and 75th percentile.
89221741|NCT01031758|Other|Group 2|Group 2 is comprised of 6 healthy subjects with high HDL-C levels > 75th percentile.
89221742|NCT01031758|Other|Group 3|Group 2 is comprised of 6 healthy subjects with low HDL-C levels < 25th percentile.
89221743|NCT05300828||Genexol PM|Genexol PM/carboplatin combination treatment is performed as an adjuvant treatment after cytoreductive surgery for newly diagnosed ovarian cancer.
89221744|NCT05300750|Experimental|Oral Fluid|The oral fluid intake was in form of peppermint or anise
89221745|NCT05300750|Experimental|Chewing Gum|Free sugar gum
89221746|NCT05300750|No Intervention|Standard hospital care|Control group
89221747|NCT00952094|Active Comparator|KRN1493 50mg group|KRN1493 50mg single oral administration
89221748|NCT00952094|Active Comparator|KRN1493 75mg group|KRN1493 75mg single oral administration
89221749|NCT00952094|Active Comparator|KRN1493 100mg group|KRN1493 100mg single oral administration
89221750|NCT00942110|Experimental|CPAP|
89221751|NCT00952250|Active Comparator|Targeted Feedback Reports|Conventional feedback reports
89221752|NCT00952250|Experimental|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement.
89221753|NCT00952328|Experimental|Limited Formula|Participants will supplement feedings with early limited formula following nursing
89221754|NCT00952328|No Intervention|Control|Participants are instructed to continue exclusively breastfeeding; no use of formula
89221755|NCT00952406||Survey of Women PFDs|Women with PFDs
89221756|NCT00946010||1|Click here for more information about this study: Investigation of Hepatitis B and Hepatitis C in Taiwan
89221757|NCT00436852|Experimental|Measurable disease by CT or MRI scan (ABT-751 chemotherapy)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
89221758|NCT00436852|Experimental|Evaluable by I-MIBG scintigraphy (ABT-751)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
89221759|NCT00946166|Placebo Comparator|Placebo Control|Subjects receive standard treatment for pneumonia and a simvastatin-like placebo
89221760|NCT00946166|Experimental|Simvastatin|Subjects receive simvastatin in addition to standard pneumonia treatment
89221761|NCT00952562|Active Comparator|cholecalciferol|3000 IU cholecalciferol per day for 16 weeks
89221762|NCT00952562|Placebo Comparator|placebo|
89221763|NCT00952640|Active Comparator|vitamin A directly post-partum|200.000 IU of vitamin A within 3 days of delivery
89221764|NCT00952640|Experimental|vitamin A delayed|200.000 IU vitamin A 6 weeks post-partum
89221765|NCT00942500|Experimental|Post-conditioning|
89221766|NCT00942500|No Intervention|Conventional primary PCI|
89221767|NCT00946244||Term infants|Healthy term infants
89221768|NCT00946244||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth
89221769|NCT00946244||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in previous study)
89221770|NCT00946244||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in previous study)
89221771|NCT00952796|Experimental|1|patients with intra-abdominal infection treated with moxifloxacin 400mg once daily
89221772|NCT00952796|Active Comparator|2|patients with intra-abdominal infection treated with ampicillin/sulbactam 1.5g 4 times daily
89221773|NCT00953030|Experimental|COACH|"web-based risk assessments with an action plan that is negotiated with a Coach who provides personalized follow-up reinforcement"
89221774|NCT00953030|Experimental|RealAge|a web-based health risk assessment and risk profile with disease-specific follow-up reinforcement modules
89221775|NCT00953030|No Intervention|light health education control|
89221776|NCT00953108|Experimental|quetiapine|
89221777|NCT00953108|Active Comparator|escitalopram|
89221778|NCT00953186|Active Comparator|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
89221779|NCT00953186|Placebo Comparator|Placebo|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
89221780|NCT00953264|Experimental|life style intervention|
89221781|NCT00953342|Experimental|Aerobic exercise|12 weeks of supervised aerobic exercise and standard care
89063559|NCT01175707|Active Comparator|Vancomycin|Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician
89063560|NCT01601249|Experimental|Polscope based embryo grading|Embryos for transfer will be selected based on highest polscope scores, unless are not grade 1-2 by conventional morphology
89063561|NCT01601249|Active Comparator|Morphology based embryo grading|Conventional embryo grading and decision making
89063562|NCT02892903|No Intervention|Conventional angiography|Routine angiography will be performed according to local best practice
89063563|NCT02892903|Experimental|Routine Measurement of FFR|Additional investigation with the measurement of FFR in all major vessels
89063564|NCT01112059|Placebo Comparator|Placebo|Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation
89063565|NCT01112059|Active Comparator|doxycycline|Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation
89063566|NCT01175668|Experimental|NMS/Clonidine|
89063567|NCT01175668|Active Comparator|NMS/Phenobarbital|
89063568|NCT01601327|Other|hypogonadism, treatment|77 patients with idiopathic hypogonadotropic hypogonadism were treated with testosterone gel, testosterone enanthate or human chorionic gonadotropin
89063569|NCT01601327|No Intervention|Control group|42 healthy controls
89063570|NCT04412499||Methylphenidate + parent-training programm|Methylphenidate and participation in a parent-training programme
89063571|NCT04412499||Methylphenidate alone|Methylphenidate alone
89063572|NCT01607723|Other|NAVA ventilatory mode|
89063573|NCT01607723|Other|PAV+ ventilatory mode|
89063574|NCT01601366|Experimental|LNG-IUS (Mirena)|"Group I the LNG-IUS group where they will have a LNG IUS (mirena) inserted for them"
89063575|NCT01601366|Active Comparator|Combined oral contraceptives|"Group II COCs group where they will receive low dose combined oral contraceptive pills for 6 months"
89063576|NCT01607762|Experimental|Cohort A: Aripiprazole|
89063577|NCT01607762|Experimental|Cohort B: Quetiapine|
89063578|NCT01607762|Experimental|Cohort C: Olanzapine|
89063579|NCT01607762|Experimental|Cohort D: Risperidone|
89063580|NCT01607762|Experimental|Cohort E: Paliperidone|
89063581|NCT01607801||non-absorbable suture NAS|having their umbilical hernia repaired with NAS
89063582|NCT01607801||Long-term-absorbable suture (LAS)|patients having their umbilical hernia repair with LAS
89063583|NCT01607801||Absorbable sutures (AS)|patients having their umbilical hernia repair with AS
89063584|NCT01607801||Mesh repair|Patients having umbilical hernia mesh repair
89063585|NCT04327869||Abdominal symptoms group|The investigators selected 10 subjects (male: female = 1: 1) from patients with a recent history of upper-gastrointestinal symptoms who met the indication of taking sucralfate suspension gel
89063586|NCT04327869||Healthy control group|The investigators selected another 10 subjects (male: female = 1: 1) from healthy volunteers.
89063587|NCT01607840|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
89063588|NCT01607840|Experimental|Cathodal|transcranial direct current stimulation using cathodal stimulation over the brain area of interest
89063589|NCT01607840|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without actually delivering tDCS
89063590|NCT04327947|Experimental|women, 18-39 y|Health volunteers, 18-39 y, with vaginal dryness
89063591|NCT04327947|Experimental|premenopause women|Health volunteers, 40 years to premenopause, with vaginal dryness
89063592|NCT04327947|Active Comparator|climacteric women|Health volunteers, climacteric, with vaginal dryness
89063593|NCT01601483|Experimental|MC-1101 1% Ophthalmic Solution|
89063594|NCT01601483|Placebo Comparator|Vehicle control|
89063595|NCT01607918|Experimental|Sequential therapy 10 days|Sequential therapy
89063596|NCT01607918|Active Comparator|Triple therapy 14 days|Triple therapy
89063597|NCT01607996|Active Comparator|Patient controlled intravenous analgesia|Fentanyl (10 microg/ml) continuous intravenous infusion at a rate of 10 to 20 microg/h
89063598|NCT01607996|Experimental|Epidural anesthesia|Carbostesin (0.1%) and Fentanyl (2 microg/ml) at a continuous flow of 6 to 15 ml/hour
89063599|NCT04361565||Individuals diagnosed for COVID-19|
89063600|NCT01601561|Experimental|High-dose insulin|
89063601|NCT01601561|No Intervention|Control|
89221782|NCT00953342|Placebo Comparator|Usual care|12 weeks of standard care
88821205|NCT04902703|Experimental|Sargramostim|250 mcg/m2/day subcutaneously 5 days/week for 24 weeks
88821206|NCT04902703|Placebo Comparator|Placebo Control - Saline|Placebo comparator (saline) subcutaneously 5days/week for 24 weeks
89063602|NCT01601717|Placebo Comparator|Sugar pill|
89063603|NCT01601717|Active Comparator|RTI-336|
89063604|NCT01601756|Experimental|navigated revision total knee arthroplasty|revision total knee arthroplasty with the aid of a navigation system
89063605|NCT01601756|Active Comparator|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
89063606|NCT04327830||Older adults and their caregivers|Older adults who have received or are receiving home care services and their caregivers
89063607|NCT04327830||Interdisciplinary health and social care providers|Interdisciplinary health and social care providers who provide home care services to older adults
89063608|NCT01601795|Active Comparator|Sevoflurane|During cardiopulmonary bypass, sevoflurane will be administered through a vaporizer integrated into heart-lung-machine.
89063609|NCT01601795|Active Comparator|Isoflurane|During cardiopulmonary bypass, isoflurane will be administered through a vaporizer integrated into heart-lung-machine.
89063610|NCT01608035|Experimental|sciatic catheter|
89063611|NCT01608035|Active Comparator|Stump catheter|
89063612|NCT04359693||SARS-CoV2 group|Patients receiving invasive mechanical ventilation for more than 48h with SARS-CoV-2 infection
89063613|NCT04359693||Flu group|Patients receiving invasive mechanical ventilation for more than 48h with influenza infection
89063614|NCT04359693||No viral infection group|Patients receiving invasive mechanical ventilation for more than 48h with no viral infection at ICU admission
89063615|NCT01601912||Atomoxetine NRI|We will modulate endogenous adrenergic pain inhibitory mechanisms by using a selective norepinephrine reuptake inhibitor (NRI).
89063616|NCT01601912||Citalopram SSRI|We will modulate serotonergic pain inhibitory mechanisms by using a selective serotonin reuptake inhibitor (SSRI)
89063617|NCT04359498||LAR for rectal cancer|Retrospective chart review for surgical complications related to the LAR surgery, the stoma (diverting loop ileostomy) creation and the stoma reversal procedure after LAR for rectal cancer.
89063618|NCT02489201|Experimental|donafenib tosilate tablets|200mg bid
89063619|NCT01601951||Hip Osteoarthritis|
89063620|NCT01601951||Knee Osteoarthritis|
89063621|NCT01111825|Experimental|Temsirolimus plus Neratinib|This is an open-label, single arm, dose-escalation phase I-II study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and efficacy of this combination when given to patients with advanced breast carcinoma. Patients with trastuzumab-refractory HER2-amplified disease or triple negative disease will be enrolled in both phases of this clinical trial.
89063622|NCT01608191|No Intervention|Ordinary primary care follow up|Ordinary follow up after 24 weeks of LCD diet + reintroduction of food.
89063623|NCT01608191|Active Comparator|CBT follow up|11 weeks intervention programme with CBT conducted via internet.
89063624|NCT01175590|Experimental|Besivance|besifloxacin ophthalmic suspension 0.6%
89063625|NCT01175590|Placebo Comparator|Vehicle|Vehicle of Besivance
89063626|NCT01601990|Placebo Comparator|Placebo|
89063627|NCT01601990|Experimental|LC15-0444|
89063628|NCT01175473|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD for up to Week 4.
89063629|NCT01175473|Active Comparator|Liraglutide|2-step initiation regimen of liraglutide: 0.6 milligram (mg) QD subcutaneously for 1 week, followed by 1.2 mg QD for 1 week, then 1.8 mg QD up to Week 4.
89063630|NCT01602107|No Intervention|Control|Participants in the control group will not receive therapist-supervised intervention. An exercise sheet briefly describing pelvic floor muscle exercises will be provided, as would be the standard practice from most physicians.
89063631|NCT01602107|Experimental|Pelvic Floor Therapy|Participants in the experimental group undergo and assessment and treatment by a registered physiotherapist. Treatments will include two sessions of biofeedback training, therapist-assisted strengthening exercises, and will a prescribed home exercise program to strengthen their pelvic floor muscles.
89063632|NCT01602146||ultramarathon runner|People who do the Mont Blanc ultramarathon (31/08/12 to 02/09/12)
89221783|NCT00953498|Active Comparator|pioglitazone|treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)
89221784|NCT00953498|Active Comparator|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
89221785|NCT00942812|Experimental|Intervention|A diarrhea Pack comprising of low osmolality ORS, Zinc, water purification sachets and pictorial chart.
89221786|NCT00942812|Other|Control|Standard Care through National LHW (Lady Health Workers)program
89221787|NCT00943046|Experimental|Siello pacemaker lead|Patients with Siello Pacemaker lead
89221788|NCT04012034|Experimental|Radiofrequency A|Treatment with radiofrequency
89221789|NCT04012034|Placebo Comparator|Placebo|Treatment with radiofrequency without energy
89221790|NCT00946400||Suspected HIT|Those who are clinically suspected of having HIT will be enrolled in this study.
89221791|NCT00943280||1 EGD|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to EGD.
89221792|NCT00943280||2 Transnasal|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to Transnasal endoscopy.
89221793|NCT00943280||3 PillCam|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to PillCam.
89221794|NCT05301296|No Intervention|Control Arm|Standard of Care.
89221795|NCT05301296|Active Comparator|Intervention Arm|Clinical examination of the breast for early detection of Cancer.
89221796|NCT00943358|Active Comparator|Vaccine|adjuvanted influenza vaccine
89221797|NCT00943358|Active Comparator|Vaccine 2|non-adjuvanted vaccine
89221798|NCT00120289|Experimental|Combination Therapy|Extended release niacin plus simvastatin
89221799|NCT00120289|Active Comparator|Monotherapy|Simvastatin alone
89221800|NCT00946556|Placebo Comparator|Placebo|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
89221801|NCT00946556|Experimental|Valacyclovir|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
89221802|NCT00946634|Experimental|Ozone Gas|Endodontic protocol preconized by University of Sao Paulo associated to ozone gas 40 mg/L
89221803|NCT00946634|Active Comparator|Control|Regular endodontic protocol preconized by University of Sao Paulo
89221804|NCT00946634|Experimental|Aqueous Ozone|Endodontic protocol preconized by University of Sao Paulo associated to Aqueous ozone 40mg/L
89221805|NCT00953732||1|
89221806|NCT04011488|No Intervention|Standard patient information data sheet|
89221807|NCT04011488|Experimental|SDM Tool|A simple, one-page tool that provides a framework for the patient discussion, which improves the consistency of the patient-provider communication. This SDM can also be customized to a specific patient based on gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).
89221808|NCT01083277|Experimental|variable ventilation|A novel means of conducting mechanical ventilation that involves an approximately 40% variation in tidal volume around a set mean tidal volume
89221809|NCT01083277|Other|conventional ventilation|This is the control arm of the study, in which tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
89221810|NCT00943748|Active Comparator|deferiprone|deferiprone 30 mg/kg/day
89221811|NCT00943748|Placebo Comparator|placebo|placebo : 30 mg/kg/day, in 2 liquid doses
89221812|NCT00953810|No Intervention|control|General heart failure population staying under regular care of their primary care physician
89221813|NCT00953810|Active Comparator|Intervention|Like control plus one education training regarding heart failure aspects and management
89221814|NCT00946790|Experimental|1|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
89221815|NCT00946790|Active Comparator|2|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
89221816|NCT00953888|Experimental|Active|AZD5069 oral solution
89221817|NCT00953888|Placebo Comparator|Placebo|Placebo oral solution
89221818|NCT00953966|Other|Starch 1|Starch 1
89221819|NCT00953966|Other|Starch 2|Starch 2
89221820|NCT00953966|Other|Starch 3|Starch 3
89221821|NCT00953966|Other|Starch 4|Starch 4
89221822|NCT00953966|Other|Starch 5|Starch 5
89221823|NCT00953966|Other|Starch 6|Starch 6
89221824|NCT00953966|Other|Starch 7|Starch 7
89221825|NCT00954044|Experimental|Exercising Together|Partnered progressive resistance exercise
89690005|NCT03073876|Placebo Comparator|Placebo|"Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment."
89690006|NCT00954109|Experimental|Exercise|exercise - supervised exercise (treadmill walking or cycle ergometer use)
89690007|NCT05006625||Adolescents and Young Adults|Adolescents and Young Adults Seeking HIV Treatment and Prevention
89690008|NCT05006625||Service Providers|Service Providers for Adolescents and Young Adults Seeking HIV Treatment and Prevention
89690009|NCT02980237|Experimental|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. The course could be access in the workplace but they will be additional support.
89690010|NCT02980237|Active Comparator|eHealth|This group will receive an e-learning education program same as the intervention group . However, the participants will not receive additional support by team.
89063633|NCT01111552|Active Comparator|Phase B: Single-blind Prospective Treatment Phase|Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the end of Week 1 based upon tolerability profile, plus one matching placebo capsule, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
89063634|NCT01111552|Active Comparator|Phase B+: Single-blind Phase B Responders|Participants with response at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B plus one matching placebo capsule, for an additional 6 weeks, in Phase B+.
89063635|NCT01111552|Active Comparator|Phase C: Escitalopram Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
89063636|NCT01111552|Active Comparator|Phase C: Aripiprazole Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any week, based upon tolerability.
89063637|NCT01111552|Active Comparator|Phase C: Aripiprazole/Escitalopram Combination Therapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.
89063638|NCT01602185|Experimental|memantine|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
89063639|NCT01602185|Experimental|dextromethorphan|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
89063640|NCT01602185|Placebo Comparator|placebo|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
89063641|NCT02886208|Experimental|Intervention|This study has a single arm. All participants in a summer employment program at an urban farm in Indianapolis, IN are invited to participate.
89063642|NCT04409184||Convalescent subjects|Convalescent, now asymptomatic, subjects with documented prior COVID-19 due to SARS-CoV-2 infection
89063643|NCT04409184||Healthy controls|
89063644|NCT05062720|Experimental|Local consolidative therapy (LCT) + systemic therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
89063645|NCT05062720|Active Comparator|Systemic therapy alone|Appropriate second-line systemic therapy, as defined in the NCCN guidelines will be used during study treatment (https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). The choice of specific regimen will be left to the discretion of the treating oncologist but cannot include other experimental or investigational treatment. Sample appropriate systemic therapies include FOLFOX or FOLFIRI with a biologic agent such as an anti-angiogenic antibody or anti-EGFR antibody.
89063646|NCT01602302|Experimental|single arm ( bDMARD withdrawal )|single arm (bDMARD withdrawal)
89063647|NCT05098171|Experimental|Signal Switch Receptor Modified TIL|2x10^8-1x10^10 in vitro expanded autologous PD-1 or TGF-β signal switch receptor modified TIL (GC201 TIL) will be infused i.v. to patients with advanced gynecologic tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
89063648|NCT02893956|Experimental|echocardiography with postural support then standard condition|the first echocardiography (ultrasound) is performed with a postural support then the second echocardiography is performed with standard condition
89063649|NCT02893956|Active Comparator|echocardiography with standard condition then support postural|the first echocardiography (ultrasounds) is performed with standard condition (usual) and the second echocardiography is performed with a postural support
89063650|NCT01602458|Other|Silicone Only Therapy (SOT)|Mepiform™ silicone will be utilized by SOT group.
89063651|NCT01602458|Other|Silicone Pressure Garment Therapy (SPGT)|Mepiform™ silicone and custom compression garments fabricated by Barton Carey™ will be utilized by SPGT group.
89221826|NCT00954044|Placebo Comparator|Usual Care|Usual Care Control
89221827|NCT00954200|Placebo Comparator|Placebo|
89221828|NCT00954200|Active Comparator|ibuprofen|
89221829|NCT00954278|Experimental|sorafenib|
89221830|NCT00550446|Active Comparator|1|
89221831|NCT00550446|Experimental|2|
89221832|NCT00550446|Experimental|3|
89221833|NCT00550446|Experimental|4|
89221834|NCT00550446|Experimental|5|
89221835|NCT00550446|Experimental|6|
89221836|NCT00550446|Placebo Comparator|7|
89221837|NCT05279820|Active Comparator|Partial Pulpotomy|After pulp exposure 2-3 mm of the pulp tissue will be amputated, a calcium silicate based material will be placed over the pulp and the tooth will be restored.
89221838|NCT05279820|Active Comparator|Full Pulpotomy|After pulp exposure the entire coronal pulp to the level of canal orifices will be amputated , calcium silicate based material will be placed over the pulp and the tooth will be restored.
89221839|NCT00953550|Experimental|Rocuronium-Sugammadex|
89221840|NCT00953550|Active Comparator|Succinylcholine|
89221841|NCT00948870|Experimental|Shugan Decoction|
89221842|NCT00948870|Placebo Comparator|low does of Shugan decoction|
89690011|NCT04718961|Experimental|Part 1 Arm 1 & Arm 2 - Volixibat 20mg/80mg|"Part 1 Arm 1 - Volixibat 20mg (Experimental) Participants randomized to this arm will receive volixibat 20mg twice daily.~Part 1 Arm 2 - Volixibat 80mg (Experimental) Participants randomized to this arm will receive volixibat 80mg twice daily."
89221843|NCT05350956|Experimental|Herombopag monotherapy|
89221844|NCT05350956|Experimental|Herombopag is treated in combination with rhTPO(Recombinant human thrombopoietin)|
89221845|NCT00953628|Active Comparator|o Group A=uHCG ovul trig|HCG for triggering
89221846|NCT00953628|Experimental|o Group B=recHCG ovul trig|recombinant HCG for triggering
89221847|NCT00949026|Experimental|A|
89221848|NCT00953784|No Intervention|1|Standard management
89221849|NCT00953784|Active Comparator|2|Extended management: with no bowel prep except enema,restricted fluids, increased O2,body warming and use of skin protectors during surgery as previously described
89221850|NCT00949104|Active Comparator|Sucrose|1 ml of 24% sucrose was administered 2 minutes before the procedure
89221851|NCT00949104|Placebo Comparator|Placebo|Double distilled water
89221852|NCT00953940|Experimental|Isotonic saline|Isotonic saline
89221853|NCT00953940|No Intervention|No treatment|Habitual therapy
89221854|NCT00436618|Experimental|Relapsed aggressive non-Hodgkin lymphoma|Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
89221855|NCT00436618|Experimental|Relapsed indolent non-Hodgkin lymphoma|Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
89221856|NCT00436618|Experimental|Uncommon lymphomas|Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
89221857|NCT03995836||Obstructive Sleep Apnea|
89221858|NCT03995836||Non Obstructive Sleep Apnea|
89221859|NCT01024660|Active Comparator|1|5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)
89221860|NCT01024660|Placebo Comparator|2|
89221861|NCT01751126|Experimental|Ciclosporin|One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).
89221862|NCT01751126|Experimental|Ciclosporin/Placebo|One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.
89221863|NCT01751126|Placebo Comparator|Placebo|One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).
89221864|NCT01570010|Experimental|Intervention group|The intervention group (n = 250) receives an intensive dietary intervention lasting for 12 months and a subsequent maintenance intervention for 14 years. Both groups are offered equal general advice of physical activity.
89221865|NCT01570010|Other|Control group|The control group (n = 250) receives no dietary intervention other than standard clinical care. Both groups are offered equal general advice of physical activity.
89221866|NCT00946868||Intermittent claudication patients|Patients with intermittent claudication with metabolic syndrome and patients with intermittent claudication without metabolic syndrome.
89221867|NCT00944060|Experimental|lifestyle intervention|Control group: usual WIC care
89221868|NCT00548808|Experimental|Insulin lispro low mixture|Insulin lispro low mixture (1, 2 or 3 daily injections)
89221869|NCT00548808|Active Comparator|Insulin glargine|Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)
89221870|NCT00944138|Experimental|Mindful meditation|Participants assigned to the mindful meditation plus standard care arm will receive individualized instruction on mindful meditation at the time they are randomized to this arm. The participants will be led through a 20 minute relaxation exercise. They will then be led through a brief eating exercise where they will be instructed to eat the food very slowly and pay attention to how the food tastes and the sensations of swallowing the food. This is done to enhance the person's awareness of what and how they are eating and enhance their intuitive sense of satiety. Finally, they will receive an MP3-player with several relaxation instructional audios loaded on the MP3 player.
89221871|NCT00944138|Active Comparator|Music for relaxation|Participants assigned to the control arm will receive the dietary counseling and will be told that relaxation can help reduce appetite. However, techniques to relax will not be taught. Instead, participants will be encouraged to sit quietly listening to music (of their choice) every day for 20 minutes. Participants assigned to the standard care arm will receive an MP3-player and will be given a choice of selection of music that they can load on their MP3 player (classical music, country music, jazz, etc.).
89221872|NCT00954434|Experimental|red wine|intervention: dietary supplement intake of red wine on a daily basis, 1 glass/day for women, 2 for men
89221873|NCT00954434|No Intervention|total abstention from alcohol|
89221874|NCT04011878|Experimental|isolated trabeculodysgensis|etiology of primary congenital glaucoma
89221875|NCT00949260||Normal, Non-Pregnant|Normal, non-pregnant patients will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
88821207|NCT04901403|Other|Education intervention|Parents in the treatment group will receive information about Earned Income Tax Credit, including how to sign up for free. They will also receive help with budgeting and finances from their home visitor.
89063652|NCT02893722|Experimental|atosiban|"Give drugs 30 minutes before the start of the embryo transfer. First step: give a 37.5 mg Atosiban (Ferring, Germany) to take 0.9 ml, that is, 6.75 mg, conduct intravenous injection in one minute.~Second step: for the remaining 4.1 ml, namely 30.75 mg, dilute to 41 ml, use the venous pump to adjust to 24 ml/h, infuse for 1 hour, namely 18 mg.~Third step: for the remaining 17 ml, use the venous pump to adjust to 8 ml/h, infuse 2.1 hours, namely 12.75 mg. Total administration time is 3 hours, total dose is 37.5 mg."
89063653|NCT02893722|Placebo Comparator|0.9% salain|intravenous injection of 0.9% saline in one minute before transfer. Then use the same dose of normal saline for intravenous infusion to set the same infusion rate with experimental group, complete the infusion in 3 hours.
89063654|NCT01602497|Active Comparator|rTMS intervention group|The rTMS intervention group undergo ten session of real TMS therapy.
89063655|NCT01602497|Placebo Comparator|Sham group|Patients will undergo ten session of sham rTMS.
89063656|NCT04407936||coronary angiography|The investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention
89063657|NCT01608269|Other|ABC/3TC (Epzicom), NRTI|
89063658|NCT01602536|Experimental|Twitter|Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.
89063659|NCT01602536|Active Comparator|Control|Control participants are not assigned to a twitter group. The baseline intervention 'smoking cessation aides' is also provided.
89063660|NCT01602575|Experimental|mindfulness treatment|Mindfulness based stress reduction is the intervention in this single arm trial
89063661|NCT01608347|Experimental|LMWH + Folic acid group|Daily 40 mg of enoxaparin (LMWH) (Clexane, Sanofi Aventis, Paris, France)subconsciously started once positive pregnancy test. Treatment will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tab once/daily until 13 weeks' of gestation.
89063662|NCT01608347|Active Comparator|Folic acid|500 microgram folic acid tab/day started once positive pregnancy test and will be continued until 13 weeks' of gestation.
89063663|NCT01608386|Experimental|anterior approach+IVC clamping|Use anterior approach combined with infrahepatic Inferior Vena Cava clamping in right hepatectomy for HCC patients.
89063664|NCT01608386|No Intervention|anterior approach|Only use anterior approach in right hepatectomy for HCC patients.
89063665|NCT01602653|Active Comparator|1|the first group of patients received an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
89063666|NCT01602653|Active Comparator|2|The second grouop of patients received 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
89063667|NCT01602770||Group 1|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
89063668|NCT01603004||everolimus, sunitinib or traditional chemotherapy|A total of 30 patients with well differentiated pancreatic NETs who have known liver metastases and who are planned to initiate therapy with either targeted (everolimus or sunitinib) or traditional cytotoxic chemotherapy will be recruited for this study. We plan to recruit approximately 10 patients for each therapy (everolimus, sunitinib, cytotoxic chemotherapy). Evidence of metastatic disease will be determined at the discretion of the oncologist based on available imaging, surgical and pathologic evidence.
89063669|NCT04328610|Experimental|LYMPHA technique group|LVA at the time of Axillary Dissection
89063670|NCT04328610|No Intervention|Non-LYMPHA technique group|No preventive surgical approach
89063671|NCT01608464|Active Comparator|Arm A|Arm A: will receive combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
89063672|NCT01608464|Experimental|Arm B|"Arm B will receive combination of cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.~PET scan will be repeated 3-4 weeks after end of concurrent chemo-radiation therapy Patients in Arm A and B will go for esophagectomy 4-6 weeks after end of concurrent chemo-radiation therapy or chemotherapy"
89063673|NCT01603160||Emergency Department Staff|"Interventions put in place in the Emergency Department will effect most staff who work in the ED, but different sub-groups will be approached for participation in specific aspects of the study:~All ED attending and resident physicians and ED nurses will be invited to complete the SCD Attitudes survey.~Select ED Staff will be invited to be members of the QI team and will be invited to participate in the FMECA.~Members of the QI team will be invited to participate in a focus group."
89063674|NCT01608503|Experimental|respiration cycle|lung inflation and deflation
89063675|NCT01608542|Experimental|Fostamatinib 100mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 100mg single and multiple twice daily doses
89063676|NCT01608542|Experimental|Fostamatinib 200mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 200mg single and multiple twice daily doses
89063677|NCT04404582||Klebsiella pneumoniae|patients with Klebsiella pneumoniae infection had different results of the drug sensitivity test. we compared the prognosis of these patients.
89063678|NCT01608698|Experimental|Belara|The participants who receive OCP in combination of 30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®).
89063679|NCT01608698|Experimental|Yasmin|The participants who receive OCP in combination of 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®).
89063680|NCT01603199|Experimental|Primary biliary cirrhosis (Non-cirrhotic)|
89063681|NCT01603199|Experimental|Primary biliary cirrhosis (Cirrhotic)|
89063682|NCT04133220||Cases|Patients with acute myeloid leukemia, associated to hyper leukocytosis
89063683|NCT04133220||Control|Patients with acute myeloid leukemia, without hyper leukocytosis
89063684|NCT01603238|Experimental|[14C]-LC15-0444|A single oral dose of [14C]-LC15-0444 50 mg , containing 4.9 MBq [14C] (batch number 110372/C/01).
89063685|NCT04132947||Cohort|Cohort Study correlating self reported exercise activity and spiroergometry results
89063686|NCT01175083|Experimental|Tritanrix-HepB/Hib+Polio Sabin <6S Group|Children below (<) 6 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
89063687|NCT01175083|Active Comparator|Tritanrix-HepB/Hib+Polio Sabin <6NS Group|Healthy children, below (<) 6 months of age at time of enrolment, who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
89063688|NCT01175083|Experimental|Synflorix 7-11S Group|Children between 7-11 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
89063689|NCT01175083|Active Comparator|Synflorix 7-11NS Group|Healthy children between 7-11 months of age at time of enrolment, who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
89063690|NCT01175083|Experimental|Synflorix 12-23S Group|Children between 12-23 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
89063691|NCT01175083|Active Comparator|Synflorix 12-23NS Group|Healthy children between 12-23 months of age at time of enrolment, who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
89063692|NCT02489708|Experimental|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
89063693|NCT04310254|Active Comparator|EDTA and CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA and CHX solution.
89063694|NCT04310254|Active Comparator|EDTA solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for EDTA solution.
89063695|NCT04310254|Active Comparator|CHX solution|Root canal irrigation was performed according to the guidelines to the manufacturers instructions for CHX solution.
89063696|NCT01174459||Patient with Restless Legs Syndrome|
89063697|NCT02480972|Other|Magnetic resonance imaging|multiparametric MRI including perfusion, diffusion, MR fat quantification and MR elastography
89063698|NCT01608737|Experimental|2. BI 201335 for 24 weeks|BI 201335 once daily low dose for 24 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
89063699|NCT01608737|Experimental|3. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
89063700|NCT01608737|Active Comparator|1. PegIFN/RBV|PegIFN/RBV for 48 weeks in treatment-naive patients
89063701|NCT01608737|Active Comparator|4. PegIFN/RBV|PegIFN/RBV for 48 weeks in prior relapser patients
89063702|NCT01608737|Experimental|5. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in prior relapser patients
89063703|NCT02886130|Placebo Comparator|Placebo|Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
89063704|NCT02886130|Experimental|Alpha-GPC|Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
89063705|NCT01174342||Pregnant women|Healthy pregnant women
89063706|NCT02881606|Active Comparator|Naso-alveolar molding (NAM)|Active plates and nasal stents (Grayson method)
89063707|NCT02881606|Active Comparator|Computer aided design NAM (CAD/NAM)|Computer aided design active plates and nasal stents
89063708|NCT01608776|Active Comparator|SOC - Standard of Care|Wound cleansing and debridement as needed, moist wound healing dressing, and off-loading
89063709|NCT01608776|Active Comparator|SOC + MIST Therapy|Wound cleansing and debridement as needed, moist wound healing dressing, off-loading, and MIST treatment
89063710|NCT01111474|Active Comparator|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
89063711|NCT01111474|Active Comparator|Laser|3 Low intensity laser application (48 hour interval). The application of 1Joule/cm^2 was performed for eight seconds at three points along the dental neck, using the infrared wavelength (795nm)
89063712|NCT01608932|No Intervention|Control Group|Treatment as usual
89063713|NCT01608932|Experimental|Telemonitoring for frail patients with chronic diseases|Telemonitoring for frail patients with chronic diseases
89063714|NCT04401930||Free-living elderly|"Free-living elderly over the age of 65 living in Metropolitan Area of Milan, in apparent good health conditions.~Male and Female"
89063715|NCT01603433|Experimental|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
89063716|NCT01603472||Subjects on Parenteral Nutrition|cases are those on Parenteral Nutrition >6 weeks for intestinal failure.
89063717|NCT01603472||Subjects not on Parenteral Nutrion|Controls are those who have never been on PN but can be fed via a feeding tube
89063718|NCT04401969||Patients with eumycetoma lesions|Patients with eumycetoma lesions
89063719|NCT04401969||Patients with actinomycetoma lesions|Patients with actinomycetoma lesions
89063720|NCT04401969||Patients with lesions of unknown causality|Patients with lesions of unknown causality
89063721|NCT01603550|Experimental|Energy Restriction|
89063722|NCT01603550|Experimental|Sleep Deprivation|
89063723|NCT01603667|Experimental|PG2 Injection 500 mg|PG2 Injection 500 mg
89063724|NCT01603667|Placebo Comparator|Placebo|Placebo
89063725|NCT01603745|Active Comparator|NOMAC-valerate estradiol|E/P therapy
89063726|NCT01603745|Active Comparator|Drospirenone/ethinylestradiol|E/P therapy
89063727|NCT02691585|Experimental|Music intervention group 1|Raga 1 will be given
89063728|NCT02691585|Experimental|Music intervention group 2|Raga 2 will be given
89063729|NCT02691585|Experimental|Music intervention group 3|Raga 3 will be given
89063730|NCT02691585|No Intervention|Control Group 4|No raga. Just collection of electrophysiological parameters will be done.
89063731|NCT01174264|Experimental|Arm I (vismodegib on empty stomach)|Patients receive a single dose of vismodegib PO on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
89063732|NCT01174264|Experimental|Arm II (vismodegib after high fat meal)|Patients receive a single dose of vismodegib PO after eating a high fat meal. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
89063733|NCT01174264|Experimental|Arm III (vismodegib after low fat meal)|Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28.
89063734|NCT01603784|Experimental|Combined|Aerobic Exercise + Cognitive Training
89063735|NCT01603784|Experimental|Exercise|Aerobic Exercise + Health Education
89063736|NCT01603784|Experimental|Cognitive|Home Exercise + Cognitive Training
89063737|NCT01603784|Experimental|Control|Home Exercise + Health Education
89063738|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin elevated|Spondylitis patients with elevated levels of fecal calprotectin. Patients are treated with adalimumab
89063739|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin normal|Spondylitis patients with normal levels of fecal calprotectin. Patients are treated with adalimumab.
89063740|NCT02893605||Cases|Patients have a sporadic form of Amyotrophic Lateral Sclerosis.
89063741|NCT02893605||Controls|Controls correspond to spouses/partners of patients.
89063742|NCT01609049||Participants with Chronic Hepatitis C|Naive and previously treated participants who received peginterferon alfa-2a in combination with ribavirin as per local labeling requirements.
89063743|NCT02893566|Experimental|Mi Band Step Challenge|
89063744|NCT01603823||Healthy volunteers|
89063745|NCT01603823||St.p. Pars plana vitrectomy|
89063746|NCT02893527|Experimental|"Group intervention"|Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
89063747|NCT02893527|No Intervention|"Group standard"|conventional support
89063748|NCT01609088|Experimental|Erythritol-containing beverage|
89063749|NCT04398342||Children with Cerebral Palsy in Denmark|Children diagnosed with cerebral palsy born 2003 - 2020 and registered in the Danish Cerebral Palsy Follow-up Program.
89063750|NCT01173718|Experimental|GORE® ACUSEAL Vascular Graft|
89063751|NCT01603862|Experimental|ThinkingFit|
89063752|NCT01609127|Experimental|Tesetaxel every 3 weeks|Tesetaxel 27 mg/m2 orally on Day 1 in a 21-day cycle
89063753|NCT01609127|Experimental|Tesetaxel weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 in a 28-day cycle
89063754|NCT01609127|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 in a 21-day cycle
89063755|NCT01603901|Experimental|Investigated Wounds|
89063756|NCT01603979|Experimental|Dose-escalation AV-203 Monotherapy|dose-escalation of monotherapy AV-203 (an ERBB3 inhibitory antibody) by IV every two weeks
89063757|NCT00592020|Active Comparator|1|Short Transverse Incision
89063758|NCT00592020|Active Comparator|2|Hockey Stick Incision
89063759|NCT01609166|Experimental|Allopurinol 3% cream|Allopurinol 3% cream in one side of the body
89063760|NCT01609166|Placebo Comparator|Placebo cream|Placebo cream in the other side of the body
89063761|NCT01609205|Experimental|Arm 1|Adalimumab
89063762|NCT04332237||Hypothermia group|Hypothermic trauma patients or hypothermic patients with traumatic brain injury specifically.
89063763|NCT04332237||Normothermia group|Normothermic trauma patients or normothermic patients with traumatic brain injury specifically.
89063764|NCT01604018||Placebo|Subjects previously randomized to receive placebo in study CP005 and completed CP005A.
89063765|NCT01604018||Cat-PAD Group 1|Subjects previously randomized to receive Cat-PAD dose 1 in study CP005 and completed CP005A.
89063766|NCT01604018||Cat-Pad Group 2|Subjects previously randomized to receive Cat-PAD dose 2 in study CP005 and completed CP005A.
89063767|NCT04331847||Quantitative observational descriptive study|among women presenting for abortion-related complications
89063768|NCT04331847||Qualitative study|among women with a near-miss or a potentially life-threatening complication
89063769|NCT04331847||Rapid health facility assessment with the health professional|in charge of Post-Abortion Care
89063770|NCT04331847||Knowledge Attitudes, Practice and Behavior quantitative survey|among health care providers involved in the management of abortion-related complications
89063771|NCT01604057|Experimental|Low Dose Nasal Spray|
89063772|NCT01604057|Experimental|Mid Dose Nasal Spray|
89063773|NCT01604057|Experimental|High Dose Nasal Spray|
89063774|NCT01604057|Active Comparator|Forteo|20ug subcutaneous injection daily
89063775|NCT01604057|Placebo Comparator|Placebo Nasal Spray|
89063776|NCT01604096|Experimental|Intervention areas|Provinces of Modena and Parma (about 1.100.000 inhabitants - campaign targeted to the general population), in Northern Italy (Emilia-Romagna Region)
89063777|NCT01604096|No Intervention|Control|All the other provinces in the Emilia-Romagna Region (where the information campaign has not been implemented)
89063778|NCT01604174|Experimental|Interactive Virtual Telerehabilitation|Rehabilitation by IVT
89063779|NCT01604174|Active Comparator|Standard rehabilitation care|Standard care rehabilitation after total knee arthroplasty
89063780|NCT01111240||Psoriatic Arthritis|Participants with Psoriatic Arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
89063781|NCT01609244|Active Comparator|Bilevel|Bilevel therapy
89063782|NCT01609244|Active Comparator|Servoventilation|servoventilation therapy
89063783|NCT01609283|Experimental|Autologous Mesenchymal Stem Cells|
89063784|NCT01604252||Cohort|
89063785|NCT00592566|No Intervention|1|Standard supportive care
89063786|NCT00592566|Experimental|2|Dexamethasone treatment
89063787|NCT00592566|Experimental|3|Desmopressin treatment
89063788|NCT01111123|Active Comparator|1|Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only
89063789|NCT01111123|Placebo Comparator|2|Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only
89690012|NCT04718961|Experimental|Part 2 Arm 1 - Volixibat Selected Dose mg|"Part 2 Arm 1 - Volixibat Selected Dose mg (experimental) Participants randomized to this arm will receive volixibat selected dose (mg) twice daily.~Part 2 Arm 2 - Placebo (Placebo Comparator) Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily."
89690013|NCT03130738|Active Comparator|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
89063790|NCT01609322|Active Comparator|Education about falls|In-person education about falls with a health educator.
89690014|NCT03130738|Active Comparator|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
89063791|NCT01609322|Experimental|Activity, Balance, Learning, and Exposure|Intervention combining medication review, exercise, home safety evaluation, and exposure therapy.
89063792|NCT04310800|Experimental|LIFT-plug|The LIFT-plug procedure was performed as followings. A portion of the fistula tract was excised from ei¬ther end within the intersphincteric space. One porcine small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures.
89063793|NCT04310800|Experimental|LIFT|The LIFT procedure was performe as followings. The curvilinear incision and dissection of the intersphincteric tract were made as in the LIFT-plug technique. After the tract was isolated, the tract was doubly-ligated and suture-ligated with absorbable sutures as close as possible to the lateral margin of the internal anal sphincter and the medial margin of the external anal sphincter. The tract was then divided between the two sutures. A portion of the fistula tract was excised after ligation of ei¬ther end within the intersphincteric space. The medial ligature was very close to the internal opening, and nearly obliterated the internal opening. The external opening was then enlarged to allow adequate drainage. The internal and external sphincters were then re-approximated, and the skin was closed loosely with interrupted 3/0 absorbable suture.
89063794|NCT00592644|Experimental|1|Pulse Dye Laser
89063795|NCT00592644|Active Comparator|2|Traditional surgeries
89063796|NCT01604330|Experimental|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
89221876|NCT00949260||Normal, Pregnant|Normal, pregnant patients in their 3rd trimester will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
89690015|NCT03130738|Placebo Comparator|14-Day Placebo - Oil Vehicle|14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
89690016|NCT05065762||Phase 1|Participants with moderate-to-severe Psoriasis (PsO) in Japan who have been recruited based on eligibility criteria
89690017|NCT05065762||Phase 2|Self-reported moderate-to-severe Psoriasis (PsO) participants in Japan
89690018|NCT02977377|Active Comparator|Whole body vibration/ Exercise|Exercise therapy and whole body vibration will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. Whole body vibration (20-30 Hz, minimum amplitude) will be applied to cases in the form of 4 sets (1 min application and 1min rest) before exercises. After 1 week washout period, exercise program will apply for 8 weeks.
89063797|NCT01604330|Placebo Comparator|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
89063798|NCT01609361|No Intervention|1: Standard surgery + Standard care|standard surgery and Standard care after surgery
89063799|NCT01609361|Other|2: Laparoscopy + Rehabilitation program|Laparoscopic colorectal surgery with rehabilitation program
89063800|NCT01173679|Other|dasatinib, rituximab, fludarabine|Single-arm, open-label
89063801|NCT02881528|Experimental|Metformin Hydrochloride|"Metformin Hydrochloride Ph Eur oral solution (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
89063802|NCT02881528|Placebo Comparator|Placebo|"Placebo (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
89063803|NCT01609439|Placebo Comparator|Placebo|
89063804|NCT01609439|Experimental|Treatment|Pre-operative Vitamin D 800 units x 4 weeks
89063805|NCT00592800||1|children between 11 and 13 years of age
89063806|NCT00592800||2|children between 14 to 15 years of age
89063807|NCT00592800||3|children between 16 and 18 years of age
89063808|NCT01110382|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose)will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
89063809|NCT01110382|Experimental|Meropenem|Meropenem 20 mg/kg per dose (up to 1 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV meropenem only or IV meropenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
89063810|NCT01604369|Experimental|Cryoablation|
89063811|NCT00592917|Active Comparator|Ia|1718 subjects randomised for active calcium and vitamin-D -intervention, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except Ib (every four months)
89063812|NCT00592917|Active Comparator|Ib|random sample of 292 of 1718 (Ia), data collection by questionnaires mentioned in Ia, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
89063813|NCT00592917|No Intervention|IIa|1714 subjects randomised to no intervention group, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except IIb (every four months)
89063814|NCT00592917|No Intervention|IIb|random sample of 314 of 1714 (IIa), data collection by questionnaires mentioned in IIa, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
89063815|NCT01609517||Obese group|patients with BMI >= 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
89063816|NCT01609517||Non-obese group|patients with BMI < 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
89063817|NCT04309903|Experimental|Manual Therapy|The experienced physiotherapist has applied manual therapy (MT) to the arthropathic joints. MT was started with myofascial release techniques (MRT), then continued with mobilization techniques using Kalternborn. Superficial MRT consisted of 3 strokes, via manual movement on the tissue, encourage release of the superficial fascia. In the Kalternborn mobilization technique, Grade I-II mobilization was applied with traction without using a strap. The same exercises given to the home exercise group were given to the patients in this group as well.
89063818|NCT04309903|Active Comparator|Home Exercise|The home exercises (HE) consisted of active ROM exercises, passive stretching exercises, progressive resistive exercises, weigh-bearing and stance exercises were performed by the patient for 30 minutes at home.
89063819|NCT02881489|Experimental|Autologous BM-MSCs injection|Intervention: Biological: Cell-based therapy of autologous bone marrow-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
89063820|NCT00593034||1|"Participants in this study will be 12-21 year old patients who have been referred to the Adolescent Substance Abuse Program for evaluation of drug or alcohol use and are participating in the parent study, Medical Office Intervention for Adolescent Drug Abuse."
89063821|NCT01604447|Active Comparator|Incubator removal-torso bag|Use plastic bag covering the torso and lower extremities for temperature regulation with standard bundling practices when removing infant from incubator
89063822|NCT01604447|Placebo Comparator|Incubator removal-no plastic bag|Standard bundling practices when removing the infant from the incubator. No plastic bag used.
89063823|NCT00593073|Experimental|1|Tailored Reminder Message
89063824|NCT00593073|Experimental|2|General Reminder Message
89063825|NCT01604486||MI without ischaemic preconditioning|Myocardial infarction unheralded by any previous cardiovascular disease diagnosis and without symptoms of chest pain in the previous 90 days.
89063826|NCT01604486||MI with longstanding disease|Patients with myocardial infarction who have had diagnosed atherosclerotic disease for longer than 90 days preceding infarct.
89063827|NCT01604486||MI with only chest pain|Patients with chest pain in the 90 days preceding MI, but with no prior atherosclerotic disease diagnoses.
89063828|NCT01604486||MI with disease and chest pain|Myocardial infarction occurring with previously diagnosed atherosclerotic disease of longer than 90 days' duration, but with chest pain in 90 days preceding infarct.
89063829|NCT02892669||patients admitted to the intensive care department|
89063830|NCT01609595|Experimental|Treatment|Study drug treatment
89063831|NCT00593151|Experimental|A, C, 320 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
89063832|NCT00593151|Experimental|B, C, 640 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
89063833|NCT00593151|Active Comparator|A, B, C PEG|Weekly subcutaneous injections of 1.5 ug/kg PegIntron (12 kDalton pegylated interferon alpha 2b) with oral ribavirin.
89063834|NCT01609634|Active Comparator|Key Group of interest|Subjects who started test product / control product 1 / control product 2 by 1-month of age
89063835|NCT01609634|Active Comparator|Other-fed Group|Subjects who started test product / control product 1 / control product 2 and continued on breast-feeding
89063836|NCT01609634|Active Comparator|Breast Fed Reference Group|Subjects who are exclusively breast-fed up to 4 months of age and not started on test product / control product 1 / control product 2.
89063837|NCT00593190|Experimental|1|
89063838|NCT01604525|Sham Comparator|Control|Participants randomized to this group received access to an untailored general interest/lifestyle website.
89063839|NCT01604525|Experimental|Tailored Health and Lifestyle Web|Participants randomized to this arm received tailored web content about health and wellness, with weekly goal-setting and feedback.
89063840|NCT01604525|Experimental|Tailored Web plus Peer Coaching|Participants randomized to this arm received access to weekly tailored health and wellness web content, plus weekly feedback from a peer health coach (videos uploaded to the web and phone calls).
89063841|NCT04327128|Active Comparator|Intervention group|Standard heart failure care and a digital heart failure support system
89063842|NCT04327128|Other|Control group|Standard heart failure care
89063843|NCT00593229||3|Familial atypical HUS
89063844|NCT00593229||4|Thrombotic thrombocytopenic purpura (TTP)
89063845|NCT00593229||1|Severe diarrhea-associated hemolytic uremic syndrome (D+HUS)
89063846|NCT00593229||2|Non-familial atypical HUS
89063847|NCT04327167|Other|Digital intervention|
89063848|NCT00593307|Experimental|Low GI|low GI breakfast
89063849|NCT00593307|Experimental|Low GI -low carb|Low GI and Low carb breakfast
89063850|NCT00593307|Experimental|High GI|High GI breakfast
89063851|NCT00593307|Experimental|High GI Low Carb|high GI low carb breakfast
89063852|NCT01604564||Colitis Ulcerosa|Colitis Ulcerosa With creation of IPAA
89063853|NCT01604564||Familial Adenomatous Polyposis|Familial Adenomatous Polyposis with creation of IPAA
89063854|NCT01173601|Experimental|12 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 12-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
89063855|NCT01173601|Experimental|18 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 1 week, followed by 18 mg, administered orally, once daily for 7 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 18-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
89063856|NCT01173601|Placebo Comparator|Placebo + SSRI|"Placebo: Tablet equivalent to LY2216684, administered orally, once daily (QD) for 11 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the placebo treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase. Participants who had received placebo were assigned to the abrupt DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
89063857|NCT01609673|No Intervention|Control|"35 patients using Cyclosporin or Tacrolimus (C0=100-200/5-10ng/mL)+ Myfortic® 1440mg/dia + Steroids.~Medications will be administered orally, twice a day"
89063858|NCT01609673|Active Comparator|Intervention|"35 randomized Patients Converted to Certican® (Everolimus C0=6-10 ng/mL) + Myfortic® 1440mg/day + Steroids.~On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
89063859|NCT01604642|Other|cachectic versus no cachectic patients|blood tests, muscular biopsies
89063860|NCT01604681|Placebo Comparator|placebo group|3 g of powdered gelatin encapsulated in opaque capsules.
89063861|NCT01604681|Experimental|Flaxseed oil group|Oil extracted from linseed by pressing the cold and encapsulated, providing 3g per day containing 1.75 g of alpha linolenic acid.
89063862|NCT01173523|Experimental|Cohort A: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort A participants had relapsed > 60 days following initial chemotherapy completion.
89063863|NCT01173523|Experimental|Cohort B: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort B participants had not responded or had relapsed </= 60 days from the completion of initial chemotherapy.
89063864|NCT01609712||Patient with vertebral compression fracture|RF kyphoplasty is standard of care in our hospital for patients with osteoporortic compression fractures. We are intersetd, if it also can improve the lung function.
89063865|NCT00593424|Active Comparator|1|Low Fat/High Carbohydrate
89063866|NCT00593424|Active Comparator|2|High Monounsaturated Fat/Low Carbohydrate
89063867|NCT02886013||Mexican adolescents|"Students without known disease, between 14 and 18 years from the Lic. Adolfo Lopez Mateos Preparatory school of the Autonomous University of the State of Mexico (UAEMex)."
89063868|NCT01173055|Experimental|Milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
89063869|NCT01173055|Experimental|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
89063870|NCT04327440||Nyambi, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)~The duration of the cohort is six months."
89063871|NCT04327440||Nyambi, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)~The duration of the cohort is six months."
89063872|NCT04327440||Kalembo, rainy season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)~The duration of the cohort is six months."
89063873|NCT04327440||Kalembo, dry season|"250 children of age-eligible for RTS,S vaccine (7-18 months) 500 siblings (>18 months, < 10 years of age)~The duration of the cohort is six months."
89063874|NCT00593502|Active Comparator|1|Oseltamivir
89063875|NCT00593502|Placebo Comparator|2|Placebo
89063876|NCT01609868|Active Comparator|control|infants in this arm will receive the current treatment that is standard of care for these infants, powder protein modular to achieve 4 gm/kg/day
89063877|NCT01609868|Experimental|experimental|this group will receive a liquid protein modular that recently became commercially avaliable, to achieve the same protein of 4 grm/kg/day as the powder comparision group
89063878|NCT01609907|Experimental|Sequence 1|
89063879|NCT01609907|Experimental|Sequence 2|
89063880|NCT01609907|Experimental|Sequence 3|
89063881|NCT01609907|Experimental|Sequence 4|
89063882|NCT01609907|Experimental|Sequence 5|
89063883|NCT01609907|Experimental|Sequence 6|
89063884|NCT00593580|Active Comparator|1|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
89063885|NCT00593580|Placebo Comparator|2|
89063886|NCT01604759|Other|Polarized probe measurement.|All patients belong under this arm as all will be measured by the polarized probe and the data will be compared to the biopsy site's pathology results.
89063887|NCT04327011|Experimental|Experimental|Single arm Toca 511 vector/5-FC prodrug
89063888|NCT01604837||Pelvic malignancy group|those with diagnosis of gynecologic or urologic malignancy
89063889|NCT01604837||Pelvic chronic disease group|those with chronic pelvic pain with constitutional cause e.g. endometriosis
89063890|NCT00593619|Active Comparator|Iron Dextran|
89063891|NCT00593619|Active Comparator|Iron Sucrose|
89063892|NCT01604915|Placebo Comparator|Group R|Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered.
89063893|NCT01604915|Experimental|Group DR|Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
89063894|NCT00593658|Experimental|single|
89063895|NCT00593697|Active Comparator|A|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 -> FE75C x3)
89063896|NCT00593697|Active Comparator|B|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
89063897|NCT02892747|Experimental|Educational Program for prevention of malnutrition|In addition to the usual nutritional assessment, the patients in the experimental arm benefit of a personalized educational program for prevention of malnutrition. This program aims to monitor energy and protein intake in addition to managing sodium intake, notably by offering personalized menu ideas and recipes.
89063898|NCT02892747|No Intervention|Control|In the control arm, patients are followed-up by the cardiologist and the nutritionist, and did not benefit of the personalized educational program for prevention of malnutrition.
89063899|NCT01604954|Other|Non-obese|Non-obese women (BMI between 18.5 and 25 kg/m2)
89063900|NCT01604954|Other|Obese|Obese women (BMI between 30 and 40 kg/m2)
89063901|NCT04327050|Experimental|Magnetic-ESD|Patients in MAG arm will be treated using magnetic anchored guided endoscopic submucosal dissection.
89063902|NCT02892786|Experimental|experimental|
89063903|NCT01601522|Experimental|Oral Immunotherapy with placebo antihistamines|500 mg Peanut Protein with placebo antihistamines
89063904|NCT01601522|Placebo Comparator|Double Placebo|Placebo (Oat flour) and placebo antihistamines
89063905|NCT01601522|Active Comparator|Oral Immunotherapy with H1 and H2 antihistamines|500 mg Peanut Protein with Dosage of desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) and ranitidine be 5ml (15mg/ml=75 mg) po bid.
89063906|NCT02892552|Experimental|Cone Beam|Patients included will have first a MultiSlice Computed tomography (MSCT) as usual and then a Cone Beam Computed Tomography (CBCT)
89063907|NCT00593775|No Intervention|control|control group without intervention
89063908|NCT00593775|Active Comparator|AH group|assisted hatching performed on the embryo
89063909|NCT01604993|Experimental|High nitrate dietary source|556 grams of high nitrate spinach soup that is orally consumed as a single dose for 7 days.
89063910|NCT01604993|Placebo Comparator|No Nitrate dietary source|556g low nitrate asparagus soup; orally consumed as a single does for 7 days.
89063911|NCT00593853|Active Comparator|1|
89063912|NCT00593853|Placebo Comparator|2|
89063913|NCT01607294|Experimental|ETC-1002|ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
89063914|NCT01607294|Placebo Comparator|Placebo|Placebo daily 4 weeks
89063915|NCT00593892||Observation|All patients who are admitted to UAB for trauma, are 19 years of age and older, and whose Injury Severity Score (ISS) is greater than 9.
89063916|NCT01601600|Placebo Comparator|Placebo|
89063917|NCT01601600|Experimental|BYM338|BYM338 active drug
89063918|NCT00593931|Experimental|A|Normal Subjects
89063919|NCT01605110|Experimental|Hyperbaric oxygen therapy|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
89063920|NCT01605110|Sham Comparator|Air sham|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
89063921|NCT00593970||1|All women presenting to our prenatal clinic and postpartum floor during the study period.
89063922|NCT01605149||Case|Patients with Type 1 Diabetes Mellitus
89221877|NCT00949260||Pregnant, PIH|Pregnant patients in their 3rd trimester with pregnancy-induced hypertension that has not been treated will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
89221878|NCT00954096|Experimental|Transdermal nicotine patch or placebo|A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.
89221879|NCT00949338|Active Comparator|Arm I|Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
89221880|NCT00949338|Experimental|Arm II|Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
89221881|NCT00954252|Experimental|Test Article|
89221882|NCT00954252|Placebo Comparator|Placebo|
89221883|NCT01563042|Experimental|Cohort 1 GSK2434735|Cohort 1: Single intravenous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
89221884|NCT01563042|Experimental|Cohort 2 GSK2434735|Cohort 2: Single subcutaneous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
89221885|NCT00110617|Experimental|Deferasirox (ICL670)|Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.
89221886|NCT00110617|Experimental|Deferoxamine (DFO) then ICL670|Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.
89221887|NCT00954330|Experimental|surgery|All twenty-five patients underwent ligament repair, where the ruptured ends of the FTA (in 11 cases) or FTA and FC (in 14 cases) ligaments were rejoined by using absorbable sutures. A supine position and a tourniquet were used. A curvilinear skin incision of 5-10 cm was made; the retinacular structures were incised and the hematoma was removed.
89221888|NCT00954330|Active Comparator|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle
89221889|NCT00949494|Active Comparator|Synvisc|
89221890|NCT00949494|Placebo Comparator|Placebo|
89221891|NCT04011462|Experimental|Prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
89221892|NCT04011462|Experimental|Prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
89221893|NCT04011462|No Intervention|Standard care|warming with cotton sheet and blanket for 20 minutes.
89221894|NCT01079377||Adolescent Surgical Candidates|Adolescents at the Center for Adolescent Bariatric Surgery, Columbia University Medical Center
89221895|NCT01079377||Obese Treatment-Seeking Adolescents|Obese Treatment-Seeking Adolescents, Maxcor Program for Overweight Education and Reduction (POWER) Program
89221896|NCT01079377||Normal-Weight Adolescents|Normal-Weight Adolescents
89221897|NCT00954408||Patients with dystonia|Patients with dystonia, 21-100 years of age.
89221898|NCT00954486|Experimental|Epoetin alfa, 10,000 units/week|Epoetin alfa is a recombinant erythropoietin.
89221899|NCT03956862|Experimental|GB001|GB001 40 mg once per day (QD) for 16 weeks
89221900|NCT03956862|Placebo Comparator|Placebo|Placebo QD for 16 weeks
89221901|NCT00550238|Experimental|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
89221902|NCT00946946|Experimental|Azathioprine|2.0-2.5 mg/kg/BW azathioprine tablets/day AND mesalazine placebo tablets
89221903|NCT00946946|Active Comparator|Mesalazine|4g mesalazine tablets/day AND azathioprine placebo tablets
89221904|NCT03956550|Experimental|REGN5069 Low Dose|Randomized in a 1:1:1 ratio
89221905|NCT03956550|Experimental|REGN5069 High Dose|Randomized in a 1:1:1 ratio
89221906|NCT03956550|Experimental|Matching Placebo|Randomized in a 1:1:1 ratio
89221907|NCT00954668|Experimental|immediate angiography|Immediate invasive angiography < 2 h after randomization
89221908|NCT00954668|Active Comparator|early invasive angiography|early invasive angiography 12-72 h after randomization
89221909|NCT01030744||Gestational Diabetes|Women with gestational diabetes who are referred to and followed in the Vanderbilt Eskind Diabetes Clinic and are participants in the gestational diabetes educational program.
89221910|NCT00947024|Experimental|1|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
89221911|NCT00947024|Active Comparator|3|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
89221912|NCT00947024|Experimental|2|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
89221913|NCT01033708|Active Comparator|treatment as usual|Treatment as usual
89221914|NCT01033708|Experimental|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
89221915|NCT00954746||Follow-up|Subjects Previously Treated with AA4500
89221916|NCT00949572|Experimental|Intramuscular administration|Intramuscular injection of HPV vaccine proteins
89221917|NCT00949572|Experimental|Sublingual administration|Sublingual administration of HPV vaccine proteins
89221918|NCT01031992|Experimental|Group I|First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
89221919|NCT01031992|Experimental|Group II|First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).
89221920|NCT04012346|Active Comparator|Active Comparator: MCI patients with real iTBS|Patients will receive real iTBS in a week-long sessions.
89221921|NCT04012346|Sham Comparator|Sham Comparator: MCI patients with sham iTBS|Patients will receive sham iTBS in a week-long sessions.
89063923|NCT00594048|Experimental|1|15 hypertensive patients use the Resperate for 9 weeks and measure their blood pressure before and after using this device
89063924|NCT00594048|Active Comparator|2|15 patients use a discman with freely chosen music for 9 weeks and measure their blood pressure before and after use of this device
89063925|NCT00594087|Active Comparator|1|Lunesta 2 or 3 mg
89063926|NCT00594087|Placebo Comparator|2|Placebo 2mg or 3 mg
89063927|NCT01605305|Experimental|FOLFOX6|
89063928|NCT00594126|Other|1|3+3 cohort dose escalation
89063929|NCT01604603||Control|
89063930|NCT01604603||Oligomenorrhea|
89063931|NCT01604603||Amenorrhea|
89063932|NCT01604603||premature ovarian failure|
89063933|NCT00594243|Experimental|Intervention|8-week mindfulness based stress reduction program
89063934|NCT00594243|Active Comparator|Wait-list control|Wait-list received no intervention during the time the treatment group received the 8-week program
89063935|NCT01605344|Experimental|Arm A|ARM A subjects will receive atorvastatin 20 mg orally once daily given for two weeks prior to FOLFIRI. The last dose of atorvastatin will be taken day 1 of FOLFIRI. ARM A will then receive no statin for the next 2 weeks. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
89063936|NCT01605344|Experimental|Arm B|ARM B subjects will receive no atorvastatin prior to day 1 of FOLFIRI. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks prior to day 15 of FOLFIRI. The last dose of atorvastatin will be taken day 15 of FOLFIRI. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
89063937|NCT04358640||Employees of Nîmes University Hospital (France)|Employees of Nîmes University Hospital (France)
89063938|NCT01605383|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head"
89063939|NCT01605383|Sham Comparator|Standard Treatment|Isolated core decompression
89063940|NCT00594282|Experimental|1|Enhanced Mammography (EM) - Women who are randomized to the Enhanced Mammography (EM) condition will receive a mammogram in which a MammoPad radiolucent breast plate cushion is used.
89063941|NCT00594282|No Intervention|2|Routine Mammography (RM) - Women who are randomized to the Routine Mammography (RM) condition will obtain a routine, un-altered mammogram during which typical exam protocol will be followed and no radiolucent cushion is used.
89063942|NCT01606865||elective and acute non-cardiac surgery|
89063943|NCT00594321|Active Comparator|2|Subjects randomized to the control arm of the study will have a standard vertebroplasty with any FDA-approved bone cement done in accordance with the usual method employed by the treating physician.
89063944|NCT00594321|Experimental|1|Subjects randomized to the experimental arm of the study will have a vertebroplasty with the SPACE CpsXL Bone cement (FDA-approved) and SPACE 360 Delivery System (FDA-approved).
89221922|NCT01323556|Experimental|Exposure with fear augmentation|exposure-based CBT, including interoceptive exposure and in-vivo exposure with fear augmentation by interoceptive exercises (e.g. hyperventilation)
89063945|NCT04357236||Experimental Group|The experimental group received 18F-FDG PET examination
89063946|NCT04357236||Control Group|The control group received 18F-FDG PET examination
89063947|NCT01607372|Experimental|GSK2245035 - 40 ng or placebo|Subjects will receive GSK2245035 - 40 nanogram (ng) or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
89063948|NCT01607372|Experimental|GSK2245035 - 80 ng or placebo|Subjects will receive GSK2245035 - 80 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
89063949|NCT01607372|Experimental|GSK2245035 - 120 ng or placebo|Subjects will receive GSK2245035 - 120 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
89063950|NCT01607372|Experimental|GSK2245035 - 160 ng or placebo|Subjects will receive GSK2245035 - 160 ng or placebo once per week, for four treatment weeks. There will be washout period of 7 days between treatment periods.
89063951|NCT04357314||Patients with STEMI in 2019|Patient with acute myocardial infarction between March 17, 2019 and April17, 2019
89063952|NCT04357314||Patients with STEMI in 2020|Patient with acute myocardial infarction between March 17, 2020 and April17, 2020.
89063953|NCT01608581|Experimental|exposure to multi-media campaign|A multimedia campaign highlighting dangers of gasoline and fire was delivered to an intervention region in the state of Queensland
89063954|NCT01605500||Medtronic ICDs|Patients with Generation 2 Medtronic ICDs
89063955|NCT00594360|Active Comparator|1|
89063956|NCT00593463|Experimental|1|Receives 2-4 of the interventions listed
89063957|NCT02270099||Subjects with suspected HSV Lesions|
89063958|NCT00594438|Experimental|1, A|Femoral reaming with the Synthes Reamer-Irrigator-Aspirator (RIA)
89063959|NCT00594438|Active Comparator|2 B|Femoral reaming with a Zimmer Sentinel Reamer.
89063960|NCT02270138|Experimental|Movement-to-music|Three movement-to-music video programs will be used by the participants. First and second videos last about 10 minutes including two songs and their movement preparation. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
89063961|NCT02270138|No Intervention|No movement-to-music|Another group will not receive movement-to-music video during intervention. However, their physical activity will be objectively measured as well.
89063962|NCT02270216|Active Comparator|elderly with isolated systolic hypertension|over 60 years of age with essential isolated systolic hypertension (stage I-II base on recommendation of JNC-VII) for the hypertension group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
89063963|NCT02270216|Active Comparator|healthy elderly|over 60 years of age with normal blood pressure in the healthy group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
89063964|NCT00592410|Experimental|1|
89063965|NCT01605656||Focus Groups + Interviews + Questionnaires|HIV-positive women recruited from the population of individuals seeking care at Thomas Street Health Center (TSHC) of the Harris County Hospital District (HCHD).
89063966|NCT00594477|Experimental|IMRT|The prescribed dose for all patients will be 5040 cGy in 28 fractions. Patients will receive external beam treatment once a day, five days a week for approximately five and a half weeks.
89063967|NCT02270294|Experimental|Thai traditional massage|
89063968|NCT02270294|Sham Comparator|No massage|
89063969|NCT00592449|No Intervention|1|Participants with knee OA who meet research diagnostic criteria for insomnia will partake in Phase 1
89063970|NCT00592449|No Intervention|2|Participants with knee OA who meet research diagnostic criteria for normal sleep will partake in Phase 1
89063971|NCT00592449|No Intervention|3|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for primary insomnia will partake in Phase 1
89063972|NCT00592449|No Intervention|4|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for normal sleep will enroll in Phase I
89063973|NCT00592449|Experimental|5|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive behavioral desensitization treatment for insomnia
89063974|NCT00592449|Experimental|6|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive cognitive behavior therapy for insomnia
89063975|NCT01605695||Normal healthy adults|The concentration of iNOS will be measured in plasma samples obtained at the time of blood donation from normal healthy adult humans
89063976|NCT04328064|Active Comparator|Rosuvastatin Drug|Active drug-rosuvastatin 40 mg
89063977|NCT04328064|Placebo Comparator|Placebo drug|Placebo oral tablet
89063978|NCT01605734|Active Comparator|Group TACE|TACE will be carried out with chemotherapeutic agents and lipiodol; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated if clinically indicated
89063979|NCT01605734|Experimental|Group Combination|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
89063980|NCT02270372|Experimental|Drug Combination|The drug combination of ONT-10 and varilumab
89063981|NCT01605773|Experimental|repaglinide|
89063982|NCT01605773|Active Comparator|glyburide|
89063983|NCT01605812||high myopia|high myopia (axial length>26mm)
89063984|NCT01605812||emmetropia|emmetropia (22<axial length<25mm) as control group.
89063985|NCT01605851|Other|Closure, Foramen Ovale|Patients undergoing device closure of PFO
89063986|NCT02270528|Experimental|HIT1|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. The second attempt, prior to the WCST, this group will perform a warm-up and 5-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
89063987|NCT02270528|Experimental|HIT2|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and a 5-minute stationary period. The second attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
89063988|NCT02270528|Other|CON|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt and second attempt, prior to the WCST, this group will participate in a 15-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
89063989|NCT00594555|Experimental|Single Arm - treatment period|"Drug Name/Days Administered~Neupogen/Days 1-6~CLAG/Days 2-6~Gleevec/Days 2-15"
89063990|NCT01605929|Experimental|Retroclavicular Brachial Plexus Block|
89063991|NCT00594594|Experimental|1|Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
89063992|NCT02270606|Experimental|Treatment(IMRT,fluorouracil,chemotherapy,surgery)|"CHEMORADIATION:Patients undergo Intensity Modulated Radiation Therapy (IMRT) once a day over 5 days for total of 5 fractions and concurrently receive fluorouracil IV continuously over 96 hours.~PREOPERATIVE CHEMOTHERAPY:Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1.Treatment repeats every 14 days for 4 courses in absence of disease progression or unacceptable toxicity.~SURGERY:Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision as therapeutic conventional surgery.~POSTOPERATIVE CHEMOTHERAPY:Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil(preoperative chemotherapy).Treatment repeats every 14 days for 6 courses in absence of disease progression or unacceptable toxicity."
89063993|NCT00594633|Experimental|1|donepezil and questionaires
89063994|NCT02270762|Experimental|1) Rest in bed|First evaluation of EIT with patient in bed at 30º of head inclination during 5 minutes.
89063995|NCT02270762|Experimental|2) Passive Verticalization|Second evaluation of EIT with patient in tilt table at 60º of verticalization during 10 minutes.
89063996|NCT02270762|Experimental|3) Rest in bed|Last evaluation of EIT with patient in bed at 30º of head inclination during 20 minutes.
89063997|NCT01605968|Experimental|BCT Silver Bandage|
89063998|NCT01605968|Active Comparator|Aquacel® Ag. Dressing|
89063999|NCT01606046|Active Comparator|vapocoolant spray|
89064000|NCT01606046|Active Comparator|topical anesthetic agent|
89064001|NCT01606046|No Intervention|Control|no interventions
89064002|NCT00594711||1|Case-group
89064003|NCT00594711||2|Control-group
89064004|NCT04354818||People living with HIV|
89064005|NCT04354818||Recipients of Solid Organ Transplants|
89064006|NCT04354818||People Living with Cancer|
89064007|NCT04354818||People with acquired immunodeficiency|Patients with acquired immunodeficiency associated with other immunosuppressive therapy.
89064008|NCT04354818||People with primary immunodeficiency|
89064009|NCT02892630||Pregnant ITP women|Pregnant women more than 18 years old, with primary ITP diagnosis before pregnancy
89064010|NCT02892630||Control ITP Women (Non pregnant)|Primary ITP women more than 18 years old, at more than one year from a precedent pregnancy
89064011|NCT02892630||De novo ITP pregnant women|Pregnant women more than 18 years old, with newly diagnosed thrombocytopenia during pregnancy
89064012|NCT01606085|Experimental|HF-DM Self Care|educational counseling intervention about integrated HF-DM self care outcomes
89064013|NCT01606085|No Intervention|Usual Care|Usual Care provided by providers
89064014|NCT00594828|Experimental|1|6 months of supervised patient self testing using an expert system
89064015|NCT00594828|Active Comparator|2|6 months of routine medical care by the anticoagulation management service
89064016|NCT02270801|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
89064017|NCT04327713||fish oil supplementation|"fish oil supplementation, usually capsules with a defined content of EPA and DHA~dosage and duration of intervention differ between the included studies of our meta-analysis"
89064018|NCT04327713||placebo supplementation|"placebo supplementation, usually capsules with a defined content of non-fish oil or other components~content, dosage and duration of intervention differ between the included studies of our meta-analysis"
89064019|NCT01606163|Experimental|group 1|"Drug:GC1102~Amount:3ml (30,000IU)"
89064020|NCT01606163|Experimental|group 2|"Drug: GC1102~Amount: 5ml(50,000IU)"
89064021|NCT01606163|Experimental|group 3|"Drug: GC1102~Amount: 8ml (80,000IU)"
89064022|NCT01606163|Placebo Comparator|group 4|drug: JW normal saline
89064023|NCT02892942|Active Comparator|Control Group|"Background therapy which is the usual COH treatment:~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®."
89064024|NCT02892942|Experimental|NATOS Group|"Background therapy which is the usual COH treatment:~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®.~GnRH antagonist treatment (Cetrotide®, MerckSerono Pharmaceuticals) will be reinforced and patients will receive 1.5 mg/day (6 ampoules of 0.25 mg), S.C., starting on day 1 (S1) of Gonal-F® treatment until dhCG"
89064025|NCT02270879||Main group|Patients having performed bilateral consecutive cataract surgery between 1st October 2012 and 24th April 2014 in a single ophthalmological center (Centro Hospitalar Baixo Vouga, Portugal).
89064026|NCT00594867|Active Comparator|1|Acetaminophen - 4 grams per day + Placebo
89064027|NCT00594867|Active Comparator|2|Aspirin - 325 mg per day + Placebo
89064028|NCT00594867|Experimental|3|Acetaminophen 4 gram per day + Aspirin 325 mg per day
89064029|NCT01606241|Experimental|Treatment (cyclophosphamide and vaccine therapy)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of course 1. Within 3-5 days, patients receive multi-epitope folate receptor alpha peptide vaccine ID on day 1. Vaccine treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89064030|NCT00595023||1|All eligible subjects
89064031|NCT02270918|Active Comparator|Apixaban with Kcentra|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of prothrombin complex concentrate Kcentra at 25 units/Kg
89064032|NCT02270918|Placebo Comparator|Apixaban with placebo|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of saline
89064033|NCT02270996||NO Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) BEFORE the implementation of the Antimicrobial Stewardship Program.
89064034|NCT02270996||WITH Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) WITH the implementation of the Antimicrobial Stewardship Program.
89064035|NCT00595062|Experimental|1|
89064036|NCT01580189|Active Comparator|Milk|Chocolate milk compared to protein supplement
89064037|NCT01580189|Active Comparator|Whey protein|Whey protein compared to milk
89064038|NCT01580189|Placebo Comparator|Sugar|Maltodextrin compared to treatments
89064039|NCT00595140|No Intervention|1|patients with acromegaly on stable pegvisomant therapy
89064040|NCT00595140|Active Comparator|2|Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg
89064041|NCT00595140|Active Comparator|3|Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally
89064042|NCT02271035|Active Comparator|Deflux|In each patient, Deflux will be injected into one of the ureteral orifices using the the HIT technique.
89064043|NCT02271035|Active Comparator|Vantris|Vantris will be injected into the other ureteral orifice using the same technique and the same amount of implant.
89064044|NCT01606358||Ovarian Cancer|
89064045|NCT02271074|No Intervention|Standard of Care|The role of this arm is to provide a baseline measure that can be used to assess the effectiveness of the combination interventions in improving the proportion of individuals entering care within 3 months. Participants in this arm only receive standard post-test counselling after they are issued with a positive HIV result. They are counselled on possible emotional resources, and given information on how to reduce risk of HIV transmission, ongoing positive living, nutrition and healthy lifestyles. These clients are given referral letters and referred to health facilities of their choice that offer HIV care/treatment. They are then followed up at the designated study time points to ascertain entry into care.
89064046|NCT02271074|Experimental|Point of care CD4 testing|Participants in this arm will receive point of care (POC) cluster differentiation 4 (CD4) testing using the PIMA™ CD4 test system.
89064047|NCT02271074|Experimental|Care facilitation|Participants receive a combination of POC CD4 testing and care facilitation.
89064048|NCT02271074|Experimental|Transport support|Participants receive a combination of POC CD4 testing and transport support.
89064049|NCT00595218|No Intervention|1|Patients whose radiation oncologist are blinded to their patient preference survey results
89064050|NCT00595218|Active Comparator|2|Patients whose radiation oncologist are not blinded to their patient preference survey results
89064051|NCT01606397|Placebo Comparator|Placebo|Placebo administered orally once daily for 4 weeks
89064052|NCT01606397|Experimental|5 mg LY2409021|5 mg LY2409021 administered orally once daily for 4 weeks
89064053|NCT01606397|Experimental|30 mg LY2409021|30 mg LY2409021 administered orally once daily for 4 weeks
89064054|NCT01606397|Experimental|60 mg LY2409021|60 mg LY2409021 administered orally once daily for 4 weeks
89064055|NCT01606397|Experimental|90 mg LY2409021|90 mg LY2409021 administered orally once daily for 4 weeks
89064056|NCT00595257|Experimental|1|injection of BMAC into ischemic limb
89064057|NCT00595257|Active Comparator|2|Injection and Infusion of BMAC into ischemic lower limb
89064058|NCT02271113|Experimental|GMI-1271|IV GMI-1271
89064059|NCT02271113|Placebo Comparator|Placebo|IV Placebo
89064060|NCT02271113|Active Comparator|Enoxaparin Sodium (Lovenox®)|SC Lovenox®
89064061|NCT02271152|Experimental|FAST ablation + PVI|FAST mapping and ablation will be performed in addition to PVI
89064062|NCT02271152|Active Comparator|PVI|Pulnonary vein isolation will be performed
89064063|NCT04349865||Idiopathic PD|PD patients without the LRRK2 G2385R mutation
89064064|NCT04349865||LRRK2 G2385R PD|PD patients with the LRRK2 G2385R mutation
89064065|NCT04349865||LRRK2 G2385R carriers|Subjects without PD who screen positive for the LRRK2 G2385R mutation
89064066|NCT04349865||Controls|Subjects without PD who screen negative for the LRRK2 G2385R mutation
89064067|NCT01606514|Experimental|Child, Parenting, & Parent Web-Intervention|Bounce Back Now Child, Parenting, & Parent Psychoeducation & Self-Help Web-Intervention.
89064068|NCT01606514|Experimental|Child & Parenting Web-Intervention|Bounce Back Now Child & Parenting Psychoeducation and Self-Help Web-Intervention.
89064069|NCT01606514|No Intervention|Child & Parent Web-based Assessment|Bounce Back Now Web-Based Symptom Assessment
89064070|NCT00595296||1|All eligible patients.
89064071|NCT02271191|Active Comparator|Nicardipine and Remifentanil|intravenous nicardipine and remifentanil during deliberate hypotension
89064072|NCT02271191|Placebo Comparator|Remifentanil|intravenous remifentanil during deliberate hypotension
89064073|NCT02271269|No Intervention|Usual Care (UC)|"Patients receiving Usual Care for Glaucoma comprising:~Education on effective glaucoma treatment~Routine check-ups with an ophthalmologist and prescription of glaucoma eye drops~Glaucoma counselling [Can be recommended by ophthalmologist for non-adherent patients] covering:~Glaucoma risk factors and symptoms~Management and treatment~Medications and optimal dosage windows~Risks of medication non-adherence~Formulation of a dosing schedule that compliments each patient's lifestyle"
89064074|NCT02271269|Experimental|Value Pricing (VP)|Patient receiving Usual Care for Glaucoma and given the opportunity to receive Value Pricing Subsidies.
89064075|NCT01606553|Experimental|High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a dual-vave prototype
89064076|NCT01606553|Active Comparator|Sham High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a sham dual-vave prototype
89064077|NCT04328025|Active Comparator|Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP|"For TGW in the intervention arm, peers will deliver HIVST and PrEP medications monthly in between quarterly clinic visits. Quarterly clinic-based testing will confirm accuracy of self-tests and identify inaccurate test results. Additionally, peers will remind TGW to self-test before opening a new PrEP bottle. They will also distribute STI self-sampling kits to TGW for own use, and with regular partners as needed. They will present smart phone instructional videos showing trans women how to self-collect pharyngeal, rectal and urine specimens for Neisseria gonorrhoeae and Chlamydia trachomatis testing.~Peers will: a) motivate ongoing adherence; b) promote repeat HIV testing; and c) support PrEP use as problems arise. Self-sampling for STIs will be performed monthly by participants (with questions answered by the peer or other study staff as needed)."
89064078|NCT04328025|No Intervention|Facility-Delivered Care|Participants will receive facility-based HIV counseling, PrEP prescriptions condoms, risk reduction counseling, and management of sexually transmitted infections as standard of care.
89064079|NCT02271308|No Intervention|Control group|Residents in control group will receive regular activity in nursing homes.
89064080|NCT02271308|Experimental|Experimental group|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
89064081|NCT01606592|Experimental|Randomized Panic Control Treatment|Patients who have been randomized to the randomization condition are assigned to PCT
89064082|NCT01606592|Experimental|Randomized Panic-Focused Psychodynamic Psychotherapy|Patients who have been randomized to the randomization condition are assigned to PFPP
89064083|NCT01606592|Experimental|Self-selected Panic Control Treatment|Patients who have been randomized to the self-selection condition choose PCT
89064084|NCT01606592|Experimental|Self-selected Panic-Focussed Psychodynamic Psychotherapy|Patients who have been randomized to the self-selection condition choose PFPP
89064085|NCT01606592|Experimental|Waiting-list|Patients who have been randomized to the waiting-list are offered sparse contact over telephone for 12 weeks and are then re-randomized to one of the other four arms
89064086|NCT00595569||Type 1 diabetes|
89064087|NCT02271347|Experimental|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
89064088|NCT01172938|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
89064089|NCT01172938|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
89064090|NCT01172938|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
89064091|NCT01172938|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
89064092|NCT02271464|Experimental|Maintenance:BEVACIZUMAB|Induction: FOLFOXIRI; Manteinance: Bevacizumab
89064093|NCT02271464|Experimental|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|Induction: FOLFOXIRI; Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE(Metronomic Chemotherapy)
89064094|NCT00595608|Active Comparator|1|Nasal Sterimar spray
89064095|NCT00595608|Active Comparator|2|Nasal saline spray
89064096|NCT01606631||Arm 1 : experimental (case)|Patients included in the study and admitted to the ICU either directly from UAA or after a hospitalization in a specialty, for a severe sepsis or septic shock on their infectious disease community.
89064097|NCT01606631||Arm 2 : control|Patients included in the study with an infectious disease community, admitted to a specialty, and have not progressed to severe sepsis or septic shock before hospital discharge.
89064098|NCT04326894|Experimental|Methotrexate|25mg oral MTX tablets
89064099|NCT04326894|Placebo Comparator|Placebo|25 mg/week placebo tablets
89064100|NCT02271542|Experimental|between 1-10 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
89064101|NCT02271542|Experimental|under 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
89064102|NCT02271542|Experimental|upper 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
89064103|NCT00595647|Active Comparator|1|Percutaneous coronary intervention
89064104|NCT00595647|Placebo Comparator|2|Percutaneous coronary intervention
89064105|NCT04315402||Group 1 (provider-patient concordant)|
89064106|NCT04315402||Group 2 (provider-patient discordant)|
89064107|NCT01109992|Active Comparator|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
89064108|NCT01109992|Experimental|Exercise + Regadenoson (Lexercise)|Exercise plus Regadenoson (Lexercise) Rubidium-82 Positron Emission Tomography
89064109|NCT02892357|Experimental|Treatment group|Participants in this group take the herbal compound of Jianpi Qinghua granules and half-dose omeprazole tablet.Jianpi Qinghua granule:one bag after 1 hour of breakfast and supper(twice a day) for 4 weeks.Half-dose omeprazole tablet:1 tablet of real omeprazole (10mg) and 1 tablet of Sham(10mg),once a day before breakfast for 4 weeks.
89064110|NCT02892357|Active Comparator|Control group|Participants in this group take the sham herbal granules twice a day as treatment group and two pieces of real omeprazole tablet(10mg each) once a day before breakfast for 4 weeks.
89064111|NCT00595686|Experimental|Single Arm|
89064112|NCT02271620|Other|nonallergic rhinitis|nonallergic rhinitis nasal allergen provocation test
89064113|NCT00595725|Experimental|1|
89064114|NCT02271659|Experimental|Brachytherapy boost|Brachytherapy boost with external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds (110Gy) or high dose rate (14Gy) with iridium-192) only to the prostate. Each center will choose the appropriate brachytherapy technique
89064115|NCT02271659|Active Comparator|Exclusive external beam irradiation|Exclusive external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
89064116|NCT00595842||Group one|Subjects are drawn from a search of all patients treated with MTA between ages 5-40
89064117|NCT01109524|Experimental|Cetuximab + Cisplatin + Vinorelbine|
89064118|NCT02271737|Experimental|Experimental|Improve infection control in health centers; improve home hygiene; improve newborn danger signs recognition by the HC staff, VHSG, and mothers; and improve care coordination between community and health facilities. The above improvements will be through the training of health center staff and VHSG; HC staff and VHSG provide health education to mothers at the health centers and at home respectively; and provide supportive supervision to both HC and VHSG. VHSG will conduct three home visits to the mothers/newborns on the first 24 hours, the 3rd day, and the 7th day after delivery.
89064119|NCT02271737|No Intervention|No Intervention|We do not make any interventions.
89064120|NCT01109173|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
89064121|NCT01109173|Active Comparator|NEVANAC|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
89064122|NCT01109173|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Ophthalmic Suspension 0.3% Vehicle, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
89064123|NCT01109173|Placebo Comparator|NEVANAC Vehicle|Nepafenac 0.1% vehicle, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
89064124|NCT02271776|Active Comparator|Galactooligosaccharide|5g 3x per day for 12 weeks
89064125|NCT02271776|Placebo Comparator|maltodextrin|3x per day for 12 weeks (isocaloric to intervention)
89064126|NCT04327596|No Intervention|Conventional Treatment|Subjects will receive management of AF consisting of either rate or rhythm control.
89064127|NCT04327596|Active Comparator|AF Ablation|Subjects will undergo early RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter
89064128|NCT02271971|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive a daily 5.000 IU vitamin D3 capsule during 6 weeks.
89064129|NCT02271971|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a daily placebo capsule during 6 weeks.
89064130|NCT02273024|Experimental|Exercise|Individuals will participate in weekly supervised and unsupervised exercise sessions prior to HSCT, during hospitalization and till 100 days from HSCT. Exercise will consist of endurance and resistance exercise 3-5 days a week.
89064131|NCT02273024|No Intervention|Usual Care|Usual care will have continue with standard of care treatment without any specific exercise instruction or guidance other than what is provided by the patient education team at the cancer centre.
89064132|NCT02272088|Experimental|physical activity-moderate|participants will be walking during 60 minutes in a moderate pace
89064133|NCT02272088|Experimental|intense physical activity|participants will be running during 60 minutes in na intense pace.
89064134|NCT01172821|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
89064135|NCT01172821|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
89064136|NCT01172821|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
89064137|NCT01172821|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
89064138|NCT02272127|Experimental|intercalated treatment|Patients will receive 4 cycles treatment: chemotherapy(day 1) plus intercalated icotinib(day 8-21) every 3 weeks, and then oral icotinib continuously for 2 years or until disease progression or unacceptable toxic effects
89064139|NCT01172275|Experimental|N-Acetylcysteine|N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
89064140|NCT01172275|Placebo Comparator|Placebo|Placebo effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
89064141|NCT00595998||1|newly onset CNV secondary to AMD
89064142|NCT00595998||2|Intermediate AMD
89064143|NCT02272283|Active Comparator|Angio-guided PCI|"Patients allocated to angio-guided PCI are having Percutaneous Coronary Intervention (PCI) with stent implantation guided by routine angiography alone.~Documentary (comparator) intravascular imaging with Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) is performed. The PCI-operator is blinded to the image aquisitions, and the analysis is performed offline later."
89064144|NCT02272283|Experimental|OCT-guided PCI|"After obtaining an angiographic optimal result, patients allocated to OCT-guided PCI have guiding Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) performed. Online image interpretation is performed by a dedicated OCT-analyst and the PCI-operator. If the OCT reveals; 1) under expansion of the stent with a minimal stent area (MSA) <90% of the distal/proximal reference vessel lumen area and/or; 2) significant acute incomplete stent apposition (defined as more than or equal to 3 stent struts detached >140 microns from the underlying vessel wall), and/or; 3) edge dissection(s) causing significant reduction in minimal lumen area(s) (MLA <4 mm2) and/or, 4) significant residual stenosis (MLA <4 mm2) at the proximal and/or distal reference segment(s), additional intervention is encouraged. The degree of optimization based upon OCT findings is left to the judgement of the PCI-operator."
89064145|NCT05036356|Experimental|Controlled App Group|"Subjects will receive access to the Headspace app and will receive weekly reminders to complete activities from the Inspiration, Ideation, Implementation block model of human-centered design in the app."
89064146|NCT05036356|Experimental|Ad lib App Group|Subjects will receive access to the Headspace app and be encouraged to use it ad lib.
89064147|NCT05034952|Experimental|VX-548|Participants will be randomized to receive different dose levels of VX-548.
89064148|NCT05034952|Active Comparator|Hydrocodone bitartrate/ acetaminophen (HB/APAP)|Participants will receive HB/APAP.
89064149|NCT05034952|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
89064150|NCT00596037|Experimental|LB03002 throughout|administered LB03002 for preceding 26 weeks
89064151|NCT00596037|Experimental|Switched to LB03002|administered placebo for preceding 26 weeks
89064152|NCT04310371|Experimental|Obese adolescents|BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention
89064153|NCT04310371|No Intervention|Control group|to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
89064154|NCT02881372|Experimental|Oral food desensitization|All of the children enrolled in the study will receive oral food desensitization with his or her specific EoE flare-inducing food antigen (e.g. cow's milk protein). The food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C) to stabilize and preserve the solution. This oral spray will need to be administered twice a day, every day for a total of 4 months.
89064155|NCT04326855|Experimental|20 patients with advanced COPD|This will be a cross sectional observational study. COPD patients will be recruited from those referred to the Pulmonary Rehabilitation programme at RVI Hospital in Newcastle upon Tyne. Potentially eligible patients will be identified by the physiotherapy team within the Trust, who will provide initial information about the study. Delegated investigators will confirm eligibility and discuss full details of the trial. Patients will be given time to consider participation in the trial before written informed consent is obtained.
89064156|NCT02272400|Experimental|IGRT of prone partial breast|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy.
89064157|NCT02273102|Experimental|TCP Dose Level 1|20mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
89064158|NCT02273102|Experimental|TCP Dose Level 2|40mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
89064159|NCT02273102|Experimental|TCP Dose Level 3|60mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
89064160|NCT02272439||Unexplained (male)|Men of couples with a diagnosis of Unexplained infertility (n=15)
89064161|NCT02272439||Unexplained (female)|Women of couples with a diagnosis of Unexplained infertility (n=15)
89064162|NCT02272439||male factor (male)|Men of couples with a diagnosis of male factor infertility (n=15)
89064163|NCT02272439||male factor (female/control)|Women of couples with a diagnosis of male factor infertility (n=15)
89064164|NCT02272439||PCOS (female)|Women of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
89064165|NCT02272439||PCOS (male/control)|Men of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
89064166|NCT02272439||healthy volunteer (male/control)|Men with a history of no reproductive dysfunction and proven fertility (n=15)
89064167|NCT02272439||healthy volunteer (female/control)|Women with a history of no reproductive dysfunction and proven fertility (n=15)
88821208|NCT04901403|Other|Control group|Control group families will receive home visiting services as usual.
89064168|NCT02272478|Active Comparator|Arm A|"Patients not known adverse karyotype~Randomise between~Daunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy~Versus~CPX-351 100 units/m2 on days 1, 3 and 5"
89064169|NCT02272478|Active Comparator|Arm B|"Patients with known adverse karyotype~5 cycles of Vosaroxin and Decitabine therapy"
89064170|NCT02272478|Active Comparator|Arm C|"Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1~Randomise between~Daunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)~Versus~Daunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive~Versus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive~Patients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)~And Randomisation to receive AC220 or not"
89064171|NCT02272478|Active Comparator|Arm D|"Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1~Randomisation to receive AC220 or not"
89064172|NCT02272478|Active Comparator|Arm E|"Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1~Randomisation between~CPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)"
89064173|NCT02272478|Active Comparator|Arm F|"Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1~Randomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)~versus~Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)"
89064174|NCT02272517|Active Comparator|Escitalopram 10-20 mg|Encapsulated tablets once daily for 8 weeks
89064175|NCT02272517|Experimental|Vortioxetine 10-20 mg|Encapsulated tablets once daily for 8 weeks
89064176|NCT02272712|Experimental|Cognitive Behavioural Therapy|A 6-week online cognitive-behavioural treatment for insomnia. Each week focuses on a different topic consistent with the cognitive-behavioural theory of insomnia.
89064177|NCT02272712|No Intervention|Control Condition|The online attention matched control arm will provide education about sleep without any focus on the active ingredients that constitute the intervention group.
89064178|NCT04344366||group A|children with low birth weight
89064179|NCT04344366||group B|children with normal birth weight
89064180|NCT02272751|Experimental|Exercise Intervention|"Subjects allocated to the Exercise arm will aim to undertake a personal prescribed home exercise programme for half an hour three times a week.~Exercises will be progressed at 6 weeks as subjects progress. All exercise sessions will be documented in the logbooks provided.~Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
89064181|NCT02272751|Experimental|Relaxation Intervention|"Subjects allocated to the Relaxation arm will aim to undertake a guided relaxation programme on a CD for half an hour three times a week.~All relaxation sessions will be documented in the logbooks provided. Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
89064182|NCT00596076|Experimental|1|Workers with low back pain
89690019|NCT02977377|Active Comparator|Exercise/ Whole body vibration|Exercise therapy will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 1 week washout period exercise therapy and whole body vibration will be applied together for 8 weeks.
89690020|NCT02976675|Experimental|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
89690021|NCT02976675|Experimental|PEG-somatropin per two weeks|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
89690022|NCT02976675|Active Comparator|Jintropin AQ|Jintropin AQ, injection, 30IU/10 mg/3ml/cartridge, 0.25mg/kg/w, once per day for 26 weeks
89690023|NCT04988373|Experimental|Single aligner appliance|Modified aligner appliance with NiTi springs
89690024|NCT04988373|Active Comparator|Traditional fixed appliances|MBT-prescription of metallic brackets.
89690025|NCT00983983|Experimental|High fat/high calorie|High fat/high calorie diet: Oxepa
89690026|NCT00983983|Active Comparator|High calorie|High calorie diet: Jevity 1.5
89690027|NCT00983983|Placebo Comparator|Control|Control diet: Jevity 1.0
89690028|NCT00984139|Experimental|Engerix-B Group|Subjects who were vaccinated with 3 doses of Engerix-B in infancy and who received a single challenge dose of Engerix-B , intramuscularly in the deltoid region of the non-dominant arm, at 12-13 years of age (Day 0).
89690029|NCT04672395|Experimental|Group 1|CpG 1018/Alum-adjuvanted SCB-2019 vaccine
89690030|NCT04672395|Placebo Comparator|Group 2|Placebo Comparator: 0.9% Saline
89690031|NCT04672395|Experimental|Booster dose of SCB-2019|Adult SCB-2019 recipients will receive 1 dose of SCB-2019 at least 4 months after the second dose
89690032|NCT04672395|Placebo Comparator|Vaccination of placebo recipients with SCB-2019|Placebo participants will be offered two doses of SCB-2019 vaccine
89690033|NCT03131206|Experimental|Phase 1 RP2D of alectinib|"The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have NSCLC, not everyone who participates in this research study will receive the same dose of the study drug. The dosage will depend on the number of participants who have been enrolled in the study and how well the dosage has been tolerated.~Alectinib~Oral, BID~A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days."
89690034|NCT03131206|Experimental|Cohort A|"Participants with RET-rearranged NSCLC with no previous history of RET-TKI therapy.~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
89064183|NCT04344327||Patients with COVID-19|Patients hospitalized in conventional sector with diagnosis of COVID-19 (positive PCR (Polymerase Chain Reaction) or diagnosis presumed by the clinical and radiographic picture)
89064184|NCT02272829|Active Comparator|Active|Participants in this arm will receive the study intervention (sessions with the BHC and the PCP).
89064185|NCT02272829|Placebo Comparator|Health Education|Participants in this arm will receive study sessions about various health topics.
89064186|NCT00596193||Group I|patients with normal or irreversible pulpitis teeth with capsaicin administered at increasing volumes.
89064187|NCT00596193||Group II|Patients with normal teeth only with capsaicin added at a specific volume only
89064188|NCT02272868|Experimental|Fecal microbiome transplant|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Fecal Microbial Transplant
89064189|NCT02272868|Placebo Comparator|Normal saline|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Normal saline
89064190|NCT02892864|Active Comparator|Control arm|Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
89064191|NCT02892864|Experimental|Experimental Virtual Arm|Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.
89064192|NCT02272907|Experimental|Non-buttressed, non-imbricated oversewing|Along the staple line, the surgical attending will oversew the length of the staple line using a 2-0 Vicryl suture in a continuous fashion.
89064193|NCT02272907|Experimental|Non-buttressed, imbricated suture line|Along the staple line, the surgical attending will oversew the staple line using a 2-0 Vicryl suture in a continuous, imbricating fashion.
89064194|NCT02272907|Experimental|Buttressed stapling|"The specimen will be stapled utilizing the same stapling device, with Seamguard applied as a buttress. We will use the standard methodology to apply Seamguard as illustrated in the company's Instructions for Use."
89064195|NCT02272907|Active Comparator|No reinforcement|Data will be collected on staple lines without any reinforcement as a baseline for leak pressure.
89064196|NCT02892825|Experimental|music group|music listening
89064197|NCT02892825|Active Comparator|no music group|no music listening
89064198|NCT02273453|Experimental|Songha® Night|
89064199|NCT02273453|Active Comparator|Placebo + Oxazepam|
89064200|NCT02273453|Placebo Comparator|Placebo|
89064201|NCT01108510|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo + ATV + FTC/TDF once daily
89064202|NCT01108510|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo + ATV + FTC/TDF once daily
89064203|NCT02273258|Experimental|Test (T)|SAR342434: single dose injection
88821209|NCT04899739|Experimental|Peripancreatic and distant lymph node assessment|All patients programmed for an endoscopic ultrasound in the context of a pancreatic cancer
89064204|NCT02273258|Active Comparator|Reference 1 (R1)|US-approved Humalog®: single dose injection
89064205|NCT02273258|Active Comparator|Reference 2 (R2)|EU-approved Humalog®: single dose injection
89064206|NCT00596232||Asthma|People who have been diagnosed with Asthma
89064207|NCT00596232||Cystic Fibrosis|People who have been diagnosed with Cystic Fibrosis
89064208|NCT00596232||Healthy|People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
89064209|NCT02273414|Experimental|BIIL 284 BS - rising dose|
89064210|NCT02273414|Placebo Comparator|Placebo|
89064211|NCT02881411|Active Comparator|Self-soft tissue therapy|Intervention group: Fibromyalgia coping skills programme plus self-soft tissue therapy (SSTT) SSTT consists of MTrP therapy on TrP sites in either the lower leg/foot or forearm/hand. MTrP therapy will be administered by the researcher for only two sessions which will include training to teach the participant how to do SSTT on themselves. All participants in the intervention group will also receive an advice booklet for SSTT.
89064212|NCT02881411|Active Comparator|Fibromyalgia coping skills programme|Control group:Fibromyalgia coping skills programme only. The FCSP is a non-pharmacological, multidisciplinary exercise and education group programme. Its main aims are to provide condition-specific, patient centred, self-management education and advice, in line with national drivers for long-term conditions and international FMS clinical guidelines.
89064213|NCT01588691|Active Comparator|Low frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
89064214|NCT01588691|Active Comparator|High frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
89064215|NCT01588691|Placebo Comparator|No stimulation|Programming parameters will be set to the lowest possible level and minimal power will be generated. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
89064216|NCT05018494|Experimental|Group A|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
89064217|NCT05018494|Active Comparator|Group B|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
89064218|NCT02881645||Best practices|Assessment of critical incidents linked to nursing with a best practices protocol
89064219|NCT02881645||Common practices|Assessment of critical incidents linked to nursing in common practices
89064220|NCT04327245|Experimental|Intervention ingest a 5000 mg of D-tagatose|Intervention: Women with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.e.
89064221|NCT04327245|No Intervention|No Intervention: Intervention ingest a water (control group)|Woman with resistance insulin who ingest a water (control group)
89064222|NCT04327245|Experimental|Intervention ingest a 15,3 mg of stevia|"Intervention: Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
89064223|NCT01588769|Experimental|One arm|3 doses of ALECSAT cell based immunotherapy planned for all enrolled patients
89064224|NCT00596310|Experimental|1|Screening CT
89064225|NCT04327401|Experimental|Intervention group|Dexamethasone. After randomization, dexamethasone [20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days] + standard treatment (according to the treatment protocol for 2019-nCoV infection).
89064226|NCT04327401|No Intervention|Control|Standard treatment (according to the treatment protocol for 2019-nCoV infection).
89064227|NCT01340027|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
89064228|NCT01340027|Active Comparator|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks
89064229|NCT01340027|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
89064230|NCT01340027|Active Comparator|Solifenacin 2.5 mg|Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks
89064231|NCT01340027|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg tablets orally once a day for 12 weeks
89064232|NCT01340027|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 10 mg tablets orally once a day for 12 weeks
89064233|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 25 mg|Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
89064234|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 50 mg|Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
89064235|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 25 mg|Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
89064236|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
89064237|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 25 mg|Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
89064238|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 50 mg|Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
89064239|NCT01327053|Experimental|LDE225 200 mg|The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
89221923|NCT01323556|Experimental|Exposure without fear augmentation|exposure-based CBT, including interoceptive and in-vivo exposure without fear augmentation during in-vivo exposure
89221924|NCT00949728|Other|Fibrin glue|
89064240|NCT01327053|Experimental|LDE225 800 mg|The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
89690035|NCT03131206|Experimental|Cohort B|"Participants with RET-rearranged NSCLC with previous history of RET-TKI therapy.~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
89064241|NCT00596349||A|epithelial ovarian cancer survivors (women disease-free at 5 to 10 years from diagnosis of ovarian cancer)
89064242|NCT00596349||B|women in second- or greater remission (women who have had one or more relapses from ovarian cancer but are considered to be currently clinically disease-free 5 to 10 years from original diagnosis of ovarian cancer).
89064243|NCT00596349||C|women surviving with epithelial ovarian cancer (women alive with disease 5 to 10 years from original diagnosis of ovarian cancer)
89690036|NCT03131206|Experimental|Cohort C|"Participants with RET-rearranged thyroid cancer~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
89690037|NCT03132298|Experimental|Implicit Theories of Personality Program|"This program is self-administered, computer-based, and 30 minutes in length. Content is designed to maximize relevance for youths with internalizing distress. The program includes 5 elements: 1. An introduction the concept of neuroplasticity; 2. Testimonials from older youths describing beliefs that people's traits are malleable, given the brain's capacity for change; 3. Further vignettes by older youths describing times when they used growth mindsets to cope with peer rejection, hopelessness, and feared embarrassment; 4. A worksheet describing strategies for applying these principles to participants' lives; 5. An exercise wherein participants write notes to younger children, using newly-gleaned information about the malleability of personal traits to help them to cope with setbacks"
89690038|NCT03132298|Active Comparator|Control Program|The Control Program is a computer-based session of supportive therapy (ST), designed to encourage youths to identify and express feelings. ST does not teach specific skills or beliefs and has been shown to be less effective than cognitive-behavioral interventions in reducing youth internalizing distress. Here, ST was designed to control for nonspecific intervention elements (eg. completing an interactive computer program) and to encourage youths to share emotions with others. ST included the same number of reading/writing activities as the experimental program and took the same amount of time (30 mins.) to complete.
89690039|NCT00985543|Active Comparator|LPV/r 400/100 mg|Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))
89690040|NCT00985543|Experimental|LPV/r 200/150 mg|Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)
89690041|NCT00985543|Experimental|LPV/r 200/50 mg|Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)
89690042|NCT05394415|Experimental|Tislelizumab plus chemoradiation group|In the single experimental arm, patients with nonresectable stage IIIb-IVa disease were subjected to receive neoadjuvant tislelizumab (200mg) plus chemoradiation (TP regimen plus 30Gy/12F irradiation) for conversion therapy. If conversion therapy succeeds, patients would proceed to surgery and adjuvant therapy. Otherwise, if patients were still not resectable after the conversion therapy, an additional radiation dose of 15Gy/6F would be scheduled for the ESCC lesions to achieve a definite radiotherapy dose, then, patients proceeded to consolidation therapy.
89690043|NCT03134092|No Intervention|Generalized Risk Communication (GRC)|Generalized Risk Communication (GRC): Participants in this arm will receive standard discharge instructions similar to instructions they would receive during usual care. This arm represents a standardized way of communicating post-discharge risk-benefit information about treatment options for patients with back pain and renal colic. The GRC, includes a standardized discharge information sheet about the clinical condition of interest and a written overview of population based evidence describing comparative benefits and side effects of alternative classes of medication acute pain.
89690044|NCT03134092|Active Comparator|Probabilistic Risk Communication (PRT)|Probabilistic Risk Communication (PRT): The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
89690045|NCT03134092|Active Comparator|Narrative Enhanced Risk Tool (NERT)|Narrative Enhanced Risk Tool (NERT): Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale related to prolonged opioid use. Narrative videos are developed from actual patient stories - put into a in a structured format of ~ 2-minute length and recorded.
89690046|NCT04352959|Active Comparator|mouth rinse with antiviral|
89064244|NCT00596388||1|Subjects diagnosed as intermediate AMD
89690047|NCT04352959|Placebo Comparator|mouth rinse without antiviral|
89690048|NCT05394181|Experimental|Notification|Notification of the presence of at least moderate coronary artery calcium on a prior non-gated chest CT
89690049|NCT05394181|No Intervention|Usual Care|
89690050|NCT03019237|Experimental|intranasal anti-IgE|Anti-IgE (Xolair) will be freshly diluted in sterile 0.9% sodium chloride solution (438 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
89690051|NCT03019237|Active Comparator|intranasal allergen|GMP produced rBet v 1 will be freshly diluted in sterile 0.9% sodium chloride solution (50 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
89690052|NCT03019237|Placebo Comparator|intranasal saline|Sterile 0.9% sodium chloride solution will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
89221925|NCT00947102||Pancreatic tubular adenocarcinoma|Patients with pancreatic tubular adenocarcinoma
89064245|NCT04342299||Responders|"Responders are participants who show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
89064246|NCT04342299||Non-responders|"Non-responders are participants who do not show a reduction of depressive symptoms of at least 50%, as assessed by the self-rated Quick Inventory of Depressive Symptomatology (16-Item; self-report; QIDS-SR16) from baseline to follow-up.~Please note that if the groups are skewed, a continuous measure (i.e. the difference between final and baseline depression scores) will be used rather than to categorise into responders and non-responders."
89064247|NCT01588808|Active Comparator|Immobilization with protein (elderly)|Immobilization with twice-daily protein supplementation - in the elderly
89064248|NCT01588808|Placebo Comparator|Immobilization without protein (elderly)|Immobilization without twice-daily protein supplementation - in the elderly
89064249|NCT01588808|Active Comparator|Immobilization without protein (young)|Immobilization without twice-daily protein supplementation - in the young
89064250|NCT01107925|Experimental|5 mg prasugrel|
89064251|NCT01107925|Active Comparator|10 mg prasugrel|
89064252|NCT01107925|Active Comparator|75 mg clopidogrel|
89064253|NCT04310293|Other|POOR RESPONDERS|poor responders low AMH LOW AFC
89064254|NCT02892396||COPD patients & conventional cigarettes|COPD patients regular smokers of conventional cigarettes with no desire to quit smoking habit.
89064255|NCT02892396||COPD patients & electronic cigarettes|COPD patients who had been users of electronic cigarettes for at least 8 weeks. They will be provided with an specific type of electronic cigarette and the same dosage of inhaled nicotine.
89064256|NCT01339832||Cohort|
89064257|NCT00596505||1|Group 1 will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
89064258|NCT00596505||2|Group 2 will not receive bevacizumab pretreatment
89064259|NCT01339559|Experimental|Brivaracetam|Brivaracetam with a maximum of 200 mg/day
89064260|NCT00596544||1|FSFI score <= 26
89064261|NCT00596544||2|FSFI score >26
89064262|NCT01588847|Experimental|Regional anesthesia|
89064263|NCT01588847|Active Comparator|General anesthesia|
89064264|NCT00107900|Experimental|15mg BID|15mg edoxaban administered twice daily (BID)
89064265|NCT00107900|Experimental|30mg QD|30mg edoxaban administered once daily (QD)
89064266|NCT00107900|Experimental|30mg BID|30mg edoxaban administered twice daily (BID)
89064267|NCT00107900|Experimental|60mg QD|60mg edoxaban administered once daily (QD)
89064268|NCT00107900|Experimental|60mg BID|60mg edoxaban administered twice daily (BID)
89064269|NCT00107900|Experimental|120mg QD|120mg edoxaban administered once daily (QD)
89064270|NCT00596583|Active Comparator|High Dose|
89064271|NCT00596583|Active Comparator|Low Dose|
89064272|NCT01339052|Experimental|Cohort 1: Surgical subjects|"Subjects scheduled for surgery~BKM120: 100 mg once daily, orally, for 8-12 days prior to surgery~Surgery: Surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
89064273|NCT01339052|Experimental|Cohort 2: Non-surgical subjects|"Subjects not candidates for surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
89064274|NCT00107315|Experimental|Arm 1|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine twice daily on days 1-7
89064275|NCT01335971|Active Comparator|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
89064276|NCT01335971|Active Comparator|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
89064277|NCT01335971|Placebo Comparator|Placebo|Microcrystalline cellulose
89064278|NCT00596661|Experimental|TRIMAXX|TRIMAXX Coronary Stent
89064279|NCT00107276|Experimental|cyclophosphamide and capecitabine|cyclophosphamide orally days 1-14 and capecitabine orally days 15-21 for 8 cycles of 21 days each
89064280|NCT04326777|Other|Ballon pulmonary angioplasty|Ballon pulmonary angioplasty(BPA) is a stepwise procedure requiring several separate sessions. The interval of a series of BPA is one month. In a series of BPA, there are 2 sessions, which are repeated at a 2-week interval. BPA is performed primarily on one side of the lung in the first session, then after 2 weeks, performed on the other side of the lung. In each session, the fluoroscopy time or the amount contrast are less than 60min and 200ml, respectively.
89064281|NCT01335698|Experimental|Stage 1: Atazanavir + Ritonavir|Participants received atazanavir powder orally (dosed by weight: 5 to <10 kg=150 mg, 5 to <10 kg=200 mg, 10 to <15 kg=200 mg, 15 to <25 kg=250 mg, 25 to <35 kg=300 mg) once daily for 24 to 48 weeks or a weight ≥35 kg. Participants also received ritonavir once daily for 24 to 48 weeks or weight ≥35 kg in the form of 80-mg/mL solution, orally (dosed by weight 5 to <25 kg=80 mg, 25 to <35 kg=100 mg); 100-mg capsule, orally (dosed by weight 25 to <35 kg=100 mg); or 100-mg tablet, orally (dosed by weight 25 to <35 kg=100 mg)
89064282|NCT00596700|Experimental|Device|"Patient preparation procedure will be done according to chapter 4 in the Given Diagnostic System user manual. In brief: to drink only clear liquids beginning 12:00 noon the day before.at least 8 hours (since 12:00 PM) fast prior to the procedure. Patient will undergo a standard capsule endoscopy. Patients will be allowed to drink clear liquids 2 hours post ingestion, and eat 4 hours post ingestion.~Eight hours post ingestion, data recorder will be removed and the patient will be dismissed.~A local experienced reader will review the RAPID video to determine the diagnosis blinded to the results of the standard workup procedures, and to each other results. Results will be recorded in the case report forms. A decoded video will be transferred to the principal investigator for reevaluation"
89064283|NCT04327362|Experimental|Cluster 1: Sham to active tDCS crossover at PE Session 4.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-3, and 20 min. of active tDCS prior to PE sessions 4-10.
89064284|NCT04327362|Active Comparator|Cluster 2: Sham to active tDCS crossover at PE Session 5.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-4, and 20 min. of active tDCS prior to PE sessions 5-10.
89064285|NCT04327362|Active Comparator|Cluster 3: Sham to active tDCS crossover at PE Session 6|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-5, and 20 min. of active tDCS prior to PE sessions 6-10.
89064286|NCT04327362|Active Comparator|Cluster 4: Sham to active tDCS crossover at PE Session 7.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-6, and 20 min. of active tDCS prior to PE sessions 7-10.
89064287|NCT04327362|Active Comparator|Cluster 5: Sham to active tDCS crossover at PE Session 8.|Participants in this cluster will receive 20 min. of sham tDCS prior to the PE sessions 1-7, and 20 min. of active tDCS prior to PE sessions 8-10.
89064288|NCT02892474||Hybrid Coronary Revascularization (HCR)|Patients who are scheduled to have the hybrid coronary revascularization (HCR) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
89064289|NCT02892474||Coronary Artery Bypass Grafting (CABG)|Patients who are scheduled to have the coronary artery bypass grafting (CABG) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
89064290|NCT00107120|Experimental|Escitalopram|Escitalopram 10mg once daily for three weeks, 10-20mg once daily for up to the remaining 5 weeks
89064291|NCT00107120|Placebo Comparator|2|Placebo once daily for up to 8 weeks
89064292|NCT00596778|Other|C, CP|Thirty-one adults were randomly assigned to control (C) and chest physiotherapy (CP) groups. Chest physiotherapy group received treatment at the post-anesthesia unit care and control group did not.
89064293|NCT00596856|Active Comparator|1|25 randomly selected pediatric practices that have never participated in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to non-participating practices)
89064294|NCT00596856|Experimental|2|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to participating practices)
89064295|NCT00596856|Experimental|3|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through an intense in-office intervention. (Intense intervention with participating practices)
89064296|NCT01335464|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
89064297|NCT01335464|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
89064298|NCT00622947|Active Comparator|repetitive transcranial magnetic stimulation|Low frequency ( 1 HZ) rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
89064299|NCT00622947|Sham Comparator|Placebo stimulation|Sham- rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
89064300|NCT00107042|Active Comparator|1|Participants receive doses of Recombivax at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
89064301|NCT00107042|Experimental|2|Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
89064302|NCT00596895|Experimental|1|Isoflavone treatment
89064303|NCT00596973|Experimental|Ileal transposition with SG|Procedure: Surgical Treatment
89064304|NCT02891772||Hypotension after anesthetic induction group|Patients with hypotension after anesthetic induction
89064305|NCT00106964|Active Comparator|1|Standard dose (20 mcg) of Hepatitis B vaccine.
89064306|NCT00106964|Active Comparator|2|40 mcg of Hepatitis B vaccine
89064307|NCT00106964|Active Comparator|3|20 mgc of Twinrix
89064308|NCT02892435|Experimental|Prevena arm|patients underwent to contaminated/dirty surgery who positioned incisional negative pressure wound therapy and kept for six days
89064309|NCT02892435|Active Comparator|Control arm|patients underwent to contaminated/dirty surgery who positioned conventional dressing
89064310|NCT00106184|Experimental|Adult Study Group 1|Refractory adult polymyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
89064311|NCT00106184|Experimental|Adult Study Group 2|Refractory adult polymyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
89064312|NCT00106184|Experimental|Adult Study Group 3|Adult dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
89064313|NCT00106184|Experimental|Adult Study Group 4|Adult dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
89064314|NCT00106184|Experimental|JDM Study Group 1|Refractory juvenile dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
89064315|NCT00106184|Experimental|JDM Study Group 2|Refractory juvenile dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
89064316|NCT00598923|Experimental|1|Phenytoin 20mg/kg load, then Topiramate, 100 mg twice daily, starting at 24 hours post-TBI for 6 days.
89064317|NCT00598923|Experimental|2|topiramate for 3 months after loading dose of phenytoin
89064318|NCT00598923|Placebo Comparator|3|Phenytoin 20 mg/kg as loading dose than 300 mg/day for total of 7 days
89064319|NCT02892318|Experimental|Cohort A1: Safety Cohort (Relapsed/refractory AML)|An initial safety evaluation of the combination will be performed in 9 participants with relapsed/refractory AML. All participants will receive atezolizumab (840 milligrams [mg] IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 milligrams per square meter [mg/m^2] subcutaneously [SC] on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit (except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
89064320|NCT02892318|Experimental|Cohort A2: Expansion Cohort (Relapsed/refractory AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, an expansion cohort of 11 participants with relapsed/refractory AML (Cohort A2) will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
89064321|NCT02892318|Experimental|Cohort A3: Safety Cohort (Previously Untreated AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, Cohort A3 will assess the safety and tolerability of the combination in 6 participants with untreated AML, who are older and unfit for induction chemotherapy. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
89064322|NCT02892318|Experimental|Cohort A4: Expansion Cohort (Previously Untreated AML)|If Cohort A3 is deemed safe and tolerable, an expansion cohort (Cohort A4) of 14 participants with untreated AML, who are older and unfit for induction chemotherapy will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
89064323|NCT01334918|Experimental|Single Photon Emission Computed Tomography (SPECT)|"Resting SPECT imaging was performed prior to regadenoson stress SPECT~imaging. Imaging was conducted with one of two radiotracers (99mTc sestamibi or tetrofosmin). Regadenoson 0.4 mg was administered prior to stress SPECT as a single bolus injection."
89064324|NCT01334918|Experimental|Multidetector Computed Tomography (MDCT)|Multidetector Computed Tomography (MDCT), composed of CCTA and regadenoson CTP. Regadenoson stress CTP was performed prior to rest CCTA/CTP imaging. Regadenoson 0.4 mg was administered prior to stress CTP as a single bolus injection. The rest CCTA/CTP was performed at least 30 minutes after completion of the stress CTP, after resolution of any symptoms brought on by the regadenoson infusion and after the participant's heart rate had returned to baseline.
89064325|NCT00598962|Experimental|azithromycin and rifabutin/rifampin|Azithromycin and rifabutin/rifampin administered three times weekly.
89064326|NCT00599001|Experimental|Escalating Dose of SD-101|
89064327|NCT00599001|Placebo Comparator|Placebo|
89064328|NCT04052516|Placebo Comparator|Placebo|Placebo oral capsules taken one daily for 52 weeks
89064329|NCT04052516|Experimental|Icosabutate 300mg|Icosabutate 300mg oral capsule taken once daily for 52 weeks
89064330|NCT04052516|Experimental|Icosabutate 600mg|Icosabutate 600mg oral capsules taken once daily for 52 weeks
89064331|NCT00599040|Active Comparator|Weight loss|Weight loss diet focused on the DASH diet
89064332|NCT00599040|Active Comparator|DASH diet|The DASH diet without weight loss
89064333|NCT00599040|Active Comparator|Diary|Dairy Intervention
89064334|NCT00597090||1|
89064335|NCT01332968|Active Comparator|Rituximab+Chemotherapy|Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
89064336|NCT01332968|Experimental|Obinutuzumab+Chemotherapy|Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
89064337|NCT00599079|Experimental|Azithromycin|Azithromycin combined with 2 other drugs given 3 times weekly for MAc lung disease
89064338|NCT04326816|Active Comparator|Direct Composite Restorations (DCR)|"All teeth were reconstructed with directly applied composite restorations. No preparation of teeth was performed except in cases of sharp occlusal edges.~Rubberdam or cotton rolls and suction devices were used for moisture control. For bonding, a 3-step etch-and-rinse adhesive was applied according to manufacturer's instructions, using 37% phosphoric acid (DMG, Hamburg, Germany), Clearfil SA Primer, and Clearfil Photobond (Kuraray, Osaka, Japan). A micro-hybrid composite (Clearfil AP-X, Kuraray) was used for posterior restorations and palatal veneer restorations. Restorations were placed according to the DSO-technique (Direct Shaping by Occlusion). In front teeth, both a palatal and buccal veneer restoration was placed.~Experimental restorations were all restorations on first molars and all palatal veneer restorations on maxillary anterior teeth."
89221926|NCT00954902|Sham Comparator|No spice, no stress|Subject are given placebo capsules and told they contain an antioxidant concentrate
89221927|NCT00954902|Sham Comparator|No Spice, Stress|Subjects are given placebo capsules and told they are receiving an equivalent amount of an antioxidant concentrate.
89690053|NCT03134248|Experimental|MyDay Toric|Participants were randomized to wear a new pair of MyDay Toric lenses each day for one week during the cross over study
89690054|NCT03134248|Active Comparator|1-Day Acuvue Moist for Astigmatism|Participants were randomized to wear a new pair of 1-Day Acuvue Moist Toric lenses each day for one week during the cross over study
89690055|NCT03134248|Active Comparator|Dailies Aquacomfort Plus Toric|Participants were randomized to wear a new pair of Dailies Aquacomfort Plus Toric lenses each day for one week during the cross over study
89690056|NCT03019159||Tele-consulting|One visit out of two takes place with teleconsulting and the other is a face-to-face consultation
89690057|NCT03019159||No tele-consulting|
89690058|NCT03134326|Experimental|Test group|All subjects will be enrolled in the test group and will receive both R1-25 and R2-25 Pulse Oximeter Sensors
89064339|NCT04326816|Experimental|Indirect Composite Restorations (ICR)|"Indirect 'tabletop' restorations were placed on all first molars (n=4) and palatal veneers ('backings') (n=6) on maxillary anterior teeth. Remaining teeth received directly applied restorations. Preparation of teeth for indirect restorations was limited to removal of sharp edges.~All indirect restorations were laboratory manufactured using a micro-hybrid composite (Clearfil Estenia C&B, Kuraray, Osaka, Japan). Adhesive surfaces of the restorations were air-abraded with aluminum-oxide powder (<50 µm). Rubberdam or cotton rolls were used for moisture control during cementation. Seating of indirect restorations was checked intraorally, followed by cleaning of its adhesive surface with phosphoric acid 37% and application of silane (Clearfil Ceramic Primer, Kuraray, Osaka Japan).The adhesive surface of the abutment tooth was etched with phosphoric acid and ED-primer II (Kuraray) was applied. Finally, restorations were cemented, using Panavia F (Kuraray)."
89064340|NCT00597129|Experimental|Multi Dose levels|different doses of 90YhPAM4 will be given only once.
89221928|NCT00954902|Experimental|Spice, no stress|
89221929|NCT00954902|Experimental|Spice and Stress|
89064341|NCT01332851|Experimental|Promoting First Relationships (PFR)|"PFR is a strengths-based 10 week in-home parenting intervention based on attachment theory. Each week has a theme for discussion, an activity, and time for joining - checking in with the parent, listening to their concerns and establishing a positive, supportive relationship. The sessions include handouts which focus on the content area covered that day and applying a topic to their relationship with their child. The provider also videotapes playtime between parent and child. On alternate weeks, the provider watches the video with the parent, reflecting on both the parent's and the child's needs. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent identify her own feelings and needs around parenting."
89064342|NCT01332851|Active Comparator|Resource & Referral|This condition consists of 1) Resource and Referral assistance provided over the phone, and 2) Local Services Resource Packet. The participant receives a phone call from a Resource and Referral Specialist to conduct a needs assessment to identify the particular needs or concerns of the family (such as housing needs, mental health, tangible goods). If a need is identified, the Referral and Referral Specialist will provide the family with local information regarding the stated need. The R&R provider makes two follow-up check in calls with the families. In addition, families can call the Research and Referral Specialist if additional needs arise. The resource packet includes information organized by type of need or resource. These packets are updated regularly as services change over time.
89064343|NCT00599235|Experimental|1|
89064344|NCT00599235|Active Comparator|2|
89064345|NCT04058834|Experimental|NNC0385-0434|Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo. Following safety observation, patients with hypercholesterolaemia will enter a fourth cohort. There will be 15 participants in this cohort.
89064346|NCT04058834|Placebo Comparator|Placebo (NNC0385-0434)|Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo.
89064347|NCT04055168|Experimental|Cohort 1 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
89064348|NCT04055168|Experimental|Cohort 2 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
89064349|NCT04055168|Experimental|Cohort 3 - Part 1|On Day 1, randomized subjects (healthy non-Asian subjects) will receive dose 3 of AZD6615 (6 subjects) or matching placebo (2 subjects).
89064350|NCT04055168|Experimental|Cohort 1 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 1 of AZD6615 (6 subjects) or matching placebo (2 subjects).
89221930|NCT00944372|Experimental|Group 1|Control, age greater than or equal to 18 with normal renal function
89221931|NCT00944372|Experimental|Group 2|Age 18 to less than 65 with mild renal impairment
89221932|NCT00944372|Experimental|Group 3|Age 18 to less than 65 with moderate to severe renal impairment
89221933|NCT00944372|Experimental|Group 4|Age 18 to less than 65 with end stage renal impairment
89221934|NCT00944372|Experimental|Group 5|Age 65 to less than 75 with mild renal impairment
89221935|NCT00944372|Experimental|Group 6|Age 65 to less than 75 with moderate to severe renal impairment
89221936|NCT00944372|Experimental|Group 7|Age 65 to less than 75 with end stage renal impairment
89221937|NCT00944372|Experimental|Group 8|Age greater than or equal to 75 with mild renal impairment
89221938|NCT00944372|Experimental|Group 9|Age greater than or equal to 75 with moderate to severe renal impairment
89221939|NCT00944372|Experimental|Group 10|Age greater than or equal to 75 with end stage renal impairment
89221940|NCT01032148|Experimental|LBH589|LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg
89221941|NCT00949806|Experimental|Administrated|All patients included will receive an intradermal administration of BNT
89221942|NCT00947180|Active Comparator|Electrogalvanic stimulation|High voltage electrical stimulation was delivered through an anal plug to induce relaxation of pelvic floor muscles.
89221943|NCT00947180|Active Comparator|Digital massage|The therapist massaged the levator ani muscles by applying firm pressure with a gloved finger and rotating from left to right.
89221944|NCT00947180|Experimental|Biofeedback|Electromyographic (EMG) activity was recorded from a probe in the anal canal, averaged and displayed to patients to help them learn to relax pelvic floor muscles during straining.
89221945|NCT01032304|Experimental|Erdosteine|600 mg/day for 12 months
89221946|NCT01032304|Placebo Comparator|Placebo|Placebo for 12 months
89221947|NCT05190510||Patient with atheromatous stenosis of the internal carotid artery|
89221948|NCT00954980||Endovenous Sclerotherapy|For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure
89221949|NCT00954642|Experimental|A|
89221950|NCT00954642|Experimental|B|
89221951|NCT00955058|Active Comparator|cyproterone compound|Before and after treatment
89221952|NCT00955058|Experimental|oral contraceptive pill|Treatment
89221953|NCT01024816|Experimental|Restorative yoga intervention|
89221954|NCT01024816|Active Comparator|Stretching group|
89221955|NCT00954720||Patient undergoing transplant|Patients with acute leukemia or MDS undergoing ablative stem cell transplantation. No intervention.
89221956|NCT01024894|Experimental|CYT107|
89221957|NCT00954798|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
89690059|NCT02976831|Experimental|AZD0284|"Part 1A:~Following an overnight fast of at least 10 hours, each subject will receive a single dose of AZD0284 or matching placebo in the form of an oral solution with water. The total volume that the subject will receive (IMP and water) will be 240 mL.~Part 1B (food cohort):~Subjects, will receive a single dose of AZD0284 at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing. The total volume that the subject will receive (IMP and water) will be 240 mL.~Part 2:~In Part 2, subjects will receive 1 dose level of AZD0284 (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (IMP with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
89064351|NCT04055168|Experimental|Cohort 2 - Part 2|On Day 1, randomized subjects (healthy Japanese subjects) will receive dose 2 of AZD6615 (6 subjects) or matching placebo (2 subjects).
89064352|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 600 mg|GEn (XP13512/GSK1838262) 600 mg
89064353|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1200 mg|GEn (XP13512/GSK1838262) 1200 mg
89064354|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1800 mg|GEn (XP13512/GSK1838262) 1800 mg
89064355|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 2400 mg|GEn (XP13512/GSK1838262) 2400 mg
89064356|NCT01332305|Placebo Comparator|Placebo|Placebo
89064357|NCT00599274||A|This group was treated with Avonex once a week
89064358|NCT00599274||B|This group was treated with Rebif three times a week
89064359|NCT01332227|Experimental|Atazanavir/Ritonavir + Raltegravir|Atazanavir + Ritonavir (heat-stable) + Raltegravir
89064360|NCT01332227|Other|Atazanavir/Ritonavir + Tenofovir/Emtricitabine|"Reference~Atazanavir + Ritonavir (heat-stable) + Tenofovir/Emtricitabine"
89064361|NCT00599352|Experimental|1|Magnesium infusion
89064362|NCT00599391|Other|1|Far Infrared Radiation
89064363|NCT01332149|Experimental|300 mg/day pregabalin (Lyrica)|Patient take pregabalin capsule twice a day
89690060|NCT02976831|Active Comparator|Placebo|"Part 1A: Following an overnight fast of at least 10 hours, each subject will receive a single dose of placebo in the form of an oral solution with water. The first cohort will receive 4.0 mg AZD0284 or placebo on Day 1. The actual dose for subsequent cohorts will be determined after review of all available safety or other pertinent data from the previous dose by the SRC Part 1B (food cohort): In Part 1B, subjects, will receive a single dose of placebo at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing.~Part 2: In Part 2, each subject will receive 1 dose level of placebo (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (placebo with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
89690061|NCT04959838|Experimental|Ophthalmology physicians and residents|"Ophthalmology physicians and residents will be followed during 34h, from 8 am to 6 pm the following day,in five different conditions:~Control day (no work)~Typical working day~Working day + one night shift~Emergency working day + two consecutive night shifts~Night shift."
89690062|NCT04965129|Placebo Comparator|Placebo Comparator: Placebo|Placebo Comparator: Placebo All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given four tablet/day for four mounths.
89690063|NCT04965129|Experimental|Experimental: Fish oil|All subjects will be given fish oil with a dose of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
89690064|NCT00986401|Experimental|Glucophage® then Sanctura XR® (AB)|Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.
89690065|NCT00986401|Experimental|Sanctura XR® then Glucophage® (BA)|Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.
89690066|NCT04957498|Active Comparator|FBT|Family Based Treatment (FBT) includes up to 15 session (50-60 minutes) with a trained therapist.
89690067|NCT04957498|Experimental|FBT-GSH|Family Based Treatment Guided Self-Help (FBT-GSH) includes an online website with educational videos, readings, discussion groups, and journals. Parents assigned to this arm will have up to 12 coaching sessions (20-30 minutes) with a trained therapist.
89690068|NCT04897594|Experimental|Part 1: TERN-201 dose level 1|Orally administered.
89690069|NCT04897594|Placebo Comparator|Part 1: Placebo|Orally Administered
89690070|NCT04897594|Experimental|Part 2: TERN-201 dose level 2|Orally administered
89690071|NCT04897594|Placebo Comparator|Part 2: Placebo|Orally administered
89690072|NCT02977143|Experimental|Fluid responsiveness test|"First, apply 10 cmH2O positive endexpiratory pressure (PEEP) and measure the increase in central venous pressure (CVP) as well as other preload indexes (central venous pressure, mean arterial pressure, stroke volume variation).~Second, measure the increase in cardiac index after administration of volulyte 300 ml.~If cardiac index increase more than 10%, fluid responsiveness is confirmed."
89690073|NCT00987415|Active Comparator|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
89690074|NCT00987415|Placebo Comparator|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
89690075|NCT04955847||PGE2|In period 1, the service protocol for induction at term on an unfavorable cervix indicated the use of a PGE2. In nulliparous women, Propess® was introduced intra-vaginally for 24 hours or until regular painful uterine contractions occurred. In the case of a multiparous woman, Prostine® gel, one or two mg depending on the cervical conditions at the time of induction, was introduced intravaginally and the cervix was reassessed after six hours. If the cervix remained unfavorable and the kinetics of the contractions were not optimal, a new dose of Prostine® one or two mg was administered to the patient.
89690076|NCT04955847||misoprostol|In period 2, patients who were induced with an unfavorable cervix at term were induced with misoprostol. Regardless of parity, the patient received oral misoprostol 25 μg, one tablet orally every two hours until a maximum of eight tablets per day, or 200 µg, was reached, with cessation of the tablets when painful, regular contractions were obtained.
89064364|NCT01332149|Placebo Comparator|Placebo|
89064365|NCT00599430|Placebo Comparator|1|Placebo
89064366|NCT00599430|Active Comparator|Active 1|One probiotic strain
89064367|NCT00599430|Active Comparator|Active 2|Blend of two strains
89064368|NCT04326270|Active Comparator|nCPAP prongs|
89064369|NCT04326270|Active Comparator|Infant cannula|
89064370|NCT04054427|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF
89064371|NCT00599469|Other|1|Far Infrared Radiation
89064372|NCT04054505|Active Comparator|Vitamin A|Rise or fall of Vitamin A after three months
89064373|NCT04054505|Active Comparator|Vitamin E|Rise or fall of Vitamin E after three months
89064374|NCT04054505|Active Comparator|Vitamin B1|Rise or fall of Vitamin B1 after three months
89064375|NCT04054505|Active Comparator|Vitamin B2|Rise or fall of Vitamin B2 after three months
89064376|NCT04054505|Active Comparator|Vitamin B6|Rise or fall of Vitamin B6 after three months
89064377|NCT04054505|Active Comparator|Vitamin B12|Rise or fall of Vitamin B12 after three months
89064378|NCT04054505|Active Comparator|Vitamin C|Rise or fall of Vitamin C after three months
89064379|NCT04054505|Active Comparator|Vitamin D|Rise or fall of Vitamin D after three months
89064380|NCT04054505|Active Comparator|Calcium|Rise or fall of Calcium after three months
89064381|NCT04054505|Active Comparator|Iron|Rise or fall of Iron after three months
89064382|NCT04054505|No Intervention|IGF1|Rise or fall of IGF1 after three months
89064383|NCT04054505|No Intervention|FT-3|Rise or fall of FT-3 after three months
89064384|NCT01316120|Experimental|HPV Dry first|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
89064385|NCT01316120|Experimental|HPV standard transport medium|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
89064386|NCT00597324|Active Comparator|1|Patients with normal Allen's test
89064387|NCT00597324|Experimental|2|Patients with intermediate Allen's test
89064388|NCT00597324|Experimental|3|Patients with abnormal Allen's test
89064389|NCT01330628|Experimental|Laser atherectomy and PTA|laser, then balloon angioplasty
89064390|NCT01330628|Active Comparator|Balloon angioplasty|
89064391|NCT02892279|Experimental|Diesel exhaust exposure|A single arm study in which first a baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute diesel exhaust will start.
89064392|NCT02892162|Experimental|With additional LAAW linear ablation|Patients who undergo CPVI+LA roof linear ablation+/ MI linear ablation, and additional LAAW linear ablation using ThermoCool SmartTouch catheter.
89064393|NCT02892162|Active Comparator|Without additional LAAW linear ablation|Patients who undergo CPVI+LA roof +/ MI linear ablation using ThermoCool SmartTouch catheter, without LAAW linear ablation.
89064394|NCT01330433|No Intervention|No CoSeal Surgical Spray|A patient randomized to the No CoSeal Surgical Spray group will not have CoSeal Surgical Spray applied at the end of their first staged procedure.
89064395|NCT01330433|Experimental|CoSeal Spray Group|CoSeal Spray will be applied at the end of the first staged procedure in patients randomized to the experimental group.
89064396|NCT00597363|Experimental|1|Neptune PAD utilization to accelerate closure of the vascular access site
89064397|NCT00597363|Active Comparator|2|manual compression for closure of the vascular access site
89064398|NCT00599508|Active Comparator|grape juice active intervention|Concord grape juice administered daily for 12 or 16 weeks
89064399|NCT00599508|Placebo Comparator|juice placebo|berry placebo juice administered daily for 12 or 16 weeks
89064400|NCT00599508|Active Comparator|blueberry juice active intervention|wild blueberry juice administered daily for 12 weeks
89064401|NCT00599508|Active Comparator|blueberry powder intervention|whole fruit blueberry powder administered daily for 16 weeks
89064402|NCT00599508|Placebo Comparator|powder placebo|placebo powder administered daily for 16 weeks
89064403|NCT01330316|Experimental|BI 201335 for 24 weeks|BI 201335 once daily dose for 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
89064404|NCT00599547|Experimental|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
89064405|NCT01316198|Experimental|Lutein and zeaxanthin|
89064406|NCT01316198|Experimental|Placebo|
89064407|NCT00599586|Experimental|group 1|specific acupoints of Shaoyang meridians
89064408|NCT00599586|Experimental|Group 2|Non-specific acupoints of Shaoyang meridians
89064409|NCT00599586|Experimental|group 3|Acupoints of other meridians
89064410|NCT00599586|Sham Comparator|group 4|Non-acupoints
89064411|NCT01316237|Other|Cohort 1|(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2) 50 mg GS-6620 or placebo QD in the morning with food [total daily dose (TDD) = 50 mg] for 5 days
89064412|NCT01316237|Other|Cohort 2|"(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS-6620 or placebo QD in the morning with food (TDD = 100 mg) for 5 days"
89064413|NCT01316237|Other|Cohort 3|"Cohort 3 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning with food (TDD = 300 mg) for 5 days"
89690077|NCT04784884|Experimental|HSI-Pilot|Diagnostic hyperspectral imaging of the bronchus stump or bronchus anastomosis after lung resection and calculating the stump or anastomotic Perfusion measures, respectively
89064414|NCT01316237|Other|Cohort 4|"Cohort 4 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS 6620 or placebo QD in the morning without food (TDD = 100 mg) for 5 days"
89064415|NCT01316237|Other|Cohort 5|"Cohort 5 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning without food (TDD = 300 mg) for 5 days"
89690078|NCT04586751|Active Comparator|study group|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed. In specific, using the in-plane insertion technique, after visualization of the entire needle as a bright hyperechoic line and aiming between pectoralis major and pectoralis minor at the 3rd rib level, 2 ml of normal saline 09% will be injected first, to verify the correct position of the needle. Followingly, 10 mL ropivacaine 0.5% will be injected in order to block the lateral and medial pectoral nerves. Finally, another 15 ml of ropivacaine 0.5% plus 4 mg of dexamethasone will be injected between the pectoralis minor muscle and the anterior serratus muscle,at the level of the 4th and 5th ribs, after negative aspiration, to block the intercostal and intercostobrachial nerves. Using the color Doppler the vessels will be identified, so that their puncture is avoided during the procedures.
89690079|NCT04586751|Sham Comparator|control group|no regional block will be performed
89690080|NCT04945395|Experimental|FES and conventional training|The experimental group will wear the Functional electrical stimulation system L3100 Go for dorsiflexion of the ankle during conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
89690081|NCT04945395|Active Comparator|AFO and Conventional training only|The control group will wear an ankle-foot-orthosis (AFO) to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
89690082|NCT03138382|Experimental|Treatment then sham|20 subjects will be randomised to first receive active vestibular nerve stimulation during indirect calorimetry. Then 2 weeks later they will return for sham stimulation during indirect calorimetry.
89690083|NCT03138382|Experimental|Sham then treatment|20 subjects will be randomised to first receive sham stimulation during indirect calorimetry. Then 2 weeks later they will return for active vestibular nerve stimulation during indirect calorimetry.
89690084|NCT00955201|No Intervention|Arm 1|Sedentary Control Group
89690085|NCT00955201|Experimental|Arm 2|Aerobic Exercise Group
89690086|NCT00955201|Experimental|Arm 3|Isokinetic Strength Exercise Group
89690087|NCT00955201|Experimental|Arm 4|Combined Aerobic and Isokinetic Strength Exercise Group
89690088|NCT04926129||Subgroup 1|Participant's eye with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) ≥74 letters (Equivalent to: Snellen 6/9 or 20/32; decimal 0.63; Logarithm of the minimum angle of resolution [LogMAR] 0.2) will be enrolled.
89690089|NCT04926129||Subgroup 2|Participant's eye with ETDRS BCVA 34-73 letters, inclusive (Equivalent to: Snellen 6/12 - 6/60 or 20/40 - 20/200; decimal 0.5 - 0.1; LogMAR 0.3-1.0) will be enrolled.
89690090|NCT04707040|Experimental|Neurocognitive Exercise Program Group|The group received NEP for 10 weeks, one hour per week conducted by the same physiotherapist with 6 years of experience in this field. Children with ADHD were given home exercises for the other six days of the week without a NEP session. Home exercises were followed with an exercise diary under the control of children's parents. The home exercise program consisted of visual-motor and auditory-motor coordination tasks (daily 15 min).
89690091|NCT04707274||Patients group|Individuals with greater trochanteric pain syndrome and gluteal tendinopathy
89690092|NCT04343547|Experimental|1|
89690093|NCT04343547|Experimental|2|
89690094|NCT04343547|Experimental|Experimental 3|
89690095|NCT04707118|Experimental|Thermal perfusion cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
89690096|NCT04707118|Active Comparator|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
89690097|NCT02977221|Experimental|Piezosurgery|Piezosurgery will be performed on the anterior lower segment of the dental arch in order to accelerate the correction of mandibular anterior crowding.
89690098|NCT02977221|No Intervention|Ordinary Alignment|Treatment will be provided to the patients without any surgical interventions.
89690099|NCT03086356|Experimental|All Subjects|Dabigatran etexilate alone (days 1-4) and (days 8-10) and with Idarucizumab (day 11)
89690100|NCT03140254|Active Comparator|comparator|Chlorhexidine gluconate
89690101|NCT03140254|Experimental|experimental|BDIP-0001
89690102|NCT03140254|Placebo Comparator|placebo|Vehicle
89064416|NCT01316237|Other|Cohort 6|"Cohort 6 (N = 10, genotype 2 or genotype 3): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo QD in the morning without food (TDD = 900 mg) for 5 days"
89064417|NCT01316237|Other|Cohort 7|"Cohort 7 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~450 mg GS 6620 or placebo, administered BID with food (TDD = 900 mg) for 5 days"
89064418|NCT01316237|Other|Cohort 9|"Cohort 9 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo BID in the with food (TDD = 1800 mg) for 5 days"
89064419|NCT01316237|Other|Cohort 11|"Cohort 11 (N = 10, genotype 1 : (Active drug: 8, Matching Placebo: 2)~Up to 450 mg GS-6620 or placebo as an oral solution, BID, 12 hours apart in the fasted state, 2 hours after a meal (up to TDD = up to 900 mg) for 5 days."
89064420|NCT02892084|Experimental|Uphill COMa training|Walking on an inclined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
89064421|NCT02892084|Experimental|Downhill COMa training|Walking on a declined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
89064422|NCT00597480|Active Comparator|1|the recommended dose in the EU of rhGH (Norditropine SimpleXx®)
89064423|NCT00597480|Active Comparator|2|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
89064424|NCT01326702|Experimental|Treatment (veliparib, bendamustine hydrochloride, rituximab)|"Patients receive veliparib PO BID on days 1-7 and bendamustine hydrochloride IV over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Once the maximum-tolerated dose is determined, a cohort of patients receives veliparib and bendamustine hydrochloride as above and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
89064425|NCT05654129|Other|F1-F2 NAFLD|Patients with NAFLD stage 1 or 2 confirmed by a biopsy less than 1 year old
89064426|NCT05654129|Other|F3-F4 NAFLD|Patients with NAFLD stage 3 or 4 confirmed by a biopsy less than 1 year old
89064427|NCT00599625|Experimental|1|Patients with active Crohn's Disease
89064428|NCT05661474|Experimental|Fitostimoline® hydrogel group|Participant randomized to the Fitostimoline® hydrogel group underwent sharp surgical debridement at each visit (every 2 weeks) to remove necrotic tissue and slough. After debridement operation, was performed disinfection with povidone-iodine, and cleansing with sterile saline solution. Then was applaied Fitostimoline ® hydrogel, finally the wound was covered with gauze.
89064429|NCT05661474|Active Comparator|Saline gauze group|Participant randomized to the Saline gauze group underwent sharp surgical debridement at each visit (every 2 weeks) to remove necrotic tissue and slough. After debridement operation, was performed disinfection with povidone-iodine, and cleansing with sterile saline solution. Then was applaied saline gauze, finally the wound was covered with gauze.
89064430|NCT00599664|Experimental|1|Drug
89064431|NCT00599664|Placebo Comparator|2|Vehicle
89064432|NCT04447157||Microspherophakia|This is a non-interventional study(NIS). All the patients diagnosed as microspherophakia are included in the study and recieved intraocular lens implantation
89064433|NCT04326699|Active Comparator|Sacroiliac joint injection group|The active group will receive bilateral sacroiliac joint injection of 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) under ultrasound guidance.
89064434|NCT04326699|No Intervention|control group|The other group will not receive the sacroiliac joint injection
89064435|NCT02891655||surgery for keratoconus|
89064436|NCT02891655||refractive surgery (control patients)|
89064437|NCT05653310|Experimental|Tradipitant|Oral Capsule
89064438|NCT05653310|Placebo Comparator|Placebo|Oral Capsule
89064439|NCT05649878|Active Comparator|Intravenously MEP|"Single dose of MEP sodium succinate intravenously administered. MEP (equivalent to 62.5 mg of Methylprednisolone).~Samples were obtained at 0.333, 0.50, 0.667, 0.833, 1, 1.0, 2, 3, 4, 6, 8, 10, 12 and 24 h after MEP administration."
89064440|NCT05649878|Active Comparator|Intranasally MEP|Volunteers were randomly assigned to receive a single dose of MEP intranasally administered (equivalent to 62.5 mg of Methylprednisolone), using a Mucosal Atomization Device (MAD Nasal). Samples were obtained at 0.333, 0.50, 0.667, 0.833, 1, 1.0, 2, 3, 4, 6, 8, 10, 12 and 24 h after MEP administration.
89064441|NCT01327703|Experimental|Panzytrat® 25,000|
89064442|NCT01327703|Active Comparator|Kreon® 25,000|
89064443|NCT01380080|Experimental|Arm A: Empiric|Study treatment for Arm A participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral treatment as soon as possible following randomization and within no more than 3 days following randomization plus a 4-drug anti-tuberculosis treatment (ATT) regimen (defined as rifampin/isoniazid/ethambutol/pyrazinamide) as soon as possible following randomization and within no more than 7 days following initiation of antiretroviral therapy. After 2 months (or 8 weeks), the 4-drug ATT will be followed with 4 months (or 16 weeks) of 2-drug ATT (defined as rifampin/isoniazid). All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only
89064444|NCT01380080|Experimental|Arm B: IPT|Study treatment for Arm B participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral therapy as soon as possible following randomization and within no more than 3 days following randomization and of initiating anti-TB treatment (ATT) only when indicated according to local standard practice and at the discretion of the site investigator. All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only. Pyridoxine is provided by the sites to all participants while they are receiving isoniazid (INH).
89064445|NCT01379768|Active Comparator|Lotrafilcon A|Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
89064446|NCT01379768|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
89064447|NCT01379768|No Intervention|No lens wear|No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
89064448|NCT02894333||Patients with Parkinson's disease|
89064449|NCT01379573|Experimental|Pregnant women with previous child with cardiac neonatal lupus|400 mg/day Hydroxychloroquine
89064450|NCT04444661||HIT-resistance exercise|High Intensity Resistance Exercise
89064451|NCT04444661||Non exercising control|Control group that maintained life style and physical activity habits
89064452|NCT01379534|Experimental|TKI258|1 treatment arm (single agent TKI258), with patients classified into 2 groups based on their FGFR2 mutation status
89064453|NCT01371851|Experimental|Doxazosin|Doxazosin extended release will be administered initially at 4 mg/day. On day 8 the dose is increased to 8 mg/day and the participant is maintained on the study until the end of the trial.
89064454|NCT01371851|Placebo Comparator|Placebo|Participants will be maintained on placebo (cellulose) throughout the trial.
89064455|NCT01371734|Experimental|Experimental Arm 1 - high dose|
89064456|NCT01371734|Experimental|Experimental Arm 2 - low dose|
89064457|NCT01371734|Placebo Comparator|Placebo Arm|
89064458|NCT01365494|Active Comparator|Group A-Zagreb|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered intramuscularly (IM) according to the 2-1-1 (Zagreb) schedule (i.e., 2 doses of vaccine administered on day 0 and 1 dose of vaccine each administered on day 7 and day 21)
89064459|NCT01365494|Active Comparator|Group B-Essen|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered IM according to the 1-1-1-1-1 (Essen) schedule (i.e., 1 dose of vaccine administered on day 0, 3, 7, 14, and 28)
89064460|NCT00637169|Experimental|1|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 85-89%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
89064461|NCT00637169|Active Comparator|2|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 91-95%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
89064462|NCT04440410||Hidradenitis suppurativa|Subjects with active mild, moderate, or severe HS disease using the HS-PGA assessment
89064463|NCT04440410||Atopic Dermatitis|Subjects with active moderate or severe AD disease using the PGA assessment
89064464|NCT04440098||Isolated Observational group|All participants socially restricted as a result of COVID-19
89064465|NCT04328870|Active Comparator|oxytocin and spinal anesthesia|spinal anesthesia combined with intravenous oxytocin infusion
89064466|NCT04328870|Active Comparator|general anesthsia|general anesthesia alone
89064467|NCT04329026|Experimental|Smart Glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
89064468|NCT04329026|Placebo Comparator|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
89064469|NCT00591539||Carotid Ultrasound|Carotid Ultrasound: Irradiated and non-irradiated sides of the neck in long-term survivors of pediatric cancers who received unilateral radiation therapy involving the carotid artery as part of their treatment
89064470|NCT00591617|Active Comparator|1: MM|Medical Management: group receives medical management from study physician and Suboxone pharmacotherapy
89064471|NCT00591617|Active Comparator|2: CBT|Cognitive Behavioral Therapy (CBT) group receives CBT, medical management and Suboxone pharmacotherapy
89064472|NCT00591617|Active Comparator|3: CM|Contingency Management (CM) group receives CM, medical management, and Suboxone pharmacotherapy
89064473|NCT00591617|Active Comparator|4: CBT + CM|Cognitive Behavioral Therapy (CBT) and Contingency Management (CM) group receives CBT, CM, medical management, and Suboxone pharmacotherapy
89064474|NCT04328987||Clopidogrel user|"* Uninterrupted (continuous) use of clopidogrel: cessation of clopidogrel less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of clopidogrel is sum of before and after the CSP~patient who stopped clopidogrel only on the day of colonoscopy and resumed the day after colonoscopy -> cessation of clopidogrel was 1 day.~patient who stopped clopidogrel from 3 days before colonoscopy and resumed the day after colonoscopy -> cessation of clopidogrel was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -> interruption of clopidogrel -> excluded from study.~patient who stopped clopidogrel from 2 days before colonoscopy and resumed 2 days after colonoscopy -> cessation of clopidogrel was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -> interruption of clopidogrel -> excluded from study."
89064475|NCT04328987||Aspirin user|"* Uninterrupted (continuous) use of aspirin: cessation of aspirin less than 4 days (=0, 1, 2, or 3 days cessation). Cessation days of aspirin is sum of before and after the CSP~patient who stopped aspirin only on the day of colonoscopy and resumed the day after colonoscopy -> cessation of aspirin was 1 day.~patient who stopped aspirin from 3 days before colonoscopy and resumed the day after colonoscopy -> cessation of aspirin was 4 days (-3, -2, -1, 0=on the day of colonoscopy). -> interruption of aspirin -> excluded from study.~patient who stopped aspirin from 2 days before colonoscopy and resumed 2 days after colonoscopy -> cessation of aspirin was 4 days (-2, -1, 0=on the day of colonoscopy, 1=the day after colonoscopy). -> interruption of aspirin -> excluded from study."
89064476|NCT01357889|Active Comparator|process 2 albiglutide|albiglutide 30mg from process 2 drug substance
89064477|NCT01357889|Active Comparator|process 3 albiglutide|albiglutide 30mg from process 3 drug substance
89064478|NCT02893748|Active Comparator|1: HyGIeaCare Prep and Colonoscopy|"Patients will receive:~HyGIeaCare Prep~Colonoscopy"
89064479|NCT02893748|Active Comparator|2: Split-dose PEG Prep and Colonoscopy|"Patients will receive:~Split-dose PEG~Colonoscopy"
89064480|NCT01357850|Experimental|GSK716155 (3.75mg)|GSK716155 (3.75mg)
89064481|NCT01357850|Experimental|GSK716155 (15mg)|GSK716155 (15mg)
89064482|NCT01357850|Experimental|GSK716155 (30mg)|GSK716155 (30mg)
89064483|NCT01357850|Placebo Comparator|GSK716155-matched placebo|GSK716155-matcued placebo
89064484|NCT01357655|Active Comparator|Arm 1: Dasatinib|
89064485|NCT01357655|Experimental|Arm2: Dasatinib + BMS-833923|Dasatinib for 1 year followed by dasatinib plus BMS-833923 for 2 years followed by dasatinib alone for approximately 2 years; depending on response
89064486|NCT01357616|Experimental|AZARGA|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, 1 drop in the affected eye(s) dosed twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
89064487|NCT01357616|Active Comparator|AZOPT + Timolol|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in the affected eye(s), followed by Timolol 0.5% ophthalmic solution, 1 drop instilled in the affected eye(s). Approximately 10 minutes separated the 2 instillations. The study drugs were instilled twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
89064488|NCT01357577|Experimental|Arm 1: TAU + CBT|The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
89064489|NCT01357577|No Intervention|Arm 2: TAU|"The no intervention group will receive treatment as usual (TAU)."
89064490|NCT01351025|Experimental|Arm A: atorvastatin / placebo|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated atorvastatin at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at the week 4 visit. At week 20, atorvastatin was stopped for a 4-week washout period.~At week 24, placebo was started for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the placebo dose was doubled at week 28. At week 44, the placebo was stopped to allow for another 4-week washout period."
89064491|NCT01351025|Experimental|Arm B: placebo / atorvastatin|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated placebo for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the dose of placebo was doubled at the week 4 visit. At week 20, the placebo was stopped for a 4-week washout period.~At week 24, atorvastatin was started at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at week 28. At week 44, atorvastatin was stopped to allow for another 4-week washout period."
89064492|NCT01349036|Experimental|PLX3397-Cohort 1|10 patients with recurrent glioblastoma who require reoperation will be treated with PLX3397 for 7 days prior to surgery and their tumor tissue will be evaluated for pharmacokinetic levels and pharmacodynamic effects.
89221958|NCT00954798|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
89221959|NCT00954798|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
89221960|NCT00110305|Experimental|TMC278 25 mg|Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
89221961|NCT00110305|Experimental|TMC278 75 mg|Participants will receive TMC278 75 mg once daily up to Week 144. Later on, participants will receive TMC278 25 mg once daily up to Week 240.
89221962|NCT00110305|Experimental|TMC278 150 mg|Participants will receive TMC278 150 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
89221963|NCT00110305|Active Comparator|Efavirenz|Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
89221964|NCT00954954|Active Comparator|Standard|Knees that will be implanted with standard posterior stabilized RP-MB knee prostheses
89221965|NCT00954954|Active Comparator|High-flexion|Knees that will be implanted with high-flexion posterior stabilized RP-MB knee prostheses
89221966|NCT00428116|No Intervention|Interrupted HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.
89221967|NCT00428116|Active Comparator|Continued HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.
89221968|NCT00560066|Experimental|cTIV|Subjects received one vaccination of cell culture-derived influenza vaccine
89221969|NCT00560066|Active Comparator|TIV|Subjects received one vaccination of egg-derived influenza vaccine
89221970|NCT00549900|Experimental|Cervarix Group|Subjects received 3 doses of GSK580299 vaccine (Cervarix™, HPV -16/18 L1 VLP AS04 vaccine) according to a 0, 1, 6-month schedule.
89221971|NCT01083355||Mechanical ventilation|Critical care patients
89221972|NCT00435994|Other|Infants with viral lower respiratory infections|Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants
89221973|NCT00435994|Other|Healthy Control|Healthy infants between the ages of 2-24 month
89221974|NCT00435994|Other|Bronchiolitis-Nasal wash only|Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only
89221975|NCT01083511||Symptomatic|Individuals with signs and symptoms of a respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
89221976|NCT01563120|Active Comparator|metformin|metformin up to 2550mg per day
89221977|NCT01563120|Active Comparator|glybenclamide|glybenclamide up to 20mg per day.
89221978|NCT00435370|Experimental|Tropisetron|Tropisetron (10mg/day) + risperidone(6mg/day)
89221979|NCT00435370|Placebo Comparator|Placebo|Placebo + risperidone (6mg/day)
89221980|NCT05098548||patients with Chronic limb threatening ischemia|"All patients with Chronic limb threatening ischemia present with one or more of the following:~Rest pain (Rutherford category 4)~Minor tissue loss (Rutherford category 5) admitted to the department of Vascular surgery for Endovascular Intervention with provided written informed consent."
89221981|NCT00096031|Experimental|Cetuximab|250 mg/m^2 on days 1, 8, 15, and 22 of every 28-day cycle.
89221982|NCT04010526|Experimental|treatment|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of autologous ADIpose will be performed
89221983|NCT04010526|Placebo Comparator|placebo|CD patients with complex refractory perianal fistula refractory to conventional medical and surgical therapy referred to the gastroenterology departments of the 3 centers in charge of treatment local co-administration of placebo will be performed
89221984|NCT05043324|Experimental|AIDS, HIV, HBV, HCV, co-infections.|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes.
89221985|NCT05043324|Experimental|"stable cancer, acquired or congenital immunodeficiency."|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes.
89221986|NCT04010604||SMA type I|
89221987|NCT04010604||SMA type II|
89221988|NCT04010604||SMA type III|
89221989|NCT04010604||Asymptomatic carriers of SMA|
89221990|NCT04010604||Relatives of SMA patients and carriers|
89221991|NCT04010604||Unrelated healthy controls|
89221992|NCT04303728|Experimental|Muscle ultrasound|Muscle ultrasound will be performed for the patient on admission and at 1-2 months from inpatient rehabilitation.
89221993|NCT00118417|Experimental|1|Participants in phase II will receive sertraline, or an equivalent medication, up to 100 mg plus a placebo pill. Participants in phase III will receive the same medication with cognitive behavioral therapy.
89221994|NCT00118417|Experimental|2|Participants in phase II will receive sertraline, or equivalent medication, up to 200 mg. Participants in phase III they will receive the same medication with flexible clonazepam augmentation.
89221995|NCT04293744|Experimental|Colloid priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL PrimECC.
89221996|NCT04293744|Active Comparator|Standard priming solution for ECC circuit|Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).
89221997|NCT01080703|Experimental|Lower extremity strengthening|
89221998|NCT01080781||Group 1|normal pressures in right auricle (<10 mmHg) /and or pulmonary artery (<35 mmHg)
89221999|NCT01080781||Group 2|high pressures in right auricle (> 10 mmHg) /and or pulmonary artery (>35 mmHg)
89222000|NCT01079455|Active Comparator|HA|Coxarthrosis
89222001|NCT01079455|Active Comparator|Corticosterone|Coxarthrosis
89222002|NCT01079455|Placebo Comparator|Bupivacaine|Coxarthrosis
89064493|NCT01349036|Experimental|PLX3397-Cohort 2|30 patients will be orally dosed with PLX3397 continuously on 28 day cycles.
89064494|NCT01348763|Experimental|Truvada, Darunavir/r and Maraviroc|Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
89064495|NCT01346969|Active Comparator|Group 1|
89064496|NCT01346969|Placebo Comparator|Group 2|
89064497|NCT01346969|Placebo Comparator|Group 3|
89064498|NCT01346969|Placebo Comparator|Group 4|
89064499|NCT01346774|Experimental|Cranberry powder capsules|"TheraCran® cranberry: based upon proanthocyanidin content, the four cranberry capsules are equivalent to two 8-ounce servings of cranberry juice.~Participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food."
89064500|NCT01346774|Placebo Comparator|Placebo capsules|Placebo: participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food.
89064501|NCT01346696|Experimental|OsseoSpeed™ TX implants|OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.
89064502|NCT01346540|Experimental|BIBF 1120|VEGF inhibitor
89064503|NCT01346540|Placebo Comparator|Placebo|BIBF 1120 placebo
89064504|NCT01342913|Experimental|Fluticasone Furoate/Vilanterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA)
89064505|NCT01342913|Active Comparator|Fluticasone Propionate/Salmeterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA
89064506|NCT01342796|Experimental|Arm 1|
89064507|NCT01342796|Active Comparator|Arm 2|
89064508|NCT01342640|Experimental|Single Arm|
89064509|NCT01342484|Experimental|linagliptin low dose|linagliptin low dose for children once daily
89064510|NCT01342484|Experimental|linagliptin high dose|linagliptin high dose for children once daily
89064511|NCT01342484|Placebo Comparator|placebo|matching placebo for each linagliptin dose once daily
89064512|NCT01342445|Experimental|lisdexamfetamine dimesylate|All participants will be assessed across five conditions (baseline, placebo, 30-mg, 50-mg, & 70-mg) in a double-blind, crossover design
89064513|NCT01342211|Placebo Comparator|Treatment A|
89064514|NCT01342211|Experimental|Treatment B|
89064515|NCT01342211|Experimental|Treatment C|
89064516|NCT01342211|Experimental|Treatment D|
89064517|NCT01342211|Experimental|Treatment E|
89064518|NCT01342094|Experimental|DE-111 ophthalmic solution|DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.
89064519|NCT01342094|Active Comparator|Timolol ophthalmic solution 0.5%|Timolol ophthalmic solution 0.5% (one drop at a time, BID) and Placebo ophthalmic solution (one drop at a time, once daily) in both eyes.
89064520|NCT01340768|Experimental|Sitagliptin|Sitagliptin 100mg taken orally once daily with or without metformin
89064521|NCT01340768|Active Comparator|Sulfonylurea Therapy|Usual sulfonylurea therapy with or without metformin
89064522|NCT01340651|Experimental|Ruxolitinib 25 mg SR/10, 15, or 20 mg IR|Participants began administration with 25 mg ruxolitinib sustained release (SR) once daily (QD). After 8 weeks, if there was inadequate efficacy, the dose level could be titrated to 50 mg SR QD or 25 mg SR every other day (QOD) alternating with 50 mg SR QOD. At Week 16, participants transitioned to ruxolitinib 10, 15, or 20 mg immediate release (IR) orally twice daily. Participants who continued to demonstrate benefit in the opinion of the investigator could remain on ruxolitinib IR until the last participant completed Week 36 or the commercial availability of ruxolitinib IR, whichever was earlier; the dose received was based on platelet counts at the time of transition.
89064523|NCT01340495|Experimental|Proton Radiation|Radiation therapy with proton beam
89064524|NCT01340300|Active Comparator|Exercise training|Exercise training with exercise physiologist
89064525|NCT01340300|Active Comparator|Exercise training with metformin|Exercise training with exercise physiologist with oral metformin
89064526|NCT01340300|Active Comparator|Metformin|Metformin
89064527|NCT01340300|Active Comparator|Control|Educational information
89064528|NCT01340066|Experimental|UISH001|
89064529|NCT01340066|Placebo Comparator|Matching placebo|
89064530|NCT02893904|Experimental|Propofol|General anesthesia by TCI Propofol and Remifentanil guided by BIS EEG monitoring intervention
89064531|NCT02893904|Experimental|Sevoflurane|General anesthesia by Sevoflurane and Remifentanil guided by BIS EEG monitoring intervention
89064532|NCT04422080||Keratoconus patient|Patient with keratoconus disease diagnosed on videotopography
89064533|NCT04422080||Healthy patient|Patient consulting for keratoconus screening with no keratoconus on videotopography
89064534|NCT04309825|Experimental|G-tube endoscopies patients|patients who will undergo an endoscopy through g-tube port
89064535|NCT05010850|Experimental|Colovac|Patients receive Colovac during colorectal surgery
89064536|NCT05010850|Active Comparator|Standard of Care|Patients receive the standard of care, a protective stoma, during colorectal surgery
89064537|NCT04397237||Systemic Lupus Erythematosus|Consecutive Systemic Lupus Erythematosus patients followed-up in each service
89064538|NCT04397237||Sjogren's Syndrome|Consecutive Sjogren's Syndrome patients followed-up in each service
89064539|NCT04397237||Axial Spondyloarthritis|Consecutive Axial Spondyloarthritis patients followed-up in each service
89064540|NCT04397237||Rheumatoid Arthritis|Consecutive Rheumatoid Arthritis patients followed-up in each service
89064541|NCT04397237||Giant Cell Arteritis|Consecutive Giant Cell Arteritis patients followed-up in each service
89064542|NCT01107535||Infants receiving Synagis (palivizumab) immunoprophylaxis|Infants born <= 32 weeks of gestation and are younger than 6 months of age, children with bronchopulmonary dysplasia who have received medical treatment in the last 6 months until the first year of life, and children 12 months or younger with hemodynamically significant acyanotic congenital heart disease (pulmonary hypertension or heart failure in treatment) prescribed Synagis (palivizumab) immunoprophylaxis according to the usual clinical practice.
89064543|NCT04397042||recurrent pregnancy loss|Group 1 included thirty women admitted to our clinic for termination of pregnancy due to absence of fetal cardiac activity or absence of fetal pole on ultrasonographic examination. Patients with a history of two or more unexplained first trimester miscarriages and no live births were included in the study
89064544|NCT02881294|Active Comparator|Food Effect|SUVN-G3031 tablets single dose
89064545|NCT02881294|Active Comparator|Gender Effect|SUVN-G3031 tablets single dose
89064546|NCT02881294|Active Comparator|Age Effect|SUVN-G3031 tablets single dose
89064547|NCT02881216|Other|Common DES|Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
89064548|NCT02881216|Other|Synergy Stent|Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
89064549|NCT04309747|Experimental|nanosecond knife group|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
89064550|NCT04420286||Hospital having ICU beds|Hospital having ICU beds during COVID-19 outbreak in France
89064551|NCT02881060|Active Comparator|Ethanol|Drinking a cocktail of ethanol (0.8 g ethanol per kg body weight), diet lemonade and water of 1:1:1 (volume distribution).
89064552|NCT02881060|Placebo Comparator|Non-ethanol|Drinking a cocktail of diet lemonade and water of 1:2 (volume distribution).
89064553|NCT04396964||surgery|subjects undergoing multilevel lumbar fusion
89064554|NCT00592085|Active Comparator|Relapse Prevention Counseling|Motivational Relapse Counseling: 6 counseling calls over two weeks accompanied by questionnaires
89064555|NCT00592085|Active Comparator|Relapse Prevention + Alcohol Counseling|Motivational Relapse Prevention Plus Alcohol Risk Reduction Counseling: 6 counseling calls over two weeks for both smoking cessation and at-risk alcohol use accompanied by questionnaires
89064556|NCT04328168|Active Comparator|Group1|Conventional Physiotherapy
89064557|NCT04328168|Active Comparator|Group2|robot-assisted gait training
89064558|NCT02880943|Experimental|Group A|"Group A: patients with bone disease mainly will be treated with XOFIGO® alone.~Node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A."
89064559|NCT02880943|Experimental|Group B|Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.
89222003|NCT00549848|Experimental|HD PEG|"Participants randomized to receive higher dose PEG-asparaginase during the continuation phase.~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
89222004|NCT00549848|Active Comparator|CD PEG|"Participants randomized to receive conventional dose PEG-asparaginase during the continuation phase..~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
89064560|NCT02881021|Experimental|Rehabilitation program and kinesiotaping.|"Each patient will attend 10 physiotherapy sessions over six. Patients from the Experimental group (KT group) will receive the same standardized rehabilitation program as control group (No-KT group) including manual therapy, movement training, stretching, muscular strengthening, and patient education.~Only KT-group (experimental) will receive therapeutic KT added to the rehabilitation program.~Kinesio® Tex Classic will be applied using a combination of techniques designed for RCTe and underlying symptoms following the instructions and principles described by Kase et al (2003).~Kinesiotaping strips will be weaned gradually, according to the individual improvements of deficits evaluated weekly by the physiotherapist treating."
89064561|NCT02881021|Active Comparator|Rehabilitation program.|"Each patient will attend 10 physiotherapy sessions over six. Patients allocated at the control group (No-KT group) will receive only the rehabilitation program, including manual therapy, movement training, stretching, muscular strengthening, and patient education.~The rehabilitation program will be exactly the same applied to the experimental group (KT group)."
89064562|NCT04420013||exposed group|for CRC patients with non-resectable hepatic metastases: surgery for CRC combined with RFA.
89064563|NCT04420013||no-exposed group|for CRC patients with resectable metastases: surgery only without RFA.
89064564|NCT04419194||Observation|Observation
89064565|NCT04328519||patient(hospitalized)|patients who are admitted to the emergency department and hospitalized.
89064566|NCT04328519||control(not hospitalized)|patients who are admitted to the emergency department and not hospitalized.
89064567|NCT04132076||Group A: Osteochondral lesion of talus (OLT)|Patients with OLT treated operatively (debridement, microfracture, allograft, mesenchymal stem cells implantation) in Department of Orthopaedic Surgery, University Medical Centre Ljubljana (UMC).
89064568|NCT04132076||Group B: Ankle joint osteoarthrosis|Patients with ankle joint osteoarthrosis treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
89064569|NCT04132076||Group C: Ankle Impingement syndrome|Patients with ankle impingement syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
89064570|NCT04132076||Group D: Ankle instability syndrome|Patients with ankle instability syndrome treated operatively in Department of Orthopaedic Surgery, UMC Ljubljana.
89064571|NCT02893982|Experimental|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
89064572|NCT00597792|Active Comparator|A|Active Plicator Treatment
89064573|NCT00597948|Experimental|1|Workshop Group: Receives Healthy Lifestyles curriculum and subsequent support.
89064574|NCT00597948|No Intervention|2|Comparison Group: Does not receive Healthy Lifestyles curriculum and subsequent support.
89064575|NCT02892006|Experimental|Intervention|All participants in the study will participate a 6 week improv intervention.
89064576|NCT00598104|Experimental|1|
89064577|NCT00598104|Placebo Comparator|2|
89064578|NCT02891928|Experimental|with rocker sole|patient were wearing the rocker soles shoes during investigation
89064579|NCT02891928|Placebo Comparator|without rocker sole|patient were wearing normal shoes during investigation
89064580|NCT04207632||Intervention|The Group of patients will receive routine treatment of muscle hypertonia with botulinum toxin type A in their elbow flexors.
89064581|NCT00598260|Experimental|1- study group|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
89064582|NCT00598260|No Intervention|2 - control group|control group
89064583|NCT00598338|Active Comparator|1|Prucalopride
89064584|NCT00598338|Placebo Comparator|2|Placebo
89064585|NCT04326348|Experimental|TQ05105 Tablet|TQ05105 tablet administered orally once. Then TQ05105 tablet administered orally, twice daily in 28-day cycle after 3 days of first administration.
89064586|NCT00598416|Experimental|Psychoeducation|
89064587|NCT00598572|Experimental|1|All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.
89064588|NCT04326426|Experimental|Tradipitant|Tradipitant 85 mg PO BID
89064589|NCT04326426|Placebo Comparator|Placebo|2 capsules of matching placebo
89064590|NCT00598728||1|Hodgkin lymphoma Survivors
89064591|NCT00598884|Experimental|6-week delay start|This group begins treatment 6 weeks after recruitment and baseline.
89064592|NCT00598884|Experimental|No delay start|This group begins treatment after enrollment and assessment with no wait period.
89064593|NCT00622986|Experimental|A1|perimenopausal women
89064594|NCT00622986|Placebo Comparator|A2|perimenopausal women
89064595|NCT00622986|Experimental|B1|early staged postmenopausal women
89064596|NCT00622986|Placebo Comparator|B2|early staged postmenopausal women
89064597|NCT00599742|Active Comparator|A|Balance training group
89064598|NCT00599742|Active Comparator|B|Motor Training
89064599|NCT00599898|Experimental|1|
89064600|NCT00599898|Experimental|2|
89064601|NCT00600054|Experimental|Single arm|
89064602|NCT00600210|Experimental|I|
89064603|NCT00600444|Active Comparator|A|Venae Sectio technique will be used to insert totally implantable access port (TIAP) by a surgeon
89064604|NCT00600444|Experimental|B|Punction of Vena Subclavia will be used to insert totally implantable access port (TIAP) by a radiologist.
89064605|NCT04326114|Experimental|Inspiratory training|
89064606|NCT04326114|Experimental|Expiratory training|
89064607|NCT04326114|No Intervention|Control|
89064608|NCT01326546|Experimental|Therapeutic HBV vaccine+Entecavir|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
89064609|NCT01326546|Placebo Comparator|placebo+Entecavir|Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
89064610|NCT00600522||1|Patients selected for hepatectomy because carriers of hepatocellular carcinoma or colorectal cancer liver metastases invading the middle hepatic vein at caval confluence (last 4 cm).
89064611|NCT00600600|Experimental|Tigecycline|tigecycline titrated dose according to patient age and clinical status
89064612|NCT00600678|Experimental|1|
89064613|NCT00623142|No Intervention|A|Patients in this arm were not treated with HBO prior to CABG
89064614|NCT00623142|Experimental|B|Patients in this arm were treated with HBO prior to CABG
89064615|NCT00623220|Experimental|A|O2 and N2O
89064616|NCT00623220|Active Comparator|B|O2 only
89064617|NCT00600834||1|patients with moderate CKD (stage 3, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
89064618|NCT00600834||2|patients with severe CKD or kidney failure (stages 4 and 5, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2).
89064619|NCT00600912|Experimental|1-SMOFlipid®|lipid emulsion based on soybean oil, medium-chain triglycerides, olive oil and fish oil SMOFlipid®-Group (n = 21)
89064620|NCT00600912|Active Comparator|2-ClinOleic 20%®|olive and soybean oil-group (n=21)
89064621|NCT00601068||Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
89064622|NCT00601224|Experimental|1|Participants will receive social cognition and interaction training plus treatment as usual
89064623|NCT00601224|Active Comparator|2|Participants will receive treatment as usual
89064624|NCT02891460|Experimental|40 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.
89064625|NCT02891460|Experimental|80 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.
89064626|NCT02891694||recurrent corneal erosion|
89064627|NCT02891694||control patients (refractive surgery)|
89064628|NCT00601692|Experimental|Regimen 1|Patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 8, patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8) and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
89064629|NCT00601692|Experimental|Regimen 2|Patients receive docetaxel IV and irinotecan hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride, docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients receive docetaxel IV, irinotecan hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy. Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8 (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and radiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
89064630|NCT04208022||Healthy Musician|At least 15 hypermobile musicians and at least 15 non-hypermobile musicians will be included in the study.
89064631|NCT04208022||Healthy Individuals|The study will include at least 15 healthy non-hypermobile individuals who do not deal with music and at least 15 healthy hypermobile individuals who do not deal with music.
89064632|NCT00601770|Experimental|IC41|8 injections of 4 x 0.125mL
89064633|NCT01325532|Experimental|Active CES|"Active CES: The FW-100 Cranial Stimulator headset was placed on the scalp over the two dorsolateral prefrontal cortex areas. The power knob was turned to maximum setting. The waveform contains a 15000Hz square wave carrier from 0-4 mAmp. The first 15Hz modulating signal provides 50msec of on and 16.7msec of off time (total 66.7msec, 50% duty cycle). A second 500Hz modulating signal changes the on time series of 15000Hz pulses (750 pulses/50msec) into 25 smaller bursts of 15 pulses of the 15000Hz carrier signal, for 375 pulses in 50msec. The consecutive positive burst and off time is followed by an opposite negative burst and off time, balancing the current component to zero. Output voltage ranges from 0-40V, positive and negative. CES automatically shut off after 20 mins."
89064634|NCT01325532|Sham Comparator|Sham CES|Shame CES: The sham devices were modified to not deliver current to the headset. The current from the active device departs from the posts at the top of the device into the headsets, creating a loop when the headset is worn by the subject with the wet electrode sponges. This loop is eliminated in the sham devices by wrapping wire around the posts, thus containing the loop within the device, with no electricity leaving the headsets. This approach allows the loop to be maintained, and therefore all of the device's green and yellow amperage lights still light up, protecting the blind.
89064635|NCT01171963|Experimental|Rotarix Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Rotarix™ vaccine, liquid formulation, at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccines were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Rotarix™ vaccine. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Rotarix™ and OPV vaccines were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
89064636|NCT01171963|Placebo Comparator|Placebo Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Placebo at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccine were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Placebo. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Placebo and the OPV vaccine were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
89064637|NCT04315207|Active Comparator|In-person visit|"In-person meeting with the patient in the out-patient department. The patient is free to bring up to four* relatives or other persons of their own choice to the in-person meeting.~(* Restriction due to space limitation)."
89064638|NCT04315207|Experimental|Telephone call|Telephone call with the patient. The patient is free to turn on loudspeaker to include relatives or other persons in the telephone conversation, alternatively to ask the physician to call and inform one relative or other person after the patient-doctor telephone call
89064639|NCT01171183|Placebo Comparator|Placebo|
89064640|NCT01171183|Active Comparator|Carvedilol controlled release|controlled release carvedilol (Coreg CR) at 80 mg/day in once daily dosing
89064641|NCT04315441||Soldiers|any soldier who attended the Military Medical Center of Sector N°5 for the annual re-engagement medical visit during the period from January 1, 2017 to November 13, 2018.
89064642|NCT04315441||Civilians|The civilian populations were recruited from two free cardiovascular risk factors screening campaigns carried out from January 04, 2017 to January 10, 2017 and from November 12, 2018 to November 18, 2018
89064643|NCT04315051|Placebo Comparator|Placebo Gel|Placebo gel daily application for 4 weeks
89064644|NCT04315051|Active Comparator|Cohort 1|DBI-001 Gel daily application for 4 weeks
89064645|NCT01170091||Pramipexole|
89064646|NCT04315129|Other|Single arm|A single arm will have biosensor (experimental) diagnoses compared to clinical (control, current standard of care). All participants in this group willl have a biosensor, with the data masked to patients, providers and clinical researchers
89064647|NCT01169779|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD up to Week 24.
89064648|NCT01169779|Placebo Comparator|Placebo|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, followed by 20 mcg QD up to Week 24.
89222005|NCT01083589|Experimental|Imatinib Mesylate + Docetaxel|Imatinib Mesylate (Gleevec) Oral 400 mg daily + Docetaxel (Taxotere) 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
89222006|NCT01080859||BAS|Patient's receiving BAS
89222007|NCT01080859||EES|Patients receiving EES
89222008|NCT01079533|Active Comparator|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
89222009|NCT01079533|Experimental|Minimal Cue and TLC|Participants randomized to the experimental arm will receive a minimal cue after completing the baseline survey. A follow up survey will be sent 9 months after completion of the minimal cue to assess whether the participant received CRCS. If the participant has not had CRCS they will receive a more intensive telephone linked communication intervention. A second follow up will be sent 9 months after the TLC is delivered to assess final screening status.
89222010|NCT05299788|No Intervention|The routine analgesia group|The routine analgesia and warming protocol was applied to patients in the control group.The routine postoperative analgesic treatment protocol at the unit comprises the administration of 75 mg IM (Intramuscular) Diclofenac Sodium before the patient wakes up, 30 mg intravenous (IV) Tramadol if the patient complains of pain when awake (maximum dose of 100 mg/day), and 10 mg/day Morphine Sulfate. In addition to, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for warming.
89222011|NCT05299788|Experimental|The routine analgesia+active external warming+ice application group|In addition to the routine analgesia protocol, the study group was administered non-pharmacological pain control interventions.
89222012|NCT01083745||IVF patients - 1|Poor responders
89222013|NCT01083745||IVF patients - 2|Good responders
89222014|NCT00949182|Experimental|Sorafenib Tosylate, Doxorubicin, Mytomicin C|Micro and Macro arteriolar blockade of hepatocellular carcinoma (HCC): Treatment with Sorafenib 400mg two weeks prior to embolization HACE which includes the use of agents such as Doxorubicin Hydrochloride and Mytomicin C, continuing same Sorafenib dose after the procedure (dose adjustment according to tolerance).
89222015|NCT00955344|Experimental|Web-based intervention (eToolbox)|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module that will embed a link to the web-based intervention (eToolbox).
89222016|NCT00955344|Active Comparator|Practice Improvement Module|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module without any link to the Web-based eToolbox.
89222017|NCT01083823|Active Comparator|Self-reported mood swings|Participants who self-identify as experiencing severe mood swings that interfere with life.
89222018|NCT01083823|Active Comparator|Healthy|Participants who self-identify as not experiencing mood swings in the past or at present and who deny past / present problems with substance use.
89222019|NCT00549770|Experimental|LCZ696 100 mg|Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
89222020|NCT00549770|Experimental|LCZ696 200 mg|Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
89222021|NCT00549770|Experimental|LCZ696 400 mg|Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
89222022|NCT00549770|Active Comparator|Valsartan 80 mg|Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
89222023|NCT00549770|Active Comparator|Valsartan 160 mg|Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.
89222024|NCT00549770|Active Comparator|Valsartan 320 mg|Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
89222025|NCT00549770|Experimental|AHU377 200 mg|Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.
89222026|NCT00549770|Placebo Comparator|Placebo|Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
89222027|NCT00548184|Experimental|Single Group Assignment|Lapatinib Trastuzumab Endocrine
89222028|NCT00955500|Active Comparator|Normal-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams).
89222029|NCT00955500|Active Comparator|Low-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral maltodextrine
89222030|NCT00955578||Segmental Dysplastic Nevi|One patient who has been diagnosed with SDN and has had previous biopsies in the past, comparing to current biopsies
89222031|NCT00955656||primary care providers|"Primary care providers who receive the survey will be the primary care provider identified by study participants enrolled in our ongoing study entitled, Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors (ARIA#53054)"
89222032|NCT00955734|Experimental|Early motion|This group of patients will begin wrist motion 1 week after surgery.
89222033|NCT00955734|Active Comparator|Immobilization|This group will be casted for 6 weeks after surgery
89222034|NCT00955812|Experimental|OPB-31121|OPB-31121 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
89222035|NCT04010994|Other|rtACS|repetitive transorbital ACS
89222036|NCT05299710||Ovarian Tissue Cryopreservation|Children faced with a fertility threatening diagnosis will be offered ovarian tissue cryopreservation.Pre-surgery assessment will be done while your child is in the hospital or in the pediatric oncology, surgery, or anesthesia clinic as an outpatient. The surgical procedure used to remove your child's ovary is called laparoscopy. It is not required for the treatment of your child's cancer. Laparoscopic surgery is done under general anesthesia (your child will be asleep during the surgery) in the operating room.
89222037|NCT00454636|Experimental|Cisplatin / Capecitabine|Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
89222038|NCT00454636|Experimental|Epirubicin / Cisplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2, orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
89064649|NCT01169701|Active Comparator|Tacrolimus|Participants continued with the same tacrolimus+Mycophenolic acid (MPA) (Myfortic® or Cell-Cept®) doses that were taken before study initiation (tacrolimus levels 4-7 ng/ml).
89064650|NCT01169701|Experimental|Everolimus|Participants received an initial dose (day 1) of Everolimus (EVL) 2mg at night and tacrolimus (if taking Prograf®, a full dose of Prograf® in the morning and a 50% dose of Prograf® at night; if taking Advagraf®, a 75% dose in the morning. On days 2 and 3, participants took EVL 2 mg twice daily (bid) without tacrolimus. On days 4 and 5, the EVL dose was adjusted and levels maintained between 5-8 ng/mL. Participants also continued with their MPA doses that were taken prior to study initiation.
89064651|NCT01168999|Active Comparator|spinal manipulation|a spinal manipulation known to be effective in the treatment of low back pain for some individuals
89064652|NCT01168999|Placebo Comparator|sham spinal manipulation|a sham spinal manipulation intended to mimic the studied spinal manipulation
89064653|NCT01168999|No Intervention|natural history|No intervention is provided to participants in this arm of the study
89064654|NCT01168999|Placebo Comparator|Enhanced sham spinal manipulation|"a sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
89064655|NCT01167907|Experimental|0.2% ropivacaine|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
89064656|NCT01167907|Placebo Comparator|Saline|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
89064657|NCT01166659|Experimental|CyPass Micro-Stent|Subjects receive the CyPass Micro-Stent
89064658|NCT02886169|Experimental|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
89064659|NCT02886169|Placebo Comparator|unsupplemented group|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
89064660|NCT02885779||Patient having an operating indication of adnexa surgery|Patient having an operating indication of adnexa surgery : unilateral or bilateral adnexectomy
89064661|NCT01115491|Experimental|A|
89064662|NCT01113931|Experimental|Doxycycline Hyclate 200 mg tablet|Once daily
89064663|NCT01113931|Active Comparator|Vibramycin 100 mg capsule|Twice daily
89064664|NCT04310761||pregnancy population after one single blastocyst transfer|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from a period between 2014 and 2018.
89064665|NCT02881879|Experimental|Allergovac depot with HDM extract|Extract of mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae (50:50) adsorbed onto aluminum hydroxide 0.33%.
89064666|NCT02881177|Experimental|Oxytocin|Oxytocin 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
89064667|NCT02881177|Placebo Comparator|Placebo|Placebo 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
89064668|NCT04187677|Active Comparator|Hand Therapy Group|
89064669|NCT04187677|Experimental|Sensory Training Group|
89064670|NCT02881723|Experimental|Treatment for oropharyngeal cancer by surgery|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by surgery
89064671|NCT02881723|Experimental|Treatment for oropharyngeal cancer by radio-chemotherapy|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by radio-chemotherapy
89064672|NCT04187599|Experimental|Paragon CRT®100 Contact Lens|participants will wear the Paragon CRT®100 lens with a follow up for no less than 12 months.
89064673|NCT02880787|Other|Adult population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
89064674|NCT02880787|Other|Adult population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
89064675|NCT02880787|Other|Pediatric population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
89064676|NCT02880787|Other|Pediatric population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
89064677|NCT02880709|Experimental|Special diet|Special diet with taste, energy-and protein content adjusted according to previous finding
89064678|NCT02880709|No Intervention|Usual diet|Patients habitual diet
89222039|NCT00454636|Experimental|Epirubicin / Oxaliplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; oxaliplatin, 130 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2 orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
89222040|NCT00454636|Experimental|Docetaxel / Cisplatin / Capecitabine|Docetaxel, 60 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 825 mg/m2, orally, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
89222041|NCT04850196|Experimental|TEAS group|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
89222042|NCT04850196|Sham Comparator|Control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS.
89222043|NCT00427960|Active Comparator|rosuvastatin|rosuvastatin 5 mg
89222044|NCT00427960|Active Comparator|atorvastatin|atorvastatin 10 mg
89222045|NCT00548340|Experimental|VEC-162 20 mg|VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks
89222046|NCT00548340|Experimental|VEC-162 50 mg|VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks
89222047|NCT00548340|Placebo Comparator|Placebo|Placebo capsules PO daily five weeks
89222048|NCT04839588||Usability study, healthy volunteers and those with cognitive impairments following chemotherapy|"2 elderly healthy volunteers and 2 participants with lasting cognitive impairments following chemotherapy for breast cancer. All will perform evaluation of a computer-based experimental system. Participants will be~Female Either healthy or breast cancer survivor;~Age 20 to 65 years;~Have st least 12 years of formal education;~Be English speakers;"
89222049|NCT03994198|Experimental|Alpha-lactalbumin|Participants will consume 60 g of alphalactalbumin (fraction of whey protein) for 3 training days.
89222050|NCT03994198|Active Comparator|Collagen peptides|Participants will consume 60 g of collagen peptides for 3 training days.
89690103|NCT04343391|Experimental|Brief Individual Psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
89690104|NCT04343391|Experimental|Brief Group Psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
89690105|NCT04343391|Active Comparator|Treatment as usual|Medication provided by a general practitioner.
89690106|NCT03140722|Experimental|vadadustat|Vadadustat daily oral dose, adjustable based on Hb level
89690107|NCT03140722|Active Comparator|epoetin alfa|Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study
89690108|NCT03142438|Experimental|F&P Seal Improvement Project|participants will be placed on this arm for a total of 14 +- 4 days from visit 1. participants will be using the trial mask during this treatment arm
89690109|NCT00982345|Other|Open label Quetiapine|Open-label Quetiapine XL 50 - 400 mg daily treatment 8 weeks
89690110|NCT03087604|Active Comparator|Traditional Technique Group|In the traditional loss of resistance technique group, the epidural catheter will be placed after achieving loss of resistance to air. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.
89690111|NCT03087604|Experimental|Electric Stimulation Group|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.Thoracic epidural block with Electrical Nerve stimulation
89690112|NCT03090256|Experimental|PanOptix IOL|AcrySof® IQ PanOptix™ IOL, bilateral implantation
89690113|NCT00987727|Experimental|1|carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)
89690114|NCT00987727|Active Comparator|2|sodium hyaluronate 0.18% (VISMED® Multi)
89690115|NCT02160535|Experimental|Treatment with OnabotulinumtoxinA|OnabotulinumtoxinA
89690116|NCT04913337|Experimental|NGM707 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
89690117|NCT04913337|Experimental|NGM707 Combination Dose Finding with pembrolizumab|Part 1b NGM707 plus pembrolizumab
89690118|NCT04913337|Experimental|NGM707 Monotherapy Dose Expansion Arm A|NGM707 in RCC
89690119|NCT04913337|Experimental|NGM707 Monotherapy Dose Expansion Arm B|NGM707 in CRC
89690120|NCT04913337|Experimental|NGM707 Monotherapy Dose Expansion Arm C|NGM707 in Ovarian Cancer
89690121|NCT04913337|Experimental|NGM707 Combination Dose Expansion Arm E|NGM707 with pembrolizumab in NSCLC
89690122|NCT04913337|Experimental|NGM707 Combination Dose Expansion Arm F|NGM707 with pembrolizumab in SCCHN
89690123|NCT05386459||Main|Ingaron (INN: recombinant human interferon gamma, lyophilizate for solution preparation for intramuscular and subcutaneous administration 500,000 IU) 1 subcutaneous injection 1 time per day (in the morning) daily for 5 days (5 injections in total) against the background of basic antibacterial and symptomatic therapy
89690124|NCT05386459||Control|Only basic antibacterial and symptomatic therapy. The use of the study drug was carried out on the basis of the decision of the medical commission with the execution of the protocol and primary medical documentation of the patient
89690125|NCT02245945|Experimental|TFV 1% gel|"Participants will be instructed to use TFV 1% vaginal gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
89064679|NCT04309435|Experimental|Self-esteem intervention|"The self-esteem intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~Engagement and listening~Positive regard and empathy~Collaboration~Development of a shared understanding of low self-esteem (a 'psychological formulation')~Provision of written or audio-visual information relating to low self-esteem~Between-session activity for participant~Provision of structured self-help material relating to low self-esteem~Testing of beliefs related to low self-esteem~Practicing new strategies related to low self-esteem~Development of a shared plan to maintain gains in self-esteem"
89064680|NCT04309435|Placebo Comparator|Self-esteem control group|'Assessment and support' for participants with low self-esteem will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
89064681|NCT04309435|Experimental|Self-stigma intervention|"The self-stigma intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~Engagement and listening~Positive regard and empathy~Collaboration~Development of a shared understanding of high self-stigma (a 'psychological formulation')~Provision of written or audio-visual information relating to self-stigma~Between-session activity for participant~Provision of structured self-help material relating to self-stigma~Testing of beliefs related to self-stigma~Practicing new strategies related to self-stigma~Development of a shared plan to maintain reductions in self-stigma"
89064682|NCT04309435|Placebo Comparator|Self-stigma control group|'Assessment and support' for participants with high self-stigma will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
89522867|NCT03389009||smartphone non users|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
89064683|NCT04309435|Experimental|Jumping to conclusions intervention group|"The 'jumping-to conclusions' (JTC) intervention involves 6 x 1-hour therapy sessions, each of which will be provided by a fully trained and supervised psychological therapist over an 8-week period (to allow for cancelled appointments etc). It will involve the following elements:~Engagement and listening~Positive regard and empathy~Collaboration~Development of a shared understanding of role of JTC (a 'psychological formulation')~Provision of written or audio-visual information relating to JTC~Between-session activity for participant~Provision of structured self-help material relating to JTC~Testing of beliefs related to JTC~Practicing new strategies related to reducing JTC~Development of a shared plan to maintain reductions in JTC"
89229782|NCT00408694|Experimental|Treatment (bevacizumab, cisplatin, fluorouracil, IMRT, 3D-CRT)|"BEVACIZUMAB AND CHEMORADIOTHERAPY: Patients receive bevacizumab IV over 30-90 minutes and cisplatin IV over 20-30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 1, patients also undergo three-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for a total of 33 fractions.~ADJUVANT THERAPY: Beginning in week 10, patients receive fluorouracil IV continuously over 96 hours on days 1-4, cisplatin IV over 20-30 minutes on day 1 OR days 1 and 2, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
89064684|NCT04309435|Placebo Comparator|Jumping to conclusions control group|'Assessment and support' for participants who demonstrate the JTC bias will also involve 6 x 1-hour sessions with a psychological therapist, over a period of 8 weeks. However, in these meetings, the therapist will work in collaboration with the person to complete a more detailed assessment of factors which help or hinder their decision-making capacity. They will provide engagement, listening, positive regard and empathy, but they will not develop a psychological formulation, nor will they provide the person with information relating to their problems. They will also not provide self-help material, or encourage the person to test their beliefs, practice new strategies or develop a shared plan for the future. Once the trial is over, however, the therapist will offer to meet with the person to share the results of the assessment and develop a psychological formulation. With the participant's consent, this information will also be shared with the clinical team.
89064685|NCT01107379||Balloon catheter device|Dilation of sinuses using Relieva Balloon Sinuplasty System
89064686|NCT01106677|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
89064687|NCT01106677|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
89064688|NCT01106677|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
89064689|NCT01106677|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52. Placebo and sitagliptin will be given with protocol-specified doses of metformin immediate release.
89064690|NCT04309045|Experimental|DBT|Standard DBT treatment
89064691|NCT04309045|Active Comparator|DDP|dynamic deconstructive psychotherapy (DDP) treatment, is part of a trend of dynamic therapies to treat borderline personality disorder. DDP is a treatment specifically developed for a population with more severe symptoms those dealing with borderline personality disorder.
89064692|NCT04309045|Placebo Comparator|control group|patients on the waiting list for treatment, or patients in the hospital under routine care. Which will form the control group.
89064693|NCT04309279|Experimental|Zentangle group|
89064694|NCT04309279|No Intervention|Wait-list Control Group|
89064695|NCT02880397|Active Comparator|Garcinia Mangostana|The constituents of mangostana containing gel were prepared under the following proportions: Mangostana powder - 4gm, Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml.
89064696|NCT02880397|Placebo Comparator|Placebo gel|The placebo gel was prepared with Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml excluding the active ingredient mangostana powder - 4 mg and maintaining same physical properties such as color and taste.
89064697|NCT01106287|Experimental|Treatment Sequence 1|Period 1: Placebo - Period 2: 80 mg - Period 3: 100 mg - Period 4: Placebo - Period 5: 140 mg
89064698|NCT01106287|Experimental|Treatment Sequence 2|Period 1: 60 mg - Period 2: 80 mg - Period 3: 100 mg - Period 4: 120 mg - Period 5: Placebo
89064699|NCT01106287|Experimental|Treatment Sequence 3|Period 1: 60 mg - Period 2: Placebo - Period 3: 100 mg - Period 4: 120 mg - Period 5: 140 mg
89064700|NCT01106287|Experimental|Treatment Sequence 4|Period 1: 60 mg - Period 2: 80 mg - Period 3: Placebo - Period 4: 120 mg - Period 5: 140 mg
89064701|NCT04309123|Experimental|Treatment|TransAeris stimulation therapy adjunctive to continued mechanical ventilation will begin 24 hours after leaving the operating room, if subject remains on mechanical ventilation. TransAeris stimulator settings (stimulus intensity, stimulus frequency, and burst on/off) will be programmed to optimize diaphragm recruitment without compromising patient comfort.
89064702|NCT04308343|Active Comparator|Methotrexate group|
89064703|NCT04308343|Active Comparator|Letrozole group|
89064704|NCT04308343|Active Comparator|Gonadotropins releasing hormone antagonist group|
89064705|NCT01104493|Experimental|1|Single dose of monovalent vaccine
89229783|NCT03993340||1|Rescue stenting group
89064706|NCT01104493|Placebo Comparator|2|Placebo
89229784|NCT00999128|Experimental|Part 1|
89229785|NCT00999128|Experimental|Part 2|
89229786|NCT00999206|Experimental|1|
89229787|NCT00999206|Experimental|2|
89229788|NCT00999206|Experimental|3|
89229789|NCT00999206|Active Comparator|4|
89064707|NCT01104415|Experimental|Telotristat etiprate - Core Phase|Following a 2-week Run-In Period, participants received telotristat etiprate capsules at a starting dose of 150 mg, orally three times daily (TID) for 14 days in the Core Phase. Dose escalations (250 mg, 350 mg, 500 mg) occurred serially every 14 days, up to a maximum dosage of telotristat etiprate 500 mg TID, as guided by specific clinical criteria for dose escalation. Upon completion of 12 weeks of treatment, participants were eligible to receive telotristat etiprate in the optional Open-label Extension Period.
89064708|NCT01104415|Experimental|Telotristat etiprate - Extension Period|Participants received telotristat etiprate at their highest tolerated dose (250 mg or 500 mg), orally, TID for 124 weeks in the Open-label Extension Period. If neither dose was tolerated participants were discontinued from the study and completed the 2-week Follow-up Visit.
89064709|NCT04303351||0-9 missing teeth|participants with 0-9 missing teeth
89064710|NCT04303351||10-19 missing teeth|participants with 10-19 missing teeth
89064711|NCT04303351||23-31 missing teeth|participants with 23-31 missing teeth
89064712|NCT04303351||Edentulous|participants with no teeth
89064713|NCT01099579|Experimental|Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg|Patients weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by patient's weight on the day of first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
89064714|NCT01099579|Experimental|Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg|Patients weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
89064715|NCT01099579|Experimental|Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg|Patients weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
89064716|NCT01103713|Experimental|AZCQ|Azithromycin/Chloroquine
89064717|NCT01103479|No Intervention|Control|Participants will complete interviewer-administered pre- and post-test
89064718|NCT01103479|Experimental|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer screening guidelines, communication skills, and health literacy training
89064719|NCT01103479|Experimental|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational digital video disc (DVD) on CRC and CRC screening
89229790|NCT00999284|Placebo Comparator|Placebo|Sham infusion of sodium chloride 0.9%
89064720|NCT01103323|Experimental|Regorafenib (Stivarga, BAY73-4506)+BSC|Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
89064721|NCT01103323|Placebo Comparator|Placebo+BSC|Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).
89064722|NCT01103245|Active Comparator|HCTZ plus ALI 150 then ALI 300|"Hydrochlorothiazide (HCTZ) 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg (ALI 150) daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 300mg ((ALI 300) for 1 month"
89064723|NCT01103245|Active Comparator|HCTZ plus ALI 150 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25mg (SPL 25) daily for one month"
89064724|NCT01103245|Active Comparator|HCTZ plus SPL 25 then SPL 50|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 25 mg (SPL 25) daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 50 mg daily for one month"
89064725|NCT01103245|Active Comparator|HCTZ plus SPL 25 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 25 mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25 mg daily for one month"
89064726|NCT04307875||Rohingya refugee camp population|A sample of 1500 randomly selected individuals aged 18 years and above living in the Rohingya refugee camp 1E.
89064727|NCT04307875||Shamlapur refugee hosting community population|A sample of 1500 randomly selected individuals aged 18 years and above living in the refugee hosting community Shamlapur neighbouring the Rohingya refugee camps.
89229791|NCT00999284|Active Comparator|Low dose arm|Infusion of 0.3 mg/kg/h ZK200775 over 4 hours
89064728|NCT01099267||Lenalidomide|No intervention was given during this extension study which gathered survival information on participants of study NCT00065156 (Celgene study CC-5013-MDS-003). During the CC-5013-MDS-003 study, participants initially took a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle. The study was amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.
89229792|NCT00999284|Active Comparator|High dose arm|Infusion of 0.75 mg/kg/h ZK200775 over 4 hours
89229793|NCT01043224|Experimental|Clobetasol propionate plus calcipotriol|
89064729|NCT02878837|Active Comparator|DEX|Patients undergoing surgical procedures under regional anesthesia sedated with a loading dose of 1 µg/Kg of Dexmedetomidine over 10 minutes followed by continuous infusion at 0.2 to 0.8 µg/Kg/h, along with 0.5µg/Kg bolus breakthrough doses of Fentanyl as necessary to achieve a RASS score between -3 and -1.
89064730|NCT02878837|Active Comparator|MDZ|Patients undergoing surgical procedures under regional anesthesia sedated with a 0.05mg/Kg bolus dose of Midazolam, along with 0.02 mg/Kg bolus doses of Midazolam plus 0.5µg/Kg bolus doses of Fentanyl as necessary to achieve a RASS score between -3 and -1
89064731|NCT02880007|Experimental|ARM A|Dose Optimization in 3D Pulsed Dose Rate Brachytherapy
89064732|NCT01098487|Experimental|Open Label|Oral eltrombopag once daily, starting dose 50 mg (or 25 mg for subjects of East Asian ancestry).
89064733|NCT00591890|Experimental|Single Arm|
89064734|NCT02878993||Intubated infants|Recording of diaphragm EMG
89064735|NCT04328792||Prospectively validation group|Two diagnosis methods will be used in the prospective validation section, one is traditional qualitative and quantitative method, the other is artificial intelligence prediction model based on videos to compare the diagnostic efficacy.
89064736|NCT04408976||Software practices|Patients with urinary tract infection in practices using the clinical decision support software
89064737|NCT04408976||Control practices|Patients with urinary tract infection in practices not using the clinical decision support software
89064738|NCT01098097||Peginterferon alpha and ribavirin|Peginterferon alpha and ribavirin will be administered at the discretion of the treating physician, in accordance per label according to local guidelines for all participating countries.
89064739|NCT01097863|Experimental|nelfilcon A, modified inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
89064740|NCT01097863|Experimental|nelfilcon A, no inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
89064741|NCT01097863|Active Comparator|nelfilcon A, inversion indicator|Nelfilcon A commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for one week.
89064742|NCT04328636|Experimental|NebMag|Neonates with PPHN receiving nebulized magnesium sulfate and intravenous placebo
89064743|NCT04328636|Active Comparator|IVMag|Neonates with PPHN receiving intravenous magnesium sulfate and nebulized placebo
89064744|NCT02893826|Experimental|EG-1962 Group|1 dose of intracisternal EG-1962 (nimodipine microparticles) 600 mg
89229794|NCT01044238|Experimental|active medication (methylphenidate)|Condition receiving active medication: 18mg/day during week 1; 36mg/day during week 2; 54mg/day during remainder of study
89064745|NCT02893826|Active Comparator|Enteral Nimodipine Group|Up to a total of 21 days of enteral nimodipine (including nimodipine received prior to randomization)
89064746|NCT00591968|No Intervention|1|The control group will receive traditional ultrasound consults (i.e. travel to nearest tertiary center for intraabdominal sonographic evaluation and return with radiologist's report).
89064747|NCT00591968|Experimental|2|The experimental group will receive the teleultrasound service. Participants are randomly assigned to this group. All patients will receive a traditional clinical work-up. An ultrasound examination will be offered if, based on initial clinical evaluation by an attending physician, the patient is found to have symptoms consistent with any the following abnormalities: ascites, blunt abdominal trauma, cholelithiasis, cholecystitis, cholangitis, pancreatitis, hydronephrosis, abdominal aortic aneurysm, hepatitis, portal hypertension, urolithiasis, abnormal uterine bleeding, ovarian mass or torsion.
89064748|NCT00592046|Experimental|Single Arm|
89064749|NCT02893436||Curarized patients|
89229795|NCT01044238|Placebo Comparator|Placebo|Condition randomly assigned to receive placebo, provided to appear identical to active medication
89064750|NCT02893358|Active Comparator|Active treatment|Treatment will be started with allisartan isoproxil 80mg once daily taken in the morning during 8:00-9:00. After 2 months, to achieve the target BP (24h BP<130/80 mmHg, and daytime BP <135/85 mmHg, and nighttime BP <120/70 mmHg), allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan Isoproxil.
89064751|NCT02893358|Placebo Comparator|Placebo|Placebo tablets are identical to the active study drugs, with a similar schedule of administration.
89064752|NCT04388540||Jamaica|School aged children 6 - 12 years living in Jamaica
89229796|NCT01043302||Surgery+chemotherapy|Primary mass was resected and systemic chemotherapy was performed as an adjuvant treatment
89064753|NCT04388540||Trinidad and Tobago|School aged children 6 - 12 years living in Trinidad and Tobago
89064754|NCT04388540||Belize|School aged children 6 - 12 years living in Belize
89064755|NCT04388540||Barbados|School aged children 6 - 12 years living in Barbados
89064756|NCT04388540||St. Lucia|School aged children 6 - 12 years living in St. Lucia
89064757|NCT04388540||Grenada|School aged children 6 - 12 years living in Grenada
89064758|NCT04388540||St. Vincent & the Grenadines|School aged children 6 - 12 years living in St. Vincent & the Grenadines
89229797|NCT01043302||Chemotherapy|Only treated with chemotherapy
89064759|NCT04388540||Antigua|School aged children 6 - 12 years living in Antigua
89064760|NCT04388540||Dominica|School aged children 6 - 12 years living in Dominica
89064761|NCT04388540||St. Kitts and Nevis|School aged children 6 - 12 years living in St. Kitts and Nevis
89064762|NCT04386044||Hospital in-patients|Cross-sectional study of hospital in-patients admitted with COVID-19 n=200
89064763|NCT04386044||Controls (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
89229798|NCT01043380|Experimental|LZ group|
89064764|NCT04386044||Cases (case-control study arm)|Case-control study of n=800 patients prospectively recruited from primary care
89064765|NCT04328480|Active Comparator|Local standard of care plus colchicine|Local standard of care plus colchicine (specific dosage schedule)
89064766|NCT04328480|Other|Local standard of care|Local standard of care for COVID-19 SARS moderate / high-risk patients
89064767|NCT00592202|Experimental|1|Adolescents between the ages 14 through 17 with a BMI of 40 or more or with a BMI of 35 or more and with an obesity related comorbidity will undergo placement of an adjustable gastric band
89064768|NCT02893124|Experimental|PEG-IFN group|HBeAg-negative CHB patients with HBsAg <1000 IU/ mL and HBV DNA<100 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
89064769|NCT02893124|No Intervention|NAs group|CHB patients do not need to change their NAs treatment.
89064770|NCT04370132||Group of patient with liver venous deprivation|Group of patient with liver venous deprivation
89064771|NCT04370132||Group of patient with portal embolization|Group of patient with portal embolization
89064772|NCT04327778|Experimental|Music therapy|Patients will be exposed every two weeks
89064773|NCT02892968|Experimental|U/S Guided Regional Anesthesia|"Fascia-Iliaca Block(FIB) Femoral Nerve Block(FNB)~All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. EPs will then be trained to use two approaches to ultrasound (U/S) guided regional anesthesia, the fascia iliaca and femoral nerve blocks. Which block that will be used will be randomly determined at the individual patient level"
89064774|NCT02892968|No Intervention|Current Local Standard Analgesia|"All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. Physicians who are in the control group will provide current local standard of analgesic care for hip fracture patients such as the use of IV opiods with supplemental acetaminophen and non-steroidal anti-inflammatory agents until they receive training."
89064775|NCT04367792||Patients died with Covid-19 disease|Sample of patients died with Covid-19 disease and pulmonary disease
89064776|NCT04367792||Patients died with Covid-19 and cardiovascular disease|Sample of patients died with Covid-19 disease and pulmonary disease with clear cardiovascular involvement
89064777|NCT04367792||Patient died with myocarditis|Sample of patient died with different types of myocarditis without Covid-19 disease. These samples are used as control and are part of database of previously collected samples of CVPath Institute Inc.
89064778|NCT02893046||Population at Risk|Population with at least one risk factor of being infected with hepatitis C; MSM population; people in precarious situations and / or attending support from addictions care structures.
89064779|NCT02893046||Prison population|"Proposal of participation to a  consultation arrivants  by the staff of medical units correctional"
89064780|NCT04365140||positive ACD to nickel|Patients with positive epicutaneous patch test to nickel
89064781|NCT04365140||negative ACD to nickel|Patients with negative epicutaneous patch test to nickel
89064782|NCT04361864||RUTI|patients with at least 3 episodes of UTI during 2019
89064783|NCT04361864||UTI|patients with one or two episodes of UTI during 2019
89064784|NCT04357496||Participants with SARS-COV-2|Participants tested positive for SARS-COV-2 aged 60 years or older
89229799|NCT01043380|Active Comparator|L group|
89229800|NCT01044316|Active Comparator|Arm 1|
89229801|NCT01044316|Active Comparator|Arm 2|
89064785|NCT04327856||Cataract surgery group|Patients which were administrated to the Ophthalmology Clinic Medical University of Bialystok due to scheduled cataract removal surgery
89064786|NCT00592436||1|
89064787|NCT04355702||Lupus patients treated by hydroxychloroquine|Lupus patients treated by hydroxychloroquine
89064788|NCT04355702||Lupus patients not treated by hydroxychloroquine|Lupus patients not treated by hydroxychloroquine
89064789|NCT04347824||low risk|"This group has a normal urine status on admission to hospital. Abnormal urine status is defined anuric OR as 2* or more of the following findings:~urine osmolarity below normal values~leukozyturia~hematuria~albuminuria/ proteinuria * if urine is positive for nitrite or bacteria, abnormal urine status is defined as 3 or more of the findings."
89064790|NCT04347824||intermediate risk|This group has an abnormal urine status on admission to hospital WITHOUT serum-albumin below 2.0 g/dl AND WITHOUT antithrombin III level below 70%.
89064791|NCT04347824||high risk|This group has an abnormal urine status on admission to hospital PLUS serum-albumin below 2.0 g/dl OR antithrombin III level below 70%.
89064792|NCT04346342||Mechanical ventilation|COVID patients receiving invasive mechanical ventilation
89064793|NCT04345328||Roux-en-Y gastric bypass|Patients who were planned for surgery with Roux-en-Y gastric bypass and were operated
89064794|NCT04345328||Sleeve Gastrectomy|Patients who were planned for surgery with Sleeve Gastrectomy and were operated
89064795|NCT04345328||Control group|Obese patients involved in a weight loss program that focuses on diet and lifestyle changes
89064796|NCT04343846||group A|low birth weight children
89064797|NCT04343846||group B|normal birth weight children
89064798|NCT04342442||Steroid-refractory a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-refractory a GvHD
89064799|NCT04342442||Steroid-responsive a GvHD|Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-responsive a GvHD
89064800|NCT04337762||Healthy|Healthy adult individuals residing in the United States with no history of COVID-19
89064801|NCT04337762||COVID-19 Confirmed|United States adults that have tested positive for SARS-CoV-2 virus which causes the human disease COVID-19 (IE novel coronavirus) or those that have been exposed to a confirmed case and are awaiting testing
89064802|NCT02892812|Experimental|LBVE013|13-valent pneumococcal conjugate vaccine
89064803|NCT02892812|Experimental|LBVE014|14-valent pneumococcal conjugate vaccine
89064804|NCT02892812|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
89064805|NCT00592670|Experimental|1|Baseline measures followed by a randomized 6 weeks treatment of Prozac.
89064806|NCT00592670|Placebo Comparator|2|Baseline followed by a 6 week randomized treatment of placebo.
89064807|NCT00622856|Experimental|1|Psychological intervention for strengthening parental authority
89064808|NCT00622856|Active Comparator|2|Diabetes education- 5 sessions with diabetes nurse, taking place once a week
89064809|NCT00622856|No Intervention|3|Control group- regular treatment without any intervention
89064810|NCT00592748|Active Comparator|Group 1|40-44 Treatments
89064811|NCT00592748|Active Comparator|Group 2|37-40 Treatments
89064812|NCT04327232|Experimental|Active|"For patients randomized to active experimental arm: Spironolactone~Patient will receive study drug for 18 months. Study drug dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day, with 1 tablet being 25mg spironolactone. Study drugs are titrated every 3 months based on patients' potassium and eGFR blood tests results."
89064813|NCT04327232|Placebo Comparator|Control|"For patients randomized to control arm: Placebo~Patient will receive placebo for 18 months. Placebo dosages are 1 tablet alternate day, 1 tablet per day, or 2 tablets per day. Placebo are titrated every 3 months based on patients' potassium and eGFR blood tests results."
89064814|NCT00593138|Experimental|1|
89064815|NCT00593216||Healthy|Healthy volunteers devoid of any ear problems
89064816|NCT00593216||Vertigo|Patients with the symptoms of vertigo
89064817|NCT04326998|Active Comparator|non-solvent|mechanical or heat treatment
89064818|NCT04326998|Experimental|solvent|GuttaClear
89064819|NCT00593294|Experimental|A,1,I|
89064820|NCT00593294|Active Comparator|B, 2, II|
89064821|NCT00593294|Placebo Comparator|C,3,III|
89064822|NCT00593528|Active Comparator|A|Naked Stents
89064823|NCT00593528|Experimental|B|PTFE Covered Stents
89064824|NCT04327076|Experimental|Robot system intervention|"Evaluate the patient and sign the informed consent~The patient was given general anesthesia~Use magnetically guided tracheal intubation and airway cleaning robot system"
89064825|NCT02892578|Experimental|electrocardiogram|Patient will take an electrocardiogram in order to detect atrial fibrillation
89064826|NCT00593996|Placebo Comparator|1|oral placebo 3 times weekly
89064827|NCT00594074|Experimental|1|This group will receive 3.25 ounces of white wine with lunch and dinner
89064828|NCT00594074|No Intervention|2|This group receives the same amount of calories as the experimental group
89064829|NCT04329260||Pediatric population|"Children between 3 to 18 years old with severe (BMI> IOTF-30) and early (before the age of 6) obesity.~A Saliva sample for screening of the deletion Δ6-8 of LEPR gene will be performed for each child."
89064830|NCT04329260||Adult member family|The screening of the same deletion according the same procedure will be proposed to the adult family member if the child presents the deletion Δ6-8 of LEPR gene.
89064831|NCT00594152|No Intervention|1Control|Standard treatment of type 1 diabetes mellitus with 3-4 subcutaneous injections of insulin daily
89064832|NCT00594152|Experimental|Treatment|Intervention: three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to standard subcutaneous insulin.
89064833|NCT00594776||1|Patients who have received a structrual allograft or vascularized fibular autograft surgery to reconstruct their tibia, femur, ulna/radius or humerus for treatment of a bone tumor.
89064834|NCT00595010|Experimental|Managing Child Behavior|Families with a high risk for or a history of child abuse and are enrolled in Comprehensive Home-Based Services and receive services as usual, which includes SafeCare, plus Managing Child Behavior module if they report significant behavior problems with their child between the ages of 2-12.
89064835|NCT00595166||B|Speculum Sheath group. Participants all received the speculum sheath.
89064836|NCT00595322|Experimental|1|bevacizumab and radiation (IMRT)
89064837|NCT00595712|Active Comparator|A|Using Iliac crest allograft in high tibial osteotomy
89064838|NCT00595712|Active Comparator|B|Using iliac crest autograft in high tibial osteotomy
89064839|NCT00596024|Experimental|1|Daily Lutein/zeaxanthin supplementation with a meal
89064840|NCT00596024|Placebo Comparator|2|
89064841|NCT00596180||1|HBOT
89064842|NCT00596258|Experimental|A-007|Single arm open label
89064843|NCT02892266||Adolescent Transplant Recipients|"Questionnaire battery at enrollment (Participants and their parents/guardians)~Clinical data from patient's chart (6 months of retrospective data & 6 months of prospective tacrolimus trough level data)"
89064844|NCT00596336|Active Comparator|Group A CLL patients|Vaccination with current trispecific influenza vaccine Day 1
89064845|NCT00596336|Experimental|Group B CLL patients|Vaccination with current trispecific influenza vaccine Day 1, together with the application of Imiquimod cream to the vaccination site on day 2 to 6.
89064846|NCT00596336|Active Comparator|Group C volunteers|Vaccination with current trispecific influenza vaccine Day 1
89064847|NCT00596414|Placebo Comparator|1|
89064848|NCT00596414|Experimental|2|midazolam
89064849|NCT00596414|Experimental|3|midazolam + pethidine
89064850|NCT00596492|Active Comparator|High Dose|
89064851|NCT00596492|Active Comparator|Low Dose|
89064852|NCT00596570||1|Patient with atrial fibrillation who underwent PCI
89064853|NCT00596648|Experimental|Phase 1 Arm|Escalating doses of XL184 + erlotinib
89064854|NCT00596648|Experimental|Phase 2 Arm 1|XL184 + erlotinib (dose determined from Phase 1 portion of study)
89064855|NCT00596648|Experimental|Phase 2 Arm 2|XL184 administered as a single agent
89064856|NCT00622934|Active Comparator|1|
89064857|NCT00622934|Placebo Comparator|2|
89064858|NCT00596882|Other|1|Threat only message. Participants hear information about the negative health consequences of smoking
89064859|NCT00596882|Other|2|Genetic threat + threat. Participants will bear infomration about genetic influences of smoking in additon to the negative health consequences of smoking.
89064860|NCT00597194|Active Comparator|OH|Inguinal hernia operated using a classic open herniotomy(OH)
89064861|NCT00597194|Active Comparator|LH|Laparoscopic herniorraphy (LH) for inguinal hernia
89064862|NCT00597350||1|Group with diabetes mellitus
89064863|NCT02892032|Experimental|Attention Modification Training|ABMT is a newly emerging intervention that trains patients to override their tendency to focus on threatening aspects of an event and to interpret events as more neutral and therefore less stressful
89064864|NCT02892032|Placebo Comparator|No Attention Modification Training|There is no disengagement of attention from a target stimulus. Attention is divided equally between two stimuli on the screen.
89064865|NCT00597662|Experimental|1|
89064866|NCT00597662|Active Comparator|2|
89064867|NCT00597974||Patients having angioplasty (case)|Patients undergoing carotid artery angioplasty and/or stent-supported angioplasty for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
89064868|NCT00597974||Patients having angiography (control)|Patients undergoing coronary angiography for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
89064869|NCT00598052|Active Comparator|A|Escitalopram + cognitive-behavior treatment
89064870|NCT00598052|Placebo Comparator|B|Placebo + cognitive-behavior therapy
89064871|NCT04207814|Experimental|Cases|
89064872|NCT00598130|Experimental|I|patients who will be treated in accordance with standard of care
89064873|NCT00598130|Active Comparator|II|patients for which the Fibrin Fleece will be applied directly on the active bleeding site.
88821248|NCT04792073|Experimental|Avelumab and Radiation Therapy|Will receive avelumab at the FDA approved dose and schedule of 800 mg IV over 60 minutes every 2 weeks (+/- 3 days) until treatment intolerance or disease progression occurs or 2 years of study therapy have been administered; standard of care Avelumab therapy after 2 years is permitted. Comprehensive Ablative Radiation Therapy (CART) will be initiated between the first and second dose of Avelumab. Comprehensive ablative radiation therapy will be given according to guidelines.
89064874|NCT00598364||Thyroidectomy or neck dissection|Patients with thyroid cancer or benign thyroid disease (nodules or goiter) who underwent thyroidectomy and/or neck dissection as standard of care.
89064875|NCT04326296|Experimental|Experimental Group|PD-L1 Monoclonal Antibody Combined With Lenalidomide
89064876|NCT00598676|Experimental|BPRES|biodegradable polymer rapamycin-eluting stent
89064877|NCT00598676|Active Comparator|PPRES|permanent polymer rapamycin-eluting stent
89064878|NCT00598676|Active Comparator|PPEES|permanent polymer everolimus-eluting stent
89064879|NCT04326218|Other|Cohort|All patients included will have to be taken blood samples
89064880|NCT00598910|Experimental|A|
89064881|NCT00598910|Placebo Comparator|B|
89064882|NCT04326374|Experimental|TransCon hGH|"TransCon hGH will be self-administered or injected by parents once weekly. The dose will be adjusted based on subject's weight.~The treatment will continue 52 weeks."
89064883|NCT04326374|Active Comparator|Daily hGH|"Daily hGH will be self-administered or injected by parents once daily. The dose will be adjusted based on subject's weight.~The treatment will continue 52 weeks."
89064884|NCT04326140|Experimental|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
89064885|NCT04326140|Sham Comparator|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
89064886|NCT00599066||Study cases|Application of a second M-Entropy probe on the forehead of the patient; at the end the patient will have 2 probes on the forehead, one in the right and one in the left.
89064887|NCT00599144|Experimental|1|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
89064888|NCT00599144|Experimental|2|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
89064889|NCT00599144|No Intervention|3|Group3: control group without any local anesthetic use.
89064890|NCT00599222|Active Comparator|TTT|TTT is given every three months
89064891|NCT00599222|Sham Comparator|Sham TTT|Sham TTT is given every three months
89064892|NCT01326962|Experimental|Single Arm|
89064893|NCT01326728||Allogeneic Stem Cell Transplant|Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells)
89064894|NCT00599378|Experimental|1|Implementation Intentions-based telephone counseling. Partnership intervention between rural Primary Care Physicians, their patients, and CRC Information Specialists using an implementation intentions based approach.
89064895|NCT00599378|No Intervention|2|Healthy Living information on Physical Activity and Nutrition
89064896|NCT01097707|Experimental|1mg LY500307|
89064897|NCT01097707|Experimental|3mg LY500307|
89064898|NCT01097707|Experimental|10mg LY500307|
89064899|NCT01097707|Experimental|25mg LY500307|
89064900|NCT01097707|Placebo Comparator|Placebo|
89064901|NCT00599456|Experimental|1|Omega 3 vitamin supplements
89064902|NCT00599456|Placebo Comparator|2|Placebo capsule
89064903|NCT00599534|Active Comparator|1|4 mg tablet for 16 weeks
89064904|NCT00599534|Placebo Comparator|2|5 mg for 16 weeks
89064905|NCT00599612|Experimental|Healthy male volunteers|Six healthy male volunteers aged between 30-60 years old will be recruited for this study,
89064906|NCT00599690|Experimental|A|Epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
89064907|NCT02878759|Experimental|Wristbot|WristBot will be used as diagnostic tool to evaluate the novel technology and the associated protocol for proprioception quantification during rehabilitation. The main objective is to provide clinicians with a reliable instrument able to overcome the limitations in proprioceptive measurement by current clinical methodologies.
89064908|NCT00600002|Experimental|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
89064909|NCT02891720|Active Comparator|ARM A: Proteus Sensor System (PSS) First|ARM A will receive Proteus Sensor System (PSS) first. At 12-week intervals participants will crossover to the next condition.
89064910|NCT02891720|No Intervention|ARM B: SOC First|ARM B will 12 weeks of FTC/TDS standard of care (SOC) first. At 12-week intervals participants will crossover to the next condition.
89064911|NCT00600158|Experimental|2|lidocaine intravenously
89064912|NCT00600158|Active Comparator|1|epidural local anesthetic
89064913|NCT04325984||Dexamethasone group|Group of patients receiving dexamethasone 8 mg as part of the multimodal analgesia.
89064914|NCT04325984||Control group|Group of patients receiving multimodal analgesia, not comprising dexamethasone; moreover, ondansetron 4 mg is administered for the control of PONV.
89064915|NCT00600314||High risk|Patients who are at high risk of developing acute or chronic GVHD
89064916|NCT00600314||GVHD|Patients who currently have either grade II or greater acute GVHD, or clinically extensive chronic GVHD
89064917|NCT02891642||Malignancy, Serous effusion|Analysis of serous effusion through immunomagnetic detection device
89064918|NCT00600392||1|patients who meet criteria for CRT-D implantation
89064919|NCT00600470|Experimental|1|Doctor-office collaborative care management
89064920|NCT00600470|Active Comparator|2|"Treatment as usual: psychoeducation and outside referral to treatment (PORT). In papers, this arm is referred to as Enhanced Usual Care (EUC)."
89064921|NCT04326062|Experimental|Main Study|A pharmacist will join the practice team for six months.
89064922|NCT04326062|Experimental|PROM Study|A nested Patient Reported Outcome Measure (PROM) study will be undertaken during month four and five of the six-month intervention period to explore the impact of the intervention in older adults (aged ≥65 years).
89064923|NCT00600548|Experimental|1.1|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Miltefosine.
89064924|NCT00600548|Active Comparator|1.2|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Meglumine antimoniate (standard treatment).
89064925|NCT00600548|Experimental|2.1|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Miltefosine.
89064926|NCT00600548|Active Comparator|2.2|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Meglumine antimoniate (standard treatment).
89064927|NCT00623090|Experimental|1 Website|Participants receive the Login information for the Internet we developed on prostate cancer screening.
89064928|NCT00623090|Active Comparator|2 Booklet|Participants receive the education booklet we developed on prostate cancer screening.
89064929|NCT00623090|Placebo Comparator|3 Usual Care|Usual care: participants receive no intervention.
89064930|NCT00623168|Experimental|Treatment Only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Ribavirin.
89064931|NCT00623246|Active Comparator|1|Participants will receive motivational enhancement therapy (MET) for 12 weeks.
89064932|NCT00623246|Active Comparator|2|Participants will receive educational therapy (ED) for 12 weeks.
89064933|NCT00623246|No Intervention|3|Participants will receive standard clinical care.
89064934|NCT00600860||MDS patients|Patients with MDS according to current WHO criteria and International Prognostic Scoring System (IPSS) classification
89222051|NCT04142814|Experimental|T-PEP|"Each T-PEP session includes 10 inspiratory/expiratory cycles, repeated 3 times and interspersed by a pause of about 3 minutes.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (as detected by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for the outcome stabilization, as confirmed also by arterial-blood gas test (ABG), spirometry, chest X-ray and chest ultrasound.~T-PEP sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks after the attainment of a stabilized effective pulmonary ventilation."
89222052|NCT04142814|Active Comparator|IPV|"Each IPV session includes 3 treatment cycles, interspersed with a pause, consisting of a first high-frequency steps, lasting about 5 minutes, immediately followed by a second low-frequency step lasting approximately one minute.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for outcome stabilization, as confirmed by ABG test, spirometry, chest X-ray and chest ultrasound.~IPV sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks, after the attainment of a stabilized effective pulmonary ventilation."
89222053|NCT04010760||PE confirmed|Patients admitted with confirmed pulmonary embolism.
89222054|NCT04010760||PE suspected|Patients admitted with suspected, but not confirmed pulmonary embolism.
89222055|NCT04010760||Controls|Healthy controls same gender and age (within af range of 10 years) as PE patients
89222056|NCT00955890|No Intervention|control arm|anthracycline chemotherapy only
89222057|NCT00955890|Experimental|low dose dexrazoxane group|anthracycline chemotherapy plus low dose dexrazoxane(10:1)
89222058|NCT00955890|Experimental|middle dose dexrazoxane group|anthracycline chemotherapy plus middle dose dexrazoxane(15:1)
88821249|NCT04791943|Experimental|Experimental Treatment - Melatonin|Premedication for three nights with 10mg melatonin
89064935|NCT00601094|Experimental|experimental arm|
89064936|NCT02891486||Incidence of surgical site infection|The number of spinal surgery patients with surgical site infections.
89064937|NCT01326026|Experimental|IDeg Simple|
89064938|NCT01326026|Experimental|IDeg Step wise|
89064939|NCT01097629|Experimental|Suvorexant HD|Drug
89064940|NCT01097629|Experimental|Suvorexant LD|Drug
89064941|NCT01097629|Placebo Comparator|Placebo|Placebo Comparator
89064942|NCT04325516|Experimental|People with a lower limb amputation|"Participants will perform four tasks in a randomized order:~sit to stand~dorsi flexion of the foot~knee extension~hip extension"
88821250|NCT04791943|Placebo Comparator|Control Treatment - Lactose|Premedication for three nights with lactose capsules
89064943|NCT04325516|Experimental|Able bodied individuals|"Participants will perform four tasks in a randomized order:~sit to stand~dorsi flexion of the foot~knee extension~hip extension"
89064944|NCT04127162||alive|
89064945|NCT04127162||dead|
89222059|NCT00956046|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
89064946|NCT04308031|Experimental|Ivabradine|Subject will be randomly assigned to either Ivabradine or Digoxin group. Ivabradine starting dose is 2.5 mg twice daily(BID). ECG will be performed at each visit during the treatment phase and dose will be adjusted based on the heart rate result from the ECG. Total treatment phase is 16 weeks ( 4 months).
88812658|NCT00891176|Experimental|Synflorix-NeisVac-C Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
89064947|NCT04308031|Active Comparator|Digoxin|Subject will be randomly assigned to either Ivabradine or Digoxin group. Digoxin starting dose is 0.125mg once daily(QD) in estimated Glomerular filtration rate(eGFR)>60， 0.125mg every other day (QOD) in estimated Glomerular filtration rate(eGFR)<60. Dose adjustment will be based on heart rate result from ECG performed at each treatment visit and Digoxin level from blood sample collected from each visit during treatment phase. Total treatment phase is 16 weeks ( 4 months).
89064948|NCT01324622|Active Comparator|Laminectomy|Control
89064949|NCT01324622|Active Comparator|Laminoplasty|Treatment group
89064950|NCT00626119||Control|
89064951|NCT00626119||diseased|
89064952|NCT01097005||Klaricid|Those with an exposure
89064953|NCT01096849|Experimental|plazomicin (10 mg/kg)|Patients received two intravenous (IV) infusions daily for 5 consecutive days: 10 milligrams per kilogram (mg/kg) plazomicin followed by placebo.
89064954|NCT01096849|Experimental|plazomicin (15 mg/kg)|Patients received two IV infusions daily for 5 consecutive days: 15 mg/kg plazomicin followed by placebo.
89064955|NCT01096849|Active Comparator|levofloxacin|Patients received two IV infusions daily for 5 consecutive days: placebo followed by 750 milligrams (mg) levofloxacin.
89064956|NCT02878447|Experimental|External Beam Radiotherapy|Patients will receive radiotherapy (3.5Gy weekly for 5 fractions to a maximum of 17G) prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue
89064957|NCT02878447|No Intervention|Control|Patients will receive best medical care.
89064958|NCT04307173|Experimental|Cohort 1|9 subjects for MAD 1 cohort. 6 subjects on KBL693, 3 subjects on placebo.
89064959|NCT04307173|Experimental|Cohort 2|9 subjects for MAD 2 cohort. 6 subjects on KBL693, 3 subjects on placebo.
89064960|NCT04915261|Active Comparator|Strict Arm|"The strict arm group will be given the following restrictions. These restrictions are the current institutional protocol at the study site and falls within common practice pattern across Canada:~No arm or shoulder movement x 24 hours~No movement of affected arm overhead x 8 weeks~No lifting anything heavier than 5 lbs (2.5kg) and avoid any kind of sports or other vigorous activities including golf, tennis, swimming or sweeping x 8 weeks~Avoid any kind of shovelling x 8 weeks"
89064961|NCT04915261|Active Comparator|Lenient Arm|"The lenient arm restriction group will be given the following restrictions. The justification for the selected lenient restriction is based on the current recommendations at a Canadian center as identified by the national survey:~No shoveling 7 days,~No golfing/swimming/tennis 14 days~No other restrictions (overhead activity and weight lifting no limitation)"
89064962|NCT01324388|Experimental|LY2189265 + Lisinopril|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
89064963|NCT01324388|Placebo Comparator|Placebo + Lisinopril|"Placebo: 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
89064964|NCT01324388|Experimental|LY2189265 (Treatment 1)/Metoprolol + LY2189265 (Treatment 2)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 1 of Treatment 1 and on Day 5 of Treatment 2 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 1 of Treatment 1 to Day 1 of Treatment 2 in Part 2 of the study)."
89064965|NCT01324388|Experimental|Metoprolol + LY2189265 (Treatment 2)/LY2189265 (Treatment 1)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 5 of Treatment 2 and on Day 1 of Treatment 1 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 7 of Treatment 2 to Day 1 of Treatment 1 in Part 2 of the study)."
89064966|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
89064967|NCT01102777|Other|Internet-mediated Walking Program|"participants in the intervention arm are asked to participate in a walking program~automated internet-mediated walking program: intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress"
89064968|NCT02878681|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab for six months
89064969|NCT02878681|Experimental|Group 2|Monthly intravitreal injections of 2 mg aflibercept for the initial three months followed by monthly intravitreal injections of 0.5 mg ranibizumab for the next three months.
89064970|NCT02878681|Experimental|Group 3|Monthly injections of 2 mg aflibercept for six months
89064971|NCT02879461|Active Comparator|Lumbar Decompression plus Physical Therapy|First group will be submitted to lumbar decompression L3 to S1 and physical therapy with exercise Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
89064972|NCT02879461|Active Comparator|Physical Therapy|Second group physical therapy alone, with exercises Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
89064973|NCT01324310|Experimental|Romidepsin and ketoconazole|"Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.~Ketoconazole 400 mg oral once daily on Days 4-8"
89064974|NCT05645666|Experimental|Well being therapy|The group of 16 which recieved well-being therapy
89064975|NCT05645666|No Intervention|Control group|The group of 16 which did not recieve well-being therapy
89222060|NCT00956046|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
89222061|NCT00956046|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
89690126|NCT02245945|Placebo Comparator|hydroxyethylcellulose (HEC) placebo gel|"Participants will be instructed to use HEC placebo gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
89690127|NCT04531761|Experimental|Immediate Access to Parent Support Program|
89690128|NCT04531761|No Intervention|Waitlist Control|
89690129|NCT03018613|Active Comparator|treatment for part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with chronic functional constipation in part 1.
89690130|NCT03018613|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline will be used in patients with chronic functional constipation in part 2 according to associated guidelines.
89690131|NCT04342845|Experimental|Motivational interviewing|The intervention group received an education program in small groups that included no more than ten members. The content was designed based on MI theory and the theory of patient empowerment. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise. Each module started with a brief introduction to relevant background knowledge, which was followed by small-group discussions about personal barriers and techniques for overcoming challenges. During the small group discussions, educators acted as MI facilitators, using group MI techniques to strengthen participants' motivation.
89690132|NCT04342845|Placebo Comparator|Traditional lectures|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI.
89690133|NCT03018535|Experimental|RITUXIMAB|1 g. IV of Rituximab on days 1 and 15
89690134|NCT03018535|Active Comparator|Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for 3 doses; oral methylprednisolone (0.4mg/kg/day) or prednisone (0.5/mg/kg/day); Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
89690135|NCT02160847|Experimental|DRIVE program|Participants in the experimental group will receive the DRIVE curriculum (15 sessions) via weekly sessions conducted in their home by a DRIVE provider.
89690136|NCT02160847|No Intervention|Control Group|"The parents in the control group will be mailed information on nutrition, physical activity, and parent-child interactions. Information on nutrition will include guidelines provided by the MyPlate website (http://www.choosemyplate.gov/preschoolers.html) in addition to information on proper nutrition and suggest levels of physical activity for preschoolers. Lastly, parents will be provided with the free publication, Adventures in Parenting: How responding, Preventing, Monitoring, Mentoring, and Modeling Can Help You Be A Successful Parent, authored by National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development. Information covered in this document includes effective parenting strategies for children at specific ages."
89690137|NCT00360477|Active Comparator|1|Floseal
89690138|NCT00360477|Active Comparator|2|Cope-Loop/Nephrostomy Tube
89690139|NCT00360477|Active Comparator|3|Fascial Stitch
89690140|NCT02975739|Experimental|Holmium-166 microspheres|Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.
89690141|NCT05386069|No Intervention|Control Arm|Routine Care per Anesthiologist/cRNA
89690142|NCT05386069|Active Comparator|Treatment Arm|Patients to receive standard weight-based ketamine bolus (0.5 mg/kg) at start of procedure, withhold opioids in post-operative period unless rescue medications fail
89690143|NCT00989911|Experimental|Bosentan|Bosentan
89690144|NCT05343091||Pulmonary Hypertension patients|patients with diagnosis of Pulmonary Hypertension from group 1 and 4 by right heart catheterization
89690145|NCT05311891||Retrospective|12000 participants positive for SARS-COV-2
89690146|NCT05311891||Prospective|600 participants positive for SARS-COV-2
89690147|NCT04038957|Experimental|SEP-363856|SEP-363856 50mg, 75mg flexible dosing, dosed once daily
89690148|NCT05189119||LVFgroup|patients with AECOPD and left ventricular failure
89690149|NCT05189119||non LVF group|patients with AECOPD and whithout left ventricular failure
89690150|NCT02977065|Active Comparator|Atorvastatin 20 mg|To administrate Atorvastatin 20 mg and 4 Placebos, PO, QD for 4weeks
89690151|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 50 mg|To administrate Atorvastatin 20 mg, CKD-519 50 mg and 3 Placebos, PO, QD for 4weeks
89690152|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 100 mg|To administrate Atorvastatin 20 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
89690153|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 200 mg|To administrate Atorvastatin 20 mg, CKD-519 200 mg and 2 Placebos, PO, QD for 4weeks
89690154|NCT02977065|Active Comparator|Rosuvastatin 10 mg|To administrate Rosuvastatin 10 mg and 4 Placebos, PO, QD for 4weeks
89690155|NCT02977065|Experimental|Rosuvastatin 10 mg + CKD-519 100 mg|To administrate Rosuvastatin 10 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
89690156|NCT03018769||chronic SCAD|
89690157|NCT04031547|Active Comparator|Active tES-fMRI|
89690158|NCT04031547|Sham Comparator|Inactive/Sham tES-fMRI|
89064976|NCT04325672|Experimental|Convalescent Plasma Group|Subjects will receive 1-2 units (300-600 mL) of plasma with an anti-SARS-CoV-2 titer of >1:64.
89064977|NCT01102231|Experimental|A|Chemoradiotherapy
89690159|NCT03018379||Assessment of body composition|The collection of the samples and the analyses were undertaken according to the guidelines of the International Atomic Energy Agency. In brief, after having emptied the bladder, each participant provided a predose saliva sample using a cotton ball.A 99.8 % deuterium dose of 0.5 g per kg body weight was given orally to the participant. The postdose sample was collected from 3h to 4h after the administration of the dose. The saliva samples were stored at 20°C until analysis by Fourier transform infrared spectroscopy (FTIR).
89690160|NCT03018379||Assessment of energy expenditure|"Each participant provided a predose urine sample. A dose of doubly labelled water 2.625 ml per kg body weight was given orally to the participant.~The post dose sample was collected at 3h to 4h , and on days 3, 7 and 14 after dosing. An aliquot of those samples were stored at 20°C in tightly sealed containers until analysis by isotope-ratio mass spectrometry (IRMS)."
89690161|NCT03018379||Assessment of physical activity|The participants were instructed to wear the accelerometer triaxial (GT3X+) attached to an elasticized belt around the waist, once they woke up until bed time at night for 7 consecutive days and to remove the accelerometer any time they were to perform activities that involve the use of water and when going to bed.
89064978|NCT04308733|Active Comparator|real tDCS|30 patients will be treated with real anodal tDCS over the contralateral pharyngeal motor cortex
89064979|NCT04308733|Sham Comparator|sham tDCS|30 patients will be treated with sham tDCS over the contralateral pharyngeal motor cortex
89064980|NCT02879539|Experimental|MP3000-ACE strategy|MP3000 sound coding strategy or ACE strategy with lower stimulation rate
89064981|NCT01094743|Other|galyfilcon A prototype lens / lotrafilcon B lens|The galyfilcon A prototype lenses will be worn during the first period and lotrafilcon B lenses will be worn during the second period. Each period consists of daily lens wear for one week.
89064982|NCT01094743|Other|lotrafilcon B lens / galyfilcon A prototype lens|The lotrafilcon B lenses will be worn during the first period and galyfilcon A prototype lenses will be worn during the second period. Each period consists of daily lens wear for one week.
89064983|NCT01095835|Experimental|PEG-IFN48|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
89064984|NCT01095835|Experimental|PEG-IFN96|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
89064985|NCT01095835|Experimental|PEG-IFN+LAM96|Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).
89064986|NCT02878525|Experimental|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
89064987|NCT02878525|Active Comparator|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
89064988|NCT04308577|Experimental|Ketogenic diet with MCT|Ketogenic Diet supplemented with MCT everyday for 6 weeks.
89064989|NCT04308811|Other|platelet rich plasma group|intrauterine platelet rich plasma injection and intrauterine balloon insertion after hysteroscopic lysis of intrauterine adhesions
89690162|NCT04343937||Retrolaminar block|Retrolaminar block for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
89690163|NCT04343937||İntravenous analgesia|İntravenous analgesia for postoperative pain managment in patients undergoing lumbar herniectomy under general anesthesia
89690164|NCT04886427||Quickscan for patients and their kin|Patients and/or kin who are treated in the hospitals will be invited to fill in the quickscan.
89690165|NCT04886427||Quickscan for healthcare professionals|Healthcare professionals working in the hospitals will be invited to fill in the quickscan.
89690166|NCT03146806|Experimental|Intranasal ketamine treatment|Study participants who are receiving intranasal ketamine treatments.
89690167|NCT03090958|Experimental|AllyQuest Pilot|The research assistant (RA) will meet with participants in person to explain the study in detail, facilitate app download and login onto participants' phones, and provide an app site tour to highlight features. Participants will complete a baseline demographic and risk assessment administered via a computer assisted survey instrument (CASI). At the end of the one-month field trial, participants will undergo a debriefing session to evaluate their experience using the app, overall satisfaction and any problems they encountered.
89690168|NCT04468516|Experimental|Treatment|Intervention is applied to the C1 of the spine.
89690169|NCT04468516|Placebo Comparator|Placebo|Intervention is applied in reduced intensity to the trapezius muscle.
89690170|NCT04468516|No Intervention|Waitlist period|Participants will have a 1 month waitlist period where no intervention takes place.
89690171|NCT04706806|Experimental|liquid vinegar|2 tablespoons (diluted in water) taken twice daily with meals
89690172|NCT04706806|Placebo Comparator|vinegar pill|1 vinegar pill taken daily
89690173|NCT00362349|Experimental|1|IVIg
89690174|NCT03997929||CASE (intra abdominal candidiasis)|Critically ill patients with a confirmed diagnosis of intra abdominal candidiasis (IAC) Definition of IAC : sterilely collected peritoneal fluid cultures that are positive for Candida spp. as determined by the signs and symptoms consistent with an active infection
89690175|NCT03997929||CONTROL (bacterial intra abdominal infection)|Critically ill patients with a non candida intra abdominal infection (bacterial peritonitis)
89690176|NCT03438357||Patients with multiple sclerosis|
89690177|NCT02975427||Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
89690178|NCT02975583|Active Comparator|Experimental: Vorapaxar|Drug: Vorapaxar 2.08 mg orally daily for a year Other name: Zontivity
89690179|NCT02975583|Placebo Comparator|Placebo Comparator: Placebos|Medication: Matching Placebo Daily tablet
89690180|NCT03983421|No Intervention|Treatment as Usual|Treatment as usual enhanced with a brief psychosis literacy training (45-60 minutes) for the counselors at the university's student health and counseling center
89690181|NCT03983421|Other|Screening|Implementation of the Prodromal Questionnaire - Brief, which is a screening tool to detect risk of psychosis.
89690182|NCT03983421|Other|Screening Plus Warm Hand-Off|Addition of a warm hand-off to coordinated specialty care (CSC) for those determined eligible on the screening tool.
89064990|NCT04308811|Other|amniotic membrane graft group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon covered by freeze-dried amniotic membranes.
89064991|NCT04308811|Other|intrauterine balloon group|the clinician will perform hysteroscopic lysis of intrauterine adhesions followed by application of intrauterine balloon
89064992|NCT02879773||Lung cancer|Patients undergoing thoracic surgery for suspected or confirmed lung cancer; including wedge resection, segmentectomy, lobectomy, bilobectomy or pneumonectomy. CTPVe will be modelled to predict postoperative lung function.
89222062|NCT00454246|Experimental|methoxy polyethylene glycol-epoetin beta|"120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
89222063|NCT00454246|Active Comparator|Epoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
89064993|NCT02879773||Emphysema|Patients undergoing assessment of emphysema/chronic obstructive pulmonary disease (COPD) for potential surgical intervention; including lung volume reduction surgery, endobronchial valve insertion or endobronchial coil insertion. CTPVe will be modelled to predict postoperative lung function.
89064994|NCT02879773||Interstitial lung disease|Patients undergoing assessment or treatment of suspected or confirmed interstitial lung disease. CTPVe will be modelled to aid diagnosis of the subtype of interstitial lung disease confirmed by histological diagnosis.
89064995|NCT04908865|Experimental|Pediatric participants receiving belimumab|
89064996|NCT04308421|Experimental|Low level red light/laser|Patients will be treated twice a week for 12 weeks with low irradiation 650 nm +/- 5 nm red light on one randomly allocated side of the face or body
89064997|NCT04308421|No Intervention|Control side|An affected area on the contralateral side of the face or body or within a single patch will not be treated
89064998|NCT01324232|Placebo Comparator|Placebo|
89064999|NCT01324232|Experimental|AVP-923-45|
89065000|NCT01324232|Experimental|AVP-923-30|
89065001|NCT01324232|Experimental|AVP-923-20|
89065002|NCT02878291|Experimental|High dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,40μg/dose
89065003|NCT02878291|Experimental|low dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,20μg/dose
89065004|NCT04841083|Experimental|Allay lamp (narrow band green light)|Subjects who purchased the Allay Lamp are asked to document the effects of spending time in the narrow band of green light it emits, on their headache or any of its associated symptoms.
89065005|NCT04306783|Experimental|Arm A: In-Home Sensor Monitoring|Older adults with cancer undergoing systemic cancer treatment will undergo passive monitoring with motion sensors and bed sensor. Passive infrared (PIR) motion sensors will be installed in their homes to detect presence in a particular room (e.g., bathroom or kitchen) as well as for specific activities. There will also be a bed sensor, which is a pneumatic strip installed under the bed linens, which measures displacement of the resident's upper torso as he or she lies on the bed. Participants will complete a baseline primarily self-administered survey, an abbreviated assessment with each follow up clinic visit (at least once per month) for 6 months of follow up and a final end of study assessment.
89229802|NCT01044394|Experimental|same day, reduced volume PEG-ELS prep|Patients with colonoscopies scheduled in the afternoon will complete 2 liters of PEG-ELS solution the morning of their colonoscopy.
89065006|NCT04306783|No Intervention|Arm B: Survey Only|Patients that choose to not proceed with in-home sensor monitoring will be asked to complete a brief survey that explores attitudes regarding in-home sensor monitoring
89065007|NCT05350891|Experimental|endoscopic surgery combined with adjuvant immunotherapy|
89065008|NCT01094119|Active Comparator|Bair Hugger heated blanket|Patients will be warmed during surgery with the Bair Hugger heated blanket.
89065009|NCT01094119|Active Comparator|LMA PerfecTemp system|Patients will be warmed during surgery with the PerfecTemp heated pad .
89065010|NCT01323920|Experimental|Velcade/Tac/MTX|"Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m^2 IV~Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid~Drug: Methotrexate. Methotrexate 15 mg/m^2 IV"
89065011|NCT01093885|Other|open label: medication Ambrisentan|"Open label study of Ambrisentan.~Ambrisentan will begin at 5mg daily for the first month.~Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week. Subjects will continue their present dose and schedule of disease modifying/antifibrotic medication for the duration of the study.~** Dose escalation was attempted however none of the patients were able to increase. Therefore all subjects remained on 5 mg daily throughout the study. 12 patients on mycophenolate mofetil, 2 on mycophenolic acid and one on methotrexate"
89065012|NCT01101997|Experimental|Experimental: Abdomen Treatment Group|All subjects were treated on the abdomen with the CoolSculpting system.
89222064|NCT00454246|Active Comparator|Darbepoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
89222065|NCT00956124||uveitic patients|
89222066|NCT00956124||patients with diabetes|
89222067|NCT04717284|Experimental|Self-compassion intervention (SCI)|Self-compassion prompt.
89222068|NCT04717284|Other|Control condition|Neutral prompt during the initial administration and no intervention during the two-week follow-up.
89222069|NCT00434590|Experimental|Full Dose Myfortic® and Reduced Dose Neoral®|The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
89222070|NCT00434590|Active Comparator|Standard Dose of Myfortic® and Standard Dose of CsA-ME|Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.
89222071|NCT01563276||Progressive Supranuclear Palsy|Patients with a diagnosis of probable or possible PSP as defined by the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) diagnostic criteria.
89065013|NCT00597597|Experimental|Open label Erlotinib|Open label; In this open label study, all enrolled subjects receive active drug, Erlotinib
89065014|NCT00597831||A|All patients in the Rijnstate Hospital with an indication for unilateral ECT treatment and a major depression or psychotic depression according to DSM IV-TR criteria.
89065015|NCT02891967|Other|Bulk full composite (3M)|bulk fill composite in posterior class one cavities
89065016|NCT02891967|Other|Incremental packing composite resin|Nano resin composite (K Z350 xt) restoration in class one cavities
89065017|NCT00597987||1|RNA samples
89065018|NCT02892045||MMG versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus Mechanomyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg.
89065019|NCT02892045||TOFWatch versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus TOF-Watch Acceleromyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg
89065020|NCT04326621|Experimental|PRT group|pressure Release Technique and exercises
89065021|NCT04326621|Active Comparator|Exercises group|Only exercises
89065022|NCT04207827|Experimental|xSmoker app|"The xSmoker app was developed with European Commission funding. xSmoker is a digital health coaching mobile app that helps individuals stop smoking and remain smoke free. The initial version of the xSmoker application was received from the developers and translated into Romanian by the research team. The content has been divided into three main sections: Daily Tips (approximately 630 items), which includes information on the beneficial effects of quitting smoking, Panic Tips (approximately 100 items), which can be accessed at that time when risk of smoking relapse is high, as well as a section called Library (about 120 items), where detailed information on the topics included in the first two sections is provided."
89065023|NCT04207827|Experimental|xSmoker app + SMSs|The xSmoker app + phone text messages with content based on the Motivation and Problem Solving approach and informed by our prior work. The investigators developed six categories of messages sent to participants: (1)Importance and trust, (2)Fear of relapse, (3)Partner support, (4)Breastfeeding, (5)The need to smoke, and (6)Relapse. Four major objectives were established based on the content of the SMS text messages, with the help of the literature: (1)supporting motivation, (2)supporting self-efficacy, (3)supporting dyadic effectiveness, and (4)developing problem-solving skills. The messages were delivered using Textit, a platform for visually building interactive SMS applications (htpps://textit.in). All the messages were uploaded in the platform and different flows and sub-flows were created for every day of the intervention to automatize the process of SMS delivery. A combination of trigger words and skip patterns was used in order to tailor the messages.
89065024|NCT04207827|Other|Control|Usual postnatal care
89065025|NCT04127565||Pre-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2013 to March 2014.~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units."
89065026|NCT04127565||Post-implementation period|"All emergency medical service missions (EMS) in the city of Aachen (Germany) from April 2015 to March 2016.~Analysis of all ambulance calls and fraction of calls with support by an physician-staffed EMS unit, help of neighboring EMS units and helicopter emergency medical service units.~Additionally analysis of all ambulance calls with telemedical support."
89065027|NCT00598299||A|Healthy adult serum
89065028|NCT00598299||B|cord blood serum
89065029|NCT00598377|Active Comparator|1|Patients with autosomal dominant polycystic kidney disease
89065030|NCT00598377|Active Comparator|2|Healthy subjects
89065031|NCT04326543||ADHD and typically developing controls|120 subject: 53 with an ADHD clinical diagnosis and 57 typically developing controls aged between 3 and 16 years old.
89222072|NCT01563276||Parkinson's Disease|"Idiopathic PD according to the UK Parkinsons Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)"
89222073|NCT01563276||Healthy Control|
89065032|NCT04326387||Research Participants (Patients)|"Inpatients symptomatic of suspected COVID-19 Baseline swab of nose/throat, nasopharyx, or endotracheal tube aspirate. SAMBA II point of care test on this swab.~Standard of care bloods taken for PHE and additional confirmatory diagnostic PCR assessment.~Serum antibody tests on any excess blood tests during inpatient stay for immune response monitoring.~Outcome assessment at 1 month"
89065033|NCT00598533|Experimental|Dual-DES|Rapamycin + Probucol-eluting stent
89065034|NCT00598533|Active Comparator|ZES|Polymer based Zotarolimus-eluting stent
89065035|NCT00598845||Consecutive numbers|Patients with endometrial cancer
89065036|NCT04207671|Other|Omission of chest tube|After wedge resection and the air-leak test, patients will receive complete omission of chest tube and directly close the incision.
89065037|NCT04207671|Experimental|Improved drainage strategy|After wedge resection and the air-leak test, patients willreceive a two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-removal.
89065038|NCT00599703||1|neurosurgical patients
89065039|NCT00599781|Experimental|PBL/HSC|
89065040|NCT00599859|Active Comparator|1|Participants in arm 1 are grouped as lactose digesters based on genetic analysis and breath hydrogen results. In discrepant cases the genetic status is accepted. Arm 1 is initially withdrawn from dairy foods(lactose) and then asked to consume lactose 50g in divided doses mixed in water for 2 weeks.
89065041|NCT00599859|Active Comparator|2|Arm 2 are lactose maldigesters: 2 interventions are a. withdrawal from lactose for 2 weeks and b. consumption of 50g lactose in divided doses mixed in water for a 2 week period.
89065042|NCT00599937|No Intervention|ATRA ->Chemo|Patients 65 years of age with a WBC count less than 5,000 were randomized to receive the reference ATRA treatment of our previous trial (APL91 trial), ie, 45 mg/m2/d ATRA followed by CT or ATRA plus CT (ATRA+CT). In the ATRA followed byCT group, patients received 45 mg/m2/d ATRA orally until CR, with a maximum of 90 days. After CR achievement, they received a course of 60 mg/m2/d daunorubicin (DNR) for 3 days and 200 mg/m2/d AraC for 7 days (course I). However, course I was added to ATRA if the WBC count was increased to greater than 6,000, 10,000, or 15,000 by day 5, 10, and 15 of ATRA treatment, respectively, because, from our experience, patients were at risk of ATRA syndrome above those thresholds.
89065043|NCT00599937|Experimental|ATRA+CT|Patients randomized to the ATRA+CT group received the same combination of ATRA and CT, with course I of CT starting on day 3 of ATRA treatment. This 48-hour interval before onset of CT was based on our previous report, because it allowed correction of coagulopathy.
89065044|NCT00599937|No Intervention|High WBC|Patients with a WBC count greater than 5,000 at presentation (irrespective of their age) and patients 66 to 75 years of age with a WBC count 5,000 were not randomized but received ATRA plus CT course I from day 1 (high WBC group) and the same schedule as in the ATRA->CT group (elderly group), respectively.
89065045|NCT00599937|No Intervention|no maintenance|No maintenance
89065046|NCT00599937|Experimental|maintenance ATRA|Intermitent ATRA as maintenance
89065047|NCT00599937|Experimental|maintenance Cxt|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) as maintenance
89065048|NCT00599937|Experimental|maintenance both|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) AND ATRA as maintenance
89065049|NCT02891421|Other|Therapeutic Horseback Riding|Therapeutic Horseback Riding: Veterans were matched to a horse by the instructor and occupational therapist for best fit and the same horse was ridden each week
89065050|NCT02891421|Other|Standard Care|Participants received standard care.
89065051|NCT00600093|Experimental|A|
89065052|NCT00600327|Experimental|1|
89065053|NCT00600405|Experimental|I|Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.
89065054|NCT00600405|Other|II|Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.
89065055|NCT00600561|Active Comparator|1-Day MBSR|One-day condensed MBSR class
89065056|NCT00600561|Experimental|8-week MBSR|8-week Mindfulness-Based Stress Reduction Intervention
89065057|NCT01324830|Experimental|arm A|14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles
89065058|NCT01324830|Experimental|arm B|5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week
89065059|NCT00600639|Experimental|1|non-invasive ventilation with BiPAP Vision or another ICU ventilator with NIV option
89065060|NCT00600639|Active Comparator|2|standard therapy + oxygen
89065061|NCT00623025|Experimental|1|
89065062|NCT00623025|Placebo Comparator|2|
89065063|NCT00600795||A|Patients diagnosed with Normal Pressure Hydrocephalus
89065064|NCT00602160|Active Comparator|1|2 different dosages
89065065|NCT00602160|Placebo Comparator|2|
89065066|NCT00600873|Experimental|1|patients with early ALS
89065067|NCT00600951||1|Patients with moderate chronic kidney disease (stage 3, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
89065068|NCT00600951||2|Patients with severe chronic kidney disease or kidney failure (stages 4 and 5, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2)
89065069|NCT04325997|Experimental|an ordinary laryngos with mouth opener|
89065070|NCT04325997|No Intervention|Video laryngoscopy intubation|
89065071|NCT04325997|Experimental|Video laryngoscope with mouth opener|
89065072|NCT00601029||1|Winter Phase - Observational
89065073|NCT00601029||2|Summer Phase - Observational
89065074|NCT01324440|Experimental|V710 without MAA|
89222074|NCT04711512||Single Arm (All Participants)|Within this arm, participants are randomized to one of the interventions described below at each of 4 times per day.
89065075|NCT01324440|Active Comparator|V710 with MAA|
89065076|NCT00598611|Active Comparator|1|desloratadine 20 mg
89065077|NCT00598611|Active Comparator|2|desloratadine 20 mg
89065078|NCT04325724|Other|Beginner psoriatic arthritis patients|Every patients consulting in dermatologic or rheumatologic department for a skin psoriasis with clinical symptoms which may lead to the suspicion of psoriatic arthritis
89065079|NCT04325724|Other|Confirmed psoriatic arthritis patients|Every patients with psoriatic arthritis followed in rheumatologic department
89065080|NCT04325724|Other|Rheumatoid arthritis or Digital osteoarthritis patients|Followed in rheumatologic department
89065081|NCT04325724|Other|Skin psoriasis patients without any articular symptoms|
89065082|NCT00601185||1|Patients undergoing a shave biopsy and confocal microscopy.
89065083|NCT00598143||Group A|Ten healthy smokers will provide a saliva sample used to genotype UGT1A7 and complete a questionnaire to assess understanding of and willingness to participate in molecular risk assessments.
89065084|NCT00598143||Group B|Thirty smokers will receive standard smoking cessation therapy and provide urine specimens for PGE-M analysis at approximate 3-monthly intervals over one year. Self-reported smoking status and expired-air carbon monoxide (CO) will also be recorded at 3-monthly clinic visits.
89065085|NCT00601263|Active Comparator|1a|Low dose ASHMI (2 caps bid).
89065086|NCT00601263|Placebo Comparator|1b|Placebo 2 caps bid.
89065087|NCT00601263|Active Comparator|2a|Medium dose ASHMI (4 caps bid).
89065088|NCT00601263|Placebo Comparator|2b|Placebo 4 caps bid.
89065089|NCT00601263|Active Comparator|3a|High dose ASHMI (6 caps bid).
89065090|NCT00601263|Placebo Comparator|3b|Placebo 6 caps bid.
89065091|NCT04325490|Experimental|Liquid powder|Liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin on the selected intertrigo area.
89065092|NCT04325490|Active Comparator|Hydrocortisone|1% hydrocortisone cream
89065093|NCT00601341|Experimental|1|lumbosacral joint manipulation
89065094|NCT00601341|Experimental|2|lumbar passive range of motion
89065095|NCT00601341|Other|3|lie on exam table for 3 minutes
89065096|NCT00601497|Experimental|1|
89065097|NCT00601497|Placebo Comparator|2|
89065098|NCT00601653|Active Comparator|1|Cognitive behavioral therapy plus general nutrition counseling
89065099|NCT00601653|Experimental|2|Cognitive behavioral therapy plus low energy density diet counseling
89065100|NCT00601809|Experimental|GG|
89065101|NCT00601809|Other|TT|
89065102|NCT02891499|Experimental|LLLT + immediate force|Use of Low-level laser therapy and not mediate orthodontic force application (150 gF the day of the implantation).
89065103|NCT02891499|Experimental|LLLT + mediate force|Use of Low-level laser therapy and mediate orthodontic force application (150 gF 4 weeks after the day of the implantation).
89065104|NCT02891499|No Intervention|Immediate force application|Not mediate orthodontic force application (150 gF the day of the implantation), without use of Low-level laser therapy.
89065105|NCT02891499|Experimental|Mediate force application|Mediate orthodontic force application (150 gF 4 weeks after the day of the implantation), without use of Low-level laser therapy.
89065106|NCT01325493|Placebo Comparator|Normal Saline|Normal Saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
89065107|NCT01325493|Active Comparator|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
89065108|NCT01323972|Experimental|GSK 257049-Lot 1 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine from the commercial scale lot 1 (formulation 1 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
89065109|NCT01323972|Experimental|GSK 257049-Lot 2 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 2 (formulation 2 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
89065110|NCT01323972|Experimental|GSK 257049-Lot 3 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 3 (formulation 3 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
89065111|NCT01323972|Experimental|GSK 257049-Pilot Group|Healthy male or female children aged 5 to 17 received 3 doses of the GSK 257049 vaccine from the pilot scale (pilot formulation of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
89065112|NCT01325337|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
89065113|NCT01325337|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
89065114|NCT01325337|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
89065115|NCT01325337|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
89065116|NCT01325337|Active Comparator|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
89065117|NCT01324947|Experimental|Pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
89065118|NCT01101841|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
89065119|NCT01101841|Placebo Comparator|Placebo capsules|Sugar pill
89065120|NCT04952545|Experimental|Cohort 1: ALXN2050 (Dose 1)|Participants will receive ALXN2050 (Dose 1) as follows under fasting conditions: 120-milligrams (mg) single dose, 3-day washout, then 120-mg twice daily (BID) dosing.
88821251|NCT04788888|Experimental|Navitor Transcatheter Aortic Valve, FlexNav Delivery System|Navitor Transcatheter Aortic Valve System Navitor valves (23mm, 25mm, 27mm, 29mm, and 35mm Titan valve), FlexNav Delivery system (small and large) and and Navitor Loading System (small, large, and LG+)
89065121|NCT04952545|Experimental|Cohort 1: Placebo (Dose 1)|Participants will receive placebo (Dose 1) as follows under fasting conditions: 120-mg placebo single dose, 3-day washout, then 120-mg placebo BID dosing.
89065122|NCT04952545|Experimental|Cohort 2: ALXN2050 (Dose 2)|Participants will receive ALXN2050 (Dose 2) as follows under fasting conditions: 180-mg single dose, 3-day washout, then 180-mg BID dosing.
89065123|NCT04952545|Experimental|Cohort 2: Placebo (Dose 2)|Participants will receive placebo (Dose 2) as follows under fasting conditions: 180-mg placebo single dose, 3-day washout, then 180-mg placebo BID dosing.
89065124|NCT04833517||Lu177 PSMA RLT|Lutetium-177 prostate-specific membrane antigen (Lu177 PSMA) radioligand therapy (RLT) according to standard local protocol
89065125|NCT04833517||Ac225 PSMA RLT|Actinium-225 prostate-specific membrane antigen (Ac225 PSMA) radioligand therapy (RLT) according to standard local protocol
89065126|NCT04833517||Tandem Lu177 / Ac225 PSMA RLT|Combined Lu177 / Ac225 PSMA radioligand therapy according to standard local protocol
89065127|NCT04833517||Ra223 chloride|Bone-targeted Radium-223 (Ra223) radionuclide therapy in standard application
89065128|NCT04833517||Sm153 EDTMP|Bone-targeted Samarium-153 (Sm153) EDTMP radionuclide therapy in standard application
89065129|NCT04833517||Y90 microspheres|Radioembolization with yttrium-90 (Y90) microspheres, standard methodology
89065130|NCT04833517||Tb161 PSMA RLT|Terbium-161 prostate-specific membrane antigen (Tb161 PSMA) radioligand therapy (RLT) according to standard local protocol
89065131|NCT01324401|No Intervention|Control|The subjects randomized to the observational control group will have follow-up visits every 6 months. Each visit will involve a medical history and physical examination. These subjects are then offered to cross-over to active treatment.
89065132|NCT01324401|Experimental|Peanut OIT|The subjects randomized to the active treatment group will receive defatted peanut flour per protocol.
89065133|NCT02877511|Experimental|Arm 1|2/3 of subjects testing the test article
89065134|NCT02877511|Active Comparator|Arm 2|1/3 of subjects testing the marketed control
89065135|NCT00625963||I,A|I=Pulmonary Hypertension Patients A=ILD patients with Pulmonary Hypertension Patients
88821252|NCT04788095|Experimental|Device feasibility (app-based mindfulness program)|Patients participate in a mindfulness-based program by using the Am app for 20-30 minutes every day, a minimum of 4 days each week over 4 weeks.
89065136|NCT01323660|Experimental|GSK573719/GW642444 125/25|125mcg/25mcg nDPI
89065137|NCT01323660|Experimental|GSK573719/GW642444 62.5/25|62.5mcg/25mcg nDPI
89065138|NCT01323660|Experimental|GSK573719/ 125|125mcg nDPI
89065139|NCT01323660|Experimental|GSK573719 62.5|62.5mcg nDPI
89065140|NCT01323660|Experimental|GW642444 25|25mcg nDPI
89065141|NCT01323660|Placebo Comparator|Placebo|Plb nDPI
89222075|NCT04010838|No Intervention|Conventional treatment|
89222076|NCT04010838|Experimental|Spinal cord stimulation and conventional treatment|
89222077|NCT04012164|Experimental|Microbiological, anthropological and historical study|"30 adult participants will be recruited to self-report daily activities and contacts with domesticated and wild animals for a five month period. Following the five months of data collection, we will collect 5ml blood and 2g stool from each participant.~From the fifth month of investigation, an additional 30 adult participants will participate in oral anthropological, historical interviews to develop the socio-historical context of their changing activities and relations with selected domesticated and wild animals. No other intervention will be performed."
89222078|NCT04674618|Experimental|US-assisted nusinersen administration|A paramedian sagittal oblique view will be used to identify with ultrasound specific lumbar interspaces. After local anesthesia the spinal needle will be used to identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
89222079|NCT04674618|No Intervention|landmark based nusinersen administration|The desired intervertebral space will be first identified by manual palpation of surface landmarks and marked on the skin. After local anesthesia the spinal needle will be usedto identify subarachnoid space. After confirmation of the flow of cerebrospinal fluid and after removing 5 ml of CSF, nusinersen will be administered intrathecally over 1-3 min.
89222080|NCT00956202|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
89222081|NCT00956202|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
89222082|NCT00956202|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
89222083|NCT02891837|Experimental|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
89222084|NCT02891837|Placebo Comparator|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
89222085|NCT00956358||Pre-HSCT|Haematological conditions requiring haemopoietic stem cell transplantation
89690183|NCT02974959|Experimental|gammaCore active device|Patients in this arm will be using an active device which delivers a treatment dose of current to the vagus nerve twice daily for 120 seconds
89690184|NCT02974959|Sham Comparator|gammaCore Sham device|Patients in this arm will be using a sham device which does not deliver a treatment dose of current, but will deliver enough current to cause tingling on the skin.
89690185|NCT03095638|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B in Part 1 and will receive A: conventional 10 mg DTG tablet (5 tablets) in Period 1 and B: conventional 50 mg DTG tablet in Period 2, administered directly to mouth.
89690186|NCT03095638|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A in Part 1 and will receive B: conventional 50 mg DTG tablet in Period 1 and A: conventional 10 mg DTG tablet (5 tablets) in Period 2, administered directly to mouth.
89690187|NCT03095638|Experimental|Treatment sequence C/D/E: Part 2|Eligible subjects will be randomized in sequence C/D/E in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
89690188|NCT03095638|Experimental|Treatment sequence D/E/C: Part 2|Eligible subjects will be randomized in sequence D/E/C in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
89690189|NCT03095638|Experimental|Treatment sequence E/C/D: Part 2|Eligible subjects will be randomized in sequence E/C/D in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
89690190|NCT03095638|Experimental|Treatment sequence C/E/D: Part 2|Eligible subjects will be randomized in sequence C/E/D in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
89690191|NCT03095638|Experimental|Treatment sequence D/C/E: Part 2|Eligible subjects will be randomized in sequence D/C/E in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
89690192|NCT03095638|Experimental|Treatment sequence E/D/C: Part 2|Eligible subjects will be randomized in sequence E/D/C in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
89690193|NCT03385629|Experimental|CSM theory-based Arm|CSM theory-based didactic education and skills training Practice EMR changes
89690194|NCT03385629|Active Comparator|AAP-based Arm|AAP-based didactic education
89690195|NCT03913923|Experimental|BCD-217 and BCD-100|Patients will receive 4 blinded infusions of BCD-217 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
89222086|NCT00956358||Post-HSCT with BOS|Occurence of bronchiolitis obliterans syndrome after haemopoietic stem cell transplantation
89222087|NCT00956358||Control|Healthy HSCT donors
89065142|NCT01092637||Cooled|Child was allocated standard intensive care plus moderate whole body hypothermia treatment within 6 hours of birth
89065143|NCT01092637||Non-cooled|Child was allocated standard intensive care only within 6 hours of birth
89065144|NCT01324323|Experimental|Romidepsin and rifampin|"Romidepsin 14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.~Rifampin 600 mg oral once daily on Days 4-8"
89065145|NCT05645601|Experimental|CD19 CAR-NK(JD010)|CD19-CAR-NK is an allogenic CD19-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
89065146|NCT02879227|Active Comparator|Arm Cisplatin|Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
89065147|NCT02879227|Experimental|Arm Oxaliplatin|Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
89065148|NCT05645445|No Intervention|control group|The routine ESWL procedure will be applied. Pre-procedural anxieties will be evaluated with the State-Trait Anxiety Inventory-State Anxiety Scale. After the ESWL procedure, their anxiety will be re-evaluated with the same scale, and their pain will also be evaluated with the Visual Analog Scale.
89065149|NCT05645445|Experimental|virtual reality group|The pre-procedure anxiety of the patients who will use virtual reality glasses during the ESWL process will be evaluated with the State-Trait Anxiety Inventory-State Anxiety Score. After the ESWL procedure, their anxiety will be re-evaluated with the same scale and in addition to the pain, the pain will be evaluated with the Visual Analog Scale.
89065150|NCT01323582|Active Comparator|erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
89222088|NCT04009590|Experimental|GROUP I (Quit4Health)|Participants utilize Quit4Health intervention that includes interactive features, coping strategies and games related to cigarettes and other tobacco products for 1 month.
89222089|NCT04009590|Active Comparator|Group II (educational booklet)|Participants read an educational booklet about cigarettes and other tobacco products for 1 month.
89222090|NCT00961974|No Intervention|Standard Care|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
89690196|NCT03913923|Active Comparator|BCD-100 monotherapy|Patients will receive 4 blinded infusions of BCD-100 plus Placebo. Starting with the fith infusion patients will receive unblinded BCD-100 monotherapy.
89690197|NCT04458688||African Americans with RRMS|Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as African American.
89690198|NCT04458688||Caucasian American with RRMS|Participants who are diagnosed with relapsing multiple sclerosis and who have chosen to start or recently started using ocrelizumab as their disease modifying therapy. Age range: 18 to 60 years old. Ethnicity: Self-described as Caucasian American.
89690199|NCT04450108|Experimental|Test Cohort|Subjects age 7 to 80 with asthma
89690200|NCT03899883|Experimental|Pegloticase|Single administration of pegloticase (8 mg IV in 250 mL 0.9% normal saline)
89690201|NCT03891849|Experimental|octreotide (25 µg/hour) perfusion|octreotide (25 µg/hour) plus norepinephrine will be administered for patient with haemorrhagic shock after variceal bleeding during 2 to 5 days according recommendations and regular protocol in the medical unit
89690202|NCT03884985|Experimental|Normal Vision|This study examines high-acuity vision, oculomotor behavior recorded using high-resolution eyetracking. Healthy participants are asked to perform different types of visual tasks, ranging from letter identification to judging facial expressions while their eye movements will be recorded with high-precision together with their behavioral performance in the task.
89690203|NCT02974569||C-SCAT|C-SCAT arm: Completes and uses Computerized Symptom Capture Tool (C-SCAT) during visit with provider for two clinic visits.
89690204|NCT04341831|Experimental|Group 1|We will be added 200mg teicoplanin powder around instrument for each level.
89690205|NCT04341831|No Intervention|Group 2|We will not used any antibiotic powder in this group.
89690206|NCT03158038|Experimental|Monovalent Influenza Vaccine|Participants will receive a single dose of monovalent influenza vaccine [10^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain] by intranasal spray on Day 1.
89690207|NCT03158038|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1.
89690208|NCT03158116|Experimental|Treatment|All participants will be receiving the study drug
89690209|NCT03096730|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
89690210|NCT03096730|Sham Comparator|Sufentanil|Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil
89690211|NCT03096730|Active Comparator|Dexmedetomidine|Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil
89690212|NCT03096730|Active Comparator|Nalmefene|Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil
89690213|NCT03096730|Active Comparator|Dexmedetomidine-Nalmefene|A dose of 0.1ug/kg nalmefene and a dose of 0.25ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil
89690214|NCT04342923||Complete cohort|All patients undergoing PD during study period in all participating center/units in Spain.
89690215|NCT03872271|Experimental|Experimental|ileal pouch-anal anastomosis without diverting loop ileostomy
89690216|NCT03872271|Active Comparator|Control|ileal pouch-anal anastomosis with diverting loop ileostomy
89690217|NCT03866031|Experimental|M:2.75|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 2.75 mm
89690218|NCT03866031|Experimental|M3.25|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 3.25 mm
89690219|NCT03866031|Experimental|S3.75|12 Patients will be provided with 2 standard sized implant-supported mandibular overdentures d: 3.75 mm
89690220|NCT03834441|Other|Oral screening|
89690221|NCT03834441|Other|Written screening|
89690222|NCT03161158|Active Comparator|Ultrafiltration Group|Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.
89690223|NCT03161158|Other|Control group (Usual care IV diuretics)|Guideline-directed therapy including IV loop diuretics according to treatment algorithm.
89690224|NCT03161938|Active Comparator|Dexamethasone 48 mg|Dexamethasone 48 mg pre-operative, single shot injection
89690225|NCT03161938|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative, single shot injection
89690226|NCT03321045|Experimental|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab [89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 millicurie (mCi) at the time of injection. The amount of injected drug is 5 mg of Trastuzumab. 5-6 days post injection the patients will undergo PET/MRI imaging.
89690227|NCT00989989|Experimental|Adjunctive treatment|Adjunctive administration of ranibizumab 0.5 mg intravitreal injections and active laser.
89690228|NCT00989989|Experimental|Monotherapy treatment|Monotherapy ranibizumab 0.5 mg intravitreal injections plus sham laser.
89690229|NCT00989989|Active Comparator|Laser control|Active laser treatment plus sham intravitreal injections.
89690230|NCT04331080|Experimental|Granexin® gel 100 μM|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Granexin® gel 100 μM will be applied four times over three days: twice during surgery, 24 hours after surgery and 48 hours after surgery. Granexin® will be applied on the right or left breast according to a randomization list."
89690231|NCT04331080|Experimental|Granexin® gel 200 μM|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Granexin® gel 200 μM will be applied four times over three days: twice during surgery, 24 hours after surgery and 48 hours after surgery. Granexin® will be applied on the right or left breast according to a randomization list."
89065151|NCT01323582|Experimental|Azithromycin|The dose of Azithromycin was determined based on our dose response curve obtained on 10 healthy subjects who were given three different doses of Azithromycin, 50 mg, 100 mg and 133 mg and underwent breath testing to determine the gastric emptying half-time. These doses were determined based on a maximum safe dosage per day of Azithromycin of 400 mg given the medication would then be administered three times daily before meals. The appearance of the medication (azithromycin) and administration period was then identical to that of Erythromycin, i.e. 5ml elixir administered orally three times a day half an hour prior to meals. The total daily dosage of Azithromycin was determined after obtaining the dose- response analysis.
89065152|NCT00626041|Other|1|referral to primary care network for management of blood pressure, lipids and diabetes.
89065153|NCT05367765|Experimental|Flumatinib mesylate tablets|
89065154|NCT05367765|Active Comparator|Imatinib mesylate tablets|
89065155|NCT05645367||premature myocardial infarction|AMI with onset age less than 55 years for men and 65 years for women.
89065156|NCT05645367||control|AMI with onset age not less than 55 years for men and 65 years for women.
89065157|NCT01323621|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
89065158|NCT01323621|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
89065159|NCT00623298|Experimental|1|NET
89065160|NCT00623298|No Intervention|3|6-months baseline
89065161|NCT00623298|Experimental|2|group IPT
89065162|NCT01323192|Experimental|JNS001|
89065163|NCT01323192|Placebo Comparator|Placebo|
89065164|NCT01323387|Other|Treatment|Interbody fusions with Anterior Plating
89065165|NCT05645289|Experimental|minodronate|Patients will take 1 mg of minodronate tablets orally in the morning.
89065166|NCT05645289|Active Comparator|alendronate|Patients will be orally given 10 mg alendronate tablets daily in the morning.
89222091|NCT00961974|Experimental|Care Plus|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
88812659|NCT00891176|Experimental|Synflorix-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
89065167|NCT05645211||Group 1: Healthy children|"140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center.~Inclusion Criteria:~Ambulatory male and female children aged 5-17 years~Normal weight at birth~Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.~Exclusion Criteria:~Genetic defects, chronic illnesses.~Current prescription medication use~Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry."
89065168|NCT05645211||Group 2: Children with GH deficiency|"16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature.~They will be representative of the diverse racial and ethnic mix of our hospital's patient population.~GH deficiency:~Inclusion Criteria:~Ambulatory male and female children aged 5-9 years who are prepubertal~Normal weight at birth~Growth failure~Peak GH response to 2 GH stimulation tests < 10 ng/ml~Normal renal and liver function~Exclusion criteria:~Multiple pituitary hormone deficiencies,~GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.~History of diabetes or malignancy~Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry."
89222092|NCT00961974|Experimental|Care Ultra|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
89222093|NCT00962130|Experimental|Blood Glucose Measurement|Subjects have sensors placed on skin before surgery and these sensors will measure the subject's glucose until the third day after surgery when they are removed.
89222094|NCT00695903|Experimental|daptomycin 10 mg/kg|Daptomycin 10 mg/kg IV every 24 hours
89222095|NCT00695903|Experimental|vancomycin high-dose|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
89222096|NCT02793167|No Intervention|Usual care|patients will receive standard clinical care by the doctor in charge.
89222097|NCT02793167|Experimental|AKI alert|an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
89222098|NCT00548262|Experimental|1|
88821253|NCT04786821|Placebo Comparator|Standard Exercise Training Programme|Participants will receive interventions by an exercise specialist based on the participant's tolerance. These sessions will be delivered by a exercise specialist.
88821254|NCT04786821|Active Comparator|Exoskeleton Exercise Programme|The Phoenix Exoskeleton suit will be used in this study. It is a powered Exoskeleton, with a modular design. Participants will receive interventions by an research physiotherapist based on the participant's tolerance.
89222099|NCT00742547|No Intervention|Control group|No telephone counseling + usual care
89222100|NCT00742547|Experimental|Telephone Counseling|Telephone counseling + usual care
89222101|NCT02565173|Experimental|trabodenoson 4.5% BID|trabodenoson 4.5% Ophthalmic Formulation
89222102|NCT02565173|Experimental|trabodenoson 6.0% QD|trabodenoson 6.0% Ophthalmic Formulation
89222103|NCT02565173|Experimental|trabodenoson 3.0% QD|trabodenoson 3.0% Ophthalmic Formulation
89222104|NCT02565173|Active Comparator|timolol 0.5% BID|timolol 0.5% Ophthalmic Formulation
89222105|NCT02565173|Placebo Comparator|placebo BID|placebo Ophthalmic Formulation
89222106|NCT04619082|Experimental|TAF prophylaxis|Using TAF to prevent HBV reactivation for HBsAg-positive cancer patients
89229803|NCT01040104||Regular wound healing, young|Regular skin repair, controlled wound healing conditions in young individuals
89065169|NCT05645211||Group 3: Children with short stature|"Idiopathic Short Stature:~Inclusion Criteria:~Ambulatory male and female children aged 5-9 years who are prepubertal~Normal weight at birth~Height >2.25 SD below mean for age~Peak GH response to 2 stimulation tests >10 ng/ml or normal IGF-1 and IGFBP-3 levels~No prior supplemental growth hormone exposure~Normal renal and liver function~Exclusion criteria:~Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.~History of diabetes or malignancy~Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry."
89065170|NCT00623259|Experimental|1|
89065171|NCT02891343|Experimental|Healthy volunteers|
89065172|NCT01321749|Experimental|RIPC+stroke secondary prevension|"Procedure/Surgery: Remote Ischemic Preconditioning (RIPC) The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.~Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)"
89065173|NCT01321749|No Intervention|stroke secondary prevention|Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)
89065174|NCT01320735||Advanced PCa|Participants with advanced PCa
89065175|NCT01320033|Experimental|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.
89065176|NCT01320033|Active Comparator|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.
89065177|NCT01320033|Placebo Comparator|Placebo|Participants receive matching placebo tablet plus placebo capsule orally once daily for 16 weeks.
89065178|NCT01101061|Experimental|Romosozumab|Japanese women in cohorts 1, 2, and 4 will receive a single dose of 1, 3, or 5 mg/kg romosozumab. Non-Japanese women in cohort 3 will receive a single dose of 3 mg/kg romosozumab.
89065179|NCT01101061|Placebo Comparator|Placebo|Participants will receive a single dose of placebo.
89065180|NCT04325295|Active Comparator|Surgical treatment strategy:|
89065181|NCT04325295|Active Comparator|Gonadotrophins treatment strategy|
89065182|NCT02891187|Active Comparator|Outpatient Clinic Visits|Outpatient clinic visits for postoperative care is currently the standard of care. Patients who undergo surgery for a pelvic floor disorder will be scheduled appointments in the outpatient clinic at 1-2 weeks, 6 weeks, and 3 months where they will be evaluated by a physician.
89065183|NCT02891187|Active Comparator|Telephone Follow-up|Patients will be called instead of returning to clinic for postoperative care at 1-2 weeks, 6 weeks, and 3 months.
89065184|NCT01317615|Experimental|RAD001 plus paclitaxel/carboplatin|Participants received RAD001 5 mg orally once daily in combination with carboplatin and paclitaxel for a maximum 4 cycles or until discontinuation.
89065185|NCT02891109||patients group|Adults patients with chronic immune thrombocytopenia
89065186|NCT02891109||control group|Adults without immune thrombocytopenia
89229804|NCT01040104||Regular wound healing, aged|Regular skin repair, controlled wound healing conditions in aged individuals
89065187|NCT05644509|Experimental|Oncolytic Virus Injection（Revottack）+PD-1|"In the first three cycles, the subjects were administered on the first day and the sixth day of each cycle respectively; At the beginning of the fourth cycle, the subjects were administered on the sixth day of each cycle, 14 days a cycle.~PD-1 inhibitor(Toripalimab) Intravenous infusion, once every 2 weeks from the 6th day."
89065188|NCT01078675|Experimental|1|
89065189|NCT02878135|Experimental|fast vulsellum|rapid ratchet of the vulsellum
89065190|NCT02878135|Active Comparator|slow vulsellum|Placement of the tenaculum over 7-10 seconds and not allowing the vulsellum to ratchet audibly.
89065191|NCT04875793|Experimental|List of health centers that randomly allocated to receive the intervention|The intervention is the integrated system which is composed of psychologist, endoscopy physician, family physician, community outreach, and audiovisuals in the waiting area. In addition to text messages of information, education and communication (IEC) delivered to the participants at the outreach, and education campaigns to mobilize individuals going for screening.
89229805|NCT01040104||Hypertrophic scarring, young|Skin repair with and without hypertrophic scarring in young individuals
89222107|NCT02724683||Symptomatic ascites drainage with CVC.|Patients with malignant, symptomatic, refractory ascites. Ascites drainage with vascular catheter (CVC) inserted into abdominal cavity will be performed. Patients will be asked to complete interview, quality of life questionnaire, nutritional status assessment and quality of procedure survey.
89222108|NCT04593342|Active Comparator|Standard + B-Cure Pro|Subjects from the Standard + B-Cure Pro group will receive standard care and in addition will self-treat at home with the B-Cure device
89222109|NCT04593342|Sham Comparator|Standard + Sham|Subjects from the Standard + Sham group will receive standard care and in addition will self-treat at home with the sham B-Cure device
89222110|NCT04060667|Experimental|Intervention|
89222111|NCT04060667|No Intervention|control|
89222112|NCT03717623|Experimental|Posaconazole prophylaxis|Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.
89222113|NCT00742703|Experimental|1|
89222114|NCT00742703|Active Comparator|2|
89222115|NCT00095173|Active Comparator|Abatacept|Double Blind Period
89222116|NCT00095173|Placebo Comparator|Placebo|Double Blind Period
89222117|NCT00095173|Experimental|Abatacept - Open Label|
89222118|NCT03704753|Active Comparator|SAPB group A|SAPB single injection. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
89222119|NCT03704753|Placebo Comparator|SAPB group B|SAPB single injection (placebo). 30ml of SodiumChloride 0.9 is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
89222120|NCT03704753|Active Comparator|SAPB group C|SAPB single injection and catheter. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery and a multi-holed catheter is left in place. 20ml of Ropivacaine 2mg/ml is injected every 12h through catheter postoperatively.
89229806|NCT01040104||Hypertrophic scarring, aged|Skin repair with and without hypertrophic scarring in aged individuals
89229807|NCT01040104||Non-diabetic, young|Skin repair in non-diabetic young individuals
89065192|NCT04875793|No Intervention|List of health centers that randomly allocated to receive routine care|The comparators will be individuals with an average risk of colorectal cancer of both genders attending the randomly selected health centres
89065193|NCT02877199||HCV triple therapy|Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy
89065194|NCT02879149||Group 1|Standard Rigid Fixation plus autograft
89065195|NCT02879149||Group 2|Standard rigid fixation plus AUGMENT® Bone Graft
89065196|NCT02877277|Experimental|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
89065197|NCT02877277|Placebo Comparator|Placebo|Oral intake of placebo tablet daily for 56 days
89065198|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules crushed and mixed in solution and administered orally at each patient's stable dose, given either once daily or twice daily.
89065199|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily
89065200|NCT04306705||Tocilizumab|Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no less than 60 minutes. Tocilizumab was administered according to the local label.
89065201|NCT04306705||Continuous Renal Replacement Therapy|Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive 3 times or more.
89065202|NCT04306705||Standard care|Standard of care therapy per local written policies or guidelines.
89065203|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF|"PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF"
89065204|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF placebo|"PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF placebo"
89065205|NCT01322490|Placebo Comparator|Placebo Control|PROSTVAC V/F Placebo + GM-CSF Placebo
89065206|NCT02877355|Experimental|Semaglutide|
89065207|NCT01314261|Experimental|ABT-267 (5 mg) once daily + pegIFN/RBV|Participants were given 5 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
89065208|NCT01314261|Experimental|ABT-267 (50 mg) once daily + pegIFN/RBV|Participants were given 50 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
89065209|NCT01314261|Experimental|ABT-267 (200 mg) once daily + pegIFN/RBV|Participants were given 200 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
89065210|NCT01314261|Placebo Comparator|Placebo + pegIFN/RBV|Participants were given matching placebo to ABT-267 once daily in combination with pegIFN/RBV for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
89222121|NCT03704753|Active Comparator|SAPB group D|Continious intercostal catheter. 20ml of Ropivacaine 7,5mg/ml is injected through intercostal catheter, which i placed under thoracoscopic visualization. After single injection a continuous infusion of Ropivacaine 2mg/ml is started (weight dependent daily dosage).
89222122|NCT03704753|Active Comparator|SIP group A|SIP single injection 20ml of Ropivacaine 7,5mg/ml is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
89222123|NCT03704753|Placebo Comparator|SIP group B|SIP single injection (placebo) 20ml of SodiumChloride 0.9 is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
89222124|NCT02565017||Breast Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
89222125|NCT02565017||Lung Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
89222126|NCT02565017||Colorectal Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
89222127|NCT00690443|Active Comparator|2|2.5 mg AEGR 733 plus atorvastatin 20 mg weeks 1-4 followed by 5 mg AEGR 733 plus atorvastatin 20 mg weeks 5-8
89222128|NCT00690443|Active Comparator|1|Following 35-day washout + diet run-in, subjects receive atorvastatin 20 mg for 8 wks.
89222129|NCT03954834|Experimental|5 mg Tirzepatide|Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
89222130|NCT03954834|Experimental|10 mg Tirzepatide|Participants received 10mg of tirzepatide as subcutaneous injection once a week.
89222131|NCT03954834|Experimental|15 mg Tirzepatide|Participants received 15mg of tirzepatide as subcutaneous injection once a week.
89222132|NCT03954834|Placebo Comparator|Placebo|Participants received placebo as subcutaneous injection once a week.
89222133|NCT00693017|Active Comparator|Zonisamide|
89222134|NCT00693017|Placebo Comparator|Placebo|
89222135|NCT03965065|Experimental|Sutureless Aortic Valve Prosthesis|Patients receiving sutureless aortic valve prostheses
89222136|NCT03965065|Active Comparator|Conventional Aortic Valve Prosthesis|Patients receiving conventional biological aortic prostheses
89222137|NCT00692237|Active Comparator|1|Sildenafil 100 mg
89222138|NCT00692237|Placebo Comparator|2|Placebo 100 mg
89222139|NCT00110149|Experimental|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
89222140|NCT03964285|Active Comparator|Rumination group|The patients will receive rumination induction. Rumination induction will follow a relevant activity for our patients: climbing steps. Rumination induction will be done right after climbing the steps.
89229808|NCT01040104||Non-diabetic, aged|Skin repair in non-diabetic aged individuals
89690232|NCT04331080|Placebo Comparator|Vehicle Gel|"Within-subject comparison of Granexin® Gel versus vehicle gel (placebo).~Vehicle gel will be applied four times over three days: twice during surgery, 24 hours after surgery and 48 hours after surgery. Granexin® will be applied on the right or left breast according to a randomization list."
89690233|NCT04282564|Experimental|CO-OP Arm (early phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 3 weeks.
89690234|NCT04282564|Experimental|CO-OP Arm (mid phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2.5 weeks.
89690235|NCT04282564|Experimental|CO-OP Arm (late phase A)|Patients will be integrated during the traditional day hospitalization follow-up, at the rate of 3 sessions per week. The patient will have 2 phases : phase A: CO-OP treatment during 6 week and phase B : without specific treatment during 2 weeks.
89690236|NCT03018301|Active Comparator|Ketamine group|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
89690237|NCT03018301|Placebo Comparator|Control group|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
89690238|NCT03100864|Experimental|Spesolimab|
89690239|NCT00990769|Experimental|"High-normal BIS (Lighter anesthesia)"|Depth of anesthesia is titrated to a BIS of 55-60
89690240|NCT00990769|Experimental|"Low-normal BIS (Deeper anesthesia)"|Depth of anesthesia is maintained at a BIS level of 40-45
89690241|NCT04242550|Experimental|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT with executive function training, enhancing CBT with a focus on teaching compensatory strategies, habit learning, and plan for generalization to real-world behaviors.
89690242|NCT04242550|Active Comparator|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
89690243|NCT03018457||patients who need a dental implants|
89690244|NCT03018067|Placebo Comparator|Placebo|Microcrystalline Cellulose (MCC), 2 g qd. Subjects assigned to the Placebo group will be randomly assigned in a 1:1:1 ratio to receive either one, two, or three bottles of drug per day.
89690245|NCT03018067|Experimental|10 g qd|RDX227675, 10 g qd
89690246|NCT03018067|Experimental|20 g qd|RDX227675, 20 g qd
89690247|NCT03018067|Experimental|30 g qd|RDX227675, 30 g qd
89690248|NCT04744857|Experimental|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
89065211|NCT02891616|Experimental|FDG-PET/CT + FLT-PET/CT + PET/MR|"-Baseline, Week 3 (between days 14-20), Week 6 (between days 35-41)~FDG-PET/CT - Patients required to fast for at least 4 hours prior to FDG administration. Roughly 60 minutes prior to PET/CT imaging, FDG will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.~FLT-PET/CT - Patients required to fast for at least 4 hours prior to FLT administration. Roughly 80 minutes prior to PET/CT imaging, FLT will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.~PET/MR - A limited whole body scan performed immediately following PET/CT imaging when possible. Should be performed at least once at each time-point. This scan will be of a more limited area and be performed for no more than 30 minutes."
89065212|NCT01321710|Active Comparator|Dietary information & standard care|"Mothers in this arm receive dietary information aimed at reducing postpartum sleep disturbance.~Infants in this arm receive no intervention beyond standard immunization care."
89065213|NCT01321710|Experimental|Sleep hygiene & standard care|"Mothers in this arm receive a sleep hygiene intervention aimed at improving their postpartum sleep.~Infants in this arm receive standard immunization care."
89065214|NCT01321710|Experimental|Sleep hygiene & acetaminophen|"Mothers in this arm receive a sleep hygiene intervention aimed at improving postpartum sleep.~Infants in this arm receive an acetaminophen intervention (12.5mg per kg infant weight, 1 dose 30 minutes prior to immunization and q4-6h thereafter, for a total of 5 doses) to minimize sleep disturbance following immunization."
89065215|NCT01321008|Experimental|Radiation + Chemotherapy|Radiation therapy total dose of 50.4 to 54 Gy over 28 to 30 treatments; CHOP Chemotherapy of Cyclophosphamide 750 mg/m2 intravenous piggyback (IVPB), Doxorubicin 50 mg/m2 IVPB, Vincristine 1.4 mg/m2 (max dose 2 mg) IVPB on Day 1, and Oral Prednisone 100 mg daily days 1-5 for four 21-day cycles.
89065216|NCT01320150||PPP and Non-PPP|Study Subjects with PPP and without PPP at followup
89065217|NCT05661396|Experimental|Experimental group|
89065218|NCT05661396|No Intervention|Control group|
89222141|NCT03964285|Experimental|distraction group|Distraction will follow a relevant activity for our patients: climbing steps. Distraction induction will be done right after climbing the steps.
89222142|NCT02530957|Experimental|Interventional|In the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied.
89222143|NCT02530957|Other|Reference|In the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) is applied.
89065219|NCT01323530|Experimental|Dose-escalation Phase (Phase 1b)|Participants with advanced and/or metastatic tumors will receive eribulin mesylate as a 2 to 5 min Intravenous (IV) bolus or infusion in two different schedules (Schedule 1 [1.2, 1.6, 2.0 mg/m2], given on Day 1 only, and Schedule 2 [0.7, 1.1, 1.7 mg/m^2], given on Days 1 and 8) and oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles) in both schedules. If maximum tolerated dose (MTD) is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m^2 bid on Days 1-14 (21-day cycles) depending on the Dose limiting toxicities (DLTs) observed and/or pharmacokinetic (PK) data when available. Based on the data and safety monitoring board review of dose escalation phase data (DLTs that will be observed in first cycle), Dose-Confirmation Phase (Phase 2) will may get initiated.
89065220|NCT01323530|Experimental|Dose-confirmation Phase (Phase 2)|Participants with advanced and/or metastatic tumors will receive Eribulin mesylate at the MTD for the selected schedule of dose escalation phase based on safety/PK data.
89065221|NCT05645198|Experimental|Oozfix|Arm with oozfix after gastrectomy
89065222|NCT05645198|Active Comparator|Greenplast|Arm with greenplast after gastrectomy
89065223|NCT04325438|Experimental|Pharmaceutical Care|Groups with usual care by health professionals and additional health interventions provided by pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
89065224|NCT04325438|No Intervention|Non-Pharmaceutical Care|Groups with usual care from health providers other than pharmacists. Number of intervention groups in each cluster is different, depending on the starting time of the intervention.
89065225|NCT02891252|Active Comparator|outpatient|outpatient
89065226|NCT02891252|No Intervention|inpatient|inpatient
89065227|NCT01313637|Experimental|GSK573719/GW642444|125/25mcg
89065228|NCT01313637|Experimental|GSK573719|125mcg
89065229|NCT01313637|Experimental|GW642444|25mcg
89065230|NCT01313637|Placebo Comparator|Placebo|Placebo
89065231|NCT01320722|Experimental|Vitamin D|Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.
89065232|NCT01320722|Experimental|Probenecid|Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).
89065233|NCT01320722|Experimental|Allopurinol|Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).
89222144|NCT01084057|Experimental|Arm I (Cohort A)|Patients receive oral vorinostat once daily on days 1-14 and ixabepilone IV over 3 hours on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89222145|NCT01084057|Experimental|Arm II (Cohort B)|Patients receive oral vorinostat once daily on days 1-7 and 15-21. Patients also receive ixabepilone IV over 3 hours on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89222146|NCT03954444|Active Comparator|Oxymetazoline hydrochloride Cream, 1%|Oxymetazoline hydrochloride cream, 1%
89222147|NCT03954444|Active Comparator|RHOFADE Cream, 1%|RHOFADE Cream, 1%
89222148|NCT03954444|Placebo Comparator|Vehicle Cream|Vehicle cream
89222149|NCT03953820|Experimental|Diazepam Buccal Film, Then Diastat Rectal Gel|Participants received a single dose of Diazepam Buccal Film following a moderate-fat meal and then received a single dose of Diastat Rectal Gel following a moderate-fat meal with a 28-day washout between doses.
89222150|NCT03953820|Experimental|Diastat Rectal Gel, Then Diazepam Buccal Film|Participants received a single dose of Diastat Rectal Gel following a moderate-fat meal and then received a single dose of Diazepam Buccal Film following a moderate-fat meal with a 28-day washout between doses.
89222151|NCT03953820|Experimental|Diazepam Buccal Film following a High-Fat Meal|Participants who volunteered to participate in the second period received a second dose of Diazepam Buccal Film at the same dose and exactly the same manner as the earlier dose with the exception that the dose was administered following ingestion of a high-fat meal.
89065234|NCT01320722|Placebo Comparator|Placebo- Vitamin D|Placebo soft gel once per week for 8 weeks.
89065235|NCT01320722|Placebo Comparator|Placebo- Uric Acid|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).
89065236|NCT01313559|Active Comparator|Cohort A (pasireotide)|Patients receive pasireotide IM once every 4 weeks
89065237|NCT01313559|Experimental|Cohort B (pasireotide and everolimus)|Patients receive pasireotide as in cohort A and everolimus PO QD
89065238|NCT02891330|Experimental|Dietary and nutritional recommendations|Postoperative personalized approach based on dietary and nutritional recommendations conducted by a nurse
89065239|NCT02891330|No Intervention|Standard of care|Postoperative standard of care
89065240|NCT00623337|Experimental|Newhints|Home visits
89065241|NCT00623337|No Intervention|Control|Community based surveillance volunteers will continue with current duties eg urging attendance at immunisation clinics and child health weeks
89065242|NCT02891031|Active Comparator|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
89065243|NCT02891031|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
89065244|NCT04325750|Placebo Comparator|Control|The simulated mode technique is applied (machine off)
89065245|NCT04325750|Experimental|TECAR THERAPY|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
89065246|NCT04325360|Experimental|Cathodal Transcranial Direct Current Stimulation (c-tDCS)|Participants in this arm of the study will receive cathode transcranial direct current stimulation.
89065247|NCT04325360|Sham Comparator|Sham-tDCS|Participants in this arm of the study will receive sham transcranial direct current stimulation.
89065248|NCT02890953|Placebo Comparator|Control|Control group receives placebo medication (normal saline)
89065249|NCT02890953|Experimental|MSC group|MSC group receives mesenchymal stem cells transplantation (Pneumostem)
89065250|NCT05644652|Experimental|control group|15 Children in this group will receive a designed physical therapy program for 60 minutes per session, three times a week, for three consecutive months.
89065251|NCT05644652|Experimental|Nordic walking group|Children in this group will receive the same designed physical therapy program for 60 minutes per session, three times a week, for three consecutive months. while the Nordic walking training for 20 minutes will replace the functional gait training.
89065252|NCT02890875|Active Comparator|Ethanol lock|70% ethanol
89065253|NCT02890875|Active Comparator|Heparin lock|Heparinized saline (100 U/mL)
89065254|NCT04324970|Experimental|Tookie vest|Participant issued with Tookie vest
89065255|NCT01312779|Other|All subjects receive implant|Subjects serve as own control
89065256|NCT01312467|Experimental|Prevention (metformin hydrochloride)|Patients receive metformin hydrochloride PO QD during week 1 and then BID during weeks 2-12. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.
89065257|NCT01310127|Experimental|Bromday|Patients receiving Bromday self-administered one drop of bromfenac 0.09% daily as a topical ophthalmic drop three days prior to cataract surgery, on the day of cataract surgery and 21 days post operatively.
89065258|NCT01310127|Active Comparator|Nevanac|Patients in this arm self-administered nepafenac topical ophthalmic drops three times daily beginning 3 days prior to cataract surgery, on the day of surgery and for 21 days postoperatively in addition to usual cataract procedure.
89065259|NCT01309893|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel contact lens for 1 week; then issued Air Optix Aqua Lens for 1 week.
89222152|NCT00117949|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
89065260|NCT01309893|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens for 1 week; then issued Investigational Lens for 1 week.
89065261|NCT01318902|Experimental|Dose Escalation Cohort: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
89065262|NCT01318902|Experimental|Dose Escalation Cohort: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
89065263|NCT01318902|Experimental|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were not treated with any other proteasome inhibitor (PI). Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
89065264|NCT01318902|Experimental|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until PD or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were previously treated with any other PI. Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
89065265|NCT05644938|Active Comparator|Standard workflow (SW)|Acute ischemic stroke caused by large vessel occlusion was diagnosed by Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission in MRI room + Recanalization therapy in angiosuite
89065266|NCT05644938|Experimental|One-stop (OS)|Acute ischemic stroke caused by large vessel occlusion was diagnosed + Recanalization therapy by the ﬂat-detector computed tomography in angiosuite at the same time.
89065267|NCT05644860|Active Comparator|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
89065268|NCT05644860|Experimental|Nanohybrid Compisite Group (Filtek Z250)|Patients in which brackets will be bonded with nanohybrid composite resin (Filtek Z250)
89065269|NCT01313858||Participants with Rheumatoid Arthritis|Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.
89065270|NCT01313858||Participants with Psoriatic Arthritis|Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.
89065271|NCT01313858||Participants with Ankylosing Spondylitis|Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.
89065272|NCT05644704|Experimental|Baseball pitcher training|
89065273|NCT05644548||Hypertension|No intervention
89065274|NCT05644548||Diabetes mellitus|No intervention
89065275|NCT05644548||Dyslipidemia|No intervention
89065276|NCT05644470||Dental implant rehabilitation|Patients having undergone dental implant treatment, with a single implant-supported restoration in anterior jaws (premolars to premolars), will be included.
89065277|NCT01090765|Experimental|TRC105 1 mg/kg every 2 weeks|Intravenous infusion at 1 mg/kg every 2 weeks
89065278|NCT01090765|Experimental|TRC105 3 mg/kg every 2 weeks|Intravenous infusion at 3 mg/kg every 2 weeks
89065279|NCT01090765|Experimental|TRC105 10 mg/kg every 2 weeks|Intravenous infusion at 10 mg/kg every 2 weeks
89065280|NCT01090765|Experimental|TRC105 10 mg/kg weekly|Intravenous infusion at 10 mg/kg weekly
89222153|NCT00117949|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
89065281|NCT01090765|Experimental|TRC105 15 mg/kg every 2 weeks|Intravenous infusion at 15 mg/kg every 2 weeks
89065282|NCT01090765|Experimental|TRC105 20 mg/kg every 2 weeks|Intravenous infusion at 20 mg/kg every 2 weeks
89065283|NCT01313780|Experimental|'Oxycodone/Naloxone'|Trade name is Targin(fixed combination drug).
89065284|NCT01313780|Active Comparator|Oxycodone|Trade name is Oxycontin(single compound).
89065285|NCT01090453|Experimental|GSK2202083A Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2202083A vaccine, co-administered with Prevenar 13® at 2, 4 and 12 months of age. The GSK2202083A and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
89222154|NCT00117949|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
89222155|NCT00117949|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
89229809|NCT01040104||Diabetic, young|Skin repair in young diabetic individuals
89229810|NCT01040104||Diabetic, aged|Skin repair in aged diabetic individuals
89229811|NCT01043458|Experimental|1|ABT-126 Low Dose
89065286|NCT01090453|Active Comparator|Infanrix hexa Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® and Menjugate® at 2, 4 and 12 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the right and upper left sides of the thigh, respectively and the Menjugate® vaccine was administered intramuscularly in the lower left thigh. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
89065287|NCT01171612||Coronary Stent|Patients with coronary Bare Metal Stent (BMS) or Drug Eluting Stent (DES) undergoing noncardiac surgery
89065288|NCT01171534|Active Comparator|Vessel Loop fasciotomy closure|Fasciotomy closure using vessel loops and staples.
89065289|NCT01171534|Experimental|DermaClose fasciotomy closure|Fasciotomy closure via DermaClose device
89065290|NCT01170598|Experimental|Exercise|
89065291|NCT01170364|Experimental|Sibutramine|Participants in this arm receive sibutramine 15mg for one week followed by two weeks of placebo.
89065292|NCT01170364|Experimental|Placebo|Participants are prescribed two weeks of placebo, followed by one week of 15mg sibutramine.
89065293|NCT01076179||Human Immunodeficiency Virus (HIV)-Infected Participants|HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists
89222156|NCT03678636|Experimental|Intervention|The wound will be treated with a silver antimicrobial dressing appropriate for the exudate level as per manufacturer instructions for use for 2 weeks +/- 3 days, in addition to any necessary standard care (e.g. compression for a venous leg wound).
89222157|NCT03678636|Active Comparator|Control|The wound will be treated as per usual care.
89065294|NCT01170208|Other|Group I|Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting and insulin dose software.
89065295|NCT01170208|Other|Group II|Type 2 diabetes treated with basal-bolustherapy and insulin dose software.
89065296|NCT01170208|Other|Group III|Type 2 diabetes treated with biphasic insulin and insulin dose software.
89065297|NCT01313624|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
89065298|NCT01313624|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
89065299|NCT05367466||Newborn with thrombossis|All admitted newborns in NICU during the study period
89065300|NCT05324410|Experimental|Part A: VX-840|Participants will be randomized to receive single dose of one of different dose levels of VX-840.
89065301|NCT05324410|Placebo Comparator|Part A: Placebo|Participants will receive placebo matched to VX-840.
89065302|NCT05324410|Experimental|Part B: VX-840|Participants will be randomized to receive multiple doses of one of different dose levels of VX-840. The dose levels will be determined based on the data from Part A.
89065303|NCT05324410|Placebo Comparator|Part B: Placebo|Participants will receive placebo matched to VX-840.
89065304|NCT02877043||patients undergoing lung resection|
89065305|NCT02891018|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
89065306|NCT02891018|Experimental|paclitaxel release coronary balloon catheter|Patients treated with paclitaxel release coronary balloon catheter
89065307|NCT01169350|Experimental|Diagnostic (18F FDG and 18F FMISO PET/CT)|Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.
89065308|NCT00623324|Active Comparator|1|Aplindore titrated to safe and tolerable dose
89065309|NCT00623324|Placebo Comparator|2|
89065310|NCT01169038|Active Comparator|Antibiotics|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
89065311|NCT04315012|Experimental|Receiving mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
89065312|NCT04315012|No Intervention|Standart|not to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
89065313|NCT01167634|No Intervention|1|
89065314|NCT01167634|Experimental|2|Deposit contract with a 1:1 match
89065315|NCT01167634|Experimental|3|Deposit contract with a 2:1 match
89065316|NCT01167634|Experimental|Experimental 4|Deposit contract with no match
89065317|NCT00624754|Experimental|1|Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
89065318|NCT00624754|Placebo Comparator|2|Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system
89065319|NCT02886052|Experimental|ICBT for insomnia|Therapist guided Internet-CBT for insomnia
89065320|NCT02886052|Active Comparator|Active control|Written information on sleep, insomnia, and sleep hygiene
89229812|NCT01043458|Experimental|2|ABT-126 High Dose
89065321|NCT01166386|Experimental|First steps treatment intervention|"A brief 10-session manualized acute neurobehavioral intervention program will be individually implemented with randomly assigned treatment participants. Session components include injury-related education, enhancement of self-awareness of deficits from the TBI, coping and cognitive skills training, and supported practice. The acronym FANCI refers to the name of the program which is First Steps Acute Neurobehavioral and Cognitive Intervention."
89065322|NCT01166386|Placebo Comparator|standard rehabilitation care|The controls will spend 10 one-half hours with a therapist viewing videos they choose from a menu, some of which have to do with brain injury. The therapist will interact naturally with the controls and occasionally relate the movie or film to brain injury rehabilitation.
89065323|NCT01114828|Experimental|3.75 mg|Once-daily oral administration of OPC-41061
89065324|NCT01114828|Experimental|7.5 mg|Once-daily oral administration of OPC-41061
89065325|NCT01313312|Experimental|Total Dysport®|A total of 254 subjects in the open label study received between 1 and 5 intramuscular (i.m) injections of Dysport® according to their individual needs, for a period of up to 12 months. All subjects were administered an appropriate dosage of Dysport® (1000 Units [U] or 500 U) on Day 1 of treatment Cycle 1. At each study visit from Week 12 onwards, subjects were assessed to determine whether a subsequent treatment cycle was required and treatment cycles were administered at intervals of a minimum of 12 weeks apart depending on the subject's safety and efficacy response. From Cycle 2 onwards, a total dose of 1500 U could be administered in subjects requiring treatment with Dysport® in their shoulder and other upper limb muscles. Subjects who showed improvement in their upper limb during the first two treatment cycles were able to receive concomitant injections of Dysport® 500 U into at least one calf muscle, from Cycle 3 onwards as long as the total dose did not exceed 1500 U.
89065326|NCT01114672|Active Comparator|Ergocalciferol|
89065327|NCT01114672|Placebo Comparator|oral placebo|
89065328|NCT01114516|No Intervention|control|emergent cerclage with no peri-operative antibiotics or indomethacin
89065329|NCT01114516|Experimental|indomethacin and antibiotics|perioperative antibiotics and indomethacin
89065330|NCT01114438|Experimental|Device|
89065331|NCT01313078|Experimental|Pegaspargase in women with cancer|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
89065332|NCT02890862||20 healthy volunteers|
89065333|NCT02890862||Dupuytren disease|10 patients dupuytren disease
89065334|NCT02890862||Tendon pathology|10 patients with tendon pathology
89065335|NCT02890862||wrist osteoarthritis|10 patients with wrist osteoarthritis
89065336|NCT01114360|Active Comparator|Melatonin|African-American subjects with mild to moderate essential hypertension will be given 8mg time release melatonin for 4 weeks. (either before or after placebo exposure).
89065337|NCT01114360|Placebo Comparator|Placebo|African-American subjects with mild to moderate essential hypertension will be given placebo for 4 weeks (either before or after exposure to melatonin)
89065338|NCT01310036|Experimental|Erlotinib|Erlotinib 150 mg daily
89065339|NCT01309100|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens.
89065340|NCT01309100|Active Comparator|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens.
89065341|NCT01309100|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens.
89065342|NCT01308788||aqueous suppressant|aqueous suppressant treated
89065343|NCT01308788||aqueous outflow|aqueous outflow treated
89065344|NCT01075321|Experimental|Arm I|Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89065345|NCT01114204|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
89065346|NCT01114204|Active Comparator|Iron Sucrose|Participants received an IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 (Baseline) and on 4 other non-consecutive days over a 14-day period, for a total cumulative dose of 1.0 g. Participants receiving their first ever exposure to IV iron sucrose, received a test dose on Day 1 prior to receiving the remainder of the first dose, as prescribed in the package insert for some countries.
89065347|NCT01075243|Experimental|Paracetamol 1000mg|Paracetamol 1000mg
89065348|NCT01075243|Experimental|Paracetamol 650 mg|Paracetamol 650 mg
89065349|NCT01075243|Placebo Comparator|Placebo|Placebo
89065350|NCT01308476||SMS group|
89065351|NCT01308476||control group|
89065352|NCT02890550||30 Patients Alström syndrome|
89065353|NCT02890550||60 Related patients Alström syndrome|
89065354|NCT01078441|Experimental|Treatment (combination chemotherapy)|Patients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89065355|NCT01308008|Experimental|Functional exercise- home physical activity|On-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with telephonic behavioral support
89065356|NCT01308008|Active Comparator|Flex and tone- home health education|Initial on-site flex and toning program continued on follow-up along with health education
89065357|NCT02876341||No chronic antihypertensives|Not on either a chronic β-blocker or ACE-Inhibitor
89229813|NCT01043458|Experimental|3|Placebo for ABT-126
89065358|NCT02876341||Chronic antihypertensives|On a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor
89065359|NCT02890706|Other|Patients|Each patient undergo the same CT protocol. Theobservers will observe the detection of the perfusion defects in two different techniques.
89065360|NCT00626665|Placebo Comparator|Placebo|One placebo tablet every alternate day for 6 weeks
89065361|NCT05644106|Active Comparator|Unaided|
89065362|NCT05644106|Active Comparator|Aided|
89065363|NCT01113892|Active Comparator|EXXCEL Soft|A vascular graft comprised of extruded, expanded polytetrafluroethylene (ePTFE), indicated for use as a vascular prosthesis for replacement or bypass of diseased peripheral arteries (510(k) K962433).
89065364|NCT01113892|Experimental|FUSION Bioline|A synthetic vascular graft constructed of two layers. The inner layer is comprised of extruded, ePTFE. The outer layer is comprised of knit polyester textile. These two layers are fused together with a proprietary polycarbonate-urethane adhesive. The vascular graft also has a heparin coating on the graft's luminal surface. The Bioline coating is a bioactive surface coating consisting of a covalent Heparin Sodium coupled to immobilized recombinant human albumin.
89065365|NCT02877979|Experimental|DS003 vaginal tablet|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
89065366|NCT02877979|Placebo Comparator|placebo|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
89065367|NCT00626353|Experimental|Intervention|Patients treated by an interdisciplinary, intersectoral and interventional team responsible for providing home-based rehabilitation.
89065368|NCT00626353|Active Comparator|Control|Control patients treated following standard care procedures in our department with no interference from the interventional team.
89065369|NCT04305847||Qual'AXI group|patients for whom distal arm surgery was performed under Axillary Brachial Plexus Block
89065370|NCT02881684|Experimental|Treatment|"Intervention:~Device: Aspiration Therapy (AspireAssist)~- Subjects randomized to the treatment group will undergo an endoscopic procedure to have the experimental device (i.e. the A-tube) inserted. This will be followed by regular follow up visits and lifestyle therapy matched to the control group. The device will be removed at the end of one year and this group will be observed for one year more to determine if there is any legacy effect.~Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy"
89065371|NCT02881684|Active Comparator|Control|"Intervention:~(1) Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy~- Subjects randomized to the control group will receive lifestyle management matched to the treatment group in the first year. At the end of one year, they will be crossed over to treatment and the A-tube will be inserted. They will then follow up the same follow up schedule of the treatment group during the first year."
89065372|NCT02876731|Other|single group|PET-CT MRI
89065373|NCT04310332||1L-PEG|Hospitalized patients who are prescribed colonoscopy with 1L-polyethylene glycole (PEG) plus ascorbic acid as bowel preparation.
89065374|NCT04310332||4L-PEG|Hospitalized patients who are prescribed colonoscopy with 4L-polyethylene glycole (PEG) as bowel preparation.
89065375|NCT01113580|Experimental|Adults|Healthy volunteers aged 18 to 59 years
89065376|NCT01113580|Experimental|Older Adults|Healthy volunteers aged 60 years or older
89065377|NCT01306214|Experimental|BI 10773 low dose|BI 10773 low dose once daily
89065378|NCT01306214|Experimental|BI 10773 high dose|BI 10733 high dose once daily
89065379|NCT01306214|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
89065380|NCT00623402|Experimental|A|
89065381|NCT01077739|Experimental|Avastin (bevacizumab) + standard of care|
89065382|NCT02876497|Experimental|Study arm|
89065383|NCT01306058|Experimental|Sorafenib & TRC105 in Hepatocellular CA|CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day
89065384|NCT02876653|Other|Severe OSA|Patients with severe OSA (AHI > 30)
89065385|NCT02876653|Other|Moderate OSA|Patients with moderate OSA (5 < AHI ≤ 30)
89065386|NCT02876653|Other|Healthy volunteers|Healthy volunteers (AHI ≤ 5)
89065387|NCT02876965|Active Comparator|Physical Exercise|Aerobic physical exercise protocol of moderate intensity, for 12 weeks, 3 sessions per week, about 12 minutes. Physical activity chosen will be pedaling on a static bike.
89065388|NCT02876965|Experimental|Muscle Stretching|Stretching program on the main muscle groups of the body, for 12 weeks, 1sessions per week, about 45 minutes.
89065389|NCT02877901|Active Comparator|tolterodine-treated group|they will receive long acting tolterodine 4 mg at bedtime for 4 weeks. After that re-evaluation. then stop medication for two weeks (washout period).
89229814|NCT00530894|Experimental|1|Cohort A: Sapien Valve
89229815|NCT00530894|Active Comparator|2|Cohort A: other surgical valve
89065390|NCT02877901|Placebo Comparator|placebo-control group|they will receive placebo at bedtime for 4 weeks. After that re-evaluation. then stop for two weeks (washout period). Then re-evaluate the nocturnal incontinence status and crosed over to receive long acting tolterodine 4 mg for 4 weeks. at the end the nocturnal incontinence status will be evaluated
89065391|NCT04306159|Sham Comparator|General anesthesia|Basal blood pressure and heart rate were recorded after midazolam administration of 0.02 mg/kg. Anesthesia was induced with sufentanil 0.4 μg/kg and propofol 2-2.5 mg/kg, IV route. An IV bolus of cisatracurium 0.1 mg/kg IV was given to facilitate tracheal intubation. Anesthesia was maintained with propofol 4-6 mg/kg/h combined dexmedetomidine 0.2 μg/kg/h(after 0.2 μg/kg/h loading dose within 15min)by bispectral index (BIS) 40-60 and additional bolus doses of remifentanil 0.2-0.5 μg/kg/min to keep arterial pressure values around 20% below baseline values. Sufentanil 0.1-0.2 μg/kg and flurbiprofen 100mg was administrated once the abdomen was closed, then a patient controlled analgesia pump was used. No RSB was performed.
89065392|NCT04306159|Experimental|Subcostal TAP combined with General anesthesia|After induction, TAP was performed. The transversus abdominis plane is imaged with the ultrasound probe obliquely on the upper abdominal wall, along the subcostal margin near the midline.The needle tip was advanced to the desired position where 20 mL 0.375%ropivacaine(Dexamethasone 5mg was added)were injected.The technique is repeated on the opposite side. Anesthesia method and management was same as general anesthesia group.
89065393|NCT04306159|Experimental|Modified RSB combined with General anesthesia|After induction, Modified RSB was performed based on midline incision-guided. The rectus muscle is imaged with the ultrasound probe in a transverse orientation below the xiphisternum and above the umbilicus.The needle tip was advanced to the two desired position where 10 mL ropivacaine 0.375% were injected causing hydrodissection of the rectus muscle away from the posterior rectus sheath.The technique is repeated on the opposite side.Anesthesia method and management was same as general anesthesia group.
89065394|NCT01305200|Placebo Comparator|Arm I (placebo)|Patients rinse and gargle with placebo over 1 minute QID beginning the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
89065395|NCT01305200|Experimental|Arm II (supersaturated calcium phosphate rinse)|Patients rinse and gargle with supersaturated calcium phosphate rinse over 1 minute QID beginning on the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
89065396|NCT01077271||Premature infants 33 - 35 wGA prophylaxed with palivizumab|Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with Synagis (palivizumab)
89065397|NCT01305044|Experimental|Tai Chi Chih|The Tai Chi Chih classes were 60 minutes sessions, held three times a week, over twelve weeks. The classes were led by an instructor who was certified and licensed in the Tai Chi Chih form.
89065398|NCT01305044|Active Comparator|Health Education Classes|Health Education classes were 60 minute sessions that occurred three times a week, over twelve weeks. These classes were taught by specialists in the class topic and focused on topics related to aging (e.g., sleep quality, nutrition, pain, etc.).
89065399|NCT01304498|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
89065400|NCT01304498|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
89065401|NCT01077193|Other|Gastric Plication Surgery|
89065402|NCT05644028|Experimental|Emotion regulation Intervention|An 8-week blended intervention targeting emotion dysregulation in ADHD
89222158|NCT04517994|Experimental|Active Treatment|The intervention includes components from empirically validated interventions for intimate relationship difficulties and PTSD. This includes core themes of trust, self-esteem, power and control, conflict-management skills, and communication skills training.
89222159|NCT04517994|Active Comparator|Supportive Treatment|Broadly based on the principles and techniques of client centered (Rogerian) therapy, and the fundamental principles and practices for experiential group psychotherapy as specified by Yalom. The group also draws upon the work of Murphy's Supportive Therapy protocol specifically for group intervention with domestic abuse perpetrators.
89690249|NCT00991081|Active Comparator|Standard treatment|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling.~A self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail~A standard 8-week course of genetically-tailored pharmacotherapy~Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~Participants with the A2 allele (CC) were assigned to receive bupropion"
89690250|NCT00991081|Experimental|Genetic feedback plus standard treatment|"In addition to the standard treatment, participants in this arm received the following interventions:~Genetic feedback, verbal - During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment~Genetic feedback, printed - After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype"
89690251|NCT03163342|Other|Open label|Licensed seasonal influenza vaccine, intramuscular
89690252|NCT03165058||Inflammatory Bowel Disease|Patients undergoing standard of care colonoscopy for inflammatory bowel disease (IBD) surveillance will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
89065403|NCT02876029|Other|Reference|White wheat bread
89065404|NCT02876029|Other|Test product|Pasta
89065405|NCT05661110||Prospective Sample Collection|Prospective sample collection from participants treated with HIPEC combined PD1/PDL1inhibitor at Affiliated Cancer Hospital & Institute of Guangzhou Medical University under standard of care treatment. Blood and tissue samples will be collected prior to initiation of conversion therapy. And thereafter at the four time points: before and after surgery(±7 days), before the start of the second cycle of adjuvant, tumour progression, blood sample will be collected too.
89065406|NCT02890628||pregnant/post-natal adolescents (<20 years)|12-24 individual with pregnant or postnatal adolescent girls (<20 years) will be interviewed.
89065407|NCT02890628||non-pregnant female adolescents (<20 years)|1 Focus group discussion of 6-10 non-pregnant female adolescents (<20 years)
89065408|NCT02890628||male adolescents (<20 year)|1 Focus group discussion of 6-10 adolescent men (<20 years)
89065409|NCT02890628||SMRU health staff of antenatal clinics (ANC)|1 Focus group discussion of 6-10 Shoklo Malaria Research Unit antenatal clinic staff
89690253|NCT03165058||control|Patients undergoing standard of care colonoscopy for age appropriate screening will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
89690254|NCT03018145|Experimental|Standard stretcher group|Use a standard stretcher car as a transporting method in the operating room
89690255|NCT03018145|Active Comparator|Wagon group|Use a wagon as a transporting method in the operating room
89690256|NCT01351623|Experimental|Carfilzomib|A single arm, open-label, single institution phase 2 clinical trial is planned.
89690257|NCT03017911||Patients with PICC Lines|All patients included in this study have undergone PICC Line placement before enrollment.
89690258|NCT03168022|Experimental|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
89690259|NCT03168022|Experimental|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
89690260|NCT03272529||Patient-specific simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. This is in addition to standard prerequisite simulation training.
89690261|NCT03272529||Idealized simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models that incorporate the necessary anatomy, physiology, and pathology of an ideal training case. This is in addition to standard prerequisite simulation training.
89690262|NCT03272529||Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in this group in addition to the standard.
89690263|NCT03017989|Experimental|NIRF imaging|After the white light (WL) imaging, NIRF imaging will be performed. 2.5 mg of ICG will be administered i.v. up to 5 times if needed. The lesions identified in WL, are inspected in NIRF mode. The surgeon indicated whether the lesions are more easily identified in WL or the NIRF mode and scores the visibility on a 1-10 scale. Next, inspection will take place for lesions that are seen in NIRF mode but not in WL. Biopsies will be taken from the lesions and from normal tissue for reference and sent for histology. Evaluation will take place whether the lesions differ in histological characteristics
89690264|NCT04342533|Experimental|ThuFLEP|Patients who underwent thulium fiber enucleation of the prostate
89690265|NCT04342533|Active Comparator|HoLEP|Patients who underwent holmium laser enucleation of the prostate
89690266|NCT03102190|Experimental|Phase Ib|The phase Ib study will consist of an accelerated titration, intrapatient dose escalation cohort, with double-dose step design of Verapamil Hydrochloride. Intranasal BID for 1 week. Dose escalation will occur weekly as a doubling of the dose from 10-120mg Verapamil delivered in 240mL buffered normal saline. If a single, any course, dose-limiting toxicity (DLT) or second, any course, IT occurs, two additional patients will be recruited at that identified dose and Phase Ib will revert to a standard 3+3 design. If any patient un-enrolls while the dose escalation is still occurring, they will be replaced to maintain 3 patient cohorts. The maximal administered dose (MAD) will be considered that at which at least 2 DLTs or 4 ITs occur and the MTD will then be assigned to the immediate preceding dose.
89222160|NCT04492956|Experimental|Ecopipam HCl ~2mg/kg/day|Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks
89065410|NCT01074931||Lopinavir/ritonavir group|This study is a non-interventional, observational study in which lopinavir/ritonavir is prescribed in the usual manner in accordance with the terms of China market authorization with regards to dose, population and indication. It is planned to enroll approximately 100 patients in total.
89222161|NCT04492956|Placebo Comparator|Matching Placebo|Matching placebo tablets for daily, oral administration for 12 weeks
89222162|NCT04478136||Major bleeders (MB)|Additional blood to be drawn from patients on ECMO who have a major bleeding event.
89222163|NCT04478136||Non-major bleeders (NMB)|
89222164|NCT00117793|Active Comparator|Arm 1|Current clinical practice
89222165|NCT00117793|Experimental|Arm 2|Novel socket system
89222166|NCT01084213|Active Comparator|IPTp with SP|Study women will receive at least two doses of SP during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
89222167|NCT01084213|Experimental|IST using RDTs|Scheduled intermittent screening using rapid diagnostic tests and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester.
89222168|NCT00695669|Experimental|Influenza A (H5N1) 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
89222169|NCT00695669|Experimental|Influenza A (H5N1) 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 14. The vaccine was administered intramuscularly in the deltoid region of the arm.
89222170|NCT00695669|Experimental|Influenza A (H5N1) 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 7. The vaccine was administered intramuscularly in the deltoid region of the arm.
89222171|NCT00695669|Experimental|Influenza A (H5N1) 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0. The vaccine was administered intramuscularly in the deltoid region of the arm.
89222172|NCT03671369||Cervarix Group|The study group comprised of 9-25 year-old male and female subjects who were administered with 3 doses of Cervarix vaccine, according to a 0, 1, and 6 months schedule, as per locally approved prescribing information (PI) in Korea. The 9-14 years old subjects were vaccinated with 2 doses, according to a 0 and 6-12 months schedule. In the 2-dose schedule, if the second dose was administered before 5 months after the first dose, the third dose vaccination was required. In the 3 doses schedule, if the vaccination schedule required flexibility, the second dose was administered between 1 and 2.5 months and the third dose was administered between 5 and 12 months after the first dose.
89229816|NCT00530894|Experimental|3|Cohort B: Sapien Valve
89065411|NCT04306003|Experimental|Enhanced Recovery After Surgery (ERAS) pathway|"Preop~Diet: Solids until midnight before surgery with a carbohydrate rich drink before midnight and 3-hours prior to surgery.~Analgesia: Acetaminophen 975mg & Celecoxib 400mg administered PO 1-hour before surgery.~Intraop~Hypothermia prevention: Forced-air warming units and core temperature monitoring.~Fluid management: Euvolemic fluid management with balanced crystalloid solution.~Analgesia: 0.25% bupivacaine block of intercostal nerves and rectus sheath by the surgical team. Additional IV analgesia by anesthesiologist with the goal to minimize opioids.~PONV prophylaxis: Ondansetron 4-8mg IV during emergence.~Postop~Diet: Clear fluids immediately post-op. Saline lock and advance to DAT on POD#1.~Analgesia: Routine administration of Acetaminophen 975mg PO q6h & Celecoxib 200mg PO q12h. Opioids used as breakthrough analgesia only. No PCA.~Early mobilization: Mobilization within the first 24 hours after surgery with assistance."
89065412|NCT04306003|Active Comparator|Standard Perioperative Care|Patients in the control arm received routine perioperative care as determined by respective surgeons participating in the study.
89065413|NCT00626587|Placebo Comparator|A|Conventional diagnostic procedures (transbronchial biopsy and bronchial washing) for peripheral pulmonary lesions
89065414|NCT04774159|Active Comparator|Colchicine|Colchicine 0.5mg daily for the duration of the trial
89065415|NCT04774159|Placebo Comparator|Colchicine-Placebo|Colchicine-Placebo daily
89065416|NCT02877745||no SDB|apnea-hyponea index <15/hour
89065417|NCT02877745||SDB|apnea-hyponea index >=15/hour
89065418|NCT01303172|Active Comparator|Gemcitabine chemotherapy|Patients in the control arm will receive normal standard of care - up to 12 cycles of Gemcitabine. Dosing of Gemcitabine is as per the normal prescribing information for pancreatic cancer.
89222173|NCT04060745|Experimental|Cooling|Participants will be cooled using an individualized cooling protocol with a water-perfused vest for two hours while resting. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
89222174|NCT04060745|Experimental|Thermoneutrality|Participants will rest for one hours. Afterwards, participants will drink 75g of D2-glucose dissolved in water and DMI will be performed.
89222175|NCT00742937|Placebo Comparator|A|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of vitamin E will be administer.
89065419|NCT01303172|Experimental|IMM-101 in addition to gemcitabine|"Patients in the experimental arm will receive IMM-101 in addition to the current standard of care, namely chemotherapy (Gemcitabine). The treatment regimen with IMM-101 will be every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~For patients in the active group, chemotherapy (Gemcitabine) will begin at least 14 days after first dose of IMM-101.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Patients who complete the Main Study and who provide informed consent are eligible to participate in a long term treatment Sub-Study (IMM-101-002A)"
89065420|NCT01302938|Experimental|Tolterodine ER|
89065421|NCT01302938|Placebo Comparator|Placebo|
89065422|NCT05643872|Experimental|PTX-022|
89065423|NCT01302548|Experimental|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
89065424|NCT01302548|Active Comparator|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
89065425|NCT01076959||Humira|The sponsor was required to include all patients diagnosed with rheumatoid arthritis and who were treated Humira in routine medical practice during the review period by the PMDA. The safety analysis set included all patients who met all eligibility criteria and received at least one dose of Humira. The full analysis set included all patients who were treated with Humira for at least 2 weeks and had complete DAS 28 assessments at baseline and at least one other time point.
89065426|NCT01302392|Active Comparator|Best Supportive Care|
89065427|NCT01302392|Experimental|Carfilzomib|
89065428|NCT01076647|Experimental|IDeg 3TW|
89065429|NCT01076647|Active Comparator|IGlar OD|
89065430|NCT04306081|Experimental|Treatment Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of evolocumab 420 mg via subcutaneous injections for 6 months.
89065431|NCT04306081|Placebo Comparator|Control Arm|43 Patients with lower extremities Peripheral Arterial Disease on maximum statin therapy will receive in addition a monthly dose of placebo via subcutaneous injections for 6 months.
89065432|NCT01074307|Experimental|Low Dose Bisoprolol|
89065433|NCT01074307|Experimental|High Dose Bisoprolol|
89065434|NCT01076335|Experimental|Neoadjuvant Hormones + Docetaxel|Neoadjuvant Hormonal Therapy plus Docetaxel followed by Radical Prostatectomy
89065435|NCT01309737|Experimental|Active Treatment 10 mg BID|
89065436|NCT01309737|Experimental|Active Treatment 5 mg BID|
89065437|NCT01309737|Placebo Comparator|Placebo Treatment|
89065438|NCT01074229|Placebo Comparator|Placebo|sterile normal saline as placebo
89065439|NCT01074229|Active Comparator|Drug .5% Ropivacaine|Instillation of 20 cc of 0.5% ropivacaine
89065440|NCT01074229|Active Comparator|20 cc of 0.25% ropivacaine|Instillation of 20 cc of 0.25% ropivacaine
89065441|NCT01106014|Experimental|1|Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose
89065442|NCT01106014|Placebo Comparator|2|Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed
89065443|NCT01073605|Active Comparator|Genotonorm A|Continuous 0.7 IU/kg/week or 0.03 mg/kg/day
89065444|NCT01073605|Active Comparator|Genotonorm B|Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day
89065445|NCT01073605|Active Comparator|Genotonorm C|Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day
89065446|NCT01073293|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
89229817|NCT00530894|Active Comparator|4|Cohort B: Medical therapy
89065447|NCT01073293|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
89065448|NCT01105936|Experimental|Paracetamol caplets|Two 665 mg sustained release paracetamol caplets administered orally with water.
89065449|NCT01105936|Placebo Comparator|Placebo caplets|Two placebo caplets administered orally with water.
89065450|NCT01309659|Experimental|Immediate Intervention Group|Subjects randomized to the immediate treatment group will be scheduled to begin treatment with IV iron infusion immediately (or within 2 business days). They will receive 200mg IV iron sucrose a week for 5 weeks followed by 19 weeks of follow up.
89065451|NCT01309659|Experimental|Wait List Control|Subjects randomized to the wait list control group will have an observation visit at week 6 and week 12. After that they will begin treatment with IV iron infusion. They will receive 200mg IV iron sucrose a week for 5 weeks followed by 7 weeks of follow up
89065452|NCT04989166|Active Comparator|Nano-curcumin|80mg of Nano-curcumin daily
89065453|NCT04989166|Placebo Comparator|Placebo|Placebo
89065454|NCT04870411||Patients with auto-immune or autoinflammatory diseases|Patients with auto-immune or autoinflammatory diseases treated with immunosuppressants and/or biologics
89065455|NCT04870411||Patients without auto-immune or autoinflammatory diseases|Patients without auto-immune or autoinflammatory diseases and not treated with immunosuppressants and/or biologics
89065456|NCT05320705|Active Comparator|dexmedetomidine|dexmedetomidine will be administered as a bolus dose, before the surgical incision, followed by infusion and stopped at the end of operation
89065457|NCT05320705|Placebo Comparator|normal saline placebo|similar bolus and infusion volumes of normal saline will be administered
89222176|NCT00742937|Experimental|B|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of 200,000 UI of retinol palmitate (vitamin A)plus vitamin E will be administer.
89222177|NCT00692003|Active Comparator|Zonisamide|
89222178|NCT00692003|Placebo Comparator|Placebo|
89222179|NCT02564315|Active Comparator|Reduction/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
89229818|NCT00300898|Active Comparator|Nucleoplasty|Procedure/Surgery: Nucleoplasty
89222180|NCT02564315|Active Comparator|Reduction/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
89229819|NCT00300898|Active Comparator|Percutaneous decompression|Procedure/Surgery: Percutaneous decompression
89229820|NCT00300898|Active Comparator|Electrothermal disc decompression (IDET)|Procedure/Surgery: Intervertebral electrothermal disc decompression (IDET)
89065458|NCT04305535|Active Comparator|Peptidic+Probiotic|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and mix of probiotics during 6 months
89065459|NCT04305535|Active Comparator|Peptidic+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
89065460|NCT04305535|Placebo Comparator|Polymeric+Placebo|Nutritional intervention and dietary recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement and placebo during 6 months
89065461|NCT04305223|Experimental|Dry needling and upper extremity stretching program Arm|"Participants will receive a combination of dry needling and upper extremity stretching.~Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin America, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.~A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter."
89065462|NCT04305223|Active Comparator|Dry Needling Arm|Dry needling in regions of the head and cervical spine will be positioned supine, sidelying or prone with the relevant myofascial trigger points treated using a Seirin L- type 30 mm needle (Seirin American, Inc., Weymouth, MA). The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 5 minutes.
89065463|NCT02875951||ER positive, HER2 negative breast cancer patients|Postmenopausal patients with hormone receptor positive, HER2 receptor negative breast cancer
89065464|NCT01104766|Experimental|Cariprazine 3mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
89065465|NCT01104766|Experimental|Cariprazine 6mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
89065466|NCT01104766|Active Comparator|Aripiprazole 10mg|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
89065467|NCT01104766|Placebo Comparator|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
89065468|NCT04305379|Experimental|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction (Sling + Intussusception)
89065469|NCT04305379|Active Comparator|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction (Intussusception Only)
89065470|NCT02880280|Experimental|Human Menopausal Gonadotropin|Human menopausal gonadotropin contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
89065471|NCT02880280|Experimental|Human Chorionic Gonadotropin|Human chorionic gonadotropin (hCG) is a hormone produced by the embryo after implantation
89065472|NCT04304287|Experimental|Experimental|Preoperative blood donations 14 day before total hip replacement procedure Donation of one dose of autologous blood 14 day before total hip replacement procedure
89065473|NCT04304287|Active Comparator|Active comparator|Preoperative blood donation 72 hours before total hip replacement procedure Donation of one dose of autologous blood 72 hours before total hip replacement procedure
89065474|NCT04304287|Other|Other|Without preoperative blood donation
89065475|NCT02879968||Head and Neck squamous cell carcinoma|"A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients.~The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott).~The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula."
89065476|NCT04743271|Experimental|High-Fat Diet|50% fat, 35% carbohydrate and 15% protein; 33% of each mono, poly and saturated fat
89065477|NCT04743271|Active Comparator|Low-Fat Diet|30% fat, 55% carbohydrate and 15% protein
89065478|NCT02880046||Melanoma (LyteloMel)|
89065479|NCT02880046||Lung cancer (TeloCap)|
89065480|NCT02880046||Renal carcinoma (EMIR)|
89065481|NCT01104376|Experimental|CYP2B6|"Healthy volunteers will receive Efavirenz and Vericonazole as follow:~In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered. In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
89065482|NCT02875873|Experimental|Plasma-Lyte, Slow Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
89065483|NCT02875873|Experimental|Plasma-Lyte, Fast Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
89065484|NCT02875873|Experimental|Saline 0.9%, Slow Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
89065485|NCT02875873|Experimental|Saline 0.9%, Fast Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
89065486|NCT02880202|Other|Massage Therapy|Massage therapy for hospice patients.
89065487|NCT02880124|Experimental|Maple syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
89065488|NCT02880124|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
89229821|NCT00300898|Experimental|Behavioral:Conservative treatment|Conservative treatment with oral medications, physical therapy, epidural steroid injections
89065489|NCT02880124|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
89065490|NCT02880124|Active Comparator|Sport drink|A Gatorade (TM) solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
89229822|NCT01040182||ischemic stroke patients|
89229823|NCT01040182||healthy subjects without cerebrovascular disease|
89229824|NCT03474094|Experimental|pre-operative radiotherapy and atezolizumab|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
89690267|NCT04353427|Experimental|Faith based educational group|"A seven-session faith-based small group educational program using the The Seven Pathways to Healing, Health and Wellness curriculum will be delivered."
89690268|NCT04342455|No Intervention|traditional scanning protocol group|In coronary CTA examination,each subject will be injected 50 ml contrast agent (Iodixanol 320) with the flow rate of 5 ml/s in tube voltage of 120 kVp.
89690269|NCT04342455|Experimental|double-low scanning protocol group|In coronary CTA examination,the tube voltage(70，80,100kVp),contrast agent(Iodixanol 320) volume and flow rate of each subject are adapted to his or her cardiac ejection fraction(EF) and body mass index(BMI).
88812660|NCT00891176|Active Comparator|Prevenar-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
89065491|NCT02880124|Placebo Comparator|Trace|A solution containing stevia (sugar substitute) and trace amounts of glucose (3g) labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
89065492|NCT01072357|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 milliliter (mL) (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
89065493|NCT01072357|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% sodium chloride (NaCl). Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
89065494|NCT01072201|Experimental|Total toothpaste|Triclosan/copolymer/fluoride toothpaste
89065495|NCT01072201|Placebo Comparator|Ultrabrite toothpaste|Fluoride Toothpaste
89065496|NCT01103362|Experimental|flibanserin 100mg|flibanserin 100mg po qd
89065497|NCT00591929|No Intervention|1|No Continuous passive motion following ORIF of fractures around the knee
89065498|NCT00591929|Active Comparator|2|Continuous Passive Motion following ORIF of fractures around the knee
89065499|NCT04208009|Experimental|Advance care planning animated videos|This arm consists of viewing four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
89690270|NCT02163811|Experimental|VETPALS|VETPALS is a five session course utilizing adult learning methods to teach self-management for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA Puget Sound clinician in conjunction with a peer facilitator (Veteran with limb loss).
89690271|NCT02163811|Active Comparator|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
89690272|NCT03168334|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
89690273|NCT03168334|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
89690274|NCT05108467||Case|Severe sepsis with or without shock
89690275|NCT05108467||Comparison|Severe dehydration with shock
89690276|NCT03102736|Placebo Comparator|Placebo and Ketamine|Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over 40 minutes
89690277|NCT03102736|Experimental|Nitroprusside and Ketamine|0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)
89690278|NCT03743103|Experimental|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
89690279|NCT03743103|Active Comparator|Nitroprusside, Sodium|0.5 mcg / kg / min every 3 minutes until reaching the pressure target
89690280|NCT04049266|Experimental|KSI-301 5 mg|"Drug: KSI-301 5 mg. KSI-301 5 mg will be administered by intravitreal injection into the study eye at 12, 16, and 20 weeks intervals as specified in the study protocol.~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
89690281|NCT04049266|Active Comparator|Aflibercept 2 mg|"Drug: Aflibercept 2 mg. Aflibercept 2 mg will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.~Drug: Sham Procedure. The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking."
89690282|NCT00992719|Active Comparator|Group 3: Non-pregnant Women: 15 mcg H1N1 Vaccine|100 non-pregnant women to receive 15 mcg inactivated H1N1 vaccine.
89690283|NCT00992719|Experimental|Group 2: Pregnant Women: 30 mcg H1N1 Vaccine|100 pregnant women to receive 30 mcg inactivated H1N1 vaccine.
89690284|NCT00992719|Experimental|Group 1: Pregnant Women: 15 mcg H1N1 Vaccine|100 pregnant women to receive 15 mcg inactivated H1N1 vaccine.
89690285|NCT03169816|Experimental|Lorcaserin|10 mg capsule taken twice daily of lorcaserin
88812661|NCT00839540|Active Comparator|micafungin 100|Patients receive Micafungin 100 mg qd
88812662|NCT00839540|Active Comparator|micafungin 200|Patients receive 200 mg Micafungin qd
89065500|NCT01103284|Experimental|DiaPep277|Administration of 1 mg DiaPep277®, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
89065501|NCT01103284|Placebo Comparator|Placebo|Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
89065502|NCT02893709|Experimental|Omeprazole|A course of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
89065503|NCT04972396|Experimental|Part 1|
89065504|NCT04972396|Experimental|Part 2|
89065505|NCT04972396|Experimental|Part 3|
89065506|NCT01070953||EZETROL® 10 mg|Participants with Hypercholesterolemia treated with EZETROL®
89065507|NCT00625924||1|autogenous tissue breast reconstruction
89065508|NCT00625924||2|tissue expander/implant breast reconstruction
89065509|NCT00625924||3|mastectomy alone
89065510|NCT02877589||solid tumor|Patients receiving chemotherapy for solid tumors in Ambulatory Medicine Unit of the Reims University Hospital (France) between May 14, 2012 and July 31, 2013.
89065511|NCT04309162|Experimental|soft tissue therapy|Soft tissue therapy includes various techniques which is usually done by manipulating the soft tissues. The techques like stroking, petrissage, percussing maniulations are proved helpful in managing various painful conditions. The main effect of the soft tissue therapy is enhanced blood circulation to the area. When the techniques of soft tissue therapy are applied they will results in stretching and rubbing the muscular tissue which results in increased venous flow to heart and removal of the lactic acid accumulation occurs as the fresh supply of blood to the area will increased. Endorphins the natural pain relievers are released as there is improved oxygenation and perfusion of oxygen in tissues.
89065512|NCT04328597||Chronic postoperative pain|Patients scoring 3 or more on the EuraHS Quality of Life assessment after elective inguinal hernia repair
89065513|NCT04328597||Non chronic postoperative pain|Patients scoring less than 3 on the EuraHS Quality of Life assessment after elective inguinal hernia repair
89065514|NCT04300543||Group 1 MS patients|patients with multiple sclerosis
89065515|NCT04300543||Group 2 patients with other neurological disorders|patients with inflammatory or non inflammatory neurological diseases other than multiple sclerosis
89065516|NCT04300543||Group 3 healthy control|No neurological or immunological disease
89065517|NCT04406519||Hemophilia Group|The inclusion criteria in the hemophilia group were as follows; patients aged 6 to 18 years who developed HA in at least one of the lower limb joints due to severe haemophilia (total lower limb HJHS ≥3); to be receiving prophylaxis but have no major bleeding that could affect the musculoskeletal system in the past two weeks; and who did not perform regular physical activity and sports.
89065518|NCT04406519||Control Group|The control group was consisted of healthy peers. The exclusion criteria in the control group were as follows: who had any auditory and visual impairment; who underwent orthopedic injuries including lower limb; and who had any neurological or cognitive impairment that could affect balance.
89065519|NCT04133207||Patients with advanced HR-positive breast cancer|patients with histologically confirmed HR-positive, HER2-negative advanced (recurrent or metastatic) breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
89065520|NCT01089361|Placebo Comparator|Normal saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
89065521|NCT01089361|Experimental|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
89065522|NCT04399733||Ethnicity|Patients will be segmented on a 1:1:1 ratio similar to the EMPOWER-1 study based on ethnicity (White, Black, South Asian).
89690286|NCT03169816|Placebo Comparator|Placebo|a placebo comparator capsule taken twice daily
89690287|NCT00362427|Experimental|Group A|
89690288|NCT00362427|Experimental|Group B|
89690289|NCT00362427|Active Comparator|Group C|
89690290|NCT03103438|Experimental|Cohort 1|his cohort includes one subject who will receive the maximum safe starting dose of BCD-089 (0.06 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
89690291|NCT03103438|Experimental|Cohort 2|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.3 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no.3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3.
89690292|NCT03103438|Experimental|Cohort 3|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.625 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4.
89065523|NCT01102972|Experimental|ATV + ABC/3TC|Subjects will change to ATV 400mg administered as two 200mg capsules orally, once daily and to the fixed-dose combination tablet of ABC 600mg/3TC 300mg (EPZICOM) administered as one tablet orally, once daily for 48 weeks. The subject's pre-study RTV will be discontinued.
89065524|NCT01102972|Active Comparator|ATV + RTV + TDF/FTC|Subjects will continue their pre-study therapy, un-modified, of ATV 300mg administered as one capsule orally, once daily plus RTV 100mg administered orally, once daily plus fixed dose combination tablet tenofovir 300mg/emtricitabine 200mg administered as one tablet orally, once daily for 48 weeks.
89065525|NCT02893319|No Intervention|Breastfeeding|control group
89065526|NCT02893319|Active Comparator|5 oz bottle|Subject will feed infant with 5oz medela bottle
89065527|NCT02893319|Active Comparator|8 oz bottle|Subject will feed infant with 8oz medela bottle
88812663|NCT00839540|Active Comparator|Caspofungin|Patients receive caspofungin 70 mg LD followed by 50 mg qd
89065528|NCT04328753|Experimental|super oxidized water group|
89065529|NCT04328753|Active Comparator|chlorhexidene group|
89065530|NCT04328753|Placebo Comparator|distilled water|
89065531|NCT04328363|Experimental|Intervention|The intervention will be carried out by primary care nurses over eight visits: baseline visit and follow-up visits which take place 15 days, 1, 2, 4, 6, 9, and 12 months after baseline with a final visit evaluation at 18 months. The intervention will be based on the social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles in people with prediabetes. The content of the intervention proposed is based on the NHS and it will be carried out at three levels (individual, group and community) to facilitate the patient empowerment and promotion of healthy lifestyles with a positive orientation using the community resources.
89065532|NCT04328363|No Intervention|Control|The Control group will receive routine standard care.
89065533|NCT04963894|Experimental|Home functional balance physiotherapy|Participants perform physical therapy at home individually with a physical therapist. The experimental program of the study of balance exercise in functional context is implemented.
89065534|NCT04963894|No Intervention|Home functional daily activity|Participants stay in home without physiotherapy. Participants maintained their normal daily activities, which included housework, shopping, or daily walks.
89065535|NCT04963894|Active Comparator|Conventional physiotherapy|Participants perform physical therapy in a rehabilitation gym and in groups of 10 people. The conventional program of physiotherapy is implemented.
89065536|NCT01309269||Cohort|
89065537|NCT01088503||ADP receptor inhibitor treatment|Participants admitted for non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) and treated with an ADP receptor inhibitor during the index hospitalization.
89065538|NCT01087489|Experimental|4% lidocaine|Eyes were anesthetized with 0.5% proparacaine and then with three cotton swabs soaked in 4% liquid lidocaine applied with moderate pressure to the site of the injection inferotemporally to the limbus. Each participant was assigned to have this prep during one of the consecutive study visits if unilateral or in one eye if patient requires bilateral injections given the same day
88812664|NCT02966912|Experimental|Magnesium|20 participants will be treated with 400 mg of Magnesium Oxide twice daily
89065539|NCT01087489|Experimental|3.5% ophthalmic lidocaine gel|Eye was anesthetized with 0.5% proparacaine and then with 3.5% ophthalmic lidocaine gel applied to the surface of the eye. Each participant was randomly assigned to receive this preparation during one of two consecutive intravitreal injection (if unilateral disease) or in one eye if requiring bilateral injections given on the same day.
89065540|NCT04306627|Active Comparator|Perindopril/Amlodipine arm|"Patients will be preliminary screened before 7-10 days for clinical and laboratory examination to meet eligibility criteria for inclusion in study.~Perindopril+amlodipine combination doses will be up titrated over two weeks in case of need to control adequate arterial blood pressure < 140/90. The 4 doses combinations and their adjustments will be made by investigating physician according to guideline based treatment of arterial hypertension and dyslipidemia."
89065541|NCT04306627|Active Comparator|Perindopril/Amlodipine/Atorvastatin arm|Subjects should not previously be on statin therapy and subjects who needs to be will start atorvastatin in combination treatment pill . We will study the effects of 6-month treatment with perindopril +amlodipin+atorvastatin combination on plasma concentrations of total cholesterol and LDL cholesterol.
89065542|NCT04306471|Experimental|Treatment arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition the study intervention involving a monthly subcutaneous injection of evolocumab 420 mg for 12 months
89065543|NCT04306471|Placebo Comparator|Control arm|16 Patients with Critical Limb Ischemia on maximum statin therapy will receive in addition a Placebo subcutaneous injection for 12 months.
89065544|NCT04758481|Experimental|Primary tumour radiotherapy + stereotactic body radiotherapy + maintenance radiotherapy|The patients, in whom disease stabilisation/partial regression will be achieved, will undergo primary tumour radiotherapy and stereotactic body radiotherapy, followed with maintenance radiotherapy.
89065545|NCT04304989|Experimental|Intervention|This group of participants will receive a video-based mHealth program which includes two main elements: 1) nurse case management supported by a social service team, 2) individual-specific video messages covering self-care topics delivered via smartphone
89065546|NCT04304989|Other|Control|The participants in this group will receive usual care
89065547|NCT04295785||autoimmune necrotizing myopathy beginning before 18|
89222181|NCT02564315|Active Comparator|Reduction/Skill Counseling+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
89222182|NCT02564315|Active Comparator|Reduction/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
89222183|NCT02564315|Active Comparator|Recycling/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
88812665|NCT02966912|Active Comparator|Comparator|20 participants will receive no treatment
88812666|NCT01437605|Active Comparator|A: recMAGE-A3 + AS15|ASCI injections without Poly IC:LC
88812667|NCT01437605|Active Comparator|B: recMAGE-A3 + AS15 + Poly IC:LC|ASCI injections with Poly IC:LC
89222184|NCT02564315|Active Comparator|Recycling/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
89065548|NCT02877667|Experimental|Open label device treatment|Up to four passes with Q-Switched laser alternating with acoustic wave device
89065549|NCT01082965|Experimental|Treatment|
89065550|NCT01082965|Placebo Comparator|Placebo|
89065551|NCT01102426|Experimental|Plitidepsin+Dexamethasone|plitidepsin + dexamethasone combination
89065552|NCT01102426|Active Comparator|Dexamethasone|dexamethasone single agent
89229825|NCT03474094|Experimental|pre-operative atezolizumab and post-operative radiotherapy|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
89065553|NCT04304365|Active Comparator|Clinic follow-up group|All participants in this group will receive the standard of care at BMC which includes receiving a follow-up visit date and time before leaving the initial visit, when they receive the medications for abortion. Patients then return to clinic 1-2 weeks later to be seen by a provider with an ultrasound for confirmation of abortion completion. Participants who do not come for a return visit receive one phone call to reschedule their appointment.
89065554|NCT04304365|Experimental|Home follow-up group|Participants enrolled in the home follow-up group will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. At enrollment, they will receive instruction for timing of contact, how to use the LSPT, as well as the test itself. The participant will take the pregnancy test at home in 14 days and answer completion questions by text message for follow-up. Patients that screen positive will be asked to return to clinic for a visit with a provider.
89065555|NCT04308772|No Intervention|Usual Care|Those randomised to the usual care arm will receive a leaflet which contains a standard programme of exercises Participants will be asked to complete their exercise programme as prescribed (at least once per day).
89065556|NCT04308772|Experimental|Web-based physiotherapy|Participants will receive a six week exercise programme, based on those in the usual care exercise sheet delivered via the web-based physio website (www.giraffehealth.com).
89065557|NCT02879422|Other|Diabetic patients with proliferative diabetic retinopathy|
89065558|NCT02879422|Other|Diabetic patients with non proliferative diabetic retinopathy|
89065559|NCT02879656|Other|Cohort 1|"Early ustable fracture:~Phase 1:~After closed reduction, if satisfactory reduction is not achieved fulfilling the inclusion criteria, the patient is allocated to Cohort 1. The patient is randomized to either non-operative (=Arm 1) or operative treatment (=Arm 2). Patients allocated to non-operative treatment will undergo a standard treatment protocol. Patients allocated to operative treatment will undergo a surgery with volar locking plate with modified Henry's volar approach."
89065560|NCT02879656|Other|Cohort 2|"Early stable fracture:~Phase 1:~After closed reduction, if satisfactory position is achieved, the patient is allocated to Cohort 2 and conservative treatment is performed as usually.~Phase 2:~Patients allocated to Cohort 2, will visit orthopedic outpatient clinic in 1 week in the hospital where the treatment was initially started. If reduction is maintained the patient will undergo standard follow-up visits. If reduction is lost to fulfill the inclusion criteria for surgery the patient is asked to participate to phase 2 of this study. After the patient´s enrollment has been confirmed and informed consent is signed, the patient is randomized to either non-operative (=Arm 3N) or operative treatment (=Arm 3O). If allocated to non-operative treatment patient will undergo the same protocol as those in the Arm 1. Patients allocated to operative treatment will undergo surgery with volar locking plate with standard volar approach."
89065561|NCT02881138|Experimental|RC48-ADC|Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.
89065562|NCT04308460|Active Comparator|arthrocentesis group|the group of internal derangement patients which was treated with arthrocentesis procedure
89065563|NCT04308460|Active Comparator|operative arthroscopy group|the group of internal derangement patients which was treated with operative arthroscopy procedure
89065564|NCT02879734|No Intervention|Without Omentopexy|Patients that did not undergo prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter
89065565|NCT02879734|Experimental|With Omentopexy|Patients that underwent prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter. Intervention = Prophylactic laparoscopic omentopexy
89065566|NCT02879344|Other|Patient undergoing ECMO|
89065567|NCT02879266|Experimental|TetraVax-DV TV005|Participants will receive a subcutaneous injection of TetraVax-DV TV005 at study entry (Day 0).
89065568|NCT02879266|Placebo Comparator|Placebo|Participants will receive a subcutaneous injection of placebo at study entry (Day 0).
89065569|NCT04308850|Experimental|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
89065570|NCT04308850|No Intervention|Control|The other group do not interfere.
89065571|NCT04308538|Active Comparator|Standard Recession|Bilateral lateral rectus muscle recession using standard tables stated by Parks.
89065572|NCT04308538|Experimental|Reduced Recession|Bilateral lateral rectus muscle recession using reduced numbers by one millimeter than the standard tables.
89065573|NCT02880670|Experimental|Single dose of radiolabeled BMS-986142|
89065574|NCT01101334|Experimental|CS-7017 plus erlotinib|
89065575|NCT01101334|Active Comparator|erlotinib|
89065576|NCT02880748|Experimental|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum.
89065577|NCT02880748|Active Comparator|Air insufflation (AI) method|Air insufflation (AI) method was used for insertion to the cecum.
89065578|NCT01327547|Experimental|1.0|
89065579|NCT01327547|Placebo Comparator|2|
89065580|NCT04386785|Experimental|Single-arm: Endovascular thermal ablation in IPV|
89065581|NCT04386395||Immuno Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
89065582|NCT04386395||Cortico Cohort|COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay. According to RECOVERY study, early routine administration of dexamethasone 6 mg/day over 10 days. Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
89065583|NCT01308567|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.
89065584|NCT01308567|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
89065585|NCT01308567|Active Comparator|Docetaxel 75 mg/m^2|Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
89065586|NCT04379141||hypotension|Patients with hypotension after induction of anesthesia
89065587|NCT04379141||non-hypotension|Patients without hypotension after induction of anesthesia
89065588|NCT00592163|Experimental|Single Arm|
89065589|NCT00592241|No Intervention|A|Subject is diagnosed as a diabetic, or subject is parent/guardian of a diabetic child age under 18 years.
89065590|NCT04377113||RCC patients|"RCC patients (30 pts) will include patients with kidney cancer (renal cell cancer).~Investigators will collect and analyze:~blood sample,~urine sample,~kidney tissue sample (healthy tissue, carcinomatous tissue and borderline tissue between them)."
89065591|NCT04377113||Healthy patients|"In this group (30 patients) will be recruiting healthy patients (volunteer).~Investigators will collect and analyze:~blood sample."
89065592|NCT04376801||Tension-band Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed tension-band fixation after olecranon osteotomy were classified into Tension-band Fixation Group.
89065593|NCT04376801||Plate Fixation Group|Patients with distal humerus fractures admitted to our hospital in 2012-2017 who had been performed open reduction and internal fixation through olecranon osteotomy approach were selected. All patients were devided into two groups by different fixation method. Patients who had been performed plate fixation after olecranon osteotomy were classified into Plate Fixation Group.
89065594|NCT02890719|Experimental|Genotype 1B|treatment 12 weeks
89065595|NCT02890719|Experimental|Genotype 1A and 4|treatment 16 weeks
89065596|NCT04374695||patients with COVID-19|Patients with positive RT-PCR for SARS-CoV-2, and patients with négative RT-PCR for SARS-CoV-2 but clinical presentation highly suggestive of COVID-19, and typical COVID-19 abnormalities on chest CT-Scan.
89065597|NCT04374695||patients without COVID-19|Patients with négative RT-PCR for SARS-CoV-2 and chest CT-Scan or chest X-ray not suggestive of COVID-19
88812668|NCT00841412|Experimental|Immediate Intervention Group|Immediate Intervention: Long term care units assigned to the Immediate Intervention group were first to receive the staff training and management intervention to improve nutritional care processes.
89065598|NCT04324983|Other|Biomarker|This single-arm study is a Phase I study to exploratively identify potential biomarkers in patients with early prostate cancer relapse and limited metastases in PSMA-PET, who need further assistance in treatment decisions (for or against local treatment options).
89065599|NCT05644197|Other|intervention group|the intervention group of 50 patients will undergo a support program over 12 weeks (1 adapted physical activity session per week, will participate in 5 workshops with the psychologist and 1 workshop with the dietician, plus a visit with the urologist after 6 weeks from prostatectomy
89065600|NCT05644197|No Intervention|control group|the control group will only undergo a classic follow-up during its 12 weeks, namely a visit to the urologist after 6 weeks of the prostatectomy
89222185|NCT02564315|Active Comparator|Recycling/Skill Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
89222186|NCT02564315|Active Comparator|Recycling/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
89222187|NCT02564315|Placebo Comparator|Preparation Phase Control/No Phase 3|"This arm includes Phase 2 (Preparation) Control Treatment and No Phase 3 (Cessation) Treatment. More specifically, treatments include the following:~Phase 2: Preparation Phase Control Treatment~Phase 3: No Treatment"
89222188|NCT02564237|Experimental|Group 1: StreptAnova™|Three (3) 0.6 mL doses (600 µg protein) of StreptAnova™ (Group A streptococcal (GAS) vaccine) will be will be administered on days 0, 30 and 180.
89222189|NCT02564237|Active Comparator|Group 2: Comparator|Three (3) 0.5 mL doses of comparator (Hepatitis B vaccine, Hepatitis A vaccine, OR Human Papillomavirus vaccine) will be administered on days 0, 30 and 180.
88812669|NCT00841412|Active Comparator|Delayed Intervention Group|Delayed Intervention: Long term care units assigned to the Delayed Intervention group were monitored under usual care conditions to serve as a control for the Immediate Intervention group. Then, these units received the staff training and management intervention at a later date.
88812670|NCT02873468|Experimental|Florence 30|
88812671|NCT02873468|Experimental|Florence 60|
88812672|NCT02873468|Experimental|Florence 90|
89222190|NCT00434512|Experimental|SB732461 adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
89222191|NCT00434512|Experimental|SB732461 adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
89222192|NCT00434512|Experimental|SB732461 adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
89222193|NCT00434512|Experimental|SB732461 non-adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
89222194|NCT00434512|Experimental|SB732461 non-adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
89222195|NCT00434512|Experimental|SB732461 non-adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
89222196|NCT02564939|Active Comparator|ramelteon|receive ramelteon
89222197|NCT02564939|Placebo Comparator|placebo|receive placebo
89222198|NCT03605771||Advanced Melanoma|"Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:~Disease onset as metastatic or unresectable disease.~First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period."
89222199|NCT00743171||1|Good adherent patient: patient performed ≥ 80% of predicted HS within 24 months
89222200|NCT00743171||2|Moderate adherent patient: patient performed ≥ 50% of predicted HS within 24 months
89222201|NCT00743171||3|Non-adherent patient: patient performed < 50% of predicted HS within 24 months.
89222202|NCT02470468|Experimental|DCVAC add on to SOC|Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)
89222203|NCT02470468|Experimental|DCVAC and immune enhancers add on to SOC|Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)
89222204|NCT02470468|Other|Standard of Care Chemotherapy|Standard of Care chemotherapy (Carboplatin, Paclitaxel)
88812673|NCT02873468|Placebo Comparator|Placebo|
88812674|NCT02154386|Experimental|8-10 week healing group|dental implant placed (and bone core biopsy harvested) 8-10 weeks after tooth extraction/grafting
88812675|NCT02154386|Active Comparator|18-20 week healing group|dental implant placed (and bone core biopsy harvested) 18-20 weeks after tooth extraction/grafting
89222205|NCT00921635|Experimental|Maintain hemoglobin level above 120 g/L|Hemoglobin level from 120 g/L to 130 g/L
89222206|NCT00921635|Active Comparator|Maintain hemoglobin level above 100 g/L|Hemoglobin level from 100 g/L to 110 g/L
89222207|NCT00427648|Active Comparator|1|xylocaine
89222208|NCT00427648|Placebo Comparator|2|normal saline
89222209|NCT02153177|Active Comparator|NSAID and pain medication arm|After a rotator cuff repair procedure subjects in the NSAID and pain medication arm will receive both Ibuprofen and Hydrocodone/Acetaminophen, and also Omeprazole.
89222210|NCT02153177|Active Comparator|pain medication arm|Patients in the pain medication arm will receive Hydrocodone/Acetaminophen after the rotator cuff repair procedure.
89222211|NCT00743327||1|Participants receiving ADT and pioglitazone
89222212|NCT00743327||2|Participants receiving ADT only
89222213|NCT00743327||3|Participants not receiving ADT and in remission from prostate cancer
89222214|NCT01032460|Active Comparator|macintosh|
89222215|NCT01032460|Active Comparator|C-MAC|
89222216|NCT01032460|Active Comparator|Airtraq|
89222217|NCT02564861|Experimental|DS-1971a (Low Dose)|Participants in Cohort 1 who receive a low dose of DS 1971a in an oral suspension
89222218|NCT02564861|Experimental|DS-1971a (Mid dose)|Participants in Cohort 2 who receive a mid dose of DS 1971a in an oral suspension
89065601|NCT02893007|Experimental|Brief family-centered care program|The Brief family-centered care (BFCC) program was developed and provided for hospitalized patients with BPD and their family caregivers.The BFCC protocol is outlined as 4 treatment sessions, specific goals, and example questions. Four 90-minute in-depth sessions for each dyad were initially held in a quiet interview room to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
89065602|NCT02893007|No Intervention|treatment-as-usual (TAU)|All patients were given the standard hospital-provided services: psychiatric nursing care, occupational therapy, and pharmacotherapy. All of the family caregivers were only to attend a routine 60-minute family discussion group about violence and suicide prevention without any specific patient-family dyad interview.
89065603|NCT04325061|No Intervention|Control group|Patients will be treated with standard intensive care
89065604|NCT04325061|Active Comparator|Dexamethasone|Standard intensive care plus dexamethasone
89065605|NCT02893085||patients with malignant biliary stricture|
89065606|NCT02893085||patients with benign biliary diseases|
89065607|NCT01307319|Experimental|BDP HFA 80 mcg/day|Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
89065608|NCT01307319|Experimental|BDP HFA 160 mcg/day|Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
89065609|NCT01307319|Placebo Comparator|Placebo nasal aerosol once daily|Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.
89065610|NCT04365647||1|Patient's in whom there is increase in tumor size after craniotomy
89065611|NCT04365647||2|Patient's in whom there was either no increase in tumor size or decrease in tumor size after craniotomy
89065612|NCT05644119|Experimental|V-looped Wire Retainer (LWR)|The LWR is a 0.569-mm (0.022-inch) Blue Elgiloy (soft) round wire (RMO). The retainer will extend from the left canine to the right central incisor.
89065613|NCT05644119|Active Comparator|Straight Wire Retainer (SWR)|The SWR is 0.8-mm twisted stainless steel wire (3M Unitek, Monrovia, Calif). The retainer will extend from the right canine to the left central incisor.
89065614|NCT02892929|Experimental|Motivational Interviewing|The motivational interview is a style of care that evokes the patient their motivations to make behavioral changes in the interests of their own health. It is a technique centered in patient to explore and resolve their ambivalence to modify unhealthy behavior.
89222219|NCT02564861|Experimental|DS-1971a (High dose)|Participants in Cohort 3 who receive a high dose of DS 1971a in an oral suspension
89222220|NCT02564861|Experimental|Pooled placebo|Participants in Cohort 1, 2 or 3 who receive matching DS-1971a Placebo
89222221|NCT00416884|Experimental|TBI, Campath, Fludarabine T-cell Deplete|(Campath) 30 mg on day -8 over 5-6 hours, Fludarabine 30 mg/m^2 on day -4 through day -2, Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0., Stem cells will be T cell depleted and given on day 0
89222222|NCT02564627|Experimental|Self-applied patch|The patients will use a self-applied patch weekly for PENS of dermatome T6. A 1200 Kcal/day diet will be also prescribed.
89222223|NCT02564627|Active Comparator|Conventional procedure|The patient will attend weekly the Outpatient Clinic for receiving the PENS of dermatome T6. The procedure will be performed by the Medicine Doctor. A 1200 Kcal/day diet will be also prescribed.
89222224|NCT02564627|Other|1200 Kcal/day diet|A 1200 Kcal/day diet will be also prescribed.
89222225|NCT01034098||Post-menopausal women|Post-menopausal women (without hormone replacement therapy)
89222226|NCT00743405|Other|Cohort 1|Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan
89222227|NCT00743405|Other|Cohort 2|Subjects will be receive GSK1034702 5 mg following the dose escalation plan
89222228|NCT01032616|Experimental|Study Period 1|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
89222229|NCT01032616|Experimental|Study Period 2|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
89222230|NCT02564081|Experimental|Static Stretching lower limb|Three 30 s bouts of static stretching for the gastrocnemius and the hamstrings respectively
89222231|NCT02564081|Active Comparator|Static stretching Cervical|Six 30 s bouts of static stretching of the cervical spine in the sagittal plane (flexion only)
89222232|NCT02564081|No Intervention|Ctrl|No intervention
89222233|NCT01032772|Experimental|CHOICES Plus Intervention|A two session intervention utilizing a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, and smoking. The interventions will (a) provide norms-based-but personalized-feedback, (b) encourage attendance at a contraceptive counseling visit, (c) encourage participation in the smoking cessation program, (c) increase motivation to change each of the target behaviors, (d) decrease temptation to engage in risk behaviors, (e) increase confidence to avoid risk behaviors, and (f) develop a personalized, tailored change plan.
89222234|NCT01032772|Active Comparator|Information|Women in the information condition receive advice and educational material from the research assistant about women's health and related referrals.
89222235|NCT00434122|Experimental|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
89222236|NCT00434122|Placebo Comparator|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
89222237|NCT00555620|Experimental|A|
89222238|NCT00555620|Experimental|B|
89222239|NCT00433966|Active Comparator|Pharmacology Arm|"To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin plus routine use of GP IIb/IIIa inhibitors, bivalirudin (with use of GP IIb/IIIa inhibitors reserved for angioplasty complications) results in:~reduced rates of major bleeding events at 30 days~similar rates of major adverse ischemic cardiac events at 30 days~reduced rates of the composite of major adverse ischemic cardiac events + major bleeding at 30 days."
89229826|NCT03474094|Active Comparator|pre-operative radiotherapy and post-operative atezolizumab|Pre-operative radiotherapy then surgery followed by 2 cycles of atezolizumab
89229827|NCT01004120|Placebo Comparator|MDn|
89229828|NCT01004120|Active Comparator|B-GOS|
89065615|NCT02892929|Active Comparator|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation. In this type of consultation the health professional who plans the action plan for the patient and determines how it will be the patient's lifestyle modification.
89065616|NCT04328051|Active Comparator|Ocean E.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and external hexagon connection.
89065617|NCT04328051|Active Comparator|Ocean I.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and internal hexagon connection.
88812676|NCT01438229|Experimental|renal artery ablation|Catheter-based RF ablation in renal artery
88812677|NCT01541735|Placebo Comparator|Placebo|Placebo of calcined magnesia, capsules
89065618|NCT04328051|Active Comparator|Ocean C.C.®, Avinent Implant System S.L.|Dental implant with geometry adapted to the biologic architecture of the bone, with platform switching with a positive angle and machined surface with micro-threads in the cervical region. Asymmetric and progressive threads in its body with a double thread pitch. Point-ratio geometry on its apical region, Biomimetic Advanced Surface and conical connection.
89065619|NCT04359173||Hypothermic machine perfusion (HMP)|patients who underwent kidney transplantation following HMP
89065620|NCT04359173||Static cold storage (SCS)|patients who underwent kidney transplantation following SCS
89065621|NCT04359719||Group mild melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
89222240|NCT00433966|Active Comparator|Stent Arm|"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~reduced rates of target lesion revascularization for ischemia at 1 year~similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~lower rates of analysis segment binary angiographic restenosis at 13 months"
89222241|NCT00743561|Other|1|
89222242|NCT00743639|Other|1|Interventional
89222243|NCT00947336|Active Comparator|Norfloxacin + Synbiotic|
89222244|NCT00947336|Placebo Comparator|Norfloxacin + Placebo|
88812678|NCT01541735|Experimental|Pantoprazole|The pantoprazole will be administered in 40mg capsules
88812679|NCT01541891|Experimental|PRO-148 Ophthalmic Solution|Drug: PRO-148 Intervention name: PRO-148 applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
89065622|NCT04359719||Group Moderate-severe melasma|"This subjects according to the modified melasma area and severity index (mMASI) score. Variables that are measure by mMASI scoring includes the degree of darkness and involvement of area. Darkness component is used to replace pigmentation and intensity in MASI scoring with modification (mMASI). Assessment using mMASI is highly dependent on the operator; hence, a new objective examination to assess skin pigmentation have been developed, which is the facial imaging analysis.~The level of serum FT4 and TSH were then measured in both groups of the patients. In addition, the degree of skin pigmentation was also measured by using the Janus II facial analysis system. In this study, there were two modalities used in the Janus II facial analysis system, which is the polarization light and ultraviolet light.~In addition, this study also analyzes the level of serum FT4 and TSH with the result of Janus II facial analysis system scoring."
89065623|NCT01080391|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.
89065624|NCT01080391|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone (CRd)|Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.
89065625|NCT00592397|Experimental|1|All participants underwent the same dietary intervention
89065626|NCT04352699||Naive patients|Group of naive patients who have undergone elective or emergency surgery during the study period
89065627|NCT04327817|Other|Multifidus ReActiv8 stimulator|The Mainstay ReActiv8 is an implantable electrical stimulation system that consists of an implantable pulse generator, implantable leads, programmer, activator and magnet.
89222245|NCT00956384|Experimental|One-stage dermal matrix/implant|One-stage breast reconstruction with dermal matrix and implant
89222246|NCT00956384|Active Comparator|Two-stage tissue expander/implant|Two-stage breast reconstruction with tissue expander and implant
89222247|NCT00955214|Experimental|2.5mm Paclitaxel-eluting stent|
89222248|NCT00947414|Active Comparator|Shockwave plus strength training|6 sessions of extracorporeal shock wave plus daily gluteal strength exercises
89222249|NCT00947414|Sham Comparator|Sham extracorporeal shock wave plus gluteal strength exercise|SHAM extracorporeal shock wave plus gluteal strength exercise
89222250|NCT00955292|Experimental|Quarfloxin|
89065628|NCT04747483|Active Comparator|Extension Oriented Treatment Approach|"The EOTA intervention involves three components. The first component is a series of active extension- oriented exercises: Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension.~The second component of the EOTA is subject education. Subjects are being educated to maintain the natural lordosis of the lumbar spine while sitting, and are being instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension.The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
89222251|NCT00956462|Experimental|NSAID|
89222252|NCT00956462|Active Comparator|Steroids|
89222253|NCT00956696||Topiramte|single arm, flexible dosing
89222254|NCT00955448|Experimental|SIS Mesh (Cook Medical)|Anterior prolapse repair will be reinforced using SIS mesh
89222255|NCT00955448|Active Comparator|No-mesh|Anterior prolapse repair with no mesh reinforcement
89222256|NCT03952650|Experimental|1a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
89222257|NCT03952650|Experimental|1b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
89222258|NCT03952650|Experimental|2a|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
89222259|NCT03952650|Experimental|2b|Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ
89222260|NCT03952650|Experimental|3a|Receiving 400,000 PfSPZ with chloroquine 2 days prior + 5 days post PfSPZibuprofen (if necessary)
89222261|NCT03952650|Experimental|3b|Receiving 400,000 PfSPZ with weekly chloroquineibuprofen (if necessary)
89222262|NCT03952650|Placebo Comparator|4a|Receiving normal saline with 75 mg pyrimethamine day 0 post injection
89222263|NCT03952650|Placebo Comparator|4b|Receiving normal saline with 75 mg pyrimethamine days 2&amp;3 post injection
89222264|NCT03952650|Placebo Comparator|4c|Receiving normal saline with weekly chloroquineibuprofen (if necessary)
89222265|NCT03952650|Experimental|5a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ (if necessary)
89222266|NCT03952650|Experimental|5b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
89222267|NCT03952650|Experimental|6a|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
89222268|NCT03952650|Experimental|6b|Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2&amp;3 post PfSPZ (if necessary)
89222269|NCT00955526|Experimental|Istradefylline 20mg|
89222270|NCT00955526|Experimental|Istradefylline 40mg|
89222271|NCT00955526|Placebo Comparator|Placebo|
89222272|NCT00955604||Group R+AD|Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days
89222273|NCT00955604||Group R|At least 2 months of rasagiline
89222274|NCT00955604||Group AD|At least 2 months of Anti-PD and Rasagiline
89222275|NCT00947570|Experimental|Cognitive behavioral therapy|Participants with panic disorder or generalized anxiety disorder (GAD) will receive a course of individual cognitive behavioral therapy targeted at their principal disorder.
89222276|NCT03623646|Other|Arm A (standard arm): Chemoradiotherapy arm|
88812680|NCT01541891|Active Comparator|Arm B. SYSTANE® Ophthalmic Solution|Drug: SYSTANE® Intervention name: SYSTANE® applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
89222277|NCT03623646|Experimental|Arm B (Experimental arm): Immunotherapy + Radiotherapy arm|
89222278|NCT00947648|Other|"Raw Group"|Participants will eat cooked food and the addition of raw fruits and vegetables.
89222279|NCT00947648|Other|"Cooked Group"|Participants will eat only cooked foods.
89222280|NCT00962286|Experimental|Furosemide, obesity, glomerular hyperfiltration|
89222281|NCT00691301|Experimental|Pemetrexed and cisplatin|Pemtrexed plus cisplatin on day 1 every 21 days
89222282|NCT04010448|Experimental|TV P2-VP8|
89222283|NCT04010448|Active Comparator|Rotarix®|
89222284|NCT00955838|Experimental|Manus|
89222285|NCT00955838|Experimental|BCI_Manus|
89222286|NCT03880643||Study Group|Patients with primary membranous nephropathy who were treated using rituximab (375 mg/m2/wk for 1-4 weeks) following resistance to at least one set of prior therapies including corticosteroids, alkylating agents or calcineurin inhibitors.
89222287|NCT03554382|Experimental|intervention|Daily use of interactive mobile phone-based system to support self-management of hypertension: a) relevant items on drug side effects related to patient's drug regimen; and b) blood pressure.
89222288|NCT03554382|No Intervention|Control|"No study intervention will be made in the control group; they will receive treatment as usual."
89222289|NCT05277480|Experimental|Apatinib+IE group|IE: Ifosfamide Plus Etoposide
89222290|NCT05277480|Active Comparator|IE group|IE: Ifosfamide Plus Etoposide
89222291|NCT03429335|Experimental|Teaching session & Just TRAC It|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will also explain Just TRAC It! and help the youth to enter their health information into their phone."
89222292|NCT03429335|Active Comparator|Teaching session & MyHealth Passport|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will help youth complete and print out a MyHealth Passport to track their medical information."
89222293|NCT00956072|Experimental|Arm I|Patients undergo surgery of residual disease.
89222294|NCT00956072|Active Comparator|Arm II|Patients receive imatinib mesylate therapy according to standard of care.
89222295|NCT03518190|Experimental|Suspected pressure injury|Patients evaluated with high-risk for pressure injury
89222296|NCT00956852||Lung cancer|Non-small cell lung cancer patients undergoing surgical lung resections
89222297|NCT02565407|Experimental|Proprioceptive training|This arm will receive specialized robot-aided proprioceptive training of the wrist next to usual care.
89222298|NCT02565407|Active Comparator|Usual care|This arm will receive what participants have been receiving from their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy at home, day rehabilitation, or outpatient visits.
89222299|NCT00962364||AMI|Patients with acute myocardial infarction treated with intracoronary administration of bone marrow derived cells
89222300|NCT00962364||ICM|Patients with ischemic cardiomyopathy treated with intracoronary administration of bone marrow derived cells
89222301|NCT00962364||DCM|Patients with dilated cardiomyopathy treated with intracoronary administration of bone marrow derived cells
89222302|NCT00947804||1. Patients with symptoms of ACS|Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG).
89222303|NCT00947804||2. Patients without symptoms of ACS|Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization.
89222304|NCT02564003||Oxycodone|Oxycodone 0,1 mg/kg iv
89222305|NCT03477708||Study group|TCCO2 monitoring
89222306|NCT03477708||Control group|Routine monitoring
89222307|NCT00956150|Active Comparator|60 GWS Rifaximin|
89222308|NCT00956150|Placebo Comparator|60 GWS Placebo|
89222309|NCT00956150|Experimental|Healthy Control|Patient is a healthy control and will not be on study intervention. Asked to perform Lactulose Breath Test to compare results with GWS patients.
89222310|NCT02564393||T|Control
89222311|NCT02564393||A|Adult with cystic fibrosis
89222312|NCT03887351||JGH Cohort|This cohort will not be subjected to any intervention.
89222313|NCT03887351||RVH Cohort|This cohort will not be subjected to any intervention.
89222314|NCT00947960|Other|Active/Placebo|Subjects receive 1-2 grams/kilogram body weight triheptanoin divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive placebo vegetable oil at the same dose and frequency for the next 6 months during the randomization phase.
89222315|NCT00947960|Other|Placebo/Active|Subjects receive 1-2 grams/kilogram body weight placebo vegetable oil divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive triheptanoin at the same dose and frequency for the next 6 months during the randomization phase.
89222316|NCT00923663|Experimental|Lenalidomide|Lenalidomide administered orally at a dose of 25 mg daily
89222317|NCT00956228|Experimental|Radioimmunoguided IMRT|All patients recieved Intensity Modulated Radiotherapy to the prostate with 75.6 Gy in 42 fractions. Additionally, they recieve a concurrent boost to the region of the prostate which enhanced on the prostascint scan to 82 Gy.
89222318|NCT00743873|Placebo Comparator|2|saline
89222319|NCT00743873|Experimental|1|Plasma Rich in Growth Factors (PRGF)
89222320|NCT04011098|Active Comparator|Control Group (No Additional Epidural Fentanyl Bolus)|The Control group will receive a 2 ml bolus of standard epidural mix solution after epidural placement followed by standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
89222321|NCT04011098|Experimental|Fentanyl bolus group|The Fentanyl bolus group will receive a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.
89222322|NCT00927563|Experimental|Tolcapone|Tolcapone 100-300mg/day
89222323|NCT00967902|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
89222324|NCT00967902|Active Comparator|Taxus® Liberté® Stent|Commercially available product
89222325|NCT00956306|Experimental|Child-Pugh A|
89222326|NCT00956306|Experimental|Child-Pugh B|
89222327|NCT00956306|Experimental|Healthy Volunteers|
89065629|NCT04747483|Experimental|EOTA+ Mechanical Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
89065630|NCT04327739|Experimental|Intervention 1 Exercise|Participants allocated to this group received a 10 weeks exercise programme for neck and upper limbs muscles
89065631|NCT04327739|Experimental|Intervention 2 Exercise and INIT|Participants allocated to this group received the same exercise programme as group 1 in combination with the integrated neuromuscular inhibition technique (INIT)
89065632|NCT04327739|Experimental|Intervention 3 Exercise and SMT|Participants allocated to this group received the same exercise programme as group 1 in combination with cervical manipulation
89065633|NCT04327739|Placebo Comparator|Control|Participants allocated to this group received general consulting instructions and a home based general exercise sheet
89065634|NCT01070329|Experimental|Duloxetine|
89065635|NCT01070329|Placebo Comparator|Placebo|
89065636|NCT04344977||Convalescent survivors of COVID-19|Convalescent survivors of COVID-19: history of COVID-19 like illness or positive test for SARS-CoV-2 and has the protocol-specified minimum anti-SARS-CoV-2 neutralizing antibody titer
89065637|NCT01069861|Experimental|one|
89065638|NCT02892851|Experimental|Deep brain stimulation (DBS)|Deep brain stimulation of the subthalamic nuclei (STN-DBS)
89065639|NCT04304521||Intensive care|Patients admitted in the intensive care unit of the University Hospital of Saint-Etienne, France between December 2018 and July 2019
89065640|NCT02875405|Experimental|Received pericardiotomy|Patient will receive a posterior left pericardiotomy at the time of surgery
89065641|NCT02875405|No Intervention|No Pericardiotomy|Patient will not receive posterior left pericardiotomy.
89065642|NCT04306549|Experimental|Bulk-fill resin composite-sonic activated|5 mm bulk-filling without capping lightcured 40s
89065643|NCT04306549|Experimental|Bulk-fill resin composite|4 mm bulk-filling without capping lightcured 10s
89065644|NCT04306549|Experimental|Microhybrid resin composite|2 mm layers, lightcured 20s
89065645|NCT02876263||Study group|Elective and emergency surgery for aneurysm or dissections of the ascending aorta, operated under extracorporeal circulation, protective deep therapeutic hypothermia and circulatory arrest.
89065646|NCT02876263||On-pump CABG Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease under extracorporeal circulation
89065647|NCT02876263||OPCAB Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease with a beating heart
89065648|NCT02875717||Control|
89065649|NCT02875717||Acetylsalicylic acid|Patients that were on medication with Acetylsalicylic acid on the date of shockwave lithotripsy
89065650|NCT02875717||Low Molecular weight heparin|Patients that were on medication with low molecular heparin on the date of shockwave lithotripsy
89222328|NCT00957164|Active Comparator|Pain Treatment Only|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
89222329|NCT00957164|Active Comparator|PTSD Treatment Only|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
89222330|NCT00957164|Active Comparator|Combined Pain and PTSD Treatment|This treatment arm will involve 5 sessions each of the Pain-Only and PTSD-Only treatments described above.
89222331|NCT00957164|No Intervention|Treatment as Usual|The treatment as usual group will complete the assessments given in each of the other study arms, but will not participate in treatment through the study. Instead, participants randomized to this group will be encouraged to seek treatment for pain and/or PTSD through existing channels. Referrals for treatment will be made for those with clinically significant symptoms for pain and/or PTSD at intake.
89222332|NCT05228340|Experimental|Intervention|Flexor tenotomy
89222333|NCT05228340|No Intervention|Controle|Usual-care
89222334|NCT00775229|Active Comparator|1|Naltrexone
89222335|NCT00775229|Placebo Comparator|2|Placebo
89222336|NCT00962442|Active Comparator|nutritional support + N-Acétylcysteine|N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
89222337|NCT00962442|Placebo Comparator|nutritional support + placebo|placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
89222338|NCT00948038|Active Comparator|Soy|Soy-based supplement to normal diet
89222339|NCT00948038|Experimental|Milk|Milk-based supplement to normal diet
89222340|NCT00967980|Active Comparator|1. Femoral Nerve Block|Patients will be randomized with a computer program to receive a femoral catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
89222341|NCT00967980|Active Comparator|2. Psoas Compartment Catheter|Patients will be randomized with a computer program to receive a psoas compartment catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
89222342|NCT00743951|Experimental|1 Patient decision aid|Patient decision aid about treatment options for osteoarthritis
89222343|NCT00743951|Active Comparator|2 Usual care|Usual patient educational materials
89222344|NCT00957320|Experimental|1|"Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL. The dose of sirolimus will be dose escalated following standard phase 1 statistical methods.~For patients with active CNS leukemia, intrathecal methotrexate, hydrocortisone and cytarabine (triple IT) will be administered weekly, with leucovorin rescue at the treating physician's discretion."
88812681|NCT01520207|Placebo Comparator|Placebo group: (0.9% normal saline)|0.9% saline will be administered (IV) during the hemodialysis session at 1.25mL/kg/hour (max 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
89065651|NCT02875639|Experimental|tonifying qi group|tonifying qi group:which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng,and so on)
89222345|NCT00957398||IBS-D|12 IBS-D patients who will all undergo MTS.
89222346|NCT00957398||IBS-C|12 IBS-C patients who will all undergo MTS.
89222347|NCT00957476|Active Comparator|Omega-3 Fish Oil|800mg DHA & 1200mg EPA
89222348|NCT00957476|Placebo Comparator|Placebo|Wheat germ oil
89222349|NCT00962676||immunocompromised group|
89222350|NCT00962676||non-immunocompromised group|
89222351|NCT04316078|Experimental|personalized engagement platform|Patients registered into personalized engagement platform (PEP) will receive personalized educational videos (PEV) according to disease, treatment protocol and side effects.
89222352|NCT04316078|No Intervention|control group|The control group will not be registered to the PEP nor receive any PEVs.
89222353|NCT00653159|Active Comparator|Mirena IUD [LNG-IUS]|Participants in this arm had a Levonorgestrel-releasing intrauterine device (LNG-IUS), also known as the Mirena IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
89222354|NCT00653159|Active Comparator|Paragard IUD [Copper T380A]|Participants in this arm had a Copper T380A intrauterine device (CuT380A), also known as the Paragard IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
89222355|NCT00948116||Diabetes mellitus, renal impairment|Patients with both diabetes mellitus and eGFR <60 ml/min
89222356|NCT03047070|Active Comparator|Lidocaine|IV Lidocaine infusion
89222357|NCT03047070|Placebo Comparator|Control|IV normal saline infusion
89222358|NCT00948272|Experimental|VRVg Group|
89222359|NCT00948272|Active Comparator|Verorab Group|
89222360|NCT00968136||a short-term trial of the ketogenic diet|
89222361|NCT00968136||long-term trial of the ketogenic diet.|
89222362|NCT00968214||Single group|DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
89222363|NCT00957554|Experimental|irbesartan/amlodipine|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 300/5 mg fixed combination for additional 5 weeks
89222364|NCT00957554|Active Comparator|irbesartan|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan 150 mg for 5 weeks followed by irbesartan 300 mg for 5 additional weeks
89222365|NCT00921713|Active Comparator|Enhanced Usual Care|An extensive packet of information including cancer education materials and treatment resources will be mailed to patients.
89690293|NCT03103438|Experimental|Cohort 4|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.0 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5.
89222366|NCT00921713|Experimental|Oncology Nurse Care Management|In addition to this mailed information packet, patients in OCNM will be contacted by an experienced Oncology nurse with additional training in self-management support and psychosocial care. The intervention nurse, supported by a Medical Oncologist and Clinical Psychologist, will work closely with patients, their primary care physicians, and other clinicians to assure that patient needs discussed are met. The nurses will be trained in and employ proven counseling and psychotherapeutic approaches-behavioral activation and problem-solving treatment. The multi-component intervention will be based on the Chronic Care Model's six elements (health care organization, community resources, self-management support, delivery system design, decision support, and clinical information system).
89222367|NCT00744029|Active Comparator|Intervention group|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
89222368|NCT00744029|No Intervention|Control group|No intervention was performed
89222369|NCT03024684|Experimental|Statin|Atorvastatin 10mg oral once daily
89222370|NCT03024684|Placebo Comparator|Placebo|Matched placebo (sugar pill) once daily
89222371|NCT00746057|Other|1|Patients aged 18 to 65 years old receiving a first cadaveric renal graft.
89222372|NCT00948350|Active Comparator|translaryngeal injection|translaryngeal injection of local anesthetics before the awake intubation
89222373|NCT00948350|Active Comparator|spray as you go|local anesthetics are given through the fiberoptic during awake intubation
89222374|NCT00968292|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
89222375|NCT00968292|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
89222376|NCT00957710|Other|langauge therapy|Naming therapy
89222377|NCT00117637|Experimental|First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg|Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression (= first intervention period, 5.7 months [median] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months [median]) on a continuous basis.
89690294|NCT03103438|Experimental|Cohort 5|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.6 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6.
89690295|NCT03103438|Experimental|Cohort 6|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7.
89690296|NCT03103438|Experimental|Cohort 7|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.9 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level.
89690297|NCT00993187|Experimental|Sitagliptin/Metformin FDC|Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.
89690298|NCT00993187|Active Comparator|Glimepiride|Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.
89065652|NCT02875639|Experimental|activating blood group|which treated by a kind of Chinese patent medicine (major components: Honghua,Taoren,Danggui，and so on)
89065653|NCT02875639|Experimental|qi and blood group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，Honghua,Taoren,Danggui，and so on)
89065654|NCT02875639|Active Comparator|QISHEN YIQI DRIPPING PILLS group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，and so on)
89065655|NCT02875639|Sham Comparator|placebo group|which treated by the simulation of Chinese patent medicine (major components:excipient)
89065656|NCT04335149||COREVALVE|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a COREVALVE
89065657|NCT04335149||EDWARDS|Patients undergoing a TAVI at Montpellier University Hospital since 2017 with implantation of a EDWARDS
89065658|NCT04741711|Experimental|Interventional group|The heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava
89065659|NCT04741711|Other|Control group|Usual care (i.e. without ultrasound guidance) will be provided.
89065660|NCT04327349|Other|COVID-19 Patients|
89065661|NCT00593099|Experimental|1|Buproprion
89065662|NCT00593099|Placebo Comparator|2|Placebo
89690299|NCT03106636|Active Comparator|KEEP-P|Caregivers are randomly assigned to one of two groups. The KEEP-P group completes a basic version of the curriculum. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
89065663|NCT00593177|Experimental|Treatment Group 1|0.05% PTH (1-34) Gel
89065664|NCT00593177|Experimental|Treatment Group 2|0.10% PTH (1-34) Gel
89065665|NCT00593177|Placebo Comparator|Treatment Group 3|Placebo (Vehicle) Gel
89065666|NCT02892773|Other|Incentive Spirometry Group|"Participant will be asked to take 10 deep breaths through the mouthpiece of an incentive spirometer, followed by a 60 second pause.~This cycle will be repeated two more times.~A Respiratory Therapist will coach participants three times per day.~Each duration of Incentive Spirometry will last about 15 minutes."
89065667|NCT02892773|Active Comparator|EzPAP® Positive Airway Pressure Group|"Participant will be coached by a Respiratory Therapist to breathe through the mouthpiece of an EzPAP® device for 10 breaths, followed by a 60 second pause.~This cycle will be repeated two more times.~The Respiratory Therapist will coach participants three times per day.~Each duration of EzPAP® therapy will last about 15 minutes."
89690300|NCT03106636|Experimental|KEEP-P+|Caregivers are randomly assigned to one of two groups. The KEEP-P+ group completes an augmented version of the intervention with curriculum that includes the addition of information about recent findings in early brain development and a video coaching component based on the Filming Interactions to Nurture Development (FIND) program. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
89690301|NCT03173170|Experimental|TAK-954 0.2 mg + Itraconazole 200 mg and TAK-954 0.2mg|TAK-954 0.2 milligram (mg), infusion, intravenously, once on Day 1 of First Intervention Period, followed by a minimum of 7-day washout period, further followed by Itraconazole 200 mg, capsule, orally, once daily on Days 1 to 8 along with TAK-954 0.2 mg, infusion, intravenously on Day 4 of Second Intervention Period.
89690302|NCT03106870|Active Comparator|oral metformin and insulin|Intervention 'Insulin Mixtard' and Intervention 'metformin' had included
89690303|NCT03106870|Active Comparator|insulin therapy only|Intervention 'Insulin Mixtard' had included
89690304|NCT00375310|Experimental|Gemcitabine + Sorafenib & radiotherapy|"Induction: Gemcitabine with Sorafenib for 4 weeks (1 cycle). Chemo-radiotherapy: Gemcitabine with Sorafenib and Radiotherapy for 5 weeks. Sorafenib will be given in escalating dose cohorts.~Sorafenib only: Sorafenib alone for 4 weeks. Consolidation: Gemcitabine with Sorafenib for 16 weeks (4 cycles). Maintenance: Sorafenib alone until disease progression."
89229829|NCT01043536|Experimental|radiotherapy + temozolomide|"Radiotherapy:~dose given at PTV-g will be 70 Gy/28 fractions level 1 75 Gy/30 fractions level 2 80 Gy/32 fractions level 3~dose given at PTV-a will be 56 Gy/28 fractions level 1 60 Gy/30 fractions level 2 60.8 Gy/32 fractions level 3~Chemotherapy:~temozolomide given at the dose of 75mg/m2"
88812682|NCT01520207|Active Comparator|Intervention: intravenous mannitol (20%)|Mannitol will be administered (IV) during the hemodialysis session at a maximum rate of 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
89065668|NCT00593723|Experimental|IMRT + Concurrent chemotherapy|"180 cGy daily fractions to a total dose of 5400 cGy to PTV1 and 200 cGy daily fractions to a total dose of 6000 cGy to PTV2. Once a day, five days a week, for approximately 6 weeks.~Planned chemotherapy: cisplatin (75 mg/m2) day 1 and 5-FU (1000 mg/m2) days 1-4 on weeks 1, 5, 10, and 14 of therapy. Please note that drug regimens and doses may vary and will be at the discretion of the medical oncologist."
89065669|NCT00593801|Active Comparator|2: late rhEPO|late EPO treatment from the fourth week for 6 weeks
89065670|NCT00593801|No Intervention|3: no EPO|control group, no EPO treatment
89065671|NCT00593801|Active Comparator|1: early rhEPO|early rhEPO treatment from the first week until 9 weeks
89065672|NCT00593879|Placebo Comparator|1|Placebo
89065673|NCT00593879|Experimental|2|
89065674|NCT00594113|Experimental|1|Multimedia Colorectal Cancer Screening
89065675|NCT00594191|Placebo Comparator|A|Placebo treatment
89065676|NCT00594191|Experimental|B|
89065677|NCT00594269|Placebo Comparator|A|Discontinuation of antipsychotic or antidepressants
89065678|NCT00594347|Experimental|Group A|Pneumo 23
89065679|NCT00594347|Active Comparator|Group B|Prevnar
89229830|NCT01004198|Experimental|MP4OX - 250|250 mL dose
89229831|NCT01004198|Experimental|MP4OX - 500|500 mL dose
89222378|NCT00117637|Active Comparator|First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg|Interferon (IFN) α-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months [median]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period.After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months [median]).
89222379|NCT00746135|Active Comparator|A|Conventional Biventricular Stimulation: RV Apex and LV Lead Tip
89222380|NCT00746135|Active Comparator|B|"Anodal-Cathodal Biventricular Stimulation: cathodal LV Stimulation und anodal RVHis Stimulation = Anodal-cathodal Bi-V."
89222381|NCT00746135|Active Comparator|C|Anodal-Cathodal Tri-V Stimulation: RV-apex and LV and RV-His
89222382|NCT00744185|Placebo Comparator|2|30-days placebo treatment
89222383|NCT00744185|Experimental|1|30-days propranolol treatment
89222384|NCT02897778|Active Comparator|Entinostat|Participants received a single oral supratherapeutic dose of 15 mg entinostat under fasted conditions.
89222385|NCT02897778|Placebo Comparator|Placebo|Participants received a single dose of placebo-matching entinostat under fasted conditions.
89222386|NCT00746291|Experimental|A|Traumatic brain injury
89222387|NCT00746291|Experimental|B|Cerebral palsy
89222388|NCT00746291|Experimental|C|Controls
89222389|NCT01084291|Experimental|DEN1 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 1.
89222390|NCT01084291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
89222391|NCT02793336||infant cohort|"The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: STOP MIP, which is a cohort of pregnant women followed up until delivery and the Baby-Cohort study, which enrols babies from mothers in the STOP MIP trial and follows them until their first year of live. When participants of the Baby-cohort Study reach study end, they are offered to participate in this study."
89222392|NCT00741689|Experimental|1|AZD1656 in 6 increasing oral single doses given to 6 groups (5 on active and 1 on placebo in each group)
89222393|NCT00963066|Active Comparator|Pressure Support ventilation|
89229832|NCT01004198|Active Comparator|Ringers Lactate solution|500 mL dose
89222394|NCT00963066|Experimental|NAVA flow triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with flow triggering
89065680|NCT04326959|Experimental|UC-MSCs + CM|A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
89065681|NCT04326959|Experimental|CM + CM|A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.
89065682|NCT04326959|Experimental|Triamcinolon acetonide|A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient.
89065683|NCT01306929|Experimental|pridopidine|45mg bid
89065684|NCT02892617||Group 1|Patients with low back pain lasting for more than 6 months, debilitating, with the presence of type 1 Modic disc disease on MRI at the operated disc, eligible for a disc prosthesis or arthrodesis anterior approach
89065685|NCT02892617||Group 2|Patients underwent surgery for nerve root pain by disc herniation on MRI viewable with a radio-clinical concordance with or without Modic 1 disc disease in the operated disc
89065686|NCT02892695|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
89065687|NCT00594503|Experimental|Hyperbaric oxygen therapy-TBI|Low pressure hyperbaric oxygen therapy
89065688|NCT00594581|Active Comparator|1|Juvista (avotermin) 50ng/100μl/linear cm wound margin
89065689|NCT00594581|Active Comparator|2|Juvista (avotermin) at 200ng/100μl/linear cm
89065690|NCT00594893|Active Comparator|1|Mini Incision Approach
89065691|NCT00594893|Active Comparator|2|2 Incision Approach
89065692|NCT00594971|Other|B|90 terminally ill cancer patients will be referred to a specialist palliative care team at time of discharge.
89065693|NCT00594971|Other|C|90 terminally ill cancer patients will be discharged from hospital with extra effort put into improving the communication between the hospital and the primary sector.
89065694|NCT00594971|No Intervention|A|90 terminally ill cancer patients will be discharged from hospital, receiving usual care.
89065695|NCT00595049|Experimental|bosentan|
89065696|NCT00595205||Group IS|Subjects <1 year of age with definite intussusception cases who had received Rotarix™.
89065697|NCT00595283|Experimental|1|Participants assigned to Parent-Child Interaction Therapy-Emotional Development
89065698|NCT00595283|Active Comparator|2|Participants assigned to Developmental Education Parenting Intervention
89222395|NCT00963066|Experimental|NAVA EMG triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram
89222396|NCT01081093|Experimental|Biventricular pacing|
89222397|NCT00744341|Experimental|1|
89222398|NCT00744341|Experimental|2|
89222399|NCT00744341|Experimental|3|
89222400|NCT00744341|Experimental|4|
89222401|NCT00744341|Placebo Comparator|5|
89222402|NCT00968370|Active Comparator|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
89222403|NCT00968370|Other|Hospital management|Hospital management: all children admitted at the hospital will be managed with injection Ceftriaxone and other micronutrients for the total duration of hospitalization as per approved protocol.
89222404|NCT02685384||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
89222405|NCT02685384||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
89222406|NCT00968448|Active Comparator|Training|respiratory muscle training (pressure threshold loading)
89222407|NCT00968448|Sham Comparator|sham training|training with low resistance
89222408|NCT00741767|Other|Salmeterol-fluticasone|Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks. Patients will cross-over and receive placebo medication for 4 weeks later in the study.
89222409|NCT00741767|Other|Placebo|Patients randomized to receive placebo medication twice daily for 4 weeks. Patients will cross-over and receive study medication later in the study.
89222410|NCT00741845|Active Comparator|1|intravaginal metronidazole 750mg + 200mg miconazole
89222411|NCT00741845|Active Comparator|2|intravaginal metronidazole 750mg
89222412|NCT00741845|Active Comparator|3|intravaginal metronidazole 37.5mg
89222413|NCT02564549|Active Comparator|Group 1 (TRUS-guided biopsy)|"Baseline and annual systematic TRUS-guided biopsy performed as per standard of care by urologists for a total of one baseline diagnostic biopsy and two active surveillance systematic biopsies.~mpMRI at the end of the 2nd year with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~Patients will be followed, as per standard of care, for any potential infections from biopsies.~Annual PSA tests performed as per routine standard of care."
89222414|NCT02564549|Experimental|Group 2 (mpMRI with targeted biopsy)|"Baseline systematic transrectal ultrasound-guided biopsy performed as per standard of care by urologists.~Baseline and annual mpMRI with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~Patients will be followed, as per standard of care, for any potential infections from biopsies.~Annual PSA tests performed as per routine standard of care."
89222415|NCT00741923|Experimental|Bean group|A group consuming 5 cups/week of navy beans for a month
89222416|NCT00690755||Group 1|type 2 diabetic individuals
89222417|NCT00690755||Group 2|type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
89222418|NCT00690755||Group 3|non-diabetic individuals who are not considered to be overweight
89222419|NCT00690755||Group 4|non-diabetic individuals who are considered to be overweight
89222420|NCT00690755||Group 5|non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
89222421|NCT00690755||Group 6|individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
89222422|NCT00690755||Group 7|healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures
89222423|NCT00746369|No Intervention|2|
89222424|NCT00746369|Experimental|Intervention|IMARA HIV Prevention Intervention. Three individual sessions for incarcerated female teens.
89222425|NCT00746447|Experimental|3.0g OD|
89222426|NCT00746447|Experimental|1.5g OD|
89222427|NCT00746447|Active Comparator|0.5g TID|
89222428|NCT00744419|Experimental|3 age groups|Assigned to the arm based on age.
89222429|NCT02563379||Dippers|"Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP monitoring- greater than 10% for systolic and/or diastolic BP.~Extreme dipping is marked nocturnal systolic and/or diastolic BP fall>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio <0.8.~Patients in this group will be dippers or extreme dippers. We aim to examine the association of this BP pattern with the development of asymptomatic episodes of paroxysmal atrial fibrillation, in hypertensive subjects."
89222430|NCT02563379||Non-dippers|"Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.~In this group we aim to examine whether an association exists between the non-dipping pattern and the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects."
89222431|NCT02563379||Morning Hypertensives|"It is known that morning surge is the excessive systolic and/or diastolic BP elevation rising in the morning.~Patients in this group will have morning hypertension that is classified into two types:~the morning-surge type, characterized by a marked increase in blood pressure in the early morning, and the nocturnal-hypertension type, characterized by high blood pressure that persists from nighttime until early morning.~In our study we will examine whether an association between morning hypertension and asymptomatic episodes of paroxysmal atrial fibrillation exists in hypertensive subjects."
89222432|NCT00549302|Active Comparator|20 mg tadalafil|20 milligram (mg) tadalafil taken once a day
89222433|NCT00549302|Active Comparator|40 mg tadalafil|40 mg tadalafil tablet taken once a day
89222434|NCT00957788|Experimental|Cohort 0|
89222435|NCT00957788|Experimental|Cohort 1|
89222436|NCT00957788|Experimental|Cohort 2|
89222437|NCT00957788|Experimental|Cohort 3|
89222438|NCT05299424|Experimental|Phase 1, Dose escalation|There are 14 dose groups in dose escalation part ( Phase 1 study).
89222439|NCT05299424|Experimental|Phase 2, Dose expansion|Based on the data of phase 1, the dose level recommended for the phase 2 study (RP2D) will be evaluated.
89222440|NCT03969914||Critically ill ventilated patients|Patients admitted to ICU with expected mechanical ventilation >48h
89222441|NCT03961724||ESRD group|
89222442|NCT03961724||Control group|
89222443|NCT00117325|Experimental|GW685698X|GW685698X
89222444|NCT00958022|Experimental|LBH589 and carboplatin with etoposide|"The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with carboplatin with etoposide in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how lung cancer responds to the LBH589 in combination with carboplatin and etoposide.~This study will also investigate how the body processes the combination of LBH589 and carboplatin with etoposide."
89222445|NCT00958100|Experimental|Tenofovir Emtricitabine Raltegravir|Patients switching to raltegravir with tenofovir+emtricitabine as backbone
89222446|NCT00958100|Experimental|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
89222447|NCT00958100|Experimental|Abacavir free|Patients switched to raltegravir whose backbone therapy should not be randomized in order to avoid the use of abacavir (HLA-B*5701 positive patients,Framingham score 20% or higher)
89222448|NCT00948584|Experimental|insulin titration by specialized system|Insulin dose titration system by using a SMS automatically produced by a knowledge matrix
89222449|NCT00958178|Experimental|Rebreathing method of preoxygenation|Subjects will breathe Oxygen through a close fitting mask, but the flow will be low so that they rebreathe some of their expired air. After 30 seconds, the flow will be turned up so that they will breathe 100% Oxygen.
89222450|NCT00958178|Active Comparator|T method of preoxygenation|Tidal breathing of 100% oxygen through a well fitting facemask, for 4 minutes.
89222451|NCT00948662|Experimental|1|active arm/healthy young
89222452|NCT00948662|Placebo Comparator|2|placebo arm
89222453|NCT00948662|Other|3|ketoconazole interaction evaluation
89222454|NCT03748472|Experimental|Bolus feeding|
89222455|NCT03748472|Experimental|continuous gavage feeding|
89222456|NCT04010084|Placebo Comparator|Control group|
89222457|NCT04010084|Active Comparator|Laser group|
89222458|NCT03571022|Experimental|USE-MI System|Immediate use of the USE-MI smartwatch and smartphone app.
89222459|NCT00948740|Experimental|ergocalciferol|After signing informed consent, all participants who meet the study criteria will receive ergocalciferol 50,000 IU weekly for 8 weeks. After completing the ergocalciferol course, participants will take a maintenance dose of cholecalciferol 1,000 IU daily.
89222460|NCT01084369|Experimental|Testosterone, Vardenafil|All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil
89222461|NCT05352308|Experimental|Common Sense Model Guided Narrative Video Group|The narrative videos is guided by the CSM and designed to provide a comprehensive resource for college students. The narrative video addresses illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers. The format of the narrative video includes (1) a direct testimonial of a college woman (in her dorm room) telling a story to her roommates about what motivated her to get vaccinated, and (2) a conversation among the roommates where information about the HPV vaccine is discussed.
89222462|NCT05352308|No Intervention|Standard of Care Group|"Participants in the standard of care group will receive the Centers for Disease Control and Prevention's Vaccine Information Statement (VIS; https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv.pdf). The VIS contains information about HPV, the HPV vaccine, and the benefits and risks of the vaccine.~The VIS will be utilized because healthcare providers are required to distribute the VIS to patients before receiving each dose of the HPV vaccine, it is easy to understand, and it is publicly available information."
89222463|NCT05352308|No Intervention|Time & Attention Group|Participants in the time and attention video group will receive a Centers for Disease Control and Prevention video on binge drinking (https://youtu.be/I9hdkDTaQWU; 4:22 minutes). The video contains information on the health risks of binge drinking including unintended pregnancy, sexually transmitted diseases, injury, car accidents, violence, and HIV/AIDS
89222464|NCT03416738|Active Comparator|Semantically focused treatment|This treatment will focus on improving word finding and comprehension of information.
89222465|NCT03416738|Active Comparator|Phonologically focused treatment|This treatment will focus on training speech sound production, targeting overall production abilities.
89222466|NCT04010006|Experimental|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
89222467|NCT04010006|Active Comparator|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
89222468|NCT04010162||Group-1: King's College Hospital|Doctors in King's College Hospital, London, The United Kingdom (Excluding Urology and Gynecology)
89222469|NCT04010162||Group-2: Uludag University Hospital|Doctors in Uludag University Hospital, Bursa, Turkey (Excluding Urology and Gynecology)
89222470|NCT04010162||Group-3: The United States|Doctors from The United States (Excluding Urology and Gynecology)
89222471|NCT04010162||Group-4: The World|Doctors from all over the world (Excluding Urology and Gynecology)
89222472|NCT02994446|Experimental|SERF Catheter Ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
89222473|NCT00116779|Experimental|Degarelix 60mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.
89222474|NCT00116779|Experimental|Degarelix 80mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.
89222475|NCT00949130|Experimental|NXL103|BID for 7-14 days orally
89222476|NCT00949130|Active Comparator|Linezolid|BID for 7-14 days orally
89222477|NCT03943290|Experimental|Part 1 Cohort 1a|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for FSHD patients
89222478|NCT03943290|Experimental|Part 1 Cohort 1b|ACE-083 240 mg/muscle administered bilaterally by injection into the BB muscle every 4 weeks for up to 6 doses for FSHD patients
89229833|NCT01004276|Experimental|Improved module|
89229834|NCT01004276|No Intervention|Standard module|
89065699|NCT04326881|Experimental|SHR-1314 A|single dosing SHR-1314 A
89065700|NCT04326881|Experimental|SHR-1314 B|single dosing SHR-1314 B
89065701|NCT04326881|Experimental|SHR-1314 C|single dosing SHR-1314 C
89065702|NCT02892461|Experimental|Umbilical cord milking|The cord will be cut at 25 cm from the umbilical stump within 30 seconds after the infant is taken out from the uterus and its blood will be milked to the infant gently and thoroughly in 30 seconds during resuscitation on the radiant warmer, and then the cord will be cut at 2 to 3 cm from the umbilical stump.
89065703|NCT02892461|No Intervention|Routine clinical treatment and care|The cord will be dealt with routine clinical method, which means it will be cut twice within 1minute after the infant is taken out from the uterus, the first cut is on the operating table, while the second cut is on the radiant warmer.
89065704|NCT00595829|Experimental|1|
89065705|NCT00595985|Experimental|A|administer sorafenib 400mg bid until disease progression or intolerable toxicity or patients withdrawal of consent
89065706|NCT00596063|Experimental|Wosulin R|Regular insulin for subcutaneous injection (recombinant human insulin), 600nmol, 100 IU
89065707|NCT00596063|Active Comparator|Novolin R|Regular insulin for injection (recombinant human insulin)
89065708|NCT00596141|Experimental|1|Conventional postoperative care and instructions on dental hygiene will be provided along with the TOWE treatment which consists of the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site 3 times daily for a period of 7 days. At three (3) days and seven (7) days postoperatively, photographs will be taken of all vertical releasing incisions (before suture removal).
89065709|NCT00596141|No Intervention|2|Conventional postoperative care and instructions on dental hygiene.
89065710|NCT00596219|Experimental|1|
89065711|NCT00596297|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
89065712|NCT00596297|Active Comparator|B|Pars plana vitrectomy only
89065713|NCT00596375|No Intervention|Routine Care Group|The routine care group will help us to quantify the routine amount of distress associated with catheterization.
89065714|NCT00596375|Experimental|Lidocaine Group|A experimental group will include patients who will have 2% Lidocaine instilled into the urethra prior to catheterization. This group of subjects receiving routine care plus Lidocaine, will be evaluated during each of the four phases of the intervention.
89065715|NCT00596375|Experimental|Instillation|This group will undergo catheterization utilizing routine care plus lubricant jelly instilled into the urethra. This placebo group will aid in discerning the effects of instillation into the urethra on pain and associated distress.
89065716|NCT00596531|Active Comparator|A|"Subjects will take acamprosate (Campral) at a dose of 666 mg. three times daily (morning, lunch time, bed time) for 28 days. Only responders will be included in the subsequent double-blind cross over arms after a minimum washout period of 4 weeks.~Subjects will randomly be assigned to Group 1 (A/B) or Group 2 (B/A) after completion of Phase I and its subsequent washout period (Figure 1, periods 1 and 2). Group 1 will receive acamprosate (Campral) at a dose of 666 mg. three times daily for 24 weeks followed by a 4-week washout period"
89065717|NCT00596531|Placebo Comparator|B|Group 2 will be assigned to the placebo group and take matched placebos for next 24 weeks followed by a 4-week washout period. After the washout period each group will be assigned to the other intervention (acamprosate or placebo) and complete another trial for 24 weeks.
89065718|NCT00596609||1|Group 1 will be subjects who receive Intrathecal Morphine.
89065719|NCT00596609||2|Group 2 will be subjects who do not receive Intrathecal Morphine.
89065720|NCT00596765|Experimental|1|Neuropsychological cognitive behavioral psychotherapy for patients with acquired brain injury consists of 25 weekly 1-hr sessions of individualized outpatient treatment. The therapeutical intervention is modularised, patients are assigned to specific interventional modules according to the results of cognitive testing and interviews. Modules concern on the one hand the treatment of deficits in attention, memory, and executive functions. On the other hand psychosocial adjustment to chronic illness is addressed through modules that concern the development of a positive self-concept, the adjustment of life-goals and coping with negative affect (e.g. depressive symptoms, irritability, guilt).
89065721|NCT00596765|Other|2|"Waiting list: Patients are randomly assigned to one of two existing groups after completion of the first session of various neuropsychological tests and interviews.~Patients assigned to the experimental group receive therapy immediately after completing the first session of various neuropsychological tests and interviews. Patients randomized to the waiting list receive the treatment as specified above after waiting for 5 month."
89065722|NCT00596843|Experimental|1|Motivational intervention
89065723|NCT00596843|Active Comparator|2|Educational intervention
89065724|NCT00622973|Other|A|Diffusion-weighted MRI
89065725|NCT00622973|Other|B|Sinerem (USPIO)- enhanced MRI
89065726|NCT04326647|Experimental|Kinesiotaping Group|We used kinesiotaping (gastrocnemius and lumbar back) plus exercise
89065727|NCT04326647|Active Comparator|Exercise Group|We used only exercise
89065728|NCT00596999||1|all subjects will be treated with UCB and HPDSC
89065729|NCT00597077|Active Comparator|Rate control|
89065730|NCT00597077|Active Comparator|Rhythm control|
89065731|NCT04326803|Experimental|Vaccine group|Administration of 3 doses hepatitis B vaccine (recombinant hepatitis B vaccine, injectable suspension for intramuscular use) at month 0, 1 and 2.
89065732|NCT02892227|Experimental|JET ECHO|Transmitral flow estimation
89065733|NCT02892227|No Intervention|NO JET ECHO|no bedside echocardiography
89065734|NCT00597311|Experimental|1|preoperative short term radiation group 5x5 Gy and surgery after 6 weeks
89065735|NCT00597311|Experimental|2|preoperative chemoradiotherapy group 50Gy + 5FU/Lv and surgery after 6 weeks.
89065736|NCT01064401|Experimental|Daclizumab High Yield Process 150 mg SC|Daclizumab High Yield Process (DAC HYP) 150mg subcutaneous (SC) injection once every 4 weeks plus placebo to IFN β-1a intramuscular (IM) injection once weekly for 96 to 144 weeks
89065737|NCT01064401|Active Comparator|IFN β-1a 30 µg IM|Interferon beta-1a (IFN β-1a) 30 µg IM once weekly plus placebo to DAC HYP SC once every 4 weeks for 96 to 144 weeks
89065738|NCT00597389|Active Comparator|1|oral solution of propranolol (propranolol HCL 20 mg/5 ml solution) or a liquid placebo twice daily for 10 days (and taper for 5 days; based on Pitman et al, 2002). Dose was calculated as determined by Famularo et al. (1988) to be 2.5 mg/kg/d with a maximum dose of 40 mg bid (Green, 2001).
89065739|NCT00597389|Placebo Comparator|2|A 25/5ml solution of placebo (a sugar solution that looks and tastes like the propranolol solution)
89065740|NCT02892071|Active Comparator|22% TCA peel|22% trichloroacetic acid medium depth chemical peel applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
89065741|NCT02892071|Active Comparator|CO2 laser|CO2 ablative fractional laser resurfacing applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
89065742|NCT02892071|Active Comparator|Qs-NdYAG laser|Long pulsed Q-switched Nd:Yag laser will be applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek), performed at 2-week intervals for six sessions.
89065743|NCT00597467|Experimental|Test Contact Lenses|VISA (comfilcon A) Silicone Hydrogel Soft contact lens
89065744|NCT00597467|Active Comparator|Control Contact Lenses|Acuvue 2 Soft Contact Lens
89065745|NCT01306617|Experimental|ABT-450/r (250/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (250/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
89065746|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
89065747|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in non-responders|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID in previous non-responders to pegylated interferon (pegIFN) and RBV.
89065748|NCT00597623|Experimental|1|2 injections of Adalimumab (Humira®)
89065749|NCT00597623|Placebo Comparator|2|2 injection of Placebo
89065750|NCT00597779|Active Comparator|EM device|Extramedullary Device (EM)
89065751|NCT00597779|Active Comparator|IM device|Intramedullary Device (IM)
89065752|NCT04326569|Experimental|adults with trans-sphenoidal endoscopic pituitary surgery|adult with trans-sphenoidal endoscopic pituitary surgery for tumour of the sellar region
89065753|NCT02874625|Active Comparator|Treatment 1|Dental restoration performed with glass-ionomer materials.
89065754|NCT02874625|Experimental|Treatment 2|Dental restoration performed with resin-based composites.
89065755|NCT02875795|Experimental|speech intelligibility|speech intelligibility is registered by an automatic speech processing tool
89065756|NCT00597857|Placebo Comparator|1|receipt of a placebo pill for 16 days
89065757|NCT00597857|Active Comparator|2|oral pill of hydrocortisone (ranging from 20mg - 2.5mg) taken for 10 days with a taper for 6 days (based on Pitman et al, 2002).
89065758|NCT00627133|Experimental|1|
89065759|NCT01306305|Experimental|Elderly|Elderly subjects aged over 60 years
89065760|NCT01306305|Experimental|Adults|Adults from 18 to 60 years old inclusive
89065761|NCT00598013|Experimental|1|
89065762|NCT00598013|No Intervention|2|
89065763|NCT04303429|No Intervention|observation group|Patients enrolled in the observation group will not receive any chemotherapy drugs
89065764|NCT04303429|Experimental|adjuvant chemotherapy group|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
89065765|NCT00598091|Active Comparator|A|
89065766|NCT00598091|Active Comparator|B|
89065767|NCT00623415|Active Comparator|Verum|flupirtine + interferon beta 1b
89065768|NCT00623415|Placebo Comparator|Placebo|placebo + interferon beta 1b
89065769|NCT02874703||HIV-positive|
89065770|NCT02874703||HIV-negative|
89065771|NCT04326725||Hydroxychloroquine|Subjects with prophylaxis
89065772|NCT01038427|Experimental|Test|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
89065773|NCT01038427|Active Comparator|Reference|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
89065774|NCT01038427|Placebo Comparator|Placebo|Placebo nasal spray administered once daily for 14 days.
89222479|NCT03943290|Experimental|Part 1 Cohort 1c|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for CMT patients
89222480|NCT03943290|Experimental|Part 2 Cohort 2a|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for FSHD patients
89222481|NCT03943290|Experimental|Part 2 Cohort 2b|ACE-083 Administered into the BB muscle q4w for up to 24 months (24 doses) for FSHD patients
89065775|NCT00598169|Experimental|CD20+ Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, rituximab 375mg/m2 on Day 1 of a 21-day cycle."
89065776|NCT00598169|Experimental|CD20- Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, 21-day cycle."
89065777|NCT00598247|Experimental|A|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks. A
89065778|NCT00598325|Experimental|NicVAX|
89065779|NCT00598325|Experimental|NicVAX Lot 2|2nd cohort receives a different lot of vaccine from the 1st cohort
89065780|NCT00598403|Experimental|1|Cefditoren pivoxil
89065781|NCT00598403|Active Comparator|2|Ciprofloxacin
89065782|NCT00598637|Active Comparator|EES|Everolimus-eluting stent (Xience)
89065783|NCT00598637|Experimental|ZES|Zotarolimus-eluting stent (Endeavor Resolute)
89065784|NCT00598715|Experimental|Same drug|sirolimus-eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
89065785|NCT00598715|Active Comparator|Different drug|paclitaxel eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
89065786|NCT04325945|Experimental|Laser acupuncture|808nm low level laser therapy
89065787|NCT04325945|Sham Comparator|Sham laser acupuncture|no low level laser output but same device
89065788|NCT01037413|Experimental|EXC 001|
88812683|NCT01203722|Active Comparator|REGIMEN B|"Pre-BMT :~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~Day -1: 400 cGy total body irradiation (TBI) administered in a single fraction~Day 0: Allogeneic blood or marrow transplantation (BMT)~Post-Transplantation Immunosuppression Consisting of:~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~Day 5: Sirolimus loading dose 6 mg PO once~Day 5 thru Day 35: Mycophenolate Mofetil (MMF) 15 mg/kg PO TID (maximum daily dose 3 g/day)~Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
89065789|NCT01037413|Placebo Comparator|Placebo|
89065790|NCT00599183|Other|1|Participants will receive baseline conventional MRI of the cervical spine as part of their clinical care with an additional diffusion tensor imaging (DTI)sequence as part of the research; they will complete an anonymized questionnaire about their condition. Participants will receive an MRI with DTI and tractography as part of the research and will complete an anonymized questionnaire about their condition. The baseline and follow up data will be compared.
89065791|NCT01326845|Experimental|Deferasirox am|Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
89065792|NCT01326845|Experimental|Deferasirox pm|Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal
89065793|NCT02873845||PATIENT|Patients with colon cancer
89065794|NCT02873845||THE SPOUSE/PARTNER|The spouse/partner of patients with colon cancer
89065795|NCT01062763|Experimental|addition of spironolactone|spironolactone is added to previous antihypertensive treatment
89065796|NCT01062763|Placebo Comparator|Placebo|Addition of placebo
89065797|NCT00599261|Experimental|1|Removal of the fibrotic pocket surrounding the generator and leads
89065798|NCT00599261|Experimental|2|Tissue is not removed
89065799|NCT00599417|Experimental|1|
89065800|NCT00599417|Placebo Comparator|2|
89065801|NCT00599573|Experimental|1|Ondansetron
89065802|NCT00599651|Experimental|1|Surfactant by LMA
89065803|NCT00599651|Other|2|Standard of care
89065804|NCT00599729||1|patient demonstrating degenerative changes in the knee joint (osteoarthritis)
89065805|NCT01048099|Experimental|PRO Onc Assay and Treatment|Blood specimens tested for circulating tumor cells followed by systemic treatment based on assay results with either trastuzumab or pertuzumab
89065806|NCT00599807|Active Comparator|1: 2000 IU D3/day|2000 IU vitamin D3 taken orally each day for 2 years
89065807|NCT00599807|Active Comparator|2: 800 IU D3 / day|800 IU vitamin D3 taken orally each day for 2 years
89065808|NCT00599885|Active Comparator|1|
89065809|NCT00599885|Active Comparator|2|
89065810|NCT00599963|Experimental|1|paricalcitol 1 mg/day for 12 weeks, followed by a washout period of 4 weeks, then crossed over to no treatment for another 12 weeks
89065811|NCT00599963|Active Comparator|2|no treatment for 12 weeks, followed by a washout period of 4 weeks, then crossed over to paricalcitol for another 12 weeks
89065812|NCT01303965|Experimental|Open Label, Single Arm|Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance
89065813|NCT00600041|Experimental|A|Pantoprazole IV
89065814|NCT00600041|Placebo Comparator|B|NaCl 0.9% IV
89065815|NCT01045993|Active Comparator|1|Heat device
89065816|NCT01045993|Sham Comparator|2|Placebo arm
89065817|NCT01045993|Active Comparator|3|Marketed analgesic
89065818|NCT01045993|Placebo Comparator|4|(Oral) Placebo comparator
89065819|NCT00600197|Experimental|Back school|a kind of educational program for low back pain
89065820|NCT00600197|Experimental|back school|
89065821|NCT02890563|No Intervention|No Compression|Patients in this group will not receive any compression after treatment.
89222482|NCT03943290|Experimental|Part 2 Cohort 2c|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for CMT patients
89222483|NCT03943290|Experimental|Part 2 Cohort 3a|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for FSHD patients
89222484|NCT03943290|Experimental|Part 2 Cohort 3b|ACE-083 Administered into the BB muscle q8w for up to 24 months (12 doses) for FSHD patients
89222485|NCT03943290|Experimental|Part 2 Cohort 3c|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for CMT patients
89222486|NCT04010318||Corrected group|The patients in which the PVI will corrected by fluid to level below 15
89222487|NCT04010318||Uncorrected group|Patients in which intravenous fluid administration didn't result any change in PVI or changed but still higher than 15
89222488|NCT00108355|Active Comparator|Albumin (Control group)|"After LVP, patients in this group received:~Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)"
89222489|NCT00108355|Experimental|Vasoconstrictor (Study Group)|"After LVP, patients in this group received:~Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose"
89222490|NCT05351996|Active Comparator|Kinesiotape|The participants received kinesiotape to the rectus femoris muscle.
89222491|NCT05351996|Sham Comparator|Sham-kinesiotape|Non-specific taping was applied.
89222492|NCT00949208||A|The study population will consist of healthy volunteers who fulfill all the inclusion criteria and do not meet any of the exclusion criteria.
89222493|NCT02755220|Experimental|Cingularbio® Heart valve|the patients will replaced by artificial heart valve
89222494|NCT00963222|Active Comparator|with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
89065822|NCT02890563|Active Comparator|Compression|Patients in this group will use compression stockings for seven days after treatment (2 days continuously and 5 days during daytime).
89065823|NCT00600431||1|Study group: 16 children under 18 years undergoing systemic chemotherapy
89065824|NCT00600431||2|Control group: 16 age and sex matched healthy children under 18 years
89065825|NCT04325867|Experimental|All patients with known cardiovascular disease|"All these patients will be provided an electronic account on a dedicated platform were they can be supervised and can call for advice / help.~This kind of tele-medical project aims to keep these patients in a so-called proximity, monitoring their vital parameters, checking their medication and providing dedicated advices according to their complaints.~Moreover, all these patients will receive digital watches with ecg-recording capabilities, thus a dedicated physician could correlate their symptoms with few clear paraclinical variables.~All of these patients' complaints will be stratified according to elaborated protocols based on the European Cardiovascular Guidelines.~Moreover, a psychologist and a chaplain will deal with their (new) problems due to social isolation."
89065826|NCT05643963|Experimental|Focus on bladder protective diet|For 12 weeks, healthy volunteers will follow a bladder protective diet.
89065827|NCT05643963|Experimental|No focus on bladder protective diet|For 12 weeks, healthy volunteers will not follow a specific diet.
89065828|NCT01303419|Experimental|CE-BMRI|Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
89065829|NCT01326533|Experimental|hydroxychloroquine|Thirteen weeks of daily hydroxychloroquine following FSIGTT testing
89065830|NCT01326533|Placebo Comparator|Placebo|Thirteen weeks of daily placebo following FSIGTT testing
89065831|NCT00600587|Experimental|A|Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)
89065832|NCT00600587|Active Comparator|B|Non-erlotinib targeted NSCLC population based on EGFR gene analysis
89065833|NCT01045447|Experimental|IDegAsp OD|
89065834|NCT01045447|Active Comparator|IGlar OD|
89065835|NCT00600665|Active Comparator|Usual Care|In Part 1 of the study, participants will access PAINReportIt and computer games. PAINReportIt helps the patient describe the pain experienced. In Part 2 of the study, participants will continue to access PAINReportIt when they are seen in the clinic, emergency department (ED), acute care center (ACCA), and hospital. They will gain access to the PAINUCope computer-based programs, which provides multimedia education tailored to the patient's misconceptions about pain management. They will receive medial usual care at the outpatient clinic, ED, ACC, and hospital.
89065836|NCT00600665|Experimental|PAINUCope/PAINConsultN|In Part 1 of the study, participants will access PAINReportIt and PAINUCope computer-based programs. PAINReportIt helps the patients describe the pain experiences and PAINUCope provides multimedia education tailored to the patient's misconceptions about pain management. In Part 2 of the study, participants will continue to access PAINReportIt and PAINUCope programs when they are seen in the clinic, emergency department (ED), acute care center (ACC), and hospital. Their doctors will have access to PAINConsultN when seen at the ED, ACC, and hospital. PAINConsultN is just-in-time decision support for the physicians with the pain data summarized and suggestions for analgesics that may be useful to help manage the patient's pain.
89065837|NCT04324827|Experimental|Graston Technique® Group|The application was applied by a GT® certified therapist with 12 years of experience in orthopedic rehabilitation and soft tissue treatments. Hamstring, gastrosoleus and plantar fascia were scanned with GT® instruments and the treated soft tissue was treated. The instruments used differ according to the application protocol and regions are determined with reference to the GT® manual. The treatment lasted 8 minutes for each leg and was applied to both legs equally and by the same person for a total of 16 minutes.
89222495|NCT00963222|Placebo Comparator|with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
89222496|NCT00963222|Active Comparator|without atherosclerosis/ vitamin A|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
89065838|NCT04324827|Experimental|Foam Roller Group|FR was applied to gastrosoleus and hamstring muscle groups and plantar fascia. TriggerPoint Grid X Foam Roller and Nano Foot X Roller were used in the application. Hamstring, gastrosoleus and plantar fascia for 3 minutes were performed for a single leg. The treatment lasted 8 minutes on one leg and was applied equally to both legs for a total of 16 minutes. Before the application, the participants were informed with verbal and visual warnings about how to do the applications. During the application, the participant was instructed about the time with a stopwatch. The patient himself regulated the pressure applied to the FR; however, the participant was instructed to apply FR as much body weight as possible. The frequency of application was about 0.5 Hz (ie, each rolling cycle lasted for about 2 seconds).
89065839|NCT04324827|Experimental|Dynamic Stretch|DS protocol was prepared with reference to the work of Faigenbaum et al 2005. The protocol consists of 10 dynamic exercises of 10 minutes of medium and high intensity. Each dynamic stretching exercise was performed at a distance of 13 meters. The participants were given a 10-second rest period between each exercise. The participants were given verbal feedback about their postures during the exercises and the video of the exercises was shown to the participant.
89065840|NCT00623051|Experimental|1|Male circumcision by experimented doctor or nurse
89065841|NCT00623207|Placebo Comparator|1|Pateints who achieve target haert rate or conclusive test will not be given Atropine
89065842|NCT00623207|Active Comparator|2|Patients who won't achieve tarhet heart rate or conclusive results will be given Atropine
89065843|NCT00600899|Experimental|A|Group A patients will receive perisciatic continuous infusion of ropivacaine 2 mg/ml through an elastomeric pump (Baxter, Deerfield, IL, USA)) 8 ml/h (reservoir of 500 ml)as postoperative analgesia.
89065844|NCT00600899|Active Comparator|B|Group B patients will receive standard treatment: continuous perisciatic infusion of 2 mg/ml ropivacaine 5 ml/t (Baxter infusor with 275 ml reservoir)
89065845|NCT04205617|Experimental|Healthy Food Prescription|Participants receive services through the Living Hungry program for food insecure diabetic patients.
89065846|NCT00600977|Active Comparator|doxorubicine|VAD
89065847|NCT00600977|Experimental|Doxorubicine pegylated|Doxorubicine pegylated 40 MG/M² J1
89065848|NCT01301625||MitraClip Implant|Eligible patients undergoing a MitraClip procedure in Australia and New Zealand
89065849|NCT00601055|Experimental|Problem Solving-Rx Adherence (PSA)|Participants will receive problem-solving therapy integrated with adherence-enhanced procedures (PSA).
89065850|NCT00601055|Active Comparator|PID-C|Participants will receive adherence-enhanced (PID-C) procedures, a treatment mobilizing patients to participate in their care.
89065851|NCT00601133||Patient Postural Instability|Participants having difficulty walking and with balance after cancer treatment that are leaving the M.D. Anderson rehabilitation hospital or after treatment through the rehabilitation mobile team.
89065852|NCT04301947|Active Comparator|Standard warm-up protocol|The standard warm-up protocol consists of 5 (five) minutes of stationary cycling, followed by calf, hamstring and quadriceps stretching. For all stretching positions 30 (thirty) seconds will be set. For calf stretching, the participant places his hands on the waist and projects his dominant limb behind of the center of mass line, the contralateral limb will be placed forward until the stretch sensation on the dominant limb start. For hamstring stretching, the participant will be instructed to bend over the hip, reaching the foot of the dominant limb in dorsiflexion. Emphasis will be placed on maintaining the heel of the dominant limb on the floor and maintaining posture. Finally, for quadriceps stretching, the participant will perform a knee flexion and will hold the dominant lower limb foot close to the gluteus with the ipsilateral upper limb hand. Emphasis will be placed on maintaining trunk posture.
89065853|NCT04301947|Experimental|Gluteal activation warm-up|"The gluteal activation warm-up protocol consists of performing a standard warm-up protocol with additional shell exercise. The shell exercise will be performed with the participant side-lying with hip and knee flexed, an elastic band (PREFORM BETTER Inc. Rhode Island, USA) will be placed around the distal thigh to promote resistance and the participants will be instructed to perform hip abduction movements. The exercise will be performed in multiple sets (3 sets) of 12 repetitions, with 30 seconds interval between exercises in order to minimize the fatigue effect. Medium and heavy elastic bands tensions will be used and adjusted according to the effort perception parameter from the OMNI scale for effort perception for resistance training."
89065854|NCT02891525|Active Comparator|50g glucose intragastric|50g glucose dissolved in 250mL tap water given via nasogastric tube
89222497|NCT00963222|Placebo Comparator|without athrosclerosis/ placebo|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive placebo
89222498|NCT05297474||SSc patiant|We recruited 95 patients with systemic sclerosis
89222499|NCT05297474||health control|We recruited 95 healthy people for control
89222500|NCT00968604|Experimental|BikDD Nanoparticle|BikDD Nanoparticle starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
89222501|NCT02703584|Experimental|Double trigger|Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
89222502|NCT02703584|Placebo Comparator|control|Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo
89222503|NCT04010292|Experimental|Patient education card|
89222504|NCT04010292|No Intervention|Control|
89222505|NCT02575976|Experimental|comprehensive CR|education and exercise-based cardiac rehabilitation
89222506|NCT02575976|Active Comparator|exercise-based CR|Exercise-based cardiac rehabilitation
89222507|NCT02575976|Other|wait list control|no cardiac rehabilitation
89222508|NCT04009980|Experimental|OMK2 group|Patients receiving topical administration of OMk2 ophthalmic solution for 36 months three times/day
89222509|NCT04009980|Placebo Comparator|Placebo group|Patients receiving receiving only the excipients of OMk2 (placebo) for 36 months three times/day
89222510|NCT02465138|Placebo Comparator|Placebo|Normal Saline will be administered prior to procedure.
89222511|NCT02465138|Active Comparator|Toradol|Intravenous ketorolac prior to ERCP
89065855|NCT02891525|Active Comparator|25g fructose intragastric|25g glucose dissolved in 250mL tap water given via nasogastric tube
89065856|NCT02891525|Active Comparator|220mg acesulfame-K intragastric|220mg acesulfame-K dissolved in 250mL tap water given via nasogastric tube
89065857|NCT02891525|Placebo Comparator|250mL tap water intragastric|250mL tap water given via nasogastric tube
89065858|NCT04304053|Active Comparator|No Intervention- SARS-CoV-2 surveillance|"Study 1- Contacts will complete a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and day 14.~Study 2- Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3 and 7.~Isolation of patient and contact tracing as per national guidelines."
89065859|NCT04304053|Experimental|Testing, treatment and prophylaxis of SARS-CoV-2|"Study 1- Contacts receive Hydroxychloroquine prophylaxis. Contacts will complete a survey collecting demographic, epidemiological and clinical and provides a swab for RT-PCR testing at baseline and day 14.~Study 2- Index case receives Hydroxychloroquine. Index case completes a survey collecting demographic, epidemiological and clinical data and provides a swab for RT-PCR testing at baseline and on days 3, and 7.~Isolation of patient and contact tracing as per national guidelines."
89065860|NCT00601679|Experimental|NT-proBNP|Surveillance NT-proBNP levels disclosed to physicians. Intervention (e.g. Diuretic management) based on NT-proBNP results.
89065861|NCT00601679|No Intervention|Usual Care|Surveillance NT-proBNP levels blinded. Intervention (e.g. Diuretic management) based on clinical judgments.
89065862|NCT00601757|Other|1|Participants assigned to the Postpartum Prevention Program
89065863|NCT00601757|Other|2|Participants assigned to enhanced care as usual
89065864|NCT00601913|Experimental|Erlotinib|Erlotinib
89065865|NCT01301391|Experimental|Milciclib|Milciclib Maleate capsules
89065866|NCT00602069|Experimental|1|Participants will receive cognitive behavioral therapy through the Helping to Overcome PTSD through Empowerment program
89065867|NCT00602069|Active Comparator|2|Participants will receive standard shelter services
89065868|NCT01036321|Active Comparator|Purified Isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler. 40 mg daily.
89065869|NCT01036321|Placebo Comparator|Methyl cellulose blend|Placebo.
89065870|NCT04325633|Experimental|1: Naproxen|Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
89065871|NCT04325633|Placebo Comparator|2: Standard of care|Standard of care
89065872|NCT04324749|Experimental|Group A (roasted peanuts)|Group A: Habitual diet + 25 g/day of whole skin roasted peanuts (RP)
89065873|NCT04324749|Experimental|Group B (peanut butter)|Group B: Habitual diet+ 2 tbsp/day (32 g/day) of peanut butter (PB)
89065874|NCT04324749|Experimental|Group C (control)|Group C: Habitual diet + 2 tbsp/day (32 g/day) of control supplement
89065875|NCT04125485||Person with Parkinson's|"Inclusion criteria for interview/focus group with people with PD: people with PD living at home, Hoehn & Yahr stage 1-4 (Hoehn and Yahr, 1967), cognitively able to participate, able to speak a conversational level of English, and at different stages of PD (early, mid, later by years of diagnosis) and ages (younger and older).~Exclusion criteria: any hospital admission within the last 1 year, whether for Parkinson's or anything else, that was for more than 24 hours i.e. not day surgery/brief checks in the emergency department after falls; patients diagnosed with PD less than 6 months ago to confirm the diagnosis and allowed them to have time for using the resources for people with PD; unwillingness to participate."
89065876|NCT04125485||Healthcare professional|"Inclusion criteria for interview/focus group for health professionals: Professionals from different disciplines (physician, neurologist, General Practitioners, nurses/specialist nurses, social worker, occupational therapist, mental health workers, physiotherapist, pharmacist, speech therapist) that provide support directly or indirectly to patients with PD and family carers.~Exclusion criteria: Not involved in direct care or support of people with PD or unwillingness to participate."
89065877|NCT04125485||Family carer|"Inclusion and exclusion criteria for all are the same for Interviews and Focus Groups.~Family carers:~Inclusion criteria: family caregivers of PD patients at different stages (early, mid, late) or friends involved in the care process. Also, family caregivers of patients with cognitive impairment will be included.~Exclusion criteria: not being involved in the care of the person with PD or unwillingness to participate in the project, and an ability to speak a conversational level of the English language.~Family carers do not need to have the person they care for in the study also and vice-versa."
89065878|NCT04125485||Stakeholder|"Stakeholders:~Inclusion criteria: non-NHS professionals or volunteers involved in policy making or working or collaborating in voluntary organisations or from different sectors; (non-NHS) Health Care, Social Services, voluntary sector, employment, food, Pharmaceutical, Education, Political, that have an impact directly or indirectly in the management of PD and development of care pathways for PD or other long-term conditions (when relevant). Exclusion criteria: unwillingness to participate in the project or lack of involvement in strategic planning or involvement in provision of community PD care."
89065879|NCT01061359||Non-Interventional Study|Chemotherapy containing Epirubicin
89065880|NCT05643417|Experimental|Liver metastasis of gastric cancer|HAIC: refer to genetic test results，D1； Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065881|NCT05643417|Experimental|Liver metastasis of breast cancer|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065882|NCT05643417|Experimental|Liver metastasis of lung cancer|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065883|NCT05643417|Experimental|Liver metastasis of nasopharyngeal carcinoma|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065884|NCT05643417|Experimental|Liver metastasis of thyroid cancer|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065885|NCT05643417|Experimental|Liver metastasis of melanoma|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065886|NCT05643417|Experimental|Liver metastasis of stromal tumor|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065887|NCT05643417|Experimental|Liver metastasis of sarcoma|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065888|NCT05643417|Experimental|Liver metastasis of other solid tumor|HAIC: refer to genetic test results，D1；Bevacizumab：7.5mg/Kg, D2, Q3W；Camrelizumab：200mg, D2, Q3W；
89065889|NCT04303975||Group 1: Patients with neoadjuvant chemotherapy|"The patients of group1 will receive one of the following treatments:~neoadjuvant chemotherapy & concurrent chemoradiotherapy~neoadjuvant chemotherapy & radiotherapy~neoadjuvant chemotherapy & radiotherapy & adjuvant chemotherapy"
89065890|NCT04303975||Group 2: Patients without neoadjuvant chemotherapy|"The patients of group2 will receive one of the following treatments:~concurrent chemoradiotherapy~concurrent chemoradiotherapy & adjuvant chemoradiotherapy~radiotherapy & adjuvant chemotherapy"
89065891|NCT00602147||Retrospective sample|People who have been diagnosed with multiple myeloma and have received high-dose melphalan.
89065892|NCT00602147||Prospective sample|People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.
89065893|NCT04303741|Experimental|Camrelizumab +Apatinib+Eribulin|Camrelizumab 200mg(3mg/kg for patient whose weight is below 50kg) iv Q3W combination with Apatinib 250mg, po, daily (d1-d21)and Eribulin1.4mg/m2 iv d1, d8 Q3W
89065894|NCT05643261|Experimental|Intervention group|All players in the intervention group will complete the targeted muscle and technique training integrated into their handball training. There will be a training of the coaches on site, who assess the training of the intervention group during the entire period and document the participation of the players accordingly.
89065895|NCT05643261|No Intervention|Control group|Players in the control group only continue their regular handball training.
89065896|NCT00626977||R|R group:15 mL of 0.125% ropivacaine (18.75 mg)
89065897|NCT00626977||RC|RC group:0.0625% ropivacaine (9.375 mg) plus 75 ug clonidine
89065898|NCT04302883|Experimental|Intervention group|TEE FEES
89065899|NCT04302883|Active Comparator|Control group|FEES
89065900|NCT00623571|Experimental|1|Patients treated by hospital-at-home service (GHHS)
89065901|NCT00623571|Active Comparator|2|Patients treated in a general medical ward (GMW)
89065902|NCT00627211|No Intervention|Room air insufflation|Air used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is current standard procedure, i.e. no experimental intervention.
89065903|NCT00627211|Experimental|CO2 insufflation|CO2 used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is not standard procedure and therefore experimental intervention.
89065904|NCT04303819||newly diagnosed T2DM participants|newly diagnosed T2DM participants without anti-diabetic drugs intake
89065905|NCT01301079|Active Comparator|Ketamine|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), remifentanil (1 μg/kg), and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group ketamine received remifentanil (0.4 μg/kg/min) and ketamine (5 μg/kg/min).~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
89065906|NCT01301079|Placebo Comparator|Saline|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), 1 μg/kg remifentanil, and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group saline received remifentanil (0.4 μg/kg/min) and saline solution.~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
89065907|NCT04303039|Experimental|Treatment A|Single 1.0 mg dose of ABP-671 in the fasted state.
89065908|NCT04303039|Experimental|Treatment B|Single 1.0 mg dose of ABP-671 in the fed state, after a standardized breakfast.
89065909|NCT05271721|Other|control group|Dexamethasone 4 mg (1ml) plus 40 mg ( 2ml) lidocaine 2% plus 1ml sterile saline
89065910|NCT05271721|Active Comparator|Magnesuim group|. 200 mg Mg sulfate (1ml) plus 4 mg dexamethasone(1ml) plus 40mg lidocaine 2% (2ml)
89065911|NCT05271721|Active Comparator|Dexmedetomidine group|Dexmedetmodine 50mic (0.5ml) ,4 mg dexamethasone (1ml), 40 mg lidocaine 2% (2ml) added to 4ml total volume with sterile saline .
89065912|NCT05642871||Magnetic Resonance Multifunctional Imaging|
89065913|NCT01301001|Placebo Comparator|Placebo oral capsule|Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
89065914|NCT01301001|Active Comparator|Gabapentin|Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
89065915|NCT01300923|Active Comparator|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
89065916|NCT01300923|No Intervention|Autism Spectrum Disorder|This baseline comparison group will participated in only the psychophysiological and biomarker portion of subject characterization.
89065917|NCT01300767|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with balafilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
89065918|NCT01300767|Active Comparator|Balafilcon A|Balafilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
89065919|NCT05642481||Antiretroviral drugs with marketing authorisation in Europe|This study includes subjects who already take antiretroviral drugs to treat HIV-1 with a marketing authorisation in Europe. These drugs already have a marketing authorisation and are prescribed by the treating physician of the subject. No adjustments to their treating regimen are made in order to participate in this study. All antiretrovirals with a marketing authorisation in Europe are eligible for inclusion in this study, but most subjects are expected to use a backbone of nucleoside reverse transcriptase inhibitors combined with either dolutegravir, raltegravir, darunavir or rilpivirine
89065920|NCT02890173|Experimental|CS-3150 2.5 mg|CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks
89065921|NCT02890173|Experimental|CS-3150 5.0 mg|CS-3150 5 mg, orally, once daily after breakfast for 12 weeks
89065922|NCT02890173|Active Comparator|Eplerenone|Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks
89065923|NCT01300455|Experimental|Suvorexant (40 mg)|In Period 1, suvorexant (40 mg tablets) administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.
89065924|NCT01300455|Placebo Comparator|Placebo|In Period 1, placebo administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered once daily for 4 consecutive days in the evening.
89065925|NCT05642169|Experimental|HIIT|Training program for 12 weeks with a frequency of 3 workouts per week.
89065926|NCT05642169|Experimental|HIIT+AF|They will develop the same training program as the HIIT group, and they will also have to perform 10,000 steps per day.
89065927|NCT05642169|Placebo Comparator|Control|They will not suffer any change in their lifestyle.
89065928|NCT01107418|Experimental|1|
89065929|NCT01107418|Experimental|2|
89065930|NCT01107418|Experimental|3|
89065931|NCT01107418|Experimental|4|
89065932|NCT05642091|Active Comparator|transudate effusion|
89065933|NCT05642091|Active Comparator|exudative effusion|
89065934|NCT01101178|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
89065935|NCT01101178|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
89065936|NCT05639205|Active Comparator|Arm A|LFD testing for Covid-19 with sickness support payment. Care providers will receive funding to reimburse the costs of employing agency staff to cover sickness absence in asymptomatic staff who test positive for COVID.
89065937|NCT05639205|No Intervention|Arm B|Usual Care
89065938|NCT05637645|Active Comparator|Group M|It will involve participants who are given spinal anesthesia through midline approach.
89065939|NCT05637645|Active Comparator|Group P|It will involve participants who are given spinal anesthesia through paramedian approach.
89065940|NCT05637645|Active Comparator|Group T|It will involve participants who are given spinal anesthesia through Taylors approach.
89065941|NCT05637021||Control group|Healthy people were randomly divided into CO2 group and control group, with 20 cases in each group. After bowel preparation, volunteers underwent colonoscopy, with air routinely insufflated into the control group during colonoscopy.
89065942|NCT05637021||Carbon dioxide group|Healthy people were randomly divided into CO2 group and control group, with 20 cases in each group. After bowel preparation, volunteers underwent colonoscopy, with CO2 insufflated into the control group during colonoscopy.
89065943|NCT05637021||After appendectomy group|Volunteers after appendectomy were included in the appendectomy group. After bowel preparation, all volunteers underwent colonoscopy, air routinely insufflated into the appendectomy group.
89065944|NCT00623649|Experimental|Cohort 1|VCH-916 100 mg three times a day (t.i.d.)
89065945|NCT00623649|Experimental|Cohort 2|VCH-916 200 mg (t.i.d.)
89065946|NCT00623649|Experimental|Cohort 3|VCH-916 300 mg twice daily for three days
89065947|NCT00623649|Experimental|cohort 4|VCH-916 400 mg twice daily for three days
89065948|NCT01101022|Active Comparator|SPD489|
89065949|NCT01101022|Placebo Comparator|Placebo|
89065950|NCT05627193|Active Comparator|Traditional out patient clinic|The volunteers of the study randomized into this group will be given traditional outpatient clinic follow up post surgery.
89065951|NCT05627193|Active Comparator|Teleclinic|The Volunteer of the study randomized into this group will be given teleclinic appointment for follow up post surgery.
89065952|NCT05622435|Experimental|T10070|
89065953|NCT01299909|Active Comparator|Mindfulness Training for Smokers|MTS participants will receive 8 classes of training in mindfulness meditation, access to the MTS website, and 2 weeks of nicotine patches.
89065954|NCT01299909|Active Comparator|Integrated Training for Smokers|ITS participants will receive 8 classes of training in smoking cessation strategies, access to the Freedom From Smoking online program, and 2 weeks of nicotine patches.
89065955|NCT01299909|Other|Quitline|Quitline participants will consist of participants who elect not to participate in the high-intensity treatments (Mindfulness Training for Smokers; Integrated Training for Smokers. This Quitline group is a Non-Randomized, Treatment as Usual group.
89065956|NCT02879110|Experimental|Sulforaphane group|The patients will take sulforaphane for 12 weeks.
89065957|NCT02879110|Placebo Comparator|Placebo group|The patients will take placebo for 12 weeks.
89229835|NCT03742778|Experimental|Incentivizing reflection|"Participants will receive three texts each week asking a question to reflect on their latest workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you felt right after your last workout? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
89222512|NCT00968916|Experimental|1|"Level 1:~15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 2:~25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 3:~35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 4:~50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal"
89222513|NCT00968994|Experimental|exSALT SD7™ Wound Dressing|The exSALT™ SD7 Wound Dressing provides an antimicrobial barrier that inhibits microbial growth in the dressing. The exSALT™ SD7 Wound Dressing consists of 3 layers: two non-adherent polyethylene mesh wound contact layers and one absorbent core made of polyester. All three layers are silver coated. The concentration of silver on the exSALT™ SD7 Wound Dressing is approximately 0.4 mg/cm2 (2.5% w/w).
89222514|NCT00968994|Active Comparator|Xeroform® Petrolatum Dressing|Xeroform® Petrolatum Dressing (Xeroform® / Control Dressing) is fine mesh gauze impregnated with 3% Bismuth Tribromophenate in a special petrolatum blend. The dressing is a non adherent dressing that clings and conforms to all body parts.
89222515|NCT00969072|Experimental|GI198745|
89222516|NCT00094861|Placebo Comparator|Placebo|"Participants received a single intravenous (IV) dose of placebo administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy was given as follows:~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~paclitaxel 50 mg/m^2 intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
89222517|NCT00094861|Experimental|Palifermin|"Participants received a single IV dose of palifermin at 180 μg/kg administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy (administered for 6 to 7 weeks) was given as follows:~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy~paclitaxel 50 mg/m^2 IV infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
89222518|NCT00963534|Experimental|lenalidomide, bendamustine, rituximab|
89222519|NCT00963612|Other|Single Arm|"In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver BOLD-MRI before hepatic resection."
89222520|NCT00963690|Experimental|CloSys HD with standard compression|CloSys Arm
89222521|NCT00963690|Active Comparator|Standard compression alone|Manual compression arm
89222522|NCT01079767|Other|Temsirolimus|Temsirolimus
89222523|NCT01151124|Experimental|CTX0E03 DP|human neural stem cell product, once only injection, increasing doses
89222524|NCT01084447|Placebo Comparator|control group|In placebo muscular training group the respiratory exercise was used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA) no load.
89222525|NCT01084447|Active Comparator|trained group|In trained group the respiratory exercise used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)the load was initially set at 40% of the maximal inspiratory pressure.
89222526|NCT00969306|Active Comparator|Chloroquine|Patients receive Chloroquine
89222527|NCT05260710|Experimental|Telemedicine intervention|Tele-critical care + continuing education activities
89222528|NCT05260710|No Intervention|Usual Care|Usual Care
89222529|NCT00958464||1|MRI protocol on 2 separate occasions
89222530|NCT00963768|Experimental|Cohort 1|JNJ-28431754 30 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89222531|NCT00963768|Experimental|Cohort 2|JNJ-28431754 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89222532|NCT00963768|Experimental|Cohort 3|JNJ-28431754 300 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89222533|NCT00963768|Experimental|Cohort 4|JNJ-28431754 600 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
89222534|NCT00963768|Experimental|Cohort 5|JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated).
89522868|NCT03388931|Experimental|Study group|Increased dose of radiation therapy for locally advanced squamous cell carcinoma of the larynx or hypopharynx. Patients will also receive standard-of-care chemotherapy with the treatment regimen to be determined by the treating physicians.
89065958|NCT04207515|Experimental|Removal of wisdom tooth under conscious sedation|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure, oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia , intraoperative time-after extraction , postoperative time . In this group removal of wisdom teeth was done under conscious sedation. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
89065959|NCT04207515|Active Comparator|Removal of wisdom tooth under local anesthesia|"patients were asked to fill MDAS form which consists of five questions. Systolic blood pressure, diastolic blood pressure , oxygen saturation , and heart rate were monitored at different time points: preoperative time ; intraoperative time-after local anesthesia, intraoperative time-after extraction, postoperative time. In this group, removal of wisdom teeth was done under local anesthesia. During surgery procedures five saliva samples were collected. Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.~Ibuprofen (600 mg every 8 h for 7 days) and amoxicillin/clavulanate (875 mg/125 mg every 8 h for 5 days) were prescribed. Detailed explanation of oral hygiene techniques and recommendations for the postoperative period were given to each patient."
89065960|NCT04324515|Other|Study Arm without cholecystectomy|Study Arm: Patients with gastric bypass without concomitant cholecystectomy
89065961|NCT04324515|Other|Control Arm with cholecystectomy|Control Arm: Patients with gastric bypass with concomitant cholecystectomy
89065962|NCT02879188|Experimental|Ambulation|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
89065963|NCT02879188|Active Comparator|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
89065964|NCT01298661|Other|Healthy Young Subjects|Subjects apparently healthy, with age of 18 to 27 years old.
89065965|NCT01298661|Other|Healthy Elderly subjects|Subjects apparently healthy, with age of 60 to 75 years old.
89065966|NCT01298661|Other|COPD Patients|Patients with clinical and spirometric diagnosis of COPD
89065967|NCT01100944|Experimental|Therapy in Thymic Malignancies|PXD101 (Belinostat) will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression. A conventional 3+3 dose escalation design was used with up to 3 additional patients added if one patient exhibited a dose limiting toxicity (DLT). Dose escalation was halted if at least 2 out of a maximum of 6 patients within a cohort exhibited a DLT.
89065968|NCT01100320|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
89065969|NCT01100320|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
89065970|NCT04309708|Experimental|Original Perfusor Line(Art.No.8723017)|
89065971|NCT04309708|Active Comparator|Original Perfusor Line(Art.No.8723010)|
89065972|NCT01100086|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
89065973|NCT01100086|Active Comparator|Original OxyContin® (OXY)10 mg|Original OxyContin® (OXY)10 mg x 1 dose
89065974|NCT01297959|Experimental|E-101 Solution 300 GU/mL|Participants will receive E-101 Solution at porcine myeloperoxidase (pMPO) concentration of 300 guaiacol units per milliliter (GU/mL) applied topically twice to surgical wound site. The first topical application will occur just after incision to the level of the rectus fascia or linea alba without penetration through the peritoneum and the second topical application will occur just after closure of the rectus fascia or linea alba but prior to closure of the incisional wound.
89065975|NCT01297959|Placebo Comparator|Placebo (Saline solution)|Participants will receive placebo (saline solution) matched to E-101 Solution applied topically twice to surgical wound site. The first topical application will occur just after incision to the level of the rectus fascia or linea alba without penetration through the peritoneum and the second topical application will occur just after closure of the rectus fascia or linea alba but prior to closure of the incisional wound.
89065976|NCT04187716|Experimental|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
89065977|NCT04187716|Other|remedies|Treatment for anemia will include remedies such as iron (oral or intravenous), hematopoietic accelerators, and blood transfusions, and will be determined by researchers at each institution to provide optimal treatment for patients.
89065978|NCT04309240|Experimental|rivaroxaban|oral Rivaroxaban 10mg per day for 90days
89065979|NCT04309240|No Intervention|blank control|mechanical prophylaxis
89065980|NCT02878954|Other|No intervention|160 men and women with PAD will be recruited.
89065981|NCT02878954|Other|Control session|40 patients (men and women) will complete this session.
89065982|NCT02878954|Other|Exercise session|40 patients (men and women) will complete this session.
89065983|NCT04309318||Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic cholecystectomy with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
89065984|NCT04309318||High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic cholecystectomy with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
89065985|NCT01035229|Experimental|Everolimus + Best Supportice Care (BSC)|Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.
89065986|NCT01035229|Placebo Comparator|Placebo + Best Supportive Care|Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.
89065987|NCT01106404|Other|6-week AdaptiveStim followed by 6-week manual programming|
89065988|NCT01106404|Other|6-week manual followed by 6-week AdaptiveStim programming|
89065989|NCT02880592|Experimental|Fresh amniotic membrane/standard of care|This group will receive the Affinity Allograft and standard of care.
89065990|NCT02880592|Active Comparator|Standard of Care|This group will receive standard of care for diabetic foot ulcers that includes offloading of the diabetic foot ulcer, debridement, and infection management using the appropriate dressings.
89065991|NCT01059799|Experimental|IDeg OD|
89065992|NCT01059799|Active Comparator|IGlar OD|
89065993|NCT02874547|Experimental|Intervention|Patients will receive five visits with a CHW during a 6 month period (two in-person and three by telephone). At the first visit, patients will meet the CHW who is trained in motivational interviewing techniques to deliver coaching to work on behavioral changes and introduce a 60 minute Digital Video Disc of five patient stories of individuals who have managed to control their hypertension.
89065994|NCT02874547|Other|Delayed Intervention|Patients will receive print materials at time of consent and randomization. Four to six months after randomization, DI patients will receive an invitation to schedule an in-person visit at the health center to begin receiving the intervention protocol.
89065995|NCT01106248|Other|Eribulin Mesylate|
89222535|NCT00969384|Experimental|waist circumferences|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
89222536|NCT00969384|Experimental|Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
89222537|NCT00958542|Experimental|Surgical Arm|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
89222538|NCT00958542|No Intervention|Non-Surgical Arm|Non-Surgical No intervention - Includes patients who have either refused to have surgery or have not been recommended to have surgery at this point. These patients will continue to be monitored closely, however, will not receive any other intervention.
89222539|NCT00969462|No Intervention|Doxorubicin|Single arm
89222540|NCT00963846|Placebo Comparator|placebo|
89222541|NCT00963846|Experimental|huperzine 0.2 mg BID|
89222542|NCT00963846|Experimental|huperzine 0.4 mg BID|
89222543|NCT00963846|Experimental|huperzine 0.8 mg BID|
89222544|NCT00958620|Active Comparator|Active ESWT|
89222545|NCT00958620|Sham Comparator|Sham ESWT|
89222546|NCT00958698|Experimental|Arm I (nurse-assisted intervention module)|Patients are given password-protected access to their own web-based message board to communicate with a research nurse. The nurse leads patients through WRITE Symptoms? intervention module, with personalized support and advice. The nurse will encourage the patient to try new selected strategies, continue with effective strategies, and work with local health care providers in an ongoing process to improve symptom management.
89222547|NCT00958698|Experimental|Arm II (self-directed intervention module)|Patients are given password-protected access to an interactive web-based computer program that will lead them through a modified WRITE Symptoms? intervention module (comprising the same elements as in arm I) without guidance and individualized recommendations from a nurse. Patients work through 3 selected symptoms using the WRITE Symptoms? intervention module over approximately 4 weeks. The program will generate an encouragement for the patient to try new selected strategies, continue with effective strategies, and continue the new approach to symptom management with local health care providers in an ongoing process to improve symptom management.
89222548|NCT00958698|Active Comparator|Arm III (standard care from local provider)|Patients are given password-protected access to online questionnaires. Patients are prompted monthly to complete online questionnaires. Patients receive standard symptom management from their local health care providers.
89222549|NCT00969696|Active Comparator|Galatamine|Galantamine is used for the treatment of mild to moderate Alzheimer's disease and various other memory
89222550|NCT00969696|Placebo Comparator|Sugar Pill|Sugar Pill
89222551|NCT04009278|Experimental|1. Self-compression arm|Intervention consist in a explanation by the radiographer to the woman how to use the self-compression device, then position the woman's breasts and reach a compression of 5 daN, that this is a minimum but sub-optimal level of compression, and that at that point the woman will have to complete the compression to reach the optimal compression level up to an acceptable pain.
89222552|NCT04009278|No Intervention|2. Control arm|The mammography will be performed as normal clinical practice, with compression controlled by the radiographer.
89222553|NCT00964080|Experimental|Study of MBP-426/leucovorin/5-FU|Study of MBP-426/leucovorin/5-FU. MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered ata dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
89222554|NCT00958932|Experimental|Speech recognition (TEAM intervention)|
89222555|NCT00958932|Active Comparator|Speech recognition (Usual care)|
89222556|NCT00969852|Experimental|Sertraline|Single Arm
89222557|NCT00959010|Experimental|Omega 3 Premium|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA
89222558|NCT00959010|Placebo Comparator|Placebo|capsules containing middle chain triglycerides
89222559|NCT04009434|Other|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care medical therapy
89222560|NCT04009434|Experimental|TAVI/MitraClip|Transfemoral transcatheter aortic valve implantation, mitral valve clipping plus optimal standard of care medical therapy.
89065996|NCT01059175|Experimental|CRT With Dual Site LV Pacing|Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
89065997|NCT01059175|Active Comparator|Standard CRT|Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
89065998|NCT04301869|Active Comparator|Intravenous therapy|Intravenous antibiotics administered for pleural space infection
89065999|NCT04301869|Active Comparator|Oral therapy|Oral antibiotics administered for pleural space infection
89066000|NCT04301479|Active Comparator|Steroid|Patients assigned for steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure > 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
89066001|NCT04301479|Placebo Comparator|Control|Patients assigned for control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal, defined by systolic arterial pressure > 90 mmHg for 12 hours after vasopressor weaning without fluid expansion.
89066002|NCT01297491|Experimental|Squamous BKM120 100mg qd|Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease.
89066003|NCT01297491|Experimental|Non-Squamous BKM120 100mg qd|Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease.
89066004|NCT04303585||SAP block|This group includes patients who receive preoperative Serratus Anterior Plane block
89066005|NCT04303585||ESP block|This group includes patients who receive preoperative Erector Spinae Plane block
89066006|NCT04324593|Experimental|IV line with an attached Deltran BP transducer|After device setup, subjects will be guided through a series of manipulations of the IV set while waveforms, pulse rate (PR), respiratory rate (RR) are collected at the start and stop of each test. At the end of the study, the PIVA algorithm will then be applied to the waveforms and calculated values will be compared with those from bedside monitors to understand the effect of common manipulations on the waveforms and determine most optimal conditions for capturing RR and PR through peripheral IV analysis.
89066007|NCT01106092|Experimental|GSK2036874A GROUP 1|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0.
89066008|NCT01106092|Experimental|GSK2036874A GROUP 2|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0.
89066009|NCT01106092|Experimental|GSK2036874A GROUP 3|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0.
89066010|NCT01106092|Active Comparator|ZILBRIX/HIB/POLIORIX GROUP|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib™ and Poliorix™ vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively.
89066011|NCT01097668|Experimental|Intradermal injection|Injections will be given by the intradermal route
89066012|NCT01097668|Experimental|Subcutaneous injection|Injections will be given by the subcutaneous route
89066013|NCT04307290|Experimental|DEX group|received intravenous dexmedetomidine (0.5 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg/h infusion from 10 min before the start of surgery to the end of surgery
89066014|NCT04307290|Placebo Comparator|CON group|received an equivalent volume of normal saline bolus and infusion as placebo until the end of surgery.
88812684|NCT01203722|Active Comparator|REGIMEN C|"Pre-BMT:~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~Day -1: 400 cGy TBI administered in a single fraction~Day 0: BMT~Post-Transplantation Immunosuppression Consisting of:~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)~Day 5 thru Day 180: Tacrolimus 1 mg administered IV QD"
89222561|NCT00959088||1|HIV-infected individuals with suspected TB co-infection.
89222562|NCT00426556|Experimental|Phase I - RAD001 5mg + PT, daily|Daily dosing schedule of EPT = Paclitaxel & Trastuzumab verolimus 5mg plus Paclitaxel plus Trastuzumab.
89222563|NCT00426556|Experimental|Phase I - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
89222564|NCT00426556|Experimental|Phase I - RAD001 30mg + PT, weekly|Weekly dosing schedule of Everolimus 30mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab.
89222565|NCT00426556|Experimental|Phase II - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
89222566|NCT00969930||healthy controls|
89222567|NCT00969930||BD type I patients|
89222568|NCT00107653|Experimental|Latino|Participants received peginterferon alfa-2a 180 microgram (mcg)/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day, which was taken orally in split doses for 48 weeks. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day (400 mg in the morning and 600 mg in the evening). Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day (600 mg in the morning and 600 mg in the evening).
89222569|NCT00107653|Experimental|Non-Latino White|Participants received peginterferon alfa-2a 180 mcg/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day which was taken orally in split doses. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day. Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day for 48 weeks.
89222570|NCT03994354||1,2|"J-P drain group~Penrose drain group"
89222571|NCT03950856|Experimental|V114 Lot 1|Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)
89222572|NCT03950856|Experimental|V114 Lot 2|Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)
89222573|NCT03950856|Experimental|V114 Lot 3|Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)
89222574|NCT03950856|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
89222575|NCT00970008|Active Comparator|Massage 30 min - 2x wk for 4 wks & 1x wk for 4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
89222576|NCT00970008|Active Comparator|Massage 60 min - 2x wk for 4 wks & 1x wkly for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
89222577|NCT00970008|Active Comparator|Massage 30 min sessions - 1x/wk for 8wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
89222578|NCT00970008|Active Comparator|Massage 60 min sessions - 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
89222579|NCT00970008|No Intervention|Usual Care Control|Continue on usual care for eight (8) week period.
89222580|NCT05281146|Active Comparator|chickpea and peanuts biscuits dependent group|children aged 8- 12 years attending the village school. This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months.
89222581|NCT05281146|Active Comparator|The chickpea and crushed peanut biscuits non-dependent group|Matched age and sex children attending the same village school. This group did not receive the fortified biscuits but received their ordinary usual breakfasts or snacks for four months.
89222582|NCT00433654|Active Comparator|MRI group|The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.
89222583|NCT00433654|Other|Control group|The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.
89222584|NCT00970086|Experimental|transversus abdominal plane block|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures with ultrasound, insertion of the stimuplex needle G22, 50mm, in an in-plane approach and administration of 0.4ml/kg levobupivacaine 0.25%."
89222585|NCT00689351|Experimental|1|13vPnC
89222586|NCT00689351|Active Comparator|2|7vPnC
89222587|NCT05448287|Experimental|Intervention|Suaahara interventions span health and family planning; nutrition; agriculture/homestead food production; and water, sanitation and hygiene (WASH). Diverse social and behavior change communication interventions are used, primarily to generate demand for access to improved services and to motivate households to adopt optimal health, nutrition, and WASH practices. All Suaahara interventions are supported by a crosscutting theme of gender equality and social inclusion (GESI), in part by targeting women and disadvantaged groups and conducting activities that address GESI-related barriers to optimal health, nutrition, and WASH behaviors.
89222588|NCT05448287|No Intervention|Comparison|Usual care.
89222589|NCT02563301|Active Comparator|McGrath Series 5|Videolaryngoscope used to perform indirect (video) laryngoscopy and tracheal intubation
89222590|NCT02563301|Active Comparator|Macintosh|Laryngoscope used to perform direct laryngoscopy and tracheal intubation
89222591|NCT03950622|Experimental|V114|Single intramuscular (IM) dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
89222592|NCT03950622|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
89222593|NCT00746525|Experimental|Brain Computer Interface Training Stroke Experimental Group|Individuals in the stroke experimental group received treatment with BCI, FES, and motor learning targeted at their upper extremity motor deficits following stroke.
89222594|NCT02563847|Active Comparator|0.52 g L-Tryptophan|0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
89222595|NCT02563847|Active Comparator|1.56 g L-Tryptophan|1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
89222596|NCT02563847|Active Comparator|1.56 g L-Leucine|1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
89222597|NCT02563847|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
89222598|NCT02563847|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
89066015|NCT04902430|Experimental|En-Masse Retraction using sliding mechanics (Friction)|6 anterior teeth (en-Masse) retracted using a crimpable hook distal to the upper lateral incisor and a power chain
89066016|NCT04902430|Experimental|En-Masse Retraction using segmental mechanics (Frictionless)|6 anterior teeth (en-Masse) retracted using a T- loop
89066017|NCT01325207|Experimental|intravenous trastuzumab infusions|A Phase I single dose study (H0407g) of intravenous trastuzumab infusions ranging from 10-500 mg resulted in dose-dependent pharmacokinetics (PK) with serum clearance of trastuzumab decreasing with an increasing dose at doses <250 mg. PK modeling of trastuzumab concentration-time data from 7 patients that were administered doses of 250 mg and 500 mg had in a mean halflife of 5.8 days (range 1-32 days).
89066018|NCT01324349|Experimental|Veriset Hemostatic Patch|Veriset Hemostatic Patch
89066019|NCT01324349|Active Comparator|Fibrin Sealant (TachoSil®)|Fibrin Sealant (TachoSil®)
89066020|NCT01095250|Experimental|AIN457 300mg s.c every 2 weeks|AIN457 300 mg s.c. at baseline, Week 1 and Week 2, then every 2 weeks.
89066021|NCT01095250|Experimental|AIN457 300mg s.c. every 4 weeks|AIN457 300 mg s.c. at baseline and Week 2, then every 4 weeks.
89066022|NCT01095250|Experimental|AIN457 150mg s.c every 4 weeks|AIN457 150 mg s.c. at baseline and Week 2, then every 4 weeks
89066023|NCT01095250|Placebo Comparator|Placebo s.c every 2 weeks|Placebo s.c at baseline, Week 1 and Week 2, then every 2 weeks
89066024|NCT01324271|Experimental|Tympanostomy tube placement|placement of tympanostomy tube under local anesthesia in office/clinic setting
89066025|NCT04325711|Experimental|CSPCH131 dose Escalation and expansion|"In the dose escalation part of Stage I, five dose levels will be tested according to the 3 + 3 dose-escalation design. Whether and how to carry out the follow-up study parts will be decided by the PI and sponsor on the basis of the achieved results of safety, tolerability and effectiveness of CSPCHA131."
89066026|NCT01095094|Experimental|Arm I|Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.
89066027|NCT01323647|Experimental|Group A|Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
89066028|NCT01323647|Active Comparator|Group B|Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.
89066029|NCT01094782|Active Comparator|Healthy - True Acupuncture|Healthy volunteers with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7.This group received true acupuncture treatment (the needles punctured the skin).
89066030|NCT01094782|Sham Comparator|Healthy - Sham Acupuncture|Healthy with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
89066031|NCT01094782|No Intervention|Healthy - No Treatment|Healthy volunteers with no neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
89066032|NCT01094782|Active Comparator|Pain - True Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received true acupuncture treatment (the needles punctured the skin).
89066033|NCT01094782|Sham Comparator|Pain - Sham Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
89066034|NCT01094782|No Intervention|Pain - No Treatment|Volunteers with radiating neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
89066035|NCT05645315|Experimental|TQB2618 injection+TQB2450 injection|TQB2618 injection combined with TQB2450 injection, 21 days as a treatment cycle.
89066036|NCT04325555||Respondents on PrEP|"On PrEP status will be operationalized in multiple ways, and sensitivity analyses will be conducted using multiple definitions as a result of the self-reported nature of the study.~Respondents on PrEP are respondents who reported that they are currently on PrEP~Respondents on PrEP are respondents who reported to have ever been on PrEP~When respondents are used as their own controls, years on PrEP will be those in which they reported to have been on PrEP for at lest 6 months, and PrEP initiation will be the first such year~A comparison group will be constructed by matching on a variety of characteristics, when this method is applied. Most importantly, age, and STD testing frequency among others, which influence the likelihood of being on PrEP and via that avenue sexual practices, as well as the likelihood of detecting STDs (i.e., ascertainment bias). In other models adjustments will be made for these factors."
89066037|NCT05645237||Applied radiotherapy protocol (subcohort) 1|60 Gy in 20 fractions of 3 Gy external beam radiotherapy
89066038|NCT05645237||Applied radiotherapy protocol (subcohort) 2|42.7 Gy in 7 fractions of 6.1 Gy external beam radiotherapy
89066039|NCT05645237||Applied radiotherapy protocol (subcohort) 3|38 Gy in 4 fractions of 9 Gy stereotactic external beam radiotherapy
89066040|NCT05645237||Applied radiotherapy protocol (subcohort) 4|27 Gy in 2 fractions of 13.5 Gy brachytherapy
89066041|NCT05645237||Applied radiotherapy protocol (subcohort) 5|72 Gy in 36 fractions of 2 Gy postoperative external beam radiotherapy
89066042|NCT05645237||Applied radiotherapy protocol (subcohort) 6|70 Gy in 35 fractions of 2 Gy on prostate combined with 52 Gy in 28 fractions of 2 Gy on pelvic lymph node areas, external beam radiotherapy.
89066043|NCT00623285|Experimental|Group 1|
89066044|NCT00623285|Placebo Comparator|Group 2|
89066045|NCT02878720|Experimental|Robotic therapy and real tVNS|This group receives REAL vagus nerve stimulation during robotic rehabilitation.
89066046|NCT02878720|Active Comparator|Robotic therapy and sham tVNS|This group receives SHAM VNS during robotic rehabilitation. Sham VNS is not effective. Both groups receive the same amount of robotic rehabilitation.
89066047|NCT01097044|Experimental|Afamelanotide|Dose: 16 mg implant; release of 16 mg over 7 to 10 days Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
89066048|NCT01097044|Placebo Comparator|Placebo|Dose: 16 mg implant; Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
89066049|NCT01322009|Experimental|Drug|Probenecid and N-acetyl cysteine will be administered at standard doses for the first 4 days after TBI.
89066050|NCT01322009|Placebo Comparator|Placebo|Placebos will be prepared for the two experimental drugs and administered at identical time periods.
89066051|NCT01321697||Vulvar Cancer|
89066052|NCT01320683|Experimental|Treatment (combination chemotherapy and radioimmunotherapy)|FOLFOX* + BEVACIZUMAB CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 12 courses in the absence of disease progression or unacceptable toxicity. RIT: Within 4-12 weeks after completion of post-hepatic resection therapy chemotherapy, patients receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes. Treatment repeats every 6-10 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. NOTE:*Patients previously failing oxaliplatin regimen receive FOLIFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, leucovorin calcium over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89066053|NCT01320293|Experimental|Adalimumab 40mg|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] Dose administered every other week for 6 months
89066054|NCT05661383|Experimental|iTBS active combined with an olfactory stimulation|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.
89066055|NCT05661383|Active Comparator|iTBS active alone|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.
89066056|NCT01318811|Active Comparator|Dilute heparin|Arm A will receive dilute heparin delivered as an intravenous infusion proximal to the dialysis filter.
89066057|NCT01318811|Active Comparator|Standard concentrated heparin|Arm B will receive standard concentrated heparin and will be delivered as an intravenous infusion proximal to the dialysis filter.
89066058|NCT05644847|Active Comparator|Group A (Core Stability Training Group)|Participants in the control group/ core stability training group will be instructed to perform core stability exercises which will include pelvic bridge, straight leg bridge, modified kneeling with elbow support, and leg lifts and squats, with 60 seconds rest intervals between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets weekly. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises. A total of 12 sessions will be conducted over a period of 04 weeks.
89222599|NCT02563847|Placebo Comparator|75 g Glucose|75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
89222600|NCT02563847|Placebo Comparator|Tap water|300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
89222601|NCT00746681|Experimental|A|Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
89222602|NCT00746681|Active Comparator|B|Tolterodine SR 4 mg once daily
89066059|NCT05644847|Experimental|Group B (Whole body Vibration Training Group)|"Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training at 50 Hz frequency.~Participants will be instructed to perform 1-3 sets of 5-12 repetitions each of pelvic bridge, straight leg bridge, modified kneeling with elbow support, and leg lifts and squats on the WBV equipment, with a 60-second rest interval between each activity. The vibration speed and no. of sets and repetitions will be increased progressively. A total of 12 sessions will be conducted over a period of 04 weeks."
89066060|NCT05644769|Active Comparator|Determine the presence of the human sequence of Ang-(1-12) in plasma on no medications|Determine the presence of the human sequence of Ang-(1-2) in the plasma of ten normal male and female hypertensive patients at baseline on no medications.
89066061|NCT05644769|Active Comparator|Determine the presence of human sequence of Ang-(1-12) on Lisinopril 40 mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients at baseline and after four weeks on Lisinopril 40 mg every day
89066062|NCT05644691||Lipikar Baume AP+M|The group applies Lipikar Baume AP+M twice daily for 3 months. Participants have 4 visits (Day0, Day 28, Day56, Day84) with different outcome measures including self-evaluations).
89066063|NCT05644691||Usual emollient|The group applies their usual emollient twice daily for 3 months. Participants have 4 visits (Day0, Day28, Day56, Day84 with different outcome measures including self-evaluations).
89066064|NCT01093846|Experimental|AIN457 300 mg every 2 weeks|
89066065|NCT01093846|Experimental|AIN457 300 mg monthly|
89066066|NCT01093846|Placebo Comparator|Placebo|
89066067|NCT01315847|Experimental|Healthy Participants (Part I)|Baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 megabecquerel [MBq]) was performed in healthy participants; this PET data served as the baseline for both Period 1 and 2 of Part I. Subsequently in study Part I, Period 1 the healthy participants received a single 1120 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~3 hours post telcagepant dose. In Part I, Period 2 the healthy participants received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part I Period 1 and 2 was to be at least 1 week.
89066068|NCT01315847|Experimental|Participants with Migraine (Part III)|In study Part III, Period 1 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine during a migraine attack (ictal phase). Later in Part III, Period 1 the participants with an ongoing migraine attack (ictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. In Part III, Period 2 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine, however, without a migraine attack ongoing (interictal phase). Later in Part III, Period 2 participants with migraine without a migraine attack ongoing (interictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part III Period 1 and 2 was to be at least 1 week.
89066069|NCT05644535||Group A|Patients were aged 60-69 years
89066070|NCT05644535||Group B|Patients were aged 70-79 years
89066071|NCT05644535||Group C|Patients were aged 80-89 years
89066072|NCT05644535||Group D|Patient age > 90 years
89066073|NCT04325399|Experimental|Planning|"The volitional help sheet (VHS) comprises of a list of challenges to being physically active (e.g. If I'm tempted not to go to the gym because it's cold outside) and a list of possible ways to overcome thes (e.g. then I will make myself go to the gym anyway because I know I will feel better afterward). In the experimental VHS link group, participants are asked to form if-then plans by drawing a line between challenges and solutions to link them together."
89066074|NCT04325399|No Intervention|No planning|Participants in the VHS tick group are presented with the exact same volitional help sheet as the experimental group, the only difference being that participants in this group are not asked to make if-then plans. Rather, participants in the control group are asked to tick challenges and solutions that they feel are relevant to them.
89066075|NCT01093534|Placebo Comparator|Placebo|Participants received 2 placebo tablets once daily for 12 weeks.
89066076|NCT01093534|Experimental|Solifenacin 5 mg|Participants received one 5 mg solifenacin tablet and one placebo tablet, once daily for 12 weeks.
89066077|NCT01093534|Experimental|Solifenacin 10 mg|Participants received two 5 mg solifenacin tablets once daily for 12 weeks.
89066078|NCT01314911|Experimental|Oseltamivir|
89066079|NCT01314911|Placebo Comparator|Placebo|
89066080|NCT02891057|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89066081|NCT01093222|Experimental|Treatment (sorafenib tosylate and erlotinib hydrochloride)|Patients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89066082|NCT02878018||TCM intervention|Participants with HSPN of the Heat-Toxin type will take the Qi-Ji Shen-Kang formula. HSPN patients of the Wet-Heat type will take the Zhu-Bai formula. Those of Qi-Deficiency with Blood-Stasis type will take the Yu-Shen formula.
89066083|NCT02878018||WM conventional intervention|The WM conventional intervention, recommended by the Chinese Medical Association's (CMA) Scientific Statement, includes angiotensin-converting enzyme (ACE) inhibitor, adrenergic receptor binder (ARB), adrenal cortical hormone, Tripterygium wilfordii polyglycosidium and an immunosuppressant.
89066084|NCT01313663|Experimental|Pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
89066085|NCT01313663|Active Comparator|Pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
89066086|NCT01092832|Experimental|Active voriconazole|All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.
89222603|NCT00746681|Placebo Comparator|C|Placebo
89066087|NCT05661305||Control|Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
89066088|NCT05661305||Cases|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.
89066089|NCT02878564|Experimental|Praziquantel treatment|Participants will be HIV-uninfected women with asymptomatic Schistosoma mansoni infection; the study will examine the impact of standard praziquantel therapy (40 mg/kg po single dose) on genital immunology and HIV susceptibility.
89066090|NCT04325477|Experimental|Nolix Device|Comparing use of device to non-treatment (pads only) phase
89066091|NCT02891135|No Intervention|Standard|Patients randomized to the standard arm will receive standard procedures for initiating antiretroviral therapy for HIV.
89066092|NCT02891135|Experimental|Intervention|Patients randomized to the intervention arm will be offered immediate treatment initiation under the intervention algorithm (SLATE).
89066093|NCT04308070|Experimental|Catheter without Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter without hemostatic agent
89066094|NCT04308070|Experimental|Catheter with Hemostatic Agent Following Aquablation|AQUABEAM System followed by catheter with hemostatic agent
89066095|NCT02890979|Experimental|Screening (cytology collection)|Patients undergo cytology specimen collection procedure using a swallowable sponge cell sampling device.
89066096|NCT02891213||LE (Lupus Erythematosus) group|"Samples of the LE (Lupus Erythematosus) group from a specimen collection : Lupus BioBanque du Rhin Supérieur (LBBR UF 9882).~It's a historical cohort of lupic patients which samples have been collected from many centers in France and Germany and stored in a biobank Lupus BioBanque du Rhin Supérieur (project : LBBR UF 9882)."
89066097|NCT01313273|Other|Arm A|
89066098|NCT01313273|Experimental|Arm B|
89066099|NCT01091974|Experimental|1 - CBT-I + placebo|CBT-I and placebo
89066100|NCT01091974|Experimental|2 - CBT-I + Armodafinil|CBT-I + Armodafinil
89066101|NCT01091974|Placebo Comparator|3 - Placebo only|Placebo only
89066102|NCT01091974|Experimental|4 - Armodafinil only|Armodafinil only
89066103|NCT01313117|Experimental|Alpha lipoic acid|Oral administration three times daily (morning, mid-day, night)
89066104|NCT01313039|Experimental|AZD6244|
89066105|NCT05644379|Experimental|Cadonilimab Injection in combination with Regorafenib|Cadonilimab Injection in combination with Regorafenib
89066106|NCT01091662|Experimental|eslicarbazepine acetate 1600 mg|Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD(Day 0) to 1200 mg once a day(Week 2) to 1600 mg QD (Weeks 3-18) and may taper down from 1600 mg to 800 mg QD 3 days after the Week 18 visit.
89066107|NCT01091662|Experimental|eslicarbazepine acetate 1200 mg|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day0) to 800 mg QDweek2) to 1200 mg QD(weeks 3-18) and may taper down from 1200 mg to 600 mg QD 3 days after the Week 18 visit.~Subjects may continue in an open-label extension study with a starting dose of 1200 mg QD, or taper off their previous antiepileptic drugs during weeks 2-8."
89066108|NCT01312961|Placebo Comparator|Placebo (for Dupilumab)|Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
89066109|NCT01312961|Experimental|Dupilumab 300 mg qw|Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
89066110|NCT00626158|Experimental|Gem/Cape|
89066111|NCT01311557|Experimental|Adacel Vaccine Group 1|Participants enrolled at 10 to < 11 years of age
89066112|NCT01311557|Experimental|Adacel Vaccine Group 2|Participants enrolled at 11 to < 12 years of age
89066113|NCT01310777|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
88820748|NCT05697380|Experimental|Experimental: Communication Bridge™|Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.
89066114|NCT01310777|Active Comparator|Brinz|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
89066115|NCT01310777|Active Comparator|Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months
89066116|NCT01310699|Experimental|High Definition NBI Colonoscopy|Use of high definition narrow band imaging colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
89066117|NCT01310699|Placebo Comparator|High Definition White Light Colonoscopy|Use of high definition white light colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
89066118|NCT01310075|Experimental|Alloderm Mesh|Alloderm Mesh - 6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
89066119|NCT01310075|Experimental|Surgimend Mesh|Surgimend Mesh - 10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
89066120|NCT01310075|No Intervention|Control (no mesh)|
89066121|NCT01309997|Experimental|Arm I (enzyme inhibitor)|Patients receive imatinib mesylate PO QD for 6 months in the absence of progression of sclerosis or unacceptable toxicity.
89222604|NCT00746681|Experimental|D|Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
89222605|NCT00746681|Experimental|E|Pregabalin 150 mg twice daily
89222606|NCT00746759||Standard of Care|
89222607|NCT00746837|Experimental|1|Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses
89222608|NCT00746837|Experimental|2|2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose
89222609|NCT00964236||Sapropterin|Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
89222610|NCT00964236||Control|Healthy individuals without phenylketonuria (PKU).
89222611|NCT00749099|Placebo Comparator|Phase I|All subject participate in Phase I
89222612|NCT00749099|Active Comparator|Phase II|All subject participate in Phase II
89222613|NCT00749177|Active Comparator|2|Traditional Healing arm Provides Traditional Healing options only
89222614|NCT00749177|Active Comparator|3|Traditional Healing and usual standard of care arm Subjects will access both treatment options
89222615|NCT00749177|Active Comparator|1|Treatment as usual
89222616|NCT00964314|Experimental|five elements music|Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
89222617|NCT00964314|Active Comparator|western music|Listening western music based on conventional therapy in China.
89222618|NCT00964314|No Intervention|Without music|no music therapy will be done in the arm.
89222619|NCT04059419|Experimental|Experimental|30 Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
89222620|NCT04059419|Active Comparator|Control|Should remain under geriatric care after randomization.
89066122|NCT01309997|Experimental|Arm II (monoclonal antibody)|Patients receive rituximab IV on days 1, 8, 15, and 22. A second treatment cycle is repeated at 3 months for a total of 8 doses of rituximab in the absence of progression of sclerosis or unacceptable toxicity.
89066123|NCT01309919|Active Comparator|IUD Arm|Subjects who receive an IUD within 48 hours of delivery (vaginal or cesarean birth)
89066124|NCT01309919|Other|Diary Arm|Subjects who will not have an IUD placed postpartum; they may use another form of contraception, or no form at all
89066125|NCT04325165|Experimental|1: Chronic SCI subjects|"These subjects will undergo:~Bilateral implantation of PPN DBS electrodes;~Electrical stimulation of the DBS electrodes and~Intensive locomotor training"
89066126|NCT01309841|Experimental|1|Oral treatment
89066127|NCT01309841|Experimental|2|Oral treatment
89066128|NCT01309841|Placebo Comparator|3|Oral treatment
89066129|NCT01308749|Placebo Comparator|Placebo|Intervention: Drug: placebo
89066130|NCT01308749|Active Comparator|Oxytocin|Intervention: Drug: Syntocinon® Nasal Spray
89066131|NCT01307891|Experimental|Abraxane + Tigatuzumab|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.
89066132|NCT01307891|Experimental|Abraxane alone|Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data.
89066133|NCT05644301|Active Comparator|High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Minocyclin + Treatment As Usual (TAU)|
89066134|NCT05644301|Active Comparator|High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Celecoxib + Treatment As Usual (TAU)|
89066135|NCT05644301|Placebo Comparator|High Sensitive C-reactive Protein (hs-CRP) < 3mg/L: Placebo + Treatment As Usual (TAU)|
89066136|NCT05644301|Active Comparator|High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Minocyclin + Treatment As Usual (TAU)|
89066137|NCT05644301|Active Comparator|High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Celecoxib + Treatment As Usual (TAU)|
89066138|NCT05644301|Placebo Comparator|High Sensitive C-reactive Protein (hs-CRP) > 3mg/L: Placebo + Treatment As Usual (TAU)|
89066139|NCT04324931|Experimental|Biomechanical corrections|In this group, biomechanical correction will be perform with the help of mobilization with movement to correct biomechanical misalignment and along with this conventional treatment, in which Hydrocollatoral packs for 20 minutes, Interferential Therapy for 15 minutes with beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program for 3 sessions of 20 minutes on alternative days for 3 weeks. Which will be given for three days a week for three weeks.
89066140|NCT02890745|Experimental|Empagliflozin|One tablet 25 mg empagliflozin every morning for 14 days
89066141|NCT02890745|Placebo Comparator|Placebo|One tablet placebo every morning for 14 days
89222621|NCT00959400|Experimental|Fentanyl Transdermal|
89222622|NCT00970398|No Intervention|Reference group|Human milk breastfeeding
89222623|NCT00970398|Active Comparator|Control formula|Standard infant formula, with no Osteopontin supplemented.
89222624|NCT00970398|Active Comparator|Formula with 50% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 50% level of that of breast milk.
89222625|NCT00970398|Active Comparator|Formula with 100% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 100% level of that of breast milk.
89222626|NCT00744575||1|Chronic Back Pain
89222627|NCT00744575||2|Healthy Sex & Age Matched Controls
89222628|NCT00959478|Experimental|Educational tool & Carbon Monoxide Alarm|"Parents will be randomly assigned into a control and intervention group. Both groups will complete a computer based survey at enrollment and at their home visits occuring two weeks and approximately six months following enrollment. Participants will be given the following materials at enrollment.~Intervention:~Fast Facts about Carbon Monoxide Educational Tool~Kidde Nighthawk Carbon Monoxide Alarm~Control:~- Central Ohio Poison Control Center Flyer"
89222629|NCT00749255||FFDM|a sum of at least 200 cancer cases, mammographically visible, on at least one image view (including masses and calcifications)
89222630|NCT03937908|Experimental|2g CAP|Single administration of 2g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
89222631|NCT03937908|Experimental|4g CAP|Single administration of 4g of Centella asiatica water extract standardized product dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
89222632|NCT00689273|Experimental|PF-04136309|
89222633|NCT00689273|Placebo Comparator|Placebo|
89222634|NCT00959634|Experimental|1|Dose 1 BID
89222635|NCT00959634|Experimental|2|Dose 2 BID
89222636|NCT00959634|Placebo Comparator|3|Placebo BID
89222637|NCT00970554|Active Comparator|Patching only|
89222638|NCT00970554|Experimental|Patching plus telescope group|
89222639|NCT00959790|Experimental|High vegetable dose|Consumption of 200 grams of vegetables daily, for four weeks.
89222640|NCT00959790|Experimental|Low vegetable dose|Consumption of 50 grams of vegetables daily, for four weeks.
89222641|NCT00959790|Active Comparator|Weight loss interventio|Consumption of - 1000 kcal daily, for four weeks to be used as a positive control for the vegetables interventions.
89222642|NCT04059575|Experimental|PERFORMANCE PLUS|performance plus better than GOLD TEX
89222643|NCT04059575|Active Comparator|GOLD TEX|GOLD TEX better than performance plus
89222644|NCT02562209|Experimental|PACER diet|High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER Diet) to be followed for 8 weeks.
89222645|NCT02562209|Active Comparator|Standard weight reducing diet|This group was prescribed Standard weight reducing diet to be followed for 8 weeks.
89222646|NCT00749333|Experimental|1|
89222647|NCT00749333|Placebo Comparator|2|
89222648|NCT02562287|Experimental|Clozapine|Clozapine, P.O., flexible dose, for up to 6 months
89222649|NCT02562287|Active Comparator|Risperidone, olanzapine or quetiapine|Risperidone, olanzapine or quetiapine, according to clinical indication, flexible dose, for up to 6 months
89222650|NCT02562053|Active Comparator|Fluoxetine|Women will receive daily oral fluoxetine 20 mg in addition to an oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation.
89222651|NCT02562053|Active Comparator|Combined oral contraceptives and fluoxetine|Women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily.
89222652|NCT02562053|Placebo Comparator|Placebo|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
89222653|NCT02563223|Other|electromyographic (EMG) measurements|Interaction between gravity (weightlessness, hypergravity, and normal gravity) and pull-down force ont EMG amplitude and EMG timing.
89222654|NCT00746993|Experimental|1|Structured contraceptive counseling and routine care.
89066142|NCT01307579|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC > 100-500/uL following the nadir or the next chemotherapy course begins.
89066143|NCT01307579|Active Comparator|Arm II (fluconazole)|Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.
89066144|NCT01057693|Experimental|pregabalin (Lyrica)|
89066145|NCT01057693|Placebo Comparator|Placebo|
89066146|NCT02878876|Experimental|Sequence A1-A2|Dietary Supplement: Oral consumption of milk with sequence A1-A2
89066147|NCT02878876|Experimental|Sequence A2-A1|Dietary Supplement: Oral consumption of milk with sequence A2-A1
89066148|NCT02875171||Anthracycline therapy|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
89066149|NCT01307501|Other|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. No more than 3 tumors in 1 lung can be treated in a single session, and no more than 5 total lung tumors (across both lungs) can be treated during the study.
89066150|NCT04325009|Experimental|RTRT|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
89066151|NCT04325009|Experimental|TRTR|"R: Lipitor 80mg Tab T: Dong-A Atorvastatin 80mg Tab"
89066152|NCT01034137|Experimental|Tocilizumab + Methotrexate|Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
89066153|NCT01034137|Active Comparator|Tocilizumab + Placebo Methotrexate|Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
89066154|NCT01034137|Active Comparator|Methotrexate + Placebo Tocilizumab|Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.
89066155|NCT02874391||AV fistula group|
89066156|NCT02874391||Control group|
89066157|NCT02874469|No Intervention|Control group (first period)|Patients treated as recommended with usual care in a center.
89066158|NCT02874469|Experimental|Group with diary (second period)|Intervention group = On top of usual care, an intensive care unit diary will be implemented for patients within the first 8 hours following their admission.
89066159|NCT02874079|Experimental|bullous pemphigoid|patients with bullous pemphigoid
89066160|NCT02874079|Active Comparator|no bullous pemphigoid|patients with basal cell carcinoma or squamous cell carcinoma and without inflammatory skin disease
89066161|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|
89066162|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|
89066163|NCT01056289|Placebo Comparator|Placebo|
89066164|NCT01039675|Experimental|GSK573719/GW642444|
89066165|NCT01039675|Placebo Comparator|Placebo|
89066166|NCT02875093|Other|ADI-PEG 20 Plus Low Dose Cytarabine|This is a phase 1, open label trial of ADI-PEG 20 (18 and 36 mg/m2) weekly in combination with low-dose cytarabine (20 mg BID [twice daily] for 10 days, every 28 days)
89066167|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 mcg once daily
89066168|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily
89066169|NCT01033825|Placebo Comparator|HFA Nasal Aerosol placebo|HFA Nasal Aerosol Placebo once daily
89066170|NCT01033825|Experimental|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
89066171|NCT01033825|Placebo Comparator|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
89066172|NCT01033825|Active Comparator|Placebo HFA plus Dexamethasone 6 mcg|Placebo HFA plus Dexamethasone 6 mg once daily
89066173|NCT01033825|Active Comparator|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mg once daily
89066174|NCT01033747|Experimental|Deferasirox|Deferasirox group consists of all participants who were initially randomized to 10 and 20 mg/kg/day deferasirox orally daily in the main study and remained on the same treatment during the comparative prolongation study (NCT00379483) and at the beginning of the 5-year non-comparative study
89066175|NCT01033747|Experimental|Deferasirox Crossover|Deferasirox Crossover group consists of participants who were initially randomized to 40 mg/kg/day deferoxamine (DFO)subcutaneously in the main study and comparative prolongation study and crossed over to 5mg/kg/day to 30 mg/kg/day deferasirox orally daily at the beginning of the 5-year non-comparative extension study
89066176|NCT00627055|Experimental|1|LPV/r monotherapy
89066177|NCT00627055|Active Comparator|2|LPV/r + 2NRTIs (TDF/FTC or TDF/3TC)
89066178|NCT02875015|Experimental|Liposomal Bupivacaine|20mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
89066179|NCT02875015|Active Comparator|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
89066180|NCT01091428|Experimental|Alisertib (Phase 1 - Ovarian cancer)|Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
89066181|NCT01091428|Experimental|Alisertib (Phase 1 - Breast cancer)|Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
89066182|NCT01091428|Experimental|Alisertib 40 mg BID+Paclitaxel 60 mg/m^2 (Phase 2)|Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
89066183|NCT01091428|Experimental|Paclitaxel 80 mg/m^2 (Phase 2)|Paclitaxel 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
89066184|NCT04307758||Healthy Adults|Healthy subjects aged 18-35 years were enrolled in this study. The muscle strength assessment of the foot intrinsic muscles was assessed with the make test and the break test. The tests were performed with the hip and knee semiflexed in prone position with a hand-held dynamometer. The experimental protocols and methods were explained in detail to all subjects. All participants provided written informed consent in keeping with the ethical principles of the Declaration of Helsinki.
89066185|NCT04307680|Active Comparator|Kegel exercise|Using high-intensity Kegel exercise regimen for 8 weeks (5 times a week; 3 times a day involved; 3 sets of 10-12 contractions)
89066186|NCT04307680|Active Comparator|Magnetic stimulation|Using 16 extracorporeal magnetic innervation treatments during 8 weeks (2 times a week).
89066187|NCT04307524|Experimental|laparoscopic repair|suture repair of cesarean scar niche using laparoscopy
89066188|NCT04307524|Active Comparator|medical treatment|conservative management
89066189|NCT04307602|Experimental|Children with cerebral palsy GMFCS IV-V|Exercise intervention in the waling aide Innowalk
89066190|NCT04307602|Active Comparator|Children with cerebral palsy GMFCS I-II|Exercise intervention on spinning bikes
89066191|NCT04307602|Active Comparator|Children without disabilities|Exercise intervention on spinning bikes
89066192|NCT01096342|Experimental|Treatment|Patients receive dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89222655|NCT00746993|No Intervention|2|Routine care.
88820749|NCT05692609||Implant overdenture group|In the control session, participants' acoustic sound quality, implant and prosthesis success will be measured.
88820750|NCT05692609||All-on-4 group|In the control session, participants' acoustic sound quality, implant and prosthesis success will be measured.
89066193|NCT01039519|Experimental|ganetespib 200 mg/m^2|Ganetespib (STA-9090) 200 mg/m^2 intravenous infusion once weekly for 3 consecutive weeks followed by one week dose free interval (3 weeks on and 1 week off represent a treatment cycle). Treatment continues until disease progression or unacceptable toxicity.
89066194|NCT04874740||Kidney transplant recipients|Collection of data from kidney transplant patients at regular outpatient check-ups.
89066195|NCT01096186|Other|Open Label IPX066|Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.
89066196|NCT01032889|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89066197|NCT01032889|Experimental|Deoxycholic acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89066198|NCT01032889|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
89066199|NCT04301830||Spinal anesthesia|Patients undergoing cesarean section under spinal anesthesia
89066200|NCT04307368|Experimental|FODMAP diet|Patients with IBS. Interventions: 8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
89066201|NCT04307368|Experimental|Elimination-rotational diet|Patients with IBS. Interventions: During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
89066202|NCT04307368|Experimental|Classic diet|Patients with IBS. Interventions: 8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
89066203|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
89066204|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
89066205|NCT01049503|Active Comparator|Caries-active 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
89066206|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
89066207|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
89066208|NCT01049503|Active Comparator|Caries-inactive 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
89066209|NCT00627289||1|patients with chronic postherniotomy pain (>1 year), affecting everyday activities severely
89066210|NCT01029925|Experimental|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart.
89066211|NCT04302415||only liver metastasis|There is no other intervention, only clinical treatment.
89066212|NCT04302415||only lung metastasis|There is no other intervention, only clinical treatment.
89066213|NCT04302415||only brain|There is no other intervention, only clinical treatment.
89066214|NCT04302415||No distant metastasis|There is no other intervention, only clinical treatment.
89066215|NCT04302415||More than two organs metastasis|There is no other intervention, only clinical treatment.
89066216|NCT02873533|Other|A-Elderly patients with cancer|geriatric care and longitudinal follow up
89066217|NCT04302649|Experimental|Intervention group|Patients received Peritoneal Equilibration Test (PET). In the intervention group, dialysate was warmed in a specific microwave oven calibrated to 37°C and infusion temperature was confirmed to be 37°C before infusion
89066218|NCT04302649|No Intervention|Control group|Patients received Peritoneal Equilibration Test (PET). In the control group, current practice was used (batch warming with a pad calibrated to 37°C) and dialysate temperature was measured just before infusion.
89066219|NCT04301557|Experimental|PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC|Induction regimen: Capeox+PD1 antibody for 1 cycle, Concurrent chemoradiotherapy regimen: Capeox+PD1 antibody for 2 cycles and concurrent , Interval regimen: Capeox+PD1 antibody for 1 cycle, TME surgery or watch and wait for cCR patients Adjuvant regimen: Capeox+PD1 antibody for 2 cycles, Capecitabine+PD1 antibody for 2 cycles
89066220|NCT02874313|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin plus continuous positive airway pressure (CPAP)
89066221|NCT02874313|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin
89066222|NCT01029691|Experimental|Positive Airway Pressure (compliant)|This arm was women who used auto-titrating positive airway pressure (APAP) for at least 4 hours per night
89066223|NCT01029691|No Intervention|Standard care|
89066224|NCT01029691|Experimental|Positive Airway Pressure (non-compliant)|No one was assigned to this arm, but for results data quality purposes, women assigned to PAP who were explicitly non-compliant (used less than 4 hours per night), were analyzed separately from women who were compliant with the PAP assignment.
89066225|NCT01029535|Experimental|Juvederm® VOLUMA™|Juvederm® VOLUMA™ injected in both sides of face (up to 4 mL per side) at Investigator's discretion to achieve at least a 2-point improvement in the Mid-face Volume Deficit Scale. Participants who completed Week 8 of Phase 1 were eligible to participate in Phase 2 and could receive an additional optional treatment if applicable.
89222656|NCT04060433|Experimental|ROCKETLAUNCH project|Intensive treatment program with focusing on the implementation of evidence based family therapy
89066226|NCT04301167|Experimental|Single group|An AB single-case experimental design will be used. An RCT would be inappropriate since the befriending intervention is known to improve wellbeing. As such participants will have data collected in a pre- and post-intervention phase, for a maximum of 13 time points. This approach has been identified by What Works Clearinghouse as an acceptable empirical design to include in evidence based practice reviews (Kratchowill et al., 2010).
89066227|NCT04302571|No Intervention|Healthy control|Voluntary subjects without peripheral arterial disease
89066228|NCT04302571|Sham Comparator|IC patients, no exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, given advices to perform regular aerobic activity
89066229|NCT04302571|Active Comparator|IC patients, exercise|Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, home-based combined physical exercise
89066230|NCT02874235|Experimental|Music therapy treatment|35 patients receiving each 16 sessions of Receptive music therapy
89066231|NCT02874235|Active Comparator|Standard treatment|35 patients receiving each 16 sessions of Psychological treatment
89066232|NCT04301635||Preoperative (Pre-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, preoperative
89066233|NCT04301635||Postoperative (Post-)|Moderate-severe obstructive sleep apnoea / hypopnoea patients, postoperative
89066234|NCT01028053|Experimental|Flutemetamol (18F) Injection|Flutemetamol (18F) Injection
89066235|NCT04301245||ETEP group|Exercise Training and Educational Program (ETEP) group. Patients who accepted the educational program in addition to the exercise training.
89066236|NCT04301245||ET group|Exercise Training (ET) group. Patients who refused the educational program and did only the exercise training.
89066237|NCT04607317|Experimental|Exercise Intervention|Participants in this arm will be enrolled in a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day). Participants will meet weekly 1:1 with a trained health coach via a Webex platform. Weekly exercise goals will be tailored to the individual's abilities and specific barriers. Coaching will utilize social cognitive theory and self-determination theory to develop self-efficacy for sustainable behavior change.
89066238|NCT04607317|Active Comparator|Control|Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks. They will continue to wear the Garmin activity tracker and can view their activity but will not be given an exercise program. They will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
89066239|NCT04300621|Experimental|Treatment Sequence 1: OTF 1, 4, 2, 3|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 1 in period 1; followed by OTF 4 in period 2; followed by OTF 2 in period 3; followed by OTF 3 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
89066240|NCT04300621|Experimental|Treatment Sequence 2: OTF 2, 1, 3, 4|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 2 in period 1; followed by OTF 1 in period 2; followed by OTF 3 in period 3; followed by OTF 4 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
89066241|NCT04300621|Experimental|Treatment Sequence 3: OTF 3, 2, 4, 1|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 3 in period 1; followed by OTF 2 in period 2; followed by OTF 4 in period 3; followed by OTF 1 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
89066242|NCT04300621|Experimental|Treatment Sequence 4: OTF 4, 3, 1, 2|Participants will receive a single dose of (S)-ketamine administered sublingually through OTF 4 in period 1; followed by OTF 3 in period 2; followed by OTF 1 in period 3; followed by OTF 2 in period 4, on Day 1 of each treatment period under fasted conditions. A washout period of at least 72 hours will be maintained between each treatment period.
89066243|NCT01023217|Experimental|Adefovir plus Entecavir|Adefovir + Entecavir for 104 weeks
89066244|NCT01023217|Active Comparator|Adefovir plus Lamivudine|Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
89066245|NCT01095796|Experimental|Stribild|Stribild plus placebo to match Atripla
89066246|NCT01095796|Active Comparator|Atripla|Atripla plus placebo to match Stribild
89066247|NCT01023061|Experimental|Treatment (antihormone therapy and radiation therapy)|Patients receive abiraterone acetate and prednisone daily for 24 weeks. Patients also receive leuprolide acetate or goserelin in weeks 1 and 13. Patients undergo external beam radiotherapy starting in week 15 for 8.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89066248|NCT01027897|Experimental|Doripenem group|Patients will receive doripenem for the treatment of their infection
89066249|NCT01027351|Experimental|5rMenB|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
89066250|NCT01027351|Experimental|5rMenB+OMV NZ|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
89066251|NCT01027351|Experimental|3rMenB|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
89066252|NCT01027351|Experimental|3rMenB+OMV NZ|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
89066253|NCT01027351|Experimental|Naive_4042|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.
89066254|NCT01027351|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.
89066255|NCT04300465|Experimental|Rheumatoid arthritis - With Partner Group|In this group patients with stable rheumatoid arthritis and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
89066256|NCT04300465|Active Comparator|Rheumatoid arthritis - Without Partner Group|"In this group patients with stable rheumatoid arthritis undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.~For the patients with rheumatoid arthritis, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
89066257|NCT04300465|Experimental|Chronic Kidney Disease - With Partner Group|In this group patients with stable stage 3 or 4 chronic kidney disease and their partners both undergo an initial assessment, the 10 week intervention phase and then an end of program assessment together. The intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications.
89066258|NCT04300465|Active Comparator|Chronic Kidney Disease - Without Partner Group|"In this group patients with stable stage 3 or 4 chronic kidney disease undergo an initial assessment, the 10 week intervention phase and then the end of program assessment. Their partners attend the initial assessment and the end of program assessment but do not partake in the 10 week intervention phase. During the 10 week period these partners receive usual care from their GP's.~For the patients with chronic kidney disease, the 10 week intervention phase includes weekly exercise classes, individualised exercise prescription, health promotion workshops, individualised goal setting and optimisation of cardioprotective medications."
89066259|NCT02873611|Experimental|MRI scanning and the genicular ablation|patients undergoing both MRI scanning and the genicular ablation procedure. additional MRI testing of apprx. 0.5-1 hour
89066260|NCT02873299|No Intervention|Treatment as usual|Treatment as usual, wait list control group
89066261|NCT02873299|Active Comparator|rTMS at 10Hz|10 Hz rTMS of the right dorsolateral prefrontal cortex
89066262|NCT02873299|Active Comparator|rTMS at 20Hz|20 Hz rTMS of the right dorsolateral prefrontal cortex
89066263|NCT01027273|Experimental|Peer-Led Stroke Recurrence Prevention Education|The intervention group will participate in a 6-session course held over a 6-week period. The Prevent Return of Stroke Workshop, led by trained peer educators, aims to help participants control the risk factors for stroke, thereby preventing recurrence of strokes.
89066264|NCT01027273|Placebo Comparator|Usual Care (Delayed Intervention)|The control group will be offered the chance to take part in the 6-week session intervention after 12 months after enrollment into the trial.
89066265|NCT04300933|Experimental|Neurofeedback therapy|Fifty participants conduct neurofeedback daily for 5 days.
89066266|NCT00627757||Food challenge test|"Patients~51 patients included"
89066267|NCT00627757||C|Controls 93 healthy controls are included
89066268|NCT01022203|Experimental|Structured Approach Therapy|Couple-Based Intervention called Structured Approach Therapy provides skills training to couple so they can reduce PTSD.
89066269|NCT01022203|Active Comparator|PTSD Family Education|Couple-Based Education called PTSD Family Education teaches couple about PTSD symptoms, related problems, and treatment.
89066270|NCT01296711|Experimental|CDP6038 (olokizumab)|
89111190|NCT02792595|Experimental|Test Product D|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
89066271|NCT05661045||Group DA|In the Group (DA), the standard consisting of electrocardiogram(ECG), peripheral oxygen saturation (Spo2), and non-invasive blood pressure will be monitored.Prior to induction, the first blood sample (To) will be taken for analysis. After induction of anesthesia with propofol and rocuronium, he will be intubated.Anesthesia will be maintained with desflurane (MAC:1), oxygen (50%), air (50%). After a high flow phase of 4 l/min for 10 min, the fresh gas flow will be reduced to 0.6 L/min and fentanyl,rocuronium will be administered intermittently. Patients will be ventilated with a ventilator at a constant tidal volume (kg x 6 mL) and respiratory rate (12/min). At the 1st hour of low flow anesthesia maintenance, a second blood sample (T1) will be taken for analysis. Patients will be awakened at the end of the case. After the recovery room, it will be transferred to the relevant service. A third blood sample (T2) will be taken at the postoperative 24th hour in the service for analysis.
89222657|NCT04060043|Experimental|Goserelin acetate Injection|Pepti 10.8mg is a generic formulation of Zoladex® 10.8mg, with the same ingredients (active and excipients), the same formulation, the same dosage, the same size and route of administration.
89222658|NCT00553358|Experimental|Arm 1 Lapatinib|1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
89066272|NCT05661045||Group NA|In the Group (NA),the standard consisting of electrocardiogram(ECG), peripheral oxygen saturation (Spo2),non-invasive blood pressure will be monitored.Prior to induction, the first blood sample (To) will be taken for analysis.After induction of anesthesia with propofol and rocuronium, patients will be intubated. Anesthesia will be maintained with desflurane (MAC:1), oxygen (50%), air (50%). After a high flow phase of 4 l/min for 10 min, the fresh gas flow will be reduced to 2.0 L/min and fentanyl, rocuronium will be administered intermittently. Patients will be ventilated with a ventilator at a constant tidal volume (kg x 6 mL) and respiratory rate (12/min). A second blood sample (T1) will be taken for analysis at the 1st hour of normal flow anesthesia maintenance. Patients will be awakened at the end of the case. After the recovery room, it will be transferred to the relevant service. A third blood sample (T2) will be taken at the postoperative 24th hour in the service for analysis
89066273|NCT01294917|Experimental|Investigational MPS|AMO Investigational MPS.
89066274|NCT01294917|Active Comparator|Clear Care|Peroxide-based lens care regimen.
89066275|NCT01294917|Active Comparator|Opti-Free RepleniSH|Multi-purpose disinfecting solution (Alcon).
89066276|NCT01294683|Experimental|Sequence 1: MK-0524B 2g/40g→MK-0524A 2g + Simvastatin 40 mg|After a 2-week placebo run-in, participants received extended release (ER) niacin/laropiprant (N/LRPT) 1 g/20 mg combination tablet (MK-0524B) once daily for 4 weeks, then ERN/LRPT/Simvastatin (SIM) 2 g/40 mg combination tablet once daily for 8 weeks. Participants then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks.
89066277|NCT01294683|Experimental|Sequence 2: MK-0524A 2g + Simvastatin 40 mg→ MK-0524B 2g/40g|After a 2-week placebo run-in, participants received ERN/LRPT 1 g (MK-0524A) co-administered with SIM 20 mg once daily for 4 weeks then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks. Participants then received ERN/LRPT/SIM 2 g/40 mg combination tablets (MK-0524B) once daily for 8 weeks.
89066278|NCT01294449||MADIT-CRT ICD|
89066279|NCT01294449||MADIT-CRT CRT-D|
89066280|NCT01294371||Leuprorelin|"Patients with genital endometriosis received leuprorelin (Lucrin Depot®) in accordance with the respective marketing authorization/manufacturer's directions. All participants received leuprorelin for up to 6 months intramuscularly at a dose of 3.75 mg once a month. If intramuscular administration was not possible, leuprorelin was injected subcutaneously at a dose of 3.75 mg once a month. The first injection was to be carried out on the 3rd day of a menstrual period.~Accepted options for add-back therapy included: monophasic combined low-dose products for hormonal replacement therapy; combined oral contraceptives; and, if use of hormones was not possible, phytoestrogens with calcium products."
89066281|NCT01293123|Experimental|Raltegravir|
89066282|NCT01293123|Active Comparator|Efavirenz|
89066283|NCT01292187|Experimental|Oral calcitonin at dinner-or bedtime|Intervention: Oral calcitonin at dinnertime or oral calcitonin at bedtime. Postmenopausal subjects with osteopenia were treated for one year (also with vitamin D and calcium supplements) to determine if oral calcitonin tablets would prevent the loss of bone mineral density compared with placebo. Randomization to active or placebo was done 2:1. After randomization, further randomization was done to divide each arm into two groups, one in which dosing was at dinnertime and the other in which dosing was at bedtime to determine if food affected efficacy or safety.
89066284|NCT01292187|Experimental|Oral placebo at dinner- or bedtime|Intervention: oral placebo at dinnertime or oral placebo at bedtime
89066285|NCT05603247||Acute myocardial infarction (AMI) and acute heart failure (AHF)|"All patients identified with the respective International Statistical Classification of Diseases and Related Health Problems (ICD) 10th revision codes for AMI and/or the phenotype of AHF will undergo detailed medical review to verify patients' diagnosis of AMI and/or AHF according to current European Society of Cardiology (ESC) guidelines that are reflected in the subsequent inclusion criteria."
89066286|NCT01026493|Experimental|Phase I: Dose Level 1|ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days
89066287|NCT01026493|Experimental|Phase I: Dose Level 2a|ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days
89066288|NCT01026493|Experimental|Phase I: Dose Level 2b|ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days
89066289|NCT01026493|Experimental|Phase I: Dose Level 3|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
89066290|NCT01026493|Experimental|Phase II: Arm 1/BEV-NAIVE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
89066291|NCT01026493|Experimental|Phase II: Arm 2/BEV-NAIVE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
89066292|NCT01026493|Experimental|Phase II: Arm 1/BEV-FAILURE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
89066293|NCT01026493|Experimental|Phase II: Arm 2/BEV-FAILURE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
89066294|NCT01026103|Experimental|Tri Staple|This is a single arm study.
89066295|NCT02873767|Placebo Comparator|Placebo|Single dose placebo comparator for each active arm
89066296|NCT02873767|Experimental|UCB4019 Dose 1|Dose 1 calculated based on body weight
89066297|NCT02873767|Experimental|UCB4019 Dose 2|Dose 2 calculated based on body weight
89066298|NCT02873767|Experimental|UCB4019 Dose 3|Dose 3 calculated based on body weight
89066299|NCT02873767|Experimental|UCB4019 Dose 4|Dose 4 calculated based on body weight
89066300|NCT01291173|Experimental|SPD489 30 mg|
89066301|NCT01291173|Experimental|SPD489 50 mg|
89066302|NCT01291173|Experimental|SPD489 70 mg|
89066303|NCT01291173|Placebo Comparator|Placebo|
89066304|NCT02873455|Experimental|watching video|Short video clip including the circumstance of operation theater, and surgeon's interview
89066305|NCT02872519|Experimental|Experimental|Patients receive (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET scans. Patients undergo PET imaging scans during 0-45 minutes, 60-75 minutes, and 105-120 minutes after injection and within 4 weeks prior to surgery (Cohort A) or within 4 weeks of SOC imaging at diagnosis and prior to subsequent treatment (Cohort B).
89066306|NCT01291017|Experimental|PD0332991|PD0332991 125 mg PO days 1 - 21
89066307|NCT01290315|Experimental|Ferric Carboxymaltose (FCM)|Intravenous iron
89066308|NCT01290315|Active Comparator|Iron Sucrose / Iron Dextran|Intravenous iron
89066309|NCT01289847|Experimental|Gammaplex|
89066310|NCT01079182||Ankylosing spondylitis|Participants with ankylosing spondylitis
89066311|NCT04830748|Active Comparator|Therapeutic exercises group|The first group will receive therapeutic exercises in the form of stretching and strengthening exercises of the knee.
89066312|NCT04830748|Experimental|Therapeutic exercises and mechanical traction group|The experimental group will receive the same exercise program of the first group preceded by continuous mechanical traction of the knee.
89066313|NCT02877784||Screening|Participants enrolled will undergo testing of the swallowing mechanism
89066314|NCT01021813|Experimental|Suvorexant|After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to <65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.
89066315|NCT01021813|Placebo Comparator|Placebo|After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.
89066316|NCT04286659||Control Group|90 Apparently healthy individuals
89066317|NCT04286659||IBD group|90 Previously or Newly Diagnosed Ulcerative Colitis and Crohn's disease
89066318|NCT01025635|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
89066319|NCT01025635|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
89066320|NCT04300387|No Intervention|customary care|customary care for CKD
89066321|NCT04300387|Active Comparator|multidisciplinary care|multidisciplinary team care for CKD
89066322|NCT01021423|Experimental|Lenalidomide|Lenalidomide - 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
89066323|NCT01021423|Experimental|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
89066324|NCT02872207|Experimental|Suncare agent 1 + control|Application of control and test product into one of the subjects two eyes.
89066325|NCT02872207|Experimental|Suncare agent 2 + control|Application of control and test product into one of the subjects two eyes.
89066326|NCT02873143||The APA2011 cohort|In September 2011, students at 4 upper secondary schools in Aalborg were invited to answer an online questionnaire and to be part of the APA2011 cohort. From 2846 potential responders, 2200 adolescents responded to the questionnaire, corresponding to a response rate of 77%. A total of 504 adolescents indicating knee pain at least monthly were successfully contacted (a response rate of 83% of those who reported their telephone numbers) and were asked standardized questions on the telephone. This forms the cohort of 504 adolescents with knee pain. In addition a random selected group of adolescents without knee pain in 2011 will be contacted and asked the same questions as those with knee pain.
89066327|NCT00628069||Group 1|performers who will participate in the training sessions.
89066328|NCT00628069||Assistants|Assisants-paired with the performers and will be allowed to assists only, without the opportunity to practice the technical skills related to the task.
89066329|NCT01020877|Experimental|1|Metronidazole Vaginal Gel
89066330|NCT01020877|Active Comparator|2|MetroGel-Vaginal®
89066331|NCT01020799|Experimental|AZD7268|The AZD7268 15 mg BID arm consisted of 3 AZD7268 5 mg capsules dosed orally in the morning and evening. In addition, 2 placebo tablets to match encapsulated escitalopram tablets were dosed orally in the morning only.
89066332|NCT01020799|Placebo Comparator|Placebo|The placebo arm consisted of 3 placebo capsules to match AZD7268 capsules dosed orally in the morning and evening. In addition, 2 placebos to match encapsulated escitalopram tablets were dosed orally in the morning only.
89066333|NCT01020799|Active Comparator|Escitalopram|The escitalopram 20 mg QD arm consisted of 3 placebo to match AZD7268 capsules dosed orally in the morning and evening. In addition, during Week 1, one encapsulated 10-mg escitalopram tablet and 1 placebo to match encapsulated escitalopram tablet were dosed orally in the morning only. During Weeks 2 through 4, two encapsulated 10-mg escitalopram tablets were dosed orally in the morning only.
89066334|NCT02872597|Experimental|Treatment|Inhaled ipratropium bromide 250mcg given via nebulization every 6 hours for up to 5 days
89066335|NCT02872597|Placebo Comparator|Placebo|Inhaled normal saline 1.25mL given via nebulization every 6 hours for up to 5 days
89066336|NCT04299919||Recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
89066337|NCT04299919||Non-recurrence|All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
89066338|NCT01288989|Experimental|IMC-3C5|Participants receiving IMC-3C5 intravenously
89066339|NCT01020487|Experimental|Part 1: Paricalcitol|Participants received a single 3 µg dose of paricalcitol capsules on Study Day 1.
89066340|NCT01020487|Placebo Comparator|Part 2: Placebo|Participants received placebo capsules three times a week (TIW) for 12 weeks during the double-blind treatment phase. From Weeks 12 to 24 participants received open-label paricalcitol at an initial dose of 1 µg three times a week. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target Kidney Disease Outcomes Quality Initiatives (KDOQI) target levels.
89066341|NCT01020487|Experimental|Part 2: Paricalcitol|Participants received paricalcitol three times a week for 12 weeks during the double-blind treatment period and during the open-label period (Weeks 12-24). The initial dose of paricalcitol was 1 µg TIW. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target KDOQI target levels.
89066342|NCT02872675|Experimental|HOST-DM059 (Prebiotic)|HOST-DM059 is the only Second Generation Prebiotic, manufactured by Clasado Biosciences/HOST Therabiomics. HOST-DM059 consists of a specific type of carbohydrate/dietary fibre (GOS), and an enzyme extracted from species of Bifidobacteria (e.g. The β-Galacotosidase Enzyme, & Bifidobacterium Bifidum). The enzyme from which HOST-DM059 is developed provides a highly selective source of energy for certain species of Bifidobacteria. HOST-DM059 encourages the growth and development of Bifidobacteria. Certain species of Bifidobacteria have been demonstrated to exert prominent immunomodulatory effects in terms of regulating systemic inflammation.
89066343|NCT02872675|Placebo Comparator|Maltodextrin|Maltodextrin will be administered as a taste/appearance-matched sugar/carbohydrate.
89066344|NCT04299217|Active Comparator|Mango Leaf Extract|300 mg Mangifera indica (mango) leaf extract standardized to ≥ 60% mangiferin (Zynamite®), plus carrier
89066345|NCT04299217|Placebo Comparator|Placebo|Carrier (placebo)
89066346|NCT02873065|Experimental|Ilaprazole|Ilaprazole -based quadruple therapy for 7days：Ilaprazole -based quadruple therapy for 7days: Ilaprazole 5mg bid.
89066347|NCT02873065|Active Comparator|Esoprazole|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid.
89066348|NCT00628225|No Intervention|1|Usual Care
89066349|NCT00628225|Experimental|2|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement)
89066350|NCT00628225|Experimental|3|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement + bupropion-SR)
89066351|NCT02872129||166 women with FM/CWP|166 women with Fibromyalgia (FM) or Chronic Widespread Pain (CWP) that participated in an Randomised Controlled Trial called GAU in western Sweden 2004-2005.
89066352|NCT01024855|Experimental|RevitaLens OcuTec Multipurpose Solution (Investigational MPS)|
89066353|NCT01024855|Active Comparator|Opti-Free RepleniSH Multipurpose Solution (MPS, Control)|
89066354|NCT01014013|Experimental|ertapenem sodium (MK0826)|ertapenem sodium
89222659|NCT00553358|Active Comparator|Arm 2 Trastuzumab|4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
89222660|NCT00553358|Experimental|Arm 3 Lapatinib plus Trastuzumab|1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
89222661|NCT00688259|Experimental|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.
89222662|NCT00688259|Active Comparator|Supportive Therapy (ST)|approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns
89222663|NCT00749489|Experimental|Femoral Nerve Block|Intervention patients will have a continuous fascia iliaca blocks placed by a regional anesthesiologist 24 hours after the initial single injection femoral nerve block or at the time of surgery.
89222664|NCT00749489|No Intervention|No Intervention|No intervention
89222665|NCT04059029||Morbidly obese patients with NAFLD|Morbidly obese patient with Nonalcoholic fatty liver disease. The starting point for each patient is the day of surgery and the end-point is 1 year after the operation. During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance. The diagnosis of NASH would be made histologically.
89222666|NCT02286830|Active Comparator|zoledronic acid|treatment with zoledronic acid for 4 years
89222667|NCT02286830|Placebo Comparator|no treatment|treatment with zoledronic acid withheld after two years
89222668|NCT00688181||Subjects treated with the Prefyx PPS System|All patients presenting to the institution for treatment of female Stress Urinary Incontinence (SUI), excluding those patients meeting any of the contraindications as noted in the Directions For Use.
89222669|NCT02563535|Experimental|Drug-eluting balloon|angioplasty with Litos drug-eluting balloon
89222670|NCT02563535|Active Comparator|conventional PTA|angioplasty with conventional balloon
89222671|NCT00749567|Experimental|1|Erlotinib/Bevacizumab
89222672|NCT04010942|Active Comparator|Vitamin D|"Group V : number of 60 women will receive 100000 IU Cholecalciferol Intramuscular every month + 2000 mg Metformin (oral: 2 tablets 1000 per day) for 5 months .~-after two months from the start:~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day,from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
89222673|NCT04010942|Placebo Comparator|Control|"Group C: number of 60 patients will receive Metformin 2000mg (oral: 2 tablets1000 mg per day) for months .~-after two months from the start:~Clomiphene citrate 100mg (2 tablets clomid 50mg each per day, from 2nd to 6th day of the cycle ) will be added every month starting from the 3rd month to the 5th month ."
89222674|NCT00749645|Active Comparator|1 - FANG(30)|1 - Active comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the active product, in addition to base medication (Mtx + Pdn)
89222675|NCT00749645|Placebo Comparator|2 - Placebo|2 - Placebo comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the placebo formulation, in addition to base medication (Mtx + Pdn)
89222676|NCT00949364|Experimental|Pomalidomide|Every patient will remain on treatment until disease progression for at least 12 cycles, withdrawal of patient's informed consent or the occurrence of unacceptable toxicity. If a patient may benefit from treatment with pomalidomide the investigator together with the principle investigator will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision. This additional treatment will be performed within the follow-up period of the study, data will be collected and duration will be maximally 12 cycles.
89222677|NCT01634048|Experimental|High protein low calorie meal replacements|Meal replacements with added protein powder(1.34g pro/kg).
89222678|NCT01634048|Sham Comparator|Normal protein, low calorie meal replacement group|The control group will have standard meal replacements (0.8g protein/kg body weight).
89222679|NCT00689117|Experimental|1|CT Gel
89222680|NCT00689117|Active Comparator|2|Clindamycin Gel (clindamycin)
89222681|NCT00689117|Active Comparator|3|Tretinoin Gel (tretinoin)
89222682|NCT00689117|Placebo Comparator|4|Vehicle Gel
89222683|NCT00949442|Experimental|1|"Before randomization (common with arm 2):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose"
89222684|NCT00949442|Active Comparator|2|"Before randomization (common with arm 1):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: NPH + OAD(s) at stable dose"
89222685|NCT00749723|Experimental|1: P-HIT-REZ 2005|"intravenous chemotherapy with carboplatin/etoposide,followed by~high dose chemotherapy with thiotepa, carboplatin, etoposide and autologous stem cell transplantation if patient have achieved a complete remission or~maintenance therapy with oral trofosfamide, etoposide"
89222686|NCT00749723|Experimental|2: P-HIT-REZ 2005|"oral chemotherapy with temozolomide, followed by~high dose chemotherapy with temozolomide, thiotepa and autologous stem cell transplantation if patient have achieved a complete remission~maintenance therapy with oral temozolomide or in case of progression with oral trofosfamide, etoposide"
89222687|NCT00749723|Experimental|3: E-HIT-REZ 2005|Phase II: oral chemotherapy with temozolomide after progression oral trofosfamide, etoposide
89066355|NCT01014013|Active Comparator|ceftriaxone sodium|ceftriaxone sodium
89066356|NCT02872051|No Intervention|Control|Standard treatment and standard vocational rehabilitation
89066357|NCT02872051|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
89066358|NCT02872051|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
89066359|NCT01013701|Active Comparator|Fluticasone Furoate|nasal steroid
89066360|NCT01013701|Placebo Comparator|Placebo|nasal spray vehicle without drug
89066361|NCT00628303|Experimental|1|Motavizumab
89066362|NCT00628303|Placebo Comparator|2|Placebo
89066363|NCT01020019|Experimental|Lofexidine and Dronabinol|Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
89066364|NCT01020019|Placebo Comparator|Placebo|Lofex. matched placebo Dronabinol placebo
89066365|NCT04285801||COVID-19 infection|critically ill patients with COVID-19 infection
89066366|NCT00627835|Experimental|Treatment Group 1: Cohort 1|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
89066367|NCT00627835|Experimental|Treatment Group 1: sorafenib and radiation: Cohort 2|Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
89066368|NCT00627835|Experimental|Treatment Group 2: Cohort 3|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
89066369|NCT00627835|Experimental|Treatment Group 2: Cohort 4|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
89066370|NCT00627835|Experimental|Treatment Group 2:Cohort 5|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
89066371|NCT01024465|Experimental|ReShape Duo Balloon|Patients seeking weight loss with a starting BMI in the 30-40 range, received the ReShape Duo Balloon
89066372|NCT02872363|No Intervention|Control|The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment.
89066373|NCT02872363|Experimental|Intervention A - Behavioural Regulation|Intervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
89066374|NCT02872363|Experimental|Intervention B - Priority|Intervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
89066375|NCT04299607||AFI patients|"Blood will be collected from patients presenting with an undifferentiated fever.~Samples will be tested with:~the Malaria Ag Pf/Pan test SD Bioline~the SD Bioline Dengue Duo IgM/IgG/NS1~the DPP Zika Chikungunya Dengue test from Chembio~the DPP Fever Panel II assay~the Leptospira IgM ELISA test from Serion~an in-house ELISA tests for scrub and murine typhus IgM~blood culture for detection of Burkholderia pseudomallei"
89066376|NCT04205461||Programmed ventricular stimulation before PVR|
89222688|NCT00749723|Experimental|Intraventricular Etoposide|Phase II, intraventricular chemotherapy with etoposide
89222689|NCT00958490|Active Comparator|First walking group|Group walking at 2 months postop
89222690|NCT00958490|Active Comparator|Second group walking|Group walking at 3 months postop
89066377|NCT04300699|Other|Ovarian cancer patients over 70 years receiving chemotherapy|Patients with ovarian cancer receiving chemotherapy as either first line treatment (i.e. newly diagnosed advanced stage III/IV cancer) or at first relapse. Patients to receive a Geriatric Assessment including interventions for functional or other identified deficits and appropriate specialist algorithm-determined interventions.
89066378|NCT01024387|Experimental|AMG 479|Patients receive AMG 479 at a dose of 18 mg/kg administered IV on day 1 (± 3 days) of every 3-week cycle. Treatment should continue until disease progression, unacceptable toxicity or withdrawal of consent.
89066379|NCT01019317|Experimental|Cytarabine + Fludarabine|Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.
89066380|NCT01024309|Active Comparator|Mini-Posterior Approach|Mini-Posterior surgical approach for total hip arthroplasty
89066381|NCT01024309|Experimental|Direct Anterior Approach|Direct Anterior surgical approach for total hip arthroplasty
89066382|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 1)|
89066383|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 2)|
89066384|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 1)|
89066385|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 2)|
89066386|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 1)|
89066387|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 2)|
89066388|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 1)|
89066389|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 2)|
89066390|NCT02877472|Experimental|Experimental group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression and porous tantalum rod implantation (experimental group).
89066391|NCT02877472|Experimental|Control group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression (control group).
89066392|NCT02877238|Active Comparator|Group A|Sevoflurane plus remote ischemic preconditioning anesthesia will be induced and maintain with sevoflurane in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
89066393|NCT02877238|Active Comparator|Group B|anesthesia will be induced and maintain with total intravenous anesthesia (propofol, midazolam plus fentanyl) during plus remote ischemic preconditioning in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
89066394|NCT01288911|Experimental|Enzalutamide|Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
89066395|NCT01288911|Active Comparator|Bicalutamide|Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
89066396|NCT01288443|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
89066397|NCT01288443|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
89066398|NCT01288443|Experimental|Alirocumab 100 mg Q2W|Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
88820751|NCT05691452|Experimental|Intervention Group|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth.
89066399|NCT01288443|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
89066400|NCT01288443|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
89066401|NCT01288443|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
89066402|NCT01288287||Week 12 Disease Activity Score (DAS) Responders|Patients achieving a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
89066403|NCT01288287||Week 12 Disease Activity Score (DAS) Non-Responders|Patients who fail to achieve a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
89066404|NCT04324203|Experimental|Experimental group|Three-dimensional Virtual Reality and Horticultural Therapy
89066405|NCT04324203|No Intervention|Control group|No intervention
89066406|NCT01288209|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
89066407|NCT01288209|Experimental|TMC435 100 mg 24 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin ( PR) for 24 weeks (Wks). Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
89066408|NCT01288053|Experimental|Allogeneic Stem Cell Therapy|Allogeneic Stem Cell Therapy will be performed after conditioning
89066409|NCT01287195|Experimental|Oral OKT3|Participants with ulcerative colitis will receive Oral OKT3 given with Omeprazole once daily for 30 days.
89066410|NCT01287117|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
89066411|NCT01287117|Experimental|Omalizumab 75 mg|Participants received omalizumab 75 mg subcutaneously every 4 weeks during the 24 week treatment period.
89066412|NCT01287117|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24 week treatment period.
89066413|NCT01287117|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
89066414|NCT01287039|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
89066415|NCT01287039|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
89222691|NCT00749801|Active Comparator|A|nattokinase-mono formula (3500FU)
89066416|NCT02889939|Other|UC + ETT|"An enriched comprehensive task-specific therapy (ETT) program combining intensive and task-specific therapy with the sensory-motor, social, and cognitive stimulation inherent to environmental enrichment.~The intervention was preceded by a baseline period of usual care (UC) for 3 weeks, which also served as a control."
89066417|NCT05575245|Active Comparator|Intervention: Drug-eluting Stent|Drug-eluting Stent group
89066418|NCT05575245|Experimental|Intervention: Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon group
89066419|NCT05572203|Active Comparator|Healthy group (Control group )|This group will include healthy participants matching Crohn's group
89066420|NCT05572203|Experimental|Crohn's group or patients group|This group will include patients with Crohn's disease.
89066421|NCT01285401|Experimental|VigantOL® oil|VigantOL oil plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
89066422|NCT01285401|Placebo Comparator|Placebo|Placebo daily plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
89066423|NCT01285401|Experimental|Rebif|Rebif alone in subjects with 25-hydroxy-vitamin D plasma levels equal or higher than 150 nmol/L
89066424|NCT01285323|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
89066425|NCT01285323|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
89066426|NCT01284621|Experimental|BI 10773|1 tablet per days for 5 days, oral administration with 240 mL water for each treatment
89066427|NCT01284621|Other|Ramipril|1 tablet on day 1 and 2 tablets per day on day 2-5, oral administration with 240 mL water for each treatment
89066428|NCT01284621|Other|BI 10773 + Ramipril|1 tablet BI 10773 and 1 tablet on day 1 and 2 tablets ramipril per day on day 2-5, oral administration with 240 mL water for each treatment
89066429|NCT04323813||Cases|CRC patients: primary, Stage I-IV (localized, node negative or node positive) colon carcinoma confirmed by tissue biopsy, and patients with advanced adenoma (including high-grade dysplasia, HGD).
89066430|NCT04323813||Controls|Controls subjects as well as healthy clean colonoscopy subjects or with hyperplastic polyps, and healthy subjects with diminutive adenoma-low grade dysplasia (LGD) and with inflammatory bowel disease (IBD).
89066431|NCT02890017|Experimental|Hotel-Ambu|Outpatient surgery with a patient-hotel night
89066432|NCT02890017|Other|conventional hospitalization|conventional hospitalization
89066433|NCT01283139|Experimental|Sifalimumab 200 milligram (mg)|Sifalimumab 200 milligram (mg) will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
89066434|NCT01283139|Experimental|Sifalimumab 600 mg|Sifalimumab 600 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
89066435|NCT01283139|Experimental|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
89066436|NCT01283139|Placebo Comparator|Placebo|Placebo matching to sifalimumab will be administered intravenously at a fixed dose every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
89066437|NCT01282203||Adults requiring anesthesia for surgery|This post-marketing observational study will be conducted in a prospective, multi-centre format. It is a non-interventional, observational study in which Sevorane is prescribed for adult patients undergoing general surgery for induction and maintenance of anesthesia in the usual manner in accordance with the terms of the local marketing authorization. Sevorane is used for induction and maintenance anesthesia by the choice of anesthesiologist. No additional procedures (other than standard of care) shall be applied to the patients. Each patient will be observed from the start of anesthesia through anesthesia end. Markers of myocardial ischemia will be detected up to the first 24 hours after anesthesia (if available). Additionally the correlation between the experience and training background of anesthesiologists and patient related outcomes of general anesthesia with Sevorane as a single anesthetic will be assessed.
89066438|NCT01281969|Experimental|Group A|Drug: Gamunex Intravenous Immunoglobulin 2.0 gm/kg total, IV (in the vein), over 2 days
89066439|NCT01281969|Placebo Comparator|Group B|Drug: Placebo Normal saline, IV (in the vein), over 2 day
89222692|NCT00749801|Experimental|B|Nattokinase compound-multiple formulae
89222693|NCT00749801|Placebo Comparator|C|Placebo
89222694|NCT00958646|Experimental|Osteopathic Manipulation|Standardized OMT procedure
89066440|NCT01281813|Experimental|Continued Treatment with DRV in Combination with rtv|HIV-1 infected children participants (aged less than [<] 12 years) will continue to receive darunavir (DRV) 200 to 600 milligrams (mg) as oral suspension twice daily (BID) along with ritonavir (rtv) 32 to 100 mg as oral solution/suspension BID. HIV-1 infected adolescent participants (aged 12-17 years) will continue to receive DRV 200 to 600 mg as oral suspension BID along with rtv 32 to 100 mg as oral solution/suspension BID. Dosing for children and adolescent participants will be based on body weight (per parent study TMC114-TiDP29-C232). HIV-1 infected adult participants (aged greater than or equal to [>=] 18 years) will continue to receive DRV 800 mg (2 tablets of 400 mg) orally every day (qd) along with rtv 100 mg tablet (per parent study TMC114-C211) or DRV 600 mg tablet orally BID along with rtv 100 mg tablet (per parent study TMC114-C214 or TMC114-TiDP31-C229).
89066441|NCT01090414|Experimental|Idelalisib|Participants will receive up to 350 mg of idelalisib twice daily until disease progression or unacceptable toxicity.
89066442|NCT01090102|Experimental|Mesalamine|
89066443|NCT01090102|Placebo Comparator|Placebo|
89066444|NCT02877160|Experimental|Reference Formulation Fasted|150 mg of AL-794 study drug in suspension dosed in a fasted condition
89066445|NCT02877160|Experimental|Test Formulation Fasted|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fasted condition
89066446|NCT02877160|Experimental|Test Formulation Fed|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fed condition
89066447|NCT02878096|Experimental|[14C]-SK-1404|
89066448|NCT01287897|Placebo Comparator|Placebo- SC injection|
89066449|NCT01287897|Experimental|Drug Dose level 1 - SC injection|
89066450|NCT01287897|Experimental|Drug Dose level 2 - SC injection|
89066451|NCT02877940|Active Comparator|ProSeal Laryngeal mask airway|ProSeal will be inserted in mechanically ventilated patients undergoing elective surgeries.
89066452|NCT02877940|Active Comparator|Laryngeal Tube Suction- Disposable|LTS-D will be inserted in mechanically ventilated patients undergoing elective surgeries.
89066453|NCT02877940|Active Comparator|Group I|i-gel will be inserted in mechanically ventilated patients undergoing elective surgeries..
89066454|NCT04306978|Active Comparator|CareLink Express RM system|Patients in the remote monitoring (RM) group will undergo the implantation of Ensura DR MRI SureScan pacing system. Patients in the RM group should visit the main follow-up clinic 12 weeks after discharge, and then the device data will be remotely transmitted to the CareLink Express Network at least once in 3 months. Research personnel will contact patients by telephone once in 6 months. If participants indicate they have experienced a study outcome event (corresponding to the study endpoints), the event will be recorded. If remote transmission or telephone call data require to make clinical decision an in-hospital visit will be induced.
89066455|NCT04306978|Active Comparator|Standard follow-up|Patients in the control group will receive Adapta DR pacing system without remote monitoring using. All patients from the control group should have the first in-hospital visit 12 weeks after pacemaker implantation. Then, the follow-up will be provided according to the standard guidelines
89066456|NCT01090024|Experimental|BI 671800 AM and PM|Patients receiving two capsules twice daily
89066457|NCT01090024|Experimental|BI 671800 AM|Patients receiving four capsules in the morning
89066458|NCT01090024|Experimental|BI 671800 PM|Patients receiving four capsules in the evening
89066459|NCT01090024|Placebo Comparator|Placebo|Patients receiving four capsules twice a day
89066460|NCT04868890|Experimental|Active|Ampion
89066461|NCT04868890|Placebo Comparator|Control|Placebo
89066462|NCT01281189|Experimental|Dexpramipexole|
89066463|NCT01281189|Placebo Comparator|Placebo|
89066464|NCT02877862|Experimental|Intervention|Receive 7-day mAGIC app intervention and handout
89066465|NCT02877862|No Intervention|Control|Handout only
89066466|NCT04306666||Walant group|Walant group
89066467|NCT04306666||Axillary Brachial Plexus Block|Axillary Brachial Plexus Block
89066468|NCT04818892||IBD and Non-Immunosuppressive Group|Clinical diagnosis of IBD, non-systemic immunosuppressive therapies, and scheduled to take an mRNA vaccine for COVID-19
89066469|NCT04818892||IBD and Immunosuppressive Group|Clinical diagnosis of IBD, treated with systemic immunosuppressive therapies, and scheduled to take an mRNA vaccine for COVID-19
89066470|NCT01280955|Experimental|Transplant Recipients|Transplant recipients from matched sibling donors and dual cord donors. Subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
89066471|NCT00623883|Experimental|1|All identified ACF eliminated by cold or hot colonoscopic biopsy forceps
89066472|NCT00623883|Sham Comparator|2|ACF quantified and observed, re-evaluated after one year
89066473|NCT01280721|Experimental|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
89066474|NCT04323969|Experimental|Specific Modification Target|A 15 degree relative increase to foot progression angle
89066475|NCT04323969|Experimental|Self-directed Modification|"A self-directed increase to foot progression angle that is as much as is comfortable."
89066476|NCT02889471|Experimental|ERCP with nasobiliary catheter|
89066477|NCT02889471|Active Comparator|ERCP only|
89066478|NCT05560581|Experimental|Intervention group|Participants will receive an one-week digital self-efficacy training (3x/day) and an one-week Ecological Momentary Assessment (3x/day questions on mood, social and virtual contacts).
89066479|NCT05560581|Active Comparator|Control group|Participants will receive an one-week Ecological Momentary Assessment (3x/day questions on mood, social and virtual contacts).
89066480|NCT01087762|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
89066481|NCT01087762|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
89066482|NCT01087762|Placebo Comparator|Placebo|"Matching Placebo to CZP injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16.~After 24 weeks, all subjects were randomized to active treatment with CZP 200 mg Q2W or CZP 400 mg Q4W."
89066483|NCT01087762|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
89066484|NCT01087762|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
89066485|NCT01087762|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
89066486|NCT01087762|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
89066487|NCT04306354|Experimental|Conventional oxytocin treatment (T + OC)|32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
89222695|NCT00958646|Placebo Comparator|Placebo|Light touch placebo procedure
89222696|NCT02561975|Experimental|Patient suffering from complex congenital heart disease|
89222697|NCT00958802|Placebo Comparator|Arm A|Chondrocyte culture with FBS medium
88820752|NCT05689671|Experimental|Pemetrexed-free Immunochemotherapy (Arm A)|Atezolizumab 1200 mg q3w, carboplatin AUC 5-6 q3w, nab-paclitaxel 100 mg/m2 qw (administered for 4 cycles with subsequent maintenance with atezolizumab monotherapy 1200 mg q3w until loss of clinical benefit or occurrence of unacceptable toxicity)
89222698|NCT00958802|Experimental|Arm B|Chondrocyte culture with PRP
89066488|NCT04306354|Placebo Comparator|Conventional treatment with placebo administration (T + PBO)|32 female cocaine users hospitalized for detoxification will receive six jets of placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment from the eighth to the seventeenth day of hospitalization (duration of placebo treatment of 10 days). Conventional treatment includes supportive individual and group psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy as needed to relieve the symptoms of anxiety, aggression and agitation typical of withdrawal and care. 21 days of hospitalization.
89066489|NCT04306354|No Intervention|Conventional treatment (T)|32 female cocaine users hospitalized for detoxification will receive conventional treatment including individual and group supportive psychotherapy (once a week), nutritional control, regular physical activity and psychopharmacotherapy if needed for symptom relief. anxiety, aggression and agitation, typical of abstinence and nursing care, during 21 days of hospitalization.
89066490|NCT04306276||Patients undergoing direct IVF|Patients directly undergo IVF without receiving previous hormonal treatment
89066491|NCT04306276||Patients pretreated with DNG|Patients having received a three-month treatment with DNG before undergoing IVF
89066492|NCT01078168|Active Comparator|Acitretin|oral, 30 mg per day, day 1-28
89066493|NCT01078168|Placebo Comparator|Placebo|oral, day 1-28
89066494|NCT01086358|Active Comparator|Triptan|Arm 1 subjects began with their prescribed triptan
89066495|NCT01086358|Active Comparator|Treximet 85Mg-500Mg Tablet|Arm 2 subjects began with Treximet (sumatriptan 85 mg/naproxen sodium 500 mg)
89066496|NCT01277601|Experimental|TDF+Peg-IFN 48 Weeks|TDF plus Peg-IFN for 48 weeks
89066497|NCT01277601|Experimental|TDF 48 Weeks + Peg-IFN 16 Weeks|TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
89066498|NCT01277601|Active Comparator|TDF 120 Weeks|TDF monotherapy for 120 weeks
89066499|NCT01277601|Active Comparator|Peg-IFN 48 Weeks|Peg-IFN monotherapy for 48 weeks
89066500|NCT01277523|Experimental|A|
89066501|NCT01277523|Experimental|B|
89066502|NCT01277523|Placebo Comparator|C|
89066503|NCT01081834|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
89066504|NCT01081834|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
89066505|NCT01081834|Experimental|Placebo/Sitagliptin|In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
89066506|NCT01276509|Placebo Comparator|Placebo-SC Injection|Placebo delivered SC, 3 doses separated by 4 weeks.
89066507|NCT01276509|Experimental|Drug Dose level 1- SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.
89066508|NCT01276509|Experimental|Drug Dose level 2-SC injection|Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.
89066509|NCT01276509|Experimental|Drug Dose level 3- SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.
89066510|NCT01079962|Experimental|Bisoprolol|
89066511|NCT01079962|Active Comparator|Atenolol|
89066512|NCT04323579||prospective cohort of stage I-II lung cancer patients|A prospective cohort of stage I-II lung cancer patients (N=80) candidates to surgery at Humanitas, and 40 controls with benign nodules.
89066513|NCT04323579||retrospective screening cohort of 50 patients|A retrospective screening cohort of 50 patients with screened lung cancer at MUG.
89066514|NCT04323579||prospective screening cohort of 30 patients|A prospective screening cohort of 30 patients with screened lung cancer and 100 matched negative controls enrolled at Humanitas cohort of 1000 participants (expected annual rate 1.5%).
89066515|NCT04323579||retrospective screening cohort from the NELSON study|A retrospective screening cohort from the NELSON study.
89066516|NCT04323579||Prospective cohort of stage IV lung cancer patients|A Prospective cohort of stage IV lung cancer patients (N=30) candidate to systemic therapy.
89066517|NCT01274637|Experimental|low molecular weight heparin|Prophylactic-dose (5000 IU/0.2ml)low molecular weight heparin (LMWH), administered subcutaneously once daily in pre-filled glass syringes for 10 days (+/- 3 days) for a total of 10 (+/-3) study drug injections.
89066518|NCT01274637|No Intervention|Control Group|No treatment control group.
89066519|NCT01079806|Active Comparator|Entecavir|Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
89066520|NCT01079806|Placebo Comparator|Placebo|Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response
89066521|NCT01078090||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 5 years.
89066522|NCT00626314|Experimental|1|myoblast
89066523|NCT00626314|Sham Comparator|2|sham injection procedure
89066524|NCT00626470|Active Comparator|-TSP|Patients operated without TSP
89066525|NCT00626470|Active Comparator|+TSP|Patients operated with TSP
89066526|NCT02876770|Experimental|Melatonin|
89066527|NCT02876770|Placebo Comparator|Placebo|
89066528|NCT01077622|Experimental|2000 mg dose|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
89066529|NCT01313676|Experimental|fluticasone furoate/vilanterol|Combination of both products in one inhaler
89066530|NCT01313676|Experimental|fluticasone furoate|comparator of individual component
89066531|NCT01313676|Experimental|vilanterol|comparator of individual component
89066532|NCT01313676|Placebo Comparator|placebo|once daily via inhaler
89066533|NCT02891304||Quarterly Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive objective feedback every 3-months on trainee overall performance including learning curves on ACE tool performance, performance relative to de-identified anonymous peers on each of the individual skills (e.g. fine tip control), and the global assessment for technical and cognitive skill achievement. For those skills which are not advanced/superior - trainees will additionally receive links to online didactic videos which teach these skills.
89066534|NCT02891304||Annual Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive learning curves at the end of each training year. Learning curves, relative to de-identified anonymous peers will be provided to program directors annually (June).
89066535|NCT05661318||BHS|Residents of Ballana from the 1,200 randomly selected households
89066536|NCT02890914|No Intervention|Standard Education|These residents received their standard residency education and experience.
89066537|NCT02890914|Experimental|DVD Intervention|These residents received a one-hour long DVD lecture in addition to standard residency education and experience.
89066538|NCT00623376|Active Comparator|1|first on treatment then on Placebo
89066539|NCT00623376|Placebo Comparator|2|first on placebo then on treatment
89066540|NCT01313286|Experimental|LY2608204 Reference, LY2608204 Test|Single oral 80 mg dose of LY2608204 reference formulation in period 1; single oral 80 mg dose of LY2608204 test formulation in period 2. There is a washout period of at least 14 days between dosing periods.
89066541|NCT01313286|Experimental|LY2608204 Test, LY2608204 Reference|Single oral 80 mg dose of LY2608204 test formulation in period 1; single oral 80 mg dose of LY2608204 reference formulation in period 2. There is a washout period of at least 14 days between dosing periods.
89066542|NCT05644392|Experimental|Cadonilimab Injection in combination with Regorafenib|Cadonilimab Injection in combination with Regorafenib
89066543|NCT01313208|Placebo Comparator|Placebo|"Participants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks.~All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period."
89066544|NCT01313208|Experimental|Etanercept|"Participants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks.~All participants continued their DMARD treatment throughout the 24-week study period."
89066545|NCT01312428|Other|Pelvic Alignment Level (PAL)|Pelvic Alignment Level Instrument Used
89066546|NCT01312428|Other|No Pelvic Alignment Level (PAL)|No Pelvic Alignment Level Instrument Used
89066547|NCT01075984|Active Comparator|POS IV 200 mg single dose (Cohort 0)|POS 200 mg IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
89066548|NCT01075984|Placebo Comparator|Dextrose 5% in water (Cohort 0)|Placebo IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
89066549|NCT01075984|Experimental|POS IV 200 mg BID (Cohort 1)|POS 200 mg IV infused over 1.5 hours BID on Day 1, followed by POS 200 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 1)
89066550|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 2)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 2). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
89066551|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 3)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 5, then by POS 200 mg oral TID or POS 400 mg oral BID through Day 28, or POS 200-300 mg IV once daily as required (Cohort 3). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
89066552|NCT04306198|Active Comparator|Lag Screw|Device: Trochanteric Fixation Nail (TFN) whit lag screw Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
89066553|NCT04306198|Active Comparator|Helical Blade|Device: Trochanteric Fixation Nail (TFN) whit helical blade Surgical stabilization of intertrochanteric hip fractures using two different proximal fixation implants
89066554|NCT02876536|Experimental|TNES with sending electrical impulses|The MS patients will receive electrical impulses by TENS device for 30 minutes a day, for 5 days a week and in 6 weeks
89066555|NCT02876536|Sham Comparator|TENS without sending electrical impulses|The MS patients will use the TENS device for 30 minutes a day, for 5 days a week and in 6 weeks without receiving any electrical impulses
89066556|NCT01024231|Experimental|Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 0.3 mg/kg solution, 60 minutes intravenous infusion every 3 (q3) weeks for 21 weeks in induction and every 12 (q12) weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
89066557|NCT01024231|Experimental|Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
89066558|NCT01024231|Experimental|Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
89066559|NCT01024231|Experimental|Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
89066560|NCT01024231|Experimental|Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 10 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
89222699|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.
89222700|NCT00547248|Active Comparator|Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.
89066561|NCT01024231|Experimental|Cohort 6: BMS-936558 (1 mg/kg)|BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
89066562|NCT01024231|Experimental|Cohort 7: BMS-936558 (3 mg/kg)|BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
89222701|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.
89222702|NCT00547248|Active Comparator|Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.
89222703|NCT02562833|Experimental|Self-Management and exercise|
89222704|NCT02562833|Active Comparator|Educational|
89222705|NCT05351060|Experimental|3D model splinting intervention group|The researcher will scan the participant's forearm, wrist, and hand with an iPhone camera through the Comb O&P Scan App. Scans will be completed individually to maintain privacy. The entire Comb O&P platform is HIPAA compliant. The data is de-identified encrypted when it moves from the iPhone app to the computer through the cloud. Precision Valve Automation (PVA) will use the de-identified scans to print the 3D models which are a precise replica of the participant's hand. Once the researcher obtains the 3D models, resting hand splints will be fabricated on the 3D models to provide custom-made hand splint(s) to each participant. The participants will receive the splint(s) to wear during the hours of sleep for six weeks.
89222706|NCT05350982||Hospital Arm|Participants will be recruited to use the SalivaBio +/- SaliPac in a hospital setting. They will be provided with collecting instructions and will be guided by a member of the research team.
89222707|NCT05350982||Stimulated Home Arm|10 participants will be randomly selected by a random number generator. This arm will also be conducted in the Hospital, and the collection using a SalivaBio +/- SaliPac will still be observed by a member of the research team. These participants will receive the same information as those in the Hospital Arm, but will receive minimal input. This is to establish whether the collection instructions provided would be suitable to use in the home environment.
89222708|NCT00688103|Active Comparator|ETN Alone|etanercept (25mg, twice/week, s.c.)
89222709|NCT00688103|Active Comparator|ETN+MTX|etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)
89222710|NCT00949598|Experimental|Arm I|Patients receive oral letrozole once daily for 16 weeks.
89222711|NCT00949598|Experimental|Arm II|Patients receive oral tamoxifen citrate once daily for 16 weeks.
89222712|NCT00964704|Experimental|Single Arm|
89222713|NCT00949676||Heart Failure|
89222714|NCT00747071|Experimental|1|Hospitalized patients with Clostridium difficile associated diarrhea.
89222715|NCT00747071|Experimental|2|Close hospital contacts of each index case
89222716|NCT05350670|Experimental|perineal massage and cold compress group|
89222717|NCT05350670|No Intervention|no intervention group|
89222718|NCT00970710|Experimental|Lifestyle counseling|VACOPP (Vaasa Childhood Obesity Primary Prevention Study): Intensified lifestyle counseling including physical activity and nutritional information beginning during maternity health care and continuing during child health care clinic visits.
89222719|NCT00958958|Other|Quality improvement program|"There are multifaceted Interventions for the clinic hospital team Including~Distribution of educational materials~Case manager~Reminders~Practical training"
89222720|NCT00958958|No Intervention|Hospital standard treatment|Hospital standard treatment
89222721|NCT00686855|Experimental|Tacrolimus|Tacrolimus Arm Closed to Accrual as of January 2012
89222722|NCT00686855|Experimental|Dexamethasone|
89222723|NCT00949754|Active Comparator|histamine|histamine in saline administered ID as active control for Apitox
89222724|NCT00949754|Experimental|Apitox pure honeybee venom|ID study drug
89222725|NCT00960024|Experimental|Individual Placement and Support-vocational rehabilitation|
89222726|NCT00960024|Active Comparator|Vocational rehabilitation available at study site|
89222727|NCT00745043|Placebo Comparator|R302|Daily placebo capsules
89222728|NCT00745043|Active Comparator|R303|Daily metoprolol 95mg capsules
89222729|NCT00745043|Active Comparator|R304|Daily propranolol 80mg capsules
89222730|NCT00745043|Active Comparator|Open Label|Daily Metoprolol 190mg capsules
89222731|NCT00949832|Active Comparator|Vitamin D + Calcium|Vitamin D and calcium supplementation
89222732|NCT00949832|Placebo Comparator|Calcium|Calcium supplementation
89222733|NCT00949832|Active Comparator|Vitamin D2|Vitamin D2 response
89222734|NCT00949832|Active Comparator|Vitamin D3|Vitamin D3 response
89222735|NCT00970788|No Intervention|verbal group|Verbal description of goals of care.
89222736|NCT00970788|Experimental|Video group|Video decision aid.
89222737|NCT00745199|Experimental|1|Patients on hemodialysis with pruritus, receiving cromolyn sodium
89222738|NCT00745199|Experimental|2|patients on hemodialysis with pruritus, receiving placebo
89222739|NCT00745199|No Intervention|3|Patients on hemodialysis but without pruritus who do not receive any treatment.
89222740|NCT00961844|Experimental|DC vaccine + Temozolomide|Dendritic cell loaded with h-TERT mRNA, survivin mRNA and autologous tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion.
89222741|NCT00959348||Asthma|Asthma patients on inhaled corticosteroids
89222742|NCT00959348||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
89222743|NCT00959426|Experimental|PF-04620110|
89222744|NCT00959426|Placebo Comparator|Placebo Comparator|
89222745|NCT05328050||Achondroplasia|
89222746|NCT05328050||Hypochondroplasia|
89222747|NCT05297162|Experimental|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"Single-arm case-control imaging trial designed to compare in parallel PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy (experimental test) with mpMRI/TRUS fusion prostate biopsy (standard test) in men suspected for PCa after at least one negative biopsy."
89222748|NCT00686777|Experimental|PEG-IFN + Ribavirin|Pegylated Interferon alfa-2b was administered to participants at 1.5 μg/kg subcutaneously once weekly for 48 weeks. Ribavirin was administered orally every day after morning and evening meals for 48 weeks at 400 mg/day.
89222749|NCT04009772|Active Comparator|"Cefepime , Maxipime® 1 gm"|"Patient will receive Cefepime ,Maxipime® 1 gm IV during cesarean section just before skin incision"
89222750|NCT04009772|Active Comparator|"Cefuroxime, Zinnat® 1gm plus metronidazoleFlagyl® 500"|"Patient will receive Cefuroxime, Zinnat® 1gm ,and metronidazoleFlagyl® 500 IV; just before skin incision for emergency cesarean section"
89222751|NCT00961922|Experimental|Neurofeedback|Children in this group receive 30 sessions of neurofeedback
89222752|NCT00961922|Sham Comparator|Placebo feedback|The children in this group receive 30 sessions of placebo feedback, based on muscular tension.
89222753|NCT00961922|No Intervention|Siblings|The siblings will be tested 1 time, they will function as a healthy control group.
89222754|NCT00959582|Experimental|1|18-F-FDG PET/CT imaging
89222755|NCT00962156|Experimental|HES 130/0.4|Volume expansion
89222756|NCT00962156|Active Comparator|Ringer acetate|Volume expansion
89222757|NCT00959738|Other|A|diverting loop ileostomy with rod
89222758|NCT00959738|Other|B|diverting loop ileostomy without rod
89222759|NCT00686699|Experimental|Preladenant 25 mg BID→Placebo BID|Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
89222760|NCT00686699|Placebo Comparator|Placebo BID→Preladenant 25 mg BID|Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
89222761|NCT00959816|Experimental|Single Dose (Part 1)|
89222762|NCT00959816|Experimental|Multiple Dose (Part 2)|
89222763|NCT01563068|Experimental|Calcipotriene Foam|Calcipotriene foam 0.005% administered under maximal-use conditions to adolescent patients with plaque psoriasis
89222764|NCT00747305|Experimental|Sunitinib|Sunitinib will be administered for 8 weeks prior to sugery
89222765|NCT05254106||Paclitaxel drug-eluting devices|Patients treated by at least one paclitaxel drug-eluting balloon or stent after an endovascular femoropopliteal artery revascularization between October 2011 and December 2019 in France.
89222766|NCT05254106||Non-drug-eluting devices|Patients exclusively treated by a non-drug-eluting balloon or stent after an endovascular femoropopliteal artery revascularization between October 2011 and December 2019 in France.
89222767|NCT00747383|Active Comparator|1|
89222768|NCT00747383|Active Comparator|2|
89222769|NCT00106639|Experimental|CP-690,550 15 mg BID|
89222770|NCT00106639|Experimental|CP-690,550 30 mg BID|
89222771|NCT00106639|Active Comparator|tacrolimus|
88820753|NCT05689671|Active Comparator|Pemetrexed-based Immunochemotherapy (Arm B)|Pembrolizumab 200 mg q3w, cisplatin 75 mg/m2 q3w OR carboplatin AUC 5-6 (each) q3w, pemetrexed 500 mg/m2 q3w (administered for 4 cycles with subsequent maintenance with pembrolizumab 200 mg AND pemetrexed 500 mg/m2 (each) q3w until loss of clinical benefit or occurrence of unacceptable toxicity)
89222772|NCT00747539||1|This group will be composed of 165 HCV-infected people who are not also HIV infected.
89222773|NCT00747539||2|This group will be composed of 165 HCV-infected people who are also HIV infected.
89222774|NCT00962234||Metabolism|Lung cancer patients who exhibit abnormalities in lipid measures.
89222775|NCT00959972|Experimental|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
89222776|NCT00959972|Experimental|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
89222777|NCT04059653|Experimental|Electrical stimulation|Neuromuscular electrical stimulation treatment
89222778|NCT04059653|Active Comparator|Treatment As Usual|Usual GP treatment
89690305|NCT03687892|Experimental|continuous Theta Burst Stimulation|The investigators will perform two applications of 40s of continuous Theta Burst Stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
89690306|NCT03687892|Experimental|intermittent Theta Burst Stimulation|The investigators will perform two applications of 40s of intermittent Theta Burst Stimulation (iTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
89690307|NCT03670953|Active Comparator|IR CD-LD - Dose Adjustment|Participants started on the same dose as the pre-study dosing regimen of IR CD-LD and then received dose adjusted IR CD-LD tablets daily orally, for a period of 3 weeks. If the participant was taking controlled release carbidopa-levodopa (CR CD-LD), the CR CD-LD was discontinued and substituted with a 1:1 milligram-equivalent dose of IR CD-LD.
89690308|NCT03670953|Experimental|IPX203 - Dose Conversion|Participants received extended release (ER) CD-LD (IPX203) capsules orally, every 6 - 12 hours for a period of 4 weeks at a dose based on their most frequent stable dose of IR CD-LD in dose adjustment period. Participant with most frequent stable dose of 25-100 milligrams (mg) IR CD-LD received 70 - 280 mg IPX203 thrice daily (TID); >25-100 - 37.5-150 mg IR CD-LD received 105-420 mg IPX203 TID; >37.5-150 - 50-200 mg IR CD-LD received 140-560 mg IPX203 TID; >50 - 200 mg IR CD-LD received 175-700 mg IPX203 TID. Participants who received a daily total dose of less than 125-500 mg IR CD-LD in dose adjustment received IPX203 every 12 hours. After initial dose conversion from IR CD-LD to IPX203 as per above mentioned dose conversion schedule, the dose of IPX203 could be further adjusted during the 4 week dose conversion period.
89690309|NCT03670953|Experimental|IPX203 - Double-Blind Maintenance|Participants received IPX203 capsules orally, every 6 - 12 hours for 13 weeks at a stable dose established at the end of dose conversion period along with placebo matched to IR CD-LD.
89690310|NCT03670953|Active Comparator|IR CD-LD - Double -Blind Maintenance|Participants received IR CD-LD tablets daily orally, for 13 weeks at a stable dose established at the end of dose adjustment period along with placebo matched to IPX203.
89690311|NCT04736914|Experimental|Zanubrutinib+R-CHOP/R-DHAOx|"Induction:~Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~ASCT conditioning~Maintenance:~Zanubrutinib, 160mg PO BID, continuously for 2 year~Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT~Requirements for start of maintenance:~ANC ≥ 1,000 cells/mm³ (1.0 X 109/L);~Platelets ≥ 50,000 cells/mm³ (50 X 109/L);"
89690312|NCT00657241|Active Comparator|(A) ARB first, beta-blocker second|Valsartan 160 mg daily (one week) and valsartan 320 mg daily (3 weeks) followed by carvedilol CR 20 mg daily (one week) and carvedilol CR 40 mg daily (3 weeks)
89690313|NCT00657241|Active Comparator|(B) Beta-blocker first, ARB second|carvedilol CR 20 mg daily (one week) and carvedilol CR 40 mg daily (3 weeks) followed by valsartan 160 mg daily (1 week) and valsartan 320 mg daily (3 weeks).
89690314|NCT04342065|Active Comparator|Group (G)|received gabapentin 300 mg capsule 2 hours preoperative and the same dose 6 hours postoperative.
89690315|NCT04342065|Active Comparator|Group (C)|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
89690316|NCT03179410|Experimental|Neuroendocrine prostate cancer (NEPC)|Subjects with neuroendocrine prostate cancer (NEPC). Avelumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
89690317|NCT05364892|Other|ANCA-associated vasculitis - patient library|It is a description of ANCA-associated vasculitis patients cohort. All the patients are included in one arm. They will undergo various type of samples.
89690318|NCT03655587|Experimental|Solid ankle foot orthotic|This is a leg brace that is made to fit the contour of the patient's foot, ankle, and lower leg. The two pull solid ankle AFO is fabricated from a rigid polypropylene outer boot and a more flexible silicone inner boot. It is commonly used in rehabilitation to improve gait in pediatric and adult populations. A certified orthotist fabricates the device. This device is lawfully marketed in the United States. It is not regulated by the FDA.
89690319|NCT03655587|Active Comparator|Resting night splint|An ankle resting night spring (RNS) is an off-the-shelf device that provides static sagittal plane dorsiflexion. The RNS is worn nocturnally to provide maximal stretch/length to the gastrocsoleus to maintain or increase dorsiflexion ROM and/or to prevent further regressions in ankle range. It is not regulated by the FDA.
89690320|NCT04982887|Experimental|Experimental Group|
89690321|NCT04982887|Experimental|Control Group|
89690322|NCT05364736|Experimental|Highland barley β-glucan group|Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 12 weeks followed by comprehensive physical and clinical examinations.
89690323|NCT05364736|Placebo Comparator|Placebo group|Participants will be given oral liquids mainly containing Corn starch once daily for 12 weeks followed by comprehensive physical and clinical examinations.
89690324|NCT05364346||Pregnant women|Pregnant women in the area of South-East Brabant, The Netherlands
89690325|NCT03155295||Physical reality simulation (rehearsal)|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. Participants with patients assigned to preoperative rehearsal will undergo pre-operative simulation only once.
89690326|NCT03155295||Virtual reality simulation|The DaVinci surgical skills simulator (DVSSS) uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. Participants with patients assigned to preoperative simulation will complete a refresher module on the Virtual reality simulator.
89690327|NCT04333030||Psychiatry|patients who come for psychiatric consultation
89690328|NCT04333030||addictology (other than tabacco)|patients who come for addictology consultation
89690329|NCT04333030||endocrinology|patients who come for endocrinology consultation
89222779|NCT04009616|Experimental|Aloe Vera mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving aloe vera mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying aloe vera mouthwash for 5 days rinsing phase."
89222780|NCT04009616|Experimental|Chlorhexidine mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving chlorhexidine mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying chlorhexidine mouthwash for 5 days rinsing phase."
89222781|NCT04009616|Placebo Comparator|Placebo mouthwash|"plaque accumulation and gingivitis will be evaluated before and after giving placebo mouthwash by studying plaque, gingival and bleeding indices.~the plaque will be accumulated for 3 days accumulation phase before applying placebo mouthwash for 5 days rinsing phase."
89222782|NCT00750035|Experimental|1|total abdominal hysterectomy and
89222783|NCT00750035|Experimental|2|Subtotal hysterectomy
89222784|NCT00106249|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
89222785|NCT00106249|Sham Comparator|Sham rTMS|Placebo Repetitive Transcranial Magnetic Stimulation (rTMS)
89222786|NCT00960128||A|Adult cohort
89222787|NCT00960128||B|Paediatric cohort
89222788|NCT01086943|Experimental|device arm|
89222789|NCT00960284|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
88820754|NCT05688475|Experimental|CC-122 and Dexamethasone|
89222790|NCT00960284|Experimental|Arm II|Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
89222791|NCT00105469|Experimental|AzaSite|1.0% azithromycin in DuraSite
89222792|NCT00105469|Active Comparator|Tobramycin|0.3% tobramycin
89222793|NCT05192408|Experimental|Multi-component intervention|"Individual intervention will comprise:~Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone.~Initial sessions will last around 30 minutes and subsequent sessions will last 15 to 30 minutes."
89222794|NCT05192408|Other|Usual Care|"Patient Education Materials (PEMs) on:~Exercise in older adults (Stay Active, Stay Strong and Stay Steady) - 3 different levels tailored to frailty level and for progression~Falls prevention~FoF"
89222795|NCT04009694|Experimental|Pelvic Floor Muscle Training|"Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist.~Participants will be assessed at weeks 0 / 4 / 10 & 16 and the outcome measures will be recorded at week 0 & week 16.~During each assessment, participants will be educated regarding the anatomy of pelvic organ prolapses and the pelvic floor muscles. They will be taught how to contract their pelvic floor, offered a vaginal examination, given a personalised pelvic floor muscle training programme (including the Knack) - up to a ten second hold long contractions (x 10 repitations) and up to 10 quick contractions. They will also be taught a sub max contraction for up to 30 seconds, offered lifestyle management advice including avoiding heavy lifting or straining. A leaflet explaining the aforementioned information will also be provided at the initial assessment."
89222796|NCT00960362|Placebo Comparator|A|
89222797|NCT00960362|Experimental|B|Intravenous cohort 1; 0.01 mg/kg
89222798|NCT00960362|Experimental|C|Intravenous cohort 2; 0.1 mg/kg
89222799|NCT00960362|Experimental|D|Intravenous cohort 3; 0.6 mg/kg
89222800|NCT00960362|Experimental|E|Intravenous cohort 4; 3.0 mg/kg
89222801|NCT00960362|Experimental|F|Intravenous cohort 5; 10 mg/kg
89222802|NCT00960362|Experimental|G|Intravenous cohort 6; 30 mg/kg
89222803|NCT00962312|Experimental|Capecitabine and Lapatinib|
89222804|NCT00962468|Experimental|Pathway|A care pathway will be implemented in this experimental group.
89222805|NCT00962468|No Intervention|Usual care|Usual care will be provided.
89222806|NCT00960518|Placebo Comparator|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
89222807|NCT00960518|Experimental|TACE+adefovir|patients received adefovir, at a dose of 10 mg daily after TACE treatment, for 48 weeks
89222808|NCT00960674|Experimental|Tactile massage|A gentle form of massage given once a week for three weeks
89222809|NCT00960674|Experimental|Relaxation|Relaxation (by the use of a CD with relaxation exercises used at least once a week for 10 weeks)
89222810|NCT04010864||SHARP-2|ShangHai At Risk for Psychosis-Phase 2
89222811|NCT01563146||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2006 and May the 31st 2007.
89222812|NCT00962546||CTA/CTP|Patients undergo CTA/CTP imaging prior to cerebral angiography
89222813|NCT05069948|Experimental|HeadOn intervention|Participants are given access to HeadOn - a web application that delivers a CBT programme to patients following concussion.
89222814|NCT00960830|Placebo Comparator|mirtazapine|
89222815|NCT00960830|Placebo Comparator|mirtazapine, sugar pill|
89222816|NCT00960908||Resolute|Prospective recruitment of Resolute arm will start in March 2009
89222817|NCT00960908||Endeavor|The retrospective recruiting period of Endeavor arm comprises a fixed 2-year time between January 2006 and December 2008. The patients, who were treated with Endeavor in that period, will be enrolled if they agree to participate in this study.
89222818|NCT00962702|Experimental|Exclusion of Left Atrial Appendage|Exclusion of Left Atrial Appendage
89222819|NCT00105235|Experimental|Alemtuzumab|Liver transplant, with two in-patient infused doses of alemtuzumab; followed by maintenance immunotherapy with cyclosporine, mycophenolate mofetil, and/or tacrolimus; with possible immunosuppression withdrawal
89222820|NCT03962803|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89222821|NCT03962803|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
89222822|NCT03962803|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
89222823|NCT00547118|Experimental|1|Rimonabant
89222824|NCT00547118|Placebo Comparator|2|Placebo
89222825|NCT01087021|Experimental|cabazitaxel|"At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2.~An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion."
89222826|NCT01084525|Experimental|OTO-104 (steroid) 3 mg|
89222827|NCT01084525|Placebo Comparator|Placebo|
89222828|NCT01084525|Experimental|OTO-104 (steroid) 12 mg|The start of 12 mg dose cohort is contingent on safety data from 3 mg dose cohort.
89222829|NCT00962936|Experimental|CT-011|
89222830|NCT00502593|Experimental|GSK1562902A-A Lot 1 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222831|NCT00502593|Active Comparator|Fluarix-A 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222832|NCT00502593|Experimental|GSK1562902A-A Lot 1 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222833|NCT00502593|Active Comparator|Fluarix-A 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222834|NCT00502593|Experimental|GSK1562902A-B Lot 2 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222835|NCT00502593|Active Comparator|Fluarix-B 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222836|NCT00502593|Experimental|GSK1562902A-B Lot 2 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222837|NCT00502593|Active Comparator|Fluarix-B 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222838|NCT00502593|Experimental|GSK1562902A-C Lot 3 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222839|NCT00502593|Active Comparator|Fluarix-C 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222840|NCT00502593|Experimental|GSK1562902A-C Lot 3 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222841|NCT00502593|Active Comparator|Fluarix-C 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
89222842|NCT01087099|Experimental|Albendazole|Treatment with albendazole
89222843|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15|POS 200 mg three times a day (TID) on Days 1-8 followed by continued randomized dosing regimen of POS 200 mg TID on Days 9-15, administered with food or oral nutritional supplements.
89222844|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg twice a day (BID) on Days 9-15, administered with food or oral nutritional supplements.
88812685|NCT01203722|Active Comparator|REGIMEN B2|"Pre-PBSCT:~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~Day -1: 400 cGy TBI administered in a single fraction~Day 0: Peripheral Blood Stem Cell Transplant (PBSCT)~Post-Transplantation Immunosuppression Consisting of:~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~Day 5: Sirolimus loading dose 6 mg PO once~Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)~Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
89222845|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg TID on Days 9-15, administered with food or oral nutritional supplements.
89222846|NCT04009538|Experimental|COPD patients participated PR program|COPD patients participated first and second PR program
89222847|NCT02561741|Experimental|COV155|
89222848|NCT00750113|Experimental|Arm 1|
89222849|NCT00750113|Experimental|Arm 2|
89222850|NCT00750113|Experimental|Arm 3|
89222851|NCT04971590||Participants with Lupus Nephritis|
89222852|NCT00745511|Active Comparator|1|
88820755|NCT05685784|Experimental|Healthy volunteer|"20 Healthy volunteers required for gait measurement: Standard gait analysis whilst simultaneously wearing the investigational sensor dots~15 Non-MS patients with an indication for polysomnography (PSG): Standard PSG whilst simultaneously wearing the investigational sensor dots"
89222853|NCT00745511|Active Comparator|2|
89222854|NCT00745511|Placebo Comparator|3|
89222855|NCT00961376|Active Comparator|Cohort A|PBMC re-infusion
89222856|NCT00961376|Experimental|Cohort B|CD25 depletion
89222857|NCT00545688|Experimental|1|
89222858|NCT00545688|Experimental|2|
89222859|NCT00545688|Experimental|3|
89222860|NCT00545688|Experimental|4|
89222861|NCT01563380|Experimental|PRP arm|Platelet-rich plasma was applied over the wound including the capsule, medial and lateral recesses.
89222862|NCT01563380|No Intervention|Control Arm|
89222863|NCT00961610||Internet support group Intervention|
89222864|NCT00961610||Control group|
89222865|NCT00961766|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010 or matching placebo
89222866|NCT00961766|Placebo Comparator|Placebo|Participants may be randomized to escalating doses of BG00010 or matching placebo
89222867|NCT00502203|Experimental|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m^2 intravenously (IV) over 3 hours and Carboplatin AUC 5 IV over 1 hour every 21 Days for 6 courses.
89690330|NCT03324724|Experimental|Adolescents with Eating Disorder|Adolescents with bulimia nervosa or binge eating disorder, with one or more of their parents, will receive integrative cognitive-affective therapy for adolescents (ICAT-A).
89690331|NCT03157336|Experimental|Peer-led Intervention|Peers (community women in leading roles) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial.
89690332|NCT03157336|Experimental|Specialist-led Intervention|Specialists (nutritionists) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial..
89690333|NCT05241392|Experimental|CAR-T cell therapy|"Dose-escalation phase:~A 3+3 dose-escalation design is used to determine MTD & R2PD. Anti-B7-H3 autologous CAR-T cells were given biweekly to patients at the following doses for each cycle, and 4 cycles as one course. Dose1: 3 patients at a dose of 20 million cells for each cycle. Dose 2: 3 patients at a dose of 60 million cells for each cycle. Dose 3: 3 patients at a dose of 150 million cells for each cycle. Dose 4: 3 patients at a dose of 450 million cells for each cycle. Dose 5: 3 patients at a dose of 900 million cells for each cycle.~R2PD confirmation phase:~Determine the R2PD based on the results from the previous dose-escalation study; Treat another 12 patients with anti-B7-H3 autologous CAR-T cells biweekly at the R2PD to further confirm the safety of R2PD.~At each dose phase, if the patients show tolerate and response to the treatment, these patients would receive several courses of treatment at PI's discretion."
89690334|NCT00421863|Other|Intensive Strategy|
89690335|NCT00421863|Other|Usual Strategy|
89690336|NCT02853292||amoxicillin crystalluria|
89690337|NCT03131102||Patients with epithelial ovarian cancer (EOC)|Patients undergoing cytoreductive surgery due to epithelial ovarian cancer
89690338|NCT03131102||Subgroup - Metabolomics in EOC patients without ascites|In a subgroup (n=10), patients without preoperative ascites will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
89690339|NCT03131102||Subgroup - Metabolomics in EOC patients with ascites >500ml|In a subgroup (n=10), patients with preoperative ascites >500ml will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
89690340|NCT05363956|Active Comparator|miswak|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique. The technique will be demonstrated to the patient and an image of the technique provided to the participants.
89690341|NCT05363956|Active Comparator|eucalyptus oil|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique. The technique will be demonstrated to the patient and an image of the technique provided to the participants.
89690342|NCT00636818|Experimental|Atomoxetine|
89690343|NCT05363722|Experimental|Arm A（IBI310 0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1，Q3W
89690344|NCT05363722|Experimental|Arm B（IBI310 0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1，Q3W
89690345|NCT05363566|Active Comparator|group I|will be inserted Single use supraglottic airway ( Baska mask® (proact Medical Ltd, Northants, UK)
89690346|NCT05363566|Active Comparator|group II|will be inserted Single use supraglottic airway ( I-gel® ) (Intersurgical Ltd, Wokingham, Berkshire, UK)
89690347|NCT05363566|Active Comparator|group III (SP Air-Q) (n = 26)|will be inserted Single use supraglottic airway (self-pressurized Air-Q intubating laryngeal airway (Air-Q SP®)) (Mercury Medical, Clearwater, FL, USA)
89690348|NCT03127995|Experimental|HYPOFRACTIONATED|"40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions~or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions"
89066563|NCT01024231|Experimental|Cohort 8: Nivolumab+Ipilimumab|"Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg solution intravenously q3 weeks, 4 doses for 12 weeks~Followed by Nivolumab 3 mg/kg solution alone intravenously q2 weeks, 48 doses for a maximum of 96 weeks"
89066564|NCT01077544|Experimental|Group 1|1 year to < 10 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
89066565|NCT01077544|Experimental|Group 2|>= 10 years to <18 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
89066566|NCT04297969||GCK Glow fixation|Patients screened with GoCheck Kids flash concentrated iPhone 7+
89066567|NCT04543201|Experimental|Early STructured Advanced care Referrals by Telehealth|"Early START visit using checklist over telephone or zoom:~A telehealth visit conducted within 4 months of patient diagnosis, with the goal of encouraging patients to discuss and document their end-of-life wishes prior to the onset of cognitive impediments common among patients with late-stage high grade glioma."
89066568|NCT02871583|Active Comparator|lichtenstein|lichtenstein procedure
89066569|NCT02871583|Active Comparator|Kugel|Kugel procedure
89066570|NCT02871583|No Intervention|control|healthy volunteers
89066571|NCT02871817||Normal Vision|Patients without significant vision deficit (20/20 vision), when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
89066572|NCT02871817||Age-related macular degeneration|Patients presenting with dry AMD or neovascular (wet) AMD, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
89066573|NCT02871817||Diabetic retinopathy|Patients presenting with Diabetic Retinopathy, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
89066574|NCT01075516||Standard Follow Up|ICD patients followed through periodic in-hospital visits
89066575|NCT01075516||Remote Follow Up|ICD patients followed with remote transmitters (Merlin@Home) that periodically communicate correct system functioning
89066576|NCT04299763|Experimental|Beta-Glucan (BETA)|experimental group, received a supplement of oats beta-glucan (5 g) for 12 weeks.
89066577|NCT04299763|Placebo Comparator|Control (CN)|placebo group, received a supplement of cellulose microcrystalline (5g) for 12 weeks.
89066578|NCT02871427|Experimental|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
89066579|NCT01012999|Experimental|Intranasal sufentanil, pain relief|Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period
89066580|NCT00628381|Experimental|AA|24 ICU patients with severe sepsis will get a L-citrulline 8 h enteral supplementation.
89066581|NCT00628381|Active Comparator|AB|24 ICU patients with severe sepsis will get an alternative isocaloric amino acid supplementation (L-alanine) during 8 hours
89066582|NCT04297813|Active Comparator|Control|The gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.
89066583|NCT04297813|Experimental|Test|Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate
89222868|NCT03049371|Other|sample size 100|24 post-op and 100 pre- non- and post-op TGW Study participants need to be of Thai nationality, at least 18 years old, male at birth and self-identify as post-op TGW for participation in study. Signed informed consent is required for study participation
89222869|NCT00546078|Experimental|Cervarix™ 4-Dose Group|Subjects who had received 3 doses of Cervarix™ in study 580299/001 (NCT00689741), received a 4th dose of Cervarix™ on Day 0 in the current study.
89222870|NCT00546078|Experimental|Cervarix™ 3-Dose Group|Subjects who had received 3 doses of placebo in study 580299/001 (NCT00689741), received 3 doses of Cervarix™ (Day 0, Month 1 and Month 6) in the current study.
89222871|NCT04819256|Experimental|Intervention arm|Providers use PACE-It mobile application as a care co-ordination platform
89222872|NCT04819256|No Intervention|Usual care|Providers use usual modes of communication (e.g., phone calls, emails)
89222873|NCT03035565|Experimental|Computerized Cognitive Training Brain HQ|Computerized cognitive training intervention using Brain HQ initiated and continued 1 hour/day, 5 days/week for 8 weeks
89222874|NCT03035565|Active Comparator|Computerized Crossword Puzzles|General cognitive stimulation puzzles intervention initiated and continued 1 hour/day, 5 days/week for 8 weeks
89222875|NCT03035565|No Intervention|Usual Care|No computerized cognitive intervention
89222876|NCT00967772|Experimental|Naftopidil|
89222877|NCT00967850|Experimental|Intravitreal Bevacizumab|Intravitreal injections of bevacizumab
89222878|NCT00967850|Active Comparator|Visudyne|Photodynamic Therapy with Visudyne
89222879|NCT00965016|Sham Comparator|No Hypothermia, No intervention, ECMO|No hypothermia used during ECPR
89222880|NCT00965016|Active Comparator|Hypothermia, intervention, ECMO|Hypothermia + intervention
89222881|NCT00965016|Active Comparator|Hypothermia, no intervention, ECMO|Hypothermia without intervention after ECMO
89222882|NCT00967928|Experimental|Single arm|All subjects receive RAD001 in combination with standard field whole pelvic radiation and cisplatin.
89222883|NCT00546000|Experimental|1|Receive between 22 and 29 days of Cutivate lotion treatment
89222884|NCT00963404|Experimental|Tumor-boost|Image-guided tumorboost of the bladder cancer.
89222885|NCT00968006|Experimental|Treatment|Sitagliptin 100 mg once daily for 4 weeks
89222886|NCT00968006|No Intervention|Control|No change in anti-diabetic treatment regimen for at least 4 weeks.
88820756|NCT05685784|Experimental|People with MS|"20 patients with MS required for gait measurement: Standard gait analysis whilst simultaneously wearing the investigational sensor dots~15 MS patients with an indication for polysomnography (PSG): Standard PSG whilst simultaneously wearing the investigational sensor dots"
89222887|NCT00971022||Low-income Populations|
89222888|NCT00963716|Experimental|Hot biopsy|Hot biopsy i.e. Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
89222889|NCT00963716|Active Comparator|Cold biopsy|Cold biopsy i.e. Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
89222890|NCT00971100|Experimental|low dose of antigen + low dose of adjuvant|
89222891|NCT00971100|Experimental|high dose of antigen + high dose of adjuvant|
89222892|NCT00971100|Experimental|high dose of antigen|
89222893|NCT00971256||Bladder cancer patients|Bladder cancer patients from one Beaumont Urologist.
89222894|NCT00968162|Experimental|Dose de-escalation|
89222895|NCT00501969|Experimental|Rotigotine|Rotigotine
88820757|NCT05685732|Experimental|Cohort 1: SDX/d-MPH in 4-5 year old|13.1 mg/2.6 mg SDX/d-MPH, 26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH
89222896|NCT03942042|Experimental|Ixekizumab|"Induction Dosing Period:~Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10.~Maintenance Dosing Period:~Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study.~Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1."
89222897|NCT00968318|Other|Rate of seroma formation|Excision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion
89222898|NCT00968396|Experimental|Stem Cell Collection + Transplantation|Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m^2 IV over 30 minutes daily on Days -2 and -1.
89222899|NCT04008732|Experimental|MED2005 (0.6 mg)|MED2005 (0.2% GTN) gel to be used topically in Part 1 of the study
89222900|NCT04008732|Experimental|MED2005 (1.2 mg)|MED2005 (0.4% GTN) gel to be used topically in Part 1 of the study
89222901|NCT04008732|Experimental|MED2005 (1.8 mg)|MED2005 (0.6% GTN) gel to be used topically in Part 1 of the study
89222902|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 1|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
89222903|NCT04008732|Active Comparator|Nitrostat (1.8 mg) - Treatment Period 2|3 x 0.6 mg tablets will be required to make up the 1.8 mg dose to be used orally in Part 1 of the study but to be dosed in two treatment periods
89222904|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 1|MED2005 (0.8% GTN) gel to be used topically in Part 1 of the study
89222905|NCT04008732|Active Comparator|Intravenous (I.V.) dose of GTN (0.3 mg)|GTN solution for infusion (1 mg/ml) to be used intravenously in Part 2 of the study
89222906|NCT04008732|Experimental|MED2005 (2.4 mg)- Part 2|MED2005 (0.8% GTN) gel to be used topically in Part 2 of the study
89222907|NCT01013727|Experimental|Postural Reconstruction|
89222908|NCT01013727|Active Comparator|muscular stretching|
89222909|NCT00960180|Experimental|1|
89222910|NCT00960180|Placebo Comparator|2|
89222911|NCT00963794|Other|Electromagnetic measurement|Electromagnetic measurement to detect rectal cancer.
89222912|NCT03992040||Reinforced SSIAD (SSIADR arm )|"Reinforced Home Nursing Care Services: Patients with a score between 11 and 21 on the regional public health authorities (ARS) score.~This arm will benefit from better coordination and delivery of care, which can reduce hospitalizations and visits to emergency departments"
89222913|NCT03992040||Classic SSIAD (Control arm)|Classic Home Nursing Care Services. For this arm, no direct benefit is expected since taking care, even for the heaviest patients, corresponds to current practice.
89222914|NCT04593290|Experimental|Mild Cognitive Impairment (MCI)|MCI is defined as an early stage of cognitive decline that lies between normal age-matched cognitive function and the onset of very mild forms of dementia, and is associated with a slight but noticeable decline in abilities such as memory and thinking skills. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
89222915|NCT04593290|Active Comparator|Cognitively Healthy|This group is 40-85 years old and has no significant neurological or psychiatric disease. Listening effort testing (with pupillometry) and cognitive testing will be administered for this group - and after a 6-week period of hearing aid use, these measures will be re-tested.
89222916|NCT00971490|Experimental|Group 1|
89222917|NCT00971490|Placebo Comparator|Group 2|
89222918|NCT00971490|Sham Comparator|Group 3|
89222919|NCT01015365|Other|Surgical revision|Surgical cementless One-stage revision of the chronic infected hip arthroplasty
89222920|NCT01013805|Experimental|Arm 1|Integrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
89222921|NCT04491045|Experimental|Community-Engaged Learning Collaborative (CELC)|The CELC arm is an integration of community engagement and learning collaborative approach which involves province-wide collaborative meetings for commune health stations (6 CHSs for each province) randomized into the CELC implementation condition. CELC CHSs will meet monthly initially for 3 months, followed by bi-monthly meetings for 12 months to engage in continuous quality improvement process, track implementation goals, problem solve implementation barriers, and engage in cross-site learning. This is in addition to usual implementation condition (supervision, workshops, technical assistance, and evidence-based toolkit)
89229836|NCT03742778|Experimental|Incentivizing Exercise|"Participants will receive three texts each week asking a question for them to reflect on. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you are feeling now? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
88820758|NCT05685732|Placebo Comparator|Cohort 1: Placebo in 4-5 year old|matching placebo
89066584|NCT00637663|Experimental|A|entecavir 0.5 mg QD
89066585|NCT00637663|Active Comparator|B|lamivudine 100 mg QD
89066586|NCT04299529|Experimental|HTM plus UPP|Urinary proteomic profiling administered on top of home blood pressure telemonitoring and guideline-endorsed non-pharmacological and pharmacological management of risk factors
89066587|NCT04299529|Other|HTM alone|Home blood pressure telemonitoring administered on top of non-pharmacological and pharmacological management of risk factors
89066588|NCT01017601|Experimental|Arm I|Patients receive a single dose of Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1.
89066589|NCT01017601|Placebo Comparator|Arm II|Patients receive a single dose of placebo IV over 1 hour on day 1.
89066590|NCT04297735|Active Comparator|Standard of care group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
89066591|NCT04297735|Experimental|Telemedicine group|Discuss new arrhythmias, review symptoms, discuss methods to help symptoms, questions and answers, monitor devices every 3 months
89066592|NCT01016977|Active Comparator|Duac & taz|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
89066593|NCT01016977|Active Comparator|Acanya & taz|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
89066594|NCT02871661|Active Comparator|Amitriptyline|This group will be treated with medication alone (amitriptyline hydrochloride, 25 mg) for chronic vulvar pain (vulvodynia).
89066595|NCT02871661|Active Comparator|Amitriptyline plus kinesiotherapy|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus pelvic floor exercises such as Kegel contractions and stretching of pelvic floor muscles with patients own hands.
89222922|NCT04491045|Experimental|Enhanced Supervision (ES)|This is an evidence-based training approach which involves 6-9 months of ongoing group supervision support from psychiatric hospital mental health specialist (psychiatrist, psychiatric nurse, or psychologist) for each community health station randomized to the ES condition. Supervision approach is structured and involves observation of sessions, feedback on fidelity and quality. Supervision support will be provided biweekly initially and monthly after completion of one practice case. This is in addition to usual implementation condition (workshops, technical assistance, and evidence-based toolkit)
89222923|NCT04491045|Active Comparator|Usual Implementation (UI)|"Usual Implementation (UI) Control intervention that will be enhanced usual implementation and includes hybrid training workshops on basic implementation and training supports for Multicomponent Collaborative Care for Depression program, which is an evidence-based stepped collaborative care intervention for integrating depression care into primary care settings. It consists of six components: routine screening, diagnostic assessment, psychoeducation, antidepressant medication, adherence management, behavior activation therapy.~This implementation and training supports includes a series of online training modules, weekly webinars, and 3 one-day in-person workshops on collaborative care for depression (MCCD), limited technical assistance, and toolkit."
89222924|NCT00104299|Experimental|Rituximab|
89222925|NCT00104299|Active Comparator|Control Group|
89222926|NCT03939312|Experimental|Atogepant 60 mg|Participants received atogepant 60 mg, orally, once daily (QD) for up to 40 weeks.
89222927|NCT00968552||Patients undergoing stent placement|Patients who are scheduled to undergo stent placement via endoscopy as part of their routine medical care.
89222928|NCT00968630|Experimental|Treatment (HIV-specific immune reconstitution after HCT)|Patients undergo leukapheresis for analysis of HIV-1 latent reservoir at baseline and at days +90, +180, +365, and +730, and then annually thereafter as feasible.
89222929|NCT00963950|Experimental|Intervention group|transvaginal cholecystectomy
89222930|NCT00963950|Active Comparator|laparoscopic cholecystectomy|Laparoscopic cholecystectomy (4 port)
89222931|NCT01563432|Experimental|febuxostat (TR)|
89222932|NCT01563432|Experimental|febuxostat (RT)|
89222933|NCT00968786|No Intervention|no home monitoring|no automated measuring devices for patients use at home
89222934|NCT00960258|Experimental|Arm 1|
89222935|NCT04566926|Experimental|Part 1: Cohort 1 (Placebo or JNJ-64140284)|Participants will receive matching placebo in Treatment A or JNJ-64140284 (as formulation 1) in Treatment B or JNJ-64140284 (as formulation 2) in Treatment C on Day 1 under fasted condition. Participants will receive treatment in either of the 6 treatment sequences (ABC, BCA, CAB, CBA, ACB or BAC) in Period 1, 2, or 3 under fasted condition. Each period is separated by washout period of 5 days.
89222936|NCT04566926|Experimental|Part 1: Cohort 2 (Placebo or JNJ-64140284)|Participants will receive matching placebo (Treatment D) or JNJ- 64140284 (as formulation 1) in Treatment E or JNJ-64140284 (as formulation 2) in Treatment F. Participants will receive treatment in either of 6 treatment sequence (DEF, EFD, FDE, FED, DFE or EDF) in Period 1, 2, or 3 under fed condition. Each period is separated by washout period of 5 days.
89222937|NCT04566926|Experimental|Part 2: Cohorts 1-7 (JNJ-64140284 or Placebo)|Participants will receive JNJ 64140284 formulation 1 or 2 or matching placebo under fasting condition in Cohorts 1 to 7 on Day 1.
89222938|NCT04566926|Experimental|Part 3: Cohorts 1-2 (JNJ-64140284 or placebo)|Participants will receive JNJ-64140284 formulation 1 or 2 or matching placebo under fed condition in Cohorts 1 to 2 on Day 1.
89222939|NCT00971568||Urine sample|To prepare for SELDI-TOF we will use 15 samples. Each sample (25ul) will be analyzed with the Luminex 100 IS (MiraiBio, South San Francisco, CA) using a LINCOplex cytokine/che-
89222940|NCT00082381|Experimental|Exenatide Arm|exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
89222941|NCT00082381|Active Comparator|Insulin Glargine Arm|subcutaneous injection, once daily; forced titration to target blood glucose level
89222942|NCT00964106|Experimental|Probe drugs|"Caffeine 100 mg CYP1A2 Pioglitazone 15 mg CYP2C8 Flurbiprofen 40 mg CYP2C9 Omeprazole 20 mg CYP2C19 Dextromethorphan 45 mg CYP2D6 Midazolam 3 mg (Part 1, Part 2 Cohorts B and C)~1 mg (Part 2 Cohort A) CYP3A4/5 Rosuvastatin 10 mg OATP1B1"
89222943|NCT00964106|Experimental|Default Inhibitors|A Ketoconazole 400 mg once-daily Day 1 through Day 9 CYP3A4 B Fluconazole 400 mg x1 dose on Day 1 200 mg once-daily Day 2 through Day 9 CYP2C9 C Rifampin 600 mg x1 dose on Day 1 and Day 8 OATP1B1
89222944|NCT00960336|Experimental|single arm|
89222945|NCT00971646||OAB|Patients with overactive bladder syndrome
89222946|NCT00971646||Osteoporosis|Patients with osteoporosis
89222947|NCT00965172|Experimental|Caphosol|Caphosol (calcium phosphate)
89222948|NCT00965172|Active Comparator|Baking Soda|Control Group (standard of care)
88820759|NCT05685732|Experimental|Cohort 2: SDX/d-MPH in 6-12 year old|26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH, 52.3 mg/10.4 mg SDX/d-MPH
88820760|NCT05685732|Placebo Comparator|Cohort 2: Placebo in 6-12 year old|matching placebo
89222949|NCT01084681|Active Comparator|SILK Artery Reconstruction Device|One arm will receive only the commercially available SILK Artery Reconstruction Device [flow diverter] (no intracranial coils are to be used in association with the SILK device).
89222950|NCT01084681|Active Comparator|Coils|The other arm will be treated with commercially available intracranial coils: the coils can be used with eventual balloon remodeling and/or stents when necessary.
89222951|NCT04505852|Experimental|EMBRACE USERS|Embrace wristband users
89222952|NCT00969020|Active Comparator|Telemedicine|RRS via telemedicine. By developing the concept of Remote Rehabilitation Support (RRS) the investigators will try to bring preoperative education of the patient, dissemination of information and postoperative support to a new level.
89222953|NCT00969020|No Intervention|Standard|The standard procedure for THA used under The Lundbeck Center for fast track hip and knee surgery
89222954|NCT03962413|Active Comparator|The middle meatal antrostomy approach.|"The middle turbinate will be gently moved medially. Then uncinectomy is the next step which will be performed in numerous ways. Once the natural ostium will be identified, an ostium seeker will be placed through the ostium and then carefully will be pushed posteriorly to widen the ostium.~Using a through-cutting forceps, the ostium will be enlarged."
89229837|NCT01004588|Experimental|Protein drink|protein drink
89066596|NCT02871661|Active Comparator|Amitriptyline plus IC (Quark)|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus electrical stimulation with Interferential Current (manufacturer: Quark Medical; Model: Dualpex 961 - program number 42): two electrodes put into the perineal surface area emitting interferential current, once a week for twenty minutes each, for eight weeks long.
89066597|NCT01012765|Experimental|Indacaterol - placebo - tiotropium|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
89066598|NCT01012765|Experimental|Placebo - Tiotropium - Indacaterol|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
89066599|NCT01012765|Experimental|Tiotropium - indacaterol - placebo|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
89229838|NCT01004588|Placebo Comparator|Placebo drink|Placebo drink
89229839|NCT00056407|Placebo Comparator|Placebo Arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
89066600|NCT01012765|Experimental|Placebo - indacaterol - tiotropium|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
89066601|NCT01012765|Experimental|Indacaterol - tiotropium - placebo|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
89066602|NCT01012765|Experimental|Tiotropium - placebo - indacaterol|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
89066603|NCT00628459|Active Comparator|1|
89066604|NCT00628459|Experimental|2|
89066605|NCT00628459|Experimental|3|
89066606|NCT00627913|Active Comparator|1|Healon 5
89066607|NCT00627913|Experimental|2|Retrobulbar Anesthetic Injection
89066608|NCT01010503|Experimental|Single Arm|
89066609|NCT00628537|Experimental|1|BION™ Experimental Group
89066610|NCT00628537|Active Comparator|2|Surface Stimulation Group
89066611|NCT00628537|Active Comparator|3|Control Group with conservative therapy (Range of motion exercises)
89066612|NCT05006053||Qualitative study with healthcare professionals|Healthcare professionals working in Child and Adolescent Mental Health Services, Sexual Assault Referral Centres or with e-therapy providers
89066613|NCT04297657|Experimental|intervention group|
89066614|NCT04297657|No Intervention|control group|
89066615|NCT04472845|Experimental|1 week|Radiotherapy dose to chest wall, axilla level III and supraclavicular fossa will be of 26Gy in 5 fractions over 1 week in the study arm. BCS patients will receive a sequential boost of 8Gy/2#/2days or simultaneous integrated boost(SIB) to a total dose of 34Gy.Supraclavicular fossa(SCF) and axilla level III will be treated in patients with T3-4 disease with lymphovascular invasion, grade 3 or N2 disease and T3-4 disease treated with neoadjuvant chemotherapy after adequate axillary dissection. Level I and II axilla will only be irradiated in patients with inadequate axillary dissection(<10 lymph nodes). Internal mammary node (IMNs) radiation will be done in T3-4 central and inner quadrant lesions and patients with N2 disease. IMNs will be irradiated with a separate single field. The first five intercostal spaces will be included in the IMN target volume.
89066616|NCT04472845|Active Comparator|2 week|Radiotherapy dose to chest wall, axilla level III and supraclavicular fossa will be 34Gy in 10 fractions over 2 weeks in the control arm. BCS patients will receive a sequential boost of 8Gy/2#/2days or simultaneous integrated boost(SIB) to a total dose of 42 Gy.
89066617|NCT01006291|Experimental|IDeg OD FF|
89066618|NCT01006291|Experimental|IDeg OD|
89066619|NCT01006291|Experimental|IGlar OD|
89066620|NCT02871349|Experimental|Propanolol and MRI|Participants will receive propranolol via oral capsule, crushed tablet, or liquid daily. The drug dosage will be titrated slowly to ensure the drug is tolerated well. Those aged 15-24 will have an MRI before starting drug.
89066621|NCT02871349|Placebo Comparator|Placebo and MRI|Participants will receive placebo via oral capsule, crushed tablet, or liquid daily. Those aged 15-24 will have an MRI before starting drug.
89066622|NCT01006135||COPD patients|
89066623|NCT01012609|Experimental|pts with high-grade astrocytoma|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
89222955|NCT03962413|Active Comparator|The endoscopic prelacrimal recess approach|A curved incision will be made between the anterior aspect of the IT and the posterior end of the nasal vestibule.the mucoperiosteum will be lifted posteriorly.Bone removal will be achieved. the anterior bony portion of the medial wall of the MS will be removed, .then the IT-NLD flap will be formed.The prelacrimal recess will be opened
89229840|NCT00056407|Experimental|dustasteride arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.
89066624|NCT01012609|Experimental|pts with diffuse pontine tumor|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
89066625|NCT04297501||All participants|All enrolled participants in this study
89066626|NCT04298749|Experimental|GX-P1 dose level 1|GX-P1 dose level 1
89066627|NCT04298749|Experimental|GX-P1 dose level 2|GX-P1 dose level 2
89066628|NCT04298749|Experimental|GX-P1 dose level 3|GX-P1 dose level 3
89066629|NCT04298281||Parents of patients who have a family care conference criteria|These will be parents of patient who have one of our defined family care conference criteria
89066630|NCT04298281||Parents of patients who do not have a family care conference criteria|These will be parents of patients who do not have one our defined family care conference criteria
89066631|NCT04298515|Other|Type 2 Diabetes group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
89066632|NCT04298515|Other|Insulin resistance group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
89066633|NCT04298515|Other|Obesity group|In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
89066634|NCT01012219|Experimental|Period 1|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
89066635|NCT01012219|Experimental|Period 2|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
89066636|NCT01012219|Experimental|Period 3|
89222956|NCT03962413|Active Comparator|The canine fossa approach.|"It will be done either transnasally or transorally:~** The transoral approach through a sublabial incision : CFA consist in a trocar placed in the canine fossa.After removal of the trocar a 4-mm microdebrider blade will be placed through the passage created by the trocar.~** The transnasal approach: A curved incision will be made between the anterior aspect of the Inferior Turbinate and the posterior end of the nasal vestibule,the mucoperiosteum will be lifted posteriorly Then the investigators will reach the anterior wall of the maxillary sinus through bone removal which will be achieved using a gauch and hammer and a high-speed electric drill."
89222957|NCT00545844|Experimental|1|montelukast sodium
89229841|NCT00388726|Experimental|1|
89222958|NCT01084915||SAGB VC group|Retrospectively patients with a SAGB-VC gastric band are inventorized. They will also be interviewed and BAROS scores will be taken.
89222959|NCT01084993|Active Comparator|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
89222960|NCT01084993|Active Comparator|Heparin|70 U/kg or standard practice
89222961|NCT00492063|Experimental|Cell culture-derived influenza vaccine (cTIV)|
89222962|NCT00492063|Active Comparator|Egg-derived influenza virus vaccine (TIV)|
89222963|NCT04008654|Active Comparator|ERAS group|This groups will receive ERAS protocol
89222964|NCT04008654|Placebo Comparator|Conventional care|This group will not receive the ERAS protocol.
89222965|NCT01085071|Active Comparator|Normal-high potassium (NHP)|A potassium target of 4.5 mmol/L.
89222966|NCT01085071|Active Comparator|Normal-low potassium (NLP)|A potassium target of 4.0 mmol/L.
89222967|NCT00960492|Experimental|Arm 1|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent during the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase.
89222968|NCT00960492|Experimental|Arm 2|XL184 will be initiated during the maintenance phase with TMZ
89066637|NCT04298125|Experimental|Exercise in Pregnancy in Community|The Expecting intervention at the ACNC includes three 30-45 minute, in-person exercise sessions per week. The sessions are gradually increased in length over the first weeks of participation, and are comprised of 15-30 minutes of moderate aerobic activity (recumbent bike, walking on a treadmill or on an elliptical machine) as well as 5-10 minutes of resistance training using hydraulic exercise equipment. The sessions conclude with stretching exercises. Throughout the session, a personal trainer assesses the rating of perceived exertion using the 6 to 20 point Borg scale of exhaustion.41 Between sessions, participants are asked to monitor their daily step count with a target of 10,000 steps per day using a pedometer provided to the participant. This number is reported to or downloaded by the personal trainer at each in-person session. These elements will be adapted to provide a similar exercise experience that is accessible to women in their local community.
89066638|NCT04298125|No Intervention|Standard Care|Participants will receive guidance on exercise from their physician as usual.
89066639|NCT01011907|Experimental|varenicline|Drug: varenicline (Chantix) 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
89066640|NCT01011907|Placebo Comparator|placebo|Drug: placebo for varenicline 12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
89066641|NCT01011673|Active Comparator|Ketorolac|Ketorolac 30mg IVSS
89066642|NCT01011673|Active Comparator|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
89066643|NCT01011439|Experimental|Milciclib Maleate (PHA-848125AC)|100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
89066644|NCT01311024||Sibling vaccinated with PCV GSK1024850A|"Older sibling of a child vaccinated with Pneumococcal conjugate vaccine GSK1024850A in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
89066645|NCT01311024||Control-vaccinated sibling|"Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
89066646|NCT02871193|Sham Comparator|Group C（Control）|Group C received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml combined with general anesthesia and intravenous patient controlled analgesia pump.
89066647|NCT02871193|Experimental|Group R(Ropivacaine)|Group R received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20 ml combined with general anesthesia and intravenous patient controlled analgesia pump.
89066648|NCT02871193|Experimental|Group D(Dexamethasone)|Group D received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg combined with general anesthesia and intravenous patient controlled analgesia pump.
89066649|NCT01310868|Experimental|5-ALA and Gliadel wafers|This is a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Gliadel wafers) in the surgical management of patients with GBM.
89066650|NCT01273155|Active Comparator|Normal Function-Belinostat 1000 mg/m(2)|Normal Liver Function was defined as bilirubin ≤Upper Limit of Normal (ULN) and aspartate aminotransferase (AST) ≤ ULN.
89066651|NCT01273155|Experimental|Mild Dysfunction-Belinostat 750 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin >Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) > ULN.
89066652|NCT01273155|Experimental|Mild Dysfunction-Belinostat 1000 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin >Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) > ULN.
89066653|NCT01273155|Experimental|Moderate Dysfunction-Belinostat 500 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin >1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
89066654|NCT01273155|Experimental|Moderate Dysfunction-Belinostat 750 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin >1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
89066655|NCT01273155|Experimental|Severe Dysfunction-Belinostat 250 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin >3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
89066656|NCT01273155|Experimental|Severe Dysfunction-Belinostat 350 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin >3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
89066657|NCT05557851|Experimental|Open Label Study of Minnelide in Patients with Metastatic Adenocarcinoma of the Pancreas|This is an open-label, Phase 1b study of MinnelideTM given once a day on Days 1 to 5, Days 8 to12 and Days 15 to 19 in combination with SOC (nab-paclitaxel [Abraxane] plus gemcitabine). The study will be conducted in patients with disease progression while on FOLFIRINOX as first treatment and who have had no prior treatment with nab-paclitaxel (Abraxane) plus gemcitabine or single agent nab paclitaxel or gemcitabine or in any other combinations. The total number of treatment cycles administered will be dependent on drug tolerability by patient.
89066658|NCT01005901|Experimental|Glycopyrronium bromide|Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
89066659|NCT01005901|Placebo Comparator|Placebo|Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
89066660|NCT02889549|Experimental|Ticagrelor 22.5 mg|Ticagrelor (22.5 mg, twice daily, oral) treatment for 1 month.
89066661|NCT02889549|Experimental|Ticagrelor 45 mg|Ticagrelor (45 mg, twice daily, oral) treatment for 1 month.
89066662|NCT02889549|Experimental|Ticagrelor 90 mg|Ticagrelor (90 mg, twice daily, oral) treatment for 1 month.
89066663|NCT02889549|Active Comparator|Clopidogrel|Clopidogrel (75mg, once daily, oral) treatment for 1 month.
89066664|NCT04968925|Experimental|O1D/P1|Eligible subjects that are habitual wearers of daily disposable soft contact lenses will randomly be assigned sequence (O1D/P1)
89066665|NCT04968925|Experimental|P1/O1D|Eligible subjects that are habitual wearers of daily disposable soft contact lenses will randomly be assigned sequence (P1/O1D)
89229842|NCT00388726|Active Comparator|2|
89222969|NCT00960492|Experimental|MTD Expansion|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent in the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase. Subjects in this group will receive XL184 and TMZ at the maximally tolerated dose levels determined in Arms 1 and 2.
89222970|NCT00971724|Placebo Comparator|Placebo|Treatment with placebo for 15 days
89222971|NCT00971724|Experimental|Prednisolone 7.5 mg daily|Treatment with prednisolone 7.5 mg daily for 15 days
89222972|NCT00971724|Experimental|Prednisolone 15 mg daily|Treatment with prednisolone 15 mg daily for 15 days
89222973|NCT00971724|Experimental|Prednisolone 30 mg daily|Treatment with prednisolone 30 mg daily for 15 days
89222974|NCT00971724|Experimental|Prednisolone 75 mg|Treatment with prednisolone 75 mg for a single day
89222975|NCT00971724|Experimental|Prednisolone 15 mg twice daily|Treatment with prednisolone 15 mg twice daily for a single day
89222976|NCT04331301|Active Comparator|vapoenucleation group|Group A
89222977|NCT04331301|Active Comparator|needlescopic enucleation|group B
89222978|NCT00971802|Experimental|Cohort 1|Healthy volunteers - PF-03882845 versus Placebo
89222979|NCT00971802|Experimental|Cohort 2|Healthy volunteers - PF-03882845 versus Placebo
89222980|NCT00971802|Experimental|Cohort 3|Healthy volunteers - PF-03882845 versus Placebo
89222981|NCT00971802|Experimental|Cohort 4|Healthy volunteers - PF-03882845 versus Placebo
89222982|NCT05181813|Experimental|Group 1: Ginge-Cal group:|primary molars were filled by creamy mixture pulpectomy paste of Gingerols and Calcium Hydroxide.
89222983|NCT05181813|Active Comparator|Group 2: Metapex group|primary molars were filled by a ready-made injectable creamy mixture pulpectomy paste of Metapex
89222984|NCT00971880||Patients receiving blood transfusions|All the patients with blood disorders that require blood transfusions
89222985|NCT02976909|Experimental|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
89222986|NCT00960648||Xience/Promus|Active prospective registration of patients receiving everolimus eluting stent
89222987|NCT00960648||Cypher|Retrospective historical controls that received sirolimus-eluting stent
89222988|NCT02878083|Experimental|VEDOLIZUMAB|300 mg IV
89222989|NCT00971958|Active Comparator|Mogen Clamp|
89222990|NCT00971958|Active Comparator|Plastibell|
89222991|NCT00971958|Active Comparator|AccuCirc|AccuCirc is a device approved by the FDA for circumcision of male infants up to ten days of life.
89222992|NCT00093145|Experimental|Albumin-bound paclitaxel, Carboplatin + Herceptin|Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.
89222993|NCT02808195|Experimental|constraint-induced therapy|training of the more affected arm and restraint the less affected arm
89066666|NCT01266993|Experimental|Nimenrix Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Nimenrix vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Nimenrix vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
89066667|NCT01266993|Experimental|Menjugate Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Menjugate vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Menjugate vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
89066668|NCT01309386|Experimental|Tapentadol ER|Tapentadol extended-release (ER) (JNS024ER) oral tablets 100 to 400 milligram (mg) daily for 8 weeks (maximum dose could be up to 500 mg daily), as per Investigator's discretion.
89066669|NCT01309386|Active Comparator|Morphine SR|Morphine sustained-release (SR) oral tablets 30 to 120 mg daily for 8 weeks (maximum dose could be up to 140 mg daily), as per Investigator's discretion.
89066670|NCT04295317|Experimental|Combined the therapy using Capecitabine and PD-1|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis) Capecitabine 2500mg / m2, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
89066671|NCT01266603|Experimental|HDIL-2 + recMAGE-A3 + AS15|HDIL-2 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle. recMAGE-A3 300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
89066672|NCT04295551|Experimental|Experimental group of ordinary COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
89066673|NCT04295551|Active Comparator|Control group of ordinary COVID-19|ritonavir/ritonavir treatment
89066674|NCT04295551|Experimental|Experimental group of severe COVID-19|Lopinavir / ritonavir tablets combined with Xiyanping injection
89066675|NCT01309308|Experimental|The membranes swept group|This group will have a sweeping of the membranes after the 38th of gestation at hospital, in order to reduce the latency period until labor. Sweeping of the membranes is done by the insertion of examiners finger between the decidua and fetal membranes and by the circular movement of the finger, the membranes are detached from the decidua.
89066676|NCT01309308|Sham Comparator|No sweeping group|This group will not have sweeping of the membranes, will only have vaginal ultrasound
89066677|NCT04282213||Control samples|For each case, neuromuscular measurements gathered with GE CARESCAPE B450 monitor (E-NMT module).
89066678|NCT04282213||Case samples|For each case, neuromuscular measurements gathered with TOFCuff monitor.
89229843|NCT01043614|Experimental|Peer group education|Small groups of female college freshmen facilitated by peer educators
89222994|NCT02808195|Experimental|kinect-based constraint-induced therapy|training of the more affected arm and restraint the less affected arm by kinect-game
89222995|NCT00965328|Active Comparator|hemofiltration at 4L/h|Hemofiltration was started at 4L/h and crossed over to 2L/h after 60 minutes of hemofiltration
89222996|NCT00965328|Active Comparator|hemofiltration at 2L/h|hemofiltration was started at 2L/h and crossed over to 4L/h after 60 min
89222997|NCT01014039|Active Comparator|Flexible Sigmoidoscopy Screening arm|Intervention by flexible sigmoidoscopy screening
89222998|NCT01014039|No Intervention|Control arm|No intervention (no screening)
89222999|NCT00965406|Placebo Comparator|glucose insulin potassium (GIK)|Glucose + insulin +6 potassium (GIK) infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours.
89223000|NCT00965406|Experimental|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
89223001|NCT00965406|No Intervention|Control group|No intervention and patients were treated with updated international recommendations of acute coronary syndrome.
89223002|NCT00960726|Experimental|NOV-002|
89223003|NCT00972036|Experimental|Unresectable colon cancer patients with liver metastases|This study will be performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.
89223004|NCT00513357|Experimental|Melatonin|20 mg of Melatonin before going to sleep at night for a period of 4 weeks.
89223005|NCT00513357|Placebo Comparator|Placebo|20 mg of Placebo before going to sleep at night for a period of 4 weeks.
89223006|NCT00960882|Experimental|DMMET-01|
89223007|NCT05163678||patient group|"All adolescents or young adults presenting for a consultation in the FSEF Relais systems.~They will be assessed upon entry into the device (T0), at the end of the follow-up (T1) and 6 months after the end of the follow-up (T6)."
89223008|NCT00972114|Experimental|CABG combined cardiomyoplasty|Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
89223009|NCT00972114|Active Comparator|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
89223010|NCT00972114|Active Comparator|CABG alone|Coronary artery bypass graft surgery alone
89223011|NCT01014117|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight oral placebo capsules once daily for 7 days.~A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days."
89223012|NCT01014117|Active Comparator|Placebo and 2.0g SRT2104|This treatment group will be administered eight oral placebo capsules once daily for 6 days followed by 2.0g SRT2104 administered as eight oral SRT2104 capsules on Day 7. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
89223013|NCT01014117|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight oral SRT2104 capsules once daily for 7 days. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
89229844|NCT01043692|Experimental|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
89229845|NCT03957655|Experimental|SHED group|SHED transplantation via peripheral vein: 1x10E6 SHEDs/kg body weight administered via peripheral vein at week 0,4,8,12.
89066679|NCT01266291|Other|Treatment with Sabril (vigabatrin)|This is a single arm study. All subjects who are eligible for treatment will begin taking vigabatrin (Sabril) during the third month of the study. Treatment will be in accordance with the FDA-approved prescribing information: upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
89066680|NCT00628771|Active Comparator|Usual Care|Participants will receive usual care for their prenatal visits.
89066681|NCT00628771|Experimental|CenteringPregnancy Plus|Participants will receive the CenteringPregnancy Plus treatment program, which includes an HIV/STD prevention component.
89066682|NCT01004263|Experimental|Rizatriptan|Rizatriptan benzoate
89066683|NCT01308762|Experimental|IMM-101|"Patients received an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28. Doses used were:~'Heat killed whole cell M. obuense (IMM-101) 0.1 mg', 'Heat killed whole cell M. obuense (IMM-101) 0.5 mg', or 'Heat killed whole cell M. obuense (IMM-101) 1.0 mg'"
89066684|NCT01265823|Experimental|Adalimumab|
89066685|NCT02890836||Pregnant women with pre-existing diabetes|Inclusion of 400 women is anticipated.
89066686|NCT02890836||Healthy pregnant women|Inclusion of 100 women is anticipated
89066687|NCT01004185|Experimental|High Dose|2.0 - 4.8 g/day Asacol dependent on body weight
89066688|NCT01004185|Experimental|Low Dose|1.2 - 2.4 g/day Asacol dependent upon body weight
89066689|NCT01265511|Placebo Comparator|Placebo|Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
89066690|NCT01265511|Active Comparator|SCY-635 600 mg|SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
89066691|NCT04325178|Experimental|Animal|Participants receive the majority of their protein from animal-derived protein sources (1.8g.kg.day).
89066692|NCT04325178|Experimental|Non-animal|Participants receive all their protein from non-animal-derived protein sources (1.8g.kg.day).
89066693|NCT04325100|Experimental|Switch - i|Individual sessions
89066694|NCT04325100|Experimental|Switch - g|Group programme
89066695|NCT04324788||Group 1|"Transtibial amputation~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
89223014|NCT00960960|Experimental|Part 1 (Cohort 1-2): Pictilisib 60 mg +Paclitaxel +Bevacizumab|Pictilisib 60 mg will be administered orally (PO) once daily (QD) for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 milligrams per meter square (mg/m^2) intravenously (IV) on Days 1, 8, and 15 and bevacizumab 10 milligrams per kilogram (mg/kg) IV on Days 1 and 15 of each 28-day cycle. In Cohort 1 (Part 1), pictilisib will be evaluated with paclitaxel only; participants in Cohort 1 (Part 1) will be eligible to receive bevacizumab starting at Cycle 2. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223015|NCT00960960|Experimental|Part 1 (Cohort 3): Pictilisib 100 mg+ Paclitaxel + Bevacizumab|Pictilisib 100 mg will be administered PO QD for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223016|NCT00960960|Experimental|Part 2 (Arm A: Cohort 1a): Pictilisib 165 mg + Paclitaxel|Pictilisib 165 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity
89223017|NCT00960960|Experimental|Part 2 (Arm A: Cohort 2a): Pictilisib 250 mg + Paclitaxel|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223018|NCT00960960|Experimental|Part 2 (Arm A: Cohort 3a): Pictilisib 330 mg + Paclitaxel|Pictilisib 330 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223019|NCT00960960|Experimental|Part2(Arm B:Cohort 1b):Pictilisib 200mg+Paclitaxel+Bevacizumab|Pictilisib 200 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223020|NCT00960960|Experimental|Part2(Arm B:Cohort 2b):Pictilisib 250mg+Paclitaxel+Bevacizumab|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223021|NCT00960960|Experimental|Part2(Arm B:Cohort 3b):Pictilisib 260mg+Paclitaxel+Bevacizumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223022|NCT00960960|Experimental|Part2(Arm C:Cohort 1c):Pictilisib 180mg+Paclitaxel+Trastuzumab|Pictilisib 180 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223023|NCT00960960|Experimental|Part2(Arm C:Cohort 2c):Pictilisib 260mg+Paclitaxel+Trastuzumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
89223024|NCT00960960|Experimental|Part 3: Pictilisib 260 mg + Letrozole|Pictilisib 260 mg will be administered PO QD continuously with letrozole 2.5 mg PO QD for each 28-day cycle. Study treatment will continue until disease progression or unacceptable toxicity.
89066696|NCT04324788||Group 2|"Transfemoral amputation~The patients will be asked to go up and down 9-step stair with the highest speed they can make."
89066697|NCT01264965|Active Comparator|Acetaminophen|
89066698|NCT01264965|Active Comparator|Long Acting Oxycodone|
89066699|NCT05644236|Experimental|experimental group|CPC-containing mouthwash solution
89066700|NCT02890680|Experimental|Platelet-rich fibrin group|Use platelet-rich fibrin after mandibular third molar extraction
89066701|NCT02890680|Placebo Comparator|Control group|mandibular third molar extraction
89066702|NCT01264887|Experimental|Tapentadol Prolonged Release|Participants allocated to this treatment arm can be flexibly dosed between 100 to 250 mg tapentadol twice daily (50 and 100 mg tablets to be dispensed).
89066703|NCT01306968|No Intervention|Standard TBI Care|Routine post-concussive symptoms (PCS) care as practiced within Departments of Defense (DoD)
89066704|NCT01306968|Experimental|HBO2 Group|Routine PCS care supplemented with hyperbaric oxygen (HBO2) at the dose of 1.5 ATA for 60 minutes administered over 40 sessions given daily Monday through Friday
89066705|NCT01306968|Sham Comparator|Sham Group|Routine PCS care supplemented with an otherwise identical sham hyperbaric air exposure at 1.2 atmospheres absolute (ATA)
89066706|NCT01306968|No Intervention|PTSD With no History of TBI|Subjects who have been diagnosed with PTSD but have no diagnosed or suspected brain injuries. This group does not receive HBO2.
89066707|NCT01264419|Experimental|Silk Road Embolic Protection System|Eligible subjects who are to receive a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
89066708|NCT04323345|Experimental|Natural Honey Group|"Natural Honey~1gm/kg/day divided into 2 to 3 doses for 14 days in addition to standard care"
89066709|NCT04323345|Active Comparator|Standard Care|Current standard care including supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
89066710|NCT01263873|Active Comparator|Mallinckrodt (ETT)|Artifical Airway Device
89066711|NCT01263873|Experimental|Parker Flex Tip (ETT)|Artifical Airway Device
89066712|NCT01263639|Experimental|Intervention Group, biosketch card|The investigators aim to improve the patient-physician relationship and improve patient satisfaction by providing a biosketch card of the attending orthopaedic trauma surgeon to the patient. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.
89066713|NCT01263639|Active Comparator|Control group, standard care|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The control group will receive the usual/standard care as provided to all orthopaedic trauma admission patients without receiving a biosketch card."
89066714|NCT01011283|Active Comparator|1|
89066715|NCT01011283|Active Comparator|2|
89066716|NCT01263561|Active Comparator|trabeculectomy|trabeculectomy filtering surgery
89066717|NCT01263561|Experimental|ExPRESS|ExPRESS miniature glaucoma drainage device
89066718|NCT01009099|Experimental|Arm 1|exercise training with breathing retraining
89066719|NCT01009099|Active Comparator|Arm 2|exercise training
89066720|NCT01263483|Active Comparator|Voglibose 0.2 mg TID|
89066721|NCT01263483|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
89066722|NCT01263483|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
89066723|NCT01306890||sipuleucel-T|
89066724|NCT01011049|Experimental|Group 1: Fluzone ID After Fluzone ID|Participants will receive Fluzone intradermal (ID) following Fluzone ID in Study FID31
89066725|NCT01011049|Experimental|Group 2: Fluzone IM After Fluzone ID|Participants will receive Fluzone intramuscular (IM) following Fluzone ID in Study FID31
89066726|NCT01011049|Experimental|Group 3: Fluzone IM After Fluzone IM|Participants will receive Fluzone intramuscular (IM) following Fluzone IM in Study FID31
89066727|NCT01011049|Experimental|Group 4: Fluzone ID After Fluzone IM|Participants will receive Fluzone intradermal (ID) following Fluzone intramuscular (IM) in Study FID31
89066728|NCT02871973|Experimental|SDP|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visit.
89066729|NCT02871973|Active Comparator|CDC Handout|Families in the control group will receive the Center for Disease Control and Prevention (CDC) Handout at enrollment.
89066730|NCT01263093|Experimental|Clopidogrel First, Then LY2216684 + Clopidogrel|"Period 1: a single 300-milligram (mg) dose of clopidogrel administered orally on Day 1 (Treatment 1).~Period 2: an 18-mg dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
89066731|NCT01263093|Experimental|LY2216684 + Clopidogrel First, Then Clopidogrel|"Period 1: an 18-milligram (mg) dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).~Period 2: a single 300-mg dose of clopidogrel administered orally on Day 1 (Treatment 1).~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
89066732|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 160 μg|160 μg once daily
89066733|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 80 μg|80 μg once daily
89066734|NCT01010971|Placebo Comparator|Placebo|Placebo
89066735|NCT01306656|Experimental|Group 1|10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
89066736|NCT01306656|Placebo Comparator|Group 2|Placebo plus a multivitamin with 400 IU vitamin D
89066737|NCT01008943|Experimental|1|
89066738|NCT02871271|Experimental|IQP-AS-121|To be taken once daily dosing of 1 tablet in the morning.
89066739|NCT04205071|Experimental|Treatment (lorcaserin)|Patients receive lorcaserin PO on day 1. The starting dose of lorcaserin will be 10 mg.
89066740|NCT01003639|Active Comparator|Acetazolamide|Acetazolamide given in escalating doses
89066741|NCT01003639|Placebo Comparator|Sugar pill|"Given in escalating dose (number of pill)"
89066742|NCT01003249|Active Comparator|Baclofen, Then Placebo|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
89066743|NCT01003249|Placebo Comparator|Placebo, Then Baclofen|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
89066744|NCT04297033|Experimental|Lovastatin intervention|combination of 40mg/d 12m lovastatin and symptomatic treatment drugs as a treatment strategy for BAVM .
89066745|NCT04297033|Placebo Comparator|placebo|combination of placebo and symptomatic treatment drugs as a treatment strategy for BAVM
89066746|NCT01001767|Active Comparator|Lovaza|Lovaza 1 gram by mouth twice a day for 24 weeks.
89066747|NCT01001767|Placebo Comparator|Placebo|Placebo capsule by mouth twice a day x 24 weeks.
89066748|NCT04338295|Experimental|Microneedling|Participants with Alopecia Areata will receive microneedling with a tattoo machine.
89066749|NCT04294537|Experimental|TAP block|Bilateral ultrasound-guided single-shot TAP block with 0,15% levobupivacaine 0,75 mg/kg per side.
89066750|NCT04294537|Active Comparator|LIA - local wound infiltration|Wound infiltration with 0,5% levobupivacaine 1.5 mg/kg
89066751|NCT04296721|Experimental|Intensive weight-loss program|The life style change program will consist of two stages. The first will consist of a 3-month period of intensive diet and progressive exercise with biweekly consultations with a nutritionist (in groups or individually). The second stage will last for 9 months, until completion, with a diet that is progressively higher in calories, with more intense exercise, under the supervision of a community nurse and an individual nutritional consultation at 9 months.
89066752|NCT04296721|Active Comparator|Standard dietary recommendations|Patients will be followed according to the usual recommendations: A written diet (designed by a hospital nutritionist) and an exercise plan, depending on the patient's age and activity level, without any other type of evaluation or visit Visits in the Sleep Disorders Unit will be scheduled at 3 and 12 months
89066753|NCT04294615|Experimental|FMT through a naso-jejunal tube|The purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
89223025|NCT00972192|Active Comparator|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and counseling immediately after the baseline interview. Patients underwent phlebotomy and serologic testing and results were disclosed the following day with post-test counseling (before they were discharged from the hospital).
89223026|NCT00972192|No Intervention|HIV testing post-discharge|Participants who were randomized to the control group were given a referral card and an appointment, by the interviewers, to return for free HIV testing and counseling at Mulago hospital one week after discharge. Participants who returned had their transport reimbursed.
89223027|NCT04315857||diabetics|diabetics receiving chemotherapy for cancer
89223028|NCT01014195||Group 1|"Survivors of pediatric leukemia treated on Total Therapy Protocol XV (TOTXV) at St. Jude Children's Research Hospital (SJCRH), who are ≥ 8 years of age and ≥ 5 years from diagnosis.~Intervention: Neurocognitive and behavioral evaluation"
89223029|NCT00972270|Experimental|IMPELLA LP 2.5|
89223030|NCT00972270|Active Comparator|Intra-Aortic Balloon Pump|
89223031|NCT01015521|Experimental|Aminoflavone Prodrug|Aminoflavone to treat ER positive breast cancer patients
89223032|NCT01015521|Experimental|Aminoflavone Prodrug with pretreatment|Aminoflavone Prodrug to treat Triple Negative Breast Cancer
89223033|NCT00961038|Experimental|Arm 1|
89223034|NCT00961038|Experimental|Arm 2|
89223035|NCT00961038|Placebo Comparator|Arm 3|
89223036|NCT00972348|Experimental|Access to Personal Health Record|Full access to the Personal Health Record including lists of diagnoses, medications and laboratory values.
89223037|NCT00972348|Active Comparator|No access to the PHR|No access to the PHR but patients will complete surveys.
89223038|NCT00961194|Placebo Comparator|placebo|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
89223039|NCT00961194|Experimental|dose of ketamine tested = 0.35 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
89223040|NCT00961194|Active Comparator|dose of ketamine tested = 0.7 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
89223041|NCT00961194|Active Comparator|dose of ketamine tested = 1.4 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
89223042|NCT03933462|Experimental|InnoSpire Go|The InnoSpire Go is a handheld, single patient use, vibrating mesh nebulizer system designed to aerosolize liquid medications for respiratory disease. The device operates continuously once initiated and automatically switches off once the medication has been delivered. The device may be used in pediatric and adult populations, as permitted by the prescribed medication, and is suitable for use in home environments or hospital/clinic settings.
89223043|NCT03933462|Active Comparator|Jet Nebulizer|Jet Nebulizers are the standard delivery system for aerosolized medications. A nebulizer breaks up medical solutions into small droplets suspended in air (aerosol) so that they may be delivered to the patient's airways for respiratory therapy.
89223044|NCT03929562|Active Comparator|Brief advice|One brief advice session, resource brochure, standard of care, and an infographic about alcohol and surgical health at patient's pre-existing pre-operative clinical visit.
89223045|NCT03929562|Experimental|Health coaching|Two health coaching sessions, resource brochure, standard of care
89223046|NCT05279586|Active Comparator|patients that will receive lactulose|Cirrhotic patients who were recovered from HE will be randomized into lactulose group receiving 30-60 ml of lactulose orally in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
89223047|NCT05279586|Active Comparator|patients that will receive colistin|colistin group receiving colistin sulfate 1.5 million I.U. tablet orally twice
89223048|NCT00965796|Experimental|Lidocaine, pain intensity and Saline|(2 mg/kg/h) and patients of group 2 (n = 20) received 0.9% saline infusion throughout the surgical procedure
89223049|NCT00415636|Experimental|LY2603618 40 mg/m^2 (4.5-hour infusion)|LY2603618 40 milligrams per square meter (mg/m^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed.
89223050|NCT00415636|Experimental|LY2603618 40 mg/m^2 (1-hour infusion)|Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m^2 [4.5-hour infusion]), the LY2603618 40 mg/m^2 dose in Cohort 2 (LY2603618 40 mg/m^2 [1-hour infusion]) was repeated, but the dose was administered over the duration of 1 hour. Dose modifications were not allowed.
89229846|NCT03957655|No Intervention|Control|Standard medication for viral hepatitis and cirrhosis
89066754|NCT04294615|Active Comparator|FMT through TET|The purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
89066755|NCT02871037|Experimental|Part 1_Cohort 1_Active|Single, escalating dose of PF-05221304
89066756|NCT02871037|Placebo Comparator|Part 1_Cohort 1_Placebo|Single dose of Placebo
89066757|NCT02871037|Experimental|Part 1_Cohort 2_Active|Single, escalating dose of PF-05221304
89066758|NCT02871037|Experimental|Part 1_Cohort 2_Placebo|Single dose of Placebo
89066759|NCT02871037|Experimental|Part 2_Active|Repeated, escalating doses of PF-05221304
89066760|NCT02871037|Placebo Comparator|Part 2_Placebo|Repeated doses of placebo
89066761|NCT02871037|Experimental|Part 3|Single dose of PF-05221304 with and without food
89066762|NCT04295629|Active Comparator|VAS (Visüel Analog Score)|VAS : 0-10 points 0 means: no pain 10 means: incredible pain
89066763|NCT04295629|Active Comparator|LANSS (Leeds Assessment of Neuropathic Symptoms and Signs)|LANSS 0-24 points >12 points : has chronic neuropathic pain <12 points: no chronic neuropathic pain
89066764|NCT01306032|Experimental|Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
89066765|NCT01306032|Experimental|Triple-negative Breast Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
89066766|NCT01306032|Experimental|BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
89066767|NCT01306032|Experimental|BRCA- positive Ovarian Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
89066768|NCT01306032|Experimental|Non-Hodgkin's: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
89066769|NCT01306032|Experimental|Non-Hodgkin's: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
89066770|NCT01263015|Experimental|Dolutegravir (N=~394):|Dolutegravir 50mg once daily + abacavir/lamivudine as the fixed-dose combination once daily + Atripla placebo once daily
89066771|NCT01263015|Active Comparator|Atripla (N=~394):|Atripla once daily + Dolutegravir placebo once daily + abacavir/lamivudine as the fixed-dose combination placebo once daily
89066772|NCT04323267|Experimental|Digital Home Exercise Program|Limber Digital Application Device (3 x a week for 8 weeks)
89066773|NCT04323267|Active Comparator|Physical therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
89066774|NCT04322877|Experimental|Body surface mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and non-invasive body surface mapping.
89066775|NCT04322877|Experimental|Catheter-based mapping and temporary pacing|Temporary pacing procedure with acute hemodynamic study and invasive catheter-based mapping.
89066776|NCT04322799|Experimental|Acetabular cup HXLPE (Intervention)|Randomization to HXLPE acetabular component.
89066777|NCT04322799|Experimental|Acetabular cup Conventional PE (control)|Randomization to Coventional PE as control group
89066778|NCT04322175|Experimental|Single dose pharmacokinetic test|The 72 healthy subjects enrolled were admitted to the trial ward the day before the trial. On the day of dosing, the subjects were given 0.1% meloxicam eye drops once, 1 drop / time.
89066779|NCT04322175|Experimental|Multiple dose tolerance test|Eight healthy subjects were enrolled in the trial ward the day before the trial. 0.1% meloxicam eye drops were administered 4 times, 1 drop / time, and were administered at 8:00, 12:00, 16:00 and 20:00 daily for 3 consecutive days.
89066780|NCT01305564|Experimental|Denali inferior vena cava filter|All subjects enrolled will receive the Denali vena cava filter.
89066781|NCT04322331||T1N+|T1 tumor with positive lymph node,N1/N2/N3
89066782|NCT04322331||T2/T3N0|T2/T3 tumor with negative lymph node
89066783|NCT04322253|Experimental|Neladenoson bialanate, mild hepatic impairment|Subjects with Child Pugh score 5 or 6 received a single immediate-release (IR) tablet dose of 10 mg neladenoson bialanate in the fasted state
89066784|NCT04322253|Experimental|Neladenoson bialanate, moderate hepatic impairment|Subjects with Child Pugh score 7-9 received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
89066785|NCT04322253|Experimental|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
89066786|NCT04322409|Experimental|NMES|The experimental treatment of Neuromuscular Electrical Stimulation over the Peroneus Longus.
89066787|NCT04322409|Placebo Comparator|TENS|The placebo treatment of Transcutaneous Electrical Nerve Stimulation over the same region as the peroneus longus
89066788|NCT04321785|Placebo Comparator|Placebo|
89066789|NCT04321785|Experimental|Caffeine|
89066790|NCT05648175|Experimental|Artificial Intelligence Allocation|"Allocation of treatment intensity by the proposed AI algorithm will be based on the machine learning and natural language processing (NLP) of textual data provided by participants and their PHQ-9 score collected through a pre-treatment screening module called the Triage Module. This module, developed by the research team, (1) provides psychoeducation on the effects of psychotherapy, (2) collects PHQ-9 scores, and (3) asks participants six open-ended questions regarding their mental health history, their experiences with mental health disorders, and what mental health difficulties they are currently facing. Based on the participant's answers to the open-ended questions, a variable called Symptomatic Score will be calculated using the NLP algorithm."
89066791|NCT05648175|Active Comparator|Healthcare Team Allocation|"Allocation of treatment intensity by the multi-professional healthcare team will be based on the following criteria:~The severity of MDD symptoms (using DSM-5 criteria).~Mental health factors (prior treatments and responses, current and past psychotic/manic episodes, current and past suicidal/homicidal ideation/attempts, family mental health history, past psychiatric history, and hospital admissions).~Medical factors (current medical conditions and medications, personal and family medical history).~Social factors (support system and living situation, and occupational, social, and personal functional impairment)."
89066792|NCT01305408|Placebo Comparator|Placebo|Participants began taking placebo to match armodafinil and following the same titration procedure. Treatment was administered for a total of 8 weeks.
89066793|NCT01305408|Experimental|Armodafinil 150 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. Treatment was administered for a total of 8 weeks.
89066794|NCT01304940||PTSD group|Individuals in this group meet criteria for PTSD as defined by DSM-IV
89066795|NCT01304940||trauma control group|individuals in this group do not meet criteria for any Axis I diagnosis as defined by DSM-IV
89066796|NCT01261611|Experimental|Dysport NG|"500U (1mL) administered as intramuscular injection on day 1 of treatment cycle 1 and 2.~250U (0.5mL), 500U (1mL) or 750U (1.5mL) administered as intramuscular injection on day 1 of treatment cycle 3.~250U (0.5mL), 500U (1mL), 750U (1.5mL) or 1000U (2mL) administered as intramuscular injection on day 1 of treatment cycle 4 and 5."
89066797|NCT01261611|Active Comparator|Dysport|500U (1mL) injected as intramuscular injection on day 1 of treatment cycle 1.
89223051|NCT00415636|Experimental|LY2603618 70 mg/m^2|Beginning with Cohort 3 (LY2603618 70 mg/m^2), dose modifications were allowed. LY2603618 70 mg/m^2 was administered over the course of 1 hour.
89223052|NCT00415636|Experimental|LY2603618 105 mg/m^2|Cohort 4: LY2603618 105 mg/m^2 administered over the duration of 1 hour.
89223053|NCT00415636|Experimental|LY2603618 150 mg/m^2|Cohort 5: LY2603618 150 mg/m^2 administered over the duration of 1 hour.
89223054|NCT00415636|Experimental|LY2603618 195 mg/m^2|Cohort 6: LY2603618 195 mg/m^2 administered over the duration of 1 hour.
89223055|NCT00961272||HIV-infected, pre-menopausal women|
89223056|NCT00965874|Experimental|Magnesium Sulfate high dose infusion|9 g Magnesium sulfate infusion over 30 minutes
89223057|NCT00965874|Active Comparator|Magnesium Sulfate low dose infusion|4.5 magnesium sulfate infusion over 30 minutes
89223058|NCT00965874|Placebo Comparator|placebo|serum salin
89223059|NCT00972426|Experimental|Treatment A Group|Mikelan LA + Xalatan
89223060|NCT00972426|Active Comparator|Treatment B Group|Timoptol XE + Xalatan
89223061|NCT00972582|Experimental|Leucine|
89223062|NCT00972660|Active Comparator|Control group|"Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)"
89223063|NCT00972660|Experimental|Mesenchymal stem cell (MSC)|"Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
89223064|NCT00961506|Experimental|LESS cholecystectomy|LESS cholecystectomy
89223065|NCT00961506|Active Comparator|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
89223066|NCT04008966|Active Comparator|single trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection
89223067|NCT04008966|Active Comparator|Dual trigger|80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2 mg subcutaneously
89223068|NCT00425854|Experimental|BIBW 2992|high dose once daily
89223069|NCT00961740|Other|Cognitive Behavioral Therapy|Design: 49 children (aged 8-12)with obesity was recruited, the children were randomly assigned to a group that started a cognitive behavioural intervention immediately after recruitment, and another group that received the same treatment after a 12-week wait list condition. For further description of the treatment, see summary. Arm 1 (this arm) started receiving a cognitive behavioural intervention immediately after randomization.
89223070|NCT00961740|Other|12-weeks waitlist condition|After an initial pre-assessment no contact were made before assessment after 12-weeks and start of intervention after this assessment. After the 12-week waitlist condition the families were offered the same familibased cognitive behavioral intervention as in arm one.
89223071|NCT02771938|Experimental|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
89223072|NCT00972972|Active Comparator|dietary supplement|Extracts of bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.)
89223073|NCT00972972|Placebo Comparator|placebo dietary supplement|Placebo juice extracts
89223074|NCT00425698|Active Comparator|intravenous erythropoietin|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
89223075|NCT00425698|Placebo Comparator|intravenous placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
89223076|NCT00966030|Experimental|1|MK0974 Tablet
89223077|NCT00966030|Active Comparator|2|MK0974 Liquid filled capsule
89223078|NCT01037530|Experimental|Ramipril|
89223079|NCT00973518||Alzheimer's Disease subjects|Subjects diagnosed with dementia of Alzheimer's type (DSM-IV-TR).
89223080|NCT00973518||Healthy Control subjects|Age & gender-matched subjects determined to be healthy.
89223081|NCT00973050|Experimental|Bicalutamide (test)|Bicalutamide Tablet, 50 mg
89223082|NCT00973050|Active Comparator|Casodex® (reference)|Casodex® Tablet, 50 mg
89223083|NCT00973128|Experimental|Group 1|Group 1: Cutaneous leishmaniasis patients randomized in Corte to receive antimony (20mg/daily for 10 days) plus GM-CSF Treatment: antimony (20mg/daily for 10 days) plus GM-CSF (400 µg, divided in two doses a week apart)
89223084|NCT00973128|Active Comparator|Group 2|Group 2: antimony in standard dose plus saline administered in an identical fashion to the GM-CSF.
89223085|NCT00966108||Healthy subjects|
89223086|NCT00966108||Glaucoma patients|
89223087|NCT00973908|Active Comparator|VSL#3|Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
89690349|NCT03127995|Other|NORMOFRACTIONATED|"50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions~or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions"
89066798|NCT01261611|Placebo Comparator|Placebo|1mL administered as, intramuscular injection on day 1 of treatment cycle 1.
89066799|NCT04321629|Experimental|Autologous Fat Tissue Group|Group of patients treated with intra-articular injections of autologous adipose tissue.
89066800|NCT04321629|Active Comparator|PRP Group|Group of patients treated with intra-articular injections of platelet-rich-plasma.
89066801|NCT04321863||Adults with Crohn's disease in remission|All patients recruited will submit two samples to facilitate faecal zinc and qFIT in addition to FC which is standard of care. All patients recruited will have an additional tube of blood taken to measure serum zinc at the same time as they have their routine (standard of care) monitoring bloods taken - no additional venepuncture will be required.
89066802|NCT04321707|Experimental|15O-H2O PET/MR|All included patients will have two 15O-H2O PET/MR scan performed.
89066803|NCT04321083|Experimental|O2 brain (central) measurement|INVOS will be applied simultaneously for monitoring along with the regular polysomnography (sleep lab) workup
89066804|NCT04321161|Experimental|AML relapse under DLI and Bicanorm treatment|Analysis of T cell metabolism, immune phenotype and serum pH before and after Bicanorm (Sodium bicarbonate) treatment.
89066805|NCT04207125|No Intervention|Without multilevel intervention|patients after liver or kidney transplantation / standard care
89066806|NCT04207125|Active Comparator|With multilevel intervention|patients after liver or kidney transplantation / multilevel intervention program
89066807|NCT04320771|Experimental|Neladenoson bialanate, mild renal impairment|Subjects with eGFR ≥60 - <90 mL/min/1.73 received a single immediate-release (IR) tablet dose of 10 mg of neladenoson bialanate in the fasted state
89066808|NCT04320771|Experimental|Neladenoson bialanate, moderate renal impairment|Subjects with eGFR ≥30 - <60 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
89066809|NCT04320771|Experimental|Neladenoson bialanate, severe renal impairment|Subjects with eGFR <30 mL/min/1.73 received a single IR tablet dose of 10 mg of neladenoson bialanate in the fasted state
89066810|NCT04320771|Experimental|Neladenoson bialanate, control group|Healthy subjects matched for age, gender and body weight received a single IR tablet dose of 10 mg neladenoson bialanate in the fasted state
89066811|NCT05555433||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
89066812|NCT05555433||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
89066813|NCT05555433||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
89066814|NCT05555433||fibromyalgia|subjects with fibromyalgia
89066815|NCT05554107|Active Comparator|Group A - Supervised exercise first|"All POTS patients will continuously be randomized into two groups (Group A and B). Group A will first start the training program and when the training program is finished group B will start the training program. While each group is not performing the training program the patients will be encouraged to physical activity according to their own abilities.~Results from questionnaires, orthostatic tests and maximal biking tests will be compared between group A and B as well as within each group."
89066816|NCT05554107|Active Comparator|Group B - Self-instruction exercise first|See above.
89066817|NCT00624039|Other|1|ultrasound biomicrocopic examinations and pilocarpine instillation
89066818|NCT05523141|Experimental|ASC10|"Part 1: Participants will be randomized to receive 100 to 1600 mg ASC10 (including 6 cohorts) in an double-blind manner~Part 2: Participants will be randomized to receive two single 800 mg doses (fed or fasted)"
89066819|NCT05523141|Placebo Comparator|Placebo|Part 1: Participants will be randomized to receive placebo
89066820|NCT01304706|Experimental|Fluocinolone Acetonide|
89066821|NCT05661240|Experimental|Tumor treating fields combined with docetaxel injection|Medical device：Tumor treating fields（EFE-P100） Tumor treating fields（EFE-P100）will be used each day. Drug: docetaxel each cycle is 21 days，docetaxel will be administered intravenously，75 mg/m2 on the first day of each cycle.
89066822|NCT05661240|Active Comparator|docetaxel injection|Drug: docetaxel each cycle is 21 days，docetaxel will be administered intravenously，75 mg/m2 on the first day of each cycle.
89066823|NCT05661162|Other|CR500 single-dose gel|Interventional study on CR500 1.5 mL will be topically administered twice a week for four weeks
89066824|NCT04324866||Group 1|Patients with chronic plaque psoriasis on immunosuppressant therapy
89066825|NCT04324866||Group 2|Psoriatic patients' partners
89066826|NCT04324866||Group 3|Patients with atopic dermatitis treated with dupilumab
89066827|NCT00624117|Experimental|A|
89066828|NCT05370651|Active Comparator|Emsella Chair Active Treatment|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
89066829|NCT05370651|Sham Comparator|Emsella Chair Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (<10% power).
89066830|NCT02889003|Experimental|CML patients following molecular response loss|
89066831|NCT01303380|Experimental|Canakinumab|
89690350|NCT01922492|Experimental|Autologous islet transplantation|Autologous islet transplantation arm: autologous islet transplantation
89690351|NCT01922492|Active Comparator|Oral anti-diabetic drugs|Metformin (starting from 500mg qd with dose adjustment thereafter) with or without vildagliptin (starting from 50mg qd with dose adjustment thereafter)
89223088|NCT00973908|Placebo Comparator|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
89223089|NCT00966342|Other|Vaccine|Everyone gets licensed Influenza vaccine
89223090|NCT00966420|Experimental|mucosa resection|
89223091|NCT00966498|Experimental|1|This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.
89223092|NCT00973986|Active Comparator|CYP3A4*1/*1|
89223093|NCT00973986|Active Comparator|CYP3A4*1/*1G|
89223094|NCT00973986|Active Comparator|CYP3A4*1G/*1G|
89223095|NCT00979524|Experimental|Comprehensive Mental Health Services|Intervention group participants will receive an array of mental health education and services based on their level of need. Study participants will fall into low, moderate, or elevated risk based on results of baseline screening. Services will be provided to each group as specified below. Low risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) education activities to promote knowledge and change attitudes around mental health; Moderate risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Short-term mental health services delivered by the LCSW-C, (c) Depression prevention intervention, (d) Education activities to promote knowledge and change attitudes around mental health; High risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Mental health treatment services, (c) Education activities to promote knowledge and change attitudes around mental health.
89223096|NCT00979524|Active Comparator|Usual Care (Employment Training Services)|"Newly enrolling Westside YO members will receive usual care services, which constitute a moderate level of mental health services and supports. The usual care services related to mental health at the Westside will include (1) the ACASI screen for all newly enrolling Westside YO members, (2) the initial visit with a LCSW-C, and (3) mental health training for Westside Case Advocates. More extensive mental health educational activities and services (e.g., additional sessions with LCSW-C, SOS Club) provided to the intervention group will not be available at the Westside YO Center during the initial study period. Also, Eastside Case Advocates will receive more extensive and ongoing mental health training."
89223097|NCT00974064||A-Healthy Non smokers|Healthy nonsmokers. Defined as non-smokers by self report and urine cotinine levels consistent with a nonsmoker (urine cotinine <5 ng/mL).
89223098|NCT00974064||B-Healthy smoker|"Healthy current smokers. Subjects categorized as healthy according to criteria under Collection (#1204012331) protocol."
89223099|NCT00974064||C-Healthy smoker to quit|Healthy smokers willing to quit. Defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL).
89223100|NCT00974064||D-Current smoker w. COPD|Current smokers with COPD. COPD as defined by the GOLD criteria and currently smoking as defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL)
89223101|NCT00974064||E-Current COPD smoker to quit|Current smokers with COPD willing to stop smoking. Subjects have COPD as defined by the GOLD criteria
89223102|NCT00966576|Experimental|Brinzolamide/Timolol Maleate Fixed Combination|
89223103|NCT00425308|Active Comparator|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|Everolimus dose has been adjusted to reach in Group 2, assessment of everolimus dose/trough level (C0), between 6 and 10 ng/ml plus Enteric-coated Mycophenolate Sodium (EC-MPS) 720 mg/d (360mg the morning and 360 mg the evening) plus steroids
89223104|NCT00425308|Active Comparator|Everolimus + Cyclosporine|Everolimus dose has been adjusted to reach in Group 1, assessment of everolimus dose/trough level (C0), between 3 and 8 ng/ml plus Cyclosporine in which Group 1 dose adjusted to reach, assessment of Cyclosporine dosage and blood concentration (C2), between 200 and 450 ng/ml plus steroids
89223105|NCT04008888|Experimental|A:Allogeneic Stem Cell Transplant Group|Fludarabine+Melphalan followed by Allogeneic SCT.
89223106|NCT04008888|Experimental|B:Autologous Stem Cell Transplant|Melphalan followed by Autologous SCT.
89223107|NCT04008888|Experimental|C:Non-Transplant|Consolidated Chemotherapy for Patients Unable to Receive Transplantation
89223108|NCT01563588|Experimental|dietary and physical training|12 days session of physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
89223109|NCT01563588|No Intervention|control|dietary counseling by a dietetician in the anticancer hospital
89223110|NCT00966732|Experimental|yoga condition|assigned to start the yoga program right away
89223111|NCT00966732|No Intervention|wait-list control condition|This condition will control for any effects of symptom measurement reactivity in patients receiving routine fibromyalgia medical care. After the 3-month assessment, the yoga intervention program will be provided to these patients.
89223112|NCT01033006|Active Comparator|Arm 1: catheter injection|40 ml of LA through the catheter
89066832|NCT01008553|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will continue for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
89066833|NCT01008553|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
89066834|NCT01008553|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
89066835|NCT05643924||Patients diagnosed with Asthma|
89066836|NCT05137041|Experimental|ITP FIRTECH|ITP FIRTECH patch will be applied and remain in position for 5 days
89066837|NCT05137041|No Intervention|No Patch Control Arm|No patch application
89066838|NCT05014503|Experimental|Adaptive version of the therapeutic game|The adaptive therapeutic game will use a game-entry level that is based on the individual visual perceptual profile of the child. Children with higher visual perceptual capacities will be able to start the game at a higher entry level compared to children with lower visual perceptual capacities. Thereby, the entry level will also be different for the different games. In addition, the adaptive game uses an in-game adaptivity system that has been developed using artificial intelligence (more specifically, reinforcement learning): this means that the game can adjust the difficulty automatically, based on the game-behaviour and success of the child. Children learning fast, will more quickly move to higher difficulty levels compared to children learning slower. Thereby, this in-game adaptivity also enables children to return to lower difficulty levels when a difficulty level is too high.
89223113|NCT01033006|Active Comparator|Arm 2: transarterial injection|30 ml deep and 10 ml superficial to the artery
89223114|NCT01033006|Active Comparator|Arm 3: catheter and transarterial injection|20 + 10 ml transarterial block and 10 ml through the catheter
89066839|NCT05014503|Active Comparator|Non-adaptive version of the therapeutic game|The non-adaptive therapeutic game will use the same, lowest entry level for all children. During game play, a fixed stepwise increase in difficulty will be built in, not adjusted to the gaming behaviour or success of the child. All children will follow the same, gradual approach in difficulty and a fixed number of trials is set for each difficulty level. To prevent extreme frustration however, a safety margin is integrated by preventing the difficulty level to increase further when a child has more than a predefined number of unsuccessful trials. Likewise, the stepwise increase in difficulty level will only continue after a fixed, predefined number of successful trials. A child will also never return to a lower difficulty level, once a difficulty level is reached.
89066840|NCT04971915|Experimental|minimalist footwear|The participants in the experimental group will receive one pair of minimalist footwear and will be asked to use them for the interventional period.
89066841|NCT04971915|No Intervention|control|The participants in the control group will be asked to wear their standard footwear as before participating in the study.
89066842|NCT04901169|Experimental|Angiotensin II (Giapreza)|Giapreza (synthetic human angiotensin II), initiated at 5 ng/kg/min and titrated to between 1.25 ng/kg/min and 40 ng/kg/min, administered by continuous intravenous infusion.
89066843|NCT04901169|Placebo Comparator|Saline|Sterile 0.9% saline, initiated and titrated at an equivalent volume infusion rate to the study drug, administered by continuous intravenous infusion.
89066844|NCT04896333||Robot interaction|"EBO is a robotic platform consisting of the following: A screen display capable of generating emotions (sadness, joy, neutral, anger, disgust and surprise), RGB camera, basic navigation system.~EBO must be controlled by a teleoperator through a user-friendly and simple interface. Communication should be as immediate as possible, as well as predefined. In any case, the dialogue flow can be modified if necessary. The interface, at the same time, allows the possibility of sending emotions and small movements to the robot, to accompany the dialogue with certain elements of emotionality.~The experiment replicates the Wizard of Oz technique. In this technique, the human tele-operator controls the robot without the person noticing it as he is in another room. For this purpose, a user interface will be displayed on the teleoperator's terminal and the commands will be reproduced by the EBO robot"
89066845|NCT04885647|Experimental|Arm1|Low dose once every 2 weeks group
89066846|NCT04885647|Experimental|Arm2|Low dose once every 4 weeks group
89066847|NCT04885647|Experimental|Arm3|High dose once every 2 weeks group
89066848|NCT04885647|Experimental|Arm4|High dose once every 4 weeks group
89066849|NCT04822155||Children|Children between 11-17 years of age will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect their physical, emotional, or mental well-being (BRIEF-II and CBCL questionnaires). The child will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality.
89066850|NCT04822155||Adults|Adults, 18 years and older will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect your physical, emotional, or mental well-being (BRIEF-A and ABCL questionnaires). The adult will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality. Additionally, the adult will need to take their blood pressure 3 times per day for 14 days and record measurements.
89066851|NCT04724109||Equfina|Participants with parkinson's disease will be administered Equfina 50 milligram (mg) tablets, orally, once daily in combination with levodopa-containing products. On the basis of symptoms, Equfina 100 mg tablet, orally, once daily may be selected for participants. All the participants will be observed for up to 24 weeks prospectively.
89066852|NCT04606407|Experimental|Treatment|Inhaled NO delivered using LungFit™ in addition to standard of care
89066853|NCT04606407|No Intervention|Standard of care|Standard of care
89066854|NCT02888847|Active Comparator|Philips Zoom! White Speed whitening lamp|Philips Zoom! White Speed whitening lamp
89066855|NCT02888847|Sham Comparator|Philips Zoom! Advanced power lamp|Philips Zoom! Advanced power whitening lamp
89066856|NCT04323891||Higher Trainee/Service Doctor|
89223115|NCT00974298||Elbow replacement|There are no other arms other then an uncemented total elbow replacement.
89066857|NCT04320537||MJ user|non-treatment-seeking chronic heavy marijuana (MJ) users of both sexes and all ethnicities between the ages of 21-40 years who are willing to follow the study protocol and abstinence from marijuana for three weeks
89066858|NCT04320537||Control|age- and sex-matched healthy control participants who are willing to follow the study protocol and remain in the study for three weeks
89066859|NCT04479267|Experimental|Treatment (polatuzumab vedotin, R-CHP)|Patients receive prednisone PO, prednisolone IV, or methylprednisolone IV on days 1-5. Patients also receive rituximab IV, polatuzumab vedotin IV over 30-90 minutes, cyclophosphamide IV, and doxorubicin hydrochloride IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89066860|NCT04320459||ankylosing spondylitis|55 patients having Ankylosing Spondylitis (AS) for at least 1 year diagnosed according to the ASAS classification criteria who presented to our hospital's outpatient clinic
89066861|NCT04320459||healthy control|age and sex matched healthy controls
89223116|NCT01033084|Experimental|Sham stimulation / sertraline|In this arm, patients will receive sham stimulation and sertraline 50mg/day. In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
89066862|NCT02888769|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week.
89066863|NCT02888769|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
89066864|NCT05523531||Patients with characteristics of idiopathic neuropathic eye pain associated with dry eye|Previously included in the QUALVIDON study
89066865|NCT04320303|Experimental|adaptive NK cells infusion post transplantation|Adaptive donors expanded NK cells infusion at day 20±3d and 27±3d post transplantation
89066866|NCT04121169|Other|Adults subjects with CDI receiving 20g a day|10 g twice a day for 10 - 14 days
89066867|NCT04121169|Other|Adults subjects with CDI receiving 40 g a day|20 g twice a day for 10 - 14 days
89066868|NCT04066959|Experimental|Question Prompt List (QPL)|A QPL is a simple, inexpensive communication tool that is comprised of list of questions related to the physical and psychosocial aspects of an illness and treatment components about which patients may want to ask their diabetes care team during a routine diabetes clinic visit.
89066869|NCT04066959|Experimental|Motivation Enhancement System (MES)|MES is a brief, 2-session computer-delivered intervention to enhance intrinsic motivation for behavior change. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. Session 1 begins with psychoeducation describing optimal diabetes self-management, then youth motivation for diabetes self-management is assessed and followed by exercises designed to increase or reinforce his/her current motivational state (e.g., decisional balance) and build self-efficacy, (e.g., building on strengths and past success). Session 1 concludes with goal setting to promote autonomous diabetes self-management. Session 2 begins with an assessment of progress toward the behavioral goal and proceeds to build motivation and self-efficacy with exercises consistent with the youth's current motivational state. Session 2 concludes with goal setting to promote autonomous diabetes self-management.
89066870|NCT04066959|Experimental|Text Message Reminders (TXT)|Participants will receive 30 days of one-way text messages targeting one of three key daily diabetes care behaviors: monitoring blood glucose, insulin administration, or carbohydrate counting. Participants will set a reminder schedule, i.e., frequency and timing of text message reminders.
89066871|NCT04066959|Experimental|QPL & MES|Participants will receive the QPL and MES interventions as described above.
89066872|NCT04066959|Experimental|QPL & TXT|Participants will receive the QPL and TXT interventions as described above.
89066873|NCT04066959|Experimental|MES & TXT|Participants will receive the MES and TXT interventions as described above.
89066874|NCT04066959|Experimental|MES, QPL & TXT|Participants will receive the MES, QPL, and TXT interventions as described above.
89066875|NCT04066959|No Intervention|Standard Medical Care|Participants will receive standard medical care at one of two participating clinical sites. Clinical practices at these sites are consistent with the standards of T1D care recommended by the American Diabetes Association and will include diabetes clinic visits every 3-4 months for routine diabetes medical care provided by an endocrinologist and/or nurse practitioner.
89223117|NCT01033084|Sham Comparator|Sham stimulation / placebo pill|"Placebo pills are sugar pills having the same size and shape of the active pills.~In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation."
89066876|NCT04021017|Experimental|Treatment|"Participants randomized to the treatment arm will be divided by maturational status:~Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months.~o These participants will also receive progesterone (Provera 10 mg tablet) orally every 4 weeks, for 7 days during the second half of the planned menstrual cycle, in order to induce a menstrual period.~Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches:~3.1 mcg/day (1/8 patch) for first six-months,~6.2 mcg/day (1/4 patch) for second six-months,~12.5 mcg/day (1/2 patch) for third six-months, and~25 mcg/day (full patch) for final six-months."
89066877|NCT04021017|No Intervention|No Treatment|The participants in this group will not receive the estrogen patch nor the oral progesterone.
89066878|NCT03764553|Experimental|Liposomal irinotecan, leucovorin and 5FU|IV Nal-IRI 80 mg/m² (expressed as irinotecan hydrochloride (HCl) salt), folinic acid 400 mg/m², fluorouracil 2400 mg/m² over 46 h, every 2 weeks.
89066879|NCT03764553|Experimental|Carboplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and carboplatin area under the curve (AUC5), every three weeks.
89066880|NCT03764553|Experimental|oxaliplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and oxaliplatin 130 mg/m2, every three weeks.
89066881|NCT04319991|Placebo Comparator|Placebo|
89066882|NCT04319991|Experimental|Probiotics product|
89066883|NCT04320225||Lower vitamin D level group|The vitamin D level is lower than 20 nmol/L.
89066884|NCT04320225||Higher vitamin D level group|The vitamin D level is higher than 20 nmol/L.
89066885|NCT04320147|Experimental|MRI tartget biopsy|"MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.~Next conventional ultrasound-guided 12-core systematic biopsy would be performed by urologist. This portion will be performed without information of the MRI report."
89066886|NCT02888925|Other|Epilepsy|Patients do face specific tests during conventional pre-lobectomy intercritical assessment hospitalization (inclusion, day 0) and after 6 and 18 months from anterior temporal lobectomy
89066887|NCT02888925|Other|Control|Control individuals do face specific tests during inclusion visit (day 0) and after X months (X = time from day 0 and lobectomy of matched patient + 6 months)
89066888|NCT03219177|Experimental|Patient education group|
89066889|NCT03219177|Active Comparator|Control- Standard of care counseling|
89066890|NCT05608941|Experimental|Experimental Group|The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
89066891|NCT05608941|Sham Comparator|Control Group|The control group will also perform the exercises using the Orygen Dual Valve device. A sham intervention will be implemented: the initial resistance of the device will be 0cmH2O, and will be maintained throughout the intervention period - there will be no load progression. All procedures adopted with experimental group, including the weekly home visit, will also be performed with individuals in the control group. However, there will be no real change in the training load. All devices will be wrapped with an opaque material so that the load or possible respiratory training load is not visualized.
89066892|NCT02866071|Active Comparator|Ketamine|50mg IN Ketamine Hydrochloride
89066893|NCT02866071|Placebo Comparator|Placebo|50mg IN placebo
89066894|NCT02888613|Other|Mini laparotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with transperitoneal approach
89066895|NCT02888613|Other|Mini lumbotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with retroperitoneal approach
89066896|NCT02890524|Experimental|Night guard|the night guard made of EVA
89066897|NCT02890524|Placebo Comparator|Placebo night guard|Placebo night guard made of EVA
89066898|NCT02890602|Experimental|Darbepoietin alfa|Hemoglobin level will be checked at every cycle's day 0 or 1(1cycle is 21days) after starting Darbepoietin alfa. It will be applied to chemotherapy until increment of hemoglobin 12.0 g/dL.
89066899|NCT01259115|Experimental|Sequence A|BTDS 10 with ketoconazole 200 mg tablets twice daily in period 1 and BTDS 10 with ketoconazole placebo tablets twice daily in period 2.
89066900|NCT01259115|Experimental|Sequence B|BTDS 10 with ketoconazole placebo tablets twice daily in period 1 and BTDS 10 with ketoconazole 200 mg twice daily in period 2.
89066901|NCT01302366|Experimental|Sea cucumber extract|TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.
89066902|NCT02888379|Experimental|TOP1288 200 mg Rectal Solution|TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks
89066903|NCT02888379|Placebo Comparator|Placebo Rectal Solution|Placebo (for TOP1288) Rectal Solution Once Daily for 4 Weeks
89066904|NCT01302054|Experimental|Fesoterodine|
89066905|NCT01302054|Placebo Comparator|Placebo|
89066906|NCT01301508|Experimental|AN2898 ointment, 1%, vs. ointment vehicle|"AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
89066907|NCT01301508|Experimental|AN2728 ointment, 2%, vs. ointment vehicle|"AN2728 ointment applied twice daily for 6 weeks to one target lesion, and AN2728 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
89066908|NCT01301274|Active Comparator|Hypotonic|Subjects in this arm will receive 0.45% NaCl/5% dextrose intravenous maintenance fluids.
89066909|NCT01301274|Experimental|Isotonic|Subjects in this arm will receive 0.9% NaCl/5% dextrose intravenous maintenance fluids.
89066910|NCT02890446|Experimental|External Focus (EF)|"Participants received arm training using the InMotion2 robot under external focus practice conditions and instructions. Participants practiced arm reaching by playing a simple video game.~EF instructions: Focus on moving the yellow ball on the screen in a smooth, straight line at a constant speed; Move the yellow ball toward the blinking red/orange light; and Hit the center of the target and try not to overshoot the target"
89066911|NCT02890446|Experimental|Internal Focus (IF)|"Participants received arm training using the InMotion2 robot without the video game interface. Participants were instructed to think about how they were moving their arm while completing the arm training tasks.~IF instructions:~think about how you're moving your arm; push your arm away from you; pull your arm toward you; move your arm to the right/left"
89066912|NCT05643612||splenic injury group|We retrospectively collected data from patients who underwent contrast-enhanced abdominal CT in the emergency department of Chang Gung Memorial Hospital, Linko, due to trauma and acute abdomen from Jul 2008 to Dec 2017. We identified 300 venous phase scans with splenic injury.
89066913|NCT05643612||control group|We retrospectively collected data from patients who underwent contrast-enhanced abdominal CT in the emergency department of Chang Gung Memorial Hospital, Linko, due to trauma and acute abdomen from Jul 2008 to Dec 2017. We randomly selected 300 additional venous phase scans without splenic injury
89066914|NCT05643456|Active Comparator|group 1 :Two muscle surgery|30 patients will underwent two muscle surgery(bilateral lateral rectus muscle recession)
89066915|NCT05643456|Active Comparator|group 2:Three muscle surgery|39 patients underwent three muscle surgery(bilateral lateral rectus muscle recession with unilateral medial rectus muscle tucking)
89066916|NCT05367726||patients having had skin coverage of the knee|patients having had skin coverage of the knee after or at the same time than an orthopedic surgery to treat a knee prosthesis infection
89066917|NCT05643222|Active Comparator|TES and performance assessment with Type A Red Tint Lens|6 subjects will be inserted with the Type A red Tint Lenses. Only the non dominant eye will be inserted. The comparison is made before and after wearing the CL.
89066918|NCT05643222|Active Comparator|TES and performance assessment with Type B Red Tint Lens|6 subjects will be inserted with the Type B red Tint Lenses. Only the non dominant eye will be inserted. The comparison is made before and after wearing the CL.
89066919|NCT05643222|Active Comparator|TES and performance assessment with Type C Red Tint Lens|6 subjects will be inserted with the Type C red Tint Lenses. Only the non dominant eye will be inserted. The comparison is made before and after wearing the CL.
89066920|NCT05643222|Active Comparator|TES and performance assessment with Type D Red Tint Lens|6 subjects will be inserted with the Type D red Tint Lenses. Only the non dominant eye will be inserted. The comparison is made before and after wearing the CL.
89066921|NCT00623532|Experimental|CA|"Cognition and action are an inseparable whole while functioning, a new intervention based approach using familiarity based movements and non judgmental approach was labeled cognition-action."
89066922|NCT00623532|Active Comparator|AT|Adapted Tai Chi is based on Tai Chi like movements
89066923|NCT00623532|No Intervention|C|Control
89066924|NCT05367648|Experimental|Elio (supplement under investigation)|3g of Elio administered orally daily with the first meal of the day for a 17 day period
89066925|NCT05367648|Placebo Comparator|Place|3g of SMCC administered orally daily with the first meal of the day for a 17 day period
89066926|NCT05642910|Experimental|Azvudine group|Patients received Azvudine orally, for 7 consecutive days (7 doses in total) .
89066927|NCT05642910|Active Comparator|Paxlovid group|Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
89066928|NCT05642754|Active Comparator|GRADE + margin of error|"Overall uncertainty using GRADE* language AND margin of error around main result~* Based on the Cochrane Effective Practice and Organisation of Care Group's guidance for communicating the certainty of evidence based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assessing the certainty of evidence"
89066929|NCT05642754|Active Comparator|Colloquial language AND margin of error|Colloquial language developed to describe overall study uncertainty AND margin of error around main result
89066930|NCT05642754|Active Comparator|No overall uncertainty language AND margin of error|No overall uncertainty language AND margin of error around main result
89066931|NCT05642754|Active Comparator|GRADE -No margin of error|"Overall uncertainty using GRADE* language and NO margin of error around main result~* Based on the Cochrane Effective Practice and Organisation of Care Group's guidance for communicating the certainty of evidence based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assessing the certainty of evidence"
88812881|NCT04381442|Active Comparator|Buccal low level laser therapy|In group II, low level laser therapy was delivered at 5 points; from buccal palatal aspects only with a total dose of 4 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
89066932|NCT05642754|Active Comparator|Colloquial - No margin of error|Colloquial language developed to describe overall study uncertainty and NO margin of error around main result
89066933|NCT05642754|Placebo Comparator|No overall uncertainty language AND no margin of error|No overall uncertainty language and NO margin of error around main result
89066934|NCT05642364|Experimental|Virtual Reality Treatment|VR-delivered JovialityTM Sessions: Treatment Group. Participants will interact with a newly-developed VR environment over a 5-week period, during regularly scheduled maintenance HD treatment. Each week, enrollees will be introduced to a new skill, all taught in distinctive VR environments-with immersive sessions lasting no more than 30 minutes. The investigators' 5-week positive psychological intervention covers the following topics: (1) noticing positive events, (2) amplifying positive events, (3) gratitude, (4) behavioral activation, (5) mindfulness/meditation, (6) positive reappraisal, (7) personal strengths, and (8) acts of kindness. Delivery of intervention content will require VR immersion for no more than 30 minutes during each HD session (i.e., 30-min. sessions thrice weekly). VR immersion will only occur chairside when patients are already sedentary and in a seated position during regularly scheduled HD treatment, thus avoiding increased sedentarism.
89066935|NCT05642364|Active Comparator|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the head-mounted display. Footage of wildlife and nature-based settings are visually displayed as part of the 'Sham' VR with inert music that does not promote high levels of relaxation or distraction. The 'Sham' VR experience has very passive features, such that it mimics viewing content on a large flatscreen television. Passive viewing during the 'Sham' VR experience rotates content using twenty different videos and has a duration time that is matched to that of JovialityTM over the 5-week intervention period.
89066936|NCT01300650|Experimental|Anakinra|
89066937|NCT01300572|Experimental|Y-90-BC8 & Allogeneic Transplant|"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180."
89066938|NCT05642286|Experimental|Robot assisted surgery group|robotic-assisted PCI
89066939|NCT01077154|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once every 4 weeks for 6 months followed by placebo subcutaneous injections once every 3 months for 4.5 years.
89066940|NCT01077154|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneous injections once every 4 weeks for 6 months followed by denosumab 120 mg subcutaneous injections once every 3 months for 4.5 years.
89066941|NCT05642130|Experimental|treatment group|(30) thirty patients with forward head received PIR for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks In addition to the program designed for control group.
89066942|NCT05642130|Sham Comparator|control group|"(30) thirty patients with forward head received static stretching exercise for upper trapezius and sternocleidomastoid .~Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles 3sets of 12 repetitions with 6 sec hold. In addition to postural advices"
89066943|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (24 Weeks)|Participants received peginterferon alfa-2a (PEG-IFNα-2a) 180 mcg once weekly + Ribavirin 800 mg daily for 24 weeks (W).
89066944|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (24 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 24 W.
89066945|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 800 mg daily for 16 W.
89066946|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 16 W.
89066947|NCT04319835|Experimental|Microdialysis catheter|Surface Microdialysis catheter will be placed onto the surgical reconstruction after esophagectomy and will be evaluated for clinical safety and performance. The metabolic profile as measured by Microdialysis will be correlated to the clinical outcome. No interventions based on the results will be performed.
89066948|NCT05640804|Experimental|CTTTQ Dasatinib tablet|Subjects receive CTTQ dasatinib tablet under fasting/fed
89066949|NCT05640804|Experimental|Sprycel Sprycel|Subjects receive Sprycel under fasting/fed
88812882|NCT00893984|Experimental|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
89066950|NCT05639478|Experimental|Intervention group|Patients in the intervention group will perform face to face foot-related exercises for 12 weeks.
89066951|NCT05639478|No Intervention|Control group|Participants in the control group will not receive any specific intervention in addition to the treatment recommended by the health professionals team (doctors, nurses, podiatrists), which includes pharmacological treatment, and self-care recommendations and foot care by international consensus.
89066952|NCT00623688|Experimental|1|Subjects receive active medication (albuterol) delivered by a Proair metered dose inhaler used with an Opti-chamber and placebo (normal saline solution) by nebulizer aerosol.
89066953|NCT00623688|Active Comparator|2|Subjects receive active medication (albuterol) delivered by nebulizer and placebo (no medicine) delivered by a demonstrator Placebo metered dose inhaler demonstrator.
89066954|NCT01300338|Experimental|Blood pressure with telemetry|Home blood pressure monitor with telemetry
89066955|NCT01300338|Active Comparator|Blood pressure without telemetry|Home blood pressure self monitor without telemetry.
89066956|NCT02890290|Active Comparator|Intervention|Marine protein hydrolysate pills (3000mg)
89066957|NCT02890290|Placebo Comparator|Control|Placebo pills (gum arabicum)
89066958|NCT01300260|Experimental|LY2189265 then Placebo|"LY2189265 (Dulaglutide) then Placebo: A single 1.5 milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 in Period 1, followed by a single SC injection of Placebo on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
88812883|NCT01552889|No Intervention|Usual Care (UC)|Patients will receive only the care provided by their primary care physicians or other medical professionals outside of the study.
89066959|NCT01300260|Experimental|Placebo then LY2189265|"Placebo then LY2189265 (Dulaglutide): A single subcutaneous injection of Placebo on Day 1 in Period 1, followed by a single 1.5 milligrams (mg) subcutaneous injection of LY2189265 on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
89066960|NCT01256385|Experimental|Arm A (cetuximab and temsirolimus)|Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89066961|NCT01256385|Experimental|Arm B (temsirolimus)|Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.
89066962|NCT05609760|Experimental|Pictogram Group|"This intervention consists of using a pictogram system called SIMAP which was developed and validated in previous research.~Participants allocated to this arm will received a pictographic depiction of their medical indications generated by an automated system. Information will include a description of inhaler functions, inhaler technique and correct aerochamber use."
89066963|NCT05609760|Sham Comparator|Usual Care Group|These patients will receive their medical indications in the usual way, as established by the health team of the participating clinics. In addition, these patients will receive a bronchial asthma information leaflet as part of the usual education when explaining the disease. No pictograms will be included in these leaflets.
89066964|NCT04324398|No Intervention|group I (control )|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping, between each file and till the final rinse
89066965|NCT04324398|Experimental|Group II|irrigation with 5% cold sodium hypochlorite (2-5°C) from the beginning of cleaning and shaping and between each file. Final rinse was done by 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
89066966|NCT04324398|Experimental|Group III|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of 5% cold sodium hypochlorite (2-5°C) for 5 minutes
89066967|NCT04324398|Experimental|Group IV|irrigation with 5% sodium hypochlorite at room temperature from the beginning of cleaning and shaping and between each file. Then final rinse with 20 mL of cold saline (2-5°C) for 5 minutes
89066968|NCT01298778|Placebo Comparator|Standard of care|Spinal consists of duramorph 150 mcg combined with fentanyl and bupivacaine in conjunction with placebo capsules 2 PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
89066969|NCT01298778|Active Comparator|Acetaminophen and increased dose of Duramorph|Spinal consists of duramorph 300 mcg combined with fentanyl and bupivacaine in conjunction with Acetaminophen 1 Gm PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
89066970|NCT01298700|Experimental|Bimatoprost 0.01% Ophthalmic Solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
89066971|NCT01298700|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
89066972|NCT01297920|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 3 times a day for 3 months
89066973|NCT01297920|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each eye 3 times a day for 3 months
89066974|NCT01297920|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each eye 3 times a day for 3 months
89066975|NCT01255761|Other|RAPID3 to assess response to Cimzia|"RAPID3 is a subject-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a patient measure tool, a tool based on patient-report outcomes (RAPID3); using a total score of 30 points"
89066976|NCT01255761|Other|CDAI to assess response to Cimzia|"CDAI is an investigator-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a clinical measures tool, a tool based on Investigator measures without the need for a lab value (CDAI)"
89066977|NCT01297062|Experimental|Exenatide|
89066978|NCT01297062|Placebo Comparator|Placebo|
89066979|NCT01297062|Active Comparator|Moxifloxacin|
89066980|NCT01254747|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
89066981|NCT01254747|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
89066982|NCT01254747|Active Comparator|Nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
89066983|NCT01254747|Active Comparator|Narafilcon A|Narafilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
89066984|NCT01296672|Experimental|Finasteride|Finasteride 5mg tablets every day by mouth for 3 months
89066985|NCT01296672|Placebo Comparator|Placebo|Placebo 5mg tablet every day by mouth for 3 months
89066986|NCT01254669|No Intervention|control, standard of care|Mothers assigned to the Control Group received the low-literacy, standard-practice, HPV-vaccine information sheet
89066987|NCT01254669|Experimental|BNI-brief Negotiated Interview|The BNI intervention addressed mothers' beliefs, values, and concerns about HPV prevention and takes their priorities for health and well-being into account.
89066988|NCT04324476|Experimental|Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI|"Induction chemotherapy:~Alternating Bevacizumab plus XELOX and Bevacizumab plus XELIRI:~Bevacizumab: 5mg/kg, iv, 30min, d1, 2w; Oxaliplatin: 85mg/㎡, iv, 120min, d1, 4w; Irinotecan: 150mg/㎡, iv, 90min, d15, 4w; Capecitabine: 1000mg/㎡, bid, d2-8, 2w.~Maintenance chemotherapy:~Bevacizumab: 7.5mg/kg, iv, 30min, d1, q3w; Capecitabine: 1000mg/㎡, bid, d2-15, 2w."
89066989|NCT04206969|Experimental|Transcultural psychotherapy|In addition to usual care, the participants in the treatment group receive transcultural psychotherapy in the inclusion centers, which consists of 5 sessions every 7 weeks (W6, W13, W20, W27, and W34). During all the research process, participants from both groups continue their usual care provided by the referent medical team outside the inclusion center.
89066990|NCT04206969|No Intervention|standard care|usual care provided by the referent medical team
89066991|NCT04206657|Experimental|Single dose administration of 1mg KHK7580|
89066992|NCT04206657|Experimental|Single dose administration of 3mg KHK7580|
89066993|NCT04206657|Experimental|Single dose administration of 6mg KHK7580|
89066994|NCT04206657|Experimental|Single dose administration of 12mg KHK7580|
89066995|NCT04206657|Experimental|Multiple dose administration of 6mg KHK7580 for 8days|
89066996|NCT01295814|Experimental|adalimumab|Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks
89223118|NCT01033084|Experimental|Active stimulation / Sertraline|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Patients will receive Sertraline 50mg/day."
89223119|NCT01033084|Experimental|Active stimulation / placebo pill|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Placebo pills are sugar pills having the same size and shape of the active pill"
89223120|NCT00979758|Sham Comparator|Atorvastatin|Atorvastatin routine dose
89223121|NCT00979758|Placebo Comparator|Intensive Atorvastatin|Atorvastatin Intensive dose
89223122|NCT00979758|Active Comparator|Atorvastatin+Transplantation|Atorvastatin routine dose+ Mononuclear cells Transplantation
89223123|NCT00979758|Experimental|Intensive Atorvastatin+Transplantation|Atorvastatin intensive dose+ Mononuclear cells Transplantation
89223124|NCT01672060|Experimental|Nurse-Family Partnership (NFP)|
89223125|NCT01672060|Active Comparator|Existing services|
89223126|NCT01034332|Experimental|One-cycle induction chemotherapy|TP-HDFL, TP-CCRT, Esophagectomy
89223127|NCT00979836|Experimental|Calcium Dobesilate|
89223128|NCT00979836|Placebo Comparator|Placebo|The placebo is a capsule with the same presence of experimental drug.
89223129|NCT01588912|Experimental|Telbivudine-Tenofovir roadmap|
89223130|NCT01588912|Active Comparator|Entecavir|
89223131|NCT00966810|Experimental|CML allogeneic stem cell transplantation|Patients with chronic myeloid leukemia suitable for allogeneic stem cell transplantation with a matched related donor.
89223132|NCT00966888|Experimental|Arm I|Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
89223133|NCT00966888|Active Comparator|Arm II|Patients receive standard of care and observation only.
89223134|NCT00974454|Active Comparator|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
89223135|NCT00974454|Placebo Comparator|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
89223136|NCT00966966|Experimental|1|SAM-531_gemfibrozil
89223137|NCT00979914|Experimental|Patient education programme|Patients with osteoarthritis who were referred to the patient education programme.The patients followed the patient education programme.
89223138|NCT00979914|No Intervention|Control|Patients randomized to control group
89223139|NCT00974532|Active Comparator|Subjects with normal kidney function|eGFR > 60 ml/min/m²
89223140|NCT00974532|Experimental|CKD late Stage 3 and Stage 4|eGFR 15-40 ml/min/m²
89223141|NCT00980070|Experimental|Positioning Device|use of positioning device
89223142|NCT00980070|Active Comparator|Control|institutional standard of care
89223143|NCT00432172|Active Comparator|Group 1 (Luminal A) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
89223144|NCT00432172|Experimental|Group 1 (Luminal A) Selective treatment|"Selective treatment:~Postmenopausal patients: exemestane x 6 months Premenopausal patients: goserelin x 6 months + exemestane x 6 months"
89066997|NCT01295814|Placebo Comparator|Inactive drug|Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks
89066998|NCT01254045|Experimental|placebo, oxytocin 24IU, oxytocin 48IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
89066999|NCT01254045|Experimental|oxytocin 24IU, placebo, oxytocin 48IU|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
89223145|NCT00432172|Active Comparator|Group 2 (Basal) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
89223146|NCT00432172|Experimental|Group 2 (Basal) Selective treatment|Selective treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv and carboplatin (Cb) (area under the curve = 6 mg/mL) iv every 21 days for 4 cycles.
89223147|NCT01034410|Active Comparator|Control|cytarabine 2g/m2 bid Days 4-7
89223148|NCT01034410|Experimental|AS1411-40|AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7
89223149|NCT01034410|Experimental|AS1411-80|AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7
89223150|NCT01034488|Active Comparator|Heparin sodium - APP|5000UI / mL
89223151|NCT01034488|Experimental|Heparin - Eurofarma|5000 UI/ mL
89690352|NCT03127137|Active Comparator|Experimental Group 1|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
89690353|NCT03127137|Placebo Comparator|Experimental Group 2|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
89223152|NCT00415168|Experimental|Pemetrexed + Cisplatin|
89223153|NCT01034566|Experimental|Arm I|Patients undergo proton beam radiotherapy 5 days a week for 6 (preoperative patients) or 8 (post-operative patients) weeks in the absence of disease progression or unacceptable toxicity.
89223154|NCT00424762|Experimental|rosiglitazone|4mg titrated to 8mg daily
89223155|NCT00424762|Placebo Comparator|Placebo|blinded matching placebo treatment
89223156|NCT00967122|No Intervention|No Arm|
89223157|NCT05140590||Participants with a diagnosis of hypertension admitted to the emergency department|"Direct questioning about general data, medical history and about the pharmacological scheme for the treatment of hypertension.~Review of clinical records to obtain data about the admission diagnosis, drugs administered during their hospital stay, and blood pressure figures at admission, during hospital stay and at discharge.~Analysis and classification of theoretical drug interactions using the IBM Micromedex Drug Interactions and iDoctus clinical decision support systems."
89223158|NCT00974610||Breast|
89223159|NCT00974610||Lung|
89223160|NCT00974610||Melanoma|
89690354|NCT05356780||Expert operators|
89690355|NCT05356780||Post-graduate students|
89690356|NCT03122847||Patients|30 patients with Graves' ophthalmopathy in which treatment with intravenous methylprednisolone is indicated
89690357|NCT05355142|Experimental|Group PM+|Intervention once a week for a total of 5 weeks
89690358|NCT05355142|No Intervention|control group|Just daily observation
89690359|NCT00636506|Experimental|AMS 700 IPP 2005 Implant Group|Male subjects 21 years of age and older who are implanted with an AMS 700 IPP with MS (Momentary Squeeze) pump for erectile dysfunction.
89690360|NCT04342221|Experimental|Hydroxychloroquine Sulfate|First dose: 800 mg. From 2nd day on, each patient will get 600 mg (3 capsules) once a day until day 7 (6 more does of 600 mg).
89690361|NCT04342221|Placebo Comparator|Placebo|Equivalent number of placebo capsules at the day of inclusion (4 capsules) and the following days (3 capsules)
89690362|NCT03632889|No Intervention|Control Arm|Subjects randomized to the control group will receive a sleep hygiene handout .
89690363|NCT03632889|Other|Computerized Group|Subjects randomized to GoToSleep program will receive a sleep hygiene handout and a unique code for home access to the GoToSleep program.
89690364|NCT03525028|Experimental|Metformin group|Oral metformin 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
89690365|NCT03525028|Placebo Comparator|Placebo group|Oral placebo 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
89690366|NCT00636194|Experimental|B&L Multipurpose solution|Bausch & Lomb Multipurpose Contact Lens Solution
89690367|NCT00636194|Active Comparator|Alcon Multipurpose Solution|Alcon OptiFree Replenish Multipurpose Contact Lens Solution
89690368|NCT03631797|Experimental|Microvascular reactivity evaluation|"Patients referred for a preoperative arterial palmar arches assessment before cardiac valvular or coronary surgery.~Intervention is measurement of microvascular reactivity with a laser speckle contrast imaging before surgery."
89690369|NCT00754312|Experimental|1|ER positive
89690370|NCT00754312|Experimental|2|ER negative and/or PR negative histology
89690371|NCT00754312|Experimental|3|triple negative histology (for ER, PR, HER-2)
89690372|NCT04736368|Experimental|EDIP Group|CD participants will receive EDIP diet information
89690373|NCT04736368|Placebo Comparator|Control Group|CD participants will be given diet suggestions according to routine experience.
89690374|NCT04744779|No Intervention|Observation|Observation only.
89690375|NCT04744779|Experimental|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
89690376|NCT03622359|Experimental|SPECT/CT perfusion imaging|Patients with peripheral artery disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo SPECT/CT imaging as part of the research protocol.
89690377|NCT03622359|Experimental|PET/CT perfusion imaging|Patients with peripheral artery disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo PET/CT imaging as part of the research protocol.
89690378|NCT03097107|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks
89690379|NCT03097107|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks
89690380|NCT03097107|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks
89690381|NCT03097107|Placebo Comparator|Placebo|Placebo tablet orally once a day for 12 weeks
89690382|NCT04767646|Experimental|C-BNP with intensive rehabilitation program|
89690383|NCT03621345|Active Comparator|ESP block group|"The bilateral erector spine plane (ESP) block will be performed with ultrasound guided, preoperatively. Following antiseptic preparation of block site with povidone iodine, ultrasound probe will be placed 3 cm lateral to spine at T5 level. After identifying the erector spinae muscle and transverse process, the overlying skin will be infiltrated with local anesthetics and 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL 1% lidocaine) will be injected deep to the erector spinae muscle. The same procedure will be performed on the other side. Also, patients will receive intravenous patient controlled analgesia with morphine, and 1 g acetaminophen for supplemental analgesia if pain score raises over 5/10 on NRS and 50 mg meperidine for rescue analgesic for persistent pain.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
89223161|NCT00974610||Pancreatic|
89223162|NCT00974610||Colorectal|
89223163|NCT00974688|Active Comparator|Group 1|
89223164|NCT00974688|Active Comparator|Group 2|
89223165|NCT00967278||Off-Pump|Patients with coronary artery disease undergoing elective off-pump CABG
89223166|NCT00967356|Experimental|A|AZD5985
89223167|NCT00967356|Placebo Comparator|B|Placebo
89223168|NCT00980304|Experimental|Rituximab in combination with ICE as salvage therapy|
89223169|NCT00974766|Active Comparator|Low-dose glucocorticoid|Low-dose steroid
89223170|NCT00974766|Active Comparator|High-dose glucocorticoid|High-dose steroid
89223171|NCT00967434|Active Comparator|Group A- atorvastatin in pre and postop|Atorvastatin 80 mg administered daily for at least 7 preoperative days, 80 mg on day of surgery and 80 mg daily for up to 7 postoperative days.
89229847|NCT01091233||Paracentesis|Paracentesis as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
89067000|NCT01254045|Experimental|oxytocin 48IU, oxytocin 24IU, placebo|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
89067001|NCT01254045|Experimental|oxytocin 24IU, oxytocin 48IU, placebo|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
89067002|NCT01254045|Experimental|oxytocin 48IU, placebo, oxytocin 24IU|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles ; intranasal oxytocin (24 international units) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
89067003|NCT01254045|Experimental|placebo, oxytocin 48IU, oxytocin 24IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
89067004|NCT04324320||outpatients (oncological rehabilitation)|the population studied in this cross-sectional study includes patients with malignant tumour diseases and benign CNS tumours who present to the Outpatient Clinic for Oncological Rehabilitation at the Department of Physical Medicine and Rehabilitation of the Medical University of Vienna
89067005|NCT01075282|Experimental|LY2189265 1.5 mg|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
89067006|NCT01075282|Experimental|LY2189265 0.75 mg|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
89067007|NCT01075282|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
89067008|NCT04324242||Group1|visual feedback
89067009|NCT04324242||Group2|traditional feedback
89067010|NCT04324086|Experimental|XP-endo Finisher file|removal of calcium hydroxide intracanal medication with XP-endo Finisher file
89067011|NCT04324086|Experimental|Irrisafe Ultrasonic tip|removal of calcium hydroxide intracanal medication with passive ultrasonic irrigation
89067012|NCT04324086|Active Comparator|side vented needle|removal of calcium hydroxide intracanal medication with conventional syringe irrigation
89067013|NCT01253811|Experimental|rFXIII 35 IU/kg|
89067014|NCT01295580|Active Comparator|ARTZ sodium hyaluronate|The comparator product, ARTZ, is manufactured by Seikagaku Corporation, Japan. Subjects randomized to the ARTZ group were administered five weekly intra-articular injections (2.5 ml, NASHA 25 mg). ARTZ is a sterile, viscoelastic nonpyrogenic solution of purified, high molecular weight (620,000-1,170,000 daltons) sodium hyaluronate having a pH of 6.8-7.8. The sodium hyaluronate is extracted from chicken combs.
89067015|NCT01295580|Active Comparator|DUROLANE hyaluronic acid|The investigational product was provided in pre-filled syringes containing stabilized non-animal hyaluronic acid (20 mg/mL). Only one injection was given for those subjects randomized to the DUROLANE group, followed by 4 sham injections. DUROLANE is free from products of animal origin and is manufactured by Q-Med AB Corporation.The sham injection procedure was same as the active injection, except that they were subcutaneous and an empty syringe was used.
89067016|NCT01253577|Active Comparator|Drug Coated|Sinus stent coated with steroid
89067017|NCT01253577|Placebo Comparator|Non coated|Sinus stent without drug coating
89067018|NCT01295034|Placebo Comparator|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
89067019|NCT01295034|Experimental|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
89067020|NCT01253421|Active Comparator|MDD-amisulpride|Subjects experiencing a current episode of major depression who are randomized to receive amisulpride
89067021|NCT01253421|Placebo Comparator|MDD-placebo|Subjects experiencing a current episode of major depression who are randomized to receive placebo
89067022|NCT01253421|Active Comparator|HC-amisulpride|Subjects having no history of mental disorder (healthy controls, HC) who are randomized to receive amisulpride
89067023|NCT01253421|Placebo Comparator|HC-placebo|Subjects having no history of mental disorder who are randomized to receive placebo
89067024|NCT01077076|Experimental|Zegerid OTC Capsules|20 mg omeprazole and 1100 mg sodium bicarbonate
89067025|NCT01077076|Active Comparator|Prilosec OTC™ tablets containing 20 mg-equivalent omeprazole|20.6 mg omeprazole-magnesium complex.
89067026|NCT01077076|Placebo Comparator|Placebo|Inert substance
89067027|NCT02876848|Experimental|Intervention Site|"The hospital that will be the intervention site will have access to the OPTIMUM e-health tool. The intervention site cancer care team will receive the following OPTIMUM e-health alerts:~An electronic alert of increased Adjuvant Endocrine Therapy discontinuation risk.~An adherence to Adjuvant Endocrine Therapy monitor.~An electronic discontinuation occurrence alert"
89067028|NCT02876848|No Intervention|Control Site|The hospital that will be the control site will not have access to the OPTIMUM e-health tool. The cancer care team will continue to deliver care according to standard processes.
89067029|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
89067030|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
89067031|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 1: SRP)|Stage 1 Safety Run-in Phase (SRP): Approximately 12 participants will receive cobimetinib 60 milligrams (mg) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 milligrams per kilogram (mg/kg) administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to Stage 2: dose expansion phase. If the results from the safety run-in phase require dose reduction in cobimetinib, then an additional Stage 1 cohort will be opened. Treatment will continue until the participant has disease progression according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
89067032|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: BC)|Stage 2 Biopsy Cohort (BC): Approximately 7 evaluable participants in the biopsy cohort in expansion phase will receive bevacizumab 5 mg/kg IV on Cycle 1 Days 1 and 15 (tumor biopsy on Cycle 1 Day 8) and cobimetinib (at dose determined during safety run-in phase) orally on Cycle 1 Day 15 to Cycle 2 Day 14 (tumor biopsy on Cycle 1 Day 22). From Cycle 2 onwards, participants will follow the same treatment regimen for bevacizumab and atezolizumab (optional tumor biopsy on Cycle 2 Day 22) as those in the safety run-in phase and expansion cohort, and for cobimetinib cycles start at Day 15 and will continue 21 days to Day 7 of next cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Biopsies must be collected before the initiation of cobimetinib and atezolizumab. Treatment will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, decision to withdraw, or pregnancy, whichever occurs first.
89067033|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: EC)|Stage 2 Expansion Cohort (EC): Approximately 14 participants will receive cobimetinib (at dose determined during safety run-in phase) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 mg/kg administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Treatment will continue until the participant has disease progression according to RECIST v1.1, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
89067034|NCT01294800|Experimental|Preladenant 2 mg|Participants will receive preladenant 2 mg taken orally twice daily (BID), one tablet in the morning and one tablet in the evening, for 12 weeks.
88812884|NCT01552889|Experimental|Collaborative Care (CC)|Patients randomized to the Collaborate Care (CC) arm of this study will receive brief screening, consultative, and referral services. This collaborative approach includes the patient, the patient's PCP, the cardiologist, and the nurse case manager (NCM), using evidence based recommendations for depression treatment and follow-up care.
89067035|NCT01294800|Experimental|Preladenant 5 mg|Participants will receive preladenant 5 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
89067036|NCT01294800|Experimental|Preladenant 10 mg|Participants will receive preladenant 10 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
89067037|NCT01294800|Placebo Comparator|Placebo|Participants will receive a placebo to preladenant tablet taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
89067038|NCT01294644|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89067039|NCT01294644|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89067040|NCT01294644|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
89067041|NCT01293240|Experimental|Lotrafilcon B|
89067042|NCT01253265|Experimental|30 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
89067043|NCT01253265|Experimental|80 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
89067044|NCT01253265|Experimental|180 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
89067045|NCT01253265|Placebo Comparator|Placebo|Placebo is administered subcutaneously in the same manner as active drug in each dose group
89067046|NCT01253265|Experimental|120 mg LY2439821|Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week
89067047|NCT01293084|Experimental|7% saline|5 mL of 7% saline was inhaled once over a 20 minute period.
89223172|NCT00967434|Active Comparator|Group B- Atorvastatin postop|Placebo administered for up to 7 preoperative days, atorvastatin 80 mg administered on day of surgery and daily for up to 7 postoperative days.
89223173|NCT00967434|Placebo Comparator|Group C- Placebo|Patients receive placebo daily for up 7 preoperative days, placebo on day of surgery and placebo daily for up to 7 postoperative days.
89223174|NCT00967512|Experimental|cenersen, idarubicin, cytarabine|cenersen, idarubicin, cytarabine
89223175|NCT00967512|Placebo Comparator|placebo, idarubicin, cytarabine|placebo, idarubicin, cytarabine
89223176|NCT00414544|Experimental|CosmetaLife|Test Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
89223177|NCT00414544|Active Comparator|Restylane|Control Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
89223178|NCT04082910|Experimental|Conditional therapy mode group|Metoprolol (12.5-25 mg per dose, every 12 hours) was initially given from the day of CRS diagnosis confirmation post CAR T cell infusions till CRS remission in patients without bulky tumor burden. For all metoprolol-treated patients, the use of antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
89223179|NCT04082910|Experimental|Prophylactic therapy mode group|Metoprolol (12.5-25 mg per dose, every 12 hours) was given starting from the day before CAR T infusion till CRS remission in patients with bulky disease. For all metoprolol-treated patients, the use of antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
89223180|NCT01618786|Experimental|Compliant Flooring (CF)|Compliant flooring
89067048|NCT01293084|Placebo Comparator|0.12% saline|5mL 0.12% saline inhaled once during 20 minutes
89067049|NCT01293006|Experimental|Suvorexant first, then placebo|"During Period 1, participants <65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening and participants ≥65 years of age were administered a 30-mg oral dose of~suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening."
89067050|NCT01293006|Experimental|Placebo first, then suvorexant|"During Period 1, participants <65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening and participants ≥65 years of age received one placebo tablet matching~suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening."
89067051|NCT02335749|Experimental|Treatment with Small Area Applicator|Each enrolled subject was treated on a single thigh, in the distal region.
89067052|NCT01253187|Experimental|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|single oral administration of 1 film-coated SHT00186D tablet (YAZ), containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)
89067053|NCT01253187|Experimental|EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532B tablet, containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
89067054|NCT01253187|Experimental|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated SHT04532C tablet, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
89067055|NCT01252563||Amlodipine 10mg Tablet|Subjects taking Amlodipine 10mg Tablet.
89067056|NCT01292226|Experimental|Mycophenolate Mofetil Monotherapy|Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks. Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.
89067057|NCT04207047|Experimental|Group A|Group A (up to n=5): Genius exposure 1-3 hours before tissue resection
89067058|NCT04207047|Experimental|Group B|Group B (up to n=5): Genius exposure 30+7 days, 14+3 days, and 7+3 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
89067059|NCT04207047|Experimental|Group C|Group C (up to n=5): Genius exposure 90+14 days, 60+10 days, and 30+7 days before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
89067060|NCT04207047|Experimental|Group D|Group D (up to n=10): Genius, LaseMD, LaseMD FLEX, eCO2 and/or PicoPlus exposure 14+3 days, 7+3 days, and 1-3 hours before tissue resection. All test spot exposure visits will have a follow-up visit at 7+3 days after the test spot exposure visit.
89067061|NCT01290822|Experimental|BiVP Pacing|BIVP optimize AVD, VVD, and LVPS parameters and assess the effect on cardiac output.
89067062|NCT01290822|Active Comparator|AAI Pacing|Traditional atrial (AAI) pacing
89067063|NCT01075048|Experimental|Phase 2: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
89067064|NCT01075048|Placebo Comparator|Phase 2: Placebo, cetuximab, irinotecan|Placebo in combination with irinotecan and cetuximab
89067065|NCT01075048|Experimental|Phase 1: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
89067066|NCT01290666||GORE® BIO-A® Fistula Plug|All patients in study receive the GORE® BIO-A® Fistula Plug.
89067067|NCT01252251|Experimental|RAD001 and pasireotide LAR|This study will be an open-label, single-arm, phase II study of RAD001 and pasireotide LAR.
89067068|NCT01289574|Placebo Comparator|Vehicle control cream|
89067069|NCT01289574|Experimental|0.025% ASC-J9 cream|
89067070|NCT01289574|Experimental|0.1% ASC-J9 cream|
89067071|NCT02888301||Basic science (18F-clofarabine biodistribution)|Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.
89067072|NCT00624273|Other|1, active ulcers|sildenafil treatment
89067073|NCT02874976|Experimental|Experimental: Group A|"Active and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before aerobic training, and the same program 1 after training"
89067074|NCT02874976|Experimental|Experimental: Group B|"Active and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before aerobic training, and program 2 after training."
89223181|NCT01618786|Placebo Comparator|Control (CON)|Non-compliant flooring
89223182|NCT00967590|Experimental|1|
89223183|NCT00967590|Placebo Comparator|2|
89223184|NCT00975078|Experimental|adrenal insufficiency|
89223185|NCT00984516|Experimental|Intradermal Juvidex|
89067075|NCT02874976|Experimental|Experimental: Group C|"Placebo and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before aerobic training, and program 1 after training."
89067076|NCT02874976|Experimental|Experimental: Group D|"Placebo and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
89067077|NCT04305964|Experimental|Nastent® users|Patients with an established diagnosis of obstructive sleep apnea with apnea/hypopnea-index (AHI) < 20/ hour sleep who receive Nastent® as treatment modality
89067078|NCT01252095|Experimental|PG545|
89067079|NCT01289418||Health care workers in Québec|Health care workers from CHUQ hospitals
89067080|NCT01289418||Health care workers in Toronto|Health care workers from the Mount Sinai Hospital
89067081|NCT01289418||Health care workers in Halifax|Health care workers from the Queen Elizabeth Hospital
89067082|NCT04306042||Treatment|Patients diagnosed with primary stage IIIB-IV squamous cell lung cancer and treated in 92 medical centers between 01 September 2019 and 30 June 2020 will be targeted for study inclusion.
89067083|NCT04305886|Experimental|Intervention|Providers were placed in small groups and given the intervention of a discussion guide to facilitate discussion.
89067084|NCT04305886|No Intervention|Control|Providers were placed in small groups and not given a discussion guide to facilitate discussion.
89067085|NCT04305730|Experimental|Pedometer Group|This group will be given a pedometer following radical cystectomy. Subjects in the experimental group will have a graduated step-count goal as follows: POD 0-2: 1,000/day. POD 3-6: 2,000/day. POD 7-9: 3,000/day. POD 10-14: 4,000/day. POD 14-21: 5,000
89067086|NCT04305730|Active Comparator|Control group|This is the control group. Following radical cystectomy subjects in the control group will receive standard of care, which includes counseling regarding the importance of ambulation following surgery.
89067087|NCT01074658||severe aortic valve stenosis|elderly patients with severe aortic valve stenosis requiring treatment
89067088|NCT01074502|Experimental|apremilast|apremilast 20 mgs twice a day for 12 weeks
89067089|NCT01289028|Experimental|Nilotinib|nilotinib 400 mg twice daily (bid).
89067090|NCT04305652|No Intervention|Control group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 19 and below )
89067091|NCT04305652|Experimental|Experimental group|Care providers of Alzheimer's patients aged 65 and over (the standardized Mini-Mental State Examination (MMSE) test cognitive levels score is 19 and below) The caregivers of Alzheimer's patients will be trained for 3 months according to the Progressively Lowered Stress Threshold Model with a home visit.
89067092|NCT02875990|Experimental|patients with invasive cervical cancer|Blood sample
89067093|NCT04777474|Experimental|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy
89067094|NCT02890056|Experimental|H2GO! intervention|H2GO! is a community-based behavioral intervention to reduce sugar-sweetened beverage consumption and promote water intake among school-age youth and parents.The intervention consists of 6 weekly group-based sessions (1-hour sessions twice a week) that target beverage knowledge, attitudes, and behaviors through interactive activities, youth-produced narratives, and parent-child activities. The intervention is delivered through a youth-based community setting (Boys and Girls Clubs of America) by trained Boys and Girls Club staff.
89067095|NCT02890056|No Intervention|Comparison|Usual care will take place at the comparison site (standard programming at the Boys and Girls Club comparison site).
89067096|NCT04303312|Active Comparator|Benzydamine Hydrochloride|"Control Group:Benzydamine Hydrochloride spray by mouth three times daily for 20 days.~Follow up: The patients will be recalled at one week interval for 20 days."
89067097|NCT04303312|Experimental|90%solcoseryl and 10% pumpkin seed oil|Intervention group: 90% solcoseryl and 10% pumpkin seed oil spray by mouth three times daily for 20 days
89067098|NCT05590026|Active Comparator|Pectointercostal and ESP block|Pectointercostal and ESP block will apply to the children after intubation. Totally bupivacain %0.25, 2.5 mg/kg will apply.
89067099|NCT05590026|Placebo Comparator|No Block|No block will apply to the patient
89067100|NCT04303546||< 30 years|
89067101|NCT04303546||30-60 years|
89067102|NCT04303546||> 60 years|
89067103|NCT05579184|Experimental|[177Lu]Ludotadipep 100 mCi|100 mCi of [177Lu] ludotadipep shall be administered to the subject repeatedly up to 6 times at intervals of 8 weeks (±2 weeks).
89067104|NCT04303624||Community sample|Representative sample of the Singapore population
89067105|NCT04305574||Community sample|We plan to recruit a representative sample of the Singapore population.
89067106|NCT01250925|Active Comparator|OPTI-FREE® RepleniSH®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
89067107|NCT01250925|Active Comparator|Clear Care®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
89067108|NCT01250925|Active Comparator|ReNu MultiPlus® MultiPurpose Solution|33 participants will be assigned to use this lens care regimen during the six-week assessment period
89067109|NCT01285908|No Intervention|Baseline|Baseline values measured at various tilt angles, so that each participant may serve as their own control.
89223186|NCT00984516|Placebo Comparator|Placebo (vehicle)|
89067110|NCT01285908|Placebo Comparator|Saline infusion|Subjects received a saline IV infusion as a placebo, while measurements were taken at various tilt angles.
89067111|NCT01285908|Active Comparator|Norepinephrine Infusion|Subjects were given an norepinephrine infusion at various tilt angles, while measurements were taken.
89067112|NCT05577234|Experimental|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of the sessions. During these sessions, the dog will be brought into the child's presence in the waiting room until the end of the dental consultation.
89067113|NCT05577234|Other|Standard care|The treatment sessions will only involve the use of conventional behavioural strategies.
89067114|NCT01250769|Active Comparator|Manual Toothbrush 1|Manual Toothbrush used for 1 minute twice a day
89067115|NCT01250769|Active Comparator|Manual Toothbrush 2|Manual Toothbrush used for 2 minutes twice a day
89067116|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 1|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used once a day
89067117|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 2|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used twice a day
89067118|NCT05574270|Experimental|IC-8 IOL Group|A monofocal or monofocal toric IOL implanted in the first eye of a subject and the IC-8 IOL implanted in the second eye.
89067119|NCT01074268|Experimental|IDeg OD|
89067120|NCT01074268|Active Comparator|IDet|
89067121|NCT04303234|Active Comparator|Artinibsa|"Powerful local anesthetic with short time for patients who can not tolerate normal doses of vasoconstrictor latency.~High lipid solubility gives a better diffusion through the soft tissue and bone being very effective in infiltrative techniques.~Duration:~Latency time: 2 minutes~Each mL contains:~4%Articaine 1:100000. Hydrochloride 40.00 mg, Epinephrine (D.C.I) 0.005 mg tartrate"
89067122|NCT04303234|Experimental|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
89067123|NCT01074190|Experimental|Group 1|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg followed by a patient controlled epidural analgesia (PCEA) maintenance infusion of bupivacaine 1mg/mL
89067124|NCT01074190|Experimental|Group 2|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg spinal followed by a PCEA infusion of fentanyl 1 micrograms/mL plus bupivacaine 0.8 mg/mL
89067125|NCT01074190|Active Comparator|Group 3|spinal fentanyl 15 micrograms plus bupivacaine 2.5mg followed by a PCEA infusion of fentanyl 2 micrograms/mL plus bupivacaine 0.625 mg/mL
89067126|NCT01073566|Experimental|Finesse|Finesse Insulin Delivery Patch
89067127|NCT01073566|Active Comparator|Usual injection device|Pen/Syringe
89067128|NCT01072396|Active Comparator|18 mcg tiotropium|Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
89067129|NCT01072396|Placebo Comparator|Placebo|Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
89067130|NCT01072396|No Intervention|Control|Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
89067131|NCT01045096|Experimental|Dexlansoprazole 15 mg QD|
89067132|NCT01045096|Experimental|Dexlansoprazole 30 mg QD|
89067133|NCT01045096|Experimental|Dexlansoprazole 60 mg QD|
89067134|NCT02876146|Other|Hepatic alveolar echinococcosis|"Follow-up of standardized clinical, biological, and imaging characteristics (according to the WHO-expert consensus). Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)~Standardized earlier withdrawal of benzimidazole :~Patients with non operable hepatic AE lesion : Withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after at least 4 years when viability markers became negative (PET-CT, serological markers)~Curative hepatectomy : Earlier withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after one year (WHO guidelines : 2 years), if viability markers became negative. Close prospective follow-up after withdrawal (PET-CT, serological markers)"
89067135|NCT02874586|Experimental|Plasma exchange combination of immunosuppressive regimens|Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis
89067136|NCT02875756|Experimental|10 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
89067137|NCT02875756|Active Comparator|20 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
89067138|NCT04305418|Experimental|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
89067139|NCT04305418|No Intervention|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
89067140|NCT02875678|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
89067141|NCT02875678|Placebo Comparator|Placebo|Placebo, capsules, single dose
89067142|NCT02874820|Experimental|Patient Group|Baseline PET scan followed by a blocked PET scan
89067143|NCT04305028||Experimental: Rivaroxaban [2.5 mg] + Aspirin|Drug: Rivaroxaban 2.5 mg twice daily, tablet Drug: Aspirin 75-100 mg once daily, tablet
89067144|NCT04305028||Active Comparator: Aspirin|Drug: Aspirin 75-100 mg once daily, tablet
89067145|NCT04304794||Group with prophylaxis|Group of 13 patients with euthyroid goiter who received prophylactic treatment before and after iodinated contrast medium (ICM) injection. 6 patients received thiamazole with sodium perchlorate, one day prior to ICM and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily). 7 patients received only thiamazole as prophylactic treatment due to lack of sodium perchlorate at the time.
89223187|NCT04007016||Pemberton osteotomy （PO）|PO group received Pemberton osteotomy
89223188|NCT04007016||"inner L shaped iliac osteotomy (ILSO)"|"ILSO group received inner L shaped iliac osteotomy"
89223189|NCT00980616|Experimental|Ropivacaine, serum, adrenalin|235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin.
89223190|NCT00980616|No Intervention|No infiltration|B: no infiltration
89223191|NCT00980694|Experimental|Ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
89223192|NCT00980850|Experimental|Groups A1 and A2|Baxter vaccine
89223193|NCT00980850|Experimental|Groups B1 and B2|GSK vaccine
89223194|NCT00414466|Placebo Comparator|Placebo (0mg/day)|Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
89223195|NCT00414466|Active Comparator|Gabapentin Low (1mg/day)|Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
89223196|NCT00414466|Active Comparator|Gabapentin Medium (6mg/day)|Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
89223197|NCT00414466|Active Comparator|Gabapentin High (30mg/day)|Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
89223198|NCT00975234|Experimental|Skeletal myoblasts|Patients who are receiving skeletal myoblasts
89223199|NCT00975234|Placebo Comparator|Placebo|Revascularisation surgery
89223200|NCT00984750|Experimental|1|Statin and acetyl-L-carnitine
89223201|NCT00984750|Placebo Comparator|2|Statin and placebo
89223202|NCT01033162|No Intervention|Usual Care|A group using a Basic ICCS provided by KPNW
89067146|NCT04304794||Group without prophylaxis|Group of 23 patients with euthyroid goiter who received no prophylactic treatment before iodinated contrast medium injection.
89067147|NCT01285518|Experimental|Treatment|
89067148|NCT01285518|Placebo Comparator|Placebo|0.9% w/v sodium chloride injection, USP
89067149|NCT01073020|Active Comparator|Gastric Band vs Intensive Diabetes & Weight Management|"Patients will be randomized to receive either 1) laparoscopic placement of an adjustable gastric band (LAGB) or 2) treatment with an intensive medical and weight management (IMWM) program.~LAGB will be placed using the pars flaccida technique. The Allergan laparoscopic band LAP BAND system will be utilized. LAGB ports will be placed in subcutaneous pockets in the right upper abdomen.~The IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education."
89223203|NCT01033162|Experimental|Intervention|A group using an enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
89223204|NCT00975312|Experimental|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.
89223205|NCT01034644||PRISMS patients|This single group includes all the patients from the PRISMS study
89223206|NCT00984906|Other|Empty Easyhaler type A|
89223207|NCT00984906|Other|Empty Easyhaler type B|
89223208|NCT00984906|Other|Empty Turbohaler|
89223209|NCT00424528|Active Comparator|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
89223210|NCT00424528|Active Comparator|Tiotropium 18 mcg once daily|Tiotropium 18 mcg once daily/Placebo Inhalation Solution
89223211|NCT00424528|Experimental|Arformoterol /Tiotropium|Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily
89223212|NCT04974996|Experimental|Part 1: Dose Escalation|Participants will receive escalating doses of loncastuximab tesirine (initial dose of 60 μg/kg and highest dose possibly tested of 150 µg/kg) in combination with R-CHOP (rituximab 375 mg/m^2, cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, and prednisone 100 mg/day) according to a standard 3+3 dose escalation design. The dose escalation part will be completed once the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) has been identified.
89223213|NCT04974996|Experimental|Part 2: Dose Expansion|Participants will receive the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as determined in Part 1.
89223214|NCT00981006|Experimental|human cardiac stem cell therapy|single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
89223215|NCT00975390|Experimental|1|Carbohydrate ingestion
89223216|NCT00975390|Experimental|2|Carbohydrate and protein ingestion
89223217|NCT00975390|Experimental|3|Carbohydrate and caffeine ingestion
89223218|NCT00981240|Experimental|Dose escalation|Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
89223219|NCT00981318|Other|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid|single arm
89223220|NCT00975468|Active Comparator|Pressure-Controlled Ventilation|The patients' lungs ventilation will be initiated with a peak airway pressure that provided a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
89223221|NCT00975468|Placebo Comparator|Volume Controlled Ventilation|The patients' lungs will ventilated with a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
89223222|NCT00984984|Experimental|methylprednisolone PO|
89223223|NCT00984984|Active Comparator|methylprednisolone IV|
89223224|NCT00985062|Active Comparator|Mild Ovarian Stimulation|
89223225|NCT00985062|Active Comparator|Conventional Ovarian Stimulation|
89223226|NCT00981552|Other|Cervix Cancer|Patients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
89223227|NCT05115786||Cohort A|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
89223228|NCT05115786||Cohort B|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
89223229|NCT05115786||Cohort C|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
89223230|NCT05115786||Cohort D|FFPE specimen collection. FFPE tumor tissue samples must be collected after surgical resection and before starting chemotherapy or other treatment.
89223231|NCT00975702|No Intervention|No RIPC Group|This group is the control group or the comparator group with RIPC
89223232|NCT00975702|Experimental|RIPC Group|In this group deceased donors will receive Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet of the lower limb prior to organ recovery.
89223233|NCT00985218|Experimental|experimental arm|Embryos cultured in SMART System
89223234|NCT00985218|Active Comparator|Control|Embryos cultured in microdrops in dishes
89223235|NCT00545532|Experimental|Conventional dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
89223236|NCT00545532|Experimental|Double dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.
89067150|NCT01073020|Active Comparator|RYGB vs Intensive Diabetes & Weight Management|"Patients will be randomized to receive either 1) Roux-en-Y gastric bypass (RYGB) surgery or 2) treatment with an intensive medical and weight management (IMWM) program.~RYGB will be performed using a 75 cm antecolic, ante-gastric Roux limb created with a 50 cm pancreaticobiliary limb. A 15-20 cc gastric pouch will be created lying along the lesser curve of the stomach, with division of the vagal trunks at the lower border of the pouch.~The IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education."
89067151|NCT02875600|Experimental|Nutri drink|MRI flow measurements of mesenterial vessels and portal vein before and after stimulation with nutritional drink
89067152|NCT02874664|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine intravenously on Day 1 of every 6-week treatment cycle for 2 cycles omitting every third cycle
89067153|NCT02889744|Active Comparator|36-TH|Core temperature 36℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
89067154|NCT02889744|Active Comparator|33-TH|Core temperature 33℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
89067155|NCT04754308|Other|Patients referred to social nurse|"After obtaining informed consent, the social nurse reviews the online-questionnaire with the patient and performs a lung function examination requiring the patient to blow into a plastic tube. If a patient is identified as having obstructive reduction of lung function, they are offered a referral to a local pulmonary medicine department or GP for further investigation - regardless of whether or not they have a diagnosed or undiagnosed lung disease.~In addition, participants are questioned about their motivation for smoking cessation and are informed of the options for this (in hospital and/or referral to the municipality)."
89067156|NCT00623844|Experimental|Intervention|Physical activity intervention: structured daily 30-min activity classes at preschool, activity homeworks, parent and teacher education
89067157|NCT00623844|No Intervention|Control|Keep usual activities in kindergarten
89067158|NCT04207554||Pregnancy Positive|Pregnant subjects within 11 weeks since the first day of last period.
89067159|NCT04207554||Pregnancy Negative|Non-pregnant subjects.
89223237|NCT00544440|Experimental|Abiraterone acetate plus prednisone|Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
89223238|NCT04006860|Experimental|SHC014748M: Fast + Fed|Participants will receive a single oral dose of SHC014748M capsules in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fed condition on Day 8 of treatment period 2.
89223239|NCT04006860|Experimental|SHC014748M: Fed + Fast|Participants will receive a single oral dose of SHC014748M capsules in fed condition on Day 1 of treatment period 1 followed by a single oral dose of SHC014748M capsules in fasted condition on Day 8 of treatment period 2.
89223240|NCT00981708|Experimental|Treatment|Lenalidomide, Dexamethasone and cyclophosphamide
89223241|NCT04007718|Experimental|Active|
89223242|NCT04007718|Sham Comparator|Control|
89223243|NCT03920670|Experimental|Tetragraph (TG)|TetraGraph placed on dominant hand, ToFscan placed on non-dominant hand
89223244|NCT03920670|Active Comparator|ToFscan (TS)|ToFscan placed on dominant hand, TetraGraph (TG) placed on non-dominant hand
89223245|NCT00430300|Experimental|150mcg, 450mcg or 1350mcg|Active treatment given BID via a double pin monodose capsule inhaler device
89223246|NCT00430300|Placebo Comparator|Placebo|Placebo treatment given BID via a single pin monodose inhaler device
89223247|NCT00981786|Active Comparator|Brinzolamide/Timolol therapy|Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops
89223248|NCT00981786|Active Comparator|Brimonidine/Timolol therapy|Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops
89223249|NCT00975858|Active Comparator|Percutaneous Coronary Intervention|
89223250|NCT00975858|Experimental|Off Pump Coronary Artery Bypass Surgery|
89223251|NCT04007562||Lipin-1 deficiency|Patients suffering from Lipin-1 deficiency havebenefited from an off-label use treatment by Hydroxychloroquine Sulfate as part of their care for at least 6 months.
89223252|NCT04007484|Experimental|HP+CPB/DHCA group|For patients randomized into the intervention group, a hemoperfusion device will be connected in series to the extracorporeal circulation machine in advance to ensure that every single patient will undergo continuous hemoperfusion from the beginning to the end of CPB.
89223253|NCT04007484|No Intervention|CPB/DHCA group|For patients randomized into the CPB/DHCA group, no hemoperfusion device will be connect to the extracorporeal circulation machine. Patients will undergo CPB and DHCA without continuous hemoperfusion.
89223254|NCT00981864|Experimental|Concurrent Boost RT|
89223255|NCT00985296||Ragweed+ Dust Mite+ CAC w/ DM|
89223256|NCT00985296||Ragweed + Dust Mite + CAC w/Saline|
89223257|NCT00985296||Ragweed + Dust Mite - CAC|
89223258|NCT00985374|Experimental|1|
89223259|NCT00975936|Experimental|[14C]-GSK706769|Single dose of 50µg [14C]-GSK706769 containing 250 nCi
89223260|NCT00975936|Experimental|[14C]-GSK706769 + Ketoconazole|An oral, 5-day repeat dose of 200 mg Ketoconazole (Q12) with a concomitant single oral dose of 50 µg [14C]-GSK706769 containing 250 nCi on day 3.
89223261|NCT00976092|Experimental|Prasugrel + Bivalirudin|60 mg prasugrel plus bivalirudin
89223262|NCT00976092|Active Comparator|Clopidogrel + Heparin|clopidogrel as loading and heparin
89223263|NCT00985452|Other|Group 2: Intervention|Subjects in Group two will received an activated GlowCaps system, which will remind them to take their medication.
89223264|NCT00985452|Other|Group 3: Intervention/financial incentive|Subjects in group 3 will receive an activated GlowCaps system, which will provide them with reminders to take their medication, Subjects in group 3 will also receive an additional financial incentive, the amount will be based on how often they remembered to take their medication during the 6-month study.
89223265|NCT00985452|Other|Group 1: Control|Subjects in group one will receive a de-activated GlowCaps system, which will not provide the reminder service.
89223266|NCT00985530|Experimental|Arm 1|Tamibarotene + Arsenic Trioxide
89223267|NCT04006782|Other|Narrow dental implants in multiple fixed prosthesis|
89223268|NCT04006470||Stannous Fluoride Dentifrice|Twice daily use
89223269|NCT04006470||Positive control dentifrice|Twice daily use
89223270|NCT04006470||Negative control dentifrice|Twice daily use
89223271|NCT01323712|Placebo Comparator|Placebo|
89223272|NCT04911036||Mothers and/or fathers with an antenatal diagnosis|
89223273|NCT04911036||Mothers and/or fathers with a postnatal diagnosis|
89223274|NCT03927846|Active Comparator|Telephone Contact (Nurse)|6 regular telephone contacts by nurses who will use a motivational interviewing technique
89223275|NCT03927846|Active Comparator|E-mail contact|6 computer generated email reminders (control arm) over an 8-week period.
89223276|NCT00982098|Experimental|Early Rehabilitation|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).~Patients will be instructed to carry on exercises at home for the following 11 months."
89223277|NCT00982098|No Intervention|Counseling and home-based exercises|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: Patients will be instructed to carry on pelvic floor exercises at home for the year after prostatectomy."
89223278|NCT00976170|Experimental|1|
88812885|NCT03214328||Determination of causes of fetal death|Both the extensive and selective protocols will be applied to each case of IUFD recruited, so that each case will serve as its own control. For each case, determination of cause from either protocol will be performed in a blind manner with respect to the other protocol.
89223279|NCT00982176||1|
89223280|NCT00982254|Experimental|Oral Insulin|oral insulin capsule formulation
89223281|NCT00982254|Active Comparator|Subcutaneous Insulin|Subcutaneous injection of regular human insulin
89223282|NCT00985608|Active Comparator|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
89223283|NCT00985608|Active Comparator|Group A: NCA 600mg +antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
89223284|NCT00985764||placental previa|
89223285|NCT00976326|Experimental|A: Healthy volunteers|
89223286|NCT00976326|Experimental|B: Subjects with mild liver impairment|
89223287|NCT00976326|Experimental|C: Subjects with moderate liver impairment|
89223288|NCT00976326|Experimental|D: Subjects with severe liver impairment|
89223289|NCT00985842|Other|Arm 1|Comparison of five different clinically used suspension and socket systems
89223290|NCT00982332|Active Comparator|betamethasone|patients treated with a single intramuscular injection of betamethasone
89223291|NCT00982332|Placebo Comparator|isotonic sodium chloride solution|
89223292|NCT00976638|Active Comparator|Chromogenic Arm|Active surveillance of colonization with MRSA or VRE by chromogenic agar with isolation of positive patients.
89223293|NCT00976638|Active Comparator|Molecular Arm|Active surveillance of colonization with MRSA and VRE by PCR; and of ESBL by chromogenic agar with isolation of positive patients
89223294|NCT04007328|Experimental|methylprednisolone|20 mg of methylprednisolone IV Q12H for 5 days
89223295|NCT04007328|Placebo Comparator|Placebo|normal saline IV Q12H for 5 days
89223296|NCT04007250||FENIX participants|Individuals being treated with the FENIX™ Continence Restoration System.
89223297|NCT04007172|Experimental|Neural Therapy & home exercise program|"Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
89223298|NCT04007172|Experimental|Physical Therapy & home exercise program|"Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.~Both the groups received education about fibromyalgia and home exercise program, which included stretching, strengthening, and aerobic exercises."
89223299|NCT00985920|Experimental|Tranexamic acid, 1.5 g|1.5 g of tranexamic acid in 50 cc of normal saline solution is given to the patients.
89223300|NCT00985920|Experimental|Tranexamic acid, 3.0 g|3.0 g of tranexamic acid in 50 cc of normal saline is given to the patients.
89223301|NCT00985920|Placebo Comparator|Placebo, saline|50 cc of sterile normal saline solution is given to the patients.
89223302|NCT00976794|Experimental|lithium plus carbamazepine|combination of the two drugs in standard dosage
89223303|NCT00976794|Active Comparator|lithium plus valproate|combination of the two drugs in standard dosage
89223304|NCT00985998|Experimental|Nimotuzumab|
89223305|NCT00982566|Experimental|Sequence I|
89223306|NCT00982566|Experimental|Sequence II|
89223307|NCT00982566|Experimental|Sequence III|
89223308|NCT00982566|Experimental|Sequence IV|
89223309|NCT00982566|Experimental|Sequence V|
89223310|NCT00982566|Experimental|Sequence VI|
89223311|NCT00982566|Experimental|Sequence VII|
89223312|NCT00982566|Experimental|Sequence VIII|
89223313|NCT00982566|Experimental|Sequence IX|
89223314|NCT00982566|Experimental|Sequence X|
89223315|NCT00982566|Experimental|Sequence XI|
89223316|NCT00982566|Experimental|Sequence XII|
89223317|NCT00982566|Experimental|Sequence XIII|
89223318|NCT00982566|Experimental|Sequence XIV|
89223319|NCT00982566|Experimental|Sequence XVI|
89223320|NCT00982566|Experimental|Sequence XV|
89223321|NCT00976872|Active Comparator|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
89223322|NCT00976872|Placebo Comparator|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
89223323|NCT00977028|Experimental|Tumescent Lidocaine with liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction
89223324|NCT00977028|Experimental|Tumescent Lidocaine No Liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction
89223325|NCT04006938|Experimental|Single Bout ('S') - 30 minutes of moderate intensity cycling|Subjects will perform a single 30-minute bout of moderate intensity cycling before breakfast
89223326|NCT04006938|Experimental|Multiple Bout ('M')|Subjects will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
89223327|NCT00982722|Experimental|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2
89223328|NCT00982722|Active Comparator|calciumcarbonate|calcium carbonate 500 mg x 2
89229848|NCT02530723|Experimental|Once a week|Group 1 will be invited to perform resistance training exercise 1 day/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
89223329|NCT00982800|Placebo Comparator|Placebo Sugar Pill|"Patients are stratified based on their initial pain score in the recovery room. patients with a pain numeric rating scale of greater than or equal to 7/10 are stratified to the high group. then randomized to receive gabapentin 200 mg tid x 9 doses, or placebo x 9 doses. Patients with a pain score equal to or less than 6/10 are stratified to the low group, then randomized to receive gabapentin 200mg tid x 9 doses or placebo x 9 doses.~All patients receive Acetaminophen 1gm every 6 hours for 3 days, Celecoxib 400mg as a loading dose then 200mg twice a day for 3 days. Patients also receive patient controlled analgesia (PCA) of hydromorphone for 24 hrs, then are transitioned to oxycodone 5-15 mg every 2 hours as needed."
89223330|NCT00982800|Active Comparator|Gabapentin 200 mg tid x 9 doses|
89223331|NCT00986076|Experimental|Enoxaparin infusion|"Congenital Cataract Surgery with IOL implantation~Intraocular infusion of Enoxaparin"
89223332|NCT00986076|Placebo Comparator|Balanced Salt Solution Infusion|Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution
89223333|NCT00977262|Experimental|Healthy control subjects, High saturated fat shake|
89223334|NCT00977262|Experimental|Healthy control subjects, High Monounsaturated fat shake|
89223335|NCT00977262|Experimental|Healthy control subjects, High Polyunsaturated fat shake|
89223336|NCT00977262|Experimental|Healthy obese subjecs, High saturated fat shake|
89223337|NCT00977262|Experimental|Healthy obese subjects, High monounsaturated fat shake|
89223338|NCT00977262|Experimental|Healthy obese subjects, High polyunsaturated fat shake|
89223339|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Saturated fat shake|
89223340|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Monounsaturated fat shake|
89223341|NCT00977262|Experimental|Obese diabetes type 2 subjects, High polyunsaturated fat shake|
89223342|NCT00984828|Experimental|vel 8 - ASCT|8 cycles of velcade with ASCT
89223343|NCT00984828|Active Comparator|vel4 - ASCT|4 cycles of velcade with ASCT
89223344|NCT00983034|Active Comparator|Membranous nephropathy|Patients with primary membranous nephropathy diagnosed by biopsy
89223345|NCT00983034|Active Comparator|IgA nephropathy|Patients with IgA nephropathy diagnosed by biopsy
89223346|NCT00983034|Active Comparator|Focal segmental glomerulosclerosis|Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy
89223347|NCT00977340|Experimental|Imagery Rehearsal Treatment|Imagery Rehearsal Treatment; 1 session on-site and 4 weeks of individual daily training; following principles Krakow and Zadra (2006)
89223348|NCT00977340|Experimental|Confrontation|Confrontation with nightmare content, until fear reaction habituates; 1 session on-site and 4 weeks of individual daily training
89223349|NCT00977340|Placebo Comparator|Imagination|Imagination of a safe and pleasant site; 1 session on-site and 4 weeks of individual daily training
89223350|NCT00977418|No Intervention|No intervention|Seniors undergo all testing but remain current lifestyle
89223351|NCT00977418|Experimental|Training|Groups will undergo either physical or mental training. Physical training is 1 hour aerobic training 3 times per week for 12 weeks. Mental training is 1 hour Strategic Memory Advanced Reasoning Training 3 times per week.
89223352|NCT00983112|Experimental|Evicel|
89223353|NCT00983112|Placebo Comparator|Placebo|
89223354|NCT04006704|Experimental|D/C/F/TAF (Whole Placebo Tablet then Split Placebo Tablet)|Participants will receive scored film-coated 10 milligram (mg) FDC matching placebo tablets (Intake period 1) swallowed whole followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed as a split tablet on Day 1. Both the intakes will be separated by at least 15 minutes.
89223355|NCT04006704|Experimental|D/C/F/TAF (Split Placebo Tablet then Whole Placebo Tablet)|Participants will receive scored film-coated 10 mg FDC matching placebo tablets (Intake period 1) swallowed as a split tablet followed by FDC of scored film-coated D/C/F/TAF 675/150/200/10 mg matching placebo tablets (Intake period 2) swallowed whole on Day 1. Both the intakes will be separated by at least 15 minutes.
89223356|NCT00986466|Experimental|exercise with vitamin D 800 IU/d|
89223357|NCT00986466|Active Comparator|exercise with placebo|
89223358|NCT00986466|Active Comparator|no exercise with vitamin D 800 IU/d|
89223359|NCT00986466|Placebo Comparator|no exercise with placebo|
89223360|NCT00977496||Nasal Swab|New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center
89223361|NCT00983190|Other|Single Group Assignment|
89223362|NCT00545298|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only
89223363|NCT00545298|Experimental|B Same treatment for 6 weeks|200ppm NO gas 8hrs/day 6 weeks NO gas in nitrogen is delivered constantly to a patch over the wound
89223364|NCT00545298|Experimental|C - modified treatment, 5 wks lower dose|200 ppm No gas 8 hrs/day 1 wk, 20ppm 8hrs/day 5 weeks Gas is NO in nitrogen delivered constantly for 8 hours to a patch over the wound
89223365|NCT00977652|Active Comparator|Active stimulation|Percutaneous posterior tibial nerve stimulation
89223366|NCT00977652|Sham Comparator|sham stimulation|Inefficient percutaneous posterior tibial nerve stimulation
89223367|NCT00977730|Active Comparator|Protandim|
89223368|NCT00977730|Placebo Comparator|Sugar pill|
89223369|NCT00983268|Experimental|Treatment Arm|
89223370|NCT00977886|Placebo Comparator|Placebo|
89223371|NCT00977886|Experimental|ELB353|
89223372|NCT00977964|Experimental|Milk Based Protein Formula Process A|
89223373|NCT00977964|Experimental|Milk Based Protein Formula Process B|
89223374|NCT00977964|Experimental|Milk Based Protein Formula Process C|
89223375|NCT00977964|Experimental|Milk Based Protein Formula Process D|
89223376|NCT00977964|Experimental|Milk Based Protein Formula Process E|
88812886|NCT01832870|Experimental|Treatment|Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.
89223377|NCT00977964|Experimental|Milk Based Protein Formula Process F|
89223378|NCT00983424|Experimental|Treatment arm|Cyclosporine A + nab-paclitaxel
89223379|NCT00983502||Integrative Medicine|Patients of MD practitioners trained in Complementary and Alternative Medicine
89223380|NCT00983502||Naturopath Doctors|Patients of practitioners who are not MD's and are trained in Naturopathic Medicine
89223381|NCT00983502||Chronic Fatigue Specialists|Patients of MD's who specialize in treating Chronic Fatigue and related conditions
89223382|NCT00983502||Control Group|Patients treated by primary care MDs in practice-based research networks
89223383|NCT00978198|Experimental|Part 1|single administration
89223384|NCT00978198|Experimental|Part 2|multiple administration
89223385|NCT00983658|Experimental|huMAb OX40L|
89223386|NCT00983658|Placebo Comparator|Placebo|
89223387|NCT00983736|Experimental|Active|
89223388|NCT00983736|Placebo Comparator|Placebo|
89223389|NCT00983970|Experimental|Interactive video cycling|Interactive video cycling arm utilized the Gamebike that interfaced a Sony Play Station 2 with a stationary bicycle and a 42 inch flat screen TV. The Gamebike has a handle bar mounted game controller allowing the participant to play most Sony Play Station 2 raced-based video games. The Gamebike reads the participants' speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks.Participants were told that they could exercise at any intensity or duration that they desired, and reading materials were provided for those who did not chose to exercise for the full 60 minute session.
89223390|NCT00983970|Active Comparator|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device.
89223391|NCT00986700|Other|different types of bad time food|Different types of bad time food
89223392|NCT00986778|Active Comparator|Lamivudine plus Adefovir|
89223393|NCT00986778|Active Comparator|Entecavir|
89223394|NCT00986778|Experimental|Entecavir plus Adefovir|
89223395|NCT00429364|Active Comparator|Atenolol|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.
89223396|NCT00429364|Active Comparator|Losartan|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).
89223397|NCT04758468|Experimental|Telerehabilitation-based pelvic floor muscle training|
89223398|NCT04758468|Active Comparator|Home-based pelvic floor muscle training|
89223399|NCT04758468|No Intervention|Control (no specific intervention)|
89223400|NCT04008342|Experimental|Intervention group|The intervention group (IG) was submitted to 16 multisensory sessions that followed the protocol.
89223401|NCT04008342|No Intervention|Control group|The control group (CG) received usual care with routine interventions and services in the LTC, such as bath, hygiene care, watching TV and so on.
89223402|NCT00984048||FOLFOX, XELOX or FOLFIRI +/- bevacizumab|Patients are scheduled to receive first-line treatment for metastatic disease. They should be receiving at least one component of either FOLFOX, XELOX or FOLFIRI regimen with or without bevacizumab.
89223403|NCT00978354|Active Comparator|Furosemide|Furosemide intravenous continuous infusion
89223404|NCT00978354|Placebo Comparator|Normal Saline|Normal saline titrated continuous intravenous infusion
89223405|NCT00987012|Experimental|Pomegranate juice|
89223406|NCT00987012|Placebo Comparator|Placebo drink|
89223407|NCT00984360|Experimental|A118G|
89223408|NCT00984360|Experimental|Wild-type|
89223409|NCT03808350|Placebo Comparator|Families Excluded From Presence at Procedures|Families not invited to remain for ICU procedures
89223410|NCT03808350|Active Comparator|Families Invited to Be Present at Procedures|Families invited to remain for ICU procedures
89067160|NCT02875522|Experimental|Patients with COPD|Stable patients with COPD participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
89067161|NCT02875522|Active Comparator|Healthy Controls|Age, sex, BMI and activity matched controls participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
89067162|NCT02874196|Experimental|Patients with painful prosthesis|
89067163|NCT01284114|Active Comparator|Aliskiren|
89067164|NCT02875444||"group abdominal aortic aneurysm"|Patients with non-operated abdominal aortic aneurysm with angio-CT realized between 01/01 2010 au 04/15/2012
89067165|NCT01283334|Experimental|A|Treatment arm with carboplatin, cetuximab and RAD001
89067166|NCT01282866|Experimental|HS treatment|Treatment with HS handpiece
89067167|NCT01071070|Active Comparator|Group 1|Initial dosing based on a formula of intact parathyroid hormone value/80 (where intact parathyroid hormone value is the baseline value in pg/mL).
89067168|NCT01071070|Active Comparator|Group 2|Dose determined by US paricalcitol injection package insert dosing instructions (starting dose at 0.04 microgram/kg)
89067169|NCT04304716|Active Comparator|Fibular free flap-Block performed|For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
89067170|NCT04304716|Active Comparator|Anterolateral thigh free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
89067171|NCT04304716|Active Comparator|Radial forearm free flap-Block performed|Description: For subjects in the experimental/regional anesthesia group for anterolateral thigh or radial forearm free flap, during the procedure a catheter will be placed into the donor site (leg or arm), wound bed
89067172|NCT04304716|No Intervention|Fibular free flap -Control|No additional procedures beyond the normal standard of care will be performed
89067173|NCT04304716|No Intervention|Anterolateral thigh free flap-Control|No additional procedures beyond the normal standard of care will be performed
89067174|NCT04304716|No Intervention|Radial forearm free flap-Control|No additional procedures beyond the normal standard of care will be performed
89067175|NCT04292860||Breast Cancer Pts|Post-operative (lumpectomy or mastectomy) female breast cancer patients who will receive radiation to the whole breast or chest wall and the regional nodes.
89067176|NCT01282476|Experimental|Panobinostat/Rituximab|single-arm, open-label; Panobinostat with Rituximab: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
89067177|NCT02889822|Experimental|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
89067178|NCT04323618|Other|Free breathing or Breathe Well|Free breathing or Breathe Well
89067179|NCT04323696|Other|Over-sewing|Patients under over-sewing arm are subjected to staple line reinforcement using over-sewing method
89067180|NCT04323696|Other|Plication|Patients under over-sewing arm are subjected to staple line reinforcement using plication method
89067181|NCT01282164|Experimental|Study patients|patients with growth hormone deficiency or hypothalamic-pituitary disorders underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT).
89067182|NCT01282164|Active Comparator|Control|"The control group will consist of healthy volunteers matched to the study group for age, gender, Body mass index (BMI) and estrogen status. Note: Allegheny site is not enrolling in the control group.~Control subjects underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT)."
89067183|NCT01250379|Active Comparator|1|
89067184|NCT01250379|Experimental|2|
89067185|NCT01072630|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
89067186|NCT01072630|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
89067187|NCT01072630|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
89067188|NCT04304638||Radiation(Chemo-radiation)|Patients in this group had been treated with definitive radiation/Chemo-radiation followed by no treatment until progression.
89067189|NCT04304638||radiation+EGFR-TKI|Patients in this group had been treated with one of the following three ways: 1) definitive radiation and concurrent EGFR-TKI followed by EGFR-TKI till progression; 2) EGFR-TKI followed by radiation and continue TKI util progression; 3) radiation and TKI thereafter until progression.
89067190|NCT04304638||EGFR-TKI|Patients in this group had been treated with EGFR-TKI without any other treatment until progression.
89067191|NCT04302532|Active Comparator|Clomiphene|clomiphene citrate 150 mg once a day for 5 days
89067192|NCT04302532|Experimental|clomiphene and coenzyme q10|clomiphene citrate 150 mg once a day for 5 days and coenzyme q 10 120 mg each day
89067193|NCT01281306|Experimental|VAL + AHU 400 mg|Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.
89067194|NCT01281306|Experimental|VAL + AHU 200 mg|Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.
89067195|NCT01281306|Experimental|VAL + AHU 100 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.
89067196|NCT01281306|Experimental|VAL + AHU 50 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.
89223411|NCT00414388|Experimental|Single agent Sorafenib|Oral Single agent Sorafenib 400mg twice daily
89067197|NCT01281306|Experimental|VAL 320 mg|Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.
89067198|NCT01281306|Experimental|LCZ 400 mg|Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.
89067199|NCT01281306|Experimental|Placebo|Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.
89067200|NCT04304560|Placebo Comparator|Control Group|Control group will receive the standard therapy for DM & HFrEF and placebo.
89067201|NCT04304560|Experimental|Dapagliflozin|Intervention group will receive 10mg of Dapagliflozin (Forxiga) ® tablet and standard therapy for HFrEF.
89067202|NCT01250145|Experimental|LY333334 + placebo|"Part A:~Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, for 22 days~Part B:~Induction phase: Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, 4 times a week for 3 weeks~Rest phase: 2 weeks with no patch application~Challenge phase: 80 microgram active patch given once for at least 6 hours"
89067203|NCT04323384|Experimental|Biotene® followed by Sham|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into either Protocol A or Protocol B. In their first session, participants in Protocol A will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the experimental condition. For the experimental condition, participants will be instructed to apply Biotene® Oralbalance Moisturizing Gel according to package directions. Testing will then be repeated. In the second session, after baseline testing, participants will receive the sham condition (instead of the experimental condition). For the sham condition, participants will be instructed to rinse their mouth with room temperature distilled water. Testing will then be repeated.
89067204|NCT04323384|Experimental|Sham followed by Biotene®|Recruited volunteers will each participate in two experimental sessions. Participants will be randomized into two protocols: 1) Protocol A and 2) Protocol B. In their first session, participants in Protocol B will undergo baseline mastication, swallowing, salivary, and oral health-related quality of life testing, then they will receive the sham condition. Testing will then be repeated. In the second session, after baseline testing, participants will receive the experimental condition (instead of the sham condition). Testing will then be repeated.
89067205|NCT01067326|Active Comparator|Aliskiren|150 mg Aliskiren once daily for a period of 4 months.
89067206|NCT01067326|Placebo Comparator|Placebo|1 pill per day by mouth for 4 months.
89067207|NCT04319601|Experimental|rituximab combined with chidamde and lenalidomide|rituximab and chidamide, lenalidomide
89067208|NCT01279200|Active Comparator|Urinary LH Kits|Patients randomized to this arm will monitor ovulation with home-based urinary LH kits (Ovulation Predictor Kits, OPK's).
89067209|NCT01279200|Active Comparator|Midcycle ultrasound + hCG injection|Patients randomized to this arm will undergo ovulation monitoring with midcycle ultrasound and receive hCG injection if evidence of a mature size follicle.
89067210|NCT04640896|Sham Comparator|Lidocaine skin wheal|They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.
89067211|NCT04640896|Active Comparator|Trigger point injection with normal saline|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
89067212|NCT04640896|Experimental|Trigger point injection with bupivacaine|Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
89067213|NCT01273818|Active Comparator|gentamicin|80 mg gentamicin topical application intraoperatively
89067214|NCT01273818|Active Comparator|Cefazolin|Application of 1000 mg cefazolin intra venously 1 hour before surgery
89067215|NCT01273818|Active Comparator|gentamicin and cefazolin|1000 mg cefazolin application 1 hour before surgery and topical 80 mg gentamicin intraoperatively
89067216|NCT01245387||Macugen|
89067217|NCT01037218|Experimental|Udenafil 50 mg|50 mg Udenafil tablet plus 100 & 150 mg placebo tablets
89067218|NCT01037218|Experimental|Udenafil 100 mg|100 mg Udenafil tablet plus 50 & 150 mg placebo tablets
89067219|NCT01037218|Experimental|Udenafil 150mg|150 mg Udenafil tablet plus 50 & 100 mg placebo tablets
89067220|NCT01037218|Placebo Comparator|Placebo|50, 100 & 150 mg placebo tablets
89067221|NCT01038856|Experimental|+JAK2V61F mutation|Patients with MPN diagnoses and polycythemia vera who also have a confirmed JAK2V617F mutation
89067222|NCT04302688||modeling cohort|The 445 patients were grouped in chronological order.
89067223|NCT04302688||validating colort|The remaining 224 patients.
89067224|NCT01066546|Experimental|Dimebon|
89067225|NCT02874118|Experimental|HIV Patient population over 50 years old|
89067226|NCT02873572|Experimental|online poker gamblers|Recruitment by forums of online poker gamblers: an explanation of the research is sent with the dedicated link of the research.
89067227|NCT02873572|Experimental|casino gamblers|Recruitment to the casino gates: an explanation of the research is sent with the dedicated e-link of the research and they could answer directly to the questionnaire (1st step) on sites.
89067228|NCT02873572|Experimental|MMORPG gamers|Recruitment by forums of MMORPG (as guilds): an explanation of the research is sent with the dedicated link of the research.
89067229|NCT02873572|Experimental|no gamer subjects|Recruitment by poster.
89067230|NCT01272804|Experimental|PF-04937319|
89067231|NCT01272804|Placebo Comparator|Placebo|
89067232|NCT01269918|Active Comparator|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
89067233|NCT01269918|Active Comparator|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
89223412|NCT00978588|Experimental|HES 130/0.4|
89223413|NCT00978588|Active Comparator|5% albumin|
89223414|NCT04006080|Experimental|Vedolizumab|
89223415|NCT01034722||Western Diet|Volunteer mothers with western diet.
89223416|NCT01034722||Vegetarians|volunteer mothers with vegetarians diet
89223417|NCT01034722||Bedouins|Volunteer mothers who are Bedouins
89223418|NCT00984438|Experimental|BCNU wafter followed by chemotherapy|Surgical Implantable BCNU wafer followed by Chemotherapy with Irinotecan and Bevacizumab for up to one year
89223419|NCT00978666||Healthy controls|Healthy comparison adolescent females
89223420|NCT00978666||Anorexia Nervosa|Adolescent females currently ill with Anorexia Nervosa, restricting type
89223421|NCT01037686|Other|PD, DBS, healthy controls|Patients with idiopathic PD before or after DBS surgery (during on or off-stimulation) and healthy controls.
89223422|NCT03920280|Experimental|LID015385|LID015385 contact lenses worn in both eyes during waking hours only for at least 8 hours per day and 5 days per week over a 3-month exposure period. Lenses will be removed nightly for cleaning with CLEAR CARE.
89223423|NCT03920280|Active Comparator|Biofinity|Comfilcon A contact lenses worn in both eyes during waking hours only for at least 8 hours per day and 5 days per week over a 3-month exposure period. Lenses will be removed nightly for cleaning with CLEAR CARE.
89223424|NCT00424372|Experimental|pregabalin|
89223425|NCT00987090|Active Comparator|Alzheimer Disease|subjects who have developed symptoms of Alzheimer Disease aged from 45 to 85 years old
89223426|NCT00987090|Placebo Comparator|Control|subjects without symptoms of Alzheimer Disease aged from 45 to 85 years old.
89223427|NCT04006236|Experimental|Experimental Infant Formula|extensively hydrolyzed casein protein
89223428|NCT04006236|Active Comparator|Control Infant Formula|extensively hydrolyzed casein protein
89223429|NCT00988104|Active Comparator|Cognitive Behavioral Therapy|
89223430|NCT00988104|Active Comparator|Supportive Counseling|
89223431|NCT00978900|Active Comparator|Acesulfame K|
89223432|NCT00978900|Active Comparator|Sucralose|
89223433|NCT00978900|Active Comparator|Aspartame|
89223434|NCT00978900|Active Comparator|Glucose|
89223435|NCT00978900|Active Comparator|Fructose|
89223436|NCT00978900|Placebo Comparator|Water|
89223437|NCT00988182|Experimental|whey protein, 5g|
89223438|NCT00988182|Experimental|whey protein, 10g|
89223439|NCT00988182|Experimental|whey protein, 20g|
89223440|NCT00988182|Experimental|whey protein, 40g|
89223441|NCT00988182|Experimental|water control|
89223442|NCT00987168|Experimental|Sandostatine LP|
89223443|NCT00978978|Active Comparator|Propofol, endoscopies, liver diseases|Propofol, endoscopies, liver diseases
89223444|NCT00978978|Active Comparator|midazolam and fentanyl, endoscopies, liver diseases|Control: midazolam and fentanyl, endoscopies, liver diseases
89223445|NCT00414310|Experimental|Decitabine|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days.
89223446|NCT00414310|Experimental|Decitabine + Valproic Acid|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.
89223447|NCT00542880|Experimental|Symbicort Turbuhaler First, then Seretide Diskus|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg
89223448|NCT00542880|Experimental|Seretide Diskus First, then Symbicort Turbuhaler|Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
89223449|NCT03726294|Experimental|NBM-BMX|
89223450|NCT00414076|Active Comparator|Letrozole|Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks.
89223451|NCT00414076|No Intervention|Standard of Care|Patients receive no treatment. Follow up every 3 months.
89223452|NCT00987246|Experimental|LAS41005|
89223453|NCT00987246|Active Comparator|LAS106521|
89223454|NCT00987246|Placebo Comparator|Placebo|
89223455|NCT01424098|Experimental|Balance Training|The treatment group will complete a specific balance training program in addition to conventional pulmonary rehabilitation.
89223456|NCT01424098|No Intervention|Usual care|The control group will undergo the usual pulmonary rehabilitation program offered at our centre with no additional balance training classes.
89223457|NCT01033318|Experimental|Part 1 A-1|"Part 1; Panel A; Sequence 1:~2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan"
89223458|NCT01033318|Experimental|Part 1 A-2|"Part 1; Panel A; Sequence 2:~Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809"
89223459|NCT01033318|Experimental|Part 1 A-3|Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
89223460|NCT01033318|Experimental|Part 1 A-4|Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
89223461|NCT01033318|Experimental|Part 1 A-5|"Part 1; Panel A; Sequence 5:~Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809"
89223462|NCT01033318|Experimental|Part 1 B-1|"Part 1; Panel B; Sequence 1:~5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food"
89223463|NCT01033318|Experimental|Part 1 B-2|"Part 1; Panel B; Sequence 2:~5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food"
89223464|NCT01033318|Experimental|Part 1 B-3|"Part 1; Panel B; Sequence 3:~5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food"
89223465|NCT01033318|Experimental|Part 1 B-4|"Part 1; Panel B; Sequence 4:~Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food"
89223466|NCT01033318|Experimental|Part 1 B-5|"Part 1; Panel B; Sequence 5:~Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food"
89223467|NCT01033318|Experimental|Part 2 C-1|"Part 2; Panel C; Sequence 1:~50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan"
89223468|NCT01033318|Experimental|Part 2 C-2|"Part 2; Panel C; Sequence 2:~50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809"
89223469|NCT01033318|Experimental|Part 2 C-3|"Part 2; Panel C; Sequence 3:~Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo"
89223470|NCT01033318|Experimental|Part 2 C-4|"Part 2; Panel C; Sequence 4:~50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809"
89223471|NCT01033318|Experimental|Part 2 C-5|"Part 2; Panel C; Sequence 5:~Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809"
89223472|NCT04006158|Experimental|LightStim LED Bed|Full body LED bed device.
89223473|NCT00988338||Trinity Evolution|
89223474|NCT01033396|Experimental|PF-03654764 + Allegra|
89223475|NCT01033396|Experimental|PF-03654764|
89223476|NCT01033396|Active Comparator|Allegra-D|
89223477|NCT01033396|Placebo Comparator|Placebo|
89223478|NCT01033474||donor eggs|
89223479|NCT01033474||infertile patients|
89223480|NCT00979056|Experimental|Rifaximin|
89223481|NCT00979056|Placebo Comparator|Lactose|
89223482|NCT04006314|Other|Receiving PRP injections or PRP plus neural prolotherapy|PRP injection into the knee joint and pes anserinus complex. Dextrose solution to the genicular nerves.
89223483|NCT00987324|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent (Taxus)
89223484|NCT00987324|Active Comparator|Plain Balloon|plain balloon angioplasty
89223485|NCT00987324|Experimental|Paclitaxel-eluting balloon|SeQuent Please
89223486|NCT00979290||Separate anti-TB drugs|
89223487|NCT00979290||Fix-dosed combination anti-TB drugs|
89223488|NCT00092677|Experimental|EZ/Simva 10/40 mg|Ezetimibe 10 mg + Simvastatin 40 mg
89067234|NCT01036594|Experimental|Ketoconazole + Hydrocortisone|"po = oral tid = 3 times per day qam = every morning qom = every evening bid = twice daily~1 cycle = 28 days~Ketoconazole: 200mg during first week of study (run-in phase), then 400mg po tid~Hydrocortisone 20mg po qam and 10mg po qpm: If participant has ≥ 30% Prostate-specific antigen (PSA) decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by Prostate Specific Antigen Working Group (PSAWG) criteria) is documented. After that, drug will be discontinued. If participant has < 30% PSA decline at 12 week evaluation, participant goes off study."
89223489|NCT00092677|Placebo Comparator|Placebo|
89223490|NCT00988572|Experimental|Intervention group|Vestibular rehabilitation, twice a week for 9 weeks
89223491|NCT00988572|No Intervention|Control group|The patients in the control group does nothing, except for normal treatment for their wrist fracture.
89223492|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 1)|
89223493|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 2)|
89223494|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 3)|
89223495|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 4)|
89223496|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 5)|
89223497|NCT04651920||Epithelial ovarian cancer patients sensitive to platinum based chemotherapy|
89223498|NCT04651920||Epithelial ovarian cancer patients resistant to platinum based chemotherapy|
89223499|NCT00542178|Experimental|Intensive glycemia control|A strategy of intensive glycemia treatment to HbA1c less than 6%
89223500|NCT00542178|Active Comparator|Standard glycemia control|A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
89223501|NCT00542178|Experimental|Intensive BP control|A strategy of BP treatment for SBP less than 120 mm Hg
89223502|NCT00542178|Active Comparator|Standard BP control|A strategy of BP treatment for SBP less than 140 mm Hg
89223503|NCT00542178|Experimental|Fibrate|Blinded fenofibrate + simvastatin 20-40 mg/d
89223504|NCT00542178|Placebo Comparator|Fibrate Placebo|Blinded placebo + simvastatin 20-40 mg/d
89223505|NCT00987636|Experimental|R1|Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients with localised Ewing sarcoma and good histological response or with initial tumour volume <200 mL compared to no add-on treatment.
89223506|NCT00987636|Experimental|R2|High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy, improves event-free survival in patients with localised Ewing sarcoma and poor histological response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus standard chemotherapy plus whole lung irradiation (R2pulm).
89223507|NCT00987636|Experimental|R3|Very High Risk R3: in a randomised trial, to examine whether the addition of high dose chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant chemotherapy alone, improves event-free survival in patients with primary disseminated disease.
89223508|NCT00424294|Active Comparator|Celecoxib|Celecoxib with placebo therapy.
89223509|NCT00424294|Other|Methotrexate|Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
89223510|NCT00424294|Experimental|CP-195,543|CP-195,543 and Celecoxib dual therapy.
89223511|NCT00979446|Experimental|Guided|
89223512|NCT00979446|Active Comparator|Self-directed|
89223513|NCT00988650|Active Comparator|North American diet|Control North American diet for five weeks in isocaloric conditions
89223514|NCT00988650|Experimental|Mediterranean diet|Mediterranean diet for five weeks in isocaloric conditions
89223515|NCT00988650|Experimental|weight loss period|Weight loss period of 20-week (minimum 5% reduction in body weight)
89223516|NCT00988650|Active Comparator|Weight stabilizing mediterranean diet|Mediterranean diet for five weeks in isocaloric weight stabilizing conditions
89223517|NCT00988728|Experimental|SCH 900435|SCH 900435 (Org 25935): a Glycine Uptake Inhibitor
89223518|NCT00988728|Placebo Comparator|Placebo|
89223519|NCT00988728|Active Comparator|Olanzapine|
89223520|NCT00988806|Active Comparator|Levosimendan|infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours.
89223521|NCT00988806|Placebo Comparator|Placebo|infusion of placebo for 24 hours.
89223522|NCT04005768|Experimental|Hydroxychloroquine Sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
89223523|NCT04005768|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
89223524|NCT00987714|Experimental|Protocolized Care|Algorithm to manage Pulse Pressure Variation, Cardiac Index, and Mean Arterial Pressure will be used in these donors.
89223525|NCT00987714|No Intervention|Standard Care|This is the Organ Procurement Organization current practices.
89223526|NCT00987792||Group 1|
89223527|NCT04459260|Experimental|Cognitive Behavior Therapy|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on cognitive behavior therapy and includes both cognitive interventions, e.g., cognitive restructuring and behavioral experiments, and behavioral interventions, behavioral activation. The treatment was manualized by Egan et al. (2016) and has been tested in several clinical trials, both via the Internet and face-to-face.
89223528|NCT04459260|Active Comparator|Unified Protocol|An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on a transdiagnostic approach derived from cognitive behavior therapy called Unified Protocol, focusing on the shared emotional aspects underlying depression and anxiety disorders. The treatment was manualized by Ellard et al. (2010) and has been tested in several clinical trials, but so far not over the Internet.
89223529|NCT00987870|Experimental|BFH772 cream 1%|
89223530|NCT00987870|Placebo Comparator|Placebo to BFH772 cream 1%|
89223531|NCT00987870|Experimental|BFH772 ointment 1%|
89223532|NCT00987870|Placebo Comparator|Placebo to BFH772 ointment|
89223533|NCT00987870|Active Comparator|calcipotriol/betamethasone ointment|
89223534|NCT00988026|Experimental|Minocycline 100 mg|Minocycline
88812887|NCT01553201|Experimental|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
89067235|NCT01036594|Experimental|Ketoconazole + Dexamethasone|"Ketoconazole: 400mg po tid~Dexamethasone 0.5mg po bid: If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
89067236|NCT05657886|No Intervention|Control group|The mothers in the control group were given routine care.
89067237|NCT05657886|Experimental|Half swaddle|HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
89067238|NCT05657886|Experimental|Kangaroo care|The application was applied at twice a day and for 60 min, every day for 6 months in a row. While the mothers were taken to the NICU and practiced at home prior to kangaroo care, hand hygiene and breast care were provided within the scope of infection prevention rules. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm and suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together.
89067239|NCT05657886|Experimental|Half swaddle+Kangaroo care|HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.The application was applied at twice a day and for 60 min, every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm and suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. In the continuation of the KB application, the mother was asked to breastfeed her baby.
89067240|NCT02874352|Other|intensive care patients|intensive care patients with tracheostomy/ high resolution impedance manometry with Automated Impedance Manometry analysis
89067241|NCT02874352|Other|healthy volunteers|control group with healthy volunteers/ high resolution impedance manometry with Automated Impedance Manometry analysis
89067242|NCT04302610|Experimental|HME MASK|During the Exercise, participants wore either an HME mask (MASK) (ColdAvenger® expedition balaclava, USA, www.coldavenger.com)
89067243|NCT04302610|Sham Comparator|SHAM mask|a sham mask (SHAM) which was the same HME mask with holes cut across the entire ventilator cup and the ventilator removed
89067244|NCT04302610|No Intervention|Control|No mask (CONT) wearing only the balaclava to which the HME and SHAM mask were attached. Mouth and face not covered.
89067245|NCT04301908||antiviral therapy group|Patients with chronic hepatitis B and cirrhosis were treated with antiviral drugs
89067246|NCT01036438|Placebo Comparator|Mepilex product|
89067247|NCT01036438|Active Comparator|Mepilex Ag|
89067248|NCT04304248|Experimental|Neoadjuvant chemo-immunotherapy|"Neoadjuvant treatment (Albumin-bound paclitaxel + carboplatin + toripalimab) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.~Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment."
89067249|NCT01268046|Experimental|Young postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
89067250|NCT01268046|Experimental|Older postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
89067251|NCT01268046|Placebo Comparator|Young postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
89067252|NCT01268046|Placebo Comparator|Older postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
89067253|NCT04302298|Experimental|Virtual Reality Group|This group will go through the virtual reality simulation of a procedure prior to doing it on a plastic SawBone.
89067254|NCT04302298|No Intervention|Technique Guide Group|This group will go be able to read through a technique guide on the procedure prior to doing it on a plastic SawBone. This is the current method of learning in surgical residencies.
89067255|NCT00627484||Group 1: GBP non-diabetic|Non-diabetic subjects scheduled to receive gastric bypass
89067256|NCT00627484||Group 2: BND non-diabetic|Non-diabetic subjects scheduled to receive gastric banding
89067257|NCT00627484||Group 3: GBP diabetic|Diabetic subjects scheduled to receive gastric bypass
88812888|NCT01553201|Placebo Comparator|Placebo|Saline, 4cc, one time intramuscular administration
89067258|NCT00627484||Group 4: VLCD diabetic|Diabetic subjects scheduled to receive very low calorie diet
89067259|NCT00627484||Group 5: SG diabetic|Diabetic subjects scheduled to receive sleeve gastrectomy
89067260|NCT00627328||1|pacemaker patients with previously diagnosed AT.
89067261|NCT00627328||2|pacemaker patients without previously diagnosed AT.
89067262|NCT01267266|Experimental|Arm I (saracatinib)|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89067263|NCT01267266|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Upon progression, patients may crossover to arm I.
89067264|NCT01034176|Active Comparator|Levofloxacin|Levofloxacin 500 mg every day (dose adjusted for renal function) for 30 days
89067265|NCT01034176|Placebo Comparator|placebo|placebo identical to levofloxacin drug daily for 30 days
89067266|NCT02889432|Experimental|Melatonin|Oral Melatonin 10mg Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
89067267|NCT02889432|Placebo Comparator|Placebo|Placebo tabs Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
89067268|NCT04323540|Active Comparator|Xenograft+collagen membrane|Reconstructive approach (Xenograft+collegen membrane)
89067269|NCT04323540|Experimental|Xenograft+collagen membrane+autologous soft tissue graft|Reconstructive approach (Xenograft+collegen membrane) plus soft tissue graft (autologous, harvested as FGG)
89067270|NCT01033942|Experimental|FTC/TDF as PrEP|Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
89067271|NCT01033942|Placebo Comparator|Placebo Pill Control|Blinded administration of placebo pill; HIV behavioral intervention
89067272|NCT01033942|Active Comparator|No Pill Control|Subjects receive HIV behavioral intervention but no pill.
89067273|NCT01062256|Placebo Comparator|Placebo|Placebo
89067274|NCT01062256|Experimental|Guaifenesin|Guaifenesin
89067275|NCT01062256|Experimental|Buckwheat Honey|Buckwheat Honey
89067276|NCT01029886|Experimental|1|
89067277|NCT01029886|Active Comparator|2|
89067278|NCT02874274|Active Comparator|100 Non-Homebound Subjects|outpatient healthcare utilization and self-reported illness.
89067279|NCT02874274|Active Comparator|60 Homebound Subjects|Will test the feasibility of offering influenza and pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort
89067280|NCT01244763|Experimental|Cohort A: Roxadustat Tiered, Weight Based Dosing TIW|Participants will receive roxadustat capsules, administered orally 3 times weekly (TIW) for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kilograms (kg)], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 60, 100, and 140 milligrams [mg] roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL.
89067281|NCT01244763|Experimental|Cohort B: Roxadustat Tiered, Weight Based Dosing TIW then BIW|Participants will receive roxadustat capsules orally for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kg], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 60, 100, and 140 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to 2 times a week (BIW) at the time of the initial Hb response.
89067282|NCT01244763|Experimental|Cohort C: Roxadustat at 50 mg TIW|Participants will receive roxadustat capsules at 50 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
89067283|NCT01244763|Experimental|Cohort D: Roxadustat at 100 mg TIW|Participants will receive roxadustat capsules at 100 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
89067284|NCT01244763|Experimental|Cohort E: Roxadustat Tiered, Weight Based Dosing BIW then QW|Participants will receive roxadustat capsules for 24 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight [45 to 60 kg], medium-weight [>60 to 90 kg], and heavy-weight [>90 to 140 kg] participants will receive 70, 100, and 150 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from BIW to 1 time a week (QW) at the time of the initial Hb response.
89067285|NCT01244763|Experimental|Cohort F: Roxadustat at 70 mg BIW then QW|Participants will receive roxadustat capsules at 70 mg for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to BIW at the time of the initial Hb response. Then after >8 weeks of stable Hb, dose frequency will be reduced from BIW to QW.
89067286|NCT01244061|Experimental|Varenicline|
89067287|NCT01244061|Placebo Comparator|Placebo|
89067288|NCT01243671|Experimental|Adalimumab|Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.
89067289|NCT04319679|Experimental|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range
89067290|NCT04319679|Sham Comparator|Control group|Sham therapy
89067291|NCT01240785|Active Comparator|Metformin|Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
89067292|NCT01240785|Active Comparator|insulin|NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
89067293|NCT01240551|Active Comparator|Mets via NaF-18 PET/CT|Patients with known bone metastases (i.e. mets).
89067294|NCT01240551|Active Comparator|No-Mets via NaF-18 PET/CT|Patients with no clinical evidence of bone metastases
89067295|NCT01239381|Experimental|SBRT-Proton|Stereotactic body radiotherapy by proton radiation
89067296|NCT01266876|Placebo Comparator|Placebo|Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
89067297|NCT01266876|Experimental|Alirocumab 150 mg Q4W|Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
89067298|NCT01266876|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
89067299|NCT01266876|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
89067300|NCT01266876|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
89067301|NCT01033240|Experimental|Safety Cohort 1 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
89067302|NCT01033240|Experimental|Safety Cohort 2 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (4 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
89067303|NCT01033240|Active Comparator|Safety Cohort 3 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (6 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
89067304|NCT01033240|Experimental|Treatment Group 1 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 1: CS-1008 (6 mg/kg [or as determined] loading, 2 mg/kg/week maintenance) + sorafenib twice daily (N=50)
89067305|NCT01033240|Experimental|Treatment Group 2 with CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 2: CS-1008 (6 mg/kg [or as determined] loading, 6 mg/kg/week [or maximum tolerated dose {MTD}] maintenance) + sorafenib twice daily (N=50)
89067306|NCT01033240|Experimental|Treatment Group 3 with Sorafenib Alone|Sorafenib. Treatment Group 3: sorafenib twice daily (N=50)
89067307|NCT01266018|Experimental|Cohort 1: Sensitive Disease|"Cohort 1 comprised subjects with sensitive disease, defined as subjects who were treated with 1 previous line of chemotherapy and maintained an appropriate response for 90 days or more. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
89067308|NCT01266018|Experimental|Cohort 2: Refractory Disease|"Cohort 2 comprised subjects with refractory disease, defined as subjects who either (a) were treated with 1 previous line of chemotherapy and either had no response or progressed < 90 days after completing treatment or (b) required third-line therapy, i.e., had completed 2 previous lines of chemotherapy, regardless of response. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
89067309|NCT01032382|Active Comparator|Paromomycin Alone Treatment|
89067310|NCT01032382|Active Comparator|WR 279,396|
89223535|NCT00988026|Active Comparator|Lymecycline 300 mg|Group B: Lymecycline
89223536|NCT00988962|No Intervention|High-Risk No Treatment|
89223537|NCT00988962|Experimental|High-Risk Treatment|
89223538|NCT00988962|No Intervention|Low-Risk|
89223539|NCT05578170||Pembro Neoadjuvant + SOC Adjuvant|
89067311|NCT01029652|Experimental|Canakinumab 150 mg|"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive re-dose of study drug on demand upon occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after previous dose. Patients completing 12 weeks core study were allowed to continue treatment in another 12-week extension for any new gout flare on demand with same treatment as assigned in core study.~After completing the first extension, patients were offered to enter second extension study, whereby all patients were treated open-label on demand with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in core study. Patients completing first 12 weeks extension study were allowed to continue to be treated in another single-arm, open-label 48 weeks extension when all patients from both treatment arms received canakinumab on demand"
89067312|NCT01029652|Active Comparator|Triamcinolone acetonide 40 mg|"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.~Patients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period Triamcinolone acetonide was not to be administered in the 48-week session."
89067313|NCT01029340|Experimental|Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS|Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between
89067314|NCT01029340|Experimental|Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973)|Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between
89067315|NCT01029340|Experimental|Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ|Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months
89223540|NCT00989118|Experimental|Laser treatment|
89223541|NCT00989118|Active Comparator|Endometrioma cystectomy|
89223542|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 15 ug & trivalent|120 participants selected by random
88812889|NCT05313542|Experimental|Physical Activity Group (PA group)|The PA group will receive a 6-week home-based self-defence training programme consisting of 120 min video training (including daily practice time) per week. Self-report questionnaires will be collected at baseline, immediate post-intervention, and 4-week follow up assessments.
89067316|NCT01029340|Experimental|Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP|Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months
89067317|NCT01029340|Experimental|Arm 5: Recombinant Factor VIII by CS/EP|Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
89067318|NCT04301752||Neurobrucellosis|Brucellosis associated with neuropsychiatric manifestations
89067319|NCT04301752||Non-neurobrucellosis|Brucellosis not associated with neuropsychiatric manifestations
89067320|NCT04304170|Experimental|Verum group|The dietary supplement under study was composed of fructo-oligosaccharides - FOS: 4.95 gr / sachet and Bifidobacterium animalis lactis: VES002 (LMG P-28149): 5 billion / sachet. They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
89067321|NCT04304170|Placebo Comparator|Placebo group|The comparative product was a placebo that looked strictly identical to the verum and contained only excipients (60% maltodextrin / 40% sucrose).They came in the form of sachets of powder to be diluted in a glass of water. Doses were 2 sachets per day for the first 5 days and then 1 sachet per day for the next 25 days.
89067322|NCT01265550|Other|Medical Treatment Group|Omeprazole or Omeprazole + baclofen or Omeprazole + desipramine
89067323|NCT01265550|Other|Surgical Treatment Group|Laparoscopic nissen fundoplications
89067324|NCT01265550|Other|Placebo Medical Treatment Group|Omeprazole + placebo
89067325|NCT01265394|Experimental|(18F) Flutemetamol|
89067326|NCT02889354|Experimental|Cognitive-behavioral therapy|
89067327|NCT01029262|Experimental|Arm #1 - Lenalidomide plus placebo|Lenalidomide 10 mg by mouth (PO) daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 60 mL/min for at least 168 days until disease progression, intolerable side effects or withdrawal of consent. Lenalidomide 5 mg PO daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 40 and < 60 mL/min.
89067328|NCT01029262|Placebo Comparator|Arm #2 - placebo|Three placebo capsules once daily for at least 168 days until disease progression occurred, intolerable side effects or withdrawal of consent.
89067329|NCT04301284|Experimental|CAD-1883|"Capsules of 150 mg of CAD-1883 will be administered orally, twice daily (BID). The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.~The initial dose regimen evaluated will be 150 mg BID. Additional dose regimens up to 600 mg BID will be determined based on forthcoming clinical data."
89067330|NCT04301284|Placebo Comparator|Placebo|Matching placebo will be provided in capsules, to be administered orally, twice daily. The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.
89067331|NCT02875210|Experimental|Patient with anterior cruciate ligament rupture|Anterior laxity of patient was measure with 4 laximeters:Telos, reference laximeter and with three other instruments called, KT-1000, GnrB and Rolimeter.
89067332|NCT00626938||sarcoidosis|sarcoidosis patients
89067333|NCT00626938||controls|healthy volunteers and other interstitial lung disease (ILD) patients
89067334|NCT02873416|Experimental|Precision cells combined with Chemotherapy treatment:|Once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
89067335|NCT02873416|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
89067336|NCT01028560|Active Comparator|No immunotherapy, receive standard of care asthma treatment|This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
89067337|NCT01028560|Experimental|Allergen immunotherapy|This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
89067338|NCT01061710||varenicline (Champix®)|Subjects who have been retreated with varenicline within 52 weeks and have been enrolled to varenicline protocol A3051109.
89067339|NCT01028014|Active Comparator|Pseudoephedrine|Pseudoephedrine 120mg extended release tablets
89067340|NCT01028014|Active Comparator|Solifenacin|Solifenacin 5mg capsule
89067341|NCT01028014|Active Comparator|Tamsulosin|Tamsulosin 0.4mg capsule
89067342|NCT01028014|Active Comparator|Imipramine|Imipramine 25mg tablet
89067343|NCT01028014|Active Comparator|Cyclobenzaprine|Cyclobenzaprine 10mg tablet
89067344|NCT01028014|Placebo Comparator|Lactose capsules|Sham
89067345|NCT04300972|Other|fixed dose|
89067346|NCT04300972|Experimental|weight and body type adapted dose|
89067347|NCT01264770|Experimental|Dosing Group A|Oral treatment and subcutaneous injection
89067348|NCT01264770|Experimental|Dosing Group B|Oral treatment and subcutaneous injection
89067349|NCT01264770|Experimental|Dosing Group C|Oral treatment and subcutaneous injection
89067350|NCT01264770|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection
89067351|NCT01264770|Placebo Comparator|Dosing Group E|Oral treatment and subcutaneous injection
89067352|NCT02873650|Experimental|Group 1 - Control group|
89067353|NCT02873650|Experimental|Group 2-Moderate hepatic impairment|
89067354|NCT02873650|Experimental|Group 3-Severe hepatic impairment|
89067355|NCT04301128|Experimental|EXPERIMENTAL GROUP|Patients in the experimental group were able to install and set up mobile application on android phones via Bluetooth and were informed about the sick android application. Patients were reminded and guided by subcutaneous anti-TNF drug treatments from mobile application. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Sub Cutan Anti-Tnf-α Therapy Questionnaire, BASDAI, ASQoL, BASFI scales.
89067356|NCT04301128|Active Comparator|CONTROL GROUP|An anti-TNF drug administration training booklet were given to patients in the control group and were required to take advantage of the booklet on subcutaneous anti-TNF drug production. Both groups of patients were then assessed using face-to-face interviews for 6 months, 6 weeks after using the Sub Cutan Anti-Tnf-α Therapy Questionnaire, BASDAI, ASQoL, BASFI scales. At the end of the study (twenty forth week) was applied to all patients.
89067357|NCT04301050|Experimental|Yoga Intervention|Participants will complete 8-week course (75-minute, weekly yoga classes) delivered online via videoconferencing software. Participants will complete patient-reported outcomes at baseline (prior to class 1) and post-intervention (after class 8), as well as post-intervention measures of feasibility/acceptability.
89067358|NCT01027702|Experimental|Infusion of donor lymphocytes|Patients will receive an infusion of donor lymphocyte after T-cell depleted transplant.
89067359|NCT01302080||Sertraline-treated|enrolled subjects beginning treatment for one of the study qualifying disorders with sertraline
89067360|NCT01302080||psychotherapy only|enrolled subjects beginning treatment for one of the study qualifying disorders with psychotherapy
89067361|NCT01238991|Experimental|ACC-001 (3 micrograms) + QS-21|Active vaccine dose of 3 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
89067362|NCT01238991|Experimental|ACC-001 (10 micrograms) + QS-21|Active vaccine dose of 10 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
89067363|NCT01238991|Experimental|ACC-001 (30 micrograms) + QS-21|Active vaccine dose of 30 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
89067364|NCT02890472||prenatal diagnosis of a fetal 22q11 deletion syndrome|
89067365|NCT05643716|Experimental|Aerobic Exercise|During this single session, participants will run on a treadmill at a moderate-vigorous intensity (65-75% age-predicted HRmax) for 20 minutes. Exercise intensity will be continuously monitored using a Polar OH1 heart rate monitor, which will be strapped to the participant's chest prior to starting the exercise session. Age-predicted HRmax will be calculated for each participant using the following formula: (HRmax = 220 - Age). Subjective units of distress related to their perceived exercise intensity will be measured in 3-minute intervals. Following the exercise session, participants will rest until their heart rate returns to within 10% of their resting heart rate (approximately 5 minutes) before starting the post-assessments.
89067366|NCT05643716|No Intervention|Static Stretching|Participants will be guided by a research assistant through a single session of static stretching which will serve as a time-matched control. During the stretching session, participants will complete a set of stretches for 20 minutes. Similar to the aerobic exercise group, participants' heart rate will be continuously monitored via a Polar OH1 heart rate monitor. Following the static stretching session, participants will rest for 5 minutes to match the exercise group before starting the post-assessments.
89067367|NCT01238835|Experimental|TAVR-TA|Transcatheter valve replacement with transapical access
89067368|NCT02888457|Other|AOM (acute otitis media)|Infants (6-30 months of age) with acute otitis media
89067369|NCT02888457|Other|DCC (day-care centers)|Healthy infants (6-30 months of age) attending day-care centers
89067370|NCT01032070|Experimental|Erlotinib|Erlotinib was administered orally at a dose of 85 mg/m^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
89067371|NCT01032070|Active Comparator|Etoposide|Etoposide 50 mg/m^2 per day was administered orally for 21 days followed by a 7-day rest period until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
89067372|NCT01237899|Experimental|1 mg LY2623091|Daily by mouth for 7 days.
89067373|NCT01237899|Experimental|10 mg LY2623091|Daily by mouth for 7 days.
89067374|NCT01237899|Experimental|25 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of 100 mg based on safety and tolerability data. The 25 mg LY2623091 was administered daily by mouth for 7 days.
89067375|NCT01237899|Experimental|0.3 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of up to 200 mg. The 0.3 mg LY2623091 was determined based on an interim analysis after the third dose level and was administered daily by mouth for 7 days.
89067376|NCT01237899|Placebo Comparator|Placebo|Daily by mouth for 7 days.
89067377|NCT01237899|Active Comparator|50 mg Eplerenone|Daily by mouth for 7 days.
89067378|NCT01264380|Experimental|1|
89067379|NCT01264380|Experimental|2|
89067380|NCT01264380|Experimental|C|
89067381|NCT01263444|Experimental|Azarga|Brinzolamide 1% / timolol 0.5% Fixed Combination administered as 1 drop in study eye(s) twice a day (8:00 AM and 8:00 PM) for 12 weeks, at a 5 minute interval from the habitual prostaglandin monotherapy.
89067382|NCT01263054|Experimental|TransDiscal System|Kimberly-Clark TransDiscal System in addition to standard medical management
89067383|NCT01263054|Other|Medical Management|Standard medical management
89067384|NCT01031836|Experimental|MEDI-545 1.0 mg/kg|Cohort 1
89067385|NCT01031836|Experimental|MEDI-545 3.0 mg/kg|Cohort 2
89067386|NCT01031836|Experimental|MEDI-545 10.0 mg/kg|Cohort 3
89067387|NCT01031836|Experimental|MEDI-545 100 mg|Cohort 4
89067388|NCT01031836|Experimental|MEDI-545 600 mg|Cohort 5
89223543|NCT00989274|Active Comparator|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|120 participants selected in random form
89067389|NCT01031836|Experimental|MEDI-545 1,200 mg|Cohort 6
89067390|NCT04301440|Active Comparator|patients with anxious and / or depressive characteristics : treated group|patients with anxious and / or depressive characteristics, The device with the electromagnetic wave will be connected
89067391|NCT04301440|Placebo Comparator|patients with anxious and / or depressive characteristics : placebo group|The device with the electromagnetic wave will not be connected
89067392|NCT01237587|Experimental|Duloxetine|"Blinded treatment period: 30mg or 60mg once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
89067393|NCT01237587|Placebo Comparator|Placebo|"Blinded treatment period:Placebo once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
89067394|NCT01031680|Experimental|1|Dapagliflozin 10 mg tablet
89067395|NCT01031680|Placebo Comparator|2|Matching placebo tablet
89067396|NCT01031446|Experimental|Treatment|
89067397|NCT02873728|Experimental|RIC|In the study group, a blood pressure cuff will be inflated to 50 mmHg above systolic blood pressure while the performing investigator examines the radial pulse to ensure complete blood flow obstruction. Ischemia will be performed for 3 cycles of 5 min each and 10 min resting between cycles.
89067398|NCT02873728|Sham Comparator|Control|In the control group, a blood pressure cuff will be inflated to 10 mmHg (Sham procedure) for 3 cycles of 5 min each and 10 min resting between cycles.
89067399|NCT01030900|Experimental|Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin + Rituximab + Campath|Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin (EPOCH) + Rituximab + campath every 3 weeks for six cycles
89067400|NCT01030822|Experimental|Group A|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 9-18 months of age.
89067401|NCT01030822|Experimental|Group B|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 15-18 months of age.
89067402|NCT01030822|Experimental|Group C|Unprimed subjects receiving a catch-up vaccination (2+1 schedule) in the second year of life.
89067403|NCT02873494||PHYSIOFLOW PF05 Lab1TM|Impedance cardiography
89067404|NCT04694872|Experimental|a) TELEREHABILITATION BASED LSVT BIG TREATMENT GROUP|It is planned to recruit 16 patients with Parkinson's Disease in this group. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
89067405|NCT04694872|Active Comparator|b) TELEREHABILITATION BASED FUNCTIONAL BALANCE AND MOBILITY EXERCISES GROUP|It is planned to recruit 16 patients with Parkinson's Disease in this group. These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.
89067406|NCT01026454|Active Comparator|acyclovir|acyclovir 400 mg orally twice daily
89067407|NCT01026454|Active Comparator|valacyclovir|valacyclovir 1.5 g orally twice daily
89067408|NCT01026220|Experimental|Regimen I (consolidation therapy)|Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.
88812890|NCT05313542|Other|Waitlist Group (WL group)|The waitlist group will receive access to the programme at the end of study.
88812891|NCT03214172||Cancer-associated thrombosis|Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
88812892|NCT01832948|Experimental|Treatment|Endostar d1-d7 15mg/d Oxaliplatin 85 mg/m2 d6 Folinic acid 400 mg/m2 d6 5-FU 400 mg/m2 d6, and then 5-FU 2,400 mg/m2 INTRAVENOUS over 46 h
89067409|NCT01026220|Experimental|Regimen II (consolidation therapy)|Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
89067410|NCT01026220|Experimental|Induction: all patient|All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.
89067411|NCT00627562|Experimental|1|robot assisted endoscopic head and neck surgery
89067412|NCT01026142|Active Comparator|A: Capecitabine + Trastuzumab|
89067413|NCT01026142|Experimental|B: Capecitabine + Trastuzumab + Pertuzumab|
89067414|NCT06055582|Other|Treatment - Mango|Subjects in mango group will be further randomized into three different groups. Each group will be tested on a different variety of mango.
89067415|NCT06055582|Other|Controlled- Bread|Subjects in bread group were given 81g (3 slices) harvest gold white bread as standard food in raw form.
89067416|NCT06055569|Experimental|Action Observation Therapy (AOT) associated with Neuromuscular Electrical Stimulation (NMES)|The group will receive 5 consecutive days a week, for 3 weeks, 60 minutes-long sessions of action observation therapy (AOT) associated with a synchronous neuromuscular stimulation of motor synergies (NMES). After AOT-NMES, subjects will be asked to repeat the observed movement.
89067417|NCT06055569|Active Comparator|Action Observation Therapy (AOT)|The group will receive 5 consecutive days a week, for 3 weeks, 60 minutes-long sessions of action observation therapy (AOT). The neuromuscular electrical stimulator will be placed on the subjects' arm without synchronous stimulation. After AOT, subjects will be asked to repeat the observed movement.
89067418|NCT06055569|Placebo Comparator|Observation of motor-neutral stimuli (MNO)|The group will receive 5 consecutive days a week, for 3 weeks, 60 minutes-long sessions of motor-neutral observation (MNO). The neuromuscular electrical stimulator will be placed on the subjects' arm without synchronous stimulation. After MNO, subjects will be asked to execute movements.
89067419|NCT06055543|Active Comparator|Fortimel Energy|Control: high-energy ONS 1.5 Kcal/m 200ml for 90 days
89067420|NCT06055543|Experimental|Fortimel PlantBased|Intervention: high-energy ONS 1.5 Kcal/m 200ml for 90 days
89067421|NCT06055517|Experimental|Pulsed low dose-rate radiotherapy (pLDRT)|
89067422|NCT06055413|Experimental|Intervention Arm|Patients receiving the intervention.
89067423|NCT06055400|No Intervention|standard US|The participants underwent CVC placement using standard ultrasound guidance.
89067424|NCT06055400|Experimental|AR-US|The participants underwent CVC placement using AR-HMD ultrasound guidance.
89067425|NCT06055387|Experimental|Frail group|All patients receive a frailty assessment within 7 days before initiating treatment, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The frail group will receive management and recommendations based on the specific impairment domain.
89223544|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 7.5 ug|120 participants selected in random form
89223545|NCT03310944|Active Comparator|Sotagliflozin dose 1 (reference formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
89067426|NCT06055387|No Intervention|Non-frail group|All patients receive a frailty assessment within 7 days before initiating treatment, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The non-frail group will not receive additional interventions, but the clinical physicians will still provide appropriate treatment based on the patient's condition.
89067427|NCT06055374|Experimental|BxC-I17e|"Subcutaneous (SC) injection of 50, or 100 ug BxC-I17e~Treatment on Day 1, 15, 29, and 43 for a total 4 biweekly doses"
89067428|NCT06055374|Placebo Comparator|Placebo|"Subcutaneous (SC) injection of the matching placebo~Treatment on Day 1, 15, 29, and 43 for a total 4 biweekly doses"
89067429|NCT06055361|Experimental|BxC-I17e|"Subcutaneous (SC) injection of 25, 50, or 100 ug BxC-I17e~Single dose on Day 1"
89067430|NCT06055361|Placebo Comparator|Placebo|"Subcutaneous (SC) injection of the matching placebo~Single dose on Day 1"
89067431|NCT06055348|Experimental|Arm A (SC0191 + Gemcitabine).|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle. Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
89067432|NCT06055348|Experimental|Arm B (SC0191 + Paclitaxel).|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle. Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
89067433|NCT06055335|Experimental|Medium flow anesthesia|After reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane.
89067434|NCT06055335|Experimental|Minimal flow anesthesia|After reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane.
89067435|NCT06055322|Experimental|Adapted Dialectical Behavior Therapy|Adapting Dialectical Behavior Therapy to focus on reducing suicide ideation for family caregivers of persons with AD/ADRD
89067436|NCT06055283|Experimental|Training group|Aerobic exercise training on moderate intensity.
89067437|NCT06055283|No Intervention|Control group|Monitoring.
89067438|NCT06055270|Placebo Comparator|Placebo Group|The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine.
89067439|NCT06055270|Experimental|Stellate Ganglion Block|The ultrasound-guided stellate ganglion blocks will be performed by a pain management specialist with extensive experience performing these blocks. The first SGB at the initial visit will be performed on the right side, and the second SGB will be on the left side 5-10 days after the first SGB, given that the patient tolerated the first SGB.
89067440|NCT06055257|Placebo Comparator|Group 1 (Control)|"Standard of care treatment for ORN consisting of conservative measures (e.g. local irrigation, antiseptic mouthwash) and approximately 60 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2.4 ATA each, scheduled Monday to Friday for 12 weeks - i.e., 5 treatments per week). At the conclusion of the study and at the discretion of the clinical team, patients randomized to the control group with residual disease may be considered for the mPENTOCLO protocol.~Simultaneously, the 4-week mPENTOCLO pre-treatment phase will be started (as defined in the intervention section), followed by a sham/placebo mPENTOCLO treatment phase for a total of 12 months."
89067441|NCT06055257|Experimental|Group 2 (Intervention)|"Standard of care treatment as described for the control group (conservative measures and 60 HBOT treatments).~Simultaneously, a comprehensive oral regimen (mPENTOCLO) will be started, including a 4-week pre-treatment phase followed by a treatment phase for a total of 12 months, as defined in the Intervention section."
89067442|NCT06055166|Experimental|untreated surgically resectable rectal cancer|
89067443|NCT06055166|Experimental|untreated locally advanced unresectable non-small cell lung cancer|
89067444|NCT06055166|Experimental|untreated locally advanced unresectable esophageal squamous cell carcinoma|
88812893|NCT03214016|Experimental|Pilates method group|The participants will do Mat Pilates.
88812894|NCT03214016|Active Comparator|Aerobic training group|The participants will do aerobic exercise on treadmill.
89067445|NCT06055166|Experimental|untreated locally advanced unresectable cervical carcinoma|
89067446|NCT06055153|Experimental|RC48+PD-1+platinum-based|"Dose 1: RC48 2.5mg/kg intravenous infusion, d1 once every 3 weeks;~Camrelizumab dose: 200mg, intravenous infusion 30-60min, d1 once every 3 weeks;~Platinum (cisplatin or nedaplatin) : Cisplatin 75mg/m2, added into 500ml 0.9% sodium chloride injection for infusion, hydration and alkalization of -1d, d1, d2, once every 3 weeks; Nedaplatin 75mg/m2 was added to 500ml 0.9% sodium chloride injection, once every 3 weeks.~Dose 2: rc48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks"
89067447|NCT06055140||Idiopathic scoliosis without pain|In this group, there will be individuals diagnosed with idiopathic scoliosis whose Cobb angle is above 15 degrees and whose pain level, as assessed by the Visual Analog Scale, is below 3.
89067448|NCT06055140||Idiopathic scoliosis with pain|In this group, there will be individuals diagnosed with idiopathic scoliosis whose Cobb angle is above 15 degrees, and their pain level, as assessed by the Visual Analog Scale, is above 3.
89067449|NCT06055140||Control|In this group, there will be healthy individuals whose pain level, as assessed by the Visual Analog Scale, is below 3.
89067450|NCT06055127|Experimental|osseodensifiction internal sinus lift / sticky bone graft material|Osseodensifiction compacts bone and simultaneously autografts it into the osteotomy walls and apex instead of removing it. The use of a Densah® drill bit at high speed counterclockwise, without a cutting edge and with a steady irrigation causes the formation of a layer of strong dense bone along the walls of the base of the osteotomy preparation.
89067451|NCT06055127|Active Comparator|piezoelectric internal sinus lift / sticky bone graft material|The piezoelectric surgical sets comprise various inserts from osteotomies to diamond-cutting inserts. The hydropneumatics pressure of the saline solution irrigation is subjected to the piezoelectric cavitation pushing the Schneiderian membrane upwards resulting in its' detachment and floating
89067452|NCT06055114||study group|Age 20-49 years old; Premenopausal; Clinical diagnosis of uterine myoma; Cervical liquid-based cytology and human papillomavirus typing test are negative.
89067453|NCT06055114||Healthy control group|Age 20-49 years old; Premenopausal; Uterine B-ultrasonography is normal; Cervical liquid-based cytology and human papillomavirus typing test are negative; No vaginal infection.
89067454|NCT06055101|Other|DEXMEDETOMIDINE|Group 1 ( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.1 ml (10 μg) DXM and 0.1 ml normal saline.
89067455|NCT06055101|Other|Neostigmine|Group 2( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.1 ml (50 μg) neostigmine and 0.1 ml normal saline.
89067456|NCT06055101|Other|Bupivacaine|Group 3 ( 18 patients ) were received 10 mg (2ml) hyperbaric bupivacaine and 0.2 ml normal saline as control.
89067457|NCT06055036|Experimental|Black Impact Intervention|Black Impact Intervention
88812895|NCT01833260|Experimental|With music|Pulmonary rehabilitation with music in the room
89067458|NCT06055036|No Intervention|Black Impact Waitlist Control|Usual Care
89067459|NCT06055023|Experimental|ZL-82 12.5mg|2 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
89067460|NCT06055023|Experimental|ZL-82 25mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
89067461|NCT06055023|Experimental|ZL-82 50mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
89067462|NCT06055023|Experimental|ZL-82 100mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
89067463|NCT06055023|Experimental|ZL-82 200mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
89067464|NCT06055023|Experimental|ZL-82 300mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
89067465|NCT06055023|Experimental|ZL-82 450mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
89067466|NCT06055023|Experimental|ZL-82 600mg|8 case，The starting dose，Take the medicine once on D1 ，D1 through 7.
89067467|NCT06055010||Healthy individuals|Healthy individuals who received an abdominal CT-scan (controls).
89223546|NCT03310944|Experimental|Sotagliflozin dose 2 (prototype p1 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
89223547|NCT03310944|Experimental|Sotagliflozin dose 3 (prototype p2 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
89223548|NCT03310944|Experimental|Sotagliflozin dose 4 (prototype p3 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
89223549|NCT04804254|Experimental|Monotherapy in Dose Escalation: ABBV-623|Participants with Relapsed/Refractory (R/R) B-cell malignancies will receive escalating doses of ABBV-623.
89223550|NCT04804254|Experimental|Monotherapy in Dose Escalation: ABBV-992|Participants with R/R B-cell malignancies will receive escalating doses of ABBV-992.
89223551|NCT04804254|Experimental|Combination in Dose Escalation|Participants with R/R B-cell malignancies will receive escalating doses of ABBV-623 and ABBV-992.
89223552|NCT04804254|Experimental|Monotherapy in Dose Expansion: ABBV-623|Participants with R/R B-cell malignancies will receive ABBV-623 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
89223553|NCT04804254|Experimental|Monotherapy in Dose Expansion: ABBV-992|Participants with R/R B-cell malignancies will receive ABBV-992 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
89223554|NCT04804254|Experimental|Combination in Dose Expansion|Participants with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) will receive ABBV-623 and ABBV-992 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
89223555|NCT05712642|Experimental|Group A recieved 0.3125mg intravitreal bevacizumab in both eyes|9 infants in group A with type 1 ROP , received 0.3125mg IVI of bevacizumab in both eyes, serum systemic levels of VEGF was measured at day 0 (before injection) , and 1 week and 4 weeks post injection .
89223556|NCT05712642|Active Comparator|Group B received 0.625mg intravitreal bevacizumab in both eyes|10 infants in group B with type 1 ROP , received 0.625mg IVI of bevacizumab in both eyes, serum systemic levels of VEGF was measured at day 0 (before injection) , and 1 week and 4 weeks post injection .
89223557|NCT00092521|Experimental|1|V501
89223558|NCT00092521|Placebo Comparator|2|Placebo
89223559|NCT00092521|Experimental|3|HPV 16 Monovalent Vaccine
88812896|NCT01833260|No Intervention|Without music|
89223560|NCT03908970|Experimental|1% OPA-15406|Twice daily
89223561|NCT03908970|Placebo Comparator|Placebo|Twice daily
89223562|NCT05712330|Experimental|non invasive ventilation|SMA patients with NIV
89223563|NCT00092443|Experimental|RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)|"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)~administered 28 to 70 days apart."
89223564|NCT00092443|Placebo Comparator|Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
89223565|NCT04005924|No Intervention|Control|Bread and sugar-free blackberry jam breakfast
89223566|NCT04005924|Experimental|Low dose|Bread and sugar-free blackberry jam breakfast with 6 g arabinogalactan
89223567|NCT04005924|Experimental|High dose|Bread and sugar-free blackberry jam breakfast with 21 g arabinogalactan
89223568|NCT01085149|Experimental|study group|simvastatin will be inserted to sockets
89223569|NCT01085149|No Intervention|control|sockets will be left to healing without material in socket
89223570|NCT04005612|Experimental|vitamin d3 group|weekly Dietary Supplement: Vitamin D3 50,000 IU Vitamin D3 / week for 8 weeks
89223571|NCT04005612|Experimental|omega3-Fatty Acid group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
89223572|NCT04005612|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3 FA) once daily
89223573|NCT04005612|No Intervention|Control group|NO INTERVENTION
89067468|NCT06055010||Individuals with pancreatic lesions|Patients who received diagnostic procedures and/or treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database
89067469|NCT06054958||ME/CFS|"ME/CFS: adolescents aged 14-17 years, fulfilling diagnostic criteria for ME/CFS according to Rowe e 2017, Jason 2006, CCC 2003, and/ or IOM 2015 at the time of recruitment.~Methods: Semi-structured interview, questionnaires, passive 10-minute standing test (NASA lean test), blood sampling."
89690384|NCT03621345|Sham Comparator|sham block|"A sham block will be performed while looking for intended location for ESP block placement. Skin will be infiltrated with local anesthetics but ESP block will not be performed, instead of ESP block 2 mL subcutaneous saline injection will be applied.~Intervention: Sham block Other: Standard Pain Followup and Monitorization"
89067470|NCT06054958||Healthy Controls (HC)|"HC: adolescents aged 14-17, clinically healthy without any known underlying disease and with no prescription drugs (except contraception).~Methods: Semi-structured interview, questionnaires, passive 10-minute standing test (NASA lean test), blood sampling."
89067471|NCT06054932|Experimental|2weeks-intervals prime dose procedure|LK101 will be administered in a prime-boost schedule, which is 4 priming vaccination as 2-weeks-intervals followed by 3 booster vaccinations
89067472|NCT06054932|Experimental|1weeks-intervals prime dose procedure|LK101 will be administered in a prime-boost schedule, which is 4 priming vaccination as 1-weeks-intervals followed by 3 booster vaccinations
89067473|NCT06054919|Experimental|50,000 IU|Vitamin D3 50,000 IU weekly a standard prenatal multivitamin (fumarate Fe 90 mg; folic acid 0.4 mg; vitamin B6 3 mg; vitamin B12 5 mcg; sulphate cupric 0.35 mg, sulphate cobalt 0.15 mg, sulphate mangan 5 mcg, vitamin C 60 mg, vitamin E 5 mg, and phosphate calcium 60 mg)
89067474|NCT06054919|Active Comparator|5,000 IU|Vitamin D3 5,000 IU daily a standard prenatal multivitamin (fumarate Fe 90 mg; folic acid 0.4 mg; vitamin B6 3 mg; vitamin B12 5 mcg; sulphate cupric 0.35 mg, sulphate cobalt 0.15 mg, sulphate mangan 5 mcg, vitamin C 60 mg, vitamin E 5 mg, and phosphate calcium 60 mg)
89067475|NCT06054906|Experimental|sintilimab+metronomic PLOF|sintilimab therapy(200mg, iv,d1,Q3W, 2cycles)and PLOF chemotherapy (Paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, 5-fluorouracil 425mg/m2, d1, QW, 6cycles) followed by adjuvant sintilimab therapy(200mg, iv,d1,Q3W, 2cycles)and PLOF chemotherapy (Paclitaxel 60 mg/m2, oxaliplatin 50 mg/m2, 5-fluorouracil 425mg/m2, d1, QW, 6cycles) neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
89690385|NCT05232136|Experimental|OH2|This arm include two doses (1x10e6, 1x10e7 CCID50/mL) of OH2 injection，the 1x10e6 CCID50/mL dose group should be delivered before the 1x10e7 CCID50/mL dose group.
89690386|NCT03410446|Experimental|Ketamine|"Three doses of ketamine will be given intranasal:~Dose 1 will be 50 mg on Day 1~Dose 2 will be between 50-100 mg on Day 4~Dose 3 will be between 50-150 mg on Day 7"
89690387|NCT04663594|Experimental|Ways of Being online Experience|Ways of Being (WoB) every day for three days
88812897|NCT01533077|Experimental|Group 1|Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
88812898|NCT01533077|Experimental|Group 2|Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
89690388|NCT04663594|Other|Ashmolean Website|The Ashmolean Website every day for three days
89690389|NCT05222386|Other|Usual Care|Community neurologists provide their usual care to enrolled participants. The clinicians may utilize other community resources to support patients and families as per their usual practice.
89690390|NCT05222386|Other|Online Community-Supported Palliative Care Intervention|Community neurologists get training in palliative care via teleconferences (ECHO model), in addition to other support from our team. Patients and carepartners will also have access to additional support services when their providers enter the intervention (Online support groups, tailored education)
89690391|NCT00994123|Experimental|Phase 1: Dose-Escalation|Escalating doses of MM-121 (QOW IV) and erlotinib (daily PO)
89690392|NCT00994123|Active Comparator|Phase 2: Control|Erlotinib (daily)
89690393|NCT00994123|Experimental|Phase 2: Treatment|MM-121 (QOW IV) and erlotinib (daily PO)
89690394|NCT03001726||Gastrectomy plus chemotherapy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
89690395|NCT03001726||chemotherapy alone|Patients received chemotherapy alone.All patients received oral S1 80 mg/m2 per day (80-120 mg/day total dose depending on the patient's body surface area as follows: <1.25 m2, 80 mg; 1.25-1.5 m2, 100 mg; and >1.5 m2, 120 mg) on days 1-21 of every 3-week cycle, oxaliplatin 100 mg/m2 on day 1 of every 3-week cycle and docetaxel 40mg/m2 on day 1 of every 3-weeks cycle.
89690396|NCT03595527|Experimental|Patients consulting in the emergency room|Patients consulting in the emergency room.
89690397|NCT04697329|Experimental|Local infiltration|
89690398|NCT04697329|No Intervention|No local infiltration|
89690399|NCT02974413|Experimental|Intervention|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.
89690400|NCT02974413|No Intervention|Control|The study will also include a Control Group (CG), and the participants of this group will participate in conversation circles at the beginning and the end of the six month follow-up.
89067477|NCT06054841|Experimental|Follow up cards|Subjects will receive a personalized postpartum health card with recommendations for follow up based on their comorbid conditions in pregnancy. They will receive education about these comorbid conditions when they receive their cards.
89067478|NCT06054841|Placebo Comparator|Standard education|Subjects will receive standard postpartum education as it is routinely performed by nurses prior to discharge.
89067479|NCT06054828|Experimental|mHELP@ICU|Participants will receive cognitive engagement twice daily, have physical activity once daily, and be monitored for their feeding. The intervention will be administered for 14 days or until hospital discharge or death.
89067480|NCT06054828|No Intervention|Control group|Participants in the control group will receive the usual care.
89067481|NCT06054789|Experimental|68Ga-PSMA-33|For the injection, subjects will receive a target dose of 3-7mCi 68Ga-PSMA-33 as a bolus injection. Among them, 3~4 subjects will additionally inject with 68Ga-PSMA-617 (3-7mCi).
89067482|NCT06054737||SPA THERAPY PROGRAM|3-week spa therapy program with Mineral Water of Royat in addition to standard of care for chronic venous insufficiency
89067483|NCT06054711|Other|Joint Fluid Aspiration|all included patients reporting prothesis complication will undergo a joint fluid aspiration
89067484|NCT06054698|Experimental|HRS9531 injection|
89067485|NCT06054698|Placebo Comparator|HRS9531 injection Placebo|
89067486|NCT06054672|Experimental|Group 1|This group will receive subthreshold stimulation
89067487|NCT06054672|No Intervention|Group II|This group will receive no stimulation
89067488|NCT06054607|Placebo Comparator|Low-amylose maize starch|Low-amylose maize starch (AMIOCA; Ingredion, Inc).
89067489|NCT06054607|Active Comparator|High-amylose maize starch+acetate/butyrate|High-amylose maize starch, (Hylon VII; Ingredion, Inc.) to which the SCFA acetate or butyrate has been chemically added.
89067490|NCT06054490|Active Comparator|Self-management group (SM group)|Subjects in this group received a scheme of self-management protocol consisting of verbal and written information on the etiology and prognosis of TMD.
89067491|NCT06054490|Experimental|Self-management plus home exercises group (SM+EX group)|Subjects in this group received self-management protocol in combination with a home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises.
89067492|NCT06054412|Other|Neurofeedback Training|Mothers in the Neurofeedback Training group will complete pre and post-training self-report surveys assessing trauma symptoms, mental health, parenting attitudes and behaviors, and infant crying patterns and socioemotional development. Mothers in this group will all be receiving in-person psychotherapy outside of the study, and they will all demonstrate clinically significant symptoms aligned with post-traumatic stress disorder and/or it's dissociative subtype.
88812899|NCT01533077|Experimental|Group 3|Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
89067493|NCT06054386|Active Comparator|Integrated ABM (I-ABM)|The I-ABM will include four progressively difficult levels of training blocks, each containing 72 trials. Participants will be required to tap or swipe the probe in the correct direction during the first and second levels of training. The inhibitory control components will be included in the third and fourth levels, where participants should not respond to the probe under certain conditions. Each training will take 10-15 minutes, and participants will complete the sessions three times a week for three weeks.
89067494|NCT06054386|Placebo Comparator|Placebo Training (PLT)|The PLT has four training blocks that follow the same basic design as the I-ABM training. However, the PLT will not aim to change social anxiety-related attention bias. Participants will simply swipe or tap the probe regardless of the stimuli condition, which is expected to exert a minimum level of effect on changing the attention bias linked to social anxiety. Participants will complete the training three times per week for three weeks.
89067495|NCT06054321|Experimental|Good responder group-stepwise pharmacotherapy group|"Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then good responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.~In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks."
88812900|NCT01533077|Experimental|Group 4|Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
88812901|NCT05312684||High anticholinergic burden|ACB scale score 1 or >1 as a high anticholinergic buden
89067496|NCT06054321|Active Comparator|Good responder group-antidepressant monotherapy group|"Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then good responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.~In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks."
89067497|NCT06054321|Experimental|Poor responder group-stepwise pharmacotherapy group|"Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then poor responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.~In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks."
89067498|NCT06054321|Active Comparator|Poor responder group-antidepressant monotherapy group|"Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then poor responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group.~In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks."
89067499|NCT06054243|Experimental|CBT-I|
89067500|NCT06054243|Active Comparator|CBT-A|
89067501|NCT06054243|No Intervention|Waiting-list control|
89067502|NCT06054139||the treated patients in ICU|Patients receiving nutrition while receiving treatment in intensive care
89067503|NCT06054100|Experimental|Colchicine group|Colchicine group, Colchicine oral tablets, loading dose 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
89067504|NCT06054100|No Intervention|STEMI standard treatment group|Control group, STEMI standard treatment only
89067505|NCT06054087|Experimental|EA group|Subjects in this group received electroacupuncture along with the basic treatment at a frequency of 2 treatments per week for 6 weeks for a total of 12 interventions. The follow-up period is one month.
89067506|NCT06054087|Other|Waiting list group|The subjects in this group will receive only basal treatment with no additional therapies during the study period. After the end of the study period, patients were given 12 acupuncture treatments
89067507|NCT06054074|Experimental|Low back pain|Participants with low back pain. They will perform the two induction procedures.
89067508|NCT06054048|Active Comparator|Telemedicine|Those patients who received specialized outpatient palliative care plus telemedicine.
89067509|NCT06054048|No Intervention|No telemedicine (Standard of Care)|Those patients who received standard specialized outpatient palliative care only.
89067510|NCT06054035|Experimental|Dapagliflozin (Forxiga®) and lifestyle counselling|
89067511|NCT06054035|Placebo Comparator|Placebo matching Dapaglifolzin and lifestyle lifestyle counselling|
89067512|NCT06054022|Experimental|patient receiving high flow nasal cannula (A)|Patient will be put on high flow nasal cannula at a fixed flow of 50L/min, at Fio2 0.3% throughout surgery. Oxygen therapy will be discontinued once surgery ends. FiO2 will be titrated by 0.1 increment to a SpO2 of ≥94%.
89067513|NCT06054022|Active Comparator|patient receiving nasoprong oxygen 2 L/min|Patient will be put nasoprong oxygen 2L/min throughout surgery. Oxygen therapy will be discontinued once surgery ends. FiO2 will be titrated by 0.1 increment to a SpO2 of ≥94%.
89067514|NCT06053996|Experimental|MSI-H mCRC|high dose radiation therapy (SBRT) targeted to the lung and liver metastases
89067515|NCT06053996|Experimental|MSS mCRC.|high dose radiation therapy (SBRT) targeted to the lung and liver metastases
88812902|NCT05312684||Normal anticholinergic burden|ACB scale score <1 as a control group
89067516|NCT06053970|Other|Random order of virtual scenes|"Eight measurements on a stabilometry platform will be performed for each of the VR signals, in random order:~Signal A Direction: anteroposterior Speed: 5 m/s~Signal B Direction: anterior-posterior Speed: 5 m/s~Signal C Direction: Oblique forward and downward Speed: 5 m/s~Signal D Direction: Oblique forwards and upwards Speed: 5 m/s~Signal E Direction: Oblique forwards and to the right Speed: 5 m/s~Signal F Direction: Oblique forward and left Speed: 5 m/s~Signal G Direction: antero-posterior + Clockwise tunnel rotation at 10°/s Speed: 5 m/s~Signal H Direction: antero-posterior + Counter-clockwise tunnel rotation at 10°/s Speed: 5 m/s"
89067517|NCT06053957|Experimental|Mobilization|Patients undergoing early mobilization program
89067518|NCT06053957|No Intervention|mobilization free|Patients not subjected to early mobilization program
89067519|NCT06053931|No Intervention|Control group|"The women will fill out an descriptive characteristics questionnaire, which include questions such as age, education and employment status, number of pregnancies and children etc. Mothers will be asked to mark before breastfeeding on their comfort on the Visual Analog Scale. The number 0 on the scale indicates that it is not comfortable at all, and the number 10 indicates that the comfort is complete.The baby's stress level will measure with the Newborn Stress Scale before breastfeeding. While the mother is breastfeeding her baby, the breastfeeding process will be evaluated by the researcher with the LATCH Breastfeeding Assessment Tool. Baby's stress level will be evaluated at the 1st minute of breastfeeding with the Newborn Stress Scale. After the breastfeeding process is completed, the mother will be asked to fill out the Visual Analog Scale again to evaluate her comfort."
89223574|NCT00413920|Experimental|Without Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, but did not subsequently receive oral corticosteroids for the remainder of the study.
89223575|NCT00413920|Active Comparator|With Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, and subsequently continued to receive daily oral prednisone.
89223576|NCT03993964|Experimental|Experimental: Pyrotinib + SHR6390|Pyrotinib combine with SHR6390 should be administrate to all subjects. pyrotinib 400mg qd combined with SHR 6390 125mg qd
88812903|NCT05310500|Experimental|ProTaper Gold (F2) - NaOCL|ProTaper Files without NaOCL
88812904|NCT05310500|Experimental|ProTaper Gold (F2) + NaOCL|ProTaper Files with NaOCL
89067520|NCT06053931|Experimental|Lullaby group|"The women will fill out an descriptive characteristics questionnaire. Mothers will be asked to mark before breastfeeding on their comfort on the scale.~The baby's stress level will measure with the Newborn Stress Scale before breastfeeding.~Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes.~During the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~The baby will be observed by the researcher at the first minute of breastfeeding, and the Newborn Stress Scale will be filled in again.~The LATCH assessment will be done within the first 15 minutes of breastfeeding. After breastfeeding is over, they will be asked to fill in the Visual Analog Scale in order to evaluate the comfort of the mother."
88812905|NCT05310500|Experimental|Dia-X ProTaper (D4) - NaOCL|Dia-X ProTaper (D4) without NaOCL
88812906|NCT05310500|Experimental|Dia-X ProTaper (D4) + NaOCL|Dia-X ProTaper (D4) with NaOCL
89067521|NCT06053931|Experimental|White noise group|"The women will fill out an descriptive characteristics questionnaire. Mothers will be asked to mark before breastfeeding on their comfort on the scale.~The baby's stress level will measure with the Newborn Stress Scale before breastfeeding.~Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes During the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~The baby will be observed by the researcher at the first minute of breastfeeding, and the Newborn Stress Scale will be filled in again.~The LATCH assessment will be done within the first 15 minutes of breastfeeding. After breastfeeding is over, they will be asked to fill in the Visual Analog Scale in order to evaluate the comfort of the mother."
89067522|NCT06053918||classic follow-up (Group A)|Group A will benefit from the classic follow-up, as it has been contractualized for several years now between the UMDSP and the hematology sector. Namely a psychological follow-up in the patient's room during the hospitalization time, once a week, more if the patient is going through a difficult passage that requires closer support. This follow-up is spread over an approximate period of 6 weeks maximum, depending on the length of hospitalization
89067523|NCT06053918||Intervention group (Group B)|Group B will benefit from this same follow-up, to which will be added an interview when leaving the sector, and the extension of follow-up of the patient at home according to the same conditions: once a week, more if necessary, over a period of two months. This follow-up is spread over an approximate period of 15 weeks maximum, depending on the length of hospitalization.
89067524|NCT06053905||Asthmatic Child|Children with asthma between 6-11 years old
89067525|NCT06053905||Healthy Controls Group|Healthy children between 6-11 years old
89067526|NCT06053892|Active Comparator|AR US|Augmented reality sonography guidance for shoulder punctures
89067527|NCT06053892|Active Comparator|standard US|standard sonography guidance for shoulder punctures
89067528|NCT06053892|Active Comparator|Fluoroscopic|Fluroscopic guidance for shoulder punctures
89067529|NCT06053879|Experimental|Biofeedback electrical stimulation|Biofeedback electrical stimulation
89067530|NCT06053814|Experimental|Part 1: NS-050/NCNP-03|Participants will be randomized and receive NS-050/NCNP-03 intravenous (IV) infusions once weekly for 2 weeks at each of MAD levels (1.95, 5, 10, 20, 40, and 80 mg/kg).
89067531|NCT06053814|Placebo Comparator|Part 1: Placebo|Participants will be randomized and receive NS-050/NCNP-03 placebo-matching IV infusions once weekly for 2 weeks at each of MAD levels.
89067532|NCT06053814|Experimental|Part 2: NS-050/NCNP-03|Participants will receive NS-050/NCNP-03 IV infusions once weekly for 24 weeks at the dosage selected by the Data and Safety Monitoring Board (DSMB) at the conclusion of Part 1.
89067533|NCT06053788|Experimental|PocDoc|All participants given PocDoc device
89223577|NCT01037764|Experimental|alloHCT|alloHCT arm: For HLA-matched sibling HCT, if a patient is 55 years old or less and without co-morbidity, the patient will receive Bu-Cy conditioning therapy and be transplanted with bone marrow cells. Patients who are older than 55 years or with co-morbidity will receive Bu-Flu-ATG conditioning and be transplanted with mobilized peripheral blood hematopoietic cells. For HLA-matched unrelated donor or HLA-mismatched familial donor HCT, the patient will receive Bu-Flu-ATG conditioning and well be transplanted with mobilized peripheral blood hematopoietic cells.
89223578|NCT01033630|Placebo Comparator|Placebo|Image-matched placebo of active treatment
89690401|NCT00995215|Experimental|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
89690402|NCT04736680||Lost Virtual Visit|Pediatric patients who had scheduled an appointment for a virtual visit and missed.
89067536|NCT06053671|Experimental|Patients with histologically confirmed FCDIIA/B undergoing or post Epilepsy Surgery|Genetic screening of DNA samples (blood, mucosal swab, brain tissue)
89067537|NCT06053437||Hyp'Op Cohort|The 'HYP'OP' cohort comprises patients who underwent endoscopic endonasal surgery (EES) for pituitary adenoma during a 10-year period spanning from January 2012 to June 2022 at the Nancy University Hospital. Post-operative hospitalization in our endocrinology department is part of the standard care protocol, which also includes a systematic reevaluation 4 -6 months following the surgical intervention.
89067538|NCT06053229|Experimental|Massage|Subjects will receive a daily 30 minute percussive massage treatment on the knee extensor muscles twice per day during the 10 day immobilization period
89067539|NCT06053229|Sham Comparator|Control|This group will lie on the bed for a total of 30 minutes, but receive no massage
89067540|NCT06052033|Experimental|ALA-PDT Group|PDT involves cervical gel application and 25-minute laser light exposure. The procedure is repeated three times.
89067541|NCT06052033|Other|CO2 Laser Group|CO2 laser therapy ablates cervical lesions with a depth of 7-10mm and a width of 3-5mm in a single session.
89067542|NCT06050824|Active Comparator|concomitant|Clarithro -pantoprazole- Metronidazole - Amoxicyllin
89067543|NCT06050824|Active Comparator|LOAD|Levofloxacin -omeprazole- nitazoxanide- Doxycycline
89067544|NCT06050499||Irreversible ischaemia|patients undergoing elective amputation of a limb (e.g. peripheral vascular disease)
89067545|NCT06050499||Reversible ischaemia|patients undergoing an operation with a limb tourniquet or intentional controlled reduction in blood flow to the lower limb (e.g. aortic cross clamping for vascular surgery).
89067546|NCT06049459|Active Comparator|Optical Correction alone|Optical correction alone (16 weeks) (Each participant will complete both study conditions.)
89067547|NCT06049459|Experimental|Therapeutic (Dichoptic) Virtual Reality Games plus Continued Optical Correction|Therapeutic (Dichoptic) Virtual Reality Games plus continued optical correction (16 weeks) (Each participant will complete both study conditions.)
89067548|NCT06040775|Experimental|Theta burst transcranial magnetic stimulation arm|Theta burst transcranial magnetic stimulation with Applied Behaviour Analysis
89067549|NCT06040775|Sham Comparator|Sham arm|Sham transcranial magnetic stimulation with Applied Behaviour Analysis
88812907|NCT03213860|Active Comparator|eye mask|
89223579|NCT01033630|Active Comparator|D&G 1g|Randomly allocated into three groups, D&G capsule 1g/day
89223580|NCT01033630|Active Comparator|D&G 2g|Randomly allocated into three groups, D&G capsule 2g/day
88812908|NCT03213860|No Intervention|Control|
89223581|NCT00091819|Experimental|Telavancin|
89223582|NCT00091819|Active Comparator|Vancomycin|
89223583|NCT01085227||Patients carrier of a LRRK2 mutation|
89223584|NCT01085227||Asymptomatic relatives of LRRK2 patients|
89223585|NCT01326871|Experimental|ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II)|
89690403|NCT04736680||Attended Virtual Visit|Pediatric patients who had scheduled an appointment for a virtual visit and attended.
88812909|NCT01534013|Experimental|Closed-loop insulin delivery|The closed loop device (bio-inspired artificial pancreas device, subcutaneous glucose monitor and insulin pump) will be applied to participants with type 1 diabetes
89690404|NCT04581031|Other|Wearable monitors - Isansys Patient Status Engine|All patients will wear the continuous vital sign monitoring sensors.
89690405|NCT04646746|Experimental|100 g of 100% wheat bread|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
89690406|NCT04646746|Experimental|Nude barley 50%|"Intake of 250 ml of tap water and 100 g of bread baked with 50% nude barley flour and 50% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
89690407|NCT04646746|Experimental|Nude barley 75%|"Intake of 250 ml of tapwater and 100 g of bread baked with 75% nude barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~Ancient nude barley naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
89690408|NCT04646746|Experimental|Gen-modified high-amylose barley|"Intake of 250 ml of tap water and 100 g of bread baked with 50% gene-modified high-amylose barley and 50% wheat. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~The gene-modified barley is produced by researchers at Aarhus and Copenhagen Universities as published in 'Carciofi M, et al., Concerted suppression of all starch branching enzyme genes in barley produces amylose-only starch granules. BMC Plant Biol. 2012 Nov 21;12:223. doi: 10.1186/1471-2229-12-223' The wheat flour is standard commercial available flour."
89690409|NCT04444843|Other|Mycophenolate Mofetil Capsules|The dosage of mycophenolate mofetil (CellCept) will be decided by the investigator and should be adjusted according to clinical response or therapeutic drug monitoring. It is not allowed to switch to other MPAs. When MMF is discontinued but is not switched to other MPA, the patients will be followed until the end of study.
89690410|NCT04341987|Experimental|brief Imagery Rehearsal Therapy|"The brief two-session, behaviorally-based imagery rehearsal intervention is based on components from previous group and individual formats that have been published, but will be presented in an abbreviated manner. In the first session, Veterans will be presented with psychoeducation about dreaming, basics of sleep hygiene and stimulus control techniques, how to change negative dreams from a learned habit perspective, re-scripting, and how to rehearse new dream imagery. They will then be asked to complete in-session practice of imagery rehearsal with the new imagery developed. Veteran will be instructed in practice post-session."
89223586|NCT01326871|Experimental|ALT-801 and Gemcitabine (Phase II only)|
89223587|NCT01081327||Patients receiving Warfarin|
89223588|NCT01081483|Active Comparator|ABT-072 Tablet|ABT-072 50 mg Tablet, every day (QD), single ascending doses, groups 1-3
89223589|NCT01081483|Placebo Comparator|Placebo|Placebo Tablet, QD, single doses, groups 1-3
89223590|NCT03964129|Experimental|Avance Nerve Graft with autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested . Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained.
89223591|NCT00540228|Experimental|GSK1247446A 1 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89690411|NCT04341987|Other|Treatment As Usual|Patients in this condition are free to receive treatment as usual for nightmares, which may be a medication, supportive counseling or no treatment.
89690412|NCT04395937|Active Comparator|respiratory physiotherapy|exercises to improve the way of breathing
89690413|NCT04395937|Experimental|respiratory physiotherapy and physical exercises|intensity determined by the VO2max measured during ergospirometric measure
89690414|NCT04395937|No Intervention|control group|
89690415|NCT01022359|Active Comparator|Tesio Catheter|Patients randomised to receive the established catheter type in use at our centre [control]
89690416|NCT01022359|Active Comparator|LifeCath|Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)
89690417|NCT00635804|Experimental|Pt 1: MK-3281 100 mg BID (Panel A)|Healthy male participants in this Part I serial panel receive 100 mg MK-3281 orally twice daily (BID) for 10 consecutive days for a total daily dose administered of 200 mg. The evening (PM) dose of MK-3281 was not administered on Day 10.
89690418|NCT00635804|Experimental|Pt 1: MK-3281 200 mg BID (Panel B)|Healthy male participants in this Part I serial panel receive 200 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 400 mg. The PM dose of MK-3281 was not administered on Day 10.
89690419|NCT00635804|Experimental|Pt 1: MK-3281 400 mg BID (Panel C)|Healthy male participants in this Part I serial panel receive 400 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 800 mg. The PM dose of MK-3281 was not administered on Day 10.
89690420|NCT00635804|Experimental|Pt 1: MK-3281 800 mg BID (Panel D)|Healthy male participants in this Part I serial panel receive 800 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 10.
89690421|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel E)|Genotype (GT)1 HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
89690422|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel F)|GT1a/GT1-nontypeable/GT3/GT1b HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
89690423|NCT00635804|Experimental|Pt 2: MK-3281 1200 mg BID (Panel G)|GT1a (and/or GT1 nontypeable) and GT1b HCV-infected male participants in this Part II serial panel receive 1200 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 2400 mg. The PM dose of MK-3281 was not administered on Day 7.
89690424|NCT00635804|Placebo Comparator|Placebo|Participants receive dose-matched placebo to MK-3281 orally BID for 7 or 10 consecutive days depending on randomization. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
89690425|NCT04353193|Experimental|Terlipressin IV bolus|Terlipressin 1mg IV bolus
89690426|NCT04353193|Experimental|Terlipressin IV continuous infusion|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
89690427|NCT04353193|Experimental|Octreotide IV bolus plus continuous infusion|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
89690428|NCT02832388||Primary aldosteronism patients for cardiac MRI|A subgroup of primary aldosteronism (PA) patients perform a cardiac MRI, including stress-testing with adenosine, and are compared to a sex- and age-matched group of healthy controls who perform the same MRI procedure
89690429|NCT02832388||Healthy controls|Healthy controls that are age-and sex-matched to the subgroup of PA patients performing cardiac MRI, perform MRI including adenosine as stress-test.
89690430|NCT02832388||Primary aldosteronism patients diagnosed from 2013 onwards|"All PA patients diagnosed or subtyped at Haukeland University from 2013 onwards are asked for inclusion in the main observational PA-study.~From 2022 onwards, PA patients diagnosed or subtyped at Oslo University hospital will also be included."
89690431|NCT01023841|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
89690432|NCT01023841|Placebo Comparator|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
89690433|NCT00635648|Experimental|Caspofungin 50 mg Intravenous (IV)|
89690434|NCT05240690|Experimental|Umbilical Cord Blood Derived MAK Immune Cells|
89690435|NCT00995449|Experimental|KB003 70 mg|
89690436|NCT00995449|Experimental|KB003 200 mg|
89690437|NCT00995449|Experimental|KB003 600 mg|
89690438|NCT00995449|Placebo Comparator|Placebo|
89690439|NCT05240456|Experimental|Intervention|This arm will receive standard behavioral therapy plus Mirabegron with adjusted-dose regimen (25-50 mg), patients of 20-40 kg will receive 25-50 mg once a day; patients >40 kg will receive 50 mg once a day, for three months.
89690440|NCT05240456|Active Comparator|Control|This arm will receive will receive standard behavioral therapy plus Solifenacin with a daily dosage of (2.5-10 mg/kg), for three months.
89067550|NCT06040307|Experimental|SPI (Surgical Pleth Index)|Opioid administration (sufentanil) guided by by Surgical Pleth Index (SPI) derived from photoplethysmography performed by the device CARESCAPE B650 Patient Monitor from the manufacturer GE (General Electric) Healthcare, Boston, Massachusetts, US. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger photoplethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range to guide opioid analgesics. 5 µg Sufentanil will be administered every 5 minutes if SPI score is calculated more than 50.
89067551|NCT06040307|No Intervention|Control|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation, sweating and spontaneous movements of the patient. As an orientation anesthesiologists are advised to administer 5 µg sufentanil if systolic blood pressure is > 140 mmHg or mean blood pressure is > 100 mmHg or heart rate is > 90 /min. If assessed necessary, the anaesthesiologists are allowed to administer higher or lower sufentanil doses up to their discretion.
89067552|NCT06039982||cervical cancer treated with surgery|The inclusion criteria were: (1) pathologically confirmed CC; (2) FIGO stage IB-IIA according to the result of physical examination and imaging; (3) abdominal MRI was performed within three weeks before surgery. Exclusion criteria were: (1) accompanied with other tumors. (2) with chronic infectious disease. (3) incomplete clinical data.
89067553|NCT06036251||Prior oncology participants|Oncology patients at University of California, San Francisco who participated in the previous study which evaluated the additional stressors imposed by COVID-19 (i.e., social isolation, loneliness) and ongoing general and disease specific stress on the symptom burden of cancer patients and survivors.
89067554|NCT06033807||Contacts|School contacts of ATB patients
89067555|NCT06024096|Active Comparator|seasonal quadrivalent influenza vaccine (QIV)|Participants will receive the seasonal QIV
89067556|NCT06024096|Active Comparator|statin therapy and a seasonal quadrivalent influenza vaccine (QIV)|Participants randomized to the Statin + QIV arm will be asked to come back for an extra visit one month prior to the date of vaccination to start statin therapy.
89067557|NCT06023485|Experimental|Experimental group (stress ball)|The patients in the experimental group will be given a stress ball before the SC injection during the routine daytime treatment of the ward at 10:00. The patient will be asked to squeeze the stress ball with his hand on the opposite extremity of the upper extremity where SC injection was applied, counting to five, and then to relax his hand. In the meantime, 0.4 ml of LMWH will be administered by SC route according to the doctor's request. During the patient's drug administration and 2 minutes after the application. The level of pain in the area where SC was applied will be evaluated with VAS.
89067558|NCT06023485|No Intervention|Control group|For the patients in the control group, 0.4 ml of LMWH will be administered by the nurse in the routine daytime treatment of the service at 10:00, according to the doctor's request. During the patient's drug administration and 2 minutes after the application. The level of pain in the area where SC was applied will be evaluated with VAS.
89067559|NCT06013917||Patients on ECG monitoring post-transcatheter aortic valve replacement (TAVR) or other cardiac event|Patients at our clinical collaborators practices who have undergone TAVR or other cardiac event and who are placed on ECG monitoring will be placed on an FDA cleared cardiac monitor. We adopt an FDA cleared, reusable, single-lead OEM patch Holter made of flexible material to make long-term wearing more comfortable and more patient compliance.
89067560|NCT06011200|Experimental|ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)|Intramuscular injection, 0.5ml
89067561|NCT06011200|Active Comparator|ACYW135 Group Meningococcal Polysaccharide Vaccine (MSPV4)|Subcutaneous injection, 0.5ml
89067562|NCT06007924|Experimental|Radioiodine-refractory (RAIR), recurrent and/or metastatic differentiated thyroid cancer (DTC)|Patients will be treated with avutometinib 3.2 mg twice weekly and defactinib 200 mg twice daily, both 3 weeks on/1 week off.
89067563|NCT06007924|Experimental|Anaplastic thyroid cancer (ATC)|Patients will be treated with avutometinib 3.2 mg twice weekly and defactinib 200 mg twice daily, both 3 weeks on/1 week off.
89067564|NCT05993936|Experimental|e mobile aplication|Postpartum period mobile application; It is an application that is prepared according to the Android Operating System, can be downloaded free of charge from the Google Play Store, and offers training and live counseling services for women who have given birth.
89067565|NCT05993936|No Intervention|control|this group will only receive the standard care provided in the hospital. no intervention will be made
89067566|NCT05983718|Active Comparator|FREE HAND (GUIDE-PIN-assisted)|
89067567|NCT05983718|Experimental|FULL GUIDED|
89067568|NCT05983354|Experimental|Oral medications|10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml NS administered over 15 minutes.
89067569|NCT05983354|Active Comparator|IV medications|2 x placebo tablets, 10 mg metoclopramide in 50 cc NS and 10 mg ketorolac in 50 ml NS administered over 15 min.
89067570|NCT05971914|Experimental|Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap|Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
89067571|NCT05969548|Active Comparator|active 1200-pulse cTBS group|active 1200-pulse cTBS combined with speech language therapy
89067572|NCT05969548|Active Comparator|active 2400-pulse cTBS group|active 2400-pulse cTBS combined with speech language therapy
89067573|NCT05969548|Active Comparator|active 3600-pulse cTBS group|active 3600-pulse cTBS combined with speech language therapy
89067574|NCT05969548|Sham Comparator|sham 1200-pulse cTBS group|sham 1200-pulse cTBS combined with speech language therapy
89067575|NCT05969548|Sham Comparator|sham 2400-pulse cTBS group|sham 2400-pulse cTBS combined with speech language therapy
89067576|NCT05969548|Sham Comparator|sham 3600-pulse cTBS group|sham 3600-pulse cTBS combined with speech language therapy
89067577|NCT05960708|Experimental|YH35324|"[Part 1] A total of 18 subjects will be randomized in a 1:1:1 ratio to the YH35324 3 mg/kg, YH35324 6 mg/kg, or omalizumab group.~[Part 2] A total of 9 subjects will be randomized in a 2:1 ratio to the YH35324 6 mg/kg or placebo group.~[Part 3] A total of 9 subjects will be randomized in a 2:1 ratio to the YH35324 6 mg/kg or placebo group."
89067578|NCT05960708|Active Comparator|Omalizumab|[Part 1] A total of 18 subjects will be randomized in a 1:1:1 ratio to the YH35324 3 mg/kg, YH35324 6 mg/kg, or omalizumab group.
89067579|NCT05960708|Placebo Comparator|Placebo|"[Part 2] A total of 9 subjects will be randomized in a 2:1 ratio to the YH35324 6 mg/kg or placebo group.~[Part 3] A total of 9 subjects will be randomized in a 2:1 ratio to the YH35324 6 mg/kg or placebo group."
89067580|NCT05959291|Experimental|anti-HER-2 Group|Participants in this group will be monitored to see if patients discontinuing maintenance of anti-HER-2 treatments with ctDNA monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission. Participants will be in this group for up to 3 years.
89067581|NCT05959044|Active Comparator|Folic acid|30 patinets will receive Orally 5mg tablet two times daily for 8 weeks
89067582|NCT05959044|Placebo Comparator|Control|30 patinets will receive Orally 5mg tablet two times daily for 8 weeks
89067583|NCT05955924|Experimental|Nicotinamide|Intervention Drug : Nicotinamide
89067584|NCT05955924|Placebo Comparator|Placebo|Intervention: Placebo Oral Capsule
89067585|NCT05954962|Active Comparator|CONTROL GROUP|"The patient will start to administer: (1) daily subcutaneous injections of gonadotropins on day 1 of ovarian stimulation (2) daily subcutenous injections of ganirelix (antagonist) on day 5 or 6 of ovarian stimulation. Both medication will be stopped 1-2 days before egg retrieval."
89067586|NCT05954962|Experimental|STUDY GROUP|The patient will start to administer: (1) daily subcutaneous injections of gonadotropins on day 1 of ovarian stimulation (2) daily oral capsules of natural micronized progesterone on day 1 of ovarian stimulation. Both medication will be stopped 1-2 days before egg retrieval.
89067587|NCT05943691|Experimental|Hetrombopag plus High-dose Dexamethasone|Hetrombopag 5mg po qd; HD-DEX 40mg qd for 4 days
89067588|NCT05943691|Active Comparator|High-dose Dexamethasone|HD-DEX 40mg qd for 4 days
89067589|NCT05935176|Experimental|Vaccine Group A|2 dose of ACYW135 group meningococcal polysaccharide conjugate vaccine(MCV4) (0.5ml)
89067590|NCT05935176|Experimental|Vaccine Group B|2 dose of (MCV4) (0.5ml)
89067591|NCT05931575|Experimental|intervention arm (low dose)|oral Fasudil solution 88 mg/day (2 x 44 mg)
89067592|NCT05931575|Experimental|intervention arm (high dose)|oral Fasudil solution 44 mg/day (2 x 22 mg)
89067593|NCT05931575|Placebo Comparator|Control intervention arm (placebo)|oral placebo solution 2x/day.
89067594|NCT05927714|Active Comparator|Use Amnio Chorion Membrane (ACM) with hemostatic agent|ACM or amnion-only membranes have been used in oral surgical procedures primarily because they contain a host of growth factors that play a role in normal wound healing.
89067595|NCT05927714|Placebo Comparator|Use of ActCel Cellulose Gauze (Commercial Hemostatic Agent)|Palatal wound dressing with hemostatic agent
89067596|NCT05919524|Experimental|SBRT with mpMRI guided focal boost|SBRT 36.25 Gy in 5 sessions of 7.25 Gy to the entire prostate (including seminal vesicles) with a DIL simultaneous integrated focal boost (SIB) up to 50 Gy in 5 sessions, with partial protection of the prostatic urethra and bladder trigone.
89067597|NCT05918744|No Intervention|Habitual Sleep|Participants will follow their normal sleep schedule for 2 weeks.
89067598|NCT05918744|Experimental|Sleep extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
89067599|NCT05907525|Experimental|Remimazolam group|To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.
89067600|NCT05907525|Active Comparator|Sevoflurane group|To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC). Remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.
89067601|NCT05901220|Experimental|Students of a school in the Campania region|
89067602|NCT05898750|Experimental|experimental group|
89067603|NCT05898750|No Intervention|Control group|
89067604|NCT05890586|Experimental|Arm B - Fluvoxamine|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.
89067605|NCT05890586|Placebo Comparator|Arm B - Placebo|Placebo - appearance and size matched to active study drug. Placebo will be self-administered orally by each participant twice a day for 10 days.
89067606|NCT05877300|Experimental|Short Segment Esophageal Replacement|
89067607|NCT05875246|No Intervention|Group 1|Does not receive a micro-intervention
89067608|NCT05875246|Experimental|Group 2|Receives brief messages for stress reduction.
89067609|NCT05875246|Experimental|Group 3|Directed to the app to listen to a stress reduction audio activity.
89067610|NCT05873946||Operated gliomas|Patients consecutively operated with a pathological diagnosis of glial tumor
89067611|NCT05869656|Experimental|Alert recommending oral fluid restriction|The alert will suggest to the treating clinician to fluid restrict the patient to 1L of oral fluid per day
89067612|NCT05869656|Active Comparator|Alert recommending no oral fluid restriction|The alert will suggest to the treating clinician to continue without any oral fluid restriction
89067613|NCT05867381|Experimental|HEPA first and sham|This group of participants will be assigned to the intervention of HEPA filtration with the capacity to reduce indoor PM2.5 levels at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to sham filters (air purifier has the same appearance but HEPA filter is removed) for 9 months.
89067614|NCT05867381|Experimental|Sham first and HEPA|This group of participants will be assigned to the intervention of sham filtration with HEPA filter removed at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to the HEPA filtration for 9 months.
89067615|NCT05866159|Experimental|Experimental Intervention|The experimental group will receive double-sided I-shaped kinesiotape. The tape will be applied from the sacroiliac joint to the thoracic 12th vertebrae, with a 10-15% tension. During the application, the participant will be positioned in maximum torso flexion.
89067616|NCT05866159|Sham Comparator|Control Intervention|For the sham group, the kinesiotape will be applied horizontally to the center of the painful area in the lumbar region without any tension (at 0%).
89067617|NCT05866055|Experimental|Part A: Single Ascending Dose|Participants will be randomized to receive a single dose of VX-973 under fasted conditions.
89067618|NCT05866055|Experimental|Part B: Multiple Ascending Dose|Participants will be randomized to receive multiple doses of VX-973 under fasted conditions. The dose and frequency will be determined based on Part A. Midazolam is planned to be administered as single oral doses of 2 mg first alone on Day -1 and then co-administered with study drug on Day 27.
89067619|NCT05866055|Placebo Comparator|Placebo Part A|Participants will be randomized to receive placebo matched to VX-973.
89067620|NCT05866055|Placebo Comparator|Placebo Part B|Participants will be randomized to receive placebo matched to VX-973. Midazolam is planned to be administered as single oral doses of 2 mg first alone on Day -1 and then co-administered with placebo matched to VX-973 on Day 27.
89067621|NCT05864625|Experimental|Remimazolam|Induction dose of 6 mg/kg/h of remimazolam with remifentanil TCI 1~4 nanogram/mL are injected together. When patient loses consciousness, rocuronium 0.8 mg/kg is given and endotracheal intubation is performed after confirming that TOF count is less than one. Anesthesia is maintained by using remimazolam dose of 1mg/kg/h~2mg/kg/h with remifentanil to maintain optimal depth of anesthesia, which will checked by Sedline value between 25 to 50.
89067622|NCT05864625|Active Comparator|Propofol/sevoflurane|1% propofol 1-2mg/kg is injected with remifentanil TCI 1~4, and when patient loses consciousness, sevoflurane is started and rocuronium 0.8mg/kg is given. After confirming that TOF count is less than one, intubation is performed and anesthesia is maintained with sevoflurane and remifentanil to keep the Sedline value between 25 and 50.
89067623|NCT05855837|Experimental|Cereal Product 1|Ready to Eat Cereal Product 1 with 6 oz of skim milk
89067624|NCT05855837|Experimental|Cereal Product 2|Ready to Eat Cereal Product 2 with 6 oz of skim milk
89067625|NCT05855837|No Intervention|Control|No intervention (i.e., no food provided)
89067626|NCT05854160|Experimental|Acquisition Stimulation Test|Single pulse stimulation will be delivered and measured prior to the rating task. Next, subjects perform the Pavlovian fear conditioning paradigm. Participants will be asked to perform a rating task automated on a PC where they continuously update a rating bar using the touchpad to indicate their confidence that a static sound is about to occur on a moment-by-moment basis (0-not confident to 100-very confident). For the stimulation experiment, research staff will explain that electrical stimulation will be applied before the rating task, in isolation, as well as on some trials at controlled time points while the patient performs the rating task
89067627|NCT05853744|Experimental|Group C|patients receiving aromatherapy using cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
89067628|NCT05853744|Active Comparator|Group M|- Group M: inhaled three drops of lavender oil through a facemask. These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer. A cotton ball soaked with water was put 10 cm next to the patient.
89067629|NCT05853744|Placebo Comparator|Group P|Placebo group: inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
89067630|NCT05852769|Experimental|BMS-986196 and/or Cocktail Probe Substrate Drugs|
89067631|NCT05850364|Experimental|group C1|Co-administration of sIPV and routine infant vaccines at 6,10,14 weeks old (N=360)
89067632|NCT05850364|Experimental|group C2|Co-administration of sIPV and routine infant vaccines at 6, 10,14 weeks old
89067633|NCT05850364|Experimental|group S1|Administration of sIPV at 6,10,14 weeks old; Administration of routine infant vaccines at 8,12,16 weeks old
89067634|NCT05850364|Experimental|group S2|Administration of routine infant vaccines at 6,10,14 weeks old; Administration of sIPV at 8,12,16 weeks old
89067635|NCT05833685||Female sexual dysfunction group|
89067636|NCT05833685||Normal females|
89067637|NCT05832736|Experimental|Patients with unilateral prostate cancer|Patients with unilateral prostate cancer
89067638|NCT05828277|Experimental|Repotrectinib (TPX-0005)|"Oral repotrectinib (TPX-0005):~Cohort 1: Patients with moderate hepatic impairment Cohort 2: Patients with severe hepatic impairment Cohort 3: Patients with normal hepatic function"
89067639|NCT05827718|Active Comparator|RCT #1, Arm #1: Contact Method, Text Only|Potential participants in the parent trial will be randomized to receive a message via text message. This message will invite them to participate in the parent trial.
89067640|NCT05827718|Active Comparator|RCT #1, Arm #2: Contact Method, Email Only|Potential participants in the parent trial will be randomized to receive a message via email. This message will invite them to participate in the parent trial.
89067641|NCT05827718|Active Comparator|RCT #1, Arm #3: Contact Method, Email+Text|Potential participants in the parent trial will be randomized to receive a message via email and text message. This message will invite them to participate in the parent trial.
89067642|NCT05827718|Active Comparator|RCT #2, Arm #1: Source of Contact, Personal Physician|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The sender of the message will be the person's personal physician.
89067643|NCT05827718|Active Comparator|RCT #2, Arm #2: Source of Contact, Research Team|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The sender of the message will be the research team.
89223592|NCT00540228|Experimental|GSK1247446A 2 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89223593|NCT00540228|Experimental|GSK1247446A 3 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
88812910|NCT01534013|Active Comparator|Open-loop (Control visit)|Subcutaneous glucose monitor and pump will be applied to participants with type 1 diabetes
88812911|NCT03216122|Active Comparator|Control group (CG)|The implant will be loaded after 3-4 months of placement (Conventional/Delayed Loading)
88812912|NCT03216122|Active Comparator|Test group (TG)|The implant will be loaded non-occlusally within 3-4 days of placement (Immediate Loading)
89067644|NCT05827718|Active Comparator|RCT #3, Arm #1: Framing Method, Appeal to Altruism|"Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will appeal to the person's altruism, for example: Research studies like this one often do not include enough Black individuals. If Black people are not included in research like this, then doctors have less information about how cardiovascular disease might affect them and how new treatments could be used to improve their health. Your participation in this research can help doctors better understand how to treat members of your community in the future."
89067645|NCT05827718|No Intervention|RCT #3, Arm #2: Framing Method, No Appeal to Altruism|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will include no appeal to altruism.
89067646|NCT05827718|Active Comparator|RCT #4, Arm #1: Framing Method, Social Proof|"Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will include language about social proof, i.e. information about participation of individuals similar to the person being contacted. For example, the message will include language such as: Clinical research studies and the development of effective new medications would not have been possible without the participation of thousands of people like you."
89067647|NCT05827718|Active Comparator|RCT #4, Arm #2: Framing Method, Perceived Scarcity|"Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will include language emphasizing constraints on enrollment/limited number of available spots for participating, i.e. perceived scarcity, For example, the message will include language such as: There are a limited number of slots available in this study, and enrollment is only possible in the next 4 weeks."
89067648|NCT05827718|No Intervention|RCT #4, Arm #3: Framing Method, No Social Proof, No Perceived Scarcity|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will include no language about social proof or perceived scarcity.
89067649|NCT05827718|No Intervention|RCT #5, Arm #1: Framing Method, Opt-In|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. Instructions on how to enroll in the parent trial will be the same as all previous arms.
89067650|NCT05827718|Active Comparator|RCT #5, Arm #2: Framing Method, Opt-Out|"Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. Instead of receiving on how to enroll in the parent trial, thy will be told they have been conditionally enrolled in the parent trial, contingent on them providing some additional information, unless they choose to opt out."
89067651|NCT05827718|Active Comparator|RCT #6, Arm #1: Incentive Structure, Gain-framed, Guarantee|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will state that, if the person decides to participate, they will be receive a guaranteed participation incentive (e.g. $50).
89067652|NCT05827718|Active Comparator|RCT #6, Arm #2: Incentive Structure, Gain-framed, Lottery|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will state that, if the person decides to participate, they will receive a guaranteed participation incentive (e.g. $25) and also be enrolled in a lottery (e.g. 1 in 40 chance) to receive a larger participation incentive (e.g. $1,000).
89067653|NCT05827718|Active Comparator|RCT #6, Arm #3: Incentive Structure, Loss-framed, Guarantee|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will state that, if the person decides to participate, their participant incentive (e.g. $50) will be placed in a virtual account that they will be able to access once they have enrolled into the parent trial.
89223594|NCT00540228|Experimental|GSK1247446A 4 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89067654|NCT05827718|Active Comparator|RCT #6, Arm #4: Incentive Structure, Loss-framed, Lottery|Potential participants in the parent trial will be randomized to receive a message inviting them to participate in the parent trial. The message will state that, if the person decides to participate, their participant incentive (e.g. $50) will be placed in a virtual account that they will be able to access once they have enrolled into the parent trial.
89067655|NCT05809700|Experimental|HA35 local injection of pain location Group|According to the ratio of 100 mg high molecular weight HA (sodium hyaluronate for injection, H20174089)/2000 units of hyaluronidase extracted from bovine testis (hyaluronidase for injection H31022111), high molecular weight HA injection and hyaluronidase injection were mixed at room temperature for 20 minutes.
89067656|NCT05808127|No Intervention|Current Opioid Misuse Measure (COMM)|On a monthly basis, patients will receive the abbreviated Current Opioid Misuse Measure (COMM), a 6-item self-report screener to identify and monitor the risk of aberrant opioid-related behavior in chronic pain patients on opioid therapy. The COMM asks patients to report their behaviors over the past 30 days using a five-point Likert-type rating scale.
89067657|NCT05808127|Experimental|Current Opioid Misuse Measure (COMM) + PainTracker|On a monthly basis, patients will receive both the abbreviated Current Opioid Misuse Measure (COMM) and PainTracker. PainTracker tracks multiple outcomes relevant to the treatment of chronic pain: pain severity, general activity interference, enjoyment of life interference, sleep (initiating and maintaining), depression, and anxiety.
89067658|NCT05803512||experimental group|urinary incontinence females with sexual dysfunction
89067659|NCT05803512||control group|Normal females
89067660|NCT05786300|Experimental|Treatment Group|"The Treatment Group will follow the rehabilitation protocol with the addition of the Neuromuscular Electrical Stimulation Superimposed onto Movement (NMES+) as part of the rehabilitation protocol.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz"
89067661|NCT05786300|Active Comparator|Control Group|"The Control Group will follow the same rehabilitation protocol with no addition of the NMES+.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
89067662|NCT05773092|Experimental|Intervention|Oral S-1 + Oral Osimertinib
89067663|NCT05759962|Experimental|Part A: Single Ascending Dose (SAD) LQT-1213|In Part A, 4 dosing cohorts will receive a single oral dose of LQT-1213. The highest dose of LQT-1213 to be administered is 1.67 mg/kg.
89067664|NCT05759962|Experimental|Part A: Food Effect LQT-1213|In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
89067665|NCT05759962|Experimental|Part B: Multiple Ascending Dose (MAD) LQT-1213|In Part B, 3 dosing cohorts will receive LQT-1213 in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.
89067666|NCT05759962|Placebo Comparator|Part A: Single Ascending Dose (SAD) Placebo|In Part A, 6 dosing cohorts will receive a single oral dose of placebo.
89067667|NCT05759962|Placebo Comparator|Part A: Food Effect Placebo|In Part A, food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.
89067668|NCT05759962|Placebo Comparator|Part B: Multiple Ascending Dose (MAD) Placebo|In Part B, 3 dosing cohorts will receive placebo in the morning on Day 1 and Day 7 and twice daily (BID) on Days 2 to 6.
89067669|NCT05758935|Experimental|Mobile application|A six weeks, rule-based chatbot intervention
89067670|NCT05745402|Experimental|Mobility Checkup Intervention|45-minute Mobility checkup that includes 5 physical performance measures and education based on outcomes compared to age and gender normative values.
89067671|NCT05743842|Experimental|TriSalus™ TriNav™Infusion System (catheter)|TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter
89067672|NCT05734443|Experimental|non-treadmill trip training|Two training sessions per week will be completed for three consecutive weeks. Each training session will last 0.5-1 hour with an active training time of 30 minutes per participant. Training will involve repeated volitional and reactive stepping movements that mimic the movements necessary to recover balance after tripping while walking.
89223595|NCT00540228|Active Comparator|Fluarix Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89223596|NCT01081561|Active Comparator|Cross-linking|Corneal collagen cross-linking with riboflavin and UVA light
89067673|NCT05734443|Experimental|treadmill trip training|Two training sessions per week will be completed for three consecutive weeks. Each training session will last 0.5-1 hour with an active training time of 30 minutes per participant. Training will involve repeated exposure to simulated trips on a treadmill. To simulate a trip, participants first stand on the stationary treadmill belt. A sudden and unexpected increase in backward treadmill belt speed induces a forward loss of balance similar to when tripping. Participants are then required to take steps to recover balance and establish a stable gait pattern before the trial ends. Trials are repeated using pseudo-random speeds that provide variability and are individualized to each participant's capabilities.
89067674|NCT05734443|No Intervention|Control|
89067675|NCT05728073||Standard (non-ERCP) Group|Patients who underwent surgery for acute cholecystitis without a previous ERCP history.
89067676|NCT05728073||ERCP group|Patients who underwent surgery for acute cholecystitis with a previous ERCP history.
89067677|NCT05713279|Experimental|FM+SOC|
89067678|NCT05713279|Placebo Comparator|FM安慰剂 +SOC|
89067679|NCT05707455||Aerobic group|long distance runners
89067680|NCT05707455||Anaerobic group|broad jumpers
89067681|NCT05699733|Experimental|Mechanical traction force 30% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 30% of the body weight as a traction force
89067682|NCT05699733|Experimental|Mechanical traction force 20% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 20% of the body weight as a traction force
89067683|NCT05699733|Experimental|Mechanical traction force 10% of body weight|will receive continuous mechanical traction from semi flexed knee, for 30 minutes using 10 % of the body weight as a traction force
89067684|NCT05690659|Experimental|cavitation ultrasonic lipolysis|on abdomen 2 sesions / week for 10 sessions , Treatment head was griped perpendicular to abdomen, and make slow circular motion with marked pressure.2 sesions / week for 10 sessions
89067685|NCT05690659|Experimental|RUSI guided core muscle exercise|"2 sesions / week for 10 sessions For diaphragm muscle the transducer was placed on the sub costal region to visualize diaphragm muscle on the screen aiming to use US as a visual feedback procedure. instructed to have 5 seconds to contract the diaphragm muscle by deep breathing and hold the contraction. At the end of the 5-second period, the image was saved on the screen, and the measurement of the resultant increase in thickness was performed. Each subject performed a total of 10 contractions (intervention session) For transverse abdominis exercise,. draw in your umbilicus toward the spine without moving back or pelvis, while comfortably breathing in and out, for 10 seconds hold and then 15 seconds rest in between, it was repeated 3 sets of ten while keeping the transducer perpendicular to the surface of the skin in a transverse plane halfway between the ASIS and the lower ribcage along the anterior axillary line"
89067686|NCT05690659|Experimental|combination of cavitation and RUSI|combination of cavitation and RUSI 2 sesions / week for 10 sessions
89067687|NCT05676359||Cases|Patients with rheumatic diseases from the outpatient clinic at a tertiary care level in Mexico City
89067688|NCT05676359||Controls|Two patients´ relatives of the same sex, age ± five years and who are known to be healthy
89067689|NCT05674903|Experimental|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets involved in pain perception Intervention: Device: Diadem prototype
89067690|NCT05674903|Sham Comparator|Sham stimulation|Low-intensity transcranial focused ultrasound stimulation using unfocused wave Intervention: Device: Diadem prototype
89067691|NCT05664932|Experimental|LYB001 Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive 30μg LYB001 at day 0 as a booster vaccination.
89067692|NCT05664932|Active Comparator|ZF2001 Booster Group|Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive ZF2001 at day 0 as a booster vaccination.
89067693|NCT05663086|Experimental|Low-dose vaccine|30μg LYB001 is to be used in the clinical trial. The number of each arm is 60.
89067694|NCT05663086|Experimental|High-dose vaccine|60μg LYB001 is to be used in the clinical trial. The number of each arm is 60.
89067695|NCT05663086|Active Comparator|Positive control|Positive-controlled vaccine is to be used in the clinical trial. The number of each arm is 60.
89067696|NCT05637814|Experimental|SpO2 and PIx Measurement|Non-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters and a ML CCHD screening algorithm will be assigning a prediction every minute.
89067697|NCT05623423|Experimental|Organically Modified Ceramic (ORMOCER) Resin Composite.|(Admira Fusion, Voco GmbH, Germany)
89067698|NCT05623423|Active Comparator|Methacrylate Based Composite|(Ceram.X Spectra ST, Dentsply Sirona, UK)
89067699|NCT05615051|Experimental|Group electrolytic approach (EA)|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) during 2 minutes
89067700|NCT05615051|Active Comparator|Group hydrogen peroxide (HP)|Group hydrogen peroxide (HP): Mechanical detoxification using curettes + NiTi brushes + hydrogen peroxide 5% for 2 minutes soaked in a gauze
89067701|NCT05613842|Experimental|Male patients with hormone sensitive disease|who demonstrate rising PSA levels (>0.2ng/ml) following definitive therapy and a negative 68Ga-PSMA-11 PET scan (defined as SUV max < 3);
89067702|NCT05613842|Experimental|Male patients with metastatic castration resistant prostate cancer|being considered for 177Lu-PSMA-617 therapy with known metastatic disease on conventional imaging and sites with low PSMA expression on 68Ga-PSMA-11 PET scan (defined as SUV max <10) in the presence of disease volume of > 1cm.
89067703|NCT05603533|Experimental|Intervention group|On top of the regular physical therapy, the participants in the intervention group will receive a music and video-based group exercise therapy in small groups of 5. On a big screen, a video of an older woman performing exercises will be shown, the participants will have to copy these exercises. In the beginning of each session, the participants will be able to choose the music they want to move to.
89067704|NCT05603533|No Intervention|Control group|The participants in the control group will receive no additional therapy.
89067705|NCT05600101|Experimental|care.coach Pilot|"The research study procedures include screening for eligibility, a brief call with a research assistant after tablet is given to subject, and a survey after a subject has completed the study.~3 consecutive cohorts of 6 RIC HCT patients each.~care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates. A subject uses the avatar for up to 3 weeks."
89067706|NCT05595720|Experimental|treatment group|
89067707|NCT05595720|No Intervention|control group|
89067708|NCT05592951|Placebo Comparator|Placebo once daily|1 stick pack dissolved in water once daily prior to breakfast
89067709|NCT05592951|Experimental|Test beverage once daily|1 stick pack dissolved in water once daily prior to breakfast
88812686|NCT01203722|Active Comparator|REGIMEN B3: HIV patients with CCRd32 homozygous donors|"Pre-PBSCT:~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~Day -1: 400 cGy TBI administered in a single fraction~Day 0: Peripheral Blood Stem Cell Transplant (PBSCT)~Post-Transplantation Immunosuppression Consisting of:~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~Day 5: Sirolimus loading dose 6 mg PO once~Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)~Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
89067710|NCT05592951|Experimental|Test beverage twice daily|2 stick packs dissolved in water, one packet at a time twice daily (after lunch and after dinner)
89067711|NCT05592951|Experimental|Test beverage three times daily|3 stick packs dissolved in water, one packet at a time three times daily (after breakfast, lunch, and dinner)
89067712|NCT05589051|Experimental|Alpha Hope|Each tablet contains 10 mg PQQ and 40 mg (19% DV) magnesium as well as malic acid, dextrose, adipic acid, citric acid, natural flavor, and blackberry leaf extract
89067713|NCT05589051|Placebo Comparator|Placebo|Same formulation as experimental with 250 mg calcium carbonate replacing the magnesium and PQQ.
89067714|NCT05583747|Experimental|Treatment Course A: E-field Modeling|Your Magnetic Resonance Image (MRI) results and rTMS calibration information (motor threshold) will be used to create a brain model and identify the targeted location, iTBS coil position and intensity for your iTBS rTMS treatment. You will undergo iTBS rTMS treatment in this study for 6 weeks. There will be 5 iTBS treatment sessions per week, lasting approximately 3 minutes each, once daily for 5 days in a row (always Monday to Friday). Each day after treatment, you will also complete a brief set of questionnaires to track your symptoms, which will take 15 minutes. After every 5 treatments, you will complete an extra interview that will take an additional 30 minutes. There will also be two follow-up visits at 1 and 4 weeks after the end of treatment, each lasting approximately 1 hour. During these follow-up visits, you will be asked to complete a brief set of questionnaires and interviews to monitor your symptoms.
89223597|NCT01081561|Active Comparator|Cross-linking plus INTACS|Corneal collagen cross-linking with riboflavin and UVA light plus INTACS
89223598|NCT04004754||Complicated CL in Gondar|Patients treated with miltefosine in Gondar will be followed up to see outcomes of treatment
89223599|NCT04004754||Complicated CL in Boru Meda|Patients treated with miltefosine in Boru Meda hospital will be followed up to see outcomes of treatment
89223600|NCT04567056||Cancer group|Patients with verified head and neck squamous cell carcinomas
89223601|NCT04567056||Control group|Matched control group without active or earlier cancer and a normal ENT examination.
89223602|NCT05919901|Experimental|HPV Intervention|
89223603|NCT05919901|Active Comparator|Active Control|
89067715|NCT05583747|Active Comparator|Treatment Course B: Beam F3|The targeted iTBS rTMS treatment location and intensity will be determined via standard parameters, specifically anatomical landmarks and your rTMS calibration information (motor threshold). You will undergo iTBS rTMS treatment in this study for 6 weeks. There will be 5 iTBS treatment sessions per week, lasting approximately 3 minutes each, once daily for 5 days in a row (always Monday to Friday). Each day after treatment, you will also complete a brief set of questionnaires to track your symptoms, which will take 15 minutes. After every 5 treatments, you will complete an extra interview that will take an additional 30 minutes. There will also be two follow-up visits at 1 and 4 weeks after the end of treatment, each lasting approximately 1 hour. During these follow-up visits, you will be asked to complete a brief set of questionnaires and interviews to monitor your symptoms.
89067716|NCT05579119|Experimental|Sitagliptin + glargine|Sitagliptin and glargine once daily + correction doses of lispro if needed.
89067717|NCT05579119|Active Comparator|Basal-plus|Glargine once daily plus correction doses of lispro if needed.
89067718|NCT05571033|Experimental|Spinal reflex conditioning|"The OC intervention includes 6 baseline sessions and 24 conditioning/ no conditioning sessions held 3 times/week.~To elicit an H-reflex, participants will be asked to stand in a comfortable position. Small pulses of energy will be applied to a nerve in the leg called the tibial nerve. We will record when the participant maintains leg muscle activity. During the intervention, participants will be trained to decrease their reflex in their calf."
89067719|NCT05549232||Hematologic Malignancies|Subjects requiring chronic transfusions with red blood cells for treatment of a hematologic malignancy will receive 1 transfusion with 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. The subjects will be monitored for all adverse events from Informed Consent through Day 28 or the subsequent standard of care transfusion, whichever occurs first.
89067720|NCT05549232||Acute Burn|Subjects requiring transfusion with red blood cells during the excision procedure after an acute burn will receive 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. As the excision treatments require transfusion of more than 2 units of red blood cells, the first 2 units transfused during the procedure will be hypoxic red blood cells. The subjects will be monitored for all adverse events through Day 28.
89067721|NCT05537376|Experimental|SUPPORT|Veterans receiving SUPPORT will be offered all modules of the intervention via weekly, 50-minute sessions with a Peer Specialist. Following the completion of a mental health evaluation by a licensed professional, the Peer Specialist leads the Veteran who is at risk for suicide through recovery planning that is tailored to the Veteran's suicidal experiences with cognitive learning strategies to enhance recall of the Veteran's safety plan and improve recovery.
89067722|NCT05537376|No Intervention|ESC|The enhanced standard care (ESC) condition contains the elements of standard practice suicide prevention delivered at VHA, which include: 1) suicide risk assessment, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, and 4) Suicide Prevention Coordinator follow-up contacts. It is enhanced due to the contact with the research study.
89223604|NCT05919875|Experimental|Unguided iMBCT intervention|
89223605|NCT05919875|Experimental|Guided iMBCT intervention|
88812913|NCT03211988|Other|Entinostat|Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.
89067723|NCT05533918|Active Comparator|Text Messaging (TM) + No Patient Navigation|"Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed.~Patients will not receive patient navigation."
89067724|NCT05533918|Active Comparator|Text Message (TM) + Request (RPN)|"Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed.~RPN will provide patients the opportunity to reply PERSON (for connection to a PN) in response to a TM offering connection to testing and/or vaccination."
89067725|NCT05533359|Active Comparator|Text Messaging (TM) + No Patient Navigation|"Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed.~Patients will not receive patient navigation."
89067726|NCT05533359|Active Comparator|Text Message (TM) + Request (RPN)|"Bidirectional text messaging with a one-touch response to connect patients to vaccination or mailed at-home rapid test kits for use as needed.~RPN will provide patients the opportunity to reply PERSON (for connection to a PN) in response to a TM offering connection to testing and/or vaccination."
89067727|NCT05533359|Active Comparator|Conversational Agent (CA)+ No Patient Navigation|"Automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.~Patients will not receive patient navigation."
89067728|NCT05533359|Active Comparator|Conversational Agent (CA) + Request PN (RPN)|"Automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.~RPN will provide patients the opportunity to reply PERSON (for connection to a PN) in response to a CA offering connection to testing and/or vaccination."
89223606|NCT05919875|No Intervention|Waiting list group|
89223607|NCT05919836|Active Comparator|Percutaneous assisted laparoscopic hernia|
88812914|NCT01450397|Other|XIAFLEX|XIAFlEX
89067729|NCT05530954|Active Comparator|Mineral trioxide aggregate (MTA)|"where the pulp tissue is exposed during final caries removal, hemostasis will be achieved by cavity irrigation with sterile saline solution for up to 4 minutes till control of bleeding~Teeth with pulp exposure less than 1mm in diameter surrounded by sound dentin will be candidates for direct pulp capping~Following the removal of the saline, the exposed pulp will be irrigated with 17% EDTA solution (Prevest Direct, India) for 1 minute~According to site of exposure, the groups will be further subdivided into Group A (n=13) with exposure in pulpal floor and Group B (n=13) with exposure in axial wall of the cavity.~Exposed pulp will be covered with fast set MTA paste after cavity dryness with sterile cotton pellet then the tooth will be restored with Self-cured glass ionomer restorative material (SDI Riva self-cure, Australia) and tooth will be covered by stainless steel crown"
89067730|NCT05530954|Active Comparator|Hard setting Calcium Hydroxide (Dycal)|"where the pulp tissue is exposed during final caries removal, hemostasis will be achieved by cavity irrigation with sterile saline solution for up to 4 minutes till control of bleeding~Teeth with pulp exposure less than 1mm in diameter surrounded by sound dentin will be candidates for direct pulp capping~Following the removal of the saline, the exposed pulp will be irrigated with 17% EDTA solution (Prevest Direct, India) for 1 minute~According to site of exposure, the groups will be further subdivided into Group A (n=13) with exposure in pulpal floor and Group B (n=13) with exposure in axial wall of the cavity.~Exposed pulp will be covered with Dycal paste after cavity dryness with sterile cotton pellet then the tooth will be restored with Self-cured glass ionomer restorative material (SDI Riva self-cure, Australia) and tooth will be covered by stainless steel crown"
89067731|NCT05522205|Experimental|Experimental group|Immediately regulated cannabis access in pharmacies.
89067732|NCT05522205|No Intervention|Control group|During the first six months participants of the control group have to continue to buy their cannabis on the illicit market. Afterthese six months they also have access to regulated cannabis access.
89067733|NCT05518929|Active Comparator|Control group(Propofol group)|Anesthesia induction:Propofol 1.5mg/kg Anesthesia maintenance: Propofol 0.75mg/kg
89067734|NCT05518929|Experimental|Experimental group(ciprofol group)|Anesthesia induction:ciprofol 0.4mg/kg Anesthesia maintenance: ciprofol 0.2mg/kg
89067735|NCT05518708|Experimental|BI 3032950 treatment group - part A|
89067736|NCT05518708|Experimental|BI 3032950 treatment group - part B|
89067737|NCT05518708|Placebo Comparator|Placebo group|
89067738|NCT05511649||Post-MI NOAF with low AF burden|Patients with post-MI NOAF who had a AF burden<10.87%. The cut-off value of AF burden of 10.87% was identified based on our previous work.
89067739|NCT05511649||Post-MI NOAF with high AF burden|Patients with post-MI NOAF who had a AF burden≥10.87%.
89067740|NCT05510050|Experimental|Manapol|1000 mg (Manapol only) Aloe Vera extract daily
89067741|NCT05510050|Experimental|Dalton Max|1000 mg (Dalton Max only) Aloe Vera extract daily
89067742|NCT05510050|Placebo Comparator|Placebo|Placebo (rice dextrin or similar) taken daily
89067743|NCT05492136|No Intervention|Arm 1: Control|"In this arm it will be permitted one/several conventional methods according to surgeon preference:~Conventional crusch-clamp or finger fracture technique~Ultrasonic dissector (CUSA, SONOK..) or Ultrasonic mediated devices~Water jet dissector~Argon beam coagulator"
89067744|NCT05492136|Experimental|Arm 2: study arm|In this arm it will be permitted to use the radiofrequency devices which have demonstrated evidence in the literature in terms of reducing local recurrence alone or in combination with any conventional method described previously in Arm. (Coolingbis device by VecMedical as well as Aquamantys (Medtronic) These devices and their operating procedure have been described in detail elsewhere Briefly, it consists of a handheld instrument that might be employed not only for margin coagulation but also as hemostatic instrument. After performing the hepatectomy the bladeless part of the device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output.in order to perform an additional margin coagulation
89067745|NCT05488340|Experimental|Part 1- Arm 4 (previously 1)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 (1x10^11 PFU) and oral TMP/SMX on D1 through D3.
89067746|NCT05488340|Experimental|Part 1- Arm 5 (previously 2)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 (1x10^10 PFU) and oral TMP/SMX on D1 through D3.
89067747|NCT05488340|Experimental|Part 1- Arm 6 (previously 3)|Intraurethral (IU) LBP-EC01 on D1 and D2 with intravenous (IV) LBP-EC01 infusion (1x10^12 PFU) and oral TMP/SMX on D1 through D3.
89067748|NCT05488340|Experimental|Part 2: LBP-EC01|LBP-EC01 given by dose regimen selected from Part 1. IU LBP-EC01 on D1 and D2 with IV LBP-EC01 (1x10^11 PFU) and oral TMP/SMX on D1 through D3.
89067749|NCT05488340|Placebo Comparator|Part 2: Placebo|Placebo given by dose regimen selected from Part 1. IU placebo on D1 and D2 with IV placebo and oral TMP/SMX on D1 through D3.
89067750|NCT05484596||Observational Group|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
89067751|NCT05481216||PLWHIV with COVID-19 cases|Patients who are at least 18 years of age with documented HIV-1 infection and confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
89067752|NCT05481216||PLWHIV without COVID-19 controls|Patients at least 18 years of age with documented HIV-1 infection.
89067753|NCT05481216||HIV seronegative patients with COVID-19 controls|Patients at least 18 years of age with confirmed SARS-CoV-2 infection by documented, or patient-reported, positive result on PCR testing of a nasopharyngeal or respiratory sample, before 1st April 2021.
89067754|NCT05477069|Experimental|First intervention group|The volunteer ingests the medical device which passes through the body for a period of 12 to 24 hours. Capsules are collected and analysis on intestinal fluid and faeces are performed
89067755|NCT05477004||Open label ketamine|Patients who receive a ketamine infusion for the treatment of chronic pain in the course of usual clinical care
89067756|NCT05453058||Patients diagnosed with possible or probable MSA|This protocol does not mandate the use of any treatments. No study medication will be administered as part of study participation. Any treatment that study patients receive will be prescribed according to the recommendations given in the local SmPCs.
89067757|NCT05450029|Experimental|Chemoradiotherapy and PD1 inhibitor|Chemoradiotherapy and PD1 inhibitor
89067758|NCT05439434|Experimental|intervention group|
89067759|NCT05428267|Experimental|Patients on the liver transplant list for cirrhosis.|Prevalence of sexual dysfunction before and after LT
89067760|NCT05422001|Experimental|Intervention, low-dose ketamine|Two 1 ml syringes with Esketamine (5 mg/ml) will be prepared and study drug will be administered as intravenous bolus dose, 0,1 mg/kg. The study drug will be administered after an intravenous morphine dose.
89067761|NCT05422001|Placebo Comparator|Placebo|Two 1 ml syringes with saline will be prepared and study drug will be administered as intravenous dose, same volume as if Esketamine. The placebo drug will be administered after an intravenous morphine dose.
89067762|NCT05421806||Treatment naive|
89067763|NCT05421806||Treatment switched|Virologically suppressed (VL < 50 copies for more than 6 months)
89067764|NCT05411406||Study cohort|Patients undergoing ENT or OMS surgery with general anesthesia with facemask ventilation and tracheal intubation (observational)
89067765|NCT05408676|Experimental|Group Acu|"a surface electrode was applied in the induction room to the P6 acupoint on the dominant upper extremity, located ∼4 cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode on the opposing dorsal aspect of the forearm. When the patient enters the operating room， an investigator connected the device to both electrodes with electrical wires, set initial electric stimulating current at 1 mA with the frequency at 2 Hz(square-wave pulses of 0.2 ms), gradually increased the current intensity until the patient felt pain or reached the discomfort threshold (ranging from 6 to 20 mA), and maintained the stimulation until end of operation.~At the start of skin closure, saline (3 ml) was administered i.v."
89067766|NCT05408676|Sham Comparator|Group Gra|"Group Gra receive the same protocol but silicone covers were attached to both electrodesin to achieve an inert control.~At the start of skin closure, granisetron (3 mg; Group Trp) was administered i.v."
89067767|NCT05408676|Sham Comparator|Group Dxm|"Group Dxm receive the same protocol but silicone covers were attached to both electrodesin to achieve an inert control.~At the start of skin closure, saline (3 ml) was administered i.v."
89067768|NCT05399082|Experimental|Standard forceps biopsy then research cryoprobe biopsy|Subjects scheduled for a biopsy of lung lesions using robotic bronchoscopy as part of their standard of care will have the lung lesion biopsied using forceps first followed by cryoprobe.
89067769|NCT05399082|Experimental|Research cryoprobe biopsy then standard forceps biopsy|Subjects scheduled for a biopsy of lung lesions using robotic bronchoscopy as part of their standard of care will have the lung lesion biopsied using the cryoprobe first followed by forceps.
89067770|NCT05398068|Experimental|Training (Exercises and Diet) Group|"Training (Exercises and Diet) Group; Patients will follow a regular diet program for 10 weeks.~Aerobic exercises will be planned for patients 2 days a week under the supervision of a physiotherapist, and 3 days a week as home exercises.~Strengthening exercises will be planned for patients 1 days a week under the supervision of a physiotherapist, and 2 days a week as home exercises."
89067771|NCT05398068|Active Comparator|Control (Diet) Group|Control (Diet) Group; Patients will follow a regular diet program for 10 weeks.
89067772|NCT05386342|Other|LeMaitre TufTex Over-the-Wire Embolectomy Catheter|The LeMaitre Over the Wire Embolectomy Catherer is indicated for use in the removal of emboli and thrombi during embolectomy and/or thrombectomy. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
89067773|NCT05386277|Other|LeMaitre TufTex Single Lumen Embolectomy Catheter|The LeMaitre® Single Lumen Embolectomy Catheter is a catheter that consists of a natural latex rubber balloon secured with ligatures to a single lumen radiopaque shaft. When the balloon the emboli and/or thrombi can be removed by withdrawing the catheter tip through the arteriotomy.
89067774|NCT05377489|Experimental|RTX-GRT7039|Participants will receive up to 5 intra-articular injections of RTX-GRT7039 into either the index knee (affected knee or in case of bilateral OA the knee with highest pain intensity), or each of both knees up to Week 52.
88812915|NCT03218072|Experimental|HLX01 250 mg/m2|HLX01 250 mg/m2 administrated intravenously
88812916|NCT03218072|Experimental|HLX01 375 mg/m2|HLX01 375 mg/m2 administrated intravenously
89067775|NCT05373992|Experimental|Screen Time Restricted|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
89223608|NCT05919836|Active Comparator|Laparoscopic Purse string closure of hernial sac|
89223609|NCT05919836|Active Comparator|Laparoscopic Total dissection of hernial sac|
89067776|NCT05373992|Experimental|Aerobic Exercise|Participants will be asked to engage in 30-minutes of aerobic exercise (AE) daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
89067777|NCT05373992|Experimental|Screen Time Restricted & Aerobic Exercise|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) as well as engage in 30-minutes of AE in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
89067778|NCT05373992|Active Comparator|Stretching|Participants will be asked to follow a daily stretching program for the first 72-hours following the initial clinic visit. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
89067779|NCT05363631|Experimental|Seleno-L Methionine (SLM) in Combination with Axitinib and Pembrolizumab|SLM only will be taken by mouth during a two-week run in period. Then patients will receive SLM and Axitinib drugs by mouth, and Pembrolizumab intravenously (IV), at the start of each 21 day cycle.
89067780|NCT05362110|Experimental|Experimental|HCP1803-3
89067781|NCT05362110|Active Comparator|Active Comparator|RLD2002
89067782|NCT05357833|Experimental|SPMS Cohort|Subjects will undergo MR imaging of the brain and cervical spine for pre- and post-administration of gadoteridol (0.2 mL/kg), then pre- and post-administration of ferumoxytol (4 mg/kg). Scans will be obtained over the course of two separate imaging visits.
89067783|NCT05351203|Active Comparator|caudal epidural group|"the patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock by betadine three times and will be covered by sterile drapes exposing the sacral area. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound linear transducer probe that is covered in sterile plastic bag . Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
89223610|NCT05919797|Experimental|All participants|Calorie restricted diet and treatment with Naltrexone/Bupropion
89223611|NCT05919732|Experimental|The Caudal Infusion Group|Continuous caudal infusion.
88812917|NCT03218072|Experimental|HLX01 500 mg/m2|HLX01 500 mg/m2 administrated intravenously
89067784|NCT05351203|Experimental|Erector spinae group|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
89067785|NCT05316701|Experimental|Orca-T|For patients randomized to the Orca-T arm, Orca-T will be administered after myeloablative conditioning regimen. Single-agent GVHD prophylaxis with tacrolimus will be administered following Tcon infusion (generally Day +3).
89067786|NCT05316701|Active Comparator|Standard of Care alloHCT Control|For patients randomized to the standard-of-care control arm, an unmanipulated allograft derived from the peripheral blood of a matched donor will be administered after a myeloablative conditioning regimen. Dual-agent prophylaxis consisting of tacrolimus plus methotrexate will be administered starting on Day -3.
89067787|NCT05316506|Other|Anticipated Discomfort Group|Participants will be prompted using anticipated discomfort language during the standard of care hysteroscopy.
89067788|NCT05316506|Other|Objective Description Group|Participants will be prompted using objective description language during the standard of care hysteroscopy.
89067789|NCT05295589|Active Comparator|Arm I (standard of care chemotherapy)|"Patients receive either paclitaxel IV OR pegylated liposomal doxorubicin hydrochloride IV, OR topotecan hydrochloride IV while on study.~Patients undergo CT scan while on study and may undergo MRI throughout the study."
89067790|NCT05295589|Experimental|Arm II (copanlisib, olaparib)|Patients receive copanlisib hydrochloride IV and olaparib PO while on study. Patients undergo CT scan while on study and may undergo MRI throughout the study.
89067791|NCT05294965|Experimental|Normal weight|"A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose of fenoterol per subject will thus be 145µg.~Mild cold exposure: During 120 minutes the water temperature in cooling sleeves, covering the participant's waist, is gradually decreased to 10 degrees or to the lowest tolerable temperature without shivering."
89067792|NCT05294965|Experimental|Overweight|"A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose of fenoterol per subject will thus be 145µg.~Mild cold exposure: During 120 minutes the water temperature in cooling sleeves, covering the participant's waist, is gradually decreased to 10 degrees or to the lowest tolerable temperature without shivering."
89067793|NCT05289713|Active Comparator|Surgery|In the surgery group, patients undergo laparoscopic appendectomy within 18 hours after randomization.
89067794|NCT05289713|Active Comparator|Symptomatic treatment|Symptomatically treated patients are hospitalized for at least 24 hours, and receive intravenous fluids and analgesics according to standard clinical practice.
89067795|NCT05287867|Experimental|Platelet treatment|A series of two treatments spaced 4 weeks apart that include platelet-rich plasma (PRP). platelet lysate (PL), and platelet poor plasma (PPP).
89067796|NCT05287867|Sham Comparator|Sham procedure|A series of two sham procedures spaced 4 weeks apart.
89067797|NCT05278520||OA cases|Twenty-five adult patients who have hip osteoarthritis.
89067798|NCT05278520||RA cases|Twenty-five adult patients who have rheumatoid arthritis in the hip joint.
89067799|NCT05278520||Non-arthritic controls|Fifteen adult patients who go through trauma-based emergency total hip arthroplasty and do not have arthritis.
88812918|NCT01833338|Other|Single arm|There is only one arm in this study. All patients undergo MSCT, IVUS and OCT.
89067800|NCT05267899|Experimental|WGI-0301|
89067801|NCT05255913|Experimental|group 1|
89067802|NCT05255913|Active Comparator|group 2|
89067803|NCT05247320||Prospective|
89067804|NCT05247320||Retrospective|
89067805|NCT05238714|Experimental|[14C] venglustat|Single dose of [14C] venglustat Oral Solution under fasting conditions
89067806|NCT05228496|Experimental|Tislelizumab combined with Sitravatinib|
89067807|NCT05223855|Active Comparator|Intervention group|The intervention group receives intervention for 8 weeks
89067808|NCT05223855|No Intervention|control group|The control group receives usual care for 8 weeks and is then offered participation in a de-stress class for 8 weeks.
89067809|NCT05192343|Experimental|Virtual Reality and nature sounds|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale for pain will apply to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires will apply, before and during the HSG procedure, the Virtual Reality and nature sounds application group watch a video with a nature view with virtual reality glasses.Glasses will introduce before the procedure. Before the procedure started, glasses will put on and training will given to continue watching the video by wearing glasses during the procedure. The women will be included in the Virtual Reality and nature sounds intervention group will make to watch a video with a nature view for 15 minutes and listening nature sounds before and during the HSG procedure. Each woman was shown the same video.
89067810|NCT05192343|Experimental|nature sounds|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale for pain will apply to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires will apply, a nature-based sound will play to the women in the nature sounds group before and during the HSG shooting.Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes.
89067811|NCT05192343|No Intervention|control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention will perform. Both groups will re-evaluated using the same scales after the hysterosalpingography.
89067812|NCT05189275|Experimental|Cannabidiol 40 mg (CBD40)|Subjects consume beverages with 40mg of CBD.
89067813|NCT05189275|Experimental|Cannabidiol 20 mg (CBD20)|Subjects consume beverages with 20mg of CBD.
89067814|NCT05189275|Experimental|Cannabidiol 0 mg (CBD0)|Subjects consume beverages with 0mg of CBD.
89067815|NCT05189275|Placebo Comparator|Placebo Beverage (PLAC)|Subjects consume calorie matched beverages with 0 CBD.
89067816|NCT05187910|Active Comparator|Patients with Voice Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
89067817|NCT05187910|Active Comparator|Patients with Swallowing Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
89067818|NCT05187910|Active Comparator|Patients with Upper Airway Disorders|This is typically diagnosed by MDs in conjunction with Speech Language Pathologists (SLPs).
89067819|NCT05183204|Experimental|Arm 1: Newly diagnosed MGMT unmethylated glioblastoma|
89067820|NCT05183204|Experimental|Arm 2: Recurrent glioblastoma, regardless of methylation status|
89067821|NCT05181748|Experimental|Experimental: Group of participants receiving PRP treatment|Women presenting with POR, treated with autologous PRP intraovarian infusion during the mid-luteal phase, undergoing a subsequent stimulated fresh ET-ICSI cycle on the first month following PRP infusion
89067822|NCT05181748|No Intervention|Control Group: Group of participants receiving standard protocol|Women presenting with POR undergoing a stimulated fresh ET-ICSI cycle
89067823|NCT05181644|Active Comparator|Control Group|To the Control Group is administered the current standard therapy for 16 weeks.
89067824|NCT05181644|Experimental|EmoLED Group|The treatment with EmoLED will be carried out once a week in correspondence with the dressing change of the lesion, for sixteen consecutive weeks, for a total of 16 treatments.
89690441|NCT03574779|Experimental|Cohort A: 1-2 prior lines of therapy (TSR-042, Bevacizumab, and Niraparib)|PARP Inhibitor-Naive Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib. TSR-042 administered 500 milligrams (mg) on Day 1 every 3 weeks (Q3W) for 4 cycles (each cycle is 21 days), followed by 1000 mg every 6 weeks (Q6W) beginning on Cycle 5 Day 1 until progressive disease (PD) or toxicity. Bevacizumab administered 15 milligram per kilogram (mg/kg) every 3 weeks for up to 15 months. Niraparib 200 or 300 mg per day until PD or toxicity.
89067827|NCT05178173|Placebo Comparator|Sterile Water|Subject participants will rinse mouth one time for 60 seconds with 20 mL of sterile water.
89067828|NCT05178173|Active Comparator|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 20 mL 27% ethanol plus essential oils.
89067829|NCT05178173|Active Comparator|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 20 mL 0.075% Cetylpyridinium Chloride.
89067830|NCT05162820|Experimental|Smoker Solarplast|Smoker's assigned to solarplast
89067831|NCT05162820|Placebo Comparator|Smoker Placebo|Smoker's assigned to placebo
89067832|NCT05162820|Experimental|Non-smoker Solarplast|Non-smoker assigned to solarplast
89067833|NCT05162820|Placebo Comparator|Non-smoker Placebo|Non-smoker assigned to placebo
89067834|NCT05153343|Experimental|flonoltinib 25mg|1 case，The starting dose，Take the medicine once on D1 ，D 5 through 21.
89067835|NCT05153343|Experimental|flonoltinib 50mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89067836|NCT05153343|Experimental|flonoltinib 100mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89067837|NCT05153343|Experimental|flonoltinib 150mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
88812919|NCT01833650|No Intervention|Standard care|This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
89067838|NCT05153343|Experimental|flonoltinib 225mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89067839|NCT05153343|Experimental|flonoltinib 325mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
89223612|NCT05919732|Active Comparator|The General Anesthesia Group|Single caudal injection with general anesthesia.
89067840|NCT05130814|Active Comparator|Control Group|"The Control Group will follow the standard treatment indicated three times a week for the 4 weeks of observation.~The standard treatment for 2° and 3° stage PU consists of: cleansing with saline or ringer's lactate, hyaluronic acid gauze plus polyurethane foam every 48 hours or as needed. In addition, zinc cream or hyaluronic acid sodium salt + metallic silver is applied to prevent and/or treat the skin maceration of the surrounding area, and eventual debridement of the lesion, application of topical treatment indicated for that stage of the lesion (as provided by the Protocol on pressure ulcers' dressing intended as the standard of care of the structure) and subsequent bandage (that generally consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system), are planned."
89067841|NCT05130814|Experimental|EmoLED Group|"The Experimental Group will undergo, in addition to the standard treatment, treatment with Emoled three times a week for 4 consecutive weeks.~This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the lesion has a greater extension than the irradiated area, multiple repeated applications will be performed, on adjacent areas, until the entire area is covered.~The treatment with EmoLED will be carried out in correspondence with the dressing change of the lesion."
89067842|NCT05130294|Active Comparator|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides.
89067843|NCT05130294|Placebo Comparator|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
89067844|NCT05124457|Experimental|Insulin Detemir|Patients are to receive insulin detemir as long acting insulin to control blood sugars
89067845|NCT05124457|Active Comparator|Insulin NPH|Patients are to receive insulin NPH as long acting insulin to control blood sugars
89067846|NCT05116865|Experimental|Single Ascending Dose Cohort A1|Subjects will receive a single dose of either dose level 1 of HH-120 or placebo
89067847|NCT05116865|Experimental|Single Ascending Dose Cohort A2|Subjects will receive a single dose of either dose level 2 of HH-120 or placebo
89223613|NCT05919719||study of diagnostic accuracy|Patients included in this study would have received fluid expansion in all cases, as the prescription of 10 to 20ml/kg crystalloid fluid expansion by the physician in charge is the main inclusion criterion.
89223614|NCT05919667|Experimental|Dairy-based Product 1|2% Cow's milk (Neilson, St-Laurent, Quebec)
89223615|NCT05919667|Experimental|Dairy-based Product 2|Regular fat cheddar cheese (Armstrong, St-Laurent, Québec)
89223616|NCT05919667|Experimental|Plant-based Product 3:|Vanilla Soy Beverage (Silk, Broomfield, Colorado)
89067848|NCT05116865|Experimental|Single Ascending Dose Cohort A3|Subjects will receive a single dose of either dose level 3 of HH-120 or placebo
88812687|NCT01520519|Experimental|Rituximab + PCI-32765|Rituximab (375 mg/m2) given intravenously (IV) on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6. PCI-32765 started on Day 2 of cycle 1 at a dose of 420 mg (3 * 140-mg capsules) orally daily and will be continued daily.
89067849|NCT05116865|Experimental|Multiple Ascending Doses Cohort B1|Subjects will receive multiple doses of either Dose level 1of HH-120 or placebo
89067850|NCT05116865|Experimental|Multiple Ascending Doses Cohort B2|Subjects will receive multiple doses of either Dose level 2 of HH-120 or placebo
89067851|NCT05116865|Experimental|Multiple Ascending Doses Cohort B3|Subjects will receive multiple doses of either Dose level 3 of HH-120 or placebo
89067852|NCT05101239||A: Acute mTBI|Consists of up to 80 patients with acute mTBI. All acute mTBI subjects will be scanned per the HHI study design at 3 to 5 timepoints relative to their time of injury ( Visit 1 within 72 hours; Visit 2, 7 +/- 4 days; Visit 3, 30 +/- 7 days; Visit 4, 90 +/- 14 days; Visit 5, 180 +/- 30 days from injury). Even though for practicality Visits 1 and 5 are optional, every effort will be made to image as close to the time of acute injury as possible and to complete imaging for all time points.
89067853|NCT05101239||B: Control|Consists of 40 age-matched participants described above who will undergo imaging twice on the MAGNUS 3.0T MRI scanner at two distinct time points. The 2 MRI imaging sessions will be at least 2 weeks apart. One of the 2 visits will include a clinical MRI scan using the same MRI acquisition protocols used for Group A. Because age-matched Controls are not expected to exhibit structural and functional changes during the study period, it was not deemed necessary for the interval between scan-visit time points to be identical for all participants in Group B.
89223617|NCT05919667|Experimental|Plant-based Product 4|Vanilla Almond Beverage (Earth's Own, Vancouver, British Columbia)
89223618|NCT05919667|Experimental|Plant-based Product 5|Plant-based Cheddar-Style Block (President' Choice, Brampton, Ontario)
89067854|NCT05101239||C: Chronic mTBI|Consists of 40 age-matched participants with chronic mTBI (≥6 months and <5 years from mTBI injury to enrollment). Participants in this group will have 1 set of procedures at the Baseline Visit. This cohort will be used to understand functional and structural changes in chronic mTBI patients to identify indications of progression of patients from the acute to chronic phase
89067855|NCT05096195|Experimental|Intervention|60 mg of denosumab (Prolia) will be administered every 6 months over a 15 - month period. Monitoring of serum calcium and phosphate will occur and bloodwork will be drawn for 7 weeks following each denosumab injection. Correction of vitamin D deficiency (if required), the adjustment of calcium dialysate and the provision of intravenous (IV) or oral (po) calcitriol/calcidiol will be administered as needed following each denosumab injection as described in the Beside Protocol. Once the study monitoring period is over, serum calcium monitoring and management will occur as per routine care in the dialysis centre. All intervention activities will occur during regularly scheduled hemodyalisis sessions.
89067856|NCT05096195|No Intervention|Usual care|Usual care participants will continue to receive the typical standard of care in their dialysis unit which includes their routine dialysis monitoring and bloodwork. They will not receive denosumab, calcium and vitamin prophylaxis. There will be no extra monitoring or bloodwork.
89067857|NCT05093959|Active Comparator|Metformin|20 weeks of metformin 1500 mg daily. Metformin is a widely used medication with an excellent safety profile. Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks. An extended release formulation will be used which improves compliance and reduces GI side effects.
89067858|NCT05093959|Placebo Comparator|Placebo|20 weeks of placebo 1500 mg daily. Placebo is a biologically inert substance placed in capsules to match appearance of active intervention (metformin). Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks.
89067859|NCT05087290||Cases|SARS-CoV-2 +ve cases
89067860|NCT05087290||Control|SARS-CoV-2 -ve cases
89067861|NCT05074667|Other|Continuous Glucose Monitor|All participants will be included in this arm
89067862|NCT05066477|Active Comparator|CalGo (Salmon bone meal)|4 capsules daily of CalGo (salmon bone meal enriched with Vitamin D3) is taken per orally. Each capsule contains ~500 mg of salmon bone meal (380 mg calcium, 200 mg phosphorus, 500 mg native collagen type 2), and 10 micrograms of vitamin D3 (400 IU). Once daily dosing. Duration: 2 years.
89223619|NCT05919641||+CGA|Patients randomised to undergo a Comprehensive Geriatric Assessment (CGA)
88812688|NCT00185744|Experimental|Accelerated Partial Breast Irradiation|lumpectomy with accelerated partial breast irradiation
89223620|NCT05919641||-CGA|Patients not randomised to undergo a Comprehensive Geriatric Assessment (CGA)
89223621|NCT05919615|Experimental|intravenous tranexamic acid|The intervention group comprised patients who went primary unilateral TKA and used two-dose intravenous tranexamic acid that was applied as follows: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride), the first dose 15 minutes before the tourniquet deflation and the second dose at 180 minutes after the first dosage.
89067863|NCT05066477|Placebo Comparator|Maltodextrin|4 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once daily dosing. Duration: 2 years.
89067864|NCT05064722|Experimental|SNAP-S|Creation of a D-I diversion in participants undergoing primary sleeve gastrectomy (SNAP-S cohort)
89067865|NCT05064722|Experimental|SNAP-PS|Creation of a D-I diversion in participants who have experienced inadequate weight loss following sleeve gastrectomy (SNAP-PS cohort)
89067866|NCT05056246|Experimental|Group 1: Japanese participants - AMG 133 low dose|Japanese participants will receive the low dose of AMG 133 administered via subcutaneous injection.
89067867|NCT05056246|Experimental|Group 2: Japanese participants - AMG 133 medium dose|Japanese participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
89067868|NCT05056246|Experimental|Group 3: Japanese participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
89067869|NCT05056246|Experimental|Group 4: Caucasian participants - AMG 133 medium dose|Caucasian participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
89067870|NCT05056246|Experimental|Group 5: Caucasian participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
89067871|NCT05049824|Experimental|SFM Treatment Arm|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion
89067872|NCT05044468|Experimental|Group A (liposomal bupivacaine)|Patients receive liposomal bupivacaine via injection into the intercostal nerve block.
89067873|NCT05044468|Active Comparator|Group B (lidocaine)|Patients receive lidocaine via injection into the pleuroscopy port incision sites and indwelling pleural catheter site.
89067874|NCT05035160||Group 1|Pregnant and postpartum birthing persons with perinatal pathology.
89067875|NCT05035160||Group 2|Healthy pregnant and postpartum birthing persons.
89067876|NCT05035160||Group 3|Healthy non-pregnant persons (healthy volunteers).
89067877|NCT05013450|Experimental|Dupilumab + anti-PD-1/PD-L1 (SOC)|Patients will continue SOC immunotherapy with PD-1/PD-L1 blockade following progression of disease, and three q3w cycles of dupilumab will be administered
89067878|NCT04989283|Experimental|Arm I (atezolizumab, chemotherapy, RT, surgery)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive one of the chemotherapy combinations below depending on their previous therapy and disease. Between the first day of chemotherapy and the first day of cycle 2 of chemotherapy, patients undergo external beam radiation therapy 5 days per week. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 21 and 90 days after treatment, patients undergo surgery. Within 42 days after completion of surgery, patients then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo a PET scan, CT scan, and MRI on study. Patients also undergo tumor biopsies and blood sample collection throughout the trial.
89223622|NCT05919615|Placebo Comparator|placebo|The control group comprised primary unilateral TKA patients who did not use TXA, just IV normal saline (0.9% sodium chloride).
89067879|NCT04989283|Active Comparator|Arm II (chemotherapy, RT, surgery)|Patients receive one of the chemotherapy combinations below depending on their previous therapy and disease. Between the first day of chemotherapy and the first day of cycle 2 of chemotherapy, patients also undergo external beam radiation therapy 5 days per week. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 21 and 90 days after treatment, patients undergo surgery. Patients may undergo a PET scan, CT scan, and MRI on study. Patients also undergo tumor biopsies and blood sample collection throughout the trial.
89067880|NCT04988841|Experimental|Fecal microbiotherapy (MaaT013) associated to ipilimumab and nivolumab|Fecal microbiotherapy MaaT013 (actif arm) enemas will be administered by nurses, at the hospital, in the dermatology department in which the patients are treated for their melanoma. Nurses will be trained to administer enemas. The enema will be administered to the patient in the left lateral position with instructions to retain it for at least 20 minutes
89067881|NCT04988841|Placebo Comparator|fecal microbiotherapy Placebo associated to ipilimumab and nivolumab|Placebo fecal microbiotherapy will be administered by nurses, at the hospital, in the dermatology department in which the patients are treated for their melanoma. Nurses will be trained to administer enemas. The enema will be administered to the patient in the left lateral position with instructions to retain it for at least 20 minutes
89067882|NCT04978571|Experimental|Active Neurostim Device|Patients in this group will receive the active devices for the initial 4 study weeks.
88812689|NCT00185744|Active Comparator|Standard Therapy|lumpectomy and whole breast irradiation
88812690|NCT03008057|Active Comparator|vitamin D supplementation|patients with type 2 diabetes receive 1 tablet (4000 IU ) vitamin D supplementation, one time a day, for 3 months.
88812691|NCT03008057|Placebo Comparator|vitamin D placebo|patients with type 2 diabetes receive one tablet of vitamin D placebo for 3 months
88812692|NCT01542125|Experimental|Liposomal Lidocaine group|Patients in this groups received 4% Liposomal Lidocaine that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing
89067883|NCT04978571|Sham Comparator|Sham Neurostim Device|Patients in this group will receive the sham devices for the initial 4 study weeks. However, they will be offered the 4 active devices after.
89067884|NCT04978571|Experimental|COVID Active Neurostim Device|Patients in this group will receive the active devices for the 6 study weeks.
89067885|NCT04977778|Active Comparator|Fatty Acids Compounds (FAG)|Individuals taking FAG mouthwash
89067886|NCT04977778|Active Comparator|Stannous Fluoride (SF)|Individuals taking SF mouthwash
89067887|NCT04973254|Experimental|Cohort 1- HIV injection at a community-based site|CAB-RPV LA administered to patients in an alternative community-based site
89067888|NCT04973254|Active Comparator|Cohort 2- HIV injection at a HIV clinic|CAB-RPV LA administered to patients in the HIV clinic
89067889|NCT04973254|Active Comparator|Cohort 3- Standard of care for HIV|Individuals who share characteristics of cohort 1 and are engaged in standard of care
89067890|NCT04964505|Experimental|Treatment (uproleselan, azacitidine, venetoclax)|Patients receive uproleselan IV over 1 hour Q12H on days 1-7, azacitidine IV or SC QD on days 1-7, and venetoclax PO QD on days 1-28. Beginning cycle 5, patients achieving MLFS or better response, may receive azacitidine IV or SC QD and uproleselan IV over 1 hour QD on days 1-6 and 8 or days 1-5 and 8-9 or days 1-5. Treatment with uproleselan repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Cycles with azacitidine and venetoclax repeat every 28 days in the absence of disease progression and unacceptable toxicity.
89067891|NCT04950153|Other|HIV Testing Intervention|Combination HIV testing and linkage to care intervention includes social media engagement and peer navigation
89067892|NCT04950153|Other|HIV Treatment Intervention|Combination HIV treatment outcomes (retention, ART adherence and viral suppression) intervention includes SMS text messaging and peer navigation
89067893|NCT04945707|Active Comparator|Arm 1|Ferric derisomaltose (Monoferric®) 1000 mg X 1 (for subject <50 kg, 20 mg/kg X1)
89067894|NCT04945707|Placebo Comparator|Arm 2|Normal Saline
89067895|NCT04942106|Other|Side-lying position followed by Supine position|In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position.
89067896|NCT04942106|Other|Supine position followed by Side-lying position|In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position.
89067897|NCT04926896|Experimental|Minimally invasive bone harvesting surgery|".Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.~Use the cortical bone opening device to open two bone holes with a diameter of 7.5 mm side by side in the iliac bone cortex ,place disposable battery-powered bone harvesting device for iliac crest bone harvesting operations.~The direction of the tool bit should be parallel to the outer iliac plate, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.~.Scrap and collect the cancellous bone by tool bit during operation.~. After collecting sufficient amount of cancellous bone, turn off the power, screw out the cabin, and pour out the cancellous bone.~. Suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage."
89067898|NCT04926896|Placebo Comparator|Traditional iliac crest bone harvesting surgery|".Applying routine approach in iliac crest bone harvesting surgery, make a 4cm long incision before or after the iliac crest, slice skin and subcutaneous tissue by layer., exposing the iliac crest ridge, outer plate and part of the iliac crest bone.~Use a bone chisel to open a lid on the iliac crest ridge cortex ,open the cover length at 3cm.~Lift the iliac crest ridge cortex plate cover, use bone knife and scraper to harvest bone in the iliac bone marrow cavity.~Avoid violence when using bone knives and scrapers, to avoid penetration of inner iliac layer, and avoid the injury to iliac blood vessels, nerves or internal organs.~After collecting sufficient amount of cancellous bone, suturing the iliac crest periosteum and deep fascia, closing the incision layer by layer, no drainage"
89067899|NCT04924491|Experimental|10.000.000 thyTreg /kg|Autologous thyTreg 10.000.000
89067900|NCT04924491|Experimental|20.000.000 thyTreg /kg|Autologous thyTreg 20.000.000
89067901|NCT04923230|Experimental|CAP Intervention|CAP is a parent-focused intervention being developed to help parents in states with legalized medical marijuana to address adolescent marijuana use. The proposed intervention will address the effects of marijuana on adolescent behavioral health, brain development, and social functioning and enhance parent motivation to use CAP concepts. Guided by formative research, CAP will build skills and provide strategies to: (1) restrict adolescent exposure to cannabis products and parent cannabis use in the home, (2) improve parent communication about their own cannabis use and expectations about youth marijuana use, (3) improve monitoring, (4) increase positive reinforcement for youth abstinence, and (5) address parent negative emotions. Parents will meet in groups with an interventionist for two 75-minute sessions. Presentations, discussion, and roleplay will be used to help parents gain mastery of preventive parenting behaviors and related strategies to reduce adolescent marijuana use.
89067902|NCT04923230|No Intervention|Wait List|Parents randomly assigned to Wait List Delayed CAP (WL) will receive no intervention for the baseline to 3-month follow-up period. Thus, the WL condition will serve as a comparison group from baseline to the 3-month assessment point. After the 3-month follow-up assessment, WL parents will be offered the CAP intervention. The final assessment for the WL participants will function as a 3-month follow-up assessment, allowing us to aggregate data all 60 parent-adolescent dyads to conduct within group analyses of pre- to post-intervention change on key variables of interest.
89067903|NCT04923165||patients with stroke|Inpatients and outpatients admitted to the investigators' rehabilitation facility .
89067904|NCT04917848||Older adults with cancer|Participants will be 70 years old or older with a diagnosis of gastrointestinal or gynecological cancer. Participants will be receiving or about to receive medical cancer treatment (e.g., chemotherapy, immunotherapy, targeted therapy, biological agents)
89067905|NCT04917224|Experimental|Cohort A: Central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from a lobar bronchus
89067906|NCT04917224|Experimental|Cohort B: Ultra-central lung tumors|Gross tumor volume (GTV) less than or equal to 1 cm from the mainstem bronchus, trachea, or esophagus
89067907|NCT04901624|Experimental|Personal Risk + Loss Protection|Personal Risk + Loss Protection
89067908|NCT04901624|Experimental|Personal Risk + Lottery Incentive|Personal Risk + Lottery Incentive
89067909|NCT04901624|Experimental|Family Risk + Loss Protection|Family Risk + Loss Protection
89067910|NCT04901624|Experimental|Family Risk + Lottery Incentive|Family Risk + Lottery Incentive
89067911|NCT04873895|Experimental|TACE+axitinib+HCQ|2 weeks of axitinib 5mg BID and hydroxychloroquine 600 mg BID followed by lobar or segmental trans arterial chemoembolization monthly until the entire tumor burden is treated, then continue axitinib/HCQ until progression or intolerable toxicity.
89067912|NCT04869436|Experimental|Dupilumab group|Patients with CRSwNP will have an initial dose of 600 mg of dupilumab, and 5 additional doses of 300mg every 4 weeks for 6 months.
89067913|NCT04860492|Active Comparator|Renalof|Patients will be given and, advised to take Renalof tablets 325mg three times a day for 90 days
89067914|NCT04860492|Placebo Comparator|Placebo|Patients will be given and, advised to take Placebo three times a day for 90 days
89067915|NCT04860154|Experimental|PDT with stent|Before photodynamic therapy, candidate patients undergoing biliary biopsy and biliary duct drainage. If pathology shows a bile duct malignancy, PDT therapy will carry out until total bilirubin drops below 100 μmol/L.Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or metal stent will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
89067916|NCT04860154|No Intervention|ERCP stent|After obtaining bile duct biopsy, the candidates were placed with biliary plastic stents or metal stents directly.
89067917|NCT04856085|Experimental|Cohort 1a (VIR-2218 + VIR-3434)|Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
89067918|NCT04856085|Experimental|Cohort 2a (VIR-2218 + VIR-3434)|Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
89067919|NCT04856085|Experimental|Cohort 3a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
89067920|NCT04856085|Experimental|Cohort 4a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
89067921|NCT04856085|Experimental|Cohort 5a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
89067922|NCT04856085|Experimental|Cohort 6a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
89067923|NCT04856085|Experimental|Cohort 7a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks
89067924|NCT04856085|Experimental|Cohort 8a (VIR-2218 + VIR-3434)|Participants will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks
89067925|NCT04856085|Experimental|Cohort 1b (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 44 weeks
89067926|NCT04856085|Experimental|Cohort 2b (VIR-3434)|Participants will receive multiple doses of VIR-3434 for 20 weeks
89067927|NCT04856085|Experimental|Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)|Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks
89067928|NCT04856085|Experimental|Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)|Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 48 weeks
89067929|NCT04856085|Experimental|Cohort 1d (VIR-2218 + PEG-IFNα)|Participants will receive multiple doses of VIR-2218 + PEG-IFNα for 48 weeks
89223623|NCT05919576||Visual-Tactile method (VTM)|In patients who come for treatment and have a prior appointment, an intraoral examination is performed using visual and tactile examination methods. A total of 639 proximal surfaces of 22 patients are examined by investigators using the visual-tactile method.
89223624|NCT05919576||Bitewing Radiography (BTW)|Bitewing radiographs available in the hospital system of patients who come to their appointment for treatment are examined. A total 639 proximal surface of 22 patient examined by investigators using bitewing radiography.
89223625|NCT05919576||Near-infrared imaging Technology (NIRI)|A total 639 proximal surface of 22 patient examined by using the NIRI feature of an intraoral scanner. Patients who came for restorative treatment were asked whether they volunteered in our study. An informed consent form was signed, and then lower and upper jaw scans were made by investigators.
89223626|NCT05919576||Panoramic radiography (PR)|Panoramic radiographs available in the hospital system of patients who come to their appointment for treatment are examined. A total 639 proximal surface of 22 patient examined by using panoramic radiography.
89223627|NCT05919563||Subjects treated with GRNOPC1 in the initial dosing study CP35A007|Subjects treated with GRNOPC1 in the initial dosing study CP35A007 will be followed for 15-year long-term safety monitoring
89223628|NCT05919550||Patients presenting a possible drug-induced adverse effects|
89223629|NCT05919498||Patients in the FASTRACS-RCT intervention arm|"The individuals in this group are patients in the intervention arm of the FASTRACS-RCT study.~Once their follow-up for the FASTRACS-RCT study is completed, they will be contacted to participate in the RECOVA-FASTRACS survey. They will be asked to conduct an individual semi-directive interview.~Patients may agree to provide contact information for people who have accompanied them on their return-to-work journey."
89223630|NCT05919498||Trajectory persons|"Trajectory persons are defined by FASTRACS-RCT patients. These persons have accompanied patients on their return-to-work journey. They may be someone close to you (family, friends, etc.), the general practitioner, a person from the company (colleagues, manager, occupational physician), or other health professionals (nurse, psychologist, etc.).~As a first step, all trajectory persons will complete an individual semi-directive interview. Then, some will be offered to participate in focus groups"
88812693|NCT01542125|Placebo Comparator|Placebo Group|This group received a placebo that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing.
88812694|NCT03216668|Experimental|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks
88812695|NCT03216668|Active Comparator|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
88812696|NCT01439087|Experimental|OFDI imaging|OFDI imaging
88812697|NCT01439633|Experimental|MGH OFDI marking and imaging|OFDI imaging
88812698|NCT02548832|Experimental|Berberine|Berberine 500 mg with breakfast, meal, and dinner.
88812699|NCT02548832|Experimental|Bezafibrate|Bezafibrate 200 mg on breakfast and dinner.
89067930|NCT04856085|Experimental|Cohort 2d (VIR-3434 + PEG-IFNα)|Participants will receive multiple doses of VIR-3434 + PEG-IFNα for 48 weeks
89067931|NCT04844931|Experimental|RIC + PostC in addition to standard treatment|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery in addition to standard treatment.
89067932|NCT04844931|Active Comparator|Standard treatment|
89067933|NCT04831606|Active Comparator|Control Arm|Patients will receive a biweekly standard treatment at home according to the International Working Group on Diabetic Foot consisting of: Debridement of the lesion, unloading with a brace up to the calf, non-removable (except for contraindications), dressing of the wound with advanced dressings in use at the specialized center and in the home care network.
89067934|NCT04831606|Experimental|EmoLED Arm|Patients on top of the standard treatment of the control arm will receive EmoLED blue light irradiation for two minutes at each biweekly medication.
89067935|NCT04812730|Other|ASD with decompensated sagittal misalignment|Adults suffering from a spinal deformity with a decompensated sagittal misalignment
89067936|NCT04812730|Other|ASD with compensated sagittal misalignment|Adults suffering from a spinal deformity with a compensated sagittal misalignment
89067937|NCT04812730|Other|ASD without sagittal misalignment|Adults suffering from a spinal deformity without a sagittal misalignment
89067938|NCT04812730|Other|Control group|Asymptomatic adults not suffering from a spinal deformity
89067939|NCT04758637|No Intervention|Control Group|Physicians in the control group will receive no notification of their patient's fatal or nonfatal overdose.
89067940|NCT04758637|Experimental|Overdose Notification Group|The overdose notifications will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses.
89067941|NCT04717050|Experimental|Progressive combine training (PCT)|"Participants will be randomly assigned to Progressive combine training (PCT) group.~Participants will have two (2) baseline tests, then begin a two phase PCT program.~Phase 1: Supervised 16-week resistance and cardiovascular exercise at a local YMCA (months 1-4) or remotely at home via Zoom~Participants will receive midpoint testing, approximately week 8.~Phase 2: Unsupervised 16-week resistance and cardiovascular exercise at a local YMCA (months 5-8) or remotely at home~Participants will receive midpoint testing, approximately two months into phase 2.~After the two (2) 16-week phases, participants will be followed for 4 months."
89067942|NCT04717050|Active Comparator|Attention Control (AC)|"Participants will be randomly assigned to Attention Control (AC) group.~Two (2) baseline tests will be performed prior to starting the program. Participants will perform 12 months of home-based stretching and have a 1x test performed during months 2, 4, 6, 8 and 10. Two (2) tests will be performed in month 12."
89067943|NCT04699201|Experimental|Prosthesis|Firstly, a laparoscopic cholecystectomy is performed. After suturing the aponeurosis with a J needle and 0 Polydioxanone, a lightweight, large-pore mesh made of PVDF monofilament (polyvinylidene fluoride - DynaMesh-CICAT, FEC Textiltechnik, Germany) will be placed onlay, overlapping 2cm in all directions from the edge of the aponeurosis incision at the umbilical trocar site. The mesh will be fixed to the aponeurosis with cyanoacrylate glue (Glubran®, GEM, Viareggio, Italy).
88812700|NCT02548832|Experimental|Berberine plus Bezafibrate|Berberine 500 mg with breakfast, meal, and dinner, and bezafibrate 200 mg only on breakfast and dinner.
88812701|NCT01440959|Experimental|TKI258|
88812702|NCT03216278|Experimental|Treatment A|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fed
88812703|NCT03216278|Active Comparator|Treatment B|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fed
88812704|NCT03216278|Experimental|Treatment C|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fasted
88812705|NCT03216278|Active Comparator|Treatment D|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fasted
88812706|NCT03216278|Experimental|Treatment E|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fed
89067944|NCT04699201|Active Comparator|Control|Firstly, a laparoscopic cholecystectomy is performed. Closure of the aponeurosis will be performed by standard procedure: under direct vision, suturing the aponeurosis with a J needle and 0 Polydioxanone, with a stitch interval of ≤ 5mm.
89067945|NCT04689009|Active Comparator|SOC Group|SOC Group (or control group) will follow the standard therapy with visits twice a week. More specifically, the treatment consists of: dressing change, cleansing and eventual debridement of the lesion, the topic treatment and compression bandage.
89067946|NCT04689009|Experimental|EmoLED Group|EmoLED Group will be visited once a week. Therapy in this case includes, in addition to the standard therapy, a treatment with EmoLED device; it consists in irradiating each 5 cm diameter area of the lesion for 60 seconds, with the blue light emitted by the device. For lesions larger than 5 cm, several applications will be applied on adjacent areas, until the whole lesion is covered.
89067947|NCT04685408|Experimental|TargEted MAnageMent Intervention (TEAM)|This arm will receive the experimental intervention, TargEted MAnageMent Intervention (TEAM)
89067948|NCT04685408|Active Comparator|Enhanced treatment as usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
89067949|NCT04665180|Experimental|Primary knee arthroplasty|Questionnaires
89067950|NCT04628871||Subjects who received SB-318|Subjects who received SB-318 in clinical study SB-318-1502
89067951|NCT04628871||Subjects who received SB-913|Subjects who received SB-913 in clinical study SB-913-1602.
89067952|NCT04628871||Subjects who received SB-FIX|Subjects who received SB-FIX in clinical study SB-FIX
89067953|NCT04620889||PVP (peripheral vascular disease)|Bypass or reconstruction of diseased or occluded blood vessels
89067954|NCT04620889||AV Access (arteriovenous access)|Arteriovenous shunting for blood access and bypass.
89067955|NCT04615403|Experimental|Implantation and Exchange|Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.
89067956|NCT04604899|Experimental|Retreated subjects|Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.
89067957|NCT04586049||Veterans with GWI|Veterans with GWI who served in the Gulf War between 1990 and 1992
89067958|NCT04586049||Veterans without GWI (Controls)|Veterans without GWI who served in the Gulf War between 1990 and 1992
89067959|NCT04577014|Experimental|Phase I: Safety Run-In / Dose Level 0|A safety run-in (dose level 0 in Table 1, below) will be performed and enroll 6 patients with advanced high-grade sarcoma who are treatment naïve. Cycle one will consist of gemcitabine plus docetaxel at the institution's standard dose and schedule: 900 mg/m2 of gemcitabine on days 1 and 8, and 75 mg/m2 of docetaxel on day 8. Intravenous Retifanlimab at a flat dose of 210 mg will be administered every 3 weeks starting on C2D1 for a total of two cycles (cycles 2 and 3). All visits are to be done +/-3 days of the scheduled timepoints.
89067960|NCT04577014|Experimental|Phase I: Dose De-escalation Level 1|"If ≤ 1 patient out of 6 at dose level 0 has a dose-limiting toxicity during this safety run-in, then the dose de-escalation portion of the protocol will commence.~Dose Level 1:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 900 mg/m2 Docetaxel (Day 8) - 75 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
89067961|NCT04577014|Experimental|Phase I: Dose De-escalation Level -1|"Dose Level -1:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 750 mg/m2 Docetaxel (Day 8) - 60 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
89067962|NCT04577014|Experimental|Phase I: Dose De-escalation Level -2|"Dose Level -2:~Retifanlimab (Day 1) - 375 mg (flat dose) Gemcitabine (Days 1 and 8) - 675 mg/m2 Docetaxel (Day 8) - 50 mg/m2 All visits are to be done +/-3 days of the scheduled timepoints."
89067963|NCT04577014|Experimental|Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma|"(UPS/MFS)~After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints."
88812707|NCT03216278|Active Comparator|Treatment F|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fed
88812708|NCT03216278|Experimental|Treatment G|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fasted
88812709|NCT03216278|Active Comparator|Treatment H|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fasted
89223631|NCT05919498||Professionals/Focus group|"This group is composed of some of the trajectory persons and professionals who participated in the delivery of the FASTRACS-RCT study intervention tools.~These individuals will participate in the focus groups."
88812710|NCT01543607|Experimental|Treatment|Radiofrequency ablation catheter
89067964|NCT04577014|Experimental|Liposarcoma/LPS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
89067965|NCT04577014|Experimental|Leiomyosarcoma/LMS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
89067966|NCT04577014|Experimental|Vascular Sarcoma|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
89067967|NCT04577014|Experimental|Other Soft tissue sarcoma/STS|After the RP2D is determined, 5 histology-specific cohorts (10 patients each), including UPS/MFS, LPS, LMS, vascular sarcoma, and other STS, will open for enrollment. Patients will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375 mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles), after which treatment with Retifanlimab will continue until unacceptable toxicity, disease progression, or the completion of 35 cycles (105 weeks) of Retifanlimab treatment. All visits are to be done +/-3 days of the scheduled timepoints.
89067968|NCT04567784|Placebo Comparator|Control|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
89067969|NCT04567784|Experimental|CBD 800mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
89067970|NCT04566107|No Intervention|Enhanced Usual Care|The enhanced usual care group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, individuals in the enhanced usual care group will receive the mobile health platform to record medications taken and BlueTooth devices to record physiologic measurements.
89067971|NCT04566107|Experimental|mHealth|The mHealth group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Subjects receive BlueTooth devices to record physiologic measurements.
89067972|NCT04566107|Experimental|mHealth Plus|The mHealth group plus will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth plus group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Participants receive BlueTooth devices to record physiologic measurements. The m-Health Plus group will receive real-time virtual visits with a nurse practitioner/community health worker team. Virtual visits are similar to an office follow-up visit with an health care provider using Zoom technology to allow for face-to-face interaction with the patient.
89067973|NCT04559620|Experimental|Maternal voice|Mother's voice will be played for 1 week between week 2 and 3 of life
89067974|NCT04559620|No Intervention|Control|NO intervention between week 2 and 3
89067975|NCT04545177|Experimental|Tissue Preservation System (TPS)|Tumor tissue will be obtained, processed, and then transported remotely to undergo multiple tests, including gene panel DNA sequencing, DNA methylation array, and bulk as well as single-cell transcriptome analyses (RNA-seq)
89067976|NCT04539574|Experimental|Diagnostic (7T MRI)|Patients undergo 7T MRI over 60 minutes.
89067977|NCT04531046|Experimental|axicabtagene ciloleucel|Single infusion administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg
89067978|NCT04517604|Experimental|iTBS+yoga|Participants will receive 6 sessions of intermittent theta burst stimulation (iTBS) and the LoveYourBrain Yoga program. The LoveYourBrain Yoga program was specifically designed for people with TBI.
89067979|NCT04511806||Primary Subjects|Children (age 0-21) with a cancer predisposition syndromes (CPS).
89067980|NCT04511806||Relatives of Children with CPS|Members of their Primary Family Unit will also be recruited for this study, including CPS-Affected Parents, Unaffected Parents and Siblings. Other adult family members (with documented or obligate CPS) are also eligible to enroll as Affected Family Members.
89067981|NCT04494503|Experimental|APG-2575 single agent in Relapse/Refractory CLL/SLL|APG-2575 orally once daily at 400mg, 600mg, 800mg dose levels respectively, every 28 days as a cycle.
89067982|NCT04494503|Experimental|APG-2575+Rituximab in Relapse/Refractory CLL/SLL|"Stage 1:APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg. Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1. Every 28 days as a cycle.~Stage 2: APG-2575 MTD/RP2D combined with rituximab. Every 28 days as a cycle."
88812711|NCT03216590|No Intervention|Standard draping|Shoulder arthroscopy will be performed using standard draping with the shoulder exposed.
89067983|NCT04494503|Experimental|APG-2575+ibrutinib in Relapse/Refractory CLL/SLL|"Stage 1: APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg.Ibrutinib 420mg orally once daily during C1D8-28 and following cycles. Every 28 days as a cycle.~Stage 2: APG-2575 MTD/RP2D combined with ibrutinib. Every 28 days as a cycle."
89067984|NCT04485611|Experimental|Prehabilitation|This pilot cohort will undergo an intervention and will be followed for up to 6 months. The study does not include a comparator group.
89067985|NCT04483713|Active Comparator|Educational Workshop|Will receive theoretical and practical training in EBP through a workshop in a structured model with themes related to the introduction to EBP, with the final proposal of a practical class that aims to structure and describe an individual case through an exercise formulated to go through the phases of a project of EBP, to base this exercise we will use a finished and consolidated project, this will be used as a template of the exercise, the description of this exercise is in the programmatic content.
89067986|NCT04483713|Active Comparator|Educational Workshop plus J. H. N. EBP Guide Tools|"Will receive the same training as group Educational Workshop, plus the presentation and availability of the Johns Hopkins Nursing Evidence-based Practice guide tools to be used in the practice class for the structuring and individual description of the EBP exercise case. The same theme of the case will be used in both groups."
89067987|NCT04477304|Experimental|Behavioral Intervention Arm|Clinicians in clinics randomized to the intervention group will be prompted with an EHR nudge when the prescribing history for the patient falls into one of the following three categories: Opioid naïve, At-risk for long-term use, or Long-term opioid recipient. These EHR-based nudges include elements of accountable justification, defaults and precommitments. Clinicians will also receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
89223632|NCT05919433||Patients with positive AMA and/or ANA anti-gp210/sp100 identified in the hospital database|
89067988|NCT04477304|No Intervention|Control|Clinicians in clinics randomized to the control group will receive web-based guideline education, consisting of an online educational module at the start of the study period. This will include educational clinical content related to the CDC guidelines, the Oregon Pain Guidance document, tapering training and other resources such as Substance Abuse and Mental Health Services Administration (SAMHSA) Medication-Assisted Treatment Physician Locator and the Naloxone Provider Guide.
89067989|NCT04451226|Experimental|Fezolinetant|Participants will receive fezolinetant 30 milligrams (mg) orally once daily for 52 weeks.
89067990|NCT04448873|Active Comparator|Maintenance treatment group|After at least 2 years of remission of KHE, the participant receives sirolimus as usual. The serum concentration is supposed to be 5-7 ng/ml. If the effect or side effects of sirolimus require discontinuation, it is allowed to modify intervention, and if so, the patient stays in the maintenance group.
89067991|NCT04448873|Experimental|Guided discontinuation group|"After at least 2 years of remission of KHE, the discontinuation measurement should be guided by the clinician with the following principles:~10% monthly reduction of the previous dose at most.~At least 5 half-lives between each reduction (2 weeks).~Blood concentration should be monitored monthly. Adjustment can be suggested according to the linear relationship between the dose and the blood concentration.~At least 6 months for the duration of guided discontinuation.~Regular assessments and evaluations should be done.~If the condition relapses or worsens during this process, dose of sirolimus should be adjusted to the previously effective dose. After a 3-month stabilization phase, 5% monthly reduction of the previous dose could be considered."
89067992|NCT04442724|Experimental|Single Arm - Bladder Chemo-Radiotherapy|Fiducial marker placement & cystogram during resection surgery, followed by radiation planning CT scan, mpMRI, chemo-radiation treatment; mpMRI and/or surveillance cystoscopy at 3, 6, and 9 months post-treatment.
89067993|NCT04368429|Experimental|Group 1: MenACYW Conjugate Vaccine|Participants received a single intramuscular (IM) dose of MenACYW Conjugate vaccine on Day 0.
89067994|NCT04368429|Active Comparator|Group 2: Menactra® vaccine|Participants received a single IM dose of Menactra® vaccine on Day 0.
89067995|NCT04364750|Experimental|Group A|"Participants in group A will undergo challenges in the order:~High-FODMAP beverage + placebo probiotic + L-Histidine~Low-FODMAP beverage + placebo probiotic + L-Histidine~High-FODMAP beverage + probiotic + L-Histidine~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
89067996|NCT04364750|Experimental|Group B|"Participants in group A will undergo challenges in the order:~Low-FODMAP beverage + placebo probiotic + L-Histidine~High-FODMAP beverage + probiotic + L-Histidine~High-FODMAP beverage + placebo probiotic + L-Histidine.~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
89067997|NCT04364750|Experimental|Group C|"Participants in group A will undergo challenges in the order:~High-FODMAP beverage + probiotic + L-Histidine~High-FODMAP beverage + placebo probiotic + L-Histidine~Low-FODMAP beverage + placebo probiotic + L-Histidine.~Challenges each last 5 days, but the FODMAP drinks and the L-Histidine capsules are only taken for the last three days. There is a 10 day washout period between challenges."
89067998|NCT04356326|Experimental|Aspirin 150 mg|Aspirin 150 mg / day (acetylsalicylic acid) once daily in the evening
89067999|NCT04356326|Placebo Comparator|Placebo|Placebo taken in the evening
89068000|NCT04349046||Patient who received the Exception stem|Patient who received the Exception stem between January 2008 and September 2012 and consented to the original data collection.
88812712|NCT03216590|Experimental|Compressive draping|After standard preparation similar to the no-intervention group, the shoulder will be draped with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA)
88812713|NCT04381754||AVG/AVF Treated with Passeo-18 Lux|Patients with failing dialysis access, treated lesions located between the anastomosis to the axillary-subclavian vein junction.
89068001|NCT04300049|Experimental|Change in Glycerol Ra|The difference in rate of lipolysis (glycerol Ra) during the basal state (-120 -0 minute) between subjects receiving glucagon and saline represents the change in whole body lipolysis caused by glucagon.
89068002|NCT04278729|Experimental|Nephrotic Syndrome Arm|Patients diagnosed with Nephrotic syndrome will be in this arm.
89068003|NCT04278729|Experimental|Healthy Arm|Healthy volunteers will be in this arm.
89068004|NCT04234204|Experimental|Fezolinetant group|Participants will receive fezolinetant once daily for 24 weeks.
89068005|NCT04234204|Placebo Comparator|Placebo group|Participants will receive matching placebo for 12 weeks, and then receive fezolinetant for 12 weeks once daily.
89068006|NCT04227574|Experimental|Zero Time Exercise training + WhatsApp anti-inertia reminders|Subjects in this group will receive daily WhatsApp anti-inertia reminders from the research assistant to remind and encourage them to practice Zero Time Exercise.
89068007|NCT04227574|Active Comparator|Zero Time Exercise training alone|Subjects in this group will not receive any WhatsApp reminders from week 8 to 24.
88812714|NCT01521845|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
88812715|NCT01521845|No Intervention|control|This group is without omega 3 : just receives standard treatment
88812716|NCT05310344|Experimental|Patients with platinum-resistant recurrent epithelial ovarian cancer|
89068008|NCT04226716|Other|Multiparous, pregnant women|
89068009|NCT04224181||Women with HIV|Individuals with female nascent sex who have been diagnosed with HIV.
89068010|NCT04224181||Women without HIV|Individuals with female nascent sex who do not have HIV.
89068011|NCT04220970||BIA-ALCL|
89068012|NCT04216017|Placebo Comparator|Controls|Patients receiving lidocaine
89068013|NCT04216017|Active Comparator|Cases|Patients receiving Kenalog
89522869|NCT03393221|Experimental|SBWC+ER|Participants randomized to the Standard Behavioral Weight Control and Emotional Regulation (SBWC+ER) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. They receive the same information as the Standard Behavioral Weight Control group, but weekly sessions also include elements of TRAC, and it is designed to help teach emotion regulation skills to decrease overeating and sedentary behaviors and increase the likelihood of maintaining diet and exercise behaviors that are taught as part of SBWC interventions.
89522870|NCT03393221|Active Comparator|SBWC|Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
89068014|NCT04206813|Experimental|Intervention group|240 eligible women will receive a 2-dose regimen of Gardasil 9 at (0 and 6 months, followed by a rescue 3rd dose at month 12)
89068015|NCT04206813|Active Comparator|Control group|120 eligible women will receive the standard 3-dose regimen of Gardasil 9 at (0, 2, 6 months)
89068016|NCT04191421|Experimental|Treatment spartalizumab and siltuximab Phase I dose level 1|Arm 1 (Phase I dose level 1) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 6 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89522871|NCT03388853|Experimental|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
89522872|NCT03388853|Placebo Comparator|Placebo|Placebo once daily for four weeks
89522873|NCT03393143||Oregon patients|Adult Medicaid patients with back pain who get their care in community health clinics in Oregon
89068017|NCT04191421|Experimental|Treatment spartalizumab and siltuximab Phase I level 2|Arm 2 (Phase I dose level 2) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 11 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89068018|NCT04191421|Experimental|Treatment spartalizumab and siltuximab phase I level 2a|Arm 3 (Phase I dose level 2a) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab 9 mg/Kg IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89068019|NCT04191421|Experimental|Treatment spartalizumab and siltuximab phase II|Arm 4 (Phase II ) Participants receive spartalizumab 300 mg IV over 30 minutes on day 1 and siltuximab at dose determined in Arm 1 to 3 IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89068020|NCT04179903|Active Comparator|Gym Trainer|Physical Activity program is performed in a group in a gym (Gym Group Training-GGT), with activity sessions conducted by a trainer graduated in Science and Techniques of Preventive and Adapted Physical Activity
89068021|NCT04179903|Active Comparator|Individual Home|Physical Activity program is performed at home individually (Individual Home Training-IHT), without the supervision of a trainer during the exercise session.
89068022|NCT04142125|Experimental|Experimental (riva + ASA)|Rivaroxaban 2.5mg bid + aspirin 81mg qd
89068023|NCT04142125|Active Comparator|Control (ASA alone)|Aspirin 81 mg qd
89068024|NCT04133194|Experimental|1600 mg Asacol (mesalazine)|1600 mg mesalazine (Asacol) treatment regimen (1 tablet per day) for a year
89068025|NCT04133194|Active Comparator|800 mg Asacol (mesalazine)|800 mg mesalazine (Asacol) treatment regimen (3 tablets per day) for a year
89068026|NCT04123379|Experimental|Cohort A|NSCLC: Nivolumab + BMS-813160
89068027|NCT04123379|Experimental|Cohort B|NSCLC: Nivolumab + BMS-986253
89068028|NCT04123379|Experimental|Cohort C|HCC: Nivolumab
89068029|NCT04123379|Experimental|Cohort D|HCC: Nivolumab + BMS-813160
89068030|NCT04123379|Experimental|Cohort E|HCC: Nivolumab + BMS-986253
89068031|NCT04122183|Experimental|Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation) and asked to complete the iManage Program. Six months after the screening participants will be asked if they visited an audiologist.
89068032|NCT04122183|No Intervention|Delayed Program Group|Following a failed hearing screening, participants will be offered the standard of care (information sheet recommending a comprehensive hearing evaluation). Six months after the screening participants will be asked if they visited an audiologist and they will be given the opportunity to complete the iManage Program.
89068033|NCT04104360|Experimental|Galacto-oligosacchardies|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
89068034|NCT04104360|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin three times daily for four weeks
89068035|NCT04103567|Experimental|Biological collection|"Fecal samples collected at different times : During inclusion consultation with surgeon, after neoadjuvant treatment and before surgery,~In parallel to this fecal collection, standardized clinical data will be entered into a database"
89068036|NCT04101630||Participants with Pulmonary Hypertension|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
89068037|NCT04101630||Healthy Volunteers|Participants will undergo activity monitoring for 12 weeks, at baseline and once a year for 3 years. Patient reported outcomes will be collected including Quality of Life questionnaires [emphasis-10, Minnesota Living with Heart Failure (MLHF), and SF-36 surveys], medication changes, hospitalization, and death.
89068038|NCT04101539|Active Comparator|Standard Ablation (PVI)|Patients in this arm will receive standard ablation for atrial fibrillation (wide-area circumferential ablation to achieve pulmonary vein isolation [PVI]).
89068039|NCT04101539|Experimental|OPTIMA Ablation|Patients in this arm will receive standard PVI ablation and supplemental ablation of reentrant driver sites identified by OPTIMA analysis as sites likely supportive of persistent atrial fibrillation.
89690442|NCT03574779|Active Comparator|Cohort C: Arm 1: Participants receiving platinum plus taxane|Participants are expected to receive 1 run-in cycle (up to 5 weeks) of carboplatin-paclitaxel during pre-screening. After confirmation that the tumor is homologous recombination-deficient (HRd). Participants will then be randomized to three 21-day cycles of platinum-taxane doublet chemotherapy (carboplatin plus paclitaxane). After interval debulking surgery (IDS), all participants will receive up to three 21-day cycles of adjuvant platinum-taxane doublet chemotherapy (and optional bevacizumab for participants deemed high-risk; third cycle is optional) followed by niraparib (and optional bevacizumab or bevacizumab biosimilar for participants deemed high- risk) maintenance treatment.
89690443|NCT03574779|Experimental|Cohort C: Arm 2: Participants receiving neoadjuvant Niraparib|Participants are expected to receive 1 run-in cycle (up to 5 weeks) of carboplatin-paclitaxel during pre-screening. After confirmation that the tumor is HRd, participants will be randomized to three 21-day cycles of neoadjuvant niraparib therapy. After IDS, all participants will receive up to three 21-day cycles of adjuvant platinum-taxane doublet chemotherapy (and optional bevacizumab for participants deemed high-risk; third cycle is optional) followed by niraparib (and optional bevacizumab or bevacizumab biosimilar for participants deemed high- risk) maintenance treatment.
89690444|NCT01922570|Experimental|Dietary supplements:parenteral nutrition|supplemental parenteral nutrition and enteral nutrition in case of failure (intake below 60% of energy needs) of enteral nutrition by day 3 after admission in the ICU or enteral nutrition only.
89690445|NCT04341883|Experimental|anti-PD-1|PD-1+albumin-bound paclitaxel
89690446|NCT05240300|Experimental|BX005-A|twice daily topical application x 8 weeks
89690447|NCT05240300|Placebo Comparator|Vehicle|twice daily topical application x 8 weeks
89690448|NCT00995761|No Intervention|biweekly schedule|docetaxel 40mg/m2 on day 1,15 every 4weeks cisplatin 40mg/m2 on day 1,15 every 4weeks
89690449|NCT00362271|Other|1|
89690450|NCT00635102|Active Comparator|Alcohol dependent|Alcohol dependent patients will receive 4 interventions
89690451|NCT00635102|Active Comparator|Healthy subjects|Healthy subjects will receive 4 interventions
89690452|NCT00996775|Active Comparator|standard care only|standard care only - harmful effects of alcohol use and NIAAA limits
89690453|NCT00996775|Experimental|Brief alcohol intervention|Group receiving brief alcohol intervention
89690454|NCT03041883|Experimental|Kpro with crosslinked graft-support|Patient will receive a crosslinked corneal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then one drop of riboflavin 0.1%/dextran 20% will be applied to 3 minutes on the de-epithelialized cornea for 15 minutes. Then, the source of ultraviolet A (UVA) will be irradiating the cornea for 30 minutes with a wavelength of 370 nanometer(nm) length with 5.4 joules(J)/ square centimeter (cm2) and 3 milliwatts(mW)/cm2. Meanwhile, the instillation of a drop of 0.1% riboflavin/dextran 20% continues every 5 minutes. Goggles against UVA are mandatory. The crosslinked graft-support will be forwarded to the surgeon according to standard procedure.
89690455|NCT03041883|Active Comparator|KPro with normal graft-support|Patient wil receive a normal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then, one drop of riboflavin 0.1% / dextran 20% will be applied to 30 secondes for 5 minutes on the de-epithelialized cornea.The minimally manipulated normal graft-support will be forwarded to the surgeon according to standard procedure.
89690456|NCT04332718|No Intervention|24 Hour Holter|Patients who are randomised to the 24 Hour Holter monitoring will be contacted within one month from randomisation. The repeat 24 Hour Holter result will be explained to the patient at the end of 30-day follow-up.
89690457|NCT04332718|Active Comparator|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
89223633|NCT05919407|Experimental|Pyridostigmine|The dose of pyridostigmine will be based on the patient's prior experience with pyridostigmine under the assumption that the patient already gained sufficient experience during their disease course to know which dose is effective for them as patients are advised by their treating neurologist to continually adjust their dose based on their symptoms and side effects.
89223634|NCT05919407|Placebo Comparator|Placebo (pyridostigmine)|"Same as Experimental, however capsules contain placebo."
89223635|NCT05919407|Experimental|Amifampridine (base) with modified release|Patients will receive amifampridine 2 dd 15 mg and amifampridine 2 dd 30 mg as add-on to the pre-study dose of pyridostigmine.
89223636|NCT05919407|Placebo Comparator|Placebo (amifampridine)|"Same as Experimental, however capsules contain placebo."
89223637|NCT05919394|Active Comparator|Triple treatment with medium doses of CSI/LABA/LA|Medium-dose inhaled triple therapy of inhaled corticosteroid: IC, long-acting beta-agonist: LABA and anticholinergic: LAMA
89522874|NCT03393143||California patients|Adult Medicaid patients with back pain who get their care in community health clinics in California
89223638|NCT05919394|Active Comparator|Treatment with high doses of CSI/LABA|High doses of of inhaled corticosteroid: IC and long-acting beta-agonist: LABA
89223639|NCT05919381|Experimental|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, combined with Paclitaxel Injection 80 mg/m2/time, D1, 8, 15 intravenous drip, a cycle every 28 days.
89223640|NCT05919381|Placebo Comparator|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, combined with Paclitaxel Injection 80 mg/m2/time, D1, 8, 15 intravenous drip, a cycle every 28 days.
89223641|NCT05919355|Experimental|Offered to try Komp|The intervention group consists of eligible service recipients in the three boroughs, who are given the offer to try Komp. Upon receiving the offer, the participant may take up to 14 days to decide. Participants who accept, receive a Komp and use it freely; participants who decline receive services as usual. Responses are documented. Participants who accepted the offer may at any point decide to stop and return the Komp to the municipality. The actual uses and effects of the technology, being a communication technology, depends on the actions of the app users (family and friends) and platform users (care services). We record the types of use and the frequency of use, but not the actual content that is transferred (e.g., we can count the number of pictures but not see the actual pictures). We can also distinguish between transfers originating from the app and the platform respectively, meaning that we can analyse the effects of private and professional use separately.
89522875|NCT04746521||Severe COVID-19 hospitalized patients|A total of 50 severe COVID-19 patients admitted to the Sub-Intensive Care Unit of A.O.R.N. Ospedali dei Colli, Cotugno Hospital, Naples (Italy) will be recruited, of which N=50 with thromboembolic complications (PE+) and N=50 without thromboembolic complications (PE-) balanced for age and sex of individuals.
89068040|NCT04095598||Syndesmotic injured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
89068041|NCT04095598||Syndesmotic uninjured group|The existing index test (ankle CT in neutral position), the new index tests (ankle CT in a stress position with extended-knee; ankle CT in a stress position with flexed-knee), and the reference test (MRI) will be applied. Foot and ankle ability measurement questionnaire (FAAM) will be applied with six months and one year after ankle CT.
89068042|NCT04095260||high school athletes|High school athletes, ages 14 to 18, who are participating in an organized sports training program.
89068043|NCT04091438|Experimental|TAK-925 Dose A + Placebo|TAK-925 112 milligram (mg), 9-hour intravenous infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by TAK-925 placebo-matching 9-hour intravenous infusion once on Day 3, Treatment Period 2.
89068044|NCT04091438|Placebo Comparator|Placebo + TAK-925 Dose A|TAK-925 placebo-matching 9-hour intravenous infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by, TAK-925 112 mg, 9-hour intravenous infusion once on Day 3, Treatment Period 2.
89068045|NCT04084769|Experimental|Group 1: MenACYW Conjugate vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 (NCT02199691) or MET43 (NCT02842853), received a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
89068046|NCT04084769|Experimental|Group 2: MenACYW Conjugate vaccine (Menveo Vaccine-primed)|Participants who received a single dose of Menveo vaccine in previous study MET50 or outside of Sanofi Pasteur trials, received a single IM dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
89068047|NCT04084769|Experimental|Group 3: MenACYW Conjugate vaccine + Trumenba vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Trumenba vaccine at Day 0 in the present study (MET59).
89068048|NCT04084769|Experimental|Group 4: MenACYW Conjugate vaccine + Bexsero vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Bexsero vaccine at Day 0 in the present study (MET59).
89068049|NCT04059224|Experimental|Arm A: advanced BRAF V600 wild-type/NRAS-mutant melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
89068050|NCT04059224|Experimental|Arm B: advanced BRAF V600 wild-type/NRAS wild-type melanoma|Patients will be treated with trametinib 2 mg once a day and dabrafenib 50 mg twice a day until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment.
89068051|NCT04045210|No Intervention|No Intervention|
89068052|NCT04045210|Experimental|Doula|
89068053|NCT04013685|Experimental|Subjects with Acute Leukemia or Myelodysplasic Syndrome, Myelofibrosis, or BPDCN|This is a non-randomized, single-arm study. All enrolled subjects will receive an allogeneic HCT with the Orca-T product.
89068054|NCT04002518||Small Screws|Patients who have surgically been treated with a 3.0mm, 4.0mm, or 5.0mm screw.
89068055|NCT04002518||Large Screws|Patients who have surgically been treated with a 6.5mm or 8.0mm screw.
89068056|NCT03994861|Active Comparator|Patients with musculoskeletal disorders|Patients with either shoulder pain, knee pain, hip pain, low back pain, pelvic pain or neck pain as their primary pain complaint, lasting for 6 weeks or longer
89068057|NCT03994861|Sham Comparator|Healthy controls|Age- and gender-matched healthy controls (without musculoskeletal pain)
89068058|NCT03958903|Experimental|Neurophysiological recording and stimulation of amygdala|Recording and stimulation of amygdala using Neuropace RNS devices at certain points through out the behavioral tasks.
89068059|NCT03940508|Experimental|MCI + IPT-A|Participants will receive the Making Connections Intervention (MCI) in addition to IPT-A for depression.
89068060|NCT03940508|Active Comparator|IPT-A Only|Participants will receive IPT-A for depression.
88812717|NCT04381676||Flipped Classroom|Residents in the flipped classroom were assigned a pre-class video lecture prior to completing the flipped classroom in-class case-based activity in groups of 2-3 each.
89068061|NCT03918850|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
89068062|NCT03918850|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
89068063|NCT03916978|Experimental|Participants receiving PRP treatment|Menopausal women minimum 45 years of age, receiving ovarian PRP treatment.
89068064|NCT03916978|Placebo Comparator|Control Group: Participants receiving Platelet Free Plasma|Women in menopause, 45-55 years old, treated with autologous PFP intra ovarian infusion.
89068065|NCT03911739|Experimental|BUP-XR|"Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.~The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
89068066|NCT03911739|Active Comparator|BUP-SL|"Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.~The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.)."
89068067|NCT03902080|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 24 weeks.
89068068|NCT03902080|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 24 weeks.
89068069|NCT03890367|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
89068070|NCT03890367|Active Comparator|Group 2: Nimenrix® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
89068071|NCT03890367|Active Comparator|Group 3: NeisVac-C® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of NeisVac-C® vaccine on Day 0.
89068072|NCT03882268|Experimental|MIYCN interventions|8 facilities run by 2 NGOs that will receive intensified MIYCN interventions.
89068073|NCT03882268|No Intervention|Comparison facilities|8 facilities run by 2 other NGOs, which will not receive any standardized MIYCN interventions.
89068074|NCT03877549|Placebo Comparator|Placebo|10cc 0.0625% bupivacaine
89068075|NCT03877549|Experimental|Low Dose|4mg Dexamethasone + 10cc 0.0625% bupivacaine
89068076|NCT03877549|Experimental|Higher Dose|8mg Dexamethasone + 10cc 0.0625% bupivacaine
89068077|NCT03871673|Active Comparator|Cornstarch|Ingestion of cornstarch, the standard treatment for hepatic Glycogen Storage Diseases.
89068078|NCT03871673|Experimental|Sweet manioc starch|Ingestion of sweet manioc starch, the starch in study.
89068079|NCT03868124|Experimental|Implant Group 1|G2-TR intraocular implant containing Travoprost 75 mcg with high elution rate, plus postoperative placebo eye drops.
89068080|NCT03868124|Experimental|Implant Group 2|G2-TR intraocular implant containing Travoprost 75 mcg with low elution rate, plus postoperative placebo eye drops.
89068081|NCT03868124|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
89068082|NCT03861923|Experimental|Dry needling and exercise|
89068083|NCT03861923|Sham Comparator|Sham dry needling and exercise|
89068084|NCT03824184|Active Comparator|Hysteroscopic evaluation|Hysteroscopic evaluation Active group : infection Manipulation of endometrium with saline
89068085|NCT03824184|Other|control group|Hysteroscopic evaluation Control group : No infection
89068086|NCT03803332|Active Comparator|Exposure Therapy|Participants receive 10 90-minute exposure therapy sessions for PTSD following the treatment procedures as outlined in the standard Prolonged Exposure therapy manual.
89068087|NCT03803332|Active Comparator|Interpersonal Psychotherapy|Participants receive 14 weekly 50-minute Interpersonal Psychotherapy sessions focused on the interpersonal sequelae of trauma in current daily life.
89068088|NCT03752099|Experimental|VERU-111 4.5mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
89068089|NCT03752099|Experimental|VERU-111 9mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
89068090|NCT03752099|Experimental|VERU-111 18mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
89068091|NCT03752099|Experimental|VERU-111 27mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
89068092|NCT03752099|Experimental|VERU-111 36mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
89068093|NCT03752099|Experimental|VERU-111 45mg|Daily dosing on Day 1-7 of each 21-day cycle for 3 cycles Treatment may continue past the planned three 21-day cycles until DLT or disease progression is observed.
89068094|NCT03751137||Breast Feeding|Infants who, when enrolled, are exclusively breast feeding.
89068095|NCT03751137||Formula Feeding|Infants who, when enrolled, are exclusively formula feeding.
89068096|NCT03747458|Active Comparator|OPN-375 186 μg BID|"Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks"
89068097|NCT03747458|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
89068098|NCT03733249|Experimental|Rimiducid and Rivogenlecleucel|"Rimiducid: to treat uncontrolled GVHD in patients who have received rivogenlecleucel Rimiducid will be given at 0.4 mg/kg weight (intravenous infusion)~No further rivogenlecleucel infusions are planned. Patients who received rivogenlecleucel in the BP-004 study will be evaluated for long-term safety and efficacy."
89068099|NCT03720717|Experimental|Opioid Tolerant - baclofen|
89068100|NCT03720717|Placebo Comparator|Opioid Tolerant - placebo|
89068101|NCT03720717|Experimental|Opioid Naive - baclofen|
89068102|NCT03720717|Placebo Comparator|Opioid Naive - placebo|
89690458|NCT03554265|Experimental|mTBI subjects|"mTBI subjects will receive recombinant human growth hormone replacement therapy daily for 6 months.~Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin~Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 6 will be dosed at 0.6 mg / day"
89690459|NCT03554265|No Intervention|Household Control Subjects|household control subjects will not receive any intervention.
89068105|NCT03704415|Active Comparator|Extended|Extended sinus surgery including all sinuses
89068106|NCT03704415|Active Comparator|Limited|Limited sinus surgery with partial ethmoidectomy
89068107|NCT03701321|Experimental|Phase I (DVd, venetoclax)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, dexamethasone PO on days 1, 8, and 15 of cycles 1-8, and venetoclax PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89068108|NCT03701321|Experimental|Phase II Arm D (DVd, venetoclax)|Patients receive venetoclax PO QD on days 1-21, daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89068109|NCT03701321|Active Comparator|Phase II Arm E (DVd)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89068110|NCT03678129|Other|AZD7325|Prepandemic. Single Dose of Placebo or AZD7325 10mg or AZD7325 20mg random order on visits separated by 1 week
89068111|NCT03678129|Other|Clobazam|Post pandemic: Single Dose Placebo or 5mg Clobazam random order on visits separated by 1 week
89068112|NCT03661684|Experimental|Prednisone in subjects with Diabetes|Group of subjects with diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
89690460|NCT03554265|Experimental|PASC subjects|"PASC subjects will receive recombinant human growth hormone replacement therapy daily for 9 months.~Drug: recombinant human growth hormone (rhgH); somatropin, Genotropin~Dose: month 0 - month 1 will be dosed at 0.4 mg / day month 1 - month 9 will be dosed at 0.6 mg / day"
89068113|NCT03661684|Experimental|Prednisone in control subjects|Group of subjects without diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
89690461|NCT03034005|Experimental|Patients with asthma|6 weeks treatment with 1600 ug budesonide
89690462|NCT03034005|No Intervention|Healthy Controls|Healthy controls to establish baseline level of Na/K pumps.
89690463|NCT04302220||high myopia|Population who have high myopia.
89690464|NCT04296916|Experimental|Intervention arm|medical reduction of IOP by eyedrops
89690465|NCT04296916|No Intervention|control arm|follow up without medication
89690466|NCT00635024|Experimental|Anti-thymocyte Globulin/Melphalan|Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)
89690467|NCT03544359|Active Comparator|Active tES|
89690468|NCT03544359|Sham Comparator|Sham/Inactive tES|
89690469|NCT01922648||2-4 months|Infants aged between 2 and 4 months (Group 1), who have not yet been exposed to RSV
89690470|NCT01922648||6 - 12 months|Infants aged between 6 and 12 months (Group 2), who will have had exposure to one single RSV season in the winter of 2011/12
89690471|NCT01922648||3 - 6 years|Children aged between 3 and 6 years (Group 3), who have been exposed to RSV over several winter seasons
89690472|NCT02975193|Active Comparator|Control group|"Healthy adults ages 18-90 without movement disorders, psychiatric disorders, or dementia. They will complete computer games and questionnaires at one time point.~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
89690473|NCT02975193|Active Comparator|Parkinson's disease group with DBS|"Parkinson's disease patients who have elected to receive DBS for treatment of their side effects of PD consent to complete computer games and questionnaires at baseline, computer games during deep brain stimulation, and computer games and questionnaires up to 2 years after surgery.~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
89690474|NCT04865458|Experimental|HEC89736 treatment|HEC89736 tablets,25 mg, 50 mg, 100 mg, 150 mg, 200 mg, QD, 28 days for each cycle
88812718|NCT04381676||Traditional Classroom|Residents in the traditional classroom were assigned a pre-class reading assignment followed by a 44-minute lecture that was delivered in-person using PowerPoint.
89068115|NCT03620071|Experimental|Intervention|Receipt of a novel mobile-health tool, GoalKeeper Plus Standard Care
89068116|NCT03620071|Experimental|Control|Standard Care
89068117|NCT03585153||T1D|Individuals with type 1 diabetes
89068118|NCT03585153||Control|Individuals without type 1 diabetes
88812719|NCT03216434|Experimental|PTSD Diagnosed|Veterans exposed to combat and diagnosed with PTSD. MRI using DaTscan.
89068119|NCT03585153||Aab+|Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies
89068120|NCT03585153||MODY|Individuals with monogenic diabetes, or maturity-onset diabetes of the young (MODY)
89068121|NCT03561376|Other|Single arm - split scar study|Surgical closures, at least 4.5cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half
89068122|NCT03560037|No Intervention|Standard Colonoscopy|Patients randomly assigned to this group will receive standard colonoscopy without the use of a distal attachment.
89068123|NCT03560037|Experimental|Endocuff Vision Assisted Colonoscopy|Patients randomly assigned to this group will receive colonoscopy with the use of the Endocuff Vision distal attachment.
89068124|NCT03550443|Experimental|RTA 402(Bardoxolone methyl)|Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
89068125|NCT03550443|Placebo Comparator|Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
89068126|NCT03536052|Experimental|Virtual Heart Guided Ablation|
89068127|NCT03520712|Experimental|valoctocogene roxaparvovec Open Label|Single administration of BMN270 at a dose of 6E13 vg/kg
89068128|NCT03497637|Active Comparator|Pd/Pa guided Therapy|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
89068129|NCT03497637|Active Comparator|FFR guided therapy|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
89068130|NCT03486938|Placebo Comparator|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
89068131|NCT03486938|Experimental|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
89068132|NCT03469271|Other|Training and Placebo|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks
89068133|NCT03469271|Other|Sham Training and Vitamin D3 Metabolite|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks
89068134|NCT03469271|Other|Training and Vitamin D3 Metabolite|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks
89068135|NCT03469271|Other|Sham Training and Placebo|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks
89068136|NCT03458260|Experimental|Experimental|Pixantrone plus rituximab, ifosfamide and etoposide.
89068137|NCT03438188|Experimental|Smoker Group|The smokers group will be scanned on 2 occasions: (1) after a 4 day monitored practice quit attempt (biochemically verified), and (2) after 4 days of smoking as usual (order counterbalanced).
89068138|NCT03438188|No Intervention|Non-Smoking Comparison Group|Healthy non-smokers will complete one period (comparable to abstinence arm) of the study to serve as a baseline comparison group.
89068139|NCT03431467|No Intervention|Control|VA-ECMO alone per standard clinical protocol.
89068140|NCT03431467|Experimental|Experimental|VA-ECMO with early institution of Impella CP LV venting
89068141|NCT03430921|Other|Enlighten™ Laser and a MLA Attachment|Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment
88812720|NCT03216434|Experimental|Designated Combat-Experienced Controls|Veterans exposed to combat, but never diagnosed with PTSD. MRI using DaTscan.
88812721|NCT01522391|Placebo Comparator|Placebo for DPK-060 ointment|
88812722|NCT01522391|Experimental|DPK-060 1% ointment|
88812723|NCT04381520|Experimental|Heat-sensitive moxibustion plus antihypertensive drugs|
88812724|NCT04381520|Active Comparator|Antihypertensive drugs|
89068142|NCT03425279|Experimental|BA3011|Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor.
89068143|NCT03425279|Experimental|Combination Therapy|Phase 2: BA3011 in combination with PD-1 inhibitor.
89068144|NCT03381573||Roflumilast exposed|Patients with COPD ever exposed to Roflumilast
89068145|NCT03381573||Roflumilast unexposed|Patients with COPD never exposed to Roflumilast
89068146|NCT03376672|Experimental|Ixazomib,lenalidomide,dexamethasone|Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle
89068147|NCT03376672|Experimental|High risk maintenance arm|Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle
89068148|NCT03376672|Experimental|Standard and low risk maintenance arm|Lenalidomide
89068149|NCT03357445|Other|Subgroup 1|Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD
89068150|NCT03357445|Other|Subgroup 2|Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner
89068151|NCT03355209|Experimental|ZX008 0.2 or 0.8 mg/kg/day|Part 1: ZX008 is supplied as an oral solution. Subjects will be randomized to receive 1 of 2 doses of ZX008 0.2 mg/kg/day or 0.8 mg/kg/day.
89068152|NCT03355209|Placebo Comparator|Matching Placebo|Part 1: Matching ZX008 placebo is supplied as an oral solution.
89068153|NCT03355209|Experimental|Open-Label|Part 2: ZX008 is supplied as an oral solution. Study medication will be administered twice a day (BID) in equally divided doses.
89068154|NCT03304730||facet inflammatory signs|patients with facet inflammatory signs identified on MRI
89068155|NCT03304730||no facet inflammatory signs|patients without facet inflammatory signs identified on MRI
89690475|NCT03005379|Active Comparator|1|Fecal Microbiota Therapy (FMT)
89690476|NCT03005379|Placebo Comparator|2|Placebo
89068156|NCT03302234|Experimental|Pembrolizumab + Ipilimumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
89068157|NCT03302234|Active Comparator|Pembrolizumab + Placebo|Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
89068158|NCT03290937|Experimental|Treatment (irinotecan hydrochloride, cetuximab, utomilumab)|Patients receive irinotecan hydrochloride IV over 90 minutes and cetuximab IV over 1-2 hours on days 1 and 15, and utomilumab IV over 1 hour on day 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89068159|NCT03272373|Other|Monoblock|Subjects that receive the NexGen TM Monoblock Tibia
89068160|NCT03272373|Other|Modular|Subjects that receive the NexGen TM Modular Tibia
89068161|NCT03247023||Integra Cadence Total Ankle System|
89068162|NCT03245892|Experimental|Carboplatin and Paclitaxel Chemotherapy With Nivolumab (Closed)|Patients will be treated with nivolumab plus standard of care dose dense paclitaxel and carboplatin for three cycles, where each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen administered as adjuvant treatment. Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle. Carboplatin dose calculation instructions can be found in Appendix 4. Nivolumab 360mg will be infused IV over approximately 30min on Day 1 of Cycles 1-6. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks.
89068163|NCT03245892|Experimental|Nivolumab plus Ipilimumab plus Paclitaxel & Carboplatin|Patients will be treated with nivolumab plus ipilimumab plus standard of care dose dense paclitaxel & carboplatin chemotherapy for 3 cycles (up to a maximum of six), each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen. Paclitaxel 80mg/m2 IV will be administered over approx 1 hour on Days 1,8, & 15 of each 21 day cycle. Carboplatin AUC6 will be administered as an approx 30 minute IV infusion, following paclitaxel admin on Day 1 of each 21 day cycle. Nivolumab 360mg will be infused IV over approx 30 min on Day 1 of Cycles 1-6 (to 9) of each 21 day cycle. Ipilimumab 1mg/kg will be infused IV over approx 30 min on Day 1 of Cycles 1 & 3, as well as Cycle 4 & Cycle 6. Of note, if patients receive more than 3 cycles in the pre-operative setting, then ipilimumab will be administered with the first & third cycle in the post-operative setting. Nivolumab will then be infused Day 1 of each 28 day maintenance phase cycle.
89068164|NCT03243591|Active Comparator|Livionex gel|Brushing area of mucositis with Livionex gel for 30 days
89068165|NCT03243591|Active Comparator|Aquafresh gel|Brushing area of mucositis with Aquafresh gel for 30 days
89068166|NCT03218137|Other|Adenosine/ Verapamil Arm|"Adenosine: 0.84 mg/kg IV (140 mcg/kg/minute IV for 6 minutes) Verapamil: 0.15 mg/kg IV~Adenosine is known to terminate ventricular arrhythmias that are due to triggered activity (ref Lerman). To study the effects of adenosine on PVC, the investigators will administer Verapamil to slow down the heart initially and adenosine after catheters are introduced to patients who are being treated for symptomatic PVC and have consented to treatment with an invasive electrophysiology study and catheter ablation."
89068167|NCT03202303|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
89068168|NCT03202303|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
89068169|NCT03157102|Experimental|HFNC group|
89068170|NCT03157102|Other|Standard Oxygen Therapy group (STO group)|
89068171|NCT03155100|Experimental|Carfilzomib, elotuzumab, dexamethasone|Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv)
89068172|NCT03126630|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
89068173|NCT03126630|Experimental|Group II (anetumab ravtansine, pembrolizumab)|Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.
89068174|NCT03125720|Experimental|GUIDED group|Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
89068175|NCT03125720|No Intervention|Control group|No Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.
89068176|NCT03066908|Experimental|Single Arm|Sinopsys® Lacrimal Stent
89068177|NCT03060473|Experimental|Azithromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
89690477|NCT03182920|Experimental|200 mg Lasmiditan (Group 1 Elderly)|200 milligrams (mg) lasmiditan on Day 1 of 1 of 2 dosing periods.
89690478|NCT03182920|Placebo Comparator|Placebo (Group 1 Elderly)|Placebo on Day 1 of 1 of 2 dosing periods.
89690479|NCT03182920|Experimental|200 mg Lasmiditan (Group 2 Young)|200 mg lasmiditan on Day 1.
89690480|NCT03185182|Experimental|experimental group|"185 megabecquerel (MBq) of Ioflupane I-123 (DaTSCAN) will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.The images from the DaTSCAN investigation will be analyzed and anatomically compared to CT-scan from the same the patient. Any adverse effects during the study will be reported.~This is a exploratory open single arm trial, including a small number of patients with suspected disseminated renal cell carcinoma."
89690481|NCT02992275|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
89690482|NCT04089280|Experimental|Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: Sanprobi Barrier-multispecies probiotic product, 2,5 x10 9 cfu/gram or placebo, cross-over design
89690483|NCT04089280|Placebo Comparator|carrier material of Sanprobi Barrier-multispecies probiotic|A randomized placebo-controlled, parallel-group study, crossover-design. Intervention: placebo comparator (carrier material of Sanprobi Barrier-multispecies probiotic product , not containing bacterial strains,similar appearance as the probiotic, cross-over design
89690484|NCT03187678|Experimental|Selexipag|Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.
89690485|NCT03192826|Active Comparator|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
89690486|NCT03192826|Active Comparator|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
89690487|NCT03192826|Placebo Comparator|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
89690488|NCT03285724|Experimental|Harpoon Medical Transapical device TSD-5|This is a prospective, single arm, nonrandomized, early feasibility study to evaluate the safety and performance of the Harpoon Medical Device.
89690489|NCT03287674|Experimental|Patient group|"All patients receive the same treatment. All patients are treated with one dose of Ipilimumab 14 days prior to surgical removal of tumor tissue for TIL expansion. Hospitalization for TIL treatment is approximately 3 weeks.~The patients are admitted to hospital on day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1. The first of 4 doses of Nivolumab is administered on day -2 and every 2 weeks for at total of 4 doses.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 13.~Interleukin-2 is administered as a daily low-dose subcutaneous injection for a total for 14 days."
89068178|NCT03060473|Active Comparator|Erythromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
89068179|NCT03047213|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89068180|NCT03025386|Other|Adult cochlear implant users|Evaluation of a concordance between the mismatch negativity amplitude mesured by electroencephalography and the capacity of logatoms discrimination by using a logatoms test
89068181|NCT02991625|Experimental|Placebos|Chronic Back Pain participants will enter an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
89068182|NCT02991625|Other|Waitlist|Chronic Back Pain participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar.
89068183|NCT02991625|Other|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
89068184|NCT02949284|Experimental|Arm I (androgen receptor ARN-509, radical prostatectomy)|Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.
89068185|NCT02949284|Active Comparator|Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)|Patients receive GnRH agonist SC on day 1, androgen receptor antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.
89068186|NCT02949284|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy.
89068187|NCT02891954|Experimental|Single arm|Healthy volunteers will receive canagliflozin to assess pharmacodynamic responses to drug.
89068188|NCT02860702|Experimental|Exclusive Human Milk|All infants randomized to this arm will receive exclusive human milk diet with addition of human milk derived fortifier from birth to 30 days post initiation of feedings after initial palliative cardiac surgery
89068189|NCT02860702|Active Comparator|Human/Bovine Milk|All infants randomized to this arm will receive exclusive human milk diet prior to randomization and will use either human and/or bovine milk and fortifier per the institution's standard practice 30 days post initiation of feedings after initial palliative cardiac surgery
89068190|NCT02766231||Physica CR|Patients who have undamaged and functional collateral and posterior cruciate ligaments for the group requiring Physica CR
89068191|NCT02766231||Physica PS|Patients who have undamaged and functional collateral ligaments for the group requiring Physica PS
89068192|NCT02754596|Experimental|Travoprost Intraocular Implant, high elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
89068193|NCT02754596|Experimental|Travoprost Intraocular Implant, low elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
89068194|NCT02754596|Active Comparator|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol, a beta blocker, will be dosed twice daily
89068195|NCT02744898|Experimental|Carboplatin AUC and Abraxane 100mg/m2|
89068196|NCT02724540|Experimental|Arm 1 - BE|Lobar or segmental bland embolization (BE) with microspheres (50-500 microns) to 2-5 heartbeat stasis.
89068197|NCT02724540|Experimental|Arm 2 - TACE|Lobar or segmental lipiodol conventional transarterial chemoembolization (TACE). Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
89068198|NCT02724540|Experimental|Arm 3 - DEB - CLOSED|Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU monthly until entire tumor burden is treated.
89068199|NCT02652195|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
89690490|NCT00634244|Experimental|Arm A (carboplatin and topotecan hydrochloride)|Patients receive carboplatin and topotecan hydrochloride IV continuously over 24 hours on days 1-5.
89068200|NCT02652195|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
89068201|NCT02565225||RheumaLive App use|RheumaLive App use and evaluation of feasibility
89068202|NCT02565225||RheumaLive App use & threshold values|RheumaLive App use and evaluation of feasibility
89068203|NCT02425345|Experimental|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults
89068204|NCT02425345|No Intervention|Usual Activity Control|Usual activity
89690491|NCT00634244|Experimental|Arm B (alvocidib, mitoxantrone, cytarabine)|Patients receive alvocidib IV over 4.5 hours QD on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9.
89690492|NCT00634244|Experimental|Arm C (sirolimus, mitoxantrone, etoposide, cytarabine)|Patients receive sirolimus PO QD on days 2-9, mitoxantrone hydrochloride IV over 15 minutes QD, etoposide IV over 1 hour QD, and cytarabine IV over 3 hours QD on days 4-8 or 5-9. (Closed to accrual)
89690493|NCT03194698|Experimental|MGX and Intense Pulsed Light Treatment (IPL)|Treatment with 4 visits and 4 treatments of IPL and Meibomian Gland Expression (MGX)
89690494|NCT03194698|Active Comparator|Meibomian Gland Expression (MGX)|Treatment with 4 visits and 4 treatments of MGX only
89690495|NCT01922804|Experimental|K2 vitamin|K2 vitamin 375 microgram a day for 3 years
89690496|NCT01922804|Placebo Comparator|placebo|1 tablet a day for 3 years
89690497|NCT03289858|Experimental|Exparel (Liposomal Bupivacaine)|"Exparel (liposomal bupivacaine) is FDA approved, with a labeled indication of single-dose infiltration into the surgical site to produce postsurgical analgesia."
89690498|NCT03289858|Placebo Comparator|Saline Control|Saline Solution (Sodium Chloride)
89690499|NCT04396418|Experimental|Intervention arm|A 16-week blended learning programme targeting stroke prevention and rhythm control therapy at the healthcare professional level, with controlled assessments, a commitment to change plan, and reinforcement actions
89690500|NCT04396418|Other|Control arm|No added education of healthcare professionals
89690501|NCT00375856|No Intervention|1|DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee
89690502|NCT00375856|Experimental|2|Rotating Platform Knee
89690503|NCT03418714|Experimental|Salvinorin A administration|All volunteers will be assigned to the salvinorin A administration arm.
89690504|NCT01922960|Other|micro-imaging|"Sublingual or subconjunctival micro-imaging of the microcirculation taken for 3 minute intervals at certain timepoints.~Timepoints for burn/trauma subjects: Day0, Day1,Day2,Day6 & Day7 Timepoints for general surgery population: post-induction, prior to resection, after resection,& closing of surgical wound."
89690505|NCT03153488|Experimental|Methylphenidate|Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication
89690506|NCT03153488|Experimental|Amphetamine|Adult subjects (ages 18-45) receiving an Amphetamine derivative medication
89690507|NCT03194776|Experimental|LLG783|Patients will receive LLG783 i.v. infusion every 4 weeks for 12 weeks.
89690508|NCT03194776|Placebo Comparator|Placebo|Patients will receive placebo to LLG783 i.v. infusion every 4 weeks for 12 weeks.
89690509|NCT03421210|Other|Nicotine Replacement Therapy|Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.
89690510|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
89690511|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
89690512|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.
89690513|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
89690514|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.
89690515|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
89690516|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
89223642|NCT05919355|No Intervention|Services as usual|"At a certain point, because the burrough runs out of Komp units to distribute or because they get halfway through the list, recruitment stops and no one else is offered to try Komp. All names on the burrough's list below this juncture are in the services as normal arm, which is the control group in this intention-to-treat trial. Services as normal means that the trial has no bearing on the participant (apart from having been informed about the project and being given the chance to opt out). They continue to receive needs-based services from their municipality, like they would have if there was no trial."
89223643|NCT05919303||Patient presenting with obstructive jaundice referred for CT evaluation|
89223644|NCT05919212|Experimental|Patients with HER2 positive Breast cancer Stage IV|"All eligible patients to T-Dxd as second line treatment will receive T-Dxd intravenous at dose of 5,4 mg/kg every three weeks until progression disease or unacceptable toxicities.~Subjects eligible to T-Dxd and who agree to participate in the study will undergo serial blood samples for liquid biopsy (LB) until progression disease."
89223645|NCT05919199||AML patients, de novo or refractory/relapsed|The investigators will collect bone marrow cells under standard clinical work-up after 18F-FDG PET/CT scan and correlate the FDG signal with extramedullary infiltration, histopathological, genomics features of the patients to explore the prognostic value of FDG signal in AML.
89223646|NCT05919186|Experimental|EmrbyORP continued at high O2|Antioxidants supplementation Every 12 hours (3.5 μL)
89223647|NCT05919186|Experimental|EmrbyORP at baseline with high O2|Antioxidants supplementation At baseline only (6.5 μL)
89223648|NCT05919186|Experimental|EmrbyORP continued at low 02|Antioxidants supplementation Every 12 hours (3.5 μL)
89223649|NCT05919186|Experimental|EmrbyORP at baseline with low o2|Antioxidants supplementation At baseline only (6.5 μL)
89223650|NCT05919121|Active Comparator|Therapeutic exercise group|Therapeutic exercise group, group A.
89223651|NCT05919121|Experimental|hydrocortisone phonophoresis group|This group (B) will receive the same exercise program in addition to hydrocortisone phonophoresis. Patients will receive topical medium phonophoresis of 10% hydrocortisone gel.
89223652|NCT05919121|Experimental|hydrocortisone iontophoresis group|This group (C) will receive the same exercise program in addition to hydrocortisone iontophoresis.
89223653|NCT05919095|Experimental|Carrilizumab plus GEMOX|Carrilizumab combinated With gemcitabine and oxaliplatin (GEMOX)
89223654|NCT05919043|Experimental|Upper limb-based movement priming (UL-priming)|The upper limb priming task will include rhythmic, bilateral priming involving the movement of at least one major joint in the upper limbs (shoulder, elbow, wrist).
89223655|NCT05919043|Active Comparator|Stimulation-based priming (Stim priming)|Participants will receive facilitatory transcranial direct current stimulation (tDCS) through a constant current stimulator.
89223656|NCT05919043|Active Comparator|Lower limb-based movement priming (LL-priming)|Participants will perform high-intensity interval-based aerobic exercise on a treadmill or recumbent stepper.
89223657|NCT05919043|Sham Comparator|Sham priming|Participants will listen to a 1 Hz metronome for 20 minutes as a form of auditory stimulation during the sham priming session.
89223658|NCT05919017|Placebo Comparator|Placebo|Placebo implant, subcutaneous abdominal implant, single dose, 10 placebo tablets implanted
89223659|NCT05919017|Experimental|Naltrexone implant 0.9 g|Naltrexone implant, abdominal subcutaneous implantation, single administration, implantation dose is 0.9g (6 naltrexone implants+4 placebo tablets)
89223660|NCT05919017|Experimental|Naltrexone implant 1.5 g|Naltrexone implant, abdominal subcutaneous implantation, single dose of 1.5g (10 naltrexone implants)
89223661|NCT05918991|Experimental|Language Intervention|The language intervention will include 18 weeks of 20-25 minutes of intervention approximately 4 days per week. The language intervention is delivered via shared book reading and focuses on English language vocabulary development as well as development of syntax knowledge and expressive language.
89223662|NCT05918991|Experimental|Daily Report Card|The Daily Report Card group will receive the Daily Report Card intervention for 18 weeks.
89223663|NCT05918991|Experimental|Combined Language and Daily Report Card|Participants in this arm will receive a combination of the language intervention and the behavioral intervention. The interventions will be implemented simultaneously for 18 weeks.
89223664|NCT05918991|No Intervention|School As Usual|Participants in the School as Usual Arm will receive neither the Behavioral Intervention nor the Language Intervention. There will be no restrictions, however, on interventions or supports that students may receive outside of the study either implemented through standard school protocol or accessed by parents. Thus, the School as Usual Arm provides a real-world practice comparison for the three active treatment groups.
89223665|NCT05918965|Active Comparator|Vagus Nerve Stimulation with 10 Hertz|"Twelve weeks home therapy with transcutaneous electrical neurostimulation (TENSeco®, CE197, Schwa-Medico Gmbh), transcutaneous 2-channel nerve stimulator.~Matching ear electrode 3 DTS.~Stimulation frequency: 10 Hertz~Intensity: sensitive threshold; clearly perceptible, but pleasant~Form of stimulation: biphasic~Duration: 30 min~Position: left ear~Frequency: daily, in the evening, when all daily activities are done"
89690517|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.
89690518|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 1|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
89690519|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 2|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
89690520|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 3|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
89690521|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 4|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
89690522|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 5|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
89068205|NCT02350764|Experimental|Nivolumab|Patients will begin treatment with nivolumab IV 3mg/kg and ipilimumab 1mg/kg. Treatment with nivolumab will continue every 2 weeks (+/- 3 days) thereafter and treatment with ipilimumab will continue every 6 weeks (+/- 3 days) thereafter. Treatment will continue until protocol-defined toxicity, confirmed progression of disease*, withdrawal of consent, or death.
89068206|NCT02095132|Experimental|Treatment (irinotecan hydrochloride, adavosertib)|Patients receive irinotecan hydrochloride PO and adavosertib PO on days 1-5. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
89068207|NCT01922388||Early Motor Complication|This group is composed of PD patients with motor complications of 3 years or less. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
89068208|NCT01922388||Late Motor Complication|This group is composed of PD patients with motor complications of more than 3 years. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
89068209|NCT01919086|Experimental|Patients with Multiple Myeloma|This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.
89068210|NCT01908543|Experimental|Iron treatment|"INTERVENTION: Ferrous sulphate 200mg oral tablet~This is a single arm study. Individuals in this arm will~have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods~receive a single tablet of ferrous sulphate 200mg~fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months~have a second blood sample later that day (20 mls of blood~Total number of participants in arm = 100"
89068211|NCT01867333|Experimental|Arm 1 - Enzalutamide alone|Enzalutamide alone. Enzalutamide will be given at the standard dose of 160 mg daily.
89068212|NCT01867333|Experimental|Arm 2 - Enzalutamide with Prostate-Specific Antigen (PSA)-TRICOM|Enzalutamide with PSA-TRICOM. Enzalutamide will be given at the standard dose of 160 mg daily with vaccine given week 1 (vaccinia-PSA-TRICOM, 2x10(8) infectious units subcutaneously) and then week 3, 5 and then monthly fowlpox-vaccine (1x10(9) infectious units subcutaneously).
89068213|NCT01833715|Active Comparator|Morphine|morphine group 0.08 mg / kg, to start surgery
89068214|NCT01833715|Experimental|Methadone|methadone group 0.08 mg / kg, to start surgery
89068215|NCT01534494|Experimental|psilocybin|
89068216|NCT01428635|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD in the absence of disease progression or unacceptable toxicity.
89068217|NCT01273441|Active Comparator|Sequential treatment:|
89068218|NCT01273441|Experimental|Concomitant treatment|
89068219|NCT01208389|Experimental|voretigene neparvovec-rzyl (AAV2-hRPE65v2)|Administration of study agent (AAV2-hRPE65v2) to the previously, uninjected contralateral eye:
89068220|NCT00968500||Parents Who Have Lost a Child to Cancer|The overall goal of the proposed cross-sectional study is to obtain information necessary to the development of an effective Meaning-Centered Grief Intervention for parents who lost a child to cancer. In order to identify a subset of parents with whom we will conduct qualitative interviews with a subset of participants to address Aims 1 and 2, we will first screen participants to determine their levels of Prolonged Grief Disorder symptoms using a quantitative assessment (PG-13). The screening measure (PG-13) and the additional questionnaires included in the quantitative battery of measures will be analyzed to achieve Aim 3.
89068221|NCT00856037|Experimental|Treatment (doxorubicin hydrochloride, topotecan hydrochloride)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes on day 6 of course 1 and on days 6, 13, and 20 of courses 2-5. Patients also receive topotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
89522876|NCT04746521||Healthy controls (comparator group)|"As control group (CTRL), we will recruit a total of N=50 healthy subjects (never diagnosed with Sars-Cov2 infection) among the volunteer blood donors attending the U.O.C. Divisione di Immunologia Clinica, Immunoematologia, Medicina Trasfusionale e Immunologia dei Trapianti, Dipartimento di Medicina Interna e Specialistica, AOU, L. Vanvitelli University of Campania (Naples, Italy)."
89068223|NCT00670852||Total shoulder replacement with anchor peg glenoid and autologous bone grafting|Patients who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting from the investigator of this study will be recruited for this study.
89068224|NCT00602797|Experimental|Treatment (vinorelbine tartrate, paclitaxel)|Patients receive vinorelbine tartrate IV over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks.
89068225|NCT00568139||Mitotane|Patients with adrenocortical carcinoma treated with mitotane monotherapy
89068226|NCT00550615|Experimental|Dasatinib Dose Escalation|Phase 1 employed a standard 3+3 dose-escalation design to assess safety, MTD and dose-limiting toxicity (DLT). Maximum Tolerated Dose (MTD) was defined as the next lowest dose level below where ≥ 2/3 or ≥ 3/6 patients experience dose limiting toxicities in cycle 1.
89068227|NCT00550615|Experimental|Dasatinib Maximum Tolerated Dose|Once the maximum tolerated dose is determined, an additional patients will be enrolled into the Phase II portion of this trial.
89068228|NCT00471848|Experimental|Treatment Arm|Antithymocyte globulin with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent
89068229|NCT00006721|Active Comparator|Arm I (CHOP only)|"Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day~1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02)"
88812725|NCT00837902|Experimental|Atenolol|"There is only 1 arm to this study. Intervention: All participants received atenolol. Genotyping for GRK5 was performed to identify if participants were GLN/GLN, GLN/LEU, or LEU/LEU.~Heart rates were measured at rest, and as participants performed graded incremental exercise on a supine bicycle ergometer (at 25, 50, and 75 W for 2 minutes each) twice, once before and once 2.5 hours after taking 25 mg of atenolol."
89522877|NCT04746521||COVID-19 patients compared with vaccinated subjects|"Patients with previous Sars-CoV-2 infection who did not undergo vaccination;~Patients with previous Sars-CoV-2 infection who undergone vaccination~Subjects without previous Sars-CoV-2 infection who undergone vaccination"
89068230|NCT00006721|Experimental|Arm II (CHOP + rituximab)|Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141.
89068231|NCT00006721|Experimental|Arm III (CHOP + tositumomab)|Patients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141.
89068232|NCT04300582|Active Comparator|Standard pharmaco-invasive strategy|Cardiac catheterization 3 to 24 hours after thrombolytic completion in STEMI patients.
89068233|NCT04300582|Experimental|Fast pharmaco-invasive strategy|Cardiac catheterization less than 3 hours after thrombolytic completion in STEMI patients.
89068234|NCT05296876||carotid endarterectomy|Patients who are treated with CEA under SSPC evaluation
89068235|NCT02873260|Experimental|TetraVax-DV-TV005 + rDEN3Δ30|Participants will receive the TetraVax-DV-TV005 vaccine at Day 0 and the rDEN3Δ30 virus at Day 180.
89068236|NCT02873260|Placebo Comparator|Placebo + rDEN3Δ30|Participants will receive placebo at Day 0 and the rDEN3Δ30 virus at Day 180.
89068237|NCT01030666|Experimental|doxycycline|"The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects~modified/simplified papilla preservation flap; scaling~Prefgel/Emdogain~0.12% chlorhexidine gluconate solution~Ibuprofen 400 mg (if necessary)~1% chlorhexidine gluconate gel (if necessary)"
89068238|NCT01030666|Placebo Comparator|placebo|"The patients of the control group will take placebo once a day for 7 days after regenerative therapy of an infrabony defect~modified/simplified papilla preservation flap; scaling~Prefgel/Emdogain~0.12% chlorhexidine gluconate solution~Ibuprofen 400 mg (if necessary)~1% chlorhexidine gluconate gel (if necessary)"
88812726|NCT01830374||Women with bulimia nervosa|This is not a treatment study. All participants will go through the same steps.
89068239|NCT01025752|Experimental|Arm 1|Ten session IVR-based cognitive behavior therapy intervention for chronic low back pain
89068240|NCT01025752|Active Comparator|Arm 2|Ten session face to face cognitive behavior therapy for chronic low back pain
89068241|NCT01030198|Experimental|Fresh surgical scars|Treatment of scars
89068242|NCT01030198|Experimental|Mature scars|Treatment of scars
89068243|NCT02873884||case-management|Patients will meet the case-manager 5 times per month during 1h30 in community living
89068244|NCT02873884||traditional nursing|Patients will meet the case-manager 2 times per month during 1h00 in hospital
89068245|NCT01301456|Placebo Comparator|Treatment Arm 1 (Stage 1A)|
89068246|NCT01301456|Experimental|Treatment Arm 2 (Stage 1A)|
89068247|NCT01301456|Experimental|Treatment Arm 3 (Stage 1A)|
89068248|NCT01301456|Experimental|Treatment Arm 4 (Stage 1A)|
89068249|NCT01301456|Placebo Comparator|Treatment Arm 5 (Stage 1B)|
89068250|NCT01301456|Experimental|Treatment Arm 6 (Stage 1B)|
89068251|NCT01301456|Experimental|Treatment Arm 7 (Stage 1B)|
89068252|NCT01301456|Experimental|Treatment Arm 8 (Stage 1B)|
89068253|NCT01301456|Placebo Comparator|Treatment Arm 9 (Stage 2)|
89068254|NCT01301456|Experimental|Treatment Arm 10 (Stage 2)|
89068255|NCT01301456|Experimental|Treatment Arm 11 (Stage 2)|
89068256|NCT01301456|Experimental|Treatment Arm 12 (Stage 2)|
89068257|NCT01301456|Experimental|Treatment Arm 13 (Stage 2)|
89068258|NCT01023256|Experimental|Group 1: MOR103, experimental|Biological: MOR103 0.3 mg/kg or placebo
89068259|NCT01023256|Experimental|Group 2: MOR103, experimental|Biological: MOR103 1.0 mg/kg or placebo
89068260|NCT01023256|Experimental|Group 3: MOR103, experimental|Biological: MOR103 1.5 mg/kg or placebo
89068261|NCT04303936|Other|Patients with severe HA under FVIII concentrates prophylaxis|
89068262|NCT01023022||Medtronic CareLink® Network|"Patients with implanted Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices, who will be monitored by the Medtronic CareLink® System.~The System consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website."
89068263|NCT04324424|Experimental|Undialyzed ESRD subjects (P1)|"Part 1: Undialyzed end stage renal disease (ESRD) patients to receive a single dose of HMS5552 ( 25mg ) tablets orally~."
89068264|NCT04324424|Experimental|Healthy volunteers (H)|"Part 1: Matched healthy volunteers to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~H group and P1 group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
89068265|NCT04324424|Experimental|Severe renal impaired subjects (P2)|"Part 2：Severe renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P2 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
89068266|NCT04324424|Experimental|Moderate renal impaired subjects (P3)|"Part 2：Moderate renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P3 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
89068267|NCT04324424|Experimental|Mild renal impaired subjects (P4)|"Part 2：Mild renal impaired subjects to receive a single dose of HMS5552 ( 25mg ) tablets orally~Matching principle:~P4 group and H group: 1:1 . The matched subjects should be in the same gender, age difference ±5 years, BMI difference ±15%"
89068268|NCT00627718|Other|A|All patients with possible neovascular ARMD are assessed with HRT to determined the positive predictive value of the test
89068269|NCT02873182|Experimental|Autonomic nervous system monitoring|During standard intraoperative neuromonitoring, additional smooth muscle free-running and stimulated EMG will be recorded from corporal tissues (corpus spongiosum) of male and female genitalia from all patients who consent to participate in the study. EMG data and additional demographics and clinical data (e.g. operative time, adverse events) will be collected for each patient.
89068270|NCT04324736||Patients with diabetes|
89068271|NCT04324736||Patients without diabetes|
89068272|NCT05643326|Experimental|Real tACS - Real tACS|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks) followed by an open-label 42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks).
89068273|NCT05643326|Sham Comparator|Sham tACS - Real tACS|42 sessions of sham stimulation (5 days/week for 9 weeks) followed by an open-label 42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks).
89068274|NCT05367674|Experimental|Summer Harvest Adventure (SHA)|Remote nutrition counseling, weekly produce harvesting, group nutrition education
89068275|NCT05367674|Active Comparator|My Summer Plate (MSP)|Nutrition education packet
89068276|NCT01058668|Experimental|Cariprazine (3-6 mg/day)|Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.
89068277|NCT01058668|Experimental|Cariprazine (6-12 mg/day)|Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.
89068278|NCT01058668|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
89068279|NCT00623558|Active Comparator|1|Docetaxel+CDDP
89068280|NCT00623558|Experimental|2|Docetaxel+CDDP+Cetuximab
89068281|NCT01301066|Experimental|Pitavastatin 4 mg QD|
89068282|NCT01301066|Active Comparator|Pravastatin 40 mg QD|
89068283|NCT01022398|Experimental|Vitamin D|Subjects will receive Vitamin D supplementation 10,000 international units of cholecalciferol (vitamin D3) by mouth weekly
89068284|NCT01022398|Placebo Comparator|Placebo|Subjects will receive placebo (an exact replica of the vitamin D capsule that does not contain any medically active substance) by mouth weekly
89068285|NCT05642624||sepsis group|invasive fungal infection patients who were diagnosed sepsis accoreding to the sepsis 3.0 guidlines.
89068286|NCT05642624||septic shock group|invasive fungal infection patients who were diagnosed septic shock accoreding to the sepsis 3.0 guidlines.
89068287|NCT05642546|Experimental|NM8074|6 subjects per each of the 5 cohorts will receive a single dose of NM8074 administered via IV (intravenous) infusion at 0.3, 1.0, 3.0, 10, or 20 mg/kg
89068288|NCT05642546|Placebo Comparator|Placebo|2 subjects per each of the 5 cohorts will receive saline placebo administered via IV infusion.
89068289|NCT04324346|Experimental|PICC-Line|Women allocated to PICC-line when receiving chemotherapy
89068290|NCT04324346|Experimental|Subcutaneous Venous Access Port (SVAP)|Women allocated to SVAP when receiving chemotherapy
89068291|NCT04286932||5-12y|
89068294|NCT02890238|Active Comparator|sildenafil citrate|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd - 7th day of the cycle and sildenafil citrate 20mg tab from 7th-11th day of the same cycle orally 3times/day
89068295|NCT02890238|Placebo Comparator|placebo group|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd- 7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day
89068296|NCT00627796|Experimental|A|Newly diagnosed patients with acromegaly
89068297|NCT05640206|Experimental|Test group|intra-articular i-PRF injection after arthrocentesis
89068298|NCT05640206|Experimental|Control group|only arthrocentesis
89068299|NCT05639582|Experimental|periodontally healthy individuals|50 subject without any periodontal disease
89068300|NCT05639582|Experimental|Stage 1 periodontitis|50 subject diagnosed with stage 1 in the periodontal disease classification
89068301|NCT05639582|Experimental|Stage 2 periodontitis|50 subject diagnosed with stage 2 in the periodontal disease classification
89068302|NCT05639582|Experimental|Stage 3 periodontitis|50 subject diagnosed with stage 3 in the periodontal disease classification
89068303|NCT04324502||Neuroendocrine neoplasms (tumours)|Patients with a diagnosis of neuroendocrine neoplasm who are due to undergo one of the following treatments: chemotherapy, everolimus, sunitinib, somatostatin analogues, peptide receptor targeted therapy, embolization/ ablative therapies or surgery.
89068304|NCT01262976|Experimental|HIV(+)-HA/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
89068305|NCT01262976|Placebo Comparator|HIV(+)-HA/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
89068306|NCT01262976|Experimental|HIV(+)-TN/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
89068307|NCT01262976|Placebo Comparator|HIV(+)-TN/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
89068308|NCT01262976|Experimental|HIV(-)/GSK692342|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
89068309|NCT01262976|Placebo Comparator|HIV(-)/Placebo|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
89068310|NCT01300286|Experimental|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
89068311|NCT05616728|Experimental|EDP-235 200mg|Once a day orally for 5 days
89068312|NCT05616728|Experimental|EDP-235 400mg|Once a day orally for 5 days
89068313|NCT05616728|Placebo Comparator|Placebo|Once a day orally for 5 days
89068314|NCT02890316|Experimental|Radiation therapy with Homeopathy|Patients in this arm will receive the homeopathy remedy during the adjuvant radiation therapy period, from treatment number 16 until the last assessment, 3 times every day.
89068315|NCT02890316|Placebo Comparator|Radiation therapy with placebo|Patients in this arm will receive the placebo remedy during the adjuvant radiation period, from treatment number 16 until the last assessment, 3 times every day.
89068316|NCT01300052|Experimental|AN2728 ointment, 2%|AN2728 ointment, 2%
89068317|NCT01300052|Placebo Comparator|Ointment Vehicle|Ointment Vehicle
88812727|NCT01830452|Experimental|Parietex Progrip mesh|Ventral hernioplasty using a (self gripping / self adhering / self fixating) Progrip mesh not needing fixation devices
88812728|NCT01830452|Active Comparator|Parietex Mesh|Ventral hernioplasty using a polyester mesh fixed with non absorbable sutures as described by Lichtenstein/Amid
89068318|NCT01299896|Active Comparator|Usual Care|Participants will continue to receive all the care currently offered in the VAPHS, including medications for smoking cessation and use of the in-person or telephone counseling options for quit smoking classes. For veterans with a co-pay, incurred fees with be reimbursed.
88812729|NCT04381598|Experimental|stevia rebaudiana bertoni|Randomly in all subjects one quadrant will be allotted as test site for placing stevia gel in the gingival sulcus having probing depth ≥ 5mm after performing thorough scaling and root planing.
89068319|NCT01299896|Active Comparator|Coordinated Care|A CTQ Coordinator will coordinate the delivery of smoking related care.
89068320|NCT01299584||Remifentanil|Patients administrated remifentanil at the site
89068321|NCT00637208|Experimental|1|
89068322|NCT00637208|No Intervention|2|Watch-full follow-up
89068323|NCT01236573|Experimental|Group 1 - CD8 + TIL expressing IL-12 1x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of interleukin-12 (IL-12) gene-transduced tumor infiltrating lymphocytes (TIL).
89068324|NCT01236573|Experimental|Group 2 - CD8 + TIL expressing IL-12 3x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068325|NCT01236573|Experimental|Group 3 - CD8 + TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068326|NCT01236573|Experimental|Group 4- CD8+TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068327|NCT01236573|Experimental|Group 5 - Bulk TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068328|NCT01236573|Experimental|Group 6 - Bulk TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068329|NCT01236573|Experimental|Group 7- Bulk TIL expressing IL-12 1x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068330|NCT01236573|Experimental|Group 8 - Bulk TIL expressing IL-12 3x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068331|NCT01236573|Experimental|Group 9 - Bulk TIL expressing IL-12 1x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068332|NCT01236573|Experimental|Group 10- Bulk TIL expressing IL12 3x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068333|NCT01236573|Experimental|Group 11 - Bulk TIL expressing MTD 1x10^9 (Phase 2)|Maximum tolerated dose (MTD). Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
89068334|NCT01236339|Experimental|TIPS|TIPS with GORE® VIATORR® TIPS Endoprosthesis
89068335|NCT01236339|Active Comparator|LVP|"Large Volume Paracentesis~*A subject may be crossed-over from large volume paracentesis to TIPS with GORE® VIATORR® TIPS Endoprosthesis if the subject has completed their six month study visit and has met the criteria for cross-over (LVP failure)."
88812730|NCT04381598|Placebo Comparator|placebo|Other quadrant will be allotted as a control site for placing placebo in the gingival sulcus having PD≥ 5mm after performing thorough scaling and root planing.
89068336|NCT01262898|Experimental|GSK962040 (10 mg)|GSK962040 10 mg
89068337|NCT01262898|Experimental|GSK962040 (50 mg)|GSK962040 50 mg
89068338|NCT01262898|Experimental|GSK962040 (125 mg)|GSK962040 125 mg
89068339|NCT01262898|Experimental|Placebo|Placebo
89068340|NCT01262820|Experimental|Single Intervention|Subjects will take Pazopanib, 800 mg daily by mouth throughout the time in study
89068341|NCT04323072|Experimental|Group A|Resection of antrum proximally 2 cm to the pylorus
89068342|NCT04323072|Active Comparator|Group B|Resection of antrum proximally 6 cm to the pylorus
89068343|NCT04323228|Experimental|Intervention|the intervention groups will receive daily oral antioxidant supplement enriched in vitamin A, C, E, Selenium and Zinc. The composition of one capsule of the intervention-supplement includes: 1500 mcg vitamin A (as β-carotene), 250 mg Vitamin C, 90 mg vitamin E, 15 ug Selenium, and 7.5 mg Zinc.
89068344|NCT04323228|Placebo Comparator|Placebo|Placebo group will receive daily intervention in form of cellulose-containing gelatin capsules with the same color and shape.
89068345|NCT04322916||RM Pressfit vitamys|Participants treated with a RM Pressfit vitamys hip cup in combination with a Mathys hip stem
89068346|NCT04322760|Active Comparator|Group A (control group)|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly without lidocaine patch
89068347|NCT04322760|Experimental|Group B|Patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly with a patch of lidocaine 5% was applied to the skin
89068348|NCT04322838||Patients|30 patients with self-reported seasonal allergic airway symptoms in the period from 1st of August to 15.th of october
89068349|NCT04322838||Controls|15 non-allergic individuals
89068350|NCT04322214|Experimental|COBI period (5 days) + Placebo period (5 days)|volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB
89068351|NCT04322214|Experimental|Placebo period (5 days) + COBI period (5 days)|volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB.
89068352|NCT02889276|Active Comparator|Control|Unsupervised activity
89068353|NCT02889276|Experimental|Functional Resistance Training (FRT)|Supervised, group-based functional resistance training
89068354|NCT05656092|Experimental|HIP0612|Taking HIP0612+HPP2202 once daily for 4 or 8 weeks.
89068355|NCT05656092|Active Comparator|RLD2204|Taking RLD2204+HPP2201 once daily for 4 or 8 weeks.
89068356|NCT01057810|Experimental|Ipilimumab|
89068357|NCT01057810|Placebo Comparator|Placebo|
89068358|NCT01262352|Experimental|Treatment Sequence 1|Ivacaftor administered in Treatment Period 1 and placebo administered in Treatment Period 2.
89223666|NCT05918965|Active Comparator|Vagus Nerve Stimulation with 25 Hertz|"Twelve weeks home therapy with transcutaneous electrical neurostimulation (TENSeco®, CE197, Schwa-Medico Gmbh), transcutaneous 2-channel nerve stimulator.~Matching ear electrode 3 DTS.~Stimulation frequency: 25 Hertz~Intensity: sensitive threshold; clearly perceptible, but pleasant~Form of stimulation: biphasic~Duration: 30 min~Position: left ear~Frequency: daily, in the evening, when all daily activities are done"
89223667|NCT05918965|Experimental|Vagus Nerve Stimulation with 2 Hertz|"Twelve weeks home therapy with transcutaneous electrical neurostimulation (TENSeco®, CE197, Schwa-Medico Gmbh), transcutaneous 2-channel nerve stimulator.~Matching ear electrode 3 DTS.~Stimulation frequency: 2 Hertz~Intensity: sensitive threshold; clearly perceptible, but pleasant~Form of stimulation: biphasic~Duration: 30 min~Position: left ear~Frequency: daily, in the evening, when all daily activities are done"
89223668|NCT05918939|Experimental|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Study product are provided in the form of liquid in vial (1 ml per vial). The vaccine will be given 1 dose (0.5 ml) once.
89223669|NCT05918939|Active Comparator|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine is CoronaVac Bio Farma vaccine, supplied by Ministry of Health of Indonesia, in the form of one dose vial (0.5 ml) once.
89223670|NCT05918926|Experimental|Exercise|Remote 12-week exercise intervention
89223671|NCT05918926|No Intervention|Control/Routine Care|No exercise intervention, continue with routine care
89223672|NCT05918874||obese|"The demographic characteristics of the children, type of asthma, dietary habits, socioeconomic income level and number of meals were asked to the child; the use of vitamin D in childhood and for how long, whether the child was breastfed or not, how many months the child was breastfed if breastfed, whether the mother had a smoking habit, and whether the mother had urinary tract infection during pregnancy were asked to the mother.~Asthma control level was recorded according to the asthma control test. Body mass index was calculated according to the Center of Disease Control and Prevention. The leisure-time activity scale and the International Physical Activity Questionnaire for Children-C (IPAQ-C) were used to assess physical activity level."
89223673|NCT05918874||non-obese|"The demographic characteristics of the children, type of asthma, dietary habits, socioeconomic income level and number of meals were asked to the child; the use of vitamin D in childhood and for how long, whether the child was breastfed or not, how many months the child was breastfed if breastfed, whether the mother had a smoking habit, and whether the mother had urinary tract infection during pregnancy were asked to the mother.~Asthma control level was recorded according to the asthma control test. Body mass index was calculated according to the Center of Disease Control and Prevention. The leisure-time activity scale and the International Physical Activity Questionnaire for Children-C (IPAQ-C) were used to assess physical activity level."
89223674|NCT05918809||CAR-T IP|Chimeric antigen receptor modified T cells inpatient cohort
89223675|NCT05918809||CAR-T OP|Chimeric antigen receptor modified T cells outpatient cohort
88812731|NCT04382144|Active Comparator|Levobupivacaine arm|Patients will receive a single injection of 10 mL of 0.5% (5 mg/mL) levobupivacaine into the common extensor origin.
89223676|NCT05918809||CAR-T Overall|Chimeric antigen receptor modified T cells overall cohort
89223677|NCT05918809||allo-HSCT|Allogeneic hematopoietic stem cell transplant cohort
89223678|NCT05918770|Experimental|experimental group|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition)
89223679|NCT05918770|No Intervention|control group|will follow the standard usual care guidelines at the centre where patients will be opportunistically referred to specialised care
89223680|NCT05918731|No Intervention|Usual Care Group|Patients who were assigned to receive usual care were instructed to continue up with their regular medical appointments and their usual check-ups/reviews and if they had any questions, to call the health coach.
89223681|NCT05918731|Active Comparator|Self-management Intervention Group|In the intervention group, a self-management program was implemented.
89223682|NCT05918627|Experimental|Dose level 1|Single Oral Doses of 20 mg SLx-2119 or placebo on Day 1
89223683|NCT05918627|Experimental|Dose level 2|Single Oral Doses of 40 mg SLx-2119 or placebo on Day 1
88812732|NCT04382144|Experimental|Liposomal Bupivacaine arm|Patients will receive a single injection of 10 mL (133mg) of liposomal bupivacaine into the common extensor origin.
89068359|NCT01262352|Experimental|Treatment Sequence 2|Placebo administered in Treatment Period 1 and ivacaftor administered in Treatment Sequence 2.
89068360|NCT01299272|Experimental|LY2216684 + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization continued their current dose of LY2216684 for another 24 weeks. Participants who completed this period or discontinued early were randomized to abrupt (placebo for 2 weeks) or tapered (12 mg LY2216684 for 4 days, 6 mg LY2216684 for 4 days, then placebo for 6 days) discontinuation of LY2216684."
88812733|NCT03215888||Obese|Obese individuals undergoing bariatric surgery
89068361|NCT01299272|Placebo Comparator|Placebo + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization were tapered from their LY2216684 dose to placebo following the regimen of 12 mg for 7 days, 6 mg for 7 days, and placebo for the remaining 22 weeks. Participants who completed this period or discontinued early continued to receive placebo for an additional 2 weeks"
89068362|NCT02889198|Experimental|Intervention group|Centers in this group will be granted immediate access to the Go NAP SACC website following randomization with minimal support from a local technical assistance provider. The center director will have 4 months to use Go NAPSACC tools.
89068363|NCT02889198|No Intervention|Control group|During the study, centers in this group will receive no intervention. However, they will be granted delayed access to the Go NAP SACC website and technical assistance support after post-intervention measures are collected.
89068364|NCT04322292|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene.
89068365|NCT01299116|Other|Preference SARC|Participants received one of a variety of oral contraceptives or DMPA
89068366|NCT01299116|Experimental|Randomized LARC|"Participants receive one of the following interventions:~Implanon® or Nexplanon®; ParaGard®; Mirena®"
89068367|NCT01299116|Active Comparator|Randomized SARC|Participants received one of a variety of oral contraceptives or DMPA
89068368|NCT04321590|Experimental|3 g 35% beta-glucan|Supplement containing 3 g of 35% oat beta-glucan
89068369|NCT04321590|Experimental|5 g 35% beta-glucan|Supplement containing 5 g of 35% oat beta-glucan
89068370|NCT04321590|Experimental|3 g 70% beta-glucan|Supplement containing 3 g of 70% oat beta-glucan
89068371|NCT04321590|Experimental|5 g 70% beta-glucan|Supplement containing 5 g of 70% oat beta-glucan
89068372|NCT04321824||the innovative programm (PASS de ville)|specific care for precarious people
89068373|NCT04321824||the standard of care|
89068374|NCT04321902|Experimental|The experimental group in acute cholecystitis|"inclusion criteria~among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used as before and during surgery."
89223684|NCT05918627|Experimental|Dose level 3|Single Oral Doses of 80 mg SLx-2119 or placebo on Day 1
88812734|NCT03215888||controls|matched non-obese controls
88812735|NCT05319938|Active Comparator|CAF only|Only Coronally Advanced Flap technique
89068375|NCT04321902|Experimental|The controled group in acute cholecystitis|"among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)~cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging~Gallbladder with surrounding organs due to gallbladder inflammation~Patients over 19 years of age~Sencond-generation cephalosporin (Shincef inj., 750mg, Cefuroxime sodium, Shin-poong pharm.co.) was used as before and during surgery."
89068376|NCT04207398|Experimental|TIPS|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver.
89068377|NCT04207398|Active Comparator|NSBB+EBL|Participants randomized to this group will receive the combination therapy of non-selective beta-blocker (NSBB) and endoscopic band ligation (EBL) . NSBB, including propranolol and carvidilol, will be started at day 5 after the index bleeding and elective EBL sessions started 2 weeks after the index bleeding.
89068378|NCT01299038|Active Comparator|Group 1|Rosuvastatin 20mg taken orally once a day for 4 weeks
89068379|NCT01299038|Active Comparator|Group 2|Rosuvastatin 40mg taken orally once a day for 4 weeks
89068380|NCT00623922|Experimental|1|Patient education
89068381|NCT00623922|No Intervention|2|Usual care
89068382|NCT04321434|Experimental|Hyperoxia|"assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests~assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
89068383|NCT04321434|Placebo Comparator|Normoxia|"assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests~assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests"
89068384|NCT04321122|Experimental|Ultrasound cyclo plasty(UCP)|Ultrasound cyclo plasty treatment for primary open-angle glaucoma patients.
89068385|NCT04321278|Experimental|Hydroxychloroquine + azithromycin|Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]
89068386|NCT04321278|Active Comparator|Hydroxychloroquine|Hydroxychloroquine [400mg 2x/day, 12/12h]
89068387|NCT01298648||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
89068388|NCT01261338|Experimental|olestra|Non-absorbable fat administered in the form of 24 potato crisps per day (12 each with mid-day and evening meal) providing approximately 15g/day of olestra.
89068389|NCT01261338|Placebo Comparator|Vegetable oil|Absorbable fat administered in the form of 12 potato crisps per day (6 each with mid-day and evening meal) in order to match the caloric intake provided by the crisps with Olestra.
89068390|NCT01260948|Experimental|Investigational Test Product|Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg
89068391|NCT01260948|Active Comparator|Reference Listed Drug|Aricept® Orally Disintegrating Tablets, 10 mg
89068392|NCT01025284|Experimental|Part A LY2523355|8 milligrams per square meter (mg/m²) per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 5, 9 of each 21-day cycle, until disease progression or unacceptable toxicity.
89068393|NCT01025284|Experimental|Part B LY2523355|5 or 6 mg/m² per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 2, 3 plus granulocyte colony-stimulating factor (G-CSF) support administered subcutaneously beginning on Day 4 of each 21-day cycle, until disease progression or unacceptable toxicity.
89068394|NCT01021852|Experimental|MK-6096 2.5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for overnight polysomnography (PSG) recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive dose-matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
89068395|NCT01021852|Experimental|Placebo/MK-6096 2.5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
89223685|NCT05918627|Experimental|Dose level 4|Single Oral Doses of 160 mg SLx-2119 or placebo on Day 1
89223686|NCT05918627|Experimental|Dose level 5|Single Oral Doses of 320 mg SLx-2119 or placebo on Day 1
89223687|NCT05918627|Experimental|Dose level 6|Single Oral Doses of 640 mg SLx-2119 or placebo on Day 1
89223688|NCT05918614|Experimental|KD025|500 mg KD025 administered orally twice daily (BID) for 28 days
89223689|NCT05918614|Placebo Comparator|Placebo|Placebo administered orally BID for 28 days
89223690|NCT05918588|Experimental|Cohort 1|500 mg KD025 or placebo once daily (QD) for 7 days
89223691|NCT05918588|Experimental|Cohort 2|800 mg KD025 or placebo QD for 7 days
89223692|NCT05918588|Experimental|Cohort 3|500 mg KD025 or placebo twice daily (BID) for 7 days
89223693|NCT05918588|Experimental|Cohort 4|1000 mg KD025 or placebo QD for 7 days
89223694|NCT05918562|Experimental|Low fiber diet group|Subjects are allowed a low fiber diet the day of their colonoscopy prep
89223695|NCT05918562|Active Comparator|Clear liquid diet group|Subjects are allowed a clear liquid diet the day of their colonoscopy prep, as is standard of care
89223696|NCT05918536||Popolation|
89223697|NCT05918471|Experimental|Very Low Energy Diet + Standard Counselling|All patients in the intervention group will receive standard patient counselling on weight loss and an active VLED protocol. The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Patients will receive a three-week supply. They will be instructed to consume four packets daily. This provides a total energy intake of 900 kcal. Patients will also be able to consume up to 2 cups of low-calorie vegetables per day along with the meal replacement product. They will be provided with a handout containing specific instructions. Patients will keep self-report diaries of their dietary intake and activity levels.
89522878|NCT03987919|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
89522879|NCT03987919|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
89522880|NCT03987919|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
89522881|NCT03987919|Active Comparator|1 mg Semaglutide|1 mg semaglutide administered SC once a week.
89522882|NCT03388957|Experimental|Propranolol|Patients in this group will be given Propranolol 0.5 mg/Kg orally.
89522883|NCT03388957|Experimental|Midazolam|Patients in this group will be given Midazolam 0.5 mg/Kg orally.
89522884|NCT03388957|Experimental|Propranolol and Midazolam|Patients in this group will be given Propranolol and Midazolam with a dose of 0.5 mg/Kg orally for each drug.
89522885|NCT03904069|Experimental|Comparison of different cell doses of AMG 553|Subjects will receive IV infusion of AMG 553
89690523|NCT01025791|Placebo Comparator|Panel C, Mild/Moderate Hypertension, Sequence 6|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na
89690524|NCT03195010|Experimental|Group I (lower dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
89690525|NCT03195010|Experimental|Group II (higher dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
89690526|NCT03423082|Experimental|18F fluciclovine PET scan|Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.
89690527|NCT04736290||Noncardiac surgery|Calculation of the NLR and PLR in patients undergoing noncardiac surgery under general anesthesia
89522886|NCT03395821|Active Comparator|Conventional training|Residents will receive the traditional training for laparoscopic surgery according to their residency program.
89522887|NCT03395821|Experimental|Virtual Reality+conventional training|Residents will receive 12 weeks of virtual training for laparoscopy and their traditional training for laparoscopic surgery according to their residency program.
89068396|NCT01021852|Experimental|MK-6096 5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
88812736|NCT05319938|Experimental|CAF+CGF|Concentrated Growth Factor (CGF) applied together with Coronally Advanced Flap (CAF) technique
89522888|NCT03390829||Patients|
89522889|NCT03390829||Doctors|
89522890|NCT02520271|Active Comparator|Depression|Behavioral activation only
89522891|NCT02520271|Active Comparator|Depression and SUD|Motivational interview and Behavioral activation
89522892|NCT03388879|Experimental|Circular frame external fixator|A Taylor Spatial Frame should consist of 2 rings with 4 half pins/K-wire attached to each ring. If possible 3, not hydroxyapatite-coated, half pins and one K-wire should be attached to each ring. The half pins/K-wire should be spread in distance and direction for optimum stability.
89522893|NCT03388879|Active Comparator|Intramedullary nail|Nailing technique according to Karladani and Styf published technique (ref: Karladani AH, Styf J. Percutaneous intramedullary nailing of tibial shaft fratures: a new approach for prevention of anterior knee pain. Injury, Int. J. Care Injury 32 (2001) 736-39)
89690528|NCT01026181||LSG|Laparoscopic Sleeve Gastrectomy
89690529|NCT01026181||LRYGB|Laparoscopic Roux-en-Y Gastric Bypass
89690530|NCT01026181||LAGB|Laparoscopic Adjustable Gastric Banding
89690531|NCT03294850|Experimental|NASH group|These are individuals that have been identified as having NASH by MRE. Confirmation with liver biopsy required for continuation in the longitudinal study.
89690532|NCT03294850|Active Comparator|Non-NASH (NAFLD or normal) group|These are individuals that do not have NASH. They either have normal liver physiology or only have evidence of hepatic steatosis. This group will be studied up until the day of their bariatric surgery and will serve as a comparator population with respect to baseline measurements.
89690533|NCT00996931|Experimental|Lenalidomide|
89690534|NCT03295630|Other|Actigraph GT3X accelerometer|Ward based patients recovering from critical illness will wear two accelerometers placed on the thigh and ankle of the non-dominant leg
89690535|NCT01026805||Hysteroscopic Morcellator|11 women previously receiving hysteroscopic myomectomy or polypectomy using the hysteroscopic morcellator device.
89690536|NCT00997555|Experimental|bronchoscopy intervention group|Group undergoing scheduled bronchoscopy.
89690537|NCT00997555|No Intervention|Control group|Standard treatment without scheduled bronchoscopy.
89690538|NCT03197038|Experimental|Home-based walking exercise|Home-based exercise program: The exercise training group will participate in an educational session on exercise for CKD. Participants will receive a packet of information with an exercise prescription and a heart rate monitor that monitors the exercise. Participants will be asked to exercise (a brisk walk) at home, 3 times per week, for 30-60 minutes for 24 weeks. Participants will be contacted via phone biweekly or more frequently if they are behind the exercise routine, and the investigators will meet with them monthly to provide encouragement and progression of exercise, and to download the heart rate monitor.
89690539|NCT03197038|Active Comparator|Control|The control group will receive standard instructions on exercise for patients with kidney disease similar to what is commonly done in clinical practice. The control group will not receive an exercise prescription or heart rate monitor. Participants will be contacted via phone biweekly to answer any questions and ensure continued study participation. The control group will not meet with the investigators monthly.
89690540|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Dose Level 1
89690541|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Dose Level 2
89690542|NCT00634088|Experimental|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Dose Level 3
89690543|NCT00634088|Experimental|Ixabepilone + Lapatinib + Capecitabine|Triplet Combination
89690544|NCT01027195|Placebo Comparator|Standard Bovie Electrocautery|Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.
88812737|NCT05319938|Experimental|CAF+A-PRF|Advanced Platelet-Rich Fibrin (A-PRF) applied together with Coronally Advanced Flap (CAF) technique
89068397|NCT01021852|Experimental|Placebo/MK-6096 5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
89068398|NCT01021852|Experimental|MK-6096 10 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
89068399|NCT01021852|Experimental|Placebo/MK-6096 10 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
89068400|NCT01021852|Experimental|MK-6096 20 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
89223698|NCT05918471|No Intervention|Standard Counselling Alone|The control group patients will receive standard counselling for weight loss without prescription of a specific preoperative weight loss intervention, as this is meant to be a pragmatic trial. Currently, there are no standardized interventions aimed at optimizing obese patients prior to undergoing non-bariatric surgery. Briefly, counselling will consist of the surgeon, at the time of the preoperative clinic visit, discussing weight loss strategies such as decreased caloric intake and increased physical activity. Patients will not receive prescriptions for preoperative VLEDs, any other weight loss supplement, or any physical activity intervention aimed at promoting weight loss prior to surgery. Patients will keep self-report diaries of their dietary intake and activity levels.
89223699|NCT05918419|Experimental|Neoadjuvant Chemoradiation|neoadjuvant chemoradiation plus PD-1 antibody (Serplulimab) Intervention: Drug: Neoadjuvant chemoradiation plus PD-1 antibody(Serpluimab)
88812738|NCT01522703|Experimental|Broccoli Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 3 consecutive days
88812739|NCT01522703|Placebo Comparator|Alfalfa Sprouts|Alfalfa Sprouts will be eaten daily in a sandwich form for 3 consecutive days
88812740|NCT01830608||300 patients with AMD|
89068401|NCT01021852|Experimental|Placebo/MK-6096 20 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
89068402|NCT02872636|Experimental|Treatment Group|
89068403|NCT02872870||Control adults|lexical tests and electroencephalogram (EEG).
89068404|NCT02872870||Dyslexic patients|lexical tests
89068405|NCT02872870||Dysphasic patients|lexical tests
89068406|NCT02875054|Active Comparator|Continued Casting|Participants with 24 hour cast wear (continued casting) for the entire duration of the constraint portion of camp (2 initial weeks).
89068407|NCT02875054|Active Comparator|Intermittent Casting|Participants who wear a univalve cast for 3 hours of constraint camp with home exercise program of 2 hours cast wear on the weekends (intermittent casting).
89068408|NCT02873026|No Intervention|Standard care|The patient will receive the standard care given to all patients that have received a vitrectomy following open globe trauma.
89068409|NCT02873026|Experimental|Triamcinolone acetonide|Triamcinolone Acetonide 4mg/0.1ml intravitreal cavity and 40mg/1ml subtenons to be injected at the time of the vitrectomy. Patients will then receive standard care following operation.
89068410|NCT00627640|Experimental|1|1 active (50 - 100 mg/day)
89068411|NCT00627640|Placebo Comparator|2|
89068412|NCT01056718|Other|Nebivolol treatment|10 week open label nebivolol treatment.
89068413|NCT01298570|Active Comparator|Regorafenib + FOLFIRI|regorafenib 160 mg + FOLFIRI
89068414|NCT01298570|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
89068415|NCT01259856|Experimental|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
89068416|NCT01259856|Active Comparator|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
89068417|NCT01020838|Experimental|Florbetaben (BAY94-9172)|
89068418|NCT00624000|Experimental|1|IA administration of Alteplace vs. IV administration of Alteplace
89068419|NCT00624000|Active Comparator|2|IA administration of Alteplase vs.IV administration of Alteplase
89068420|NCT01259466|Experimental|Cognitive Behavioral + Nicotine Patch|Cognitive Behavioral Therapy + Nicotine Replacement Patch
88812741|NCT01830686|Experimental|Sugarcane bagasse|10 subjects will consume food (brownies and cookies) made with 13 g of sugarcane bagasse everyday for 4 weeks
89068421|NCT01259466|Active Comparator|Health Education + Nicotine Patch|Health Education + Nicotine Replacement Patch
89068422|NCT01259388|Experimental|Lithium|"Lithium-treatment phase~Lithium Carbonate: Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time."
89068423|NCT01259388|No Intervention|Observation|During observation subjects continue on their standard of care disease modifying agent (or no agent at all if judged not appropriate by the treating physician).
89068424|NCT01298492|Experimental|Open-Label Treatment|Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008
89068425|NCT05525910|Active Comparator|Treatment A: Nirmatrelvir/ritonavir|Nirmatrelvir and ritonavir tablets
89068426|NCT05525910|Experimental|Treatment B: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir test tablets
89068427|NCT05525910|Experimental|Treatment C: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir test tablets
89068428|NCT05525910|Experimental|Treatment D: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir test tablets
89068429|NCT05525910|Experimental|Treatment E: Nirmatrelvir/ ritonavir|Nirmatrelvir/ ritonavir test tablets
89068430|NCT04320654|Experimental|advice of staying active|The patients will be advised to stay as physically active as possible and continue their everyday activities as normally as possible.
89068431|NCT04320654|Experimental|walking program|Patients will be encouraged to go about their normal daily activities. At week one, patients will be asked to familiarize themselves with wearing the pedometer and recording their daily steps in a walking diary for the subsequent 7 days. The patients will return to see the physiotherapist at the end of week one to discuss any issues with the program, pedometer or recording of desired information. A step target for week two will be agreed between the physiotherapist and the patient by referring to the mean daily step count recorded at baseline, and the average step count calculated from the walking diary
89068432|NCT04320654|Experimental|Backward walking|All patients will be instructed to walk at their desired pace 3 days per week with a steady rhythm. The duration of each training session will initially be 15 minutes and will gradually increase, and finally reach 25 minutes, for every session (Hao Chen, 2011). There will be no constraint or indication about head and trunk position during backward training
89068433|NCT04320654|Experimental|Targeted home-based hip exercise|Patients who will be assigned in this group will perform a hip exercise program for six weeks, three times / week to ensure an adequate recovery between exercise sessions (appendix V). The strengthening exercises will focus on strengthening the gluteus maximus (GMax), gluteus medius (GMed), gluteus minimus (GMin) and short hip external rotator muscles (Distefano et al., 2009).
89068434|NCT04320654|No Intervention|control group|The patients will not be given any intervention and will be asked to come after 6 weeks for re-assessment
89068435|NCT01297322|Active Comparator|Manual compression|Using manual compression to reach hemostasis
89068436|NCT01297322|Experimental|VASCADE™ Vascular Closure System|The Cardiva VASCADETM Vascular Closure System (VCS) is indicated for the percutaneous closure of common femoral artery access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular catheterization procedures utilizing 6 Fr or 7 Fr procedural sheaths.
89068437|NCT02888886|Experimental|COPD|
89068438|NCT00624078|Experimental|1|Patients who arrive to emergency room with scorpion sting envenomation will be evaluated according to inclusion/exclusion criteria. After informed consent has been signed they will be assigned to unique treatment arm with Anascorp.
89068439|NCT00624156||1|emotional disclosure writing intervention
89068440|NCT00624156||2|control writing
89068441|NCT05396586|Active Comparator|Condition 1|Training type 1 will be administered in the first part of the crossover trial and Training type 2 will be administered in the second part of the trial. Each training part consists of 20 twenty-minute long sessions with the recommended frequency of 2 sessions per work day. Thus each training part can be completed in 10 work days (2 weeks).
89068442|NCT05396586|Active Comparator|Condition 2|Training type 2 will be administered in the first part of the crossover trial and Training type 1 will be administered in the second part of the trial. Each training part consists of 20 twenty-minute long sessions with the recommended frequency of 2 sessions per work day. Thus each training part can be completed in 10 work days (2 weeks).
89223700|NCT05918393|Other|Functional communication training (FCT)|During FCT, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both severe destructive behavior (SDB) and communication are on extinction) will be alternated within a single session. During the treatment-challenge evaluation, SDB will remain on extinction throughout and all communication responses will be reinforced on an FR-1 schedule during the signaled reinforcement intervals.
89223701|NCT05918380|Other|Low CVD risk|PAL2
89223702|NCT05918380|Other|High CVD risk|Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA)
89223703|NCT05918341|Experimental|Piracetam arm (single arm)|The single to take once weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg piracetam consecutively. Urine was collected 24 and 72 hours after the weekly doses were taken. It was chosen to administer all these doses in each healthy volunteer to account for inter-individual differences in urine concentrations, as these concentrations depend on individual characteristics such as volume intake and renal function.
89223704|NCT05918315|Active Comparator|Dorsolateral approach urethroplasty|Use of dorsolateral(Kulkarni technique) urethroplasty.
89223705|NCT05918315|Active Comparator|Dorsal approach urethroplasty|Use of dorsal (Barbagli technique) urethroplasty
89223706|NCT05918289|Experimental|Intervention and control|Treatment group taken intervention of education program designed for elders and the control group did not take any intervention but at the end of the time duration they were taken the opportunity of 3 days class room intervention
89223707|NCT05918276|Experimental|OBG|
89223708|NCT05918263|Experimental|Group A: 16-Week HIIT Exercise Program|"Participants will be allocated in a 1:1 ratio, using a permuted blocked design with varying block size. Study procedures will be conducted as follows:~Testing visits at Week 1, 9, and 19 for physical exams, physical fitness and function assessments, survey questionnaires, and cardiopulmonary fitness assessment.~Virtual, aerobic training sessions three times weekly with trained oncology exercise specialist."
89690545|NCT01027195|Experimental|Bipolar Radiofrequency|Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (<100 degrees Celsius) than standard Bovie electrocautery.
89690546|NCT00998023|Experimental|Mynx VCD|Mynx Vascular Closure Device
89690547|NCT00998023|Active Comparator|AngioSeal VCD|AngioSeal Vascular Closure Device
89690548|NCT03428230|Experimental|30 mg Paracetamol 3% (1 mL)|30 mg Paracetamol 3% (1 mL), solution for injection, single dose by intrathecal injection (IT)
89690549|NCT03428230|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3% (2 mL), solution for injection, single dose by intrathecal injection (IT)
89690550|NCT03428230|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3% (3 mL), solution for injection, single dose by intrathecal injection (IT)
88812742|NCT01830686|Active Comparator|Non-caloric, non-fermentable fiber|10 subjects will consume food (brownies and cookies) made with 13 g of non caloric, non-fermentable fiber everyday for 4 weeks
89690551|NCT03428230|Placebo Comparator|Placebo, 0.9% saline solution|Placebo, 0.9% saline solution (1 mL, 2 mL or 3 mL), solution for injection, single dose by intrathecal injection (IT)
89690552|NCT01027819|Active Comparator|Mobile bearing|Mobile bearing type between polyethylene insert and tibial component MB type will be randomly used in total knee arthroplasty
89690553|NCT01027819|Active Comparator|Fixed bearing|Fixed bearing type between polyethylene insert and tibial component FB type will be randomly used in total knee arthroplasty
89690554|NCT02163967|Other|Dose sequence: Sham, Low, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -1 milliamp stimulation intensity, Day 3 - 2milliamp stimulation intensity
89690555|NCT02163967|Other|Dose sequence: Sham, High, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -2 milliamp stimulation intensity, Day 3 - 1milliamp stimulation intensity
89690556|NCT02163967|Other|Dose sequence: Low, Sham, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 -Sham stimulation; Day 3 - 2milliamp stimulation intensity
89690557|NCT02163967|Other|Dose sequence: Low, High, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 - 2milliamp stimulation intensity; Day 3 - Sham stimulation
89690558|NCT02163967|Other|Dose sequence: High, Sham, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - Sham stimulation; Day 3 - 1 milliamp stimulation intensity
89690559|NCT02163967|Other|Dose sequence: High, Low, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - 1 milliamp stimulation intensity; Day 3 - Sham stimulation
89690560|NCT03296800|Experimental|Bexagliflozin/probenecid|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.
89690561|NCT03296800|Experimental|Bexagliflozin/rifampin|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.
89690562|NCT03296800|Experimental|Bexagliflozin/verapamil|Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.
89690563|NCT00634010|Active Comparator|Morphine Capsule|Morphine 15 mg slow release orally every 12 hours + additional doses as needed
89690564|NCT00634010|Active Comparator|Methadone Capsule|Methadone 5 mg orally every 12 hours + additional as needed doses up to 40-50 mg/day
89223709|NCT05918263|Experimental|Group B: 16-Week Usual Care|"Participants will be allocated in a 1:1 ratio, using a permuted blocked design with varying block size. Study procedures will be conducted as follows:~Testing visits at Week 1 and 18 for physical exams, physical fitness and function assessments, and survey questionnaires.~Upon completion of post-intervention assessments, participants will have the option to take part in the 16-week HIIT exercise program."
89223710|NCT05918172||manual group|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O throughout the follow-up of the patients.
89223711|NCT05918172||automatic group|The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.
89223712|NCT05918068|Other|Control group|Newly diagnosed patients with T2DM, treated with non-pharmacological therapy (lifestyle modification).
89223713|NCT05918068|Active Comparator|Metformin only group|T2DM patients treated with metformin 500 mg/day in addition to non-pharmacological therapy (lifestyle modification)
89223714|NCT05918068|Experimental|Combination group|T2DM patients treated with metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy (lifestyle modification)
89223715|NCT05917977|Other|Control group (Education Materials)|After completing the baseline screening, survey and randomization, the participants in the control group will receive educational materials regarding topics including: (1) what IGD is and its consequences, (2) how to communicate with parents about the gaming time, and (3) how to develop a healthy lifestyle, etc.
89690565|NCT04053751|Experimental|closed suctioning system|Closed suctioning system will be compared with open suctioning system
89690566|NCT04053751|No Intervention|open suctioning system|The patient will be monitored with closed system for one day and open aspiration system on the other day.
89690567|NCT03202264||TAPERMD|80 Long term care residents on 5 or more medications aged over 70 from 2 long term care facilities
89690568|NCT00633932|Experimental|1|Esomeprazole 20mg
89223716|NCT05917977|Experimental|Intervention group (Collective Motivational Interviewing plus Education Materials)|Participants in the intervention group will be given the same Internet Gaming Disorder (IGD) education materials as those in the control group, thus, they will further participate in four counseling sessions with Collective Motivational Interviewing (CMI) (each session 60 mins). In the first session, adolescents with Internet Gaming Disorder will be implemented a standard MI session to elicit and strengthen the client's motivation to change. In the second session, a nominated CSO of the client will participate in a standard MI session to elicit their motivation to help the client toward change and prepare positive attitudes of CSO for the conjoint session. Afterward, the third and fourth sessions (75 mins) will be conjoint sessions. The Collective Motivational Interviewing practitioners will create a safe platform for both parties to share their perspectives with openness and trustfulness, in turn, to reach an agreed goal (e.g., develop a change plan on internet gaming behaviors).
89223717|NCT05917925|Experimental|COLLAGEN (COL)|Subjects in this group will intake 10 g/day of a hydrolyzed collagen-based supplement.
89223718|NCT05917925|Placebo Comparator|PLACEBO (PLA)|Subjects in this group will intake 10 g/day of placebo (maltodextrin).
89223719|NCT05917886|Active Comparator|Monaural beat stimulation|20 min sound recording of 8Hz monaural beat
89223720|NCT05917886|Sham Comparator|Control|20 min sound recording of 220Hz pure sine wave
89690569|NCT00633932|Experimental|2|Esomeprazole 40mg
89690570|NCT00633932|Active Comparator|3|Omeprazole 20mg
89690571|NCT01028131|No Intervention|Control|Participants randomized by the computer into this condition will only view the 20-minute video clips of music and tv videos.
89690572|NCT01028131|Experimental|Computerized brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model (ask, advise, assess, assist & arrange) and Motivational Interviewing.
89690573|NCT01028131|Experimental|Contingency Management Alone|Participants randomized by the computer into this condition will view a 20-minute music and tv video clip after completing the brief assessment. The research assistant will then briefly describe the CM process, with some time to discuss questions regarding procedure to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
89690574|NCT01028131|Experimental|Combined Brief Intervention and CM|Combined intervention. Participants in this condition will receive both the brief intervention and the brief description of the CM process.
89690575|NCT03831542||direct aspiration group|Transvaginal ultrasound-guided oocyte retrieval was performed 36 hours after ovulation trigger. A 17-gauge double lumen needle will be used to aspirate a single follicle without flushing. If an oocyte is obtained, the subject will be assigned to group 1. If not, operator will proceed with follicular flushing.
89690576|NCT03831542||flushing group|If an oocyte is not obtained with direct aspiration, operator will proceed to follicular flushing and the subject will be assigned to group 2 if an oocyte is obtained following follicular flushing.
89690577|NCT01028677|Experimental|intranasal spray with oxytocin|Twice daily intranasal oxytocin spray (24 IU, 6 insufflations/dose) for 6 weeks
89690578|NCT01028677|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin (six 0.1 ml insufflations/dose) for 6 weeks.
89690579|NCT03298048|Active Comparator|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
89690580|NCT03298048|Active Comparator|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
89690581|NCT03298048|Active Comparator|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
89690582|NCT01923038|Active Comparator|Patients ventilated with zero end expiratory pressure (ZEEP)|patients undergoing gynecologic laparoscopic surgery ventilated at zero end expiratory pressure
89690583|NCT01923038|Active Comparator|Patients ventilated with positive end expiratory pressure|patients undergoing gynecologic laparoscopic surgery ventilated at PEEP
88812743|NCT01830686|Placebo Comparator|Minimal fiber|10 subjects will consume food (brownies and cookies) made with 4 g of dietary fiber everyday for 4 weeks
89068443|NCT01297244|Experimental|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
89068444|NCT04320420|Experimental|Experimental arm|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~3 supervised APA sessions/week on site:~two muscle strengthening sessions, stretching, flexibility in the gym~a cardio session (Nordic Walking: outdoors)~at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~the first 3 months:~2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~1-hour cardio session/week independently~the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
89068445|NCT05183022|Experimental|Total30 Sphere Contact Lenses|All qualified participants will be refit into Total30 Sphere contact lenses.
89068446|NCT02890394|Experimental|2 minutes Group|The group was perform the technique inhibition suboccipital two minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
89068447|NCT02890394|Experimental|4 minutes Group|The group was perform the technique inhibition suboccipital four minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
89690584|NCT01923038|Active Comparator|recruitment plus PEEP|patients undergoing gynecologic laparoscopic surgery undergoing recruitment plus PEEP
89690585|NCT01923116|Experimental|HPV-16 vaccine|
89690586|NCT01028911|Experimental|PF-03654746|
89690587|NCT01028911|Placebo Comparator|Placebo|
89690588|NCT03204526|Experimental|low frequency stimulation (LFS)|Low-frequency deep brain stimulation of the subthalamic nucleus
89690589|NCT03302416|Experimental|[C-11]NOP-1A PET Scan conditions|Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition
89690590|NCT03435562|Experimental|electronic cigarette vs own brand use|Participants will come in for three session. During one session, participants will first complete a 10-puff product use bout with JUUL, and then a 90-minute ad lib product use bout with JUUL (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with IQOS, and then a 90-minute ad lib product use bout with IQOS (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with their own brand cigarettes, and then a 90-minute ad lib product use bout with their own brand cigarette (the session will be approximately 3 hours). The order of the sessions will be determined randomly and data about session will not be recorded or used in the analysis.
89690591|NCT01000285|Experimental|Arm 1|"Bortezomib 1.0 mg/m2 intravenous (IV) Days 1-4~Etoposide 50 mg/m2/d 96 hour continuous intravenous infusion (CIVI) on Days 1-4~Vincristine 0.4 mg/m2/d 96 hour CIVI on Days 1-4~Doxorubicin 10 mg/m2/d 96 hour CIVI on Days 1-4~Prednisone 60 mg/m2/d PO on Days 1-5~Cyclophosphamide 375 mg/m2 IV on Day 5~Raltegravir 400 mg PO twice per day (BID) every day starting with cycle 2 therapy for the entire duration of the cycle.~Cycles will be repeated every 21-28 days for 2 cycles beyond best response, or a maximum of 6 cycles."
89690592|NCT03207022|Active Comparator|lidocaine 2% with normal saline|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with 2 ml of 0.9% normal saline.
89690593|NCT03207022|Experimental|lidocaine 2% with clonidine|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with clonidine 1µg/kg in 2 ml of 0.9% normal saline.
89690594|NCT03208192|Experimental|ErbeJet|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).
89690595|NCT03208192|Experimental|Misonix|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)
89690596|NCT01000987|Experimental|varenicline|varenicline 1mg/day or 2mg/day
89690597|NCT01000987|Placebo Comparator|placebo|placebo
89690598|NCT00633464|Experimental|Arm A (ixabepilone 40 mg^2)|ixabepilone 40 mg/m^2 every 3 weeks
89690599|NCT00633464|Experimental|Arm B (cetuximab 250 mg/m^2 + ixabepilone 40 mg/m^2)|cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks
89690600|NCT03436810|Experimental|Experimental group|The experimental group will receive training programs of Motor imagery (MI) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration of program session will be 90 minutes. Training for 3 times a week over duration of 4 weeks.
89690601|NCT03436810|Active Comparator|Control group|The control group receives programs of Health education (HE) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration will be 90 minutes. They will be trained for 3 times a week over duration of 4 weeks.
89690602|NCT03129776|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|Participants will be injected with the study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43 ml/kg and will have their cervix imaged using MRI.
89690603|NCT03129776|Active Comparator|18F-FDG|Participants will be injected with the study drug 18F-FDG at a dose of 5 MBq/kg to a a maximum of 500 MBq (megabecquerel) and will have their cervix imaged using PET-CT imaging.
89690604|NCT03437044|Experimental|Ticagrelor|180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD
89690605|NCT03437044|Active Comparator|Clopidogrel|600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD
89690606|NCT01923194|Experimental|Test Group|
89690607|NCT01923194|Active Comparator|Comparator Group|
89690608|NCT03303196|Experimental|Bihormonal bionic pancreas admission|Four day inpatient admission where participants will have blood sugar managed by the Bihormonal Bionic Pancreas. Blood sugars will be monitored for safety by study staff.
89690609|NCT03303196|No Intervention|Standard care admission|Four day inpatient admission where participants will have blood sugar managed by the participant's home-glucose control regimen. Blood sugars will be monitored for safety by study staff.
88812744|NCT03215654|Experimental|Sensitization Program (SP)|Include the concepts of mental health and mental disorder, healthy and risky behaviors of mental health, and use of health services. Duration 1 hour.
89068448|NCT02890394|Experimental|8 minutes Group|The group was perform the technique inhibition suboccipital eight minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
89068449|NCT02890394|No Intervention|not intervention Group|The not intervention group will be asked to lie supine on the table for ten minutes, collecting data by measuring with algometer and test repositioning of the head before and after laying.
89068450|NCT04746378||extracorporeal shockwave lithotripsy|Patients that are included in the study and undergo a shockwave lithotripsy. The pre- and postoperative assessment remains the same across groups
89068451|NCT04746378||uretero(reno)scopy|Patients that are included in the study and undergo a semirigid or flexible uretero(reno)scopy. The pre- and postoperative assessment remains the same across groups
89068452|NCT04746378||percutaneous nephrolithotomy|Patients that are included in the study and undergo a percutaneous nephrolithotomy. The pre- and postoperative assessment remains the same across groups
89068453|NCT04735692|Placebo Comparator|Periodontitis quadrant Scaling root planing|Patients undergo non surgical quadrant scaling and root planing performed per quadrant
89068454|NCT04735692|Active Comparator|Periodontitis full mouth scaling root planing|Patients undergo non surgical full mouth scaling and root planing
89068455|NCT04320576|Experimental|Bulk-fill resin composite|Bulk-fill resin composite will be places with bulk technique.
89068456|NCT04320576|Active Comparator|Nano-fill resin composite|Nano-fill resin composite will be placed with 2 mm thickness layering technique.
89068457|NCT04554732|Experimental|Part 1 - Initial group treatment|For part 1 of the study, subjects will be enrolled into a prospective single arm phase where all of them get the study treatment. We plan to enroll up to 25 subjects to have 20 evaluable subjects to this phase.
89068458|NCT04499820|Experimental|NUTROF Group|vitamin and DHA supplementation
89690610|NCT04759508|Active Comparator|500 mg BD Flax Oil Capsule with Antihypertensive drug|Flax Oil Capsule 500 mg twice a day will be administered alongside antihypertensive drug in newly diagnosed hypertensive subjects
89690611|NCT04759508|Placebo Comparator|Placebo(Soya Oil) Capsule with Antihypertensive drug|No flax oil capsule,only placebo(soya oil) capsule will be administered alongside equivalent antihypertensive drug in newly diagnosed hypertensive subjects.
89068459|NCT04499820|Placebo Comparator|MERALUT Group|vitamin A, natural flavonoids, lutein and zeaxanthin and no DHA
89690612|NCT01923272|Sham Comparator|Sham Device|inactive AlphaCore device
89690613|NCT01923272|Active Comparator|AlphaCore|Active AlphaCore device
89690614|NCT03082664|No Intervention|Standard dressing|Standard dressing will be applied after C-section.
89690615|NCT03082664|Experimental|PICO dressing|Device: PICO Single Use Negative Pressure Wound Therapy
89690616|NCT00633152|Experimental|Ceftaroline|Intramuscular every 12 hours
89690617|NCT00633152|Active Comparator|linezolid plus optional aztreonam|Intravenous every 12 hours
89690618|NCT01030783|Experimental|tivozanib (AV-951)|
89690619|NCT01030783|Active Comparator|sorafenib|
89690620|NCT00633074|Experimental|Thiomersal-free FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal-free FluAS25 adjuvanted vaccine
89690621|NCT00633074|Experimental|Thiomersal reduced FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal reduced FluAS25 adjuvanted vaccine
89690622|NCT01929278|Experimental|CT Gel patch|CT Gel is a reformulation of VELAC Gel that contains the same active ingredients (clindamycin 1% and tretinoin 0.025%) in a modified vehicle. The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
89690623|NCT01929278|Placebo Comparator|Vehicle gel patch|The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
89690624|NCT01929278|Experimental|Blank patch|Blank patches did not contain CT Gel or vehicle gel.
89690625|NCT01929356|Experimental|chest physiotherapy|session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device
89690626|NCT01923350|Experimental|Weight Reduction Intervention|
89690627|NCT01923350|Active Comparator|Weight Reduction Control Arm|
89690628|NCT01923350|Active Comparator|Tested for diabetes|
89690629|NCT01923350|Active Comparator|Not tested for diabetes|
89690630|NCT03210376|Experimental|Deep Neuromuscular Blockade (NMB) + Sugammadex|"Deep Neuromuscular Blockade (NMB) given during surgery.~Sugammadex intravenously as a single bolus injection after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
89690631|NCT03210376|Experimental|Moderate Neuromuscular Blockade (NMB) + Neostigmine|"Moderate Neuromuscular Blockade (NMB) given during surgery.~Neostigmine intravenously slowly over a period of at least 1 minute after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
89690632|NCT01929434|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
89690633|NCT01929434|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
89690634|NCT01929434|Experimental|stem cell injection|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
89690635|NCT01929512|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 750/20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
89690636|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
89690637|NCT01929512|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 750/20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
89223721|NCT05917860|Experimental|3-month neoadjuvant Degarelix followed by whole-gland MRI-guided transurethral ultrasound ablation|After three months of neoadjuvant ADT with Degarelix, the subject will undergo whole-prostate gland MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) treatment.
89690638|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
89690639|NCT03127904|Experimental|Vein Fitness|"Lymphomiokinetic exercises will be performed during a 1 hour period, with the patients in a supine position, legs elevated and properly positioned on a carpet; the knees will be mildly flexed to a comfortable point. The patients will put feet on the pedals of ankle extension/flexion device. The frequency will be around 15 to 20 cycles/minute, while the amplitude will be individually adjusted according to the range of movement of each patient. During the exercises, study personnel will manually drain the lower members.~Compressive therapy will be applied as described in the control group arm.~Care of the wound will be delivered as described in the control group arm."
89223722|NCT05917834||Imframammary|Imframammary- NSM using imframammary incision
89223723|NCT05917834||Radial/Peri-areolar|Radial/Peri-areolar- NSM using Radial/Peri-areolar incision
89223724|NCT05917808|Experimental|Study arm|Only study arm in the study. Participants consume a ready-to-eat wholegrain porridge on two consecutive evenings and repeat OGTT
89223725|NCT05917769|Experimental|Group A (Rocabdo exercises)|The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day. It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction.
89223726|NCT05917769|Experimental|Group B (Postural correction exercises)|This group will perform posture correction exercises for six days and six times per day. Posture correction exercises include chest stretch , wall stretch , chin tuck in and face down arm lifts.
89223727|NCT05917756|Experimental|Group A (experimental group)|MWM techniques combined with a tailored therapeutic exercise program
89223728|NCT05917756|Active Comparator|Group B (control group)|Conventional physiotherapy combined with a tailored therapeutic exercise program
89223729|NCT05917743|Experimental|Mat Pilates|Mat Pilates exercises targeting core strength, flexibility, and muscle control
89223730|NCT05917743|Active Comparator|General Exercises|
89223731|NCT05917730||Experimental: Emotional Regulation and Interpersonal Abilities group Therapy (MERITA).|12 sessions of 75 minutes each and are carried out weekly. MERIT aims to improve emotional regulation, to cope with problems, promoting interpersonal skills and attachment security. Sessions will be lead by two psychologists with accredited experience in MERITA.
89223732|NCT05917730||Control: Treatment As Usual|The treatment as usual provided in children and adolescents who witnesses DV is mainly individual psychotherapy.
89223733|NCT05917704|Active Comparator|Guitar then physical therapy|Subjects will learn classical guitar then have physical therapy sessions.
89223734|NCT05917704|Active Comparator|Physical therapy then guitar|Subjects will have physical therapy sessions then learn classical guitar
89223735|NCT05917691||Dependent functional status|"223 patients; dependent for those documented as partially dependent or totally dependent."
89223736|NCT05917691||Independent functional status|"65404 patients; independent for those documented as such."
89223737|NCT05917652||RedCap surverys|The study team will use REDCap to send an IRB approved secure electronic survey
89223738|NCT05917652||Interviews|The study team plans to do about 18-23 one-on-one interviews with clinicians (burn care nurses, physicians, advanced practice providers, therapists) or will progress until data saturation is reached.
89223739|NCT05917600|Experimental|Interventional group|The interventional group meets an Advanced Practice Nurses (APN) between the ambulatory hospitalization (AH) and the MD consultation
89223740|NCT05917600|No Intervention|Control group|The control group of patients keeps a traditional follow-up (ambulatory hospitalization (AH) then consultation with a MD)
89223741|NCT05917561|Experimental|Phototherapy associated with active treatment|Anifrolumab 300mg/infusion/month for 36 weeks + UVB TL01: 2 times a week during 24 weeks. (Phototherapy will be started 12 weeks after the beginning of anifrolumab)
89223742|NCT05917561|Placebo Comparator|Phototherapy associated with placebo|Placebo once a month infusion for 36 weeks + UVB TL01: 2 times a week during 24 weeks.
89223743|NCT05917535|Experimental|Intervention group|Patients offered mentalizing course supplemental to treatment as usual
89223744|NCT05917535|No Intervention|Control|Control group - treatment as usual.
89223745|NCT05917093|Experimental|Culturally tailored HLWD|
89223746|NCT05915338||Experimental Group|"-Pre-test data were obtained by using the descriptive information form, İUBGF, VAS, and HRAS.~The patients were asked to self-administer a dose of insulin that day, and the ability of the patients to administer the insulin dose was recorded in the IUBGF as the 1st follow-up by the researchers. Afterwards, individual insulin use training was given and the Educational Manual on the Use of Insulin for Individuals with Type 2 Diabetes was given to the patients and the first follow-up was completed.~-2 weeks later, post-test data were obtained from the patients using IUBGF, VAS, and HRAS. The ability of the patients to administer the insulin dose was recorded in the IUBGF as the second follow-up by the researchers.~After 8 weeks, post-test data were obtained by using IUBGF, VAS, and HRAS as retention tests. The ability of the patients to administer the insulin dose was recorded by the researchers as the 3rd follow-up retention test in IUBGF."
89223747|NCT05915338||Control Group|"-Pre-test data were obtained by using the descriptive information form, İUBGF, VAS, and HRAS.~The patients were asked to self-administer a dose of insulin that day, and the ability of the patients to administer the insulin dose was recorded in the IUBGF as the 1st follow-up by the researchers.~-2 weeks later, post-test data were obtained from the patients using IUBGF, VAS, and HRAS. Patients were asked to self-administer a daily dose of insulin. The ability of the patients to administer the insulin dose was recorded in the IUBGF as the second follow-up by the researchers.~After 8 weeks, post-test data were obtained by using IUBGF, VAS, and HRAS as retention tests. Patients were asked to self-administer a daily dose of insulin. The ability of the patients to administer the insulin dose was recorded in IUBGF as the 3rd follow-up retention test by the researchers."
89223748|NCT05914766|Experimental|Study Phase I: PATHWAYS Intervention|Participants assigned to the PATHWAYS Intervention will receive: 1) four coaching sessions, 2) a comprehensive patient education guidebook, and 3) a coaching session workbook.
89068460|NCT04481256|Experimental|1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy|"Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.~External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy"
89068461|NCT02888964|Experimental|ACTOS treatment|Imatinib mesylate at the same daily dose and pioglitazone as add-on therapy at 30 mg/d during 2 months and then 45 mg/d in the absence of serious adverse events
89068462|NCT04416516|Experimental|Arm 1, Patients with 1 Tumour|"Participants with 1 Target Tumour will receive 3 x ASN-002 1.0x10(11) Injections~+ VISMODEGIB (150 mg) daily for 4 weeks."
89068463|NCT04416516|Experimental|Arm 2, Patients with 3 or more Tumours|Participants with 3 or more Target Tumours will receive 3 x ASN-002 1.0x10(11) Injections (per tumour) + VISMODEGIB (150 mg) daily for 4 weeks.
89068464|NCT04387110||Ocrelizumab|Women receiving treatment for multiple sclerosis with ocrelizumab infusion between 2 and 36 weeks postpartum.
89068465|NCT04207008|Experimental|iBDecide App Decision-support Arm|Participants will download the iBDecide app on their smartphone approximately two weeks prior to the scheduled clinic visit. Approximately one week after the clinic visit, survey data, along with demographic data will be collected from all participants via a brief telephone call. We will collect data on app use between installation and the clinic visit as well as in the 3 months following the clinic visit.
89068466|NCT04207008|No Intervention|Control Arm|Control participants will not use the iBDecide app prior to their clinic visit. They will complete a brief telephone survey approximately one week from clinic visit.
89068467|NCT04206930|No Intervention|Control|Standard support: information on alcoholic pathology, medico-psycho-social assessment, relapse prevention program
89068468|NCT04206930|Experimental|Art-Therapy|in addition to standard treatment, art therapy treatment program: 1 session of 2 hours per week in a closed group for 10 weeks
89068469|NCT02889042|Experimental|Volunteers repeated drug poisoning|performing MRI and a biological assessment
89068470|NCT02889042|Other|Volunteers single drug poisoning|performing MRI and a biological assessment
89068471|NCT02889042|Other|alcoholic|performing MRI and a biological assessment
89068472|NCT02889042|Other|volunteers|performing MRI and a biological assessment
89068473|NCT02888808||Erosive GERD|Gastroscopy examination.
89068474|NCT02888808||Control population|Gastroscopy examination.
89068475|NCT04320108|Experimental|Experimental group|3,000 pulses per time, low energy under 0.3 mJ/mm^2, tolerable range
89068476|NCT04320108|Sham Comparator|Control group|Sham therapy
89068477|NCT03582150|Experimental|Receiving Soberlink Device|
89068478|NCT03456726|Experimental|FL with EZH2 gene mutation|Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
89068479|NCT03456726|Experimental|DLBCL with EZH2 gene mutation|Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
89068480|NCT03377478|Experimental|Lung Transplant|Patients will be transplanted with HCV positive lung. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).
89068481|NCT03181932|Experimental|Double-blind vancomycin inhalation powder|Vancomycin inhalation powder 30 mg is administered twice daily (BID) during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
89068482|NCT03181932|Placebo Comparator|Double-blind placebo inhalation powder|Matching placebo is administered BID during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
89068483|NCT03181932|Experimental|Open-label vancomycin inhalation powder|In the 24-week Period 2, all participants receive AeroVanc 30 mg BID by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
89068484|NCT02864862|Active Comparator|Immediate implant|Immediate implant alone
89068485|NCT02864862|Active Comparator|Immediate implant combined with SCTG|Subepithelial connective tissue graft (SCTG)
89068486|NCT02864862|Active Comparator|Immediate implant combined with ADM|Acellular dermal matrix (ADM)
89068487|NCT02888730|Experimental|Tobramycin nebulized nasally|Nebulized Tobramycin, one bulb (tobramycin 300 mg and sodium chloride 11.25 mg) nasally twice a day for 15 days
89068488|NCT02888730|Placebo Comparator|Physiologic serum nebulized nasally|Nebulized sodium chloride 0.9%, one bulb twice a day nasally for 15 days
89068489|NCT02058264|Experimental|Low Strength BBI-4000 and Vehicle|
89068490|NCT02058264|Experimental|High Strength BBI-4000 and Vehicle|
89068491|NCT01598298|Experimental|Arm I|Patients receive duloxetine hydrochloride orally (PO) once daily (QD) on days 1-7, twice daily (BID) on days 8-84, and then QD on days 85-91.
89068492|NCT01598298|Placebo Comparator|Arm II|Patients receive placebo PO QD on days 1-7, BID on days 8-84, and then QD on days 85-91.
89068493|NCT01235949|Experimental|Group IIBU|Immediate ibuprofen group: subjects receiving immediate ibuprofen treatment after each primary vaccine dose
89068494|NCT01235949|Active Comparator|Group DIBU|Delayed ibuprofen group: subjects receiving delayed ibuprofen treatment after each primary vaccine dose
89068495|NCT01235949|Active Comparator|Group NIBU|No ibuprofen group: subjects receiving no prophylactic ibuprofen treatment after each primary vaccine dose
89068496|NCT01235949|Experimental|Group IPARA|Immediate paracetamol group: subjects receiving immediate paracetamol treatment after each primary vaccine dose
89068497|NCT01235949|Experimental|Group DPARA|Delayed paracetamol group: subjects receiving delayed paracetamol treatment after each primary vaccine dose
89068498|NCT01235949|Active Comparator|Group NPARA|No paracetamol group: subjects receiving no prophylactic paracetamol treatment after each primary vaccine dose
89068499|NCT01235949|Experimental|Group IIBU-IIBU|1/3 of the subjects from the primary IIBU group receiving immediate ibuprofen treatment after booster vaccination
89068500|NCT01235949|Experimental|Group IIBU-DIBU|1/3 of the subjects from the primary IIBU group receiving delayed ibuprofen treatment after booster vaccination
89068501|NCT01235949|Experimental|Group IIBU-NIBU|1/3 of the subjects from the primary IIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
89068502|NCT01235949|Experimental|Group DIBU-IIBU|1/3 of the subjects from the primary DIBU group receiving immediate ibuprofen treatment after booster vaccination
89068503|NCT01235949|Experimental|Group DIBU-DIBU|1/3 of the subjects from the primary DIBU group receiving delayed ibuprofen treatment after booster vaccination
89068504|NCT01235949|Experimental|Group DIBU-NIBU|1/3 of the subjects from the primary DIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
89068505|NCT01235949|Experimental|Group NIBU-IIBU|1/3 of the subjects from the primary NIBU group receiving immediate ibuprofen treatment after booster vaccination
89068506|NCT01235949|Experimental|Group NIBU-DIBU|1/3 of the subjects from the primary NIBU group receiving delayed ibuprofen treatment after booster vaccination
89068507|NCT01235949|Active Comparator|Group NIBU-NIBU|1/3 of the subjects from the primary NIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
89068508|NCT01235949|Experimental|Group IPARA-NPARA|subjects from the primary IPARA group receiving no paracetamol treatment after booster vaccination
89068509|NCT01235949|Experimental|Group DPARA-IPARA|subjects from the primary DPARA group receiving immediate paracetamol treatment after booster vaccination
89068510|NCT01235949|Experimental|Group NPARA-IPARA|subjects from the primary NPARA group receiving immediate paracetamol treatment after booster vaccination
89068511|NCT00691158|Placebo Comparator|1- Normal Saline|4.7 mls normal saline IV bolus
89068512|NCT00691158|Active Comparator|2 Metreleptin|IV Leptin bolus
89068513|NCT00691158|Active Comparator|3 Pramlintide|IV Pramlintide bolus at Timpoint +0 and +30 minutes
89068514|NCT00691158|Active Comparator|4 Leptin plus Pramlintide|leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes
89068515|NCT01235793|Experimental|DRBEAT Regimen|
89068516|NCT01258998|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89068517|NCT05601648|Experimental|Psilocybin|Eligible adults to undergo a single drug session with psilocybin (25mg tablet) plus supportive psychotherapy
89068518|NCT01235715|Active Comparator|Evicel|Evicel is a fibrin sealant used for hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical. It has been shown to stop bleeding in 2 minutes or less. Evicel is a combination of a biologic activated component containing human fibrinogen and topical thrombin that functions on wet, actively bleeding tissue. It is a bioresorbable and biocompatible agent.
89068519|NCT01235715|No Intervention|no evicel|Patients will receive standard treatment for bleeding as practiced at the Hospital for Special Surgery.
89068520|NCT01235403|Experimental|Lacosamide|Flexible dosing between 200mg/day and 400mg/day
89068521|NCT01024036|Experimental|Siltuximab+best supportive care (BSC)|Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
89068522|NCT01024036|Placebo Comparator|Placebo+BSC|Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC. Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.
89068523|NCT01234467|Experimental|Bendamustine, Rituximab|This is a single arm intervention where patients will receive bendamustine at a dose of 120 mg/m^2 infused over 60 minutes in days 1 and 2 of each 21 day cycle along with rituximab 375 mg/m^2 after bendamustine on day 1 of each cycle. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 at baseline were allowed to receive bendamustine at a dose of 90 mg/m^2 daily with a dose increase to 120 mg/m^2 daily if their ECOG improved.
89068524|NCT04300036|Experimental|longan syrup|Take 15 ml of longan syrup once a day for 3 months
89068525|NCT04300036|Placebo Comparator|Placebo syrup|Take 15 ml of placebo syrup once a day for 3 months
89068526|NCT02875912|No Intervention|Usual Care|Family members are surveyed at enrollment, day 5 (if patient is still in ICU), and 90 days post ICU discharge for symptoms of PTSD, depression, and anxiety as well as for concordance of care at enrollment and ICU day 5. Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed to establish baseline data
89068527|NCT02875912|Experimental|Family Care Rituals Intervention|At enrollment, family members are given a handout/pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so. The families are then surveyed in the same way as they were during the usual care, with nursing completing the same surveys as well to compare against the baseline data
89068528|NCT01233999|Placebo Comparator|Botox|single-drug dosage comparison cross-over study
89068529|NCT01233687|Experimental|AMG 102 and erlotinib|Combination of AMG 102 and erlotinib
89068530|NCT01023958|Experimental|single arm|open label
89068531|NCT01233609|Active Comparator|Valproic Acid|Subjects who receive valproic acid
89068532|NCT01233609|Placebo Comparator|Placebo|Subjects who receive placebo
89068533|NCT01232283|Experimental|Apremilast|Participants were initially randomized 2:1 and received apremilast 30 mg twice a day (BID). Participants maintained dosing through Week 32. At Week 32, responders, those with a Psoriasis Area Severity Index response -≥75 (PASI-75) and partial responders (≥PASI-50) were re-randomized 1:1 to apremilast 30 mg BID or matching placebo (treatment withdrawal). Participants could resume apremilast 30 mg BID at the time of loss of 50% of improvement in PASI score response which was observed at Week 32 compared to baseline), and no later than Week 52. At Week 52, the non-responders (<PASI-50) had the option of adding topical therapies and/or phototherapy to their treatment regimen. Those re-randomized to apremilast 30 mg BID continued dosing through Week 52. At Week 52, participants continued treatment with apremilast 30 mg BID.
89068534|NCT01232283|Placebo Comparator|Placebo|Participants will be initially randomized to placebo, identically matching during Weeks 0-16. At Week 16, Placebo participants will be switched to receive apremilast 30 mg BID. All participants will maintain Apremilast dosing through Week 32. At Week 32, participants originally randomized to placebo at baseline (Week 0) and are considered non-responders i( < PASI-50) will have the option of adding topical therapies and/or phototherapy to their Apremilast treatment regimen. At Week 52, all participants will continue treatment with apremilast 30 mg BID. Participants will be followed and evaluated for safety and efficacy for up to an additional 4 years (years 2 through 5).
89068535|NCT01232127|Other|Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI|The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
89068536|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
89068537|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
89068538|NCT01258608|Experimental|Sorafenib plus mapatumumab|Mapatumumab 30 milligrams (mg)/kilogram (kg) intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
89223749|NCT05914766|Active Comparator|Study Phase I: Enhanced Usual Care|Participants assigned to the enhanced usual care will receive: 1) an information resource guide for navigating information online.
89223750|NCT05914766|Experimental|Study Phase II: PATHWAYS Intervention|Participants assigned to the PATHWAYS Intervention will receive: 1) four coaching sessions, 2) a comprehensive patient education guidebook, and 3) a coaching session workbook.
89223751|NCT05914766|Active Comparator|Study Phase II: Enhanced Usual Care|Participants assigned to the enhanced usual care will receive: 1) an information resource guide for navigating information online.
89223752|NCT05914636||Ruptured|Patient with a ruptured intracranial sacciform aneurysm for all location. The diagnosis of ruptured aneurysm is made on MRI, Angio-CT or digital substraction angiography with no doubt
89223753|NCT05914636||unruptured|Patient with an unruptured intracranial sacciform aneurysm for all location. The diagnosis of unuptured aneurysm is made on MRI, Angio-CT or digital substraction angiography with no doubt
89223754|NCT05913817||Adalimumab Reference Product to AVT-02|Patients switching from the high-volume, low concentration, citrate containing Adalimumab reference product to the low-volume, high-concentration, citrate-free AVT-02 Adalimumab Biosimilar.
89223755|NCT05913817||Other Adalimumab Biosimilar to AVT-02|Patients switching from another high-volume, low concentration, citrate-containing or citrate-free Adalimumab biosimilar product to the low-volume, high-concentration, citrate-free AVT-02 Adalimumab Biosimilar.
89223756|NCT05912764|Experimental|Early home return arm|Nurses will coordinate the patients' care prior to their intervention and when they leave the Clinics.
89223757|NCT05912764|No Intervention|Standard Of Care arm|Patients will not receive any support before and after intervention and hospital leave
89223758|NCT05898386|No Intervention|Control Group|No intervention was made in the control group. The women in the control group were called during the 3-month follow-up to ask whether they received treatment for urinary incontinence simultaneously with the telephone calls of the intervention group.
89223759|NCT05898386|Experimental|Intervention Group|"A training and counseling program based on the pender's health promotion model was applied to the intervention group.~After the training, 3 home visits and 3 phone calls were made to support the implementation of behavioral and lifestyle changes in coping with urinary incontinence."
89223760|NCT05897866|Experimental|Issa3|Dr.A.Sayed Issa and his team
89223761|NCT05896644|Experimental|Eat Well|The experimental group will participate in the Eat Well Produce Prescription program, receiving an $80 monthly benefit for eligible produce for 12 months and diabetes education materials through email, including curated nutrition and diet information from the Diabetes Resource Page, consistent with standard of care at Duke University Health System.
89223762|NCT05896644|No Intervention|Control|The control group will receive usual care (including diabetes educational materials) without the prescription benefit.
89223763|NCT05890976|Experimental|Semaglutide 50 mg|Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 44 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), 25 mg (weeks 13 to 16) and 50 mg (weeks 17 to 44).
89223764|NCT05890976|Placebo Comparator|Semaglutide Placebo|Participants will receive placebo tablets matched to semaglutide orally once daily for 44 weeks.
89223765|NCT05883241|Experimental|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 12 weeks combined with 2.5% diclofenac patch. The SAM Device emits continuous ultrasound at 3-megahertz (MHz) frequency and 0.132 watts/cm^2 intensity.
89223766|NCT05882669||Knee arthroplasty|All adult patients undergoing primary total knee replacement surgery at the Traumatology, Orthopedics and Joint Pathology Clinic of the I.M. Sechenov First Moscow State Medical University (Sechenov University) who meet the inclusion criteria (described below) will be included.
89223767|NCT05882656||Hip arthroplasty|All adult patients undergoing primary total hip replacement surgery at the Traumatology, Orthopedics and Joint Pathology Clinic of the I.M. Sechenov First Moscow State Medical University (Sechenov University) who meet the inclusion criteria (described below) will be included.
89223768|NCT05880888|Experimental|Renuva Injection|Each subject will receive a single injection of up to 3ccs of Renuva into their diseased fat pad.
89223769|NCT05874245|Experimental|Group D; oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia.
89223770|NCT05874245|Experimental|Group K; oral ketamine group|will receive 6 mg/kg oral Ketamine diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia.
89068539|NCT01258608|Placebo Comparator|Sorafenib plus Placebo|Placebo intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
89068540|NCT01015612|Experimental|Medtronic CoreValve® System Implantation|Patients with symptomatic severe aortic stenosis who have an elevated surgical risk
89068541|NCT04319874|Sham Comparator|sham group|Treated with conventional chemotherapy drugs
89068542|NCT04319874|Placebo Comparator|NC group|Treated with conventional chemotherapy drugs and Placebo
89068543|NCT04319874|Experimental|experimental group|Treated with conventional chemotherapy drugs and Ganoderma lucidum
89068544|NCT01231659|Experimental|Everolimus + Letrozole|All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.
89068545|NCT02875288|Experimental|Liposomal Bupivicaine arm|"Post procedure, infiltrate wounds with liposomal bupivacaine~Liposomal Bupivacaine (Brand name Exparel) 266 milligram (mg)/20 mL to be diluted to 30 mL with normal saline~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
89068546|NCT02875288|Active Comparator|Plain Bupivicaine|"Post procedure, infiltrate wounds with plain bupivicaine~Plain Bupivacaine 0.25%, volume of 30 mL~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
89068547|NCT01054222|Other|Fesoterodine 4 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
89068548|NCT01054222|Other|Fesoterodine 8 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
89068549|NCT01052428|Active Comparator|Toprol XL|beta 1 receptor blockade; generic name metoprolol succinate
89068550|NCT01052428|Placebo Comparator|Placebo|Pill that looks like Toprol XL but does not have the active ingredients
89068551|NCT01052272|Active Comparator|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
89223771|NCT05874245|Experimental|Group M; oral Midazolam group|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol [Paracetamol syrup 150 mg/5ml] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia.
89068552|NCT01052272|Active Comparator|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
89068553|NCT01052272|Active Comparator|Ramipril and Allopurinol|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily. It is anticipated that the starting dose of each drug will be initiated in hospital and that the second dose will be implemented prior to discharge from the hospital. The starting dose of Allopurinol is 300 mg daily.
89068554|NCT01052272|Active Comparator|Candesartan cilexetil and Allopurinol|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily. The starting dose of Allopurinol is 300 mg daily.
89068555|NCT01257204|Active Comparator|Control|Placebo + Pegylated interferon alfa-2a + Ribavirin
89068556|NCT01257204|Experimental|12 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
89068557|NCT01257204|Experimental|16 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
89068558|NCT01231581|Experimental|GSK1120212 plus Gemcitabine|GSK1120212 administered orally plus gemcitabine IV
89068559|NCT01231581|Active Comparator|Placebo plus Gemcitabine|Placebo administered orally plus gemcitabine IV
89068560|NCT01050634||Observational|
89068561|NCT01020526|Experimental|Pregabalin|
89068562|NCT01020448|Experimental|Triptorelin (Decapeptyl®) 22.5 mg|
89068563|NCT02872324|Experimental|Sessions of Mindfulness Based Cognitive Therapy (MBCT)|
89068564|NCT01256658|Experimental|Intervention|Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.
89068565|NCT01256658|Experimental|Control|Participants received COA566 treatment for symptomatic malaria episodes only.
89068566|NCT01256502|Other|Implanted Participants|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
89068567|NCT01256190|Experimental|Fibrocaps + Gelatin sponge|Topical Fibrocaps powder followed by application of gelatin sponge
89068568|NCT01256190|Active Comparator|Gelatin Sponge|approved device for surgical bleeding
89068569|NCT01255722|Experimental|Iobitridol|Patients were IV injected with a single dose of iobitridol before a coronary CT angiography
89068570|NCT01255722|Active Comparator|Iopromide|Patients were IV injected with a single dose of iopromide before a coronary CT angiography
89068571|NCT01255722|Active Comparator|Iomeprol|Patients were IV injected with a single dose of iomeprol before a coronary CT angiography
89068572|NCT02888574|Experimental|Intranasal Oxytocin|Oxytocin nasal spray delivered bi-daily over a 14-day period at 24-IU per dose
89068573|NCT02888574|Placebo Comparator|Placebo|Placebo nasal spray containing the same ingredients as the active nasal spray minus the oxytocin and packaged in an identical bottle. To be delivered bi-daily over a 14-day period at 24-IU per dose
89068574|NCT01231503|Experimental|RTS,S Neo-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 14 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
89068575|NCT01231503|Experimental|RTS,S Neo-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanri xHepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
89223772|NCT05873257|Other|main arm|Non comparative - One armed - open labelled Intervention - subjects will wear the test dressing in a four weeks period with planned dressing changes once pr. week.
89223773|NCT05870189|Experimental|Remote CMR|adults with SCI without restriction for race, sex or socio-economic status randomized to CMR intervention.
89223774|NCT05870189|Placebo Comparator|Remote exercises|adults with SCI without restriction for race, sex or socio-economic status randomized to remote exercise intervention.
89068576|NCT01231503|Experimental|RTS,S 6-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 14 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
89068577|NCT01231503|Experimental|RTS,S 6-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
89068578|NCT01231503|Experimental|Engerix-B Neo/RTS,S 6-10-26 Group|Subjects received one dose of Engerix-B (HBV) when ≤ 7 days of age followed by 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E and HBV vaccines were administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
89068579|NCT01231503|Experimental|RTS,S 10-14-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 10, 14 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
89068580|NCT01231503|Experimental|RTS,S 14-26-9M Group|Subjects received 3 doses of RTS,S/AS01E (or GSK257049) at 14 and 26 weeks of age and at 9 months of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
89068581|NCT01231503|Active Comparator|Engerix-B Neo Group|Subjects in this group received one dose of Engerix-B (HBV) ≤ 7 days of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The HBV vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
89068582|NCT01230489|No Intervention|Standard Care|This group will undergo the current standard of care for post operative exit sites at the involved institutions. This group will act as the control or the group to which the interventional group will be compared too.
89223775|NCT05869318|Experimental|Vaping|All participants will undergo two vaping sessions: one using their own device and one using the study device
89690640|NCT03127904|Active Comparator|Control group|"Compressive therapy will be applied to both groups by properly trained personnel. Each layer of the compressive boot will have a 50% overlap, from the base to of the fingers to 3 cm bellow the popliteal fossa. The interface pressure used will be of at least 50mmHg in supine position.~Wound care will be delivered to every individual in both groups, 1 or 2 times each week by a nurse certified in wound management, following the principles of maintenance of a moisturized surface between the wound and its cover. The nurse will also carry out mechanical wound debriding and biofilm removal."
89690641|NCT04447898|Experimental|Low dose|10 μg + Montanide™ ISA 51 VG
89690642|NCT04447898|Experimental|High dose|50 μg + Montanide™ ISA 51 VG
89690643|NCT03211234|Experimental|2.0 mg DE-122|2.0 mg DE-122 and Lucentis ® 0.5 mg
89690644|NCT03211234|Experimental|4.0 mg DE-122|4.0 mg DE-122 and Lucentis ® 0.5 mg
89690645|NCT03211234|Sham Comparator|Sham|Sham and Lucentis ® 0.5 mg
89690646|NCT01030861|Active Comparator|teplizumab|Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by a 2 hour observation period.
89690647|NCT01030861|Placebo Comparator|Placebo infusion|Intravenous infusion of placebo (saline) will be given for 14 consecutive days. Infusions will take approximately 30 minutes and will be followed by a two hour observation period.
89690648|NCT03105518|Experimental|Analgesia options|Protocolized analgesia based on VAS degree of discomfort and time. Analgesic options include heating pad, acetaminophen, percocet (oxycodone), fentanyl 0.5-1 mcg/kg.
89690649|NCT01929668|Active Comparator|polyethylene glycol|4L polyethylene glycol
89690650|NCT01929668|Experimental|polyethylene glycol with ascorbic acid|2L polyethylene glycol and ascorbic acid
89068583|NCT01230489|Experimental|MediHoney|This study group will have the dry 2 x 2 dressing replaced with a honey 2 x 2 dressing. Additionally all indentations in the exit site wound will be filled with honey ointment prior to the application of the dressing.
89068584|NCT01229397|Active Comparator|Inflexal V 0.25 mL x 2|
89068585|NCT01229397|Experimental|Inflexal V 0.5 mL x 1|
89068586|NCT05492097|Experimental|Exercise Group|For the patients in this group, 3 days a week for 4 weeks; various exercises and walking training will be given in sitting, crawling, kneeling, half-kneeling and standing positions and 20 minutes NMES will be applied.
89068587|NCT05492097|Experimental|Exercise and Robotic Group|In addition to the exercise group treatment, patients will receive gait training for 4 weeks, 3 sessions a week, with the last effector fixed robot Lokohelp.
89068588|NCT01228071|Experimental|40 mg daily dose of testosterone gel 2%|testosterone gel 2%
89068589|NCT04319289|Experimental|Group (A)|"Included 15 patients who are participating in an aerobic interval training exercise program with vitamin D supplementation (cholecalciferol 400 IU/day).~The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks."
89068590|NCT04319289|Experimental|Group (B)|Included 15 patients who are receiving vitamin D supplementation only . One capsule containing (cholecalciferol 400 IU) was taken every day for 12 weeks
89068591|NCT04319289|Experimental|Group (c)|Included 15 patients who are participating in an aerobic interval training exercise program only. The aerobic interval training is conducted for one hour, three days per week on a total period of 12 weeks.
89068592|NCT04319133|Experimental|intervention|Participants will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
89068593|NCT04319133|No Intervention|control|Participants will not doing fasting or intake restriction within 8 weeks
89068594|NCT01008475|Experimental|Safety part: EMD 525797 250 mg + Standard of Care (SoC)|EMD 525797 250 mg in combination with cetuximab and irinotecan
89068595|NCT01008475|Experimental|Safety part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
89068596|NCT01008475|Experimental|Safety part: EMD 525797 750 mg + SoC|EMD 525797 750 mg in combination with cetuximab and irinotecan
89068597|NCT01008475|Experimental|Safety part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg in combination with cetuximab and irinotecan
89068598|NCT01008475|Experimental|Randomized part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
89068599|NCT01008475|Experimental|Randomized Part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg (or dose as defined by safety monitoring committee (SMC)] in combination with cetuximab and irinotecan.
89068600|NCT01008475|Other|Randomized Part: SoC|Cetuximab and irinotecan
89068601|NCT04294303|Experimental|Telemonitoring|Subjects were assigned to web based telemonitoring system.
89068602|NCT04294303|Other|Control|Subjects were assigned to conventional monitoring.
89068603|NCT02870725|No Intervention|Control Group (Treatment As Usual)|Individuals randomized into the control condition will not receive any active treatment but will have access to customary, community-based supportive services. These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of comparison for those in the other arm of the study.
89068604|NCT02870725|Experimental|CBT Individual Psychotherapy (Treatment)|Behavioral Intervention (Individual Psychotherapy). These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of determining whether or not the intervention was effective compared to the control arm.
89068605|NCT01226745|Experimental|ONO-4641 0.15 milligram (mg) - 0.15 mg|
89068606|NCT01226745|Experimental|ONO-4641 0.10 mg - 0.10 mg|
89068607|NCT01226745|Experimental|ONO-4641 0.05 mg - 0.05 mg|
89068608|NCT01226745|Experimental|Placebo - ONO4641 0.15 mg|
89068609|NCT01226745|Experimental|Placebo - ONO4641 0.10 mg|
89068610|NCT01226745|Experimental|Placebo - ONO4641 0.05 mg|
89068611|NCT02870647|Other|Single arm study|only 1 arm - no comparison nor randomization in this study
89068612|NCT01226511|Experimental|Duloxetine|30-120 mg flexible dosing once daily for 10 weeks. At the end of the 10 week blinded treatment period, participants may participate in an 18 week extension
89068613|NCT01226511|Placebo Comparator|Placebo|Administered once daily for 10 weeks. At the end of the 10 week blinded treatment period, placebo participants receive duloxetine in the 18 week extension
89068614|NCT02691351||non-Hodgkin T-cell Lymphoma|
89068615|NCT01226121|Active Comparator|Day 1 manipulation|Finger manipulation one day following Clostridial collagenase injectable
89068616|NCT01226121|Active Comparator|Day 2 manipulation|Finger manipulation two days following Clostridial collagenase injectable
89068617|NCT01226121|Active Comparator|Day 4 manipulation|Finger manipulation four days following Clostridial collagenase injectable
89068618|NCT01226043|Experimental|Lantus (insulin glargine) vial & syringe|10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
89068619|NCT01226043|Experimental|Lantus (insulin glargine) SoloSTAR pen|3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
89068620|NCT04206579|Experimental|10% Dextrose|Oral 10% Dextrose
89068621|NCT04206579|Experimental|Natrium Dextrose|Oral Natrium Dextrose
89068622|NCT01001377|Active Comparator|Cetuximab|"Cetuximab 400 mg/m^2 as an initial dose, followed by 250 mg/m^2 intravenously (IV) every 7 days.~Participants were treated until disease progression, intolerability, withdrawal of consent, or death."
89068623|NCT01001377|Experimental|Panitumumab|Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
89068624|NCT01225887|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89068625|NCT04326829|Experimental|QL1604 Injection|
89068626|NCT01001299|Experimental|Single arm|
89068627|NCT01296932|Experimental|Patients with relapsed CLL|Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
89068628|NCT01296698|Placebo Comparator|Placebo|0 mg Oral NRT, up to 4 times per hour for 12 weeks
89068629|NCT01296698|Experimental|Nicotine|1 mg Oral NRT, up to 4 times per hour for 12 weeks
89068630|NCT01001221|Experimental|Cabazitaxel + gemcitabine|"Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.~On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel."
89690651|NCT01031095|Experimental|Low dose intracoronary heparin|Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin
89068631|NCT01296152|Experimental|Depo-medroxyprogesterone acetate (DMPA)|At study entry/ Day 0, subjects will receive depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
89690652|NCT01031095|Active Comparator|Standard treatment arm|Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin
89690653|NCT01929746|Experimental|BIIB019, 75 mg|BIIB019 delivered via Subcutaneous Injection
89068632|NCT02870257|Experimental|Progressive overload strengthening group|"Strengthening protocol with progressive load~Strengthening muscle exercises for the shoulder and scapular with progressive increase of load during 10 weeks (20 sessions)"
89068633|NCT02870257|Active Comparator|Strengthening group|"Strengthening protocol without progressive load~Strengthening muscle exercises for the shoulder and scapular without increase of load (minimal load) during 10 weeks (20 sessions)"
89068634|NCT01002547|Placebo Comparator|Arm 1|Diabetic with proven NASH by biopsy
89068635|NCT01002547|Active Comparator|Arm 2|Diabetic with proven NASH by biopsy
89068636|NCT01002547|Other|Arm 3|Diabetic with proven NASH by biopsy
89690654|NCT01929746|Experimental|BIIB019, 150 mg|BIIB019 delivered via Subcutaneous Injection
89068637|NCT04295161|Active Comparator|Reference|
89068638|NCT04295161|Experimental|Prototype 1|
89068639|NCT04295161|Experimental|Prototype 2|
89068640|NCT04295161|Experimental|Prototype 3|
89068641|NCT04295161|Experimental|Prototype 4 fasted|administered in fasted state
89068642|NCT04295161|Experimental|Prototype 4 fed|Administered in fed state
89068643|NCT04367623|Active Comparator|Control|Patients receiving conventional hand therapy, time matched to the duration of total intervention in the Active group
89068644|NCT04367623|Active Comparator|Active|Patients receiving BCI FES prior to the conventional therapy
89068645|NCT05240911|Experimental|Poisson regression model dosing scheme|daily levothyroxine dose=e[2.02+0.01(W)-0.0037(A )-0.098(F)-0.01(B)+0.007(T)+0.108(I)-0.014(M), where W is the weight of the patient (Kg), A is the age of the patient (years), and F is the gender (for women 1, male is 0), B represents the patient's body mass index (BMI), T represents the preoperative TSH level, I represents whether the patient takes iron preparations (1, if not 0), M represents whether the patient takes multivitamins/minerals (1, if not 0).
89068646|NCT05240911|Active Comparator|weight-based dosing scheme|daily levothyroxine dose=1.6 μg /kg/d
89068647|NCT02870491|No Intervention|Control|Existing standard of care.
89690655|NCT03212638|Experimental|Baricitinib T1 (Part A)|4 mg (milligram) baricitinib suspension test formulation (TF) administered orally (PO) without water following a 10 hour fast. (Baricitinib T1)
89690656|NCT03212638|Experimental|Baricitinib T2 (Part A)|4 mg baricitinib suspension formulation (TF) administered PO prior to 240 mL water following a 10 hour fast (Baricitinib T2)
89690657|NCT03212638|Experimental|Baricitinib R (Part A)|4 mg baricitinib tablet administered PO, taken with 240 mL water following a 10 hour fast (baricitinib R)
89690658|NCT03212638|Experimental|Baricitinib TF Fasted (Part B)|4 mg baricitinib suspension test formulation (TF) administered after 10 hour fast. (TF fasting)
89690659|NCT03212638|Experimental|Baricitinib TF Fed (Part B)|4 mg baricitinib suspension TF administered after a high fat meal.(baricitinib TF Fed)
89690660|NCT03506048|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO QD for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity. Patients also receive radioactive iodine (RAI) I-131 orally as standard of care.
89690661|NCT02161705|Experimental|Ropivacaine Group|Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
89690662|NCT02161705|Placebo Comparator|Saline Group|Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.
89690663|NCT03216382|Experimental|Attention Training Technique|Participants in this arm will listen to the Attention Training Technique. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
89690664|NCT03216382|Placebo Comparator|Control Condition|Participants in this arm will listen to the control condition recording. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
89690665|NCT01031953|Experimental|Fosaprepitant|
89690666|NCT03310450||Group 140kms cycling|"Participants of Tour de Borobudur 2017 140 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
89690667|NCT03310450||Group 100kms cycling|"Participants of Tour de Borobudur 2017 100 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
89690668|NCT03310450||Group 240kms cycling|"Participants of North Coast 2017 240 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
89690669|NCT01923584|Active Comparator|EPI-743 400mg|EPI-743 at a dose of 400 mg three times daily
89068648|NCT02870491|Experimental|Free Distribute+Preemptive Delivery|Community health workers (CHWs) will deliver oral rehydration salts (ORS) and zinc for free to all households in their catchment area with a child under 5-years-old at the beginning of the study.
89068649|NCT02870491|Experimental|Cost Sharing + Preemptive Delivery|CHWs will visit all households with a child under 5-years-old at the beginning of the study and offer to sell ORS and zinc to caretakers at the time of the visit for them to store in their homes.
89068650|NCT02870491|Experimental|Free Distribution Upon Retrieval|CHWs will visit all households with a child under 5-years-old at the beginning of the study and inform caretakers that they have ORS and zinc available for free that caretakers can retrieved from the CHWs home if needed.
89068651|NCT04452253|Experimental|PS128|"The PS128, which belongs to Lactobacillus plantarum subsp. plantarum, 2 caps daily use and used in both sub-project 1 and 2.~Sub-project 2 (Open label) for IT specialists only take PS128."
89068652|NCT04452253|Experimental|PS23 live|The PS23 belongs to Lactobacillus paracasei group, 2 caps daily use, only used in sub-project 1.
89068653|NCT04452253|Experimental|PS23 heat-treated|PS23 heat-treated, 2 caps daily use, only used in sub-project 1.
89068654|NCT04452253|Placebo Comparator|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use, only used in sub-project 1.
89068655|NCT00628849||1|This group will have 2 mm plates and screws placed according to Champy principles
89068656|NCT00628849||2|This group will have 2 mm plates placed according to modified Champy principles
89068657|NCT00628849||3|This group will have larger (2.3 mm or greater) plates and screws placed according to the AO technique
89068658|NCT00628615||2|male patients with lower urinary tract symptoms
89068659|NCT00628615||1|Female patients with overactive bladder syndrome
89068660|NCT01225731|Experimental|Part 1: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4
89068661|NCT01225731|Experimental|Part 1: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4
89068662|NCT01225731|Experimental|Part 1: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4
89068663|NCT01225731|Experimental|Part 1: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4
89068664|NCT01225731|Placebo Comparator|Part 1: Placebo|Participants receive placebo, SC, at Weeks 0 and 4
89068665|NCT01225731|Experimental|Part 2: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks
89068666|NCT01225731|Experimental|Part 2: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks
89068667|NCT01225731|Experimental|Part 2: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks
89068668|NCT01225731|Experimental|Part 2: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks
89068669|NCT01225731|No Intervention|Part 3: Tildrakizumab 5 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
89068670|NCT01225731|No Intervention|Part 3: Tildrakizumab 25 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
89068671|NCT01225731|No Intervention|Part 3: Tildrakizumab 100 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
89068672|NCT01225731|No Intervention|Part 3: Tildrakizumab 200 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
89068673|NCT01225731|No Intervention|Part 3: Placebo Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
89068674|NCT04280107||Temporomandibular Dysfunction|For this study, 154 patient files who were admitted to the radiology department of the faculty of dentistry between 2013 and 2019 with complaints such as TMJ pain, mouth opening restriction, joint sound, joint function disorder were scanned retrospectively. Inclusion criteria: TMD patients with MR and CBCT images recorded in the digital archive. Exclusion criteria: Patients who have been operated or treated from TMJ, patients with head and neck trauma, patients with orthodontic treatment.
89690670|NCT01923584|Active Comparator|EPI-743 200mg|EPI-743 at a dose of 200 mg three times daily
89690671|NCT01032733|Experimental|Lifestyle Counseling|In the experimental condition, participants attended a group-based weight management session plus three supervised exercise sessions each week.
89690672|NCT01032733|Placebo Comparator|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss.
89690673|NCT01928420|Experimental|NIC5-15|Subjects with Alzheimer's Disease Intervention: Drug: NIC5-15
89690674|NCT01928420|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Drug: Placebo
89690675|NCT03441178|Experimental|Colectomy/Gynecological/Thoracic|Any colectomy/gynecological/thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
89690676|NCT01004107|Experimental|Radiesse Injectable Dermal Filler|Device: Radiesse Injectable Dermal Filler
89690677|NCT01004107|Active Comparator|Delayed Treatment|Cross over to treatment with Radiesse Injectable Dermal Filler at 3 Months
89690678|NCT05593861||This investigation was conducted on chief surgeons at each center.|This investigation was conducted on chief surgeons at each center.
89690679|NCT03218566|Other|Single Arm|Single Arm - Use of Indigo Aspiration System (mechanical thrombectomy) to treat pulmonary embolism
89690680|NCT00630344|Experimental|RAD001 + Bicalutamide|"RAD001: once daily dose of 10 mg (5 mg tablets)~Bicalutamide: once daily dose of 50 mg (50 mg tablets)~1 cycle=28 days~Both agents are administered continuously until progression of disease or unacceptable toxicity."
89690681|NCT02167867|Experimental|Lay End Users|Employees of the test sites (that were fitness centers or spas) who were provided with a User's Manual to operate the ZERONA Z6 to administer 6 40-minute evenly spaced treatments over 2 consecutive weeks to the front and back of the waist, hips and thighs of one Treatment Subject.
89690682|NCT02167867|Experimental|Treatment Subject Group|Treatment subjects received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
89690683|NCT01923818|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo rivaroxaban from day 1 to day 30
89068675|NCT04319211||People who isolate at home with the danger of coronavirus|Demographic data of the individuals participating in the study will be recorded. International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
89068676|NCT01007149|Experimental|Omalizumab|Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
89068677|NCT01007149|Placebo Comparator|Placebo|Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.
89068678|NCT04295083|Experimental|Experimental group|The experimental group will be six 1,5 h weekly of clay based group study and interviewed face-to-face twice by the researchers.
89068679|NCT04295083|No Intervention|Control group|The control group will interviewed face-to-face twice
89690684|NCT01923818|Experimental|Rivaroxaban 5mg|Receiving a 5-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
89690685|NCT01923818|Experimental|rivaroxaban 10mg|Receiving a 10-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
89690686|NCT03442036|Active Comparator|Through-the-Needle Technique|"Perineural catheters are inserted through a straight hollow-bore needle.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
89690687|NCT03442036|Experimental|Suture-Method Technique|"Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
89690688|NCT02913261|Experimental|Ruxolitinib|These patients were administered Ruxolitinib orally twice per day (b.i.d) at a dose of 10 mg bid, as two 5-mg tablets. Ruxolitinib was taken without regards to food.
89690689|NCT02913261|Active Comparator|Best Available Therapy (BAT)|These patients were administered BAT per the Investigator's best judgement based on a specific list of BAT.
89690690|NCT02169115|Experimental|Omalizumab 150mg|
89690691|NCT02169115|Experimental|Omalizumab 300mg|
89690692|NCT02169115|Placebo Comparator|Placebo|
89690693|NCT03219892|Experimental|High-frequency rTMS|Patients randomized to this group will receive rTMS delivering over the supplementary motor area (SMA). Each treatment consists 1000 pulses (5-second burst of 10Hz rTMS, repeated 20 times at every minute ).Stimulus intensity is 90% of resting motor threshold. A figure-of-8 coil is connected to a biphasic magnetic stimulator, and the induced current is perpendicular to the midline.
89690694|NCT03219892|Sham Comparator|Sham rTMS|Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.
89690695|NCT03656107|Experimental|Cognitive training|Participants selected to brain training will be given instructions on how to access and use the program at home for 15-30minutes, 3-5 times per week for 8-12 weeks.
89690696|NCT03656107|No Intervention|Waiting-list control|Control participants will be waiting listed to receive the brain training program at the end of the study. control participants will undergo usual care.
89690697|NCT03015415|Experimental|surgical|Patients undergoing surgical elbow arthrolysis. Elbow Open Arthrolyses
89690698|NCT03015415|Experimental|non-surgical|Patients submitted to a non-surgical rehabilitation protocol using splints Non-surgical intervention
89690699|NCT03220048|Other|Cohort A: Sentinel Group|Sentinel group in which subjects received a challenge virus inoculum volume of 100uL on Day 0.
89690700|NCT03220048|Experimental|Cohort B: PrEP-001|PrEP-001 6400μg dose administered equally over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
89690701|NCT03220048|Experimental|Cohort B: Placebo|Nasal dose of placebo Comparator equally divided over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
89690702|NCT00635882|Experimental|MF/F MDI 100/10 mcg|
89690703|NCT00635882|Experimental|MF/F MDI 200/10 mcg|
89690704|NCT00635882|Experimental|MF/F MDI 400/10 mcg|
89690705|NCT00635882|Experimental|MF DPI 200 mcg|
89690706|NCT00635882|Experimental|MF MDI 200 mcg|
89690707|NCT00635882|Experimental|Placebo|
89690708|NCT03148015||ADH/LCIS|Atypical Ductal Hyperplasia or Lobular carcinoma in situ with DCIS
89690709|NCT03148015||DCIS|Pure Ductal Carcinoma in Situ
89690710|NCT03148015||Invasive|invasive ductal carcinoma with DCIS
89690711|NCT03445156|Experimental|Pilot Study|After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game or a nonviolent shooting video game for 20 minutes. Video game play was recorded. A debriefing followed.
89690712|NCT03445156|Experimental|Experiment Proper|"After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro bullets. A debriefing followed."
89690713|NCT03082495|Experimental|Exercise|Aerobic exercise
89690714|NCT03082495|No Intervention|Usual Care|Standard medical care
89690715|NCT03001063|Experimental|Intervention|This arm will receive the Supported Self- Management intervention, which consists of bibliotherapy that is provided with the regular support of health or social workers for a duration of two months.
89690716|NCT03001063|Other|Control|This arm will receive enhanced treatment as usual, which consists of a leaflet with information about depression and regular care as provided by primary care centres. The control arm will receive the intervention after the intervention arm has completed the intervention period.
89690717|NCT03316378|Experimental|Group with Achilles Tendinopathy|Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.
89223776|NCT05824143|Experimental|Darigabat Followed by Darigabat + Carbamazepine|"Participants will receive darigabat tablet orally once on Day 1 of Treatment Period 1.~Participants will receive carbamazepine tablets, titrated up to a steady-state dose, orally, twice daily (BID) from Day 1 to 17 along with the darigabat tablet orally once on Day 16 of Treatment Period 2."
89223777|NCT05813769|Active Comparator|Dairy protein 1|
89068680|NCT00998335|Active Comparator|Insulin detemir only|Patients with uncontrolled T2DM are treated with insulin detemir for 6 months. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl. This group will receive Long-acting bedtime insulin detemir (Levemir).
89068681|NCT00998335|Experimental|Insulin detemir plus aspart|After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.
89068682|NCT04204681||Study|Patients aged 16 years or younger who were to undergo tonsillectomy surgery were eligible for inclusion in this group. Tongue areas were measured twice by submental USG.The first measurements (TA2) were done immediately after endotracheal intubation but before insertion and placement of the tonsillar retractor. The second measurements (TA1) were done after tonsillectomy surgery and after removal of the tonsillar retractor but just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
89068683|NCT04204681||Control|This group included patients aged 16 years or younger who did not need tonsillectomy surgery and any head and neck procedures. Tongue areas of the patients were measured twice by submental USG as in the study group. TA1s were done immediately after endotracheal intubation, and TA2s were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., (TA2-TA1) was used to defined the occurrence of tongue edema.
89068684|NCT02871505|Experimental|Molecular subtyping (14d/f) of Treponema pallidum|Benzathine Penicillin G treatment
89068685|NCT02871505|Experimental|Molecular subtyping (others) of Treponema pallidum|Benzathine Penicillin G treatment
89068686|NCT01294670|Experimental|Vorinostat and Etoposide|This is a multi-center, open label, phase I/II trial of escalating doses of vorinostat in combination with etoposide.
89068687|NCT01006603|Experimental|1|Saxagliptin 5 mg
89068688|NCT01006603|Active Comparator|2|Glimepiride 1 - 6 mg
89068689|NCT02870335|Experimental|Manual Therapy|The objective of treatment is to restore esta possible limitation of global mobility to major lower limb joints and remove any tensions from the musculature involved in a relevant way in this sport.
89068690|NCT02870335|Active Comparator|Proprioceptive neuromuscular facilitation|It is a stretching technique with the aim of increasing the ROM. It includes passive static stretching and contract-relax.
89068691|NCT02870569|Experimental|Donafenib1|This is the lower dose group. Donafenib 200mg bid
89068692|NCT02870569|Active Comparator|Donafenib2|This is the higher dose group. Donafenib 300mg bid
89068693|NCT00997321|Active Comparator|Propofol|propofol 1 milligram per kilogram intravenous bolus followed by 0.5 millligrams per kilogram as needed for mooderate procedural sedation
89068694|NCT00997321|Active Comparator|Ketamine|ketamine 1 milligram per kilogram followed by 0.5 millgram per kilogram as needed for moderate procedural sedation
89068695|NCT01294592|Active Comparator|Dutasteride plus tamsulosin|Dutasteride plus tamsulosin arm + lifestyle advice
89068696|NCT01294592|Experimental|Watchful waiting with escalation to tamsulosin|Watchful waiting with escalation to tamsulosin
89068697|NCT00997243|Experimental|5-azacytidine and Lintuzumab|"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC(subcutaneous)daily on days 1-7.~Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7."
89068698|NCT01294514||Healthy Volunteers|Healthy volunteers ASA Class 1
89068699|NCT02869321|Experimental|Fentanyl|"Administration of Morphine Sulfate Placebo and Fentanyl~Morphine Sulfate Placebo: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy~+~Fentanyl: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy~Administration 1+2 if pain after 4 hours from gastrostomy"
89068700|NCT02869321|Placebo Comparator|Morphine Sulfate|"Administration of Morphine Sulfate and Fentanyl Placebo~Morphine Sulfate: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy~+~Fentanyl Placebo: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy~Administration 1+2 if pain after 4 hours from gastrostomy"
89068701|NCT01294436|Experimental|Open label treatment|
89068702|NCT04293913|Experimental|intervention group|In the intervention group, communication was established with the illustrated communication material. The pain, anxiety scores, and hemodynamic data of the patients were recorded by the intensive care nurse in three consecutive measurements starting with the first communication (0th minute) and at 30th and 60th minutes. On the first postoperative day, the satisfaction of the communication established with them, as well as their evaluations regarding the adequacy of this communication and their comfort levels were determined during the time they received mechanical ventilation therapy.
89068703|NCT04293913|No Intervention|control group|no intervention
89223778|NCT05813769|Active Comparator|Dairy protein 2|
89068704|NCT04293211||Control|Upon completion of B-Con presentation, this group will be tested regarding tourniquet placement using the rubric. A tourniquet is regarded as appropriately placed if it is 2 inches above the wound, not located on a joint, appropriate tightness (meaning a finger cannot be placed under it and it is indenting the mannequin). This is as per prior studies. Feedback will be given at the end of this session.
89068705|NCT04293211||Simulation|This group will have to interact with a panicked actor/actress as well as the SIM MAN 3G who will have two wounds under his clothes. One that will be actively pumping a large amount of arterial blood that will require tourniquet placement and the other wound with trace venous bleeding that will require simple pressure with a clean cloth. Participants will be given feedback on items that they missed. The observer will fill out the rubric and give feedback to the group.
89068706|NCT02870413|Experimental|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 12 weeks post-partum. Services will be available through mobile phone app.
89068707|NCT02870413|No Intervention|Usual care|Participants in the control arm will receive care as usual.
89068708|NCT04296487|Experimental|Autologous Chondrocyte Injection|Autologous chondrocytes were isolated and expanded in laboratory, then injected at 2x10^6 of cells per cm^2 of the cartilage defect.
89068709|NCT04292821||Patients consulting for breast lesion Bi Rads 4 or 5|Patients consulting for breast lesion Bi Rads 4 or 5
89068710|NCT02870179||Healthy volunteer|Smoker or non-smoker
89068711|NCT02869477||Patients with cardia cancer diagnosis|
89068712|NCT00995371|Active Comparator|Vertos mild® Minimally-Invasive Lumbar Decompression|Patients in the Vertos mild® treatment group will be treated by appropriately trained physicians in accordance with the product labeling and indications for use.
89068713|NCT00995371|Active Comparator|Epidural Steroid Injection|Patients in the Epidural Steroid Injection (ESI) group will have ESI performed by appropriately trained physicians in accordance with product labeling and indications for use.
89068714|NCT02869555||Patients with multiple myeloma diagnosis|
89068715|NCT02870023|Experimental|Balance training|"All sessions will start with a ten minute warm-up on either a treadmill or a cycle.~The balance intervention will be conducted in stations/domains where balance is challenged in the five different functions: standing, walking, sit to stand, stepping, and a station that exercises vestibular and gaze control.~Progression is achieved by adding exercises with increased balance requirements and by adding additional motoric and cognitive tasks to the exercises-dual-tasking.~Intensity of the exercises is defined from an error-rate where an adequate level is 20-40 percent.~The intervention is conducted according to a standardized framework that describes examples of exercises and progressions."
89223779|NCT05813769|Experimental|Plant protein 1|
89223780|NCT05813769|Experimental|Plant protein 2|
89223781|NCT05813769|Experimental|Plant protein 2 + added AA|
89223782|NCT05813769|Experimental|Plant protein 2 + Dairy protein 2|
89223783|NCT05789199||Cefiderocol Treated|Participants who have been treated with at least 72 hours of cefiderocol through the EAP in Spain.
89223784|NCT05788965|Other|Single Arm|This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with CFRD.
89690718|NCT03316378|No Intervention|Group without Achilles Tendinopathy|The control group did not receive an injection between test repetitions
89690719|NCT00637130|Experimental|Travoprost 0.0008%|Travoprost ophthalmic solution, 0.0008%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
89690720|NCT00637130|Experimental|Travoprost 0.001%|Travoprost ophthalmic solution, 0.001%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
89690721|NCT00637130|Experimental|Travoprost 0.0012%|Travoprost ophthalmic solution, 0.0012%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
89690722|NCT00637130|Active Comparator|TRAVATAN + Vehicle|TRAVATAN, one drop in study eye(s) once daily (8 PM), and Vehicle, one drop in study eye(s) once daily (8 AM), for two weeks
89690723|NCT00637130|Placebo Comparator|Vehicle|Vehicle, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
89690724|NCT02847559|Experimental|Treatment (bevacizumab, electric field therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89690725|NCT00637052|Experimental|ARRY-520|
89690726|NCT01921868|Experimental|Acetyl-L-Carnitine|Open-label administration of Acetyl-L-Carnitine, up to 2 g/day for 24 months.
89690727|NCT02150785|Experimental|Adminstering Streptokinase|treatment with 15,000 units/Kg of streptokinase in ischemic stroke patients with symptoms onset for less than 3 hours
89690728|NCT03220204|Experimental|PP-based health behavior intervention|Participants will undergo a 12-week, Positive Psychology (PP)-based health behavior intervention. Each weekly session will include (a) a review of the week's PP exercise, (b) a discussion of the rationale of the next week's PP exercise through a guided review of the PP manual, and (c) assignment of the next week's PP exercise. Additionally for the goal-setting portion, participants will (a) review their goals and behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week.
89690729|NCT03220204|Experimental|MI-based educational control condition|Participants will undergo 12 weekly phone sessions to learn about a different health behavior topic related to cardiac health. This Motivational Interviewing (MI)-based educational control condition will introduce these participants to motivational interviewing topics in concert with the health behavior education topics.
89690730|NCT03220204|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group will not receive any interventions between the baseline visit and follow-up visits.
89690731|NCT01925534|Experimental|Optiflow|High-flow humidified nasal oxygen delivery system
89690732|NCT01925534|Active Comparator|Oxygen therapy|Standard oxygen therapy
89068716|NCT02870023|Experimental|Strength training|"All sessions will start with a ten minute warm-up on a stationary bicycle, followed by strength training of primary muscle synergies in the lower extremities. All exercises will be performed on machines with patients sitting or lying, adequately supported. The exercises are leg press, knee extension, hip flexion, hamstring curl, and hip extension. Exercises are performed with a fast concentric phase and a slow eccentric phase..~Set, repetition, and load:~Weeks 1 and 2, 3 sets of 10 repetitions at a load of 15 repetitions maximum (RM)~Weeks 3 and 4, 3 sets of 12 repetitions at a load of 12RM~Weeks 5 and 6, 4 sets of 12 repetitions at a load of 12RM~Weeks 7 and 8, 4 sets of 10 repetitions at a load of 10RM~Weeks 9 and 10, 4 sets of 8 repetitions at a load of 8RM."
89068717|NCT02870023|No Intervention|Control group|On a waitlist. After ten weeks of waiting, and intervention that contains 50 percent strength training and 50 percent balance training begins.
89068718|NCT01294358|Experimental|Gemcitabine Dose Escalation|gemcitabine dose escalation
89068719|NCT00994279|Active Comparator|Arm 1: Yoga Intervention|Yoga Intervention
89068720|NCT00994279|Active Comparator|Arm 2: Educational Wellness Group|Educational Wellness Group
89690733|NCT02165605|Experimental|HylaCare|HylaCare cream Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to the contra-lateral breast in the same fashion, as a further control. The study drug and placebo will be applied three (3) times daily, but not within 4 hours prior to radiation treatment.
89068721|NCT01294046|Experimental|Deep brain stimulation of SPG for migraine|Electrical SPG for Treatment of Migraine
89068722|NCT01224639|Experimental|Group 1: Low Dose; SC|TDV-1: 8 x 10^3 Plaque Forming Units (PFU), TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
89068723|NCT01224639|Experimental|Group 2: Low Dose; ID|TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
89068724|NCT01224639|Experimental|Group 3: High Dose; SC|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
89068725|NCT01224639|Experimental|Group 4: High Dose; ID|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
89068726|NCT01224639|Placebo Comparator|Placebo (SC)|Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.
89068727|NCT01224639|Placebo Comparator|Placebo (ID)|Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.
89068728|NCT01293968|Experimental|5cc Ibuprofen100mg,10 cc Diphenhydramine25mg,10 cc AlMgS550mg|
89068729|NCT01293968|Active Comparator|100 cc Diphenhydramine, 25 mg and 100 cc AlMgS 550 mg|
89068730|NCT04292587||Women with hirsutism|Women between the ages of 18-45 with hirsutism
89068731|NCT04292587||Women without hirsutism|Women between the ages of 18-45 without hirsutism
89068732|NCT04324190|Experimental|Online support program|Guided online support program, consisting of modules (structured in chapters) aiming at reduce stress related to the COVID-19 pandemic.
89690734|NCT02165605|Placebo Comparator|Placebo|The patient is her own control.
89690735|NCT01926158|Experimental|Denosumab|Subcutaneous injection of denosumab 60 mg 4 weeks before surgery and 22 weeks after surgery
89690736|NCT01926158|Placebo Comparator|Placebo|Subcutaneous injection of placebo 4 weeks before surgery and 22 weeks after surgery
89690737|NCT03445390|Experimental|Acetaminophen First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive acetaminophen first.
89690738|NCT03445390|Experimental|Placebo First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive placebo first.
89690739|NCT00981890|Experimental|Sunitinib|
89690740|NCT02165761|Active Comparator|GORE® Hybrid Vascular Graft|GORE® Hybrid Vascular Graft
89690741|NCT02165761|Other|Non-heparin bonded synthetic graft|Non-heparin bonded synthetic graft
89690742|NCT03221764|Experimental|Amiodarone with CoSeal administered with CO2 driver|Lung Transplant Recipients who receive Intraoperative application of an Amiodarone containing hydrogel at the time of transplant.
89690743|NCT03122444|Experimental|Imipramine|Imipramine will initially be 50mg and this will be increased by 50mg every other day as tolerated to 200 mg.
89690744|NCT05593783||patients with lithiasis treated with ureterolithotripsy|patients with lithiasis treated with ureterolithotripsy
89690745|NCT05593783||patients with lithiasis treated with percutaneous nephrolithotomy|patients with lithiasis treated with percutaneous nephrolithotomy
89690746|NCT05593783||patients with lithiasis treated with extracorporeal shockwave lithotripsy|patients with lithiasis treated with extracorporeal shockwave lithotripsy
89690747|NCT01924130|Experimental|One Healthy Breakfast Program|Classroom feeding, nutrition education lessons, social marketing, and parent outreach.
89690748|NCT01924130|No Intervention|Control|Only receive assessments.
89690749|NCT02848989|Experimental|Qigong Mind-Body Exercise (QMBE)|"After the screening procedures confirm that you are eligible to participate in the research study:~Breast cancer survivors with persistent post-surgical pain (PPSP) into a 12-week program of Qigong mind-body exercise (QMBE).~Outcome assessments related to pain, function, and quality of life"
89690750|NCT03317002|Experimental|AZD5718 Dose A|AZD5718 Dose A once daily
89690751|NCT03317002|Experimental|AZD5718 Dose B|AZD5718 Dose B once daily
89690752|NCT03317002|Placebo Comparator|Placebo|Matching placebo once daily
89690753|NCT02390505|Experimental|Vitamin C|Patients receive vitamin C at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
89690754|NCT02390505|Placebo Comparator|Placebo|Patients receive placebo at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
89068733|NCT04324190|Active Comparator|Waiting period (WHO recommendation)|"Waiting period (2 weeks duration) during which subjects are provided with the WHO recommendations Coping with stress during the 2019 nCoV outbreak. Following the 2 weeks waiting period, subjects are provided with the guided online support program outlined in the arm 'online support program'."
89068734|NCT04324190|No Intervention|No intervention (natural course)|"This non-randomised arm (recruited separately; anticipated sample size of 500 subjects, not counted in the overall anticipated sample size) consists of subjects not intending to participate in the Selfapy online support program. Assessment points in this arm are comparable to those in the arm Online support program (in the 'No intervention (natural course)' arm, T1 refers to time of study inclusion)."
89068735|NCT02869867|No Intervention|Qutenza® without refrigerated cushion|Qutenza® without refrigerated cushion
89068736|NCT02869867|Experimental|Qutenza® with refrigerated cushion|Qutenza® with refrigerated cushion
89068737|NCT04292665|Experimental|Classical Massage|Patients will receive a total of fourteen individual applied classical massage sessions, twice daily for seven days, each session lasting 30 minutes.
89068738|NCT04292665|Experimental|Relaxation|Patients will receive a total of fourteen individual counseling sessions, in a quiet room, twice daily for seven days, each session lasting 20 minutes.
89068739|NCT04292665|Other|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
89068740|NCT01293032|Experimental|Group 1 (RS < 11)|"Patients with a Recurrence Score (RS) less than 11 (RS <11) are assigned to Group 1, neoadjuvant hormonal therapy either tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~Hormonal therapy:~Tamoxifen Citrate (pre-menopausal women) OR~Aromatase Inhibition Therapy (post-menopausal women)"
89068741|NCT01293032|Experimental|Group 2 Arm 1 (RS 11-25)|"Patients with an intermediate RS (11-25) assigned to Group 2. Randomized to Arm 1, neoadjuvant hormonal therapy as in Group 1.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~Hormonal therapy:~Tamoxifen Citrate (pre-menopausal women) OR~Aromatase Inhibition Therapy (post-menopausal women)"
89068742|NCT01293032|Experimental|Group 2 Arm 2 (RS 11-25)|"Patients with an intermediate RS(11-25) assigned to Group 2. Randomized to Arm 2, neoadjuvant chemotherapy 6-8 courses of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~Systemic chemotherapy"
89068743|NCT01293032|Experimental|Group 3 (RS > 25)|"Patients with a high RS (> 25) assigned to Group 3, neoadjuvant chemotherapy as in Group 2 Arm 2.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~Systemic chemotherapy"
89068744|NCT04279327||cases|cytology positive for malignancy
89068745|NCT04279327||controls|cytology negative for malignancy
89068746|NCT01292876|Other|Extracellular Matrix|Implantation of Extracellular Matrix
89068747|NCT01224171|Placebo Comparator|Placebo|Participants received placebo intravenous infusion at Weeks 0, 2 and 6.
89068748|NCT01224171|Experimental|Vedolizumab|Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.
89068749|NCT01292486|Experimental|Patients with multiple myeloma|Multiple myeloma patients who receive autologous stem-cell transplants, collected using the Spectra Optia Apheresis System, following myeloablative therapy. The study is limited to subjects who are expected demonstrate normal neutrophil recovery.
89068750|NCT01223937|Experimental|Desmopressin 25 μg|Participants took 1 orally disintegrating tablet of desmopressin 25 μg every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
89068751|NCT01223937|Placebo Comparator|Placebo|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
89068752|NCT01290224|Experimental|Supportive Care|See Detailed Description
89068753|NCT01223235|Experimental|bevacizumab & polyvalent vaccine-KLH conjugate + OPT-821|This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
89068754|NCT01290068|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, bilateral implantation
89068755|NCT01290068|Experimental|ReSTOR +3 Toric|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative corneal astigmatism, bilateral implantation, or implanted in 1 eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the other eye
89068756|NCT01290068|Active Comparator|Monofocal|Monofocal IOL, bilateral implantation
89068757|NCT00998881|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
89068758|NCT00998881|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
89068759|NCT01222767|Experimental|Arm 1|
89068760|NCT00993967|Experimental|Idebenone|1350 mg/day or 2250 mg/day for patients weighing ≤45 kg or >45 kg, respectively.In case of poor tolerability, dose reduction to 450 mg/day or 900 mg/day, respectively, were allowed.
89068761|NCT04204603|Placebo Comparator|Placebo|
89068762|NCT04204603|Experimental|CKD-506 Dose A|
89068763|NCT04204603|Experimental|CKD-506 Dose B|
89068764|NCT04204603|Experimental|CKD-506 Dose C|
89068765|NCT01222533|Experimental|Tiotropium low|Tiotropium inhalation solution low dose
89068766|NCT01222533|Experimental|Tiotropium medium|Tiotropium inhalation solution medium dose
89068767|NCT01222533|Experimental|Tiotropium high|Tiotropium inhalation solution high dose
89068768|NCT01222533|Active Comparator|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
89068769|NCT01222533|Placebo Comparator|Tiotropium placebo|Placebo inhalation solution
89068770|NCT01221753|Experimental|TPF Induction Chemotherapy followed by Chemoradiotherapy|Patients received 3 cycles (21 days each) of TPF induction chemotherapy: docetaxel 75 mg/m2 IV day 1; cisplatin 100 mg/m2 IV day 1 (carboplatin substitute permitted); 5-FU 1000 mg/m2/day IV pump continuous days 1-4. Concurrent chemoradiotherapy followed 4-6 weeks after day 1 of cycle 3 TPF induction: cetuximab 400 mg/m2 IV loading dose 1 week prior and 250 mg/m2 IV weekly (panitumumab substitute permitted); carboplatin AUC 1.5 (Calvert formula) IV weekly; Intensity modulated radiation therapy (IMRT)-response based dosing for 6-7 weeks.
89068771|NCT01221597|Experimental|AA4500|collagenase clostridium histolyticum
89068772|NCT01221597|Placebo Comparator|Placebo|placebo
89068773|NCT01221363|Active Comparator|Lifestyle counselling|Theory based individually tailored lifestyle counselling aimed at reduction of sitting time during leisure time and at work. Four individual sessions over a six months period.
89068774|NCT01221363|No Intervention|Control group|No intervention control group
89068775|NCT01221285|Experimental|German cockroach allergenic extract|Participants will receive weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
89068776|NCT02888223|Experimental|Group A|a single dose administration of SCT800 followed by Xyntha (50 IU.kg-1, based upon the manufacturer's labeled potency)
89068777|NCT02888223|Experimental|Group B|a single dose administration of Xyntha followed by SCT800(50 IU.kg-1, based upon the manufacturer's labeled potency)
89068778|NCT01014988|Other|Single Arm|A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir in an expedited manner. This study design also facilitates the provision of safety data on a real-time basis, if necessary.
89068779|NCT04299724|Experimental|Injection of Covid-19/aAPC vaccine|
89068780|NCT01014910|Active Comparator|Continuous pulse oximetry monitoring|Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
89068781|NCT01014910|Active Comparator|Intermittent pulse oximetry monitoring|Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
89068782|NCT04298866|Other|Experimental arm|
89068783|NCT02872480|Experimental|ACTIVE Training|Healthy participants will be progressed from 60-80% of their VO2max as determined by the progressive exercise test over the course of 6 30-minute training sessions. Concussed participants will begin 30-minute training sessions at 60% of the VO2 achieved at symptom exacerbation of the exercise test. Intensity will be progressed as tolerated by the participant and training sessions will continue until the participant is asymptomatic for 24 consecutive hours (total number of sessions variable based on clinical recovery).
89068784|NCT02872480|No Intervention|Control|Healthy controls will be asked to follow their normal routine for rest and physical activity. Concussed controls will be asked to follow the guidance for rest and activity as prescribed by the physicians and athletic trainers overseeing their clinical care.
89068785|NCT04297930||Paul Glaucoma Implant Surgery|Patients who had surgery with the Paul Glaucoma Implant
89068786|NCT01019980|Experimental|Diclofenac potassium|
89068787|NCT01019980|Active Comparator|Acetaminophen|
89068788|NCT00993499|Experimental|BIBW 2992 + Sirolimus|Dose escalation of the combination BIBW 2992 plus Sirolimus.
89068789|NCT04293367|Experimental|Exercise|14 African American Women with obesity will be randomly assigned to the 14-week high intensity interval training program
89068790|NCT04293367|No Intervention|Control|14 African American Women with obesity will be randomly assigned to serve as a reference group, i.e. follow the same protocol as the experimental group, however, they will not undergo exercise training
89068791|NCT01014442|Experimental|Mycophenolate Mofetil; Cystic Fibrosis|Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
89068792|NCT01014442|Experimental|Mycophenolate Mofetil; Other|Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
89068793|NCT00628264|Experimental|AP214|
89068794|NCT00628264|Placebo Comparator|Placebo|
89068795|NCT04298398|Experimental|Mindfulness (MBCT)|Group therapy based on Mindfulness Based-Cognitive Therapy (MBCT).
89068796|NCT04298398|Experimental|Emotion Focused Therapy (EFT-CR)|Group therapy based on Emotion Focused Therapy for Cancer Recovery (EFT-CR).
89068797|NCT04298398|Other|Control Group|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
89068798|NCT04297774|Experimental|virtual reality group|18 sessions of standard treatment plus virtual reality treatment.
89068799|NCT04297774|Active Comparator|standard treatment group|18 sessions of standard treatment plus balance training.
89068800|NCT00996307|Experimental|3.75_(50)MF59|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
89068801|NCT00996307|Experimental|7.5_(0)MF59|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
89068802|NCT00996307|Experimental|7.5_(50)MF59|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
89068803|NCT00996307|Experimental|15_(0)MF59|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
89068804|NCT04293835||Cancer group|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.
89068805|NCT04293835||Normal group|200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
89068806|NCT04293991|Active Comparator|High flow nasal cannula (HFNC) group|HFNC group will receive immediate connection to HFNC with a flow of 60L/min, and FIO2 adjusted to have SpO2 of 92% or more, through a heated humidifier and a oxygen blender of the same machine. In case of patient intolerance to high flow, flow will be diminished to the highest tolerated by the patient. Patients will be encouraged to have their mouth closed during HFNC to augment positive end expiratory pressure (PEEP) created by high flow.
89068807|NCT04293991|Active Comparator|Non invasive ventilation (NIV) group|NIV group, patients will be connected to ICU ventilatoron NIV mode for at least 4 hours, through a NIV continuous positive airway pressure (CPAP)mask with ventilator settings; pressure support (PS) level of 8 cmH2O and PEEP level of 5 cmH2O,which can be increased to 10 cmH2O to maintain tidal volume between 6-8 ml/Kg and FiO2 adjusted to keep SpO2 equal or more than 92%.At least patient will be on NIV for 12 hours during the day, alternating with Venturi mask 10-15 L/min to keep FiO2 equal or more than 92%.
89068808|NCT04263337|Other|Low Cognitive Functioning/Low Concussion History|Former NFL players with low cognitive function and low concussion history will be included in this group.
89068809|NCT04263337|Other|High Cognitive Functioning/ High Concussion History|Former NFL players with high cognitive function and high concussion history will be included in this group.
89068810|NCT04263337|Other|Low Cognitive Functioning/High Concussion History|Former NFL players with low cognitive function and high concussion history will be included in this group.
89068811|NCT04263337|Other|High Cognitive Functioning/Low Concussion History|Former NFL players with high cognitive function and low concussion history will be included in this group.
89068812|NCT04263337|Other|Healthy Male Controls|Healthy male demographically matched controls will be included in this group.
89068813|NCT04263337|Other|Low Cognitive Functioning/Medium Concussion History|Former NFL players with low cognitive function and medium concussion history will be included in this group.
89068814|NCT04263337|Other|Medium Cognitive Functioning/Low Concussion History|Former NFL Players with medium cognitive functioning and low concussion history with be included in this group.
89068815|NCT04263337|Other|Medium Cognitive Functioning/Medium Concussion History|Former NFL Players with medium cognitive functioning and medium concussion history with be included in this group.
89068816|NCT04263337|Other|Medium Cognitive Functioning/High Concussion History|Former NFL Players with medium cognitive functioning and high concussion history with be included in this group.
89068817|NCT04263337|Other|High Cognitive Functioning/Medium Concussion History|Former NFL Players with high cognitive functioning and high concussion history with be included in this group.
89068818|NCT02869165|Experimental|Conjugated equine estrogen topical cream|The conjugated equine estrogen topical vaginal cream 0.5 grams per vagina two times per week at nights for 3 months.
89068819|NCT02869165|Experimental|Apricot kernel oil|One teaspoonful per vagina every night for 3 months.
89068820|NCT00629161|Experimental|A|
89068821|NCT00629161|Placebo Comparator|B|
89068822|NCT01219959|Active Comparator|Non-glucose Sparing|Dianeal only
89068823|NCT01219959|Experimental|Glucose Sparing|Dianeal, Extraneal, Nutrineal
89068824|NCT00993421|Placebo Comparator|placebo|
89068825|NCT00993421|Experimental|LY377604 (75 mg)|
89068826|NCT00993421|Active Comparator|sibutramine (30 mg)/metoprolol (200 mg)|
89068827|NCT00993421|Experimental|LY377604 (40 mg)/sibutramine (30 mg)|
89068828|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (30 mg)|
89068829|NCT00993421|Experimental|LY377604 (15 mg)/sibutramine (30 mg)|
89068830|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (15 mg)|
89068831|NCT04292509|Experimental|SAP with predictive stop before low|Sensor-augmented pump therapy with the use of the predictive stop before low mode of action
89068832|NCT04292509|Active Comparator|SAP with stop on low|Sensor-augmented pump therapy with the use of the predictive stop on low mode of action
89068833|NCT02868853|Experimental|Photo App|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile dietary tracking application(Photo App). This Photo App allows participants to track meals by taking photos.
89068834|NCT02868853|Active Comparator|Diet App|Participants in this group will receive podcasts twice weekly in conjunction with an app (Diet App) to track their diet by entering in foods and beverages consumed.
89068835|NCT01014208|Experimental|OFATUMUMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with ofatumumab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with ofatumumab. All subjects will receive the same ofatumumab regimen and dose.
89068836|NCT01014208|Active Comparator|RITUXIMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with rituximab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with rituximab. All subjects will receive the same rituximab regimen and dose.
89068837|NCT04205578|Active Comparator|Butylphthalide (NBP)|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
89068838|NCT04205578|Placebo Comparator|Normal saline|For patients without obvious intracranial hemorrhage on CT scan at 4 hours after surgery, 100 mL of normal saline was administered intravenously since the day of surgery and continued twice daily for 14 postoperative days.
89068839|NCT04297540|Experimental|Active-tDCS group|8 sessions (in two weeks) of active tDCS combined with a virtual reality training
89068840|NCT04297540|Sham Comparator|Sham-tDCS group|8 sessions (in two weeks) of sham tDCS combined with a virtual reality training
89068841|NCT00628420|Other|1|Patients recieved single low dose of ACP-104
89068842|NCT00628420|Other|2|Patients recieved a high dose of ACP-104
89068843|NCT00628420|Other|3|Patients recieved a placebo
89068844|NCT00991939|Experimental|High dose pulse dexamethasone|
89068845|NCT00991939|Active Comparator|Standard prednisone therapy|
89068846|NCT00629005|Experimental|Arm 1|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus 1 hour of strength training for the arms and hands 3x/week
89068847|NCT00629005|Active Comparator|Arm 2|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus non-resisted arm and hand movements for 1 hour 3x/week
89068848|NCT02869087|Experimental|Single Group|Single Arm study, study subjects are assigned to treatment with the Akesys Prava Scaffold
89068849|NCT04291807|Experimental|Video education|A video of ERCP procedure has been viewed to the patients who will undergo ERCP and questions about the procedure had been answered by the primary investigator (experienced endoscopy nurse)
89068850|NCT04291807|No Intervention|Direct ERCP|Patients arranged ERCP for any reason underwent directly to the ERCP without any video education.
89068851|NCT02868697|Active Comparator|A|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of of all Hemodialysis sessions and during all interdialytic periods
89068852|NCT02868697|Experimental|B|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of the first two session only per week and during first two interdialytic periods then TauroLock U 25000at the end of third session before week end, (over the week end).
89068853|NCT02868385|Active Comparator|Control group (A)|1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).
89068854|NCT02868385|Experimental|Intervention group (B)|4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.
89068855|NCT02868307|Experimental|Patient prsenting schizophrenia|
89068856|NCT00993265|Experimental|N-acetylcysteine (NAC)|Patients randomized to this arm will receive N-Acetylcysteine, at a standard dose titrated to 2400 mg. They will receive NAC in addition to the medication regimen they are on at enrollment.
89068857|NCT00993265|Placebo Comparator|Placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
89068858|NCT04211389|Active Comparator|ARQ-151 cream 0.3%|Active comparator
89068859|NCT04211389|Placebo Comparator|ARQ-151 cream vehicle|Placebo comparator
89068860|NCT00993031|Experimental|Group A|ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
89068861|NCT00993031|Active Comparator|Group B|ZDV 300mg/3TC 150mg/EFV 600mg
89068862|NCT01010776|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
89068863|NCT04291729|Experimental|Ganovo+ritonavir with or without interferon nebulization|
89068864|NCT02868775||Interstitial cystitis/bladder pain syndrome|These are the patients that will be evaluated in this study.
89068865|NCT00637702|Experimental|ARRY-334543|
89068866|NCT04291963|Active Comparator|DGG + TUN|The multiple adjacent gingival recession sites were treated with DGG in conjunction with TUN technique.
89068867|NCT04291963|Active Comparator|SCTG + TUN|The multiple adjacent gingival recession sites were treated with SCTG in conjunction with TUN technique.
89068868|NCT04170985|Other|Single Cohort|All participants will receive cWGS testing revealed to the site PI/clinician at Day 180. Participants will all receive standard of care testing throughout the study.
89068869|NCT02868619|Other|Healthy controls|Non obese adolescents without Binge Eating Disorder (BED)
89068870|NCT02868619|Other|Patients with BED|Obese adolescents with BED with Binge Eating Disorder (BED)
89068871|NCT00637741|Experimental|Everflex 200|study group treated with at least one 200 mm Everflex stent
89068872|NCT02868931|Experimental|INPUT|INPUT consists of 12 lessons comprising all relevant information in order to treat diabetes with an insulin pump. Patients learn to effectively use the different features of their pump in order to improve not only glycemic control but also to improve the implementation of pump therapy in daily life. Psychological and motivational aspects of living with diabetes and living with an insulin pump are addressed as well.
89068873|NCT02868931|No Intervention|Waiting list|Patients are randomly assigned to the waiting list. After completion of the 6-month follow-up, these patients will also receive training with INPUT.
89068874|NCT01018810|Experimental|180 mg LY2525623|
89068875|NCT01018810|Placebo Comparator|Intravenous Placebo|
89068876|NCT01018810|Placebo Comparator|Subcutaneous Placebo|
89068877|NCT01018810|Experimental|3 mg LY2525623|
89068878|NCT01018810|Experimental|10 mg LY2525623|
89068879|NCT01018810|Experimental|30 mg LY2525623|
89068880|NCT01018810|Experimental|90 mg LY2525623|
89068881|NCT02867917|Other|Total group|Volcolon sugar free & Metamucil Orange & Psyllium Orange in a randomized order.
89068882|NCT01018732|Experimental|I: MenACWY-CRM vaccine|Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.
89068883|NCT01018732|Experimental|II: Licensed Polysaccharide Meningococcal vaccine|Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.
89068884|NCT01018732|Experimental|III: Meningococcal Naive|Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.
89068885|NCT01218867|Experimental|Cohort 1 (1x10(6) cells (high dose IL-2)|Patients will receive (1x10(6) cells plus high dose aldesleukin
89068886|NCT01218867|Experimental|Cohort 2 (3x10(6) cells (high dose IL-2)|Patients will receive (3x10(6) cells plus high dose aldesleukin
89068887|NCT01218867|Experimental|Cohort 3 (1x10(7) cells (high dose IL-2)|Patients will receive (1x10(7) cells plus high dose aldesleukin
89068888|NCT01218867|Experimental|Cohort 4 (3x10(7) cells (high dose IL-2)|Patients will receive (3x10(7) cells plus high dose aldesleukin
89068889|NCT01218867|Experimental|Cohort 5 (1x10(8) cells (high dose IL-2)|Patients will receive (1x10(8) cells plus high dose aldesleukin
89068890|NCT01218867|Experimental|Cohort 6 (3x10(8) cells (high dose IL-2)|Patients will receive (3x10(8) cells plus high dose aldesleukin
89068891|NCT01218867|Experimental|Cohort 7 (1x10(9) cells (high dose IL-2)|Patients will receive (1x10(9) cells plus high dose aldesleukin
89068892|NCT01218867|Experimental|Cohort 8 (1x10(9) cells (low dose IL-2)|Patients will receive (1x10(9) cells plus low dose aldesleukin
89068893|NCT01218867|Experimental|Cohort 9 (3x10(9) cells (low dose IL-2)|Patients will receive (3x10(9) cells plus low dose aldesleukin
89068894|NCT01218867|Experimental|Cohort10(1x10(10) cells (low dose IL-2)|Patients will receive (1x10(10) cells plus low dose aldesleukin
89068895|NCT01218867|Experimental|Cohort11(3x10(10) cells (low dose IL-2)|Patients will receive (3x10(10) cells plus low dose aldesleukin
89068896|NCT01018264|Experimental|solifenacin succinate (VESIcare)|
89068897|NCT01018264|Placebo Comparator|placebo|
89068898|NCT04318899|Experimental|Dialectical Behaviour Therapy|Dialectical Behavior Therapy, delivered for 20 weeks for adolescents (DBT-A) or 52 weeks for adults (standard DBT.
89068899|NCT01018186|Experimental|Fluticasone furoate/GW642444|
89068900|NCT01018186|Active Comparator|Fluticasone propionate|
89068901|NCT00987337|Experimental|Arm A|"Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
89068902|NCT00987337|Experimental|Arm B|"Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
89068903|NCT00987337|Placebo Comparator|Arm C|Placebo + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks
89068904|NCT00992407|Experimental|Risperidone long acting injectables|
89068905|NCT00992407|Active Comparator|Risperidone tablets|
89068906|NCT00986479|Experimental|AZD6765 (150 mg) / Placebo|Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period.
89068907|NCT00986479|Placebo Comparator|Placebo / AZD6765 (150 mg)|Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period.
89068908|NCT00986245|Active Comparator|Ropinirole PR QD first, then BID|Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing
89068909|NCT00986245|Active Comparator|Ropinirole PR BID first, and then QD|Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing
89068910|NCT00989833|Active Comparator|A|budesonide 400yg + terbutaline 0.4 mg as-needed
89068911|NCT00989833|Active Comparator|B|placebo + terbutaline 0.4 mg as-needed
89068912|NCT00989833|Active Comparator|C|placebo + budesonide/formoterol 160/4.5 yg as-needed
89068913|NCT04292119|Experimental|Lorlatinib and Crizotinib|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~Phase 1 (the dose-finding portion of the study) will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~Lorlatinib will be administered orally once daily at a predetermined dose for 28 days~Crizotinib will be administered orally twice daily at a predetermined dose for 28 days~Phase II patients will be treated with Lorlatinib and Crizotinib at a dose recommended based on the phase I study."
89068914|NCT04292119|Experimental|Lorlatinib and Binimetinib|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~The phase I part of the study will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~Lorlatinib will be administered orally once daily at a predetermined dose for 28 days~Binimetinib will be administered orally twice daily at a predetermined dose for 28 days.~Phase II patients will be treated with Lorlatinib + Binimetinib at a dose recommended based on the phase I study."
89223785|NCT05774223|Active Comparator|Active iTBS on working memory|Participants will receive active 80% rMT iTBS over the left DLPFC in this arm. The working memory assessments will be performed pre-stimulation and at 0-, 10-, 20-, 30-, and 40-min post-stimulation. The working memory assessment is measured using a 2-minute 3-back task. The fNIRS will monitor the prefrontal hemoglobin change throughout the whole procedure.
89068915|NCT04292119|Experimental|Lorlatinib and TNO155|"The research study procedures include screening for eligibility and study treatment. Study treatment will include evaluations, biopsies, and follow up visits.~The phase I part of the study will follow a standard 3+3 design. Enrollment to the different study arms will occur in parallel.~Lorlatinib will be administered orally once daily at a predetermined dose for 21 days~TNO155 will be administered orally once daily at a predetermined dose for 14 out of 21 days.~Phase II patients will be treated with Lorlatinib + TNO155 at a dose recommended based on the phase I study."
89068916|NCT01218477|Experimental|Dasatinib, 100/140 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
89068917|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase) plus BMS-833923, 50 mg, QD
89068918|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD|Participants received BMS-833923, 100 mg twice daily (BID) for 7 days then once daily (QD) + dasatinib, 100/140 mg QD, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
89068919|NCT01218477|Experimental|Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD|Participants received BMS-833923, 200 mg twice daily (BID) for 7 days then 200 mg once daily (QD) plus dasatinib, 100 /140 mg QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
89068920|NCT04318509|Experimental|PKU GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
89068921|NCT01218243|Experimental|acupoint|Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
89068922|NCT01218243|Sham Comparator|non-acupoint|Take the place 2 cun far from BL33 on the outside horizontally as the non-point. Needle on the non-point for 60-80mm with a 45°angle. A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.
89068923|NCT00989287|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89068924|NCT00989287|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89068925|NCT01218087|Experimental|Cranial cup device and Moldable positioner device|The cranial cup for 12/24 hours and the moldable positioner device was used for positioning infants the remainder of the 24 hours
89068926|NCT01218087|Active Comparator|Moldable positioner device|Moldable positioner device was used for positioning infants for 24/24 hours
89068927|NCT04291339|Experimental|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
88812920|NCT01833650|Experimental|Candy plus thymus honey mouthwash 12|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
89068928|NCT04291339|Active Comparator|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
89068929|NCT01218009|Experimental|Albuterol Spiromax|Albuterol multi-dose dry powder inhaler (Spiromax) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they take albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
89068930|NCT01218009|Placebo Comparator|Placebo Spiromax|Placebo delivered using a multi-dose dry powder inhaler (Spiromax) as 2 inhalations four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they administer albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
89068931|NCT04291183|Experimental|elderly people to undergo hortic culture therapy|Horticultural Therapy will be applied to the elderly in the experimental group in the form of two days a week visit for eight weeks. Flower and vegetable seedlings suitable for the season will be planted in the garden with the elderly. The elderly will be asked to take care of the plants they planted every day (irrigation and collecting extra herbs) and the elderly people will be observed by doing these processes twice a week
89068932|NCT04291183|No Intervention|elderly people who will not receive horticultural therapy|pre-test data forms will be applied to the control group. Post-test data forms will be reapplied after 8 weeks
89068933|NCT04291417||CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis. Results will not be used to manage patients.
89068934|NCT00992017|Experimental|H1N1 vaccine|Pregnant women enrolled received two doses of H1N1 vaccine, administered 21 days apart.
89068935|NCT01217463|Active Comparator|Trafermin 0.01% spray|
89068936|NCT01217463|Placebo Comparator|Matching placebo spray|
89068937|NCT02868151|No Intervention|GROUP A|Standard treatment followed in the regional cancer center for prevention and treatment of oral mucositis during chemo radiotherapy of cancers. 20% Benzocaine 15grms. twice daily for the entire treatment period
89068938|NCT02868151|Experimental|GROUP B|"Ascorbic acid oral supplementation 1g four times daily for the entire treatment period of 30 days and after treatment by tapering the dose of the drug to half for another month. The drug has to be started 2 days prior to initiation of treatment of cancer.~Subdivided into 2 groups , 30 patients in each : sub group 1: only radiotherapy patients, subgroup 2 includes concurrent chemo-radiotherapy patients."
89068939|NCT02868151|Experimental|GROUP C|Zinc acetate tablets 50mg orally
89068940|NCT01217307|Experimental|Metformin|metformin 500mg twice daily during 4 months
89068941|NCT01217307|Placebo Comparator|Placebo|Placebo twice daily during 4 months
88812745|NCT03215654|Experimental|Mental Health Literacy Program (MHL)|MHL module contents are: 1) Our emotions. Definitions of mental health and mental disorders. Mental health multidisciplinary team network; 2) Healthy and risky behaviors of mental health; 3) Social skills and antisocial behavior, bullying and cyberbullying; 4) Anxiety, depression, self-harm, and suicidal behaviors; 5) Eating and behavioral disorders; 6) Substance abuse (alcohol and cannabis), an psychotic disorder. Duration 6 hours.
89068942|NCT02868073|Experimental|H1N1 (high dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (high dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
89068943|NCT02868073|Experimental|H1N1 (low dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (low dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
89068944|NCT02868073|Placebo Comparator|Placebo Tablets|Singe dose of VXA Placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
89068945|NCT01217229|Experimental|PLX3397|
89068946|NCT04318743|Experimental|autoinjector - vial/syringe - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
89068947|NCT04318743|Experimental|vial/syringe - autoinjector - vial/syringe|Single dose of Glepaglutide 10 mg for each treatment sequence
89068948|NCT04318743|Experimental|vial/syringe - vial/syringe - autoinjector|Single dose of Glepaglutide 10 mg for each treatment sequence
89068949|NCT01013740|Experimental|Lapatinib + Vinorelbine|Lapatinib + Vinorelbine
89068950|NCT01013740|Active Comparator|Lapatinib + Capecitabine|Lapatinib + Capecitabine
89068951|NCT02872246|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
89068952|NCT01013350||Never Exposed to Cladribine|All participants who received placebo matched to cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826 , NCT00641537, NCT00938366 and NCT00725985).
89068953|NCT01013350||Exposed to Cladribine|All participants who received cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826, NCT00641537, NCT00938366 and NCT00725985).
89068954|NCT00627874|Experimental|1|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
89068955|NCT00627874|No Intervention|2|
89068956|NCT04299256|Experimental|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
89068957|NCT04299256|No Intervention|Control|Like the intervention group, the control group session (attention-matched education) which composed of 10-12 participants were performed with a booklet containing hemodialysis and its use in a silent room located in the hemodialysis units. The patient information provided in-person training on hemodialysis and its use for 20 min in a group session at the hemodialysis unit, on the first day of the study. During the study period, the participants in the control group were not subjected to any additional intervention.
89068958|NCT01018030|Experimental|FFNS 110 mcg QD|
89068959|NCT01018030|Experimental|FFNS 110 mcg BID|
89690755|NCT00362739||1: Lung Disease|Individuals with at least one of the following: (1)symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; (7) individuals suspected of history of lung diseased based on history and/or physical examination
89690756|NCT00362739||2: Normal Controls|Individuals without a history of lung disease
89690757|NCT05592925||N0|gastric cancer patients with no lymph node metastasis
89690758|NCT05592925||N+|gastric cancer patients with lymph node metastasis, including patients with N1, N2 and N3 stage cancer
89690759|NCT03223246|No Intervention|Usual care|
89690760|NCT03223246|Experimental|Additional teaching|
89690761|NCT02169427|Experimental|Opicapone (OPC)|100 mg OPC
89690762|NCT02795247|Active Comparator|Hybrid Transtibial Technique|Reconstruction of the ACL using the hybrid transtibial technique
89690763|NCT02795247|Active Comparator|Accessory Anteromedial Portal Technique|Reconstruction of the ACL using the accessory anteromedial portal technique
89690764|NCT02795247|Active Comparator|Transtibial Technique|Reconstruction of the ACL using the transtibial technique.
89690765|NCT03452176|Experimental|Scrambler|This arm will receive the Scrambler intervention for 1 hour daily x10 days.
89690766|NCT03452176|Sham Comparator|Sham-Control|This arm will receive the Sham-Control intervention for 1 hour daily x10 days.
89690767|NCT03454048|Experimental|Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 1 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg).
89068960|NCT01018030|Placebo Comparator|Placebo Nasal Spray|
89068961|NCT01217073|Experimental|Omarigliptin 0.25 mg (Base)|Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
89068962|NCT01217073|Experimental|Omarigliptin 1 mg (Base)|Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
89068963|NCT01217073|Experimental|Omarigliptin 3 mg (Base)|Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
89068964|NCT01217073|Experimental|Omarigliptin 10 mg (Base)|Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
89068965|NCT01217073|Experimental|Omarigliptin 25 mg (Base)|Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
89068966|NCT01217073|Placebo Comparator|Placebo (Base)|Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
89068967|NCT01217073|Experimental|Pooled omarigliptin (Extension)|Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
89068968|NCT01217073|Active Comparator|Placebo/Metformin|Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.
89068969|NCT00985621|Experimental|1|
89068970|NCT00985621|Experimental|2|
89068971|NCT00985621|Active Comparator|3|
89068972|NCT00985621|Placebo Comparator|4|
89068973|NCT01215981|Active Comparator|Participants Receiving 1 Dose of Vaccine|"Control group participants (healthy volunteers):~Age 18 to 50 years~No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~No flu vaccine in previous 4 months~and/or HSCT recipients who are greater than 60 days post transplant."
89068974|NCT01215981|Active Comparator|Participants Receiving 2 Doses of Vaccine|Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.
89068975|NCT02887833||XRT for Cancer induced bone pain|Will have community based assessment before and after radiotherapy to assess feasibility of using a clinical biomarker (thermal sensory testing) to predict treatment response
89068976|NCT01215513|Experimental|Degarelix|
89068977|NCT01215435|Experimental|Pre-breakfast BIAsp 30|
89068978|NCT01215435|Experimental|Pre-dinner BIAsp 30|
89068979|NCT01215357|Experimental|Ecopipam|Ecopipam is a selective antagonist of one the classes of dopamine receptor.
89068980|NCT05433441|No Intervention|Standard care|
89068981|NCT05433441|Experimental|ESPark Intervention|Under medical prescription and in addition to medical and physiotherapy care, the ESPark will intervene in an ecological way with Parkinson's patients in order to rehabilitate them, maintain their autonomy in their daily life and their social life with the aim of improving the quality of life of the patient and his main caregiver. Beyond a rehabilitative intervention in the home, the ESPark's mission would also be to optimize the patient's living environment and possibly help with the implementation of the necessary aids in the continuity of medical care.
89068982|NCT00984295|Experimental|1|ProQuad + Tripedia + Comvax at Day 0 (Concomitant)
89068983|NCT00984295|Experimental|2|ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)
89068984|NCT00984295|Active Comparator|3|Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)
89068985|NCT04291027|Experimental|Aquatic Group Exercise|
89068986|NCT04291027|Active Comparator|Land Based Group Exercise|
89068987|NCT00628186|Experimental|1|Pancreaticojejunostomy has a risk factor of pancreatic fistula. Type of stent tube (external stent vs. short stent)across pancreaticojejunostomy was randomized for the patients with pancreaticoduodenectomy.
89068988|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
89068989|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
89068990|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
89068991|NCT01017952|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
89068992|NCT01214655|Experimental|LY2523355 on Days 1, 2, and 3|Starting dose was 2 milligrams per meter squared (mg/m^2) administered by a 1-hour intravenous (IV) infusion on Days 1, 2, and 3 of every 21-day Cycle.
89068993|NCT01214655|Experimental|LY2523355 on Days 1, 5, and 9|Starting dose was 8 milligrams per meter squared (mg/m^2) administered by a 1-hour IV infusion over 1 hour on Days 1, 5, and 9 of every 21-day Cycle.
89068994|NCT01017874|Experimental|Pemetrexed + Cisplatin + Gefitinib|
89068995|NCT01017874|Active Comparator|Gefitinib|
89068996|NCT04299568|Experimental|Anti gravity treadmill training|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization followed by Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes.
89068997|NCT04299568|Active Comparator|Control|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization only
89068998|NCT00627952|Active Comparator|amlodipine 10 mg|
89068999|NCT00627952|Active Comparator|manidipine 20 mg|
89069000|NCT01015768|Experimental|Test eye|Uses ReNu Multiplus as multipurpose soaking solution
89069001|NCT01015768|Active Comparator|Control|A new lens (PureVision) is soaked for 2 hours in non-preserved saline
89069002|NCT04426630|Other|mHealth|Heart failure patients enrolled in the mHealth program
89069003|NCT01010230|Placebo Comparator|LMHF mechanical stimulation placebo device|The placebo device is identical in appearance and function to the active platform; except when activated, it emits the same sound as the active device but does not deliver the vibration.
89069004|NCT01010230|Active Comparator|LMHF mechanical stimulation|"Low magnitude, high frequency mechanical stimulation device (vibrating) platform"
89069005|NCT01009840|Experimental|IV busulfan|Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.
89069006|NCT04297696|Experimental|exercise group|therapeutic exercises
89069007|NCT04297696|No Intervention|control group|
89069008|NCT04205500|Experimental|Children with juvenile idiopathic arthritis|The specific carbohydrate diet has been shown to have beneficial effects on IBD and has been implemented in Seattle Children's IBD centre, with some patients using SCD either as primary or complementary therapy. The SCD is a nutritionally balanced diet focused on removing many complex carbohydrates such as grains, dairy products except for yoghurt fermented over 24 hours, vegetables rich in starch and sugars except for monosaccharides like in honey. Participants can eat meat but since it has to be unprocessed food the investigator's experience is that the amounts of meat are not very big. Fish, eggs, sea-food is allowed. Bread is baked from nut and almond flour.
89069009|NCT04285294||RDEB patients with a cSCC|
89069010|NCT04285294||Non-RDEB patients with a SCC induced by ultraviolet radiation|
89069011|NCT04285294||Healthy donors without RDEB nor SCC|
89069012|NCT04295980||Geschwind's area BAVMs|
89069013|NCT04295980||Healthy controls|
89069014|NCT02872090|Experimental|Arm 1|The patients receive once a week during 4 weeks, in the order: indacaterol, tiotropium, glycopyrronium and placebo
89069015|NCT02872090|Experimental|Arm 2|The patients receive once a week during 4 weeks, in the order: tiotropium, glycopyrronium, placebo and indacaterol
89069016|NCT02872090|Experimental|Arm 3|The patients receive once a week during 4 weeks, in the order: glycopyrronium, placebo, indacaterol and tiotropium,
89069017|NCT02872090|Experimental|Arm 4|The patients receive once a week during 4 weeks, in the order: placebo, indacaterol and tiotropium and glycopyrronium
89069018|NCT04514458|Experimental|EHR-based alert|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
89069019|NCT04514458|No Intervention|Usual Care|Providers will not receive an alert and will proceed with usual care.
89069020|NCT04296058||SOX4 high|Nuclear expression of SOX4 over 90% in tumor specimen was defined as SOX4 high group
89069021|NCT04296058||SOX4 low|Nuclear expression of SOX4 less than 90% in tumor specimen was defined as SOX4 low group
89069022|NCT04295746|Experimental|Serious Game ShopAut|Each participant played 10 game sessions, one per week, for no more than 30 minutes.
89069023|NCT00982657|Experimental|Cohort 1|CVX-060 + sunitinib
89069024|NCT00982657|Experimental|Cohort 2|CVX-060 + sunitinib
89069025|NCT00982657|Experimental|Cohort 3|CVX-060 + sunitinib
89069026|NCT00982657|Experimental|Expanded cohort|CVX-060 + sunitinib
89069027|NCT00982657|Experimental|Phase II - Arm A|CVX-060 + sunitinib
89069028|NCT00982657|Active Comparator|Phase II - Arm B|sunitinib alone
89069029|NCT02867683|Experimental|Vibrotactile Feedback|Balance exercises completed while vibration was applied to the trunk (anterior, posterior, right, and left) if postural sway exceeded a pre-determined threshold during the exercise.
89069030|NCT02867683|No Intervention|Without Vibrotactile Feedback|Balance training without feedback
89069031|NCT02867839|Experimental|A: postoperative Oxaliplatin plus S-1|"Patients in arm A will receive standard distal gastrectomy with D2 lymphadenectomy first, and 8 cycles of adjuvant Oxaliplatin plus S-1 (SOX) later.~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3W S-1: 40~60mg bid, po, d1~14, q3W (6 months)"
89069032|NCT02867839|Active Comparator|B: postoperative S-1 only|"Patients in arm B will receive standard distal gastrectomy with D2 lymphadenectomy first, and 16 cycles of adjuvant S-1 later.~S-1: 40~60mg bid, po, d1~14, q3W (12 months)"
89069033|NCT02867293|Active Comparator|Preop-drainage|ascites drained over the pre-operative week through multiple ultrasound guided paracentesis
89069034|NCT02867293|Active Comparator|Op-drainage|ascetic fluid drained through an abdominal incision after anesthesia
89069035|NCT02867137||Mild TBI patients|
89069036|NCT02867371|Experimental|-Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
89069037|NCT02867215|Active Comparator|Barley bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
89069038|NCT02867215|Active Comparator|Wheat bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
89069039|NCT01005316||Cohort A: Non-Sensitized|"Cohort A will include participants who are alloantibody Luminex(TM) LABScreen. There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen. Non-sensitized recipients receive steroid-free maintenance immunosuppression:~Induction Therapy (anti-T cell antibody induction)~Tacrolimus (Prograf®)~Mycophenolate Mofetil- MMF (CellCept®)."
89069040|NCT01005316||Cohort B: Sensitized|"Cohort B will include participants who are alloantibody positive (Sensitized) as determined by Luminex LabScreen for Class I or Class II with specificities identified by single antigen testing.~There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen.~Sensitized recipients receive:~Induction Therapy (anti-T cell antibody induction)~Intraoperative plasma exchange/pheresis~Short-term post-operative plasmapheresis~Post-transplant course of intravenous immunoglobulin (IVIG) therapy~Maintenance corticosteroids (Prednisone)~Tacrolimus (Prograf®)~Mycophenolate Mofetil-MMF (CellCept®)."
89069041|NCT01004848|Experimental|Peer-Led Lifestyle Education on Weight Loss|"Project HEED (Help Educate to Eliminate Diabetes), a community-based, peer-led weight loss program for overweight adults with pre-diabetes.~The intervention group will participate in an 8-session course held over a 10-week period. Project HEED (Help Educate to Eliminate Diabetes), led by trained peer educators, aims to help participants lose weight, thereby preventing their progression to diabetes."
89069042|NCT01004848|Placebo Comparator|Delayed Intervention|The control group will be offered the chance to participate in the 8-session course 1 year after enrollment into the trial.
89069043|NCT01009294|Experimental|Ataluren|Ataluren was provided as a vanilla-flavored powder to be mixed with water, apple juice, or milk. Study drug dosing was based on milligrams of drug per kilogram of body weight. The dose level for ataluren was 20 milligrams/kilograms (mg/kg) in the morning, 20 mg/kg at midday, and 40 mg/kg in the evening. Administration within 30 minutes after a meal was recommended. Study drug was taken for up to 50 days.
89069044|NCT04205422|Active Comparator|BIPAP group|Biphasic Intermittent Positive Airway Pressure group
89069045|NCT04205422|Active Comparator|APRV group|Airway Pressure Release Ventilation group:
89069046|NCT04205188|Experimental|exercises and verbal information|therapeutic exercises 3 days in a week and total 8 weeks and 60 minutes verbal information
89069047|NCT04205188|No Intervention|verbal information|60 minutes information about effects of exercises on joint functions
89069048|NCT01009060|Experimental|GSK239512|Repeat dose.
89069049|NCT01009060|Placebo Comparator|Placebo|Repeat dose. Placebo to match GSK239512
89069050|NCT00988429|Active Comparator|800 mg QD Eslicarbazepine acetate|tablets
89069051|NCT00988429|Active Comparator|1200 mg QD Eslicarbazepine acetate|tablets
89069052|NCT00988429|Placebo Comparator|Placebo|tablets
89069053|NCT01008904|Experimental|Supportive care (magnesium oxide)|Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.
89069054|NCT04295590|Experimental|Frequency then Intensity|Training period 1: Frequency comparison Training period 2: Intensity comparison
89069055|NCT04295590|Experimental|Intensity then Frequency|Training period 1: Intensity comparison Training period 2: Frequency comparison
89069056|NCT04291495|Experimental|ANDROSITOL®TEST|At least 45 patients (13 for each category: low, medium, and high responders, + 15% of hypothetical drop-outs)
89069057|NCT04290793|Experimental|Experimental group|Patients will receive the test drug (Pyrotinib) combined with Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
89069058|NCT04290793|Active Comparator|Control group|Patients will only receive Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab
89069059|NCT01004614|Experimental|Cohort 1|24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.
89069060|NCT01004614|Active Comparator|Cohort 2|24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water
89069061|NCT02871700|Experimental|Action observation therapy (AOT)|Action observation therapy (AOT)
89069062|NCT02871700|Experimental|Mirror therapy (MT)|Mirror therapy (MT)
89069063|NCT02871700|Active Comparator|Control group|Customary bilateral UE training
89069064|NCT02871076|Experimental|Verum Acupuncture|Patients will receive verum acupuncture twice weekly for twelve weeks.
89069065|NCT02871076|Placebo Comparator|Sham Placebo Acupuncture|Patients will receive sham placebo acupuncture twice weekly for twelve weeks.
89069066|NCT04297462|Experimental|3-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during three consecutive days after the contact with influenza
89069067|NCT04297462|Active Comparator|7-days postexposure chemoprophylaxis|Oseltamivir given orally, 3mg per each body kg, once a day during seven consecutive days after the contact with influenza
89069068|NCT00981409|Experimental|Fondaparinux|
89069069|NCT00981409|Other|unfractionated heparin|
89069070|NCT04297228|Experimental|Step by Step Program|"Thirteen 1.5 hour weekday educational sessions, five 1-hour weekday fitness classes and seventeen 1 hour weekend walks/farmer's market trips were scheduled over 22 weeks. The planned total contact time was 41.5 hours, above the minimum effective amount and recommended by the USPSTF. Children participated in all activities. Weekly text messages with motivational messages and reminders were planned.~Educational Topics included:~Intro and Goal Setting How to Read Nutrition Labels How to Build a Healthy Meal Choose My Plate/Walking for Fitness Healthy Fast Food Add More Fruits/Vegetables to Meals Add More Physical Activity Each Day Healthy Snacks and Drinks Healthy Desserts Circuit Training at Home Favorite Recipe Makeover Step by Step Jeopardy Celebration of Completion"
89069071|NCT04298710|Experimental|Arm Cycling|Arm cycling on an arm crank ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
89069072|NCT04298710|Experimental|Leg Cycling|Leg cycling on a leg cycling ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
89069073|NCT04298710|Placebo Comparator|Sitting|Participants will remain seated after carbohydrates consumption.
89069074|NCT02865655||CSD-TVU|Cesarean Section Scar Evaluation by TVU
89069075|NCT02865655||CSD-MRI|Cesarean Section Scar Evaluation by MRI
89069076|NCT02865655||CSD-MRI with saline|Cesarean Section Scar Evaluation by MRI with saline
89069077|NCT02865655||CSD-Hysteroscopic|Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy
89069078|NCT04297072||Rivaroxaban|Participants in this group administered oral anticoagulant Rivaroxaban
89069079|NCT04297072||Vitamin-K antagonists (VKAs)|Participants in this group administered oral anticoagulants VKAs
89069080|NCT03993847||Prospective Cohort of Undiagnosed Back Pain|"All consecutive patients referred to a rheumatologist with current undiagnosed back pain of ≥3 months duration with onset ≤45 years of age will comprise the prospective cohort.~This is a classification study; no intervention will be administered"
89069081|NCT02871310|Experimental|IQP-AS-118|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
89069082|NCT02871310|Placebo Comparator|Placebo|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
89069083|NCT01008748|Experimental|Smoking Cessation Treatment|Nicotine replacement therapy (NRT), self-help materials, + brief in-person and telephone counseling, all conducted in Spanish. Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
89069084|NCT02865265||Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral PaB was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
89069085|NCT04295512|No Intervention|Usual Care|Community therapists delivering routine care to participant children with no training in UOT
89069086|NCT04295512|Experimental|UOT Training|Therapists enrolled in UOT Training
89069087|NCT04289545|Placebo Comparator|Control Bread|no added guar gum
89069088|NCT04289545|Active Comparator|Functional Bread 1|10% guar gum, low molecular weight
89069089|NCT04289545|Active Comparator|functional Bread 2|10% guar gum, high molecular weight
89069090|NCT04289545|Active Comparator|Functional Bread 3|15% guar gum, low molecular weight
89069091|NCT04289545|Active Comparator|Functional Bread 4|15% guar gum, high molecular weight
89069092|NCT00628732|Experimental|1|
89069093|NCT04289701||Hypertension Cohort|"Hypertension patients recruited in the Hypertension Prevention and Control Initiative in China project."
89069094|NCT02867449|Experimental|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
89690768|NCT03454048|Experimental|Group 2 (Cohort A) LD-PIP/LD-PIP2/SP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 2(LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
89069095|NCT02867449|Experimental|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
89069096|NCT02866825|Active Comparator|IFX-1|dose escalating single i.v. administration of IFX-1 (verum)
89069097|NCT02866825|Placebo Comparator|Placebo|dose escalating mimicing single i.v. administration of placebo
89069098|NCT04290715||group A|
89069099|NCT04290715||group I|
89069100|NCT04273711||Obese patients|
89069101|NCT04273711||Non-obese patients|
89069102|NCT02870998|Experimental|Active learning|Educational strategies will be used to foster active learning.
89069103|NCT02870998|Active Comparator|Passive learning|Traditional educational strategies (lecture) will be used.
89069104|NCT05212441|Experimental|Group A (LED group)|This group includes 30 burned patients who will receive LED therapy in addition to their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
89069105|NCT05212441|Active Comparator|Group B (Control group)|This group includes 30 burned patients who will receive their physical therapy program (splinting, stretching ex., strengthening ex. and ROM ex.) and medical treatment.
89069106|NCT04298788|Placebo Comparator|White dishware|standard white dishware used in the home
89069107|NCT04298788|Experimental|blue dishware|specially designed blue dishware, plates and bowls
89069108|NCT02865577||Adult asthma|"Adult asthma subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.~Participants will undergo following study assessments:~Clinical History~Health status and disease control questionnaires~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
89069109|NCT02865577||Adult COPD|"Adult COPD subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.~Participants will undergo following study assessments:~Clinical History~Health status and disease control questionnaires~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
89069110|NCT02865577||Healthy participants|"Healthy participants with no past history of cardiovascular or respiratory disease.~Participants will undergo following study assessments:~Clinical History~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
89069111|NCT02865421|Experimental|Stem cells|adipose tissue derived stromal vascular fraction was used
89069112|NCT02865421|Experimental|platelet rich plasma|platelet rich plasma isolated after centrifugation from the pt was transplanted
89069113|NCT04205344|Experimental|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
89069114|NCT04205344|Experimental|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
89069115|NCT01004146|Placebo Comparator|Control group|Patients assigned to the control group were educated on the proper technique of using the incentive spirometer and were instructed to use it for 3 breaths once per day to become able to use the device properly and consistently.
89069116|NCT01004146|Experimental|Experimental Group|Patients assigned to the experimental group were instructed to use the spirometer by inhaling as slowly and deeply as possible in a set of 10 times and to repeat the process at least 5 times every day until the day of surgery.
89069117|NCT01012414|Experimental|oral paricalcitol 2 mcg daily|oral paricalcitol 2 mcg daily
89069118|NCT01012414|Placebo Comparator|Placebo|one oral placebo drug daily
89069119|NCT00975715|Experimental|TRI476|Participants received TRI476 based on body weight with titration up to the maintenance dose, in addition to their traditional antiepileptics dosage.
89069120|NCT00975715|Placebo Comparator|Placebo|Participants received placebo to TRI476 without any adjustment to the dosing regimen, in addition to their traditional antiepileptics dosage.
89069121|NCT04295668||Usual care|A contemporaneous control group of patients was build using propensity score matching (PSM) methodologies taking into account the following matching variables: type of surgery, age, sex, American Society of Anesthesiologists Index (ASA) and adjusted morbidity groups (GMA) grading.
89069122|NCT04295668||Prehabilitation|"Prospective sample of risk patients who are candidates for major surgery attended in the outpatient offices of the Hospital Clínic de Barcelona.~Inclusion criteria: i) American Society of Anesthesiologists Index (ASA) 3-4; and / or, ii) age ≥ 75 years; and / or iii) major aggressive surgery; and, iv) solid organ transplant candidate.~Exclusion criteria: i) Non-elective surgery; ii) Known metastatic disease before surgery; iii) Unstable respiratory or heart disease; or, iv) Locomotive or cognitive limitations that prevent adherence to the program."
89069123|NCT02866981|Experimental|Observation|Patients that meet all inclusion and exclusion criteria are monitored every 2 months for two years or until a therapeutic intervention is warranted.
89069124|NCT00629317|Active Comparator|A|
89069125|NCT00629317|Placebo Comparator|B|
89069126|NCT04298476|Placebo Comparator|A|Saline will be placed in syringe instead of ropivicaine 0.2% and the nerve block will be placed in the adductor canal at the desired location by the anesthesiologist
89069127|NCT04298476|Active Comparator|B|An adductor canal block will be placed with local anesthetic in the proximal 1/3 of the operative leg
89069128|NCT04298476|Active Comparator|C|An adductor canal block will be placed with local anesthetic in the middle 1/3 of the operative leg
89069129|NCT04298476|Active Comparator|D|An adductor canal block will be placed with local anesthetic in the distal 1/3 of the operative leg
89069130|NCT02866591|Experimental|Arm A|Patients have a mammography performed by themselves according to auto-compression procedure. The radiologist leads the compression at a minimum threshold of 40 Newton, then leaves the control of the compression to the patient. The radiologist treats only the positioning of the breast on the sensor.
89069131|NCT02866591|Active Comparator|Arm B|Patients have a mammography performed by the radiologist according to standard procedure.
89069132|NCT02871154|Experimental|Delay|Delaying oocyte pick up beyond 39 hours post hCG
89069133|NCT03962491|Other|Daily Self-Monitoring Surveys|Asked to complete daily self-monitoring surveys.
89069134|NCT03962491|Experimental|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete daily self-monitoring surveys, with opportunity for monetary rewards.
89069135|NCT02866513|Other|Patient mechanically ventilated with APRV mode|
89069136|NCT04290637|Experimental|No sea swimming|Stop sea swimming for 4-6 weeks
89069137|NCT04290637|Active Comparator|Sea swimming|Continue sea swimming for 4-6 weeks
89069138|NCT00978757|Experimental|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
89069139|NCT00978757|Placebo Comparator|Placebo|Placebo: saline solution
89069140|NCT01214421|Experimental|Tolvaptan|Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligrams (mg) in the morning [AM]/15 mg in the evening [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily until the last participant originating from prior studies (either 156-04-251 or 156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290) who was eligible for efficacy analysis completed the Month 24.
89069141|NCT04102111|Experimental|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily for 12 weeks.
89069142|NCT04102111|Placebo Comparator|Placebo|Participants will receive oral tablets of matching placebo twice daily for 12 weeks.
89069143|NCT01214187|Experimental|carbon monoxide inhalation|The primary intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
89069144|NCT01214187|Placebo Comparator|Oxygen 21%|
89069145|NCT02866903|Experimental|Patients with peritoneal carcinosis|Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
89069146|NCT02865031|Experimental|Decorin|Intravitreal injection of 200-400 ug of Decorin.
89690769|NCT03454048|Experimental|Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 3 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg)
89690770|NCT03454048|Experimental|Group 4 (Cohort B) LD-PIP/LD-PIP2/SP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 4 (LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
89069147|NCT02864875|No Intervention|Control|Not to receive an early replacement of fibrinogen
89690771|NCT02165839|Active Comparator|Healthy Eating Education Learning (HEAL)|Control group.
89690772|NCT02165839|Experimental|Brief Behavioral Therapy for Insomnia (BBT-I)|
89690773|NCT04396184|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 288 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once every two weeks for 3 times.
89690774|NCT04396184|Active Comparator|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 140 J/cm2) after applying 5% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once every two weeks for 3 times.
89069148|NCT02864875|Experimental|Intervention|Receive early replacement through fibrinogen concentrate (50mg per kg of body weight)
89069149|NCT01003990|Experimental|Atazanavir|
89069150|NCT01003990|Experimental|Atazanavir/Ritonavir|
89069151|NCT01003990|Active Comparator|Lopinavir/Ritonavir|Ritonavir-boosted Lopinavir (LPV/RTV 400/100 mg) administered twice a day (BID) with Tenofovir/ Emtricitabine (TDF/FTC).
89069152|NCT01003210|Experimental|Homeopathic ear drops|Commercially available homeopathic ear drops
89069153|NCT01003210|No Intervention|standard therapy|standard therapy for otitis media, no ear drops
89069154|NCT01002820|Experimental|participants|all subjects participating in 0602 are receiving ganaxolone for seizure control
89069155|NCT01012258|Experimental|Cetuximab|All eligible subjects will receive cetuximab treatment only during week 1 of the treatment course and concomitant cetuximab and boost radiotherapy (RT) during week two to week seven of the treatment course
89069156|NCT00628810|Experimental|FOLFIRI fort plus bevacizumab|Bevacizumab 5 mg/kg D1, irinotecan 260 mg/m2 D1, LV 400 mg/m2 D1, 5FU 400 mg/m2 IV bolus D1, and 5FU 2,400 mg/m2 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.
89069157|NCT04298320|Experimental|SHR-1210 + AIN457|SHR-1210 was administered 200mg iv every 2 weeks in combination with AIN457 150mg or 300mg ih every 2 weeks
89069158|NCT04298164|Experimental|Intervention group|Group that receives the intervention
89069159|NCT04298164|Active Comparator|Control group|Group that receives treatment as usual
89690775|NCT03226366||Pre-implementation (intervention site)|Adult patients age ≥18 years who received usual care after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
89690776|NCT03226366||Post-implementation (intervention site)|"Adult patients age ≥18 years eligible to receive immediate evaluation by multidisciplinary team (swarming) after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017"
89069160|NCT01011946|Experimental|Positron Emission Mammography|
89069161|NCT04296682|No Intervention|Atraumatic Extraction Without Gingival Graft|Alveolar closure with elevation of total flaps and simple suture (Silk thread 4.0, Ethicon, Johnson & Johnson, SJC).
89069162|NCT04296682|Experimental|Atraumatic Extraction With Gingival Graft|Closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual palate.
89069163|NCT04296760||Women with suspicious of deep posterior pelvic endometriosis|
89069164|NCT00975481|Experimental|dimebon 20 mg|
89069165|NCT00975481|Experimental|dimebon 40 mg|
89069166|NCT00975481|Experimental|dimebon 60 mg|
89069167|NCT00975481|Placebo Comparator|placebo|
89069168|NCT00975481|Active Comparator|alprazolam 1 mg|
89069169|NCT00975481|Active Comparator|alprazolam 3 mg|
89069170|NCT01011868|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose daily
89069171|NCT01011868|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose daily
89069172|NCT01011868|Placebo Comparator|placebo|Patients receive placebo to match BI 10773 daily
89069173|NCT04290013|Experimental|norethisterone -women with Dysfunctional uterine bleeding|
89069174|NCT04290013|Experimental|tranexemic acid-women with Dysfunctional uterine bleeding|
89069175|NCT04288999|Experimental|Arm A|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)~Adjuvant chemotherapy: CAPOX (capecitabine+oxaliplatin) or mFOLFOX6 (5-fluorouracil+l-leucovorin+oxaliplatin) or capecitabine or 5-fluorouracil (FU) +l-leucovorin (LV)~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
89069176|NCT04288999|Active Comparator|Arm B|"Surgery plus Adjuvant chemotherapy~Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
89069177|NCT01213251|Experimental|Single Site Pacing|
89690777|NCT03226366||Pre-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
89690778|NCT03226366||Post-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017
89069178|NCT01213251|Experimental|Dual Site Pacing|
89069179|NCT01213251|No Intervention|Control|
89069180|NCT03934177|Experimental|Blueberry powder|4 weeks of supplementation of 24 g whole blueberry powder
89069181|NCT03934177|Placebo Comparator|Placebo powder|4 weeks of supplementation of 24 g placebo powder (maltodextrin)
89069182|NCT02864017|Experimental|L-Citrulline group|Enteral nutrition 5-day L-citrulline treatment (10 grams/day)
89069183|NCT02864017|Placebo Comparator|Control group|Enteral nutrition 5-day placebo treatment
89069184|NCT01213173|Active Comparator|1|
89069185|NCT01213173|Experimental|2|
89069186|NCT04318431|Other|Data collection and rhinopharyngeal swab|"After information, the collection of consent will be carried out. A clinical information sheet will be completed by the investigator in order to collect socio-demographic data, history, clinical symptoms and signs, and complementary examinations performed.~During the same consultation, a rhinopharyngeal swab will be taken for the detection of SARS -Cov2 and other respiratory pathogens by PCR."
89690779|NCT04395872||COVID-19|Among patients who were confirmed as COVID-19 and admitted to the COVID-19 management ward of Daegu Catholic University Hospital, patients who were consulted by the Department of psychiatry was selected as participants. Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R). were collected from participants. It evaluates whether there is a difference in the psychological scale according to the difference in participants' sociodemographic status and medical severity, and evaluates the effectiveness of psychiatric counseling by comparing clinical psychological measures before and after referral to department of psychiatry.
89690780|NCT03015337|Experimental|New Physical Education Instructions|
89690781|NCT04395092|Experimental|K-NK002|
89690782|NCT03015571|Experimental|NBI|Use of Narrow Band Imaging with regular care of cervical inlet patches detection.
89690783|NCT03015571|Placebo Comparator|WL|Use of High Definition White Light (WL) with regular care of cervical inlet patches detection.
89690784|NCT03015571|Experimental|NBI increased care|Use of Narrow Band Imaging with increased care of cervical inlet patches detection.
89690785|NCT03015571|Placebo Comparator|WL increased care|Use of High Definition White Light (WL) with increased care of cervical inlet patches detection.
89690786|NCT01924286|Experimental|Prednisone|Prednisone oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
89690787|NCT01924286|Placebo Comparator|Placebo|Placebo oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
89690788|NCT04443439||No related neurological symptoms and transient ischemic attack|Mild stenosis group: CTA suggested carotid stenosis < 30%; Moderate stenosis group: CTA suggested carotid stenosis of 30-69%; Severe stenosis group: CTA indicated carotid stenosis ≥70%;
89069187|NCT02866435|Experimental|Euglycemia pre-conditioning|Participants will undergo two euglycemia (normal blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where the target glucose during the clamp will be 95 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
89069188|NCT02866435|Experimental|Hypoglycemia pre-conditioning|Participants will undergo two hypoglycemia (low blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where target glucose during the clamp will be 50 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
89069189|NCT04287751|Other|Overnight Oximetry|Participants record simultaneously overnight oximetry on night 1 and continue with prolonged recordings alone for a total of 4 nights
89069190|NCT01212159|No Intervention|No self monitoring device|Standard or usual care of high LDL including lab lipid profiles after treatment with statin therapy. No device or telemedicine education will be provided
89069191|NCT01212159|Experimental|Self Monitoring Lipid Analyzer|Self measured blood lipids using a home lipidometer, and telephone reporting of data to the clinical center.
89069192|NCT00973765|Active Comparator|bactrim DS (800/160) 2 pills po BID x 7 days|active comparator
89069193|NCT00973765|Placebo Comparator|Matched placebo 2 pills po BID x 7 days|placebo
89069194|NCT04287595|Experimental|intervention group|inhalation aromatherapy with orange essential oil
89069195|NCT04287595|No Intervention|control group|routine care
89069196|NCT01211769|Experimental|PUFAs|Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;
89069197|NCT01211769|Active Comparator|Naltrexone|Naltrexone chlorhydrate 50 mg
89069198|NCT01211769|Placebo Comparator|Placebo|"Naltrexone Placebo: pill with 50mg of talcum powder, identical to the pill of naltrexone;~Polyunsaturated fatty acids Placebo (PUFAs Placebo): yellow liquid paraffin identical to the pills of borage seed and fish oil."
89069199|NCT01211769|Other|Naltrexone + PUFAs|"Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;~Naltrexone chlorhydrate 50 mg"
89069200|NCT04287673|Experimental|RIST-UR|"Group having performed the rehabilitation involving strongly the trunk for the first 3 months and then having performed its usual rehabilitation for the last 3 months.~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
89069201|NCT04287673|Experimental|UR-RIST|"Group having performed its usual rehabilitation for the first 3 months and then having performed the rehabilitation involving strongly the trunk for the last 3 months.~Before and after each 3-months period, an evaluation of the postural control of the trunk (using the Trunk Control Measurement Scale and a dynamic posturography on an unstable sitting device) and a clinical gait analysis were performed."
89069202|NCT04287673|No Intervention|Typically Developing children|Typically developing children who served as a control group in the first assessment (Trunk Control Measurement Scale, dynamic posturography on an unstable sitting device, clinical gait analysis)
89069203|NCT04288609|Experimental|Intendu FBT inpatient|Motion Based Cognitive Video Games Software
89069204|NCT04288609|Active Comparator|paper and pencil tasks|paper and pencil tasks
89069205|NCT04288765|Experimental|Group A - Non transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone
89069206|NCT04288765|Active Comparator|Group B - transplant|Carfilzomib Lenalidomide Daratumumab Dexamethasone Autologous stem cell transplantation (ASCT)
89069207|NCT01211613|Experimental|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
89069208|NCT01211613|Experimental|Mechanical Manipulation|Doctor of chiropractic will apply a mechanically-assisted thrust to the lumbar spine of research participants using the Activator IV Instrument.
89069209|NCT01211613|Active Comparator|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
89069210|NCT02864797|Experimental|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software.
89069211|NCT01211535|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days
89069212|NCT01211535|Active Comparator|ReNu Biotrue|ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days
89069213|NCT04287439|Experimental|Relaxation|"Patients will receive a training session for progressive muscle relaxation exercise.~They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence."
89069214|NCT04287439|Experimental|Meditation|Patients will receive a training session for minfullness meditation They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
89069215|NCT04287439|Active Comparator|Attention matched control group|Patients will receive a training session focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods.
89069216|NCT02863861|Experimental|Group PK|Propofol-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV propofol 1mg.kg-1 for induction with added doses of propofol 1mg.kg-1 when needed.
89069217|NCT02863861|Experimental|Group DK|Dexmedetomidine-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV dexmedetomidine 0.5 mcg.kg-1 for induction with additional doses of dexmedetomidine 0.5mcg.kg-1 when required
89069218|NCT05406765|Active Comparator|Spinal|Spinal anesthesia
89069219|NCT05406765|Placebo Comparator|Placebo|Placebo spinal
89069220|NCT01011556|Active Comparator|20 mcg Subcutaneous Teriparatide|Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.
89069221|NCT01011556|Experimental|30 mcg Transdermal Teriparatide|Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
89069222|NCT01011556|Experimental|50 mcg Transdermal Teriparatide|Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
89069223|NCT01011556|Experimental|80 mcg Transdermal Teriparatide|Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
89069224|NCT01211145|Placebo Comparator|1|Placebo
89069225|NCT01211145|Experimental|2|ZOMIG 0.5 mg
89069226|NCT01211145|Experimental|3|ZOMIG 2.5 mg
89069227|NCT01211145|Experimental|4|ZOMIG 5.0 mg
89069228|NCT00977665|Experimental|rasagiline mesylate|rasagiline tablet, 1 mg/day for up to 48 weeks.
89069229|NCT00977665|Placebo Comparator|placebo|placebo tablet for up to 48 weeks.
89069230|NCT04298008|Experimental|AZD6738 + Durvalumab Cohort|This is a study enrolling advanced BTC patients who have been previously treated with immunotherapy, to explore the combination of AZD6738+durvalumab
89069231|NCT02871544|Sham Comparator|Low BNP and Low NGAL Group|BNP≤100pg/ml and NGAL≤153pg/ml
89069232|NCT02871544|Active Comparator|High BNP and Low NGAL Group|BNP>100pg/ml and NGAL≤153pg/ml
89069233|NCT02871544|Active Comparator|Low BNP and High NGAL Group|BNP≤100pg/ml and NGAL>153pg/ml
89069234|NCT02871544|Active Comparator|High BNP and High NGAL Group|BNP>100pg/ml and NGAL>153pg/ml
89069235|NCT04295278||Systemic inflammatory response syndrome|Systemic inflammatory response syndrome in patients in the pediatric intensive care unit.
89069236|NCT00628342|Experimental|1|
89069237|NCT00628342|Experimental|2|
89069238|NCT00628342|Placebo Comparator|3|
89069239|NCT04290325|Experimental|HMPL-453|HMPL-453
89069240|NCT01210443|Experimental|Sitaxentan treatment|
89069241|NCT02870764|Active Comparator|Dan-shen extract|Based on the standard medical care, 200mg of Danshenduofensuanyan, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours, once a day during the patients' hospitalization. Danshen drop spill (30 pill/day) taken orally for 60 days after discharge.
89069242|NCT02870764|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 200mg of glucose, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours.
89069243|NCT04287361||Loading dose < 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam < 0.03 mg / kg
89069244|NCT04287361||Loading dose ≥ 0,03 mg/kg|Patient being treated for a status epilepticus who received an initial dose of clonazepam ≥ 0.03 mg / kg
89069245|NCT02864719|Experimental|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
89069246|NCT01007812|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week, followed by Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week.
89069247|NCT01007812|Other|Comfilcon A / Lotrafilcon B|Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week, followed by Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week.
89069248|NCT04204525||Patients with chronic whiplash associated disorders|Male or female, aged between 18 and 65 years. Inclusion: 1) whiplash trauma (at least three months old) and pain since at least 3 months, self-reported mild to severe pain-related disability (score of 5/50 or more on the neck disability index), classified as wad II or wad III on the modified Quebec task force scale; 2) not undertaking exercise 1 day before the experiment; 3) not starting new treatments or medication and continuing their usual care 6 weeks prior to and during study participation (to obtain a steady state); 4) native dutch speaker and 5) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments
89069249|NCT04204525||Healthy controls|Male or female, aged between 18 and 65 years. Inclusion: 1) no history of whiplash trauma, no pain with a mean pain intensity of more than 2/10 on the visual analogue scale for > 8 consecutive days in the preceding year in the neck-shoulder-arm region 2) painfree at the day of testing 3) native dutch speaker and 4) refraining from non-opioid analgesics 48h before the assessments, and refraining from caffeine, alcohol and nicotine 24h before the assessments.
89069250|NCT01208961|Active Comparator|Epanova-Lovaza-Epanova-Lovaza|
89069251|NCT01208961|Active Comparator|Lovaza-Epanova-Lovaza-Epanova|
89069252|NCT01001572|Active Comparator|Valsartan 160 mg|One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
89069253|NCT01001572|Experimental|Valsartan/amlodipine 160/5 mg|One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks
89069254|NCT01001572|Other|Single-Blind Run-In Valsartan 160 mg|Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.
89069255|NCT01208415|Experimental|Device Implant|
89069256|NCT02871232||Intentional exposures among adolescents and adults|
89069257|NCT02871232||Unintentional exposures among infants and children|
89069258|NCT04287205|Experimental|women with endometriosis|
89069259|NCT00628576|Active Comparator|1|UFH: patients treated with unfractionated heparin
89069260|NCT00628576|Experimental|2|FH: patients treated with low-molecular-weight (fractionated) heparin
89069261|NCT01208337|Other|Alemtuzumab induction|Intestine transplant recipients who receive induction with alemtuzumab prior to transplantation.
89069262|NCT04295122|Active Comparator|Phacoemulsification + ECP laser|"Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. The viscoelastic will be washed-out of the capsular bag after IOL insertion. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment.~Intracameral cefuroxime and dexamethasone will be injected into the anterior chamber and sutures used to close the incisions as required."
89069263|NCT04295122|Active Comparator|Phacoemulsification alone|Cataract surgery will be performed using standard anesthesia and phacoemulsification techniques. A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion. For this study, monofocal IOLs are required.
89069264|NCT04370548|Experimental|Clindamycin phosphate vaginal gel, 2%|
89069265|NCT04370548|Placebo Comparator|Placebo vaginal gel (Universal HEC Placebo Gel)|
89069266|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.
89069267|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.
89069268|NCT01208181|Experimental|Etoricoxib 90 mg|The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
89069269|NCT01208181|Placebo Comparator|Placebo|The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
89069270|NCT02870842|Placebo Comparator|Control|Perform recruitment maneuver with fraction of inspired oxygen (FiO2) of 1.0 after intubation under lung ultrasound guidance and maintain FiO2 of 0.6 during the general anesthesia.
89069271|NCT02870842|Active Comparator|Low FiO2|Perform recruitment maneuver with low FiO2 of 0.3 after intubation under lung ultrasound guidance and maintain FiO2 of 0.3 during the general anesthesia.
89069272|NCT04319523||COPD patients|
89069273|NCT04319523||Healthy subjects|
88812746|NCT03215654|Experimental|MHL more Stigma Reduction (ER)|Includes the six teaching units of MHL and a first contact presentation with lived experience of any mental disorder, who will be delivered by a voluntary member of Activament Catalunya Associació (http://www.activament.org/es), a non-profit group specialized in reducing stigma. Duration 7 hours.
89069274|NCT01208103|Experimental|Treatment (oxaliplatin, bevacizumab, capecitabine)|Participants receive oxaliplatin via CVC over 2 hours and bevacizumab IV over 30-90 minutes on day 1. Participants also receive capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89069275|NCT01206777|Experimental|Rituximab|
89069276|NCT01001494|Experimental|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation
89069277|NCT01001494|Experimental|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation
89069278|NCT01001494|Placebo Comparator|Placebo|Placebo
89069279|NCT01205685|Experimental|OSI-906 + Erlotinib + Letrozole + Goserelin|"OSI-906 in a pill form, by mouth, twice a day (12 hours a part)~Erlotinib in a pill form, by mouth, once a day~Letrozole in a pill form, by mouth, once a day~Goserelin, by injection once per month for women who are pre-menopausal"
89069280|NCT04362514|Experimental|IG|Intervention Group
89069281|NCT04362514|Active Comparator|aCG|Control Group
89069282|NCT01205529|Other|AF with ST changes on ECG|Those patients with ST segment or J Point elevation on electrocardiogram. Can be on initial screening electrocardiogram or on electrocardiograms during procainamide infusion. These subjects will harbor cardiac sodium channel gene variants.
89069283|NCT04295200|Experimental|Dry needling with electrical stimulation|Use of dry needles (this is the generic name for sterile, solid filament needles) are inserted into the lumbar multifidi. Intramuscular electrical stimulation will then be applied by attaching a six-lead electrical stimulation unit to the needles. Electrical stimulation will be applied through the needles at the participant's desired frequency (between 4-6 Hz) and for up to 10 minutes total.
89069284|NCT01205451|Experimental|BTX-A|Botulinum toxin type A
89069285|NCT04294732|Placebo Comparator|Only spinal anesthesia|Only spinal anesthesia without peripheral nerve block
89069286|NCT04294732|Active Comparator|high concentration|8 ml saline with 8 ml bupivacaine
89069287|NCT04294732|Experimental|low concentration|8 ml bupivacaine with 16 ml of saline
89690789|NCT03455218|Experimental|Nitric Oxide|20 ppm of Nitric Oxide delivered to the oxygenator via the INOmax device for the duration of the cardiopulmonary bypass time
89690790|NCT03455218|Placebo Comparator|Placebo|INOmax device attached to the oxygenator, but no gas is delivered through the device
89690791|NCT01920230|Experimental|Mindfulness-ACT-intervention|Group meetings face-to-face and web-based program using principles of mindfulness and ACT.
89690792|NCT01920230|Experimental|Control|Control group, no intervention.
89069288|NCT04294888|Experimental|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80% of a patient's active motor threshold. rTMS will be administered in an excitatory iTBS pattern. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
89069289|NCT04294888|Sham Comparator|Sham stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80% of a patient's active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory performance, or whether practice effects or other non-specific effects are responsible for any changes in memory which may be observed.
89069290|NCT02887677|Active Comparator|Dapagliflozin|Dapagliflozin for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
89069291|NCT02887677|Placebo Comparator|Placebo|Placebo for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
89069292|NCT02871466|Experimental|stem cells infusion|
89069293|NCT01001104|Experimental|0.75 mg LY2189265|
89069294|NCT01001104|Experimental|0.5 mg LY2189265|
89069295|NCT01001104|Experimental|0.25 mg LY2189265|
89069296|NCT01001104|Placebo Comparator|Placebo|
89069297|NCT04296526|Experimental|Precontemplation|
89069298|NCT04296526|Experimental|Contemplation|
89069299|NCT04296526|Experimental|Preparation|
89069300|NCT00628654||Volunteers|Serum samples will be obtained from volunteers, but no tissue specimens. Volunteers will complete a questionnaire.
89069301|NCT00628654||Patients with cancer|Ascites from patients with ovarian, peritoneal, and fallopian tube cancers for basic science studies
89069302|NCT00628888|Experimental|Unified Protocol for Adolescents (UP-A)|Participants receive the UP-A intervention for 8-21 weeks immediately following randomization.
89069303|NCT00628888|Experimental|Delayed Treatment/Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the UP-A treatment for 8-21 weeks.
89069304|NCT02870686|Active Comparator|ERCP without the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to the EUS guided ERCP without fluoroscopy clear all of the bile duct stones.
89069305|NCT02870686|Active Comparator|ERCP with the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to underwent ERCP with the use of fluoroscopy to clear all of the bile duct stones.
89069306|NCT04204954|Other|Group 1: Topical 0.3% Ciprofloxacin [Cipro]|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days.
89069307|NCT04204954|Active Comparator|Group 2: Cipro + 50% diluted baby shampoo|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with 50% diluted baby shampoo for three days.
89069308|NCT04204954|Active Comparator|Group 3: Cipro + Blephaclean|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with Blephaclean Sterile Eyelid Wipes (Thea Pharmaceuticals) for three days.
89069309|NCT04204954|Experimental|Group 4: Cipro + Tea tree oil.|Ciprofloxacin Ophthalmic Ointment 0.3% every four hours for three days. Twice a day eyelid margin cleansing with tea tree oil shampoo for three days.
89069310|NCT02870608|Experimental|preterm labor group|Pregnant women hospitalized for preterm labor
89069311|NCT02870608|Other|control group|Pregnant women with a normal pregnancy
89069312|NCT04344886|Experimental|Conventional (dual-phase) SPECT/CT|Adult patients with primary hyperparathyroidism undergoing conventional (dual-phase) SPECT/CT (after 10 and 150 minutes) and conventional minimally-invasive radio-guided parathyroidectomy in a time span 2-3 hours from radionuclide administration.
89690793|NCT01050907|Experimental|Miltefosine|2.5 mg/kg/day for 28 days
89069313|NCT04344886|Experimental|Multi-phase SPECT/CT|Adult patients with primary hyperparathyroidism undergoing multi-phase SPECT/CT (after 10, 90, 150, 210 minutes) and individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
89069314|NCT00998764|Experimental|Bapineuzumab 0.5 mg/kg|
89069315|NCT01204671|Experimental|GSK2321138A Lot 1 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
89069316|NCT01204671|Experimental|GSK2321138A Lot 2 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
89069317|NCT01204671|Experimental|GSK2321138A Lot 3 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
89069318|NCT01204671|Active Comparator|Fluarix Group|Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
89069319|NCT01204671|Active Comparator|GSK2604409A Group|Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
89069320|NCT02887755|Experimental|Amputee Group|In this study n=20 returning US military combatants between 18 and 45 years of age who have unilateral transtibial or transfemoral amputation will be asked to perform two aerobic exercise tests while we4aring the NIRS sensor. Subjects must be medically cleared and able to complete approximately 30 minutes of physical activity.
89069321|NCT01202955|Active Comparator|Tolcapone|Tolcapone
89069322|NCT01202955|Placebo Comparator|Placebo|Placebo
89069323|NCT01202877|Experimental|5-azacytidine + PKC412|5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
89069324|NCT01202409|Experimental|Panitumumab|Starting Dose of Panitumumab: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
89069325|NCT01202175|Experimental|Nebivolol|
89069326|NCT01202175|Placebo Comparator|Sugar pill|
89069327|NCT01201785|Experimental|Aspirin dose range|
89069328|NCT01201317|Experimental|AZD2423, 150 mg|Tablets, 150 mg once daily in the morning.
89069329|NCT01201317|Experimental|AZD2423, 20 mg|Tablets, 20 mg once daily in the morning.
89069330|NCT01201317|Placebo Comparator|Placebo|Tablets, placebo, once daily in the morning.
89069331|NCT04318353||early enteral feeding|start enteral feeding within 2 days postoperative
89069332|NCT04318353||control|start enteral feeding after 2 days postoperative according to clinician discretion based on clinical progress(ranging from 1-5 days after passage of flatus or stool.
89069333|NCT04317885|Experimental|Prizloncabtagene Autoleucel|Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion
89069334|NCT01200069|Placebo Comparator|Sugar water|500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3
89069335|NCT01200069|Active Comparator|Ibuprofen|300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3
89069336|NCT01199601|Experimental|Concentrated postpartum counseling|Women randomized to receiving concentrated postpartum counseling from the retrained provider.
89069337|NCT01199601|No Intervention|Routine postpartum counseling|Women receiving intra-partum testing and post-partum counseling from existing cadres of hospital providers at standard of care.
89069338|NCT01199289|Placebo Comparator|Placebo|Participants will receive the matching placebo administered as subcutaneous (SC) injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
89069339|NCT01199289|Experimental|AMG 827 140 mg|Participants will receive AMG 140 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
89069340|NCT01199289|Experimental|AMG 827 210 mg|Participants will receive AMG 210 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
89069341|NCT01199289|Experimental|AMG 827 280 mg|Participants will receive AMG 280 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
89069342|NCT01199055|Experimental|CS-7017+Carboplatin/Paclitaxel|"Drug: CS-7017 from 0.25 mg twice a day (BID) to 0.50 mg BID for up to 4~6 cycles (1 cycle: 3 weeks)~Drug: Carboplatin IV, Area under the curve (AUC) of 6 mg/mL*min, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)~Drug: Paclitaxel IV, 200mg/m^2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)"
89069343|NCT01198977|Active Comparator|Brief telephone-based counseling|Telephone based counseling and instructional video
89690794|NCT03120650|Experimental|Scalp acupuncture|number:58 The needle will be maintained in place for 30 minutes. Patients in both groups will receive rehabilitation five times per week (Monday through Friday) for 8 consecutive weeks.
89690795|NCT03120650|Active Comparator|Conventional rehabilitation|number:58 Rehabilitation will be conducted for 1 hour five times per week (Monday through Friday) for 8 weeks.
89690796|NCT01924520|Experimental|Group 1 (FK949E lower dose)|Oral
89690797|NCT01924520|Experimental|Group 2 (FK949E middle dose)|Oral
89690798|NCT01924520|Experimental|Group 3 (FK949E higher dose)|Oral
89690799|NCT04433845|Experimental|Psilocybin|25mg of Psilocybin
89690800|NCT01920308||5 mm Bard LifeStent Vascular Stent|"The study population will be comprised of subjects who present with moderate lifestyle-limiting claudication to mild tissue loss (Rutherford Category 2-5) that are candidates for PTA and stenting.~Subjects with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be considered for enrollment. The reference vessel diameter will be appropriate for treatment with available stent diameter of 5.0 mm (by visual estimate)."
89690801|NCT04431973|Experimental|Shoulder prothesis|Evaluate the performance of the Medacta Shoulder System total reverse shoulder prothesis
89690802|NCT01920386|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|1tab PO within 5hours from teeth extraction
89069344|NCT01198977|Placebo Comparator|Education Counseling|Mailed Physical Activity information and instructional video only
89069345|NCT01198587|Experimental|Outpatient Zinc Sulfate|Zinc Sulfate
89069346|NCT01198587|Experimental|Inpatient Zinc Sulfate|Zinc Sulfate
89069347|NCT01198587|Placebo Comparator|Outpatient Placebo|Placebo oral capsule
89069348|NCT01198587|Placebo Comparator|Inpatient Placebo|Placebo oral capsule
89069349|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - doxycycline|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
89069350|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - vancomycin|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
89069351|NCT01198509|No Intervention|RA, PsA, healthy|"Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.~Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.~Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients."
89069352|NCT01198275|Active Comparator|n-3 PUFAs|
89069353|NCT01198275|Placebo Comparator|placebo|
89069354|NCT01197417|Experimental|Magnesium group|Intravenous Magnesium Sulfate
89069355|NCT01197417|Placebo Comparator|Placebo group|Normal Saline placebo
89069356|NCT04206267|Experimental|Acceledent group|Patients up to 18 years old who were planned first premolar extractions assigned to study group. AcceleDent Aura appliance was applied for 20 minutes per day. during canine retraction.
89069357|NCT04206267|No Intervention|Control group|Patients up to 18 years old who were planned first premolar extractions assigned to control group. The canine retractions were performed without any additional vibrational device.
89069358|NCT00977431|Experimental|Regimen U|BIBW2992 + Radiotherapy
89069359|NCT00977431|Experimental|Regimen M|BIBW2992 + Temozolomide + Radiotherapy
89069360|NCT04290169|Other|Adults with hemiplegic spastic cerebral palsy|Adults (> 18 years old) with hemiplegic spastic cerebral palsy, with reduced hand function and spasticity as prevalent finding under clinical examination. Also these patients can walk but have problems with balance. Participants' cognitive function does not limit them to perform video game training.
89069361|NCT02864095|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
89069362|NCT02864095|Experimental|Topical epinephrine|Topical epinephrine
89069363|NCT02864095|Active Comparator|Control|No epinephrine
89069364|NCT02864641|Experimental|TX Group: Planet K Treatment|Participants in the TX Group will receive access to Planet K. Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Adolescent and young adult participants will then receive a mobile phone preloaded with the Planet K app and a brief orientation to the app and associated website.
89069365|NCT02864641|No Intervention|CO Group: Treatment-as-usual|A national sample of CKD participants will be recruited. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet K app and website but will receive email reminders to complete surveys online at each time point.
89069366|NCT04286893||TAVI group|Consecutive patients undergoing TAVI
89069367|NCT04290247|Experimental|Ultrasound + X-ray|Ultrasound first then x-ray examination
89069368|NCT02863939|Other|NICAS|There is only one arm - a single cohort. All patients undergoing the nuclear stress test will also have the NICAS evaluation.
89069369|NCT00977197|Active Comparator|Pregabalin|"Subjects randomized to this arm will receive the following dosage:~75 mg (one tablet) twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study."
89069370|NCT00977197|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo matching the study drug.
89069371|NCT04065139|Active Comparator|Control Arm|
89069372|NCT04065139|Experimental|Experimental Arm : PIPAC|
89069373|NCT04288297||distal minimally invasive distal chevron|The investigators compare the results of a consecutive cohort of patients treated with the above mentioned technique in comparison to the results of patients treated with the minimally invasive Reverdin-Isham technique, presented in literature
89069374|NCT04288219|Active Comparator|Standard of Care Treatment|Continuous supplemental oxygen and nifedipine 30mg will be administered to patients.
89069375|NCT04288219|Experimental|Non-Invasive Positive Pressure Ventilation Management|CPAP at 10mmHg with supplemental oxygen, as well as nifedipine 30mg will be administered to patients.
89069376|NCT00974311|Experimental|Enzalutamide|Formerly MDV3100
89069377|NCT00974311|Placebo Comparator|Placebo|
89069378|NCT00974233|Experimental|Induction/Maintenance chemotherapy|Bendamustine + rituximab induction therapy followed by lenalidomide maintenance therapy
89069379|NCT02866123|Experimental|patient with insertion of an NGT|
89069380|NCT00973921||Stent deployment evaluation|The study group consisted of patients that underwent IVUS guided stent implantation. Stent deployment evaluation was done with the experimental StentOptimizer as well as IVUS and QCA.
89069381|NCT00629395|Experimental|1|Participate in 12 week computer program.
89069382|NCT02863627|Experimental|Newborn Care Pathway|two telephone interviews conducted after the emergency department visit will be used to gather data to meet the objectives of this study.
89069383|NCT00972595|Experimental|A|clinical trial formulation
89069384|NCT00972595|Active Comparator|B|non-U.S. marketed formulation
89069385|NCT01196091|Experimental|LY2127399 every 2 weeks|Administered SC
88812747|NCT03215654|No Intervention|Control group|Control group will be a waiting list condition and they will receive the full program of 7h at the next year of academic course
89069386|NCT01196091|Experimental|LY2127399 every 4 wks|During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
89069387|NCT01196091|Placebo Comparator|Placebo|Administered SC
89069388|NCT01195623|Active Comparator|varicose vein surgery with preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination and has then the extra information available from a preoperative duplex examination to plan surgery more in detail
89069389|NCT01195623|No Intervention|varicose vein surgery no preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination only
89069390|NCT01195545|Experimental|Veritas Mesh in Hernia Repair|Subjects undergoing laparoscopic paraesophageal hiatal hernia repair using a bovine pericardium mesh (BP) (Veritas® Collagen Matrix, Synovis ®, St. Paul MN) as a reinforcing material during repair.
89069391|NCT01194999|Experimental|Pubovaginal sling procedure|Patients undergoing pubovaginal slings for stress urinary incontinence.
89069392|NCT01194531|No Intervention|CONTROL arm|Subjects assigned to this arm of the study will receive no PGS testing.
89069393|NCT01194531|Other|TEST arm|Subjects assigned to this arm of the study will receive PGS testing.
89069394|NCT00972517|Experimental|Group A|Subjects receiving alternative dose of GSK23440272A vaccine
89069395|NCT04286737|Experimental|Intervention Group|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
89069396|NCT04286737|No Intervention|Control Group|The therapeutic touch will not be applied to the control group infants. However, the routine follow-up and behavior of the weekly baby will be evaluated to ensure that parents are blind.
89069397|NCT00972283|Experimental|IDeg OD|
89069398|NCT00972283|Active Comparator|IGlar OD|
89069399|NCT05366049|Experimental|using a medicine pacifier to give acetaminophen|
89069400|NCT05366049|Active Comparator|using an enjector to give acetaminophen|
89069401|NCT02887599|Other|Patient Group|Pancreatic cancer patients
89069402|NCT02887599|Other|Control Group|Healthy people without evidence of malignancy
89069403|NCT00969709|Experimental|1|40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
89069404|NCT00969709|Experimental|2|80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
89069405|NCT00969709|Experimental|3|120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
89069406|NCT00969709|Placebo Comparator|4|Matching placebo capsules, oral administration, once daily.
89069407|NCT01193517|Experimental|Phase I|Dose Escalation of Azacitidine + CAPOX (Capecitabine, Oxaliplatin)
89069408|NCT01193517|Experimental|Phase II|MTD of Azacitidine + CAPOX
89069409|NCT02866045|Active Comparator|EUS-guided Fine Needle Biopsy|EUS-FNB is performed using a 22 or 25 G SharkCore biopsy needle with a minimum of 3 passes into the lesion.
89069410|NCT02866045|Experimental|Single incision needle knife biopsy|SINK biopsy is performed under direct endoscopic visualization via EGD with a minimum of 3 biopsy samples obtained.
89069411|NCT02863705|Experimental|COMBIGAN®|One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months
89069412|NCT02863705|Experimental|COMBIGAN® + LUMIGAN® 0.01%|LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.
89069413|NCT01193283|Experimental|SAA hematologic response|Treatment-naive severe aplastic anemia patients will receive a low dose of cyclophosphamide (120mg/kg) and low dose cyclosporine ( target therapeutic level of 100-200 micrograms per liter). Cyclophosphamide will be given once daily for 4 doses. Cyclosporine will be started after cyclophosphamide completion, cyclosporine will be given twice daily. The dosing will be modified to attain the therapeutic level.
89069414|NCT00971425|Experimental|Placebo-Pandemrix-Fluarix Group|Subjects received one dose of placebo intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21, and 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day 42.
89069415|NCT00971425|Experimental|Fluarix-Pandemrix-Placebo Group|Subjects received 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid of the non-dominant arm at Day 0 and 21, and 1 dose of placebo intramuscularly in the deltoid of the non-dominant arm at Day 42.
89069416|NCT02863471|Experimental|Gemcitabine|1000 milligram (mg)/ square meter (m²) body surface, intraperitoneal use, unique intraoperative application for 60 minutes
89069417|NCT01193127|Experimental|OMS302 Solution|OMS302 Solution
89069418|NCT01193127|Experimental|OMS302 Mydriatic Solution|OMS302 Mydriatic Solution
89069419|NCT01193127|Experimental|OMS302 Anti-inflammatory Solution|OMS302 Anti-inflammatory Solution
89069420|NCT01193127|Placebo Comparator|Balanced Salt Solution (BSS) Solution|Balanced Salt Solution (BSS) Solution
89069421|NCT01192815|Experimental|Arm I|Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89069422|NCT01192191|Experimental|Fluticasone Furoate/GW642444 100/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
89069423|NCT01192191|Experimental|Fluticasone Furoate/GW642444 200/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
89069424|NCT04317729|Experimental|Diagnostic|Collection of whole blood via fingerstick and venipuncture
89069425|NCT01307267|Experimental|Portion A|PF-05082566 single agent in patients with advanced cancer
89069426|NCT01307267|Experimental|Portion B|PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma
89069427|NCT01307111|Experimental|Misoprostol|Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.
89069428|NCT01307111|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
89069429|NCT01306877|Experimental|EEA Hemorrhoid and Prolapse Stapling Set|
89069430|NCT01306877|Active Comparator|Endosurgery Proximate PPH03 Stapling Set|
89069431|NCT01191801|Experimental|Group A: vosaroxin + cytarabine|vosaroxin (short IV infusion within 10 minutes) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
89069432|NCT01191801|Placebo Comparator|Group B: placebo + cytarabine|placebo (short IV infusion within 10 minutes and volume matched to vosaroxin) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
89069433|NCT01306643|Experimental|Idelalisib|
89069434|NCT04317495|Experimental|Computerized Cognitive Training (CCT)|The patients will receive CCT during their standard rTMS treatments (after having 5 days of treatment until the pre-taper treatment).
89069435|NCT04317339|Experimental|Zhigancao Tang granule group|Participants in experimental group will receive Zhigancao Tang granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters, diuretics as needed.
89069436|NCT04317339|Placebo Comparator|Zhigancao Tang placebo group|Participants in experimental group will receive Zhigancao Tang placebo granule therapy for 12 weeks. In addition, participants will receive standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
89069437|NCT05656833|Active Comparator|Fractional 1927nm Low-Powered Diode Laser combined with Topical Cysteamine|One side of the face of participants will be randomized to receive fractional 1927nm Low-Powered Diode Laser in combination with topical cysteamine. There are 3 total treatments with the laser, in combination with using the topical cysteamine cream every day for the duration of the study (12 weeks)
89069438|NCT05656833|Active Comparator|Topical Cysteamine Alone|The other side of the face that is not randomized to receive laser treatment will be subject to treatment with the topical cysteamine cream alone. Participants will use the topical cysteamine cream every day for the duration of the study (12 weeks).
89069439|NCT05656755|Experimental|strengthening running program|The experimental group will undergo a specific running training based on leg strength training and interval running
89069440|NCT05656755|Active Comparator|Running program|This running group will serve as control and will undergo a traditional running program composed of only running
89069441|NCT05656677|No Intervention|Two nurses executing facilitated tucking (FT)|Usual care
88812748|NCT01830764|Other|Red light dose (PDT) 75 J/cm2|Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2
88812749|NCT01830764|Other|Red Light (PDT) 150 J/cm2|Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2
88812750|NCT03215966|Experimental|Sequence A/B|Subjects receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 1, then after a washout period of at least 7 days they receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 2
89069442|NCT05656677|Active Comparator|One parent watching passively|One parent watching passively the 2 nurses executing FT
89069443|NCT05656677|Active Comparator|One parent actively involved|One parent actively executing FT
89069444|NCT01306331|Active Comparator|Conceptrol|100 mg (4% concentration) of nonoxynol-9 in 2.5 mL volume of gel
89069445|NCT01306331|Experimental|Amphora|Citric acid USP, potassium bitartrate USP, and L-lactic acid USP
89069446|NCT05656287|Experimental|Arm A|(Arm A): For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if >90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if >90% medication adherence.
89069447|NCT05656287|Experimental|Arm B|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders.
89069448|NCT05656287|Experimental|Arm C- Control|Participants (54) in the Control (Arm C) will not receive SMS reminders or mobile money
89069449|NCT00624663|Active Comparator|1|(1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule) X 2 per day, total of 5 intakes
89069450|NCT00624663|Active Comparator|2|(2 x 1.5 mg Exelon® Capsules) X 2 per day, total of 5 intakes
89069451|NCT00624663|Placebo Comparator|3|(2 x Placebo Capsules) X 2 per days, total of 5 intakes
89069452|NCT05656209|No Intervention|Control group|The patient received conventional care after surgery, with no other interventions.
89069453|NCT05656209|Experimental|LA treatment group|The patient received conventional treatment and Lactobacillus acidophilus treatment for three months after surgery.
89069454|NCT04317573|Active Comparator|Personalised card|The personalised card was printed by the attending ophthalmologist for the patient via a web accessible software we have developed. The software allowed the reviewing physician to select the medications the patient was prescribed and auto-generate a personalised card that will be sent to the network printer. The card illustrated the patient's eye drop regime in a simple pictorial format using coloured pictures of the eye drop bottles and universally recognised symbols. It can be folded to a compact size of 11cm x 7.5cm to allow patients to carry around in their wallets. This card will be given to patients at the end of their consult and explanation will be provided by the attending physician who will manually tick in the corresponding boxes depending on the frequency of administration
89069455|NCT04317573|Active Comparator|Personalised card and telereminder|Patients who were recruited into the group receiving tele-monitoring were contacted via text messages daily by a programmed software at the scheduled time of eye drop administration. They were required to acknowledge the reminder by replying a 'Yes' if they had administered the eyedrop and 'No' if they had not. A nil reply was taken as a 'No'.
89069456|NCT04317573|No Intervention|No intervention|No intervention
89069457|NCT01306253|Experimental|Elderly|Elderly subjects aged over 60 years
89069458|NCT01306253|Experimental|Adults|Adults from 18 to 60 years old inclusive
89069459|NCT05655975|Active Comparator|upper gi endoscopy after rygb gastric bypass / weight loss|In all patients undergoing RYGB gastric bypass and success > %50 EWL , an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
89069460|NCT05655975|Active Comparator|upper gi endoscopy after rygb gastric bypass / regain|In all patients undergoing RYGB gastric bypass and regain , an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
89069461|NCT02890823|Experimental|EIAEDs-1000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
89069462|NCT02890823|Experimental|EIAEDs-3000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
89069463|NCT02890823|Experimental|EIAEDs-6000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
89069464|NCT02890823|Active Comparator|non-EIAEDs-1000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
89069465|NCT02890823|Active Comparator|non-EIAEDs-3000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
89690803|NCT01920386|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|1tab PO within 5hours from teeth extraction and then 1tab more after 6hours
89690804|NCT04408027|Experimental|Virtual-Care Cognitive Behavioural Therapy|
89690805|NCT03460990|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
89690806|NCT03460990|Experimental|VX-659/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
89690807|NCT01924598|Experimental|DBS surgery|
89690808|NCT01052545|Experimental|Arm 1- Intervention: Audit-Feedback|Baseline surveillance for the clinical outcomes will begin in year 1 at the intervention site and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will occur during year 2 of the study at the intervention site. Feedback will be delivered to individual health care providers at the intervention site during year 2.Unit-level audit feedback will be delivered at the intervention site during years 2 and 3 of the study. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the intervention site in years 2 and 3 of the project.
89690809|NCT01052545|No Intervention|Arm 2- Control|At the control site, baseline surveillance for the clinical outcomes will begin in year 1 at the and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will not occur at the control site. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the control site in year 3 of the project.
89690810|NCT01924832|Experimental|BG00012 Part 1|BG00012 120 mg delivered to varying locations of the GI tract
89690811|NCT01924832|Experimental|BG00012 Part 2|BG00012 240 mg delivered to varying locations of the GI tract
89690812|NCT04332562|No Intervention|normotensive control group|Normotensive volunteer
89690813|NCT04332562|No Intervention|hypertensive control group|Hypertensive patients with no restriction on their salt intake
89690814|NCT04332562|Experimental|hypertensive interventional group|intervention is going to be salt restriction
89690815|NCT01920542|Experimental|no dexmedetomidine|no administration of dexmedetomidine
89069466|NCT02890823|Active Comparator|non-EIAEDs-6000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
89069467|NCT05655897|Experimental|A single set of test|The GeminiOne Transcatheter Valve Edge-to-Edge Repair System consists of a transcatheter valve clamping system and an adjustable curved introducer catheter.
89069468|NCT05655663|Experimental|ICI|Patients under ICI treatment for their cancer will have vascular investigation and biological assessment
89069469|NCT04317261|Experimental|Hematuria patients|
89069470|NCT05359263|Experimental|Dapagliflozin 10 mg once daily|
89069471|NCT05359263|Placebo Comparator|Placebo once daily|
89069472|NCT01305941|Experimental|Everolimus +Vinorelbine + trastuzumab|daily everolimus plus weekly (Days 1, 8, and 15) vinorelbine and trastuzumab
89069473|NCT05658549|Experimental|N-acetylcysteine injection 1200 mg|N-acetylcysteine injection 1200 mg per day
89069474|NCT05658549|Experimental|N-acetylcysteine pill 1200 mg|N-acetylcysteine pill 1200 mg orally per day
89069475|NCT05658549|Experimental|N-acetylcysteine pills 600 mg per day|N-acetylcysteine pills 600 mg per day orally
89069476|NCT05658549|Placebo Comparator|placebo|Capsule with shape and appearance similar to N-acetylcysteine
89069477|NCT04316949||Derivation cohort|"Derivation cohort: Italian retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from February 20 to March 19 2020.~."
89069478|NCT04316949||Validation cohort|Validation cohort: European and non-European retrospective cohort of all consecutive hospitalized patients with SARS-CoV-2 pneumonia in the participating centers, from March 19 to April 18 2020.
89069479|NCT02887365|Experimental|tegafur-uracil|tegafur-uracil treatment in patients with stage II MSI-L or MSS colon cancer
89069480|NCT02887365|No Intervention|Observation|Observation for one year
89069481|NCT05658315|No Intervention|Baseline|Participants will be randomly assigned to either a 5-, 6-, or 7-week baseline phase.
89069482|NCT05658315|Experimental|ApplTree intervention|Following baseline, participants will complete training in the use of ApplTree and a 5-week intervention phase, where they will utilise ApplTree to set reminders about weekly prospective memory tasks.
89690816|NCT01920542|Active Comparator|dexmedetomidine|administration of 0.5ug/kg dexmedetomidine for 10 min and infusion of 0.5ug/kg/h of dexmedetomidine until weaning of cardiopulmonary bypass
89690817|NCT03319810|Experimental|infusion of IVIG|
89069483|NCT01305239||Postmenopausal ER+ patients treated by Aromasin.|
89069484|NCT04317027|Experimental|All subjects|All subjects in this trial will receive the new fighting clothing while performing the study protocol
89069485|NCT05380557||Germline Pathogenic Variant in non-BRCA/PALB2 Gene|Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing.
89069486|NCT05380557||Strong family history of pancreatic cancer but no identifiable germline pathogenic variant|Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing.
89069487|NCT05380557||Negative germline testing and absence of strong family history|Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing.
89690818|NCT01052701|Active Comparator|Ribavirin plus Abacavir|Ribavirin plus Abacavir Administration intervention
89690819|NCT01052701|Active Comparator|Ribavirin alone|Ribavirin alone administration
89690820|NCT01920620|Experimental|Intervention Arm|Inpatient weight loss counseling Motivational interviewing and troubleshooting via phone
89690821|NCT01920620|No Intervention|Usual Care Arm|Participants in the usual care group were not provided with any specific instructions regarding weight loss, diet or exercise prior to discharge. Follow-up phone calls for usual care subject were used only to obtain weight and assess for changes in medications or health condition.
89690822|NCT01920776|Experimental|Rutine treatment group, Ultrasound group|
89690823|NCT03322930||Retinitis Pigmentosa|patients with a diagnosis of retinitis pigmentosa and reduced rod function on baseline testing
89690824|NCT03322930||Age-related Macular Degeneration|patients with a diagnosis of intermediate AMD and reduced rod function on baseline testing
89690825|NCT05528809|Experimental|Experimental group|Patients with Gougerot-Sjögren's syndrome meeting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) disease definitions
89690826|NCT05528809|Active Comparator|Positive control group|Patients with diffuse systemic scleroderma meeting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) disease definitions
89690827|NCT01921010|Active Comparator|Niaspan|Patients will be randomized to Niaspan 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of Niaspan will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
89690828|NCT01921010|Placebo Comparator|Control|patients will be randomized to placebo 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of placebo will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
89690829|NCT02246491|Other|iPSCs without gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
89069488|NCT05380557||Pathogenic Variant in BRCA1/2 or PALB2|Patients will be offered enrollment into the sister trial, APOLLO (NCT04858334). Patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-5.
89069489|NCT05658081|Experimental|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
89069490|NCT05658081|Other|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
89069491|NCT05657847||Rheumatoid arthritis|Rheumatoid arthritis patients. (American College of Rheumatology (ACR) 1987, ACR/European League Against Rheumatism (EULAR) >18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis (including RF, ACPA)
89069492|NCT05657847||Psoriatic arthritis|Psoriatic arthritis patients. (CASPAR Criteria) >18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis.
89069493|NCT05657847||Crystal arthropathies|Crystal arthropathies patients. >18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis.
89069494|NCT04317183|Experimental|Chamomile topical gel|"Topical oral chamomile gel three times daily for three weeks.~Topical oral chamomile gel is prepared with the aid of Pharmacognosy and pharmaceutics departments, faculty of pharmacy, Alexandria University and mucoadhesive hydrogels (Carbopol® 970)."
89069495|NCT04317183|Active Comparator|conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel BBC oral spray Oracure gel~Dose: Three times a day for three weeks"
89069496|NCT04317183|Experimental|combination therapy|"Topical oral chamomile gel three times daily for three weeks in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel BBC oral spray Oracure gel~Symptomatic treatment dose: Three times a day for three weeks"
89069497|NCT01194219|Active Comparator|Apremilast|Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost). At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
89069498|NCT01194219|Placebo Comparator|Placebo|Subjects initially randomized to placebo, are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject's participation in the study.
89069499|NCT01194219|Active Comparator|Apremilast 30 mg|Apremilast 30 mg by mouth (PO) twice a day (BID). Participants initially randomized to apremilast 30 mg BID, and who were able to demonstrate a Psoriasis Area Severity Index (PASI) -75 response at week 32 were randomized (1 to 1) to either apremilast 30 mg BID or oral placebo (until effect is lost). At relapse/loss of response to therapy prior to Week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at Week 52, participants were re-treated with apremilast 30 mg BID for the duration of their participation in the study. Non-responders or partial responders (PASI response <75) received additional topical therapies or phototherapy beginning at Week 32.
89069500|NCT01304693|Experimental|ESBA1008|ESBA1008 solution, single intravitreal injection
89069501|NCT01304693|Active Comparator|LUCENTIS|Ranibizumab 0.5 mg, single intravitreal injection
89069502|NCT04316793|Experimental|Dry needling (DN)|Intramuscular insertion
89069503|NCT04316793|Sham Comparator|Sham needling (SN)|Intradermal insertion
89069504|NCT05657067|Experimental|Emotionally Focused Family Therapy (EFFT)|For this pilot study we aim for 15-20 included families who will be treated by three to five family therapists.
89069505|NCT05656989||Stage 3 Grade C Periodontitis|Generalized S3GC periodontitis patients had PD ≥ 6 mm and interproximal CAL ≥ 5 mm and with radiographic alveolar bone loss extending at least to the middle third of the root at 30 % of the teeth or more. These patients showed no more than four teeth loss due to periodontitis. The percentage bone loss/age values in this group were > 1.0
89069506|NCT05656989||Gingivitis|Gingivitis patients exhibited PD ≤ 3 mm and no interproximal CAL or radiographic bone loss. These patients had BOP ≥ 30% of probe sites.
89069507|NCT05656989||Periodontal health|Periodontally healthy controls had an intact periodontium or a reduced periodontium in a non-periodontitis patient (without interproximal CAL or radiographic bone loss). PD was ≤ 3 mm and BOP was < 10 % in this group.
89069508|NCT01304147|Experimental|Ketamine|Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
89069509|NCT01304147|Placebo Comparator|Placebo|Subjects randomized to this arm will receive intranasal saline.
89069510|NCT05661227|Sham Comparator|C group|Before induction of anesthesia, general anesthesia was performed after ultrasound-guided femoral nerve block
89069511|NCT05661227|Experimental|DEX group|Before induction of anesthesia, general anesthesia was performed after ultrasound-guided femoral nerve block. Dexmedetomidine 0.8μg/kg was pumped intravenously for 10min 15min before induction of anesthesia, and then continued to be infused at 0.5μg/ (kg·h) until 30min before the end of surgery
89069512|NCT05661227|Experimental|ERIPC group|Before induction of anesthesia, ultrasound-guided femoral nerve block was performed, and then general anesthesia was performed. After induction of anesthesia, orthopedic tourniquet was tied and inflated to 200 mmHg(1 mmHg=0.133 kPa) for 5 min and deflated for 5 min, and three cycles were repeated
89069513|NCT05661227|Experimental|LRIPC group|An orthopedic pressure tourniquet was placed on the lower extremity 24 h before surgery and inflated to 200 mmHg for 5 min and deflated for 5 min. Three cycles were repeated
89069514|NCT04325087|Experimental|Active iTBS|Active stimulation of the dlPFC directly after trauma exposure and on the following two days
89069515|NCT04325087|Placebo Comparator|Placebo iTBS|Same procedure as in the active stimulation group but with a placebo stimulation imitating the sensation of a real iTBS protocol.
89069516|NCT05643989|Active Comparator|Self-expandable metal stent (SEMS) endoscopic placement.|Anesthesia will include only propofol injection. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis.
89069517|NCT05643989|Placebo Comparator|Stoma formation.|Anesthetic care will include general endotracheal anesthesia with positioning of nasogastric tube and bladder catheterization. The diverting stoma formation will be proceed in 10 sm proximally to tumor.
89069518|NCT01303445|Active Comparator|Treatment A|Aggrenox alone
89069519|NCT01303445|Experimental|Treatment B|Aggrenox and omeprazole
89069520|NCT01303445|Active Comparator|Treatment C|Omeprazole alone
89069521|NCT01303445|Experimental|Treatment D|Aggrenox and omeprazole
89069522|NCT01188681|Experimental|Phase 1: 15 mg/kg TRU-016 + Bendamustine|TRU-016 (15 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
89069523|NCT01188681|Experimental|Phase 1: 20 mg/kg TRU-016 + Bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
89069524|NCT01188681|Experimental|Phase 2: TRU-016 and bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 32 patients
89069525|NCT01188681|Active Comparator|Phase 2: Bendamustine|Bendamustine (70 mg/m2), n = 33 patients
89069526|NCT02887131|Experimental|Healthy volunteers|
89069527|NCT02887131|Experimental|Arthritis|
89069528|NCT02887131|Experimental|Instability|
89069529|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
89069530|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule placebo to HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
89069531|NCT04324775||Group 1|Exercise+Manual Lymphatic Drainage
89069532|NCT04324775||Group 2|Exercise+Swedish Massage
89069533|NCT05643833||Male recipient|
89069534|NCT05643833||Female recipient|
89069535|NCT05643833||Male donor|
89069536|NCT05643833||Female donor|
89069537|NCT01187901|Active Comparator|Erlotinib and Sulindac|Erlotinib 75 mg per day in combination with sulindac 150 mg twice daily for 6 months.
89069538|NCT01187901|Placebo Comparator|Placebo A and Placebo B|Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months
89069539|NCT01302119|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
89069540|NCT01302119|Placebo Comparator|Solution Vehicle|Solution Vehicle
89069541|NCT05931900|Experimental|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
89069542|NCT05927922|Experimental|Premedication with 600 mg of Oral Ibuprofen|Premedication with 600 mg of Oral Ibuprofen (Abbott, Egypt) will be given 1 hour before IANB.
89069543|NCT05927922|Placebo Comparator|Placebo will be given 1 hour before inferior alveolar nerve block|
89069544|NCT05927883|Experimental|Intervention group|Adolescents who scored high on IGD-SF-9. The group will be given IACBTGA
89690830|NCT02246491|Other|iPSCs with gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
89690831|NCT01921088|Experimental|Contingent|Contingent RT-fMRI-NF of brain activity in the target region of interest
89690832|NCT01921088|Sham Comparator|Non-contingent|Sham RT-fMRI-NF of brain activity of previously recorded subject
89690833|NCT01921244|No Intervention|Usual Care|"Approximately 120 families will be asked to participate as usual care subjects and will complete surveys before and immediately after their visit, and approximately 3 months after the visit. These families will not receive the decision aid nor will their provider have been trained how to use the decision aid. All participating providers will have up to 10 usual care patients enrolled at baseline prior to allocation. During the trial, the control group [usual care providers] will have up to 10 additional patients enrolled for ongoing usual care data collection. After the trial is complete, the control group providers will cross over to the intervention arm."
89690834|NCT01921244|Experimental|Intervention|Approximately 80 families/patients with regularly scheduled clinic follow-up visits in the Division of Developmental and Behavioral Pediatrics (DDBP) at Cincinnati Childrens with providers trained on shared decision making will receive the decision aid prior to their index visit and complete surveys before and immediately after their visit, and approximately 3 months later.
89690835|NCT01921400||HCV-infected mothers|in situ hybridization
89069545|NCT05927883|Active Comparator|Intervention group with Parental Psycho-education|Adolescents who scored high on IGD-SF-9, parents of adolescents will also be added in intervention and CBT based psycho-education will be provided to parents and adolescents will be provided IACBTGA.
89069546|NCT05927883|No Intervention|Control|This group will not be given no intervention
89069547|NCT05927857|Experimental|Phase 1b/II|"Infusional nal-IRI (ONIVYDE, free form) 50/60/70 mg/m2 over 90 minutes day 1.~Infusional Ramucirumab(Cyramza)8 mg/kg over 60 minutes day 1.~oral Trifluridine/Tipiracil TAS-102 (LONSURF) 30 mg/m2/b.i.d. day 1-5.~Every 14 days count as one cycle."
89069548|NCT05927844|Experimental|Treatment ARM1|Drugs1：XH30002 Capsual 300mg，Qd，28d; Drug2：Afatiinb tablets 30mg，Qd，28d
89069549|NCT05927844|Experimental|Treatment ARM2|Drugs1：XH30002 Capsual 400mg，Qd，28d; Drug2：Afatiinb tablets 30mg，Qd，28d
89069550|NCT05927831|Experimental|Grape seed extract|grape seed extract with 95% proanthocyanins will be applied topically to the hypersensitive dentin area for 10 minutes, followed by rinsing with water.
89069551|NCT05927831|Experimental|Low-level laser therapy|The low-level laser diode treatment of 810 nm will be performed using a commercially available diode laser device. The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode starting at a distance of 5-6 mm away from the hypersensitive tooth area and slowly approaching within a distance of 2-3mm in a scanning motion covering the entire hypersensitive tooth area for a period of 30 seconds to 1 minute.
89069552|NCT05927831|Experimental|Combination of low-level laser therapy and grape seed extract|Grape seed extract will be applied topically to the hypersensitive dentin area for 10 minutes, followed by low-level laser diode treatment.
89069553|NCT05927818|Experimental|Sentinel Lymph Node Biopsy and Systematic Lymph Node Dissection (Single Arm)|This is a single arm interventional study in which the interventional and control arms are the same participant (each participant becomes its own control since the sentinel node biopsy- interventional arm - results are to be compared to systematic lymphadenectomy results-control arm). Intervention is injection of 2-4 mL sterile charcoal to the infundibulopelvic ligament or mesovarium of the suspicious adnexal mass followed by collection of stained sentinel lymph nodes and lymph nodes by systematic lymphadenectomy.
89069554|NCT05927805|Experimental|Intervention group|Eight weekly sessions of e-bibliotherapy. Participants in the intervention group will use the e-bibliotherapy app we develop, and accept e-bibliotherapy via the app.
89069555|NCT05927805|Sham Comparator|Control group|Eight weekly sessions of self-learning of general daily living knowledge that this different from the intervention contents from the same e-bibliotherapy app.
89069556|NCT05927779|Experimental|Dose escalation|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of TFX06 tablet.Safety Expansion: Additional patients will be enrolled to further evaluate the safety, tolerability and RP2D of TFX06 tablet.~Part B ,Dose Expansion, A cohort of patients will be enrolled to evaluate preliminary preliminary efficacy of the TFX06 tablet in RP2D in a group of patients with at least 6 months of standard endocrine therapy prior to disease progression."
89069557|NCT05927766|Active Comparator|patients with chronic kidney disease|
89069558|NCT05927766|Active Comparator|patients without chronic kidneys disease|
89069559|NCT05927740|Other|1 ( Hyperemesis gravidarum )|55 hyperemesis gravidarum patient (11-14th gestational week of pregnancy)
89069560|NCT05927740|Other|2( Control group)|55 healthy pregnant women (11-14th gestational week of pregnancy)
89069561|NCT05927727|Active Comparator|Malign Group|The group includes patients who have malignant axillary lymph nodes which are proven by biopsy
89069562|NCT05927727|Active Comparator|Benign Group|The group includes patients who have benign axillary lymph nodes which are proven either by biopsy or follow-up
89069563|NCT05927675|Experimental|Exercise intervention|
89069564|NCT05927662||Type 2|Patients with Roussouly type 2 sagittal profile
89069565|NCT05927662||Type 1,3,4|Patients with other Roussouly type sagittal profiles (1,3,4)
89069566|NCT05927636||Study population|Patients with cancer referred for systemic treatment of the outpatient clinic at the departments of Medical Oncology at participating centres.
89069567|NCT05927623|Experimental|Misterfit online group|The Misterfit online group will receive a 12-month virtually-delivered fracture prevention intervention that includes a personalized gender-tailored strength training and balance-based exercise program, nutritional counselling and fall and fracture prevention education.
89069568|NCT05927623|Other|MisterFit offline group|The Misterfit offline group will act as an attention control group receiving a fracture prevention intervention with the same components as the experimental group, but the components will not be virtual, personalized or gender-tailored.
89069569|NCT05927597|Experimental|Part A: Cohort 1 (Dose 1)|Japanese and Caucasian participants will receive INS1007 at Dose 1 or matching placebo, orally, once on Day 1, and Day 4 through Day 30 in Part A under fasted conditions.
89069570|NCT05927597|Experimental|Part A: Cohort 2 (Dose 2)|Japanese and Caucasian participants will receive INS1007 at Dose 2 or matching placebo, orally, once on Day 1, and Day 4 through Day 30 in Part A under fasted conditions.
89069571|NCT05927597|Experimental|Part A: Cohort 3 (Dose 3)|Japanese and Caucasian participants will receive INS1007 at Dose 3 or matching placebo, orally, up to Day 30 in Part A under fasted conditions. Enrollment will commence in this cohort once the safety and tolerability data in Cohort 2 is deemed acceptable by the principal investigator (PI) and the Sponsor's medical monitor.
89069572|NCT05927597|Experimental|Part B: Treatment Sequence 1|Japanese and Caucasian participants will receive INS1007 at the dose established in Part A after a high-fat and high-calorie breakfast on Day 1 followed by a dose established in Part A on Day 8 under fasted conditions in Part B of the study.
89069573|NCT05927597|Experimental|Part B: Treatment Sequence 2|Japanese and Caucasian participants will receive INS1007 at the dose established in Part A under fasted conditions on Day 1 followed by dose established in Part A on Day 8 after a high-fat and high-calorie breakfast in Part B of the study.
89069574|NCT05927545|Active Comparator|Home Exercise: Patient Education and Preventive Exercise|Group 1: The home Exercise Program includes an educational training program about parafunctional activities and correction exercises for patients having TMD-related headaches. The program includes tongue resting position, diaphragmatic breathing, head posture correction exercises, stretching and strengthening exercises for shoulder and back muscles, and active cervical and thoracic mobilization.
89069575|NCT05927545|Active Comparator|Manual Therapy Combined with Home Exercise|Group 2: MT group includes in addition to the home exercise program, deep friction massage, myofascial release techniques and stretching techniques to masticatory and neck muscles, temporomandibular joint and cervical mobilization will be applied.
89069576|NCT05927545|Active Comparator|Cognitive Exercise Therapy Approach Combined with Home Exercise|Group 3: Cognitive Exercise Therapy Approach (CETA) includes cognitive exercise therapy and the home exercise program. The Cognitive Exercise Therapy approach is an innovative exercise approach that aims to change the patient's cognition about the disease through exercise and is suitable for the biopsychosocial model. CETA is an exercise approach aimed at changing the patient's cognitive perception of the disease through exercise, placing the responsibility of disease management on the patient. The approach will be explained in the first session, and patients will be taught proper posture for the neck, shoulders, thoracic, and lumbopelvic region, as well as correct breathing control. Each 1-hour session will include a warm-up, exercise period, and cool-down.
89069577|NCT05927506||Adolescents with ADHD|Observational study of behavior cognitive and motor control
89069578|NCT05927506||Adolescents without ADHD|Observational study of behavior cognitive and motor control
89069579|NCT05927493||Upper gastrointestinal bleeding|Patients with upper gastrointestinal bleeding hospitalized after ED visit
89069580|NCT05927428|Active Comparator|BRM424 Ophthalmic Solution|
89069581|NCT05927428|Placebo Comparator|Vehicle|
89069582|NCT05927337|Experimental|Cognitive Behavioral Therapy for managing Obesity|"Participants will be enrolled in a 4-month programme of cognitive behavioural therapy for obesity management. The programme is described in more detail in the annex. The programme will consist of 12 individual sessions, with weekly sessions for the first eight weeks and bi-monthly sessions for the following eight weeks.~Treatment as usual: participants will receive three sessions with a dietician to receive basic information on appropriate diet, energy deficit and nutrition plan and three sessions with a kinesiologist to receive advice on physical activity."
89069583|NCT05927337|No Intervention|Control group|Treatment as usual: participants will receive three sessions with a dietician to receive basic information on appropriate diet, energy deficit and nutrition plan and three sessions with a kinesiologist to receive advice on physical activity.
89069584|NCT05927298||Cohort 1|Upfront resectable PDAC
89069585|NCT05927298||Cohort 2|Advanced (unresectable PDAC or metastatic)
89690836|NCT01921400||Uninfected mothers|in situ hybridization
89690837|NCT03325816|Experimental|Phase II - Arm 1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~The Phase II dose of 177Lu-DOTA0-Tyr3-Octreotate will be the maximum tolerated dose as determined in the Phase I portion."
89690838|NCT03325816|Experimental|Phase I - Dose Level -1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 3.7 GBq (100 mCi) every 8 weeks for 4 doses."
89690839|NCT03325816|Experimental|Phase I - Dose Level 0|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 7.4 GBq (200 mCi) every 8 weeks for 4 doses."
89690840|NCT03325816|No Intervention|Phase II - Arm 2|Patients randomized to this arm will be followed (observation). Cross-over to Phase II Arm 1 at the time of disease progression will be allowed
89690841|NCT01921478||Cohort|
89690842|NCT00986570|Experimental|Xeomin®|Botulinum Toxin A
89690843|NCT00986258|Experimental|Tapentadol Prolonged Release|"Other Names:~Nucynta~Palexia"
89690844|NCT00986180|Experimental|001|NUCYNTA 50 75 or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
89690845|NCT00986180|Active Comparator|002|Oxycodone IR 5 10 or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
89690846|NCT01053013|Experimental|Macrobead Implantation|patients will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
89690847|NCT03015493|Experimental|Neural mobilization and traction|Patients in this group are treated with neural mobilization techniques combined with cervical traction
89690848|NCT03015493|Experimental|Traction group|Patients in this group are treated with cervical traction
89690849|NCT03015493|No Intervention|Control group|Patients in this group comprise the control group and are not treated with any intervention
89690850|NCT01054183|Experimental|Intubation using GlideScope Ranger|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team A to use the GlideScope Ranger for all intubations on that day.
89223786|NCT05774223|Sham Comparator|Sham iTBS on working memory|Participants will receive sham 80% rMT iTBS over the left DLPFC (by putting the coil perpendicular to the left DLPFC) in this arm. The working memory assessments will be performed pre-stimulation and at 0-, 10-, 20-, 30-, and 40-min post-stimulation. The working memory assessment is measured using a 2-minute 3-back task. The fNIRS will monitor the prefrontal hemoglobin change throughout the whole procedure.
89223787|NCT05763459|Experimental|ABBV-CLS-7262|ABBV-CLS-7262 + Digoxin + Rosuvastatin
89223788|NCT05727332|Experimental|Intervention|The intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks.
89223789|NCT05727332|No Intervention|Time-Matched Control|The control group will be asked to maintain pre-intervention habits/behavior over 4 weeks.
89223790|NCT05725863|No Intervention|Control|No psychological intervention was offered. Postpartum mothers in the control condition were informed that they would receive MBCT after a waiting period of 2 months.
89223791|NCT05725863|Experimental|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
89223792|NCT05725616|Experimental|Snuff box puncture|Puncture of the radial artery at of the anatomical snuff box or on the back of the hand during coronary angiography
89223793|NCT05725616|Active Comparator|Wrist puncture|Puncture of the radial artery at the level of the base of the wrist during coronary angiography
89223794|NCT05724875|Experimental|Arm A: FLASH RT|
89223795|NCT05724875|Active Comparator|Arm B: Conventional RT|
89223796|NCT05713981|Experimental|non-invasive Meibomian gland (MG) expression|"Baseline testing of visual acuity, contrast sensitivity, color vision, and Innova, Inc. cone and B/W low contrast vision will be measured.~The intervention will be standard clinical expression of Meibomian superior and inferior glands (MG) using a sterile cotton tip applicator to apply gentle pressure in a rolling motion in the direction of the MGs along the upper and lower eyelid margins to allow oil secretion of the tested eye. One drop of sterile saline will be instilled following the intervention to remove debris. The subject's visual acuity, contrast sensitivity, color vision, and Innova, Inc. cone and B/W low contrast vision will be measured before and after this intervention."
89223797|NCT05689749||Participants with Sjögren's syndrome|Participants with the diagnose of Sjögren's syndrome; Patients with a confirmed diagnosis who are being followed and treated by a rheumatologist.
89223798|NCT05689749||Volunteers who has not dry eye complaints and Sjögren's syndrome diagnosis.|Voluntary participants without any rheumatic disease diagnosis, without Sjögren's syndrome diagnosis, without dry eye complaints will constitute the other group.
89223799|NCT05678595|Active Comparator|A hot laser derived from a Nd: YAG laser|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
89223800|NCT05678595|Sham Comparator|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
89223801|NCT05664568|Active Comparator|Standard of care TB|Standard of care treatment for TB (rifampicin, isoniazid, ethambutol and pyrazinamide according to WHO)
89223802|NCT05664568|Experimental|Cephalexin + amoxicillin-clavulanate|Intervention arm: cephalexin 1g thrice daily + amoxicillin-clavulanate 500/125 mg thrice daily.
89223803|NCT05659303||Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
89223804|NCT05656768|Experimental|Constant Routine Protocol|Participants complete a 30-hour constant routine protocol to directly examine markers of endogenous circadian rhythms. In a constant routine protocol, participants remain in a dimly lit room (<10 lux), in a semi-recumbent posture, remain awake, and consume iso-caloric snacks. Saliva samples are collected and core body temperature and blood pressure are measured.
89223805|NCT05610124|Experimental|Ad libitum full-fat French fries with beef meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum full-fat French fries with beef meatballs (25 g protein)
89223806|NCT05610124|Experimental|Ad libitum instant mashed potatoes with beef meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum instant mashed potatoes with beef meatballs (25 g protein)
89223807|NCT05610124|Experimental|Ad libitum macaroni pasta with beef meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum macaroni pasta with beef meatballs (25 g protein)
89223808|NCT05610124|Experimental|Ad libitum full-fat French fries with vegetarian substitute meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum full-fat French fries with vegetarian substitute meatballs (25 g protein)
89690851|NCT01054183|Active Comparator|intubation using direct laryngoscopy|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team B. Team B will do intubations using direct laryngoscopy only that day.
89690852|NCT01054339|Experimental|Low dose|rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg
89690853|NCT01054339|Experimental|Middle dose|rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg
89690854|NCT01054339|Experimental|High dose|rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg
89690855|NCT04247971||Obese, early-onset asthmatics|Obese adults (BMI>or= 30) between the ages of 21-60 with an initial asthma diagnosis at <12 years of age
89690856|NCT04247971||Obese, late-onset asthmatics|Obese adults (BMI > or = 30) between the ages of 21-60 with an initial asthma diagnosis at >12 years of age
89690857|NCT04247971||Obese non-asthmatics|Obese adults (BMI > or = 30) between the ages of 21-60 with no asthma diagnosis
89223809|NCT05610124|Experimental|Ad libitum instant mashed potatoes with vegetarian substitute meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum instant mashed potatoes with vegetarian substitute meatballs (25 g protein)
89223810|NCT05610124|Experimental|Ad libitum macaroni pasta with vegetarian substitute meatballs|Ad libitum carbohydrate side with fixed amount of protein: Ad libitum macaroni pasta with vegetarian substitute meatballs (25 g protein)
89223811|NCT05583695|Experimental|mindfulness-based music therapy|
89223812|NCT05583695|Experimental|mindfulness-based therapy|
89223813|NCT05583695|Active Comparator|routine care|
89223814|NCT05568004|Experimental|Combined exercise group|Aerobic plus resistance exercise intervention
89223815|NCT05568004|Experimental|Aerobic exercise group|Only aerobic exercise intervention
89223816|NCT05568004|No Intervention|Control group|
89223817|NCT05536908|Experimental|resWET|Residential Written Exposure Therapy (resWET): Treatment as Usual (TAU) plus 5-individual Written Exposure Therapy (WET) sessions (40-60 min each; Marx & Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
89223818|NCT05536908|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive substance use disorder (SUD) residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with Post-traumatic Stress Disorder (PTSD) are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
89223819|NCT05528939|Experimental|EndeavorRx|Children will be asked to begin digital attentional control training at home within 6 weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).
89223820|NCT05528939|Active Comparator|Control|An active control program designed to replicate aspects of the intervention (e.g., regular use of digital device to access fun educational activities) while engaging cognitive skills not particularly involving attention.
89223821|NCT05524584|Experimental|Fulvestrant + Anastrozole + Abemaciclib|"Fulvestrant, intramuscular, Initial: 500 mg on days 1 and 15; Maintenance: 500 mg once monthly.~Anastrozole, oral, 1mg tablet daily~Abemaciclib 150 mg twice daily"
89223822|NCT05510739|Experimental|Motor-cognitive exercise using eHealth|10-week eHealth based motor-cognitive home training using digital tablets. Cognitive behavioural strategies to promote increase in physical activity levels (walking). Participants will be encouraged to perform 150 minutes of home exercise per week, occurring on three non-consecutive days.
89223823|NCT05510739|Active Comparator|Individualised home training program|Participants will receive an individualized home exercise program on paper and one instructional session. They will receive written instructions on performing the program 2-3 times weekly and instructions on exercise progression. They will receive no support during the 10-week period.
89223824|NCT05508295||COVID positive case with mAb treatment|
89223825|NCT05508295||COVID positive case having not received mAb treatment|
89223826|NCT05508295||COVID negative cases|
89223827|NCT05495503|Experimental|Prototype (814A-v1)|Application of the prototype (814A-v1) at D0 and D7.
89223828|NCT05495503|Experimental|Prototype (814B-v1)|Application of the prototype (814B-v1) at D0 and D7.
89690858|NCT01056601|Experimental|Pancreatic Cancer Patients|Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.
89690859|NCT01056913|Other|NITI CAR27 (ColonRing)|
89690860|NCT05429203|Active Comparator|Duodenoscope with single-use distal cover|Patients will undergo ERCP using a duodenoscope with a single-use distal cover
89690861|NCT05429203|Active Comparator|Conventional Duodenoscope|Patients will undergo ERCP using a conventional duodenoscope
89690862|NCT03014947|Experimental|MSB11022|
89690863|NCT03014947|Active Comparator|US-licensed Humira|
89690864|NCT03014947|Active Comparator|EU-approved Humira|
89690865|NCT01057225|Experimental|Arm I|Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
89690866|NCT01057381|Active Comparator|Dexmedetomidine 0.75 mcg/kg|Intraoperative administration for analgesia.
89690867|NCT01057381|Active Comparator|Dexmedetomidine 1mcg/kg|Intra-operative administration of dexmedetomidine 1 mcg/kg for analgesia
89690868|NCT01057381|Active Comparator|Morphine 50 mcg/kg|Intra-operative administration of morphine 50 mcg/kg for analgesia
89690869|NCT01057381|Active Comparator|Morphine 100mcg/kg|Intra-operative administration of morphine 100mcg/kg for analgesia
89690870|NCT00986102|Other|001|doripenem 500mg vial by injection every 8 hours for 5 to 14 days
89690871|NCT01058239|Experimental|Rituximab plus Bortezomib|This is a single arm trial adding the new drug bortezomib to the standard drug rituximab
89690872|NCT01058941|Experimental|Lipoic acid and Omega-3 fatty acids|Three 1-gram fish oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two lipoic acid (LA) capsules per day in the morning. Total daily dose of study drug: 675 mg DHA, 975 mg EPA, 600 mg LA.
89690873|NCT01058941|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two placebo LA capsules per day in the morning.
89690874|NCT04150549|Placebo Comparator|Autologous Transplants|
89690875|NCT04150549|Active Comparator|Allogeneic Transplants|
89690876|NCT00985946|Experimental|panobinostat|This is a single arm trial. All patients will take panobinostat
89690877|NCT01059877|Active Comparator|1072nm Infrared Photobiomodulation|Received treatment for dementia with transcranial 1072nm infrared light stimulation.
89690878|NCT01059877|Placebo Comparator|Placebo|Placebo device simulated transcranial photobiomodulation
89690879|NCT05351983|Experimental|Organoid generation|All patients will included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation.
89069586|NCT05927259|Active Comparator|study group|Patients who will receive (conventional treatment of acute organophosphorus poisoning plus NAC)
89069587|NCT05927259|Other|control group|Patients who will receive conventional treatment only
89069588|NCT05927246||Patients with Thoracic Malignancies|All patients undergoing RT for Thoracic Malignancies
89069589|NCT05927246||Patients with Breast Cancer|All patients undergoing RT for Breast Cancer
89069590|NCT05927220||cohesive (I-III) worst patterns of invasion at tumor host interface|
89069591|NCT05927220||non-cohesive (IV-V) worst patterns of invasion at tumor host interface|
89069592|NCT05927194|Experimental|Using the Connect|Using The Connect (UTC) is a game-based learning program designed for middle school-aged youth (ages 9-15 or grades 6-8) consisting of four games played in a facilitated environment, and one take-away activity. The goals of the program include:To be a vehicle that encourages community sharing of healthy teen behavior. To facilitate safe connections between youth and adults in their community. To empower youth to lead healthy sexual lives. The four games each focus on specific health content or skills including growth and development, accessing information, positive communication, and decision-making. Each of the four games is intended to be played for a total of 90 minutes, split up into sessions of 30 minutes per game. When combining all gameplay sessions, along with the instructions for the take-away activity and program wrap-up activity, organizations will dedicate approximately 8 hours to the program.
89069593|NCT05927194|No Intervention|Business as Usual|Participants will not receive the Using the Connect curriculum.
89069594|NCT05927181|Experimental|Trimodal Approach with Osseous and Mucosal compartment modification: TAOM|Flapless immediate implant placement and provisional restoration with alveolar filling and connective tissue graft.
89069595|NCT05927181|Active Comparator|Trimodal Approach: TA|Flapless immediate implant placement and provisional restoration.
89069596|NCT05927168|Experimental|TENS group|TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed.
89069597|NCT05927168|No Intervention|Control group|TENS will not be applied to the control group
89069598|NCT05927155|Experimental|LABA (olodaterol)|After 4-5 days washout period, during the first visit, participants received a long-acting beta2-agonist (LABA)
89069599|NCT05927155|Experimental|LAMA (tiotropium)|Two days after the first visit, during the second visit , participants received a long-acting muscarinic antagonist (LAMA)
89069600|NCT05927129|Active Comparator|medication therapy group|Patients randomized to the medication therapy group will receive standardized treatment with antidepressant medications according to clinical guidelines.
89069601|NCT05927129|Active Comparator|Interpersonal Psychotherapy group|The participants will receive standardized IPT treatment for 12 weeks. IPT therapists have received training from IPT workshops in both China and the United States and obtained the corresponding certifications. IPT therapists focus on the interpersonal domains associated with the onset and maintenance of depression. They guide clients in identifying the connections between their emotional changes and interpersonal difficulties, exploring problems, actively seeking potential interpersonal support and assistance, improving interpersonal skills, helping clients alleviate symptoms, enhance their quality of life, and adapt better to society.
89069602|NCT05927129|Experimental|combination of medication therapy and Interpersonal Psychotherapy group|Patients randomized to this group will receive standardized treatment with antidepressant medications according to clinical guidelines. The participants will also receive standardized IPT treatment for 12 weeks. IPT therapists have received training from IPT workshops in both China and the United States and obtained the corresponding certifications. IPT therapists focus on the interpersonal domains associated with the onset and maintenance of depression. They guide clients in identifying the connections between their emotional changes and interpersonal difficulties, exploring problems, actively seeking potential interpersonal support and assistance, improving interpersonal skills, helping clients alleviate symptoms, enhance their quality of life, and adapt better to society.
89069603|NCT05927103||Coffee drinkers|Healthy adults between 30 and 50 years-old that consume 3 to 5 cups of caffeinate coffee daily
89069604|NCT05927103||Non-coffee drinkers|Healthy adults between 30 and 50 years-old that never consume coffee
89069605|NCT05927077||healthy study participants who undergo planned surgeries for weight reduction from Central Europe|The investigators will take benefit of planned surgeries for weight reduction to collect study material that allows to determine the chemical exposome of the participants
89069606|NCT05927077||healthy study participants who undergo planned surgeries for weight reduction from North America|The investigators will take benefit of planned surgeries for weight reduction to collect study material that allows to determine the chemical exposome of the participants
89069607|NCT05927077||healthy study participants who undergo planned surgeries for weight reduction from South Korea|The investigators will take benefit of planned surgeries for weight reduction to collect study material that allows to determine the chemical exposome of the participants
89069608|NCT05927051|Experimental|Stabilization exercises|Core stability exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
89069609|NCT05927051|Experimental|McKenzie exercises|McKenzie exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
89069610|NCT05927051|Experimental|Home exercises|Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
89069611|NCT05927038|Experimental|Caffeinated coffee|4 sachets (1.8 grams each) of instant, caffeinated coffee
89069612|NCT05927038|Experimental|Decaffeinated coffee|4 sachets (1.8 grams each) of instant, decaffeinated coffee
89069613|NCT05927025|Experimental|Hand K-files|NiTi K type hand file (Perfect Medical Instrument Co., Ltd. Shenzhen, China), Contrary to stainless steel files, turning is produced with the buckling method. torsional resistance and bending resistance of files compared to stainless steel files found more successful in comparison. 16 mm of the files are finished It has the edge. Our Work is 25mm long; 15K (white), 20K (yellow), 25K (red), 30 K (blue) files were used. NiTi K type #15, #20, #25, and #30 hand files were used with a quarter-turn pulling motion, respectively.
89223829|NCT05495503|Experimental|Prototype (814C-v1)|Application of the prototype (814C-v1) at D0 and D7.
89223830|NCT05495503|Experimental|Prototype (814D-v1)|Application of the prototype (814D-v1) at D0 and D7.
89223831|NCT05494437|Experimental|PP-01 High Dose|Oral PP-01 High Dose tapered/titrated over 34 days
89069614|NCT05927025|Experimental|ProTaper Next|The ProTaper Next (PTN) system is produced by adding M-Wire alloy to the ProTaper Universal (PU) system. With the M-Wire alloy, it is aimed to increase the flexibility and cyclic fatigue resistance of the files. The combination of three important design features in PTN files, including changing taper on a single file, M-wire technology and offset design, is one of the important features that distinguish it from other files. PTN X1 and X2 files have both an ascending and a descending conical design on a single file; PTN X3, X4 and X5 files have a constant taper from D1-D3, then taper design that tapers off over the rest of their active segments.
89069615|NCT05927025|Experimental|WaveOne Gold|They are produced by applying Gold-wire process to the WaveOne (WO) system. The WOG file system exhibits repetitive back-and-forth mutual 'reciprocation' motion during preparation, in contrast to the continuous rotational motion. While rotating 150° counterclockwise during the reciprocating motion, clockwise It turns 30° in the direction of, and after 3 cycles, it completes 1 full cycle. Thus, it contributed positively to the file reaching the apical without applying excessive pressure, increasing the cutting efficiency, and accelerating the coronal movement of the debris. Small (yellow-20/0.07), WO Primary (red-25/0.07), and WOG Medium (green-35/0.06) files were used with the appropriate speed and torque values recommended by the manufacturer (300 rpm and 2.0 Ncm) by applying crown down technique. WOG files were operated in a reciprocating motion (150° counterclockwise, 30° clockwise).
89069616|NCT05927025|Experimental|AF Baby Rotary File|AF Baby rotary file is specially designed for milk teeth. Entry file 11 mm other the files are 16 mm long and consist of 4 different rotary instruments; (17/.08), (20/.04), (25/.04) and (30/.04).The cross-sections of the files are triangular and heat treatment is applied to the NiTi wire. produced as a result. Thus, an increase in resistance to cyclic fatigue and an increase in dentin It is aimed to reduce screwing. Root canal thanks to its flexibility It adapts very well to the curvatures in its anatomy. AF Baby rotary files #20, #25, and #30 were used with the crown down technique with the appropriate speed and torque values (350 rpm and 2.0 Ncm) recommended by the manufacturer.
89223832|NCT05494437|Experimental|PP-01 Low Dose|Oral PP-01 Low Dose tapered/titrated over 34 days
89690880|NCT00985790|Experimental|GSK2321138A Group|"Subjects aged between 18 and 47 months received the GSK2321138A. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the GSK2321138A-Primed Group) received 1 dose of GSK2321138A vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the GSK2321138A-Unprimed Group) received 2 doses of GSK2321138A vaccine at Days 0 and 28. The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm."
89690881|NCT00985790|Active Comparator|Fluarix Group|"Subjects aged between 18 and 47 months received the Fluarix™ vaccine. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the Fluarix-Primed Group) received 1 dose of Fluarix™ vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the Fluarix-Unprimed Group) received 2 doses of Fluarix™ vaccine at Days 0 and 28. The Fluarix™ vaccine was administered intramuscularly in the deltoid of the right arm."
89690882|NCT03016273|Experimental|Bladder flap|The bladder flap is made by superficially incising and dissecting the peritoneal lining to separate the urinary bladder from the lower uterine segment.
89690883|NCT03016273|No Intervention|Non bladder flap|
89690884|NCT01060345|Experimental|Women with Ductal Carcinoma in Situ|Women who have been diagnosed with ductal carcinoma in situ (DCIS) and will be taking Polyphenon E
89690885|NCT02170519|Experimental|Phase 2: Inhaled Iloprost continuous|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy."
89690886|NCT02170519|Experimental|Phase 1: Inhaled Iloprost 3 doses|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose."
89690887|NCT04072705||1. Poor and intermediate metabolizer group|Poor and intermediate metabolizer group: acute ischemic stroke patients with poor and intermediate metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
89690888|NCT04072705||2. Extensive metabolizer group|Extensive metabolizer group: acute ischemic stroke patients with Extensive metabolizer genotype of cytochrome P450 2C19 for clopidogrel.
89690889|NCT05239117|Experimental|Plenhyage Thin|Sixteen patients will be administered Plenhyage® Thin for the treatment of minor -sized dermal tissue defects (scars, atrophic scars, depressed plaques, and lipodystrophy defects).
89690890|NCT05239117|Experimental|Plenhyage Medium|Sixteen patients will be administered Plenhyage® Medium for the treatment of medium-sized dermal tissue defects (scars, atrophic scars, depressed plaques, and lipodystrophy defects).
89690891|NCT05239117|Experimental|Plenhyage Strong|Sixteen patients will be administered Plenhyage® Strong for the treatment of major-sized dermal tissue defects (scars, atrophic scars, depressed plaques, and lipodystrophy defects).
89690892|NCT00985712|Experimental|HumaPen Luxura|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Luxura daily for 24 weeks
89690893|NCT00985712|Experimental|HumaPen Memoir|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Memoir daily for 24 weeks
89690894|NCT04275284||PCV10 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks and 9 months of age.
89690895|NCT04275284||PCV13 1+1, 6 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks and 9 months of age.
89690896|NCT04275284||PCV10 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 14 weeks and 9 months of age.
89690897|NCT04275284||PCV13 1+1, 14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 14 weeks and 9 months of age.
89690898|NCT04275284||PCV10 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV10 (Synflorix 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
89690899|NCT04275284||PCV13 2+1, 6&14 weeks & 9 months|Follow-up of children who were previously randomized to PCV13 (Prevnar 13, 0.5ml injection) administered at 6 weeks, 14 weeks and 9 months of age.
89690900|NCT02984150|Experimental|fatty acid|the nutrient that can be widely found in daily food.
89690901|NCT02984150|Sham Comparator|saline|saline
89690902|NCT04347746|Active Comparator|Clinical group|Individuals with bilateral idiopathic CTS with clinical criteria and mild to moderate ENMG severity and symptom evolution time above six months.
89690903|NCT04347746|Active Comparator|Surgical group|Individuals with bilateral idiopathic CTS with clinical criteria and severe ENMG in at least one hand and symptom evolution time above six months. These will be submitted to surgery on the severe hand and if equal severity on both hands, the dominant hand will be operated, with the patient's consent.
89690904|NCT01921556|Active Comparator|QualiCCare education|"QualiCCareeducation is a training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
89690905|NCT01921556|No Intervention|usual care|The practices randomized to the control group apply care as usual
89690906|NCT01924910|Placebo Comparator|Placebo Pill|Received identical pills that do not contain vitamin D. Blood levels of 25(OH)D determined at 10 days, 3 months, and 1 year following placebo dose.
89690907|NCT01924910|Active Comparator|Vitamin D|250,000 IU cholecalciferol as single, oral dose. Blood levels 25(OH)D measured at 10 days, 3 months, and 1 year following dose.
89690908|NCT04395638|Experimental|Weekly Vitamin D group|
89690909|NCT04395638|Experimental|Daily Vitamin D group|
89069617|NCT05927025|Experimental|EndoArt NiTi Pedo Golf File|EndoArt NiTi Pedo Gold file is specially designed for primary teeth. 18mm length consists of 4 different rotary tools: (15/06) white, (20/04) yellow, (25/04) red, (30/04) blue. The cross-sections of the files are triangular, and Gold wire technology is used in the production phase. were produced using Thus, a titanium oxide layer on the surface of the instrument Happened. Thus, it is more flexible and more flexible than conventional NiTi alloys. resistant and 2 times better cyclic fatigue resistance than conventional files exists. EndoArt NiTi Pedo Golf File; EndoArt NiTi Pedo Gold #15, #20, and #30 files were used with the crown down technique with the appropriate speed and torque values recommended by the manufacturer (350 rpm and 2.0 Ncm).
89069618|NCT05926986|Experimental|Study group|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
89069619|NCT05926986|Experimental|Control group|No additional treatment will be practiced to the control group.
89069620|NCT05926973||Before intervention|Standard care as per ALS guidelines prior to October 2021
89069621|NCT05926973||After intervention|Enhanced cardiac arrest management as per TVAA guideline from October 2021 onwards
89069622|NCT05926934|Experimental|Single strand β-Ti fixed retainer|Single strand β-Ti fixed retainer 0.011in diameter, bonded on each tooth separately from #33-43
89069623|NCT05926934|Experimental|SS fixed retainer|SS fixed retainer 0.028in diameter, bonded on each tooth separately from #33-43
89223833|NCT05494437|Placebo Comparator|Placebo|Oral placebo, given daily for 34 days
89069624|NCT05926934|Experimental|Twisted fixed retainer|Twisted fixed retainer 0.027in diameter, bonded on each tooth separately from #33-43
89069625|NCT05926908||Geriatric ward|Interventions are: Patients' self-reported level of mealtime mobilisation, observations of the patients' mobilisation level and environment at mealtimes, focus group interviews with health care professionals at the wards, survey on mobilisation awareness among the nursing staff, a Mobilisation Initiative, and formal education for all nursing staff
89223834|NCT05494437|Active Comparator|Nabilone|oral nabilone, tapered/titrated over 28 days
89223835|NCT05494437|Active Comparator|Gabapentin|oral gabapentin, tapered/titrated over 34 days
89223836|NCT05444504|Other|Group 1|24 hours of use each of leaking freely, leaking freely, cup, and then cup+
89223837|NCT05444504|Other|Group 2|24 hours of use each of leaking freely, cup, cup+, and then cup
89690910|NCT01921712|Experimental|PUR0200 low dose|PUR0200 low dose, single dose inhalation
89690911|NCT01921712|Experimental|PUR0200 mid dose|PUR0200 mid dose, single dose inhalation
89690912|NCT01921712|Experimental|PUR0200 high dose|PUR0200 high dose, single dose inhalation
89690913|NCT01921712|Placebo Comparator|Placebo|PUR0200 matched placebo, single dose, inhalation
89690914|NCT01921712|Active Comparator|Active Comparator|Active Comparator, single dose, inhalation
89690915|NCT04395404|Experimental|Single arm|
89690916|NCT04395716|Experimental|Treatment Group|This group will be treated with nebullized ResCure™ while hospitalized every 4 to 6 hours, depending on disease severity and ventilator status.
89690917|NCT04347980|Experimental|Dexamethasone and Hydroxychloroquine (HCQ/DXM)|"Patients included in the HCQ / DXM group will benefit from standardized ventilatory management and administration of HCQ in the same manner as the HCQ group. They will receive in addition to DXM at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of DXM before."
89690918|NCT04347980|Active Comparator|Hydroxychloroquine (HCQ)|"Patients included in the HCQ  group will benefit from standardized ventilatory management. Patients included in the HCQ group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before."
89690919|NCT01925300|Experimental|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd|Single administration : 6 days, per oral
89690920|NCT01925300|Experimental|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd|Single administration : 6 days, per oral
89690921|NCT01925300|Experimental|Concor 5mg 2T and Crestor 20 mg 1Tab, qd|Combination administration : 6 days, per oral
89690922|NCT04395794||Medical Employees|Asymptomatic medical employees in high-volume cardiovascular center.
89690923|NCT03326986|Experimental|Panel A|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
89690924|NCT03326986|Experimental|Panel B|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
89690925|NCT03326986|Experimental|Panel C|Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
89690926|NCT04275596|Active Comparator|2QR complex|Patients who undergo anal surgery will apply 2QR complex topical agent on the wound until healing
89690927|NCT04275596|Active Comparator|Placebo|Patients who undergo anal surgery will apply placebo cream on the wound until healing
89690928|NCT01921946|Other|Part A|Fimasartan (7 days) → Fimasartan + Rosuvastatin (7 days)
89690929|NCT01921946|Other|Part B|Rosuvastatin (7 days) → Fimasartan + Rosuvastatin (7 days)
89690930|NCT01925378|Experimental|Nelfinavir|This is a single arm intervention trial of nelfinavir in women with grade 2/3 or grade 3 cervical intraepithelial neoplasia
89690931|NCT03328624|Experimental|DVT Cuff users|Current or previous DVT cuff users
89690932|NCT01925456|Other|Toviaz|Patients willingness to take Toviaz 4mg and 8mg
89690933|NCT04395950|Active Comparator|PF-0522130|PF-05221304 10 mg daily (two 5mg tablets daily in the morning).
89690934|NCT04395950|Placebo Comparator|Placebo|Placebo (two tablets daily in the morning).
89690935|NCT01925690|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
89690936|NCT01925690|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
89690937|NCT03229252|Placebo Comparator|Placebo|Placebo Inhalation solution twice daily for 28 days.
89690938|NCT03229252|Experimental|SPX-101 Low Dose|Inhalation solution twice daily for 28 days.
89690939|NCT03229252|Experimental|SPX-101 High Dose|Inhalation solution twice daily for 28 days.
89690940|NCT01922180||COPD Exacerbation|COPD patients aged 18 years or more, were included at the time of an exacerbation episode leading to admission in our hospital, which corresponds to a severe episode. There were no exclusion criteria. Patients underwent chest CT scans and PFT. After a minimum of two weeks free of any acute symptom after discharge, CT scans and PFT were redone.
89069626|NCT05926908||Medical ward|Interventions are: Patients' self-reported level of mealtime mobilisation, observations of the patients' mobilisation level and environment at mealtimes, focus group interviews with health care professionals at the wards, survey on mobilisation awareness among the nursing staff, a Mobilisation Initiative, and formal education for all nursing staff
89069627|NCT05926895|Experimental|Patients with subacromial impingement syndrome (central sensitization positive)|Subacromial steroid injection While the patient is in a sitting position the subacromial space and the rotator cuff will be evaluated with the sonosite-m turbo ultrasonography device linear probe. The area where the rotator cuff and subacromial bursa are most prominent will be determined under the deltoid muscle. The injection site is first covered with povidone iodine and then with 80% alcohol solution will be wiped to provide antisepsis. The subacromial bursa between the deltoid muscle and the rotator cuff will be advanced from lateral to medial with an inplane approach with a 21 g 38 mm needle under the guidance of ultrasonography. Bleeding after making sure that the needle tip is in the bursa by checking, 1 cc betamethasone dipropionate + betamethasone sodium phosphate and 4 cc 2% prilocaine mixture will be injected, showing that it is evenly distributed in the bursa.
89223838|NCT05436457||18-24 Year Olds in Emergency Department|Individuals age 18-24 recruited from one of the four study sites in Flint (1 hospital), Seattle (1 hospital), and Philadelphia (2 hospitals)
89223839|NCT05423600|Experimental|BES+TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
89690941|NCT03330262|Experimental|BALCAP prosthesis, then Control|Participants performed exercises daily at home wearing the BALCAP prosthesis for 6 weeks. After 6 weeks, participants performed the control condition (the same exercises without the BALCAP). Tests were performed before and after each 6-week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
89690942|NCT03330262|Experimental|Control, then BALCAP prosthesis|Participants performed exercises daily at home for 6 weeks without wearing the BALCAP prosthesis (control), followed by another 6 weeks of the same exercises with the BALCAP prosthesis (intervention). Tests were performed before and after each 6 week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
89690943|NCT03235180|Experimental|Crohn's Disease Subjects|"Subjects will receive ultrasound exams of the bowel with 2 different machines (Ultrasound Elastography and Ultrasound Vascularity) at three time points: baseline, 4 weeks, and 6 months. The ultrasound exams will be performed at first with no contrast agent, and then ultrasound measurements will be repeated with 1-2 ml of Sulfur Hexafluoride, a contract agent.~Subjects also will receive Magnetic Resonance Enterography (MRE) exams at baseline and 6 months as part of their clinical care."
89690944|NCT03470740|Other|intervention group|An individualized rheumatoid arthritis self-management program for managing RA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their RA situations.
89690945|NCT03470740|No Intervention|control group|The control group received general information on rheumatoid arthritis care and follow-up.
89690946|NCT03471832|Experimental|stenfilcon A lens|MyDay contact lens
89690947|NCT03471832|Active Comparator|narafilcon A lens|1-Day Acuvue TruEye
89690948|NCT00985166|Experimental|1|ProQuad + Placebo
89690949|NCT00985166|Active Comparator|2|M-M-R II + Placebo
89690950|NCT00985166|Active Comparator|3|M-M-R II + Varivax
89690951|NCT04735120|Experimental|Laser to reduce pain intraoperatively and post operatively|Diode lasers are used to assess its efficacy in reducing intraoperative and postoperative pain following root canal treatment in mandibular molar teeth with acute irreversible pulpitis
89690952|NCT03235414|Experimental|Normals|Will receive an MRI and a blood draw
89690953|NCT04735900|Experimental|First-line FOLFOX/FOLFIRI and panitumumab.|Chemotherapeutic agents will be given as an intravenous infusion at a dose and interval consistent with standard institutional practice.
89690954|NCT03474172|Experimental|Genuine Tuina|Participants will receive genuine tuina manipulated on their skin in addition to the conventional therapy given by the doctors. The whole process of the Tuina, which may last for 15 minutes, should be completed under the Cloak Shape device. After that the parents and the observers may be required to fill out corresponding questionnaires. The outcomes assessors will ask the child the sense perception of the manipulation via a questionnaire if he is equal or older than 3 years old.
89690955|NCT03474172|Sham Comparator|Sham Tuina|Except for the conventional therapy given by doctors, participants in this group will receive sham Tuina. A cloak shape device will be adopted, while inside the cover the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead of childrens' hand or childrens' body. The acupoints and the manipulation time are the same as real Tuina group. Same questionnaires as those adopted in real Tuina group are also required to be completed.
89690956|NCT03474874|Other|Collagen Dressing and Comparator|NeoMatriX Collagen Dressing and Comparators - positive control and normal saline will be applied to the absorbent pad portion of the exclusive dressing.
89690957|NCT03476278||regional, questionnaire|patients who underwent surgery under regional anesthesia.
89690958|NCT02264379||normal fractionated irradiation|
89690959|NCT02264379||hypo fractionated irradiation|
89223840|NCT05423600|Experimental|BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
89690960|NCT03335254|Experimental|Dose-Escalating Arm 1|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~Assigned Intervention: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89069628|NCT05926895|Experimental|Patients with subacromial impingement syndrome (central sensitization negative)|Subacromial steroid injection While the patient is in a sitting position the subacromial space and the rotator cuff will be evaluated with the sonosite-m turbo ultrasonography device linear probe. The area where the rotator cuff and subacromial bursa are most prominent will be determined under the deltoid muscle. The injection site is first covered with povidone iodine and then with 80% alcohol solution will be wiped to provide antisepsis. The subacromial bursa between the deltoid muscle and the rotator cuff will be advanced from lateral to medial with an inplane approach with a 21 g 38 mm needle under the guidance of ultrasonography. Bleeding after making sure that the needle tip is in the bursa by checking, 1 cc betamethasone dipropionate + betamethasone sodium phosphate and 4 cc 2% prilocaine mixture will be injected, showing that it is evenly distributed in the bursa.
89069629|NCT05926882|Experimental|Apremilast tablet|Patients will be given Oral Apremilast 30 mg twice daily after 05 days initial titration dose. The effect of treatment will be evaluated using photographs of the patients before and after the study and clinical evaluation of patients.
89069630|NCT05926869|Experimental|Group A Clindamycin gel|
89069631|NCT05926869|Experimental|Group B Dapsone gel|
89069632|NCT05926843|Experimental|Individuals with functionally complete/incomplete spinal cord injury|Individuals with functionally complete/incomplete spinal cord injury (ASIA grade A, B or C) who will undergo SCS for chronic pain
89223841|NCT05387187|Experimental|Pu Yang Wan Wu Tang plus Pentoxifylline|
89223842|NCT05387187|Active Comparator|Pentoxifylline|
89223843|NCT05365893|Experimental|PHL (Paricalcitol, Hydroxychloroquine, Losartan)|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
89223844|NCT05365893|Active Comparator|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
89069633|NCT05926791||Educated group with product|"Subjects receiving the SPF50+ sunscreen product and a targeted educational action~Route of administration: Topical~Application duration: from 5 up to 21 days~Application modalities: The investigational product will be applied during the outdoor sun exposure on all exposed parts of the body (face and body). The investigational product will be applied in sufficient amount to cover the exposed areas (2mg/cm2 recommended), 15 to 30 minutes before each sun exposure. The product should be reapplied as many times as required during sun exposure (systematic reapplication of the product after sweating and/or swimming and/or wiping)."
89069634|NCT05926791||Control group|Subjects receiving neither product nor targeted education
89069635|NCT05926778||Fibrosis Cohort|Adult(10 patients) and pediatric(10 patients) liver transplant recipients with fibrosis determined by histological examination of liver biopsy
89069636|NCT05926778||Control Cohort|Adult(20 patients) and pediatric(20 patients) liver transplant recipients without fibrosis determined by histological examination of liver biopsy
89069637|NCT05926752|Active Comparator|Photobiomodulation|The participant will be treated with intravaginal SoLá photobiomodulation therapy for a total of nine treatments (two treatments a week). Each treatment lasting 5 minutes.
89069638|NCT05926752|Active Comparator|Pelvic Floor Physical therapy|The participant will be treated with pelvic floor physical therapy once a week for 8 weeks. Physical therapy involves standard approach of manual therapy including trigger point release, soft tissue mobilization, stretching, biofeedback, breathing techniques, relaxation yoga, and therapeutic exercises.
89069639|NCT05926739||Standard of care|Electrical stimulation and biofeedback by the medical device PHENIX LIBERTY
89069640|NCT05926726|Experimental|CAR-GPC3 T cells|The safety and efficacy of JWATM214 will be evaluated in a 'BOIN'-designed dose escalation approach. 3 CAR-T dose levels will be tested in this study: 1×10^8, 3×10^8, and 10×10^8, whereas the dosage 0.5×10^8 and 30×10^8 CAR-T cells will be selected as optional back-up doses for potential escalation or de-escalation.
89069641|NCT05926713|Experimental|nutritional supplements and supervised exercise on Sarcopenia group and Severe Sarcopenia group|The intervention consisted of providing nutritional supplements and supervised exercise for 12 weeks. After the intervention (the 12th week), the trial commissioned company provides nutritional supplements with a market price of about NT$4,000 per month for three months free to participants who are willing to continue taking the products. Those participants will be tracked for one year.
89069642|NCT05926700|Experimental|intervention group|The subject will be treated with Candonilimab + anlotinib every 21 days as a treatment cycle: Candonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was taken orally for 2 weeks and stopped for a week. Until the subject has disease progression, intolerable toxicity, and the investigator's decision, the subject withdraws informed consent, death or other reasons specified in the protocol.
89069643|NCT05926596|Experimental|Robotic Exoskeleton|All participants will be interfered with a wearable robotic exoskeleton.
89069644|NCT05926531|Experimental|acute insomnia treatment group|CBTI and VR intervention for one week
89069645|NCT05926531|No Intervention|acute insomnia control group|no intervention
89069646|NCT05926531|Experimental|chronic insomnia treatment group|CBTI and VR intervention for one week
89069647|NCT05926531|No Intervention|chronic insomnia control group|no intervention
89069648|NCT05926518||COVID-19 ICU patients|Patients were administered as standard care once daily nadroparin 5700 IU sc (below 100 kg) or twice daily nadroparin 5700 IU sc (above 100 kg).
89069649|NCT05926518||non-COVID-19 ICU patients|Patients were administered as standard care once daily nadroparin 2850 IU sc.
89069650|NCT05926492|Experimental|Surufatinib plus chemotherapy|Patients were to receive surufatinib plus chemotherapy every 30 days as neoadjuvant treatment. After receiving 2 cycles of treatment, patients will be evaluated for tumor necrosis rate.
89069651|NCT05926492|Active Comparator|Chemotherapy|Patients were to receive chemotherapy every 30 days as neoadjuvant treatment. After receiving 2 cycles of treatment, patients will be evaluated for tumor necrosis rate.
89069652|NCT05926414||patient diagnosed with type2 diabetes mellitus|patient diagnosed with type2 diabetes mellitus
89069653|NCT05926375|Experimental|first intervention group (Supp-Con sequence)|The first intervention group used HINEX Jelly as daily breakfast during the first to 8th weeks of the experiment, the 9th to 12th week is the wash out period, the 13th to the 20th week is the selfcontrol period.
89069654|NCT05926375|Experimental|post intervention group (Con-Supp sequence)|the post-intervention group is in the first to the 8th week of self-control period,the 9th to 12th week is the wash out period, and the 13th to the 20th week is used HINEX Jelly as daily breakfast.
89069655|NCT05926271|Experimental|Genotype guided arm|"In this study arm, patients with Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) who are extensive or ultra-rapid metabolizers as per their CYP2C19 genotype and have undergone successful percutaneous coronary intervention (PCI) will receive a genotype-guided monotherapy.~The intervention will be clopidogrel, a potent P2Y12 inhibitor, administered in accordance with the patient's specific genotype. Clopidogrel following PCI will be given with an initial loading dose (300-600mg orally), followed by a maintenance dose of 75mg daily for a defined period, at least 6 months."
89069656|NCT05926245|Placebo Comparator|Placebo Group|15 adult healthy volunteers to serve as controls for the experimental group. This group will receive a placebo-topical spray with empty nanoparticles.
88812751|NCT03215966|Experimental|Sequence B/A|Subjects receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 1, then after a washout period of at least 7 days, they receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 2
89069657|NCT05926245|Experimental|Glutathione Group|15 adult healthy volunteers will serve in the experimental group. This group will receive glutaryl treatment topical spray with nanoparticles containing GSH.
89069658|NCT05926206|Experimental|TiTE-CRM Dose Escalation|Devimistat at Dose Level IV 2 hrs + modified FOLFIRINOX
89069659|NCT05926206|Experimental|Expansion Cohort A|Devimistat 500 mg/m2 IV 2 hrs + modified FOLFIRINOX
89069660|NCT05926206|Experimental|Expansion Cohort B|Devimistat at MTD IV 4 hrs + modified FOLFIRINOX
89069661|NCT05926154|Experimental|LOP + 50 mmHg|As a result of randomization, the surgical tourniquet pressure is 50 mmHg higher than the limb occlusion pressure. Limb occlusion pressure is calculated using the formulation by Graham: LOP = [(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)] + Diastolic Pressure
89069662|NCT05926154|Experimental|LOP + 100 mmHg|As a result of randomization, the surgical tourniquet pressure is 100 mmHg higher than the limb occlusion pressure. Limb occlusion pressure is calculated using the formulation by Graham: LOP = [(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)] + Diastolic Pressure
89069663|NCT05926141|No Intervention|Control phase|"After the first data collection session, participants spend 12 weeks and enter a control phase where they receive no intervention. At the end of the 12 weeks, participants will attend another data collection session."
89069664|NCT05926141|Experimental|ACE intervention|The ACE Program is a culturally inclusive, 4-H after school club where youth meet once a week for 12 weeks after school in person. They also receive groceries to make a meal 1 day a week.
89069665|NCT05926128|Other|CML patient TKI discontinuation study|Treatment free remission in patients with chronic myeloid leukemia in chronic phase who achieved deep molecular response with tyrosine kinase inhibitors
89069666|NCT05926076||Kidney Transplant Recipients Group (KTR)|
89069667|NCT05926076||Non-Kidney Transplant Recipients Group（NKTR）|
89069668|NCT05926050|Experimental|Dietary supplement intervention|Participants were treated with 2 tablets containing extracts of American ginseng, bacopa monnieri and coffee fruit
89069669|NCT05926050|Placebo Comparator|Placebo Treatment|Participants received 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
89069670|NCT05925296|Experimental|double-site high frequency rTMS over the bilateral M1 of the lower leg and SMA|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral M1 of the lower leg and SMA.
89069671|NCT05925296|Active Comparator|single-site high frequency rTMS over the bilateral primary motor cortex of the lower leg|Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.
88812752|NCT01522937|Experimental|Liver cancer patients|The aim of this study is to determine the safety and effectiveness of individualized Stereotactic Body Radiation Therapy (SBRT) in patients who either (1) have had previous liver treatments, and/or (2) have primary hepatocellular carcinoma (HCC).
89069672|NCT05925296|Sham Comparator|sham magnetic stimulation on motor cortex|Patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on M1.
89069673|NCT05925244|Experimental|Control|The control condition did 30 minutes of walking exercise with their own body mass.
89069674|NCT05925244|Experimental|+12% Body Mass|The +12% body mass condition did 30 minutes of walking exercise wearing a weighted vest with +12% of their body mass applied.
89069675|NCT05925244|Experimental|-12% Body Mass|The -12% body mass condition did 30 minutes of walking exercise using a lower body positive pressure treadmill with -12% of their body mass applied.
89069676|NCT05924568|Experimental|Median Sternotomy|
89069677|NCT05922644|Experimental|Spinal cord electrical stimulation group|According to the EDC system, patients are randomly assigned to receive 21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
89069678|NCT05922644|Sham Comparator|Conventional treatment group|According to the EDC system, patients are randomly assigned to receive only routine brain resuscitation and rehabilitation awakening treatment.
89223845|NCT05330455|Experimental|Part 1 Cohort 1: GSK3965193 and placebo|Healthy participants will be randomized to receive single ascending doses of GSK3965193 and placebo in one of 4 treatment sequences in a 3:1 ratio in fasted conditions. In period 1, participants will receive GSK3965193 (Dose 1) + Placebo; in period 2: GSK3965193 (Dose 2) + Placebo; in period 3: GSK3965193 (Dose 3) + Placebo and in period 4: GSK3965193 (Dose 4) + Placebo. There will be a minimum of 7 days washout between dosing in each treatment period.
88812753|NCT01830998||control,MCI, Olfactory dsfunction|There are different groups:control,MCI, Olfactory dsfunction.
88812754|NCT01830998||control, MCI|control and MCI group.Glycaemic control
89069679|NCT05922176||patient group of House dust mist allergic rhinitis|"Adult male and female patients aged 19 to 60 with allergic rhinitis caused by the antigen of the American house dust mite (It is judged that the positive for the house dust mite is MAST ≥ Class 3 or ImmunoCAP® ≥3.5 kUA/L)~Moderate-severe persistent rhinitis when evaluated according to ARIA (Allergic rhinitis and its impact on asthma)~A person who has signed a written consent to participate in this clinical trial at his/her own discretion after fully explaining the purpose, contents, characteristics of the test drug, and expected adverse reactions prior to participation in the clinical trial"
89069680|NCT05922176||control group|"Adults 19 years of age or older who are judged to be free from skin diseases or allergic diseases through medical examination and visual observation by a specialist~A person who agrees to provide samples derived from the human body~A person who voluntarily agreed to this study and prepared a consent form after approval of the IRB"
89069681|NCT05914831|Active Comparator|Partial Breast Irradiation|
89069682|NCT05914831|Experimental|Whole Breast Irradiation|
89069683|NCT05910671|Experimental|Physical Activity Phone Calls and Notebook|The intervention will last 8 weeks. As part of the intervention the participants (parents) will receive a notebook with weekly newsletters that discuss behavioral strategies for physical activity changes, note pages, listing of local parks, and age-appropriate physical activities that parents and young children can do together. The intervention group will also have individual weekly telephone meetings with a physical activity coach. The weekly meeting is expected to last approximately 30 minutes. During this meeting, participants will discuss that week's behavioral strategy to promote physical activity, report on the past week's physical activity goals, failures and successes, and set goals for the next week. Each week parents will be asked to set a goal to be physically active with their child and a goal to be physically active alone.
89069684|NCT05910671|No Intervention|Control|During the 8 weeks the participants in the control group will neither receive the intervention material nor have any contact with physical activity coaches. They will continue interacting with their young child as normal.
89069685|NCT05907343|Active Comparator|Sham TBS|
89069686|NCT05907343|Active Comparator|Closed-Loop TBS|
89069687|NCT05907343|Active Comparator|Open-Loop TBS|
89069688|NCT05907239|Experimental|Treatment group|Treatment group will undergo treatment with focal shock wave therapy for 5 weeks, with weekly sessions and guidance by a trained physiotherapist on habits, stretching and exercises for adequate strengthening and ergonomic guidelines to promote a better quality of life
89069689|NCT05907239|Placebo Comparator|Placebo|Patients in the placebo group will undergo treatment with placebo focal shockwave therapy (using a dummy applicator) for 5 weeks and guidance by a trained physiotherapist on habits, stretching and exercises for adequate strengthening and ergonomic guidelines to promote a better quality of life
89069690|NCT05896306||Term neonates|
89069691|NCT05896306||Preterm neonates|
89069692|NCT05892653|Experimental|Dose Escalation and Dose Expansion|"During the dose escalation stage, a classic 3+3 design will be used to guide dose escalation to determine MTD and RP2D. Three to six subjects are expected to be enrolled in each dose group and at least 6 subjects are enrolled in the MTD/highest dose group. The total number of subjects enrolled during the dose escalation stage will depend on the amount of DLT and the total number of dose levels explored. If DLT is not observed in the first 3 subjects enrolled for each dose level, the Safety Monitoring Committee (SMC) will review the cumulative safety data of subjects at each dose level and decide whether to proceed with dose escalation upon the completion of study treatment at least for the DLT evaluation period (28 days of Cycle 1). The dose expansion stage in this study will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level (MTD or the optimal dose needs to be reviewed by the SMC and subjects are safe and tolerable at that dose level)."
89069693|NCT05882370|Experimental|SCALE|TIPS plus Cadonilimab
89069694|NCT05876182|Experimental|Oral Vancomycin 750|28 subjects with PSC will be randomized to this arm. They will take 2 tablet (1 of vancomycin 250 mg and 1 of placebo), three times a day administered orally (total dose 750 mg/daily).
89069695|NCT05876182|Experimental|Oral Vancomycin 1500|28 subjects with PSC will be randomized to this arm.They will take 2 tablet of 250 mg of vancomycin three times a day administered orally (total dose 1500mg/daily)
89069696|NCT05876182|Placebo Comparator|Placebo|28 subjects with PSC will be randomized to this arm. They will take 2 tablet (placebo-to-match oral vancomycin) administered orally three times a day.
89069697|NCT05874596|Experimental|Intervention|AI-aided clinical feedback system coupled with multi-aspect intervention based on the Behaviour Change Wheel model
89069698|NCT05874596|No Intervention|Control|AI-aided clinical feedback system only
89069699|NCT05873140|Experimental|Study group|Continuously receiving education (video clips and infographics) via application LINE
89069700|NCT05873140|No Intervention|Control group|No application LINE
89069701|NCT05864196|Experimental|Men with low to intermediate risk prostate cancer|Once a patient is deemed eligible, they will be scheduled for treatment with SBRT, which should be completed within 14 days of screening. Follow up will occur 30 days post radiation and every 4 months, post- radiation for the first 2 years. After the first 2 years of follow up, visits will occur every 6 months until year 5.
89069702|NCT05848427||LUSZ WOSS-3|hospitalized COVID-19 patients classified as WOSS-3 (as per the WHO Ordinal Severity Scale) who didn't need oxygen therapy
89069703|NCT05848427||LUSZ WOSS-4|hospitalized COVID-19 patients classified as WOSS-4 (as per the WHO Ordinal Severity Scale) who needed oxygen therapy by mask or traditional nasal cannula
89069704|NCT05848427||LUSZ WOSS-5|hospitalized COVID-19 patients classified as WOSS-5 (as per the WHO Ordinal Severity Scale) who needed oxygen therapy NIMV or HFNC
88812755|NCT01830998||control and MCI|treatment and without treatment
89069705|NCT05848427||LUSZ WOSS-6|hospitalized COVID-19 patients classified as WOSS-6 (as per the WHO Ordinal Severity Scale) who needed oxygen therapy IMV & intubation
89069706|NCT05848050|Other|brain metastases from solid cancer|Excision of the cerebral metastasis
89069707|NCT05836168|Active Comparator|Probiotic|multi-strain probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19 in a matrix of maize starch, maltodextrin, inulin, potassium chloride, rice protein, magnesium sulfate, fructooligosaccharides, amylases and mangane sulfate at a dose of 2 x 3g per day for 4 weeks.
89069708|NCT05836168|Placebo Comparator|Placebo|2 x 3g of a similar looking and tasting placebo per day for 4 weeks.
89069709|NCT05833321|Experimental|Interventionnal|"Hand Grip Dynamometer Walk test SEFI Nutritional Intake Assessment Questionnaire"
89069710|NCT05830461|Experimental|Experimental group|The experimental group will receive the self-applied intervention through a digital platform. The intervention consists of three stages, depending on the situation of the patient: 1) Patients who undergo screening and obtain negative results for malignancy, 2) patients with suspicion and undergo a biopsy, 3) Patients with positive results for breast cancer.
89069711|NCT05830461|Active Comparator|Control group|The experimental group will receive the self-applied intervention through written visual material that will be given to them. The content of the material will be the same as the experimental group.
89069712|NCT05826834|Experimental|Ball rolling|The ball-rolling group will be asked to roll the ball on the trapezius muscle.
89069713|NCT05826834|No Intervention|Control|The control group with no intervention
89069714|NCT05791071|Experimental|Floreo VR Building Social Connections|Participants will receive Floreo VR Building Social Connections lessons approximately 3 times a week for no more than 15 minutes per session.
89069715|NCT05791071|Sham Comparator|Sham|Participants will receive non-interventional active VR videos approximately 3 times a week for no more than 15 minutes per session.
89069716|NCT05789238|No Intervention|Control|No labels for products high in added sugar, saturated fat, or sodium
89069717|NCT05789238|Experimental|ANVISA|Levels of added sugars, saturated fat, and sodium, if exceeded according to the Brazil Nutrient Profile Model, will require the magnifying glass FOPL below on the front of the package for either solid food or liquid food.
89069718|NCT05789238|Experimental|PAHO|PAHO Model is not based on thresholds (cut-off limits), but by percentage of regulated nutrient values in total calories amount and by NOVA categories. Therefore, the Brazil team has classified products from the dataset into NOVA categories and created calculations to apply the PAHO model to PdeA products.
89223846|NCT05330455|Experimental|Part 1 Cohort 2: GSK3965193 and placebo|Healthy participants will be randomized to receive single ascending doses of GSK3965193 and placebo in one of 4 treatment sequences in a 3:1 ratio in fasted conditions. In period 1, participants will receive GSK3965193 (Dose 5) + Placebo; in period 2: GSK3965193 (Dose 6) + Placebo; in period 3: GSK3965193 (Dose 7) + Placebo and in period 4: GSK3965193 (Dose 8) + Placebo. There will be a minimum of 7 days washout between dosing in each period.
89223847|NCT05330455|Experimental|Part 2A Cohort 3: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses of either GSK3965193 (Dose X) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
89223848|NCT05330455|Experimental|Part 2A Cohort 4: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses either GSK3965193 (Dose Y) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
89223849|NCT05330455|Experimental|Part 2A Cohort 5: GSK3965193 or placebo|Healthy participants will be randomized 3:1 to receive repeat doses either GSK3965193 (Dose Z) or placebo under fasted conditions. Part 2A may start while Part 1 is still ongoing. The starting dose in Part 2 will be at least 3-fold below the highest dose completed in Part 1.
89223850|NCT05330455|Experimental|Part 2B Cohort 6: GSK3965193|Healthy Participants will be randomized 1:1 to receive single doses of GSK3965193 (Dose A) under fasted and fed conditions in treatment period 1. In period 2, the participants who received GSK3965193 (Dose A) under fasted conditions in treatment period 1 will receive the same dose under fed conditions, and vice versa. In the third period, all participants will receive a single dose of GSK3965193 (Dose B) different strength under fasted conditions. The dose level for the third period will be selected based on the results of the first two periods. There will be a minimum of 7 days washout between dosing in each treatment period.
89223851|NCT05330455|Experimental|Part 3 Cohort 7: GSK3965193 or placebo|PLWCHB on stable nucleos(t)ide analog (NA) therapy will be randomized 3:1 to receive repeat dose of either GSK3965193 (Dose E) or placebo. This part will commence after completion of both Part 1 and Part 2.
89223852|NCT05330455|Experimental|Part 4 Cohort 8: GSK3965193 and bepirovirsen or placebo and bepirovirsen|PLWCHB participants on stable NA therapy who have not participated in Part 3 of the study will be randomized 3:1 to receive repeat dose either GSK3965193 or placebo. In addition, all participants in this cohort will also receive bepirovirsen. This part will commence after completion of Part 3, contingent on the clinical safety and efficacy data from Part 3.
89223853|NCT05312671|Experimental|Atezolizumab with Platinum and Etoposide, followed by cystectomy.|"The study population will include male and female patients over the age of 18 with invasive (cT1-cT4) small cell / neuroendocrine carcinoma of the bladder (MIBC), with or without urothelial cancer component, who are eligible for platinum based chemotherapy and immunotherapy. All patients will be fit to undergo surgical resection of their cancer by cystectomy. Patients with resectable N1 disease within the true pelvis are eligible.~Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg Day 1 of every 21 day cycle with chemotherapy x 4 cycles. Following cystectomy, Atezolizumab maintenance Q 21 days will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status (e.g., symptomatic deterioration such as pain secondary to disease), or up to 1 year (e.g., 16 cycles)."
89690961|NCT03335254|Experimental|Dose-Escalating Arm 2|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 633 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89069719|NCT05778526|Experimental|Social VR Intervention|Social VR intervention is developed to enhance the social interaction skills of children. The participants will wear a head-mounted display for the Social VR intervention. Each session of the Social VR intervention lasts for a maximum of 20 minutes to ensure the participants focus on the intervention and prevent causing any physical effect. The duration will be adjusted depending on the emotion of the participants during the intervention. The Social VR intervention will mainly help the participant to enhance their social interaction skills and executive function. The intervention contains three real-life virtual scenarios, including (1) classroom and playground, (2) MTR station and compartment, and (3) supermarket and restaurant. One scenario will be adopted in each session. The sequences of the scenarios used in each session will be the same for all participants.
89069720|NCT05778526|Active Comparator|Traditional social skills training|An experienced SEN teacher will teach the participants social interaction skills through tradidactic instructions and role-play activities. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise. These modules have been applied in many studies (Braswell & Bloomquist, 1991; Huang et al., 2015). The content of this training will be as similar as possible to the Social VR training. The training lasts 20 minutes which depends on the emotion of the participants.
89069721|NCT05778526|No Intervention|Waitlist control group|The participants in this group will receive no training and they can participate in the social VR training after the intervention period. To ensure the consistency of the experiment, the participants are not allowed to initiate or change their pharmacological treatment during the 3-week intervention period.
89069722|NCT05773001|Other|Cohort 1|No history of SARS-CoV-2
89069723|NCT05773001|Other|Cohort 2|Documented mild SARS-CoV-2 infection
89069724|NCT05773001|Other|Cohort 3|SARS-CoV-2 pneumonia
89069725|NCT05765045|Experimental|Nursing triage group|Using a triage protocol for medical imaging conducted by a triage nurse in the emergency department
89069726|NCT05765045|No Intervention|Regular care group|Regular triage in the emergency department
89069727|NCT05741853|Experimental|Lexical Retrieval Training|Naming intervention for individuals with logopenic or semantic variant PPA.
89069728|NCT05741853|Experimental|Video Implemented Script Training for Aphasia|Script training intervention for individuals with nonfluent/agrammatic PPA.
89069729|NCT05723861|Experimental|VR group|Participants will receive Virtual Reality intervention in addition to routine care during colonoscopy.
89069730|NCT05723861|No Intervention|Control group|Receive routine treatment.
89069731|NCT05701228||day 0 of transplantation|This cohort will include 450 patients at the time of transplantation. The following number of participants will be enrolled in the cohort according to strata defined by organ-transplanted type and baseline immune status.
89069732|NCT05701228||day 0 of infection|This cohort will include 150 patients at the time of the infection: Approximatively 75 patients will be drawn from the cohort of solid-organ transplant recipients included at day 0 of transplantation. Additional 75 patients developing a CMV infection will be also included.
89069733|NCT05690984|Experimental|Isatuximab in combination with lenalidomide and dexamethasone.|The isatuximab, lenalidomide, and dexamethasone (IsaRD) therapy will be administered on an outpatient basis.
88812756|NCT01830998||MCI and Olfactory function|observation between MCI and Olfactory function groups.
89069734|NCT05688332|Experimental|Voglibose + Metformin (Group B)|In the B treatment group, 59 participants will be randomly assigned to initially voglibose 0.2mg TDS immediately before meals + metformin 500mg BD immediately before meals daily. Individual drug doses will be adjusted to the next higher doses after 6 to 12 days, at next clinical visits based on home based recorded blood glucose profiles. The maximum daily recommended dose of metformin of 2g and voglibose 0.9mg will not be exceeded.
89690962|NCT03335254|Experimental|Dose-Escalating Arm 3|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
88812757|NCT03215498|Experimental|Faster aspart followed by insulin aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
88812758|NCT03215498|Experimental|Insulin aspart followed by faster aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
89069735|NCT05688332|Active Comparator|Glibenclamide + Metformin (Group A)|"In treatment group A, 59 participants will initially be randomly allocated by study team members to the glibenclamide 5mg O.D + metformin 500mg BD regimen.~In this study, 10mg glibenclamide and 2g metformin will not be exceeded daily."
89069736|NCT05685147|Experimental|Intervention group|the intervention group using morphology and niPGT-A
89069737|NCT05685147|No Intervention|Control group|the control group based on morphology alone.
89069738|NCT05680688|Experimental|Painful Manual Therapy|Manual therapy treatment shall be carried out at a high intensity that causes pain to the patient. The aim is to provoke a medium intensity pain to the patient of 5/10 in the NRS. The physiotherapist will ask every 30 seconds the pain provoked by the treatment with the numeric rating scale (NRS) and the patient will give continuous feedback. Based on this, the physiotherapist will adapt the intensity of the treatment to provoke a medium intensity pain.
89069739|NCT05680688|Active Comparator|Painless Manual Therapy|Manual therapy treatment shall be performed at a low intensity that does not cause pain to the patient. The aim is for the patient to report a pain intensity of 0/10 in NRS throughout treatment. The physiotherapist will ask every 30 seconds the pain provoked by the treatment with NRS and the patient will give continuous feedback. Based on this, the physiotherapist will adapt the intensity of the treatment to be performed below the pain threshold.
89069740|NCT05647304|Other|5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
89069741|NCT05647304|Other|10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
89069742|NCT05642962|Experimental|Arm 1|Participants with stage 4 Pancreatic Ductal Adenocarcinoma / PDAC will receive 384 units lipase/kg of body weight per meal or snack
89069743|NCT05642962|Experimental|Arm 2|Participants with stage 4 Pancreatic Ductal Adenocarcinoma / PDAC will receive 1350 units lipase/kg of body weight per meal or snack
89069744|NCT05619445|Experimental|Whole Liquid Egg|Whole Liquid Eggs
89069745|NCT05619445|Experimental|Plant-Based Egg Substitute|Plant-Based Egg Substitute
89069746|NCT05597735|Experimental|Tecovirimat|
89069747|NCT05597735|Placebo Comparator|Placebo|
89069748|NCT05578781|Experimental|Music Therapy|The Music Therapy (MT) group will participate in 1 live session of music therapy with a board certified Music therapist while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
89069749|NCT05578781|Experimental|Music Medicine|The Music Medicine (MM) group will participate in 1 audio session of music while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
89069750|NCT05578781|Experimental|Control condition|the Control group will participate in 1 session of an audio of text being read to them while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about lasting effects and pain
89069751|NCT05578781|Active Comparator|Control group without low back pain|This group will participate in 1 session of an audio of the music therapy session while wearing an EEG cap. Afterwards, they will complete a brief questionnaire about the experience and pain. They will also complete a brief questionnaire 24 hours later about the lasting effects and pain
89069752|NCT05549960|Other|pancreatic lesions|Individuals with a histological diagnosis of locally advanced or metastatic (stage III or IV) pancreatic adenocarcinoma, functioning or non-functioning neuroendocrine tumor, pancreatic metastasis from inoperable renal cell carcinoma, or in affected patients not prone to treatment.
89069753|NCT05535348|Experimental|Open Pilot|An adapted version of the Relaxation Response Resiliency Program (3RP) for fathers of CYSHCN. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
89069754|NCT05492032|Experimental|Active cathodal (inhibitory) tDCS vs. Sham-tDCS condition|"Experimental group: active multisession tDCS + active booster tDCS vs Active control group: sham multisession tDCS + sham booster tDCS~To test whether active cathodal [inhibitory] tDCS over the left dlPRC will facilitate learning through stimulation and thus improve cognitive function in patients with ASD, the primary outcomes (SRS-2 scores) of the two groups at the start (T0), 1-month (T1), 3-month (T2), 6-month (T3), and at the end of study i.e. 12-months (T4) will be compared."
89069755|NCT05492032|Experimental|Active booster tDCS treatment vs. Sham booster tDCS treatment|"Experimental group: active multisession tDCS + active booster tDCS vs Active control group: active multisession tDCS + sham booster tDCS~To test whether booster treatment cycles of tDCS will prolong the cognitive benefits in individuals with ASD), the primary outcome, the total SRS-2 score, and the secondary outcomes, the E/I ratio and the cognitive composite score at the start (T0), 1-month (T1), 3-month (T2), 6-month (T3), and at the end of study i.e. 12-months (T4), will be compared."
89069756|NCT05492032|Experimental|Change in EEG E/I ratios in the active tDCS vs. sham tDCS groups|"Experimental group: active multisession tDCS + active booster tDCS vs Active control group: sham multisession tDCS + sham booster tDCS~To test whether enhanced neuronal network organization, as indicated by EEG E/I ratios, in patients with ASD will mediate the beneficial effects of tDCS in terms of improvements in cognitive function, measurements taken at baseline, 1-day and 1-month after tDCS treatment will be compared. The change in EEG E/I ratios in patients in the active tDCS and sham tDCS groups will be compared using E/I ratios averaged from channels Fp1, F3, and F7 to increase the signal-to-noise ratio of the EEG data and to represent the left frontal E/I ratio."
89069757|NCT05488431|Experimental|Bempedoic acid (BA)|Patients randomized into the BA arm will receive 180 mg BA administered orally once daily without food for 52 weeks.
89069758|NCT05488431|Placebo Comparator|Placebo|Patients randomized into the placebo arm will receive 180 mg placebo administered orally once daily without food for 52 weeks.
89069759|NCT05467228|Experimental|Low dose / continuous VTS|Low dose refers to receiving VTS 5 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
89069760|NCT05467228|Experimental|Low dose / speech activated VTS|Low dose refers to receiving VTS 5 times/week for 20 minutes each; VTS during connected speech
89069761|NCT05467228|Experimental|High dose / continuous VTS|High dose refers to receiving VTS 7 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
89069762|NCT05467228|Experimental|High dose / speech activated VTS|High dose refers to receiving VTS 7 times/week for 20 minutes each; VTS during connected speech
89069763|NCT05436925||Dexcom G6 sensor Continuous Glucose Monitor (CGM)|All participants will be assigned to use the continuous glucose monitor
89069764|NCT05405283|Active Comparator|Comirnaty® (Pfizer-BioNTech)|
89522894|NCT03388801|Experimental|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
89069765|NCT05405283|Experimental|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|
89069766|NCT05392179|Experimental|ADX-2191 Three Injections|
89069767|NCT05392179|Experimental|ADX-2191 Six Injections|
89069768|NCT05904223|No Intervention|Standard of Care|"standard of care (SOC) group = control group:~Routine laboratory parameters (CBC, CRP, kidney and liver parameters, etc.) on the day of admission and when clinically necessary - decision is made by the physician in charge~Sputum microscopy for quality assessment (via Bartlett score)~Chest X-ray on the day of admission or the day after~2 Sets of blood cultures (if temperature >38°)~Pneumococcus urine antigen test for every patient with proven or suspected pneumonia~Legionella urine antigen test for every patient with proven or suspected pneumonia and clinical suspicion for Legionella infection (travel history, air condition, elevated CK, hyponatremia, reduced kidney function)~Antibiotic treatment if deemed necessary by the treating physician"
89069769|NCT05904223|Experimental|Standard of Care + Respiratory Panel|"Pneumonia panel plus group = intervention group~Sputum analysis via the BIOFIRE® FILMARRAY® Pneumonia Panel plus~Routine laboratory parameters (CBC, CRP, kidney and liver parameters, etc.) on the day of admission and when clinically necessary - decision is made by the physician in charge~Sputum microscopy for quality assessment (via Bartlett score)~Chest X-ray on the day of admission or the day after~2 Sets of blood cultures~Pneumococcus urine antigen test for every patient with proven or suspected pneumonia~Legionella urine antigen test for every patient with proven or suspected pneumonia and~Antibiotic treatment if deemed necessary by the treating physician"
89069770|NCT05378841|Experimental|Surgical denervation|It consists of a section of the nerve branches destined for the PIPJ, coming from the digital collateral nerves as well as the dorsal sensory branches of the radial and ulnar nerves respectively for the index and fifth fingers.
89069771|NCT05377359|Experimental|Participants with Hearing Loss|Individuals with hearing loss that meet the candidacy to wear hearing aids with various coupling methods. All interventions are associated with the fitting of binaural hearing aids with various coupling methods. All participants will be assessed under all interventions.
89069772|NCT05377320||Clinical Decision Aid Group|In this group, physicians will use standard care plus the clinical decision aid.
89069773|NCT05377320||Control Group|In this group, physicians will use standard care only.
89069774|NCT05365269|Experimental|Computer-generated feedback on health risk behaviors|Proactive Automatized Lifestyle intervention Frequency: 3 times (month 0, 1, 3) Dosage: Individually tailored feedback corresponding to about 1-6 pages Duration: 3 months
89069775|NCT05354453|Experimental|SRD Part|Single-rising dose (SRD)
89069776|NCT05354453|Placebo Comparator|SRD Part: Placebo|
89069777|NCT05354453|Experimental|Skin Challenge Part|
89069778|NCT05354453|Placebo Comparator|Skin Challenge Part: Placebo|
89223854|NCT05304208|Experimental|Treatment arm|Before standard-of-care chemotherapy, a leukapheresis will be performed and monocytes will be used for differentiation to DCs using specific cytokines. Allogeneic tumor lysate (Pheralys) loaded autologous DCs (MesoPher) will be re-injected 3 weeks after completing chemotherapy, 2 times every other week. Four weeks after the first injection with DCT, patients will undergo eP/D surgery and receive three bi-weekly injections with DCT (starting 4 weeks after surgery). If there is a surplus of vaccinations, a 6th and 7th vaccination at 3 and six months after the last vaccination could be considered by the treating physician.
89223855|NCT05291351|Experimental|Pea|Treatment 1: crackers made with 25% whole pea flour + 75% all-purpose wheat flour; Treatment 2: crackers made with 25% coarse pea flour + 75% all-purpose wheat flour; Treatment 3: crackers made with 25% fine pea flour + 75% all-purpose wheat flour; Treatment 4: crackers made with 100% all-purpose wheat flour (control)
89223856|NCT05291351|Experimental|Lentil|Treatment 1: crackers made with 25% whole lentil flour + 75% all-purpose wheat flour; Treatment 2: crackers made with 25% coarse lentil flour + 75% all-purpose wheat flour; Treatment 3: crackers made with 25% fine lentil flour + 75% all-purpose wheat flour; Treatment 4: crackers made with 100% all-purpose wheat flour (control)
89223857|NCT05291351|Experimental|Oats|Treatment 1: porridge made with whole oat flour; Treatment 2: porridge made with coarse oat flour; Treatment 3: porridge made with fine oat flour; Treatment 4: porridge made with commercial oat flour (control)
89223858|NCT05254574|Experimental|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
88812759|NCT03215108|Experimental|Flower-CSEMS|EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
88812760|NCT03215108|Experimental|Conventional-CSEMS|Conventional-CSEMS (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
89069779|NCT05344378|No Intervention|1 Month Baseline Period|Initial baseline period for rollout at 6 different clinics throughout the year-long intervention period using a step-wedge design.
89069780|NCT05344378|Experimental|Stage 1 Enrollment|Enrollment of 2 clinics over 4 months including 5 PCPs per clinic (2 total clinics).
89069781|NCT05344378|Experimental|Stage 2 Enrollment|Addition of 2 clinics with modifications over 4 months including 5 PCPs per clinic (4 total clinics).
89069782|NCT05344378|Experimental|Stage 3 Enrollment|Addition of 2 clinics with modifications over 4 months including 5 PCPs per clinic (4 total clinics).
89069783|NCT05333341|Active Comparator|TCM|TCM uses clinical pharmacists leading LTOT reassessment and, when indicated for underlying OUD, buprenorphine (BUP) initiation in consultation with a BUP-prescribing physician. Clinical pharmacists will lead LTOT reassessment and, when indicated for underlying OUD, buprenorphine (BUP) initiation in consultation with a BUP-prescribing physician.
89069784|NCT05333341|Experimental|TCM plus COPES|Participants in this arm will use TCM plus COPES that will augment the effectiveness of TCM alone.
89069785|NCT05303116||Control|Patients with COVID who are NOT experiencing altered mental status
89069786|NCT05303116||COVID patients|COVID patients who are experiencing confusion,
89069787|NCT05286151|Experimental|Children who stutter|Children who stutter
89069788|NCT05286151|Experimental|Children who do not stutter|Children who do not stutter
89069789|NCT05282095||Women aged from 18-45 with histopathologically confirmed CIN2|In the enrollment, women whose cervical histopathological results have been diagnosed as cervical intraepithelial neoplasia (CIN2) for the last 3 months with abnormal results will be included in this study. All participants will be followed up four, at 3th month, 6th month, 9th month and 12th month.
89069790|NCT05223218||Breast Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Mammogram, ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
89069791|NCT05223218||Pancreatic Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
89069792|NCT05223218||Colon Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
89069793|NCT05223218||Prostate Cancer|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
89069794|NCT05223218||Melanoma|"Individuals aged between 18-100 years who are presenting for an evaluation of an abnormal exam or test (Ultrasound, MRI, PET, etc.); presenting for the evaluation of a palpable lump or mass; presenting with a mass pre or post-biopsy as long as there is a portion of the mass remaining; or have been diagnosed with breast cancer but have not received treatment.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
89069795|NCT05223218||Healthy Control|"Individuals aged between 18-100 years who do not currently have a previous diagnosis of any cancer for which they are currently being treated.~Lacrimal tear fluid samples are collected using a Schirmer strip, a Class I Medical Device typically used to test for dry eye."
89069796|NCT05203900|Experimental|Investigational formula|Infant formula with Human Milk Oligosaccharide
89069797|NCT05203900|Placebo Comparator|Control formula|Infant formula without Human Milk Oligosaccharide
89069798|NCT05198700|Experimental|Experimental Group|Participants in this group will be randomized to receive the probiotic formulation for 4 weeks.
89069799|NCT05198700|Placebo Comparator|Control Group|Participants in this group will be randomized to receive the placebo for 4 weeks.
89223859|NCT05254574|Placebo Comparator|Placebo SAM Ultrasound Device and Diclofenac Patch|Patients receive placebo treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 0% diclofenac patch.
88812761|NCT01441037|Experimental|Danazol|Single arm in which danazol is administered orally at 800 mg daily for 2 years.
89069800|NCT05159076|Experimental|Behavioral Intervention|Participants will undergo an eight-week behavioral intervention protocol (once a week) aimed at increasing the level of physical activity, consisting of a brief educational program: brief education for asthma and benefits of physical activity and behavioral intervention based on Social Cognitive Theory and the Theory of Stages of Behavior Change.
89069801|NCT05135546|Experimental|Experimental|Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight.
89069802|NCT05135546|Placebo Comparator|Placebo control|Placebo
89069803|NCT05117099|Experimental|FCU Online + Coach|Parents in this arm will receive access to the FCU Online website and telehealth coaching/ support provided by a trained mental health provider. The FCU Online website includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include videos, animated videos, parenting tips, and interactives to help practice parenting skills.Telehealth coaching sessions will focus on Healthy Behaviors, Positive Parenting, Rules and Consequences, School Support, and Communication.
89069804|NCT05117099|No Intervention|Waitlist Control|Parents in this arm will initially serve as the control group but will receive access to the FCU Online website and telehealth coaching after completing three waves of data collection (baseline, 2-mo, and 4-mo follow-up).
89069805|NCT05112640|Active Comparator|Suture wound closure|Absorbable sutures for closure of cesarean skin incision using Monocryl manufactured by Ethicon.
89069806|NCT05112640|Experimental|Absorbable staple wound closure|Staples will be applied as per the manufacturer's instructions intraoperatively using INSORB device manufactured by Cooper Surgical.
89069807|NCT05085834|Experimental|Zinc gluconate|Patients received Zinc gluconate 45 mg capsules orally twice daily for 24 weeks.
89069808|NCT05085834|Placebo Comparator|Placebo|Patients received Zinc gluconate Placebo capsules orally twice daily for 24 weeks.
89069809|NCT05081596|Experimental|Problem Adaptation Therapy for Pain (PATH-Pain)|Problem Adaptation Therapy-PAIN (PATH-PAIN) is an emotion regulation intervention aimes to reduce stress and decrease depression and disability.
88812762|NCT00891878|Experimental|Arm I|Patients receive oral capecitabine twice daily on days 1-14. Patients experiencing disease progression may crossover to arm II at the physician's discretion.
89069810|NCT05081596|No Intervention|Attention Control Usual Care|Usual Care involves the continued medical attention and treatment provided by the subject's physician and other medical professionals in primary care. This may include medical intervention or referrals to specialists to address issues of depression, pain or memory difficulties. Subjects will also be asked to meet with a study research assistant for structured interviews and educational sessions consisting of general questions regarding health habits and other non-medical topics unrelated to cognitive impairment, pain, and depression. Additionally, subjects will receive an educational booklet on pain and depression.
89069811|NCT05066113|Experimental|Healthy Participants|Electrothermolysis treatment using varying levels of RF energies
89069812|NCT05046873|Experimental|NNC0480-0389 + semaglutide(co-formulation)and placebo|Sequence A: The participants will be administered a single subcutanous (s.c.) dose of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate dosing visits separated by at least 8 weeks. The two drugs will be administered as a co-formulation by a single injection and a placebo injection
89069813|NCT05046873|Active Comparator|NNC0480-0389 + semaglutide (separate injections)|Sequence B: The participants will be administered 0.5 mg semaglutide and 5 mg NNC0480 0389 as an subcutaneus injection (s.c) on two separate dosing visits separated by at least 8 weeks. The two drugs will be administered as two separate injections.
89069814|NCT05038982|Experimental|Prurigo Nodularis|Prurigo Nodularis (PN) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
89069815|NCT05038982|Experimental|Chronic Pruritus of Unknown Origin|Chronic Pruritus of Unknown Origin (CPUO) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).
89069816|NCT04992650|Experimental|Breast reconstruction with fat grafting|fat grafting
89069817|NCT04992650|No Intervention|breast reconstruction without fat grafting|No Fat grafting
89069818|NCT04983966|Experimental|Desflurane group|General anesthesia with volatile agent of desflurane
89069819|NCT04983966|Active Comparator|Remimazolam group|Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
89069820|NCT04983797|Experimental|OPTRELL Mapping Catheter|Participants diagnosed with cardiac arrhythmias who are scheduled to have a clinically-indicated catheter mapping and ablation procedure of arrhythmia management for Atrial and ventricular procedures will be using multi-electrode OPTRELL mapping catheter.
89069821|NCT04980872|Experimental|Miransertib|Participants with either PROS or PS receive miransertib orally once daily between 5 and 35 mg/m^2 based on prior approved dosing for up to 48 cycles. A cycle is 28 days long.
89069822|NCT04972942|Other|Interventional|"Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~Daratumumab (DARA) treatment post-HCT~Induction: DARA IV weekly x 8 doses (Weeks 1-8)~Consolidation: DARA IV every 2 weeks x 8 doses (Weeks 9-24)~Maintenance: DARA IV every 4 weeks (Stop at Day +270)"
88812763|NCT00891878|Experimental|Arm II|Patients receive oral capecitabine as in arm 1 and oral sunitinib malate once daily on days 1-21.
89069823|NCT04953897|Experimental|Group A: Severe Renal Impairment|Cancer participants with severe renal impairment not requiring dialysis (creatinine clearance [CLcr] <30 mL/min/1.73m^2)
89069824|NCT04953897|Active Comparator|Group B: Normal Renal Function|Cancer participants with normal renal function (CLcr ≥80 mL/min/1.73m^2)
89069825|NCT04935775|Experimental|Untrained Touch Provided|
89069826|NCT04935775|No Intervention|Standard of Care|
89069827|NCT04917406|Experimental|Use of iontophoresis|Lidocaine (local anesthetic) associated with dexamethasone (corticosteroid) will be administered by iontophoresis technique. Dose per session and iontophoresis: 10 minutes with an intensity of 4 mA.
89069828|NCT04917406|Active Comparator|Use of ultrasound|The treatment for the control group will be applied with a frequency of 3 times a week as usually performed in the ACP of the University of Seville. The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and 1MZ head.
89069829|NCT04916639|Experimental|Active group|Physiomer®, undiluted seawater nasal spray
89069830|NCT04916639|No Intervention|control group|
89069831|NCT04916249|Experimental|Tibetree pain relieving plaster|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
89069832|NCT04916249|Placebo Comparator|Placebo plaster groups|Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.
89069833|NCT04908215|Experimental|INM-755 (cannabinol) cream|Cannabinol cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.
89069834|NCT04908215|Placebo Comparator|Vehicle cream|Vehicle cream, topically applied daily in thin layer on non-wound index areas and every 1, 2 or 3 days in thick layer on dressings for index wounds for a 28-day period.
89069835|NCT04867785|Experimental|0.5 milligrams (mg) LY3437943|Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).
89223860|NCT05254574|Active Comparator|Over the Counter Arthritis Pain Gel|Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.
88812764|NCT01442129|Experimental|MPC Intramyocardial injection|Intramyocardial injections of 25 million Mesenchymal Precursor Cells (MPCs)
89223861|NCT05219929|Active Comparator|Tetracycline First|Tetracycline for first 3 months, placebo for second 3 months.
89223862|NCT05219929|Placebo Comparator|Placebo First|Placebo for first 3 months, tetracycline for second 3 months.
89223863|NCT05210530|Experimental|VCTX210A combination product|Up to seven (7) units will be implanted
89223864|NCT05205382|Experimental|Electronic cigarette pods (SREC or NJOY) with 5% nicotine concentration|Participants will complete a lab visit where they will use 5% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
89223865|NCT05205382|Experimental|Electronic cigarette pods (NJOY) with 3% nicotine concentration|Participants will complete a lab visit where they will use 3% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
89223866|NCT05205382|Experimental|Electronic cigarette pods (SREC) with 0% nicotine concentration|Participants will complete a lab visit where they will use 0% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
89223867|NCT05203185|Experimental|Intervention Site|Full time employed Emergency Department providers will use the new CDS tool, Pulmonary Embolism Risk Kalculator (PERK), which includes nudges to improve use and will be integrated into the electronic medical record and will be accessible for 6 months
89223868|NCT05203185|No Intervention|No Intervention Site|Full time employed Emergency Department providers used a CDS tool, Pulmonary Embolism Calculator (PE CALC), without nudges to improve use, to reduce unnecessary imaging in the diagnosis of pulmonary embolism (PE) in the emergency department (ED).
89223869|NCT05202847|Experimental|pulsed radiofrequency ablation to modified points group|pulsed radiofrequency ablation aimed at the adjusted target point of Park et al. under C-arm guidance
89223870|NCT05202847|Active Comparator|pulsed radiofrequency ablation to conventional points group|pulsed radiofrequency ablation aimed at conventional target point under C-arm guidance
89069836|NCT04867785|Experimental|4 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
89069837|NCT04867785|Experimental|4 mg LY3437943 (4 mg)|Participants received 4 mg LY3437943 administered as SC injection QW.
89069838|NCT04867785|Experimental|8 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
89069839|NCT04867785|Experimental|8 mg LY3437943 (4 mg)|Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.
89069840|NCT04867785|Experimental|12 mg LY3437943 (2 mg)|Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.
89069841|NCT04867785|Active Comparator|1.5 mg Dulaglutide|Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.
88812765|NCT01442129|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
89069842|NCT04867785|Placebo Comparator|Placebo|Participants received placebo administered as SC injection QW.
89069843|NCT04866199||High-risk colon or bladder surgical patients|Patients who are diagnosed with colon or bladder cancer requiring surgical resection.
89069844|NCT04850573|Experimental|EAA|Participants in this arm will take part in eight weekly thirty minute sessions of equine facilitated learning where they interact with a horse and learn basic horsemanship skills.
89069845|NCT04850573|No Intervention|Control|
89069846|NCT04812912||Participants with Colon Cancer|This patient population will have hormone biomarker analysis, questionnaire (QOL) administration, and, if the patient is male, semen analysis
89069847|NCT04812912||Participants with Rectal Cancer|This patient population will have hormone biomarker analysis, QOL administration, and, if the patient is male, semen analysis
89223871|NCT05132829|Other|Cefazolin and Indomethacin|Control arm- perioperative cefazolin and indomethacin
89223872|NCT05132829|Experimental|Azithromycin + control|perioperative azithromycin, cefazolin and indomethacin
89223873|NCT05126355|Experimental|On the Move|On the Move group exercise program to improve walking. Delivered twice per week for 12 weeks.
89069848|NCT04806958|Experimental|Conventional Emergency Dispatch PLUS PulsePoint notification|Eligible 911 calls randomized to the experimental arm of the study will undergo usual dispatch of emergency services personnel as per pre-existing local protocols and activation of the PulsePoint system. When triggered, the system will push location data to all PulsePoint mobile application users within 400 meters of the emergency. Devices receiving the alerts from the PulsePoint system will alarm with auditory, tactile and visual stimuli. The application will present a map showing the exact location of the emergency and the closest public access defibrillator.
89069849|NCT04806958|No Intervention|Conventional Emergency Dispatch|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures as per pre-existing local protocols (e.g. dispatch of emergency vehicles, attempted dispatch-assisted CPR) without activation of the PulsePoint system. 911 calls randomized to the control arm will not be associated with any PulsePoint alerts.
89069850|NCT04774224|Active Comparator|Baricitinib|Baricitinib is an oral JAK1/JAK2-selective inhibitor. Dosage: The dose of baricitinib is 1 x 4mg tablet once daily Duration of administration: 48 weeks Mode of administration: Orally, with or without food
89069851|NCT04774224|Placebo Comparator|Placebo|One placebo tablet once daily for a duration of 48 weeks. Placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
89069852|NCT04771858||Study Group|No intervention
89069853|NCT04761302|Experimental|Group 1: Intravenous Ketorolac and oral acetaminophen|Group 1 will be composed of patients receiving the following standard pain control protocol: ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group. Patients who determine pain to be unbearable and wish to opt out of the non-opioid group will receive may do so.
89069854|NCT04761302|Active Comparator|Group 2: Intravenous Morphine and oral oxycodone|Group 2 will be composed of patients receiving the following pain control protocol: morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
88812766|NCT01445873||PAH patients receiving Sitaxentan|
88812767|NCT03838328|Experimental|Dose group 1|The dose regimen of tranexamic acid in group 1 includes a loading dose of 30mg/kg before skin incision and a maintenance dose of 20mg/kg/hr until the end of the operation.
89069855|NCT04717557|Experimental|Hyperbaric Oxygen Plus Regular Care|Hyperbaric oxygen (2 hours at 2 atmospheres absolute) to be administered 1-2 times daily for up to 10 treatments after amputation. Usual care for patients with amputation will be administered in parallel.
89069856|NCT04717557|No Intervention|Regular Care|Usual care for patients with amputation.
89069857|NCT04702373|Experimental|Passive range-of-motion|daily assisted exercise sessions lasting 15-20 minutes, conducted by trained physical therapists, for up to 21 days prior to hospital discharge, plus standard of care
89069858|NCT04702373|No Intervention|Standard of care|standard of care at study site
89069859|NCT04695717|Placebo Comparator|Vaccine|Received two doses of IVACFLU-S vaccine intramuscularly in children aged 6 months to under 9 years old and one dose of IVACFLU-S vaccine in children from 9 years old to under 18 years old adult over 60 years old
89069860|NCT04695717|Other|Placebo|Received two doses of placebo intramuscularly in children aged 6 months to under 9 years old and one dose placebo in children from 9 years old to under 18 years old adult over 60 years old
89069861|NCT04687033|Experimental|Dual-tDCS & PT|"Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about~1 hour). The current intensity is fixed at 2 mA and the current will flow continuously. Physical therapist will give an intervention program for lower limb performance."
89069862|NCT04687033|Active Comparator|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, the current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performance.
89069863|NCT04630158|Placebo Comparator|SAF312 Placebo|Randomized to a 1:1:1 topical eye drops, twice daily
89069864|NCT04630158|Experimental|SAF312 dose 1|Randomized to a 1:1:1 topical eye drops, twice daily
89069865|NCT04630158|Experimental|SAF312 dose 2|Randomized to a 1:1:1 topical eye drops, twice daily
89069866|NCT04618185||p.Phe508del homozygous genotype|People with CF with 2 copies of p.Phe508del and previously eligible for Symkevi (Tezacaftor/Ivacaftor)
89069867|NCT04618185||p.Phe508del heterozygous genotype|People with CF with 1 copy of p.Phe508del and not previously eligible for any CFTR modulator
89069868|NCT04541004|Experimental|HDM SLIT Tablet|House dust mite (HDM) Sublingual allergy immunotherapy tablet
89069869|NCT04513041|Experimental|Pinhole/Tunnel|Participants will receive Pinhole surgical technique for treatment of soft tissue recession at one side of the mouth and Tunnel technique for treatment of soft tissue recession at the other side of the mouth
89069870|NCT04478240|Experimental|Intervention (access to PeerLearning.net)|Teachers and students in intervention schools will be given access to PeerLearning.net software for the purposes of instruction for the 2021-2022 school year.
89069871|NCT04478240|No Intervention|Passive Control (no intervention)|Teachers and students in control schools will conduct instruction as usual without PeerLearning.net.
89069872|NCT04466917|Experimental|ABP 215|"Subjects will be randomized to receive ABP 215 every 3 weeks (Q3W) for 6 cycles.~All subjects will receive carboplatin and paclitaxel after the ABP 215 IV infusion every Q3W for at least 4 and not more than for 6 cycles."
89069873|NCT04466917|Active Comparator|Bevacizumab|"Subjects will be randomized to receive Bevacizumab every 3 weeks (Q3W) for 6 cycles.~All subjects will receive carboplatin and paclitaxel after the Bevacizumab IV infusion every Q3W for at least 4 and not more than for 6 cycles."
89069874|NCT04444076|Experimental|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a bovine mesh that will be implanted following supraspinatus tendon repair.
89069875|NCT04444076|No Intervention|Standard of Care|Supraspinatus tendon repair.
89069876|NCT04422730||pancreatectomy in cancer patients|
89069877|NCT04422730||pancreatectomy in non-cancer patients|
89069878|NCT04422730||mastectomy|
89069879|NCT04422730||Acute leukaemia|
89069880|NCT04370483|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89069881|NCT04290091||Patients with CAD|Patients who have hemodynamically significant CAD.
89069882|NCT04290091||Patients without CAD|Patients who don't have hemodynamically significant CAD.
89069883|NCT04283656|Other|Period I|Sequence E, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone Sequence F, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone
89069884|NCT04283656|Other|Period II|Sequence E and F, Treatment B: Single-dose estradiol and spironolactone co-administered with placebo
89069885|NCT04283656|Other|Period III|Sequence E, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone Sequence F, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone
89069886|NCT04274374|Experimental|experimental arm|In the experimental arm will receive at least 6 gluten-free breads per day + 200 g of gluten-free penne pasta per week + 6 rice flavor capsules per day
89069887|NCT04274374|Active Comparator|control arm|the control arm will received 6 gluten-containing breads per day + 200 g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day
89069888|NCT04270630|No Intervention|Standard of care|Patients in the control arm of the study will undergo standard of care treatment, discussing catheterization with their treating physicians.
89069889|NCT04270630|Experimental|Shared decision aid|Patients in the interventional arm of the study will discuss catheterization with their treating physicians, in addition to having access to the shared decision aid tool and a shared decision conversation with a co-investigator clinician.
89069890|NCT04238624|Experimental|BRAF-mutant ATC|Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer
89069891|NCT04233385|Experimental|Myofascial Massage|Participants randomized to this group will receive 30 minutes of myofascial massage to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed 8 week protocol developed with a massage therapy consultant and the study team.
89069892|NCT04233385|Active Comparator|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months.
89069893|NCT04219709|Experimental|Very low carbohydrate diet|Dietary Intervention, food delivery
89069894|NCT04219709|Active Comparator|Standard diet|Dietary Intervention, food delivery
89069895|NCT04200391|Experimental|Very low carbohydrate diet|Dietary Intervention, food delivery
89069896|NCT04114422|Experimental|Seven-day preoperative exercise training program|All patients will undergo to seven-day preoperative exercise training program that includes aerobic and resistance exercises
89069897|NCT04106414|Experimental|Nivolumab alone|Nivolumab 480 mg every 4 weeks.
89069898|NCT04106414|Experimental|Nivolumab with IDO-inhibitor, BMS- 986205|Nivolumab 480 mg every 4 weeks with BMS-986205 100 mg.
89069899|NCT04091646|Active Comparator|Roflumilast Foam 0.3%|Participants apply roflumilast foam 0.3% once daily (QD) to all areas of seborrheic dermatitis once daily for 8 weeks.
89069900|NCT04091646|Placebo Comparator|Vehicle Foam|Participants apply inactive vehicle foam matched to roflumilast foam QD for 8 weeks.
89069901|NCT04090957|Experimental|Estetrol 15 mg - Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for up to 53 weeks.
89069902|NCT04090957|Experimental|Estetrol 20 mg - Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for up to 53 weeks.
89069903|NCT04090957|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for up to 53 weeks.
89069904|NCT04090957|Experimental|Estetrol 20 mg - Safety Part|Estetrol (E4) 20 mg will be administered orally once daily for up to 53 weeks.
89069905|NCT04086550|Experimental|Investigational arm|Application of LIQOSEAL after closure of dura mater
89069906|NCT04086550|Active Comparator|Control arm|Application of Adherus or DurSeal after closure of dura mater
89069907|NCT04081298|Experimental|Health services research (eHealth program)|Patients attend 6 online nutrition and PA education classes, cooking sessions, and participate in physical activities over 120 minutes each. Patients also receive text messages, electronic newsletters and have access to an interactive nutrition website.
89069908|NCT04063241|No Intervention|Parent: Pre-implementation|Parents in the pre-implementation group will receive standard care: verbal counseling by the doctor/nurse using text-based instructions they have prepared (not standardized).
89069909|NCT04063241|Experimental|Parent: Post-Implementation|Doctors and nurses will be able to customize the web-based disease-specific instructions with the research team's help. They will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
89069910|NCT04063241|Other|Provider|Baseline measures will be assessed for providers. They will then take part in a 20-minute training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data. At the end of the study, assessments will be performed for those who use the health literacy-informed tool at least once during the study period.
89069911|NCT04053335||Cohort 1: Multicomponent Physician Performance Peer-Comparison|"Cohort 1 (6 groups):~Inova/Signature Parters, Sentara/Sentara Quality Care Network, Ballad Health, Carilion Clinic, Health Care Associates Virginia/Virginia Care Partners, and Virginia and Commonwealth University Health System~Note that the original design for the intervention was a step-wedge randomization. However, this was changed due to the COVID-19 pandemic, which necessitated a delay in all study activities from March 2020 - September 2020. The intervention began in September 2020. Data collection concluded in December 2022."
89069912|NCT04053335||Cohort 2: Multicomponent Physician Performance Peer-Comparison|Cohort 2 (6 groups): Six comparable control health systems identified via matching
89069913|NCT04051541|Other|Simulation arm|All patients were entered into the Simulation arm and received 3 pushes of agitated saline via 3 different methods of delivery. All patients received all methods. The order of the methods for each patient was randomized.
89069914|NCT04047914|Experimental|experimental aPDT group|Application of 0.01% methylene blue with enough sterile swab to cover the inner nostril extension with a 10 minute pre-irradiation time. The irradiations were carried out with a red light-emitting diode (LED) (λ = 660 nm), for 300 seconds, irradiance of 400 mW / cm2, radiant exposure 124 J / cm2, with uniform application in each anterior nostril.
89069915|NCT04047914|Active Comparator|control mupirocin group|A standard treatment will be performed conventionally with topical mupirocin. Will be performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
89069916|NCT04042753|Experimental|Pituitary Cancer|Participants will have a pituitary adenoma/carcinoma of any histology
89069917|NCT04040933|Active Comparator|Marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
89069918|NCT04040933|Active Comparator|Marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed only on Days 3, 5, 7, 9, 11, 13, 15, and 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
89069919|NCT04040933|Active Comparator|Non-marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
89223874|NCT05126355|Other|On the Move - Delayed|Individuals in this arm will be placed on a wait-list for 12 weeks and will receive no intervention during this time. At the end of the 12 weeks they will receive the On the Move group exercise program. This is a wait-list control group.
89223875|NCT05122689|Experimental|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
89223876|NCT05122689|Placebo Comparator|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
89223877|NCT05117450|Active Comparator|HeprAN first|Each included patient will have hemodialysis sessions with HeprAN membrane and then HYDROLINK
89223878|NCT05117450|Active Comparator|HYDROLINK first|Each included patient will have hemodialysis sessions with HYDROLINK and then HeprAN membrane
89223879|NCT05104450|Experimental|lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention in addition to usual care.
89223880|NCT05104450|No Intervention|usual care control|Participants in this arm will continue with usual care without the lifestyle intervention.
89223881|NCT05102669||vaccinated|COVID19 vaccinated subjects
89223882|NCT05102669||non vaccinated|COVID19 non vaccinated subjects
89223883|NCT05099874|Experimental|EndeavorRx|Children will be asked to begin attentional control training at home within two weeks of baseline testing and to complete 6 training missions per day (25-30 minutes), 5 days per week, for 4 weeks (total = 120 training missions).
89223884|NCT05064098||Pre-Surgical Breast Cancer Patients|Adult female patients newly diagnosed with stage 0-III breast cancer seen as a surgical consultation from 06/01/2019 to present.
89223885|NCT05064098||Breast Cancer Survivors|Breast Cancer Survivors
89223886|NCT05063357|Other|Radioactive iodine-labeled monoclonal antibody omburtamab|Single arm
89223887|NCT05050448|Experimental|SAM Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
89223888|NCT05050448|Experimental|SAM2 Ultrasound Device and Diclofenac Patch|Patients receive treatment from the wireless SAM Ultrasonic Diathermy Device for 1 hour at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
89223889|NCT05050448|Placebo Comparator|Topical Pain-Relief Gel|Patients apply topical 1% diclofenac gel three times per day, at least 5 days per week for 8 weeks.
89223890|NCT05030935|Experimental|Intervention Group|This group will be able to use the mHealth App.
89069920|NCT04040933|Experimental|Non-marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
89069921|NCT04040933|Experimental|Non-marketed Adhesive Bandage #3|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
89069922|NCT04040933|Experimental|Non-marketed Adhesive Bandage #4|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
89069923|NCT04040933|Experimental|Non-marketed Adhesive Bandage #5|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
89069924|NCT04040933|No Intervention|No Treatment (Uncovered, Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as negative control.
89069925|NCT04030338||Prostate cancer|Participants with histologically confirmed prostate cancer, that is either newly diagnosed OR progressive as defined by standard PCWG3 criteria. Patients w ill remain on study until 30 days after their last PSMA imaging timepoint required by their companion therapeutic protocol.
89069926|NCT04026490|Experimental|Immediate intervention|The student will have a conversation with an Interventionist.
89069927|NCT04026490|Active Comparator|Waitlist intervention|These students will be approached for intervention for the months following the implementation of the immediate intervention group using the same procedures.
89223891|NCT05030935|No Intervention|Control group|The Instructions Manual consists of a hard copy of the mHealth App bibliographical content. In addition, a calendar that can be used as a reminder for patient position switching is present and a hard copy explanation of the scale which can be used by the caregiver and through handwriting, determine the need for support surfaces.
89223892|NCT05013385|Experimental|Spesolimab|
89223893|NCT05013385|Placebo Comparator|Placebo|
89223894|NCT04982198|Experimental|TKA assisted with ROSA® Knee System|TKA assisted with ROSA® Knee System
89069928|NCT04026477|Experimental|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Universal Trauma-Informed Care and Cultural Humility Training. After video and workshop training, staff will have ability to recognize trauma and racism and its impact on school procedures, practices, and children themselves. Staff will be able to apply core principles of cultural humility. Staff will examine their own cultural identity and how it influences their interactions and relationships with students of diverse cultural backgrounds (Principle 1). Staff will learn ways that privilege and oppression relate to their cultural identity and identify ways to flatten power hierarchies between themselves and students, including handling misbehavior from a trauma-informed, culturally humble perspective (Principle 2). Staff will problem-solve ways for their schools to be accountable for equitable discipline practices (Principle 3).
89069929|NCT04026477|Active Comparator|Waitlist Universal Trauma-Informed Care and Cultural Humility Training|All staff from waitlisted schools will receive Universal Trauma-Informed Care and Cultural Humility Training at the end of the waitlist period.
89069930|NCT04024956|Experimental|Sealing Device|Sealing Device applied in hepatic resection or distal pancreatectomy
89069931|NCT03995355|Experimental|Test Eye Drops|Eligible subjects that are non-contact lens wearers will be randomized to the Test group throughout the duration of the study.
89069932|NCT03995355|Active Comparator|Control Eye Drops|Eligible subjects that are non-contact lens wearers will be randomized to the Control group throughout the duration of the study.
89069933|NCT03995212|Active Comparator|CR845 1.0 mg|Oral CR845 1.0 mg tablet administered twice daily
89069934|NCT03995212|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
89069935|NCT03946618|Experimental|Epilepsy|Patients with dominant temporal lobe epilepsy and bilateral temporal lobe epilepsy
89069936|NCT03933397|Experimental|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home, what was needed during their past hospital and emergency department visits to treat pain and doses that have been effective and safe in the past.
89069937|NCT03933397|Experimental|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight.
89069938|NCT03925090|Experimental|Neoadjuvant and Adjuvant Toripalimab+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: Toripalimab Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT Other Names:anti-PD-1 antibody, JS001
89223895|NCT04982198|Active Comparator|TKA with conventional surgical instrumentation|TKA with conventional surgical instrumentation
89069939|NCT03925090|Placebo Comparator|Neoadjuvant and Adjuvant Placebo+CCRT|Drug: Cisplatin cisplatin 100mg/m2(every three weeks),D1,D22,D43 of intensity modulated radiotherapy Other Names: DDP Drug: placebo placebo 240mg every 2 weeks with a total of 2 cycles as neoadjuvant treatment; placebo 240mg every 3 weeks with a total of 8 cycles as adjuvant treatment 2 weeks after CCRT.
89069940|NCT03919266|Other|Control|usual antibiotic treatment
89069941|NCT03919266|Experimental|Intervention|targeted antibiotic treatment according to the results of PCR multiplex
89069942|NCT03913273|Experimental|Intervention group|Intervention: AMI transtibial amputation
89069943|NCT03913273|Active Comparator|Control group|Intervention: Standard transtibial amputation
89069944|NCT03899753|Experimental|2-Octyl Cyanoacrylate and mesh|The wound will be closed with 2-Octyl Cyanoacrylate and a mesh
89069945|NCT03899753|Active Comparator|2-Octyl Cyanoacrylate|The wound will be closed with just 2-Octyl Cyanoacrylate
89069946|NCT03896672|Experimental|Treatment with Continuous Positive Airway Pressure|All patients will undergo to physiotherapeutic treatment based on the previous training of the physiotherapist
89069947|NCT03829436|Experimental|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
89069948|NCT03829436|Experimental|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression.
89069949|NCT03829436|Experimental|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
89069950|NCT03829436|Experimental|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
89069951|NCT03827187|Experimental|Motor imagery based Brain computer interfacing|Brief assessment of motor imagery in response to command, auditory feedback training and responding to binary yes-no closed questions through Electroencephalography based Brain-computer interfacing.
89069952|NCT03825965|Experimental|MPL-001 (CBD: THC 25:1)|125mg CBD/5 mg THC oil for oral use
89069953|NCT03825965|Placebo Comparator|Placebo|Visually identical placebo (medium chain triglyceride oil)
89069954|NCT03790488|Experimental|JTX-4014|Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion
89069955|NCT03788434|Experimental|VE303 High Dose|Study subjects assigned the high dose VE303 arm took 10 capsules (dosage: 8.0 × 10^9 CFU daily) containing VE303 per day for 14 days.
89069956|NCT03788434|Experimental|VE303 Low Dose|Study subjects assigned to the low dose VE303 arm took 2 capsules (dosage: 1.6 × 10^9 CFU daily) containing VE303 per day for 14 days.
89069957|NCT03788434|Placebo Comparator|Placebo|Study subjects assigned to the placebo dose arm took placebo capsules each day for 14 days. The capsules did not contain any VE303.
89069958|NCT03767257|Experimental|Participants with Myeloma|Individuals with Myeloma on lenalidomide maintenance who experience grade 2 or more diarrhea
89069959|NCT03758261|Other|Erector Spinae Nerve Block|Erector Spinae nerve block
89069960|NCT03758261|Other|Paravertebral Nerve Block|Paravertebral nerve block
89069961|NCT03713268||Healthy (ocular health) participants|"Adult subjects with normal, ocular health will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system for reproducibility testing in humans, provide feedback to engineers, and verify that the system functions to produce high quality images of the desired areas of the eye after ex vivo development before surgical use.~Each healthy subject will be imaged by the MIOCT system. There will be no surgery or intervention on these healthy volunteer subjects. We anticipate that a portion of the volunteer subjects would have repeat imaging (e.g. for reproducibility testing)."
89223896|NCT04957641||Participants with HAE|Participants' data will be collected retrospectively from electronic medical records using chart review of de-identified data on participant demographics, HAE medical history and information on diagnostics, treatments and disease course assessments that are routinely performed in accordance with current guidelines and/or local standard of care which are entered into an Electronic data capture (EDC) system over multiple data collection waves up to 6 months.
89069962|NCT03713268||Surgeons as research subjects|Duke Eye Center surgical trainees (residents and fellows), attending surgeons, and surgeons from other medical institutions will be enrolled as subjects as we will test their performance with and without microscope integrated optical coherence tomography and with and without advances in 4D MIOCT in model surgeries in the research wet lab to better understand the utility of specific aspects and of this next generation MIOCT as a whole for specific anterior segment and retinal surgical tasks.
89069963|NCT03713268||Surgical patients|Adult and minor (> 4 months of age) surgical patients will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system during clinically indicated vitreoretinal and anterior segment surgical procedures.
89069964|NCT03710928|Experimental|very low carbohydrate diet|Dietary Intervention, food delivery
89069965|NCT03710928|Active Comparator|standard diet|Dietary Intervention, food delivery
89069966|NCT03689634|Experimental|Move For Surgery Preconditioning Program Intervention Group|
89069967|NCT03689634|No Intervention|Standard Preoperative Care Group|
89069968|NCT03672019||Patients Undergoing Percutaneous Biliary Drainage|Following Percutaneous Biliary Drainage (PBD), participants will complete Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
89069969|NCT03668977|No Intervention|Routine care|"In all four groups, the following antenatal and post-natal interventions will be offered:~Women encouraged to enroll in routine antenatal care at their local health post/center.~A clean birthing kit consisting of a clean blade, string, and plastic disc for cutting the cord, a plastic sheet, a bar of soap, and a tube of chlorhexidine ointment for application to the umbilical stump.~Women encouraged to deliver at a certified birthing facility and participate in the government's incentive scheme.~Nutritional, hygiene, and infant care counseling.~Tetanus toxoid (if needed) and iron-folic acid supplements."
89223897|NCT04956250|Experimental|Traffic Calming Curb Group|Traffic calming curbs are yellow concrete slabs designed by the City of Calgary to be the same height as other roadside curbs and improve safety by reducing the street width, similar to curb extensions.
89069970|NCT03668977|Experimental|Supplementation-pregnancy|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing throughout pregnancy. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
89069971|NCT03668977|Experimental|Supplementation-lactation|A daily fortified balanced protein-energy nutritional supplement beginning after delivery and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
89069972|NCT03668977|Experimental|Supplementation-pregnancy & lactation|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
89069973|NCT03642327|Active Comparator|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
88812768|NCT03838328|Experimental|Dose group 2|The dose regimen of tranexamic acid in group 2 includes a loading dose of 20mg/kg before skin incision and a maintenance dose of 15mg/kg/hr until the end of the operation.
89069974|NCT03642327|Experimental|Maintenance of Certification (MOC)|MOC involves a guided learning experience, approved by the American Board of Pediatrics and the American Board of Family Medicine for Maintenance of Certification credits. This involves a Quality Improvement project with 3 waves of data collection to assess and improve implementation while participating in 4 monthly webinars led by Dr. Dubowitz.
89069975|NCT03624881|Experimental|VISITAG SURPOINT Module with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
89111186|NCT02792595|Active Comparator|Positive Control|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, positive control will be applied. The dose of positive control will be measured in accordance to the application volume (2 milligram (mg)/centimeter (cm)^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Positive control will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 seconds (s). After waiting for 15 to 30 minutes (min), the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the SPF of positive control, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
89069976|NCT03594487|Experimental|Interventional FMT Treatment Arm|"After providing written informed consent, subjects will undergo screening and baseline assessments of stool and blood sampling, questionnaires, physical examination, MS rating scales, and MRI. Subjects will then initiate an oral antibiotic regimen for 5 days to precondition the gut for the Fecal Microbiota Transplantation (FMT) of FMP30 donor stool and optimize engraftment of the FMP30 donor stool microbiome. Following standard bowel preparation for colonoscopy, subjects will undergo the FMT procedure by an experienced gastroenterologist. Subjects will return for scheduled assessments and follow-up MRI for 12 weeks, with additional safety and biomarker follow-up for 36 weeks.~The active study time is designed to be short (12 weeks active phase) to minimize time not on other MS disease modifying therapy (DMT). This arm of the study will last for approximately 52 weeks total (4 weeks of screening + 12 weeks active treatment phase + 36 weeks of safety follow up)."
89069977|NCT03594487|Active Comparator|Observational Control Arm|"Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.~After providing written informed consent, subjects will undergo screening and baseline assessments, including collection of blood and stool samples, demographic data collection, concomitant medication review, and an MS Relapse assessment. At week 2, subjects will mail in stool samples with a prepaid air bill and packaging. Weeks 4, 8, and 12 assessments will include concomitant medication review, relapse assessment, and blood and stool collection.~The duration of the study for the observational control arm will last for 12 weeks. All study procedures will be performed at the University of California, San Francisco."
89069978|NCT03588975|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
89069979|NCT03588975|Active Comparator|microfracture|surgical procedure
89069980|NCT03573947|Experimental|nivolumab, ipilimumab and paclitaxel|
89069981|NCT03569449|Experimental|Group 1- Goat|Clinic-based visit, usual care, standard pediatric surveillance, and structured visits
89069982|NCT03569449|Experimental|Group 2- Cow|Clinic-based visit, usual care, enhanced pediatric surveillance, and structured visits
89069983|NCT03569449|Experimental|Group 3- Horse|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and structured visits
89069984|NCT03569449|Experimental|Group 4- Pig|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and structured visits
89069985|NCT03569449|Experimental|Group 5- Sheep|Clinic-based visit, usual care, standard pediatric surveillance, and individually-tailored visits
89069986|NCT03569449|Experimental|Group 6- Llama|Clinic-based visit, usual care, enhanced pediatric surveillance, and individually-tailored visits
89069987|NCT03569449|Experimental|Group 7- Cat|Clinic-based visit, technology-enhanced care coordination, standard pediatric surveillance, and individually-tailored visits
89069988|NCT03569449|Experimental|Group 8- Dog|Clinic-based visit, technology-enhanced care coordination, enhanced pediatric surveillance, and individually-tailored visits
89069989|NCT03569449|Experimental|Group 9- Donkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and structured visits
89069990|NCT03569449|Experimental|Group 10- Bear|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and structured visits
89069991|NCT03569449|Experimental|Group 11- Tiger|Clinic and community visits, technology enhanced care coordination, standard pediatric surveillance, and structured visits
89069992|NCT03569449|Experimental|Group 12- Lion|Clinic and community visits, technology enhanced care coordination, enhanced pediatric surveillance, and structured visits
89069993|NCT03569449|Experimental|Group 13- Monkey|Clinic and community visits, usual care coordination, standard pediatric surveillance, and individually-tailored visits
89069994|NCT03569449|Experimental|Group 14- Zebra|Clinic and community visits, usual care coordination, enhanced pediatric surveillance, and individually-tailored visits
88812769|NCT03838328|Active Comparator|Dose group 3|The dose regimen of tranexamic acid in group 3 includes a loading dose of 10mg/kg before skin incision and a maintenance dose of 10mg/kg/hr until the end of the operation.
89069995|NCT03569449|Experimental|Group 15- Elephant|Clinic and community visits, technology-enhanced care, standard pediatric surveillance, and individually-tailored visits
89069996|NCT03569449|Experimental|Group 16- Giraffe|Clinic and community visits, technology-enhanced care, enhanced pediatric surveillance, and individually-tailored visits
89069997|NCT03557697|Active Comparator|wait-list control|3 measurement visits, baseline, 3, and 6 months
89069998|NCT03557697|Active Comparator|SMS intervention|3 measurement visits, baseline, 3, and 6 months
89069999|NCT03548883||Alzheimer subject Group|In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.
89522895|NCT03388723||Arm 1: Discovery phase|"Approximately 150 women with Gestational Diabetes Mellitus (GDM) and 150 controls, and their offspring will be recruited in Pune (from KEM Hospital and Vadu). The objective will be:~Identification of epigenetic signatures~Measurements of B vitamins and 1-C metabolites in mothers' blood and cord blood~Glucose, insulin and lipids in mothers during pregnancy~Anthropometry and blood pressure"
89522896|NCT03388723||Arm 2: Validation phase|Approximately 200 women with Gestational Diabetes Mellitus (GDM) and 200 controls, and their offspring will be recruited in Punjab, and 150 stored cord blood samples of GDM offspring in Pune will be investigated to validate the epigenetic signatures discovered in Arm 1.
89070000|NCT03548883||Control Group|In phase II, up to 50 age, sex, race ethnicity, group matched healthy controls will be recruited and screened until we have 6 healthy control subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
89223898|NCT04956250|Experimental|In-Street Sign Group|In-street pedestrian signs are regulatory signs placed along the centre line of the street, to remind road users of a pedestrian right-of-way at the marked/unmarked crosswalk.
89229849|NCT02530723|Experimental|Twice a week|Group 2 will be invited to perform resistance training exercise 2 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
89070001|NCT03548883||Type 2 diabetes group|In phase III, up to 50 age, sex, race ethnicity, group matched T2D patients will be recruited and screened until we have 6 T2D subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
89070002|NCT03532880|Experimental|Participants with Small Cell Lung Cancer|
89070003|NCT03531957|Experimental|ASN002 40 mg|40 mg ASN002
89070004|NCT03531957|Experimental|ASN002 60 mg|60 mg ASN002
89070005|NCT03531957|Experimental|ASN002 80 mg|80 mg ASN002
89070006|NCT03531957|Experimental|Placebo Oral Tablet|Matching placebo for ASN002 doses
89070007|NCT03531255|Experimental|1,080 mg pegcetacoplan administered subcutaneously|1,080mg pegcetacoplan administered subcutaneously twice weekly or every three days.
89070008|NCT03473795||healthy participants and participants diagnosed with NCDs|This protocol will entail prospective collection of data on healthy participants and participants diagnosed with NCDs managed at collaborating institutions in SSA. Information to be obtained includes socio-demographic data, risk factors, disease-specific data, investigation and treatment details, as well as findings during follow-up. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. Follow-up data will be updated during clinic visits and also via phone calls.
89070009|NCT03450824||The study group|The participants with patellofemoral pain.
89070010|NCT03450824||The control group|The participants without patellofemoral pain.
89070011|NCT03446079|Experimental|Primary Subjects|Male or female subjects 21 or older that meet the specified inclusion/exclusion criteria taking genetic test and applying topical anti aging cream per the protocol.
89070012|NCT03435042|Experimental|Children with cancer + their siblings|
89070013|NCT03435042|Experimental|Parents of children with cancer|
89070014|NCT03428997|Experimental|Lotion|Test sites were patched with the lotion F #13451-131.
89070015|NCT03428997|Other|Negative Control|Test sites were patched with undosed occlusive patch.
89070016|NCT03313999|Other|Durometer Measurement|All patients participating in the study will receive standard of care treatment for their lymphedema. As part of the study they will be measured by the durometer in addition to other, standard diagnostics to further characterize their lymphedema progression.
89070017|NCT03252431|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
89070018|NCT03252431|Active Comparator|Neulasta|6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
89070019|NCT03234595|Experimental|single arm|There is 1 treatment arm with 4 dose cohorts in Phase I and 1 treatment arm in Phase IIa.
89070020|NCT03216486|Experimental|BPS804 Dose 1|BPS804 IV Infusion
89070021|NCT03207945|Experimental|Alirocumab|Patients randomized into the alirocumab arm will start off with 75 mg alirocumab administered every two weeks for two doses and will be upwardly titrated to 150 mg alirocumab if subjects demonstrate LDL ≥ 50 mg/dL at week 4. Subjects demonstrating LDL-C <50mg/dl will remain on the same 75mg dose throughout the trial.
89070022|NCT03207945|Placebo Comparator|Placebo|Patients randomized into the placebo arm will receive 75 mg or 150 mg or placebo administered once every two weeks throughout the trial
89070023|NCT03149757|Experimental|YouTHrive|YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
89070024|NCT03149757|Active Comparator|Thrive Tips|Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
89070025|NCT03134703|Experimental|Methadone Treatment Group|NAS infants treated for withdrawal symptoms with methadone
89070026|NCT03134703|Active Comparator|Comparison Group|NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
89070027|NCT03126851|Experimental|No age range / no explicit warning|Label: No age range and no explicit warning on front display panel of medication box.
89070028|NCT03126851|Experimental|age range / no explicit warning|Label: Age range present but no explicit warning on front display panel of medication box.
89070029|NCT03126851|Experimental|age range / explicit warning in words|Label: Age range present with explicit warning in words on front display panel of medication box.
89070030|NCT03126851|Experimental|age range / explicit warning+pictogram|Label: Age range present with explicit warning in words plus pictographic warning on front display panel of medication box.
89070031|NCT03118674|Experimental|Harvoni|1 tablet per day, oral, taken with or without food. 8 weeks for patients without cirrhosis, not previously treated with HCV GT1 and HCV rNA < 6 million IU/mL; 12 weeks for patients without cirrhosis; 24 weeks for patients with compensated cirrhosis
89522897|NCT03388723||Arm 3: Stability phase|"Approximately 500 offspring of women with Gestational Diabetes Mellitus (GDM) from Pune (~ half below 10 years and the rest over 10 years) will be investigated to study:~Stability of epigenetic signatures in offspring through childhood and adolescence~Relation of these signatures with phenotype"
89070032|NCT03085056|Experimental|Trametinib in Combination With Paclitaxel|Patients will receive paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
89070033|NCT03069352|Experimental|Venetoclax + Low Dose Cytarabine (LDAC)|Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
89070034|NCT03069352|Placebo Comparator|Placebo + LDAC|Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
89070035|NCT03037437|Experimental|No prior systemic treatment|Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
89070036|NCT03037437|Experimental|Progress on sorafenib|As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.
89070037|NCT03036488|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
89070038|NCT03036488|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline solution) Q3W + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by placebo + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
89070039|NCT03033927||Participants with Stage IV Pancreatic Cancer|
89070040|NCT03006315||Cohort A: <65 years|Cohort A will be comprised of participants <65 years old and will accrue a total of 20 patients.
89070041|NCT03006315||Cohort B: >/= 65 years|Cohort B will be comprised of participants >/= 65 years and will accrue a total of 20 patients.
89070042|NCT02993523|Placebo Comparator|Group 1 and Group 2: Placebo + Azacitidine 75 mg/m^2|Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax-matching placebo, orally, every day (QD), from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m^2, subcutaneously (SC) or intravenously (IV), QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
89070043|NCT02993523|Active Comparator|Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2|Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax 100 mg, once orally, on Day 1 of Cycle 1 followed by venetoclax 200 mg, once orally, on Day 2 of Cycle 1 and venetoclax 400 mg, orally, QD, on Day 3 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
89070044|NCT02993523|Active Comparator|Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2|Participants received venetoclax 400 mg, orally, QD, from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m^2, SC, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).
89070045|NCT02957058|Active Comparator|SERT 0, SCAR (low risk)|Patients with Sydney EMR Recurrence Tool (SERT scoring) score 0. These patients will be invited to return for follow up at 18 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
89070046|NCT02957058|Active Comparator|SERT 1-4, SCAR (high risk)|Patients with Sydney EMR Recurrence Tool score 1-4 (SERT scoring). These patients will be invited to return for follow up at 4-6 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
89070047|NCT02905617||Primary Augmentation|Subjects undergoing general breast enlargement receiving Sientra Style 207 Silicone Gel Breast Implant.
89070048|NCT02905617||Revision Augmentation|Subjects undergoing revision surgery with Sientra Style 207 Silicone Gel Breast Implant to revise or improve the result of a primary breast augmentation surgery.
89070049|NCT02884219|Active Comparator|Early Treatment with cyclooxygenase inhibitors|Treatment of PDA that starts within the first 3 days of life using cyclooxygenase-inhibitors (Ibuprofen or Indomethacin)
89070050|NCT02884219|Sham Comparator|Expectative Treatment|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
89070051|NCT02795429|Experimental|Phase Ib: Capmatinib 200 mg BID + Spartalizumab 300 mg Q3W|Capmatinib 200 mg administered orally on a continuous twice daily (BID) dosing schedule in combination with spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase Ib
89070052|NCT02795429|Experimental|Phase Ib: Capmatinib 300 mg BID + Spartalizumab 300 mg Q3W|Capmatinib 300 mg administered orally on a continuous twice daily (BID) dosing schedule in combination with spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase Ib
89070053|NCT02795429|Experimental|Phase Ib: Capmatinib 400 mg BID + Spartalizumab 300 mg Q3W|Capmatinib 400 mg administered orally on a continuous twice daily (BID) dosing schedule in combination with spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase Ib
89070054|NCT02795429|Experimental|Phase II: Capmatinib 400 mg BID + Spartalizumab 300 mg Q3W|Capmatinib 400 mg administered orally on a continuous twice daily (BID) dosing schedule in combination with spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase II
89070055|NCT02795429|Experimental|Phase II: Spartalizumab 300 mg Q3W|Spartalizumab 300 mg administered intravenously once every 3 weeks (Q3W) in Phase II
89229850|NCT02530723|Experimental|Thrice a week|Group 3 will be invited to perform resistance training exercise 3 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
89070056|NCT02792114|Experimental|T-cell infusion|A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined & can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via intravenous catheter or central line (i.e., mediport). Patients will be monitored in the hospital and discharged home after a minimum of 48 hours. Patients will be monitored closely as outpatients for the next 2 months. Patients will be followed weekly as outpatients for the first 8 weeks after treatment. All patients will be hydrated intravenously, premedicated with acetaminophen & diphenhydramine, & administered cyclophosphamide at 1.5 g/m2 2 to 7 days (Day -7 to Day -2) before administration of mesothelin-targeted T cells.
89070057|NCT02783625|Experimental|Romidepsin + duvelisib|Romidepsin/duvelisib: Cycle 1 and beyond Days 1, 8, 15* Romidepsin IVPB over 4 hours, days 1, 8, 15 duvelisib by mouth twice daily, days 1-28
89070058|NCT02783625|Experimental|Bortezomib + duvelisib|Bortezomib/duvelisib: Cycle 1 and beyond Days 1, 4, 8, and 11* Bortezomib subcutaneous injection, days 1, 4, 8, 11** duvelisib by mouth twice daily, days 1-28
89070059|NCT02605486|Experimental|Palbociclib in Combination with Bicalutamide|This is a non-randomized, open-label, phase I/II trial for patients with AR(+) MBC . There will be a dose finding phase I portion of the study to establish the recommended phase II dose (R2PD). This will be followed by a phase II where efficacy is evaluated. Patients with AR(+)ER(-) breast cancer treated on the phase I at the recommended phase II dose will be counted towards the primary endpoint analysis for the phase II study.
89070060|NCT02552186|Active Comparator|Pectus Excavatum Group|The first group (PE Group) will consist of patients presenting to the All Children's Hospital Johns Hopkins Medicine (ACH JHM) Pediatric Surgery or Cardiac Surgery Clinics and the outpatient clinic system at Johns Hopkins Hospital for evaluation of pectus excavatum. Clinical measurements will be obtained using calipers.
89070061|NCT02552186|No Intervention|Control Group|The second group (Control Group) will be age and gender matched patients presenting to the Radiology department of ACH JHM undergoing CT chest for indications other than chest wall deformity.
89522898|NCT03125785||contact lens and eye drops|Contact lenses collected from patients that have used eye drops containing dexamethasone and benzalkonium chloride for a set period of time and set dosage after surgery
88812770|NCT03838406|Experimental|BRCA1 positive|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
88812771|NCT03838406|Active Comparator|BRCA1 negative|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
89070062|NCT02538198|Experimental|Lenalidomide|Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
89070063|NCT02507141||SCC of the oral cavity scheduled for surgery|The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.
89070064|NCT02484287|Active Comparator|Integra External Drainage Catheter|The Integra External Drainage Catheter non antibiotic-impregnated EVD catheter
89070065|NCT02484287|Active Comparator|Ventriclear EVD Antibiotic Catheter|The Ventriclear EVD Antibiotic Catheter antibiotic-impregnated EVD catheter
89070066|NCT02484287|Active Comparator|Codman Bactiseal EVD Catheter Set|The Codman Bactiseal EVD Catheter Set antibiotic-impregnated EVD catheter
89070067|NCT02341144|Active Comparator|Pre-op percutaneous rectus sheath block|ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist
89070068|NCT02341144|Active Comparator|Intra-operative rectus sheath block|rectus sheath block with ropivacaine under direct visualization by the attending surgeon
89070069|NCT02301767||women that are diagnosed with breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
89070070|NCT02301767||women at high risk of breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
89070071|NCT02213328|Experimental|Truvada|All participants will take Truvada, once daily by mouth for the first 12 weeks of the study. After Week 12 of the study, only participants who indicate a willingness to use Truvada PrEP and who do not have any medical reasons not to do so will continue to receive the Truvada tablets through Week 52.
89070072|NCT02204241|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16."
89070073|NCT02200250||Post Barretts Excision|Patients who have undergone an EMR for Barretts Oesophagus
89070074|NCT02198729|Active Comparator|Endoscopic Mucosal Resection|Participants randomised to this arm will receive standard of care Endoscopic Mucosal Resection for removal of their lesions.
89070075|NCT02198729|Experimental|Endoscopic Submucosal Dissection|Participants randomised to this arm will receive Endoscopic Mucosal Dissection to remove their lesion.
89070076|NCT02185820|Experimental|1|"Treatment schedule for 8 cycles of induction:~Carfilzomib = 20 mg/m2 IV once daily on days 1 of cycle 1 only followed by 27/36/45/56 mg/m2 days 8, 15 in cycle 1, then for all subsequent doses 27/36/45/56 mg/m2 IV once daily on days 1, 8, 15 followed by 13-day rest period (day 16 through 28).~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22 every 28 days.~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib = at the MTD achieved in the phase I of the study on days 1, 8, 15 in 28-days cycles.~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22."
89070077|NCT02150967|Experimental|BGJ398 (infigratinib)|To estimate the anti-tumor activity of BGJ398 (infigratinib)
89070078|NCT02137603|Experimental|Fast track|Patients discharged home the same day following appendectomy
89070079|NCT02137603|No Intervention|Admission|Patients are admitted to the inpatient unit following appendectomy for suppurative appendicitis and treated per the current standard of care.
89070080|NCT02127398|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
89070081|NCT02085408|Active Comparator|A (Induction:daunorubicin/cytarabine; consolidation:cytarabine; maintenance:observation/transplant)|See Detailed Description
89070082|NCT02085408|Experimental|B (Induction: clofarabine; Consolidation: clofarabine; Maintenance: decitabine or transplant)|See Detailed Description
89070083|NCT02004782|Active Comparator|Prenisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
89070084|NCT02004782|Placebo Comparator|Placebo|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
89070085|NCT01908777|Experimental|high dose chemo w/asct + maintenance txt|High dose chemotherapy (Carmustine), VP-16 (etoposide, Vepesid®), Cytarabine (Ara-C), Melphalan (Alkeran)with autologous stem cell transplant followed by maintenance therapy with Romidepsin (Istodax)
89229851|NCT02530723|No Intervention|wait-control|Participants in this group will serve as controls prior to participating in power training in 1 of the above treatment groups. The control period will last as long as the exercise period, or 3 months. Controls will participate in the same testing time points as the exercisers (baseline, midpoint, and post-intervention).
89229852|NCT00387790|Experimental|Arm I|Patients receive motexafin gadolinium IV over 5-10 minutes once daily (prior to radiotherapy) 5 days a week for 6 weeks. Patients undergo focal cranial radiotherapy once daily 5 days a week for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89229853|NCT00073021|Active Comparator|Asacol 2.4 g/day|Asacol (2.4 g/day)
89229854|NCT00073021|Experimental|Asacol 4.8 g/day|Asacol (4.8 g/day)
89070086|NCT01892397|Experimental|Optune (NovoTTF-100A)|The treatment plan is to have patients use the Optune device in monotherapy for ≥ 18 hours per day as per the treatment standard established from prior studies. A medical professional will see each patient at least once per month while on the device for toxicity assessment, compliance evaluation via downloading of the log-file on the device by the Novocure technician (which involves the technician simply attaching the device to a computer via USB where software reads how many hours per day on each day the device was used), and physical examination. Extent of disease evaluations will occur at baseline, 8 weeks, and then every 8 weeks thereafter. These evaluations will include MRI of the brain with and without contrast and perfusion (or CT head if a patient cannot undergo MRI).
89070087|NCT01873326|Experimental|Paclitaxel, Ifosfamide and Cisplatin (TIP)|"Paclitaxel 120 mg/m2 IV over 120-180 min Days 1 and 2 (+/- 4 days)* Mesna 120 mg/m2 IV (duration of infusion per institutional guidelines) approximately 30 minutes prior to initiation of ifosfamide Days 1-5 (+/- 4 days)* Ifosfamide 1200 mg/m2 IV over approximately 60 to 120 min Days 1-5 or per institutional guidelines (mixed 1:1 with mesna) (+/- 4 days)* Mesna** 1200 mg/m2 IV over approximately 60-120 min or per institutional guidelines (mixed 1:1 with ifosfamide)(+/- 4 days)* Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)*~**Additional mesna may be given at the discretion of the investigator~*Paclitaxel or Ifosfamide or Mesna or Cisplatin or any combination of these agents can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
88812772|NCT01525667|Experimental|150M PLX-PAD|Single course, multiple IM injections
88812773|NCT01525667|Experimental|300M PLX-PAD|Single course, multiple IM injections
88812774|NCT01525667|Placebo Comparator|Placebo|Single course, multiple IM injections
89070088|NCT01873326|Active Comparator|Bleomycin, Etoposide and Cisplatin (BEP)|"Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)* Etoposide 100 mg/m2 IV over approximately 1 hour Days 1-5 (+/- 4 days)* Bleomycin 30 U flat dose IV push Days 2, 8 and 15 (all +/- 4 days)~*Etoposide or Cisplatin or both can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
89070089|NCT01862315|Experimental|No prior chemo or responded/stable with prior chemo|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day30} pump flow rate) on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
89070090|NCT01862315|Experimental|patients who have failed systemic therapy|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day 30}/ pump flow rate) on day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
89229855|NCT01583725|Experimental|Roux-en-Y Gastric Bypass|30 subjects who plan to undergo Roux-en-Y Gastric Bypass bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
89070091|NCT01862315|Experimental|pts who have had prior oxaliplatin & have existing neuropathy|All patients receive will receive gemcitabine alone with HAI FUDR/Dex Gemcitabine (800 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
89070092|NCT01854151|No Intervention|Standard Practice|Parents whose children are prescribed medication and meet inclusion/exclusion criteria will fill their medication at their regular pharmacy and receive medication with labeling and dosing instruments as per routine
88812775|NCT01831310|Active Comparator|Control (standard) (Kabiven)|an isocaloric and iso-nitrogenous standard parenteral nutrition (Kabiven)
89070093|NCT01854151|Experimental|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication and meet inclusion/exclusion criteria will receive medications with health literacy informed labels and dosing instruments
89070094|NCT01806558|Experimental|Women with lesion on MBI|Women with lesion on MBI
89070095|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone + stem cell|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.
89070096|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone Alone|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.
89070097|NCT01737567|Experimental|Bright Narrow Band Imaging|Use of B-NBI to detect colonic adenomas.
89070098|NCT01737567|Active Comparator|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
89070099|NCT01483664||initial survivorship planning consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
89229856|NCT01583725|Experimental|Gastric Banding (Lap-band)|30 subjects who plan to undergo Gastric Banding bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
89070100|NCT01483664||initial wellness rehabilitation consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
89070101|NCT01475786|Active Comparator|Low Dose 16mg Engensis (VM202) and Placebo|intramuscular injections in each calf for a total of 16mg Engensis (VM202): Day 0 - 32 injections / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) and 16 injections of normal saline 0.5mL / calf Day 14 - 32 injections / calf and 16 injections of normal saline 0.5mL / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
89070102|NCT01475786|Active Comparator|High Dose 32mg Engensis (VM202)|Day 0 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) For a total of 32mg VM202
89070103|NCT01475786|Placebo Comparator|Control - Placebo (normal saline)|32 injections / calf of 0.5 mL normal saline at Day 0 and Day 14
89070104|NCT01372696|Other|Tissue sample|Patients who consent to participate in this study will have a small sample of their polyp and normal tissue sent for molecular testing.
89070105|NCT01369316|Experimental|Circumferential Submucosal Incision Resection|
89070106|NCT01369316|Active Comparator|Endoscopic Mucosal Resection|Patients randomised into this arm will receive the conventional treatment Endoscopic Mucosal Resection in which the sessile lesion is injected and snared by piecemeal technique.
89070107|NCT01368289||Colonic Polyps|Patients who present with colonic polyps >20mm
89070108|NCT01290692|Experimental|TVI-Brain-1|All patients will receive the full TVI-Brain-1 treatment.
89070109|NCT00996866|Placebo Comparator|Placebo|Half of subjects will be randomized to the placebo group.
89070110|NCT00996866|Active Comparator|Vitamin D3|This is the study group that receives Vitamin D supplementation.
89070111|NCT00876993|Experimental|Dose Level 0|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 75 mg/m^2 PO
89070112|NCT00876993|Experimental|Dose Level 1|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 125 mg/m^2 PO
89070113|NCT00876993|Experimental|Dose Level 2|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 175 mg/m^2 PO
89070114|NCT00876993|Experimental|Dose Level 3|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 200 mg/m^2 PO
89070115|NCT00876993|Experimental|Dose Level 4|Bevacizmuab 10 mg/kg IV Irinotecan 150 mg/m^2 IV Temozolomide 200 mg/m^2 PO
89070116|NCT00700882|Experimental|Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89070117|NCT00673309|Experimental|Growth Hormone|Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
89070118|NCT00673309|Experimental|Insulin High Dose|Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
89070119|NCT00673309|Experimental|Oxandrolone|Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
89070120|NCT00673309|Experimental|Propranolol|Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
89070121|NCT00673309|Experimental|IGF-1/IGFBP-3|IGF-1/IGFBP-3 will be administered until 95% wound healing
89070122|NCT00673309|Experimental|Insulin Low Dose|Insulin Low Dose will be administered until 95% wound healing.
89070123|NCT00673309|Experimental|Itraconazole|Itraconazole will be administered until 95% wound healing.
89070124|NCT00673309|Experimental|Growth Hormone and Propranolol|Growth Hormone and Propranolol will be administered until 95% wound healing.
89070125|NCT00673309|Experimental|Oxandrolone and Propranolol|Oxandrolone and Propranolol will be administered until 95% wound healing
89070126|NCT00673309|Placebo Comparator|Control/Placebo|Placebo or Control will be administered until 95% wound healing
89070127|NCT00666835|Experimental|HX575 epoetin alfa Hexal AG|Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
89070128|NCT00666835|Active Comparator|ERYPO®, Janssen-Cilag|Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
89070129|NCT00588068||1|Tumor and Marrow Markers
89229857|NCT01583725|Experimental|Formula Diet Weight Loss|30 subjects who plan to begin a formula diet to lose weight. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before subjects undertake a 12-week weight loss intervention (T1), at the end of the weight loss intervention (T2) and 18 months after they completed the weight loss intervention(T3).
89229858|NCT01583725|Experimental|No Treatment|30 subjects who do not undergo any treatment for weight loss. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed at baseline (T1) and at 3 months (T2) and 18 months (T3) later.
89070130|NCT00551759|Experimental|Neoadjuvant therapy, Surgery, adjuvant therapy|"Neoadjuvant chemoradiotherapy and cetuximab: Patients (pts) receive oxaliplatin IV over 2 hours on days 1, 15, and 29, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, and 5-FU IV over 24 hours on days 1-35. Pts also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Pts then proceed to surgery.~Surgery: Pts undergo surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab. Pts with an R0 or R1 resection proceed to adjuvant therapy. Pts whose tumors have not been completely resected or who have metastatic disease discontinue protocol therapy and receive further therapy at the discretion of the treating physician.~Adjuvant therapy: Within 4-8 weeks after surgery, pts receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
89070131|NCT00335140|Experimental|Rituximab + standard chemotherapy|Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.
89070132|NCT00304239|Experimental|Metvix-PDT|Participants received Metvix-PDT (methyl aminolevulinate hydrochloride-Photodynamic therapy) 160 milligrams per gram (mg/g) cream on face and/or scalp for 3 hours on Day 0 and Day 7.
89070133|NCT00304239|Placebo Comparator|Vehicle-PDT|Participants received Vehicle cream (Vehicle-PDT) on face and/or scalp for 3 hours on Day 0 and Day 7.
89070134|NCT00101283|Experimental|Pemetrexed/Carboplatin|Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to area under the curve (AUC) 5 IV over 30 minutes on day 1 of a 21-day cycle.
89070135|NCT00101283|Experimental|Pemetrexed/Gemcitabine|Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
89070136|NCT01302041|Experimental|Enzalutamide|Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.
89070137|NCT01301729|Experimental|Trastuzumab|Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m^2), every 3 weeks or paclitaxel 90 mg/m^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.
89070138|NCT05643677|Experimental|Fruquintinib combined with irinotecan|Fruquintinib combined with irinotecan as a second-line treatment for advanced gastric cancer
89070139|NCT01187043|Experimental|ARM 1|1 mg Proellex
89070140|NCT01187043|Experimental|ARM 2|3 mg Proellex
89070141|NCT01187043|Experimental|ARM 3|6 mg Proellex
89070142|NCT01187043|Experimental|ARM 4|9 mg Proellex
89070143|NCT01187043|Experimental|ARM 5|12 mg proellex
89070144|NCT02890589|Experimental|SYNERGY Stent|The SYNERGY™ stent is a Device marked CE (European Conformity), platinum chromium coronary stent, currently developped by Boston Scientific™. This stent has been designed with the goal of providing optimal and rapid healing within the vessel using a bioabsorbable polymer to elute everolimus.
89070145|NCT02890589|Experimental|BVS device|The ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold (BVS 1.1, Abbott Vascular, California, USA, CE approved) is Device marked CE, currently the most studied PLA (Polylactic acid) based scaffold. It consists of PLLA (Poly I-lactic acid) backbone with 1:1 PDLLA (Poly-DL Lactic Acid) drug surface coating and a total strut thickness of 156 μm.
89070146|NCT05357001|Experimental|Connective tissue manipulation|technique to remove muscle spasticity
89070147|NCT05357001|Experimental|stretching exercise|exercises to remove muscle spasticity
89070148|NCT05643521|Experimental|Control Arm|2 days of eucaloric control diet prior to MRS estimating liver fat (control arm)
89070149|NCT05643521|Experimental|Hypocaloric low carbohydrate|2 days of eucaloric control diet + 2 days of hypocaloric (500-600 kcal m/f) low carbohydrate diet prior to liver fat estimated by MRS and metabolic testday.
89070150|NCT05643521|Experimental|Eucaloric low carbohydrate|2 days of eucaloric control diet + 2 days of eucaloric low carbohydrate diet prior to liver fat estimated by MRS and metabolic testday.
89070151|NCT05643443|No Intervention|Control Group|Control Group
89070152|NCT05643443|Experimental|Active Group|Active Group
89070153|NCT01186809|Experimental|Cytokine Induced Killer|Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
89070154|NCT05367713||patients having had an osteitis of the cranial flap after craniectomy|
89070155|NCT00623519||1|Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole
89070156|NCT05643053|Experimental|thomas fixation|
89070157|NCT05643053|Experimental|elastic band|
89070158|NCT05643053|Experimental|normal fixation adhesive tape|
89070159|NCT05643053|Experimental|reinforced adhesive tape fixation|
89070160|NCT01186419|Experimental|SPD602 (16mg)|
89070161|NCT01186419|Experimental|SPD602 (32mg)|
89070162|NCT01301027|Active Comparator|Pioglitazone|15 mg/day pioglitazone for 2 weeks, then 30 mg/day for remaining 24 weeks
89070163|NCT01301027|Placebo Comparator|Placebo|1 placebo pill a day matching the pioglitazone treatment for 26 weeks
89070164|NCT01185639|Experimental|SBRT for metastatic NSCLC|SBRT for lung lesions, liver lesions, adrenal lesions, spinal lesions
89070165|NCT04207385|Active Comparator|A group: Routine treatment group|Routine dosage of venlafaxine during the first 4 weeks.
89070166|NCT04207385|Experimental|B group: PGx-guided group|The PGx test results guide the dosage of venlafaxine during the first 4 weeks.
89070167|NCT04207385|Active Comparator|C group: Routine PGx-guided group|The PGx test results guide the dosage of venlafaxine between 4th and 8th weeks.
89070168|NCT04207385|Active Comparator|D group: The combination of PGx and TDM group|The PGx and TDM test results guide the dosage of venlafaxine between 4th and 8th weeks.
89070169|NCT01185561|No Intervention|Usual medical care|Participants assigned to this arm represent the control group and will receive usual medical care only.
89070170|NCT01185561|Experimental|Psychoeducational intervention|Participants assigned to this arm represent the experimental group and will receive group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes
89070171|NCT02887209|Experimental|CBT-I|This is a single arm study in which all participants receive the intervention (cognitive behavioural therapy for insomnia)
89070172|NCT05367557||Group A|pneumoperitoneum pressure of 12 mmHg
89070173|NCT05367557||Group B|pneumoperitoneum pressure of 8 mmHg
89070174|NCT01185249|Experimental|Body weight taken in a standing position|Subjects will be weighed in the early morning, as standard of care dictates. They will also be weighed after evening medications are given, around 9pm. The evening weight is not standard, therefore considered the study intervention.
89070175|NCT05641883|Experimental|Experimental|All eligible patients that are enrolled with receive the CardiaMend patch soaked in amiodarone
89070176|NCT02886897|Experimental|D-CIK and anti-PD-1 Immunotherapy|D-CIK was incubated with anti-PD-1 antibody before infused back into participants
89070177|NCT05619497|Active Comparator|Care Post Clinic-Wide Trainings|Participants in this arm will receive care in a clinic where providers and staff have been trained in shared decision making and trauma-informed care. Participants in this arm will not view the decision support tool in this phase.
89070178|NCT05619497|Experimental|Care Post Clinic-Wide Training and HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive care in a clinic where providers and staff have been trained in shared decision making and trauma informed care, and receive the HIV prevention DST intervention immediately before their provider visit.
89070179|NCT05619497|No Intervention|Standard Care without the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma-informed care. These participants also will not have viewed the HIV prevention DST. These participants were recruited in Aim 1 of this study.
88812776|NCT01831310|Experimental|Standard parenteral-glutamine (S-D)|alanine-glutamine (aln-gln) (Dipeptiven) supplemented parenteral nutrition (S-D group, n=8),
88812777|NCT01831310|Experimental|Standard-Omega-3 fatty acid (S-O)|Omega-3 fatty acid (Omegaven) supplemented parenteral nutrition (S-O group, n=8)
89070180|NCT05619497|Active Comparator|Standard care with the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma-informed care. These participants will view the HIV prevention DST. These participants were recruited in Aim 1 of this study.
89070181|NCT01184859|Experimental|Desmopressin 10µg|Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.
89070182|NCT01184859|Experimental|Desmopressin 25µg|Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.
89070183|NCT01184859|Experimental|Desmopressin 50µg|Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.
89070184|NCT01184859|Experimental|Desmopressin 100µg|Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.
89070185|NCT01184859|Placebo Comparator|Placebo|Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.
89070186|NCT00623675|Experimental|A|
89070187|NCT02890511|Experimental|DHP107(Oral paclitaxel)|"Phase I (determining MTD) The patients diagnosed with either advanced or metastatic solid cancers were enrolled. The administered dose was escalated in a step-wise manner by an increment of 2 x 50 mg/m2 at each dose level. Three patients were treated for toxicity evaluation for each dose level.~Phase IIa (efficacy evaluation) The safety and efficacy of the corresponding dose was investigated more closely by increasing the patient number to 6 or more patients in the dose tentatively determined as recommended dose for phase IIa clinical trial."
89070188|NCT05609981|Other|Intervention|The intervention at t=0 consists of a 5-step patient-centred CMR focused on deprescribing supported by a toolbox provided to the pharmacists
89070189|NCT05609981|No Intervention|Control|Usual care.
89070190|NCT01184079|Experimental|12 months|Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine
89070191|NCT01184079|Active Comparator|6 month|Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine
89070192|NCT04316403|Experimental|Laser-assisted corticotomy|Er:YAG laser beam was used to perform several perforations to the alveolar bone around the canine in one side of the mouth hoping that would accelerate canine retraction
89070193|NCT04316403|No Intervention|Traditional treatment|Canines in this group were retracted by the conventional manner.
89070194|NCT05340699|Experimental|experimental group|A group of children wearing Xingyouxue Defocus Distributed Multi-point lens
89070195|NCT05340699|Active Comparator|control group|A group of children wearing single vision lens
89070196|NCT04316325||Women and girls seeking abortion.|
89070197|NCT01190865|Other|HP802-247|Assessment Duration = 8 days Assessment Duration = 15 days Assessment Duration = 22 days Assessment Duration = 29 days Assessment Duration = 31 days Assessment Duration = 43 days Assessment Duration = 50 days Assessment Duration = 57 days
88812778|NCT01831310|Experimental|Standard-glutamine-omega 3 (S-D-O)|ala-gln and omega 3 fatty ascid supplemented parenteral nutrition (S-D-O group, n=10).
89070198|NCT01190475|Experimental|BGS649 high dose|1 BGS649 1.0mg capsule with three 0.1 mg placebo capsules.
89070199|NCT01190475|Experimental|BGS649 low dose|1 BGS649 1.0 mg placebo capsule and 3 BGS649 0.1 mg capsules
89070200|NCT01190475|Placebo Comparator|Placebo to BGS649|1 matching placebo 1.0mg matching and three matching 0.1 mg placebo capsules
89070201|NCT01289990|Experimental|BI 10773 low (drug naive)|BI 10773 tablets once daily
89070202|NCT01289990|Experimental|BI 10773 high (drug naive)|BI 10773 tablets once daily
89070203|NCT01289990|Placebo Comparator|Placebo (drug naive)|Placebo tablets matching BI 10773 / Sitagliptin once daily
89070204|NCT01289990|Active Comparator|Sitagliptin 100mg (drug naive)|Sitagliptin once daily
89070205|NCT01289990|Experimental|BI 10773 low (pioglitazone)|BI 10773 tablets once daily
89070206|NCT01289990|Experimental|BI 10773 high (pioglitazone)|BI 10773 tablets once daily
89070207|NCT01289990|Placebo Comparator|Placebo (pioglitazone)|Placebo tablets matching BI 10773 once daily
89070208|NCT01289990|Experimental|BI 10773 low (metformin)|BI 10773 tablets once daily
89070209|NCT01289990|Experimental|BI 10773 high (metformin)|BI 10773 tablets once daily
89070210|NCT01289990|Placebo Comparator|Placebo (metformin)|Placebo tablets matching BI 10773 once daily
89070211|NCT01289990|Experimental|BI 10773 low (metformin+sulfonylurea)|BI 10773 tablets once daily
89070212|NCT01289990|Experimental|BI 10773 high (metformin+sulfonylurea)|BI 10773 tablets once daily
89070213|NCT01289990|Placebo Comparator|Placebo (metformin+sulfonylurea)|Placebo tablets matching BI 10773
89070214|NCT04206345|Experimental|Blood Flow Restriction Group|Elbow bending exercises with resistance exercise band (%20 of 1 maximum repetition) for one session. Blood flow restriction band will be placed during exercise session. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
89070215|NCT04206345|Experimental|Exercise Group|Elbow bending exercises with resistance exercise band (%70 of 1 maximum repetition) will be performed for one session.
89070216|NCT04206345|No Intervention|Control Group|10 minutes resting period will be given between evaluation.
89070217|NCT02886975|Experimental|low protein diet plus α-keto acid|A comparison of normal diet and low protein diet plus α-keto acid after intervention in the same individual
89070218|NCT01190007|Experimental|Caduet|
89070219|NCT01189461|Experimental|pegaptanib sodium arm|all patients will receive pegaptanib sodium
89522899|NCT03125785||contact lens and no eye drops|Contact lenses used for the same period of time collected from a control group that has had no surgery and no eye drops in combination with their contact lenses.
89070220|NCT01189227|Experimental|Arm 1: Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
89070221|NCT01189227|Experimental|Arm 2: Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
89070222|NCT01300247|Experimental|Obinutuzumab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6), fludarabine (25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6), and cyclophosphamide (250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6).
89070223|NCT01300247|Experimental|Obinutuzumab + Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6) and bendamustine (90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6).
89070224|NCT02890277|Experimental|Treatment group|
89070225|NCT01289678|Experimental|interleukin-2|interleukin-2 therapy during lymphocyte recovery
89070226|NCT02886741|Other|Quality Improvement Campaign|"IHI designed and encouraged implementation of a five-component enhanced surgical site infection (SSI) prevention bundle with three relatively new evidence-based practices and two Surgical Care Improvement Program (SCIP) practices.~The campaign recruited state organizations to share information about evidence-based practices and publicize IHI activities and intervention materials (a How-to Guide, evidence reviews, a summary of the business case for interventions, and tip sheets for surgeons, other providers, patients and families). A project website and email listserv offered learning opportunities including webinar calls, faculty-led office hours, and town hall meetings."
89070227|NCT02886741|No Intervention|Comparison|Matched state pairs received no campaign intervention and experienced usual care
89070228|NCT02886819|Experimental|WBV group|whole-body vibration (WBV) group
89070229|NCT01289210|Other|VTX-2337 plus radiation|
89070230|NCT01183221|Experimental|Syntocinon then Placebo|24IU intranasal oxytocin, minimum of 3 weeks off, then placebo
89070231|NCT01183221|Placebo Comparator|Placebo then Syntocinon|Placebo, minimum of 3 weeks off, then 24IU intranasal oxytocin or placebo
89070232|NCT01183143|Experimental|GONAL-f®|
89070233|NCT01183065|Experimental|pralatrexate and vitamin supplementation|This will be an open-label, single arm, Simon optimal two-stage design phase II study.
89070234|NCT01182441|Experimental|WATCHMAN|Subjects assigned to receive the WATCHMAN device.
89070235|NCT01182441|Active Comparator|Warfarin|Subjects assigned to warfarin therapy.
89070236|NCT02886507|Active Comparator|NSK-SD (nattokinase)|One capsule (100 mg) nattokinase/day for the 8-week study duration.
89070237|NCT02886507|Placebo Comparator|Placebo|One capsule placebo/day for the 8-week study duration.
89070238|NCT01182285|Experimental|A - Phase I Radioiodine-Resistant|Drug: Valproic Acid Week 1 - 10 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
89070239|NCT01182285|Active Comparator|B1 - Phase 2 Schedule 1|Drug: Valproic Acid Week 11 - 17 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Drug: Cytomel (25 micrograms) Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Liothyronine Sodium (Cytomel) for 4 weeks (25 micrograms twice a day)
89229859|NCT01583725|Experimental|Sleeve Gastrectomy Surgery|30 subjects who plan to undergo Sleeve Gastrectomy bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
89229860|NCT01094509|Experimental|Tai Chi|Tai Chi exercises
89223899|NCT04946344|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 3 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant will be prescribed an individual walking prescription by the exercise leader, which will be adjusted accordingly, as each participant progresses throughout the 3 months. The exercise will be of moderate intensity. Alternate forms of aerobic exercise, such as but not limited to stationary bike, elliptical trainer, or treadmill walking, can be used in place of over-ground walking. This choice could be based on participant preference, the limitations of the exercise facility, or the participant's pain level.
89223900|NCT04946344|Active Comparator|Attention Control|The attention control intervention will cover an 3 month period. There will be two face to face group meetings over the 3 months, with one meeting each at months 1 and 3; and during the other months (month 2) participants will receive a combination of text messages, emails, and phone calls based on continued monitoring of participant needs and delivered via their preferred mode of contact.
89223901|NCT04922606|Other|US of GSV|Ultrasound of the Great Saphenous Vein
89223902|NCT04913701||1 - Health workers|A total number of 200-300 healthcare workers, exposed to close contact with patients, will be asked to participate to the study and will be asked to sign the informed consent.
89229861|NCT01094509|Experimental|Guided autobiography|Autobiographical writing during class sessions and at home
89070240|NCT01182285|Active Comparator|B2 - Phase 2 Schedule 2|Drug: Valproic Acid Week 11 - 52 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Weeks 17-52: Patients who show a response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have a decreased thyroglobulin level from Day 1 of the treatment (registered as a partial response to the treatment) will continue on valproic acid at their current dose for a total of 52 weeks.
89070241|NCT04315935|Experimental|butorphanol group|Butorphanol (10-20 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
89070242|NCT04315935|Active Comparator|fentanyl group|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
89070243|NCT04316091|Experimental|Experimental group|neoadjuvant chemotherapy+SPIONs/SMF
89070244|NCT04316091|Sham Comparator|Control group|neoadjuvant chemotherapy
89070245|NCT04206423||Healthy Controls|Age and sex matched healthy controls
89070246|NCT04206423||Lateral epicondylitis|"Newly diagnosed lateral epicondylitis patients.~Pain in lateral epicondylitis region~Pain increase with palpation~Positivity in two diagnostic test out of three (Maudley's test, Mill's test or Cozen's test)"
89070247|NCT04188015|Experimental|2.5mg ANX007|1 in every 3 subjects will be randomized to 2.5mg dose of ANX007.
89070248|NCT04188015|Experimental|5.0mg ANX007|1 in every 3 subjects will be randomized to 5.0mg dose of ANX007.
89070249|NCT04188015|Sham Comparator|Sham Procedure|1 in every 3 subjects will have a sham procedure performed instead of receiving ANX007.
89070250|NCT01182207|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
89070251|NCT01182207|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
89070252|NCT01181895|Experimental|Vilanterol|Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
89070253|NCT01181895|Active Comparator|Salmeterol|Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
89070254|NCT01181895|Placebo Comparator|Placebo|Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
89070255|NCT04187781|Other|external microphone old|
89070256|NCT04187781|Other|external microphone new|
89070257|NCT01181271|Experimental|Autologous then Allogeneic transplant|"All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.~Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.~Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD)."
89070258|NCT01180647|Active Comparator|Extended-release naltrexone (XR-NTX)|A single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
89070259|NCT01180647|Placebo Comparator|Motivational Enhancement Counseling Only|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
89070260|NCT02886663|Experimental|immediate rehabilitation|
89070261|NCT02886663|Other|delayed rehabilitation|
89070262|NCT00969553|Experimental|BI 6727|Schedule A
89070263|NCT04285957||pre-test Group|"Consecutive recruitment of 10 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.~Inclusion criteria: age 18-90, stroke occurred within 3 months from enrollment; clinical stability (SIC = 0). The exclusion criteria are: stroke recurrence; visual and / or hearing disorders; cognitive decline (MMSE <21) and/or severe aphasia, which would limit the the patients' understanding of and the reliable answering to the two assessment tools"
89070264|NCT04285957||Validation Group|Recruitment of 60 post-stroke patients undergoing intensive rehabilitation treatment at the Neurological Rehabilitation Unit, Foundation don Gnocchi Scientific Institute.Inclusion criteria: age 18-90, stroke occurred within 8 months from enrollment; clinical stability (SIC = 0). If the following criteria are present: visual and / or hearing disorders; cognitive decline (MMSE <21) and/or severe aphasia, which would limit the patients' understanding of and the reliable answering to the two assessment tools, the interview shall be carried out with a proxy
89070265|NCT02863159|Active Comparator|Treatment Group 1|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +3.25D (ZLB00) in their non-dominant eye.
89070266|NCT02863159|Active Comparator|Treatment Group 2|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +4.00D (ZMB00) in their non-dominant eye.
89070267|NCT01179399|Experimental|TAK-960|
89070268|NCT01178853|Experimental|Pitavastatin/Rosuvastatin|
89070269|NCT01178853|Experimental|Rosuvastatin/Pitavastatin|
89070270|NCT02863393|Experimental|Diaphragmatic breathing exercise|The aim of this study is to ameliorate hepatic inflammation by using diaphragmatic breathing exercises instead of aerobic exercise to reduce the fat in liver inflammation.
89070271|NCT01178385|Experimental|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
89223903|NCT04913701||2 - Patients|A total number of 100-200 patients admitted to the rehabilitation facility, referred from other healthcare facilities or from their own home, will be asked to participate to the study.
89223904|NCT04913701||3 - Real life participants|A total number of 100 real-life participants, will be represented by volunteers (other employees, staff not in contact with patients
89070272|NCT01178385|Active Comparator|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
89070273|NCT02863315|Experimental|tsDCS|In the tsDCS group, anodal tsDCS will be applied for 20 minutes.
89070274|NCT02863315|Placebo Comparator|sham|In sham tsDCS group, the current of anodal tsDCS will be discontinued after 30 s while the power indicator remained on for 20 minutes.
89070275|NCT04286035|Active Comparator|Femoral group|
89070276|NCT04286035|Active Comparator|Adductor group|
89070277|NCT02865889||Uterine oncologic Indications for surgery|
89070278|NCT04286815|Experimental|Experimental Group|a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined immune deficiency）.
89070279|NCT02863237||weaning failure group|Patients reconnected to the ventilator within 48 hours after SBT will be designated the weaning failure group
89070280|NCT02863237||weaning success group|Patients who pass the SBT and breathing without ventilator support within 48 hours are designated the weaning success group
89070281|NCT02865967|Experimental|Block1_Intervention|Usual care + a-GPS
89070282|NCT02865967|Other|Block1_Control|Usual Care
89070283|NCT02865967|Experimental|Block2_Intervention|Usual care + a-GPS
89070284|NCT02865967|Other|Block2_Control|Usual care
89070285|NCT02865967|Experimental|Block3_Intervention|Usual care + a-GPS
89070286|NCT02865967|Other|Block3_Control|Usual care
89070287|NCT04289857|Experimental|Experimental group|Each session will last a maximum of 5 minutes, taking place for 3 days a week, over a period of 4 weeks. The intervention will be performed at the start of training (before warm-up).
89070288|NCT04289857|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
89070289|NCT01288976||MitraClip Therapy|Patients treated with the MitraClip System.
89070290|NCT01288976||Medical Management|Patients with MR managed non-surgically based on standard hospital clinical practice.
89070291|NCT01288976||Mitral Valve Surgery|Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
89070292|NCT05187169|Active Comparator|Treatment A|4.0 mg VS-6766, following an overnight fast of at least 10 hours
89070293|NCT05187169|Active Comparator|Treatment B|4.0 mg VS-6766, administered 30 minutes after the start of a high-fat/high-calorie meal breakfast
89070294|NCT02863081||Healthcare providers|All healthcare providers working in the participating LTACH will be asked to complete 2 surveys and invited to participate in focus group meetings
89070295|NCT02863081||Patients|81 LTACH patients will be enrolled over the course of a 9 month period. Each patient and their LAR will be interviewed at the time of LTACH admission to garner information about their pre hospitalization physical, functional, and cognitive health status. Each day enrolled patients will undergo daily symptom assessments and medical record reviews. At the time of LTACH discharge all enrolled patients will be interviewed again to garner information about their discharge physical, functional, and cognitive health status.
89070296|NCT02862925|No Intervention|Pre-Intervention|A consecutive sample of 350 patients will be collected. After informed consent, data will be abstracted from the patient's record including day and time of delivery, method of delivery, parity, gestational age, meconium presence, heart rate abnormality and induction methods. For CD, the following data will be collected: decision-to-delivery time, Partogram adherence, time of each FSST, Apgar score, date and time of delivery and Comorbidities such as: Hypertension-spectrum disorders, Malaria, Postpartum Hemorrhage, Macrosomia, History of CD, Diabetes, Sickle Cell, and HIV status.
89070297|NCT02862925|Experimental|Post-intervention|The study will take place on the labor ward at KCMC in Moshi, Tanzania. It will involve women who present to the labor ward in labor or who undergo an induction of labor. A consecutive sample of 350 patients will be collected. Study investigators will be present for 24 hours a day, 7 days a week on a rotating schedule during the enrollment period. All patients who fit inclusion and exclusion criteria will be approached if they are deemed medically stable.
89070298|NCT00629473|Experimental|Arm AM: advanced malignancies|Dose Escalation - 9 dose cohorts NPI-0052 on Days 1, 8, 15 every 28 days NPI-0052 doses ranging from 0.1 to 0.9 mg/m2
89070299|NCT00629473|Experimental|Arm MM: multiple myeloma|Dose Escalation - 8 dose cohorts NPI-0052 on Days 1, 4, 8, 11 every 21 days NPI-0052 doses ranging from 0.075 to 0.6 mg/m2 Dexamethasone 20 mg oral or IV day before and day after NPI-0052 dosing.
89070300|NCT04286503|Experimental|Carrimycin|basic treatment + Carrimycin
89070301|NCT04286503|Active Comparator|lopinavir/ritonavir or Arbidol or chloroquine phosphate|any of basic treatment + lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
89070302|NCT00970489|Experimental|Omega-3 fatty acid capsules|
89070303|NCT00970489|Placebo Comparator|Olive Oil capsule|
89070304|NCT00968617|Experimental|MK2578 1.0 mcg/kg|MK2578
89070305|NCT00968617|Experimental|MK2578 2.0 mcg/kg|MK2578
89070306|NCT00968617|Experimental|MK2578 3.6 mcg/kg|MK2578
89070307|NCT00968617|Active Comparator|Darbepoetin alfa|darbepoetin alfa
89070308|NCT00968539|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89070309|NCT00968539|Experimental|GSK2340269A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89070310|NCT00976573|Experimental|Arm I (bevacizumab, paclitaxel, and carboplatin)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89070311|NCT00976573|Experimental|Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)|Patients receive bevacizumab, paclitaxel, and carboplatin as in Arm I. Patients also receive everolimus PO QD on 3 days a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89070312|NCT02865733|Experimental|Remodulin Injection|Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours
89070313|NCT02865733|Placebo Comparator|Distilled water group|Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours
89070314|NCT00976495|Experimental|Dapagliflozin|
89070315|NCT00976495|Active Comparator|Hydrochlorothiazide|
89070316|NCT00630019|Experimental|1|
89070317|NCT00630019|Active Comparator|2|
89070318|NCT01288430|Experimental|DS-2248|"Study Part 1: DS-2248 oral capsule(s) of increasing strength in a dose escalation study in subjects with advanced solid tumors, administered once daily in 21-day cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression is observed.~Study Part 2: DS-2248 oral capsule(s) dose of 4.5 mg/m^2, in subjects with non-small cell lung cancer who have developed acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors or whose tumors carry an ALK translocation and are resistant to ALK inhibitor therapy, administered once daily in 21 day-cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression are observed."
89070319|NCT02889848|Sham Comparator|Saline only|Injection of saline to assess the injection procedure
89070320|NCT02889848|Experimental|1.16 mg EN3835|Injection of maximum marketed dose of EN3835 regardless of fibroid size
89070321|NCT02889848|Experimental|Dose 1|Injection of 0.05 mg EN3835 per cm3 fibroid
89070322|NCT02889848|Experimental|Dose 2|Injection of 0.1 mg EN3835 per cm3 fibroid
89070323|NCT02889848|Experimental|Dose 3|Injection of 0.2 mg EN3835 per cm3 fibroid
89070324|NCT01287416|Experimental|Applied Suicide Intervention Skills Training (ASIST)|"ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The training is designed for anyone (especially those in a position of trust), from professionals and volunteers to members of the community. Participants range from those in caring roles to people concerned about family members or friends. The theory is that suicide can be pre¬vented with the help of prepared caregivers. ASIST is designed to help all caregivers become more willing, ready and able to help persons at risk. Just as CPR skills make physical first aid possible, training in suicide intervention develops the skills used in suicide first aid."
89070325|NCT01287416|Active Comparator|Resilience Retreat|The two days will be divided into cultural activities, sharing circles, small group discussions, story telling and dance. Two First Nations community leaders will be identified to lead each of the two retreats.
89070326|NCT05660252|Experimental|Collaborative request|The patient's relative is approached by the ICU team and an organ procurement coordinator together.
89070327|NCT05660252|No Intervention|Routine request|The patient's relative is approached by the clinical team only.
89070328|NCT00998296|Experimental|BIBW 2992 + BIBF 1120|This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
89070329|NCT01178073|Active Comparator|Combination ambrisentan + tadalafil|ambrisentan + tadalafil
89070330|NCT01178073|Active Comparator|Monotherapy ambrisentan|ambrisentan
89070331|NCT01178073|Active Comparator|Monotherapy tadalafil|tadalafil
89070332|NCT00997984|Experimental|Extended-release Guanfacine Hydrochloride (SPD503) AM|
89070333|NCT00997984|Experimental|placebo|
89070334|NCT00997984|Experimental|SPD503 PM|
89070335|NCT04206111||Preoxygenation|
89070336|NCT01177293|Active Comparator|treatment A - reference w/ water|
89070337|NCT01177293|Experimental|Treatment B - ODT (test) w/o water|
89070338|NCT01177137|Experimental|TRT|TRT includes treatment with a conventional sound generator (SG) and directive counseling (DC)
89070339|NCT01177137|Other|Partial TRT|Partial TRT includes treatment with a placebo sound generator (placebo SG) and directive counseling (DC).
89070340|NCT01177137|Other|Standard of Care (SC)|The standard of care arm includes care as typically delivered in US military medical centers
89070341|NCT02886429|Active Comparator|Group A|Ultrasound guided paravertebral block with bupivacaine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) via paravertebral route.
89070342|NCT02886429|Active Comparator|Group B|Ultrasound guided paravertebral block with bupivacaine and dexmedetomidine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg) via paravertebral route (Bupivacaine plus Dexmedetomidine)
89070343|NCT01177059|Other|Anti-HIV-1 Ribozyme (OZ1) transduced cells|OZ1 transduced cells Long term follow up of previously infused OZ1 transduced cells
89070344|NCT04315779|Active Comparator|Conventional laparoscopy|In this arm, patients will be treated via conventional laparoscopy
89229862|NCT01094509|Experimental|Qigong|Qigong exercises (exploratory, not part of the original protocol, added to gain experience with this intervention)
89070345|NCT04315779|Active Comparator|Transvaginal natural orifice transluminal endoscopic surgery|In this arm, patients will be treated via transvaginal natural orifice transluminal endoscopic surgery
89070346|NCT01176513|Experimental|GE 148-002|
89070347|NCT01299389|Experimental|Paliperidone palmitate|
89070348|NCT01299389|Placebo Comparator|Placebo|
89070349|NCT02886351|Experimental|nitrous oxide|Administration of high concentration of nitrous oxygen in pediatric dentistry
89070350|NCT02890667||Beneficiaries|Incident cancer for Beneficiaries present in the EGB on January 1, 2012.
89070351|NCT01298999|Experimental|YF476|YF476 (gastrin-receptor antagonist)
89070352|NCT01298999|Placebo Comparator|Placebo|Placebo pill (identical in appearance to YF476 pills)
89070353|NCT04324541||Mexican American Adults|No intervention
89070354|NCT01007032|Experimental|Cixutumumab|Participants receive IV cixutumumab every 2 or 3 weeks. A cycle equals 6 weeks, with radiological evaluation of tumor response after each cycle. After 1st cycle, pts with a complete response (CR), PR, or SD continue to receive cixutumumab cohort dose and schedule disease progression. 3 pts enroll in each cohort. Starting dose in Cohort 1 is 6 mg/kg every 2 weeks. Dose escalation from Cohort 1 to Cohort 2 (10 mg/kg every 2 weeks) occurs at least 3 pts in Cohort 1 completes 1 cycle of therapy. Enrollment into Cohort 3 (starting dose: 15 mg/kg administered every 3 weeks) will not proceed until at least 3 pts have completed one cycle of therapy in Cohort 2. Pts enroll in Cohort 4 once at least 3 pts have completed once cycle of therapy in Cohort 3; pts in Cohort 4 receive 20 mg/kg every 3 weeks.
89070355|NCT00976027|Experimental|Fluzone® High Dose Group|
89070356|NCT00976027|Active Comparator|Fluzone® Group|
89070357|NCT01298765|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
89070358|NCT04296214||A|Azacitidine 50 mg/m2 for 10 days each 28 days
89070359|NCT04296214||B|Azacitidine 75 mg/m2 for 7 days each 28 days
89070360|NCT04296370|Experimental|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
89070361|NCT04296370|Experimental|Single Arm|Fluzoparib
89070362|NCT04296370|Active Comparator|Physician's choice chemotherapy|Capecitabine or Vinorelbine
89070363|NCT02870296|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
89229863|NCT01094509|Active Comparator|Successful aging|Seminars on the theme of successful aging
89070364|NCT02870296|Experimental|Intervention|Interventions will be administered to this group. Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
89070365|NCT04204720|Active Comparator|Group Whitacre|Group whitacre receives the whitacre needle during caudal block
89070366|NCT04204720|Experimental|Group Chiba|Group chiba receives the chiba needle during caudal block
89070367|NCT00997438|Experimental|MS - Secondary Progressive|1200 mg of Lipoic acid supplement
89070368|NCT00997438|Experimental|MS - Relapsing Remitting|1200mg of Lipoic acid supplement
89070369|NCT00997438|Experimental|Healthy Controls|1200 mg of Lipoic acid supplement
89070370|NCT00997126|Active Comparator|Propofol|Propofol 1m g/kg IV followed by 0.5 mg/kg IV prn sedation
89070371|NCT00997126|Active Comparator|Alfentanil|Sedation using alfentanil 10 ug/kg followed by 5 ug/kg prn sedation
89070372|NCT01000636|Experimental|Metvix PDT|
89070373|NCT00965419|Experimental|Edivoxetine|All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
89070374|NCT04433494|Experimental|TY-302 ; TY-302 combine with Tamoxifen|"TY-302~Find the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D) of TY-302, given orally.~Increased dose cohorts from low dose to MTD, starting at 25mg daily.~TY-302 combine withTamoxifen in dose-escalation stage~TY-302: RP2D-1to RP2D daily for 28 days of each 28 day cycle.~Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle.~TY-302 combine withTamoxifen in dose-expansion stage~TY-302: RP2D daily for 28 days of each 28 day cycle.~Tamoxifen: 20mg twice daily for 28 days of each 28 day cycle."
89070375|NCT01000480|Experimental|Pemetrexed|Pemetrexed and cisplatin are given as induction therapy followed after by pemetrexed and cisplatin with concurrent radiotherapy.
89070376|NCT02862691|Active Comparator|Oral analgesic|2 tablets of acetaminophen 325 mg/ oxycodone 5 mg orally once
89070377|NCT02862691|Experimental|Injectable local anesthetic|local injection or nerve block with bupivicaine 0.5%
89070378|NCT02871388|Experimental|CONECT|12 week program with additional follow up at 24 weeks.
89070379|NCT02871388|No Intervention|Control|Waitlist control. No intervention for first 12 weeks. Participants given the option to participate in the program after 24 weeks.
89070380|NCT00965341|Active Comparator|Testosterone|Testosterone Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
89070381|NCT00965341|Placebo Comparator|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
89229864|NCT01094509|Experimental|Combination|Combination of Tai Chi exercises and autobiographical writing
89070382|NCT01175811|Experimental|Premixed Insulin|Twice daily (before breakfast and lunch) insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension [LM50]) and once daily (before dinner) insulin lispro mix 25 (25% insulin lispro, 75% insulin lispro protamine suspension [LM25])
89070383|NCT01175811|Active Comparator|Basal-Bolus|Once daily (bedtime) insulin glargine and three pre-meal insulin lispro
89070384|NCT04293952|Experimental|BRACE group|BRACE include combination of exercises including, Balance, Resistance, Aerobic, Cognition Exercises.
89070385|NCT04293952|Active Comparator|BRE group|this group include Balance Resistance Exercises Stretching Range Of Motion exercises Ankle flexion Ankle extension Knee flexion Knee extension Hip flexion Hip extension Hip adduction Hip abduction
89070386|NCT00965263|Experimental|Low dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 82ul
89070387|NCT00965263|Experimental|High Dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 360ul
89070388|NCT02869594||Patients with prostate cancer diagnosis|
89070389|NCT04206189|Active Comparator|Carbohydrate group|
89070390|NCT04206189|No Intervention|Control group|
89070391|NCT04283695|Experimental|Part 1|IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg
89070392|NCT04283695|Experimental|Part 2|IV: [14C]-GX-I7 40 µg
89070393|NCT04283695|Experimental|Part 3|IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg
89070394|NCT02886195|Experimental|PC plus erlotinib|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1; concurrent erlotinib 150mg/d d1-21, per 3 week, for 4-6cycles, then erlotinib 150mg/d maintain therapy
89070395|NCT02886195|Active Comparator|erlotinib|"erlotinib 150mg/d until progress disease"
89070396|NCT02886195|Active Comparator|PC|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1 for 4-6 cycles
89070397|NCT05331963|Experimental|Kinesio taping with rehabilitation program group|Rehabilitation program will be given to this group in addition to Kinesio taping on skin for 72 hour.
89070398|NCT05331963|No Intervention|Rehabilitation plan group|The rehabilitation program will be provided individually to all participants (twice weekly during the first 4 weeks, then once weekly)
89070399|NCT02862769|Experimental|Lidocaine infusion|first group (lidocaine group) will include those who receive a intraoperative lidocaine infusion (Induction bolus dose of 1.5 mg/kg body weight followed by a continous lidocaine infusion
89070400|NCT02862769|Placebo Comparator|Saline Infusion|The second group will include those who receive a intraoperative placebo i(Induction bolus dose of 1.5 mg/kg body weight of lidocaine followed by a continous saline infusion at the same rate as the lidocaine infusion.
89070401|NCT00965185|Experimental|Atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
89070402|NCT00965185|Placebo Comparator|placebo|
89070403|NCT01174563|Experimental|Single Arm|
89070404|NCT02861599|Experimental|proprioceptive therapy|
89070405|NCT02861599|Placebo Comparator|speech therapy|
89070406|NCT01298531|Active Comparator|etanercept|Group A: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
89070407|NCT01298531|Placebo Comparator|etanercept-placebo|Group B: placebo subcutaneous (SC) injections once weekly for (how many) weeks follwed by etanercept 50 mg SC injections once weekly.
89070408|NCT02862145|Experimental|Treatment with MRX34|Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.
89070409|NCT04284709|Experimental|exercise group|exergames with simultaneous cognitive-physical training
89070410|NCT04284709|Active Comparator|control group|multicomponent exercise intervention focused on physical and cognitive training
89229865|NCT01094509|Placebo Comparator|Comparison|No assigned experimental activity (exploratory, not part of the original protocol, added to gain experience with a placebo comparator)
89229866|NCT01094587|Active Comparator|Sutured closure|
89070411|NCT01174173|Experimental|Ranolazine|1000 mg PO BID
89229867|NCT01094587|Active Comparator|Sutureless closure|
89070412|NCT04315623|Experimental|Reginal citrate anticoagulation|Patients accepted regional citrate anticoagulation for CRRT. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L. Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+. Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level.
89070413|NCT04315623|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
89070414|NCT05281653|Experimental|Neuromuscular Training Group|Athletes in this group will receive progressive neuromuscular exercise training in addition to routine 2 weekly training sessions.
89070415|NCT05281653|Experimental|Control Group|The routine will continue with 2 workouts per week.
89070416|NCT05661071||Duchenne Muscular Dystrophy|Children with Duchenne Muscular Dystrophy (DMD) between the ages of 7 and 16 who have been diagnosed with DMD as a result of genetic testing
89070417|NCT05661071||Typically Developed Children|Typically Developed Children with similar physical characteristics between the ages of 7 and 16
89070418|NCT00964795|Experimental|Open-label Intravitreal Aflibercept Injection|Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.
89070419|NCT01173471|Experimental|1) AZD4017|Europe: 200 mg AZD4017
89070420|NCT01173471|Placebo Comparator|2) Placebo|Europe: placebo
89070421|NCT01173471|Experimental|3) AZD4017|USA: 800 mg AZD4017
89070422|NCT01173471|Placebo Comparator|4) Placebo|USA: placebo
89070423|NCT01172847|Active Comparator|A|
89070424|NCT01172847|Active Comparator|B|
89070425|NCT01172847|Experimental|C|
89070426|NCT04285645|Experimental|Experimental group|Each session will last 15 minutes, taking place 2 days a week, over a period of 4 weeks. Prior to training, the exercise protocol will be carried out. Prior to the start of the intervention, the exercises to be performed will be explained to the participants and it will be verified that they are capable of performing them correctly.
89070427|NCT04285645|No Intervention|Control group|Athletes included in the control group will continue with their usual training routine.
89070428|NCT00966355|Active Comparator|Terlipressin|treat with terlipressin IV for 5 days and endoscopic treatment
89070429|NCT00966355|Active Comparator|Somatostatin|treat with somatostatin IV for 5 days and endoscopic treatment
89070430|NCT00966355|Active Comparator|Octreotide|treat with octreotide IV for 5 days and endoscopic treatment
89070431|NCT02861209|No Intervention|Non-care pathway|"This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months.~The decision to start with an oral anticancer therapy depends solely on the treating physician."
89229868|NCT01584115|Experimental|NY-ESO-1|NY-ESO-1 combined with MPLA vaccine
89229869|NCT01089673||no treatment|retrospective data analysis
89070432|NCT02861209|Experimental|Care Pathway|"This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months.~The decision to start with an oral anticancer therapy depends solely on the treating physician."
89070433|NCT02862301|Other|Control group|Healthy volunteers, free of any inflammatory disease. A blood sample is performed on the day of inclusion.
89070434|NCT02862301|Experimental|CIS group|patients with Clinically isolated syndrome. A blood sample is performed on the day of inclusion and after 3 months.
89070435|NCT04283305|Experimental|Virtual reality approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training in the virtual reality. Alcoholic beverages are pushed away with a controller and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
89229870|NCT00531752|Experimental|Flexible Dose|
89229871|NCT00531752|Placebo Comparator|Placebo|
89229872|NCT00531752|Experimental|Fixed Dose|
89229873|NCT00395746|Experimental|0.6 mg + SU|Liraglutide 0.6 mg + sulphonylurea
89229874|NCT00395746|Experimental|0.9 mg + SU|Liraglutide 0.9 mg + sulphonylurea
89070436|NCT04283305|Active Comparator|Computer-based approach avoidance training|Participants will receive six sessions (three sessions per week for two weeks; session duration = 30 mins) of approach-avoidance training on the computer. Alcoholic beverages are pushed away with a joystick and soft-drinks will be pulled towards oneself. Training will begin approximately three weeks before discharge from the inpatient clinics to measure the add-on effect and to ensure that the add-on treatment does not extend the treatment period.
89070437|NCT04283305|No Intervention|Treatment as usual|Participants will receive treatment as usual on the wards. For ethical reasons, participants in this condition will get the offer to undertake the already scientifically validated computer-based approach avoidance training after their completion of the study.
89070438|NCT01172535|Experimental|Lopinavir/ritonavir|Participants will receive lopinavir/ritonavir in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.
89070439|NCT05160493|Experimental|S-ketamine and pregabalin|"Drug: S-ketamine and pregabalin~Drug: Pregabalin 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~Drug: S-ketamine infusion 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
89070440|NCT05160493|Placebo Comparator|Normal saline and placebo capsule|"Drug: Normal saline and placebo capsule~Drug: Placebo capsules :Two placebo capsules(2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~Drug: Normal saline• 0.9% saline bolus after induction of anesthesia +intravenous infusion for 48 hours"
89070441|NCT00966277|Experimental|Group 1: Dalteparin|Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.
89070442|NCT00966277|No Intervention|Group 2: Control|No study drug.
89229875|NCT00395746|Placebo Comparator|SU Mono - 1|Liraglutide placebo 0.6 mg + sulphonylurea
88812779|NCT01526213|Other|Sequence 1: Water, GFJ, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
89070443|NCT03625063|Active Comparator|Exercise training group|Inspiratory muscle, upper extremity aerobic exercise and progressive resistance trainings
89070444|NCT03625063|Sham Comparator|Control training group|Upper extremity aerobic exercise and progressive resistance trainings
89070445|NCT02862223|Experimental|Neoprinol|
89070446|NCT01298141|Experimental|Replagal®|All eligible patients may receive Replagal produced by the bioreactor process (AF Replagal) on this treatment plan until AF Replagal is commercially available for the patient, the patient's participation is discontinued, or the study is discontinued, whichever comes first.
89070447|NCT01171989|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of GSK2202083A and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of GSK2202083A vaccine at Day 0 and of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
89070448|NCT01171989|Active Comparator|INFANRIX HEXA/MENJUGATE GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and 2 doses of Menjugate® vaccine in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with Menjugate® vaccine at Day 0. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
89070449|NCT01171989|Active Comparator|INFANRIX HEXA/NEISVAC-C + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with NeisVac-C® vaccine at Day 0 and 1 dose of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
89070450|NCT01297517|Experimental|Brinzolamide/Brimonidine|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, one drop instilled in each eye three times a day for 3 months
89070451|NCT01297517|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, one drop instilled in each eye three times a day for 3 months
89070452|NCT01297517|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, one drop instilled in each eye three times a day for 3 months
89070453|NCT01171677|Experimental|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
89070454|NCT01171677|No Intervention|Treatment as Usual|
89070455|NCT01171521|Experimental|DermaClose Group|DermaClose device applied to complex soft-tissue wound, with or without negative pressure wound therapy, and prospectively followed for primary and secondary outcomes for one year.
89070456|NCT01296347|No Intervention|Saline|Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.
89070457|NCT01296347|Experimental|ketamine|Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
89070458|NCT01296035|Experimental|Panitumumab and Gemcitabine|Panitumumab and Gemcitabine
89070459|NCT01294787|Experimental|indacaterol and glycopyrronium bromide (QVA149)|QVA149 delivered once daily via single-dose dry powder inhaler.
89070460|NCT01294787|Placebo Comparator|placebo|Placebo, delivered once daily via single-dose dry powder inhaler.
89070461|NCT01294787|Active Comparator|tiotropium|Tiotropium delivered once daily via HandiHaler® device.
89070462|NCT04207463|Experimental|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89070463|NCT01294553||rosiglitazone/metformin group|Korean subjects who are administered rosiglitazone/metformin according to the prescription information
89070464|NCT01294397|Experimental|Etanercept + Denosumab|Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.
89070465|NCT01293695|Active Comparator|Hypnosis|Receives 5 weeks of hypnotic relaxation therapy
89070466|NCT01293695|Placebo Comparator|Structured Attention|Meets with therapist for five weekly sessions, but receives no hypnotic relaxation therapy
89070467|NCT01293539|Other|Intraocular Retinoblastoma Patients|Single group assignment of patients with intraocular retinoblastoma, unilateral or bilateral.
89070468|NCT01292837|Experimental|Levetiracetam|Twice daily (morning and evening) orally
89070469|NCT00965731|Active Comparator|Erlotinib|
89070470|NCT00965731|Experimental|Erlotinib + PF-02341066|
89070471|NCT03252847|Experimental|Phase 1 (Part 1, Dose Escalation)|Participants receive one of three doses of AAV2/5-RPGR
89070472|NCT03252847|Experimental|Phase 2 (Part 2; Expansion)|Participants receive one of two doses of AAV2/5-RPGR
89070473|NCT02861989||Osteoporotic women|women over 50 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
89070474|NCT02861989||At risk women|women over 50 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
89070475|NCT02861989||Osteoporotic men|Men over 60 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
89070476|NCT02861989||At-risk men|Men over 60 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
89070477|NCT02861989||General practitioners|General practitioners from the Rhône area, France
89070478|NCT02861911|Sham Comparator|Control group|The current intensity is generally defined between the sensory and motor threshold (patients feel the power but no visible muscle contraction will be obtained).
89070479|NCT02861911|Active Comparator|Active NMES group|Tthe current intensity must always meet and exceed the motor threshold (patients feel the current and quadriceps muscle will contract a visible and quantifiable if possible).
89070480|NCT00965575|Experimental|Melatonin|Subjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks
89070481|NCT00965575|Placebo Comparator|Placebos|Subjects will take a placebo 30 minutes before bedtime for four weeks
89070482|NCT04282837||NW|normal weight control
89070483|NCT04282837||MHO|metabolic healthy obesity
89070484|NCT04282837||LMO|hypometabolic obesity
89070485|NCT04282837||HMO-U|hypermetabolic obesity with hyperuricemia
89070486|NCT04282837||HMO-I|hypermetabolic obesity with hyperinsulinemia
89070487|NCT04285177||Horizontal muscle surgery|Patients suffering from esotropia or exotropia, will have medial/lateral rectus recession/resection
89070488|NCT04285177||Patients with Inferior Oblique Overaction|Will undergo inferior Oblique Myectomy
89070489|NCT04285177||Patients with combined horizontal and oblique muscle surgery|Having combined surgery
89070490|NCT02862847||gastroenteritis|
89070491|NCT02862847||control|
89070492|NCT04285099|Experimental|PD patients with FOG after STN-DBS[A]|Initially started by A setting
89070493|NCT04285099|Experimental|PD patients with FOG after STN-DBS[B]|Initially started by B setting
89070494|NCT02862613|Experimental|Precision Cells|"Precision Cells combined with Transcatheter Arterial Chemoembolization:~Transcatheter Arterial Chemoembolization:~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
89070495|NCT02862613|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
89070496|NCT00965497|Experimental|Escitalopram|All patients will receive escitalopram 20 mg daily.
89070497|NCT00963937|Active Comparator|Sumatriptan 25 mg|
89070498|NCT00963937|Active Comparator|Sumatriptan 50 mg|
89070499|NCT00963937|Placebo Comparator|Placebo|
89070500|NCT03375697|Experimental|SAD (Part 1): Healthy Subjects|In Part 1, single ascending intravenous (IV) doses of JNJ-63733657 or placebo will be administered to sequential cohorts (Cohorts 1 to 5) of healthy subjects on Day 1. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. Here, SAD indicates single ascending dose.
89070501|NCT03375697|Experimental|MAD (Part 2): Subjects With Alzheimer's Disease (AD)|In Part 2, multiple ascending IV doses of JNJ-63733657 or placebo will be evaluated at three dose levels in sequential cohorts in subjects with prodromal or mild AD; 3 doses will be administered over a period of 8 weeks (Day 1, Day 29, Day 57). The starting dose will be decided based on the data from Part 1. Escalations will be done based on safety and tolerability similar to Part 1. Doses will not exceed those tested in Part 1. Here, MAD indicates multiple ascending dose.
89070502|NCT04284241|Experimental|Intervention group|"Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. Parents also undergo and active health education by the investigator with the  Parents' Health-Education Handbook, and Handbook will be given to them. Handbook includes the knowledge of symptoms, hazards, epidemiology, risk factors, therapy, and prevention of pediatric urolithiasis, and also baby's right feeding methods. Follow up is made every year in the first three years, and the program is done as the baseline."
89229876|NCT00395746|Placebo Comparator|SU Mono - 2|Liraglutide placebo 0.9 mg + sulphonylurea
89229877|NCT00994838|Active Comparator|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
89229878|NCT00994838|No Intervention|standard diet|
89070503|NCT04284241|No Intervention|Control group|Participants include newborns and their parents. The baseline of newborns includes demographic data, blood cell analysis, urinary tract ultrasonographic examination. Newborns' parents will be asked to answer a questionnaire which regarding the knowledge, attitudes, and practices (KAP questionnaire) related to pediatric stone. But parents do not undergo active health education. And Handbook will not be given to them. However, a poster which has the same content as the Handbook is normally displayed in the maternity ward. Parents have the opportunity to see the poster, but without any special remind. Follow up is made every year in the first three years, and the program is done as the baseline.
89070504|NCT01170663|Experimental|Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel|Ramucirumab (IMC-1211B) DP and Paclitaxel
89070505|NCT01170663|Placebo Comparator|Placebo and Paclitaxel|Placebo and Paclitaxel
89070506|NCT04315155|Experimental|Double Regimen|belinostat in combination with nivolumab
89070507|NCT04315155|Experimental|Triplet Regimen|belinostat in combination with nivolumab and ipilimumab
89070508|NCT01170273|Placebo Comparator|Placebo Arm|placebo capsule
89070509|NCT01170273|Experimental|Cholecalciferol 4000 IU|cholecalciferol 4000 IU daily
89070510|NCT04315077|Experimental|Experimental Group|Subjects will consume one serving per day (25mg) of the treatment condition (Oceanix ®) for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
89070511|NCT04315077|Placebo Comparator|Placebo Group|Subjects will consume one serving per day (25mg) of the microcrystalline cellulose-based placebo condition for 21 days following baseline testing. Days 1 through 14 subjects will consume the supplement with the first meal of the day and refrain from resistance training. Days 15 through 19, subjects will complete one supervised resistance training each day and consume the supplement approximately 30 minutes prior to the training session. On days 20 and 21, subjects will complete follow-up testing in a manner identical to baseline and consume the supplement approximately 30 minutes prior to their arrival at the laboratory.
89070512|NCT01170039|Active Comparator|Lubiprostone|
89070513|NCT01170039|Placebo Comparator|Placebo|
89070514|NCT01169649|Experimental|islet cell carcinomas and carcinoid tumors|This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.
89070515|NCT01169493|Experimental|VVI-40 to RV DDD-40 to Bi-V DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
89070516|NCT01169493|Experimental|VVI-40 to Bi-V DDD-40 to RV DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
89070517|NCT01169493|Experimental|Bi-V DDD-40 to VVI-40 to RV DDD-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
89070518|NCT01169493|Experimental|Bi-V DDD-40 to RV DDD-40 to VVI-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
89229879|NCT00999362||Early kidney-transplant recipients|Patients receiving a kidney transplantation at Aarhus University Hospital, Skejby and receiving tacrolimus as part of their immunosuppressive regime.
89070519|NCT01169493|Experimental|RV DDD-40 to VVI-40 to Bi-V DDD-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
89070520|NCT01169493|Experimental|RV DDD-40 to Bi-V DDD-40 to VVI-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
89070521|NCT01287104|Experimental|Pre-Bone Marrow Transplant (BMT) Prep Regimen|Pre-bone marrow transplant (BMT) Prep Regimen with Stem Cell and natural killer (NK) Cell Infusions coupled with Induction therapy
89070522|NCT05593562|Experimental|SPH3127|Oral 100 mg [14 c] SPH3127 mixed suspension
89070523|NCT01286558|Experimental|80mg telmisartan and 5mg amlodipine FDC|once daily
89070524|NCT01286558|Active Comparator|40mg telmisartan and 5mg amlodipine FDC|once daily
89070525|NCT01169103|Experimental|recombinant human growth hormone|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
89070526|NCT01169103|Placebo Comparator|Placebo|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
89070527|NCT01286480|Experimental|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
89229880|NCT00999362||stable kidney transplant recipients|Tacrolimus treated kidney-transplant recipients from the out-door clinic at Aarhus University Hospital, Skejby and more than two years after transplantation
89229881|NCT00055471|Experimental|ZD4054 10 mg|1 x 10 mg oral tablets once daily
89229882|NCT00055471|Experimental|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
89229883|NCT00055471|Experimental|ZD4054 22.5 mg|2 x 10 mg + 1 x 2.5 mg oral tablets once daily
89223905|NCT04899388|Active Comparator|PENG|the patients lied in the supine position. The probe was originally placed in a transverse plane above the anterior superior iliac spine in the ipsilateral surgical site and then counterclockwise rotated about 45 degrees to line up with the pubic ramus. The iliopubic eminence, iliopsoas muscle and tendon, femoral artery, and pectineus muscle were all visible in this view. By an in-plane technique, from lateral to medial, a 22-gauge, 80-mm needle was placed in the musculofascial plane between both the psoas tendon anteriorly and the pubic ramus posteriorly .The local anesthetic medication was delivered after negative aspiration while looking out for proper fluid distribution for a total volume of 20 mL of Bupivacaine 0.25%
89223906|NCT04899388|Active Comparator|ESPB|"TThe patient was positioned at the lateral decubitus posture in the ipsilateral surgical site. The convex USG transducer was moved from the midline to the side of the operation and positioned 4-6 cm lateral to the L3 spinous process in a longitudinal parasagittal plane. The needle was advanced using the in-plane superior-to-inferior approach. The needle was advanced with the tip introduced up to the plane anterior to the erector spinae muscle and the posterior surface of the L3 transverse process. 0.5-1 ml of normal saline was administered for hydrodissection and to ensure proper placement .If there was any resistance during administering local anesthesia, the needle was modified by drawing it back a few millimeters. the prepared local anesthetic solution 20 ml bupivacaine 0.25 % was delivered through the point between both the transverse process and the erector spinae muscle"
89223907|NCT04899388|Placebo Comparator|control|patients received spinal anesthesia without any block
89223908|NCT04887571||Observational ACS Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an acute coronary syndrome will be recruited into the PERFUSION registry across the study duration.
89223909|NCT04880785|Experimental|Dovato (Dolutegravir+lamivudine)|Treatment: Dolutegravir 50 mg/Lamivudine 300 mg, one film coated-tablet once daily during 96 weeks
89223910|NCT04878601|Experimental|hbART|Home-Based ART initiation and continuation for 3-months with male-specific counseling and assisted facility navigation at 4-months.
89223911|NCT04878601|Active Comparator|fbART|Facility-Based ART initiation and continuation with male-specific counseling.
89223912|NCT04874246|Active Comparator|Diluted Vasopressin Group 1|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 50 ml of normal saline to make a total of 100 ml) was injected before uterine serosal incision.
89223913|NCT04874246|Active Comparator|Diluted Vasopressin Group 2|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 200 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
89223914|NCT04874246|Active Comparator|Diluted Vasopressin Group 3|During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 400 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
88812921|NCT01833650|Experimental|Candy plus thymus honey mouthwash 24|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
89223915|NCT04865731|Experimental|Dermaprazole|30 HNC patients who will be using Dermaprazole twice daily for 7 weeks
89070528|NCT01286480|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies. Time-pressured clinic visits limit the opportunity to discuss many of the topics noted above.
89070529|NCT01286168|Experimental|Antisepsis Side|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days. The drainage bulb will be irrigated with 10ml of 0.125% sodium hypochlorite (Dakin's solution) twice a day.
89070530|NCT01286168|Other|Control Side|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
89070531|NCT01286012|Active Comparator|SFP in liquid bicarbonate|
89070532|NCT01286012|Placebo Comparator|Placebo: Conventional Liquid Bicarbonate|Control concentrate lacking SFP does not contain SFP (total iron = 0)
89070533|NCT02889692|Experimental|TCM granules plus EGFR-TKIs|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day，until progression or unacceptable toxicity."
89070534|NCT02889692|Placebo Comparator|Placebo granules plus EGFR-TKIs|Placebo granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day until progression or unacceptable toxicity.
89070535|NCT05569382|Active Comparator|Verapamil|
89070536|NCT05569382|Active Comparator|Bisoprolol|
89070537|NCT05569382|Placebo Comparator|Placebo|
89070538|NCT00623792|No Intervention|1|Usual preoperative care
89070539|NCT00623792|Experimental|2|Preoperative Lifestyle Intervention
89070540|NCT00963547|Experimental|Pt. 1: MK-2206 45mg, QOD + Trastuzumab|Participants in Part 1 (Pt. 1) receive MK-2206 45 mg every other day (QOD), taken orally. In combination with MK-2206, trastuzumab is administered by intravenous (IV) infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg every 3 weeks (q3wk).
89070541|NCT00963547|Experimental|Pt. 1: MK-2206 60mg, QOD + Trastuzumab|Participants in Pt. 1 receive MK-2206 60 mg QOD, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
89223916|NCT04865731|Active Comparator|Aquaphor|15 HNC patients using Aquaphor, the current clinical standard of care
89223917|NCT04844944||Heart Failure|Hospitalized patients diagnosed with Heart Failure. No Intervention.
89223918|NCT04844944||Coronary Artery Disease|Hospitalized patients diagnosed with Coronary Artery Disease. No Intervention.
89070542|NCT00963547|Experimental|Pt. 1: MK-2206 135mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 135 mg once weekly (QW), taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
89223919|NCT04844944||Atrial Fibrillation|Hospitalized patients diagnosed with Atrial Fibrillation. No Intervention.
89229884|NCT01004666||Women with equivocal findings on Mammography, US and/or MRI|Women with equivocal findings on Mammography, US and/or MRI
89223920|NCT04813159|Active Comparator|Remote Ischaemic Conditioning (RIC)|Consented STEMI participants presenting < 24 hours who are randomised to the RIC protocol, will receive blood pressure cuff inflation by the automated RIC blood pressure device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
89223921|NCT04813159|Sham Comparator|Sham-control|Consented STEMI participants presenting < 24 hours who are randomised to the sham protocol will receive low-pressure cuff inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff. The sham control protocol will be repeated daily for the next 2 days.
89223922|NCT04813159|No Intervention|Observational|Consented STEMI participants presenting > 24 hours but within 72 hours of MI onset will be recruited into the observational arm of the study which will have the same study endpoints as the RCT. These participants will not be randomised or receive any trial intervention.
89223923|NCT04808869|Sham Comparator|Control|Cycling at 70 rpm 3 times/week without any blood flow restriction cuffs
89223924|NCT04808869|Experimental|BRF 60% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in one leg.
89223925|NCT04808869|Experimental|BFR 80% Unilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in one leg.
89070543|NCT00963547|Experimental|Pt. 1: MK-2206 200mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 200 mg QW, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
89070544|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 500mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the maximum tolerated dose defined in Part 1 (Pt. 1 MTD). MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 500 mg taken orally once daily (QD).
89223926|NCT04808869|Experimental|BFR Bilateral 60%|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 60% occlusion in both legs.
89223927|NCT04808869|Experimental|BFR 80% Bilateral|Cycling at 70 rpm 3 times/week with blood flow restriction cuffs at 80% occlusion in both legs.
89070545|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 750mg, QD|Participants in Pt. 2 receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 750 mg taken orally QD.
89070546|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 1000mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 1000 mg taken orally QD.
89070547|NCT01285310|Experimental|Apremilast 30 mg|
89070548|NCT01285310|Experimental|Apremilast 20 mg|
89070549|NCT01285310|Placebo Comparator|Placebo|
89070550|NCT01254630|Experimental|V212-STM|Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
89070551|NCT01254630|Experimental|V212-HM|Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
89070552|NCT01254630|Placebo Comparator|Placebo-STM|Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
89070553|NCT01254630|Placebo Comparator|Placebo-HM|Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
89070554|NCT01284140|Experimental|Sleep promotion protocol|Behavioral: 48 hours of sleep and circadian rhythm promotion including timed light exposure.
89070555|NCT01284140|Active Comparator|Usual care|Behavioral: 48 hours of usual care.
89070556|NCT01254318||Participants at high risk for IFI|Participants will be considered high risk if they are undergoing high dose chemotherapy for leukemia. This includes, but is not limited to participants with acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. Participants are also considered to be at high risk for IFI if they have undergone allogeneic hematopoietic stem-cell transplantation.
89070557|NCT04319796||Ataxia & HSP|Patients suffering of Ataxia or HSP or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these Rare Neurological Disease (RND).
89070558|NCT04319796||Leukodystrophies|Patients suffering of Leukodystrophies or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
89070559|NCT04319796||Frontotemporal Dementia|Patients suffering of Frontotemporal Dementia or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
89070560|NCT04319796||Dystonia, Paroxysmal Disorders and Neurodegeneration with|Patients suffering of Dystonia, Paroxysmal Disorders and Neurodegeneration with Brain Iron Accumulation (NBIA) or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
89070561|NCT04319796||Atypical Parkinsonism|Patients suffering of Atypical Parkinsonism or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by this RND.
89070562|NCT04319796||Huntington's Disease & Choreas|Patients suffering of Huntington's Disease or Choreas or probands who are at risk to develop such a disease since they are first degree relatives of patients affected by these RND.
89070563|NCT01284062|Experimental|Arm 1|200 mg PF-05230917, Anrukinzumab active dose level
89070564|NCT01284062|Experimental|Arm 2|400 mg PF-05230917, Anrukinzumab active dose level
89070565|NCT01284062|Experimental|Arm 3|600 mg PF-05230917, Anrukinzumab active dose level
89070566|NCT01284062|Placebo Comparator|Arm 4|Matching placebo - administered at matching dose level 200 mg, 400 mg or 600 mg.
89070567|NCT01253304|Experimental|Normal hepatic function|LY2189265: A single, subcutaneous (SC) 1.5-milligram (mg) injection on Day 1 in participants with normal hepatic function
89070568|NCT01253304|Experimental|Mild hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with mild hepatic impairment (Child-Pugh A)
89070569|NCT01253304|Experimental|Moderate hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with moderate hepatic impairment (Child-Pugh B)
89070570|NCT01253304|Experimental|Severe hepatic impairment|LY2189265: A single, SC-1.5 mg injection on Day 1 in participants with severe hepatic impairment (Child-Pugh C)
89070571|NCT04319484|Experimental|lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
89070572|NCT04319484|Placebo Comparator|Placebo|The placebo pills are made identical to the investigating lenvatinib in appearance
89070573|NCT01253226|Experimental|30 milligrams (mg) Tabalumab|30 mg tabalumab every 4 weeks (Q4W) for 20 weeks (6 doses of study drug)
89223928|NCT04777006|Experimental|Cluster 1 (First Cluster of Clinics Randomized to Receive Care)|Arm 1 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 3 of the trial
89070574|NCT01253226|Experimental|60 mg Tabalumab|60 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
89070575|NCT01253226|Experimental|120 mg Tabalumab|120 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
89070576|NCT01253226|Placebo Comparator|Placebo Q4W|Q4W for 20 weeks
89070577|NCT01253226|Experimental|120 mg once every 2 weeks (Q2W) Tabalumab|Initial loading dose of 240 mg tabalumab followed by 120 mg Q2W for 20 weeks (10 doses of study drug)
89070578|NCT01253226|Placebo Comparator|Placebo Q2W|Q2W for 20 weeks
89070579|NCT01252290|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
89070580|NCT02888418|Experimental|One dose of HPV vaccine in women aged 18 to 30|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 18 to 30.
89070581|NCT02888418|Placebo Comparator|Placebo in women aged 18 to 30|Placebo in women aged 18 to 30.
89070582|NCT02888418|Experimental|One dose of HPV vaccine in women aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 9 to 17.
89070583|NCT02888418|Placebo Comparator|Placebo in women aged 9 to 17|Placebo in women aged 9 to 17.
89070584|NCT02888418|Experimental|One dose of HPV vaccine in men aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in men aged 9 to 17.
89070585|NCT02888418|Placebo Comparator|Placebo in men aged 9 to 17|Placebo in men aged 9 to 17.
89070586|NCT02888340|Experimental|Acupuncture|One session of acupuncture prior to receiving pain medications after arriving to the emergency department with pain as a symptom.
89070587|NCT02888340|No Intervention|Usual Care|Usual care for pain, without intervention, after arriving to the emergency department with pain as a symptom.
89070588|NCT01252134|Other|Synergi, then Biotrue, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
89229885|NCT01004666||Discrepancy between clinical examination and imaging|Women with discrepancy between clinical examination and breast imaging
89070589|NCT01252134|Other|Synergi, then OTE, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
89070590|NCT01252134|Other|Biotrue, then OTE, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
89070591|NCT01252134|Other|Biotrue, then Synergi, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
89070592|NCT01252134|Other|OTE, then Biotrue, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
89070593|NCT01252134|Other|OTE, then Synergi, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
89070594|NCT01251744|Experimental|CMV Mothers' Group|Pregnant subjects with confirmed primary CMV infection.
89070595|NCT01251744|Experimental|CMV Newborns' Group|Offsprings of the CMV Mothers' Group, also tested for CMV infection, comprising infants that were live born.
89070596|NCT00624312|Active Comparator|1|Pre-operatively randomized to Procrit
89070597|NCT00624312|Placebo Comparator|2|Pre-operatively randomized to placebo
89070598|NCT01251354|Experimental|BN83495|
89070599|NCT01251276|Experimental|Modified Process Hepatitis B Vaccine in Base Study|Participants who received 3 doses of Modified Process Hepatitis B Vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
89070600|NCT01251276|Experimental|ENGERIX-B™ Vaccine in Base Study|Participants who received 3 doses of ENGERIX-B™ vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
89070601|NCT01251120|Experimental|1|
89070602|NCT01251120|Active Comparator|2|
89070603|NCT01250418|Active Comparator|Ketamine Group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
89070604|NCT01250418|No Intervention|No ketamine|No ketamine added to anesthesia regimen
89070605|NCT04319562|Experimental|needle-embedding therapy|The participants in this group will be treated with intradermal thumbtack needle.
89070606|NCT04319562|Sham Comparator|shame needle-embedding therapy|The participants in this group will be treated with shame intradermal thumbtack needle.
89070607|NCT05490810|Experimental|Trunk stabilization|Trunk stabilization exercises were given three times a week for two weeks.
89070608|NCT05490810|Experimental|Activation exercises|Activation exercises exercises performed twice for 5s, with 2 min rest between them for three times a week for two weeks.
89070609|NCT01292603|Experimental|1|
89070610|NCT01292603|Experimental|2|
89070611|NCT01292603|Experimental|3|
89070612|NCT01292057|Active Comparator|Aripiprazole|Medication
89070613|NCT01292057|Placebo Comparator|Sugar pill|
89070614|NCT01291277|Active Comparator|Ligation: 1-week interval|Endoscopic variceal ligation performed at 1-week intervals
89070615|NCT01291277|Active Comparator|Ligation 2-week interval|Endoscopic variceal ligation performed at 2-week intervals
89070616|NCT01290887|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.
89070617|NCT01290731|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24 (PR 24). Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels less than (<) 1.2 log10 IU/mL detectable or undetectable of at Week 4, and undetectable HCV RNA levels at Week 12. All other participants will continue PR until Week 48 (PR 48).
89070618|NCT01290341|Experimental|NAFT-600 ( naftin 2 % gel)|Topical; applied once daily for two weeks
89070619|NCT01290341|Placebo Comparator|Placebo|Topical; applied once daily for two weeks.
89070620|NCT01290263|Experimental|Amgen 386|Cohort A will assess recurrent Glioblastoma Multiforme (GBM) patients who receive AMG 386 monotherapy at 30mg/kg every week. As of August 1, 2013, Cohort A was closed to new accrual following early interim analysis of first 10 participants enrolled on study. None of these patients had achieved stable disease or response at their initial evaluation after 1-2 months of study therapy. Therefore, study investigators and sponsor agreed that the level of single-agent anti-tumor activity associated with AMG386 for recurrent glioblastoma patients is most likely insufficient to satisfy the stopping rule for low efficacy outlined in Section 14.5 for Cohort A.
89223929|NCT04777006|Experimental|Cluster 2 (Second Cluster of Clinics Randomized to Receive Care)|Arm 2 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 6 of the trial
89070621|NCT01290263|Experimental|Amgen 386 and Bevacizumab|Cohort B will assess recurrent Glioblastoma Multiforme(GBM) patients who receive AMG 386 plus bevacizumab. Because the maximum tolerated dose of this combination therapy has not yet been established, a 3x3 Phase I study was used to determine the maximum tolerated dose. As of June 6, 2014, the MTD was determined to be AMG386 30 mg/kg administered intravenously every week(dose level +1) in combination with bevacizumab at 10mg/kg administered intravenously every other week. As of July 25, 2014 the Cohort B, Phase II portion of the study was opened to accrual.
89070622|NCT01290029|Experimental|Cinacalcet|Participants received a single, oral dose of 0.25 mg/kg cinacalcet.
89070623|NCT02890199|Active Comparator|Lidocaine group|0.5% lidocaine mixed with 1:200,000 epinephrine 70 milliliters (mL) will be used for local injection at the sacrospinous ligament and for anterior / posterior colporrhaphy
89070624|NCT02890199|Experimental|Bupivacaine liposomal group|1.3% bupivacaine liposomal (20 mL) injected at the sacrospinous ligament 0.5% lidocaine mixed with 1:200,000 epinephrine 50mL for the anterior / posterior colporrhaphy
89070625|NCT04324073|Experimental|SARILUMAB|Sarilumab (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1).
89070626|NCT04324073|No Intervention|Standard of care|best standard of care
89070627|NCT01289639|Placebo Comparator|Placebo|matching placebo 1 po qd
89070628|NCT01289639|Experimental|Fenofibrate|micronized fenofibrate 200 mg 1 po qd
89070629|NCT01289639|Experimental|Pioglitazone|pioglitazone 30 mg po qd
89070630|NCT01289015|Experimental|NAFT-600 ( naftin 2 % gel)|
89070631|NCT01289015|Placebo Comparator|Placebo|
89070632|NCT01288937|Experimental|Milnacipran|Patients will receive Milnacipran
89070633|NCT01288937|Placebo Comparator|Placebo|Patients will receive Placebo
89070634|NCT01288469|Placebo Comparator|Placebo + Atorvastatin 80 mg|Placebo (for alirocumab) subcutaneous (SC) administration every 2 weeks (Q2W) in combination with atorvastatin 80 mg orally once daily for 8 weeks.
89070635|NCT01288469|Experimental|Alirocumab + Atorvastatin 10 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 10 mg orally once daily for 8 weeks.
89070636|NCT01288469|Experimental|Alirocumab + Atorvastatin 80 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 80 mg orally once daily for 8 weeks.
89070637|NCT02890043|Experimental|Robot|Intervention: Surgery: robot-assisted spine surgery, device: TiRobot surgery system
89070638|NCT02890043|Active Comparator|Free-hand|Intervention: Surgery: free-hand surgery
89070639|NCT01288079|Experimental|1|TC-5214, 1 mg BID
89070640|NCT01288079|Experimental|2|TC-5214, 4 mg BID
89070641|NCT01288079|Active Comparator|3|Duloxetine 60 mg Q Day
89070642|NCT01288079|Placebo Comparator|4|Placebo
89070643|NCT00623753|Experimental|A|
89070644|NCT01287221|Active Comparator|Rifampicin|Subjects randomized to this arm will receive 300 mg Rifampicin two times a day for 12 months.
89070645|NCT01287221|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo capsules twice daily for 12 months. The capsules will contain riboflavin (vitamin B2).
89070646|NCT01168401|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus Bivalent GI.1 and GII.4 VLP Vaccine, adjuvanted with 50 microgram (mcg) MPL and 500 mcg Al(OH)3, IM, on Days 0 and 28.
89070647|NCT01168401|Placebo Comparator|Saline|
89070648|NCT02889965||Radiologically Isolated Syndromes (RIS)|
89070649|NCT02889965||Clinically Isolated Syndromes (RIS)|
89070650|NCT02889965||Primary progressive MS (PPMS)|
89070651|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - AM dosing|FF(100mcg)/Vilanterol(25mcg) in the morning (approx 09.00) for 14 days (± 2 days).; placebo in evening (approx 21.00) for 14 days (± 2 days).
89070652|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - PM dosing|Placebo in morning (approx 09.00) for 14 days (± 2 days); FF(100mcg)/Vilanterol(25mcg) in evening (approx 21.00) for 14 days (± 2 days).
89070653|NCT01287065|Placebo Comparator|Placebo|Placebo given in morning (approx 09.00) and in evening (approx (21.00) for 14 days (± 2 days).
89070654|NCT04314999||Patients diagnosed with a chronic spontaneous urticaria|Patients with a chronic spontaneous urticaria who were being treated at the allergology of the university hospital Basel between the 1st of June and the 30th of September
89070655|NCT01167153|Experimental|Valsartan/amlodipine|Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
89070656|NCT01167153|Active Comparator|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
89070657|NCT02886273||Group 1|SCA with first MI (n = 43)
89070658|NCT02886273||Group 2|SCA with AMI and previous MI (n = 10)
89070659|NCT02886273||Group 3|SCA without AMI and without former heart disease (n = 3)
89070660|NCT02886273||Group 4|SCA without AMI and with known heart disease (n = 18)
89070661|NCT01166763|Experimental|high dose vitamin D3 (10,000 IU weekly)|Group/Cohort Label vitamin D3
89070662|NCT02886039|Other|patients|Patient with cardiac arrest benefiting an electroencephalogram
89070663|NCT02885961|Other|Dabigatran|"All patients will be entered into the arm, i.e. this is a single arm study. All patients will complete 2 FDG PET scans. All patients will receive dabigatran (direct thrombin inhibitor) at a dose of 110mg twice daily (oral).~The drug will be given for 24 days (+/-3 days). The variation in duration reflects that scans are completed Monday to Friday only."
89070664|NCT02885727|Experimental|Durvalumab + Radiation therapy|"Durvalumab (MEDI4736) 750 mg (or 10mg/kg if the patient weighs <30 kg) IV Q2W over 1 hour for all patients + Radiation therapy~First lesion to receive 25 Gy / 5 daily consecutive fractions of 5 Gy~Second lesion to receive15 Gy / 5 daily consecutive fractions"
89229886|NCT01004666||Women with dense breast|Women with dense breast
89070665|NCT01166373|Experimental|Enrollment video arm|Arm of subjects that will be shown a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
89070666|NCT01166373|No Intervention|No video intervention arm|This group of subjects will not view a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
89070667|NCT01166373|Experimental|ULS|Uterosacral Ligament Suspension was one of the randomized surgical treatments in the OPTIMAL study
89070668|NCT01166373|Experimental|SSLF|Sacrospinous Ligament Fixation was one of the randomized surgical treatments in the OPTIMAL study.
89070669|NCT01166373|Experimental|PMT|Perioperative Behavioral Therapy/Pelvic Muscle Training was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
89070670|NCT01166373|Other|Usual Care|No Perioperative Behavioral Therapy/Pelvic Muscle Training (i.e., usual care) was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
89070671|NCT04314765|Experimental|bayonet flap|Bayonet flap is performed to extract the the lower third molar
89070672|NCT04314765|Experimental|envelope flap|Envelope flap is performed to extract the the lower third molar
89070673|NCT00963235|Experimental|1|
89070674|NCT02861833||Patients with a cancerous wound|major patients followed in a cancer ward and holders of a cancerous wound.
89070675|NCT04284163|Experimental|Gamification group|Problem solving based methodology
89070676|NCT04284163|Active Comparator|Traditional teaching group|Master lesson methodology
89070677|NCT04284085|Experimental|Intervention group|There will be psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
89070678|NCT04284085|No Intervention|Control group|They will receive a fact sheet on suicide and also tips on how to increase suicidal ideation.
89070679|NCT01165281|Experimental|001|R331333 (referred to as JNS024 ER or CG5503) One 25 mg to 200 mg capsule twice daily for 4 weeks.
89070680|NCT01165281|Active Comparator|002|Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.
89070681|NCT04283929|Experimental|Intervention 1 (Int1)|Facilities assigned to the enhanced package for Int1 will receive alerts and reminders to promote linkage of HIV positives from diagnosis to care.
89070682|NCT04283929|No Intervention|Control 1 (Ctrl1)|Facilities assigned to the Ctrl1 will not receive any additional equipment, software tools, training or other forms of support.
89070683|NCT04283929|Experimental|Intervention 2 (Int2)|Randomise the Intervention 1 group into two additional arms: Intervention 2 (Int2) and Control (Ctrl2). Facilities assigned to Int2 will also receive alerts and reminders to improve lab reporting as part of their enhanced package.
89070684|NCT04283929|No Intervention|Control 2 (Ctrl2)|Facilities assigned to the Ctrl2 will not receive any additional equipment, software tools, training or other forms of support to improve lab reporting as part of their enhanced EMR.
89070685|NCT04283929|Experimental|Intervention 3 (Int3)|Randomise the Intervention 2 group into two additional arms: Intervention 3 (Int3) or Control (Ctrl3). Facilities assigned to Int3 will receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
89070686|NCT04283929|No Intervention|Control (Ctrl3)|Facilities assigned to Ctrl3 will not receive alerts and reminders to improve clinical response to the detection of treatment failure as part of their enhanced package.
89070687|NCT02861053|Experimental|chronic quiet inflammatory bowel disease patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with regular and moderate physical activity
89070688|NCT02861053|Sham Comparator|chronic quiet inflammatory bowel disease Patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with no regular and moderate physical activity more than usual
89070689|NCT02860897|Experimental|Vaginal estrogen cream|
89070690|NCT02860897|Experimental|Vaginal estrogen tablet|
89070691|NCT04314609|Experimental|Ultrasound , fluroscope|After injection of corticosteroids with 1 ml contrast in sacroiliac joint using ultrasound and withdrawal of the needle, an antero-posterior fluoroscopy image will be obtained and recorded for the injected joint to detect the spread pattern of the contrast and whether its pre-dominantly intra or periarticular.
89070692|NCT02860819|Experimental|Gemcitabine, Carboplatin, Veliparib|Gemcitabine 800mg/m2 day 1 and 8 every 3 weeks; Carboplatin AUC = 4, day 1, every 3 weeks, Veliparib 250mg bid day continuously.
89070693|NCT05367453|Active Comparator|Lactase|Volunteers will consume once a day for 1 month a tropical juice (orange, mango, pineapple and turmeric) and a lactase tablet
89070694|NCT05367453|Experimental|Probiotic|Volunteers will consume once a day for 1 month the probiotic added to a liquid matrix (tropical juice) and and a placebo tablet (cornstarch)
89070695|NCT04284007|Active Comparator|Perineural levobupivacaine with intravenous saline|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous saline.
89070696|NCT04284007|Experimental|Perineural dexamethasone in addition to levobupivacaine|Patients will receive levobupivacaine-dexamethasone in interscalene brachial plexus block plus intravenous saline.
88812922|NCT01833650|Experimental|Candy plus thymus honey mouthwash 1|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
88812923|NCT03213470|Other|Intracranial artery dissection|Patients with intracranial artery dissection who were diagnosed based on the clinical and radiological (including MRI) diagnoses at the symptom onset after Jan-01-2016
89070697|NCT04284007|Experimental|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive levobupivacaine plus saline in interscalene brachial plexus block in addition to intravenous dexamethasone.
89070698|NCT02861677|No Intervention|Control group|The control group will receive the usual medical care by physicians and nurses
89070699|NCT02861677|Experimental|Intervention group|the intervention group will receive clinical pharmacy services
89070700|NCT02861287||Study cohort|patients with Multiple Myeloma who underwent PBSC mobilization since December 2009 and who received plerixafor in line with inclusion criteria
89229887|NCT01004666||Women in high risk for Breast Cancer|Women in high risk for Breast Cancer. Including patients with genetic high risk and/or strong family history.
88812924|NCT01833728|Experimental|nefopam-propacetamol combination group|
89070701|NCT02861287||Historical cohort|patients with Multiple Myeloma who underwent PBSC mobilization immediately prior to marketing authorization and clinical utilization of Plerixafor which is before December 2009 (over the 2007-2009 period)
89070702|NCT01165203|Experimental|GSK1437173A Group|Subjects who received three doses of GSK1437173A vaccine (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
89229888|NCT01004900|Active Comparator|Trabeculoplasty|
89229889|NCT01004900|Active Comparator|Control (Medication)|
89070703|NCT01165203|Placebo Comparator|Placebo Group|Subjects who received three doses of placebo (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
89070704|NCT00960661|Experimental|Exenatide (BET)|Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET)
89070705|NCT00960661|Active Comparator|Insulin Lispro (BBT)|Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT)
89070706|NCT04282993|Experimental|Wearable Devices Monitoring|Patients will be provided with wearable devices for at-home monitoring heart rhythm and rate, blood pressure, pulse oximetry, quality and quantity of sleep, and pace counting.
89070707|NCT04282993|Active Comparator|Standard of Care Monitoring|Patients will be evaluated by periodical clinical visits.
89070708|NCT00960193|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
89070709|NCT00960193|Experimental|Colchicine with Seville Orange Juice|colchicine pharmacokinetics in presence of Seville orange juice
89070710|NCT00960115|Experimental|Tecemotide (L-BLP25) + Cyclophosphamide|Active
89070711|NCT00960115|Placebo Comparator|Placebo + Saline|Control
89070712|NCT04281355|Experimental|Randomisation A - Intervention|In pathologically node-negative patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, no regional radiotherapy is given and no axillary lymph node dissection are performed.
89070713|NCT04281355|Experimental|Randomisation B - Intervention|In pathologically node-positive patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, full axillary and regional radiotherapy is given but no axillary lymph node dissection performed.
88812925|NCT01833728|Active Comparator|propacetamol alone group|
89070714|NCT04281277|Active Comparator|low target group|"target of mean arterial pressure(MAP) at 65-70 mmHg.~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
89223930|NCT04777006|Experimental|Cluster 3 (Third Cluster of Clinics Randomized to Receive Care)|Arm 3 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 9 of the trial
89070715|NCT04281277|Experimental|high target group|"target of mean arterial pressure (MAP) at 80-85 mmHg.~The therapeutic means used to obtain the MAP objectives within each group (increase in catecholamines and / or volume expansion) are left to the discretion of the clinician, in accordance with the recommendations."
89070716|NCT04281121|Active Comparator|supplemented|Life style modification, diet regimen and Omega-3 fatty acids supplementation
89070717|NCT04281121|Active Comparator|non supplemented|Life style modification and diet regimen
89070718|NCT00959647|Experimental|Vismodegib 150 mg|Participants received 150 mg vismodegib orally once a day until disease progression, intolerable toxicity, or withdrawal from the study. If a participant had been receiving combination chemotherapy and/or biotherapy (FOLFOX, FOLFIRI, bevacizumab) in a parent study, the same combination chemotherapy and/or biotherapy as specified in the parent study could be continued in this study at the discretion of the investigator.
89070719|NCT02859493|Active Comparator|Saccharomyces cerevisiae|Inactivated whole yeast Saccharomyces cerevisiae presented in vaginal capsules. 1 capsule a day for 14 days.
89070720|NCT02859493|Placebo Comparator|Maize starch and magnesium stearate|Placebo presented in a vaginal capsule. 1 capsule a day for 14 days
89070721|NCT02859649|Experimental|healthy volunteers|
89070722|NCT02808403||Evolocumab exposed|Patients for whom evolocumab is prescribed. Dosage, period (start/end date), frequency of injection (Every 2 weeks (Q2W), Every 4 weeks (Q4W)), drug withdrawal (Yes or No, date, reason) and injection site (upper arm, abdomen, thigh) of evolocumab will be collected.
89070723|NCT00957931|Experimental|Mesenchymal stromal cells|
89070724|NCT00957853|Experimental|Group 1: Cetuximab|Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes
89070725|NCT00957853|Experimental|Group 2: IMC-A12|IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3.
89070726|NCT00957853|Experimental|Group 3: Cetuximab + IMC-A12|"Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes.~IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3."
89070727|NCT02858167|Experimental|FDG-PET|
89070728|NCT02858245||Commercial MitraClip® patients|Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device
89070729|NCT00957229|Placebo Comparator|Sugar pill|placebo pill by mouth once daily
89070730|NCT00957229|Experimental|GDC-0449|vismodegib 150MG by mouth once daily
89070731|NCT02604511|Experimental|Ibrutinib|This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
89223931|NCT04777006|Experimental|Cluster 4 (Fourth Cluster of Clinics Randomized to Receive Care)|Arm 4 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 12 of the trial
89070732|NCT02858011|Active Comparator|Control and comparison group -cash transfer program|The program is implemented during 48 months. During the first 36 months the control group does not receive any intervention. During the last 12 months eligible beneficiaries receive cash transfer and accompanying information sessions on health, child nutrition, household economics every three months (identical to experimental group).
89070733|NCT02858011|Experimental|Jigisemejiri cash transfer program|Unconditional cash is distributed every 3 months to beneficiaries of the Jigisemejiri program. During cash handouts, information sessions on health, child nutrition, households economics and education are organized by local NGOs.
89070734|NCT02858011|Experimental|Jigisemejiri - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women receiving rations of fortified flour (PNP) during the last 12 months of the project
89070735|NCT02858011|Active Comparator|Control and comparison group - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women
89070736|NCT02859571|Active Comparator|Continuous oxytocin|oxytocin will be used at a starting dose of 1-2 mIU/min and the dose will be increased by 2 mIU/min at every 15 minutes until regular contractions will be obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin will 40 mIU/min and oxytocin will be administered until delivery.
89070737|NCT02859571|Experimental|intermittent oxytocin|oxytocin will be discontinued when cervical dilation will 5 cm and 2 hours after discontinuation oxytocin will be reused at a starting dose of 1-2 mIU/min and will be increased as the same protocol will be used for continuation oxytocin group.
89070738|NCT04282369|Active Comparator|HHFNC|In this group patients will receive respiratory support by high flow nasal cannula.
89070739|NCT04282369|Active Comparator|nCPAP|In this group patients will receive respiratory support by nasal CPAP.
89070740|NCT04282369|Active Comparator|nIPPV|In this group patients will receive respiratory support by nasal IPPV.
89070741|NCT04282369|Active Comparator|nHFO|In this group patients will receive respiratory support by nasal high frequency oscillatory. ventilation.
89070742|NCT04280809|Experimental|Laser|Subsequently to the suture, laser was applied in the right or left side randomly on each patient, according to a sheet of randomization. GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2.
89070743|NCT04280809|No Intervention|Non-laser|Every patient, on the control side, the same handpiece was applied intraorally, but laser was not activated
89070744|NCT00956839|Active Comparator|Group A|IM Vitamin D3 3,00,000 Units single dose
89070745|NCT00956839|Active Comparator|Group B|IM vitamin D3 6,00,000 Units single dose
89070746|NCT00956839|Active Comparator|Group C|Oral vitamin D3 500 Units/ day
89070747|NCT00956293|Active Comparator|Control group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group continued with a CNI-based regimen of MPA and CsA.
89070748|NCT00956293|Experimental|Everolimus group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group made a stepwise switch to a CNI-free regimen of everolimus and MPA.
89070749|NCT04204369|Experimental|Teaching arm|This group received the teaching intervention and was evaluated before and after the intervention. Improvement was compared to their performance prior to the intervention.
89070750|NCT04282291||SIPB (block)|patients who underwent a modified BRILMA (intercostal rami block, middle axilary line) ultrasound-guided block with portable device with lineal probe and needle 80 mm. With the patient lying supine, the probe was placed in the sagittal plane of the middle axillary line to identify the aim thoracic structures. Under aseptic conditions, the needle was inserted in plane, caudo-craneal, to reach the fascial plane between the serratus anterior muscle and the external intercostal muscle at the eighth rib. A bolus dose of levobupivacaine 0.25% was administered, 3 ml of local anesthetic for each segment we want to block
89070751|NCT04282291||control (morphine)|PCA (patient controlled analgesia) morphine was initiated immediately postoperatively using CADD Smith Medical pumps. All patients received PCA-morphine with the initial dose being 0.5-1 mg. The bolus dose was 0.01mg/kg mg morphine, with lockout time interval of 15 - 30 min, limiting of 8mg/hour, as the default program. The continuous (basal) dose was increased after 12-24 hours if using frequent demand doses or if pain not controlled and decreasing if no bolus was taken.
89070752|NCT00955825|Experimental|300 IR|300 IR grass pollen allergen extract tablet
89070753|NCT00955825|Placebo Comparator|Placebo|Pacebo tablet
89070754|NCT02859181|Experimental|Active, Adolescent males|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
89070755|NCT02859103|Active Comparator|Treatment|Patients in this arm will receive treatment with desvenlafaxine for 8 weeks.
89070756|NCT02859103|No Intervention|Healthy Control|Patients in this arm are healthy controls and will not receive any medication.
89070757|NCT04282135||Infected|patients with detected Influenza RNA in nasopharyngeal swabs
89070758|NCT04282135||not infected|patients without detected Influenza RNA in nasopharyngeal swabs
89070759|NCT04282135||SARS CoV2|patients with SARS-Cov-2 infection
89070760|NCT02859025|Active Comparator|A:Iiac|Treated with anterior iliac crest spongy bone to fill defects, followed by coverage with collagen membrane.
89070761|NCT02859025|Experimental|B:MSCs+LRCP|Treated with lateral ramus cortical bone plate (LRCP) to create a protected healing space by fixing it to adjacent walls of the cleft defect. BFPScs were loaded on NBBM and delivered to the defect
89070762|NCT02859025|Experimental|C:MSCs+liac|Treated with anterior iliac crest spongy bone as in Group 1, but BFP-derived mesenchymal stem cells (MSCs ) cultured over NBBM were put over the spongy bone and covered with a collagen membrane.
89070763|NCT02869009|Experimental|clopidogrel plus aspirin group|the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
89070764|NCT02869009|Experimental|aspirin group|the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.
89070765|NCT01164579|Experimental|Tofacitinib (CP 690,550) 10 mg BID plus MTX|
89070766|NCT01164579|Experimental|Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX|
89070767|NCT01164579|Active Comparator|Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk|
89070768|NCT02859259|Experimental|Treatment A: reference extended-release (ER) 1 tablet at 600mg|A single dose of BMS-663068 administered orally as specified
89070769|NCT02859259|Experimental|Treatment B: low-dose ER 4 tablets at 150mg|A single dose (4 tablets) of BMS-663068 administered orally as specified
89070770|NCT04280731|Experimental|Fermented drink|
89070771|NCT02858947|Active Comparator|Aelite Flo|Microhybrid flowable composite
89070772|NCT02858947|Active Comparator|x-tra base|Bulk-fill flowable composite
89070773|NCT00958789|Other|Triathlon TS Knee|Triathlon TS Knee System
89070774|NCT02857777|Experimental|Cohort 1: Japanese elderly subjects (Esketamine)|Subjects will receive Treatment A (28 milligram [mg] of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0) in Period 1, Treatment B (56 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0 and 5 minutes) in Period 2 and then Treatment C (84 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0, 5, and 10 minutes) in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
89070775|NCT02857777|Active Comparator|Cohort 2: Japanese healthy subjects (Esketamine)|Subjects will receive Treatment A in Period 1, Treatment B in Period 2 and then Treatment C in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
89070776|NCT02858635|Experimental|Suicide attempters|Clinical and neuropsychological assessment. Blood and saliva samples in order to answer objectives study.
89070777|NCT05367375||removing patellofemoral joint osteophytes|remove osteophyte at patella, medial femoral condyle and lateral femoral condyle
89229890|NCT01583491|Active Comparator|prf group.peridontal problem|prf insert into surgical site immediate after surgery
89070778|NCT05367375||non-removing patellofemoral joint osteophytes|no remove osteophyte at patella, medial femoral condyle and lateral femoral condyle
89070779|NCT00630643|Placebo Comparator|1|
89070780|NCT00630643|Experimental|2|
89070781|NCT03202849|Experimental|Vitamin D and A Supplementation|Participants receive a single dose of vitamin D and a single dose of vitamin A prior to HSCT.
89070782|NCT03202849|Active Comparator|Vitamin D Supplementation with Placebo|Participants receive a single dose of vitamin D and a single dose of placebo prior to HSCT.
89070783|NCT04277533||Patient group|NEC preterm neonates with gestational ages are between 28-36 weeks regardless of birth weight. NEC diagnosis and staging will be according to Bell's staging criteria .
89070784|NCT04277533||Control group|Stable preterm neonate with matched gestational and postnatal ages without infectious diseases.
89070785|NCT04277221|Experimental|Standard therapy with ADCTA vaccine (study group)|"- ADCTA vaccine as study treatment~Dose(s): Ten doses, including 2~4×10^7 cells for the 1st dose (double doses), and 1~2×10^7cells for the 2nd to 10th doses.~Administrative route: The ADCTA vaccine will be injected in axillar or inguinal regions close to lymphnodes subcutaneously at clinic.~Frequency: The primary immunization inoculation is followed by 3 vaccines bi-weekly and then 6 vaccines monthly inoculation, for a total of 10 doses.~- Bevacizumab as standard therapy"
89070786|NCT04277221|Active Comparator|Standard therapy (control group)|"No study treatment~Bevacizumab as standard therapy"
89070787|NCT02445391|No Intervention|Arm A (observation) (closed to accrual 05/16/2016)|Patients undergo observation.
89070788|NCT02445391|Experimental|Arm B (cisplatin or carboplatin)|Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
89070789|NCT02445391|Active Comparator|Arm C (capecitabine)|Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89070790|NCT01246986|Experimental|Part A Cohort 1-160 milligram (mg) LY2157299|"Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. As of May 25,2012, all newly enrolled participants will receive 300 mg LY2157299.~80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
89070791|NCT01246986|Experimental|Part A Cohort 2 - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
89229891|NCT01583491|Placebo Comparator|control group|
89229892|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 610|
89223932|NCT04777006|Experimental|Cluster 5 (Fifth Cluster of Clinics Randomized to Receive Care)|Arm 5 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 15 of the trial
89070792|NCT01246986|Experimental|Part B - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
89070793|NCT01246986|Experimental|Part C Cohort 1 - 160 mg LY2157299 + 800 mg Sorafenib|"80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
89070794|NCT01246986|Experimental|Part C Cohort 2 - 300 mg LY2157299 + 800 mg Sorafenib|"150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
89223933|NCT04766086|Experimental|GBS6 and Tdap|Multivalent group B streptococcus vaccine and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
89223934|NCT04766086|Experimental|GBS6 and Placebo|Multivalent group B streptococcus vaccine and Placebo
89223935|NCT04766086|Experimental|Placebo and Tdap|Placebo and Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
89223936|NCT04717986|Experimental|Intervention Group|Dapagliflozin 10 mg every 24 hours for 12 months
89070795|NCT01246986|Experimental|Part D Cohort 1 - 160 mg LY2157299 + 8 mg/kg Ramucirumab|"80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
89070796|NCT01246986|Experimental|Part D Cohort 2 - 300 mg LY2157299 + 8 mg/kg Ramucirumab|"150 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
89070797|NCT01164501|Experimental|BI 10773 low dose|BI 10773 tablets once daily
89070798|NCT01164501|Experimental|BI 10773 high dose|BI 10773 tablets once daily
89070799|NCT01164501|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
89070800|NCT05322291|Experimental|Experimental Group|The developed mobile application will be installed on the phones of hemodialysis patients in the experimental group. Online consultancy and training will be provided with the application.
89070801|NCT05322291|No Intervention|Control Group|No intervention will be made. They will continue to receive routine care.
89070802|NCT04276831|Active Comparator|Laryngoscope McCoy|Patients will be intubated using laryngoscope McCoy
89070803|NCT04276831|Active Comparator|Laryngoscope Macintosh|Patients will be intubated using laryngoscope Macintosh
89070804|NCT04282057|Experimental|shockwave therapy group|This group performed aerobic exercise just after shock wave therapy in the abdominal region.
89070805|NCT04282057|Experimental|radiofrequency group|This group performed aerobic exercise just after radiofrequency in the abdominal region.
89070806|NCT04282057|Active Comparator|control group|This group only performed aerobic exercise.
89070807|NCT04319640|Experimental|CBTI|N= 80 participants are offered Cognitive behaviour therapy for insomnia (CBT-I)
89070808|NCT04319640|Active Comparator|psychoeducation|N= 80 participants are offered psychoeducation about information on ASD
89070809|NCT04275271|Experimental|Intervention group|Intervention group will be received sexuality teaching skills for promotion of professional competence based on information, motivation and behavioral skills model for adolescent sexuality after signing informed consent form and being informed about the goals and details of intervention for 6 sessions (one two hour session per week).
89070810|NCT04275271|No Intervention|Control group|The control group will not receive any intervention until the end of the research.
89070811|NCT00958711|Experimental|Biologic - Unite Biomatrix|
89070812|NCT00958711|Active Comparator|Saline and Gauze|
88812926|NCT01833884|Other|Single arm|Collection of blood specimen for Cytokines dosing scheduled before, during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
89070813|NCT01163721|Experimental|Ranolazine|Participants were randomized to receive ranolazine for 12 weeks.
89070814|NCT01163721|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ranolazine for 12 weeks.
89070815|NCT03178981|Active Comparator|Conventional cigarette|Commercially-available combustible cigarette
89070816|NCT03178981|Experimental|Second-generation e-cigarette A|Prototype second-generation (closed-tank) e-cigarette
89070817|NCT03178981|Experimental|Second-generation e-cigarette B|Prototype second-generation (closed-tank) e-cigarette
89070818|NCT03178981|Experimental|Second-generation e-cigarette C|Prototype second-generation (closed-tank) e-cigarette
89070819|NCT03178981|Experimental|Second-generation e-cigarette D|Prototype second-generation (closed-tank) e-cigarette
89070820|NCT03178981|Active Comparator|Second-generation e-cigarette E|Commercially-available second-generation (closed-tank) e-cigarette
89070821|NCT02885493||Falls is <or = 1 year|Patients whose number of falls is <or = 1 year
89070822|NCT02885493||falls is> 1 year|Patients whose numbers falls is> 1 year
89070823|NCT04314453||T group|The degenerative lumbar spinal stenosis patients accepted the PELD with TESSYS procedure.
89070824|NCT04314453||U group|The degenerative lumbar spinal stenosis patients accepted the PELD with U route procedure.
89070825|NCT00958243|Placebo Comparator|Placebo|Placebo
89070826|NCT00958243|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose
89070827|NCT00958243|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose
89070828|NCT04280419||Healty Subjects|Healthy Subjects Twenty-five healthy individuals will be included in the study. Physical properties of cases will be recorded. Respiratory functions and respiratory muscle strength will be evaluated. Physical activity will be assessed using the International Physical Activity Survey (IPAQ). Respiratory muscle endurance will be evaluated using an incremental workload test and fixed threshold load test. Tests will be repeated three times as motivational music, slow-paced music, and music. Heart rate, respiratory frequency, perceived exertion will be evaluated before and after the test.
89070829|NCT02858791||Healthy Controls|"Subjects are made up of healthy adults~Interventions:~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
89070830|NCT02858791||Affected|"Subjects have Pulmonary Hypertension Subjects have Pulmonary hypertension with Interstitial lung disease Subjects have Interstitial lung disease~Interventions:~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
89070831|NCT01241760|Experimental|001 T(q8h) / PR|Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
89070832|NCT01241760|Experimental|002 T(b.i.d.) / PR|Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
89070833|NCT04280263|Active Comparator|Caffiene|This group will receive 150mg caffeine tablets to be taken twice per day
89070834|NCT04280263|Placebo Comparator|placebo|
89070835|NCT02858557|Experimental|Group A|Patients will be allocated to 7 days of Mediterranean diet and then will cross over to 7 days of specific carbohydrate diet
89070836|NCT02858557|Experimental|Group B|Patients will be allocated to 7 days of specific carbohydrate diet and then will cross over to 7 days of Mediterranean diet
89070837|NCT00958165|Experimental|EAS-AC|PVI with EAS-AC
89223937|NCT04717986|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 12 months
89229893|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
89070838|NCT04280185|Experimental|Hyperthermic Intraperitoneal chemotherapy|Hyperthermic Intraperitoneal chemotherapy was started immediately after CRS, or the first HIPEC was completed within 48 hours after surgery: temperature 43℃, duration 60 minutes, Paclitaxel (60mg/m2) was selected. The second HIEPC was completed 7 days after the first HIPEC: temperature 43℃, duration 60min, carboplatin AUC (5-6) was selected. 30 minutes before using Paclitaxel, 10ML saline + 10mg dexamethasone intravenous infusion, 20mg diphenhyramine intramuscular injection, and 100ML saline + 0.3g cimetidine intravenous infusion. On the eighth day, intravenous chemotherapy with Paclitaxel (135mg/m2) was finally completed. 5 courses of TC intravenous chemotherapy were performed after 3 weeks
89070839|NCT04280185|No Intervention|intravenous chemotherapy|intravenous chemotherapy were performed 6 Cycles after CRS. Paclitaxel: 175mg/m2, iv infusion, no less than 3h per infusion, followed by carboplatin: AUC 5-6, iv infusion, no less than 1h per infusion, 1 dose on the first day of a week, 1 cycle every 3 weeks, a total of 6 cycles. Paclitaxel should be pretreated to prevent severe allergic reactions.
89070840|NCT02858479|Other|patients with pain allodynic peripheral|
89070841|NCT02858479|Other|patients with pain allodynic central|
89070842|NCT02857075||Rhesus positive individuals|Red cell concentrates from RH1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
89070843|NCT02857075||Rhesus negative individuals|red cell concentrates from RH-1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
89070844|NCT00953407|Experimental|Nelfilcon A|Nelfilcon A contact lens
89070845|NCT00953407|Active Comparator|Narafilcon A|Narafilcon A contact lens
89070846|NCT00953407|Active Comparator|Etafilcon A|Etafilcon A contact lens
89070847|NCT00953407|Active Comparator|Omafilcon A|Omafilcon A contact lens
89070848|NCT00953407|Active Comparator|Hilafilcon B|Hilafilcon B contact lens
89070849|NCT00953329|Experimental|Alefacept 15 mg IM qweek|Alefacept will be given to subjects with plaque psoriasis who have failed treatment with Fnbrel.
88812927|NCT03217682|Experimental|Music Therapy|Music therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
88812928|NCT03217682|Experimental|Massage Therapy|Massage therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
89070850|NCT02857153|Experimental|Low-level MAP|According to grouping, MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
89070851|NCT02857153|Experimental|High-level MAP|According to grouping, MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
89070852|NCT02856997|Experimental|Chidamide with ICE regimen|"Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours during Ifosfamide transfusion, ivg, d1-4; Carboplatin AUC=4, d2,ivg; etoposide 65mg/m 2, d1-4, ivg. 3 weeks as 1 course, for 6 courses.~if the effect is PR or better than PR, go to auto-stem cell transplantation, no further treatment with Chidamide is needed.~If the effect is PR or better than PR and no auto-stem cell transplantation available,Chidamide 20mg orally, twice every week, till the end of the trial."
89070853|NCT00953017|Active Comparator|Miralax plus Amitiza|106 patients randomized to Miralax plus Amitiza will take one 24mcg gelcap of Amitiza at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
89070854|NCT00953017|Active Comparator|Miralax plus Dulcolax|107 patients randomized to Miralax plus Dulcolax will take two 5mg tablets of Dulcolax at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
89229894|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 430|
89229895|NCT04001348|Experimental|HTL-STREFA S.A.safety lancet type 520|
89070855|NCT00953017|Active Comparator|Miralax|106 patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
89070856|NCT00953017|Active Comparator|Golytely (polyethylene glycol)|106 patients will take 1 gallon of golytley (Polyethylene glycol) and drink 1/2 of the solution at 4 p.m. The remaining 1/2 of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy
89070857|NCT02856841||optimum cytoreduction|without any gross tumor residue after surgery
89070858|NCT02856841||Suboptimum cytoreduction|with any gross tumor residue after surgery
89223938|NCT04689529|Experimental|Breast cancer patients undergoing mastectomy after neoadjuvant chemotherapy|Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) after receiving neoadjuvant chemotherapy
89070859|NCT00952705|Experimental|Q/LAIV-BFS (MEDI8662)|Q/LAIV-BFS (quadrivalent influenza vaccine) (MEDI8662) was supplied in the blow-fill-seal delivery system that delivers a nominal dose of 0.2 mL into a single nostril. Each dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), B/Victoria (B/Malaysia/2506/2004), and B/Yamagata (B/Florida/4/2006).
89070860|NCT00952705|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata was administered intranasally using a Becton Dickinson Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Yamagata (B/Florida/4/2006)
89070861|NCT00952705|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria was administered intranasally using a BD Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Victoria (B/Malaysia/2506/2004).
89070862|NCT00955357|Experimental|First Add-on|Lacosamide added to first adequate monotherapy (no history of Antiepileptic Drug [AED] polytherapy) and epilepsy diagnosis < or = 24 months at Screening.
88812929|NCT03838250|Experimental|Cellgram™ (Bone marrow-derived MSCs)|Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.
88812930|NCT03838172||Parents|Parents who have a burned child
89070863|NCT00955357|Experimental|Later Add-on|Lacosamide added to 1 to 3 Antiepileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis > or = 5 years at Screening.
89070864|NCT00955279|Placebo Comparator|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
89070865|NCT00955279|Experimental|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
89070866|NCT00955279|Experimental|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
89070867|NCT00954733|Experimental|All participants|All participants, one arterial blood draw
89070868|NCT00630721|Other|IFNbeta-1b|no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.
89070869|NCT00954421|Experimental|Deep Brain Stimulation|Multiple Sclerosis Tremor treated with VIM and VO Deep Brain Stimulation
89522900|NCT03390751||Aged patients|Data collection of patients admitted to the orthopedic department of the University Hospital of Toulouse for surgical management of a fracture of the upper end of the femur in emergency or for the installation of a hip or knee prosthesis.
89070870|NCT02857309|Other|Device implant|Patients randomized to the treatment group will receive optimal medical therapy for heart failure. and implantation of the OPTIMIZER System.
88812931|NCT03213392||SUPRA ORBITAL KEYHOLE CLIPPING/ COILING|Aneurysms should be either clipped or coiled to prevent re rupture general anesthesia is required to carry out these procedures.various anesthetic agents are used as an maintenance agents.
89070871|NCT02857309|Active Comparator|Optimal medical therapy|Patients randomized to the control group will receive optimal medical therapy for heart failure.
89070872|NCT02857465|Experimental|Epidural analgesia + DEXAMETHASONE|Single epidural injection of Dexamethasone Mylan (8 mg) concomitant to epidural analgesia (ropivacaine+ sufentanil)
88812932|NCT03219788|Placebo Comparator|Group 1(Normal saline)|Patients who will receive placebo (one ml normal saline). The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
89070873|NCT02857465|Placebo Comparator|Epidural analgesia + PLACEBO|Single epidural injection of sodium chloride (0.9%) Lavoisier concomitant to epidural analgesia (ropivacaine + sufentanil)
89070874|NCT02857387|Experimental|acute coronary syndrome|
89070875|NCT04273009|Active Comparator|Renew Anal Insert|The device is intended for self-insertion through the anal canal aided by a fingertip applicator.
89070876|NCT04273009|Active Comparator|Percutaneous tibial nerve stimulation|A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points.
89223939|NCT04689529|Active Comparator|Breast cancer patients without neoadjuvant chemotherapy and undergoing mastectomy|Patients who underwent total mastectomy (including simultaneous reconstruction surgery) through preoperative examinations (MRI, breast ultrasound, mammography, etc.) even in patients who did not receive neoadjuvant chemotherapy as a control group.
89223940|NCT04687137|Experimental|TAK-743|
89223941|NCT04678102|Experimental|Cohort 1 (PHI-101 40mg/day)|In the starting dose cohort 1 subject will be administered 40mg/day PHI-101 and will be assessed for DLT ('single subject cohort'), and until an ADR ≥ [CTCAE version 5.0] grade 2 occurs, higher doses will be explored in single subject cohorts in a stepwise fashion. If an ADR ≥ [CTCAE version 5.0] grade 2 occurs, the accelerated 3+3 design will be immediately switched to the standard 3+3 scheme.
89223942|NCT04678102|Experimental|Cohort 2 (PHI-101 80mg/day)|In cohort 2, the subject will be administered 80mg/day PHI-101.
88812933|NCT03219788|Active Comparator|Group 2 (Remifentanil 0.1 ug/kg)|Patients who will receive remifentanil at a dose of 0.1 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
88812934|NCT03219788|Active Comparator|Group 3 ((Remifentanil 0.2 ug/kg))|Patients who will receive remifentanil at a dose of 0.2 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
89223943|NCT04678102|Experimental|Cohort 3 (PHI-101 120mg/day)|In cohort 3, the subject will be administered 120mg/day PHI-101.
89223944|NCT04678102|Experimental|Cohort 4 (PHI-101 160mg/day)|In cohort 4, the subject will be administered 160mg/day PHI-101.
89070877|NCT01241448|Placebo Comparator|Placebo|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
89070878|NCT01241448|Experimental|2.5 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
89070879|NCT01241448|Experimental|10 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
89070880|NCT01241448|Experimental|20 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
89070881|NCT04319406|Experimental|PROLOTHERAPY|Prolotherapy will be performed with 12.5 % Dextrose into superior joint space of involved TMJ
89070882|NCT04319406|Active Comparator|DRY NEEDLING|Dry needling will be performed into superior joint space of involved TMJ
89070883|NCT01240356|Experimental|Phase I: Healthy Volunteers|Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
89070884|NCT01240356|Experimental|Phase II: 0-3 hour Patients|Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.
89070885|NCT04206618||premenopausal normal|premenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
89070886|NCT04206618||postmenopausal normal|postmenopausal women with normal BMD who will be subjected to a single morning, fasting blood drainage
89070887|NCT04206618||postmenopausal osteopenia|postmenopausal women with osteopenia who will be subjected to a single morning, fasting blood drainage
89070888|NCT04206618||postmenopausal osteoporosis|postmenopausal women with osteoporosis who will be subjected to a single morning, fasting blood drainage
89070889|NCT04206618||hip fracture|postmenopausal women at the moment of hip fracture who will be subjected to a single, fasting blood drainage right before osteosynthesis
89070890|NCT04206618||controls (knee osteoarthitis)|postmenopausal women with knee osteoarthritis who will be subjected to a single, fasting blood drainage right before arthroplasty and serve as controls
88812935|NCT01833962||Actifuse|Patients who recieved Actifuse synthetic bone brafting material
89070891|NCT04206618||teriparatide group|postmenopausal women with osteoporosis who will be treated with teriparatide (Forsteo) 1 injection of 20mcg subcutaneously daily for 12 months
89070892|NCT04206618||denosumab group|postmenopausal women with osteoporosis who will be treated with denosumab (Prolia) 1 injection of 60mg subcutaneously every 6 months for 12 months
89070893|NCT01239732|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive bevacizumab 15 mg/kg IV on Day 1 every 3 weeks from Cycle 1 to Cycle 36 (initially concurrent with chemotherapy, then continued as a single agent following the completion of chemotherapy), or until protocol defined disease progression or until unacceptable toxicity (whichever occurred first). Participants will receive paclitaxel 175 mg/m^2 IV on Day 1 every 3 weeks or 80 mg/m^2 IV every week and carboplatin (AUC 5-6) IV on Day 1 every 3 weeks for a minimum of 4 and maximum of 8 cycles (including up to 4 pre-surgical cycles), or until protocol defined disease progression, or unacceptable toxicity (whichever occurred first).
89070894|NCT02227147|Experimental|rhNGF 20 µg/ml|rhNGF 20 µg/ml eye drops solution, formulation containing anti-oxidant
89223945|NCT04678102|Experimental|Cohort 5 (PHI-101 200mg/day)|In cohort 5, the subject will be administered 200mg/day PHI-101.
89223946|NCT04678102|Experimental|Cohort 6 (PHI-101 240mg/day)|In cohort 6, the subject will be administered 240mg/day PHI-101.
89223947|NCT04648436|Other|Early surgery|
88812936|NCT01834040|Other|intralesional and Intravenous|Intralesional/ Intravenous of Autologous Stem cells.
88812937|NCT03213314|Experimental|Main cohort|Patients undergoing liver resection
89223948|NCT04648436|Other|Initial conservative treatment|
89070895|NCT02227147|Placebo Comparator|Placebo|Vehicle: formulation containing anti-oxidant
89070896|NCT02856919|Other|Mirvaso® gel|Mirvaso® gel (5 mg/g brimonidine tartrate)
88812780|NCT01526213|Other|Sequence 2: Water, FC-free GFJ, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
89070897|NCT02854735||Head and neck neoplasm|Patients with stage III-IV head and neck cancer (squamous cell carcinoma) patient undergoing CCRT
89070898|NCT00948025|Active Comparator|Avance Nerve Graft|Commercially available Avance Nerve Graft for repair of nerve gap
89070899|NCT00948025|Active Comparator|Hollow Tube Conduit|Commercially available hollow tube conduit for repair of nerve gap.
89070900|NCT02854579|Experimental|Neural progenitor cell|Three doses of Neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
89070901|NCT02854579|Experimental|Paracrine factors|Three doses of concentrated paracrine factors of human mesenchymal stem cell （0.5ml） intrathecally at 12h,24h,48h after birth.+routine therapy
89070902|NCT02854579|Experimental|Progenitor cell and paracrine factors|Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
89070903|NCT02854579|No Intervention|Routine therapy|neonates only receive routine therapy
89070904|NCT02854423||biodegradable polymer|
89070905|NCT02854423||durable-polymer|
89070906|NCT02854267||group without guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all registered situations of brain death patients on the database (nationwide) minus the situations occuring in the group with guide (22 intensive care units forming the 'RESEAU NORD FRANCILIEN' network). The period before the diffusion of the guide is from 1st of july 2012 to 30th of june 2014
89070907|NCT02854267||group without guide, after guide's diffusion|For this group, only the primary objective (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all the registered situations of brain death patients on the database minus the situations occuring in the group with guide ('RESEAU NORD FRANCILIEN'). The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
89070908|NCT02854267||Group with guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018.
89070909|NCT02854267||Group with guide, after guide's diffusion|For this group, the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database. The secondary endpoints (level of anxiety of the caregivers before the meeting with the next of kins as measured by the french short version of Spielberger test and compliance to the guide) will be assessed by the datasheet prospectively filled by the caregivers. The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
89070910|NCT00947011|Placebo Comparator|Placebo|
89070911|NCT00947011|Active Comparator|Januvia|
89070912|NCT02856685|Experimental|PLM60|Mitoxantrone Hydrochloride Liposome
89070913|NCT02860663|Active Comparator|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
89070914|NCT02860663|Active Comparator|Vitamin D2|10 ug/d of vitamin D2 for 6 weeks
89070915|NCT02860663|Active Comparator|25OHD|10 ug/ of 25OHD for 6 weeks
89070916|NCT04270513||EVT by Flying Intervention Team in primary stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, for whom a Flying Intervention Team is flown to the primary stroke center in order to perform endovascular treatment.
89070917|NCT04270513||EVT after secondary transfer to comprehensive stroke center|Patients with ischemic stroke and large vessel occlusion admitted to a primary stroke center, who are transferred to a comprehensive stroke center for endovascular treatment.
89070918|NCT02854189|Other|patients with genu recurvatum|The medial osteoarthritis knees with genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
89690963|NCT03335254|Experimental|Dose-Escalating Arm 4|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease to 507 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
88812938|NCT03213314|Experimental|Nested cohort PVE|Patients undergoing liver resection after portal vein embolisation
89070919|NCT02854189|Other|patients without genu recurvatum|The medial osteoarthritis knees without genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
89223949|NCT04643106|Experimental|Hemostatic agent group|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL® Fibrin Sealant, Ethicon, USA), which consist of thrombin and coagulating proteins, mainly fibrinogen and fibronectin. If hemostasis is not fulfilled enough by using it, a additional intervention such as electrocoagulation with bipolar forceps and barbed suture is required to stop bleeding.
89223950|NCT04643106|Active Comparator|Suturing group|During operation, barbed suture will be applied to the inner surface of ovarian parenchyme where ovarian endometriosis was attached. In this group, if bleeding is continued after suturing, additional electrocoagulation with bipolar forceps will be conducted.
89223951|NCT04636437|Experimental|DOR 100 mg + TAF/FTC (or TAF/3TC, depending on location)|By mouth daily with or without food
89223952|NCT04636437|Experimental|DOR 100 mg + TDF/FTC (or TDF/3TC, depending on location)|By mouth daily with or without food
89223953|NCT04636437|Experimental|Continuation of entry INSTI+TAF/FTC (or TAF/3TC)|
89223954|NCT04622774|Experimental|IMGC936|Single-arm. IMGC936 administered every 3 weeks.
89223955|NCT04615078|Experimental|"Telemonitoring group"|Medical Telemonitoring in Non-Invasive Ventilation
89223956|NCT04615078|No Intervention|"Standard of Care group"|Standard medical follow-up: standard home Non-Invasive Ventilation service, with transmission of their ventilator data without analysis leading to alerts
89223957|NCT04600648|Active Comparator|Weight loss with bariatric surgery|Patients scheduled to undergo bariatric surgery will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
89070920|NCT02854345|Experimental|Tomoscintigraphic parathyroid imaging on a CZT camera|Tomoscintigraphic parathyroid imaging on a CZT camera
89070921|NCT04281823||Cardiovascular Magnetic Resonance|All patients who present to the Houston Methodist CMR Laboratory
89223958|NCT04600648|Active Comparator|Weight Loss|Patients to receive lifestyle weight loss treatment will be tested pre and post bariatric surgery. Interventions to be measured are serum Insulin and leptin levels, sweet taste responsiveness, body fat percentage, and z-BMI
89070922|NCT02853877|Experimental|Weekly Incentive|Participants in the Weekly Incentive arm will be asked to weigh in each week during a 12 week intervention period. They will receive tailored messages and have an opportunity to win a financial reward each week they meet their weight loss goal. Participants will be asked to complete a final weight measurement at week 24.
89070923|NCT02853877|No Intervention|Weekly Weigh-In|Participants in the Weekly Weigh-In arm will be asked to weigh in each week during a 12 week intervention period. Participants will be asked to complete a final weight measurement at week 24.
89070924|NCT02854111|Active Comparator|oral glucose tolerance test|75-g glucose A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink a sweet liquid containing 75 g-glucose. Blood samples will be collected at timed intervals of 1 and 2 hours after you drink the glucose. This is a standard method for diagnosis of diabetes mellitus that called oral glucose tolerance test or OGTT.
89070925|NCT02854111|Experimental|ice cream|A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink ice cream that contained carbohydrate 73.9 g. Blood samples will be collected at timed intervals of 1 and 2 hours after you eat the ice cream.
89070926|NCT01239342|Experimental|Arm I (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who are progression free after 1 year may receive a 12 week study drug supply of Akt inhibitor MK2206.
89070927|NCT01239342|Experimental|Arm II (everolimus)|Patients receive everolimus PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89070928|NCT04319250|Active Comparator|Group 1|Ischemic compression and rehabilitation program applied to the group 1
89070929|NCT04319250|Active Comparator|Group 2|IASTM and rehabilitation program applied to the group 2
89070930|NCT00946309|Experimental|High Sulforaphane Extract|
89070931|NCT00946309|Placebo Comparator|Placebo|
89070932|NCT04269499|Other|Study patients|All patients receive holmium radioembolization as per usual
89070933|NCT02853799|Other|Continuous Enteral Feeding|"Crossover Study:~Randomized to continuous enteral feeding first then crossed over to receive versus intermittent enteral feeding next."
89070934|NCT02853799|Other|intermittent enteral feeding|"Crossover Study:~Randomized to intermittent enteral feeding first then crossed over to receive versus continuous enteral feeding next."
89070935|NCT02888496||PMR patients|Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)
89070936|NCT02888496||Healthy controls|Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease
88812939|NCT03213314|Experimental|Nested cohort neoadjuvant chemotherapy|Patients undergoing liver resection after neoadjuvant chemotherapy
89070937|NCT01236534|Active Comparator|Lubiprostone|
89070938|NCT01236534|Placebo Comparator|Sugar pill|
89070939|NCT01235598|Other|Placebo followed by Certolizumab Pegol (CZP)|Placebo, saline solution for sc injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
89070940|NCT01235598|Experimental|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) 400 mg for subcutaneous injection at Weeks 0, 2 and 4 followed by 200 mg 2-weekly from Week 6 to Week 40
89070941|NCT01235442|Experimental|etanercept and clobetasol|Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24)
89070942|NCT01235442|Experimental|etanercept|Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks
88812940|NCT03213314|Experimental|Nested cohort TACE|Patients undergoing trans arterial chemoembolisation for presumed hepatocellular carcinoma
89223959|NCT04600180||Palliative treatment with immunotherapy|
89223960|NCT04583670||Patient physical examination with ultrasound|No intervention
89223961|NCT04542161|Active Comparator|NAC 900mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 900mg/day caplets for a four week period
89223962|NCT04542161|Active Comparator|NAC 3600mg/day|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 3600mg/day caplets for a four week period
89223963|NCT04542161|Placebo Comparator|NAC 0mg/day (Placebo)|Subjects who pass screening may be randomly assigned to this arm where they will self administer NAC 0mg/day (placebo) caplets for a four week period
89223964|NCT04469595|Active Comparator|ILUVIEN Arm|Intravitreal ILUVIEN
89223965|NCT04469595|Active Comparator|Aflibercept Arm|Intravitreal aflibercept
89223966|NCT04399460|Experimental|Low Dairy Energy Restrictive Diet|Low-dairy (<1 serving/day) and 500kcal/deficit per day energy restrictive diet
89223967|NCT04399460|Experimental|3 Servings of Full-Fat Dairy with Energy Restrictive diet|Energy-restrictive diet (500 kcal/deficit per day) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
89223968|NCT04399460|Experimental|3 Servings of Full-Fat Dairy but no energy restriction|Normal diet (no energy restriction) with 3 servings of full-fat dairy products from full-fat milk, and assorted yogurts and cheeses
89223969|NCT04370496|Experimental|SOLUTION group|Patients enrolled in this clinical trial will undergo radical hysterectomy through minimally invasive surgery using an endoscopic stapler which both cuts and simultaneously sutures the open vaginal stump.
88812941|NCT01834196|Other|retinal vascular occlusion arm|Patients with existing retinal microvascular disease will undergo imaging.
89070943|NCT01163253|Experimental|Active Treatment|"The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market.~All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion"
89070944|NCT01162863|Active Comparator|Lubiprostone 8 mcg BID|
89070945|NCT01162863|Active Comparator|Lubiprostone 24 mcg QD|
89070946|NCT01162863|Placebo Comparator|Placebo|
89070947|NCT02885805|Experimental|SPF evaluation + Control|Fair-skinned subjects in good health with Skin Types I, II or III.
89070948|NCT01162473|Active Comparator|Delayed Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 16 and continue thru Week 50. Total active participation will last 51 weeks.
89070949|NCT01162473|Active Comparator|Immediate Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 3 and continue thru Week 35. Total active participation will last 38 weeks.
89223970|NCT04331340|Experimental|Pharmacist Intervention|Pharmacist assessment of LUTS, with recommendations and education regarding lifestyle, behaviour, and/or medications related to bladder health. Follow-up at 3 and 6 weeks.
89223971|NCT04331340|Active Comparator|Control|Pharmacist questions regarding presence of LUTS, with provision of healthy aging literature. Follow-up at 6 weeks.
89223972|NCT04294407||Stroke group|20 to 65 years old patients, with the clinical diagnosis of stroke (Mini-mental state examination (MMSE) score of ≥25)
89223973|NCT04294407||Healthy group|20 to 65 years old healthy subjects, without the clinical diagnosis of stroke
89223974|NCT04254796|Experimental|TARA Training|12-week group TARA Training
89223975|NCT04254796|No Intervention|Control|Waitlist Control
89223976|NCT04251663||HS subjects|Subjects with active HS disease, among which at least 5 will be treatment-naïve
89223977|NCT04251663||Healthy Controls|Healthy subjects
89070950|NCT04314921|Experimental|10-week Yoga|Eighteen healthy elderly people, who were classified into two age groups, participated in this study. All participants had not practiced yoga before and were asked not to perform any sports activities while the research was ongoing. In the experimental group, participants (n = 18) had to participate in 10 weeks of yoga classes. In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life. All experimental group subjects participated in Himalayan yoga classes, which lasted 10 weeks: 2 times per week, 90 min per session. Yoga classes were conducted by 16-year-old qualified yoga instructor from Yoga Academy, Kaunas.
89070951|NCT04314921|No Intervention|Control|In the control group, participants (n = 15) did not perform any exercises or other changes in their daily living life.
89070952|NCT02885649|Experimental|Treatment (enzalutamide, nephrectomy)|Patients receive enzalutamide PO daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.
89070953|NCT02885883|Active Comparator|a control group|
89070954|NCT02885883|Experimental|patients with paroxysmal or persistent AF|
89070955|NCT02885883|Experimental|patients with permanent AF|
89070956|NCT01162239|Experimental|Extended Brief Contact|Following standard brief treatment, participants have monthly meetings with medical staff.
89070957|NCT01162239|Experimental|Extended Health Education|Following standard treatment, participants receive monthly counseling with content based on a health education model.
89070958|NCT01162239|Experimental|Extended Relapse Prevention plus varenicline|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.
89070959|NCT01162239|Experimental|Extended Relapse Prevention|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.
89070960|NCT01161537|Experimental|VX-770|"Part A: Subjects received placebo tablets matched to VX-770 150 milligram (mg) orally twice daily from Day 1 to 14 (Placebo run-in period), followed by VX-770 150 mg tablets orally twice daily from Day 15 to 42 (VX-770 treatment period), and then placebo tablets matched to VX-770 150 mg orally twice daily from Day 43 to 57 (Placebo washout period) during Part A of the study.~Part B: Subjects received VX-770 150 mg tablets orally twice daily for 48 weeks during Part B of the study. Part B included subjects from Part A and newly enrolled subjects."
89522901|NCT00535405|Experimental|1|Each patient will receive 1 active treatment dose & 2 Placebo (Pbo) doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
89070961|NCT04314297|Experimental|Anlotinib In Combination With Durvalumab|
89229896|NCT03956251|Experimental|Combined Mineralized/Demineralized Putty Allograft|Ridge preservation with a Mineralized/Demineralized Putty allograft
89229897|NCT03956251|Active Comparator|Demineralized Putty Allograft|Ridge preservation with Demineralized Putty allograft
89070962|NCT02885571|Active Comparator|MAD for subjective compliance|MAD for subjective compliance group wears the same SomnoDent Flex with DentiTrac to objective group, but they are subjected to be prescribed based on the subjective compliance data, which are acquired from patient's explanation. Compliance (average daily time,
89223978|NCT04250636|Experimental|Study Participants|HIV-infected individuals, off ART, and with plasma HIV-1 RNA levels between 500 and 100,000 copies/ml by standard assays. Study participants will receive a single intravenous infusion of 3BNC117-LS and a single infusion of 10-1074-LS. The antibodies will be administered sequentially and dosed at 30 mg/kg.
89223979|NCT04233749|Experimental|Treatment|All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.
89223980|NCT04225897|Experimental|RV521|"sisunatovir is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. The RV521 dry powder blend will be supplied in capsules containing 10, 20, or 50 mg RV521. The Investigational Medicinal Product (IMP) will be dispersed in a defined volume of suspending diluent prior to oral administration on a mg/kg basis. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of suspending diluent prior to administration will be provided in the Pharmacy Manual.~The proposed dosing regimen for Part A is a single open label dose of RV521. Part B and C is RV521 or placebo administered BID, 12 hours apart, for a period of 5 consecutive days with a total of 10 doses. However, this is subject to the recommendation of the DSMC."
89223981|NCT04225897|Placebo Comparator|Placebo|The placebo capsules administered in Part B and C will contain mannitol and microcrystalline cellulose (vehicle). The placebo dry powder will be dispersed in suspending diluent and given orally BID. Instructions for opening the capsule(s) and dispersing the contents in a fixed volume of suspending diluent prior to administration will be provided in the Pharmacy Manual.
89223982|NCT04201561|Experimental|Experimental group|The patient will receive an intravenous selenium 2000 μg/40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
89223983|NCT04201561|Placebo Comparator|Placebo group|The patient will receive an intravenous normal saline 40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
89223984|NCT04190589|Experimental|Robotic CME|Robot-assisted extended right colectomy
89223985|NCT04151602||PWUD with active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with active TB disease
89223986|NCT04151602||PWUD with no active TB|People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with no active TB disease
89223987|NCT04151602||non-PWUD with active TB|People who do not use meth/mandrax who have active TB disease
89223988|NCT04097184|Active Comparator|"active tDCS group"|Patients will benefit from a series of 10 double-blind effective tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
89223989|NCT04097184|Sham Comparator|"sham tDCS group"|Patients will benefit from a series of 10 double-blind placebo tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
89223990|NCT04081220|Experimental|IMG-7289|
89223991|NCT04061421|Experimental|ASTX727 + itacitinib|ASTX727 and itacitinib will be taken by mouth
89223992|NCT04046900|Active Comparator|Vaginal microbiome transplant|Women in this group will be randomized to receive two doses of vaginal fluid from a healthy donor
89223993|NCT04046900|Placebo Comparator|Saline placebo|Women in this group will be randomized to receive two doses of sterile saline
89223994|NCT03989115|Experimental|RMC-4630 and Cobimetinib|RMC-4630 and Cobimetinib for oral administration
89223995|NCT03989115|Experimental|RMC-4630 and Osimertinib|RMC-4630 and Osimertinib for oral administration
89223996|NCT03946748|Experimental|REGN3918|"Cohort A (Dose Confirmation) If a decision is made to expand Cohort A, patients will be assigned to Cohort A.~Cohort B (Dose Expansion) If a decision is made to progress to Cohort B, patients will be assigned to Cohort B."
89229898|NCT00395512|Experimental|Alogliptin 25 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
89229899|NCT00395512|Active Comparator|Pioglitazone 30 mg QD|Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
89229900|NCT00395512|Experimental|Alogliptin 25 mg QD+ Pioglitazone 30 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
89070963|NCT02885571|Experimental|MAD for objective compliance|MAD for objective compliance group wears the same SomnoDent Flex with DentiTrac to subjective group, but they are subjected to be prescribed based on the objective compliance data, which are acquired from data recorded within SomnoDent Flex with DentiTrac.
89070964|NCT01234350||FIRMAGON|
89070965|NCT01234350||GnRH Agonist|
89070966|NCT01233258|Experimental|Arm 1: rFVIII on demand first CS/EP then CS/ADJ|Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
89070967|NCT01233258|Experimental|Arm 2: rFVIII on demand first CS/ADJ then CS/EP|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
89070968|NCT01233258|Experimental|Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
89070969|NCT01233258|Experimental|Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
89070970|NCT01233258|Experimental|Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
89070971|NCT01233258|Experimental|Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
89070972|NCT01232868|Other|Age 25-40|Trivalent Influenza vaccine given to age 25-40
89070973|NCT01232868|Other|Age ≥65|Trivalent Influenza vaccine given to age≥65
89070974|NCT01232790|Experimental|Group A: Intervention/Placebo|Group A first receives the commercially available sustained release form of N-acetylcysteine, then the matching placebo capsules both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
89070975|NCT01232790|Placebo Comparator|Group B: Placebo/Intervention|Group B first receives the placebo and then receives a commercially available sustained release form of N-Acetylcysteine. In each arm, the capsules are both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
89070976|NCT01232556|Experimental|1|Inotuzumab ozogamicin+rituximab
89070977|NCT01232556|Active Comparator|2|Investigator's choice of (1) rituximab+gemcitabine, or (2) rituximab+bendamustine
89070978|NCT00946153|Experimental|Lenvatinib|
89070979|NCT01914367|Active Comparator|Cervarix group|One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme.
89070980|NCT01914367|Active Comparator|Gardasil Group|One sib of each twin pair will be given Gardasil according to the 0, 1, 6 month vaccination scheme.
89070981|NCT02856529|Experimental|Intervention|A BICSL certified trainer conduct the intervention. It includes hand on training session standardized in a scientific way. The participants trained on hand hygiene and use of PPE. Also, it includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator.
89070982|NCT02856529|Active Comparator|Control|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
89070983|NCT02856373|Other|CPVT|catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
89070984|NCT02856373|Other|long QT syndrome|long QT syndrome patients
89070985|NCT02856373|Other|ARVC|arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
89070986|NCT02856373|Other|HCM|hypertrophic cardiomyopathy (HCM) patients
89070987|NCT02856373|Other|DCM|dilated non-ischemic cardiomyopathy (DCM) patients
89070988|NCT02856373|Other|ICM|ischemic cardiomyopathy (ICM) patients
89070989|NCT02856607||Group I|patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery
89070990|NCT02856607||Group II|patients secondary addressed to a referent center with cardiac surgery
89070991|NCT02856607||Group III|patients for which the totality medical care are performed in non-referent health center
89070992|NCT01160289|Experimental|1 milligram (mg) LY2452473 + 5 mg tadalafil|
89070993|NCT01160289|Experimental|5 mg LY2452473 + 5 mg tadalafil|
89070994|NCT01160289|Experimental|5 mg LY2452473 + placebo|
89070995|NCT01160289|Active Comparator|10 mg tadalafil + placebo|
89070996|NCT01160289|Active Comparator|5 mg tadalafil + placebo|
89070997|NCT01159665|Experimental|PPV 5-30 minutes after injection|Primary Pars Plana Vitrectomy 5 to 30 minutes after 125µg of ocriplasmin intravitreal injection
89070998|NCT01159665|Experimental|PPV 31-60 minutes after injection|Primary Pars Plana Vitrectomy 31 to 60 minutes after 125µg of ocriplasmin intravitreal injection
89070999|NCT01159665|Experimental|PPV 2-4 hours after injection|Primary Pars Plana Vitrectomy 2 to 4 hours after 125µg of ocriplasmin intravitreal injection
89071000|NCT01159665|Experimental|PPV 24 hours (+2 hours) after injection|Primary Pars Plana Vitrectomy 24 hours (+2 hours)after 125µg of ocriplasmin intravitreal injection
89071001|NCT01159665|Experimental|PPV 7 days (+1 day) after injection|Primary Pars Plana Vitrectomy 7 days (+1 day)after 125µg of ocriplasmin intravitreal injection
89071002|NCT01159665|No Intervention|PPV without injection|Control Arm, no ocriplasmin intravitreal injection
89071003|NCT01159431|Experimental|Active|
89071004|NCT01159431|Other|Control|
89071005|NCT04314141||Transgender patients|Transgender patients who carry out sex reassignment surgery.
88812781|NCT01526213|Other|Sequence 3: GFJ, FC-free GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
89071006|NCT04314141||Cismale patients|Cismale patients who carry out surgery to correct a congenital or acquired lack of penis.
89071007|NCT02885259|Experimental|HyQvia|human immunoglobulin and one vial of recombinant human hyaluronidase (rHuPH20
89071008|NCT01158261||Vascular Surgery Subjects Treated with EVICEL|
89071009|NCT02885103|Placebo Comparator|inhalation with nebulizer|inhalation with an nebulizer via mouth
89071010|NCT02885103|Active Comparator|inhalation with nebulizer and NHF|inhalation with combination of nebulizer and nasal high flow (NHF) via nasal cavity
89071011|NCT04313829|Active Comparator|Intervention group|The intervention group received Pharmacist counseling for 15 minutes include giving standard medicine information service and explaining the validated pharmacist counseling module which contained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed dose.
89071012|NCT04313829|No Intervention|Control group|The control group received standard medicine information services by Pharmacists.
89071013|NCT01157169|Experimental|Investigational Test Product|Buprenorphine 8 mg Sublingual Tablets
89071014|NCT01157169|Active Comparator|Reference Listed Drug|Subutex® 8 mg Sublingual Tablets
89071015|NCT04313907|Experimental|Acitve laser+topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus topical clonazepam 1 mg, 3 times at day, same 14 days both
89071016|NCT04313907|Sham Comparator|Sham laser+topical clonazepam|Using sham laser (six sesions) plus topical clonazepam 1 mg, 3 times at day, same 14 days both
89071017|NCT04313907|Placebo Comparator|Active laser+placebo of topical clonazepam|Using active laser (six sesions) 980 nm, 14 j , plus placebo of topical clonazepam (lactose), 3 times at day, same 14 days both
89071018|NCT01231620|Experimental|Intravenous (IV) Zanamivir 300mg Twice Daily|300mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
89071019|NCT01231620|Experimental|Intravenous (IV) Zanamivir 600mg Twice Daily|600mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
89071020|NCT01231620|Active Comparator|Oral Oseltamivir 75mg Twice Daily|75mg oral oseltamivir twice daily plus intravenous placebo zanamivir twice daily
89071021|NCT05511558|Experimental|Dosing Group|All 8 subjects will receive a single dose of study drug
89071022|NCT01231464|Placebo Comparator|placebo|vehicle placebo nasal spray
89071023|NCT01231464|Experimental|FFNS|fluticasone furoate nasal spray
89071024|NCT01156311|Experimental|Glatiramer acetate (GA) and dimethyl fumarate|Participants taking a stable dose of GA for at least 12 months prior to the study remain on that dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
89071025|NCT01156311|Experimental|Interferon beta (IFNβ) and dimethyl fumarate|Participants taking a stable dose of one of the IFNβ products for at least 12 months prior to the study remain on that product and dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
89071026|NCT02888028|Active Comparator|ICD remote monitoring|Active Comparator: ICD remote monitoring additionally to regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement
89071027|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
89071028|NCT01230060|Experimental|enVista|enVista One-Piece Hydrophobic Acrylic Intraocular Lens
89071029|NCT04281745|Experimental|Coretox®|Botulinum toxin type A to be intramuscularly injected at 4 sites of corrugator muscle and at 1 site of procerus muscle with 0.1 mL (4U) at each site, for a total of 0.5 mL (20U). The administration of the investigational product was performed once at the start of each cycle
89071030|NCT02853721|Experimental|Experimental group|iPTH at 6 hours after surgery
89071031|NCT02853721|Other|Control group|no dosage of iPTH
89071032|NCT02860429|Experimental|Cinobufacini injection|"Capsule Dosage and frequency:This group receives cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.~Duration:6 chemotherapy cycles."
89071033|NCT02860429|Other|Control group|Only receive the same chemotherapy with the experimental groups.No Cinobufacini injection.And have the same adjuvant treatment with the experimental groups.
89071034|NCT01155531|Experimental|Telenzepine - Group A|Group A: No Sertraline; 0, 1, 2, 3 mg/day Telenzepine
89071035|NCT01155531|Experimental|Sertraline plus Telenzepine - Group B|Sertraline 50 mg/day; 0, 1, 2, 3 mg/day Telenzepine
89071036|NCT01155531|Experimental|Sertraline plus Telenzepine - Group C|Sertraline 50, 100 mg/day; 0, 1, 2, 3 mg/day Telenzepine
89071037|NCT01155531|Experimental|Sertraline plus Telenzepine - Group D|Sertraline 50, 100, 150 mg/day; 0, 1, 2, 3 mg/day Telenzepine
89071038|NCT02856061|Other|PRT|Children with ASD who are currently receiving PRT treatment.
89071039|NCT02856061|No Intervention|Wait List / Non-Treatment Control|Children with ASD who are not currently receiving PRT treatment.
89071040|NCT02856061|No Intervention|Typically Developing|Children without ASD or developmental delay.
89071041|NCT01138579|Experimental|1|
89071042|NCT04313595|Experimental|Breathing frequency monitoring|
89071043|NCT02860195|Experimental|healthy volunteers|
89071044|NCT01155219|Experimental|Geltim LP®|Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
89071045|NCT01155219|Active Comparator|Xalatan®|Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
89071046|NCT01229436|Experimental|Xiapex Injection|
89071047|NCT02856139||1 (MB- and VL-)|without mottled fluorescent band (MB) and vascular leakage (VL)
89071048|NCT02856139||2 (MB+ and VL-)|with mottled fluorescent band (MB), without vascular leakage (VL)
89071049|NCT02856139||3 (MB-/+ and VL+)|with or without mottled fluorescent band (MB), with vascular leakage (VL)
89071050|NCT01155141|Experimental|No arms|There are no arms to this study. All patients receive drug (H.P. Acthar Gel)
89071051|NCT00631033|Placebo Comparator|1|Placebo
89071052|NCT00631033|Experimental|2|Diazoxide
89071053|NCT00631033|Experimental|3|Metformin + Diazoxide
89071054|NCT01155063||Main Group|Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy
89071055|NCT04313517|Experimental|Yoga@Work|Yoga session were developed to practice at work anytime feasible.
89071056|NCT04313517|No Intervention|Wait list Control group|Control group with no intervention. After Intervention period, group was offered same sessions.
89071057|NCT04313673||randomized|Patients who were followed up in our clinic with a diagnosis of preterm labor that spontaneously took action and were born before 37 weeks of gestation will form a group.
89071058|NCT01154673|Experimental|Intensive HAART|"Patients in this arm will receive the following HAART regimen:~Raltegravir 400 mg BID + Maraviroc 150mg BID + emtricitabine 200mg /tenofovir 300mg QD + lopinavir 400 mg/ritonavir 100mg BID for 96 weeks"
89071059|NCT01154673|Placebo Comparator|Placebo Arm|Placebo (in place of raltegravir and maraviroc) will be added to standard HAART (Emtricitabine 200mg /tenofovir 300mg QD + Lopinavir 400 mg/ritonavir 100mg BID) for 48 weeks and then offered open label Raltegravir and Maraviroc after 48 weeks
89071060|NCT02884869|Experimental|Intubating laryngeal Mask|Intubating laryngeal Mask
89071061|NCT02884869|Active Comparator|Direct laryngoscopy|Intubating laryngeal Mask
89071062|NCT01154283|Active Comparator|Bi-level, standard, NIPPV|Standard NIPPV with both an inspiratory and expiratory positive airway pressure.
89071063|NCT01154283|Experimental|IPAP-only, NIPPV|NIPPV with only inspiratory positive airway pressure, no expiratory positive airway pressure
89071064|NCT00944125|Active Comparator|Dual Site LV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
89071065|NCT00944125|Active Comparator|BiV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
89071066|NCT02884713|Experimental|Levofloxacin and Doxycycline and Esomeprazole|The rescue treatment was given for ten days consisting of levofloxacin 500 mg once daily, doxycycline 100 mg twice daily, and esomeprazole 20 mg twice daily
89071067|NCT00912223|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
89071068|NCT04313439|Experimental|Treatment|Online Cognitive Therapy (I-CT)
89071069|NCT01154127|Experimental|NVA237 followed by Placebo|"Period 1: 50 μg NVA237 via NEOHALER inhaler device for 21 days~Period 2: Matching placebo via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
89071070|NCT01154127|Experimental|Placebo followed by NVA237|"Period 1: Matching placebo of NVA237 via NEOHALER inhaler device for 21 days~Period 2: 50 μg NVA237 via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
89229901|NCT00395512|Active Comparator|Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
89229902|NCT03956017|Experimental|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
89229903|NCT03956017|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
89223997|NCT03937843|Experimental|Arm with 2 cohorts|"Cohort 1: Primary stage IIA and recurrent stage IIA seminoma after active surveillance for stage I:~Within 7 days after registration, the patients will receive one infusion of carboplatin AUC (Area under the curve) 7 at day 1 of trial treatment, followed 3 weeks later by 12 x 2 Gy involved-node radiation therapy (RT). RT should ideally start on day 22 (range: day 19-25) from the date of carboplatin administration, preferably on a Monday.~Cohort 2: Primary stage IIB and recurrent stage IIB seminoma after active surveillance for stage I OR stage IIA/B seminoma after adjuvant carboplatin or radiotherapy for stage I:~Within 7 days after registration, the patients will receive one cycle of etoposide 100 mg/m2/d + cisplatin 20 mg/m2/d at days 1 to 5 of trial treatment, followed 3 weeks later by 15 x 2 Gy involved-node radiation therapy. RT should ideally start on day 22 (range: day 19-25) from the date of chemotherapy start, preferably on a Monday."
89223998|NCT03896711|Experimental|Active Intervention|Intervention arm with MEMORI Corps program
89223999|NCT03896711|Other|Control|Augmented waitlist control.
89224000|NCT03839823|Active Comparator|Comparator arm|Combination chemotherapies of docetaxel/capecitabine, paclitaxel/gemcitabine or capecitabine/vinorelbine will be administer to patients enrolled in the control group. The chemotherapy regimen will be decided by the treating physician.
89224001|NCT03839823|Experimental|Ribociclib arm|"Combination of non-steroidal aromatase inhibitor: NSAI (letrozole or anastrozole) + goserelin + ribociclib.~Ribociclib (600 mg) is dosed orally for the first 21 days out of a 28 day cycle.~Letrozole (2.5 mg) or anastrozole (1 mg) are dosed orally daily (28 days out of the 28 day cycle).~Goserelin (3.6 mg) is continuously released via a subcutaneous implant injected on Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days."
89224002|NCT03822702|No Intervention|1st part:System development of Adult|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
89224003|NCT03822702|No Intervention|1st part:System development of Child|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
89224004|NCT03822702|No Intervention|2nd part:Handwriting Difficulty|No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour with sensors on the hand. A handwriting screening questionnaire shall be filled.
89224005|NCT03822702|Experimental|3rd part: Biofeedback Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Biofeedback Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
89522902|NCT00535405|Experimental|2|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
89071071|NCT01228734|Experimental|Cetuximab + FOLFOX-4|Subjects received cetuximab in combination with FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA). Cetuximab was always administered every 7 days with an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions, followed by oxaliplatin 85 mg/m^2 infused over 120 minutes at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin, FA was administered at a dose of 200 mg/m^2 infused over 120 minutes, on Day 1, Day 2, and every 2 weeks and then 5- FU was administered as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infused over 22 hours, on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
89071072|NCT01228734|Active Comparator|FOLFOX-4|Subjects received FOLFOX-4 chemotherapy regimen that consists of a combination of oxaliplatin with 5-FU/FA. Oxaliplatin 85 mg/m^2 infused over 120 minutes was administered first or simultaneously with FA at a dose of 200 mg/m^2 infused over 120 minutes on Day 1, Day 2, and every 2 weeks and then 5-FU was administered as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infused over 22 hours on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
89071073|NCT01227954|Other|WBRT with Hippocampal Avoidance|Whole brain radiotherapy (WBRT) with hippocampal avoidance using intensity-modulated radiation therapy (IMRT)
89071074|NCT01153971|Experimental|1|
89071075|NCT01153893|Experimental|Synflorix/Infanrix primed Group|Subjects previously primed with the Synflorix™ vaccine in the primary study 110521 (NCT00678301) received a booster dose of the Synflorix™ vaccine co-administered with a booster dose of the Infanrix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
89522903|NCT00535405|Experimental|3|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
89071076|NCT01153893|Experimental|Synflorix/Infanrix unprimed Group|Unprimed subjects from the primary study 110521 (NCT00678301), not previously vaccinated with any pneumococcal vaccine, received a 2-dose catch-up vaccination of Synflorix™ vaccine at 15-21 and 17-23 months of age and a booster dose of Infanrix™ vaccine co-administered with the first dose of Synflorix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
89071077|NCT00951379|Experimental|Arm I (Pioglitazone Hydrochloride)|Three (3) Pioglitazone 15 mg capsules by mouth once daily for 24 weeks
89071078|NCT00951379|Placebo Comparator|Arm II (Placebo)|Three (3) placebo capsules by mouth once daily for 24 weeks
89224006|NCT03822702|Experimental|3rd part: Motor Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Motor Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
89071079|NCT02855749|No Intervention|landmark group|percutaneous tracheostomy with traditional landmark technique
89071080|NCT02855749|Active Comparator|ultrasound-guided long axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided in plane technique
89071081|NCT02855749|Active Comparator|ultrasound-guided short axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided out of plane technique
89071082|NCT01153815|Placebo Comparator|placebo|Sodium chloride
89071083|NCT01153815|Experimental|GSK1358820(Botulinum Toxin Type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
89071084|NCT02855983|Experimental|A (Fat grafting initially)|"A PATHWAY -~Intervention: autologous fat grafting to the foot, occur first~Fat graft study intervention procedure to occur first, next post-operative follow up visits (V1-V4). The Subject will after Month 6 (V4) crossover to Pathway B to complete Observation visits V1 (Month 2) and V2 (Month 6). After completion of V2 (Month 6), the subject will have completed study participation."
89224007|NCT03822702|No Intervention|3rd part:Control Group|"No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~The same procedure will be ask to do again about one and a half month later."
89224008|NCT03805009|Experimental|Robotic Group (RG)|Robotic Group (RG) will perform, in addition to conventional therapy, gait training using an end-effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 20 sessions. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
89224009|NCT03805009|No Intervention|Conventional Group (CG)|Conventional Group (CG) will perform conventional gait rehabilitation program. The treatment will include: muscle strengthening exercises and stretching of the lower limb, and static and dynamic exercises for the recovery of balance in the supine and standing positions using assistive devices; training gait exercises with parallel bars or in open spaces performed both with and without assistive devices; training to climb up and down stairs; exercises to improve proprioception in the supine, sitting and standing positions, using a proprioceptive footboard; exercises to improve trunk control.
89071085|NCT02855983|Other|B (Standard of care initially)|"B PATHWAY -~Intervention: standard of care (observation) for the first year, followed by autologous fat grafting to the foot~Observation visit will occur first, next the subject will have two Observation visits V1 (Month 2) and V2 (Month 6). The subject will then crossover to Pathway A. The subject will be assessed by the PI his/her for continued study eligibility. Once the continued eligibility has been determined, the subject will have the interventional fat graft procedure and subsequent post-operative follow up visits (V1-V4). After completion of Post-op V4 (Month 6), the subject will have completed study participation."
89071086|NCT01153425|Active Comparator|Teriparatide (Forteo)|20 µg of Teriparatide will be self-injected subcutaneously once a day for 12 months and an MRI at 3T ('Virtual Bone Biopsy') will be performed at 0 and 12 months.
89071087|NCT01153425|Active Comparator|Zoledronic Acid (Reclast)|5 mg of zoledronic Acid will be administered intravenously at baseline and 12 months and an MRI at 3T ('Virtual Bone Biopsy) will be performed at 0 and 12 months.
89071088|NCT01153347|Experimental|SSRI/Serotonin/SNRI+ TC-5214 0.5 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.5 mg BID
89071089|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 2 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 2 mg BID
88812942|NCT03219944|Experimental|Platelet Rich Fibrin for soft tissue augmentation|blood will be drawn from the patient vein for PRF. The blood sample will be centrifuged for 10-12 min. PRF membrane is obtained
89071090|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
89071091|NCT01153347|Placebo Comparator|SSRI/Serotonin/SNRI + Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
89071092|NCT02884557|Other|PSC + IBD group|collection of gut biopsies collection of blood samples in patients with PSC and IBD
89071093|NCT02884557|Other|IBD alone group|collection of gut biopsies collection of blood samples in patients with IBD alone
89071094|NCT01153269||HIV-infected patients with hepatitis co-infection|HIV-infected patients with co-infections of Hepatitis B or Hepatitis C
89071095|NCT02884635|Experimental|ASP1707|ASP1707 will be orally administered for 12 weeks.
89071096|NCT02884635|Placebo Comparator|Placebo|Placebo will be orally administered for 12 weeks.
89071097|NCT02884479|Experimental|PT-112 + Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
89071098|NCT01152021|Active Comparator|Dexmedetomidine Group|Dexmedetomidine given as 2mcg/kg bolus over 10 minutes followed by 1.5mcg/kg/hr infusion for duration of scan. The bolus may be repeated up to 2 times at any time during the sedation in the event that adequate sedation conditions (minimum Ramsay Sedation Score of 4) are not achieved. In the event that dexmedetomidine is unable to achieve motionless conditions, after a total of 3 boluses, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg, per established protocol.
89071099|NCT01152021|Active Comparator|Propofol Group|Propofol bolus at an initial dose of 1 mg/kg over 1 minute then up to two additional 1 mg/kg boluses may be administered (total 3 mg/kg) - each over a one (1) minute interval, waiting 30 seconds after completion of each bolus to reassess sedation level. Once a minimum Ramsey Sedation Score 4 is achieved, an infusion at 125 mcg/kg/min is initiated. It may be titrated to 300 mcg/kg/min. If there is movement or awakening the patient may be rebolused with no more than 2 doses of Propofol at 1 mg/kg over 1 minute, in the same dosing manner as described above, waiting 30 seconds between doses. If adequate sedation is not achieved, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg.
89071100|NCT00624975|Experimental|Vaccine|
89071101|NCT00624975|Placebo Comparator|Placebo|
89071102|NCT01151085||Voriconazole|Subjects who are treated with voriconazole
89071103|NCT01149681|Experimental|Arm one|
89071104|NCT04313127|Experimental|Low-dose Group|Subjects received one dose of 5E10 vp Ad5-nCoV at 18 to 60 years old
89071105|NCT04313127|Experimental|Middle-dose Group|Subjects received one dose of 1E11 vp Ad5-nCoV at 18 to 60 years old
89071106|NCT04313127|Experimental|High-dose Group|Subjects received one dose of 1.5E11vp Ad5-nCoV at 18 to 60 years old
89071107|NCT02883933||melanoma|Patients with melanoma.
89071108|NCT01149369|Active Comparator|Aprepitant|Aprepitant 125 mg per day
89071109|NCT01149369|Placebo Comparator|Aprepitant-placebo|Placebo aprepitant 125mg per day
89071110|NCT02853487||Cluster headache patients|Episodic cluster headache patients in- and outside of bout will wear an actigraph and fill out a diary for 2 weeks.
89071111|NCT02853487||Control group|Healthy, headache-free controls will wear an actigraph and fill out a diary for 2 weeks.
89071112|NCT00879931|Experimental|1|methylprednisolone
89071113|NCT00879931|Placebo Comparator|2|Placebo (NaCl 0.9%)
89071114|NCT01149057|Experimental|Single Arm|
89071115|NCT04281589|Experimental|Group 1|tidal volüm is 4 ml/kg
89071116|NCT04281589|Experimental|Group 2|tidal volüm is 6 ml/kg
89071117|NCT04281589|Experimental|Group 3|tidal volüm is 8 ml/kg
89071118|NCT04281589|Experimental|Group 4|tidal volüm is 10 ml/kg
89071119|NCT01227564|Experimental|ACC-001 3 μg/ QS-21 50 μg|
89071120|NCT01227564|Experimental|ACC-001 10 μg/ QS-21 50 μg|
89071121|NCT01227564|Placebo Comparator|Placebo- Phosphate buffered saline (PBS)|
89071122|NCT00739141|Experimental|1|There are three chemotherapy drugs involved. They are called fludarabine (5 doses), cyclophosphamide (1 dose), and thiotepa (2 doses). Also two days of radiation therapy. This is called Total Body Irradiation or TBI. The TBI if given for two days before, the transplant. On transplant day, the cord blood cells will be given through a catheter. The immune suppressing drugs given are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through the catheter. Later they can be given as tablets.
89071123|NCT01148979|Experimental|Adjunct Lisdexamfetamine (Vyvanse)|Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
89071124|NCT01148979|Placebo Comparator|Adjunct Placebo|Participants receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they receive Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.
89071125|NCT04281433|Experimental|unilateral|
89071126|NCT04281433|Experimental|bilateral|
89071127|NCT01735825|Experimental|iopromide paclitaxel-eluting balloon|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter (iopomide coating)
89071128|NCT01735825|Active Comparator|drug eluting stent|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
89071129|NCT01735825|Other|seal-wing PEB|"Observational, non-randomised arm:~Pts with ISR treated by seal-wing paclitaxel-eluting balloon catheter"
89071130|NCT02855905|Experimental|Coronary artery disease patients|Coronary artery disease patients are exposed to brief cold exposure (-15 C for 30 min) mainly subjected to facial region during which their cardiovascular responses are registered. Exposure was repeated 4 times: rest and exercise in 22 C and rest and exercise in -15 C.
89071131|NCT01148511|Experimental|Treat and Extend|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. If the disease was inactive 4 weeks later, the next visit was postponed 2 weeks to 6 weeks later. If the disease was inactive during subsequent visits, the next visit was postponed an additional 2 weeks to 8 weeks later, the maximum interval between visits. If the disease became active at any visit, the patient received ranibizumab 0.5 mg ivt and the follow-up schedule started over.
89071132|NCT01148511|Active Comparator|Treat and Observe|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. All subsequent visits occurred monthly. If the disease was active, the patient received ranibizumab 0.5 mg ivt. If the disease was inactive, no treatment was administered and the patient was instructed to return 1 month later.
89071133|NCT02860117|Active Comparator|Ketatamine|Ketamine continuous infusion 0,2mg/kg/h
89071134|NCT02860117|Placebo Comparator|Placebo|Placebo in continuous infusion
89071135|NCT02853253|Experimental|SMOF|parenteral nutrition using SMOFlipid® (FreseniusKabi France, Sèvres, France)
89071136|NCT02853253|Active Comparator|Medialipide®|parenteral nutrition using Medialipide® 20% (B Braun Medical, Boulogne, France)
89224010|NCT03800927|Placebo Comparator|Sham Ultrasound Device|No ultrasound treatment
89224011|NCT03800927|Active Comparator|Active Ultrasound Device|Active treatment
89071137|NCT00547339|Experimental|Phase 1: Stereotactic Body Radiation Therapy (SBRT) 45 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated - 45 Gy
89071138|NCT00547339|Experimental|Phase 1: Stereotactic Body Radiation Therapy (SBRT)- 47.5 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated- 47.5 Gy
89071139|NCT00547339|Experimental|Phase 1: Stereotactic Body Radiation Therapy (SBRT)- 50 Gy|The Phase 1 portion of the study will have a 3+3 design. The dose of SBRT is escalated- 50 Gy
89071140|NCT00547339|Experimental|Phase 2: Stereotactic Body Radiation Therapy (SBRT)- 50 Gy|The dose of SBRT is escalated - 50 Gy in Phase 2
89071141|NCT04269187|Experimental|With theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU and before administration of theophylline; 200 mg/d orally for 12 days then reassessment of diaphragm by ultrasound.
89071142|NCT04269187|No Intervention|No theophylline treatment|This group will be for: diaphragmatic ultrasound after admission to ICU then reassessment of diaphragm by ultrasound before discharge
89071143|NCT02853565|Experimental|CAN008|CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.
89071144|NCT02856217|Active Comparator|tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal tunneling in SCP: creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum.
89071145|NCT02856217|Active Comparator|non-tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal non-tunneling group in SCP: incised and sutured peritoneum between vaginal apex and sacrum
89071146|NCT04269109||Control Cohort|A control cohort from September 1, 2018 - October 31, 2018
89071147|NCT04269109||Intervention Cohort|An intervention cohort from March 1, 2019 - April 30, 2019
89071148|NCT04268953|Experimental|AC-SD-03|Study drug administered concurrently with a standard meal
89071149|NCT01227252|Experimental|LY2886721|
89071150|NCT01227252|Placebo Comparator|Placebo|
89071151|NCT02855671||Healthy volunteers|
89071152|NCT02855671||Sepsis|
89071153|NCT02855671||Severe sepsis/septic shock|
89224012|NCT03797898|Experimental|Intervention|Parents will meet with a Parent Coach during child's routine well visits, and have access to the parent coach between visits for additional follow up and concerns, and have access to a preventive care text messaging services (Healthy Txt).
89690964|NCT03335254|Experimental|Dose-Escalating Arm 5|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89224013|NCT03797898|No Intervention|Control|usual care well child care
89224014|NCT03787680|Experimental|Cohort 1 (DRPro)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).
89224015|NCT03787680|Experimental|Cohort 2 (DRDef)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).
89690965|NCT03335254|Experimental|Dose-Escalating Arm 6|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 507 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690966|NCT03335254|Experimental|Dose-Escalating Arm 7|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690967|NCT03335254|Experimental|Dose-Escalating Arm 8|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690968|NCT03335254|Experimental|Dose-Escalating Arm 9|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690969|NCT03335254|Experimental|Dose-Escalating Arm 10|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 443 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690970|NCT03335254|Experimental|Dose-Escalating Arm 11|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690971|NCT03335254|Experimental|Dose-Escalating Arm 12|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690972|NCT03335254|Experimental|Dose-Escalating Arm 13|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89071154|NCT01227018|Experimental|STA-9090|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89071155|NCT01659541|Experimental|Procedure & Device|Procedure/Surgery: Implantation of device; Device: Expiratory Muscle Stimulator
89071156|NCT01226472|Experimental|KW-0761|
89071157|NCT04268563|Placebo Comparator|Placebo|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
89071158|NCT04268563|Experimental|Metformin|Intervention group 1: received Metformin (Glucophage, Merck, West Drayton, UK; 500 mg ,two times daily
89071159|NCT04268563|Experimental|Sitagliptin|Intervention group2: received Sitagliptin (Januvia, Merck,West Drayton, UK. 50 mg, two times daily
89071160|NCT04268563|Experimental|sitagliptin/metformin|Intervention group3: received Sitagliptin/metformin (Janumet, Merck,West Drayton, UK. 50/500 mg), two times daily
89690973|NCT03335254|Experimental|Dose-Escalating Arm 14|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 380 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690974|NCT03335254|Experimental|Dose-Escalating Arm 15|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690975|NCT03335254|Experimental|Dose-Escalating Arm 16|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 253 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690976|NCT03335254|Experimental|Dose-Escalating Arm 17|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690977|NCT03335254|Experimental|Dose-Escalating Arm 18|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690978|NCT03335254|Experimental|Dose-Escalating Arm 19|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690979|NCT03335254|Experimental|Dose-Escalating Arm 20|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
89690980|NCT02226159|Active Comparator|Lidocaine|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc normal saline
89690981|NCT02226159|Experimental|Lidocaine with Dexamethasone|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc of Dexamethasone (10 mg/cc)
89690982|NCT03335800|Experimental|Apple Heart Study App|
89690983|NCT02202369|Experimental|Multimodal Analgesia (MMA) Treatment|
89690984|NCT02202369|Active Comparator|Standard of Care Pain Managment Protocol|
89690985|NCT03338686|Active Comparator|Free Gingival Graft|Free Gingival Graft (FGG)
89690986|NCT03338686|Experimental|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft (CTG) followed by Laser Gingivoplasty
89690987|NCT03241030|Experimental|Experimental Group|Subjects will receive sucralfate
89690988|NCT03241030|Placebo Comparator|Placebo Group|Subjects will receive a placebo
89690989|NCT03479944|Experimental|FLACS|Femtosecond laser assisted cataract surgery (FLACS) in 1 eye, with manual conventional surgery in the fellow eye, as randomized
89690990|NCT03479944|Active Comparator|Conventional|Manual conventional surgery in 1 eye, with FLACS in the fellow eye, as randomized
89690991|NCT03241810|Experimental|Arm A|"Seribantumab~Fulvestrant"
89071161|NCT04206462||Osteoarthritis|Questionnaire of eating habits, markers of oxidative stress
89071162|NCT01225146|Active Comparator|Treatment Experienced (Cohort 1|"Previously treated with 6 or more intravitreal ranibizumab with persistent edema followed in RAVE 1 (FVF3348s).~Cohort 1 patients will receive 1 dose of ranibizumab 2.0 mg, followed by PRN based on pre-defined retreatment criteria"
89071163|NCT01225146|Active Comparator|Treatment Naive (Cohort 2)|Treatment naïve. Cohort 2 patients will receive 6 doses of ranibizumab 2.0 mg, followed by PRN based on pre-defined re-treatment criteria.
89690992|NCT03241810|Active Comparator|Arm B|"Placebo~Fulvestrant"
89690993|NCT02129751|Experimental|bupropion hydrobromide|study drug
89690994|NCT02129751|Placebo Comparator|placebo|placebo
89690995|NCT03242590|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
89690996|NCT02710383||Participants genetically diagnosed with Cystic fibrosis|Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years
89690997|NCT03481270|Placebo Comparator|Discordant|Does not receive the concordant provider.
89690998|NCT03481270|Experimental|Concordant|The intervention is that the subject receives the concordant provider.
89690999|NCT03247738|Experimental|Cangrelor|Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
89691000|NCT03247738|Placebo Comparator|Placebo|Normal saline bolus and infusion for 2 hours
89691001|NCT02660385|Experimental|Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-I) will be provided in a group format, led by an interventionist. CBT-I includes strategies for modifying thoughts and behaviors about sleep. Participants will be instructed on and practice methods for modifying their thoughts and behaviors about sleep and insomnia. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
89691002|NCT02660385|Active Comparator|Heart Failure Self-Management Education|Heart Failure Self-management education is an intervention that will be provided by a nurse in a group format. This includes standard components, such as education about fluid and sodium management, heart failure medications, diet and physical activity. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
89691003|NCT03341728|Experimental|Intervention, then Control|Older adults will walk during exposure to optical flow perturbations
89691004|NCT03341728|Experimental|Control, then Intervention|Older adults will walk normally (without optical flow perturbations)
89691005|NCT03345160|Experimental|Peanut Flour: Open label peanut OIT|This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study
89691006|NCT01874067||Arthritis glove|Early inflammatory, rheumatoid or hand osteoarthritis with hand/wrist swelling and pain
89691007|NCT03345394|Active Comparator|Standard Treatment|12 weeks of standard treatment offered by Unidade Recomeço Helvétia treatment program
89691008|NCT03345394|Experimental|Contingency Management|12 weeks of standard treatment offered at Unidade Recomeço Helvétia treatment program associated with Contingency Management
89691009|NCT01567605|Experimental|Lidocaine lubricant (then placebo)|In this arm, on the first test day subjects will use lidocaine lubricant in their normal bowel care routine (rather than standard lubricating jelly). After a washout period they will repeat testing with the placebo lubricant.
89691010|NCT01567605|Placebo Comparator|Placebo lubricant (then lidocaine)|In this arm, on the first test day subjects will use regular lubricant (AMG MedPro lubricating gel) in their normal bowel care routine. After a washout period they will repeat testing with a the lidocaine lubricant.
89691011|NCT02604537|Active Comparator|Betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone (Celestone)
89691012|NCT02604537|Experimental|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac (Toradol)
89691013|NCT02603133|Other|Cohort 1|The intervention will begin for all NICUs, with baseline surveys as necessary pre-work. For those unable to attend, a link to the baseline survey will be emailed with site champion instructions to complete in groups at staff meetings and during shift change. Two weeks later, three randomly (random number generator) assigned NICUs (block 1) included in the first block webinar will then receive Module 1 of the intervention with Modules 2-6 being rolled out monthly. The second block of three NICUs starts approximately six-month later.
89691014|NCT02603133|Other|Cohort 2|This second block of 3 NICUs will start approximately six-months after roll-out of group 1. At time point 0 this NICUs in this group will receive a lecture on safety culture, unrelated to the burnout intervention.
89691015|NCT02603133|Experimental|Cohort 3 (July cohort) WISER 2.0|"Individually randomized to one of two cohorts. Cohort 1 to start will serve as the waitlist control 1 before starting their version of the intervention. Each cohort will experience modified versions of WISER, which only differ by the spacing of intervention. Participants will receive 10-day sequential or 10-day non-sequential rollout of the resilience tools. Seq will receive the tools on ten consecutive days. NSeq will receive messages daily noThursdays, Fridays and Saturdays.~Days 1 through 3 will be offered 3GT. Day 4 will continue with 3GT but add a single day activity for Gratitude. Day 5 adds a single activity for Awe. Day 6 adds a single day activity for RAK. Days 7 -10 the participant is offered the choice of Gratitude, Awe or RAK to accompany their daily 3GT. At 1 month follow-up time point, participants will receive 8 days of the 1 Good Chat tool, as a booster. At 6 month follow-up, participants will receive a gratitude exercise."
89691016|NCT02539329||patient|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.
89691017|NCT02539329||control|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and negative for anti-FGFR3 antibodies
89691018|NCT01352403|Other|Psychotherapy-enhanced lifestyle intervention (PELI)|Intensive lifestyle intervention over 12 months including medically supervised dietary counseling and physical activity enhanced by a psychotherapeutic intervention
89691019|NCT01352403|Other|Roux-en-Y-gastric bypass (RYGB)|Laparoscopic Roux-en-Y gastric bypass surgery
89071164|NCT01223196|Placebo Comparator|Placebo|One arm of the study subjects will be treated with Placebo only, once a day, for 6 months
89071165|NCT01223196|Active Comparator|Pioglitazone|One arm of the study subjects will be treated with Pioglitazone, 15mg, once a day, for 6 months
89071166|NCT01222416|Experimental|fluorodeoxyglucose PET/CT (FDG-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
89071167|NCT01222416|Experimental|fluorodeoxythymidine PET/CT (FLT-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
89071168|NCT01222104||Angio-Seal|Angio-Seal attempted and/or deployed
88812943|NCT03219944|Active Comparator|sub epithelial connective tissue graft|The connective tissue graft will be harvested from the palate. Then the SCTG will be placed over the recipient site extending palataly and sutured.
89071169|NCT01222104||Not deployed|Other method of closure
89071170|NCT01221948|Experimental|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
89071171|NCT01221090|Experimental|Personal Digital Assistant|Individuals in this arm were taught to use a diabetes self-care software, Diabetes Pilot™ (Digital Altitudes, Arlington Heights, IL), developed for PalmOS® (Palm, Sunnyvale, CA) which was loaded on to compatible PDAs, the Tungsten™ E2 handheld device. The Diabetes Pilot allowed participants to monitor their blood glucose, blood pressure, medication usage, physical activity, and dietary intake by tracking these measures in an electronic diary.
89071172|NCT01221090|Active Comparator|CDSMP|6-week, classroom-based program for diabetes self-management. The CDSMP, developed by Stanford University, equipped participants with the education and skill sets needed to take a more proactive approach in managing their chronic condition(s) and related symptoms.
89071173|NCT01221090|Active Comparator|PDA/CDSMP|Combined intervention
89071174|NCT01221090|No Intervention|Control|Usual Care
89071175|NCT00950911|Experimental|1|
89071176|NCT02855515|Experimental|Short-time diagnostic anaesthesia|The study population will consist of patients with obstructive sleep apnoea, which will be classified as mild, moderate, severe (patients who failed or refused primary CPAP treatment). The patients will undergo a short-time general anaesthesia in order to diagnose OSA when relaxed.
89071177|NCT01220856|Experimental|Reparixin|"Reparixin + Immunosuppression~Reparixin was administered at a dose of 2.772 mg/kg body weight/hour for 7 days (168 hours) at each transplant. It was administered as a continuous IV infusion into a (high-flow) central vein. Investigational Product infusion was to begin approximately 12 hours (range between 6 to 16 hours) before each pancreatic islet infusion was started. The Investigator identified the time to start study drug administration.~Reparixin was given to all patients of this arm using the same dosing solution (reparixin 11.00 mg/mL), but the pump rate was adjusted to provide an infusion rate of approximately 0.25 mL/kg/hour.~For immunosoppression regimen see the other arm description."
89071178|NCT01220856|No Intervention|No experimental intervention|Immunosuppression only. Induction: First islet infusion: anti-thymocyte globulin (ATG), administered IV (central vein) at the dose of 1.5 mg/kg on Day -1, 0, 1, and 2 of islet infusion. The first ATG injection was preceded by a bolus IV injection of 500 mg methylprednisolone. Induction for the second islet infusion was to be administered per center practice. Maintenance: Mycophenolate mofetil (MMF), administered orally at the dose of 1 g twice a day, starting on Day -1 of the first islet infusion; Tacrolimus, administered orally starting on Day -1 of the first islet infusion at a dose of 0.087 mg/kg twice a day. Thereafter, dosing was to be targeted to blood trough levels of 8 to 10 ng/mL. Administration continued up to Month 3 after the first transplant. Rapamycin was to replace tacrolimus from Month 3 after the first transplant. It was to be administered orally at the starting dose of 0.1 mg/kg once a day, then targeted to a blood trough level of 10 to 12 ng/mL.
89071179|NCT04206228|Active Comparator|Active treatment|Active drug: Intravenous iron isomaltoside dissolved in 100 ml NaCl 0.9 %
89071180|NCT04206228|Placebo Comparator|Placebo|Placebo: Intravenous NaCl 0.9 % dissolved in 100 ml
89071181|NCT01218594|Experimental|Endostatin combine CCRT|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
89071182|NCT01610557|Experimental|Group 1 - Ranibizumab-Ranibizumab-Bevacizumab Injection Series|"Group 1 eyes were assigned to Ranibizumab-Ranibizumab-Bevacizumab (RRB) treatment sequence and received intravitreal injections of ranibizumab at baseline, Weeks 4, and 8 (period 1), and Weeks 12, 16 and 20 (period 2), then crossed over to receive intravitreal injections of bevacizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
89071183|NCT01610557|Experimental|Group 2 - Ranibizumab-Bevacizumab-Bevacizumab Injection Series|"Group 2 eyes were assigned to Ranibizumab-Bevacizumab-Bevacizumab (RBB) treatment sequence and received intravitreal injections of ranibizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of bevacizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
89071184|NCT01610557|Experimental|Group 3 - Bevacizumab-Bevacizumab-Ranibizumab Injection Series|"Group 3 eyes were assigned to Bevacizumab-Bevacizumab-Ranibizumab (BBR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4, 8, 12, 16 and 20 (periods 1 and 2), then crossed over to receive intravitreal injections of ranibizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
89071185|NCT01610557|Experimental|Group 4 - Bevacizumab-Ranibizumab-Ranibizumab Injection Series|"Group 4 eyes were assigned to Bevacizumab-Ranibizumab-Ranibizumab (BRR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of ranibizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
89071186|NCT00943735||Fesoterodine arm|subjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy
89071187|NCT02853097||Ancillary-Correlative (blood collection)|Patients undergo blood collection every 4-12 weeks during ADT, abiraterone, enzalutamide, or docetaxel treatment. Patients switched from ADT to either abiraterone or enzalutamide during the study will undergo phlebotomy every 6-12 weeks. Samples are analyzed for cfRNA, and cfDNA, AR-V7, and other AR-Vs via quantitative RT-PCR.
89071188|NCT00943579|Experimental|Kuvan®|Kuvan® (sapropterin) will be administered to all subjects at 20 mg/kg/day for 16 weeks.
89071189|NCT04204213||8 Section Brocade Tai Chi Therapy|Subject participants with end stage osteoarthritis knee were enrolled into a customised multidisciplinary education program that consisted of one hour healthcare education seminars followed by another hour of 8 Section Brocade (Baduanjin) sitting Tai Chi classes for 4 consecutive weeks.
89071190|NCT02852707||Unilateral overhead throwing athletes|Volleyball attackers involved in competitive events ≥ 2 years, ≥18 years of age
89071191|NCT02852707||Bilateral overhead athletes|Swimmers involved in competitive events ≥ 2 years, ≥18 years of age
89071192|NCT02852707||Non-athletes|Persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers), ≥18 years of age
89071193|NCT02852551|Experimental|PAT-1251 Single Dose|Oral solution of PAT-1251, 150 - 4000 mg administered once
89071194|NCT02852551|Placebo Comparator|Placebo Single Dose|Matching placebo solution administered once
89071195|NCT02852551|Experimental|PAT-1251 Multiple Dose|Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days
89071196|NCT02852551|Experimental|Placebo Multiple Dose|Matching placebo tablets administered daily for 7 days
89071197|NCT01147809|Active Comparator|Eltrombopag|Drug: eltrombopag olamine thrombopoietin receptor agonist
89071198|NCT01147809|Placebo Comparator|Placebo|Other: Placebo Placebo tablets with no active pharmaceutical ingredient
89071199|NCT00943111|Experimental|Investigational|Eliglustat tartrate
89071200|NCT00943111|Active Comparator|Imiglucerase|
89071201|NCT04268719||Gastro-Esophageal Reflux Disease|Patients defined as having GERD as per Lyon Consensus
89071202|NCT04268719||Non-acid Reflux|Patient excluded for GERD as per Lyon Consensus
89071203|NCT01147497|Experimental|misoprostol|Misoprostol 400mcg taken buccally 2 hours prior to IUD insertion visit
89071204|NCT01147497|Placebo Comparator|placebo|Pill that is identical to the study drug in appearance, taste, and smell, taken buccally 2 hours prior to IUD insertion visit
89071205|NCT01147341|Placebo Comparator|placebo|Placebo (0.9% sodium chloride) given as 2 subcutaneous (sc) injections at weeks 0, 2, and 4, followed y 1 sc injection given an weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
89224016|NCT03743636|Active Comparator|Nicotinamide riboside + resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 1,000 mg of NR and 125 mg of resveratrol daily for six months.
89071206|NCT01147341|Active Comparator|active treatment with Cimzia|400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 0, 2, and 4, followed by 1 sc injection at weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
89071207|NCT00950755|Experimental|Tositumomab and Iodine I 131 Tositumomab (anti-B1 antibody)|In the first phase (dosimetric dose) patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of Anti B1 Antibody (35 mg) which has been trace-labeled with 5 mCi of Iodine 131. Whole body gamma camera scans will be obtained following the dosimetric dose. Using the dosimetric data, a patient-specific dose of Iodine 131 Anti B1 Antibody to deliver the desired total body dose of radiotherapy will be calculated. In the second phase, (radioimmunotherapeutic dose), patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of 35 mg Anti B1 Antibody labeled with the patient-specific dose of Iodine 131 to deliver a whole body dose of 75 cGy. Patients will be treated with saturated solution potassium iodide, Lugol's solution, or potassium iodide tablets starting at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion of Iodine 131 Anti B1 Antibody.
89071208|NCT01147107|Experimental|Raltegravir based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
89071209|NCT01147107|Active Comparator|Efavirenz based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
89071210|NCT02852473|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP) will be administered using FDA-approved equipment.
89071211|NCT02852863|Experimental|Ultrasound (case only)|Subjects will fast for a minimum of 8 hours. Ultrasound assessment of gastric volume and content will determine basal conditions. Next, subjects will chew gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
89071212|NCT00942409|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
89071213|NCT02852317||Spina bifida patient|
89071214|NCT02852317||Patients with multiple sclerosis|
89071215|NCT02852317||Patients with spinal cord injury|
89071216|NCT02852317||Patients with overactive bladder|
89071217|NCT01146951|Experimental|Rufinamide (E2080)|
89071218|NCT01146951|Placebo Comparator|Placebo|
89071219|NCT01146873|Active Comparator|Group 1: Lopinavir/ritonavir (LPV/r)|Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher.
89071220|NCT01146873|Experimental|Group 2: Efavirenz (EFV)|Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.
89071221|NCT01146873|Active Comparator|Group D: Stavudine (D4T)|Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily
89071222|NCT01146873|Experimental|Group A: Abacavir (ABC)|Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.
89071223|NCT01146795|Experimental|Carboplatin, Paclitaxel, and Bevacizumab|"Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab.~After 3 cycles of chemotherapy patients will be considered for surgical cytoreduction. Patients must fulfill all criteria to be considered eligible for surgical exploration: 1) ≥50% reduction in pretreatment cancer antigen 125 (CA-125) and 2) No medical contraindications to surgery.~After surgical cytoreduction all patients will receive an additional 6 cycles of chemotherapy (cycles 4-9) regardless of disease status at the time of exploration. Chemotherapy should be re-instituted within 6 weeks of the surgical procedure. Bevacizumab will be omitted from cycle 4 of chemotherapy. Patients who do NOT undergo surgical resection should receive cycles 4-9 of therapy. In this instance bevacizumab may be included in cycle 4."
89071224|NCT00625053|Experimental|1|Laparoscopic repair
89071225|NCT00625053|Active Comparator|2|Open repair
89071226|NCT01146561|Experimental|Tanezumab 20 mg|
89071227|NCT01146561|Placebo Comparator|Placebo|
89071228|NCT00942175|Other|Regimen A|Clopidogrel 75 mg QD
89071229|NCT00942175|Other|Regimen B|Clopidogrel 75 mg QD and Lansoprazole 30 mg QD
89071230|NCT00942175|Other|Regimen C|Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD
89071231|NCT00942175|Other|Regimen D|Clopidogrel 75 mg QD and Omeprazole 80 mg QD
89071232|NCT00942175|Other|Regimen E|Clopidogrel 75 mg QD and Esomeprazole 40 mg QD
89071233|NCT01145625|Experimental|5% MTF|5% Minoxidil Topical Foam
89071234|NCT01145625|Active Comparator|2% MTS|2% Minoxidil Topical Solution
89071235|NCT02852941||Patients after kidney transplantation|The study included who had been admitted to a nephrology-transplantation outpatient clinic 0.5 to 30 years after kidney transplantation.
89071236|NCT02852941||Healthy subjects|Medical staff: medical doctors, nurses
89071237|NCT02884167||Patients with constipation|
89071238|NCT02884167||Healthy individuals without constipation|
89071239|NCT02852083|Experimental|A: Biomodulatory treatment|treosulfan 250 mg p.o. twice daily, pioglitazone 45 mg p.o. once daily, clarithromycin 250 mg p.o. twice daily until progression or no clinical benefit observed, whichever comes first.
89071240|NCT02852083|Active Comparator|B: Standard Treatment|Nivolumab, 3 mg per kilogram of body weight every 2 weeks until disease progression according to RECIST 1.1 or unacceptable toxicity
89071241|NCT02852395|Experimental|Part 1 Single Dose|Part 1 single daytime oral dose of JNJ-48816274 or placebo. Doses of JNJ-48816274 will start at 5 milligram (mg) and increase sequentially to a maximum dose of 250 mg.
89071242|NCT02852395|Experimental|Part 2 Crossover Sleep Study|Part 2 single nighttime oral dose of JNJ-48816274 or placebo administered during each of 3 or 4 crossover periods separated by 7-9 days. The doses of JNJ-48816274 will be selected based on data from Part 1 (not to exceed 250 mg).
89071243|NCT02852395|Experimental|Part 3 Repeated Dose (Optional)|Part 3 daytime oral dose of JNJ-48816274 or placebo administered once daily for 7 consecutive days. Doses will be determined based on data from Part 1, and may increase sequentially (not to exceed 250 mg/day).
89071244|NCT01144377|Experimental|180 mg LY2541546 Q4W + Placebo|"LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
89071245|NCT01144377|Experimental|180 mg LY2541546 Q2W|LY2541546: 180 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
89071246|NCT01144377|Experimental|270 mg LY2541546 Q2W|LY2541546: 270 milligrams (mg) LY2541546 administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
89071247|NCT01144377|Experimental|270 mg LY2541546 Q12W + Placebo|"LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
89071248|NCT01144377|Placebo Comparator|Placebo Comparator Q2W|Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
89071249|NCT02884011||No chronic antihypertensives|not on either a chronic β-blocker or ACE-Inhibitor
89071250|NCT02884011||β-blocker|on chronic β-blocker
89071251|NCT02884011||ACE-Inhibitor|on chronic ACE-Inhibitor
89071252|NCT02884011||Both β-blocker and ACE-inhibitor|on both chronic β-blocker and ACE-inhibitor
89071253|NCT00950599|Experimental|Saxagliptin (2.5 mg)|
89071254|NCT00950599|Experimental|Saxagliptin (5 mg)|
89071255|NCT00950599|Experimental|Saxagliptin (10 mg)|
89071256|NCT00950599|Experimental|Saxagliptin (20 mg)|
89071257|NCT00950599|Experimental|Saxagliptin (40 mg)|
89071258|NCT00950599|Experimental|Saxagliptin (100 mg)|
89071259|NCT00950599|Placebo Comparator|Placebo|
89071260|NCT01144299|Experimental|Fluarix Adult Group|Subjects aged 18 to 60 years received one dose of Fluarix™.
89071261|NCT01144299|Experimental|Fluarix Elderly Group|Subjects aged > 60 years received one dose of Fluarix™.
89071262|NCT04313205|Active Comparator|Capsule|JKB-122 capsule on period 1 followed by JKB-122 Tablet on period 2
89071263|NCT04313205|Active Comparator|Tablet|JKB-122 tablet on period 1 followed by JKB-122 capsule on period 2
89071264|NCT02883621|Active Comparator|Group A|subjects receive standard upper endoscopy
89071265|NCT02883621|Experimental|Group B|subjects receive cap assisted upper endoscopy
89071266|NCT02883699|Active Comparator|Endurance Training Group 1|Standard endurance training
89071267|NCT02883699|Experimental|Endurance Training Group 2|Polarized endurance training
89071268|NCT02883699|Active Comparator|Resistance Training Group 1|Standard resistance training
89071269|NCT02883699|Experimental|Resistance Training Group 2|Daily undulating periodization resistance training
89071270|NCT04313049|Active Comparator|Motor control|
89071271|NCT04313049|Experimental|Vocal control|
89071272|NCT01143207|Experimental|Medroxyprogesterone acetate|Single injection of Medroxyprogesterone acetate (hormonal contraceptive)
89224017|NCT03743636|Active Comparator|Nicotinamide riboside + placebo|Participants randomized to the NR + placebo arm of the study will receive 1,000 mg of NR and a placebo daily for six months.
89224018|NCT03743636|Placebo Comparator|Placebo + placebo|Participants randomized to the placebo + placebo arm of study will receive placebo pills.
89071273|NCT04312893|Experimental|Acupuncture group (ACU)|Patients in acupuncture group will receive traditional Chinese acupuncture combined with Tung's style acupuncture using Press Tack Needle (PYONEX Φ0.20×0.6 mm made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles. The following acupoints will be used: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment will use bilateral acupuncture (if patient's condition does not allow it, unilateral acupuncture will be done). The patient will lie in a supine position during the treatment. Acupuncturist will disinfect the acupoint location with an alcohol pad (70% alcohol), then the acupuncturist will press the needles sticker to the mentioned above acupoints. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
89224019|NCT03726775|Experimental|RT-durvalumab|durvalumab at fixed dose of 1120 mg on Day1 of RT and every 3 weeks during the RT. Durvalumab with be continued at a fixed dose of 1500 mg every 4 weeks during 6 months following RT.
89224020|NCT03718039|Experimental|Treatment Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
89224021|NCT03718039|Experimental|Treatment Group 2: HTX-011 + Aprepitant|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation; Aprepitant, three single doses of aprepitant will be administered orally.
89224022|NCT03718039|Experimental|Treatment Group 3: HTX-011 + Non-Opioid MMA Regimen|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation and a scheduled multimodal analgesic (MMA) regimen.
89071274|NCT04312893|Placebo Comparator|Control group (CON)|Patients randomized to the control group will receive press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element. The point selection will be identical to acupuncture group: HT 7 (Shen Men), PC 6 (Nei Guan), Yin Tang (EX-HN 3), San Shang (55-02) (three point from Dong's acupuncture system) and the auricular Shen Men point. The treatment methods and patients position will be identical to acupuncture group. Interventions will be given on day 1, 3, and 5 after patient's enrolment.
89071275|NCT01143051|Active Comparator|Treatment C|Active comparator arm utilizing marketed Primatene Mist with CFC propellant at the labeled dose.
89071276|NCT01143051|Experimental|Treatment 1|T1 is HFA propelled epinephrine inhalation aerosol 125 mcg/inhalation
89071277|NCT01143051|Experimental|Treatment 2|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation
89071278|NCT02883543|Experimental|icotinib plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy.
89071279|NCT02883543|Active Comparator|icotinib|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib monotherapy.
89071280|NCT02883543|Active Comparator|chemotherapy plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive chemotherapy plus concurrent radiotherapy.
89071281|NCT05199597|Experimental|All participants|All participants will receive all four drops in randomized order
89071282|NCT01142661|Experimental|Eribulin mesylate|
89071283|NCT01142193|Experimental|USL255|
89224023|NCT03688165||Treadmill-based Robotic Gait Training|The Treadmill-based Robotic Gait Training (TRGT) period will last 20 sessions, 3-5 days/week for at least 400' of exercise totally. The parameters to be respected for the robotic training will be the following for all patients: 0.9 km / h starting speed up to a maximum of 2.5 km / h; weight support not exceeding 40-45% of the body weight at the beginning and gradual progressive reduction depending on the case; for Lokomat: maximum assistance required at the start of treatment and gradual decrease during the treatment. The TRGT will always be associated with the traditional gait rehabilitation, and will be part of the Individual Rehabilitation Project which normally includes 3 hours of rehabilitation treatments for patients in the subacute phase, 60' of treatment for those in chronic phase.
89071284|NCT01142193|Placebo Comparator|Placebo|
89071285|NCT01142115|Experimental|Monza|nonCE marked intermittent catheter
89071286|NCT01142115|Active Comparator|control|SpeediCath coated catheter
89071287|NCT01140477|Experimental|Crystalens toric IOL|Toric Accommodating Lens Crystalens toric silicone multi-piece accommodating IOL (Models AT-50T/AT-52T)
89071288|NCT01140477|Active Comparator|Crystalens IOL|Accommodating Lens Crystalens silicone multi-piece accommodating IOL (Models AT-50SE/AT-52SE)
89071289|NCT01139775|Experimental|Phase 1: LY2603618 130 to 275 mg|"Cycle 1-2 (21-day cycle):~Day 1: pemetrexed 500 milligrams per meter square (mg/m^2) + cisplatin 75 mg/m^2~Day 2: LY2603618 at 130-275 milligrams (mg)~After 2 cycles, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
89071290|NCT01139775|Experimental|Phase 2: Pemetrexed + Cisplatin + LY2603618|"Cycles 1-4 (21-day cycle):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~Day 2: LY2603618 dose from phase 1 portion of trial~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Experimental Arm (every 21 days):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2~Day 2: LY2603618 dose determined from phase 1~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2~If, as of 25 Oct 2012, participant was in maintenance therapy and randomized to the experimental arm, the participant is eligible to continue with pemetrexed (Day 1)/LY2603618 (Day 2) therapy if the investigator deems it is in the best interest of the participant and the participant consents."
89071291|NCT01139775|Active Comparator|Phase 2: Pemetrexed + Cisplatin|"Cycle 1-4 (21-day cycle):~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Comparator Arm: Phase 2 (every 21 days):~Day 1: pemetrexed 500 mg/m^2"
89071294|NCT02883777|Experimental|High Protein and Low Glycemic Index Diet|A protocol of a high protein and low glycemic index diet.
89071295|NCT02883777|Active Comparator|Conventional Diet|A protocol of a conventional diet.
89071296|NCT02883465|Other|Single arm|
89071297|NCT04312425||Group C|General anesthesia was induced with classic rapid sequence induction protocol.
89071298|NCT04312425||Group M|General anesthesia was induced with modified rapid sequence induction protocol.
89071299|NCT01283516|Experimental|LDK378 750 mg: Arm 1A and Arm 1B|NSCLC patients previously treated with an ALK inhibitor
89071300|NCT01283516|Experimental|LDK378 750 mg: Arm 2|NSCLC patients not previously treated with an ALK inhibitor
89071301|NCT01283516|Experimental|LDK378 750 mg: Arm 3|Patients with other tumors that are ALK positive other than NSCLC
89071302|NCT04205721|Experimental|Scripted lesson plan life orientation curriculum|Participants in this arm were in schools where the life orientation teachers in grades 7-9 (in 2016 and 2017) and grade 10 in 2018 were trained to use the new life orientation curriculum that included scripted lesson plans for the sexual and reproductive health content of the program. There are eight lessons for grade 7, eight for grade 8, 11 for grade 9, and 10 for grade 10.
89071303|NCT04205721|No Intervention|Standard life orientation curriculum|Participants in this arm were in schools where the standard life orientation curriculum was used with no additional training and no use of the new materials.
89071304|NCT01137435|Experimental|Study Group|
89224024|NCT03688165||Traditional Over-ground Gait Training|"The Traditional Over-ground Gait Training (TOGT) period will last 20 sessions, 3-5 days / week for a total time that corresponds to the same total time of traditional overground gait training, or at least 400' totally at the end of the period.~By Traditional Therapy we mean any technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids."
89224025|NCT03681080|No Intervention|lying|cognitive tests are performed during lying in all groups (SFN, AAN, EDS, POTS and controls)
89224026|NCT03681080|No Intervention|standing|cognitive tests are performed during active Standing in all groups (SFN, AAN, EDS, POTS and controls)
89224027|NCT03681080|Experimental|crossed legs|cognitive tests are performed during leg crossing in all groups (SFN, AAN, EDS, POTS and controls)
89522904|NCT00535405|Experimental|4|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
89071305|NCT01283282|Active Comparator|Clopidogrel/Placebo|Subjects were randomized to clopidogrel 75 mg daily for 6 weeks. Then immediately transitioned to a placebo daily for 6 weeks.
89071306|NCT01283282|Active Comparator|Placebo/Clopidogrel|Subjects were randomized to a placebo daily for 6 weeks. Then immediately transitioned to clopidogrel 75 mg daily for 6 weeks.
89071307|NCT01282814|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules.
89071308|NCT01282814|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
89071309|NCT00941863|Experimental|Sorafenib 100 mg (50-mg tablet)|Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
89071310|NCT00941863|Experimental|Sorafenib 200 mg (50-mg tablet)|Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
89071311|NCT00941863|Experimental|Sorafenib 400 mg (50-mg tablet)|Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
89071312|NCT00941863|Experimental|Sorafenib 400 mg (200-mg tablet)|Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet). Treatment were planned until primary completion date (PCD).
89071313|NCT00941863|Experimental|Sorafenib 400 mg (Expansion)|Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion. Treatment were planned until primary completion date (PCD). 25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib until 18 Sep 2008.
89071314|NCT02854969|No Intervention|epinephrine auto-injector|3 months using the epinephrine auto-injector alone, and after that 3 more months using the epinephrine auto-injector + medical device
89071315|NCT02854969|Experimental|epinephrine auto-injector + medical device|"Device: Anapphylaxis is a medical device with a case for an epinephrine autoinjector that connects via Bluetooth to a mobile application~3 months using the epinephrine auto-injector + medical device , and after that 3 more months using the epinephrine auto-injector alone"
89071316|NCT02852239|Experimental|Group 1 - Normal renal function|Subjects with normal renal function defined as GFR ≥ 90 mL/min at baseline and matching to the renal impaired subject based on gender, race, age, and weight.
89071317|NCT02852239|Experimental|Group 2 - Severe renal function|Subjects with severe renal impairment defined as GFR of 15-29 mL/min at baseline.
89071318|NCT02852239|Experimental|Group 3 - End stage renal disease (ESRD)|Subjects with end stage renal disease (ESRD), defined as GFR of <15 mL/min at baseline.
89071319|NCT02854813||Group 1|Patients with a OAB-V8 score ≥8
89071320|NCT02854813||Group 2|Patients with a OAB-V8 score <8
89071321|NCT01282424|Experimental|Idelalisib|Treatment with idelalisib will be continued until tumor progression or development of unacceptable toxicity.
89224028|NCT03602014|Experimental|Study 1: Dose Optimization of Northera|Subjects will be administered oral droxidopa in a dose escalation, open-label manner beginning with 200 mg. The dose will be adjusted upwards by 100 mg on subsequent visits until average Systolic Blood Pressure (SBP) recorded 60-120 minutes after dose administration is 111-139 mmHg in males and 101-139 mmHg in females, sustained elevation (≥ 30 consecutive minutes) in seated SBP ≥ 140/100 mmHg, maximum dose of 800 mg is reached without adequate SBP response. Subjects will visit the testing laboratory on as few as 1 (200 mg) and as many as 7 (800 mg) days. Seated cardiovascular assessments will be monitored and recorded at 15-minute intervals for 4-hours, and the side effects questionnaire will be administered hourly during the 4-hour study. Each study visit will take about 5 hours.
89071322|NCT02852785||Asymptomatic volleyball attackers|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
89071323|NCT02852785||Asymptomatic bilateral overhead athletes|Asymptomatic swimmers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
89071324|NCT02852785||Asymptomatic non-athletes|Asymptomatic persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers),
89071325|NCT02852785||Asympt. athletes / scapula dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
89071326|NCT02852785||Symptom. athletes / scapula dyskinesis|Volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis and complaints of shoulder pain and disability
89071327|NCT01281956|Experimental|Placebo Then PRX|Subjects are administered Placebo x3 months followed by PRX (selective 5HT1A agonist) x3 months
89071328|NCT01281956|Experimental|PRX Then Placebo|Subjects are administered PRX (selective 5HT1A agonist) x3 months followed by Placebo x3 months
89071329|NCT02889536||Focus group interview, stoma clinics|Qualitative data collection. Patients attending stoma clinics in the capital region
89071330|NCT02889536||Focus group interview, referred|Qualitative data collection. Patients referred to repair surgery at a specific hospital in the capital region
89071331|NCT00623870|Experimental|1|
89071332|NCT04323410|Experimental|Cast immobilization|"In the casting group, padded synthetic dorsal above elbow and volar below elbow splints are applied in ED without local or general anesthesia. Dorsal displacement and shortening of the radius are not corrected, but the forearm is attempted to be manipulated straight during application of the splints. The casted forearm is then supported by a collar and cuff sling. Splints are removed in an outpatient clinic at 4 weeks.~Cast immobilization is discontinued after 4 weeks and when the fracture site is nontender. If palpated tenderness is still present, the patient is given a dorsal forearm splint which can be removed (maximum of 2 weeks usage)."
89522905|NCT00535405|Experimental|5|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
89071333|NCT04323410|Active Comparator|Percutaneus pinning|In the surgery group, a padded dorsal above elbow splint is applied in ED. Reduction and percutaneous pinning are performed under anesthesia in operating room by an experienced attending pediatric orthopedic surgeon within 7 days from the injury. Pin fixation is performed with two 1.6 mm pins. Padded dorsal above elbow and volar below elbow splints are applied. Splints and pins are removed at the outpatient clinic at 4 weeks after surgery.
89071334|NCT05561270|Sham Comparator|White LED light|Exposure to white LED light for 1-2 hours/day x 10 weeks
89071335|NCT05561270|Experimental|Green LED light|Exposure to green LED light for 1-2 hours/day x 10 weeks
89071336|NCT00949975|Active Comparator|1|AZD9668 active treatment
89071337|NCT00949975|Active Comparator|2|AZD9668 active treatment
89071338|NCT00949975|Active Comparator|3|AZD9668 active treatment
89071339|NCT00949975|Placebo Comparator|4|AZD9668 placebo treatment
89071340|NCT00939055|Experimental|StomaphyX|Post-Roux-en-Y revisional surgery using the StomaphyX device.
89071341|NCT00939055|Sham Comparator|Sham Procedure|No intervention
89071342|NCT00602563|Experimental|1 Attention Modification Program (AMP)|The AMP is a computer-delivered attention modification
89071343|NCT00602563|Active Comparator|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
89071344|NCT00602563|Placebo Comparator|Clinical monitoring control|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions ; however, they will not be randomized to treatment until after the 3-month follow-up assessment. To control for the effects of psychoeducation, symptom monitoring, contact by project staff, and maturation effects, participants will be asked to complete pre-, mid- and post-assessments, and will be informed that they will receive treatment.
89071345|NCT00602563|Experimental|Combining the AMP and AR|Both AMP and AR
89071346|NCT04268017|Experimental|Healthy volunteer|
89071347|NCT00604357|Experimental|1|Prior to reperfusion 500 mg Prednisolone will be administered i.v.. After the transplantation, a combination of anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure), and MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake) will be applied. Earliest, on day 10 after LT Sirolimus will be introduced aiming at 24 hours trough-levels for Sirolimus between 4 and 8 ng/mL. Steroids will be started on day 1 after transplantation with 1mg/kg BW and will be tapered every 2 days for 5 mg to a dosage of 20 mg and for 2.5 mg every two days to 7.5 mg. Thereafter the dosage will be reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter. Additionally, every patient with risk constellation will receive cytomegalovirus (CMV) prophylaxis and prophylaxis against Pneumocystis carinii infection during the first 3 months after liver transplantation.
89071348|NCT05381701||Group I|Minimal Flow Anesthesia (0.25L/dk oxygen, 0,25 L/min air)
89071349|NCT05381701||Group II|Low Flow Anesthesia (0.5L/dk oxygen, 0,5 L/min air)
89071350|NCT05381701||Group III|Medium Flow Anesthesia (1L/dk oxygen, 1 L/min air
89071351|NCT04269733||Subjects with a DDD-pacemaker due to high-degree AV block|
89691020|NCT01063075|Experimental|Cetuximab and Carboplatin (D)|"Group D:~Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m ²) cetuximab administered intravenously (I.V) on week 1,day 1. Carboplatin area under the curve (AUC=5) administered I.V on week 1,day 1.~Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on week 1, day 1.~After 1 cycle, participants may then receive cetuximab as determined by clinical exam or radiological imaging studies until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants were placed into Group D only."
89691021|NCT01063075|Experimental|Cetuximab and Carboplatin (C)|"Group C: Cycle 1 (4 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1.1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week1,day1.1000 mg/m ²/d 5-FU as a 96-hour C.I. starting on week1, day1. 250 mg/m ² cetuximab administered I.V on Week 1-3, day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
89071352|NCT02854657|Experimental|skin self-examination|"Participants from the treatment arms of the original RCT. It is anticipated that 228 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study. These subjects received Skin Self- examination structured training.~The subject are being followed for an additional period of time after receiving an educational intervention."
89071353|NCT02854657|Experimental|Skin Self- examination:Distance (remote) learning|Participants receive the Skin Self- examination structured training with partner assistance educational intervention via mailed workbook while under the customary care of their own dermatologists. It is anticipated that 50 new participant dyads will be recruited and randomized to this group.
89071354|NCT02854657|Active Comparator|Active control|"Participants from the control arm of the original RCT. It is anticipated that 100 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study.~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the Skin Self- examination structured training with partner assistance."
89071355|NCT02854657|Placebo Comparator|Assessment-only control|"Participants who receive customary care from their own dermatologists. It is anticipated that 150 new participant dyads will be recruited and randomized to this group.~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the structured training in skin self-examination with partner assistance."
89071356|NCT02854657|No Intervention|Observational study 1|"Feasibility of wearing 2 sensors No intervention. At the conclusion of the study, participants receive a report of their UV exposure and physical activity over the 7 days of the study.~N= 10"
89071357|NCT02854657|No Intervention|Observational study 2|"Feasibility of completing online daily survey. The research team will strive to integrate event level data in real -time No intervention. At the conclusion of the study, participants receive an event level reports of their daily UV exposure and physical activity over the 7 days of the study.~N= 30"
89224029|NCT03602014|Placebo Comparator|Study 2: Blinded Placebo & Northera|Participants will then be administered either oral optimal dose of Northera (Droxidopa) or matching placebo in a double-blinded manner and will remain in the supine position for 60 minutes. Subjects will remain in their wheelchair for instrumentation, which will include: 1) ECG, 2) brachial BP, 3) finger arteriolar BP and 4) Cerebral Blood Flow velocity (CBFv).
89224030|NCT03559192|Placebo Comparator|Lead-in Period: Placebo|Participants will receive matching placebo for the entire duration of the lead-in period.
89071358|NCT02854657|No Intervention|Relationship Factors Study Observational Study|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.~No intervention- Control group. n=144 Results pending*"
89071359|NCT02854657|Active Comparator|Relationship Factors Study- Skin Self Examination|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.~Intervention= Skin self-examination training n=197 Results Pending*"
89071360|NCT02854657|Active Comparator|Comparison of distance (remote) learning vs in-person learning|Controls re-enrolled from the original study (n=38) and newly enrolled in the distance (remote) learning (n=106) are compared with participants receiving the workbook in-person in the original study and re-enrolled (n=134) and participants newly enrolled in distance (remote) learning, who had the workbook mailed to them (n=63). Online surveys assessed SSE knowledge, confidence, anxiety and performance. Electronic health record review identified biopsies of concerning moles and the number of melanomas identified.
89071361|NCT00604435|Active Comparator|chemotherapy|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin
89071362|NCT00604435|Experimental|chemotherapy plus endostatin|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin
89071363|NCT01136967|Experimental|Cohort 1 (V600E BRAF negative)|Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma.
89071364|NCT01136967|Experimental|Cohort 2 (V600E BRAF positive)|Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy.
89071365|NCT01218516|Active Comparator|Farletuzumab plus Chemotherapy|During Combination Therapy, farletuzumab will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6, cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive farletuzumab as monotherapy until disease progression.
89071366|NCT01218516|Placebo Comparator|Placebo plus Chemotherapy|During Combination Therapy, placebo will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6 cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive placebo as monotherapy until disease progression.
89071367|NCT00938431|Experimental|Lacosamide - Age 5 - 11 years|Cohort 1 (Age 5 - 11 years); up to 8 mg/kg/day
89071368|NCT00938431|Experimental|Lacosamide - (Age 12 - 17 years)|Cohort 2 (Age 12 - 17 years); 12 mg/kg/day.
89071369|NCT00938431|Experimental|Lacosamide (Age 2 - 4 years)|Cohort 3 (Age 2 - 4 years); 12 mg/kg/day.
89071370|NCT00938431|Experimental|Lacosamide (Age 5 - 11 years)|Cohort 4 (Age 5 - 11 years); 12 mg/kg/day.
89071371|NCT00938431|Experimental|Lacosamide (Age 1 month - < 2 years)|Cohort 5 (Age 1 month to < 2 years); 12 mg/kg/day
89071372|NCT02851927|Experimental|Mini Thoracoscopy|Thoracoscopy procedure shall be performed using the Rigid Mini Thoracoscope
89071373|NCT02851927|Active Comparator|Semirigid Thoracoscopy|Thoracoscopy procedure shall be performed using the SemiRigid Thoracoscope
89071374|NCT05381545|Experimental|group A|This 32-patient research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week, combined with low calorie diet for).This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34&28, ST25&36&40, SP6, and CV4&9&12.
89071375|NCT05381545|Active Comparator|Group B|This 32-patient research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week, combined with low calorie diet ).
89071376|NCT04312815|Experimental|SM03 600 mg|"SM03: 600 mg intravenous (IV) Randomizd period:on week 0,2,4 and 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.~Open-lable treatment on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
89071377|NCT04312815|Placebo Comparator|Placebo|"placebo: 600 mg intravenous (IV) on week 0,2, 4, and week 12,14,16;Participants with inadequate response (defined as less than 10% improvement from baseline in TJC and SJC by Week 12) were rescued with open label SM03 600 mg IV treatment.~SM03: 600 mg intravenous (IV) on week 24,30,36,42,48; Methotrexate: 7.5-20 mg/wk oral."
89071378|NCT05381389|Active Comparator|Group In-plane approach:|An in-plane approach was used for the interscalene block. The needle was brought in the same plane as the probe at a shallow angle to the skin, some distance away from the edge of the probe in a lateral to medial direction so that the whole length of the needle can be visualized. After negative aspiration and assurance that high resistance to injection was absent, the LA was injected in a 5 ml increment below the lower root, between the 3 roots and above the upper root.
89071379|NCT05381389|Active Comparator|Group Out-of-plane approach|An out-of-plane approach was used for the interscalene block. The needle was inserted cranial to the probe and after negative aspiration and assurance that high resistance to injection was absent, the LA was injected in a 10 ml increment; lateral and medial to the nerve roots. The needle appeared as a bright dot on the screen and by tilting the probe, the tip was identified as the point where further tilting leads to no longer visualization of the bright dot on the screen.
89071380|NCT01136811|Experimental|Computer assisted surgery|
89071381|NCT00949117|Experimental|Arm I- cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
89071382|NCT00949117|Experimental|cyproheptadine HCl & PediaSure or Ensure|Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
89071383|NCT04312347|Experimental|Personalized dosing of tamoxifen|Increase tamoxifen dose into 40 mg/day for patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype.
89071384|NCT00631267|Placebo Comparator|1|Manual Manipulation
89071385|NCT00631267|Active Comparator|2|Finger Trap Traction
89071386|NCT00938041|Experimental|Retreatment of NHL with Iodine-131 Anti-B1 Antibody|Patients with non-Hodgkin's lymphoma who previously responded with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy will undergo two phases of study. In the first phase, patients will receive a dosimetric dose of unlabeled Anti-B1 Antibody (450 mg) followed by Anti-B1 Antibody (35 mg) which has been radiolabeled with 5 mCi of Iodine-131. Whole body gamma camera scans will be obtained after the dosimetric dose and data from three imaging time points will be used to calculate a patient-specific dose to deliver the desired total body dose of radiotherapy. In the second phase, patients will receive the therapeutic dose of unlabeled Anti-B1 Antibody (450 mg) followed by 35 mg of Anti-B1 Antibody labeled with the patient-specific dose to deliver the desired whole body dose of radiation. Patients will be treated with thyroid blocking medication at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion.
89071387|NCT00604513|Experimental|1|
89071388|NCT00604513|Sham Comparator|2|
89071389|NCT05381233|Other|hemiplegic group|hemiplegic patient
89071390|NCT05381233|Other|Group diaplegic|diaplegic patient
89071391|NCT05381233|Other|group quadriplegic|quadriplegic patient
89071392|NCT04266691||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.
89071393|NCT04266691||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.
89071394|NCT02851693|Experimental|Optical Coherence Tomography (OCT)|
89071395|NCT05379283|Experimental|lidocaine pretreated skin|one arm will be pretreated with lidocaine before exercise in the heat
89071396|NCT05379283|No Intervention|control skin|the other arm will act as the control condition
89071397|NCT02851849|Active Comparator|LGD-6972-5 mg|5 mg LGD-6972 QD
89071398|NCT02851849|Active Comparator|LGD-6972-10 mg|10 mg LGD-6972 QD
89071399|NCT02851849|Active Comparator|LGD-6972-15 mg|15 mg LGD-6972 QD
89071400|NCT02851849|Placebo Comparator|Placebo|Placebo QD
89071401|NCT01218438|Experimental|Study Epochs 1-4|"Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.~Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.~Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.~Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion."
89071402|NCT05381077|Other|Whole body MRI|There is only one cohort where each patient have the standard of care follow up (PET/CT) and Whole body MRI- ZTE sequence for the study
89071403|NCT00604591|Placebo Comparator|Placebo then Tolcapone|"Participants take placebo during study week 1 and then tolcapone during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
89071404|NCT00604591|Experimental|Tolcapone then Placebo|"Participants take tolcapone during study week 1 and then placebo during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
89071405|NCT05380999||Patients with pulmonary nodules (diameter ≤3cm) plan to diagnosis benign and malignant|Patients with pulmonary nodules (diameter ≤3cm) plan to use biopsy or surgery or treatment to diagnosis benign and malignant.
89071406|NCT00606073|Active Comparator|I|IVF Procedure-IVF Medium
89071407|NCT00606073|Active Comparator|II|IVF Procedure - ISM1 Medium
89071408|NCT00606073|Active Comparator|III|ICSI Procedure - IVF Medium
89071409|NCT00606073|Active Comparator|IV|ICSI Procedure - ISM1 Medium
89071410|NCT02691156||Premature Infants|Premature infants GA 24 to ≤34 wks at risk for hyperbilirubinemia will have BBC, ETCOc, and COHbc measured during 0-7 days of life.
89071411|NCT00603031|Experimental|GLP-1|time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
89071412|NCT00603031|Placebo Comparator|NaCl|time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
89071413|NCT00603031|Experimental|GIP|time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
89071414|NCT04268329|Other|Educational website: Patient|Patients with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. Patients will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. Patients will be asked to review the material on the website between their initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. Patients will be asked to record the number of times they visit the website and the time spent during each visit. Patients will be given a log sheet to document their use/time on the website. During the 2nd clinic visit patients will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, the patient's participation in the study will be completed.
89071415|NCT04268329|Other|Educational website: Family member|A family member of a patient with a head and neck cancer will be asked to complete an 8 item questionnaire during their clinic visit. They will be shown the head and neck website (available in both English and Spanish) by a member of the study investigation team on a computer and also given the URL address to the study website. They will be asked to review the material on the website between their relatives initial visit and there second follow-up visit. The time between visits will be between 1 and 4 weeks. The family member will be asked to record the number of times they visit the website and the time spent during each visit. They will be given a log sheet to document their use/time on the website. During the 2nd clinic visit the family member will be asked to complete the same questionnaire that they completed during their initial study visit along with an additional 7 item survey. Following completion of the 2 documents, their participation in the study will be completed.
89071416|NCT00935701|Experimental|Acupuncture and Acupressure|In Phase 1, 10 children with ASD will receive acupressure for four weeks. At week 5, they will be introduced to acupuncture which will be continued throughout the rest of the study as tolerated. In Phase 2, 40 children with ASD will receive acupressure twice weekly for 12 weeks. Parents will be trained in the acupressure techniques and will be asked to do this daily, at bedtime, and/or as requested by the child or deemed needed by the parent. Children will begin to be assessed for their ability to participate in acupuncture treatment between weeks 5 and 7 at the discretion of the acupuncturist. By week 7, all children will have been introduced to acupuncture/needling. If needling is still refused at this time, acupressure will continue for the remainder of the study.
89071417|NCT04266613||All Subjects Enrolled|High immune risk transplant recipients who are undergoing routine management under current standard of care
89071418|NCT00604747|Other|1, 2|
89071419|NCT04268095|Experimental|No dressing change|Patients do not change dressing from procedure to first clinic followup after 14 days.
89071420|NCT04268095|Experimental|Ambulatory dressing change|Patients change dressing by an ambulatory nurse (not associated with the study) 2 times a week from surgery to first clinic followup after 14 days
89071421|NCT04268095|Experimental|No dressing|Patients take off dressing at post operative day 1 and clean it 3 times per day as instructed.
89071422|NCT02851459|Experimental|Morally Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations.
89071423|NCT02851459|Experimental|Morally Non-Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations.
89071424|NCT02851459|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
89071425|NCT05378815|Experimental|PRP group|"PRP will be prepared with The Regenkit BCT kit provided by the RegenLab laboratory. This is a 2B medical device with the CE mark. 5mL will be injected in knee under ultrasound guidance.~The PRP extracted using this kit is poor in leukocytes, has a platelet concentration multiplied by 1.6 on average compared to circulating blood and is not activated (P2Bbeta according to the PAW classification; 3B according to the Mishra's classification)."
89071426|NCT05378815|Placebo Comparator|Placebo group|5 mL of NaCl will be injected in knee under ultrasound guidance.
89071427|NCT00603343|Active Comparator|1|
89071428|NCT00603343|Placebo Comparator|2|
89071429|NCT04266535||TCI|Patients receiving Target Controlled Infusion (TCI) Anesthesia
89071430|NCT04266535||MCI|Patients receiving Manually Controlled Infusion (MCI) Anesthesia
89071431|NCT00606385|Experimental|laparoscopic liver resection|Patients who underwent laparoscopic liver resection for HCC
89071432|NCT00606385|Active Comparator|open liver resection|Patients who underwent open liver resection for HCC
89071433|NCT05378659||With Post-Operative Cognitive Dysfunction|"Subjects determined to have post-operative cognitive dysfunction based on the results of:~4AT Delirium Test~Scoring on :~Montreal Cognitive Assessment~Oral Trails Test~Stroop Test~Symbol Digit Modalities Test~All subjects will undergo:~Blood sample collection~Cerebral spinal fluid collection~ERP testing~NACC Cognitive Battery~Grooved Pegboard testing"
89071434|NCT05378659||Without Post-Operative Cognitive Dysfunction|"Subjects determined to not have post-operative cognitive dysfunction based on the results of:~4AT Delirium Test~Scoring on :~Montreal Cognitive Assessment~Oral Trails Test~Stroop Test~Symbol Digit Modalities Test~All subjects will undergo:~Blood sample collection~Cerebral spinal fluid collection~ERP testing~NACC Cognitive Battery~Grooved Pegboard testing"
89071435|NCT01277510|Placebo Comparator|Placebo|Participants received standard of care and placebo once daily for 30 weeks during the double-blind phase. During the open-label phase, participants received cinacalcet with standard of care for an additional 30 weeks. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks up to Week 54 to a maximum dose of 4.2 mg/kg.
89071436|NCT01277510|Experimental|Cinacalcet|Participants received standard of care and cinacalcet once daily for 30 weeks during the double-blind phase. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks until Week 24 to a maximum dose of 4.2 mg/kg. During the open-label phase participants continued to receive cinacalcet with standard of care for an additional 30 weeks.
89071437|NCT04323332|Experimental|Traditional Chinese Medicine|TCM prescription and conventional treatments
89071438|NCT04323332|No Intervention|Control|conventional treatments
89071439|NCT00937495|Experimental|Treatment (vorinostat, bortezomib)|Patients receive 400 mg vorinostat orally once daily on days 1-14. Patients also receive 1.3 mg/m^2 bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89071440|NCT04323488|Experimental|Lindamood-Bell Seeing Stars|Subjects receive reading instruction focusing on the building blocks of reading
89071441|NCT04323488|No Intervention|Control|Subjects are followed longitudinally but do not receive intervention
89071442|NCT00603421|Experimental|1|Patient benefits from treatment as usual plus access to a crisis 24 hour phone line.
89071443|NCT00603421|Active Comparator|2|Patient benefits from treatment as usual
89071444|NCT05378581|Active Comparator|standard|Use local anesthesic cream + nurse or parents distraction +/- anesthesic or anxiolytic gas
89071445|NCT05378581|Experimental|virtual reality|Use local anesthesic cream and virtual reality mask
89071446|NCT02851381|Other|FG-3019|Treatment of Pancreatic Cancer with FG-3019
89071447|NCT01268306|Experimental|B+L Biotrue MPS and B+L PureVision|Successful contact lens wearers switched to B&L BioTrue MPS while wearing B+L PureVision lenses
89071448|NCT04265833|Active Comparator|calcium hydroxide|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with calcium hydroxide. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed to prevent pulp exposure. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity.The residual demineralized dentin was covered with a thin layer of Ca(OH)2 (approximately 1 mm2) in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
89071449|NCT04265833|Experimental|Biodentine|Thirty seven primary molar teeth were selected to apply indirect pulp therapy with Biodentine. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide-bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. A thin layer of tricalcium silicate-containing pulp-capping material (Biodentine) (approximately 1 mm2) consisting of powder and liquid was applied to the demineralized dentin tissue and a 12-min setting time was allowed for hardening, in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
89071450|NCT04265833|Experimental|TheraCal LC|Thirty six primary molar teeth with deep caries lesion were selected to apply indirect pulp therapy with TheraCal LC. The carious peripheral dentin was removed at the enamel-dentin junction using a high-speed tungsten-carbide bur and the infected and necrotic soft dentin layer in the center was carefully removed. Cavity excavation was stopped when the residual dentin over the pulp tissue showed increased resistance to manual instrumentation, and the demineralized dentin (affected dentin) was left at the floor of the cavity. Flowable form of resin-reinforced tricalcium silicate-containing material (TheraCal LC) was applied directly onto the demineralized dentin at a maximum thickness of 1 mm and was polymerized for 20 sec (Valo LED), in accordance with the recommendations of the manufacturer. Afterwards capsule glass ionomer cement was placed on each capping material. Following the etching and bonding process, permanent restoration was finished with composite resin.
89071451|NCT00604903|Experimental|Patients implanted with Pressure Sensor|Implant of Pressure sensor. These are patients, who were implanted with the Remon CHF Implantable Pressure Sensor utilizing the corresponding delivering system.
89071452|NCT00606541|Experimental|1|Quetiapine XR 50mg-400mg per day
89071453|NCT00606541|Placebo Comparator|2|Placebo
89071454|NCT04266067|Active Comparator|PNF exercise|In the PNF exercise group; exercises were performed in company with a physiotherapist 5 days a week (30 minutes ) for 4 weeks. Five specific techniques were applied to the patients: dynamic stabilization, rhythmic stabilization, combined isotonic contractions, and hold-relax active motion
89071455|NCT04266067|Active Comparator|Frenkel exercise|In the Frenkel exercise group, Frenkel coordination exercises were given in home exercise program 5 days a week for 4 weeks.The physiotherapist demonstrated Frenkel exercises to them once.
89071456|NCT02851225|Experimental|telemedicine transmission|telemedicine transmission of biological results in the treatment of transfusion supportive care
89071457|NCT02851225|No Intervention|without telemedicine transmission|no telemedicine transmission of biological results in treatment in the treatment of transfusion supportive care
89071458|NCT00604981|Experimental|1|Multisystemic Therapy (MST)
89071459|NCT00604981|Active Comparator|2|Shapedown
89071460|NCT00605059|Experimental|Assess [123I] AV94 and SPECT imaging|
89071461|NCT00936715|Experimental|FTC/TDF|
89071462|NCT00606619|No Intervention|1|Conventional feeding : They begin ingesting sips of water on third postoperative day and continued with a liquid diet for the next two days. Patients were given a soft diet on sixth postoperative day.
89071463|NCT00606619|Experimental|2|Early oral feeding : The patients begin ingesting sips of water on the first postoperative day. If they are tolerable, they continued with a clear liquid diet the next day and a soft diet on the third post operative day.
89071464|NCT05378191|Active Comparator|VACCINATION|One standard dose of COMIRNATY in adult subjects (18 years old) having received prior VAXZEVRIA vaccination.
89071465|NCT05378191|No Intervention|NO INTERVENTION|No vaccination in adult subjects (18 years old) having received prior VAXZEVRIA vaccination. If primary analysis at day 14th confirms the starting hypothesis, subjects randomized to this arm will be considered for administration of one dose of COMINARTY at day 28th according to Public Health Department of the Ministry of Health recommendations on heterologous vaccination.
89071466|NCT00603499|Active Comparator|1|Magnesium chloride
89071467|NCT00603499|Placebo Comparator|2|Placebo
89071468|NCT04267627|No Intervention|Usual Care|No intervention.
89071469|NCT04267627|Experimental|CARING with telemedicine|Patients will receive the nurse-led supportive care intervention over telemedicine videoconferencing from home or from a satellite telemedicine site in Virginia.
89071470|NCT04267627|Experimental|CARING face-to-face|Patients will receive the nurse-led supportive care intervention in person.
89071471|NCT00606775|Experimental|Carvedilol|
89071472|NCT00606775|No Intervention|Control|
89071473|NCT04265989|Experimental|coronary artery aneurysm with branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, accompany with branches origin from the aneurysm
89071474|NCT04265989|Experimental|coronary artery aneurysm without branches|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, without any branch origin from the aneurysm
89071475|NCT04265989|Experimental|Coronary artery aneurysm with localized stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. localized stenosis defined as lesion to more than 70% stenosis and length less than 20 mm
89071476|NCT04265989|Experimental|Coronary artery aneurysm with diffuse stenosis|The diameter of coronary artery aneurysm is more than 5mm and less than 10mm, associated with severe stenosis of adjacent sites. Diffuse stenosis defined as lesion to more than 70% and length more than 20 mm
89071477|NCT04267471|Experimental|Tai Chi|3 sessions of Tai Chi per week for 12 weeks
89071478|NCT04267471|Active Comparator|Walking|3 sessions of walking per week for 12 weeks
89071479|NCT04267471|No Intervention|Waiting-list|
89071480|NCT00605371|Experimental|Subjects receiving regimen A|Eligible subjects will receive regimen A containing lamotrigine extended release tablet of 200 milligrams plus 50 milligrams in fasted state
89071481|NCT00605371|Experimental|Subjects receiving regimen B|Eligible subjects will receive regimen B containing lamotrigine extended release caplet of 250 milligrams in fasted state.
89224031|NCT03559192|Experimental|Treatment Period: JNJ-67953964 or Placebo|Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
89224032|NCT03559192|Placebo Comparator|Withdrawal Period: Placebo|Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
89224033|NCT03552718|Experimental|Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)|
89071482|NCT00605371|Experimental|Subjects receiving regimen C|Eligible subjects will receive regimen C containing lamotrigine extended release caplet of 250 milligrams in fed state.
89071483|NCT04265677|Experimental|Telemedicine FCR|These patients will be eligible to use telemedicine for Family Centered Rounds
89071484|NCT04265677|Placebo Comparator|Control|These patients will not be eligible to use telemedicine for Family Centered Rounds (standard of care)
89071485|NCT01267994|Experimental|Single Arm-Open Label|Single Arm-Open Label use of Anakinra
89071486|NCT00606853|Experimental|1|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
89071487|NCT00606853|Experimental|2|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $560 in prizes and twice-weekly breath and urine samples.
89071488|NCT00606853|Experimental|3|Standard Treatment plus prize contingency management for attendance with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
89071489|NCT00606853|No Intervention|4|Standard Treatment
89071490|NCT02850757|Experimental|U shaped Guedl's airway|
89071491|NCT02850757|Experimental|Modified William's airway(Fekry airway )|
89071492|NCT05379751|Experimental|Patients diagnosed with Spigelian hernia who underwent prosthetic repair with the tentacle mesh|Patients diagnosed with Spigelian hernia who underwent prosthetic repair with the tentacle mesh Freedom Octomesh VHR XS
89071493|NCT02850913|Active Comparator|Doxycycline|"115 participants will be randomized to oral Doxycycline 100 mg daily for six weeks.~Each capsule contains doxycycline hyclate equivalent to 100 mg of doxycycline base.~Treatment will be initiated in hospital but will be continued at home.~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
89071494|NCT02850913|Placebo Comparator|Placebo|"115 participants will be randomized to the placebo arm for matching capsules containing no active ingredients daily for six weeks.~Placebo will be initiated in hospital but will be continued at home.~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
89071495|NCT00603655|Experimental|A|This group will receive a low glycemic load
89071496|NCT00603655|Active Comparator|B|This group will receive a high glycemic load
89071497|NCT05371561|Active Comparator|Goggles + surgical mask|Dentist wearing Goggles + surgical mask will examin the patient
89071498|NCT05371561|Active Comparator|Face shield+ surgical mask|Dentist wearing Face shield+ surgical mask will examin the patient
89071499|NCT05371561|Experimental|Half face reusable respirator+ Filter|Dentist wearing Half face reusable respirator+ Filter will examin the patient
89071500|NCT05371561|Experimental|Full face reusable respirator+ Filter|Dentist wearing Full face reusable respirator+ Filter will examin the patient
89071501|NCT02850835|Experimental|Video Decision Aid|This group will be shown a video decision aid along with their standard of care.
89071502|NCT02850835|No Intervention|Standard Care|This group will not see the video decision aid and will only receive standard of care.
89071503|NCT00934843|Experimental|Single dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive ONE dose intravenous methylprednisolone (IVMP) prior to heart surgery.
89071504|NCT00934843|Experimental|Two Dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
89071505|NCT04268251|Experimental|Deep learning based denoising MR|1 mm slice thickness coronal contrast-enhanced T1 weighted imaging with deep learning based denoising vs. 3 mm slice thickness coronal contrast-enhanced T1 weighted imaging
89071506|NCT00607009|Experimental|Intervention|ALIVE - received emails about chosen behavioral intervention path - physical activity, fruits/vegetables or fats/sugars
89071507|NCT00607009|No Intervention|Control|no intervention
89071508|NCT04265521|Experimental|Biocool Footcare|"Treatment regime:~During week 1: Once daily for 7 days (7 doses) During week 2 and 3: Once every second day for 14 days (7 doses)"
89071509|NCT00605605|Experimental|1|
89071510|NCT04267237|Experimental|Atezolizumab|Participants will receive atezolizumab on Day 1 of each 28-day cycle (Q4W) for 12 cycles.
89071511|NCT04267237|Experimental|Atezolizumab + RO7198457|Participants will receive atezolizumab Q4W along with RO7198457 for 12 cycles.
89071512|NCT05379517|No Intervention|Control Group (CG)|Patients in the control group will receive a booklet with general information on a health education program where they will be taught global stretching exercises to be performed themselves at least twice a week at home for 20 minutes. In addition, hygienic postural care will be included.
89071513|NCT05379517|Experimental|Experimental group 1|People will receive a three times-weekly 60 min pulmonary rehabilitation program (PRP) for 8 weeks. Exercise training will be structured in three stages. Exercise will start with a warm-up period (4 minutes); followed by the core phase of aerobic exercises (15-18 minutes), upper and lower limb strength (9 minutes), exercises of the respiratory muscles with diaphragmatic breaths with retentions (10 minutes) and the final cooling-stretching (4 minutes) for a total 45 min, coupled with 15 minutes of breathing retraining with the Threshold Inspiratory Muscle Training® (IMT) device (Philips Respironics). Respiratory muscle training will start at 10% of the initial MIP achieved at startup and will increase by 5% every two weeks until reaching 20% of the initial MIP. The intensity of the exercise training will be at 60-75% of the maximum heart rate rate achieved in the exercise capacity test.
89071514|NCT05379517|Experimental|Experimental group 2|Patients will receive a pulmonary rehabilitation program (PRP) supplemented with pulsed electromagnetic field therapy. The latter will be applied for 5 weeks, a total of 3 sessions per week. The BTL-6000 Super Inductive System (SIS) will be used with the 'focus field' type manual applicator. The parameters will be: intensity of the magnetic field up to 2.5 Tesla (T), the frequency range to achieve the analgesic effect will vary between 10-20 Hz and, finally, an adjustable relative intensity up to 100%, depending on the perception subjective of the patients. Sessions will last 10 minutes. The parameters and procedure of therapy follow the manufacturer's recommendations. The SIS will be applied in the area where the patient presents the highest level of pain.
89071515|NCT00605995|Experimental|Simvastatin|Simvastatin, 20 mg Tablet, given once daily. Dosage increased to 40 mg/day at the end of week 4 until endpoint.
89071516|NCT00605995|Placebo Comparator|Placebo|Placebo pill, similar in its appearance to Simvastatin, taken once daily for the duration of the trial.
89071517|NCT00605683|Active Comparator|1|50 mg/day Safinamide
89071518|NCT00605683|Active Comparator|2|Safinamide 100mg/day
89071519|NCT00605683|Placebo Comparator|3|Placebo 0mg/Safinamide
89071520|NCT05379361|Experimental|Emotional Intelligence Intervention Group|Nursing students, whose Emotional Intelligence skills were aimed to be developed, formed the intervention group.
89071521|NCT05379361|Placebo Comparator|Environmental Awareness Educational Group|It is a group created to eliminate the risk of interaction about the intervention made due to the fact that nursing students are studying in the same semester and at the same faculty. Different from the intervention group, the students selected for this group were trained on environmental awareness, which is not related to Emotional Intelligence concepts and skills.
89071522|NCT05379361|No Intervention|No Intervention: Control Group|The control group consisted of the students who continued their nursing education and did not have any intervention or application for the development of emotional intelligence skills.
89071523|NCT01266902|Experimental|Rilpivirine|Rilpivirine 25 mg once daily
89071524|NCT04266847|Experimental|unilateral mild cataract patients|The patients who underwent monocular IOL implantation before and then present mild cataract in the fellow eye.
89071525|NCT00605761|Experimental|Cohort 1|50 mg treatment
89071526|NCT00605761|Experimental|Cohort 2|150 mg treatment
89071527|NCT05365867|Experimental|iCAN Group|iCAN is comprised of text messaging, GPS technology, preloaded apps, and telephone case management integrated within a community-based navigation center. Participants will receive 3 - 5 messages daily regarding medication adherence and appointment reminders, general health messages, motivational messages, and as needed messages for local information (e.g., weather updates). Within 48 - 72 hours of enrollment, participants will be called on their study phone by the study case manager for an intake assessment that will take 30 - 45 minutes in duration. The purpose of the assessment is to identify relevant health and social needs that the case manager can assist the participant in addressing by connecting with other medical and social services in the community. Within 48 - 72 hours of notification of a ED or hospital visit the iCAN case manager will call the participant on the study phone to assess care coordination needs for managing discharge instructions.
89071528|NCT05365867|No Intervention|Usual Care Control (UCC)|Participants randomized to the UCC group will have access to their personal phones and use it in the usual manner with no installment of apps, text messages, or case manager interventions. Since the majority of PEH have a cell phone of some type, this will allow us to compare the intervention to how PEH typically use their cell phones. Also, the UCC will have access to all of the services available at any of the enrollment sites but no formal interaction from the iCAN case manager and no option of text messaging with the iCAN case manager.
89071529|NCT05363995|Experimental|Experimental|Blended e-health intervention
89071530|NCT01266824|Experimental|Proparacaine|Infants in this group will receive 1 drop of Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) into each eye prior to receiving mydriatic eye drops
89071531|NCT01266824|No Intervention|Standard of Care|Infants in this arm will not receive Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) prior to mydriatic eye drops.
89071532|NCT05383027|Active Comparator|Music Listening Control(MLC)|
89071533|NCT05383027|Experimental|Heart Focused Breathing|
89071534|NCT04266769|Experimental|Patients with Malocclusion|
89071535|NCT01266590|Experimental|LY2216684 + digoxin|Two oral 0.5-milligrams (mg) (two 0.25-mg tablets) doses of digoxin separated by 12 hours on Day 1, followed by once daily 0.25-mg (single 0.25-mg tablet) dose of digoxin on Days 2-14. Daily oral 18-mg (two 9-mg tablets) doses of LY2216684 on Days 8-14.
89071536|NCT01266122|No Intervention|HIV/STI voluntary counseling and testing|Participants enrolled in the control arm will receive study assessments only.
89071537|NCT01266122|Experimental|Behavioral intervention|Participants enrolled in the experimental condition will receive 4 group sessions and 4 individual sessions over 3 months. This intervention focuses on psychosocial concerns and HIV risk for MSM in India.
89071538|NCT05313139||Unvaccinated participants|Participants who did received the rVSV-ZEBOV vaccine nor had any prior close contact with EBOV patients nor presenting a travel history to East DRC
89071539|NCT05313139||Primary vaccinated participants|Participants who received a first rVSV-ZEBOV vaccine dose as part of the WHO vaccination campaign organized in Goma region (end of 2021), of which vaccination date and brand is known
89071540|NCT05313139||Participants vaccinated < 1 year ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose less than a year prior to inclusion of which vaccination date and brand is known
89071541|NCT05313139||Participants vaccinated 1-2 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose between 1-2 years prior to inclusion of which vaccination date and brand is known
89071542|NCT05313139||Participants vaccinated 2-3 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose between 2-3 years prior to inclusion of which vaccination date and brand is known
89071543|NCT05313139||Participants vaccinated > 3 years ago (from date of enrollment)|Participants who received a rVSV-ZEBOV vaccine dose > 3 years prior to inclusion of which vaccination date and brand is known
89071544|NCT00607555||Observation|Premature infants over 23 weeks of gestation and less than 1.25 kilograms at birth, who are tolerating feedings, and are clinically stable
89071545|NCT00607633||1|Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT
89071546|NCT04264975|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation in patients who have advanced solid cancer with primary (group 1) or secondary resistance (group 2) to immuno-oncology
89071547|NCT00603811|Experimental|1|VAX102, a recombinant fusion protein that links the influenza A virus M2e antigen to S. typhimurium flagellin, a TLR5 ligand.
89071548|NCT00603811|Placebo Comparator|2|Vaccine buffer
89071549|NCT05089435|Other|14-day EZYPRO and 24-hr Holter|Patients wear simultaneously 14- day continuous ECG moniter (EZYPRO) and 24-hr Holter monitor.
89071550|NCT01265498|Active Comparator|Obeticholic acid|obeticholic acid
89071551|NCT01265498|Placebo Comparator|Placebo|Placebo
89071552|NCT00603967|Other|Aromatase inhibitor|
89071553|NCT00607711|Experimental|Single arm|
89071554|NCT01265420|Experimental|Injectable clostridial collagenase|Patients with thumb 1st web contracture secondary to Dupuytren's disease will be treated with 0.58mg of collagenase
89071555|NCT04323644||Cohort 1|Patients with COVID-19 infection undergoing surgery
89071556|NCT01264718|No Intervention|Control|After randomization to the control group, minority low-income parents of uninsured, Medicaid/CHIP-eligible children received only traditional Medicaid/Children's Health Insurance Program (CHIP) outreach and enrollment.
89224034|NCT03552471|Experimental|Treatment (mirvetuximab soravtansine, rucaparib)|Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89224035|NCT03542409|Experimental|Cohort 1, Group A (contrast enhancing tumor)|Group A patients will undergo standard tumor preoperative imaging and MR perfusion scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with MR perfusion scan during surgical resection.
89224036|NCT03542409|Experimental|Cohort 1, Group B (non-enhancing tumor)|Group B patients will undergo standard tumor preoperative imaging and 2HG spectroscopy scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with 2HG spectroscopy scan during surgical resection.
89224037|NCT03542409|Experimental|Cohort 2|"During the analysis for cohort 1, we found significant differences in the pre MRI samples and the post intraoperative MRI samples. Cohort 2, which will include 10 additional patients, has be created to confirm these differences. Unlike cohort 1, advanced imaging (2-HG spectroscopy and MR perfusion) is not needed to make this comparison. The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples. The specific aim of Cohort 2 is:~1. Compare areas from initial surgery with that of extended resection after intraoperative SOC MRI in 10 additional subjects (Cohort 2)."
89224038|NCT03525951|Other|Typically Developing Children Study 2 (TD2)|No-intervention comparison group measured over time.
89224039|NCT03525951|Experimental|Children with Dev Language Disorder Study 2 (DLD2)|Enhanced Milieu Teaching
89224040|NCT03525951|Experimental|Children with Autism Spectrum Disorders Study 2 (ASD+DLD 2)|Enhanced Milieu Teaching
89224041|NCT03525951|Other|Typically Developing Children Study 1 (TD1)|No-intervention group for observational data comparison.
89224042|NCT03525951|Other|Children with Dev Language Disorder Study 1 (DLD1)|No-intervention group for observational data comparison.
89224043|NCT03523585|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
89224044|NCT03523585|Active Comparator|Trastuzumab+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
89071557|NCT01264718|Experimental|Parent Mentors|After randomization to the Parent Mentor group, minority low-income parents of uninsured Medicaid/CHIP-eligible children received face-to-face instruction and guidance from Parent Mentors on obtaining and keeping Medicaid/CHIP for their child; getting a doctor, dentist, and pharmacist; and addressing social determinants of health.
89071558|NCT01264016|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use an investigational blood glucose monitoring system.
89071559|NCT01263782|Experimental|Carboplatin + Pemetrexed|"The chemotherapy will be Carboplatin (AUC 6) and Pemetrexed (500 mg/m2) every 3 weeks for 4 cycles.~Then maintenance Pemetrexed (500 mg/m2 every 3 weeks) will be administered until disease progression or excessive toxicity.~If patients are randomized into one of the arms with a biologic therapy, patients will take the chemotherapy prescribed above, but will also receive the biologic therapy during the same time period."
89071560|NCT01263782|Experimental|Chemo (Carbo/Peme) + Bevacizumab|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle. Bevacizumab 15 mg/kg by vein on day 1 of each 21 day cycle.
89071561|NCT01263782|Experimental|Chemo (Carbo/Peme)|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.
89071562|NCT01263782|Experimental|Chemo (Carbo/Peme) + Cixutumumab|"Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.~Cixutumumab 20 mg/kg by vein on day 1 of each 21 day cycle."
89071563|NCT01263704|Experimental|Rituximab plus Fludarabine and Cyclophosphamide|Elderly participants with chronic lymphocytic leukemia (CLL) will receive combination treatment with low-dose fludarabine and cyclophosphamide combined with standard-dose of rituximab for 6 months. Treatment is followed by a follow up period of 36 months.
89071564|NCT01263470|Placebo Comparator|Placebo|
89071565|NCT01263470|Experimental|Alogliptin 6.25 mg QD|
89071566|NCT01263470|Experimental|Alogliptin 12.5 mg QD|
89071567|NCT01263470|Experimental|Alogliptin 25 mg QD|
89071568|NCT01263470|Experimental|Alogliptin 50 mg QD|
89071569|NCT01263470|Active Comparator|Voglibose 0.2 mg TID|
89071570|NCT04322942||Non-infection|
89071571|NCT04322942||Infection without sepsis|
89071572|NCT04322942||Sepsis-2|
89071573|NCT04322942||Sepsis-3|
89071574|NCT04322630||Pediatric Cardiac Bypass Patients|Blood samples obtained from patients ages from birth-19 years-old as well as cyanotic and acyanotic cardiac lesions who underwent cardiac bypass.
89071575|NCT04322786||ACEI user|Individuals with an ACEI prescription in the study population.
89071576|NCT04322786||Matched controls|Individuals without an ACEI prescription, and matched to the users by sex and 10-year age categories.
89071577|NCT04322240|Experimental|type 2 DM with peripheral neuropathy|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication, antidiabetic drugs, or medications used for managing arterial hypertension or dyslipidaemia during the study.
89071578|NCT01262456|Experimental|Desmopressin 50 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 50 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
89071579|NCT01262456|Experimental|Desmopressin 75 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 75 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
89071580|NCT01262456|Placebo Comparator|Placebo Double-Blind / Desmopressin 100 μg Open-Label|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
89071581|NCT02889380||Cetrotide|This study will retrospectively collect the data from the subjects who had been treated with 0.25 milligram (mg) of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available assisted reproductive technology (ART) outcome.
89071582|NCT02889302|Experimental|KPS-0373|
89071583|NCT02889302|Placebo Comparator|Placebo|
89071584|NCT04321850|Placebo Comparator|Group1|Control
89071585|NCT04321850|Experimental|Group 2|Intervention (Zinc)
89071586|NCT04321616|Active Comparator|Hydroxychloroquine|
89071587|NCT04321616|Active Comparator|Remdesivir|
89071588|NCT04321616|Active Comparator|Control group - SoC|
89071589|NCT04321772|Experimental|High Intensity Interval Resistance Training (HIIRT)|"HIIRT technique consisted of three sets of: 6 repetitions at 80% 1RM (1 repetition maximum) and then 20 seconds of rest and 2/3 repetitions (until exhaustion) repeated for 3 times with 2'30 rest between sets; while TRT consisted of 3 sets of 15 reps with 75 sec of rest between sets."
89071590|NCT04321772|Active Comparator|Traditional Resistance Training (TRT)|"TRT protocol performed 3 series of 15 repetitions at 60% 1RM with 75 of rest between sets."
89071591|NCT04207658|Experimental|Valsalva's Pushing|The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. At the expulsion phase (baby's head is visible in vulva), they are encouraged to perform the Valsalva's manoeuvre that they have practised in routines of delivery; When contractions start, breathe twice normally. Take a deep breath and hold. Compress the air with the help of diaphragm and abdominal muscles. Push strongly and long (for 10-15 sec). Breathe out and take another deep breath, hold it and push as strongly as possible for another 10-15 seconds. Stop pushing when contractions are mild. Breathe 2-3 times in normal style. Relax and have a rest until the next contraction.
89071592|NCT04207658|No Intervention|control|Practices on Spontaneous Pushing Group The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. Just after feeling the push, the gravitas are requested perform pushing as follows; Breathe normally until participants feel the push when contractions start, pull back muscles surrounding the uterus while breathing. Start pushing gradually and breathe out smoothly by minimizing lips. Push between breaths for 5-6 seconds while pushing downwards by breathing out. Breathe normally when contractions weaken.
89071593|NCT00623948|Other|Arm 1|
89071594|NCT04321304|Sham Comparator|Sham|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is turned on (2 mA) for the 30 seconds at the beginning and the end of the trial, but stays at 0 mA in the intervening time.
89071595|NCT04321304|Experimental|2 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 2 mA over the first 30 seconds and stays at 2 mA for the remainder of the stimulation time.
89071596|NCT04321304|Experimental|4 mA|Participants will have the anode (active electrode) placed over the brain area the controls their dominant leg and the cathode (return electrode) above the ipsilateral eyebrow. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
89071597|NCT00932893|Experimental|PF-02341066|
89071598|NCT00932893|Active Comparator|Pemetrexed or Docetaxel|Investigator selection of either pemetrexed or docetaxel as the active comparator
89071599|NCT04320992||tested group|
89071600|NCT04320992||controlled group|
89071601|NCT04321070|Experimental|Clindamycin Phosphate|Topical, once daily, for 84 days.
89071602|NCT04321070|Active Comparator|Clindamycin Phosphate RLD|Topical, once daily, for 84 days
89071603|NCT04321070|Placebo Comparator|Vehicle of the test product|Topical, once daily, for 84 days
89071604|NCT04321226|Experimental|Femtosecond Laser guided Arcuate Keratotomy|Arcuate keratotomy will be performed together with Laser cataract surgery
89071605|NCT02889224|Active Comparator|Obese|Subjects with BMI between 30 - 40 kg/m2 and no alteration of corticotrope axis.
89071606|NCT02889224|Experimental|Hypercortisolism|Subject with BMI between 18 - 40 kg/m2 and presenting a hypercortisolism defined by HAS (Haute Autorité de Santé).
89071607|NCT02889224|Experimental|Hydrocortisone|Subject with BMI between 18 - 30 kg/m2 and with adrenal or corticotrope failure
89071608|NCT02889224|Experimental|Control|Subject with BMI between 18 - 30 kg/m2 and with a pituitary or adrenal tumor without effect on corticotrope axis.
89071609|NCT02889146|Active Comparator|Control group|Conventional Physical Therapy: motor physical therapy delivered by the intensive care unit physical therapists, according to his own criteria, without following any protocol. Respiratory therapy.
89071610|NCT02889146|Experimental|Protocol group|Early and progressive mobilization program: motor physical therapy delivered by a trained physical therapist according to the mobilization protocol, in which patient progress according to his performance. Respiratory therapy.
89071611|NCT01260896|Experimental|Investigational Test Product|150 mg Venlafaxine Hydrochloride Extended-Release Capsules
89071612|NCT01260896|Active Comparator|Reference Listed Drug|150 mg Effexor® XR Extended-Release Capsules
89071613|NCT00932737|Active Comparator|Hyoscine butylbromide (HBB) 20mg 1-5 tablets per episode|Patient to receive 1-5 tablets containing 20mg HBB per Abdominal pain associated with cramping (APC) episode
89071614|NCT00932737|Placebo Comparator|Placebo|patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode
89071615|NCT00607399|Experimental|Single arm|
89071616|NCT00939523|Experimental|Lapatinib|All participants will be asked to take Lapatinib daily for a total of six months during the research study.
89071617|NCT05382247|Active Comparator|pediatric patients with neuromuscular diseases|
89071618|NCT05382247|Active Comparator|children not suffering from neuromuscular diseases|
89071619|NCT04264429|Experimental|Infrapatellar strap|This group will perform the functional tests with the infrapatellar strap positioned on the painful knee.
89071620|NCT04264429|Experimental|Elastic Band|This group will perform the functional tests with the elastic band positioned on the painful knee.
89071621|NCT04264429|No Intervention|Control|This group will perform the functional tests without elastic band or infrapatellar strap positioned on the painful knee.
89071622|NCT01260584|Experimental|Prasugrel|Prasugrel 10 mg film-coated tablet daily dose × 10 days. To maintain blinding, placebo film-coated tablets matching clopidogrel in appearance will be given daily × 10 days to subjects in the prasugrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
89071623|NCT01260584|Active Comparator|Clopidogrel|Clopidogrel 75 mg film-coated tablet daily dose x 10 days To maintain blinding, placebo film-coated tablets matching prasugrel in appearance will be given daily × 10 days to subjects in the clopidogrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
89071624|NCT05176327|Experimental|Intervention|Subjects will receive 2 consecutive courses of exoskeleton training with twelve 45-minute sessions, each to be completed in 6 to 8 weeks. The total period of training will be 12 to 16 weeks.
89071625|NCT05176327|Active Comparator|Control|Subjects will receive twelve 45-minute sessions of usual physiotherapy treatment, consisting of maintenance exercise in the first 6 to 8 weeks, and then one course of exoskeleton training with twelve 45-minute sessions in the following 6 to 8 weeks.
89071626|NCT05331313||patients with a diagnosis of multiple myeloma|This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing.
89071627|NCT00609349|Other|connective tissue disease|all patients suffer from a connective tissue disease representing a risk for the development of pulmonary hypertension
89071628|NCT04262635|Experimental|ArmA Cetuximab plus Capecitabine|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W); plus capecitabine in 2-week cycles until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
89071629|NCT04262635|Active Comparator|ArmB Cetuximab|Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W) until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
89071630|NCT00608101|Experimental|1|Day 1 hyperinsulinemic euglycemic clamps with either 0.2 mg fludrocortisone, 0.75 mg Dexamethasone, or both given orally before each morning and afternoon clamp. Day 2 hyperinsulinemic hypoglycemic glucose clamp.
89071631|NCT00608101|Experimental|2|Fludrocortisone will be administered in doses of 0.05mg, 0.1mg and 0.2 mg form at the start of each clamp period on day 1. Dexamethasone will be administered orally in the doses of 0.18 mg, 0.375mg and 0.75mg doses. The combination of the 0.05mg fludrocortisone and 0.18mg dexamethasone and 0.1mg of fludrocortisone and 0.375 mg doses will be administered at the start of each day 1 clamp period. Day 2 90 minutes of moderate exercise.
89071632|NCT04264039|Experimental|anti-CD19 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD19 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
89071633|NCT00608179|Experimental|1|
89071634|NCT00608179|Experimental|2|
89071635|NCT00608179|Experimental|3|control-euglycemia
89071636|NCT00608179|Experimental|4|control-hypoglycemia
89071637|NCT00608335|Experimental|1. Micafungin 3.0 mg|IV
89071638|NCT00608335|Experimental|2. Micafungin 4.5 mg|IV
89071639|NCT00927589|Experimental|1|
89071640|NCT04264117|Active Comparator|FlexAbility (Mesh-like irrigated tip catheter) group|
89071641|NCT04264117|Experimental|TactiCath (Contract force monitoring catheter) group|
89071642|NCT04262557|Experimental|Sunrise+PSG|PSG and Sunrise® will be set at the patient's home by IC@dom. The first night, the patient will be equipped by both PSG and Sunrise® and only by the Sunrise® for the two following nights.
89071643|NCT04262245|Other|irrigation activation method|Irrigation activation is a crucial stage of root canal treatment. Therefore, the effect of activation methods on post treatment is an important fact for the comfort of patients.
89071644|NCT00932425|Experimental|Outpatient cardiac monitoring|Patients will be assigned to wear a portable outpatient cardiac telemetry device for 21 days
89071645|NCT00932425|No Intervention|Control|Patients will be discharged home with standard clinical follow-up
89071646|NCT04260061|Experimental|exoskeleton group|The Hand of Hope therapy device will be used in this group. The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
89071647|NCT04260061|Experimental|end effector group|The Amadeo Hand-Therapy-System will be used in this group. The Amadeo is a mechatronic rehabilitation device that allows each individual finger to move independently and separately. The main target group are patients suffering from functional motor disabilities of the distal upper extremity. The Amadeo consists of the electrically driven moment mechanism, a supportive framework which is adjustable in height and includes a hand-arm support, and a control and operating unit (all-in-one PC). The finger slides can produce flexion/extension movement of the fingers and the thumb. The fingers and the thumb of the affected hand are attached to the slides and then passive, assistive, active or interactive therapy regime can be started. The integrated sensors for force and position measurement enable quantitative recording and evaluation of the finger range of movement and force.
89071648|NCT04264273||Participants with Parkinson´s disease.|Participants who fulfilled the diagnostic criteria of Parkinson´s disease.
89071649|NCT04264273||Participants without a neurological disease|25 neurologically healthy patients of the local otolaryngological clinic, in whom submandibular gland needle biopsy was performed due to a clinical indication.
89071650|NCT05938751|Experimental|Intervention group|Participants in this group received the TEAm_YOUNG ADULTS program, an intervention to promote and develop self-determination-related skills.
89071651|NCT05938751|No Intervention|Waiting list group|Participants in this group were on the waiting list. That means they had to wait until the intervention group received the intervention and post-test evaluation to receive the intervention. They could keep their intervention as usual during the whole study.
89071652|NCT05938738|Experimental|PEP-buddy|Patients will use the PEP-buddy as needed.
89071653|NCT05938686|Experimental|Interventional Group|Home_Based Digital Mindful Dance Program for 12 weeks
89071654|NCT05938686|No Intervention|Control Group|Routine care for 12 weeks.
89071655|NCT05938673|Sham Comparator|Sham repetitive transpinal magnetic stimulation|In the Sham group a coil will be positioned in the T2-T3 thoracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus.
89071656|NCT05938673|Active Comparator|Active repetitive transpinal magnetic stimulation|In the Active group, the patient will receive intermittent theta burst stimulation (iTBS) in the T2-T3 region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.
89071657|NCT05938660|Experimental|Acupressure group|The participants received a 5-minutes acupressure on Sanyinjiao point of both legs per day from 5 days ago of one period untill the third day of the period. The participants received the same intervention in the coming period again.
89071658|NCT05938569|Experimental|All subjects|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
89691022|NCT01063075|Experimental|Cetuximab and Carboplatin (B)|"Group B:~Cycle 1 (3 weeks, single-agent cetuximab):~400 mg/m² cetuximab administered I.V on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 2 and 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V weeks 1- 3,day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011,any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
89691023|NCT01063075|Experimental|Carboplatin and Cetuximab (A)|"Group A:~Cycle 1 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m ² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 1- 3, day 1.~After 7 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
89691024|NCT01341405|Experimental|CG100649 2 mg|capsule, once daily for 28 days
89691025|NCT01341405|Experimental|CG100649 4 mg|capsule, once daily for 28 days
89691026|NCT01341405|Active Comparator|celecoxib 200 mg|capsule, once daily for 28 days
89691027|NCT02981485|Experimental|Experimental|Treatment of breast cancer related lymphedema by fat grafting
89691028|NCT03015103|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
89071659|NCT05938504|Placebo Comparator|Control group|Subjects will receive two packs of placebo ONS (ONS_320275) orally daily
89071660|NCT05938504|Experimental|Test group|Subjects will receive two packs of test ONS (ONS_211567) orally daily
89071661|NCT05938478||Tralokinumab-Exposed Cohort|Pregnant women with AD exposed to tralokinumab anytime during pregnancy, or within 16 weeks before conception
89071662|NCT05938478||AD Cohort- Phototherapy or Systemic Treatment Exposed|Pregnant women with AD who have not been exposed to tralokinumab, but who have been exposed to phototherapy or systemic therapy for the treatment of AD during pregnancy
89071663|NCT05938478||AD Cohort - With or Without Treatment|Pregnant women with AD who may or may not have received treatment for AD, but who have not been exposed to any dose of tralokinumab, phototherapy or systemic therapy during pregnancy
89071664|NCT05938478||Tralokinumab-Exposed Case Series|Pregnant women with AD exposed to tralokinumab anytime during pregnancy, or within 16 weeks before conception, who don't meet the eligibility criteria for the tralokinumab-exposed cohort group
89071665|NCT05938400|Experimental|One step polyvinylsiloxane impression technique|All impressions in this group will be recorded in a single stage, mixing light-bodied PVS material and putty PVS material simultaneously and recording of impression of prepared tooth
89071666|NCT05938400|Active Comparator|Two step polyvinylsiloxane impression technique|All impressions in this group will be made in two stages, recording putty PVS impression first and then reloading it with light-bodied PVS material to record final impression.
89071667|NCT05938374|Experimental|Preoperative moderately fractionated RT with Fluzoparib|"Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr). One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).~Wide resection surgery would be done around 6 -10 weeks post-RT."
89071668|NCT05938374|Experimental|Preoperative moderately fractionated RT without Fluzoparib|"Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr). No radio-sensitizing drugs was given.~Wide resection surgery would be done around 6 -10 weeks post-RT."
89071669|NCT05938361||Single group|Cohort of patients with difficult-to-treat psoariasis locations on the nail, scalp, genital and/or palmoplantar area.
89691029|NCT01113567|Placebo Comparator|Diet and lactose-free milk|Lactose-free milk
89691030|NCT01113567|Active Comparator|Diet and whole milk|Whole milk with lactose
89691031|NCT01064323|Other|Intermittent leg compression|Intermittent leg compression daily for 3 hrs a day for 4 weeks
89691032|NCT01064713|Experimental|Tesetaxel|Therapy initiated at a flat dose of 40 mg for subjects in Cohort A and at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.
89691033|NCT01065571|Experimental|carrageenan-free diet with placebo|This is the experimental arm in which subjects will be on a no-carrageenan diet and receive placebo capsules. This will test whether the no carrageenan diet leads to longer relapse-free interval for patients with ulcerative colitis.
89691034|NCT01065571|Active Comparator|carrageenan-free diet w/ carrageenan|The carrageenan-free diet with carrageenan supplement will mimic the carrageenan normally consumed in the diet. The study will permit blinded comparison of carrageenan-free vs. carrageenan consumption.
89691035|NCT05136157|Active Comparator|Study group|Bolus-Infusion approach of rapidly acting crystalline insulin. The patient intra-operative blood glucose will be divided by 100. The resultant rapidly acting crystalline insulin units will be given intravenously over 10 minutes, and then continued as an intra-venous infusion per hour. The Capillary Blood Glucose (CBG) will be measured every 30 minutes and in the PACU with readjustment of the bolus-infusion dose as required
89691036|NCT05136157|Active Comparator|Control group|The sliding scale approach of rapidly acting crystalline insulin will be used according to the intra-operative blood glucose; 4 IU of insulin will be given when the CBG 180-250 mg/dl, 6 IU of insulin will be given when the CBG 251-300 mg/dl, 8 IU of insulin will be given when the CBG 301-350 mg/dl and 10 IU of insulin will be given when the CBG 351-400 mg/dl (5). The CBG will be measured every 30 minutes and in the PACU.
89691037|NCT03936127|Experimental|Transperineal (TP) Ultrasound (US) Targeted Fusion Biopsy|Transperineal (TP) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
89691038|NCT03936127|Active Comparator|Transrectal (TR) Ultrasound (US) Targeted Fusion Biopsies|Transrectal (TR) ultrasound (US) targeted fusion biopsy (which is performed using a validated Health Canada approved elastic software fusion platform).
89691039|NCT01921790|Experimental|Avastin+ GemAOD|Avastin+ GemAOD means Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone
89691040|NCT02153541|Placebo Comparator|Glycerin with Oxyquinoline Sulfate|For those participants who receive glycerin with oxyquinoline sulfate placebo, we do not anticipate any change in the usage of rescue inhalers, spirometer scores, asthma diaries, and expired fractionated nitrous oxide levels.
89691041|NCT02153541|Active Comparator|Antipyrine-benzocaine otic solution|Will be used on 50% of participants, we anticipate reduction in the usage of rescue inhalers, spirometer scores, asthma diaries, and expired fractionated nitrous oxide levels.
89691042|NCT03248440|Experimental|SUN-131 1.5% TDS|
89691043|NCT03248440|Placebo Comparator|Placebo TDS|
89691044|NCT03487276|Placebo Comparator|Cohort 1|Placebo
89691045|NCT03487276|Experimental|Cohort 2|Minimum Dose IFX-1 (400 mg Q4W)
89691046|NCT03487276|Experimental|Cohort 3|Low dose IFX-1 (800 mg Q4W)
89691047|NCT03487276|Experimental|Cohort 4|Medium Dose IFX-1 (800 mg Q2W)
89691048|NCT03487276|Experimental|Cohort 5|High Dose IFX-1 (1200 mg Q2W)
89691049|NCT04352803|Experimental|Autologous Adipose Derived Mesenchymal Cells|Conventional treatment plus MSC's IV
89691050|NCT04352803|No Intervention|Untreated|Conventional treatment only
89691051|NCT03487588|Experimental|A-101 Topical Solution|Open Label Arm
89691052|NCT03250234|Other|Adequate Carbohydrate|Carbohydrate beverage (1 g/kg/hr) Adequate carbohydrate diet 6.0 g/kg/d
89691053|NCT03250234|Other|Low Carbohydrate|Non-nutritive control beverage. Low carbohydrate diet 1.2 g/kg/d
89691054|NCT03489850|Active Comparator|Ibudilast|20mg BID Days 1-2 50mg BID Days 3-14
89691055|NCT03489850|Placebo Comparator|Placebo|Matched to active
89691056|NCT03490942|Experimental|CSGI high infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
89071670|NCT05938348|Experimental|pain scores of patients before and after (6h, 12h, 24h, 48h, 72h) angiopuncture.|investigators done angiopuncture on perforators in human. Pain score will be assessed on both before and after the treatment.
89071671|NCT05938335|Experimental|severe obese children|children with severe obesity with BMI > 3sds
89071672|NCT05938322|Experimental|Ketogenic Diet|In the group of intervention is prescribed a ketogenic diet plan.
89071673|NCT05938322|Active Comparator|Standard Diet|The control group (SD) will follow the Mediterranean diet pattern based on ESPEN (European Society of Parenteral and Enteral Nutrition) guidelines
89071674|NCT05938309||large group|laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors
89071675|NCT05938309||small group|laparoscopic resection of less than 5cm gastric gastrointestinal stromal tumors
89071676|NCT05938257|Experimental|TMJ dysfunction|TMJ discopexy
89071677|NCT05938244||case/ diseased patients|ultra sound anterior chest wall echocardiogram pulmonary function test diaphragmatic ultra sound lipid profile Rheumatoid factor Anti-ccp
89071678|NCT05938244||control/ normal population|ultra sound anterior chest wall echocardiogram pulmonary function test diaphragmatic ultra sound lipid profile Rheumatoid factor Anti-ccp
89071679|NCT05938231|Experimental|trial group|In the trial group, the patients are treated with Gastric Bypass Stent System implanted under the gastroscope as well as the dietary intervention; The trial is carried out for 9 months, of which in the trial group, the patients have 3-month treatment period and then have 6-month follow-up period after the Gastric Bypass Stent System is removed.
89071680|NCT05938231|Other|control group|In the control group, the patients are treated only with dietary intervention; the patients have 9-month dietary intervention in the corresponding period.
89071681|NCT05938218|Experimental|intervention|In this intervention, VR glasses with an information module are utilized, lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures
89071682|NCT05938218|No Intervention|Control Group|Usual Care
89071683|NCT05938205|Experimental|Exe-H + placebo|high intensity physical exercise combined with placebo
89071684|NCT05938205|Experimental|Exe-H + AA-1|high intensity physical exercise combined with low dose of aminoacids
89071685|NCT05938205|Experimental|Exe-H + AA-2|high intensity physical exercise combined with high dose of aminoacids
89071686|NCT05938192||Patients with HPV-related disease|Patients with HPV-related disease including cervical and vaginal lesions
89071687|NCT05938153||geriatrics individuals|
89071688|NCT05938140|Other|Paxlovid group|Patients will take Paxlovid.On the first day, Nematavir tablet 300mg/Ritonavir tablet 100mg orally once, then Nematavir tablet 150mg/ Ritonavir tablet 100mg orally once a day for 4 days. Dialysis patients must took the medication after dialysis.
89071689|NCT05937997|Active Comparator|Group A high intensity|Physiotherapy with high intensity and no restrictions
89071690|NCT05937997|Active Comparator|Group B moderate intensity|Physiotherapy with medium intensity and some restrictions
89071691|NCT05937997|Active Comparator|Group C low intensity|Physiotherapy with low intensity and many restrictions
89071692|NCT05937984|Active Comparator|Active cTMS|Controlled Transcranial Magnetic Stimulation (cTMS) will be delivered at 10 Hz, 1500 pulses targeting the hand representation of the left primary motor cortex. cTMS delivery will require ~9 min to complete. This intervention will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
89071693|NCT05937984|Sham Comparator|Sham cTMS|Sham cTMS will be delivered at as a placebo control. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active cTMS. This will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
89071694|NCT05937919|Experimental|68Ga-PMD22 PET/CT dynamic scan|68Ga-PMD22 PET/CT scan Dosimetry study about 6 patients were injected with 2-4 (MBq) per kilogram body weight of 68Ga-PMD22 PET/CT in one dose intravenously and underwent wholebody scan at 5min#15min#30min#60min#90min#120min#180min, then analysis of dosimetric distribution of radiopharmaceuticals in human body by HERMES software.
89071695|NCT05937919|Experimental|68Ga-PMD22 PET/CT scan at one time|After the dynamic scan completed, choose an optimal imaging examination time for PET examination of other patients.
89071696|NCT05937880|Experimental|Administration of Leflunomide in refractory skin Henoch-Schonlein purpura|Rashes are dense and large in area, often treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rash does not subside or new rash still appears, and it frequently repeats more than 3 times during hospitalization.
89071697|NCT05937867|Experimental|HS-10353 Capsules|
89071698|NCT05937867|Experimental|Placebo for HS-10353 Capsules|
89071699|NCT05937841|Experimental|assessment of microvascular function|The investigators use intradermal microdialysis to deliver compound 21 and L-NAME to the cutaneous microvasculature
89071700|NCT05937828||Immune thrombocytopenia (ITP)|Immune thrombocytopenia (ITP) : defined according to the international working group criteria (Rodeghiero et al., Blood 2009).
89071701|NCT05937828||Autoimmune Hemolytic anemia (AIHA)|Autoimmune haemolytic anaemia (AIHA) : Hb < 110 g/L with a positive direct antiglobulin test (DAT) and at least one of the following haemolysis criteria: reticulocyte count > 120 G/L, free bilirubin > 17 mmol/L, or haptoglobin < 10 mg/dL.
89071702|NCT05937828||Evans syndrome (all bi or tri cytopenias)|Evans syndrome (ES) : simultaneous (less than 1 month) or sequential association of at least two autoimmune cytopenia among ITP, AIHA and autoimmune neutropenia (AIN).
89071703|NCT05937815|Experimental|patients with cystic fibrosis|patients with cystic fibrosis before and one year after the start of treatment with elexacaftor/tezacaftor/ivacaftor
89071704|NCT05937802|Experimental|Osmotin|Administration of a nutraceutical supplement provided in capsules, that consists of lyophilised and pulverised kiwi leaves from bioengineered kiwi (Actinidia Deliciosa) plants overexpressing the tobacco protein Osmotin.
89071705|NCT05937711|Experimental|PTNS+Duloxetine|Posterior tibial nerve stimulation (PTNS), twice weekly, 3-4 days apart + Duloxetine 30 mg 1X1 p.o PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes
89071706|NCT05937711|Active Comparator|Duloxetine|Duloxetine 30 mg 1X1 p.o
89071707|NCT05937633|Experimental|Tranformational Education|A total of 82 Participants will be assigned to experimental group. Transformational educational programme is administered to all the participants.
89071708|NCT05937633|No Intervention|Educational Booklet|Study participants (Charge Nurses and Acting Charge Nurses) of educational booklet group will be distributed with educational booklet.
89071709|NCT05937607|Experimental|Hand massage|hand massage was applied to the patients to receive intracavitary brachytherapy using lavender baby oil for three sessions of 10 minutes each, starting 5 minutes before the procedure.
89071710|NCT05937607|No Intervention|Control Group|The control group did not receive any intervention during the study period
89071711|NCT05937594||Infants exposed to in utero opiates|Infants that meet IRB-approved inclusion/exclusion criteria.
89071712|NCT05937529|Experimental|Daylight PDT + Cicaplast|Pretreatment with currettage. Metvix cream. Daylight PDT. Application of Cicaplast to test area immediately after dPDT. Cicaplast application twce daily for 14 days.
89071713|NCT05937529|Active Comparator|Daylight PDT|Pretreatment with currettage. Metvix cream. Daylight PDT. No post treatment.
89071714|NCT05937516|Sham Comparator|Control Group|Nasotracheal intubation will be applied conventionally to patients in this group.
89071715|NCT05937516|Active Comparator|Study Group|In the study group (Group S), a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
89071716|NCT05937490|Experimental|Group 1 (Long)|COH will be performed using a long GnRH agonist protocol(administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle). COH will be commenced when pituitary desensitization was achieved(~14 days after the initiation of GnRH agonists) as evidenced by the absence of ovarian follicles &gt;10 mm and endometrial thickness &lt;4 mm on TV-US examination.
89071717|NCT05937490|Experimental|Group 2 (Long + high dose DNG)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle). COH will be commenced when pituitary desensitization was achieved (~14 days after the initiation of GnRH agonists), as defined above.
88812782|NCT01526213|Other|Sequence 4: GFJ, Water, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
89071718|NCT05937490|Experimental|Group 3 (ultra-long):|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times). COH will be commenced when pituitary desensitization was achieved (~14 days after the initiation of GnRH agonists), as described above.
89071719|NCT05937490|Other|Control group (without adenomyosis)|COH will be performed by using a long GnRH agonist protocol as previous described or using a flexible GnRH antagonist protocol. During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH (luteinizing hormone) suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
89071720|NCT05937464|Experimental|Exoskeleton ExoAthlet group|
89071721|NCT05937464|Experimental|Lokomat Free-D group|
89071722|NCT05937438|Experimental|Experimental Arm|Esophagectomy+postoperative radiotherapy+immunotherapy
89071723|NCT05937438|Other|Controlled Arm|Esophagectomy+postoperative radiotherapy
89071724|NCT05937412|Active Comparator|alcohol group|70% isopropyl alcohol will be topically applied and spread uniformly on a prespecified area of at least 3 cm x 3cm on the dorsum of the hand. A skin swab will be obtained from the selected skin area just before and 20 seconds after topical application of alcohol and honey.
89071725|NCT05937412|Active Comparator|honey group|honey will be topically applied and spread uniformly on a prespecified area of at least 3 cm x 3cm on the dorsum of the hand. A skin swab will be obtained from the selected skin area just before and 20 seconds after topical application of alcohol and honey.
89071726|NCT05937347|Experimental|TAU + UP4H|UP4H is a face-to-face and virtual non-pharmacological program based on Mindfulness Training and Cognitive Training.
89071727|NCT05937347|Active Comparator|TAU + M4H|M4H is a face-to-face non-pharmacological program based on Mindfulness Training.
89071728|NCT05937347|Active Comparator|TAU + CT|CT is a virtual non-pharmacological program based on Cognitive Training.
89071729|NCT05937347|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) consisted of the prescribed drugs adapted to the ADHD symptomatic profile of each child.
89071730|NCT05937243|Experimental|Base self-help CBT program plus Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
89691057|NCT03490942|Experimental|CSGI low infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
89691058|NCT03490942|Placebo Comparator|Placebo high infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
89691059|NCT03490942|Placebo Comparator|Placebo low infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
89691060|NCT01069003|Placebo Comparator|Placebo Arm|Subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
89691061|NCT01069003|Active Comparator|Thienopyridine Therapy|Subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
89691062|NCT01069003|Other|Surveillance Arm|Non randomized subjects followed through 24 months
89691063|NCT00376870|Active Comparator|Pioglitazone|Pioglitazone 30mg/d
89691064|NCT00376870|Placebo Comparator|Placebo|
89691065|NCT03015025||Stable treatment with acenocoumarol|Patients in stable anticoagulant treatment with acenocoumarol for auricular fibrillation, venous thromboembolic disease and/or cardiac valve replacement.
89691066|NCT01069315|Experimental|Normal saline and High pressure|Irrigation with normal saline delivered at high pressure
89691067|NCT01069315|Experimental|Soap solution and High pressure|Irrigation with soap solution delivered at high pressure
89691068|NCT01069315|Experimental|Normal saline and Low pressure|Irrigation with saline solution delivered at low pressure
89691069|NCT01069315|Experimental|Soap solution and Low pressure|Irrigation with soap solution delivered at low pressure
89691070|NCT03350542|Experimental|SYNERGY 48 mm|SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)
89691071|NCT03014869|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37 degree centigrade.
89691072|NCT03014869|No Intervention|Noninvasive positive ventilation|Parameters are set according to NPPV protocols
89691073|NCT03252964|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
89691074|NCT01070095|Experimental|Electronic Asthma Action Plan System|Electronic Asthma Action Plan System (eAAPS)
89691075|NCT01070173||Short Stature|Poor linear growth
89691076|NCT01070173||Poor Weight Gain (Failure-To-Thrive)|Poor Weight Gain
89691077|NCT01070173||Isolated Gastrointestinal Symptoms|No growth symptoms
89071731|NCT05937243|Experimental|Base self-help CBT program plus Just-in-time, adaptive interventions (JITAIs)|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
89224045|NCT03523585|Active Comparator|Lapatinib+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
89071732|NCT05937243|Experimental|Base self-help CBT program plus JITAIs plus Advanced Digital Data Sharing with Coaches|When Advanced DDS with Coaches and JITAIs are both ON, participants will receive machine learning-informed interventions. In addition, participants will also receive weekly emails from coaches to provide additional support to improve treatment adherence and skills utilization.
89071733|NCT05937243|Active Comparator|Base self-help cognitive behavior therapy (CBT) program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participants to set personalized goals each week. Modules will be completed in succession over the course of 12 weeks and a new module will be made open each week. At the end of each weekly module, participants will complete an end-of-the-week survey and report on the frequency of skills use in the past week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
89071734|NCT05937191|Experimental|IPH Patients|Leflunomide+Steroid treatment
89071735|NCT05937191|Active Comparator|Control Group|Steroid treatment
89071736|NCT05937178||Recommend to initiate treatment in 2022 Chinese Guideline, but not in 2019 Chinese Guideline|Untreated population who does not be recommended to initiate treatment in 2022 Chinese Guideline, but not in 2019 Chinese Guideline. The initate treatment is to receive a first-line nucleos(t)ide analogue, i.e., entecavir, tenofovir disoproxil, or tenofovir alafenamide, tenofovir amibufenamide
89071737|NCT05937178||Recommend to initiate treatment in 2019 and 2022 Chinese Guideline, but not in AASLD/EASL guidelines|Untreated population will receive a first-line nucleos(t)ide analogue , i.e., entecavir, tenofovir disoproxil, or tenofovir alafenamide, tenofovir amibufenamide, and the population should meet the conditions that are recommended to initiate treatment in 2019 and 2022 Chinese guideline, but not in AASLD/EASL guidelines
89071738|NCT05937178||Treatment experienced and with partial response|Treatment experienced population who has received a first-line nucleos(t)ide analogue(NA) as monotherapy at least 48 weeks, i.e., entecavir, tenofovir disoproxil, or tenofovir alafenamide, tenofovir amibufenamide, and has partial response to NA. They will continue the original therpay or plans to change the therapy (e.g. switch another first-line NA, add-on another first-line NA, switch another first-line NA and add-on peginterferon alpha)
89071739|NCT05937139|Experimental|Training group 1|After the scales are applied to the fathers in training group 1 on the 3rd postpartum day, breastfeeding education will begin. The training will last 39 days and the scales will be re-administered on the 42nd postpartum day and at the 12th week postpartum.
89071740|NCT05937139|Experimental|Training group 2|Breastfeeding education will begin to the fathers in training group 2 on the 3rd postpartum day. The training will last 39 days and the scales will be re-administered on the 42nd postpartum day and at the 12th week postpartum.
89071741|NCT05937139|No Intervention|Control group 1|The scales will be administered to the fathers in the control group 2 on the 3rd day, 42nd day, and 12th week postpartum.
89071742|NCT05937139|No Intervention|Control group 2|The scales will be administered to the fathers in the control group 2 on the 42nd day, and 12th week postpartum.
89071743|NCT05937126||Standard culture and antimicrobial susceptibility testing (AST)|Lower respiratory tract sputum samples (expectorated sputum, induced sputum, tracheal secretions, or bronchoalveolar lavage) collected in the inpatient setting per standard of care from adults with lower respiratory tract infections will receive standard culture and antimicrobial susceptibility testing (AST).
89071744|NCT05937126||Standard culture and AST PLUS rapid identification and AST|Lower respiratory tract sputum samples (expectorated sputum, induced sputum, tracheal secretions, or bronchoalveolar lavage) collected in the inpatient setting per standard of care from adults with lower respiratory tract infections will receive standard culture and AST PLUS rapid identification and AST using the FDA-approved/cleared FilmArray Pneumonia Panel
89071745|NCT05937100|Active Comparator|control: Formocresol|Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute then removed and pulp stumps will be dressed with a layer of zinc oxide-eugenol (ZOE) paste.
89071746|NCT05937100|Experimental|Group A : (Biodentine)|The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps, and allowed to set.
89071747|NCT05937100|Experimental|Group B : (Hyaluronic acid gel)|Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes. Then the pulp stumps will be dressed with a layer of zinc oxide-eugenol (ZOE) paste.
89071748|NCT05937061||Milk allergy|Children with milk allergy.
89071749|NCT05937061||Egg Allergy|Children with egg allergy
89071750|NCT05937061||Peanut allergy|Children with peanut allergy
89071751|NCT05937061||Control group|Patients withhout food allergy (bee venom or drug allergy).
89071752|NCT05937048|Experimental|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
89071753|NCT05937048|Active Comparator|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
89071754|NCT05937035|Other|Customized allogenic bone block|1 group to study
89224046|NCT03495986|Experimental|Home-Based Exercise & Diet Group|16-week home based functional electrical stimulation leg cycle ergometry exercise program and diet intervention
89224047|NCT03495986|Placebo Comparator|Home-Based Diet Alone Group|Diet intervention
89071755|NCT05936983||Patients with Bipolar disorder|Participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, Anthropometric Measurements, Eurofit test battery, Rapid Depressive Symptom Inventory-Self-Report Form and International physical activity questionnaire will be applied respectively.
89071756|NCT05936983||Patients with Schizophrenia group|Participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, Anthropometric Measurements, Eurofit test battery, Rapid Depressive Symptom Inventory-Self-Report Form and International physical activity questionnaire will be applied respectively.
89071757|NCT05936983||Healthy group|Participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, Anthropometric Measurements, Eurofit test battery, Rapid Depressive Symptom Inventory-Self-Report Form and International physical activity questionnaire will be applied respectively.
89071758|NCT05936957||Acute heart failure|These are acutely decompensated heart failure
89071759|NCT05936957||Chronic heart failure|These are stable heart failure patients being followed up in the outpatient clinic
89071760|NCT05936918|Experimental|TT group|Bilateral Neiguan acupuncture points (PC6), Hegu acupuncture points (LI4), Zusanli (ST36) were selected, and percutaneous acupuncture points were electrically stimulated with electronic acupuncture equipment 30min before anesthesia, and then bilateral abdominal transverse plane blockade was performed
89071761|NCT05936918|Active Comparator|TE group|Bilateral Neiguan acupuncture points (PC6), Hegu acupuncture points (LI4), Zusanli (ST36) were selected, and percutaneous acupuncture points were electrically stimulated with electronic acupuncture equipment 30min before anesthesia
89071762|NCT05936918|Active Comparator|TA group|Bilateral transverse abdominal plane block is performed prior to anesthesia
89071763|NCT05936918|No Intervention|C group|Percutaneous electrical stimulation of acupoints and transverse abdominis plane block are not permitted before anesthesia
89071764|NCT05936905|Experimental|Acupuncture therapy|This study aims to compare acupuncture therapy administered one time per month
89071765|NCT05936905|Experimental|Chiropractor therapy|This study aims to compare chiropractic therapy administered one time per month
89071766|NCT05936892|Experimental|upper extremity aerobic training|upper extremity aerobic training
89071767|NCT05936892|Experimental|upper extremity resistance training|upper extremity resistance training
89071768|NCT05936879|Experimental|Inspiratory muscle training and early ambulation|Intervention group will be treated with Inspiratory muscle training once in a week for at least 3 weeks
89071769|NCT05936879|Experimental|physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.|Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs once in a week for at least 3 weeks
89071770|NCT05936853|Active Comparator|Total intravenous anaesthesia (TIVA)|This arm will receive maintenance of anaesthesia through a total intravenous anaesthesia approach (TIVA)
89071771|NCT05936853|Active Comparator|Inhalational anaesthesia|This arm will receive maintenance of anaesthesia through an inhalational anaesthesia approach
89071772|NCT05936840||Regular cycles|To characterize quantitative hormones in the urine using the Mira monitor, along with other menstrual cycle biomarkers, and validate these in reference to serum hormonal measurements and the gold-standard of the ultrasound-day of ovulation in participants with normal menstrual cycles (cycle length 24-38 days).
89071773|NCT05936840||Polycystic ovarian syndrome|To identify hormonal and other menstrual cycle biomarker variations in polycystic ovarian syndrome (PCOS) with oligomenorrhea.
89071774|NCT05936840||Athletes|To identify hormonal and other menstrual cycle biomarker variations in oligomenorrheic athletes.
89071775|NCT05936827||athletic group|Moderate to high PA levels according to IPAQ.
89071776|NCT05936827||non-athletic group|Low levels of PA according to IPAQ.
89071777|NCT05936801|Experimental|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days"
88812783|NCT01526213|Other|Sequence 5: FC-free GFJ, GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
89071778|NCT05936801|Experimental|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
89071779|NCT05936788|Experimental|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
89071780|NCT05936788|Experimental|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
89071781|NCT05936775|Experimental|Nano-hydroxy apatite arm|in this groups patients will receive nano-hydroxy apatite coated titanium implants
89071782|NCT05936775|Active Comparator|SLA arm|in this group patients will receive sandblasted large thread acid etched titanium implants
89071783|NCT05936762|Experimental|Neoial|Treatment with the MD
89071784|NCT05936723|Active Comparator|Voluntary Isocapnic Hyperpnoea (VIH)|Group performing respiratory muscle training with Voluntary Isocapnic Hyperpnoea (VIH) method.
89071785|NCT05936723|Active Comparator|Inspiratory Pressure Threshold Loading (IPTL)|Group performing respiratory muscle training with Inspiratory Pressure Threshold Loading (IPTL) method.
89071786|NCT05936697|Sham Comparator|Sham Group|During training, participants will be asked to follow the instructions on a computer screen and complete five rounds of task. Each round starts with a 30-s rest phase followed by 4.5 min of self-regulation phase. At the rest phase, a fixed cross will appear onscreen, and participants will be instructed to sit still and relax. At the regulation phase, they will be asked to make the person smile (as an intrinsic social reward) but without tips. The intensity of smiling will be manipulated by morphing photographs of a neutral and a happy face and will represent the increase in either frontal alpha asymmetry or frontal oxyhaemoglobin asymmetry. The values at the moment will be compared against the baseline. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity. In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings.
89071787|NCT05936697|Experimental|fNIRS Group|During training, participants will be asked to follow the instructions on a computer screen and complete five rounds of task. Each round starts with a 30-s rest phase followed by 4.5 min of self-regulation phase. At the rest phase, a fixed cross will appear onscreen, and participants will be instructed to sit still and relax. At the regulation phase, they will be asked to make the person smile (as an intrinsic social reward) but without tips. The intensity of smiling will be manipulated by morphing photographs of a neutral and a happy face and will represent the increase in either frontal alpha asymmetry or frontal oxyhaemoglobin asymmetry. The values at the moment will be compared against the baseline. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity. In the fNIRS condition, participants will receive visual feedback based on their own fNIRS recordings.
89071788|NCT05936697|Experimental|EEG Group|During training, participants will be asked to follow the instructions on a computer screen and complete five rounds of task. Each round starts with a 30-s rest phase followed by 4.5 min of self-regulation phase. At the rest phase, a fixed cross will appear onscreen, and participants will be instructed to sit still and relax. At the regulation phase, they will be asked to make the person smile (as an intrinsic social reward) but without tips. The intensity of smiling will be manipulated by morphing photographs of a neutral and a happy face and will represent the increase in either frontal alpha asymmetry or frontal oxyhaemoglobin asymmetry. The values at the moment will be compared against the baseline. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity. In the EEG condition, participants will receive visual feedback based on their own EEG recordings.
89071789|NCT05936658|Other|The positive predictive values (PPV) of [18F]Florastamin PET/CT imaging|The positive predictive values (PPV) of [18F]Florastamin PET/CT imaging for the detection of recurrent or metastatic prostate cancer in subjects are evaluated.
89071790|NCT05936476||Skeletal Class I (Control Group)|
89071791|NCT05936476||Skeletal Class II|Class II malocclusion is characterized by the upper jaw (maxilla) being positioned more forward in relation to the lower jaw (mandible), resulting in an overbite.
89071792|NCT05936476||Skeletal Class III|Class III malocclusion is characterized by the lower jaw (mandible) being positioned more forward in relation to the upper jaw (maxilla), resulting in an underbite.
89071793|NCT05936476||Anterior Open Bite|Anterior open bite is characterized by a lack of vertical overlap or contact between the upper and lower front teeth when the back teeth are in contact (occlusion).
89071794|NCT05936463||Orthodontics brackets|
89071795|NCT05936463||Clear aligner appliances|
89071796|NCT05935059|Active Comparator|pregabalin group (group P)|pregabalin group (group P) patients will receive pregabalin (Lyrica, Pfizer, NY) 50 mg with a sip of water one hour before induction of anesthesia and repeated every 8 hours for five days after surgery. The pregabalin capsules will be given to patients by nurses blinded to the study. Neither the researcher allocating the participants, nor the assessing person knew the decoding of the groups in its relation to the allocation sequence. Data will be collected by a junior pain resident blinded to the study protocol.
89071797|NCT05935059|Active Comparator|Tianeptine group (group T)|Tianeptine group (group T) patients will receive Tianeptine 12.5 mg (Stablon, Servier, France)with a sip of water one hour before induction of anesthesia and repeated every 8 hours for five days after surgery. The Tianeptine capsules will be given to patients by nurses blinded to the study. Neither the researcher allocating the participants, nor the assessing person knew the decoding of the groups in its relation to the allocation sequence. Data will be collected by a junior pain resident blinded to the study protocol.
89071798|NCT05933746|Experimental|Sleep Hygiene Intervention|1-hour, on-line set of three modules pertaining to various sleep hygiene behaviors
89071799|NCT05933746|Placebo Comparator|Non-behavioral Sleep Education|active, matched placebo condition that controls for engagement and rationale
89071800|NCT05933707|No Intervention|Metabolically healthy lean - Baseline testing only|"Metabolically healthy lean - Lean individuals that have good glucose (sugar) control (defined as normal fasting glucose, glucose tolerance and hemoglobin A1c), normal insulin sensitivity (defined as Homeostatic Model Assessment of Insulin Resistance [HOMA-IR] <2.5) and normal intrahepatic triglyceride (fat) levels.~Dietary intervention - None."
89224048|NCT03493581|Experimental|NSCLC patients|
88812784|NCT01526213|Other|Sequence 6: FC-free GFJ, Water, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
89071801|NCT05933707|No Intervention|People with Metabolically Healthy Obesity - Baseline testing only|"People with Metabolically Healthy Obesity - Persons with obesity that have good glucose (sugar) control, normal insulin sensitivity and normal intrahepatic triglyceride (fat) levels.~Dietary intervention - None."
89071802|NCT05933707|Experimental|People with Metabolically Unhealthy Obesity - Low Calorie Diet|"People with Metabolically Unhealthy Obesity - Persons with obesity with plasma glucose and intrahepatic triglyceride (fat) levels higher than recommended in combination with insulin resistance (defined as HOMA-IR ≥2.5).~Dietary intervention - Low calorie diet."
89071803|NCT05932719||Peritoneal Carcinosis|Patients hospitalized for peritoneal carcinosis between 2017 and 2020.
89071804|NCT05932719||Hepatocellular Carcinoma|Patients hospitalized for hepatocellular carcinoma between 2017 and 2020.
89071805|NCT05931523|Experimental|Stress First Aid|Fire Departments received the Stress First Aid intervention trainings, tools, and resources.
89071806|NCT05931523|No Intervention|Wait List Control|Fire Departments in this condition did not receive any intervention or training until the end of their observation year.
89071807|NCT05929534|Active Comparator|active iTBS group|active iTBS combined with speech language therapy
89071808|NCT05929534|Sham Comparator|sham iTBS group|sham iTBS combined with speech language therapy
89071809|NCT05929391|Experimental|sandblasted group (T1)|the side of mouth patient that receives fixed orthodontic appliance that renewed by sandblast
89071810|NCT05929391|Placebo Comparator|control group (T3)|the side of mouth patient that receives new fixed orthodontic appliance.
89071811|NCT05929391|Experimental|tungsten bur group (T0)|the side of mouth patient that receives fixed orthodontic appliance that renewed by tungsten bur.
89071812|NCT05929391|Placebo Comparator|control group (T2)|the side of mouth patient that receives new fixed orthodontic appliance.
89071813|NCT05928962|Experimental|PD-1 With Recombinant Human Adenovirus Type 5 Injection|"Recombinant Human Type 5 Adenovirus Injection:~Drug specification: 5.0 x 1011vp/0.5ml/stem. Dosage: Dilute with equal volume of saline before injection. For injection of lesions with a longest diameter ≥10mm and ≤40mm, 2 injections of recombinant human type 5 adenovirus injection per tumour, 1ml in total; for injection of lesions with a longest diameter ≥40mm and ≤80mm, 4 injections of recombinant human type 5 adenovirus injection per tumour, 2ml in total.~PD1 monoclonal antibody (Tremelimumab):~Dosage: 3mg/kg."
89071814|NCT05927285|Experimental|VeXUS group|The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
89071815|NCT05927285|Active Comparator|Control group|The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested.
89071816|NCT05920746|Experimental|Kinesiotherapy with Static Magnetic Field|Patients have kinesiotherapy of hand and static magnetic field. All patients without steroid anti-inflammatory drugs.
89071817|NCT05920746|Experimental|Kinesiotherapy with low-frequency pulsed magnetic field|Patients have kinesiotherapy of hand and low-frequency pulsed magnetic field. All patients without steroid anti-inflammatory drugs.
89071818|NCT05919914|Experimental|Wrist extensor exercise with Blood Flow Restriction|"Blood flow restriction training. Patients will execute a wrist extension exercise on standing position with the elbow extended. The load (dumbbells) will be set according to a pain monitoring approach ( exercise should not provoke pain >2/10) during wrist extension. Load is increased by 0.5 to 1kg. We will allow a 30 sec break. The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France).~An 40% occlusion pressure is set and subjects perform 4 sets of wrist extension (30-15-15-15 reps)."
89224049|NCT03485911|Experimental|BCX7353 110 mg once daily|BCX7353 administered as oral capsules once daily
89071819|NCT05919914|Active Comparator|Wrist extensor exercise without Blood Flow Restriction|Patients will execute a wrist extension exercise on standing position with the elbow extended. The load (dumbbells) will be set according to a pain monitoring approach ( exercise should not provoke pain >2/10) during wrist extension. Load is increased by 0.5 to 1kg. We will allow a 30 sec break.
89071820|NCT05912894||Videolaparoscopic cholecystectomy|Patients undergoing Videolaparoscopic cholecystectomy
89071821|NCT05910190|Experimental|Intervention|Receiving buprenorphine with short acting full agonist opioid with CPM Rx app to document medication use.
89071822|NCT05908435|Experimental|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The DFS+ experimental group is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens in 8 Boston parks and 3 Maine beaches. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
89071823|NCT05908435|No Intervention|Dispensers, Flyers, Signage|The DFS control group includes dispensers, flyers, and standard signage at 8 Boston parks and 3 Maine beaches. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. Standard signage will be present on the dispenser in the control parks/beaches.
89071824|NCT05905861|Placebo Comparator|Group_A: skin incision with scalpel.|In the scalpel group, the skin incision will be made using the traditional method, with a scalpel (No. 22).
89071825|NCT05905861|Active Comparator|Group_B: skin incision with diathermy.|In the diathermy group, the incision will be made using a small flat blade pen electrode without applying pressure. The electrode will be set to cutting mode, delivering a sinusoidal current of maximum 120 watts.
89071826|NCT05902910|Active Comparator|Experimental Scheme : A,B,C|The phase B treatment (1.5 hours a day, 5/7 days of conventional rehabilitation and 30mn a day, 5/7 days of treatment with the robot) is scheduled before phase C (2 hours a day, 5/7 days of conventional rehabilitation). The duration of phase B is randomized between 6 and 11 evaluations (2 to 3.5 weeks).
89071827|NCT05902910|Active Comparator|Experimental Scheme : A,C,B|The phase C treatment (2 hours a day, 5/7 days of conventional rehabilitation) is scheduled before phase B (1.5 hours a day, 5/7 days of conventional rehabilitation and 30mn a day, 5/7 days of treatment with the robot). The duration of phase C is randomized between 6 and 11 evaluations (2 to 3.5 weeks).
89071828|NCT05898919|Experimental|Acupuncture|
89071829|NCT05898919|Placebo Comparator|Sham acupuncture|
89071830|NCT05898919|Active Comparator|Neostigmine|
89071831|NCT05881291|Experimental|group ciprofol|Patients receive ciprofol for general anesthesia
89071832|NCT05881291|Active Comparator|group propofol|Patients receive propofol for general anesthesia
89071833|NCT05871125|Experimental|Patients receiving reimbursement|Monthly reimbursement to offset trial-related expenses
89071834|NCT05870280|Experimental|RESPONSE GROUP|After signing the voluntary consent form, the participants will be filled in the socio-demographic data collection form, the hypoglycemic attudes and behavior scale, the risk perception scale. A total of 4 group nurse coaching meetings will be held with individuals with type 1 diabetes, one to one over 7 days, under the framework of Theory of Integrative Nurse Coaching. Each of these interviews will last an average of 40-60 minutes. Interviews will be held online through the Zoom® webconferencing program at times scheduled jointly with the client. After the coaching meetings are over, the scales will be filled again and the HbA1c level will be requested from the blood results ordered at the doctor's request. In the coaching interviews, the materials specific to the coaching training received by the researchers (techniques such as the wheel of life, imagination, sabotage work, strong questions, Cartesian questions, SWOT analysis) will be used.
89071835|NCT05867563|Experimental|TQB2103 for Injection|"Dose escalation:~intravenous infusion of TQB2103 for injection once every three weeks, 21 days as one treatment cycle.~(0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 mg/kg, 4.0 mg/kg, 5.0mg/kg)~Dose expansion:~Chose one or two appropriate dose groups in the dose escalation experiment to expand."
89071836|NCT05867342|Experimental|Endoscopic sinus surgery|Participants receive topical 1:1000 epinephrine plus saline in one nostril, and topical 1:1000 epinephrine plus infiltration of 1% lidocaine with 1:100,000 epinephrine in the other nostril, during endoscopic visualization while undergoing Endoscopic sinus surgery (ESS).
89071837|NCT05866952||Post-Acute Sequelae of SARS-CoV-2 (PASC) Group|Subjects with PASC with a documented history of COVID-19 and persistent symptoms of fatigue, dyspnea, and/or exercise intolerance
89071838|NCT05866952||Control: Fully recovered COVID-19|Subjects with a history of COVID-19 who have fully recovered from COVID-19 with no post-acute sequelae of SARS-Cov-2
89071839|NCT05866952||Control: No history of COVID-19|Healthy subjects without a documented history of COVID-19, no current symptoms, and a normal baseline High resolution CT of the chest
89071840|NCT05854368|Other|Patients with gastric lesion|"Patients with:~Gastric epithelial dysplasia~Glandular atrophy of the gastric mucosa~Intestinal metaplasia of the gastric mucosa~Proximal gastric adenocarcinoma~Distal gastric adenocarcinoma"
89071841|NCT05854368|Other|Control|Healthy Volunteers
89071842|NCT05853757|Experimental|Zzowin Nutra Tablet|Zzowin Nutra Tablet contains Melatonin, Tagar, L-theanine, L-Tryptophan, vitamin B6, Iron, Zinc, and Magnesium. which is helpful to provide deep, calm, and restful sleep.
89071843|NCT05843448|Experimental|Treatment (IO102-IO103, pembrolizumab)|Patients receive PD-L1/IDO peptide vaccine SC and pembrolizumab IV on study. Patients also undergo CT and/or CT/PET and collection of blood samples throughout the trial.
89071844|NCT05836051|Experimental|Hexyl Acetate|E-cigarette liquid containing hexyl acetate, propylene glycol, vegetable glycerin and methylbutyl acetate with nicotine salt.
89071845|NCT05836051|Active Comparator|Ethyl Acetate|E-cigarette liquid containing ethyl acetate, propylene glycol, vegetable glycerin and methylbutyl acetate with nicotine salt.
89071846|NCT05829759|Experimental|Tele-B6|The tele-B6 intervention includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
89071847|NCT05829759|Other|Wait-list control -delayed intervention|Await-list control design to safeguard ethical treatment of participants by ensuring that a potentially impactful intervention will be available to all after a brief waiting period.
89071848|NCT05828602|Active Comparator|Conventional treatment|
89071849|NCT05828602|Experimental|TeleRehabilitation|
89071850|NCT05821322|Active Comparator|Temporary target of 8.3 mmol/L|Current commercial artificial pancreas thresholds. Temporary target set 60 minutes before the intervention.
89071851|NCT05821322|Experimental|Temporary target of 8.8 mmol/L|Temporary target set 60 minutes before the intervention
89071852|NCT05821322|Experimental|Temporary target of 9.3 mmol/L|Temporary target set 60 minutes before the intervention
89071853|NCT05820022||Physical Medicine and Rehabilitation Specialists|Physical medicine and rehabilitation specialists
89071854|NCT05818319|Other|12 hours ETI pause|
89071855|NCT05818319|Other|36 hours ETI pause|
89071856|NCT05818319|Other|60 hours ETI pause|
89071857|NCT05812651|Experimental|IMF arm|"The interventional protocol will include healthy older adults age above 60 years. At baseline - all measurements will be collected. After 3 days to one week, as per feasibility, participants will come to the lab again and perform inspiratory Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80%MIP).~Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure Maximum Inspiratory Pressure (MIP), until MIP measurement decrease of more than 10% from baseline will be performed. When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation. After the consent of participants an initial evaluation, Anthropometric measurements, Pulmonary function tests, PASE Questionnaire will be taken."
89071858|NCT05810480||Autoimmune Hepatitis|This group includes patients with a diagnosis of Autoimmune Hepatitis according to the simplified diagnostic criteria by Hennes et al. made by the local treating physician. The diagnosis of autoimmune hepatitis additionally requires steroid dependency > six months for this study to discriminate Autoimmune Hepatitis from autoimmune like drug-induced liver injury (DILI) which are hard to discriminate at diagnosis and with the latter often being treating with a short course of corticosteroids less than six months. One serum sample will be stored for anonymized evaluation of serum autoantibodies
89224050|NCT03485911|Experimental|BCX7353 150 mg once daily|BCX7353 administered as oral capsules once daily
89224051|NCT03485911|Placebo Comparator|Placebo|Matching placebo administered as oral capsules once daily
89071859|NCT05810480||non-autoimmune hepatitis liver disease|This group includes patients with a diagnosis of any non-viral liver disease that is not autoimmune hepatitis and whose diagnosis necessitated a diagnostic liver biopsy in the work-up of the liver disease for local care. One serum sample will be stored for anonymized evaluation of serum autoantibodies
89071860|NCT05802836||Inhibitor negative, FVIII on demand or regularly|Patients with severe hemophilia A receiving emicizumab therapy which are negative for factor VIII Inhibitor (including patients post ITI) and are receiving factor VIII therapy either on demand or regularly,
89071861|NCT05802836||Inhibitor positive, FVIII therapy regularly (ITI)|Patients with severe hemophilia A receiving emicizumab therapy which are positive for factor VIII Inhibitor and are receiving regularly factor VIII therapy (ITI)
89071862|NCT05802836||Inhibitor positive, no FVIII therapy|Patients with severe hemophilia A receiving emicizumab therapy which are positive for factor VIII Inhibitor and are receiving no factor VIII therapy
89071863|NCT05798533|Experimental|Treatment of Neo-T and anti-PD1|Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with MEL or NSCLC at escalating doses of 1.2×10^9 cells and 3.6×10^9 cells.
89071864|NCT05793632|Experimental|Quetiapine|The patients with multiple risks for delirium will receive 25 mg/day PO
89071865|NCT05793632|No Intervention|Non pharmacological preventive bundle|The patients will only be monitored with application of delirium preventive bundle without pharmacological agent
89071866|NCT05789277|Active Comparator|Conventional training program group|The control group will perform conventional training program
89071867|NCT05789277|Experimental|Eccentric hamstring training group|The interventional group will perform eccentric hamstring training
89071868|NCT05789251|Experimental|Standardized breakfast to replace in fine oral induced hyperglycemia test|Standardized breakfast to replace in fine oral induced hyperglycemia test
89071869|NCT05787782|Experimental|Masimo INVSENSOR00063|All subjects are enrolled into this arm and will have temperature measurements obtained.
89071870|NCT05768191|Active Comparator|Humulin N plus Humulin R|10 subjects will receive insulin human isophane suspension (Humulin N) twice daily plus regular human insulin (Humulin R) before meals
89071871|NCT05768191|Experimental|Premix human isophane suspension plus insulin human injection|10 subjects will receive premix insulin human isophane suspension and insulin human injection twice daily
89071872|NCT05762666|No Intervention|Group Standart of care|Patients will be followed with standard monitorization only along with pain scales and receive rescue analgesia according to them
89071873|NCT05762666|Experimental|Group Nociception level index monitor|Patients will acquire NOL monitorization throughout the ICU stay and have the same rescue analgesia under NOL guidance with concurrent pain scales
89224052|NCT03470025|Experimental|Psychological Intervention|A weekly combined face to face & telephone-based PI (F-TPI); Psychological Intervention and medical therapy
89224053|NCT03470025|Experimental|A telephone-based PI (TPI)|Psychological Intervention - A telephone-based PI (TPI); Psychological Intervention and medical therapy
89224054|NCT03470025|No Intervention|Optimal medical therapy|Patients will receive optimal medical therapy
89691078|NCT03491800|Other|Question/Topic Prompt List|The Question/Topic Prompt List is provided to HF Patients and their family member (if applicable) for completion prior to being seen by the doctor.
89691079|NCT02246725||Contact with palliative care unit versus contact when needed.|
89071876|NCT05758987|Experimental|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|B-Tf-CBT shares key features with Internet-based CBT (I-CBT) in that it is based on a digital support accessible to the patient. This digital support equips blended treatment with the same proposed advantages as I-CBT in terms of improving treatment accessibility, adherence, and reducing therapist-time. In addition, incorporating 6 biweekly face-to-face sessions to facilitate and augment delivery of more demanding components of TF-CBT such as memory exposure.
89071877|NCT05758987|Active Comparator|Prolonged exposure|Gold standard Tf-CBT Prolonged exposure will constitute the control condition. Prolonged exposure will be delivered by trained therapists under supervision adhering to the evidence based manual delivered face-to-face over 9-15 weeks.
89071878|NCT05751083|Experimental|brisk walk+ low intensity aerobic exercises group|"this group will perform the following exercises Brisk Walking Protocol~The brisk walking protocol will consist of :~10 min of warm-up period with flexibility exercises of the knees, hips and back~30 min of walking~5 min of cool down.~General flexibility Exercises Protocol Chair Sitting exercise Standing Balance Exercises"
89071879|NCT05751083|Active Comparator|brisk walk group|"this group will perform the following exercises Brisk Walking Protocol~The brisk walking protocol will consist of :~10 min: warming up of the knees, hips and back by flexibility exercises~30 min of walking~5 min of cool down."
89071880|NCT05738733|Experimental|MsChief Classic Natural Lubricant|MsChief Classic natural lubricant contains aqua, propylene glycol, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide. MsChief Classic natural lubricant is a special moisturizer with aloe vera, vitamin E and sea buckthorn. It not only conditions but also moisturises the skin. This lubricant is water-based is free of sugar or saccharine. This product does not contain paraben or glycerine. This product has a unique formulation pH ideal for intimate area.
89071881|NCT05738733|Experimental|MsChief Ylang Ylang Natural Lubricant|MsChief Ylang Ylang natural lubricant contains aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide. MsChief Ylang Ylang natural lubricant is a special moisturizer with aloe vera, vitamin E and sea buckthorn It not only conditions but also moisturise the skin. This lubricant is water-based contain natural flavour and free of sugar or saccharine. This product does not contain paraben or glycerine. This product has a unique formulation pH ideal for intimate area.
89071882|NCT05738733|Experimental|MsChief Vanilla & Citrus Natural Lubricant|MsChief vanilla and citrus natural lubricant contain aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide. MsChief vanilla and citrus natural lubricant is a special moisturizer with Aloe vera, vitamin E and sea buckthorn. It not only conditions but also moisturise the skin. This lubricant is water based contain natural flavour and free of sugar or saccharine. This product does not contain paraben or glycerine. This product has a unique formulation pH ideal for intimate area.
89071883|NCT05738733|Experimental|MsChief Tea & Peach Natural Lubricant|MsChief tea & peach natural lubricant contains aqua, propylene glycol, flavour, hydroxyethyl cellulose, ethyl menthane carboxamide and methyl diisopropyl propionamide, aloe barbadensis leaf juice, benzoic acid, hippophae Rhamnoides extract, tocophersolan, sodium hydroxide. MsChief tea & peach natural lubricant is a special moisturizer with Aloe vera, vitamin E and sea buckthorn. It not only conditions but also moisturises the skin. This lubricant is water-based contains natural flavour and is free of sugar or saccharine. This product does not contain paraben or glycerine. This product has a unique formulation pH ideal for intimate area.
89071884|NCT05735808|Active Comparator|Standart physicain based education|In this arm, patient education will be conducted by the physician as the gold standard.
89071885|NCT05735808|Experimental|VR based education|In this arm, patient education will be performed using 3D educational material presented in VR glasses.
89071886|NCT05731284|Active Comparator|Adjunct Platelet rich plasma (PRP) therapy|Study Interventions: PRP will be injected in a systematic grid like fashion into the fibromuscular connective tissue of the anterior compartment following vaginal incision and dissection.
89691080|NCT05017207||Patient with periampullary cancer and pancreaticoduodenectomy|Only one group of patient with periampullary cancer
89691081|NCT03256162|Experimental|Ketamine|Participants will receive four once-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
89691082|NCT03256162|Active Comparator|Midazolam|Participants will receive four once-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
89691083|NCT03493828|Active Comparator|TAP using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
89691084|NCT03493828|Active Comparator|TAP using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
88812785|NCT01548833|Experimental|Dailies Total 1|Delefilcon A, followed by narafilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
89071887|NCT05731284|Placebo Comparator|Normal saline|Placebo: Normal saline will be injected in a systematic grid like fashion into the fibromuscular connective tissue of the anterior compartment following vaginal incision and dissection.
89071888|NCT05719610|Experimental|Cawthorne Cooksey Exercises|
89071889|NCT05719610|Experimental|Swiss Ball Exercises|
89071890|NCT05706961|Experimental|Power Walking|
89071891|NCT05706961|Active Comparator|Standardized Outpatient Cardiac Rehabilitation|
89071892|NCT05706948|Experimental|High Intensity Interval Training (With Face Mask)|
89071893|NCT05706948|Experimental|High Intensity Interval Training (Without Face Mask)|
89071894|NCT05696327|Experimental|Experimental Group|tyler twist wrist extensor strengthening exercises Treatment protocol will be followed for thrice a week for 4 weeks. The session will be of approximately 20 minutes. The initial Conventional therapy program will be the same as discussed in the control group except strengthening exercise which is excluded in experimental group because of Tyler twist exercise which is being used as a strengthening protocol.
89071895|NCT05696327|Active Comparator|Control Group|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.) The treatment will continue for 4 weeks and 3 sessions/ week i.e. thrice a week. The session will be of approximately 20 minutes.
89071896|NCT05665855|Experimental|Ketone higher dose|An acute bout of exercise performed after the ingestion of a commercial supplement intended to provide ~0.6 g of ketone monoester per kg body mass of the participant.
89071897|NCT05665855|Experimental|Ketone lower dose|An acute bout of exercise performed after the ingestion of a commercial supplement intended to provide ~0.3 g of ketone monoester per kg body mass of the participant.
89071898|NCT05665855|Placebo Comparator|Control|An acute bout of exercise performed after the ingestion of a taste-matched placebo supplement.
89071899|NCT05665426|Other|AW group|(1) AW group: acupuncture at Weizhong point,
89071900|NCT05665426|Other|AC group|(2) AC group: acupuncture at Chize point,
89071901|NCT05665426|Other|MW group|(3) MW group: moxibustion at Weizhong point,
89071902|NCT05665426|Other|MC group|(4) MC group: moxibustion at Chize point.
89071903|NCT05635110|Experimental|Part A|Participants will receive a single dose of VX-548 on Day 1 and a single dose of omeprazole once daily (qd) on Days 10 through Day 12. On Day 13, participants will receive omeprazole followed by VX-548 under fasted conditions.
89071904|NCT05635110|Experimental|Part B|Participants will receive a single dose of VX-548 on Day 1 followed by rifampin qd on Days 10 through Day 27. On Day 19, participants will be co-administered rifampin and VX-548 under fasted conditions.
89071905|NCT05630807|Experimental|Bepirovirsen|
89071906|NCT05630807|Placebo Comparator|Placebo|
89071907|NCT05616702|Experimental|Pressure Biofeedback Therapy + Progressive Muscle Relaxation Technique + Thermotherapy.|"This study ARM will receive following therapies~Pressure Biofeedback Therapy~Progressive Muscles Relaxation Technique~Thermotherapy"
89071908|NCT05616702|Active Comparator|Progressive Muscle Relaxation Technique + Thermotherapy|"This study ARM will receive following therapies~Progressive Muscles Relaxation Technique~Thermotherapy"
89071909|NCT05615025|Experimental|Sevoflurane arm|In this arm, anesthesia will be maintained by sevoflurane.
89071910|NCT05615025|Experimental|Propofol arm|In this arm, anesthesia will be maintained by propofol.
89071911|NCT05602181|Experimental|ALL Phonics Instruction|Lessons for the treatment group will be 30-min. long using the ALL app with a known service provider. Lessons will include systematic instruction with four subskills per session (e.g., letter-sounds, sound blending, typing, and sight words). The words and subskills with rotate based on the data collected and the machine learning within the technology. The child will complete 100 lessons. The systematic instruction with subksills (e.g., sound blending, decoding) includes 10 trials per word and an instructional sequence that introduces the skill, two models, six trials of guided practice, and two trials of independent practice with corrective feedback.
89071912|NCT05602181|Active Comparator|ALL Sight Word|Lessons for the comparison group will be 30-min. long using the ALL app with a known service provider. Lessons will include systematic instruction with sight words. The child will also complete 100 lessons.No phonics instruction will be provided to this group through the ALL app.
89071913|NCT05583461|Experimental|PEEP level according to the low PEEP-FiO2 table|Positive end-expiratory pressure (PEEP) level selected based on patient's fraction of inspired oxygen (FiO2) according to the low PEEP-FiO2 table proposed by the Acute Respiratory Distress Syndrome Network Guidelines
89071914|NCT05583461|Experimental|PEEP minimizing the risk of overdistension and atelectasis|Positive end-expiratory pressure (PEEP) level selected based on the intersection between the curves of the cumulative percentages of compliance loss due to alveolar overdistension and atelectasis, respectively, as assessed with an electrical impedance tomography-based decremental PEEP trial
88812786|NCT01548833|Active Comparator|TruEye|Narafilcon A, followed by delefilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
89071915|NCT05583461|Experimental|PEEP minimizing the risk of overdistension|Highest positive end-expiratory pressure (PEEP) level associated with no alveolar overdistention selected based on the curve of the cumulative percentage of compliance loss due to alveolar overdistension, as assessed with an electrical impedance tomography-based decremental PEEP trial
89071916|NCT05583461|Experimental|PEEP minimizing the risk of atelectasis|Lowest positive end-expiratory pressure (PEEP) level associated with no alveolar collapse selected based on the curve of the cumulative percentage of compliance loss due to alveolar collapse, as assessed with an electrical impedance tomography-based decremental PEEP trial
89071917|NCT05549414|Experimental|Patients with locally recurrent, previously irradiated thoracic cancer|Prospective study shall evaluate treatment efficacy, toxicity, QOL and plan parity in patients with recurrent thoracic cancer previously irradiated, undergoing proton radiation therapy
89071918|NCT05549414|Experimental|Patients with recurrent Head and Neck, Brain and Spinal Cord tumors, indicated for re- irradiation|The prospective study shall evaluate treatment Efficacy, Toxicity, Quality of Life (QOL), and plan parity in adult patients with recurrent Head and Neck and Brain cancer undergoing proton radiation therapy
89071919|NCT05549414|Experimental|Patients with unresectable pancreatic cancer|This prospective study shall evaluate treatment feasibility utilizing the CBGS for unresectable pancreatic cancer with concurrent chemotherapy
89071920|NCT05541627|Experimental|Cohort 1|Low-dose of AB-1001
89071921|NCT05541627|Experimental|Cohort 2|High-dose of AB-1001
89071922|NCT05521256|Experimental|NNC0113-6856 (Oral Cohort)|Participants will receive single oral dose of NNC0113-6856 tablets in dose escalated manner.
89071923|NCT05521256|Placebo Comparator|Placebo|Participants will receive single oral dose of placebo (NNC0113-6856) tablets in dose escalated manner.
89071924|NCT05521256|Experimental|NNC0113-6856 (i.v. Cohort)|Participants will receive single dose of 1.5 milligrams (mg) NNC0113-6856 intravenously (i.v.).
89071925|NCT05519644|Active Comparator|Placebo First|Patients will be randomize to take the placebo for the first trial of the intervention, then after a 2 week washout, participants will perform the same intervention but with a ketone ester.
89071926|NCT05519644|Experimental|Ketone Ester First|Patients will be randomize to take the ketone ester for the first trial of the intervention, then after a 2 week washout, participants will perform the same intervention but with a placebo
89071927|NCT05501002|Experimental|Device Arm|The Device Arm receives the eShunt® Implant
89071928|NCT05485441|Experimental|Students|The students
89071929|NCT05485441|Experimental|Parents|The parents
89071930|NCT05456815|Other|Standardized diet|Standardized food products/meals will be tested
89071931|NCT05453071|Active Comparator|BETY Group|Since 2004, group exercise sessions have been organized as a routine form of treatment for individuals diagnosed with rheumatism in the Department of Physiotherapy and Rehabilitation of Hacettepe University. The first evaluation will be made if the individuals who come to the routine doctor's examination agree to participate in the study. According to being included in one of the two groups as those who decided to attend the BETY sessions that have been going on for 18 years and those who did not agree to attend the sessions; The individuals included in the BETY group (Group 1) will be evaluated on the day of the last exercise session after their participation in the 12-week exercise group.
89071932|NCT05453071|No Intervention|Control Group|Individuals (Group 2), who do not agree to participate in BETY sessions but agree to participate in evaluations with 12-week intervals, will be evaluated when they come for their routine check-ups at 12-week intervals, and recommendations given routinely.
89071933|NCT05429372|Experimental|PF-06939926|
89071934|NCT05423925||monopolar|monopolar electrodes, and have their corresponding distension media.
89071935|NCT05423925||bipolar|bipolar electrodes, and have their corresponding distension media.
89071936|NCT05413603|Active Comparator|fluoroscopic focus Shock wave lithotripsy|Shock wave lithotripsy, accurate localization of the shock waves is performed by the fluoroscope (FS) to fully focus the shock waves on the stone
89071937|NCT05413603|Active Comparator|ultrasonic focus Shock wave lithotripsy|Shock wave lithotripsy, accurate localization of the shock waves is performed by the ultrasound (US), to fully focus the shock waves on the stone
89071938|NCT05410938||Intraperitoneal group|The intraperitoneal regimen was given as 135 mg/m2 intravenous paclitaxel over a 3 or 24 hours period on day 1, followed by 75-100 mg/m2 intraperitoneal cisplatin on day 2 and 60 mg/m2 intraperitoneal paclitaxel on day 8. For women with significantly impaired renal function (i.e., estimated glomerular filtration rate<50 mL/min/1.73 m2), carboplatin (area under the curve [AUC]=6) was used instead of cisplatin.
89071939|NCT05410938||Triweekly group|The triweekly intravenous chemotherapy regimen was given as 175 mg/m2 paclitaxel and carboplatin at a dose calculated to produce an AUC of 6 mg/mL/min on day 1. Bevacizumab was given at a dose of 7.5mg/kg intravenously on day 2 since cycle 2. The treatments were repeated every 3 weeks for 6 cycles. Those women without achievement of complete response after 6 cycles of chemotherapy might be treated with an additional 1-2 cycles of chemotherapy. Bevacizumab was continued for 12 additional cycles or until disease progression, death, unacceptable toxic effects, or patient voluntary withdrawal [5].
89071940|NCT05393193|Other|HIV-exposed neonates|Point-of-care HIV testing at birth
89071941|NCT05393193|Other|HIV-positive infants identified through birth HIV screening|Early antiretroviral treatment per standard of care, including dolutegravir-based regimen beginning at 4 weeks of age for infants weighing at least 3.0kg.
89071942|NCT05385718||Observational|The observational group may include those 18 years and older, with retrospective MRI data, or those whom prospective MRI images are collected as a participant. This study is decentralized, non-therapeutic and non-interventional.
89071943|NCT05381753||Ava-mGSIT-P18|Unresectable or metastatic PDGFRA exon 18 GIST
89071944|NCT05381753||Ava-Perioperative|Perioperative PDGFRA exon 18 GIST
89071945|NCT05381753||Ava-mGIST-other|Unresectable or metastatic GIST without KIT exon 13，14，or PDGFRA exon 18 mutation
89071946|NCT05381753||TKI|Unresectable or metastatic PDGFRA exon 18 GIST
89071947|NCT05350813|Experimental|PCT-guided arm|Group of patients whose duration of antibiotic therapy will depend on procalcitonin (PCT) plasma levels on days 0 and 1, then on PCT plasma level every 48 hours and on patient clinical evolution evaluated by the fever, the infected organ, and the pSOFA (Pediatric Sequential Organ Failure Assessment) score every day until cessation of antibiotics in hospital or until discharge from hospital if the patient is discharged with an antibiotic treatment.
89071948|NCT05350813|Active Comparator|standard-of-care arm|A group of patients whose duration of antibiotic therapy will be determined by the type of infection, microbiological findings and clinical, biological and/or radiological course, according to standard practice based on guidelines.
89071949|NCT05350267|Experimental|Treatment|HALO is a mixed-delivery intervention (online learning, digital technologies, telehealth visits) co-designed with mothers that (a) uniquely tailors intervention content to integrate post-bariatric surgery guidelines to recommendations to reduce child obesity risk, (b) teaches mothers evidence-based parenting behaviors to support intergenerational lifestyle and home food environment changes, and (c) addresses unique barriers to family-level change identified by mothers post-bariatric surgery.
89071950|NCT05350267|Active Comparator|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
89071951|NCT05333107|Experimental|Sequence 1|Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2).
89071952|NCT05333107|Experimental|Sequence 2|Participants will receive oral dose of NNC0385-0434 G tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2).
89071953|NCT05333107|Experimental|Sequence 3|Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 B tablet orally in the 5-day treatment period (period 2).
89071954|NCT05333107|Experimental|Sequence 4|Participants will receive oral dose of NNC0385-0434 F tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2).
89071955|NCT05333107|Experimental|Sequence 5|Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 G tablet orally in the 5-day treatment period (period 2).
89071956|NCT05333107|Experimental|Sequence 6|Participants will receive oral dose of NNC0385-0434 B tablet for the initial 10-day treatment period (period 1) and the NNC0385-0434 F tablet orally in the 5-day treatment period (period 2).
89071957|NCT05318352|Experimental|Transcranial Direct Current Stimulation (tDCS)|Athletes with poor sleep quality will receive tDCS over the right and left prefrontal cortex (F3 and F4 areas) with a constant current of 1.5 mA intensity that lasts for 20 minutes, 3 times a week for 2 weeks in daytime.
89071958|NCT05318352|Sham Comparator|Sham transcranial Direct Current Stimulation (tDCS)|Athletes with poor sleep quality will receive sham tDCS over the right and left prefrontal cortex.
89071959|NCT05305963||Case|250 women diagnosed with BC when they were aged 30-39 years
89071960|NCT05305963||Control|750 controls currently aged 30-39 years
89071961|NCT05295420|Experimental|platelet-rich plasma|to assess the role of platelet-rich plasma in the treatment of SUI as a non-invasive method
89071962|NCT05295004|No Intervention|No Treatment|Patient will receive no mindfulness meditation training.
89071963|NCT05295004|Experimental|Mindfulness at Pre-Op|Patient will receive a one time training at their pre-operative appointment.
89071964|NCT05295004|Experimental|Multiple Mindfulness Meditation|Mindfulness Video Training at Pre-Op, 1 Day Prior to surgery, 3 day's Post OP and 2 Weeks Post OP.
89071965|NCT05278312|Experimental|Otago Exercise Program|Older adults will receive the Otago Exercise Program for 8 weeks plus health awareness videos.
89071966|NCT05278312|No Intervention|Control group|Older adults will receive only health awareness videos every 2 weeks.
88812787|NCT01548833|Active Comparator|Clariti|Filcon II 3, followed by narafilcon A and delefilcon A in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
89071967|NCT05278013|Experimental|Glue Group (GG)|Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
89071968|NCT05278013|No Intervention|No Glue Group (NG)|Randomization will take place utilizing serial randomization to Glue Group (GG) and No Glue Group (NG) where skin closure will be assigned serially to a week of GG alternating with a week NG.
89071969|NCT05276206|Active Comparator|NSAID|The Control group will be given nothing and only non-steroidal anti-inflammatory drugs on need
89071970|NCT05276206|Active Comparator|Nalufin|group will be given IV nalufin
89071971|NCT05276206|Active Comparator|local anesthetic group|the local anesthetic group will be given a S.C injection of local anesthetic in the wound
89071972|NCT05276206|Active Comparator|TAP block|Total abdominal plain block group will be given a TAP block
89071973|NCT05274178|Experimental|Naive listeners|"Participants who have never worn a hearing aid before. This group will be tested with both sets of devices, those labeled as OTC and those labeled as Prescriptive"
89071974|NCT05274178|Experimental|Experienced users|"Participants who have at least six months experience wearing hearing aids. This group will be tested with both sets of devices, those labeled as OTC, and those labeled as Prescriptive"
89071975|NCT05265689|Experimental|Bike Club|Participants will receive a 12-hour bicycle safety education program
89071976|NCT05265689|Experimental|Bike Club Plus|Participants will receive an enhanced version of the 12-hour bicycle safety education program which will include a parent training session on bicycling safety best practices, child development as it relates to bicycling, strategies for practice at home, and feedback on their adolescent's bicycling performance.
89071977|NCT05265689|No Intervention|Control Group|The control group will not receive any bicycle safety education programming.
89071978|NCT05262062|Experimental|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.3. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.Once the position of ease was identified, it was held for 20 to 30 seconds."
89071979|NCT05262062|Experimental|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
89071980|NCT05262062|Experimental|Integrated Neuromuscular Inhibition Technique|"1. Group c will receive Combination of exercise (strain counter strain , muscle energy & ischemic compression. In ischemic compression patient will receive compression,2. After MTrPs identification, 3. Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~4. The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright."
89071981|NCT05250505|Experimental|Treatment Arm|The Treatment Arm receives the eShunt Implant.
89071982|NCT05249829|Experimental|Part 1: mRNA-1273.529|"Phase A: Participants will receive 1 intramuscular (IM) dose of mRNA-1273.529 on Day 1.~Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
89224055|NCT03454256|Experimental|Virtual Reality Group (VRG)|The Virtual Reality Group (VRG) will perform the rehabilitation trough the Virtual Reality Rehabilitation system (VRRS, Khymeia,Italy). The patient standing upright on a balance board will practice exercises of vertical position control with a visual biofeedback received from the VRRS and interacting with the serious video-games. The difficulty level of the exercises will increase gradually session by session. Every session will last 45 minutes with a frequency of at least 5 times a week.
89224056|NCT03454256|No Intervention|Control Group (CG)|The Control Group (CG) will perform the traditional treatment consisting of the exercises of rehabilitation of gait and postural passages, exercises for postural control, and proprioceptive exercises in a vertical position according to the method chosen by the physiotherapist. Every session will last 45 minutes with a frequency of at least 5 times a week.
89071983|NCT05249829|Active Comparator|Part 1: mRNA-1273|"Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1.~Phase B: After Day 179, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
89071984|NCT05249829|Experimental|Part 2: mRNA-1273.214|"Phase A: Participants will receive 1 IM dose of mRNA-1273.214 on Day 1.~Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
89071985|NCT05249829|Active Comparator|Part 2: mRNA-1273|"Phase A: Participants will receive 1 IM dose of mRNA-1273 on Day 1.~Phase B: After Day 85, eligible participants may choose to be unblinded and to receive an additional booster outside of the study."
89071986|NCT05246111|Experimental|M6620, [14C]M6620 and Topotecan|
89071987|NCT05243303|Experimental|Active taVNS|These patients will self-administer transcutaneous auricular vagus nerve stimulation (taVNS).
89071988|NCT05243303|Sham Comparator|Sham taVNS|These patients will self-administer a sham procedure mimicking the active taVNS procedure.
89071989|NCT05228015|Experimental|Experimental: IK-930 Single Agent Dose Escalation|
89071990|NCT05228015|Experimental|Experimental: IK-930 Single Agent Dose Expansion|
89071991|NCT05211466||Depressive disorder, major|Patients with major depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
89071992|NCT05211466||Depressive disorder, bipolar|Patients with bipolar depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
89071993|NCT05211466||Depressive disorder, recurring|Patients with recurring depression admitted into round-the-clock care, before and after the introduction of a digital healthcare platform.
89071994|NCT05211466||Digital care staff|Staff working most of their time (20% or more) with the digital healthcare platform.
89071995|NCT05211466||Traditional care staff|Staff working traditionally, using the digital healthcare platform to a very little extent.
89071996|NCT05207436|Experimental|Brief Cognitive Behavioral Conjoint Therapy for PTSD plus Intranasal Oxytocin|Couples will receive Brief Cognitive-Behavioral Conjoint Therapy (B-CBCT) weekly. Prior to each session, the Veteran participant will self-administer intranasal oxytocin. The estimated length of treatment participation is 8 to 15 weeks. All procedures take place in the Veterans home via home-based clinical video teleconferencing (CVT).
89071997|NCT05206331|Experimental|contrast enhanced mammography|Women who have been recently diagnosed with a suspicious abnormality for which they have scheduled a breast biopsy and meet inclusion criteria will be invited to have a contrast enhanced mammography before their scheduled biopsy procedure.
89071998|NCT05206123||Adolescents with perinatal acquired HIV infection|group of Adolescents with perinatal acquired HIV infection
89071999|NCT05184998||Hypokalemia group|defined as sK range (0, 3.5] mmo/L
89072000|NCT05184998||Normokalemia group|defined as sK range (3.5, 5.0] mmo/L
89072001|NCT05184998||Hyperkalemia group|defined as sK range (5.0, ~) mmo/L
89072002|NCT05165927|Experimental|BFR Group|BFR cuffs will be used for specific exercises and added to the current SOC for post hip scope PT.
89072003|NCT05165927|No Intervention|SOC Group|Current SOC for post hip scope PT will be assigned.
89072004|NCT05163301|Experimental|Computer delivered RPI|2 session computer delivered counseling to prevent relapse to hazardous drinking
89072005|NCT05163301|Experimental|Person delivered RPI|2 session counselor delivered counseling to prevent relapse to hazardous drinking
89072006|NCT05163301|No Intervention|Treatment as Usual|Counseling for alcohol use available in clinic as treatment as usual
89072007|NCT05145738|Experimental|C-Raven + Avatar|Computer delivered intervention with Avatar as virtual counselor plus linkage to community health worker
89072008|NCT05145738|Active Comparator|C-Raven|Computer-delivered intervention without virtual counselor, with linkage to community health worker
89072009|NCT05139498|Experimental|Conservative Management for Placenta Accreta Spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
89072010|NCT05139498|Active Comparator|Hysterectomy at time of delivery for Placenta Accreta Spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
89072011|NCT05129969||Ovarian cancer|"Female patients with high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):~with newly diagnosed FIGO stage IIb-IV OC who are starting systemic treatment, independent of the treatment intention (adjuvant/curative or palliative) or~with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting their systemic treatment for first recurrent/relapsed disease."
89072012|NCT05129969||Endometrial cancer|Female patients with locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.
89072013|NCT05103618|Active Comparator|Healthy Control Couple Pairs|All healthy control subjects, 6 couple pairs (12 subjects) healthy controls in which neither member has Parkinson's Disease will receive a baseline and follow up FDOPA PET scan. All subjects will be asked to complete the surveys. The control group will receive training materials in the practice of OM which the couple will be asked to practice for the next 2-3 months. The couple-pair will begin the OM practice initially (in between the baseline and follow up scans. FDOPA scans and surveys will be conducted with both members of the couple pair at approximately 2-3 months.
89072014|NCT05103618|Active Comparator|Active Couple Pairs Parkinson's Group|"15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD.~The female subject will undergo the baseline scan. Both members of the couple will complete surveys. The active group will receive training materials in the practice of OM which they will be asked to practice for the next 2-3 months The active couple-pair will begin the OM practice initially (in between the baseline and follow up). FDOPA scans will be conducted with female members with PD the couple pair at approximately 2-3 months."
89072015|NCT05103618|Other|Waitlist Couple Pairs Parkinson's Group|15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD. The female subject will undergo the baseline scan. Both members of the couple will complete surveys The waitlist period in which the female member with PD will continue to receive standard of care for those 2-3 months; who then receive follow up scan. After the follow up scan, the waitlist group may be trained in the practice of OM for the next two months (but there will not be an additional FDOPA scan). Couple-pairs in the waitlist group will be asked to complete surveys at baseline and follow up scan and again after completing the OM Meditation practice. Couple pairs will engage in OM Meditation together approximately 3-4 times a week after the baseline and follow up scans for 2-3 months but female subjects with PD will not receive and additional post OM Meditation FDOPA scan
89072016|NCT05082181|Experimental|Arm 1: UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is a telephone-based depression self-management program for people with epilepsy.
89072017|NCT05082181|Active Comparator|Arm 2: BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program for people with epilepsy.
89072018|NCT05057221|Experimental|Uproleselan|Uproleselan injection is a sterile solution for IV administration, supplied in single-dose vials at a concentration of 50 mg/mL.
89072019|NCT05054842|Experimental|treatment group A|
89072020|NCT05054842|Placebo Comparator|treatment group B|
89072021|NCT05040477|Experimental|Experimental Group (1): Muscle energy techniques,Moist Hot pack and TENS.|"Experimental group included Moist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45C.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle.These pre and post intervention values were mentioned in questionnaire. The participants were administered with muscle energy technique (PIR) and data was collected again 2 and 4 weeks after the interventions."
89224057|NCT03446690|Experimental|MI Varnish Group|33 subjects were prospectively recruited for the project in the MI Varnish group. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, UAB. MI Varnish were applied on their teeth initially for 4 weeks (twice) and then 3 monthly intervals.
89072022|NCT05040477|Experimental|Experimental Group (2): Facets joint mobilizations, Moist Hot pack and TENS.|"Experimental group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Facet joint mobilization (UPA & SNAGS) and data was collected again 2 and 4 weeks after the interventions."
89072023|NCT05040477|Active Comparator|Control Group:Conventional Therapy (Stretching, strengthening , Moist Hot pack and TENS)|"Control group includedMoist Hot pack of 14/15' over cervical region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Conventional TENS applied for 10 mins.~Baseline NPRS, NDI, Cervical ROMs, and posterior tangent angle. These pre and post intervention values were mentioned in questionnaire. The participants were administered with Conventional (sustained stretching and isometric strengthening) physical therapy and data was collected again 2 and 4 weeks after the interventions."
89072024|NCT05039528|Experimental|Intervention|Participants will receive the personalized OSA messages.
89072025|NCT05039528|Placebo Comparator|Control|Placebo participants will receive no treatment during the experiment.
89072026|NCT05024916|Experimental|Intervention|Participants will receive the dietary intervention. Participants will take 1 serving of blueberries/day.
89072027|NCT05024916|Active Comparator|Control|Participants will receive a placebo. Participants will take 1 serving of placebo/day.
89072028|NCT05015478|Active Comparator|Active Tailored Rhythmic Lighting|1 hour intervention period where active lighting is experienced by participants.
89072029|NCT05015478|Placebo Comparator|Inactive Placebo Rhythmic Lighting|1 hour intervention period where an inactive, placebo lighting condition is experienced by participants.
89072030|NCT04957745|Experimental|Visual confusion|Participants viewed peripheral targets in three different visual confusion conditions (three interventions): binocular visual confusion (unilateral opaque target), unilateral monocular visual confusion (unilateral see-through target), and bilateral monocular visual confusion (bilateral see-through target). Each intervention was presented twice in a randomized order, resulting in a total of six trials. During each trial, a peripheral target was presented in front of a forward-moving background for one minute. Participants were instructed to hold down the controller button while the target was visible and release it when a third or more of the target disappeared. After each trial, participants could take a brief break before the next trial in a different visual confusion condition was presented in a randomized order.
89072031|NCT04950166|Experimental|Fluorescence imaging with pegsitacianine|1 mg/kg of pegsitacianine administered IV 24-72 hours prior to surgery.
89072032|NCT04945655|Experimental|Arm 1: component 1 + component 2 + component 3|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2) + Access to vaccination at school (component 3)
89072033|NCT04945655|Experimental|Arm 2: component 1 + component 2|Adolescents and parents' education and motivation at school (component 1) + General practitioners' training (component 2)
89072034|NCT04945655|Experimental|Arm 3: component 1 + component 3|Adolescents and parents' education and motivation at school (component 1) + Access to vaccination at school (component 3)
89072035|NCT04945655|Experimental|Arm 4: component 1|Adolescents and parents' education and motivation at school (component 1)
89072036|NCT04945655|Experimental|Arm 5: component 2|General practitioners' training (component 2)
89072037|NCT04945655|No Intervention|Arm 6: Control|No intervention
89072038|NCT04945642|Experimental|Treatment (HDR-BT, SBRT)|Patients undergo HDR-BT for up to 24 hours and undergo SBRT every other day or consecutive days for up to 14 consecutive chronologic days in the absence of disease progression or unacceptable toxicity.
89072039|NCT04915508|Experimental|Treatment (SBRT, hormone therapy)|Patients undergo SBRT every other day or on consecutive days for up to 14 days. Patients may receive hormonal therapy at the discretion of the treating physician.
89072040|NCT04864028|Experimental|Healthy volunteer|
89072041|NCT04818008|Experimental|Otago Exercise Program|Patients will receive the Otago Exercise Program for 8 weeks plus health awareness videos about topics related to MS.
89072042|NCT04818008|No Intervention|Control group|Patients will receive health awareness videos only about topics related to MS.
89072043|NCT04793867||CF and Non-CF Bronchiectasis|In the first arm (Aims 1 & 2) Up to 50 subjects will be recruited-approximately 25 with normal FEV1 (>85% predicted) and 25 with mild to moderate disease. All subjects will be asked to undergo longitudinal (i.e., approximately annually) 129Xe and UTE MRI, spirometry, and lung clearance index (LCI) measurement.
89072044|NCT04793867||Healthy Subjects|Up to 50 age and sex matched control subjects (i.e., subjects with no known cardiopulmonary disorders) may also be recruited to provide a reference data set from healthy subjects for comparison.
89072045|NCT04792918||NEC/LOS preterm infants|Collection of biological samples (stool, stomach fluid, blood) and health-related data over the first few weeks of life, additional stool samples after onset of NEC/LOS
89072046|NCT04792918||Preterm infants not developing NEC/LOS|Collection of biological samples (stool, stomach fluid, blood) and health-related data over the first few weeks of life
89072047|NCT04792918||Family members of preterm infants|Collection of biological samples (stool, breastmilk, vaginal swab) and health-related data at one timepoint after the birth of the preterm infant from members of the family (mother, father)
89072048|NCT04790526|Experimental|Group A|This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 3 sessions per week up to 12 weeks.
89072049|NCT04790526|Experimental|Group B|This group includes 15 female participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 3 sessions per week up to 12 weeks.
89072050|NCT04790526|Experimental|Group C|This group includes 15 male participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 5 sessions per week up to 12 weeks.
89072051|NCT04790526|Experimental|Group D|This group includes 15 female participants who will be given 10 minutes of warm and cool down sessions that includes stationary bicycle without resistance and stretching. Intervention will be given with declination of treadmills at 16 degree and 3 session of 10 minutes duration will be given with 1 minutes of rest in each group. Intervention will be given for 5 sessions per week up to 12 weeks.
89072052|NCT04758611|Experimental|Treatment Arm|The Treatment Arm receives the eShunt implant
89072053|NCT04752462|No Intervention|Standard of Care with provider|Participant will continue follow up for sleep apnea with provider.
89072054|NCT04752462|Experimental|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
89072055|NCT04749433|Experimental|Participants with diagnosis of ALS|Participants with a diagnosis of ALS will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
89072056|NCT04749433|Experimental|Healthy Participants without a diagnosis of ALS|Healthy participants (without a diagnosis of ALS) will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
89072057|NCT04700800|Experimental|Exercise, Infusion of Amino Acids|Exercise followed by infusion of amino acids, or infusion of amino acids alone.
89072058|NCT04700800|Active Comparator|Exercise|Exercise with no infusion of amino acids
89072059|NCT04698018|Experimental|Faster aspart|Subjects will receive 2 injections of a single dose of faster aspart at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
89072060|NCT04698018|Active Comparator|NovoRapid®|Subjects will receive 2 injections of a single dose of NovoRapid® at a predefined fixed dose level (0.2 U/kg body weight) for type 1 diabetes and (0.3 U/kg body weight) if subject has type 2 diabetes.
89072061|NCT04657367||Diabetes|Patients with diagnosed diabetes
89072062|NCT04657367||Prediabetes|Patients with diagnosed prediabetes defined as impaired fasting glucose and/or impaired glucose tolerance
89072063|NCT04657367||Normoglycemia|Patients with normoglycemia, based on the OGTT - normal fasting glucose and normal glucose tolerance
89072064|NCT04634591||Obesity - undergoing bariatric surgery|Patients with morbid obesity, treated with the bariatric surgery
89072065|NCT04634591||Obesity - without bariatric surgery treatment|Patients with morbid obesity, not treated with the bariatric surgery
89072066|NCT04634591||Non-obese|Non-obese patients - control group (without obesity and without the bariatric surgery treatment)
89072067|NCT04600518||Low risk|good prognosis with surgery only and adjuvant chemotherapy patients
89072068|NCT04600518||Intermediate risk|moderate prognosis
89072069|NCT04600518||High risk|poor prognosis
89072070|NCT04577729|Experimental|Allogenic FMT group|Allogenic FMT group: patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
89072071|NCT04577729|Placebo Comparator|Autologous FMT group|Autologous FMT group: patients receiving their own stool in terms of sham FMT.
89072072|NCT04566159|Experimental|CBI + CHW|2 Session Computer Delivered Intervention with use of Nicotine Replacement Therapy and Community Health Worker Follow Up
89072073|NCT04566159|Other|Routine Care|Routine Tobacco Cessation Advice to Stop Smoking and Nicotine Replacement Therapy as offered by the inpatient team
89072074|NCT04561453||Resected Biliary Duct Cancer|
89072075|NCT04526860|No Intervention|Standard Infant Feed Group|Infants will receive human milk or formula milk ad libitum.
89072076|NCT04526860|Other|Calibrated Infant Feed Group|Infants will have reduced human milk or formula milk intake.
89072077|NCT04520490|Active Comparator|Exenatide once weekly extended-release|Weekly subcutaneous injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (2mg) for 24 weeks in randomized intervention.
89072078|NCT04520490|Placebo Comparator|Matching placebo|Weekly subcutaneous injections of placebo for 24 weeks.
89072079|NCT04483778|Experimental|SCRI-CARB7H3(s)|Autologous CD4+ and CD8+ T-cells genetically modified to express an B7H3-specific CAR
89072080|NCT04483778|Experimental|SCRI-CARB7H3(s)x19|Autologous CD4+ and CD8+ T-cells genetically modified to a bispecific B7H3xCD19 CAR
89072081|NCT04483778|Experimental|SCRI-CARB7H3(s)x19 plus pembrolizumab|Autologous CD4+ and CD8+ T-cells genetically modified to express a bispecific B7H3xCD19 CAR given in combination with pembrolizumab
89072082|NCT04480554|Experimental|Methadone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone (MET) and antiretroviral therapy (cART).
89072083|NCT04480554|Experimental|Buprenorphine/naloxone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone and antiretroviral therapy (cART).
89072084|NCT04480554|Experimental|XR-Naltrexone|Participants in this arm will receive a 48-week integrated treatment program for opiate use disorder with monthly injection extended-release naltrexone (XR-NTX) and antiretroviral therapy (cART).
89072085|NCT04477889||COVID-19 Cohort|Patients treated at MHS facilites for COVID-19
89072086|NCT04477889||Synopsis for COVID Bariatric, Hepato-Biliary and Colorectal surgery study|"30 Day Mortality after surgery in patients with COVID19 infection who undergo elective bariatric, hepato-biliary and colorectal surgery.~Patients diagnosed with COVID-19 at the time of surgery up to seven days before surgery~Patients diagnosed with COVID-19 within 30 days after surgery"
89072087|NCT04472000|Experimental|Vitamin C|Patients who are assigned to the experimental treatment group will be given extended release capsules with 500 mg of ascorbic acid orally two times daily, packed in PET/PP-bottles identical as used for the licenced product.
89072088|NCT04472000|Placebo Comparator|Placebo|The control intervention of this study consists of treatment with no active substance (placebo) but in the same schedule as the experimental treatment (verum).
89072089|NCT04463446|Experimental|The app arm|Use of CHD app
89072090|NCT04463446|Active Comparator|Nurse-led intervention arm|Nurse-led intervention
89072091|NCT04427930|Experimental|JOINTSTEM|Long Term Follow-up after Jointstem Transplantation
89072092|NCT04398394|Experimental|Group 1|Individuals with healthy retina, 18 to 50 years old.
89072093|NCT04398394|Experimental|Group 2|Individuals with healthy retina and presenting with myopia, 18 to 50 years old.
89072094|NCT04398394|Experimental|Group 3|Individuals with healthy retina, over the age of 50.
89072095|NCT04398394|Experimental|Group 4|Patients with early and intermediate AMD, over the age of 50.
89072096|NCT04398394|Experimental|Group 5|Patients with other retinopathies than AMD, over the age of 18.
89072097|NCT04378452||COM-COVID cohort|Individuals of >16 years old evaluated during the COVID-19 outbreak by an anonymous survey and willing to respond. Expected timeframe for the collection of completed surveys: March 31th, 2020-September 30th, 2020]
89072098|NCT04371861||Treatment of lower extremity lesion via transradial access.|Interventions performed are standard of care for treatment of a peripheral lesion.
89072099|NCT04355195||Cohort before training|500 patients should be asked to participate in the project in the phase of zero value measurement. The documentation of the routine data before the training phase relates to patients aged ≥70 years, male and female, who are undergoing surgery.
89072100|NCT04355195||Cohort after training 1|From October 1st, 2020, the documentation of the routine data will begin after the training phase: 2,500 patients in 12 months, each aged ≥70 years, male and female, who will have surgery until the end of the contract on June 30th, 2023.
89072101|NCT04355195||Cohort after documentation of routine data until June 2023|From July 1st, 2023, the documentation of the routine data will go on: 1,700 patients in 12 months, each aged ≥70 years, male and female, who will have surgery until the end of the contract on June 30th, 2028.
89072102|NCT04340362|Experimental|VX-147|All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks. Part A was enrolled in 2 cohorts: Cohort 1 and Cohort 2. Cohort 1 included participants with urine protein to creatinine ratio (UPCR) approximately greater than or equal to (≥) 3 g/g (± 10%) and less than (<) 10 g/g and estimated glomerular filtration rate (eGFR) approximately ≥30 mL/min/1.73 m2 (± 10%). Cohort 2 included participants with UPCR approximately ≥0.8 g/g (± 10%) and <2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2.
89072103|NCT04290806||ESCC|250 patients with esophageal squamous cell carcinoma
89072104|NCT04290806||GAC|250 patients with gastric adenocarcinoma
89072105|NCT04290806||GEJAC|250 patients with gastroesophageal junction adenocarcinoma
89072106|NCT04290806||EAC|150 patients with esophageal adenocarcinoma
89072107|NCT04272216||Treatment with HydroPearl via radial access|all patients will be in the same group/cohort in this open-label, single-arm, observational registry.
89072108|NCT04269031|Experimental|Cohort 1|On Day 1, randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
89072109|NCT04269031|Experimental|Cohort 2|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
89072110|NCT04269031|Experimental|Cohort 3|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
89072111|NCT04269031|Experimental|Cohort 4|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
89072112|NCT04269031|Experimental|Cohort 5|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
89072113|NCT04269031|Experimental|Cohort 6|On Day 1, randomized subjects will receive a SC injection of AZD2373 dose 6 (6 subjects) or matching placebo (2 subjects).
89072114|NCT04268498|Experimental|Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)|Participants in this group will receive Bortezomib, Lenalidomide and Dexamethasone on a 21 day treatment cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
89072115|NCT04268498|Experimental|Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)|Participants in this group will receive Carfilzomib, Lenalidomide and Dexamethasone on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
89072116|NCT04268498|Experimental|Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)|Participants in this group will receive Carfilzomib, Lenalidomide, Dexamethasone with Daratumumab, Acetaminophen, Diphenhydramine and Montelukast on a 28 day cycle. Participants achieving a PR or better at the end of 4 cycles will continue to receive a total of 8 cycles of combination therapy. Participants with less than PR after completing 4 cycles will go off study therapy. After 8 cycles of therapy, participants who are MRD positive will have the option to receive an ASCT if stem cells were able to be extracted, before initiating maintenance therapy with Lenalidomide for up to 2 years, and patients who are MRD negative will go directly on to receive maintenance therapy with Lenalidomide for up to 2 years.
89072117|NCT04264819|Experimental|RTH258/Brolucizumab|This is a single arm study in which all patients will be treated with brolucizumab 6mg; 3 loading injections (at Screening/Baseline, week 4 and week 8) followed by treat-to-control phase with adjustable treatment frequency based on disease activity from every 8 to up to 16 weeks; last treatment at week 44/46 based on the treatment regimen.
89072118|NCT04220931|Experimental|botulinum toxin injection|"Injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.~The endoscopic procedure will be performed under unconscious sedation with intravenous injection of propofol by an anesthesiologist."
89072119|NCT04220931|No Intervention|standard care|standard care (no endoscopy)
89072120|NCT04198688||With cancer|Patients diagnosed with cancer (with at least one of the following ICD-10 diagnoses: C00-43; C46.1-99; D09)
89072121|NCT04198688||Without cancer|Patients without cancer (without any of the following ICD-10 diagnoses: C00-99; D09; D30.1-9; D32-33; D35.2-4; D41.1-9; D44.3-5)
89072122|NCT04194775|Experimental|Nofazinlimab (CS1003)|
89072123|NCT04194775|Placebo Comparator|Nofazinlimab (CS1003) placebo|
89072124|NCT04146545|Experimental|Cases|"Community Rx-Dementia CRxD Caregiver Resources"
89072125|NCT04146545|No Intervention|Control|Usual Standard Care
89072126|NCT04104217||patients|Participate in 30-60 minute interviews after each music therapy session.
89072127|NCT04104217||caregivers|Participate in 30-60 minute interviews after each music therapy session (ideally within 3 days).
89072128|NCT04104217||nurses|Participate in 10-15 minute interviews after initial music therapy session.
89072129|NCT04104217||music therapists|Music therapist will notify the researcher if he/she has provided music therapy for a patient who is identified as having delirium. Music therapists will also be interviewed about the clinical process after initial and follow up music sessions.
89072130|NCT04098432|Experimental|Arm 1|4-weeks stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks
89072131|NCT04083534|Experimental|REGN5459|Cohorts of multiple REGN5459 dose levels
89072132|NCT04073628|Active Comparator|Active Lighting intervention|The active lighting intervention will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. Combining spectrum and light level, the intervention will allow us to: (1) use a light source that will stimulate the circadian system and (2) provide the participants with options as to how the light treatment will be delivered
89072133|NCT04073628|Placebo Comparator|Control Lighting Intervention|The control lighting intervention will consist of low levels of a warm light source designed not to impact the circadian system.
89072134|NCT04069702|Experimental|VR Blue|VR Blue is a protocol for patients with advanced stage colorectal cancer who experience persistent pain. Participants will complete a single 30-minute laboratory-based virtual reality underwater/sea environment (VR Blue) session. VR Blue is an immersive computer-generated environment featuring calming scenic graphics and relaxing nature music.
89072135|NCT04048356|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
89072136|NCT04048356|Active Comparator|Povidone Iodine|Povidone iodine vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
89072137|NCT03985761|Experimental|Home Telerehabilitation_Motivation Enhanced HTme|The Home Telerehabilitation Motivation Enhanced (HTme) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTme group will use three simulations that will provide the user with eight to twelve levels of gradually increasing difficulty and complexity. A screen announces each level change and the graphics for each new level change substantially. Scoring opportunities increase at each new level.
89072138|NCT03985761|Active Comparator|Home Telerehabilitation_Unenhanced (HTu)|The Home Telerehabilitation Motivation Enhanced (HTu) group will use the NJIT-HoVRS system to play a series of three games to train movement of their shoulder, elbow, wrist and fingers. The study team will set up the apparatus in their home at the initial visit and train them to use the system. After this, subjects will practice in their homes with on-line or in-person support as needed (once a week in person for the first month, and then an average of two times per month in person and two times per month on line). Subjects will be instructed to perform three of the simulations assigned to them as much as possible, but at least twenty minutes, daily for twelve weeks. The HTu group will use three simulations. Difficulty will be increased utilizing an adaptive control algorithm that increases difficulty based on performance. Difficulty changes are extremely incremental making them imperceptible for most subjects. Graphics and scoring do not change as difficulty level changes.
89072139|NCT03980808|Experimental|ASL-ADE Intervention Arm|One-half of enrolled participants will view the ASL-ADE video intervention.
89072140|NCT03980808|Sham Comparator|Control Arm|One-half of enrolled participants will view a non-health related video approximately the same length as the video intervention.
89072141|NCT03976219|Experimental|Evoked potentials of ECAPs and SSEPs|Patients implanted with a spinal cord stimulator. In this arm, we are measuring the evoked potentials of electric compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs).
89072142|NCT03972215|Experimental|Berberine treatment|
89072143|NCT03972215|Placebo Comparator|Placebo control|
89072144|NCT03956238|Experimental|Males and Alcohol Intoxication|Men assigned to alcohol intoxication arm (target BAC .08%)
89072145|NCT03956238|Placebo Comparator|Males and Placebo Control|Men assigned to placebo control arm
89072146|NCT03956238|Experimental|Females and Alcohol Intoxication and Objectifying Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and objectifying gazes arm
89072147|NCT03956238|Experimental|Females and Alcohol Intoxication and Eye Gazes|Women assigned to alcohol intoxication arm (target BAC .08%) and eye gazes arm
89072148|NCT03956238|Experimental|Females and Placebo Control and Objectifying Gazes|Women assigned to placebo control arm and objectifying gazes arm
89072149|NCT03956238|Placebo Comparator|Females and Placebo Control and Eye Gazes|Women assigned to placebo control arm and eye gazes arm
89072150|NCT03955055|Experimental|Early Capsule Group|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the clinical decision unit. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
89072151|NCT03955055|No Intervention|Standard of Care Work-up|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
89072152|NCT03953157|Experimental|Arm I (dietary intervention)|Patients receive a controlled anti-inflammatory diet over 12 weeks.
89072153|NCT03953157|Experimental|Arm II (exercise intervention)|Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
89072154|NCT03943953|Experimental|Facial Palsy - Trial of ITG|In this arm of the trial individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
89072155|NCT03927573|Experimental|GEM3PSCA|Application of GEM3PSCA, a PSCA targeted bispecific antibody engaging T-cells
89072156|NCT03906136|Experimental|TREAT-TO-TARGET (T2T)|"Participants received secukinumab at a dose of 150 milligrams (mg) as subcutaneous (s.c.) injection at 150 mg dose at Baseline, Week 1, 2, 3, 4 and 8. From Week 12, only responders continued to receive 4-weekly doses until Week 32 if they maintained the response. In the event these patients experienced a loss of response from week 24 they were escalated to secukinumab 300 mg s.c. every 4 weeks until Week 32.~Patients who were non-responders at Week 12 will received 4-weekly secukinumab 300 mg s.c. until Week 24. From Week 24, only responders continued to receive 4-weekly secukinumab 300 mg s.c. until Week 32. Patients who are non-responders to secukinumab 300 mg at Week 24 receive biweekly of adalimumab biosimilar 40 mg s.c. until Week 34"
89072157|NCT03906136|Active Comparator|Standard-of-care (SOC)|SOC treatment up to the maximum recommended dose at the discretion of the investigator as according to current recommendation for treatment of axSpA
89072158|NCT03896529|No Intervention|No-stress control group|Participants in this group will perform the psychology tasks (virtual navigation) without any manipulation of psychological stress
89072159|NCT03896529|Experimental|Stress group|Participants in this group will perform the psychology tasks (virtual navigation) under manipulated psychological stress (anticipatory threat of shock)
89072160|NCT03876301||Observational Cohort|Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200
89072161|NCT03875820|Experimental|Dose Escalation Phase|"Escalating doses of VS-6766 (RO5126766) and Defactinib (VS-6063) were evaluated in patients with advanced solid tumours to establish the recommended phase II dose. Dose escalation followed a 3+3 design with a maximum of four patient cohorts.~This arm is now complete."
89072162|NCT03875820|Experimental|Dose Expansion KRAS mutant NSCLC Cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS mutant NSCLC (20 patients).~This arm is now complete."
89072163|NCT03875820|Experimental|Dose Expansion biopsy cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients advanced RAS mutant solid tumours with biopsiable disease (6 patients).~This arm is now complete."
89072164|NCT03875820|Experimental|Dose Expansion LGSOC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with LGSOC (20 patients).
89072165|NCT03875820|Experimental|Dose Expansion CRC cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with CRC (10 patients).~This arm is now complete."
89072166|NCT03875820|Experimental|Dose Expansion KRAS G12V mutant NSCLC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with KRAS G12V mutant NSCLC (10 patients).
89072167|NCT03875820|Experimental|Dose Expansion RAS/RAF mutant endometrioid cancer cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with RAS/RAF mutant endometrioid subtype of gynaecological cancers (ovarian, endometrial, endometriosis-related) (10 patients).
89691085|NCT03493828|Placebo Comparator|Placebo|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
89691086|NCT03014557||WATCHMAN|subjects with non-valvular atrial fibrillation intended to be implanted with a WATCHMAN left atrial appendage closure device
89224058|NCT03446690|Other|Control group|A control group was comprised of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham. No intervention for this group.
89224059|NCT03429413|Active Comparator|Parents|Parents of 11-12 year old children who visit participating interventional clinics during study period.
89224060|NCT03429413|Active Comparator|Health Care Provider|Health care providers and clinic staff for 11-12 year old patients at 4 participating pediatric clinics.
89691087|NCT04936633|No Intervention|No intervention by medical staff|The patients who start FSGM and receive general education on FSGM only.
89691088|NCT04936633|Experimental|Intervention by medical staff based on a cloud system|The patients who start FSGM and receive general education on FSGM and remote intervention based on a cloud system.
89691089|NCT03495856|Experimental|Mindfulness Training For Chronic Pain|The intervention is adapted from the mindfulness-based stress reduction program. The adapted mindfulness training program consists of four, weekly 90 minute group sessions that focus on education on chronic pain and mindfulness, instruction and in-class mindfulness skills practice, and group discussion.
89691090|NCT03496324|Active Comparator|Test (fed): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fed condition~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
89691091|NCT03496324|Active Comparator|Test (fasted): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
89691092|NCT03496324|Experimental|Reference (fed): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fed condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
89691093|NCT03496324|Experimental|Reference (fasted): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
89691094|NCT03354598|Experimental|Sulopenem-etzadroxil/probenecid|Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days
89691095|NCT03354598|Active Comparator|Ciprofloxacin|Ciprofloxacin 250 mg PO administered twice daily for 3 days
89691096|NCT02718027||Participants with Alport Syndrome|Participants diagnosed with Alport syndrome aged between 2 months and 50 years
89691097|NCT02169895|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~Every period with concomitant single oral administration of Prolopa® 100-25"
89691098|NCT02169895|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
89691099|NCT02169895|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
89691100|NCT02169895|Active Comparator|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
89691101|NCT01072669|Active Comparator|ambrisentan|"drug arm~use of ambrisentan in limited scleroderma patients with raynaud's to evaluate digital microvascular flow"
89691102|NCT01072669|Placebo Comparator|sugar pill|those getting sugar pill to evaluate if the active drug improves digital microvascular flow in limited scleroderma patients
89691103|NCT03014713|Active Comparator|Control Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h.
89691104|NCT03014713|Experimental|Dexmedetomidine Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h,dexmedetomidine 0.1μg/kg/h.
89691105|NCT03354754|Experimental|LYS228|IV infusion every 6 hours for at least 5 days
89691106|NCT03354754|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
89691107|NCT01073449||Cardiac device|All patients implanted with a cardiac device, pacemaker(PM)or Implantable Cardioverter Defibrillator (ICD)
89691108|NCT03270436|Experimental|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|The Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program (WORD DPP) is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. The first 8 modules are intended to be delivered weekly. The last 8 modules are intended to be delivered every other week. Participants in the WORD DPP will be encouraged to maintain a daily weight, nutrition, physical activity and prayer log.
89691109|NCT03270436|Experimental|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|The Partnership for Improving Lifestyle Intervention Diabetes Prevention Program (PILI DPP) is a family and community based diabetes prevention curriculum that teaches participants to engage their social support (family and community) to have a healthy weight, eat healthy, and be physically active. The PILI DPP includes 14 modules that are intended to be delivered over a 24 week period and each module approximately 90 minutes in length. The first 4 modules are intended to be delivered weekly. The last 10 modules are intended to be delivered every other week. Participants will be encouraged to track their weight, physical activity, and their nutrition in a log on a daily basis.
89691110|NCT01074463|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
89691111|NCT01074463|Active Comparator|2|Mirapex® 0.25 mg Tablets
88812944|NCT03219710|Active Comparator|Arm A|"Patient on control group (ODA) with weight category of 15-40 kg will receive:~D1-D3 Dexamethasone 3 mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg;~The patient on control group with weight category of > 40 kg will receive:~D1- Dexamethasone 3 mg/m2 , ondansetron(0.15 mg/kg ), Aprepitant 125 mg; D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg~Note: Aprepitant will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
89072168|NCT03875820|Experimental|Dose Expansion pancreatic cancer|The dose expansion phase will evaluate the recommended phase II dose of the combination of VS-6766 (RO5126766) and Defactinib (VS-6063), as decided in the dose escalation phase in patients with pancreatic cancer (10 patients).
89072169|NCT03860935|Experimental|acoramidis HCl 800 mg|Subjects will receive acoramidis HCl 800 mg twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP levels, and change from baseline in distance walked on the 6MWT will be assessed after 30 months of treatment.
89072170|NCT03860935|Placebo Comparator|Placebo|Subjects will receive placebo to match twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP levels, and change from baseline in distance walked on the 6MWT will be assessed after 30 months of treatment.
89072171|NCT03818243|Experimental|RLS-|patients with Parkinson disease without RLS
89072172|NCT03818243|Experimental|RLS+|patients with Parkinson disease with RLS
89072173|NCT03800524|Experimental|Tauroursodeoxycholic acid (TUDCA)|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
89072174|NCT03800524|Placebo Comparator|Reference therapy|"Placebo capsules identical to active compound~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
89072175|NCT03776682||Acute inflammation|Patients with RA and active inflammation (by exam or inflammatory markers)
89072176|NCT03776682||Chronic remission|Patients with RA who are in remission (clinically)
89072177|NCT03742076|Active Comparator|High-dose prebiotic|10 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
89072178|NCT03742076|Active Comparator|Low-dose prebiotic|5 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
89072179|NCT03742076|Placebo Comparator|Placebo|2 gm powdered fiber daily for at least 6 weeks
89072180|NCT03733028|Experimental|Mobile Intervention for Reducing Anger (MIRA)|Participants in this arm will be provided with a device that has the MIRA application (app) and asked to use the app for a period of 4 weeks.
89072181|NCT03733028|Active Comparator|Mindfulness Intervention|Participants in this arm will be provided with a device that has the Mindfulness application (app) and asked to use the app for a period of 4 weeks.
89072182|NCT03695744|Experimental|Daratumumab Bortezomib Dexamethasone|IV daratumumab 16mg/kg body weight weekly for weeks 1-9 followed by daratumumab 16mg/kg body weight once every 3 weeks from weeks 10 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; S.C bortezomib and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 9 months from start of study. After 9 months, patient only continues on daratumumab until progression.
89072183|NCT03690869|Experimental|Phase 1|Patients in both the Solid Tumor Cohort and the CNS Cohort will receive cemiplimab monotherapy. Each Cohort will have 2 subgroups by age (0 to <12 years, 12 to <18 years).
89691112|NCT01075087|Placebo Comparator|Placebo|(control group) will receive sterile normal saline in the block
89691113|NCT01075087|Active Comparator|Active comparator|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
89691114|NCT01075399|Experimental|[F 18]HX4|[F18]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.
89691115|NCT03358576|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment
89691116|NCT03358576|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead
89691117|NCT03016117|Experimental|Pecs II block and parasternal block|Pecs II block and parasternal block performed to provide anesthesia of breast, before of quadrantectomy with or without axillary dissection. Pecs II block performed at the 4th rib level and 20 ml of 0.5% Levobupivacaine injected, and parasternal block performed at the level of the 2nd and 4th intercostal space level, and 4 ml of 0.375% Levobupivacaine injected
89691118|NCT03822013|Experimental|Miglustat|"Miglustat is administered, dose is adjusted according to Body Surface Area as below:~>1.25 : 200 mg TDS 0.88-1.25 : 200mg BID 0.73-0.88 :100mg TDS 0.47-0.73 : 100mg BID <0.47 :100mg daily"
89691119|NCT03822013|No Intervention|No Miglustat|
89691120|NCT03800563|Experimental|Laser assisted liposuction|Laser Assisted Liposuction with the LipoLife system. Each subject underwent laser assisted liposuction surgery w/wo facial fat grafting , using the LipoLifeTM system. Pre-surgery evaluation visit was carried out 1 week prior to the surgery. Follow up visits to evaluate safety and efficacy will take place at 1, 3 and 6 months after the surgery.
89691121|NCT00376480|Experimental|administration of adoptive donor lymphocyte infusion|administration of donor lymphocytes made using costimulatory blockade ex vivo
89691122|NCT03016039|Experimental|Dietary supplementation|This group will receive Dietary supplementation
89691123|NCT03016039|No Intervention|conventional treatment|conventional Antibiotic treatment without curcumin supplementation
89691124|NCT03362944|Experimental|Active Music Therapy|
89691125|NCT03362944|Experimental|Passive Music Therapy|
89691126|NCT03497026|Experimental|Robotic Bronchoscopy|Robotic bronchoscopy with Robotic Bronchoscopy Platform
89691127|NCT02175979|Placebo Comparator|standard|standard of care
89691128|NCT02175979|Experimental|enriched enteral nutrition|enriched enteral tube feeding 1.5ml/ minute perioperative
89691129|NCT03498196|Experimental|Avelumab|Avelumab 10 mg/kg intravenously, over 60 minutes every 2 weeks for 3 cycles or 42 days.
89072184|NCT03690869|Experimental|Efficacy with Newly Diagnosed DIPG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
89072185|NCT03690869|Experimental|Efficacy with Newly Diagnosed HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
89072186|NCT03690869|Experimental|Efficacy with Recurrent HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
89072187|NCT03670628|Active Comparator|720 shockwave therapy Group|Participants in this group will receive a total of 5 daily sessions of shockwave therapy within a week. Each therapy session will consist of 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
89072188|NCT03670628|Sham Comparator|Sham shockwave therapy|Participants in this group will receive a total of 5 daily sessions of sham shockwave therapy within a week. Sham therapy will be applied to the penis and to the left and right crus (shaft near the base).
89072189|NCT03637764|Experimental|Cohort A: HCC: Isatuximab + Atezolizumab|Participants with hepatocellular carcinoma (HCC) received atezolizumab 1200 milligrams, every 3 weeks (Q3W), intravenous (IV) infusion along with isatuximab 10 milligrams per kilogram (mg/kg), IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable adverse events (AE), participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 106 weeks).
89072190|NCT03637764|Experimental|Cohort B: SCCHN: Isatuximab + Atezolizumab|Participants with squamous cell carcinoma of the head and neck (SCCHN) received atezolizumab 1200 milligrams,Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 108 weeks).
89072191|NCT03637764|Experimental|Cohort C: EOC: Isatuximab + Atezolizumab|Participants with epithelial ovarian cancer (EOC) received atezolizumab 1200 mg, Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 61 weeks).
89072192|NCT03637764|Experimental|Cohort D-1: GBM: Isatuximab + Atezolizumab|Participants with glioblastoma multiforme (GBM) received atezolizumab 1200 mg, Q3W, IV infusion along with isatuximab 10 mg/kg, IV infusion, once weekly for 3 weeks (i.e., on Day 1, Day 8 and Day 15 of Cycle 1) and then Q3W (i.e., on Day 1 of each 21- day treatment cycle) until disease progression, unacceptable AE, participant's decision to stop the treatment, or death or study cut-off whichever occurred first (maximum duration of exposure: 54 weeks).
89072193|NCT03636022|Experimental|VR System|Participants will then be assigned one week of daily exposure homework. Patients randomized to the intervention condition will take home the VR system for homework.
89072194|NCT03636022|Experimental|Control Condition|Participants will then be assigned one week of daily exposure homework. Participants assigned to control will be instructed to complete imaginal exposures.
89072195|NCT03594266|Experimental|Therapy A Spinal Cord Stimulation Parameter Set|
89072196|NCT03594266|Experimental|Therapy B Spinal Cord Stimulation Parameter Set|
89072197|NCT03591965|Experimental|ATG-008|To enroll approximately 40 hepatitis B virus (HBV) positive, unresectable HCC subjects who have previously received at least one prior line of systemic therapy. Among which, approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg, once daily (QD) and another approximately 20 subjects will receive oral ATG-008 at an initial dose of 20 mg, twice daily (BID). The pharmacokinetic (PK) samples will be collected from 10 subjects each in the two dose groups.
89691130|NCT03613519|Placebo Comparator|Patient education (sleep hygiene)|A web-based program that presents ways to improve behaviors and environments that can affect sleep.
89691131|NCT03613519|Active Comparator|SHUTi (Sleep Healthy Using the Internet)|SHUTi is web-based cognitive-behavioral therapy instrument for insomnia (CBT-I)
89691132|NCT03613519|Active Comparator|modified SHUTi (SHUTi modified for Black women)|The CBT-I instrument tailored for Black women.
89691133|NCT03500302|Experimental|Evolocumab|All enrolled patients will receive evolocumab sq once a month for a total of two doses
89691134|NCT02176837|Experimental|Sodium Nitrite|One dose cohort is planned, 64 nmol/min/kg sodium nitrite (0.1325 mg/hour/kg; 0.0442 ml/hour/kg at a concentration of 3mg/ml).
89072198|NCT03589794|Experimental|Group 1|10 subjects receive 10 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
89072199|NCT03589794|Experimental|Group 2|10 subjects receive 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
89072200|NCT03589794|Experimental|Group 3|10 subjects receive 30 mcg rCSP intramuscularly (IM) on days 1, 29 and 85.
89072201|NCT03589794|Experimental|Group 4|9 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
89072202|NCT03589794|Experimental|Group 4B|10 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
89072203|NCT03589794|Experimental|Group 5|10 subjects receive 10 mcg or 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85 if immunogenicity analysis conducted 28 days post-2nd dose in Groups 1, 2, and 3 show promise (at least fourfold increase in geometric mean anti-CSP antibody or geometric mean anti-CSP titer of 20). Otherwise, subjects will receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ). Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
89072204|NCT03589794|Other|Group 6|6 subjects receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain.
89072205|NCT06268938|Experimental|Muscle obliteration|Mastoid cavity obliteration by muscle
89072206|NCT06268938|Active Comparator|Bone obliteration|Mastoid cavity obliteration by bone
89072207|NCT06268925|Experimental|Study group|single arm group exercises will be given to the patients
89072208|NCT06268912|Experimental|Cold Mepivacaine|Mepivacaine 3% at 5ºC
89072209|NCT06268912|Active Comparator|Mepivacaine at room temperature|Mepivacaine 3% at room temperature
89224061|NCT03429413|No Intervention|Adolescents at Intervention clinics|Adolescents between 11-12 years of age. Adolescent vaccination data is used in the study, adolescents will assent to participate. The parents, however, use the HIT system.
89224062|NCT03429413|No Intervention|Adolescents at Control Clinic|Parents of 11-12 year old children who visit participating control clinics during study period.
89224063|NCT03429413|No Intervention|Health Care Provider at Control Clinic|Health care providers and clinic staff for 11-12 year old patients at 3 participating pediatric control clinics.
89691135|NCT03501550|Experimental|CDI-31244 + SOF/VEL|CDI-31244 in combination with SOF/VEL
89691136|NCT03503578|Experimental|EEG Dynamics|EEG data will be collected on patients receiving sevoflurane, and sevoflurane and ketamine together.
89691137|NCT03506386||Multiple Myeloma Participants|Participants with multiple myeloma (MM) were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.
89691138|NCT03270514|Experimental|Exparel Injectable Product|Liposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the liposomal bupivacaine (Exparel) group (~30).
89691139|NCT03270514|Active Comparator|Bupivacaine Hydrochloride|Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (~30).
89691140|NCT03277378|Active Comparator|Group 1 (AB)|Group 1 (AB): anatomic lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
89691141|NCT03277378|Active Comparator|Group 2 (TB)|Group 2 (TB): targeted lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
89691142|NCT02178241|Experimental|Treatment (eribulin mesylate and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89691143|NCT03509974|Experimental|Bone Anchored Hearing Device (OSIA)|All subjects will receive the Bone Anchored Hearing Device (OSIA)
89691144|NCT03015727|Experimental|IC+RT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2. And then radiation using IMRT/TOMO without concurrent chemotherapy.
89691145|NCT03015727|Active Comparator|IC+CCRT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2.And then chemoradiation using IMRT/TOMO with 2 cycles of cisplatin concurrent chemotherapy at 100mg/m2.
89691146|NCT03584659|No Intervention|Standard of care|This arm will continue standard procedure regarding side effect registration and handling
89691147|NCT03584659|Experimental|PRO|This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life. A specifically developed alert-algorithm will in real-time guide both patient and alert clinical staff if symptoms are increasing or quality of life is deteriorating.
89691148|NCT03015883|Experimental|Diffusing Alpha Radiation Emitters Therapy (DaRT)|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed Devices
89691149|NCT01077973|Experimental|Treatment A|
89691150|NCT01077973|Active Comparator|Treatment B|
89691151|NCT01077973|Placebo Comparator|Treatment C|
89691152|NCT03514420|Experimental|AKCEA-ANGPTL3-LRx 20 mg|Participants received AKCEA-ANGPTL3-LRx 20 milligrams (mg) administered every week for 26 weeks by subcutaneous (SC) injection.
89072210|NCT06268899|Experimental|First mobilization protocol|The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed >60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
89072211|NCT06268899|No Intervention|Control|No intervention was made to the control group, only data were collected at the same time as the study group.The patients in the control group was mobilized by the researchers according to the routine clinical mobilization practice.
89072215|NCT06268873|Experimental|Baxdrostat/dapagliflozin|Participants randomised to the baxdrostat/dapagliflozin arm will initially receive a dose of baxdrostat lower dose and dapagliflozin. For participants that meet the up-titration criteria, baxdrostat may be up-titrated to higher dose.
89072216|NCT06268873|Active Comparator|Dapagliflozin|Patients will receive one dose of dapagliflozin (active comparator) in combination with matching placebo daily
89072217|NCT06268847|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
89072218|NCT06268847|Experimental|ACT01|The test product is a food supplement presented as a capsule containing a fish hydrolysate.
89072219|NCT06268847|Experimental|ACT02|The test product is a food supplement presented as a capsule containing a fish hydrolysate.
89072220|NCT06268834|Experimental|Using PPI|Group receiving a long-term PPI (omeprazole, lansoprazole, pantoprazole, esomeprazole and rabeprazole) every day for at least 6 months or at least twice a week for at least 2 years.
89072221|NCT06268834|Experimental|Control|A control group was formed from individuals who had never used PPI.
89072222|NCT06268821|Other|Intervention|FreeStyle Libre 2 Flash Glucose Monitoring System
89072223|NCT06268808|Other|Intervention|FreeStyle Libre 2 Flash Glucose Monitoring System
89072224|NCT06268769|Experimental|Envarsus|Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.
89072225|NCT06268769|Active Comparator|Advagraf|Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice.
89072226|NCT06268756||students|students
89691153|NCT02973646|Experimental|Nucleos(t)ide analogues treatment|Patients with interferon receptor level down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 24th week, then nucleos(t)ide analogues (entecavir tablet 0.5mg/d or tenofovir tablet 300mg/d) from 25th to 36th week, then peginterferon alfa-2b injection 80ug/d again from 36th to 48th week.
89072228|NCT06268717|Active Comparator|Food challenge with pork meat containing alpha-gal, then pork meat without alpha gal sugar|Participants receive a food challenge, consuming pork meat that contains alpha-gal. After a >10-day washout period, participants undergo a food challenge with pork which does not contain alpha-gal.
89072229|NCT06268717|Active Comparator|Food challenge with pork meat without alpha gal sugar, then pork meat containing alpha-gal|Participants receive a food challenge consuming pork meat that does not contain alpha-gal sugar. After a >10-day washout period, participants undergo a food challenge with pork which does contain alpha-gal.
89691154|NCT02973646|Active Comparator|Peginterferon treatment|Patients with interferon receptor level not down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 48th week.
89691155|NCT03296059|Experimental|RBC transfusion with conventional treatment|Besides conventional treatment,neonates diagnosed with ARDS is treated with RBC transfusion.
89072232|NCT06268691|No Intervention|Control arm|The study was conducted in 20 clusters of 2000 dwellings each, where 10 clusters were randomly assigned to the control arm and 10 clusters to the intervention arm
89072233|NCT06268691|Experimental|Intervention arm|The study was conducted in 20 clusters of 2000 dwellings each, where 10 clusters were randomly assigned to the control arm and 10 clusters to the intervention arm
89072234|NCT06268678|Experimental|Follicular|Follicular phase assessment of muscle protein synthesis.
89072235|NCT06268678|Experimental|Luteal|Luteal phase assessment of muscle protein synthesis
89072236|NCT06268665|Experimental|Arm 1: High-Dose Tart Cherry Juice Supplement|1 oz tart cherry juice concentrate diluted in water up to 8oz.
89072237|NCT06268665|Experimental|Arm 2: Low-Dose Tart Cherry Juice Supplement|¼ oz tart cherry juice concentrate diluted in water up to 8oz.
89072238|NCT06268652|Experimental|Organoid-guided personalized treatment|Subjects randomly assigned to OGPT need to provide sufficient tissue for organoid culture. After successful organoid culture, drug screening will be performed, and they will be treated with drugs predicted to be sensitive by PDO drug susceptibility screening.
89691156|NCT03296059|Active Comparator|conventional treatment|neonates diagnosed with ARDS is treated with conventional treatment.
89691157|NCT03369340|Active Comparator|Product Sequence 1|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4"
89691158|NCT03369340|Active Comparator|Product Sequence 2|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4"
89691159|NCT03369340|Active Comparator|Product Sequence 3|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4"
89691160|NCT03369340|Active Comparator|Product Sequence 4|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4"
89691161|NCT03369340|Active Comparator|Product Sequence 5|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4"
89691162|NCT03369340|Active Comparator|Product Sequence 6|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4"
89691163|NCT01078363|Active Comparator|ramipril|ramipril, 5mg starting dose to maximum dose of 20mg daily dose for one year.
89691164|NCT01078363|Placebo Comparator|Placebo|Sugar pill manufactured to mimic ramipril 5mg starting dose , increasing to 20mg daily for one year.
89691165|NCT03370042|Active Comparator|Semilunar Coronally Positiones Flap + Free Gingival Graft|semilunar coronally positioned flap with free gingival graft for root coverage
89691166|NCT03370042|Sham Comparator|Semilunar Coronally Positioned Flap|semilunar coronally positioned flap alone without free gingival graft for root coverage
89691167|NCT03371836|Other|Clobazam|open label (single treatment arm)
89072239|NCT06268652|Active Comparator|Treatment of physician's choice|Subjects in the TPC arm will receive treatment with one of the following regimens selected by the physician following NCCN guidelines: capecitabine, gemcitabine, vinorelbine, and eribulin. If it is HER2-positive, anti-HER2 therapy can be combined with it, except for ADC drugs.
89072240|NCT06268626||EIN/EC BIOPSY RESULT|Vaginal DNA, microbiome, pH, and saliva samples sequenced. Participation ends here.
89072241|NCT06268626||EH BIOPSY RESULT|Vaginal DNA, microbiome, pH, and saliva samples sequenced. All invited to move on to Part B and samples sequenced for 6 additional months.
89072242|NCT06268626||NEGATIVE BIOPSY RESULT|"Control for natural and spontaneous changes in vaginal DNA, microbiome, pH, and saliva samples sequenced.~Random subset selected to move on to Part B and samples sequenced for 6 additional months."
89072243|NCT06268587||control group|The control group is made up of patients, without age limit, who underwent an outpatient surgery from 01/09/19 to 28/02/20 inclusive and accepted post-operative monitoring by SMS. These patients leaves the hospital with instructions and prescriptions.
89072244|NCT06268587||experimental group|The experimental group is made up of patients, without age limit, who underwent an outpatient surgery procedure from 1/9/21 to 28/2/22 inclusive and accepted post-operative monitoring by SMS. The patients leaves the hospital with instructions, analgesics for a maximum of two days with detailed dosages and an explanatory booklet on postoperative pain.
89072245|NCT06268574|Experimental|RVU120 single agent|RVU120 oral capsules administered at dose of 250 mg every other day on Days 1-13 of each 21-day cycle of treatment.
89072246|NCT06268561||OZURDEX patients|Patients treated by Dr Garcin and Pr Thuret CHU of Saint Etienne in the context of post-OZURDEX endophthalmitis
89072247|NCT06268548|Experimental|Study|Experimental , diaphragmatic activation with medical treatment ,15patients with gastroesophageal reflux disease do manual diaphragmatic activation in additional to traditional medical treatment
89072248|NCT06268548|No Intervention|Control|30 patients with gastroesophageal reflux disease taking traditional medical treatment only
89072249|NCT06268522|Experimental|Mindfulness-Oriented Recovery Enhancement: (MORE) group|
89072250|NCT06268522|Placebo Comparator|Psychoeducation|
89072251|NCT06268509|Experimental|Intervention group|"Participants in the intervention group will receive:~Fetomaternal ultrasound examination each trimester by fetomaternal consultants~Complete laboratory examination for nutritional panel (complete blood count with reticulocyte profile and iron profile, vitamin D level, zinc level, fatty acid profile, electrophoresis for Thalassemia) as an addition to standard maternal routine laboratory examination~Supplements: multivitamin, minerals, vitamin D, fatty acid~Intervention regarding any abnormal results of nutritional panel~All standard maternal health services according to Indonesian Ministry of Health protocol"
89072252|NCT06268509|No Intervention|Control group|"Participants in the control group will receive:~- All standard maternal health services according to Indonesian Ministry of Health protocol"
89072253|NCT06268483|Active Comparator|Oral supplementation of hyaluronic acid + anti-inflammatory|Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months
89072254|NCT06268483|Active Comparator|Anti-inflammatori|Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
89072255|NCT06268457||Performed chemoembolization|
89072256|NCT06268444|Experimental|New born|
89072257|NCT06268431|Experimental|60-minute oxytocin rest|
89072258|NCT06268431|No Intervention|Usual care with continuous oxytocin infusion|
89072259|NCT06268405|Experimental|Liquid Biopsy and Positron Emission Mammography (PEM)|"To perform the Liquid Biopsy assays, a baseline blood sample will be collected prior to the MRI-guided biopsy, and a follow-up blood and a tissue sample (if available) may be requested post-surgery If malignancy is confirmed by the standard of care histopathology results.~To perform the Positron Emission Mammography (PEM), participants will be injected with 74 megabecquerel (MBq) of commercially distributed 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (F-18 FDG). Following a delay of one hour for F-18 FDG uptake, the study participants will undergo a bilateral 4-view combination PEM scan."
89072260|NCT06268340|Experimental|Intervention|ECochG monitored CI surgery incl. corrective action guide
89072261|NCT06268340|Active Comparator|Control|Routine CI surgery without ECochG monitoring
89072262|NCT06268327|Experimental|cisplatin and gemicitabine|patients with triple negative breast cancer will recieve adjuvant cisplatin and gemicitabine in non pathological complete response after neo-adjuvant standard chemotherapy with dose of cisplatin 70mg/m2 at day one and gemicitabine 1000mg/m2 day one and day eight every 21 day for six cycle
89072263|NCT06268327|Experimental|capecitabine|patients with triple negative breast cancer will recieve adjuvant capecitabin in non pathological complete response after neo-adjuvant standard chemotherapy with dose of capecitabine 1000-1250 mg/m2 every 21 day for six cycle
89072264|NCT06268301|Experimental|Sequence 1: BOS 2 mg Fasted, then Fed|Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fasted condition (Treatment A). Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fed condition (Treatment B).
89072265|NCT06268301|Experimental|Sequence 2: BOS 2 mg Fed, then Fasted|Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fed condition (Treatment B). Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fasted condition (Treatment A).
89072266|NCT06268288|Active Comparator|Standard Postural Orthostatic Tachycardia Syndrome management/ STEPS|The General Pediatric and Adolescent Medicine providers at Mayo Clinic utilize a specific management program for their patients with Postural Orthostatic Tachycardia Syndrome utilizing the acronym STEPS. S is for liberal intake of salt, T is for drinking 90-100 ounces/day of fluid, E is for slowly and gradually improve continuous aerobic exercise duration to a goal of 50 minute most days of the week, P is for possible utilization of 1 of two prescription medications (metoprolol or midodrine), and S is for setting priorities and goals such as encouraging good sleep hygiene, attendance at school, social interactions, and counseling.
89072267|NCT06268288|Experimental|STEPS + GammaCore Intervention (noninvasive vagal nerve stimulation)|Utilization of STEPS management goals plus the addition of non invasive vagal nerve stimulators for two 2 minutes of intervention performed three times a day.
89072268|NCT06268275|Experimental|Group S|Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.
89072269|NCT06268275|Active Comparator|Group E|Receive intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application.
89072270|NCT06268236|Experimental|Electro-acupuncture group|Patients in EA group receive acupuncture at Shuigou (also known as Renzhong, GV26) and Yintang (updated number GV24+, previous number GV29). Paired electrodes from the EA apparatus are clipped to the needle handles at Shuigou and Yintang. The electroacupuncture stimulation lasts for 30 minutes with a wave of rarefaction and condensation (10 Hz / 50 Hz) and a current intensity of the maximum withstand current within 7mA. All patients receive EA at 9 am for 30 minutes once a day for consecutive 14 days.
89072271|NCT06268236|Sham Comparator|Sham electro-acupuncture group|Patients in sham-EA group receive sham-EA at sham-Shuigou and sham-Yintang.Acupuncture needles are inserted into the adhesive pads but do not pierce the skin. Paired electrodes from the EA apparatus via sham connecting cords are clipped to the needle handles at sham-Shuigou and sham-Yintang. The sham connecting cords are similar in appearance to the normal ones, but the inner wires in sham connecting cords are cut off and cannot conduct electricity. All patients receive sham-EA at 9 am for 30 minutes once a day for consecutive 14 days.
89072272|NCT06268223|Experimental|Study Group|
89072273|NCT06268223|Active Comparator|Control Group|
89072274|NCT06268210|Experimental|Experimental|"Patients will receive a combination therapy of Lazertinib and Pemed-S + Carboplatin as neoadjuvant treatment before surgery, followed by post-surgery maintenance with Lazertinib at a dosage of 240 mg once daily for a duration of 3 years.~Dosages:~Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)"
89072275|NCT06268210|Active Comparator|Comparator|Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
89072276|NCT06268197|Experimental|Yoga Intervention|Interoception-based yoga intervention, 2x/week for 6 weeks.
89072277|NCT06268184|Active Comparator|omega 3|D3LAB syrup each 5 ml contain :EPA 825 mg and DHA 550 mg each child receive 3.6 ml every day for 6 months
89072278|NCT06268184|Placebo Comparator|placebo|Placebo capsules contain only the standard ingredients of soft gelatin capsules (gelatin, water, glycerin, and vitamin E in minute amounts as preservatives).
89072279|NCT06268171||Study group|transplant patients with ultrasound measurement of the cross-sectional area of the rectus femoris
89072280|NCT06268158|Experimental|Intervention group|Patients in the experimental group will wear an eye patch after 22:00, when clinical interventions are less frequent, and will be listened to calming music once a day for 1 hour for 3 days.
89072281|NCT06268158|No Intervention|Control group|No treatment will be performed on patients in the control group outside of their clinical routine.
89072282|NCT06268145|Experimental|Fixed Sequence 1|Participants will receive single dose of ECC5004 F1 at fasted state, followed by F2 at fasted state, F1 at fed state and F2 at fed state in four treatment periods.
89072283|NCT06268145|Experimental|Fixed Sequence 2|Participants will receive a single dose of ECC5004 F2 at fasted state, followed by F1 at fasted state, F2 at fed state, and F1 at fed state with four treatment periods.
89072284|NCT06268119|No Intervention|Control group (standard clinical care)|Control group receiving standard care administered by doctors and nurses for delirium management in the intensive care unit
89072285|NCT06268119|Experimental|Intervention group (care with protocol)|The intervention group received care in line with the postoperative delirium prevention, diagnosis and intervention protocol after the delirium training given by the researcher to intensive care unit nurses.
89072286|NCT06268106|No Intervention|Standard procedure informative|Patients in this group undergo procedure with standard explanation of the procedure itself, so they do not receive and visualize graphic novel.
89072287|NCT06268106|Experimental|Graphic novel visualization|Patients in this group do receive and visualize graphic novel in addition to standard explanation of the procedure.
89072288|NCT06268093|Experimental|Thalidomide|Oral Thalidomide
89072289|NCT06268080|Experimental|Light general anesthesia|General anesthesia with Bispectral Index (BIS) of 55, or equivalent light anesthesia using other processed electroencephalography (pEEG) monitor
89072290|NCT06268080|Active Comparator|Deep general anesthesia|General anesthesia with Bispectral Index (BIS) of 40, or equivalent light anesthesia using other processed electroencephalography (pEEG) monitor
89072291|NCT06268067||Chronic kidney diseased patiens|chronic kidney diseased patients
89072292|NCT06268067||Normal|normal subjects
89072293|NCT06268041|Active Comparator|Moderate-Intensity Aerobic Training|
89072294|NCT06268041|Experimental|High-Intensity Interval Training|
89072295|NCT06267976||Healthy volunteers|Health adult volunteers will undergo a controlled desaturation to collect data for validation of the RPMO2 device.
89072296|NCT06267937||hip fracture|patients that were diagnosed with a hip fracture between 2012 and 2017
89072297|NCT06267885|Active Comparator|Patients with fracture neck of femur fixed by cannulated screws|Fix the fracture by two to three cannulatef screws
89072298|NCT06267885|Active Comparator|Patient with fracture neck of femur fixed by wagner's technique|Fix the fracture by three to four k-wires
89072299|NCT06267872|Experimental|Part A - Group 1|• 60 mcg of CD4BS CH505M5 Pr-NP1, to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4.
89691168|NCT01078753|Experimental|Desmopressin|During treatment period I participants received 120 μg per day desmopressin oral lyophilisate tablet for 14 days. Participants for whom treatment was effective (a reduction of ≥ 75% from Baseline in the number of wet nights), and who showed no problems with tolerability, continued to receive the same treatment for a further 14 days in treatment period II. Participants for whom efficacy was inadequate (a reduction of <75% from Baseline in the number of wet nights), but who showed no tolerability problems, received an increased dose of desmopressin oral lyophilisate tablet 240 µg for 14 days in treatment period II.
89691169|NCT01078753|Placebo Comparator|Placebo|Participants received matching placebo tablets during treatment periods I and II according to the same efficacy criteria as participants in the Desmopressin treatment group.
89691170|NCT03372382|Active Comparator|ibuprofen plus acetaminophen|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
89691171|NCT03372382|Experimental|ibuprofen plus acetaminophen/hydrocodone|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)
89691172|NCT03372928|Experimental|Standard EAA Dose|EAA dose provided at 0.10 g/kg body mass
89691173|NCT03372928|Experimental|High EAA Dose|EAA dose provided at 0.30 g/kg body mass
89691174|NCT03373162|Experimental|MRI Scans Pre and Post-Botox Injection|Participants will receive MRI scans pre and post-Botox injection, including magnetic resonance spectroscopy, structural, and functional MRI.
89691175|NCT03373240|Experimental|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on learning and decision making.
89691176|NCT03373240|Placebo Comparator|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
89691177|NCT03374176|Active Comparator|AMX-MET|"AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules.~1 capsule tid during 7 days."
89691178|NCT03374176|Experimental|Clindamycin|"Clindamycin Clindamycin 300 mg + placebo. Capsules.~1 capsule tid during 7 days."
89691179|NCT03281200||Anatomical main group:|
89691180|NCT03281200||Therapeutic subgroup|
89691181|NCT03281200||Pharmacological subgroup|
89691182|NCT03281200||Chemical subgroup|
89691183|NCT03281200||Chemical substance|
89691184|NCT03514966|No Intervention|Conventional group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the conventional group will receive no intervention. Thirty and 40 min after dimethicone administration, subjects will additionally take 200 ml and 800 ml water, respectively, and undergo MCE examination.
89691185|NCT03514966|Experimental|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
89691186|NCT03520348|Experimental|PRO-167|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom
89691187|NCT03520348|Active Comparator|Corneregel®|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom of the right eye sac.
89691188|NCT03282682|Experimental|hypogonadal males without TRT|Strength training
89691189|NCT03282682|Experimental|hypogonadal males with TRT|Strength training and regular prescribed testosterone therapy given by participant urologist.
89691190|NCT03282682|Active Comparator|healthy eugonadal males|Strength training
89691191|NCT03380026|Experimental|Valchlor 0.016% Topical Gel|0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.
89691192|NCT03380026|Active Comparator|Valchlor plus Triamcinolone|0.016% w/w topical mechlorethamine gel (once, nightly) and Triamcinolone acetonide 0.1% ointment (up to three times daily) applied in over a minimum of 8 cm2, over a period of 4 months.
89691193|NCT03380572|Experimental|Senhance Cholecystectomy|Cholecystectomy operation performed using Senhance robotic system
89691194|NCT03380572|Active Comparator|Laparoscopic Cholecystectomy|Cholecystectomy operation performed using standard laparoscopic instruments
89691195|NCT01079143|Experimental|Certican EMT+|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
89072300|NCT06267872|Experimental|Part B - Group 2|"60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 1.0 mg of ACU-026-001-1 adjuvant to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4~Followed by 300 mcg of CH505TF chTrimer, admixed with 1.0 mcg of ACU-026-001-1 adjuvant to be administered at months 6 and 8."
89072301|NCT06267872|Experimental|Part B - Group 3|"60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 2.0 mg of ACU-026-001-1 adjuvant to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4~Followed by 300 mcg of CH505TF chTrimer, admixed with 2.0 mg of ACU-026-001-1 adjuvant to be administered at months 6 and 8."
89691196|NCT01079143|Experimental|Certican EMT-|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
89691197|NCT01079143|Active Comparator|Neoral EMT+|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
89691198|NCT01079143|Active Comparator|Neoral EMT-|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
89691199|NCT03284398||Parenteral nutrition bag type|Groups with different parenteral nutrition bags (3CBs or HCBs)
89691200|NCT03381742|Experimental|ticagrelor 45mg bidpo.|To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
89691201|NCT03381742|Experimental|ticagrelor 90mg qdpo.|To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
89691202|NCT03381742|Active Comparator|ticagrelor 90mg bidpo.|To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
89691203|NCT03381742|Active Comparator|clopidogrel 75mg qdpo.|To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
89691204|NCT01079299|Experimental|IPC plus standard compression|
89691205|NCT01079299|Active Comparator|Standard compression alone|
89691206|NCT04735042||SGLT2 and DPP-4 inhibitors|Patients undergoing SGLT2i and DPP4i.
89691207|NCT04735042||SGLT2 inhibitors only|Patients undergoing SGLT2i alone.
89691208|NCT04734964|No Intervention|Control group|Participants underwent only common physical education classes twice per week for 45 minutes each and no additional after-school exercises.
89691209|NCT04734964|Experimental|Coordinative exercise group|Participants had common physical education classes twice per week for 45 minutes each, and additional exercise sessions were held three times per week for 45 minutes after school.
89691210|NCT04734964|Experimental|Cardiovascular exercise group|Participants had common physical education classes twice per week for 45 minutes each, and additional exercise sessions were held three times per week for 45 minutes after school.
89691211|NCT00376012|Active Comparator|1|2EHRZ3/4RH3
89691212|NCT00376012|Experimental|2|2EHRZ3/7RH3
89691213|NCT04564807|Active Comparator|Web-Based Insomnia Education Program|Adult heavy drinkers with insomnia.
89691214|NCT04564807|Experimental|SHUTi Intervention|Adult heavy drinkers with insomnia.
89691215|NCT00376090|Experimental|Group I Vaccine|
89691216|NCT00376090|Placebo Comparator|Group I Placebo|
89691217|NCT00376090|Experimental|Group II Vaccine|
89691218|NCT00376090|Placebo Comparator|Group II Placebo|
89691219|NCT00376090|Experimental|Group III Vaccine|
89691220|NCT00376090|Placebo Comparator|Group III Placebo|
89691221|NCT00376090|Experimental|Group IV Vaccine|
89691222|NCT00376090|Placebo Comparator|Group IV Placebo|
89691223|NCT04521439|Experimental|MS Patients Group|
89691224|NCT04521439|Sham Comparator|Healthy Volunteers Group|
89691225|NCT03530098|No Intervention|Control (Without-AI)|This is the control arm where no intervention is provided; represents current standard of care.
89691226|NCT03530098|Experimental|Experiment (With-AI)|"This is the experiment arm where the intervention, BoneAgeModel, is provided. The participating radiologists in this arm will receive the output of the Artificial Intelligence algorithm. They will be asked to incorporate this new information with their normal workflows to make a diagnosis. The radiologists' diagnosis will be considered final."
89691227|NCT03386110|Experimental|Couples Health Project (CHP)|The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
89691228|NCT03386110|Active Comparator|Education|The Education intervention is a attention-matched control three-session intervention that occurs once a week for three weeks. The education intervention will be delivered by trained health educators. The education intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
89691229|NCT01082575||Major Surgery|Oxygen Monitoring
89691230|NCT03578926|Experimental|fanfilcon A toric lens|Randomized participants will wear fanfilcon A toric contact lenses bilaterally for two weeks then switch to senofilcon A toric contact lenses for another two weeks.
89691231|NCT03578926|Active Comparator|senofilcon A toric lens|Randomized participants will wear senofilcon A toric contact lenses bilaterally for two weeks then switch to fanfilcon A toric contact lenses for another two weeks.
89691232|NCT03172273|Experimental|TIPS with PTFE|Transjugular Intrahepatic portosystemic shunt with PTFE covered stents
89691233|NCT03172273|Active Comparator|paracentesis|Paracentesis with albumine invision
89691234|NCT01083199|Experimental|CONTINUUMTM|
89691235|NCT03388294|Experimental|PC followed by SR|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention pre-linguistic (PC) domain to identify their child's pre-linguistic communication bids during daily routines and respond to those bids in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on sensory reactivity bids.
89691236|NCT03388294|Experimental|SR followed by PC|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention sensory reactions (SR) domain to identify their child's sensory reactions to daily activities and respond to those reactions or modify the environment in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on pre-linguistic communication bids.
89691237|NCT02171611|Experimental|Dabigatran etexilate pellets|
89691238|NCT02171611|Experimental|Dabigatran etexilate powder|
89691239|NCT02171611|Active Comparator|Dabigatran etexilate capsule|
89691240|NCT03389854|Sham Comparator|Group 1 - Control|No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.
89691241|NCT03389854|Experimental|Group 2 - PTT 1x daily x 3 months|Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
89691242|NCT03389854|Experimental|Group 3 - PTT 2x daily x 3 months|Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
89691243|NCT03389854|Experimental|Group 4 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
89691244|NCT01083667|Experimental|Pyrimethamine|Open label. Only one arm will receive the intervention.
89691245|NCT01083901|Experimental|Resistance training with Acetaminophen|Acetaminophen
89691246|NCT01083901|Experimental|Resistance Training with ibuprofen|Ibuprofen
89691247|NCT01083901|Placebo Comparator|placebo|Placebo
89691248|NCT03533374||Patients with epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
89691249|NCT03533374||Patients with non-epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
89691250|NCT01083979|Experimental|Liposomes|Intravesical instillation of Liposomes in sterile water totally 40 cc at four weekly treatments.
89691251|NCT03585790|Other|Multifocal Optics first, then Single Vision Optics|First Intervention (1 week) Second Intervention (1 week)
89691252|NCT03585790|Other|Single Vision Optics first, then Multifocal Optics|First Intervention (1 week) Second Intervention (1 week)
89691253|NCT00942305|Placebo Comparator|Placebo|"Cohort 1 = 40 mg of matching placebo administered once weekly (QW)~Cohort 2 = 100 mg of matching placebo administered QW~Cohort 3 = 200 mg of matching placebo administered QW~Cohort 4 = 200 mg of matching placebo administered twice weekly (BIW)~Cohort 4A = 100 mg of matching placebo administered BIW"
89691254|NCT00942305|Experimental|Brincidofovir|"Cohort 1 = 40 mg brincidofovir (BCV) administered once weekly (QW)~Cohort 2 = 100 mg BCV administered QW~Cohort 3 = 200 mg BCV administered QW~Cohort 4 = 200 mg BCV administered twice weekly (BIW)~Cohort 4A = 100 mg BCV administered BIW"
89691255|NCT01084759|Experimental|Etoposide and Testosterone|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days.
89691256|NCT03012997|Active Comparator|Active Comparator: 40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the induction, surgery and in Postoperative care unit.
89691257|NCT03012997|Active Comparator|Active Comparator: 100% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen during 100% induction and with 60-70% ( determined according to the arterial blood gas sample results) during surgery and in Postoperative care unit.
89691258|NCT01110187|Experimental|IV LCM (lacosamide)|Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
89691259|NCT01110187|Active Comparator|IV fPHT (fos-phenytoin)|Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin
89691260|NCT04357223|Experimental|Experimental|
89691261|NCT04357223|Placebo Comparator|Placebo|
89691262|NCT04357301|Experimental|Closed-loop|Closed-loop administration of norepinephrine
89691263|NCT03013231||s/p ACLR|Patients having undergone ACL Reconstruction Surgery with goal of returning to sport. 6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
89691264|NCT04358939|Experimental|Prone decubitus group|Prone positioning of patients on nasal high-flow oxygen therapy with usual care
89691265|NCT04358939|No Intervention|Control group|Patients on nasal high-flow oxygen therapy with usual care and positioned in supine
89691266|NCT04357145|Active Comparator|Standard Exercise Group|Exercise training is given to patients in the form of a home exercise program.
89691267|NCT04357145|Experimental|High Dosage Exercise Group|The high dosage exercise training group will implement the recommended exercise program 3 times more than the standard exercise group.
89691268|NCT01110421|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
89072302|NCT06267872|Experimental|Part B - Group 4|"60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 5 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4~Followed by 300 mcg of CH505TF chTrimer, admixed with 5 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered to be administered at months 6 and 8."
89072303|NCT06267872|Experimental|Part C - Group 5|"Low dose:~100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 1.0 mg of ACU-026-001-1 adjuvant to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4,~Followed by 300 mcg of CH505TF chTrimer, admixed with 1mg empty LNP adjuvant to be administered at months 6 and 8.~OR,~High Dose:~100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 2.0 mg of ACU-026-001-01 adjuvant to be administered as two 0.5 mL doses intramuscularly at month 0, 2, and 4,~Followed by 300 mcg of CH505TF chTrimer, admixed with 2.0 mg of ACU-026-001-1 adjuvant to be administered at months 6 and 8."
89072304|NCT06267872|Experimental|Part C - Group 6|"100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 3 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4,~Followed by 300 mcg of CH505TF chTrimer, admixed with 3 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered to be administered at months 6 and 8."
89072305|NCT06267872|Experimental|Part C - Group 7|"100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 5 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4~Followed by 300 mcg of CH505TF chTrimer, admixed with 5 mcg of 3M-052-AF adjuvant along with 500 mcg of Alum to be administered to be administered at months 6 and 8."
89072306|NCT06267833|Active Comparator|Control group|Receiving the Otago exercise program
89072307|NCT06267833|Experimental|Study group 1|Receiving additional trunk and upper extremity exercises with traditional methods added to the Otago exercise program
89072308|NCT06267833|Experimental|Study group 2|Receiving additional trunk and upper extremity exercises with mobile game method added to the Otago exercise program
89072309|NCT06267820|Active Comparator|TAP block with bupivacaine and ketorolac|Ultrasound guided TAP block with bupivacaine 0.25% (0.5 ml/kg) and ketorolac (0.5 mg/kg).
89072310|NCT06267820|Active Comparator|TAP block with bupivacaine|ultrasound guided TAP block with bupivacaine 0.25% (0.5 ml/kg).
89072311|NCT06267807|Other|MR lymphangiography contrast injection|"GBCM will be administered. Any routinely used macrocyclic GBCM can be used for MR lymphangiography, we generally use Dotarem® (Gadoteric acid- gadoterate meglumine). The dose used is the same standard dose of 0.1 mmol/kg of body weight used for routine intravenous injection. The guidelines and precautions used for intravenous injection of GBCM, should be followed for MR lymphangiography.~Subsequently, post-contrast imaging is performed (again, this will take around 20 minutes)"
89072312|NCT06267794|Experimental|Prolonged release pirfenidone (PR-PFD), 1200 mg group|Subjects will receive one tablet during breakfast and 2 tablets during dinner.
89072313|NCT06267794|Active Comparator|PR-PFD, 1800 mg group|Subjects will receive one tablet during breakfast and 2 tablets during dinner.
89072314|NCT06267794|Placebo Comparator|Placebo group|Subjects will receive one tablet during breakfast and 2 tablets during dinner.
89224064|NCT03421964|Active Comparator|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after traumatic brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, virtual sessions.
89691269|NCT01110421|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefipime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
89072315|NCT06267781||aHSCT|n.10 patients with RRMS referred for pharmacological treatment with myeloablative autologous hematopoietic stem cell transplantation (aHSCT) according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria and guidelines and recommendations from the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
89072316|NCT06267781||BCDT|n.10 patients with RRMS referred for pharmacological treatment with anti-CD20 monoclonal antibody (ocrelizumab or ofatumumab - B cell depleting therapies) according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria.
89072317|NCT06267781||LEM|n.10 patients with RRMS referred for pharmacological treatment with anti-CD52 monoclonal antibody (alemtuzumab) according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria.
89691270|NCT04356911|Placebo Comparator|PLACEBO (Negative Control)|The dental elements of this group had no desensitizing treatment. After whitening therapy, a water-soluble placebo gel (KY®, Johnson & Johnson, SP, Brazil) was applied to dental oral surfaces, then the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of Low Level Laser Therapy (LLLT).
89691271|NCT04356911|Experimental|FBM|The group received the application of a placebo gel associated with LLLT after office bleaching.
89691272|NCT04356911|Experimental|ESTRÔNCIO|After whitening in-office bleaching, the group was treated with desensitization to 10% strontium chloride. Subsequently, a laser tip was positioned at two points (apical and cervical), without emitting light (placebo).
89691273|NCT04356911|Experimental|FBM+ESTRÔNCIO|After whitening in the office, the group received a 10% strontium chloride desensitizer associated with low level light therapy.
89691274|NCT04357067|Experimental|Lingual brackets|Patients with moderate crowding without extraction treated with Incognito lingual bracket (3M Unitek, Bad Essen, Germany)
89691275|NCT04357067|Experimental|Labial brackets|Patients with moderate crowding without extraction treated with labial bracket (3M Unitek, Ca, USA
89691276|NCT04358627||DEXMEDETOMIDINE|Patients receiving dexmedetomidine continuous infusion since their admittance to ICU. Continuous checking of the primary and secondary outcomes
89691277|NCT04358627||No-DEXMEDETOMIDINE|Historical Control patients matched for ICU admittance diagnosis, age, and concomitant disease and medication state. No Dexmedetomidine. CONtinuous checking of primary outcomes
89691278|NCT04356677|Experimental|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
89691279|NCT04356677|Experimental|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
89072320|NCT06267755|Experimental|Extracorporeal Shockwave therapy|Thirty patients will receive Extracorporeal Shockwave therapy and Traditional physical therapy three times per week for six consecutive weeks.
89072321|NCT06267755|Active Comparator|Traditional physical therapy|Thirty patients will receive Traditional physical therapy three times per week for six consecutive weeks.
89072322|NCT06267690||high fibrosis group|No intervention had been adminstered during treatment of patients.
89072323|NCT06267690||low fibrosis group|No intervention had been adminstered during treatment of patients.
89072324|NCT06267677|Experimental|High protein liquid formula|Patients allocated in the intervention group (n=15) received 4 high-protein shakes and the corresponding standard vitamin-mineral (VM) supplementation according to our post BS protocol, then progressed towards a diet that combines traditional foods with 2 hLF shakes per day and VM supplementation for 15 days. Over the following 15 days, patients continued to normalize their diet, including a single hLF shake per day and continued with VM supplementation.
89072325|NCT06267677|No Intervention|Standard care diet|Patients in the control group (n=35) followed the traditional protocol after bariatric surgery (sCD-group) consisting of a progressive diet with traditional foods, recommendation of 23g/d of protein powder and standard vitamin-mineral supplementation during the first 2 weeks after the surgery. From then on and according to current dietary protocols, the recommendation for protein powder decreases from 23g to 15g up to the end of the study.
89072326|NCT06267625||Elderly Individuals|This group will consist of individuals aged 65 and over
89072327|NCT06267612|Experimental|Corheart 6 LVAS|Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) to be used on patients with advanced heart failure.
89072328|NCT06267599||Bladder suture group|This group consisted of patients in whom we could not open the bladder and uterine cervix by dissection, so we had to open the bladder. In this group, the bladder dome was opened and a special suture was passed through the bladder to control bleeding. This procedure was performed to control bleeding.
89072329|NCT06267599||Control group|For the patients in this group, the vascular structures between the bladder and cervix were coagulated one by one. The bladder was not opened during this procedure.
89072330|NCT06267560|Experimental|TQJ230|TQJ230 80mg QM s.c.
89072331|NCT06267560|Placebo Comparator|Placebo|Matching placebo.
89072332|NCT06267547|Experimental|HAIL Online Platform + Fit and Strong! Program|Participants (N=60) will be recruited from two racially diverse churches or senior centers (30 participants per church/center) to examine the efficacy of the HAIL Online platform + F&S! program for older adults in black communities. Participants will complete the 8-week F&S! exercise program (with access to the adjunct HAIL online platform), which will be delivered in-person as well as remote, and then continue to use the HAIL online platform during the 3-mo follow-up.
89072333|NCT06267547|Active Comparator|Fit and Strong! Program|Participants (N=60) will be recruited from two racially diverse churches or senior centers (30 participants per church/center) to examine the feasibility and acceptability of the HAIL Online platform. Participants will complete the 8-week F&S! exercise program (without access to the adjunct HAIL online platform), which will be delivered in-person as well as remote, and then complete the 3-mo follow-up.
89072334|NCT06267534|Experimental|mindfulness-based mobile applications program|mindfulness-based mobile applications program. There are five audio files, listen to one audio file for two days.
89072335|NCT06267534|No Intervention|NO intervention|The control group received no intervention, Scale exam was performed before and after the program in both groups at the same time.
89072336|NCT06267508||Cohort A|HIV-exposed infants and their mothers enrolled in the study
89691280|NCT04356833|Experimental|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - cohort 1|For patients in the rt-PA group, 10 mg of rt-PA dissolved in 5 ml of diluent will be given every 6 hrs for 66 hrs, in addition to standard of care for COVID-19 acute respiratory distress syndrome (ARDS). 6 patients will be receiving Invasive mechanical ventilation and another six will be receiving Non Invasive ventilation.
89691281|NCT04356833|No Intervention|Historical matched controls - cohort 1|"Matched historical controls who received standard of care were also recruited at a ratio of 2 controls to every 1 treatment arm patient. Matching will be done according to the following criteria in the order stated:~Ventilation and oxygen type (IMV and non-invasive oxygen support)~Severity as determined by PaO2/FiO2 ratio~Gender~Age (+/- 2 years, up to a maximum of 10 years)~Ethnicity"
89691282|NCT04356833|Experimental|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - cohort 2|In cohort 2, fewer timepoints will be collected, which will allow for more rapid recruitment while at the same time not compromising safety monitoring. A more flexible dosing regimen for rtPA will be utilised. 30 patients will be recruited in total, with an aim to recruit a minimum of 10 IMV patients and 10 patients on non-invasive oxygen support.
89691283|NCT04664387||patients with myocardial bridge|patients who underwent coronary angiography and was diagnosed as myocardial bridge
89691284|NCT04664387||patients without myocardial bridge|patients who underwent coronary angiography and was diagnosed as without myocardial bridge
89691285|NCT04358783|Experimental|Plasma|Convalescent plasma from cured COVID-19 patients y Supportive management depending on individual needs
89691286|NCT04358783|Experimental|Best Available Therapy|Will receive supportive management depending on individual needs including.
89072337|NCT06267508||Cohort B|HIV-positive infants, identified in the first 12 weeks, and their mothers will be rolled over from Cohort A to Cohort B for long-term follow-up for up to 12 months.
89072338|NCT06267495||Epithelium-on corneal cross-linking group|Patients in this group underwent epithelium-on accelerated corneal cross-linking (epi-on CXL) for the eye with no clinical signs of keratoconus.
89072339|NCT06267495||Follow-up group|Patients in this group were planned to have regular follow-up visits, without intervention, for the eye with no clinical signs of keratoconus.
89072340|NCT06267482|No Intervention|Control|Standard of care medial parapetallar approach
89072341|NCT06267482|Active Comparator|ROSA PSA Parapatellar Approach|Arm using the ROSA with PSA and medial parapetallar approach
89072342|NCT06267482|Active Comparator|ROSA PSA Subvastus Approach|Arm using the ROSA with PSA and medial subvastus approach
89072343|NCT06267469|Other|Grip strength|Using a hydraulic handgrip dynamometer by Saehan according to the procedure to measure grip strength
89072344|NCT06267469|Other|DASH Questionnaire|The DASH questionnaire assesses upper limb disability and consists of 30 questions in the general section and an additional work module with 4 questions and a sport/instrument playing module with 4 questions. Assess symptoms and the inability to perform certain activities based on health status.
89072345|NCT06267469|Other|Likert scale|Measurement strategy, used in surveys to gain knowledge about the degree of acceptance of the orthosis
89072346|NCT06267469|Other|Kapandji score|Is a tool useful for assessing the opposition of the thumb
89072347|NCT06267469|Other|NRS scale|Requires the patient to rate their pain on a defined scale
89072348|NCT06267469|Other|Pinch strength|Using a hydraulic handgrip dynamometer by Saehan according to the procedure to measure grip strength
89072349|NCT06267443|Active Comparator|Group 1|in this group erector spina plane block will be performed before surgery for post operative analgesia
89072350|NCT06267443|Active Comparator|Group 2|in this group after endotracheal intubation bilateral parasternal block will be performed and to the chest tube sides local anesthetic infiltration will be performed
89072351|NCT06267430|Experimental|Intervention group|The participants allocated to the intervention group will receive the personalised training program 'KleuterExtra', developed by dr. Lex Wijnroks from Utrecht University. All parents will receive the book 'Speels Brein' ('Playful Brain') and an age-appropriate addition for preschoolers to this book.
89072352|NCT06267430|No Intervention|Control group|As described, the parents of the control group will also receive the book 'Speels Brein' ('Playful Brain') and the age-appropriate addition for preschoolers to this book.
89072353|NCT06267417|Experimental|Laser|21 patients will receive Low Level Laser therapy using the wavelength (660 nm) to provide biostimulation at 44 different points in the oral cavity along with the standard preventive protocol in the hospital.
89072354|NCT06267417|Sham Comparator|Placebo|21 patients will receive a mock treatment which is the exact repetition of the treatment modality but without any laser emission beside the standard preventive protocol applied in the hospital.
89072355|NCT06267391|Experimental|ReCET Arm|Treatment Arm will receive the ReCET procedure.
89072356|NCT06267391|Sham Comparator|Control Arm|Control Arm will receive a sham procedure.
89072357|NCT06267365||Adult Patients with Painful Chronic Pancreatitis|Participants with chronic pancreatitis scheduled for endoscopic therapy will undergo baseline assessments including EEG, quantitative sensory testing, and psychosocial questionnaires. Follow-up questionnaires will be completed at approximately 3, 6, 12 and 18 months post-procedure.
89072358|NCT06267339|Experimental|Grasp Task|Participants will practice a fine motor grasping task for 20 min during tRNS or sham stimulation.
89691287|NCT04358861|Experimental|Experimental group|Nonsurgical Root canal therapy was performed using dental operating microscope in the experimental group.
89691288|NCT04358861|Active Comparator|Control group|Nonsurgical Root canal therapy was performed without any magnification aid in control group.
89691289|NCT04356521|Active Comparator|Group LS|Ultrasound-guided infraclavicular block - lateral sagittal approach (20 ml 0.5% bupivacaine)
89691290|NCT04356521|Active Comparator|Group CC|Ultrasound-guided infraclavicular block - costoclavicular approach (20 ml 0.5% bupivacaine)
89691291|NCT05620277|Other|Group 1|30 patients will be examined for changes in tooth color.
89691292|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
89691293|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
89691294|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
89691295|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
89691296|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
89691297|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
89691298|NCT01110499|Experimental|Part 2, AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
89691299|NCT01110499|Active Comparator|Part 2, bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.
89691300|NCT04358471|Active Comparator|Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection|Intravitreal AAVACGsCD59 at a dose of 1.071x10e12 vg administered once on Day 0
89691301|NCT04358471|Active Comparator|Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection|Intravitreal AAVACGsCD59 at a dose of 3.56x10e11 vg administered once on Day 0
89691302|NCT04358471|Sham Comparator|Sham Intravitreal Injection|Intravitreal Sham injection administered once on Day 0
89072359|NCT06267339|Experimental|Reach Task|Participants will practice a reaching task for 20 min during tRNS or sham stimulation.
89072360|NCT06267326|Other|Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years|Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years eighteen patients presented with COVID 19 and seventeen patients presented to our hospital post healing with history of using large doses of systemic corticosteroids. patients were managed by aggressive surgical debridement, antifungal drugs Amphotericin B and adjunctive treatment like local irrigation with amphotericin B and hyperbaric oxygen according to systemic conditions of patients. Hyperbaric oxygen was used in five patients post-surgically. all investigations were done with mean values of blood glucose level, hemoglobin and WBC were noticeably abnormal. The degree of severity, length of stay, and mortality rate were significantly correlated with the severity of systemic predisposing factors
89072361|NCT06267326|Experimental|Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17|Twenty-one (60%) males and fourteen (40%) females, mean age was 44.17 years eighteen patients presented with COVID 19 and seventeen patients presented to our hospital post healing with history of using large doses of systemic corticosteroids. patients were managed by aggressive surgical debridement, antifungal drugs Amphotericin B and adjunctive treatment like local irrigation with amphotericin B and hyperbaric oxygen according to systemic conditions of patients. Hyperbaric oxygen was used in five patients post-surgically. all investigations were done with mean values of blood glucose level, hemoglobin and WBC were noticeably abnormal. The degree of severity, length of stay, and mortality rate were significantly correlated with the severity of systemic predisposing factors
89072362|NCT06267287||cases of PJI 2018-2019|All cases of monomicrobial and polymicrobial periprocthetic infection for 2018-2019. Microbiological identification of pathogens of periprosthetic infections and determination of their sensitivity to antibiotics.
89072363|NCT06267287||cases of PJI 2021-2022|All cases of monomicrobial and polymicrobial periprocthetic infection for 2021-2022. Microbiological identification of pathogens of periprosthetic infections and determination of their sensitivity to antibiotics.
89691303|NCT04356131|Experimental|experimental group|Students in the experimental group were taught about massage and progressive relaxation exercises (PRE). The phases of the massage and PRE trainings were first explained by being demonstrated by the author on herself. In the meantime, the trainings were video-taped and uploaded to the mobile phones of the students. After the author, each student was made to perform massage and PRE. Both the exercises and massage techniques were daily performed 3 times a day after pain had started and relaxation exercises lasted 30 minutes whereas massage was performed for 15 minutes consecutively
89691304|NCT04356131|No Intervention|control group|The students in the control group continued their routines during the study.
89072366|NCT06267261|Experimental|Patients with face mask|Birch pollen allergen exposure in ALYATEC chamber with face mask
89072367|NCT06267261|No Intervention|Patients without face mask|Birch pollen allergen exposure in ALYATEC chamber without face mask
89072368|NCT06267235|Experimental|Acute meal test|acute intake of a low protein, high carbohydrate diet. No drug intervention
89072369|NCT06267235|Experimental|Chronic low protein, high carbohydrate diet|Low protein, high carbohydrate diet and habitual diet. No drug intervention
89072370|NCT06267235|Experimental|Low protein , high fat diet|Low protein, high fat diet and habitual diet. No drug intervention
89072371|NCT06267222|Experimental|TRANS-SPINAL STIMULATION IN SCA|The tDCS sessions will be conducted with an intensity of 2mA, utilizing the anodic electrode positioned over the cerebellar region and the cathodic electrode over the thoracic region of the spinal cord (approximately at vertebra T11). These sessions will be integrated into a gait and postural control training protocol, which will progressively increase in difficulty over 4 consecutive weeks on weekdays, excluding weekends. A total of 20 sessions will be administered, each lasting approximately 30 minutes. During each session, the electrodes will be placed, and participants will perform a single leg test on each side of the body. The exercise protocol will then be executed while the tDCS is applied, lasting for 20 minutes. Following the exercise, the single-leg test will be repeated, and the electrodes will be removed.
89072372|NCT06267209||Observacional group|"Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors."
89072373|NCT06267196|Active Comparator|Stress ball group|The patient group in which a stress ball is used during spinal anesthesia.
89072374|NCT06267196|No Intervention|The control group|The group that receives only standard spinal anesthesia
89072375|NCT06267183|Experimental|SV001|
89072376|NCT06267183|Placebo Comparator|Placebo|
89072377|NCT06267157|Experimental|virtual reality training|Data Collection Forms will be administered face to face to nursing students before training. LactaVerse will be introduced to the students in the experimental group. After the introduction and information are given, virtual reality glasses, lenses and pupil distances will be adjusted and placed on their heads. Each student will be given a disposable goggle mask. Students will then be asked to use their devices in a virtual environment; In the first breastfeeding room, the patient will be asked to touch the entire anatomy, including the breast tissue, ductus, and areola, and examine every angle with the finger. In the next stage; The patient will be asked to go to the second breastfeeding room and assist the mother and baby there. In this room, the student will be expected to complete the skill steps without skipping. He/she will not be able to proceed to the next application without making the correct application.
89072378|NCT06267157|Other|theoretical breastfeeding training|This group will receive 2 hours of theoretical breastfeeding training. Model dolls and breasts will be used in theoretical education by applying the classical education model. Entrance Data Collection Form, Breastfeeding Information Form, Basic Empathy Level Scale, Nursing Counseling Skills Scale and Presence Scale will be applied to the students whose informed consent form has been obtained.
89691305|NCT04347083|Experimental|Experiment|Reflex latency will be measured in this arm
89072379|NCT06267144||immunotherapy and chemotherapy|Participants received two to three cycles of neoadjuvant chemoimmunotherapy before surgery. Adjuvant chemotherapy was also administered for 2-3 cycles after surgery. In addition, MRD was detected within 30 days before surgery, 1 week after surgery, 1 month ±7days after surgery, 6 months after surgery.
89072380|NCT06267131|Other|Enrolled patients|All enrolled patients will have brain pulse monitoring
89072381|NCT06267118|Active Comparator|Hypertonic saline nebulization group|First group of patients diagnosed as acute bronchiolitis will be nebulized with hypertonic saline every 6 hours and data will be recorded on a Performa
89072382|NCT06267118|Active Comparator|Adrenaline nebulization group|Second group of patients will be nebulized with adrenaline every 6 hours and data will be recorded on a Performa
89072383|NCT06267105|Experimental|Longitudinal incision|Incision performed longitudinally
89072384|NCT06267105|Experimental|Transverse incision|Incision performed transversally
89072385|NCT06267079|Other|study group|"Core stability Exercises. Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).~+ Selected physical therapy program."
89072386|NCT06267079|Other|control group|Selected physical therapy program. all participants in both groups (A & B) had three sessions per week for a month and a half, every other day. of Selected physical therapy program which consist of (Exercises for tone modulation, balance, lower limb muscular strengthening, and stretching)
89072387|NCT06267066|Active Comparator|Topical Corticosteroids|Patients will be prescribed topical steroids cream twice daily and topical emollient once daily for 3 months.
89072388|NCT06267066|Active Comparator|Fractional carbon dioxide|Patients will receive 3 monthly laser sessions, in addition to the use of topical emollients only once daily in between the sessions.
89072389|NCT06267066|Active Comparator|Combined topical corticosteroids and Laser|Patients will receive 3 monthly laser sessions, in addition to topical steroids twice daily and topical emollient once daily in between the sessions.
89072390|NCT06267053||Kellgren Lawrence Grade|Patients are divided into four groups based on Kellgren lawrence stage
89072391|NCT06267040||women diagnosed with uncomplicated cystitis|women older than 18 years diagnosed with uncomplicated cystitis and treated accordingly
89072392|NCT06267040||control group|women older than 18 years presented for reasons unlikely to affect the lower urinary tract
89072393|NCT06267027|Active Comparator|Exercise|All study groups will be trained on a home exercise program that includes stretching and eccentric strengthening exercises.
89072394|NCT06267027|Experimental|Kinesiotaping and exercise|This study groups will be trained on a home exercise program and kinesiotaping. Kinesiotaping, muscle inhibition and fascia correction techniques will be applied in the forearm as described by Kase et al.
89072395|NCT06267027|Experimental|High intensity laser therapy and exercise|This study groups will be trained on a home exercise program and high intensity laser therapy.
89072396|NCT06267014|Experimental|Virtual Reality sessions|
89072397|NCT06266988|Experimental|Test Product|Sacubitril and Valsartan Tablets 97mg/103mg to be orally administered
89072398|NCT06266988|Active Comparator|Reference product|Entresto® (97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex) to be orally administered
89072399|NCT06266962|Active Comparator|1% Atropine drops|
89072400|NCT06266962|Active Comparator|Epinephrine|
89072401|NCT06266949||Patients|Participants will undergo a visual acuity test. Next they will perform the SONDA test 2 times at one visit and once more in a later visit Participants will fill in a questionnaire
89072402|NCT06266949||Healthy controls|Participants will perform the SONDA test 2 times
89072403|NCT06266936||Cohort with health students|
89072404|NCT06266923|Experimental|SPH6516 tablets|
89072405|NCT06266910|Experimental|Three-dimensional (3D) viewing group|Participants in this group watch a 10-minute training video displayed in 3D mode, twice a day (totaling 20 minutes), five days a week, for four consecutive weeks.
89072406|NCT06266910|Placebo Comparator|Two-dimensional (2D) viewing group|Participants in this group watched a 10-minute training video displayed in 2D mode, twice a day (totaling 20 minutes), five days a week, for four consecutive weeks.
89072407|NCT06266897||EM group|Patient diagnosed with endometriosis after confirmation by laparoscopic surgery and pathologic examination.
89691306|NCT01112293|Experimental|Investigational drug infusion-for safety and effectiveness|Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment
89691307|NCT02174419|Experimental|nalbuphine HCl ER 90mg|nalbuphine HCl ER tablets 90 mg BID
89072408|NCT06266897||Control group|Patient diagnosed without endometriosis after confirmation by laparoscopic surgery and pathologic examination, usually with benign gynecologic conditions such as uterine fibroids or teratomas.
89691308|NCT02174419|Experimental|nalbuphine HCl ER 180 mg|nalbuphine HCl ER tablets 180 mg BID
89691309|NCT02174419|Placebo Comparator|Sugar pill|Placebo tablets BID
89691310|NCT00942851|Experimental|active|AH-8 containing topical intervention
89691311|NCT00942851|Placebo Comparator|placebo|topical intervention WITHOUT AH-8
89691312|NCT05620589||Amoxicillin + Tetracycline + Bismuth + Esomeprazole|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
89691313|NCT05620589||Amoxicillin + Tetracycline + Bismuth + Vonoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
89691314|NCT05620589||Amoxicillin + Tetracycline 5+ Bismuth + Tegoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegoprazan 50mg bid
89691315|NCT05620511|Experimental|Mindfulness based stress reduction|"Age > 55 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 24 on the MMSE"
89691316|NCT05620511|Placebo Comparator|Relaxation|"Age > 55 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 24 on the MMSE"
89691317|NCT01086475|Experimental|D-cycloserine|Subjects randomized to D-cycloserine will be administered 50 mg 30 minutes prior to each of ten Social Skills Training Sessions
89691318|NCT01086475|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive placebo pill 30 minutes prior to each of ten Social Skills Training Sessions
89691319|NCT01112683|Experimental|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
89691320|NCT01112683|Placebo Comparator|Placebo|These are identically-looking pills to the ones in the Memantine Arm
89691321|NCT02245373||Antidepressants|Naturalistic assignment: Patients whose physician decides to indicate antidepressants.
89691322|NCT02245373||Active Monitoring|Naturalistic assignment: Patients whose physician considers starting an Active Monitoring intervention.
89691323|NCT04355741||Ambulatory|Patients that are self-isolated at home
89691324|NCT04355741||Ward|Patients that are in an isolated room at the hospital
89691325|NCT04355741||ICU|Patients that are in the ICU of the hospital
89691326|NCT03032549|Experimental|RTD|2.1 g. beta alanine, 1.3 g arginine nitrate, 200 mg caffeine, 65 mg niacin, 325 mcg folic acid, 45 mcg vitamin B12
89691327|NCT03032549|Placebo Comparator|Placebo|dextrose and non-caloric flavoring
89691328|NCT01113385|Experimental|Galactose|Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.
89691329|NCT04355351|Other|hospital staff exposed to SARS-Cov-2|
89691330|NCT04355351|Other|SARS-Cov-2 infected patient|
89691331|NCT04355507||Patients with suspicions of COVID-19 pneumonia|Patients with suspicions of COVID-19 pneumonia
89691332|NCT01087801|Active Comparator|ChiRhoStim|Human Secretin for Injection
89691333|NCT01087801|Placebo Comparator|Placebo|Saline for Injection
89691334|NCT04355273|Experimental|Heparin with a concentration of 2 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
89691335|NCT04355273|Experimental|Heparin with a concentration of 4 U/ml|heparin dilution is placed in a pressure bag with a pressure of 300 mmHg
89691336|NCT04355273|Placebo Comparator|normal saline|normal saline is placed in a pressure bag with a pressure of 300 mmHg
89691337|NCT04352725|Experimental|experimental procedure|"end-expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat<28cmH2o~incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
89691338|NCT04355429|Experimental|CAPTOPROL|Inhalation administration by nebulization
89691339|NCT04355429|No Intervention|STANDARS CARE|According to surviving covid-Campaign guidelines
89691340|NCT01114555|Experimental|Bevacizumab, Irinotecan and Temozolomide|This is a phase II study of the combination of irinotecan, temozolomide and bevacizumab in patients with resistant NB.
89691341|NCT01114945|Experimental|Video-Mac|Video-Mac device used during intubation procedure
89691342|NCT01114945|Experimental|GlideScope|GlideScope device used during intubation procedure
89691343|NCT01114945|Experimental|McGrath|McGrath device used during intubation procedure
89691344|NCT01114945|Active Comparator|Direct Macintosh Laryngoscopy|Direct Macintosh Laryngoscopy (DL) used during intubation procedure
89691345|NCT01115101|Experimental|Oxycodon|
89691346|NCT01115101|Active Comparator|Patient controlled analgesia (PCA) device with Pritramid|
89072409|NCT06266884|Experimental|Kangaroo care group|The contact numbers of the prospective fathers will be taken and a training video and presentation on kangaroo care will be sent via WhatsApp. Kangaroo care will be applied to the fathers in the experimental group during birth.
89072410|NCT06266884|No Intervention|Control Group|After the fathers are informed that the birth has started, the postpartum questions prepared for the control group will be sent via WhatsApp and filled in by the fathers within the first 24 hours after birth. No other application will be applied to the control group. Father-Baby Attachment Scale questions will be sent to fathers via WhatsApp in the first and fourth months after birth and their answers will be received.
89072411|NCT06266871|Experimental|SOX+Tislelizumab+LDRT|"Laparoscopic exploration is required in all patients to detect occult peritoneal metastases.~All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~Then, LDRT will be performed in the target area (including the primary gastric lesion and positive/suspected positive lymph nodes).~After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab regimen.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab regimen.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."
89072412|NCT06266858|Other|UCG in pre-anaesthetic group|The fasting patients receive UCG in pre-anaesthetic.
89072413|NCT06266858|Other|UCG in post-anaesthetic group|The fasting patients receive UCG in post-anaesthetic.
89072414|NCT06266858|Other|UCG in post-rehydration group|The fasting patients in anaesthetised receive UCG in post-rehydration.
89072415|NCT06266858|Other|cardiac magnetic resonance （CMR） group|The non-fasting patients receive CMR in another time.
89072416|NCT06266845|Other|Knowledge Test|
89072417|NCT06266845|Other|Knowledge Test Satisfaction and Self-Confidence Scale|
89072418|NCT06266845|Other|Perceived Gains Scale and DASS-21 (Depression, Anxiety, and Stress Scale-21)|
89224065|NCT03421964|Experimental|Resilience/Adjustment Counseling with Booster Sessions|Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, virtual sessions; however individuals within this study arm will receive three additional 60-minute, virtual sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
89691347|NCT00943631|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
89691348|NCT00943631|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
89691349|NCT02245529||Patients with benign prostatic hyperplasia (BPH)|
89691350|NCT00947765|Experimental|Autologous blood injection group|This is the study group in whom autologous blood injection was injected at lateral epicondylitis site.
89691351|NCT00947765|Active Comparator|Local corticosteroid injection group|This is the control group in whom the commonly used treatment modality-local corticosteroid injection was given at lateral epicondyle site.
89691352|NCT04311515|Active Comparator|30 mg PU AD|75 subjects will be treated with active PU-AD on a 1:1 ratio qd
89691353|NCT04311515|Placebo Comparator|30 mg Placebo|75 subjects will be treated with placebo SyrSpend on a 1:1 ratio qd
89691354|NCT01089595|Active Comparator|Nilotinib|Nilotinib 400 mg po bid
89691355|NCT01089595|Active Comparator|Nilotinib + Imatinib|Nilotinib 400 mg BID with Imatinib 400 mg daily
89691356|NCT04268693||Study cohort|urinary bisphenol and phthalate levels
89691357|NCT03032159|No Intervention|Control Group|Participants randomized to the control group will receive their usual asthma care from their provider. Additionally, participants in the control group will receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment.
89691358|NCT03032159|Experimental|Text2Breathe Study Group|"The study group spends about 10-20 minutes learning about ways to have better communication with their child's primary care provider about his/her asthma. Additionally this group is enrolled in the Text2Breathe messaging program which sends asthma related educational text messages 2 times a week for 3 months. Participants randomized to the study group will also receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment."
89691359|NCT01089751|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.
89691360|NCT01089751|Placebo Comparator|Placebo|Placebo once daily on an empty stomach for 14 weeks.
89691361|NCT03032315|Experimental|TAH(80/10/12.5) tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide(80/10/12.5) tablet
89691362|NCT03032315|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
89691363|NCT01090921|Experimental|Single-Arm|Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.
89691364|NCT03537274|Experimental|PEG-Intron, 0.5 mg/kg|PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
89691365|NCT03537274|Experimental|PEG-Intron, 1.0 mg/kg|PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
89691366|NCT03537274|Experimental|PEG-Intron, 1.5 mg/kg|PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
89691367|NCT03537274|Active Comparator|Interferon Alfa-2b|Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.
89691368|NCT01091155|Experimental|ColonRing TM|
89691369|NCT00939653|Experimental|Single Arm - Clofarabine with Chemo|All patients receive the same treatment regimen consisting of clofarabine, etoposide, cyclophosphamide, cytarabine, and filgrastim. Up to 4 courses of therapy may be given.
89072419|NCT06266832|Experimental|Total Neoadjuvant Therapy with Short-course Radiation followed by Adebrelimab plus CAPEOX|"The enrolled patients with MSS-type advanced ultra low rectal adenocarcinoma will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and biopsy or local excision.~Radiotherapy uses a short-range mode, irradiating the primary tumor and high-risk areas with dose of 25 Gy.~After radiotherapy, PD-L1 antibody (20mg/kg, intravenously guttae, 2courses) immunotherapy combined with 2 courses of CAPEOX chemotherapy was performed.~1-4 weeks after the end of the combined treatment plan in step 2), biopsy or local excision of the lesion is performed."
89072420|NCT06266819|Experimental|the chewing of a mint-flavored gum group|In data collection, pregnant women will sign an informed consent form before the application. Personal Information Form, VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled out. In addition to the routine treatment plan, the application will begin at least 4 hours after the antiemetic administration. The application will continue by chewing mint-flavored gum twice a day for at least 15 minutes for 3 days. The VAS scale will be filled after the morning chewing application, and the VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled in after the evening application. The forms of patients discharged during this period will be filled in via phone.
89229904|NCT00999440|Experimental|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done.Patients who start with any opiate and then switch to methadone, move to methadone follow up
89691370|NCT02527291||Study Group|"The Study group will comprise of seropositive CMV patients undergoing cardiothorathic surgery and having a complicated postoperative course.~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done three times: at enrollment, follow up 1 (7 days post operation) and follow up 2 (14 days post operation).~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
89691371|NCT02527291||Control Group 1|"The first control group will be comprised of patients who are seropositive CMV undergoing cardiothorathic surgery and having a normal postoperative course.~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done two times: at enrollment and follow up 1 (7 days after discharge).~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
89072421|NCT06266819|No Intervention|control group|In data collection, pregnant women will sign an informed consent form before the application. At least 4 hours after the antiemetic administration, the Personal Information Form, VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled out. Routine treatment and nursing care will be applied to the control group, and no intervention will be performed. 1. After the forms are applied, the forms will continue to be filled for 3 days: VAS Scale in the morning, VAS Scale in the evening, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale. The forms of discharged patients will be filled in via phone.
89072422|NCT06266780|Experimental|Intervention Group|Group receiving enhanced package of postpartum family planning support
89072423|NCT06266780|No Intervention|Control Group|Group receiving basic postpartum family planning information
89072424|NCT06266767|Experimental|Group 1|PIEB bolus vol (ml) : 8 PIEB time interval (min) : 60 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
89072425|NCT06266767|Experimental|Group 2|PIEB bolus vol (ml) : 8 PIEB time interval (min) : 45 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
89072426|NCT06266767|Experimental|Group 3|PIEB bolus vol (ml) : 10 PIEB time interval (min) : 30 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
89072427|NCT06266767|Experimental|Group 4|PIEB bolus vol (ml) : 10 PIEB time interval (min) : 45 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
89229905|NCT00054691|Experimental|Iressa (ZD1839)|Iressa (ZD1839) 250 mg by mouth daily.
89072428|NCT06266767|Experimental|Group 5|PIEB bolus vol (ml) : 10 PIEB time interval (min) : 60 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
89072429|NCT06266767|Experimental|Group 6|PIEB bolus vol (ml) : 10 PIEB time interval (min) : 75 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
89072430|NCT06266767|Experimental|Group 7|PIEB bolus vol (ml) : 12 PIEB time interval (min) : 60 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
89072431|NCT06266767|Experimental|Group 8|PIEB bolus vol (ml) : 12 PIEB time interval (min) : 45 PCEA bolus vol (ml) : 5 PCEA lockout time interval (min) : 20
89072432|NCT06266754|Experimental|Oral polio vaccine|Oral polio vaccine, 2 drops on a sugar lump
89072433|NCT06266754|Placebo Comparator|Placebo|Saline, 2 drops on a sugar lump
89072434|NCT06266741||Patients with infective endocarditis|Patients between the ages of 18-65 diagnosed with infective endocarditis according to the Duke criteria
89072435|NCT06266741||Patients without infective endocarditis|Patients between the ages of 18-65 without diagnosed with infective endocarditis according to the Duke criteria
89072436|NCT06266650|Experimental|Pelvic Muscle Energy - One sided|Receives pubic abduction/adduction somatic dysfunction combinations one sided
89072437|NCT06266650|Active Comparator|Pelvic Muscle Energy - two sided|Receives pubic abduction/adduction somatic dysfunction combinations two sided
89072438|NCT06266598|Other|obesity|"Children with obesity were recommended to have a diet appropriate for their age and gender and exercise at least 3 days a week for at least 60 minutes each time.~All obese children under the age of 14 were started on metformin treatment at 1000 mg (500 mgx2) per day, and children over this age were started on metformin treatment at the adult dose of 2000 mg (1000 mgx2) per day."
89072439|NCT06265896|Experimental|Kinesio taping +Pelvic floor exercise training|They will be treated by Elastic Kinesio-tape of (K-Active) brand which will be applied over abdomen, which will be changed every 3 days and this will be maintained along four weeks, plus conventional pelvic floor exercises; 30 minutes, 3 times/week for 12 sessions.
89072440|NCT06265896|Active Comparator|Pelvic floor exercise training|They will be treated by conventional pelvic floor exercises; 30 minutes, 3 times/week for 12 sessions.
89072441|NCT06265870|Active Comparator|Specific anthelminthic|Participants were asked to provide stool samples for three consecutive days for testing through microscopy, culture, and PCR to detect parasites. Following the analysis of the stool samples, participants will receive specific anthelminthic treatment tailored to the results of the stool tests.
89072442|NCT06265870|Placebo Comparator|Empirical anthelminthic|Participants will receive an empirical anthelminthic regimen consisting of albendazole 400 mg twice a day for seven consecutive days. Following this treatment, a follow-up complete blood count (CBC) will be requested to assess responsiveness.
89072443|NCT06265714||One ICCU Registry|The cohort was observed receiving all the necessary treatment in the ICCU.
89072444|NCT06265376|Experimental|Educational Video Intervention|Participants have been randomly selected into this arm to receive intervention via the educational video in addition to regular treatment and recovery options.
89072445|NCT06265376|No Intervention|No Intervention|Participants have been randomly selected into this arm to not receive intervention and continue with regular treatment and recovery options.
89072446|NCT06264557|Experimental|Treatment group|"Device : SB-100~Cognitive training will be conducted once a day, and it will take 15 to 30 minutes.~It consists of cognitive training and educational videos."
89072447|NCT06264557|Other|Contol group|Educational book : book of education on daily rules for preventing dementia
89072448|NCT06264414|Experimental|DTT106|1 hard capsule once a day, consistently 30 minutes after the same meal each day
89072449|NCT06264414|Active Comparator|dutasteride and tamsulosin|1 hard capsule once a day, consistently 30 minutes after the same meal each day
89072450|NCT06264310|Placebo Comparator|Placebo|8 study subjects will receive placebo once daily subcutaneous injection for 7 days.
89229906|NCT02530879|Experimental|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
89072451|NCT06264310|Experimental|5.0 mg R2R01|8 study subjects will receive 5.0 mg R2R01 once daily subcutaneous injection for 7 days.
89072452|NCT06264310|Experimental|7.5 mg R2R01|8 study subjects will receive 7.5 mg R2R01 once daily subcutaneous injection for 7 days.
89072453|NCT06264310|Experimental|10.0 mg R2R01|8 study subjects will receive 10.0 mg R2R01 once daily subcutaneous injection for 7 days.
89072454|NCT06264271||Group with nutrition education|Patients who experienced at least one structured education session between 24 months before sensor initiation and 6 months after sensor initiation were allocated to the group with education.
89072455|NCT06264271||Group without nutrition education|Patients who received standard care, which may have included short education during routine visits or self-education through online resources or educational materials, were assigned into the group without education.
89072456|NCT06263816|Experimental|Carvédilol|
89072457|NCT06263816|Placebo Comparator|Placebo|
89691372|NCT02527291||Control Group 2|"The second control group will include seronegative patients for CMV undergoing cardiothorathic surgery with complicated and uncomplicated post-operative course.~Blood work for CMV PCR and IL28 will be done at enrollment. All other visits include data collection from computerized medical records only."
89691373|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 50 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
89691374|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 65 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
89072461|NCT06263088|Other|EQUITY GI|"Data gathering~Program development and implementation~Health literacy"
89072462|NCT06262867|Experimental|Intervention|Participants randomized to the intervention group will receive an early allergen introduction supplement.
89072463|NCT06262867|No Intervention|Control|Participants randomized to the control group will follow the guidance of their pediatrician.
89072464|NCT06261632|Experimental|Experimental group|"The intervention will consist of carrying out a physiotherapy protocol, consisting of strength training through blood flow restriction, with an occlusion pressure of 40-50% of the LOP (Limb Occlusion Pressure) and a load of 20-30%. of 1RM performed ad hoc for patients with hemophilic arthropathy.~The intervention protocol will be carried out in person under the supervision of the main researcher. The intervention will last 4 weeks, with a frequency of 3 weekly sessions. In total there will be 12 sessions lasting approximately 30-45 minutes"
89072465|NCT06261632|No Intervention|Control group|The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients.
89072466|NCT06261593|Experimental|Experimental group|"The intervention will consist of carrying out a physiotherapy protocol, consisting of strength training through blood flow restriction, with an occlusion pressure of 40-50% of the LOP (Limb Occlusion Pressure) and a load of 20-30%. of 1RM performed ad hoc for patients with hemophilic arthropathy.~The intervention protocol will be carried out in person under the supervision of the main researcher. The intervention will last 4 weeks, with a frequency of 3 weekly sessions. In total there will be 12 sessions lasting approximately 30-45 minutes."
89072467|NCT06261593|No Intervention|Control group|The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients
89072468|NCT06261411|Experimental|Lung Ultrasound|Lung ultrasound based on specified protocol as primary method of investigation
89072469|NCT06261411|No Intervention|Routine Care|Routine care defined as conventional chest x-ray as primary method of investigation
89072470|NCT06257238|Experimental|Experimental|The study group includes 38 post neck dissection surgeries with shoulder dysfunction patients treated with fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller) for 30 min., each session includes three games exercise (Dance loop, Tennis and Boxing) with 10 min. for each game and 1 min. rest in between; in addition to their physical therapy program (Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
89072471|NCT06257238|Active Comparator|Active comparator|The study group includes 38 post neck dissection surgeries with shoulder dysfunction patients treated with traditional physical therapy program (Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
89072472|NCT06257212|Active Comparator|BCG vaccine|Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
89072473|NCT06257212|Active Comparator|MMR vaccine|Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
89072474|NCT06257212|Placebo Comparator|Placebo|Subcutaneous saline + intradermal saline at inclusion and after 3 months.
89072475|NCT06254534|Placebo Comparator|Control|In the control group, only unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
89072476|NCT06254534|Experimental|Lidocaine|lidocaine (1.5 mg/kg) within unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
89072477|NCT06254534|Experimental|magnesium|magnesium (20 mg/kg) within unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
89072478|NCT06254534|Experimental|dexmedetomidine|Dexmedetomidine (1 mcg/kg) within unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
89072479|NCT06254534|Experimental|Esmolol|Esmolol (1 mcq/kg) within unlabeled saline prepared in 50 ml will be administered intravenously for 10 minutes before general anesthesia induction after standard monitoring on the operating room table.
89072480|NCT06254014|Experimental|Exendin-4 Fc fusion protein injection(1.2mg）|1.2mg,Subcutaneous injection in the abdomen,Bi-weekly for 54 weeks.
89691375|NCT04355039|Experimental|Pomalidomide, Dexamethasone & INCB053914 80 mg twice daily|INCB053914 will have a dose escalation in a 3 + 3 design.
89229907|NCT02530879|Active Comparator|Antireflux medication|"Intervention includes treatment with one of the following:~Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~Lansoprazole-Dose range 15mg per day- 30mg twice a day~Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~Rantidine-Dose range: 150 mg twice a day or 300 mg once a day.~Rantidine may be used in combination with any of the above"
89522906|NCT03395431|Active Comparator|FAB group|Arm A - Finger prick autologous blood (FAB) plus conventional treatment The patients will use FAB alongside conventional therapy as recommended by their treating ophthalmologist. A fingertip of the hand will be wiped with an alcohol steret and self-pricked using a standard diabetic lancet. The drop of blood is produced as normal and applied to the lower fornix of the affected eye(s) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards
89229908|NCT02530879|Experimental|Voice therapy and Anti-reflux therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
89229909|NCT03957499|Placebo Comparator|the control group|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
89072481|NCT06254014|Experimental|Exendin-4 Fc fusion protein injection(2.4mg）|The first dose of 1.2 mg of JY09 injection was administered, the dose was adjusted to 2.4 mg after two weeks, after which 2.4 mg was maintained to continue subcutaneous injection in the abdomen, bi-weekly treatment for 52 weeks.
89072482|NCT06254014|Placebo Comparator|placebo(0.6ml）|JY09 placebo injection 0.6 ml, biweekly abdominal subcutaneous injection for 26 weeks, followed by randomization in a 1:1 ratio into JY09 (1.2 mg) and JY09 (2.4 mg) for 28 weeks, biweekly subcutaneous injections.
89072483|NCT06253091|No Intervention|robit-assist transperitoneal laparoscopic radical cystectomy|robit-assist radical cystectomy was performed transperitoneal
89072484|NCT06253091|Experimental|robit-assist extraperitoneal laparoscopic radical cystectomy|robit-assist radical cystectomy was performed extraperitoneal
89072485|NCT06251492|Experimental|Experimental Group|Stereotactic body radiotherapy of 8 Gray (Gy) x 3 on targeted metastasis determined by MDT + Adebrelimab 20mg/kg IV every 3 weeks (Q3W) for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
89072486|NCT06249711|Active Comparator|Active stimulation|Low-intensity transcranial focused ultrasound stimulation of deep brain targets involved in food addiction
89072487|NCT06249711|Sham Comparator|Sham stimulation|Zero-intensity transcranial focused ultrasound stimulation of deep brain targets involved in food addiction
89072488|NCT06247800|Active Comparator|Patient undergoing chest drain with the use of VR device|Patient undergoing chest drain with the use of VR device on, for those on VR device, they will be shown a video consisting of calming nature scene together with soothing instrumental music.
89072489|NCT06247800|Active Comparator|Patient undergoing chest drain without the use of VR device|Patient undergoing chest drain without the use of VR device on, as per standard practise
89072490|NCT06246721|Active Comparator|Subjects Agree Self-management Group|Women with pelvic organ prolapse requires ring pessary for treatment. Those who agree to join the study and agree to learn how to self-management of vaginal pessary.
89072491|NCT06246721|Placebo Comparator|Subjects Refuse Self-management Group|Women with pelvic organ prolapse requires ring pessary for treatment. Those who agree to join the study and refuse to learn how to self-management of vaginal pessary.
89522907|NCT03395431|No Intervention|Control group|Arm B - Conventional treatment only The patients will use conventional therapy (artificial tears, cyclosporin drops and punctal plugs/cautery) as recommended by their treating ophthalmologist
89522908|NCT03125863|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove enlarged prostatic tissue. Following the aquablation intervention, a urinary catheter will be inserted to apply pressure on treated tissue for hemostasis.
89691376|NCT03537664|Experimental|Total bacteria analysis after 1rst- and 2nd-visit procedures|DNA levels and activity (RNA/DNA ratio) of total bacteria after the first-visit procedures (root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation) and the second-visit protocol (intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation). Additionally, the composition of the active microbiome will be assessed by Next Generation Sequencing (NGS) analysis of the root canal samples, and the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
89072492|NCT06244550|Experimental|Placebo + metformin|"Double blinded: matching placebo + metformin~Placebo daily metformin 1500mg daily"
89072493|NCT06244550|Experimental|Ganwei + metformin|"Double blinded: Ganwei + metformin~Ganwei 500mg/15 kg of body weight, daily metformin 1500mg daily"
89691377|NCT03537664|Other|Bacterial species analysis after root canal preparation|DNA levels and activity (RNA/DNA ratio) of Bacteroidaceae sp. 272 , Cutibacterium acnes, Selenomonas spp., and Enterococcus faecalis after root canal preparation.Additionally, the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
89691378|NCT01116037|Other|ATS 3f Aortic Bioprosthesis|ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
89691379|NCT02524405||Normal Controls|Upto 85 normal elders, 50-90 years old who are within normal limits on the study neuropsychological battery will be enrolled. All patients involved in the study will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET.
89691380|NCT02524405||Alzheimer's Disease (AD)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
89691381|NCT02524405||Mild Cognitive Impairment (VCI)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association criteria for amnestic or multi-domain MCI with MoCA score ≥18 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
89691382|NCT02524405||Subcortical Vascular Impairment (VCI)|Sixty-five subjects meeting the American Heart Association-American Stroke Association (AHA-ASA) criteria for probable vascular dementia (VaD) or probable vascular mild cognitive impairment (VaMCI) due to subcortical ischemic vascular disease , and probable or possible Cerebral Amyloid Angiopathy using the Modified Boston Criteria116 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
89691383|NCT02524405||LBD Spectrum|Sixty- five subjects with: Dementia with Lewy Bodies (DLB) meeting the criteria for probable Dementia with Lewy Bodies with MMSE score ≥20; or PD-MCI meeting the proposed Level I criteria for Mild Cognitive Impairment in Parkinson's Disease with MoCA score 18-24; or; PDD meeting the criteria for probable Parkinson's Disease - Dementia and MMSE score ≥20 will be enrolled. All patients involved will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
89691384|NCT03538678|Experimental|Kwit app|Use of Kwit smartphone app
89691385|NCT03538678|No Intervention|Standard of care|Patient initiated follow-up post discharge
89691386|NCT03032081|Experimental|High Intensity Group|3 set of 4 minutes of cycling intense exercise, 4 days per week, for 8 weeks at about 80% to 90% of heart rate reserve
89691387|NCT03032081|Active Comparator|Moderate Intensity Group|40 to 47 minutes of continuous cycling exercise at 50% to 60% of heart rate reserve, 4 days per week, for 8 weeks.
89691388|NCT03014323|Experimental|Galantamine then Placebo, WW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in white women (WW)
89691389|NCT03014323|Placebo Comparator|Placebo then Galantamine, WW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks in white women (WW)
89691390|NCT03014323|Experimental|Galantamine then Placebo, AAW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in African American Women (AAW)
89691391|NCT03014323|Placebo Comparator|Placebo then Galantamine, AAW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks African American Women (AAW)
89691392|NCT04352413|Experimental|Cohort A: PLM60|20 mg/m2, 4 weeks/cycle, administered on day 1 of each cycle
89691393|NCT04352413|Experimental|Cohort B: PLM60|15mg/m2, 3 weeks/cycle, administered on day 1 of each cycle
89691394|NCT02448823|Experimental|Stylish Events and Mass Media|Mass Media (radio, posters) and annual Stylish Man/Stylish Living Event (SMLEvent), a multimedia event promoting CHP.
89691395|NCT02448823|Active Comparator|Control arm: mass media only|Mass media
89691396|NCT03393208|Experimental|First Test GIR (Fasting), Then Reference GIR (Fasting)|Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
89691397|NCT03393208|Experimental|First Reference GIR (Fasting), Then Test GIR (Fasting)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
89691398|NCT03393208|Experimental|First Test GIR (Fed), Then Reference GIR (Fed)|Participants received a single oral dose of 500 mg of test GIR tablet (SASS/ China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (MSS/France) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
89224066|NCT03410823|Experimental|PUSH Plus Protein and Nutrition|Participants will be given a whey-based protein supplement containing 27.6g of protein daily for 16 weeks and receive the PUSH intervention. PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive two visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
89224067|NCT03395717|Experimental|Exoskeleton-Assisted Gait Training|Patients conduct sessions of gait training, each lasting 60 minutes, using the powered wearable exoskeleton (Ekso) in addition to conventional therapy. Before the treatment's beginning, a PT checks the correct alignment of the subject's joints with Ekso and the areas of greater pressure between body's skin and device, to set a proper Ekso fit as to customize the padding as well. The best individualized exoskeleton settings should be verified to plan a tailored robotic treatment. During treatment, subjects are trained to interface with the Ekso, with optimal postural arrangement and weight shifting strategies. No strength is required from the patient; only an appropriate balance and weight shifts are necessary to achieve walking, since steps are triggered by the user's lateral weight shift.
89224068|NCT03395717|No Intervention|Traditional Over ground Gait Training|"The Control Group (CG) performs 60 minutes. lasting sessions of Traditional Over ground Gait Training with a senior PT. In the starting phase, the gait task facilitation is allowed by the Pt's assistance or by using aids, such as walkers, tripods etc.~Traditional Over ground Gait Trainings include:~Sit-to-Stand tasks~Exercises for upright position control (right/left load shift): these tasks will allow to include people who are unable to walk in the CG.~CG patients will not use any other robots or treadmill for gait training."
89522909|NCT03390517|Experimental|ICG group|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice with the addition of intraoperative imaging using fluorescence angiography with indocianyne green to assess colon and rectal tissue perfusion.
89522910|NCT03390517|No Intervention|Standard|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice.
89072494|NCT06244550|Placebo Comparator|Placebo|"Double blinded: matching placebo~Placebo daily"
89072495|NCT06244550|Experimental|Ganwei|"Double blinded: Ganwei~Ganwei 500mg/15 kg of body weight, daily"
89072496|NCT06242288|No Intervention|control group|age and sex matched healthy control
89072497|NCT06242288|Active Comparator|Comparative group|20 acne patients taking isotretinoin 20 mg once daily
89072498|NCT06241352|Experimental|Statin addition to chemotherapy|Chemotherapy plus atorvastatin was used in locally advanced pancreatic cancer.
89072499|NCT06238245|Experimental|Combination of PTCy and ATG for GVHD prophylaxis|ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
89072500|NCT06234189|Experimental|Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)|
89072501|NCT06234150|Experimental|Aerobic dance|50 minutes of moderate-intensity aerobic dance three times a week
89072502|NCT06234150|Experimental|Fast-walking|50 minutes of moderate-intensity fast walking three times a week
89072503|NCT06234150|No Intervention|Usual care|Maintain the usual lifestyle and receive medical treatment as normal as the rest of the group.After the baseline evaluation, participants in the control group are asked to maintain their regular lifestyle, including their level of physical activity, and to continue receiving medical treatment and care by standard procedures for 12 weeks. The control group did not receive any encouragement from the researcher to increase the time they spent exercising because, at the time of patient data collection, they were not routinely informed about the benefits of exercise during chemotherapy. Control patients were allowed to engage in the same experimental exercise condition after the 24-week study cycles; if they declined, the study would be stopped.
89072504|NCT06233864|Experimental|Disitamab Vedotin combined with Gemcitabine，2L|Disitamab Vedotin 2.5 mg/kg，iv，Q3W; Gemcitabine 1g/m2，iv，d1, d8 Q3W; Disitamab Vedotin+Gemcitabine is used as second-line treatment for HER2-expressive patients who have failed first-line gemcitabine-free regimen or are intolerant to gemcitabine-containing regimen.
89072505|NCT06233864|Experimental|Disitamab Vedotin，3L|Disitamab Vedotin 2.5 mg/kg，iv，Q3W; Disitamab Vedotin in HER2-expressive patients who have failed at second-line standard treatment or are intolerant
89072506|NCT06233513|Experimental|Healthy Adult Speakers|healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
89072507|NCT06230822|Experimental|VUM02 Injection (hUCT-MSCs)+Conventional treatment|3 predefined dose groups: 5x10^7 cells/person/time, 1x10^8 cells/person/time and 2x10^8 cells/person/time, administered intravenously on D0, D3 and D6 for a total of 3 doses.
89522911|NCT00271817|Active Comparator|Part 1 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
89072508|NCT06230575|Active Comparator|erector spinae block|
89072509|NCT06230575|Experimental|retrolaminar block|
89072510|NCT06230575|Experimental|serratus anterior block|
89072511|NCT06230575|Experimental|pectoral nerve block|
89072512|NCT06230289|Active Comparator|Group B: Transabdominal plane block group|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (RedCAP, Ver 6.6.2 Vanderbilt University, Tennessee, USA) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group B will receive a four-point TAP block.
89072513|NCT06230289|No Intervention|Group C: no interventional group|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (RedCAP, Ver 6.6.2 Vanderbilt University, Tennessee, USA) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group C which will be performed no interventional procedures.
89522912|NCT00271817|Active Comparator|Part 1 -Arm 2|ezetimibe/simvastatin
89072516|NCT06223841|Experimental|Phase Ib - Dose escalation|
89072517|NCT06223841|Experimental|Phase II - Clinical Exploratory Stage|
89072518|NCT06221735|Experimental|Cy-TB test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
89072519|NCT06221735|Experimental|STANDARD F TB-Feron FIA test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
89072520|NCT06221735|Active Comparator|QuantiFERON-TB Gold Plus assay|The QuantiFERON-TB Gold Plus assay will be used as the study's reference standard
89072521|NCT06210334|Experimental|HAIC combined with Tislelizumab and Lenvatinib (HAI-TIS-LEN) group|HAIC with modified FOLFOX (oxaliplatin, 85 mg/ m2, leucovorin 400 mg/ m2, 5-fluorouracil bolus 400 mg/m2 on day 1; and 5-fluorouracil infusion 2400 mg/ m2 for 46 h) on day1-2 every 3 weeks. Tislelizumab injection intravenously after 24h of HAIC every 3 week. Lenvatinib 12/8 mg (weight ≥ 60 kg/< 60 kg) orally once daily starting 1-3 days after HAIC.
89072522|NCT06206746|Experimental|Device arm|May Health procedure performed with the use of the May Health system intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to Polycystic Ovary Syndrome.
89072523|NCT06206746|No Intervention|Control arm|No fertility medication. Crossover participants who choose to crossover after the 3 month follow up visit will restart follow up as per the Device arm.
89072524|NCT06203587|Experimental|patients with colorectal cancer|Subjects were recruited from the Department of Gastroenterology, Huashan Hospital, Fudan University, Shanghai, China.
89072525|NCT06202612|Experimental|SHR0302 quick release tablet and sustained-release tablet|
89072526|NCT06202612|Experimental|SHR0302 sustained-release tablet and quick release tablet|
89072527|NCT06202495|Experimental|Laser and Fluoride|The treatment group will be treated with amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface. For treatment will be used 400 μm diameter and 5 mm long tips of for 4 minutes
89072528|NCT06202495|Active Comparator|Fluoride|The control group will be treated with amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) for 4 minutes.
89072529|NCT06201728|Experimental|Intervention|"The intervention will include 3 follow-up visits in the flare up clinic - one month after hospital discharge (from ED or admission), 3 months after the first visit, 6 months after the second visit. 18 months after the first visit there will be an additional phone-call with structured interview.~Each clinic visit will include:~i. Pulmonologist examination, review of disease state and care, and adjustment of treatment.~ii. Vital signs (blood pressure, saturation in room air, pulse). iii. Blood sample for complete blood count. iv. Filling Asthma Quality of Life Questionnaire (AQLQ). v. Spirometry. vi. Impulse oscillometry and FeNO tests. vii. Arrangement of next follow-up visit."
89072530|NCT06201728|No Intervention|Control|"The control group will undergo 4 phone-call follow-ups with structured interview based on a predefined questionnaire, at the following time frames - 1, 4, 10, and 19 months after hospital discharge.~Each follow-up call will include:~i. Assessment of ACT score. ii. Whether they attend pulmonologist follow-up visit, additional evaluations (IOS or spirometry), and interventions (pulmonary rehabilitation and smoking cessation programs).~iii. Current treatment. iv. Asthma exacerbations, use of systemic steroids, and relevant management."
89072531|NCT06195943|Other|Application Useage Arm|Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
89072532|NCT06192082|Experimental|The conscious sedation group|conscious sedation
89072533|NCT06192082|Active Comparator|Intravenous general anesthesia group|Intravenous general anesthesia
89072534|NCT06191692|Active Comparator|3 months of daily rifampicin plus isoniazid regimen (Arm A)|"Participants will receive rifampicin (dosage based on their weight*, 10mg/kg/day, maximum 600mg), 300 mg of isoniazid, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day from week 1 to week 12 for a total of 90 doses.~* Weight will be monitored and dosing adjusted as needed during treatment"
89072535|NCT06191692|Experimental|1 month of daily rifapentine plus isoniazid regimen (Arm B)|"Participants will receive rifapentine (dosage based on their weight* 300 mg daily for participants body weight of 30kg -&amp;amp;lt;35 kg, 450 mg daily for a weight of 35 to 45 kg, and 600 mg for a weight of &amp;amp;gt;=45 kg), 300 mg of isoniazid, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day from week 1 to week 4 for a total of 28 days.~* Weight will be monitored and dosing adjusted as needed during treatment"
89072536|NCT06190561|Experimental|Treatment A: PF-07940367 Product II|tablet by mouth
89072537|NCT06190561|Experimental|Treatment B: PF-07940367 Product I|tablet by mouth
89072538|NCT06187428|Experimental|PainSMART-strategy (intervention) group|"Patients eligible for inclusion first contact the physiotherapy department and are triaged by a physiotherapist and booked for an initial physiotherapy consultation. After triage, study information and the consent to participate, patients randomised to the intervention group receive the PainSMART-strategy as an adjunct to usual MSKP physiotherapy management.~The strategy includes; exposure to the film 'Be PainSMART:er' at baseline, together with ratings of the clarity of the film's key-messages, a second film exposure prior to the initial consultation and three questions related to the film at the initial consultation.~Baseline data collection will occur prior to first exposure to the film. The film is available exclusively via the questionnaires via Region Östergötland's Quick channel. Therefore it is not shareable or available via online searching."
89072539|NCT06187428|Active Comparator|Usual physiotherapy management (control) group|Patient participants randomised to the control group will follow the usual physiotherapy management pathway at the physiotherapy departments participating in the study.
89072540|NCT06185881|Experimental|Short fiber reinforced resin modified glass ionomer restorations (GC Europe)|
89072541|NCT06185881|Active Comparator|Resin modified glass ionomer restoration. (Fugi II LC, GC Europe)|
89072542|NCT06185296|Experimental|Intelligent telemonitoring|The subjects will be telemonitored using the intelligent telemonitoring system. All subjects will use a CGM, a Fitbit, and a smart pen during the trial period. Staff at the endocrinology clinic will monitor the data and contact the subjects continuously throughout the trial (depending on the individual needs of each subject) using the intelligent telemonitoring system with embedded decision support to facilitate treatment evaluation and adjustments. The subjects will have access to a smartphone app that is able to provide a risk for nocturnal hypoglycemia before bed.
89072543|NCT06185296|Active Comparator|Telemonitoring|The subjects will be telemonitored. All subjects will use a CGM, a Fitbit, and a smart pen during the entire trial period. Staff at the endocrinology clinic will monitor the data and contact the subjects continuously throughout the trial (depending on the individual needs of each subject)
89072544|NCT06185296|No Intervention|Usual care|The subjects will wear a blinded CGM the first 20 days after inclusion, 20 days before the second visit to the trial site, and the final 20 days of the trial. The subjects will use a blinded smart pen throughout the trial period. Hence, the subjects cannot see their measured data during the trial and will not be monitored.
89072545|NCT06185218|Active Comparator|MAP 1 (Posterior wall only)|Type 1 map injection will be used to bladder in one session. In this arm, Botulinum toxin type A injection will be apply to non-trigonal only posterior wall of bladder. The application will be done with cystoscopy and, 20 different point will be aimed. Totally 100 IU Botulinum toxin type A will be applied.
89072546|NCT06185218|Active Comparator|MAP 2 (Posterior wall + bilateral side walls)|Type 2 map injection will be used to bladder in one session. In this arm, Botulinum toxin type A injection will be apply to non-trigonal posterior wall + bilateral side walls of bladder. The application will be done with cystoscopy and, 20 different point will be aimed. Totally 100 IU Botulinum toxin type A will be applied.
89072547|NCT06185218|Active Comparator|MAP 3 (Non-trigonal all walls)|Type 3 map injection will be used to bladder in one session In this arm, Botulinum toxin type A injection will be apply to non-trigonal all walls of bladder. The application will be done with cystoscopy and, 20 different point will be aimed. Totally 100 IU Botulinum toxin type A will be applied.
89072548|NCT06182566|Active Comparator|Control|Catheter ablation including PVI and posterior wall ablation
89072549|NCT06182566|Experimental|Intervention|Convergent ablation Surgical epicardial ablation/ LAA clip/ ablation of ligament of Marshall Catheter Ablation including PVI and posterior wall ablation
89072550|NCT06174961|Experimental|Unfractionated heparin + No exercise|15,000 units of unfractionated heparin will be administered in the thigh. No exercise will be performed afterwards.
89072551|NCT06174961|Experimental|Unfractionated heparin + Double-legged cycle ergometer exercise|15,000 units of unfractionated heparin will be administered in the thigh. Double-legged cycle ergometer exercise will be performed for 1 hour afterwards
89072552|NCT06174961|Experimental|Unfractionated heparin + Single-legged ipsilateral cycle ergometer exercise|15,000 units of unfractionated heparin will be administered in the thigh. Single-legged cycle ergometer exercise in leg where unfractionated heparin injection is given will be performed for 1 hour afterwards
89072553|NCT06174961|Experimental|Unfractionated heparin + Single-legged contralateral cycle ergometer exercise|15,000 units of unfractionated heparin will be administered in the thigh. Single-legged cycle ergometer exercise in contralateral leg to where unfractionated heparin injection is given will be performed for 1 hour afterwards
89072554|NCT06174467|Experimental|First group to receive the intervention|This cluster of classes of different scholls will be instructed in the social emotional and ethical learning training (SEELearning) and being tested trought questionaries.
89072555|NCT06174467|Experimental|Second group to receive the intervention|The cluster of classes of different scholls forming the second group, will not be instructed in the social emotional and ethical learning training (SEELearning) in the first semester, but will answer the questionaries during this period. Than, in next semester they will receive the Training.
89072556|NCT06172894|Experimental|APN401|Intravenous infusion of APN401 in 3-weekly (i.e. 21 days) intervals for a maximum of 4 doses at either 1.5x10^7 PBMCs/kg (i.e., Dose Level 1) or 4.5x10^7 PBMCs/kg (i.e., Dose Level 2), depending on assigned cohort
89072557|NCT06162429||Flexible Thoracoscopy|Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy in the Respiratory Unit, Department of Internal Medicine, Faculty of Medicine UKM
89072558|NCT06162429||Semi-Rigid Pleuroscopy|Subjects with pleural effusion who underwent semi-rigid pleuroscopy using flexible bronchoscopy in the Respiratory Unit, Department of Internal Medicine, Faculty of Medicine UKM
89072559|NCT06161948|Experimental|Time-restricted group|Time-restricted enteral nutrition therapy group
89072560|NCT06161948|Other|Continuous group|Continuous enteral nutrition control group
89072561|NCT06158906||Study group|Dry eye patients were recruited to fill in the questionnaire
89072562|NCT06155981|Experimental|Coke Zero Arm|The participant will be given a Coke Zero before each night-call duty for consumption.
89072563|NCT06155981|Active Comparator|Coke Arm|The participant will be given a Coke before each night-call duty for consumption.
89072564|NCT06152731|Other|HRD tests|To determine HRD status on the tumor, 2 different tests will be used concomitantly
89072565|NCT06149624|Placebo Comparator|control|participants randomized to control group
89072566|NCT06149624|Experimental|Intervention group|participants randomized to intervention group
89072567|NCT06148935||Korean adult participants with HFrEF|Korean heart failure participants with reduced ejection fraction (HFrEF) who are prescribed Verquvo (Vericiguat) for an approved indication by the Ministry of Food and Drug Safety (MFDS) in Korea
89072568|NCT06142877|Experimental|Social Media Use Reduction|
89072569|NCT06142877|No Intervention|Social Media Use as Usual|
89072570|NCT06142825|Experimental|CFTC|Community-Facility Transfusion Committees (CFTCs) will be established at the facilities randomized to this arm.
89072571|NCT06142825|No Intervention|Control|
89072572|NCT06137469|Experimental|Acetaminophen+SHR20004|
89072573|NCT06137469|Experimental|Acetaminophen+Placebo|
89072574|NCT06137287|Experimental|Group 1|In Period 1, participant will receive 6 injections of BOTOX VISTA Dose A on Day 1. In Period 2, participants who meet the retreatment criteria will receive 6 injections of BOTOX VISTA Dose A on either Day 180, 210, 240, or 270.
89072575|NCT06137287|Experimental|Group 2|In Period 1, participant will receive 6 injections of BOTOX VISTA Dose B on Day 1. In Period 2, participants who meet the retreatment criteria will receive 6 injections of BOTOX VISTA Dose B on either Day 180, 210, 240, or 270.
89522913|NCT00271817|Active Comparator|Part 1 - Arm 3|Niacin (ER)
89072576|NCT06137287|Experimental|Group 3|In Period 1, participant will receive 6 injections of BOTOX VISTA placebo on Day 1. In Period 2, participants who meet the retreatment criteria will receive 6 injections of BOTOX VISTA Dose A on either Day 180, 210, 240, or 270.
89072577|NCT06137287|Experimental|Group 4|In Period 1, participant will receive 6 injections of BOTOX VISTA placebo on Day 1. In Period 2, participants who meet the retreatment criteria will receive 6 injections of BOTOX VISTA Dose B on either Day 180, 210, 240, or 270.
89072578|NCT06135337|Experimental|Group THIODERM ELATE|Subjects who will receive THIODERM ELATE into upper and lower lip (66.7% of enrolled subjects)
89072579|NCT06135337|Active Comparator|Group JUVÉDERM ULTRA 3|Subjects who will receive JUVÉDERM ULTRA 3 into upper and lower lip (33.3% of enrolled subjects)
89072580|NCT06133140||Blinded monitoring|Continuous postoperative vital sign monitoring blinded to clinicians and investigators.
89072581|NCT06133140||Unblinded monitoring|Continuous postoperative vital sign monitoring unblinded to clinicians and investigators.
89072582|NCT06128109|Other|Group THIODERM LEFT|Split Face Design: Test Device left midface and Comparator Device right midface
89072583|NCT06128109|Other|Group JUVÈDERM LEFT|Split Face Design: Test Device right midface and Comparator Device left midface
89072584|NCT06122311|Experimental|N-acetylcysteine|amphotericin b (0.5-1.25 mg/kg )over 6-8 hours +NAC 600mg twice daily throughout amphotericin b treatment
89072585|NCT06122311|No Intervention|amphotericin b|amphotericin b (0.5-1.25mg/kg)over 6-8 hours infusion
89072586|NCT06113068|Experimental|Fistura procedure|
89072587|NCT06112626|Experimental|Intervention Group|Intervention Group: In addition to the current educational document available for CHG bathing, patients in the intervention group would be provided access to a CHG bathing video through multiple avenues (QR codes placed in the room/unit, video provided on unit iPads). Nurses will be instructed to provide QR codes to patients to scan and watch the video. Patients can scan the QR code using their own smart device or through unit-based iPads. After viewing the video, there is another QR code to scan that goes to a short patient survey.
89072588|NCT06112626|No Intervention|Control Group|Control Group: Patients in the control group would have access to the current education available (patient education document) - usual care
89072589|NCT06112353|Active Comparator|Neostigmine plus Glycopyrrolate|"0.07 mg/kg Neostigmine plus 0.014 mg/kg glycopyrrolate~2 syringes numbered 1 and 2~Syringe #1: Glycopyrrolate~Syringe #2: Neostigmine"
89691399|NCT03393208|Experimental|First Reference GIR (Fed), Then Test GIR (Fed)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/ France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
89072590|NCT06112353|Active Comparator|Sugammadex|"2.0 mg/kg of Sugammadex plus saline equivalent~2 syringes numbered 1 and 2~Syringe #1: 0.9% sodium chloride~Syringe #2: : full Sugammadex dose + 0.9 sodium chloride (QS to match volume)"
89072591|NCT06110936|Experimental|ts-DCS Group|ts-DCS will be administered using a direct current stimulator (TCT Research Limited, Hong Kong). 2-mA intensity ts-DCS will be applied to the experimental group, with the active electrode being the cathode electrode. The two electrodes (35-cm2) to be used will be immersed in saline solution (0.9% NaCl). The stimulation electrode (cathodal) will be placed slightly above the spinous process of the T10 vertebral process, while the reference electrode (anodal) will be placed horizontally on the left deltoid.
89072592|NCT06110936|Sham Comparator|Control Group|ts-DCS will be administered using a direct current stimulator (TCT Research Limited, Hong Kong). 2-mA intensity ts-DCS will be applied to the control group, with the active electrode being the cathode electrode. The two electrodes (35-cm2) to be used will be immersed in saline solution (0.9% NaCl). The stimulation electrode (cathodal) will be placed slightly above the spinous process of the T10 vertebral process, while the reference electrode (anodal) will be placed horizontally on the left deltoid. In the application to the control group, the placement of the electrodes will be the same as the active protocol, and unlike the experimental group, the stimulation will be stopped after 30 seconds. This sham procedure has been reported to be a good pseudostimulation method that does not cause significant experimental effects due to the initial itching sensation it provides.
89072593|NCT06107062|Experimental|400mg Full Spectrum Cannabidiol (fsCBD)|
89072594|NCT06107062|Experimental|400mg Broad Spectrum Cannabidiol (bsCBD)|
89072595|NCT06107062|Placebo Comparator|Placebo|
89072596|NCT06105528|Experimental|Cohort 1 PMN310 175mg or placebo|PMN310 175mg or placebo administered as a 60-minute infusion.
89072597|NCT06105528|Experimental|Cohort 2 PMN310 350mg or placebo|PMN310 350mg or placebo administered as a 60-minute infusion.
89072598|NCT06105528|Experimental|Cohort 3 PMN310 700mg or placebo|PMN310 700mg or placebo administered as a 60-minute infusion.
89072599|NCT06105528|Experimental|Cohort 4 PMN310 1400mg or placebo|PMN310 1400mg or placebo administered as a 60-minute infusion.
89072600|NCT06105528|Experimental|Cohort 5 PMN310 2800mg or placebo|PMN310 2800mg or placebo administered as a 60-minute infusion.
89072601|NCT06094686||Ankylosing spondylitis group|Thirty patients with AS according to the modified New York criteria were included in this cross-sectional study.
89072602|NCT06094686||Healthy volunteers|Control group was consisted of 31 healthy volunteers
89072603|NCT06094556|Experimental|SHR-1826|Dose escalation; Dose expansion; Therapeutic effect expansion.
89691400|NCT04352491||Patients with liver disease|All people who have shown at Institute of Liver and Biliary Sciences (1st January 2018 - 31st March 2020), will be sent the SMS for participation.
89691401|NCT01092559|Experimental|nitric oxide via GeNO Nitrosyl system|Nitric Oxide via GeNO Nitrosyl system
89072604|NCT06089837|Experimental|EC5026|Multiple Ascending Doses of oral EC5026
89072605|NCT06089837|Experimental|Placebo|Single doses of matching oral placebo
89072606|NCT06089317|Experimental|Compound Decoction (CD) group|
89072607|NCT06089317|Active Comparator|Dendrobii Caulis (DC) group|
89691402|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
89691403|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
89691404|NCT01116661|Experimental|ALA for glioma (WHO G1-IV) subjects|Up to 300 patients with diagnosed glioma (WHO G1-IV) eligible for surgery will be entered into the trial and will be given 5-Aminolevulinic Acid (ALA) orally at a dose of 20mg/kg body weight preoperatively
89691405|NCT00944021|Experimental|PA-824 50 mg/qd|
89691406|NCT00944021|Experimental|PA-824 100mg/qd|
89691407|NCT00944021|Experimental|PA-824 150mg/qd|
89691408|NCT00944021|Experimental|PA-824 200mg/qd|
89691409|NCT00944021|Active Comparator|Rifafour e-275mg|
89691410|NCT04354883|Active Comparator|Schmitz-Hinkelbein-Method|
89691411|NCT04354883|Active Comparator|Hinkelbein-Schmitz-Method|
89691412|NCT03393754|Experimental|Sci-B-Vac® Hepatitis B Vaccination|Sci-B-Vac® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.
89691413|NCT03393754|Active Comparator|Engerix-B® Hepatitis B Vaccination|Engerix-B® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 20ug, IM injection at Days 0, 28, and 168.
89691414|NCT03394768||NICOM Cheetah®|Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac.
89691415|NCT03394768||FloTrac®|Same patient population as the NICOM Cheetah® group as described above as all patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice).
89691416|NCT03587428|Experimental|Zinc-A toothpaste|In this arm, participants received Zinc-A toothpaste (test product 1) in the form of slurry.
89691417|NCT03587428|Experimental|Zinc-B toothpaste|In this arm, participants received Zinc-B toothpaste (test product 2) in the form of slurry.
89691418|NCT03587428|Other|Mineral Water|In this arm, participants received mineral water.
89691419|NCT03593200|Experimental|Experimental: Cohort 1|270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364*
89072608|NCT06089317|Experimental|Houttuynia Cordata (HC) group|
89072609|NCT06089317|Placebo Comparator|Placebo Atomization (PA) group|
89072610|NCT06089317|Active Comparator|Artificial Tears (AT) group|
89072611|NCT06087640|Experimental|aQIV|MF59-adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains
89072612|NCT06087640|Other|Comparator QIV|Non-adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains
89072613|NCT06081725|Experimental|Playful interactions first session in a face-to-face format|Playful interactions operationalized by dramatic improvisation techniques based on verbal and non-verbal elements in a face-to-face format. This arm will take part in the playful interactions in a face-to-face format in the first session and in the active control in the second session
89072614|NCT06081725|Active Comparator|An active control condition first session in a face-to-face format|An active control condition that involves introductory conversation and movement exercises in a face-to-face format. This arm will take part in the active control in a face-to-face format in the first session and in the playful interaction in the second session
89072615|NCT06081725|Experimental|Playful interactions first session in an online format.|Playful interactions are operationalized by dramatic improvisation techniques based on verbal and non-verbal elements in an online format. This arm will take part in the playful interactions in an online format in the first session and the online active control in the second session
89072616|NCT06081725|Active Comparator|An active control condition first session in an online format|An active control condition that involves introductory conversation and movement exercises in an online format. This arm will take part in the active control in an online format in the first session and in the online playful interaction in the second session.
89072617|NCT06079385|Experimental|Acupuncture group|The patients who received acupuncture treatment in addition to a standard rehabilitation program
89072618|NCT06079385|No Intervention|Control group|The patients who received the standard rehabilitation program.
89072619|NCT06065826||subjects with myogenic TMD|"Subjects diagnosed as myogenic TMD according to the presence of trigger points in masseter, temporalis, upper trapezius and C5-C6 articular pillars Subjects are heavy smartphones users, using the SAS-SV, the cuffof value for males is 31 and for females is 33.~Subjects have forward head posture assessed by CVA <49.9 degrees"
89072620|NCT06065826||subjects without myogenic TMD|"Subjects are heavy smartphones users, using the SAS-SV, the cuffof value for males is 31 and for females is 33.~Subjects have forward head posture assessed by CVA <49.9 degrees"
89072621|NCT06065670|Experimental|Clemastine 12 mg, then clemastine 8 mg, then Placebo|Group 1 will receive the treatment (clemastine) for the first 90 days. They will receive clemastine 12 mg for 14 days followed by clemastine 8 mg for 76 days, and then switch to the placebo (a sugar pill) for the remaining 90 days
89072622|NCT06065670|Experimental|Placebo, then Clemastine 12 mg, then Clemastine 8 mg|Group 1 will receive the placebo for the first 90 days. Then, they will switch to clemastine (treatment) for 90 days. They will receive clemastine 12 mg for 14 days followed by clemastine 8 mg for the remaining 76 days.
89072623|NCT06053710|Other|Patients with chronic kidney failure|Patients with chronic kidney failure will wear bioimpedance sensors at the upper back and lower anterior leg for three weeks.
89072624|NCT06053710|Other|Patients with severe overhydration|Patients with severe overhydration will wear bioimpedance sensors at the upper back, lateral thorax, anterior thigh, and lower anterior leg throughout an intensive dialysis treatment regime (~2-10 days).
89072625|NCT06041789|Experimental|Donepezil|
89072626|NCT06041789|Placebo Comparator|Placebo|
89072627|NCT06039137||Clemastine group|Subjects receiving standard of care treatment with paclitaxel either as monotherapy or as part of a combination for any standard of care oncologic indication. Subjects received a paclitaxel premedication regimen containing dexamethasone 10 mg IV and clemastine 2 mg IV
89072628|NCT06039137||Cetirizine group|Subjects receiving standard of care treatment with paclitaxel either as monotherapy or as part of a combination for any standard of care oncologic indication. Subjects received a paclitaxel premedication regimen containing dexamethasone 10 mg IV and cetirizine 10 mg PO
89072629|NCT06039098||Participants|Participants are patients who are undergoing invasive ICP and ABP measurement as part of their normal medical treatment.
89072630|NCT06032637|Active Comparator|Pfannenstiel incision|Patients randomized to the Pfannenstiel incision arm will undergo a transverse skin incision 2-3cm above the symphysis pubis. Subcutaneous tissue will be dissected until anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the inferior epigastric arteries. Rectus muscles will be separated manually along midline using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally with uterine traction to deliver fetus. The visceral peritoneum will not be closed. Rectus muscles will not be re-approximated. Subcutaneous tissue will not be irrigated. Subcutaneous tissue will be closed if over 2cm depth. Skin will be closed with non-absorbable suture subcuticularly.
89072631|NCT06032637|Experimental|Supra-Umbilical|Patients randomized to the supra-umbilical transverse incision arm will undergo a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. Subcutaneous tissue will be bluntly dissected until anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. Rectus muscles will be split manually along midline using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally with uterine traction to deliver fetus. The visceral peritoneum will not be closed. Rectus muscles will not be re-approximated. Subcutaneous tissue will not be irrigated. Subcutaneous tissue will be closed if over 2cm depth. Skin will be closed with non-absorbable suture subcuticularly.
89224069|NCT03395314|Placebo Comparator|midazolam|Midazolam IV; 0.04mg/kg over 40 minutes
89224070|NCT03395314|Active Comparator|low dose ketamine|ketamine IV; 0.5 mg/kg over 40 minutes
89224071|NCT03329092|Experimental|Aztreonam-Avibactam ± Metronidazole|All patients randomised to this arm will receive ATM-AVI; all patients with cIAI will receive MTZ for anaerobic cover
89224072|NCT03329092|Active Comparator|Meropenem ± Colistin|All patients randomised to this arm will receive MER; addition of COL will be at investigator's discretion in line with local practice
89224073|NCT03293680|Experimental|Pembrolizumab Arm|1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks
89224074|NCT03290261|Experimental|Patients with reccurent cystitis|Patient perform 3 hypnosis sessions
89224075|NCT03205124|Experimental|Pre-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Once the stimulation is complete, the stimulator is detached and the patient is informed of the surgical date. The wires are taken out at the conclusion of the pre-operative appointment. These patients will have fine gauge wires for post-operative sham stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. However, the voltage will only be increased to a level they are able to sense.
89224076|NCT03205124|Sham Comparator|Sham stimulation|These patients will have the stimulator attached to their wires 3 days prior to scheduled surgical date and postoperatively as were in the previous groups. However, the voltage will only be increased to a level they are able to sense. The stimulator was then be turned off without the patients' knowledge. All connections are left in place for anhour duration. These patients will similarly have their wires removed after the conclusion of their pre-operative appointment and at the first post-operative follow-up within 1 week of surgery.
89224077|NCT03205124|Experimental|Pre and Post-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date and then again immediately post operatively. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Patients randomized to this group will also receive 1 hour of continuous electrical stimulation post-operatively. These patients will have fine gauge wires for post-operative stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit for one hour.
89224078|NCT03172975|Experimental|Na-GST-1/Alhydrogel|100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
89224079|NCT03172975|Experimental|Na-GST-1/Alhydrogel + CPG 10104|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
89224080|NCT03172975|Experimental|Na-GST-1/Alhydrogel + GLA-AF|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
89224081|NCT03172975|Placebo Comparator|Saline Placebo|Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
89224082|NCT03155022|Experimental|RIC+ ICIC +|Patients with remote ischemic conditioning and intracoronary ischemic conditioning
89224083|NCT03155022|Other|RCI - ICIC -|Control group with no remote ischemic conditioning and no intracoronary ischemic conditioning
89224084|NCT03037879|Experimental|SPT|Speed of Processing Training
89224085|NCT03037879|Active Comparator|Control Group SPT|Control group to SPT treatment group
89072632|NCT06031259|Experimental|Idursulfase-IT|Participants will receive idursulfase-IT once monthly and weekly IV infusions of elaprase at the dose used in previous studies (HGT-HIT-045/SHP609-302) via IDDD until benefit is no longer derived from the treatment, or treatment is no longer tolerable, or up to approximately 10.4 years.
89072633|NCT06028503|Experimental|Acceptance and Commitment Therapy + Continuous Glucose Monitoring + Lifestyle Education (ACT+CGM+LE)|Participants assigned to ACT+CGM+LE will have both of the above modules in addition to three ACT modules based on Gregg et al.8 and traditional ACT therapy19. Two facilitators will lead the ACT sessions: Dr. Marek or Dr. Ratcliff and one trained doctoral-level clinical psychology student under their direct supervision (i.e., one licensed provider paired with a student). We will run all sessions in a group format. Participants will be given breaks between modules and one long lunch break.
89072634|NCT06028503|Experimental|Continuous Glucose Monitoring + Lifestyle Education (CGM+LE)|Participants assigned to CGM+LE will attend the group LE workshop. CGM training will occur after the 5 hour lifestyle education delineated above (same content, but less informal discussion). This will include training on using blood glucose monitoring devices, setting up the App on the smartphone (including activating the hypoglycemic alarm) and how to apply the glucose sensors on the arm. If a sensor does fall off a participant, a member of the study team will provide a spare sensor to the participant. The glucose range for participants will be set at between 70 and 140 mg/dL, unless the study physician (Dr. Olaiya) determines otherwise. The CGM device will allow us to calculate the percentage of 'time in range' per day, peak glucose, nocturnal glucose and number of hypoglycemic events. The CGM training will be managed by Dr. Olaiya and/or Dr. Kelly, and a medical/dietetic students.
89072635|NCT06028503|Active Comparator|Lifestyle Education (LE)|Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy.
89072636|NCT06026397|Experimental|Cohort 1|Participants will receive dose A of SK10 (n=6) or placebo (n=2)
89072637|NCT06026397|Experimental|Cohort 2|Participants will receive dose B of SK10 (n=6) or placebo (n=2)
89072638|NCT06026397|Experimental|Cohort 3|Participants will receive dose C of SK10 (n=6) or placebo (n=2)
89072639|NCT06021639|Experimental|Low fiber diet group|250 ml Sennozit A+B calcium (half dose is taken orally at 17.00 on the day before the procedure and the other half at 19.00 will be consumed. Enema 210 cc (Monobasic sodium phosphate 28.5 g. Dibasic sodium phosphate 10.5 g.) The procedure is rectal at 07.00 in the morning. will be used as Routine feeding of the patient up to the last 24 hours before the procedure. He/she will consume low fiber food in the last 24 hours.
89072640|NCT06021639|No Intervention|Clear diet group|250 ml Sennozit A+B calcium (half dose is taken orally at 17.00 on the day before the procedure and the other half at 19.00 will be consumed. Enema 210 cc (Monobasic sodium phosphate 28.5 g. Dibasic sodium phosphate 10.5 g.) The procedure is rectal at 07.00 in the morning. will be used as Routine feeding of the patient up to the last 24 hours before the procedure. The last 24 hours will consume clear diet.
89072641|NCT06019507|Experimental|Arm 1|TCD601administered after liver transplant with splenectomy with cyclophosphamide and immunosuppression therapy
89072642|NCT06014580||Patients diagnosed with endometrial cancer|Patients diagnosed with endometrial cancer between January 2016 and December 2019 at participating sites will be included.
89072643|NCT06013384|Experimental|Active/Active Group|This group will receive eight total treatments of LIFUP across two days one week apart (four treatments each day).
89224086|NCT03037879|Experimental|mSMT|Story Memory Technique
89691420|NCT03398278|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
89691421|NCT03398278|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
89691422|NCT03593902|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
89691423|NCT00948935|Experimental|Chemotherapy|Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
89691424|NCT04354805|Experimental|Group A|The group of 50 patients are going to receive Chlorpromazine (oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days) every 24 hours for 14 days in addition to the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
89691425|NCT04354805|No Intervention|Group B|A group of 50 patients control group who will recieve only the convential treatment of COVID-19 according to the Egyptian Ministry of Health protocol.
89691426|NCT04354571|Experimental|GROUP (Erector spinae block):|were given general anesthesia plus Erector spinae plane block
89691427|NCT04354571|Active Comparator|GROUP (caudal block):|were given general anesthesia plus caudal block
89691428|NCT03944681|Other|Droperidol group|Droperidol (Xomolix, Kyowa Kirin) 1.25 mg i.v. bolus
89691429|NCT03032003|Active Comparator|Cysticlean arm|Cysticlean (2 BID for 15 days)
89691430|NCT03032003|Placebo Comparator|Placebo arm|Placebo (2 BID for 15 days)
89691431|NCT01116895|Active Comparator|LEO 22811 0.5 mg|LEO 22811 0.5 mg: Oral solution
89691432|NCT01116895|Active Comparator|LEO 22811 1.5 mg|LEO 22811 1.5 mg: Oral solution
89691433|NCT01116895|Active Comparator|LEO 22811 3.0 mg|LEO 22811 3.0 mg: Oral solution
89691434|NCT01116895|Placebo Comparator|Placebo|Placebo: Oral solution
89691435|NCT03935555|Experimental|Oral - 50mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
89691436|NCT03935555|Experimental|Oral -100 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
89691437|NCT03935555|Experimental|Oral - 200 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
89691438|NCT03935555|Experimental|Oral - 300 mg|PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
89691439|NCT03031691|Experimental|Brontictuzumab and trifluridine/tipiracil|Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label.
89691440|NCT03031613|Experimental|PEEP group|Application of 5 cmH2O PEEP during mechanical ventilation
89224087|NCT03037879|Active Comparator|Control mSMT|Control group to mSMT treatment group
89229910|NCT03957499|Active Comparator|Group dexamethasone/Bupivacaine:|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml).(
89229911|NCT03957499|Active Comparator|Group Magnesium sulphate/Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
89072644|NCT06013384|Other|Sham/Active Group|This group will receive sham LIFUP for four treatments over one day, followed by four total treatments of active LIFUP across one day one week after sham.
89072645|NCT06003192|Other|Universal Opt-out HIV Screening|The intervention is offering universal opt-out HIV screening to all adolescents 15 to 21 years of age that are seeking care in the emergency department.
89072646|NCT05991518|Experimental|Phase Ia - Dose escalation|To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and/or recommended phase II dose (RP2D) of intravenous IAH0968 in combination with the GC regimen for adult patients with HER2-positive advanced solid tumors who have failed standard treatment.
89072647|NCT05991518|Experimental|Phase IIa - Clinical Exploratory Stage|The RP2D determined from the Phase Ib study is used as the first-line treatment for HER2-positive advanced or metastatic biliary tract cancer (BTC) patients who have not received prior systemic therapy. The efficacy of IAH0968 in combination with the GC regimen is compared to the efficacy of placebo in combination with the GC regimen based on the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, using the objective remission rate (ORR) as the evaluation criteria.
89072648|NCT05988827|Experimental|NGenuity|NGenuity allowing a reduced light intensity to 15% during cataract surgery
89072649|NCT05988827|No Intervention|SOM|microscope without NGenuity with light intensity of 60%, similar to a Standad Operating Microscope (SOM)
89072650|NCT05987410|Experimental|Nordic Walking (NW)|Nordic walking is a form of physical activity that originated in Finland and has gained popularity worldwide. It involves walking with the use of specially designed poles that resemble ski poles. This activity engages both the upper and lower body, making it a full-body workout. In summary, Nordic walking offers several benefits for cardiovascular individuals with Type II diabetes and those who are obese or overweight. These benefits include improved heart and lung function, better blood glucose control, weight management, low joint impact, muscle strengthening, improved balance and posture, and social engagement. However, it is important to consult with a healthcare provider before starting any new exercise program to ensure it is safe and suitable for individual health conditions and goals. Regular monitoring and adjustments by healthcare professionals can help optimize the benefits and ensure ongoing progress.
89072651|NCT05987410|Active Comparator|Standard Rehabilitation (SR)|A standard rehabilitation program for cardiovascular individuals with Type II diabetes and obesity/overweight typically involves a combination of cardiovascular exercise, strength training, and education on lifestyle modifications. The program is prescribed by a cardiologist and supervised by physiotherapists or exercise specialists. It includes an initial assessment to determine exercise parameters, cardiovascular exercise to improve heart function and manage blood glucose levels, strength training to increase muscle mass and aid in weight management, education on nutrition and lifestyle modifications, and progress tracking and monitoring to optimize outcomes. These programs provide benefits such as improved cardiovascular fitness, better blood glucose control, weight management, enhanced muscle strength, and overall well-being.
89072652|NCT05987410|Other|Control Group (CG)|Cardiological counseling for cardiovascular individuals with Type II diabetes and obesity/overweight often includes recommendations for unsupervised aerobic physical activity. This type of counseling typically involves a cardiologist providing guidelines and recommendations for safe and effective exercise routines. In summary, it involves an initial assessment to determine exercise capacity and precautions. The cardiologist prescribes specific guidelines for unsupervised aerobic physical activity, including the type, frequency, intensity, and duration of exercise sessions. Safety considerations are provided. The benefits of unsupervised aerobic physical activity include improved cardiovascular health, enhanced blood glucose control, weight management, psychological well-being, and increased energy and stamina.
89072653|NCT05983458|Other|patients with severe symptomatic aortic stenosis|Real-world patients with severe symptomatic aortic stenosis allocated to TAVI treatment by local heart Team will be included in the study according to the inclusion and exclusion criteria specified below.
89522914|NCT00271817|Active Comparator|Part 2 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
89522915|NCT00271817|Placebo Comparator|Part 2 - Arm 2|ezetimibe/simvastatin combination tablet + niacin (Pbo)
89224088|NCT03028103|Experimental|Part A and B|"Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.~Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19."
89224089|NCT03023163||Older SCI|Individuals that are between the ages of 50-75 years old, have a traumatic SCI, level of injury between C1-T12, non-ambulatory (wheelchair dependent), AIS grade A, B, or C, and injury occurred more than 1 year ago.
89224090|NCT03023163||Older Able-Bodied Controls|Individuals that are between the ages of 50-75 years old and primary language is English.
89224091|NCT03023163||Longitudinal SCI|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
89224092|NCT03023163||Longitudinal Able-Bodied Controls|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
89224093|NCT03020589|Experimental|CYP3A5 based tacrolimus dosing|Subjects in this treatment arm will receive initial tacrolimus based on their genotype i.e., CYP3A5*1/*1 and CYP3A5*1/*3 (Expressers) will receive the initial tacrolimus dose of 0.2 mg/kg/day, with maximum of 20 mg/day in 2 divided doses. For CYP3A5*3/*3 (Non-Expressers), the subjects will receive initial tacrolimus dose of 0.1 mg/kg/day in 2 divided doses.
89224094|NCT03020589|No Intervention|Control|Subjects in the prospective control group will receive standard tacrolimus dosing as recommended per package insert and will not be dosed based on their genotype. Similarly, subjects that underwent renal transplant after 2010 and received standard tacrolimus dosing (per package insert) will serve as historical controls.
89224095|NCT02932475|Active Comparator|Treatment|Metformin 1000 mg twice a day
89224096|NCT02932475|Sham Comparator|Placebo|Placebo, identical to Metformin
89224097|NCT02919917|Experimental|Usual Care Group|"Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.~Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.).~Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine ."
89224098|NCT02919917|Experimental|BP Threshold Treatment Group|"Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay.~This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.).~If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg."
89224099|NCT02893553|Experimental|Study 1|Study 1: is a dose escalation to determine the individualized dose of each of 3 medications (midodrine, pyridostigmine, mirabegron) that increases SBP into the normal range (111-139 mmHg). The investigator will be using midodrine hydrochloride, pyridostigmine bromide and mirabegron.
89224100|NCT02893553|Experimental|Study 2|Study2: is a randomized placebo-controlled double-blinded investigation to determine the effect of the normalization of SBP on cerebral blood flow, cognitive function (memory and attention processing) and quality of life. The investigator will be using midodrine hydrochloride, pyridostigmine bromide, mirabegron and placebo.
89224101|NCT02886936|Experimental|Transtibial Testing|This is a feasibility and effectiveness study to assess the iFIT transtibial prosthesis as a viable alternative to a traditional prosthesis. We also hope to gain information that will influence future design iterations.
89224102|NCT02886936|Experimental|Transfemoral Testing|This is a feasibility and effectiveness study to assess the iFIT transfemoral prosthesis as a viable alternative to a traditional prosthesis. We also hope to gain information that will influence future design iterations.
89224103|NCT02879630||Obese Patients|Obese patients (patients whose weight is >190% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by adjusted body weight as part of their routine care.
89224104|NCT02879630||Non-obese Patients|Normal weigh patients (patients whose weight is 80-120% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by total body weight as part of their routine care.
89224105|NCT02756702||All-Poly|All-polyethylene tibia VEGA System® PS - A posterior stabilized total knee arthroplasty (TKA) system using solely all-polyethylene tibia components
89224106|NCT02734485|Active Comparator|active Deep Tms|Each DTMS session consisted in two consecutive stimulations: a first low-frequency (1 Hz) stimulation in the motor cortex (110% of the motor threshold, for 15 minutes)and a second high-frequency (10Hz) one in the prefrontal cortex (100% motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).The coil contains two symmetric devices, perfectly designed to rouse both hemispheres at the same time.
89224107|NCT02734485|Sham Comparator|sham deep tms|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an inactive DTMS coil.
89224108|NCT02507687|Experimental|Bimatoprost Sustained-Release (SR)|Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
89691441|NCT03031613|Active Comparator|ZEEP group|No application of PEEP during mechanical ventilation
89229912|NCT00387712|Experimental|Velocity based treadmill training|6 month of progressive treadmill walking with treadmill speed gradually progressed to meet the training heart rate goals for moderate intensity aerobic exercise, when hemiparetic gait velocity can no longer be safely progressed, incline is added to achieve the heart rate training goals.
89072654|NCT05979935||patients with high-risk of esophageal varices bleeding in liver cirrhosis|The diameter of varices vein is over 0.5cm with red sign in patients with esophageal varices due to liver cirrhosis.
89072655|NCT05979935||patients with low-risk of esophageal varices bleeding in liver cirrhosis|The diameter of varices vein is below 0.5cm with negative red sign in patients with esophageal varices due to liver cirrhosis.
89072656|NCT05979337|Experimental|Empowered Relief (ER) class|Daily Diaries
89072657|NCT05979337|Experimental|Health Education (HE) class|
89072658|NCT05979337|Experimental|Empowered Relief (ER) class and Health Education (HE) class|If randomized to both classes, the HE class will occur first with a week break in between to the ER class.
89072659|NCT05979337|Other|Treatment as Usual (TAU)|
89072660|NCT05977582|Experimental|Spanish Version eBodyProject|"The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance."
89072661|NCT05977582|Active Comparator|Psychoeducational Prevention Program|Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
89072662|NCT05976763|Experimental|Induction therapy (Zanubrutinib, rituximab)|Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.
89072663|NCT05976763|Experimental|Arm A (Zanubrutinib)|Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.
89072664|NCT05976763|Active Comparator|ARM B (Observation)|Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.
89072665|NCT05976581|Experimental|Electronic alert plus structured communication of test results|An electronic health record alert will guide diagnostic testing for pneumonia. For patients with low or moderate probability of bacterial pneumonia, test results will be communicated to the primary team with guidance to consider discontinuing or de-escalating antibiotics.
89072666|NCT05976581|Active Comparator|Electronic alert without structured communication of test results|An electronic health record alert will guide diagnostic testing for pneumonia. The primary care team will access and interpret test results and decide upon composition and duration of antimicrobial without external guidance.
89224109|NCT02507687|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Assigned Primary Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
89224110|NCT02383407|Experimental|Stimulation group 2 Hz|Patient will be randomized to a stimulation group of 2 Hz using Medtronic deep brain stimulation device
89224111|NCT02383407|Experimental|Stimulation group 5 Hz|Patient will be randomized to a stimulation group of 5 Hz using Medtronic deep brain stimulation device
89224112|NCT02321501|Experimental|Treatment (ceritinib, everolimus)|Patients receive ceritinib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89224113|NCT02237079|Experimental|Bazedoxifene/Conjugated Estrogens (BZA/CE)|"Participants assigned to BZA/CE will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. BZA/CE (bazedoxifene/conjugated estrogens) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. The recommended and only FDA approved dosage is one BZA/CE tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications."
89229913|NCT00387712|Experimental|Duration based treadmill training|6 month of progressive treadmill walking with duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress.
89229914|NCT01091389|Experimental|GP ablation|Thoracoscopic PV isolation with GP ablation
89229915|NCT01091389|Experimental|No GP ablation|Thoracoscopic PV isolation with no GP ablation
89229916|NCT01091467||Patients with HF|Each patient seen in hospital emergency or for congestive heart failure and with an ejection fraction above 45%
89229917|NCT01040338||OPRM1 A118G AA genotype|Individuals with the AA genotype at the OPRM1 A118G polymorphism.
89072667|NCT05968144|Experimental|Time-restricted eating|Participants will meet with a nutritionist to discuss dietary recommendations for patients with prostate cancer undergoing ADT. Participants will self-select a 10-hour window in which to consume all food and beverages (with the exception of black coffee and unsweetened tea in the mornings; water is okay at all times).
89072668|NCT05968144|Active Comparator|Unrestricted eating|Participants will meet with a nutritionist to discuss dietary recommendations for patients with prostate cancer undergoing ADT. Participants will try to follow recommendations will no suggestion for meal timing.
89072669|NCT05961241|Active Comparator|running group|women who run on a regular basis
89072670|NCT05961241|Experimental|control|women who do not run
89072671|NCT05956587|Experimental|Study treatment|Participants received SI-B003 and BL-B01D1+SI-B003 in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
89072672|NCT05955729|Experimental|Nap group|The experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
89072673|NCT05955729|Active Comparator|Control group|The control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
89522916|NCT03388567|Experimental|Staff pharmacy whith intervention|Staff pharmacy who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
89522917|NCT03388567|No Intervention|Staff pharmacy without intervention|Staff pharmacy who will receive only pharmacy information
89522918|NCT03390439|Active Comparator|Nd-Yap 1340nm laser|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of Nd-yap 1340nm laser.
89072678|NCT05950997|Experimental|previously untreated chronic lymphocytic leukemia.|Previously untreated CLL patients with ≥1 of the IWCLL 2018 criteria for requiring treatment will be enrolled. Treatment with acalabrutinib may be continued until treatment for 24 months, or until an unacceptable drug-related toxicity occurs or until disease progression, whichever occurs first. Dose modification provisions are provided in the study protocol. Treatment with obinutuzumab or obinutuzumab/chlorambucil is up to 6 cycles per the obinutuzumab package insert.
89072679|NCT05950256|Experimental|N95 mask group|Continuously wearing N95 mask for 4 hours
89072680|NCT05950256|Active Comparator|Surgical mask group|Continuously wearing surgical mask for 4 hours
89072681|NCT05949099|Experimental|Nirogacestat 150 mg|Patients will receive 3-cycle lead-in with systemic therapy with nirogacestat 150 mg po BID, given continuously.
89072682|NCT05944016|Experimental|Dapagliflozin|Dapagliflozin (standard dose 10 mg p.o. once daily).
89072683|NCT05944016|Placebo Comparator|Placebo|Placebo therapy.
89072684|NCT05934942|Experimental|Yasmin® (Reference treatment (R)) followed by BI 1358894 and Yasmin® (Test treatment (T))|
89072685|NCT05933382|Experimental|Corticosteroid Group|A conventional treatment program will be applied to individuals in both groups 5 days a week for 3 weeks. The conventional exercise program will consist of wand exercises, Codman exercises, stretching exercises for all ranges of motion, and TENS (100Hz, 15 minutes). A corticosteroid injection will be administered to the shoulder region of the first group prior to treatment.
89072686|NCT05933382|Experimental|Mulligan Group|A conventional treatment program will be applied to individuals in both groups 5 days a week for 3 weeks. The conventional exercise program will consist of wand exercises, Codman exercises, stretching exercises for all ranges of motion, and TENS (100Hz, 15 minutes). In addition to the conventional treatment program, a mobilization technique with movement will be applied twice a week, with 10 repetitions.
89072688|NCT05931406|Experimental|Emergency medical dispatchers|
89072689|NCT05931406|Experimental|Firefighter|
89072690|NCT05928416||SLA group|300 patients
89072691|NCT05928416||Control group|300 patients
89072692|NCT05924776|Experimental|Plasmodium immunotherapy group|This is a single arm study that is planed to enroll 30 patients with advanced ovarian cancer and each patient will be inoculated with P.vivax-infected red blood cells containing approximately 1-5 × 10^6 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
89229918|NCT01040338||OPRM1 A118G AG or GG genotype|Individuals with the */G allele at the OPRM1 A118G polymorphism
89229919|NCT01089829||CKD Stage 4|eGFR <30
89229920|NCT01089829||CKD Stage 5|Receiving Haemodialysis or Peritoneal dialysis therapy
89072693|NCT05922722||Participants with lupus|
89072694|NCT05910619|Active Comparator|Active brain stimulation|These participants will receive focused TPS (pulsed stimulation) of the specified default mode network regions as specified in the detailed study description.
89072695|NCT05910619|Sham Comparator|Sham brain stimulation|"These participants will also receive focused TPS (pulsed stimulation) of the specified default mode network regions as specified in the detailed study description, though the device will be set to Sham in a blinded fashion by the biostatistician by placing an air pouch in the device hand piece."
89072696|NCT05909332|Experimental|Arm-A|"BP102 (10 mg/kg) iv D1 and D15 repeated administration of Q4W + Chemotherapy ddEC-P(described below). This was followed by maintenance therapy with BP102 (10 mg/kg) iv D1 and D15 repeated administration of Q4W to complete treatment with a total duration of 1 year from the first dose.~Chemotherapy: ddEC-P (dose-dense Epirubicin and Cyclophosphamide followed by Nab-paclitaxel). Epirubicin (75-100 mg/m2) iv D1 + Cyclophosphamide (600 mg/m2) iv D1 repeated administration of Q2W for a total of 4 doses, followed by Nab-paclitaxel (125 mg/m2) once weekly (QW) for 4 weeks."
89072697|NCT05909332|Active Comparator|Arm-B|Chemotherapy: ddEC-P (dose-dense Epirubicin and Cyclophosphamide followed by Nab-paclitaxel). Epirubicin (75-100 mg/m2) iv D1 + Cyclophosphamide (600 mg/m2) iv D1 repeated administration of Q2W for a total of 4 doses, followed by Nab-paclitaxel (125 mg/m2) once weekly (QW) for 4 weeks.
89072698|NCT05906771|Placebo Comparator|CONTROL GROUP|Nutraceutical placebo intake group
89072699|NCT05906771|Experimental|EXPERIMENTAL GROUP|Intake of natural herbal dietary supplement composed of a combination of Hibiscus sabdariffa flowers and Lippia citriodora leaves.
89072700|NCT05899166|Experimental|ketogenic diet|"The diet will be high in protein and healthy fats and comprise meat, fish, fibrous vegetables, nuts, dairy, and berries. Macronutrient composition will be ~ 5% carbohydrate, 20% protein, 70% fat.~Participants will receive a daily multi-vitamin, magnesium supplement, and supplemental salt (bouillon cubes) to ascertain micronutrient sufficiency and help with transition to the diet."
89072701|NCT05899166|Active Comparator|standard diet|"The diet will be consistent with prevailing dietary guidelines and recommendations and contain meat, fish, grains, vegetables, fruit and dairy. At least 50% of grain-based products will be whole grains. Meats will be primarily lean, and dairy products will be fat-free or low-fat. Macronutrient composition will be ~50% carbohydrate (<10% added sugars), 20% protein, 30% fat.~Participants will receive a daily multi-vitamin supplement to ascertain micronutrient sufficiency."
89072702|NCT05895136|Experimental|Enoxaparin plus human albumin|Cohort 1 will receive standard medical treatment plus a combinatorial therapy of enoxaparin and human Albumin.
89072703|NCT05895136|Active Comparator|Standard medical treatment|Cohort 2 (control) will receive only standard medical treatment.
89072704|NCT05894564|Experimental|Arm E - Fluvoxamine 100|Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 1 day, followed by a dose of 100 mg twice a day for 12 days.
89072705|NCT05894564|Placebo Comparator|Arm E - Placebo|"Placebo - appearance and size matched to active study drug.~Placebo will be self-administered orally by each participant, with number of tablets matched to active study drug dosing."
89072706|NCT05889975|Active Comparator|interdental tooth brush|the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily,then the brush will be used after completion of manual tooth brushing it will be gently inserted between the teeth and orthodontic appliance, the patient will be instructed to use appropriate size brush and a smaller brush size if it feels too tight.
89072707|NCT05889975|Active Comparator|single tufted brush|the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily,then the brush will be used after completion of manual tooth brushing it will be gently inserted between the teeth and orthodontic appliance.
89072708|NCT05889975|Active Comparator|water irrigator|the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily,thenThe patients will be instructed to use water irrigator after manual tooth brushing with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation.
89072709|NCT05888116|Experimental|Hidratante HA|"The investigational product consists of a new vaginal moisturizing gel (class IIb medical device) presented in the form of 5 ml single-dose containers. Each patient will be given 12 single-dose containers inside white boxes identified only with the patient code.~For each participant, the total duration of treatment will be 4 weeks."
89072710|NCT05888116|Active Comparator|Cumlaude Hidratante Interno®|"The investigational product is a marketed vaginal moisturizing gel (class IIb medical device) presented in the form of 5 ml single-dose containers. Each patient will be given 12 single-dose containers inside white boxes identified only with the patient code.~For each participant, the total duration of treatment will be 4 weeks."
89072711|NCT05886062|Experimental|Experimental Group|In addition to routine basketball technical-tactical training, the athletes in the experimental group will be given motor imagery training to facilitate sensorimotor relearning.
89072712|NCT05886062|Active Comparator|Control Group|Individuals in the control group will only continue their routine basketball technical-tactical training.
89072713|NCT05885685|Experimental|Healthy Participants|Participants will be prescribed a 1 week daily oral dose of nabilone which will begin at 0.25 mg and work their way up to 2 mg over the course of 7 days.
89072714|NCT05881733|Other|Study population|This study will have only a single arm. Patients will undergo pulmonary vein isolation using the 31 mm balloon size of POLARx FIT. High-definition 3D maps will be constructed before and after cryoablation to assess the antral lesion size.
89072715|NCT05876377||Boosted with Pfizer-BioNTech COVID-19 bivalent mRNA vaccine|Patient identified in the vaccine registry having a single dose Pfizer-BioNTech COVID-19 bivalent mRNA vaccine after completion of the primary series
89072716|NCT05876377||Not Boosted with Pfizer-BioNTech COVID-19 bivalent mRNA vaccine|Patient not located in the vaccine registry having a single dose Pfizer-BioNTech COVID-19 bivalent mRNA vaccine after completion of the primary series
89072717|NCT05873504|Experimental|High Oscillatory Index Device|Patients in this arm will receive a device that vibrates with high oscillatory index.
89072718|NCT05873504|Active Comparator|Low Oscillatory Index Device|Patients in this arm will receive a device that vibrates with low oscillatory index.
89072719|NCT05870917|Experimental|VRD-based regimen Combined CART-ASCT-CART2|"VRD：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle. Autologous BCMA-directed CAR-T cells, Double infusion intravenously at a target dose of (2-4)±20％ x 10^6 anti-BCMA CAR+T cells/kg respectively.~Participants will receive VRD-based induction, first CAR-T infusion, VR consolidation, ASCT followed by the second CAR-T infusion, and R maintenance."
89072720|NCT05870228|Other|Single-arm intervention group|Single-arm intervention
89072721|NCT05866094|Experimental|Nutrition Intervention|Intervention Feasibility Testing (11-months, Phase 2)
89072722|NCT05865405|Experimental|Arm 1: 12 month MS CATCH tool intervention|Participants in arm 1 will receive 12 months of use of the MS CATCH tool. This will include in-visit interventions and monthly questionnaires.
89072723|NCT05865405|Other|"Arm 2: 6 month usual care, 6 month MS CATCH tool intervention"|"Participants in arm 2 will receive 6 months usual care followed by 6 months of MS CATCH tool intervention. These first 6 months will be used to assess the definition of usual care."
89072724|NCT05864144|Experimental|Part A - SNS-101 Monotherapy Dose Escalation and Dose Expansion|"SNS-101 IV alone every 21 days. Patients will initially enroll in dose escalation cohorts until the MTD/RP2D is determined.~Patients will receive the MTD/RP2D for dose expansion."
89072725|NCT05864144|Experimental|Part B - SNS-101 in combination with cemiplimab and Dose Expansion|"SNS-101 IV and cemiplimab IV every 21 days. Patients will initially enroll in dose escalation cohorts until the MTD/RP2D is determined.~Patients will receive the MTD/RP2D for dose expansion."
89229921|NCT01091545|Other|FFDM+DBT|Single-armed study. Women are their own controls with paired images of digital mammography and breast tomosynthesis.
89072726|NCT05864144|Experimental|Part C - Cohort Expansion - SNS-101 alone or in combination with cemiplimab|SNS-101 IV alone or in combination with cemplimab IV every 21 days at the RP2D.
89072727|NCT05851768|Active Comparator|Erector spinae plane block with 0.25% bupivacaine|Patients will receive ultrasound guided ESPB with 0.25% bupivacaine
89072728|NCT05851768|Experimental|Erector spinae plane block with 0.25% bupivacaine and Magnesium|Patients will receive ultrasound guided ESPB with 0.25% bupivacaine and magnesium
89072729|NCT05851768|Experimental|Erector spinae plane block with 0.25% bupivacaine and Dexmedetomidine|Patients will receive ultrasound guided ESPB with 0.25% bupivacaine and dexmedetomidine
89072730|NCT05848297||Prolonged automated TCD|
89072731|NCT05839925||Ankylosing spondylitis group|The patients were selected on a randomized form among the patients with a diagnosis of AS according to the modified New York criteria who referred to Istanbul Physical Medicine Rehabilitation Training and Research Hospital.
89072732|NCT05839925||Healthy volunteers|Healthy volunteers between the ages of 18-75 were selected randomly.
89072733|NCT05837494|Active Comparator|Group ozone|
89072734|NCT05837494|Active Comparator|Group PRGF(plasma rich in growth factors)|
89072735|NCT05836896|Experimental|MDC-CAR-BCMA001|MDC-CAR-BCMA001 will be administered intravenously in ascending dose levels. This trial will test a total of 4 dose levels in order to identify the MTD and/or recommended phase 2 dose for MDC-CAR-BCMA001.
89072736|NCT05824598|Experimental|Treatment|The cases (active treatment) will be treated with an approach that includes osteopathic treatment for pain control (by the Osteopath Bruno Bordoni), systematic swallowing screening (Speech Therapist, Leone Stilo), psychological counseling (Psychologist, Eleonora Volpato, Giulia Novembre ). The duration of treatment will be that of hospitalization, on average about 3 weeks. The osteopathic treatment will last 5 sessions, while the counseling will have one session at the admission and one at the discharge and up to two sessions a week (variable according to individual needs); the swallowing screening will have one session at the admission and one at discharge and about two-three sessions a week (variable according to individual needs).
89072737|NCT05824598|No Intervention|Controls|Controls will follow good clinical practice (in this case systematic screening from a swallowing point of view will not be applied, nor will osteopathic treatment and systematic psychological counseling be considered).
89072738|NCT05812807|Active Comparator|Arm I (pembrolizumab)|Patients receive pembrolizumab IV on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up.
89072739|NCT05812807|Experimental|Arm II (observation)|Patients undergo observation on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up.
89072740|NCT05809687|Active Comparator|Control group|DKP21102_A, DKP21102_C
89072741|NCT05809687|Experimental|Treatment group|DKP21102_A, DKP21102_B
89072742|NCT05800210|Experimental|Allogeneic stem cell transplant with ⍺/β CD3+ T-cell and CD19+ B-cell depleted graft|
89072743|NCT05793450|Experimental|IBI362 - Mild and Moderate Renal Impairment|Group 2 - IBI362 administered SC to participants with mild and moderate renal impairment.
89229922|NCT03955939|Experimental|LY3295668 Erbumine Part A|"LY3295668 erbumine administered orally (Part I).~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
89072744|NCT05793450|Experimental|IBI362 - Healthy|Group 1 - IBI362 administered subcutaneously (SC) to healthy participants with normal renal function.
89072745|NCT05793450|Experimental|IBI362 - Severe Renal Impairment|Group 3 - IBI362 administered SC to participants with severe renal impairment.
89072746|NCT05791305|Experimental|Intervention arm|Will be provided an intervention.
89072747|NCT05791305|No Intervention|Controll arm|Will not be provided the intervention.
89224114|NCT02237079|Placebo Comparator|Placebo|"Participants assigned to placebo will receive a daily tablet that matches the BZA/CE to maintain the blind. Placebo tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. Also to assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication.Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications, again to maintain the blind."
89224115|NCT02162511|Experimental|ARM A Malignant TBI|Malignant diseases Conditioning including total body irradiation and chemotherapy
89224116|NCT02162511|Experimental|ARM B Malignant Non-TBI|Malignant diseases chemotherapy based conditioning
89224117|NCT02162511|Experimental|ARM C Non-malignant|Non-malignant diseases Chemotherapy based conditioning
89072748|NCT05784012|Experimental|Cohort A|"Three stages:~Neoadjuvant: single dose of dostarlimab 500 mg intravenously on day -21 and niraparib 200 or 300 mg orally once daily starting on day -14 until 48 hours prior to the start of definitive radiotherapy (day 0).~Concurrent: definitive radiotherapy (70 Gy in 35 fractions, 1 fraction per day from Monday to Friday) with concurrent Cisplatin at a dose of 100 mg/m2 intravenously on day 1 of week 1, week 4 and week 7.~Maintenance: dostarlimab to be administered as a single infusion dose of 500 mg on day 1 every 21 days from week 11 to week 48. Niraparib will be given once daily at a dose of 200 or 300 mg in cycles of 21 days."
89072749|NCT05784012|Experimental|Cohort B|"Three stages:~Neoadjuvant: single dose of dostarlimab 500 mg intravenously on day -21 and niraparib 200 or 300 mg orally once daily starting on day -14 until the start of definitive radiotherapy (day 0).~Concurrent: definitive radiotherapy (70 Gy in 35 fractions, 1 fraction per day from Monday to Friday). Niraparib is to be given once daily on a continous basis (200 to 300 mg), from w1 d1 until end of w10 in cycles of 21 days.~Maintenance: dostarlimab to be administered as a single infusion dose of 500 mg on day 1 every 21 days from week 11 to week 48. Niraparib will be given once daily on a continous basis at a dose of 200 or 300 mg in cycles of 21 days."
89072750|NCT05775861|Experimental|single shot interscalene brachial plexus with dexmedetomidine added to ropivacaine|A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block.
89072751|NCT05775861|Active Comparator|continuous interscalene brachial plexus block with ropivacaine|A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
89072752|NCT05772637|Experimental|MS Patient with Bladder disorders|
89072753|NCT05766514|Experimental|Arm A (investigational arm): cladribine, cytarabine, and decitabine|
89072754|NCT05766514|Active Comparator|Arm B (control arm): azacitadine with venetoclax or decitabine with venetoclax|
89072755|NCT05759949|Experimental|RLY-5836 Single Agent Arm|RLY-5836 single agent arm for participants with unresectable or metastatic solid tumors
89072756|NCT05759949|Experimental|RLY-5836 + Fulvestrant Arm|RLY-5836 + fulvestrant combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
89072757|NCT05759949|Experimental|RLY-5836 + Palbociclib + Fulvestrant Arm|RLY-5836 + palbociclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
89072758|NCT05759949|Experimental|RLY-5836 + Ribociclib + Fulvestrant Arm|RLY-5836 + ribociclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
89072759|NCT05759949|Experimental|RLY-5836 + Abemaciclib + Fulvestrant Arm|RLY-5836 + abemaciclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer
89072760|NCT05757492|Active Comparator|Dose Optimization Phase - Arm A|Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
89072761|NCT05757492|Active Comparator|Dose Optimization Phase - Arm B|Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
89072762|NCT05757492|Active Comparator|Indication-specific Expansion Phase - Cohort 1 NSCLC-NS|NSCLC-NS participants will receive CHS-006 in combination with toripalimab Q3W
89072763|NCT05757492|Active Comparator|Indication-specific Expansion Phase - Cohort 2 HCC|HCC participants will receive CHS-006 in combination with toripalimab Q3W
89072764|NCT05756348|Other|receives both product|all participants receive both products under evaluation.
89072765|NCT05751993|Experimental|ADAPT intervention|Participants will receive a smart scale and a physical activity tracker and will have three daily goals: weigh daily, a daily personalized active minutes goal, and a daily calorie goal. For 12 weeks, participants will receive 0-3 text messages per day about their behaviors and progress towards their goals which they will be able to rate (like/dislike), along with weekly personalized feedback, progress graphs, and lessons and resources available on the website.
89072766|NCT05751668|Experimental|Arm I (paclitaxel, GM1)|Patients receive GM1 IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.
89072767|NCT05751668|Placebo Comparator|Arm II (paclitaxel, placebo)|Patients receive placebo IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.
89072768|NCT05744063|Experimental|emapalumab|emapalumab solution for infusion twice weekly at a starting dose of 1 mg/kg
89072769|NCT05743179|Experimental|Zoledronate|Zoledronate intravenous infusion (5mg) once and usual care will be provided to the patient and mark the start of 12-month follow-up period
89072770|NCT05743179|No Intervention|Control|Only usual care will be provided to the patient with 12-month follow-up period.
89072771|NCT05740839|Experimental|HIIT Exercise Program Group|"Participants will be randomly assigned to the HIIT exercise group and receive:~3x weekly for 16 week home-based virtually supervised High-Intensity Interval Training.~16-week self-directed exercise follow up period.~3 On-site visits at Week 1, 18 and 34 for assement testing and completion of questionnaires"
89072772|NCT05740839|Active Comparator|Control Group|"Participants will be randomly assigned to the HIIT waitlist control group and receive:~Daily usual activities~2 On-site visits at Week 1, and 18 for assement testing and completion of questionnaires~Option to complete 16 week, 3x weekly HIIT exercise program after initial 16 week period."
89072773|NCT05739279||Lipedema Group|Patients between the ages of 18-85, diagnosed with lipedema, accepted to participate in the study, and at the appropriate sociocultural level to participate in the study are included in this group.
89072774|NCT05739279||Control Group|Those between the ages of 18-85, in an age group similar to the lipoedema group, who agreed to participate in the study, and who were at the appropriate sociocultural level to participate in the study are included in this group.
89072775|NCT05737212|Experimental|Group 1|"Radiation dose: 9 Gy-Eq~Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 9 Gy-Eq"
89072776|NCT05737212|Experimental|Group 2|"Radiation dose: 11 Gy-Eq~Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 11 Gy-Eq"
89072777|NCT05737212|Experimental|Group 3|"Radiation dose: 13 Gy-Eq~Investigational product, boronophenylalanine, DMX-101 500mg/kg/3hr~Investigational Device, DM-BTPS, DM-BNCT - neutron irradiation to reach maximum BNCT dose in brain of 13Gy-Eq"
89072778|NCT05736835|Experimental|CVXGA|CVXGA single intranasal dose 10e7 PFU
89072779|NCT05736835|Placebo Comparator|Placebo|0.9% sterile saline
89522919|NCT03390439|Experimental|Microneedling|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of dermaroller 2,5mm.
89072782|NCT05729724||Change treatment|Deprescribing (patients on hypotensive medications): withdrawal or reduction of one or more medications among cardiovascular and psychoactive drugs with known hypotensive effects (Table) Prescription of vasoactive medications (patients with constitutional hypotension): prescription of Fludrocortisone or other drugs that actively increase blood pressure.
89072783|NCT05720637|Other|Waiting list group|This group will include 40 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist. At the end of this trial, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
89072784|NCT05720637|Sham Comparator|SIA group|This group will include 40 patients with MDD who will be treated with sham intradermal acupuncture (SIA) combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
89072785|NCT05720637|Experimental|AIA group|This group will include 40 patients with MDD who will be treated with active intradermal acupuncture (AIA) combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
89072786|NCT05718934|Active Comparator|"Group N for Standard reversal"|Standard reversal of 50 µg.kg-1 neostigmine (up to a maximum dose of 5mg) and 7 µg.kg-1 glycopyrrolate at the end of surgery (when surgeons finish deep tissues closure) with starting TOF 1-3.
89072787|NCT05718934|Experimental|"Group S for Sugammadex"|Sugammadex 0.5 mg.kg-1 IV will be performed at the end of surgery (when surgeons finish deep tissues closure) with starting TOF 1-3.
89072788|NCT05718427|Experimental|Ayres Sensory Integration Therapy Group|Ayres Sensory Integration (ASI) therapy will be applied to children in the intervention group. In the intervention group, Ayres Sensory Integration Therapy will be performed 3 days a week for a total of 10 weeks, 60 minutes each session, in accordance with the Ayres Sensory Integration Fidelity Measure (ASI-FM). A manualized protocol will be followed based on the principles of ASI-FM, Ayres sensory integration.
89072789|NCT05718427|No Intervention|Waiting Group|The children in the control group will be wait just 10 weeks. The second evaluation will be repeated 10 weeks after the first evaluation. In order for the children in the control group to benefit from sensory integration therapy, after a 10-week waiting period, after the result measurements are applied again, Ayres sensory integration therapy will be applied 3 days a week with 60 minutes each session in accordance with the Ayres Sensory Integration Fidelity Measure (ASI-FM).
89072790|NCT05716425|Experimental|Arm A|"STI-1558~n=600"
89072791|NCT05716425|Placebo Comparator|Arm B|"Placebo~n=600"
89224118|NCT01992861||Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)|Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.
89224119|NCT01955941||Cohort A|Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
89072792|NCT05711030|Active Comparator|Thoracic paravertebral block multiple (3) injections|"Patients will either be in the sitting or prone position for the block. The block will be performed with the ultrasound transducer in the sagittal position about 2.5 to 3 centimeters (cm) lateral to the spinous process using a caudal to cranial in-plane needle approach. The thoracic vertebral levels will be identified by finding the first rib under ultrasound guidance and counting down levels appropriately.~The needle (80 mm 22-gauge echogenic SonoPlex needle from Pajunk) will be introduced in-plane in a caudal to cranial direction until it punctures the costotransverse ligament. Saline in 1 ml increments will be injected to confirm correct placement of the needle tip. Injection of saline or local anesthetics deep to the costotransverse ligament will lead to an anterior displacement of the parietal pleura.~For the 3-level technique, injections will be done at the levels of T2-T3, T3-T4, and T4-T5 with 10 ml of ropivacaine 0.5% at each level."
89111187|NCT02792595|Experimental|Test Product A|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
89072793|NCT05711030|Experimental|Thoracic paravertebral block single injection|"Patients will either be in the sitting or prone position for the block. The block will be performed with the ultrasound transducer in the sagittal position about 2.5 to 3 cm lateral to the spinous process using a caudal to cranial in-plane needle approach. The thoracic vertebral levels will be identified by finding the first rib under ultrasound guidance and counting down levels appropriately.~The needle (80 mm 22-gauge Pajunk) will be introduced in-plane in a caudal to cranial direction until it punctures the costotransverse ligament. Saline in 1 ml increments will be injected to confirm correct placement of the needle tip. Injection of saline or local anesthetics deep to the costotransverse ligament will lead to an anterior displacement of the parietal pleura.~For the single-injection technique, injection of 30 ml of ropivacaine 0.5% will be done at the T3-T4 paravertebral space after negative aspiration."
89072794|NCT05710406|Experimental|Arm I (encorafenib, cetuximab)|Patients receive encorafenib PO and cetuximab IV on study. Patients also undergo collection of blood samples throughout the study and CT or MRI during screening and follow-up.
89072795|NCT05710406|Active Comparator|Arm II (patient observation)|Patients undergo observation per usual care on study. Patients also undergo collection of blood samples throughout the study and CT or MRI during screening and follow-up.
89072796|NCT05707468|Active Comparator|A (hormone)|The patients in arm A with oligometastatic PCa will receive long-term ADT combined with abiraterone.
89072797|NCT05707468|Experimental|B (neoadjuvant hormone and RT)|The patients in arm B with oligometastatic PCa will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
89072798|NCT05706532||Healthy|30 healthy subjects; age >18; sinus rhythm; absence of autonomic diseases or dysfunctions.
89072799|NCT05701306|Experimental|APG-115 monotherapy in part1|Multiple dose cohorts, to determine the RP2D of APG-115.
89072800|NCT05701306|Experimental|APG-115 combined with APG-2575 in part2|Multiple dose cohorts of APG-2575, to determine the RP2D of APG-2575 combined with APG-115.
89072801|NCT05694871|Active Comparator|Arm I (palbociclib)|Patients receive palbociclib PO on study. Patients will be allowed to cross over to Arm II following documentation of disease progression. Patients undergo MRI or CT scans throughout the trial. Patients may also undergo blood sample collection on study.
89072802|NCT05694871|Experimental|Arm II (palbociclib, cemiplimab)|Patients receive palbociclib PO and cemiplimab IV on study. Patients undergo MRI or a CT scan throughout the trial. Patients may also undergo blood sample collection on study.
89224120|NCT01955941||Cohort B|Patients with uveal melanoma who have previously undergone I-125 plaque brachytherapy will be considered for enrollment into this study to evaluate blood flow in eyes with more advanced radiation-induced changes. This group will only undergo a one-time study session. Up to 40 subjects will be recruited for this group.
89224121|NCT06271551|Experimental|Transdermal estradiol|Participants (n=155) receiving transdermal estradiol and androgen deprivation therapy.
89224122|NCT06271551|Active Comparator|Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy.
89224123|NCT06271525|Experimental|cupping therapy|patients with cervical spondylosis will receive cupping therapy one time per month for three months
89224124|NCT06271512||All Participants|Participants with β-thalassemia treated with beti-cel in the post-marketing setting will be followed in this registry study for up to 15 years after infusion with beti-cel to collect real-world longitudinal data.
89224125|NCT06271499|Active Comparator|Group I|Patients underwent radial artery catheterization using standard USG
89224126|NCT06271499|Active Comparator|Group II|Patients underwent radial artery catheterization using smart glasses integrated UGG
89224127|NCT06271486|Active Comparator|Group A (pregabalin group)|Received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
89224128|NCT06271486|Active Comparator|Group B (EBP group)|Received active therapy in the form of an EBP and Group C (control group) received conservative treatment.
89224129|NCT06271486|Active Comparator|Group C (the control group)|received conservative treatment.
89224130|NCT06271473|Active Comparator|subjecting to vitrectomy + ILM peeling only|
89224131|NCT06271473|Active Comparator|subjecting to vitrectomy + ILM peeling + planned foveal detachment|
89224132|NCT06271408|Experimental|Vibrating Mesh Nebulizer First|Participants will receive albuterol delivered via vibrating mesh nebulizer as their first treatment, followed by albuterol delivered via metered dose inhaler and then albuterol delivered via jet nebulizer.
89224133|NCT06271408|Experimental|Jet Nebulizer First|Participants will receive albuterol delivered via jet nebulizer as their first treatment, followed by albuterol delivered via vibrating mesh nebulizer and then albuterol delivered via metered dose inhaler.
89224134|NCT06271408|Experimental|Metered Dose Inhaler First|Participants will receive albuterol delivered via metered dose inhaler as their first treatment, followed by albuterol delivered via jet nebulizer and then albuterol delivered via vibrating mesh nebulizer.
89224135|NCT06271382|Experimental|Acupressure Group|In the research, acupressure will be applied to the patients in the acupressure group on LR 3 Taichung(LR 3), Tai Xi (KI 3), San Yin Jiao(SP 6), Xue Hai (SP 10), Zusanli(ST 36 ) points.
89224136|NCT06271382|Sham Comparator|Sham Acupressure Group|"The same process will continue with the acupressure group by applying pressure to different points in the group where acupressure is applied to the sham points.~Pressure will be applied on the bone area where the meridians do not pass, parallel to the points where acupressure is applied to the sham points (approximately 1-1.5 cm away)."
89224137|NCT06271382|Experimental|Foot Ankle Exercise Group|"The foot and ankle exercise complex includes the following exercises.~Pulling the foot towards itself from the ankle up~Bending the foot downwards from the ankle~Opening the feet like a fan, moving the toes inward and outward, left and right~Circling exercise with ankle~Towel folding exercise~Bottle rolling exercise under your feet (The water in the bottle will be warm tap water)"
89224138|NCT06271369||Tisa-cel cohort|Patients with at least one ICD-10 diagnosis for DLBCL who were at least 18 years old. Patients also had at least three months of continuous health plan enrollment before administration of CAR-T therapy and received tisa-cel following DLBCL diagnosis.
89224139|NCT06271369||Axi-cel cohort|Patients with at least one ICD-10 diagnosis for DLBCL who were at least 18 years old. Patients also had at least three months of continuous health plan enrollment before administration of CAR-T therapy and received axi-cel following DLBCL diagnosis.
89224140|NCT06271356|Experimental|BC-Navi|Apply TCI's patient navigation-and-coaching program and its website/mobile app (Breast Cancer-Navigate) platform to improve timely initiation to patient adjuvant chemotherapy treatment among diverse breast cancer patients.
89224141|NCT06271317||Nissen sleeve gastrectomy|Nissen sleeve gastrectomy patients
89224142|NCT06271317||Sleeve gastrectomy with the data of PMSI|Sleeve gastrectomy with the data of PMSI
89072803|NCT05689645|Experimental|F573 for injection groups|"The first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg,2 mL intramuscular injection (IM), once a day for 7 days,and the subsequent 9 patients with CHB were given doses of 2 mL intramuscular injection (IM), once a day for 7 days, according to the results of the efficacy and safety trials of the first 16 patients. The dosage of the second stage was determined according to the results of efficacy and safety trials of the the first stage . The dosage volume was 2 mL by intramuscular injection (IM), once a day for 14 days.The dosage of the third stage was determined according to the results of the first and second stage efficacy and safety trials. The dosage volume was 2 mL and intramuscular injection (IM) was administered once a day for 28 consecutive days.~The dosage of the above three stages of administration was calculated according to the weight of the most recent visit."
89072804|NCT05689645|Placebo Comparator|Placebo Comparator|"The first stage: the first 16 patients with liver injury,and the subsequent 9 patients with CHB were treated with Sterilizing water for injection , the dose volume was 2 mL, intramuscular injection (IM), once a day for 7 consecutive days, Basic treatment: receiveDiammonium glycyrrhizate enteric-coated capsules at a dose of 150 mg 3 times a day.~The second stage: the dosage volume was 2 mL by intramuscular injection (IM) once a day for 14 days.Basic treatment: receiveDiammonium glycyrrhizate enteric-coated capsules at a dose of 150 mg 3 times a day.~The third stage: the Screen eligible subjects were treated with Sterilizing water for injection. The dose volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days. Basic treatment: receive acetylcysteine injection at a dose of 8 g / d once a day."
89072805|NCT05688241|Experimental|Group A: patients who undergo allogeneic HCT|Patients with EBV driven lymphomas (e.g., natural killer (NK)/T-cell lymphoma), with EBV complications (e.g. haemophagocytic lymphohistiocytosis (HLH), CAEBV) or patients with primary immunodeficiency disorders with high risk for EBV complications (e.g. SCID) with planned allogeneic HCT.
89072806|NCT05688241|Experimental|Group B: patients after HCT or SOT|EBV-driven PTLD that develop after a HCT or solid organ transplantation (SOT) and show decreased response to rituximab.
89072807|NCT05686694|Experimental|Education Group|"Follow-up (<24 weeks): Questionnaire for Descriptive Characteristics of Pregnants and Informed Consent Form and pretest application Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test will be made.~Follow-up (<24. Week): Watching education videos:the education will end in 3 weeks. After that,post-test application Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test will be applied. They will be asked about their intention to have an OGTT.~Follow-up (24-28. weeks): (Waiting after 75 mg dose is administered during OGTT): State Anxiety Scale will be applied. The OGTT implementation status of the pregnant woman will be recorded.~Follow-up (30-34. weeks): 6 weeks after the video education, the Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test post-test application will be made."
89072808|NCT05686694|No Intervention|Control Group|"Follow-up (<24 weeks): Questionnaire for the Introductory Characteristics of Pregnants and Informed Consent Form, and pre-test application Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test will be made.~Follow-up (before OGTT implementation at 24-28 weeks): A posttest application will be madeKnowledge Level Form on Pregnancy Diabetes and Oral Glucose Tolerance Test. It will be asked about their intention to have an OGTT.~Follow-up (24-28. weeks) (Waiting after 75 mg dose is administered during OGTT):State Anxiety Scale will be applied face-to-face while the pregnant woman is waiting after 75 mg dose is administered during the OGTT application while she is with the pregnant woman on the test day. In addition, the OGTT implementation status of the pregnant woman will be recorded.~Follow-up (30-34 weeks): The post-test application of the Knowledge Level Form on Pregnancy Diabetes and Oral Glucose Tolerance Test will be made."
89072809|NCT05686642|Experimental|LT3001 Drug:high dose|
89072810|NCT05686642|Placebo Comparator|Placebo|
89072811|NCT05686642|Experimental|LT3001 Drug:low dose|
89072812|NCT05682053|Other|patients with medullary sponge kidney|Patients with medullary sponge kidney attending medical consultation
89072813|NCT05682053|Other|Patients with glomerular filtration rate > 60 mL/min/1.73m2 without kidney stone|Patients with glomerular filtration rate > 60 mL/min/1.73m2 without kidney stone attending a renal exploration.
89072814|NCT05681130||1 women attending IVF programme|Women attending to IVF programme will be evaluated for pscyhological parameters before and after the precedure
89072815|NCT05681130||2 partners of women attending to IVF programme|Men who are partners of women attending to IVF programme will be evaluated for pscyhological parameters before and after the precedure
89072816|NCT05674318|Experimental|Alpha-lactalbumin|
89072817|NCT05673512|Active Comparator|IAH0968+ CAPEOX|IAH0968+ CAPEOX in HER2 positive metastatic colorectal cancer patient
89072818|NCT05673512|Active Comparator|CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
89072819|NCT05669352|Experimental|CA-4948 and Pembrolizumab|
89072820|NCT05667454|Active Comparator|Low dose atropine|Atropine 0.05% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.
89072821|NCT05667454|Active Comparator|High dose atropine|Atropine 0.5% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.
89072822|NCT05667441|Active Comparator|Standard recommendations|The first group (n=50) will receive standard care recommendations (according to Netherlands Scientific Society of Ophthalmology 2014, 'Richtlijn Leeftijdsgebonden Maculadegeneratie;): refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish; and recommendations for supplementation with antioxidants according an established formula.
89224143|NCT06271265|Experimental|EXPAREL|A total of approximately 24 subjects (8 subjects per Part) will be enrolled. Subjects in this arm will receive EXPAREL
89072823|NCT05667441|Active Comparator|Standard recommendations + Risk profiling|The second group (n=50) receives standard care plus personalized risk profiling. A risk scoring based on currently available literature for lifestyle and genetic risk will be used to determine personalized risks of conversion to late AMD. Individuals will be informed about their own risk profile and a personalized strategy will be communicated.
89072824|NCT05667441|Active Comparator|Standard recommendations + Risk profiling + Additional coaching|The third group (n=50) receives standard care (see 1); personalized risk profiling (see 2); and coaching. A coach will employ behavioral change techniques (BCT) to enhance adherence using motivational interviews, feedback on behavior; and focus on the advantages of following recommendations.
89072825|NCT05667012|Experimental|High intensity|Women who practice sports professionally.
89072826|NCT05667012|Active Comparator|Low intensity|Women who practice sport in a non-professional way.
89072827|NCT05666401||group 1|follicles with a diameter of 17 mm and more
89072828|NCT05666401||group 2|follicles with a diameter of 14 mm to 17 mm
89072829|NCT05662501|Experimental|Subjects receiving the Pleioflow-RF device|Subjects receiving the Pleioflow-RF device in conjunction with IABP
89072830|NCT05647265|Experimental|Treatment (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV, ipilimumab IV, and may undergo surgery on study. Patients also undergo CT or MRI and PET throughout the trial.
89072831|NCT05643859|Experimental|Supportive care (oral fiber)|Patients receive dietary fiber PO QD for 28 days. Patients may undergo standard of care proctoscopy or anoscopy with biopsy on study and at follow up or may undergo standard of care colonoscopy on study. All patients also undergo collection of blood samples on study and at follow up.
89072832|NCT05641194|Experimental|Single arm - intervention|
89072833|NCT05639946|Experimental|Experimental group|Participants with severe neuropathic pain will receive brivaracetam treatment
89072834|NCT05639946|Placebo Comparator|Control group|Participants with severe neuropathic pain will receive placebo drug
89072835|NCT05638880|Experimental|Control Group|30 patients will receive Valsartan 80 mg once daily titrated till blood pressure ≤ 130/80 plus Empagliflozin 10 mg once daily for 3 months
89072836|NCT05638880|Active Comparator|Levocetirizine group|30 patients will receive Valsartan 80 mg once daily titrated till blood pressure ≤ 130/80 plus Empagliflozin 10 mg once daily plus Levocetirizine 5 mg once daily in the evening titrated according to creatinine clearance for 3 months.
89072837|NCT05637086|Experimental|Control Group|This group will receive 100 mg of phenytoin 3 times daily for 6 months.
89072838|NCT05637086|Active Comparator|Pentoxifylline group|This group will receive 100 mg of phenytoin 3 times daily plus pentoxifylline 400 mg two times daily for 6 months
89072839|NCT05631847|Sham Comparator|Direct endovascular treatment group|Direct endovascular treatment (EVT) without intravenous thrombolysis (IVT)
89072840|NCT05631847|Active Comparator|Bridging treatment group|Intravenous thrombolysis (IVT) followed by endovascular treatment (EVT)
89072841|NCT05630235|Experimental|CBD followed by placebo group|Participants in this group will receive CBD on day one followed by placebo within a two week follow-up visit.
89072842|NCT05630235|Experimental|Placebo followed by CBD group|Participants in this group will receive placebo on day one followed by CBD within a two week follow-up visit.
89072843|NCT05628103|Experimental|SEP-363856|SEP-363856 flexibly dosed
89072844|NCT05623397||Breast cancer patients administered ribociclib.|Prospective cohort of consecutive breast cancer patients requiring ribociclib for their standard of care at the clinically indicated dose, as per treating physician prescription (600mg to 200mg/day for 21 days per 28 days cycle). Association with other hormone-derived therapeutics will be allowed.
89072845|NCT05622747|Experimental|Passive heating intervention|1 h hot water immersion (to the clavicle, @40°C, rectal temperature ~38.5°C and <39°C)
89072846|NCT05618197|Experimental|Passive heating intervention|~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature ~38.5°C and <39°C) sessions over a period of 6 weeks.
89072847|NCT05618197|No Intervention|Control|6 weeks of no hot water immersion
89072848|NCT05612581|Experimental|STRIVE: Cohort 1a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total
89072849|NCT05612581|Experimental|STRIVE: Cohort 2a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total
89072850|NCT05612581|Experimental|STRIVE: Cohort 3a (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 36 or 40 weeks total
89072851|NCT05612581|Experimental|STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)|Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 20 or 44 weeks total
89072852|NCT05612581|Experimental|STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)|Participants will receive combination therapy with VIR-3434 + VIR-2218 +TDF + PEG-IFNα for 48 weeks total
89072853|NCT05612581|Experimental|THRIVE: Cohort 1b (VIR-3434 + TDF)|Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks
89072854|NCT05612581|Experimental|THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)|Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 44 weeks total
89072855|NCT05610163|Active Comparator|Group I (LCRT, FOLFOX or CAPOX)|Patients receive long-course chemoradiation therapy on study and then receive either: FOLFOX regimen consisting of leucovorin IV, fluorouracil IV, and oxaliplatin IV or CAPOX consisting of capecitabine PO, and oxaliplatin IV on study. Patients undergo CT scan, MRI, and biospecimen collection throughout the trial. Patients also undergo sigmoidoscopy throughout the trial and biopsy during screening.
89522920|NCT03390361|Active Comparator|LCS|Laser cataract surgery will be performed. 5-minutes after LCS aqueous humour will be collected and frozen in -80° celsius.
89072856|NCT05610163|Experimental|Group II (LCRT, FOLFIRINOX)|Patients receive long-course chemoradiation therapy on study and then receive FOLFIRINOX regimen consisting of leucovorin IV, fluorouracil IV, irinotecan IV, and oxaliplatin IV on study. Patients undergo CT scan, MRI scan, and blood specimen collection throughout the trial. Patients undergo sigmoidoscopy throughout the trial and biopsy during screening.
89072857|NCT05608655|Experimental|DKutting|DKutting LL Scoring Balloon, DK Medtech Co Ltd
89072858|NCT05608655|Active Comparator|Chocolate|Chocolate Balloon, TriReme Medical LLC
89072859|NCT05602454|Experimental|Digital Heart Failure Medication Titration|The Story Health platform will remotely receive daily vital signs directly from a blood pressure cuff and scale provided to the participant. Participants will also report any symptoms. All of this data will be transmitted, via the platform, to the treating clinician at the site, who will create care plans for medication titration and make clinical decisions. The care plans will be implemented with assistance from health coaches from Story Health Inc.
89072860|NCT05602454|No Intervention|Usual Care|Routine clinical care will be followed. Participants will also receive a blood pressure cuff and scale, though the data will not be routinely fed back to the treating clinicians unless requested.
89072861|NCT05596734|Experimental|SSA: qIRV + bivalent BNT162b2 (dose level combination 1)|Administered intramuscularly into the deltoid muscle of the right arm
89072862|NCT05596734|Experimental|SSA: qIRV + bivalent BNT162b2 (dose level combination 2)|Administered intramuscularly into the deltoid muscle of the right arm
89072863|NCT05596734|Experimental|SSA: qIRV + bivalent BNT162b2 (dose level combination 3)|Administered intramuscularly into the deltoid muscle of the right arm
89072864|NCT05596734|Experimental|SSA: qIRV (dose level 1)|Administered intramuscularly into the deltoid muscle of the right arm
89072865|NCT05596734|Experimental|SSA: qIRV (dose level 2)|Administered intramuscularly into the deltoid muscle of the right arm
89072866|NCT05596734|Experimental|SSA: bivalent BNT162b2 (dose level 1) + QIV|BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm
89072867|NCT05596734|Experimental|SSB: QIV + bivalent BNT162b2 (original/Omi BA.4/BA.5)|BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm
89072868|NCT05596734|Experimental|SSB: QIV + bIRV/bivalent BNT162b2 (original/Omi BA.4/BA.5)|BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm
89072869|NCT05596734|Experimental|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 1|Administered intramuscularly into the deltoid muscle of the right arm
89072870|NCT05596734|Experimental|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 2|Administered intramuscularly into the deltoid muscle of the right arm
89072871|NCT05596734|Experimental|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 3|Administered intramuscularly into the deltoid muscle of the right arm
89072872|NCT05596734|Experimental|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 4|Administered intramuscularly into the deltoid muscle of the right arm
89072873|NCT05596734|Experimental|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 5|Administered intramuscularly into the deltoid muscle of the right arm
89072874|NCT05596734|Experimental|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 6|Administered intramuscularly into the deltoid muscle of the right arm
89072875|NCT05596734|Experimental|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 7|Administered intramuscularly into the deltoid muscle of the right arm
89072876|NCT05596734|Experimental|SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 8|Administered intramuscularly into the deltoid muscle of the right arm
89072877|NCT05596734|Experimental|SSB: tIRV/bivalent BNT162b2(original/Omi\BA.4/BA.5)|Administered intramuscularly into the deltoid muscle of the right arm
89072878|NCT05596734|Experimental|SSB: qIRV|Administered intramuscularly into the deltoid muscle of the right arm
89072879|NCT05591534|Experimental|Endorectal brachytherapy|Endorectal brachytherapy
89072880|NCT05590169|Experimental|Group I|They will be included in exercise training as a group (three or four participants) with telerehabilitation (via Zoom application) for eight weeks. Exercise program includes: (F) 3 times a week, (I) at 60-70% of the maximum heart rate, (T): breathing, stretching, aerobic, plyometric, balance exercises, (T) 30 minutes each session, a total of 8 week. During the exercise sessions, the heart rate will be monitored via a Polar Unite Fitness Watch, and the oxygen saturations will be monitored with a pulse oximeter.
89072881|NCT05590169|Experimental|Group 2|They will be individually included in exercise training with (via Zoom application) for eight weeks. Exercise program includes: (F) 3 times a week, (I) at 60-70% of the maximum heart rate, (T): breathing, stretching, aerobic, plyometric, balance exercises, (T) 30 minutes each session, a total of 8 week. During the exercise sessions, the heart rate will be monitored via a Polar Unite Fitness Watch, and the oxygen saturations will be monitored with a pulse oximeter.
89072882|NCT05590169|No Intervention|Group 3|They will continue their routine treatment (medical treatment, airway cleaning techniques, physical activity counseling).
89072883|NCT05579886|Active Comparator|Control Lens|All participants wore the Control Lens for 2 weeks (Period 1)
89072884|NCT05579886|Experimental|Test Lens|All participants wore the Test Lens for 2 weeks (Period 2)
89072885|NCT05577910|Experimental|Group A|One session VTP at month 0.
89072886|NCT05577910|Experimental|Group B|Four sessions IPL+MGX at month 0,1,2,3.
89072887|NCT05577910|Active Comparator|Group C|Twice daily EW for 15 months.
89072888|NCT05575505|No Intervention|Control Group|Mesalamine group, who will receive 1 g mesalamine three times daily for 6 months.
89072889|NCT05575505|Active Comparator|Pentoxifylline group|The pentoxifylline group will receive 1 g mesalamine three times daily plus pentoxifylline 400 mg two times daily for 6 months.
89072890|NCT05574387|No Intervention|Control Group|This group will take mesalamine 1 g three times daily
89691442|NCT02430103||Chemotherapy plus GnRHa|Patients of the group will receive (neo)chemotherapy plus GnRHa ( Goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration).
89691443|NCT02430103||Chemotherapy|Patients of the group will receive (neo)chemotherapy merely.
89691444|NCT03031535|Experimental|Study Part 1 - Arm 1|Day 1 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 7 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms.
89691445|NCT03031535|Experimental|Study Part 1 - Arm 2|Day 1 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 5 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 2000 micrograms.
89691446|NCT03031535|Experimental|Study Part 1 - Arm 3|Day 1 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 3 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 1200 micrograms.
89691447|NCT03031535|Experimental|Study Part 1 - Arm 4|Day 1 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 400 micrograms.
89691448|NCT03031535|Experimental|Study Part 2 - Arm 1|Day 1 - 1 microgram/kilogram of growth hormone-releasing hormone (GHRH) + 30 grams arginine hydrochloride; Day 3 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
89691449|NCT03031535|Experimental|Study Part 2 - Arm 2|Day 1 - 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 3 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
89691450|NCT03014245||Pregnant|Normal pregnant women (first baby) singleton
89691451|NCT03014245||Control|Non pregnant healthy women
89691452|NCT03031925|Experimental|SLE patients|Systemic Lupus Erythematosus
89691453|NCT03031925|Active Comparator|control subjects|age- and sex-matched control subjects
89691454|NCT01118221|Experimental|Arm 1|enroll in pulmonary rehabilitation program
89691455|NCT01118221|No Intervention|Arm 2|no structured exercise
89691456|NCT04353947||Healthy older adults|Healthy older adults with 65 years or older
89691457|NCT04353947||Older adults with Alzheimer's disease|Older adults with Alzheimer's disease with 65 years or older
89072891|NCT05574387|Active Comparator|Metformin group|This group will take mesalamine 1 g three times daily plus metformin 500 mg two times daily
89072892|NCT05572931|Sham Comparator|Sham comparator|In addition to the routine analgesic (Acetaminophen 500mg, TID), the patients were treated with sham FSN at the 1st, 24th, and 48th hours after surgery. The sham FSN was used a fine acupuncture needle without swaying movement and reperfusion approach.
89072893|NCT05572931|Experimental|Experimental|In addition to postoperative routine analgesic (Acetaminophen 500mg, TID), patients were received FSN treatment. The FSN insertion point and time are the same as control group. And then we performed swaying movement and reperfusion approach.
89072894|NCT05570760|Experimental|Adaptos®Ortho Wedge|Bone augmentation after Open Wedge High Tibial Osteotomy (OWHTO), with Adaptos®Ortho Wedge (Biomendex Oy, synthetic bone graft material) in combination with a load bearing TomoFix® Medial High Tibia Plate (DePuy Synthes).
89072895|NCT05570760|Sham Comparator|No bone graft|OWHTO with unfilled bony defect of the osteotomy gap with a load bearing TomoFix® Medial High Tibia Plate (DePuy Synthes).
89072896|NCT05570760|Active Comparator|chronOS® Wedge|Bone augmentation, after OWHTO, with chronOS® Wedge (DePuy Synthes, synthetic beta-TCP bone graft) in combination with a load bearing TomoFix® Medial High Tibia Plate (DePuy Synthes).
89072897|NCT05570045|No Intervention|Usual Diet|(n=300): Children eat usual dietary (not using nutrient products) for 3 months. After that, they will use the products
89072898|NCT05570045|Experimental|Colos Gain Dietary Supplement|(n=300): Children eat usual dietary, but with 2 glasses of the nutrient product as the side meals. The product provides GOS(Galactooligosaccharides), Calcium, Probiotics, HMO, DHA, and Taurine within 3 months of use.
89072899|NCT05567328|Experimental|Adult patient (age >= 18 y.o) followed for a liver disease, all etiologies combined|Adult patients followed in the Hepatology or Endocrinology department for a liver disease, all etiologies combined.
89072900|NCT05566171|No Intervention|Control Group|This group will be just follow-up for 4 weeks without any intervention
89072901|NCT05566171|Experimental|Interventional Group|This group will consume 125 g plain Activia Probiotic Yogurt without any aroma/fruit during 4 weeks/1 month
89072902|NCT05560867|Other|Patient Robot-Assisted Training Group|Patients will undergo robot-assisted physical therapy three times a week, for a total of 9 sessions, while functional near-infrared spectroscopy data is collected.
89072903|NCT05558657|Experimental|Intervention group|The intervention group will receive home-based acupressure and nursing education.
89072904|NCT05558657|Active Comparator|Control group: Home-based sham group , acupressure combined with nursing interventions|The control group will receive home-based, manual light touch of the abdomen combined with nursing education.
89072905|NCT05556837|Placebo Comparator|Control Cereal|A portion of cereal (25g available carbohydrate) that contains no beta-glucan
89072906|NCT05556837|Experimental|OBG Cereal|A portion of cereal (25g available carbohydrate) that contains approximately 1.4g of oat beta-glucan (OBG)
89072907|NCT05556837|Experimental|BBG Cereal|A portion of cereal (25g available carbohydrate) that contains approximately 1.4g of barley beta-glucan (BBG)
89072908|NCT05555940|Experimental|TMS true stimulation group|Transcranial magnetic stimulation and medication. The stimulation parameters were 10Hz frequency and 120%MT intensity. 50 treatment sequences were given each time, with 60 stimulation times for each sequence, the sequence interval was 30 seconds, and a total of 3000 stimulation times for each treatment. The patients were treated once a day for 15 days. Medical treatment is selective serotonin reuptake inhibitors/serotonin-noradrenaline reuptake inhibitors (SSRIs/SNRIs).
89072909|NCT05555940|Sham Comparator|TMS sham stimulation group|Sham stimulation and medication. The pseudo-stimulation method was to flip the magnetic head at 90 degrees with the scalp, The stimulation parameters were 10Hz frequency and 120%MT intensity. 50 treatment sequences were given each time, with 60 stimulation times for each sequence, the sequence interval was 30 seconds, and a total of 3000 stimulation times for each treatment. The patients were treated once a day for 15 days. Medical treatment is selective serotonin reuptake inhibitors/serotonin-noradrenaline reuptake inhibitors (SSRIs/SNRIs).
89072910|NCT05555628|Experimental|Mandibular Exercise|At the beginning of the treatment, the therapist will perform a soft tissue massage to the patient's muscles. Then, an exercise protocol for specific muscles (masseter, temporal muscles, mandibular region muscles) will be administered. This group, the exercise will focus only on the chin area, not general like posture.
89224144|NCT06271265|Active Comparator|bupivacaine|A total of approximately 24 subjects (8 subjects per Part) will be enrolled. Subjects in this arm will receive bupivacaine
89224145|NCT06271252|Experimental|OriCAR-017|Single OriCAR-017 infusion
89072911|NCT05555628|Experimental|Mandibular and Postural Exercise|The patients will perform posture exercises, including stabilization of the upper body and cervical region, accompanied by a physiotherapist. A theraband suitable for the patient's muscular strength will be used for posture exercises,. The appropriate therabant selection will be decided by a maximum repetition method.
89072912|NCT05555628|Active Comparator|Occlusal Splint|"The patients assigned to this group will be treated by the occlusal splint administered by the dentist and the recommendations that they should pay attention to in daily life.~Occlusal splints will be prepared according to previously published criteria by Okeson and other researchers. Occlusal splint measurement and production will be done by technicians with 5 years of experience. Using the models obtained from the maxillary measurements of the patients, 0.5 mm thick thermoplastic rigid splints will be prepared and adjusted according to the patient's occlusion. Occlusal splints will be prepared for night use only. Patients will use splints every night for 6 weeks. Splint use of the patients and possible side effects or plaque-related disorders will be followed up with phone calls to be made every 2 weeks."
89072913|NCT05550402|Active Comparator|Salbutamol then ipratropium|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
89072914|NCT05550402|Active Comparator|Ipratropium then salbutamol|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
89072915|NCT05550402|Active Comparator|Salbutamol plus ipratropium|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium)
89072916|NCT05550402|Placebo Comparator|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
89072917|NCT05537467|Experimental|Music|Music arm will listen to pre-selected music during their duration of the exercise testing via headphones that will be provided to the patients by the study personnel.
89072918|NCT05537467|No Intervention|Non-music|Non-music arm will not have pre-selected music playing during their duration of the exercise testing via the headphones provided to the patients by the study personnel.
89072919|NCT05530590|Experimental|Training to Serve (TTS) in person training|Participants are provided access to the pretest one week before the training. On the day of training, when the trainers arrive, participants have a final opportunity to complete the baseline survey before the intervention. Tablets will be available to complete pre- and post- surveys. The training for management takes 3-4 hours, and for staff, one hour. For consistency and feasibility, both trainings are conducted by the same trainers at the same visit. Immediately after the intervention, participants complete the post-intervention seminar evaluation assessing knowledge and attitudes/comfort in serving SGM clients.
89072920|NCT05530590|Experimental|Training to Serve online training (eTTS)|Participants are provided a unique identifier to access the online website. The opening page welcomes them to the study, then directs them to the chunked consent materials and baseline survey. As soon as they have completed this, they receive access to the intervention, which for management is expected to take 1-2 hours and for staff, 30-45 minutes (i.e., the online equivalent of 3-4 and 1 hour, respectively). After completion of the required modules, participants receive access to the optional modules as well as the posttest survey to evaluate the training. Once the post-test is complete, they are thanked for their involvement and informed they will receive an e-mail to access a follow-up survey in six months' time.
89072921|NCT05530590|No Intervention|Waitlist control|Participants complete the baseline survey, then they receive a note thanking them for completing all activities and informing them the intervention will be available in 6 months' time.
89072922|NCT05521672|Experimental|Single Dose|"This is an uncontrolled trial, phase IIa, proof of concept. Group control has not been included.~All patients will receive one single dose of 120 million cells"
89072923|NCT05507827|Experimental|Dose escalation|Bayesian dose escalation design for the dosing of the donor CD19/CD22-CAR T cells
89224146|NCT06271239|Experimental|Intervention group (ViviFrail)|Intervention Group: 25 participants will be guided to perform one of the home-based exercise programs from the VIVIFRAIL® protocol, tailored to their clinical conditions and functional capacity.
89229923|NCT03955939|Experimental|LY3295668 Erbumine Part B|"LY3295668 erbumine administered orally (Part I).~Approximately the first 10 participants enrolled in this arm will be administered midazolam."
89072924|NCT05478200|Experimental|Semi-directed Therapeutical Exercise and pain education program|Patients will receive physical exercise, combined with pain education and healthy lifestyle habits: an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength 13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
89072925|NCT05478200|Active Comparator|Pain release passive therapy based on manual therapy, thermotherapy and electroanalgesia|"Patients will receive 35-40 minutes of passive analgesic techniques sessions (2 per week, over 8 weeks). The following treatment will be applied:~15 minutes of massage on the lumbopelvic musculature, lower lumbar segments and sacroiliac joints rhytmic-passive mobilization. The hip may also be mobilised at physiotherapist's discretion, 10 minutes of electrotherapy (interferential current in the lumbar region) Medium frequency current, interrupted alternating sinusoidal pulse with a frequency of up to 250 Hz and thermotherapy (10-15 minutes local in the lumbar region) with antenna electrodes placed at a distance of 20 cm from the patient's skin, at an intensity of 70 to 120 watts."
89072926|NCT05471973|Other|Quality Improvement Program|The quality improvement program will consist of development and/or refinement of participating health system's patient care pathways tailored to address the gaps and barriers around recognition and treatment of CIED infections. Interventions will be customized and modified as needed based on regular reviews and implementation progress.
89072927|NCT05464251||Subjects with spinal epidural abscess with a history of drug abuse|
89072928|NCT05464251||Subjects with spinal epidural abscess with no history of drug abuse|
89072929|NCT05459402|Active Comparator|Treatment as Usual (TAU)|Participants in treatment as usual group will receive 100% active methadone in AM + placebo in PM.
89072930|NCT05459402|Experimental|Split-dosing|Participants in split dosing group will receive 50% active methadone + placebo twice daily.
89072931|NCT05454410|Experimental|MIJ821 - low dose|Single subcutaneous administration of low dose of MIJ821 on Day 1
89072932|NCT05454410|Experimental|MIJ821 - medium dose|Single subcutaneous administration of medium dose of MIJ821 on Day 1
89072933|NCT05454410|Experimental|MIJ821 - high dose|Single subcutaneous administration of high dose of MIJ821 on Day 1
89072934|NCT05454410|Placebo Comparator|Placebo|Single subcutaneous administration of 0.9% sodium chloride on Day 1
89072935|NCT05425823|Experimental|Education and message|"In Intervention Group 1, a face-to-face training session based on the Health Belief Model will be given once a week and SMS-based short messages will be sent to the spouse.~Vaccination rates of children in the intervention group-1 in the study at the end of the 1st, 6th and 12th months will be evaluated. Public Attitudes Towards Vaccination Scale-Health Belief Model sub-dimensions (severity, susceptibility, benefit, barrier, health motivation) scores of the intervention group-1 at the 1st, 6th, and 12th months after birth will be evaluated."
89072936|NCT05425823|Experimental|Education|"In Intervention Group 2, face-to-face training will be provided one day a week based on the Health Belief Model.~Vaccination rates of children in the intervention group-2 in the study at the end of the 1st, 6th and 12th months will be evaluated. Public Attitudes Towards Vaccination Scale-Health Belief Model sub-dimensions (severity, susceptibility, benefit, barrier, health motivation) scores of the intervention group-2 at the 1st, 6th, and 12th months after birth will be evaluated."
89072937|NCT05425823|No Intervention|Standard Care Group|"Standard information about childhood vaccines will be provided to the Standard Care Group at the Family Health Care Center.~Vaccination rates of children in the Standard Care Group in the study at the end of the 1st, 6th and 12th months will be evaluated. Public Attitudes Towards Vaccination Scale-Health Belief Model sub-dimensions (severity, susceptibility, benefit, barrier, health motivation) scores of the Standard Care Group at the 1st, 6th, and 12th months after birth will be evaluated."
89072938|NCT05424003|Experimental|Semaglutide|Semaglutide administered subcutaneously (under the skin) once weekly. There will be a 20 week lead in period of dose escalation before reaching the target dose of 2.4mg weekly. Semaglutide will then be administered at the maximum tolerated dose for 52 weeks.
89072939|NCT05424003|Placebo Comparator|Placebo|Placebo administered subcutaneously (under the skin) once weekly.
89072940|NCT05422638|Experimental|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
89072941|NCT05422638|Active Comparator|PCT|8-week health promotion group focused on providing support and facilitating problem solving
89072942|NCT05419661|Experimental|PPO +|Operational Pre-Planning + intracranial aneurysm embolization treatment
89072943|NCT05419661|No Intervention|PPO -|Only intracranial aneurysm embolization treatment
89072944|NCT05411172|Experimental|Experimental|"The Effect of the Education Based on the Mastery Learning Model on the Practical Skills of Student Nurses in Chemical, Biological, Radiological, and Nuclear Hazards.~The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks."
89072945|NCT05411172|No Intervention|Control|No intervention
89072946|NCT05402202|Experimental|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
89072947|NCT05402202|Active Comparator|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment
89072948|NCT05393804|Experimental|Cohort 1|Participants with relapsed/refractory MM who had an autologous hematopoietic stem cell transplant (AHCT). In an AHCT, their own blood-forming stem cells are collected. Participants are then treated with high doses of chemotherapy which kills the cancer cells, but it also gets rid of the blood-producing cells that are left in the bone marrow. Afterward, the collected stem cells are put back into the bloodstream, allowing the bone marrow to produce new blood cells.
89072949|NCT05393804|Experimental|Cohort 2|Participants with relapsed/refractory MM who had an allogeneic hematopoietic cell transplant (alloHCT). In an alloHCT, a person's stem cells are replaced with new, healthy stem cells from a donor.
89072950|NCT05392114|Experimental|OLE Participants|Group 1 and Group 2 participants will be administered donidalorsen by SC injection for up to 157 weeks.
89072951|NCT05387057|Experimental|Intervention Group - Exergame Training|Participants in the intervention group will perform a twelve-week training intervention in addition to their usual care (as provided by the (memory) clinics where the patients are recruited). The training intervention will be prescribed according to our newly developed exergame-based training concept (called 'Brain-IT' exergame-based training concept). Our complete 'Brain-IT' exergame-based training concept has recently been published including sufficient details about the exergame components as well as the exercise and training characteristics (i.e. including all predefined levels of task demands as well as the detailed progression rules) to allow full replication (i.e. consider supplementary file 3 of doi: 10.3389/fnagi.2021.734012). This training concept was planned and will be reported using the Consensus on Exercise Reporting Template (CERT; doi: 10.1136/bjsports-2016-096651).
89072952|NCT05387057|Active Comparator|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
89072953|NCT05384392|Experimental|Intervention|All patients included in the study will be required to complete the examinations specified in the protocol.
89072954|NCT05384015|Experimental|Experimental|Trial Treatment administration: at induction phase cycles will be administered every 3 weeks. For carboplatin (AUC5) and etoposide (100mg/m2) the maximum dose exposure will be 4 cycles or until reaching a discontinuation criterion. At this induction phase lenvatinib (8mg) will be orally administered daily and pembrolizumab (200mg) IV every 3 weeks. At maintenance phase lenvatinib will be administered at 20 mg dose and pembrolizumab at the same dose (200mg) until study intervention completion (total of 35 cycles of pembrolizumab/no treatment duration limit for lenvatinib) or reaching a discontinuation criterion.
89072955|NCT05375019|Experimental|Intervention group (positive discipline program)|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program.
89072956|NCT05375019|Active Comparator|Active control group (free interaction)|while the active control group was provided with 8 weekly 90 minute sessions of free interaction.
89072957|NCT05375019|No Intervention|No-contact group|No intervention was performed with the no-contact control group.
89072958|NCT05372653|Experimental|OPA-15406|
89072959|NCT05371717|Experimental|Trial Group|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment application
89072960|NCT05371717|Active Comparator|Control group|Domiciliary use of Biorepair Total Protection
89072961|NCT05362877|Experimental|Earplug|Earplug group- using earplugs, n=30 Patients will use only earplugs
89072962|NCT05362877|Experimental|Splint|Occlusal splint group- using occlusal splints, n=30 Patients will use only occlusal splints
89072963|NCT05362877|Experimental|Physical|Exercise group- using physical therapy, n=30 Patients will do only exercise
89072964|NCT05362877|No Intervention|control group|Control group-no intervention, n=30
89072965|NCT05362877|Experimental|Earplug and splint|Earplug group- using earplugs and splints, n=30 Patients will use both interventions
89072966|NCT05362877|Experimental|Earplug and Physical|Earplug group- using earplugs and exercise, n=30 Patients will use both interventions
89072967|NCT05361941|Experimental|Treatment Arm|The device will be placed in voids at Stage 1. This will be followed by IV therapy for a minimum of six weeks, followed by a pathology assessment of infection by needle aspiration, after week 8, with a stage 2 surgery scheduled after week 9. During the stage 2 surgery, the surgeon makes a qualitative assessment of new bone, and completes the procedure with affixing the revision implants. If the surgeon observes a depression in the surface layer resulting from subsidence due to partial resorption of the device, the surgeon may fill such gaps with additional granules of the device. An intraoperative set of radiographic images are taken during the stage 2 surgery.
89072968|NCT05361941|Active Comparator|Control Arm|In the standard of care arm, voids are left empty and a bone cement spacer placed during stage 1 surgery. This is followed by IV therapy for a minimum of six weeks, followed by a pathology assessment of infection by needle aspiration, after week 8, with a stage 2 surgery scheduled after week 9. During the stage 2 surgery, the spacer is removed and procedure completed by affixing the revision implants.
89072969|NCT05351281|No Intervention|Standard of care|Patients in the standard of care arm will receive the usual treatment
89072970|NCT05351281|Experimental|CDSS-OPTIMED|In the experimental arm, attending physicians will receive weekly medication alerts from the Clinical Decision Support System (CDSS) within 1 week after inclusion of the patient. The CDSS-OPTIMED will send a medication advice on a weekly basis, based on a weekly analysis of patient's medication. The medication alerts will be sent to the physician's email address. The physician is free to follow or ignore the advice in the alerts. If the physicians thinks these alerts are relevant for the patient, the physician will discuss these alerts with the patient and/or relatives. After this conversation, the physician will prescribe or deprescribe medications based on the alerts.
89072971|NCT05348733||Participants diagnosed with CKD and T2D|Participants who are newly prescribed finerenone under routine treatment conditions.
89072972|NCT05334069||Screening (questionnaire, biospecimen collection)|Participants complete a questionnaire at baseline. Participants undergo collection of blood samples at registration and at 12 months after registration. Patients with a cancer diagnosis may undergo collection of tissue samples at registration and 12 months after registration.
89072973|NCT05329987||Parkinson Disease|Rehabilitation according to Physiotherapy and Occupational Therapy European Guidelines for Parkinson Disease.
89072974|NCT05303792|Experimental|Arm A (inotuzumab ozogamicin, chemotherapy)|"Induction: For cycles 1-4 on days 2 and 8, patients receive inotuzumab ozogamicin IV and IT chemotherapy consisting of alternating Cytarabine and Methotrexate. Patients with leukemic blasts expressing CD20 also receive rituximab IV on days 2 and 8 of cycles 1-4. For cycles 1,3,5,7, patients receive cyclophosphamide intravenously (IV) on days 1-3, mesna IV, vincristine IV on days 1 and 8, and dexamethasone IV or orally (PO) on days 1-4 and 11-14. For cycles 2,4,6,8, patients receive methotrexate on day 1, cytarabine IV on days 2-3, and methylprednisolone on days 1-3. Patients >= 70 years of age receive either 2 or 4 cycles of treatment. Patients < 70 years of age receive up to 8 cycles of treatment.~Maintenance: Patients receive vincristine IV on day 1, prednisone PO on days 1-5, mercaptopurine PO on days 1-28, and methotrexate PO weekly. Treatment occurs for up to 24 cycles or 2 years, whichever comes first, in the absence of disease progression or unacceptable toxicity."
89072975|NCT05303792|Active Comparator|Arm B (chemotherapy)|"Induction: For cycles 1-4 on days 2 and 8, patients receive IT chemotherapy consisting of alternating Cytarabine and Methotrexate. Patients with leukemic blasts expressing CD20 also receive rituximab IV on days 2 and 8 of cycles 1-4. For cycles 1,3,5,7, patients receive cyclophosphamide intravenously (IV) on days 1-3, mesna IV, doxorubicin IV on day 4, vincristine IV on days 1 and 8, and dexamethasone IV or orally (PO) on days 1-4 and 11-14. For cycles 2,4,6,8, patients receive methotrexate on day 1, cytarabine IV on days 2-3, and methylprednisolone on days 1-3. Patients >= 70 years of age receive either 2 or 4 cycles of treatment. Patients < 70 years of age receive up to 8 cycles of treatment.~Maintenance: Patients receive vincristine IV on day 1, prednisone PO on days 1-5, mercaptopurine PO on days 1-28, and methotrexate PO weekly. Treatment occurs for up to 24 cycles or 2 years, whichever comes first, in the absence of disease progression or unacceptable toxicity."
89072976|NCT05297552|Experimental|RC48-ADC + JS001|Participants received 6 preoperative cycles of RC48-ADC PLUS JS001, followed by surgery, followed by up to 20 cycles of postoperative JS001.
89072977|NCT05288491||Participants With Malignant Lymphoma|All participants diagnosed with histopathologically confirmed malignant lymphoma will be enrolled and observed retrospectively. Complete medical information will be collected at the time of enrollment via chart review.
89072978|NCT05277168|Experimental|Single Arm|Single Arm : SHR-A1904
89072979|NCT05267093|Experimental|Acupuncture group|Participants in acupuncture group will receive treatment at bilateral Baxie (EX-UE9), bilateral Houxi (SI3), bilateral Waiguan (TE5) and Ashi points. The acupuncture treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 4 weeks.
89072980|NCT05267093|Placebo Comparator|Sham acupuncture group|Participants in sham acupuncture group will receive treatment at bilateral Baxie (EX-UE9), bilateral Houxi (SI3), bilateral Waiguan (TE5) and Ashi points. The sham acupuncture treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 4 weeks.
89072981|NCT05263622|Experimental|Group A|Half of patients will be included in this group according to the split-mouth design.
89072982|NCT05263622|Experimental|Group B|Half of patients will be included in this group according to the split-mouth design.
89072983|NCT05251909|Experimental|Benralizumab|This arm is a subcutaneous dose of Benralizumab
89072984|NCT05251909|Placebo Comparator|Placebo|This arm is a subcutaneous dose of Placebo
89072985|NCT05247905|Experimental|Arm I (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89072986|NCT05247905|Experimental|Arm II (capecitabin, temozolomide)|Patients receive capecitabine PO BID days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89072987|NCT05241860|Experimental|Treatment (discontinue hormonal medication, follow up)|Patients stop both hormonal medications (medication to decrease testosterone levels in the body and potent oral hormonal medication to block growth signals from male hormones in the cancer cells). Patients are then followed every 12 months for symptoms. Patients with an increase in PSA level to greater than or equal to 5 ng/ml, changes on imaging studies suggesting that their cancer is growing back, or symptoms that the doctor thinks is related to their cancer growing back, resume both hormonal treatments.
89072988|NCT05241457||Standard of care group|Patients will receive the standard physical therapy sessions that they would normally receive during their IRF stay, (60 to 90 min sessions, 5 to 6 days/week). This group will not receive Ekso exoskeleton gait training.
89072989|NCT05241457||Ekso exoskeleton gait training group|Patients in the Ekso group will have several (2 to 3) of their standard of care sessions replaced with Ekso gait training sessions each week.
89072990|NCT05231824|Active Comparator|BWL-S|1 year of remote gold standard, small group-based behavioral weight loss treatment with an MS-level clinician.
89072991|NCT05231824|Experimental|BWL-AI|1 year of remote weight loss treatment made up of a combination of (1) remote small group-based behavioral weight loss sessions, (2) 12-minute individual video calls, (2) automated text messages. An MS-level clinician will deliver the group treatment. Most video calls will be delivered by a paraprofessional coach, but some by an MS-level clinician. Each week the AI system will select one of the interventions for each participant based on which treatment the participant has responded to the best, within certain time constraints.
89072992|NCT05225675|Experimental|ARGX-117|Intravenous administration of ARGX-117
89072993|NCT05225675|Placebo Comparator|Placebo|Intravenous administration of placebo
89072994|NCT05220410|Experimental|Psilocybin|25mg of Psilocybin
89072995|NCT05217615|Experimental|ezParent+ coach|"ezParent - Program is a 6-module digital adaptation of the group-based Chicago Parent Program, 12-session program for parents of young children. A core objective of the CPP is to promote positive parenting behavior - for example, teaching parents to limit the amount of attention given to negative behaviors and reward the positive - to decrease child behavior problems and increase child prosocial behavior.~Coach - The purpose of the brief weekly telephone coaching calls is to provide parents with an opportunity to receive clarification of intervention content, encouragement and reinforcement of intervention completion, and support tailoring of intervention content for their child. The coaching calls will be guided by a semi-structured script aimed at supporting parent learning and motivation. Coaches will be trained in active and empathic listening and problem solving techniques to facilitate learning and support of parents."
89072996|NCT05217615|Experimental|ezParent|ezParent - Program is a 6-module digital adaptation of the group-based Chicago Parent Program, 12-session program for parents of young children. A core objective of the CPP is to promote positive parenting behavior - for example, teaching parents to limit the amount of attention given to negative behaviors and reward the positive - to decrease child behavior problems and increase child prosocial behavior.
89072997|NCT05217615|Active Comparator|Active Control+coach|"Active Control - The active control is an adaptation of a digital application used in our previous study (HS024273). The program will include general information typically provided during well-child or NICU follow up visits but unrelated to parenting or child development and behavior. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes digital handouts, websites, and resources provided to parents of children in this age group.~Coach - The purpose of the brief weekly telephone coaching calls is to provide parents with an opportunity to receive clarification of intervention content, encouragement and reinforcement of intervention completion, and support tailoring of intervention content for their child. The coaching calls will be guided by a semi-structured script aimed at supporting parent learning and motivation."
89072998|NCT05217615|Placebo Comparator|Active Control|The active control is an adaptation of a digital application used in our previous study (HS024273). The program will include general information typically provided during well-child or NICU follow up visits but unrelated to parenting or child development and behavior. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes digital handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks (~1 topic every 1.5 weeks) to match the dose and timing of contact that the intervention groups will receive.
89072999|NCT05215119||Immediate|NC endometrial preparation will start immediately after blastocyst cryopreservation confirmation.
89073000|NCT05215119||Delayed|NC endometrial preparation will start on day 1 of the patient's 2nd menstruation after the oocyte retrieval cycle menstruation or in a subsequent cycle.
89073001|NCT05214729|Experimental|Fast to Slow Group|The Fast to Slow Group corresponds to enrolled patients randomized, following the sequential crossover design, to first perform the fast UF challenge immediately after inclusion, followed by the slow UF challenge after a washout period of 24 hours.
89073002|NCT05214729|Experimental|Slow to Fast Group|The Slow to Fast Group corresponds to enrolled patients randomized, following the sequential crossover design, to first perform the slow UF challenge immediately after inclusion, followed by the fast UF challenge after a washout period of 24 hours.
89073003|NCT05205850|Experimental|RC118-ADC|Participants will be allocated to one of the following dose groups: 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC118-ADC followed by 14 days of dose limited toxicity (DLT) observation period.
89073004|NCT05205174|Other|Feasibility|This is a preliminary, prospective interventional study to investigate the feasibility of using depth electrodes in conjunction with novel analytical algorithms to detect CSDs in TBI patients.
89073005|NCT05205109|Experimental|ATG-037+Keytruda(Pembrolizumab, MK-3475)|Part I: Dose Escalation Phase of ATG-037 Monotherapy PartII: Dose Escalation Phase and Dose Expansion Phase of ATG-037 in Upfront Combination with Keytruda(Pembrolizumab, MK-3475)
89073006|NCT05200000|Experimental|SygeLIX-Coll-T|Extract of umbilical cord lining constituted of Wharton's jelly put in suspension in microvials. Instillation by the patient in the sick eye of 1 drop 5 times a days (morning, noon, afternoon, evening and bedtime) for 40 days.
89224147|NCT06271239|Active Comparator|Group Suggestions for a Healthy Life (CG)|The control group, also consisting of 25 participants, will receive exercise suggestions and guidance on maintaining a healthy routine for three months. Subsequently, the participants will undergo the intervention with the VIVIFRAIL® program for three months.
89522921|NCT03390361|Placebo Comparator|MCS|Manual cataract surgery will be performed. Aqueous humour will be collected and frozen in -80° celsius before MCS starts.
89522922|NCT03388541|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
89073007|NCT05188183|Experimental|M1 anodal home-based tDCS and somatosensory training|Investigators will use the Soterix Medical 1X1 tDCS mini-CT stimulator device (© Soterix Medical Inc.) an home-based tDCS device used in several clinical trials with no adverse events. It sends a low-level current from the positive electrode, anode, to the negative electrode, cathode. During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. HB-TDCS will be combined with somatosensory training that will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks.
89073008|NCT05188183|Experimental|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
89073009|NCT05179343|Experimental|Active arm|Participants in this arm will receive the active AffeX-CT device.
89073010|NCT05179343|Sham Comparator|Sham arm|Participants in this arm will receive the sham (inactive) AffeX-CT device.
89073011|NCT05174507|Other|Group 1 (anakinra; placebo; empagliflozin)|"Group 1:~study day 1: anakinra; study day2: placebo; study day 3: empagliflozin"
89073012|NCT05174507|Other|Group 2 (placebo; anakinra; empagliflozin)|study day 1: placebo; study day2: anakinra; study day 3: empagliflozin
89073013|NCT05174507|Other|Group 3 (empagliflozin; placebo; anakinra)|study day 1: empagliflozin; study day2: placebo; study day 3: anakinra
89073014|NCT05174507|Other|Group 4 (empagliflozin; anakinra; placebo)|study day 1: empagliflozin; study day2: anakinra; study day 3: placebo
89073015|NCT05174507|Other|Group 5 (placebo; empagliflozin; anakinra)|study day 1: placebo; study day2: empagliflozin; study day 3: anakinra
89073016|NCT05174507|Other|Group 6 (anakinra; empagliflozin; placebo)|study day 1:anakinra; study day2: empagliflozin; study day 3: placebo
89073017|NCT05168865|Experimental|PCOS women will receive letrozole ovarian stimulation.|Polycystic ovarian disease (PCOS) women undergoing frozen embryo transfer (FER) will use Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
89073018|NCT05168865|Active Comparator|PCOS women will receive Estradiol and Progesterone (hormonal endometrial preparation).|PCOS women will use daily Cetorelix acetate 0.25 mg injections for 5 days from day 1-3 of the menstrual follow or after progesterone (P4) withdrawal bleeding. They will commence daily oral Estradiol Valerate (E2) 2 mg twice daily for 5 days starting from day 3 of the menstrual flow or after P4 withdrawal bleeding, then-after three times daily. When endometrial thickness reaches 7 mm or more, the dose of E2 will be reduced to 4 mg/ day. Women will start using vaginal micronized P4 100 mg three times daily starting from 8PM. After 48 hours of starting the vaginal P4, oral Dydrogesterone 10 mg three times daily will commence.
89073019|NCT05166395|Experimental|Er:YAG laser Group|The study is a split-scar model. Participants will have half of their lesion receive a total of three sessions using 2940 nm Er:YAG laser spaced over a 4-week study participation interval.
89073020|NCT05166395|No Intervention|Control (No Intervention) Group|The study is a split-scar model. Participants will serve as their own control and have half of their lesion receive no intervention.
89073021|NCT05161013|Experimental|The LINFU™ test|LINFU™ to increase sensitivity of pancreatic juice cytology LINFU™ consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. Lumason, will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected.
88812788|NCT01549223|Active Comparator|Standard Care Group|"Standard Care Group (reflects current clinical regimen at BWH) will receive a 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request. The obstetrician and anesthesiologist will be asked to consider this infusion oxytocin. If inadequate uterine tone exists in which the obstetrician desires alternative uterotonic agents, these will be provided on their request (e.g. methylergonovine maleate (methergine) 0.2 mg IM (intramuscular) or carboprost tromethamine (hemabate) 0.25 mg IM. The time of the requests will be recorded.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
89073022|NCT05145283|Active Comparator|Conestat alfa (Ruconest®) intervention group|The intervention group will receive conestat alfa (Ruconest®) as a 10-minute slow intravenous injection (up to 56 ml) once during the TAVI procedure followed by a second administration (up to 28 ml) again three hours later. The first administration will include a dosage of 100 U/kg (maximum 8400 U) conestat alfa. The dosing of the second administration will be 50 U/kg (maximum 4200 U).
89073023|NCT05145283|Placebo Comparator|saline injection placebo group|Subjects randomized into the placebo group will receive an intravenous normal saline injection with corresponding volume over 10 minutes during the TAVI procedure and three hours later after the first administration.
89229924|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Cohort 1|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part II).
89229925|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Continuation Part C|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
89522923|NCT03388541|Placebo Comparator|Placebo|NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
89073024|NCT05127733|Experimental|Online Cogntivie Behavioural Therapy|"Breaking Free Online (BFO) is an online intervention, supporting adults struggling with substance use. It provides psychoeducation and skills building exercises in CBT and compatible approaches. The intervention strategies contained within BFO are provided via a six-domain biopsychosocial model used in CBT. Each domain of the model corresponds to a module in the BFO program which contains psychoeducation and an 'action' strategy to facilitate behaviour change. Data captured at the baseline assessment is used by the program to provide feedback to the individual on their levels of functioning across the six domains. The program then guides the user to concentrate on intervention strategies for domains with the greatest level of impairment.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
89073025|NCT05127733|Experimental|Online Cognitive Behavioural Therapy Plus Individual Peer Support|"BFO delivered with peer support will comprise BFO with at least weekly contact with a peer with lived experience. Peer support workers will receive training on how to facilitate participant engagement with and progress through the BFO program, as well as a weekly session plan. As part of this training, peer support workers will be given their own access code to use BFO and be encouraged to use the program. Session One constitutes an initial orienting to the program. Subsequent sessions review each information and action strategy in the BFO program, with a series of prompts to guide peer support of this content.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
89073026|NCT05127733|Active Comparator|Group Peer Support|"The control condition will consist of group peer support facilitated by trained peers and offered through the Community Addictions Peer Support Association (CAPSA). The group meets weekly and will offer participants a space to share their experiences and receive support.~All groups will receive 'clinical monitoring,' including biweekly study assessments during the acute treatment period and monthly assessments during the six month follow-up period."
89073027|NCT05119556|No Intervention|Standard of Care|Participants will receive standard of care for COPD management per local guidance. In addition, they will receive 4-weekly phone calls for 13 weeks post discharge to inquire about health status and exacerbations.
89073028|NCT05119556|Active Comparator|Video Telehealth Pulmonary Rehabilitation|In addition to standard of care, participants will be asked to participate in rehabilitation sessions administered at home via live videoconferencing for approximately 60 minutes a session, three times a week. A total of 36 sessions will be planned to be completed by week 13 post-discharge. Exacerbations and health status will be ascertained every 4-weeks for 13 weeks.
89073029|NCT05108363|Other|Lifestyle modification program|Patients with obstructive sleep apnea and prediabetes will have lifestyle modification program for 12 months
89073030|NCT05104255||Twin neonates|The demographic data and characteristics of the twins were evaluated.
89691458|NCT04353947||Older adults with Parkinson's disease|Older adults with Alzheimer's disease with 65 years or older
89691459|NCT01093417|Placebo Comparator|Placebo|Participants that have been randomized into this arm will receive placebo pills.
89691460|NCT01093417|Active Comparator|Vitamin D 4000 IU|Participants that have been randomized into this arm will receive Vitamin D 4000 IU (International Units) daily.
89691461|NCT04354415|Active Comparator|Tourniquet Group|Tourniquet application during procedures
89691462|NCT04354415|Experimental|Non-Tourniquet group|No application of tourniquet for procedures
89229926|NCT03955939|Experimental|LY3295668 Erbumine + Endocrine Therapy Switch Part D|LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).
89691463|NCT01586455|Experimental|Group A|related cord blood with ≥3/6 HLA match to the patient and related HPDSC
89691464|NCT01586455|Experimental|Group B|unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
89691465|NCT01586455|Experimental|Group C|unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
89691466|NCT01586455|Experimental|Group D|double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
89691467|NCT04354337|Experimental|Intervention Group|8-weeks online program with weekly modules for parents to learn about specific sleep topics and implement behavioral changes to improve their child's sleep.
89691468|NCT03031379|No Intervention|A - control|standard fast, at least 6 hours prior to tracheotomy
89691469|NCT03031379|Experimental|B - shortened fast|fast of only 45 minutes prior to incision
89691470|NCT01093651|Experimental|DPPIV inhibition|Four to six months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
89691471|NCT01093651|Placebo Comparator|Placebo|Four to six months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
89691472|NCT00362895|Experimental|Tobradex AF|
89691473|NCT00362895|Active Comparator|TOBRADEX|
89691474|NCT03031301|Active Comparator|Vibrant capsule|Patients will receive the Vibrant capsule 5 times a week for 8 weeks of treatment
89691475|NCT03031301|Sham Comparator|Sham capsule|Patients will receive the sham capsule (activated, non-vibrating) 5 times a week for 8 weeks of treatment
89691476|NCT03013465|Other|Control Diet|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of broccoli (control).
89691477|NCT03013465|Active Comparator|Brassica Diet|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily.
89691478|NCT04744623|Experimental|effect of large dose corticosteroids with intra-lestional injection in treatment of MMP|10 patients suffering from MMP were selected referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intra-lesion injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I)
89224148|NCT06271226|Experimental|acupressure|Information about the pre-procedure intervention will be given. Before acupressure, the participant's physiological parameters and pain score will be recorded, then the hands will be washed in preparation for the acupuncture application and the patient will be placed in a supine or semi-sitting position. Compression points are HT7, P6, P7, Li4, Lv3 points and the location will be determined by the patient's own finger size. Before pressing, a relaxing-relaxing patting motion will be applied to these points for 10 seconds. Then, 1.5 minutes, 5 seconds of thumb pressure and 1 second of free pressure to each point will be applied to each point twice a day (morning and evening). In total it will take 15 minutes to press all the dots. At the end of the application and 15 minutes and 30 minutes after the application, the participant's physiological parameter data and pain score will be re-evaluated and recorded. These data will be recorded twice a day (morning and evening) for 2 days.
89224149|NCT06271226|Active Comparator|plasebo acupressure|In the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch.
89224150|NCT06271226|Other|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
89224151|NCT06271213||Respiratory Disease|Children with respiratory complications receiving general anaesthesia undergoing bronchoscopy
89224152|NCT06271213||Gastrointestinal Disease|Children with G.I. complications receiving general anaesthesia undergoing endoscopy
89224153|NCT06271213||Orthopaedic controls|Children with orthopaedic issue receiving general anaesthesia undergoing orthopaedic correction
89224154|NCT06271213||Asthma Control|Children with Asthma/wheeze not indicated for biologics therapy
89224155|NCT06271213||Asthma Treatment|Children with Asthma/wheeze indicated for biologics therapy
89224156|NCT06271200|Experimental|Intensive lifestyle intervention|"Participants assigned to the Intensive lifestyle intervention (ILI) group will be instructed intensive lifestyle intervention, including: (1) reduce calories intake and eat as 168 pattern, namely, eating foods for 8 hours while fast for 16 hours at daily basis, and plus (2) walking more than 10,000 steps per day. While participants in the ULI group will be instructed to keep habitual meal timing. Those participants of ILI will be instructed to follow a diet restriction of reduction of 500 kcal per day (40-55% of energy as carbohydrate, 15-20% as protein, 20-30% as fat) Those participants of ILI will be instructed to follow a diet restriction of reduction of 500 kcal per day (40-55% of energy as carbohydrate, 15-20% as protein, 20-30% as fat)."
89224157|NCT06271200|No Intervention|Usual lifestyle intervention|Usual lifestyle
89224158|NCT06271187|Experimental|Dynamic-orthosis training group|Participants will undergo traditional occupational therapy (2-3 times per week, one hour per session, for a total of six weeks), supplemented with an additional home-based dynamic orthotic therapy program (five days per week, one hour per session, for six weeks). The style of the dynamic orthosis will be selected by the researchers based on the participants' movement performance and rehabilitation goals, and it will be adjusted or replaced as their abilities progress.
89224159|NCT06271187|Other|Regular training group|Participants will receive traditional occupational therapy (2-3 sessions per week, one hour per session, for a total of six weeks). The training program includes muscle strength training, reaching and grasping exercises, manual tone control, motor facilitation, and activities of daily living training. During the study period, participants will not wear any hand dynamic orthosis during training.
89224160|NCT06271174|Experimental|Loco-Regional Analgesia|"Patients will receive Loco-Regional Analgesia during General Anesthesia, and systemic analgesia if necessary~Carbocaine"
89224161|NCT06271174|Active Comparator|Systemic Analgesia Only|"Patients will just receive General Anesthesia and systemic analgesia.~_ Profofol and/or Suxaméthonium and/or Sévoflurane"
89224162|NCT06271148||Female surgeons|Female surgeons
89224163|NCT06271135|Experimental|Participants with rosacea|
89229927|NCT01094665|Experimental|Focal Laser Thermal Therapy|Thermal therapy delivered to lesion visible on MRI.
89229928|NCT01091623|Active Comparator|strength training|
89229929|NCT01091623|Active Comparator|endurance training|
88820761|NCT05685277|Other|Sequence TR|25 subjects assigned to the sequence TR will receive a single 10 mg/25 mg dose of the test product Ramipril/Hydrochlorothiazide (1 x 10 mg/25 mg tablet), marked as T in the sequence, in Period 1 and a single 10 mg/25 mg dose of the reference product Tritace® Plus (1 x 10 mg/25 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89691479|NCT04744623|Experimental|effect of of (MMF), dapsone and cortisone in treatment of MMP|10 patients suffering from MMP were selected referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intra-lesion injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
89691480|NCT00939731|Experimental|PIC|
89691481|NCT00939731|Experimental|IRT|
89691482|NCT03031223|Experimental|low-level laser therapy|"The treatment group will receive LLLT following the protocol outlined below:~LLLT protocol - radiance will be administered to the injury site transcutaneously at a wavelength of 808 nm using a Twin Flex Evolution diode laser (MMO Equipamento Opto-Eletronicos, Brazil). Twelve sessions will be held (three per week over four weeks). The dose administered to the surface of the skin will be 983 J/cm2 per session, with a treatment area of 4.72 W/cm² and total radiant energy of 25 J. According to the literature, this dose is capable of enhancing functional recovery following an injury."
89073040|NCT05100264|Experimental|Vaginal washing 5% acetic acid|
89073041|NCT05100264|Placebo Comparator|Vaginal washing 0.9% N/S|
89073042|NCT05095727|Experimental|SAD: mRNA-3745|Participants will receive a single intravenous (IV) dose of mRNA-3745 on Day 1 in an inpatient setting. Participants that are/have been enrolled in the study and receive an administration of mRNA-3745 may also enroll in one of the MAD cohorts. The first MAD dose must occur at least 21 days after the SAD dose.
89073043|NCT05095727|Experimental|MAD: mRNA-3745|Participants will receive multiple IV doses of mRNA-3745 in an inpatient setting. Participants will have the option to continue treatment in the OLE.
89073044|NCT05094388||Critically ill patients|Patients admitted to intensive care units
89073045|NCT05089734|Experimental|Sacituzumab Govitecan-hziy (SG)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) until progressive disease (PD), death, unacceptable toxicity, or another treatment discontinuation criterion is met.
89073046|NCT05089734|Active Comparator|Docetaxel|Participants will receive docetaxel 75 mg/m^2 on Day 1 of a 21-day cycle (ie, once every 3 weeks) until PD, death, unacceptable toxicity, or another treatment discontinuation criterion is met.
89073047|NCT05082233|Experimental|SHR7280 tablets|Treatment group A: oral SHR7280 tablets; 300mg bid p.o.; Treatment group B: oral SHR7280 tablets; 200mg bid p.o.; Treatment group C: oral SHR7280 tablets; 200mg qd p.o.; Treatment group D: oral SHR7280 tablets; 400mg bid p.o.; as an alternative.
89073048|NCT05066711||ACP System|
89073049|NCT05060003|Experimental|Arm 1: Atezolizumab + Tiragolumab|"Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).~Tiragolumab is given as an IV infusion every 4 weeks at a dose of 840 mg over 60 minutes (+/- 15 minutes).~Treatment can continue for up to 13 cycles."
89073050|NCT05060003|Active Comparator|Arm 2: Atezolizumab|"Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).~Treatment can continue for up to 13 cycles."
89073051|NCT05058495|Experimental|mobile programme users|Patients will receive and use Mobile Lymphedema Self-Care Support Program application and will receive standart lymphedema education.
89073052|NCT05058495|Active Comparator|control group|Patients who will receive standart lymphedema education
89073053|NCT05041595||Sick Cohort|Borreliosis Subjects - All comers expressing signs and symtoms consistent with suspicion of acute Borreliosis and under medical examination for Lyme disease Borreliosis subjects with an Erythema Migrans Rash (subgroup)
89073054|NCT05041595||Apparently Healthy|Apparently healthy subjects living in an area non-endemic for Lyme disease Apparently healthy subjects living in an area endemic for Lyme disease
89073055|NCT05039086||PDE5 inhibitors|Exposure group
89073056|NCT05039086||Endothelin receptor antagonists|Reference group
89073057|NCT05020158|Experimental|Family Talk intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
89073058|NCT05008848|Experimental|Group I (SGR program, text messages)|Patients participate in schedule gradual reduction program over 8 weeks to reduce the frequency of cigarette use. Patients also receive cessation support messages via text messages for 12 weeks.
89073059|NCT05008848|Active Comparator|Group II (booklet)|Patients receive NCI's Clearing the Air booklet to help plan to gradually quit smoking.
89229930|NCT01091623|Active Comparator|combined training|
89691483|NCT03031223|Placebo Comparator|placebo|laser therapy is applied at low intensity without emitting radiation.
89691484|NCT05620199|Experimental|Study population|All included patients will have an upfront surgery of the primary tumor, followed by chemoradiotherapy. Resection will be done within 2-4 weeks after presentation in the multidisciplinary team meeting (MDT). After resection, restaging will take place preceding start of CRT, which should start within 4-6 weeks after resection.
89691485|NCT00633945|Experimental|Lenalidomide|Open label lenalidomide received.
89691486|NCT00633945|Experimental|Lenalidomide 2|Open label lenalidomide received.
89691487|NCT03729713|Experimental|Intervention|Computerized Cognitive Rehabilitation
89691488|NCT03729713|Sham Comparator|Placebo|Video game
89073060|NCT05004610|No Intervention|standard of care|Patients will receive the standard of care infusion (balanced crystalloids)
89073061|NCT05004610|Experimental|treatement group|half molar sodium lactate infusion 15 µmol/Kg/min
89073062|NCT05002777|Experimental|Rilzabrutinib|Oral rilzabrutinib 400 mg BID
89073063|NCT04998903||Stem cell transplant with Graft versus host disease|Patients who following hematopoietic stem cell transplant suffered from graft versus host disease and presented with pulmonary infiltrates.
89073064|NCT04998682|Experimental|Targeted Axillary Dissection (TAD)|During standard of care (SoC) surgery to remove breast cancer, study participants will undergo a sampling of lymph nodes in the axilla first and then complete removal of axillary lymph nodes under the arm.
89073065|NCT04996511|Experimental|Colorectal Surgery Patients|
89073066|NCT04994769|Experimental|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling
89229931|NCT01094821|Experimental|3 mg ATI-7505|3 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
89073067|NCT04993677|Experimental|Melanoma Arm|SEA-CD40 + pembrolizumab
89073068|NCT04993677|Experimental|NSCLC Arm|SEA-CD40 + pembrolizumab + pemetrexed + carboplatin
89073069|NCT04989504|Active Comparator|Arm I (standard of care)|Patients receive standard of care skin management during radiation therapy for up to 6 weeks.
89073070|NCT04989504|Experimental|Arm II (Mepitel Film)|Patients receive Mepitel Film applied to breast or chest wall every week before radiation therapy for up to 6 weeks.
89073071|NCT04984577|Experimental|Compound Edaravone Injection-Low dose|
89073072|NCT04984577|Experimental|Compound Edaravone Injection-High dose|
89073073|NCT04984577|Active Comparator|Edaravone Injection|
89073074|NCT04984577|Placebo Comparator|Placebo Injection|
89073075|NCT04980638|Experimental|ER004|Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor binding domain fusion protein.
89073076|NCT04978493|Experimental|BI 706321 + ustekinumab|
89073077|NCT04978493|Placebo Comparator|Placebo + ustekinumab|
89229932|NCT01094821|Placebo Comparator|Placebo|Placebo capsule three times daily for 9 days followed by transit scintigraphy
89073078|NCT04971642|Experimental|Ultrasound scanning|"The subjects recruited are existing patients of the Orthodontic Clinic - Oral Health Clinic-Dentistry, University of Alberta. An intraoral ultrasound scanning will be done on the buccal side of the upper and lower incisor/canine/premolar/molar teeth for a total of sixteen (16) teeth (four(4) teeth in each of the four quadrants) of these subjects.~The ultrasound scans will be done separately by a research assistant not involved in patient care. The whole procedure for ultrasound scanning and data storage will take about 25-30 min including 3-5 min preparation time and 22-25 min of data acquisition and storage time."
89073079|NCT04966624|Experimental|interventional|
89073080|NCT04966624|Active Comparator|control|
89073081|NCT04951583|Experimental|Immune checkpoint inhibitor (ICI) therapy in combination with fecal microbial transplantation (FMT).|"Metastatic or advanced NSCLC: Single-agent Pembrolizumab (2 mg/kg or 200 mg every 3 weeks) in combination with investigational FMT capsules as follows: Full FMT at least 7 days prior to first cycle of Pembrolizumab.~Metastatic melanoma and uveal melanoma: Combination therapy of Ipilimumab plus Nivolumab (Ipilimumab 3 mg/kg every 3 weeks and Nivolumab 1 mg/kg every 3 weeks x 4 doses, followed by Nivolumab 3 mg/kg or 240mg every 2 weeks or 6 mg/kg or 480mg every 4 weeks) in combination with investigational FMT capsules as follows: full FMT at least 7 days prior to first treatment with Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the second cycle with combination Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the third cycle of Ipilimumab plus Nivolumab."
89073082|NCT04945278|Other|Patients|"Both patients and healthy volunteers arms will undergo the double mirror test within a day.~But the patients arm will additionally respond to the EASE test."
89073083|NCT04945278|Other|Healthy volunteers|Both patients and healthy volunteers arms will undergo the double mirror test within a day.
89073084|NCT04944316|Active Comparator|Low-fat, vegan diet|For a 12-week period, participants will be asked to follow a low-fat, vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
89073085|NCT04944316|Active Comparator|Portion-controlled diet|For a 12-week period, participants will be asked to follow a portion-controlled diet that is compliant with American Diabetes Association (ADA) guidelines. This diet will include individualized diet plans that reduce daily energy intake by 500-1,000 kcal for overweight (body mass index > 25 kg/m2) participants and keep carbohydrate intake reasonably stable over time. It will derive 15-20% from protein, <7% saturated fat, 60-70% carbohydrate and monounsaturated fats and ≤200 mg/day of cholesterol/day.
89073086|NCT04939090|Experimental|Arm I (olanzapine)|Patients receive olanzapine PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
89073087|NCT04939090|Active Comparator|Arm II (megestrol acetate)|Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
89073088|NCT04934514|Experimental|Ia stage-Dose escalation|"Using the 3+3 model, 1 subject was included in the 6 mg/kg dose group, and then 3 to 6 patients with HER2-positive advanced solid tumors that failed standard treatment were included in the fixed 3 dose groups (10 mg/kg, 15 mg/kg, and 20 mg/kg) ."
89073089|NCT04934514|Experimental|Ib stage-Dose extension|In the three fixed dose groups (10 mg/kg, 15 mg/kg and 20 mg/kg), when a certain dose group meets the condition of increasing the dose to the higher dose (after the DLT observation period for the last subject in the dose group), the second phase of the dose expansion study for this dose group can be carried out. Each dose group includes 6 patients with HER2-positive advanced solid tumors who have failed the standard treatment, and the interval between enrollment is determined by the investigator.
89073090|NCT04934514|Experimental|IIa stage-Single-agent study (cohort 1)|After the completion of the dose escalation in the 20 mg/kg dose group (Phase Ia), a total of 30 patients with HER2-positive advanced biliary system tumors who have failed standard treatment will be enrolled in the 20 mg/kg dose group. Every 3 weeks is a cycle, and the drug is administered once on the first day of each cycle, and the treatment is continued until any end-point event occurs.
89073091|NCT04934514|Experimental|IIa stage - IAH0968 combined GP regimen study (cohort 2)|After the completion of the dose escalation in the 20 mg/kg dose group (phase Ia), a total of 30 patients with newly treated HER2-positive advanced biliary system tumors will be enrolled in the 20 mg/kg dose group combined with the GP regimen (gemcitabine + cisplatin) . Every 3 weeks is a cycle, treatment until any end-point event occurs.
89073092|NCT04934137|Active Comparator|Sensoria first intervention|Group 1 participants will receive the Sensoria intervention during the first intervention phase for 4 weeks, and then the AW-Shift intervention during the second intervention phase for 4 weeks.
89073093|NCT04934137|Active Comparator|AW-Shift first intervention|Group 2 participants will receive the AW-Shift intervention during the first intervention phase for 4 weeks, and then the Sensoria intervention during the second intervention phase for 4 weeks.
89073094|NCT04926818|Experimental|ofatumumab - 20 mg injection/ placebo|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
89073095|NCT04926818|Experimental|siponimod - 0.5 mg, 1 mg or 2 mg/ placebo|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
89691489|NCT02980445|No Intervention|Control|
89073096|NCT04926818|Active Comparator|fingolimod - 0.5 mg or 0.25 mg/ placebo|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
89073097|NCT04914676|Experimental|Prospective HiDAC Treatment (HiDAC 123)|Subject on this arm will be treated with HiDAC prospectively.
89073098|NCT04914676|Other|Historical HiDAC Treatment (HiDAC 135)|Subjects on this arm will be historical controls who have previously received treatment with HiDAC.
89073099|NCT04908995|Experimental|EC5026|Single 8 mg oral dose of EC5026
89073100|NCT04908995|Placebo Comparator|Placebo|Single dose of matching oral placebo
89073101|NCT04906616|No Intervention|Control Comparison|Standard of care, e.g. regular HIV care plus brief advice on alcohol use
89073102|NCT04906616|Experimental|Mlambe Intervention|A couples-based intervention to reduce problematic drinking and improve economic and HIV outcomes.
89073103|NCT04903119|Experimental|Level 1|Patients in this group will receive 100mg Nilotinib PO BID.
89073104|NCT04903119|Experimental|Level 2|Patients in this group will receive 200mg Nilotinib PO BID.
89073105|NCT04903119|Experimental|Level 3|Patients in this group will receive 300mg Nilotinib PO BID.
89073106|NCT04903119|Experimental|Level 4|Patients in this group will receive 400mg Nilotinib PO BID.
89073107|NCT04899544|Experimental|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|A 16-week center-based PRT intervention (PRT-C) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
89073108|NCT04899544|Experimental|Home-Based Pivotal Response Treatment (PRT) Intervention (PRT-H)|A 16-week home-based PRT intervention (PRT-H) consisting of 12 hours per week including 1 hour of parent training. This intervention targets social communication deficits.
89073109|NCT04899544|No Intervention|Treatment As Usual (TAU)|This is a control group that consists of children who are receiving treatment as usual (TAU) for a 16-week period. These families will be invited to participate in PRT after completing the 16-week TAU phase.
89073110|NCT04886453|Experimental|Intervention|
89073111|NCT04886453|Active Comparator|Controle|
89073112|NCT04886180|Experimental|Experimental|
89073113|NCT04886180|Active Comparator|Control|
89229933|NCT01094821|Experimental|10 mg ATI-7505|10 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
89073114|NCT04880733|Experimental|Acupuncture|This arm will receive acupuncture for pain management, and any pain medications will be delayed until after receipt of acupuncture.
89073115|NCT04880733|Active Comparator|Usual Care|This arm will receive usual care for pain management.
89073116|NCT04875260||Critically ill patients|Patients received critical care in the intensive care units
89073117|NCT04873401|Experimental|Chain Referral|"In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing; these recruits are then trained to do the same."
89073118|NCT04873401|Experimental|Credible Messenger|In the credible messenger intervention, peers identified as popular and socially influential individuals within their respective communities with lived experience are trained to engage within formal and informal social networks to promote behavior change.
89073119|NCT04870970||Tobacco Users|Participants in this group use some form of tobacco.
89073120|NCT04870970||Non-Tobacco Users|Participants in this group do not use tobacco products.
89073121|NCT04862143|Experimental|Alpelisib + fulvestrant|Participants were administered alpelisib at a daily dose of 300 mg for 12 cycles of 28 days and fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and Day 1 of each subsequent cycle up to Cycle 12. Pre-menopausal women also received goserelin at a dose of 3.6 mg on Day 1 of each cycle.
89073122|NCT04858126|Experimental|Single Group Assignment|ECOM endotracheal cardiac output monitor in patients undergoing cardiac and liver surgery.
89073123|NCT04857242|Experimental|apnea test, recruitment manoeuvre|"Continuous electric impedance tomography (EIT) recording. Recording of initial vital parameters and arterial blood gas results. Adjusment of PaCO2 between 38-42 mmHg, 10 minutes of preoxygenation with FiO2 of 1.0 then disconnection of the patient from the ventilator.~Continuous administration of 6 L/min O2 flow via a catheter into the tracheal tube.~Arterial blood gas sampling and recording of vital parameters in every second minutes. Detection of any spontaneous respiratory movement by the apnoe test investigator or by EIT signals.~Reconnection with respirator if there is any sign of spontaneous breathing effort or if there is no spontaneous breathing effort and the PaCO2 is over 60 mmHg. Recording of vital parameters.~Recruitment manoeuvre (PEEP 20 cmH2O, pressure control 20 cmH20 for 40 minutes) then set up of the initial ventilator parameters.~Terminal arterial blood gas results and vital parameters 5 minutes following the end of the recruitment manoeuvre."
89073124|NCT04828668|Experimental|Formula C|30 participants will be randomized to masked active study product (Formula C) for 28-days; they will continue to the open label extension phase (with commercially available product for an additional 28-days when they will receive commercially available product.
89073125|NCT04828668|Placebo Comparator|Placebo|30 participants will be randomized to placebo for 28-days; they will roll-over to the open label extension phase of study product (Formula C) for an additional 28-days when they will receive commercially available product.
89073126|NCT04799288|Experimental|Teriflunomide|Teriflunomide 14 mg daily
89073127|NCT04791540||Patients with trachestomy|Patients, attending a respiratory rehabilitation program, who underwent tracheostomy decannulation
89073128|NCT04770571||Vuepoint II OCT|
89073129|NCT04770571||Reline-C|
88820762|NCT05685277|Other|Sequence RT|25 subjects assigned to the sequence RT will receive a single 10 mg/25 mg dose of the test product Tritace® Plus (1 x 10 mg/25 mg tablet), marked as R in the sequence, in Period 1 and a single 10 mg/25 mg dose of the reference product Ramipril/Hydrochlorothiazide (1 x 10 mg/25 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89073130|NCT04757376|Experimental|CT-P41|60 mg/mL single dose administration, Solution for injection in prefilled syringe(PFS)
89073131|NCT04757376|Active Comparator|US-licensed Prolia|60 mg/mL single dose administration, Solution for injection in PFS
89073132|NCT04744844|Experimental|DNA-amplification selection|In the experimental arm, all blastocysts will undergo routine morphological assessment, with the 3 top-scoring blastocysts undergoing blastocoel fluid biopsy (BF-biopsy) and whole-genomic amplification. A single blastocyst with no DNA amplification will be selected for transfer in a frozen embryo transfer cycle.
89691490|NCT02980445|Experimental|Outdoor Activity 1|40min outdoor time in total.
89691491|NCT02980445|Experimental|Outdoor Activity 2|80min outdoor time in total
89691492|NCT02980289||Patients|Patients over 18 years old with advanced cancer defined as metastatic disease, no curable treatment options. The patients may not have received chemotherapy or irradiation within 4 weeks, no operations within 2 weeks and no general anesthesia within 4 days.
89691493|NCT03031067|Experimental|Machine perfusion - Kidney|The marginal kidney will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
89073133|NCT04744844|Active Comparator|Morfological-score selection|In the active comparator arm, all blastocysts will undergo routine morphological assessment. The (single) top-scoring blastocyst will be selected for transfer in a frozen embryo transfer cycle.
89073134|NCT04740294|Experimental|Magnesium Sulfate|The patient will receive a bolus of 50mg/kg MgSO4 over twenty minutes.
89073135|NCT04740294|Placebo Comparator|Placebo|The patient will receive a bolus of Normal Saline over twenty minutes.
89229934|NCT01094821|Experimental|20 mg ATI-7505|20 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
89229935|NCT00072475|Experimental|Vatalanib|Adult patients with MDS receive treatment with vatalanib.
89691494|NCT03031067|No Intervention|Static cold storage - Kidney|The marginal kidney that was stored to cold (SCS), previously.
89691495|NCT03031067|Experimental|Machine perfusion - Liver|The marginal liver will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
89073136|NCT04736199|Experimental|Darolutamide+ADT|Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy
89073137|NCT04736199|Placebo Comparator|Placebo+ADT|Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy
89073138|NCT04734535|Experimental|investigational|HEMOBLAST™ Bellows
89073139|NCT04734535|Active Comparator|control|absorbable gelatin sponge with thrombin
89073140|NCT04731142|Experimental|T2DEx remote care service|
89691496|NCT03031067|No Intervention|Static cold storage - Liver|The marginal liver that was stored to cold (SCS), previously.
89691497|NCT01118845|Experimental|SyB L-0501|
89691498|NCT03031457||1|Patients undergo primary fascial closure of abdominal donor-site
89691499|NCT03240887|Experimental|Peer Group Connection (PGC)|Ninth-grade participants are assigned to small groups of 10-14 students that attend weekly peer group outreach sessions led by older peer leaders.
89691500|NCT03240887|No Intervention|Business as usual|Ninth grade students remain in their regularly scheduled school classes or activities during PGC outreach times.
89691501|NCT03162731|Experimental|Treatment ( nivolumab, ipilimumab, radiation therapy)|Patients receive nivolumab IV over at least 30 minutes every 2 weeks and ipilimumab IV over at least 90 minutes every 6 weeks. Beginning week 3, patients undergo simultaneous integrated boost intensity modulated radiation therapy or volumetric modulated arc therapy for 5 days per week over 7 weeks. Patients continue nivolumab every 2 weeks for 12 doses and ipilimumab every 6 weeks for 4 doses. Courses repeat for up to 23 weeks in the absence of disease progression or unacceptable toxicity.
89691502|NCT03030911|Active Comparator|Dexmedetomidine group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.~Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1)~Intervention: indirect calorimetry"
89691503|NCT03030911|Placebo Comparator|midazolam group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.~Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1.~Intervention: indirect calorimetry"
89691504|NCT01120405|Experimental|Xenon|0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)
89691505|NCT01120405|Active Comparator|sevoflurane|0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)
89691506|NCT03399370|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.
89691507|NCT03399370|Placebo Comparator|Saline Solution|Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.
89691508|NCT02859779|Other|mediterranean adolescents with type 1 diabetes|
89691509|NCT03013387|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|"The 90Y--DOTA-tyr3-Octreotide initial, Cycle 1 dose will be 50 mCi/m2 in children; 120 mCi in adults. Treatment consists of 3 cycles, 6-8 weeks apart. Cycle 1 dose is fixed. Cycles 2 and 3 doses will be determined by dosimetry-based calculation of renal doses from previous cycles; total renal dose ≤ 23Gy. 90Y-DOTA-tyr3-Octreotide will be administered with an amino acid solution to prevent radiation damage to kidneys. Amino acid infusion will begin 30 min prior to infusion of 90Y-DOTATOC and continue 3.5 hrs after infusion of study drugs.~68Ga-DOTATOC will be administered intravenously to perform the PET/CT scan. The dose will be 3-5 mCi (target 4mCi). The pediatric dose will be 0.043 mCi/kg with a minimum dose of 0.3 mCi and a maximum dose of 3 mCi in children <18 years old."
89691510|NCT00950729|Active Comparator|Driving with Running Shoes|
89691511|NCT00950729|Active Comparator|Driving with Plaster cast|
89073141|NCT04731142|Other|Matched control group|This study will create a matched control group using propensity score matching (PSM), a quasi-experimental method used to mimic the characteristics of a randomised control trial that has been shown to reduce biases. PSM uses statistical techniques to construct an artificial control group by matching each study participant with a non-treated participant of similar characteristics. PSM computes the probability that a person would enrol in a program based on pre-defined characteristics, giving a 'propensity score'.
89229936|NCT02530645|Experimental|OnTrack + BMI|Brief motivational interview plus the use of a smartphone application to monitor alcohol and marijuana use and sexual risk behaviors.
89691512|NCT00950729|Active Comparator|Driving with Aircast|
89691513|NCT02784353|Active Comparator|Conventional|No intervention; conventional perioperative management without perioperative rehabilitation program
89691514|NCT02784353|Experimental|Intervention - PReHeBP|conventional perioperative management with preoperative and postoperative rehabilitation program
89691515|NCT03597178|Experimental|senofilcon A|Subjects that are of at least 60 years of age and non-habitual contact lens wearers will receive instructions to insert and remove a contact lens from each eye.
89691516|NCT01782989|Experimental|ORACEA®|40mg doxycycline
89073143|NCT04710420||WIfI stage 1|Very low risk of amputation was determined according to the SVS WIfI classification system.
89073144|NCT04710420||WIfI stage 2|Low risk of amputation was determined according to the SVS WIfI classification system.
89073145|NCT04710420||WIfI stage 3|Moderate risk of amputation was determined according to the SVS WIfI classification system.
89073146|NCT04710420||WIfI stage 4|High risk of amputation was determined according to the SVS WIfI classification system.
89073147|NCT04709380|Experimental|Radiotherapy plus Toripalimab|Patients in the experimental group will be given local vein tumor thrombus/hepatic vein tumor thrombus +/- intrahepatic large lesions with hypofractionated intensity modulated radiotherapy (tumor area dose 40-60Gy/10-20f), concurrent with and followed by 240mg Q3W of toripalimab within 1 week of radiotherapy.
89073148|NCT04709380|Active Comparator|Sorafenib|Patients in the control group will be treated with sorafenib (400mg, twice a day).
89073149|NCT04708067|Experimental|Treatment (hypofractionated radiation, bintrafusp alfa)|Patients undergo hypofractionated radiation therapy QD on weekdays (Monday-Friday) for 15 fractions in the absence of disease progression or unacceptable toxicity. Beginning 1 week after completion of radiation therapy, patients receive bintrafusp alfa IV over 1 hour on day 1. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89073150|NCT04697771|Experimental|Intervention Group|First Evaluation - Fine Motor Skills Training - 8 week - 3 session per week - 40 minute per session - Second Evaluation
89073151|NCT04697771|No Intervention|Control Group|First Evaluation - 8 week waiting period - Second Evaluation
89691517|NCT01782989|Placebo Comparator|Placebo|
89691518|NCT03544216|Experimental|Single Vision First|Subjects in this group will receive the single vision spherical (Bausch + Lomb ULTRA®) lens for the first two weeks and be crossed over to the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lens for the second two weeks.Therefore, this group will receive both study interventions.
89691519|NCT03544216|Experimental|Multifocal first|Subjects in this group will receive the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lenses for the first two weeks and be crossed over to the single vision spherical (Bausch + Lomb ULTRA®) lens for the second two weeks. Therefore, this group will receive both study interventions.
89691520|NCT02245607|Experimental|Compensatory Cognitive Training|Compensatory Cognitive Training
89691521|NCT02245607|Active Comparator|Recreational Therapy|Recreational Therapy
89691522|NCT01120639|Experimental|Stereotactic Radiosurgery (25 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
89691523|NCT01120639|Experimental|Stereotactic Radiosurgery (30 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
89691524|NCT01120639|Experimental|Stereotactic Radiosurgery (35 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
89691525|NCT01120639|Experimental|Stereotactic Radiosurgery (40 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
89691526|NCT00951821|Experimental|Concurrent treatment|Concurrent treatment - experimental condition: Adolescent participants and their parents will receive concurrent cognitive behavioral therapy.
89691527|NCT00951821|Active Comparator|Adolescent treatment only|Adolescent treatment only - Active Comparator: Only adolescent participants will receive cognitive behavioral therapy.
89691528|NCT00676351|Other|A|body plethysmography Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
89691529|NCT02422043|Experimental|type 1 diabetes adolescents cohort|The participants of the prospective cohort of adolescents will be 12 to 17 years of age, type 1 diabetics with insulin, included in TPE program
89691530|NCT01095757|Other|Plerixafor + Chemo and G-CSF|Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
89691531|NCT03549598|Experimental|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan, 18FDG PET/CT scan and 13NH3 PET/CT scan will be performed on each subject
89691532|NCT05497817|Experimental|Algorithmically Matched|Individuals that identify as a current and/or former Care Partner for a person with dementia will be matched to other care partners using an algorithm based on personal preferences.
89691533|NCT05497817|Active Comparator|Randomly Matched|Individuals that identify as a current and/or former Care Partner for a person with dementia will be randomly matched to other care partners.
89691534|NCT01034527|Experimental|Neuromuscular Training|Combination of exercises and phases designed to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
88820798|NCT05639647|Experimental|ATM-AVI|ATM-AVI administered iv every 6 or 8 hours and dosed according to participant's weight and kidney function for up to 14 days depending on response. At the investigator's discretion, the participant may be switched to oral therapy after 3 days of iv ATM-AVI therapy
89073153|NCT04689854||Cohere Cervical|
89073154|NCT04689854||Modulus Cervical|
89073155|NCT04680481|Experimental|Stimulation Theta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 4 Hz (theta condition).
89073156|NCT04680481|Experimental|Stimulation Beta Group|Participants will experience traveling wave transcranial alternating current stimulation over the fronto-parietal regions at 23 Hz (beta condition).
89073157|NCT04671966|Experimental|Fasting only|To acutely elevate myocardial triglyceride content, subjects will be asked to abstain from eating for 2 days (reproducibly causes a significant and physiological increase in myocardial fat deposition, transiently). Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
89073158|NCT04671966|Experimental|LBNP Only|Subjects undergo lower body negative pressure at 40 mmHg.
89073159|NCT04671966|Experimental|Estrogen add back with GnRHant|Subjects are given estradiol patch.
89073160|NCT04671966|Experimental|Placebo add back with GnRHant|Subjects are given placebo patch.
89073161|NCT04660682|Experimental|Modified static cross-body posterior shoulder stretching group|The participants will perform active-assistive static stretching in the modified cross-body stretching position. Additionally, they will receive standard physiotherapy program.
89073162|NCT04660682|Experimental|Traditional static cross-body posterior shoulder stretching group|The participants will perform active-assistive static stretching in the traditional standing cross-body stretching position. Additionally, they will receive standard physiotherapy program.
89073163|NCT04660682|Active Comparator|Control Group|The participants in this group will receive sham stretching and standard physiotherapy.
89073164|NCT04660240|Active Comparator|Abluminus Sirolimus Eluting Stent System (ASES)|The Abluminus sirolimus eluting stent manufactured by Envision and distributed by Concept Medical.
89073165|NCT04660240|Experimental|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|The Orsiro sirolimus eluting stent manufactured by Biotronik.
89073166|NCT04655976|Experimental|Participants receiving cobolimab+dostarlimab+docetaxel|
89073167|NCT04655976|Experimental|Participants receiving dostarlimab+docetaxel|
89073168|NCT04655976|Active Comparator|Participants receiving docetaxel|
89073169|NCT04641442|Experimental|MAS825|Experimental drug
89073170|NCT04641442|Placebo Comparator|Placebo|matching placebo
89073171|NCT04622150|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the experimental intervention, Customized Adherence Enhancement (CAE).
89229937|NCT02530645|Active Comparator|Treatment as Usual|Treatment as usual involves substance use/HIV referral and treatment as regularly offered to all participants who report substance use and sexual risk behaviors at Covenant House New York.
89073172|NCT04622150|Active Comparator|Enhanced Treatment as Usual (eTAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (eTAU).
89073173|NCT04617314|Experimental|RC108|Participants will be allocated to one of the following dose groups: 0.1, 0.3, 0.9, 1.5, 2.0, 2.5, and 3.0mg/kg, and receive a treatment of RC108-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
89073174|NCT04600336|Experimental|low-dose oxybutynin|Patients receive low-dose oxybutynin chloride (2.5 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
89073175|NCT04600336|Experimental|high-dose oxybutynin chloride|Patients receive high-dose oxybutynin chloride (5.0 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
89073176|NCT04600336|Placebo Comparator|low-dose placebo|Patients receive a low-dose placebo (2.5 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to experimental arm - low-dose oxybutynin per physician discretion.
89073177|NCT04600336|Placebo Comparator|high-dose placebo|Patients receive a high-dose placebo (5.0 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to experimental arm - high-dose oxybutynin chloride per physician discretion.
89073178|NCT04596423||A|Extended fetal heart examination
89073179|NCT04596423||B|Modified extended heart examination
89073180|NCT04596423||C|Sief_Twist sign only examination
89073181|NCT04587154|Experimental|Intervention Group|This arm will follow a low-fat vegan diet in addition to 1/2 a cup of cooked soybeans each day for the duration of the study. They will also weigh themselves each week, and report weight and hot flash frequency/severity weekly.
89073182|NCT04587154|No Intervention|Control Group|This arm will not change their diet for the duration of the study. They will also weigh themselves each week and report weight and hot flash frequency/severity weekly.
89073183|NCT04582812|Experimental|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training|
89073184|NCT04582812|Active Comparator|Isolated high-intensity inspiratory muscle training|
89073185|NCT04570150|Active Comparator|Sugammadex|
89073186|NCT04570150|Placebo Comparator|Neostigmine|
89073187|NCT04569032|Experimental|CD30-negative Cohort|Participants with CD30 expression level < 1%
89073188|NCT04569032|Experimental|CD30-positive Cohort|Participants with CD30 expression level ≥1% to < 10%
89073189|NCT04561648|Experimental|High Dose of Unfractionated Heparin|100 IU/Kg of Unfractionated Heparin
89073190|NCT04561648|Active Comparator|Standard Dose of Unfractionated Heparin|5000 IU of Unfractionated Heparin.
89073191|NCT04547673||NPC group|Patients pathologically diagnosed as NPC by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
89073192|NCT04547673||Non-NPC group|Patients pathologically diagnosed as non-NPC (including inflammatory hyperplasia, Atypical hyperplasia, Papilloma etc.) by agreement of 2 experienced pathologists who were blinded to the corresponding endoscopic assessment.
89073193|NCT04536077|Experimental|CDX-1140 Monotherapy|Patients randomized to the CDX-1140 monotherapy arm will receive a single IV infusion at a dose of 1.5 mg/kg, with surgery to follow 7-12 days after administration of CDX-1140.
89073194|NCT04536077|Experimental|CDX-1140 + CDX-301|Patients randomized to the CDX-301 + CDX-1140 arm will receive CDX-301 at 75 mcg/kg/day as a subcutaneous injection every day for 5 days (Days 1-5) with CDX-1140 IV at 1.5 mg/kg on Day 8 +/-1 day. Surgery will be 7-12 days after administration of CDX-1140.
89073195|NCT04535999|Experimental|Open Label|Secukinumab
89073196|NCT04510727|Experimental|OCT Guided C&D Group|Participants in this group will receive OCT imaging immediately prior, immediately after and 2 months after post standard of care C&D.
89073197|NCT04497779||Screening (biospecimen collection, medical record review, CCP)|"PROSPECTIVE CCP DONORS: Participants undergo collection of blood and/or nasopharyngeal swabs at the time of screening. Participants' medical records are reviewed.~CONVALESCENT BLOOD DONORS WHO CHOOSE NOT TO DONATE CCP: Participants undergo collection of blood sample at the time of screening. Participants' medical records are reviewed.~CCP RECIPIENTS: Patients undergo collection of blood samples at baseline, 12-24 hours after each CCP infusion, and 7 days after last CCP infusion. Patients' medical records are reviewed."
89073198|NCT04467489||CA (non-CASH)|Cavernous Angioma (CA) without symptomatic hemorrhage cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
89073199|NCT04467489||CA (CASH)|Cavernous Angioma (CA) with Symptomatic Hemorrhage (SH) cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
89073200|NCT04467489||Young with seizure|Young (<30 years old) healthy control cohorts with seizures in the prior year
89073201|NCT04467489||Young without seizure|Young (<30 years old) healthy control cohorts without seizures in the prior year
89073202|NCT04467489||Older with HMA|Older (>50 years old) with hemorrhagic microangiopathy (HMA)
89073203|NCT04467489||Older without HMA|Older (>50 years old) without hemorrhagic microangiopathy (HMA)
89073204|NCT04466488|No Intervention|Standard of care study arm|"The standard TPT implementation is for a clinician to screen for TB and to consider TPT for those who do not have presumptive TB. Clinicians in the study district (and most districts in South Africa) have received training and job aids to assist in appropriate application of the TPT initiation algorithm. Prescribing for TPT and ART is done by writing, by hand, the prescription in the patient's paper file. As part of this study, all study clinic providers will have access to standard Department of Health printed material and clinical training."
89073205|NCT04466488|Experimental|Choice Architecture study arm|"In the choice architecture implementation strategy, all opt-out clinic providers and pharmacists will be trained on the approach. The fundamental tenant of this approach is that TPT will be prescribed with any ART initiation and any ART re-prescribing for 3-12 months of TPT (adherent to current guidelines) if TPT has not been previously prescribed. This will be facilitated by co-prescribing ART and TPT. That is when ART is being prescribed TPT is meant to be prescribed at the same time of the clinic visit.~The simultaneous prescribing will be facilitated through the introduction of an ink stamp or pre-printed sticker to use for quick entry of the ART prescription along with TPT and cotrimoxazole. The stamp/sticker for ART prescription, the prescription for TPT and for cotrimoxazole will be automatically included. Active canceling of these prescriptions (and indicating the reasons) will be needed to not have TPT dispensed."
89073206|NCT04464226|Experimental|Darolutamide (BAY1841788)|Participants enrolled in the current study will use the dose they were assigned to in the feeder study they come from.
89073207|NCT04457596|Active Comparator|Arm I (trastuzumab emtansine, placebo)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
89073208|NCT04457596|Experimental|Arm II (trastuzumab emtansine, tucatinib)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
89073209|NCT04455698|Experimental|Remote Telegenetics: TELEPHONE (ARM A)|"Remote Phone Telegenetics:~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - TELEPHONE."
89073210|NCT04455698|Experimental|Remote Telegenetics: VIDEOCONFERENCING (ARM B)|"Remote Videoconferencing Telegenetics:~Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - VIDEOCONFERENCING."
89073211|NCT04455698|Experimental|USUAL CARE (ARM C)|"Usual Care:~Participants will receive referrals to genetic counseling providers, initiating services on their own. At 6 months, if participants have not sought and received genetic counseling services, they will be offered randomization to ARM A/ARM B."
89073212|NCT04453722||Monitor only mode|Randomization will be to Oxalert in monitor-only mode
89073213|NCT04453722||Monitor in normal mode|Randomization will be to Oxalert in monitor normal mode which provides progressive audible and tactile alerts for hypoxemia.
89073214|NCT04450966|No Intervention|Usual Care|Clinicians randomized to this arm will not receive training in delivery of cSBI until study completion, and their participating patients will receive usual care.
89073215|NCT04450966|Experimental|Computer-facilitated screening and brief intervention|Clinicians randomized to this arm will receive training in delivery of cSBI and their participating patients will then receive the experimental intervention.
89073216|NCT04428307|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
89073217|NCT04428307|Experimental|Arm 2 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
89073218|NCT04428307|Experimental|Arm 3 (client-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
89073219|NCT04424225|Experimental|Psilocybin First|Participants in this arm will receive psilocybin first, then niacin
89073220|NCT04424225|Experimental|Niacin First|Participants in this arm will receive niacin first, then psilocybin
89073221|NCT04418830||Base Interfixated System|
89073222|NCT04418830||Brigade Interfixated System|
89073223|NCT04418830||Coalesce Thoracolumbar Interbody|
89073224|NCT04418830||Cohere XLIF Interbody System|
89073225|NCT04418830||CoRoent Ti PLIF Interbody System|
89073226|NCT04418830||CoRoent Ti TLIF Interbody System|
89073227|NCT04418830||MLX - Medial Lateral Expandable Interbody System|
89073228|NCT04418830||Modulus TLIF Interbody System|
89073229|NCT04418830||Modulus XLIF Interbody System|
89073230|NCT04418830||TLX Interbody System|
89073231|NCT04418830||XLX ACR Interbody System|
89073232|NCT04418830||CoRoent Ti XLIF Interbody System|
89073233|NCT04418830||Cohere TLIF|
89073234|NCT04418830||Modulus ALIF|
89224164|NCT06271122|Experimental|Voluntary activation assessed by magnetic stimulation group|The inclusion visit (V0) will be conducted at the beginning of the stay. On Day 1 (D+1), the patients will undergo the first visit (V1), during which specific evaluations (maximal quadriceps force test, transcranial and femoral magnetic stimulation) will be performed. Subsequently, the patients will follow the standard 4-week PR program. On Day 28 (D+28), patients will undergo the second visit (V2), during which they will undergo the same evaluations as those performed in V1.
89224165|NCT06271109||laparoscopic Anatomical liver resection|
89073235|NCT04409301|Experimental|MSAD Intervention|Children receiving cancer treatment in a hospital randomized to the My Special Aflac Duck (MSAD) intervention.
89073236|NCT04409301|Active Comparator|Control Group|Children receiving cancer treatment in a hospital randomized to be a control hospital. Children in the control hospitals will receive the My Special Aflac Duck (MSAD) at the end of the intervention period.
89073237|NCT04405102|Experimental|Ozanimod + standard of care|During hospitalization, the experiment treatment of Ozanimod will be given with the standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data.).
89073238|NCT04405102|Active Comparator|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
89073239|NCT04404283|Experimental|Experimental Arm|Brentuximab vedotin + lenalidomide + rituximab
89073240|NCT04404283|Active Comparator|Control Arm|Placebo + lenalidomide + rituximab
89073241|NCT04374877|Experimental|Part A Monotherapy Dose Escalation|The Part A monotherapy dose escalation portion of the study will evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of CHS-388 as monotherapy in up to 30 patients with advanced solid tumors.
89073242|NCT04374877|Experimental|Part B CHS-388 Monotherapy Expansion|Part B monotherapy expansion will evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of CHS-388 monotherapy at the recommended phase 2 dose (RP2D) in up to 40 patients with ccRCC, up to 40 patients with HCC, and up to 40 patients with NSCLC.
89073243|NCT04374877|Experimental|Part C CHS-388 in Combination with Pembrolizumab|Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of CHS-388 in combination with pembrolizumab in patients with advanced RCC or HCC, or anti-PD(L)1 relapsed/refractory advanced NSCLC.
89073244|NCT04374877|Experimental|Part D CHS-388 in Combination with Toripalimab|Part D will evaluate the safety, preliminary efficacy, tolerability, and PK of CHS-388 in combination with toripalimab in patients with anti-PD(L)1 relapsed/refractory advanced NSCLC.
89073245|NCT04342390|Experimental|Exercise Group|Study participants in this group will be asked to complete 4 weeks of high-intensity interval training (HIIT).
89073246|NCT04342390|No Intervention|Control Group|Study participants in this group will not undergo HIIT exercise training during this study.
89073247|NCT04340141|Experimental|Arm I (perioperative chemotherapy, surgery)|Patients receive oxaliplatin intravenously (IV) over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Within 2-8 weeks of completing neoadjuvant chemotherapy, patients undergo surgical resection. Patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89224166|NCT06271109||laparoscopic Non Anatomical liver resection|
89073248|NCT04340141|Active Comparator|Arm II (surgery, adjuvant chemotherapy)|Patients undergo surgical resection. Beginning 3-12 weeks after surgery, patients then receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-3. Treatment repeats every 14 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
89073249|NCT04337619|Experimental|Standard Behavioral Weight Loss Treatment|
89073250|NCT04337619|Experimental|Behavioral + Mindful Acceptance|
89073251|NCT04337619|Experimental|Behavioral + Values|
89073252|NCT04337619|Experimental|Behavioral + Mindful Awareness|
89073253|NCT04337619|Experimental|Behavioral + Acceptance + Values|
89073254|NCT04337619|Experimental|Behavioral + Acceptance + Awareness|
89073255|NCT04337619|Experimental|Behavioral + Values + Awareness|
89073256|NCT04337619|Experimental|Behavioral + Acceptance + Values + Awareness|
89073257|NCT04336878|Experimental|Healthy Habits in Pregnancy and Beyond intervention|Intervention delivered in early pregnancy during an existing antenatal appointment. 1:1 intervention session (15-20 minutes) with the intervention facilitator (clinician/researcher). Participants provided with a self-guided leaflet for weight management focusing on making 10 simple diet and activity behaviours habitual, including advice on food choice & purchasing, portion size, eating behaviour & keeping active. The tips promote habit formation, nutrition awareness, avoidance of behavioural relapse, and reiterate guidance for pregnant women. Participants provided with a record-keeping logbook and access to an 'app' to self-monitor their weight and behaviours against the 10 target behaviours, during pregnancy and up to 6 weeks postpartum.
89224167|NCT06271083|Experimental|Behavior therapy with exposure and response prevention|
88820799|NCT05639647|Active Comparator|Best available therapy (BAT)|BAT will be selected by the investigator and administered iv. At the investigator's discretion, the participant may be switched to oral therapy after 3 days of iv BAT
88820800|NCT05635019|Active Comparator|Behavioral weight loss counseling (BWL) alone|BWL counseling alone
89073258|NCT04336878|No Intervention|Control group|The control group will receive 'usual' antenatal care which does not involve routinely delivered specific or standardised dietary advice.
89073259|NCT04285658||Ureteroscopy|
89073260|NCT04285658||Percutaneous Nephrolithotomy|
89073261|NCT04285658||Shock Wave Lithotripsy|
89073262|NCT04271280||High Risk and Very High Risk Dyslipidemic Participants|Participants are classified as High and Very High Risk (as assessed by the Framingham risk score for High Risk participants and the SMART score for Very High Risk participants) as well as if previously or newly diagnosed.
89073263|NCT04248140|Experimental|WiFi - Sham|first Intervention WiFi, second intervention sham
89073264|NCT04248140|Experimental|Sham - WiFi|first intervention sham, second intervention WiFi
89073265|NCT04242095||Observational (biospecimen collection, medical record review)|Patients undergo collection of tissue and blood samples (and optional stool samples from patients experiencing colitis) at the time of registration (within 72 hours of confirmation of one or more severe irAEs) and at 1 month after registration. Patients' medical records are also reviewed for up to 1 year.
89073266|NCT04226599|Experimental|Dissolve AVF Group|This group treated with Peripheral scoring drug balloon.Dissolve AVF
89073267|NCT04226599|Active Comparator|PTA Group|This group treated with plain balloon catheter.Armada 35
89073268|NCT04224545|Experimental|Colchicine|Colchicine 1 mg day (COLCHICINA LIRCA ® ACARPIA Farmaceutici S.r.l.)
89073269|NCT04224545|Placebo Comparator|Placebo|Sugar pill
89073270|NCT04199299||Persons who cannot communicate unequivocally|Persons with intellectual disability, childhood autism, and/or cerebral palsy who cannot communicate unequivocally and therefore cannot communicate their needs and wishes, e.g. whether they are uncomfortable, in pain, scared, angry, happy, pleased.
89073271|NCT04198701|Experimental|Pilot|First group of patients enrolled in the study.
89073272|NCT04198701|Experimental|Pivotal - Roll-In|First patient treated by each physician in the pivotal phase.
89073273|NCT04198701|Experimental|Pivotal - Paroxysmal AF|Non roll-in patients with paroxysmal AF (intermittent AF).
89073274|NCT04198701|Experimental|Pivotal - Persistent AF|Non roll-in patients with persistent AF (AF that lasts longer than 7 days).
89073275|NCT04195906|Experimental|SNF472 (Double-Blind Period)|Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.
89073276|NCT04195906|Placebo Comparator|Placebo (Double-Blind Period)|Matching placebo (saline) diluted in 100 mL physiological saline.
89073277|NCT04195906|Experimental|SNF472 (Open-Label)|Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.
89073278|NCT04194203|Experimental|Treatment A|Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
89073279|NCT04194203|Placebo Comparator|Treatment B|Participants will receive placebo, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with placebo, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
89691535|NCT01034527|No Intervention|Speed Training|Sham training will consist of sagittal plane only running drills designs solely to enhance sprint speed. A sham sagittal plane sprint training protocol that will be instituted with the teams that are randomly selected for sham treatment. Five phases will be utilized to facilitate progressions designed to improve the athletes' forward sprinting speed. Training volume will be approximately equivalent for the TNMT and sham protocols. They each will take athletes approximately 30 minutes to complete
89691536|NCT03031145|Active Comparator|Felis Domesticus treated Non-smoker|
89691537|NCT03031145|Active Comparator|Felis Domesticus treated E-cigarette smoker|
89073283|NCT04175847|Experimental|RC88|
89073284|NCT04174014|Experimental|Recruitment manoeuvre|"Volume control (VC) ventilation mode with a tidal volume of 6 mL/kg of ideal body weight~P/V tool assessment~Baseline measurements~CT scan of chest without EIT belt~Re-establishment of EIT belt, continuous EIT and transpulmonary pressure measurement during the recruitment and de-recruitment manoeuvre.~increment phase:~constant volume settings~increasing PEEP with 4 cmH2O following each 10 consecutive controlled breath until reaching a peak pressure of 40 cmH2O~decrement phase:~constant volume settings~decreasing PEEP with 4 cmH2O following each 10 consecutive controlled breath not lower than 2 cmH20 from target PEEP~target PEEP level is defined where the end-expiratory transpulmonary pressure is 0-1 cmH2O~P/V recruitment with target end-PEEP level~Removal of EIT belt, CT scan of chest~Continuous EIT and transpulmonary pressure measurement with the initial FiO2 and the new PEEP settings"
89073285|NCT04169321|Experimental|Single Arm|All participants will receive a mass dose of 40 μg or less of [68Ga]-NOTA-hGZP (radioactivity dose of 3 mCi to 8 mCi) and have a PET and CT scan.
89073286|NCT04165590|Experimental|Blood-stage infection of P.vivax|This is a single arm study that is planed to enroll 60 patients with advanced malignant solid tumor and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.
89073287|NCT04147234|Experimental|Arm A: BI 1387446|superficial lesions
89073288|NCT04147234|Experimental|Arm B: BI 1387446 in combination with ezabenlimab (BI 754091)|superficial lesions
89073289|NCT04141293|Experimental|Eligible patients|
89073290|NCT04119999|Active Comparator|CPAP|Continuous Positive Airway Pressure
89073291|NCT04119999|Experimental|MAD|Mandibular Advancement Device
89073292|NCT04119557|Placebo Comparator|Placebo|Participants received placebo administered subcutaneously (SC) every 2 weeks for a period of 12 weeks.
89073293|NCT04119557|Experimental|Cohort 1 - 10 (Microgram Per Kilogram) μg/kg LY3471851|Participants received 10 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.
89073294|NCT04119557|Experimental|Cohort 2 - 24 μg/kg LY3471851|Participants received 24 μg/kg of LY3471851 SC every 2 weeks for a period of 12 weeks.
89073295|NCT04118088|Experimental|Darvadstrocel|Participants who have previously received darvadstrocel would receive a single repeat dose of darvadstrocel 120 million cells (5 million cells/mL), by local injection into the fistula.
89073296|NCT04102358||Single injection|Patients who received an infraclavicular block with a single injection technique were included in Group-S.
89073297|NCT04102358||Triple injection|Patients who received an infraclavicular block with a triple injection technique were included in Group-T.
89073298|NCT04098874|Experimental|Bupropion|Participants randomized to extended-release bupropion. Once-daily
88820801|NCT05635019|Experimental|BWL+VOUCHER|BWL counseling and gift cards to grocery stores
88820802|NCT05635019|Experimental|BWL+HOME|BWL counseling and home-delivered boxes of groceries
89073299|NCT04098874|Placebo Comparator|Placebo|Participants randomized to placebo. Once-daily
89224168|NCT06271083|Active Comparator|Psychoeducation with general psychological support|
89224169|NCT06271057|Experimental|golcadomide post CAR T-cells|0.3 mg - Per Os - every week - 6 months
89691538|NCT03031145|Active Comparator|Felis Domesticus treated Cigarette smoker|
89691539|NCT03830125|Experimental|Single Ascending Doses|
89691540|NCT03830125|Experimental|Multiple Ascending Doses|
89691541|NCT02245451|Experimental|TPV/r with methadone|
89691542|NCT01096771|Experimental|ClinOleic 20%|96 hour continuous infusion.
89691543|NCT01096771|Active Comparator|Intralipid 20%|96 hour continuous infusion.
89691544|NCT00951899|Experimental|Colesevelam|Treatment with colesevelam hydrochloride in addition to Metformin and Diet
89691545|NCT00951899|Placebo Comparator|Placebo|Treatment with placebo in addition to Metformin and Diet
89691546|NCT01035151|Active Comparator|Delayed Control|Women in the delayed control condition received culturally sensitive smoking cessation written materials at week 1, and mailed materials at week 6, 12, and 18. At the end of the study (i.e., after the 12 month data collection), participants were offered counseling, nicotine patches, and community health worker contacts.
89691547|NCT01035151|Experimental|Experimental|Women in neighborhoods randomized to the S2S received 24-week bundled multi-level intervention. Individual-led strategies were led by paid community health workers (CHWs). The CHWs provided 1:1 contact to reinforce social support, and enhanced self-efficacy with cessation attempts. A certified smoking cessation counselor led behavioral group sessions using the S2S handbook based on the PHS Guidelines. The weekly group sessions were initiated during the 1st week of the intervention, with a total of 6 group sessions over a 6-week period. Transdermal nicotine patches were offered to participants who set a quit date. Within the 24-week study period, the neighborhood tenant association, in partnership with study staff, implemented at least two neighborhood level anti-smoking activities
89691548|NCT01097395|Active Comparator|Standard Weight-Based Ribavirin Dosing|1000 mg daily in patients weighing <75 kg and 1200 mg daily in patients weighing ≥ 75 kg
89691549|NCT01097395|Experimental|Concentration-Controlled Ribavirin Dosing|Dose adjusted based on first dose AUC0-12
89691550|NCT03030521||experimental group|In this group, the specimen of aortic wall is bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
89691551|NCT03030521||control group|In this group, the specimen of aortic wall is not bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
88820803|NCT05627219||Supportive care (training, education, discussion)|"AIM 1: Peer genetic coaches undergo training and education on study.~AIM 2: Patients receive an educational booklet and attend a discussion with a peer genetic coach on study."
89073300|NCT04066465||Proton Therapy|Patients receive proton Radio(chemo)therapy according to clinical standard. Proton Treatment is indicated BEFORE inclusion into the trial ans is not part of the trial. Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases. In addition to the treatment parameters of the radio(chemo)therapy protocol, further radiation doses to brain substructures and organs at risk are documented.
89073301|NCT04066465||No Radiotherapy - Surgical only group|"Patients are included AFTER surgery of their brain tumour and receive no radiotherapy due to their disease (i.e. according to clinical standard). This Treatment is not part of the trial, but stratifies the Patient in this second Group.~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely during follow-up using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
89073302|NCT04066465||Control Group|"Healthy kids are recruited as Standard Group.~Neurological status and neurocognitive testing on core executive functions (inhibition, working memory, cognitive flexibility) and Quality of life measurements are performed regularely using standardized KINDL® questionnaires for general quality of life and specific for oncologic diseases."
89073303|NCT04062214|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
89073304|NCT04062214|No Intervention|Usual Care|A Veteran who completes a Compensation examination ordinarily has no further treatment, referral or debriefing as part of the Compensation examination. Veterans will be advised that they should continue to pursue whatever counseling they need outside the study.
89073305|NCT04061798|Experimental|ACT guided heparinization|Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.
89073306|NCT04061798|Active Comparator|5 000 IU of heparin|A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Depending on that ACT value near the end of surgery, the local protamine can be given to neutralize the effect of heparin. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.
89073307|NCT04032301|Experimental|Intravenous ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
89073308|NCT04032301|Placebo Comparator|Intravenous saline infusions|Six infusions of normal saline solution over 3 weeks.
89073309|NCT04024774||index cases and their parents|
89073310|NCT03994796|Experimental|Arm I (CDK gene mutation)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89073311|NCT03994796|Experimental|Arm II (PI3K gene mutation)|Patients receive PI3K inhibitor paxalisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89073312|NCT03994796|Experimental|Arm III (NTRK/ROS1 gene mutation)|Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89073313|NCT03994796|Experimental|Arm IV (KRAS G12C mutation)|Patients receive adagrasib (MRTX849) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89073314|NCT03991962|Experimental|mFOLFIRINOX followed by SBRT|Patients will receive mFOLFIRINOX, followed stereotactic body radiotherapy (SBRT).
89073315|NCT03973983|Experimental|Ultrasound-guided pudendal nerve injection group|Patients who received Ultrasound-guided pudendal nerve injections
89073316|NCT03973983|Experimental|Finger-guided pudendal nerve injection group|Patients who received Finger-guided pudendal nerve injections
89073317|NCT03971500|Experimental|IVUS-guidance|In the IVUS-guided DES implantation group, optimal stent deployment criteria included: 1) the MLA in the stented segment is >5.0 mm^2, or 90% of the MLA at the distal reference segments; 2) plaque burden 5-mm proximal or distal to the stent edge is <55%; and 3) absence of >=Type B edge dissection. Further treatment will be required if any of those 3 criteria was not met.
89073318|NCT03971500|Active Comparator|Angiography-guidance|In the Angiography-guided DES implantation group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of >Type B dissection.
89073319|NCT03971500|Experimental|SAPT group|Ticagrelor + aspirin for 1 month followed by ticagrelor plus matching placebo for an additional 11 months.
88820804|NCT05623046|Experimental|Treatment|8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes.
89073320|NCT03971500|Active Comparator|DAPT group|Ticagrelor + aspirin for 12 month.
89073321|NCT03948490|Other|Arm 1 Cohort 1: Interventional arm/In-person rehab (CLOSED)|"The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.~n = 20 patients"
89224170|NCT06271044|No Intervention|RAILESS|Railess group including patients to bw followed up wihtout postoperative radioiodine treatment
89224171|NCT06271044|Active Comparator|rairinn|THose patients receiving radioiodine treatment according to the normal treatment practice at that time
89224172|NCT06271018||Aortitis in GCA|Adult patients with active aortitis associated with GCA, requiring treatment with Tocilizumab biosimilar used within the scope of its market authorization (standard of care)
89224173|NCT06271005|Active Comparator|Treatment with NeuroTears|
89224174|NCT06271005|Placebo Comparator|Placebo|
89229938|NCT01094899|Experimental|Type 1 Diabetics without Neuropathy|Adult male with type 1 diabetes and without peripherical neuropathy
89073322|NCT03948490|Experimental|Arm 1 Cohort 2: Interventional arm/ReMind iPad app (CLOSED)|"The ReMind iPad-based cognitive rehabilitation was developed with collaborators at Tilburg University, The Netherlands, and is an evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors. Brain plasticity-based computerized cognitive training is a newly developing field of therapeutics for neurological and psychiatric disorders that uses frequent game-like training sessions to drive improvements in cognitive functions.~n = 20 patients"
89073323|NCT03948490|Experimental|Arm 1 Cohort 3: Interventional arm/Healthy SMS texting (CLOSED)|"The mobile phone texting intervention was developed with collaborators at Zuckerberg San Francisco General Hospital and is currently being studied in individuals with depression and traumatic brain injury. Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.~n = 20 patients"
89073324|NCT03948490|No Intervention|Arm 2 Cohort 4: Longitudinal arm/Upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
89073325|NCT03948490|No Intervention|Arm 1 Cohort 5: Longitudinal arm/No upfront radiation|Patients will undergo longitudinal global cognitive and HRQOL assessments at baseline prior to surgery, after surgery, 3 months after surgery and every 6 months for 3 years. Clinical data will be collected at the time of each assessment. This will include changes in serial imaging e.g. in T2 tumor volume, DTI scalar quantification, resting-state fMRI connectivity n = 50 patients
89073326|NCT03948490|Other|Arm 1 Cohort 1A: Telehealth Cognitive Rehabilitation|"The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning. During treatment implementation, patients acquire, apply, and adapt evidenced based strategies based on neuropsychological testing and conjointly developed treatment planning goals.~N=20"
89073327|NCT03947307|Experimental|Experimental Intervention (treatment / medical device)|Patients in the experimental group will receive lymphtaping using Easytape® according to common practice on day 1 after surgery by specifically trained physiotherapists. The tape has an elasticity of 150%. The material is moisture- and air-permeable with a hypoallergenic adhesive coating that is activated by body temperature to increase durability of contact. If possible the taping will be left for 7 days, in case of insufficient adhesion taping will be repeated.
89073328|NCT03947307|Active Comparator|Control Intervention (compression treatment )|Patients in the control group will be treated with manual lymphatic drainage followed by compression treatment using compressive stockings if accepted or compressive bandaging in cases with pronounced swelling depending on medical necessity.
89073329|NCT03947307|Sham Comparator|Control Intervention (sham taping)|Patients in the control group will be treated by sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
89073330|NCT03936270|Experimental|Palbociclib 125mg + Letrozole 2.5mg|Palbociclib 125mg per day, administered orally in 4-week cycles (3 weeks of treatment followed by 1 week off) PLUS Letrozole 2.5mg per day administered orally (continuous treatment).
89073331|NCT03932240|Experimental|Fibrinogen Concentrate (FC)|"Neonates undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB) who are randomized to receive platelets and FC after separation from bypass. The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
89229939|NCT01094899|Experimental|Type 2 Diabetics without Neuropathy|Adult male with type 2 diabetes and without peripherical neuropathy
89229940|NCT01094899|Experimental|Type 1 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
89224175|NCT06270992||Lung cancer group|"192 patients diagnosed with lung cancer with the following inclusion criteria:~To be between the ages of 18 and 65,~Not having been previously diagnosed with and treated for lung cancer,~Not having received any cancer treatment in the last 2 years,~Not having been operated on within the last two years,~Not having a hospitalization history in the last year,~Not having used antibiotics in the last six months,~Not having used products manufactured to support the oral microbiome, such as probiotic (lozenges, sublingual drops) for at least the last six months,~Not being pregnant, not breastfeeding,~Not having undergone dental procedures such as root canal treatment, implants, prostheses, tooth extraction, fillings in the last 6 months, Not having dominant immune-origin lesions , viral-origin lesions, dominant bacterial infections like tonsillitis, and/or thermal or chemical mucosal traumas in the mouth."
89224176|NCT06270992||Benign lung disease group|"192 patients diagnosed with non-cancer diseases with the following inclusion criteria:~To be between the ages of 18 and 65,~To have visited our clinic with complaints related to the lungs and/or respiratory tract,~Not having been diagnosed with lung cancer after clinical evaluation,~Not having received any cancer treatment in the last 2 years,~Not having been operated on within the last two years,~Not having a hospitalization history in the last year,~Not having used antibiotics in the last six months,~Not having used products manufactured to support the oral microbiome, such as probiotics for at least the last six months,~Not being pregnant or breastfeeding,~Not having undergone dental procedures such as root canal treatment, implants, prostheses, tooth extraction, fillings in the last 6 months,~Not having dominant immune-origin lesions, viral-origin lesions, dominant bacterial infections like tonsillitis, and/or thermal or chemical mucosal traumas in the mouth."
89224177|NCT06270992||Healthy control group|"292 individuals without lung cancer or another lung disease diagnosis with the following inclusion criteria:~To be between the ages of 18 and 65,~Not to have a diagnosed lung disease or suspicion thereof,~Not to have complaints related to the lungs and/or respiratory tract,~Not to have alcohol or severe substance dependency,~Not having a hospitalization history in the last year,~Not having used antibiotics in the last six months,~Not having used products manufactured to support the oral microbiome, such as probiotics (lozenges, sublingual drops) for at least the last six months,~Not being pregnant or breastfeeding,~Not having undergone dental procedures such as root canal treatment, implants, prostheses, tooth extraction, fillings in the last 6 months,~Not having dominant immune-origin lesions, viral-origin lesions, dominant bacterial infections like tonsillitis, and/or thermal or chemical mucosal traumas in the mouth."
89224178|NCT06270979||Leiehome vzw|Participant recruitment entails including persons aged 65 years or older living in an assisted housing or a nursing home.
89224179|NCT06270979||University Hospital Antwerp/University of Antwerp|Participant recruitment entails including persons aged 65 years or older undergoing rehabilitation at University Hospital Antwerp.
89224180|NCT06270966|Experimental|Virtual Reality Cognitive Remediation + treatment as usual|15 Participants with more than 65 years and with MCI diagnosis will undergo a cognitive remediation program using fully immersive VR. Participants will continue with standard care during the experimental intervention
89224181|NCT06270966|No Intervention|Treatment as usual|The control group, 15 participants with more than 65 years and with MCI diagnosis, will continue with standard care.
89224182|NCT06270927||MRI|patients assigned to MRI
89224183|NCT06270927||CT|patients assigned to CT
89224184|NCT06270914|Experimental|Intervention|The intervention group will receive the intervention Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling).
89224185|NCT06270914|Active Comparator|Active control|Control group in the first wave of data collection is selected in accordance quasi-experimental design with nonequivalent control group. The teachers in the control group will, instead of a wait-list intervention, a shortened version of SW-PBIS containing only classroom leadership lectures. The schools that are part of the classroom management group also send staff for instructor training (ten training sessions, 25 hours in total, just as much as the SW-PBIS schools). Similar to the SW-PBIS group, the instructors in this group educate and supervise school staff, supported by a team at the school. Both groups have access to a manual and supporting materials. This design does not pose threats to the internal validity of the study, as classroom leadership is one of principles of PBIS framework. In this way it will be possible to explore the specific contribution of schoolwide PBS in contrast to classroom leadership only.
89224186|NCT06270914|No Intervention|Control|Control group in the second wave of data collection constitutes a wait-list control group and will not be engaged in any kind of intervention during the intervention period.
89224187|NCT06270888|Experimental|Group 1 - Dose Schedule 1|"In this study, there will be 4 different radiation schedules, ranging from 1-10 daily treatments. Participants will be assigned to one of the dose schedules and they will know this ahead of time. The study doctor will tell each participant which study group and dose schedule they been assigned.~For most participants, the actual time on the radiation treatment machine will be in the range of 30 to 60 minutes. The mold will be removed after the treatment. The number of treatments to each tumor will depend on which treatment group the participant is enrolled on: The longest possible treatment group would be 10 treatments in duration of about 2 weeks of treatment and the shortest possible treatment group would be 1 treatment."
89224188|NCT06270888|Experimental|Group 2 - Dose Schedule 2|"In this study, there will be 4 different radiation schedules, ranging from 1-10 daily treatments. Participants will be assigned to one of the dose schedules and they will know this ahead of time. The study doctor will tell each participant which study group and dose schedule they been assigned.~For most participants, the actual time on the radiation treatment machine will be in the range of 30 to 60 minutes. The mold will be removed after the treatment. The number of treatments to each tumor will depend on which treatment group the participant is enrolled on: The longest possible treatment group would be 10 treatments in duration of about 2 weeks of treatment and the shortest possible treatment group would be 1 treatment."
89224189|NCT06270888|Experimental|Group 3 - Dose Schedule 3|"In this study, there will be 4 different radiation schedules, ranging from 1-10 daily treatments. Participants will be assigned to one of the dose schedules and they will know this ahead of time. The study doctor will tell each participant which study group and dose schedule they been assigned.~For most participants, the actual time on the radiation treatment machine will be in the range of 30 to 60 minutes. The mold will be removed after the treatment. The number of treatments to each tumor will depend on which treatment group the participant is enrolled on: The longest possible treatment group would be 10 treatments in duration of about 2 weeks of treatment and the shortest possible treatment group would be 1 treatment."
89073332|NCT03932240|Active Comparator|Cryoprecipitate|"Neonates undergoing elective cardiac surgery requiring cardiopulmonary bypass (CPB) who are randomized to receive platelets and cryoprecipitate. Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL (based on findings by Downey et al., published in Anesthesia and Analgesia in 2020).~If a patient in either arm continues to have post-bypass bleeding, the anesthesiologist will use point of care testing and the transfusion thresholds outlines in the transfusion algorithm to determine appropriate products for transfusion."
89073333|NCT03924167|Experimental|Families Receiving Weaving Healthy Families Intervention|The Weaving Healthy Families curriculum is a cognitive-behavioral, support group model for high-risk families related to alcohol, tobacco, or other drugs (ATOD) and/or or domestic violence, child abuse, or neglect. This curriculum is tailored for all ages (i.e., (a) parents/caregivers; (b) early childhood (5-7); (c) children (8-11); and (d) adolescent (12-17) and is aimed at reducing alcohol and other drug (AOD) abuse, promote unity, address mental health problems, strengthen parenting skills, and bolster wellness and resilience.
89073334|NCT03924167|No Intervention|Families who have not yet receive the Weaving Healthy Families|Baseline group --data will be collected prior to receiving the intervention in this stepped-wedge trial design.
89073335|NCT03900429|Placebo Comparator|Matching Placebo|Placebo Daily
89073336|NCT03900429|Active Comparator|80 mg MGL-3196|80 mg daily
89073337|NCT03900429|Active Comparator|100 mg MGL-3196|100 mg daily
89073338|NCT03892226||1, no myocardial injury|normal troponin level (hs-troponin T ≤ 99. percentile, i.e. 14ng/ml)
89073339|NCT03892226||2, chronic myocardial injury|elevated, but stable troponin level; (hs-troponin T> 99. percentile and rise/fall ≤ 20% in the control)
89073340|NCT03892226||3, acute myocardial injury|dynamic troponin elevation; (hs-troponin T> 99. percentile and rise/fall >20% in the control)
89073341|NCT03886948|Experimental|125 mg LY3074828 Prefilled Syringe (PFS)|"Reference 1: Participants received 125 mg LY3074828 solution formulation subcutaneously (SC) via 1-mL pre-filled syringe (PFS) administered in the arm.~Reference 2: Participants received 125 mg LY3074828 solution formulation SC via 1-mL PFS administered in the thigh.~Reference 3: Participants received 125 mg LY3074828 solution formulation SC via 1-mL PFS administered in the abdomen."
89073342|NCT03886948|Experimental|125 mg LY3074828 Autoinjector (AI)|"Test 1: Participants received 125 mg LY3074828 solution formulation SC via 1-mL Autoinjector (AI) administered in the arm.~Test 2: Participants received 125 mg LY3074828 solution formulation SC via 1-mL AI administered in the thigh.~Test 3: Participants received 125 mg LY3074828 solution formulation SC via 1-mL AI administered in the abdomen."
89073343|NCT03884075|Experimental|Arm A: Steatosis|Participants with steatosis on baseline biopsy
89073344|NCT03884075|Experimental|Arm B: NASH|Participants with NASH on baseline biopsy
89073345|NCT03884075|No Intervention|Arm C: Healthy|Healthy Volunteers
89229941|NCT01094899|Experimental|Type 2 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
89073346|NCT03875339|Active Comparator|Navigator Arm|Examination of adherence to follow-up with a navigator.
89073347|NCT03875339|No Intervention|Non-Intervention Arm|Examination of adherence to follow-up without a navigator.
89073348|NCT03863613|Active Comparator|Pessary group|A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH & Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
89073349|NCT03863613|Active Comparator|Cerclage group|Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
89073350|NCT03863613|Active Comparator|Pessary plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
89229942|NCT01091701|Experimental|Ex vivo cultured adult allogenic MSCs|
89229943|NCT01091701|Placebo Comparator|Plasmalyte-A|
89073351|NCT03863613|Active Comparator|Cerclage plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
89073352|NCT03861234|Experimental|BI 836880|Single Rising Dose part followed by a Multiple Rising Dose part
89073353|NCT03860480|Active Comparator|ESP with Bupivacaine 0.5%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of bupivacaine at a concentration of 0.5% with epinephrine 1:200 000 will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
89073354|NCT03860480|Sham Comparator|ESP with Saline 0.9%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of a placebo solution (normal saline) will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
89073355|NCT03858348||fluticasone / salmeterol treatment|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol (Group A)
89073356|NCT03858348||fluticasone / salmeterol and extra LAMA|The evaluation of pulmonary function in patients with COPD receiving and maintaining a stable combination of fluticasone / salmeterol and extra a long-acting muscarinic receptor antagonist (anticholinergic, LAMA) (Group B).
89073357|NCT03812653|Experimental|Intervention Arm: CPAP with Usual Care.|6 months of CPAP plus usual medical therapy.
89229944|NCT01091779||Hypertensive and normotensive|
89691552|NCT01036009|No Intervention|Group I: Observation|Group I (observation): Patients with full donor chimerism and no evidence of MRD continue to undergo clinical monitoring for acute and chronic graft-vs-host disease and relapse until 3 years post-transplant. Patients undergo repeat chimerism testing at 12 and 24 months post-transplant.
89691553|NCT01036009|Experimental|Group II: Intervention|Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.
89691554|NCT00467987|Experimental|androgel|androgel
89691555|NCT00467987|Placebo Comparator|placebo|placebo gel
89073358|NCT03812653|No Intervention|Control Arm: Usual Care.|6 months of usual medical therapy alone.
89073359|NCT03801369|Experimental|Arm I (olaparib, durvalumab)|Patients receive olaparib PO BID on days 1-28 of each cycle and durvalumab intravenously (IV) over 1 hour on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
89691556|NCT00467987|No Intervention|no treatment|eugonadal comparison arm
89691557|NCT00433589|Active Comparator|Chemotherapy randomization: Arm I (anthracycline-based)|"FEC 100~Canadian CEF~CAF~FAC~E-CMF"
89691558|NCT00433589|Experimental|Chemotherapy randomization: Arm II (docetaxel and capecitabine)|"Docetaxel~Capecitabine"
89691559|NCT00433589|Active Comparator|Endocrine therapy randomization: Arm I|2 years of tamoxifen followed by 5 years of letrozole
89691560|NCT00433589|Experimental|Endocrine therapy randomization: Arm II|7 years of letrozole
89691561|NCT00433589|Active Comparator|Treatment decision randomization: Arm I|chemotherapy-decision-making according to clinical criteria (using Adjuvant! Online)
89691562|NCT00433589|Experimental|Treatment decision randomization: Arm II|chemotherapy-decision-making according to genomic prognosis using the 70-gene signature
89691563|NCT03013075|Experimental|SPINAL PLUS GENERAL ANESTHESIA|Patient will receive the intervention SPINAL ANESTHESIA before the start of surgery using Bupivacaine heavy 40 mg and Morphine 250 micro grams comprising a total volume of 8 ml to achieve a spinal block up to T2 level followed by general anesthesia
89691564|NCT03013075|Active Comparator|ONLY GENERAL ANESTHESIA|Patient will receive only general anesthesia before the start of surgery
89691565|NCT02180893|Experimental|Paravertebral block|Patient receiving a PVB prior to robotic mitral valve surgery
89691566|NCT02180893|Placebo Comparator|No block|Patients who did not receive PVB
89691567|NCT03014089|Experimental|mRNA-1325|
89691568|NCT03014089|Placebo Comparator|Placebo|0.9% sodium chloride
89691569|NCT03030677|Other|Interventional Without Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound without injecting 10 ml of lidocaine 1% as a dissecting solution
89691570|NCT03030677|Other|Interventional With Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound after injecting 10 ml of lidocaine 1% as a dissecting solution
89691571|NCT03035513||CSWS patients|The data of CSWS patients will be statistically compared to healthy volunteers
89691572|NCT03035513||healthy volunteers|The data of CSWS patients will be statistically compared to healthy volunteers
89691573|NCT03030365||Healthy Controls|"Age matched controls for the various clinical groups will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi (millicurie) of 18F (fluorodeoxyglucose) -FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
89691574|NCT03030365||Amnestic Mild cognitive impaired|"Patients diagnosed with mild cognitive impairment, exhibiting impairment mostly in memory that is significant but does not interfere with everyday activities.~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
89073360|NCT03801369|Experimental|Arm II (olaparib, selumetinib)|Patients receive olaparib PO BID on days 1-28 of each cycle and selumetinib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
89073361|NCT03801369|Experimental|Arm III (olaparib, capivasertib)|Patients receive olaparib PO BID on days 1-28 of each cycle and capivasertib PO BID 4 days on and 3 days off of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
89073362|NCT03801369|Experimental|Arm IV (ceralasertib)|Patients receive ceralasertib PO BID on days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, continue on therapy beyond the planned 13 cycles.
89073363|NCT03793426||Fibryga|Fibryga (human plasma-derived fibrinogen concentrate)
89691575|NCT03030365||Alzheimer's disease patients|"Patients exhibiting significant loss of intellectual ability that interferes with everyday functioning that meet Alzheimer's pattern of decline, and following exclusion of alternative neurodegenerative, cerebrovascular, and metabolic etiologies.~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
89691576|NCT01122901|Experimental|Group A (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89691577|NCT01122901|Experimental|Group B (gamma-secretase inhibitor RO4929097, surgery)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days -6 to -1. Patients undergo surgical resection on day 0. Within 30 days after surgical resection, patients receive gamma-secretase inhibitor RO4929097 as in group A.
89691578|NCT03035435||study group|fast-track rehabilitation
89691579|NCT03035435||control group|standard care rehabilitation
89691580|NCT01097785|Active Comparator|Simvastatin|40 mg Simvastatin 1 pill every day for 30 days
89691581|NCT01097785|Placebo Comparator|Placebo|Placebo cap 1 pill every day for 30 days
89691582|NCT03030287|Experimental|OMP-305B83 plus paclitaxel|
89691583|NCT01098253|Experimental|Adherence Intervention|Factors affecting adherence to oral hypoglycemic agents and antidepressants were addressed using a problem solving process.
89691584|NCT01098253|No Intervention|Usual Care|
89691585|NCT03030209||Distal Pancreatectomy|Patients undergoing distal pancreatectomy
89691586|NCT03035279|Experimental|Arm A|SC-006 Dose regimen finding
89691587|NCT03035279|Experimental|Arm B|SC-006 Dose expansion
89691588|NCT03035279|Experimental|Arm C|SC-006 and ABBV-181 Combination escalation and expansion
89691589|NCT03035357|Experimental|Daratumumab|Participants receive Daratumumab by vein over about 1 hour 1 time a week during Weeks 1-4.
89691590|NCT00940589|Experimental|Circadin|Drug
89691591|NCT00940589|Placebo Comparator|Placebo|drug
89691592|NCT03603106|Experimental|Part I (Phase I)|In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
89691593|NCT03603106|Experimental|Part II (Phase IIA)|In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.
89691594|NCT02574078|Experimental|Group A Nivolumab|Opdivo specified dose on specified days
89691595|NCT02574078|Experimental|Group A Nivolumab + SOC maintenance therapy|"Opdivo/Bevacizumab specified dose on specified days~Opdivo/Pemetrexed specified dose on specified days"
89691596|NCT02574078|Active Comparator|Group A SOC maintenance therapy|"Bevacizumab specified dose on specified days~Pemetrexed specified dose on specified days"
89691597|NCT02574078|Experimental|Group B Nivolumab|Opdivo specified dose on specified days
89691598|NCT02574078|Other|Group B Best supportive care|Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
89691599|NCT02574078|Active Comparator|Group C Investigator's choice chemotherapy|"Carboplatin/nab-paclitaxel specified dose on specified days~Carboplatin/paclitaxel specified dose on specified days~Carboplatin/pemetrexed specified dose on specified days~Carboplatin/docetaxel specified dose on specified days~Carboplatin/gemcitabine specified dose on specified days~Paclitaxel specified dose on specified days~Docetaxel specified dose on specified days~Gemcitabine specified dose on specified days~Pemetrexed specified dose on specified days"
89691600|NCT02574078|Experimental|Group C Nivolumb|Opdivo specified dose on specified days
89691601|NCT02574078|Active Comparator|Group D Erlotinib|Erlotinib specified dose on specified days
89691602|NCT02574078|Experimental|Group D Nivolumab + Erlotinib|Opdivo/Erlotnib specified dose on specified days
89691603|NCT02574078|Experimental|Group E Nivolumab + Crizotinib|Opdivo/Crizotinib specified dose on specified days
89691604|NCT03029897|Experimental|experimental|Patients are educated on the use of a mobile application to report adverse drug reactions
89691605|NCT03029897|No Intervention|control|Patients are not educated on the use of a mobile application to report adverse drug reactions
89691606|NCT03030053|Experimental|Active|Cocoa-Flavanol Supplements: 3 capsules per day each containing 300mg (total dose of 900mg daily) for 24 weeks
89691607|NCT03030053|Placebo Comparator|Control|Control Supplements: 0mg cocoa-flavanols per day for 24 weeks
89691608|NCT03605914|Experimental|NSAID|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
89691609|NCT03605914|Active Comparator|opioid|The Opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
89691610|NCT04353479|Experimental|Camrelizumab(SHR-1210) Combined With Decitabine|Patients will be administered Camrelizumab(SHR-1210) at D1 and D15 and decitabine at D1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity.
89691611|NCT03027791|Experimental|Parishoners at HUMC|African-American adults aged 18-85 who attend services at Holman United Methodist Church will be exposed to Group Sessions for 12 weeks and Virtual Reality for 6 weeks.
89691612|NCT03554746|Experimental|GC group|It mainly involve core stability exercise, stretching exercise and gluteal control training. All of above will be arranged 3 times a week for a total 6 weeks.
89073364|NCT03777306|Experimental|ARM A EARLY INTERVENTION GROUP|In Arm A, the intervention group, the participants will start on the program immediately. The participants will receive MPI educational program, implemented in parallel with standard of care treatment. The MPI is implemented at the time of enrollment x 12 weeks
89073365|NCT03777306|Experimental|ARM B DELAYED INTERVENTION GROUP|Arm B, is a wait-list control group that will serve as the control. The wait-list control group will be observed for an initial 12 week period while receiving usual care and then have the educational intervention implemented from week 12-24 in parallel with standard of care
89073366|NCT03745235|Experimental|"Mindfulness group"|
89073367|NCT03745235|Other|Control group|Treatment as Usual
89073368|NCT03743649|Experimental|Group I (haloperidol, placebo)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
89073369|NCT03743649|Experimental|Group II (lorazepam, placebo)|Patients receive lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
89691613|NCT03554746|Experimental|CG group|It involve core stability exercise and stretching exercise. All of above will be arranged 3 times a week for a total 6 weeks.
89073370|NCT03743649|Experimental|Group III (haloperidol, lorazepam)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed until discharge from palliative care unit.
89073371|NCT03743649|Experimental|Group IV (placebo, lorazepam)|Patients receive two different placebos IV every 4 hours. Patients then receive placebo IV and lorazepam IV over 3-15 minutes every hour as needed until discharge from palliative care unit.
89073372|NCT03728179|Experimental|Cohort 1|0,5 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
89073373|NCT03728179|Experimental|Cohort 2|1 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
89073374|NCT03728179|Experimental|Cohort 3a|1 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
89073375|NCT03728179|Experimental|Cohort 4a|2 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
89073376|NCT03728179|Experimental|Phase I b|Recommended Phase Ib RT dose (RP1bD) + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib
89073377|NCT03728179|Experimental|Cohort 3b|1 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
89073378|NCT03728179|Experimental|Cohort 4b|2 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
89073379|NCT03698955|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
89073380|NCT03698955|Active Comparator|Mediterranean diet|The diet group will be asked to follow a Mediterranean diet for 16 weeks.
89073381|NCT03668223|Experimental|Promoting Resilience in Stress Management (PRISM)|Resilience Skills Training
89073382|NCT03668223|No Intervention|Usual Care|Standard psychosocial care
89073383|NCT03661970||Normal subjects hearing group|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
89691614|NCT05260307|Other|Experimental condition|Participants will be presented with sound stimuli under a number of experimental conditions that simulate different hearing-aid conditions.
89691615|NCT05252507|Experimental|Paint Night|
89691616|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement|Vitamin D replacement (50.000 IU/per week, for 8 weeks)
89691617|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement and exercise|Vitamin D replacement (50.000 IU/per week, for 8 weeks) and Core and balance exercises for 8 weeks.
89691618|NCT03608488|Experimental|Vitamin D<10 ng/ml; exercise|Core and balance exercises for 8 weeks.
89691619|NCT03608488|Active Comparator|Vitamin D>30ng/ml; exercise|Core and balance exercises for 8 weeks.
89691620|NCT03034889||Exposed|Children age 4-10 who required general anesthesia before the age of 36 months in the context of surgical and diagnostic procedures or sedation during intensive care, excluding neurosurgical interventions or cardiac surgery as well as preexisting hereditary or acquired neurocognitive deficits
89691621|NCT03034889||Control|Children age 4-10 who did not require any anesthesia before the age of 36 months. Excluding preexisting hereditary or acquired neurocognitive deficits.
89691622|NCT03035045|Experimental|Comparator1: Paracetamol 650 mg (325 mg/tablet) oral|Drug: Paracetamol Comparison pain score between paracetamol and placebo
89691623|NCT03035045|Placebo Comparator|Comparator 2: Placebo oral|Drug: placebo Comparison pain score between paracetamol and placebo
89691624|NCT03557086|Experimental|Advanced Care Planning Video Decision Support Tool|We designed a 3-minute advance care planning video to provide patients with advanced liver disease general understanding of the types of medical care patients may receive at the end of life (EOL) and a description of medical interventions such as hospitalizations, intensive care unit (ICU) admission, cardiopulmonary resuscitation (CPR), and intubation. The video begins by addressing the importance of the patient's personal goals and perspectives by asking the viewer to reflect on their concerns about getting sick and their overall goals for their EOL care. The physician narrator then introduces a framework for choices of medical care at the EOL including: 1) life-prolonging care; 2) limited medical care; and 3) comfort care followed by visual images illustrating each of these EOL care choices. All three sequences of video images accompanying the narration attempt to help the viewer imagine the experience and likely outcomes of receiving these medical interventions at the EOL.
89691625|NCT03557086|Active Comparator|Verbal Narrative Control|Immediately after completing baseline assessments and randomization, patients assigned to the verbal narrative control arm will listen to the same description of the 3 goals of care used in the video arm read out by a research assistant
89073384|NCT03661970||Cochlear implant subjects with good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
89073385|NCT03661970||Cochlear implant subjects without good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
89073386|NCT03650933|Experimental|G-CHOP|GB241 plus CHOP, six cycles. GB241: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
89073387|NCT03650933|Active Comparator|R-CHOP|Rituximab plus CHOP, six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
89073388|NCT03649490||Smooth PEEK Interbody Implants in XLIF|Smooth PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) provide maximum surface area and structural stability with large central apertures to allow bony through-growth. Multiple length options enable optimal apophyseal support, thus reducing the chance of subsidence. Additionally, lordotic profiles are available to induce proper sagittal alignment.
89073389|NCT03649490||3D-Printed Titanium Interbody Implants in XLIF|3D-printed, fully porous titanium interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) have a porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding and improved radiographic imaging. The advanced microporous surface topography creates an ideal environment for bone in-growth.
89073390|NCT03649490||Porous PEEK Interbody Implants in XLIF|Porous PEEK interbody implants for XLIF (with allograft chips and BMA or cancellous allograft) combine the osseointegration capabilities of porous metal implants with the favorable imaging and mechanical properties of traditional PEEK implants. The Porous PEEK architecture, with 60% porosity and 300 mm average pore size, is specifically tailored to elicit the optimal osteogenic cell response and promote bone tissue ingrowth inside the pores, as demonstrated in preclinical studies.
89073391|NCT03642665|Experimental|Natural cycle|no medication
89073392|NCT03642665|Active Comparator|Artificial cycle|"Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.~Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy."
89073393|NCT03612271|Experimental|mGlide Intervention|Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
89073394|NCT03612271|No Intervention|Clinical Care Comparison|Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.
89073395|NCT03609216|Experimental|Arm I (gemcitabine, cisplatin, bladder sparing)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage < cT1 undergo bladder sparing.
89073396|NCT03609216|Experimental|Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage >= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
89073397|NCT03561103|Experimental|RCT: Intervention|Participants in the RCT intervention arm will receive client-centered representative payee services in addition to the standard of care.
89073398|NCT03561103|No Intervention|RCT: Control|Participants in the RCT control group will receive the standard of care.
89073399|NCT03561103|Experimental|Choice Intervention|Participants in the Choice intervention arm will receive client-centered representative payee services in addition to the standard of care. They will not be randomly assigned.
89073400|NCT03561103|No Intervention|Choice Control|Participants in the RCT control group will receive the standard of care. They will not be randomly assigned.
89073401|NCT03555643||transient ischemic attack (TIA)|Patients with transient ischemic attack
89073402|NCT03555643||transient neurological attack (TNA)|Patients with transient neurological attack
89073403|NCT03530969|Experimental|GI/GU/Lymphoma Oncologists|Doctors specializing in treating gastrointestinal cancer (cancer of the stomach, pancreas, colon, etc.), genitourinary cancer (cancer of the genitals and urinary tract), and lymphoma (cancer affecting the blood and lymph nodes)
89073404|NCT03530969|Active Comparator|Participants with GI/GU/Lymphoma Cancer|Patients of the physicians in group 1
89073405|NCT03530969|Active Comparator|Caregivers of Participants with GI/GU/Lymphoma Cancer|Family members or caregivers of the patients in group 2
89073406|NCT03509909|Experimental|Hatha yoga|12- week group-based yoga class
89073407|NCT03509909|Active Comparator|Supportive exercise|12-week group-based stretching and strengthening class
89073408|NCT03503097||Ancillary-Correlative (questionnaires, Color kit, counseling)|Participants receive web-based or hard-copy questionnaires and saliva collection kits via mail or in person. Participants also provide saliva samples to be mailed back to Color Genomics for genetic testing once complete. Participants then receive phone-based genetic counseling if they are identified to have an inherited mutation in a DNA repair gene. All participants have access to phone-based genetic counseling whether or not they are not found to have a mutation.
89073409|NCT03500380|Experimental|RC48-ADC|Participants will receive RC48-ADC 2.0 mg/kg intravenous (IV) infusion each 14-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
89073410|NCT03500380|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg orally once daily during each 21-day cycle + capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.
89073411|NCT03485677|Experimental|Cohort 1: Eliglustat monotherapy|"Eliglustat for at least two years. Cohort 1 patients that experience significant clinical decline will receive rescue treatment.~Rescue Treatment Step 1: Switch from eliglustat to imiglucerase monotherapy.~Rescue Treatment Step 2: Patients who after 6 months of rescue therapy with imiglucerase monotherapy do not show improvement in the parameter(s) that led to the switch from eliglustat to imiglucerase, will then receive combination therapy with eliglustat + imiglucerase."
89073412|NCT03485677|Experimental|Cohort 2: Eliglustat plus imiglucerase|Eliglustat plus imiglucerase for three years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
89073413|NCT03474822|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 30 patients in each type cancer and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites. The treatment will last 4-6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
89073414|NCT03463824|Experimental|Experimental Group 1|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
89073415|NCT03463824|Experimental|Experimental Group 2|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
89073416|NCT03406091||Poor Mobilizer (PM) in Multiple Myeloma (MM) patients|
89073417|NCT03401788|Experimental|Open Label Belzutifan|Participants receive 120 mg belzutifan orally once daily. Participants may continue to receive belzutifan in the absence of unacceptable treatment related toxicity or unequivocal disease progression.
89073418|NCT03396341||patients receiving a positive BRCA1/2 mutation result|All interested participants will provide a saliva sample for genetic risk modifier testing, and will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
89073419|NCT03390322|Experimental|Duodenal Glycemic Control™|
89073420|NCT03379857|Other|Cannabis User|
89073421|NCT03376646|Experimental|Cohort A: Dissolve™|
89073422|NCT03376646|Active Comparator|Cohort A: Resolute™ Integrity|
89073423|NCT03376646|Experimental|Cohort B: Dissolve™-2.00mm|Cohort B is single arm.
89073424|NCT03375983|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
89073425|NCT03373695|Experimental|Dissolve™|
89073426|NCT03373695|Active Comparator|SeQuent®Please|
89073427|NCT03367741|Experimental|Arm A (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15, then on day 1 beginning cycle 5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89073428|NCT03367741|Experimental|Arm B (nivolumab)|Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time of disease progression. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89073429|NCT03362658||Patients|ALS patients (as well as patients with other related disorders such PLS, PMA, and ALS-FTD) will be recruited from ALS clinics under the direction of neurologists who are participating in this study. ALS patients should meet research criteria for suspected, possible, probable, probable laboratory supported, or definite ALS.
89073430|NCT03362658||Controls|Healthy controls who are age and gender matched to patients.
89073431|NCT03355482|Active Comparator|Depomedrol arm|Patients are treated with new or ascending doses of subcutaneous methotrexate, and receive a single intramuscular dose of Depomedrol (160mg) at baseline.
89073432|NCT03355482|Sham Comparator|Placebo arm|Patients are treated with new or ascending doses methotrexate, and receive a single intramuscular placebo injection at baseline.
89691626|NCT03034733|Experimental|dexamethasone 0,15 mg/kg|single-dose intravenous dexamethasone 0,15 mg/kg, intraoperative
89073433|NCT03345784|Experimental|Treatment (radiation therapy, adavosertib, cisplatin)|Patients undergo external beam radiation therapy on days 1-5 and receive adavosertib PO on days 1, 3, and 5 or QD on days 1-5 and cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.
89073434|NCT03345576|Experimental|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
89073435|NCT03345576|Sham Comparator|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
89073436|NCT03327805|Experimental|Short Term Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate for 4 weeks prior to and during the testing period.
89073437|NCT03327805|Placebo Comparator|Short Term Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo (maltodextrin) for 4 weeks prior to and during the testing period.
89073438|NCT03326947|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
89073439|NCT03326947|No Intervention|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
89073440|NCT03313180|Experimental|Nintedanib|"Patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) who took part in the parent trials 1199.214 (Nintedanib or Placebo) or 1199-0340 (Nintedanib). Patients continued in this trial and received Nintedanib 150 mg (milligram) twice daily (bid) unless they had reduced their dose to 100 mg bid trial medication (Nintedanib or Placebo) in the parent trial.~Patients receiving 100 mg bid trial medication at the end of the parent trial could receive either Nintedanib 100 mg bid or 150 mg bid at the discretion of the investigator."
89073441|NCT03307824|Experimental|IfabondTM|Use of the synthetic glue IfabondTM
89073442|NCT03307824|Active Comparator|sutures|Glue-Free Suture Technique
89073443|NCT03275285|Experimental|Isatuximab + Carfilzomib + Dexamethasone (IKd)|Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth [po]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.
89073444|NCT03275285|Active Comparator|Carfilzomib + Dexamethasone (Kd)|Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle.
89073445|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab: Triple Negative Breast Cancer (TNBC)|Participants with TNBC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10^6 plaque-forming units/milliliter (PFU/mL) on Day 1 of Cycle 1 and 10^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
89073446|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab: Colorectal Cancer (CRC)|Participants with CRC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10^6 PFU/mL on Day 1 of Cycle 1 and 10^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
89073447|NCT03227055||CKD|Children and adolescents with stage G1-G4 CKD, age 3 to 18 yr
89691627|NCT03034733|Experimental|dexamethasone 0,25 mg/kg|single-dose intravenous dexamethasone 0,25 mg/kg, intraoperative
89073448|NCT03192007||Patients with Stable Renal Function|Patients will be given MRI
89229945|NCT03960229|Experimental|MicroFluidic Sperm Sorting Chips|Sperm Sorting microfluidic chips (for ICSI) will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
89691628|NCT03034733|Placebo Comparator|Sodium Chloride, (24)NaCl 0,9%|single-dose intravenous saline, intraoperative
89691629|NCT05512416|Experimental|cohort 1|patients with stage IIB-III HR+/HER2- breast cancer
89691630|NCT03034499|Active Comparator|Single-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by single-port sacrocolpopexy.
89073449|NCT03192007||Patients with Worsening Renal Function due to complications|MRI
89073450|NCT03150732|Active Comparator|Systemic nalbuphine group|53 patients will receive nalbuphine systemically
89073451|NCT03150732|Active Comparator|Local nalbuphine group|53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA)
89073452|NCT03150693|Active Comparator|Arm I (frontline chemotherapy)|See detailed description.
89691631|NCT03034499|Active Comparator|Multi-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by multi- port sacrocolpopexy.
89691632|NCT03557476|Experimental|Octacosanol|Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
89691633|NCT03557476|Placebo Comparator|Placebo|A placebo pill was taken twice daily in replacement of the octacosanol supplement
89691634|NCT05512338|Experimental|PACT treatment group|PACT treatment will include an initial physical assesment with feedback, identification of value-based goals, individualized physical exercise based on the DNS concept, manual therapy, addressing barriers and facilitators to self-management, and skills training to promote psychological flexibility.
89073453|NCT03150693|Experimental|Arm II (frontline chemotherapy, inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
89073454|NCT03052608|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
89073455|NCT03052608|Active Comparator|Crizotinib|Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously
89073456|NCT03047603||Healthy control|The healthy control group consist of people undergoing routine medical examination. Serum samples are collected.
89073457|NCT03047603||Metastatic liver cancer patients|Serum samples are collected.
89073458|NCT03047603||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
89073459|NCT03047603||Chronic liver disease patients|This group is comprised of liver cirrhosis and chronic hepatitis B patients. The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
89073460|NCT03023540|Active Comparator|PXT3003 dose 1|Period 1, PXT3003 : Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months
89073461|NCT03023540|Active Comparator|PXT3003 dose 2|"Period 1, PXT3003: Liquid oral solution (1.2 mg/mL baclofen, 0.14 mg/mL naltrexone HCl and 420 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months~Period 2, PXT3003: Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 10 mL bid (taken morning and evening with food)"
89073462|NCT03008369|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
89073463|NCT03004183|Experimental|Single arm|"ADV/HSV-tk (5 x 1011 virus particles) in a 2-mL total volume will be injected intratumorally on Day 0.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days from Day 1 to Day 15.~SBRT of 30 Gy (6 Gy X 5 fractions) will be administered over 2 weeks from Day 2 to Day 16.~Pembrolizumab (200 mg) will be administered intravenously over 30 minutes every 3 weeks starting on Day 17 and continuing until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression."
89073464|NCT03003117|Experimental|Intervention Program|Experimental: Intervention Program
89073465|NCT03003117|Active Comparator|Usual Care|Active comparator: Usual Care
89073466|NCT03000439|Experimental|Tofacitinib 5 mg BID|oral, twice daily, tablet or solution.
89073467|NCT03000439|Placebo Comparator|Placebo|
89073468|NCT02957240|Active Comparator|Standard Care|Four clinic-based intervention sessions where the focus will be on home program competency and advancement and standard home program 3x daily for 15 minutes.
89073469|NCT02957240|Experimental|Standard Care and Motor Representation Techniques|4 clinic-based intervention sessions including 'standard care' intervention in addition to a 'movement representation' intervention. Home Program for Standard Care and Motor Representation 3x daily for 30 minutes.
89073470|NCT02949128|Experimental|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks for 26 weeks in the Initial Evaluation Period.~After the Initial Evaluation Period, participants could enter an Extension Period and receive ravulizumab until the product registration or approval (in accordance with country-specific regulations) or for up to 4.5 years, whichever occurs first."
89073471|NCT02901899|Experimental|Treatment (guadecitabine, pembrolizumab)|Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89073472|NCT02832505||Non-CKD (Control)|"Patients without CKD (eGFR ≥ 60 ml/min/1.73 mm2) (non-CKD controls).~No intervention but only observational."
89073473|NCT02832505||CKD (chronic kidney disease)|"Patients with Patients with moderate to severe CKD (eGFR ranging from 26 to 44 ml/min/1.73 mm2).~No intervention but only observational."
89073474|NCT02832505||ESRD (end-stage renal disease)|"Patients with advanced CKD (eGFR < 15 ml/min/1.73 mm2), preparing for or undergoing the standard thrice-weekly HD or standard PD treatment (end-stage renal disease (ESRD) patients).~No intervention but only observational."
89073475|NCT02826083|Experimental|XXS|
89073476|NCT02826083|Placebo Comparator|Placebo|
89073477|NCT02821572||patient|
89073478|NCT02821572||control|
89073479|NCT02804074|Active Comparator|Group 1|Management strategy of blood pressure based on office BP as a guide to treatment
89073480|NCT02804074|Experimental|Group 2|Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment
89073481|NCT02756845|Experimental|Talimogene Laherparepvec (TVEC)|The first dose of talimogene laherparepvec will be administered at a dose of up to 4.0 mL of 10ᶺ6 PFU/mL followed by a dose of up to 4.0 mL of 10ᶺ8 PFU/mL 21 days (+3 days) later. Subsequent doses of up to 4.0 mL of 10ᶺ8 PFU/mL will be administered every 14 days (± 3 days) thereafter. Cohorts will be assigned as follows: Cohort A1 (age 12 to ≤ 21 years). Cohort B1 (age 2 to < 12 years). The DLRT will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If dose de-escalation is needed and if permissible based on the incidence of DLTs, additional DLT-evaluable subjects will be enrolled and treated at a lower dose level of talimogene laherparepvec. Dose de-escalation cohorts will be assigned as follows and the same DLT rules will be applied: Cohort A2 (age 12 to ≤ 21 years), Cohort B2 (age 2 to < 12 years).
89073482|NCT02725879||AIT Subclinical Hypothyroid Group|"30 children and adolescents with subclinical hypothyroidism due to Hashimoto's thyroiditis.~No special intervention is to be administered, only routine LT4 treatment. Reassessment at 6 months."
88820838|NCT05586802|Experimental|Group 1 (Fertility) - negative mTESE biopsy 1, then randomized to Arm A|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have negative sperm retrieval (no detectable spermatozoids), subsequently randomized to receive an hormonal stimulation for 26 weeks
89073483|NCT02725879||Control Group|"30 healthy individuals with no chronic autoimmune thyroiditis and normal thyroid function (age- and sex-matched with the AIT Subclinical Hypothyroid Group).~No special intervention is to be administered. No reassessment at 6 months."
89073484|NCT02725879||AIT Euthyroid Group|"30 children and adolescents with chronic autoimmune thyroiditis and euthyroidism (age- and sex-matched with the AIT Subclinical Hypothyroid Group).~No special intervention is to be administered. No reassessment at 6 months."
89073485|NCT02722252||Embryoscope group|
89073486|NCT02722252||Embryo culture without incorporated camera group|
89073487|NCT02719574|Experimental|PH1 Dose Escalation & Expansion FT-2102 (olutasidenib)|
89073488|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine|
89073489|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine|
89073490|NCT02719574|Experimental|PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent|Relapsed or Refractory (R/R) AML
89073491|NCT02719574|Experimental|PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent|AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation
89073492|NCT02719574|Experimental|PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent|R/R AML/MDS, previously treated with FT-2102
89073493|NCT02719574|Experimental|PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy
89073494|NCT02719574|Experimental|PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy
89073495|NCT02719574|Experimental|PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have been previously treated with single-agent FT-2102 as their last therapy prior to study enrollment
89073496|NCT02719574|Experimental|PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent|Treatment naïve AML for whom standard treatments are contraindicated
89073497|NCT02719574|Experimental|PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine|Treatment naïve AML who are candidates for azacitidine first line treatment
89073498|NCT02675452|Experimental|AMG 176 - Part 1a|Part 1a - Participants with muliple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion for two-consecutive days (QD2) followed by a 5 days break.
89073499|NCT02675452|Experimental|AMG 176 - Part 1b|Part 1b - Participants with multiple myeloma (MM) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
89073500|NCT02675452|Experimental|AMG 176 - Part 3a|Part 3a - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion once a day, for two-consecutive days (QD2) followed by a 5 day break.
89073501|NCT02675452|Experimental|AMG 176 - Part 3b|Part 3b - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
89073502|NCT02675452|Experimental|AMG 176 - Part 3c|Part 3c - Participants in Japan only with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW) followed by 6 days break.
89073503|NCT02675452|Experimental|AMG 176 - Part 3d|Part 3d - Participants in the United States with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, once a week (QW), for 3 weeks, in combination with itraconazole.
89073504|NCT02675452|Experimental|AMG 176 - Part 4|Part 4 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion, either once a week (QW) followed by 6 days break, or once a day, for two-consecutive days (QD2), in combination with azacitidine.
89073505|NCT02675452|Experimental|AMG 176 - Part 5|Part 5 - Participants with acute myeloid leukemia (AML) administered AMG 176 as an intravenous (IV) infusion at the maximum tolerated combination dose from Part 4, either once a week (QW) followed by 6 days break, or once a day, for two-consecutive days (QD2), in combination with azacitidine.
89073506|NCT02523014|Experimental|Arm A (vismodegib)|Patients receive vismodegib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018)
89073507|NCT02523014|Experimental|Arm B (FAK inhibitor GSK2256098)|Patients receive FAK inhibitor GSK2256098 PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017)
89073508|NCT02523014|Experimental|Arm C (capivasertib)|Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity.
89073509|NCT02523014|Experimental|Arm D (abemaciclib)|Patients receive abemaciclib PO Q12H. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89073510|NCT02452697|Active Comparator|Cohort A - NK cell enriched-DLI only|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
89073511|NCT02452697|Experimental|Cohort A - NK-DLI + DUK-CPG-001|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
89073512|NCT02452697|Active Comparator|Cohort B - NK cell enriched-DLI only|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
89073513|NCT02452697|Experimental|Cohort B - NK-DLI + DUK-CPG-001|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
89073514|NCT02369731||Translarna|Participants with nmDMD receiving Translarna will be followed for at least 5 years from their date of enrollment, or until participant withdrawal of consent or death, whichever occurs first.
89073515|NCT02363335|Placebo Comparator|Placebo|randomized, double-blind, placebo-controlled cross-over study
89073516|NCT02363335|Experimental|Roflumilast|randomized, double-blind, placebo-controlled cross-over study
89073517|NCT02363335|Experimental|Roflumilast/Sitaglip|randomized, double-blind, placebo-controlled cross-over study
89073518|NCT02363335|Experimental|Sitagliptin|randomized, double-blind, placebo-controlled cross-over study
89073519|NCT02354911|Experimental|Immunoregulatory Dendritic Cells (iDC)|Biological intervention consisting of autologous dendritic cells treated in vitro to convert to active immunoregulatory dendritic cells.
89073520|NCT02354911|Placebo Comparator|Placebo Control|Saline injections administered blinded to subject and all study staff except for research pharmacist who is not involved in study conduct
89073521|NCT02333448||patients with suspected invasive candidiasis|
89073522|NCT02325557|Experimental|Part A: ADXS31-142|"Participants received ADXS31-142 1 × 10^9 colony-forming units (CFU), 5 × 10^9 CFU, or~1 × 10^10 CFU intravenously (IV) every 3 weeks (Q3W) in a 12-week cycle for up to 24 months or until disease progression or discontinuation."
89073523|NCT02325557|Experimental|Part B: ADXS31-142 + Pembrolizumab|Participants received ADXS31-142 1 × 10^9 CFU) IV Q3W (in a 12-week cycle) in combination with 200 mg pembrolizumab IV Q3W for three times, with a fourth pembrolizumab dose 3 weeks later (in 12 week-cycles) for up to 24 months or until disease progression or discontinuation.
89073524|NCT02312960|Other|Arm 1|The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.
89073525|NCT02284737|Experimental|PADN + sildenafil|Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
89073526|NCT02284737|Sham Comparator|sham PADN + sildenafil|The radiofrequency ablation catheter placed, no ablations.
89073527|NCT02254746|Experimental|Phase I (dose escalation)/ Phase II|"Phase I~Prostate tumor: starting dose 9 Gy per fraction in 5 fractions (total 45 Gy) and subsequent dose escalation up to 10 Gy.~Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions (no dose escalation). Total 36.25 Gy.~Phase II~Additional patients will be treated at either the maximum tolerated dose (MTD) or at the highest dose level as determined by the investigators from the Phase I portion of the study."
89073528|NCT02226276|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET)|Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.
89073529|NCT02213458|Experimental|Navigated Care|Comprehensive longitudinal continuing care program
89073530|NCT02213458|No Intervention|Survey of Care|Control group that will undergo the same regular assessments as patients enrolled in Navigated Care
89073531|NCT02056756|Experimental|CBD|
89073532|NCT02003924|Sham Comparator|Placebo|Sugar pill manufactured to mimic enzalutamide 40 mg capsule
89073533|NCT02003924|Experimental|Enzalutamide|160 mg by mouth once daily
89073534|NCT01973452|Experimental|Dexmedetomidine|continuous infusion of 0.4 mcg/kg/hr
89073535|NCT01973452|Placebo Comparator|Placebo|continuous infusion of 0.4 mcg/kg/hr
89073536|NCT01937117|Experimental|Trastuzumab and Pertuzumab|Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET)
89073537|NCT01910402|Experimental|DTG/ABC/3TC FDC|As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
89073538|NCT01910402|Active Comparator|ATV +RTV +TDF/FTC FDC|As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food
89073539|NCT01860365|Experimental|Complementary medicine counseling|Patients receiving chemotherapy who are referred by their oncology provider to complementary medicine consultation and treatment provided in addition to conventional supportive care
89073540|NCT01860365|Active Comparator|Conventional supportive care|Patients receiving conventional supportive care
89073541|NCT01857115|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.~Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
89073542|NCT01754402|Experimental|Cohort 1: benda 120mg + pom 3mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
89073543|NCT01754402|Experimental|Cohort 2: benda 120mg + pom 4mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
89073544|NCT01754402|Experimental|Expansion|"Pomalidomide 3mg: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine 120 mg: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
89073545|NCT01740297|Experimental|Phase 1b: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque-forming units (PFU)/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until complete response (CR), all injectable tumors had disappeared, confirmed disease progression per the modified immune-related response criteria (irRC), or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab administered intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
89073546|NCT01740297|Active Comparator|Phase 2: Ipilimumab|Participants received ipilimumab 3 mg/kg intravenously every 3 weeks for a total of 4 infusions starting at week 1.
89073547|NCT01740297|Experimental|Phase 2: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ PFU/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until CR, all injectable tumors had disappeared, confirmed disease progression per the modified irRC, or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
89073548|NCT01644591|Experimental|Treatment (SRS)|Patients undergo SRS on day 1.
89073549|NCT01588015|Experimental|Arm I (vaccine therapy)|Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
89073550|NCT01588015|Active Comparator|Arm II (control)|Patients undergo immune monitoring only.
89073551|NCT01572506|Active Comparator|Group 1|Age 70 and older with unexplained anemia
89073552|NCT01572506|Active Comparator|Group 2|Age 70 and older with iron deficient anemia
89073553|NCT01572506|Active Comparator|Group 3|Age 70 and older without anemia
89073554|NCT01572506|Active Comparator|Group 4|Age 18 - 50 without anemia
89073555|NCT01539720|Experimental|Levonorgestrel Intrauterine System|Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following.
89073556|NCT01539720|Active Comparator|Ulipristal acetate|Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception.
89073557|NCT01236560|Experimental|Arm I (vorinostat, Phase II Arm A)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at the maximum-tolerated dose determined in the feasibility study. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
89073558|NCT01236560|Experimental|Arm II (temozolomide, Phase II Arm B)|Patients undergo RT as in the feasibility arm and receive temozolomide PO once daily for 42 days by day 5 of RT. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
89073559|NCT01236560|Experimental|Arm III (Bevacizumab, Phase II Arm)|Patients undergo RT as in the feasibility arm and receive bevacizumab IV over 30-90 minutes on days 22 and 36. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
89073560|NCT01236560|Experimental|Arm IV (temozolomide, Phase 3 Arm B)|Patients undergo RT as in the Arm II and receive temozolomide PO once daily for 42 days beginning on day 5 of RT. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
89229946|NCT03960229|Active Comparator|gradient-density centrifugation|gradient-density centrifugation technique will be used when preparing sperm of male partner and microinjection (ICSI) will be made with separated sperm
89691635|NCT05512338|Active Comparator|Usual physiotherapy care group|UC will include an initial physical assesment with feedback, treatment considered suitable by their treating physiotherapist that will be based on exercises according to the DNS concept and manual therapy.
89691636|NCT03027011|Active Comparator|Remote Ischemic Preconditioning(RIPC)|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
89691637|NCT03027011|Placebo Comparator|Control|Control group without remote ischemic preconditioning
89691638|NCT04734496||Chronic Liver Disease|Patients with end-stage liver disease. Standard of care treatment will be nutrition and exercise as per European Association Study of Liver nutrition guidelines.
89691639|NCT04734496||Rheumatoid Arthritis/Psoriatic arthropathy|Patients requiring biological therapy due to ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
89691640|NCT04734496||Inflammatory Bowel Disease|Patients with Crohns or Ulcerative Colitis with ongoing inflammation (requiring anti-Tumour Necrosis Factor therapy) - i.e. standard of care - escalation in therapy
89691641|NCT04734496||Healthy volunteers (n=20)|Healthy volunteers
89691642|NCT04353635||Patients with class III dentofacial deformity|No intervention as it will be a retrospective study
89691643|NCT03403504|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 10 mg
89691644|NCT03403504|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 10 mg
89691645|NCT04598802||Covera Plus|
89691646|NCT05512728|Placebo Comparator|midazolam group|
89691647|NCT05512728|Active Comparator|VR group|
89691648|NCT03609658|Experimental|Nurse Navigator Pathway Group|Participants in this Nurse Navigator led ACP pathway group will participate in ACP discussions, surveys, and participant visit(s) for duration of the study (12 months)
89691649|NCT03609658|Sham Comparator|Usual Care Group|Participants in the Usual Care group will follow usual daily living activities for the duration of the study (12 months).
89691650|NCT02565810|Experimental|SB5 40mg|
89691651|NCT00940901|Experimental|sildenafil|Participants assigned to this arm were given sildenafil 50 mg tablet daily for 16 weeks.
89691652|NCT00940901|Placebo Comparator|placebo|Participants assigned to this arm were given a placebo pill for the first 8 weeks, and then Sildenafil 50 mg for weeks 9-16.
89691653|NCT05512650|Active Comparator|VR first|At their first visit, subjects will engage in a virtual reality meditation while wearing the VR headset. At their second visit, they will engage in a non-immersive meditation without the 3D VR aspect.
89691654|NCT05512650|Active Comparator|VR second|At their first visit, subjects will engage in a non-immersive meditation without the 3D VR aspect. At their second visit, they will engage in a virtual reality meditation while wearing the VR headset.
89691655|NCT04353713|Experimental|Dextrose Gel|"Dextrose 40% gel will be given immediately following stabilization at birth via massage into the buccal membrane. This will be prior to transport from the Delivery Room to the Neonatal Unit.~A dose of 1 ml of gel (Dextrose) will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required.~Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth.~A total dose of 0.5 ml of gel (Dextrose) will be administered to infants born less than or equal to 29+0 weeks gestation.~Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of administering person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth."
89691656|NCT04353713|Placebo Comparator|Placebo|"2% carboxymethylcellulose gel will be given following stabilization at birth via buccal route. This will be prior to in-house transport from the Delivery Room to the Neonatal Unit.~A standard total dose of 1 ml of placebo gel will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required.~Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth.~A total dose of 0.5 ml of gel (Placebo) will be administered to infants born less than or equal to 29+0 weeks gestation.~Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth."
89691657|NCT03611062|Experimental|VR Executive Functions Training|Participants will receive training of executive functions in a virtual reality environment.
89073561|NCT01236560|Experimental|Arm V (vorinostat/bevacizumab, Phase 3, Chemoradiotherapy)|Patients receive treatment as in phase II, arm I or phase II, arm III, whichever was established as superior in phase II. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
89073562|NCT01236560|Experimental|Feasibility (vorinostat)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at 230 mg/m2/day. In the event of 2 or more DLTs, participants will de-escalate to vorinostat at 180 mg/m2/day. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
89073563|NCT01163942|Active Comparator|No G-CSF, No 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
89073564|NCT01163942|Active Comparator|No G-CSF, yes 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) but they do receive early retreatment in case of no response.
89073565|NCT01163942|Active Comparator|Yes G-CSF, No 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
89073566|NCT01163942|Active Comparator|Yes G-CSF, Yes 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to receive early retreatment in case of no response.
89073567|NCT01069588||Calaxo|Received Calaxo screw
89073568|NCT01069588||Milagro|Received a Milagro screw
89073569|NCT00887146|Experimental|Arm A (RT, procarbazine, lomustine, vincristine)|Patients undergo 3D-CRT or IMRT on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride PO on days 8-21, lomustine PO on day 1 and vincristine sulfate IV on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89073570|NCT00887146|Experimental|Arm B (RT, temozolomide)|Patients undergo RT as in arm I and receive temozolomide PO QD on days 1-5 for 5-7 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD days 1-5. Treatment with adjuvant temozolomide repeats every 4 weeks for 6-12 courses in the absence of disease progression and unacceptable toxicity.
89073571|NCT00725049|Active Comparator|Dental implant (Nanotite)|Dental implants of short length placed without sinus lifts
89073572|NCT00725049|No Intervention|Control group|Dental implants of standard length placed simultaneously with sinus augmentation
89073573|NCT00333801|Active Comparator|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP). VRP is the treatment as usual, which mostly consisted of transitional work program (TWP) in which client is placed in a set-aside noncompetitive job for time-limited period and then pursues competitive employment at time of discharge from VRP. Limited integration with treatment team and limited follow-along supports that are time-limited
89073574|NCT00333801|Experimental|Individual Placement and Support (IPS)|Inidividual Placement and Support (IPS). IPS Supported Employment involves an IPS specialists working with client to identify job preferences, rapidly begin community-based job search, engage in competitive employment, sustain employment via open-ended IPS follow-along supports, and integrate IPS within the PTSD treatment team.
89073575|NCT03498495|Experimental|SMART Intervention|
89073576|NCT03498495|No Intervention|Usual Care|
89073577|NCT03483116|Experimental|High dose RV3-BB neonatal schedule|High dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
89073578|NCT03483116|Experimental|Mid dose RV3-BB neonatal schedule|Mid dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
89073579|NCT03483116|Experimental|Low dose RV3-BB neonatal schedule|Low dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
89073580|NCT03483116|Experimental|High dose RV3-BB infant schedule|High dose infant RV3-BB vaccine schedule. Placebo for Investigational product dose 1 (0-5 days) and RV3-BB Vaccine for Investigational product doses 2 (week 6) 3 (week 10) and dose 4 (week 14)
89073581|NCT03481569|Experimental|Pharmacokinetic sample|Plasma and cerebrospinal fluid samples performed at different timepoint during administration of antibiotic prescribed in routine use
89073582|NCT03443791|Experimental|women enrolled|pregnant women enrolled in trial
89073583|NCT03443791|Other|newborns of female study participants|newborns will be tested to determine if virus is present.
89073584|NCT03393546|Experimental|Auricular Point Acupressure - Interventionist|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day). The treatment will be administered by the research team's trained acupressure interventionist.~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
89073585|NCT03393546|Experimental|Auricular Point Acupressure - Caregiver Training|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day).~If participants live more than 15 miles away from the research team's office, the caregiver will receive in-person training by the interventionist on how to administer the treatment to their patient for the 4 weeks of treatment.~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
89073586|NCT03320577|Active Comparator|Class instruction of breathing exercises|Class participation/instruction weekly for 6 weeks and requested to practice Pranayama breathing exercises of 15 minute duration for an additional 4x during the week; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
89073587|NCT03320577|Active Comparator|DVD instruction of breathing exercises|Received DVD with instructions and 15 minute Pranayama breathing exercises of 15 minute duration. Participants requested to practice breathing exercises 5x during the week for 6 week intervention; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
89073588|NCT03320577|Placebo Comparator|Control|Completed log that indicated time of eating dinner; weekly blood pressure measurements for the 6 week intervention; control participants also turned in dinner time logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
89073589|NCT03286387|Experimental|Memory for naturalistic episodes|Encoding of episode in real life situations (using Smartphones) or in a virtual environment, followed by memory retrieval (either behavior only or with fMRI, in successive studies)
89073590|NCT03222076|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients continue nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89691658|NCT03611062|Placebo Comparator|Control|Participants will play a virtual reality game using the same hardware and similar environments, but without the training of executive functions.
89691659|NCT05507502|Active Comparator|In-patient vaccination arm|Participants in this arm will receive the influenza vaccination during their heart failure hospitalization.
89691660|NCT05507502|Active Comparator|In-clinic vaccination arm|Participants in this arm will receive the influenza vaccination during their follow up visit in the heart failure clinic 30 days post-discharge.
89691661|NCT02981771|Experimental|experiment|A physical activity program that is based on balance and coordination exercises
89691662|NCT02981771|Placebo Comparator|control|A physical activity program that is based on strength exercises
89691663|NCT05512572|Experimental|Experimental group|Receiving IPL-MGD treatment.
89691664|NCT05512572|Active Comparator|Control group|Another set of age, sex and diagnosis matched consecutive cases of chalazion, who received conservative treatment or excision with curettage but without IPL-MGX treatment as a control (Non-IPL group).
89691665|NCT03034655|Experimental|CDP exercises (10 sessions)|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
89691666|NCT03034655|Experimental|CDP exercises (5 sessions)|Group B. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
89691667|NCT03034655|Experimental|Mobile posturography exercises (10 sess)|Group C. Up to six tasks with the most prominent deviations from normative control values were included in the training program. Training was performed by using the training function of Vertiguard1-RT device. This neurofeedback system contains one vibration stimulator on the front, back, left and right side, respectively. Training was performed daily under supervision of a physician over 2 weeks (10 sessions, weekend was excluded). A training session consisted of 5 repetitions of six selected training tasks. The patient received a vibrotactile feedback signal during training in those directions which showed a higher body sway than preset thresholds. Vibration was reinforced with increasing sway No vibrotactile feedback was applied if the patient's sway was below preset thresholds. The exercise difficulty was progressively increase throughout the rehabilitation sessions.
89691668|NCT03034655|Experimental|Mobile posturography exercises (5 sess)|Group D. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
89691669|NCT03560128|Experimental|Endocuff Vision Arm|Colonoscopy with Endocuff Vision device attached to the distal end of the scope.
89073591|NCT03222076|Experimental|Arm B (ipilimumab, nivolumab)|Patients receive ipilimumab IV over 90 minutes on day 1 and nivolumab as Arm A. Treatment repeats every 2 weeks for up to 3 cycles for nivolumab in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89073592|NCT02970747||Car/Len/Dex (KRd)|Patients treated with carfilzomib, lenalidomide and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
89073593|NCT02970747||Car/Dex (Kd)|Patients treated with carfilzomib and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
89073594|NCT02970747||Car/Dex/Dara (KdD)|Patients treated with carfilzomib, dexamethasone and daratumumab dosage form, dosage, frequency and duration of treatment according to current SmPC
89073595|NCT02936843|Experimental|Salsalate|Salsalate, 1 gram by mouth, 3 times daily (3 grams per day) for 12 months.
89073596|NCT02936843|Placebo Comparator|Comparator|Placebo for Salsalate, 2 tablets by mouth, 3 times daily for 12 months
89073597|NCT02828202||Prospective cohort Resectable stage II or III|Patients with resectable stage II or III melanoma
89073598|NCT02828202||Prospective cohort Unresectable stage III or stage IV (resectable or not) or unresectable primary|Patients with unresectable stage III, or stage IV (resectable or not) or unresectable primary melanoma
89073599|NCT02816879|Experimental|Screening (anal cytology collection)|Patients undergo anal cytology collection using 2 NF swabs and 1 Dacron swab for analysis via Pap staining, HPV genotyping, and PCR.
89073600|NCT02811861|Experimental|Lenvatinib 18 mg plus Everolimus 5 mg|Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily in each 21-day cycle.
89073601|NCT02811861|Experimental|Lenvatinib 20 mg plus Pembrolizumab 200 mg|Lenvatinib 20 mg administered orally, once daily, in each 21-day cycle plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks on Day 1 of each 21-day cycle.
89073602|NCT02811861|Active Comparator|Sunitinib 50 mg|Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment in each 21-day cycle.
89073603|NCT02700451|Placebo Comparator|Intravenous (IV) Placebo|IV Placebo arm
89073604|NCT02700451|Experimental|IV Ketorolac|IV Ketorolac arm
89073605|NCT02700451|Experimental|IV Acetaminophen|IV Acetaminophen arm
89073606|NCT02697344|Experimental|Treatment (AT-101, lenalidomide, and dexamethasone)|Patients receive R-(-)-gossypol acetic acid PO QD on days 1-21. Beginning in course 2, patients also receive lenalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, and 15 of courses 2-12. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89073607|NCT02696343|Experimental|EPI experimental|Preterm infants randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
89073608|NCT02696343|Sham Comparator|EPI control|Preterm infants randomized to receive the Sham (blind pacifier) during tube feedings.
89073609|NCT02667418|Other|Fidaxomicin|Standard 10-day fidaxomicin treatment for Clostridium difficile
89073610|NCT02667418|Other|Vancomycin T/P|Standard 10-day vancomycin treatment followed by taper and pulse vancomycin treatment for Clostridium difficile
89073611|NCT02667418|Other|Vancomycin|Standard 10-day vancomycin treatment for Clostridium difficile
89073612|NCT02623426|Active Comparator|Dexamethasone intravitreal implant 0.7mg|"Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Re-treatment criteria:~Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon Spectral Domain (SD) Optical Coherence Tomography (OCT) and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.~IOP of <25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;"
89224190|NCT06270888|Experimental|Group 4 - Dose Schedule 4|"In this study, there will be 4 different radiation schedules, ranging from 1-10 daily treatments. Participants will be assigned to one of the dose schedules and they will know this ahead of time. The study doctor will tell each participant which study group and dose schedule they been assigned.~For most participants, the actual time on the radiation treatment machine will be in the range of 30 to 60 minutes. The mold will be removed after the treatment. The number of treatments to each tumor will depend on which treatment group the participant is enrolled on: The longest possible treatment group would be 10 treatments in duration of about 2 weeks of treatment and the shortest possible treatment group would be 1 treatment."
89224191|NCT06270862|Experimental|Active aging with resilience (AR)|"In the active aging with resilience (AR) condition, participants will complete physical, cognitive, and social engagement training modules, starting with a 15-min resilience-building module."
89224192|NCT06270862|Active Comparator|Active aging without resilience (AA)|"The traditional active aging (AA) training involves the same multi-domain active aging training without the initial resilience-building module, which will be replaced by watching 15 minutes of educational video on topics such as health, nature or travel."
89224193|NCT06270862|Placebo Comparator|Workshop training (WT)|"The workshop training (WT) control condition involves workshops following the same 4-week schedule on aging-related topics."
89224194|NCT06270849||Female with LUTS|Females who has symptoms of lower urinary tract symptoms
89224195|NCT06270849||Normal control group|Females who no history of LUTS or urinary tract disease
89224196|NCT06270836|Experimental|Tarcocimab 5 mg (Treatment Group A)|Tarcocimab 5 mg via intravitreal injection at Day 1, Week 4, Week 8, Week 20, and Week 44.
89224197|NCT06270836|Sham Comparator|Treatment Group B|Sham injection on the same schedule as Treatment Group A
89224198|NCT06270823|Experimental|interventional arm|As soon as the infant is out of the uterus a Knee-to-chest flexion (KCF) maneuver is performed for 30 seconds while the infant remains attached to the cord. When applying KCF, we essentially bring the newborn back into the fetal position, flexing the knees to the chest. This is similar to the holding position applied for performing lumbar puncture in neonates. Except for KCF, the infant will receive normal routine care and there are no co-interventions.
89224199|NCT06270823|No Intervention|control|As soon as the infant is out of the uterus normal routine care is given
89224200|NCT06270797||normal intubation|during general anesthesia, normal intubation without any difficult airway or difficult intubation were recorded in the note.
89224201|NCT06270797||difficult airway or difficult intubation|during general anesthesia, any type of difficult airway or difficult intubation were recorded in the note.
89224202|NCT06270784|Active Comparator|Traditional Extraction Group|
89224203|NCT06270784|Experimental|Orthodontic Extraction Group|
89224204|NCT06270771||Transfusion Dependent|Patients who are currently receiving transfusions will be assigned to this cohort
89691670|NCT03560128|Experimental|AmplifEYE Arm|Colonoscopy with AmplifEYE device attached to the distal end of the scope.
89691671|NCT02981927|No Intervention|Control|24 h habitual physical activity fed in energy balance
89691672|NCT02981927|Experimental|Bed rest matched diet|24 hour period of whole body bed-rest with a matched diet
89691673|NCT02981927|Experimental|Bed rest balanced diet|24 hour period of whole body bed-rest fed in energy balance
89691674|NCT05107739|Experimental|Safety Run In|Patients with gynecological malignancies
89691675|NCT05107739|Experimental|EOC|Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary peritoneal and fallopian tube carcinoma
89691676|NCT05107739|Experimental|Cervical|Recurrent, metastatic, or persistent cervical carcinoma
89691677|NCT05107739|Experimental|Endometrial|Advanced or recurrent endometrial cancer
89691678|NCT03614416|Experimental|EOXY device and Gold standard oximter and SaO2 measures|Heart rate and SPO2 measures provided from EOXY device Heart rate measures provided from gold standard oximeter. SaO2 measures provided from blood sampling There is only one arm: all subjects have simultaneously three interventions (as required in the European standard ISO 80601-2-61), to qualify a pulse oximeter
89224205|NCT06270771||Transfusion Independent|Patients who are not currently receiving transfusions will be assigned to this cohort
89224206|NCT06270758||Fractured subjects|Post-menopausal women who have been hospitalised because of a femur fracture.
89224207|NCT06270758||Control subjetcs|Post-menopausal women without history of fracture
89229947|NCT00066469|Experimental|Cyclophosphamide, prednisone, rituximab|Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease
89691679|NCT05507268||older patients undergoing noncardiac surgery|older patients (aged ≥65 years) scheduled for noncardiac surgery
89691680|NCT02981693|Experimental|iRoot SP sealer|iRoot SP sealer was used as root canal sealer in root canal obturation.
89691681|NCT02981693|Active Comparator|AH Plus sealer|AH Plus sealer was used as a gold standard to be compared with iRoot SP sealer in root canal obturation.
89691682|NCT03026465|Experimental|Coroflex ISAR stent|PCI with a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR stent) with very thin struts (50 µm). During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
89691683|NCT03026465|Active Comparator|Biomatrix stent|PCI with a biodegradable-polymer biolimus-eluting stent (Biomatrix stent) with 120 µm struts. During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
89691684|NCT03564886|Experimental|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
89691685|NCT03564886|Placebo Comparator|Normal Saline|Lactate Ringer's (LR, 273mOsm/L) is commonly used at our facility as our isotonic standard irrigation solution and will serve as the control to be evaluated against a hyperosmolar (1.9%, 600mOsm) solution.
89691686|NCT05086133|Experimental|cTBS stimulation|The participants randomized into experimental group will receive cTBS stimulation of left M1 area for 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
89073613|NCT02623426|Active Comparator|Intravitreal methotrexate 400µg in 0.1mL|"Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection."
89073614|NCT02623426|Active Comparator|Intravitreal ranibizumab 0.5mg in 0.05mL|"Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.~Re-treatment permitted at later time points if re-treatment criteria met."
89073615|NCT02580058|Experimental|avelumab|Arm A: avelumab alone
89073616|NCT02580058|Experimental|avelumab plus pegylated liposomal doxorubicin (PLD)|Arm B: avelumab plus PLD
89073617|NCT02580058|Active Comparator|PLD|Arm C: PLD alone
89073618|NCT02539394|Experimental|Treatment|Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
89073619|NCT02539394|Placebo Comparator|Control|Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
89073620|NCT02530437|Experimental|Step I (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib PO for 7 days, followed by taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
89073621|NCT02530437|Experimental|Step II (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
89073622|NCT02412670|Experimental|Arm A (methotrexate, vinblastine, doxorubicin, cisplatin)|Patients receive methotrexate IV over 2-3 minutes, vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1. Pegfilgrastim at 6 mg is given once 24-48 hours after completion of chemotherapy. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
89073623|NCT02412670|Experimental|Arm B (gemcitabine, carboplatin)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
89073624|NCT02405208||Primary cohort|Primary cohort will receive the PyroTITAN HRA device
89073625|NCT02206360||Individuals at elevated risk for pancreatic cancer|Individuals with an elevated risk of developing pancreatic cancer as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk.
89073626|NCT01973153|Active Comparator|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
89073627|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Phone Calls (BMC+Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
89073628|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Home Visits (BMC+Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
89073629|NCT01889199|Placebo Comparator|Sugar pill|Placebo intervention
89073630|NCT01889199|Experimental|Flutamide|Flutamide 125 mg orally daily for six 28-day cycles.
89073631|NCT01816152|Active Comparator|Active Intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where active lighting is experienced by patients.
89073632|NCT01816152|Placebo Comparator|Inactive intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where an inactive lighting is experienced by patients
89073633|NCT01494103|Experimental|iCaspase9-transduced T cells|"The 5 dose levels are:~1 x 10^4 T cells/kg~1 x 10^5 T cells/kg~5 x 10^5 T cells/kg~1 x 10^6 T cells/kg~5 x 10^6 T cells/kg~AP1903 will be administered if there is development of Grade 1 or greater GvHD."
89073634|NCT01263379|Experimental|LEAES treatment|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
89073635|NCT00992238|Experimental|Flavoxate Hydrochloride Tablets, 100mg|
89073636|NCT00992238|Active Comparator|Urispas® Tablets, 100mg|
89073637|NCT00858897|Experimental|Normoglycemia|80-140 mg/dL
89073638|NCT00858897|Experimental|Hyperglycemia|200-250 mg/dL
89073639|NCT05940922||CIDP GBS hATTR|Adult patients diagnosed and treated at the study centre for chronic inflammatory demyelinating polyneuropathy (CIDP), or Guillain-Barre syndrome (GBS), or heredofamilial amyloidosis (hATTR).
89073640|NCT05940909|Other|Sequence TR|25 subjects assigned to the sequence TR will receive a single oral dose of the test product Perindopril Erbumine/Indapamide/Amlodipine (1 x 8 mg/2.5 mg/10 mg tablet), marked as T in the sequence, in Period 1 and a single oral dose of the reference product Triplixam® (1 x 10 mg/2.5 mg/10 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89073641|NCT05940909|Other|Sequence RT|25 subjects assigned to the sequence RT will receive a single oral dose of the reference product Triplixam® (1 x 10 mg/2.5 mg/10 mg tablet), marked as R in the sequence, in Period 1 and a single oral dose of the test product Perindopril Erbumine/Amlodipine/Indapamide (1 x 8 mg/2.5 mg/10 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89073642|NCT05940883|Experimental|Y-2 sublingual tablet dose group 1|
89073643|NCT05940883|Experimental|Y-2 sublingual tablet dose Group 2|
89073644|NCT05940883|Experimental|Y-2 sublingual tablet dose Group 3|
89073645|NCT05940883|Experimental|Y-2 sublingual tablet dose Group 4|
89073646|NCT05940883|Experimental|Y-2 sublingual tablet dose Group 5|
89073647|NCT05940883|Placebo Comparator|Placebo|Certain subjects in group 1 and group 2 will receive placebo.
89073648|NCT05940844|Experimental|open label OB-002 monotherapy 0.25 mg/kg|Dose Level 1
89073649|NCT05940844|Experimental|open label OB-002 monotherapy 0.5 mg/kg|Dose Level 2
89073650|NCT05940844|Experimental|open label OB-002 monotherapy 1.0 mg/kg|Dose Level 3
89073651|NCT05940844|Experimental|open label OB-002 monotherapy 1.5 mg/kg|Dose Level 4
89073652|NCT05940844|Experimental|open label OB-002 monotherapy expansion cohort|Dose Expansion
89073653|NCT05940831|Experimental|Intervention|Scheduled SMS-audio messages from the final messaging prototype (SM), messages, plus social supporter engagement through SMS (SS)
89073654|NCT05940831|Active Comparator|Control|Routine care/ information giving
89073655|NCT05940818|Experimental|experimental group|In the study group, the intensive care oral care frequency assessment scale was applied to 55 patients at the end of the 16th hour, in addition to the assessment of pain and thirst at the 1st, 4th, 8th, and 16th hours postoperatively. In patients with a thirst of 3 and above, the bedside was lifted 30-450 times (to prevent bronchoaspiration), and cold water spray (kept in the refrigerator at +4°C and stored) was sprayed 3 times (approximately 2 ml) into the mouth of the patient every hour. Evidence suggests that the risk of bronchoaspiration is minimal up to the 50 mL and 1.5 mL/kg limit of gastric volume (Doi et al., 2021). For this, it is thought that the application of an average of 32 ml of cold water applied to the patients is reliable. The standard oral care of the clinic was applied to the patients who needed oral care. It was also recorded how many times oral care was given to the patients included in the study within 16 hours.
89073656|NCT05940818|No Intervention|control group|In the control group, standard nursing care was applied to 55 patients with the pain, thirst and intensive care oral care frequency assessment scale at the 1st, 4th, 8th, and 16th hours postoperatively.
89073657|NCT05940805|Experimental|Protocol Group (PG)|"The PG received the following combination of four therapeutic modalities twice a week for five weeks:~Low-frequency transcranial electrical stimulation;~Paraspinous block;~Dry needling of spastic upper limb muscles;~Muscular functional electrical stimulation (FES)."
89073658|NCT05940805|Sham Comparator|Sham Group (SG)|The Sham Group also received the four modalities of the intervention, but these modalities were all inactive. For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used. The patients were blinded to their assigned treatment group.
89073659|NCT05940792|Experimental|intervention group|The intervention group received 45 min of conventional physiotherapy after nonelastic taping, which provides eversion support.
89073660|NCT05940792|Active Comparator|control group|The control group received 45 min of conventional physiotherapy
89073661|NCT05940779|Experimental|Exercise group|
89073662|NCT05940779|No Intervention|Control group|
89073663|NCT05940766|Experimental|"Intervention With CFM alerts arm"|"Routine clinical care, which includes, among others, discrete fever measurements using ear thermometers in case of clinical deterioration or suspected fever, at the discretion of patients where applicable, parents and the treating team~Plus CFM with a CORE® WD running, with alerts being sent automatically to participants if the CFM detects an estimated core body temperature fulfilling the fever criterion of the respective study site (≥38.5°C or 39.0°C)."
89073664|NCT05940766|No Intervention|"Control Without CFM alerts arm"|"Routine clinical care as in With CFM alerts~Plus CFM with a CORE® WD running as in With CFM alerts, but with alerts being sent only if a clinically dangerous temperature of ≥40.0°C is detected, which will very rarely be the case before fever is detected by routine clinical care."
89073665|NCT05940753||Cohort: medical oncology patients in the out-patient clinic or treatment unit on 13 or 14 march 2023|No interventions.
89073666|NCT05940740|Experimental|INTERFERENCE (EXPERIMENT)|"Giving patients with colorectal cancer about 20-30 minutes of training during chemotherapy with the mobile health application and answering face-to-face questions about the use of mobile health application.~Sending a reminder message about the use of mobile health application via phone once a week. Answering the questions about the mobile health application and the training given during the chemotherapy application every two weeks / summarizing the training"
89073667|NCT05940740|No Intervention|CONTROL|"Giving approximately 20-30 minutes of routine treatment and care and answering questions during premedication application to colorectal cancer patients when they come to the unit to receive 1st cure chemotherapy.~Pre-test-post-test at the beginning of the 1st course of treatment and at the end of the 3rd cycle of treatment"
89073668|NCT05940727|Active Comparator|Usual macroalgae consumption|Crossover design with habitual macroalgae consumption at baseline
89073669|NCT05940727|Experimental|Cessation of macroalgae consumption|Cessation of macroalgae consumption as an experimental intervention.
89073670|NCT05940714|Experimental|Video participants|Patients treated at the Hospital Odontològic Universitat de Barcelona (HOUB) who go for a routine visit in the period of the study and wish to participate. Parameters are measured and an oral hygiene teaching intervention is carried out.
89073671|NCT05940714|No Intervention|Non video participants|Patients treated at the Hospital Odontològic Universitat de Barcelona (HOUB) who go for a routine visit in the period of the study and wish to participate. Parameters are measured and and no initial intervention is performed.
89073672|NCT05940701|Experimental|intervention group|The intervention group will receive Curasept toothpaste with instructions and additionally at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.
89073673|NCT05940701|Placebo Comparator|control group|The control group will receive a fluoridated toothpaste (Colgate toothpaste) and instructed to brush at least three times/day.
89073674|NCT05940662|Experimental|Immediate Implant Placement|"Immediate implant placement~The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
89073675|NCT05940662|Experimental|Early Implant Placement|"Early implant placement~The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
89073676|NCT05940662|Active Comparator|Late Implant Placement|"Late implant placement~The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
89073677|NCT05940597|Active Comparator|Cryoablation arm|Market approved cryoablation system
89073678|NCT05940597|Experimental|PFA arm|Market approved PFA ablation system (Farapulse - Boston Scientific system).
89073679|NCT05940571|Experimental|MBF-362 128.7 mg|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
89073680|NCT05940571|Experimental|MBF-362 257.4 mg|Drug: Two MBF-362 128.7 mg hard gelatin capsules EP2/EP4 antagonist 28 days single oral daily dosing cycles
89073681|NCT05940571|Experimental|MBF-362 514.8 mg|Drug: Four MBF-362 128.7 mg hard gelatin capsules EP2/EP4 antagonist 28 days single oral daily dosing cycles
89073682|NCT05940571|Experimental|MBF-362 772.2 mg|Drug: Six MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
89073683|NCT05940558|Experimental|MBF-018 100mg oral multiple dose|Drug: MBF-018 100mg oral capsules. Single daily dose. One hard gelatin capsules during 28 days
89073684|NCT05940558|Experimental|MBF-018 200mg oral multiple dose|Drug: MBF-018 100mg oral capsules. Single daily dose. Two hard gelatin capsules during 28 days
89073685|NCT05940532|Experimental|Interventional arm|Patients will receive 3 cycles of induction therapy with sugemalimab and chemotherapy before curative local therapy.
89073686|NCT05940480|Experimental|TCM Daoyin intervention group|Participants randomized to TCM Daoyin intervention group receive health education plus a TCM Daoyin training program. The TCM Daoyin training program was a 16-week, instructor-led group training program.
89073687|NCT05940480|Active Comparator|Health education control group|Participants randomized to the health education control group only receive health education and no additional training program.
89073688|NCT05940454|Experimental|Pericapsular nerve group block (Group P)|Pericapsular nerve group block will be performed with 20 ml of 0.5% bupivacaine hydrochloride before general anesthesia is applied to the patients in Group P.
89073689|NCT05940454|No Intervention|control group (Group C)|No block will be applied to patients in Group C.
89073690|NCT05940389|Experimental|NAM appliance Group|The NAM appliance is constructed according to the Grayson technique [8] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed. The surgical lip repair technique involved will be done by one surgeon using the Delare technique without the blind dissection of the alar cartilage.
89073691|NCT05940389|Experimental|Taping with nasal elevator:|"For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.~The surgical lip repair technique involved will be done by one surgeon using the Delare technique without the blind dissection of the alar cartilage."
89073692|NCT05940376||Control|Group A was assigned to receive preservative-free lubricants and prophylactic antibiotics.
89073693|NCT05940376||Study|Group B was assigned to receive topical insulin [1 unit per drop] 4 times per day (QID) in addition to previous treatment.
89073694|NCT05940363||Liaoning Provincial Maternal and Child Health Hospital|Liaoning Provincial Maternal and Child Health Hospital
89073695|NCT05940363||Shenyang Maternal and Infant Hospital|Shenyang Maternal and Infant Hospital
89073696|NCT05940363||Guangdong Women and Children's Hospital|Guangdong Women and Children's Hospital
89073697|NCT05940363||Guangzhou Women and Children's Medical Center|Guangzhou Women and Children's Medical Center
89073698|NCT05940363||Guangdong Provincial People's Hospital|Guangdong Provincial People's Hospital
89073699|NCT05940363||Shandong Maternal and Child Health Hospital|Shandong Maternal and Child Health Hospital
89073700|NCT05940363||Fujian Provincial Maternal and Child Health Hospital|Fujian Provincial Maternal and Child Health Hospital
89073701|NCT05940363||Maternal and Child Health Hospital of Hubei Province|Maternal and Child Health Hospital of Hubei Province
89073702|NCT05940363||Anhui Provincial Maternal and Child Health Hospital|Anhui Provincial Maternal and Child Health Hospital
89073703|NCT05940363||Peking University First Hospital, Ningxia Women and Children's Hospital|Peking University First Hospital, Ningxia Women and Children's Hospital
89073704|NCT05940363||Sichuan Maternal and Child Health Hospital|Sichuan Maternal and Child Health Hospital
89073705|NCT05940298|Experimental|Prostate cancer|At least five (5) evaluable subjects with prostate cancer
89073706|NCT05940298|Experimental|Breast cancer|At least five (5) evaluable subjects with breast cancer
89073707|NCT05940272||Hematologists|
89073708|NCT05940272||Patients|
89073709|NCT05940259|Experimental|[68Ga]P3|Subjects with suspected or confirmed Prostate will receive an intravenous injection of 68Ga-P3 followed by PET imaging.
89073710|NCT05940246|Experimental|Motivational interviewing|Motivational Interviewing over the phone 1 time before surgery and 6 times (3-5 weeks interval) the first 6 months after surgery. Patients can contact a physical therapist in the first 6 months after surgery for additional questions and extra support.
89073711|NCT05940246|No Intervention|Standard treatment|Standard treatment
89073712|NCT05940233|Experimental|Letrozole plus Misoprostol|We give the Letrozole 10 mg PO daily at day 1-3 prior to Misoprostol 800 mcg SL in day 4.
89073713|NCT05940233|Active Comparator|Misoprostol|We give only Misoprostol 800 mcg SL.
89073714|NCT05940207|Experimental|e-Bandages 3 hours|Three subjects will wear the e-Bandage on their skin for 3 hours.
89073715|NCT05940207|Experimental|e-Bandages 6 hours|Three subjects will wear the e-Bandage on their skin for 6 hours.
89073716|NCT05940207|Experimental|e-Bandages 12 hours|Three subjects will wear the e-Bandage on their skin for 12 hours.
89073717|NCT05940207|Experimental|e-Bandages 24 hours|Three subjects will wear the e-Bandage on their skin for 24 hours.
89073718|NCT05940181|Experimental|XH001+ sintilimab|XH001: 2 dose level Sintilimab: 200mg iv, 21 day per cycle
89073719|NCT05940168|Active Comparator|Navigator ACT group|This is a manualized Acceptance and Commitment Therapy group-intervention for 8-16 parents of children with disabilities. The intervention consists of five group sessions with different themes, as well as a booster-session at three months after the fifth session. The intervention is held by two group leaders.
89073720|NCT05940168|Experimental|I-Navigator ACT|This intervention is an internet-delivered version of the manualized Acceptance and Commitment Therapy group. The internet-delivered version is given as an individual treatment via a secure online treatment platform. It consists of ten separate chapters or modules. The duration of the intervention is 10-12 weeks, with a individual follow up-session by phone or video at three months after completion.
89073721|NCT05940155||mild cases|
89073722|NCT05940155||moderate cases|
89073723|NCT05940155||severe cases|
89073724|NCT05940064|Experimental|Elderly Treatment-naive Diffuse Large B-cell Lymphoma|Elderly Treatment-naive Diffuse Large B-cell Lymphoma
89073725|NCT05940051|Experimental|R/R Diffuse Large B-cell Lymphoma|
89073726|NCT05939986|Experimental|Multimodal Virtual Reality Exposure Treatment (VRET-M)|VRET with multimodal feedback including visual, auditory and vibrotactile cues.
89229948|NCT01091935||Lidocaine|"Adults >18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes~Consecutive patients from two time periods:~June 15 to August 21, 2009~October 15-Dec 22,2009"
89229949|NCT01094977|Experimental|Low Dose|TXA 10mg/kg bolus before incision and 5 mg/kg infusion until skin closure
89229950|NCT01094977|Experimental|High Dose|TXA 100 mg/kg bolus before incision and 10 mg/kg infusion until skin closure
89073727|NCT05939986|Active Comparator|Bimodal Virtual Reality Exposure Treatment (VRET-B)|VRET with bimodal feedback including visual and auditory cues.
89073728|NCT05939986|Active Comparator|Imagery Exposure Treatment (IET)|Imagery exposure treatment without sensory cues.
89073729|NCT05939973|Other|Crossover|Continuation of POSE2.0 expansion study evaluating the safety and preliminary effectiveness of the Pose 2 procedure using the g-Cath EZ Suture Anchor Delivery Catheter as a primary weight loss intervention in the control arm, defined as crossover subjects from POSE2.0 Expansion Study.
89073730|NCT05939960||Normal group|GCT time within normal range；Normal coagulation function
89073731|NCT05939960||hypercoagulable group|GCT time reduction； Normal coagulation function,
89073732|NCT05939934|No Intervention|control group|Patients will be ask not to use any OSAS treatment during the 2 weeks of the study (after the CPAP withdrawal)
89073733|NCT05939934|Experimental|mandibular advancement device|Patients will be asked to use mandibular advancement device during the 2 weeks CPAP withdrawal
89073734|NCT05939882|Experimental|0.01% atropine|0.01% atropine eye drop
89073735|NCT05939882|Experimental|0.02% atropine|0.02% atropine eye drop
89073736|NCT05939882|Experimental|0.04% atropine|0.04% atropine eye drop
89073737|NCT05939882|Placebo Comparator|placebo|placebo eye drop
89073738|NCT05939817|Experimental|umbilical cord-derived mesenchymal stem cells (UC-MSC)|"UC-MSC was collected in 50 mL of transport medium, which contained alpha minimal essential medium (αMEM [GIBCO 12000-0221]), penicillin/streptomycin (final concentration 300u/mL [GIBCO 15140-122]) and amphotericin B (final concentration 7500ng /mL [JR Scientific 50701]), and processed in less than 8 hours after collection.~Group 1 was given UC-MSC 2 million cells/mL/cm3"
89073739|NCT05939817|Experimental|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|group 2 was given UC-CM 1 mL/cm3
89073740|NCT05939817|Active Comparator|triamcinolone acetonide|group 3 was given TA 40 mg/mL/cm3
89073741|NCT05939778|Experimental|TH-SC01 local injection treatment group|"The trial was conducted in a non-randomized, single-center, single-arm, dose-escalation design. Three dose groups were preset, which were as follows:~Low dose group: 3×10^7 live cells/person (6mL); Medium dose group: 6×10^7 live cells/person (12mL) ; High dose group: 1.2×10^8 live cells/person (24mL); Each subject should receive only one corresponding dose. Three subjects were enrolled in the low-dose group,If the safety of the subjects was good, the researchers evaluated the safety and efficacy data and entered the next dose group for treatment. The medium and high-dose groups were enrolled according to the 5+7 principle.~For the first 3 dose groups, after safety evaluation by the investigators, the maximum dose could reach 2.4×10^8 live cells/person (48mL). If the MTD group is not identified by the highest dose group, it is up to the investigator to decide whether to continue with dose escalation."
89073742|NCT05939661|Experimental|TNT|Neoadjuvant radiation therapy : 5Gyx5 Neoadjuvant chemo therapy : CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles Operation: Total methorectum excision wiht radical lymph node dissection
89073743|NCT05939557|Experimental|Jones technique group|Performs Jones technique 12 participants.
89229951|NCT01094977|Placebo Comparator|Placebo|Normal saline 10 ml before skin incision and infusion according to weight until skin closure
89229952|NCT01095055|Experimental|Group 1|AdCh63 AMA1
89073744|NCT05939557|Experimental|kinesio tapping group|Performs kinesiotape 14 participants.
89073745|NCT05939557|Experimental|combined therapy group|Performs Jones technique and kinesiotape 12 participants.
89073746|NCT05939466|Experimental|FM patients treated with Bedrocan®|Medical cannabis was administered by herbal tea or decoction as described by the Ministry of Health through the Ministerial Decree of 9 November 2015.
89073747|NCT05939440|Experimental|Proactive Cost of Care (P-COC) intervention|"One time session with trained educator to review:~Cost Information Flyer: Anticipated out of pocket costs flyer by cancer type and stage~Cost Tracking workbook: Out-of-pocket cost tracker Participants also review a Insurance, Employment, and Financial Assistance flyer Participants will be reminded to track their costs once a month through an automated text message or e-mail based on patient preference.~Participants also receive an existing patient pamphlet Patient and Family Guide"
89073748|NCT05939440|Active Comparator|Usual Care|"Participants receive an existing patient pamphlet Patient and Family Guide"
89073749|NCT05939375|Experimental|FCC educational training|"The administration of the pre-tests, the planning of the educational process, including the development of e-learning modules and video lectures, was shared with the nurses.Each week, the topics were delivered to the nurses through online interactive methods, with each session lasting approximately 45-60 minutes. Six weeks after the completion of the six-week educational training, the nurses were administered the FCCAS post test via an online form.~The PedsQL HCPSS was utilized to assess the level of healthcare satisfaction among parents whose children received care in pediatric clinics. To assess parental healthcare satisfaction before the training, the mean scores of the PedsQL HCPSS from the institutional data of the hospital in January 2021 were used. Post training parental data were collected in May-June 2021 using the PedsQL HCPSS from parents whose children received care in pediatric clinics."
89073750|NCT05939284|Active Comparator|Group C|
89073751|NCT05939284|Active Comparator|Group S|
89073752|NCT05939271||persons with DM who underwent a lower extremity amputation|
89073753|NCT05939271||persons with DM who did not underwent a lower extremity amputation|
89073754|NCT05939271||persons without DM who underwent a lower extremity amputation|
89073755|NCT05939258||Mapo Fire Station|
89073756|NCT05939232||X-ALD|X-linked adrenoleukodystrophy (X-ALD) patients.
89073757|NCT05939232||Carrier-control (CC)|Carriers of mutation in gene encoding ATP-binding cassette subfamily D member 1 (ABCD1), who have no X-linked adrenoleukodystrophy and are matched with the X-ALD group according to age, sex and education.
89073758|NCT05939180|Experimental|VA regimen|VA regimen: azacytidine and venetoclax
89073759|NCT05939180|Active Comparator|DA regimen|DA regimen: daunorubicin and cytarabine
89073760|NCT05939154||mental disorders|Patients in Shanghai Mental Health Center; meet ICD-11 or DSM-5 diagnosis of depressive disorders, bipolar disorders, schizophrenia, obsessive-compulsive disorder, anxiety disorders, addictive disorders and sleep-wake disorders (do not limit subtypes and current disease state); age ≥15 years and < 60 years.
89073761|NCT05939154||healthy controls|Age ≥15 years and < 60 years; gender match with patient group; understand the research content and sign the informed consent; no family history of mental disorders.
89073762|NCT05939141||OLE Subjects|adult OSA patients with and without complete concentric collapse of the soft palate who have successfully been implanted with the Genio IS in a Nyxoah sponsored Clinical Investigation and having the device in-situ at the time of enrollment (with therapy activated or de-activated).
89073763|NCT05939115|Active Comparator|Left unilateral aTBS|Participants who are randomly assigned to this group will receive iTBS (intermittent theta burst stimulation) to the left dorsolateral prefrontal cortex (LDLPFC) determined using Beam method for 1800 pulses with an intertreatment interval of fifty minutes. Stimulation was at 90% of resting motor threshold. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
89073764|NCT05939115|Active Comparator|Sequential bilateral aTBS|Participants who are randomly assigned to this group will receive ten sessions daily for five consecutive days for a total of fifty sessions. During each session continuous theta burst stimulation (cTBS) in which (1800 pulses) are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDLPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDLPFC) with using beam method for target localization. Stimulation was at 90% of resting motor threshold.
89073765|NCT05939102|Active Comparator|Conventional bracket bonding technique|
89073766|NCT05939102|Experimental|V-prep combined with RMGIC for bracket bonding|
89073767|NCT05939076|Active Comparator|Cryoballoon pulmonary vein isolation|Cryoballoon (Arctic Front AdvanceR, Medtronic) for pulmonary vein isolation
89073768|NCT05939076|Active Comparator|Antiarrhythmic drug|"Tablet Dronedarone:- 400 mg twice daily or Tablet Flecainide:- (50-)100 (-200) mg twice daily or slow release (100-)200 mg once daily.~If these drugs fail or give side effects:~Tablet Propafenone:- 150 mg 3 times daily increasing to 300 mg twice daily, if necessary max 300 mg three times daily. Dose reduction for patients <70 kg bodyweight.~Tablet Sotalol:- 80 mg twice daily up to 160 mg twice daily. Dose reduction to half dosage if a creatinine clearance is 30-60 ml/min."
89073769|NCT05939050|Experimental|Partisipants|
89073770|NCT05938998|Experimental|Social Support and Yoga|This is a single arm trial. This arm includes one hour of a guided social support group and one hour of yoga, weekly for 12 total weeks.
89073771|NCT05938985||with dry eye disease (DED)|DED diagnosis defined by the Dry Eye Workshop (DEWS) II.
89073772|NCT05938985||control (non-DED)|No significant ocular disease other than refractive error and no systemic disease likely to be associated with dry eye. The non-DED group will be sex-matched and age-matched to the DED patients.
89073773|NCT05938881||self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
89073774|NCT05938881||mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
89073775|NCT05938868|Experimental|Group A (LIPUS group)|This group will include 17 patients who received Dental Implant Surgery. Patients will be treated with low intensity pulsed ultrasound in addition to standard care.
89073776|NCT05938868|Experimental|Group B (LLLT group)|This group will include 17 patients who received Dental Implant Surgery. The patients will be irradiated with low level diode laser therapy (GaAs) in addition to standard care.
89073777|NCT05938868|Active Comparator|Group C (Control group)|This group will include 17 patients who received Dental Implant Surgery. Patients will be treated with standard care only after surgery for 2 weeks.
89073778|NCT05938855||Standard of care|Electrical stimulation and biofeedback by the medical device PHENIX LIBERTY
89073779|NCT05938842|Experimental|Online DBT-Mindfulness intervention|"Experimental group Dialectical behavior therapy (DBT) is a type of cognitive behavioral intervention. The module of Mindfulness is directed to balance emotion with reasoning in order to achieve wise mind, to act with awareness and to decrease characteristic mood dependent."
89073780|NCT05938842|Active Comparator|Online psychoeducational intervention|Active control group,
89073781|NCT05938829|Other|Ultrasound using SMFM guidelines, then ultrasound using ISUOG guidelines|Each site will utilize SMFM guidelines for the first 12 months and then there will be a 2 week washout period, after which each site will utilize ISUOG guidelines for 12 months
89073782|NCT05938179|Experimental|HS-10353 Capsules|
89073783|NCT05938179|Experimental|HS-10353 matched-placebo oral capsules|
89073784|NCT05938166|Experimental|experimental group (EG)|Behavioral: The EG will receive augmented reality (AR) simulation training intervention with traditional classroom oral health education.
89073785|NCT05938166|No Intervention|Control group (CG)|The CG only receive traditional classroom oral health education.
89073786|NCT05938049||Group A|patients whom fluid management will be guided by their IVC & carotid Doppler measurements
89229953|NCT01095055|Experimental|Group 2|AdCh63 AMA1 followed by MVA AMA1
89073787|NCT05938049||Group B|patients in whom the fluid management will not guided by IVC & carotid Doppler measurements.
89073788|NCT05937737|Experimental|Type 2 Diabetes|Individuals with type 2 diabetes were followed for 12 weeks with an appropriate diet specific to their type 2 diabetes condition, and necessary measurements were taken at the beginning, 4th week, and 12th week.
89073789|NCT05937737|No Intervention|Healthy Controls|No dietary intervention was made for the control group, and necessary measurements were taken at the beginning and 12th week.
89073790|NCT05937282|Placebo Comparator|Control group|Patients will receive infusion of 25 ml normal saline in 50 ml syringe pump.
89073791|NCT05937282|Active Comparator|Dexmedetomidine group|Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
89073792|NCT05937282|Active Comparator|Propofol|Patients will receive propofol infusion in the dose of 3 mg/kg/hr. (12) 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump
89073793|NCT05937282|Active Comparator|Lidocaine|Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr. (15) 25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.
89073794|NCT05936814||Intraarticular|The control group with intraarticular varus deformity and Kellgren and Lawrence grade 4 gonarthrosis.
89073795|NCT05936814||Metaphyseal|The case group with Metaphyseal varus deformity and Kellgren and Lawrence grade 4 gonarthrosis.
89073796|NCT05936268|Experimental|Genacumab group|Genakumab 200mg single injection
89073797|NCT05936268|Active Comparator|cholchicine group|Colchicine 0.5mg qd po.for 12 weeks
89073798|NCT05935787|Experimental|Cytoflavin|
89073799|NCT05935787|Placebo Comparator|Placebo|
89073800|NCT05933642|Active Comparator|Treatment group|Intravenous (IV) infusion of (aminophylline 150mg and frusemide 120mg diluted to 50ml NS), IV load 10ml over 60 minutes, followed by IV infusion of 4 ml/hour
89073801|NCT05933642|Active Comparator|Control group|IV infusions of furosemide (120mg diluted to 50ml NS), IV load 10ml over 60 minutes, followed by IV infusion of 4 ml/hour
89229954|NCT01095133|Experimental|Amiloride|
89229955|NCT01095133|Placebo Comparator|Placebo|
89229956|NCT01092013|Active Comparator|Operating room training|
89073802|NCT05933226|Experimental|Khanya|Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Khanya is delivered as a stepped-care package in which the least resource-intensive part of the intervention (i.e., Life-Steps, a single session problem solving intervention for HIV medication adherence) will be delivered first. Only individuals randomized to the Khanya intervention who are still struggling with HIV medication adherence after the first session will be stepped up to receive the more comprehensive, resource-intensive part of the intervention (i.e., six additional sessions of the intervention). Khanya Step 2 includes evidence-based treatment components to improve ART adherence and SU, including motivational interviewing, behavioral activation, and mindfulness-based relapse prevention strategies, which have previously been piloted in this community.
89073803|NCT05933226|No Intervention|Enhanced Standard of Care (ESOC)|Enhanced Standard of Care (ESOC) includes the local standard of care, which is referral to a free local outpatient substance use treatment program, enhanced with facilitated referrals. To enhance the standard of care, study staff will provide participants with a detailed description of the program's referral process and offer to help the participant set up an intake at the program. Additionally, the team will follow up on the referral. Participants in this arm will also receive Wisepill, a wireless adherence monitoring advice, at the baseline assessment.
89073804|NCT05933109|Experimental|TMR group|Patients will receive a sound S1 while they generate a positive outcome of imagery rehearsal therapy (IRT). They will also receive the sound S1 during REM sleep.
89073805|NCT05933109|Active Comparator|Control group|Patients will not receive the sound S1 while they generate a positive outcome of imagery rehearsal therapy (IRT). During REM sleep, they will receive the same sound as the experimental group (S1) under the same conditions.
89073806|NCT05932251||Low insulin sensitivity|Women will be classified as having low insulin sensitivity, if their Matsuda-index is in the lowest quartile of a reference cohort
89073807|NCT05932251||Low insulin secretion|Women will be classified as having low insulin secretion if their Stumvoll-index is in the lowest quartile of a reference cohort
89073808|NCT05932173|Experimental|OlyCAR-019 Cell Infusion|OlyCAR-019 cell infusion will be administered by vein after short-time manufacture.
89073809|NCT05932108||Staff|Educational intervention in TERMA. All staff are required to attend the education.
89073810|NCT05932108||Patients|Patients will not attend any education in TERMA. Data will be collected before and after the staffs education to se if the patients think the attitude of the staff have changed.
89073811|NCT05928520|Experimental|Tramadol group|Swabs soaked with tramadol 5% 2 mg/kg diluted with saline 0.9%
89073812|NCT05928520|Active Comparator|Lidocaine group|Swabs soaked with lidocaine 2% 2mg /kg diluted with saline 0.9%
89073813|NCT05927441|Experimental|DragonFly Transcatheter Mitral Valve Repair System-DMR|Transcatheter mitral valve repair with the DragonFly System in patients with degenerative mitral regurgitation
89073814|NCT05927441|Experimental|DragonFly Transcatheter Mitral Valve Repair System-FMR|Transcatheter mitral valve repair with the DragonFly System in patients with functional mitral regurgitation
89073815|NCT05927324|Experimental|Active treatment|CAVEAT active treatment group
89073816|NCT05924048|Experimental|Group of 2% oxygen concentration.|Incubate human embryo at 2% oxygen concentration.
89073817|NCT05924048|No Intervention|Group of 5% oxygen concentration.|Incubate human embryo at 5% oxygen concentration.
89073818|NCT05923411|Experimental|Treatment A (Cohort 1)|Participants will receive PF-07220060 tablet by mouth
89073819|NCT05923411|Experimental|Treatment B (Cohort 2)|Participants will receive PF-07220060 tablet by mouth
89073820|NCT05923411|Experimental|Treatment C (Cohort 3)|Participants will receive PF-07220060 tablet by mouth
89073821|NCT05923411|Experimental|Treatment D (Cohort 4)|Participants will receive PF-07220060 tablet by mouth
89073822|NCT05923411|Experimental|Treatment E (Cohort 5)|Participants will receive PF-07220060 tablet by mouth
89073823|NCT05923411|Experimental|Treatment F (Cohort 6)|Participants will receive PF-07220060 and Rabeprazole tablets by mouth
89073824|NCT05923411|Experimental|Treatment G (Cohort 7)|Participants will receive PF-07220060 and Rabeprazole tablet by mouth
89073825|NCT05923190|Active Comparator|Enfortumab vedotin (EV) monotherapy|"EV will be administered at standard dose of 1.25 mg/kg IV on days 1, 8 and 15 of a 28-day cycle for 3 cycles.~First schedule de-escalation of EV will occur in patients with disease control per RECIST v1.1 (complete response/partial response/stable disease) on their first scan in the EV at 12 weeks. In these patients, EV will be administered on days 1 and 15 of a 28-day cycle.~Second schedule de-escalation of EV will occur in patients with disease control per RECIST v1.1 (complete response/partial response/stable disease) on their second scan in the EV monotherapy (at 24 weeks). EV will be administered on day 1 of a 21-day cycle."
89229957|NCT01092013|Active Comparator|Skills lab training|
89229958|NCT00387088|Other|Tiotropium|Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
89229959|NCT00387088|Other|Placebo|Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
89229960|NCT01095211|Active Comparator|B-Vitamins|folic acid, cobalamin, vitamin B6
89224208|NCT06270732|Experimental|Experimental: iMentalize Program (iMentalize)|iMentalize is a structured new program specifically designed to foster mentalization in non-clinical general population. Inspired in Mentalization Based Treatments, which foster mentalization as a principal factor for salutogenesis in clinical settings, iMentalize aims to promote the parents' mentalization stance by using 30 structured sessions where parents are trained in MISC components (Mediational Intervention for Sensitizing Caregivers) to specifically help children to mentalize about cartoon's characters, about themselves, about the caregiver's mental states and about other close others. iMentalize is administered to parent-child dyads who work together in weekly 45-minutes sessions across 1 year.
89224209|NCT06270732|Experimental|Mediational Intervention for Sensitizing Caregivers, Self-Administered (MISC-SA)|This MISC version (MISC-SA) aims to transfer the MISC original training to wider communities by diminishing the cost of the teaching and learning. By implementing the MISC lessons in an online platform, thus allowing self-learning, the new Self- Administered version of MISC allows to obtain MISC training in 30 weekly sessions distributed across 12 months, in 2 blocks: 18 sessions from February to June, and 12 additional sessions from October to December. In contrast to the original version of MISC, this version allows the simultaneous self-training of a high number of participants with very low intervention of a supervisor, which diminishes the cost. MISC-SA keeps the core component of MISC training (video-feedback) by fostering participants to record interactions and then visualize them using guided reﬂection.
89224210|NCT06270732|Active Comparator|Mediational Intervention for Sensitizing Caregivers - Readings (MISC-R): Treatment as Usual (TAU)|"MISC-R is a more theoretical version of MISC training lacking the core MISC component (video-feedback). MISC-Readings provides the theoretical knowledge of MISC but lacking practice and reﬂection about MISC components by watching one's own video recorded interactions with the child. MISC-Readings substitutes all the time for practice and video-feedback with theoretical pills and readings, that is, with theoretical knowledge. Thus, this more theoretical MISC version can be assimilated to common intellectual trainings based on cognitive knowledge and pencil-and-paper exercises instead of skill-based training based on true practice for social-emotional skills development."
89224211|NCT06270706|Experimental|Part 1 Dose Escalation: PLN-101095 given as monotherapy and in combination with Pembrolizumab|
89224212|NCT06270706|Experimental|Part 2 Dose Expansion: PLN-101095 in combination with Pembrolizumab|
89224213|NCT06270693|Experimental|CAD WITH AP|CORONARY ARTERY DISEASE WITH APICAL PERIODONTITIS
89224214|NCT06270693|No Intervention|CAD WITHOUT AP|CORONARY ARTERY DISEASE WITHOUT AP
89224215|NCT06270654|Active Comparator|Control group|Pre incision of 0.375% ropivacaine 10ml local infiltration will be given.
89224216|NCT06270654|Experimental|Ropivacaine group|Bilateral erector spinae plane block (0.375% 20ml ropivacaine on each side + adrenaline 1:200,000) pre incision.
89229961|NCT01095211|Placebo Comparator|placebo|none of the vitamins (99.5% mannitol)
89229962|NCT01089985|Experimental|Serum eye drops|Patient's autologous serum is diluted in saline solution
89229963|NCT00053365|Experimental|Treatment (irofulven)|Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
89691687|NCT05086133|Sham Comparator|Sham stimulation|The participants randomized into experimental group will receive sham stimulation of left M1 area for 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.
89691688|NCT05512026|Experimental|Feasibility Assessment|The Poseidon System is investigational and indicated to provide a pathway to control waste fluid during irrigation of the colon. All consented patients will receive the Device use during their colonoscopy procedure.
89691689|NCT03034109|Experimental|tDCS conventional stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left dorsal lateral prefrontal cortex (DLPFC) and the cathode will be placed over the right supraorbital cortex. This is the standard 1 anode by 1 cathodal convention. Stimulation will last 20 minutes."
89691690|NCT03034109|Experimental|High Definition (HD)-tDCS stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and 4 cathodes will be placed surrounding the anode. This is the 4 cathode by 1 anode HD-tDCS montage for more focal stimulation. Stimulation will last 20 minutes."
89691691|NCT03034109|Sham Comparator|tDCS sham stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and the cathode over the right supraorbital cortex. A short stimulation will be given to the subjects that will mimic the sensation of an actual stimulation but will last much shorter. The session will still last 20 minutes in total to blind both subjects and investigators."
89691692|NCT03565666|Active Comparator|Adult RCT: Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy) for 7 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM) and half of all subjects also were a senseonics CGM. The usual care period was followed by the other 2 arms according to each subject's randomization schedule
89691693|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
89691694|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet using Fiasp|Participants randomized to the iLet with Fiasp first started the insulin-only iLet arm using faster insulin aspart (Fiasp) in PumpCart, where the pharmacokinetic (PK) parameter for tmax used by the insulin-dosing algorithm was set to the same value as is used for Humalog and Novolog (65 minutes). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
89691695|NCT03034343|Experimental|TAU+mindfulness applied face to face|4 sessions of 90 minutes/session Mindfulness based intervention applied in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is one month.
89073826|NCT05923190|Experimental|EV/pembrolizumab|"EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles. Radiographic assessment will be conducted every 9 weeks.~Schedule de-escalation of EV will occur in patients with disease control per RECIST v1.1 (complete response/partial response/stable disease) on their first scan in the EV/pembrolizumab arm at 9 weeks. In these patients EV and pembrolizumab will be administered on day 1 of a 21-day cycle."
89073827|NCT05922657||Treated patients|This is a registry study with no active intervention outside standard of care. Women will be treated with Cerene per standard of care.
89073828|NCT05919173|Experimental|Bupivacaine 0.25%|Bupivacaine 0.25% Dose: 1mL/kg body weight
89073829|NCT05919173|Experimental|Bupivacaine+DEX|Bupivacaine 0.25% plus Dexmedetomidine 1microgram/kg Dose: 1mL/kg
89073830|NCT05910580|Experimental|SBIRT|Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools (AUDIT-C and NIDA ASSIST) will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment.
89073831|NCT05910580|No Intervention|Usual Care|None of the clinic sites have implemented standardized screening, brief intervention, or referral to treatment components. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
89073832|NCT05908747|Experimental|surufatinib + gemcitabine + nab-paclitaxel|
89073833|NCT05908240|Other|Care Coordination|
89073834|NCT05904808|Active Comparator|Diuretic comparison|each participant will be followed for 4 consecutive weeks. during which 3 different diuretic regimens will be given (random sequence). Last week follow up without protocol regimen.
89073835|NCT05899426|Experimental|Motor learning based clinical pilates|Participants in this group will receive training for 60 minutes 2 times a week for 12 weeks and will be followed up with the same assessments at the 3rd months after the treatment.
89073836|NCT05899426|Active Comparator|Conventional Physiotherapy|Participants in this group will receive training for 60 minutes 2 times a week for 12 weeks and will be followed up with the same assessments at the 3rd months after the treatment.
89073837|NCT05897931|Experimental|Connective tissue massage|Participants will receive TENS and infrared treatment for 25 minutes, 5 days a week. Then Connective Tissue Massage will be applied.
89073838|NCT05897931|Experimental|Kinesio Tape Application|Participants will receive TENS and infrared treatment for 25 minutes, 5 days a week. Kinesio tape application will be applied 2 days a week for 4 weeks.
89073839|NCT05897502|Experimental|the theoretical model nutritional education|instruction with multimedia
89073840|NCT05897502|Placebo Comparator|control|instruction with traditional paper
89073841|NCT05896280|Active Comparator|EST in common bile duct stones|With routine EST surgery, the sphincter is cut open and stones are removed
89073842|NCT05896280|Experimental|ECPP in common bile duct stones|Common bile duct stones are removed after EST, and then ECPP is performed.
89073843|NCT05895721|No Intervention|Control|Standard Of Care only
89073844|NCT05895721|Other|Intervention|Standard Of Care + VR Modules
89073845|NCT05893901||Consumers of cereal products|Caregivers with children under 5 years of age who are consumer of cereal products in the Maradi, Falwell and Tera areas in Niger.
89691696|NCT03034343|Experimental|TAU + Mindfulness ICTs intervention|4 sessions of 60 minutes/session Mindfulness based intervention applied by ICTs (Internet-based program). The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the online program is two months.
89691697|NCT03034343|No Intervention|Usual medical treatment (TAU)|In this group the general practitioner will apply the usual treatment (medication) but there will be no psychological treatment.
89691698|NCT05502822|Active Comparator|real stimulation|Stimulation electrodes were arranged in a 4 × 1 ring configuration at F1, F2, C1 ,C2 and FCz, with the central one delivering an alternating current 2 mA and the surrounding 4 electrodes delivering one-fourth of the central electrode's current in the opposite polarity. The average peak-to-peak stimulation intensity across participants was 2 mA for the 6-Hz tACS. Participants will receive real tACS once daily for two weeks.
89691699|NCT05502822|Sham Comparator|sham stimulation|In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention. Participants will receive sham tDCS once daily for two weeks.
89691700|NCT05502744|Experimental|Emergency Versus Elective Cholecystectomy in Acute Cholecystitis in the Era of Laparoscopy|A Prospective Randomized Comparative Study.
89691701|NCT03026153|Other|Control group - Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
89691702|NCT03026153|Other|Intervention Group - Oral Survey 2|Oral Survey 2 will be administered as the intervention : patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
89691703|NCT05502666|Experimental|Intervention Arm|Intervention Arm: ¡Salud! Por la vida Educational Intervention After completing eligibility and baseline surveys, trained lay health workers delivered an educational intervention for colorectal cancer screening with included a tailored interactive multimedia intervention (TIMI), newsletter, infographics, and a provider prompt for colorectal cancer screening. This educational session was delivered at intervention clinics and lasted about 1 hour. Follow-up data was collected starting at 6 months post educational session.
89691704|NCT05502666|No Intervention|Control Arm|Control Arm: No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 6 months post-baseline survey.
89691705|NCT03620890|Active Comparator|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
89691706|NCT03620890|Active Comparator|Detemir|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
89691707|NCT05507112|Experimental|Neoadjuvant chemoradiotherapy plus PD-1 inhibitor|"Capecitabine 1650mg/m2 is given 5 days a week in parallel with radiotherapy 45 to 50 Gy during 5 consecutive weeks.~Tislelizumab is given on day 1 of week 2, 5 and 8 at 200 mg i.v. 8-12 weeks after completion of radiation therapy, patients undergo total mesorectal excision (TME)."
89691708|NCT05507112|Active Comparator|Neoadjuvant chemoradiotherapy|"Capecitabine 1650mg/m2 is given 5 days a week in parallel with radiotherapy 45 to 50 Gy during 5 consecutive weeks.~8-12 weeks after completion of radiation therapy, patients undergo total mesorectal excision (TME)."
89691709|NCT03024983|Active Comparator|Control|Glucose monohydrate (isoglucidic portion -50 g of available carbohydrates-)
89691710|NCT03024983|Experimental|Semolina|Semolina soup (isoglucidic portion -50 g of available carbohydrates-)
89691711|NCT03024983|Experimental|Bread|Bread (isoglucidic portion -50 g of available carbohydrates-)
89691712|NCT03024983|Experimental|Short pasta (fresh)|Fresh penne (isoglucidic portion -50 g of available carbohydrates-)
89691713|NCT03024983|Experimental|Short pasta (dry)|Short pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
89691714|NCT03024983|Experimental|Long pasta (dry)|Long pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
89691715|NCT03569020|Experimental|Dietitian-Directed Diet|Participants will be provided $105/week ($15/day) to purchase foods in servings that correspond to the DASH diet and thus include fruits, vegetables, lean meat, low fat dairy, and high fiber foods. Participants will also be asked to restrict red meat, sweets, and sugary beverages during this intervention period. A dietitian will help participants order foods from a digital supermarket. Foods will be delivered to the Johns Hopkins ProHealth Research Clinic for weekly pick-up. This study period will last 4 weeks.
89691716|NCT03569020|No Intervention|Self-Directed Diet|Participants will be asked to consume their typical diet for 4 weeks. There will be no subsidy during this period.
89691717|NCT03833609|Experimental|Online yoga training (Group A)|Participants will receive an e-pamphlet on physical exercise developed by The Arthritis Society, and will be invited to complete a yoga training program. The yoga training program is a structured low-intensity Vishwas-Raj. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
89691718|NCT03833609|Experimental|Online aerobic dance training (Group B)|Participants will receive the e-pamphlet on physical exercise and will be invited to complete an aerobic dance program. The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
89691719|NCT03833609|No Intervention|Wait list control (Group C)|Participants will receive the e-pamphlet on physical exercise and will be instructed to continue with their current medical care while they are on the wait list (12 weeks). After the completion of the study, the yoga and aerobic dance training videos will be available to all participants including those in the control group. In recruitment documents, this group will be termed the e-pamphlet group.
89691720|NCT05502510||MyHealthyPregnancy (MHP)|Use of the MyHealthyPregnancy application in conjunction with usual care.
89691721|NCT05502510||Usual Prenatal Care (usual care)|Usual prenatal care consisting of biweekly visits with the patient care team.
89691722|NCT00952133|Experimental|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery.
89691723|NCT00952133|Placebo Comparator|Palonosetron only|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Intravenous Palonosetron and Saline solution
89691724|NCT05511636|Experimental|those that receive the conventional oxygen|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU will be given HFNC . The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
89073846|NCT05891782|Experimental|Intervention group|A HAPA-based multicomponent fall intervention will use group education, individualized plans and face-to-face interviews to develop health behaviors, such as fall emergency management, IC enhancement (exercise management, diet management, cognitive improvement, psychological regulation, vision protection), medication and disease management, environmental improvement, and fall self-efficacy enhancement.
89691725|NCT05511636|Experimental|those that receive the high flow oxygen therapy.|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU will be given standard oxygen therapy . The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
89691726|NCT03033953|Placebo Comparator|Milk supplementation|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g milk protein.
89691727|NCT03033953|Experimental|Native whey|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g native whey protein.
89691728|NCT05506644|Experimental|HRV-Biofeedback|
89073847|NCT05891782|Experimental|Control Group|Usual care and health education will be provided at the nursing home. In order to avoid an ethical dilemma between the individuals in the control and intervention groups, the related information will be provided for control group at the end of the study.
89073848|NCT05891184||1|the 1st group will be patients with current or past history of variceal bleeding,
89073849|NCT05891184||2|the 2nd group will be patients having gastroesophageal varices without variceal bleeding,
89073850|NCT05891184||3|3ed group will be patients without gastroesophageal varices or variceal bleeding.
89691729|NCT03033797|Experimental|MoviLetrando-MoveHero|Half of the children will play first two different levels of the game MoviLetrando (2 minutes each) and, after the game MoveHero, more 2 minutes
89691730|NCT03033797|Experimental|MoveHero-MoviLetrando|The other half of the children will play first 2 minutes of the game MoveHero and after, two different levels of the Game MoviLetrando, two minutes each.
89691731|NCT04293978|Experimental|Virtual Reality relaxation|Participants may request to use the application at any time during their stay at the ward, as many times as they wish. Participants sign in using an anonymous study ID and sessions (and outcomes) are automatically logged by the device to this ID.
89073851|NCT05888350|Experimental|Foster treatment group|Participant inhales Foster (Inhaled Beclometasone Dipropionate and Formoterol Inhalation Aerosol) 1 puff bid for 4 weeks.
89073852|NCT05888350|Placebo Comparator|Placebo controlled group|Participant inhales matched placebo 1 puff bid for 4 weeks.
89073853|NCT05881083|Experimental|Intervention group|1-week nicotine replacement therapy sample + Brief cessation advice
89073854|NCT05881083|Active Comparator|Control group|Brief cessation advice
89073855|NCT05874271|Experimental|Revised case management package|
89073856|NCT05872100|Experimental|RESPONSE GROUP|Mindfulness-based psycho-education program will be applied to the students in the experimental group. After the end of the study, the mindfulness-based psychoeducation program given in the experimental group will also be applied to the control group. A 45-minute training and preliminary information will be given to the student group. Participants will meet for the first session. After the trainer, who is a clinical psychologist, introduces himself and meets the participants, 10 minutes will be given to ensure that all participants meet and look at each other. Then, the aim of the research will be discussed by sharing the content of the three-week program. After three weeks, post-tests will be administered.
89073857|NCT05872100|No Intervention|control group|A pre-test will be applied to the control group. No intervention will be made. The final test will be applied.
89073858|NCT05871983|Experimental|Single-Arm|This is a prospective, non-randomized, single-arm, international, multicenter, clinical study designed to evaluate the safety, efficacy, and performance of the P&F MUNICH TMVR System in a population of patients with moderate to severe symptomatic Mitral Regurgitation.
89073859|NCT05870683|Experimental|14-day Tegoprazan-Amoxicillin dual therapy|14-day Tegoprazan-Amoxicillin dual therapy, Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid, Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid
89073860|NCT05870683|Active Comparator|14-day Esomeprazole-Amoxicillin dual therapy|14-day Esomeprazole-Amoxicillin dual therapy, Esomeprazole（Astrazeneca Pharmaceutical Co., LTD.) 20mg qid, Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid
89691732|NCT03570658|Experimental|Single-Ascending Dose (SAD)|Participants will receive a single dose of RO7049389.
89691733|NCT03570658|Experimental|Multiple-Ascending Dose (MAD)|Participants will receive multiple doses of RO7049389.
89073861|NCT05870293|Experimental|RESPONSE GROUP|The study will be done online and the application will be explained to the patients. Randomly selected groups will be made using a single-blind technique, not knowing which group is the intervention group. Pre-test will be applied to the diabetic patients included in the experimental groups and control groups. After the preliminary tests are applied to the individuals with diabetes in the intervention 1 group, a nurse coaching interview will be held with diabetes by applying the 'walt disney' method. In accordance with the principles of coaching, 2 sessions will be held under the management of the patient. After the first session, 10 days later, in the second session, life coaching with diabetes will be done with the Walt Disney method. After 10 days after the 2nd interview, the final tests will be applied at the end of the 1st month.
89073862|NCT05870293|No Intervention|control group|The control group will be given a pre-test and a post-test 1 month later without any intervention.
89073863|NCT05862675||experimental group|meeting the specific diagnostic criteria for acute Lung Injury
89073864|NCT05862675||control group|Healthy children
89073865|NCT05860400||Pre-treatment Group|IR-CAD patients before receiving comprehensive treatment.
89073866|NCT05860400||Post-treatment Group|IR-CAD patients after receiving comprehensive treatment.
89691734|NCT03570658|Placebo Comparator|Placebo|Participants will receive either a single dose (SAD cohorts) or multiple doses (MAD cohorts) of placebo matched to RO7049389.
89073868|NCT05850052|Other|Efficacy of conventional direct laryngoscopy|The researchers seeks to compare the efficacy of conventional direct laryngoscopy using a Macintosh blade,
89073869|NCT05850052|Experimental|McGrath Videolaryngoscope for rapid endotracheal intubation|The researchers will use the McGrath videolaryngoscope for rapid sequence endotracheal intubation.
89073870|NCT05847452||All participants|"All eligible participants will be consented and enrolled into the study and given the IMP as follows:~Benzraliziumab 30mcg once a month for 3 months"
89073871|NCT05842499|Experimental|Line set strategy|Pulmonary vein isolation, roof line, posterior wall isolation (posterior box), anterior septal line and cavo-tricuspid isthmus.
89073872|NCT05842499|Active Comparator|Conventional strategy|Mapping and ablation of the present flutter and those that could be induced later until sinus rhythm is obtained.
89073873|NCT05837507|Experimental|Experimental|"A group of 29 patients with ALS will be formed to the multimodal digital platform associated with Non Invasive Ventilation (NIV) and usual management~Patients will be treated with NIV equipment from the manufacturer LOWENSTEIN and will benefit from the usual follow-up carried out at the reference center of Montpellier University Hospital."
89073874|NCT05837507|Active Comparator|Control Comparator|"A group of 29 patients with ALS will be formed : control group following usual management including NIV.~Patients will be treated with NIV equipment from the manufacturer LOWENSTEIN and will benefit from the usual follow-up carried out at the reference center of Montpellier University Hospital."
89073875|NCT05834387|Experimental|Control group|
89073876|NCT05834387|Experimental|Experimental group|
89073877|NCT05833776|Experimental|group F|received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)
89691735|NCT00941681|Experimental|Cohort 1: MR 50 mg BID|Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.
89691736|NCT00941681|Experimental|Cohort 2: IR 37.5 mg TID|Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.
89691737|NCT00941681|Experimental|Cohort 3: MR 100 mg BID|Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days
89691738|NCT05042375|Experimental|camrelizumab + famitinib|
89691739|NCT05042375|Experimental|pembrolizumab|
89691740|NCT05042375|Experimental|camrelizumab|
89691741|NCT03571672|Experimental|DEFINITY|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
89691742|NCT05502120|Active Comparator|Macintosh blade|Visualisation of entrance to larynx using Standard Macintosh blade laryngoscope followed by Visualisation of entrance to larynx using Vie-Scope laryngoscope
89691743|NCT05502120|Experimental|Vie-Scope|Visualisation of entrance to larynx using Vie-Scope laryngoscope after visualisation using Macintosh blade laryngoscope
89691744|NCT04592172|Experimental|Bedtime Routine Education|50 families will be randomly assigned to receive the bedtime routine intervention, 3 Cs for Bedtime ZZZs delivered by research assistants at the 12-month and 15-month well-child visits, in additional to receiving usual clinical care. The intervention will take approximately 30-45 minutes to implement at each study visit. Research assistants will be trained and supervised by board-certified Behavioral Sleep Medicine providers. This intervention focuses on developing an individualized bedtime routine, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling, based on parent's preferences. Families will receive appropriate materials for their bedtime routine, including a CuddleBright kit, bedtime books, toothbrush/toothpaste, and the created bedtime chart to take home.
89691745|NCT04592172|No Intervention|Control group|50 families will be randomly assigned to control group (usual care).
89691746|NCT00952211|Active Comparator|CPAP|CPAP at therapeutic pressure
89691747|NCT00952211|Sham Comparator|sub-therapeutic CPAP|CPAP administered at sub-therapeutic pressure
89691748|NCT03023189|Active Comparator|Tranexamic acid|At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h
89691749|NCT03023189|Placebo Comparator|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h
89691750|NCT04590534|Experimental|study Group A|patients will receive one capsule of [garcinia 500 mg and chromium 281 mg] 3 times daily for 12 weeks.
89691751|NCT04590534|Active Comparator|Active control Group B|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
89691752|NCT04590534|Placebo Comparator|Placebo Group C|patients will receive placebo 3 times daily for 12 weeks
89691753|NCT03033719|Active Comparator|Laparotomy|Open surgery
89691754|NCT03033719|Experimental|Laparoscopy|Minimally invasive surgery
89691755|NCT03033485|Experimental|Melanoma patients|Melanoma patients enrolled for the clinical diagnosis study are performed with both 18F-P3BZA PET/CT and18F-FDG PET/CT scans before surgery.
89691756|NCT03033641|Experimental|Ablation procedure|
89691757|NCT00941993|Experimental|local anesthesia|tympanic membrane local anesthesia delivery system
89224217|NCT06270628|Experimental|Exercise group|Participants will be offered three live-remote exercise training sessions per week. Each participant in the trial will be provided with the base module twice a week, which will involve a personalized training intensity. This module aims at targeting the participants' HRQOL, which is the first primary endpoint of the trial. Additionally, each participant will receive one out of four specific modules once a week to address their individual main side-effect (based on shared decision-making (SDM)) (second primary outcome). The intervention also includes an educational component about exercise and cancer.
89224218|NCT06270628|No Intervention|Wait list control group|Regular care The control group will receive the same exercise program after the 12 weeks intervention period
89224219|NCT06270615||Prehospital severe trauma patients|Every severe trauma patient 18 years of age or older to be admitted to a participating center excluding those already diagnosed with active hemorrhage from computed tomography findings and those with prior traumatic cardiac arrest
89224220|NCT06270602||Cohort A (Retrospective):|All consecutive patients entered in the ROC platform from the start of platform activation (November 2018) until the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients) will be enrolled. The retrospective cohort will be made by more than 40000 patients already included in the platform and entered a GOM path
89224221|NCT06270602||Cohort B (Prospective):|All consecutive patients who enter in the ROC platform as for clinical practice from the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients).
89224222|NCT06270589|Experimental|A Single Bout Of Mindful High-Intensity Interval Training (Mindful HIIT)|
89224223|NCT06270589|Active Comparator|A Single Bout Of High-Intensity Interval Training (HIIT)|
89224224|NCT06270589|Active Comparator|A Single Bout Of Mindfulness|
89224225|NCT06270589|Other|A Single Bout Of Sitting Rest|
89224226|NCT06270576|Active Comparator|Asthma Group|Subjects diagnosed with one of the three asthma endotypes being studied (T2, T1, or T17).
89224227|NCT06270576|Active Comparator|Control Group|Subjects with no diagnosis of asthma or other respiratory disease and are deemed healthy.
89224228|NCT06270563|Active Comparator|Group A|They received postural advice and traditional exercise treatment (stretching and strengthening exercises) for 3 times per week for 12 weeks.
89224229|NCT06270563|Experimental|Group B|They received postural advice, traditional exercise treatment (stretching and strengthening exercises), and scapular stabilization exercises 3 times per week for 12 weeks.
89224230|NCT06270563|Experimental|Group C|They received postural advice, traditional exercise treatment (stretching and strengthening exercises), and high intensity laser therapy 3 times per week for 12 weeks.
89224231|NCT06270550|Experimental|Dynamic movement intervention based group.|
89224232|NCT06270550|Experimental|Selective physical therapy program based group.|
89224233|NCT06270524|Experimental|IgG4-RD patient|Patients suffering from Immunoglobulin G4-related disease (IgG4-RD).
89224234|NCT06270524|Experimental|patient in remission|Patients suffering from Immunoglobulin G4-related disease (IgG4-RD) but in remission.
89224235|NCT06270524|Other|healthy volunteers|
89073878|NCT05833776|Experimental|group I|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
89073879|NCT05832957|Experimental|Drive fun|The intervention will include 11 sessions and last 11-13 weeks. Seven intervention meetings will be individual sessions of one hour at the driving lab at Tel Aviv University and four 90-minute meetings will be group sessions (3-6 participants) and will be conducted remotely by Zoom. The parents will be present during the first and last individual sessions
89073880|NCT05832957|Experimental|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
89224236|NCT06270498|Active Comparator|Sucrosomial iron|
89224237|NCT06270498|Placebo Comparator|Placebo|
89224238|NCT06270485|Other|ventilated children|Application of different PEEP-levels during invasive mechanical ventilation
88820839|NCT05586802|Experimental|Group 1 (Fertility) - negative mTESE biopsy 1, then randomized to Arm B|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have negative sperm retrieval (no detectable spermatozoids), subsequently randomized to receive an hormonal stimulation for 26 weeks
89073881|NCT05832957|Other|No Intervention|one-time short guidance on safe driving at the end of the study.
89073882|NCT05830981||Phase 1|n=600
89073883|NCT05830981||Phase 2|n=504
89073884|NCT05822869|Experimental|EIT guided group|During prone ventilation, the PEEP level is adjusted based on EIT monitoring.
89073885|NCT05822869|Other|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
89073886|NCT05821244|Experimental|Morning Group|Participants must start their exercise between the hours of 5am and 10am.
89073887|NCT05821244|Experimental|Evening Group|Participants must start their exercise between the hours of 3pm and 8pm.
89073888|NCT05816616||COPD-TLD patients|COPD patients to be treated with Targeted Lung Denervation and enrolled in Airflow-3 clinical trial at Temple University Hospital, and which are also willing to participate in hyperpolarized xenon imaging of their lungs prior and poste TLD treatment.
89073889|NCT05809349|Experimental|DRE patients|There will be 50 drug-refractory epilepsy (DRE) patients in this study.
89073890|NCT05805475|Active Comparator|Endotracheal suctioning without expiratory pause|Conventional endotracheal suctioning in closed suction system
89073891|NCT05805475|Experimental|Endotracheal suctioning with expiratory pause|Endotracheal suctioning in closed suction system associated with expiratory pause maneuver
89073892|NCT05804825|Active Comparator|Simple forewarning message|Participants will receive a simple short forewarning message to read and rate.
89073893|NCT05804825|Experimental|Argument inoculation messages|Participants will view a random sample of 3 text-only short messages (from a corpus of 100 arguments) to read and rate.
89073894|NCT05798572|Experimental|Sildosin group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with the daily preoperative intake of 8 mg silodosin for one week.
89073895|NCT05798572|Experimental|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
89073896|NCT05795140|Experimental|Iptacopan 200 mg|Open label , single arm
89073897|NCT05792189|Active Comparator|Open reduction and internal fixation (ORIF) of distal femur fracture|Su Type 2 or 3 periprosthetic distal femur fractures about a total knee after undergoing ORIF for a minimum of 2 years
89073898|NCT05792189|Active Comparator|Distal femur replacement total knee arthroplasty (DFR) of distal femur fracture|Su Type 2 or 3 periprosthetic distal femur fractures about a total knee after undergoing DFR for a minimum of 2 years
89073899|NCT05781906|Experimental|HMPL-523|HMPL-523 Tablet 300 mg QD7 days followed by a single oral dose of [14C]HMPL-523 suspension
89073900|NCT05777005|Experimental|Intervention group|5A's/5R's advice+ Chatbot-led group support+ Counselor-led individual support+ health warning leaflet+ Self-help booklet
89073901|NCT05777005|Active Comparator|Control group|5A's/5R's advice+ Chatbot-led group support+ health warning leaflet+ Self-help booklet
89073902|NCT05771389|Active Comparator|Psoriatic arthritis|Patients meeting the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria
89073903|NCT05771389|Active Comparator|Axial spondyloarthritis|Patients meeting the ASAS classification criteria for axial spondyloarthritis
89073904|NCT05771389|Placebo Comparator|Healthy controls|Healthy people who do not have inflammatory conditions.
89073905|NCT05760261|Experimental|GSK3882347 and MDZ|Period 1: Participants will receive MDZ on Day 1. Period 2: Participants will receive 14-days of repeat dosing of GSK3882347 Followed by one dose of MDZ co-administered with GSK3882347 on Day 15.
89073906|NCT05759832|Experimental|Modified HFNC oxygen therapy group|
89073907|NCT05759832|Other|Face mask group|
89073908|NCT05756192|Experimental|Video and physician counseling arm|This groups will complete a pre survey and will then watch the 10-minute educational video on cervical cancer screening and prevention prior to seeing their provider. Patients will then see the provider and will complete a post survey following appointment.
89073909|NCT05756192|No Intervention|Physician counseling arm|This group will complete a pre survey and will then see their provider. Following provider visit patients will complete a post survey.
89073910|NCT05751915||PET CAV 0|Normal perfusion with normal global stress (> 1.7 mL/min/g)
89073911|NCT05751915||PET CAV 1|Normal perfusion with abnormal global stress MBF (<1.7 mL/min/g and ejection fraction >45%) OR Single vessel perfusion defect with normal global stress MBF.
89073912|NCT05751915||PET CAV 2/3|Normal perfusion with abnormal global stress MBF (<1.7 mL/min/g) and ejection fraction < 45% OR Single vessel perfusion defect with abnormal global stress MBF (<1.7 mL/min/g) OR Multivessel perfusion defects v
89224239|NCT06270459|Experimental|HMAN robot @ Home|4 weeks of daily HMAN robot training at participant's home (for up to 120 minutes per day with rest breaks) interspersed with 2 sessions of conventional therapy sessions (COTS) and 2 additional COTS upon completion of 4-week HMAN robot training at home.
89224240|NCT06270446|Other|Outpatient|Usual care, outpatient physiotherapy
89224241|NCT06270446|Active Comparator|CRC|Community based physiotherapy
89224242|NCT06270433|Experimental|Toludesvenlafaxine hydrochloride sustained-release tablets treatment group|
89224243|NCT06270433|Active Comparator|Desvenlafaxine succinate sustained-release tablets treatment group|
89073913|NCT05748730|Experimental|iCHART|"iCHART is an intervention that includes 3 components previously studied in within the ETUDES Center including a:~Safety Planning App for suicidal youth which enables a primary care provider to streamline the gold standard of care for those with current suicidality symptoms through an app (instead of a paper based version);~Mental Health Screener questionnaire that gathers additional mental health symptoms, treatment preferences, and family's readiness for treatment engagement to help primary care provider make a personalized, tailored treatment plan a suicidal youth is more likely to adhere to;~Text Messages which aims to provide texts for 2-3 weeks to motivate you to engage with the safety plan and recommended treatment following the patient visit.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
89073914|NCT05748730|Active Comparator|Treatment As Usual (TAU)|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
89073915|NCT05746377|Experimental|Metoclopramide|Given 10 mg Metoclopramide prior to Endoscopy
89073916|NCT05746377|Placebo Comparator|Placebo|Given saline flush prior to Endoscopy
89073917|NCT05744180|Other|Arm Not Applicable|
89073918|NCT05725798||DM and Sitagliptin treatment|Cardiac surgery patients who suffer from diabetes mellitus type 2 and take Sitagliptin.
89073919|NCT05725798||DM without Sitagliptin treatment|Cardiac surgery patients who suffer from diabetes mellitus type 2 and do not take Sitagliptin.
89073920|NCT05725798||No DM|Cardiac surgery patients who do not suffer from diabetes mellitus type 2 and do not take Sitagliptin.
89073921|NCT05725525|Other|Wearable Device Intervention|An open label, non randomized trial that requires all participants to wear a Garmin watch throughout the course of the trial (~12 weeks).
89073922|NCT05721157|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool.
89073923|NCT05721157|No Intervention|Control|Patients randomized to control will continue routine practice.
89073924|NCT05704296|Experimental|Y-composite grafting|The saphenous vein is anastomosed to the middle portion of the left internal thoracic artery as Y-composite fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
89073925|NCT05704296|Active Comparator|Aortocoronary grafting|The saphenous vein is anastomosed to the ascending aorta as aortocoronary fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.
89073926|NCT05699252|Active Comparator|Cognitive Behavioral Therapy (CBT) condition|Participants randomized to this arm will be taught about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
89073927|NCT05699252|Experimental|Hypnotic Cognitive Therapy (HYP-CT) condition|Participants randomized to this arm will be taught about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
89224244|NCT06270420|Experimental|HosmartAI training|HosmartAI training will consist of motor training provided by technological devices (i.e. OAK, VRRS, AMADEO, PABLO) in the HoSmartAI room.
89224245|NCT06270407|Active Comparator|Tranexamic acid arm|Anonymous ampoule containing 5 ml of 100 mg/ml Tranexamic Acid. If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
89224246|NCT06270407|Placebo Comparator|Placebo arm|Anonymous ampoule containing 5 ml of 0.9% NaCl. If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
89229964|NCT00387010|Experimental|fentanyl buccal tablets|Successful dose strength for each participant was determined during a titration period of no more than 10 days. Participants used the successful dose of 100, 200, 400, 600, or 800 mcg during the four week open-label treatment period.
89224247|NCT06270394|Experimental|68Ga-FAPI PET/MRI scan|"The 68Ge/68Ga generator was eluted with 0.1 M HCL solution to achieve 3.0 ml of liquid, which was mixed thoroughly with 20 µg FAPI precursor and 375 µl of 1.25 M sodium acetate. The mixture was placed in a thermostat at 95°C for 10 min. The finished liquid was passed through an activated Sep-pak 18C column and 0.8 ml of 80% ethanol was passed through the Sep-pak 18C column and a 0.2 µm microporous membrane (Pall Co., Ltd.) before the product was collected in a sterile product vial.~The equipment scan pf PET/MRI is the SIGNA PET/MR manufactured by GE Healthcare. The scan is performed approximately 40 min after injection of 1.85-3.7 MBq 68Ga-FAPI-04 per kg body weight. Breath-gated corrected step-and-shoot (SS) acquisition mode was used. The scan time was 60 ± 10 min (50-70 min). Dedicated T1- and T2-weighted images and diffusion-weighted images (DWI) of the head and neck, chest, abdomen, and pelvis were acquired."
89224248|NCT06270381|Experimental|Arm 1|Participants that receive EMPOWER intervention
89224249|NCT06270381|Active Comparator|Arm 2|Participants that receive treatment as usual (TAU) intervention
89224250|NCT06270342||MS|patients with multiple sclerosis
89224251|NCT06270342||Control|healthy volunteers
89224252|NCT06270329|Experimental|neuromuscular training program|Participants were administered the neuromuscular training program 60 min a day, 2 days a week for 8 weeks.
89224253|NCT06270329|Active Comparator|conventional physical therapy program|Participants were administered the conventional physiotherapy program 60 min a day, 2 days a week for 8 weeks.
89224254|NCT06270316|Experimental|Cohort 1|Cohort 1 - Dose level 1: 6.0 x 10e13 gc/kg - 3 Participants (plus additional 3 if needed to assess dose-limiting toxicity)
89224255|NCT06270316|Experimental|Cohort 2|Cohort 2 - Dose level 2: 3.0 x 10e14 gc/kg - 3 Participants (plus additional 3 if needed to assess dose-limiting toxicity)
89224256|NCT06270303|Experimental|Access flap + bone substitute|Furcation defect will be treated by access flap debridement followed by application of a bone substitute material.
89224257|NCT06270303|Active Comparator|Access flap|Furcation defect will be treated by access flap debridement alone.
89224258|NCT06270290||RBD group|Participants with a diagnosis of REM sleep behaviour disorder
89224259|NCT06270290||Control group|Participants without a diagnosis of REM sleep behaviour disorder
89224260|NCT06270264|Experimental|The NOL|The caregiver nurse assessed pain by NOL monitorization along with a pain assessment tool (CPOT) and applied one mcg/kg fentanyl if NOL >25 over one minute at the monitor.
89224261|NCT06270264|No Intervention|The Control|If CPOT values were still high, then one mcq/kg bolus of fentanyl at each time would be applied and repeated at five-minute intervals, if necessary, during care and 30 minutes after.
89224262|NCT06270251|Experimental|Study group|Youth ages 12-21 years with chronic tics will complete a course of 10 outpatient, weekly CBIT sessions with pre-, post-, 1-month and 3-month follow up assessments.
89224263|NCT06270225|Experimental|SSGJ-613 100 mg|Subjects will receive 100mg SSGJ-613 on Day 1.
89224264|NCT06270225|Experimental|SSGJ-613 200 mg|Subjects will receive 200mg SSGJ-613 on Day 1.
89224265|NCT06270225|Active Comparator|Colchicine 0.5mg|Subjects will receive 0.5mg/d Colchicine for 12 weeks.
89224266|NCT06270212|Active Comparator|STAIRWAY|Unpaired evaluation of STAIRWAY during induction of steady-state sedation in volunteer study participants (PART A), and during induction and maintenance of PS according to SOC in study patients (PART B).
89224267|NCT06270212|Other|NO DEVICE|Unpaired evaluation of NO DEVICE during induction of steady-state sedation in volunteer study participants (PART A), and during induction and maintenance of PS according to SOC in study patients (PART B).
89073928|NCT05699252|Experimental|Mindfulness-Based Cognitive Therapy (MBCT) condition|Participants randomized to this arm will be taught about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
89073929|NCT05699252|No Intervention|Usual Care (UC) Control Group condition|In the Usual Care condition, participants will not participate in a study treatment, but rather they will continue with their usual care for chronic pain and will complete the seven study assessment sets. At the end of the study, after the final 6-month follow-up assessment period, participants will be given the opportunity to receive any one of the three treatments that they would like as part of an open label phase of the study UNLESS participants have developed new problems that would make them ineligible.
89073930|NCT05683964|Experimental|Androgen Receptor Antagonist Monotherapy|"Participants will receive pre-determined doses of apalutamide, darolutamide, or enzalutamide per standard care.~Participants will undergo Prostate-Specific Membrane Antigen (PSMA) PET/CT scans at weeks 1 and 4."
89073931|NCT05678998|Experimental|WTX-330 dose escalation|Patients with relapsed/refractory advanced or metastatic solid tumors
89073932|NCT05678998|Experimental|WTX-330 dose expansion in patients for whom CPI therapy is indicated (Arm A)|WTX-330 dose expansion in patients with tumor types for which a CPI is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1-based regimen
89073933|NCT05678998|Experimental|WTX-330 dose expansion in patients for whom CPI therapy is not indicated (Arm B)|WTX-330 dose expansion in patients with tumor types for which a CPI is not indicated/ approved
89073934|NCT05638802|Experimental|DS-7011a|Participants with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) who will be randomized to receive DS-7011a 20 mg/kg every 4 weeks by intravenous infusion.
89073935|NCT05638802|Placebo Comparator|Placebo|Participants with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) who will be randomized to receive placebo every 4 weeks by intravenous infusion.
89073936|NCT05633888|Experimental|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
89073937|NCT05627869|Active Comparator|Transversus thoracic muscle plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
89073938|NCT05627869|Active Comparator|Pecto-intercostal fascial plane block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
89073939|NCT05625594|Experimental|Treatment (leukapheresis, CD19-CAR T cells)|Patients may undergo catheterization, undergo leukapheresis, may receive fludarabine IV and cyclophosphamide IV, and receive CD19-CAR T cells ICV on study. Patients also undergo MRI, PET, CT, collection of blood samples, and CSF aspiration throughout the trial, and lumbar puncture as clinically indicated.
89073940|NCT05622565||Training set|Multimodal ocular fundus images and corresponding reports collected from multiple screening sites in China.
89073941|NCT05622565||Internal Validation set|Records separated from the training set.
89073942|NCT05622565||External Test set|Multimodal ocular fundus images and corresponding reports collected from multi-centers in China and around the world.
89073943|NCT05618158|Experimental|4 Corners Rural Cancer Prevention|Four separate Facebook groups, which provide information via posts within the private groups about cancer risk factors (e.g. reducing alcohol consumption, tobacco use cessation, increasing physical activity), behavioral skills to reduce them, benefits of, social support for, and ways to reduce social/financial costs of cancer prevention, and advice from health care providers to decrease barriers. Posts will seek to improve self- and response-efficacy and perceived risk, and link cancer prevention to personal goals.
89073944|NCT05596695|Experimental|Intervention Group|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anesthesia.
89224268|NCT06270199|Active Comparator|Control|Standard cell therapy (control group)
89224269|NCT06270199|Experimental|Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions|Treatment: three infusions of MSC 5x10^6/Kg
89073945|NCT05596695|No Intervention|Standard of Care Group|Intraoperative blood pressure management will be performed according to local clinical standard of care.
89073946|NCT05590975|Experimental|Peer Supporter and Adult coach intervention|Intervention group will receive PACT module through peer supporters and adult coaches
89073947|NCT05590975|Experimental|Adult coach intervention|Intervention group will receive PACT module through adult coaches only
89073948|NCT05590975|No Intervention|Control Group|Control group will receive PACT intervention after the completion of intervention and evaluation with 1st PACT intervention arm.
89073949|NCT05576636|Experimental|Intervention group|After the pre-tests (the COVID-19 Disease Perception Scale, and the Fear of COVID-19 Scale) , the students were given simulation education for one months.
89073950|NCT05576636|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
89073951|NCT05549778|Experimental|Polaprezinc group|Patients will be on abiraterone plus polaprezinc (75 mg b.i.d. for 6 months)
89073952|NCT05549778|Active Comparator|Control group|Patients will be on abiraterone, radiotherapy or chemotherapy for 6 months
89073953|NCT05541796|Other|Contralateral implantation of Tecnis Synergy and Tecnis Symfony IOLs|Non-comparative study involving contralateral implantation of Tecnis Synergy and Tecnis Symfony IOLs.
89073954|NCT05535933|Experimental|HMPL-523|"Phase II: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 8 weeks and at least 16 weeks open-label treatment.~Phase III: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 24 weeks and enter open-label phase in the opinion of the Investigator."
89073955|NCT05535933|Placebo Comparator|Placebo|"Phase II: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 8 weeks and at least 16 weeks open-label treatment.~Phase III: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 24 weeks and enter open-label phase in the opinion of the Investigator."
89073956|NCT05513924|Active Comparator|Group A (topical latanoprost)|20 vitiligo patients will receive topical latanoprost solution (the concentration of the solution is 0.005%, pharmaceutically available eye-drop formulation)
89073957|NCT05513924|Active Comparator|Group B (topical 5-fluorouracil)|20 vitiligo patients will receive topical 5-fluorouracil 5% solution available as ampoules (Utoral®, EIMC United Pharmaceuticals, Egypt)
89073959|NCT05496062|Experimental|F&P Toffee Nasal and Toffee Nasal Pillows Mask|Participants will be placed in the experimental arm for 14 days, during which they will be using either the Toffee Nasal or Toffee Nasal Pillows mask for PAP therapy.
89073960|NCT05470205|Experimental|Reproducibility - Cohort 1|"Patients scheduled for hepatic venous pressure gradient (HVPG) measurements will subsequently undergo two consecutive SHAPE procedures using different ultrasound contrast agents (Definity and Sonazoid in randomized order) to estimate portal pressures with a Logiq E10 scanner (GE Healthcare).~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.~Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min."
89073961|NCT05470205|Experimental|HCC monitoring - Cohort 2|"Patients identified as having CSPH will be monitored every 6 ± 2 months to check for HCC by SHAPE with Sonazoid for the duration of this project ( for 18-24 months on average).~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min."
89073962|NCT05470205|Experimental|New β-blockers - Cohort 3|Patients newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
89073963|NCT05470205|Experimental|Ccreening for varices - Cohort 4|"Patients with compensated advanced chronic liver disease scheduled for an endoscopy examination for screening of varices according to the Baveno VI or the expanded-Baveno VI criteria as well as the AST to Platelet Ratio Index and FIB-4 will undergo a SHAPE examination.~Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min."
89073964|NCT05463835|Experimental|RubusElite dairy beverage|The active treatment is a novel beverage, which has been formulated and developed by food Scientists at UCC. The RubusElite beverage is a science-led formulation of blackberry puree and high protein milk.
89073965|NCT05463835|Active Comparator|'Protein rich' dairy beverage|The high protein dairy beverage will be a commercially available high protein milk which is commercially produced.
89073966|NCT05463835|Sham Comparator|'Low Protein' dairy beverage|The control beverage will be commercially available Taranis Dalia liquid commercially available low protein milk which will be purchased from the manufacturer for use in this study.
89073967|NCT05451979|Experimental|MedBIKE HIIT|Participants will complete the baseline assessments and begin the MedBIKE HIIT Exercise Program intervention within 2-weeks. After the completion of the 12-week program, participants will return for follow-up assessments which will be repeated at 6- and 12-months post intervention.
89073968|NCT05451979|No Intervention|Standard of Care|Participants will complete the baseline assessments and continue with standard of care (no intervention) for 12-weeks then return for a repeat assessment. Participants will then crossover into the MedBIKE HIIT Exercise Program intervention group for 12-weeks. A post-intervention assessment will be completed and follow-up assessments at 6- and 12-months post intervention.
89073969|NCT05447416|Active Comparator|Hyperbaric Oxygen Therapy - HBOT|The protocol comprises of 40 consecutive hyperbaric oxygen treatment (HBOT) sessions, 5 sessions per week within a two months' period. The HBOT group will train for 60 minutes after the HBOT sessions, 3 times per week, in a normobaric normoxic environment according to individualized training protocol
89073970|NCT05447416|Active Comparator|Intermittent Hypoxic Training - IHT|The protocol comprises of 24 consecutive Intermittent Hypoxic Training (IHT) sessions, 3 sessions per week within a two months' period. Subjects will train according to individualized training protocol.
89073971|NCT05444777|Experimental|Ketamine group (Group K)|Group K was given ketamine @ 0.5mg/kg (prepared by dilution in 0.9% normal saline in 10 ml syringe) at the time of wound closure.
89073972|NCT05444777|Other|Saline group (Group S)|Group S was given saline in 10 ml syringe
89073973|NCT05433961|Experimental|Hyperpolarized Xenon MRI assessment of lung function in endobronchial valve treated COPD patients|Volunteer patients scheduled for receiving endobronchial valve treatment as part of clinical care will be imaged with hyperpolarized xenon prior and post EBV for assessing lung function and improvement.
89073974|NCT05429411|Experimental|Gel treated scar|Gel treated scar
89073975|NCT05429411|No Intervention|Control scar|No intervention, standard of care
89073976|NCT05423613|Experimental|Microneedling treated scar|Microneedling
89073977|NCT05423613|No Intervention|Control scar|No intervention, standard of care
89073978|NCT05421130|Other|SP-GRIPFLOW|This is a single-arm clinical investigation. Enrolled subjects will have cerebral perfusion with the investigational device during surgical repair of the aortic arch. A total of 1-3 investigational devices will be used per subject.
89224270|NCT06270199|Experimental|Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions|Treatment: six infusions of MSC 5x10^6/Kg
89224271|NCT06270186|Other|Type 1 myotonic dystrophy|"Type 1 myotonic dystrophy patients doing classical neuropsychological test and on Good Diag NMD software"
89224272|NCT06270173|Experimental|Intervention|Tripod-Fix will be used to treat osteoporotic vertebral compression fractures.
89224273|NCT06270147|Experimental|Early TAP block|Patients in this group will receive TAP blocks at the beginning of the procedure
89224274|NCT06270147|Active Comparator|Late TAP block|Patients in this group will receive TAP blocks at the end of their procedure, which is the current standard practice.
89224275|NCT06270134|Active Comparator|Lower dialysate bicarbonate concentration (32 versus mmol/L)|Patients at each dialysis unit will be randomly allocated into one of two study arms in a 1:1 ratio to receive a dialysate bicarbonate concentration of 32 mmol/L.
89224276|NCT06270134|Active Comparator|Higher dialysate bicarbonate concentration (38 mmol/L)|Patients at each dialysis unit will be randomly allocated into one of two study arms in a 1:1 ratio to receive a dialysate bicarbonate concentration of 38 mmol/L.
89224277|NCT06270121|Experimental|Living-lab digital intervention group|Digital devices (wearable and motion sensor) and mobile application will be utilized to monitor mental and physical health status and provide daily individualized health status information to an older adult user and their community and family caregivers. The older adult users are also asked to participate in pre-mid-post surveys to evaluate health, usability, effectiveness, and safety of the developed platform service.
89224278|NCT06270121|No Intervention|Control group|The participated in the control group are asked to participate in pre-mid-post surveys to evaluate health status.
89224279|NCT06270095||Exposed|Aircrew exposed to a fume event
89224280|NCT06270095||Non-exposed|Aircrew not exposed to a fume event but present on a control flight
89224281|NCT06270056||early medication abortion via telemedicine|Medication abortion up to 84 days gestation using misoprostol alone regimen consisting of three doses 800mcg (4 tablets of 200mcg misoprostol each) taken every 3 hours. An extra dose (800mcg) may also be taken if there was no bleeding after administering the earlier doses.
89224282|NCT06270017|Experimental|Colon cancer|Tumour tissue from each patients tumour will be implanted in zebrafish embryos and evaluated regarding growth and response to chemotherapy
89224283|NCT06270004|Active Comparator|nonsmoker periodontitis patients|
89224284|NCT06270004|Active Comparator|smoker periodontitis patients|cigarette smoker more the three years ago
89224285|NCT06269991||bow category|the athletes using recurve bow or compound bow will investigating.
89224286|NCT06269978|Experimental|Treatment (oxaliplatin, 5FU)|Patients undergo placement of indwelling IP port for chemotherapy infusion. Patients receive oxaliplatin and 5FU over 1-2 hours via IP infusion on days 1 and 15 of each cycle. Cycles repeat every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo diagnostic laparoscopy, biopsy, CT/MRI, and collection of blood samples at screening and on study and undergo collection of IP fluid samples on study.
89224287|NCT06269939|Experimental|Experimental group|The experimental group will receive memory techniques training administered twice a week for four weeks (8 training sessions).
89224288|NCT06269939|Placebo Comparator|Control group|The control group will receive memory exercises administered twice a week for four weeks (8 sessions).
89224289|NCT06269900|Experimental|dexamethasone + standard of care|"Dexamethasone 0.2mg.kg-1.day-1 intravenous for a minimal duration of 5 days, and a maximal duration of 7 days in case of persistence of ARDS criteria (PaO2/FiO2 ratio < 200).~Standard of care: antimicrobial therapy in compliance with European guidelines. Briefly, intravenous antimicrobial therapy with the narrowest spectrum to cover at-risk and/or identified pathogens for 7-8 days."
89224290|NCT06269900|Placebo Comparator|Placebo + Standard of care|"Placebo 0.2mg.kg-1.day-1 intravenous for 5 days and a maximal duration of 7 days in case of persistence of ARDS criteria (PaO2/FiO2 ratio < 200).~Standard of care: antimicrobial therapy in compliance with European guidelines. Briefly, intravenous antimicrobial therapy with the narrowest spectrum to cover at-risk and/or identified pathogens for 7-8 days."
89224291|NCT06269861|Other|inward patients|The inward patients who will be weighed with bathroom scale and patient transfer scale
89224292|NCT06269861|Other|critically ill patients|The critically ill patients who will be weighed with patient transfer scale
89224293|NCT06269822||Cases|Group-1: Patients with TLE of both genders and aged > 18 years old
89224294|NCT06269822||Controls|Group-2: Age/gender matched healthy controls
89224295|NCT06269809|Experimental|Temporary artery clipping|Patients undergoing a robotically-assisted myomectomies, with temporary clipping of the uterine arteries and the utero-ovarian ligmants.
89224296|NCT06269809|Active Comparator|Control|Patients undergoing a robotically-assisted myomectomies, without temporary clipping of the uterine arteries and the utero-ovarian ligmants.
89224297|NCT06269796||Preschool Children|A prospective study was conducted, aiming at the early detection of neuromotor signs in preschool children with suspected Developmental Coordination Disorder (DCD) in Greece.The Little Developmental Coordination Disorder Questionnaire (LDCDQ) was used to evaluate motor skills of the children. Children with scores that indicated suspicion of DCD were offered the option to undergo the BOT-2 test.
89224298|NCT06269757|Experimental|Individualized Exercise Program|"Patients with diagnosed ITB syndrome indicated for non-operative management who are assigned to an individualized exercise program.~Duration of therapy will be approximately 3 months. Patients will be followed for 6 months to assess longitudinal outcomes."
89224299|NCT06269757|Active Comparator|Standard Physical Therapy|"Patients with diagnosed ITB syndrome indicated for non-operative management who are assigned to receive standard physical therapy.~Duration of therapy will be approximately 3 months. Patients will be followed for 6 months to assess longitudinal outcomes."
89229965|NCT01092091|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
89229966|NCT01092169||Sickle cell beta|
89073979|NCT05410821|Experimental|177Lu-DOTA-EB-FAPI 1|177Lu-DOTA-EB-FAPI A maximum of 2 cycles of 60 mCi (2.22 GBq) 177Lu-DOTA-EB-FAPI, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 2 cycles, every 6 weeks
89073980|NCT05410821|Experimental|177Lu-DOTA-EB-FAPI 2|177Lu-DOTA-EB-FAPI A maximum of 2 cycles of 90mCi (3.33 GBq) 177Lu-DOTA-EB-FAPI, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 2 cycles, every 6 weeks
89073981|NCT05410821|Experimental|177Lu-DOTA-EB-FAPI 3|177Lu-DOTA-EB-FAPI A maximum of 2 cycles of 135 mCi (4.99 GBq) 177Lu-DOTA-EB-FAPI, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 2 cycles, every 6 weeks
89073982|NCT05410743|Experimental|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
89073983|NCT05410743|Experimental|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
89073984|NCT05410743|Experimental|177Lu-LNC1010 3|The patients were intravenously injected with single dose 5.18 GBq (140mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
89073985|NCT05408546|Placebo Comparator|Placebo|Placebo + standard of care (SOC) anticoagulation
89073986|NCT05408546|Experimental|Low dose TS23|TS23 low dose + SOC anticoagulation
89073987|NCT05408546|Experimental|Intermediate dose TS23|TS23 medium dose + SOC anticoagulation
89073988|NCT05408546|Experimental|Higher dose TS23|TS23 highest dose + SOC anticoagulation
89073989|NCT05402579||Cases|Patients with type 2 diabetes mellitus who were hospitalized with SGLT2 inhibitor-associated DKA
89073990|NCT05402579||Controls|There are two sources for controls. [1] Patients hospitalized at one of the participating hospitals who were on an SGLT2i and do not have DKA. [2] Population controls using publicly available data from the Canadian Longitudinal Study on Aging (CLSA) database.
89073991|NCT05388526||Parkinson|"Patients with a diagnosis of PD or secondary parkinsonism belonging to the Health Area V of the Health Service of the Principality of Asturias, Spain.~Patient origin: Rehabilitation Service Instituto de Rehabilitación Astur S.A. and Asociación de Parkinson Jovellanos, from Gijón, Asturias, Spain."
89073992|NCT05384431|Active Comparator|Muscle5 and TRIM7|"MUSCLE5 and TRIM7 natural health product supplementation~Name of natural health product (brand name, generic) - MUSCLE 5, chocolate Is this a market-approved natural health product (per Health Canada)? - Yes Dose - 1 scoop Ingredients (per dose) - Whey protein isolate (24g), milk protein isolate (16g), Creatine (3g), Calcium (450mg), Vitamin D (1000 IU) Frequency of administration - Once/day Duration (e.g., six weeks) - 12 weeks Route of administration - Oral~Name of natural health product (brand name, generic) - TRIM7 Is this a market-approved natural health product (as per Health Canada)? Yes Dose - 3 capsules Ingredients (per dose) - Alpha lipoic acid (200mg), CoEnzyme Q10 (100mg), beet root extract (250mg), green coffee bean extract (250mg), green tea extract (250mg), forskolin (25mg), Vitamin E (22 mg AT) Frequency of administration - Twice/day Duration (e.g., six weeks) - 12 weeks Route of administration - Oral"
89073993|NCT05384431|Placebo Comparator|Placebo|"Placebo collagen and microcrystalline cellulose intake~Placebo Control 1 (Counter to MUSCLE5) Dose - 1 scoop Ingredients (per dose) - Collagen (40g) Frequency of administration - once/day Duration - 12 weeks Route of administration - Oral~Placebo Control 2 (Counter to TRIM7) Dose - 3 capsules Ingredients (per dose) - Microcrystalline cellulose (400 mg) Frequency of administration - twice/day Duration - 12 weeks Route of administration - Oral"
89073994|NCT05355168|Experimental|Neoadjuvant treatment|Neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab
89073995|NCT05352542|Experimental|LCAR-H93T Cells|Each subject will receive LCAR-H93T cells
89073996|NCT05342337|Experimental|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management."
89073997|NCT05342337|Active Comparator|Control Group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
89073998|NCT05340868|Experimental|Semaglutide (oral)|In this study, each participant will receive a regimen of oral semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for a duration of twelve weeks. The dosage will begin at 3 mg/day for weeks 1-2, gradually increasing to 7 mg/day for weeks 3-4, 14 mg/day for weeks 5-6, 28 mg/day for weeks 7-8, and finally, to 42 mg/day for the last four weeks (weeks 9-12).
89073999|NCT05330130|Active Comparator|Daily 150 IU recFSH|Follitropin beta injection 150 IU daily
89074000|NCT05330130|Active Comparator|Daily 300 IU recFSH|Follitropin beta injection 300 IU daily
89074001|NCT05326711|Experimental|Telerehabilitation-based motor imagery training|"The first 2 weeks of the treatment period, will reserved for implicit motor imagery / lateralization training. It will be performed by the noi group application application that can be downloaded to the participants' mobile devices. Participants will be asked to use the app 3 times a day. In each application session, the right / left discrimination of the region in the photograph will be requested within 5 seconds and 30 photographs will be shown for each painful region. Each session will last 2-3 minutes on average. For 3rd to 8th weeks of the treatment period telehabilitation-based motor imagery training will be given to the participants individually, in synchronization, using the Google Meet videoconference platform, under the guidance of a physiotherapist. The duration of the sessions will last 20-30 minutes."
89074002|NCT05326711|No Intervention|Control|No specific intervention
89074003|NCT05323981|Experimental|HS627(210mg/7ml)|
89074004|NCT05323981|Experimental|HS627(420mg/14ml)|
89074005|NCT05323981|Active Comparator|PERJETA|
89074006|NCT05319860|Active Comparator|Standard of Care With No Study Intervention|Participants will receive standard medical care, consisting of antiemetic medicine at the first sign of Chemotherapy-Induced Nausea and Vomiting (CINV) on a schedule as prescribed by the healthcare provider.
89074007|NCT05319860|Experimental|Standard of Care With Study Intervention|Participants will receive an aromatherapy inhaler for complementary in addition to their standard of care antiemetic medication for Chemotherapy-Induced Nausea and Vomiting (CINV).
89074008|NCT05311475|Experimental|Mometasone + Azelastine|Mometasone + Azelastine (50 + 140 mcg per actuation)
89074009|NCT05311475|Active Comparator|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
89074010|NCT05311475|Active Comparator|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
89074011|NCT05311475|Placebo Comparator|Placebo|Placebo nasal spray
89074012|NCT05309226||Pregnant Cannabis User|"Pregnant individuals who disclose cannabis use in pregnancy~We will examine patterns of cannabis use including the type of cannabis used, amount and frequency of cannabis use during the perinatal and postpartum periods. If participant decides to stop using cannabis in pregnancy, they will not be excluded from the study."
89074013|NCT05309226||Pregnant Cannabis Non-User|Pregnant individuals who report not using cannabis in pregnancy and who have not used cannabis products for at least 3-months prior to pregnancy.
89074014|NCT05309226||Offspring of Pregnant Cannabis User|Infants born to pregnant participants who disclose cannabis use in pregnancy
89074015|NCT05309226||Offspring of Pregnant Cannabis Non-User|Infants born to pregnant participants who report no cannabis use in pregnancy
89074016|NCT05309226||Partners|Partners of pregnant participants enrolled in this study.
89074017|NCT05294549|Experimental|Caring Contact|
89074018|NCT05292781|Experimental|CHOICES|Experimental arm: receives the web-based reproductive education for individuals with sickle cell disease or sickle cell trait
89074019|NCT05292781|Sham Comparator|eBook (electronic-Book)|Control arm with eBook education focused on sickle cell disease and sickle cell trait.
89074020|NCT05292599|Experimental|Supervised|All participants in this arm will receive physiotherapy treatment that includes craniocervical flexion exercise (CCFE), isometric flexion exercises (IFE), isometric extension exercises (IEE), self-resistance exercise for neck flexion and extension (RFE), self-resistance exercise for neck rotation (RRE), midscapular exercise (ME) in 2 sessions for week, 60 minutes each, for 8 weeks. CCFE will focus on the recruitment of the deep cervical flexor muscles and will be performed from lower to higher complexity. Each of the exercises will be for 3 sets of 10 repetitions with 10 seconds of isometric contraction during the 8 weeks. IFE and IEE consist of 3 sets of 8 repetitions with 6 seconds of isometric contraction, for 6 weeks. For self-resistance exercises, the patient performs RFE and RRE. These exercises will be performed with 3 sets of 8 repetitions with 6 seconds of isometric contraction during the 8 weeks. The ME will be performed in 3 sets of 8 repetitions during the 5 weeks.
89074021|NCT05292599|Active Comparator|No supervised|The participants will perform the same exercises as the supervised group. However, in this arm will be instructed to perform the same exercises as the experimental group at home, without any supervision. These instructions will be given by the physiotherapist through videos and/or photos.
89074025|NCT05255666|Experimental|Pembrolizumab + Liposomal Irinotecan|"400 mg of pembrolizumab intravenously on Day 1 of each Cycle (Cycle is 42 days)~50 mg/m^2 of liposomal irinotecan (Nal-IRI) intravenously every 2 weeks of each Cycle (Cycle is 42 days)"
89074026|NCT05255146|Experimental|Intervention Group: Cryoanalgesia|Patients receiving cryoanalgesia peri-operatively during minimally invasive cardiothoracic surgery
89074027|NCT05255146|No Intervention|Control Group: No Cyroanalgesia|Patients receiving minimally invasive cardiothoracic surgery who do not receive cryoanalgesia.
89074028|NCT05252728||Healthy control|
89074029|NCT05252728||Childhood-onset type 1 diabetes|
89074030|NCT05252728||Adult-onset type 1 diabetes|
89074031|NCT05252728||Type 2 diabetes|
89074032|NCT05247541|Active Comparator|Healthy Participants|
89074033|NCT05247541|Experimental|Study participants|
89074034|NCT05199259||HCC positive Group|Multi-analyte blood test screen in participants with a recent confirmed untreated diagnosis of HCC by CT scan, MRI or biopsy.
89229967|NCT03960385||Hospitalized and controls|Age-matched case of hospitalized dengue and non-dengue control
89224302|NCT06269718|Experimental|The IOPI group|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength
89224303|NCT06269718|Active Comparator|The general swallowing group|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
89224304|NCT06269705|Experimental|ZILRETTA|100 subjects will receive 32 mg ZILRETTA
89224305|NCT06269705|Active Comparator|TCA-IR|100 subjects will receive 40 mg TCA-IR
89224306|NCT06269705|Placebo Comparator|Placebo|50 subjects will receive normal saline placebo
89224307|NCT06269692|Experimental|Implantable Loop Recorder|Patients identified at very low-risk of VT/VF randomized to be implanted with an ILR (experimental strategy). Following randomization, these patients will be followed using remote ILR monitoring.
89224308|NCT06269692|Other|Implantable Cardioverter Defibrillator|Patients identified at very low-risk of VT/VF randomized to be implanted with an ICD (reference strategy), which corresponds to the currently recommended treatment in post-MI patients with a LVEF ≤35% (European Society of Cardiology guidelines 2015) (Zeppenfeld et al., 2022).
89224309|NCT06269679|No Intervention|OPT|Orthopantomogram = current recommended clinical examination approach (comparator procedure)
89224310|NCT06269679|Experimental|CBCT|Cone Beam Computed Tomography = experimental clinical examination approach (procedure under evaluation)
89224311|NCT06269666|Other|Imaging Session|Various scans will be captured
89224312|NCT06269614|Experimental|Probiotic Treatment|Pediatric Probiotic Treatment
89224313|NCT06269614|No Intervention|No Probiotic Treatment|No intervention
89224314|NCT06269588|Experimental|Endoscopic hemostasis using Nexpowder|Subjects with non variceal upper GI bleeding will undergo nndoscopic hemostasis using Nexpowder as primary treatment
89224315|NCT06269575|Experimental|experimental|safe nutrition arm
89224316|NCT06269575|No Intervention|control arm|control arm
89224317|NCT06269562|Experimental|Block|consists of 5 patients in whom both techniques were applied
89224318|NCT06269536|Experimental|Heart-rate variability (HRV) biofeedback intervention + standard of care|Deep paced breathing with the HRV monitoring performed three times a day for seven minutes during three months with standard of care.
89224319|NCT06269536|No Intervention|Standard of care|Gemcitabine 1000 mg/m2 + Cisplatin 70 mg/m2 day 1 (new course day 22) or Methotrexate 30 mg/m2 day 1, Doxorubicin 30 mg/m2 day 2, Vinblastine 3 mg/m2 day 2, Cisplatin 70 mg/m2 day 2 with Pegfilgrastim 6 mg s.c. day 4 (new course day 15) up to 4 courses followed by radical cystectomy or irradiation with cisplatin 70 mg/m2 weekly.
89224320|NCT06269523|Active Comparator|Treatment group|18 sessions of functional and proprioceptive re-education, manual lymphatic drainage associated with kinesio taping.
89224321|NCT06269523|Active Comparator|Control group|18 sessions of functional and proprioceptive re-education and manual lymphatic drainage.
89224322|NCT06269497|Experimental|Scaffold|After tooth extraction will one scaffold be placed in the extraction alveola, covered by a membrane and then covered by the gingival tissue.
89224323|NCT06269471||Trailers|Group of major trail runners who have already taken part in at least one trail running competition in their lives.
89229968|NCT03960385||Outpatient and controls|Age-matched dengue case and non-dengue control
89229969|NCT00386776|Experimental|'Computer-based medical history|A computer-based medical history to take in their homes via the Internet. The history is divided into 24 modules- family history, social history, cardiac history, pulmonary history, and the like.
89074035|NCT05199259||HCC negative Group: Sub-Group 1|Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by CT or MRI (No lesion, LR-1 or LR-2)
89074036|NCT05199259||HCC negative Group: Sub-Group 2|Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by ultrasound. Participants will be scheduled for a 6 month visit (at least 5 months but no more 9 months form enrollment) for a confirmatory ultrasound.
89074037|NCT05198609|Experimental|Camrelizumab, Apatinib Plus FOLFOX-HAIC|
89074038|NCT05198609|Active Comparator|Camrelizumab and Apatinib|
89074039|NCT05191004|Experimental|Phase 1b Dose Escalation|"NUV-422 will be administered orally at escalating dose levels in combination with fulvestrant until the recommended Phase 2 combination dose (RP2cD) is determined.~500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter."
89074040|NCT05191004|Experimental|Phase 2 NUV-422 + fulvestrant|"NUV-422 will be administered orally at the RP2cD in combination with fulvestrant.~500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter."
89074041|NCT05191004|Experimental|Phase 2 NUV-422 monotherapy|NUV-422 will be administered orally at the RP2cD.
89074042|NCT05191004|Experimental|Phase 2 fulvestrant monotherapy|500 mg fulvestrant will be administered IM on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter.
89074043|NCT05190926|Experimental|Smart Treatment for Anorexia Nervosa Recovery (STAR) app|STAR incorporates elements from the Unified Protocol and Acceptance and Commitment Therapy to reduce emotion avoidance and improve disordered-eating behaviors and negative emotions. Participants will complete 1-2 weekly modules in STAR for 12 weeks. During this time, participants will continue working with their outpatient therapist. Outcome and target engagement measures will be assessed daily or weekly within the STAR app. Participants will complete additional measures of outcome and target engagement at 3-months and 6-months after treatment. Parents will be asked to complete outcome measures at baseline, 12 weeks, 3-months, and 6-months.
89074044|NCT05190926|Placebo Comparator|Present-focused Anorexia Nervosa Coping Treatment (PACT) app|PACT is an adapted form of Present-Centered Therapy and focuses on daily life stressors, problems, and concerns that may impact AN. Participants will complete 1 weekly module in Weeks 1, 2, and 12 and complete a Daily Diary of life stressors thereafter for 9 weeks. During this time, participants will continue working with their outpatient therapist. Outcome and target engagement measures will be assessed daily or weekly within the PACT app. Participants will complete additional measures of outcome and target engagement at 3-months and 6-months after treatment. Parents will be asked to complete outcome measures at baseline, 12 weeks, 3-months, and 6-months.
89074045|NCT05144347|Experimental|XL114 Dose-Escalation Cohorts|Subjects (Cohort A1-An) will accrue in cohorts of 3-12 subjects in a i3+3 design.
89074046|NCT05144347|Experimental|XL114 Expansion Cohorts|The recommended dose from the Dose-Escalation stage, will be used in subjects with activated B-cell-like diffuse large B-cell lymphoma [ABC-DLBCL] (Cohort B), mantle cell lymphoma [MCL] (Cohort C), chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL] (Cohort D). Subjects will also be enrolled in a Biomarker cohort (Cohort E).
89074047|NCT05132881|Active Comparator|Transcutaneous Auricular Vagal Nerve Stimulation Intervention Group Distressed Healthcare Workers|"Two subgroups will be included in fMRI in the Active Comparator Group where scans performed during the initial evaluation period (pre) and at 3 months (post). Subgroup I of 30 subjects will undergo fMRI scans that will include structural imaging and functional imaging with Blood Oxygen Level Dependent Imaging (BOLD) scan and two arterial spin labeling (ASL) scans. This same imaging protocol, which takes a total of about 45 minutes, will be performed initially and then after the 3 month TaVNS program or the waitlist period. All scans will be co-registered and comparable slices of the cerebral cortex will be examined.~Subgroup II will consist of 10 study subjects all receiving the TaVNS program who will undergo fMRI initially and then again at 3 months. This group will be scanned while wearing the TaVNS system (a special one that can be used in the MRI environment) and the fMRI will be used to evaluate the direct effects of the TaVNS while turned on and off in the scanner."
89074048|NCT05132881|Active Comparator|Waitlist Control Distressed Healthcare Workers Delayed TaVNS Group|After baseline and 3 month imaging is completed. The waitlist control subgroups will be included in fMRI scans performed during the initial evaluation period (pre) and at 3 months (post). Subgroup I of 30 subjects will undergo fMRI scans that will include structural imaging and functional imaging with Blood Oxygen Level Dependent (BOLD) scan and two arterial spin labeling (ASL) scans. a typical morning waking up). This same imaging protocol, will be performed initially and then after the 3 month waitlist period. All scans will be co-registered and comparable slices of the cerebral cortex will be examined. After the waitlist imaging is completed the subjects will be offered the TaVNS health device.
89074049|NCT05132881|Other|Healthy Controls: Group II and III|The Investigators will also plan to recruit 10 healthy controls with no reports of psychological distress (i.e. less than 2 on the SUDS). These 10 healthy controls will have the TaVNS placed while receiving two fMRI scans approximately 3 months apart. These control subjects will be used to compare the subgroup of study subjects to ensure that any changes are not associated with test-retest effects.the Investigators also plan to recruit 50 additional healthy controls with no reports of psychological distress (i.e. less than 2 on the SUDS.) These 50 controls will have the TaVNS placed while receiving one fMRI scan sequence in one day while wearing a non-metalllic set of the TaVNS ear buds to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device.
89074050|NCT05128461|Experimental|Exercise Group|The group will receive modified-Constraint Induced Movement Therapy via telerehabilitation and a home exercise program.
89074051|NCT05128461|Active Comparator|Control group|The group only will be given a home exercise program.
89074052|NCT05111145|Experimental|ELX/TEZ/IVA|Participants received ELX 200 mg once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for up to 36 weeks.
89074053|NCT05101824|Other|Single arm|All recruited patients are treated with SABR.
89074054|NCT05095272|Experimental|Healthy malaria-naive US adults|A single dose of cryopreserved inoculum containing blood-stage P. vivax will be administered IV
89074055|NCT05064826|No Intervention|Standard visit|Participants will have standard Emergency Department visit as per standard operating procedures which should last approximately 3 -5 hours.
89074056|NCT05064826|Experimental|Extended visit with Observation|Participants will have extended Emergency Department visit by having an observation (which could be up to 23 hours) time in addition to the standard ED visit. In addition, information will be gathered about about the participants, use of opioids, healthcare visits, the quality of health, life, and treatment, and other topics. Urine or saliva or both may also be collected.
89074057|NCT05050864|Active Comparator|internal ventricular shunt (neurosurgery)|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
89074058|NCT05050864|Active Comparator|endovacascular stenting (interventional neuroradiology)|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid.
89074059|NCT05042921||DMT Treated Participants|Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 60 months and the available data is collected retrospectively.
89074060|NCT05042921||Untreated Participants|Participants with SMA who received no treatment will be followed prospectively for up to 60 months.
89074061|NCT05032755|Experimental|VLNC Group|Participants in this condition will be provided with Spectrum NRC102/103 (nonmenthol/menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco with reported nicotine yield (ISO) of 0.03 +/- 0.01 mg and a tar yield of 9 +/- 1.5. Participants will be asked to smoke only study cigarettes for 4 weeks.
89074062|NCT05032755|Active Comparator|NNC Group|Participants in this condition will be provided with Spectrum NRC600/601 (non-menthol/menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco with reported nicotine yield (ISO) of 0.8 +/- 0.15 mg and a tar yield of 10.5 +/- 1.5.
89074063|NCT05023980|Experimental|Arm A (Pirtobrutinib)|Pirtobrutinib administered orally
89074064|NCT05023980|Active Comparator|Arm B (BR)|Bendamustine plus rituximab administered intravenously (IV)
89229970|NCT01092247|Placebo Comparator|Standard diet: Nutritional support|
89074065|NCT05007522|Experimental|Study Drug|Ketotifen 2 mg administered in tablet form twice a day (every 12 hr). Indomethacin sustained-release (SR) 75 mg, twice a day (every 12 hr). Patients will be administered 28 doses in total of ketotifen/indomethacin combination.
89074066|NCT05007522|Placebo Comparator|Placebo|Placebo pills matching in appearance to study drug twice a day for 28 doses total.
89074067|NCT05004012|Other|Control|No diagnosis of gastroparesis, functional dyspepsia, or prior G-POEM
89074068|NCT05004012|Other|Gastroparesis|Patients with a diagnosis of gastroparesis meeting the inclusion criteria
89074069|NCT05004012|Other|Functional Dyspepsia|Patients with a diagnosis of functional dyspepsia meeting the inclusion criteria
89074070|NCT05004012|Other|G-POEM|Patients who received a G-POEM procedure meeting the inclusion criteria
89074071|NCT05003349|Experimental|Experimental group|Occlusal Splint (OS) + Pain Neuroscience Education (PNE) + Motor Imagery (MI) + Action Observation (AO) + Jaw and Neck Exercises (JNE) All participants in this arm will receive OS (they must use every night during the study) and will receive physiotherapy treatment including PNE, MI, AO and JNE, in 2 sessions per week, each lasting 60 minutes, during 5 weeks. For PNE a power-point presentation with metaphors, images and videos will be employed. For the MI, the participants will be asked to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The AO will be carried out using videos of mandibular and cervical exercises. The JNE program will be performed 3 sets of 10 repetitions. The exercises will be executed with a total time per session of 20 minutes, initially at the clinic and later at home.
89074072|NCT05003349|Active Comparator|Active comparator|"Occlusal Splint (OS) + Counselling + Jaw and Neck Exercises (JNE). All participants in this arm will receive OS and will receive physiotherapy treatment including Counselling and JNE, in 2 sessions per week, each lasting 40 minutes, during 5 weeks. The JNE will be administered in the same way as in the other arm of the study.~Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth)."
89074073|NCT04971278||HealthFirst Intervention|Patients attributed to HealthFirst who will receive the intervention
89074074|NCT04971278||HealthFirst Control|Patients attributed to HealthFirst who will not receive the intervention
89074075|NCT04971278||Mortality Model Intervention|Patients who are identified as High Risk by the mortality predictive model and who receive the intervention.
89074076|NCT04971278||Mortality Model Control|Patients who are identified as High Risk by the mortality predictive model and who do not receive the intervention.
89074077|NCT04957537|Other|6 weeks phase A|"According to SCED methodology design :~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 weeks (i.e. 18 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
89074078|NCT04957537|Other|8 weeks phase A|"According to SCED methodology design :~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 8 weeks (i.e. 24 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
89074079|NCT04953000||All Participants|Male participants with severe or moderate hemophilia A who have been treated with FVIII concentrate octocog alfa (Advate) during at least 12 months prior to the study enrollment, who started octocog alfa treatment in 2021 or currently being treated with octocog alfa will be observed in this study.
89074080|NCT04952779||Xultophy®|Korean adults with type 2 diabetes mellitus (T2DM) initiating Xultophy® under routine clinical practice and according to approved label in Korea.
89074081|NCT04941573|Experimental|Hyperpolarized Xenon MRI for lung transplant diagnosis|"All post lung transplant patients will undergo hyperpolarized 129-Xenon MRI and conventional proton MR imaging of the lung. Recent HRCT and spirometry measurements as part of clinical care will be available in the medical history for comparison. There will be multiple administered inhalation of HP Xenon during an imaging session. Maps of xenon ventilation (distribution) will be used for analyzing function of the lungs. These maps will be compared against 3D high-resolution CT images for regional correlations, and against spirometry as global measurements of lung health status. Additionally, xenon dissolved in lung parenchyma and blood, allows for measurement of gas exchange properties.~Each subject will have a secondary imaging session after six-months for evaluating potential changes in the lung function and early detection of lung transplant complications such as CLAD."
89074082|NCT04936776||Text message 1|Text messaging frame = safety and cleanness of clinic site. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
89074083|NCT04936776||Text message 2|Text messaging frame = importance of vaccines. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
89074084|NCT04936776||No text message|No text sent.
89074085|NCT04934995||Study Population|Adult women undergoing cesarean delivery at The Ohio State University Wexner Medical Center under spinal anesthesia, ASA physical status I-III with a BMI during pregnancy ≥ 35 kg/m2 and singleton pregnancy.
89229971|NCT01092247|Experimental|Nutritional intervention: Ketogenic diet.|
89229972|NCT00065065|Experimental|Rosiglitazone|4 mg of rosiglitazone taken twice daily for 12 weeks.
89229973|NCT00065065|Placebo Comparator|placebo|Identical in appearance to study drug taken twice daily for 12 weeks.
89229974|NCT00386308|Experimental|1|
89229975|NCT00386308|Placebo Comparator|2|
89229976|NCT00064987|Experimental|Group 1 (FSH)|Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
89074086|NCT04900623|Experimental|LOW RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits~NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what radiation dose received . The specimens will be de-identified. The specimens will be banked for future use.~Radiation Therapy: Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.~Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
89074087|NCT04900623|Experimental|INTERMEDIATE RISK RT (ALONE OR WITH SOC CHEMO|"The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits~NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what dose of radiation received. The specimens will be de-identified. The specimens will be banked for future use.~Radiation Therapy: Higher risk participants will receive standard radiation dose for up to 7-8 weeks~Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.~Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy"
89074088|NCT04899180|Other|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
89074089|NCT04899050|Experimental|Absence Seizures Treated with Epidiolex|This is a pilot, open-label study consisting of a screening period of up to 28 Days, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (EPIDIOLEX ), and a 30-day safety follow-up period following the last dose of study medication.
89074090|NCT04874441|No Intervention|blood culture-based diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a blood culture-based diagnostic strategy
89074091|NCT04874441|Experimental|C. glabrata / krusei PCR diagnostic strategy|Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a diagnostic strategy based on C. glabrata / krusei PCR
89074092|NCT04870099|Experimental|Guided self-help|"Participants are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Each participant is assigned an eCoach -- an undergraduate, post-baccalaureate, or graduate research assistant -- who will meet with the participant for a 60-minute welcome call describing the intervention and 3-6 sessions of guidance focused on promoting adherence to the manual and using skills in everyday life."
89074093|NCT04868994|Experimental|ENMG and muscle analyses on whole body muscles MRI.|Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria
89074094|NCT04859335|Other|Schwannomas patients needing gammaknife radiosurgery|"Patients will undergo balance and hearing questionnaires before and after gammaknife radiosurgery.~This is a before/after analysis needing only one arm: the before data will serve as control to the after data"
89074095|NCT04829071|Experimental|Evaluating motor learning and brain structures post-stroke|We will use a single arm design to determine the impact of post-stroke cognitive impairment on two forms of motor learning (implicit and explicit) and evaluate the structural integrity of relevant brain structures in 65 individuals post stroke
89074096|NCT04828551|Other|MGH and UCSD Study subjects|"This study will enroll patients with suspected or confirmed diagnosis of NAFLD. Based on protocol-specified FIB-4 values, about one-third are expected to have low, one-third to have intermediate, and one-third to have high likelihood of advanced fibrosis.~Sex: 50:50 - Note- no stratification will be done based on sex Age: ≥ 18 yrs Demographic group: Patients with a high probability of NAFLD based on the eligibility criteria General health status: Patients with suspected or confirmed diagnosis of NAFLD Geographic location: Boston, MA (greater metropolitan areas) and San Diego, CA (greater metropolitan areas)"
89074097|NCT04825717|Experimental|Intervention group|Patients in this group will be administered nutrition and fluid plans prepared by the department dietitian using calorimetry-based measurements
89074098|NCT04825717|No Intervention|Control group|Nutrition plans of patients in this group will be calculated by the department dietitian using the standard, currently accepted RDI (recommended dietary intake) formula.
89074099|NCT04823988||Adults 18 and over|Adults 18 and over
89074100|NCT04823130|No Intervention|Healthy Participants: Control|Healthy participants with site, age, gender, race, location of targeted lesional and non-lesional skin area matched to selected AD participants, received no treatment, and were considered as a control group.
89074101|NCT04823130|Experimental|Participants With AD: Dupilumab|Participants with moderate to severe AD received dupilumab 600 milligrams (mg) subcutaneous (SC) injection on Day 1, followed by dupilumab 300 mg SC injection every 2 weeks (Q2W) from Week 3 to Week 15.
89074102|NCT04822129|Active Comparator|Treatment as usual|Intervention for TAU group: Actual participation in the intervention will begin with the first videoconference. The general format for each conference will be a brief presentation (10-15 minutes) by Dr. Ownby on a specific topic related to brain health, with the remainder of the time spent in discussion of the topic's importance and in answering participants' questions about the topic or about any other concerns they have related to developing a brain healthy lifestyle. The first videoconference will also provide participants with an overview of the daily log form, instructions for completing it and entering results every week in RedCap, and a reminder on the process of compensation for completion of the logs.
89074103|NCT04822129|Experimental|Cogtrastim model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model. Early videoconference sessions will also focus on strategies for behavior change, including realistic goal setting, problem solving about possible difficulties, and assistance in formulating a written plan to improve brain health. Participants will be encouraged to develop a written program for brain health and to also develop self-monitoring habits.
89074104|NCT04820595||Control group|Patients who have RASS < +2 and have not delirium according CAM-ICU immediately upon emergence from anesthesia
89074105|NCT04820595||Agitated non-delirious group|Patients who have RASS = +2 or more and have not delirium according CAM-ICU immediately upon emergence from anesthesia
89074106|NCT04820595||Agitated delirium group|Patients who have RASS = +2 or more and have delirium according CAM-ICU immediately upon emergence from anesthesia
89074107|NCT04808622|Experimental|TSC 0.5 mg/kg|TSC 0.5 mg/kg given as a one-time IV bolus injection
89074108|NCT04808622|Experimental|TSC 1.0 mg/kg|TSC 1.0 mg/kg given as a one-time IV bolus injection
89074109|NCT04808622|Experimental|TSC 1.5 mg/kg|TSC 1.5 mg/kg given as a one-time IV bolus injection
89074110|NCT04808622|Experimental|TSC 2.0 mg/kg|TSC 2.0 mg/kg given as a one-time IV bolus injection
89074111|NCT04808622|Experimental|TSC 2.5 mg/kg|TSC 2.5 mg/kg given as a one-time IV bolus injection
89074112|NCT04808622|Placebo Comparator|Placebo|7 mL normal saline given as a one-time IV bolus injection
89074113|NCT04802603|Other|Radiotherapy|Cohort 1 (De novo) No Prior radiotherapy Cohort 2 (Prior radiotherapy) Prior radiotherapy
89074114|NCT04783675|Experimental|Intervention/treatment|
89074115|NCT04782856|Active Comparator|Single therapy|"Levothyroxine (LT4) and placebo (a look-alike inactive substance, a sugar pill) Patients in the LT4 group will be started at a dose of 1.6 mcg/Kg (52 The VCU Investigational Pharmacy will over-encapsulate LT4 plus placebo, in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation."
89074116|NCT04782856|Experimental|Combination therapy|"Liothyronine/levothyroxine (LT3/LT4) combination therapy. LT4/LT3 group will have 25 mcg of LT4 substituted with 5 mcg LT3 twice daily, to mimic the average daily T3 production form the thyroid The VCU Investigational Pharmacy will over-encapsulate LT4 plus 5 mcg LT3 in AM and PM color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation. No changes will be made in LT3."
89074117|NCT04781374|Experimental|Neratinib|"The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.~- Neratinib-once daily with 28 consecutive days defined as a treatment cycle"
89074118|NCT04767009|Experimental|SBRT for oligoprogressive NSCLC|
89074119|NCT04746170|Experimental|Multiparous|Pregnant women in the experimental group will be given a labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
89074120|NCT04746170|No Intervention|Multiparous Control|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
89074121|NCT04746170|Experimental|Primipar|Pregnant women in the experimental group will be given a labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
89074122|NCT04746170|No Intervention|Primiparous control|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
89074123|NCT04736316|Experimental|Early CCLAD|Early community client-led ART delivery groups
89074124|NCT04720456|Experimental|SHAPE with Sonazoid|Up to 60 children (6-21 years of age) with a diagnosis of chronic liver disease, including some who will have portal hypertension who are followed at The Children's Hospital of Philadelphia (CHOP) will be enrolled in this arm. A SHAPE measurement using the ultrasound contrast agent Sonazoid® (perfluorobutane microbubbles) will be performed during a single visit. A dose of three vials with 16 μL each of microbubbles will be prepared. An infusion of the ultrasound contrast agent at the rate of 0.18 mL/kg/hour will be co-infused with an infusion of saline at the rate of 120 mL/hour resulting in an effective dosage of 1.44 μL microbubbles/kg/hour as per the FDA approved IND through an IV line in a peripheral vein. The total duration of contrast agent infusion is expected to range from 4 to 8 minutes, which includes a 2 min calibration period followed by 2-6 minutes of SHAPE acquisition (i.e., ultrasound imaging).
89074125|NCT04720456|Active Comparator|SHAPE with Lumason|Up to 60 children (6-21 years of age) with a diagnosis of chronic liver disease, including some who will have portal hypertension who are followed at CHOP will be enrolled in this arm. A SHAPE measurement using the ultrasound contrast agent LUMASON® (sulfur hexafluoride lipid-type A microspheres) will be performed during a single visit. Two doses of 0.03 mL/kg (or 2.4 mL maximum) as per package labeling will be prepared and mixed with saline at a 1:10 dilution in a 50 ml bag of saline. The diluted preparation of Lumason will be through an IV line in a peripheral vein up to 4 mL/min using an infusion setup. The total duration of contrast agent infusion is expected to range from 4 to 8 minutes, which includes a 2 min calibration period followed by 2-6 minutes of SHAPE acquisition (i.e., ultrasound imaging).
89074126|NCT04720456|Experimental|Longitudinal SHAPE|SHAPE will be used to monitor subjects identified in the initial examination as having portal hypertension for up to 18 months. These subjects will undergo laboratory testing every 6 months as a part of their clinical standard of care. During these times the SHAPE examination will also be repeated using the same ultrasound contrast agent and infusion methodologies (including dosages) as during the initial study.
89074127|NCT04709653|Experimental|Intervention Group|Occupation-based nursing program
89074128|NCT04709653|Experimental|Control Group|Routine nursing care
89074129|NCT04695080|Active Comparator|Cladribine (MAVENCLAD®)|
89074130|NCT04695080|Placebo Comparator|Placebo|
89074131|NCT04648124||Patients for whom there is no planned implant surgery|
89074132|NCT04648124||Patients for whom implantation surgery is planned|
89074133|NCT04648124||case|
89074134|NCT04624932|Experimental|Risk Reframing (RR) Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: reflecting on their own childhood play activities; what they got out of these experiences; outdoor play activities of the children at their center; what they do to promote children's outdoor play; what gets in the way in promoting children outdoor play.~Chapter 2: imagining themselves in six video segments where they must decide how to communicate with parents; and, whether they allow children to engage in rough and tumble play, play at heights, play with tools, play at speed/mud play, and resolve conflicts amongst themselves~Chapter 3: reflecting on their barriers and things that helped them promote and support the children's outdoor play at their center. Participants to assess whether there is anything they want to change to set a realistic goal, outlining steps for attaining that goal."
89074135|NCT04624932|Sham Comparator|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play.~It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety."
89074136|NCT04609319||Cohort 1|
89074137|NCT04605484|Experimental|Posoleucel|Arm 1: Regimen A
89074138|NCT04605484|Experimental|Posoleucel and Placebo|Arm 2: Regimen B
89074139|NCT04605484|Placebo Comparator|Placebo|Arm 3: Regimen A
89074140|NCT04594473|No Intervention|Standard of Care (SOC)|Participants randomized to SOC will be instructed to continue their typical lifestyle activity.
89074141|NCT04594473|Experimental|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|Participants randomized to CORE will be instructed to follow the clinical algorithm for this study. An in-clinic assessment consisting of two questionnaires will be used to identify the appropriate pathway for triage. Participants will be triaged into one of three pathways: Physical Medicine & Rehabilitation, Personal Optimism With Exercise Recovery, or Exercise Self-Management.
89074142|NCT04592588|Experimental|Common Elements Toolbox (COMET)|The Common Elements Toolbox is an online intervention consisting of modules from empirically supported treatments for common mental health problems.
89074143|NCT04592588|Sham Comparator|Wait-list control condition|
89074144|NCT04591353|Experimental|"Investigational group (PENG Block group)"|Participants in the pericapsular nerve group block (PENG) arm will receive a PENG block preoperatively in the block area placed under direct ultrasound guidance as follows: Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area Anatomical landmarks identified using ultrasound and skin will be numbed using 2-3 cc of 2% lidocaine. Long acting local anesthetic, a bolus of 25 cc of 0.5 % Bupivacaine will be injected lateral to iliopubic eminence (IPE). A Curvilinear low frequency (2-5 MHz) ultrasound probe will be used to identify landmarks. A 22 G, 10 cm needle will be inserted using in-plane technique and advanced to target site (17).
89074145|NCT04591353|Active Comparator|Control group|"Control group participants will be transferred to the block area preoperatively, and care will proceed as if they were receiving injection.~Patients will be placed in the supine position resting comfortably. Standard noninvasive monitors will be applied, and oxygen will be administered via nasal cannula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area. The ultrasound probe will be used to identify the iliopubic eminence (IPE). Only skin will be numbed using 2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected."
89074146|NCT04580914|Experimental|Treatment with Ablation Catheter|Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation
89074147|NCT04556123|Experimental|Fluid overload: BIS-guided decongestion|
89074148|NCT04556123|Active Comparator|Fluid overload: Decongestion based on clinical judgement|
89074149|NCT04556123|No Intervention|No fluid overload: standard of care|
89074150|NCT04502758|Active Comparator|Sequential bilateral accelerated theta burst stimulation|Three sessions of Sequential bilateral accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).
89074151|NCT04502758|Sham Comparator|Sham seqential billateral accelerated theta burst stimulation|Three sessions of Sequential bilateral sham accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).
89074152|NCT04488055|Experimental|Crisis Line Facilitation (CLF)|This single-session intervention addresses the individuals' perceived barriers and facilitators of crisis line use during periods of suicidal crisis.
89074153|NCT04488055|Active Comparator|Enhanced Usual Care (EUC)|Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with the NSP Lifeline and a list of outpatient mental health and substance use resources and encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms.
89074154|NCT04461626||Persona fixed bearing knee system|Persona fixed bearing knee system (All patients will received Persona fixed bearing knee system)
89074155|NCT04427254|Experimental|Neurological biological samples|
89074156|NCT04411303|Experimental|Reducing interlimb asymmetry with biofeedback post-stroke|We will use a randomized crossover design to determine the performance and retention effects following single-day training sessions with biofeedback of three different gait variables (i.e., step length, propulsive force, and interlimb asymmetry) in 25 individuals with chronic stroke.
89074157|NCT04411303|Experimental|Evaluating capacity for biofeedback use at varied intensities|We will use a within-session randomized crossover design to test the capacity of persons post-stroke (second cohort; n=25) to reduce their interlimb asymmetry using the biofeedback variable found to be the most effective for the group in Aim 1 while walking in three aerobic intensity zones: low, moderate, and vigorous (30-40%, 50-60%, and 70-80% of heart rate reserve, respectively).
89074158|NCT04402385|Experimental|Aspirin|Participants randomized to 81 mg of Aspirin daily
89074159|NCT04402385|Placebo Comparator|Placebo|Participants randomized to placebo daily
89074160|NCT04399031|Experimental|E-cigarette e-liquid 1|Participants will self-administer an e-cigarette e-liquid.
89074161|NCT04399031|Experimental|E-cigarette e-liquid 2|Participants will self-administer an e-cigarette e-liquid.
89074162|NCT04399031|Experimental|E-cigarette e-liquid 3|Participants will self-administer an e-cigarette e-liquid.
89074163|NCT04399031|Experimental|E-cigarette e-liquid 4|Participants will self-administer an e-cigarette e-liquid.
89074164|NCT04399031|Experimental|E-cigarette e-liquid 5|Participants will self-administer an e-cigarette e-liquid.
89074165|NCT04399031|Experimental|E-cigarette e-liquid 6|Participants will self-administer an e-cigarette e-liquid.
89074166|NCT04399031|Experimental|E-cigarette e-liquid 7|Participants will self-administer an e-cigarette e-liquid.
89074167|NCT04399031|Experimental|E-cigarette e-liquid 8|Participants will self-administer an e-cigarette e-liquid.
89224324|NCT06269458|Experimental|Baby Massage|"In the baby massage application, mothers were trained on baby massage and the massage applied by the mother to her baby was observed once. The baby massage video prepared by the researchers was shared with mothers. Baby massage application was performed 90 minutes after feeding and each application was performed at the same time. Mothers massaged their babies for 15 minutes three times a week for a month. The Massage Application Content included one minute face, two minutes chest, four minutes arm, two minutes abdominal, four minutes leg and two minutes back massage (Virgian and Setiawati, 2021; Yenigün 2020; Yılmaz, 2019). All mothers were called once a week by a researcher to provide counseling and follow-up of the process.~At the end of four weeks, measurement tools were applied to all mothers and the groups were changed, massage was applied to the yoga group, and yoga intervention was applied to the massage group, as in the beginning of the research."
89229977|NCT00064987|Active Comparator|Group 2 (GnRH)|Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.
89229978|NCT00374452|Experimental|ATHENA-CDS-HTN plus Guideline Link|ATHENA-CDS-HTN plus Guideline Link. ATHENA-CDS-HTN display on the cover sheet of electronic health record, plus link to the guidelines
89074168|NCT04399031|Experimental|E-cigarette e-liquid 9|Participants will self-administer an e-cigarette e-liquid.
89074169|NCT04399031|Experimental|E-cigarette e-liquid 10|Participants will self-administer an e-cigarette e-liquid.
89074170|NCT04399031|Experimental|E-cigarette e-liquid 11|Participants will self-administer an e-cigarette e-liquid.
89074171|NCT04399031|Experimental|E-cigarette e-liquid 12|Participants will self-administer an e-cigarette e-liquid.
89074172|NCT04399031|Experimental|E-cigarette e-liquid 13|Participants will self-administer an e-cigarette e-liquid.
89074173|NCT04399031|Experimental|E-cigarette e-liquid 14|Participants will self-administer an e-cigarette e-liquid.
89074174|NCT04399031|Experimental|E-cigarette e-liquid 15|Participants will self-administer an e-cigarette e-liquid.
89229979|NCT00374452|Other|Guideline Link Only|Guideline Link Only. Link to The Seventh Report of the Joint National Committee on Prevention Detection and Treatment of High Blood Pressure (JNC7) and to VA-Department of Defense (DoD) hypertension guidelines
89229980|NCT00064753|Experimental|High Dose Multivitamin|Multivitamin with increased folic acid, vitamin B6 and vitamin B12
89229981|NCT00064753|Active Comparator|Low Dose Multivitamin|Multivitamin devoid of folic acid and with estimated average requirement amounts of vitamin B6 and vitamin B12
89074175|NCT04399031|Experimental|E-cigarette e-liquid 16|Participants will self-administer an e-cigarette e-liquid.
89074176|NCT04399031|Experimental|E-cigarette e-liquid 17|Participants will self-administer an e-cigarette e-liquid.
89074177|NCT04399031|Experimental|E-cigarette e-liquid 18|Participants will self-administer an e-cigarette e-liquid.
89074178|NCT04399031|Experimental|E-cigarette e-liquid 19|Participants will self-administer an e-cigarette e-liquid.
89074179|NCT04399031|Experimental|E-cigarette e-liquid 20|Participants will self-administer an e-cigarette e-liquid.
89074180|NCT04396730|Placebo Comparator|Placebo followed by cannabidiol|Oral contraceptives will be taken daily for 24 days along with placebo (oral) once daily for cycle 1. During cycle 3, cannabidiol will be taken once daily along with OCPs.
89074181|NCT04396730|Experimental|Cannabidiol follow Placebo|Oral contraceptives will be taken daily for 24 days along with Cannabidiol 400mg once daily for cycle 1. During cycle 3. placebo will be taken once daily along with OCPs.
89074182|NCT04378868|Active Comparator|Surgery within 8 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Operation can be done during the night time. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
89074183|NCT04378868|Experimental|Surgery within 24 hours, no antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
89074184|NCT04378868|Experimental|Surgery within 8 hours, antibiotics|Patients are planned for urgent operation, that should be done within 8 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
89074185|NCT04378868|Experimental|Surgery within 24 hours, antibiotics|Patients are planned for urgent operation, that should be done within 24 hours. Operations are not done during the night time (00:00 - 08:00), unless necessary to avoid delay over 24 hours. Antibiotics (cefuroxime 1.5g and metronidazole 500mg every 8 hours) are given while waiting surgery.
89074186|NCT04347135|Experimental|F-18 FES PET/MRI|16α-(18)F-fluoro-17β-estradiol ([F-18] FES)
89074187|NCT04305769|Placebo Comparator|Alanyl-glutamine 0g|
89074188|NCT04305769|Experimental|Alanyl-glutamine 4g|
89074189|NCT04305769|Experimental|Alanyl-glutamine 24g|
89074190|NCT04305769|Experimental|Alanyl-glutamine 44g|
89074191|NCT04301206|Experimental|Intervention: Receiving video material|The parents who accepts to participate and receives videos and action cards by sms
89074192|NCT04301206|No Intervention|Control group|The parents who accepts to participate, but proceed to 1813 and do not receive videos and action cards
89074193|NCT04254185|Active Comparator|Simple decompression|In-situ decompression releases only the compressive ligamentous structures overlying the ulnar nerve.
89074194|NCT04254185|Active Comparator|Subcutaneous anterior transposition|Anterior transposition repositions the ulnar nerve, providing decompression and lengthening by moving the nerve anterior to the axis of elbow rotation
89074195|NCT04253379|Experimental|pediatric epilepsy children|
89074196|NCT04253379|Active Comparator|healthy children|
89074197|NCT04221269|Active Comparator|Enhanced Treatment as Usual|Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
89074198|NCT04221269|Experimental|Coping Long-term with Active Suicide Program for Schizophrenia|Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
89074199|NCT04218357|Experimental|Probenecid|2g probenecid, one pill by mouth once, for one day
89074200|NCT04218357|Placebo Comparator|matching placebo|Placebo, one pill by mouth once, for one day
89074201|NCT04204330|Experimental|CardioQVARK group|"Inclusion criteria:~Males and females aged 20 to 96 years having one or more of the following risk factors:~hypertensive heart disease;~history of ischemic stroke or transient ischemic attacks;~type 1 and 2 diabetes;~class 1-3 obesity;~heart failure or decreased tolerance to physical activity due to dyspnea;~coronary artery disease (CAD) or chest pain without established CAD diagnosis;~peripheral artery atherosclerosis;~abnormal heart rhythms (episodes of palpitations, pauses in heartbeat).~A patient's consent to participate in the study and the ability to sign an informed consent form.~Exclusion criteria:~acute coronary syndrome;~acute ischemic or hemorrhagic stroke;~mental illness;~severe concomitant disease with life expectancy less than 2 years.~Withdrawal criteria:~1. Refusal to participate in the study."
89074202|NCT04203550|Active Comparator|Irrigation group (IR)|A burr-hole craniostomy is performed and the dura is opened sharply and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. Subdural space is irrigated by repeated rinsing with body temperature saline solution with a syringe and blunt needle until surgeon considers exudate to be clear. Minimum volume of irrigation will be 200 ml per operated side. The subdural drain is inserted 3-5 cm underneath the skull and parallel to it. The total volume of irrigation as well as the duration of operation is recorded.
89074203|NCT04203550|Experimental|No-Irrigation group (N-IR)|A burr-hole craniostomy is performed and a small incision to the dura is made and 10 ml of subdural exudate is aspired with blunt aspiration needle for a CSDH sample to be stored in -70℃ to be used for later analysis. The subdural drain is inserted approximately 3-5 cm underneath the skull and parallel to it. The duration of operation is recorded.
89074204|NCT04166877|Experimental|Magnesium Group|The magnesium group arm will receive a 40 mg/kg IBW (maximum 4 g) bolus of intravenous magnesium sulfate, followed by a continuous infusion of 0.5 g/hr for a total of 24 hours.
89074205|NCT04166877|Placebo Comparator|Control Group|The control arm will receive the same volume and rate of saline as if they were in the experimental group.
89074206|NCT04164979|Experimental|Cabozantinib and Pembrolizumab|Subjects receive Cabozantinib 40mg PO daily on days 1-21 and Pembrolizumab 200mg IV on day 1 every 21 days.
89074207|NCT04135846|Experimental|doxazosin|16 mg, or maximum tolerated dose (MTD)
89074208|NCT04135846|Placebo Comparator|placebo|matching placebo
89074209|NCT04117893|Experimental|Duloxetine combined with intra-articular injection|
89074210|NCT04117893|Active Comparator|Intra-articular injection|
89074211|NCT04098003|Experimental|Rosuvastatin|rosuvastatin 20 mg daily for eight weeks
89074212|NCT04098003|Placebo Comparator|Placebo|placebo daily for eight weeks
89074213|NCT04054414|Active Comparator|Normal Saline|Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.
89074214|NCT04054414|Experimental|PMZ-1620|Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).
89074215|NCT04049851|Experimental|Moxidectin|
89074216|NCT04049851|Active Comparator|Ivermectin|
89074217|NCT03936361|Active Comparator|Statin|The same statin agent and dose that subjects were using at the time of ICH onset.
89074218|NCT03936361|No Intervention|No-statin|Subjects will discontinue the statin agent that they were taking at the time of ICH onset. No placebo will be prescribed for these subjects.
89074219|NCT03907644|Experimental|Active FPS|We use Starstim AC (alternative current) -Stimulator R32. FPS protocol will be used with 20 minutes 2mAmp 6 Hz tACS to the middle frontal gyrus (DLPFC, F4 in EEG electrodes with 10-20 system measurement) and inferior parietal cortex (IPC, P4), as the main nodes of the frontoparietal network, in synchronous oscillation. The 4 return electrodes will receive 0.5 mAmp each around each active electrode (High Definition Montage). The electrodes are silver/silver chloride that are wet with conductive gel. We will use surface landmarks and EEG caps on the head to place the electrodes, which are held in place by head caps with holes indicating places for electrode positioning.
89229982|NCT00374140|Experimental|RAD001 (Everolimus)|RAD001 (Everolimus)10 mg by mouth daily without interruption
89229983|NCT00665561||Maraviroc exposed|
89074220|NCT03907644|Sham Comparator|Sham FPS|In the sham stimulation mode, the device shows pseudorandom numbers on the screen that look like real stimulation is being delivered. The device gives a low level of stimulation at the very beginning and at the very end of the stimulation session (30 seconds ramp up and 30 seconds ramp down) in order to recreate the feeling of tingling that subjects perceive at the beginning and end of real stimulation.
89074221|NCT03886909|Active Comparator|Home-Based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and periodical phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of transplant.
89074222|NCT03886909|Active Comparator|Prehabilitation Education|Will be offered a prehabilitation and stem cell education class at the Penn State Hershey Cancer Institute.
89074223|NCT03880162|Experimental|Study intervention|Participants will follow an energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates) for minimum two weeks.
89074224|NCT03880162|Active Comparator|Control intervention|Participants will follow an energy deficient (30% deficit) standard diet (50% of carbohydrates) for minimum two weeks.
89074225|NCT03860805|Active Comparator|Laparoscopic tubal ligation|Patients who seek for surgical permanent contraception and randomized to laparoscopic tubal ligation
89074226|NCT03860805|Active Comparator|Laparoscopic bilateral salpingectomy|Patients who seek for surgical permanent contraception and randomized to laparoscopic bilateral salpingectomy
89074227|NCT03837847|Experimental|Intervention|Participants in this group will receive 12 weekly health coaching calls followed by 12 weeks of living a normal life.
89074228|NCT03837847|Active Comparator|Attention Control|Participants in this group will receive 6 educational guides and 6 calls to remind them to read the educational guides (over a 12 week period). The participants will then move to 12 weeks of weekly health coaching calls.
89074229|NCT03827031|No Intervention|Control group|
89074230|NCT03827031|Experimental|B1 interventional group|
89074231|NCT03827031|Experimental|B2 interventional group|
89074232|NCT03810105|Experimental|Castration Sensitive Biochemically Recurrent Prostate Cancer|Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer
89074233|NCT03785210|Experimental|1/Arm 1 - Nivolumab, Tadalafil and Oral Vancomycin|Nivolumab, tadalafil and oral vancomycin
89074234|NCT03750968|Experimental|Carotenoid group|The Carotenoid group will receive a commercially available prenatal vitamin/mineral/Docosahexaenoic acid (DHA) softgel plus a softgel containing lutein/zeaxanthin in safflower oil.
89074235|NCT03750968|Active Comparator|Control group|The Control group will receive the same prenatal vitamin/mineral/Docosahexaenoic acid (DHA) softgel plus a softgel containing only safflower oil.
89074236|NCT03742817|Experimental|Sweet-Flavor 4.5% Nicotine (Salt)|Participants will self-administer a sweet-flavored e-cigarette containing 4.5% nicotine by volume.
89074237|NCT03742817|Placebo Comparator|Sweet-Flavor 0 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 0 mg/mL nicotine.
89074238|NCT03742817|Experimental|Sweet-Flavor 6 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 6 mg/mL nicotine.
89074239|NCT03742817|Active Comparator|Usual e-Cigarette|Participants will self-administer either their preferred brand combustible cigarette or e-cigarette with usual nicotine nicotine concentration.
89074240|NCT03722498|Experimental|HAIC of FOLFOX|Hepatic arterial infusion chemotherapy with oxaliplatin, leucovorin, and 5-fluorouracil
89074241|NCT03722498|Active Comparator|Sorafenib|Sorafenib 400 mg orally twice a day
89074242|NCT03710824||Subjects with Idiopathic Pulmonary Fibrosis|
89074243|NCT03699826|Experimental|Active TMS|Active TMS stimulation administered for tinnitus symptoms (no sham stimulation).
89074244|NCT03665922|Experimental|BroccoMax®|Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
89074245|NCT03665922|Placebo Comparator|Placebo|Following randomization, subjects will begin to take four placebo tablets in the morning with breakfast and four tablets in the evening with dinner.
89074246|NCT03648892|Other|Main|Healthy volunteers, within three BMI strata, under controlled overnight fasting conditions following a period of dietary stabilization
89074247|NCT03626831|Active Comparator|Treatment|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug by Evolocumab Prefilled Syringe (1x SC 420 mg evolocumab).
89074248|NCT03626831|Placebo Comparator|Placebo|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of Placebos (1x SC Placebo).
89074249|NCT03619213|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
89074250|NCT03619213|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
89074251|NCT03570515|Experimental|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days.
89074252|NCT03570515|Active Comparator|Educational Film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
89074253|NCT03527992|Other|Automated oxygen therapy|An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. Patients will receive O2 automated intervention.
89074254|NCT03527992|Other|Standard Oxygen therapy|Patients will receive O2 standard therapy
89074255|NCT03481049|Experimental|Usual CM|Participants will earn at least 3 prize draws each time they submit an alcohol negative urine samples during weeks 5-20, plus treatment as usual
89074256|NCT03481049|Experimental|High-Magnitude CM|Participants will earn twice as many prize draws than those in the Usual CM for alcohol abstinence during weeks 5-20, plus treatment as usual.
89074257|NCT03481049|Experimental|Shaping CM|Participants will earn prize draws for light drinking during weeks 5-8 instead of alcohol abstinence and will then earn prize draws for abstinence during weeks 9-20, plus treatment as usual.
89074258|NCT03445949|Other|30 days DAPT and long-term treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
89074259|NCT03445949|Other|6 months DAPT and long-term treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
89074260|NCT03445949|Other|30 days DAPT and 6 months treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
89074261|NCT03445949|Other|6 months DAPT and 6 months treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
89074262|NCT03342690||Eplerenone|Patients with CHF receiving Selara (eplerenone)
89074263|NCT03262662|Experimental|Extended Run-In|"** 4 weeks of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
89074264|NCT03262662|Active Comparator|Standard Run-In|"** 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
89074265|NCT03257267|Experimental|Experimental Therapy|Cemiplimab
89074266|NCT03257267|Active Comparator|Control Therapy|Investigator choice (IC) chemotherapy
89074267|NCT03245645|Experimental|100% Fructose|The fructose group will help to determine whether an absolute amount of fructose will lead to IBS symptoms.
89074268|NCT03245645|Placebo Comparator|100% Glucose|The glucose group will serve as a control since glucose is not a FODMAP and as a result is not expected to lead to recurrent symptoms.
89074269|NCT03245645|Active Comparator|Fructose and Glucose|The glucose/fructose mixture group is a cross comparison group that will determine whether the relative excess fructose concentration is an important cause of IBS symptoms.
89074270|NCT03190668|Active Comparator|First Regimen Group|The first regimen will consist of a bolus dose of Cefazolin 30mg/kg up to a maximum of 2000mg IV administered prior to surgical incision. The same pre-operative dose of Cefazolin will be repeated every 3 hours until the completion of surgery. Two will paraspinal muscle microdialysis catheters and two subcutaneous microdialysis catheters will be inserted.
89229984|NCT00665561||Maraviroc unexposed|
89229985|NCT03955705|Experimental|Nefopam|Nefopam: 20 mg (infuse at least 15 minutes) every 4-6 hours, max 120 mg/day
89229986|NCT03955705|Placebo Comparator|Normal saline solution|Normal saline or 0.9% Sodium Chloride (NaCl) or NSS
89074271|NCT03190668|Active Comparator|Second Regimen Group|The second regimen will consist of an initial bolus dose of 30 mg/kg up to maximum of 2000 mg. Following the initial bolus dose a continuous Cefazolin drip will start until the end of surgery. Cefazolin drip dose will be 10 mg/(kg*h) up to maximum of 667 mg/h.Two microdialysis catheters will be inserted into a paraspinal muscle and two microdialysis catheters will be inserted subcutaneously.
89074272|NCT03162653|Active Comparator|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
89074273|NCT03162653|Placebo Comparator|Placebo|mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
89074274|NCT03144206|Experimental|Hyperbaric Oxygen Group|Patients will receive Hyperbaric Oxygen treatments in the immediate postoperative period
89074275|NCT03144206|No Intervention|Standard of Care Group|Patients will not receive Hyperbaric Oxygen treatments in the immediate postoperative period
89074276|NCT03098004|Experimental|Sweet-Flavored e-Cigarette|Participants will self-administer a sweet-flavored e-cigarette containing 3 mg/mL of nicotine.
89074277|NCT03098004|Active Comparator|Tobacco-Flavored e-Cigarette|Participants will self-administer a tobacco-flavored e-cigarette containing 3 mg/mL of nicotine.
89074278|NCT03025789|Experimental|Inpatients|Participants received fexinidazole orally for 10 days as inpatients (at the hospital)
89074279|NCT03025789|Experimental|Outpatients|Participants received fexinidazole orally for 10 days as outpatients (at home)
89074280|NCT02999932|Experimental|Low SpO2 group|SpO2 90-95%, with FiO2 as low as possible.
89074281|NCT02999932|Active Comparator|High SpO2 group|SpO2 96-100%, with FiO2 no lower than 30%.
89074282|NCT02991456|Active Comparator|Sequence A|Daily ondansetron alone for 3 weeks, followed by the use of rolapitant (one dose on day 22) plus continued daily ondansetron for 3 weeks.
89074283|NCT02991456|Active Comparator|Sequence B|Single dose of rolapitant (one dose on day 1) plus daily ondansetron for 3 weeks, followed by daily ondansetron alone for 3 weeks.
89074284|NCT02876640|Experimental|Treatment (retinoid 9cUAB30)|Patients receive retinoid 9cUAB30 PO QD for 14 to 28 days. Patients then undergo tumor resection surgery. Patients undergo blood and urine sample collection throughout the study.
89074285|NCT02848586|Active Comparator|ECIGS|Subjects will receive e-cigarettes for a total of 4 weeks. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. After 4 weeks, subjects will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks after transition to ECIG (Visit 4) and again 2 weeks after stopping ECIG (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
89074286|NCT02848586|Active Comparator|Usual brand|Subjects will receive their usual brand of combustible cigarettes for a total of 4 weeks. A mobile contingency management mCM procedure will be used. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks later (Visit 4) and again 2 weeks later (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
89074287|NCT02842827|Experimental|Cohort 1a: bomedemstat 0.75 mg/kg/day|Participants receive bomedemstat 0.75 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
89074288|NCT02842827|Experimental|Cohort 1b: bomedemstat 1.5 mg/kg/day|Participants receive bomedemstat 1.5 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
89074289|NCT02842827|Experimental|Cohort 1c: bomedemstat 3 mg/kg/day|Participants receive bomedemstat 3 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
89074290|NCT02842827|Experimental|Cohort 1d: bomedemstat 6 mg/kg/day orally|Participants receive bomedemstat 6 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
89074291|NCT02842827|Experimental|Cohort 1x3: bomedemstat 3 mg/kg/day orally plus tretinoin 45 mg/m^2 /day3|Participants receive bomedemstat 3 mg/kg/day orally plus tretinoin 45 mg/m^2/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
89229987|NCT03154138|Experimental|Prismatic adaptation (PA) group|Patients in the experimental group will benefit from 10 sessions of adaptation prismatic (PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
89074292|NCT02842827|Experimental|Cohort 1x6: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day|Participants receive bomedemstat 6 mg/kg/day orally plus tretinoin 45 mg/m^2/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
89074293|NCT02842827|Experimental|Cohort 3x: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day|Participants receive bomedemstat 6 mg/kg/day orally plus tretinoin 45 mg/m^2/day orally in 21-day cycles consisting of 14 days of treatment and 7 days of rest. Participants will receive up to 2 cycles (21-day cycles) for up to a total of up 42 days (28 days on treatment).
89074294|NCT02842827|Experimental|Cohort 4x: bomedemstat 6 mg/kg/day plus tretinoin 45 mg/m^2/day|Participants receive bomedemstat 6 mg/kg/day orally for 21 days plus tretinoin 45 mg/m^2/day orally in 28-day cycles consisting of 21 days of treatment and 7 days of rest. Participants will receive at least 1 cycle (28-day cycles) and will receive subsequent cycles at the discretion of the investigator.
89074295|NCT02778750||Stable Group|
89074296|NCT02778750||Rapid Decliner Group|
89074297|NCT02666378||CMR/ECHO|"Prior to starting chemotherapy treatment, the participant will undergo the following procedures:~Cardiac Magnetic Resonance Imaging (CMR)~Echocardiogram (ECHO) in patients with no clinically indicated scans~Each imaging procedure will be repeated at predetermined times during the protocol~Simple blood collection for plasma biomarker analysis"
89074298|NCT02503774|Experimental|Dose-escalation: Oleclumab Dose 1|Participants will receive oleclumab Dose 1 intravenously (IV) every two weeks (Q2W) until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074299|NCT02503774|Experimental|Dose-escalation: Oleclumab Dose 2|Participants will receive oleclumab Dose 2 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074300|NCT02503774|Experimental|Dose-escalation: Oleclumab Dose 3|Participants will receive oleclumab Dose 3 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074301|NCT02503774|Experimental|Dose-escalation: Oleclumab Dose 4|Participants will receive oleclumab Dose 4 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074302|NCT02503774|Experimental|Dose-escalation: Oleclumab Dose 1 + Durvalumab Dose 1|Participants will receive oleclumab Dose 1 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074303|NCT02503774|Experimental|Dose-escalation: Oleclumab Dose 2 + Durvalumab Dose 1|Participants will receive oleclumab Dose 2 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074304|NCT02503774|Experimental|Dose-escalation: OleclumabDose 3 + Durvalumab Dose 1|Participants will receive oleclumab Dose 3 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074305|NCT02503774|Experimental|Dose-escalation: OleclumabDose 4 + Durvalumab Dose 1|Participants will receive oleclumab Dose 4 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074306|NCT02503774|Experimental|Dose-expansion (CRC): Oleclumab Dose 4 + Durvalumab Dose 1|Participants with previously treated microsatellite stable-colorectal cancer (MSS-CRC) will receive oleclumab Dose 4 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
88820840|NCT05586802|Active Comparator|Group 2 (Metabolic Risk) - randomized to Arm C|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an active comparator by a testosterone gel
89074307|NCT02503774|Experimental|Dose-expansion (Pancreatic adenocarcinoma): Oleclumab Dose 4+ Durvalumab Dose 1|Participants with previously treated pancreatic adenocarcinoma will receive oleclumab Dose 4 IV Q2W followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074308|NCT02503774|Experimental|Dose-expansion (NSCLC): Oleclumab Dose 4 + Durvalumab Dose 1|Participants with previously treated EGFRm NSCLC will receive oleclumab Dose 4 IV followed by durvalumab Dose 1 IV Q2W until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
89074309|NCT02476734||Diffuse Large B-cell Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
89074310|NCT02476734||Follicular Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
89074311|NCT02432274|Experimental|Cohort 1: Single-Agent Dose-Finding|Children and adolescents with relapsed or refractory solid malignant tumors.
89074312|NCT02432274|Experimental|Cohort 2A: Single-agent Expansion (DTC)|Children and adolescents with 131 iodine-refractory DTC.
89074313|NCT02432274|Experimental|Cohort 2B: Single-agent Expansion (Osteosarcoma)|Participants with relapsed or refractory osteosarcoma.
89074314|NCT02432274|Experimental|Cohort 3A: Combination Dose-finding|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
89074315|NCT02432274|Experimental|Cohort 3B: Combination Expansion|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
89074316|NCT02424955|Experimental|3D Perfusion Ultrasound|undergo 3D ultrasound perfusion imaging with perflutren
89074317|NCT02369393|Experimental|Behavioral Activation|BA treatment for depression is a simple, cost-effective method. There is evidence that the behavioral component may be the active mechanism of change in cognitive-behavioral treatments of clinical depression. One of the main objectives of the treatment is to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions. Treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components are: 1) psycho-education, 2) identifying important values and significant activities, 3) activity structuring and scheduling, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
89074318|NCT02369393|No Intervention|Waiting list control group|In the waiting list control group (WL), subjects will receive no treatment during 8 weeks. We will not interfere but we will monitor carefully through self-report. Then participants will be randomised to the two treatment groups.
89074319|NCT02369393|Experimental|Physical Activity|There is evidence to suggest that the addition of cognitive behavioral therapies, specifically exercise, can improve treatment outcomes for many patients. Exercise is a behavioral intervention that has shown great promise in alleviating symptoms of depression. The treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the PA treatment are: 1) psychoeducation: understand the mental health benefits of physical activity, 2) learn about the types and amounts of physical activity recommended, 3) motivation to perform and maintain physical activities, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
89074320|NCT02095288||Healthy volunteers|Blood draw
89074321|NCT01827098|Experimental|Delayed induction|The root canal is disinfected and calcium hydroxide is placed in the canal. Blood clot is induced in the canal 4 weeks later. Endodontic Regeneration is performed.
89074322|NCT01827098|Experimental|Immediate Induction|Blood clot is induced after disinfection of the canal during the same visit. Endodontic regeneration is performed.
89074323|NCT01622335|Placebo Comparator|General anesthesia with oxygen|General anesthesia and Air
89074324|NCT01622335|Experimental|nitrous oxide and general anesthesia|General anesthesia with Nitrous Oxide
89074325|NCT01359592|Active Comparator|PET Negative: R-CHOP|R-CHOP x 3 Cycles
89074326|NCT01359592|Experimental|PET Positive: IFRT +Zevalin|Standard IFRT+ Zevalin IV per ABW
89074327|NCT01331018|Experimental|Treatment (hematopoietic stem progenitor cells)|"STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim SC BID for up to 6 days (on days 1-6 of mobilization). Patients receive plerixafor SC QD on days 4-6 of mobilization. PBSC count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of >= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days.~BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells.~REINFUSION: Patients receive methylprednisolone IV or prednisone PO on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0."
89074328|NCT01091857|Experimental|Exercise intervention (STRIDE)|
89074329|NCT01091857|Active Comparator|Health and Wellness Control|
89074330|NCT00930111|Active Comparator|2 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 2 weeks.
89074331|NCT00930111|Placebo Comparator|4 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 4 weeks.
89229988|NCT03154138|Placebo Comparator|Sham group|Patients in the sham group will benefit from 10 sessions of sham adaptation prismatic (S-PA) by means of one daily session of 20 minutes (5 times by week; 2 weeks), performed by an experienced physical therapist or occupational therapist. All patients will also benefit from conventional rehabilitation (Standard physical therapy, standard occupational therapy, standard speech therapy …) according to the needs of the patients.
89074332|NCT00840853|Experimental|Group A with disease|"CD19+ B-ALL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
89074333|NCT00840853|Experimental|Group A without disease|"CD19+ B-ALL undergoing allogeneic HSCT, without detectable disease post-HSCT.~Patients will receive CD19CAR/virus specific T cells - Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
89074334|NCT00840853|Experimental|Group B with disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
89074335|NCT00840853|Experimental|Group B without disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, without detectable disease post-HSCT~Patients will receive CD19CAR/virus specific T cells -~Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
89074336|NCT00710892|Experimental|Dose Level 1-3|Administration of suicide gene-modified allodepleted T cells.
89074337|NCT00699816|Experimental|Immunotherapy Group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 16 times(4 treatments at a frequency of once per week, followed by 4 treatments every 2 weeks, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks.
89074338|NCT00699816|No Intervention|Control Group|Patients who had undergone curative treatment(surgical resection, radiofrequency ablation[RFA], or percutaneous ethanol injection[PEI]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
89074339|NCT00697073|Experimental|1|high dose Idebenone
89074340|NCT00656331|Active Comparator|1|Amlodipine
89074341|NCT00656331|Active Comparator|2|HCTZ
89074342|NCT00653432|Experimental|Monovisc®|Injectable Hyaluronic Acid Gel
89074343|NCT00653432|Placebo Comparator|Saline|0.9% Sterile Saline
89074344|NCT00537680|Experimental|Arm 1 - 900 mg/day Idebenone|mid dose Idebenone
89074345|NCT00537680|Experimental|Arm 2 - up to 2250 mg/day Idebenone|high dose Idebenone
89074346|NCT00537680|Placebo Comparator|Arm 3 - Placebo|Placebo
89074347|NCT00446043|Experimental|Adapalene/Benzoyl Peroxide|Participants were treated with adapalene 0.1 percent (%) [weight by weight (W/W)] and benzoyl peroxide 2.5 percent (%) (W/W) gel topically to the face and trunk area once daily in the evening.
89074348|NCT00400725|Experimental|Initial Phase:- Clobex® Shampoo|In initial open-label phase, participants were applied Clobex® shampoo (Clobetasol Propionate) 0.05 percent (%) weight by weight (W/W) topically to the scalp once daily (twice a week) for 4 weeks (weekly dose was not more than 50 grams [50 Milliliter]).
89229989|NCT01095289||Total Laryngectomized|
89074349|NCT00400725|Experimental|Maintenance Phase: Clobex® Shampoo|In maintenance double-blind phase, participants presented with a good efficacy (Global severity score [GSS] less than or equal to [<=] 2) in initial phase were randomized to apply Clobetasol Propionate shampoo 0.05 % weight by weight (W/W) twice weekly up to 6 months (wherein weekly dose were not exceeded beyond 50 grams [50 milliliter]). In case of relapse (that is [i.e.], GSS greater than [>] 2) participants were re-entered to 4-week daily treatment with Clobetasol Propionate shampoo 0.05%. After this 4-week period of daily treatment, if GSS <= 2, participants were re-entering the maintenance regimen (twice a week).
89074350|NCT00400725|Placebo Comparator|Maintenance Phase: Clobex® Vehicle Shampoo|In maintenance double-blind phase, participants presented with a good efficacy (Global severity score [GSS] <= 2) in initial phase were randomized to apply Clobex® vehicle shampoo twice weekly up to 6 months (wherein weekly dose was not more than 50 grams [50 milliliter]). In case of relapse (i.e., GSS [greater than] > 2) participants were re-entered to 4-week daily treatment with Clobetasol Propionate Shampoo 0.05 % (W/W). After this 4-week period of daily treatment, if GSS <= 2, participants were re-entering the maintenance regimen (twice a week).
89074351|NCT04263961||COPD GOLD I - II|"Inclusion for mild-moderate COPD patients (n = 100):~Age between 45-65 years.~GOLD classification I or II according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC <0.7) [2].~Cessation of smoking for ≥6 months.~≥5 packyears of smoking.~Absence of asthma.~Written informed consent."
89074352|NCT04263961||Controls|"Inclusion for healthy controls (n = 100):~Age between 45-65 years.~Absence of COPD according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria (post bronchodilator FEV1/FVC <0.7) [2].~Cessation of smoking for ≥6 months.~≥5 packyears of smoking.~Absence of asthma.~Written informed consent."
89074353|NCT04264195|Experimental|Constraint-induced movement therapy|Constraint-induced movement therapy (PEPS-MIT)
89074354|NCT04264195|Active Comparator|Bimanual manipulation|Bimanual manipulation (PEPS-Bimanual)
89074355|NCT04263883|Active Comparator|Conventional treatment|Usual Care Group: Conventional treatment: moist hot pack. manual therapy, Therapeutic Exercise.Home program routine.
89074356|NCT04263883|Experimental|Study or Experimental Group|"moist hot pack.~manual therapy.~Therapeutic Exercise.~Home program routine. 5.3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill. For 10 weeks(3Times/week for 20 minutes)."
89074357|NCT00932113|Active Comparator|Adalimumab|Dosing will be on day 1 and then weekly. For the injections, dosing will occur according to product recommendations. Patients will receive 80mg adalimumab (2 pre-filled syringes, each with 40mg) on day 1, and then 40mg on week 1 and then every 2 weeks (from week 1 through week 15).
89074358|NCT00932113|Active Comparator|Methotrexate (MTX)|Patients will be dosed according to the CHAMPION study in single weekly doses of methotrexate: 7.5mg at week 0, 10mg at week two, and 15mg at week 4 for all patients. For each subject if the PASI did not decrease by at least 50% from baseline (PASI-50) at week 8, dosing will be increased to 20mg per week; the dose will be maintained at 15mg per week if PASI-50 was achieved at week 8. If PASI-50 was not achieved at week 12, dosing will be increased to 25mg per week; the dose will be maintained at 20mg per week if the PASI-50 was achieved at week 12. All patients on methotrexate will also receive a dietary supplement of oral folate (5mg per week). Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
89074359|NCT00931801|Experimental|Intervention Arm No.1|
89074360|NCT00931801|Experimental|Intervention Arm No.2|
89074361|NCT00931801|Active Comparator|Control Arm|Continue baseline regimen
89229990|NCT01090219|Experimental|two differents meshes|Heavy-weight versus low-weight polypropylene meshes
89074362|NCT04263805|Experimental|Vignette with research climate|Participants in this arm will receive vignettes describing a dilemma situation in research (e.g adding honorary author) with additional sentence describing research climate (i.e. an environment where their peer had detrimental practice in a similar situation)
89074363|NCT04263805|Active Comparator|Vignette without research climate|Participants in this arm will receive vignettes describing a dilemma situation in research without the additional sentence describing research climate
89074364|NCT00931723|Active Comparator|1|Seroquel XR and Lithium
89074365|NCT00931723|Placebo Comparator|2|Seroquel XR and placebo
89074366|NCT05025397|Experimental|Cohort A1: Danavorexton Low Dose|Danavorexton low dose or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
89074367|NCT05025397|Experimental|Cohort A2: Danavorexton Middle Dose|Danavorexton middle dose or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
89074368|NCT05025397|Experimental|Cohort A3: Danavorexton High Dose|Danavorexton high dose or danavorexton placebo-matching infusion, single, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction anesthetic and inhaled sevoflurane as the primary maintenance anesthetic.
89074369|NCT05025397|Experimental|Cohort P: Danavorexton TBD|"Danavorexton dose to be decided (TBD) or danavorexton placebo-matching infusion, once, intravenously on Day 1 in healthy adult participants with intravenous propofol as induction and primary maintenance anesthetic.~Dose of danavorexton will be based on the review of observed safety and tolerability data and pharmacokinetic (PK) data of previous cohorts."
89074370|NCT00608803|Experimental|Single arm|Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy.
89074371|NCT05234359||CHILD Cohort Study|"CHILD Cohort Study, a general population cohort of 3500 families (n~12,000) with children born in BC, AB, MB and ON between 2009-12. CHILD has dense longitudinal data (pregnancy to children aged 5-8 years) on physical and mental health, emotional wellbeing, child behaviour problems, and parenting stress, providing the powerful opportunity to identify and study changes in these parameters during the pandemic. CHILD participants have also granted permission for data linkage, providing the opportunity to link study data with administrative health data including clinical diagnoses, hospitalization and medication use. In this grant, the investigators will monitor SARS-CoV-2 seroprevalence among CHILD families and collect information about how they are experiencing the COVID-19 pandemic over the next 12 months.~Interventions - Diagnostic Testing via home kit at 2 timepoints:~Blood sample, Saliva sample, Stool sample"
89074372|NCT00931411|Experimental|Formulation 609580 20 then 609209|Formulation 609580 20 cream is applied topically to the entire body twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609209 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
89074373|NCT00931411|Active Comparator|Formulation 609209 then 609580 20|Formulation 609209 cream is applied topically to entire body, twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609580 20 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
89074374|NCT00609037||1|Individuals who has had a weight reduction procedure such as gastric bypass and have body contouring surgery to remove the excessive skin due to the weight loss
89074375|NCT00609037||2|Normal controls include individuals who schecule to have an abdominoplasty and are within normal for height and weight
89074376|NCT00931255|Active Comparator|Tacrolimus|Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
89074377|NCT00931255|Active Comparator|Sirolimus|5 mg, PO , daily
89074378|NCT05204485|Active Comparator|Fibular intramedullary nail|Randomized in the OR to ankle fracture repair with fibular intramedullary nail
89074379|NCT05204485|Active Comparator|Open reduction and internal fixation (ORIF)|Randomized in the OR to ankle fracture repair with ORIF
89074380|NCT04263103|Experimental|Experimental group with SJ-RS-WL2015|Item code: SJ-RS-WL2015, a visual training software program, 15 minutes of one section, twice a day, and for 1 year
89074381|NCT04263103|No Intervention|control group|No special treatment, but observation
89074382|NCT00609193||1|Study subjects receiving lithium
89074383|NCT00609193||2|Study subjects receiving quetiapine
89074384|NCT00930553|Experimental|Previously treated with alemtuzumab|Alemtuzumab 12 mg per day administered through IV, once a day for 3 consecutive days (participants might receive additional cycles of alemtuzumab upon documented evidence of resumed disease activity, but not within same 12-month period)
89074385|NCT00930553|Experimental|Previously treated with interferon beta-1a (Rebif®)|Alemtuzumab 12 mg per day administered through IV, once a day for 5 consecutive days during the first cycle and 12 mg per day administered through IV, once a day for 3 consecutive days during the second cycle, 12 months later. Participants might qualify for as-needed retreatment (12 mg per day administered through IV, once a day for 3 consecutive days) after their second fixed annual cycle.
89074386|NCT00609427|Experimental|EA|Training in external memory aids
89074387|NCT00609427|Experimental|MT|Mnemonic training intervention
89074388|NCT00609427|No Intervention|WL|Wait-list control
89074389|NCT00609505|Other|TM|Telemedicine genetic counseling group
89074390|NCT00609505|Other|FTF|Face-to-face genetic counseling group
89074391|NCT04262011|Other|immediate treatment|After randomization, patients who are allocated to the immediate treatment group will receive treatment.
89074392|NCT04262011|Other|postponed treatment|After randomized patients will be allocated to this group, they will wait for the follow-up of the study to receive delayed treatment.
89074393|NCT04261933||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
89229991|NCT01090297|Active Comparator|Fixed pressure|
89074394|NCT00609661||1|Patients presenting to the Ohio State University Emergency Department or directly admitted to the Ohio State University Burn Unit following thermal burn.
89074395|NCT00609661||2|Healthy volunteers
89074396|NCT00609817|Experimental|GCS-100|
89074397|NCT00929695|Experimental|Arm I (Low-dose)|Patients receive low-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
89074398|NCT00929695|Active Comparator|Arm II (Standard-dose)|Patients receive standard-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
89074399|NCT04261465|Experimental|Paclitaxel Carboplatin Olaparib|"Subjects will receive weekly therapy with paclitaxel 60 mg/m2 IV and carboplatin AUC 2 IV for 3 weeks out of 4, and olaparib tablets at the dose of 150 mg bid administered orally for 3 consecutive days (D1-D3), every week for each cycle.~After 3 cycles patients will be evaluated for interval debulking surgery. After surgery they will receive consolidation treatment with paclitaxel and carboplatin according to Investigator's choice"
89074400|NCT05115643|Experimental|Immobilized arm|Left arm of participant
89074401|NCT05115643|No Intervention|Non-immobilized arm|Right arm of participant
89074402|NCT04260997|Experimental|Oral Probiotic Product|
89074403|NCT04260997|Placebo Comparator|Placebo product|
89074404|NCT04260763|Experimental|Social Cognition Group|Social Cognition Group
89074405|NCT05080465|Experimental|Treatment Arm|A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
89074406|NCT00610285||non-invasive immobilization system|This is a feasibility study to evaluate the accuracy of an alternative, non-invasive immobilization system in combination with image guided patient setup for SRS treatments. The aim is to determine whether or not the non-invasive system can provide comparable accuracy as the conventional invasive head ring system. If successful, patient discomfort can be significantly reduced for such treatments.
89074407|NCT00610519|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
89074408|NCT00610519|Placebo Comparator|2|spray containing placebo.
89074409|NCT05063617|No Intervention|Wait-List Control|The wait-list control group will be instructed to maintain their current health habits and not to engage in any new physical activity or health programs for the next 8-weeks. The wait-list control group will be invited to access the intervention after 8-weeks.
89074410|NCT05063617|Experimental|mHealth Intervention|Intervention participants will be directed to the App store to download the Stronger Together app to proceed with app registration. Participants will then be connected with the community coach who is a 'real live person' who monitors in-app activity (this will be the program lead, SL). Other in-app features include peer discussion groups, behavioural support, and educational modules to support strategies to increase the quantity and quality of physical activity.
89074411|NCT00610597||1|alcoholic liver disease
89074412|NCT00610597||2|chronic hepatitis C virus infection
89074413|NCT04875325|Experimental|Standardized surveillance|Standardized surveillance strategy with routine imaging and serum tumor marker testing.
89074414|NCT04875325|No Intervention|Non-standardized surveillance|Non-standardized surveillance strategy according to current clinical practice.
89074415|NCT00927355|Active Comparator|Pioglitazone|half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qd for 4 weeks and dose increased to 30mg (2 tablets) qday if no adverse effects noted at the four week mark by study physician.
89074416|NCT00927355|Placebo Comparator|Placebo|"The other half will be randomized to placebo for 6 months. The placebo pills also start out with one 15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
89074417|NCT00923845|Other|Donors|A sibling who is 6/6 HLA --matched with the recipient. Donors undergo donor lymphocyte harvest and stem cell mobilization and harvest.
89074418|NCT00923845|Other|Recipients|Recipients undergo induction therapy, allogeneic stem cell therapy and GVHD prophylaxis.
89074419|NCT05329597||100mg|After 15 consecutive days of takeing 100mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
89074420|NCT05329597||200mg|After 15 consecutive days of takeing 200mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
89074421|NCT05329597||400mg|After 15 consecutive days of takeing 400mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
89074422|NCT05329597||600mg|After 15 consecutive days of takeing 600mg Umorestat capsule of each participant, 2 mL of peripheral venous blood is collected at 3 h, 8 h and 24 h (D16) on the 15th day into the vacuum blood collection tube via EDTA anticoagulation for genotyping and metabolite determination.
89074423|NCT05329519|Experimental|Music group|Patients in this groups underwent VATS with wedge recession, performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player and head phones on postoperative three days.
89074424|NCT05329519|No Intervention|Controlled group|Patients in this groups underwent VATS with wedge recession, performed deep breathing and coughing exercises for postoperative three days without music
89074425|NCT04256239|Experimental|Dignity Therapy Group|"Dignity Therapy is a short-term psychotherapy aimed at improving patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress. Therapy sessions, lasting between 20 and 60 minutes, were offered at the patients' bedside and audiotaped, and were conducted by a trained psyco-oncologist. After each therapy session, the audiotaped interview data were transcribed verbatim by a different psycho-oncologist and edited and reshaped into a written narrative by an expert in DT over the course of the next two to three days. Once the editing process was completed, another session was held to allow the therapist to read the generativity document to the patient and to make any editorial changes the patient deemed necessary. The final version of the generativity document was given to the patient to bequeath it to individuals of their choosing"
89074426|NCT04256239|No Intervention|Control Group (Standard Palliative Care)|Standard Palliative Care was performed by a multidisciplinary care team composed of a palliative doctor, a psycho-oncologist, a nurse, a physiotherapist, a healthcare assistant, a social assistant, a volunteer and a spiritual assistant, tailoring care to the needs of patients and their families.
89224325|NCT06269458|Experimental|Mother-Baby Yoga|The mothers in the Mother-Baby Yoga group were given a 10-minute training on mother-baby yoga before the application, and then a session was applied together. Mothers were asked to choose the most suitable time of day for themselves and the baby, to ensure that the baby was fed at least 45 minutes before yoga, and to practice yoga in a calm and dimly lit environment, listening to music or white noise of their choice. One yoga session lasted approximately 20 minutes. Mothers and their babies did mother-baby yoga three times a week for four weeks. Mother baby yoga content; Mood regulation: belly breathing, warm touch from the heart, chair pose, scoop hug, bukka bukka, vortex creation, lush falls one hand two hands, tiny stretches, here and now awareness and dolphin pose.
89224326|NCT06269445|Experimental|Icaritin Combined With Bevacizumab and FOLFIRI|"Icaritin: 600 mg orally, bid; Bevacizumab: Intravenous infusion, 5 mg/kg per dose, every 14 days; FOLFIRI: ①Irinotecan: Irinotecan should be given on the first day of chemotherapy at a dose of 180mg/m2 by intravenous drip.The infusion time should be >30-90min.~②Calcium folinate: give irinotecan at a dose of 400mg/m2 by intravenous drip in conjunction with irinotecan infusion, and the infusion time should be up to 2h.~③5-fluorouracil: give intravenous infusion at a dose of 400mg/m2 on the first day of chemotherapy, then give an intravenous drip at a dose of 1200mg/m2 for 2 days, the total amount of 2400mg/m2 , and continue to be infused for 46-48h."
89224327|NCT06269432|Experimental|Precision Antiplatelet Therapy Trial Group|Platelet function testing guides antiplatelet drug selection
89224328|NCT06269432|Active Comparator|Traditional Antiplatelet Therapy Control Group|Aspirin 100mg orally once a day
89224329|NCT06269406|Experimental|Intervention Group ibuprofen 400 and Curcumin|
89224330|NCT06269406|Experimental|Intervention Group ibuprofen 200 and Curcumin|
89224331|NCT06269406|Placebo Comparator|Intervention Group ibuprofen 400 and placebo|
89224332|NCT06269393|Placebo Comparator|Placebo|Participants with TAO will be randomized to receive 4 intravenous infusions of placebo with an interval of 3 weeks, followed by 4 intravenous infusions of IBI311 with an interval of 3 weeks.
89224333|NCT06269393|Active Comparator|IBI311|Participants with TAO will be randomized to receive 8 intravenous infusions of IBI311 with an interval of 3 weeks.
89224334|NCT06269354||Traumatic bone defect in lower limb|Traumatic bone defect in lower limb
89224335|NCT06269354||Infective lower limb bone defect|Infective lower limb bone defect
89224336|NCT06269354||Neoplastic bone defect in lower limb|Neoplastic bone defect in lower limb
89224337|NCT06269341||high-risk|Smoker and Drinker with Esophageal Squamous Cell Carcinoma after Esophagectomy
89224338|NCT06269341||low-risk|Non-Smoker and Non-Drinker with Esophageal Squamous Cell Carcinoma after Esophagectomy
89224339|NCT06269315|Experimental|Exposure arm|Prepared test products, such as household cleaner, hand disinfectant, their ingredients, and control on patch testing tapes will be posted on the selected areas of forearm skin.
89224340|NCT06269302||Patients with recurrent gastrointestinal bleeding|The data of all patients who applied to Samsun Training and Research Hospital for 12 months in 2022 and diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy were included in the study.Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of use of new generation oral anticoagulants in patients with rebleeding was determined, and data such as rebleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it.
89224341|NCT06269289|Experimental|intervention group|It will be determined using a table of random numbers. The group has been diagnosed for at least 1 year, It will consist of people (25) between the ages of 18-65, who can read and write in Turkish, who volunteer to participate in the study and who have not received any training before. After meeting the individuals and obtaining their verbal and written consent, they will be asked to fill out the Patient Information Form, Patient Empowerment Scale and Asthma Control Test obtained through Google Forms. Post-tests will be applied to individuals who complete all 5 modules of training.
89224342|NCT06269289|Active Comparator|Control group|The participants will be individuals who apply to the Allergy and Immunology Clinic of Istanbul Sureyyapasa Chest Diseases and Surgery Training and Research Hospital, have been diagnosed with asthma for at least one year and agree to participate in the study. It will consist of people who are between the ages of 18-65, understand Turkish, know how to read and write. Twenty five people selected by the randomization table method will be in the control group. They will be given the Ministry of Health's asthma education brochure. As in the intervention group, pre-test and post-test will be conducted.
89224343|NCT06269263|Experimental|Home-based cardiac rehabilitation|Home-based cardiac rehabilitation
88820841|NCT05586802|Experimental|Group 2 (Metabolic Risk) - randomized to Arm D|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an an experimental treatment
89224344|NCT06269250||sample assessed in Wave 2023|Participants can be any healthcare worker, including dental and medical assistants, aged 18 or older.
89224345|NCT06269250||sample assessed in Wave 2024|Participants can be any healthcare worker, including dental and medical assistants, aged 18 or older.
89074427|NCT04260451|Experimental|Driving pressure group|Positive end expiratory pressure is adjusted to tidal volume of 5 mL/kg of ideal body weight, inspiratory:expiratory=1:2, and minimize driving pressure (plateau pressure minus end expiratory pressure) during one-lung ventilation. Other procedures are same with the control arm.
89074428|NCT04260451|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 5mL/kg of ideal body weight and positive end expiratory pressure of 5cmH2O during one-lung ventilation
89074429|NCT04260373|Experimental|[14C]SHR4640|Patients will receive single dose of [14C]SHR4640 (Suspension, 10mg/80μCi).
89074430|NCT05052541|Experimental|Analgesia Arm: THC (tetrahydrocannabinol), then THC/CBD (cannabidiol), then Placebo|Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
89074431|NCT05052541|Experimental|Analgesia Arm: THC, then Placebo, then THC/CBD|Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
89074432|NCT05052541|Experimental|Analgesia Arm: THC/CBD, then THC, then Placebo|Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
89074433|NCT05052541|Experimental|Analgesia Arm: THC/CBD, then Placebo, then THC|Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
89074434|NCT05052541|Experimental|Analgesia Arm: Placebo, then THC, then THC/CBD|Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
89074435|NCT05052541|Experimental|Analgesia Arm: Placebo, then THC/CBD, then THC|Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.
89074436|NCT05052541|Experimental|Reduction Arm: THC/CBD|Subjects in this parallel arm will be assigned to 13 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.
89074437|NCT05052541|Placebo Comparator|Reduction Arm: Placebo|Subjects in this parallel arm will be assigned to 13 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
89074438|NCT04260685|Active Comparator|lidocaine|the Patient will receive IV bolus of 1.5mg/kg lidocaine 1% over ten minutes followed by continuous infusion of 1.5mg/kg/h
89074439|NCT04260685|Active Comparator|esmolol|the Patient will receive IV bolus of esmolol 0.5 mg/kg over ten minutes followed by continuous infusion of 100-300 ug/kg/min
89074440|NCT04259593|Experimental|Exercise Training Group|Exercise training group performed three weekly sessions for 16 weeks. This program consisted of moderate intensity aerobic, resistance, balance, and stretching exercises. The duration of every exercise session was 35 minutes during the first week and 65 minutes from the second week onward.
89074441|NCT04259593|No Intervention|Control Group|The control group received usual lymphoma care
89074442|NCT05052151|Active Comparator|Low temperature|Dialysate temperature
89074443|NCT05052151|Active Comparator|High temperature|Dialysate temperature
89074444|NCT05052151|Active Comparator|Low bicarbonate|Dialysate bicarbonate concentration
89074445|NCT05052151|Active Comparator|High bicarbonate|Dialysate bicarbonate concentration
89074446|NCT05013853|Active Comparator|Resin Z350 of proximal posterior teeth|Restorative with Z350 composite of proximal caries lesions or restorations replacement
89074447|NCT05013853|Active Comparator|Resin Tetric N Ceram Bulkfill of proximal posterior teeth|Restorative with Tetric N Ceram Bulkfill composite of proximal caries lesions or restorations replacement
89074448|NCT05013853|Experimental|Resin Fill Up! of proximal posterior teeth|Restorative with Fill Up! composite of proximal caries lesions or restorations replacement
89074449|NCT00610831|Experimental|DirectView CR Mammography|Each subject will have routine clinical care imaging obtained and 4 standard mammogram views (RMLO, RCC, LMLO, LCC) using CR mammography. If routine mammograms were obtained on a day previous to enrollment in the study, those images (4 views; 2 views for mastectomy patients) will not be repeated for this study; only the CR images will be obtained.
89224346|NCT06269237|Experimental|IPL|Participants in the group with 3 sessions of IPL, 2 weeks apart.
89074450|NCT05013463|Experimental|Hydroxychloroquine and Indapamide|Oral Hydroxychloroquine, 200mg BID Oral Indapamide, 2.5 mg OD
89074451|NCT05011591|Experimental|swimming economy|This is a study based on a comparative clinical trial (effect of an imposed V and/or SR on the swimming economy of swimmers or para-swimmers). This longitudinal study is carried out on a representative sample of swimmers and para-swimmers selected for their potential at the Paris 2024 Olympic and Paralympian Games. Following a standardized warm-up, all swimmers will perform intermittent swimming tests of progressive velocity in a 50 m indoor pool in their swimming specialty with or without an imposition of the SR to adopt. During the trials, the swimmers and para-swimmers will be equipped with inertial measurement units, as well as a heart rate monitor and tissue oximeters. The swimming and non-swimming phases will also be filmed continuously. Gas exchanges will be recorded 2 minutes after the warm-up and during the 7 minutes of passive recovery. Micro blood samples will be taken from the earlobe at the end of the warm-up and at 1, 3, 5 and 7 minutes of recovery between each trial.
89074452|NCT00922987||Lyrica|Adult patients with partial seizures (type of epilepsy). Inclusion criteria according to Summary of Product Characteristics
89074453|NCT00610909|Experimental|1|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
89074454|NCT00610909|Placebo Comparator|2|Same shape placebo
89074455|NCT05331079|Experimental|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
89074456|NCT05331079|No Intervention|Control|20 minutes of rest
89074457|NCT05046691|Experimental|Intervention group|8-week .b Foundations course
89074458|NCT05046691|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after their counterparts in experimental group completed the intervention.
89074459|NCT00928135|Active Comparator|7% Hypertonic saline|5 ml of 7% saline twice daily
89074460|NCT00928135|Experimental|Hypertonic xylitol|5 ml of 15% xylitol twice daily
89074461|NCT04259827|Experimental|Online cognitive training|6-week online personalized cognitive training using Neuronation platform 4 training session three times a week. Each session is composed of 5 exercises from one out of 4 cognitive domains: Memory, Attention, Speed and Reasoning
89074462|NCT04259827|Active Comparator|Aspecific online games|online application not created with a cognitive training purpose, for the same amount of time and frequence as the experimental group
89074463|NCT04259827|No Intervention|No online cognitive training|normal clinical follow-up without cognitive training or gaming
89074464|NCT00928057|Experimental|4 mm / 8 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 8mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
89074465|NCT00928057|Experimental|4 mm / 5 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 5mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
89074466|NCT05331547||BioFreedom BA9 (SS) Ultra DCS|STEMI patients treated with one or several BioFreedom stent(s)
89074467|NCT00927901|Experimental|Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate|In treatment period 1, patients received indacaterol maleate 400 μg; in treatment period 2, patients received placebo to indacaterol; in treatment period 3, patients received indacaterol xinafoate 400 μg; and in treatment period 4, patients received indacaterol acetate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89074468|NCT00927901|Experimental|Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo|In treatment period 1, patients received indacaterol xinafoate 400 μg; in treatment period 2, patients received indacaterol maleate 400 μg; in treatment period 3, patients received indacaterol acetate 400 μg; and in treatment period 4, patients received placebo to indacaterol 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89074469|NCT00927901|Experimental|Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate|In treatment period 1, patients received indacaterol acetate 400 μg; in treatment period 2, patients received indacaterol xinafoate 400 μg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89074470|NCT00927901|Experimental|Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate|In treatment period 1, patients received placebo to indacaterol; in treatment period 2, patients received indacaterol acetate 400 μg; in treatment period 3, patients received indacaterol maleate 400 μg; and in treatment period 4, patients received indacaterol xinafoate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89224347|NCT06269237|Sham Comparator|control|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart.
89229992|NCT01090297|Active Comparator|Auto-adjusting pressure|
89074471|NCT04255771|Experimental|Effect of adjuvant chemotherapy on pTanyN0M0 UTUC with LVI|This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study. Therapeutic value of adjuvant chemotherapy for LVI(+) patients with pT1N0M0, pT2N0M0, and pT3-4N0M0 upper urinary urothelial carcinoma, respectively.
89074472|NCT04255771|Placebo Comparator|Effect of placebo on pTanyN0M0 UTUC with lymphatic invasion|As a control, this clinical trial also set up a placebo control group. The effect of adjuvant chemotherapy was obtained by random grouping and comparing the effects of patients in the experimental group and the control group.
89074473|NCT05329363|Experimental|PEPITS programme|
89074474|NCT05329363|Active Comparator|Usual care|
89074475|NCT01218204|Other|Part A Run-in|Subjects on stable 40mg atorvastatin > 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.
89074476|NCT01218204|Experimental|Part A Co-Dosing 800mg GSK1292263|Dosing for 14 days
89074477|NCT01218204|Other|Part B Washout|Washout for 4 weeks
89074478|NCT01218204|Active Comparator|Part B Run-in 10mg atorvastatin|Dosing for 4 weeks
89074479|NCT01218204|Active Comparator|Part B Run-in 80mg atorvastatin|Dosing for 4 weeks
89074480|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 100mg GSK1292263|Dosing for 14 days
89074481|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 300mg GSK1292263|Dosing for 14 days
89224348|NCT06269211|Experimental|Toripalimab|Neoadjuvant Toripalimab 240 mg IV on cycle 1 day 1 (C1D1), C2D1 and C3D1 before radical surgery for lung cancer. The participants will attend follow-up visits based on molecular residual disease (MRD) and receive adjuvant treatment including EGFR-TKI or chemotherapy if recommended.
89224349|NCT06269159||Health care providers|10 health care providers: physiotherapist working with adults with overweight and obesity
89074482|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
89074483|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 10mg ezetimibe|Dosing for 14 days
89074484|NCT01218204|Experimental|Part B Dosing 100mg GSK1292263|Dosing for 14 days
89074485|NCT01218204|Experimental|Part B Dosing 300mg GSK1292263|Dosing for 14 days
89074486|NCT01218204|Experimental|Part B Dosing 800mg GSK1292263|Dosing for 14 days
89074487|NCT01218204|Experimental|Part B Dosing Placebo GSK1292263|Dosing for 14 days
89074488|NCT01218204|Experimental|Part B Co-Dosing 80mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
89074489|NCT01218204|Experimental|Part B Co-dosing 80mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
89074490|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
89074491|NCT00926575|Experimental|orBec®|Investigational drug
89074492|NCT00926575|Placebo Comparator|Placebo|Control
89074493|NCT01218126|Experimental|losmapimod 2.5 mg|losmapimod 2.5 mg
89074494|NCT01218126|Placebo Comparator|placebo|
89074495|NCT01218126|Experimental|losmapimod 7.5 mg|losmapimod 7.5 mg
89074496|NCT01218126|Experimental|losmapimod 15 mg|losmapimod 15 mg
89074497|NCT05456412|Experimental|Treatment JAK inhibitor|Clinical practice is followed for all patients treated with JAK inhibitor. Additional biopsies and blood is taken.
89074498|NCT01217892|Experimental|1|Dapagliflozin 2.5 mg twice-daily plus open-label metformin
89074499|NCT01217892|Experimental|2|Dapagliflozin 5.0 mg twice-daily plus open-label metformin
89074500|NCT01217892|Experimental|3|Dapagliflozin 10 mg once-daily plus open-label metformin
89074501|NCT01217892|Placebo Comparator|4|Placebo plus open-label metformin
89074502|NCT01217814|Placebo Comparator|Placebo|Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.
89074503|NCT01217814|Active Comparator|Golimumab 50 mg|Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.
89074504|NCT01217814|Experimental|Sarilumab 150 mg|Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.
88820842|NCT05586802|Experimental|Group 2 (Metabolic Risk) - randomized to Arm E|Men with Klinefelter syndrome not interested in fertility that present with high metabolic risk and consent to a wash-out of testosterone replacement therapy. They are subsequently randomized to receive an hormonal treatment to improve metabolic health. This arm will receive an an experimental treatment
89074505|NCT01217190|Experimental|Ondansetron ODFS then Zofran ODT|Single dose of Ondansetron Orally Dissolving Film Strip 8 mg followed by single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg with 7 days washout between the 2 periods
89074506|NCT01217190|Experimental|Zofran ODT then Ondansetron ODFS|Single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg followed by single dose of Ondansetron Orally Dissolving Film Strip 8 mg with 7 days washout between the 2 periods
89074507|NCT01136733|Experimental|Lenvatinib|
89074508|NCT01136733|Experimental|Lenvatinib plus Everolimus|
89074509|NCT01136733|Active Comparator|Everolimus|
89074510|NCT05178693|Experimental|Treatment|
89074511|NCT01136655|Experimental|BUD 160/FM 2.25|2.25 μg formoterol (as 80/2.25 μg Symbicort pMDI × 1 inhalation) + 40 μg budesonide HFA pMDI × 2 inhalations
89074512|NCT01136655|Experimental|BUD 160/FM 4.5|placebo HFA pMDI × 1 inhalation + 4.5 μg formoterol (as 80/2.25 μg Symbicort pMDI × 2 inhalations)
89074513|NCT01136655|Experimental|BUD 160/FM 9.0|placebo HFA pMDI × 1 inhalation + 9 μg formoterol (as 80/4.5 μg Symbicort pMDI × 2 inhalations)
89074514|NCT01136655|Placebo Comparator|BUD 160|placebo HFA pMDI × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
89074515|NCT01136655|Active Comparator|BUD 160/Foradil 12.0|Foradil Aerolizer 12 μg × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
89074516|NCT04312581|Experimental|First group (shock wave)|Extracorporeal shock wave therapy
89074517|NCT04312581|Active Comparator|Second group (conventional rehabilitation)|conventional rehabilitation
89074518|NCT01135017|Experimental|Dronedarone|Dronedarone 400 mg twice a day for 12 weeks
89074519|NCT01135017|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day for 12 weeks
89074520|NCT01134939||HIV-infected women and men|
89074521|NCT02883153|Experimental|Zirconium-89 girentuximab PET/CT|A Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq).
89074522|NCT01134783|Experimental|Intervention Group|The CHOICES intervention included a 1-credit, academic college course focusing on healthy weight behaviors and participation in a social networking and social support website
89074523|NCT01134783|No Intervention|Control Group|Control group (serving as a comparison group)
89074524|NCT01134705|Experimental|BDP HFA 320 µg/day|During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
89074525|NCT01134705|Placebo Comparator|Placebo|During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
89074526|NCT00927823|Experimental|PF-04691502 Treatment|
89074527|NCT01134627|Experimental|Minocycline group|
89074528|NCT01134627|Placebo Comparator|Placebo Group|
89074529|NCT04992715|Experimental|Metastatic Non-Small Cell Lung Cancer|"Subjects with metastatic non-small cell lung cancer will be recruited as per protocol inclusion/exclusion criteria and will undergo [99mTc]-anti-PDL1 single-domain antibody ([99mTc]-NM-01) SPECT/CT imaging.~[99mTc]-NM-01 SPECT/CT images will be compared to immunohistochemistry PD-L1 expression results."
89074530|NCT01134393|Experimental|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of blood pressure goal
89074531|NCT05331469|Active Comparator|Daily basal insulin titration|Participants in this intervention arm will be started with basal insulin of 10 units or 0.2 unit/kg (whichever lower) at pre-bed time. They will then check their morning fasting CBG the following day. If they have no hypoglycemia symptoms or documented hypoglycemic CBG (<3.9mmol/L), and their fasting CBG is more than 7mmol/L, they will then self-titrate their basal insulin by 1 unit (ie 10+1) the following night. This same process is going to be repeated until their fasting CBG achieve 7mmol/L or lower. Then, they will continue and maintain on the desired basal insulin dosage till their appointment. The maximum basal insulin that is allowed to be titrated by the participants is up to 0.5unit/kg. Participants are required to document down their CBG and any hypoglycemia symptoms in a simple table method provided to them
88820843|NCT05583474|Experimental|subject receive OPC-1085EL solution|OPC-1085EL group ，one drop for each eye, once per day for 8 weeks
89074532|NCT05331469|Active Comparator|3 daily basal insulin titration|Participants in this intervention arm will be started with basal insulin of 10 units or 0.2 unit/kg (whichever lower) at pre-bed time. They will then check their morning fasting CBG the following 3 days. If they have no hypoglycemia symptoms or documented hypoglycemic CBG (<3.9mmol/L), and their fasting CBG is more than 7mmol/L (for 2 out of 3 days), they will then self-titrate their basal insulin by 2 units (ie 10+2) on the 3rd night. This same process is going to be repeated until their fasting CBG achieved 7mmol/L or lower. Then, they will continue and maintain on the desired basal insulin dosage till their appointment. The maximum basal insulin that is allowed to be titrated by the participants is up to 0.5unit/kg. Participants are required to document down their CBG and any hypoglycemia symptoms in a simple table method provided to them.
89074533|NCT00610753|Experimental|Family Behavioral Therapy|This intervention focuses on counseling the parents (and other family members) on refeeding their child. When weight is being steadily regained the focus of therapy shifts to allow the child more independence.
89074534|NCT00610753|Active Comparator|Systems Family Therapy|This therapy focuses primarily on clarifying psychological processes within the family.
89074535|NCT00922441|Experimental|Fimasartan 1|Fimasartan 60 mg group
89074536|NCT00922441|Experimental|Fimasartan 2|Fimasartan 120 mg group
89074537|NCT00922441|Active Comparator|Valsartan|Reference (Valsartan 80 mg) group
89074538|NCT01217112|Active Comparator|GWP42004 and placebo|Contains GWP42004 5 mg and placebo (excipients only)
89074539|NCT01217112|Active Comparator|1:1 GWP42003 : GWP42004|Contains 5 mg each of GWP42003 and GWP42004
89074540|NCT01217112|Active Comparator|20:1 GWP42003 : GWP42004|Contains 100 mg GWP42003 and 5 mg GWP42004
89074541|NCT01217112|Placebo Comparator|Placebo|Contains excipients only
89074542|NCT01217112|Active Comparator|GWP42003 and placebo|Contains 100 mg GWP42003 and placebo (excipients only)
89074543|NCT01216332|Experimental|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
89074544|NCT01216332|Active Comparator|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
89074545|NCT00922207|Experimental|1|
89074546|NCT00922207|Experimental|2|
89074547|NCT00922207|Placebo Comparator|3|
89074548|NCT05316103|Experimental|Endoscopic biopsy and probe-based confocal laser endomicroscopy biopsy|In this study , endoscopic biopsy and pCLE-targeted optical biopsy will be successively performed for local rectal scars in rectal cancer patients after neoadjuvant chemoradiotherapy.
89074549|NCT04255459|Other|Moist Snuff users|Subjects for whom moist snuff is their usual brand of tobacco product.
89074550|NCT04255459|Other|Camel Snus users|Subjects for whom Camel Snus is their usual brand of tobacco product.
89074551|NCT04255459|Other|Dual users of Camel Snus and cigarette|Subjects who use both Camel Snus and cigarettes as their usual brands of tobacco products.
89074552|NCT04255459|Other|Dual users of moist snuff and cigarettes|Subjects who use both moist snuff and cigarettes as their usual brands of tobacco products.
89074553|NCT04255459|Other|Cigarette smokers|Subjects for whom cigarettes is their usual brand of tobacco product.
89074554|NCT04255459|Other|Non-tobacco users|Subjects who do not use tobacco products.
89074555|NCT01134315||Paricalcitol|Pediatric participants who received paricalcitol capsules to treat secondary hyperparathyroidism (SHPT). Paricalcitol was prescribed by each physician under the usual and customary practice of that physician.
89074556|NCT01134315||Calcitriol|Pediatric participants who received calcitriol to treat secondary hyperparathyroidism (SHPT). Calcitriol was prescribed by each physician under the usual and customary practice of that physician.
89074557|NCT04253431|Experimental|L01|Finger pricking using lancing device with personal lancets
89074558|NCT04253431|Experimental|L02|Finger pricking using lancing device with personal lancets
89074559|NCT04253431|Experimental|L03|Finger pricking using lancing device with personal lancets
89074560|NCT04253431|Experimental|L04|Finger pricking using lancing device with personal lancets
89074561|NCT04253431|Experimental|L05|Finger pricking using lancing device with personal lancets
89074562|NCT04253431|Experimental|L06|Finger pricking using lancing device with personal lancets
89074563|NCT04253431|Experimental|L07|Finger pricking using lancing device with personal lancets
89074564|NCT04253431|Experimental|L08|Finger pricking using lancing device with personal lancets
89074565|NCT04253431|Experimental|L09|Finger pricking using lancing device with personal lancets
89074566|NCT04253431|Experimental|L10|Finger pricking using lancing device with personal lancets
89074567|NCT01216176|Experimental|Phase 1 - Cohort A|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer
89074568|NCT01216176|Active Comparator|Phase 2 - Cohort B [Anastrozole + AZD0530]|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression or 4-6 months of treatment completed.
89074569|NCT01216176|Placebo Comparator|Phase 2 - Cohort B [Anastrozole + Placebo]|Dual treatment with 1 mg anastrozole orally once daily together with Placebo orally once daily, or as specified per protocol, until disease progression or4-6 months of treatment completed.
89074570|NCT05330845|Other|Patients with COVID-19 acute respiratory distress syndrome|Patients with acute respiratory distress syndrome due to COVID-19 and requiring mechanical ventilation
89074571|NCT01133847|Experimental|Intensive Reading Instruction|Specialized phonologically-based reading instruction provided by well-trained tutors either individually (one-on-one) or to groups of two students for 45 minutes, four days per week, for 16 weeks. The instructional approach includes an individualized combination of published programs targeting word reading and decoding; reading fluency; and reading comprehension.
89074572|NCT01133847|Experimental|ADHD Intervention|Carefully-managed medication and behavioral parent training. Medication treatment begins with a four-week titration period, beginning with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions provided by a psychologist addressing ADHD and its treatment, principals of behavior modification, and evidence-supported practices for managing behavior.
89074573|NCT01133847|Experimental|Combined ADHD and Reading Instruction|"All interventions described in Reading Instruction and ADHD treatment arms:~Phonologically-based reading instruction provided for 45 minutes, four days per week, for 16 weeks. Carefully-managed medication and behavioral parent training. Medication treatment begins with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions on parenting a child with ADHD."
89074574|NCT05000125||Slides from the German Co-Screening program|From 32506 LBC slides (ThinPrep, Hologic Inc., USA) from the German Co-screening program measured in 2020 with the TIS all abnormal findings according to Munich III groups (II-p - V) and 3% of normal slides (Munich III groups (I+II-a)) will be selected for the additional measurement with the Genius Digital cytology system.
89074575|NCT02887950|Active Comparator|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
89074576|NCT02887950|Experimental|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
89074577|NCT02887950|Experimental|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
89074578|NCT02883075|Sham Comparator|Supine position|Supine position Supine position after placement of spinal anesthetic
89074579|NCT02883075|Active Comparator|Right lateral position|Right lateral position Right lateral after placement of spinal anesthetic
89074580|NCT02883075|Active Comparator|Left lateral position|Left lateral position Left lateral after placement of spinal anesthetic
89074581|NCT04984525|Experimental|Part 1 Cohort 1 MAD HV: SYNB1934 (3 x 10^11 live cells)|HV subjects receive SYNB1934 (3 x 10^11 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
89074582|NCT04984525|Experimental|Part 1 Cohort 2 Crossover HV: SYNB1934 (6 x 10^11 live cells)|HV subjects receive SYNB1934 (6 x 10^11 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2 Following a ≥ 7-day washout period HV subjects receive SYNB1618 (6 x 10^11 live cells), at least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
89074583|NCT04984525|Experimental|Part 1 Cohort 3 MAD HV: SYNB1934 (1 x 10^12 live cells)|HV subjects receive SYNB1934 (1 x 10^12 live cells) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
89074584|NCT04984525|Experimental|Part 1 Cohort 4 MAD HV: SYNB1934 (optional)|HV subjects receive SYNB1934 (at a dose to be determined based on the data from the first 3 cohorts) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
89074585|NCT04984525|Experimental|Part 1 Cohort 5 MAD HV: SYNB1934 (optional)|HV subjects receive SYNB1934 (at a dose to be determined based on the data from the first 3 cohorts) At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
89074586|NCT04984525|Experimental|Part 2 Crossover with PPI vs No PII|HV subjects receive SYNB1934 (at or below the MTD from Part 1) with PPI At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2 Following a ≥ 14-day washout period HV subjects receive SYNB1934 (at or below the MTD from Part 1) without PPI At least 3 times per day (TID) on Treatment Day 1 and once at breakfast on Treatment Day 2
89074587|NCT04255537||Patients with STEACS intended for urgent angio/reperfusion.|This population mostly includes STEACS patients for whom primary PCI is intended. A minority of this population includes patients with STEACS intended for urgent angiography for persistent ST elevation and/or symptoms but with symptoms onset > 12 hours (secondary PCI), urgent angiography after failed fibrinolysis (rescue PCI), or patients receiving fibrinolysis.
89074588|NCT04255537||Patients with STEACS NOT intended for urgent angio/reperfusion|This population mostly includes STEACS patients not receiving reperfusion for late presentation (i.e. > 12 hours) or patient preference. Note that patient in this category may receive diagnostic angiography for better diagnostic assessment and/or risk stratification but NOT on an urgent basis.
89229993|NCT03955549|Experimental|Insight Enhancement Program (IEP)|The insight enhancement program is a dynamo-cognitive therapeutic modality with the main target of improving insight in psychotic patients as a means of improving their overall outcome.
89074589|NCT04255537||Patients with NSTEACS intended for invasive management|This population includes patients with NSTEACS managed invasively with coronary angiography within 72 hours. Most patients are a high-risk feature (i.e. positive troponin, GRACE risk score > 140, hemodynamic/electrical instability) for whom angiography is intended.
89074590|NCT04255537||Patients with NSTEACS NOT intended for invasive management|This population includes patients who are candidate for an initially conservative strategy. Note that this category may include patients who are subsequently managed with coronary angiography, including recurring symptoms of myocardial ischemia, or hemodynamic/ electrical instability.
89074591|NCT01133379|Experimental|PO-019|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride (12027-019)
89074592|NCT01133379|Experimental|PO-020|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride (12027-020)
89074593|NCT01133379|Sham Comparator|PO-021|Vehicle Control Mouthrinse (without potassium oxalate and without fluoride) (12027-021)
89074594|NCT04259437|Experimental|High Protein, Energy Dense Nutritional Supplement|2 servings per day
89074595|NCT04259515|Active Comparator|Bukcberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
89074596|NCT04259515|Experimental|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
89074597|NCT04259671|Experimental|Intervention- My Autism Passport App|"Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. The contact information for a member of the research team who will be able to provide technical support will be available on the consent form. Families will use the mobile application for a total of 18 months.~Given that this is a pragmatic trial of a tool that tracks services, it also may be used to communicate service access to other providers."
89074598|NCT04259671|No Intervention|Control-Standard of care|Families in the control group will continue with standard of clinical care, and receive any of the usual supports their clinic and region provides, including access to physicians, service navigators, social workers, nurses, etc.
89074599|NCT01132755|Experimental|Patients who require diagnostic laparoscopy|Diagnostic peritoneal lavage will be performed at the time of laparoscopy utilizing a Veress needle/Seldinger technique to insert a peritoneal dialysis catheter. This is not a new technique. The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon.
89074600|NCT04312035|Experimental|End-range mobilization|End-range mobilization performed in end-position of the knee joint
89074601|NCT04312035|Experimental|Non end-range mobilization|Non end-range mobilization performed in loose-packed position of the knee joint
89074602|NCT04312035|Placebo Comparator|Control|Sham technique performed in loose-packed position of the knee joint
89074603|NCT04311957|Active Comparator|Boosted PI Group|"Continuation of the same second-line regimen taken prior to entry:~This includes either Lopinavir/ritonavir (LPVr) 400 mg/100 mg BID or Atazanavir/ritonavir (ATV/r) 300 mg/100 mg QD~plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)."
89074604|NCT04311957|Experimental|B/F/TAF Group|Combination tablet of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
89074605|NCT02882997|Experimental|Duck Duck Punch|"Community dwelling stroke survivors: Stroke survivors will install an interactive computer game in their home. Subjects will be instructed to play the computer game as much as you want to every day for 7 days. Inpatient stroke patients: The interactive computer game will be installed at a local inpatient stroke rehabilitation hospital. Subjects will be instructed to play this game as much as you want to during non-therapy hours (evenings and weekends) over the next 7 days."
89074606|NCT02882997|Active Comparator|Standard activities|"Community dwelling stroke survivors: Subjects will receive a hard-copy handout of an arm home exercise program and given the instructions to do these exercises as many times as you can daily. Inpatient stroke patients: Subjects will be encouraged to participate in standard evening/weekend recreational activities and to remember to use the paretic arm as much as you can."
89074607|NCT00919711|Experimental|Denosumab 60 mg|
89074608|NCT00919711|Active Comparator|Risedronate 150 mg QM|
89074609|NCT01131585|Experimental|Active laser photocoagulation and ranibizumab|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
89074610|NCT01131585|Active Comparator|Active laser photocoagulation and sham injection|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
89074611|NCT01131507|Experimental|EUR-1008 (APT-1008)|
89074612|NCT01131351|Experimental|Delamanid 250 mg BID+ OBR|Participants received delamanid five 50 milligrams (mg) (250 mg) tablets, twice a day (BID), along with at least 2 additional anti-TB medications per optimized background regimen (OBR) for up to 28 weeks.
89074613|NCT01131351|Experimental|Delamanid 300 mg BID+ OBR|Participants received delamanid six 50 mg (300 mg) tablets, BID, along with at least 2 additional anti-TB medications per OBR for up to 28 weeks.
89074614|NCT04311879|Experimental|Soft tissue laser Diode laser application|Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices. Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product
89074615|NCT04311879|Placebo Comparator|conventional root canal treatment|Placebo : conventional root canal conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with mock laser intervention
89074616|NCT00919633|Experimental|Group 1: interferon alfa-2b (dose 1)|continuous subcutaneous infusion for 48 weeks
89074617|NCT00919633|Experimental|Group 2: interferon alfa-2b (dose 2)|continuous subcutaneous infusion for 48 weeks
89074618|NCT00919633|Experimental|Group 3: interferon alfa-2b (dose 3)|continuous subcutaneous infusion for 48 weeks
89074619|NCT00919633|Active Comparator|Group 4: peginterferon alfa-2b (1.5 μg/kg)|subcutaneous weekly for 48 weeks
89074620|NCT04311801|Experimental|OCT Arm|Each patient underwent OCT examinations.
89074621|NCT05143905|Experimental|Cohort 1: AZD7503 dose 1|Randomised healthy participants will receive a single dose 1 of AZD7503.
89074622|NCT05143905|Experimental|Cohort 2: AZD7503 dose 2|Randomised healthy participants will receive a single dose 2 of AZD7503.
89074623|NCT05143905|Experimental|Cohort 3: AZD7503 dose 3|Randomised healthy participants will receive a single dose 3 of AZD7503.
89074624|NCT05143905|Experimental|Cohort 4: AZD7503 dose 4|Randomised healthy participants will receive a single dose 4 of AZD7503.
89074625|NCT05143905|Experimental|Cohort 5 : AZD7503 dose X|Randomised healthy participants will receive a single dose X of AZD7503.
89074626|NCT05143905|Experimental|Cohort 6: AZD7503 dose Y|Randomised healthy participants will receive a single dose Y of AZD7503.
89074627|NCT05143905|Placebo Comparator|Pooled Placebo for AZD7503 (Cohorts 1 to 6)|Randomised healthy participants will receive placebo.
89074628|NCT05143905|Experimental|Japanese Cohort 1: AZD7503 dose 3|Randomised healthy Japanese participants will receive a single dose 3 of AZD7503.
89074629|NCT05143905|Experimental|Japanese Cohort 2: AZD7503 dose 4|Randomised healthy Japanese participants will receive a single dose 4 of AZD7503.
89074630|NCT05143905|Placebo Comparator|Placebo (Japanese Cohorts)|Randomised healthy Japanese participants will receive placebo.
89074631|NCT05143905|Experimental|Chinese Cohort: AZD7503 dose 4|Randomised healthy Chinese participants will receive a single dose 4 of AZD7503.
89074632|NCT05143905|Placebo Comparator|Placebo (Chinese Cohort)|Randomised healthy Chinese participants will receive placebo.
89074633|NCT04859647|Other|Therapy Intervention|Method of Levels Therapy Intervention - Clients will choose how many sessions to attend during the 6 months therapy window. Clients will also choose how often to attend sessions and the duration of each session.
89074634|NCT04255225|Experimental|10-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
89074635|NCT04255225|Experimental|20-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
89074636|NCT04255225|Experimental|30-minute Treadmill Walking|All participants will walk on the treadmill and perform a battery of cognitive tasks immediately prior and immediately after the walking session. Participants will be randomized the length of time spent walking on the treadmill: 10, 20 or 30 minutes.
89074637|NCT01130883||Respiratory Infections|Czech patients with acute tracheitis, acute tracheobronchitis or acute bronchitis; or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid®SR treatment 6 weeks prior to the next Klacid®SR dose or in intervals: 7-week - 3- month, 4- month - 12- month, 13- month - 24- month prior to the next Klacid®SR dose (next Klacid®SR dose = dose administered within this PMOS).
89074638|NCT00926029|Placebo Comparator|Fluoride control -A|Winterfresh Gel
89074639|NCT00926029|Active Comparator|Triclosan/Fluoride - B|Positive control (Total toothpaste)
89074640|NCT00926029|Experimental|Triclosan/fluoride/metal salt- C|test toothpaste
89074641|NCT04254835|Experimental|intervention group|Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will applied to this group once at the beginning of the study.Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.
89074642|NCT04254835|Active Comparator|control group|"Varnish containing Fluoride (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein). will applied to this group once at the beginning of the study.~Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks."
89074643|NCT04254991||Infectious disease group|
89074644|NCT04254991||Non-infectious disease group|
89074645|NCT04980547|Experimental|ACUMED® Scapholunate Repair System|All participants in this trial will undergo the surgical RASL procedure using the ACUMED® Scapholunate Repair System.
89074646|NCT04254757|Other|Percutaneous endoscopic surgery group|
89074647|NCT04254757|Other|Open decompression and fusion surgery group|
89074648|NCT01130493|Other|IPX066-CLE-OLE|Dose conversion from CLE to IPX066, IPX066 (Part 1 Period 1), Open-label IPX066, CLE (Part 1 Period 2), OLE (Part 2)
89074649|NCT01130493|Other|CLE-IPX066-OLE|Dose conversion from CLE to IPX066, CLE (Part 1 Period 1), Open-label IPX066, IPX066 (Part 1 Period 2), OLE (Part 2)
89074650|NCT04255069|Placebo Comparator|Placebo|Placebo, oral, daily
89074651|NCT04255069|Experimental|Dose 1|JKB-122, Dose 1, oral, daily
89074652|NCT04255069|Experimental|Dose 2|JKB-122, Dose 2, oral, daily
89074653|NCT04252651||Blood Draw|This study will involve blood draws to test for specific cytokines
89074654|NCT01130337|Experimental|1|
89074655|NCT04901689|Experimental|Leronlimab (700 mg)|Leronlimab 700 mg intravenously once a week (up to 4 doses) until hospital discharge
89074656|NCT04901689|Placebo Comparator|Placebo|Placebo intravenously once a week (up to 4 doses) until hospital discharge
89074657|NCT04252963|Experimental|Mucolase|
89074658|NCT04252963|Placebo Comparator|Placebo|
89074659|NCT04258657|Experimental|Paclitaxel-albumin and S-1|
89074660|NCT04252729|Experimental|Psychotherapy|Psychotherapy sessions based on the theoretical line of Psychoanalytic Psychosomatics for 1 year, every 10 days.
89074661|NCT04252729|No Intervention|No psychotherapy|Follow-up according to institutional routine, without psychotherapy sessions.
89074662|NCT01130103|Experimental|Paroxetine|Paroxetine and Prolonged Exposure Therapy
89074663|NCT01130103|Placebo Comparator|Placebo pill|Placebo pill plus Prolonged Exposure Therapy
89074664|NCT04254523|Experimental|Programmed intermittent epidural bolus (PIEB)|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour.
89074665|NCT04254523|Experimental|Continuous epidural infusion (CEI)|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate in milliliters per hour.
89074666|NCT02882919|Experimental|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
89074667|NCT02882919|No Intervention|Usual care|In the usual care group, patients are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors
89074668|NCT04258501|Experimental|Mulberry fruit extract|1.5 g of mulberry fruit powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
89074669|NCT04258501|Experimental|Mulberry leaf extract|1.0 g of mulberry leaf powdered extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
89074670|NCT04258501|Experimental|White bean extract|3 g of white bean powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
89074671|NCT04258501|Experimental|Apple extract|2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
89074672|NCT04258501|Experimental|Elderberry extract|2 g of elderberry powder extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
89074673|NCT04258501|Experimental|Turmeric extract|0.18 g of curcumin powdered extract mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
89074674|NCT04258501|Experimental|Turmeric extract + Apple extract|0.18 g of curcumin powdered extract + 2 g of apple powdered extract standardized in phloridzin mixed into a bowl containing 60 g of extruded rice + 300 ml of boiling water
89074675|NCT04258501|Experimental|Turmeric extract + Elderberry extract|0.18 g of curcumin powdered extract + 2 g of elderberry powder extract mixed into aa bowl containing 60 g of extruded rice + 300 ml of boiling water
89074676|NCT04258501|Placebo Comparator|Rice porridge control|Bowl containing 60 g of extruded rice + 300 ml of boiling water
89074677|NCT00625209|Placebo Comparator|1|placebo of hydrocortisone, placebo of fludrocortisone and placebo of activated protein C
89074678|NCT00625209|Active Comparator|2|Hydrocortisone plus fludrocortisone and a placebo of activated protein C
89074679|NCT00625209|Active Comparator|3|placebo of hydrocortisone, placebo of fludrocortisone and activated protein C
89074680|NCT00625209|Active Comparator|4|hydrocortisone plus fludrocortisone plus activated protein C
89074681|NCT04254445|Experimental|Training video arm|Patients will watch a personalized custom training video, in addition to the standard explanation provided by the medical staff
89074682|NCT04254445|No Intervention|Verbal explanation arm|Patients will standard explanation about the procedure, provided by the medical staff
89074683|NCT02882841|Other|Single-arm study|
89074684|NCT04254601|Experimental|Experimental group 1|Patients in group (A) consisted of 15 participants, received a program of NBUB, DIXWELL EMLY 98 -ABRP 64 ,made in France (wavelength 311 to 313nm) , in addition to topical aknemycin medications (topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period after 8 weeks).
89074685|NCT04254601|Experimental|Experimental group 2|Participants in-group (B) consisted of 15 participants, received a program of R-LLLT that was conducted through laser equipment InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia) with fluence 12 J/cm2, two sessions per week for 8 weeks Plus topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
89074686|NCT04254601|Active Comparator|Control group|Patients in the group C, consisted of 15 participants, were asked to apply topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period.
89074687|NCT04851223||Pre Diabetics|
89074688|NCT01129557|Active Comparator|Tekturna|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months
89074689|NCT01129557|Active Comparator|Diovan|Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months
89074690|NCT01129557|Active Comparator|Tekturna & Diovan|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily & Diovan (Valsartan), an angiotensin receptor (ARB) 160 mg by mouth once daily for 9 months
89074691|NCT04976413|Experimental|Experimental|Experimental arm will receive eight phase EMDR treatment using standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12 -14 weeks . Follow up will be conducted after 12 weeks of treatment completion.
89074692|NCT04976413|Active Comparator|Control|Control group will receive treatment as usual (supportive counselling) for 12 -14 weeks
89074693|NCT04831567|Experimental|Interventional|The participants will be submitted to metaiodobenzylguanidine 4 doses of 7.400 Mbq (million of Becquerels) (200 mCi). Each dose will be repeated with a minimum interval of 60 days.
89074694|NCT04884295|Experimental|XVR011|Single Ascending Dose with 3 dose cohorts: low dose - medium dose - high dose (Phase 1)
89074695|NCT04254679|Experimental|Opioid analgesia|
89074696|NCT04254679|Active Comparator|Opioid-free analgesia|
89074697|NCT01129011|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
89074698|NCT01129011|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
89074699|NCT04254211||EVAR|Patinets with AAA, treated electively by EVAR. The values of simple inflammatory markers,neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), were measured pre- and postoperatively. Adverse events included any major adverse cardiovascular events (MACE), acute kidney injury and death from any cause
89074700|NCT04253041|Experimental|Control|The control group will be exposed to 15 different appearance-neutral images of interior design, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was most prevalent in the previous image?) regarding characteristics of the last image they were exposed to.
89074701|NCT04253041|Experimental|Fitspiration|Participants assigned to the Fitspiration condition (n=30) will be exposed to 15 different fitspiration images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
89074702|NCT04253041|Experimental|Body Positive|Participants assigned to the Body Positive condition (n=30) will be exposed to 15 different body positive images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.
89074703|NCT02882607|Experimental|Intervention group|Reproductive Health Peer Groups
89074704|NCT02882607|No Intervention|Control group|no intervention
89074705|NCT04203589|Experimental|The Explorer Early Intervention Program|The Explorer Early Intervention Program is used in this group.
89074706|NCT04203589|Active Comparator|Neurodevelopmental Therapy|Neurodevelopmental therapy is used in these group by two experienced and certificated physiotherapist
89074707|NCT02882763|Experimental|Parents As Teachers (PAT)|c.f. intervention
89074708|NCT02882763|No Intervention|control group condition|Families in the control group condition did not receive the home visiting program PAT, but were informed about support services in their community. The use of these services was permitted for ethical reasons; however, parents were regularly asked about the nature and intensity of the retrieved services. Additionally, all parents received incentives, such as greeting cards, small birthday presents, and monetary reimbursements.
89074709|NCT02882373|Experimental|Group I (arginine)|Patients receive arginine PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
89074710|NCT02882373|Placebo Comparator|Group II (placebo)|Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
89074711|NCT04258735|Other|Metastatic breast cancer cohort|Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome
89074712|NCT04873765|Experimental|Pegfilgrastim Megalabs|Pegfilgrastim injectable 6 mg in a single subcutaneous application.
89074713|NCT04873765|Active Comparator|Pegfilgastrim Neulastim|Neulastim injectable 6 mg in a single subcutaneous application.
89229994|NCT03955549|Experimental|Metacognitive Training for Psychosis (MCT)|The metacognitive training program, developed by Moritz et al. (Moritz & Woodward, 2007) targets cognitive biases putatively involved in the formation and maintenance of psychotic symptoms.
88820844|NCT05583474|Active Comparator|subject receive 0.005% latanoprost ophthalmic solution|0.005% latanoprost ophthalmic solution group ，one drop for each eye, once per day for 8 weeks
88820845|NCT05580536|Other|Project Dulce + Dulce Digital|Participants will participate in a peer-led group diabetes self-management education and support program and receive ongoing support via text messages designed to improve knowledge, health beliefs, self-management behaviors and clinical outcomes.
89074714|NCT04254055|Experimental|Experimental group|"Exercise 1 with medicine ball. Standing player with 90º shoulder abduction and elbow flexion. He will receive the ball with an external rotation returning it with internal rotation. Exercise 2 with elastic band. From standing, he will fix the elastic band with his foot and perform a shoulder flexion with his contralateral limb. Exercise 3 of iron with support of the hands on the floor and shoulder, elbow and wrist aligned. You should perform a scapula approach and separation without altering its initial position. Exercise 4 BodyBlade ©. From standing with 90º of 90 ° shoulder abduction and elbow flexion. It will perform an anteroposterior thrust, causing a wave effect to stabilize the shoulder joint for 30 seconds.~Athletes will do 15 repetitions of each exercise."
89074715|NCT04254055|No Intervention|Control group|Players included in the control group will not receive any intervention.
89074716|NCT04252885|Experimental|Group A-Standard treatment+lopinavir/ritonavir|In group A, 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days).
89074717|NCT04252885|Active Comparator|Group B-Standard treatment+arbidol|In group B, 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days).
89074718|NCT04252885|No Intervention|Group C-Standard treatment|In group C, 25 cases are only given ordinary treatment.
89074719|NCT04258345|Other|Active Feeding Arm|This is a feeding study.
89074720|NCT04252417|Active Comparator|Patients with hepatic impaired function|8 patients with hepatic impairment of moderate Child Pugh category
89074721|NCT04252417|Active Comparator|Healthy subjects|Healthy volunteers will be matched with impaired hepatic function patients
89074722|NCT02887872|Experimental|Pilot data|Four participants with chronic stroke participated in a 45-minute combined electrical stimulation-dynamic hand orthosis regimen using the affected upper extremity (UE) 5X/week for 6 weeks.
89074723|NCT04939207|Experimental|CT-derived FFR|In this study arm, the need for coronary revascularization will be determined by CT-derived Fractional Flow Reserve (FFR) calculations
89074724|NCT04939207|Experimental|Angiography-derived FFR|In this study arm, the need for coronary revascularization will be determined by FFR-calculations derived from angiographic images
89074725|NCT04939207|Active Comparator|Routine Care|In this study arm, the need for coronary revascularization will be determined by angiography and invasive FFR-measurements
89074726|NCT04253743|Experimental|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households were randomly assigned to receive either: (1) $40 extra in SNAP benefits per eligible child (<5 years) per month (n=1,919); (2) $40 extra in SNAP benefits per eligible child per month plus case management and nutrition education (n=1,919); or (3) only regular monthly SNAP benefit (n=7,467). The first two groups were the treatment arms and the third was the control group.
89074727|NCT04253743|No Intervention|Control Group|The control group received regularly allotted SNAP benefits.
89229995|NCT03955549|Active Comparator|Treatment As Usual (TAU)|"Treatment as usual will be used as a control condition to assure ethicality of our procedure.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
89229996|NCT00786617||Nurse-driven|Mechanically ventilated patients weaned by nurse-driven ventilator weaning protocol
89074728|NCT04258189|Experimental|Panel 1: Treatment Sequence ABDC|Participants will receive Treatment A (a single dose of JNJ-64417184 [oral solution with preservatives] in fasted condition) in treatment Period 1; followed by Treatment B (a single dose of JNJ-64417184 [oral solution with preservatives] in fed [high-fat meal] condition) in treatment Period 2; followed by Treatment D (a single dose of JNJ-64417184 [oral solution without preservatives] in fed [high-fat meal] condition) in treatment Period 3, followed by Treatment C (a single dose of JNJ-64417184 [oral solution without preservatives] in fasted condition) in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074729|NCT04258189|Experimental|Panel 1: Treatment Sequence BCAD|Participants will receive Treatment B in treatment Period 1; followed by Treatment C in treatment Period 2; followed by Treatment A in treatment Period 3, followed by Treatment D in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074730|NCT04258189|Experimental|Panel 1: Treatment Sequence CDBA|Participants will receive Treatment C in treatment Period 1; followed by Treatment D in treatment Period 2; followed by Treatment B in treatment Period 3, followed by Treatment A in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074731|NCT04258189|Experimental|Panel 1: Treatment Sequence DACB|Participants will receive Treatment D in treatment Period 1; followed by Treatment A in treatment Period 2; followed by Treatment C in treatment Period 3, followed by Treatment B in treatment Period 4 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074732|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence EFG|Participants will receive Treatment E (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fasted condition) in treatment Period 1; followed by Treatment F (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fed [high-fat meal] condition) in treatment Period 2; followed by Treatment G (a single dose of JNJ-64417184 [oral solution with or without preservatives] in fed [high-fat meal] condition) in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074733|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074734|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074735|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074736|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074737|NCT04258189|Experimental|Optional Panel 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3 on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each study drug intakes.
89074738|NCT04962841||Frail older adults treated with nutraceuticals and drugs|
89074739|NCT04962841||Frail older adults not treated with nutraceuticals and drugs|
89074740|NCT04253197|Other|Morbidly adherent placenta|This arm was given stage according to ultrasound features.
89074741|NCT00919867|Active Comparator|A: SPD503 (4mg)|
89074742|NCT00919867|Active Comparator|B: VYVANSE (50mg)|
89074743|NCT00919867|Active Comparator|C: SPD503 (4mg) + VYVANSE (50mg)|
89074744|NCT04252261|Experimental|sulforaphane|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
89074745|NCT04252261|Placebo Comparator|placebo|To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
89074746|NCT01215942|Experimental|120 milligrams (mg) of LY2127399|"Given every 4 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 240 mg loading dose when initiating treatment.~Or~Given every 4 weeks for 168 weeks for those participants from Study BCDM."
89074747|NCT01215942|Experimental|90 mg LY2127399|"Given every 2 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 180 mg loading dose when initiating treatment.~Or~Given every 2 weeks for 168 weeks for those participants from Study BCDM."
89074748|NCT04251871|Experimental|Conventional medicines and TCMs granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: one bag, p.o, bid, for 14 days."
89074749|NCT04251871|Active Comparator|Conventional medicines|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
89074750|NCT04253353|Experimental|rosuvastatin and tafamidis fixed sequence|"Period 1: rosuvastatin 10 mg (single oral administration)~Washout~Period 2: tafamidis 61 mg capsule(multiple doses, twice a day) + rosuvastatin 10 mg (single oral administration)"
89074751|NCT04924543|Active Comparator|Received short refresher training on optical diagnosis|All participants receive access to the training module, with assessments at baseline, week 2 and week 8-12 Half of participants randomized 1:1 will also receive access to brief refresher training by week 8
89074752|NCT04924543|Active Comparator|No refresher training|All participants receive access to the training module, with assessments at baseline, week 2 and week 8-12 This arm does not also receive access to brief refresher training
89074753|NCT01128621|Other|Part A|Part A is open label, in T2DM subjects on established metformin monotherapy. Subjects will receive a single dose of GSK1292263 with food. This will permit a comparison of GSK1292263 exposures in this cohort with those observed in study GPR111598 in which T2DM subjects were drug naïve or washed off prior anti-diabetic medications.
89074754|NCT01128621|Placebo Comparator|Part B - PLA|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
89074755|NCT01128621|Active Comparator|Part B - Active|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
89074756|NCT01128621|Active Comparator|Part B - Sitagliptin|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
89074757|NCT00918463|Experimental|all patients|
89229997|NCT00786617||Physician-initated|Mechanically ventilated patients weaned by physician-initiated, non-protocol methods
89229998|NCT00786695|Placebo Comparator|Placebo|Identical looking Placebo
89074758|NCT04251793||Er:YAG laser-assisted debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with the aid of the laser treatment two years ago at the Graduate Periodontics Clinic at University of Michigan.
89074759|NCT04251793||Standard mechanical debridement|Subjects who were randomly selected to receive debridement and surface detoxification of their implant surface and removal of the inflamed tissue with dental scalers two years ago at the Graduate Periodontics Clinic at University of Michigan.
89074760|NCT04811989|Experimental|Video Watching Group|Participants will watch an instructive video on diabetic foot care and will receive face-to-face teaching on diabetic foot care.
89074761|NCT04811989|Experimental|Real-time Leaflet Reading Group|Participants will receive a leaflet with diabetic foot care information, whose reading will be guided in real-time by the Researcher, and will also receive face-to-face teaching on diabetic foot care.
89074762|NCT04811989|Active Comparator|Standard Care Group|Participants will receive the standard care that includes face-to-face teaching about diabetic foot care and will take a leaflet on diabetic foot care to read at home.
89074763|NCT04251637||adult patients scheduled for thoracic pulmonary|"Adult patients scheduled in Louis Pradel hospital operating theater (Lyon University Hospital) for elective Lung surgery (lobectomy, bilobectomy or pneumonectomy); by thoracotomy and / or thoracoscopy.~- Having stated their non opposition to be part of this protocol"
89074764|NCT04251559|Active Comparator|patients with gestational diabetes mellitus|study group
89074765|NCT04251559|Placebo Comparator|healthy participants|control group
89074766|NCT05048641|Experimental|WhatsApp Reminder group|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
89074767|NCT05048641|No Intervention|No Reminder (NR) group|Subjects who are allocated to the NR group received standard-of-care service which is no reminder text messages via WhatsApp Messenger prior to their scheduled repeat mammography and no follow up phone reminder until the completion of the outcome measurement period.
89074768|NCT05330065|Experimental|Bevacizumab and Camrelizumab for Malignant Pleural Effusion|
89074769|NCT01128543|Active Comparator|lapatinib 1250mg|Patients will receive 1250mg lapatinib once a day for 24 weeks.
89074770|NCT01128543|Active Comparator|Vinorelbine 25mg/sqm|Patients will receive vinorelbine 25mg/sqm IV Day 1 and Day 8, every 3 week for 24 weeks.
89074771|NCT01128387|Experimental|Dose Level -1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 60mg/m2 cisplatin, 750mg/m2 5FU (Fluorouracil)
89074772|NCT01128387|Experimental|Dose Level 1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 80mg/m2 cisplatin, 1000mg/m2 5FU (Fluorouracil)
89074773|NCT01214850|Experimental|rMenB+OMV|Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart
89074774|NCT01214850|Experimental|MenACWY|Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart
89074775|NCT01214850|Active Comparator|Control|Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart
89074776|NCT01128153|Experimental|Saxagliptin 5 mg once daily|
89074777|NCT01128153|Placebo Comparator|Placebo once daily|
89074778|NCT04318782|Experimental|Thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
89074779|NCT00925015|Experimental|Cetux/Irin - Dmab 10 mg/kg|After treatment with Cetuximab (Cetux) and Irinotecan (Irin), Dalotuzumab (Dmab) was administered as an intravenous infusion at 10 mg/kg in Cycle 1 on Days 22, 29 and 36; followed in subsequent cycles by treatment with 10 mg/kg on Days 1, 8, 15, 22, 29 and 36. Each cycle was 6 weeks long.
89074780|NCT00925015|Experimental|Cetux/Irin - Dmab 15/7.5 mg/kg|After treatment with Cetux/Irin, Dmab was administered as an intravenous infusion at 15 mg/kg in Cycle 1 on Days 8, 22 and 36; followed in subsequent cycles by treatment with 7.5 mg/kg on Days 8, 22 and 36. Each cycle was 6 weeks long.
89074781|NCT00925015|Experimental|Dmab 10 mg/kg - Cetux/Irin (DDI)|Dmab was administered in each cycle as an intravenous infusion at 10 mg/kg once weekly on Days 1, 22 and 29; followed by treatment with Cetux/Irin. For Drug-Drug Interaction (DDI). Each cycle was 6 weeks long.
89229999|NCT00786695|Experimental|esomeprazole|esomeprazole (40 mg o d) for 14 days
89074782|NCT01127763|Experimental|RAD001+carboplatin|Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.
89074783|NCT04251403|Experimental|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
88820846|NCT05579548||Pregnant Women with PKU|This study will enroll pregnant women diagnosed with PKU who have been treated with pegvaliase from 2 weeks prior to LMP or at any time during pregnancy.
89074784|NCT04251325||Basic Life Support Course Participants|The study population includes all Danish citizens who attended a BLS training course certificate from 2016-2018 above the age of 15.
89074785|NCT04251325||Background population|The entire danish population above 15 years whom have not attended a BLS training course certificate from 2016-2018.
89074786|NCT04257409|Experimental|DF patient active|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
89074787|NCT04257409|Active Comparator|DF patient control|Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
89074788|NCT04257409|Experimental|Diabetic patient with mild neuropathy|Patients with Type 2 diabetes mellitus with mild form of peripheral sensory neuropathy
89074789|NCT04257409|Experimental|Diabetic patient with severe neuropathy|Patients with Type 2 diabetes mellitus with severe form of peripheral sensory neuropathy
89074790|NCT04250779|Placebo Comparator|Control Group|In this arm, patients are provided with standard-of-care instructions on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned off.
89074791|NCT04250779|Active Comparator|Treatment Group|In this arm, patients are provided with active guidance from CapMedic device on using MDIs correctly and regularly at home. The MDI usage is recorded using CapMedic device with active guidance turned on.
89074792|NCT05252299|Experimental|Refresher Training Group|"This study will use telemedicine to facilitate an innovative use of rolling refresher training (RRT), a technique used in medical education to provide hands-on interactive training at regular intervals with the goal of improving psychomotor skills required for high stakes procedures such as cardiopulmonary resuscitation. This study seeks to interrogate our hypothesis that providing instruction on CSS use to caretakers via telemedicine every 3 months during the first year of an infant's life is feasible and acceptable to caregivers."
89074793|NCT05252299|No Intervention|Traditional Group|They leave the hospital without the additional training and under hospital's normal discharge plan
89074794|NCT04771195||Class of 2023|Stanford undergraduate students who are expected to graduate in Spring of 2023
89074795|NCT04771195||Class of 2024|Stanford undergraduate students who are expected to graduate in Spring of 2024
89074796|NCT01127607|Experimental|stimulant medication|blinded lisdexamfetamine at the optimal dose for the individual participant as previously determined during the med optimization portion of the study
89074797|NCT01127607|Placebo Comparator|placebo pill|placebo medication identical in appearance to active med
89074798|NCT00924781|Experimental|MK2578 1 mcg for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment every week (QW).
89074799|NCT00924781|Experimental|1 mcg of MK2578 for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
89074800|NCT00924781|Experimental|MK2578 1 mcg for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
89074801|NCT00924781|Experimental|1 mcg of MK2578 for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
89074802|NCT00924781|Experimental|MK2578 1 mcg for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
89074803|NCT00924781|Experimental|1 mcg of MK2578 for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
89074804|NCT05252065||Patients with NSCLC|all stage N2-3 non-small cell lung cancer patients receive intensity-modulated radiotherapy (IMRT). The prescription dose of PTV is 60-70Gy.
89074805|NCT00631423||1|Patients with vena cava inferior thrombosis
89074806|NCT00631423||2|Patients with isolated lower-extremity DVT matched for gender and age
89074807|NCT05251987||High PD1+ T Cell Expression|high PD1+ T cell expression in peripheral blood
89074808|NCT05251987||Low PD1+ T Cell Expression|low PD1+ T cell expression in peripheral blood
89074809|NCT01127451|Experimental|Denileukin Diftitox on Days 1 to 4|Participants received Denileukin Diftitox 12 mcg/kg/day (microgram per kilogram) on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks).
89074810|NCT01127451|Experimental|Denileukin Diftitox on Days 1, 8, and 15|"Participants received Denileukin Diftitox 12 mcg/kg/day on Days 1, 8, and 15 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks).~ARM 2 was closed. Participants experiencing clinical benefit (irSD, irPR, or irCR per irRC) after 4 cycles of treatment, may continue their denileukin diftitox treatment for up to 8 cycles."
89074811|NCT01127373|Experimental|radiation therapy via multi-beam IMRT|This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall and regional lymph nodes, including the internal mammary lymph nodes.
89074812|NCT01127139||Czech patients with essential hypertension|Czech hypertensive patients (women and men) with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg who can be treated with fixed-combination Tarka®.
89074813|NCT01214616|Experimental|afatinib and vinorelbine IV|patient to receive 20mg or 40mg of po daily afatinib in combination with vinorelbine IV
89074814|NCT01213836|Active Comparator|First Seroquel XR then Seroquel IR|Patients randomised to Seroquel XR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel IR for 10-16 days
89074815|NCT01213836|Active Comparator|First Seroquel IR then Seroquel XR|Patients randomised to Seroquel IR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel XR for 10-16 days
89074816|NCT01127061|Experimental|Exercise Training|Participants in the exercise group will undergo 4 months of training, 4-7 days per week with a minimum of 20 minutes per day. The protocol will be custom designed in consultation with an exercise physiologist based on data from the initial cardiopulmonary stress test. Exercise regimen will begin at a low level of intensity then increase in duration and training intensity to a goal of 60 minutes a day and 70% of the heart rate reserve during the 1st month of the study protocol with maintenance of the program thereafter. There is no need to come to a participating site for actually doing the exercise regimen. No strength training or burst activity will be prescribed and all activities will fall well within the recommended national guidelines for recreational exercise.
89074817|NCT01127061|No Intervention|Usual Activity|Participants in this group are not restricted in their activities. They simply are not guided in their physical activities by the study team. At the end of the 4 month study period, they will also receive an individualized exercise prescription for personal use.
89074818|NCT00924703|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses dependent on safety and efficacy.
89074819|NCT01213524|Active Comparator|Active nicotine replacement (NRT) + denicotinized cigarettes|42 mg nicotine replacement plus sensorimotor replacement
89074820|NCT01213524|Active Comparator|Placebo NRT + denicotinized cigarettes|inactive transdermal patches plus sensorimotor replacement
89074821|NCT01213524|Active Comparator|Active NRT + no cigarettes|42 mg nicotine replacement with no sensorimotor replacement
89074822|NCT01213524|Placebo Comparator|Placebo NRT + No cigarettes|Double placebo: No nicotine or sensorimotor replacement
89074823|NCT01213524|Active Comparator|usual brand smoking|positive control: usual brand smoking
89074824|NCT01212744|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses
89074825|NCT01212588|Experimental|Mifepristone|Mifepristone 600mg once daily x 7 days
89074826|NCT01212588|Placebo Comparator|Placebo|Matching placebo tablets one daily
89074827|NCT00918385|Active Comparator|1|High Androgen Receptor (AR) activity
89074828|NCT00918385|Active Comparator|2|Low Androgen Receptor (AR) activity
89074829|NCT05253235|Experimental|SAAF Intervention|Parents and youth will receive an online, family-centered intervention consisting of 7 weekly sessions.
89074830|NCT05253235|Other|Control Group|Control group members will receive a book entitled, Parenting for Liberation: A Guide for Raising Black Children
89074831|NCT04727281|Experimental|dialysis patients|Patients included in the study will be recruited from the dialysis units in Alexandria University Hospitals.
89074832|NCT05251831|Experimental|Activated plasma rich in platelets|Group A: patients were treated by intradermal injections of PRP activated with Calcium chloride 10% solution.
89074833|NCT05251831|Placebo Comparator|Non- activated plasma rich in platelets|Group B: patients were treated by intradermal injections of PRP without activation.
89074834|NCT04761679|Experimental|Intervention Group|
89074835|NCT04761679|No Intervention|Control Group|
89074836|NCT04899037||Osseointegrated Device Uptake|The participants in this group will be in the 18-85 year age range who have a hearing loss configuration that would benefit from an OID and choose to uptake an OID.
89074837|NCT04899037||Osseointegrated Device Non Uptake|The participants in this group will be in the 18-85 year age range and who a hearing loss configuration that would benefit from an OID but choose to not uptake an OID.
89074838|NCT04257643|Experimental|Experimental group|water-based exercise was conducted at a hydrotherapy pool for the Eden Heelth Care,Cairo The pool measures 8 × 15 m and ranges from 1 to 1.8 m in depth with access via steps. Interventions were conducted predominately in the deeper section of the pool so participants immerse their neck in water. Thermo neutral water temperature, 30-32 °C at room temperature. Females were instructed to adjust water depth completely covering clavicles from standing position. Diaphragmatic breathing during exercise routine to assist with lymph fluid clearance. Exercise continuously for 40 to 45 min Full-body warm-up exercise for 10 min and cooling down for 10 minutes. Plus land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.
89074839|NCT04257643|Active Comparator|Control group|Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles
89074840|NCT04703725|Experimental|Experimental Group|Infertile women recruited to the experimental group by randomization will be given a counseling program including psychosocial care in addition to routine (drug explanation during the treatment, preparation before the egg pick up and embryo transfer and post operative care). IVF treatment
89074841|NCT04703725|No Intervention|Control Group|Routine (drug explanation during the treatment, preparation before the egg pick up and embryo transfer and post operative care) IVF treatment will be applied to infertile women who are randomized to the control group.
89074842|NCT05253079|Active Comparator|subcostal transversus abdominis plane block group|subcostal transversus abdominis plane block
89074843|NCT05253079|Active Comparator|erector spinae plane block group|erector spinae plane block
89074844|NCT04758715|Other|Food provided|Food provided from a commercial meal service provider for a week
89074845|NCT04256863|Experimental|Breakfast / Lunch (BFL)|This group will complete a 16-week standard behavioral weight control intervention in which they will be asked to consume >50% of their daily energy goal before 3PM. To do so, they will complete weekly experiential learning sessions in conjunction with the SBT lessons.
89074846|NCT04256863|Active Comparator|Dinner (DIN)|This group will complete a 16-week standard behavioral weight control intervention. They will not be given any recommendations regarding the timing of their energy consumption, but instead encouraged to follow the same energy goals at the BFL group.
89074847|NCT00631501|Placebo Comparator|2|
89074848|NCT00631501|Experimental|Doxycycline|100 mg twice daily
89074849|NCT04782037|Experimental|L-methylfolate supplementation|Children under 1 year of age in group A will receive 3 drops (90mcg) of L-methylfolate calcium) while those older than 1 year of age will be given 5 drops (150mcg) daily fior 5 days
89074850|NCT04782037|Placebo Comparator|distilled water|Subjects in Group B will receive equal amount of distilled water as placebo (i.e. 3 drops to <1yr age and 5 drops to >1 yr.
89074851|NCT04257019|Experimental|Lavender|Lavender mask before and during procedure
89074852|NCT04257019|Active Comparator|Almond|Almond oil mask before and during procedure
89074853|NCT04257019|Sham Comparator|Water|Water mask before and during procedure
89074854|NCT01211262|Experimental|IMCgp100 weekly dosing regimen|Weekly intravenous (IV) infusions of IMCgp100 over treatment cycles of 8 weeks each.
89074855|NCT01211262|Experimental|IMCgp100 daily dosing regimen|Daily IV infusions of IMCgp100 administered on days 1 to 4 and days 22 to 25 of a six-week treatment cycle.
89074856|NCT01211184|Placebo Comparator|Fasting|patients undergo surgery in the fasting state
89074857|NCT01211184|Active Comparator|Water administration|Patients undergo hip surgery after receiving 800 ml water by mouth the morning 2 hours before surgery
89074858|NCT01211184|Active Comparator|carbohydrate drink|Patients undergo hip surgery after receiving 800 ml carbohydrate drink by mouth
89074859|NCT00924469|Experimental|Abiraterone plus leuprolide plus prednisone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.
89074860|NCT00924469|Active Comparator|Leuprolide then abiraterone plus leuprolide plus prednisone|Leuprolide acetate will be administered at a dose of 22.5 mg as intramuscular injection once every 12 weeks up to Week 24. From Week 13 to 24, abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day with prednisone tablets administered orally as 5 mg once daily.
89074861|NCT04256551|Experimental|Machine Learning App + Registered Dietitian facilitator|The ML-RD group will be provided access to the Heali mobile application as well as a personal RD to provide nutrition support and answer any questions through a real-time messaging system within the mobile app. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
89074862|NCT04256551|Active Comparator|Machine Learning App|The ML-APP group receives access to the Heali mobile dietary application. Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
89074863|NCT04256551|Placebo Comparator|Standard Dietary Education|Group will receive a link to resources regarding the Low FODMAP diet: website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System
89074864|NCT00924313|Experimental|11C-acetate for Prostate Cancer Patients|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
89074865|NCT01209780|Experimental|TIV (3-8 years)|Non-Naive subjects received one dose and naive subjects received two doses, administered 4 weeks apart, of investigational trivalent influenza vaccine (TIV)
89074866|NCT01209780|Active Comparator|Control TIV (3-8 years)|Non-Naive subjects received one dose and Naive subjects received two doses, administered 4 weeks apart, of control vaccine. Subjects aged 3 to <4 years and subjects aged 4 to 8 years received different control TIV.
89074867|NCT01209780|Experimental|TIV ( 9-17 years)|All subjects received one dose of investigational TIV. The subjects in this cohort were included only for safety analysis.
89074868|NCT01209780|Active Comparator|Control TIV ( (9-17 years)|All subjects received one dose of the control vaccine. The subjects from this cohort were included only for safety analysis.
89074869|NCT00916357|Active Comparator|Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout period), followed by a SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3 to 14 day washout period.
89074870|NCT00916357|Active Comparator|Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
89074871|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase PH20(rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
89074872|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog following a 3- to 14-day washout period.
89074873|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
88820847|NCT05571878|Experimental|Crossover: Insulin and Placebo|"Twelve adolescents who have a confirmed depression diagnosis or experiencing depression will be used as the study population group against 12 healthy adolescents who will be used as the healthy study population group.~Both the health control group and medication-free adolescents with depression will receive the same drug conditions (intranasal insulin and intranasal placebo)."
89230000|NCT00786773||1|GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy
89230001|NCT00786851|Experimental|1|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
88820848|NCT05570409|Experimental|Immunosuppressive treatment|Mycophenolate mofetil (MMF) 1g bid and prednisolone at initially 1mg/kg in a step-down regime
89074874|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog alone following a 3- to 14-day washout period.
89074875|NCT00916279|Experimental|Lutonix Catheter|
89074876|NCT05329753|Experimental|Intervention group|Mobile application
89074877|NCT05329753|No Intervention|Control group|Usual education
89074878|NCT04849897|Active Comparator|Active Comparator: Audio Only Guided Imagery Audio Recordings of Guided Imagery via tablet|Listen to narrative scripts based on traditional GI audio recordings. The narrative scripts will include psychoeducation content that explains how the mind and brain can influence physical pain and how they can be trained to effect changes in experienced chronic pain. Narration will guide users in breathing and relaxation exercises and explain how patients can continue to exert control over their pain outside of the GI experience.
89074879|NCT04849897|Experimental|Experimental: Virtual Reality Guided Imagery Platform and VR Headset|VR headset for guided imagery with audiovisual computer-generated VR content to accompany the GI narration. The narrative scripts will include psychoeducation content that explains how the mind and brain can influence physical pain and how they can be trained to effect changes in experienced chronic pain. Narration will guide users in breathing and relaxation exercises and explain how patients can continue to exert control over their pain outside of the VR-GI experience.
89230002|NCT00786929|Experimental|drainage|
89230003|NCT00786929|Active Comparator|2|Conservative treatment
89230004|NCT00663923|Experimental|cross-cylinder|In this technique the laser is programmed with the axis and amount of cylinder,so that the steepest meridian is flattened with central cylindrical ablation and the flattest meridian steepens with paracentral ablation
88820849|NCT05570409|Placebo Comparator|Placebo|Mycophenolate mofetil (MMF) and prednisolone Placebo
89224350|NCT06269159||Adults with overweight and obesity|"Inclusion criteria~Adults aged 25-64 years~Active on the job market for at least 50 percent~BMI ≥25kg/m²~Exclusion criteria~Retirement and early retirement~Unemployment~Working for less than 50 percent~Working in night shifts~Physical (e.g. amputations, paralysis, recovering from stroke, osteoarthritis), cognitive (e.g. dementia, psychological disorders) and major medical (e.g. Chronic respiratory diseases, heart failure, cardiovascular diseases, cancer) conditions that obstruct daily functioning~Diabetes diagnosed by a general practitioner~Pregnancy~Pregnancy <1 year ago~Currently involved in study specific weight loss interventions~Post-surgery weight loss interventions~Waitlist for weight loss surgery~Hospitalized"
89224351|NCT06269146|Active Comparator|Pramipexole 1 mg/d|Each participant will take pramipexole in identical capsular form twice daily for 6 weeks.
89224352|NCT06269146|Active Comparator|Pramipexole 2.5 mg/d|Each participant will take pramipexole in identical capsular form twice daily for 6 weeks.
89224353|NCT06269146|Placebo Comparator|Placebo|Each participant will take placebo in identical capsular form twice daily for 6 weeks.
89224354|NCT06269120||Patients with type 2 diabetes|Participants with Type 2 Diabetes (T2D) will initiate oral semaglutide at the discretion of the treating physician, based on approved oral semaglutide label in Hungary and independent from the decision to include the patient in the study.
89224355|NCT06269068||Patients|Patients with lumbar disc herniation
89224356|NCT06269042|Experimental|Intervention group|The EG (experimental group) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their MIP (Maximum Inspiratory Pressure) through a threshold valve device. The participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts.
89691758|NCT02561832|Experimental|Arm 1|Part A: ascending doses of olaparib in combination with carboplatin will be administered to investigate safety and tolerability and to define the MTD and/or RD for part B. Patients will be treated with this combination up to cycle 4, after cycle 4 they can continue with combination or monotherapy (carboplatin or olaparib). Cohorts will be started sequentially, based on SRC recommendation. Part B will start after MTD/RD identification in part A. Patients will receive olaparib and carboplatin combination for first 4 cycles (21 days per cycle), at the dose, frequency and schedule recommended from Part A. This will be followed by another 4 cycles of standard cancer therapy consisting of anthracycline and cyclophosphamide regimen. Total of 8 treatment cycles will be given before final surgery
89691759|NCT02982161|Active Comparator|MR308 100 mg bid|Tramadol/Celecoxib 100 mg
89691760|NCT02982161|Active Comparator|MR308 150 mg bid|Tramadol/Celecoxib 150 mg
89691761|NCT02982161|Active Comparator|MR308 200 mg bid|Tramadol/Celecoxib 200 mg
89691762|NCT02982161|Active Comparator|Tramadol 100 mg qid|Tramadol IR 100 mg
89691763|NCT02982161|Placebo Comparator|Placebo|Placebo to match MR308 and Tramadol IR
89691764|NCT05506488|Active Comparator|Dasatinib plus Quercetin|Day 0: (15 per arm, randomization). week 7: blood, fibroscan, ECG, questionnaires. week 14: blood, fibroscan, ECG, questionnaires. Week 21: blood, fibroscan, ECG, questionnaires, liver biopsy. end of study
89691765|NCT05506488|Placebo Comparator|placebo|Day 0: (15 per arm, randomization). week 7: blood, fibroscan, ECG, questionnaires. week 14: blood, fibroscan, ECG, questionnaires. Week 21: blood, fibroscan, ECG, questionnaires, liver biopsy. end of study
89691766|NCT00942149|Experimental|Daptomycin cohort|
89691767|NCT03033563||Testicular tissue versus ejaculate|Evaluation of ICSI outcome.
89691768|NCT03023111|Active Comparator|Sbv|"Meglumine antimoniate (Glucantime):~Dosage: 20 mg / kg / day, intravenously, during 20 days."
89691769|NCT03023111|Experimental|Miltefosine plus placebo|Miltefosine (28 days / 2.5mg / Kg / day at a maximum dose of 150mg / day orally) + Topical placebo (gel cream, 2 times a day for 28 days)
89691770|NCT03023111|Experimental|Miltefosine plus GM-CSF|Miltefosine (28 days / 2.5mg / kg / day at a maximum dose of 150mg / day orally) + Topical GM-CSF (0.01% gel cream, 2 times a day for 28 days)
89691771|NCT03022253|Experimental|Liberal Platelet transfusion group|"Platelet transfusion to maintain a platelet count above 1,00,000 per microliter until one of the endpoints is met.~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
89691772|NCT03022253|Active Comparator|Restrictive platelet transfusion group|"Platelet transfusion for standard criteria.~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
89691773|NCT03033407|Experimental|Intervention-Maintenance group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. This study was divided into two phases. In six-month phase 1 study, the participants in I-M group received tailored mobile coaching. And during the second half six-month phase 2 study, they could receive only regular information messages without individualized coaching.
89691774|NCT03033407|Active Comparator|Control-Intervention group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. In six-month phase 1 study, the participants in Control-Intervention group maintained usual care for diabetes. During the second half six-month phase 2 study, they received tailored mobile coaching.
89691775|NCT01037881|Experimental|LEO 29102 0.03 mg/g cream|
89691776|NCT01037881|Experimental|LEO 29102 0.1 mg/g cream|
89691777|NCT01037881|Experimental|LEO 29102 0.3 mg/g cream|
89691778|NCT01037881|Experimental|LEO 29102 1.0 mg/g cream|
89691779|NCT01037881|Experimental|LEO 29102 2.5 mg/g cream|
89691780|NCT01037881|Placebo Comparator|LEO 29102 cream vehicle|
89691781|NCT01037881|Active Comparator|Elidel® cream (pimecrolimus) 10 mg/g|
89691782|NCT03017651|Experimental|OM3-supplement 1|1 g capsule for OM3-supplement 1 given once
89691783|NCT03017651|Active Comparator|OM3-supplement 2|1 g capsule for OM3-supplement 2 given once
89224357|NCT06269042|No Intervention|Control group|they will not receive any intervention. Just sit and wait the same amount of time that the intervention and the activation group needs to finish their protocol (around 10 minutes)
89224358|NCT06269042|Active Comparator|Activation group|The activation group will perform the protocol of 2 sets of 30 repetitions at 40% of their MIP, one-on-one, and in a single session, breathing against submaximal inspiratory loads using a threshold valve device. The participants will follow a free pattern of breathing until complete the protocol.
89224359|NCT06269029|Experimental|patients with COPD assigned for chest mobility|This study will be carried on 30 patients with Chronic obstructivepulmonarydisease. Patients will be selected from department (3) Kaser EL-Ainy, Cairo University.
89224360|NCT06269029|Experimental|patients with COPD assigned for PNF|This study will be carried on 30 patients with Chronicobstructivepulmonarydisease. Patients will be selected from department (3) Kaser EL-Ainy, Cairo University.
89224361|NCT06269016|Experimental|control group no intervention|no intervention for 3 months with assessment for maximum vaginal squeeze pre and post experiment using bio feedback device and urinary distress inventory UDI-6 short form.
89224362|NCT06269016|Experimental|study group hip muscles strengthening exercise.|hip muscles exercises (hip abductors, adductors and gluteus maximus) for 3 months with assessment for maximum vaginal squeeze pre and post experiment using bio feedback device and urinary distress inventory UDI-6 short form.
89224363|NCT06269016|Experimental|study group hip muscles strengthening exercise combined with pelvic floor muscles exercise.|hip muscles exercises (hip abductors, adductors and gluteus maximus) combined with pelvic floor muscles exercises for 3 months with assessment for maximum vaginal squeeze pre and post experiment using bio feedback device and urinary distress inventory UDI-6 short form.
89224364|NCT06269016|Experimental|study group pelvic floor muscles exercise.|pelvic floor muscles exercises for 3 months with assessment for maximum vaginal squeeze pre and post experiment using bio feedback device and urinary distress inventory UDI-6 short form.
89224365|NCT06269003|Experimental|Source|Participants in the source arm will receive e-cigarette education messages manipulated in one of two source types.
89224366|NCT06269003|Experimental|Sidedness|Participants in the sidedness arm will receive e-cigarette education messages manipulated in one of two sidedness types.
89224367|NCT06268990|Active Comparator|RYGB-FMT intervention group|morbidly obese patients randomized for FMT from patients successfully treated with RYGB surgery
89224368|NCT06268990|Active Comparator|LEAN-FMT intervention group|morbidly obese patients randomized for FMT from normal weight (lean) volonteers
89224369|NCT06268990|Sham Comparator|M-FMT intervention group|morbidly obese patients randomized for autologous FMT
89224370|NCT06268964|Experimental|Trimebutine + Probiotic|Participants received trimebutine in 200 mg tablets or 20 mg/ml suspension at a dose of 15 mg/kg/day adjusted to their weight, divided into 2 doses (morning and night) + Lactobacillus rhamnosus 5 billion Colony Forming Units (CFUs) in chewable tablets, a single dose (night), for a period of 8 weeks.
89224371|NCT06268964|Active Comparator|Trimebutine + Placebo|Participants received trimebutine in 200 mg tablets or 20 mg/ml suspension at a dose of 15 mg/kg/day adjusted to their weight, divided into 2 doses (morning and night) + Placebo, 250 mg microcrystalline cellulose tablets, a single dose (night), for a period of 8 weeks.
89224372|NCT06268964|Active Comparator|Probiotic + Placebo|Participants received Lactobacillus rhamnosus 5 billion Colony Forming Units (CFUs) in chewable tablets + Placebo, 250 mg microcrystalline cellulose tablets, a single dose (night), for a period of 8 weeks.
89224373|NCT06268470|Active Comparator|Desloratadine|Oral desloratadine 20 mg/day (antihistamine) for 4 weeks
89224374|NCT06268470|Experimental|Desloratadine plus cilostazol and dipyridamole|Oral desloratadine 20 mg/day (antihistamine) in conjunction with cilostazol 150 mg/day and dipyridamole 50 mg/day (antiplatelets) for 4 weeks
89691784|NCT03021863|Active Comparator|Group A Reminder|Tone of reminder email (duty 14 days followed by duty for non-responders 28 days)
89691785|NCT03021863|Active Comparator|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement for non-responders 28 days)
89691786|NCT03021863|Active Comparator|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
89691787|NCT03021863|Active Comparator|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
89691788|NCT03021863|Active Comparator|Group E Reminder|Tone of reminder email (generic reminders at 14 days followed by generic for non-responders 28 days)
89691789|NCT03021863|Active Comparator|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
89691790|NCT03021863|Active Comparator|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
89074880|NCT00631345|Experimental|Lifestyle|This Group-Based Lifestyle Intervention (Phases 1 and 2) will be led by lay health counselors (LHCs). The 6-month Phase 1 includes weekly meetings on nutrition and physical activity, psychosocial factors related to health behaviors, and question and answer periods. The 18-month Phase 2 will consist of monthly group meetings and individual telephone contacts. Intervention participants who choose to participate in the study continuation (Phase 3) will be further randomized to receive either extended group or self-directed maintenance. Those who are randomized to receive Extended Group Maintenance (Phase 3) will continue attending monthly meetings; those who receive Self-Directed Maintenance (Phase 3) will no longer attend groups.
89074881|NCT00631345|Other|Comparison|The comparison condition exceeds the usual care provided to similar community members and is an individual education program that builds on an increased awareness of existing community resources. In the initial trial, these subjects will receive two individual sessions with the RD and a monthly newsletter. In the study continuation, comparison participants will receive biannual nutrition counseling and a monthly newsletter.
89074882|NCT05252455|Other|exercise group|pelvic and abdominal mechanics exercise
89074883|NCT05252455|No Intervention|control group|Normal prenatal examination
89074884|NCT04698421||patients with rare autoimmune neurological diseases|
89074885|NCT05217823|Experimental|Er:YAG laser|Teeth treated with Er:YAG laser
89074886|NCT05217823|Active Comparator|Hand instruments|Teeth treated with Gracey curettes
89074887|NCT01209078|Experimental|Regimen 1|GSK1322322 1500mg and Placebo Linezolid given twice a day (BID) for 10 days
89074888|NCT01209078|Active Comparator|Regimen 2|Linezolid 600mg and placebo GSK1322322 given BID for 10 days
89074889|NCT04708561|Experimental|Brain-injured participants|
89074890|NCT04672135|Active Comparator|Study Drug|Each subject receives either a single dose (SAD) or a multiple dose (MAD) of REM0046127 as oral solution with a concentration of 100 mg/mL REM0046127. The starting dose for the first cohort in the SAD is 35mg up to a maximum of 2000mg at cohort 5. The starting dose for the MAD study is 0,75 of the Maximum Tolerated Dose (MTD) from the SAD.
89074891|NCT04672135|Placebo Comparator|Placebo|Each subject receives either a single (SAD) or multiple (MAD) dose of REM0046127 as oral solution with a concentration of 0 mg/mL REM0046127. The dose for each cohort is corresponding the amount of solution needed in the verum group.
89074892|NCT04584385||Childhood epilepsy|Children with refractory tonic, myoclonic or atonic seizures
89074893|NCT04318470||PPROM|Preterm premature rupture of membranes between 16 0/7 and 33 6/7 weeks gestation
89074894|NCT04318470||Healthy controls|Gestational-age-matched controls without preterm premature rupture of membranes or other pregnancy complications
89074895|NCT04318158|Experimental|Group(B)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% on each side.
89074896|NCT04318158|Active Comparator|Group(BD)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
89074897|NCT04318158|Active Comparator|Group(BF)|Patients will receive single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
89074898|NCT05418426|Experimental|IVR: estradiol 80 ug/day + progesterone 4mg/day|28-day IVR 80/4
89074899|NCT05418426|Experimental|IVR: estradiol 160 ug/day + progesterone 8mg /day|28-day IVR 160/8
89074900|NCT05418426|Active Comparator|Oracle Estrace(R)/Prometrium(R)|29 days (estradiol 1mg/progesterone 100 mg oral capsule)
89074901|NCT05416710||Solid tumor cancers|Adult participants with a diagnosis of a solid tumor cancer who are able to consent to the study and who are interested in undergoing germline genetic testing will receive testing using Invitae's 84 gene Multi-Cancer panel.
89074902|NCT01207596|Active Comparator|Hydromorphone|
89074903|NCT00915343|Experimental|Novel once daily modified release|"Test drug: hydrocortisone (modified release), oral tablet, available as 20 mg and 5 mg.~The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state"
89074904|NCT00915343|Active Comparator|Conventional TID hydrocortisone|Reference drug: hydrocortisone, oral tablet, 10 mg. The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM)in the same total daily dose as the experimental drug. The morning dose was administered in the fasting state.
89074905|NCT04667533|Experimental|Desidustat tablet|
89074906|NCT04578301||Surgery|Patients with and without liver cirrhosis undergoing surgery.
89074907|NCT04651621|Experimental|Open label active cTBS|Four consecutive days with 40s cTBS, 100% MT over the SMA, five times a day with 50 minutes between stimulations
89074908|NCT04651621|Experimental|active cTBS|One test session with 40s active cTBS, 100% MT, over the SMA in the initial double blind cross-over phase
89074909|NCT04651621|Sham Comparator|Sham cTBS|One test session with 40s sham cTBS, 100% MT, over the SMA in the initial double blind cross-over phase with a special sham coil that diverts the magnetic field to be only superficial
89074910|NCT04203043|Active Comparator|Pycnogenol oral product to prevent Hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
89074911|NCT04203043|Placebo Comparator|Placebo to prevent hyperpigmentation|Evaluate hyperpigmentation post foam sclerotherapy with placebo versus pycnogenol use
89074912|NCT04435015|Experimental|Camostat mesylate 200 mg|Participants will be given Camostat mesylate three times daily.
89224375|NCT06268028|Experimental|EXPERIMENT GROUP|"The training group will be given discharge training prepared by the researcher by reviewing the literature. The individual identification form will be filled out initially by face-to-face interview technique. An explanation will be given regarding filling out the scale and they will be asked to fill it out by self-reporting method under observation. When the mothers in the training group feel good and ready; Discharge training will be given using the discharge training brochure prepared by the researchers by reviewing the literature. Discharge training will be given one-on-one in the mother's own room, lasting approximately 30-45 minutes. Mothers will be asked to fill out the HTHÖ-YDAF themselves again, close to postnatal discharge."
89224376|NCT06268028|No Intervention|CONTROL GROUP|"Starting from the first (smallest number) room in the clinic, the individual identification form will be filled out initially by face-to-face interview technique for mothers who meet the appropriate conditions and agree to participate in the study, according to the randomization order. An explanation will be given regarding filling out the scale and they will be asked to fill it out by self-reporting method under observation. Mothers will be asked to fill out the HTHÖ-YDAF themselves again, close to discharge after birth."
89224377|NCT06267989|Active Comparator|Extraction|Extraction of the primary canine
89224378|NCT06267989|Experimental|Expansion|Rapid maxillary expansion without extraction of the primary canine
89224379|NCT06267989|No Intervention|Control|No intervention during the observation period (18 months)
89224380|NCT06267703||Participants with chronic atrophic gastritis|Corpus-dominant chronic atrophic gastritis was characterized by a PGI/PGII ratio of less than 3.
89224381|NCT06267703||Healthy participants|Healthy participants in the TwinGene cohort were included.
89224382|NCT06267664||Patients with migraine treated with triptans, Lasmiditan or Gepants|Patients that fulfill the criteria for migraine, according to the International Classification of Headache Disorders, 3rd version treated with triptans, Lasmiditan or Gepants as acute therapies according to their responsible physician criteria under routine clinical practice criteria
89224383|NCT06267313|Experimental|Attention Bias Modification|
89224384|NCT06267313|Active Comparator|Attention Control Training|
89224385|NCT06267313|Placebo Comparator|Neutral Training|
89224386|NCT06266806|No Intervention|Control Group|The control group will not receive individual counseling; they will go through the hospital's routine monitoring and counseling process.
89224387|NCT06266806|Experimental|Intervention Group|Individual counseling will be provided to the intervention group within the scope of the Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP), based on Denis's Breastfeeding Self-Efficacy theory and hypnobreastfeeding philosophy. EMÖZGEDAP, which will be applied to pregnant women and their family relatives, will consist of 5 sessions lasting 7.5 hours (2 sessions with the woman and her family relatives, two sessions with the woman alone, and one with her family relatives alone).
89224388|NCT06266793|Active Comparator|Holmium Laser|Participants in this arm are randomized to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser
89224389|NCT06266793|Active Comparator|Thulium Laser|Participants in this arm are randomized to be treated using the Olympus Soltive SuperPulsed Thulium Fiber Laser
89224390|NCT06266702|Experimental|Group 1A - High Vitamin D, Experimental Oil|High dose Vitamin D mixed with Experimental Oil
89224391|NCT06266702|Active Comparator|Group 1B - High Vitamin D, Control Oil|High Dose Vitamin D mixed with Control Oil
89224392|NCT06266702|Experimental|Group 2A - Low Vitamin D, Experimental Oil|Low dose Vitamin D mixed with Experimental Oil
89224393|NCT06266702|Active Comparator|Group 2B - Low Vitamin D, Control Oil|Low Dose Vitamin D mixed with Control Oil
89224394|NCT06266689|Other|Intervention|Participants in this group will receive the standard infant dietary guidance packet via email or mail and will additionally be presented with their infant's own dietary DNA metabarcoding data from stool samples collected as part of Project HOPE 1000 and this study. Diet data will be returned via electronic report or a paper report mailed to the participant following the visit.
88820850|NCT05562973|Experimental|Dose Sequence 1 (15, 20, 25)|"Psilocybin dose sequence~Session 1: 15 mg Session 2: 20 mg Session 3: 25 mg"
88820851|NCT05562973|Experimental|Dose Sequence 2 (20, 25, 30)|"Psilocybin dose sequence~Session 1: 20 mg Session 2: 25 mg Session 3: 30 mg"
89224395|NCT06266689|Other|Control|"Participants in this group will receive a dietary information packet via mail or email, which will consist of the sections of the DGA relevant to 12-24 month old children (Included as a supplemental document, Standard dietary guidance). This dietary guidance will also be provided at the 18- and 24-month visits. Please note that participants in this arm will receive their personalized diet information at the conclusion of the study."
89224396|NCT06266676|Experimental|micro-course|The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
89224397|NCT06266676|Active Comparator|slide presentation|The control group, on the other hand, employs a unidirectional teaching method by the instructor, offering self-directed learning through online asynchronous courses, primarily using researcher-created online presentations.
89224398|NCT06266637|Experimental|Study group|The experimental group will receive the same standard treatment in addition to Physiotherapeutic Scoliosis-Specific Exercise
89224399|NCT06266637|Active Comparator|Control group|The control group will receive the standard care composed of trunk muscles strengthening exercises, trunk proprioception exercises .
89224400|NCT06266624|Experimental|Tourniquet Test|Patients with HHT patients who undergo the Tourniquet Test
89224401|NCT06266611|Experimental|Full-Spectrum Hemp-Derived CBD (fsCBD)|8 weeks of use of a daily dose of cannabis (200mg CBD/4mg THC)
89074913|NCT04435015|Placebo Comparator|Microcrystalline Cellulose|Participants will be given placebo three times daily.
89074914|NCT04170361|Active Comparator|Control Group|Patients will be admitted to chest physiotherapy program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization.
89074915|NCT04170361|Experimental|Training Group|In addition to conventional chest physiotherapy program, patients in this group will also be taught to use Triflo ® and apply at two-hour intervals.
89074916|NCT04817293||COVID-19 positive|
89074917|NCT04817293||COVID-19 negative|
89074918|NCT04408651|Experimental|Acceptance and Commitment Therapy|
89074919|NCT04408651|Experimental|Compassion-Focused Therapy|
89074920|NCT04576429|Experimental|experimental group|
89074921|NCT04576429|Active Comparator|comparator group|
89074922|NCT04203277|Experimental|Step Wedge Randomized Group 1|Includes two pediatric practices randomized to the first step of the step-wedge randomized trial
89074923|NCT04203277|Experimental|Step Wedge Randomized Group 2|Includes two pediatric practices randomized to the second step of the step-wedge randomized trial
89074924|NCT04203277|Experimental|Step Wedge Randomized Group 3|Includes two pediatric practices randomized to the third step of the step-wedge randomized trial
89074925|NCT04203277|Experimental|Step Wedge Randomized Group 4|Includes two pediatric practices randomized to the fourth step of the step-wedge randomized trial
88812945|NCT03219710|Experimental|Arm B|"weight category of 15-40 kg will receive: D1-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)~Weight category of > 40 kg in study group will receive:~D1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg, ), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant & Olanzapine will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
89074926|NCT00631813|Active Comparator|1|Prucalopride 0.5 mg
89074927|NCT00631813|Active Comparator|2|Prucalopride 1 mg
89074928|NCT00631813|Active Comparator|3|Prucalopride 2 mg
89074929|NCT00631813|Placebo Comparator|4|
89074930|NCT04404049|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
89074931|NCT04404049|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
89074932|NCT04404049|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
89074933|NCT00911989|Other|Transvaginal Sleeve Gastrectomy|Transvaginal Sleeve Gastrectomy using Steerable Flex Trocar (SFT) for transvaginal endoscope placement (endoscopic visualization)
89074934|NCT04911517|Experimental|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
89074935|NCT04617379|Experimental|Active Treatment Group|15 minutes daily stretch for 1 year
89074936|NCT04617379|No Intervention|Control Group|No stretches
89074937|NCT04234633||SLE patients|Any SLE patients between 18 and 40 years old.
89074938|NCT04503655|Experimental|Intervention group|"The randomized centres in this group will be follow a training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
89074939|NCT04503655|No Intervention|Control group|The randomized centres in this group will not change their practices.
89074940|NCT04853563|Experimental|High PEEP|Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 8 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. Thereafter, the PEEP level is adjusted to 1 centimetre of water higher to a minimum PEEP level of 10 with every 30 minutes.
89224402|NCT06266611|Experimental|Broad-Spectrum Hemp-Derived CBD (bsCBD)|8 weeks of use of a daily dose of cannabis (200mg CBD)
89224403|NCT06266611|Placebo Comparator|Placebo|
89074941|NCT04853563|Active Comparator|Low PEEP|Immediate after initiation of invasive mechanical ventilation and randomization, the PEEP level is set to be at 5 centimetre of water with an inspired oxygen fraction (FiO2) between 0.21 and 0.6. In this arm, the PEEP level is adjusted to 1 centimetre of water lower to a minimum PEEP level of 3 with every 30 minutes while maintaining a partial pressure of arterial blood oxygen above 65 millimeter of mercury or oxygen saturation >92% with pulse oxymetry.
89074942|NCT03880279|Experimental|TAC01-CD19|TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.
89074943|NCT00637897|Experimental|Paricalcitol (Zemplar)|Paricalcitol (Zemplar)
89074944|NCT03992443|Experimental|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 milligrams (mg) per 2 milliliter (mL) directly into the catheter lumen. Participants received the first dose at minute (min) 0, and the second dose, if needed, at min 90. Assessments were performed at min 30, 60, 90, 120, 150, and 180.
89074945|NCT04334707||Acute Kidney Injury Cohort|The focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN). KPMP will also include a special population of patients at risk for AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of clinically indicated laparotomy.
89074946|NCT04334707||Chronic Kidney Diseases Cohort|High priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD will also be included.
89074947|NCT03926689|Experimental|Suaahara II Standard + SMS|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.) Suaahara II monthly SMS campaign targeting all adult household members of households in the 1000-day period between conception and a child's second birthday
89074948|NCT03926689|Active Comparator|Suaahara II Standard|Suaahara II standard multi sectoral nutrition interventions (home visits, radio program, etc.)
89074949|NCT03915535|Active Comparator|MaxSimil|Subjects of group A will receive a constant daily dose of 4.3g of MaxSimil, a combination of EPA + DHA in proportions of 500/200, for a period of 90 days.
89074950|NCT03915535|Experimental|MAG-EPA|Subjects of group B will receive a constant daily dose of 4.4g of MAG-EPA, a purified formulation of EPA with traces of DHA (730/050), for a period of 90 days.
89074951|NCT04816513|Active Comparator|Ustekinumab (Using Reference Device)|Participants will receive a single subcutaneous (SC) injection of ustekinumab in Device 1 as a reference device on Day 1.
89074952|NCT04816513|Experimental|Ustekinumab (Using Test Device)|Participants will receive a single SC injection of ustekinumab in Device 2 as a test device on Day 1.
89074953|NCT03858283|Experimental|Mindfulness Based Health Care Program|
89074954|NCT03858283|No Intervention|Control|
89074955|NCT04203511|Experimental|Chemoradiation therapy + INCMGA00012|
89074956|NCT04203511|Active Comparator|Chemoradiation therapy + Placebo|
89074957|NCT04203121|Experimental|arm1|"An initial 5 patients will be enrolled in the first treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.~subjects 1-5 : 9 Gy in 5 fractions of 1.8 Gy on 5 consecutive days"
89074958|NCT04203121|Experimental|arm2|"Subjects in this arm will be enrolled in the second treatment scheme and will be followed for 6 months after completion of treatment to assess safety and any toxicity events associated with treatment.~subjects 6-10 : 5.4 Gy in 3 fractions of 1.8 Gy on 3 consecutive days"
89074959|NCT04297891||ARSACS|Participants with genetically confirmed ARSACS (ORPHA:98) will be recruited. Target sample size for the ARSACS cohort is 120.
89074960|NCT04297891||SPG7|Participants with genetically confirmed SPG7 (ORPHA:99013) will be recruited. Target sample size for the SPG7 cohort is 72.
89074961|NCT04297891||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as the ARSACS and SPG7 cohort. Target sample size for the control cohort is 50.
89074962|NCT03690037|Experimental|Intervention Group 1|Intervention Group 1: 1g intravenous Tranexamic Acid 100 milligrams (MG)/ML peri-operatively plus 1g oral Tranexamic Acid 500mg Tablets every 8hrs for up to 24hrs
89074963|NCT03690037|Experimental|Intervention Group 2|Intervention Group 2: 1g intravenous Tranexamic Acid 100 MG/ML peri-operatively
89074964|NCT03690037|No Intervention|Control Group 3|Standard care - no TXA
89074965|NCT00910273|Experimental|1|etanercept 50 mg/week
89074966|NCT04202653|Active Comparator|Naive:ETV|Entecavir 0.5 mg po daily for 24 weeks in naive patients
89074967|NCT04202653|Experimental|Naive:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in naive patients
89074968|NCT04202653|Experimental|Naive:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus inhibitor of TQ-B2450 for 24 weeks in naive patients
89074969|NCT04202653|Active Comparator|Experienced:ETV|Entecavir 0.5 mg po daily for 24 weeks in treatment experienced patients
89074970|NCT04202653|Experimental|Experienced:ETV+TQ-A3334|Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in treatment experienced patients
89074971|NCT04202653|Experimental|Experienced:ETV+TQ-A3334+TQ-B2450|Entecavir 0.5 mg po daily plus TQ-A3334 plus TQ-B2450 for 24 weeks in treatment experienced patients
89074972|NCT00910039|Experimental|Sunitinib malate|"Oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo neuropsychological battery testing at baseline and periodically during study to assess cognitive function (memory, verbal fluency, visual-motor speed, executive function, and motor dexterity), activities of daily living, and quality of life."
89074973|NCT00632437||Speckle-Contrast Imaging|
89074974|NCT00909181|Experimental|Oxybutynin Gel 56 mg/day|
89074975|NCT00909181|Experimental|Oxybutynin Gel 84 mg/day|
89074976|NCT00909181|Placebo Comparator|Placebo Gel|
89074977|NCT02691169|Experimental|18F-DCFPyL Injection|The subjects will receive the 18F-DCFPyL Injection (less than or equal to 9 mCi (333 MBq)) at visits 2 and 3.
89074978|NCT03944161|Experimental|Intervention group|Participants in the intervention group will receive an oral nutrition supplement bottle (200/220 ml) with >20 % of protein and 1.5 Kcal/ml without fibre twice a day during 12 weeks and nutritional advice.
89074979|NCT03944161|Active Comparator|Control group|Participants in the control group will receive nutrition advice
89074980|NCT04268797|Experimental|HR rTMS H7-coil intervention group|
89074981|NCT04268797|Sham Comparator|sham control group|
89074982|NCT01286987|Experimental|Talazoparib|
89074983|NCT01286753|Experimental|Tyrosine Kinase Inhibitor (TKI) Naive|Vemurafenib in participants naive to any prior systemic TKI therapy.
89074984|NCT01286753|Experimental|TKI Experienced|Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).
89074985|NCT01286129|Active Comparator|Allergic asthmatic|Subjects with allergic asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
89074986|NCT01286129|Active Comparator|Allergic rhinitic without asthma|Subjects with allergic rhinitis without asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
89074987|NCT05590013|Active Comparator|Pectointercostal and ESP|Ultrasound (USG) guided erector spinae block will perform at T6 level (bilaterally) and pectointercostal plane block at 4-5 intercostal space to the 30 patients under general anaesthesia in Group block . Sevoflurane+remifentanil and O2/air combination will perform to the all patients during the surgery. Totally bupivacaine %0.25 2.5 mg/kg will use for blocks and 1 ml epinephrin will add to the each local anesthetic solutions in each side.10 ml %0.25 bupivacain will apply to the chest tube area at the end of surgery.
89074988|NCT05590013|Placebo Comparator|Control Group|Block will not perform to the control group.
89074989|NCT01285349|Experimental|Couple-based HIV prevention|7-session couple-based HIV/STI risk reduction intervention (CSTI)
89074990|NCT01285349|Active Comparator|Individual HIV/STI Prevention|7-session individual HIV/STI intervention comparison condition (ISTI) provided to the index participant alone, which is identical in content to the CSTI.
89074991|NCT01285349|Placebo Comparator|Couple Wellness Promotion|7-session couple-based stress reduction intervention (CSR) that serves as an attentional control condition.
89074992|NCT01284959|Experimental|risperidone|Drug: risperidone 3mg, PO two times Groups: risperidone
89074993|NCT01284959|Placebo Comparator|placebo|drug: lactose, PO 3 times group: placebo
89074994|NCT01284959|Experimental|paliperidone ER|drug : Paliperidone ER 6mg PO, two times group: paliperidone ER
89074995|NCT01284491|Active Comparator|Standard of Care (SOC)|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
89074996|NCT01284491|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
89074997|NCT02889887||preterm|infants who born before 37 completed weeks
89074998|NCT01283009|Placebo Comparator|Arm 1: Inactive substance|Inactive substance
89074999|NCT01283009|Active Comparator|Arm 2: Methylprednisolone|Methylprednisolone
89075000|NCT01282463|Active Comparator|Docetaxel|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
89075001|NCT01282463|Experimental|Docetaxel + Ramucirumab DP|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
89075002|NCT01282463|Experimental|Docetaxel + Icrucumab|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
89075003|NCT01282229|Active Comparator|LANAP Quadrant|Treated with LANAP
89075004|NCT01282229|No Intervention|Modified Widman Flap|Quadrant treated with Modified Widman Flap surgery
89075005|NCT01282229|No Intervention|Scaling and Root Planing|Quadrant treated with scaling and root planing alone
89075006|NCT01282229|No Intervention|Coronal Debridement|Quadrant treated with coronal debridement
89075007|NCT01281917|Experimental|Velcade plus Temsirolimus|"Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)~Treat for up to 6 cycles, cycles are 35 days long."
89075008|NCT01281839|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
89075009|NCT01281839|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
89075010|NCT01280981|Experimental|Tranexamic acid|Two 650 mg tablets orally 3 times per day with liquids for up to 5 days (not to exceed 3 doses in 1 day or 15 doses during the menstrual period).
89075011|NCT01280903|Experimental|STAR Intervention|Staying Active with Arthritis Intervention
89075012|NCT01280903|Placebo Comparator|Attention-Control|Senior Health Information Intervention
89075013|NCT04323605|Experimental|outpatient assistance program|
89075014|NCT01280591|Experimental|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|
89075015|NCT01280591|Experimental|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|
89075016|NCT01280591|Active Comparator|Naproxen sodium 440 mg (BAYH6689)|
89075017|NCT01280591|Active Comparator|DPH 50 mg|
89075018|NCT04323683||Low progesterone|Women with progesterone level below 15 ng/ml
89075019|NCT04323683||Normal progesterone|Women with progesterone level above 15 ng/ml
89075020|NCT01280357|Active Comparator|Monitor Philips 50XM (K954351)|CTG Fetal Monitor If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
89075021|NCT01280357|Experimental|Monica AN24 (K101801)|EHG Fetal Monitor
89075022|NCT04323917||Cases|Subjects affected by Pancreatic carcinoma (PC) confirmed by tissue biopsy
89075023|NCT04323917||Controls|Healthy Subject enrolled following colon cancer screening via colonoscopy
89075024|NCT05566223|Experimental|CISH CRISPR TIL / Phase I Arm|"Dose Escalation/Expansion Cohort~Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin"
89075025|NCT05566223|Experimental|CISH CRISPR TIL plus pembrolizumab / Phase I Arm|"Dose Expansion with Maintenance Therapy Cohort~Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin~Maintenance pembrolizumab during follow-up"
89075026|NCT05566223|Experimental|CISH CRISPR TIL / Phase II Arm PD-L1 Negative Cohort|"Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +recommended phase II dose (from phase I) of CISH inactivated TIL + high-dose aldesleukin~May include maintenance pembrolizumab during follow-up"
89224404|NCT06266559|Experimental|Initial Drink Group|Consume one bottle of Chang Geng Healthy Drink per day for the first eight weeks of the trial.
89224405|NCT06266559|Experimental|Subsequent Drink Group|Consume one bottle of Chang Geng Healthy Drink per day for the last eight weeks of the trial.
89075027|NCT05566223|Experimental|CISH CRISPR TIL / Phase II Arm PD-L1 Positive Cohort|"PD-L1 positive is defined as tumors with a PD-L1 Tumor Proportion Score (TPS) ≥ 1%.~Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +recommended phase II dose (from phase I) of CISH inactivated TIL + high-dose aldesleukin~May include maintenance pembrolizumab during follow-up"
89075028|NCT01274351|Experimental|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
89075029|NCT01271933|Experimental|Pregabalin|
89075030|NCT01271933|Placebo Comparator|Placebo|
89075031|NCT01269125|Active Comparator|Endometriosis, leuprolide, IVF|Women with stage II endometriosis received GnRH-a (leuprolide) prior to an IVF attempt.
89075032|NCT01269125|Active Comparator|Endometriosis, IVF|Women with mild endometriosis who underwent an IVF attempt without prior administration of GnRH-a.
89075033|NCT01269125|Active Comparator|Tubal infertility, IVF|Women with tubal infertility underwent an IVF attempt.
89075034|NCT01268891|Placebo Comparator|Placebo|
89075035|NCT01268891|Experimental|Azilect®|
89075036|NCT01268501|Experimental|Lotrafilcon B multifocal|Lotrafilcon B multifocal contact lenses worn bilaterally for 3 weeks on a daily wear basis
89075037|NCT04323527|Active Comparator|Low Dose Chloroquine Diphosphate (5 days) (Study stage 1) - Clorocovid 1|Low dose chloroquine group consists of 450 mg bid (3 tablets of 150 mg + 1 placebo tablet, every 12 hours) on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10 . Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
89075038|NCT04323527|Active Comparator|High Dose Chloroquine Diphosphate (10 days) (Study stage 1) - Clorocovid 1|High dose chloroquine group consists of 600 mg bid (4 tablets of 150 mg, every 12 hours) for 10 days. Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020).
89075039|NCT04323527|Placebo Comparator|Placebo (5 days) (Study stage 2) - Clorocovid 3|Placebo group consists of 3 placebo tablets bid (day 1), and 3 placebo tablets once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
89230005|NCT00663923|Active Comparator|single|In this technique ,cylinder is treated only on one meridian by performing an elliptical ablation to to flatten the steeper meridian to match the flatter meridian.
89230006|NCT00787007|Experimental|1|10 mg
89230007|NCT00787007|Experimental|2|20 mg, fasted and fed
89230008|NCT00787007|Experimental|3|40 mg
89230009|NCT00787007|Experimental|4|80 mg
89230010|NCT00787007|Experimental|5|160 mg
89230011|NCT00787007|Experimental|6|320 mg
89230012|NCT00787007|Placebo Comparator|7|placebo capsule
89230013|NCT00787085||Case|Patients hospitalized with a urine or blood culture positive for fungi
89230014|NCT00787085||Control|Patients hospitalized with a urine culture negative for fungi
89230015|NCT00787163|Experimental|1|amnioinfusion
89230016|NCT00787163|No Intervention|2|expectant management
89230017|NCT00791063|Experimental|18F ML-10|Intervention - 18F ML-10 PET/CT imaging for early detection of response of brain metastases to WBRT
88812946|NCT01532141|Experimental|Group 1|Period 1: 50 mg BIA 9-1067 alone Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
89075040|NCT04323527|Active Comparator|Low Dose Chloroquine Diphosphate (5 days) (Study stage 2) - Clorocovid 3|Low dose chloroquine group consisted of 450 mg bid (3 tablets of 150 mg) on D1, and 3x150mg tablet once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
89075041|NCT01268267|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using an investigational blood glucose monitoring system (development name Ninja 2).
89075042|NCT01267253|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89075043|NCT04378777||Surveillance cohort|Cohort descriptive data will include demographic variables (e.g. age, sex, race, ethnicity), clinical information on enrollment and key aspects of medical history (e.g. concomitant medications, for example). Patients will be longitudinally followed, up to 12 months.
89075044|NCT02889419|Experimental|Evaluation of underwear Selfia®|Every patient is his own control.
89075045|NCT02889497|Experimental|300 subjects receive the first batch vaccine|300 subjects will be randomly received the first batch vaccine
89075046|NCT02889497|Experimental|300 subjects receive the second batch vaccine|300 subjects will be randomly received the second batch vaccine
89075047|NCT02889497|Experimental|300 subjects receive the third batch vaccine|300 subjects will be randomly received the third batch vaccine
89230018|NCT00784355|Experimental|1:Laparoscopic cholecystectomy|Surgery
89230019|NCT00784355|No Intervention|2:controls|non-surgical control group
89230020|NCT00795119|Experimental|NIRS|Children who undergo NIRS
89230021|NCT00795197||Screening Group|Screening Group
89230022|NCT00787397|Experimental|1. Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy-Sleep
89230023|NCT00791141|Experimental|Cetuximab|Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
88812947|NCT01532141|Experimental|Group 2|Period 1: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 alone Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
89075048|NCT01266317|Experimental|Combined PEX, Rituximab and Steroids|"Standard Steroid Treatment: One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent). Methylprednisolone 100 mg I.V. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone I.V. (or P.O. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the principle investigator.~Plasma exchange (PEX) will consist of 1.5x estimated plasma volume exchanges for 3 successive days (0, 1,2) and then, after a one day interval to enable equilibration of autoantibodies sequestered in tissues, two more daily treatments on days 4 and 5.~Rituximab: One gm I.V. will be administered on day 5 (after completion of the last PEX) and day 13."
89075049|NCT01266161|Experimental|Ibuprofen 600 mg extended release|
89075050|NCT01266161|Placebo Comparator|Placebo|
88812948|NCT01532141|Experimental|Group 3|Period 1: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone
89075051|NCT01265849|Experimental|LI + CIZ + SOC|LI plus CIZ (cyclophosphamide, indomethacin and zinc-multivitamins) was given as neoadjuvant therapy prior to standard of care (SOC).
89075052|NCT01265849|Active Comparator|Standard of Care (SOC) only|SOC for previously untreated SCCHN patients is currently surgery (with curative intent) followed by either radiotherapy or combined radiochemotherapy depending on the patient's risk status for recurrence as determined at surgery.
89075053|NCT01265849|Experimental|LI + SOC|LI was administered without CIZ to determine the contribution of CIZ to the effects of LI.
89075054|NCT01265615|Active Comparator|Paricalcitol treatment|6-8 μg daily per os (orally) without special diet
89075055|NCT01265615|Active Comparator|Calcitriol treatment|2-4 μg daily orally under with dietary restrictions of vitamin D
89075056|NCT01265615|Active Comparator|Cholecalciferol|alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day
89075057|NCT01265615|Other|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
89075058|NCT00623909|Experimental|1|To demonstrate the safety of the AvicennaTM class IV laser for application over the skin of human subjects. This study was terminated prior to subject enrollment and closed.
89075059|NCT01264679|Experimental|Ferumoxytol|When a participant has persistent or recurrent IDA (defined as hemoglobin <12.0 grams [g]/deciliter [dL] and with either transferrin saturation <40% or ferritin <100 nanograms/milliliter), the participant will begin a 7-week treatment period. Participants will receive 2 IV injections of ferumoxytol 7.0 milligrams (mg) iron/kilogram (maximum of 510 mg/dose), the first dose administered on Day 1 and the second on Days 3 through 9 of the Treatment Period.
89075060|NCT02889341|Placebo Comparator|Placebo|Placebo
89075061|NCT02889341|Active Comparator|500 mg DHA/day|500 mg DHA/day
89075062|NCT02889341|Active Comparator|1g DHA/day|1g DHA/day
89075063|NCT02889341|Active Comparator|2g DHA/day|2g DHA/day
89075064|NCT05542043||Women with normal blood loss (BV < 500 mL)|
89075065|NCT05542043||Women with increased blood loss (BV ≥ 500 mL)|
89075066|NCT01263665|Experimental|25cm Gore VIABAHN|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
89075067|NCT04323371||Acute decompensated heart failure|patients admitted with Acute decompensated heart failure Complicated by cardiogenic shock
89075068|NCT01263509|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
89075069|NCT01263509|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
89230024|NCT04046783||Group A included subjects without a history of C-section|Group A consisted of 47 women without a prior a history of C-section: 24 controls and 23 subjects who used patch. These latest 23 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
89075070|NCT01263197|Experimental|LY2216684, albuterol, LY2216684+albuterol|LY2216684 as an 18 milligram (mg) oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
89075071|NCT01263197|Experimental|albuterol, LY2216684+albuterol, LY2216684|Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
89075072|NCT01263197|Experimental|LY2216684+albuterol, LY2216684, albuterol|LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in second intervention period, Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
89075073|NCT01263197|Experimental|LY2216684, propranolol, LY2216684+propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
89691791|NCT03021863|Active Comparator|Group H Reminder|Tone of reminder email (duty 14 days followed by generic for non-responders 28 days)
89691792|NCT03021863|Active Comparator|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic for non-responders 28 days)
89691793|NCT03017807|Experimental|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance.
89691794|NCT01099111||Irritable Bowel Syndrome|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
89691795|NCT01099111||Ulcerative Colitis|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
89691796|NCT01099111||Crohn's Disease|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
89691797|NCT01099111||Colo Rectal Cancer|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
89691798|NCT01099111||Control: Normal Subjects|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
89691799|NCT00947219|Active Comparator|HairMax LaserComb 2009, 12 Beam|Low Level Laser Medical Device 2009 with 12 laser beams
89691800|NCT00947219|Active Comparator|HairMax LaserComb 2009 9 Beam|Low Level Laser Mecial Device 2009 with 9 laser beams
89691801|NCT00947219|Active Comparator|Control device|The control device appears identical to the active device, but utilizes 9 LED lights instead of laser lights. The randomized devices are blinded to the study investigator and distributed in a blinded manner to the participants.
89691802|NCT01124305|Active Comparator|Traditional Instrumentation|Control group: Cases performed with traditional surgical instruments
89691803|NCT01124305|Experimental|Customized Patient Instrumentation|Experimental group: Cases performed with custom instruments specifically made for each patient using pre-op CT scans.
89691804|NCT03408730|Experimental|Sci-B-Vac Lot A Hep B Vaccination|Sci-B-Vac Lot A Hepatitis B Vaccination
89691805|NCT03408730|Experimental|Sci-B-Vac Lot B Hep B Vaccination|Sci-B-Vac Lot B Hepatitis B Vaccination
89691806|NCT03408730|Experimental|Sci-B-Vac Lot C Hep B Vaccination|Sci-B-Vac Lot C Hepatitis B Vaccination
89691807|NCT03408730|Active Comparator|Comparator: ENGERIX-B Hep B Vaccination|Active Comparator: ENGERIX-B Hepatitis B Vaccination
89691808|NCT03408808|Active Comparator|Aspiration alone|The patients will have their dorsal wrist ganglion aspirated and then pressure dressing for 48 hours.
89691809|NCT03408808|Experimental|Aspiration plus platelet rich plasma|The patients will have their dorsal wrist ganglion aspirated, and then injected with platelet rich plasma (derived from a blood sample taken at the same visit) and then pressure dressing for 48 hours.
89691810|NCT03021941|Other|Elelyso 60 units/kg|All patients receive 60 units/kg of Elelyso.
89691811|NCT03410914|Experimental|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery
89691812|NCT03017495|Experimental|Food effect and Drug-Drug interaction|Treatments will be given to all subjects in the same fixed sequence: Treatment A (Day 1, single dose of midazolam, fasted), Treatment B (Day 2, single dose of ACT-541468 followed by single dose of midazolam, fasted), Treatment C (Day 4, single dose ACT-541468, fed), Treatment D (multiple doses of ACT-541468 from Day 5 to Day 8 + single dose of midazolam on Day 8, fasted).
89691813|NCT03021161|Experimental|intervention group|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019 (probiotic formula).
89691814|NCT03021161|Placebo Comparator|Placebo Oral Capsule|The control group will receive once daily similar capsules containing placebo.
89691815|NCT01039207|Experimental|Treatment (rilotumumab)|Patients receive rilotumumab IV over 30-60 minutes on days 1 and 14. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Tumor tissue and blood samples may be collected periodically for further laboratory analysis.
89691816|NCT03417466|Experimental|Study arm|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6).
89691817|NCT03830047|Active Comparator|nd yag laser|Applying nd yag laser to vulva
89691818|NCT03830047|Sham Comparator|Co2 laser|Applying CO2 laser to vulva
89691819|NCT02981537|Experimental|two-staged|positioning endobronchial blockers to appropriate bronchus with two-staged methods
89691820|NCT02981537|Active Comparator|single-staged|positioning endobronchial blockers with traditional single-staged methods
89691821|NCT03033173||CTS group|
89691822|NCT03033173||Healthy subjects|
89691823|NCT03621202|Experimental|Saranas Early Bird Bleed Monitoring System (EBBMS)|
89691824|NCT01125163|Active Comparator|multivitamin with iron|daily oral multivitamin providing 2mg/kg of iron
89691825|NCT01125163|Placebo Comparator|multivitamin without iron|daily oral multivitamin without iron
89691826|NCT03033329|Experimental|Single intravenous doses of MRX-4|Single escalating intravenous doses of MRX-4 from 150 mg to 1800 mg
89691827|NCT03033329|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-4
89691828|NCT03033329|Active Comparator|Multiple intravenous doses of MRX-4|Twice daily escalating intravenous doses of MRX-4 for 10 days: 600 mg, 900 mg, 1200 mg, and 1500 mg
89691829|NCT03033329|Placebo Comparator|Multiple intravenous doses of placebo|Twice daily intravenous doses of placebo to match MRX-4 for 10 days
89691830|NCT03033329|Active Comparator|Single dose of intravenous and oral MRX-4|Crossover of single dose of intravenous and oral MRX-4
89691831|NCT03020693|Experimental|Invasive electrostimulation combined with exercises.|Dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to therapeutic intensity) combined with exercises program.
89075074|NCT01263197|Experimental|propranolol, LY2216684+propranolol, LY2216684|Placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
89075075|NCT01263197|Experimental|LY2216684+propranolol, LY2216684, propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in second intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
89075076|NCT01263119|Experimental|Warfarin, LY2216684 + Warfarin|Period 1: Single 10-milligram (mg) warfarin oral dose on Day 1; Washout Period of at least 14 days; Period 2: 18-mg LY2216684 oral dose, once daily on Days 1 to 12, with single 10-mg warfarin oral dose coadministered on Day 3.
89075077|NCT05537597|Experimental|M1-rTMS group|
89075078|NCT05537597|Sham Comparator|sham-rTMS group|
89075079|NCT01262651|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
89075080|NCT01262651|Placebo Comparator|Placebo (GA-0034)|Placebo Comparator: Placebo (GA-0034) Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol: propylene glycol (50:50)
89075081|NCT01262573|Experimental|Barbed|Vaginal cuff closure with barbed suture
89075082|NCT01262573|Active Comparator|Smooth|Vaginal cuff closure with smooth suture
89075083|NCT04323059|Experimental|Standardized milk-based formulation|Formulation of maize with milk that is rich in methionine
89075084|NCT04323059|Experimental|Standardized non-milk based formulation|Formulation of maize with soybeans that is rich in methionine and lysine
89075085|NCT04323059|Active Comparator|Hospital-based formulation|Formulation of maize, milk and soybeans
89075086|NCT04323215||Support system users|Usual care (behavioral treatment) plus the support system for self-monitoring of weight and communication with the clinic during one year of treatment.
88820852|NCT05562973|Experimental|Dose Sequence 3 (25, 30, 35)|"Psilocybin dose sequence~Session 1: 25 mg Session 2: 30 mg Session 3: 35 mg"
88820853|NCT05562973|Experimental|Dose Sequence 4 (30, 35, 40)|"Psilocybin dose sequence~Session 1: 30 mg Session 2: 35 mg Session 3: 40 mg"
89075087|NCT04323215||Control group|Children treated with usual care according to regular treatment routines registred in BORIS the Swedish childhood obesity treatment register
89075088|NCT04322903|Experimental|Trauma-informed mindfulness-based stress reduction program|The program includes three 2-hr sessions to promote physical and emotional wellbeing through mindfulness techniques and health promotion activities; two home visits to provide individualized sessions with a nurse and a community health navigator; and a follow-up session 4 weeks after intervention to discuss perception of the intervention.
89075089|NCT04322045|Experimental|participants|All tested serum PSA. Some conducted mpMRI with/without prostate biopsy under instruction.
89075090|NCT04322201|Experimental|Intervention group - Continuous passive paracentesis|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care.
89075091|NCT04322201|Active Comparator|Control group - Large volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter performed and repeated during ICU stay according to standard-of-care clinical practice.
89075092|NCT02889185|Experimental|Adaptative optics retinal camera|
89075093|NCT01262027|Experimental|Dovitinib|A complete treatment cycle defined as 28 days or 4 weeks (+/- 2 days). Patients receive a single daily oral dose of 500 mg of dovitinib for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule).
89075094|NCT01261793|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
89075095|NCT01261793|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles
89075096|NCT01261793|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
89075097|NCT04321967|Experimental|Nitroglycerine paste|The randomized breast will receive Nitroglycerine paste and Dermabond.
89075098|NCT04321967|Placebo Comparator|Dermabond|The control breast will receive Dermabond only
89075099|NCT04321655|Experimental|High Intensity LASER Therapy group (HILT)|Forty patients with chronic KOA in HILT group will received Class IV LASER therapy. A Class IV LASER emits power more than 500 milliwatt (mW) .
88820854|NCT05562973|Experimental|Dose Sequence 5 (35, 40, 45)|"Psilocybin dose sequence~Session 1: 35 mg Session 2: 40 mg Session 3: 45 mg"
89075100|NCT04321655|Experimental|Ibuprofen gel phonophoresis (IGP) group|Patients with chronic KOA in ibuprofen gel phonophoresis (IGP) group will administered with continuous ultrasound set at a frequency of 1 megahertz (MHz) and an intensity of 1 W/cm2 was applied on a circular basis.
89075101|NCT04321655|Experimental|Transcranial direct current stimulation (tDCS) group|Fourty patients with chronic KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
89075102|NCT04321655|Active Comparator|Conventional physiotherapy group (CPT)|Individual with chronic KOA will be educated on how to do the set of exercises correctly at their home during the first session. All the groups will receive the same, standardized exercise protocol for KOA which consisted of nine exercises including muscle strengthening and flexibility training.
89075103|NCT04207541|Experimental|Control group and Intervention group|For control group, participants will be treated with usual care. For intervention group, participants will be provided a session of education regarding insulin initiation with brief motivation interviewing.
89075104|NCT05532605|Active Comparator|Cardiac rehab phase I protocols|will be treated with cardiac rehab phase I protocols
89075105|NCT05532605|Experimental|Cardiac rehab phase I protocols + Mindfullness base therapy|will be treated with cardiac rehab phase I protocols along with Mindfullness base therapy
89075106|NCT04321499||lung cancer|stage IA-IIIA lung cancer
89075107|NCT04321499||benign nodules|ruled out lung cancer via Operation or CT-scan follow-up
89075108|NCT04321577||Residual disease|Participants with incidental gallbladder cancer with presence of residual disease in the re-resection specimen or in intra-operative findings.
89075109|NCT04321577||No residual disease|Participants with incidental gallbladder cancer with absence of residual disease in the re-resection specimen or in intra-operative findings.
89075110|NCT04321889|Experimental|BEO|Subjects of both sexes of age >65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
89075111|NCT04321889|Placebo Comparator|Placebo|Subjects of both sexes of age >65 years who have received diagnosis of severe dementia and clinically relevant agitation hospitalized in the enrolment center.
89075112|NCT04321421|Experimental|treated|treated with hyperimmune plasma
89075113|NCT02889107|No Intervention|standard care|Patients received standard listening strategies for 10 weeks
89075114|NCT02889107|Experimental|intervention|Patients received an assistive listening device (personal frequency modulated systems) for 10 weeks
89075115|NCT04320875|Experimental|Transcranial direct current stimulation (tDCS) group|Fourty patients with KOA will receive structured tDCS (MA-tDCS, Walnut-Medical, Johnstown, PA) treatment. Two pair of sponge electrodes soaked with saline and fixed to head with elastic bands. The transcranial direct current stimulation will be applied by a constant current device with an intensity of 2mA
89075116|NCT04320875|Active Comparator|Conventional Physiotherapy (CPT) group|Individual with KOA will be educated on how to do the set of exercises correctly at their home during the first session. Consisted of nine exercises including muscle strengthening and flexibility training.
89075117|NCT01261325|Placebo Comparator|Placebo|Matching placebo tablets administered twice daily
89075118|NCT01261325|Experimental|Brivaracetam 100 mg/ day|Brivaracetam 50 mg/ day administered twice daily.
89075119|NCT01261325|Experimental|Brivaracetam 200 mg/ day|Brivaracetam 100 mg/ day administered twice daily
89075120|NCT01260701|Experimental|Treatment (CLOSED TO ACCRUAL 05/01/13)|Patients receive Akt inhibitor MK2206 PO every other day on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89075121|NCT01260467|Experimental|memantine arm|
89075122|NCT01260311||Patients prescribed with Fesoterodine|Patients diagnosed with Over-active bladder and prescribed with fesoterodine.
89075123|NCT00623987|Active Comparator|A|warfarin treatment
89075124|NCT00623987|No Intervention|B|withholding warfarin therapy
89075125|NCT01259375|Experimental|All patients|All participants who received Amrubicin.
89075126|NCT05487053|Experimental|Single-shot adductor canal block|
89075127|NCT05487053|Active Comparator|Continuous femoral nerve block|
89075128|NCT05468021|No Intervention|Comparison control|The control condition will consist of standard of care. The participants in the control arm will not receive the educational intervention after assessment.
89075129|NCT05468021|Experimental|Intervention condition|The participants in the intervention arm will receive the educational intervention after assessment.
89075130|NCT02888873|Active Comparator|Charisma|applied randomly
89075131|NCT02888873|Active Comparator|Charisma classic|applied randomly
89075132|NCT00624143|Active Comparator|1|Oral Voriconazole
89075133|NCT00624143|Active Comparator|2|IV Amphotericin B
89075134|NCT05284799|Experimental|OVX836 480µg + Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) at commercial dose|"OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the incluenza virus. One single administration intramuscularly of 480µg dose on Day 1~AND~Fluarix® Tetra (GlaxoSmithKline Biologicals): Inactivated and purified split influenza vaccine."
89075135|NCT05284799|Active Comparator|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) at commercial dose + Placebo|"Fluarix® Tetra (GlaxoSmithKline Biologicals): Inactivated and purified split influenza vaccine.~AND~Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50mL. One single administration intrumuscularly of a 0.8mL dose on Day 1"
89075136|NCT05284799|Placebo Comparator|OVX836 480µg + Placebo|"OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the incluenza virus. One single administration intramuscularly of 480µg dose on Day 1~AND~Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50mL. One single administration intrumuscularly of a 0.8mL dose on Day 1"
89075137|NCT05245253||Trauma patients|Trauma patients 20-60 years of age
89075138|NCT05154695|Active Comparator|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
89075139|NCT05154695|Active Comparator|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
89075140|NCT02889029|Experimental|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
89691832|NCT03020693|Active Comparator|Placebo electrostimulation and exercises.|Sham dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to non-therapeutic intensity) with surface electrodes combined with exercises program.
89691833|NCT01099969|Experimental|Glidescope with non-styletted Endotrol ETT|The patients in this arm will be intubated using a Glidescope videolaryngoscope with non-styletted Endotrol endotracheal tube (ETT).
89075143|NCT02888951||Diabetic Group|A group of diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
89691834|NCT01099969|Active Comparator|Glidescope with styletted regular ETT|The patientsin this arm will be intubated using the glidescope videolaryngoscope and regular endotracheal tube (ETT) with gliderite stylet.
89691835|NCT01099969|Experimental|McGrath with non-styletted Endotrol ETT|The patients in this arm will be intubated using McGrath videolaryngoscope and non-styletted Endotrol endotracheal tube (ETT).
89691836|NCT01099969|Active Comparator|McGrath with with styletted regular ETT|The patients receiving this arm will be intubation using McGrath videolaryngoscope and regular endotracheal tube (ETT) with Gliderite stylet.
89691837|NCT03017339|Experimental|Laser Group|The subjects participated in a functional exercise program associated with low level laser therapy applied in the quadriceps, hamstrings and triceps sural
89691838|NCT03017339|Placebo Comparator|Placebo Group|The subjects participated in a functional exercise program associated with placebo low level laser therapy applied in the quadriceps, hamstrings and triceps sural
89691839|NCT03417778|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
89691840|NCT03417778|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
89691841|NCT03417778|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
89691842|NCT03020147||early BCG|Children received BCG soon after their birth between 2008 and 2013.
89691843|NCT03020147||delayed BCG|Children received BCG when they are 2,5kg between 2008 and 2013.
89691844|NCT03013855|Active Comparator|FIT-SOC|Fecal immunochemical test performed on spontaneously passed stool as noted in the standard instructions.
89691845|NCT03013855|Experimental|FIT-DRE|Fecal immunochemical test completed with stool collected during digital rectal exam.
89691846|NCT03013153|Experimental|Low ligation with apical lymph node dissection|Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
89691847|NCT03013153|Active Comparator|High ligation|Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
89691848|NCT03032861|Experimental|Orange juice|Ten women will consume 100% orange juice (300 mL/day) during 60 days.
89691849|NCT03033017||HIV-infected on antiretroviral therapy 2 years|HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
89691850|NCT05308147|Other|Arm 1 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89691851|NCT05308147|Other|Arm 2 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89691852|NCT05308147|Other|Arm 3 (Reference)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89691853|NCT05308147|Other|Arm 4 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89691854|NCT05308147|Other|Arm 5 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89691855|NCT05308147|Other|Arm 6 (Concept)|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89691856|NCT03575962|Experimental|GSK3640254 Bis-hydrochloride followed by GSK3640254 mesylate|The subjects in this arm will receive an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsules(reference), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1, during Period 2 of the study. The drug will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
89691857|NCT03575962|Experimental|GSK3640254 Mesylate followed by GSK3640254 Bis-hydrochloride|The subjects in this arm will receive an oral administration of 200 mg as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsule, 100 mg (reference), as single oral dose, on the morning of Day 1 during Period 2, of the study. The drug, will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
89691858|NCT03019991|Experimental|PK Group (Danoprevir,Ritonavir)|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14;100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13;
89691859|NCT03019991|Placebo Comparator|Placebo Group|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13 for 14 days;
89691860|NCT05307835|Experimental|Personalized neoantigen vaccines|iNeo-Vac-P01 (peptides)： 300 mcg per peptide
89691861|NCT05307835|No Intervention|control group|observe
89075144|NCT02888951||Non-Diabetic Group|A group of non-diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
89075145|NCT04320641|Experimental|acupressure|
89075146|NCT04320641|Experimental|music|
89075147|NCT04320641|No Intervention|control|
89075148|NCT02888795|Experimental|hypertonic dextrose prolotherapy|
89075149|NCT04320095|Experimental|Bizact device for one tonsil|Bizact tonsillecotmy device which is an advanced bipolar device using radiofrequency and pressure to ligate the encountered vessels during tonsillectomy.
89075150|NCT04320095|Active Comparator|Electrocautery for second tonsil|Electrocautery is the standard technique used at our institution.
89075151|NCT04320095|Experimental|Bizact device for both tonsils|Consecutive cases of tonsillectomy will be done using Bizact device and compare the operative time collectively for those cases and compare it to same number of cases done using the standard procedure ( Electrocautery)
89075152|NCT04320095|Active Comparator|Electrocautery for both tonsils|As explained on the above arm description
89230025|NCT04046783||group B subjects who had already undergone previous C-section|Group B consisted of 46 women already undergone previous C-section: 22 controls and 24 subjects who used patch. These latest 24 subjects applied overnight a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks
89075153|NCT04232735|Experimental|Intervention|"The Source tool is used by care givers for informing patients about the outcomes of treatment. Prediction models are developed and built in the website in order to generate a personalized prediction of the outcomes: survival, toxicity and/or complications and HRQL. These predictions are visualized in clear and comprehensible graphs with a broad variation of options available for tailoring of the visualizations.~In order for care givers to be able to use this tool effectively, we designed the Source training. This communication skills training is comprised of an e-learning, two face-to-face group sessions and an individual booster session. Aside from an instruction video on the navigation within the Source tool, the e-learning consists of theory and tips and tricks on how to inform patients and communicate risks. The face-to-face components of the training are focused on getting the skilled use of the source tool into practice, by receiving personal feedback on the performance."
89075154|NCT04111211||Individuals at high risk of developing Alzheimer's dementia|
89075155|NCT04005287|Placebo Comparator|WST-057 Matching placebo 2 mL volume|
89075156|NCT04005287|Placebo Comparator|WST-057 Matching placebo 4mL volume|
89075157|NCT04005287|Active Comparator|WST-057 (4% pirenzepine) 2mL volume|
89075158|NCT04005287|Active Comparator|WST-057 (4% pirenzepine) 4mL volume|
89075159|NCT03763799|Experimental|multiplex PCR strategy|FilmArray® Pneumonia Panel plus
89075160|NCT03763799|Active Comparator|standard strategy|
89075161|NCT04319861|Experimental|Anal fistula plug|The anal fistula plug procedure was performed as followings. A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
89075162|NCT02888717|Experimental|OSNA stadification during surgery|The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and will be analysis both by histological analysis and OSNA analysis
89075163|NCT03741569|Other|parturients (gestational age ≥37 weeks).|
89075164|NCT03616379|Placebo Comparator|Psychoeducational Control|
89075165|NCT03616379|Experimental|Affect Regulation Condition|
89075166|NCT03616379|Experimental|Affect Labelling Condition|
89075167|NCT04320173|Experimental|Lidocaine Patch (Sequence ABC)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 1, 3 lidocaine 1.8% patches were applied in Period 1, and 3 lidocaine 5% patches were applied in Period 2, and 3 lidocaine 5% medicated plasters were applied in Period 3.
89075168|NCT04320173|Experimental|Lidocaine Patch (Sequence CAB)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 2, 3 lidocaine 5% medicated plasters were applied in Period 1, and 3 lidocaine 1.8% patches were applied in Period 2, and 3 lidocaine 5% patches were applied in Period 3.
89075169|NCT04320173|Experimental|Lidocaine Patch (Sequences BCA)|Subjects received all three topical lidocaine products in Periods 1, 2, and 3. The sequence in which they received the lidocaine products was determined by random assignment. For subjects in Arm 3, 3 lidocaine 5% patches were applied in Period 1, and 3 lidocaine 5% medicated plasters were applied in Period 2, and 3 lidocaine 1.8% patches were applied in Period 3.
88812949|NCT03213080||TLD Procedure|All subjects who are enrolled and meet the eligibility criteria will undergo Targeted Lung Denervation (TLD). TLD is a bronchoscopically-guided, minimally-invasive procedure using the Nuvaira™ Lung Devervation System. The Nuvaira System is intended for the long-term maintenance treatment of airway obstruction associated with COPD. TLD uses radiofrequency (RF) energy to ablate the airway nerve trunks of the vagus nerves that travel parallel to and outside of the main bronchi and into the lungs. Ablation of the nerves opens the airways and makes breathing easier.
89075170|NCT03002519|Experimental|PLX-R18|Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.
89075171|NCT02915549|Experimental|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
89075172|NCT02915549|Active Comparator|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
89075173|NCT02914301|Active Comparator|Babyscripts Prenatal App|For patients allocated to the experimental group, they will be assisted in downloading the BRx app to their smartphone and set up the connected weight scale and blood pressure cuff. At time of enrollment, research assistant will also collect baseline demographic and clinical data. For patients allocated to this study arm, the clinician will be informed and therefore, will be receiving regular app-based education while the clinician will be receiving regular blood pressure and weight measurements. Following that communication, it will be the physicians' judgement to reduce in-person visits from usual care.
89230026|NCT04046393|Experimental|Traditional Chinese Medicine(TCM) group|nasal irrigation with Traditional herbal medicine(licorice) extract-saline isotonic solution
89075174|NCT02914301|Placebo Comparator|Placebo|For patients cared for by clinicians allocated to the control (usual care) arm, the clinician will discuss the management options and scheduling procedures with the patient in that clinician's usual fashion. The patient will not be given access to the BRx app but will consent to the study data collection and survey administration. All potential study subjects will receive standard medical care per DoD/VA Clinical Practice Guidelines for Management of the uncomplicated pregnancy (REF) and local preference by board-certified OB/GYN physicians.
89075175|NCT02693093|Placebo Comparator|placebo|TID Day for 28 Days
89075176|NCT02693093|Experimental|100 mg NI-03|TID Day for 28 Days
89075177|NCT02693093|Experimental|200 mg NI-03|TID Day for 28 Days
89075178|NCT02693093|Experimental|300 mg NI-03|TID Day for 28 Days
89075179|NCT01613495|Placebo Comparator|Placebo|Normal Saline
89075180|NCT01613495|Active Comparator|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
89075181|NCT01429493|Active Comparator|Conventional radiotherapy|
89075182|NCT01429493|Experimental|Biological image-guided radiotherapy with conventional dose.|
89075183|NCT01429493|Experimental|Biological image-guided SBRT with dose-escalation.|
89075184|NCT00694733|Placebo Comparator|1|Men on placebo injections for 4 months
89075185|NCT00694733|Active Comparator|2|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.
89075186|NCT00694733|Active Comparator|3|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.
89075187|NCT00694733|Placebo Comparator|4|Women on placebo cream
89075188|NCT00694733|Active Comparator|5|Women on estrogen cream
89075189|NCT04320953|Experimental|Non-contact MCE examination|Study subject in this arm receives non-contact MCE examination.
89075190|NCT01259297|Experimental|Aliskiren + Amlodipine|"In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period."
89075191|NCT01259297|Experimental|Aliskiren + Hydrochlorothiazide (HCTZ)|"In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily."
89075192|NCT01259297|Experimental|Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg"
89075193|NCT01259297|Experimental|Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily"
89075194|NCT01259297|Experimental|Amlodipine + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily"
89075195|NCT01259297|Experimental|HCTZ + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily"
89075196|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily"
89075197|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily"
89075198|NCT01126437|Experimental|tiotropium 2.5 mcg and placebo|Patients receive one of the active tiotropium arms daily
89075199|NCT01126437|Active Comparator|tiotropium 18 mcg and placebo|Patients receive one of the active tiotropium arms daily
89075200|NCT01126437|Experimental|tiotropium 5 mcg and placebo|Patients receive one of the active tiotropium arms daily
89075201|NCT01258595|Experimental|High-Dose Trivalent Inactivated Influenza Vaccine|
89075202|NCT01258595|Active Comparator|Trivalent Inactivated Influenza Vaccine|
89075203|NCT01257737|Experimental|HPN-100|Participants continued HPN-100 treatment after completion of HPN-100-005SE, HPN-100-007, or HPN-100-012SE.
89075204|NCT01126359|Placebo Comparator|Lidocaine then Placebo-Saline|
89075205|NCT01126359|Active Comparator|Placebo-Saline then Lidocaine|
89075206|NCT00637533|Placebo Comparator|Placebo|Saline injection
89075207|NCT00637533|Experimental|Botulinum Toxin Type A|Sympathetic Blockade containing Botulinum Toxin Type A
89075208|NCT01125813|Experimental|human cl-rhFVIII|
89075209|NCT00996892|Experimental|Dose Escalation Stage 1: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 20 milligrams [mg]) and pictilisib capsules (at a starting dose of 80 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
89075210|NCT00996892|Experimental|Dose Escalation Stage 1A: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
89230027|NCT04046393|Placebo Comparator|Saline control group|nasal irrigation with saline isotonic solution
89230028|NCT00386152|Experimental|epoetin alfa (120,000 Units)|epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
89230029|NCT00386152|Experimental|epoetin alfa (80,000 Units)|epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
89075211|NCT00996892|Experimental|Dose Escalation Stage 1B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 40 mg) and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
89075212|NCT00996892|Experimental|Dose Expansion Stage 2: Cobimetinib + Pictilisib|Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).
89075213|NCT00996892|Experimental|Dose Expansion Stage 2A: Cobimetinib + Pictilisib|Participants received cobimetinib capsules on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1A. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant NSCLC; EGFR T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; KRAS mutant CRC, and KRAS mutant endometrioid carcinoma.
89691862|NCT00947297|Experimental|HPN-100|Patients who were treated with HPN-100
89691863|NCT03576118|Experimental|Deep neuromuscular block|Deep neuromuscular relaxation and low pressure pneumoperitoneum
89691864|NCT03576118|Active Comparator|Moderate neuromuscular block|Moderate neuromuscular relaxation and standard pressure pneumoperitoneum
89691865|NCT03017417|Experimental|Exercise Intervention arm|"exercise training intervention to include:~DEXA scan will collect data on via a full body scan to determine post-cranial appendicular whole body LM, whole body fat free mass (FFM) and whole body FM.~Muscle Strength assessment~Physical function assessment~Questionnaires and diet diaries"
89691866|NCT03017417|Active Comparator|standard of care arm|"standard treatment~exercise advice~Questionnaires"
89691867|NCT03623698||Before treatment|Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)
89691868|NCT03623698||After treatment|Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)
89691869|NCT03017183|Other|EBUS-TBNA - Endobrochial Forceps Biopsy|In this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy
89691870|NCT03017183|Other|Forceps - EBUS-TBNA|In this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA
89691871|NCT03019835|Active Comparator|GROUP 1|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 1 response of 4 in TOF mode (Train Of Four)
89691872|NCT03019835|Active Comparator|GROUP 2|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 2 response of 4 in TOF mode (Train Of Four)
89691873|NCT03019835|Active Comparator|GROUP 3|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 3 response of 4 in TOF mode (Train Of Four)
89691874|NCT03019835|Active Comparator|GROUP 4|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 4 response of 4 in TOF mode (Train Of Four)
89691875|NCT03019835|Active Comparator|CONTROL|A control group : not receiving an antagonist (spontaneous recovery)
89691876|NCT03628456|Experimental|AffloVest Monarch Arm|Devices placed on highest intensity / highest frequency
89691877|NCT00955877|Experimental|DepoDur80|DepoDur will be administered at 80μg/kg (not to exceed 5 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
89691878|NCT00955877|Experimental|DepoDur120|DepoDur will be administered at 120μg/kg (not to exceed 10 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
89691879|NCT00955877|Placebo Comparator|Control|Preservative-free normal saline (2.5ml) will be placed in the L1 laminectomy defect and also dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter prior to wound closure.
89691880|NCT03951610|Experimental|Test lens|Subjects wearing the test lens for one week, either randomized as the first or second pair.
89691881|NCT03951610|Active Comparator|Control lens|Subjects wearing the control lens for one week, either randomized as the first or second pair.
89691882|NCT04332328||Ulcerative patients|
89691883|NCT04332328||Non ulcerative patients|
89075214|NCT00996892|Experimental|Dose Expansion Stage 2B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.
89075215|NCT04311645|Other|1st group|Oral activated charcoal in a dose of 30 gm/day
89075216|NCT04311645|Other|2nd group|Dry seeds in a dose of 1 gm/ day
89075217|NCT04311645|No Intervention|3rd group|control group
89075218|NCT01257581|Experimental|Creatine 30gm|"Creatine will be taken as a powder mixed into food or liquid twice a day. Volunteers in this arm will take a total of 30gm of creatine per day for 38 weeks. Volunteers will also take placebo capsules twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Creatine is a nutritional supplement and is not approved by the U.S. Food and Drug Administration (FDA) for treating ALS."
89075219|NCT01257581|Experimental|Tamoxifen 40mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 40mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
89075220|NCT01257581|Experimental|Tamoxifen 80mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 80mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
89075221|NCT01257503|Experimental|Homeopathic cold remedy|5 ml of homeopathic cold remedy given by mouth up to 6 times per day as needed for cold symptoms
89075222|NCT01257503|Placebo Comparator|placebo|5 ml of placebo given by mouth up to 6 times per day as needed for cold symptoms
89075223|NCT02869750||Obese PCOS|PCOS patients with BMI more than 25 kg/m2
89075224|NCT02869750||Lean PCOS|PCOS patients with BMI less than 25 kg/m2
89075225|NCT02869750||PCOS with normal HOMA2-1R|PCOS without Insuline resistance
88812950|NCT04380194||victims|thirteen patients affected by lightning in collective fulguration
89075226|NCT02869750||PCOS with elevated HOMA2-IR|PCOS with Insuline resistance
89075227|NCT04205032|Experimental|CARDIOSPACE II|Test of the different devices integrated in cardiospace II.
89075228|NCT02870452|Experimental|Hypnosis|Hypnosis for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
89075229|NCT02870452|Experimental|Cognitive-Behavioral Therapy|Cognitive Behavioral Therapy for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
89075230|NCT02870452|No Intervention|Control Group|No psychological intervention - standard Haemophilia care
89075231|NCT00995566||Thelin Registry Patients|
89075232|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.|
89075233|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.|
89075234|NCT00995488|Experimental|ABI-007|ABI-007 combined with Carboplatin, and Gemcitabine
89075235|NCT04293172|Experimental|Ticagrelor|The double-blinded study drug dose will be weight dependent.
89075236|NCT04293172|Placebo Comparator|Placebo|The double-blinded study drug dose will be weight dependent
89075237|NCT01256879|Experimental|CimTest-A|200mg cimetidine (as 2 capsules)
89075238|NCT01256879|Experimental|CimTest-B|200mg cimetidine (as 2 capsules)
89075239|NCT01256879|Active Comparator|Sorbitol-free cimetidine solution|200mg cimetidine (as oral liquid)
89075240|NCT01256879|Experimental|Commercial cimetidine solution|200mg cimetidine (as oral liquid)
89075241|NCT04293250|Experimental|Physical activity group|"Investigators employ the recommendations of the American College of Sport Medicine and the World Health Organization for adults to divide our enrolled patients having moderate-intensity as 30-60 min∙d-1 (≥150 min∙wk-1 ) or vigorous-intensity as 20-60 min∙d-1 (≥75 min∙wk-1) for 6-8 weeks preoperatively.~The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.~The operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
89230030|NCT00386152|Active Comparator|darbepoetin alfa (500 mcg)|darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks
89230031|NCT00787475|Experimental|1|CHW intervention
89075242|NCT04293250|Experimental|non-physical activity group|"No any moderate-intensity or vigorous-intensity physical activity for our enrolled patients preoperatively.~The severity of postoperative pain are measured prospectively at 1, 4, 7, 10 and 24 hours after the surgical operations.~Various types of operations are performed under inhalation general anesthesia with endotracheal intubation or through laryngeal mask."
89075243|NCT04292938|Active Comparator|Ketogenic diet|patients will follow a low carbohydrate high lipid personalized diet causing blood BOHB level to be between 1.5-4 mmol/l for six months
89075244|NCT04292938|No Intervention|control group|Patients will be asked to maintain their usual dietary regimen
89075245|NCT04293718||Acute erosive gingivitis|Patients presenting acute erosive gingivitis, isolated or predominant compared to other oral lesions, which required at least one papillary gingival biopsy for diagnostic purposes. Patients were included in the study regardless of age and general health.
89075246|NCT02869672|Experimental|age of 18-50 years old, experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
89075247|NCT02869672|Active Comparator|age of 18-50 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
89075248|NCT02869672|Experimental|age of 7-17 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
89075249|NCT02869672|Active Comparator|age of 7-17 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
89075250|NCT02869672|Experimental|age of 2-6 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
89075251|NCT02869672|Active Comparator|age of 2-6 years old,control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
89075252|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg)|
89075253|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg)|
89075254|NCT01125189|Placebo Comparator|Placebo plus peg-interferon alfa-2a and ribavirin|
89075255|NCT01256567|Experimental|ramucirumab and docetaxel combination|
88812951|NCT04380194||healthy witnesses|fourteen healthy witnesses who have never been in contact with lightning, matched on age and sex
89075256|NCT00996736|Active Comparator|Topical Natamycin|
89075257|NCT00996736|Experimental|Topical Voriconazole|
89075258|NCT00996658|Experimental|Linagliptin|Linagliptin tablets once daily
89075259|NCT00996658|Placebo Comparator|Placebo|Placebo tablets once daily
89075260|NCT01124643|Experimental|Replagal 0.2 mg/kg EOW|Intravenous, 0.2mg/kg EOW
89075261|NCT05108025|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
89075262|NCT05108025|Experimental|Study Treatment 2|Placebo powder mixed with Hydrogen Peroxide
89075263|NCT01256411|Experimental|LCZ696|
89075264|NCT00996580|Experimental|DR-103|"Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by;~21 days combination therapy of 25 mcg EE/150 mcg LNG followed by;~21 days combination therapy of 30 mcg EE/150 mcg LNG followed by;~7 days of 10 mcg EE."
89075265|NCT01124175|Experimental|Generic Test Product|Losartan 100 mg Tablets
89075266|NCT01124175|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
89075267|NCT04259554|Experimental|OFC rTMS|repetitive transcranial magnetic stimulation
89075268|NCT00625521|Experimental|1|Drug: ASF 1096 0.5 % cream applied twice daily
89075269|NCT00625521|Placebo Comparator|2|Cream vehicle for ASF 1096 cream applied twice daily
89075270|NCT01256177|Experimental|1|
89075271|NCT01256177|Placebo Comparator|2|
89075272|NCT02882451|Experimental|pinaverium bromide|take 50 mg pinaverium bromide three times a day 1 days before and then 100 mg 1 hour before the examination orally
89075273|NCT02882451|Placebo Comparator|Vitamin C|take 50 mg Vitamin C three times a day 1 days before and then 100 mg 1 hour before the examination orally
89075274|NCT00999544|Experimental|Placebo aprepitant/0 mg oxycodone IN PO|Placebo aprepitant/Placebo oxycodone IN/PO
89075275|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 15 IN 0 PO|Placebo aprepitant/ oxycodone 15 IN 0 PO
89075276|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 30 IN 0 PO|Placebo aprepitant/ oxycodone 30 IN 0 PO
88812952|NCT00899600|Placebo Comparator|Normal saline|
88812953|NCT00899600|Experimental|Ketamine|
89075277|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 20 PO|Placebo aprepitant/ oxycodone 0 IN 20 PO
89075278|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 40 PO|Placebo aprepitant/ oxycodone 0 IN 40 PO
89075279|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 0 PO|Aprepitant 40 mg/ oxycodone 0 IN 0 PO
89075280|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 20 PO|Aprepitant 40 mg/ oxycodone 0 IN 20 PO
89075281|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 40 PO|Aprepitant 40 mg/ oxycodone 0 IN 40 PO
89075282|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 15 IN 0 PO|Aprepitant 40 mg/ oxycodone 15 IN 0 PO
89075283|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 30 IN 0 PO|Aprepitant 40 mg/ oxycodone 30 IN 0 PO
89075284|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 0 PO|Aprepitant 200 mg/ oxycodone 0 IN 0 PO
89075285|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 20 PO|Aprepitant 200 mg/ oxycodone 0 IN 20 PO
89075286|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 40 PO|Aprepitant 200 mg/ oxycodone 0 IN 40 PO
89075287|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 15 IN 0 PO|Aprepitant 200 mg/ oxycodone 15 IN 0 PO
89075288|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 30 IN 0 PO|Aprepitant 200 mg/ oxycodone 30 IN 0 PO
89075289|NCT02869984|Experimental|Treatment|ramosetron treatment for 4 weeks from 1mo after anterior resection for rectal cancer
89075290|NCT02869984|No Intervention|Control|No treatment
89075291|NCT01124097|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
89075292|NCT01124097|Experimental|Eslicarbazepine acetate 1200 mg QD|
89075293|NCT01124097|Experimental|Eslicarbazepine acetate 1600 mg QD|
89075294|NCT01124097|Placebo Comparator|Placebo|
89075295|NCT02882529|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89075296|NCT02882529|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89075297|NCT02882529|Experimental|Visible light exposure Yellow 30 lux|The participants will be exposed to yellow LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89075298|NCT02882529|Experimental|Visible light exposure Yellow 120 lux|The participants will be exposed to yellow LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89075299|NCT02882529|Experimental|Visible light exposure Violet 30 lux|The participants will be exposed to violet LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89075300|NCT02882529|Experimental|Visible light exposure Violet 120 lux|The participants will be exposed to violet LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89075301|NCT01123941|Experimental|NVGH Vi-CRM197 conjugate vaccine|
89075302|NCT01123941|Active Comparator|Vi-polysaccharide vaccine|
89075303|NCT01123395|Experimental|Colcrys® (colchicine USP) 0.6 mg intact tablet|One Colcrys® (colchicine USP) 0.6 mg intact tablet taken by mouth
89075304|NCT01123395|Experimental|Colcrys® 0.6 mg tab in apple juice|One Colcrys® 0.6 mg tablet crushed and dissolved in apple juice
89075305|NCT01255787|Experimental|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 10 weeks.
89230032|NCT00787475|No Intervention|2|Enhanced usual care (brochure mailings)
89075306|NCT01255787|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
89075307|NCT01255787|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
89075308|NCT01255787|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, followed by vortioxetine 20 mg, tablets, orally, once daily for 7 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily, for 2 weeks.
89075309|NCT01123161|Active Comparator|Group1: IV t-PA and normothermia|IV tpa and normothermia
89075310|NCT01123161|Active Comparator|Group 2 : IV t-PA and hypothermia and anti-shivering treatment|IV tpa and hypothermia and anti-shivering treatment
89075311|NCT01255631|Sham Comparator|Sham PEMF device|
89075312|NCT01255631|Active Comparator|PEMF Device|
89075313|NCT04540835|Experimental|Teethmate|Half of the cavities will be applied Teethmate Desensitizer following manufacturer instructions before restoration
89075314|NCT04540835|No Intervention|Negative Control|Half of the cavities will be restored without application of Teethmate Desensitizer
89075315|NCT00999466|Experimental|1|AZD8848 (30 μg PILOT part and 60 μg MAIN part)
89075316|NCT00999466|Placebo Comparator|2|Placebo
89075317|NCT01255163|Experimental|Exendin-4|Exenatide 5 mcg or 10 mcg SC twice daily
89075318|NCT01255163|Placebo Comparator|Placebo|Placebo SC twice daily
89075319|NCT01123083|Experimental|otelixizumab|otelixizumab
89075320|NCT01123083|Placebo Comparator|placebo|placebo
89075321|NCT02870062|Experimental|Chlorhexidine|Intervention: daily baths with chlorhexidine wipes, oral spray and shampoo. This arm will receive daily bathing with chlorhexidine wipes at 2% (CLORHEXI-WIPES ONE-STEP, G70 Antisepsis, León, México) plus an oral spray application of chlorhexidine chlorhydrate at 0.12%. For scalp washing, a chlorhexidine shampoo at 0.12% concentration will be applied.
89075322|NCT02870062|Placebo Comparator|Placebo|Intervention: daily baths with placebo wipes, oral spray and standard shampoo. This arm will receive wipes with the same components as arm #1 plus an oral spray application with the same components except chlorhexidine. For scalp, a standard shampoo will be used. These products will have the same labels and smell as the products in arm #1.
89075323|NCT02869516||Patient with new diagnosis of Acute Leukemia|
89075324|NCT02870140|Experimental|SUPRAFLEX|Percutaneous Coronary Intervention with the SUPRAFLEX Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
89075325|NCT02870140|Active Comparator|XIENCE|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
89230033|NCT00787553|Active Comparator|cefazolin|
89075326|NCT01254305|Experimental|1|40 -120 mg/day Levomilnacipran ER capsules, oral administration
89075327|NCT01254305|Active Comparator|2|Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) - Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing
89075328|NCT01254305|Placebo Comparator|3|Matching placebo capsules, oral administration
89075329|NCT02869360||Multiple Sclerosis (MS) patients|4 Secondary Progressive MS patients on no disease modifying therapy 4 Primary Progressive MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on Glatiramer Acetate 40 mg three times a week
89075330|NCT02869360||Healthy Controls|4 Healthy volunteers aged between 18-60 years of age
89075331|NCT01122927|Experimental|Phase 1 and Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
89075332|NCT02869906||FFR and iFR|The investigators compare FFR and iFR values in the acute phase of STEMI and in the subacute phase, 5-7 days after STEMI.
89075333|NCT02869828|Other|monitoring by arterial catheter and Spot-on|
89075334|NCT02869828|Other|monitoring by oesophagus tube and Spot-on|
89075335|NCT01254227|Experimental|Deferasirox|Deferoxamine combination followed by Deferasirox monotherapy
89075336|NCT04311333|Experimental|All patients|"All patients undergo endostomal three-dimensional ultrasonography, computerized tomography, clinical examination and laparotomy/laparoscopy.~At all the respective examinations, the presence of a parastomal hernia as well as hernia location and size is evaluated."
89075337|NCT00995410|Experimental|PA32540 tablet|325 mg enteric coated (EC) ASA and 40 mg omeprazole to be taken by mouth once daily
89075338|NCT04311255|Active Comparator|intercostal group|group of patient receiving inrercostal nerve block as analgesia
89075339|NCT04311255|Active Comparator|pecs group|group of patient receiving pectoralis nerve block as analgesia
89075340|NCT02691299|Active Comparator|Treatment Arm|All subjects will receive study treatment in 4-week cycles: Fruquintinib, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease progression.
89075341|NCT02691299|Placebo Comparator|Control Arm|All subjects will receive study treatment in 4-week cycles: Placebo, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease
89075342|NCT00995020|Experimental|SWETZ|The intervention administered in this arm is the straight wire excision of the transformation zone, a electrosurgical method to perform a cone biopsy using a 1 cm straight wire of 0.20 mm wire. The activated wire is used in much the same way as a cold knife or laser beam fashioning the surgical specimen to achieve two centimeters cm at cervical canal..
89075343|NCT00995020|Active Comparator|LLETZ cone|The intervention administered in this arm is the large loop excision of transformation zone as a cone biopsy, performed using a large loop electrode of 2 cm depth, applied to the cervix to achieving two centimeters at cervical canal .
89075344|NCT01122381|Experimental|Arm 1-ethosuximide|"ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
89075345|NCT01122381|Placebo Comparator|Arm 2-placebo comparator|"placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
89230034|NCT00787553|Active Comparator|tinidazole|
89230035|NCT00787553|Active Comparator|cefazolin plus tinidazole|
89075346|NCT00996034|Experimental|Healthy Smoker|There is only one arm to the study. All subjects will receive NicVax, [123I]5-I-A-85380,and Nicotine bitartrate.
89075347|NCT04311021||Diabetes type 1|
88812954|NCT04379882|Experimental|Digital sedation|30 minutes Silva module
89075348|NCT01253447|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 200 mg orally once a week for each 28 day treatment cycle
88812955|NCT03219554|Experimental|palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
89075349|NCT04230382||Adults|Adults (above 18 years) with completed National Health and Health System Survey 2019 (without diagnosis of diabetes)
89075350|NCT00994240|Active Comparator|ED&C times 3 cycles|
89075351|NCT00994240|Active Comparator|ED & C times 1 cycle|
89075352|NCT01253369|Experimental|Pazopanib|Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit.
89075353|NCT04292548||study group (passive smoking children)|
89075354|NCT04292548||control group|
89075355|NCT04292236|Placebo Comparator|Placebo|Administered at time 0 min and 300 min. Cellulose was used as the placebo.
89075356|NCT04292236|Active Comparator|Dietary Supplement|Administered at 0 min and 300 min. Combination of lauric acid, perilla oil and diindolylmethane was used as the dietary supplement.
89075357|NCT01121913|Experimental|Trazodone Contramid® OAD (test product 1)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
89075358|NCT01121913|Experimental|Trazodone Contramid® OAD(test product 2)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
89075359|NCT01121913|Active Comparator|Triticco®|
88812956|NCT03213236|Experimental|OSA Homemonitoring|Homemonitoring diagnostic system
89075360|NCT01121913|Active Comparator|Desyrel®|
89075361|NCT00994162|Experimental|Negative Pressure Wound Therapy|Application of NPWT therapy to the wound
89075362|NCT02882139||Electrical storm|Documentation of 3 or more episodes of sustained ventricular arrhythmia within 24h or documentation of sustained ventricular tachycardia lasted at least 12h
89075363|NCT02869048||ALS patients|Patients diagnosed with ALS will be included in this group. Blood and spinal fluid samples will be stored in biobank and later analyzed. A subset of this group (20 ALS patients) will give blood and spinal fluid every 6 months during progression of the disease. A subset of 10 will donate a muscle biopsy.
89075364|NCT02869048||Control group with patients with other neurological disease|Patients referred to hospital with symptoms of acute or chronic headache.
89075365|NCT02869048||Neurologically healthy control group|Patients having orthopaedic surgery performed in spinal anaesthesia.
89075366|NCT04292158||Main Group|Hospitalized for at least 1 day clinic stay at the participating hospitals
89075367|NCT02868814|Experimental|330mg/day|330 mg QD taken orally,1 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
89075368|NCT02868814|Experimental|495mg/day|495 mg QD taken orally,2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
89075369|NCT02868814|Placebo Comparator|Placebo|1 or 2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
89075370|NCT04292314|Experimental|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
89230036|NCT00795353||1. Amevive Exposure|Canadian subjects with moderate to severe chronic plaque psoriasis
89230037|NCT00791297|Active Comparator|1|Contraceptive Vaginal Ring delivering a daily dose of 1500 μg of CDB-2914
89075371|NCT04292314|Experimental|Nigella sativa experimental group|"50 patients from each participating hospital that will receive Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months.~in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved."
89075372|NCT04292314|Experimental|Hydroxyurea experimental group|"50 patients from each participating hospital that will receive hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
89075373|NCT04292314|Experimental|Natural honey experimental group|"50 patients from each participating hospital that will receive natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved."
89075374|NCT04292314|Active Comparator|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of iron chelator agent of deferoxamine or deferasirox (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.~in addition to iron chelator agent, this group receive regular blood transfusion session."
89230038|NCT00791297|Active Comparator|2|Contraceptive Vaginal Ring delivering a daily dose of 2500 μg of CDB-2914
89075375|NCT00993928|Experimental|Arm A: Home-based sleep intervention with Device #1|Participants listen to a pre-recorded mp3 device #1 before retiring to sleep. Only patients in Arm A will have assigned bed and wake times based on their baseline diary.
89075376|NCT00993928|Active Comparator|Arm B: Home-based sleep intervention with Device #2|Participants will listen to a pre-recorded mp3 device #2 before retiring to sleep. At the end of the study, participants assigned to pre-recorded mp3 device #2 will be offered pre-recorded mp3 device #1 for their own use.
89075377|NCT01253291|Experimental|30mg/120 mg LY2127399|Participants in the 30 milligrams (mg) every 4 weeks arm of the lead-in study will receive 30 mg every 4 weeks until the safety of the 120 mg every 4 weeks dose is confirmed in the lead-in study.
89075378|NCT01253291|Experimental|120 mg LY2127399|Participants in the 60 mg every 4 weeks, 120 mg every 4 weeks and 120 mg every 2 weeks arms of the lead-in study will receive 120 mg every 4 weeks as these participants will enroll in this study after the safety of the 120 mg every 4 weeks dose in the lead-in study is confirmed.
89075379|NCT04292002|Experimental|Health Checks|Workplace health checks - in this intervention employees can select from a range of optional health checks/tests and receive tailored health advice and a health resource pack.
89075380|NCT01121757|Experimental|Azacitidine followed by Lenalidomide|"Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.~Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1."
89075381|NCT01121757|Experimental|Lenalidomide followed by Azacitidine|"Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.~Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a."
89075382|NCT04319471|Experimental|Sufficient Chemotherapy Combine With Maintenance Chemotherapy|Patients with oligometastatic Nasopharyngeal Carcinoma was given S-1 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving sufficient chemotherapy and consolidative local therapy
89075383|NCT02882217|Active Comparator|XC8 10mg|Cohort 1: 8 subjects will be randomized in a 3:1 ratio to be treated either with 10mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
89075384|NCT02882217|Active Comparator|XC8 50mg|Cohort 2: 8 subjects will be randomized in a 3:1 ratio to be treated either with 50mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
89075385|NCT02882217|Active Comparator|XC8 200mg|Cohort 3: 16 subjects will be randomized in a 3:1 ratio to be treated either with 200mg XC8 (12 subjects) or placebo (4 subjects, see placebo arm)
89075386|NCT02882217|Placebo Comparator|Placebo|Placebo comparator arm consists of 2 subjects in the cohorts 1 and 2 each and 4 subjects in the cohort 3.
89075387|NCT04275544||Patients with PCs|"HOCM Patients developing postoperative complications (PCs) following septal myectomy.~PCs include all-cause mortality, heart failure, low cardiac output syndrome, stroke, spinal cord injury, acute respiratory distress syndrome, reintubation, reoperation, permanent implantable cardioverter defibrillator, kidney injury, renal failure, liver injury, and liver failure."
89075388|NCT04275544||Patients without PCs|HOCM Patients do not develope postoperative complications following septal myectomy.
89075389|NCT01253135|Placebo Comparator|Control|White Petrolatum
89075390|NCT01253135|Other|Test article|Vehicle (fibrinogen)
89075391|NCT02882061|Experimental|CTDT positive|All subjects with a positive cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
89224406|NCT06266520|Experimental|Group 1 (MNK therapy to release the superficial fascia)|The patient, positioned supine and wearing shorts for full lower limb exposure, undergoes layered palpation by the practitioner at the procedure points, identifying tender nodules and swelling in superficial fascia and muscles, followed by disinfection with an iodophor cotton swab. The practitioner, donning sterile latex gloves, holds the micro-needle-knife between the thumb and index finger of the right hand, inserting it parallel to the body's longitudinal axis, while the left thumb presses and holds the cord-like nodules for parallel incisions, with a maximum insertion depth of 5mm, performing lifting and cutting motions. Depending on the nodule size, 1-3 incisions are made. Post-procedure, any bruising or tissue fluid is expelled by massaging from distal to proximal around the incision. The area is then compressed with dry sterile gauze until bleeding ceases. Treatments are administered every other day, totaling six sessions.
89224407|NCT06266520|Active Comparator|Group 2 (acupuncture)|Group 2 receives acupuncture treatment, employing needles produced by Suzhou Medical Supplies Factory Co., Ltd., with specifications of 0.30mm*40mm and conforming to standard GB2024-1994. Patients, positioned prone or laterally with exposed lower limbs below the knee, are disinfected with an iodophor cotton swab. Acupuncture points selected include GB34, GB39, BL60, BL40, ST41, KI9, and KI6. The practitioner applies pressure to the points with the left hand and swiftly inserts the needle with the right, using a 0.30mm*40mm disposable sterile acupuncture needle, penetrating the skin about 0.5-0.8 inches. After achieving deqi, the needle is twisted and thrust several times, left in place for 30 minutes. Upon removal, the needle site is compressed with a dry cotton swab until bleeding stops. Treatments occur every other day, totaling six sessions
89224408|NCT06266507|Experimental|Research Group|Mothers who will receive a 10-week occupational therapy-based parent coaching intervention will be included in this group.
89224409|NCT06266507|Other|Control Group|The control group will not receive an active intervention, but will be provided with an informative brochure on dealing with nutritional problems.
89224410|NCT06266494|Active Comparator|Aim 1: Aloe Vera|Aloe Vera will be applied topically to participant's frostbitten tissues twice daily.
89224411|NCT06266494|Experimental|Aim 1: Long-Acting Silver Dressings|Long-Acting Silver dressings will be applied topically to participant's frostbitten tissues every 4 days.
89224412|NCT06266494|Experimental|Aim 2: Dalbavancin|Participants will receive one 1500mg dose of Dalbavancin intravenously.
89224413|NCT06266481|Active Comparator|dexamethasone group|An endotracheal tube was soaked in 8mg of dexamethasone for group I intubation
89224414|NCT06266481|Active Comparator|lidocaine group|10% lidocaine was sprayed over the tube
89075392|NCT02882061|Active Comparator|CTDT negative|All subjects with a negative cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
89075393|NCT02881905|Active Comparator|ball attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the conventional ball attachment
89075394|NCT02881905|Experimental|CM LOC attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the cm loc attachment
89075395|NCT00993616|Experimental|Treatment|Patients receive belinostat IV over 30 minutes on days 1-5 and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are clinically responding or who, in the opinion of their physician, would continue to benefit from treatment may continue treatment beyond 6 courses.
89075396|NCT01120899|Experimental|Minocycline|
89075397|NCT01120275|Experimental|Treatment (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89075398|NCT00991510|Experimental|Reference/Test/Test|"The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
89075399|NCT00991510|Experimental|Test/Reference/Reference|"The test product was Myfenax® and the reference product was CellCept®. In period I, participants received Myfenax on Days 1-14. In period II, participants crossed-over to receive CellCept on Days 15-28. In period III, participants received CellCept until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
89075400|NCT01119963|Active Comparator|17-alpha hydroxyprogesterone caproate, Makena®|250 mg of 17P, Makena® intramuscular (IM) weekly.
89075401|NCT01119963|Placebo Comparator|Placebo|Castor Oil (Placebo)intramuscular (IM) weekly
89075402|NCT02868736||Suspected Periprosthetic Joint Infection|Individuals who are suspected of having Periprosthetic Joint Infection (PJI)
89075403|NCT01252667|Experimental|Part 1 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
89224415|NCT06266468|Experimental|Intervention|12 weeks of mobile intervention (website and text messaging)
89224416|NCT06266468|Placebo Comparator|Waitlist|No intervention for 12 weeks, or until completion of 2nd study visit
89075404|NCT01252667|Experimental|Part 1 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
89075405|NCT01252667|Experimental|Part 1 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
89224417|NCT06266416|Experimental|Experimental (IMAGE) Group|The IMAGE group will receive an 8-10-hour HIV/STI group-based (6-8 dyads) prevention program delivered to Black male caregivers and girls over 2-days.
89224418|NCT06266416|Active Comparator|Control (FUEL) Group|The FUEL group will receive a caregiver-adolescent general health promotion program identical in length and intensity to IMAGE.
89224419|NCT06266403|Experimental|People with amyotrophic lateral sclerosis, age-matched speakers|People with ALS and age-matched speakers will participate in structured communicative interaction.
89075406|NCT01252667|Experimental|Part 2 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
89075407|NCT01252667|Experimental|Part 2 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
89075408|NCT01252667|Experimental|Part 2 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
89075409|NCT04292626|Experimental|Lymphoma|At least five (5) evaluable subjects with Hodgkin Lymphoma or Non Hodgkin Lymphoma. The tested injected dose of 500 MBq.
89075410|NCT02881827|Active Comparator|Infrared Laser|Using a laser in the infrared wave spectrum (780 nm)
89075411|NCT02881827|Active Comparator|Red Laser|Using laser red wave spectrum (662 nm)
89075412|NCT02881827|Placebo Comparator|Placebo|Simulation of treatment with the device switched off
89075413|NCT02881827|Active Comparator|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two ( statistically ) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug , which serves to prevent bias and isolating effects of such drugs."
89075414|NCT02868580|Experimental|Single arm open label|All subjects will receive open label Triumeq following a lead-in phase. Triumeq is abacavir 600mg, lamivudine 300mg, dolutegravir 50mg
89075415|NCT02868658|Experimental|Health-care workers|Health-care workers recruited in the study will have blood sampling and naso-pharyngeal bottle-brush sampling
89075416|NCT02881749|Experimental|TSEBT & mechlorethamine gel 0.016%|All subjects enrolled in the study will receive two weeks of low dose total skin electron beam therapy (TSEBT) (12 Gy total divided into 6 fractions delivered over two weeks) followed by a weekly maintenance mechlorethamine gel 0.016% regimen for one year. The initiation of the mechlorethamine gel regimen is dependent on their disease stage downgrading to IA and IB following low dose TSEBT.
89075417|NCT00629044|Active Comparator|G|
89075418|NCT00629044|Active Comparator|AMD|
89075419|NCT00629044|Active Comparator|Healthy subjects|
89075420|NCT01119105|Experimental|BC-3781 dose 100mg|
89075421|NCT01119105|Experimental|BC-3781 dose 150mg|
89075422|NCT01119105|Active Comparator|Vancomycin|
89075423|NCT01118949|Experimental|Lacosamide|
89075424|NCT04310865|Experimental|Yinhu Qingwen Granula Group|Based on the standard medical treatment, the patients will be given Yinhu Qingwen Granula for 10 days.
89075425|NCT04310865|Placebo Comparator|Yinhu Qingwen Granula Low-dose Group|Based on the standard medical treatment, the patients will be given 10% dose of Yinhu Qingwen Granula for 10 days.
89075426|NCT01252355|Experimental|Teriflunomide 7 mg + IFN-beta|Teriflunomide 7 milligram (mg) once a day concomitantly with IFN-beta therapy.
89075427|NCT01252355|Experimental|Teriflunomide 14 mg + IFN-beta|Teriflunomide 14 mg once a day concomitantly with IFN-beta therapy.
89075428|NCT01252355|Placebo Comparator|Placebo + IFN-beta|Placebo (for teriflunomide) once a day concomitantly with IFN-beta therapy.
89075429|NCT01118325|Experimental|AZD6140 45 mg bd|
89075430|NCT01118325|Experimental|AZD6140 90 mg bd|
89075431|NCT01118325|Active Comparator|Clopidogrel 75 mg od|
89075432|NCT01117857|Experimental|Duloxetine|After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.
89075433|NCT02888405|Experimental|High-carbohydrate diet|Single day of 9 g/kg body weight consumption of carbohydrate. Isocaloric to very low-carbohydrate condition.
89075434|NCT02888405|Experimental|Very low-carbohydrate diet|Single day of 1 - 1.5 g/kg body weight consumption of carbohydrate. Isocaloric to high-carbohydrate condition.
89075435|NCT01251887|Experimental|Diet A: Low omega-3 (n-3) + High linoleic acid (LA)|Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks
89075436|NCT01251887|Experimental|Diet B: Low omega-3 (n-3) + Low linoleic acid (LA)|Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks
89075437|NCT01251887|Experimental|Diet C: High omega-3 (n-3) + Low linoleic acid (LA)|Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks
89075438|NCT00991276|Experimental|pregabalin|
89075439|NCT00991276|Placebo Comparator|placebo|
89075440|NCT00991276|Active Comparator|pramipexole|
89075441|NCT02869282||Prospective cohort|Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.
89075442|NCT02869204|Experimental|Leucocyte - Platelet rich Plasma and Dietary Supplements|"An application of an autologous platelet concentrate (20 ml). This is injected once, locally in the muscle after closure of the inner fascia and before closure of the outer fascia.~A daily dietary supplement of Vitamin C, Zinc and L-Arginine. Provided from POD2-3 until POD30"
89075443|NCT02869204|No Intervention|Treatment as usual|Patients are treated as usual.
89075444|NCT04291846|Experimental|A|
89075445|NCT04291846|Experimental|B|
89075446|NCT04291924||Ablebodied individuals|
89075447|NCT04291924||Spinal Cord Injured Individuals|
89075448|NCT02869126|Experimental|Patients|Patients with abnormalities of myocardial perfusion detected with stress tomoscintigraphy, undergo double isotope myocardial tomoscintigraphy using Thallium-201 and 99mTc-sestamibi and traditional myocardial tomoscintigraphy using 99mTc-sestamibi with a semiconductor camera
89075449|NCT00990652|Experimental|Bortezomib + Temozolomide|Patients receive an injection of bortezomib 1.7mg/m^2 on days 1, 4 and 8. Patients then undergo their standard of care surgery on day 8 or 9 to remove the tumor. Once recovered from surgery, patients receive combination treatment with temozolomide and bortezomib in periods called cycles (1 cycle = 28 days). Temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle, and bortezomib injections are given on days 7 and 21 of each cycle.
89075450|NCT02867878|Experimental|Adenosine|Patients in this arm will receive systemic infusion of adenosine at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
89075451|NCT02867878|Placebo Comparator|Saline solution|Patients in this arm will receive systemic infusion of saline solution at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
89075452|NCT00990340|Active Comparator|Tev-Tropin® needle-free|needle-free injection method (T-jet®)for 14 days before cross-over to other arm
89075453|NCT00990340|Active Comparator|Tev-Tropin® by Needle-syringe|needle-syringe injection method for 14 days before cross-over to other arm
89075454|NCT01207440|Experimental|Cohort A: CP-CML R-I|CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
89075455|NCT01207440|Experimental|Cohort B: CP-CML with T315I Mutation|CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
89075456|NCT01207440|Experimental|Cohort C: Accelerated Phase (AP)-CML R-I|AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
89075457|NCT01207440|Experimental|Cohort D: AP-CML with T315I Mutation|AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
88820855|NCT05559931|Experimental|Part A: Single Dose Active|Subjects will receive a single IV dose of DMT, administered as a bolus loading dose followed by a 6-h infusion. The starting dose will be 1.5 mg bolus, followed by a 0.105 mg/min infusion. Subsequent doses will be based on the safety and tolerability data from previous groups.
89075458|NCT01207440|Experimental|Cohort E: Blast Phase (BP)-CML/Ph+ ALL R-I|BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
89075459|NCT01207440|Experimental|Cohort F: BP-CML or Ph+ ALL with T315I Mutation|BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
89075460|NCT01207440|Experimental|Unassigned to Cohorts A-F|Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not R-I to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
89075461|NCT00990184|Experimental|Colesevelam Hydrochloride|
89075462|NCT00986830|Experimental|Balloon Dilation|Balloon dilation of the maxillary sinuses using the FinESS Sinus Treatment device.
89075463|NCT00990106|Active Comparator|prazosin hydrochloride|"prazosin Pfizer Minipress~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
89224420|NCT06266390|Active Comparator|Positive Correlation Target|TMS treatment will be administered using a TMS target positively correlated with the sgACC.
89075464|NCT00990106|Placebo Comparator|placebo|"placebo~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
89075465|NCT02867566|Experimental|IBI301|IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
89075466|NCT02867566|Active Comparator|Rituximab|Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
89075467|NCT02868502||Trabeculectomy|Subjects with OAG s/p Trabeculectomy. IOP measurement in different positions.
89075468|NCT02868502||Ahmed Glaucoma Valve implantation|Subjects with OAG s/p Ahmed valve implantation. IOP measurement in different positions.
89075469|NCT02868502||Cyclophotocoagulation|Subjects with OAG s/p Cyclophotocoagulation. IOP measurement in different positions.
89075470|NCT02868502||Ocular hypotensive eye drops|"Subjects with OAG treated with ocular hypotensive eye drops and no ocular surgical hypotensive treatments.~IOP measurement in different positions."
89075471|NCT02868502||Ocular Hypertension|"Subjects with no evidence of glaucomatous damage, but with IOP measurements above 21 mmHg..~IOP measurement in different positions."
89075472|NCT02868502||Control|"Subjects with healthy eyes, apart for refraction errors, post cataract surgery, strabismus or amblyopia.~IOP measurement in different positions."
89075473|NCT02868424|Experimental|fRPE cells|Subretinal transplantation of fRPE cells in experimental eye
89075474|NCT02867722|Experimental|Daylight PDT|Patients will receive daylight-PDT treatment (aminolevulinic acid)
89075475|NCT04291222|Experimental|IBS implantation|Implantation of IBS in PDA in duct-dependent cyanotic CHD
89075476|NCT02867800|Experimental|Standard GVHD Prophylaxis + Abatacept|"Subjects will receive~premedication (Diphenhydramine, Acetaminophen, Methylprednisolone; and Meperidine as needed)~immunosuppression (Alemtuzumab, or Thymoglobulin)~conditioning regimen (Fludarabine, Thiotepa, and Melphalan)~GVHD prophylaxis: calcineurin inhibitor (Cyclosporine,Tacrolimus, Sirolimus or Mycophenolate Mofetil with permission of the sponsor) and Methotrexate plus Abatacept on days -1, +5, +14 and +28, and a marrow infusion on day 0."
89075477|NCT00983476|Experimental|Arm 1|in-person MOVE! SMI
89075478|NCT00983476|Experimental|Arm 2|web-based MOVE! SMI
89075479|NCT00983476|No Intervention|Arm 3|usual care + educational handouts regarding weight loss
89075480|NCT00629200|Experimental|SSG + Intron A|Sodium Stibogluconate (SSG) 400 mg/m^2 intravenous (IV) daily on days 1-5 + Interferon Alfa-2b (Intron A) 3x10^6 units subcutaneously three times weekly
89075481|NCT02867176|Other|Corneal collagen CXL epi-off|For the epithelium-off procedure, the corneal epithelium is removed with a 10-minute soak time with isotonic riboflavin 0.1% solution and 4 minutes of exposure with 30 mw/cm2 ultraviolet-A irradiation.
89075482|NCT02867176|Other|Corneal collagen CXL epi-on|For the epithelium-on procedure, riboflavin is applied for a total soak of 4 minutes; the cornea is then completely rinsed with additional riboflavin for a total of 6 minutes. The ultraviolet-A irradiation is performed for 2 minutes and 40 seconds at 45mw/cm2.
89075483|NCT02868034|Experimental|SMT Only|Patients receive 2 sessions on SMT during week 1, no additional treatment.
89075484|NCT02868034|Experimental|SMT extended|2 sessions of SMT in week 1 and 6 additional sessions of SMT during weeks 2-4.
89075485|NCT02868034|Experimental|SMT with Activation Exercises|2 sessions of SMT during week 1 and 6 additional sessions of lumbar multifidus activating exercises during weeks 2-4.
89075486|NCT02868034|Experimental|SMT with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of spinal mobilizing exercises during weeks 2-4.
89075487|NCT02868034|Experimental|SMT with Mobilizing and Activation Exercises|2 sessions of SMT during week 1; 6 sessions of lumbar multifidus activating exercises and spinal mobilizing exercises during weeks 2-4.
89075488|NCT02868034|Experimental|SMT extended with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and spinal mobilizing exercises during weeks 2-4.
89075489|NCT02868034|Experimental|SMT extended with Activation Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and lumbar multifidus activating exercises during weeks 2-4.
89075490|NCT02868034|Experimental|SMT extended with Activation and Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT, multifidus activating and spinal mobilizing exercises during weeks 2-4.
89075491|NCT02867254||Groups1|15 patients with type 2 diabetes mellitus with periodontal endodontic lesions
89075492|NCT02867254||Groups 2|15 non-diabetics with periodontal endodontic lesions
89075493|NCT00982228|Experimental|IDeg OD|
89075494|NCT00982228|Active Comparator|IGlar OD|
89075495|NCT02867956|Experimental|Apatinib + Etoposide|"Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.~Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles."
89075496|NCT04290832|Experimental|CO intervention|"South Africa: All health facility staff working in facilities assigned to the intervention arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers) plus the CO intervention.~Mexico: Doctors/anyone eligible to be an abortion provider working in facilities assigned to the intervention arm receive the CO intervention."
89075497|NCT04290832|No Intervention|Control|"South Africa: All health facility staff working in facilities assigned to the control arm receive standard Ipas support (including monitoring of abortion service provision and support to Ipas-trained abortion providers).~Mexico: No intervention"
89075498|NCT04291066|Experimental|Treatment|oral N-acetyl cysteine and oral multivitamin tablets
89075499|NCT04291066|No Intervention|Non-Treatment|Routine Care
89075500|NCT04290910|Experimental|Weight Loss Program|Single arm, all participants receive the weight loss program
89075501|NCT01260350|Experimental|Group 1: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive (TN) participants with genotype (GT) 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
89075502|NCT01260350|Experimental|Group 2: SOF+RBV 12 wk+PEG 4 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 4 weeks.
89075503|NCT01260350|Experimental|Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 8 weeks.
89075504|NCT01260350|Experimental|Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily+weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 12 weeks.
89075505|NCT01260350|Experimental|Group 5: SOF 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily for 12 weeks.
89075506|NCT01260350|Experimental|Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 8 weeks.
89075507|NCT01260350|Experimental|Group 7: SOF+RBV 12 wk: GT 1, TE|Treatment-experienced (TE) participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
89075508|NCT01260350|Experimental|Group 8: SOF+RBV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
89075509|NCT01260350|Experimental|Group 9: SOF+RBV 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
89075510|NCT01260350|Experimental|Group 10: SOF+RBV 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 8 weeks.
89075511|NCT01260350|Experimental|Group 11: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus split-dose RBV (800 mg in a divided daily dose) for 12 weeks.
89075512|NCT01260350|Experimental|Group 12: SOF+RBV+LDV 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
89075513|NCT01260350|Experimental|Group 13: SOF+RBV+LDV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
89075514|NCT01260350|Experimental|Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
89075515|NCT01260350|Experimental|Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
89075516|NCT01260350|Experimental|Group 16: LDV/SOF FDC 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection and Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
89075517|NCT01260350|Experimental|Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection with Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
89075518|NCT01260350|Experimental|Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
89075519|NCT01260350|Experimental|Group 19: LDV/SOF FDC 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
89075520|NCT01260350|Experimental|Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, hemophiliac|Hemophiliac participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
89075521|NCT01260350|Experimental|Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 6 weeks.
89075522|NCT01260350|Experimental|Group 22: LDV/SOF FDC 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection were randomized to receive LDV 90 mg/SOF 400 mg FDC once daily for 6 weeks.
89075523|NCT04150120|Active Comparator|Reconstructive paediatric surgery (Area I)|The overall incidence of congenital malformations in the gastrointestinal and urinary tract needing surgical interventions is about 1:1000 (Swedish national malformation registers) with a morbidity during childhood about 20-60%. Advanced paediatric surgery for the diagnosis Hirschsprung's disease, anorectal malformations, bladder extrophy, congenital diaphragmal hernia, and esophageal atresia is from July 2018 only performed at two NCSM in Sweden. The NCSM at Skåne University Hospital (SUS) in Lund forms one context. The quality of postoperative care is of immense importance both for short and long-term outcome. Legal guardians describe their situation after leaving the hospital as extremely stressful as they have not only to take responsibility for their new-born child but also of surgical wounds, medications, treatments, and special nutritional needs.
89075524|NCT04150120|Active Comparator|Congenital heart disease (Area II)|In Sweden, about 8-10 in 1000 children per year are born with congenital heart disease (CHD). CHD is a birth defect that leads to frequent hospitalisation, long hospital stays, and extreme anxiety for parents (18). In Sweden, paediatric heart surgery is concentrated to two NCSM of which one is situated at SUS, Lund where 250-300 children have cardiac surgery every year. Children with complicated CHD require contact and follow-up visits for a long time after the heart surgery and many families have to travel long for surgery (for example from Iceland), postoperative care and follow-up visits. Telemedicine after reconstructive cardiac surgery in children is shown to be feasible, although challenging and reduced unscheduled visits.
88820856|NCT05559931|Placebo Comparator|Part A: Single Dose Placebo|Subjects will receive a single IV dose of placebo, administered as a bolus loading dose followed by a 6-h infusion.
88820857|NCT05559931|Experimental|Part B: Multiple Dose Active|Subjects will receive a total of 6 doses of DMT, given as a bolus loading dose, followed by a IV infusion over 6 h, on Days 1, 3, 5, 8, 10, and 12 of a 2-week treatment period. Dose to be determined from single dose phase.
89075525|NCT04150120|Active Comparator|Preterm born (Area III)|Most prematurely born children grow up to be healthy, but as a group, they are at a greater risk of developing cognitive, emotional and behavioural problems. Every year 7% of all children are born prematurely (gestational age of less than 37 weeks) and the numbers of preterm births are rising in Sweden as well as internationally. Preterm births often involve long hospitalisations for children and parents, and discharge from the hospital often means a difficult transition for parents in both short and long-term perspectives. Traditionally, communication with parents following discharge has been through home visits or telephone calls. By communicating through digital technology, it may be possible to improve the support to parents and thereby make the transition from hospital to home less stressful.
89075526|NCT04150120|Active Comparator|Paediatric oncology (Area IV)|For children with cancer, treatment and follow-up at home is common. At the same time, families wish to minimize the negative impact on family members' social and everyday life. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care and regular follow-up in their home with an increased need for education as well as clinical management support. At present, there are no, or limited, professional outreach support to support them and their families. Communication with parents following discharge has been through e-mail and/ or telephone calls. By communicating through digital technology, it may be possible to improve the support to children and parents.
89075527|NCT04150120|Active Comparator|Intravenous infusion therapy at home (Area V)|For children with LTI administration of intravenous infusion therapy at home is an increasingly important area. Home medication management is a high-risk area and medication errors are common, particularly among parents of children with cancer. Thus, parents are responsible for complex care in their home with an increased need for educational as well as clinical management support during home infusion therapy. At present, children and adolescents with LTI at the University Hospital of Copenhagen receive home infusion therapy by a portable pump with no assistance from an outreaching team to support them and their families.
89075528|NCT04150120|Active Comparator|Children with cerebral palsy (VI)|Cerebral palsy (CP) is the most common physical disability in childhood. Approximately 2-2.5/1000 children have CP with affected muscle tone, movement and motor skills, often accompanied by pain, epilepsy and intellectual, communicational and behavioural impairment. Early detection is challenging but important for minimizing the consequences from neurodevelopmental impairment by an early and right treatment. General Movement Assessment (GMA), an observational method for classification of spontaneous movements in young infants, is currently the most accurate method for early identification of CP. Video recordings are taken with a standardised video set-up in the hospitals regular follow-up clinics when the child is 10 to 20 weeks post-term age. Performing video recordings at home by the parents at a time, which suits the family and the child, would optimize the chances for a successful recording.
89075529|NCT04291378|Active Comparator|Photon radiation therapy|The patient is treated with standard radiation therapy based on photons
89075530|NCT04291378|Experimental|Proton radiation therapy|The patient is treated with experimental radiation therapy based on protons
89075531|NCT01260194|Experimental|1|
89075532|NCT04320758|Experimental|single crown in dental aesthetic zone|teeth in dental aesthetic zone
89075533|NCT04320758|Experimental|teeth need single crown in dental aesthetic zone|teeth in dental aesthetic zone
89075534|NCT04207112|Experimental|Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Drug: Bedaquiline Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
89075535|NCT04207112|Experimental|Regimen 2: Bedaquiline, Pretomanid, Linezolid, Clofazimine|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
89224421|NCT06266390|Active Comparator|Anticorrelation Target|TMS treatment will be administered using a TMS target anticorrelated with the sgACC.
88820858|NCT05559931|Placebo Comparator|Part B: Multiple Dose Placebo|Subjects will receive a total of 6 doses of placebo, given as a bolus loading dose, followed by IV infusion over 6 h, on Days 1, 3, 5, 8, 10, and 12 of a 2-week treatment period.
89075536|NCT04207112|Experimental|Regimen 3: Bedaquiline, Pretomanid, Linezolid|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
89075537|NCT04207112|Active Comparator|Control regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB
89075538|NCT01259726|Placebo Comparator|Placebo|
89075539|NCT01259726|Experimental|VP20621 Low Dose and Placebo|
89075540|NCT01259726|Experimental|VP20621 High Dose and Placebo|
89075541|NCT01259726|Experimental|VP20621 High Dose|
89075542|NCT05527730|Active Comparator|Screening, intake and first fit (either PRO-FIT or SELF-FIT fitting )|This multi-center, prospective, randomized cross-over clinical trial compares two methods of fitting individuals with hearing loss with a therapeutic amplification device (i.e., hearing aids). Subjects will wear the Whisper Hearing System for the PRO-FIT and SELF-FIT for two weeks each, totalling to approximately 1 month of wear throughout the trial. At the first visit, all individuals will go through intake procedures and a basic audiologic evaluation. After this is completed, individuals are randomized into one of two arms of the study Individuals in the first visit of the study will receive the conventional PRO-FIT method for the first two weeks, then will switch to the experimental SELF-FIT method for the last half of the study.
89075543|NCT05527730|Sham Comparator|Second fit (either PRO-FIT or SELF-FIT fitting )|Conversely, individuals in the second visit of the study will receive the experimental SELF-FIT method for the first two weeks, then will switch to the conventional PRO-FIT method for the last two weeks. The two fitting methods (PRO-FIT and SELF-FIT) will be compared to evaluate the efficiency and reliability of the Whisper hearing system self-fitting algorithm.
89075544|NCT01259492|Experimental|Ritalin LA 40 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2, continued in same dose till week 9. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
89075545|NCT01259492|Experimental|Ritalin LA 60 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14.In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
89075546|NCT01259492|Experimental|Ritalin LA 80 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3 and to 80 mg at week 4. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
89075547|NCT01259492|Placebo Comparator|Placebo|Period 1- Placebo controlled Period 2 - The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose (40, 60 or 80 mg). In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
89075548|NCT04320446|Experimental|Caffeine|A dose of 3 mg/kg of caffeine (i.e. a vegetable extraction from green coffee beans, Harrison Sport Nutrition®, Spain) was ingested before the beginning of each test.
89075549|NCT04320446|Placebo Comparator|Placebo|A dose of 3 mg/kg of placebo (i.e. 100% purity microcrystalline cellulose, Acofarma, Spain) was ingested before the beginning of each test.
89075550|NCT00624026|Experimental|1|
89075551|NCT05512910|Experimental|Treatment group|Patients randomized to the treatment group will receive oral minocycline in addition to endovascular treatment and other standard medical. The first dose of minocycline will be administered 200 mg orally prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting. If the patient is considered to be at any risk for aspiration or is unable to swallow based on swallowing evaluation, study drug will be oral via feeding tube.
89075552|NCT05512910|No Intervention|Control group|Patients randomized to the control group will receive endovascular treatment and other standard treatment, without minocycline treatment.
89075553|NCT02888990|Experimental|Treatment Arm|standard treatment + dasatinib
89075554|NCT05476016|Experimental|Open-label, single arm with identical intervention for all participants|Glycated keratin assessed by near-infrared and glycated haemoglobin (HbA1c) assessed based on finger prick blood drop sample
89075555|NCT05463302|Active Comparator|Active EMF blanket|participants will receive the real EMF blocker blanket
89075556|NCT05463302|Placebo Comparator|Sham EMF blanket|participants will receive the sham EMF blocker blanket
89075557|NCT00624104||1|Lean male
89075558|NCT00624104||2|Males with type 2 diabetes
89075559|NCT02889068||Intellectual disability|
89075560|NCT05252078|Experimental|Anlotinib|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally (D1-D14); TQB 2450 1200 mg, iv (D1).~If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg, until un-tolerable toxicity again."
89075561|NCT05118386|Experimental|RSM01|Participants will be randomized to receive different dose levels of RSM01. Participants will be randomized in a ratio of 6:1 where for every 6 participants receiving active drug (RSM01) 1 participant will receive Placebo.
89075562|NCT05118386|Placebo Comparator|Placebo|Participants will receive placebos matched to RSM01.
89075563|NCT05101928|Experimental|Intravitreal Dexamethasone Implant Group|Subjects randomized to the experimental group will receive a 0.7mg intravitreal dexamethasone (DEX) implant which will be injected in the vitreous cavity as one of the treatments of interest in this study.
89075564|NCT05101928|Active Comparator|Prednisone Taper Group|Subjects randomized to the comparator group will receive oral prednisone. The initial dose is expected to range between 40 to 60mg of oral prednisone per day, with gradual tapering to the lowest dose that controls inflammation and eventually transitioning to a maintenance dose. Maintenance dose will be gradually lowered as per standard of care if remission is achieved for 6 to 12 months.
89075565|NCT05069714|Experimental|MTX 1 week hold|Patients who will hold MTX for 1 week after an influenza vaccine.
89075566|NCT05069714|Active Comparator|MTX 2 week hold|Patients who will hold MTX for 2 weeks after an influenza vaccine.
89075567|NCT05048966|Experimental|Group Wellness Class 1|
89075568|NCT05048966|Active Comparator|Group Wellness Class 2|
89075569|NCT04207034|Experimental|flap surgery and diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
89224422|NCT06266377|Experimental|Intervention group|"Children afferent to the elementary school where Milano Ristorazione delivers meals and adolescents and young adults enrolled in the State Agricultural Technical Institute Giuseppe Garibaldi (Rome) and Institute I.P.S.E.O.A. Tor Carbone - A. Narducci."
89224423|NCT06266351||IOP measurement with CATS|
89075570|NCT04207034|Active Comparator|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
89075571|NCT02888912|Active Comparator|EQUIA|randomly applied
89075572|NCT02888912|Active Comparator|Gradia Direct Posterior|randomly applied
89075573|NCT04320524|Experimental|All subjects|
89075574|NCT04795700|Experimental|The intervention group|Patients in the intervention group receiving the 8 weeks MSC intervention sessions.
89075575|NCT04795700|No Intervention|The control group|No interventions except conventional care were performed for the control group.
89075576|NCT04685720|Experimental|Inhaled NO delivered using LungFit|Inhaled Nitric Oxide in doses up to 250 ppm
89224424|NCT06266351||IOP measurement with GAT|
89075577|NCT04678544|Experimental|Intervention Group|Before the chemotherapy, patients in intervention group will use cooling cap 30 minutes before chemotherapy. Once chemotherapy drug be ready, patients will receive chemotherapy. After the chemotherapy, patients go to the cooling cap area (room) and wear the cooling cap additional 20 minute for Taxane and 90 minute for other drugs, respectively.
89075578|NCT04678544|No Intervention|Controlled Group|chemotherapy with usual care
89075579|NCT04654052|Other|VerifyNow® PRUTest ≤30 (De-escalated Prasugrel Ticagrelor )|Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will be de-escalated to Clopidogrel 75 mg q.d during 11 months.
89075580|NCT04654052|Other|VerifyNow® PRUTest ≤30 (Prasugrel or Ticagrelor )|Active comparator: Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will continue with these previous treatment during 11 months.
89075581|NCT01117623|Experimental|Arm 1|
89075582|NCT01117623|Experimental|Arm 2|
89075583|NCT01117623|Experimental|Arm 3|
89075584|NCT01117623|Experimental|Arm 4|
89075585|NCT01117623|Experimental|Arm 5|
89075586|NCT01117623|Experimental|Arm 6|
89075587|NCT01117623|Experimental|Arm 7|
89075588|NCT01117623|Experimental|Arm 8|
89075589|NCT05625308|Experimental|Co-treatment with EGCG, FA, B12, and HA|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid for twelve weeks.
89075590|NCT05625308|No Intervention|Control|Untreated women.
89075591|NCT02888834||Adverse drug reaction|Patients aged over 65 years who presented a serious adverse drug reaction notified to the Regional Pharmacovigilance Center of Champagne-Ardenne between January and May 2013 were included in the study.
89075592|NCT04291664|Experimental|Prostate Cancer|
89075593|NCT04310553|Experimental|Arm 1|This project plans to enroll 40 patients receiving nanoknife treatment, our center enrolls 20 patients, and the other two centers will enroll 10 patients each. The number of patients expected to participate in the study is 240.
89075594|NCT04187469|Experimental|Regimen 1: 2HRM/4HR|Two month of chemotherapy with Moxifloxacin, Isoniazid and Rifampicin, followed by four month of Isoniazid and Rifampicin only.
89075595|NCT04187469|Active Comparator|Regimen 2: 2HRZE/4HR (control regimen)|Two month of chemotherapy with Isoniazid, Rifampicin, Pyrazinamide and Ethambutol, followed by four month of Isoniazid and Rifampicin only.
89075596|NCT04320212|Active Comparator|lumber epidural analgesia|: the patient will be placed in the lateral position, Lidocaine will be given using 5 ml syringe and a 18 G Tuohy needle will be introduced in the epidural space, using the ultrasound, under strict aseptic precautions. The ultrasound probe will be placed 90 degrees into transverse orientation and slided cephalad or caudad to obtain the transverse interspinous view (TI view) 2 levels above the operation level. patient will receive 20 ml of 0.25% plain bupivacaine after negative aspiration for blood or cerebrospinal fluid. Then, the patient will be placed in prone position to start the surgical procedure
89075597|NCT04320212|Active Comparator|erector spinae analgesia|the patient will be placed in the prone position. Then, the Erector Spinae block will be given by a high-frequency linear ultrasound transducer. The Erector Spinae muscle and transverse process will be then identified, and a 18 G Tuohy needle will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side)
89075598|NCT01116687|Experimental|Treatment (RO4929097)|See detailed description.
89075599|NCT04139486|Experimental|combined EMBOTRAP II or III and Contact Aspiration|
89075600|NCT04139486|Active Comparator|Contact Aspiration alone|
89075601|NCT00625599||1|Salvadorian students at the Evangelical University in non-health track studies over the age of 18. The students must accept the invitation to participate along with signing the informed consent to be eligible.
89075602|NCT00625599||2|Patients over the age of 45 presenting to Hospital Zacamil with an acute fracture. Patients must accept the invitation to the study and sign the informed consent to be eligible.
89075603|NCT02867020|Active Comparator|Abiraterone acetate + Prednisone + ADT (Goserelin)|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250-mg tablets)~Prednisone administered at a 5 mg twice daily oral dose~Goserelin administered as subcutaneous injections of 10.8mg every 3 months"
89075604|NCT02867020|Experimental|APALUTAMIDE monotherapy|o APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)
89075605|NCT02867020|Experimental|Abiraterone acetate + Prednisone + APALUTAMIDE|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250 mg tablets)~Prednisone administered at a 5 mg twice daily oral dose~APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)"
89075606|NCT05067855|Experimental|Pilates exercise program group|The pilates exercise program group will perform five exercises
89075607|NCT04320056|Active Comparator|Control group|"Usual care will be provide to patients concerning their medical management.~In the Control Group usual, oxygen will be delivered as per usual local practices"
89075608|NCT04320056|Experimental|Intervention group|"Usual care will be provide to patients concerning their medical management.~In the Intervention group, automated oxygen administration will be delivered with FreeO2"
89075609|NCT03817502|Experimental|Cariprazine 1.5 mg/d|Cariprazine capsules, oral administration, once daily.
89075610|NCT03817502|Experimental|Cariprazine 4.5 mg/d|Cariprazine capsules, oral administration, once daily.
89075611|NCT03817502|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
89075612|NCT04319978|Active Comparator|Group A|Group A will receive single dose of dexamethasone IM 8mg 1 hour pre-operatively.
89075613|NCT04319978|Active Comparator|Group B|Group B will receive a single dose of dexamethasone IM 8mg immediately after surgery.
89075614|NCT01114737|Experimental|Sapropterin dihydrochloride|
89075615|NCT01114737|Placebo Comparator|Tablet without active ingredient|
89075616|NCT00624182|Experimental|Phase I study|
89075617|NCT02881983||STA group|Short-term alcohol abstinent patients (after 1 month of withdrawal)
89075618|NCT02881983||LTA group|Long-term alcohol abstinent patients (at least 6 months of abstinence)
89075619|NCT02881983||Control group|Healthy subjects
89075620|NCT05131269|Experimental|Prolotherapy|"A solution of 7.5 ml of 15% dextrose with 2 ml of 40% lidocaine and 10.5 water is given to these shoulder segments as follows.~Supraspinatus muscle 2-4 ml~Infraspinatus muscle 2-4 ml~Teres minor muscle 2-3 ml,~Subscapularis muscle 2-3 ml.~Intraarticular glenohumeral joint 5 ml~Bursa sub acromial 1-2 ml,~Long head tendon biceps 1-2 ml~Acromioclavicular joint 1 ml"
89075621|NCT05131269|Placebo Comparator|Normal Saline 0.9%|"A solution of 20 ml normal saline 0.9% is given to these shoulder segments as follows.~Supraspinatus muscle 2-4 ml~Infraspinatus muscle 2-4 ml~Teres minor muscle 2-3 ml,~Subscapularis muscle 2-3 ml.~Intraarticular glenohumeral joint 5 ml~Bursa sub acromial 1-2 ml,~Long head tendon biceps 1-2 ml~Acromioclavicular joint 1 ml"
89075622|NCT03292874|Other|Paired imaging|Single arm, paired imaging of high resolution MRI (hrMRI) and stand MRI (sMRI)
89075623|NCT00625677|Experimental|1|"Pediacel - 2,3,4 months Prevenar - 2,4 months Menjugate - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
89075624|NCT00625677|Experimental|2|"Pediacel - 2,3,4 months Prevenar - 2,4 months Neis-vacC - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
89075625|NCT03258008|Experimental|Utomilumab + ISA101b|"Utomilumab by vein every 4 weeks for up to 12 doses beginning on Cycle 1 Day 1.~ISA101b as an injection under the skin every 4 weeks for 3 doses. Participants receive 2 injections each time."
89075626|NCT05116605|Experimental|Photobiomodulation (PBM)|Participants will utilize the NovoTHOR whole body light pod
89224425|NCT06266325||Derivation|Individuals whose randomly selected assessment was done between April 1, 2010 and March 31, 2018, in whom model will be developed
89075627|NCT01113879|Experimental|Aphasia therapy with an exercise adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Aerobic exercise: An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate."
89075628|NCT01113879|Placebo Comparator|Aphasia therapy with a stretching adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Stretching: Stretching will occur for 50 minutes a day, three days/week for 12 weeks."
89075629|NCT00979576|Experimental|BIBF 1120 BID + Pemetrexed|Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m^2 pemetrexed once every 3 weeks
89075630|NCT00979576|Experimental|BIBF 1120 BID (RD) + Pemetrexed|PHase II part: Study arm
89075631|NCT00979576|Experimental|BIBF 1120 BID(Placebo) + Pemetrexed|Phase II part: Comparator arm
89224426|NCT06266325||Validation|Individuals whose randomly selected assessment was done between April 1, 2018 and March 31, 2020, in whom model's performance will be assessed
89224427|NCT06266312|Experimental|multimodal lifestyle intervention|"A group receiving a multimodal prehabilitation programme consisting of three modalities:~MIET during neoadjuvant intravenous chemotherapy infusion~HITT and strength training during the last six weeks prior to surgery~Optimising nutritional intake throughout the total preoperative period"
89224428|NCT06266299|Experimental|Part 1|KK2269 will be administered at each dose level, intravenous infusion.
88812957|NCT03837782|Experimental|minimally invasive surgery|"Patients were randomized to undergo minimally invasive radical resection (endoscopic surgery or robotic assisted surgery). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability)."
89075632|NCT02867332|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
89075633|NCT02867332|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment."
89075634|NCT00979420||HIV treatment|
89075635|NCT02867098|Experimental|Cohort 1|Dose Level 1 XmAb5871 given SC Q14days X 3
89075636|NCT02867098|Experimental|Cohort 2|Dose Level 2 XmAb5871 given SC Q14days X 3
89075637|NCT02867098|Experimental|Cohort 3|Dose Level 3 XmAb5871 given SC Q14days X 3
89075638|NCT02867098|Experimental|Cohort 4|Dose Level 4 XmAb5871 given IV Q14days X 3
89075639|NCT02867098|Experimental|Cohort 5|Dose Level 5 XmAb5871 given SC Q7days X 3
89075640|NCT02702180|Experimental|Double-blind molgramostim once daily|Inhalation of molgramostim nebuliser solution 300 mcg once daily for 24 weeks
89075641|NCT02702180|Experimental|Double-blind molgramostim intermittent|Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 weeks (12 cycles)
89075642|NCT02702180|Placebo Comparator|Double-blind placebo|Inhalation of placebo nebuliser solution once daily for 24 weeks
89075643|NCT02702180|Experimental|Open-label molgramostim intermittent|Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 or 48 weeks from completion of the double-blind period
89075644|NCT00980980|No Intervention|Arm 1: Usual Care-Active Surveillance|Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+
89075645|NCT00980980|Active Comparator|Arm 2: Targeted Decolonization|Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
89075646|NCT00980980|Active Comparator|Arm 3: Universal Decolonization|Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
89075647|NCT02866864||Subjects with animal allergy|Subjects who suffer from allergic symptom during contact with animal
89075648|NCT02866864||Subjects without animal allergy|Subjects who do not suffer from allergic symptom during contact with animal
89075649|NCT00980200|Experimental|C/E/A/B/D|GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD/GW642444 Dose 3 QD
89075650|NCT00980200|Experimental|D/C/E/A/B|GW642444 Dose 3 QD/GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD
89075651|NCT00980200|Experimental|A/B/C/D/E|placebo/GW642444 Dose 1 BD/GW642444 Dose 2 QD/GW642444 Dose 3 QD/GW642444 Dose 4 QD
89075652|NCT00980200|Experimental|B/A/D/E/C|GW642444 Dose 1 BD/placebo/GW642444 Dose 3 QD/GW642444 Dose 4 QD/GW642444 Dose 2 QD
89075653|NCT00980200|Experimental|E/D/B/C/A|GW642444 Dose 4 QD/GW642444 Dose 3 QD/GW642444 Dose 1 BD/GW642444 Dose 2 QD/placebo
89075654|NCT04116502|Experimental|A- Ruxolitinib|Treatment with Ruxolitinib
89075655|NCT04116502|Active Comparator|B- Hydroxycarbamide OR Interferon A|Best Available Therapy (BAT), Treatment with hydroxycarbamide OR Interferon A
89075656|NCT04290442|Active Comparator|Adductor canal block (ACB)|
89075657|NCT04290442|Experimental|Adductor canal block plus SPANK block|
89075658|NCT02866708|Experimental|Intermittent negative pressure (INP) therapy|"At baseline, the participants will be randomized into 2 groups: 1) INP therapy or 2) control with no INP therapy.~The 1) patients randomized to INP therapy will start with 8 weeks INP therapy two hours per day divided into timed sections (1-3 times per day or use the device as many times as practical for the individual as long as the total time is two hours). After 8 weeks of INP therapy, final measures will be performed at the Vascular lab before the participants starts their 8-week control period."
89224429|NCT06266299|Experimental|Part 2|"KK2269 will be administered at each dose level intravenously in combination with docetaxel.~Docetaxel will be administered intravenously (Q3W)."
89075659|NCT02866708|No Intervention|Control|The participants randomized to control will continue their usual wound care for 8 weeks without INP therapy. The control group will start INP therapy after 8 weeks. After 8-weeks without intervention, the participants allocated to the control-group will be asked to start with INP therapy for 8 weeks before a final examination. The participants in the control group will receive vascular assesment at baseline, week 8 (end of control).
89075660|NCT02866786|Active Comparator|OCP only arm|OCP containing 35 microgram ethinyl estradiol and 2 milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
89075661|NCT02866786|Active Comparator|Metformin arm|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
89075662|NCT00979654|Experimental|Sifalimumab (MEDI-545) 500 or 600 milligram (mg)|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
89075663|NCT02866552|Placebo Comparator|PLACEBO|Patients will receive an injection of placebo
89075664|NCT02866552|Experimental|DRUG : Stromal Vascular Fraction|Patients will receive an injection of Stromal Vascular Fraction injection
89230039|NCT00385918|Experimental|Lokomat training|Subjects will receive active exercise treatment in the Lokomat device 3 times per week for 3 months. Each session will last approximately 45 minutes.
89230040|NCT00385918|Active Comparator|Home stretching then Lokomat training|Patients will participate in a home stretching program for 3 months. They will then be crossed over to an active Lokomat treatment for a subsequent 3 months.
89230041|NCT02554409||Pregnancy Cases|No Intervention as part of this protocol
89230042|NCT00791375|Experimental|Physical Activity Intervention|Participants in this arm will be given access to a website designed to help them increase their levels of physical activity
89075665|NCT00978562|Experimental|Diagnostic (DSC-MRI with ferumoxytol, DCE-MRI with gadolinium)|Patients receive ferumoxytol and gadolinium IV and then undergo DSC-MRI and DCE-MRI. An optional MRI without injection of a contrast agent may be obtained after 20-24 hours at the discretion of the clinician. Patients may receive up to 3 more scans at least 3 weeks apart over up to 2 years.
89075666|NCT04289974||Palbociclib+fulvestrant|"100 cases of patients with ER+, HER2- breast cancer, experienced resistance after first line endocrinotherapy, will be assigned participants into treatment regimen, including palbociclib combined with fulvestrant.~FFPE blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals on the points before administration and since resistance appearance. The tissue will be sequenced by a pan-cancer DNA panel (500+ genes) and whole transcriptome sequencing (WTS).~5-10 ml peripheral blood will be collected from each patient on the points before administration, 1 month after treatment, every subsequent visit and resistance appearance. The liquid biopsy will be sequenced by a pan-cancer ctDNA panel (300+ genes).~The genomic characteristics of patients received resistance will be analyzed. The relevant pathway mechanisms will be identified."
89075667|NCT02866630||Cardiopulmonary bypass (Sevoflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of sevoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
89075668|NCT02866630||Cardiopulmonary bypass (Desflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of desflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
89075669|NCT02866162||patients with neutropenia|
89230043|NCT00791375|Placebo Comparator|Cancer Website Control Group|Participants in this arm will be given information on cancer-related websites (that do not provide information on physical activity)
89230044|NCT00385840|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the Fluarix™ vaccine in study NCT00321763, received 1 dose of Fluarix™ vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89075670|NCT02865616|Experimental|MET-2 Capsules|"Patients will be on vancomycin to control symptoms up until the time of the treatment.~Initial Loading Dose: Patients will be given an initial daily loading dose of 5 g MET-2 over 2 days followed by a maintenance dose of 1.5 g over 8 days. Patients who do not experience treatment failure between Day 14 and Day 40 will be monitored until Day 130.~Second Loading Dose: Patients experiencing treatment failure after the first dose may be offered a second, higher loading dose 10 g of MET-2 in the form of 20 MET-2 capsules per day for two days, there will not be additional daily dosing beyond the first 10 days.~Colonoscopy: Patients failing the second loading dose of MET-2 may be offered 15 g of MET-2, equivalent to a 30 MET-2 capsule loading dose by weight, via colonoscopy..~All patients will be followed up for 120 days after the last treatment has been received."
89075671|NCT02865460|Experimental|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
89075672|NCT02865460|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x 200 mg for 4 months) with food each morning-upon waking
89075673|NCT01206816|Experimental|two experimental arms|patients receive increasing doses of BI 6727 in combination with increasing doses of BIBW 2992
89075674|NCT01206582|Active Comparator|Hemin|Panhematin®, Ovation Pharmaceuticals, Deerfield, Illinois (IL). Hemin was diluted in 25% albumin to obtain a concentration of 2.4 mg/mL and administered at a dose of 1.25 mL/Kg and at a rate of 60 mL/hour. 10 iv infusions for 8 weeks
89075675|NCT01206582|Placebo Comparator|Albumin|10 iv infusions for 8 weeks
89075676|NCT05409456|Experimental|mild aerobic exercise|group A was given mild aerobic exercise on treadmill with warm up exercise
89075677|NCT05409456|Experimental|moderate aerobic exercise|group B was moderate aerobic on treadmill with warm up exercise
89075678|NCT01259102|Experimental|No Rest|BTDS 10 with no application site rest period prior to application of second BTDS
89075679|NCT01259102|Experimental|7-Day Rest|BTDS 10 with 7-day rest period prior to application of second BTDS
89075680|NCT01259102|Experimental|14-Day Rest|BTDS 10 with 14-day rest period prior to application of second BTDS
89075681|NCT01259102|Experimental|21-Day Rest|BTDS 10 with 21-day rest period prior to application of second BTDS
89075682|NCT01259102|Experimental|28-Day Rest|BTDS 10 with 28-day rest period prior to application of second BTDS
89075683|NCT00978250|Experimental|5-Fluro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd (100 mg/m(2)) + THU (350 mg/m(2)) administered 5 days/week for 2 weeks in 28-day cycles
89075684|NCT01259024|Experimental|doxorubicin-eluting LC Bead|transarterial chemoembolization using doxorubicin-eluting LC Beads
89075685|NCT04319900|Experimental|favipiravir tablets+chloroquine phosphatetablets tablets group|favipiravir tablets+chloroquine phosphatetablets tablets
89075686|NCT04319900|Experimental|favipiravir tablets group|favipiravir tablets
89075687|NCT04319900|Placebo Comparator|placebo treatment group|placebo
89075688|NCT01257698|Active Comparator|Dorzolamide-timolol topical drops|
89075689|NCT01257698|No Intervention|Standard of care|
89075690|NCT01257542|Experimental|Active|
89075691|NCT01257542|Placebo Comparator|Placebo|
89075692|NCT01257230|Placebo Comparator|placebo|once daily, delivered with Respimat inhaler
89075693|NCT01257230|Experimental|tiotropium low dose|once daily, delivered with Respimat inhaler
89075694|NCT01257230|Experimental|tiotropium high dose|once daily, delivered with Respimat inhaler
89075695|NCT01113801|Placebo Comparator|Placebo|
89075696|NCT01113801|Experimental|2 mg LY2382770|
88812789|NCT01549223|Active Comparator|Protocol Group|"Protocol Group will receive 3 mL syringes marked study solution-oxytocin which contain 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).~If inadequate uterine tone is noted at 9 min, the 1 mL syringe marked marked study solution-9 min, containing methylergonovine maleate (methergine) 0.2mg, will be given IM.~If inadequate uterine tone is noted at 12 min, the 1 mL syringe marked marked study solution-12 min, containing carboprost tromethamine (hemabate) 0.25 mg, will be given IM.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
89075697|NCT01113801|Experimental|10 mg LY2382770|
89075698|NCT01113801|Experimental|50 mg LY2382770|
89075699|NCT01256684|Placebo Comparator|Placebo|
89075700|NCT01256684|Experimental|0.25% DHEA|
89075701|NCT01256684|Experimental|0.5% DHEA|
89075702|NCT01204710|Experimental|Olaratumab + Mitoxantrone|1 cycle = 3 weeks (21 days)
88812790|NCT01549925|Other|standard surgical resection|standard surgical resection using clamps and surgical ligatures
89075703|NCT01204710|Active Comparator|Mitoxantrone: Optional Olaratumab Monotherapy|"1 cycle = 3 weeks (21 days)~Participants who experience progressive disease (PD) have the option to receive olaratumab monotherapy treatment."
89075704|NCT02881359||LifeSeal® Kit|creation of a coloanal or colorectal anastomosis
89075705|NCT01256450|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
89075706|NCT01256450|Placebo Comparator|BEMA Placebo|placebo buccal soluble film
89075707|NCT01204398|Experimental|eligible hypertension patient|Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
89075708|NCT04318236|Experimental|Online-Program + factors 1,2,3,4|"In this arm all four factors are set to active (i.e. yes):~diagnostic interview~motivational module~guidance~e-mail reminders"
89075709|NCT04318236|Experimental|Online-Program + factors 1,2,3|"In this arm three factors are set to active (i.e. yes):~diagnostic interview~motivational module~guidance"
89075710|NCT04318236|Experimental|Online-Program + factors 1,2,4|"In this arm three factors are set to active (i.e. yes):~diagnostic interview~motivational module~e-mail reminders"
89075711|NCT04318236|Experimental|Online-Program + factors 1,2|"In this arm two factors are set to active (i.e. yes):~diagnostic interview~motivational module"
89075712|NCT04318236|Experimental|Online-Program + factors 1,3,4|"In this arm three factors are set to active (i.e. yes):~diagnostic interview~guidance~e-mail reminders"
89075713|NCT04318236|Experimental|Online-Program + factors 1,3|"In this arm two factors are set to active (i.e. yes):~diagnostic interview~guidance"
89075714|NCT04318236|Experimental|Online-Program + factors 1,4|"In this arm two factors are set to active (i.e. yes):~diagnostic interview~e-mail reminders"
89075715|NCT04318236|Experimental|Online-Program + factor 1|"In this arm one factor is set to active (i.e. yes):~- diagnostic interview"
89075716|NCT04318236|Experimental|Online-Program + factors 2,3,4|"In this arm three factors are set to active (i.e. yes):~motivational module~guidance~e-mail reminders"
89075717|NCT04318236|Experimental|Online-Program + factors 2,3|"In this arm two factors are set to active (i.e. yes):~motivational module~guidance"
89075718|NCT04318236|Experimental|Online-Program + factors 2,4|"In this arm two factors are set to active (i.e. yes):~motivational module~e-mail reminders"
89075719|NCT04318236|Experimental|Online-Program + factor 2|"In this arm one factor is set to active (i.e. yes):~- motivational module"
89075720|NCT04318236|Experimental|Online-Program + factors 3,4|"In this arm two factors are set to active (i.e. yes):~guidance~e-mail reminders"
89075721|NCT04318236|Experimental|Online-Program + factor 3|"In this arm one factor is set to active (i.e. yes):~- guidance"
89075722|NCT04318236|Experimental|Online-Program + factor 4|"In this arm one factor is set to active (i.e. yes):~- e-mail reminders"
89075723|NCT04318236|Experimental|Online-Program + no factor|"In this arm no factor is set to active (i.e. yes):"
89075724|NCT01111851|Experimental|Fosaprepitant 150 mg|Fosaprepitant 150 mg
88812791|NCT01549925|Active Comparator|LIGASURE|Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
89075725|NCT01111851|Experimental|Aprepitant 165 mg|Aprepitant 165 mg
89075726|NCT01111851|Experimental|Aprepitant 250 mg|Aprepitant 250 mg
89075727|NCT01256294|Experimental|Sequence 1 - Branded Tacrolimus / Generic Tacrolimus|In Period 1 (Days 1-14) participants received branded tacrolimus (Prograf) orally twice a day and in Period 2 (Days 15 - 28) participants received generic tacrolimus (Sandoz) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
89075728|NCT01256294|Active Comparator|Sequence 2 - Generic Tacrolimus / Branded Tacrolimus|In Period 1 (Days 1 - 14) participants received generic tacrolimus (Sandoz) orally twice a day and in Period 2 (Days 15 - 28) participants received branded tacrolimus (Prograf) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
89075729|NCT04310241||Control subjects|Subjects who state they have no eye or neurologic problems or disease other than perhaps wearing glasses or contact lenses and upon review of medical history.
89075730|NCT04310241||Amblyopia|Clinical diagnosis of amblyopia
89075731|NCT01256060|Experimental|Intanasal Oxytocin|A modified dose finding method will be used to determine safety among four dose levels for Intranasal Oxytocin. Half the dose (0.2 IU/kg /dose) is the minimum dose and two intermediate doses will also be evaluated (0.26 and 0.33 IU/kg / dose) Dose-finding escalations will be done in groups of three patients.Three patients will be studied at the first dose level. If none of these patients experience dose limiting toxicity, the dose will be escalated. If one experiences dose limiting toxicity, up to three more will be accrued at the same level. If none of these experience dose limiting toxicity, the dose will be escalated. If one or more of these experience dose-limiting toxicity, entry at that dose level will be stopped. Up to three more patients will be treated at the next lower dose. If zero out of these experience dose limiting toxicity, an additional three patients will be treated at that dose.
89075732|NCT02880501|Experimental|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled will undergo proximal femoral nail antirotation (PFNA) implantation.
89075733|NCT01255904|Experimental|Arm 1|Oral Chloral and intranasal placebo
89075734|NCT01255904|Experimental|Arm 2|oral placebo and intranasal dexmedetomidine
89075735|NCT01255670|Active Comparator|penicillin and metronidazole|After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess
89075736|NCT01255670|Placebo Comparator|penicillin and placebo|After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess
89075737|NCT01255592|Experimental|1|Treatment arm AZD5069
89075738|NCT01255592|Placebo Comparator|2|Placebo dose.
89075739|NCT01255436|Experimental|SMS text reminders|Participants in this arm will receive SMS text messages on top of the usual care they receive from their physicians.
89075740|NCT01255436|Other|Usual Care|Participants in this arm will receive the usual care they receive from their physicians.
89075741|NCT01203930|Experimental|Idelalisib|This arm consists of 2 cohorts. Participants in Cohort 1 will receive idelalisib for up to twelve 28-day cycles (or development of unacceptable toxicity) plus rituximab (8 doses through the end of Cycle 2). Upon completion of twelve 28-cycles, participants are eligible to remain on idelalisib in a continuation protocol. Participants in Cohort 2 will receive idelalisib until disease progression or development of unacceptable toxicity.
89075742|NCT01254890|Experimental|Azacitidine + Sorafenib|Azacitidine (AZA) 75 mg/m^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days; Sorafenib 200 mg orally twice a day.
89075743|NCT01203852|Experimental|Metoprolol + Chlorthalidone|Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additional weeks if blood pressure (BP) > 120/70 mmHg. BP measures were again recorded. Participants entered a washout where metoprolol was titrated, then discontinued, and the patient's hypertension was re-established. After another set of identical baseline labs, study participants were initiated on chlorthalidone 25 mg four days per week (Monday, Wednesday, Thursday, Saturday) 15 mg daily for two weeks, followed by 25 mg daily for an additional six weeks.
89075744|NCT01105533|Experimental|Cohort 1|
89075745|NCT01105533|Experimental|Cohort 2|
89075746|NCT01105533|Experimental|Cohort 3|
89075747|NCT01105533|Experimental|Cohort 4|
89075748|NCT01105533|Experimental|Cohort 5|
89075749|NCT01105533|Experimental|Cohort 6|
89075750|NCT01105533|Experimental|Cohort 7|
89075751|NCT01105533|Experimental|Cohort 8|
89075752|NCT01105533|Experimental|Cohort 9|
89075753|NCT01105533|Experimental|Cohort 10|
89075754|NCT01203072|Experimental|DU-176b 5 mg|
89075755|NCT01203072|Experimental|DU-176b 15 mg|
89075756|NCT01203072|Experimental|DU-176b 30 mg|
89075757|NCT01203072|Experimental|DU-176b 60 mg|
89075758|NCT01203072|Placebo Comparator|Placebo|
89075759|NCT01105377|Experimental|Treatment (entinostat, azacitidine)|Patients receive azacitidine subcutaneously on days 1-5 and 8-10 and oral entinostat on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89075760|NCT04309071|Experimental|Salivary insulin responses to mixed meal tolerance test|Saliva samples and finger prick glucose will be collected after at least 4 hours of fasting and then at 60 and 90 minutes following ingestion of a standardized meal tolerance test.
89075761|NCT01105065|Experimental|Patients with RVD|Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.
89075762|NCT01111539|Experimental|Phase B: Single-blind Prospective Treatment Phase|Participants received initial dose of escitalopram 10 milligram (mg) blinded capsule (over-encapsulated tablet), orally, once daily, increased to 20 mg/day at the end of Week 1 based upon tolerability profile, for up to maximum of Week 8. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
89075763|NCT01111539|Experimental|Phase B+: Single-blind Phase B Responders|Participants with response (≥50% reduction in depressive symptom severity in Hamilton Depression Rating Scale {HAM-D17} Total Score; or a HAM-D17 Total Score of <14 at Week 8 or a Clinical Global Impression of Improvement {CGI-I} Score of <3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B, for up to maximum of Week 14, in Phase B+.
89075764|NCT01111539|Experimental|Phase C: Aripiprazole/Escitalopram Combination|Participants with incomplete response (less than 50% reduction in depressive symptom severity between Baseline and Week 8 measured by the HAM-D17 Total Score and HAM-D17 Total Score of ≥14 at Week 8 and CGI-I Score of ≥3 at Week 6 and 8) at Week 8 received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily at Week 9. Participants were up titrated to aripiprazole target dose of 12 mg/day at Week 10 (if initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on initial 6 mg/day dose), and thereafter received same dose up to maximum of Week 14. No dose increases were allowed for aripiprazole after end of Week 12, however, doses might be decreased at any visit based upon tolerability. In combination with aripiprazole, participants received escitalopram (10 or 20 mg/day blinded capsules) taken during final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments allowed for escitalopram during Phase C.
89075765|NCT01111539|Experimental|Phase C: Escitalopram Monotherapy|Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received escitalopram dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
89224430|NCT06266286|Active Comparator|Active Comparator|"Active stimulation sessions will last 1 hour each.~Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate several groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body."
89075766|NCT01111539|Experimental|Phase C: Aripiprazole Monotherapy|Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily for Week 9. Participants were up titrated to the aripiprazole target dose of 12 mg/day at Week 10 (if the initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on the initial 6 mg/day dose), and thereafter received the same dose for up to maximum of Week 14. No dose increases were allowed for aripiprazole after the end of Week 12, however, doses might be decreased at any visit based upon tolerability.
89075767|NCT02880345|Active Comparator|Cohort 1 - 8 Gy x 3 fractions|8 Gy x 3 fractions
89075768|NCT02880345|Active Comparator|Cohort 2 - 17 Gy x 1 fractions|17 Gy x 1 fraction
89075769|NCT02880267|Other|CGM Users|Glucose challenge during a clinic sessions to assess performance of CGM compared to reference measurement
89075770|NCT02879955|Experimental|10 gastric bypass operated patients|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
89075771|NCT02879955|Experimental|10 healthy control subjects|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
89075772|NCT02880033|Active Comparator|Parkinson's disease|ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
89075773|NCT02880033|Active Comparator|Amyotrophic lateral sclerosis|ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
89075774|NCT02880033|Placebo Comparator|healthy age and sex matched controls|ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
89075775|NCT02880111||group 1|CF patients with Pseudomonas aeruginosa chronic colonization.
89075776|NCT02880111||group 2|CF patients without a Pseudomonas aeruginosa chronic colonization.
89075777|NCT05052645|No Intervention|Standard of Care Group|Subjects will receive standard of care neuropathic pain treatment without acupuncture.
89075778|NCT05052645|Experimental|Acupuncture Treatment Group|Subjects will receive acupuncture treatment in addition to to the standard of care neuropathic pain treatment.
89075779|NCT00625911|Active Comparator|morphine only|standard analgesia protocol
89075780|NCT00625911|Experimental|morphine ketamine|alterantive regimen for intravenous patient controlled analgesia
89075781|NCT04110496|Experimental|RTX-134|Escalating doses of RTX-134 will be administered by intravenous infusion one time
89075782|NCT01111149|Placebo Comparator|Sugar Pill|Sugar pill will be given to patients as a comparison group to the active varenicline group. In the fist week, one placebo pill will be given per patient, followed by 2 pills per day for the remaining 12 weeks of the study.
89075783|NCT01111149|Experimental|Varenicline|Varenicline has not previously been examined for its efficacy and safety in subjects with schizophrenia. Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study. This is an experimental group to be compared against both placebo and bupropion HCl.
89075784|NCT01111149|Active Comparator|Bupropion HCl|Bupropion HCl is an established smoking cessation agent and will be used to compare its efficacy and safety against varenicline. Subjects in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study.
89075785|NCT01254656|Experimental|LRV 500mg|
89075786|NCT01254656|Experimental|LRV 750mg +TVD|
88812792|NCT00895934|Experimental|Phase 1 - Dose Finding|Varying schedules and dose levels of vorinostat, azacitidine and gemtuzumab ozogamicin. Includes cohorts 1-3.
89075787|NCT01254656|Active Comparator|EFV|
89075788|NCT01254656|Experimental|LRV 750mg+ DRV/r + OBT|
89075789|NCT01254656|Experimental|LRV 1000mg +DRV/r + OBT|
89075790|NCT01254656|Active Comparator|ETR|
89075791|NCT01110915|Experimental|MRI group|Subjects randomized to the MRI group will undergo a one-hour MRI scan, including 16 individual sequences in the chest and head region, at 9-12 weeks post-implant.
89075792|NCT01110915|Active Comparator|Control group|Subjects randomized to the Control group will wait for one hour without having any MRI scan at 9-12 weeks post-implant.
89075793|NCT01254344|Experimental|Ertapenem sodium 1 g|Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
89075794|NCT01254344|Active Comparator|Ceftriaxone sodium 2 g|Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose
89075795|NCT02879877|Experimental|UCB7858 (intravenous)|Various single doses, administered to various cohorts.
89075796|NCT02879877|Placebo Comparator|Placebo (intravenous)|Single dose placebo comparator for each cohort of iv administration.
89075797|NCT02879877|Experimental|UCB7858 (subcutaneous)|Various single doses, administered to various cohorts.
89075798|NCT02879877|Placebo Comparator|Placebo (subcutaneous)|Single dose placebo comparator for each cohort of sc administration.
89075799|NCT02888366||1|Breath samples taken, no treatment given.
89075800|NCT05051007|Active Comparator|fentanyl group|
89075801|NCT05051007|Active Comparator|lidocaine group|
89075802|NCT02881671||Patients with congenital atrioventricular block|Patient with congenital atrioventricular block
89075803|NCT02881671||relatives with congenital atrioventricular block|Normal relatives of patients with congenital atrioventricular block
89075804|NCT02881671||Patients with progressive Cardiac Conduction Disease|Patients with progressive Cardiac Conduction Disease,
89075805|NCT02881671||relatives with progressive Cardiac Conduction disesae|Normal relatives of patients with progressive Cardiac Conduction Disease
89075806|NCT02879565|Other|qualitative and neuroimaging research|
89075807|NCT04310319|Other|Normal salt, low protein treatment period|6 grams of sodium chloride daily / Placebo
89075808|NCT04310319|Other|Normal salt, normal protein treatment period|6 grams of sodium chloride daily / 40 grams of protein daily
89075809|NCT04310319|Other|Low salt, low protein treatment period|Double placebo
89075810|NCT04310319|Other|Low salt, normal protein treatment period|Placebo / 40 grams of protein daily
89075811|NCT01102803|Placebo Comparator|Sugar Pill|Participants will receive placebo augmented cognitive behavioral therapy
89075812|NCT01102803|Experimental|D-Cycloserine|Participants will receive D-Cycloserine augmented cognitive behavioral therapy
88812793|NCT00895934|Experimental|Phase 2 - Treatment at Selected Dose|Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, gemtuzumab ozogamicin 3 mg/m2/day on days 4 and 8.
89075813|NCT01254188|Experimental|Nilotinib|300 mg BID
89075814|NCT01109979|Active Comparator|Estradiol+MPA|
89075815|NCT01109979|Active Comparator|Estradiol+DRSP|
89075816|NCT01102491|Experimental|Ramosetron prophylaxis|ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery
89075817|NCT01102491|No Intervention|Control|no antiemetic prophylaxis
89075818|NCT01102257|Experimental|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 esssential fatty acid i.e Omega-3 EFA supplement comprised of:~2000 mg EPA 1000 mg DHA"
89075819|NCT01102257|Placebo Comparator|Olive Oil|Gel Capsule
89075820|NCT01253564|Experimental|Single Arm|
89075821|NCT04309149|Experimental|MCT fats|Kanso MCT oils and margarine will be consumed daily for 7 days each to assess tolerability and compliance
89075822|NCT01108809||Patients with arterial hypertension|
89075823|NCT01253408|Experimental|Dronabinol 2.5 mg bid|Dronabinol 2.5 mg will be taken orally with water twice per day for two days.
89075824|NCT01253408|Experimental|Dronabinol 5 mg bid|Dronabinol 5 mg will be taken orally with water twice per day for two days.
89075825|NCT01253408|Placebo Comparator|Placebo|Placebo will be taken orally with water twice per day for two days.
89075826|NCT02879799|Experimental|Implement Family Integrated Care|Dynamic education and support intervention for families of preterm infants.
89075827|NCT02879799|No Intervention|Monitor Standard Practices|Standard nursing care of preterm infants and their families.
89224431|NCT06266286|Sham Comparator|Sham Comparator|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
89075828|NCT02879643|Experimental|Cohort A: Marqibo and UK ALL R3 backbone|"Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.~Dexamethasone orally twice daily on days 1-5 and 15-19.~Mitoxantrone: given by intravenous (IV) infusion on days 1 and 2.~PEG-asparaginase: given as an injection into the muscle on says 3 and 17.~Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
89075829|NCT02879643|Experimental|Cohort B: Marqibo and lower intensity UK ALL R3 backbone|"Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.~Dexamethasone orally twice daily on days 1-5 and 15-19.~PEG-asparaginase: given as an injection into the muscle on days 3 and 17.~Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
89075830|NCT02879643|Experimental|Cohort C: Marqibo and maintenance regimen|"Marqibo®: given by intravenous (IV) infusion on day 1~Dexamethasone orally twice daily on days 1-5~Methotrexate: given orally on days 1 and 8~Mercaptopurine: given orally daily on days 1-13"
89075831|NCT02879487|Active Comparator|Coagulation mode|Colpotomy will be performed by monopolar needle electrode using coagulation mode
89075832|NCT02879487|Active Comparator|Cut mode|Colpotomy will be performed by monopolar needle electrode using cut mode
89075833|NCT02879721|No Intervention|no drug|No drug and no intervention
89075834|NCT02879721|Active Comparator|AT1R-antagonist|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily
89075835|NCT02879721|Active Comparator|ACE-inhibitor|Angiotensin converting enzyme inhibitor, (enalapril) 5 mg once daily
89075836|NCT01253174|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 film-coated SHT470FA tablet (Yasmin with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
89230045|NCT00385840|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the GSK1247446A vaccine in study NCT00321763, received 1 dose of adjuvanted GSK1247446A vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89230046|NCT01045876|Experimental|Dexamethasone|
89075837|NCT01253174|Experimental|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532A tablet (with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
89075838|NCT01253174|Active Comparator|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SHT04532C, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
89075839|NCT01108731|Active Comparator|Patients taking the drug Milnacipran|Randomize patients signing informed consent and give 50% of them Milnacipran -- blinded to the investigators.
89075840|NCT01108731|Placebo Comparator|Patients taking the placebo|Randomize patients signing informed consent and give 50% of them the placebo -- blinded to the investigators.
89075841|NCT04308447|Experimental|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
89075842|NCT01253018|Experimental|Robot Therapy|12 weeks of robotic therapy
89075843|NCT01253018|Active Comparator|Transition to Task Training|12 weeks of task specific practice combined with robotic therapy
89230047|NCT01045876|Placebo Comparator|Placebo|
89224432|NCT06266273|Other|Overhead athletes with shoulder pain|"Male and female athletes aged between 18-35,~Engaged professionally in sports involving overhead activities for at least 3 years (volleyball, basketball, swimming, badminton, water polo, tennis, American football, handball, etc.),~Actively participating in competitions for at least 1 year,~Experiencing current traumatic or non-traumatic pain, or having a history of shoulder pain, or having chronic shoulder pain~Native Turkish speakers."
89075844|NCT04308915|Experimental|Game-based training|Participants play games for cognitive training
89075845|NCT04308525||ERAS Group|Prospectively included patients after introduction of an ERAS programme
89075846|NCT04308525||Control group|We retrospectively evaluated our procedures for the period 2014-2016
89075847|NCT02881437|Experimental|IgHy10 (HyQvia)|"Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after IgHy10 (HyQvia) administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods:~The first period is a one-week ramp-up period. The first administration of IgHy10 (HyQvia) will be with a one-week dose~During the first three-month follow-up period, IgHy10 (HyQvia) will be administered, every other week at a dose equivalent to the dose administered with the previous treatment (standard SCIG).~At the end of this first follow-up period, the dose of IgHy10 (HyQvia) will be increased for the next infusion to reach a 3-4 week equivalent dose."
89075848|NCT01108341|Experimental|Bendamustine and Ofatumumab|There are 6 planned and 2 optional 28-day cycles in which participants are administered both bendamustine and ofatumumab in the following doses: Bendamustine administered at 90 mg/m^2 intravenously (iv) on study days 1 and 2. Ofatumumab administered at 300 mg iv on day 1 and 1000 mg iv on day 8 of cycle 1. Ofatumumab administered at 1000 mg iv on day 1 of all additional cycles.
89075849|NCT01108263|Active Comparator|Integra Flowable on wound bed|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
89075850|NCT01108263|Active Comparator|INTEGRA Flowable on wound & injected subcutaneously|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
89075851|NCT01108185||Acute Respiratory Infections|Slovak patients with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).
89075852|NCT01252940|Experimental|FTC/RPV/TDF|Participants will switch from their existing treatment regimen to the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) at the beginning of the study.
89224433|NCT06266247|Other|patients|"Group: Behcet patients~Group: Healty people"
88812794|NCT01447121|Experimental|Intended Users of the System|Untrained subjects with diabetes use an investigational blood glucose monitoring system (Tatsu/Tradewind Investigational BG Monitoring System) to self-test capillary blood obtained from fingerstick.
88812795|NCT01831388|Experimental|The breath training program|Approximately 30-minutes of group instruction session on breathing techniques delivered at a Main Campus outpatient clinic, followed by approximately 15 minutes twice daily home practice for six weeks with weekly telephone coaching. The intervention will conclude at about week 6. Patients will be encouraged to continue the practice, but there will be no further phone calls to remind patients or to confirm their continuing practice.
89230048|NCT01040416||Bleeding marginal ulcer after RYGB|
89075853|NCT01252940|Experimental|SBR/Delayed Switch|Participants will stay on baseline regimen (SBR; their existing treatment regimen of PI+RTV plus 2 NRTIs) at the beginning of the study through Week 24, and may switch to the FTC/RPV/TDF STR (Delayed Switch) at the Week 24 visit.
89075854|NCT02879331|Active Comparator|10 coils in upper lobes|10 coils in upper lobes
89075855|NCT02879331|Experimental|15 coils in upper and lower lobes|15 coils in upper and lower lobes
89230049|NCT01044550|Other|Treatment|Laparoscopy on a group of randomly selected patients with left thoracoabdominal stab wounds to obtain the incidence of occult diaphragm injury
89230050|NCT01044550|Active Comparator|Control|Assess the incidence and clinical outcome of delayed diaphragm visceral herniation in the study group.
89224434|NCT06266221|Experimental|Systemic Corticosteroids|"Oral prednisone at 1 mg/kg/day for 3 days, tapered to 0.75 mg/kg/day for 3 days, 0.50 mg/kg/day for 3 days, 0.25 mg/kg/day for 3 days.~If the oral route is not possible, IV methylprednisolone will be used at 0.8 mg/kg/day for 3 days, ta-pered to 0.6 mg/kg/day for 3 days, 0.4 mg/kg/day for 3 days, 0.2 mg/kg/day for 3 days (equivalent predni-sone dosage).~In the event of a change of route administration (IV then Oral or Oral then IV), the posology of prednisone or methylprednisolone or placebo will correspond to the dosage equivalent to that prescribed at the time of the switch."
89224435|NCT06266221|Placebo Comparator|Placebo|Oral or IV placebo with the same decrease of dose: same number of tablets for prednisone placebo and same volume as methylprednisolone for its placebo
89224436|NCT06266208||Group A (non-operated):|This group will consist of patients with clinical and radiological diagnosis of painful claw nail with wide nail curvature and presence of dorsal osteophyte on radiograph. They will not have received previous surgery for this condition. They will be followed up conservatively for 1 month, with baseline measurements of nail curvature, nail thickness, osteophyte height and nail-phalange distance. This group will allow correlating the osteophyte height with the degree of nail deformity without surgical intervention.
89224437|NCT06266208||Group B (operated):|This group will include patients who meet the same inclusion criteria as Group A. They will receive surgical treatment for claw nail by partial matrixectomy and removal of the osteophyte. They will be followed up postoperatively for 1 month, with baseline and evolutionary measurements. This group will allow to evaluate the effect of surgery on nail anatomy and symptomatology. At the end of the study, baseline and evolutionary measurements will be compared between groups to analyze the effect of surgical treatment.
89224438|NCT06266195||GRUPPO CIRROSI|32 soggetti uomini o donne, >18 anni con diagnosi di cirrosi epatica di differente eziologiA
89224439|NCT06266195||GRUPPO HCC|32 pazienti uomini o donne, con diagnosi di neoplasia primitiva del fegato
89224440|NCT06266169|Experimental|intervention|People undergoing IVF treatment with developed medical decisions support models
89224441|NCT06266169|No Intervention|control|People undergoing IVF treatment without developed medical decisions support models
89224442|NCT06266156||Firts Dental Visit|Dental anxiety level, heart rate and oxygen saturation of participants in first dental visit.
89224443|NCT06266156||Second dental visit|Dental anxiety level, heart rate and oxygen saturation of participants in second dental visit.
89224444|NCT06266143|Experimental|Experimental group|Y101D combined with Gemcitabine and Nab-Paclitaxel
89224445|NCT06266130|Other|Treatment Group|Digital Bonding Tray. Brackets will be bonded to each subject's teeth with a digital bonding tray.
89224446|NCT06266130|Active Comparator|Control Group|Direct bonding method. Brackets will be bonded to each subject's teeth by direct placement.
89224447|NCT06266104|Placebo Comparator|Dye Spray Chromoendoscopy|Patients undergoing surveillance with dye spray chromoendoscopy
89224448|NCT06266104|Active Comparator|TXI|Patients undergoing surveillance with TXI (Texture and Colour Enhancement Imaging)
89224449|NCT06266104|Active Comparator|LCI|Patients undergoing surveillance with LCI (Linked Colour Imaging )
89224450|NCT06266091|Experimental|M701 group|M701 will be administered via intra-peritoneal infusion following sufficient drainage of malignant ascites. The treatment regimen consists of a leading dose of 50μg on Day 1, followed by three infusions of the full dose of 400 μg M701 on Days 4, 11, and 18. If well tolerated, patients will continue to receive M701 infusions every 2 weeks as maintenance treatment. Additionally, these patients will receive systemic therapy as determined by the investigator.
89075856|NCT04319744||Assistants who have a habit of playing video|"Group I:Anesthesia assistants who have a habit of playing video games before Video game will be played for 5 days a day with 0.5 hours mobile phone (Pubg mobile) for those who have previous game experience.~Intubation training will be provided with video style.Within the scope of this training, 1-All participants will watch videos about Video style application.~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first~4-Responsible investigators will practice and show on the real patient.~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
89075857|NCT04319744||Assistants who do not have the habit of playing video|"Group II:Anesthesia assistants who do not have the habit of playing video games No video game will be played before intubation with video style for this group.~Intubation training will be provided with video style. Within the scope of this training, 1-All participants will watch videos about Video style application.~2-Verbal explanation will be made by the responsible and investigators of the study 3- All participants will practice on the model first~4-Responsible investigators will practice and show on the real patient.~5-Then all participants will perform the application on the real patient under the supervision of responsible and investigators.~Tracheal intubation time, success rate, number of interventions will be recorded by responsible and investigators."
89075858|NCT04206878||HIV-exposed infants (HEI) eligible for birth testing|All HEI live births born at, or presenting to, one of the 3 study sites, within 3 days of birth.
89075859|NCT01252238|Placebo Comparator|Valsartan and Aliskiren|Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
89075860|NCT01252238|Experimental|Aliskiren|
89075861|NCT01252238|Placebo Comparator|Placebo Group|Only taking Amlodipine
89075862|NCT01101477|Active Comparator|Titration by target effect site concentration (Cet) 0.5μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
89075863|NCT01101477|Active Comparator|Titration by Cet 0.2μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
89075864|NCT01101477|Active Comparator|Titration by Cet 0.1μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
89075865|NCT00624260|Active Comparator|2|Usual follow up : Pet-TDM for current indication (high isolated markers or before a metastasis curative resection)
89075866|NCT00624260|Experimental|1|Semi-annual systematic PET-TDM (M6, M12, M18, M24, M30 and M36 after initial surgery)
89075867|NCT04308213|Experimental|Bone Marrow aspirate|All the patients enrolled in the study will be treated with the bone marrow aspirate obtained with the Bone Marrow Cellution Kit.
89075868|NCT01251770|Experimental|half saline|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
88812796|NCT05315102|Experimental|Experimental group|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
89075869|NCT01251770|Active Comparator|third saline|Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
89075870|NCT01101321|Experimental|Reformulated OXY 80 mg (Totowa)|Reformulated OXY 80 mg (Totowa) x 1 dose
89075871|NCT01101321|Active Comparator|Reformulated OXY 80 mg (Wilson)|Reformulated OXY 80 mg (Wilson) x 1 dose
89075872|NCT04309929||Women with breast cancer|Female patients (age> 18yrs) in ASA class <4; candidate for a planned surgery for simple mastectomy, simple mastectomy with immediate reconstruction, mastectomy with sentinel node biopsy, modified radical mastectomy (unilateral or bilateral)
89075873|NCT01101165|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
89075874|NCT01101165|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
89075875|NCT01100853|Active Comparator|Extended release VIVITROL injection 380 mg, 24 weeks|Efficacy of 24 week course of Extended Release VIVITROL 380 mg with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
89075876|NCT01100853|Placebo Comparator|VIVITROL placebo injection, 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
89075877|NCT02881281|Other|Education|Education program
89075878|NCT02881281|Other|Control Group|no intervention
89075879|NCT00626067|Active Comparator|1 Fully functional monitoring device|Fully functional monitoring device
89075880|NCT00626067|Active Comparator|2 Partially functional monitoring device|Partially functional monitoring device
89075881|NCT00626067|Sham Comparator|3 Non-functional monitoring device|Non-functional monitoring device
89075882|NCT01100307|Experimental|pegaptanib sodium|
89075883|NCT01100307|Sham Comparator|sham injection|
89075884|NCT01100073||Patients with Parkinson's disease|Early and advanced Parkinson's disease patients
89075885|NCT01099917|Experimental|Maitake|This is a phase II trial examining hematopoietic response in MDS patients.
89075886|NCT02879097|Experimental|CBT124 arm|CBT124 plus carboplatin and paclitaxel
89075887|NCT02879097|Active Comparator|EU Sourced Avastin® arm|EU-sourced Avastin® plus carboplatin and paclitaxel
89075888|NCT05356845||PD group|
89075889|NCT05356845||Control group|
89075890|NCT04307901||Incomplete colonoscopy|Individuals referred to colon capsule endoscopy due to incomplete colonoscopy investigation.
89075891|NCT04307901||Colonoscopy general anesthesia|Individuals referred to colon capsule endoscopy as alternative to colonoscopy under general anesthesia.
89075892|NCT04307901||Colonoscopy declined|Individuals referred to colon capsule endoscopy after completion of bowel preparation for colonoscopy, but who have declined colonoscopy to be carried out.
89075893|NCT04307823|Active Comparator|Treadmill training group|Treadmill training according to American College of Sports Medicine's guidelines
89075894|NCT04307823|Experimental|Treadmill protocol and respiratory training group|Treadmill training, slow breathing training and incentive spirometry
89075895|NCT02880969|Experimental|Patient with end stage renal disease undergoing dialysis|
89075896|NCT01099215|Other|PVS-10200|Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.
89075897|NCT02878941|Other|Elbow Fracture|Patients with an intraarticular elbow fracture and/or dislocation. Synovial fluid from the injured elbow will be obtained during the subject's emergency department encounter by one of the Chief Residents or Attending surgeon as part of standard of care procedures for pain control-related injection and aspiration. Patients with an intraarticular elbow fracture and/or dislocation receive an intraarticular elbow injection with anesthetic (i.e. lidocaine or marcaine) to provide analgesia for elbow range of motion testing and orthopaedic reduction maneveuers as the current standard of care. The patients would be asked to consent for 2 elbow joint aspirations: 1.Aspiration of the injured elbow at time of surgical fracture fixation; 2.Aspiration of the uninjured elbow at time of surgical fracture fixation.
89075898|NCT02879019|Sham Comparator|Stretching exercise group|Patients will receive two session per week of stretching classes.
89075899|NCT02879019|Experimental|Walking training group|Patients will perform two walking sessions per week.
89075900|NCT05087745|Experimental|Tumor Infiltrating Lymphocytes|1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
89075901|NCT02878863|Experimental|Paeoniflorin + phosphatidylcholine or silymarin|Paeoniflorin tablets(600mg, tid)combination of phosphatidylcholine or silymarin
89075902|NCT02878863|Active Comparator|Phosphatidylcholine or silymarin|Phosphatidylcholine or silymarin
89075903|NCT02881125|Experimental|Treatment (paclitaxel, nortriptyline hydrochloride)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nortriptyline hydrochloride PO QD on days 1-7, BID on days 8-14, and TID on days 15-28 of course 1 and TID on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89075904|NCT02880657|Experimental|SODB®-physical training|This arm receives daily two capsules of SODB® 40mg containing 560 UI of superoxide dismutase, associated with standardized physical training
89075905|NCT02880657|Experimental|Placebo-physical training|This arm receives daily two capsules of Placebo containing excipients only, associated with standardized physical training
89075906|NCT01097655||HIV-infected Participants|"HIV-infected participants starting with Kaletra tablets.~Participants included 3 subgroups:~antiretroviral therapy (ART) treatment-naïve participants starting with Kaletra tablets~participants receiving their first protease inhibitor (PI)-containing regimen (apart from Kaletra) pretreated with any non nucleoside reverse transcriptase inhibitor (NNRTI)-containing or nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen~participants pretreated with a PI-containing regimen (apart from Kaletra)."
89075907|NCT02880735|Experimental|Non Invasive Ventilation.|"It will provide noninvasive mechanical ventilation with the following specifications:~Bilevel devices: Pressurized bilevel mode Spontaneous/Time. Interface: Facial mask Usage: During sleep Frequency: Daily Duration: Three months."
89075908|NCT02880813|Experimental|Gastric|gastric infusion
89075909|NCT02880813|Experimental|Duodenal|Duodenal infusion
89075910|NCT05354193||vasoplegic syndrome|Patients undergoing on-pump coronary artery bypass graft who develops vasoplegic syndrome 24 - 48 hours after surgery.
89075911|NCT05354193||control|Patients undergoing on-pump coronary artery bypass graft who does not develop vasoplegic syndrome.
89075912|NCT01107405|Active Comparator|Loteprednol etabonate base (QD)|Loteprednol etabonate ophthalmic base dosed once/day.
89075913|NCT01107405|Active Comparator|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base dosed two times/day
89075914|NCT01107405|Active Comparator|Loteprednol etabonate base (QID)|Loteprednol etabonate ophthalmic base dosed four times/day.
89075915|NCT01107405|Active Comparator|Loteprednol etabonate suspension (QID)|Loteprednol etabonate ophthalmic suspension dosed four times/day
89075916|NCT01107405|Placebo Comparator|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate, dosed either QD, BID, or QID
89075917|NCT01097577|Experimental|pregabalin|Oral Pregabalin 75 mg capsule twice daily administered prior to PRK and continued for 5 days
89075918|NCT01097577|Placebo Comparator|Placebo|Oral placebo capsule (Lactose) twice daily administered prior to PRK and continued for 5 days
89075919|NCT01097421||Patient with parkinsons disease|
89075920|NCT02878395||Crohn's disease|
88812797|NCT05315102|Sham Comparator|Control group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor.No spinal adjustment will be performed during any control intervention.
89075921|NCT04205877||Registry Group|All participants will have the same data collected at the same time points.
89075922|NCT01251614|Experimental|Adalimumab 0.4 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.4 mg/kg (up to a maximum of 20 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.4 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.4 mg/kg eow.
89075923|NCT01251614|Experimental|Adalimumab 0.8 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.8 mg/kg (up to a maximum of 40 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
89224451|NCT06266091|Active Comparator|Control group|Patients in the control group will undergo paracentesis on Day 1 and Day 18. If necessary, they may receive additional paracentesis during this period. Additionally, these patients will receive systemic therapy as determined by the investigator.
89224452|NCT06266078|Experimental|Innovative PPE|The healthcare workers will perform tasks using non-traditional personal protective equipments.
89224453|NCT06266078|Active Comparator|Traditional PPE|The healthcare workers will perform tasks using traditional personal protective equipments.
89224454|NCT06266052|Experimental|Group 1|triangular flep design will be use in third molar impacted surgery
89224455|NCT06266052|Experimental|Group 2|Berwick flep design will be use in third molar impacted surgery
89075924|NCT01251614|Active Comparator|Methotrexate|Participants received 0.1 mg/kg methotrexate at Baseline (Week 0), and up to 0.4 mg/kg weekly (maximum dose of 25 mg/week) in Period A. Participants also received adalimumab placebo as a single subcutaneous loading dose at Week 0, followed by every other week (eow) dosing from Week 1. Participants who were non-responders in period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
89075925|NCT01106625|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
89075926|NCT01106625|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
89075927|NCT01106625|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
89075928|NCT01251380|Experimental|Dysport|Dysport was injected into either one or both lower limbs in up to 4 cycles of treatment, a minimum of 12 weeks apart and up to a maximum of 40 weeks apart. Doses varied from 5 Units (U)/Kg to 20 U/kg for one leg, or from 10 U/Kg to 30 U/kg for two legs, with a maximum dose of no more than 30 U/Kg overall, or 1000 U, whichever was reached first.
89075929|NCT04307979|Experimental|Bulletproof Coffee|A black coffee (bullet proof coffee keurig pod) with 29 grams of added fat (1 tablespoon bullet proof brain octane medium chain triglyceride oil, and 1 tablespoon bullet proof grass fed ghee) blended for 20 seconds with butter scent that is added to the lid.
89075930|NCT04307979|Placebo Comparator|Black Coffee|Black coffee that is blended for 20 seconds with butter scent added to the top of the lid.
89075931|NCT04309539|Active Comparator|Fascia iliaca block|Patients will receive Fascia iliaca block
89075932|NCT04309539|Active Comparator|combined LFCN block with PENG block|Patients will receive a combined lateral femoral cutaneous nerve block with pericapsular nerve group block
89075933|NCT01251146|Experimental|Bisoprolol|
89075934|NCT01251146|Active Comparator|Atenolol|
89075935|NCT04309695|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
89075936|NCT04307745||Physiotherapist|
89075937|NCT04307745||Doctor|
89075938|NCT04307745||Physical trainer|
89075939|NCT04307745||Trainer|
89075940|NCT02888678|Experimental|ES + HIV Prevention|"Economic Strengthening + HIV prevention education combined intervention consists of 2 parts.~Impumelelo: This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.~Vhutshilo 2.2: . This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy."
89075941|NCT02888678|Experimental|ES only|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
89075942|NCT02888678|Experimental|HIV only|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
89075943|NCT02888678|No Intervention|No intervention (control)|The control group will not receive the ES or HIV prevention interventions. They will receive the basic package of services available to all beneficiaries of Future Families.
89075944|NCT00626145|Placebo Comparator|1|Patients receive intracoronary injections of saline 7 days after PCI.
89075945|NCT00626145|Experimental|2|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
89075946|NCT02878707|Experimental|DEX|Intraoperative intravenous infusion of dexmedetomidine
89075947|NCT02878707|Placebo Comparator|Control|Intraoperative intravenous infusion of 0.9% saline
89075948|NCT02878551|Experimental|Prehabilitation program|Multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
89224456|NCT06266052|Experimental|Group 3|Saurez flep design will be use in third molar impacted surgery
89224457|NCT06266052|Experimental|Group 4|Heitz
89075949|NCT02878317||Malnourished participants|"Presence of malnutrition will be assessed by using the Subjective Global Assessment.~Once the identified malnourished participants have given their informed consent, they will receive intensive dietitian supervised nutritional support with the aim of improving their malnutrition. In addition, participants will receive standard dietary advice for people on dialysis based on the Nutritional Guidelines in CKD published by the Renal Association in March 2010 in the UK (Wright and Jones, 2010) and will include the following: energy (35 kcal/kg/day) and protein intake (1.2 g/kg/day), as well as potassium, phosphate and sodium restriction, according with biochemical blood parameters."
89075950|NCT01096017|Experimental|1|Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler®
89075951|NCT01096017|Experimental|2|salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI
89075952|NCT00626223|Experimental|A|patients treated with intravenous 5-MTHF (Prefolic®, Knoll, Milan, Italy) 50 mg at the end of each hemodialysis session; The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week
89224458|NCT06266013|Experimental|intervention group|The EG (experimental group) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their MIP (Maximum Inspiratory Pressure) through a threshold valve device. The participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts.
89075953|NCT00626223|Active Comparator|B|"treated with 5 mg per day of oral folic acid (Folina® Schwarz Pharma, Milan, Italy).~The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week"
89075954|NCT04908111|Experimental|Safety Run In|Six evaluable patients will receive the trial vaccines with standard of care treatment to confirm they are safe before opening the next stage of the trial. These patients will not be randomised.
89075955|NCT04908111|Experimental|Arm A: Trial vaccines with standard of care treatment|Approximately 40 patients will be randomised to receive the trial vaccines with standard of care treatment in this arm.
89075956|NCT04908111|Other|Arm B: Standard of care treatment|Approximately 40 patients will be randomised to receive standard of care treatment alone in this arm.
89075957|NCT02880423|Other|salpingectomy group I|salpingectomy during cesarean section for sterilization
89075958|NCT02880423|Active Comparator|tubal ligation group II|tubal ligation in cesarean section
89075959|NCT04307199|Experimental|Group A|Membrane sweep @ 39 weeks' gestation only
89075960|NCT04307199|Experimental|Group B|Membrane sweep @ 40 weeks' gestation only
89075961|NCT04307199|Experimental|Group C|Membrane sweep @ 39, 40 and 41 weeks' gestation or until onset of labour
89075962|NCT04307199|Experimental|Group D|Membrane sweep @ 40 and 41 weeks' gestation or until onset of labour
89075963|NCT04307199|No Intervention|Control Group|Women in the control arm will not receive a membrane sweep and will receive usual care (as defined by local hospital protocols and vaginal examination to determine Bishop score only).
89075964|NCT01106157|Experimental|Anti-Thymocyte Globin plus pegylated GCSF|Subjects will receive an infusion of Anti-Thymocyte Globin (ATG) followed by 6 doses of pegylated GCSF every 2 weeks for 10 weeks.
89075965|NCT01106157|Placebo Comparator|Placebo|Saline infusion will be given on both Day 1 and Day 2 followed by placebo injection given in identical volumes in identical syringes in the identical subcutaneous manner
89075966|NCT01094301|Experimental|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
89075967|NCT04835571|Experimental|CARMA study participants|All patients in the study are in the same treatment arm: all were treated for 12 months according to routine care and international guidelines for cardiovascular disease prevention in patients with very high cardiovascular risk. Through study physicians patients received an individual assessment and optimized cardiovascular risk management, including life style advice and adjustments in their medical preventive treatment, based on drugs used in standard care (eg. lipid lowering medication, anti-hypertensive-treatment, anti-thrombotic treatment). All treatment goals were set in accordance with current guidelines at the time for study participation.
89075968|NCT04828005|Experimental|Intranasal Nalmefene|Nalmefene hydrochloride nasal spray, 3mg, 1 spray
89075969|NCT04828005|Active Comparator|Intranasal Naloxone|Naloxone hydrochloride nasal spray, 4mg, 1 spray
89075970|NCT04306887|Experimental|TQ-B3101|TQ-B3101 capsule administered orally.
89075971|NCT02877459|Experimental|AeriSeal System|Subjects will be treated with AeriSeal Foam.
89111188|NCT02792595|Experimental|Test Product B|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
88812798|NCT01550471|Experimental|1 Treatment Sequence-A and O, Q and B, P and P|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
89075972|NCT04306497||Cohort of western medicine|"Routine treatment：~① support treatment:maintain water and electrolyte balance .~②oxygen therapy: give nasal catheters to inhale oxygen.~③ basic treatment of traditional Chinese and western medicine: antiviral drugs and proprietary Chinese medicines with similar composition or function to the observed scheme of differentiation and treatment of traditional Chinese medicine are not included in the scope of such drugs.~Antiviral drugs ：Clinicians can judge according to the patient's condition according to the latest version of the diagnosis and treatment plan for COvID-19 issued by the General Office of the National Health Commission / the Office of the State Administration of traditional Chinese Medicine (currently the latest version is the sixth trial edition). Select any of the recommended antiviral drugs(for example:IFN-α、lopinavir-ritonavir、Ribavirin、Chloroquine Phosphate、Arbidol)or a combination of two antiviral drugs."
89224459|NCT06266013|No Intervention|control group|they will not receive any intervention. Just sit and wait the same amount of time that the intervention and the activation group needs to finish their protocol (around 10 minutes)
89075973|NCT04306497||Cohort of integrated TCM and western medicine|"routine treatment + Antiviral drugs + the following TCM regimens. 1.TCM regimens:① Early stage: Dampness trapped in exterior and interior. Recommended prescription: Huoxiang 15g, Suye15g, Cangzhu15g, Houpo10g, Qianhu15g, Chaihu15g, Huangqin10g, Qinghao20g, Xingren10g, JInyinhua15g, Lianqiao15g.~Take decocted or granule, one dose a day.~② Middle stage: Dampness-toxicity blocking lung Recommended prescription: Zhimahuang9g, Xingren10g, Sangbaipi30g, Tinglizi20g, Dongguazi20g, Fabanxia10g, Houpo10g, Suzi15g, Baijiezi10g, Gualoupi15g, Xuanfuhua9g, Xiangfu10g, Yujin10g, Taoren10g, Huangqi20g.~Take decocted or granule, one dose a day."
89075974|NCT02878161|Experimental|A group|Infliximab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
89075975|NCT02878161|Experimental|B group|Etanercept plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
89075976|NCT02878161|Experimental|C group|Adalimumab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
89075977|NCT02877069|Experimental|VYC-12 Injectable Gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection on Day 0 in the face and if applicable neck areas. Participants are eligible to receive up to 3 treatments including an optional top-up and an optional second treatment.
89075978|NCT02877225|Experimental|Treatment Sequence 1 : ABAB|Participants will receive 140 milligram (mg) of ibrutinib administered as one IMBRUVICA 140-mg oral capsule (Treatment A) in Period 1, 140 mg of ibrutinib administered as one ibrutinib 140-mg oral tablet (Treatment B) in Period 2, then Treatment A in period 3 and then followed by Treatment B in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
89075979|NCT02877225|Experimental|Treatment Sequence 2 : BABA|Participants will receive (Treatment B) Period 1, then Treatment A in Period 2, then Treatment B in Period 3 and then followed by Treatment A in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
89075980|NCT01093755|Active Comparator|dexlansoprazole|Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
89075981|NCT01093755|Active Comparator|omeprazole|Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
89075982|NCT01093599|Active Comparator|Quit Line Only|Control Participants will call the Wisconsin Tobacco Quit Line intervention including phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
89075983|NCT01093599|Active Comparator|Quit Line plus MTS|Participants in the study group will receive the Quit Line intervention (talk to a Quit Line Counselor, receive quit smoking materials and get 4 weeks of nicotine patches) and also receive 4 weeks of training in mindfulness meditation through the mindfulness for smokers intervention.
89075984|NCT01092663|Active Comparator|Colesevelam HCl: 3 tablets, 2x/day|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
89075985|NCT01092663|Active Comparator|Colesevelam plus Sitagliptin|"Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.~Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks."
89075986|NCT02877147|Experimental|$60 SEBTC Benefit Group|Households received $60 per summer month when school was not in session for each eligible child (Summers 2011-2013).
89075987|NCT02877147|Experimental|$30 SEBTC Benefit Group|Households received $30 per summer month when school was not in session for each eligible child (Summer 2013 only).
89075988|NCT02877147|No Intervention|No Intervention Group|Households with eligible children were not issued SEBTC benefits (Summers 2011 and 2012)
89075989|NCT01078623|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
89075990|NCT01078623|Placebo Comparator|Placebo|Placebo twice daily
89075991|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
89075992|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
89075993|NCT01078623|Experimental|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
89075994|NCT01092507|Experimental|JE-CV Group|Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV)
89075995|NCT01092507|Active Comparator|SA14-14-2 vaccine Group|Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®)
89075996|NCT05051397|Experimental|HYPERCAPNIA|Under general anesthesia with mechanical ventilation, PaCO2=50mmHg will be targeted
89075997|NCT05051397|Active Comparator|NORMOCAPNIA|Under general anesthesia with mechanical ventilation, PaCO2=40mmHg will be targeted
89075998|NCT02877381|Active Comparator|Single IV Dose|• 1 gram IV TXA administered at time of prepping and draping
89075999|NCT02877381|Active Comparator|Double Dose IV|"1 gram IV TXA administered at time of prepping and draping~1 gram IV TXA administered prior to tourniquet deflation"
89076000|NCT02877381|Active Comparator|IV + Topical|"1 gram IV TXA administered at time of prepping and draping~1 gram topical TXA injected intra-articular following closure of the arthrotomy"
89076001|NCT02877381|Active Comparator|Repeated Oral Dose|• Three 650 mg tablets of TXA administered two hours prior surgery with a second dose given 6 hours postoperatively and a final dose given the morning of postoperative day 1
89076002|NCT02878239||Early OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with early knee osteoarthritis because their Kellgren-Lawrence Scores were Grade I.
89076003|NCT02878239||Moderate OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade II.
89076004|NCT02878239||Severe OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade III/IV.
89076005|NCT02878239||Asymptomatic Participants|The asymptomatic participants（>35 years） has no history of knee pain, trauma, surgery, or obvious gait abnormalities. They are set as controls in the study.
89076006|NCT01078545||Adv. PCa patients with LUTS treated with GnRH analogue|Patients with advanced prostate cancer and lower urinary tract symptoms treated with GnRH analogue Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine)
89076007|NCT04301817||Prone position|Patients undergoing surgery in prone position
89076008|NCT01202760|Experimental|120 mg LY2127399|"LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.~During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.~After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
89076009|NCT01202760|Experimental|90 mg LY2127399|"LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.~After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
89076010|NCT01202760|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.~After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
89076011|NCT01091259|Experimental|Irinotecan with Bevacizumab|Irinotecan is administered every 3 weeks at a dose of 175 mg/m^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.
89076012|NCT04307043||postnatal age|
89076013|NCT04307043||General information and echocardiographic data|General information:(1)Record the gestational age, birth weight, length, delivery way, Apgar score, maternal pregnancy status, prenatal bleeding or not after admission.(2)PS use, ventilator mode, other illness and complications should be recorded during hospitalization. (3) Record the baby's heart rate, respiratory rate, blood pressure, body surface area on every check.
89076014|NCT05381844||HIV-1-infected, untreated|Patients recently diagnosed with chronic HIV-1-infection with detectable HIV-1 RNA in plasma, sampled before treatment initiation
89076015|NCT05381844||HIV-1-infected, undetectable viral load|Patients with chronic HIV-1 infection on antiretroviral treatment for less than a year, with a plasma HIV-1 RNA < 50 copies/ml plasma since at least 6 months
89076016|NCT01091103|Experimental|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.
89076017|NCT01078389|Experimental|Febuxostat 40 mg or 80 mg|Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
89076018|NCT01078389|Placebo Comparator|Placebo|Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
89076019|NCT01090323|Experimental|ICL670|
89224460|NCT06266013|Active Comparator|activation group|The activation group will perform the protocol of 2 sets of 30 repetitions at 15% of their MIP, one-on-one, and in a single session, breathing against submaximal inspiratory loads using a threshold valve device. The participants will follow a free pattern of breathing until complete the protocol.
89224461|NCT06266000|Experimental|Saw palmetto extract|Saw palmetto extract taken as 2 capsules per day
89076020|NCT01078155||Participants with Active Rheumatoid Arthritis (RA)|Participants (women and men) with active early and long-standing RA according to American College of Rheumatology revised criteria from 1987 were prescribed adalimumab in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines. The decision to prescribe or not to prescribe an anti-TNF was taken prior to a participant's enrollment in the study.
89076021|NCT00626301|Experimental|1|Children who have completed HIV-NAT 017. Children treated with other double boosted PIs such as indinavir plus lopinavir/ ritonavir are also included.
89076022|NCT02878005|Active Comparator|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
89076023|NCT02878005|Active Comparator|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
89076024|NCT00626457|Experimental|Maintenance First|
89076025|NCT00626457|Active Comparator|Weight Loss First|
89076026|NCT02876991|Other|Sodium fluoride PET|"Before inclusion, patients undergo choline PET to assess an occult recurrence of prostate cancer.~After inclusion, they undergo sodium fluoride PET."
89076027|NCT01201356|Experimental|Fingolimod 0.5 mg/day|Open-label fingolimod 0.5 mg, taken orally once daily
88812799|NCT01550471|Experimental|2 Treatment Sequence-A and O, P and P, Q and B|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
89076028|NCT04872153|Experimental|Intervention Group|The patients allocated to the intervention group will conduct simultaneously combined cognitive-motor training in form of exergames using the Dividat Senso in addition to the standard rehabilitation treatment plan. Both the Dividat Senso and the training games are specifically developed considering the needs and requirements of older adults but also clinicians/therapists.
89076029|NCT04872153|No Intervention|Control Group|The patients of the control group follow the standard rehabilitation treatment plan including: 3x 30min physiotherapy, 8x 30min group therapy, 3x 45min group therapy (group therapy includes body- focused therapy, mindfulness therapy, respiratory therapy, gymnastics, hiking etc.)
89076030|NCT00626535|Experimental|1|20mg once daily
89076031|NCT00626535|Placebo Comparator|2|Oral once daily
89076032|NCT05400642|Experimental|High Flow Oxygen Therapy|Surgery conducted under High Flow Oxygen Therapy
89076033|NCT05400642|Active Comparator|Mechanical ventilation|Surgery conducted under orotracheal intubation and mechanical ventilation
89076034|NCT01200810|Placebo Comparator|Arm I|"Patients receive oral placebo once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
89076035|NCT01200810|Experimental|Arm II|"Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
89076036|NCT01200342|Experimental|Genasense + Paclitaxel + Carboplatin|Genasense 900 mg intravenous (IV) on a fixed-dose as a 1-hour infusion on Days 1, 3, and 5 of a 21 day cycle; Paclitaxel 175 mg/m^2 IV over 3 hours Day 3 after Genasense; Carboplatin dose in mg (target area under the concentration [AUC)]=6) administered over 30 minutes IV Piggyback (IVPB) on Day 3 after Paclitaxel.
89076037|NCT01199016||1|
89076038|NCT01198548|Experimental|Treatment (FOLXFOX, bevacizumab, cholecalciferol)|Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
89076039|NCT01198470|Experimental|TRIUMPH® Artificial Disc|Treatment of degenerative disc disease with the TRIUMPH Lumbar Artificial Disc. This is a non-randomized pilot study with only one arm (no control).
89076040|NCT00977938|Placebo Comparator|12m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
89076041|NCT00977938|Active Comparator|30m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.
89076042|NCT02716675|Experimental|Group 1: Low-Dose VRC01|Participants will receive an intravenous (IV) infusion of 10 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
89076043|NCT02716675|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
89076044|NCT02716675|Placebo Comparator|Group 3: VRC01 Placebo|Participants will receive an IV infusion of placebo for VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
89076045|NCT00632515||Questionnaire|Patients with Colorectal Cancer and their First Degree Relatives (FDRs).
89076046|NCT04259203|Experimental|Erickson hypnosis|5 sessions of Erickson hypnosis (1 session per week), associated with autohypnosis at home in-between sessions.
89076047|NCT04259203|No Intervention|Usual care|Usual management of pain symptoms
89076048|NCT00977548|Experimental|Erlotinib Treatment|Erlotinib was given as an oral 150 mg daily dose for 16 weeks. The dose was adjusted for diarrhea, rash and pulmonary toxicity.
89076049|NCT04290208|Active Comparator|Intravenous Administration of Acetaminophen|A single peri-operative dose of acetaminophen 1000 mg IV over 15 minutes after skin is closed.
89076050|NCT04290208|Active Comparator|Per Oral Administration of Acetaminophen|A pre-operative liquid dose of acetaminophen 1000mg orally in the on-call to Operative Room.
89076051|NCT02865382|Active Comparator|Group A|white light was used for both insertion and withdrawal of the colonoscope
89076052|NCT02865382|Experimental|Group B|Insertion to cecum was performed under white light and once the cecum was reached,the OE mode was swithed on during withdrawal of endoscope for complete colonic examination
89076053|NCT01090011|Experimental|combination arm|patients to receive medium BIBW 2992 once daily plus biweekly cetuximab infusion at low, median and high dose level
89076054|NCT01090011|Experimental|sequential arm|patients to receive BIBW 2992 once daily, upon progression add biweekly cetuximab
89076055|NCT03206905|Experimental|Endoscopic Sleeve Gastroplasty|
89076056|NCT03206905|Active Comparator|Diet and exercise only.|
89076057|NCT04257331|Experimental|SREIA group|Participants in this arm will be families who attend the first wave of the two rounds of delivery. They will be the intervention group.
89076058|NCT04257331|No Intervention|Waitlist Control|Participants in this arm will be families who attend the second wave of the two rounds of delivery. They will be the control group.
89076059|NCT04242355|Active Comparator|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
89076060|NCT04242355|Placebo Comparator|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
89076061|NCT02877615|Experimental|S 44819 150 mg twice a day|
89076062|NCT02877615|Experimental|S 44819 300 mg twice a day|
89076063|NCT02877615|Placebo Comparator|Placebo|
89076064|NCT02437279|Active Comparator|Arm A|Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
89076065|NCT02437279|Active Comparator|Arm B|A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
89076066|NCT01251653||Afatinib and docetaxel|
89076067|NCT01251653||Afatinib and gemcitabine|
89076068|NCT00910663|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by Cellcept® 250 mg Capsule dosed in second period.
89076069|NCT00910663|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
89076070|NCT04306185|Experimental|OVARIAN FRAGMENTATION|Ovarian fragmentation through laparoscopy in patients who meet criteria ( Poor ovarian responders and poor ovarian reserve).
89076071|NCT01077375|Placebo Comparator|Placebo|Placebo tablets, twice a day, oral administration
89076072|NCT01077375|Experimental|Milnacipran|Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses.
89076073|NCT00624299|Experimental|Botox|Botox
89076074|NCT00624299|Placebo Comparator|Placebo|Saline injection
89076075|NCT02877849||Individuals with Alcohol Use Disorder|Individuals with Alcohol Use Disorder will be recruited from Lodging Plus treatment program (Fairview Riverside Hospital, Minneapolis, MN). All patients will have between 2-3 weeks of abstinence from alcohol use. We will collect brain imaging data, this is an observational study.
89076076|NCT02877849||Healthy Volunteers|Healthy volunteers with comparable age and gender to the patient group will be recruited through community advertisements. We will collect brain imaging data, this is an observational study.
89076077|NCT02877771|Experimental|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses CGM values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
89076078|NCT04306653|Experimental|ACTH|patients with acute gout treated with ACTH
89076079|NCT04306653|Active Comparator|Betamethasone|patients with acute gout treated with betamethasone
89076080|NCT04306731|Experimental|Interventional (Group M)|The group of patients given nanotechnology structured water magnalife
89076081|NCT04306731|Active Comparator|Control (Group T)|The group of patients given Trimethoprim
89076082|NCT04306731|Placebo Comparator|Placebo (Group O)|The group of patients given ordinary bottled drinking water
89076083|NCT02877537|Experimental|Asthma child|
89076084|NCT02877537|Experimental|Control adult|
89076085|NCT02877537|Experimental|Control child|
89076086|NCT01250873|Experimental|LY2216684/sertraline/LY2216684 + sertraline|"Period 1: LY2216684 18 milligram (mg) oral (po) dose on Days 1-3.~Period 2: Sertraline 50 mg po dose on Day 4 followed by sertraline 100 mg po dose on Days 5-10.~Period 3: LY2216684 18 mg po dose + sertraline 100 mg po dose on Days 11-13."
89076087|NCT01250171|Experimental|Secukinumab 10 mg/kg|Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period.
89076088|NCT01250171|Experimental|Canakinumab 10 mg/kg|Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period.
89076089|NCT01250171|Placebo Comparator|Placebo|Patients received a single placebo infusion intravenously over a 2 hour period.
89076090|NCT02888327|Other|Oseltamivir and AL-794|Oseltamivir alone and with AL-794 over fourteen days.
89076091|NCT02888327|Other|Digoxin, Midazolam, and AL-794|Single doses of Digoxin and Midazolam with and without AL-794 over seventeen days.
89076092|NCT02888327|Other|Pitavastatin and AL-794|Single doses of Pitavastatin with and without AL-794 over seventeen days.
89076093|NCT02888327|Other|JNJ-63623872 and AL-794|JNJ-63623872 alone and with AL-794 over fourteen days.
89076094|NCT01077063|Active Comparator|paracentesis|cutting and draining procedure for malignant ascites
89076095|NCT01077063|Active Comparator|Pleurx catheter|a catheter drainage system the subject uses himself/herself.
89076096|NCT01248065|Placebo Comparator|Ciclesonide + placebo|
89076097|NCT01248065|Experimental|Ciclesonide + Vitamin D|
89076098|NCT01250756|Experimental|1|Experimental
89076099|NCT01250756|Experimental|2|Active comparator
89076100|NCT01250054|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B multifocal contact lenses worn first, with comfilcon A multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
89076101|NCT01250054|Other|Comfilcon A /Lotrafilcon B|Comfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
89076102|NCT00977470|Experimental|Erlotinib|Erlotinib 150 mg oral daily
89076103|NCT00977470|Experimental|Erlotinib and Hydroxychloroquine|Erlotinib 150 mg oral daily plus Hydroxychloroquine (HCQ) 1000 mg oral daily
89076104|NCT04319666|Experimental|PCI to left main with IVL|
89076105|NCT04289896|Experimental|Experimental group|Each session will last 20 minutes, taking place 2 days a week, for a period of 4 weeks. Prior to the completion of the routine training of each team, the plyometric exercise program will be carried out in the experimental group. When the intervention ends, the members of the experimental group will perform the usual training
89076106|NCT04289896|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
89076107|NCT01245374|Experimental|Nordiflex Norditropin®|Individually adjusted dose administered with Norditropin NordiFlex® for 6 weeks. Dosage depended on age, weight, etiologies and according to the summary of product characteristics (SPC)
89076108|NCT02865304|Experimental|endostar; taxane|Endostar was administered at 7.5 mg/m2, d1-14, q21d and was continued until progressive disease, unacceptable toxicity, consent withdrawal, or completion of 24 months. In the same time,Taxane-based chemotherapy was continued until progressive disease, unacceptable toxicity, consent withdrawal, or up to 8 cycles.
89076109|NCT04289272|Experimental|Dove Confident Me|Dove Confident Me body image intervention to be delivered to students 1 lesson per week for 5 weeks (5 x 45 minute lessons).
89076110|NCT04289272|No Intervention|Control|Students receive lessons-as-usual.
89076111|NCT04075474|Experimental|silver diamine fluoride|38% silver diamine fluoride
89076112|NCT04075474|Active Comparator|sodium fluoride|5% sodium fluoride
89076113|NCT00977314|Experimental|SoundBite Hearing System|The objective of this study was to assess the safety and effectiveness of the SoundBite hearing system by Sonitus Medical and to support its intended use for the treatment of unilateral hearing loss. The SoundBite hearing system is a Bone Conduction Device (BCD) and is occasionally referred to as such in the protocol and within this report.
89076114|NCT02866396||Pregabalin patients|Same dose of preoperative pregabalin 1h after surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration (PACU if NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
89076115|NCT02866396||Naive patients|Pregabalin 150mg PO initiated 1h before surgery and associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
89076116|NCT01087203|Experimental|Tanezumab|
89076117|NCT01087203|Placebo Comparator|Placebo|
89076118|NCT02865226|Experimental|experimental group|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)
89076119|NCT02865226|Active Comparator|control group|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual)
89076120|NCT01246583|Experimental|Treatment Group A|
89076121|NCT01246583|Placebo Comparator|Treatment Group B|
89076122|NCT01246583|Experimental|Treatment Group C|
89076123|NCT01246583|Placebo Comparator|Treatment Group D|
89076124|NCT01084239|No Intervention|Standard of care|Subjects in this arm (50% of the total cohort) continued to receive standard non-invasive evaluation of acute chest pain symptoms in the emergency department - mostly comprising of, but not limited to - exercise treadmill test, stress test with imaging and stress echocardiography.
89076125|NCT01084239|Experimental|Cardiac CT|Subjects in this arm (50% of the total cohort) were randomized to receive a cardiac computed tomography scan as part of the initial evaluation of acute chest pain symptoms, upon presentation to the emergency department.
89076126|NCT01244906|Experimental|Reduced Intensity Allogeneic Stem Cell Transplantation|All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
89076127|NCT01080807|Experimental|150 mg/day armodafinil|
89076128|NCT01080807|Placebo Comparator|Matching placebo|
89076129|NCT01079949|Experimental|r-hLH + r-hFSH|
89076130|NCT01079949|Active Comparator|r-hFSH|
89076131|NCT04306263|Experimental|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics (Human milk oligosaccharide, Glucooligosaccharides) and probiotics.
89076132|NCT04306263|Active Comparator|Standard formula|Infants receiving a standard infant formula.
88812800|NCT01550471|Experimental|3 Treatment Sequence-Q and B, A and O, P and P|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
88812801|NCT01550471|Experimental|4 Treatment Sequence-Q and B, P and P, A and O|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
89076133|NCT04306263|Active Comparator|Breastfeeding arm|Infants exclusively or predominantly breastfed (>75%).
89076134|NCT00909727|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
89076135|NCT00909727|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
89076136|NCT00977080|Active Comparator|IV Paricalcitol|Participants in the IV stratum received intravenous (IV) paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at 0.07 mcg/kg with titration every 2 weeks.
89076137|NCT00977080|Active Comparator|Cinacalcet (at sites with IV paricalcitol)|Participants in the IV stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (doxercalciferol IV 1 mcg 3 times weekly (TIW) at sites in the US and alfacalcidol capsules 0.25 mcg daily at sites in Russia).
89076138|NCT00977080|Active Comparator|Oral paricalcitol|Participants in the oral stratum received oral paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at mcg = IPTH/60 3 times weekly (TIW) with titration every 2 weeks.
89076139|NCT00977080|Active Comparator|Cinacalcet (at sites with oral paricalcitol)|Participants in the oral stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (alfacalcidol capsules 0.25 mcg daily).
89076140|NCT04098055|Experimental|Custom-made foot orthoses|
89076141|NCT04098055|Placebo Comparator|Control Group|
89076142|NCT05581381|Experimental|Interventional empathy training program|Provide empathy training for the experimental group for a total of 8 weeks (1 time a week, 1 hour each time).In the 8th week, both the experimental group and the control group must fill in the ECRS Empathy Scale; the experimental group must fill in the Learning Satisfaction Scale
89076143|NCT05581381|No Intervention|No intervention empathy training program|The control group did not offer empathy training.In the 8th week, both the experimental group and the control group must fill in the ECRS Empathy Scale.
89076144|NCT03873649||Patients with subacute or chronic hypersensitivity pneumonitis|"Procedures that each subject will undergo include:~Chest CT scan to determine extent of disease.~Pulmonary function testing to determine severity of disease.~Bronchoscopy with lavage.~Venipuncture."
89224462|NCT06266000|Active Comparator|Comparator saw palmetto extract|Commercial saw palmetto extract taken as 2 capsules per day
89224463|NCT06266000|Placebo Comparator|Placebo|Palm oil taken as 2 capsules per day
89224464|NCT06265961|Active Comparator|Education group|Among the nurses who meet the inclusion criteria (N = 30), 15 nurses will be assigned to the education group after the randomization process at the beginning of the study.
89076145|NCT03873649||Healthy Controls|"Inclusion:~Adult between the ages of 18 and 80 years old.~Non-smoker or previous smoker quit >6months ago.~Able to understand the consent process and procedures involved in the study.~Exclusion:~Unable to understand the consent process or procedures involved in the study.~Pregnancy.~Suspicion of current infection or within the past 3 months.~Bleeding disorder or on anti-coagulants other than aspirin.~Any co-morbid condition that increases risk of bronchoscopy including but not limited to cardiac disease, uncontrolled hypertension, uncontrolled diabetes and/or morbid obesity."
89076146|NCT00975676|Experimental|Triptorelin plus tamoxifen|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.
89076147|NCT00975676|Experimental|Triptorelin plus exemestane|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.
89076148|NCT03770221|Experimental|Financial Incentive|"Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.~Additionally, participants in this arm will receive $20 for every week they maintain contact with CATCH service providers, as required by their care plan. Contact can be by phone, text, email, or in person with CATCH service providers over 6 months of follow up, or until they are successfully transitioned to longer-term supports (for up to $80/month per participant)."
89076149|NCT03770221|Active Comparator|Usual Care|Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.
89076150|NCT03766087|Experimental|surgery group|Decompressive craniectomy associated with optimal medical management of intracranial pressure.
89076151|NCT03766087|No Intervention|conservative group|Optimal medical management of intracranial pressure only.
89076152|NCT02866240|Experimental|Single arm|Cathodal Transcranial Direct Current Stimulation (tDCS)
88812802|NCT01550471|Experimental|5 Treatment Sequence-P and P, A and O, Q and B|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
89076153|NCT02866318||Novice practitioners|Residents in Emergency department who has no experiences of echocardiography prior to the study.
89076154|NCT02865148|Experimental|Cognitive behavioral therapy (CBT) group|Participants will receive 4 sessions that lasts approximately 50 mins. The sessions will teach patients to manage their symptoms.
89076155|NCT02865148|No Intervention|Waitlist control (WLC) group|The WLC group receives standard usual care before being offered the same CBT protocol and assessment thereafter.
89076156|NCT00629434|Experimental|1|This arm will receive diabetes education via telemedicine
89076157|NCT00629434|Active Comparator|2|diabetes education in-person
89076158|NCT03935854|Experimental|Ketogenic Diet 16 Week Group|Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support
89076159|NCT04289584|Experimental|Experimental group|Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session. Prior to training, strength and proprioception exercises will be performed.
89076160|NCT04289584|No Intervention|Control group|The players included in the control group will follow their usual routine prior to their Taekwondo training.
89076161|NCT03857191||Patients already treated for OSA|The first group involves patients already diagnosed and treated for sleep apnea that will follow the nutritional psychocomportemental rehabilitation
89076162|NCT03857191||Patients with a high OSA risk|This group concerns patients with a high OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
89076163|NCT03857191||Patients with a low OSA risk|This group concerns patients with a low OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
89076164|NCT04289818|No Intervention|Control|Conventional Education Class
89076165|NCT04289818|Experimental|Coaching|Health Coaching
89076166|NCT03812809|Experimental|BPI-7711|BPI-7711: 180mg, QD, oral
89076167|NCT04083157|Experimental|Intradermal hepatitis B vaccine with imiquimod|Subjects in the study arm will receive 20 mcg intradermal Engerix-B at two separate sites (10 mcg/0.5 ml) with topical imiquimod ointment pre-treatment 5 minutes before injection.
89076168|NCT04083157|Active Comparator|Intramuscular hepatitis B vaccine with aqueous cream|Subjects in the control arm will receive 20 mcg intramuscular Engerix-B at two separate sites (10 mcg/ 0.5 ml) with topical placebo aqueous cream pretreatment 5 minutes before injection.
89076169|NCT05522101|Experimental|Mini-sized MCE|AKES-31SW Capsule Endoscopy
89076170|NCT05522101|Placebo Comparator|Normal sized CE|PillCam Capsule Endoscopy
89076171|NCT00975286|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
89076172|NCT00975286|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
89076173|NCT00907777|Experimental|Pn Group|Subjects receiving GSK 1024850A vaccine.
89076174|NCT00907777|Active Comparator|Prev Group|Subjects receiving Prevenar™ vaccine.
89076175|NCT02866084|Experimental|Device|Neuromodulation
89076176|NCT02865772||observational|healthy newborns
89076177|NCT00908011|Active Comparator|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
89076178|NCT00908011|Active Comparator|Standard Care|Increased dose of rosuvastatin to 20mg/day
89076179|NCT02864836||Patients with head or neck cancer|Samples collection
89076180|NCT02864836||Patients with lymphoma|Samples collection
89076181|NCT02864836||Patients without tumoral pathology|Samples collection
89076182|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed|Bevacizumab + Pemetrexed
89076183|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab + Pemetrexed + Carboplatin
89076184|NCT01243151|Placebo Comparator|A|
89076185|NCT01243151|Experimental|B|
89076186|NCT01243151|Experimental|C|
89076187|NCT01243151|Experimental|D|
89076188|NCT01243151|Experimental|E|
89076189|NCT00629512|Experimental|1|20mg oral daily
89076190|NCT00629512|Experimental|2|40mg oral daily
89076191|NCT00629512|Placebo Comparator|3|
89076192|NCT01711021|Active Comparator|d-Amphetamine Transdermal patch|"The study was conducted in 2 parts: a 5-week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Subjects who reached the optimal dose by end of dose optimization treatment period were randomized to receive double-blind treatment.~Participants first received study patches everyday for one week, then subjects were crossed-over to receive the placebo treatment.~d-Amphetamine Transdermal System: Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
89224465|NCT06265961|Active Comparator|Bibliotherapy group|Among the nurses who meet the inclusion criteria (N = 30), 15 nurses will be assigned to the bibliotherapy group after the randomization process at the beginning of the study.
89076193|NCT01711021|Placebo Comparator|Placebo patch|"The study was conducted in 2 parts: a 5-week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Subjects who reached the optimal dose by end of dose optimization treatment period were randomized to receive double-blind treatment.~Participants first received placebo patches everyday for one week, then subjects were crossed-over to receive the study treatment.~Placebo patch: Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
89076194|NCT02864680|Other|Cannabis users|
89076195|NCT02864680|Other|Healthy volunteers, not cannabis/tobacco users|
89076196|NCT02864680|Other|Healthy volunteers, tobacco users|
89076197|NCT02864680|Other|Schizophrenia patients|
89076198|NCT02864602|Experimental|Dexamethasone 2mg|The experimental intervention in this arm will be an IV infusion of 2mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
89076199|NCT02864602|Experimental|Dexamethasone 4mg|The experimental intervention in this arm will be an IV infusion of 4mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
89076200|NCT02864602|Experimental|Dexamethasone 8mg|The experimental intervention in this arm will be an IV infusion of 8mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
89076201|NCT03788083|Placebo Comparator|placebo|
89076202|NCT03788083|Active Comparator|TriMix|
89076203|NCT04289506||Community-acquired pneumonia (Sepsis)|Community-acquired pneumonia with organ dysfunction
89076204|NCT04289506||Abdominal sepsis|Abdominal infection due to peritoneal soiling, biliary infection, urinary tract infection leading to organ dysfunction
89076205|NCT04289506||Infection of unknown origin (Sepsis)|Infection of unknown origin of less than 72 hours duration, including bacteraemia with organ dysfunction
89076206|NCT04289506||Organ dysfunction related to non-infectious cause (SIRS)|Patients admitted to the ICU following out-of hospital cardiac arrest OR Patients admitted to the ICU following major trauma (ISS>12) OR Patients admitted to the ICU following pancreatitis with organ dysfunction
89076207|NCT04289506||Healthy volunteers|Healthy volunteers
89076208|NCT00993148|Experimental|Maraviroc plus darunavir/ritonavir|Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks
89076209|NCT03775369|Active Comparator|Endurance training|"Endurance Training (warm-up; endurance on bike; brisk walking; cooling down; group sessions; supervised; moderate and individualized exercising load):~6 weeks, 2 sessions/week, 40-60min/session"
89076210|NCT03775369|Active Comparator|Resistance training|"Resistance Training (warm-up; resistance training units; cooling down; group sessions; supervised; moderate and individualized exercising load):~6 weeks, 2 sessions/week, 40-60min/session"
89076211|NCT03775369|Active Comparator|Control condition|"Control condition (individualized counselling, but not intended as a bona fide intervention, that is to say: not intended to actively improve participants' well-being):~6 weeks, social support and counseling,1-2 sessions/week; 30 min/session"
89076212|NCT03661177|Experimental|Diet intervention|
89076213|NCT03661177|No Intervention|Control|
89076214|NCT05505955|Experimental|Part 1|single ascending dose, randomized, double-blind study，with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions. The food impact study consisted of 10 subjects, 8 of whom received HRS-5965 tablets and 2 of whom received placebo. The remaining cohorts required 8 subjects each, with 6 receiving HRS-5965 tablets and 2 receiving placebo.
89076215|NCT05505955|Experimental|Part 2|Multiple ascending dose, randomized, double-blind study，with 4 dose groups preset; Each dose group consisted of 8 healthy adult subjects randomly assigned 6:2 to HRS-5965 tablets or placebo.
89076216|NCT05505955|Experimental|Part 3|an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function. Subjects took HRS5965 tablets.
89076217|NCT00907621|Experimental|Acupuncture|"Acupuncture with Seirin 020x15 mm sterile acupuncture needle:~Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36 on infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks."
89076218|NCT00907621|No Intervention|Control|"Infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks.~The Control group will have no intervention."
89076219|NCT03601117|Experimental|Dorsolateral Prefrontal Cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC), for 10 sessions per day for up to 5 days.
89076220|NCT03601117|Experimental|Anterior Cingulate Cortex|The accelerated theta burst stimulation protocol will be applied to the left anterior cingulate cortex (ACC), for 10 sessions per day for up to 5 days.
89230051|NCT00385684|Experimental|A1: hydrocodone/APAP w placebo PRN|This is a fully crossed study, each participant serves as his own control. Phase A (closed label) has two arms: A1 is the experimental and A2 is the placebo comparator. Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
89076221|NCT03587233|Active Comparator|Women with higher professional status|"Women with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
89076222|NCT03587233|Active Comparator|Women with lower professional status|"Women with lower professional status in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
89076223|NCT03587233|Active Comparator|Men with higher professional status|"Men with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
89076224|NCT03587233|Active Comparator|Men with lower professional status|"Men with lower professional status working in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form' and the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
89076225|NCT03581695||Pulmonary Hypertension and Congenital Heart Disease|Pulmonary Hypertension and Congenital Heart Disease
89076226|NCT03581695||Congenital Heart Disease|Congenital Heart Disease
89076227|NCT03581695||Healthy Controls|Healthy Controls
89076228|NCT03517111|Experimental|Nutrition/substance use prevention|Parenting and nutrition curriculum targeting substance use prevention and diet improvement.
89076229|NCT03517111|Active Comparator|Substance use prevention only|Parenting curriculum targeting substance use prevention only.
89076230|NCT03517111|Sham Comparator|Academic success program|Control program focused only on academic success.
89076231|NCT00907153|Experimental|Vitamin D|
89076232|NCT00907153|Placebo Comparator|Placebo|
89076233|NCT03984799|Experimental|Bronchoscopy|Research bronchoscopy
89076234|NCT00904033|Active Comparator|Multivitamin|Multivitamin used as control group.
89076235|NCT00904033|Experimental|Exercise|Exercise consisting of progressive walking and resistance band training.
89076236|NCT00904033|Experimental|Calcitriol|Calcitriol pill taken once per week.
89076237|NCT00904033|Experimental|Calcitriol and Exercise|Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.
89076238|NCT05175625|Experimental|SpikoGen COVID-19 Vaccine|
89076239|NCT05175625|Placebo Comparator|Saline Placebo|
89076240|NCT02647177||Pancreatic Cyst Group|Only the eligible participant in the study are considered for inclusion in this group.
89076241|NCT00903877|Experimental|Placebo followed by T3|Participants receive placebo for 4 weeks. Following placebo, participants begin T3 treatment at 25 mcg per day, for 4 weeks. Following this, participants begin T3 treatment at 50 mcg per day, for 4 more weeks.
89076242|NCT00632593|Active Comparator|Circular Stapled|Patients operated performing the gastric pouch of the gastric bypass with a circular staple device
89076243|NCT00632593|Active Comparator|Handsewn anastomosis|Patients operated performing the gastric pouch of the gastric bypass in a handsewn manner
89076244|NCT03353389||No AKI|Adult admissions without Acute Kidney Injury during their stay
89076245|NCT03353389||CA-AKI|Adult admissions with Acute Kidney Injury diagnosed within 48 hours during their stay (Community-acquired Acute Kidney Injury)
89076246|NCT03353389||HA-AKI|Adult admissions with Acute Kidney Injury diagnosed after 48 hours during their stay (Hospital-acquired Acute Kidney Injury)
89076247|NCT05332249||Lumbar|Patients undergo lumbar spinal surgery for degenerative lumbar spinal disease.
89076248|NCT05332249||Cervical|Patients undergo cervical spinal surgery for degenerative cervical spinal disease.
89076249|NCT01241591|Experimental|CP 690,550 5 mg BID+Placebo BIW|
89076250|NCT01241591|Experimental|CP 690,550 10 mg BID+Placebo BIW|
89076251|NCT01241591|Active Comparator|Placebo BID+Etanercept 50 mg BIW|
89076252|NCT01241591|Placebo Comparator|Placebo BID+Placebo BIW|
89076253|NCT02513251||Case group|Chronic pain patient
89076254|NCT05332171|No Intervention|physical activity counseling|Home exercises will be taught to the physical activity counseling group and will be followed up under the supervision of a physiotherapist with weekly controls. Evaluation will be done before and after treatment.
89076255|NCT05332171|Active Comparator|training group|Breathing exercises and calisthenic exercises will be taught to the training group, and they will be followed under the supervision of a physiotherapist for 8 weeks, 3 days a week. Evaluations will be made before and after treatment. Individuals in the calisthenic exercise group will be given exercise training at the level of 65%-80% of the maximal heart rate for 30-40 minutes, 3 days a week for 8 weeks.
89076256|NCT03315247|No Intervention|Treatment as Usual|Participants assigned to the Treatment as Usual group will attend routine clinic visits at the Toronto Western Hospital Bariatrics Surgery Program (TWH-BSP). These visits generally include education on bariatric surgery and nutrition. Patients meet with select members of the multidisciplinary team at 1, 2, and 3 years post-surgery, and may attend an optional monthly support group. Participants' service utilization (i.e., attendance at optional sessions) will be documented and compared across groups.
89076257|NCT03315247|Experimental|Telephone-Based CBT|"The Tele-CBT intervention will be delivered 1 year following bariatric surgery. Participants will receive 6 weekly Telephone-based Cognitive Behavioural Therapy sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration and scheduled at a time convenient for the participants."
89076258|NCT04319705|Experimental|Azithromycin|Azithromycin, 500mg capsule, 3 times per week, during a 12-week period, administered orally
89076259|NCT04319705|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP, capsule, 3 times per week, during a 12-week period, administered orally
89076260|NCT04319393|Experimental|CBT Nurses|Interventional group
89076261|NCT04319393|No Intervention|Consultation Nurses|Control Group
89076262|NCT00906373|Active Comparator|Cohort 1, IMC A12 - 10 mg/kg|Treatment cycles will repeat until there is evidence of progressive disease (PD), toxicity, or withdrawal. If any participant experiences a dose-limiting toxicity (DLT), an additional 3 participants will be enrolled at this dose level (for a total of 6). If no further DLTs, enrollment into Cohort 2 will occur.
89076263|NCT00906373|Active Comparator|Cohort 2, IMC A12 20 - mg/kg|Treatment cycles will repeat until there is evidence of PD, toxicity, or withdrawal.
89076264|NCT02850445|Experimental|Integrated Treatment|
89076265|NCT02850445|Active Comparator|antipsychotic medication alone treatment|
89076266|NCT02850211|Experimental|Celecoxib|1 capsule of 200mg Celebrex twice a day for 14 days
89076267|NCT02850211|Active Comparator|Traditional NSAIDs|1 tablet of 385mg Ibuprofen twice a day for 14 days
89076268|NCT02850211|Active Comparator|Opioid drug|1 tablet of 50mg Tramadol twice a day for 14 days
89076269|NCT02850289||Pegylated Interferon (PEG-IFN) alfa-2a and Ribavirin|Participants with hepatitis C who were to be treated with combination of pegylated interferon (PEG-IFN) alfa-2a and ribavirin, within 7 days of baseline, with ongoing management at investigator's discretion.
89076270|NCT02393521|Experimental|Vibration group|Patients in the vibration therapy group received 10 self-administered sessions of vibration therapy (45-50 Hz), one session per day, remaining on their Shindo® vibration mattress at home in supine for 15 min.
89076271|NCT02393521|No Intervention|Control group|Subjects in the control group did not receive vibration therapy
89076272|NCT05176171|Experimental|Photorefractive Keratectomy with Corneal Cross-Linking|For correction of refractive error
89076273|NCT04984057|Experimental|PS is stopped when the pressure is equal between bPDA and aPDA|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
89076274|NCT04984057|Active Comparator|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
89076275|NCT03204409||Symptomatic adults|adult patients (>18 years) presenting with febrile or rash illness of short duration (<72h)
89076276|NCT05331781|Experimental|transversus abdominis plain block group|post-cesarean section tap block will be given by ultrasound guidance using 20 ml bupivacaine local anesthetic 0.25% concentration for each side as an adjuvant to spinal anesthesia
89076277|NCT05331781|Experimental|intrathecal morphia group|intrathecal 150 microgram morphine in a 0.5 ml volume as an adjuvant to spinal anesthesia
89076278|NCT04202887|Active Comparator|Low Fentanyl (LF)|fentanyl cumulative dose below 100mcg
89076279|NCT04202887|Active Comparator|High Fentanyl (HF)|fentanyl cumulative dose above 100mcg
89076280|NCT05331703|Experimental|group A|will receive a designed physical therapy program in addition to program of virtual reality
89076281|NCT05331703|Experimental|group B|will receive a designed physical therapy program in addition to program of mirror therapy.
89076282|NCT02850367|Active Comparator|Acute intake|Evaluation after acute intake of the food supplement.
89076283|NCT02850367|Active Comparator|Chronic intake|Evaluation before and after chronic intake of the food supplement.
89076284|NCT02850523|Experimental|Experimental|After an initial assessment, the experimental group will receive 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety (n=6 per group) for perinatal anxiety. They will then be re-assessed at post-treatment and 3 months post-treatment to determine the effectiveness of the treatment and whether these effects are maintained 3 months after treatment.
89076285|NCT02850523|No Intervention|Waitlist Control|After an initial assessment, the wait-list control group will not receive any treatment for 6 weeks. They will then be re-assessed after 6 weeks and this data will be used to compare this group to the experimental group to determine the effectiveness of the treatment. After this re-assessment they will be offered the same treatment as the experimental group: 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety
89076286|NCT05117203|Experimental|WB-EMS group|
89076287|NCT05117203|Experimental|EMS group|
89076288|NCT05117203|Sham Comparator|Control group|
89076289|NCT05331001||Medical doctors|Medical doctors who are employed as permanent staff in a cardiac arrest center which provides extracorporeal membrane oxygenation.
89076290|NCT05331001||Nurses|Nurses who are employed as permanent staff in a cardiac arrest center which provides extracorporeal membrane oxygenation.
89076291|NCT05324215|Active Comparator|Transversalis Fascia Plane Block and Rectus Sheath Block Group|Transversalis Fascia Plane Block and Rectus Sheath Block will be administered to this group.
89076292|NCT05324215|Sham Comparator|Control Group|No regional anesthesia technique will be applied to the control group.
89076293|NCT05070559|Experimental|Active Release Technique Group|Patients in this group will receive Active Release Technique along with conventional therapy
89076294|NCT05070559|Experimental|Graston Technique Group|Patients in this group will receive Instrumental Assisted Soft Tissue Mobilization along with conventional therapy
89076295|NCT02850133|Experimental|Spinal cord injury|Cardio-pulmonary exercise testing and aerobic exercise training
89076296|NCT04202419|Experimental|Single Group|Single Arm: All subjects will undergo treatment of pigmented lesions with a 1940 nm diode laser
89076297|NCT02849821|Other|hypobaric pressure chamber|The healthy volunteers and IBD patients will have a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Before and after the pressure chamber sigmoidoscopy will be performed. During stay in the pressure chamber repetitive measurements of bladder volume will be performed by sonography.
89076298|NCT04202575|No Intervention|conventional setup|Blood and gas from the coronary and cardiotomy suction devices is continuously evacuated via the additional reservoir to the standard reservoir.
89076299|NCT04202575|Experimental|Intervention setup|The connecting tube between the additional and standard venous reservoir is clamped. Thus, blood and gas from the coronary and cardiotomy suction devices are collected in the additional venous reservoir. During the intervention setup, the blood in the additional venous reservoir is only evacuated to the standard reservoir if the volume exceeded 800ml, and always with a remaining volume of 100 mL blood to keep the CO2-gas trapped in the additional venous reservoir.
89076300|NCT00905437|Placebo Comparator|Placebo|Placebo as an adjunct to standard of care
89076301|NCT00905437|Active Comparator|Pregabalin|Pregabalin as an adjunct to standard of care
89076302|NCT05081947|Other|Heart failure patients|patients will try the Compass intervention
89076303|NCT05007691|Experimental|Occlusal splints|"In a clinical setting, participants test the closure of the occlusal splint with the antagonistic dentition.~Only one of the two occlusal splints (mandibular splint and maxillary splint) is used at a time. Occlusal splints are applied separately and alternately."
89076304|NCT01238861|Placebo Comparator|Eosinophilic phenotype (EOS+) Placebo|EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent] positive and/or FeNO [fraction of exhaled nitric oxide] greater than or equal to [>=] 50 parts per billion [ppb]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
89076305|NCT01238861|Experimental|EOS+ Benralizumab (2 mg)|EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
89076306|NCT01238861|Experimental|EOS+ Benralizumab (20 mg)|EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
89076307|NCT01238861|Experimental|EOS+ Benralizumab (100 mg)|EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
89076308|NCT01238861|Placebo Comparator|Non-eosinophil phenotype (EOS-) Placebo|EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
89076309|NCT01238861|Experimental|EOS- Benralizumab (100 mg)|EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
89076310|NCT04319549|Experimental|group 1 ketorolac tromethamine irrigant|group 1 patients with acute irreversible pulpitis with apical periodontitis
89076311|NCT04319549|Active Comparator|group 2 sodium hypochlorite irrigant|group 2 patients with acute irreversible pulpitis with apical periodontitis
89076312|NCT00903409|Experimental|"Simvastatin + Lovaza® (Non-switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + Lovaza® in the double-blind trial, hence in this open-label extension, they are termed Non-switchers"
89076313|NCT00903409|Experimental|"Simvastatin + Lovaza® (Switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + placebo in the double-blind trial, hence in this open-label extension, they are termed Switchers"
89076314|NCT02850055|Experimental|Specific Manual Therapy Group|Conventional Physiotherapy and Specific manual therapy, six one hour treatment sessions. An hour for week.
89076315|NCT02850055|Active Comparator|Multimodal Group|Conventional Physiotherapy, six one hour treatment sessions. An hour for week.
89076316|NCT02849665|Experimental|Kangaroo Position|The newborn remains in a vertical position, with limbs flexed, dressed in light clothes, maintaining skin-to-skin contact and the face on the adult's thorax.
89076317|NCT02849665|No Intervention|Not Kangaroo Position|The newborns will be not placed in the position Kangaroo.
89076318|NCT01237223|Placebo Comparator|Placebo|In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.
89076319|NCT01237223|Active Comparator|Aliskiren 150 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
89076320|NCT01237223|Active Comparator|Amlodipine 2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
89076321|NCT01237223|Active Comparator|Amlodipine 5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
89076322|NCT01237223|Experimental|Aliskiren/amlodipine 150/2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."
89076323|NCT01237223|Experimental|Aliskiren/amlodipine 150/5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
89076324|NCT01236755|Experimental|ortho-k lenses|Children were switched to wear ortho-k lenses for 7 months after wearing single-vision glasses for 7 months
89076325|NCT01236365|Experimental|Atorvastatin|
89076326|NCT01236365|Placebo Comparator|Placebo|
89076327|NCT01235975|Experimental|Group A|
89076328|NCT01235975|Active Comparator|Group B|
89076329|NCT00903331|Experimental|ACT-064922|ACT-064922 tablet (macitentan), 10 mg, once daily
89076330|NCT00903331|Placebo Comparator|Placebo|Matching placebo, once daily
89076331|NCT02849431|Experimental|Mindfulness-based intervention|
89076332|NCT01235741|Experimental|Group A|Pramlintide+Metreleptin
89076333|NCT01235741|Placebo Comparator|Group B|Placebo
89076334|NCT02849353|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89076335|NCT02849353|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89076336|NCT04206527|Experimental|Intervention - Women|Women who receive enhanced FP counseling from an ASHA
89076337|NCT04206527|No Intervention|Control - Women|Women who receive standard FP counseling from an ASHA
89076338|NCT04206527|Experimental|Intervention - ASHA|ASHA who receive enhanced FP counseling training
89076339|NCT04206527|No Intervention|Control ASHA|ASHA who receive standard FP training
89076340|NCT04571827|Experimental|Placebo Effect|"Group with positive expectation: it is a very effective technique that achieves excellent results in the improvement of the cervical musculature~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
89076341|NCT04571827|Experimental|Nocebo Effect|"Group with negative expectation: this is a technique that will cause discomfort in the area of intervention of the cervical muscles after applying it .~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
89076342|NCT04571827|Experimental|Neutral Effect|"Group with neutral expectations: It's a physical therapy technique used to treat neck pain and we're investigating its effects~Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced."
89076343|NCT01235507|Experimental|Single Arm|
89076344|NCT01933477|No Intervention|Local Standard of Care|Arm A: Referral of post-partum women from the antenatal clinic to general adult ART services at approximately 4-8 weeks postpartum (the local current standard of care in this setting)
89076345|NCT01933477|Active Comparator|MCH-focused ART services|Arm B: Continued receipt of MCH-focused ART services based at the antenatal clinic throughout the period of breastfeeding. Post-partum women will only be referred to general adult ART services after the end of breastfeeding and once infants' final HIV status is determined.
89076346|NCT01235351|Active Comparator|Clopidogrel - for CYP2C19*2 carriers|Clopidogrel for CYP2C19*2 gene carriers
89076347|NCT01235351|Active Comparator|Clopidogrel - for CYP2C19*2 non-carriers|Clopidogrel for CYP2C19*2 gene NON-carriers
89076348|NCT01076205||Adalimumab|Adults with moderate to severe active rheumatoid arthritis (RA) who initiated adalimumab therapy during routine clinical care.
89076349|NCT01234883|Experimental|multiple electrolyte solution|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
89076350|NCT01234883|Active Comparator|saline|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
89076351|NCT01234649|Experimental|Metformin XR plus liraglutide|Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated
89076352|NCT01234649|Active Comparator|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
89076353|NCT02876679|Experimental|Cyclophosphamide|50mg/Kg/day cyclophosphamide (day +3 and +4)
89076354|NCT02876679|Active Comparator|Anti-Thymocyte Globulin|2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1)
89076355|NCT01075815|Experimental|rFSH + rhLH|Recombinant human luteinizing hormone (rhLH,Luveris®) injection 150 IU subcutaneously daily along with rFSH 300 IU subcutaneously daily from S1 to S4 and then rFSH dose can be adjusted depending on the ovarian response till r-hCG administration day.
89076356|NCT01075815|Active Comparator|rFSH|rFSH injection 300 IU subcutaneously daily from S1 to S4 and then dose can be adjusted depending on the ovarian response till r-hCG administration day.
89076357|NCT02876913||Group Nasotracheal Intubation|Patients who are scheduled for nasotracheal intubation for general anesthesia
89076358|NCT02876523||Patients with a hilar biliary stricture requiring a drainage|Drainage performed by endoscopy, echo-endoscopy or percutaneously
89076359|NCT02876367||Acute scrub typhus (Group 1)|Participants presenting with a fever will be verbally consented for a scrub typhus RDT, using <1ml of blood that is likely to be taken as part of routine clinical assessment. If the RDT tests positive, the patient will be informed about the study and asked to give written informed consent. If they agree to join the study, participants will be asked to give a further blood sample of 10mls (2 teaspoons) for ELISA, PCR and culture testing to confirm the presence of scrub typhus.
89076360|NCT02876367||Scrub typhus serosurvey (Group 2)|Villagers who are living in an identified scrub typhus environment will be informed about the study and asked to give written informed consent. If they agree to join the study they will be asked to give a finger prick dried blood spot (DBS) test on which scrub typhus ELISA and IFA will be performed.
89076361|NCT04306107|Experimental|NIV with prone position|Use of prone position during NIV
89076362|NCT04306107|Placebo Comparator|NIV (conventional)|NIV on conventional position
89076363|NCT04306107|Experimental|HFNC on prone position|Prone position during HFNC
89076364|NCT04306107|Placebo Comparator|HFNC (conventional)|HFNC on conventional position
89076365|NCT01075191||HIV-infected participants|"HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor.~Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (three 133 mg/33 mg capsules twice daily or two 200 mg/50 mg tablets twice daily)."
89076366|NCT00905359|Active Comparator|Aperius™ PercLID™ System|Aperius™ PercLID™ System arm. Patients randomized to this arm will undergo treatment with the Aperius™ PercLID™ System.
89076367|NCT00905359|Active Comparator|Standalone Decompressive Surgery|Patients randomized to this arm will receive Standalone Decompressive Surgery, defined as decompressive surgery without instrumentation or fusion.
89076368|NCT01072149|Experimental|50mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
89076369|NCT01072149|Experimental|100mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
89076370|NCT01072149|Experimental|200mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
89076371|NCT01072149|Placebo Comparator|placebo|placebo
89076372|NCT04413253|Active Comparator|Xiidra Only Group|Patients with dry eye disease Xiidra only
89076373|NCT04413253|Experimental|Xiidra + Dextenza Group|Patients with dry eye disease Xiidra + Dextenza
89076374|NCT01071915|Experimental|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
89076375|NCT02876445|Other|Caregiver Evaluation|ZARIT Burden Interview
89076376|NCT02849275|Placebo Comparator|Lactose free 1% milk|Diet will be recorded with a 7-day diet record and participants will include an isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
89076377|NCT02849275|Experimental|Probiotic treatment|Diet will be recorded with a 7-day diet record and participants will include an isocaloric fermented milk (probiotic), consumed once daily, over 4-5 weeks.
89076378|NCT02876133|Experimental|Narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
89076379|NCT02876133|Placebo Comparator|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
89076380|NCT01679119|Experimental|IO-R-CVP|Inotuzumab Ozogamicin plus Rituximab and CVP (Cyclophosphamide, vincristine & prednisolone).
89076381|NCT01679119|Active Comparator|Gem-R-CVP|Gemcitabine plus Rituximab and CVP (Cyclophosphamide, Vincristine and Prednisolone).
89076382|NCT04778787|Experimental|the intervention group|The intervention group includes patients with decompensated chronic heart failure. The diagnosis will be made according to the criteria described above
89076383|NCT04778787|Experimental|the control group|The control group will be identical to the main group.
89076384|NCT02876289||patients treated with Perampanel|
89076385|NCT04304391|Experimental|Group A|Conventional Gingivectomy:Technique is performed with conventional surgical instruments.
89076386|NCT04304391|Experimental|Group B|Diode Laser Assisted Gingivectomy: Technique is performed with using diode laser.
89076387|NCT04304391|Experimental|Group C|Er:YAG Laser Assisted Gingivectomy: Technique is performed with using Er:YAG laser.
89076388|NCT04304391|No Intervention|Group D|Negative Control Group
89076389|NCT04304157|Experimental|satisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
89076390|NCT04304157|Experimental|unsatisfactory|0.4 µg.kg of dexmedetomidine, with 0.1 µg.kg dose interval. If IVRA outcome was satisfactory, the dose went down for the next patient by 0.1 µg.kg. Vice versa, if the outcome was unsatisfactory, the dexmedetomidine dose was stepped up by 0.1 µg.kg for the following patient
89076391|NCT04305717|Experimental|ReDS-guided strategy|For patients in this arm, daily measurements from the device will be revealed to the treating physician. Discharge can be planned when the clinical stability is achieved and the ReDS value is ≤35%. In case of a ReDS value >35%, treating physicians will follow a predefined algorithm before discharge to improve the results of ReDS test.
89076392|NCT04305717|No Intervention|Standard of care strategy|The drugs dosage, especially diuretics, will be selected according to the presence of symptoms and signs of systemic congestion and according to current recommendations. All the daily ReDS measurements will be blinded to the treating physician.
89076393|NCT02875587|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
89076394|NCT02875587|Experimental|Calcium gluconate infusion group|Calcium gluconate is administered starting on the day of HCG administration.
89076395|NCT00904969|Experimental|AMS Transobturator Male Sling System|
89076396|NCT01070979|Experimental|Estradiol acetate (E3A)|
89076397|NCT01070979|Active Comparator|Estradiol|
89076398|NCT01070979|Active Comparator|Conjugated equine estrogens (CEE):|
89076399|NCT00626847||1|Primary Open Angle Glaucoma (POAG)
89076400|NCT00626847||2|Controls (Normals, patients without glaucoma)
89076401|NCT01234337|Experimental|Sorafenib (Nexavar, BAY43-9006) + Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
89076402|NCT01234337|Placebo Comparator|Placebo + Capecitabine|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
89076403|NCT02848963|Active Comparator|ketamine-propofol mixture 5/1|Ketamine-propofol mixture will be compare for every groups.
89076404|NCT02848963|Active Comparator|ketamine-propofol mixture 10/1|Ketamine-propofol mixture will be compare for every groups.
89076405|NCT02848963|Active Comparator|Ketamine-propofol mixture 6,7/1|Ketamine-propofol mixture will be compare for every groups
89076406|NCT01070043|Experimental|Amlodipine 5mg/Valsartan 80 mg|During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.
89076407|NCT01070043|Active Comparator|Valsartan 160 mg|In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.
89076408|NCT01070043|Other|Run-In Valsartan 80 mg|During run-in period, oral valsartan 80 mg once daily for 4 weeks.
89076409|NCT02849119|Experimental|Transperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through transperitoneal approach
89076410|NCT02849119|Experimental|Retroperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through retroperitoneal approach
89076411|NCT04772391|Other|Exercise Treatment Group|Exercise Sessions
89076412|NCT04718545|Active Comparator|Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a conventionally prepared recipient site and sutured to cover the mucosal recession
89076413|NCT04718545|Experimental|Modified Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a modified recipient site and sutured to cover the mucosal recession
89076414|NCT02849197||Primary Closure|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: primary closure. Technical details: An elliptical incision was made, and the excision included sinus openings at the median line and extended down to the pre-sacral fascia. One suction drain was placed in the wound cavity. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and skin was closed with interrupted 2-0 silk suture."
89076415|NCT02849197||Limberg Flap Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: Limberg Flap Technique. Technical details: A rhomboid incision was made as to include all sinus openings, and an excision was made down to the pre-sacral fascia. A bisector drawn in the rhombohedron was extended laterally to a length similar to that of a corner of the rhombohedron. Then, the flap was prepared by removing gluteal muscle with its fascia. One suction drain was placed at the wound cavity. The base of the flap was approximated with the presacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable sutures, and the skin was closed with interrupted 3-0 prolene suture."
89076416|NCT02849197||Modified Limberg Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: Modified Limberg Flap Technique. Technical details: As in Limberg flap technique, a rhomboid incision was made. Upper and lower corners of the excision were lateralized 2 cm away from the midline in order to keep the suturing line at the inferior from overlapping the midline. An excision was made down to the pre-sacral fascia. One suction drain was placed at the wound cavity, and the base of the flap was approximated with the pre-sacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and the skin was closed with 3-0 prolene."
89076417|NCT01074255||Korean Participants Treated With EMEND (aprepitant)|Participants receiving EMEND on Treatment Days 1, 2, and 3 concomitantly with a corticosteroid and a 5-hydroxytryptamine 3 (5-HT3) antagonist.
89076418|NCT02848807|Active Comparator|NUTRIDRINK Compact Protein|NUTRIDRINK Compact Protein Oral nutritional supplement Dietary advice
89076419|NCT02848807|No Intervention|without oral nutritional supplements|Dietary advice alone
89076420|NCT01073943|Experimental|PicoPrep|"Day Before method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy."
89076421|NCT01073943|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
89076422|NCT05254483|Experimental|Intervention group (IG)|Receiving exercise program immediately
89076423|NCT05254483|Active Comparator|Waitlist Control Group (WCG)|Receiving exercise program after 12 week wait.
89076424|NCT01073865|Experimental|1|"Zoladex 10.8 mg (goserelin acetate) will be injected once every 12 weeks (± 7 days).~One oral tamoxifen 20 mg tablet also will be taken daily"
89076425|NCT01073865|Active Comparator|2|Zoladex 3.6 mg (goserelin acetate) will be injected once every 4 weeks (± 7 days). One oral tamoxifen 20 mg tablet will also be taken daily.
89076426|NCT02900053|Active Comparator|Arm 1|Cerebral modulation using tDCS (transcranial Direct-Current Stimulation) associated with repetitive traumatic exposure using a personal traumatic script
89076427|NCT02900053|Placebo Comparator|Arm 2|Placebo cerebral modulation using sham-tDCS associated with repetitive traumatic exposure using a personal traumatic script
89076428|NCT04862065|Other|Screening|Alinity s Anti-HCV and Alinity s Anti-HCV II. A follow-up visit may be needed if investigational Alinity s Anti-HCV II result is discordant after supplemental testing.
89076429|NCT04714645|Experimental|Intervention group|VR+ training
89076430|NCT04714645|Sham Comparator|Control group|VR- training
89076431|NCT01064635|Active Comparator|Letrozole for 3-2 years|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for 3-2 years. Total duration of early adjuvant endocrine therapy: 5 years
89076432|NCT01064635|Experimental|Letrozole for 5 year|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for additional 5 years. Total duration of early adjuvant endocrine therapy: 7 years for patients pretreated with 2 years of TAM and 8 years for patients pre-treated with 3 years of TAM
89076433|NCT00930007||Hyperandrogenemic|Girls with elevated free testosterone concentrations
89076434|NCT00930007||Controls|Girls with normal free testosterone concentrations
89076435|NCT04697485|Experimental|Low-Dose, Triple Polydiuretic Therapy (LDTPT)|Polydiuretic therapy will consist of bumetanide 0.5 mg + eplerenone 25 mg + dapaglifozin 5 mg once daily for 4 weeks.
89076436|NCT02768935|Other|Diabetes|
89076437|NCT02768935|Other|normoglycaemic|
89076438|NCT00928759||peripubertal obese girls|Peripubertal obese girls, aged 8 - 16 years, who are obese (BMI-for-age percentile greater or equal to 95)
89076439|NCT01073631||1|Patients who are indicated for use of voriconazole tablet.
89076440|NCT00626769||1|Postmenopausal women with established osteopenia receiving aglycone genistein 54 mg/day for 3 years
89076441|NCT00626769||2|Postmenopausal women with established osteopenia receiving placebo (Calcium and vitD) for 3 years
89076442|NCT04305171||coronary heart disease patients with periodontitis|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.~Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) > 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth."
89076443|NCT04305171||coronary heart disease patients without periodontitisHD|"Coronary heart disease patients confirmed through coronary angiography as having at least 50% diameter stenosis in at least one coronary artery and clinically stable with the absence of any potentially confounding inflammatory conditions for at least 6 months.~Non-periodontitis classified as having PD ≤ 3 mm."
89076444|NCT04305171||non-coronary heart disease patients with periodontitis|Periodontitis classified as havingbleeding on probing (BOP), pocket depth (PD) > 4 mm, clinical attachment level (CAL) ≥ 5 mm and radiographic evidence of bone loss were presented at the same site of at least 4 teeth.
89076445|NCT04305171||non-coronary heart disease patients without periodontitis|Non-periodontitis classified as having PD ≤ 3 mm.
89076446|NCT02875743|Experimental|Posaconazole|
89076447|NCT01073163|Experimental|Bendamustine with Rituximab|Participants were administered bendamustine intravenous (IV) infusion at 90 mg/m^2 on Days 1 and 2 of each 28-day cycle, and rituximab IV infusion at 375 mg/m^2 on Day 1 of each 28-day cycle.
89076448|NCT04305483|Active Comparator|Laser Bleaching|35% Hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative containing bleaching agent activated with diode laser
89076449|NCT04305483|Active Comparator|Chemical Bleaching|35% Hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water containing chemical bleaching agent used for control group without a laser activation
89076450|NCT04304859||Cases referred from GP|BASIC (Brief Assessment of Impaired Cognition) MMSE (Mini Mental State Examination) Extensive diagnostic work-up including clinical interview, neurological and physical examination, laboratory screening tests, structural neuroimaging
89076451|NCT04304859||Healthy controls|"Test performed:~BASIC MMSE GDS-15 (Geriatric Depression Scale)"
89076452|NCT02875665|Experimental|geko device arm|geko™ devices (acting on the posterior tibial nerve) to be used on alternate days over seven days, for an hour per day
89076453|NCT02875821|Experimental|Group IMP|Group IMP (Ipragliflozin with Metformin with Pioglitazone)
89076454|NCT02875821|Active Comparator|Group MP|Group MP (Metformin with Pioglitazone)
89076455|NCT04721535|Experimental|DWJ1248|Camostat mesilate 200mg
89076456|NCT04721535|Placebo Comparator|Placebo|Placebo
89076457|NCT02875119|Experimental|Griffithsin Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer Griffithsin Gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
89076458|NCT02875119|Placebo Comparator|Placebo Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer placebo gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
89076459|NCT04757415|Experimental|Traction straight leg raise technique for hamstring.|Experimental group underwent conventional physiotherapy treatment (hot pack) followed by five main gluteal activation exercises three in first five sessions and rest two in remaining five sessions along with traction straight leg raise technique. Each session took 30 minutes . Participants were treated 10 times over a 5 week period with 2 treatment sessions per week. Pre and Post treatment readings were taken in 1st and 10th session over a 5 week period respectively. Assessment was done via Numeric pain rating scale and sphygmomanometer for assessing pain intensity and muscle strength of gluteus maximus.
89076460|NCT04757415|Experimental|Gluteal activation exercises|Experimental group underwent conventional physiotherapy treatment (hot pack) followed by five main gluteal activation exercises three in first five sessions and rest two in remaining five sessions. Each session took 30 minutes . Participants were treated 10 times over a 5 week period with 2 treatment sessions per week. Pre and Post treatment readings were taken in 1st and 10th session over a 5 week period respectively. Assessment was done via Numeric pain rating scale and sphygmomanometer for assessing pain intensity and muscle strength of gluteus maximus.
89076461|NCT04304313|Experimental|Sildenafil citrate tablets|
89076462|NCT01072929|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
89076463|NCT01072929|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
89076464|NCT01072929|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
89076465|NCT02875197||Healthy Controls|"Males and females 18-50 years old~Up to 20 able-bodied sex, age, height, and weight-matched subjects"
89076466|NCT02875197||Lower Extremity Amputees|"Males & females 18-50 years old~Must have a unilateral, transtibial amputation & must have been prescribed a running-specific prosthesis~Subject with amputations resulting from trauma, congenital reasons, or cancer treatment unless cancer is in remission or treatments do not impact gait function~Physician approval to run~4 months experience using a running-specific prosthesis"
89076467|NCT04305015|Active Comparator|Routine opioid management|Clinicians will be blinded to NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when
89076468|NCT04305015|Experimental|NOL-guided opioid administration|Clinicians will titrate fentanyl to keep NOL under 25 - always using good clinical judgement for individual patients
89076469|NCT04304937||Cohort 1|test-retest at baseline and 7 days later
89076470|NCT04304937||Cohort 2|test at baseline and 8 weeks post treatment
89076471|NCT01231607|Active Comparator|1mg Finasteride|1mg finasteride active plus dutasteride placebo, by mouth once daily
89076472|NCT01231607|Active Comparator|0.02mg Dutasteride|0.02mg dutasteride active plus finasteride placebo, by mouth once daily
89076473|NCT01231607|Active Comparator|0.1mg Dutasteride|0.1mg dutasteride active plus finasteride placebo, by mouth once daily
89076474|NCT01231607|Active Comparator|0.5mg Dutasteride|0.5mg dutasteride active plus finasteride placebo, by mouth once daily
89076475|NCT01231607|Placebo Comparator|Placebo|1mg finasteride placebo plus dutasteride placebo, by mouth once daily
89076476|NCT04304547|Active Comparator|Sequence A|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
89076477|NCT04304547|Active Comparator|Sequence B|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
89076478|NCT04304547|Active Comparator|Sequence C|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
89076479|NCT01231373|Experimental|polidocanol injectable foam, 0.125%|
89076480|NCT01231373|Experimental|polidocanol injectable foam, 0.5%|
89076481|NCT01231373|Experimental|polidocanol injectable foam, 1.0%|
89076482|NCT01231373|Placebo Comparator|Vehicle|
89076483|NCT00975130|Experimental|SC-GLM50|In Part 1 of the study, participants received subcutaneous golimumab treatment at a dose of 50 mg once monthly for 6 months in combination with background DMARD treatment.
89076484|NCT00975130|Experimental|IV GLM 2 mg/kg + GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive intravenous (IV) golimumab at a dose of 2 mg/kg once monthly for a period of 6 months or until remission is achieved. Participants will receive IV GLM at a dose of 2 mg/kg at the start of Month 7, and then at the start of Month 8 and Month 10 if the subject has not achieved remission at any of these IV administration visits. If remission is achieved, participants were switched to subcutaneous golimumab at a dose of 50 mg once monthly until study end, in combination with background DMARD treatment.
89076485|NCT00975130|Experimental|GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months, in combination with background DMARD treatment.
89076486|NCT01230827|Experimental|CNTO 148 (Golimumab)|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response at Week 16 and who are randomly allocated to golimumab, will receive 30 mg per square meter every 4 weeks through Week 48. Patients will continue to receive golimumab 30 mg per square meter after Week 48 in a long-term extension until Week 248. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
89076487|NCT01230827|Placebo Comparator|Placebo|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive placebo every 4 weeks through Week 48. However, patients receiving placebo and who will have lack/loss of clinical response will be eligible to receive golimumab 30 mg per square meter every 4 weeks through Week 48. At Week 48, patients do not have a clinical response will begin to receive golimumab 30 mg per square meter in a long-term extension until Week 248 and patients who have a clinical response will be discontinued from the study. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
89076488|NCT01230749|Experimental|JNJ-41443532 250 mg|Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.
89076489|NCT01230749|Experimental|JNJ-41443532 1000 mg|Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.
89076490|NCT01230749|Active Comparator|Pioglitazone|Participants will receive pioglitazone 30 mg in morning for 28 days.
89076491|NCT01230749|Placebo Comparator|Placebo|Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.
89076492|NCT04292392|Experimental|A - ACB + Periarticular Block|Group A: patient will receive a preop ACB, followed by Intra-articular block during TKA surgery
89076493|NCT04292392|Experimental|B - ACB + IPACK Block|Group B: patient will receive a preop ACB+IPACK block before TKA surgery only
89076494|NCT04292392|Experimental|C - ACB + IPACK + Periarticular Block|Group C: patient will receive a preop ACB+IPACK block, followed by Intra-articular block during TKA surgery
89076495|NCT00903175|Experimental|everolimus 1L/sunitinib 2L|everolimus First Line: 10 mg orally, once daily, (two 5 mg tablets), continuous treatment. sunitinib Second Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2)
89076496|NCT00903175|Active Comparator|sunitinib 1L/everolimus 2L|sunitinib First Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2) everolimus Second Line: 10 mg orally, once daily (two 5 mg tablets), continuous treatment
89076497|NCT02864212||Glucose monitoring|Glucose will be monitor in patients using fast-acting insulin.
89076498|NCT02864212||Depth of anesthesia monitoring|Depth of anesthesia will be monitor in patients undergoing cardiac surgery.
89076499|NCT02864212||Blood pressure monitoring|Invasive blood pressure will be monitor in patients undergoing cardiac surgery.
89076500|NCT01229735|Experimental|Levetiracetam|250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks
89076501|NCT01229735|Active Comparator|Topiramate|25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks
89076502|NCT03866200|Experimental|Resveratrol, Then Placebo|Participants first received Resveratrol 125 mg/day or 5 ml daily for 90 days. After a washout period of 30 days, they then received Placebo 5ml daily for 90 days.
89076503|NCT03866200|Placebo Comparator|Placebo, Then Resveratrol|Participants first received Placebo 5ml daily for 90 days. After a washout period of 30 days, they then received Resveratrol 125 mg/day or 5 ml daily for 90 days.
89076504|NCT02742493|Experimental|0.028 bonded to canines|lower fixed canine and canine retainer and upper removable Hawley (Intervention A)
89076505|NCT02742493|Experimental|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer and upper removable Hawley (Intervention B)
89076506|NCT02742493|Active Comparator|removable Hawley-type|lower hawley-type and upper hawley removable retainer (Control)
89076507|NCT02848183|Experimental|Pediatric de novo acute myeloid leukemia|"I. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide~II. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning"
89076508|NCT00974974|Experimental|IPX066|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
89076509|NCT00974974|Active Comparator|IR CD-LD|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).
89076510|NCT02715583|Experimental|Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease.|"Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease planning to undergo Ra-223 therapy may be eligible for this study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania.~Positron emission tomography (PET/CT) imaging will use the investigational radiotracer [11C]acetate. Imaging will occur prior to Ra-223 therapy and after 2 cycles, in addition to standard of care 99mTcMDP bone scan at baseline and a research 99mTc-MDP bone scan post-therapy~Patients will also undergo serial lab tests (PSA, and alkaline phosphatase levels). If these tests are done as part of clinical standard of care they will not need to be repeated for this study. Patients will be asked to complete a quality of life metric (short form of the McGill pain questionnaire) on the day of each PET/CT scan."
89076511|NCT02848417|Experimental|Curcumin|12 weeks 400mg orally twice a day
89076512|NCT02848417|Experimental|Liposomal Glutathione|12 weeks 630mg orally twice a day
89076513|NCT02848417|Experimental|Placebo Liquid or Capsules|"Placebo liquid for Glutathione 120 ml per/ bottle 420 mg/5 ml~Placebo capsules for Curcumin 60 capsules per bottle 400 mg /cap"
89076514|NCT04204642||Cerebral amyloid angiopathy (CAA)|Cerebral amyloid angiopathy (CAA) patients
89076515|NCT02847403|Experimental|exenatide|long-acting exenatide 2 mg subcutaneously once-weekly
89076516|NCT02847403|Placebo Comparator|placebo|no drug assigned
89076517|NCT04801537||normal body temperature and warm extremities|standard set of environmental temperature is done, and the infant's body temperature is normal and extremities are warm
89076518|NCT04801537||normal body temperature and cold extremities|standard set of environmental temperature is done, and infant's body temperature is normal and extremities are cold
89076519|NCT02863900|Experimental|Experimental arm|subtypes of BC (namely luminal A and luminal B, HER2+, TN)
89076520|NCT04288492|Experimental|biofeedback|Respiratory exercise using biofeedback device(ResCalm) 2-3 times / day for 3 minutes until discharge from hospital, once in recovery room before surgery
89076521|NCT04288492|No Intervention|general|General surgical schedule without control exercise
89076522|NCT00632671||Obese persons cohorte|constitution of a prospective data collection (biological, clinical, paraclinical and questionnaires) in morbidly obese persons.
89076523|NCT04288180||Social Anxiety Disorder|A group of adults with social anxiety disorder will be recruited for a psychological/behavioral research study.
89076524|NCT02847481|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
89076525|NCT02847481|Placebo Comparator|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
89076526|NCT02847481|Experimental|FMT after antibiotic pretreatment v1|fecal microbiota transplantation after antibiotic pretreatment
89076527|NCT02847481|Experimental|FMT after antibiotic pretreatment v2|fecal microbiota transplantation after antibiotic pretreatment
89076528|NCT04287634|Experimental|Segmental Mobilization|Hot Fermentation Soft tissue mobilization + Targeted Segmental Mobilization Home plan exercise= cervical muscles stretching, postural care
89076529|NCT04287634|Experimental|Entire Spine Mobilization|Hot fermentation Soft tissue mobilization + Entire spine mobilization Home plan exercises=cervical muscles stretches, postural care
89076530|NCT04795453||assessment of usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
89076531|NCT04795453||assessment of score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
89076532|NCT04287712||Participants received surgery|Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved.
89076533|NCT04288102|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|Participants will receive standard of care plus 3 does of UC-MSCs
89076534|NCT04288102|Placebo Comparator|Placebo|Participants will receive standard of care plus 3 does of placebo
89076535|NCT02848261|Experimental|Developmental Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving.
89076536|NCT02848261|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
89076537|NCT02848261|Experimental|Remote Monitoring|Optimize the use of remote monitoring by focusing on situational demands and problem solving.
89076538|NCT02848261|Experimental|Fear of Hypoglycemia|Decrease fear of hypoglycemia, particularly focusing on overnight glycemic control.
89076539|NCT02848261|Placebo Comparator|No Intervention|Serves as the control group comparator. No intervention provided.
89076540|NCT04287244|Experimental|Active tSDCS|Anodal tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (designed by Sooma). The anode will be positioned over the spinal cord area at the level of the spinous processes of 10th-11th thoracic vertebra.
89076541|NCT04287244|Sham Comparator|Sham tSDCS|Sham stimulation will be delivered to the same spinal cord area using a sham tSDCS device that delivers a direct current for 10 seconds at the beginning and end of tSDCS to provide sensory experiences similar to active stimulation.
89076542|NCT02848105|Experimental|VPA+Methyl|VPA added to standard methylpredisonlone treatment for aGVHD
89076543|NCT02864524|Experimental|Manipulative and Massage Therapy|"Ten sessions (2/week):~High speed and low amplitude technique to lower cervical spine (C3-C4).~Dog technique flexion for high thoracic area (T1-T4).~Dog technique flexion for mid-thoracic area (T5-T8).~Dog technique flexed to low thoracic (T6-T12).~Classic Massage Therapy during 40 minutes (2 time / week):"
89076544|NCT02864524|Active Comparator|Exercise Program|Ten sessions (2 time/ week): Initial heating and continuing with aerobic and muscle stretching exercises.
89076545|NCT04288024|Experimental|Postural|During training, participants in this group are instructed to focus on their posture during weight-shifting.
89076546|NCT04288024|Experimental|Suprapostural|During training, participants in this group are instructed to focus on their suprapostural task during weight-shifting.
89076547|NCT02847793|Active Comparator|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial
89076548|NCT02847793|Placebo Comparator|Placebo intervention|Using a matching procedure (i.e., yoked control group), participants are required to maintain their gaze in a given picture (e.g., a happy face), for the same average time that their counterparts in the Gaze training group (i.e. Experimental group)
89076549|NCT02847325|Experimental|AC0058TA|Drug: 50 mg AC0058TA Drug: 100 mg AC0058TA Drug: 200 mg AC0058TA Drug: 400 mg AC0058TA
89076550|NCT02847325|Placebo Comparator|Placebo capsules|Drug: Placebo capsules
89076551|NCT02847013|Placebo Comparator|Placebo- Tap block w normal saline|After completion of surgery with closer of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, 20cc of Normal saline will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
89076552|NCT02847013|Experimental|Intervention-Tap block w Liposomal bupivacaine|After completion of surgery w closure of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, Liposomal bupivacaine 0.33% (10 ml diluted to 20 ml using sterile normal saline) will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
89076553|NCT02844595|Active Comparator|Standard cognitive-behavioural smoking cessation treatment|
89076554|NCT02844595|Active Comparator|Standard smoking cessation treatment and behavioral activation|
89076555|NCT02844595|No Intervention|Control group|It will be a delayed treatment control group for a period of 3 months.
89076556|NCT00831571||All Participants|Patients receiving Oxaliplatin
89076557|NCT00831571||Desensitization|Patients that have experienced a moderate to severe hypersensitivity reaction to oxaliplatin
89076558|NCT01233869|Experimental|Cohort A|
89076559|NCT01233869|Experimental|Cohort B|
89076560|NCT01233869|Placebo Comparator|Cohort C|
89076561|NCT02847091|Experimental|Ipragliflozin Group|Ipragliflozin will be administered orally for 24 weeks.
89076562|NCT02846935|Experimental|Decitabine + Tetrahydrouridine|"oral THU dosed by weight, followed by oral decitabine dosed by weight for 60 minutes (± 10 minutes) after the THU, twice weekly on consecutive days.~Treatment on protocol monitoring continues for 52 weeks."
89076563|NCT02844751|Experimental|Cohort 1|Interventions assigned by Principal Investigator
89076564|NCT02844751|Experimental|Cohort 2|Interventions assigned by Principal Investigator
89076565|NCT02844829|Other|MRI and biomarkers|Prostate MRI. Blood and urine biomarkers. Both prior to biopsy. Tissue samples during prostatectomy.
89076566|NCT02844673|Active Comparator|Standard monitoring (SM) arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) with standard monitoring. Standard monitoring is defined as a follow-up visit two weeks after initiation of therapy and monthly follow-ups thereafter
89076567|NCT02844673|Experimental|mDOT arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) and Mobile Directly Observed Therapy (mDOT) consisting of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Participants will receive alerts on their cell phone at pre-arranged times to remind them to take their medications. Participants will be followed-up at two weeks after initiation of therapy and monthly thereafter.
89076568|NCT02847247|Experimental|CCRE|20,000 EU of CCRE (Clinical Center Reference Endotoxin)
89076569|NCT00992992|Experimental|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Tositumomab and Iodine I 131 Tositumomab followed by CHOP
89076570|NCT04201951|Active Comparator|Tranexamic group|Group A will receive 1gm Tranexamic acide diluted in 20 ML 5% glucose water
89076571|NCT04201951|Placebo Comparator|Placebo group|Group B will receive 30ML 5% glucose water
89076572|NCT02847715|No Intervention|Audit phase|In the audit-phase, a group of 59 patients will be recruited and followed over a 12 month period. Data will be collected on clinical and patient outcomes in an audit in order to be able to compare to the intervention (after-phase) group.
89076573|NCT02847715|Experimental|Intervention (pilot-phase)|In the pilot-phase, a group of 59 patients will be recruited and followed over a 6-12 month period. Patients in this group will be assigned to the new remote monitoring follow-up pathway (ePRIME), whereby instead of attending routine outpatient appointments they are monitored remoted via a online symptom monitoring questionnaire and related clinical tests undertaken remotely. All information is collated in the patient's electronic patient record, and clinicians will review/respond to the data as necessary.
89076574|NCT00992836|Experimental|Influenza A (H1N1) 2009 monovalent vaccine|All participants received two doses of the H1N1 influenza virus vaccine, administered 21 days apart.
89076575|NCT04753723|Experimental|Platform wound device with antibiotic|Antibiotic cream will be applied to study wounds and then dressed with the platform wound device.
89076576|NCT04753723|No Intervention|Standard of Care|Study wounds will be treated per the standard of care.
89076577|NCT04751851|Experimental|A.1: Medium duration withdrawal programme with ACT|Medium duration withdrawal programme with Acceptance and Commitment Therapy
89076578|NCT04751851|Experimental|A.2: Long duration withdrawal programme with ACT|Long duration withdrawal programme with Acceptance and Commitment Therapy
89076579|NCT04751851|Active Comparator|B.1: Medium duration withdrawal programme without ACT|Medium duration withdrawal programme without Acceptance and Commitment Therapy
89076580|NCT04751851|Active Comparator|B.2: Long duration withdrawal programme without ACT|Long duration withdrawal programme without Acceptance and Commitment Therapy
89076581|NCT02844517|Experimental|Artificial Pancreas|The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
89076582|NCT03901729|Experimental|Arm 1|BAY1753011 30mg in addition to standard of care (SoC) for part A and part B
89076583|NCT03901729|Placebo Comparator|Arm 2|Placebo of BAY1753011 in addition to SoC for part A and part B
89076584|NCT03901729|Experimental|Arm 1-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
89076585|NCT03901729|Active Comparator|Arm 1-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
89076586|NCT03901729|Experimental|Arm 2-A|BAY1753011 30mg in addition to Placebo Furosemide 80mg for part B
89076587|NCT03901729|Active Comparator|Arm 2-B|Furosemide 80mg in addition to Placebo BAY1753011 30mg for part B
89076588|NCT03834844|No Intervention|Usual Care|patient receives same care as patients not enrolled in study intervention
89076589|NCT03834844|Experimental|AF education|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week.
89076590|NCT03834844|Experimental|Mindfulness Meditation Practice|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
89076591|NCT03834844|Experimental|Weekly Phone Calls|Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
89076592|NCT03834844|Experimental|AF Education and Mindfulness Meditation|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
89076593|NCT03834844|Experimental|AF Education and Weekly Phone Calls|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
89076594|NCT03834844|Experimental|Mindfulness Meditation and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
89076595|NCT03834844|Experimental|Meditation and Education and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
89076596|NCT02846857|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
89224466|NCT06265948||The sample will be randomly assigned into one of two equal groups ((Group-I (n|"Sample size calculation was carried out using G*Power 3 software (Faul et al., 2007)1 calculated minimum sample of 80 patient candidate for cancer surgery will be needed.~The sample will be randomly assigned into one of two equal groups ((Group-I (n=40):~will receive standard general anesthesia as control, and Group III (n=40): will receive~Ketofol in addition to the standard general anesthesia. The calculated sample will be~needed to detect an effect size of 0.1~in the RM-ANOVA (within group-between groups~and interaction) on repeated measurements (every 2-hours postoperatively) for the~mean VAS score, with an error probability of 0.05 and 95% power."
89224467|NCT06265922|Active Comparator|High frequency cerebellar repetitive transcranial magnetic stimulation|Twenty patients will be treated by high frequency repetitive transcranial magnetic stimulation (Hf-rTMS) targeting the cerebellum beside a tailored physical therapy program designed for the ataxic manifestation The protocol of rTMS included 6 sessions over 2 weeks. MagPro R20 device will be applied over midline of cerebellum using circular coil. Ten repetition rate in 40 trains with one inter train interval will be applied two times within the same session, 5 minutes rest in between Tailored physiotherapy program for ataxic manifestation will be applied for 10 days in the same 2 weeks
89224468|NCT06265922|Sham Comparator|Sham cerebellar repetitive transcranial magnetic stimulation|"Twenty patients will be treated by sham cerebellar rTMS with the same parameters, same duration 6 sessions over 2 weeks except the coil will not be on the middle of the cerebellum instead it will be perpendicular away from it.~But the program of physiotherapy is the same"
89230052|NCT00385684|Placebo Comparator|A2: placebo w hydrocodone/APAP PRN|This is a fully crossed study, each participant serves as his own control. Phase A: Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
88812803|NCT01550471|Experimental|6 Treatment Sequence-P and P, Q and B, A and O|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
88812804|NCT01528319|Experimental|MG-1|Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1
89076597|NCT02846857|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
89076598|NCT02846857|Active Comparator|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon mini-boluses will be infused using two separate subcutaneous infusion pumps to regulate glucose levels (MiniMed® Paradigm® Veo™, Medtronic). Participant's usual fast-acting insulin analog and Glucagon (Eli Lilly) will be used. Every 10 minutes, the glucose level as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Newly reconstituted glucagon will be used every 24 hours.
89076599|NCT04287322|Experimental|Tactile-kinesthetic stimulation|Received tactile-kinesthetic stimulation three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
89076600|NCT04287322|Experimental|Recorded maternal voice|Listened to recorded maternal voice stimulation, three times a day (morning, afternoon and evening) for 10 days starting on day 3 of life (initial contact).
89076601|NCT04287322|No Intervention|Control|Received only standard nursery care
89076602|NCT03833128|Experimental|Group 1 - Part A|REN001 Low Dose oral once daily x 12 weeks
89076603|NCT03833128|Experimental|Group 2 - Part A|REN001 High Dose oral once daily x 12 weeks
89076604|NCT03833128|Experimental|Group 3 - Part B|REN001 High Dose oral once daily x 12 weeks
89076605|NCT04672525|Active Comparator|RIFAMPICIN|Patient with staphylococcal PJI, treated with DAIR strategy, and randomized in the control group will receive rifampicin in association with another antibiotic except rifabutin, as-per recommendations for 12 weeks.
88812805|NCT03215264|Experimental|Dose level 1|Regorafenib 160mg daily 1-21 of 28-day cycle , Entinostat 3mg weekly, HCQ 600mg daily.
89076606|NCT04672525|Experimental|RIFABUTIN|Patient with staphylococcal PJI treated with DAIR strategy, and randomized in the experimental group, will receive rifabutin in association with another antibiotic except rifampicin, as-per recommendations for 12 weeks.
89076607|NCT00992446|Experimental|Treatment (chemotherapy, ASCT, bortezomib, vorinostat))|All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
89076608|NCT04452565|Active Comparator|Active Comparator: NA-831 alone|Arm 1: NA-831 30 mg orally twice a day for one day, followed by 30 mg once day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule
89076609|NCT04452565|Active Comparator|Active Comparator: NA-831 plus Atazanavir Sulfate|"Arm 2: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule.~AND Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets."
89076610|NCT04452565|Active Comparator|Active Comparator: NA-83 plus Dexamethasone|"Active Comparator: NA-831 30 mg capsule plus Dexamethasone 4 mg Arm 3: NA-831 60 mg orally twice a day for one day, followed by 30 mg once a day for four consecutive days (Five days in total). The drug will be supplied in 30 mg capsule.~AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets."
89076611|NCT04452565|Active Comparator|Active Comparator: Atazanavir and Dexamethasone|"Atazanavir 400 mg orally twice a day for one day, followed by 200 mg daily for four consecutive days (five days total). The drug will be supplied in 200 mg tablets.~AND Dexamethasone 8 mg orally twice a day for one day, followed by 4 mg daily for four consecutive days (five days total). The drug will be supplied in 4 mg tablets."
89076612|NCT04615195||children between 8 and 15 years old|answer to the CRIES 13 questionnaire
89076613|NCT04285840|Other|Single arm study|To establish a standardized procedure for venous ACT sampling during atrial fibrillation ablation. Analyses will examine the relationship and agreement between venous and arterial ACTs.
89076614|NCT04440319|Experimental|Intervention groups (4 PHC/clinics)|Intervention group are individual with T2DM who will receive DM nutrition counseling at selected Public Health Care (PHC). There are 75 subjects in Intervention group at selected 2 districts by randomly and 4 PHC which is selected based on cluster. DM nutrition counseling will be delivered by a selected nutritionist at each PHC. Nutritionist will educate the subjects following DM nutrition education module properly. DM nutrition education will be delivered for 3 months and 30 minutes for each meeting.
88812806|NCT03215264|Experimental|Dose level 2|Regorafenib 160mg daily 1-21 of 28-day cycle Entinostat 5mg weekly, HCQ 600mg daily
88812807|NCT03215264|Experimental|Dose level 3|Regorafenib 160mg daily 1-21 of 28-day cycle, Entinostat 5mg weekly, HCQ 600mg BID (1200mg daily).
88812808|NCT05312528||Study Group|Stage 3 and 4 endometriosis patients
88812809|NCT05312528||Control Group|Patients without endometriosis, who required surgery for tubal ligation, benign ovarian cysts or uterine fibroids were included.
89076615|NCT04440319|Experimental|Control groups (4 PHC/clinics)|As the same with intervention group, the control group will have 75 subjects but at the different districts and PHC to avoid contaminant. Control group will follow conventional DM nutrition education. Therefore, there is a selected nutritionists will deliver DM counseling at each PHC.
89076616|NCT02863120|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 10cc of normal saline and 30cc of bupivacaine HCl administered prior to cementation of knee implants
89076617|NCT02863120|Active Comparator|Adductor canal and tibial nerve block|Preoperative tibial nerve block with 15cc bupivacaine HCl and adductor canal block with 20cc adductor canal block. Postoperative continuous adductor canal block with 550cc ropivacaine at 8cc per hour
89076618|NCT04201795|Experimental|pressure and traction|pressure and traction durin 5 minutes will be applied in plantar fascia
89076619|NCT04201795|Sham Comparator|Laser|Applied during 5 minutes each plantar fascia of sham laser
89076620|NCT02846701|Other|patient treated by duloxetine|
89076621|NCT04344301|Experimental|AUDIO|"Participant clinic visits will be audio recorded locally on a secure, HIPAA-compliant server. Patient access to recordings will be performed via a secure web-based platform.~Additionally, participants will be offered the After Visit Summary (AVS) prior to clinic departure, per Usual Care (UC)"
89076622|NCT04344301|No Intervention|Usual Care|During the trial, patients will be offered to receive the AVS prior to clinic departure as is the current standard at each site.
89076623|NCT00970294|Experimental|Health Promotion Program|Supervised exercise, educational sessions, dietary counseling
89076624|NCT04285918||Cohort A|Patients ≥60 y/o with ESUS and PFO that is likely to have causative role (high-risk anatomical feature)
89076625|NCT04285918||Cohort B|Patients ≥60 y/o with ESUS without PFO, or with non-high risk PFO
89076626|NCT02844283|Experimental|treatment group|Single dose of Ad-HGF given by investigator via intracoronary injection into infarct-related artery
89076627|NCT02844283|Sham Comparator|control group|0.9% sodium chloride (NaCl) injection of same volume given by investigator via intracoronary injection into infarct-related artery
89076628|NCT02844361|Experimental|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
89076629|NCT02844361|Active Comparator|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
89076630|NCT04286698|Active Comparator|Complex decongestive physiotherapy program group|Manuel lymph drainage, compression mask, exercises and skin care
89076631|NCT04286698|Active Comparator|Home program group|Self-manuel lymph drainage and home exercises
89076632|NCT04286698|No Intervention|Control group|No intervention
89076633|NCT05337865||Transgender women|Well-trained transgender women.
89076634|NCT05337865||Cisgender Women|Well-trained cisgender women.
89076635|NCT05337865||Cisgender Men|Well-trained cisgender men.
89076636|NCT02864056|No Intervention|Control|Usual care
89076637|NCT02864056|Experimental|Tai Chi|Completes 50 hours of Tai Chi, a combination of in-class and at-home practise.
89076638|NCT05242861||Cervix radical BT|
89076639|NCT05242861||Cervix adjuvant BT|
89076640|NCT05242861||Cervix palliative BT|
89076641|NCT05242861||Uterus BT|
89076642|NCT05242861||Other GO cancer BT|
89076643|NCT02863822|Experimental|Low FODMAP|Subjects will be given dietary education in the low FODMAP diet, which they will continue for 4 weeks. Subjects will then followup with the dietician and subjects with a symptomatic response will be given instructions for reintroduction.
89076644|NCT02863822|Active Comparator|Choose My Plate|Subjects will receive dietary counseling in the choose my plate diet as defined by choosemyplate.gov. Subjects will also receive 2 dietician visits, 4 weeks apart.
89076645|NCT04292704|Experimental|Laser group|Fractional CO2 laser therapy in consolidation treatment once a month for 3 months and treatment was prohibited during menstrual period.
89076646|NCT04292704|Other|Clotrimazole group|Clotrimazole tablets 500mg PV biw q3d in consolidation treatment once a month for 6 months and treatment was prohibited during the menstrual period.
89076647|NCT05242783|Active Comparator|intramyometrial Terlipressin injection|"intramyometrial Terlipressin injection in women undergoing open myomectomy procedure using haemostatic tourniquets.~(After the uterus has been reached, the Foley's urethral catheter will be adapted as a uterine tourniquet and will be applied at the base of the uterus before enucleating the fibroid masses. intramural Terlipressin will be injected, and then the uterine incision is done and the surgeon can now separate out the fibroids with ease and then amount of blood loss is calculated)"
89076648|NCT05242783|Active Comparator|intramyometrial Carbetocin injection|"intramyometrial Carbetocin injection in women undergoing open myomectomy procedure using haemostatic tourniquets.~(After the uterus has been reached, the Foley's urethral catheter will be adapted as a uterine tourniquet and will be applied at the base of the uterus before enucleating the fibroid masses. intramural carbitocin will be injected, and the uterine incision is done and the surgeon can now separate out the fibroids with ease and then amount of blood loss is calculated)"
89076649|NCT05242783|Placebo Comparator|intramyometrial saline injection|"intramyometrial saline injection in women undergoing open myomectomy procedure using haemostatic tourniquets.~After the uterus has been reached, the Foley's urethral catheter will be adapted as a uterine tourniquet and will be applied at the base of the uterus before enucleating the fibroid masses. intramural saline as a aplacebo will be injected, and the uterine incision is done and the surgeon can now separate out the fibroids with ease and then amount of blood loss is calculated) and amount of blood loss and operative time is compared between all arms"
89076650|NCT04181944|Experimental|Exercise Treatment Group|
89076651|NCT05336305|Placebo Comparator|Placebo Group|Administration of corn starch daily for 2 months
89076652|NCT05336305|Experimental|polydextrose|Administration of 12g polydextrose daily for 2 months
89076653|NCT02846467|Experimental|Portable video media|Patients who receive informed consent trough portable video media around 10 minutes
89076654|NCT02846467|Active Comparator|Traditional IC|Patients who receive traditional IC (written consent) during 10 to 15 minutes
89076655|NCT03987685|Experimental|Oratopo|To determine the Maximum Tolerated Dose (MTD) of oral topotecan with HM30181A administered once daily for 5 consecutive days every 21 days.
89076656|NCT00969436|Experimental|Priorix-Tetra Group|Subjects received 2 doses of Priorix-Tetra® vaccine, 1 at Day 0 and 1 at Month 6, administered subcutaneously in the left anterolateral thigh.
89076657|NCT00969436|Experimental|Priorix/ Priorix-Tetra Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix-Tetra® vaccine at Month 6, both administered subcutaneously in the left anterolateral thigh.
89076658|NCT00969436|Active Comparator|Control Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix™ vaccine co-administered with Varilirix™ vaccine at Month 6, administered subcutaneously in the left and right anterolateral thigh.
89076659|NCT00900757|Experimental|Palonosetron|Single Arm trial of Palonosetron for the prevention of RINV in primary malignant glioma patients receiving radiation therapy (RT) and concomitant temozolomide (TMZ)
89076660|NCT05242393||Retrospective cohort|Patients with acute ischemic stroke admitted to the Stroke Unit of one participating center in 2018-2022. The data collected within clinical routine will be analyzed including stroke characteristics at baseline and at discharge (10-14 days after admission), neuroimaging data, sleep characteristics (routine polygraphy study), heart rate variability, routine blood tests.
89076661|NCT05242393||Prospective cohort|Approximately 200-250 patients with acute ischemic stroke admitted to the Stroke Unit of one participating center in 2022-2024 will undergo the assessment of medical records, stroke characteristics, the assessment of sleep characteristics and blood sampling for the evaluation of genetic biomarkers of circadian rhythms at baseline (within 2-3 days of admission) and at 10-14 days (at discharge).
89076662|NCT05242237||HCC patients|HCC patients with initial diagnosis
89076663|NCT05242237||Liver cirrhosis patients|Liver cirrhosis patients
89076664|NCT02846311||Group with support that will be usually performed|"During the first phase (before), the assumption will be that usually achieved.~The doctor continues to support according to information it has and according to good practice and service protocols."
89076665|NCT02846311||Group with a flu test|"During the second phase (after), a flu test is routinely performed within the home emergency department by the doctor who supports the patient.~The doctor continues to support according to information it has and according to good practice and service protocols."
89076666|NCT00969280|Experimental|Standardized Acupuncture group|
89076667|NCT00969280|Placebo Comparator|Non-acupoint shallow penetration group|
89076668|NCT04136743|Active Comparator|Corticosteroid|Participants will receive a corticosteroid injection (BMS, Kenacort-A 40 mg [triamcinolone acetonide]) into the subacromial space under direct ultrasound guidance by means of a 5-mL syringe with a 22-guage needle.
89076669|NCT04136743|Experimental|Micro-Fragmented Adipose Tissue|Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear, subacromial bursa, glenohumeral joint, acromioclavicular joint) under ultrasound guidance using an 18 gauge x 3.5 inch needle.
89076670|NCT03931057|Experimental|ADV6209|ADV6209 (= gamma-cyclodextrin-Midazolam) 0.25 mg/kg p.o. once 30 min. before anesthesia
89076671|NCT03931057|Active Comparator|Midazolam|Midazolam (in orange flavored syrup) 0.25 mg/kg p.o. once 30 min. before anesthesia
89076672|NCT00969124|Experimental|Third Eye Retroscope|All subjects underwent the same intervention, consisting of examination of the colon using a colonoscope along with the Third Eye Retroscope device, with removal of any polyps that were detected during the procedure.
89076673|NCT02846155|Placebo Comparator|clear water group|the patients only drink 1000ml clear water before checking
89076674|NCT02846155|Experimental|simethicone group|the patients drink 950ml clear water and 15ml simethicone before checking
89076675|NCT02846155|Experimental|simethicone combined with pronase group|the patients drink 900ml clear water and 15ml simethicone and 20，000iu pronase before checking
89076676|NCT02846077||College students|College students will be monitored and will complete online surveys, install apps on their mobile phones, wear physiological sensors and provide saliva samples for later assay.
89076677|NCT03825523|Experimental|Group A Immediate treatment (iART)|Other: time to start the ART within 48 hours of admission to hospitalization
89076678|NCT03825523|Active Comparator|Group B Conventional treatment (cART)|Other: time to start the ART, after the opportunistic disease has been controlled, at the discretion of infectious disease specialist.
89076679|NCT03744403|Experimental|CS1001 monoclonal antibody|
89076680|NCT02845921|Placebo Comparator|Group C Control|Patient will be shifted to operation theatre. Electrocardiography (ECG), pulse oximeter and non-invasive blood pressure (NIBP) monitors will be attached. Baseline vitals will be noted. Intravenous access will be secured and crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs will be neither elevated or wrapped. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube.
89076681|NCT02845921|Experimental|Group E Leg elevation|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs are elevated and supported on a stand making an angle of 30 degree to the horizontal. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Stand will be removed and legs will be brought to horizontal position 10 minutes after intubation.
89076682|NCT02845921|Experimental|Group W Leg wrapping|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl. Each lower limb will be elevated alternately and wrapped from toe to mid-thigh with Esmarch bandage. Care will be taken to avoid compressing the legs to greater than arterial pressure by confirming the presence of pulse using a saturation probe. Following wrapping, the lower limbs will be brought to horizontal position. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol injected over 30 seconds. Muscle relaxation by inj. vecuronium. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Esmarch bandage will be removed 10 minutes after intubation.
89076683|NCT05336149|Experimental|Whole-tooth dentin graft|The extracted tooth will be prepared as whole-tooth dentin graft and inserted in the extraction socket.
89076684|NCT05336149|Active Comparator|Particulate dentin graft|The extracted tooth will be prepared as particulate dentin graft and inserted in the extraction socket.
89076685|NCT02845843|Experimental|Combination of Lopinavir /Ritonavir and IntErferon Beta 1B|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
89076686|NCT02845843|Placebo Comparator|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
89076687|NCT02845999|Experimental|Allogenic NK cells transfer|Patients will be treated with a conditioning chemotherapy including 60 mg/kg intravenous cyclophosphamide, 25 mg/m2 intravenous fludarabine for 5 consecutive days and cetuximab. A lymphapheresis from an haploidentical related donor will be performed and T cells will be depleted . Allogenic NK cells will then be adoptively transferred by hepatic intraarterial infusion according to a dose escalation protocol (three doses with at least three patients per cohort)to define the dose-limiting toxicity (DLT). T
89076688|NCT00632905||1|Normal - BMD with T-score at or above -1.0
89076689|NCT00632905||2|Osteopenic - BMD with T-score between -1.1 and -2.4
89076690|NCT00632905||3|Osteoporotic - BMD with T-score at or below -2.5
89076691|NCT00900601|Experimental|Sacroilliac fusion|Pastient are treated with sacroiliac joint arthrodesis to the sacroiliac joint and symphysis
89076692|NCT03671239|Other|Product Sequence A|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
89076693|NCT03671239|Other|Product Sequence B|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
89076694|NCT03671239|Other|Product Sequence C|Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period.
89076695|NCT03671239|Other|Product Sequence D|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period.
89076696|NCT03671239|Other|Product Sequence E|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
89076697|NCT03671239|Other|Product Sequence F|Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
89076698|NCT02845687||Participants|All participants are patients within the Quit at Duke Smoking Cessation Program. This is an observational study with no interventions.
89076699|NCT02845609|Experimental|Intervention|Sialic acid-Extended release 2000 mg, three times per day (TID) for 3 months
89076700|NCT05177185|Experimental|SRS with hippocampal-sparing|Stereotactic radiosurgery with hippocampal-sparing
89076701|NCT05337085|Active Comparator|Dexmedetomidine|Inj. Dexmedetomidine (precidex) 200/mcg/2ml given to participants in infusion form for 10 mins of surgery and maintenance dose given till the end of surgery
89076702|NCT05337085|Active Comparator|Midazolam|Inj midazolam 0.5 mg/kg stat dose will be given to participants during surgery
89076703|NCT02845765||Patients with erectile dysfunction|Patients with erectile dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline and 6 months after therapy with Phosphodiesterase type 5 Inhibitor (PDE5I).
89076704|NCT02845765||Subject healthy volunteers|Patients without erectile dysfunction or ocular disease. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline
89076705|NCT05097937|Sham Comparator|Sham intervention|The needle will be inserted for 90 seconds without galvanic current.
89076706|NCT05097937|Experimental|Low intensity percutaneous electrolysis|Galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
89076707|NCT05097937|Experimental|High intensity percutaneous electrolysis|Participants will receive three impacts of galvanic current with an intensity of 3 mA for 3 seconds each.
89076708|NCT01723579|Experimental|NOMAC-E2 2.5 mg/1.5 mg|Participants will receive combined oral contraceptive NOMAC-E2 2.5 mg/1.5 mg tablet for 13 consecutive 28-day cycles. Each 28-day cycle with consist of 24 active tablets and 4 placebo tablets taken at approximately the same time each day.
89076709|NCT03648931||Pregnant or Breastfeeding Women|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
89076710|NCT03648931||Male Partners|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
89076711|NCT03648931||Grandmothers|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
89076712|NCT03648931||Key Informants|No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures.
89076713|NCT01638481||Group #1 - Burns affecting less than 10% BSA|
89076714|NCT01638481||Group #2 - Burns affecting 10%-30% TBSA|
89076715|NCT01638481||Group #3 - Burns affecting 31%-50% TBSA|
89076716|NCT01638481||Group #4 - Burns affecting 51%-70% TBSA|
89076717|NCT01638481||Group #5 - Burns affecting >70% TBSA|
89076718|NCT01481935|Experimental|Enhanced Cleaning|Rooms in the Enhanced Cleaning arm will receive cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
89076719|NCT01481935|Sham Comparator|Sham Enhanced Cleaning|Rooms in the Sham Enhanced Cleaning arm will receive a sham cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
89076720|NCT00901927|Experimental|Bendamustine + Mitoxantrone + Rituximab|Bendamustine starting dose 90 mg/m^2 intravenously (IV) over 30-60 minutes on Days 1 and 2 of each 8-day cycle. Mitoxantrone 10 mg/m^2 IV over 15 minutes on Day 2 of each cycle. Rituximab 375 mg/m^2 IV over several hours on Day 1 of each cycle.
89076721|NCT01400269|Experimental|Pacific Autism Center for Education (PACE)|Behavioral: Pacific Autism Center for Education (PACE) developmentally based parent delivered intervention
89076722|NCT02845141|Experimental|Actifuse|Actifuse to fill bone tunnel
89076723|NCT02845141|Active Comparator|bone graft|bone graft to fill bone tunnel
89076724|NCT04602871|Experimental|COVID 19 Positive patients|Patients with COVID-19, qPCR for SARS-CoV-2 confirmed
89076725|NCT04602871|Other|Healthy subjects|COVID-19 Negative subjects
89076726|NCT05335837||General Anesthesia|patients received general anesthesia for inguinal hernia repair
89076727|NCT05335837||Regional Anesthesia and Sedation|patients received ilioinguinal/iliohypogastric nerve blocks and sedation for inguinal hernia repair
89076728|NCT05336929|Experimental|education arm (n=30)|Roy adaptation model-based training was given to the training arm.
89076729|NCT05336929|No Intervention|control arm (n=30)|Roy adaptation model-based training not given to the training arm
89076730|NCT00903721||1|Patients with perennial allergic rhinitis
89076731|NCT00903721||2|Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)
89076732|NCT02844985||Addict Group|In-patient and out-patient adult men and women who meet diagnostic criteria for sexual addiction.
89076733|NCT02844985||Control Group|Individuals from the general community and college student populations who have no history of identifiable psychopathology.
89076734|NCT04900987|Experimental|Treatment group|After putting adequate manual pressure proximal to radial puncture site, dry and sterile application of steri-strip followed by pneumatic TR band for 1 to 2 hour.
89076735|NCT04900987|No Intervention|Control group|Application of pneumatic TR band alone for 4 hours as per usual practice
89076736|NCT02845219|Experimental|Oral contraceptive/SNAC/Oral Trial drug|
89076737|NCT00968968|Experimental|Arm 1: Lapatinib plus Trastuzumab|
89076738|NCT00968968|Active Comparator|Arm 2: Trastuzumab|
89076739|NCT02842801|Other|Hip Manipulation|Hip manipulation: high velocity low amplitude thrust mobilization
89076740|NCT02862886|Other|N°1|
89076741|NCT00973102|Experimental|Premarin IV|Patients who were randomized to receive a single dose of 0.5 mg/kg Premarin® IV.
89076742|NCT00973102|Placebo Comparator|Placebo|Patients who were randomized to receive a single dose of 0.5 mg/kg placebo. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with hemorrhagic shock.
89076743|NCT04689061||Biocomposite FastThread Interference Screw|The absorbable Biocomposite Interference Screws combine the inherent degradation characteristics of a biocompatible polymer with the bioactivity of a ceramic. They are made of a combination of 70% poly (L-lactide-co-D, L-lactide) (PLDLA) and 30% biphasic calcium phosphate (BCP). The material has withstood the test of time with over a decade of clinical use and millions of implantations. It has been shown that the Biocomposite Interference Screw integrates well into the surrounding bone, produces little to no inflammatory response, and partially degrades 2 years after implantation
89076744|NCT04622605|Experimental|Treatment Group|Cataract extraction and intraocular lens placement with combined placement of glaucoma microstent
89076745|NCT05205070|Experimental|Rosnilimab (ANB030)|ANB030 biological humanized monoclonal antibody, SC injections every 4 weeks
89076746|NCT05205070|Placebo Comparator|Placebo solution|Placebo solution, SC injections every 4 weeks
89076747|NCT04210297||Training cohort|Training cohort consists of the cirrhotic patients who collected from January 2018 to December 2019 of Qilu Hospital retrospectively.
89076748|NCT04210297||Internal validation cohort|Internal validation cohort consists of the cirrhotic patients who enrolled from January 2020 of Qilu Hospital prospectively.
89076749|NCT04210297||External validation cohort|External validation cohort consists of the cirrhotic patients who enrolled from January 2020 in Jinan Central Hospital prospectively.
89076750|NCT02863588|Experimental|seropositive for Toxoplasma gondii|
89076751|NCT03691090|Experimental|SHR-1210 + paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance
89076752|NCT03691090|Active Comparator|placebo+paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance
89076753|NCT00783211|Experimental|1|desloratadine
89076754|NCT00783211|Active Comparator|2|fexofenadine
89076755|NCT00783211|Placebo Comparator|3|placebo
89076756|NCT00779545|Placebo Comparator|Placebo|The placebo group was divided into 3 groups receiving 1, 2 or 4 sprays/nostril. The regimen of each placebo group was BID
89076757|NCT00779545|Experimental|Mometasone furoate nasal spray 100 mcg QD|
89076758|NCT00779545|Experimental|Mometasone furoate nasal spray 200 mcg QD|
89076759|NCT00779545|Experimental|Mometasone furoate nasal spray 400 mcg QD|
89076760|NCT00779545|Experimental|Mometasone furoate nasal spray 100 mcg BID|
89076761|NCT00779545|Experimental|Mometasone furoate nasal spray 200 mcg BID|
89076762|NCT00901459|Active Comparator|rTMS 90% MT - Low frequency rTMS|Intervention type: device. Intervention description: low frequency rTMS was administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues using 90% MT (Motor Threshold) 1 Hz rTMS Dose on Superior Frontal Gyrus
89076763|NCT00901459|Active Comparator|Location Control|rTMS Dosing: 90% MT (Motor Threshold) 1 Hz rTNS Location: Motor Cortex
89076764|NCT00901459|Active Comparator|Frequency Control|rTMS Dosing: 90% MT (Motor Threshold) 10 Hz rTNS Location: Superior Frontal Gyrus
89076765|NCT02842567|Experimental|TREATED GROUP|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks.
89076766|NCT02842567|Placebo Comparator|PLACEBO GROUP|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
89076767|NCT02842489|Experimental|left lateral tilt-down position|patients will be positioned on left lateral tilt-down position during colonoscopy until sigmoid-descending junction were examined, and then patients will be positioned on the left lateral horizontal position during colonoscopy
89076768|NCT02842489|Active Comparator|left lateral horizontal body position|patients will be positioned on the left lateral horizontal position during colonoscopy insertion
89076769|NCT02133703|Experimental|Mutation Carrier: Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool.
89076770|NCT02133703|Experimental|Mutation Carrier: Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support intervention without a preference clarification tool.
89076771|NCT02133703|Active Comparator|Mutation Carrier: Enhanced Print DA|BRCA1/2 carriers randomized to this arm will be sent a print-based decision aid with a print preference clarification tool.
89076772|NCT02133703|Active Comparator|Mutation Carrier: Print DA|BRCA1/2 carriers randomized to this arm will receive a print decision aid without a preference clarification tool.
89076773|NCT02133703|Experimental|Inconclusive Results: DA|Participants who receive inconclusive results who are randomized to this arm will have access to an Internet decision tool designed to facilitate management decision making
89076774|NCT02133703|No Intervention|Inconclusive Results: Usual care|Participants who receive inconclusive/uninformative results who are randomized to this arm will receive usual care but no additional decision support intervention
89076775|NCT02842645||Control|Children born at term and not exposed to drugs during pregnancy
89076776|NCT02842645||Case|Case = Children exposed to drugs during pregnancy
89076777|NCT00896233|Experimental|MRE|
89076778|NCT00705211||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
89076779|NCT00705211||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
89076780|NCT02839993|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
89076781|NCT02839993|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
89076782|NCT02842255|Experimental|Healthy volunteers|
89076783|NCT02840071|Experimental|Intervention|Psychological therapy.
89076784|NCT02839837|Experimental|Depressed and non-depressed controls|All participants will participate in three different conditions: Low intensity aerobic exercise and paired associative stimulation, high intensity aerobic exercise and paired associative stimulation, no exercise control and paired associative stimulation. The order of conditions will be randomized.
88812810|NCT01447511|Other|CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
89076785|NCT02839759|Experimental|TELLYHealth Group|Subjects will receive the standard of care in hearing aid education and the TELLYHealth intervention for use over an 8 to12-week period and will be followed by their audiologist for 8 to 12 weeks.
89076786|NCT02839759|No Intervention|Standard of Care Group|Subjects will receive the standard of care in hearing aid education and will be followed by their audiologist for 8 to 12 weeks.
89076787|NCT02839525|Placebo Comparator|Omega 3|"3000mg of olive oil~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
89076788|NCT02839525|Placebo Comparator|Isolate whey protein|"23g of maltodextrin~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
89076789|NCT02839525|Placebo Comparator|Omega 3 and Isolate whey protein|"3000mg of olive oil and 23g of maltodextrin~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
89076790|NCT02839213|Active Comparator|group A (Hyoscine Butyl bromide group)|The women will be given Hyoscine Butyl bromide
89076791|NCT02839213|Active Comparator|group B (Saline group)|The women will be given saline
89076792|NCT05334043|Experimental|CuminUP30,then Curcumin capsules|Participants first received CuminUP30 3500mg on the first day in a fasting state.After a washout period of 7days,they then received curcumin capsules 2250mg on the eighth day in a fasting state.
89076793|NCT05334043|Experimental|Curcumin capsules,then CuminUP30|Participants first received curcumin capsules 2250mg on the first day in a fasting state.After a washout period of 7days,they then received CuminUP30 3500mg on the eighth day in a fasting state.
89076794|NCT02839369||children|post Traumatic Brain Injury With Cerebral Palsy Typically developed
89076795|NCT04250623|Experimental|subjects, 18-70 y, healthy|subjects, 18-70 y, healthy
89076796|NCT04250701||Dyslexia (D)|
89076797|NCT04250701||Intellectual Disability (ID)|
89076798|NCT04250701||Control (C)|
89076799|NCT02838823|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
89076800|NCT05333887|Experimental|PFC+|In this condition, therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support.
89076801|NCT05333887|No Intervention|Waitlist|In this condition, parents are placed on a waitlist where they continue life as usual. After the waitlist they participate in the PFC+ program.
89076802|NCT03340207|Experimental|Pneumaglide|After induction of anesthesia Pneumaglide device will be placed in the mouth of the pneumaglide assigned patients.
89076803|NCT03340207|No Intervention|non-pneumaglide|The patients in non-pneumaglide will not have Pneumaglide insertion prior to intubation.
89076804|NCT04201717|Active Comparator|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed.After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
89076805|NCT04201717|Experimental|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion.In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
89076806|NCT00156091|Active Comparator|1|Olanzapine 20 mg QD
89076807|NCT00156091|Experimental|2|Asenapine 5 or 10 mg BID
89076808|NCT00156091|Other|3|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041021 or 041022 asenapine trials, were randomized (double-blind) Into the long-term 041512 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52 week trial.
89076809|NCT00899431|Active Comparator|Group 1: Lenalidomide|Chemotherapy, Plus Lenalidomide - Lenalidomide starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months. Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine). Allopurinol 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
89076810|NCT00899431|Active Comparator|Group 2: No Lenalidomide|Chemotherapy Treatment, No Lenalidomide - Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
89076811|NCT05335213||Participants with cirrhosis and urinary tract infections|"Participants collect urine and fecal specimens at first two days when they admit to hospital, after 7-10 days and last two days hospital treatment and during episodes of complications (variceal bleeding, hepatic coma, hepatorenal syndrome).~Urine samples take from patients via clean catch if the patient not have a catheter placed, otherwise take from urinary catheters if present. Straight catheterization utilize if the patient unable to void and doesn't have a catheter placed.~Fecal specimens collect using a toilet specimen collection kit. Clinical, standart laboratory and cultural test, molecular genetic methods, using 16S rRNA gene sequencing of the V4-V5 hypervariable region be administered."
89076812|NCT05335213||Participants with cirrhosis without urinary tract infections|"Participants ask to collect urine and fecal specimens at first two days when they admit to hospital, after 7-10 days and last two days hospital treatment and during episodes of complications (variceal bleeding, hepatic coma, hepatorenal syndrome).~Urine samples take from patients via clean catch if the patient not have a catheter placed, otherwise take from urinary catheters if present. Straight catheterization utilize if the patient unable to void and doesn't have a catheter placed.~Fecal specimens collect using a toilet specimen collection kit. Clinical, standart laboratory and cultural test, molecular genetic methods, using 16S rRNA gene sequencing of the V4-V5 hypervariable region be administered."
89076813|NCT02843971|Experimental|Healthy volunteers|
89076814|NCT00899353|Experimental|Omega 3 supplement|Omega 3 supplement will be added to diet, 3 capsules per day for one month then 6 capsules per day for one month then 9 capsules per day as tolerated
89076815|NCT02844127|Other|Apex First|Patients born in odd-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the apex and then in the septum. Final lead position will be determined at the discretion of the implanting physician.
89076816|NCT02844127|Other|Septum First|Patients born in even-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the septum and then in the apex. Final lead position will be determined at the discretion of the implanting physician
89076817|NCT02843893|Other|Intubated and Mechanically Ventilated Patients|Intubated and Mechanically Ventilated Patients receiving by continuous intravenous an hypnotic sedation (midazolam or propofol) associate with a morphine type drug (fentanyl, sufentanil, rémifentanil, or morphine) since at least 6 hours and for a predictable duration over 24 hours.
89076818|NCT00898807|Experimental|Citalopram and psychosocial intervention|Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
89076819|NCT00898807|Placebo Comparator|Placebo and psychosocial intervention|Matching placebo, oral, and psychosocial intervention
89076820|NCT05335135||Pre-Implementation|Usual care will be provided during all ED patient encounters.
89224469|NCT06265909||AmDTx engaged|Data were collected between March 2015 and December 2022 on 36,160 unique users in a manner compliant with the Health Insurance Portability and Accountability Act (HIPAA), Personal Health Information Protection Act (PHIPA), and General Data Protection Regulation (GDPR). Of these, 2,786 unique individuals engaged in biometric and self-report data collection. To protect the real-world applicability of the results, users were not given any special instruction or information about the nature or possibility of the current analyses. As consequence, user data varied greatly in terms of engagement and app-use characteristics. To create a single, unified, and consistent dataset that could be leveraged across all intended analyses, data were filtered to only include English-language psychotherapy sessions that contained the required session payloads for algorithm inclusion (see below), and only when all the objective and two subjective measures were completed both before and after each session.
89076821|NCT05335135||Post-Implementation|TriageGo-MDW CDS will be made available during all ED patient encounters at two points in the ED care continuum: (1) shortly after arrival during initial ED triage (First Triage) and (2) after initial laboratory results have been populated within the EHR. General illness severity estimates will be provided to nurses at ED triage in the form of recommended triage acuity scores (CDS for First Triage). General illness severity estimates along with estimated risk for specific outcomes including sepsis and septic shock will be presented to clinicians after laboratory results have populated (CDS for Early Assessment). TriageGO-MDW risk estimates will be generated by machine learning algorithms using routinely available clinical data as predictor inputs. Nurses and clinicians will receive risk estimates within existing EHR workflows, along with brief and rapidly interpretable explanations of the logic driving each risk estimate.
89076822|NCT02842177|Active Comparator|Group I (classic method)|
89076823|NCT02842177|Active Comparator|uterine sound sparing group|
89076824|NCT02842411||chronic constipation|patients with chronic constipation based on Rome Ⅳ
89076825|NCT01229267|Experimental|V212 Consistency Lot 1|Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
89076826|NCT01229267|Experimental|V212 Consistency Lot 2|Participants randomized to receive V212 consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
89076827|NCT01229267|Experimental|V212 Consistency Lot 3|Participants randomized to receive V212 consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
89076828|NCT01229267|Experimental|V212 High Antigen Lot|Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
89076829|NCT01229267|Placebo Comparator|Placebo|Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
89076830|NCT02690779|Experimental|Patients watching educational video|The educational intervention will consist of a 2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration. This video will be posted on YouTube. Group 1 will consist of 30 subjects who will be instructed to view this video prior to beginning their colonoscopy preparation. Information to access the YouTube video will be provided to the patients by endoscopy nurse assessment staff when contacting the patients as per standard practice to review appointment scheduling and procedure-day logistics.
89076831|NCT02690779|Sham Comparator|Patients not watching educational video|Group 2 will consist of 30 subjects who will not receive instructions to view the video. They will be given routine care instructions for bowel prep.
89076832|NCT00897715|Active Comparator|Interleukin-1 receptor antagonist|active drug
89076833|NCT00897715|Placebo Comparator|Placebo|matching placebo
89076834|NCT00633295|Experimental|nilotinib|
89076835|NCT02842099|Experimental|TA or TAC plus X|Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.
89076836|NCT02842099|Active Comparator|TA or TAC|Standard chemotherapy (TA or TAC) followed by no more chemotherapy
89076837|NCT02842021|Active Comparator|S2G6T-1|Topical cream
89076838|NCT02842021|Active Comparator|S2G6T-2|Topical Cream
89076839|NCT02842021|Active Comparator|S2G6T-3|Topical Cream
89076840|NCT02842021|Placebo Comparator|S2G6T-4|Topical Cream
89076841|NCT02839057||Surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated with surgical fracture stabilisation
89076842|NCT02839057||Non-surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated non-surgically
88812487|NCT04223505|Experimental|CCT arm|As per local protocol, a non-contrast enhanced prospective ECG-triggered image acquisition will be acquired. This will be followed by a contrast-enhanced prospective ECG-triggered will be acquired using a tri-phasic contrast protocols. Delayed CT images will be acquired 60 seconds after the initial contrast-enhanced CT scan.Cardiac CT image interpretation will be performed as per clinical routine. The LA and LAA will be assess for filling defects and characterized based upon attenuation values. If LA/LAA thrombus cannot be excluded, filling defects will be assessed on the delay images. Increases in attenuation would be consistent with pseudo-thrombus from 'slow flow' and 'incomplete opacification'. Areas where attenuation does not change significantly (persistent filling defect) will be diagnosed as thrombus. It will be recommended that patients with thrombus will undergo TEE.
89076843|NCT01229111|Experimental|Treatment (cediranib maleate and modified FOLFOX)|Patients receive cediranib maleate PO QD on days 1-14 and modified FOLFOX6 comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.
89076844|NCT00894361|Active Comparator|rotating-platform design TKA|patients who were randomized to receive the rotating platform mobile-bearing TKA design
89076845|NCT00894361|Active Comparator|all-polyethylene tibia design TKA|patients who were randomized to receive the all-polyethylene tibial component design
89076846|NCT02843815|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
89076847|NCT02843815|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
89076848|NCT01228175|Active Comparator|Varenicline|Varenicline
89076849|NCT01228175|Placebo Comparator|Microcrystal Cellulose|Microcrystal cellulose placebo
89076850|NCT01228019||All participants|Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)
89076851|NCT02987959|Experimental|TAK-228 treatment|Patients with complex genomic sarcomas exhibiting PI3K pathway dysregulation will be treated with TAK-228
89076852|NCT05335057|Active Comparator|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
89076853|NCT05335057|Active Comparator|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
89076854|NCT05335057|Active Comparator|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
89076855|NCT05335057|Experimental|Time 4|Participant will be randomly assigned to the remainingintervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
89076856|NCT02841631||Post-Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
89076857|NCT01227707|Experimental|Single Arm|
89076858|NCT05334745|Experimental|application of Alvogyl in the palatal wound with stent|
89076859|NCT05334745|Other|application of 0.2% Hyaluronic acid is placed in the palatal wound with stent .|
89076860|NCT04586179|Active Comparator|Aerobic (treadmill) Exercise|Participants will wear a heart rate monitor and complete the Buffalo Concussion Treadmill Test
89076861|NCT04586179|Experimental|Dynamic Exercise|Participants will wear a heart rate monitor and complete a dynamic exertion assessment that incorporates directional changes that incrementally increases in exercise intensity
89076862|NCT00785005||1|Females with Type 2 Diabetes
89076863|NCT00785005||2|Females without Type 2 Diabetes
89076864|NCT04209829||Patients with haematological malignancy|Patients, aged 15 years or over, with haematological malignancy (Lymphoma, ALL, MM) integrated into a CAR-T Cells program treatment
89076865|NCT02821273|Experimental|Modified INSURE|Modified INSURE is intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
89076866|NCT02821273|Active Comparator|INSURE|INSURE technique meas surfactant administration through intubation-surfactant-extubation. And noninvasive ventilation is immediately used after surfactant.
89076867|NCT02838589|Active Comparator|Byetta|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
89076868|NCT02838589|Placebo Comparator|Isotonic saline|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
89076869|NCT02838511||Non-cardiac surgery|Hopkins Frailty Score (HFS) or Modified Frailty Index (MFI) will be obtained during during pre anesthesia evaluation
89076870|NCT02839135|Experimental|Reformulated scopolamine patch|Participants will receive reformulated scopolamine Transdermal Delivery System (TDS) patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
89076871|NCT02839135|Active Comparator|Marketed scopolamine patch|Participants will receive currently marketed scopolamine TDS patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area, with delivery of approximately 1.0 mg over 72 hours.
89076872|NCT00895843|Active Comparator|Conventional ibuprofen|
89076873|NCT00895843|Experimental|Brufen retard|
89076874|NCT02838433|Experimental|Biological samples|"Blood samples will be collected :~at baseline,~6 months after the first-line therapy or at disease progression (if occurs first).~In particular case of patient with immunotherapy or targeted therapy, 3 blood samples will be collected :~at baseline~3 months after the initiation of immunotherapy or targeted therapy~at disease progression Tumor tissues will be collected if available."
89076875|NCT05333809|Experimental|1|Pembrolizumab plus Disitamab vedotin
89076876|NCT02838277||Lipedema|Women with all stages of lipedema
89076877|NCT02838277||Dercum's disease|Men and women with nodular, mixed and diffuse Dercum's disease
89076878|NCT02838277||Control|Sex, age and BMI matched controls.
89076879|NCT02838277||Familial Multiple Lipomatosis|Women and men with multiple lipomas and/or angiolipomas
89076880|NCT02838277||Madelung's disease|Men and women with different types of Madelung's disease.
89076881|NCT02838667|No Intervention|Standard of Care|If participants are randomized into the non-intervention group, the participants' information during the study period will be collected. Participants will be managed by a care provider as per the standard of care. Participants may receive nephrology consultation as indicated clinically.
89076882|NCT02838667|Experimental|Standard of Care plus Nephrology Care|If participants are randomized into the intervention group, participants' information will be checked by the study investigators daily for 7 days (2 days pre-op and 5 days post-op). When appropriate, investigators may give suggestions to minimize the participants' risk(s) for AKI. Participant's primary care providers may take the suggestions into consideration. Participants' primary care providers are not obligated to carry out the suggestions that are given.
89076883|NCT05333731||Cesarean section group|In the cesarean section group, all the pregnant women had only one prior cesarean section.
89076884|NCT05333731||Non-cesarean section group|In the non-cesarean section group, all the pregnant women are primipara, and never had a cesarean section.
89076885|NCT02838355|Active Comparator|Standard Respiration Monitoring|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring throughout their stay in the ICU.
89076886|NCT02838355|Experimental|Standard Respiration Monitoring + Continuous ETCO2-NC|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring and continuous end-tidal capnography monitoring via nasal cannula (ETCO2-NC) throughout their stay in the ICU.
89076887|NCT02843581|Experimental|Cryosurgery and NK immunotherapy|We use comprehensive cryosurgery to destroy big tumors, and use multiple (more than 6 times) NK immunotherapy to destroy small tumors
89076888|NCT02843581|Active Comparator|Cryosurgery|We use comprehensive cryosurgery to destroy big tumors
89076889|NCT02843503|Experimental|Arterialized-venous reference YSI|CGM monitoring performance per arterialized venous reference measurement (YSI)
89076890|NCT02843503|Experimental|Venous reference samples YSI|CGM monitoring performance per venous reference measurement (YSI)
89076891|NCT02815813|Experimental|PeerFIT|PeerFIT is a group-based lifestyle intervention enhanced by mobile health technology and social media designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
89076892|NCT02815813|Active Comparator|BEAT|BEAT involves basic education in fitness and nutrition supported by a wearable activity tracking device designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
88812811|NCT01447511|Other|CYP2C9*1B/*1B Haplotype|Individuals with the CYP2C9*1B/*1B haplotype have two CYP2C9*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
89224470|NCT06265883||Len+DEB-TACE+HAIC|Patients were treated with Len+DEB-TACE+HAIC.
89224471|NCT06265883||Len+DEB-TACE|Patients were treated with Len+DEB-TACE.
89224472|NCT06265831|Experimental|Intervention group|At the first meeting of the intervention group, the Patient Identification Form, Vital Signs Form, Modified Borg Scale, and Saint George Respiratory Questionnaire Form will be filled out. Afterward, training will be given (accompanied by an academic advisor) on how to apply cold air to the face with a hand fan (3 times a day for 5 minutes) for dyspnea management. Additionally, patients will be given a hand-fan application brochure. The researchers will monitor the patient every day for a week (7 days), fill out the vital signs form, and the final test will be administered by the researchers on the 8th day.
89224473|NCT06265831|No Intervention|Control group|In the control group, the Patient Diagnosis Form, Vital Signs Form, Modified Borg Scale, and Saint George Respiratory Questionnaire Form will be filled in at the first interview. The clinic's routine care protocol will be applied to the patients in the control group, and the researchers will fill out a vital signs form every day for a week, and the patients will be followed up.
89224474|NCT06265766|Experimental|Active cTBS|Active cTBS delivered with an active TMS coil
89224475|NCT06265766|Sham Comparator|Sham cTBS|Sham cTBS delivered with a sham TMS coil
89224476|NCT06265753|Experimental|Experimental Group|Who received 10 minutes gastrocinemius function massage and 45 minutes classic physiotherapy exercise
89224477|NCT06265753|Sham Comparator|Control group|Who received 10 sham applicaiton massage and 45 minutes classic physiotherapy exercise
89224478|NCT06265740|Other|cohort of pregnant women at -risk of preterm delivery|vaginal swab
89224479|NCT06265688|Experimental|CX-2051|
89224480|NCT06265675|Experimental|Phenol block group|
89224481|NCT06265675|Active Comparator|Corticosteroid and local anesthetic|
89224482|NCT06265662|Experimental|The Intervention Arm|"Participants will engage in various activities, including:~Attending four group health education sessions, each lasting one hour, over a six-month period.~Having access to individual chat consultations with a healthcare team, including doctors, dietitians, fitness coaches, and psychologists, available from 9:00 AM to 5:00 PM on workdays, excluding public holidays, with no limit on consultation times."
89224483|NCT06265649||Surgical Group (SG)|Patients with ALCD undergoing NOM admitted to the surgical ward
89224484|NCT06265649||Non-Surgical Group (NSG)|Patients with ALCD undergoing NOM admitted to the medical ward
89224485|NCT06265636|Experimental|Experimental Group|Manual Therapy, exercise and percutaneous electrical nerve stimulation.
89224486|NCT06265636|Active Comparator|Control Group|Manual Therapy, exercise.
89076893|NCT02690857|Experimental|Docosahexaenoic acid|"Each capsule of DHA contains 100 mg DHA in triglycerides from algal oil, 0.125 mg alpha-tocopherol and 0.125 mg ascorbic acid.~Subjects receive an orally and daily ingestion of DHA capsules (5mg/kg for 15 days followed by 10 mg/kg for another 15 days without interruption between the 2 periods)."
89076894|NCT02690857|Placebo Comparator|Sunflower oil|Placebo capsules contain the same quantities of antioxidants and triglycerides of sunflower oil. Subjects receive an orally and daily ingestion of placebo capsules for 28 days.
89076895|NCT02843269|Active Comparator|Multi-component lifestyle intervention 1|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
89076896|NCT02843269|Active Comparator|Multi-component lifestyle intervention 2|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
89076897|NCT02843269|Active Comparator|Multi-component lifestyle intervention 3|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
89076898|NCT02843347||Biorepository substudy participants|Participants from the main study who give consent for the genetic testing substudy.
89076899|NCT02843113|Experimental|4 Your Child Program|Program integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
89076900|NCT02843113|Experimental|4 Your Child + Case Management|Participants assigned to treatment group that includes case management will receive an initial assessment to determine their strengths and needs. The participant will then work collaboratively with their case manager to connect to community resources to meet his needs. To do so, the case manager will meet with the participant using the following schedule: Months 1-2: intervention in the form of weekly face-to-face meeting with a case manager, plus a weekly phone call from a case manager; Months 3-4: intervention in the form of face-to-face meeting every other week, plus a weekly phone call; Months 5-6: intervention in the form of face-to-face meeting once a month, plus a weekly phone call.
89076901|NCT02843113|No Intervention|Waiting list control|Individuals who are randomly assigned to this condition will receive no treatment for a period of months in parallel with the experimental intervention conditions. Data will be gathered from them, and they will be randomly assigned to a treatment condition when possible.
89076902|NCT02841319|Experimental|Intervention|Virtual reality exercises using Hand Tutor for 8 weeks
89076903|NCT02841319|No Intervention|Control|Home exercises for 8 weeks
89076904|NCT02841007|Experimental|geko device arm|Patients consenting to take part will receive the geko device prior to surgery to internally fixate their fractured ankle, to reduce and prevent oedema
89076905|NCT02842957|Experimental|Lifestyle intervention|Behavioral: The Lifestyle arm is the experimental group that will be exposed to an intensive, individualized approach aimed at assisting these CKD patients to adhere to lifestyle changes that are expected to be beneficial to their health and wellbeing. Patients will receive direction to implement a plant based diet, along with more physical activity in their lives. They will be assisted with the optimal use of their prescribed medications by pharmacy professionals and they will receive behavioral counseling by experts in that area.
89076906|NCT02842957|No Intervention|Usual Care|The Usual Care arm will continue to receive the current standard of care involving all the services provided at a contemporary nephrology practice in Western Massachusetts
89076907|NCT02615353|Experimental|Lifestyle Intervention|6 months of a bi-weekly Nutrition Education, Physical Activity, and Behavioral Modification program
89076908|NCT02615353|Placebo Comparator|Usual Care Control|Medical screening and dietary counseling with a Endocrinologist and Registered Dietitian
89076909|NCT02842879|Experimental|Outpatient Foley cervix priming|Patients randomized to outpatient cervix priming will have the insertion of the catheter in the same conditions defined by the Department protocol for inpatient cervix priming. They will be discharged after a reassuring cardiotocogram following the introduction of the Foley catheter. When discharged, the patients will be instructed to apply manual traction to the catheter every 6 hours and they will be given a written document with all the information that should bring them back to hospital.
89076910|NCT02842879|No Intervention|Inpatient Foley cervix priming|The introduction of a deflated catheter (Foley catheter nº 16F) through the outer cervix orifice is preceded by iodine disinfection of the cervix. The intracervical catheter is distended with 40mL of a saline solution. The end of the catheter is taped to the medial portion of the thigh and manual traction is applied to the catheter every 6 hours. If it is not spontaneously extruded it is removed after 24h. Cervix priming occurs in an inpatient setting.
89076911|NCT05334667|Placebo Comparator|Control group|Patients will receive routine management only.
89076912|NCT05334667|Active Comparator|CRRT group|Patients will receive CRRT and routine management.
89076913|NCT05334667|Active Comparator|PPH group|Patients will receive plasmapheresis and routine management.
89076914|NCT00895453|Active Comparator|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid).
89076915|NCT00895453|Active Comparator|itraconazole + lactobacilli agent|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid). Additionally, Lactobacillus vaginal tablets monthly given through 6 days.
89076916|NCT00895453|Active Comparator|classic homeopathy (CH)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
89076917|NCT00893971|Experimental|1|Inhaled PT001 18 μg
89076918|NCT00893971|Experimental|2|Inhaled PT005 2.4 μg
89076919|NCT00893971|Experimental|3|Inhaled PT003 (PT001 18 μg / 2.4 μg PT005)
89076920|NCT00893971|Experimental|4|PT001 18 μg + PT005 2.4 μg
89076921|NCT00893737|Experimental|Treximet|Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.
89076922|NCT00893113|Placebo Comparator|Placebo, Then Alfuzosin|Participants first received 1 Placebo tablet once daily for 12 weeks. Participants then received a 10 mg tablet of Alfuzosin daily for 12 weeks.
89076923|NCT00893113|Experimental|Alfuzosin, Then Placebo|Participants first received a 10 mg tablet of Alfuzosin once daily for 12 weeks. Participants then received 1 Placebo tablet once daily for 12 weeks.
89076924|NCT05333653|Experimental|Continous Supportive Care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.
89076925|NCT05333653|Experimental|Control|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
89076926|NCT02838199|Experimental|TAVR|Transcatheter aortic valve replacement with SAPIEN 3
89076927|NCT02838199|Active Comparator|SAVR|Surgical aortic valve replacement
89076928|NCT02840929|Experimental|Second-look OGD group|"Second-look OGD within 16 to 24 hours after primary OGD, in addition to standard care (esomeprazole infusion for three days, followed by oral esomeprazole.~OGD will be offered if signs of rebleeding present)"
89076929|NCT02840929|Active Comparator|Standard care group|Esomeprazole infusion for three days, followed by oral esomeprazole. OGD will be offered if signs of rebleeding present
89076930|NCT04201483|Active Comparator|DCE group|DCE exercise without RUSI feedback
89076931|NCT04201483|Experimental|DCE + RUSI group|DCE exercise with RUSI feedback
89076932|NCT02837887|Experimental|Group I (immediate treatment)|Patients undergo computerized cognitive behavior therapy consisting of 45-60 minute sessions once per week for 8 weeks. Patients also complete the PHQ-9 and GAD7 at weeks 1, 3, 5, 7 and 8 and complete other questionnaires for 15-30 minutes each that assess psychosocial and physical symptoms.
89076933|NCT02837887|Experimental|Group II (wait-list)|Patients are placed on an 8-week wait-list and then undergo computerized cognitive behavior therapy and receive questionnaires as in Group I.
89076934|NCT02840617|Experimental|ICG injection group|ICG will be intravenously administered over a 10 second period immediately after the patient was anesthetized. The fluorescence will be performed during and after the surgery, respectively.
89076935|NCT02838121|Experimental|Aclasta|Aclasta IV once annual for 2 years
89076936|NCT02838121|Placebo Comparator|Placebo|Placebo group
89076937|NCT04250389||Patients with VS receiving methylene blue infusion|The studied population will be all patients receiving methylene blue for refractory vasoplegic shock (VS) after Cardiopulmonary Bypass (CPB). Refractory VS is defined as follow: a dose of norepinephrine > 0.5µg/kg/min to obtain a mean arterial pressure of 65-75 mmHg with a normal or increase cardiac (> 2 L.min-1.m-2). Patients will be included in the investigator's 20-bed adult cardiothoracic intensive care unit (ICU) in a tertiary teaching hospital (Hopital Cardiologique Louis Pradel, Hospices Civils de Lyon).
89076938|NCT02838043|Experimental|Participant|All participants will be experimental and receive Probio'Stick.
89076939|NCT00892957|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr will be applied to the study suture line.
89076940|NCT00892957|Active Comparator|Manual compression with surgical gauze pads|Dry gauze pads will be positioned to cover the complete study suture line.
89076941|NCT02834611|Experimental|Ceramide NanoLiposome|Dose escalation of Ceramide NanoLiposome
89076942|NCT02834689|Experimental|Walking|Walking on a treadmill at 3.5 metabolic equivalents (METS) for 50 minutes
89076943|NCT02834689|Experimental|Seated Control|Sitting for 50 minutes
89076944|NCT05322733|Experimental|Treatment (oFCG)|See Detailed Description.
89076945|NCT00968812|Active Comparator|Glimepiride|Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
89076946|NCT00968812|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
89076947|NCT00968812|Experimental|Canagliflozin 300 mg|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
89076948|NCT02834767|Experimental|Group 1 Primary Snoring Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
89076949|NCT02834767|Placebo Comparator|Group 2 Primary Snoring Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
89076950|NCT02834767|Experimental|Group 3 Primary OSA Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
89076951|NCT02834767|Placebo Comparator|Group 4 Primary OSA Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
89076952|NCT02834845|Experimental|Sevoflurane|
89076953|NCT02834845|Experimental|Desflurane|
89076954|NCT02840851||Healthy young women|Healthy young women between the age of 20-34 years.
89076955|NCT02840851||Healthy young men|Healthy young men between the age of 20-34 years.
89076956|NCT02840851||Healthy older women|Healthy older women between the age of 50-64 years.
89076957|NCT02840851||Healthy older men|Healthy older men between the age of 50-64 years.
89076958|NCT02834533|Active Comparator|column heading in tables.|The group 1 (G1, n=20) underwent Lokomat-Nanos training. Each patient underwent 40 1h-training sessions (for 3 times a week). Both the study groups were treated by Lokomat (Hocoma Inc., Zurich, Switzerland), which includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . The overall duration of Lokomat therapy, including the time to get on and off, was 60min, while the robotic gait training lasted around 40min.
89076959|NCT02834533|Active Comparator|row and column in table|The group 2 (G2, n=20) underwent Lokomat-Pro training, with the same G1 sessions. The Pro device offers instead a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
89076960|NCT02834299|Experimental|DBT Guided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and receive six brief therapy sessions via video-calling."
89076961|NCT02834299|Experimental|DBT Unguided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and asked to follow the manual on their own."
89076962|NCT02834299|Active Comparator|Self-Esteem-Focused Unguided Self-Help|"Participants will be provided with the self-help manual Self-Esteem by McKay & Fanning (2016) as asked to follow the manual on their own."
89076963|NCT05333575|Experimental|Experimental Group: Lullaby|The mothers in this group sang lullabies to their babies next to the incubator during feeding.
89076964|NCT05333575|Experimental|Experimental Group: Classic Music|Babies in this group were listened to classical music during feeding.
89076965|NCT05333575|No Intervention|Control Group|Premature newborns in the control group were fed according to the routine of the clinic and no intervention was performed other than routine practice.
89076966|NCT00992056|Experimental|Metoprolol/Nebivolol|Metoprolol/Nebivolol: Metoprolol 50 mg titrated to 100 mg then nebivolol 5 mg titrated to 10 mg
89076967|NCT00992056|Experimental|Nebivolol/Metoprolol|Metoprolol 50 mg titrated to 100 mg then Nebivolol 5 mg titrated to 10 mg
89076968|NCT02837653|Experimental|Experimental|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home, and a personalized Physical Activity Counseling based on the Cardiovascular Risk of Each Patient
89076969|NCT02837653|Active Comparator|Control|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home.
89076970|NCT01696747||Diabetic|participants with a primary etiology of diabetic gastroparesis
89076971|NCT01696747||Idiopathic|participants with a primary etiology of idiopathic gastroparesis
89076972|NCT01696747||Post-Nissen|participants with a primary etiology of post-Nissen fundoplication gastroparesis
89076973|NCT04249999|Experimental|Intervention|Access to online physical activity platform (www.activonline.com.au) in addition to usual care.
88812812|NCT01447511|Other|CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
89076974|NCT04249999|No Intervention|Control|No access to online physical activity platform. Continue with usual care.
89076975|NCT04286074|Experimental|Experimental group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the muscle training technique will be performed against a resistance of 50% of the maximum inspiratory pressure of each athlete"
89076976|NCT04286074|Active Comparator|Control group|"Each session will last 10 minutes, taking place 5 days a week, over a period of 6 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the muscle training technique will be performed against a resistance of 10% of the maximum inspiratory pressure of each athlete"
89076977|NCT04249921||Experimental|"Use acupuncture to treat the patients who received the surgery of CPA tumor. Acupoints of reference: Yifeng(TE17),Tinggong(SI19),Xiaguan(ST07),Wind Pool(GB20),Outer Pass(SJ5),Union Valley(LI4),Yang Mound Spring(GB34),Leg Three Li(ST36).~Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS)."
89076978|NCT04249921||Control|1.Use questionnaires to evaluate.The questionnaires including House-Brackmann Grading Scale,WHOQOL-BREF Taiwan Version,Functional Assessment of Cancer Therapy: General(FACT-G),Visual Analogue Scale(VAS).
89076979|NCT02834221|Experimental|Real-time ultrasound-guided puncture|Cannulate each femoral veins with two wires with real-time ultrasound-guided method.
89076980|NCT02834221|Other|Anatomical landmark guided puncture|Cannulate each femoral veins with two wires with the anatomical landmark guided method.
89076981|NCT00972322|Experimental|MK-8245 50 mg|MK-8245, 50 mg, twice daily for 28 days
89076982|NCT00972322|Placebo Comparator|Placebo|Placebo to MK-8245, 50 mg, twice daily
88812488|NCT04217109|Experimental|Odour sampling|Odour collection will be obtained by positioning a compress on the breast concerned during the night preceding the day of samplings. The compress, once removed, will be placed in specific envelope for the study. Envelope will be given to the investigating centre during the appointment of percutaneous samples and then sent to the sponsor center (Institute Curie Paris).
89076983|NCT02840773|Active Comparator|Test group-baseline|Press-fit implant connection was monitored at baseline
89076984|NCT02840773|Active Comparator|Test group-12 month|Press-fit implant connection was monitored at 12 month after prosthesis delivered.
89076985|NCT02840773|Active Comparator|Control group-baseline|Screw-retained connection was monitored at baseline
89076986|NCT02840773|Active Comparator|Control group-12 month|Screw-retained connection was monitored at 12 month after prosthesis delivered.
89076987|NCT02863744|Experimental|CAF+SCTG|
89076988|NCT02834377|Experimental|Treatment algorithm|Patients allocated to the study group will be connected to a cardiac output monitor. An initial haemodynamic assessment will be performed at the beginning of surgery and at regular time intervals (every 15 minutes) during surgery. The personal cardiac output value is targeted.
89076989|NCT02834377|No Intervention|Standard of Care|Patients allocated to the control group will receive the standard care of the hospital.
89076990|NCT02834455|Active Comparator|CE-CT scanning|Contrast-enhanced CT scan of the thorax and abdomen.
89076991|NCT02834455|Active Comparator|PET-CT scanning|Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
89076992|NCT02837575|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 4 doses
89076993|NCT02837575|Placebo Comparator|Phosphate-buffered saline, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 4 doses
89076994|NCT04249765|Experimental|Hand strength|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned.~The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer."
89076995|NCT05334355||Positive Family History of Hypertension|Young normotensive generally healthy adult with one or more biological parents with diagnosed hypertension.
89076996|NCT05334355||Negative Family History of Hypertension|Young normotensive generally healthy adult with no biological parent with diagnosed hypertension.
89076997|NCT02840695||AS patients|Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures
89076998|NCT02837497|No Intervention|Control|Standard ICU resuscitation practices
89076999|NCT02837497|Experimental|ICU-RESUS CPR Improvement Bundle|ICU-RESUS bundle implementation: 1) point-of-care bedside CPR training; and 2) post-cardiac arrest debriefings.
89077000|NCT00967798|Experimental|Sitagliptin|"CF patients receiving Sitagliptin.~Intervention: Dose is 100 mg taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
89077001|NCT00967798|Placebo Comparator|Sugar pill|"CF patients receiving placebo.~Intervention: Placebo is taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
89077002|NCT04248361|Experimental|TEM-PCR Diagnosis|The TEM-PCR diagnostic technology will be used to assess for a source pathogen involved in the subject's acute respiratory illness. Results of the TEM-PCR URI Panel will be used by the physician to guide treatment decisions. If indicated, the investigator may also utilize rapid strep testing and rapid influenza testing for diagnosis. In the event a lower respiratory infection is suspected a chest x-ray or complete blood count (CBC) with differential may also be performed.
89077003|NCT04248361|Active Comparator|SOC/Empiric Diagnosis|The Standard of Care for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
88812489|NCT04214535|Experimental|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Cervical Cage at one or two-levels
88812490|NCT04139967|Experimental|Elderly rectal cancer patients|
88812491|NCT04125238|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future events they are looking forward to at five time points in the future (1 day, 1 week, 1 month, 3 months, 1 year, 5 years, and 25 years). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
89077004|NCT02862496||hyperemesis gravidarum|hyperemesis gravidarum group consisting of 30 pregnant women between 7-20 weeks of gestation with diagnosed hyperemesis gravidarum.
89077005|NCT02862496||Control group|control group consisting of 30 health pregnant women between 7-20 weeks of gestation with excluded hyperemesis gravidarum.
89077006|NCT04248439|Experimental|RP-L102|RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
89077007|NCT02863510|Experimental|Renal Denervation|Participation receiving renal sympathetic denervation
89077008|NCT04286464||Term born group (H)|Healthy, white and term Born infants and Children Born 38-42 weeks postconceptional
89077009|NCT04286464||Preterm group (P)|Healthy, white preterm Born infants and Children Born <37 weeks postconceptional Which comply with the international criteria (Jobe and Bancalari) of a diagnosis of bronchopulmonary dysplasia (BPD), or of chronic lung disease of the new-born (CLD)
89077010|NCT04286464||Risk pregnancy group (RP)|White preterm Born infants and Children, including Twins Born <37 weeks postconceptional With fetal growth restriction (FGR), intrauterine growth restriction (IUGR) or preeclampsia (PE) With gestational Diabetes (GDM) With IVF or Amnion dysfunction
89077011|NCT02833831|Experimental|Part 1: Group 1|Participants will receive Treatment A (a single dose of ALS-008176 1,500 mg) or Treatment B (a single dose of placebo) under fasted conditions.
89077012|NCT02833831|Experimental|Part 1: Group 2|Participants will receive Treatment C (a single dose of ALS-008176 2,500 mg) or Treatment D (a single dose of placebo) under fasted conditions.
89077013|NCT02833831|Experimental|Part 1: Group 3|Participants will receive Treatment E (a single dose of ALS-008176 3,000 mg) or Treatment F (a single dose of placebo) under fasted conditions.
89077014|NCT02833831|Experimental|Part 2: Sequence GHI|Participants will receive Treatment G (a single dose of ALS-008176 3,000 mg + a single dose of moxifloxacin placebo under fasted conditions) then Treatment H (a single dose of ALS-008176 placebo + a single dose of moxifloxacin 400 mg under fasted conditions) then Treatment I (a single dose of ALS-008176 placebo + a single dose of moxifloxacin placebo under fasted conditions). There will be a washout period of at least 14 days between subsequent treatments.
89077015|NCT02833831|Experimental|Part 2: Sequence HIG|Participants will receive Treatment H then Treatment I and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
89077016|NCT02833831|Experimental|Part 2: Sequence IGH|Participants will receive Treatment I then Treatment G and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
89077017|NCT02833831|Experimental|Part 2: Sequence IHG|Participants will receive Treatment I then Treatment H and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
89077018|NCT02833831|Experimental|Part 2: Sequence HGI|Participants will receive Treatment H then Treatment G and then Treatment I. There will be a washout period of at least 14 days between subsequent treatments.
89077019|NCT02833831|Experimental|Part 2: Sequence GIH|Participants will receive Treatment G then Treatment I and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
89077020|NCT02833987||Treated with direct oral anticoagulants (DOACs)|Patients who received a new prescription for a DOAC (apixaban, dabigatran, or rivaroxaban) in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
89077021|NCT02833987||Treated with warfarin|Patients who received a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
89077022|NCT02833909|Experimental|HS|
89077023|NCT02833909|Experimental|Controls|
89077024|NCT02833675||bradykinin angioedema|Hereditary angioedema with or without C1Inhibitor Drug induced angiodema
89077025|NCT02833675||Histaminergic angioedema|Allergic and non allergic angioedema
89077026|NCT02833675||Control group|Patients with abdominal pain
89077027|NCT02833363||patients with non-atrophic gastritis|
89077028|NCT02833363||Patients with gastritis|
89077029|NCT02833363||Patients with intestinal metaplasia|
89077030|NCT02833363||Patients with intrepithelial neoplasia|
89077031|NCT02833363||Patients with non-cardia gastric cancer|
89077032|NCT02833519|No Intervention|control group|Standard care, mentally vulnerable women
89077033|NCT02833519|Active Comparator|group exercise|Supervised Group training
89077034|NCT02833441|Experimental|Peer Support Intervention|Adolescents/young adults in the Peer Support Intervention arm will be referred to a Peer Support Intervention support group within their own or nearby community. This support group will meet monthly and will be facilitated by a professional HIV counsellor together with a Peer Support Intervention counselor. The Peer Support Intervention counsellors will provide regular counselling to their allocated participants through home visits and SMS messages. Each participant will be visited once a week in their home. Whatsapp messages will be delivered daily to each participant by the Community Adolescent Treatment Supporters. The agreed messages will briefly enquire about the participant's well-being without specifically making reference to HIV or ARVs. In addition, participants' caregivers will be invited to a 3-session intervention to build knowledge, skills and confidence to better support their adolescents.
89224487|NCT06265623||COPD patients with exertional desaturation|Patients with chronic obstructive pulmonary disease stages 2-3, groups B or E according to the GOLD Guideline (2023), who experience a drop in arterial oxygen saturation (by pulse oximetry) to <90% or a drop by 4% or greater of the basal value during a six-minute walk test.
89077035|NCT02833441|No Intervention|Standard of Care Practice|"Participants in the standard of care group will receive adherence evaluations and counseling at the clinic as per the current standard of care. Current procedures involve a group counseling session given on Monday morning during which topics are discussed that are relevant to adolescents. In general children aged between 13-19 years attend these sessions. After the group counseling, adolescents also receive an individual counseling session before being evaluated by the clinic doctor. Youth are also encouraged to complete a self reported adherence questionnaire and may periodically undergo pill counts by the clinic counselors.~The adolescents may belong to peer support groups in their communities, however these activities are not part of the clinic program. No interventions are typically targeted at their caregivers."
89077036|NCT04248049|Experimental|Experimental side|Roots covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
89077037|NCT04248049|Active Comparator|Control side|Roots covered with coronally advanced flap (CAR)
89077038|NCT04247893|Active Comparator|Exercises with blood flow restriction|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Device: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.
89077039|NCT04247893|Experimental|Exercises with blood flow restriction + photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted.Photobiomodulation a mesh composed of multiple diodes containing 50 Infrared LEDs.
89077040|NCT04247893|Placebo Comparator|Blood flow restriction exercises + placebo photobiomodulation|Exercise: 10 minutes of heating on a treadmill without changing the inclination and adopting a standardized speed; Supine bridge, Supine unilateral bridge, Flexion of the hip with the knee extended, Knee extension, volunteer in sedation; Prone knee flexion; Squat on the wall associated with isometric contraction; Abduction of the hip, lateral rotation and knee extension in lateral decubitus associated with isometric contraction; Abduction, lateral rotation of the hip, slight knee and hip flexion performing abduction with the feet together: associated with isometric contraction; Abduction of the hip in orthostatic associated with isometric contraction.Devices: The blood flow restriction in mmHg will be performed using a vascular occlusion training manometer, positioned in the thigh inguinal region and inflated to the point where the auscultatory pulse of the tibial artery is interrupted. Photobiomodulation turned off with a mesh composed of multiple diodes containing 50 Infrared LEDs.
89077041|NCT02837341|Other|Volunteers|Monitoring of respiratory rates via camera-based System Monitoring of respiratory rate by Philips®Vital Sign Device - Camera-based system (Prototype) and capnography simultaneously.
89077042|NCT02837185|Experimental|Cervical Dystonia|'Botulinum Toxin injection' will be done and 'physiological measures' will then be collected.
89077043|NCT02837185|Other|Healthy controls|No Botulinum toxin is injected, 'physiological measures' will be collected as a healthy comparator.
89077044|NCT00965458|Experimental|Alefacept|Subjects in this group receive weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
89077045|NCT00965458|Placebo Comparator|Placebo|Subjects in this group received weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
89077046|NCT02837107|Active Comparator|Supplement|The supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).
89077047|NCT02837107|Placebo Comparator|Placebo|A look-alike placebo were prepared and donated by LR Healthy and Beauty Systems LTD. The placebo contained Aloe barbadensis Miller Gel (USA/Mexico 3.6%), ascorbic acid, and some excipients.
89077048|NCT04249531|Experimental|Amikacin|Patients will receive once amikacin i.v. 7,5 mg/kg in the first week
89077049|NCT02836951||Patient|This group consists of patients that are hospitalized due to a head injury. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
89077050|NCT02836951||Healthy controls|This group consists of healthy volunteers. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
89077051|NCT02836639|Experimental|Busulfan, Etoposide, Bendamustine|All patients will receive the conditioning regimen followed by autologous stem cell transplantation.
89077052|NCT00972244|Experimental|1|1mg dapagliflozin
89077053|NCT00972244|Experimental|2|2.5mg dapagliflozin
89077054|NCT00972244|Experimental|3|5mg dapagliflozin
89077055|NCT00972244|Experimental|4|10mg dapagliflozin
89077056|NCT00972244|Placebo Comparator|5|Placebo
89077057|NCT00892723|Experimental|Low Dose|
89077058|NCT00892723|Experimental|High Dose|
89077059|NCT00892723|Placebo Comparator|Placebo|
89077060|NCT03811912|Experimental|CTP-543 8 mg BID|Participants received 1 x 8 mg CTP-543 tablet and 1 x CTP-543 matching placebo tablet, twice daily (BID) for 24 weeks.
89077061|NCT03811912|Experimental|CTP-543 16 mg QD|Participants received 16 mg (2 x 8 mg) CTP-543 tablets, once daily (QD) and after 12 hours, received 2 x CTP-543 matching placebo tablets, QD for 24 weeks.
89077062|NCT02836561|Experimental|Intervention Message|Participants who are randomized to the intervention message will receive contraception information in advance of their appointment that may be helpful in their decision-making.
89077063|NCT02836561|No Intervention|Control Message|Participants who are randomized to the control message will receive appointment logistic information that may be a helpful reminder.
89077064|NCT05333419|Experimental|Single Dose 100ng/day PA5346 Latanoprost FA SR Ocular Implant|After washout, eligible subjects will be dosed with a single 100ng/day PA5346 Latanoprost FA SR Ocular Implant at study Day 0.
89077065|NCT04285996|Other|All patients|Pilot study: All registered patients will undergo a PET scan using [18F]-FBA-A20FMDV2.
89077066|NCT02836795|Experimental|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
89077067|NCT04285762||Patients underwent supermicrosurgical LVA|Patients underwent supermicrosurgical LVA by a single surgeon from March 2016 to October 2018.
89077068|NCT02836483|Experimental|Group 1|LCB01-0371 800mg, QD
89077069|NCT02836483|Experimental|Group 2|LCB01-0371 400mg, BID
89077070|NCT02836483|Experimental|Group 3|LCB01-0371 800mg, BID
89077071|NCT02836483|Active Comparator|Group 4|Tubes 3~5Tablet, QD
89077072|NCT02836483|Active Comparator|Group 5|Zyvox 600mg, BID
89077073|NCT02836483|Experimental|Group 6|LCB01-0371 1200mg, QD
89077074|NCT02836171|Experimental|Treatment|subjects receiving a single 250 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then Itraconazole capsules 100 mg/day orally for 6 days with a single 250 mg oral dose of apatinib mesylate tablets co-administered on day 4 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
89077075|NCT00971932|Experimental|Cetuximab + Cisplatin/Carboplatin + Fluorouracil (5-FU)|
89077076|NCT02840305|Other|Expérience 1|Brain bases of spatial frequencies treatment 30 young adults, 20 old adults 20 children between 4 and 6 years, 20 children between 6 and 12 years and 20 young adults
89077077|NCT02840305|Other|Expérience 2|Brain bases of Computer to Film (CtF) analysis 30 young adults, 20 old adults
89077078|NCT02840305|Other|Expérience 3|Part of parahippocampal gyrus in Computer to Film (CtF) analysis 30 young adults, 20 old adults.
89077079|NCT00629746|Experimental|NIM (Nerve Integrity Monitor)|
89077080|NCT04400929|Experimental|Group A: Treatment Group|Day 1 - 5: Receive study medication Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
89077081|NCT04400929|Placebo Comparator|Group B: Placebo Group|Day 1 - 5: Receive normal saline 0.9% daily (via infusion into the vein) in addition to standard of care treatments
89077082|NCT04400929|Experimental|Group C|Day 6 - 10: Subjects in Group A who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
89077083|NCT04400929|Experimental|Group D|Day 6 - 10: Subjects from Group B to receive study medication (based on the treating physician's assessment), Leukine® 125mcg/m2 body surface area daily (via infusion into the vein) in addition to standard of care treatments
89077084|NCT04400929|Experimental|Group E|Day 11 - 15: Subjects in Group D who require mechanical ventilation to receive an additional 5 days of IV Leukine® 125mcg/m2 body surface area daily, in addition to standard of care treatments (based on the treating physician's assessment)
89077085|NCT02836405||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder (ASD) will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
89077086|NCT02836405||Healthy Control|Typically developing individuals without a history of autism will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
89077087|NCT04285138|Experimental|Phantom limb exercises|Participants in this group will be treated with routine physical therapy, mirror therapy and Phantom limb exercises. Treatment time: 1 hour
89077088|NCT04285138|Active Comparator|conventional treatment|In this group, participants will be treated by routine physical therapy and mirror therapy protocol. Treatment time: 35 minutes
89077089|NCT02862652|Experimental|children with acute lymphoblastic leukemia|
89077090|NCT04284982|Experimental|Heavy resistance training program|
89077091|NCT00970684|Experimental|Bevacizumab, Docetaxel, and Gemcitabine|Treatment repeats every 21 days for up to 6 courses.
89077092|NCT00967330|Experimental|1|
89077093|NCT00967330|Active Comparator|2|
89077094|NCT02863276|Experimental|Intensified insulin group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.
89077095|NCT02863276|No Intervention|Control group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses
89077096|NCT00967018|Experimental|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. For patients treated with goserelin in the previous trials (CS28, CS30 and CS31),a starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to the end of the trial. For patients treated with degarelix in the previous trials, maintenance doses of 80 mg (20 mg/mL) degarelix were continued and were administered as single 4 mL s.c. injections at 28 day intervals to the end of the trial.
89077097|NCT00965146|Experimental|Scorpio® CR Total Knee System|Scorpio® CR Total Knee System Study Device
89077098|NCT02863042|Experimental|Deltoid Tendon Repaired|Repair Deltoid Tendon
89077099|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|
89077100|NCT04286152|Experimental|Mirabegron and narcotic analgesia|Drug: Mirabegron 50mg tablet, oral, daily from stent insertion until removal - 7days Drug: Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
89077101|NCT04286152|Placebo Comparator|Placebo|Drug: Placebo for Mirabegron, 1 tablet, oral, daily from stent insertion until removal - 7days Drug:Hydromorphone 1mg tablet oral, every 4 hours as necessary Drug: Tylenol ES 500mg tablet , oral, every 6 hours as necessary
89077102|NCT00629902||A1|Patients with prosthesis-patient mismatch after mitral valve replacement
89077103|NCT00629902||A2|Patients without prosthesis mismatch after mitral valve replacement
89077104|NCT00966940|Other|Travoprost-to-tafluprost|Travoprost first, with tafluprost second. Each product dosed for six weeks.
89077105|NCT00966940|Other|Tafluprost-to-travoprost|Tafluprost first, with travoprost second. Each product dosed for six weeks.
89077106|NCT00965848|Experimental|Nosocomial Pneumonia|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with nosocomial pneumonia up to maximum of 14 days.
89077107|NCT00965848|Experimental|Complicated Intra-Abdominal Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated intra-abdominal infections up to maximum of 14 days.
89077108|NCT00965848|Experimental|Complicated Urinary Tract Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated urinary tract infections up to maximum of 10 days.
89077109|NCT04284748|Experimental|Plyometric training with blood flow restriction|Routine physiotherapy program + Plyometric training with blood flow restriction, 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
89077110|NCT04284748|Active Comparator|Plyometric training|Routine physiotherapy program + Plyometric training 3 days a week for 8 weeks Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
89077111|NCT03447574|Experimental|Aim 1|The ethanol dilution is, in essence, a non-invasive dilution method. It is of interest because of how ethanol readily dissolves itself exclusively into the water space of the body[4], is non-toxic in reasonable concentrations, is metabolized in a 0th order reaction above concentrations of 0.015 g/dL[4], and there are non-invasive methods for determining blood alcohol concentration[5, 6]. Thus, by drinking a known amount of ethanol, total body water can be calculated after a few hours of periodic breathalyzer analyses. Ethanol has been validated against deuterium oxide, the invasive gold standard for determining total body water[4]. The ethanol dose will be 0.5g/kg body weight.
89077112|NCT03447574|Active Comparator|Aim 2|30mL/kg body weight of saline will be rapidly infused after the baseline measurements completed in Aim 1. Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated. To determine if non-invasive fluid volume techniques can accurately determine fluid changes in healthy participants.Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated.
89077113|NCT04284826|Experimental|mitomycin C injection group|A submucosal needle injection of 4mL of a MMC preparation (0.5mg/mL) into the tearing esophageal wall after esophageal bougie dilation on refractory benign esophageal stricture
89077114|NCT04284670|Experimental|Eccentric treadmill training|The intervention group will perform an 8 week program, 2 sessions a week for a total of 16 sessions. training will be done on a designated negative gradient treadmill. first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
89224488|NCT06265623||COPD patients without exertional desaturation|Patients with chronic obstructive pulmonary disease stages 2-3, groups B or E according to the GOLD Guideline (2023), who do not experience a drop in arterial oxygen saturation (by pulse oximetry) to <90% or a drop by 4% or greater of the basal value during a six-minute walk test.
89224489|NCT06265610||group 1|Total intravenous anesthesia with target-controlled infusion (TCI/TIVA) was applied as an anesthesia method to be applied to patients during cardiology angiography procedures.
89224490|NCT06265610||Group 2|In the anesthesia method to be applied to patients during cardiology angiography procedures, inhalation anesthesia was applied.
89224491|NCT06265597|No Intervention|Control group|It includes obese children who are not given a Healthy Nutrition and Yoga Programs.
89224492|NCT06265597|Experimental|İntervention group|It includes obese children who are given Healthy Nutrition and Yoga Programs.
89224493|NCT06265571||GROUP I|Interscalene block (group I)15 ml of 0.5% bupivacaine was applied with a single injection to 12 of 18 patients,
89224494|NCT06265571||GROUP II|7.5 ml of interscalene and 7.5 ml of suprascapular block (GROUP II) were applied to 6 patients with posterior approach.
89224495|NCT06265558|Active Comparator|Standard care|Conventional post-operative care
89224496|NCT06265558|Experimental|Negative pressure therapy (NPT)|Immediate post-operative negative pressure therapy
89224497|NCT06265545|Experimental|Arm 1|"With IDH1 gene mutation(up to 2 cycles available):IVA :~Ivosidenib 500mg d1-28 Azacitidine 75mg/m2/d d1-7 Venetoclax100mg d1,200mg d2,400mg d3-21 400mg ;d22-28(If the proportion of 21st bone marrow blasts is greater than 5%)"
89224498|NCT06265545|Experimental|Arm 2|"FLT3/ITD or FLT3/TKD gene mutation (up to 2 cycles available)~GV :~Gilteritinib 120mg, d1-28 Venetoclax 100mg d1, 200mg d2, 400mg d3-21 400mg d22-28 (if the proportion of 21st bone marrow blasts are greater than 5%)"
89077115|NCT04284670|Experimental|Control group|The control group will receive the same amount of training under neutral gradient surface(0%).The program will be 8 weeks while in each week there will be two exercise sessions and a total of 16 sessions. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. Training intensity will be 70%-80% out of maximal heart-rate.
89077116|NCT03442192|Other|PrEP Care Anywhere Services|The PrEP Care Anywhere intervention adapts peer PrEP case management for virtual delivery and provides clinical services through a tele-health program, delivered by the same clinic providers. After an initial face-to-face intake clinical evaluation within the clinic, will then receive the remaining PrEP clinical evaluations via telemedicine using the HIPPA compliant polycom platform. Case management interventions will be conducted virtually via the PrEPme application, telephone consultation, text, or email.
89077117|NCT04284904||matched sibling hematopoietic stem cell transplantation|aGVHD biomarker in matched sibling donor hematopoietic stem cell transplantation
89077118|NCT04284904||unrelated allogeneic hematopoietic stem cell transplantation|aGVHD biomarker in unrelated donor hematopoietic stem cell transplantation
89077119|NCT04284904||haploidentical hematopoietic stem cell transplantation|aGVHD biomarker in haploidentical donor hematopoietic stem cell transplantation
89077120|NCT04284592|No Intervention|Control group|Patients do not receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
89077121|NCT04284592|Experimental|RIP group|Patients receive remote ischemic post-conditioning (RIP) after cardiopulmonary bypass
89077122|NCT04204564||paclitaxel coated balloon angioplasty|Procedures with paclitaxel coated balloon angioplasty of the superficial femoral-popliteal artery
89077123|NCT04204564||plain balloon angioplasty|Procedures with plain balloon angioplasty of the superficial femoral-popliteal artery
88812813|NCT01447511|Other|CYP2C9*2/*3 Genotype|Individuals with the CYP2C9*2/*3 genotype have one *2 and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
89077124|NCT04204564||paclitaxel eluting stent|Procedures with paclitaxel eluting stenting of the superficial femoral-popliteal artery
89077125|NCT04204564||bare metal stenting|Procedures with bare metal self expanding stenting of the superficial femoral-popliteal artery
89077126|NCT04285528|Experimental|General Anesthesia|The first group which will undergo general anesthesia, will be anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Laryngeal mask airway will be inserted afterwards.
89077127|NCT04285528|Experimental|PFK group|The second group will undergo intravenous sedation and analgesia by using a mixture of Fentanyl, Propofol and Ketamine (PFK mixture). The mixture consists of 100 mcg Fentanyl, 100 mg Propofol, 100 mg of Ketamine. In addition, 40 mg of Lidocaine will be added, this aims to reduce the pain on injection caused by Propofol. Moreover, 4 ml of water for injection will be added to the mixture.
89077128|NCT00629824|Active Comparator|A|110 naïve CHC patients who are 65 to 80 years of age
89077129|NCT00629824|Active Comparator|B|140 naïve CHC patients who are 50 to 64 years of age
89077130|NCT00629824|Active Comparator|C|40 HCV-1 infected patients with an RVR who are 65-80 years of age will receive 24 weeks of treatment
89077131|NCT04285216|Experimental|Dry needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
89077132|NCT04285216|Active Comparator|Strain counter strain|Hot pack 10 minutes, stretching,Neck isometrics, Strain counter strain (S C S)
89077133|NCT00961636|Experimental|ERN/LRPT|"One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg~tablets daily (2g/40 mg total) for 28 weeks"
89077134|NCT00961636|Experimental|ERN/LRPT then ERN|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.
89077135|NCT00961636|Placebo Comparator|Placebo|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.
89077136|NCT04285060|Experimental|Training Group|All participants are assigned to the training group with the Samsung GEMS-H.
89077137|NCT02862262|Experimental|Blinded, Prospective Arm (1)|Clinical performance of the ARIES Bordetella Assay for the detection of B. pertussis and B. parapertussis will be evaluated in prospectively collected, de-identified, left-over, clinical specimens.
89077138|NCT02862262|Experimental|Blinded, Pre-selected Arm (2)|In the event that an insufficient number of positive specimens are acquired for B. pertussis / B. parapertussis in Arm 1, clinical performance of the ARIES Bordetella Assay will be tested using banked, pre-selected, positive clinical specimens.
89077139|NCT02862262|Experimental|Blinded, Contrived Arm (3)|Contrived specimens will be tested using the ARIES Bordetella Assay to evaluate detection of B. parapertussis in the event that an insufficient number of positive specimens are acquired in Arm 2.
89077140|NCT02862340|Other|Autistic disorder|Children over 4 years with an autistic disorder of unknown etiology with the techniques currently available and accessible in routine diagnostics.
89077141|NCT04283422||patintes on mechanical ventilation|
89077142|NCT04283422||patintes not on mechanical ventilation|
89077143|NCT00964678|Experimental|carvedilol|Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI
89077144|NCT00964366|Experimental|Clindamycin/BPO gel|Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.
89077145|NCT00964366|Active Comparator|Dapsone gel|Twice-daily applications of dapsone gel to one side of the face.
89077146|NCT02861326|Other|Patients|Non-surgical periodontal treatment has performed to patients. Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
89077147|NCT02861404||Salicylate ointment|patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)
89077148|NCT02861404||Imiquimod|patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)
89077149|NCT02861404||5-Fluoro-Uracil|patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)
89077150|NCT02861404||Cryotherapy|patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)
89077151|NCT02861404||placebo|patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)
89077152|NCT03523702|Experimental|PembroRT Cohort|Subjects with PD-L1 expression ≥ 50% Combination of pembrolizumab and dose-painted radiotherapy for locally advanced NSCLC patients with high (≥ 50%) PD-L1 expression.
89077153|NCT03523702|Active Comparator|ChemoRT Cohort|Subjects with PD-L1 expression < 50% Subjects with PD-L1 expression below 50% will be enrolled and treated with standard concurrent chemoradiotherapy.
89077154|NCT04284514|Experimental|AKB-9778 Ophthalmic Solution|Up to 4 daily dose levels of AKB-9778 Ophthalmic Solution will be evaluated. Doses will be administered in both eyes daily for 7 days.
89077155|NCT04284514|Placebo Comparator|Vehicle Control Ophthalmic Solution|Matched vehicle-control ophthalmic solution will be administered in both eyes daily for 7 days.
89077156|NCT02861248|Experimental|Laser treatment|Fractional micro-plasma radiofrequency treatment given to 95 patients with non-hypertrophic burn scar.
89077157|NCT04283344|Experimental|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula: (1) a fixed deduction, depending on county of residence, for transportation costs for six round trips to the grocery store per month; and (2) an earnings deduction equal to 10 percent of earned income for households with at least one employed household member.
89077158|NCT04283344|No Intervention|Control Group|Households in the control group continued to receive their regular monthly SNAP benefit amounts.
89077159|NCT02860078|Active Comparator|Ultrasound|The group I will be subjected to epidural infiltration using methylprednisolone acetate diluted in ropivacaine 0.1%. Initially the sacral hiatus is identified by palpation. After, the ultrasound device is used (USG) for the puncture, with a linear transducer of high frequency. At the end of corticosteroid administration, the placement of the needle tip will be checked with fluoroscopy and noted.
89077160|NCT02860078|Active Comparator|Radioscopy|The group II will be subjected to infiltration using methylprednisolone acetate diluted in ropivacaine 0.1% . However, only radioscopy be used to guide the puncture.
89077161|NCT02859922|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
89077162|NCT02859922|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
89077163|NCT02860936|Experimental|Lenvatinib|24 mg of lenvatinib will be administered daily to patients until progression of disease or intolerable toxicity or other criteria for discontinuation is met.
89077164|NCT04283266|Active Comparator|Synbiotic group|The synbiotic was composed of fructo-oligosaccharides (FOS): 4.95 g/ sachet and Bifidobacterium animalis lactis: 5 billion / sachet (n=13)
89077165|NCT04283266|Placebo Comparator|Placebo group|A placebo was composed of maltodextrin (60%) and sucrose (40%) : 5 g /sachet (n =14)
88812814|NCT01447511|Other|CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
89077166|NCT04281550|Experimental|Think drink intervention|The Think Drink multicomponent hydration intervention was introduced into the intervention group care homes through a staff workshop.
89077167|NCT00630214|No Intervention|C|No supplements after total thyroidectomy and central neck dissection
89077168|NCT00630214|No Intervention|D|No central neck dissection group (total thyroidectomy alone)
89077169|NCT00630214|Active Comparator|A|Oral calcium plus vitamin D supplements after total thyroidectomy and central neck dissection
89077170|NCT00630214|Active Comparator|B|Oral calcium alone supplement after total thyroidectomy and central neck dissection
89077171|NCT04204486|Experimental|Face to face exercise intervention|Participants will participate in face to face exercise programme delivered by a strength and conditioning coach. Sessions will last 1 hour, 3 times a week, and will be offered at the work place. The coach will register attendance in order to monitor compliance.
89077172|NCT04204486|Active Comparator|Online exercise intervention|"Participants will be given the same training programme as the face to face group, but via an online app. Sessions should last 1 hour and should be completed 3 times a week. Participants will be asked to post a work-out picture on the social platform of the app as proof that they completed their session."
89077173|NCT04204486|No Intervention|Control|This group will undergo all pre and post tests, but will not receive an intervention.
89077174|NCT04284358|No Intervention|Standard Instruction workshop|Standard instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and then attempt it themselves.
89077175|NCT04284358|Experimental|Technology Integrated Instruction workshop|Technology integrated instruction neuromuscular training warm-up workshop. Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation and. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application.
89077176|NCT02859766|Experimental|Abicipar Pegol_Repeat Dose|Treatment Group 1: Abicipar pegol 2 mg administered to the study eye by intravitreal injection, 3 injections 4 weeks apart. [Day 1, Weeks 4 and 8]
89077177|NCT02859766|Experimental|Abicipar Pegol_Single Dose|Treatment Group 2: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1.
89077178|NCT04282798|Experimental|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
89077179|NCT02860156||HIV+/DD+|Subjects are HIV positive and have diastolic dysfunction
89077180|NCT02860156||HIV+/DD-|Subjects are HIV positive and do not have diastolic dysfunction
89077181|NCT02860156||HIV-/DD+|Subjects do not have HIV and have diastolic dysfunction
89077182|NCT02862028|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
89077183|NCT02860858|Experimental|Aflibercept|
89077184|NCT00960154|Experimental|PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
89077185|NCT00960154|Active Comparator|SOC|The SOC consists of scalpel for the skin incision and traditional electrosurgery for the entirety of the subcutaneous dissection.
89077186|NCT02861170|Experimental|Brief Mindfulness-Based Intervention|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety as well as a 10-minute mindfulness-based intervention called a body scan at 3 different time-points (T1 - 1 week prior to surgery, T2 - within 4 hours before surgery, and T3 - approximately 24 hours after transfer from recovery to the orthopedic floor).
89077187|NCT02861170|No Intervention|Education|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety.
89077188|NCT00960076|Experimental|1|Saxagliptin
89077189|NCT00960076|Active Comparator|2|Metformin Extended Release
89077190|NCT02859688||SRS patient|
89077191|NCT02859688||father SRS patient|
89077192|NCT02859688||control patient|
89077193|NCT04281082||ICP|To study the genetic polymorphisms in pregnant women with ICP and in their first degree relatives
89077194|NCT04284202|Experimental|PD-1 plus Dasatinib|
89077195|NCT01227629|Experimental|dabigatran 50 mg twice daily (bid)|Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).
89077196|NCT01227629|Experimental|dabigatran 50 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.
89077197|NCT01227629|Experimental|dabigatran 50 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
89077198|NCT01227629|Experimental|dabigatran 150 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
89077199|NCT01227629|Experimental|dabigatran 150 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
89077200|NCT01227629|Experimental|dabigatran 150 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
89077201|NCT01227629|Experimental|dabigatran 300 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
89077202|NCT01227629|Experimental|dabigatran 300 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
89077203|NCT01227629|Experimental|dabigatran 300 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
89077204|NCT01227629|Active Comparator|warfarin|once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0
89077205|NCT00963820|Experimental|0.24 mg/m^2|Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate
89077206|NCT00963820|Experimental|0.48 mg/m^2|Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077207|NCT00963820|Experimental|0.80 mg/m^2|Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077208|NCT00963820|Experimental|1.20 mg/m^2|Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period.
89077209|NCT00963820|Experimental|1.68 mg/m^2|Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077210|NCT00963820|Experimental|2.23 mg/m^2|Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077211|NCT00963820|Experimental|2.97 mg/m^2|Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077212|NCT00963820|Experimental|3.95 mg/m^2|Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077213|NCT00963820|Experimental|Relapsed and Refractory (RR)|Ixazomib citrate, 2.97 mg/m^2 established Maximum Tolerated Dose (MTD), capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077214|NCT00963820|Experimental|VELCADE-Relapsed (VR)|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077215|NCT00963820|Experimental|PI naïve|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077216|NCT00963820|Experimental|Carfilzomib|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
89077217|NCT03241186|Experimental|Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV|"Cycles 1-4: Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV Day 1 of each Cycle Each Cycle = 21 days~Cycles 5-15: Nivolumab IV 480 mg Day 1 of each Cycle Each Cycle = 28 days"
89077218|NCT01227395||Azithromycin|Patients taking Azithromycin.
89077219|NCT02859532|Experimental|Diagnosis of deep vein thrombosis|All subjects with proximal DVT will have quantitative elastography SWIRE, thrombin generation test and rotational thromboelastometry test.
89077220|NCT04319003|No Intervention|Control School|This school did not receive intervention (until after the study was completed)
89077221|NCT04319003|Experimental|Intervention School|This school received a one-week sugar-reduction intervention
89077222|NCT04281238|Experimental|yoga group|Participants in this group will be given yoga training 3 days a week for 8 weeks. In addition, patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
89077223|NCT04281238|Other|Control group|Patients in this group will be taught home exercises and asked to do these exercises 5 days a week for 8 weeks.
89077224|NCT02859376|Active Comparator|sucrose24% 2 minutes before|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure
89077225|NCT02859376|Experimental|sucrose24% 2minutes before and during|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure
89077226|NCT04283032||Multiparametric magnetic resonance + transrectal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transrectal biopsy (BPTE)
89077227|NCT04283032||Multiparametric magnetic resonance + transperineal biopsy|The patient underwent a previous multiparametric magnetic resonance (RMmp) and a transperineal biopsy (BPTP)
89077228|NCT04283032||Transrectal biopsy|The patient underwent a transrectal biopsy (BPTE)
89077229|NCT04283032||Transperineal biopsy|The patient underwent a transperineal biopsy (BPTP)
89077230|NCT01226459|Experimental|Minoxidil Foam|5% Minoxidil Topical Foam
89077231|NCT01226459|Placebo Comparator|Vehicle Foam|Vehicle Topical Foam
89077232|NCT01225991|Experimental|Milnacipran, active drug, open-label|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day, or to their maximum tolerated dose in the course of the first week. The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day). Final efficacy assessments will be made at the termination visit, and the study medication will be tapered down following 12 weeks of drug treatment.
89224499|NCT06265545|Experimental|Arm 3|For R/R AML patients without IDH1 or FLT3 mutations who have not been exposed to Venecra in the last 3 months, the investigators will determine whether they are fit patients based on physical status and comorbidivities, and if they are, they can be randomly assigned to Arm3 or Arm4 DAV/IAV/MAV Cytarabine 100mg/m2/d, d1-5 Daunorubicin 60mg/m2/d, d1-2, or Idarubicin 12mg/m2/d, d1-2, or mitoxantrone 8mg/m2/d d1-2 Venetoclax 100mg d3, 200mg d4, 400mg d5-11;
89224500|NCT06265545|Experimental|Arm 4|"HAV :~Cytarabine 100mg/m2/d, d1-5 Homoharringtonine 2mg/m2 d1-5 Venetoclax 100mg d3, 200mg d4, 400mg d5-11"
89077233|NCT00959374|Active Comparator|V-loc and Monocryl|Subjects served as their own control, and they were randomized to receive an intervention of a standard closure using 3-0 Monocryl™ on one side of the body and the test closure device, V-Loc 180/90, on the other side. The standard closure technique was agreed on by study investigators for control side, and included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl™ sutures, spaced no further than 2 cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl™ sutures. The test closure side, closure of the deep dermal layer was optional. If deep dermal sutures were used, interrupted 3-0 Monocryl™ sutures were required to be placed no closer than 5 cm apart followed by closure of the intradermal layer with test device, V-Loc 180/90.
89077234|NCT02859298|Experimental|Suspicion of threat of premature delivery|10 consecutive patients arriving at the Brugmann maternity with suspicion of a threat of premature delivery will be encouraged to participate in this study, before the onset of any tocolytic treatment. The patient will receive an standard examination of the cervix and at the same time a polarimetric measurement.
89077235|NCT02859298|Active Comparator|Normal pregnancy|10 control patients, with the same term of pregnancy, will be benefit from the same measurements.
89077236|NCT04283110|Active Comparator|Midazolam group|Midazolam group will receive 1 mg intrathecal midazolam once during induction for anethesia
89077237|NCT04283110|No Intervention|control group|control group will receive placebo ( 0.5cm of sterile saline
89077238|NCT00630448||Group 1|Control Group. Normal (healthy) individuals without Von Willebrand Disease.
89077239|NCT00630448||Group 2|Case Group. Individuals with known Von Willebrand Disease.
89077240|NCT02859610|Other|cirrhotic patients|We prospectively included 90 cirrhotic patients .
89077241|NCT02859610|Other|healthy volunteers|The pilot cohort was compared with 10 healthy volunteers.
89077242|NCT02860780|Experimental|Part A: prexasertib + ralimetinib|"Cohort 1: 60 milligrams (mg) prexasertib (LY2606368) given intravenously (IV) and 100 mg ralimetinib given orally.~Cohort 2: 60 mg prexasertib (LY2606368) given intravenously (IV) and 200 mg ralimetinib given orally."
89077243|NCT02860780|Experimental|Part B1: prexasertib + ralimetinib (colorectal cancer)|60 mg prexasertib (LY2696368) given IV and 200 mg ralimetinib given orally. Participants receive prexasertib IV on Days 1 and 15 and ralimetinib every 12 hours (Q12H) Days 1 and 14 of a 28 day cycle.
89077244|NCT01225835|Experimental|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
89077245|NCT01225835|Active Comparator|Follitrophin Alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
89077246|NCT00962650|Experimental|NOTES Toolbox|Multiple devices designed for trans-orifice use during surgical procedures; used for transvaginal cholecystectomy in this trial
89077247|NCT04282252|Experimental|IV fluid restriction group|"No IV fluids should be given unless one of the below occurs; in these cases, IV fluid may be given:~In case of severe hypoperfusion or severe circulatory impairment defined by:~Lactate 4 mmol/L or above or mean arterial blood pressure below 50 mm Hg or mottling beyond the kneecap or urinary output less than 0.1 mL/kg bodyweight/h, but only in the first 2 hours after randomisation. A bolus of 250-500 mL of IV crystalloid solution may be given.~In case of overt fluid losses (eg, vomiting, large aspirates, diarrhoea, drain losses, bleeding or ascites tap) IV fluid may be given to correct for the loss.~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to correct dehydration or electrolyte imbalances and/or to ensure a total fluid input of 1 L per 24 hours."
89077248|NCT04282252|Active Comparator|Standard care group|There will be no upper limit for the use of IV or oral/enteral fluids. In particular: IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline. IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid. IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte imbalances.
89077249|NCT04282096|Experimental|Caseine micellar|
89077250|NCT04282096|Other|Sodium Casein|
89077251|NCT04282096|Other|Calcium casein|
89077252|NCT04284046||High CT score|
89077253|NCT04284046||Low CTscore|
89224501|NCT06265545|Experimental|Arm 5|"A patient with R/R AML without IDH1 or FLT3 mutation who has not been exposed to Venetoclax in the last 3 months but who is judged by the investigators to be unfit based on physical fitness and comorbidivities is unfit to enter Arm5.~Arm5: (up to 4 cycles available)~VA :~Azacytidine 75mg/m2/d d1-7 Venetoclax 100mg d1, 200mg d2, 400mg d3-21 400mg d22-28 (if the proportion of 21st bone marrow blasts are greater than 5%)"
89224502|NCT06265545|Experimental|Arm 6|"Patients with R/R AML without IDH1 or FLT3 mutations who have been exposed to Vinecra within the last 3 months may be enrolled in the exploratory protocol group based on a comprehensive assessment of local drug availability and patient status:~Arm6:~The Investigator's choice (IC) option involves a range of drugs such as clatabine, PI3K inhibitors, histone deacetylase inhibitors, celinisol, and novel liposomes."
89224503|NCT06265545|Experimental|Arm 7|According to the patient's condition and physical condition, evaluate whether there is a suitable new drug clinical trial to be enrolled. If there is, enter the Arm 7 (new drug clinical trial).
89224504|NCT06265532|Active Comparator|EGCG 300 mg|Patients enrolled in this group will be given oral capsule EGCG 300 mg daily with doctor provided anti-fibrotic for 12 weeks.
89224505|NCT06265532|Placebo Comparator|Placebo for EGCG 300 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided anti-fibrotic. The number of placebo capsules will be equal to that of 300 mg EGCG.
89224506|NCT06265532|Active Comparator|EGCG 600 mg|Patients enrolled in this group will be given oral capsule EGCG 600 mg daily with doctor provided anti-fibrotic for 12 weeks.
89224507|NCT06265532|Placebo Comparator|Placebo for EGCG 600 mg|Patients enrolled in this group will be given oral capsule Placebo daily for 12 weeks with doctor provided anti-fibrotic. The number of placebo capsules will be equal to that of 600 mg EGCG.
89224508|NCT06265519|Active Comparator|Patients before surgery|Men between the ages of 50 and 80 diagnosed with BPH before surgery
89224509|NCT06265519|Active Comparator|Patients after surgery|Men between the ages of 50 and 80 diagnosed with BPH after surgery
89224510|NCT06265519|No Intervention|Healthy|Men between the ages of 50-80 years without lower urinary tract disease
89224511|NCT06265506|Active Comparator|Control Condition (Non-contingent Incentives + CBT4CBT)|Participants will receive 8 weeks of Computer Based Training for Cognitive Behavioral Health (CBT4CBT). CBT4BCT is a self paced web-based program that uses videos and lessons to help people learn skills they can use to cut down or stop drinking. Participants will receive a $10 e-gift card for every PEth sample submitted within 48 hours of the visit regardless of the result. Participants will receive gift card incentives when they attend visits and provide blood samples (PEth Samples). Participants will submit PEth samples weekly for the first four weeks of the study, then every two weeks (weeks six, eight), then every four weeks (weeks 12,16, 20, 24), and at week 26. Each time they submit a PEth sample, they will receive gift cards equal to the average CM earnings during the previous month, resulting in total average earnings equivalent to the CM group. This group will receive incentives regardless of the results of their PEth tests.
89077254|NCT00630136||A|Adult parent or legally authorized representative (LAR) of child who has consented to undergo an out-patient endoscopy at Children's Mercy Hospital as a diagnostic procedure
89077255|NCT04280770|Sham Comparator|Non retinal detachment group|35 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
89077256|NCT04280770|Active Comparator|retinal detachment group|15 participants did 23 vitrectomy followed for 3-6 months. After that, we removed the oil and followed them for 6 weeks.
89077257|NCT02899000|Experimental|Acne treatment|"Topical adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (one application daily for 12 weeks)~Oral doxycycline hyclate, 200 mg per day (two 50-mg tablets twice daily for 12 weeks)"
89077258|NCT02858986|Experimental|3D laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 3D laparoscopic system
89077259|NCT02858986|Experimental|4K laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 4K laparoscopic system
89077260|NCT02859220|Other|group 1|group 1 : Roche Elecsys intact PTH
89077261|NCT02859220|Other|group 2|group 2 : PTH 1-84 complete (PAC) report and CAP / PTH 7-84 (CIP), Duo PTH IRMA Scantibodies
89077262|NCT04281862|Experimental|Group A|Dextenza
89077263|NCT04281862|Active Comparator|Group B|Topical Prednisolone
89077264|NCT00958828|Other|Nelfilcon A / Narafilcon A|Nelfilcon A contact lenses, then Narafilcon A contact lenses
89077265|NCT00958828|Other|Narafilcon A / Nelfilcon A|Narafilcon A contact lenses, then Nelfilcon A contact lenses
89077266|NCT03122002||Patients With Ischemic Stroke|The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.
89077267|NCT03122002||Healthy Control|The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.
89077268|NCT02858596|Experimental|Semi-solid feed group|Given semi-solid feed protocol
89077269|NCT02858596|Placebo Comparator|Liquid feed group|Given liquid feed protocol
89077270|NCT02861872||IP Patients|women, aged younger than 70 years, who will receive standard IP chemotherapy for advanced epithelial ovarian cancer, who are in an adequate physical and biochemical state to receive chemotherapy will be studied.
89077271|NCT02861482|Experimental|Bakri Ballon|All the enrolled patients who would undergo the laying of Bakri Balloon
89077272|NCT02861716|Experimental|fentanyl and dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl and dexmedetomidine in 2ml volume will be injected slowly over 20 seconds.
89077273|NCT02861716|Active Comparator|dexmedetomidine and placebo for fentanyl|intrathecal bupivacaine (0.5%) 0.4mg/kg plus dexmedetomidine 0.2 μg/kg in 2ml volume and placebo (for fentanyl 0.2 μg/kg) it will be injected slowly over 20 seconds.
89077274|NCT02861716|Active Comparator|fentanyl and placebo for dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl 0.2 μg/kg in 2ml volume and placebo (for dexmedetomidine 0.2 μg/kg) it will be injected slowly over 20 seconds.
89077275|NCT00960934|Experimental|MK-5442 2.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.
89077276|NCT00960934|Experimental|MK-5442 5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.
89077277|NCT00960934|Experimental|MK-5442 7.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.
89077278|NCT00960934|Experimental|MK-5442 10 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.
89077279|NCT00960934|Experimental|MK-5442 15 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.
89077280|NCT00960934|Placebo Comparator|Placebo|Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.
89077281|NCT00892177|Experimental|Arm I|Patients receive bevacizumab on Day 1 and dasatinib on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89077282|NCT00892177|Active Comparator|Arm II|Patients receive bevacizumab on Day 1 and placebo on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89077283|NCT00962104|Experimental|Atomoxetine|
89077284|NCT00962104|Placebo Comparator|Placebo|
89077285|NCT02821000|Experimental|Pembrolizumab|Participants receive pembrolizumab 2 mg/kg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
89077286|NCT02836327||Multiple sclerosis|Multiple sclerosis patients confirmed by neurologist according to the 2010 revised Mcdonald criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
89077287|NCT02836327||Neuromyelitis optica spectrum disorders|Neuromyelitis optica spectrum disorders confirmed by neurologist according to the 2015 revised diagnostic criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
89077288|NCT02836327||Health control|Health control is defined as no other nervous system diseases such as ischemic stroke, alzheimer disease and so on. The baseline data(age,education background etc.) is similar to multiple sclerosis and neuromyelitis optica spectrum disorders patients.All participants performed magnetic resonance imaging.
89077289|NCT02860624|Experimental|10 mg ilaprazole|
89077290|NCT02860624|Active Comparator|40 mg esomeprazole|
89077291|NCT02831647|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PRAGUE for a period of 9 days.
89077292|NCT02860468|Experimental|Cranberry juice consumption|participants in this arm will be provided cranberry juice to consume for 21 days in total
89077293|NCT02860468|Placebo Comparator|Placebo juice consumption|participants in this arm will be provided placebo juice to consume for 21 days in total
89077294|NCT02858518||patients with atrial fibrillation with anticoagulant treatment|
89077295|NCT00892099|Experimental|High Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol weekly
89077296|NCT00892099|Experimental|Low Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol per month
89077297|NCT00892099|Placebo Comparator|Placebo|Receives no ergocalciferol
89077298|NCT00960856|Experimental|Fenofibric Acid 105 mg - Low-Fat Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
89077299|NCT00960856|Experimental|Fenofibric Acid 105 mg - Standard Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a standard breakfast.
89077300|NCT00960856|Experimental|Fenofibric Acid 105 mg - High-Fat/High-Calorie Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
89077301|NCT00960856|Experimental|Fenofibric Acid 105 mg - Fasted State|Fenofibric Acid 105 mg tablet administered after an overnight fast of at least 10 hours
89077302|NCT04248907|Experimental|Socket A|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
89077303|NCT04248907|Active Comparator|Socket B|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
89077304|NCT04248907|Active Comparator|Socket C|To eliminate variables while casting the student investigators will be using a system very similar to that of Ossur's ICEX, developed in Reykjavik, Iceland. The ICEX system uses an air bladder system that allows a socket to be constructed directly onto the residuum; resulting in even pressure distribution during the time of casting. The ICEX system will ensure that the student investigators are obtaining consistent socket pressures and that the team will be precisely testing the distraction values on the multiple sockets obtained in this experiment. During this experiment, the researchers will be using a modified air bladder system.
89077305|NCT02835937|No Intervention|Transfuse|Patients will receive a transfusion under standard care
89077306|NCT02835937|Experimental|No-Transfuse|Patients will not receive a transfusion
89077307|NCT02835781||Acellular dermal matrix arm|The females undergoing breast reconstruction surgery after breast removal because of breast cancer. The breast reconstruction will be performed using acellular dermal matrix implantation.
89077308|NCT00958438|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept ) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
89077309|NCT00958438|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
89077310|NCT00958438|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
89077311|NCT02835859|Experimental|Group 1- Oral solution|Participants will be randomly assigned to drink two oral solutions made of different combinations of saccharin, lactisole, acetaminophen, 3-O-methyl glucose, or glucose.
89077312|NCT02835703|Active Comparator|Deep hypothermic arrest|Surgical repair of coarctation of aorta under deep hypothermic circulatory arrest
89077313|NCT02835703|Active Comparator|Selective antegrade cerebral perfusion|Surgical repair of coarctation of aorta using selective antegrade cerebral perfusion
89077314|NCT02835703|Active Comparator|Double arterial cannulation|Surgical repair of coarctation of aorta using cerebral antegrade perfusion with descending aortic cannulation
89077315|NCT02835469||Menopur® Multidose|Treatment according to routine clinical practice.
89077316|NCT02858674|Experimental|Active Alerting Mechanism|Traditional Pop Up Alert used in Epic
89077317|NCT02858674|Active Comparator|Passive Alerting Mechanism|Noninterruptive alert that sits in the checklist
89077318|NCT02860390|No Intervention|Adolescent - Control|Usual care arm of subjects aged 13-19 years old
89077319|NCT02860390|Experimental|Adolescent - SMS|Subjects aged 13-19 years and receiving Denver Health Asthma Management Program (text messaging intervention)
89077320|NCT02860390|Experimental|Adolescent - SMS plus support person|Subjects aged 13-19 years, Denver Health Asthma Management Program (text messaging intervention) sent to subjects and subjects' chosen Person of Support.
89077321|NCT02860390|No Intervention|Adult - Control|Usual care arm of subjects aged 20-40 years old.
89077322|NCT02860390|Experimental|Adult - SMS|Subjects aged 20-40 years and receiving Denver Health Asthma Management Program (text messaging intervention).
89077323|NCT02832973|Experimental|Spironolactone, Furosemide Amiloride|Spironolactone 25 mg qd, Furosemide 20 mg qd, Furosemide 40 mg qd, Amiloride 5 mg qd
89077324|NCT02832973|Active Comparator|Ramipril, Bisoprolol|Ramipril 5 mg qd, Ramipril 10 mg qd, Bisoprolol 5 mg qd, Bisoprolol 10 mg qd
89077325|NCT02832739|Experimental|SENACA - self-management support system|Use of enhanced SENACA - ICT based self-management support system prototype by study participants at home for 75-100 days
89077326|NCT00958360|Experimental|Arm 1|Interdisciplinary Low Vision Rehabilitation: Low vision examination, prescription and dispensing of low vision devices, low vision therapy and homework.
89077327|NCT00958360|Active Comparator|Arm 2|Basic Low Vision Care: Low vision examination, prescription and dispensing of low vision devices without low vision therapy or assigned homework.
89077328|NCT02832895|Experimental|Transcranial Doppler examination|Transcranial Doppler examination
89077329|NCT02860312|Active Comparator|Exercisers|Intradialytic exercise on stationary bicycles
89077330|NCT02860312|Placebo Comparator|Non Exercisers|No intradialytic exercise
89077331|NCT02831491|Experimental|Ramucirumab + Docetaxel|Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.
89077332|NCT02860234||Group A:Clinical complete response (cCR)|Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
89077333|NCT02860234||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
89077334|NCT02860234||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Total Mesorectal Excision(TME).
89077335|NCT02858752|Experimental|Healthy Children|Memory and Attention in healthy children will be assessed non-invasively through behavioral and electrophysiological measures while participants will perform passive or active computer task involving auditory and/or visual perception.
89077336|NCT02832583|Experimental|Mesotherapy of PRP-HA into the cheeks|Three sessions of PRP-HA prepared with RegenKit BCT-HA Cellular Matrix into each cheek separated by 1 month interval.
89077337|NCT04280380||Mechanical ventilated patients without cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.~Inclusion criteria: (a) age >=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
89230053|NCT00385684|Active Comparator|B: Open label hydrocodone/acetaminophen|Phase B: If tolerated study medication during Phase A (i.e., the closed label, double-blind phase of the trial) then enter a six-week, open-label phase. Participants judged as responders during Phase A continue the same dose of study medication. Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
89077338|NCT04280380||Mechanical ventilated patients with cancer|"This observational, cohort, retrospective and multicenter study will be performed during a period of 16 months at the 5 medical/surgical ICUs from HM Hospitals group.~The recruitment will be performed by volume of patients: recruitment of the first 300 patients without cancer will start the 15th of January 2018 and will end once the last patient has been included; likewise, recruitment of the first patient with cancer will start on the same date and will end once the last patient (of 100) is recruited. Patients undergoing any type of anticancer therapy within the previous 3 month of ICU admission will be analyzed as part of the overall group but also as an independent subgroup of patients.~Inclusion criteria: (a) age >=18 y.o., (b) admission to the intensive care unit with an expectancy to stay longer than 72 hours and requiring invasive mechanical ventilation."
89077339|NCT04280146|Active Comparator|Degree of food processing|unprocessed vs ultra-processed foods according to NOVA table.
89077340|NCT04280146|Active Comparator|eating rate|slow vs fast eating rate (kcal/min), manipulated by food form
89077341|NCT05263141|Experimental|RASSET group|Patients in the retro-auricular single-site endoscopic thyroidectomy (RASSET) group will receive endoscopic thyroid lobectomy and central lymph node dissection.
89077342|NCT05263141|Active Comparator|traditional open thyroid lobectomy group|Patients in the traditional open thyroid lobectomy group will receive thyroid lobectomy and central lymph node dissection.
89077343|NCT00630370|Placebo Comparator|1|2 Placebo tablets, TID, orally, 58 days
89077344|NCT00630370|Experimental|2|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
89077345|NCT00630370|Experimental|3|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
89077346|NCT00630370|Experimental|4|2 ATI 40mg tablets, TID, orally, 58 days
89077347|NCT02832349|Experimental|EA group (Educational Actions)|Epileptic patients participating to the educational actions program
89077348|NCT02832349|No Intervention|Control group|Epileptic patients with standard follow-up
89077349|NCT04280068|Active Comparator|Clinician Guide|Clinician Guide is an evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
89077350|NCT04280068|Active Comparator|Clinician Guide plus HealthCall|Clinician Guide plus the use of HealthCall, a smartphone application to monitor daily alcohol use, ART adherence and other health behaviors.
89077351|NCT02835547||Systemic lupus erythematosus|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
89077352|NCT02835547||Rheumatoid arthritis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
89077353|NCT02835547||Psoriasis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
89077354|NCT02835547||Scleroderma|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
89077355|NCT02835547||Hematopoietic stem cells transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
89077356|NCT02835547||Kidney transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
89077357|NCT02835391|Active Comparator|PerClot|PerClot® Polysaccharide Hemostatic System (PerClot) is a medical device composed of absorbable polysaccharide particles (AMPs) and delivery applicators. Investigators will have the option to choose 3g or 5g dependent on the requirements of the patient
89077358|NCT02835391|Active Comparator|Usual Care|Usual care will consist of any other haemostat the Investigator would normally use in the control of bleeding i.e arista, Floseal, surgical, surgiflo. If the Investigator would not normally use a haemostat to control bleeding then electrocautery or diathermy may be used in this arm
89077359|NCT02997826|Other|1 to 21-days old child|
89077360|NCT02835001|Other|Patient with severe emphysema|Patients with severe emphysema, stable, symptomatic, not controlled despite of international recommendations treatments will have bronchoscopy
89077361|NCT02835235|Experimental|NNC9204-0530|Dose-escalation within the cohort before reaching final dose
89077362|NCT02835235|Placebo Comparator|Placebo|
89077363|NCT02831101|Experimental|Sufentanil|Sufentanil intravenously, continuously with effect-site concentration of 0.3 ng/ml until the end of the study
89077364|NCT02831101|Other|Placebo|Saline intravenously, continuously with the same effect-site concentration as sufentanil (recorded on administration device) until the end of the study
89077365|NCT02831101|No Intervention|Propofol|Open administration using a separate target controlled infusion system and the PK/PD model by Schnider. Initial effect-site concentration 0.5 mcg/ml increased by 0.5 mcg/ml until LOC
89077366|NCT02834923|Active Comparator|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change. CTH utilizes web-based interactive behavior change technology, based on a logic model of behavior and maintenance that is informed by social-cognitive and social ecological theories. Prior to diabetes visits with a clinician, health educator, or care manager, patients complete a pre-visit CTH assessment at their practice through a tablet computer or computer kiosk. CTH assesses multiple diabetes management behaviors (diet, physical activity, medication adherence, alcohol and tobacco use, stress, mood) using brief assessment measures, each with cut-points highlighting areas of deficit. Action planning plays a central role, through a web-based platform that allows the patient and health care team to select and set goals collaboratively.
89230054|NCT01044628|Experimental|Nocturnal oxygen therapy (N-O2)|Oxygen will be delivered overnight to the patients to allow their oxygen saturation to be >90%
89230055|NCT01044628|Sham Comparator|Sham concentrator|Sham therapy with ambient air will be given to the patients at night
89230056|NCT00661661|Experimental|CP-690,550|
89077367|NCT02834923|Experimental|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH seamlessly integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol specifically designed to enhance patient engagement in SMS activities. Key components of MI have been incorporated into a practical and systematic engagement protocol that includes: (1) acknowledging the patient's point of view; (2) identifying and labeling the patient's ambivalence (both the good reasons for making the change and the good reasons for not making the change); (3) evaluating whether change is really worth the effort; (4) identifying, reflecting and labeling accompanying feelings and concerns about change; and (5) establishing a small and meaningful goal by the end of the encounter.
89077368|NCT04247659|Experimental|Experimental group|In the experimental group, sodium aescinate is added on the basis of conventional treatment(such as anti-platelet and improve circulation).The treatment course of sodium aescinate is 10 days,20mg/day.
89077369|NCT04247659|No Intervention|Control group|The control group will receive conventional treatment(anti-platelet and improve circulation) without sodium aescinate.
89077370|NCT02831413|Placebo Comparator|Control|Control group members will receive an alternate curriculum that is not related to relationship education. Family Bridges has identified a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
89077371|NCT02831413|Experimental|RS+|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
89077372|NCT02831413|Experimental|RS+ with enhanced facilitator support|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making. Affiliates assigned to this enhanced treatment group will participate in enhanced facilitator training and support activities.
89077373|NCT04201327|Active Comparator|PrEP information only arm|Information to for accessing HIV prevention tools will be provided to participants.
89077374|NCT04201327|Experimental|PrEP counseling arm|Stigma focused counseling (one-session) aimed at addressing barriers to health care access will be provided.
89077375|NCT04201327|Experimental|PrEP counseling plus text messaging arm|Stigma focused counseling (one-session) and interactive text messaging aimed at addressing barriers to health care access will be provided.
89077376|NCT04201327|Experimental|PrEP counseling plus text messaging and on demand counseling|Ongoing stigma focused counseling and interactive text messaging aimed at addressing barriers to health care access will be provided.
89077377|NCT04245787|Experimental|Self assembling peptide with fluoride|
89077378|NCT04245787|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|
89230057|NCT00791453||I|Established patients at the Clarksdale Diabetes and Metabolism Center
89077379|NCT02831803|Experimental|Intervention|All participants will receive an 8-week supply of walnuts and Extra Virgin Olive Oil (EVOO). Study supplements will consist of 28 gm of walnuts and 32 gm of EVOO per day. Participants will be instructed how to consume the proper amount of walnuts and EVOO and to report their consumption using a compliance diary. The walnuts are pre-packaged in daily servings (one 28 g packet per day) and measuring spoons will be provided with the olive oil to assist participants in consuming it appropriately. Participants will also receive recipes and other written information that will assist them in incorporating both the nuts and olive oil into their existing dietary patterns.
89077380|NCT00633451|Experimental|1|Manual Therapy + Exercise
89077381|NCT00633451|Active Comparator|2|Exercise Only
89077382|NCT02828605|No Intervention|Control Group|Only receive surveys.
89077383|NCT02828605|Experimental|Experimental Group|Receive VIP Transplant App and surveys.
89077384|NCT02831179|Experimental|Treatment (capecitabine, temozolomide, veliparib)|Capecitabine PO BID on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14.
89077385|NCT04245553|Experimental|All Participants|
89077386|NCT04245631||RAA assay for 2019-nCoV|a simple, fast and portable recombinase aided amplification (RAA) assay for 2019-nCoV
89077387|NCT02828683|Experimental|Ultimaster, Drug Eluting Stent|Primary PCI in patients with ST segment elevation myocardial infarction with a new Drug Eluting Stent, Ultimaster
89077388|NCT02828683|Active Comparator|Kaname, Bare metal stent|Primary PCI in patients with ST segment elevation myocardial infarction with a Bare Metal Stent - Kaname
89077389|NCT04245007|Experimental|Intervention|Subject will ask to do 5:2 intermittent fasting (2 non-consecutive days a week) within 8 weeks
89077390|NCT04245007|No Intervention|Control|Subject will prohibited from doing fasting or intake restriction within 8 weeks
89077391|NCT05097469|Active Comparator|Laser treatment|Carbon dioxide laser treatment
89077392|NCT05097469|Sham Comparator|Sham treatment|Sham laser treatment
89230058|NCT00038467|Active Comparator|B|
89077393|NCT02830789|Experimental|Calcium Carbonate|1 tablet Unikalk Forte + 1 placebo tablet by mouth three times daily equal to 1200 mg elementary calcium and 57 µg Vitamin D3
89077394|NCT02830789|Experimental|Calcium Citrate|2 tablets Unikalk Citrat by mouth three times daily equal to 1200 mg elementary calcium and 60 µg Vitamin D3
89077395|NCT04243993|Other|Bio-MA|Calcium silicate cement containing calcium chloride accelerator
89077396|NCT04243993|Other|ProRoot MTA|Calcium silicate cement without calcium chloride accelerator
89230059|NCT00038467|Experimental|A|
89077397|NCT04243603|Experimental|Internet-based ERITA-DK|ERITA is a youth-adapted version of Emotion Regulation Group Therapy (ERGT), based on cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and Acceptance and Commitment Therapy (ACT), which encounters emotional recognition and regulation, crisis strategies and skills training. The ERITA intervention is provided as add-on to TAU and consists of 12 weeks, manualized, therapist guided internet-based therapy. The intervention also provides six modules for the parents focusing on NSSI and other risk-taking behaviors, emotional awareness, and validation skills. The participants must complete one module every week while the parents must complete a module every second week. A mobile app is available to complement the online treatment. The app includes reminders of homework and skills and allows to report on both self-destructive behaviors and impulses daily.
89077398|NCT04243603|Active Comparator|Treatment as Usual (TAU)|Child and Adolescent Mental Health Services (CAMHS) offer specialized treatment for children and adolescents. TAU encounters a variety of clinical treatment and assessment offers, representing a highly inhomogeneous group of treatments, for instance: Pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy, supportive counselling and psychoeducation. Throughout the trial course the treatment responsibility is handled by clinicians providing TAU.
89077399|NCT02828293||GMK Sphere|Patients who underwent total knee replacement using GMK Sphere implants. Patients underwent surgery before the inclusion in the study.
89077400|NCT02828293||GMK PS Fixed Bearing|Patients who underwent total knee replacement using GMK PS Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
89077401|NCT02828293||GMK UC Fixed Bearing|Patients who underwent total knee replacement using GMK UC Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
89077402|NCT04245163|Experimental|Intervention Group|Participants in the intervention group will be invited for the training program.
89077403|NCT04245163|No Intervention|Control Group|Participants who will be randomized in control group will receive normal care (the care that each clinic provides to the patients) and will be given an educational material (without telling them that they are in the control group). They will receive, however, the education class later (at the end of the study).
89077404|NCT04245319|Other|NbUVB|Group A: patients will receive three NB-UVB sessions per week for 48 sessions.
89077405|NCT04245319|Experimental|Combined nbUVB and Acitretin|Group B: patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin in a dose of 0.3mg/kg/day daily.
89077406|NCT02828449|Experimental|therapeutic education program|therapeutic education program which aims is to improve the adherence to the treatment and management of adverse effects of this treatment in patients taking an oral chemotherapy for active cancer
89077407|NCT02828371|Experimental|Erigo|Single daily sessions of verticalization, using a tilt table with an integrated robotic stepping device (Erigo. Hocoma AG, Switzerland) located in the ICU room. Sessions were performed five times per week (Monday-Friday) for three consecutive weeks (a total of 15 sessions per patient). On the same days the patients received conventional physiotherapy for 30 minutes a day. Before the verticalization period the experimental group received conventional in-bed physiotherapy for 60 minutes a day.
89077408|NCT02828371|Active Comparator|Conventional|treated with conventional in-bed physiotherapy for 60 minutes a day, from Monday to Friday, throughout the ICU stay.
89077409|NCT05143099|Experimental|1|tislelizumab combined with cetuximab and irinotecan
89077410|NCT02827903|Experimental|Group I|Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
89077411|NCT02827903|Active Comparator|Group II|Metformin + placebo, Dosing to Type II DM with Dyslipidemia
89077412|NCT02827903|Active Comparator|Group III|Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
89077413|NCT05135923|Active Comparator|Benchmark gluten-free products|Products containing less than 6g fibre per 100g product.
89077414|NCT05135923|Experimental|Optimised gluten-free products|Products containing less than 6g fibre per 100g product.
89077415|NCT02830945|Other|Control Brochure Arm|Control Arm households receive a culturally tailored Stroke and CVD brochure for prevention.
89077416|NCT02830945|Experimental|Motivational Interviewing Intervention Arm|The MI intervention households receive three aspects of the intervention: digital stories, motivational interviewing talking circle and the option to receive text messages to adhere to the action plan.
89077417|NCT04247113|Experimental|PBP-B|Parent-based Prevention following a Bariatric Surgery (PBP-B) is a 6-session parent-based program designed to guide parents who have undergone a weight loss surgery and their partners in developing healthy eating habits in their children
89077418|NCT00888433|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications
89077419|NCT00888433|No Intervention|Control|Maintenance of anti-hypertensive medications with option for cross-over treatment after 6-months
89077420|NCT01243424|Experimental|linagliptin|patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)
89077421|NCT01243424|Active Comparator|glimepiride 1-4 mg QD|patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)
89077422|NCT02831023|Active Comparator|SP-AQ only|Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.
89077423|NCT02831023|Experimental|SP-AQ plus PQ|Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
89077424|NCT02831023|Active Comparator|DP only|Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.
89077425|NCT02831023|Experimental|DP plus MB|Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).
89077426|NCT02826967|Experimental|Colonic Irrigation|A designated health professional will administer to the patient the colonic irrigation procedure -using the Hydro-San Plus colon therapy system, an FDA approved and ISO certified device for colonic irrigation and cleansing before endoscopic procedures (FDA #2027347).
89077427|NCT04244539|Experimental|Experimental group|a received routine physical therapy program, in addition to HILT. Patients in the study group received pulsed Nd: YAG laser treatment, produced by a HIRO 3 device (ASA Laser, Arcugnano, Italy). The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2),
89077428|NCT04244539|Active Comparator|Control group|The control group received traditional physical therapy program in the form of strengthening exercise, stretching , and range of motion exercise.for the affected digits and wrists. for one hour, three sessions per week for 8 weeks.
89077429|NCT02827669|Experimental|One Drop Experts Program|Participants will be able to use the One Drop mobile app and One Drop Experts program on their smartphones. The One Drop mobile app is a diabetes management platform that allows users to track and log their blood glucose levels, medications, food, and activities. One Drop Experts is a diabetes education and coaching program delivered entirely through the One Drop mobile application.
89077430|NCT02827669|Experimental|One Drop Experts Program + Apple Watch|An Apple Watch will be provided to study participants in this arm. In addition to using the One Drop mobile app and One Drop Experts program on their smartphones, participants will also be able to engage with the app and program on their Apple Watch.
89077431|NCT04244695|Experimental|Dexamethasone 16 mg|Dexamethasone (4mg) 4 tab oral once daily in the morning
89077432|NCT04244695|Active Comparator|Dexamethasone 8 mg|Dexamethasone (4mg) 2 tab and placebo 2 tab oral once daily in the morning
89077433|NCT04244695|Placebo Comparator|Placebo|Placebo 4 tab oral once daily in the morning
89077434|NCT00887809|Experimental|gemcitabine and docetaxel with bevacizumab|Patients will receive bevacizumab at 15 mg/kg on day 1 of each 21-day cycle intravenously over 30 minutes followed by a one hour (+30/-15 min) break. For cycles 1 through 6, gemcitabine will be administered at 900 mg/m2 over 90 minutes on day 1 and 8 of a 21-day cycle. Docetaxel will be administered at 75 mg/m2, over 60 minutes, on day 8. This will be followed by either 5 days of filgrastim or a single injection of pegfilgrastim. For cycles 7 and beyond, gemcitabine will be given at 800 mg/m2 over 30 minutes on day 1 and 8; docetaxel will be given at 35 mg/m2 over 30 minutes, also on days 1 and 8.
89077435|NCT02830399|Active Comparator|active rTMS-ECT|5 active high frequency rTMS before 5 bilateral ECT
89077436|NCT02830399|Placebo Comparator|sham rTMS-ECT|5 sham rTMS before 5 bilateral ECT
89077437|NCT02826889|Experimental|Fluid loading group|
89077438|NCT04244617|Experimental|iCBT with addition of peer-support (iCBT-PS)|Participants in the iCBT-PS, are guided by both a psychologist and a peer-support in the iCBT-program used in the study.
89077439|NCT02827747|Placebo Comparator|Placebo with Dietary Sources of Vitamins|Persons assigned to placebo, who obtain Vitamins A, C, E and Glutathione from dietary sources alone, and have not been on oral RDA supplementation, in the 1 month leading up the time of enrollment and throughout the study period.
89077440|NCT02827747|Active Comparator|Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum|Persons assigned to the study medication, and are continuing the take an oral RDA supplementation, in the form of Centrum.
89077441|NCT02827747|Active Comparator|Antioxidants (Vitamins A,C, E) plus GSH|Persons assigned to the study medication alone, without oral RDA supplementation in the 1 month leading up the time of enrollment and throughout the study period.
89077442|NCT02827747|Active Comparator|Placebo plus Centrum|Persons assigned to placebo, who have been on oral RDA supplementation, who would continue to do so throughout the study.
89077443|NCT02830633|Experimental|LNTME|Laparoscopy-assisted nerve-preserved TME (LNTME) is conducted in rectal cancer patients
89077444|NCT02830633|Active Comparator|OTME|Open TME (OTME) is conducted in rectal cancer patients
89077445|NCT04244851||Malnourished patients|Malnourished patients
89077446|NCT00958126|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
89077447|NCT00958126|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
89077448|NCT00958126|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
89077449|NCT00958126|Placebo Comparator|Placebo|Vaccine diluent. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
89077450|NCT02861560|Experimental|dHACM|Dehydrated human amnion/chorion membrane (dHACM)
89077451|NCT04281394|Experimental|Robot assisted gait training|Robot assisted gait training(RAGT) group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks. SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements.
89077452|NCT04281394|Active Comparator|conventional physical training group|The conventional group underwent conventional physical therapy( even level gait training and range of motion exercises) twice a day, 5 times a week in 12 weeks.
89077453|NCT04281628|Placebo Comparator|Control group|control group: where normal saline will be administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
89077454|NCT04281628|Active Comparator|ketamine group|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
89077455|NCT02859844|Experimental|TTNS ON|Transcutaneous tibial nerve stimulation
89077456|NCT02859844|Sham Comparator|TTNS OFF|Sham/placebo stimulation
89077457|NCT04280302|Experimental|Virtual reality based therapy|
89077458|NCT04280302|Active Comparator|Conventional Therapy|
89230060|NCT01095367|Active Comparator|Seprafilm™|Subject will have 3 sheets of Seprafilm™ placed in her abdominal cavity (in the pelvis, upper abdomen and below the incision) at the end of debulking surgery. At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
89230061|NCT01095367|No Intervention|No Seprafilm™|Subject will undergo debulking surgery without Seprafilm™ placement (standard care). At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
89077459|NCT04279756|Active Comparator|Mildly Impaired Group|This group is with participants with mildly impaired hip internal range of motion, from 25-30 degrees.
89077460|NCT04279756|Active Comparator|Moderately Impaired Group|This group is with participants with moderately impaired hip internal range of motion, from 20-24 degrees.
89077461|NCT04279756|Active Comparator|Severely Impaired Group|This group is with participants with severely impaired hip internal range of motion, less than 20 degrees.
89077462|NCT02861638|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
89077463|NCT02861638|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
89077464|NCT00887341|Experimental|1|
89077465|NCT00887341|Active Comparator|2|
89077466|NCT04279600|Experimental|Taurine supplementation|Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks
89077467|NCT04279600|Active Comparator|Taurine supplementation associated to exercise training|"Taurine supplementation composed of capsules of taurine powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
89077468|NCT04279600|Placebo Comparator|Placebo supplementation associated to exercise training|"Placebo supplementation composed of capsules of starch powder. Dosage: 3 grams/day Frequency: 1 time/day Duration: 8 weeks~Exercise training Exercise Protocol: a combination of strength and aerobic exercises Duration: 2 weeks of adaptation and 8 weeks of physical training. Frequency: 3 times/week Duration: 55 minutes/session Intensity: 75 to 90% of maximum heart rate"
89077469|NCT02830321||case|"Pregnant women who suffered from hyperemesis gravidarum and admitted in the hospital~Age: 18-40 years old~Gestational age: less than 16 weeks confirmed by pelvic u/s~Excessive pregnancy - related nausea and /or vomiting that prevent adequate intake of food and fluids.~All pregnant (case and control) were asked to bring a stool sample in a clean container. Collected samples were tested in a laboratory (Ain Shams Univerisity hospital).~Stool samples were be tested by using one step H.pylori stool antigen test (CER TEST BIOTEC) for the detection of H. pylori antigen."
89077470|NCT02830321||control|Control patients which are selected from pregnant women presenting to the outpatient clinics for routine antenatal care of the same gestational age, same age range and same socioeconomic standard as cases.
89230062|NCT01095445|No Intervention|Standard of care treatment|Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
89230063|NCT01095445|Active Comparator|Extended therapy|Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.
89230064|NCT00660179|Experimental|1|Macitentan (ACT-064992) tablet, 3 mg, once daily
89077471|NCT04246645|No Intervention|CONTROL GROUP|received the selective physiotherapy exercises
89077472|NCT04246645|Experimental|STUDY GROUP|received the same selective physiotherapy exercises program in addition to core stability exercises three times/week for 60 min for 12 weeks
89077473|NCT00886795|Experimental|Abatacept|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.
89077474|NCT02783482|Experimental|GC5107|GC5107 Immune globulin intravenous (human) solution, 10% liquid
89077475|NCT00889681|Experimental|Ablation|All study subjects will be receive cryo ablation with the experimental devices and, optionally, an Atrial Fibrillation Drug.
89077476|NCT05048095||Screened women in Region Östergötland Linkoping|
89077477|NCT00957658|Other|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem Study Device
89077478|NCT00953680|Active Comparator|losartan /HCTZ combination tablet|single dose losartan 100 mg/HCTZ 12.5 mg combination tablet
89077479|NCT00953680|Active Comparator|losartan tablet + HCTZ capsule|Single dose losartan 100 mg tablet + HCTZ 12.5 mg capsule
89077480|NCT00890929|Experimental|Azacitidine followed by lenalidomide|Dose escalation then dose expansion
89077481|NCT04279366||Winter course|The recruited particpants attending the winter course
89077482|NCT04279366||Fall course|The recruited particpants attending the winter course
89230065|NCT00660179|Experimental|2|Macitentan (ACT-064992) tablet, 10 mg, once daily
89230066|NCT00660179|Placebo Comparator|3|Matching placebo, once daily
89230067|NCT00050167|Experimental|Weekly Paclitaxel (WP)|Weekly Paclitaxel (WP) for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles
89230068|NCT00050167|Experimental|Docetaxel and Capecitabine (DX)|Docetaxel + Capecitabine (DX) days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.
89077483|NCT04246567|Active Comparator|Total intravenous anesthesia technique for group 1 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 6-10 mg / kg / h propofol and 0.0,4mcg / kg remifentanyl infusion / min. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
89077484|NCT04246567|Active Comparator|Inhalation anesthesia technique for group 2 patients|"Procedure/Surgery:Mean Blood Pressure (MBP) Mean blood pressure (MBP) 50-65 mmHg was applied with 40% Oxygen 60% N2O2 and Sevoflurane at a concentration of 1.5-3.5% with 2 L / minTGA to provide a value of BIS between 40-60. When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS,TOF and SpO2 were recorded at 5 minute intervals.~Blood samples were taken from patients during preop preparation (t0), 30th minute (t1), 1st hour (t2) and 2nd hour (t3) of the operation. 5 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
89077485|NCT04271566|Experimental|Experimental|Patients receiving an education program along with usual medical care
89077486|NCT04271566|No Intervention|Non Experimental|Patients receiving usual medical care
89077487|NCT04243681|Experimental|Combination MSC and HSC|Patient will receive a combination of mesenchymal and Hematopoetic stem cell through hepatic artery under fluroscopic guidance
89077488|NCT04243681|Active Comparator|Standard of care for Cirrhosis management|Diuretics, Hepatoprotective agents and Lactulose
89077489|NCT00886639|Other|First of 2 6-minute-walking test with oxygen|Continuous flow of 2 liters per minute First with oxygen, second with medical air
89077490|NCT00886639|Other|First of 2 6-minute-walking tests with medical air|Medical air is compressed room air. First test with medical air, second with oxygen
89077491|NCT04244383|Experimental|chronic hepatitis C virus patients|50 chronic hepatitis C virus patients taking will be trated with direct acting antiviral treatment with three months regimen (Sofosbuvir + Daclatasvir).
89077492|NCT04244383|Experimental|treated chronic hepatitis C virus patients|the selected 50 chronic hepatitis C virus patients received direct acting antivirals: Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virological response at 12 weeks following the end of treatment (SVR12).
89077493|NCT04244305|Experimental|Treadmill Training|"Participants in the treadmill training group will perform endurance training during the post-operative period using a treadmill (Salter Housewares, UK) for a minimum of 20 sessions. Intensity of training will be set according to 80% of the mean speed achieved during the 6MWT for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week.~After the endurance training, participants will perform resistance training for 20 - 30 minutes for conditioning of the main muscles in the upper and lower limbs using elastic bands, dumbbells and body-weight exercises. Intensity will progressively increase up to 70% of the maximum isometric strength measured with a hand-held dynamometer. Volume of training will also increase from 1 to 3 sets of 12 repetitions each. When needed patients will also be taught breathing exercises and airway clearance techniques."
89077494|NCT04244305|Active Comparator|Cyclo-ergometry Training|Participants in this group will perfom endurance training during the post-operative period using a cycle ergometer (Monark 828e, Monark AB, Sweeden) for a minimum of 20 sessions. Intensity of training will be set according to the results of a symptom-limited incremental cycle-ergometry test performed on the first day to achieve 80% of the maximal workload obtained for a targeted time of 30 minutes. Intensity and duration will be adapted to the participant's physical condition, especially during the first week. Participants in this group will also perfom resistance training and breathing exercises as in the treadmill training group.
89077495|NCT02830243|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
89077496|NCT02830243|Experimental|Desflurane|Anesthesia was maintained with desflurane.
89077497|NCT02830009|Other|Primary Hyperoxaluria patient|
89077498|NCT02830009|Other|Primary Hyperoxaluria patient's siblings|
89077499|NCT02830009|Other|Idiopathic hypercalciuria patients|
89077500|NCT02830009|Other|Healthy volunteers|
89077501|NCT00889603||1|
89077502|NCT04244071|Active Comparator|Group C|"Usual care (Group C): The patients in this group received routine hospital care.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
89077503|NCT04244071|Experimental|Group A|"The patients in Group A were warmed up using a gown blowing warm air starting at least 30 min prior to the surgery until they were anesthetized.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
89077504|NCT04244071|Experimental|Group B|"Routine care was provided for the patients in Group B in the preoperative and intraoperative periods. In the postoperative period, patients were warmed up using a gown blowing warm air after they were transferred to the post-anesthesia care unit, and continued to be warmed up on the basis of the temperature set by themselves until they wore their own clothes in the ward.~Vital signs, thermal comfort, and anxiety levels of the patients were evaluated."
89077505|NCT04244149|Experimental|Intervention group|Participants will exert an exercise prolonged session
89077506|NCT04243135|Active Comparator|ESWT group|All patients in both groups were applied with a hot pack for 40-minutes, transcutaneous electrical nerve stimulation for 30-minutes (100 Hz frequency and 60 milliseconds pulse duration), and a home-based exercise program around the knee for 30-minutes per day for three weeks. Also, each patient in group 1 received shockwaves of continuous frequency and intensity (2000 shocks, 10 Hz, 2.0 to 3.0 bar), while the second group of patients received sham-ESWT. In group 1, for a total of 3 weeks, r-ESWT was undertaken with 2000 pulse each time at a week interval totaling 6000 pulse by using a radial shock wave therapy system (vibrolith ortho tip ESWT (ELMED Turkey)).
89077507|NCT04243135|Sham Comparator|Sham-ESWT group|The other group received sham-ESWT at 0.1 bar in the same area. The patients were placed supine with the affected knee at 90 degrees flexion at each treatment session. The shock wave probe was held stationary on painful points around the knee or at the patellofemoral and tibiofemoral borders of the target knee.
89077508|NCT02826577|Active Comparator|Pregnenolone 175mg|- Single dose of 175mg
89077509|NCT02826577|Active Comparator|Pregnenolone 400mg|- Single dose of 400mg
89077510|NCT02826577|Placebo Comparator|Placebo|- Single dose of placebo
89077511|NCT02826577|No Intervention|Matched healthy controls|- No intervention
89077512|NCT00886483|Active Comparator|Active neurofeedback|In the active neurofeedback condition, the intervention is active neurofeedback (actual neurofeedback) either twice weekly or three times a week (randomized to frequency), with the same amount of total treatment over 40 sessions, varying only in frequency. Neurofeedback will be via the CyberLearning technology, using videogame race car speed and steering as feedback governed by EEG theta-beta ratio through the interface. the game controller is used in the usual fashion, but maximal speed is capped by the threshold theta-beta ratio, which changes from minute-to-minute by fuzzy logic based on the previous minute's ratio. If theta power exceeds a threshold, the rumble function of the controller comes on as a warning. The feedback is transparent to the patient, who just plays the videogame.
89230069|NCT01092325|Experimental|Cohort 1 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
89230070|NCT01092325|Placebo Comparator|Cohort 1 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
88812492|NCT04125238|Sham Comparator|Control Episodic Thinking (CET)|Participants will generate positive recent past events that have happened to them at five time points in the recent past (last night from 7pm-10pm, yesterday between 4pm-7pm, yesterday between 1pm-4pm, yesterday from 10am-12pm, yesterday between 7am-10am, the night before last between 7pm-10pm, and evening before last between 4pm-7pm). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions.
88812493|NCT04096040|Experimental|Device Data Engagement Assessment|This arm will assess the endpoints of investigator engagement with the device data.
88812494|NCT04090671|Active Comparator|COPD Exacerbation|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
89230071|NCT01092325|Experimental|Cohort 2 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
89077513|NCT00886483|Sham Comparator|Sham Neurofeedback|The sham condition will appear identical to the neurofeedback in all aspects: equipment, duration, frequency, and videogame choices. The only difference is that the interface module will be pre-programmed to give random feedback rather than contingent on the participant's brainwave power spectrum.
89077514|NCT00886015|Experimental|TT Clamp|The TT clamp will be used in trichiasis surgery.
89077515|NCT00886015|Active Comparator|Standard BLTR Technique|Standard BLTR technique will be used in trichiasis surgery.
89077516|NCT02829853||sporadic cases (SP)|Sporadic cases are defined as patients diagnosed for sarcoidosis, for which the familial history did not reveal any other cases, whatever the relative degree is: 1, 2, 3 or 4. The clinical follow-up and the genetic studies performed in the frame of this project are the same as for the familial group. During the regular follow-up, patients are regularly questioned about the putative occurrence of the disease in their family, and if such a situation occurred, the patient (and his relative) may change from the SP to the familial (FAM) group. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
88812495|NCT04090671|Active Comparator|CHF|the questionnaire MDP will be administered at the day of hospital admission and at the day of discharge.
89077517|NCT02829853||familial cases (FAM)|Familial cases are defined as patients diagnosed for sarcoidosis with a first and/or second degree relative parent also affected by a well-proven sarcoidosis syndrome. More than 70% of SARCFAM families included two first-degree affected individuals, with both a vertical or horizontal transmission. The Mendelian trait seems to be autosomal dominant. 20 to 30% of the families consists of 3, 4 or more cases, with a subset of families including more than 5 cases. Patients are managed as for the sporadic one, and in such families, an informed consent was also provided with a clear explanation on the complexity of the genetic background of the disease. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
89230072|NCT01092325|Placebo Comparator|Cohort 2 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
89230073|NCT01092325|Active Comparator|Echo Cohort A CXL-1020|A 4 hour infusion of a fixed dose of CXL-1020 which was studied in Cohort 1 or Cohort 2 which is expected to be well tolerated and have hemodynamic effect
89224512|NCT06265506|Experimental|CM Condition (Contingency Management + CBT4CBT)|Participants will receive 8 weeks of CBT4CBT and incentives for timely shipping. In addition, those in the CM Condition will receive at least $20 for each PEth-negative sample. Participants will receive an additional $5 for each week of consecutive negative PEth tests, with a $90 cap. In Initiation Phase, participants will attend virtual visits, provide PEth samples, and be rewarded for a decrease in PEth weekly. Maintenance Phase will begin when a participant's PEth sample is < 20 ng/mL. In Maintenance Phase, participants will attend visits and submit PEth samples every two weeks for four weeks (i.e., weeks 6 & 8). They will then attend visits and submit PEth samples every four weeks (weeks 12, 16, 20, 24), and on week 26. If participants submit a positive PEth sample, they will return to Initiation Phase and receive $20 for their next negative sample. Participants will attend visits and submit samples weekly until their PEth level is < 20 ng/mL and they restart Maintenance Phase.
89224513|NCT06265480|Experimental|FallFitness intervention group|FallFitness 8-weeks exercise program, pre-and post assessment.
89224514|NCT06265480|No Intervention|Control group|No treatment, standard information about fall prevention, pre-and post assessment.
89224515|NCT06265467|Experimental|Test Group- Closed Sinus elevation|Maxillary sinus floor elevation using osteotomes through a crestal approach. Followed by bone grafting using allogenic bone graft and simultaneous dental implant placement.
89224516|NCT06265467|Active Comparator|Control Group- Open sinus elevation|Maxillary sinus floor elevation using sinus elevation tools through a lateral window approach. Followed by bone grafting using allogenic bone graft and simultaneous dental implant placement.
88812496|NCT04090671|Active Comparator|COPD|In stable state of COPD, the questionnaire MDP will be administered once during a routine control visit at the hospital or the medical practice.
89077518|NCT00890695|Active Comparator|Ready to use supplementary food (RUSF)|The RUSF intervention consists of a food paste made of maize, soya, sorghum, vegetable oil, sugar, dried skim milk and vitamin/mineral premix, prepared by VALID Nutrition in collaboration with Insta Products, Kenya in accordance with composition specified by the latest WHO expert consultation in 2008. Children in the intervention arm receive 4 weeks supply of RUSF. The amount supplied is based on the child's weight to give energy supplement of 100kcal per kg per day, equivalent to 25g RUSF per kg per day.
89077519|NCT00890695|No Intervention|Normal diet (standard of care)|For equity, parents or guardians of children in the usual diet arm will be given 2 bags of maize meal(4Kg) for family consumption instead of RUSF. All parents and carers in both arms will also receive standard nutritional advice as specified in the current WHO IMCI handbook.
89077520|NCT02826655|Active Comparator|Healthy Controls|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
89077521|NCT02826655|Experimental|Subjects with diabetic retinopathy|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
89077522|NCT02826499|Active Comparator|Fluoroscopy|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy.
89077523|NCT02826499|Experimental|Fluoroscopy and Pediguard|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy, with the Pediguard system.
89224517|NCT06265454|Active Comparator|myopic children atropine 0.05%|they will receive topical atropine 0.05% for 12 weeks and all investigations will be done before administration of atropine (baseline assessment), then after 1 month, 2 months, 3 months.
89077524|NCT04242979|Other|Human albumin use in liver cirrhosis|"Each participant involved in the study will be assessed for his or her knowledge using (tool I).~5-Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~6-Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~7-Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians."
89077525|NCT02829541|Experimental|Cohorts 1|6 participants randomized (4:2) to receive a single-ascending dose (SAD) administered orally in tablet
89077526|NCT02829541|Experimental|Cohort 2|6 participants randomized (4:2) to receive a SAD administered orally in tablet(s)
89077527|NCT02829541|Experimental|Cohort 3|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
89077528|NCT02829541|Experimental|Cohort 4|8 participants randomized (6:2) to receive a SAD administered orally in tablet
89077529|NCT02829541|Experimental|Cohort 5|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
89077530|NCT02829541|Experimental|Cohort 6|14 participants (all active) to receive a SAD administered orally in tablet(s)
89077531|NCT02827123|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
89077532|NCT02827123|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
89077533|NCT05041543|Experimental|NTX-101 Group A|Day 1: One time administration, single drop. 4 subjects randomized 3:1 to NTX-101 or placebo.
89077534|NCT05041543|Experimental|NTX-101 Group B|Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
89077535|NCT05041543|Experimental|NTX-101 Group C|Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
89077536|NCT05041543|Experimental|NTX-101 Group D|Day 1: One time administration, two drops. Day 3-7: Two time administration, two drops each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
89077537|NCT05041543|Experimental|NTX-101 Group E|Day 1: One time administration, four drops. Day 3-7: Two time administration, four drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.
89077538|NCT02826265||pulmonary disease|patients with known or suspected pulmonary disease
89077539|NCT04246411|Active Comparator|Ultrasound|Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field
89077540|NCT04246411|Placebo Comparator|Auscultation|Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field
89077541|NCT02829385|Experimental|Apatinib combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
89077542|NCT02826109|Experimental|Interventional: Cyanoacrylate Application|Application of cyanoacrylate adhesive to one quadrant of mouth
89077543|NCT02826109|No Intervention|Control: Absence of Cyanoacrylate Application|No application of cyanoacrylate adhesive to the other quadrant of mouth
89077544|NCT02826343|Other|COPD Advair|"Subjects will undergo hyperpolarized xenon MRI with perfusion imaging, before and after a 90 day course of Adair.~All subjects belong to one arm and will receive same treatment. Then they are compared at baseline and 3 month post intervention (described below) for within same-subject changes.~Subjects will be administered with~Hyperpolarized Xenon129 inhalation during MRI twice (at baseline and post 3 month Advair)~Gadolinium intravenous contrast during MRI twice (at baseline and post 3 month Advair)~Advair diskus: strength 250mcg/50mcg, one puff twice a day for 3 months."
89077545|NCT04246255|Placebo Comparator|Group C|Serum Physiologic %0,9 ampules ; 0,3ml {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
89077546|NCT04246255|Experimental|Group L|xylocaine %10 pump spray ; 30mg lidocaine {spraying three times from a pump spray bottle that sprays 0,1 ml each time to Tegaderm + (2,5 cm x 4 cm) Non-Adherent Pad} 10 minutes before the IV cannula application
89077547|NCT04246099||Group opioid free anesthesia|Patient benefit of the opioid free anesthesia protocol
89077548|NCT04246099||Group opioid based anesthesia|Patient don't benefit of the opioid free anesthesia protocol
89077549|NCT02824861|Experimental|Text Intervention|Participants receive text messages to a personal cell phone over 8 weeks, wear a fitbit to monitor physical activity, and communicate with a health coach intermittently over 2 weeks
89077550|NCT02824861|Active Comparator|Active Control|Participants receive and wear a fitbit only for 8 weeks
89077551|NCT02825953|Active Comparator|Nebulized surfactant|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV), and than premature babies with RDS breathing spontaneously will be administered surfactant by nebulizer.
89077552|NCT02825953|Active Comparator|Endotracheal bolus application|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The investigators will administer surfactant via fundamental method.
89077553|NCT02825953|Active Comparator|Minimally invasive surfactant therapy|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). After randomisation, the investigators will administer surfactant via minimally invasive surfactant therapy (MIST) method which is recently very popular method
89077554|NCT02826187||Patients with acetabular implant|"Data to be collected are :~Early complications data related to implant or procedure of implantation~Late stage complications data~Efficacity of treatment with HIP score~Patient satisfaction~Radiographic evaluation during standard follow-up"
89077555|NCT05210725|Experimental|Stable coronary artery disease|Patients with stable coronary artery disease with an indication for single antiplatelet therapy according to international (ESC) guidelines, with a high cardiovascular risk.
89077556|NCT02826031|Experimental|Sodium Hyaluronate Injection + DICL-SR|"Each syringe (2.5mL) contains 25mg of sodium hyaluronate, and one Artz® will be administered via intra-articular injection into the target knee at the baseline and Weeks 1, 2, 3 and 4 respectively for the combination group.~From the run-in period to the end of study, both groups will receive DICL-SR 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID） daily"
89077557|NCT02826031|Active Comparator|DICL-SR|From the run-in period to the end of study, both groups will receive Diclofenac Sodium Sustained-release Tablets(DICL-SR) 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID daily）. A subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse effects.
89077558|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 2.5 mL|Perineural injection of ropivacaine 0.2 %, 2,5 mL
89077559|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
89077560|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
89077561|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
89077562|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
89077563|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
89077564|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
88812497|NCT04090671|Active Comparator|OSA|The questionnaire MDP will be administered once during the first visit in the sleep laboratory.
89077565|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
89077566|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
89077567|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 30 mL|Perineural injection of ropivacaine 0.2 %, 30 mL
89077568|NCT04980469|Experimental|Vitex negundo + Zingiber officinale|Dosage: 200 mg/ Capsule;1 capsule twice daily Route: Oral
89077569|NCT04980469|Placebo Comparator|Placebo (MCC)|Dosage: 200 mg/ Capsule; 1 capsule twice daily Route: Oral
89077570|NCT02829151|Experimental|Triple antiplatelet therapy group|Patient group with triple antiplatelet therapy using aspirin, clopidogrel, and cilostazol
89077571|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) A|Patient group with dual antiplatelet therapy using aspirin and clopidogrel
89077572|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) B|Patient group with angioplasty using aspirin and cilostazol
89077573|NCT05207137|Experimental|Telephone call from family physician|Individuals allocated to the experimental arm will receive a phone call from the their family physician, where they are offered the opportunity to raise questions they might have about the COVID-19 vaccine.
89077574|NCT05207137|No Intervention|Usual care|
89077575|NCT02825719|Experimental|Ulipristal|Patients will be prescribed Ulipristal acetate 5mg daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
89077576|NCT02825719|Placebo Comparator|Placebo|Patients will be prescribed placebo pills daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
89077577|NCT04241653|Active Comparator|Spontaneous Ventilation|Patients will spontaneously ventilated. Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
89077578|NCT04241653|Active Comparator|Unparalyzed Controlled Ventilation|Patients will be mechanically ventilated without muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
89077579|NCT04241653|Active Comparator|Paralyzed Controlled Ventilation|Patients will be mechanically ventilated with muscle relaxation.Laryngeal mask airway will be inserted and anesthesia is maintained with sevoflurane.
89077580|NCT05199961|Experimental|Single Arm Cohort Receiving Digital Health Coaching|A single cohort of up to 100 individuals receiving chimeric antigen receptor T cell therapy will be enrolled in the study, all of whom will be enrolled in a 6-month digital health coaching program. Individuals will be enrolled at The Ohio State University Comprehensive Cancer Center.
89077581|NCT04241731|Experimental|Raltitrexed Plus Cetuximab|Raltitrexed Plus Cetuximab
89077582|NCT02829073|Experimental|Oasis™ device|Treatment using the Neuromonics Tinnitus Treatment Program and the Neuromonics Oasis™ treatment device.
89077583|NCT02829073|Placebo Comparator|Placebo device|Treatment using the Neuromonics Tinnitus Treatment Program and an identical-appearing placebo device.
89077584|NCT02824159||Patient with haematologic malignancies|"Interventions to be administrated are :~Clinical examinations~Biological statement~Blood samples for pharmacokinetics exploration~Imagery with positron emission tomography scan or resonance magnetic imagery~Saliva samples for genetics analyses~Blood samples for treatment mutation resistance search~Quality of life scale questionary~Detection of adverse events"
89077585|NCT04241887|Experimental|group PVB|standard analgosedation + paravertebral thoracic blockade with 20 ml 0.25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa warszawa S.A.)
89077586|NCT04241887|Active Comparator|group BB|standard analgosedation + local anesthesia of the skin and subcutaneous tissue with 5ml 0,5% lignocaine (Lignocainum hydrochlorici, WZF 1%).
89077587|NCT05660005|Active Comparator|Piriformis Muscle Stretching|Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
89224518|NCT06265454|Active Comparator|myopic children atropine 0.01%|they will receive topical atropine 0.01% for 12 weeks and all investigations will be done before administration of atropine (baseline assessment), then after 1 month, 2 months, 3 months.
89224519|NCT06265454|Placebo Comparator|myopic children placebo|they will receive placebo for 12 weeks and all investigations will be done before administration of placebo (baseline assessment), then after 1 month, 2 months, 3 months.
89077588|NCT05660005|Active Comparator|Piriformis Muscle Self Myofascial Release|The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
89077589|NCT05660005|Experimental|Control Group|The individuals who refused to apply stretching or releasing included to the control group. They perform only home exercises of hip strengthening
89077590|NCT04242745|Experimental|Intervention group|Procedure/Surgery:The intervention group was given education and a wristwatch which gave an audible alarm to remind them to drink liquid.
89077591|NCT04242745|No Intervention|Control group|The control group was given only education.
89077592|NCT02825875||adenocarcinoma of the prostate|
89077593|NCT02828995||Comprehensive Diabetes Stigma Survey|Participants in the END STIGMA study will be adult patients who have been receiving diabetes-related medical care for a minimum of 12 months in the Vanderbilt University Medical Center Diabetes Clinic and who take at least 1 medication to manage their diabetes.
89077594|NCT02825485|Other|Control Group|The control patients will be the patients with antenatal hydronephrosis who get a routine VCUG to evaluate for vesicoureteral reflux, as part of routine care.
89077595|NCT02825485|No Intervention|Observation Group|Receives no intervention
89077596|NCT02825563|Experimental|Anlotinib(In the fasting state)|In the fasting state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
89077597|NCT02825563|Experimental|Anlotinib(In the high fat diet state)|In the high fat diet state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
89077598|NCT02825797|Experimental|Group 1A|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074), each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
89077599|NCT02825797|Experimental|Group 1B|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion 10-1074, each dosed at 30 mg/kg, OR placebo (sterile saline), on day 0.
89077600|NCT02825797|Experimental|Group 1C|HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.
89077601|NCT02825797|Experimental|Group 2|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 and 42. Participants enrolled in Group 2 will undergo an analytical treatment interruption and they will discontinue their antiretroviral (ART) regimen on day 2.
89077602|NCT02825797|Experimental|Group 3|HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 and 28.
89077603|NCT04241497|Experimental|Patients with Pulmonary Arterial Hypertension|12 weeks home-based rehabilitation
89077604|NCT02824315|Experimental|AL-335+Simeprevir (SMV)+Odalasvir (ODV)|Participants will receive AL-335 800 milligram (mg) once daily from day 1-3; SMV 75 mg once daily from Day 4-13; loading dose of ODV 150 mg on Day 14, followed by ODV 50 mg once daily from Day 15 to 23; ODV 50 mg once daily + AL-335 800 mg once daily from day 24-26; ODV 50 mg once daily + SMV 75 mg once daily from Day 27-33 and ODV 50 mg once daily + SMV 75 mg once daily + AL-335 800 mg once daily from Day 34 to 36.
89077605|NCT00633529|Experimental|I|Single arm: triple combination
89077606|NCT02823613|Experimental|Healthy male test subjects 1-5|High salt diet followed by low salt diet
89077607|NCT02823613|Experimental|Healthy male test subjects 6-10|Low salt diet followed by high salt diet
89077608|NCT02824081|Other|Depressive patients|Blood samples (inflammatory biomarkers and genetic purpose) on depressive patients with or without story of suicidal behavior
89077609|NCT04242433||Viremic Person living with HCV|All persons enrolled in the MMPHCRF treatment programme are provided free of charge direct acting antiviral agents and followed up for outcomes.
89077610|NCT02825407|Experimental|main study|
89077611|NCT04242511||Cases|"Tuberculosis patients with diabetes mellitus:~Subject aged 18 years of age or over~Written, informed consent obtained.~New diagnosis of tuberculosis and started on anti-tuberculosis treatment~Known diagnosis of diabetes or two consecutive raised IFCC HbA1c levels (>= 48 mmol/mol) at the time of TB diagnosis"
89077612|NCT04242511||Controls|"Tuberculosis patients without diabetes mellitus:~1), 2), 3) as above 4) IFCC HbA1c level < 48mmol/mol 5) Weight matched to cases (+/- 2kg)"
89077613|NCT02825173|Experimental|Seal-G|A surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
89077614|NCT05659771|Experimental|low energy density, hard texture|Sandwich with a hard texture (slow eating rate) and relatively low energy density (kcal/g)
89077615|NCT05659771|Experimental|low energy density, soft texture|Sandwich with a soft texture (fast eating rate) and relatively low energy density (kcal/g)
89077616|NCT05659771|Experimental|High energy density, hard texture|Sandwich with a hard texture (slow eating rate) and relatively high energy density (kcal/g)
89077617|NCT05659771|Experimental|High energy density, soft texture|Sandwich with a soft texture (fast eating rate) and relatively high energy density (kcal/g)
89077618|NCT05659771|Active Comparator|Average energy density and medium hard texture (control)|Sandwich with a medium texture (medium eating rate) and medium energy density (kcal/g)
89077619|NCT04242589|Active Comparator|Radiotherapy|Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)
89077620|NCT04242589|Experimental|Vertebroplasty + Radiotherapy|"Vertebroplasty followed by radiotherapy within 2-3 weeks~Radiotherapy dose: 20 Gy/5 fractions/1 week or 8 Gy/1 fraction (at the discretion of the Radiation Oncologist)"
89077621|NCT04201249|Active Comparator|Mesotherapy with piroxicam and lidocaine|
89077622|NCT04201249|Sham Comparator|Mesotherapy without piroxicam and lidocaine|
89077623|NCT00633685|Experimental|Fluoxetine|Receives Fluoxetine at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
89077624|NCT00633685|Placebo Comparator|Placebo|
89077625|NCT02823691|Experimental|Lanreotide and Metformin|"Dose and Treatment Regimen:~LANREOTIDE ATG 120 mg/28 days (equivalent to 1 cycle), deep subcutaneous injection (SC) in combination with METFORMIN 2550 mg daily (maximum dose), oral administration (OS).~Metformin starting dose 850 mg/day to be increased up to 1700 mg/day at day 14, 2550 mg/day at day 28, (maximum dose), if well tolerated."
89077626|NCT04888195||Questionnaire|This study aims to examine the cancer patient's symptom clusters and their changes over chemotherapy among pediatric patients with blood cancer in Hong Kong
89224520|NCT06265428|Experimental|DB-1303/BNT323|Enrolled patients will receive DB-1303/BNT323 by intravenous (I.V.) infusion
89077627|NCT02825095|Active Comparator|Talc Pleurodesis|"For patients in this group, chest tube type PIGTAIL 10 - 14 Fr will be inserted by by chest ultrasound guided and under local anesthesia, allowing good draining of the hemithorax, in case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed, chest tube will be removed 24 - 48 hours later on. the patient will be admitted in the hospital during the whole procedure course.~If the patient developed non expanded - trapped lung post chest tube insertion, or if he had persistence high chest tube output for more than 10 days, then the patient will remain with the PIGTAIL as an Indwelling Pleural Catheter."
89224521|NCT06265428|Experimental|T-DM1|Enrolled patients will receive T-DM1 by I.V. infusion
89077628|NCT02825095|Active Comparator|Indwelling Pleural Catheter|"All patients from this group will have Indwelling Pleural Catheter insertion type PLEURAX inserted by ultrasound guided and under local anesthesia.~the patient and his/her family will be instructed and educated about the proper way of using the catheter, and how to perform pleural draining at home.~the duration of treatment with the Pleurax depends on the rate and amount of pleural effusion draining."
89077629|NCT04241263|Other|Comparative assessment of data quality|Quantitative comparison between the current wired system and the new wireless system
89077630|NCT04241263|Other|Usability|Qualitative assessment of the new wireless system
89077631|NCT02823535|Experimental|Iwin: Individual Well-Being Navigator|Iwin intervention during 6-month intervention period plus study assessments at baseline, 6, and 9 months.
89077632|NCT02823535|No Intervention|Control group|Study assessments at baseline, 6 months, and 9 months, plus two short surveys unrelated to the study behaviors at 4 and 5 months.
89077633|NCT02823379|Experimental|Physical Activity|A culturally relevant physical activity promotion program delivered using a Smartphone application.
89077634|NCT02823379|Active Comparator|Wellness Contact Control|A wellness contract control condition delivered using a Smartphone application.
89077635|NCT02825017|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89077636|NCT02824939|Experimental|Transversus Abdominis Plane group|
89077637|NCT02824939|Experimental|Quadratus Lumborum group|
89077638|NCT02824939|No Intervention|Control group|
89077639|NCT02822443|Experimental|TAU - EFT|This arm integrates emotion focused components (EFT; Greenberg, 2010) into psychological therapy (PT) as treatment-as-usual (TAU), aiming at clarifying and transforming maladaptive emotions. 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
89077640|NCT02822443|Experimental|TAU - SR|This arm focuses on the training of self-regulation strategies (SR; Carver & Scheier, 2000) in the context of psychological therapy (PT) as treatment-as-usual (TAU). 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions.
89077641|NCT02824393|Experimental|Mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
89077642|NCT02824393|No Intervention|Control patients|The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell.
89077643|NCT02824003|Experimental|ISIS-GCGRRx|ISIS-GCGRRx once weekly dosing for 13 weeks
89077644|NCT02824003|Placebo Comparator|Placebo|once weekly dosing for 13 weeks
89077645|NCT04240951|Other|Study Session 1|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the laboratory
89077646|NCT04240951|Other|Study Session 2 (repeat of Study Session 1)|Arm Type: Validation: Regional sweat collection with prototype vs. reference patch in the laboratory
89077647|NCT04240951|Other|Study Session 3|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
89077648|NCT04240951|Other|Study Session 4 (repeat of Study Session 3)|Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory
89077649|NCT04240951|Other|Study Session 5|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
89077650|NCT04240951|Other|Study Session 6 (repeat of Study Session 5)|Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field
89077651|NCT04241107|Active Comparator|Laparoscopic approach group(A)|Uterine niche will be repaired through Laparoscopic approach.
89077652|NCT04241107|Active Comparator|Transvaginal approach group(B)|Uterine niche will be repaired through Transvaginal approach.
89077653|NCT02822365||Diagnostic (PET/CT)|Patients undergo a PET/CT scan as part of their standard clinical care. While still positioned for the clinical scan, patients undergo additional research PET/CT scans in a smaller region over 10 minutes with the pocket phantom placed nearby and a low-dose single bed position CTAC.
89077654|NCT02823301|Experimental|VAMOS group|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
89077655|NCT02823301|No Intervention|Control group|Group that will not receive the VAMOS program as intervention.
89077656|NCT04806607|Active Comparator|19Gauge Fine Needle Biopsy|19Gauge Fine Needle
89077657|NCT04806607|Active Comparator|22 Gauge Fine Needle Biopsy|22Gauge Fine Needle
89077658|NCT02822131|Other|low phosphate|low phosphate will be induced by low phosphate diet and additional treatment with oral phosphate binder sevelamer.
89077659|NCT02822131|Other|high phosphate|high phosphate diet will be induced by oral supplementation with sodium phosphate.
89077660|NCT02820649|Experimental|Exercise training|7 weeks of exercise training
89077661|NCT02820649|Sham Comparator|Control|Sedentary group
89077662|NCT04240873|Experimental|MASTER cell|Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis
89077663|NCT04240873|Placebo Comparator|Saline|Intraarticular injection of saline, 1 time, 5cc, into knee joint of patients with osteoarthritis
89077664|NCT02820805|Experimental|Meal skipping|No meal given
89077665|NCT02820805|Experimental|Mashed potatoes|Carbohydrate Test Meal (50 g of available carbohydrates)
89077666|NCT02820805|Experimental|French fries|Carbohydrate Test Meal (50 g of available carbohydrates)
89077667|NCT02820805|Experimental|Hash browns|Carbohydrate Test Meal (50 g of available carbohydrates)
89077668|NCT02820805|Experimental|Rice|Carbohydrate Test Meal (50 g of available carbohydrates)
89077669|NCT02820805|Experimental|Beans|Carbohydrate Test Meal (50 g of available carbohydrates)
89077670|NCT02821975|Experimental|Cognitive computer training|This is the intervention group receiving cognitive computer training three times a week for three months.
89077671|NCT02821975|No Intervention|cogntrol group|The control group do not receive cognitive computer training for three months
89077672|NCT04239469|Active Comparator|KL16-012|Patients will use a liquid standardized extract of cannabis sativa. Each drop will contain 1 mg of THC and 0.45 mg of CBD. Administration will be sublingual, while dosing will begin at 3 drops per day and be escalated to 15 drops per day by week 5 according to an escalation chart.
89077673|NCT04239469|Placebo Comparator|Placebo|Patients will use a liquid placebo identical to the active principle in both appearance and taste.
89077674|NCT04240795|Experimental|Low lubricity (LL) hydrogels containing fibre-based beads|"Participants are given a preload of 30 g of low lubricity hydrogels (alginate beads in kappa-carrageenan hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
89077675|NCT04240795|Active Comparator|High lubricity (HL) hydrogels containing no fibre-based beads|"Participants are given a preload of 30 g of high lubricity hydrogels (no beads in kappa-carrageenan and alginate mixed hydrogels) after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
89077676|NCT04240795|Placebo Comparator|Water|"The water containing the same watermelon flavor, color and sweetness was given as control to match the gels. Participants receive the same amount of water like hydrogels - 30 g after 2.5 hours after a standardized breakfast. After 30 minutes of the preload, participants are given ad libitum lunch. They are asked to eat as much or as little as they want, until they feel comfortably full."
89077677|NCT02821897|Experimental|Target-controlled Intravenous Anaesthesia|Patients have a target controlled intravenous anaesthesia to implant the spinal cord stimulation lead with active cooperation during the surgery.
89077678|NCT02821897|Active Comparator|Total anesthesia|Patients have a total anaesthesia to implant the spinal cord stimulation lead without active cooperation during the surgery.
89077679|NCT04239547|Experimental|Recruitment|Patients classified to receive recruitment maneuver + 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
89077680|NCT04239547|Experimental|Non-recruitment|Patients classified to receive only 5 mmHg positive end-expiratory pressure after anesthesia induction and intubation.
89224522|NCT06265415|Active Comparator|group A|(20 patients) will receive Labetalol intravenous infusion. The starting infusion rate is 5mg/h,the infusion rate will be changed 1mg/h up every 10 minutes until the desired goal achieved which is a decrease in systolic blood pressure (SBP) to 120 - 140 mmHg and a decrease in diastolic blood pressure (DBP) to 80 - 90 mmHg every 10 minutes
89077681|NCT02822209|Experimental|Coordinating nurse added to the personalized care program|"The coordinating nurse (CN) is dedicated to the newly diagnosed patient to optimize their personalized care program.~The CN is the connection between the medical team and the patient. They act according to the instructions from the multidisciplinary staff in charge of bronchopulmonary cancer patients.:~e.g. Schedule an exam or an hospitalization, collect and share results of useful information to correct treatment's side effects etc~Main contact of the patient, the general practitioner and the patient's relatives, they give practical information for the patient's case~Quality of life questionnaires - EORTC QLQ-C30 and EORTC QLQ-LC13 - completed by the patient throughout the study.~2 Satisfaction questionnaires completed :~satisfaction questionnaire - patient,~satisfaction questionnaire - general practitioner or home nurse"
89224523|NCT06265415|Active Comparator|group B|(20 patients) will receive calculated dose of Nitroglycerine started as intravenous infusion, The starting infusion rate is 4.8mg/h ,the infusion rate will be changed 1mg/h every 10 minutes up until the therapeutic goal achieved, which is a decrease in systolic blood pressure (SBP) to 120 - 140 mmHg and a decrease in diastolic blood pressure (DBP) to 80 - 90 mmHg
89077682|NCT02822209|Active Comparator|Personalized care program as routine practice|"A personalized care program is decided for the newly diagnosed patient by the multidisciplinary team in charge of lung cancer.~The care provided will be organized by the medical team, and besides the oncologist, no principal coordinating contact will be in charge of the patient.~The quality of life questionnaire - EORTC QLQ-C30 and QLQ-LC13 - will be completed by the patient throughout the study.~2 Satisfaction questionnaires completed :~satisfaction questionnaire - patient,~satisfaction questionnaire - general practitioner or home nurse"
89077683|NCT02690623|Experimental|Pediatric hospitalist program|As currently planned, hospitalist services will involve an in-house hospitalist at all hours. The attending hospitalist on each hospitalist service will make morning rounds on weekdays and be present supervising the residents or providing care throughout the day. A different hospitalist will cover at night. On weekends, one hospitalist will cover up to 2 services each day. None will work for more than 25 hours at a stretch.
89077684|NCT02690623|Active Comparator|General Pediatric Inpatient Services|The attending pediatrician on each service conducts daily morning rounds on weekdays, supervises the students and house staff and is available to the residents by phone or in person during the day. On some afternoons the attending physician may be responsible for supervising care in a pediatric clinic. On weeknights, an on-call pediatrician is available to the residents by phone. On weekends two on-call pediatricians make rounds, supervise the residents, and take call from home for the 4 services. Each service usually maintains 10-20 patients at a time and generally accepts 8-12 new admissions per admitting day. This approach on the General Pediatric Services will not be changed materially as hospitalists assume responsibility for one or more of the 4 services.
89077685|NCT02823067||Nursing home patients|Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
89077686|NCT02820493|Other|single arm study|Vedolizumab 300 mg iv at week 0, week 2 and week 6, than every 8 weeks.
88812498|NCT04080427|Placebo Comparator|Placebo capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
89077687|NCT02820415||infertile couples undergoing ICSI for PGS/PGT|patients aged between 29.0 and 42.3 years, with basal FSH on day 3 between 2.9 and 12.0 IU/l. Undergoing 36 patients for RIF or RM. In each couple, the two partners had a normal karyotype. The patients underwent one to two cycles of ovarian stimulation to vitrify and accumulate oocytes and a last (second or third) cycle of ovarian stimulation. Ovarian stimulation was performed by the administration of recombinant FSH and LH (Gonal-F and Luveris: Merck-Serono, London, UK or Puregon, MSD, Franklin Lakes, USA) from cycle day 3 and luteal gonadotrophin-releasing hormone antagonist flexible schema (Cetrotide : Merck-Serono, London, UK).
89077688|NCT02822053|Experimental|US-guided laser ablation for refractory neoplasms|The investigators used percutaneously US-guided laser ablation for patients with small hepatocellular carcinoma (single or multiple nodules of less than 3 cm in diameter), Child-Pugh A/B, PLT ≥ 50*10E9/L and PT ≤ 20s. Then the investigators estimated the safety and efficacy of this treatment through follow-up of US/CEUS/CT/MRI and the tumor markers every three months.
89077689|NCT02822989|Active Comparator|Vagus Nerve Stimulation|Subjects randomized to this arm will receive transcutaneous vagus nerve stimulation for 5 minutes on 4 consecutive days.
89077690|NCT02822989|Sham Comparator|Sham Vagus Nerve Stimulation|Subjects randomized to this arm will receive sham stimulation for 5 minutes for 4 consecutive days.
89077691|NCT04239391|Experimental|Triferic via IV and Hemodialysate|Upon completion of the Baseline observational periods, all enrolled patients will transition to the interventional period where they will then receive Triferic. The Triferic will be administered via the liquid bicarbonate concentrate at a dialysate concentration of 2 uM or via IV at a dose of 0.1 mg Fe/kg, if the patient does not receive dialysis using liquid bicarbonate, for up to an additional 36 weeks (depending on duration of observational Baseline period). Hgb and CHr will continue to be measured bi-weekly and iron profiles will be obtained at 4 week intervals. In the Triferic phase of the study,changes in ESA dose will be allowed according to the study site existing protocol. IV iron will only be administered if ferritin meets the criteria for iron deficiency. Patients will remain in the interventional period for either 36 or 28 weeks (depending on randomization assignment), at which time a final study visit will take place
89077692|NCT04239391|No Intervention|Historic Control Observational Arm|Up to 75 patients will be enrolled in the Observational Arm. Patients who participate in the historical control observational arm will not receive any study medication, but will have Hgb, CHr and serum iron profiles collected at 4 week intervals for up to a total of 44 weeks.
89077693|NCT04780087||Weight lifting women|Experienced resistance exercise trained and pregnant women
89077694|NCT04780087||Reference women|Physically active pregnant women (not experienced with free weight lifting)
89077695|NCT02823223|Experimental|ELVR with Endobronchial Valves|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Endobronchial Valves (Zephyr valve) inserted into the target lobe of the lung with the aim of complete lobar exclusion.
89077696|NCT02823223|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice
89077697|NCT02821663|Experimental|Vocal intervention|Vocal intervention
89077698|NCT02822755|Experimental|Video Recording Group|The experimental group participants will be recorded on their personal smartphone performing their prescribed exercises with individualized instruction from the participating physical therapist. The prescribing therapist will record participants on their own smartphones doing the exercise program in the clinic so that participants can have that video recording of the exercises to help remind them how to do the exercises properly at home. Participants will not be asked to record themselves performing future exercise sessions as documentation of improvement. Intervention: Home Exercise Program and Adherence Logs
89077699|NCT02822755|Active Comparator|Conventional Printed Group|The active comparator group will receive individualized instruction from the participating physical therapist on how to perform their home exercise program as well as printed instructions of the exercises. No video recording of the control group participants will be performed. Intervention: Home Exercise Program and Adherence Logs
89077700|NCT02821585|Active Comparator|Mediterranean Diet|Participants will receive nutritional lessons on the principles of the Mediterranean diet. This type of diet is defined with a carbohydrate intake of 45-55% of total energy intake, 15-20% of proteins, 30-35% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
89077701|NCT02821585|Placebo Comparator|Low Fat Diet|Participants will receive nutritional lessons on the principles of the low fat diet. This type of diet is defined with a carbohydrate intake greater than 45% of total energy intake, 15-20% of proteins, less than 30% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
89077702|NCT02821351|Experimental|DiamondTemp|Bilateral pulmonary vein isolation by RF ablation using DiamondTemp temperature controlled catheter and RF generator/pump system
89077703|NCT02820103|Active Comparator|Information leaflet (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge. The information from two leaflets: 1. 'Using GTN', produced by the hospital and 'Angina' produced by the British Heart Foundation, published 08/04/2014 and available at https://www.bhf.org.uk/publications/heart-conditions/angina . The information explains the symptoms of angina and heart attack and advises what to do in the event of experiencing these symptoms. This information will be presented in written text format on screen.
89077704|NCT02820103|Experimental|Text+Visual BCT-based intervention (Intervention Group 1)|Participants in the visual intervention group will receive the control condition specified above PLUS a specifically developed Text+Visual BCT-based intervention, comprising the 12 BCTs identified earlier in a Systematic Review and expert consensus study. The BCTs are Problem solving; Action planning; Social support (practical); Social support (emotional); Instruction on how to perform the behaviour; Information about health consequences; Salience of health consequences; Prompts/cues; Credible source; Pro's & Con's; Comparative imagining of future outcomes; Mental rehearsal of successful performance
89077705|NCT02820103|Experimental|Text-only BCT-based intervention (Intervention Group 2)|Information leaflet (usual care) plus text-only BCT-based intervention (Intervention group 2) Participants in the text-only BCT-based intervention group will receive the control condition specified above plus a text-only BCT-based intervention. This was developed in the same way as the text+visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen instead.
89077706|NCT05658991|Active Comparator|Intermittent fasting healthy group|Healthy participants with intermittent fasting dietary habit.
89077707|NCT05658991|Active Comparator|Obesity group|Subjects with body mass index more than 30.
89077708|NCT02822833|Experimental|Sentinel lymph node mapping|Sentinel lymph node mapping with indocyanine green injection to cervix in endometrial cancer patients operated laparoscopically
89077709|NCT02821429||Patient with mechanical ventilation|Patient will be followed with combined Thoracic Echography Record
89077710|NCT00633763||1|Healthy individuals with normal C-peptide levels following i.v. glucagon challenge. These individuals will be administered 18F-fallypride and then subjected to PET-CT scanning of the pancreas and brain. The subject will be positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen carried out (with subjects breathing normally). A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame). The subject will then be repositioned for a low-dose CT scan of the head (15-20 secs) following which a 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).
89224524|NCT06265415|Active Comparator|group C|, (20 patients) will receive calculated dose of nifedipine the content (100 µL) of a 10 mg capsule of nifedipine was drawn up into an insulin syringe and deposited sublingually, every 30 min.( Maximum dose of nifedipine 120 mg/day) ) until the therapeutic goal achieved, which is a decrease in systolic blood pressure (SBP) to 120 - 140 mmHg and a decrease in diastolic blood pressure (DBP) to 80 - 90 mmHg
89077711|NCT00633763||2|Patients with longstanding T1DM and <20% C-peptide levels following i.v. glucagon challenge will be consented. 18F-Fallypride injected intravenously and subjects allowed to wait for approx 1 hr for the uptake.(b) Subject positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen (pancreas) carried out (with subjects breathing normally).(c) A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame).(d) Subject repositioned for a low-dose CT scan of the head (15-20 secs).(e) A 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).(f) End of PET/CT scanning procedures. Subject taken out of the scanner.
89077712|NCT02822911|Other|Alcohol Used Disorders Identification Test (AUDIT C)|Submission of Audit-C questionnaire to all the patients of the study. When the result to the AUDIT-C questionnaire reaches at least 1 point, the analysis of the Carbohydrate deficient transferrin (CDT) is performed within 3 days after the beginning of the study. Results of Gamma glutamyl transpeptidase (GGT) and Mean Corpuscular Volume (MCV) performed as routine practice collected at the same time as the CDT analysis.
89077713|NCT02820025|Experimental|doxapram group|the doxapram group iv doxapram 1mg/kg,
89077714|NCT02820025|Placebo Comparator|Controlled group|the controlled group given equal volume of saline with the doxapram group.
89077715|NCT02819869|Experimental|Taking both statin and metformin Group|The experimental group take Lotidon 500mg/ tablet per day and Lipitor 10mg/ tablet per day for two years or until of a recurrence.
89077716|NCT02819869|No Intervention|Non- taking both statin and metformin Group|Non- taking both statin and metformin.
89077717|NCT02819713|Placebo Comparator|ultrasound gel|
89077718|NCT02819713|Active Comparator|Instillagel|
89077719|NCT02821117|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
89077720|NCT02820883|Experimental|High dosage vaccine|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
89077721|NCT02820883|Experimental|Middle dosage vaccine|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
89077722|NCT02820883|Experimental|Low dosage vaccine|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
89077723|NCT00633841|Active Comparator|1|AFFITOPE AD02 without adjuvant
89077724|NCT00633841|Active Comparator|2|AFFITOPE AD02 with adjuvant
89077725|NCT04811287|Active Comparator|CTR with PRP|Carpal tunnel release with adjuvant platelet-rich plasma.
89077726|NCT04811287|Placebo Comparator|CTR without PRP|Carpal tunnel release without adjuvant platelet-rich plasma.
89077727|NCT04200859|Experimental|Cold application with ice pack|Before the chest tube was removed, two ice packs with a size of 15.5x9cm were inserted around the chest tube so as to make as much contact as possible
89077728|NCT04200859|Experimental|Cold application with gel pad group|Before the chest tube was removed, a gel pad with a radius of 15 cm was completely inserted around the chest tube
89077729|NCT04200859|No Intervention|Control group|Routine analgesic drugs are not administered to patients before removal of the chest tube in thoracic surgery clinic. However, analgesic is performed according to the severity of pain after the procedure.
89077730|NCT02819245|Other|Age before and after 18 years old|Surgical treatment before and after skeletal maturity
89077731|NCT04200703|Experimental|Intervention|Implementation of the Adult and Survivor Centered Approach.
89077732|NCT04200703|No Intervention|Comparison|No implementation of intervention.
89077733|NCT02819089|Active Comparator|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
89077734|NCT02819089|Placebo Comparator|NSS|NSS loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
89077735|NCT02818699|Placebo Comparator|Placebo Capsule|Participants assigned to this group will receive placebo capsules identical in appearance to EMIQ capsules.
89077736|NCT02818699|Experimental|EMIQ Capsule|Participants assigned to this group will receive EMIQ capsules identical in appearance to placebo capsules.
89077737|NCT02690311|Sham Comparator|LED with bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
89077738|NCT02690311|Experimental|LED without bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
89077739|NCT04238923|Experimental|Topical Gentamicin and Vancomycin|Immediately prior to closure of the incision, 1g of vancomycin will be mixed in 4mL of normal saline and applied as a paste directly to the muscle, fascia and subcutaneous tissue. Gentamicin-eluting collagen sponges will be cut to the appropriate size to cover the defect and applied after application of vancomycin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
89077740|NCT04238923|No Intervention|Control|The surgical wound is closed in the standard fashion with 3 layer closure with staples for skin. Following closure, the surgical site will be covered with a sterile dressing and left in place for 48hrs.
89077741|NCT02819167|Other|neurologic and neuropsychological evaluation|
89077742|NCT04239001|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF): jinyouli injection was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle
89077743|NCT04240015||Periodontitis|Periodontitis group consisted of patients diagnosed with periodontitis
89077744|NCT04240015||Patients without periodontitis|Patients without periodontitis group constituted patients without periodontitis
89077745|NCT02818933||Aim 1|This group follows a crossover design where adolescents 12-17 years old (n=10) complete a diet recall using one of the two methods (interviewer-administered vs web-based), and then does another diet recall using the other method about a week later. Participants are randomly assigned to the order in which they complete each method of diet recall.
89077746|NCT02818933||Aim 2, interviewer-administered recall|This group of adolescents 12-17 years old (n=10) completes an interviewer-administered diet recall once a week for 6 weeks.
89077747|NCT02818933||Aim 2, web-based recall|This group of adolescents 12-17 years old (n=10) completes a web-based self-administered diet recall once a week for 6 weeks.
89077748|NCT02815657|Active Comparator|SP2086 and Valsartan|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from A stage to B stage.
89077749|NCT02815657|Active Comparator|Valsartan and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from B stage to A stage.
89077750|NCT04597333|Active Comparator|2nd Dinoprostone.|Women induced with a second dinoprostone insert.
89077751|NCT04597333|Active Comparator|Cervical ripening balloon.|Women induced with a cervical ripening balloon.
89077752|NCT00957580|Experimental|Regimen 1 (Part 1)|
89077753|NCT00957580|Experimental|Regimen 2 (Part 1)|
89077754|NCT00957580|Experimental|Regimen 3 (Part 1)|
89077755|NCT00957580|Experimental|Regimen 1 (Part 2)|
89077756|NCT00957580|Experimental|Regimen 2 (Part 2)|
89077757|NCT02817373|Other|transvaginal ultrasound study|Patients with a well established infertility requiring IVF treatment and who are <40. Cohort will consist of patients going through a fresh day 5 transfer with a planned transfer of a single good quality embryo. Patients will go thorough a Ultrasound scan performed through a vaginal probe on the morning of the embryo transfer.
89077758|NCT04279210|Experimental|PRP Treatment|Women with SUI received PRP injection into anterior vaginal wall (near external urethral sphincter) once per month for three times.
89077759|NCT02817295||elderly|patients underwent bariatric surgery and are above 65 years old
89077760|NCT02817295||non-elderly|patients underwent bariatric surgery and are below 65 years old
89077761|NCT00957424|Other|Overall|Single-armed study
89224525|NCT06265402|Active Comparator|Retrolaminar block in abdominal plastic surgery|In first group induction done with general anaesthia then Patient will receive bilateral us guided rertrolaminar block then bubivacane ,25%with dexa methasone 4mg as addiditive injected on the lamina at dose 20ml injected each side
89224526|NCT06265402|Active Comparator|Tab block as post operative analgesia in abdominal plastic surgery|In secound group after general anaesthia induction bilateral us guided tap block with ,25%bupivacaine with dexamethasone 4mg as addiditve injected on the lamina at doses 20ml in each side
89224527|NCT06265389|Experimental|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form at a dose of 20 mg/kg/day, as an adjunct therapy to the usual pneumonia treatment for 5 days
89224528|NCT06265389|No Intervention|50 children with community-acquired pneumonia with the standard pneumonia treatment.|50 children with community-acquired pneumonia with the standard pneumonia treatment as a control group
89224529|NCT06265350|Active Comparator|Bevacizumab+Cadonilimab group|Patients accepted Bevacizumab (7.5mg/kg，Q3W， IV) plus Cadonilimab (375mg，Q3W， IV)
89224530|NCT06265350|Experimental|Cryoablation+Bevacizumab+Cadonilimab|Patients accepted Cryoablation of pulmanary metastases combined with Bevacizumab (7.5mg/kg，Q3W， IV) and Cadonilimab (375mg，Q3W， IV)
89224531|NCT06265337|Experimental|LAC|
89224532|NCT06265337|Placebo Comparator|CTR|
89224533|NCT06265324|Experimental|Control|
89224534|NCT06265311|Experimental|IDUS examination during ERCP|CBD stones cases with high recurrence risks apply IDUS during ERCP
89224535|NCT06265311|No Intervention|Control|CBD stones cases with high recurrence risks don't apply IDUS during ERCP
89224536|NCT06265298|Experimental|Intervention|Patients undergoing conjunctival reconstruction using oral mucosa
89224537|NCT06265272||Cirrhosis|55 Patients with liver cirrhosis
89224538|NCT06265246|No Intervention|Habitual Diet (Control)|33 participants in this arm will continue to take their usual diet without any intervention.
89224539|NCT06265246|Experimental|Habitual Diet + 1.5 Servings of Milk|
89224540|NCT06265246|Experimental|Habitual Diet + 2 Servings of Yogurt|
89224541|NCT06265220|Experimental|Phase 1: Dose confirmation of AB-101 as Monotherapy|
89224542|NCT06265220|Experimental|Phase 1: Dose confirmation of AB-101 plus Rituximab combination|
89077762|NCT02817061|Experimental|NIR brain stimulation|"An Omnilux device will be used to put NIR light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
89077763|NCT02817061|Sham Comparator|Sham|"An Omnilux Device will be used at a safe wavelength not associated with photobiomodulation, putting sham light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
89077764|NCT02818855|Experimental|Collagen Matrix plus coronally advanced flap (CAF)|A new collagen matrix (Mucograft) associated to coronally advanced flap
89077765|NCT02818855|Active Comparator|Subepithelial connective tissue graft plus CAF|Subepithelial connective tissue graft associated to coronally advanced flap
89077766|NCT04278976|Experimental|CoBaTriCE|Implementation of CoBaTrICE. The implementation of CoBaTrICE is based on: 1. Training the trainers; 2. Multiple Workplace-based assessment exercices; 3. The use of an electronic portfolio.
89077767|NCT04278976|No Intervention|Control|The participants of the control group will follow the current official model of training in ICM in Spain, which is based on exposure to experiences through time-based clinical rotations; a generic report, non-based on formal assessment, about knowledge, technical and nontechnical skills is performed after every clinical rotation, and yearly by the tutor.
89077768|NCT02818621|Active Comparator|Group Dex|"The Dex group received 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure.~Interventions:~◦Drug: Dexmedetomidine"
89077769|NCT02818621|Placebo Comparator|Group Placebo|"The Placebo group received equal amount of normal saline.~Interventions:~◦Drug: Normal saline"
89077770|NCT04642651|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
89077771|NCT04642651|Placebo Comparator|Control group|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml. Postoperatively, patient-controlled intravenous analgesia is provided for at least 48 hours. The formula is sufentanil (1.25 μg/ml), diluted with normal saline to 100 ml. 5-HT3 receptor antagonist is added when necessary. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h.
89077772|NCT01061151|Active Comparator|Antepartum Arm A|Mothers received ZDV + sdNVP + TRV Tail
89077773|NCT01061151|Experimental|Antepartum Arm B|Mothers received Triple ARV (3TC-ZDV + LPV-RTV)
89077774|NCT01061151|Experimental|Antepartum Arm C|Mothers received Triple ARV (TRV + LPV-RTV)
89077775|NCT01061151|Other|Late Presenters|Registration to facilitate a structure to screen women and infants for randomization in the Postpartum Component.
89077776|NCT01061151|Experimental|Postpartum Arm A (Maternal Prophylaxis)|Mothers received prophylaxis [preferred regimen: TRV + LPV-RTV]. Infants received short-course NVP.
89077777|NCT01061151|Experimental|Postpartum Arm B (Infant Prophylaxis)|Infants received extended NVP.
89077778|NCT01061151|Experimental|Maternal Health Arm A (Continue triple ARVs)|Mothers continued receiving triple ARV regimen [preferred regimen: TRV + LPV-RTV].
89077779|NCT01061151|Active Comparator|Maternal Health Arm B (Discontinue triple ARVs)|Mothers discontinued triple ARV regimen.
89077780|NCT02818543|Experimental|Cohort 1|LYC-30937 25 mg single oral dose
89077781|NCT02818543|Experimental|Cohort 2|LYC-30937 100 mg single oral dose
89077782|NCT05658679||patients with pancreatic cancer|Patients with pancreatic tumors diagnosed clinically or pathologically
89077783|NCT05658679||Participants without pancreatic cancer|Participants who judged the pancreas to be completely healthy through medical examination
89077784|NCT04472143|Experimental|Granisetron Transdermal Delivery System|The patch will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days
89077785|NCT04303923||Male group|Male patients who performed transthoracic echocardiography with arterial ultrasonography
89077786|NCT04303923||Female group|Female patients who performed transthoracic echocardiography with arterial ultrasonography
89077787|NCT00634075|Experimental|1|
89077788|NCT00634075|Placebo Comparator|2|
89077789|NCT01241552|Experimental|MK-3415 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI
89077790|NCT01241552|Experimental|MK-6072 + SOC|Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI
89077791|NCT01241552|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI
89077792|NCT01241552|Placebo Comparator|Placebo + SOC|Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI
89077793|NCT04748523|Active Comparator|Intervention group|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
89077794|NCT04748523|Placebo Comparator|Placebo group|arm to receive 15 to 30 mg of placebo for a period of 8 weeks.
89077795|NCT02817217|Other|SP2086 and Valsartan|
89077796|NCT00948922|Other|A: Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.
89077797|NCT00948922|Other|B: Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.
89077798|NCT00948922|Other|BE: Group B Expansion|Group B Expansion on Bortezomib Maintenance: Autologous Only.
89077799|NCT02817139|Active Comparator|active tDCS over primary motor cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left primary motor cortex.
89077800|NCT02817139|Experimental|active tDCS over prefrontal cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left prefrontal cortex.
89077801|NCT02817139|Placebo Comparator|sham tDCS over primary motor cortex|Duration: 20 minutes; The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham; Placement: left primary motor cortex.
89077802|NCT04238065|Experimental|VR treatment|"The arm will use the virtual reality headset reproduces dynamic video content with perceptual learning and binocular perception (including stereopsis) that is visually perceived a little bit faster, brighter, and higher contrast to the amblyopia eyes .~The each VR therapy length is 30 minutes with 5 minute break after 15 minutes' therapy sequence, 3 times per week, total 13 weeks.~All amblyopia eyes are best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity."
89077803|NCT04238065|Placebo Comparator|control|"This arm of amblyopia eyes are all best optical correction or combining patching non-amblyopia eyes if there're more than 2 lines difference best corrected vision acuity.~No VR therapy."
89077804|NCT04237909|Experimental|Ovarian Reserve|Patients with diminished ovarian reserve or premature ovarian insufficiency
89077805|NCT04237831|Experimental|Arm A: Normal Renal Function|
89077806|NCT04237831|Experimental|Arm B: Mild Renal Impairment|
89077807|NCT04237831|Experimental|Arm C: Moderate Renal Impairment|
89077808|NCT04237831|Experimental|Arm D: Severe Renal Impairment|
89077809|NCT00634309|Active Comparator|1|
89077810|NCT00634309|Placebo Comparator|2|
89077811|NCT01239992|Experimental|Niacin/ Laropiprant|
89077812|NCT02816905|Active Comparator|Group A|20 eyes that received topical 0.1% Dexamethasone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
89077813|NCT02816905|Active Comparator|Group B|20 eyes that received topical 0.1 % Fluorometholone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
89077814|NCT02816905|Active Comparator|Group C|40 eyes that received topical 1% Rimexolone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
89077815|NCT02816827|Experimental|E-AG-01|550 mg of 2 capsules having AG-01 and AG-07 will be administered orally twice daily for one day.
89077816|NCT02816827|Experimental|E-AG-02|550 mg of 2 capsules having AG-05 and AG-06 will be administered orally twice daily for one day.
89077817|NCT02816827|Experimental|E-AG-03|550 mg of 2 capsules having AG-01 and AG-05 will be administered orally twice daily for one day.
89077818|NCT02816827|Experimental|E-AG-04|550 mg of 2 capsules having AG-06 and AG-07 will be administered orally twice daily for one day.
89077819|NCT01239680|Placebo Comparator|Ringer's Lactate and Placebo for Glutamine|Ringer's Lactate 1 liter once over 6 hours
89077820|NCT01239680|Experimental|Ringer's Lactate with 25 grams Glutamine|Ringer's Lactate with 25 grams Glutamine (1 liter) once over 6 hours
89077821|NCT02816749|Experimental|Maggot debridement therapy(MDT)|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
89077822|NCT02816749|Active Comparator|Conventional Dressing Therapy(CDT)|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
89077823|NCT05515094|Experimental|Intervention Arm (Empowerment Counseling Intervention)|The Empowerment Counseling Intervention (ECI) entails directly linking women to on-site case managers who will provide first-line support (i.e., a brief psychosocial support session) and a safety and health assessment to women who are attending to receive ANC and disclose violence. The intervention (e.g., the initial counselling session), adapted from current case management guidelines and the Safe and Sound intervention at health facilities, will be administered directly at the health facility after a woman screens positive for IPV. In line with a survivor centered approach, as part of the initial session, the survivor participant will be invited back for further counselling sessions as part of the intervention curriculum, in addition to being supported to access other services based on her preferences, such as group psychosocial support. The intervention manual acts as a guide and support for trained social workers to support the unique needs of each survivor.
89077824|NCT05515094|No Intervention|Standard of Care|Women in the comparison arm will receive the standard of care and be referred to support services at the nearby IRC Women's Protection and Empowerment (WPE) office.
89077825|NCT05654077|Experimental|CAR-T Cell Injection|"A total of 24 patients with recurrent or refractory NPC received a single intravenous infusion of CAR-T cells at doses of 3.0 × 10^6cells/kg, 9.0 × 10^6cells/kg, and 1.5 × 10^7cells/kg, respectively, and were enrolled according to the conventional 3+3 dose escalation."
89077826|NCT04303767|Experimental|Test (ART + CPP-ACP)|In this group, teeth selected will receive intervention with CPP-ACP and restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
89077827|NCT04303767|Active Comparator|Control (ART)|in this group, teeth selected will receive restorations with light cured Glass Ionomer restorations after excavating the carious lesions preserving the caries affected dentine using the ART
89077828|NCT01238900||benign biliary strictures|All patients who have a medical indication for an ERCP to place a stent in their benign biliary strictures
89077829|NCT04303299|Experimental|Oseltamivir plus Chloroquine in Mild COVID19|Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 800 mg per day In mild COVID19
89077830|NCT04303299|Experimental|Darunavir and Ritonavir plus oseltamivir|Darunavir 400 mg every 8 hours Ritonavir 200 mg (or 2.5 mg/kg ) per day plus plus Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 400mg per day in Mild COVID19
89077831|NCT04303299|Experimental|Lopinavir and Ritonavir plus Oseltamivir in mild COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In mild COVID19
89077832|NCT04303299|Experimental|Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19|Lopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In moderate to critically ill COVID19
89077833|NCT04303299|Experimental|Favipiravir lopinavir /Ritonavir for mod. To severe|Lopinavir 800 mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day in Mild COVID19 In moderate to critically ill COVID19
89077834|NCT04303299|Experimental|Darunavir /ritonavir oseltamivir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg (or 4-6 mg /kg ) per day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
89077835|NCT04303299|Experimental|Darunavir /ritonavir favipiravir chloroquine mod-severe|Darunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19
89077836|NCT04303299|No Intervention|Conventional Qurantine|Patient who unwilling to treatment and willing to quarantine in mild COVID19
89077837|NCT04190329||10 non-frail (robust) study patients|Patients fulfill 0 criteria according to modified Fried frailty score.
89077838|NCT04190329||10 pre-frail study patients|Patients fulfill 1-2 criteria criteria according to modified Fried frailty score.
88812499|NCT04080427|Experimental|Dronabinol 7.5 milligram oral capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will administer a single oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to each weekly exposure session (up to 9 sessions) in a standard prolonged exposure treatment protocol comprising 12 session overall.~Half of the participants will receive 7.5mg dronabinol (n=50) and the other half of the participants will receive placebo (n=50)."
89077839|NCT04190329||10 frail study patients|Patients fulfill 3, 4 or 5 criteria according to modified Fried frailty score.
89077840|NCT02874963|Active Comparator|Surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Non-Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Intervention:~Procedure: Surgery (Tooth Extraction)"
89077841|NCT02874963|Active Comparator|Surgical and non-surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Non-Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Interventions:~Procedure: Surgery (Tooth Extraction)~Procedure: Non-surgical periodontal therapy-full mouth scaling and root planing (FM-SRP) with ultrasonic device and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus, post operative rinsing thrice a day for 3 weeks."
89077842|NCT02818465|Experimental|Patients|
89077843|NCT02818309|Experimental|Lesogaberan|Lesogaberan
89077844|NCT02818309|Placebo Comparator|Placebo|Placebo
89077845|NCT01238822|Placebo Comparator|Placebo|
89077846|NCT01238822|Active Comparator|Low Dose Methylphenidate|Low dose: 18 mg methylphenidate
89077847|NCT01238822|Active Comparator|Medium Dose Methylphenidate|Medium Dosage: 36 mg if more than 50 kg and 27 mg if less than 50 kg
89077848|NCT01238822|Active Comparator|High Dose Methylphenidate|54 mg if more than 50 kg and 36 mg if less than 50 kg
89077849|NCT04303455||Study group|"The study will evaluate a cohort of participants meeting the following inclusion criteria:~Admission to ICU after elective and emergency cardiac surgery following cardiopulmonary bypass~Age 18 years and above~Arterial, central venous and pulmonary arterial catheters have been inserted as part of routine care~Data collection, serum renin among routine blood collection on admission, 6 and 24 hours after admission to ICU"
89077850|NCT02818387|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
89077851|NCT02818387|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
89077852|NCT02818387|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by midazolam 0.015 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.~Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary."
89077853|NCT05296629|Experimental|DFD-29|DFD-29 (40 mg) extended release capsules
89077854|NCT05296629|Active Comparator|Doxycycline 40 mg|Doxycycline 40 mg modified release capsules
89077855|NCT05296629|Placebo Comparator|Placebo|Placebo capsules matching DFD-29
89077856|NCT01238588|Other|Sevelamer Carbonate (Renvela)|Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
89077857|NCT04303143||Primary|Primary
89077858|NCT02818231||NON EXPOSED|"Male, >50 years, unexposed to wood dust, without any nasal pathology, without known tumor~-> Brushing of the olfactory cleft"
89077859|NCT02818231||EXPOSED|"Male, >50 years, exposed to wood dust, without any nasal pathology, without known tumor~-> Brushing of the olfactory cleft"
89077860|NCT00627003|Experimental|1|
89077861|NCT00627003|Experimental|2|
89077862|NCT04238611|Experimental|Lactate microneedle|Measurement of lactate through microneedle
89077863|NCT02818153|Experimental|questionnaire for allergic rhinitis control|Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
89077864|NCT04238533|Active Comparator|eADAPT|This arm includes transradial amputees who will be assessed while using the eADAPT trainer.
89077865|NCT04238533|Active Comparator|Conventional program|This arm includes transradial amputees who will be assessed while using the conventional training program.
89077866|NCT05657509|Experimental|Male field hockey players of Functional training|Functional training exercises focus on improving physical fitness and movement skills performance. Functional training targets the neuromuscular system through engagements of muscle groups as well as nerve function to optimize movements. The present study applied functional training to elite male field hockey players to assess fitness level as well as skill performance. Post-test 1 will be after 6 weeks, and post-test 2 after 12 weeks to measure performance.
89077867|NCT05657509|Active Comparator|Male field hockey players of traditional regular type of training exercises|The traditional training method involves exercises to increase the strength and durability of a certain muscle. Male field hockey players will be continuing their regular traditional type training exercises for 12 weeks.
89077868|NCT04238221|Experimental|Doxofylline+inhalation therapy|4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy, followed by 4-week treatment of maximal inhalation therapy only
89077869|NCT04238221|Experimental|Inhalation therapy|4-week treatment with maximal inhalation therapy only, followed by 4-week treatment with doxofylline tablets 400 mg bid in addition to maximal inhalation therapy
89077870|NCT02815423|Experimental|UCMSCs|Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.
89077871|NCT02815423|Placebo Comparator|Placebo|The patients with fracture and bone nonunion who underwent percutaneous injection of placebo.
89077872|NCT01047501|Placebo Comparator|Placebo|
89077873|NCT01047501|Experimental|AMR101 (ethyl icosapentate) - 2 g/day|
89077874|NCT01047501|Experimental|AMR101 (ethyl icosapentate) - 4 g/day|
89077875|NCT01238120|Active Comparator|Placebo and Home-Based Exercise|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
89077876|NCT01238120|Active Comparator|Ibuprofen 200mg BID, Home-Based Exercise|200mg ibuprofen (taken twice a day at least 8 hours apart) and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
89077877|NCT01238120|Placebo Comparator|Placebo|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks.
89077878|NCT01238120|Active Comparator|Ibuprofen 200 mg BID|200mg ibuprofen (taken twice a day at least 8 hours apart) for a period of 6 weeks.
89077879|NCT05655481|Experimental|Telerehabilitation|"AEROBIC TRAINING~2 training sessions per week for a period of 8 weeks~Connection platform: WhatsApp~The research participant will use a 20 cm step on which he will have to go up and down until he reaches the predicted training heart rate.~Intensity: 60-80% of the maximum heart rate reached at the peak of the incremental step test~5 minutes warm-up: 60% of maximum heart rate~20 minutes of Training: 60 to 80% of the maximum heart rate reached at the peak of the incremental step test~5 minute cool down: 60% of maximum heart rate~Duration 30 minutes~RESISTANCE TRAINING~Devices: Anklet (variable load), these devices will be made available to the research participant~Exercises for upper limbs, shoulder flexion, elbow flexion and shoulder abduction, and for lower limbs hip flexion and extension.~Intensity: 70% of the maximum starting load of a 1RM repetition~3 sets of 8 repetitions~Duration: 30 minutes"
89077880|NCT05655481|Experimental|Telehealth|"Guidelines leaflet with health education proposals Explanations about your disease, what it is, psychopathological diagnoses and pharmacological and non-pharmacological treatment), information about the importance of physical activity in your daily life, such as walking, stretching or some daily physical activity according to your preference .~This group will not receive aerobic or resistance training.~You will receive telemonitoring twice a week over a period of 8 weeks as a form of teleconsultation in health with the physiotherapist for monitoring throughout the research.~After this period it will be reassessed."
89077881|NCT01237340|Experimental|Saizen®|
89077882|NCT02818075|Experimental|Mobile Phone Based Peer Support|Mobile phone-based peer support (MPPS)
89077883|NCT02818075|Active Comparator|Usual Care|Standard community prenatal and postpartum support services
89077884|NCT04303533|Experimental|EFP-NF|
89077885|NCT02816515||Ectoin® mouth wash|The treatment will be started on the first day of radio- and/or chemotherapy, before development of mucositis
88812500|NCT04057794|Active Comparator|Site-Based Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.
88812501|NCT04057794|Active Comparator|Centralized Genetic Counseling|Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.
88812502|NCT04040348|Experimental|hMSC Treatment group|Participants in the hMSC treatment group will receive a total of 4 doses of the hMSC intervention. Each dose will be administered once about every 13 weeks within a year period.
89077886|NCT02816515||Ectoin mouth wash|The treatment will be started after oral mucositis development in patients receiving radio- and/or chemotherapy
89077887|NCT02816515||Supersaturated electrolyte mouth rinse|The treatment will be started after oral mucositis development in patients receiving radio and/or chemotherapy
89077888|NCT02816593|Experimental|Group 1 - HP 6%|Group 1: Experimental: Office; hydrogen peroxide 6%,
89077889|NCT02816593|Experimental|Group 2 - HP 15%|Group 2: Experimental: Office; hydrogen peroxide 15%,
89077890|NCT02816593|Active Comparator|Group 3 - CP 10%|Group 3: Control: Homemade; Carbamide Peroxide 10%,
89077891|NCT04237987|Experimental|Interleukin-2 and ciclosporin and corticosteroid|One million units of Recombinant Human Interleukin-2 (IL-2) will be administered subcutaneously every other day for 3 months. Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 3 months after withdraw of IL-2.
89077892|NCT04237987|Active Comparator|ciclosporin and corticosteroid|Ciclosporin and corticosteroid will be administered according to the doctor's decision. All patients were followed up for 6 months.
89077893|NCT01045707|Experimental|IDegAsp OD|
89077894|NCT01045707|Experimental|IGlar OD|
89077895|NCT02816125|Active Comparator|Habitual supplemented|habitual diet with 1.2 g EPA+DHA in capsule form/day.
88812503|NCT03933631|Experimental|Pilocarpine, Prednisolone acetate and Ofloxacin|This group will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
88812504|NCT03933631|Active Comparator|Prednisolone acetate and Ofloxacin (standard of care)|This group will use only Prednisolone acetate and Ofloxacin, without pilocarpine.
89077896|NCT02816125|Experimental|Low-fat supplemented|Reduce dietary fat to less than 20% energy, add 1.2 g EPA+DHA in capsule form/day.
89077897|NCT02816437|Experimental|OpenBiome FMT retention enema|OpenBiome Fecal Microbiota Transplantation retention enema, one rectal application.
89077898|NCT04303221|Experimental|GAJL - Young adult with lymphedema|Women age 35 to 59 years (young adult) with lymphedema - exercise group
89077899|NCT04303221|Experimental|GAJ - Young adult without lymphedema|Women age 35 to 59 years (young adult) without lymphedema - exercise group
89077900|NCT04303221|Experimental|GIL - Elderly with lymphedema|Women aged 60 to 80 years (elderly) with lymphedema - exercise group
89077901|NCT04303221|Experimental|GI - Elderly without lymphedema|Women aged 60 to 80 years (elderly) without lymphedema - exercise group
89077902|NCT04238377|Active Comparator|Stellate Group|will receive pre-operative ultrasound guided stellate ganglion block one hour before surgery and multimodal analgesia and will be followed for 6 months for neuropathic pain as the Stellate Group
89077903|NCT04238377|Placebo Comparator|Control Group|will receive multimodal analgesia only and will be followed for 6 months for neuropathic pain as the control Group
89077904|NCT04302831|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
89077905|NCT04302831|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
89077906|NCT02817685||1|Chronic Hepatitis B patient
89077907|NCT02817685||2|Chronic Hepatitis B patient
89077908|NCT02817685||3|cirrhotic patient
89077909|NCT02817685||4|cirrhotic patient
89077910|NCT02817685||5|ultrasound-difficult patient
89077911|NCT02817685||6|ultrasound-difficult patient
89077912|NCT02874807|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg once daily for four days
89077913|NCT02874807|Placebo Comparator|Placebo|Treatment with Placebo once daily for four days
89077914|NCT02817529|Experimental|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
89077915|NCT02817529|Active Comparator|RC-Cornet|The RC-Cornet is a device that provides oscillatory positive expiratory pressure (OPEP) therapy for the detachment and removal of pulmonary secretions. Through variable pressure settings and optional aerosolized medication delivery, patients realize maximum efficacy specific to their unique clinical needs.The RC-Cornet uses the patient's full expired air volume to produce pressure and oscillatory vibrations. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
89077916|NCT02875431||ACDF or cervical vertebral body replacement|
89077917|NCT02817607|Experimental|Surgery|
89077918|NCT00627159|Other|1|high risk
89077919|NCT00627159|Other|2|low to moderate risk
89077920|NCT02814097|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
89077921|NCT02814097|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
89077922|NCT02814331||symptomatic partial epilepsy|whose brain MRI is abnormal multimodal high-resolution EEG-NIRS
89077923|NCT02814331||not symptomatic partial epilepsy|whose brain MRI is normal multimodal high-resolution EEG-NIRS
89077924|NCT02875275|No Intervention|Glucose Solution only|Control drink containing 50 g carbohydrate
89230074|NCT01092325|Active Comparator|Echo Cohort B CXL-1020|CXL-1020 administered at a fixed rate for the initial 2 hours and at a higher fixed rate for the last 2 hours of a 4 hour infusion at doses which were studied in Cohort 1 or Cohort 2 and expected to be well tolerated and have hemodynamic effects
88812505|NCT03919435|Experimental|On Drug|
89077925|NCT02875275|Active Comparator|Glucose with grass jelly solution|Control drink plus 3.12 g grass jelly powder
89077926|NCT02875275|Active Comparator|Glucose with grass jelly (solid)|Control drink plus 3.12 g grass jelly powder in solid form
89077927|NCT02875275|No Intervention|Porridge and juice only|Control breakfast containing 50 g carbohydrate.
89077928|NCT02875275|Active Comparator|Porridge and juice with coconut oil|Control breakfast, plus 25g coconut oil
89077929|NCT02875275|Active Comparator|Porridge and juice with coconut oil gel|Control breakfast, plus 25g coconut oil gel
89077930|NCT01054599|Experimental|Memantine|Subjects will randomly assigned to take either a placebo or memantine for 13 weeks. The assignment will be double-blind, neither the study members nor the subject will know if he/she is taking memantine or a placebo.
89230075|NCT03957265|Experimental|Syncone|Tapered abutment connection
89077931|NCT01054599|Placebo Comparator|Sugar Pill|Subjects will be randomly assigned to take either memantine or a placebo. The study is double-blind, and neither the study members nor the subject will know if he/she is taking memantine or a placebo.
89077932|NCT02813863|Experimental|SP2086 and Metformin|In the first day,the subject takes metformin 1000mg once,and from Day 4 to Day 7 they need to take SP2086 100mg everyday. In Day 8,they will be given SP2086 100mg and metformin 1000mg.
89077933|NCT02874729||Healthy donors|No interventions
89077934|NCT02874729||Cancer patients|No interventions
89077935|NCT04275661|Placebo Comparator|Group (C) (control group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7.
89077936|NCT04275661|Experimental|Group (K) (Ketamine group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg ketamine at each level with total dose 2mg/kg
89077937|NCT04275661|Experimental|Group (M) (magnesium sulphate group)|Patient will receive 10 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5 and 10 ml at level of T7+ 1 mg / kg MgSo4 at each level with total dose 2mg/kg
89077938|NCT02813941|Experimental|Alternative GRADE SoF table|Two SoF tables (alternative GRADE SoF table and EPC SoF table) will be used in this randomized controlled non-inferiority trial as an intervention. The alternative GRADE SoF table format will be developed from a user-testing survey.
89077939|NCT02813941|Experimental|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published.
89077940|NCT02813941|Active Comparator|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
89077941|NCT02875041|Experimental|Transcranial Magnetic Stimulation (TMS) MAGSTIM Rapid2 Therapy|TMS is a non-invasive device that employs the use of a magnet on the scalp to measure and potentially modulate cortical excitability. The use of TMS for Parkinson's treatment is experimental.
89077942|NCT02875041|Active Comparator|MAGSTIM Rapid2 Therapy System|MAGSTIM Rapid2 Therapy System has been FDA cleared for the treatment of refractory depression.
89077943|NCT04187521|Other|Sensitivity defect|Participants defined as having abnormal insulin sensitivity without an absolute defect in insulin secretion.
89077944|NCT04187521|Other|Secretory defect|Participants defined as having abnormal insulin secretion without a defect in insulin sensitivity.
89077945|NCT04187521|Other|Unclassified|Participants who cannot be classified as having abnormal insulin secretion or abnormal insulin sensitivity or who have both abnormal insulin sensitivity and abnormal insulin secretion.
89077946|NCT00948766|Experimental|Rivastigmine 13.3 mg/24 h transdermal patch|In the core study, patients were titrated to the rivastigmine 13.3 mg/24 h dose in 2 steps. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-8, patients received rivastigmine 9.5 mg/24 h and placebo. For Weeks 9-24, patients received rivastigmine 13.3 mg/24 h and placebo. In the extension study, all patients were switched to rivastigmine 9.5 mg/24 h for a 4-week titration period and were then titrated up to 13.3 mg/24 h for a further 20 weeks of treatment.
89077947|NCT00948766|Active Comparator|Rivastigmine 4.6 mg/24 h transdermal patch|In the core study, patients received rivastigmine 4.6 mg/24 h daily. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-24, patients received rivastigmine 4.6 mg/24 h and placebo. No patients received this treatment in the extension study.
89077948|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
89077949|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
89077950|NCT02813629|Active Comparator|SS-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
89077951|NCT02813629|Sham Comparator|SS-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
89077952|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
89077953|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
89077954|NCT02813629|Active Comparator|SC-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
89077955|NCT02813629|Sham Comparator|SC-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
89077956|NCT04206722|Experimental|Treatment group|Shock Wave therapy on the affected hip, for 10 days, 1 application every 2 days
89077957|NCT04206722|Active Comparator|Control group|Ultrasound therapy on the affected hip, for 10 days, 1 application daily
89077958|NCT01053663|Experimental|1|
89077959|NCT00634387|Active Comparator|A|Anthocyans
89077960|NCT00634387|Placebo Comparator|B|no effective agent
89077961|NCT01235546|Placebo Comparator|Placebo and standard of care|250 cc normal saline
89077962|NCT01235546|Experimental|Azithromycin and Standard of care|500 mg Azithromycin in 250 cc normal saline
89077963|NCT02813395|No Intervention|Control group|Volunteers remained at rest before and after the fatigue protocol.
89077964|NCT02813395|Placebo Comparator|Placebo group|Volunteers were subjected to laser application simulation for approximately four minutes with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
89077965|NCT02813395|Experimental|Laser before|Volunteers received effective application of laser before fatigue protocol.
89077966|NCT02813395|Experimental|Laser after|Volunteers received effective application of laser after fatigue protocol.
89077967|NCT01053429||observational cohort|
88812506|NCT03911414|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
89077968|NCT01233284|Experimental|tiotropium low dose once daily|once daily, delivered by the Respimat® inhaler
89077969|NCT01233284|Experimental|tiotropium medium dose once daily|once daily, delivered by the Respimat® inhaler
89224543|NCT06265207|Experimental|Experimental group|Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.
89224544|NCT06265207|Active Comparator|Control group|No additional application to routine procedures will be applied to the control group.
89077970|NCT01233284|Experimental|tiotropium high dose once daily|once daily, delivered by the Respimat® inhaler
89077971|NCT01233284|Placebo Comparator|Placebo once daily|once daily, delivered by the Respimat® inhaler
89077972|NCT00627237|Experimental|Immediate start|Starts the 12 week intervention immediately after enrollment
89077973|NCT00627237|Experimental|Waitlist group|Starts the 12 week intervention 12 weeks after initial enrollment
89077974|NCT00948688|Experimental|Vorinostat, 5-FU, Radiation Therapy|Vorinostat at varying doses; orally, days 1-7, weeks 1-6 5-FU 225 mg/m2/day; intravenous; days 1-5, weeks 1-6 until completion of radiation therapy; Radiation therapy; 180cGy daily Monday-Friday; 28 days of treatment (6 weeks)
89077975|NCT02857114|Other|massage|
89077976|NCT01233050|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
89077977|NCT01233050|Active Comparator|Iodine Povacrylex/74% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
89077978|NCT01232894|Experimental|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
89077979|NCT01232894|Active Comparator|Long-acting beta2-agonist|Participants' current long-acting beta2-agonist (LABA) bronchodilator therapy
89077980|NCT01049217|Experimental|Active drug|
89077981|NCT01049217|Placebo Comparator|Control|
89077982|NCT01232738|Experimental|rasagiline|Treated for 12 months with rasagiline 2mg orally, once daily.
89077983|NCT04206644||Systemic sclerosis patients|SSc patients according to the ACR/EULAR 2013 classification criteria
89077984|NCT04206644||Healthy donors|HD healthy donors from EFS (Etablissement Français du sang)
89077985|NCT04206644||LUPUS Patiets|Lupus patients according to the ACR 2019 classification criteria
89077986|NCT00957268|Experimental|Alogliptin 12.5 mg (age 10 to < 14 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
89077987|NCT00957268|Experimental|Alogliptin 25 mg (age 10 to < 14 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
89077988|NCT00957268|Experimental|Alogliptin 12.5 mg (age 14 to < 18 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
89077989|NCT00957268|Experimental|Alogliptin 25 mg (age 14 to < 18 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
89077990|NCT00957268|Experimental|Alogliptin 25 mg (age 18 to 65 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
89077991|NCT02888444|Active Comparator|Varenicline plus behavioural support|12 weeks extended treatment with varenicline, plus relapse prevention-orientated behavioural support
89077992|NCT02888444|Placebo Comparator|Placebo plus behavioural support|12 weeks extended treatment with placebo, plus relapse prevention-orientated behavioural support
89077993|NCT02888132|Experimental|Hypertrophic Obstructive Cardiomyopathy|
89077994|NCT01230788|Experimental|rituximab|study drug given
89077995|NCT04269694|No Intervention|Control|No dressing applied in the donor site after harvesting the graft
89077996|NCT04269694|Experimental|Test|An antibacterial honey dressing material (Medihoney, http://www.medihoney.com) will be applied to donor site.
89077997|NCT01230710|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once a day for 48 weeks.
89077998|NCT04269616|Experimental|Numerical survival, followed by disability information|Participants in this arm were presented with a pictograph displaying numerical survival information, followed by a pictograph displaying disability information.
89077999|NCT04269616|Experimental|Survival with description, followed by disability information|Participants in this arm were presented with a pictograph displaying survival information including the average course of stay in the NICU, followed by a pictograph displaying disability information.
89078000|NCT04269616|Experimental|Disability information, followed by numerical survival|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying numerical survival.
89078001|NCT04269616|Experimental|Disability information, followed by survival with description|Participants in this arm were presented with a pictograph displaying disability information, followed by a pictograph displaying survival information including the average course of stay in the NICU.
89078002|NCT00627081|Placebo Comparator|1|general anesthesia and thoracic epidural administration of saline
89078003|NCT00627081|Active Comparator|2|general anesthesia and thoracic epidural administration of chirocaine
89078004|NCT02816281||Reasons of case cancellation|"will be recorded and categorized into 6 groups including~patient issue such as surgery refusal, no show on the day of surgery, transport problems~facility such as equipment needs, improper estimate case time, case bumps~Surgeon unavailable, due to administrative schedules and other problems or changed line of management respectively~anesthesiologist fail to adequately prepare the patient, lead to some misunderstanding communication such as NPO violation, preoperative drug error~medical condition that may impact the patient's ability to endure anesthesia techniques or surgical procedure~miscellaneous."
88812507|NCT03911414|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700mg QD) based on age .
89078005|NCT01230554|Experimental|Prism I|Bausch & Lomb daily disposable cosmetic tint contact lens
89078006|NCT04302909|Active Comparator|Active Comparator|fESWT
89078007|NCT04302909|Sham Comparator|Sham Comparator|Sham fESWT
89078008|NCT02888054|Experimental|Sequence ABBA|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
89078009|NCT02888054|Experimental|Sequence BABA|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
89078010|NCT02888054|Experimental|Sequence ABAB|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
89078011|NCT02888054|Experimental|Sequence BAAB|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
89078012|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
89078013|NCT05477810|Experimental|Treatment A (CHILD-IVITAB) before Treatment B (STROMECTOL)|"A single oral dose of 12 mg CHILD-IVITAB administered as four ODTs of 3 mg (given in the fasted state in the morning).~A single oral dose of 12 mg STROMECTOL administered as four tablets of 3 mg (given in the fasted state in the morning).~The wash-out period between doses will be at least 7 days."
89078014|NCT05477810|Active Comparator|Treatment B (STROMECTOL) before Treatment A (CHILD-IVITAB)|"A single oral dose of 12 mg STROMECTOL administered as four tablets of 3 mg (given in the fasted state in the morning).~A single oral dose of 12 mg CHILD-IVITAB administered as four ODTs of 3 mg (given in the fasted state in the morning).~The wash-out period between doses will be at least 7 days."
89078015|NCT02815969||Healthy volunteers|If no material of healthy volunteers of the SERT study can be used, then other matched volunteers are asked for a vena punction and urine collection
89078016|NCT02815969||Patients|Patients are asked for a vena punction and urine collection, if not already done because of medical care.
89078017|NCT02811367|Experimental|HPV self-test|Women will perform the HPV self-test.
89078018|NCT01040793|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
89078019|NCT01040793|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
89078020|NCT01040793|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally from the Respimat inhaler
89078021|NCT04204447|Experimental|Brochure intervention|Subjects will be asked to read an educational brochure about Hepatitis C
89078022|NCT04204447|Experimental|Video intervention|Subjects will be asked to watch an educational video about Hepatitis C
89078023|NCT04155151|Experimental|Single Arm|6 Minute Walking Test
89078024|NCT02811055|Experimental|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
89078025|NCT02811055|Placebo Comparator|Administration of placebo|Administration of Placebo once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
89078026|NCT04192903|Experimental|Chidamide combined with Cisplatin|"Chidamide: 30mg,PO,biw one week before cycle 1 treatment~Combined treatment period:~Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off Patients whose efficacy was evaluated as Complete Response (CR) / Partial Response (PR) / Stable Disease (SD) after the end of the combined treatment period received maintenance treatment with chidamide combined with cisplatin reduction.~Maintenance treatment period:~Cisplatin 25mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off"
89078027|NCT02810899|Experimental|Dexmedetomidine group|A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.
89078028|NCT02810899|Placebo Comparator|Control group|Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.
89078029|NCT02810665||Normal vision group|Individuals with VA 20/20 to 20/25
89078030|NCT02810665||Impaired vision group|Individuals with impaired vision: VA of 20/32 to 20/200 due to either cataract, diabetic macular edema, or age-related macular degeneration
89078031|NCT04237129|Experimental|Gan & Lee Insulin Aspart|100 units/mL, 3 ml prefilled pen
89078032|NCT04237129|Active Comparator|NovoRapid® Insulin Aspart|"Product approved and marketed in the EU~FlexPen100 units/mL prefilled pen"
89078033|NCT04237129|Active Comparator|NovoLog® Insulin Aspart|"Product approved and marketed in the US~FlexPen100 units/mL prefilled pen"
89078034|NCT02810587||Topical antibiotics group|Those who receive topical antibiotics after intravitreous injection as home medication for 7 days.
89078035|NCT02810587||No topical antibiotics group|Those who does NOT receive topical antibiotics after intravitreous injection as home medication.
89078036|NCT02810353|Experimental|Expander with differential opening group|The experimental group will comprise 25 patients who will be submitted to rapid maxillary expansion using the expander with differential opening. The expander will be composed by two 11-mm screws, one anteriorly and the other posteriorly positioned on the palate (Great lakes Orthodontics Ltd, NY, EUA).
89078037|NCT02810353|Active Comparator|Hyrax group|The control group will be comprised by 25 patients who will undergo rapid maxillary expansion using the conventional Hyrax expander. The expander will be composed by one 11-mm screw centrally positioned on the palate (Dentaurum, Ispringen, Germany).
89078038|NCT04187365|No Intervention|GROUP 1 (NonSevere PUR and women without PUR)|Women in GROUP 1 will be prospectively observed to characterize their clinical outcomes.
89078039|NCT04187365|Experimental|GROUP 2 (Severe PUR)|Women in GROUP 2 will be a randomized to either 3 or 7 days of indwelling catheterization.
89078040|NCT02810275|Experimental|Folinic Acid|Folinic acid group received 5 mg daily during four weeks
89078041|NCT02810275|Placebo Comparator|Placebo|Placebo group received a tablet daily during four weeks
89078042|NCT05646745|Experimental|Autologous Fascia lata TOT|"Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, ~1 cm× ~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
89078043|NCT02809807|Experimental|Baseline|Without a gas mask. We measure baseline respiratory index, parameters and the comfort.
89078044|NCT02809807|Experimental|Assessment with gas mask and canister A|With a gas mask, the measurement have been done with a high resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
89078045|NCT02809807|Experimental|Assessment with gas mask and canister B|With a gas mask, the measurement have been done with a low resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
89078046|NCT00948064|Experimental|Vorinostat with Azacitidine|ARM A: Azacitidine 75 mg/m^2/day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Vorinostat 200 mg by mouth three time a day with food for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
89078047|NCT00948064|Experimental|Azacitidine|ARM B: Azacitidine 75 mg/m^2 /day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
89078048|NCT02813239||HCG triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG when at least 2 follicles had a mean diameter of 17 mm.
89224545|NCT06265194|Experimental|Intervention (TAU and EMDR)|Intervention Group: Received TAU and EMDR Therapists delivering EMDR Therapy provided psychotherapeutic services to clients in the experimental group using the EMDR Fibromyalgia Treatment.
89078049|NCT02813239||HCG + GnRH agonist triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG and GnRH agonist when at least 2 follicles had a mean diameter of 17 mm.
89078050|NCT02815501||women|"attending the emergency room and/or hospitalised or followed for: Spontaneous and/or repeated miscarriage Foetal death Pre-eclampsia Retroplacental haematoma Post-partum haemorrhage Premature delivery~Blood samples"
89078051|NCT04271098||Open-heart surgery|Patients undergoing open-heart surgery with cardiopulmonary bypass
89078052|NCT02813005|Experimental|Jet ventilation/ group A|Frequency : 120-200/min Pressure : 1-2 bars Inspiratory fraction of oxygen : 100% and 50% if Expiratory pressure : 5 -10 cmH2O
88812508|NCT03902184|Experimental|Cohort 1: Relapsed/refractory Sezary Syndrome|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
89078053|NCT02813005|Sham Comparator|Standard ventilation/ group B|Apnea made by the anesthesiologist to the request of the radiologist.
89230076|NCT01096927|Experimental|Non operative Treatment group|Patients with Lower Abdominal and suspected Acute Appendicitis, treated non-operatively with 7 days antibiotic therapy (Amoxicillin and Clavulanic Acid)
89078054|NCT02858206|Experimental|Neoadjuvant nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
89078055|NCT02858206|Active Comparator|Neoadjuvant chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
89230077|NCT01092403|Experimental|ASM-024|ASM-024 once daily by inhalation
89230078|NCT01092403|Placebo Comparator|Placebo|Placebo once daily by inhalation
89078056|NCT02858206|Experimental|Radical nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
89078057|NCT02858206|Active Comparator|Radical chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
89078058|NCT05581615|Active Comparator|Pure inulin|2 x 5 g/d inulin
89078059|NCT05581615|Experimental|Shortbread containing inulin|2 x per day shortbread containing 5 g inulin per serving
89078060|NCT05581615|Experimental|Rice drink containing inulin|2 x per day rice drink containing 5 g inulin per serving
89078061|NCT05581615|Experimental|Milk chocolate containing inulin|2 x per day milk chocolate containing 5 g inulin per serving
89078062|NCT02810119|Experimental|LO2A|Sodium Hyaluronate
89078063|NCT02810119|Placebo Comparator|Placebo-Controlled Saline|Placebo
89078064|NCT02810041|Experimental|yoghurts enriched with XXS|
89078065|NCT02810041|Placebo Comparator|yoghurts non enriched with XXS|
89078066|NCT02809885|Experimental|Transplanted patients|All patients included are in the same arm.
89078067|NCT02815189|Experimental|Post operative Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg taken a week after. Incidence of flare ups after a single vs multiple visits root canal treatments.
89078068|NCT02815189|Experimental|Flare up|Acetaminophen 325 mg for Flare Up. Taken second day after. Incidence of Post operative pain after root canal treatment in one vs two visits.
89078069|NCT02809963|Active Comparator|Eplerenone|Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
88812509|NCT03902184|Experimental|Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
88812510|NCT03902184|Experimental|Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing (closed)|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
88812511|NCT03902184|Experimental|Cohort All comers: Stage IB-IV Mycosis Fungoides,KIR3DL2 expressing and non-expressing|IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity.
89078070|NCT02809963|Placebo Comparator|placebo|sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.
89078071|NCT02815111||Control Group|Intensivists will proceed with analgesia utilizing conventional opioid based pain order sets.
89078072|NCT02815111||Study Group|The investigators plan to study an analgesic regimen of Ketamine and lidocaine as infusions with Neurontin and Acetaminophen delivered orally for postoperative analgesia and the subsequent effect on ventilator days and ICU stay.
89078073|NCT04236895|Active Comparator|Lantus ® US|Insulin glargine (Lantus®, product approved and marketed in the USA (US RLD)), 100 U/mL in 3 mL pre-filled pens
89078074|NCT04236895|Active Comparator|Lantus ® EU|Insulin glargine (Lantus®, product marketed in Germany (EU RP)), 100 U/mL in 3 ml pre-filled pens
89078075|NCT04236895|Experimental|Gan & Lee Insulin Glargine|Insulin glargine 100 U/mL in 3 mL pre-filled pens
89078076|NCT02809651|Experimental|Ischemic stroke|patients suffering from ischemic stroke diagnosed by clinical examination and CT-scan
89078077|NCT02809651|Experimental|Brain tumor|patients diagnosed with a brain tumor diagnosed by clinical examination and CT-scan or MRI
89078078|NCT02809651|Experimental|Brain surgery|patients that have undergone brain surgery
89078079|NCT02809651|Active Comparator|Intracranial hemorrhage|patients with intracranial hemorrhage diagnosed by clinical examination and CT-scan
88812512|NCT03900754|Experimental|Intranasal Oxytocin|Dosages of oxytocin: 20IU or 40IU.
88812513|NCT03900754|Placebo Comparator|Placebo|Saline
89078080|NCT02809651|Experimental|Headache|patients with headache complaints and a normal CT-scan of the brain
89078081|NCT02809651|Experimental|Headtrauma|patients with head trauma and a normal CT-scan of the brain
89078082|NCT02809729|Placebo Comparator|placebo|The patients will receive 0.9% saline for intravenous bottle with 100ml looks identical to the antibiotic at the start of anesthetic induction
89078083|NCT02809729|Active Comparator|cefazolin|The patients will receive 2 g of cefazolin diluted in 0.9% saline by endovenous at the start of anesthetic induction
89224546|NCT06265194|Active Comparator|Control (TAU)|Control Group: TAU Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.
88812514|NCT03897075|Experimental|Arm A|
88812515|NCT03897075|Placebo Comparator|Arm B|
89224547|NCT06265181|Experimental|Intervention Group|"Diabetes coaching will be provided to experimental group participants. In this study, one chemistry interview and eight diabetes coaching meetings are planned to be held.~Interviews will be conducted in accordance with the standards of the GROW technique, which is based on a scientific framework. Interviews will be held every 10 days, via a video-free phone call, and will last between 45-60 minutes."
89078084|NCT04303377|Experimental|Evolocumab|Evolocumab administration in the acute phase of ST elevation myocardial infarction
89078085|NCT04303377|No Intervention|Standard of care|
89078086|NCT00953524|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
89078087|NCT00953524|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
89078088|NCT00953524|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Vaccine formulation 3
89078089|NCT00953524|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
89078090|NCT02809573|Experimental|study drugs|Lead-in period is 4 days. Patients take a single dose of Chidamide tablet, then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle. Cyclophosphamide, adriacin and vincristine are given in intravenous infusion on Day 1. On Day 1 to 5, prednisone is given orally. Treatment cycles are repeated every 3 weeks .The combination therapy lasts for at most 6 cycles. Patients enter the single agent therapy if attained complete response after 6-cycle combination therapy. In this stage, patients take chidamide orally on Day 1, 4, 8 and 11 of each cycle.
89078091|NCT02812927|Other|Standard infusion line|The standard insulin infusion system consisted in regular human insulin administration through a six-stopcock manifold connected to the distal line of a multilumen central venous catheter by 150 cm tubing. Insulin was systematically infused by syringe pump on the patient proximal port of the manifold. Carrier was infused via pump through the manifold. All others medicines were infused through the other five stopcocks.
89078092|NCT02812927|Experimental|Optimised infusion line|The optimised insulin infusion system consisted in regular human insulin administration through a multilumen device (Edelvaiss Multiline-8, Doran International, Toussieu, France). This device had ports for eight infusions which run through separate channels within a 150 cm flexible plastic tube. Since fluids from the individual channels do not meet until they exit the distal tip. Carrier was infused through the high flow (HF) line and insulin was infused by syringe pump systematically next to the HF line port. All others medicines were administered via adjacent ports on the Multiline-8.
89078093|NCT04388683|Experimental|Intervention|Will receive study drug treatment.
89078094|NCT04388683|No Intervention|Control|Will receive standard of care.
88812516|NCT03861091|Experimental|Risedronate|Risedronate 150 mg given once 7-21 days prior to initiation of SBRT
88812517|NCT03861091|Placebo Comparator|Matching Placebo|Matching placebo, dose not applicable given once 7-21 days prior to initiation of SBRT
88812518|NCT03854916|Experimental|Caminemos Juntas App|Participants use the Caminemos app.
88812519|NCT03854916|Active Comparator|World Walking App|Participants use the World of Walking App.
89078095|NCT02809261|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (3cc) between proximal carpal tunnel and median nerve.
89078096|NCT02809261|Placebo Comparator|Perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and median nerve.
88812520|NCT03843021||VAD Healthcare Providers|Adult healthcare providers of VAD therapy recipients.
89078097|NCT01040403|Experimental|olodaterol (BI 1744) low and placebo|low dose inhaled olodaterol orally once daily from the Respimat inhaler
89078098|NCT01040403|Experimental|olodaterol (BI 1744) low and low tio|low dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
89078099|NCT01040403|Experimental|olodaterol (BI 1744) low and medium tio|low dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
89078100|NCT01040403|Experimental|olodaterol (BI 1744) low and high tio|low dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
89078101|NCT01040403|Experimental|olodaterol (BI 1744) high and placebo|high dose inhaled olodaterol orally once daily from the Respimat inhaler
89078102|NCT01040403|Experimental|Olodaterol (BI 1744) high and low tio|high dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
89078103|NCT01040403|Experimental|Olodaterol (BI 1744) high and medium tio|high dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
89078104|NCT01040403|Experimental|Olodaterol (BI 1744) high and high tio|high dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
89078105|NCT02809339||Epithelial ovarian cancer|
89078106|NCT00957034|Placebo Comparator|placebo|placebo patch
89078107|NCT00957034|Experimental|300 µg/day testosterone|300 micrograms/day transdermal testosterone patch
89078108|NCT00957034|Experimental|450 µg/day testosterone|450 micrograms/day transdermal testosterone patch
89078109|NCT02812693|Experimental|Treatment (pembrolizumab, imatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and imatinib mesylate orally PO QD on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89224548|NCT06265181|No Intervention|Control Group|Diabetes treatment and care of the participants in this group will continue routinely, and no additional intervention will be performed.
89224549|NCT06265168||Physicians|Volunteering intensivists, emergency physicians, internists, and neurologists.
89224550|NCT06265142|Other|Catheterization|Group A: is the control group, participant will undergo bladder catheterization. (The standard practice)
89224551|NCT06265142|Experimental|Clean Catch|Group B: is the experimental group, participant will undergo clean catch urine via bladder massage technique.
89078110|NCT02812459|Experimental|Kinesio taping plus exercise|Kinesio taping application for low back plus back exercises.This protocol will be administered three a week for 4 weeks.
89078111|NCT02812459|Active Comparator|Electrical stimulation plus exercise|Electrical stimulation for control pain applied in low back plus exercises.This protocol will be administered three a week for 4 weeks.
88812521|NCT03792243||Parastomal hernia|Patients undergoing parastomal hernia repair in Denmark between 2007 and 2017
89078112|NCT02857972|Experimental|Wondaleaf®|This is a single arm clinical trial, all female subjects will be recruited to the arm using investigational device only.
89078113|NCT04270552|Experimental|Ismigen|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
89078114|NCT04270552|Placebo Comparator|Placebo|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
89078115|NCT04237597|Experimental|K-877 & CSG452|K-877 Single dose on Day 1 and Day 15 CSG452 Repeat dose on Day 2 Through Day 15
89078116|NCT02854462|Experimental|Language comprehension intervention|The intervention will run for 4 weeks. Caregivers will be provided with storybooks (e.g., Percy the Park Keeper) that have been amended to include inference-eliciting questions. Caregivers will be trained (with a video) to ask these questions and respond to their children's answers during shared reading sessions. They will be asked to read one book per day. Caregivers will keep a reading diary.
89078117|NCT02854462|Active Comparator|Counting intervention|The intervention will run for 4 weeks. Caregivers will be provided with a book 'At home with counting' that is made up of age appropriate maths exercises. Caregivers will trained (with a video) to work through one page of the book per day. This should take the same amount of time as the activity in the language intervention condition. Caregivers will keep a counting diary.
89078118|NCT02812381|Active Comparator|SCS (Jones tecnique)|18 patients were treatment with straincounterstrain
89078119|NCT02812381|Sham Comparator|KT Kinesiotaping|18 patients were treatment with neuromuscular bandage
89078120|NCT02854774|Active Comparator|Knee muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of knee extensor muscles.
89078121|NCT02854774|Active Comparator|Hip muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of hip extensor muscles.
89078122|NCT02812849||Suspected cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
89078123|NCT02812849||Known cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
89078124|NCT02812849||Other inflammatory cardiac disease|Cu-64 DOTATATE PET/CT or PET/MRI
89078125|NCT02812303||Population Health Coordinator Support|"8 practices received the support of central population health coordinators (PHCs). PHCs utilized a population health management (PHM) information technology (IT) tool and performed administrative tasks including appointment scheduling, ordering overdue laboratory testing, chart reviews, and obtaining outside tests/labs. In addition, PHCs regularly met with physicians to review those patients who required clinical intervention to develop an action plan.~The network did not have sufficient resources to implement a PHC in all of the 18 network practices. So PHCs were allocated by responses from the practice leader, baseline quality scores, size of the practice, nature of the practice (health center vs not), and location of the practice. These decisions were made in a way that sought to equitably distribute available PHC resources within the practice network as a way to get network buy-in and maximize the impact of the program, both for practices with and without PHCs."
89078126|NCT02812303||No Population Health Coordinator Support|Ten practices without PHC support were provided training on how to use the PHM IT tool. The staff in these practices remained primarily responsible for managing administrative tasks.
89078127|NCT02809417||LICORNE platform|
89078128|NCT02809417||Control|
89078129|NCT02809495||Patients who will use the clinical application|
89078130|NCT02809495||Patients who do not make use of clinical application|
89078131|NCT04236973|Experimental|clinical performance of the Truenat™ HCV assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the Common Technical Specifications 2009/886/EC (CTS) of the CE-IVDD and WHO TSS-10 (draft) for IVDs medical devices used for the qualitative and quantitative detection of Hepatitis C RNA.
89078132|NCT04236973|Active Comparator|comparison CE-IVD marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
89078133|NCT02689999|Experimental|Dexrabeprazole 10 mg Enteric-Coated Tablets|Dexrabeprazole 10 mg Enteric-Coated Tablets / once daily
89078134|NCT02808793|Experimental|AK002|IV dose of AK002
89078135|NCT02809105|Experimental|Part I ASP0456|ASP0456 will be administered orally for 4 weeks.
89078136|NCT02809105|Placebo Comparator|Part I Placebo|Placebo will be administered orally for 4 weeks.
89078137|NCT02809105|Experimental|Part II ASP0456|ASP0456 will be administered orally.
89078138|NCT00953056|Experimental|Cohort I - RotaTeq™, Adults|Adults randomized to receive a single dose of RotaTeq™.
89078139|NCT00953056|Placebo Comparator|Cohort I - Placebo, Adults|Adults randomized to receive a single dose of matching placebo to RotaTeq™.
89078140|NCT00953056|Experimental|Cohort II - RotaTeq™, Children|Children randomized to receive a single dose of RotaTeq™.
89078141|NCT00953056|Placebo Comparator|Cohort II - Placebo, Children|Children randomized to receive a single dose of matching placebo to RotaTeq™.
89078142|NCT00953056|Experimental|Cohort III - RotaTeq™, Infants|Infants randomized to receive 3 doses of RotaTeq™.
89078143|NCT00953056|Placebo Comparator|Cohort III - Placebo, Infants|Infants randomized to receive 3 doses of matching placebo to RotaTeq™.
89078144|NCT02811289|Experimental|Mirabegron|Mirbetriq (Mirabegron) (50mg) will be administered orally at time 0 to activate brown adipose tissue.
89078145|NCT02811289|Active Comparator|Cold exposure|Cold exposure protocol using a water-conditioned cooling suit will be applied
89078146|NCT02809027|Active Comparator|Ginger|Ginger capsule (500 mg), oral form, 2 capsules 3 time after meal for 3 days
89078147|NCT02809027|Sham Comparator|Placebo|Placebo capsule, oral form, 2 capsules 3 time after meal for 3 days
89078148|NCT02857660|Experimental|Whole-Body Electromyostimulation and Protein|16 weeks of whole-body intervention 1.5 x 20 min week with bipolar current up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
89078149|NCT02857660|Active Comparator|Protein supplementation|up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
89078150|NCT02857660|No Intervention|sedentary Control Group|No protein supplementation or WB-EMS-application, but up to 800 IU/d Vitamin D-Supplementation
89078151|NCT02874495||Healthy volunteers|22 persons.
89078152|NCT02874495||Patients with Crohn's disease|22 patients.
89078153|NCT02808949|Experimental|Age Groups|Dapivirine levels in breast milk will be measured in 16 participants. All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.
89078154|NCT02854306|Active Comparator|Surgery|Obese patient without mindfulness program in parallel.
89078155|NCT02854306|Active Comparator|Surgery with mindfulness program|Obese patient following a mindfulness program in parallel.
89078156|NCT02854384||Epilepsy Patients|males and females whose age more than 18 years, diagnosed with epilepsy, regardless of whether symptomatic,idiopathic ,focal or generalized
89078157|NCT02854384||Healthy Control|males and females whose age more than 18 years
89078158|NCT02812147|Active Comparator|L-DOPS|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. L-dihydoxyphenylserine will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of L-DOPS three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over). After a 7-day washout, participants will cross over to the Placebo arm.
89078159|NCT02812147|Placebo Comparator|Placebo|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. Placebo will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of placebo three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over) After a 7-day washout, participants will cross over to the L-DOPS arm.
89078160|NCT04303065|Experimental|Dexamethasone|"Dexamethasone will be a short and descending course: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).~Dexamethasone (Fortecortin®) will be acquired from ERN, SA. Laboratories (Barcelona, Spain). The Son Espases Pharmacy Department will be in charge of developing and conditioning the 4mg, 2mg and 1mg dexamethasone / placebo capsules needed for 12 days of treatment, keeping the researchers blind"
89078161|NCT04303065|Placebo Comparator|Control|"The preparation and conditioning of the capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).~The Son Espases Pharmacy Department will be responsible for identifying the containers and sending them by courier to the participating hospitals. A record of the dispensing of test samples will be kept and will be sent in acknowledgment of receipt for control"
89078162|NCT02814955||referred for paroxysmal atrial fibrillation with fluindione|
89078163|NCT02814955||referred for paroxysmal atrial fibrillation with previscan|
89078164|NCT02814955||referred for paroxysmal atrial fibrillation with apixaban|
89078165|NCT02814955||referred for paroxysmal atrial fibrillation with rivaroxaban|
89078166|NCT02814955||referred for paroxysmal atrial fibrillation with dabigatran|
89078167|NCT02874417|Experimental|Psychoeducation|The program was designed to dispel exaggerated thoughts surrounding the danger of the experience of anxiety symptoms, specifically focusing on fears regarding feelings of cognitive dyscontrol. The psychoeducation portion contains video animation and audio narration throughout, as well as some interactive features . Participants are provided with corrective information about the experience of anxiety-related sensations, with a particular focus on dispelling myths commonly held by individuals with high anxiety sensitivity cognitive concerns . Participants are taught that anxiety-related sensations are not dangerous and that they may have developed a conditioned fear to these symptoms of arousal.
89078168|NCT02874417|Placebo Comparator|Health and Wellness|The controlled condition consisted Physical Health Education Training (PHET), a computerized presentation which focuses on information on general healthy living. The PHET program contains information on nutrition, alcohol, water consumption, exercise, sexual health, hygiene, stress management, life organization, social support, positive outlook, and sleep.
89078169|NCT02081248|Active Comparator|Standard Consent|This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
89078170|NCT02081248|Experimental|Easy-to-Read Informed Consent|This arm will receive the Consent Form Specific Format 2 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent (ETRIC) is the newly approved consent.
89078171|NCT04302129|Experimental|ultrasound guided erector spinae block and general anaesthesia|Ultrasound guided erector spine plane block is done after general anaesthesia and prone positioning
89078172|NCT04302129|Active Comparator|Multimodal analgesia with general anaesthesia|Multimodal analgesia given with general anaesthesia in form of ketorolac and paracetamol
89078173|NCT02856958|Experimental|Operative|Peroneal nerve decompression
89078174|NCT02856958|Active Comparator|Non-operative|Physical therapy
89078175|NCT00952822|Experimental|1|ADVATE reconstituted in 2 mL sterile water for infusion
89078176|NCT00952822|Active Comparator|2|ADVATE reconstituted in 5 mL sterile water for infusion
89078177|NCT02857738|Experimental|SPF evaluation|Subjects with Good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
89078178|NCT02854072|Experimental|GV1001 + gemcitabine/capecitabine|
89078179|NCT02854072|Active Comparator|gemcitabine/capecitabine|
89078180|NCT01038297|Experimental|EXC 001|
89078181|NCT01038297|Placebo Comparator|Placebo|
89078182|NCT02537314|Active Comparator|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
89078183|NCT02537314|Placebo Comparator|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
89078184|NCT02808559|Experimental|Bodystudio ATBM|The PASI of the patients will be evaluated by two dermatologists then by the bodystudio ATBMs.
89078185|NCT04278040|Experimental|Non-cystic fibrosis bronchiectasis (NCFB) patients|Inhalations with Melphalan 0,1 mg dissolved in 2 ml sodium chloride (NaCl) 0,9% 1 per day for 5 consequent days
89078186|NCT02812069|Other|minor to moderate surgical procedure|The ThermaZone® Device will be used for 30 minutes to warm the cervical spine during
89078187|NCT05641675||right heart catheterization cohort|The study investigators will screen up to 50 Veterans undergoing right heart catheterization for clinical indications with the intention to consent up to 20 Veterans. Veterans will be screened by study investigators. Veterans who decline to consent and vulnerable populations (pregnant, incapacitated, incarcerated) will be excluded from the study.
89078188|NCT00955708||Implants|Patients successfully implanted with the ACUITY Spiral Lead
89078189|NCT02811757|Experimental|tenodesis|
89078190|NCT02811757|Active Comparator|tenotomy|
89078191|NCT02814799||bone donors|
89078192|NCT02856724|Experimental|Early amniotomy and PGE2|10 mg PGE2 vaginal ovul(Propess) Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
89078193|NCT02856724|Active Comparator|PGE2|10 mg PGE2 vaginal ovul(Propess)
89078194|NCT02811835||Renal Transplant Recipients|Renal Transplant Recipients that were more than 1 year post-transplantation
89078195|NCT02811835||Healthy Controls|Healthy subjects being evaluated as potential living kidney donors
88812522|NCT03772717|Experimental|Non-invasive vagus nerve stimulation (nVNS)|Participants will use the electrical neuromuscular stimulator device, VitalStim 400, which has been used in previous clinical studies for modulation of pain and has received FDA approval. Participants will also continue to take their standard of care medication.
89078196|NCT02808637|Experimental|Manual Pressure|
89078197|NCT02808637|Experimental|Rapid Injection without Aspiration|
89078198|NCT02808637|Experimental|Manual Pressure + Rapid Injection without Aspiration|
89078199|NCT02808637|Experimental|Control|
89078200|NCT02808325|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
89078201|NCT02808325|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
89078202|NCT01037985|Experimental|EXC 001|
89078203|NCT01037985|Placebo Comparator|Placebo|
89078204|NCT00955474|Experimental|Quetiapine|Patients assigned to receive Quetiapine
88812523|NCT03770403|Experimental|ARGX-113|
88812524|NCT03740100|Other|Open single arm|Bimiralisib capsules orally
88812525|NCT03732170|Experimental|TotalFill® Bioceramic sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
89078205|NCT00955474|Active Comparator|Quetiapine and SSRI|Patients assigned to receive Quetiapine and SSRI
89078206|NCT02808247|Experimental|Experimental arm (arm A): Nintedanib|Nintedanib 200 mg twice daily orally. Nintedanib will be given continuously until clinically relevant disease progression according to the investigator's assessment or until other criteria for treatment discontinuation are met as specified in the protocol. Dosing beyond RECIST 1.1 progression is allowed for the oral agent if the patient still derives benefit from the treatment.
89078207|NCT02808247|Active Comparator|Standard arm (arm B): Ifosfamide|Ifosfamide 3 g/m2 intravenously on days 1, 2 and 3 every 21 days for up to a maximum of 6 cycles.
89078208|NCT02037334||Pregnancy|
89078209|NCT02808091|Experimental|Early stage (IB or bulky disease - II)|who will receive GIFOX-B chemotherapy followed by involved field radiotherapy.
89078210|NCT02808091|Experimental|Advanced stage (III - IV)|will receive only chemotherapy alone
89078211|NCT02807935|Other|OCT imaging of surgical/pharmacological/laser branch|"to evaluate the effect on the conventional outflow pathway, and specifically on the Schlemm's canal (SC) anatomy in the surgical branch:~Before and after trabeculotomy~Before and after cataract surgery~Before and after vitrectomy surgery~Before and after XEN™ Gel Stent implant~pharmacological branch-~Before and during the treatment with prostaglandins analogs~Before and during the treatment with alpha blockers~Before and during the treatment with beta blockers~Before and during the treatment with carbonic anhydrase inhibitor~laser branch-~Before and after trabeculoplasty~Before and after laser iridotomy~Before and after yag capsulotomy laser"
89078212|NCT02874183|Experimental|Pharmacist intervention group|"The intervention group will receive:~A phone call 48h-72h after discharge from the hospital to ensure that the patient filled their prescriptions and started taking their medication.~A phone call five to seven days after discharge to reinforce the education using the teach back technique1. Patients will be asked about their medications, what are they for, how to use them, and what side effects to watch for, based on the education and information that was provided to them at discharge."
89078213|NCT02874183|No Intervention|usual care group|The control group will receive the usual standard care available at West Kendall Baptist Hospital.
89078214|NCT02808013|Experimental|NDS-446|NDS-446
89078215|NCT02808013|Placebo Comparator|Placebo|Placebo
89078216|NCT04302519|Experimental|Pulp mesenchymal stem cells|1. 3, 7 days to increase the injection of mesenchymal stem cells
89078217|NCT02811991|Active Comparator|Experimental:Paracetamol Injection|325mg(32.5mL)or 500mg(50mL) iv q6h according to assignment
89078218|NCT02811991|Placebo Comparator|Placebo:Normal Saline Injcetion|32.5mLor 50mL iv q6h according to assignment.
89078219|NCT02873793||7/8 cases pure seminomas|
89078220|NCT02873793||5 cases of non-seminoma|
89078221|NCT02873793||3 cases of composite tumours seminoma/non-seminoma.|
89078222|NCT02873637|Experimental|under sartorial catheter|catheter under sartorial
89078223|NCT02873637|Other|femoral catheter|femoral catheter
89078224|NCT04237675||regional anesthesia|
89078225|NCT04237675||general anesthesia|
89078226|NCT02807701|Active Comparator|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy Under general anesthesia, the patient is placed in a supine position with the legs abducted. Carbon dioxide pneumoperitoneum is established using an open technique through a 10-mm trocar over the umbilicus. A 30 telescope is inserted to examine the peritoneal cavity, liver, stomach, and mesentric vessels.Then 4 to 6 more trocars are inserted under direct vision in the epigastrium and upper quadrants~dissection~reconstruction"
89224552|NCT06265116|Active Comparator|Bis-GMA-containing, HEMA-containing, one-step universal adhesive.|Each patient will randomly receive one class II restoration with one of the tested restorative systems
88812526|NCT03732170|Active Comparator|AH plus® sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
89078227|NCT02807701|Active Comparator|Open pancreaticoduodenectomy|"Open pancreaticoduodenectomy Abdomen is opened from the Bilateral Subcostal incision. (Chevron's Incision) 2. Abdominal cavity is explored for metastasis especially in liver, base of mesentary, mesocolon and pelvis.~Dissection Reconstruction Pancreaticogastrostomy Hepaticojejunostomy is next- Done in single layer and can be performed in interrupted or continuous fashion.~Gastrojejunostomy is the final step of reconstruction."
89078228|NCT05638165|Experimental|Cohort QD, NCP112 Gel 0.05%|Single dose of NCP112 Gel 0.05% or Single dose of Placebo
89078229|NCT05638165|Experimental|Cohort BID, NCP112 Gel 0.05%|Multiple dose of NCP112 Gel 0.05% or Multiple dose of Placebo
89078230|NCT05598853|Experimental|Intrathecal nivolumab and intrathecal ipilimumab|The experimental treatment will be combined from cycle 2 with systemic nivolumab and systemic ipilimumab
89078231|NCT04237285|Experimental|Lavender 15|Participant who inhalates lavender oil for 15 minutes.
89078232|NCT04237285|Experimental|Lavender 60|Participant who inhalates lavender oil for 60 minutes.
89078233|NCT04237285|Placebo Comparator|Jojoba|Participant who inhalates jojoba oil for 15 minutes.
89078234|NCT04237363|Experimental|Exercise|Walk training
89078235|NCT01229150|Active Comparator|KRAS Mut 2|KRAS Mutant patients randomized to combination therapy arm
89078236|NCT01229150|Active Comparator|KRAS Mut 1|KRAS Mutant patients randomized to monotherapy arm
89078237|NCT01229150|Active Comparator|WT KRAS 1|Wild-Type KRAS patients randomized to monotherapy arm
89078238|NCT01229150|Active Comparator|WT KRAS 2|Wild-Type KRAS patients randomized to combination therapy arm
89078239|NCT00634465||1|
89078240|NCT02807389|Experimental|MSC Fistula plug: Single Treatment Group|All patients received treatment of a stem cell coated fistula plug.
89078241|NCT02804737||Web Group|Patients given web site (aiddly) instructions for colonoscopy
89078242|NCT02804737||Paper Group|Patients given paper instructions for colonoscopy
89078243|NCT00952588|Experimental|AZD1152 1200 mg|AZD1152 1200 mg, iv, 7 day infusion monotherapy
89078244|NCT00952588|Active Comparator|LDAC 20 mg|LDAC 20 mg, sc, bd, 10 days (400mg per cycle)
89224553|NCT06265116|Active Comparator|Bis-GMA-free, HEMA-containing, one-step universal adhesive|Each patient will randomly receive one class II restoration with one of the tested restorative systems
89078245|NCT02814409|Active Comparator|Alteplase - standard care|Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).
89078246|NCT02814409|Experimental|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).
89078247|NCT02804893|Active Comparator|VATS GROUP|VATS lobectomy or segmentectomy
89078248|NCT02804893|Active Comparator|RATS GROUP|Robotic lobectomy or segmentectomy
89078249|NCT02853916|Active Comparator|500 mg InSea2®|
89078250|NCT02853916|Active Comparator|250 mg InSea2®|
89078251|NCT02853916|Placebo Comparator|Placebo|
89078252|NCT02853838|Experimental|Prolonged slow expiration+provoked coughing+ST|Prolonged slow expiration+provoked coughing+Standard Therapy
89078253|NCT02853838|Active Comparator|Manual chest wall vibration+ST|Manual chest wall vibration+Standard Therapy
89078254|NCT05527717|Active Comparator|Culprit-lesion only PCI arm|Patients will receive culprit-lesion only PCI.
89078255|NCT05527717|Experimental|Immediate multi-vesesl PCI arm|Patients will receive immediate multi-vessel PCI.
89078256|NCT04236505|Experimental|ACT group intervention|4 weekly 2hour group therapy interventions drawing from an Acceptance and Commitment Therapy (ACT) based protocol.
89078257|NCT04236505|Experimental|Mindfulness skills group intervention|4 weekly 2 hour group therapy interventions drawing from an Mindfulness based stress reduction (MBSR) based protocol
89078258|NCT04236505|Placebo Comparator|Wait list control group|Wait list control group who at the time of the experimental group interventions are not attending a group and receiving treatment as usual. This group are offered a Mindfulness skills group intervention after the follow up data has been collected.
89078259|NCT02804581|Experimental|Gum Arabic|Oral intake of 30 gram of Gum Arabic daily for 12 weeks
89078260|NCT01227902|Experimental|Retigabine IR|Open Label flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
89078261|NCT00946192|Experimental|Estrogen Patch|17Beta-estradiol transdermal patch twice weekly application for 12 months
89078262|NCT00946192|Active Comparator|Estrogen Pill|One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.
89078263|NCT00946192|Sham Comparator|Control|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
89078264|NCT01037127|Experimental|Cohort A|Subjects who have had previous treatment with a BRAF inhibitor.
89078265|NCT01037127|Experimental|Cohort B|Subjects who have had previous chemotherapy or immunotherapy without a BRAF inhibitor.
89078266|NCT02806999|Experimental|Berberine; Insulin|"Follow the previous administration program，participants will continue to receive intensive insulin therapy; Besides injecting insulin, participants will receive 500mg berberine twice a day for 8 days.~Drug: Berberine; Insulin"
89078267|NCT02806999|Active Comparator|Insulin|"Besides receiving intensive insulin therapy, participants will take a placebo twice a day for 8 days.~Drug: Insulin"
89078268|NCT02874261|Experimental|Whole Body Periodic Acceleration|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation is 120 cycles/minute; cpm) as well as a distance traveled 16 mm."
89078269|NCT02806921|Active Comparator|ZenLens with Low limbal clearance|Scleral contact lens designed to provide approximately 25 microns of limbal clearance.
89078270|NCT02806921|Active Comparator|ZenLens with High limbal clearance|Scleral contact lens designed to provide approximately 80 microns of limbal clearance.
89078271|NCT02807077|Experimental|Subjects with mild renal impairment|Group 1, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
89224554|NCT06265116|Active Comparator|Bis-GMA- free, HEMA-free, acrylic-based one-step universal adhesive|Each patient will randomly receive one class II restoration with one of the tested restorative systems
89078272|NCT02807077|Experimental|Subjects with moderate renal impairment|Group 2, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
89078273|NCT02807077|Experimental|Subjects with severe renal impairment|Group 3, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
89078274|NCT02807077|Experimental|Subjects with ESRD|Group 4, will consist of patients with ESRD requiring hemodialysis who have been on a stable dialysis regimen for at least 6 months. In this cohort only, patients will participate in 2 treatment periods, Dialysis and Inter-Dialysis, separated by a 14-day period between pacritinib administration. In the Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered 4 hours prior to each patient's normally scheduled hemodialysis. In the Inter-Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered immediately after the end of the patient's normally scheduled hemodialysis session.
89078275|NCT02807077|Experimental|Healthy subjects|Group 5, will consist of 8 healthy subjects enrolled to match the sex-, age-, and weight of the patients with mild, moderate, and severe renal impairment and patients with ESRD enrolled in the study. Healthy subjects will be administered a single 400 mg dose of pacritinib.
89078276|NCT04302363||Control Group|Healthy controls must be 18-75 years old with no tumors and no history of cancer.
89078277|NCT04302363||Test Group|Inclusion criteria in the experimental group are age 18-75 years old, colonoscopy revealing colon or rectal tumor, biopsy-confirmed adenocarcinoma or adenoma, no chemotherapy or surgery, and no history of other cancer. Both groups must be able to understand and be willing to sign informed consent.
89078278|NCT02804503|Experimental|Calorie Labels|A menu with rank ordered calorie labels and a statement on the energy needs per meal.
89078279|NCT02804503|Experimental|Exercise Labels|A menu with rank ordered exercise labels showing minutes of brisk walking necessary to burn the food calories.
89078280|NCT02804503|Active Comparator|No Labels|A menu with no labels
89224555|NCT06265116|Active Comparator|Bis-GMA- containing, HEMA-containing, amide-based one-step universal adhesive|Each patient will randomly receive one class II restoration with one of the tested restorative systems
89078281|NCT04302285|Experimental|Exercise trial|In this trial, participants were asked to exercise for one hour under controlled laboratory conditions. Participants were exercising on the treadmill at speed and grade corresponding to 60% of their V̇O2max. Participants were wearing a HR monitor and a face mask while exercising, connected to indirect calorimetry equipment. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
89078282|NCT04302285|Experimental|Control trial|In this trial, participants were asked to rest for one hour. Appetite questionnaires were obtained, and blood samples were collected at 30, 60, 90 and 120 pre-meal, 150, 180, 210, 240 and 300 min post-meal. Metabolic rate was measured every 30 min after each blood sample. Participants were presented to a standard isocaloric PKU type meal at 120 min. After the completion of the last measurement, the participants were presented with an ad libitum buffet test meal.
89078283|NCT04261582||AERD participants|Participants with aspirin exacerbated respiratory disease. Adults with aspirin allergy, nasal polyps and adult-onset severe asthma.
89078284|NCT04261582||Healthy controls|Healthy participants that do not have asthma.
89078285|NCT04261582||Non-aspirin sensitive asthma participants|Participants with asthma, but that do not have a sensitivity to aspirin.
89078286|NCT02804425|Experimental|"actor-spectator group"|actor at least once during the immersive simulation session
89078287|NCT02804425|No Intervention|"spectator-only group"|observer during the whole one-day session but participation in the debriefing part of the four scenarios
89078288|NCT00627471|Active Comparator|A|This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
89078289|NCT00627471|Active Comparator|B|This is the control group, following the physician's standard practice.
89078290|NCT04269382|Other|Combined non-invasive and invasive BP measurements|Patients will all undergo measurement of BP through 3 different techniques over a 30-min period: continuous noninvasive BP measurement (with the finger cuff and Clearsight™ device), repeated intermittent oscillometric NIBP measurements with a cuff placed around a calf or an arm, and continuous invasive BP measurement (through an indwelling arterial catheter).
89078291|NCT04302441|Experimental|NXH group|Patients should receive four cycles of NXH regimen (vinorelbine at 25 mg/m2 iv infusion on day 1 and day 8 plus capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle, trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year).
89078292|NCT04302441|No Intervention|H group|Patients should receive trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year.
89078293|NCT04236427|Experimental|Treatment Group|Chinese Medicine of Angong Niuhuang Wan
89078294|NCT04236427|Placebo Comparator|Placebo Group|Placebo of Angong Niuhuang Wan
89078295|NCT02853682||presence of a vascular dysfunction|plasma
89078296|NCT02853682||absence of vascular dysfunction|plasma
89078297|NCT02874027||TBI Patients with depression|All the patients should be diagnosed by CCMD-3(evaluation of depression)
89078298|NCT02874027||TBI Patients without depression|
89078299|NCT02800447|Experimental|Treatment|baseline BEACOPP regimen
89078300|NCT02800447|Active Comparator|controlled group|ABVD regimen
89078301|NCT01038921|Experimental|Melatonin|Melatonin 8mg one hour before bedtime for 10 weeks
89078302|NCT01038921|Placebo Comparator|Placebo|Placebo administered 1 hour before bedtime for 10 weeks
89078303|NCT01088542|No Intervention|No intervention|Communities in the no intervention arm received no intervention from the project and continued to implement prevention services as usual.
89078304|NCT01088542|Experimental|Communities That Care Intervention|Communities randomly assigned to the experimental condition received 5 years of training and technical assistance (from 2003 to 2008) to implement the Communities That Care (CTC) prevention system in their communities. They also received 5 years of funding to support a full-time community coordinator and 4 years of seed money to implement tested and effective prevention programs selected as a result of their CTC process.
89078305|NCT02804347||Patient|Patients will be receiving either ECT or iTBS as a depression management. Olfactory functioning will be assessed at pre-treatment and 6 weeks later at post-treatment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
89078306|NCT02804347||Control|Controls will have their olfactory functioning assessed at baseline and 6 weeks after the baseline assessment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
89078307|NCT02804191|Experimental|LO2A|Sodium Hyaluronate
89078308|NCT02804191|Placebo Comparator|Placebo-Controlled|Saline.
89078309|NCT02804113|Experimental|Supera Peripheral Stent System|
89078310|NCT02374372|Active Comparator|conventional hemodialysis|conventional hemodialysis
89078311|NCT02374372|Active Comparator|hemodiafiltration On-line|hemodiafiltration On-line
89078312|NCT04236349||CO1TB: observational|patients with pulmonary and extrapulmonary tuberculosis
89078313|NCT04236349||CO2TB: immunogenetics|"patient with pulmonary and extrapulmonary tuberculosis and meet the following criteria:~informed consent form signed by the patient or by the representative of parental authority~affiliation to social security (beneficiary or assignee)~HIV negative"
89078314|NCT01038687|Experimental|A3309 15 mg|Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.
89078315|NCT01038687|Experimental|A3309 20 mg|Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.
89078316|NCT01038687|Placebo Comparator|Placebo|Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.
89078317|NCT02803957|Experimental|Treatment Group|Subjects with degenerative mitral valve insufficiency treated with artificial chordae implanted using the NeoChord DS1000
89078318|NCT02803957|Active Comparator|Control Group|Subjects with degenerative mitral valve insufficiency treated with standard surgical mitral valve repair
89078319|NCT02856568|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, ricolinostat)|Patients receive cisplatin IV followed by gemcitabine hydrochloride IV on days 1 and 8, and ricolinostat PO on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89078320|NCT02804269||Healthy Volunteer|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
89078321|NCT02804269||Dilated Cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
89078322|NCT02804269||Hypertrophic cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
89078323|NCT02804269||Ischemic heart disease with reduced EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
89078324|NCT02804269||Ischemic heart disease with normal EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
89078325|NCT04236583|Experimental|Telehealth|Eligible patients will be given the option to consent to having one virtual visit with their primary care physician within four weeks after discharge from the hospital. Usual follow-up care will occur during this visit.
89078326|NCT02874105|Experimental|experimental group|Dynamic Humeral Centering
89078327|NCT02874105|Active Comparator|control group|Conventional physiotherapy
89078328|NCT04081831||New-users of Low-dose aspirin (exposed group)|New-users of low-dose aspirin is defined as patients who did not receive any prescriptions of low-dose aspirin one year prior to the index date.
89078329|NCT04081831||Users of Paracetamol (non-exposed group)|Users of Paracetamol is defined as patients who receive first prescription of paracetamol during the study period. Since the patients receiving low-dose aspirin are potentially less healthy compared to non-users of aspirin, patients receiving paracetamol as the control group can minimise healthy user bias.
89078330|NCT02807155|No Intervention|Non-Intervention Control|No intervention will be delivered.
89078331|NCT02807155|Experimental|Continuity Group|"Continuity Group participants aged 20-21 (i.e. the last year of the LEAP Program) will be seen at one of the 2 study centers - 1) the newly established LAC+USC Diabetes Transition Clinic; or 2) Children's Hospital Los Angeles Pediatric Endocrinology Clinic, and will receive the full 1-year Transition Empowerment Program - Continuity Group"
89078332|NCT02807155|Experimental|Rescue Group|"Rescue Group participants aged 21-25 will be connected to a diabetes healthcare home (medical clinic or doctor's office) in Los Angeles County based on geography and personal preference. Those individuals connected to the LAC+USC Diabetes Transition Clinic will receive the full 1-year Transition Empowerment Program - Rescue Group (TEP-RG). Those assigned to other providers in LA County will have access to the web-based curriculum."
89078333|NCT01081912|Active Comparator|Hydrocodone Bitartrate Capsules|Hydrocodone Bitartrate Controlled-Release Capsules
89078334|NCT01081912|Placebo Comparator|Placebo comparator|
89078335|NCT02800525|Experimental|Picosecond laser|"The pigmented lesions on this half-side of the face would be treated with picosecond laser.~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
89078336|NCT02800525|Active Comparator|Q-switched Nd:YAG laser|"The pigmented lesions on this half-side of the face would be treated with q-switched Nd:YAG laser.~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
89078337|NCT01038609|Placebo Comparator|Placebo|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
89078338|NCT01038609|Active Comparator|Acetaminophen|1 dose of 1 placebo capsule (for morphine extended release) plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
89078339|NCT01038609|Active Comparator|Morphine Extended Release|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 morphine extended release capsule, administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
89078340|NCT01038609|Active Comparator|Morphine Extended Release / Acetaminophen|1 dose of 1 morphine extended release capsule plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
89078341|NCT01038609|Experimental|Hydrocodone/Acetaminophen Extended Release|1 dose of 1 hydrocodone/acetaminophen extended release tablet plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
89078342|NCT02803879|Experimental|Cardiogoniometry (CGM)|All patients attending clinic for follow up appointments following the implantation of a CRT device will be eligible for inclusion in the study. If they consent for enrolment in the study each patient will undergo a series of 4 CGM recordings whilst in their follow up appointment. They will undergo each of these during different pacemaker settings. These are: 1) No pacing, 2) Paced from the right ventricular lead; 3) Paced from the left ventricular lead and 4) Paced from both ventricular leads. After this has been done the participants involvement in the study will have finished.
89230079|NCT00660023|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia previously treated with ESA therapy will receive intravenous Mircera, also known as continuous erythropoietin receptor activator (CERA), every 4 weeks for a total of 52 weeks in this single-arm study. The first dose will be determined by the dose of ESA received prior to administration of study treatment, and subsequent doses will be adjusted to achieve target Hb concentrations.
89078343|NCT02800759|Active Comparator|100% of JOINTRUS®|After randomization, 100% dose of JOINTRUS® is taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
89078344|NCT02800759|Active Comparator|80% of JOINTRUS®|After randomization, 80% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
89078345|NCT02800759|Active Comparator|62.4% of JOINTRUS®|After randomization, 62.4% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
89078346|NCT02800759|Placebo Comparator|Starch 100%|After randomization, starch 100% was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
89078347|NCT02857582|Active Comparator|Vancomycin|Secondary treatment for relapse of Clostridium difficile infection.
89078348|NCT02857582|Experimental|Cultured human intestinal microbiota1|Cultured intestinal microbiota is experimental treatment for relapse of Clostridium difficile infection.
89078349|NCT02857582|Experimental|Cultured human intestinal microbiota2|Cultured intestinal microbiota is thirdly experimental treatment for second relapse of Clostridium difficile infection.
89078350|NCT04301973|Other|Healthy people|
89078351|NCT02803801|Experimental|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
89078352|NCT04301895|Other|Interactive|Subject will be asked to continually interactive with the investigators, answering a series of standard questions during the remifentanil infusion and recovery periods.
89078353|NCT04301895|Other|Non-interactive|All verbal interaction will be avoided and extraneous sounds will be eliminated from the environment during the remifentanil infusion and recovery periods.
89078354|NCT02357134|Experimental|Arm I (high-flow oxygen)|Patients receive high-flow oxygen via nasal prongs during a structured stationary bicycle exercise session.
89078355|NCT02357134|Experimental|Arm II (high-flow air)|Patients receive high-flow air via nasal prongs during a structured stationary bicycle exercise session
89078356|NCT02357134|Active Comparator|Arm III (low-flow oxygen)|Patients receive low-flow oxygen via a nasal cannula during a structured stationary bicycle exercise session.
89078357|NCT02357134|Active Comparator|Arm IV (low-flow air)|Patients receive low-flow air via a nasal cannula during a structured stationary bicycle exercise session.
89078358|NCT04200781|Experimental|Shengdi Dahuang Decoction|To clarify the clinical effects of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke and to explore the possible mechanism. Participants will take the granules of Shengdi Dahuang Decoction that contains 15 grams of rehmannia and 5 grams of rhubarb, one pack per time, twice a day for 7 days.
89078359|NCT04200781|Placebo Comparator|Placebo|To explore the effective clinical therapy in acute hemorrhagic stroke. Participants will take placebo contains 2% rehmannia and rhubarb, one pack per time, twice a day for 7 days.
89078360|NCT04302675|Experimental|Prevention, Maternal Immunization|
89078361|NCT02806765|Experimental|Dietary Supplement|This experimental arm reflects administration of a softgel capsule containing a dose of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol below the upper tolerable limit
89078362|NCT02806765|Experimental|Control|This experimental arm reflects administration of placebo in softgel capsule
89078363|NCT02853526|Experimental|TIPS arm|Transjugular intrahepatic portosystemic shunt(TIPS) is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension.TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (also called p-TIPS or modified TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
89078364|NCT02853526|Active Comparator|conservative treatment arm|Conservative treatment including endoscopic therapy，non-selective beta blockers (propranolol)and anticoagulation therapy (warfarin).
89078365|NCT04200469|Experimental|QFR Intervention|Patients submitted to a coronary angiogram with at least one non-left main stable coronary stenosis between 50 and 90% and PCI indication with paired assessment of QFR, dFR, RFR and FFR, before and after PCI once informed consent is provided.
89078366|NCT03898531||hip prosthesis metal/polyethylene in simple mobility|
89078367|NCT03898531||hip prosthesis metal/polyethylene in double mobility|
89078368|NCT03898531||hip prosthesis ceramic/polyethylene in simple mobility|
89078369|NCT03898531||hip prosthesis ceramic/polyethylene in double mobility|
89078370|NCT03898531||Primary implanted hip prosthesis|
89078371|NCT03898531||metal / metal prosthesis removed|
89078372|NCT03898531||ceramic / ceramic prosthesis removed|
89078373|NCT02806531|Experimental|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in aged 6-35 months old, 28 days interval.
89078374|NCT00630682|Active Comparator|Dextroamphetamine|Active drug
89078375|NCT00630682|Placebo Comparator|Placebo|Placebo of drug
89078376|NCT04236193||SIRVA|Subjects with shoulder pain >7 days after vaccination
89078377|NCT04236193||Controls|Subjects from a prospective influenza vaccine study
89078378|NCT00745420|Experimental|Hematopoietic Stem Cell Transplantation|Bone Marrow Transplant with GVHD Prophylaxis Regimen
89078379|NCT02800681||Asperger syndrome|"Expert panel evaluation for identification of participants with typical symptoms~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being~Other general interviewer ratings for assessing functioning and severity of psychopathology"
89078380|NCT02800681||Schizotypal disorder|"Expert panel evaluation for identification of participants with typical symptoms~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being~Other general interviewer ratings for assessing functioning and severity of psychopathology"
89078381|NCT02806609|Other|Group 1|Cold water immersion, with 10 degrees, for 10 minutes
89078382|NCT02806609|Other|Group 2|immersion in water at room temperature
89078383|NCT02806609|Other|Group 3|active recovery - running
89078384|NCT02806609|Other|Group 4|rest in the chair
89078385|NCT02857348|Experimental|Adventure video game|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for one hour.
89078386|NCT02857348|Active Comparator|Educational Module|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least one hour on the combined tasks.
89078387|NCT05095870||CANVAS Patients|Patient with a CANVAS diagnosis with genetic evidence (RFC1+)
89078388|NCT05095870||control group|Patient with axonal sensory-motor or pure sensitive neuropathy confirmed by electroneuromyography
89078389|NCT04269460|Active Comparator|subcostal transversus abdominis plane block (sTAP)|patients will be in the supine position; after preparing the skin with with povidone iodine, a high frequency (5-10 MHz) ultrasound probe will be used tp identify the rectus abdominis muscle, then 1 mL/Kg of bupivacaine 0.25% will be injected in the plane between rectus abdominis and transversus abdominis muscles.The patient will then be positioned for the procedure if other than supine position is chosen.
89078390|NCT04269460|Active Comparator|quadratus lumborum block (QLB)|patients will be positioned in the lateral decubitus position so that the blocked side will be the uppermost one. After skin sterilization with povidone iodine the ultrasound probe will be positioned to identify the quadratus lumborum muscle. then 1 mL/Kg of bupivacaine 0.25% will be injected behind the QL muscle on the lateral border of the erector spinae muscle.The patient will then be positioned for the procedure if other than lateral decubitus position is chosen.
89078391|NCT04236037|Active Comparator|Ultrasound-guided thoracentesis|Ultrasound guided thoracentesis
89078392|NCT04236037|Experimental|Ultrasound-guided pleural biopsy and thoracentesis|Ultrasound-guided biopsy of the parietal pleura is taken through the same incision as the optimal site for thoracentesis and immediately prior to ultrasound-guided thoracentesis
89078393|NCT04236115|Active Comparator|Articaine 4% with 1:00.000 Adrenaline|if the patient was in articaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
89078394|NCT04236115|Active Comparator|Prilocaine with 3% Felypressin (0.03 I.U. per ml)|if the patient was in prelocaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.
89078395|NCT02853370|Experimental|Bendamustine and Rituximab|"Induction Phase (Cycle 1 to Cycle 3 ):~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1**~Extended Phase (Cycle 4 to Cycle 6):~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1~From Cycle 4 to Cycle 6, every 4 weeks, depending on the response after the first 3 Cycles~*Or days 2-3 according to institutional/patient/physician preference~**Administration of Rituximab during cycle 1 and cycle 2 can be postponed to day 8 or 14 in case of risk of tumor lysis syndrome (TLS)"
89078396|NCT04044625|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
89078397|NCT04044625|Active Comparator|Low-intensity NPPV|The patients will receive low-intensity noninvasive positive pressure ventilation.
89078398|NCT02806219|Active Comparator|Certolizumab Pegol injection by prefilled syringe|
89078399|NCT02806219|Experimental|Certolizumab Pegol injection by e-Device|
89078400|NCT05491837|Experimental|Interventional group|"Interventional group will be provided a brief sequence of acute hypoxia consisting of 9% oxygen via device HYP 123 for one minute followed by normoxia 21% of oxygen for a total of 15 repetition.~This protocols will be provided 3 times/week for a period of 4 weeks."
89078401|NCT05491837|Sham Comparator|Control group|"SHAM group' participants will be provided 21% of O2 (normoxia), comprised of 15 repetitions of 1-minute then switching to another 1-minute of 21% O2.~This protocols will be provided 3 times/week for a period of 4 weeks."
89078402|NCT00954538|Experimental|Part I, Healthy Participants|Healthy participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
89078403|NCT00954538|Experimental|Part II, HE and AD Participants|HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
89078404|NCT00954538|Experimental|Part III, HE and AD Participants|HE and AD participants will receive two separate IV doses of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
89078405|NCT02690155||Rivaroxaban|NVAF patients who were initiated on rivaroxaban for stroke prevention
89078406|NCT02690155||VKA (Vitamin K antagonist)|NVAF patients who were initiated on VKA for stroke prevention
89078407|NCT00630760|Experimental|1|NRX 194204 capsules in escalating doses, starting at 3mg/m2.
89078408|NCT02806375|Experimental|PTCy and ruxolitinib|
89078409|NCT02856256|Experimental|RedBull® energy drink|
89078410|NCT02803489|Experimental|medical device intervention|
89078411|NCT02856334||Chronic pelvic pain|Women with chronic pelvic pain
89078412|NCT02856334||Control group|Healthy women
89078413|NCT02800603|Experimental|Family Check Up|FCU Intervention: All 280 participants will undergo screening and a baseline FCU assessment before randomization. Once randomized, the FCU group (n=140) will be provided with a feedback visit and up to 6 optional sessions of the EDP curriculum over 16 weeks.
89078414|NCT02800603|No Intervention|Community Control|The Community Control group (n=140) will receive general information that includes a list of all the relevant services available in Hamilton. As such, the community control group would be provided with all the information needed to obtain standard care.
89078415|NCT04269148||Head and Neck Cancer patients|Turkish patients diagnosed with head and neck cancer
89078416|NCT04269226|Experimental|Recruitment maneuver|Recruitment maneuver
89078417|NCT04269226|Active Comparator|No recruitment maneuver|No recruitment maneuver
89078418|NCT02803567|Experimental|Intervention|Those in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education on substance use. Content in the intervention will focus on health promotion and will deliver positive messages about health.
89078419|NCT02803567|No Intervention|Control|Those in the control arm will receive treatment as usual.
89078420|NCT04273984|Active Comparator|1- Group 1 (misoprostol 200 mcg|"Group 1 :will take 1 tablet (200 mcg) of misoprostol and 1 placebo tablet,~.,"
89078421|NCT04273984|Active Comparator|2- Group 2 (misoprostol 100 mcg)|Group 2: will take1 tablet (100 mcg) of misoprostol and 1 placebo tablet,
89078422|NCT04273984|Placebo Comparator|3- Group 3 (placebo group)|Group 3 ): will take2 placebo tablets
89078423|NCT02806297|Experimental|Early cholecystectomy with IOC|The experimental arm will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
89078424|NCT02806297|Active Comparator|Late cholecystectomy with IOC|The comparator will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
89078425|NCT02857504|Other|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
89078426|NCT02857504|Other|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
89078427|NCT02806453|Active Comparator|Group A|Group A: Mg alginate/thickened formula
89078428|NCT02806453|Active Comparator|Group B|Group B: thickened formula/Mg alginate
89078429|NCT04235803|Experimental|Telemedicine|Patients in the telemedicine arm will have their post-operative week one visit via a telemedicine portal.
89078430|NCT04235803|No Intervention|Routine|Patient in the routine arm will have their post-operative week one visit in clinic.
89078431|NCT00943852|Active Comparator|1|losartan 100 mg
89078432|NCT00943852|Active Comparator|2|ISMN 60 mg
89078433|NCT00943852|Active Comparator|3|losartan 100 mg + ISMN 15 mg
89078434|NCT00943852|Active Comparator|4|losartan 100 mg + ISMN 60 mg
89078435|NCT00943852|Placebo Comparator|5|Placebo
89078436|NCT02803645|Experimental|healthy|blood sample
89078437|NCT02853136|Experimental|Reference Treatment (pilot phase)|BI 409306 low dose
89078438|NCT02853136|Experimental|Test Treatment (pilot phase)|Fluvoxamin and low dose of BI 409306
89078439|NCT02853136|Experimental|Reference Treatment (main phase)|BI 409306 medium or high dose
89078440|NCT02853136|Experimental|Test Treatment (main phase)|Fluvoxamin and medium or high dose of BI 40930
89078441|NCT02800369|Experimental|ZFN-603 and ZFN-758|Subjects will receive suppository with ZFN-603 or ZFN-758
89078442|NCT02803723|Experimental|Holding-cuddling + Sucrose|The Holding-cuddling is started 5 minutes before and the sucrose administration is started 2 minutes before blood sampling.
89078443|NCT02803723|Active Comparator|Sucrose alone|The sucrose administration is started 2 minutes before blood sampling.
89078444|NCT02803255|Experimental|Assist-As-Needed Control|"Subjects in this group will interact with a robotic exoskeleton, the MAHI Exo-II, programmed with an adaptive mode. In this mode, the robot will continuously assist motion along pre-defined trajectories, but will employ an assist-as-needed protocol.~Here, the amount of assistance provided by the robot will not be always the 100% of that required to complete the task (as in the position control mode), but only a fraction of it. The robot will continuously estimate the residual movement capabilities of the subject, depending on the specific joint addressed in the movement, and will estimate the remaining contribution needed to complete the movement following a predefined trajectory, thus avoiding to over-support motion."
89078445|NCT02803255|Active Comparator|Subject-Triggered Control|Subjects in group B will interact with a robotic exoskeleton, the MAHI Exo-II, controlled via the subject-triggered mode, as in a previous clinical trial with the MAHI Exo II robotic system. In the subject triggered mode, the MAHIExo II is commanded to regulate joints motion following a position-control control scheme, and using as desired trajectories standardized single-joints profiles that require motion of one of the axes of the exoskeleton (i.e. elbow flexion and extension, forearm pronation and supination, wrist radial and ulnar deviation, wrist flexion and extension). The switch to position control of the exoskeleton is triggered by the application of sufficient force by the subject, in a previous phase where the robot implements a virtual wall.
89078446|NCT02803099|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89078447|NCT02803177|Experimental|BMC2012 + beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical standard, filled with a clinically established scaffold (beta-TCP Chronos® Synthes), and loaded with 1.3 x 10E6 BMC/ml TCP per 1 ml beta-TCP in situ.
89224556|NCT06265103||Barrow Neurological Institute Comprehensive Epilepsy Center|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
89224557|NCT06265103||Cincinnati Children's Hospital Comprehensive Epilepsy Center|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
89224558|NCT06265103||Children's Hospital of Philadelphia (CHOP)|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
89224559|NCT06265103||Children's Hospital of Orange County (CHOC)|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
89078448|NCT02803177|Placebo Comparator|beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical Standard and filled with a clinically established scaffold (beta-TCP Chronos® Synthes).
89078449|NCT04236661|Experimental|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
89078450|NCT02806141|Experimental|Aerosolized plus intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
89078451|NCT02806141|Active Comparator|Intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)
89078452|NCT02805985|Experimental|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
89078453|NCT02806063|Other|Intraoperative samples|During this study of health care procedure evaluating microbiological setting in PJI prior prosthesis implantation with one stage surgery, 3 additional perioperative samples will be performed prior prosthesis implantation for every patient.
89078454|NCT02805751|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have weight-bearing as tolerated from day 0. They are also instructed to perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
89078455|NCT02805751|Experimental|Early loading|The patients in the early loading group are also allowed to have weight-bearing as tolerated from day 0 and perform tendon strain exercises 3 times each day from 2 weeks after the rupture. The patients in this group will also remove the walker twice a day and use a special training pedal for 5 weeks (until walker removal).
89078456|NCT02803021|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89078457|NCT02802787|Experimental|Camp Discovery|One week activity based camp
89078458|NCT04235881|Experimental|MBSR group|Enforcement of the standardized program Mindfulness-Based Stress Reduction
89078459|NCT04235881|Experimental|App group.|Enforcement of the emotional regulation program based on mindfulness (ERM) through the mobile phone application REM volver a casa
89078460|NCT04235881|No Intervention|Control group|Usual care
89078461|NCT02805673|Experimental|OSTEO group|usual medical treatment + 6 osteopathic interventions
89078462|NCT02805673|No Intervention|witness group|usual medical treatment
89078463|NCT00952276|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)
89078464|NCT00952276|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)
89078465|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
89078466|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 4|Participants will receive A/H1N1 vaccine formulation 4
89078467|NCT00952276|Placebo Comparator|Placebo Group 5|Participants will receive a placebo vaccine
89078468|NCT02802709|Experimental|SB-061|SB-061
89078469|NCT02802709|Placebo Comparator|Placebo|Placebo
89078470|NCT02805829|Experimental|Trastuzumab + NK cells|"On Cycle 1,day -2, patients will receive IV loading dose 8mg/Kg trastuzumab, followed by collection blood on day 0. After NK expansion and verification that the resulting NK cells meet release criteria, NK cells were washed and resuspended in isotonic sodium chloride for intravenous transfusion on day 14.~NK cellular therapy conduct 2 cycles per year. The maintenance dose of trastuzumab monotherapy is 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress."
89078471|NCT02856178|Experimental|F901318 + Caspofungin|"Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:~Day 1: 4.0 mg/kg i.v. b.i.d.~Day 2 until resolution of neutropenia (max. until day 14): 2.0 mg/kg i.v. b.i.d.~Day after last i.v. application: 2.0 mg/kg oral q.d.~Concomitant medication:~For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:~Chemo day 4: Caspofungin 70 mg i.v. q.d.~Chemo day 5 until resolution of neutropenia or until end of F901318 treatment (day 15): Caspofungin 50 mg i.v. q.d.~All patients will undergo chemotherapy for acute leukaemia according to local clinical standard."
89078472|NCT02852980||gestational diabetes women|Women who had childbirth in the Hospital center Rene Dubos and who had gestational diabetes.
89078473|NCT02800135|Experimental|Furosemide stress test|
89078474|NCT02853058|Active Comparator|normal PI|Uterine artery PI expresserd in MoM is <95e percentile
89078475|NCT02853058|Active Comparator|pathological PI|Uterine artery PI expressed in Multiple of Mediane (MoM) is >=95e percentile
89078476|NCT02805283||Dapagliflozin, dapagliflozin/met ER|Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
89078477|NCT02805283||Sulfonylurea|Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
89078478|NCT00943384|Experimental|chronOS Strip|This is a single arm, outcome study for treatment of patients with degenerative disc disease (DDD), with or without stenosis, with interbody fusion, posterolateral pedicle screw system, and the study device (chronOS Strip).
89078479|NCT04235647|Experimental|Study group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
89078480|NCT04235647|Active Comparator|Control group|Older, sedentary adults (age 50-75 years) with and least one other cardiovascular risk-factor
89078481|NCT02805205|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
89078482|NCT02799979||Case|Echocardiographic data : 3D right ventricular imaging on 100 pulmonary hypertension patients at Baseline and after six months
89078483|NCT02799979||Control|Echocardiographic data : 3D right ventricular Imaging on 50 patients without pulmonary hypertension only at baseline
89078484|NCT02805439|Experimental|S47445 15mg|
89078485|NCT02805439|Experimental|S47445 50mg|
89078486|NCT02805439|Placebo Comparator|Placebo|
89078487|NCT02802163|Experimental|Combination Therapy|Combination Therapy: Panobinostat, Carfilzomib, Lenalidomide, Dexamethasone (Ca-R-Pa-Diem) . Participants will receive up to 8 cycles of the combination as induction after which will proceed with consolidation therapy with transplant as per institutional standards. After transplant, participants receive maintenance with panobinostat/lenalidomide. The maintenance dose and schedule of panobinostat will be same given during induction for 1 year. The maintenance dose of lenalidomide will be 10 mg given for 21 days of 28 days cycle until disease progression.
89078488|NCT02799511|Other|protein expression|
89078489|NCT02802007|Experimental|Elipse Intragastric Balloon|Patients seeking weight loss received the Elipse Intragastric Balloon.
89078490|NCT02801773|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and adjunct probiotic one lozenge containig Lactobacillus reuteri per day during 3 month
89078491|NCT02801773|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and one lozenge containig placebo (mint lozenge) per day during 3 month
89078492|NCT02802085||Knee Arthroplasty|Vega Knee Arthroplasty
89078493|NCT02801851|Experimental|Intervention SCREEN-ED|This is the arm that will receive the SCREEN-ED. SCREEN-ED is an innovative, yet practical intervention that combines screening with informing clinicians of the results and provides a checklist for delirium management that is tailored to the time-limited ED setting.
89078494|NCT02801929|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89078495|NCT02801461|Experimental|Three-sessions of ESWT|ESWT was given once a week for 3 weeks.
89078496|NCT02801461|Active Comparator|One-session of ESWT|Single ESWT was given.
89078497|NCT00943306|Experimental|lomitapide|Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
89078498|NCT02805049|Experimental|The study population|The study population consisted of patients admitted to the ICU for septic shock associated with secondary peritonitis and requiring antifungal therapy via echinocandins (micafungin or caspofungin).
89078499|NCT02805127||Patients with COPD and Asthma .|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken form the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions"
89078500|NCT02799589|Experimental|Remifentanil-dexmedetomidine and caudal|Anesthesia will be induced with inhaled sevoflurane which will be discontinued once IV access is obtained and the airway is secured with an endotracheal tube. Patients will receive remifentanil loading dose of 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min) and dexmedetomidine load at 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr) A caudal block with 0.2% ropivacaine will be performed in all patients for intraoperative and postoperative pain control.
89078501|NCT02801695|Experimental|L-Citrulline|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
89078502|NCT02801695|Placebo Comparator|Lactose|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
89078503|NCT02856100||Patients with CRPC, evidence of metastases, planned treatment|
89078504|NCT02801539|Experimental|Respiratory muscle training (RMT)|Subjects in the experimental arm will be given an inspiratory and expiratory RMT device to use during Duke-based and home-based RMT therapy.
89078505|NCT02801539|Sham Comparator|Sham-RMT|Subjects in control arm will be given an inspiratory and expiratory sham-device and will complete Duke-based and home-based sham-RMT therapy.
89078506|NCT04272970|Active Comparator|New gene / protein variant functional study|Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional familial thrombocytopenia.
89078507|NCT04272970|Sham Comparator|Normal gene / protein variant functional study|"Morphological and functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to provide control observations / analyses / measures for the Active Comparator arm"
89078508|NCT02801383|Active Comparator|Treatment group|received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment
89078509|NCT02801383|Placebo Comparator|controlled group|received 1g gel (without biological active ingredient) every other day for consecutive 6-10 courses of treatment
89078510|NCT02856022|Experimental|Electrical ilioinguinal nerve stimulation|
89078511|NCT02856022|Active Comparator|Intravesical Irrigation|
89078512|NCT02801305|Placebo Comparator|Vaseline|About 60 patients will be considered to be in control group receiving vaseline ointment as the placebo applying 2 times daily on their ulcers for 8 weeks.
89078513|NCT02801305|Experimental|Diltiazem Gel 2%|About 30 patients will receive Diltiazem Gel 2% applying 2 times daily for 8 weeks on their digital ulcers.
89078514|NCT02801305|Experimental|Nitroglycerin Ointment 2%|About 30 patients will receive nitroglycerin 2% applying 2 times daily for 8 weeks on their digital ulcers.
89078515|NCT02795845|Experimental|Primary prevention- probiotic capsules|"patients with normal vaginal flora in the experimental arm will be treated with Probiotic capsules (containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus, Bifidobacterium bifidum and B. Lactis).~one capsule twice a day until delivery."
89078516|NCT02795845|Placebo Comparator|Primary prevention - Placebo|patients with normal vaginal flora in the placebo arm will be treated with a capsule without active ingredient, one capsule twice a day until delivery.
89078517|NCT02795845|Experimental|Secondary prevention - probiotic capsules|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given probiotic capsules.
89078518|NCT02795845|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given placebo without active ingredient.
89078519|NCT00637975|Experimental|A|oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops
89078520|NCT00637975|Active Comparator|B|pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops
89078521|NCT02799433|Active Comparator|Usual Services|This group of child care centers receives standard services from the San Francisco Department of Public Health Child Care Health Program. CCHP offers services to child care centers annually. The standard services include nurse consultation, health education, monitoring of nutrition and physical activity resource need, vision, hearing, oral health, and height and weight screenings.
89078522|NCT02799433|Experimental|Usual services + HAP|This group of child care centers receives all the standard services plus invitation to participate in the voluntary Healthy Apple Program (HAP). The Healthy Apple program involves child care provider self-assessment, followed by an iterative process of goal setting, technical assistance/training, and re-assessment.
89078523|NCT02801149|No Intervention|No further imaging|Patients randomised to this group will receive standard care, i.e. will not undergo additional imaging scans at A&E/Urgent Care Centre.
89078524|NCT02801149|Experimental|Wrist Magnetic Resonance Imaging (MRI)|Patients randomised to this group will undergo an additional 3-sequence wrist MRI during the initial A&E/Urgent Care Centre episode.
89078525|NCT02801227|Experimental|Oxytocin|
89078526|NCT02801227|Experimental|Prostaglandin E2|
89078527|NCT02795611|Experimental|Treatment group|Patients who receive 'family-centered occupational therapy' in our hospital
89078528|NCT02795611|Active Comparator|Control group 1|Patients who receive regular occupational therapy in our hospital
89078529|NCT02795611|Other|Control group 2|Patients who don't receive intervention in our hospital
89078530|NCT02799121|Experimental|ReGenerCell™|Debridement and/or a sterile saline rinse of ulcer, as clinically indicated, followed by ReGenerCell™ treatment and appropriate dressing and off-loading
89078531|NCT02795455|Experimental|Interoceptive Exposure (IE)|IE is an exposure-based intervention that involves consuming a food in session and tolerating uncomfortable feelings around eating.
89078532|NCT02795455|Active Comparator|Family Based Therapy-Weight Gain Control (FBT-WG)|Family-based therapy uses parent(s) to help modify disordered eating and develop contingencies to motivate eating.
89078533|NCT02795455|No Intervention|Healthy Controls (HC)|HC participants will only participate in the pre and post-intervention visits and not in the intervention sessions.
89078534|NCT02795299|Active Comparator|Gerilimzumab 5/2 mg/Methotrexate/folate|• 5 mg gerilimzumab loading dose followed by 2 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
89078535|NCT02795299|Active Comparator|Gerilimzumab 10/5mg/Methotrexate/folate|• 10 mg gerilimzumab loading dose followed by 5 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
89078536|NCT02795299|Active Comparator|Gerilimzumab 20/10mg/Methotrexate/folate|• 20 mg gerilimzumab loading dose followed by 10 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
89078537|NCT02795299|Placebo Comparator|Placebo/Methotrexate/folate|• Placebo every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
89078538|NCT03930277||Pregnant women in labor.|Pregnant women in labor during the 2nd stage of labor.
89078539|NCT02799043|Active Comparator|Standard PVI|Standard catheter ablation including pulmonary vein isolation (PVI) procedure.
89078540|NCT02799043|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by PVI.
89078541|NCT02801071|Experimental|L-citrulline|15 g L-citrulline p.o. per day (3x 5g) for 24 weeks
89078542|NCT02801071|Placebo Comparator|Placebo|L-citrulline Placebo 3 times daily p.o. for 24 weeks
89078543|NCT02790619|Active Comparator|Meditation and Active Stimulation 1|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 1 milliamp(mA) stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
89078544|NCT02790619|Active Comparator|Meditation and Active Stimulation 2|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 2 mA stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
89078545|NCT02790619|Sham Comparator|Meditation and Sham Stimulation|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.The participants in the sham study will receive Sham tDCS (no stimulation) with Anode over F8 and cathode over left supraorbital area with intervention administration delivered by Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor
89078546|NCT04233931|Experimental|participant|all participants in the study receive the mobile app.
89078547|NCT02795377||male subjects with arterial hypertension|Measurements will be taken at baseline.
89078548|NCT02795377||male subjects without arterial hypertension and no CAD|Measurements will be taken at baseline.
89078549|NCT02795377||male subjects with hypertensive crises|Measurements will be taken before and after 4 hours and normalization of arterial blood pressure by urapidil.
89078550|NCT02795377||male subjects with stable CAD|Measurements will be taken before and after transfemoral coronary diagnostic angiography.
89078551|NCT03981757|Experimental|NeurOS Group|Apply the single use NeurOS cerebral oximetry sensor adhesive onto patients' head who are going to have CEA surgery in the operating room before anesthesia induction.
89078552|NCT02799277|Experimental|Testosterone|14mg testosterone will be administered intranasally in a 1milliliter aqueous solution
89078553|NCT02799277|Placebo Comparator|Placebo|1ml blank (containing no drug) aqueous solution will be administered intranasally
89078554|NCT04235179|Experimental|SABR|Pelvic SABR for post-op endometrial cancer
89078555|NCT02794831||patient|Adult patient hospitalized in MCO in one of the study centers for severe community bacterial infection, infected with more than one site, and / or abscess collection, and / or a per-cutaneous drainage of the infection, and / or septic surgery.
89078556|NCT02794831||control|Patient hospitalized in the same center (different service or not), during the week or months of the inclusion of cases for infection without abscess or invasive procedure, only one infected site
89078557|NCT01198002|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 100 weeks. Participants receive a 240 mg loading dose when initiating treatment. During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Weeks 16 and 52, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
89078558|NCT01198002|Experimental|90 mg LY2127399|"Given Q2W for 100 weeks. Participants receive a 180 mg loading dose when initiating treatment.~At Weeks 16 and 52, responders will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
89078559|NCT01198002|Placebo Comparator|Placebo|"Given Q2W for 52 weeks. At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 52 weeks.~At Week 52, responders are randomized to receive 1 of the 2 doses of LY2127399, with loading dose of 240 mg or 180 mg of LY2127399, followed by 120 mg of LY2127399 Q4W or 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.~At Week 16, NR will receive a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
89078560|NCT02790307|Experimental|Daily stimulation (30mins/day)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
89078561|NCT02790307|Experimental|Weekly stimulation (30mins/week)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
89078562|NCT02790151|Active Comparator|Standard Therapy|Learning and practicing memory strategies
89078563|NCT02790151|Experimental|Experimental Intervention|Computerbased working memory training and Recollection training
89078564|NCT02794909|Experimental|CPUS group|The group of patients in the CPUS group will be those who receive a cardiopulmonary ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has received specific training in the CPUS protocol.
89078565|NCT02794909|No Intervention|Control group|The group of patients in the control group will be those who do not receive an ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has not received specific training in the CPUS protocol.
89078566|NCT02798887|Experimental|Ridge preservation membrane|Positive control Patients will receive ridge preservation intrasocket allograft and overlay xenograft resorbable with membrane
89078567|NCT02798887|Experimental|Ridge preservation no membrane|test patients will receive ridge preservation intrasocket allograft and overlay xenograft with no membrane
89078568|NCT02795065|Active Comparator|Enoxaparin 40 mg subcutaneous once daily|
89078569|NCT02795065|Experimental|Bemiparin 3500 IU subcutaneous once daily|
89078570|NCT02794987||Classification group|Group of endoscopists that will use the previous classification to select the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes
89078571|NCT02794987||No classification group|Group of endoscopists that will classified the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes without using the classification.
89078572|NCT02789995|Experimental|Patients with and without sepsis|"Patients with sepsis, Patients with inflammatory disease without sepsis, Patients without inflammatory disease without sepsis.~Human biological samples collected for research :~Blood sample~Muscle biopsy~Bone marrow sample (mesenchymal stem cells)"
89078573|NCT02790229|Experimental|anti-gravity treadmill arm|Treatment with anti-gravity treadmill (alter G®)
89078574|NCT02790229|Other|control arm|Treatment with standardized physiotherapy
89078575|NCT02798965|Other|Control|patients with goiter or nodule
89078576|NCT02798965|Experimental|Graves' disease|patients with Graves' disease
89078577|NCT02798809||GeOrGS cohort|Clinical dental examination of all Children born in 2008 and 2009 in Chivari District (Italy)
89078578|NCT04233697|Experimental|Copanlisib and Romidepsin|"Copanlisib and romidepsin will be both administered via IV (through a vein in arm) on days 1, 8, and 15 every 28 days, also called a cycle."
88820859|NCT05559892|Experimental|Diabetes-Tailored CCTs (DM-CCT) Intervention|Participants randomized to DM-CCT will receive cash transfers of $500 per month for 6 months, but the cash transfers will be conditional on attending a 60-minute diabetes education/skills training (30 minutes) and stress/coping (30 minutes) session delivered by trained nurses every 2 weeks for 6 months (12 sessions). Therefore, they will only receive cash transfer payments if they attend two sessions per month.
89078579|NCT04234009|Experimental|Healthy lifestyle|Healthy lifestyle intervention, which includes physical activity and dietary advice according to the dutch guidelines.
89078580|NCT04234009|No Intervention|Control|Maintenance of habitual physical activity and diet
89078581|NCT02857036|Experimental|responder|responder to antidepressant treatment
89078582|NCT02857036|Experimental|non responder|non responder to antidepressant treatment
89078583|NCT04234087|No Intervention|Control group|The supervised exercise program included: continues endurance training on cycle ergometers (6 sessions a week). Every session included warm up (<50% target intensity 2 min, gradually increasing load 1-10 w/min up to target intensity within 5 - 10 min); exercise phase (100% of the target intensity (30-50% watts or 30-50% HRmax), starting with >5 minutes and gradually prolonged up to 30 min); cool down with gradual reduction of the load within 3 minutes); additional aerobic exercises performed sitting and/or standing (30 minutes, 5 days/week); respiratory muscle training (7 days/week, for 15 minutes) using ball trainer.
89078584|NCT04234087|Other|Intervention group|Exercise program as for a control group together with additional resistance and balance training 3 sessions/week. The resistance training was started with low intensity (<30% 1-RM, RPE ≤ 11, 5-10 repetitions), increased gradually to moderate intensity (30-50% and up to 60% 1-RM, RPE 12-13, after 8-15 repetitions) with 3 sets and 3 minute rest between sets, if tolerated. The balance training included exercises to improve static as well as dynamic balance ability. It was performed on 2-3 days/week for 10-15 minutes. The complexity of the balance exercises was selected and incremented individually by changing the stand-position, the base on which the stands were performed and/or using unstable surfaces. If tolerated, the visual information was varied and/or additional tasks performed while balancing. After completion participants were encouraged to continue exercise training at home according to recommendations.
89078585|NCT02794753|Experimental|True intervention|Working memory training on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
89078586|NCT02794753|Active Comparator|Active control|Similar time spent playing on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
89078587|NCT02794519|Experimental|Sirukumab 50 mg/mL administered subcutaneously every 4 weeks|Subjects will receive sirukumab 50 milligram/milliliter (mg/mL) subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Sirukumab will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
89230080|NCT03953521|Experimental|navigated|Positioning of the coil according to neuronavigation (Mylius et al., 2013, Definition of DLPFC and M1 according to anatomical landmarks for navigated brain stimulation: Inter-rater reliability, accuracy, and influence of gender and Age, NeuroImage 78, 224-232).
89078588|NCT02794519|Placebo Comparator|Placebo administered subcutaneously every 4 weeks|Subjects will receive placebo subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Placebo will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
89078589|NCT05463523||Digital camera|A Real-time Augmented Reality Device with Artificial Intelligence Integration, acquisition of patient skin lesion images as data
89078590|NCT03826303|Experimental|E-cigarette with ethanol, 1 puff|
89078591|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 1 puff|
89078592|NCT03826303|Experimental|E-cigarette with ethanol, 10 puffs|
89078593|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 10 puffs|
89078594|NCT02794675|Experimental|Cesium 131 brachytherapy|Cesium 131 is the radioactive isotope in the protocol. The prescribed dose will range from 50-80 Gy at maximal delivery. It comes in 0.5 cm seeds that will be placed in the tumor resection bed at 1cm intervals. They are implantable seeds that do not require removal.
89078595|NCT02798653|Experimental|Choriomon®|subjects receive 1,500 IU of hCG (Choriomon®; IBSA) intramuscular (IM) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
89078596|NCT02798653|Experimental|Choriomon®+Endometrin ®|patients will receive 1,500 IU of hCG (Choriomon®; IBSA) (IM) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
89078597|NCT02798653|Experimental|Endometrin ®|patients will receive only Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
89078598|NCT02794363|Other|Autologous platelet rich plasma|Autologous platelet rich plasma injection into vulvar skin. There are no placebo, sham, or active comparator arms
89078599|NCT04234789|Other|Cardiopulmonary exercising test|All patients underwent to diagnostic tests protocol
89078600|NCT02794051|Experimental|Unified Protocol for Children|Child participants with behavior problems between the ages of 8-12 and their caregivers will participate in a transdiagnostic group therapy protocol.
89078601|NCT02789683|Experimental|Fine emulsion|Emulsion with small lipid droplet size served together with white bread
89078602|NCT02789683|Experimental|Coarse emulsion|Emulsion with large lipid droplet size served together with white bread
89078603|NCT02789683|Experimental|Control|Non-emulsified oil and water served together with white bread
89078604|NCT02789761|Active Comparator|High-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days)
89078605|NCT02789761|Placebo Comparator|Low-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately <1 mg of (-)-epicatechin for 2-weeks (14 days)
89078606|NCT02798497|Other|staphylococcus aureus PVL-|patients with staphylococcus aureus PVL-
89078607|NCT02798497|Other|staphylococcus aureus PVL+|patients with staphylococcus aureus PVL+
89078608|NCT02789917|Experimental|Dual therapy (incl. NOAC)|Apixaban plus Clopidogrel
89078609|NCT02789917|Active Comparator|Triple therapy (incl. VKA)|Phrenprocoumon plus Clopidogrel plus ASA
89078610|NCT03863587|Experimental|HLX12 group|HLX12 are given intravenous infusion 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
89230081|NCT03953521|Active Comparator|F3|Positioning of the coil according to EEG (electroencephalography) electrode Position F3 (marking this Position on a head cap).
89078611|NCT03863587|Active Comparator|Cyramza (Ramucirumab) group|Ramucirumab are given intravenous infusion of Cyramza 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
89078612|NCT02789605|Experimental|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months
89078613|NCT02789605|Placebo Comparator|Placebo|Patient receiving placebo, orally taken, 4 times a day, during 3 months
89224560|NCT06265103||Partners - MGH/BWH|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
89230082|NCT00787709|Experimental|1|Receives Pathways universal school-based health promotion curriculum from 4th-6th grade
89078614|NCT02789839|Experimental|Healthy volunteer|Blood test Medullar test
89078615|NCT04233463|Active Comparator|Modulen Diet|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
89224561|NCT06265103||Penn State Hershey|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
89224562|NCT06265103||University of Cincinnati Gardner Neuroscience Institute|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
89224563|NCT06265103||University of Southern California (USC)/(CHLA)|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
89230083|NCT00787709|No Intervention|2|Control group of students who do not receive the intervention
89078616|NCT04233463|Active Comparator|Budesonide Treatment|Crohn patients will be given Budesonide treatment
89078617|NCT02794129|Experimental|Bipolar Disorder patients|
89078618|NCT02794129|Experimental|Healthy Controls|
89078619|NCT02793973|Active Comparator|80% discrepancy lift height correction|Each participant will be given 80% discrepancy shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
89078620|NCT02793973|Experimental|optimal lift height correction|Each participant will be given the optimal shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
89078621|NCT02793895|Experimental|Enhanced cardiac rhythm monitoring|Subjects in this group will receive up to 30 days of continuous cardiac rhythm monitoring with an adhesive monitor. Cardiac rhythm monitoring will begin on the day of randomization. The device that will be used is the Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
89078622|NCT02793895|Active Comparator|Usual care|Subjects randomized to the usual care arm will be discharged from hospital without protocol-mandated continuous cardiac rhythm monitoring. Within the first 30 days after randomization, no protocol-mandated cardiac rhythm assessment will be arranged. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
89078623|NCT04234711||Conventional surgical group|Patients with total pulmonary venous connection undergo conventional surgical repair
89078624|NCT04234711||Sutureless surgical group|Patients with total pulmonary venous connection undergo sutureless surgical repair
89078625|NCT02793427|Experimental|Type 1 diabetes|
89078626|NCT02793427|Experimental|control|
89078627|NCT02793739|Experimental|20 subjects|20 subjects will be enrolled to take part in this study and followed for a period of 12 months. Subjects will receive hyaluronic acid filler injection in the dorsal fingers (2-4 syringes) at the initial visit for volume restoration. If warranted, subjects will receive touch-up of hyaluronic acid at day 14 (1-2 syringes). The investigators expect volume restoration to last 9-12 months.
89078628|NCT02793661|Experimental|RenalGuard Arm|In order to prevent patients from acute kidney injury, patients will receive the RenalGuard Therapy delivered by the RenalGuard system from one hour before the cardiovascular intervention to 4 hours after the intervention.
89078629|NCT02793661|Active Comparator|Control Arm|Patient will received standard treatment, as per ESC Guidelines 2014, to prevent from acute kidney injury.
89078630|NCT03874039||Healthy Adults|Healthy adults with no prior diagnosis of atopic dermatitis
89078631|NCT03874039||Atopic Dermatitis|Adults with prior diagnosis of Atopic Dermatitis from board certified dermatologist
89078632|NCT02798419|Experimental|DFD05 Cream|DFD05 Cream
89078633|NCT02798419|Active Comparator|Active01 Cream|Active01 Cream
89078634|NCT02793505||Pregnant patient exposed to metformin|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to metformin (Anatomical Therapeutic Chemical A10BA02) any time during pregnancy (i. e. any time from conception to week 42 after last menstrual period (LMP)).
89078635|NCT02793505||Reference group|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to any drug not known as a major teratogen or fetotoxicant and different than metformin, insulin or any other hypoglycaemic agent.
89078636|NCT02789371|Other|Arm A|the first pass is made with 5ml suction technique
89078637|NCT02789371|Other|Arm B|the first pass is made with modified wet suction technique
89078638|NCT02789293|Experimental|Focused Ultrasound treatment|Ultrasound ciliary pasty (UCP) using focused ultrasound
89230084|NCT02555345||classic asthma/No intervention|Patients with classic asthma were stable.Chest X-ray or CT scan was normal.Fenofibrate(FeNO) was performed.Spirometry was needed. The leicester cough questionnaire (LCQ) was offered to physicians.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
89078639|NCT02797873|Experimental|EIP|"Patients from the DBT unit suffering from symptoms of Emotional Instability (n=30), with different levels of ADHD symptoms as assessed by questionnaires Brown-ADD, ASRS and SDQ.~Interventions:~fMRI - Stroop task~fMRI - MID task~Stop Signal task~Structural T1 MRI scan~Structural T2 MRI scan~DTI MRI scan~Resting state MRI scan~FEFA 2~SCID-II~SDQ~ASRS~AQ~TAS-20~Raven's SPM~Reading ability~Ishihara's tests for colour deficiency~Additional questionnaire~Brown-ADD~MFQ~STAI-T~BIS~DAWBA~STAI-S~Sleepiness rating x 6~Motivation rating x 6"
89078640|NCT02797873|Experimental|Healthy controls|"Matched healthy controls (according to age, IQ and socio economic status) recruited from high schools in Stockholm area (n=30).~Interventions:~fMRI - Stroop task~fMRI - MID task~Stop Signal task~Structural T1 MRI scan~Structural T2 MRI scan~DTI MRI scan~Resting state MRI scan~FEFA 2~SCID-II~SDQ~ASRS~AQ~TAS-20~Raven's SPM~Reading ability~Ishihara's tests for colour deficiency~Additional questionnaire~Brown-ADD~MFQ~STAI-T~BIS~DAWBA~STAI-S~Sleepiness rating x 6~Motivation rating x 6"
89078641|NCT02793193|Experimental|Active (rifaximin/B.longum 1714)|
89078642|NCT02793193|Experimental|Placebo|
89078643|NCT02793271|Active Comparator|PRIME|The behavioral intervention will be the PRIME/mhGAP training. This is standard mental health training for prescribers (primary care workers who can prescribe psychotropic medication, e.g., health assistants) and non-prescribers (primary care workers who cannot prescribe medications, e.g., auxilliary nurse midwives). For prescribers, training includes introduction to psychosocial techniques and mhGAP. For non-prescribers, training includes psychosocial techniques.
89078644|NCT02793271|Experimental|PRIME+RESHAPE|The behavioral intervention will be the PRIME/mhGAP training plus the RESHAPE training adjunct. This is the PRIME training plus social contact component in which mental health service users participate as training co-facilitators. The intended goal of the additional component is to reduce stigma against persons with mental illness.
89078645|NCT02793349|Experimental|Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
89078646|NCT01197534|Experimental|Dosing Regimen A|Oral Treatment
89078647|NCT01197534|Experimental|Dosing Regimen B|Oral Treatment
89078648|NCT01197534|Placebo Comparator|Dosing Regimen C|Oral Treatment
89078649|NCT04234321|Experimental|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
89078650|NCT04234321|Experimental|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
89078651|NCT04234321|Placebo Comparator|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
89078652|NCT02793115|Experimental|Arm 1|Disclosure Letter-RISKS
89078653|NCT02793115|Experimental|Arm 2|Disclosure Letter-BENEFITS
89078654|NCT02793115|Experimental|Arm 3|Disclosure Letter-RISKS AND BENEFITS
89078655|NCT02793115|Experimental|Arm 4|Disclosure Letter-NO RISKS OR BENEFITS
89078656|NCT02793115|Placebo Comparator|Arm 5|Letter-APPOINTMENT REMINDER
89078657|NCT03832933|Experimental|High Protein Diet|
89078658|NCT03832933|Active Comparator|Standard Protein Diet|
89078659|NCT02797717|Other|"A-COPDAC-28"|"standard COPDAC-28 (chemotherapy cycle:Cyclophosphamide,Doxorubicin,Prednisone,Dacarbazine), chemotherapy and standard involved node radiotherapy.~drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15. Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3. Vincristine 15mg/m2 , I.V. , day1+day 8. Cyclophosphamide 500mg/m2,infusion,day 1+day 8."
89078660|NCT02797717|Experimental|"B- DECOPDAC-21"|"DECOPDAC-21(chemotherapy cycle:Dacarbazine,Etoposide,Doxorubicin,Cyclophosphamide,Prednisone,Vincristine) intensified chemotherapy and no RT or restricted fields of radiotherapy.~Drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15:~Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3 Vincristine 15mg/m2 , I.V. , day1+day 8 Cyclophosphamide 625mg/m2,infusion,day1+day2 Etoposide 100mg/m2/day,infusion,day 1- day 3 Doxorubicin 25mg/m2, infusion, day 1"
89078661|NCT02793037|Experimental|A proof of concept of using zirconia bonded bridge|
89078662|NCT04235569|Experimental|Group I|"a group of 25 patients received 5mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period."
89078663|NCT04235569|Experimental|Group II|"a group of 25 patients received 3mg Marevan ® tablets as initiation warfarin dose in combination of enoxaparin (Clexane® ) as a bridging agent.INR was monitored daily and dose adjustments were done to reach therapeutic INR range (2-3) at which the Enoxaparen was discontinued.Follow up was continued till first INR reading in therapeutic range.~Bleeding events due to overanticoagulation were monitored through the follow up period."
89078664|NCT02789449||precapillary|patients with PH and PAWP<12mmHg
89078665|NCT02789449||postcapillary|patients with PH and PAWP>18mmHg
89078666|NCT01197378|Experimental|Cysteamine Bitartrate|Cysteamine bitartrate delayed-release capsules were administered twice daily for up to 96 months.
89078667|NCT02797639|Experimental|Co-PID|Eight collaborative consultation meetings between occupational therapist to each teacher in purpose of enhancing participation of students in class
89078668|NCT02797639|Active Comparator|In-service|Three in- service meetings to all homeroom teachers together, in purpose of enhancing participation of students in class
89078669|NCT02789527|Experimental|Healthy volunteers in Ethiopia|Phenotype and genotype of enzymes involved in drug metabolism in Ethiopia population
89078670|NCT02789527|Experimental|Healthy volunteers in Oman|Phenotype and genotype of enzymes involved in drug metabolism in Oman population
89078671|NCT02789527|Experimental|Healthy volunteers in the Czech Republic|Phenotype and genotype of enzymes involved in drug metabolism in Czech Republic population
89078672|NCT02789527|Experimental|Healthy volunteers in Greece|Phenotype and genotype of enzymes involved in drug metabolism in Greek population
89078673|NCT04233307|Other|Wound photographs|Telethermographic photographs of fracture wound and contralateral limb before and after propofol infusion.
89078674|NCT02789215|Experimental|Intervention|Receive new CACFP menu pattern
89078675|NCT02789215|No Intervention|Control|Follow existing CACFP menu pattern
89078676|NCT02792647|Placebo Comparator|Placebo|Placebo
89078677|NCT02792647|Experimental|Experimental: IX-01|2 different dose groups 1,600 mg and 2,400 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
89230085|NCT02555345||CVA/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered to physicians. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
89078678|NCT02792491|Experimental|Reduced dose R-CHOP|"Reduced dose R-CHOP is regimen including Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.~In this study, Rituximab 375 mg/m2, Cyclophosphamide 600 mg/m2, Doxorubicin 30 mg/m2 and Vincristine fixed dose of 1mg will be administrated through intravenous on day 1. and Prednisone 40mg will be administrated orally on day 1-5. This chemotherapy will be repeated every 21 days."
89078679|NCT02792803|Experimental|Xalatan --> Apo-/Co-Latanoprost|Patients in this arm will be prescribed Xalatan for the first four week period of the study and one of the generics, Apo- or Co-Latanoprost, for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
89078680|NCT02792803|Experimental|Apo-/Co-Latanoprost --> Xalatan|Patients in this arm will be prescribed one of the generics, Apo- or Co-Latanoprost, for the first four week period of the study and Xalatan for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
89078681|NCT02792569|Experimental|Biopsy at Right side|Biopsy of ovarian cortical tissue (50% right side)
89078682|NCT02792569|Experimental|Biopsy at Left side|Biopsy of ovarian cortical tissue (50% left side)
89230086|NCT02555345||EB/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
89078683|NCT02797795|Experimental|NEV801|"Part A - Dose escalation and de-escalation for the determination of the Maximum tolerated dose. All subjects will receive NEV801 intravenously on days 1, 8, 15 and 22 during each 28-day cycle.~Part B - Subjects will receive NEV801 at or below the highest tolerable dose from Part A."
89078684|NCT02789059|Experimental|muscle oxygenation|assesment of muscle oxygenation and gas exchanges
89078685|NCT02797249|Experimental|aspirin|Low dose aspirin (100 mg) starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy, taking at night.
89078686|NCT02797249|Other|blank|Routine examination during pregnancy.
89078687|NCT02792335||patients naive to oral anticoagulant treatment|NVAF patients naïve to oral anticoagulant treatment (Naïve)
89078688|NCT02792335||patients with prior warfarin therapy|NVAF patients with prior warfarin therapy (Warfarin treated)
89078689|NCT02792023|Other|Colonoscopy followed by upper endoscopy|In case of a positive immunochemical fecal occult blood test result, colonoscopy will be the first examination
89078690|NCT02792023|Other|Upper endoscopy followed by colonoscopy|In case of a negative immunochemical fecal occult blood test result, upper endoscopy will be the first examination
89078691|NCT02792179|Experimental|[18F]RO6958948|Each participant will receive a single intravenous (IV) dose of [18F]RO6958948 and a single PET scan approximately 9-24 months after the baseline scan (in Study BP29409).
89078692|NCT01197300|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
89078693|NCT02797405|Other|Standard treatment|The patients will receive standard treatment according to international recommendations depending on their type of cancer.
89078694|NCT02791867|Active Comparator|Active|AphoelineBrake administration
89078695|NCT02791867|Placebo Comparator|Placebo|Placebo Administration
89078696|NCT04234243||HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis treated with cytoreduction and HIPEC
89078697|NCT04234243||No HIPEC|women, with ovarian cancer stage III-IV or recurrent with carcinomatosis, treated with systemic chemotherapy only
89078698|NCT04200235|Experimental|High weight group|High weight group
89078699|NCT04200235|Experimental|Low weight group|Low weight group
89078700|NCT02791789|Other|Autism Spectrum Disorder|clinical exam, speech and language therapy and neuropsychological evaluations, Training to the SEMATIC serious game
89078701|NCT02791711|Other|High Flow Nasal Cannula|Use of High Flow Nasal Cannula
89078702|NCT02791555||Pradaxa|20 men and 20 women on Pradaxa for non valvular atrial fibrillation
89078703|NCT02791555||Warfarin|20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort
89078704|NCT02791243|Experimental|Finasteride 0.25%|approximately 0.2 ml of P-3074 (0.25% finasteride)
89078705|NCT02791243|Placebo Comparator|Placebo for Finasteride 0.25%|approximately 0.2 ml of the vehicle cutaneous solution
89078706|NCT02791243|Other|Negative Control|approximately 0.2 ml of 0.9% aqueous NaCl
89078707|NCT02791477|Other|Attune FB PS|Attune FB PS knee arthroplasty
89078708|NCT04234165|Active Comparator|Monopolar arm|monopolar cautery was used for TURBT
89078709|NCT04234165|Experimental|Bipolar Arm|bipolar cautery was used for TURBT
89078710|NCT05393635|Experimental|Cohort 1|Participants with cervical cancer whose disease has progressed during or after treatment with platinum-based chemotherapy. Participants with combined positive score ≥ 1 should also have disease that has progressed during or after treatment with CPI.
89078711|NCT05393635|Experimental|Cohort 2|Participants with head and neck squamous-cell carcinoma (HNSCC) whose disease has progressed during or after platinum-based chemotherapy and previous CPI.
89078712|NCT05393635|Experimental|Cohort 3|Participants with non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy and a CPI. Participants with targetable mutations (e.g. EGFR/ALK) are required to have disease which has progressed on targeted therapy and platinum-based chemotherapy.
89078713|NCT02797483|Experimental|Test Fat Blue|16 weeks interventions
89078714|NCT02797483|Experimental|Test Fat Green|16 weeks interventions
89078715|NCT02797483|Experimental|Test Fat Red|16 weeks interventions
89078716|NCT02791087||Coronary Artery Disease for CABG|Patients undergoing or underwent Coronary Bypass Surgery with at least one saphenous vein graft. Intra-operative graft flow rate measurement will be done during CABG surgery.
89078717|NCT02791087||Stable/Unstable Angina|Patients with no known history of coronary artery disease undergoing Computed Tomography Angiography scan due to stable/Unstable Angina.
89078718|NCT02797015|Experimental|1 mg RPC1063|1 mg RPC1063 oral capsule daily
89078719|NCT02797015|Experimental|0.5 mg RPC1063|0.5 mg RPC1063 oral capsule daily
89078720|NCT02791009||Diagnosed Heart Failure [Prior]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
89078721|NCT02791009||Control [Prior]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
89078722|NCT02791009||Control [New]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
89078723|NCT02791009||Diagnosed Heart Failure [New]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection, Cognitive Test and Clinical Assessment.
89078724|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 1|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 1
89078725|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 2|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 2
89078726|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 3|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 3
89078727|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 4|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 4
89078728|NCT04010695|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor point-of-care G6PD test and the point-of-care HemoCue Hb test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
89078729|NCT02790931|Experimental|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months.
89078730|NCT02790931|No Intervention|Control Group|Patients will not receive any exercise treatment, will not have acess to the software, but they will keep their recommended clinical treatment.
89078731|NCT02790697||Mechanically ventilated ICU patient|Indirect calorimetry measurements will be conducted using the new calorimeter and the mass spectrometer system at the same time for all enrolled patients.
89078732|NCT02790385|Experimental|NPWT|subjects will undergo negative pressure wound therapy
89078733|NCT02790385|Active Comparator|Standard Gauze|standard method of using gauze and dressing will be utilized
89078734|NCT02788435|No Intervention|Control|Patients in the control arm will undergo a graduated prescription of voice use immediately following surgery.
89078735|NCT02788435|Experimental|Absolute Voice Rest|Patients in the experimental arm will undergo 7 days of absolute voice rest following surgery.
89078736|NCT04233151|Experimental|mFOLFOX6 + QL1203|Participants receive QL1203, 6mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity
89078737|NCT04233151|Active Comparator|mFOLFOX6 + Placebo|Participants received Placebo，6 mg/kg on Day 1 and mFOLFOX6 chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
88820860|NCT05559892|Active Comparator|Unconditional Cash Transfer-UCTs Intervention|Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
89224564|NCT06265103||UT Southwestern Children's Dallas|Centers participating in ELHS will work towards accomplishing the improved process and clinical outcomes by implementing changes via Quality Improvement methodology in the context of a Chronic Care model. Specifically, programs will introduce common data elements and standardized epilepsy care metrics followed by rapid cycle feedback via site specific and overall network outcomes. Interventions will then be introduced based upon evidence-based recommendations to improve outcomes. Network-based changes to practice such as those suggested have never been realized in the domain of epilepsy to date.
88820861|NCT05551169||Patients with stable COPD in Stage1|no intervention
88820862|NCT05551169||Patients with stable COPD in Stage2|no intervention
88820863|NCT05551169||Non-COPD subjects in Stage2|no intervention
89230087|NCT02555345||Healthy/No intervention|Chest X-ray or CT scan was normal.FeNO was performed.Spirometry was needed. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
89078738|NCT04233541||Fallers|Participants who reported one or more falls within the 12 months preceding the study consist the group of ''fallers''.
89078739|NCT04233541||Non-fallers|Participants with no fall history consist the group of ''non-fallers''
89078740|NCT02796703|Placebo Comparator|Control Group|Dietary Supplement: Placebo 2 cc/day of placebo diluted in mother's milk (when available) or premature formula.
89078741|NCT02796703|Active Comparator|Treatment Group|"Dietary Supplement: Heat Inactivated Probiotics~1 tsp heat inactivated Biotikid powder will be diluted in 2 cc of mother's milk (when available) or premature formula."
89078742|NCT02796547|Experimental|Levobupivacaine|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with Levobupivacaine. This is the only intervention specific to the study, as compared to the standard of care.
89078743|NCT02796547|Placebo Comparator|Placebo|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with physiological serum.This is the only intervention specific to the study, as compared to the standard of care.
89078744|NCT01196988|Experimental|GSK2321138A 1 Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
89078745|NCT01196988|Active Comparator|Fluarix Group|Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
89078746|NCT01196988|Active Comparator|GSK2604409A Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
89078747|NCT01196988|Experimental|GSK2321138A 2 Group|Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
89078748|NCT02790541|Experimental|Treatment|Hyperbaric Oxygen Therapy: 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
89078749|NCT02790541|Other|Control/Crossover|Hyperbaric Oxygen Therapy: 3 months control period (no treatment) followed by 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
89078750|NCT02796469||Pentoxifylline + Corticosteroid|Association of treatment by pentoxifylline and corticosterone during 28 days
89078751|NCT02796469||Corticosteroid|treatment by corticosteroid during 28 days
89078752|NCT02796469||Pentoxifylline|treatment by pentoxifylline during 28 days
89078753|NCT02796469||Placebo|
89078754|NCT02796157|Active Comparator|absorb arm|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold
89078755|NCT02796157|Experimental|Xience arm|PCI with Xience everolimus-eluting metallic stent
89078756|NCT03328741|Experimental|Joint Academy|Online osteoarthritis treatment
89078757|NCT03328741|Active Comparator|The BOA program|Face-to-face osteoarthritis treatment
89230088|NCT02554955|Experimental|Daclizumab + Mycophenolate mofetil|Participants will receive intravenous (IV) daclizumab (2 milligrams per kilogram [mg/kg] within 6 hours after transplantation and 1 mg/kg every 2 weeks for a total of five doses), along with mycophenolate mofetil (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg twice daily [BID] within first week and 1 grams per day [g/day] BID from second week onwards) and sirolimus (3 mg/day) for 6 months.
89230089|NCT00062647|Experimental|Telavancin|
89078758|NCT02786797|Experimental|MBSR(BC) 6 Week Program|Participants who are randomized to MBSR(BC) program will receive of educational material; group practice of mindfulness meditation (MM) and homework assignments; and group processes related to the practice of MM and supportive group interaction. Participants who receive MBSR will receive training in (1) sitting meditation anchored to the breath; (2) body scan (observing body sensations from the toes to the head); (3) Gentle Yoga (postures and stretches that increase awareness and balance; and (4) walking meditation. Through this arm of the study the goal is to enhance executive cognition through training in self-regulation of attention and acceptance of experience.
89078759|NCT02786797|Active Comparator|BCES Education Support Program|Participants who are randomized to the BCES program will be scheduled for 6 weekly, 2-hour sessions. BCES compared to MBSR(BC) meets the following criteria: (1) professional contact and group support time matched equally to the MBSR(BC) program; and (2) the content or activities of the BCES program does not include meditation or attention, relaxation, yoga, body scan, or walking meditation. This program is as an active control condition that accounts for nonspecific effects related to attention from the leader and favorable outcome expectancy, the educational materials provided and supportive interaction between group members and is matched for homework activity time over the 6 months. This group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
89078760|NCT02786797|No Intervention|Usual Care|Participants who are randomized to the Usual Care (UC) or control group will continue to receive standard post-treatment medical and nursing clinic visits that will not be modified by study participation. The UC participants will participate in their standard care appointments and will not be required to alter their UC regimen; however, they will be asked not to initiate a mindfulness program during the study period. The UC group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
89078761|NCT04200001||adjuvant hormonal therapy for breast cancer|women less than 51 years old, during adjuvant hormonal therapy for breast cancer
89078762|NCT01196052|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.
89224565|NCT06265090|Experimental|ball and balloon exercises|"Ball and balloon exercise exercises:~The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Instructions~supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~Insert a ball measuring between four and six inches in diameter in the space between your knees.~Put your left hand upon a balloon and your right arm above your head.~Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle."
89078763|NCT02689921|Experimental|Neoadjuvant Biological Therapy|"Subjects will receive an aromatase inhibitor for the duration of the study [exemestane (tablet, oral, 25 mg/day), letrozole (tablet, oral, 2.5 mg/day) or anastrozole (tablet, oral, 1 mg/day)]. Premenopausal subjects will receive leuprolide acetate (11.25 mg, intramuscular injection, 3-month intervals).~Pertuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 840 mg, infused over 60-90 minutes; subsequent cycles: 420 mg, infused over 30-60 minutes).~Trastuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 8 mg/kg, infused over 60-90 minutes; subsequent cycles: 6 mg/kg, infused over 30-60 minutes)"
89078764|NCT03116425|Experimental|Verum 1 - Premotor|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the premotor region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
89078765|NCT03116425|Experimental|Verum 2 - Prefrontal|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the prefrontal region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
89078766|NCT03116425|Active Comparator|Placebo|Stimulation of a region with normal rCBF and putatively unrelated to catatonic symptoms (parietal cortex).
89078767|NCT02887638|Experimental|headache|Patients diagnosed (neurologist - anesthesiologist - manual therapist) with tension-type and/or cervicogenic headache. During a first phase the sitting-posture, dura mater profile and pain-profile of the Headache-group will be analyzed. In a second phase, the patients will be sub-classified according to the data-analysis and receive intervention (Individual Profile Analysis +Physical therapy Intervention)
89078768|NCT02887638|No Intervention|asymptomatic controls|Asymptomatic controls, matched for gender and age. During a first phase the sitting-posture, dura mater profile and pain-profile of the control-group will be analyzed.
89224566|NCT06265090|Active Comparator|core stability exercises|"Core stability exercises (CSE): Subjects in this group were handled with core stability exercises that targeted deep abdominal muscles. This included a series of exercises as well as a baseline therapeutic management of ultrasonic as well as TENS. A physiotherapist supervised these exercises.~For four weeks, all groups did core stability exercises for 30 minutes three times per week.exercises. Based on the patient's success, the intensity of the individual training steadily increased with decreasing therapist support. Patients were told to contract their abdominal muscles and hold the contraction while continuing to breathe normally during each repetition of each exercise."
89224567|NCT06265077|Active Comparator|Intervention|(intervention group) patients who will receive filgrastim plus oral famotidine 20 mg once daily and loratadine 10 mg once daily for the full filgrastim treatment period.
89224568|NCT06265077|Placebo Comparator|Control|(control group) patients who will receive placebo plus filgrastim.
89224569|NCT06265064||Difficult mask ventilation|Difficult Mask Ventilation Grading (by Han et al.) Grade 1 mask ventilation can be easily performed by a single person Grade 2 requires the use of equipment such as an oropharyngeal airway Grade 3 necessitates the involvement of two or more personnel for mask ventilation or increasing oxygen flow Grade 4 indicates an inability to perform mask ventilation If the grade is ≥ 3, it signifies difficult mask ventilation
89224570|NCT06265064||non-difficult mask ventilation|Difficult Mask Ventilation Grading (by Han et al.) Grade 1 mask ventilation can be easily performed by a single person Grade 2 requires the use of equipment such as an oropharyngeal airway Grade 3 necessitates the involvement of two or more personnel for mask ventilation or increasing oxygen flow Grade 4 indicates an inability to perform mask ventilation If the grade is < 3, it signifies non-difficult mask ventilation
89224571|NCT06265051|Experimental|Tirofiban group|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
89230090|NCT00062647|Active Comparator|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram/12 hours or nafcillin, oxacillin, or cloxacillin 2 Gram/6 hours (IV) intravenously
88820864|NCT05543681|Active Comparator|Active Comparator: IGC-AD1Active|IGC-AD1 Active Treatment THC plus another API plus excipients.
88820865|NCT05543681|Placebo Comparator|Placebo Comparator: IGC-AD1 Placebo|IGC-AD1 Placebo, similar to Active in color, taste, and texture, with excipients but without APIs.
89230091|NCT00570323|Active Comparator|ARM A / Arimidex with Faslodex|Arimidex with Faslodex in postmenopausal women
88820866|NCT05538754|Other|EVO ICL|STAAR EVO implantable collamer lens (ICL) for the correction or reduction of myopia or myopia with astigmatism.
89078769|NCT02786485|Experimental|Rivogenlecleucel & Rimiducid|"All subjects will receive 3 courses of rivogenlecleucel (BPX-501 T cells) infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0 and DL2 on Days 30 and 60.~Escalating doses of rimiducid (AP1903) (0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after rivogenlecleucel infusion."
89078770|NCT04198753||Parent of Peanut Allergic Child|"The researchers will identify patients or study subjects aged 1-18 who have been diagnosed with peanut allergy based on skin prick testing, serologic testing, and/or history of reaction. They will then contact mothers or fathers of these patients/subjects who are 18 and older and enroll those who do not themselves have a history of food allergy, with a goal of 40 subjects per group.~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
89078771|NCT04198753||Parent of Non-atopic Child|"To establish normal controls, the researchers will enroll parents age 18 or older with no history of food allergy or eczema in themselves or their offspring.~The researchers will perform a very limited physical exam followed by skin tape stripping (30 strips) for lipid profile and protein expression, and transepidermal water loss (TEWL) measurements every 5 strips. They will obtain blood work to define FLG mutation and vitamin D status. Questionnaires on their background, other concurrent atopic and nonatopic diseases, and exposures, will also be collected."
89078772|NCT01195662|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablets
89078773|NCT01195662|Placebo Comparator|Placebo matching Dapagliflozin|Placebo tablets matching dapagliflozin tablets
89078774|NCT02786407|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose,dextran and gelatin.
89078775|NCT02786407|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but include sucrose,dextran and gelatin.
89078776|NCT03028519|Experimental|Treatment|Vitamin D levels will be measured at the time of routine blood work. If Vitamin D levels are found to be low, patients will take 50,000 IU of vitamin D3 weekly daily as maintenance therapy. There is no prospective control arm.
89078777|NCT02786563||Participants with RA receiving adalimumab|This group contains participants in China with RA receiving adalimumab
89078778|NCT02786641|Active Comparator|Group A|low risk NPC treated with concurrent chemoradiotherapy
89078779|NCT02786641|Active Comparator|Group B|high risk NPC treated with concurrent chemoradiotherapy
89224572|NCT06265051|Placebo Comparator|placebo group|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the control group. Placebo 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
89224573|NCT06265038|Other|Prospective, single-arm, open-label clinical trial.|Single center, prospective cohort, single-arm, open-label clinical trial Standard-of-care & Sanatmetal ReSpace TiCell Cage implantation A single-center study is sufficient to provide confirmatory data on performance and safety of the investigational device.
89224574|NCT06265025|Experimental|Treatment (GM103): Part A_Dose escalation|"Multiple escalating dose levels of GM103~(1 x 10^11 vp, 3 x 10^11 vp, 1 x 10^12 vp, 3 x 10^12 vp)"
89224575|NCT06265025|Experimental|Treatment (GM103): Part B_Dose expansion|"Dose expansion study of GM103 as monotherapy~(GM103 RP2D for HNC, GM103 RP2D for CRC)"
88820867|NCT05536973|Experimental|Dose 1|A single intravitreal injection of ADVM-022 2E11 vg/eye
88820868|NCT05536973|Experimental|Dose 2|A single intravitreal injection of ADVM-022 6E10 vg/eye
89078780|NCT02786641|Experimental|Group C|high risk NPC treated with induction chemotherapy plus concurrent chemoradiotherapy
89078781|NCT02787967|Experimental|NEXThaler® 35/4µg|CHF 1535 35/4µg NEXThaler® Dry Powder Inhaler, 4 inhalations. Total Dose: BDP 200µg FF 16µg
89078782|NCT02787967|Active Comparator|Reference treatment|Drug: free comb. beclomethasone DPI and formoterol DPI 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
89078783|NCT02788123|Experimental|bismuth tripotassium dicitrate and pantoprazole|Participants will receive bismuth tripotassium dicitrate (twice daily) and pantoprazole (once daily) as single tablets
89078784|NCT02788123|Active Comparator|pantoprazole|Participants will receive pantoprazole (once daily) as single tablet
89078785|NCT03631771|Experimental|Iodixanol, iohexol, iopromide, or ioversol|Investigational medicinal product administered intravascularly per usual clinical practice at each participating institution. Doses will be per usual practice. The dose of ICM, timing of ICM administration in relation to the diagnostic procedure, rate of ICM administration, and route of ICM administration will be determined by the physician performing the enhanced radiologic procedure per medical need and local clinical practice.
89078786|NCT04317768|Experimental|Study group|They will be educated and motivated by an intensive program consisting of verbal instructions, Power Point lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
89078787|NCT04317768|Other|Control group|They will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
89230092|NCT00570323|Active Comparator|ARM B Arimidex without Faslodex|Arimidex without Faslodex in postmenopausal women.
88820869|NCT05536388||Parkinson's Disease|Subjects in this group will have a diagnosis of Parkinson's disease with or without a known GBA gene mutation.
89078788|NCT02787889|Experimental|Uneven Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks.Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
89078789|NCT02787889|Experimental|Even Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks. Each participant will consume 33% of total protein consumed each meal
89078790|NCT04232995|Experimental|Experimental Group|"Balance training by 9 positions with 1 min hold, repeated twice~Stand with feet together, eyes remain open~Stand with together, eyes closed~& 4) Tandem Standing with Right and Left in front alternately~5) Forward Reaching 6) & 7) Single Leg Standing, with Right and Left foot alternately 8) & 9) Step up, with Right and Left foot alternately~General Exercises for 25 min~Active Range of Motion Exercises and Foot Care Education-5 min~Treadmill- 15 min~Cycling -5 min~No. Of Sessions 24, thrice a week for 8 weeks"
89078791|NCT04232995|Active Comparator|Control Group|"General Exercises for 25 min~Active Range of Motion Exercises and Foot Care Education-5 min~Treadmill- 15 min~Cycling -5 min~No. Of Sessions 24, thrice a week for 8 weeks"
89078792|NCT02796235|Other|Spinal cord injury (SCI) patient|
89078793|NCT02787733|Experimental|Citrus flavonoid|Citrus peel extract containing >90% flavonoids
89078794|NCT02787733|Placebo Comparator|Placebo|Identical looking placebo
89078795|NCT02787577|Experimental|Sleep Lengthening|The intervention group will receive a personalised sleep consultation session to lengthen sleep by 1-1.5 hours per night by targeting sleep hygiene using behaviour change techniques for 4 weeks.
89078796|NCT02787577|No Intervention|Control|The control group will be asked to resume their normal lifestyle.
89078797|NCT01195272|Experimental|Single Arm|
89078798|NCT02796079|Experimental|Autologous Bone Marrow Stem Cell|Mesenchymal stem cells derived from bone marrow infusion
89078799|NCT02796079|Placebo Comparator|saline|saline injections
89230093|NCT00791531|Experimental|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
89078800|NCT01194804|Experimental|Eculizumab|Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol
89078801|NCT02785627||Group A: ADT|Men with non-metastatic prostate cancer, about to start or within 2 weeks of starting ADT
89078802|NCT02785627||Group B: ADT + chemotherapy|Men with newly diagnosed hormone sensitive metastatic prostate cancer, starting ADT and who will have chemotherapy
89078803|NCT02785627||Group C: Controls|Healthy age matched men
89078804|NCT04232605|Active Comparator|GLP-1|Receive intravenous infusion of GLP-1.
89078805|NCT04232605|Placebo Comparator|Placebo|Receive intravenous infusion of saline.
89078806|NCT00638053|Experimental|1|
89078807|NCT02787421|Experimental|Functional Rhinoplasty|Participants undergoing functional rhinoplasty for nasal valve compromise and obstruction at the Emory Aesthetics Center.
89078808|NCT03560635|Active Comparator|Control|Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.
89078809|NCT03560635|Experimental|Reverse Diet|Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.
89078810|NCT02771353|Active Comparator|WT_vDIBH|Wide tangent radiotherapy in voluntary deep inspiratory breath hold
89078811|NCT02771353|Active Comparator|VMAT_FB|Volumetric modulated arc therapy in free breathing.
89078812|NCT02786095||Code-AF registry|
89224576|NCT06265025|Experimental|Treatment (GM103 and pembrolizumab): Part C_Dose escalation and dose expansion|"Dose-escalation and dose-expansion of GM103 in combination with pembrolizumab~Safety run in cohorts (GM103 1 dose level below RP2D + Pembrolizumab 200mg, GM103 RP2D + Pembrolizumab 200mg)~Dose expansion (GM103 RP2D*+ Pembrolizumab 200mg for HNC, GM103 RP2D* + Pembrolizumab 200mg for CRC)~*Recommended dose based on previous safety run in cohorts"
89224577|NCT06264986|Experimental|KSM-66|600mg (5% withanolides) KSM-66 ashwagandha, hydroxypropyl methylcellulose capsule
89224578|NCT06264986|Placebo Comparator|Placebo|600mg Gluten-free chickpea powder, hydroxypropyl methylcellulose capsule
89224579|NCT06264960|Active Comparator|Music therapy|After the patient was taken to the angiography laboratory, music was played using a digital MP3 player approximately 10 minutes before the angiography procedure began.
89224580|NCT06264960|Active Comparator|Breathing exercise|Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography
89224581|NCT06264960|No Intervention|Control Group|All data collection steps were applied identically to the control group patients, except for music application and deep breathing exercises. All patients in the study group received the same routine care.
89224582|NCT06264947|Experimental|laser acupuncture group|3 minutes for each time, and 3 times per week, with duration of 4 weeks
89224583|NCT06264947|Sham Comparator|sham laser acupuncture group|3 minutes for each time, and 3 times per week, with duration of 4 weeks
89224584|NCT06264908|Experimental|Early intervention arm|8 weeks integrated self-management programme delivered by occupational therapists and rheumatology nurse
89224585|NCT06264908|No Intervention|Routine Clinical care (Control)|Patients will receive routine clinical care for hand osteoarthritis for 26 weeks, then cross-over to the integrated programme after 26 weeks.
89224586|NCT06264895|Experimental|Evaluation of an exercise intervention for women experiencing homelessness and addiction.|A 3 times weekly exercise intervention with protein supplementation will be delivered to all study participants for 10 weeks.
89224587|NCT06264882|Experimental|Degarelix plus transdermal placebo|At baseline & 10 weeks: 80-mg subcutaneous injection of degarelix acetate plus Placebo transdermal patch (applied twice per week)
89224588|NCT06264882|Experimental|Degarelix plus transdermal estradiol|At baseline & 10 weeks: 80-mg subcutaneous injection of degarelix acetate plus 0.075mg estradiol transdermal patch (applied twice per week)
89224589|NCT06264869|Experimental|IGCT + CTG|Interdental guided creeping technique (IGCT) + Connective tissue graft (CTG)
89224590|NCT06264869|Experimental|IGCT + CM|Interdental guided creeping technique (IGCT) + Collagen membrane (CM)
89224591|NCT06264856|Experimental|bronchoscopic suction|Bronchoscopic suction is a medical procedure used to remove excess mucus, secretions, and foreign objects from the airways through a bronchoscope. The patient would receive bronchoscopic sputum suction every 24-48 hrs after randomization until leaving ICU.. The patient could still receive blind negative pressure aspiration suction as the usual medical routine(every 2-4 hrs sputum suction if needed).
89224592|NCT06264856|Active Comparator|blind negative pressure aspiration suction|Negative pressure aspiration suction is a medical procedure that uses suction to remove fluids, mucus, or other materials from the body by creating a negative pressure or vacuum. The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient would receive blind negative pressure aspiration suction as the usual medical routine(every 2-4 hrs sputum suction if needed).
89224593|NCT06264830|Active Comparator|Conventional-binocular-microscope-assisted standard cataract operation|In this group, patients undergo standard modern cataract operation during which the surgeon use conventional binocular microscope
89224594|NCT06264830|Experimental|Alcon-NGENUITY® (NG)-System-assisted standard cataract operation|In this group, patients undergo standard modern cataract operation during which the surgeon use the Alcon NGENUITY® (NG) System
89224595|NCT06264817|Active Comparator|Control group : compressive bandaging|"Control group : compressive bandaging:~Intensive phase (3 weeks): compressive bandaging (day and night-time) according to the usual practice~Maintenance phase (5 weeks): usual compression sleeve during the day + Self bandages at night"
89224596|NCT06264817|Experimental|Intervention group: MOBIDERM Autofit Armsleeve|"Intervention group: MOBIDERM Autofit Armsleeve~Intensive phase (3 weeks): MOBIDERM Autofit Armsleeve (day and night-time)~Maintenance phase (5 weeks): usual compression sleeve during the day + MOBIDERM Autofit Armsleeve at night"
89224597|NCT06264791|Experimental|Stress alcohol|These participants will undergo a stress induction and receive alcoholic beverages to raise their BAC to .06%
89224598|NCT06264791|Experimental|Stress no alcohol|These participants will undergo a stress induction and receive non-alcoholic beverages
89224599|NCT06264791|Experimental|No stress alcohol|These participants will undergo a neutral induction and receive alcoholic beverages to raise their BAC to .06%
89224600|NCT06264791|No Intervention|No stress no alcohol|These participants will undergo a neutral induction and receive non-alcoholic beverages
88820870|NCT05536388||Gaucher Disease|Subjects in this group with have a diagnosis of Gaucher disease with or without a known GBA gene mutation.
89224601|NCT06264778|Experimental|Dabrafenib|This study is a single-arm study that does not involve randomization or blinding, nor does it establish a parallel control group and uses external control.
89224602|NCT06264765|Other|scalp block|Following induction of anesthesia, a scalp block will be performed before the surgery begins.
89078813|NCT02785861|Experimental|supervised practice|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.~Each patient of supervised walking group will meet the student each session"
89078814|NCT02785861|Experimental|distance supervised physical activity|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.~Each patient of home-based walking group will be called by phone every week by the student to inform the patient of the progress of the training, collect the work and answer any questions"
89078815|NCT02786017|Sham Comparator|Conventional therapy|
89078816|NCT02786017|Experimental|Injectable Collagen Scaffold + HUC-MSCs|
89078817|NCT02785549|Experimental|Symptomatic treatment with NSAID|1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
89078818|NCT02785549|Active Comparator|Antibiotic+symptomatic treatment with NSAID|875/125mg /8h amoxicillin/clavulanic acid and symptomatic treatment with 1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
89078819|NCT02720653||Appropriate Medical Therapy|Patients will self-select continued, non-standardized, appropriate medical management of symptoms associated with chronic sinusitis.
89224603|NCT06264765|Other|incisional infiltration|Following induction of anesthesia, incisional infiltration will be performed before the surgery begins.
89224604|NCT06264752|Experimental|Protocolized stage-based intervention|The intervention uses an automated alerting system to identify patients: 1) receiving a high-risk drug or drug combination associated with AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval.
89224605|NCT06264752|Active Comparator|Usual Care|A Cerner EMR-based AKI passive alert which is standard of care at UPMC.
89224606|NCT06264739|Other|group 1|Dexmedetomidine (dekstomid) infusion will be administered for intraoperative analgesia.
89224607|NCT06264739|Other|group 2|remifentanyl (ultiva) infusion will be administered for intraoperative analgesia.
89224608|NCT06264726|Experimental|Intervention Group|This group will receive the intervention
89224609|NCT06264700|Experimental|Video Directly Observed Therapy (VDOT)|Participants randomized to this arm will be connected with Scene Health by a study staff member (not the PI or Co-I's). After submitting and receiving approval of a test video submission, the participants' hydroxyurea dosing schedule will be entered into the VDOT app by the research staff and will be updated by these staff after their routine hematology visits and/or hospitalizations. Participants will receive VDOT for 180 days, beginning the day after randomization. After that time, they will start a 180-day ongoing monitoring period, during which VDOT participants will receive monthly telephone calls and intermittent text messages from Scene Health staff to encourage ongoing adherence. The Scene Health staff will access the electronic adherence platform and use this data to inform their communications during the ongoing monitoring period. Participants in both arms will be offered a smartphone with a data plan at enrollment to ensure equal opportunity for participation.
89224610|NCT06264700|Other|Attention Control|Participants randomized to this arm will receive an automated, daily, short health or safety tip alert.
89224611|NCT06264674|Experimental|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-152a|Active ingredients: BDP/FF/GB 200/6/12.5 μg per actuation; Excipients: HFA-152a propellant.
89224612|NCT06264674|Active Comparator|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a|Active ingredients: BDP/FF/GB 200/6/12.5 μg per actuation; Excipients: HFA-134a propellant.
89224613|NCT06264648|Experimental|Manual Therapy using group|This group includes physiotherapists that using manual therapy techniques.
89224614|NCT06264648|Experimental|Non Manual Therapy using|This group includes physiotherapists using different techniques during working, not manual therapy
89224615|NCT06264622|Experimental|Low Dose|250 mg/day of Garlic Extract
89224616|NCT06264622|Experimental|High Dose|600 mg/day of Garlic Extract
89224617|NCT06264622|Placebo Comparator|Placebo|Placebo tablets
89224618|NCT06264609|Experimental|Group 1 Low Turnover - crossover|Alendronate
89224619|NCT06264609|Experimental|Group 2 Low Turnover - crossover|Teriparatide
89224620|NCT06264609|Experimental|Group 2 Low Turnover - continuation|Alendronate
89224621|NCT06264544|Experimental|zinc, selenium, and L-tyrosine supplementation|
89224622|NCT06264544|Placebo Comparator|placebo group|
89224623|NCT06264479||Trial Cohort|Patients with advanced or metastatic kidney cancer, due to start a new line of systemic therapy (targeted drug, immunotherapy, etc.)
89224624|NCT06264466|Experimental|POEM with Speedboat Ultraslim|Participants aged 18-years and above, referred to the participating center (IECED) with a diagnosis of achalasia and indication for POEM, POEM procedures will be performed using the Speedboat UltraSlim
89224625|NCT06264453|Experimental|Group A|KH001 0.2mg/mL
89224626|NCT06264453|Experimental|Group B|KH001 0.4mg/mL
89224627|NCT06264453|Placebo Comparator|Group C|Water for Injection
89230094|NCT00788021||Tacrolimus|Recipients of deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
89224628|NCT06264427|Experimental|Intervention arm|All participants will undergo examination for genom sequencing, diabetic complications and obstructive sleep apnea. Treatment for these conditions will not be randomized, but will be offered any participant who fulfills the excision treatment criteria
89224629|NCT06264401|Experimental|placepo group|"Alendronate:~the experimental and control group received (Alendronate) 70 mg 1 tab every week for 4 months."
89224630|NCT06264401|Experimental|exercises and alendronate group|"alendronate: the experimental and control group received (Alendronate) 70 mg 1 tab every week for 4 months.~treatment exercises: the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program which include 5 min warming up and 5 min cooling down at the end of the session each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 min including 10 min warming up and 10 min cooling down in form of stretching."
89224631|NCT06264388|Experimental|DB107-RRV and DB107-FC Group|Patients will receive DB107-RRV during the tumor resection/biopsy procedure. Approximately 6 weeks after surgery, patients will start drug therapy with a 7-day oral regimen of 220 mg/kg/day DB107-FC, which is to be self-administered. This 7-day regimen, which is considered one cycle of treatment, is to be repeated every 6 weeks for up to 12 months. Patients will undergo follow up procedures for at least 5 years after last DB107-RRV treatment.
88820871|NCT05536388||Healthy Control|Subjects in this group will serve as healthy controls.
88820872|NCT05532696|Experimental|ABT-101|"Part 1- dose-escalation: ABT-101 in patients with advanced cancer disease~Part 2- dose expansion: ABT-101 in patients with NSCLC with confirmed HER2 mutations"
89224632|NCT06264375|Experimental|Specific physical training|3 times training per week for approx. 30 minutes for 8 weeks. The training contains high intensity interval training (HIIT) elements. Moreover, exercises to improve grip strength, reaction times and anticipation are included.
89224633|NCT06264375|Experimental|General physical training|3 times training per week for approx. 30 minutes for 8 weeks. The training contains high intensity interval training (HIIT) elements.
89224634|NCT06264375|No Intervention|No Training|Control group
89224635|NCT06264362|Experimental|Tailored Physical Activity Program for Pain|Specific characteristics of the intervention delivered in Phase 2 will be based on the information gathered from stakeholders in Phase 1.
89078820|NCT02720653||Endoscopic Sinus Surgery|Patients will self-select endoscopic sinus surgery for symptoms associated with chronic sinusitis.
89078821|NCT03429829|Experimental|Flairesse varnish|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as fluoridated toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. In addition, fluoride varnish (22.600 ppm, DMG, Hamburg, Germany) was applied in 3-monthly intervals by the local non-professional assistants who had been trained beforehand and supervised at the first application.
89230095|NCT00788021||Sirolimus|Recipients of deceased or living donor renal transplants maintained on immunosuppressive regimen using sirolimus
89224636|NCT06264258|Experimental|DVx-T1D+Standard Care|Participants will continue receiving the clinic's standard of care. Anthropometrics, clinical and laboratory data will be collected at three time points, baseline, 6 weeks and 3 months. Participants will be asked to maintain food, glucose, and activity logs. In addition, participants in this arm will be provided a tablet that has the gaming applications already loaded and receive training on the application. Exposure time will be tracked by the application.
89224637|NCT06264258|No Intervention|Standard Care|Participants will receive the clinic's standard of care. Anthropometrics, clinical and laboratory data will be collected at three time points, baseline, 6 weeks and 3 months. Participants will be asked to maintain food, glucose, and activity logs.
89224638|NCT06264115||Three ports Laparoscopic Cholecystectomy group|
89224639|NCT06264115||Four ports Laparoscopic Cholecystectomy group|
89224640|NCT06263894|Experimental|Experimental group|The application of the Alexander Technique to the women included in the experimental group will be created by providing body awareness by directing their current posture and movements in line with three principles. In this way, self-management of the birth process in primiparous women will be established. In order to develop the body awareness of the primiparous woman, the Alexander Technique will be applied with the training program created by the researcher in line with the three principles.
89224641|NCT06263894|Other|Conventional group|The conventional (control group) will receive routine midwifery care during the birth process. Routine midwifery care includes follow-up of the pregnant woman and the baby and uninterrupted midwife support during the birth process.
89224642|NCT06263868||Precocious puberty group|Girl < 8 years old or boy < 9 years old when the first signs of development appear.
89224643|NCT06263868||Advanced puberty group|Girl aged ≥ 8 and < 10 years or boy ≥ 9 and < 11 years old when the first signs of development appear.
89224644|NCT06263868||Control group|Boy or girl without any signs of puberty development (Tanner 1)
89224645|NCT06263855|Experimental|Intervention|Clinicians who care for patients randomized to intervention will have access to CURE to assist with discharge summary writing.
89224646|NCT06263855|No Intervention|Control|Clinicians who care for patients randomized to control will continue with standard practice for discharge summary writing.
89224649|NCT06263699||Patients with diagnosed Dupuytren's disease|Range of motion measurement of the MCP and PIP joints in digits 4 and 5
89230096|NCT00788021||Healthy controls|Age, race and gender-matched individuals not on immunosuppressive regimens. Whenever possible an transplant recipient's donor may be recruited to serve as healthy control
89224650|NCT06263660|Active Comparator|Keto-like supplement|Participants will receive standardized 9.25g stick packs of the keto-like supplement. The study participants will take one of these stick packs dissolved in water three times a day (morning, noon, and evening) for 8 weeks.
89230097|NCT00788099|Experimental|1|Plitidepsin and Sorafenib
89230098|NCT00788099|Experimental|2|Gemcitabine and Plitidepsin
89224651|NCT06263660|Placebo Comparator|Placebo|Participants will receive standardized 9.25g stick packs of placebo. The study participants will take one of these stick packs dissolved in water three times a day (morning, noon, and evening) for 8 weeks.
89230099|NCT00795587|Active Comparator|mannitol high dose|mannitol 20% 0,8 g/ kg on minutes
89224652|NCT06263582|Experimental|Artesunate vaginal inserts/ pessaries|Artesunate vaginal inserts/pessaries are used as a treatment for cervical precancerous lesions.
89224653|NCT06263010|Experimental|Allo APOE4 carriers|Group of 5 participants who are carriers of the APOE4 gene and will receive allopregnanolone 4mg administered weekly via a 30-min IV infusion for a duration of 12 weeks.
89224654|NCT06263010|Active Comparator|Allo APOE4 none-carriers|Group of 5 participants who are none-carriers of the APOE4 gene and will receive allopregnanolone 4mg administered weekly via a 30-min IV infusion for a duration of 12 weeks.
89224655|NCT06262503|Other|Group1(Control )|Will receive conventional physiotherapy for one month and measure the pain intensity and lower extremity function
89224656|NCT06262503|Experimental|Group2 (Experimental)|Will receive conventional physiotherapy and Virtual Reality for phantom Pain for one month and measure the pain intensity and lower extremity function
89224657|NCT06262425|Experimental|repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex|Participants in the experimental group will receive 5 weekly sessions of repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks. An excitatory stimulation over the primary somatosensory area corresponding to the dominant hand will be applied. For this purpose, the motor area will be localized and a coil will be placed 2 cm posterior to it. An isolated pulse will be applied to the motor area to ensure that the coil is not placed over the motor area using 110% of the motor resting threshold. After this, 22 trains of 10 Hz at an intensity of 90% of the motor resting threshold will be applied for 4 seconds, with a rest between series of 10 seconds (a total of 880 pulses). After the stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.
89230100|NCT00795587|Active Comparator|mannitol low dose|mannitol 20% 0,4 g/ kg on minutes
89230101|NCT00791687||PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers received full course of betamethasone before delivery.
89230102|NCT00791687||NON PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers did not receive full course of betamethasone before delivery.
89224658|NCT06262425|Active Comparator|repetitive Transcranial Magnetic Stimulation over primary motor cortex|Participants in the active comparator group will receive 5 weekly sessions of repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks. An excitatory stimulation over the primary motor cortex corresponding to the dominant hand will be applied. For this purpose, the motor area will be localized, and an isolated pulse will be applied to the motor area to ensure that the coil is placed over the motor area using 100% of the motor resting threshold. After this, 22 trains of 10 Hz at an intensity of 90% of the motor resting threshold will be applied for 4 seconds, with a rest between series of 10 seconds (a total of 880 pulses). After the stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.
89224659|NCT06262425|Sham Comparator|Sham repetitive transcranial magnetic stimulation|Participants in the sham group will receive 5 weekly sessions of sham repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks.To achieve the placebo, the localization of the area to be stimulated will be carried out but the coil will be placed in a vertical position so the current will not go through the skull and the patient will just feel the vibration, communicating to the participant that it is likely that during the stimulation process he/she will not feel anything. After the sham stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.
89224660|NCT06262360|Experimental|General anesthesia with spontaneous mask ventilation|Patients under general anesthesia with spontaneous mask ventilation
89224661|NCT06262360|Experimental|General anesthesia and spontaneous laryngeal mask ventilation|Patients under general anesthesia and spontaneous laryngeal mask ventilation
89224662|NCT06262360|Experimental|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Patients under general anesthesia with spontaneous laryngeal mask ventilation with pressure support
89224663|NCT06262347|Experimental|Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)|"Drug: Naloxone kit~Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to participants, which may be useful in the event of a future opioid overdose.~Behavioral: Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)~TOME entails a trained RA: 1) administering a REDCap survey to assess an individual's opioid-overdose/MOUD knowledge; and 2) reviewing the personal feedback reports with the recipient."
88820873|NCT05531448|Experimental|2wT (2-way texting)|2wT participants will receive weekly motivational messages without any HIV-related information. They will receive visit reminders with an option to respond they will attend, they transfered, or they need scheduling help. If they do not attend their visit, they will be traced at 14 days.
89078822|NCT03429829|No Intervention|Control|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. Beyond that, the children in this arm were left untreated.
89078823|NCT02785705|Experimental|cIPV-bOPV-bOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two bivalent types 1 and 3 oral poliovirus vaccine sequentially.
89078824|NCT02785705|Experimental|cIPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
89078825|NCT02785705|Experimental|cIPV-cIPV-bOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one bivalent types 1 and 3 oral poliovirus vaccine sequentially.
89078826|NCT02785705|Experimental|cIPV-cIPV-tOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
89224664|NCT06262347|Active Comparator|Control|"Drug: Naloxone kit~Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to participants, which may be useful in the event of a future opioid overdose.~Behavioral: SAMHSA handouts~SAMHSA handouts: 1) Opioid Overdose Prevention Toolkit: Safety Advice for Patients and Family Members; 2) Opioid Overdose Prevention Toolkit: Recovering from Opioid Overdose; and 3) Medication-Assisted Treatment for Opioid Addiction: Facts for Families and Friends. These handouts can be offered as physical copies or electronically."
89224665|NCT06261970|Experimental|Connect Community Level Enhancements|"Community Support Groups (CSGs)*: Connect enhances Lishe Endelevu's to require at least four FTMs to be recruited into each CSG established. Connect enhances the CSG toolkit to include FTM focused content, including information on birth spacing and PPFP.~Home visits*: the CHWs who facilitate the community support groups also conduct home visits to FTMs. CHWs are provided a job aid to counsel FTMs and their families on PPFP. Counseling addresses myths about FP, norms around fertility and spacing, and includes prompts to engage family and male partners when present. Counseling also integrates timely nutrition information from the support groups with PPFP information. CHWs can provide non-clinical FP methods (pills, condoms) and provide referrals for services at public health facilities"
89224666|NCT06261970|No Intervention|Control|No additional Connect intervention. Lishe Endelevu Community Support Groups Operate per usual.
89224667|NCT06261619|Active Comparator|Bag mask ventilation with Adult Sotair device|The anesthesia provider will manually bag ventilate with the Adult Sotair® device for 3 minutes with an average respiratory rate of 12 breaths per minute with a deep breath every 30 seconds.
89224668|NCT06261619|No Intervention|Bag mask ventilation|The anesthesia provider will manually bag ventilate for 3 minutes with an average respiratory rate of 12 breaths per minute with a deep breath every 30 seconds.
89224669|NCT06260995||Social Prescribing|Participants are those who are referred or self-referred to a social prescribing link worker for any reason and who undergo an intervention delivered by an intermediary i.e., undergo assessment, follow-up, and onward connection to local physical activities.
89224670|NCT06260995||Local Sports Partnership|Participants are those who are referred or self-referred to a local sports partnership community development officer for any reason and who undergo an intervention delivered by an intermediary i.e., undergo assessment, follow-up, and onward connection to local physical activities.
89224671|NCT06260631|Experimental|high-intensity laser acupuncture and an exercise therapy program.|The patients will receive high-intensity laser acupuncture and an exercise therapy program.three times a week for four weeks.
89224672|NCT06260631|Sham Comparator|sham laser acupuncture and an exercise therapy program.|The patients will receive a sham acupuncture laser and an exercise therapy program three times a week for four weeks.
89224673|NCT06260618|Active Comparator|Gelfoam Arm|"The current standard of care in middle ear packing material has been Gelfoam, Gelfoam is an absorbable gelatin sponge manufactured from denatured porcine skin. Generally, Gelfoam resides within the middle ear for 2 to 9 weeks prior to being degraded via phagocytosis.~A single Gelfoam sponge is divided into small pieces and used within the ear. One piece of Gelfoam can typically be cut into over 200 smaller pieces. The surgeon uses approximately 10 to 20 of these smaller pieces per surgery. Approx a third of the product is applied into the middle ear, as a support material for the graft. After graft suturing is complete, the remaining two thirds are applied into the external ear canal as a packing agent.~The surgeon administers the foam during the surgery as they would with the standard TMP repair surgery. The product comes in a sterile package to be opened and cut up by Scrub Nurse."
89224674|NCT06260618|Experimental|Chitodex Arm|"Chitosan-dextran gel is packaged within a syringe and has a cannula attached, much like the Gelfoam syringe system. Approx 3-5mL of product is applied during the surgery. Approx 2mL into the middle ear, as a support material for the graft. After graft suturing is complete, another 3mL (approx) is applied into the external ear canal as a packing agent. This is the same procedure as Gelfoam is currently used for this purpose.~The surgeon will administer the gel during the surgery as they would with the standard of care Gelfoam. The product comes in a sterile kit to be opened by Scrub Nurse."
89224675|NCT06260215|No Intervention|Control|Participants in this arm will receive no intervention
89224676|NCT06260215|Experimental|ST|Participants in this arm will participate in a soccer training (ST) session for 60 minutes. During the training the participans will execute the warm-up process, the part of soccer technical exercises and they will play a small-side-game.
89224677|NCT06259136|Experimental|Pal-Cycles Intervention|The patients in the intervention arm will be exposed to the Pal-Cycles intervention.
89078827|NCT02785705|Experimental|cIPV-cIPV-cIPV poliovirus vaccine|Participants would be vaccine with three shots of trivalent conventional inactivated poliovirus vaccine.
89078828|NCT02785705|Experimental|tOPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with three times of trivalent types 1, 2 and 3 oral poliovirus vaccine .
89078829|NCT02785783|Active Comparator|Standard colonoscopy|A standard colonoscope will be used to complete the procedure
89078830|NCT02785783|Active Comparator|EndoRings™|An EndoRings™ device will be placed at the distal end of a standard colonoscope
89078831|NCT02821507|Experimental|sirolimus and cyclophosphamide|combining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule
89078832|NCT02787265||spinal cord stimulation|Failed back surgery syndrome patients will receive high density spinal cord stimulation
89078833|NCT02785393|Placebo Comparator|Sugar Pill|
89078834|NCT02785393|Active Comparator|Doxazosin|
89078835|NCT02787109|Experimental|CTH522-CAF01|"CTH522-CAF01: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
89078836|NCT02787109|Experimental|CTH522-Al(OH)3|"CTH522-Al(OH)3: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
89078837|NCT02787109|Placebo Comparator|Placebo|Saline for IM and In administrations
89078838|NCT03427255|Active Comparator|CBT group treatment|CBT group treatment-plus involving partners: 10 group sessions and 3 couple sessions
89078839|NCT03427255|Other|Waiting list|Six months waiting-list control condition.
89078840|NCT04232527||Professional Footballers|About 110 players (out of about 400 competing in the Premier League of Bosnia and Herzegovina) would be included in the research.
89078841|NCT02787031||Neuraxial anesthesia|Participants in this group will be those who had a spinal or epidural anesthetic without concurrent general anesthesia
89078842|NCT02787031||General anesthesia|Participants in this group will be those who had general anesthesia, including those who had a general plus a concurrent spinal or epidural anesthetic.
89078843|NCT04200079||COPD|Long term (at least 10 years) multidimensional (clinical, laboratory, physiological and radiological) follow up of chronic Obstructive Pulmonary Disease patients.
89078844|NCT03398395|Active Comparator|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
89224678|NCT06259136|No Intervention|Care as usual|The patients included in this intervention will be given care as usual.
88820874|NCT05531448|No Intervention|Routine retention|Control participants will have routine Back to Care retention support services and tracing at 14 days after a visit it missed.
88820875|NCT05528653|Other|Open Label Descovy|Descovy for PrEP
88820876|NCT05522738|Experimental|study group|Fruquintinib combined with FOLFIRI
88820877|NCT05522478||ADHD group|Children who were diagnosed with ADHD for the first time were classified in the ADHD group (n=33)
89224679|NCT06258837|Experimental|Drug-Induced Sleep Endoscopy|DISE will be performed at the time of surgery under the same sedation. The decision on specific surgical approach will be made at that time based on DISE findings. Prior to intubation, patients will be sedated with either a propofol infusion or a combination of ketamine and dexmedetomidine. Once adequate sedation is achieved, endoscopy will be performed using a flexible endoscope advanced through the nose. The nasal airway will be evaluated on both sides, then the endoscope will be advanced into the pharynx. The degree of obstruction is scored on a 3-point rating scale. Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery. Caregivers will be consented for all possible procedures with the understanding that only those needed based on DISE will be performed. Importantly, these procedures are all established treatments with published outcomes data.
89224680|NCT06258837|Active Comparator|Adenotonsillectomy|Adenotonsillar hypertrophy is the most common risk factor for OSA in children, and adenotonsillectomy (AT) is the first line treatment. An adenotonsillectomy is an operation to remove both the adenoids and tonsils.
89224681|NCT06258460|Experimental|the two-day psychotherapy training program with 8-week follow-ups intervention group|All participants from the intervention group will receive the two-day psychotherapy training program. They will receive a hard copy booklet of the psychotherapy training program at recruitment. In addition, supervision-based group meeting will be hold at week 1, 2, 4, and 8 during follow-ups, and each meeting will be lasted for approximately two hours. At each follow-up meeting, the teachers, including psychotherapists and psychiatrists, will be prepared to answer any psychotherapy related questions, encourage them to practice psychological interventions, and provide more information for participants' clinical application of psychotherapy.
88820878|NCT05522478||treatment group|children with ADHD who were treated with MPH for a minimum of 3 months were classified in the treatment group (n=32)
89078845|NCT03398395|Active Comparator|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
89078846|NCT04182685||ZIKV-exposed children|Children age 5-15 with a positive Zika virus PCR test result.
89078847|NCT04182685||ZIKV-unexposed children|Children age 5-15 who have not had a Zika virus infection as determined by serological assays.
89078848|NCT02784301|Experimental|Belly breathing with biofeedback app|
89078849|NCT02784301|No Intervention|Standard of Care|
89078850|NCT02784301|Active Comparator|Belly breathing without biofeedback app|
89078851|NCT02784301|Active Comparator|Belly breathing + visual distraction|
89078852|NCT02784223|Experimental|PET-CT with F18-choline|PET-CT with F18-choline examination will be performed before surgery
89078853|NCT02784379||The breast with mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast with mastalgia.
89078854|NCT02784379||The breast without mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast without mastalgia.
89078855|NCT05262751|Experimental|Part IA - Nintedanib formulation 1, OFEV® (Reference (R))|
89078856|NCT05262751|Experimental|Part IB - Nintedanib formulation 2, R|
89078857|NCT05262751|Experimental|Part II - Nintedanib formulation 1, nintedanib formulation 2, R|
89078858|NCT05262751|Experimental|Part III - Nintedanib formulation 1/nintedanib formulation 2, R|
89078859|NCT02785315|Experimental|rehabilitation & remediation approach|The intervention group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention with various compensatory strategies. Investigators will use group discussion to discuss everyday situations with memory problem and specific strategies (internal and external) related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
89078860|NCT02785315|Active Comparator|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
89078861|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in first lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
89078862|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in first lesion|Patients with Ultimaster® Drug-eluting stent in first lesion
89078863|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in second lesion|Patients with with Ultimaster® Drug-eluting stent in first lesion
89078864|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in second lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
89078865|NCT04231123|Experimental|PENG group|PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine
89078866|NCT04231123|Placebo Comparator|Placebo group|PENG block with 20 ml of 0,9% saline
89078867|NCT04231279|Active Comparator|ChiRhoStim Group 1|Patients undergoing EGD with ePFT for symptoms of suspected or known pancreatic insufficiency.
89078868|NCT04231279|Experimental|ChiRhoStim Group 2|Patients undergoing diagnostic EGD that consent to undergo ePFT.
89078869|NCT02782585|Experimental|Experimental group 1|Cervical Manipulation
89078870|NCT02782585|Experimental|Experimental group 2|Cervical lateral glide
89078871|NCT02782585|Placebo Comparator|Control group|Cervical Mobilisation
89078872|NCT02605759|Experimental|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation for the treatment of esophageal squamous cell dysplasia
89078873|NCT02782273|Active Comparator|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
89078874|NCT02782273|Active Comparator|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
89078875|NCT02787811|Active Comparator|Pregnant|women with positive serum beta HCG done 14 days after Intrauterine insemenation
89078876|NCT02787811|Active Comparator|Nonpregnant|women with negative serum beta HCG done 14 days after Intrauterine insemenation
89078877|NCT05179135|Active Comparator|Control|Standardized meal, without exercise
89078878|NCT05179135|Experimental|Low-intensity walking|
89078879|NCT05179135|Experimental|Moderate-intensity cycling (MOD)|
89078880|NCT05179135|Experimental|High-intensity interval exercise (HIIT)|
89078881|NCT05179135|Experimental|Intermittent high-intensity exercise (IHE)|
89078882|NCT05342389|Experimental|Experimental group|A fixed dose of Camrelizumab 200mg will be administered intravenously (without preventive medication), and each infusion lasts 45min (no less than 30min, no more than 60min), once every two weeks; During the treatment period, 250 mg of Apatinib mesylate tablets will be taken orally daily continuously, and every 2 weeks is a treatment cycle. The treatment lasts for up to 2 years or until disease progression, death or intolerable toxicity occurred.
89078883|NCT05342389|Active Comparator|Control group|Apatinib mesylate tablets 500 mg will be taken orally daily continuously, every 2 weeks as a treatment cycle. Treatment lasts for up to 2 years or until disease progression, death or intolerable toxicity occurs.
89078884|NCT04230655|Active Comparator|Control group|"All participants in the control group are treated with LED and CBT-based group treatment as described below.~All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants. Two groups of about the same size start simultaneously.~The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended."
89224682|NCT06258460|Placebo Comparator|the wail-list control group|After consent is given, participants who are allocated to the wail-list control group will receive a message encouraging them to complete all questionnaires from baseline to the last follow-up at 8 weeks. They will receive messages via WeChat to thank them for being in the study and reminding them of the time until the completion of the study at 8 weeks follow-up. They will receive a digital booklet of the psychotherapy training program via the WeChat individual messaging platform at recruitment, or a hard copy on request. After the trial ends, participants in the control arm will be able to receive the psychotherapy training program for free.
89224683|NCT06257771||Women 1-5 years post-SG|"Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal~Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)"
89224684|NCT06257771||Men 1-5 years post-SG|"Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal~Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)"
88820879|NCT05522478||control group|typically developing children were classified in the third-the control group (n=20)
89078885|NCT04230655|Experimental|IGB group|"All participants in the IGB group are treated with LED and CBT-based group treatment as described for the control group.~Participants in the intervention group are treated with an IGB for 6 months from 6 months from start."
89078886|NCT02784067|Experimental|Treatment|Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
89078887|NCT02784067|Placebo Comparator|Placebo|Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
89078888|NCT05260099||Retrospective|Patients not treated with LPS Adsorber
89078889|NCT05260099||Prospective|Patients treated with LPS Adsorber
89078890|NCT02310217||1|Hypertensive
89078891|NCT02310217||2|Normotensive
89078892|NCT02268175|Experimental|ARM 1|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle~Enzalutamide- Once daily at prespecified dose, orally~Abiraterone Acetate- Once daily at prespecified dose, orally~Prednisone-Once daily at prespecified dose, orally~Leuprolide Acetate-Intermuscular injection at prespecified dose and duration"
89078893|NCT02268175|Experimental|ARM 2|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle.~Enzalutamide- once daily at prespecified dose, orally~Leuprolide Acetate- Intermuscular injection at prespecified dose and duration"
89078894|NCT02207647||Patients with syndromes requiring lumbar puncture|
88820880|NCT05518968|Experimental|Acceptance and Commitment Therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
89078895|NCT02783989|Active Comparator|White wine|Two glasses of a market white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14 g in women). It is estimated that wine will contain about 8-9 mg/l of tyrosol. Therefore the dose of tyrosol ingested in two glasses would be 2-2.5 mg (1-1.25 mg in women).
89078896|NCT02783989|Experimental|White wine plus tyrosol capsules|Two glasses of white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14g in women), in combination with capsules of 25 mg of TYR (each one to be ingested with a glass of wine), two capsules along the day for men (at lunch and at dinner) and one for woman (at lunch).
89078897|NCT02783989|No Intervention|Water|Drinking water along with meals
89078898|NCT02783833|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
89078899|NCT02783833|Experimental|MMV390048 dose to be determined mg|MMV390048 dose to be determined mg, tablets, single dose
89078900|NCT02783755|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
89078901|NCT02783677||DM with PAD before angioplasty|Diabetic patients diagnosed with peripheral artery disease via vascular Duplex.
89078902|NCT02783677||DM without PAD|Diabetic patients diagnosed without peripheral artery disease via vascular Duplex.
89078903|NCT02783677||Healthy volunteers|Healthy volunteers
89078904|NCT02783677||DM with PAD after angioplasty|Diabetic patients diagnosed with PAD underwent balloon-angioplasty
88820881|NCT05517278|Experimental|Treatment Group|The treatment group will receive SurgX™ Antimicrobial Wound Gel™ applied over incision after closure and then re-applied at first dressing change on day of discharge in addition to standard of care.
89078905|NCT02782429|Experimental|Ketamine|This group received ketamine in a dose 0.5 mg / in anesthesia, in addition to other drugs used for induction, which will be standardized.
89078906|NCT02782429|Placebo Comparator|Placebo|This group received the equivalent volume of saline, in addition to other drugs used for induction, which will be standardized.
89078907|NCT04229719|Experimental|Melatonin group|Melatonin powder (N-Acetyl-5-methoxytryptamine) 1.2mg topical application in osteotomy site.
89078908|NCT04229719|No Intervention|Control group|No drug intervention
89078909|NCT02782351|Experimental|CAR-T|In interventional studies, patients enrolled will receive autologous 2nd generation CAR-T cells, which contain a humanized single chain antibody sequence against CD19.
89078910|NCT04231903||EAC|Patients undergoing surgery endo-aortic clamp.
89078911|NCT04231903||TTC|Patients undergoing surgery through trans-thoracic aortic clamp.
89078912|NCT05342233||Endovascular treatment Group|Patients receiving endovascular treatments
89078913|NCT05342233||Conservative treatment Group|Patients receiving conservative treatments, including blood pressure control, bowel rest, antithrombotic therapy, nutrition treatment and pain management.
89078914|NCT02784847|Other|treatment arm|pilot-study with single arm of 10 migraine patients treated for 3 months with triheptanoin 1mg/kg/day
89078915|NCT04230889|Other|Usual Diet Group|Instructed to continue to maintain a diet pattern of three main meals (breakfast, lunch and dinner) with two daily snacks including a usual snack (of their own choosing) mid-morning and a usual snack (of their own choosing) mid-afternoon.
89078916|NCT04230889|Experimental|Group 1 Nutritional Shake|Instructed to consume one nutrition shake instead of their usual breakfast and consume the second nutrition shake for their mid-afternoon snack.
88820882|NCT05517278|Other|Control Group|The control group will receive standard of care.
89078917|NCT04230889|Experimental|Group 2 Nutritional Shake|Instructed to consume one Study Shake instead of their usual breakfast and the second Study Shake for the second snack before bed-time.
89078918|NCT01855867|Other|Stribild|Single dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) taken for 28 days, within 72 hours of a possible sexual exposure to HIV
89078919|NCT02689843|Active Comparator|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone acetate 2mg+Ethinyl estradiol 35 mcg) once daily + Spironolactone 50 mg twice daily
89078920|NCT02689843|Active Comparator|Metformin|Metformin 1500 mg daily
89078921|NCT02689843|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily
89078922|NCT02783365|Experimental|Intervention|The intervention uses photo-elicitation and online group support (via Facebook) to improve patients' overall experience of chronic pain and patient-identified areas of function. This intervention was informed by the Photovoice methodology developed by Wang and Burris (1994). Photovoice participants will utilize cameras that enable them to record issues related to their experiences, and subsequently display them in office visits with their physician or mid-level clinician.
89078923|NCT02783365|No Intervention|Control|Patients in the control practices will receive usual care and will be eligible to participate in the intervention after their participation in the study is completed at 12 months.
89078924|NCT02783521|Experimental|Intervention|Includes changing eating behaviors, increasing physical activity, and attending regular in-person weight loss meetings for 12 weeks. To support additional weight loss/weight maintenance, participants will receive bi-weekly phone calls across a 12 week follow-up.
89078925|NCT02783521|Other|Wait List Control|Wait-list control participants will not receive any intervention for the first 12 weeks. After 12 weeks, participants will receive the weight loss intervention plus mHealth technology support.
89078926|NCT05171725||Sleep and Circadian Disorders|Observational deep phenotyping of people presenting with Sleep and Circadian disorders. Participants will undergo a comprehensive multidisciplinary protocol of clinical assessment by an expert clinician, neuropsychological testing by a neuropsychologist through paper-and-pencil and tablet tests, actigraphy, polysomnography with concurrent electroencephalography, pre- and post- sleep cognitive testing and biosample acquisition, and where available provide access to wearable data, therapeutic device data (e.g., PAP/NIV), and brain imaging
89078927|NCT05171725||Neurocognitive Disorders|Observational deep phenotyping of people presenting with Dementia (including Alzheimer's disease, vascular disease, frontotemporal dementia). Participants will undergo a comprehensive multidisciplinary protocol of clinical assessment by an expert clinician, neuropsychological testing by a neuropsychologist through paper-and-pencil and tablet tests, actigraphy, polysomnography with concurrent electroencephalography, pre- and post- sleep cognitive testing and biosample acquisition, and where available provide access to wearable data, therapeutic device data (e.g., PAP/NIV), and brain imaging
89078928|NCT05171725||Epilepsy disorders|Observational deep phenotyping of people presenting with seizures and Epilepsy disorder. Participants will undergo a comprehensive multidisciplinary protocol of clinical assessment by an expert clinician, neuropsychological testing by a neuropsychologist through paper-and-pencil and tablet tests, actigraphy, polysomnography with concurrent electroencephalography, pre- and post- sleep cognitive testing and biosample acquisition, and where available provide access to wearable data, therapeutic device data (e.g., PAP/NIV), and brain imaging
89224685|NCT06257771||Women, non-operated control|"Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal~Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)"
89224686|NCT06257771||Men, non-operated control|"Alcohol orally administered (0.5 grams per kg of Fat-free mass) after overnight fast or after a standard meal~Alcohol administered IV using an alcohol clamp (target concentration of 0.6g/L after an overnight fast or one hour after consuming a standard mixed meal)"
89078929|NCT05171725||Healthy controls|Participants will undergo a comprehensive multidisciplinary protocol of clinical assessment by an expert clinician, neuropsychological testing by a neuropsychologist through paper-and-pencil and tablet tests, actigraphy, polysomnography with concurrent electroencephalography, pre- and post- sleep cognitive testing and biosample acquisition, and where available provide access to wearable data, therapeutic device data (e.g., PAP/NIV), and brain imaging
89078930|NCT05341999|Experimental|Final irrigation with cold saline (cryotherapy).|20ml of 2.5°C cold saline for 5 min
89078931|NCT05341999|Experimental|Ibuprofen post-operative medication.|a single dose of Ibuprofen 400 mg immediately after completion of root canal treatment
89078932|NCT05341999|Active Comparator|Final irrigation with normal saline, and no post-operative medication|final irrigation will be done using normal saline at room temperature.
89078933|NCT02781805|Experimental|Alendronate|Subjects will take the study drug alendronate, a nitrogenous bisphosponate, for approximately one to three weeks before their breast surgery.
89078934|NCT02781493|Experimental|Prucalopride group|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
89078935|NCT02781493|Placebo Comparator|Placebo group|2 mg Placebo plus 2 L Polyethylene Glycol regimen
89078936|NCT02783287|Experimental|Medication text message|Once daily text message reminder.
89078937|NCT02783287|Experimental|Exercise text message|4x daily text message reminder.
89078938|NCT02783287|No Intervention|Usual care, medication adherence|Usual care for medication adherence.
89078939|NCT02783287|No Intervention|Usual care, exercise regimen|Usual care for exercise regimen.
89078940|NCT02783053|Other|Metformin use|The investigators compare the use of metformin vs no metformin
89078941|NCT02783053|No Intervention|Lean or Obese|The investigators compare the effect of metformin on 18F-FDG uptake between lean and obese men.
89078942|NCT04230343|Experimental|Self-benefit arm|
89078943|NCT04230343|Active Comparator|Social-benefit arm|
89078944|NCT02783209|Other|Cataract surgery|Patient acts as his own control
89078945|NCT02689609||Single arm|All patients will receive intensity-modulated radiation therapy (IMRT) with or without adjunct chemotherapy as standard of care. They will have baseline pre-treatment and post-IMRT serum thyroid function test at least yearly after IMRT.
89078946|NCT02783131|Experimental|MedNav|Team getting taught to use mednav, and using mednav in simulation managing Post partum Haemorrhage.
89078947|NCT02783131|No Intervention|non MedNav|Team undergoing routine simulation training in Post Partum Haemorrhage.
89078948|NCT02782975|Experimental|aducanumab IV|Infusion of aducanumab over approximately 1 hour
89078949|NCT02782975|Experimental|aducanumab SC|Subcutaneously via injection
89078950|NCT01324531|Active Comparator|Bankart repair|
89078951|NCT01324531|Active Comparator|Bankart repair and remplissage|
89078952|NCT02782819|Placebo Comparator|Crystalloid|Isotonic crystalloid solution resuscitation
89078953|NCT02782819|Active Comparator|Crystalloid plus Colloid|Colloid solution resuscitation
89078954|NCT02781415|Experimental|Acupuncture|Traditional Acupuncture Session:Patients in this group will benefit from a 30 minutes acupuncture session made by an experimented physician.
89078955|NCT02781415|Active Comparator|Titrated Morphine|Morphine Titration:Patients will receive an intravenous titration of morphine by a qualified nurse.
88816155|NCT01171118|Experimental|Sedation & Physostigmine & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
89078956|NCT02785003|Experimental|Ketamine Infusion|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the ketamine solution at a calculated dose of 0.25 mg/kg. A continuous infusion of ketamine will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
89078957|NCT02785003|Placebo Comparator|Saline Placebo|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the saline solution at a calculated dose of 0.25 mg/kg. A continuous infusion of saline will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
88816156|NCT01171118|Placebo Comparator|Sedation & Placebo & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
89224687|NCT06256809||Oral Lesion Risk Assessment Group|This group comprises individuals undergoing evaluation for dermatoglyphic patterns indicative of a predisposition to oral premalignant and malignant lesions. The group includes two sub-cohorts: one consisting of patients with diagnosed oral conditions like Oral Leukoplakia (OL), Oral Submucous Fibrosis (OSF), and Oral Squamous Cell Carcinoma (OSCC), and a control sub-cohort of individuals without these conditions. Dermatoglyphic analysis, including qualitative (whorls, loops, arches) and quantitative (Total Finger Ridge Count (TFRC), atd angles) parameters, will be conducted to assess potential predictive patterns and their correlation with oral lesion risks. No direct interventions are involved; the study focuses on observation and pattern analysis for potential early diagnosis and risk assessment.
89078958|NCT02781259|Experimental|Selective Lymph Node Dissection|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery. Routine axillary lymph node dissection is performed. Acquired lymph nodes are separated to fluorescent positive lymph nodes and fluorescent negative lymph nodes with imaging devices.
89078959|NCT02782897|Experimental|IVIg group|Participants will receive immunoglobulin therapy plus standard management. The first intravenous infusion of immunoglobulin must be given within 72 hours after the onset.
89078960|NCT02782897|Other|Control group|Participants will receive standard management according to Chinese guidelines for intracerebral Hemorrhage.
89078961|NCT04229953||US scan with 3D/4D VRU software|
89078962|NCT05280847|Experimental|10 ml ESP group|ESP group using 10 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
89078963|NCT05280847|Experimental|20 ml ESP group|ESP group using 20 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
89078964|NCT00638131|Experimental|1|Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
89078965|NCT00638131|Placebo Comparator|2|placebo given bid same as experimental arm;
89078966|NCT05142475|Experimental|Tumor Infiltrating Lymphocytes (TIL)|1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced breast cancer after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
89078967|NCT02781181|Other|CAS with CPD|CAS performed under neuroprotection
89078968|NCT02781181|Active Comparator|CAS without CPD|CAS without neuroprotection
89078969|NCT02781103|Experimental|Guided imagery plus active tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
89078970|NCT02781103|Sham Comparator|Guided imagery plus Sham tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will be turned off. The device will remain in place, however, for 20 minutes while the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
89078971|NCT04229251|Experimental|Online Mindfulness-based Intervention|iMBI will be delivered to participants in 8 online sessions, approximately 2 hours per session.
89078972|NCT04229251|Sham Comparator|Online Introductory Psychology Program|An online introductory psychology courses will be delivered to participants in 8 online sessions, approximately 2 hours per session.
89078973|NCT02780245|Experimental|Group (X) Prophylactic Tranexamic Acid|Intravenously at 20 minutes preoperatively had an intervention of a single bolus TXA dose of 20•0 mg/kg, which was administered in Z solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g) (NCT02739815).
89224688|NCT06256809||Healthy Control Group|"This group consists of individuals with no history or diagnosis of oral premalignant or malignant lesions. They serve as a baseline comparison to the Oral Lesion Risk Assessment Group. The dermatoglyphic patterns (whorls, loops, arches) and quantitative parameters (Total Finger Ridge Count (TFRC), atd angles) of this group are analyzed and compared with those of the patient group to identify distinctive patterns or traits associated with oral health conditions. This comparison aims to enhance the understanding of dermatoglyphic variations and their potential role in predicting oral health risks. No interventions are involved; the group is purely observational for comparative analysis"
89078974|NCT02780245|Experimental|Group (Y) Intraoperative Uterine Cooling|Firstly intravenously at 20 minutes preoperatively had only the Z solution, and secondly [Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen].
89078975|NCT00634699|Experimental|One|Ischemic Compression on Triggers Points on Muscles along the Median Nerve. Active Comparator
89078976|NCT05341063|Experimental|Intervention Group|Following the first meeting after the pre-tests, a weekly training was created via Zoom. Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.
89078977|NCT05341063|Experimental|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
89078978|NCT05340985|Experimental|25(OH)D3 (Calcifediol)|50 micrograms per day 25(OH)D3 or vitamin D hydroxylated for 24 weeks
89078979|NCT05340985|Experimental|Cholecalciferol|50 micrograms (2000IU) per day Cholecalciferol for 24 Weeks
89078980|NCT05340829|Experimental|ThisCART19A 2×10^6 cells/kg for dose level 1|Patients will receive 2×10^6 cells/kg of ThisCART19A
89078981|NCT05340829|Experimental|ThisCART19A 3×10^6 cells/kg as dose level 2|Patients will receive 3×10^6 cells/kg of ThisCART19A
89078982|NCT05340829|Experimental|Patients will receive 4×10^6 cells/kg as dose level 3|Patients will receive 4×10^6 cells/kg of ThisCART19A
89078983|NCT02780791|Active Comparator|Transplantation into pelvic wall|Ovarian transplantation into the pelvic wall after cryopreservation of ovarian tissue before cytotoxic therapies
89078984|NCT02780791|Active Comparator|Transplantation into the ovary|Ovarian transplantation into ovary after cryopreservation of ovarian tissue before cytotoxic therapies
89078985|NCT02780947|Active Comparator|Prophylactic substrate ablation group|Prophylactic substrate ablation group will undergo substrate mapping and ventricular tachycardia substrate ablation
89078986|NCT02780947|No Intervention|Control group|Control group will undergo substrate mapping
89078987|NCT02784457|Active Comparator|GnRHant|women who received GnRH antagonist
89078988|NCT02784457|No Intervention|Control|women who did not receive GnRH antagonist
89078989|NCT05338177|Experimental|Immunosuppression reduction|Participants stop mycophenolate or azathioprine for two weeks peri-vaccination. Treatment is stopped on week before vaccination and only restarted one week after vaccination
89078990|NCT05338177|Active Comparator|No immunosuppression reduction|no alterations to immunosuppression
89078991|NCT02780323|Experimental|CELBESTA® and CELEBREX® placebo|CELBESTA® and CELEBREX® placebo is administered twice daily for 6 weeks
89078992|NCT02780323|Active Comparator|CELEBREX®|CELEBREX® and CELBESTA® placebo is administered twice daily for 6 weeks
89078993|NCT05331859|Placebo Comparator|conventional|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated only with conventional postoperative eye drops.
89078994|NCT05331859|Active Comparator|Insulin|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated with topical insulin and conventional postoperative eye drops.
89078995|NCT05331859|Active Comparator|Autologous serum eye drops|Corneal epithelial wound healing in patients who received photorefractive keratectomy (PRK) treated with Autologous serum eye and conventional postoperative eye drops.
89078996|NCT04229407|Experimental|Dietary supplement|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).~After 32 subjects in MRI strata is reached. subjects will be randomized to intake Dietary supplement twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks"
89224689|NCT06255873|Experimental|ketogenic diet with L - Carnitine supplementation.|Patients with drug resistant epilepsy who received ketogenic diet with L - Carnitine supplementation.
89078997|NCT04229407|Placebo Comparator|vitamin B|"subject will be evaluated for the eligibility of MRI assessment to assign subjects in randomization strata (MRI or non-MRI).~After 32 subjects in MRI strata is reached. subjects will be randomized to intake placebo vitamin B twice daily (every morning and night, 30 minutes after exercise if do exercise) for 12 weeks."
89224690|NCT06255873|Active Comparator|ketogenic diet.|Patients with drug resistant epilepsy who received ketogenic diet only.
89224691|NCT06255301||Control group|150 patients with eye diseases other than dry eye syndrome or limbal stem cell deficiency will be included.
89224692|NCT06255301||dry eye syndrome|100 patients with dry eye syndrome will be included.
89224693|NCT06255301||limbal stem cell deficiency|50 patients with limbal stem cell deficiency will be included.
89224694|NCT06254430||Epidural analgesia|"The patients were fasted for 8 hours before the operation without premedication. The patient was taken to the operation room. In all cases, a vein on the back of the hand was cannulated for peripheral venous catheter was cannulated from the back of the hand. Standard monitoring was applied.~In the epidural group, 42 patients received a standard 18 G injection at the appropriate level between T8 and T10. The epidural space was entered by loss of resistance method with touchy needle. 15 µg in 3 mL saline The test dose was administered by administering epinephrine. Then the epidural catheter was inserted towards the cranium. was advanced five cm. Bupivacaine 0.25% was started as infusion through the catheter.~Since the mean arterial pressure dropped below 60 mm/hg in 5 patients, epidural infusion was stopped and inotropic treatment was started."
89224695|NCT06254430||Erector Spina Plan(ESP) Block|"Esp group included 28 patients in the preoperative operating theatre between T8 and T10 1 hour before the operation.~level, the USG (ultrasonography) probe is placed in the midline in the cephalocaudal direction and then the USG (ultrasonography) probe is placed approximately 3 cm laterally over the transverse processes and transverse with the erector spinae muscle 0.25 % bupivacaine 20 cc each in the fascial plane between the processes bilateral thoracic erector spina block and then 50 mg dexketoprofen before surgery implemented."
89224696|NCT06253611|Experimental|Nivolumab Combined With FOLFOX and EXL01|Nivolumab 240 mg IV q2w and FOLFOX q2w plus EXL01 orally once daily
89224697|NCT06253611|Active Comparator|Nivolumab and FOLFOX|Nivolumab 240 mg IV q2w and FOLFOX q2w
89224698|NCT06253260|Active Comparator|(Group A): rapid sequential group|
89224699|NCT06253260|Active Comparator|(Group B): normal sequential group|
89224700|NCT06251232|Active Comparator|Active treatment|Oral prednisone
89224701|NCT06251232|Placebo Comparator|Placebo treatment|Placebo
89224702|NCT06251050|Experimental|0.03 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid, transparent colorless liquid. In this group, 10 ml of 0.03 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
89224703|NCT06251050|Experimental|0.06 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid, transparent colorless liquid.. In this group, 10 ml of 0.06 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
89224704|NCT06251050|Experimental|0.10 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid,transparent colorless liquid. In this group, 10 ml of 0.10 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
89078998|NCT05340595|Other|Control group|The primer (Transbond XT Primer; 3M Unitek, California) was applied in a thin and uniform coat. Then the adhesive resin (Transbond LR Light Cure Adhesive Paste; 3M Unitek, California) was administered to the lingual surface of the anterior teeth and the lingual retainer was placed in position. The adhesive resin was polymerized from two directions for a total of 20 s using a visible-light curing unit (Hilux 200, Benlioglu Dental Inc., Ankara, Turkey) with an output power of 600 mW/cm2.
89078999|NCT05340595|Active Comparator|Study group|In the study group, the SEP (3M Unitek, Monrovia, California) was used according to the manufacturer's instructions, namely it was administered to the lingual surfaces of the teeth and rubbed for 3 s. Then a gentle burst of dry air was delivered to thin the primer. In the control group, the lingual surfaces of the teeth were etched using 37% phosphoric etchant liquid gel (3M Espe, St Paul, Minnesota, USA) for 30 s, followed by rinsing and drying.
89079000|NCT04231435|Experimental|Treatment Administration|"All subjects will receive the following oral doses of IP following an overnight fast in the fixed-sequence below:~Day 1 (Period 1): 1 × 0.25-mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet.~Day 7 (Period 2): 6 × 100-mg fedratinib capsules PLUS (after approximately 1 hour from the time of fedratinib administration) 1 × 0.25 mg digoxin tablet, 1 × 10-mg rosuvastatin tablet, and 1 × 1000-mg metformin tablet."
89079001|NCT05340517|Experimental|video-assisted rib planting|
89079002|NCT05340439|Experimental|Incobotulinumtoxin A treatment|The study will consist of three injection cycles. In each, an injection visit is followed by an observation period of 12 to 20 weeks.
89079003|NCT05340361||In vivo|OCT examination is performed using a frequency-domain OCT system (C7 DragonflyTM OPTISTM Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
89079004|NCT05340361||In vitro|In vitro study with phantom tube model regarding tapered vessel type
89079005|NCT01194414|Experimental|Tocilizumab SC|"Participants received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab intravenous (IV) infusion every 4 weeks for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
89079006|NCT01194414|Experimental|Tocilizumab IV|"Participants received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
89079007|NCT01194414|Experimental|Tocilizumab SC Then Tocilizumab IV|"Participants who received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab IV infusion every 4 weeks for 24 weeks in double blind treatment period switched to tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
89079008|NCT01194414|Experimental|Tocilizumab IV Then Tocilizumab SC|"Participants who received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly in double blind treatment period switched to tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose will be continued throughout the study."
89079009|NCT05340283||Observational group|Patients with Parkinson's disease who were referred to a Home Rehabilitation Service in Gijón, Asturias region, Spain, during the years 2015 to 2021.
89079010|NCT02686411||Observational (survey)|Patients and caregivers complete surveys over 5-10 minutes before and after care in the PCU.
89079011|NCT05340127|Experimental|Subjects examined by the study participants using CEREBO®|"CEREBO® - A non-invasive intracranial haemorrhage detector~Scan Duration - 40 seconds per subject~Frequency - Every operator will perform CEREBO® scan on at least 10 different subjects~Adverse Effect: None"
89079012|NCT05327413||Group 1|
89079013|NCT04228705||The elders|Patients aged over 59 years old
89079014|NCT04228705||The young adults|Patients aged from 18 to 59 years old
89079015|NCT02784769|Experimental|aneurysm diameter of below 75 mm|
89079016|NCT02784769|Experimental|aneurysm diameter above 75 mm|
89079017|NCT02173405|Active Comparator|Treatment Group|20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.
89079018|NCT02173405|Placebo Comparator|Placebo group|20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles.
89079019|NCT04228939|Experimental|Intervention group (IG)|
89079020|NCT04228939|Active Comparator|Control group (CG)|
89079021|NCT05017051||Dysexecutive patients|Patients with dysexecutive syndrome
89079022|NCT05017051||Healthy subjects|Healthy subjects to be used as control group
89079023|NCT05339971|Experimental|block perforation|
89079024|NCT02780557|Experimental|Contingent Reading Intervention|
89079025|NCT02780557|Other|Book Provision Control|
89079026|NCT04231045||Patients on PiCCO monitoring system|ALL intensive care patients on PiCCO monitoring system and over 18 years old and on PiCCO for more than 24 hours. Those medical or surgical patients admitted in a UK NHS unit, elective, semi-elective or emergency admission.
89079027|NCT04228471|Experimental|Spontaneous Breathing Group|"Spontaneous breathing activity will be allowed during APRV within one hour after randomization throughout the first 48 hours.~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
89079028|NCT04228471|Experimental|Controlled Mechanical Ventilation Group|"Pressure controlled mechanical ventilation will be applied throughout the first 48 hours.~After 48 hours, standard routine care should be provided in both groups, although we suggest moderate sedation while spontaneous breathing is maintained with APRV, pressure support ventilation (PSV), or other assisting ventilator modes. Weaning off mechanical ventilation will be performed after 48 hours according to a protocol using spontaneous breathing trials."
89079029|NCT02784145|Other|RS|Resistant starch supplementation (5 g twice a day)
89079030|NCT02784145|Other|No RS|PD patients who do not receive resistant starch, but who receive recommendations concerning healthy Nutrition (based on the guidelines of the German Society for Nutrition)
89079031|NCT05322031|Experimental|Onset of depression|15 participants with onset of schizophrenia who, after a period of stabilization with aripiprazole in oral formulation, would begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole since no more than two weeks.
89079032|NCT02779621|Experimental|Self-sampling|(Self-collecting a vaginal sample with a swab for HPV testing) Women in the experimental arm will have the option of vaginal self-sampling for HPV testing, in addition to the routine screening test. They can choose one of them.
89079033|NCT02779621|Active Comparator|Routine smear|(Collection of cervical sample for routine cervical screening) Women in the control arm will only receive the routine cervical screening invitation letter.
89079034|NCT02780011|Experimental|Alsertib and Brentuximab Vedotin|Brentuximab vedotin at a fixed dose of 1.8 mg/kg will be administered by intravenous infusion on day 1 of every 21-day cycle. MLN8237 at a dose of 60 mg will be orally administered daily in 2 divided doses (30 mg qAM, 30 mg qPM) from days 1 to 7 of each 21-day cycle. MLN8237 dose will be escalated in 20-mg increments to the maximum dose of 100 mg (Level 2) or de-escalated in a 20-mg decrement to the minimum dose of 40 mg (Level -1).
89079035|NCT02780479|Experimental|Dexamethasone|Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
89079036|NCT02780479|Active Comparator|Prednisone|Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.
89079037|NCT05252923|Experimental|Sulodexide|Standard treatment plus oral sulodexide
89079038|NCT05252923|No Intervention|Control|Standard treatment only
89079039|NCT00634855||Complicated|Women with pregnancies complicated by intrauterine growth restriction or preeclampsia
89079040|NCT00634855||Normal|Women with normal pregnancies
89079041|NCT05097079|Experimental|MYOBLOC Low Dose|Weight-based dose (5.0 units/kg for submandibular gland and 25.0 units/kg for parotid gland) will be administered as single treatment and compared to placebo
89079042|NCT05097079|Experimental|MYOBLOC High Dose|Weight-based dose (10.0 units/kg for submandibular gland and 40.0 units/kg for parotid gland) will be administered as single treatment and compared to placebo
89079043|NCT05097079|Placebo Comparator|Placebo|A volume-matched placebo will be administered as single treatment
89079044|NCT02779309||Development Cohort|437,000 home care recipients who received services from January 1, 2007 to December 31, 2012.
89079045|NCT02779309||Validation Cohort|122,000 home care recipients who received services from January 1, 2013 to December 31, 2013.
89079046|NCT02780635|Experimental|App + Couples Coach Intervention|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse. Those assigned to this arm will also receive mailed materials that are designed to help increase positive communication strategies.
89079047|NCT02780635|Active Comparator|App Alone|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse.
89079048|NCT02779387|Experimental|GnRH-a|"patients treated with GnRH-a after surgery and Outpatient guidance~."
89079049|NCT02779387|No Intervention|non GnRH-a|patients treated with outpatient guidance only.
89079050|NCT04228315|Experimental|Early primaquine group|Thirty (30) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and 15 mg/day of oral primaquine for 14 days
89079051|NCT04228315|Active Comparator|Delayed Primaquine group|Sixty (60) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and the primaquine regimen (15 mg/day for 14 days) not given until 42 days after enrollment
89079052|NCT04228315|No Intervention|Healthy control group|Ten (10) age- and gender-matched controls will be enrolled for one day to obtain biological samples to be compared to the 2 intervention arms
89079053|NCT04228393|Active Comparator|Standard treatment regimen|6-mercaptopurine was administered according to the Chinese Children Cancer Group (CCCG) protocol-ALL 2015.
89079054|NCT04228393|Experimental|Individualized treatment regimen|6-mercaptopurine was administered on the basis of Chinese Children Cancer Group (CCCG) protocol-ALL 2015 combined with Clinical Pharmacogenetics Implementation Consortium (CPIC), genotypes and the concentrations of 6-TGN in red blood cells.
89079055|NCT05246761||Cesarean section group|In the cesarean section group, all the pregnant women had only one prior cesarean section.
89079056|NCT05246761||Non-cesarean section group|In the non-cesarean section group, all the pregnant women are primipara，and never had a cesarean section.
89079057|NCT02779777|Experimental|Tipifarnib, Oral|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
89079058|NCT05296915|Experimental|tVNS + CBT-E group|N=10 Interventional group with transcutaneous stimulation of the auricular branch of the vagus nerve associated with targeted cognitive-behavioral therapy (following the CBT-E protocol, CG Fairburn - 2010.
89079059|NCT05296915|Experimental|rTMS + CBT-E group|N=10 Interventional group with repetitive transcranial magnetic stimulation associated with targeted cognitive-behavioral therapy (following the CBT-E protocol, CG Fairburn - 2010.).
89079060|NCT05296915|Experimental|Only CBT-E group|N=10 Group with only cognitive-behavioral therapy of eating disorders.
89079061|NCT05286697|Other|effect of increase intracranial pressure on postoperatve cognitive function|All patient will be given a mini mental test before and after the surgery and the optic nerve diameter will be measured 5 times during the surgery.
89079062|NCT05339425||Osteoporotic fracture|No additional intervention will be administered.
89079063|NCT05340049|Placebo Comparator|"Primary Group Control"|41 patients of the total sample are part of the placebo group, being these patients without active primitive reflexes and/or cranial blocks, or in smaller quantities than the other participants of the study
89079064|NCT05340049|Active Comparator|"Secondary group Rhythmic Movement Therapy"|40 patients of the total sample are part of the rhythmic movement therapy group, having 1 or all of the primitive reflexes active and/or cranial blocks studied.
89079065|NCT05340049|Experimental|"Tertiary group Craniosacral Therapy"|39 patients of the total sample are part of the rhythmic movement therapy group, having 1 or all of the primitive reflexes active and/or cranial blocks studied.
89079066|NCT05339347|Active Comparator|Active Comparator: Active Photoneuromodulation|Active stimulation with light fields as described in the intervention
89079067|NCT05339347|Sham Comparator|Sham Comparator: Sham Photoneuromodulation|The blinding will be done with sham light, which consists of fields that do not reproduce light, but which have the same size and thickness as the true one.
89079068|NCT05044975|Experimental|Sleep restriction, Stimulus control, and Systematic light exposure|
89079069|NCT05044975|Experimental|Sleep restriction and Stimulus control|
89079070|NCT05044975|Experimental|Sleep restriction and Systematic light exposure|
89079071|NCT05044975|Experimental|Stimulus control and Systematic light exposure|
89079072|NCT05044975|Experimental|Sleep Restriction|
89079073|NCT05044975|Experimental|Stimulus control|
89079074|NCT05044975|Experimental|Systematic light exposure|
89079075|NCT05044975|No Intervention|Sleep tracking|
89079076|NCT05339191|Experimental|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
89079077|NCT05339035|Experimental|experimental group|In the first stage, the participants will be trained according to the IMB model. In the second stage, 6 sessions of individual motivational interviews will be held for a total of 7 weeks. Finally, participants will be given hippotherapy 1 hour a week for 8 weeks.
89079078|NCT05339035|No Intervention|control group|attempt will not be implemented.
89079079|NCT01880359|Placebo Comparator|Radiotherapy+ Cisplatin+ Placebo|Accelerated radiotherapy (Therapeutic Planning Target Volume (PTV): 70 Gray (Gy), 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) Patients will receive placebo (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only).
89079080|NCT01880359|Experimental|Radiotherapy+ Cisplatin+ Nimorazole|"Accelerated radiotherapy (Therapeutic PTV: 70 Gy, 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) .~Patients will receive nimorazole (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only)."
89079081|NCT05338489|Experimental|Selpercatinib - Part 1 Period 1|Selpercatinib administered orally.
89079082|NCT05338489|Experimental|Selpercatinib and Itraconazole - Part 1 Period 2|Selpercatinib and itraconazole administered orally.
89079083|NCT05338489|Experimental|Selpercatinib - Part 2 Period 1|Selpercatinib administered orally.
89079084|NCT05338489|Experimental|Selpercatinib and Rifampin - Part 2 Period 2|Selpercatinib and rifampin administered orally.
89079085|NCT02779699|Experimental|AL2846|AL2846 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89079086|NCT05266417|Experimental|Active|Insulin (Novolin R) and Glutathione (INS-GSH)
89079087|NCT05266417|Placebo Comparator|Control|Placebo
89224705|NCT06251050|Experimental|0.15 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid, transparent colorless liquid. In this group, 10 ml of 0.15 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
89079088|NCT04228081||UTI Positive|"In phase I of the study testing residual urine samples the aim is to include at least 50 positive samples from each bacterial species known to be commonly associated with urinary tract infections. We selected 2000 positive urines to enable capturing enough of these organisms in the development process.~For phase II of the study, the same number of positive samples in order to include all common species causing urinary tract infection. The number of negative samples included is reduced to 1000.~Phase 3 - approximately one third of all urine sample submitted will be positive for a uropathogen. Sample size of 3000 we expect 1000 these to be culture positive. We expect most uropathogens occurring at a frequency of 5% or more will be included with sufficient numbers in the validation process."
89079089|NCT04228081||UTI Negative Control|2000 negative urine samples are being run as controlled to ensure the false positivity rate is low.
89079090|NCT05338411||Early or precocious puberty who receive GH|Children with early or precocious puberty who receive exogenous growth hormone
89079091|NCT05338411||Early or precocious puberty who does not receive GH|Children with early or precocious puberty who does not receive exogenous growth hormone
89079092|NCT05338411||Healthy|Healthy children without any past medical history
89079093|NCT02779465|Experimental|Vitamin D|Drug: Vitamin D3 800 IU daily besides the anti-virus treatment with nucleos(t)ide medicine
89079094|NCT02779465|No Intervention|Control|chronic hepatitis B patients with long term anti-virus therapy
89079095|NCT04985305|Experimental|Intervention Group|"Educational session for GPs~Instructed to complete 10-15 home visits at the nursing home with the optimizing antidepressants and other psychotropic drugs~Instructed to evaluate neuropsychiatric symptoms before and after the visit using a structured form~Instructed to complete a teaching session at the nursing home with a pre-defined teaching material~Instructed to contact the nursing home before the home visit to encourage participation of regular staff and relatives in the home visit or, alternatively, to obtain information from regular staff and relatives before the home visit~Dialogue tool"
89079096|NCT04985305|Active Comparator|Control Group|"Educational session for GPs~Instructed to complete 10-15 home visits at the nursing home with the optimizing antidepressants and other psychotropic drugs~Instructed to evaluate neuropsychiatric symptoms before and after the visit using a structured form"
89079097|NCT02779231|Experimental|Texting group|This group will be enrolled in bi-directional texting to send back blood pressure.
89079098|NCT02779231|No Intervention|Standard of care group|
89079099|NCT02776189|Experimental|Midazolam & Dexmedetomidine|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
89079100|NCT02776189|Active Comparator|Midazolam & Propofol|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous propofol 2 mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
89079101|NCT04841707|Experimental|COVID-19 patients|
89079102|NCT04226287|Experimental|Monterey Pneumatic Compression Device|All participants will receive treatment with the Monterey investigational pneumatic compression device
89079103|NCT02778139||youth smokers|
89079104|NCT02778139||non-smokers|
89079105|NCT04228003|Experimental|Pendulum|Pendulum Glucose Control formulation for T2D will be taken twice daily - 1 capsule with the morning meal and 1 capsule with the evening meal for 8 weeks with an option of continuing up to 6 months.
89079106|NCT02776267|Experimental|Angiolite stent - 3-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 3-month post index PCI.
89079107|NCT02776267|Experimental|Angiolite stent - 6-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 6-month post index PCI.
89224706|NCT06251050|Experimental|0.21 mol/L lithium mouthwash|The main ingredients of mouthwash are lithium carbonate and citric acid, transparent colorless liquid. In this group, 10 ml of 0.21 mol/L lithium mouthwash is used to gargle and left in the mouth for 5 min to be spat out from the first day of radiotherapy up to the end of treatment.
89079108|NCT02776345|Active Comparator|Ultrasound guided Needle Fragmentation|"Ultrasound guided Needle Fragmentation (Intervention):~Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed."
89224707|NCT06251050|Active Comparator|Lithium mouthwash|Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions.
89224708|NCT06251050|Placebo Comparator|Placebo mouthwash|Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid.
89079109|NCT02776345|Active Comparator|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
89079110|NCT02776345|Placebo Comparator|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
89079111|NCT02776111||Healthy Controls|Participants in this group will have a one time blood sample taken.
89079112|NCT02776111||Kidney Transplant Group|Participants in this group have had a kidney transplant and blood samples will be obtained as described in study plan
89079113|NCT02775955|Experimental|RX0041-002|Active
89079114|NCT04931407|Experimental|Interdisciplinary complex intervention|The intervention includes patient education, physical exercise, a group-based cognitive behavioral program and individual nutritional counseling
89079115|NCT05045833|Experimental|5 mg SYN-020|1 x 5 mg oral capsule, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
89079116|NCT05045833|Experimental|15 mg SYN-020|1 x 15 mg oral capsule, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
89079117|NCT05045833|Experimental|45 mg SYN-020|3 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
89079118|NCT05045833|Experimental|75 mg SYN-020|5 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
89079119|NCT05045833|Experimental|≤ 75 mg SYN-020 (new formulation)|≤ 5 x 15 mg oral capsules, 14 days, dosing every 12 hours, 6 subjects receive active, 2 subjects receive placebo
89079120|NCT02778217|No Intervention|Uninterrupted single embryo culture|The same single medium is used throughout the 5-6 days of culture with no replenishment on day 3.
89079121|NCT02778217|Experimental|Interrupted single medium culture|The single step medium is renewed on Day 3 of embryo culture.
89079122|NCT02777983|Experimental|Education Group|This will consist of a 6-minute educational video app created and delivered within an application (mobile app) that will be interactive in nature, asking multiple-choice questions at the end to help reinforce key points of the video message. It will include self-management guidance based on evidence related to activity, exercise, and other behavioral components known to influence the prognosis of low back pain. Subjects will also receive the 1-page general conditioning handout that the usual care group will receive.
89079123|NCT02777983|No Intervention|Usual Care Group|Subjects randomized to usual care will receive a 1-page generic informational handout on general conditioning recommended for low back pain, in addition to whatever education the subject's PCP decides to provide.
89079124|NCT05214937|Experimental|Intervention|Participants will be provided with a FitBit Inspire 2 and assigned a movement specialist. They will be asked to monitor their daily steps over the 12-week intervention period. Participants will attend 6 remotely-delivered behaviour change sessions (4 one-on-one sessions with their movement specialist, 2 group-based webinars). Sessions will be delivered bi-weekly and last ~30 minutes.
89079125|NCT05214937|Active Comparator|Fitbit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living (e.g., 24-hour movement guidelines).
89079126|NCT01194258|Experimental|Lispro-PH20/Insulin lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next, participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (combined: Lispro-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
89079127|NCT01194258|Experimental|Aspart-PH20/Insulin Lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 U/mL insulin glulisine, injected SC, pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 µg/mL rHuPH20 (combined: Aspart-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
88816157|NCT03011918||Observational Single Event Faller|one documented fall as an in-patient. It is hypothesized that the nutrition factors present prior to the first fall may be related to fall frequency. Data on exposure to nutrition supplementation will be collected for future analysis. Subpopulation alalysis of individuals with dementia will also be conducted
89079128|NCT04883437|Experimental|Treatment (acalabrutinib, obinutuzumab)|"INDUCTION PHASE: Patients receive acalabrutinib PO BID on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of cycle 3, then on day 1 of cycles 4-8. Treatments repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~FOLLOW-UP PHASE: After cycle 12, patients who are in CR are randomized to either discontinue acalabrutinib or to continue acalabrutinib monotherapy in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after cycle 12 continue acalabrutinib monotherapy in the absence of disease progression or unacceptable toxicity. Patients with disease progression after cycle 12 discontinue study treatment. Patients with disease progression at any time prior to the conclusion of cycle 12 may continue study therapy if they are felt to be benefiting by the treating physician, but not past cycle 12."
89079129|NCT02777905|Experimental|MBCT intervention|"Mindfulness Based Cognitive therapy (MBCT) will consist of group meditative practices, lasting 2 hours per week (or whatever the patient can tolerate). The interventions will be conducted at the centre local de services communautaires (CLSC) Benny Farm, once a week. Patients will be invited to try various techniques during sessions. The patients will be encouraged to practice the Mindfulness techniques, that includes formal mindfulness meditation and informal mindfulness practices (e.g. being in the present moment while not meditating), at home, between sessions, and will be provided with meditation compact discs to help them do so. MBCT interventions also include a cognitive therapy perspective. Specifically, the interventionists will offer education regarding depression and anxiety and will work on automatic mental processes that are believed to be at the root of the recurrence of depressive and anxious symptoms."
89079130|NCT02777905|No Intervention|Control Group|Patients randomized to the control group will be offered literature on mental health promotion and will receive treatment as usual in the primary care health center setting. After the end of the study, the control group will be offered MBCT.
89079131|NCT01193556|Active Comparator|Standard of Care|Traditional electrosurgery will be used for the tonsillectomy.
89079132|NCT01193556|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the tonsillectomy.
89079133|NCT02775877|Experimental|letrozole and clomiphene|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and clomiphene100 mg tablet orally once a day from 11-15 day of menstrual cycle.
89079134|NCT02775877|Active Comparator|Letrozole and human menopausal gonadotropin (HMG)|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and HMG 75u once a day by intramuscular injection from 11-15day of menstrual cycle
89079135|NCT02778763|Experimental|One injection of CBLB612 after Сhemo|One injection of placebo at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of 4 μg CBLB612 at Day 1 (24 hours after AC chemotherapy treatment)
89079136|NCT02778763|Experimental|One injection of CBLB612 prior Сhemo|One injection of 4 μg CBLB612 at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of placebo at Day 1 (24 hours after AC chemotherapy treatment)
89079137|NCT02778763|Placebo Comparator|Placebo|Two injections of placebo at Day -2 and Day 1 (48 hours prior and 24 hours after AC chemotherapy treatment)
89079138|NCT04228159|Experimental|Perturbation training|"Session1 - baseline assessment (detailed above) Session2 - 13 - each session will begin with reassessment and documentation of balance tutor parameters for each participant as were calibrated at the end of previous session.~After reassessment the training program will include:~Warm up - walking without perturbation.~Perturbation during standing position.~Perturbation during walking.~Perturbation during tandem position.~Perturbation with vestibular stimulation.~Rest according to patient needs The relative duration of each component, as well as intensity and frequency of perturbations, will be adjusted to each individual according to his ability, reassessment parameters and progression.~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
89224709|NCT06250309|Active Comparator|Mediterranean Diet (MD)|The Mediterranean Diet (MD) includes similar food patterns to those described in the Healthy Mediterranean-Style Dietary Pattern in the Dietary Guidelines for Americans, 2020-2025. The daily caloric needs of participants will be calculated to ensure weight stability. For a daily 2,000 kcal diet, participants will consume 2.5 cup equivalents of vegetables, 2.5 cup equivalents of fruits, 3 ounce equivalents of whole grains, 2 cup equivalents of dairy, 6 ounces equivalent of protein foods (with 32% from seafood, and 11% from nuts, seeds and soy products), and 27 grams of canola or olive oil, per day. No more than 12% of calories per day will come from discretionary foods (I.e., added sugar, saturated fat).
89224710|NCT06250309|Active Comparator|Western Diet (WD)|The Western Diet (WD) includes similar food patterns to those described in the Data Tables of What We Eat in America, NHANES (13) . We will match intake according to gender and age group in years (I.e., 20-29; 30-39; 40-49; 50-59; 60-69; 70 and over). On average, participants will consume 1.6 cup equivalent of vegetables, 0.9 cup equivalents of fruits, 0.8 ounce equivalents of whole grains,1.4 cup equivalents of dairy, 6.3 ounces equivalent of protein foods (with 10% from seafood, and 14% from nuts, seeds and soy products). The diet will contain 12% of calories per day from saturated fat, and 12.7% of calories from added sugars.
89224711|NCT06250088|Active Comparator|Emdogain (EMD)|
89224712|NCT06250088|Sham Comparator|Control|
89079139|NCT04228159|Active Comparator|Balance and strengthening exercise|"Session1 - baseline assessment (detailed above).~Session2 - 13 - each session will include:~Warm up (free walking or cycling).~Static balance exercise - standing position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.~Dynamic balance exercise - walking position. Exercise will be performed using different bases of support (narrow, tandem, and one leg stance), eyes open/closed, unstable surfaces, functional and cognitive dual task, and vestibular stimulation.~Strengthening exercise - general strengthening, particularly for lower limb.~Cool down. Level of difficulty and duration of each component will be adjusted to each individual according to his ability and progression.~Session14 - full reassessment of all baseline examinations including: Mini-BESTest, ABC scale, PASE, and number of falls."
89079140|NCT04226989|Experimental|Administration of CT-RD06|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89079141|NCT04875013|Experimental|Vestibular rehabilitation with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
89079142|NCT05021107|Experimental|Group A|Fascial Distortion Model with neck isometrics
89079143|NCT05021107|Active Comparator|Group B|Fascial Distortion Model with neck isometrics
89224713|NCT06248411|Experimental|KK2260 (Dosing regimen 1)|
89224714|NCT06248411|Experimental|KK2260 (Dosing regimen 2)|
89079144|NCT02777359|Experimental|the closure group|In the closure group, the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA, in combination of clopidogrel(50mg/d, 3mon) and aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
89079145|NCT02777359|No Intervention|the medication group|In the medication group, in combination of clopidogrel (50mg/d, 3mon) and aspirin (0.1g/d, 6mon), current medication resumed, including conventional prescription for migraine as β-receptor blockers, calcium-ion antagonists, antiepileptics, antidepressants and non-steroid anti-inflammatory drugs (NSAID).
89079146|NCT02777671|Experimental|Group A|Period 1 - BIA 2-093 + Gliclazide Period 2 - Gliclazide
89079147|NCT02777671|Experimental|Group B|Period 1 - Gliclazide Period 2 - BIA 2-093 + Gliclazide
89079148|NCT02777515|Other|Patients using electronic cigarette|The patients under the age of 35 followed at the consultation of rythmology for a cardiovascular assessment and already smoking the electronic cigarette and this since at least 1 month. The patient will receive a clinical examination, an electrocardiogram, a Holter-ECG and an echocardiogram before and after electronic cigarette consumption for 15 minutes.
89079149|NCT02777437|No Intervention|Laparoscopic surgery|Patients with T4 colon cancer receive laparoscopic surgery only.
89079150|NCT02777437|Experimental|Neoadjuvantive chemotherapy + Laparoscopic surgery|Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
89079151|NCT04226521|Experimental|Photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
89079152|NCT04226521|No Intervention|No prophylactic photopheresis|Standard post-transplant protocol without prophylactic extracorporeal photopheresis
89079153|NCT02775721|Other|Cohort A|"Head and Neck Cancer patients receiving Radiation Therapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts B and C.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
89079154|NCT02775721|Other|Cohort B|"Head and Neck Cancer patients receiving Chemotherapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and C.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
89224715|NCT06244459|Experimental|Hemiplegia Group|Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.
89224716|NCT06243861||kangaroo unit|
89224717|NCT06243861||postnatal care|
89079155|NCT02775721|Other|Cohort C|"Head and Neck Cancer patients receiving Chemotherapy and Radiation therapy. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and B.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
89079156|NCT04903951|Experimental|ASV therapy + best medical treatment for stroke, including rehabilitation|Adaptive Servoventilation (ASV) therapy plus best medical treatment for stroke, including rehabilitation.
89079157|NCT04903951|Active Comparator|Best medical treatment for stroke, including rehabilitation|Best medical treatment for stroke, including rehabilitation.
89079158|NCT02775487||COPD and air quality|Persons enrolled in the study will have been diagnosed with Stage III or IV COPD and samples of air taken from their home environment.
89079159|NCT04225741|Experimental|training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs.22,23 Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.22-24
89079160|NCT04225741|No Intervention|Control Group|None of the interventions described above were applied to the control group.
89079161|NCT02775253|Experimental|Chronic cold acclimation group|All patients will be conducted a chronic cold acclimation intervention for 33 days.
89079162|NCT04227691|Active Comparator|Long-pulsed Nd YAG laser treatment|Ten patients will be randomized to receive Long-pulsed Nd:YAG in either left or right axilla. (The other axilla will serve as within-person control)
89079163|NCT04227691|Active Comparator|IPL treatment|Ten patients will be randomized to receive IPL treatment in either left or right axilla. (The other axilla will serve as within-person control)
89079164|NCT02775175|No Intervention|Fasting as Usual|This group will continue to practice their usual fasting regimen during Ramadan
89079165|NCT02775175|Experimental|Modified Ramadan Fasting|This group will receive an educational intervention providing knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
89079166|NCT02778841|Experimental|XBox Kinact Exercise|Kinact game intervention group performed three times per week on non-consecutive days for eight weeks
89079167|NCT02778841|Experimental|conventional balance exercises|conventional balance exercises group performed three times per week on non-consecutive days for eight weeks
89079168|NCT02778841|Experimental|concurrent exercise group|Concurrent group performed mixed conventional balance and Xbox Kinact exercises three times per week on non-consecutive days for eight weeks
89079169|NCT02778841|No Intervention|control Group|There is no exercise for this group
89079170|NCT02775097||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
89079171|NCT02775097||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus.
89079172|NCT01129687||ANSRS group|Patients qualifying for the study.
89079173|NCT02775019|Active Comparator|Lactobacillus reuteri lonzenges|2x daily repeated intake of lozenges containing 10E9 CFU Lactobacillus reuteri each for 42 days
89079174|NCT02775019|Placebo Comparator|Placebo lozenges|2x daily repeated intake of lozenges being void of Lactobacillus reuteri for 42 days.
89079175|NCT04194853|Experimental|EMG Biofeedback assisted Quadriceps exercises.|Hot Pack will be applied before session for general relaxation for 10 minutes. Knee isometric exercises will be performed via an EMG Biofeedback device; patients in the EMG BF group will receive visual and auditory feedback.Knee isometrics will be performed with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets) Session will be performed thrice a week for six weeks.
89079176|NCT04194853|Active Comparator|Quadriceps exercises without EMG Biofeedback|Hot Pack will be applied before session for general relaxation 10 minutes. In the control group, the active electrode will not be connected, so subjects will not receive any feedback from the device. Knee isometrics perform with 5 seconds hold. Then, the muscle will be relaxed for 10 seconds and the cycle repeated for a total of 15 minutes. (20 reps, 3 sets)Session will be performed thrice a week for six weeks.
89079177|NCT02774863||"Group Maternal and Child Protection"|Followed by the doctor and pediatric nurse of the Maternal and Child Protection . A child psychiatric consultation (usual care) can take place during the monitoring of this patient.
89079178|NCT02774863||"Group Home passages"|A child psychiatric consultation is scheduled in the month following the inclusion and three home passages between the 2nd and 3rd months of follow up.
89079179|NCT02778919|Experimental|KLH-2109, lowest dose|
89079180|NCT02778919|Experimental|KLH-2109, low dose|
89079181|NCT02778919|Experimental|KLH-2109, medium dose|
89079182|NCT02778919|Experimental|KLH-2109, high dose|
89079183|NCT02778919|Placebo Comparator|Placebo|First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels
89079184|NCT02778919|Other|Leuprorelin acetate|Active reference
89079185|NCT02779153|Experimental|Acthar low dose (40 U)|
89079186|NCT02779153|Experimental|Acthar high dose (80 U)|
89079187|NCT04226443|Active Comparator|Group 1|In Group 1(n=50); continuous infusion of intravenous midazolam (Dormicum, Deva Pharmaceutical, Turkey) at a dose of 0.02 to 0.04 mg/kg/h was started at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
89079188|NCT04226443|Active Comparator|Group 2|in Group 2 (n=49), intravenous bolus doses of midazolam at a dose of 0.015 mg/kg every 10 minutes were administered at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
89079189|NCT04180891||successful test|Students that have successfully passed the test procedure (directly with written exam or after written and oral interviews) and that can enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery).
89079190|NCT04180891||failed test|Students that have failed to enter one of the four medical courses of health studies (medicine, pharmacy, dentistry, midwifery) after the selection procedure.
89079191|NCT02776891|Experimental|Gallium citrate|The patients will be organized into two cohorts. Cohort 1 will receive 10 mCi and will be imaged 4 and 6 hours post injection. Cohort 2 will receive 15 millicurie (mCi) and will be imaged 4 and 6 hours post injection. Cohort 2 will be imaged if the optimal protocol identified image quality from cohort 1 does not allow for the resolution of cancer lesions.
89079192|NCT02776813|Experimental|ACTR087, in combination with rituximab|
89079193|NCT02776657|Active Comparator|Cohort 1 (Stable Angina)|20 patients with stable angina planned to undergo elective coronary angiography will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries.
89079194|NCT02776657|Active Comparator|Cohort 2 (Acute Coronary Syndrome)|20 patients diagnosed with acute coronary syndrome will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries. If thrombus is identified, participants will be asked to undergo a repeat MRI scan at one and three months.
89079195|NCT02774551|Experimental|Physical activity intervention group|The physical activity program includes 150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week are demonstrated by the research nurse. The resistance training is progressive by increasing resistance in the band based on patient's adaptability during the intervention.
89079196|NCT02774551|No Intervention|Standard care control group|Patients follow their routine daily physical activity.
89079197|NCT02778607||Progressive Supranuclear Palsy|Patients with a current clinical diagnosis of Progressive Supranuclear Palsy (PSP)
89079198|NCT02778607||Multiple System Atrophy|Patients with current clinical diagnosis of Multiple System Atrophy (MSA).
89079199|NCT02778607||Atypical Parkinsonian Syndrome|Atypical Parkinsonian Syndrome (APS) patients who do not fulfil existing criteria for PSP/CBD/MSA, but may represent variant clinical syndromes related to tau pathology including pure akinesia with gait freezing (PAGF), PSP-parkinsonism, overlap syndromes and atypical parkinsonian disorders not meeting clinical diagnostic criteria at entry
89079200|NCT02778607||Controls|Participants unaffected by neurological or psychiatric disease
89079201|NCT02778607||Corticobasal Degeneration|Patients with a current clinical diagnosis of Corticobasal Degeneration (CBD)
89079202|NCT02774395||endometrioid adenocarcinoma grade I|
89079203|NCT02774395||endometrioid adenocarcinoma grade II|
89079204|NCT02774395||endometrioid adenocarcinoma garde III|
89079205|NCT02774395||healthy endometrioid|obtain after hysterectomia provided for
89079206|NCT02774317|Active Comparator|FFP|Patients receive FFP as clinically indicated (INR 1.5 or more)
89079207|NCT02774317|Experimental|FP24|Patients receive FP24 as clinically indicated (INR 1.5 or more)
89079208|NCT02774161|Experimental|Diagnostic (B-mode ultrasound imaging)|Patients undergo B-mode ultrasound imaging of the liver over 15 minutes.
89079209|NCT04936243|Experimental|FOLLOW UP VISIT-TELEMEDICINE|After initial in-person routine followup care, participants will be randomly assigned to receive telemedicine care delivery for their subsequent follow up appointment. Participants will complete a survey after each visit.
89079210|NCT04936243|Experimental|FOLLOW UP VISIT-FACE TO FACE|After initial in-person routine followup care, participants will be randomly assigned to receive face-to-face care delivery for their subsequent follow up appointment. Participants will complete a survey after each visit.
89079211|NCT02774083|Active Comparator|Feuerstein Program|The participants of the Intervention Group will participate in the Feuerstein mediated learning cognitive program.
89079212|NCT02774083|Placebo Comparator|Adler Program|The Control Group will participate in the program of the Adler Institute dealing with social and emotional development without specific cognitive skills training.
89079213|NCT05157997|Experimental|Casirivimab and Imdevimab Antibody Cocktail|Patients receiving a Covid-19 positive liver, kidney, or heart transplant.
89079214|NCT02776501|Experimental|BAY987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89079215|NCT02776579|Experimental|Girls-only resistance training|8 weeks of 2-3x/week girls-only resistance training class with a female strength and conditioning specialist.
89079216|NCT02776579|No Intervention|No resistance training|8 weeks of usual activity.
89079217|NCT02778373|Placebo Comparator|Placebo|Flavored Water
89079218|NCT02778373|Active Comparator|Low Molecular Weight Carbohydrate|low molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
89079219|NCT02778373|Experimental|High molecular weight carbohydrate|high molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
89079220|NCT02772835|Active Comparator|nHFOV|Starting treatment mode: nHFOV with Medin-cno. Targeted oxygen saturation: 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the beginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A second capillary BGA will be performed at the end of second period.
89079221|NCT02772835|Active Comparator|nCPAP|Starting treatment mode: nCPAP with Medin-cno. Targeted oxygen saturation of 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the be-ginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A se-cond capillary BGA will be performed at the end of second period.
89079222|NCT02773147|Experimental|Triobe|Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.
89079223|NCT02773147|No Intervention|Control|
89079224|NCT02773927|Experimental|Agave inulin + Metformin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
89079225|NCT02773927|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
89079226|NCT02773927|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
89079227|NCT02773927|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
89079228|NCT02773771|Placebo Comparator|Placebo + Vital HP|GROUP 1 will receive Placebo (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas.
89079229|NCT02773771|Experimental|B-hydroxy-B-methylbutyrate (HMB) + Vital HP|GROUP 2 will receive beta-hydroxy-beta-methylbutyrate (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas. The investigators will limit HMB dosing to 3g/day since this is the most widely studied dose.
89079230|NCT02773693|Active Comparator|CPT|Cognitive Processing Therapy-cognitive only version (typically labeled CPT-C, but labeled CPT in this grant for simplicity) is a type of Cognitive Therapy addressing daytime symptoms of PTSD. This arm will have 12 twice-weekly sessions, followed by 6 weekly sessions.
89079231|NCT02773693|Active Comparator|CBTin+CPT|Cognitive Behavioral Therapy of Insomnia and nightmares (CBTin) will be used to address nighttime symptoms of PTSD during 6 weekly sessions, followed by 12 twice-weekly sessions of CPT.
89079232|NCT02773693|Active Comparator|CPT+CBTin|12 twice-weekly sessions of CPT followed by 6 sessions of CBTin.
89079233|NCT02773459|Experimental|Phase 1 part|to assess the maximal tolerated dose (MTD) of MEK162+Capecitabine combination
89079234|NCT02773459|Experimental|Expansion part|to assess the efficacy (PFS) of MEK162+Capecitabine combination
89079235|NCT02773303|Active Comparator|Active|Children receiving Mente Autism™ neurofeedback therapy to use at home for 40 minutes a day for 12 weeks
89079236|NCT02773303|Sham Comparator|Control|Children not receiving neurofeedback based therapy, but receiving the Sham therapy
89079237|NCT02773225|Experimental|Eltrombopag + Ciclosporin A|"Eltrombopag, 75 mg film tablets, starting dose: 2 tablets (150 mg per day), daily, per os~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
89079238|NCT02773225|Placebo Comparator|Placebo + Ciclosporin A|"Placebo for Eltrombopag 75 mg film tablets, 2 tablets, daily, per os~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
89079239|NCT02773381|Experimental|Semaglutide 3 mg, 7 mg, 14 mg|
89079240|NCT02773381|Placebo Comparator|Placebo|
89079241|NCT04818229|Experimental|Investigational Group 1|Therapeutic and supratherapeutic multiple oral doses of CBP-307.
89079242|NCT04818229|Placebo Comparator|Investigational Group 2A|Moxifloxacin (positive control for method validation) and Placebo oral administration.
89079243|NCT04818229|Placebo Comparator|Investigational Group 2B|Moxifloxacin (positive control for method validation) and Placebo oral administration.
89079244|NCT02772991|Experimental|Cases|All patients will be submmited to troponin measurements and CCTA. If CCTA shows coronary stenosis ≥ 50%, patient will initiate the ACS treatment and be hospitalized to have coronary cineangiography. If CCTA shows lesions < 50%, the patient will be discharged and monitored for 30 days. A second sampling of the troponin will be obtained from all patients three hours after the first collection in order to evaluate for an increase/decrease of troponin.
89079245|NCT02772913||acute mesenteric ischemia|patients with abdominal pain and acute mesenteric ischemia
89079246|NCT02772913||non-acute mesenteric ischemia|patients with abdominal pain without mesenteric ischemia
89079247|NCT02773069|Experimental|Weight loss program|Participants will attend a 12 session weight loss program accompanied by maintenance support delivered by a church. Program will include peer education, telenutrition counseling and mobile health feedback.
89079248|NCT02772523|Other|Intervention|
89079249|NCT04771741||Multimodal Pain Pathway|"This group will receive the multimodal pain pathway cocktail of medications. This cocktail includes:~Tylenol (acetominophen), 1000 mg, every 6 hours as needed for pain~Ketorolac (Toradol), 10 mg, every 6 hours as needed for pain until post-op day 3~Mobic (Meloxicam), 15 mg once daily, beginning on post-op day 4~Flexeril (Cyclobenzaprine), 10 mg every 8 hours as needed for pain~Pregabalin (Lyrica), 75 mg every 12 hours as needed for pain"
89079250|NCT02772445|Experimental|STROKE-CARE Intervention|In STROKE-CARE, caregivers will learn a problem-solving strategy. Participants will receive approximately 10 sessions by an occupational therapist in the home over a 5 week process.
89079251|NCT02772601|Experimental|All patients|
89079252|NCT02772055|Experimental|moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
89079253|NCT02772055|Experimental|smoke-free moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants and have a purification device at the top of the moxibustion to remove the moxa smoke.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
89079254|NCT02772133||STEMI patients|
89079255|NCT02772133||Healthy subjects|
89079256|NCT02772133||Unstable angina|
89079257|NCT02772211|Experimental|D-cycloserine|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral D-cycloserine, titrated slowly up to 1000mg/d over the next 8 weeks.
89079258|NCT02772211|Placebo Comparator|Placebo|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral Placebo pills, titrated slowly up to 1000mg/d over the next 8 weeks.
89079259|NCT02767687|Experimental|Noninvasive ventilation (NIV)|Noninvasive mechanical ventilation is a resource used to treat respiratory failure or to reestablish respiratory comfort and function. It is commonly used in the ICU with a regular mechanical ventilator and is offered using an interface that connects the machine to the patient. The interface used for adults and in this study, was a silicon facial mask that covers the nose and mouth of the patient, allowing him or her to open the eyes.
89079260|NCT02767297|Experimental|Part 1: Single dose (cross over)|FDL169 reference formulation and test formulation administered as a single dose in healthy subjects
89079261|NCT02767297|Experimental|Part 2: Multiple dose (dose level 1)|FDL169 test formulation (Dose level 1) administered as repeat doses in healthy subjects
89079262|NCT02767297|Experimental|Part 2: Multiple dose (dose level 2)|FDL169 test formulation (Dose level 2) administered as repeat doses in healthy subjects
89079263|NCT02767297|Experimental|Part 2: Multiple dose (dose level 3)|FDL169 test formulation (Dose level 3) administered as repeat doses in healthy subjects
89079264|NCT02767297|Experimental|Part 3: Single dose|FDL169 test formulation administered as a single dose in CF subjects
89079265|NCT02772289|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
89079266|NCT02772289|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
89079267|NCT02772289|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
89224718|NCT06241963|Active Comparator|Unilateral real High definition transcranial direct current stimulation|"The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10 .~In the unilateral treatment group, HD-tDCS treatment based on Epileptic discharge is placed on either the left or right side of the brain.Ten 2-mA sessions were applied for 30 minutes,once a day over 10 consecutive workdays."
89224719|NCT06241963|Active Comparator|Bilateral real High definition transcranial direct current stimulation|"The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10 .~In the bilateral treatment group, HD-tDCS treatment was placed on the left and right sides of the brain, at least eight hours apart.. Twenty 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 30 minutes,twice a day over 10 consecutive workdays."
89079268|NCT04225195|Experimental|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"Patients with invasive candidiasis (IC) will only receive intravenous treatment with ABCD. ABCD will be administered once a day at a dose of 3-4 mg/kg.~Patients with invasive aspergillosis (IA) will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. ABCD dosing regimen will be the same as that for IC patients."
89079269|NCT02771821|Experimental|Group Intervention|Individual routine consultation with the Family Health Unit team and participation in operative groups based on methodology of problematization
89079270|NCT02771821|No Intervention|Control Group|Individual routine consultation with the Family Health Unit team
89079271|NCT02771899|Experimental|EOS + spineEOS software in adults|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
89079272|NCT02771899|Active Comparator|EOS in adults|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
89079273|NCT02771899|Experimental|EOS + spineEOS software in children|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
89079274|NCT02771899|Active Comparator|EOS in children|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
89079275|NCT04227223|Experimental|Study Group|Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy
89079276|NCT04227223|Active Comparator|Control Group|Control Group - 14 patients, healthy volunteers.
89079277|NCT02771509|Active Comparator|ANG-3777|Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
89079278|NCT02771509|Placebo Comparator|Normal Saline|The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
89079279|NCT02697019|Experimental|Internet-delivered ERITA|
89079280|NCT02696941|Experimental|Metformin|Participants with insulin resistance who have not yet started any diabetic medication will be recruited and will be prescribed metformin at standard clinical doses.
89079281|NCT02696941|Experimental|SGLT2|Participants with poorly controlled type 2 Diabetes (T2DM) who have been recommended to start an SGLT2 inhibitor will be recruited.
89079282|NCT02771665||Breast cancer women with known recurrences|Breast cancer women with known recurrences (locoregional recurrence and distant metastasis)
89079283|NCT02771665||Breast cancer women without recurrences|Breast cancer women without recurrences
89079284|NCT02767375|Active Comparator|HAIC treatment group|HAIC treatment after resection Intervention: Drug: Oxaliplatin, 5-fluorouracil (5-FU) Procedure/Surgery: Hepatic arterial catheter implantation
89079285|NCT02767375|No Intervention|No HAIC treatment group|Best support care and follow up
89079286|NCT02767453|Active Comparator|TSA with drain placement|Hemovac drains are placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
89079287|NCT02767453|Active Comparator|TSA without drain placement|Hemovac drains will not be placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
89079288|NCT02767219|Other|Dexamethasone and 5-fluorouracil|The control arm consists of current standard therapy of subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of 5-fluorouracil as required for 4 consecutive weeks after entry into the trial.
89079289|NCT02767219|Active Comparator|Dexamethasone and Avastin|Subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of bevacizumab will be given for 4 consecutive weeks from time of entry into trial
89079290|NCT02766829|Experimental|CLSP Group|Those with cross leg sitting position: patients sit with both their knees flexed medially, hip flexed, resulting in pelvic leaning posteriorly and reducing lumbal lordosis.
89079291|NCT02766829|Active Comparator|TSP Group|Those with traditional sitting position: patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion.
89079292|NCT04711993|No Intervention|Control group|No application will be made to the control group. However, these patients will be included in the exercise program they want after the 8-week treatment period is completed.
89079293|NCT04711993|Experimental|Aerobic exercise group|Patients in the aerobic exercise group will exercise under the supervision of the therapist.
89079294|NCT04711993|Experimental|Stretching exercise group|Patients in the stretching-mobility exercise group will do stretching exercises under the supervision of the therapist
89079295|NCT02771587|Experimental|Alcohol and energy drink|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
89079296|NCT02771587|Active Comparator|Alcohol|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
89079297|NCT02771587|Active Comparator|Energy drink|3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.
89079298|NCT02771587|Placebo Comparator|Placebo|"3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.~Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration."
89079299|NCT04742725|Placebo Comparator|Placebo|
89079300|NCT04742725|Experimental|Prothione ™|
89079301|NCT02778451|Other|Ultrasonography-experienced surgeons|Attending physicians and consultants in head and neck surgery using head and neck Ultrasonography on a daily basis.
89079302|NCT02778451|Other|Ultrasonography novices|Physicians participating in their one-year internship at other surgical or medical departments with no experience with head and neck US or head and neck surgery.
89079303|NCT02771743|Experimental|High risk neuroblastoma|"Nine cycles of induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen~Upfront surgery or surgery after 6 cycles of chemotherapy~Peripheral stem cell mobilization after 7 cycles of chemotherapy~Tandem high dose chemotherapy with autologous stem cell transplantation (Tandem HDCT/auto-SCT)~Dose of chemotherapeutic agents of 1st HDCT is tailored according to the residual positron emission tomography (PET)/Metaiodobenzylguanidine (MIBG) uptake before 1st HDCT~Dose of MIBG of 2nd HDCT is tailored according to the residual PET/MIBG uptake before 2nd HDCT~Radiotherapy after tandem HDCT~Immunotherapy and differentiation therapy with Interleukin-2/isotretinoin"
89079304|NCT02762851|Experimental|Influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine prior to the influenza season.
89079305|NCT02762851|Placebo Comparator|Placebo vaccine|Participants at high risk for adverse vascular events will be vaccinated with a 0.5 ml dose of sterile saline prior to the influenza season.
89079306|NCT02771431|No Intervention|Standard|Group 1 will consist of patients receiving in-person attending-patient encounters while inpatients.
89079307|NCT02771431|Experimental|Tele-rounding|Group 2 will consist of patients receiving video-conference attending-patient encounters. The intervention is being seen via ipad
89079308|NCT02770963|Experimental|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~Huatuo Brand needle (0.3*75 mm) will be used for BL25 and Huatuo Brand needle (0.3*40mm) will be used for BL23, BL40 and BL57."
89079309|NCT02770963|Sham Comparator|Sham acupuncture|The acupoints will be the same as the acupuncture group. Specially designed sham needles (0.3*25 mm) will be used . The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).
89079310|NCT02771041|Experimental|Group with D-8 medical consultation|"A medical consultation 8 days before surgery would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
89079311|NCT02771041|No Intervention|Group without D-8 medical consultation|
89079312|NCT04224805|Active Comparator|Control|Interocclusal conventional splint is used to reposition the maxilla.
89079313|NCT04224805|Experimental|Study|Bone-borne splint is used to reposition the maxilla.
89079314|NCT04710433|Active Comparator|Non-invasive Neuromodulation|"Application of non-invasive sacral nerve stimulation for 12 weeks, at least 8 hours per day.~Two adhesive electrodes are placed paravertebrally between L1 and L4 and periumbilically, generating an electrical field with a 15 Hz frequency for a duration of 210µs. Stimulation intensity is individually determined to achieve an effective and comfortable stimulation beyond the pain threshold (adjustable amplitude between 0-10mA).~Medical and behavioral therapy is to be continued as started before intervention."
89079315|NCT04710433|Other|Medical/behavioral Therapy|Patients receive an optimized conventional treatment for 12 weeks, including lifestyle changes, toilet training and weight-adjusted medication. Conventional medical options include oral laxative medication with polyethyleneglycol or rectal medication with saline enemas in possible combination with a stimulant laxative (glycerin or bisacodyl).
89079316|NCT02766985||FSHD|Participants with FSHD-1 or FSHD-2. No intervention is given to participants. Participants will undergo series of tests and procedures in order to make a standardized and scalable Rasch-built clinical severity scale.
89079317|NCT02767063|Experimental|Experimental Arm_ACTOS|"TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months~PIOGLITAZONE (Actos®):~30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE."
89079318|NCT02767063|No Intervention|controled Arm|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
89079319|NCT02767063|Experimental|Experimental Arm_AVELUMAB|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period.(If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
89079320|NCT02766751|Placebo Comparator|Health Education|The seven sessions will cover: 1) nutrition (2 sessions), 2) sleep hygiene, 3) building immunity (e.g., how to avoid colds/flu), 4) injury/disease prevention (e.g., seat belts, sunscreen, when to get regular check-ups/screenings etc.), 5) benefits of exercise/cardiac health, 6) alternative medicine (massage, acupuncture). These sessions will be primarily didactic and consist of health education, followed by discussion as to how this information compares to that which the participants may have been exposed to in the past.
89079321|NCT02766751|Experimental|HIVPASS|Over 7 sessions, the interventionist and the participant will explore the relationship between pain, depressive symptoms, and HIV. General information about pain, HIV and depression will be discussed, as will avoidance of physical activity. Psychoeducation about these areas will be tied to the participant's stated life goals, and exposure exercises and goal lists will be developed. Later sessions will integrate continued efforts towards reaching goals and reducing avoidance. A release of information will be obtained from the participant to allow study session chart notes to be placed in the medical record at the participant's PCP office and to allow the PCP and the study interventionist to discuss treatment coordination.
89079322|NCT02766595|Other|hyperventilation|Non-drug: performing hyperventilation while sitting up during routine EEG
89079323|NCT04224103||Inhaled nitric oxide|
89079324|NCT02766439||Rhupus syndrome, SLE without RA|Rhupus syndrome, SLE without RA
89079325|NCT04651075|Experimental|music theraphy|One of the 4 music genres (Turkish Folk, Classical, Turkish Art and Sufi Music), which was determined by the researcher by scanning the literature 30 minutes before the CAG procedure, and the expert opinion was taken to the participants in this group was played with a 5-minute headset. The musical genres were arranged in instrumental, nonverbal, 70 decibels in terms of rhythm and duration and played according to the individual's choice.
89079326|NCT04651075|Experimental|information education|Participants in this group were trained to inform them about CAG in visual, audio and written form. Information training was provided by the researcher 30 minutes before the CAG procedure after the outpatient clinic controls of the patient. Information education prepared by the researcher by scanning the literature and getting expert opinion; It includes 7 minutes of video explanation about the CAG process, discussion after video watching, question and answer, and the delivery of a training book prepared in written form.
89079327|NCT04651075|No Intervention|nursing care|Individuals in this group received routine nursing care and no intervention was made by the researcher. In routine nursing care for individuals who will receive CAG procedure in the clinic; Preparation for the CAG procedure, which involves opening the vascular access and dressing the surgical gown, is included in the pre-and post-procedure routine once and more frequently when there are deviations from normal, and if the patient asks questions about the procedure, measurement of blood pressure, heart rate and oxygen saturation.
89079328|NCT04223869|No Intervention|periodontally healthy group|Control
89079329|NCT04223869|Active Comparator|Chronic Periodontitis|non-surgical periodontal treatment was performed
89079330|NCT04223869|Active Comparator|Aggressive Periodontitis|non-surgical periodontal treatment was performed
89079331|NCT02766361|Experimental|Cognitive Behavioral Rehabilitation|12 sessions of new intervention of cognitive behavior therapy and cognitive rehabilitation
89224720|NCT06241963|Sham Comparator|Sham High definition transcranial direct current stimulation|"The left electrical stimulation cathode was placed over CP5 with return electrodes placed at FT7, C1, P03 and P9 . The right electrical stimulation cathode was placed over CP6 with return electrodes placed at FT8, C2, PO4 and P10.~The 30 subjects were randomly divided into two groups, 15 receiving bilateral Sham HD-tDCS and 15 receiving unilateral Sham HD-tDCS.~Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds."
89224721|NCT06241742|Active Comparator|HT-6184 Treatment Arm|
89224722|NCT06241742|Placebo Comparator|HT-6184 Placebo|
89224723|NCT06238297|Experimental|Intervention|Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
89224724|NCT06238297|No Intervention|Control|Patients randomized into the control arm will continue pneumonia treatment as per standard of care
89224725|NCT06237712|Active Comparator|Sodium chloride|40 mmol of oral sodium chloride daily for 5 days
89224726|NCT06237712|Active Comparator|Sodium bicarbonate|40 mmol of oral sodium bicarbonate daily for 5 days
89224727|NCT06237712|Active Comparator|Potassium chloride|40 mmol of oral potassium chloride daily for 5 days
89224728|NCT06237712|Active Comparator|Potassium bicarbonate|40 mmol of oral potassium bicarbonate daily for 5 days
88816158|NCT03011918||Observational Multiple event faller|multiple falls documented during in-patient stay It is hypothesized that frequent fallers will demonstrate statistically greater weight decline, Hgb decline, Vitamin D deficiency and Higher C-Reactive Protein values prior to the first fall. Data on exposure to nutrition supplementation will be collected for future analysis.. Subpopulation analysis of individuals with dementia will also be conducted.
88816159|NCT05296460|Experimental|dapsone gel and trichloroacetic acid|trichloroacetic acid peeling on right side of face and dapsone gel on left side
89224729|NCT06237712|Active Comparator|Potassium gluconate|40 mmol of oral potassium gluconate daily for 5 days
89224730|NCT06237712|Placebo Comparator|Placebo|
89079332|NCT02766361|Active Comparator|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
89079333|NCT02766127|Experimental|Xerostomic Patients|"Patients with evident clinical signs of xerostomia who experienced dentinal hypersensitivity after undergoing radiation therapy due to head and neck cancer.~The following dental materials will be used following the manufacturers' instructions: Veritise Flow; Universal Dentin Sealant; Clearfil Protect Bond, and Flor-Opal® Varnish. In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~the application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
89079334|NCT02766049|Active Comparator|(a) DC|Autologous dendritic cells (3x10e7)
89079335|NCT02766049|Active Comparator|(b) DC 10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
89079336|NCT02766049|Active Comparator|(c) DC 10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
89079337|NCT02765971|Active Comparator|chewing gum group|180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval
89079338|NCT02765971|Active Comparator|laxatives group|180 women will receive laxatives after their operating room discharge by 3 hours
89079339|NCT02765971|Placebo Comparator|control|they will not receive neither gum nor oral fluids. They will be on intravenous fluid. starting oral fluids after hearing intestinal sounds
89079340|NCT02765815|Active Comparator|Exparel plus multi-drug cocktail|Liposomal bupivacaine, 266mg plus Bupivacaine 0.25% with Epinephrine, Ketorolac 30mg, and Morphine 10mg.
89079341|NCT02765815|Active Comparator|Multi-drug cocktail alone|Bupivacaine 0.5% with Epinephrine, Ketorolac 30mg, Morphine 10mg.
89079342|NCT02765893|No Intervention|Foley|Patients will have Foley in place overnight after completion of surgery, which is currently standard of care at our institution.
89079343|NCT02765893|Active Comparator|No Foley|Patients will have Foley catheter removed 6 hours post-op.
89079344|NCT02765581|Experimental|Verum acupuncture (VA)|Participants will be treated by verum acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
89079345|NCT02765581|Sham Comparator|Sham acupuncture (SA)|Participants will be treated by sham acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
89079346|NCT02765581|Placebo Comparator|Usual care (UA)|Participants will undergo a clinical interview once a month, complete the headache diary assessment, have counseling and health education, and rescue medication if necessary. In addition, they will be scheduled to receive 20 sessions of verum acupuncture treatments for free after a waiting period of 24 weeks.
89079347|NCT02765347|Other|Metformin and Insulin|MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g bid or tid) for 24 weeks
89079348|NCT02765347|Other|Insulin|Accept insulin for 24 weeks
89079349|NCT02765425|Experimental|Training Group|Subjects will receive the same outcome measures at baseline, after 3 months training and 6 months later. Intervention will comprise of three sessions seated at the AMES device. Each training session will include 15 min of training of each ankle. Training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
89079350|NCT02765425|No Intervention|Control Group|Subjects will receive no intervention. Subjects will receive all outcome measures at baseline and at 3 months post enrollment. Subjects will also receive a fall-incidence reporting form 9 months post enrollment. No other intervention - i.e. no treatment - is given.
89079351|NCT04223713|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
89079352|NCT04223713|Experimental|Aortic valve replacement|Biological prosthesis, Device: Edwards Perimount
89079353|NCT02764957|Active Comparator|intervention|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
89079354|NCT02764957|Placebo Comparator|control|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
89079355|NCT02765113|Active Comparator|Facial nerve combing|Facial nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
89079356|NCT02765113|Active Comparator|Facial and Trigeminal nerve combing|Facial nerve combing、trigeminal nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
89079357|NCT04686175|Experimental|INZ-701|"The study design during the Dose Evaluation Period is a MAD 3 + 3 with 3 dose cohorts. The planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly.~During the Extension Period, subjects will be administered INZ-701 at the dose and dose schedule assigned in the Dose Evaluation Period. However, the administered dose and dose schedule for a subject may change once the selected dosing regimen has been determined upon completion of the Dose Evaluation Period, at which time all subjects will be assigned to the selected dosing regimen."
89079358|NCT02764879|Experimental|omega 3 group|scaling and root planing omega3 received 2 times daily-for 6 months
89079359|NCT02764879|Placebo Comparator|control group|scaling and root planing placebo soft gelatin capsules 2 times daily-for 6 months
89079360|NCT02764645|Experimental|CardioGard group|"Patients in whom the CardioGard Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in two points: 1. The aortic vent.~2. The suction cannula of the 'Cardiogard cannula'."
89079361|NCT02764645|Active Comparator|Control group|Patients in whom a 22Fr curved Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in the aortic vent alone.
89079362|NCT02770885|Experimental|Verum first|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
89079363|NCT02770885|Placebo Comparator|Placebo first|Placebo: 0.5 ml normal saline (0.9% sodium chloride [0.9% sodium chloride (NaCl)]), injection sc via syringe once weekly for 3 weeks.
89079364|NCT02770651||Optical Coherence Tomography|To evaluate the incidence of late incomplete stent apposition (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting stent (EES) with bioabsorbable polymerversus zotarolimus-eluting stent (ZES) with permanent polymer implantation in patients with AMI at 12 months.
89079365|NCT02770573|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense; Kuraray Teethmate™ Desensitizer; Ghimas Dentin Desensitizer.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
89079366|NCT02770729|Active Comparator|Intracameral moxifloxacin|Intracameral injection of 0.5% moxifloxacin at conclusion of cataract surgery (150 micrograms)
89079367|NCT02770729|Sham Comparator|No injection of moxifloxacin|No injection of moxifloxacin at conclusion of cataract surgery
89079368|NCT02770807|Experimental|EDS-EP dose range of ~5-10 mg DSP/infusion|"Drug: EDS-EP dose range of ~5-10 mg DSP/infusion EDS-EP dose range of ~5-10 mg DSP/infusion: A DSP loading quantity of 50.0 mg will be added to the EDS process, by using 2.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of ~5-10 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 13.0 mL.~Other Names:~EryDex System end product"
89079369|NCT02770807|Experimental|EDS-EP dose range of ~14-22 mg DSP/infusion|"Drug: DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion: A DSP loading quantity of 125 mg will be added to the EDS process, by using 5.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of 14-22 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.~Other Names:~EryDex System end product"
89079370|NCT02770807|Placebo Comparator|Placebo EDS infusion|Patients will be treated with autologous erythrocytes prepared with the EDS process using a placebo solution (5 mL of 0.372% NaCl solution) instead of experimental drug (DSP). Placebo is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.
89079371|NCT02770495|Experimental|Postoperative endoscopic recurrence|Patients with a diagnosis of Crohn's disease who undergo an ileo-colonic curative resection
89079372|NCT02770417|Active Comparator|COPD (beta-alanine)|
89079373|NCT02770417|Placebo Comparator|COPD (placebo)|
89079374|NCT02770417|Other|Healthy controls|
89079375|NCT02770027|Placebo Comparator|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
89079376|NCT02770027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
89079377|NCT02769871|Active Comparator|Standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at the participant's initial interview. Participants will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
89224731|NCT06237231|Experimental|DIT112|"The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet DIT112, oral;~1 capsule tramadol placebo, oral;~1 tablet dipyrone placebo, oral."
89079378|NCT02769871|Experimental|Neuroimages of stroke|Participants in the intervention group will undergo standardized smoking cessation counseling (as offered to the active comparator group) and will also be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, participants will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Participants will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
89079379|NCT02769637||ON PPI|Subjects on proton pump inhibitor (PPI) treatment
89079380|NCT02769637||OFF PPI|Subjects off proton pump inhibitor (PPI) treatment
89079381|NCT02769559||Patients with macromasty|Female adult patients with symptomatic macromasty selected for elective reduction surgery
89079382|NCT02696707|Active Comparator|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
89079383|NCT02696707|Active Comparator|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
89079384|NCT02769715|Active Comparator|cast removable partial denture|patients received cast removable partial dentures fabricated using traditional lost-wax casting technique.
89079385|NCT02769715|Experimental|laser-sintered removable partial denture|patients received removable partial dentures fabricated using laser-sintering.
89079386|NCT02769793|Experimental|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
89079387|NCT02769793|Active Comparator|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
89079388|NCT02769325|Experimental|Atropine|Patients under a standardised general surgery will receive 1mg atropine (10ml) at induction of anesthesia
89079389|NCT02769325|Placebo Comparator|placebo|Patients under a standardised general surgery will receive 10 ml of saline at induction of anesthesia
89079390|NCT02770261|Experimental|CR group|DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
89079391|NCT02770261|Active Comparator|CP group|DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
89079392|NCT02770261|Active Comparator|PR group|DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg
89079393|NCT02769403|Experimental|Treatment|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The treatment participants will use it daily for all 12 weeks, and will have the added component of weekly visits for the first 6 weeks of the study from the study team. The weekly visits is focused on reinforcing accountability and achievement of coherence. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
89079394|NCT02769403|Active Comparator|Control|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The control participants will use it daily only for weeks 7-12. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
89079395|NCT04224649|Experimental|Test Device Group(HARA filler)|
89079396|NCT04224649|Active Comparator|Comparator Group(Restylane® Lidocaine)|
89079397|NCT02769169|Experimental|double-dose|"double-dose~Lucentis® (Raibizumab), 1mg, 3+prn"
89079398|NCT02769169|Active Comparator|regular-dose|"regular-dose~Lucentis® (Raibizumab), 0.5mg, 3+prn"
89224732|NCT06237231|Active Comparator|DIPYRONE|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 tablet dipyrone, oral;~1 tablet DIT112 placebo, oral;~1 capsule tramadol placebo, oral."
89224733|NCT06237231|Active Comparator|TRAMADOL|"The patient must take 3 pills, with a minimum interval of 6/6 hours for 3 days, if pain, as follows:~1 capsule tramadol, oral;~1 tablet dipyrone placebo, oral;~1 tablet DIT112 placebo, oral."
89224734|NCT06235892|Experimental|Ultra-low TACROLIMUS arm|Ultra-low TACROLIMUS (TAC) arm based on MMF/MPA (Mycophenolate Mofetil/ Mycophénolic Acid) with or without CS (Cortico Steroid ) and TACROLIMUS to achieve 2-3.5 ng/ml trough levels during all the duration of the study.
89224735|NCT06235892|No Intervention|SOC ( Standard of care)-TACROLIMUS arm|SOC-TAC arm based on MMF/MPA with or without CS and TACROLIMUS to achieve 4 and 7 ng/ml trough levels during all the duration of the study
89079399|NCT02768857|Experimental|Early sensorimotor reeducation intervention|The experimental group received 15 minutes of touch-observation and task-based mirror therapy program, followed by 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the mirror therapy program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
88816160|NCT01136798|Placebo Comparator|Usual T2 DM med regimen|Subjects will continue on Type 2 DM therapy but will add placebo injected subcutaneously twice daily to their regimen for a total of 6 weeks.
89079400|NCT02768857|Active Comparator|Traditional sensorimotor reeducation intervention|The control group received received 15 minutes traditional sensory reeducation program, 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the protective sensory reeducation program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
89079401|NCT02769013||S. haematobium positives in Gabon|Asymptomatic volunteers infected with S. haematobium and living in Gabon
89079402|NCT02769013||S. haematobium negatives in Gabon|Volunteers not infected with S. haematobium and living in Gabon
89079403|NCT02769013||S. haematobium positives in Ghana|Asymptomatic volunteers infected with S. haematobium and living in Ghana
89079404|NCT02769013||S. haematobium negatives in Ghana|Volunteers not infected with S. haematobium and living in Ghana
89079405|NCT02768779||HIV negative and positive individuals|HIV Negative or HIV positive individuals, aged 18 years or older, who have been taking their ARV medication for at least 3 months and are adherent based on blood plasma HIV RNA of <50 copies/mL or HIV negative status. Hair analysis.
89079406|NCT02765503|Active Comparator|Control|'Standard' external beam radiotherapy to deliver 66Gy in 33 fractions treating with 6 fractions a week.
89079407|NCT02765503|Experimental|HYPNO|The experimental regimen in which patients receive external beam radiotherapy to deliver 55Gy in 20 fractions treating 5 times a week.
89079408|NCT02768545|Experimental|Liver transplant candidates|Ezetimibe in a dose of 10 mg/d for 12 weeks.
89079409|NCT02768623|Active Comparator|Control Group|Patients in the control group will receive standard, dispensing services they currently receive from pharmacists. Control group pharmacists will continue to provide these services in accordance with the standards of practice adopted by the Ontario College of Pharmacists. They will not provide either of the 3 intervention components outlined above. Should a control group patient request additional information and/or services, the pharmacist will comply and provide these as deemed necessary for the particular patient. This could include the full range of educational and drug therapy optimization services outlined for the intervention group. If this occurs then the pharmacists will document all services provided in order for the research team to account for this in the analysis.
89079410|NCT02768623|Experimental|Intervention Group|"Pharmacists in the intervention group will provide patients with a comprehensive disease management program for asthma. The 3 major components of pharmacists' intervention are outlined below. The services delivered will be customized based on each patient's case.~Medication review and drug therapy optimization~Patient education~Improving patient adherence"
89079411|NCT04224259|Experimental|ultrasound pre-scan group|Perform ultrasound pre-scan before central venous cannulation
89079412|NCT04224259|Sham Comparator|landmark guidance group|Use the traditional landmark method to perform central venous cannulation
89079413|NCT02764723|Active Comparator|Hyperbaric bupivacaine|12.5 mg of 0.5% hyperbaric bupivacaine
89079414|NCT02764723|Experimental|Isobaric ropivacaine|15 mg of 0.5% isobaric ropivacaine
89079415|NCT02764567|Experimental|Aromatherapy|"The participants randomized to aromatherapy will be offered one of three essential oils, 'applied' to their smell zone via cotton ball that are known to have anti-anxiety effect. These are:~ginger~calming~lavender The participant's choice will be documented in a database. The participant can chose an oil each time (i.e., they are not bound to use only the first choice oil). Pain and anxiety will be measured prior to receiving the essential oils and again after the phlebotomy procedure. Blood pressure and pulse will also be measured post-phlebotomy."
89079416|NCT02764567|No Intervention|Standard of Care|The participants randomized to standard of care will proceed to the outpatient phlebotomy room in the Heart Care Clinic as per usual care. Pain, anxiety, blood pressure and pulse will be assessed pre and post-procedure.
89079417|NCT04664959|Experimental|SB16 (Proposed Denosumab Biosimilar)|Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.
89079418|NCT04664959|Active Comparator|Prolia® (Denosumab)|"Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects in Prolia® treatment group will be re-randomised in a 1:1 ratio to either continue on Prolia® treatment or be transitioned to SB16 treatment. After re-randomisation, subjects transited to SB16 group will receive SB16, and subjects remaining in Prolia® group will continue to receive Prolia® at Month 12."
89079419|NCT02762695|Experimental|Case Management|
89079420|NCT02762695|Active Comparator|Control|Usual Care at Primary Health Care
89079421|NCT00951496|Experimental|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
89079422|NCT00951496|Experimental|Arm II (paclitaxel, bevacizumab, carboplatin IP)|Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
89079423|NCT00951496|Experimental|Arm III (paclitaxel IP, bevacizumab, cisplatin IP)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
89079424|NCT02764177|Experimental|Protein|In this arm the subjects were provided with a PROTEIN drink to consume after exercise. This protein drink contained whey protein isolate that provided 0.3 g/ kg body mass of protein.
89079425|NCT02764177|Experimental|Carbohydrate|In this arm the subjects were provided with a CARBOHYDRATE drink to consume after exercise. This carbohydrate drink was energy matched to the protein drink in the other arm of the experiment.
89079426|NCT02764255||embryoscope group|cases with embryos continuously monitored by the embryoscope followed by embryo selection based on a multivariable model
89079427|NCT02764255||control group|cases with embyos cultured in the standard incubator and evaluated only by morphology
89079428|NCT02696629||Education and follow up|Participants who refuse or fail to have PAP treatment or Oral appliance or other treatments for sleep apnea. They also refuse or have counter-indication for surgical treatment. The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
89079429|NCT02696629||Upper airway surgery|Participants who undergo uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery.
89079430|NCT02696629||Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
89079431|NCT02696551|Experimental|Interventional hospital|Interventional hospital, which will receive 3-month medical education
89079432|NCT02696551|No Intervention|Non-interventional hospital|Non-interventional hospital, which will not receive 3-month medical education.
89079433|NCT02764411|Experimental|Onreltea ( Brimonidine)|All the patients enrolled in the study will apply Onreltea ( Brimonidine 0.33%) gel on the affected skin area for 12 weeks (from Day 0 to Week 12 visit).
89079434|NCT02764099|Experimental|Life Skills Training|"All youth who consent to participate in the proposed study will 1) complete the youth peer court sanction delivered by the jury of peers (e.g., apologies or essays, restitution, curfew and travel restrictions, counseling, etc.), which will constitute treatment as usual; and 2) complete pre, post, and six-month follow-up surveys. Those randomized to the intervention condition (n=280) will participate in the LST program concurrently during the weeks when they serve as peer court jurors."
89079435|NCT02768077|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
89079436|NCT02768077|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
89079437|NCT01193244|Experimental|Orteronel + prednisone|
89079438|NCT01193244|Placebo Comparator|Placebo + prednisone|
89079439|NCT02768467|Experimental|Tissue Matrix Graft Placement|After the buccal mucosa is removed during reconstructive surgery, the wound is covered with an acellular tissue collagen matrix
89079440|NCT02768467|Active Comparator|Without stitches|After the buccal mucosa is removed during reconstructive surgery, no stitches will be used for the wound to heal.
89079441|NCT04224337|Experimental|Experimental|Durvalumab + doxorubicin + ifosfamide
89079442|NCT02768311|Experimental|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system post-treatment pain after using neolix rotary system
89079443|NCT02768311|Experimental|waveone rotary system (reciprocating system)|Procedure: waveone rotary system post-treatment pain after using waveone rotary system
89079444|NCT02768311|Experimental|hand files k-files|Procedure: hand files post-treatment pain after using hand files
89079445|NCT02768233|Experimental|Educational programme|Group 1: Educational programme + standard treatment
89079446|NCT02768233|No Intervention|Standard treatment|Standard treatment
89079447|NCT02768155|Experimental|AF 4.0|Amniotic Fluid 4.0ml dose
89079448|NCT02768155|Experimental|AF 2.0|Amniotic Fluid 2.0ml dose
89079449|NCT02768155|Placebo Comparator|Placebo|Saline Placebo Control
89079450|NCT04223167|Experimental|Energy Drink 1|The participants in this group are caffeine naive and consumed 473 ml Red Bull Energy Drink
89079451|NCT04223167|Experimental|Energy Drink 2|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately 130 mg caffeine and consumed 473 ml Red Bull Energy Drink
89079452|NCT04223167|Experimental|Energy Drink 3|The participants in this group were low-habitual caffeine consumers with an estimated daily intake of approximately more than 200 mg caffeine and consumed 473 ml Red Bull Energy Drink
89079453|NCT04223167|Placebo Comparator|Control|The participants in this group are caffeine naive and consumed 473 ml water
89079454|NCT02764021|Experimental|1.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
89079455|NCT02764021|Active Comparator|2.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
89079456|NCT02762617|Experimental|TDF IVR group|"The Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core which contains the experimental drug, TDF, and sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
89079457|NCT02762617|Placebo Comparator|Placebo IVR group|"The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
89079458|NCT02696473|Experimental|High Carrot Dose|The volunteer will eat 250g carrot for breakfast with 2 slices of bread and 10g butter
89079459|NCT02696473|Experimental|Low Carrot Dose|The volunteer will eat 100g of carrot for breakfast with 2 slices of bread and 10g butter
89079460|NCT02696395|Active Comparator|DePuy Tri-Lock®|Total hip replacement with DePuy Tri-Lock® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
89079461|NCT02696395|Active Comparator|DePuy Corail®|Total hip replacement with DePuy Corail® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
89079462|NCT01192152|Experimental|5 mg saxagliptin + 2 Glucophage XR 500 mg tablet|
89079463|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)|under fed state, single dose
89079464|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)|under fed state, 4 days
89079465|NCT02763709||Cases|Children admitted in Pediatric ICU for more than 24 hours with Pediatric Risk of Mortality (PRISM) score III > 20
89079466|NCT02763553|Experimental|Ketogenic Feed|A low-carbohydrate, high-fat enteral feed (Nutrison KetoCal 4:1) containing 0.4g of carbohydrate and 10g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
89079467|NCT02763553|Active Comparator|Standard Feed|Standard enteral feed (Nutrison ProteinPlus MF 1.28) containing 11.1g of carbohydrate and 3.8g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
89079468|NCT02689531||High-Risk (Adult =>18 years old)|"Treated with one or more of the following respiratory modalities for at least 12 continuous hours, either currently or within the prior 7 days:~Invasive mechanical ventilation~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)~High-flow, supplemental oxygen therapy via nasal cannula. Only include systems that using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask). Only include systems using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
89079469|NCT02689531||Other-ICU/Standard Risk|Patients do not fulfill high-risk criteria, but, are receiving an antibiotic for treatment of lower respiratory tract infection or undifferentiated sepsis.
89079470|NCT02689531||High-Risk (Pediatric ≥120 days old and <18 years old)|"Currently treated with one or more of the following respiratory modalities for at least 24 hours:~Invasive mechanical ventilation via endotracheal intubation~New initiation of mechanical ventilation, BiPAP or CPAP via tracheostomy~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)~High-flow, supplemental oxygen therapy delivering at least 1.5LMP with 100% FiO2 via nasal cannula when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask) when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
89079471|NCT02689531||High-Risk (Pediatric <120 days old)|Currently treated with mechanical ventilation via endotracheal intubation for at least 5 days
89079472|NCT04317924|Experimental|Reinforcement of air leak|Participants in this arm will receive reinforcement with the NEOVEIL (polyglycolic acid felt) which will be impregnated with human fibrinogen and thrombin.
89079473|NCT04317924|Active Comparator|No reinforcement of air leak|Participants in this arm will receive standard of care for air leak post lung resection.
89079474|NCT04222933|Experimental|Motorized cryotherapy|Application of motorized cryotherapy after ACL reconstruction for 6 postoperative days
89079475|NCT04222933|Active Comparator|Classical cryotherapy|Application of ice bags for 6 postoperative days
89079476|NCT02758249|Active Comparator|sevoflurane|patients under sevoflurane anesthesia
89224736|NCT06230302|Experimental|Kefir Postbiotics Group|"30 healthy adult participants~Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor~Period of use: 12 months~Storage method: Store at room temperature~Manufacturing method: The whey postbiotics derived from kefir lactic acid bacteria used in the test food are produced in the laboratory at Hanyang University, and additional ingredients are purchased from finished products. Laboratory collects the ingredients and delivers them to the manufacturer, Neo Natural, to manufacture them so that there are no differences in properties and formulations."
89079477|NCT02758249|Active Comparator|propofol|patients under propofol anesthesia
89079478|NCT02758405|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89079479|NCT02758405|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89079480|NCT02758405|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89079481|NCT02758405|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
89079482|NCT02763787|Experimental|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
89079483|NCT02763787|Experimental|10 mg|1 x 10 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
89079484|NCT02763787|Experimental|30 mg|3 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
89079485|NCT02763787|Experimental|50 mg|5 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
89079486|NCT02763787|Experimental|100 mg|1 x 100 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
89079487|NCT02763787|Experimental|200 mg|2 x 100 mg BIA 3-202 tablets
89079488|NCT02763787|Experimental|400 mg|4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
89079489|NCT02763787|Experimental|800 mg|8 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
89079490|NCT02763787|Experimental|Food Effect (fed/fasted)|400 mg BIA 3-202: 4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
89079491|NCT02763631|Experimental|Run In Phase|Eligible patients will have 6-Minute Walk Test (6-MWT) on self ventilation and on CPAP
89079492|NCT02763631|Experimental|Treatment|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:~Treatment arm - Patients will be setup onto portable CPAP during the day"
89079493|NCT02763631|Sham Comparator|Standard Care Arm|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:~Control Arm - Standard care arm."
89079494|NCT02762305|Experimental|RSVP Bone Builder group exercise|A group of older adults who are participating in the RSVP Bone Builder group exercise.
89079495|NCT04223011|Experimental|In-Hospital Recovery Coach Intervention|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically in-hospital manualized sessions with the recovery coach.
89079496|NCT02758327|Experimental|TheraTears Lubrication Drop|TheraTears Lubricating Eye Drops to be instilled 1 drop in both eyes 4 times per day over a period of 8 weeks.
89079497|NCT02758093|Experimental|Speed of Processing Training (10 hours)|Participants randomized to this arm will receive 10 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
89224737|NCT06230302|Placebo Comparator|Control Group|"30 healthy adult participants~Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor~Period of use: 12 months~Storage method: Store at room temperature~Manufacturing method: The same product without whey postbiotics."
89079498|NCT02758093|Experimental|Speed of Processing Training (20 hours)|Participants randomized to this arm will receive 20 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
89079499|NCT02758093|Sham Comparator|Internet Navigational (10 hours)|In this group, participants will receive 10 hours of Internet Navigation Training. Specifically, participants will be given instructional materials and exercises on how to navigate the Internet. For more computer savvy participants, they will be directed to the Thinks.com website. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
89079500|NCT02763475|Experimental|Natural Killer (NK) Cells + Chemotherapy|Starting on day -6, 60mg/Kg cyclophosphamide by vein will be administrated. Day -5 to -1 fludarabine administrated by vein at 25 mg/m2. 24-48 hours after chemotherapy completion, NK cell infusion will be injected (day 0). On day 7 a second NK cell infusion will be administrated. First infusion consist of 5x10^7/kg NK CD3-CD56+ NK cells. The second NK cell infusion will include up to 5x10^8 CD3-CD56+ cells if no treatment related toxicity occurred. Subcutaneous IL-2 (1x10^6 UI/m2) three times a week for two weeks will be administrated after first NK infusion.
89079501|NCT02762383|Experimental|Peginterferon Alfa-2a|Participants will receive a low dose of peginterferon alfa-2a for 18 months.
89079502|NCT02763163||outdoor workers|Subjects with an excessive exposure to the sun on a daily basis
89079503|NCT02763163||office workers|Subjects who spend most of the day in a closed shaded room
89079504|NCT02763241|Experimental|Cleanoze®|"Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
89079505|NCT02763241|Active Comparator|Syringe irrigation|"Nasal irrigation using sterile 0.9% NaCl 250 ml by 20 ml syringe~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
89079506|NCT02763397|Experimental|NBM-DBS on|DBS is programmed to stimulate the NbM
89079507|NCT02763397|Placebo Comparator|DBS off|DBS is turned off, no stimulation will be exerted
89079508|NCT04223245|Experimental|exercise+MMSF|Group of PWPD who performed a base exercise program of speed and large amplitude stepping and standing balance exercises with Multimodal real-time sensory feedback
89079509|NCT04223245|Active Comparator|exercise only|Group PWPD who did the same exercise program without MMSF
89079510|NCT02758015|Active Comparator|Standardized Meal|Standardized meal given to patients.
89079511|NCT02758015|Experimental|Beatine PO (by mouth) 1500mg|Betaine (natural supplement)
89079512|NCT02758015|Experimental|Betaine PO (by mouth) 3000mg|Betaine (natural supplement)
89079513|NCT02758015|Experimental|Betaine PO (by mouth) 4500mg|Betaine (natural supplement)
89224738|NCT06229444|Experimental|Proactive ILI content & Predictions|Participants will receive predictive alerts, reactive content after reporting symptoms or receiving an asymptomatic prediction, and ILI-related health educational content
89079514|NCT02757937|Experimental|Health & Wellness Website|Subjects will receive access to an interactive health & wellness website for 6 months. The site aims to provide patients with information, tools, and resources to manage their chronic condition (e.g., Type 2 diabetes). The website will send subjects emails with tips to help them take better care of their diabetes, such as how to track diet and exercise habits and how to cook healthy meals. The study researchers will keep track of how many times subjects access the website and which parts of the site are most commonly viewed. Intervention subjects will receive questionnaires assessing engagement and satisfaction with the website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline.
89079515|NCT02757937|Other|Control Arm|Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline. Control subjects will be granted access to the health & wellness website after the study is completed.
89079516|NCT04221685|Active Comparator|Artinibsa|Powerful local anaesthetic with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.4%Articaine 1:100000.
89079517|NCT04221685|Experimental|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride,Epinephrine (D.C.I) (tartrate) 0.01 mg
89079518|NCT02762461||Exposed group|Women with peritoneal/ovarian endometriosis and DIE (rectovaginal and rectosigmoid endometriosis) undergoing ART (IVF or ICSI).
89079519|NCT02762461||Reference group 1|Women with infertility because of factors other than endometriosis, e.g. male factor, undergoing ART (IVF or ICSI).
89079520|NCT02762461||Reference group 2|Women with medically treated endometriosis not undergoing ART.
88816161|NCT01136798|Experimental|Usual T2 DM med regimen plus Exenatide|Subjects will continue on Type 2 DM therapy but will add injectable exenatide to their regimen There will be twice daily treatment with subcutaneous injections of 5 µg of Exenatide for 2 weeks followed by 4 weeks of treatment with twice daily subcutaneous injections of 10 µg of Exenatide.
88816162|NCT01172522|Experimental|Fexofenadine left; placebo right|"Topical treatment active versus placebo.~Double blind randomized placebo controlled split face intrasubject comparison."
89224739|NCT06229444|Experimental|No Proactive ILI content & Predictions|Participants will receive predictive alerts and reactive content after reporting symptoms or receiving an asymptomatic prediction, but will not receive proactive ILI content
88816163|NCT01172522|Experimental|Fexofenadine right; placebo left|Split face double blind
88816164|NCT01172600|Active Comparator|Entonox|Patients will receive inhaled Entonox along with the interventional block they are scheduled.
89224740|NCT06229444|Experimental|Proactive ILI content & No Predictions|Participants will not receive predictive alerts or reactive content after reporting symptoms but will receive proactive ILI content
89224741|NCT06229444|Experimental|No Proactive ILI content & No Predictions|Participants will not receive predictive alerts or reactive content after reporting symptoms or proactive ILI content
89224742|NCT06229431|Experimental|CSNAT intervention|District nurses will be trained to use the CSNAT-I on family caregivers to persons with multimorbidity at home.
89224743|NCT06229431|No Intervention|Control|Standard support and care.
89224744|NCT06229236|Experimental|Diabetes Navigator|Support and guidance of Diabetes Navigator in addition to standard care
89224745|NCT06229236|No Intervention|Standard of Care|Standard care provided by the healthcare staff during routine diabetes clinic visits.
89224746|NCT06226974|No Intervention|Control Condition|5-minute rest.
89224747|NCT06226974|Active Comparator|Static Stretching of 30 seconds Condition|"Static stretching of 30 seconds of muscles around the shoulder of the dominant upper limb:~Shoulder extension - shoulder extension with the hand resting on a door;~Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~Shoulder flexion - arms above the head against a wall;~Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
89224748|NCT06226974|Active Comparator|Static Stretching of 90 seconds Condition|"Static stretching of 90 seconds of muscles around the shoulder of the dominant upper limb:~Shoulder extension - shoulder extension with the hand resting on a door;~Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~Shoulder flexion - arms above the head against a wall;~Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
89079521|NCT02762539|No Intervention|Control group|Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion
89079522|NCT02762539|Experimental|SMOF group|SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days.
89079523|NCT02757703|Active Comparator|somatostatin group|Somatostatin (Somatosan, BAG Health Care GmbH, Lich, Germany) was given by intravenous bolus (250 μg) followed by 250 μg/hour and continued for 3 days in group S.
89079524|NCT02757703|Placebo Comparator|terlipressin group|Terlipressin (Glypressin, Ferring GmbH, Kiel, Germany) was started at 2mg bolus injection and followed by 1 mg infusion every 6 hours for 3 days in group T.
89079525|NCT02757781|No Intervention|Control Group|Group of healthcare professionals that NOT receive the intervention (community of practice)
89079526|NCT02757781|Experimental|Intervention group|Group of healthcare professionals that receive the intervention (community of practice)
89079527|NCT02763007|Experimental|alogliptin+pioglitazone|A group who treat with alogliptin+pioglitazone: The Combination of Alogliptin 25 mg and pioglitazone 30 mg daily add on metformin for 28 week as extension and followed by 2 years of observation
89079528|NCT02763007|Active Comparator|alogliptin|A group who treat with alogliptin: Alogliptin 25 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
88816165|NCT01172600|Placebo Comparator|Oxygen|Patients will receive inhaled oxygen along with the interventional block they are scheduled.
88816166|NCT01137032|Experimental|Pandel Cream 0.1%|Pandel Cream 0.1%
88816167|NCT02246816|Experimental|All Subjects|Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
89079529|NCT02763007|Active Comparator|pioglitazone|A group who treat with pioglitazone: Pioglitazone 30 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
89079530|NCT02753101|Experimental|Single Arm|[18F]-FTC-146
89079531|NCT02762227|Experimental|gallbladder polyps patients|"All patients with a gallbladder polypoid lesion visited our department, diagnosed by conventional transabdominal US, were enrolled in this study.~Of these patients, we excluded: (1) gallbladder polyp with a diameter less than 10 mm. (2) lesions highly suspected to be cancer due to visible metastasis. (3) allergy to contrast agents and cannot received CT or CEUS examination. (4) women in pregnancy or lactation.~All patients received transabdominal US, abdominal high resolution CT and contrast-enhanced ultrasonography (CEUS) before the cholecystectomy."
89079532|NCT00635323|Experimental|A|
89079533|NCT02752789||Pediatric Heart Transplant Recipients|CTOTC-04 (ClinicalTrials.gov ID NCT01005316) participants who consent to long-term follow-up as part of this study as well as candidates less than 21 years of age who are listed for isolated orthotopic heart transplantation at one of the participating sites
89079534|NCT01191840|Experimental|Algorithm-determined therapy|
89079535|NCT01191840|Active Comparator|Standard of Care|
89079536|NCT04534543|Other|Imaging|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
89079537|NCT05656950||Observed|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide. Patient's age, gender, day of hospitalization in pediatric intensive care units, medical diagnosis/diagnoses, presence of chronic disease, state of consciousness, body temperature, oral care application method, oral care application frequency, oral care product used, amount taken/extracted, drugs used, albumin and haemoglobin data on values were obtained from the observation form of the patient.
89079538|NCT02752555|No Intervention|Antioxidant group|In the control group, all patients will go a double-blind therapy of a three-months period of treatment with oral carnitine (2g daily). After this period, all patients will undergo conventional intacytoplasmic sperm injection (ICSI).
89079539|NCT02752555|Experimental|Antioxidant+modifiable lifestyle factors|In the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.
89079540|NCT04472377|Experimental|study population|"We enroll a total of 1,200 women, as follows,~120 cases with no history or current cervical intraepithelial lesion or malignancy.~180 cases with a history of abnormal Pap test including ASCUS, CIN1, or atypical glandular cell.~240 cases with a history of atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma.~240 cases with current ASCUS, CIN1, or atypical glandular cell.~420 cases with current abnormal Pap test as atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma."
89079541|NCT00624546||1|gerd patients
89079542|NCT00624546||2|non gerd controls
89079543|NCT05656872|Active Comparator|TAP Block|Transversus abdominus plane (TAP) block will be used as postoperative analgesia
89079544|NCT05656872|Active Comparator|IIIH Block|Ilioinguinal-iliohypogastric (IIIH) block will be used as postoperative analgesia
89079545|NCT02757469|Experimental|Yasmin|Pregnancies will occur while the women are taking oral contraceptives (Yasmin). The possible role of exogenous estrogens in sensitizing the granulosa cells to the effect of follicle-stimulating hormone and thereby inducing ovulation and conception in some women with premature ovarian failure is examined.
89079546|NCT05656716|Experimental|Intervention group|Participants randomized to receive the multimodal intervention (nutrition and exercise)
89079547|NCT05656716|No Intervention|Control group|Participants will not receive the multimodal intervention.
89079548|NCT02762149|Active Comparator|0.1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
89079549|NCT02762149|Active Comparator|1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
89079550|NCT02757391|Experimental|Treatment (CD8 +T cell therapy, pembrolizumab)|Beginning 2 days prior to CD8+ T cell infusion, patients receive cyclophosphamide IV over 30 minutes. Patients undergo CD8+ T cell infusion IV over 2 hours on day 0 and receive aldesleukin SC BID on days 1-14. Beginning on day 1 about 24 hours after CD8+ T cell infusion, patients receive pembrolizumab IV over 30-60 minutes on weeks 3, 6, 12, and 15.
89079551|NCT00624624||1|"Eugonadal men with Lapband"
89079552|NCT00624624||2|"Hypogonadal men with Lapband"
89079553|NCT00624624||3|Eugonadal men with gastric bypass procedure
89079554|NCT00624624||4|Hypogonadal men with gastric bypass procedure
89079555|NCT02757157|Experimental|COPD (normal weight)|People with COPD (BMI 21 kg/m2 to 29 kg/m2)
89079556|NCT02757157|Experimental|COPD (obese)|People with COPD (BMI >/= 30 kg/m2)
89079557|NCT02757079|Experimental|NPC-15 Granule|NPC-15 granule 1 mg, 2 mg or 4 mg once a day, administered orally before going to bed.
89079558|NCT04221217|Experimental|MND-2119 2g|MND-2119 2 g, orally, once daily after breakfast for 52 weeks.
89079559|NCT04221217|Experimental|MND-2119 4g|MND-2119 4 g, orally, once daily after breakfast for 52 weeks.
89079560|NCT02696161|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
89079561|NCT02696161|Placebo Comparator|5% dextrose|5% dextrose for hydrodissection
89224749|NCT06223295|Active Comparator|Focal therapy|Patients in this group will receive focal therapy, i.e. TULSA, IRE or Hifu.
89224750|NCT06223295|Active Comparator|Usual care|Patients in this group will receive usual care for prostate cancer, i.e. radical prostatectomy or radiotherapy
89224751|NCT06220435|Experimental|HYPO-RT-PC boost|Ultra-hypofractionated seven-fraction radiotherapy regimen including focal boost and lymph node irradiation.
89224752|NCT06219668|Active Comparator|omentopexy with LSG|We performed omentopexy on staple line after LSG
89224753|NCT06219668|Active Comparator|Clips with LSG|we performed Clips on staple line after LSG
89224756|NCT06218706|Experimental|LIFU Treatment|
89079562|NCT02887560|Experimental|All patient|Only one arm has been specified for the protocol. This arm included all study patient (33) for which the intervention is to be administered
89079563|NCT04220749|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
89079564|NCT04220749|Experimental|Arm 2, TOS + Neck Dissection|Trans-oral Surgery (TOS) + Neck Dissection (plus radiation is required)
89079565|NCT02752321|Experimental|eDischarge + Standard Discharge (SDeD)|"Patients in this arm will be enrolled in the eDischarge technology prior to hospital discharge. Upon hospital discharge, these patients will receive a personalized eDischarge, containing text and multimedia information, in addition to receiving the standard discharge process.~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
89079566|NCT02752321|No Intervention|Standard Discharge (SD)|"Patients in this arm will receive the standard discharge process upon hospital discharge.~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
89079567|NCT02768389|Experimental|Modified Atkins Diet and Bevacizumab|Patients and caregivers will be educated by a nutritionist skilled in the MAD. Patients will also be receiving Bevacizumab as standard of care.
89079568|NCT04529005|Experimental|Angiotensin II (Giapreza)|
89224757|NCT06218706|Sham Comparator|Sham treatment|
89079569|NCT05357040|Active Comparator|Treatment; Nitrous Oxide 50% or 25%, group|Four-weekly, 60-minute inhalation sessions of 25% or 50% nitrous oxide, randomly assigned.
89079570|NCT05357040|Placebo Comparator|Control; Oxygen-air mixture, group|Four-weekly, 60-minute inhalation sessions of an oxygen and air mixture.
89079571|NCT05655390|No Intervention|Treatment As Usual|(TAU)
89079572|NCT05655390|Experimental|Intervention Group|Treatment As Usual + Safety Intervention Planning.
89079573|NCT00943072|Experimental|VEGF Trap-Eye|Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
89079574|NCT00943072|Sham Comparator|Sham|Monthly Sham IVT injection until Week 24 Primary Endpoint
89079575|NCT04315818||study group|expermintal
89079576|NCT04315818||control group|placebo
89079577|NCT04222855|Experimental|Diltiazem|Postpartum patients were administered (60 mg) orally every 8 hours with diltiazem (tables).
89079578|NCT04222855|Active Comparator|Nifedipine|Postpartum patients were administered (10 mg) orally every 8 hours with nifedipine (capsule).
89224758|NCT06218615|Experimental|Health Services Research|Participants watch a culturally tailored decision aid video. Surveys are completed before and after the video.
89079579|NCT00942994|Experimental|Triple Therapy (Aliskiren/Amlodipine/HCTZ)|At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg.
89079580|NCT00942994|Active Comparator|Dual Therapy (Aliskiren/Amlodipine)|At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg.
89079581|NCT02756767||Completed subjects|Subjects will complete patient-reported outcomes assessments during and after radiation therapy.
89079582|NCT02761525|Experimental|gel silver nanoparticles|topic gel silver nanoparticles 12 ppm
89079583|NCT02761525|Placebo Comparator|placebo|topic innocuous gel
89079584|NCT04317222|Experimental|eCRRT group|Initiated CRRT within the first 24 post-transplant hours.
89079585|NCT04317222|No Intervention|Control group|Standard treatment.
89079586|NCT04268602|Experimental|Intervention Group|intradermal 1% lidocain injection 4 cc+ exercise and transcutaneous electrical nerve stimulation
89079587|NCT04268602|No Intervention|Control Group|exercise and transcutaneous electrical nerve stimulation
89079588|NCT05658354|Experimental|Computerized cognitive program|25 participants with metabolic syndrome and mild cognitive deficits; receive health advice using the World Health Organization's guidelines for Risk Reduction of Cognitive Decline and Dementia, and perform the computerized cognitive training program (BrainHQ) for 45 minutes per session, twice per week, over the 3-month intervention period.
89079589|NCT05658354|No Intervention|Control group|25 participants with metabolic syndrome and mild cognitive deficits; receive health advice using the World Health Organization's guidelines for Risk Reduction of Cognitive Decline and Dementia.
89079590|NCT02756455||gastric cancer pts undergoing surgery|all pts receiving gastric resection for cancer, with anastomosis
89079591|NCT00942604|Active Comparator|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
89079592|NCT00942604|Placebo Comparator|Vehicle gel|Vehicle gel once daily for 2 consecutive days
89079593|NCT02756221|Experimental|Probiotics|Probiotics capsules, one capsule daily for 90 days.
89079594|NCT02756221|Placebo Comparator|Placebo|Starch capsules, one capsule daily for 90 days
89079595|NCT00624702|Active Comparator|1|Active Comparator 1 different salt formulation of Indacaterol.
89079596|NCT00624702|Active Comparator|2|Active Comparator 2 different salt formulation of Indacaterol.
89079597|NCT00624702|Active Comparator|3|Active Comparator 3 different salt formulation of Indacaterol.
89079598|NCT00624702|Placebo Comparator|4|
89079599|NCT02857192|Experimental|Horton|
89079600|NCT02857192|Placebo Comparator|control|
89079601|NCT02756377|Active Comparator|cetylpyridinium chloride|mouthwash (cetylpyridinium chloride)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
89079602|NCT02756377|Active Comparator|Chlorhexidine mouthwash|mouthwash ( Alcohol-free chlorhexidine)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
89079603|NCT02752009|Experimental|Axillary Lymph Node Sampling Clip|"Axillary Lymph Node Biopsy~-- Axillary lymph node sampling with clip placement into the sampled lymph node. After the tissue sampling of any suspicious nodes, a marker clip will be placed to allow for intra-operative identification of the biopsied nodes.~Neoadjuvant therapy at the discretion of the treating Medical Oncologist. Once Neoadjuvant therapy is completed, surgery in the form of either Lumpectomy or Mastectomy is performed.~Wire-localization of the clipped node on the day of surgery.~Lymphatic mapping performed with either radiocolloid and/or blue dye.~Sentinel lymph node biopsy will be performed on the day of surgery.~--- If the clipped node which contains the wire is not part of this sentinel lymph node specimen, then it will be removed separately and be sent to Pathology as a separate specimen.~Axillary lymph node dissection as is the standard of care."
89079604|NCT04220437||CAG and OCT group|Images of CAG and OCT patients obtained from ISR patients were retrospectively collected and analyzed.
89079605|NCT02752477|Experimental|Opioid-free anesthetic (OFA) group|
89079606|NCT02752477|Active Comparator|Traditional Anesthesia (TA) group|
89079607|NCT05658042||rivaroxaban 10mg qd|nonintervention
89079608|NCT05658042||rivaroxaban 10mg qd+rifampicin|nonintervention
89079609|NCT05658042||rivaroxaban 20mg qd+rifampicin|nonintervention
89079610|NCT05658042||rivaroxaban 15mg bid+rifampicin|nonintervention
89079611|NCT02761681|Experimental|ACT-CL Web-based guided self-help|Behavioral: Experimental Web-based guided self-help Program This intervention will involve counselor training and student use of the developed program. Counselors will complete training and invite students to participate, and will monitor and guide students in completing the series of 8 web-based sessions based on Acceptance and Commitment Therapy.
89224759|NCT06218602|Experimental|Arm A|Will receive FMT therapy (both as a colonoscopy / FMT procedure and as capsules taken by mouth) plus the scheduled chemotherapy and CAR-T cell therapy.
89079612|NCT02761681|Active Comparator|Control Web-based guided self-help|Behavioral: Control Web-based guided self-help program This intervention will be created for the current study. It will involve psycho-education on how students might get the most out of counseling. Counselors will go through the psycho-education session before inviting students to participate.
89079613|NCT04220593|Experimental|aETCC before TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
89079614|NCT04220593|Experimental|aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
89079615|NCT04220593|Experimental|aETCC after TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
89079616|NCT04220593|Sham Comparator|Simulated aETCC during TCog|Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
89079617|NCT04204096|Experimental|Vi-DT Multi-dose|"750 participants (6 mo - 45 yrs)~Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)~Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (multi-dose formulation Vi-DT contains preservative 2 PE)~Mode of Administration: Intramuscular injection~Frequency of administration: Once"
89079618|NCT04204096|Experimental|Vi-DT Single-dose|"750 participants (6 mo - 45 yrs)~Dose: 0.5mL, Vi polysaccharide typhoid vaccine conjugated with Diphtheria toxoid protein (Vi-DT), manufactured by SK bioscience (Republic of Korea)~Dosage form: Liquid, 25µg Vi polysaccharide/0.5mL, presented in Type I glass vial (single dose formulation Vi-DT without any preservative)~Mode of Administration: Intramuscular injection~Frequency of administration: Once"
89079619|NCT04204096|Active Comparator|Control|"300 participants (6 mo - 45 yrs)~Dose: 0.5mL, Locally available Meningococcal conjugate vaccine~Dosage form: Lyophilized white powder~Mode of Administration: Intramuscular injection~Frequency of administration: Once (For participants 6 months to 1 year, one more dose will be provided after the study unblinding)"
89079620|NCT05376852|Experimental|treatment group|Based decitabine and olverembatinib（HQP1351)chemotherapy
89079621|NCT02756143|No Intervention|Control Group|Non- supervised physical exercise program during pregnancy
89079622|NCT02756143|Experimental|Exercise Group|Supervised physical exercise program during pregnancy
89079623|NCT05657730|Experimental|Active group|
89079624|NCT02756299|Active Comparator|Device and Standard Care|Positive Airway Pressure Device and Standard Support
88816168|NCT01137890|Experimental|Zonisamide|Participants administered blind capsules containing either placebo or zonisamide.
88816169|NCT01137890|Placebo Comparator|Placebo|Participants administered only placebo capsules containing lactose.
89079625|NCT02756299|Active Comparator|Device and Educational Care|Positive Airway Pressure Device and Educational Support
89079626|NCT05657574|Experimental|CKD-391|D377 + CKD-331 + placebo (for D086)
89079627|NCT05657574|Active Comparator|CKD-331|CKD-331 + placebo (for D377) + placebo (for D086)
89079628|NCT05657574|Active Comparator|D377|D377 + placebo (for CKD-331) + placebo (for D086)
89079629|NCT05657574|Active Comparator|D086|D086 + placebo (for D377) + placebo (for CKD-331)
89224760|NCT06218602|Experimental|Arm B|Will receive no FMT therapy and only receive their scheduled chemotherapy and CAR-T cell therapy.
89079630|NCT02761447|Experimental|Treatment Traditional and Motor Imaginary Program|"Amputees patients also conservative protocol will undergo physiotherapy techniques work Motor Imaginary Program, based on a system of two videos that allow the patient to recreate the normal way. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases. This protocol will be applied 3 days a week (25-30minutos) for one month."
89079631|NCT02761447|Active Comparator|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physical therapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
89079632|NCT00061282|Placebo Comparator|1|
89079633|NCT00061282|Active Comparator|2|Clotrimazole Therapy
89079634|NCT00061282|Active Comparator|3|Clotrimazole Therapy
89079635|NCT02756065||Control|Individuals between 18-30 years old No diagnosis of Bipolar Disorder or Schizophrenia No intervention used
89079636|NCT02756065||Bipolar Disorder|Individuals between 18-30 years old Diagnosis of Bipolar Disorder No intervention used
89079637|NCT02756065||Schizophrenia|Individuals between 18-30 years old Diagnosis of Schizophrenia or Schizoaffective Disorder No intervention used
89079638|NCT04268524|Experimental|monotherapy miltefosine|Miltefosine capsules (Impavido®) 2.5 mg/kg daily PO for 28 days <30 kg BW allometric miltefosine dose based on fat-free mass. (approx. 2.5 mg/kg); >30 - ≤44kg BW: 100 mg/day BID; ≥45kg BW 150mg TDS
89079639|NCT04268524|Experimental|Thermotherapy|Thermotherapy (ThermoMed 1.8 ®) 50°C for 30 seconds, 1 session
89079640|NCT04268524|Experimental|Combination miltefosine and thermotherapy|Miltefosine capsules 2.5 mg/kg daily PO for 21days, and thermotherapy 50°C for 30 seconds, one session on day 1 of the miltefosine.
89079641|NCT04268524|Active Comparator|° Meglumine antimoniate (Glucantime®) intralesional|Meglumine antimoniate (Glucantime®) intralesional injections 0.5-3ml, 8 sessions, bi-weekly
89079642|NCT05657418|Experimental|JS107|
89079643|NCT05657418|Experimental|JS107 combination with Toripalimab|
89079644|NCT02695693|Experimental|TeachTown|Students in kindergarten-through-second-grade autism support classrooms in this arm receive access to TeachTown, an online academic and pre-academic intervention designed for students with autism. Their teachers also receive coaching in the use of TeachTown, as well as coaching in other evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
89079645|NCT02695693|Active Comparator|Control|Teachers in kindergarten-through-second-grade autism support classrooms in this arm receive coaching in evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
89079646|NCT02855632|Experimental|G-CSF|G-CSF(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
89079647|NCT02855632|Placebo Comparator|Normal saline|equal volume of normal saline(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
89079648|NCT05657340|Experimental|seasickness susceptible|43 seasickness susceptible maritime crewmembers underwent video-head impulse test
89079649|NCT05657340|Other|seasickness non-susceptible|43 seasickness non-susceptible maritime crewmembers underwent video-head impulse test
89079650|NCT02761213|Experimental|Oral sulfate solution (OSS)|oral sulfate solution (OSS)
89079651|NCT02761213|Active Comparator|2-L PEG/Asc|low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)
89079652|NCT02852746||Asympt. athletes / scapular dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
89079653|NCT02852746||Symptom. athletes / scapular dyskinesis|Symptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
89079654|NCT05657262|Experimental|experimental group|The experiment group will be applied with the Z technique. While applying the medicine with the Z technique, the tissue will be lifted with the thumb and forefinger of the left hand and pulled to the right, and the medicine will be slowly applied after the injector needle enters the tissue. When the application is finished, first the injector will be withdrawn, then the tissue will be released and the tissues will be restored (Altun, 2018).
89079655|NCT05657262|Other|Control group|In the control group, the vaccine will be administered slowly with the standard technique.
89079656|NCT00635635|Active Comparator|1|Guided Imagery Audio
89079657|NCT00635635|Active Comparator|2|Music Audio
89079658|NCT02852668|Experimental|Power Training Group|Physical exercises. Strength training performed quickly
89079659|NCT02852668|Experimental|Strength Training Group|Physical exercises. Strength training performed in moderate speed
89079660|NCT02852668|No Intervention|Control Group|This group maintained the same physical activity level during the intervention period.
89079661|NCT02887326||age 15-25 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
89079662|NCT02887326||age 25-35 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
89079663|NCT02887326||age 35-45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
89079664|NCT02887326||> age 45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
89079665|NCT04220281|Active Comparator|propofol group|propofol group will receive propofol infusion
89079666|NCT04220281|Active Comparator|nitroglycerin group|will receive nitroglycerin infusion
89079667|NCT02852512|Active Comparator|Laparoscopic sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be laparoscopic
89079668|NCT02852512|Active Comparator|Robotic assisted Sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be robotic assisted
89079669|NCT02751619|Experimental|Lidocaine Group|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, PA, USA) measuring 10 x 14 cm and containing 700 mg of Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
89079670|NCT02751619|Active Comparator|Placebo Patch|A patch, that was identical in appearance to the active patch but did not contain Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
89079671|NCT04316988||Ultrasonography|Ultrasonography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by ultrasound machine over the trachea.
89079672|NCT04316988||Capnography|Capnography group in whom after endotracheal intubation, the endotracheal tube position was confirmed by capnograph, evaluationg the graph character and end tidal CO2 value.
89079673|NCT02751541|Experimental|BAY987519|All subjects are patched
89079674|NCT02755753|Experimental|Study Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast~Mucosta® (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
89079675|NCT02755753|Placebo Comparator|Control Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast~Mucosta®-placebo (rebamipide-placebo), 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
89079676|NCT01188564|Experimental|rhC1INH|
89079677|NCT01188564|Placebo Comparator|Placebo (Saline)|
89079678|NCT02755909|Other|Subjects|Pra-anesthetic education given to the subjects includes the anatomy of a normal heart, normal blood circulation, anatomy and pathophysiology of the disease in the respected subject, surgery procedures needed, anesthetic procedures needed for the surgery, and cardiopulmonary bypass procedures. Education and discussion were given repeatedly until subjects could repeat the materials given correctly.
89079679|NCT04222777|Other|Heatlhy volunteers.|Healthy volunteers will undergo two cinematographic recordings of the cervical spine
89079680|NCT04316598|Experimental|Cannabis (B)|"Subjects will be admitted in the center to receive 4 doses of inhaled cannabis in 3 days.~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every cannabis administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
89079681|NCT04316598|Placebo Comparator|Cannabis placebo (B)|"Subjects will be admitted in the center to receive 4 doses of an inhaled treatment based on placebo-THC in 3 days.~Vital signs, blood test and electroencephalogram (Starlab® helmet) will be performed before and after every administration. Cannabis subjective effects will be assessed and a psychiatric research interview will also be performed at different times after administration."
89079682|NCT02761369|Experimental|A PAS protocol, right-to-left, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the right DLPFC
89079683|NCT02761369|Experimental|A PAS protocol, left-to-right, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the left DLPFC
89079684|NCT02761369|Sham Comparator|A sham PAS protocol, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a sham PAS protocol, starting with the right DLPFC (@ 40% of individual MT)
89079685|NCT02761135||Side-fire|Using side-fire technique during transrectal ultrasound.
89079686|NCT02761135||End-fire|Using end-fire technique during transrectal ultrasound.
89079687|NCT02761291|Experimental|gemcitabine dose escalation|In three combined drugs used in nasopharyngeal carcinoma, the valproic acid and valganciclovir administration will be followed by indication to find the maximum tolerance dose of gemcitabine.
89079688|NCT02755363|Active Comparator|osteopathic manual therapy (OMT group)|patients who will undergo manual osteopathic therapy.
89224761|NCT06218121||Frail Older Adult Patients|For the cohort study, 500 frail older adult patients will be evaluated by means of instrumental and functional tests that assess their functional capacity, in addition to ultrasound imaging to study sarcopenia and nutrition, as well as psychological variables. The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters. All available information will be collected during the follow-up in order to generate Big Data on the objective evolution and symptomatology of these patients, generating profiles that facilitate the most accurate and appropriate treatment for each patient.
89224762|NCT06217796|Other|Open Label Treatment|A single metered spray of Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray)1%/2.5%
89224763|NCT06217250|Active Comparator|Hot EMR|Initial submucosal injection of physiological solution and methylene blue, followed by 'piece-meal' resection using a 10 or 15 millimetre diathermic snare and ablation of the margins with the snare tip
89224764|NCT06217250|Experimental|Cold EMR|Initial submucosal injection of physiological solution and methylene blue, followed by 'piece-meal' resection using a dedicated cold snare
89224765|NCT06216899|Experimental|Smoothie|In the smoothie arm, you will be provided instructions, a blender, and food components to prepare the smoothie at home.
89224766|NCT06216899|Active Comparator|Formula|In the formula arm, you will be given conventional formula as per the direction of the gastroenterology team along with our dieticians.
89224767|NCT06216522|Experimental|Intervention|5 drops/0.25mls of 100% sesame oil will be applied to the IV cannula site, from 3cm above the insertion point to 10cm along the vein, with a width of 2cm on either side, every 12 hours for 72 hours.
89079689|NCT02755363|Placebo Comparator|control group (C group)|patients who will undergo manual therapy not aimed to decrease hyperinflation.
89079690|NCT00602212|Active Comparator|VR + Mobile Phone without Biofeedback|In this experimental condition patients received an eight-session VR-based treatment including relaxation and exposure
89079691|NCT00602212|Experimental|VR + Mobile Phone with biofeedback|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
89079692|NCT02755675|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.
89079693|NCT02755519||Primary Aldosteronism|"Those with hypertension, and with or without hypoglycemia;~Those with PAC/PRC≥42.95 pg·mL-1/µIU·mL-1"
89079694|NCT02755519||Non-Primary Aldosteronism|"Those with Primary Hypertension;~Those with adrenal diseases except for Primary Aldosteronism"
89079695|NCT02855866|Experimental|cryotherapy|
89079696|NCT02855866|Active Comparator|Cortisone aerosol|
89079697|NCT02855866|Placebo Comparator|Management|
89079698|NCT02751463|Experimental|BAY987519|All subjects are patched .
89079699|NCT04316520|Experimental|Ketogenic diet|Ketogenic diet + standard of care
89079700|NCT02751307|Active Comparator|metformin 500 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, the dosage was revised to 500 mg of metformin in the morning and the placebo in the evening. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
89079701|NCT02751307|Active Comparator|metformin 1000 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, 500 mg of metformin twice a day was administered. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
89079702|NCT02751307|Placebo Comparator|placebo; clozapine 100 mg|In the first week, one pill of placebo was given and in the second week, placebo BID was given. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
89079703|NCT05356494|Experimental|postural drainage|(Group A will be treated with postural drainage)
89079704|NCT05356494|Experimental|positive expiratory pressure technique|(Group B will be treated with positive expiratory pressure technique).
89079705|NCT00638209|Active Comparator|I|
89079706|NCT00638209|Placebo Comparator|P|
89079707|NCT02760745||Febrile Shivering|
89079708|NCT02760745||Fever without Shivering|
89079709|NCT04220047|Experimental|Left Atrial Appendage Resection|
89079710|NCT04220047|No Intervention|off-pump coronary artery bypass|
89224768|NCT06216522|Placebo Comparator|Control|5 drops/0.25mls of liquid paraffin oil will be applied to the IV cannula site, from 3cm above the insertion point to 10cm along the vein, with a width of 2cm on either side, every 12 hours for 72 hours.
89224769|NCT06215703|Experimental|Order 1|Participants randomized to Order 1 will complete the four music playing tasks in the following order: (1) No improvisation (maintain beat), no live accompaniment (recorded accompaniment); (2) Improvisation, no live accompaniment (recorded accompaniment); (3) No Improvisation (maintain beat), live accompaniment; (4) Improvisation, live accompaniment.
89224770|NCT06215703|Experimental|Order 2|Participants randomized to Order 2 will complete the four music playing tasks in the following order: (1) Improvisation, no live accompaniment (recorded accompaniment); (2) No improvisation (maintain beat), no live accompaniment (recorded accompaniment); (3) Improvisation, live accompaniment; (4) No improvisation (maintain beat), live accompaniment.
89224771|NCT06215703|Experimental|Order 3|Participants randomized to Order 3 will complete the four music playing tasks in the following order: (1) No improvisation (maintain beat), live accompaniment; (2) Improvisation, live accompaniment; (3) No improvisation (maintain beat), no live accompaniment (recorded accompaniment); (4) Improvisation, no live accompaniment (recorded accompaniment).
89224772|NCT06215703|Experimental|Order 4|Participants randomized to Order 3 will complete the four music playing tasks in the following order: (1) Improvisation, live accompaniment; (2) No improvisation (maintain beat), live accompaniment; (3) Improvisation, no live accompaniment (recorded accompaniment); (4) No improvisation (maintain beat), no live accompaniment (recorded accompaniment).
89224773|NCT06215404|Active Comparator|Liberal group|stroke volume variation < 10%
89224774|NCT06215404|Experimental|restrictive group|stroke volume variation < 18%
89224775|NCT06210776||Cohort A|Patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens.
89224776|NCT06210776||Cohort B|Patients with unresectable or metastatic HER2-low breast cancer patients who have received at least a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
89224777|NCT06209528||School-aged children|No intervention
89224778|NCT06207084|Experimental|asynchronous exercise responder|Individuals only receiving asynchronous exercise content and are responding
89224779|NCT06207084|Experimental|Asynchronous exercise and health coaching responder|Individuals receiving asynchronous exercise content and health coaching and are responding
89224780|NCT06207084|Experimental|Asynchronous exercise non-responder and 1 on 1 live training|Individuals receiving asynchronous exercise content and are not responding. The are receiving 1 on 1 live exercise sessions.
89224781|NCT06207084|Experimental|Asynchronous exercise and health coaching non-responder and 1 on 1 live training|Individuals receiving asynchronous exercise content and health coaching and are not responding. The are receiving 1 on 1 live exercise sessions.
89224782|NCT06207084|Experimental|Asynchronous exercise non-responder and group live training|Individuals receiving asynchronous exercise content and are not responding. The are receiving group live exercise sessions.
89224783|NCT06207084|Experimental|Asynchronous exercise and health coaching non-responder and group live training|Individuals receiving asynchronous exercise content and health coaching and are not responding. The are receiving group live exercise sessions.
89224784|NCT06207071|Active Comparator|Intervention|A DHA supplement will be added to expressed human milk or donor human milk administered during the first 3 weeks after birth.
89224785|NCT06207071|No Intervention|Control|No DHA supplement will be added to expressed human milk or donor human milk administered during the first 3 weeks after birth.
89079711|NCT05429749|Experimental|Ferinject group|This group of hip fracture patients are treated with intravenous Ferinject between the admission and the surgery day.
89079712|NCT05429749|Active Comparator|Control group|This group of hip fracture patients are treated with normal saline as a control group.
89079713|NCT05429671|Active Comparator|Group A (Control-negative group)|include participants undergoing total knee arthroplasty with Stryker Surgical Simplex P cement containing no antibiotic
89079714|NCT05429671|Active Comparator|Group B (tobramycin group)|includes participants undergoing total knee arthroplasty with Stryker Surgical Simplex P cement with tobramycin antibiotic.
89079715|NCT05429671|Active Comparator|Group C (gentamicin group)|Include participants undergoing total knee arthroplasty with Huraeus Palacos R+G cement containing gentamicin antibiotic.
89224786|NCT06206824|Experimental|Part 1 : Single Ascending Doses in Healthy Volunteers|A total of 48 healthy male volunteers will be randomized into six consecutive single ascending dose cohorts of 8 subjects, 6 receiving one dose of Leucettinib-21 and 2 receiving placebo.
89079716|NCT05429671|Active Comparator|Group D (Control-positive group)|Include participants undergoing the first of a two-stage exchange arthroplasty for confirmed infection, using an antibiotic-loaded cement spacer. These patients will have a spacer implant made of vancomycin and tobramycin antibiotics using Huraeus Palacos non-antibiotic loaded cement
89079717|NCT02755207||Suspected ACS group|Patients admitted to the hospital with the diagnosis of ACS
89079718|NCT02755207||Blank control group|Patients admitted to the hospital without the diagnosis of ACS
89079719|NCT02754973|Experimental|Experimental group|During hospitalization for cancer treatment, besides receiving usual care, participants in the experimental group will first receive a health education talk Participants will then be taught and encouraged to practice with some stretching and relaxing exercises during their hospitalization. After hospitalization, participants will receive an integrated experiential training program with coaching by nursing students through home visits.
89079720|NCT02754973|Placebo Comparator|Placebo Control group|Since participants in both groups are hospitalized in the same unit, to avoid contamination, participants in the placebo control group will receive the same intervention as those participants in the experimental group during their hospitalization. When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures.
89079721|NCT04222621||Pregnant women|
89079722|NCT01186770|Experimental|MNTX 150 mg|Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).
89224787|NCT06206824|Experimental|Part 2 : Food-Effect in Healthy Volunteers|A total of 12 healthy male volunteers will be randomly assigned to one of two sequences in this cross over study part. All subjects will receive the same one dose of Leucettinib-21 in each sequence.
89224788|NCT06206824|Experimental|Part 3 : Multiple Ascending Doses over 14 days in Healthy Volunteers|A total of 36 healthy male volunteers will be randomized into three consecutive multiple ascending doses cohorts of 12 subjects, 9 receiving one dose of Leucettinib-21 and 3 receiving placebo everyday for 14 days.
89224789|NCT06206824|Experimental|Part 4 : Single Dose in People with Down Syndrome and Alzheimer's Disease|A total of 12 people with Down Syndrome and 12 people with Alzheimer's Disease will receive the same one dose of Leucettinib-21.
89224790|NCT06206356|Experimental|PNS Injectrode F1|
89224791|NCT06206070|Experimental|The Hong Kong version of Westmead Feeling Program 2|The treatment group will receive the WFP2-HK program which consists of 15 school-based training sessions over 18 weeks. Three parent- and teacher-training workshops will be delivered separately and preceding each Child Module by coaches or advisors. A booster session will be conducted for the treatment group after 5 months upon completion of the training programs.
89224792|NCT06206070|No Intervention|Waitlist Group|While the treatment group is receiving training, the waitlist group will be waiting. After 18 weeks of waiting and when the treatment group completes the training. The waitlist group will receive the same training program as that of the treatment group, but no booster session will be provided to the waitlist group.
89224793|NCT06202092|Experimental|Honey Group|will receive phonophoresis with honey and conventional physical therapy treatment in the form of transcutaneous electrical nerve stimulation (TENS) current and exercise . The parameters of the application of phonophoresis will be the continuous modality, 1 MHz frequency, intensity of 1 or 1.5 W/cm2, and an application time of 10 minutes
89224794|NCT06202092|Other|Control Group|will receive ultrasound therapy with gel media and the same conventional physical therapy treatment (control group)
89224795|NCT06200545|Active Comparator|Standard of care PrEP services|Standard of care (SOC) PrEP services include PrEP eligibility assessment, rapid HIV antibody testing prior to provision and/or refill of PrEP, and PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines. Specifically, SOC services do not generally include point of contact STI testing (with the exception of rapid syphilis and Hepatitis B antigen testing, if kits are available, at PrEP initiation) nor tracing for missed PrEP visits. Participants randomized to the SOC condition will receive these standard PrEP services.
89224796|NCT06200545|Experimental|Intervention package PrEP services|"The intervention package is integrated into PrEP visits and includes evaluation of barriers and facilitators to ongoing PrEP use, point of contact STI testing to inform counseling regarding ongoing PrEP care engagement, tracing for any missed PrEP visits, and offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period. Recognizing increasingly cyclical PrEP use patterns, navigators serve as a direct entry point to retain or re-engage participants in HIV prevention care."
89224797|NCT06199999|No Intervention|Group GA: General anesthesia only|This group receives general anesthesia only and surgical procedure will follow standard conditions.
89224798|NCT06199999|Active Comparator|Group ESP: Erector Spinae Block|This group receives general anesthesia with regional pain block (Erector Spinae Block) prior to incision.
89224799|NCT06199999|Active Comparator|Group LIA: Local Infiltration|This group receives general anesthesia and surgical procedure will take place as planned. Prior to being awakened, the area of procedure will be infiltrated.
89224800|NCT06199531|Experimental|Cohort 1a|13-18 years old, then 6-12 years old (Low dose GS-100)
89224801|NCT06199531|Experimental|Cohort 2a|13-18 years old, then 6-12 years old (Mid dose GS-100)
89224802|NCT06199531|Experimental|Cohort 3a|13-18 years old, then 6-12 years old (High dose GS-100)
89079723|NCT01186770|Experimental|MNTX 300 mg|Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
89079724|NCT01186770|Experimental|MNTX 450 mg|Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
89079725|NCT01186770|Placebo Comparator|Placebo|Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).
89079726|NCT02754817||Insulin degludec/liraglutide|
89079727|NCT02755051|Experimental|CBT-CI-A Therapy|Participants in this group receive Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder (CBT-CI-A)
89079728|NCT05429515|Experimental|HFR-SUPRA|haemodiafiltration with ultrafiltrate regeneration by adsorption on resin (HFR-SUPRA) combined with chemotherapy. HFR-SUPRA everyday for 3 days, then 3 times per week.
89079729|NCT05429515|Active Comparator|Hemodialysis|hemodialysis combined with chemotherapy. Hemodialysis everyday for 3 days, then 3 times per week.
89079730|NCT01186692|Experimental|Melody TPV Implant|Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
89079731|NCT04230031|Experimental|1: Daratumumab|Pre-ASCT and Post-ASCT: Daratumumab
89079732|NCT01186458|Experimental|Fludarabine, Velcade and Rituximab|Fludarabine, Velcade and Rituximab
89079733|NCT01185600|Active Comparator|Transfusion with washed RBC|Subject assigned to this arm will be transfused with washed RBC
89079734|NCT01185600|Active Comparator|Transfusion with unwashed RBC|Subjects assigned to this arm will be transfused with unwashed RBC
89079735|NCT02754895|Experimental|PP-weekly|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week.
89079736|NCT02754895|Experimental|PP-daily|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day.
89079737|NCT02754895|Experimental|Shortened PP-weekly plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week.
89079738|NCT02754895|Experimental|Shortened PP-daily plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day.
89079739|NCT02754895|Experimental|PP-weekly with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
89079740|NCT02754895|Experimental|PP-daily with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
89079741|NCT02754895|Experimental|Shortened PP-weekly plus MI + boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
89079742|NCT02754895|Experimental|Shortened PP-daily plus MI with boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
89079743|NCT01185522||Tocilizumab|Eligible participants receiving tocilizumab according to summary of product characteristics in a real life setting will be observed for 4 months
89079744|NCT01185366|Experimental|Everolimus Group 1|Everolimus 10 mg by mouth once a day.
89079745|NCT01185366|Active Comparator|Sunitinib Group 2|Sunitinib 50 mg by mouth daily for 4 weeks on / 2 weeks off.
89079746|NCT01185288|Experimental|Adalimumab + Low Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
89079747|NCT01185288|Active Comparator|Adalimumab + High Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).
89079748|NCT01184508|Experimental|LY2300559|
89079749|NCT01184508|Placebo Comparator|Placebo|
89079750|NCT02887014|Experimental|Group A|Participants getting SPECIFIC VERBAL INSTRUCTIONS before starting bowel preparation (Group A).
89079751|NCT02887014|No Intervention|Group B|Participants getting ordinary instructions as usual in each of the participating centers (Group B).
89079752|NCT01184118|No Intervention|FP Discontinued|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
89079753|NCT01184118|Active Comparator|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
89079754|NCT01183884|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles.
89079755|NCT05344248|Experimental|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Ib：60mg、150mg、300mg、600mg；Each patient can only receive multiple doses at one dose level.Each patient received weekly dosing (QW) at weeks 0, 1, 2, 3, and 4, and quad-weekly dosing (Q4W) beginning at week 5 through week 12。 II：Multiple subcutaneous injections of the study drug and placebo in two doses of 300mg and 150mg were performed.Each patient can only receive multiple doses at one dose level.Weekly dosing (QW) was given at 0, 1, 2, 3, and 4 weeks, and quad-weekly dosing (Q4W) was given from 5 weeks to 12 weeks.
89079756|NCT05344248|Placebo Comparator|Placebo|Ib：60mg、150mg、300mg、600mg；Each patient can only receive multiple doses at one dose level.Each patient received weekly dosing (QW) at weeks 0, 1, 2, 3, and 4, and quad-weekly dosing (Q4W) beginning at week 5 through week 12。 II：Multiple subcutaneous injections of the study drug and placebo in two doses of 300mg and 150mg were performed.Each patient can only receive multiple doses at one dose level.Weekly dosing (QW) was given at 0, 1, 2, 3, and 4 weeks, and quad-weekly dosing (Q4W) was given from 5 weeks to 12 weeks.
89079757|NCT01183260|Experimental|Trabecular Metal Revision Cup|Patients randomized to this arm will receive a trabecular metal revision component which does not have a titanium inner surface and requires a cemented highly crosslinked polyethylene liner.
89079758|NCT01183260|Active Comparator|Trabecular Metal Modular Cup|Patients randomized to this arm will receive a trabecular metal modular component which has a titanium inner surface and requires a non-cemented highly crosslinked polyethylene liner.
89079759|NCT01191762|Active Comparator|sevelamer carbonate|2400 mg (3 pills) with each meal
89079760|NCT01191762|Placebo Comparator|placebo control|3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
89079761|NCT04315974||Nonvalvular atrial fibrillation patients (NVAF)|Eligible patients comprise men and women aged 18 years or older with nonvalvular atrial fibrillation diagnosis undergoing ablation procedure.
89079762|NCT04316208|Experimental|Supratentorial tumor surgery|Patients undergoing elective supratentorial tumor surgery under general anesthesia will be ventilated with positive end-expiratory pressures of 0, 5 and 10 cmH2O after craniotomy.
89079763|NCT01711138||Intervention|Intervention group is geographically located near a built environment intervention (neighbourhood redevelopment).
89079764|NCT01711138||Comparison|Comparison group is not exposed to the built environment intervention according to their geographic location.
89079765|NCT02855788|Experimental|POLF regimen|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
89079766|NCT01190514|Experimental|Bioequivalence and Food effect|
89079767|NCT00604240||1|Parents / caregivers of any infant who has a length of stay of at least 1 week in the NICU at Christiana Hospital or Thomas Jefferson University Hospital.
89079768|NCT02852356|No Intervention|Control Incubator|Standard Incubator
89079769|NCT02852356|Experimental|MIRI-TL Timelapse Incubator|Timelapse incubator
89079770|NCT02852356|Experimental|Culture Coin Dish|Culture Coin dish for embryo culture
89079771|NCT02852356|No Intervention|Control dish|Control Dish for embryo culture
89079772|NCT02886858|Experimental|tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
89079773|NCT02886858|Sham Comparator|Sham tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
89079774|NCT04268290|Experimental|SILS plus one assistant ERAS|"Preoperative:~preadmission information, education, counseling, optimization ( breathing training), shortening fasting time and carbohydrate load~Intraoperative:~The intravenous fluid therapy is restricted. All patients undergo single incision plus one port laparoscopic surgery(SILS plus one).~A suitable warming device (such as forced-air heating blankets) and warmed intravenous fluids are been adopted routinely to keep body temperature~Postoperative:~multimodal analgesia (surgical site infiltration, a nonsteroidal anti-inflammatory drug, epidural analgesia) early oral intake and move. nasogastric tubes should not be used routinely. Nasogastric tubes inserted during surgery are been removed before reversal of an aesthesia."
89079775|NCT00604318|Placebo Comparator|placebo|To receive the placebo treatment in connection with the primary RI therapy and the T3 tablets and rh-TSH injections prior to second RI uptake measurement
89079776|NCT00604318|Active Comparator|rh-TSH|To continue with L-T3 and to receive rh-TSH stimulation with 0,9 mg Thyrogen® (Genzyme) x 2 days minus 1 and 2 prior to RI therapy, and following this to have placebo tablets and placebo injections with isotone NaCl prior to the RI uptake measurement 4-6 months later
89079777|NCT01190436|Experimental|Bisoprolol|
89079778|NCT02852122|Experimental|C-11 choline|
89079779|NCT01035255|Experimental|LCZ696|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. LCZ696 200mg BID during double blind treatment period
89079780|NCT01035255|Active Comparator|Enalapril|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. Enalapril 10 mg BID during double blind treatment period
89079781|NCT04268056||RT patients|100 patients with breast cancer undergoing radiation therapy
89079782|NCT00631072|Other|GM-CSF +INKT|"INKT will be administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.~GM-CSF will be given subcutaneously once daily for 10 days beginning the second day of the second and third infusion"
89079783|NCT01190124||CohortHIV|Adult multiple-experienced HIV infected patients who needed to change their antiretroviral therapy and initiated raltegravir + optimized background therapy under the Early Access Program.
89079784|NCT01189890|Experimental|Sitagliptin|Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
89079785|NCT01189890|Active Comparator|Glimepiride|Glimepiride 1-6 mg QD
89079786|NCT01189812|Placebo Comparator|sugar pill|
89079787|NCT01189812|Active Comparator|Lithium|
89079788|NCT00950950|Placebo Comparator|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
89079789|NCT00950950|Experimental|Romosozumab|Participants were randomized to receive 3 mg/kg romosozumab administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
89079790|NCT00950872|Experimental|Duet TRS|Subjects receive Duet TRS
89079791|NCT04302597|Active Comparator|Staples|Women who underwent repeated cesarean section with skin closure using staples.
89079792|NCT04302597|Experimental|Tissue adhesive|Women who underwent repeated cesarean section with skin closure using 2-octylcyanoacrylate tissue adhesive.
89079793|NCT01189500|Experimental|Tamoxifen and Desvenlafaxine SR|
89079794|NCT02874339|Experimental|Optiflow Group|High flow nasal oxygen therapy
89079795|NCT02874339|Active Comparator|NIV group|
89079796|NCT04291911||INTENSIVE CARE UNITS|
89079797|NCT00627315||Surgery|Obese adult men and women who are undergoing bariatric surgery (gastric bypass or gastric banding).
89079798|NCT00938860|Experimental|Neoral|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
89224803|NCT06199531|Experimental|Cohort 1b|2-5 years old (Low dose GS-100)
89224804|NCT06199531|Experimental|Cohort 2b|2-5 years old (Mid dose GS-100)
89224805|NCT06199531|Experimental|Cohort 3b|2-5 years old (High dose GS-100)
89224806|NCT06198959|Experimental|ABCDE|A. Volunteers will be covered with the Adult Blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. B. After a 40 minutes washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. C. After a 40-minute washout period, the volunteers will be covered with the Blanket full body, 30000 connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. D. After a 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes. E. Finally and after a last 40-minute washout period, the volunteers will be covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes.
89079799|NCT00938860|Active Comparator|tacrolimus|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
89079800|NCT05381584|Active Comparator|fractionated intraumbilical microports group|two 4-5-mm micro ports will be done intra umbilically; a 4-mm scope is inserted through one of them, followed by a 4-mm catheter inserter through the second intra umbilical port.
89079801|NCT05381584|Experimental|fully monitored entry group|only one 4mm intra umbilical port will be done and a second port at a point of lies 8 cm from midline and 5 cm above anterior superior iliac spine. After performing laparoscopic evaluation of the pelvis the telescope will be moved from the umbilical port to the ancillary port and the catheter loaded inserter will be introduced through the umbilical port its insertion will be fully monitored from the point of entry at the umbilicus until the pelvic floor.
89079802|NCT00938470|Experimental|Arm I (combination chemotherapy, radiation therapy, surgery)|Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1. Patients also receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. After completion of the second course, patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity. Approximately 4-12 weeks after completion of radiotherapy, patients undergo surgery.
89079803|NCT00938470|Active Comparator|Arm II (oxaliplatin, fluorouracil, radiation, and surgery)|Patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy and then surgery as in Arm I.
89079804|NCT00602680|Experimental|1|dose 1
89079805|NCT00602680|Experimental|2|dose 2
89079806|NCT00602680|Experimental|3|dose 3
89079807|NCT00602680|Placebo Comparator|4|
89079808|NCT00602680|Active Comparator|5|
89079809|NCT02852200||SEGAm|Elderly community-dwelling people
89079810|NCT00938392|Experimental|FluNG Aged Group|Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).
89079811|NCT00938392|Experimental|FluNG Fresh Group|Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).
89079812|NCT00602758|Experimental|Enhanced Counseling|Participants meet with a counselor trained in motivational interviewing and cognitive behavioral techniques
89079813|NCT00602758|No Intervention|Standard Care|Participants receive usual clinical care provided by health care providers and they participate only in evaluation components of the study
89079814|NCT00602758|Experimental|Enhanced Counseling/Modified Directly Observed Therapy|Participants receive their ART medications delivered to them by study staff and they receive the enhanced counseling
89079815|NCT02851888|Experimental|Iliac Fascia Block (Ropivacaine)|These patients will receive a preoperative iliac fascia block performed as a single shot in the standard fashion prior to hip arthroscopy with general anesthesia.
89079816|NCT02851888|Sham Comparator|Control (Normal Saline Sham Injection)|These patients will receive a preoperative sham block of normal saline in the same fashion as a standard singl shot iliac fascia block prior to hip arthroscopy with general anesthesia.
89079817|NCT05381428|Active Comparator|Indomethacin Group (Control Arm)|Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
89079818|NCT05381428|Experimental|Indomethacin and Lactated Ringer Group (Intervention Arm)|Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
89079819|NCT00604474|Active Comparator|1|
89079820|NCT02852044|Active Comparator|Rest|Remain rested prior to the oral glucose tolerance test
89079821|NCT02852044|Experimental|Exercise|Complete exercise prior to the oral glucose tolerance test
89079822|NCT02851654||Dry eye syndrome|Meibomian gland dysfunction responsible of moderate to severe dry eye syndrome
89079823|NCT02851966|Other|TEX101|This is a single arm study. All patients will be asked to provide multiple semen samples and all samples will be tested with TEX101 ELISA assay. Timing of mTESE maybe changed according to the assay results.
89079824|NCT02851732|No Intervention|Control|"Clusters randomized to the control group will keep their usual practice standards. Patient screening will be performed at the outpatient clinics and primary care centers. Both groups must complete the following forms: Admission, 06 months, and 12 months. Data collection will be performed from medical records by an independent professional not involved in patient care. Furthermore, study coordinator and data collectors from the sites, when asked, must provide appropriate documents for adjudication purposes."
89079825|NCT02851732|Experimental|Intervention|Educational multifaceted intervention can increase the evidence based prescriptions. If this is the case, this tool package may be offered as a quality improvement intervention for all hospitals. Health care professionals from each institution one being a physician (acting as a local leader) and the other being a research nurse (acting as a case manager) must attend the training course for high cardiovascular risk patients that will take place at HCor.
89079826|NCT02855320|Experimental|PE (patient education)|Nurse-led self-management education intervention : The intervention group will benefit from the nurse intervention in addition to usual care : follow up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
89079827|NCT02855320|No Intervention|Standard|The control group will be followed up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
89079828|NCT04204174|Experimental|Tyrosine loading|
89079829|NCT01022853|Experimental|BIBF 1120 and BI 6727|Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120
89079830|NCT05381272||Cases|Infants born before 34 weeks of gestational age (WGA) with severe and early antenatal diagnosed intra uterine growth restriction
89079831|NCT05381272||Controls|infants born before 34 WGA at the same period, with no IUGR, apparied on sex and gestationnal age
89079832|NCT01034709||Symptomatic|Subjects with a confirmed CMV viremia by the site's CMV-LDT as well as CMV symptoms
89079833|NCT01034709||Asymptomatic|Subjects who must have been serologically positive for CMV IgG prior to transplantation and do not have any CMV symptoms
89079834|NCT00937768|Experimental|Arm A (antihormone therapy)|Patients receive leuprolide acetate IM on day 1 OR goserelin acetate SC on day 1. Courses repeat every 3 months for 9 months in the absence of disease progression or unacceptable toxicity.
89079835|NCT00937768|No Intervention|Arm B (no antihormone therapy)|Patients undergo observation every 3 months for 9 months.
89079836|NCT04204018|Experimental|Experimental|Experimental-arm providers will complete four simulated patient cases (CPVs) with two additions described in the next column:
89079837|NCT04204018|No Intervention|Control|These providers will complete four simulated patient cases (CPVs) only.
89079838|NCT00602914|Experimental|1|10 healthy volunteers will receive 0.1 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
89079839|NCT00602914|Experimental|2|10 Type II DM subject will receive 0.2 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
89079840|NCT00940888||No treatment: ICD/CRTD-indicated|
89079841|NCT00631228||1|The group will be monitored to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
89079842|NCT02851576|Experimental|Infusion of ADV specific T cells|This one arm study consists in ADV-specific T cell infusion after HSCT from a (M)MUD or, for the first time, from a haploidentical donor for patients having undergone previous UCB transplantation, in the event of refractory ADV infection or disease. Specific anti-ADV immune reconstitution was observed in all patients, and viral load clearance in all but one.
89230103|NCT00661505|Experimental|C.E.R.A. 120, 200, or 360 mcg|Eligible participants were administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) at a dose of 120, 200, or 360 microgram (mcg), intravenously (IV), every 4 weeks i.e. Weeks 4, 8, 12, 16 and 20 but not on Weeks 24 and 28. The initial dose of C.E.R.A.was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA). The ESA therapy was administered from enrollment to the 4 weeks stability verification period (SVP), weekly, either as epoetin (<8000 IU, 8000-16000 IU, or >16000 IU) or darbepoetin alpha (<40 mcg, 40-80 mcg, or >80 mcg). A telephone follow-up visit took place 4 weeks after the end of C.E.R.A. treatment (Week 28).
89079843|NCT05381038|Experimental|QPOP + CURATE.AI|Participants will undergo two study stages: QPOP drug selection and CURATE.AI-guided dosing modulation. In the QPOP drug selection stage, participants will undergo a baseline biopsy for organoid generation and subsequently receive treatment as per SOC. During this time, QPOP will identify optimal drug combinations for the participant based on ex vivo experiments on the participant's organoid. Participants who are identified via QPOP to potentially benefit from azacitidine in combination therapy (azacitidine + docetaxel, azacitidine + paclitaxel or azacitidine + irinotecan) will move on to the CURATE.AI-guided dosing modulation stage with treatment with azacitidine. Azacitidine treatment will begin once disease progression after SOC treatment is determined based on CT scans. Only azacitidine dose in the selected azacitidine combination will be modulated by CURATE.AI
89079844|NCT00603070||1|All physicians and nurse practitioners at 1 ambulatory care clinics
89079845|NCT00603070||2|All physicians and nurse practitioners at 1 ambulatory care clinics
89079846|NCT05380960||copd in acute excerbtion|(1) The first group (COPD group) in acute exacerbaction: We plan to include COPD patients who will be admitted to the Chest Diseases Department with severe exacerbation requiring admission to the RICU (severe dyspnea that responds inadequately to initial emergency therapy, changes in mental status, persistent or worsening hypoxemia, persistent or worsening respiratory acidosis, the need for ventilatory support, and/or hemodynamic instability.
89079847|NCT05380960||(2) The second group (non-COPD lung diseases group).|We plan to include patients admitted at the RICU with bronchial asthma, bronchiectasis, pneumonia, and interstitial lung disease.
89079848|NCT05380960||normal persons|have no diseases
89230104|NCT04047095|Experimental|Intervention|"Normal daily meals plus one sachet three times a day of immune nutrients for five days after the surgery.~8 a.m. - normal meal plus one sachet immune nutrients~1 p.m - normal meal plus one sachet immune nutrients 6 p.m. - normal meal plus one sachet immune nutrients"
89224807|NCT06198959|Experimental|BDECA|B. Volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. D. After a 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes. E. After a 40-minute washout period, the volunteers will be covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. C. After a 40-minute washout period, the volunteer will be covered with the Blanket full body, 30000 connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. A. Finally and after a last 40-minute washout period, the volunteers will be covered with the Adult Blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes.
89224808|NCT06198959|Experimental|CEBAD|C. Volunteers will be covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. E. After a 40-minute washout period, the volunteers will be covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. B. After a 40-minute washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. A. After a 40-minute washout period, the volunteers will be covered with the adult blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. D. Finally and after a last 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes.
89230105|NCT04047095|Active Comparator|Control|"Normal daily meals. 8 a.m. - normal meal~1 p.m. - normal meal 6 p.m. - normal meal"
89230106|NCT00788333|Experimental|A|Combination
89230107|NCT00922103|Experimental|INRA|Patients treated for medical refractory Ulcerative Colitis
89230108|NCT00922103|Active Comparator|IPAA|Patients treated for medical refractory Ulcerative Colitis
89230109|NCT00795899|Experimental|1|Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression
89230110|NCT00795977|Experimental|dendritic cells|
89230111|NCT00796055|Experimental|1|MEDI-547
89224809|NCT06198959|Experimental|DCAEB|D. Volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes. C. After a 40-minute washout period, the volunteers will be covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 for 30 minutes. A. After a 40-minute washout period, the volunteers will be covered with the adult blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. E. After a 40-minute washout period, the volunteers will be covered with the blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. B. Finally and after a last 40-minute washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes.
89224810|NCT06198959|Experimental|EADBC|E. Volunteers will be covered with the blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system for 30 minutes. A. After a 40-minute washout period, the volunteers will be covered with the adult blanket plus, MA2220 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. D. After a 40-minute washout period, the volunteers will be covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system for 30 minutes. B. Finally and after a last 40-minute washout period, the volunteers will be covered with the Premium Adult Blanket, 3320 connected to the Mistral Air, Blower MA1200-PM system for 30 minutes. C. Finally and after a last 40-minute washout period, the volunteers will be covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 for 30 minutes.
89224811|NCT06198712|Experimental|Etavopivat|Participants will receive Etavopivat once daily (QD) orally.
89224812|NCT06194604|Experimental|experimental group|In addition to the routine physical therapy program, Instrument-assisted soft tissue mobilization will be applied 3 days a week, for a total of 18 sessions. Each session will last 5 minutes.
89224813|NCT06194604|Other|Control group|Only the routine physical therapy program will be applied.
89224814|NCT06191965|Experimental|MitoQ|20 mg 2 capsules once daily for 12 weeks (total daily dose 40 mg)
89224815|NCT06191965|Placebo Comparator|Placebo|2 capsules (identical in appearance to MitoQ capsules) once daily for 12 weeks
89224816|NCT06191874||Surgery planning by SOC methods, then by HoloDBS|Standard-of-care (SOC) surgery plan is built before the HoloDBS hypothetical surgery plan
89079849|NCT02851498|Experimental|Novel high-protein pasta and cereal|High-protein pasta (orzo and fusilli) enriched with gluten and egg white protein (%energy: 27/30/43 for protein/fat/carbohydrate) and high-protein flaked breakfast cereal enriched with gluten (%energy: 30/35/35 for protein/fat/carbohydrate) were manufactured by Zone Inc.(Boston, MA). The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as control meals.
89079850|NCT02851498|Sham Comparator|Control pasta and cereal|Commercial gluten-free pasta (Barcilla orzo and fusilli; %energy: 13/24/63 for protein/fat/carbohydrate) and commercial flaked cereal (Post Honey Bunches of Oats; %energy: 6/18/76 for protein/fat/carbohydrate) were used as the control foods. The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as experimental foods.
89079851|NCT02690272|Experimental|Psychic processes|Quantitative and qualitative approche of the psychic process for patients awaiting kidney transplant
89079852|NCT02851420|Placebo Comparator|control|
89079853|NCT02851420|Experimental|patient|
89079854|NCT00604630|Placebo Comparator|placebo|50ml 0.9% NaCL
89079855|NCT00604630|Active Comparator|verum|erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl
89079856|NCT05380882|Experimental|TQB2930 injection|Drug:Weekly intravenous infusion of TQB2930 injection,21 days as a treatment cycle. (2.5mg/kg, 5mg/kg, 10mg/kg) Drug:Every two weeks intravenous infusion of TQB2930 injection , 28 days as a treatment cycle.(20mg/kg) Drug:Every three weeks intravenous infusion of TQB2930 injection, 21 days as a treatment cycle. (30mg/kg)
89079857|NCT01189266|Experimental|Arm 1 Phase I Vorinostat 180 mg/m^2|Patients in phase I received vorinostat at 180 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89079858|NCT01189266|Experimental|Arm 2 Phase 1 Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89079859|NCT01189266|Experimental|Arm 3 Phase II Evaluation Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/ day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89079860|NCT01189032|Experimental|High concentration|
89079861|NCT01189032|Experimental|Low concentration|
89079862|NCT01189032|Placebo Comparator|Placebo|
89079863|NCT01188798|Experimental|Transplant recipients receiving Methotrexate|Participants will be biologically stratified according to disease, donor, and KIR match. In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
89079864|NCT01188798|Experimental|Transplant recipients receiving Pentostatin|Participants will be biologically stratified according to disease, donor, and KIR match.between donor and host.In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
89224817|NCT06191874||Surgery planning by HoloDBS, then by SOC methods|HoloDBS hypothetical surgery plan is built before the standard-of-care (SOC) surgery plan
89224818|NCT06191731|Experimental|excretion kinetics of gadolinium contrast agents in patients|urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
89230112|NCT00796133|Active Comparator|1|0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
89230113|NCT00796133|Active Comparator|2|1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
89230114|NCT00796133|Active Comparator|3|1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
89230115|NCT00796211|Experimental|1|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
89079865|NCT04316052|Experimental|aerobic training group|At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine.
89079866|NCT04316052|Experimental|strength training group|Strength training prescriptions will be in accordance with recommendations of the American College of Sports Medicine.
89079867|NCT01183104|Experimental|Sitagliptin|
89079868|NCT01183104|Active Comparator|Glimepiride|
89079869|NCT02886468|Experimental|ultrasound images|ultrasound images of the anterolateral aspect of the mid-right thigh
89079870|NCT01163292||Adalimumab|Participants who continued adalimumab treatment after completion of Study NCT00870467 (M06-859)
89079871|NCT01163292||Non-Adalimumab|Participants who discontinued adalimumab treatment after completion of Study NCT00870467(M06-859)
89230116|NCT00796211|Experimental|2|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
89224819|NCT06190249|Experimental|LN-144 Therapy|"All patients will receive LN-144 therapy, consisting of these steps:~Harvest (surgical resection of tumor tissue) to provide the autologous tissue that serves as the source of LN-144.~Production of LN-144 investigational product (IP) at a central Good Manufacturing Practice (GMP) facility~A 5-day nonmyeloablative lymphodepletion (NMA-LD) preparative regimen~Infusion of the LN-144 product (Day 0)~Administration of IV interleukin-2 (IL-2) for ≤ 6 doses.~Infusion of pembrolizumab 200 mg (Week 12) every 3 weeks for up to 1 year (17 cycles)"
89224820|NCT06188559|Experimental|Part 1, Dose Optimization, Cohort 1|HER2-positive or HER2-low, unresectable or metastatic BC.
89224821|NCT06188559|Experimental|Part 1, Dose Optimization, Cohort 2|HER2-positive or HER2-low, unresectable or metastatic BC.
89224822|NCT06188559|Experimental|Part 1, Dose Optimization, Cohort 3|HER2-positive or HER2-low, unresectable or metastatic BC.
89079872|NCT04188132|Experimental|EEG BCI closed loop feedback for rehabilitation of upper limb|"This study is a pilot study to examine the feasibility of a SMR based EEG BCI using motor task and motor imagery and involve a gaming feedback for same.~The first two days will be used for calibrating the BMI using commands in computer screen followed by further two days for testing the BMI and feedback control during gaming in computer to move the ball in the computer screen."
89224823|NCT06188559|Experimental|Part 2, Dose Expansion|HER2-positive or HER2-low, unresectable or metastatic BC.
89079873|NCT04187664|Experimental|EXCARE Pathway Group|The proposed pathway comprises a range of actions that include individual patient-centered risk assessment by the SAMPE Risk Model (30-day probability of death), specialized care in Post-Anesthetic and Intensive Care Units, and also in the surgical wards performed by the nursing, anesthesia, clinic and surgery teams.
89079874|NCT02885688|Other|Standard-of-Care Treatment for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment alone for up to 7 days.
89079875|NCT02885688|Experimental|Standard-of-Care Treatment Plus Liquid Nutrition for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment plus plus liquid nutrition for up to 7 days.
89079876|NCT00950248|Active Comparator|Idebenone|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
89079877|NCT00950248|Placebo Comparator|Placebo|Placebo tablets administered orally as five tablets, three times per day with food.
89079878|NCT02851264||Optical enhancement technology examination|After routine examination by white-light endoscopy,the imaging mode will be switched to optical enhancement.Suspicious area will be recorded in detail. Then all enrolled patients will have their esophagus sprayed with iodine solution. Suspicious area will be also recorded in detail.After that biopsy specimens will be obtained respectively by forceps from each suspicious lesion recorded for histologic diagnosis.
89079879|NCT00950170|Experimental|1|The investigator treats subjects with ReFacto AF in the usual care setting.
89079880|NCT02851342||MS|patients with multiple sclerosis
89079881|NCT02851342||CO|matched control subjects
89079882|NCT00603226||1|Patients diagnosed with slow coronary artery flow during coronary angiography
89079883|NCT00603226||2|Patients with normal coronary artery flow observed during coronary angiography
89079884|NCT05380804||Patients with primary Sjögren's syndrome|Cutaneous silent period measurement was performed in patients with the primary Sjögren's syndrome classified according to the 2016 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) criteria.
89079885|NCT05380804||Healthy population|Cutaneous silent period measurement was also performed in healthy population.
89079886|NCT02851030|Experimental|Move, Play, Learn! Intervention|This arm will receive the 10-week Move, Play, Learn! intervention immediately.
89079887|NCT02851030|No Intervention|Waitlist Control|This arm will receive the 10-week intervention once follow-up measures on the primary outcome have been collected for both groups.
89079888|NCT04267666|Experimental|Inspiratory Muscle Strength Training|in the form of: Inspiratory threshold muscle trainer in addition to traditional chest physical therapy intervention (Deep breath, cough training)
89079889|NCT04267666|Experimental|Incentive Spirometer|incentive spirometer, three sessions per week for six weeks
89079890|NCT00604864|Experimental|1|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
89079891|NCT00604864|Placebo Comparator|2|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
89079892|NCT01227824|Experimental|GSK1349572 (N=~394)|GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
89079893|NCT01227824|Active Comparator|raltegravir (N=~394)|raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily
89079894|NCT00949702|Experimental|Single arm|
89079895|NCT01034631|Active Comparator|Combination Arm A: Everolimus + BNC105P|Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
89079896|NCT01034631|Active Comparator|Sequential Arm B:Everolimus followed by BNC105P Monotherapy|"Sequential Arm B: Everolimus 10 mg, 21 day cycle~Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy."
89079897|NCT02854852||Patients undergoing general anesthesia|Patients ASA 1-3, undergoing different types of general anesthesia, in supine position, with standard or advanced hemodynamic monitoring.
89079898|NCT01227668|Experimental|Aripiprazole|
89079899|NCT01227668|Placebo Comparator|Placebo|
89079900|NCT00603460|Active Comparator|A|
89079901|NCT00603460|Active Comparator|B|
89079902|NCT02851186|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|Subjects in the treatment group will receive EA combined with AA two hours before operation, immediately post-operation and once a day for the subsequent 5 days.
89079903|NCT02851186|Sham Comparator|Sham acupuncture|Subjects in the control group will receive non-invasive sham procedure in the same schedule as the treatment group.
89079904|NCT04319432|Experimental|3 days voice rest|
89079905|NCT04319432|Experimental|7 days voice rest|
89079906|NCT01227512|Experimental|Tolvaptan 15-60mg|Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
89079907|NCT01227512|Active Comparator|Fluid Restriction|Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
89079908|NCT01227278|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
89079909|NCT01227278|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
89079910|NCT01034397|Experimental|1|
89079911|NCT01034397|Placebo Comparator|2|
89079912|NCT01227044|Active Comparator|NTX + MM/MC|Naltrexone + Medical Management/Medication Coaching
89079913|NCT01227044|Placebo Comparator|Placebo + MM/MC|Placebo plus Medical Management/Medication Coaching
89224824|NCT06187025|Other|Standardized clinical evaluations, and screening of substance use|Standardized clinical evaluations, and screening of substance use will be performed for all using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST).
89224825|NCT06186063|Experimental|Pramlintide infusion|A stable amylin analogue.
89224826|NCT06186063|Placebo Comparator|Placebo infusion|Isotonic saline (0.9% NaCl).
89224827|NCT06184880|Active Comparator|A control group|"Patients will receive standard care, recommendations on physical activity.~patients should wear the wristband continuously for 7 days prior to scheduled hospital visit T0, T1, T2, T3, T4, T5"
89224828|NCT06184880|Experimental|B experimental Group|"1 or 2 physical activity sessions per week, either face-to-face or by videoconference at patient convenience: low-to-moderate intensity aerobic and anaerobic muscle-strengthening session and a 40-minute stretching/yoga session.~patients should wear the wristband continuously for 7 days prior to scheduled hospital visit T0, T1, T2, T3, T4, T5"
89224829|NCT06181279|Experimental|Individualized PEEP group|After recruitment maneuver, PEEP is titrated decreasingly using driving pressure guided individualised PEEP ventilation strategy, and the PEEP corresponding to the lowest driving pressure is the individualised PEEP.
89224830|NCT06181279|Other|Fixed PEEP group|After recruitment maneuver, PEEP is fixed at 8cmH2O.
89224831|NCT06180356|Experimental|Niraparib|
89224832|NCT06179108|Experimental|LB-102, 50 mg QD|Oral LB-102: 50 mg (n ~ 105)
89224833|NCT06179108|Experimental|LB-102, 75 mg QD|Oral LB-102: 75 mg (n ~ 105)
89224834|NCT06179108|Experimental|LB-102, 100 mg|Oral LB-102: 100 mg (n ~ 35)
89224835|NCT06179108|Placebo Comparator|Placebo comparator|"Drug: Placebo~Matched placebo tablets"
89224836|NCT06179004|Experimental|Supraclavicular Liposomal Bupivacaine group|This group will receive the liposomal bupivacaine
89224837|NCT06179004|Active Comparator|Supraclavicular Plain Bupivacaine group|This group will receive the plain bupivacaine
89230117|NCT00796211|Active Comparator|3|0.1% nortriptyline HCl topical cream
89224838|NCT06175546|Experimental|Compression regimen 6-8 hours per day 4 weeks|40 participants. A physical examination and duplex ultrasound of the veins of the lower extremities are performed. It is suggested to wear the compression socks 6-8 hours a day for 4 weeks
89224839|NCT06175546|Active Comparator|Compression regimen 10-12 hours per day 4 weeks|40 participants. An physical examination and duplex ultrasound of the veins of the lower extremities are performed. It is suggested to wear the compression socks 10-12 hours a day for 4 weeks
89224840|NCT06175026|Experimental|Health messages|Messages shown will be related to the health impacts of making certain dietary substitutions (replacing beef with chicken and vegetarian entrees; replacing juice with whole fruit; replacing dairy milk with non-dairy milk; replacing sugar-sweetened beverages with water).
89224841|NCT06175026|Experimental|Environment messages|Messages shown will be related to the environmental impacts of making certain dietary substitutions (replacing beef with chicken and vegetarian entrees; replacing juice with whole fruit; replacing dairy milk with non-dairy milk; replacing sugar-sweetened beverages with water).
89224842|NCT06175026|Experimental|Health and environment messages|Messages shown will be related to the health and environmental impacts of making certain dietary substitutions (replacing beef with chicken and vegetarian entrees; replacing juice with whole fruit; replacing dairy milk with non-dairy milk; replacing sugar-sweetened beverages with water).
89224843|NCT06175026|Active Comparator|Neutral messages|Messages shown will be neutral and unrelated to the health or environmental impacts of making certain dietary substitutions (replacing beef with chicken and vegetarian entrees; replacing juice with whole fruit; replacing dairy milk with non-dairy milk; replacing sugar-sweetened beverages with water).
89224844|NCT06174948|Experimental|people with Parkinson's disease and related disorders|"Intervention~All participants will use the CUE1 device as follows:~during the first two weeks (e.g., 1-2 weeks) of the 9 weeks in the study: once a day for a continuous duration of 2 hours in the morning, 1 hour after taking the medication (if any) for PD or related disorder, every single day;~during the weeks 4-5 of the 9 weeks in the study: once a day for a continuous duration of 8 hours, starting from morning, 1 hour after taking the medication (if any) for PD or related disorder, every single day;~during the weeks 7-8 of the 9 weeks in the study: only at night, through all night, every single night and not during the day at all;~Assessments Four face to face appointments will be arranged for each participant. The appointments will take place at week-0 (baseline), week-3 (follow up 1), -6 (follow up 2), and -9 (follow up 3). Each appointment will last approximately half a day."
89230118|NCT00796211|Active Comparator|4|0.005% calcipotriol topical cream
89230119|NCT00796211|Placebo Comparator|5|Vehicle of CRx-197 topical cream (placebo)
89224845|NCT06172348|Experimental|Treatment Sequence 1|Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
89079914|NCT02872779|Experimental|Patients Treated for Metastatic Colorectal cancer|Blood sampling for free mutant DNA analysis for Patients Treated for Metastatic Colorectal cancer
89079915|NCT01225952|Experimental|Crystalens AO|Bausch & Lomb silicone multi-piece accommodating IOL is a modified plate haptic lens
89079916|NCT01225952|Active Comparator|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
89079917|NCT01225952|Active Comparator|AMO Tecnis Multifocal|A foldable hydrophobic acrylic IOL,(Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL
89079918|NCT01034163|Experimental|Panobinostat (PAN)|Participants received 45 mg orally 3 times a week (TIW), every other week (QOW),
89079919|NCT01034163|Placebo Comparator|Placebo|Participants received matching placebo to PAN TIW, QOW.
89079920|NCT01033851|Active Comparator|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is an 8-week group intervention that trains participants in mindfulness meditation techniques.
89079921|NCT01033851|Active Comparator|Stress Management Education|Stress Management Education (SME) is an 8-week group intervention that educates participants about stress physiology and health lifestyle changes.
89079922|NCT01162122|Experimental|aTIV|Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).
89079923|NCT01162122|Experimental|Licensed TIV|Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).
89079924|NCT01033071|Experimental|Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD|
89079925|NCT01033071|Experimental|Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD|
89079926|NCT01033071|Active Comparator|Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD|
89079927|NCT04313946||Symptomatic Patients|Our goal is to identify an artificial intelligence algorithm that can be run on lung radiographs in patients with influenza / respiratory viral symptoms who come to the emergency department / triage. This algorithm aims to identify the radiographs of patients with COVID-19 and those with influenza pneumonitis, with accuracy verified by COVID-19 tests.
89079928|NCT01032915|Experimental|AIN457 300mg s.c weekly for 3 weeks|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
89079929|NCT01032915|Experimental|AIN457 300mg s.c at baseline and Week 2|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
89079930|NCT01032915|Experimental|AIN457 150mg s.c at baseline and Week 2|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
89079931|NCT01032915|Placebo Comparator|Placebo s.c weekly for 3 weeks|Placebo s.c weekly for 3 weeks then every 2 weeks
89079932|NCT00627783|Experimental|Intervention|Patients are referred to a cardiologist for a systematic detection of silent ischemia by a bicycle exercise test performed according to the French Society of Cardiology protocol after washout of cardiovascular medications likely to interfere with the test. Dipyridamole Single Photon Emission Computed Tomography (SPECT) is used in patients unable to perform the exercise test, with a sub-maximal negative exercise test result or with electrocardiographic abnormalities impairing the interpretation of the exercise test. Subsequent investigations (such as coronary angiography) and treatments (such as revascularization procedures) are left at the cardiologist's decision.
89079933|NCT00627783|No Intervention|Control|Patients are treated according current guidelines but are not referred to a cardiologist
89079934|NCT01161498|Active Comparator|Radiation/Cisplatin|Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42. Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period.
89079935|NCT01161498|Experimental|Talimogene Laherparepvec + Radiation/Cisplatin|The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming units (PFU)/mL, administered into all injectable affected nodes on Day 0. Subsequent doses were up to 8 mL total volume (up to 4 mL per lesion) at 10⁸ PFU/mL on Days 21, 42, and 63. Participants also received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42 and radiation administered concurrently in 35 fractions over a 7-week period.
89079936|NCT02873559|No Intervention|Controls|A control group, which is 20 weeks with placebo injections without training.
89079937|NCT02873559|Experimental|Testosterone|A testosterone group given 20 weeks on testosterone injections without training
89079938|NCT02873559|Experimental|Training|A Training Group, which is 20 weeks with placebo injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
89079939|NCT02873559|Experimental|Testosterone and training|A combination group that is 20 weeks with testosterone injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
89079940|NCT01180998|Other|Spherical contact lens users|Habitual spherical contact lens (non-toric lens) users tried one of two toric lenses in a daily wear modality.
89079941|NCT01180998|Other|Contact lens drop-outs|Habitual spectacle users (for vision correction) who have failed contact lens fit and wear, tried one of two toric lenses in a daily wear modality.
89079942|NCT01180998|Other|Habitual Correction with Spectacles (Neophytes)|Habitual spectacle lens wearers (for vision correction) who have never used or been fitted with contact lenses tried one of two toric lenses in a daily wear modality.
89079943|NCT01029795|Experimental|LY2599506|Combinations of 50-milligram (mg) or 100-mg capsules of LY2599506 or matching placebo capsules (each dose contains at least 1 capsule of active drug). LY2599506 will be administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day.
89079944|NCT01029795|Active Comparator|Glyburide|Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
89224846|NCT06172348|Experimental|Treatment Sequence 2|Ritlecitinib 100 mg MR capsule 1 (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 2), followed by ritlecitinib 100 mg solution (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
89079945|NCT02885766|Experimental|PF-114|"PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 % is applied if there were Grade 2 ADRs. In the absence of Grade 2 or 3 ADRs an increase of 100 % is applied.~When the dose reaches 400 mg/day, the following increase in dose can be made after discussing results of safety findings of PF-114 between the Investigators and the Sponsor.~Orally, once daily"
89079946|NCT02885454|Experimental|OC + AL-335 + ODV + 3-DAA combination|Participants will receive single dose of 3 milligram (mg) drospirenone/0.02 mg ethinylestradiol [OC] on Day 1, AL-335 800 mg once daily on Days 5 and 6, a single dose of AL-335 800 mg + a single dose of OC on Day 7, ODV 25 mg once daily on Days 12 to 24, followed by a single dose of ODV 25 mg and a single dose of OC on Day 25, followed by ODV 25 mg + AL-335 800 mg + simeprevir (SMV) 75 mg [3-DAA combination] once daily on Days 26 to 31, followed by a single dose of 3-DAA combination and a single dose of OC on Day 32.
89079947|NCT02885610|Placebo Comparator|Placebo Comparator|Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses
89079948|NCT02885610|Experimental|RC18 80 mg plus standard therapy|RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses
89079949|NCT02885610|Experimental|RC18 160 mg plus standard therapy|RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses
89079950|NCT02885610|Experimental|RC18 240 mg plus standard therapy|RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses
89079951|NCT04314180||Slit-lamp image quality assessment|Device: an artificial intelligence system for quality assessment of slit-lamp images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center
89079952|NCT01032837|Experimental|Oseltamivir standard dose 5 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
89079953|NCT01032837|Experimental|Oseltamivir standard dose 10 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 10 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 10 days.
89079954|NCT01032837|Experimental|Oseltamivir high dose 5 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
89079955|NCT01032837|Experimental|Oseltamivir high dose 10 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 10 days. Children aged 1- 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 10 days.
89079956|NCT04314102||1|"Individuals will be evaluated before knee arthroplasty surgery. They will come for control in the 1st and 3rd months after surgery.~No intervention will be made."
89079957|NCT01180296|Experimental|Progesterone Group|Oral Micronized Progesterone
89079958|NCT01180296|Placebo Comparator|Placebo|Identical Placebo Tablet
89224847|NCT06172348|Experimental|Treatment Sequence 3|Ritlecitinib 100 mg MR capsule 2 (fasted, Period 1), followed by ritlecitinib 100 mg solution (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 1 (fed, Period 4)
89224848|NCT06172348|Experimental|Treatment Sequence 4|Ritlecitinib 100 mg solution (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
89224849|NCT06172348|Experimental|Treatment Sequence 5|Ritlecitinib 100 mg MR capsule 1 (fasted, Period 1), followed by ritlecitinib 100 mg MR capsule 2 (fasted, Period 2), followed by ritlecitinib 100 mg solution (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
89224850|NCT06172348|Experimental|Treatment Sequence 6|Ritlecitinib 100 mg MR capsule 2 (fasted, Period 1), followed by ritlecitinib 100 mg solution (fasted, Period 2), followed by ritlecitinib 100 mg MR capsule 1 (fasted, Period 3), and followed by ritlecitinib 100 mg MR capsule 2 (fed, Period 4)
89224851|NCT06171750|Experimental|ANK-101 IT Injection|IT injections of ANK-101 once every 3 weeks
89224852|NCT06171165||Hospitalized Patients Across Disease Categories|We included the patients, namely, patients with head-and-neck cancer, stroke, and Parkinson's disease, as well as the elderly patients in acute care settings.
89224853|NCT06168851|Experimental|Experimental: Intervention (Anti-CD38 antibody)|20 enrolled subjects : once a week x 8 doses
89224854|NCT06167486|Experimental|SG2918|SG2918 monotherapy
89224855|NCT06167369||Newly diagnosed sleep apnea patients, starting clinical prescribed positive airway pressure therapy|
89224856|NCT06166992|Experimental|BI 1291583 alone (not radio-labelled, low dose) then [14C]-BI 1291583 (radio-labelled)|
89224857|NCT06166992|Experimental|BI 1291583 alone (not radio-labelled, high dose) then [14C]-BI 1291583 (radio-labelled)|
89224858|NCT06165887||Moderate-to-severe Psoriasis patients|Participants will fill out questionnaires to assess sleep status and the severity of psoriasis.
89224859|NCT06165887||Healthy people|Participants will fill out questionnaires to assess sleep status
89224860|NCT06162052|Experimental|A Standard of Care group (SOC)|Participants will receive standard of care education by the physical or occupational therapist regarding performance of the prescribed movements prior to discharge. Participants will complete the study about 6 months after discharge.
89224861|NCT06162052|Experimental|A Standard of Care group (SOC) combined with technology enhancement|Participants will receive standard of care education by the physical or occupational therapist regarding performance of the prescribed movements prior to discharge. Participants will undergo additional training in the use of a goniometer to measure range of motion at home and record the measurement once a week for 6 months. Participants will engage in 4 virtual sessions as well as wear a Fitbit
89224862|NCT06161584||Observation|
89224863|NCT06157944|Active Comparator|GPT-4|Group will be given access to GPT-4.
89224864|NCT06157944|No Intervention|Usual resources|Group will not be given access to GPT-4 but will be encouraged to use any resources they wish besides large language models (UpToDate, Dynamed, google, etc).
89224865|NCT06154668||Cohort #A|monotherapy anti-PD1 first line
89224866|NCT06154668||Cohort #B|monotherapy anti-PD1 second line
89224867|NCT06154668||Cohort #C|monotherapy anti-PD1 adjuvant
89224868|NCT06154668||Cohort #D|combotherapy anti-PD1/CTLA-4 first line
89224869|NCT06154668||Cohort #E|untreated stage I and II melanoma patient
89079959|NCT01160640|Placebo Comparator|Ceftriaxone/Doxycycline/Placebo Oral Cap|ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo oral capsule PO bid x 14 days
89079960|NCT01160640|Active Comparator|Ceftriaxone, Doxycycline, Metronidazole|ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days
89079961|NCT01160484|Experimental|DVD-R single arm|"Dose schematic of Dexamethasone + Bortezomib + Pegylated Liposomal Doxorubicin + Lenalidomide (DVD-R) Therapy:~Dexamethasone*- 40 mg IV Bortezomib**- 1.0 mg/m2 IV Push Pegylated Liposomal Doxorubicin*- 4.0 mg/m2 IV Lenalidomide***- 10 mg PO~Per 28 Day Cycle~Intravenous infusion (IV) Days 1, 4, 8 and 11 ** Intravenous push (IVP) Days 1, 4, 8 and 11 *** Per Orem (PO) Days 1-14"
89079962|NCT01032291|Experimental|lenalidomide plus cetuximab|Combination therapy of lenalidomide plus cetuximab
89079963|NCT01032291|Experimental|lenalidomide|Single agent therapy of lenalidomide
89079964|NCT01159938|Experimental|T2DM, albuminuria but normal kidney function|
89079965|NCT01159938|No Intervention|Healthy participants|
89079966|NCT01159938|Experimental|T2DM, normal urinary albumin excretion rate (UAER)|
89079967|NCT02873871|Other|Control group|Standardized compressive dressing
89079968|NCT02873871|Experimental|Intervention group|Hemostasis with TerumoBand®
89079969|NCT04301739|Experimental|HLX10 + chemotherapy→ HLX10|HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → HLX10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → HLX10 (9 cycles)
89079970|NCT04301739|Placebo Comparator|Placebo + chemotherapy→ Placebo|Placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → Placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → Placebo (9 cycles)
89079971|NCT04301583|Active Comparator|Procyanidin B2 enriched cocoa|Participants receiving cocoa capsules
89079972|NCT04301583|Placebo Comparator|Placebo group|Participants maltodextrin capsules
89079973|NCT01029405|Active Comparator|1. AN2728 Ointment B|2%, administered twice daily
89079974|NCT01029405|Placebo Comparator|2. AN2728 Ointment B Vehicle|
89079975|NCT01029405|Active Comparator|3. AN2728 Ointment B|2%, administered once daily
89079976|NCT01029405|Active Comparator|4. AN2728 Ointment B|0.5%, administered twice daily
89079977|NCT01029405|Active Comparator|5. AN2728 Ointment B|0.5%, administered once daily
89079978|NCT02872623|Experimental|experimental group|patients clinically suspected of having a tumor of the small intestine
89079979|NCT01021683||Itraconazole|Participants who have been receiving itraconazole will be observed prospectively. Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
89079980|NCT01021293|Experimental|Poliorix Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.
89224870|NCT06154564||Observed group|No intervention will be administered on behalf of the project. The participants will be tested using ALBA and PICNIR (non-invasive) cognitive tests, and further FAQ-CZ and GDS-CZ questionnaires will be administered.
89079981|NCT01021293|Active Comparator|Control Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.
89079982|NCT04625725|Experimental|AZD7442|"Approximately 5150 participants will be randomized in a 2:1 ratio~• Arm 1 (n=approximately 3433) will receive a single dose (× 2IM injections) of 300 mg of AZD7442"
89079983|NCT04625725|Placebo Comparator|Placebo|"Approximately 5150 participants will be randomized in a 2:1 ratio~• Arm 2 (n=approximately 1717) will receive saline placebo"
89079984|NCT04625725|Experimental|Sub-study AZD7442 Arm 1|"Approximately 500 participants will receive AZD7442 in the repeat dose sub-study.~-Sub-study Arm 1 (~ 12 month repeat dose interval): Participants who received AZD7442 300 mg IM on Day 1 of the parent study will receive a second dose of AZD7442 300mg IM on sub-study Day 1."
89079985|NCT04625725|Experimental|Sub-study AZD7442 Arm 2|"Approximately 500 participants will receive AZD7442 in the repeat dose sub-study.~-Sub-study Arm 2(~ 6 month repeat dose interval): Participants who received placebo on Day 1 of the parent study will receive their first dose of AZD7442 300mg IM on sub-study Day1 followed by a second dose on sub-study Day 183."
89079986|NCT04625725|Experimental|Sub-study AZD7442 Arm 3|A subset of Arm 1 and Arm 2 participants who will receive additional doses of AZD7442, 600mg, at Day 183 and Day 366 of the sub-study.
89079987|NCT01021215|Experimental|Arm I: Zileuton|Zileuton 1200 mg twice orally twice a day on days 1-6.
89079988|NCT01021215|Experimental|Arm II: Zileuton and Celecoxib|Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.
89079989|NCT01021137||TBI & Blast|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure and a diagnosis of mild TBI
89079990|NCT01021137||Blast Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure without TBI
89079991|NCT01021137||TBI Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with a history of mild TBI and no blast exposure
89079992|NCT01021137||Healthy Controls|Age and gender matched control participants with no complaints of dizziness and/or imbalance or history of TBI or blast exposure
89224871|NCT06151769|Experimental|Pomegranate seed oil|In addition to the routine care of patients, pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days.
89224872|NCT06151769|Active Comparator|Sesame oil|In addition to the routine care of patients, Sesame oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days.
89224873|NCT06151769|No Intervention|Control group|Patients will not be interfered with in their routine care. Patient monitoring will be done every afternoon for 6 days.
89224874|NCT06149975|Experimental|Intervention|"In addition to the usual care, the study participants receive the motor-cognitive training StepIt. The StepIt will be conducted as an approximately 15-minute one on one training for at least 3 to max. 10 sessions during the stay at the hospital."
89224875|NCT06148870|Active Comparator|MCL1|The MCL1 is a myopia control lens that will be worn in one eye for 6 months.
89224876|NCT06148870|Experimental|MCL2|The MCL2 is a myopia control lens that will be worn on the contralateral eye for 6 months.
89224877|NCT06148090|Experimental|Treated with clobetasol propionate|
89224878|NCT06146959|Experimental|Group A|Group A: will receive corrective kinesiotaping (50-75% stretch) for 4 weeks, 2 times per week, with 1 day rest
89224879|NCT06146959|Active Comparator|Group B|Group B: will receive a placebo non-corrective kinesio taping (without tension) with no mechanical correction of calcaneus
89224880|NCT06146959|Placebo Comparator|Group C|Group C: will receive a home program of intrinsic foot strengthening and stretching exercises.
89224881|NCT06142032|Experimental|Metaverse support group|Online intervention
89224882|NCT06142032|Active Comparator|In-Person support group|In-person intervention
89224883|NCT06142032|No Intervention|Waitlist|Control
89224884|NCT06140537|Experimental|Dapagliflozin|Participants will receive dapagliflozin 10mg daily
89224885|NCT06140537|Placebo Comparator|Placebo|Participants will receive one placebo tablet daily
89224886|NCT06140290|Experimental|Fixed Sequence|Single oral dose of etrasimod 2mg tablet under fasted conditions with site staff led assessments and training on how to use wearable sensors followed by single oral dose 2mg tablet under fasted conditions with participant led assessments with wearable sensors.
89224887|NCT06137534|Experimental|Exercise Group|Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.
89224888|NCT06132269|Placebo Comparator|Placebo sachet|consume 1 sachet per day for 8 weeks
89224889|NCT06132269|Experimental|AKK formula sachet|consume 1 sachet per day for 8 weeks
89224890|NCT06131957|Experimental|Fluoride varnish with SBGC|This group will receive applications of fluoride varnish (containing 5% NaF) with 7.5% SBGC every 3 months for 36 months.
89224891|NCT06131957|Active Comparator|Fluoride varnish without SBGC|This group will receive 5% NaF varnish with SBGC every 3 months for 36 months.
89224892|NCT06128733|Experimental|Group 1: MenPenta Formulation 1|Participants (ACWY naive and primed adults or adolescents) will receive injections of the pentavalent meningococcal ABCYW vaccine and placebo
89079993|NCT01021137||Excluded|Participants who did not meet inclusion criteria, did not return to complete evaluation, and/or were excluded from data analysis.
89079994|NCT01020981||Group 1|Michigan State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
89079995|NCT01020981||Group 2|Indiana State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
89079996|NCT02760979|Active Comparator|Denosumab|Patients treated with Denosumab
89079997|NCT02760979|Placebo Comparator|Placebo|Patients treated with placebo
89079998|NCT04301115|Active Comparator|conventional group|conventional partial denture
89079999|NCT04301115|Experimental|attachment group|unlateral attachment retained partial denture
89080000|NCT04301115|Experimental|tooth implant supporeted prosthesis|tooth implant supported bridge
89080001|NCT05429281|Active Comparator|Pilates-based Core Strengthening Group|Participants in this group performed eight PsCS exercises geared predominantly to the core muscles.
89080002|NCT05429281|Active Comparator|Plyometric-based Muscle Loading Group|Participants in this group performed 10 PlyoML exercises primarily focused on the lower body.
89080003|NCT05429281|Experimental|Combined training group|Participants in this group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions.
89080004|NCT02873403|Experimental|KNEEMO knee brace & Popular knee brace|Patients having medial knee osteoarthritis
89080005|NCT02873403|Experimental|Popular knee brace &KNEEMO knee brace|Patients having medial knee osteoarthritis
89080006|NCT02754505|Other|Early rehabilitation group|Directly after transfer to a general ward the early rehabilitation group started with an early rehabilitation program, as ordered by an experienced physiatrist. The applied intervention (early rehabilitation) is a combination out of different therapeutic modalities (for further information please see interventions).
89080007|NCT02754505|Other|Usual care group|The usual care group received single physical therapy sessions as ordered by the primary care team after transfer from the ICU to the general ward. The applied intervention (usual care) is a combination out of different therapeutic modalities (for further information please see interventions).
89080008|NCT04301193|Other|Pregnant Women|All subjects will have the same intervention. Samples will be taken and manipulated in the laboratory for use of the Hemosonic Qauntra Analyzer
89080009|NCT02760901|Active Comparator|Mannitol group|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
89080010|NCT02760901|Active Comparator|ACTZ group|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.
89080011|NCT02760901|Active Comparator|NAC group|patients received acetylcysteine NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.
89080012|NCT04301427|Other|Obese patient|
89080013|NCT00635713|Experimental|1|Faslodex 125mg and Arimidex 1 mg
89080014|NCT00635713|Experimental|2|Faslodex 250mg and Arimidex 1mg
89080015|NCT02760823|Active Comparator|Alpha Lipoic Acid|Subjects in this arm will receive ALA IV, as a dose of 600 mg/12 hours.
89080016|NCT02760823|Placebo Comparator|Non-Alpha Lipoic Acid|Subjects in this arm will to receive standard treatment only (without Alpha Lipoic Acid, instead they will receive placebo , which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment.
89080017|NCT04222543|Active Comparator|HPV Negative tumours|Patients will receive four scans.
89080018|NCT04222543|Active Comparator|HPV positive tumours|Patients will receive four scans.
89080019|NCT02760511|Placebo Comparator|Control|Intake of placebo capsules
89080020|NCT02760511|Active Comparator|20 mg|Daily intake of 20 mg anthocyanin
89080021|NCT02760511|Active Comparator|40 mg|Daily intake of 40 mg anthocyanin
89080022|NCT02760511|Active Comparator|80 mg|Daily intake of 80 mg anthocyanin
89080023|NCT02760511|Active Comparator|160 mg|Daily intake of 160 mg anthocyanin
89080024|NCT02760511|Active Comparator|320 mg|Daily intake of 320 mg anthocyanin
89080025|NCT02754739|Experimental|Pravastatin|Pravastatin 40mg tablet by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
89080026|NCT02754739|Placebo Comparator|Placebo|Placebo drug indistiguishable from pravastatin 40mg tablet, by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
89080027|NCT02754739|Other|Open-label control|No medication. Only nutritional education was provided to participants by a nutritionist, and participants were instructed to follow the educated guideline.
89080028|NCT04300101||DLBCL patients|All patients with diagnosis of DLBCL
89080029|NCT01020435|Active Comparator|Spinal Manipulation High Velocity|This non-rotary upper cervical procedure uses an impulse thrust with a controlled depth (high velocity). The participant's head is supported by a specially designed cushion and the doctor usually approaches the participant from in front of his or her head to contact soft tissue over the atlas transverse process, posterior to the lateral mass or occasionally on the C2 lamina or spinous process, with the pisiform process of one hand. The thrust is delivered by a contraction of the triceps muscles of both arms, which straightens the arms and applies the thrust to the participant.
89224893|NCT06128733|Experimental|Group 2: MenPenta Formulation 2|Participants (ACWY naive and primed adults or adolescents) will receive injections of the pentavalent meningococcal ABCYW vaccine and placebo
89224894|NCT06128733|Active Comparator|Group 3: Bexsero® + Menveo®|Participants (ACWY naive and primed adults or adolescents) will receive injections of Bexsero® + Menveo® vaccine
89224895|NCT06128733|Active Comparator|Group 4: Trumenba® + Menveo®|Participants (ACWY naive and primed adults or adolescents) will receive injections of Trumenba® + Menveo® vaccine
89080030|NCT01020435|Placebo Comparator|Sham Spinal Manipulation|The sham assessment procedures will be similar to the active group. It has been developed and validated by Vernon et al.
89080031|NCT02754349|Experimental|Validation|SphygmoCor version 7, AtCor Medical, Sydney, Australia
89080032|NCT02873949|Other|1. Periodontitis patients|30 patients consulting at Odontology department for periodontal treatment
89080033|NCT02873949|Other|2. Control|10 patients not affected by periodontitis consulting at Odontology department for checkup of teeth state and/or scaling
89080034|NCT02754271|Experimental|Intervention|A research-based film (Fit for Dialysis) and a 16-week exercise program involving activities during dialysis, at home, and in the community.
89080035|NCT02754271|No Intervention|Control|The 16-week exercise program involving activities during dialysis, at home, and in the community.
89080036|NCT01031979|Experimental|Yohimbime Group|Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.
89080037|NCT01031979|Placebo Comparator|Placebo Group|Patients will take a placebo one hour before first imaginal exposure in PE.
89080038|NCT04502173||Training|Study participants trained on how to use the Ellavi intra-uterine balloon tamponade via virtual webinar training. Feedback on training course elements will be obtained for future improvements prior to scaling.
89080039|NCT04502173||Managing PPH|Study participants who provided refractory PPH care using an Ellavi UBT device will give feedback on the barriers and facilitators to use of the newly registered, low-cost medical device.
89080040|NCT02760589||ACL tear - conservative|conservative treatment
89080041|NCT02760589||ACL tear - ACL reconstruction|reconstruction of the ACL with autologous tendons
89080042|NCT02760589||ACL tear - Internal brace|augmentation of the ruptured ACL with Internal brace
89080043|NCT02760589||healthy subjects|control group of healthy subjects with no previous injury
89224896|NCT06128733|Active Comparator|Group 5: MenQuadfi®|Participants (ACWY naive and primed adults or adolescents) will receive injections of MenQuadfi® vaccine and placebo
89080044|NCT02754193|Experimental|Moderate hypothermia|Moderate hypothermia :Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of moderate hypothermia during 24 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
89080045|NCT02754193|No Intervention|Normothermia|Normothermia: Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
89080046|NCT02753803|Experimental|A group|Evogliptin Pioglitazone Evogliptin+Pioglitazone
89080047|NCT02753803|Experimental|B group|Pioglitazone Evogliptin Evogliptin+Pioglitazone
89080048|NCT02753803|Experimental|C group|Evogliptin Evogliptin+Pioglitazone Pioglitazone
89080049|NCT02753803|Experimental|D group|Pioglitazone Evogliptin+Pioglitazone Evogliptin
89080050|NCT02753803|Experimental|E group|Evogliptin+Pioglitazone Evogliptin Pioglitazone
89080051|NCT02753803|Experimental|F group|Evogliptin+Pioglitazone Pioglitazone Evogliptin
89080052|NCT04219579|Experimental|Continuous infusion|Immediately after operation, 2000 international unit (IU) of Antithrombin-III (AT-III) concentrate is loaded for 1 hour. AT-III concentrate 3000 IU is continuously infused through following 71 hours.
89080053|NCT04219579|Active Comparator|Intermittent infusion|Every 6 hours, 500 IU of AT-III concentrate is infused through 1 hour during the first 72 hours after liver transplantation.
89080054|NCT04613947|Active Comparator|Control|The group with standard (written and verbal) information without multiple intelligence test
89080055|NCT04613947|Experimental|Visual/Spatial:|The group with higher visual intelligence according to the multiple intelligence test results and watch video. Also, will given with a written informed consent document
89080056|NCT04613947|Experimental|Verbal/Linguistic|The group with higher verbal/linguistic intelligence according to the multiple intelligence test results and verbally informed in detail about the operation. lso, will given with a written informed consent document
89080057|NCT04613947|Experimental|Bodily/Kinesthetic|The group with higher bodily/kinesthetic intelligence according to the multiple intelligence test results and informed with a dental model. lso, will given with a written informed consent document
89080058|NCT00635401|Experimental|0.5 mg BID|
89080059|NCT04199065|Experimental|Good Practice Guidelines group|Implementation of Good Practice Guidelines
89080060|NCT04199065|No Intervention|usual practices group|Not Implementation of Good Practice Guidelines, so working as the usual way
89080061|NCT05424055|Experimental|Multicomponent Exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance training, and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening).
89080062|NCT05424055|No Intervention|Usual care|Participants randomly assigned to the usual care group will receive normal hospital care, including physical rehabilitation when needed
89080063|NCT02753959|Experimental|Acute Intervention|Patients will need to be Clinically stable patients with established neuromuscular disease with clinical secretions or cough PEF <270 and history of chest infections. Patients are required to be stable for the preceding 4 weeks with no changes to medications or ventilator settings.
89224897|NCT06128733|Experimental|Group 6: Sanofi MenB|Participants (ACWY naive and primed adults or adolescents) will receive injections of SP MenB vaccine and placebo
89224898|NCT06128642||Toe separator orthosis|The silicone toe spreader orthosis does not use tape or straps to separate the first and second toes and pull them medially to realign the first metatarsal. Orthotics reduce the pain in the bunion area by reducing the high friction between the shoe and the bunion. Participants will be asked to use their orthoses for an average of 8 hours per day for 1 month.
89224899|NCT06128642||Dynamİc orthosis|The dynamic orthosis contains a free joint that does not hinder the movement of the first metatarsophalangeal joint. The working principle of the orthosis is to provide healing of the deformity with low torque and long-term stretching. The dynamic orthosis corrects the hallux valgus angle by realigning the hallux, thus allowing plantarflexion and dorsiflexion. Participants will be asked to use their orthoses for an average of 8 hours per day for 1 month.
89224900|NCT06127797||Questionnaire/Interview|"Participants will take part in this study, before and after your routine breast MRI scan, participants will be asked to answer a series of questions about your experience with this MRI. It may take 10 to 20 minutes to answer. Participants may answer these questions in 1 of 3 ways:~In-person in the clinic with the study team (either through speaking or writing down your answers on a paper or electronic questionnaire form);~by phone at a later time; or~by paper or email at a later time."
89224901|NCT06124014|Experimental|Cranial Electrotherapy Stimulation (CES)|Alpha-Stim AID ® is an FDA-cleared device for the treatment of anxiety that delivers CES through two earclip electrodes.
89080064|NCT02753959|Experimental|Stable Intervention|Patients with established neuromuscular disease admitted to either the Lane Fox Respiratory Unit or Critical Care at St Thomas' Hospital with acute respiratory deteriorations and with the need for respiratory physiotherapy for secretion management.
89080065|NCT02753725|Active Comparator|Fentanyl group|Fentanyl given at a dose of one micro gram per kilogram body weight
89080066|NCT02753725|Placebo Comparator|normal saline group|placebo arm will be given normal saline at a volume equivalent to Fentanyl dose as per body weight.
89080067|NCT01020123|Experimental|1|AZD1656
89080068|NCT01020123|Experimental|2|AZD1656
89080069|NCT01020123|Experimental|3|AZD1656
89080070|NCT01020123|Experimental|4|AZD1656
89080071|NCT01020123|Experimental|5|AZD1656
89080072|NCT01020123|Placebo Comparator|6|
89080073|NCT01020123|Active Comparator|7|Glipizide administered to 1 group of patients
89080074|NCT04603027|Experimental|Cohort 1|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 0.8 x 10^11 cells, capsule, once daily, 16 weeks
89080075|NCT04603027|Experimental|Cohort 2|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 3.2 x 10^11 cells, capsule, once daily, 16 weeks
89080076|NCT04603027|Experimental|Cohort 3|75 subjects with mild to moderate psoriasis; 50 on EDP1815, 25 on placebo. Dose = 8.0 x 10^11 cells, capsule, once daily, 16 weeks
89080077|NCT04300959|Experimental|Experimental group|Anlotinib in combination with Sintilimab with Gemcitabine plus(+)Cisplatin
89080078|NCT04300959|Active Comparator|Control group|Standard platinum-based chemotherapy
89080079|NCT04299711||Baseline|This study intends to recruit 3,428 Chinese adolescent students exposed to the novel coronavirus disease 2019 in the baseline survey
89080080|NCT04299711||6-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 6 follow-up study.
89080081|NCT04299711||12-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 12 follow-up study.
89080082|NCT04299711||18-month follow-up|This study will track the mental health status among these recruited 3,428 participants exposed to the novel coronavirus disease 2019 in the 18 follow-up study.
89080083|NCT02760355|Experimental|Active treatment|Ledipasvir 90 mg/Sofosbuvir 400 mg, one tablet once a day + b.w. dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks
89080084|NCT01028391|Experimental|Sitagliptin + Pioglitazone|
89080085|NCT01028391|Active Comparator|Pioglitazone + Placebo|
89080086|NCT02753491|Active Comparator|Intervention|In intervention group, three or four motivational short interview made with every participants.
89080087|NCT02753491|No Intervention|Control|non intervention group,
89080088|NCT01179672|Experimental|Duloxetine|
89080089|NCT01179672|Placebo Comparator|Placebo|
89080090|NCT02872545|Experimental|forward tilted|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in forward tilted position
89080091|NCT02872545|Other|semi sitting|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in semi sitting
89080092|NCT02872545|Other|dorsal decubitus|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in dorsal decubitus
89080093|NCT04321915|Other|Children with Autism spectrum disorder|"Patients will realised quesstionnaires, a blood sample will be collected, the feces will be collected too.~The analysis of intestinal microbiota and neuroinflammation markers will be processed."
89080094|NCT04301349|Experimental|vaginal dinoprostone|vaginal dinoprostone 6 mg (two tablets) 3 hours prior to IUD insertion
89080095|NCT04301349|Active Comparator|vaginal misoprostol|vaginal misoprostol 400 mcg (two tablets) 3 hours prior to IUD insertion
89080096|NCT04301349|Placebo Comparator|placebo|two tablets of placebo similar in shape ,color, odor to the study drugs
89080097|NCT02753647|Experimental|Chidamide plus R-CHOP|Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Doxorubicin 50mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Chidamide 20mg/d PO d1, 4, 8, 11 Frequency every 21 days for 6 cycles
89080098|NCT02872389|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
89080099|NCT02872389|Experimental|Desflurane|Anesthesia was maintained with desflurane.
89080100|NCT02760199|Experimental|89Zr-AMG211 and 89Zr-AMG211 PET|
89080101|NCT02695927|Experimental|Chronic|Crossover study on the benefits of computer rehabilitation glasses on chronic sufferers of hemispatial neglect
89080102|NCT02695927|Experimental|Acute|Randomized, controlled study on the benefits of computer rehabilitation glasses on acute sufferers of hemispatial neglect
89080103|NCT02695927|Experimental|Optimization|Study to identify optimal operating parameters of computer rehabilitation glasses
89080104|NCT02695927|Active Comparator|Duration|Study to determine duration of effect of computer rehabilitation glasses
89080105|NCT04307251|Experimental|Navio™ Robotics-assisted Surgical System|
89080106|NCT04307251|Experimental|Conventional, non-robotics-assisted total knee surgical system|
89080107|NCT01030965|Experimental|GSK573719 125mcg|125mcg once-daily via novel dry powder inhaler
89080108|NCT01030965|Experimental|GSK573719 250mcg|250mcg once-daily via novel dry powder inhaler
89080109|NCT01030965|Experimental|GSK573719 500mcg|500mcg once-daily via novel dry powder inhaler
89080110|NCT01030965|Placebo Comparator|Placebo|once-daily via novel dry powder inhaler
89080111|NCT02753179|Experimental|Bilateral vestibular hypofunction|Patients suffering from chronic bilateral vestibular hypofunction.
89080112|NCT02752867|Experimental|Jianpi Yishen Huatan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
89080113|NCT02752867|Placebo Comparator|The control group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
89080114|NCT01179516|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
89080115|NCT01179516|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
89080116|NCT01179516|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
89080117|NCT02752945|Experimental|One-day CBT workshop (+Usual Care)|"One-day CBT-based workshop (DISCOVER), followed by up to three brief telephone contacts to review goals set in workshop."
89080118|NCT02752945|Active Comparator|Usual care|Usual care afforded by local CAMHS services
89224902|NCT06124014|Sham Comparator|Sham Cranial Electrotherapy Stimulation (CES)|The device for sham stimulation is physically identical and delivers a non-therapeutic dose of stimulation to replicate salient features of device usage.
89224903|NCT06123481|Active Comparator|Core decompression (CD)|Core decompression of the femoral head with sham bone marrow aspiration
89224904|NCT06123481|Experimental|Bone Marrow Aspirate Concentrate (BMAC)|Autologous bone marrow aspiration is concentrated and injected into the necrotic bone of the femoral head through the core decompression opening.
89224905|NCT06122350|Experimental|Experimental Group|The experimental group will be trained within the scope of the Earthquake Preparedness Guide.
89224906|NCT06122350|No Intervention|Control Group|No intervention will be applied.
89224907|NCT06121921|Experimental|Intervention|Perioperative multi-component intervention
89224908|NCT06121921|No Intervention|Control|Routine inpatient care
89224909|NCT06120218|Experimental|Emergent Stenting (ES)|Emergent Stenting in acute ischemic stroke caused by tandem occlusions
89224910|NCT06119841|Experimental|Tonsillectomy|Tonsillectomy was performed with cold dissection including the whole tonsil and capsule, and bleeding was controlled with bipolar cauterisation.
89080119|NCT01018953|Experimental|BIM 23A760|This dose adaptive study is planned to treat up to 20 patients in each starting dose cohort, with a maximum of three starting dose cohorts. The doses planned to be assessed are 1, 2, 4, 6 and 8 mg, however, the maximum starting dose will be 4 mg. The starting dose of the first cohort will be 1 mg; the first cohort will include at least five patients. After the first fifteen patients have been treated for 4 weeks, the results will be reviewed by a Data Review Committee. An extension phase (Part B) is planned for those subjects completing the initial study and fulfilling specific eligibility criteria (symptoms control, willingness to participate, safety and tolerability).
89080120|NCT04219657|Experimental|skin grafting only|All the cases in this group are managed with skin grafting only. Every odd case are kept in skin grafting only group.
89080121|NCT04219657|Experimental|skin grafting and stem cell group|All the cases in this group are managed with skin grafting and application of stem cells. every even cases are kept in skin grafting and stem cells group.
89080122|NCT04315740|Sham Comparator|Clean Air|Just clean air - no exposure
89080123|NCT04315740|Experimental|Cooking|Four ovens were frying pork - one at a time. When the first oven finished, the next oven started and so forth for approx. 7 hours.
89080124|NCT04315740|Experimental|Candles|10 lit candles were placed at a table. Burning for approx. 7 hours with light ventilation.
89080125|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 1: A-B-C|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
89080126|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 2: A-C-B|Participants will receive single oral dose of TF1 (Treatment A) evobrutinib on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
89080127|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 3: B-A-C|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by TF2 (Treatment C) on Day 5 under fed condition in period 3. There will be 48 hours washout period between each treatment period.
89080128|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 4: B-C-A|Participants will receive single oral dose of TF2 (Treatment B) on Day 1 under fasted condition in period 1, followed by TF2 (Treatment C) on Day 3 under fed condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
89080129|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 5: C-A-B|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 3 under fasted condition in period 2, followed by single oral dose of TF2 (Treatment B) on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
89080130|NCT04314024|Experimental|Evobrutinib: Treatment Sequence 6: C-B-A|Participants will receive single oral dose of TF2 (Treatment C) on Day 1 under fed condition in period 1, followed by single oral dose of TF2 (Treatment B) on Day 3 under fasted condition in period 2, followed by single oral dose of TF1 (Treatment A) evobrutinib on Day 5 under fasted condition in period 3. There will be 48 hours washout period between each treatment period.
89080131|NCT00635791|Experimental|Sorafenib tosylate and vorinostat|Patients receive sorafenib tosylate by mouth twice a day on days 1-21 and vorinostat by mouth every day on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89080132|NCT02695849||NSCLC Participants|Participants with non-squamous NSCLC will be enrolled in this study.
89080133|NCT04219501|No Intervention|Control Group|Subjects presenting for PVC/VT ablation will undergo ablation procedures using standard of care invasive electroanatomical mapping systems.
89080134|NCT04219501|Experimental|VIVO Arm|Subjects presenting for PVC/VT ablation, that have a previously acquired cardiac CT/MRI scan or are having a cardiac CT/MRI scan as per routine care, will undergo ablation procedures using VIVO, a novel, non-invasive mapping system.
89080135|NCT02753023||acute coronary syndromes|No intervention related
89080136|NCT02753023||acute decompensated heart failure|No intervention related
89080137|NCT02753023||warfarin intoxication|No intervention related
89080138|NCT02753023||acute pulmonary edema|No intervention related
89080139|NCT02753023||acute aortic dissection|No intervention related
89080140|NCT02753023||chest pain|No intervention related
89080141|NCT02753023||pulmonary embolism|No intervention related
89080142|NCT02753023||syncope|No intervention related
89080143|NCT01158924|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
89080144|NCT02760121|Experimental|Acetazolamide|Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.
89080145|NCT02760121|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.
89080146|NCT02760121|Placebo Comparator|Placebo|Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.
89080147|NCT05218447|Experimental|Low Frequency|Subjects will receive 2 sessions of robotic gait training (RGT) per week for 12 weeks
89080148|NCT05218447|Experimental|Moderate Frequency|Subjects will receive 3 sessions of robotic gait training (RGT) per week for 8 weeks
89080149|NCT05218447|Experimental|High Frequency|Subjects will receive 4 sessions of robotic gait training (RGT) per week for 6 weeks
89080150|NCT05218447|Active Comparator|Control Group|Subjects will receive usual care gait training without robotic gait training
89080151|NCT00635869||ARCC standard|RNs on unit receiving basic ARCC information with staff nurse champion
89080152|NCT00635869||ARCC enhanced|RNs on unit receiving ARCC standard content plus with an EBP mentor
89080153|NCT00635869||C|RNs on the unit receiving the placebo intervention
89080154|NCT05215873|Active Comparator|misoprostol group|25µg misoprostol oral tablet every 4 hours with maximum200 µg
89080155|NCT05215873|Active Comparator|oxytocin group|"oxytocin infusion according to ASUMH local protocol: Put 3IU oxytocin (3000mIU) +50ml of normal saline in syringe pump= (60mIU/ml). Commence at 1ml/hour (1mIU/min) for 1/2 hour.~If contractions inadequate +fetal monitor healthy 2 ml/hour for 1/2 hour.~If contractions inadequate +fetal monitor healthy 4 ml/hour for 1/2 hour.~If contractions inadequate +fetal monitor healthy 6 ml/hour for 1/2 hour.~If contractions inadequate +fetal monitor healthy increase by 2ml/hr. for max. 27ml/hour.~At any point there's fetal or maternal distress (e.g. pathological FHR pattern, antepartum hemorrhage, etc.) the study intervention will be stopped, and the maternal/fetal condition will be managed by cesarean section."
89080156|NCT02759887|Other|DS adult group|Consists of 15 DS subjects aged 21 and older who do not qualify for the diagnosis of dementia at the beginning of the study. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
89080157|NCT02759887|Other|DS/AD group|Consists of 15 DS subjects aged 40 and older who do qualify for the diagnosis of dementia by DSM-IV criteria. Diagnoses will be by standard consensus review of all cases. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
89080158|NCT02759887|Other|NC adult|Consists of 10 cognitively normal, non-DS individuals, age-matched to the DS adult group. Interventions include biospecimen collection, cognitive assessments, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
89080159|NCT02750917|Experimental|GROUP LORNOXICAM|Immediately in postoperative care unit patients received lornoxicam 8 mg PO/12 hours for 48 hours
89080160|NCT02750917|Active Comparator|GROUP ETORICOXIB|Immediately in postoperative care unit patients received etoricoxib 120 mg PO and another pill at 24 hours.
89080161|NCT02750839||proximal humerus fracture|Patients with proximal humerus fracture treated with mini-invasive plate.
89080162|NCT02759809||Children previously assigned to donor milk in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive donor milk when mother's own breastmilk was unavailable. Donor milk was from a milk bank part of the Human Milk Banking Association of North America (HMBANA).
89080163|NCT02759809||Children previously assigned to formula in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive preterm formula when mother's own breastmilk was unavailable. Preterm formula was either Similac Special Care or Enfamil Premature depending on hospital contract with formula companies.
89080164|NCT02759653||Symptomatic|Symptomatic carotid artery disease
89080165|NCT02759653||Asymptomatic|Asymptomatic carotid artery disease
89080166|NCT02750995|Experimental|Vaccination|Azacitidine + NPMW-peptide vaccine
89080167|NCT01027845|Experimental|10Pn Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of Synflorix (10Pn) vaccine, administered intramuscularly on alternating (left/right) sides of the anterolateral thigh and DPT KAKETSUKEN Syringe (DTPa) vaccine administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm. Both vaccines were administered at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
89080168|NCT01027845|Active Comparator|DTPa Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of the DPT KAKETSUKEN Syringe (DTPa) vaccine, administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
89080169|NCT04222075||Acute Pancreatitis|Patients after acute pancreatitis
89080170|NCT04219345|Active Comparator|Active group|In the group A will be administered anodic tDCS and instructed in mindfulness practices.
89080171|NCT04219345|Sham Comparator|Sham group|In the group B will be administered sham tDCS and instructed in mindfulness practices.
89080172|NCT05113225|Active Comparator|DG-ICSI|Oocytes of this arm will be injected using sperm previously processed by DG method and located in the commonly used ICSI dishes with the common PVP microdroplets
89080173|NCT05113225|Experimental|H pattern-ICSI|Oocytes of this arm will be injected using sperm that directly located in a specific H pattern PVP droplets in a commonly used ICSI dishes without pre-processing of the semen
89080174|NCT04288557||Sleep clinic patients|All adult patients, from 18 years and up to and including 65 years of age, on the waiting list for overnight polysomnography (PSG) recording at Leicester General Hospital.
89080175|NCT04288557||Healthy volunteers|All adults, from 18 and up to and including 65 years of age without a known sleep disorder.
89080176|NCT04221919|Experimental|Carvedilol|
89080177|NCT04221919|Experimental|Bisoprolol|
89080178|NCT04221919|Experimental|Metoprolol tartrate|
89080179|NCT04221919|Experimental|Metoprolol succinate|
89080180|NCT04299633|Experimental|Part 1: vadadustat plus sevelamer carbonate|Participants will receive vadadustat 300 milligrams (mg) once on Days 1, 3, 5, and 7. Participants will receive sevelamer carbonate 1600 mg once on Days 3, 5, and 7.
89080181|NCT04299633|Experimental|Part 2: vadadustat plus calcium acetate|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive calcium acetate 1334 mg once on Days 3, 5, and 7.
89080182|NCT04299633|Experimental|Part 3: vadadustat plus Auryxia®|Participants will receive vadadustat 300 mg once on Days 1, 3, 5, and 7. Participants will receive Auryxia® 2 grams once on Days 3, 5, and 7.
89080183|NCT02695459|Experimental|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
89080184|NCT02759497||Serum amyloid A level in SBP|serum amyloid A level
89080185|NCT02759497||Serum amyloid A level in cirrhosis|Serum amyloid A level
89080186|NCT00627549|Active Comparator|1|
89080187|NCT00627549|Active Comparator|2|
89080188|NCT04299789||Probable Civilian|This cohort represents those in which the Military Service Identification Tool has determined are a civilian and have not served in the Armed Forces.
89080189|NCT04299789||Probable Veteran|This cohort represents those in which the Military Service Identification Tool has determined are a military veteran and have served in the Armed Forces.
89080190|NCT04217863|Experimental|The experimental intervention (GDP): It includes three writing|"Participants will be required to describe memories associated with traumatic event in a sequential order, with an objective and detached attitude~They will be asked to describe~Their opinion regarding the traumatic event and emotions perceived during the experience~Its impact on their daily lives, and how it has altered their attitudes toward life.~The actual situation will be focused, while reviving the whole traumatic event experience which aids in exploring the following aspects:~Present thoughts and feelings regarding the traumatic experience, and also clarify the differences between the ones felt at the time of traumatic event in comparison to the current feelings.~How much they understand and appreciate themselves for successfully dealing with the traumatic event~To what extent the traumatic event has modified their vision, attitude, knowledge, and skills, and how it can help in their future;~What will be their future reactions to other similar events."
89080191|NCT04217863|No Intervention|The control intervention:|A day prior to each writing session, the researcher will communicate with each study subject via telephone in order to give them a reminder to perform the writing task and to check their understanding regarding the instructions given in the booklet. Details regarding the inability to contact the subject will also be recorded in the patient form.
89080192|NCT02872233|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
89224911|NCT06119841|Experimental|Expansion sphincter pharyngoplasty|In the ESP technique, following bilateral tonsillectomy with cold dissection and bleeding control with bipolar cauterisation, the palatopharyngeus muscle was identified and a superior-based muscle flap was formed by cutting the upper two-thirds of the muscle on both sides from the lower third attachment site. By opening tunnels to the anterior plica mucosa, the dissected palatopharyngeus muscle was placed in these tunnels, and was sutured to the pterygomandibular raphe with vicryl 2-0 sutures. The mucosal cuts were closed with vicryl 3-0 sutures
89224916|NCT06118489||sevoflurane|
89224917|NCT06118489||desflurane|
89224918|NCT06117592||Pre-Intervention|Retrospective data collection for pre-education intervention period: 1st April 2023- 1st June 2023
89080193|NCT04219423|Experimental|multimodal physical therapy|The multimodal intervention is 75 minutes in duration and meets two days per week for two weeks, then once per week for six weeks, followed by weekly phone calls to determine adherence to home-exercise program (HEP) for four weeks. The total duration of the intervention is twelve weeks. The intervention will be led in a group format with a ratio of one physical therapist to two participants and groups never exceeding 4 participants. All verbal and written communications in the intervention will be conducted in Spanish. The multimodal intervention consists of progressive lower extremity strengthening training targeting the quadriceps and gluteal groups in both legs, progressive stationary bicycle exercise, self-management training and education, manual therapy and home exercise program (HEP) instruction. Participants are asked to do their strengthening exercises at least three days per week for the 12-week study duration including sessions in the clinic
89080194|NCT04599231|Experimental|Study group|"The investigators would perform the following tests preoperatively on the study subjects.~Hospital Anxiety and Depression Scale (HADS)~Amsterdam Preoperative Anxiety and Information Scale (APAIS)~Coping and Adaptation Processing Scale-Short Form (CAPS-SF)~Quality of Recovery -15 (QOR-15)"
89080195|NCT04219267|Experimental|The intervention group|Character strengths-based intervention, 3 sessions every week for three weeks. 30 minutes each session.
89080196|NCT04219267|Placebo Comparator|The control group|Early memories for placebo control, 3 sessions every week for three weeks. 30 minutes each session.
89080197|NCT01017549|Other|Treatment|This is a single arm study where all patients are treated with FDA cleared electronic brachytherapy treatment.
89080198|NCT00635947|Active Comparator|1|isotonic solution - 1.5L
89080199|NCT00635947|Active Comparator|2|water- 1.5L
89080200|NCT00635947|Placebo Comparator|3|water-200mL
89080201|NCT04299243|Experimental|Spherical Lens|Randomized to Spherical Lens worn in a daily disposable mode
89080202|NCT04299243|Active Comparator|SiHy Daily|Randomized to SiHy Daily worn in a daily disposable mode
89080203|NCT01030341|Experimental|CGMS and insulin pump|Continuous glucose monitoring in conjunction with insulin pump
89080204|NCT02750449|Experimental|Arm 1|All subjects are patched.
89080205|NCT04301037|Active Comparator|Tension band wiring|This group was treated by k-wires fixation and tension band wiring
89080206|NCT04301037|Active Comparator|Cannulated screws|This group was treated by 2 cannulated screws
89080207|NCT02750293|Active Comparator|cholecalciferol|vitamin D (as a 20 000 IU capsule) will be given once a week for 4 months
89080208|NCT02750293|Placebo Comparator|placebo|placebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months
89080209|NCT04217785|Active Comparator|A-AT eye drops|Optive Fusion UD eye drops + Genteal lubricant gel
89080210|NCT04217785|Active Comparator|B-UCS eye drops|UCS eye drops + GentTeal lubricant gel
89080211|NCT01026831|Experimental|Tafluprost|Preservative-free tafluprost
89080212|NCT01026831|Active Comparator|timolol maleate|Preservative-free timolol maleate
89224919|NCT06117592||Post-Intervention|Retrospective data collection for post-education intervention period: 1st October 2023- 31st December 2023
89080213|NCT04299165|Experimental|Device: KAIA COPD-App (Medical Mobile Application).|The study intervention is an exercise training program that requires only a chair or water bottles, consisting of training elements with progressive levels of intensity, individually adaptable to the participant's exercise level. This training program is delivered to the participants with the help of KAIA COPD-App. Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database.
89080214|NCT04299165|Active Comparator|Usual Care|"The Training of the control-group is performed by regular recommendations/ Standard of care. Standard of care in this context means to hand out the brochure  Besser Leben mit COPD  including an emergency plan, providing exercise training examples, to hand out addresses of out-patient physiotherapists and to hand out a detailed medical report including medical recommendations.Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database."
89080215|NCT05103943|Experimental|SPECT MPI (myocardial perfusion imaging) Group|the SPECT MPI protocol will be modified to evaluated MBF and MFR. This modification will result in no added radiation; the radiopharmaceutical dose will still be the same compared to a standard MPI protocol.
89080216|NCT04299399||nomal|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of biomechanics with other groups will be performed.
89080217|NCT04299399||seasonal allergic conjunctivitis(SAC)|Eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of corneal biomechanics with other groups and correlation analysis of corneal biomechanical parameters and other measurement indicators will be performed.
89224920|NCT06116591|Experimental|mPnC candidate|Participants will receive the mPnC candidate at Visit 1 and Visit 3 (approximately 8 weeks apart). PCV10 will also be given at Visit 1.
88816170|NCT01138124||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
89080218|NCT04299399||vernal keratoconjunctivitis (VKC)|At first visit, eye rubbing frequency, ocular allergy symptom scores, physical sign scores, corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured. All patients will adopt a unified medication regimen:0.1% tacrolimus eye drops four times daily; 0.1% flumirone eye drops twice daily; azelastine hydrochloride eye drops four times daily; hyaluronic acid sodium eye drops four times daily. After 1M, 0.1% flumilone eye drops will be replaced with 0.02% flumirone eye drops twice daily, and rest of the medication will remain unchanged. The same ophthalmological examinations will be performed again after 3 month medication.
89080219|NCT04299399||keratoconus|Corneal biomechanics, corneal topographic parameters, corneal epithelial thickness, tear inflammatory cytokines levels and conjunctival microvascular parameters will be measured, and comparative analysis of these parameters with other groups will be performed.
89224921|NCT06116591|Active Comparator|mPnC control|Participants will receive the mPnC control at Visit 1 and Visit 3 (approximately 8 weeks apart). PCV10 will also be given at Visit 1.
89080220|NCT02759341|Other|Cardiac X Syndrome (CSX)|patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)
89080221|NCT02759341|Other|Takotsubo Cardiomyopathy (TTC)|Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)
89080222|NCT02759341|Other|Acute myocardial infarction (AMI)|Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)
89224922|NCT06115044|Experimental|Intermittent|Bolus feeding over 30 to 60 minutes at 0800, 1300 and 1800
89080229|NCT01016067|Experimental|INFUSE/MASTERGRAFT|Patients received INFUSE/MASTERGRAFT granules with rigid internal fixation.
89080230|NCT01016067|Active Comparator|Autograft bone|Patients received autograft bone with rigid internal fixation.
89080231|NCT04905511|Experimental|TRUE Vascular Graft|Patients will be implanted with the TRUE Vascular Graft in the upper arm or forearm
89224923|NCT06115044|Active Comparator|Continuous|Continuous feeding over 24 hours
89080232|NCT04843891|Experimental|Healthy Volunteers|In 10 healthy volunteers the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied.
89080233|NCT04843891|Experimental|Cardiovascular Disease|In 30 subjects with a history of recent myocardial infarct, the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the infarct site will be correlated with cardiac MRI.
89080234|NCT04843891|Experimental|Cancer|In 30 subjects with an epithelial malignancy the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.
89224924|NCT06113939|Active Comparator|Standard of Care|IV ceftriaxone/24 hours 3 doses
89224925|NCT06113939|Experimental|Subglottic aspiration|Continuos aspiration of subglottic secretions
89224926|NCT06113939|Experimental|Cough Simulator|Mechanical exsufflator
89080235|NCT04843891|Experimental|Sarcoidosis|In 30 subjects with sarcoidosis the radiation dosimetry, normal organ distribution, and safety of [64Cu]-Macrin injection will be studied. In addition, the ability of [64Cu] Macrin to concentrate at the tumor site will be correlated with imaging and histopathology, where available.
89080236|NCT04830475|Experimental|NIV Group|In poostoperative period, patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
89080237|NCT04830475|Active Comparator|Control Group|In the postoperative period, patients were offered VenturiMask with Fio2 60% at 15 l / m.
89080238|NCT00636025||Observational|
89080239|NCT00636103|Experimental|CUF2|
89080240|NCT00636103|Placebo Comparator|Placebo|
89080241|NCT04423393|Experimental|VIR-3434|
89080242|NCT04423393|Placebo Comparator|Placebo|
89080243|NCT04169581||Experimental Group|The experimental group received 18F-FDG PET examination
89080244|NCT04169581||Control Group|The control group received 18F-FDG PET examination
89080245|NCT04687735|Experimental|Intervention arm|Patients with frozen shoulders at any stage
89080246|NCT02760043|Experimental|Dexamethasone|LIA mixture with the addition of 8mg Dexamethasone.
89080247|NCT02760043|Sham Comparator|Saline|LIA mixture with the addition of 2mL of 0.9% NaCl Saline.
89080248|NCT02696005||Group I|15 patients who will continue participation in Exercise- Based Cardiac Rehabilitation Programme after completion initial 3-months period.
89080249|NCT02696005||Group II|15 patients who will stop participation in Exercise- Based Cardiac Rehabilitation Programme after the initial 3-months period.
89080250|NCT02750059|Experimental|TDF/3TC/EFV + Telmisartan|The subjects will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART
89080251|NCT02750059|Active Comparator|TDF/3TC/EFV only|Subjects will receive ART only
89080252|NCT02759029|Active Comparator|Susceptibility-guided group|Drugs according to antimicrobial susceptibility-guided treatment
89080253|NCT02759029|Sham Comparator|triple therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk
89080254|NCT02759029|Sham Comparator|concomitant therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
89080255|NCT02759263|Experimental|Working Memory Intervention|The group randomized to the Working Memory intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the adolescents' responses, time spent on each task, and evolution curves.
89230120|NCT00792233|Experimental|1|Participants taking anti-TNF medications will be monitored for signs of their disease for 6 months. If, after 6 months, their disease has become inactive, they will stop taking anti-TNF medications for up to 8 months. If participants who are no longer taking anti-TNF medications have a disease flare-up, they will begin treatment again.
89230121|NCT00788567|Experimental|1|
89080256|NCT02759263|No Intervention|Control group - Standard of Care|Adolescents randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, an adolescent in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like adolescents assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
89080257|NCT02749825|Experimental|Trelstar|Per prescribing information
89080258|NCT02749825|Active Comparator|Lupron|Per prescribing information
89080259|NCT02749825|Active Comparator|Zoladex|Per prescribing information
89080260|NCT02758873|Experimental|Personalised Medicine|If an add-on controller is required, young people in this arm will be prescribed personalised medicine by results of the genotyping for the adrenergic beta2-receptor gene (ADRB2). Health professional's will be advised to prescribe inhaled salmeterol as 'add-on' controller if trial participants have the Gly/Gly variant on ADRB2, and montelukast if they have Arg/Arg or Arg/Gly variant on ADRB2.
89080261|NCT02758873|Active Comparator|Standard care|If an add-on controller is required, young people will be prescribed medication as per the choice of the primary or secondary care physician, without knowledge of genotypic status.
89080262|NCT02749747|Active Comparator|Sulpiride use|50mg sulpiride once a day use for 60 days
89080263|NCT02749747|Placebo Comparator|Placebo|50mg placebo once a day use for 60 days
89080264|NCT02749591|Experimental|Robot-assisted therapy (RT)|After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.
89080265|NCT02749591|Experimental|Mirror therapy (MT)|After injection with Botulinum Toxin Type A, a schedule of mirror therapy appointments will be established.The MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
89080266|NCT02749591|Active Comparator|Control Intervention (CI)|After injection with Botulinum Toxin Type A, a schedule of control intervention appointments will be established.The CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
89080267|NCT04460833|Experimental|Test group|All children will have the 6 feedback modalities + the control given randomly
89080268|NCT04359979|Experimental|tamsulosin treatment|patients will receive 0.4mg/day of Tamsulosin tablet for 3 months
89080269|NCT04218955||1|Asking parents if they can accept staining from treat their children by silver Diamine Flouride or Not
89080270|NCT04180813||Linagliptin Initiators|
89080271|NCT04180813||Acarbose Initiators|
89080272|NCT04221607|Experimental|Feasibility|Sensate Focus Exercises aim to help couples be more present with one another through talking and through touch.
89080273|NCT04148443|Experimental|3 minutes period of preoxygenation|3 minutes of preoxygenation : participants in this group will receive 3 minutes of preoxygenation before intubation
89080274|NCT04148443|Experimental|5 minutes period of preoxygenation|5 minutes of preoxygenation: participants in this group will receive 5 minutes of preoxygenation before intubation
89080275|NCT04116775|Experimental|Treatment|"INITIAL TREATMENT PHASE: Patients progressing on enzalutamide will receive 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy.~ASSESSMENT PHASE: After completion of the initial treatment phase, patients will have their disease assessed by tumor imaging. Patients who respond to treatment will become stool donors to patients who do not respond. Non-responders will move on to the retreatment phase.~RETREATMENT PHASE: Non-responders will undergo a fecal transplant and be retreated with 200 mg of pembrolizumab IV over 30 minutes. Treatment repeats every 3 weeks for an additional 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive standard of care enzalutamide PO daily and androgen deprivation therapy."
89080276|NCT02749435||Standard of Care + digital disease management cohort|Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.
89080277|NCT02749435||Standard of Care cohort|Participants will have standard care with no access to the digital disease management tool.
89080278|NCT04217083||Colorectal cancer patients|Patients with histologically proven Colorectal cancer detected during the colonoscopy
89080279|NCT04217083||healthy controls|Patients with no sign of any colorectal disease who are submitted to colonoscopy
89080280|NCT04216849|Experimental|experimental group|The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.
89080281|NCT04216849|Placebo Comparator|control group|The control group will be given the same dose of saline containing human albumin.
89080282|NCT02749357|Active Comparator|Control|"Intervention: Control group, with 30 training sessions in robotic orthosis with duration of 30 minutes during 6 weeks.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
89080283|NCT02749357|Experimental|Experimental|"Intervention: Experimental group, with 30 training sessions in robotic orthosis with duration of 60 minutes during 6 weeks.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
89080284|NCT03933553|Experimental|Easy sleep complex essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
89080285|NCT03933553|Active Comparator|Lavender essential oil|Aromatherapy for 2 hours starting 10 minutes before sleep with 5 drops of the essential oil diluted in 50ml water
89080286|NCT02758561|No Intervention|Standard of care|Standard of care
89080287|NCT02758561|Experimental|Workshop|90 minute workshop on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (POP)
89080288|NCT03913741|Experimental|Experimental tisotumab vedotin|Open label, single arm trial where tisotumab vedotin will be administered
89080289|NCT02758639|Experimental|W & W Intervention|Wonders & Worries Psychosocial intervention is a 6 week group or individual sessions for children who have a parent with cancer focusing on psycho-educational information about cancer, treatment and its side effects, feelings expression, positive coping strategies, and family communication about the illness.
89080290|NCT02758639|Other|Wait list control|Wait list group will complete baseline, 6 week and 8 week follow up measures and then will be enrolled to receive W & W intervention.
89080291|NCT02749669|Other|Qualitative research|Semi-structured interviews
89080292|NCT02749669|No Intervention|Economic evaluation|Questionnaire
89080293|NCT02758795|Placebo Comparator|CONTROL|A placebo nutrient drink with no anti-inflammatory bioactivity (measure by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
89080294|NCT02758795|Active Comparator|NUTRIENT|A nutrient drink with confirmed anti-inflammatory bioactivity (measured by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
89080295|NCT02749123|Active Comparator|Lidocaine5% v Lidocaine3.6%,Menthol1.25%|Daily patch Q12 followed by Q12 of no patch
89230122|NCT00792311|Experimental|Tsui test|Tsui test administration.
89080296|NCT02749123|Placebo Comparator|Lidocaine 3.6%, menthol 1.25% v placebo|Daily patch Q12 followed by Q12 of no patch
89080297|NCT02758483|Other|Test diet|"Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
89080298|NCT02758483|Other|Control diet|"Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
89080299|NCT04218253|Experimental|nutritional intervention|300 or 500 calories nutritional support before operation according to the level of malnutrition
89080300|NCT04218253|Other|control group|Dietary education was conducted according to preoperative nutritional requirements
89080301|NCT02748811|No Intervention|Control group|The control group receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change in treatment or progression. If the patient has other health problems, those issues will be assessed either by the oncologist or by the general practitioner. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
89080302|NCT02748811|Active Comparator|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. They will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
89080303|NCT02748733|Active Comparator|Adapted double mini PET|"PET = Peritoneal Equilibration Test, a test routinely performed to measure peritoneal transport rates of solutes and water in peritoneal dialysis patients. To this end the routinely administered dialysis fluid is infused into the peritoneal cavity. The test will be modified (adapted):~A short, small cycle (0.6 mL/m² BSA, 30 min) followed by a long, large cycle (1.4 mL/m², 120 min) will be performed in each patient and compared to a standard double mini PET."
89080304|NCT02748733|Placebo Comparator|Standard double mini PET|The Standard double mini PET consists of two identical cycles (fill volume 1 L/m², 75 min of dwell time)
89080305|NCT02748967|Experimental|Group 1|Participants with age (greater than or equal to [>=] 20 to less than [<] 50 years) will receive single dose of 0.5 milliliter (mL) of ExPEC4V (4:4:4:4) or placebo on Day 1.
89080306|NCT02748967|Experimental|Group 2|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
89080307|NCT02748967|Experimental|Group 3|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
89080308|NCT02748967|Experimental|Group 4|Participants with age greater than or equal to [>=] 50 will receive single dose of 0.5 mL of ExPEC4V (4:4:4:4) or placebo on Day 1.
89080309|NCT02748967|Experimental|Group 5|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
89080310|NCT02748967|Experimental|Group 6|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
89080311|NCT02748655|Placebo Comparator|Tap water|Oral consumption of tap water
89080312|NCT02748655|Active Comparator|Alkaline ionized water|Oral consumption of alkaline ionized water
89080313|NCT02747017||CDI patients|Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant.
89080314|NCT02748499|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
89080315|NCT02748499|Active Comparator|Control|The control group maintains daily activities.
89080316|NCT02748577|Experimental|Migraine|Participants with migraines will complete one study visit where they will complete several questionnaires and will also complete Quantitative Sensory Testing (QST) Pain Measurements. They must be migraine-free during the visit and no migraine within 48 hrs of study visit
89080317|NCT02748577|Active Comparator|Healthy Controls|Healthy Controls will complete one study visit where they will complete several questionnaires and will complete Quantitative Sensory Testing (QST) Pain Measurements.
89080318|NCT02748187|Experimental|Intervention|Cognitive Behavioural Analysis System of Psychotherapy
89080319|NCT02748421|Other|Lumera Microscope with OCT RESCAN|in the group microscope coupled to OCT, patients will undergo retinal surgery using the Lumera microscope with Rescan OCT Zeiss
89080320|NCT02748421|Other|Conventional Microscope|control group without OCT RESCAN
89080321|NCT02748265|Other|Inhaled Epoprostenol, phenylephrine, sevoflurane|Inhaled Epoprostenol (Flolan), phenylephrine, volatile anesthesia maintenance (Sevoflurane)
89080322|NCT02748265|Other|Inhaled Epoprostenol phenylephrine & Propofol|Inhaled Epoprostenol (Flolan), phenylephrine and intravenous anesthesia maintenance (Propofol)
89080323|NCT01015833|Experimental|Arm I (doxorubicin hydrochloride, sorafenib tosylate)|Patients receive doxorubicin hydrochloride IV on day 1 and sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
89080324|NCT01015833|Experimental|Arm II (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89230123|NCT00788645|Experimental|Forecast|COPD patients receiving advice and poor weather warning
89230124|NCT00788645|Experimental|No Forecast|COPD patients receiving advice and poor weather warning
89230125|NCT00788645|No Intervention|Control|Age matched non - COPD subjects
89230126|NCT00792389|Experimental|1|Patients receiving warmed, humidified gas
89230127|NCT00792389|Active Comparator|2|Patients receiving cool, day gas
89230128|NCT00788723|Experimental|1|Patients with severe brain injury, awake, but have cognitive problems
89230129|NCT00788723|Experimental|2|Patients with severe brain injury and disorders of consciousness ( in minimally conscious or in vegetative state)
89230130|NCT00788723|Experimental|3|Healthy volunteers
89230131|NCT00788801|Experimental|Baseline|
89230132|NCT00788801|Experimental|ABT-614 Low Dose|
89224927|NCT06113809|Experimental|Combination of Palbociclib with Pembrolizumab|Palbociclib given for 2 weeks following a pre-treatment ultrasound guided biopsy used to establish an immunological baseline of the tumor microenvironment. After the conclusion of palbociclib therapy, a post-treatment biopsy will be performed to assess the impact of palbociclib on the tumor microenvironment; pembrolizumab will be started the same day as the second biopsy. After 2 doses of pembrolizumab, a third (optional) biopsy could be performed.
89230133|NCT00788801|Experimental|ABT-614 High Dose|
89080325|NCT04218175|Experimental|neuromobilization stretching group|In the neuromobilization stretching group; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed.
89080326|NCT04218175|Experimental|neuromobilization shifting group|In the neuromobilization shifting group, the subjects were brought to shoulder depression and 90 degrees of abduction while the dominant forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side. Thus, the participants performed median nerve shift.
89080327|NCT04218175|No Intervention|Control Group|The dominant sides of the individuals are experimental sides and the other nondominant sides of the participants are control sides. And no intervention was made. All measurements were done bilaterally before and after.
89080328|NCT03523273|Experimental|Liraglutide|Liraglutide initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
89080329|NCT03523273|Experimental|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
89080330|NCT02746939|No Intervention|Pre-curriculum assessment|Assessments will be administered to 3rd and 4th grade students prior to receiving curriculum training in fitness and nutrition.
89080331|NCT02746939|Experimental|Post-curriculum assessment|Assessments will be administered to 3rd and 4th grade students (matched from pre-curriculum assessment) after receiving 4-6 week InSciEd Out Fitness and Nutrition Curriculum.
89080332|NCT04217941|Active Comparator|Health Education with practical demonstration|Participants assigned to the intervention arm received health education with practical demonstration of nasal spray and intranasal ointment .
89080333|NCT04217941|Placebo Comparator|Health education without practical demonstration|Participants assigned to the control arm received only health education regarding nasal spray and intranasal ointment .
89080334|NCT04217629|Experimental|SY-005 single-dose 0.75mg|4 subjects will be envolved in this group and be injected with 0.75mg of SY-005.
89080335|NCT04217629|Placebo Comparator|SY-005 single-dose 2.5mg|This group will be intiated in healthy subjects at a 2.5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
89080336|NCT04217629|Placebo Comparator|SY-005 single-dose 5mg|This group will be intiated in healthy subjects at a 5mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
89080337|NCT04217629|Placebo Comparator|SY-005 single-dose 10mg|This group will be intiated in healthy subjects at a 10mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
89080338|NCT04217629|Placebo Comparator|SY-005 single-dose 15mg|This group will be intiated in healthy subjects at a 15mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
89080339|NCT04217629|Placebo Comparator|SY-005 single-dose 20mg|This group will be intiated in healthy subjects at a 20mg dose. 12 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 5:1.
89080340|NCT04217629|Placebo Comparator|SY-005 multiple-doses 5mg|This group will be intiated in healthy subjects at a 5mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
89080341|NCT04217629|Placebo Comparator|SY-005 multiple-doses 10mg|This group will be intiated in healthy subjects at a 10mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
89230134|NCT00662909|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
88816171|NCT02437890|Placebo Comparator|Placebo|"Two s.c. injections with placebo every 2 weeks (q2w).~***~Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
89080342|NCT04217629|Placebo Comparator|SY-005 multiple-doses 20mg|This group will be intiated in healthy subjects at a 20mg dose. 10 subjects will be envolved in this group and the proportion of subjects injected SY-005 to placebo is 4:1. The subjects will be injected with SY-005 or placebo for 7days.
89080343|NCT02748343|Active Comparator|allograft bone|traditional allograft bone
89080344|NCT02748343|Experimental|tissue-engineered bone|tissue-engineered bone
89080345|NCT02695381|Experimental|Etodolac-lidocaine Topical Patch|Therapy with experimental drug
89080346|NCT02695381|Placebo Comparator|Placebo|Therapy with placebo
89080347|NCT02748109|Experimental|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback
89080348|NCT02748109|Active Comparator|Vestibular Rehabilitation|Vestibular rehabilitation
89080349|NCT02746861|Experimental|Diabetes Self-Management Support (DSMS)|Patient receives 6-months of DSMS while receiving support from a trained peer mentor (Peer-supported DSMS).
89080350|NCT02746861|No Intervention|Usual Care|Patient continues to receive usual care.
89080351|NCT02746783|Active Comparator|Group 1|Single dose of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
89080352|NCT02746783|Experimental|Group 2|Double dose of MUTAGRIP® (one dose into the right deltoid area and the other one into the left deltoid area) containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
89080353|NCT02748031|Experimental|eligible patients group|
89080354|NCT02747953|Experimental|afatinib|
89080355|NCT02747797|Experimental|Advanced cancer with lucitanib-targeting biomarker(s)|Lucitanib 10 mg orally daily
89080356|NCT02747719|Experimental|Light and exercise|Exposure to light with exercise
89080357|NCT02747641|Other|treatment|only one arm
89080358|NCT02747563|Experimental|Active Surveillance|Patients with known prostate cancer eligible for active surveillance Intervention - PSA measurement
89080359|NCT02747563|Active Comparator|Controls|Patients without known diagnosis of prostate cancer Intervention - PSA measurement
89080360|NCT02655523|Active Comparator|Bupivacaine+Triamcinolone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 40 mg of triamcinolone.
89080361|NCT02655523|Active Comparator|Bupivacaine+Dexamethasone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 4 mg of dexamethasone.
89080362|NCT02655523|Placebo Comparator|Bupivacaine+Saline|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL of preservative free normal saline.
89080363|NCT02644291|Experimental|mebendazole|oral mebendazole as dose escalation (three groups), or l oral mebendazole at maximum dose for extended cohort. Given in 3 divided doses with meals as chewable 500 mg tablets based on calculated patient surface area.
89080364|NCT02559739||Sleep deficiency/fragmentation|Patients with sleep deficiency/fragmentation
89080365|NCT02559739||No sleep deficiency/fragmentation|Patients without sleep deficiency/fragmentation
89080366|NCT01015677|Experimental|MK-6913 75 mg|MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and Stage 2)
89080367|NCT01015677|Active Comparator|17-β estradiol 1 mg|17β-estradiol 1 mg tablet and matching placebo for MK-6913 75 mg capsule once daily for 4 weeks (Stage 1 and Stage 2)
89080368|NCT01015677|Placebo Comparator|Placebo|Matching placebo for MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and State 2)
89080369|NCT01015677|Experimental|MK-6913 25 mg|MK-6913 25 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 2)
89080370|NCT02281981|Experimental|Curcumin supplement|200 mg, curcuminoids, 7d of supplementation in capsular form
89080371|NCT02281981|Placebo Comparator|Placebo|sucrose, capsular
89080372|NCT00628017|Experimental|1|omega-3 PUFAs(180mg eicosapentaenoic acid[EPA] + 120mg docosahexaenoic acid[DHA]/capsule), 3 capsules twice daily, total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA
89080373|NCT00628017|Placebo Comparator|2|three identical placebo capsules twice daily which contained olive oil esters.
89080374|NCT04298619||Standard cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:~symptom assessment~blood tests~physical examination"
89080375|NCT04298619||Imaging cohort|"Clinical-based surveillance after first complete remission in High risk Hodgkin Lymphoma patients:~symptom assessment~blood tests~physical examination~Positron Emission Tomography (PET)/Computed Tomography (CT) or Chest X-Ray ultrasonography scan of superficial, mediastinal, abdominal and pelvic lymph nodes"
89080376|NCT04297839|Active Comparator|Control Group|"Patients in this group will receive heparin during hemodialysis sessions, at a dose of 1.000 units at the beginning and 500 units per hour in a syringe infusion pump.~If the patient has a contraindication for the heparin use, it will receive saline continuous administration.~This is the actual standard of care performed in extended hemodialysis sessions."
89080377|NCT04297839|Experimental|Citrate Group|Patients in this group will receive regional citrate anticoagulation, with acid-citrate-dextrose 2.2% (ACD). Dose of 3 mmol per liter of filtered blood. The systemic calcium levels are measured every two hours and a solution of calcium chloride is infused in a peripheral venous access, accordingly to citrate infusion rate and the systemic calcium values.
89080378|NCT02746549|Experimental|1.5 Tesla MRI|Measurement of renal perfusion by 1.5 Tesla MRI with arterial spin labelling
89080379|NCT02746549|Experimental|3.0 Tesla MRI|Measurement of renal perfusion by 3.0 Tesla MRI with arterial spin labelling
89230135|NCT00662909|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
89230136|NCT00662909|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 m tablets, orally once a day for 12 weeks
89080380|NCT02751229|Experimental|Honest Open Proud|"The group program is about disclosure ('coming out') versus secrecy of one's mental illness. The groups are facilitated by peers (young adults with mental illness) and mental health professionals. Each group runs for three weeks, one meeting per week, and two hours per meeting.~Fidelity to manual: rated by PhD student in each session as proportion of key topics covered"
89080381|NCT02751229|No Intervention|Control Group|treatment as usual (TAU)
89080382|NCT02751151|Experimental|1|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
89080383|NCT02747251|Experimental|Strengthen your Shoulder & Usual Care|"Instructions in a home-based intervention consisting of progressive high volume resistance training with an elastic band. Instructions provided 0, 2, 5, and 10 weeks after baseline. Usual care includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
89080384|NCT02747251|Active Comparator|Usual Care|"Includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
89080385|NCT02695303|Experimental|BAY 987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89080386|NCT02747173||RCC patients with bone metastases|Patients will receive the standard TKI treatment for first line treatment naive metastatic RCC. Sunitinib or pazopanib as decided by the investigator.
89080387|NCT04216459|No Intervention|Low risk group|no specific treatment will be given
89080388|NCT04216459|No Intervention|High risk control|no specific treatment will be given
89080389|NCT04216459|Active Comparator|High risk DP|patients will receive one intramuscular (IM) injection of 400,000 IU of cholecalciferol on day- 1 Also, starting from day 1 and till day 6 (for consequential 6 days), patients will receive lactobacillus probiotics (10 billion colony forming unit) in a dose of 6 sachets per day
89080390|NCT04216459|Active Comparator|High risk CB|Patients will receive vitamin C plus thiamine starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
89080391|NCT02747485|Experimental|organic left-sided regurgitant valve|
89080392|NCT04216771|Experimental|IDA with ID Cytarabine|
89080393|NCT04216771|Active Comparator|ID Cytarabine|
89080394|NCT02747095|Experimental|Spectral CT image|Interventions: IQon Spectral CT
89080395|NCT02737033|Experimental|Rhodiola|Rhodiola rosea 800mg single dose
89080396|NCT02737033|Placebo Comparator|Placebo|placebo 800mg single dose
89080397|NCT02736799|Sham Comparator|Sham vibrating capsule|Sham vibrating capsule
89080398|NCT02736799|Active Comparator|Vibrant Capsule (1 vibration)|1 vibration/min
89080399|NCT02736799|Active Comparator|Vibrant Capsule (3 vibration)|3 vibrations/min
89080400|NCT02736799|Active Comparator|Vibrant Capsule (5 vibration)|5 vibrations/min
89080401|NCT02736487|Active Comparator|Group A: True-Washout-Sham|Subjects in group A receives true air filtration intervention, then at least two weeks of washout period, followed by sham air filtration intervention.
89080402|NCT02736487|Active Comparator|Group B: Sham-Washout-True|Subjects in group B receives sham air filtration intervention, then at least two weeks of washout period, followed by true air filtration intervention.
89080403|NCT03565939|Active Comparator|Trichuris suis ova (TSO)|7500 TSO suspension, orally every second week for 24 weeks.
89080404|NCT03565939|Placebo Comparator|Placebo|Solution without TSO orally every second week for 24 weeks
89080405|NCT02736331|Experimental|Treatment 1 Beverage|Treatment 1
89080406|NCT02736331|Placebo Comparator|Treatment 2 Beverage|Treatment 2
89080407|NCT02736019|Active Comparator|Celecoxib|Women will receive oral celecoxib 200mg 2 hours before the procedure
89080408|NCT02736019|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
89080409|NCT02736019|Placebo Comparator|Placebo|Women will receive a placebo similar to celecoxib and a placebo similar to Tramadol
89080410|NCT02735863|Experimental|ABX464|Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
89080411|NCT02735863|Placebo Comparator|ABX464 Matching placebo|Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
89080412|NCT02735941||UC group|Patients with ulcerative colitis (active or remission)
89080413|NCT02735941||CD group|Patients with Crohn's disease (active or remission)
89080414|NCT02735941||Colon cancer group|Patients with colon cancer or metastasis
89080415|NCT02735941||control group|healthy individuals
89080416|NCT02735785|Experimental|intervention|behavioral intervention
89080417|NCT02735785|No Intervention|control|control
89080418|NCT04286581|Experimental|Igel Larnygeal Mask Airway|Group 1 will receive the I-Gel Laryngeal Mask Airway for airway maintenance during general anesthesia
89080419|NCT04286581|Active Comparator|Ambu Auragain Laryngeal mask airway|Group 2 will receive the Ambu Auragain Laryngeal Mask Airway for airway maintenance during general anesthesia
89080420|NCT05595889|Experimental|Surufatinib combined with irinotecan|Surufatinib combined with irinotecan as a second-line treatment for small cell lung cancer
89080421|NCT02735629|Experimental|CX1739 - 300 mg|Study Drug - low dose
89080422|NCT02735629|Placebo Comparator|Placebo|Placebo
89080423|NCT02735629|Experimental|CX1739 - 600 mg|Study drug - mid Dose
89080424|NCT02735629|Experimental|CX1739 - 900 mg|Study drug - high dose
89080425|NCT02735395|Placebo Comparator|Control|Scaling and root planing (SRP) + two placebo pills thrice a day (TID) for 14 days (control group)
89080426|NCT02735395|Active Comparator|MTZ 250 (7 days)|SRP + MTZ (250mg/TID) + AMX, for 7 days and placebos for another 7 days
89080427|NCT02735395|Active Comparator|MTZ 400 (7 days)|SRP + MTZ (400mg/TID) + AMX, for 7 days and placebos for another 7 days
89080428|NCT02735395|Active Comparator|MTZ 250 (14 days)|SRP +MTZ (250mg/TID) + AMX for 14 days
89080429|NCT02735395|Active Comparator|MTZ 400 (14 days)|SRP +MTZ (400mg/TID) + AMX for 14 days
89080430|NCT02741947|Active Comparator|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
89080431|NCT02741947|Experimental|Levodopa Benserazide Teva Italia|Levodopa Benserazide Teva Italia100+25mg and 200+50mg, tablet, tid e qid, for four weeks
89080432|NCT05629195|Experimental|tunneled PICC|Placement of PICC catheter through tunnel technology
89080433|NCT05629195|Active Comparator|conventional PICC|Placement of PICC catheter through conventional technology
89080434|NCT02741869|Experimental|single arm|This is a single arm, open label study. Subjects who meet eligibility criteria will be treated with photodisinfection therapy (MRSAid™).
89080435|NCT02741557|Experimental|DTG/RPV FDC-DTG plus RPV|Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 2 under fed state.
89080436|NCT02741557|Experimental|DTG plus RPV-DTG/RPV FDC|Subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 2 under fed state.
89080437|NCT02741479|Experimental|K Tape Group|
89080438|NCT02741479|Active Comparator|Sham Group|
89080439|NCT02741479|Experimental|No Tape|
89080440|NCT02741401|Active Comparator|Therapy standard|Patients receive usual postoperative care
89080441|NCT02741401|Experimental|Therapy standard + hand-foot massage|Patients receive usual postoperative care and hand-foot massage
89080442|NCT02741167||CRS and HIPEC|Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy
89230137|NCT00050011|Experimental|Zoledronic Acid upfront|Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
89080443|NCT02740933|Experimental|Demeclocycline|"All subjects will take Demeclocycline 300 mg po bid. Patients will be advised to take demeclocycline on an empty stomach, at least 1-2 hours before meals, and they will be warned that it can reduce the efficacy of oral contraceptives.~The investigators will begin by treating subjects with 2 days of demeclocycline. The investigators will increase the numbers of days that subjects are exposed to demeclocycline in increments of 1 day until at least 80% of patients at a given dose have detectably fluorescent tumors, or participants reach 5 days of drug, whichever comes first."
89080444|NCT02741089||Indication for a flexible bronchoscopy|Patients representing to the hospital with the indication for a flexible bronchoscopy
89080445|NCT02694991|Experimental|OMT Group|Osteopathic Manipulative Treatment 15 minutes once a day for 8 days
89080446|NCT02694991|No Intervention|Control Group|No intervention, only usual care
89080447|NCT02741011|Other|Radiological imaging|Mentally handicapped patients underwent sedation anesthesia with IV Propofol and then tomographic images were obtained with NewTom 5G. Orthopantomographies (OPGs) were obtained by processing the raw images and radiological examination of the patients were performed on OPGs.
89080448|NCT02740621||Patients with coronary heart disease|coronary angiography with finding coronary heart disease currently no cancer 40 years or older
89080449|NCT02740621||control patients|coronary angiography with exclusion coronary heart disease or other patients with non-cardiac diseases currently no cancer 40 years or older
89080450|NCT02740465|Experimental|COPD Patients|
89080451|NCT00636337|Experimental|1|Participants meeting inclusion criteria will be provided with a laptop computer outfitted with a wireless card for the duration of the intervention and will be trained in the use of RoboMemo in the clinic by study personnel. Although many participants may have ready access to home computers, we decided that all participants will be required to use laptops provided by the study for two reasons: 1) to ensure that coaches and participants are blind to treatment condition (as described above), and 2) to ensure that participants will always have access to the intervention program (i.e., they will not compete with other family members for computer time). Once trained, children will complete the intervention at home. The intervention will consist of four 30- to 45-minute sessions per week for 8 weeks (total = 32 sessions). This intervention schedule is similar to the schedule employed by Klingberg and colleagues in their home-based CT trials with ADHD children.
89080452|NCT00636337|Placebo Comparator|2|The design will be a double-blind, placebo-controlled trial in which half of the participants will be randomized to the intervention condition and half will receive a comparison computer program. Specifically, participants assigned to the comparison (placebo) condition will complete a modified version of the CT at home. The treatment and comparison CT programs begin identically, at the lowest difficulty level. Those in the treatment condition will complete activities of increasing difficulty over the intervention period. Those in the placebo condition, in contrast, will complete the same basic tasks during each session of the intervention, regardless of performance. In this way, a true estimate can be obtained of the efficacy of the treatment program.
89080453|NCT02740387|Experimental|OTO-104|12 mg dexamethasone
89080454|NCT03699163||Endoscopy patients|Patients who are attending hospital for a colonoscopy as part of their routine clinical care, or as part of the Bowel Cancer Screening Programme, will be asked to give a sample of their breath prior to the procedure.
89080455|NCT03699163||Colorectal cancer patients|Patients who have known pre-diagnosed colorectal cancer (adenocarcinoma) attending hospital as part of their clinical care will be asked to give a breath sample prior to their cancer operation.
89080456|NCT02746393|Experimental|Intervention|Health Advocates Program
89080457|NCT02746393|Active Comparator|211 Arm|211 Information Sheet
89080458|NCT02740309|Experimental|Integrated Brief Behavior Therapy (IBBT) Intervention|4-sessions of IBBT for youth anxiety and depression.
89080459|NCT02740309|Active Comparator|Treatment as usual|Treatment as usual
89080460|NCT02746237|Experimental|KAR5585|KAR5585 Capsules
89080461|NCT02746237|Placebo Comparator|Placebo|Placebo capsules
89080462|NCT02740075||Hand-ventilated|This group will be transported from the operating room to the intensive care unit with the anesthesia provider ventilating the patient by hand via Mapleson circuit and supplemental oxygen. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators. The anesthesia provider will be blinded to the end-tidal carbon dioxide levels and respiratory rate.
89080463|NCT02740075||Mechanically ventilated|This group will be transported from the operating room to the intensive care unit with the patient being ventilated by a transport ventilator with controlled tidal volume, respiratory rate, and positive end-expiratory pressure. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators.
89080464|NCT02739841|Experimental|Ventilator hyperinflation|For the ventilator hyperinflation techniques (VHI), the study consists of three consecutive periods 1) baseline period: 10 minutes rest in side lying by effected lung uppermost with head-up 30 degree 2) Intervention period: Patients were positioned as same as baseline period and 4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial 3) recovery period: 10 minutes rest in the same position but reduce VT to initial.
89080465|NCT02739841|Experimental|Chest physical therapy|For the conventional chest physical therapy (CPT), the study will be performed in the similar procedure except the intervention period, the patient will be received vibration and passive of the both upper extremity.
89080466|NCT02739763|Experimental|Plasmodium falciparum sprozoite (PfSPZ) challenge|Challenge agent
89080467|NCT02739685|Experimental|Bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
89080468|NCT02739685|Active Comparator|Stent|Implantation everolimus-eluting stent in chronic total occlusion
89080469|NCT02735317|Experimental|FORRAD group|"This group of patients will receive Oral Ulcer Gargle (FORRAD®) during study for prevention and treatment of acute radiation-induced oral mucositis (OM).~This is the experimental group."
89080470|NCT02735317|Active Comparator|Quadruple mixture group|"This group of patients will receive quadruple mixture, which is composed of dexamethasone, gentamicin, vitamin B12, and procaine, during study for prevention and treatment of acute radiation-induced oral mucositis (OM).~This is the active comparator group."
89080471|NCT02735161|Experimental|Exercise training|"Four exercise training sessions. Two endurance training sessions, one with high intensity interval training and one session of moderate intensity of longer duration. Two strength training session; one with high load and few repetitions and one with low load and many repetitions.~Fatigue and lactate will be measured before, after and 24 hours post-exercise. Trainings sessions will be randomized."
89080472|NCT02746315|Experimental|Experimental 1|Once daily subcutaneous dose for 7 Days of HS-20004 0.02 mg or Matched Placebo.
89080473|NCT02746315|Experimental|Experimental 2|Once daily subcutaneous dose for 7 Days of HS-20004 0.04 mg or Matched Placebo.
89080474|NCT02746315|Experimental|Experimental 3|Once daily subcutaneous dose for 7 Days of HS-20004 0.06 mg or Matched Placebo.
89080475|NCT02746315|Experimental|Experimental 4|Once daily subcutaneous dose for 7 Days of HS-20004 0.08 mg or Matched Placebo.
89080476|NCT05548621||Pre-test|Patients with RCC receiving usual care (without use of the decision aids)
89080477|NCT05548621||Post-test|Patients with RCC using the decision aids
89080478|NCT02739529|Experimental|Cohort 1|Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
89080479|NCT02739529|Experimental|Cohort 2|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
89080480|NCT02739529|Experimental|Cohort 3|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1
89080481|NCT02739607|Experimental|Transdiagnostic program|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
89080482|NCT02739607|No Intervention|Wait list control group|This arm represents the wait-list comparison group.
89080483|NCT05629975|Experimental|Intervention group|"In addition to the normal diet in the hospital, patients in the intervention group received a package of nutritional powder in the morning and evening of every day, and each package was diluted with 500 ml of water.~Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum& bifidobacterium (500 mg) every day for 7 days."
89080484|NCT05629975|No Intervention|Control group|Patients in the control group received normal diet provided by the hospital.
89080485|NCT02739451|Active Comparator|standard oxygen group|Oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system
89080486|NCT02739451|Experimental|High-flow nasal oxygen (HFNO) group|"Device that delivers humidified and warmed high-flow oxygen at flows greater than 15 L/min.~HFNO will be initiated at a flow rate of 50 L/min and 100% FiO2. If the target SpO2 is not reached, the flow rate will be increased to 60 L/min. Then, FiO2 will be tapered to target an SpO2≥95. The minimal flow rate will be 45 L/min"
89080487|NCT02734927|Active Comparator|schizophrenia group|Schizophrenia patients suffering
89080488|NCT02734927|Sham Comparator|control group|subjects showing no psychological or neurological disorder
89080489|NCT05629819|Experimental|PNS group|"In addition to conventional respiratory therapy and pulmonary rehabilitation, neuromuscular electrical stimulator was used for PNS~Device Settings Strength: Maximum current tolerated by the patient (0-100mA, commonly used below 13mA) ； Stimulation time: 1.0s; Frequency: 40Hz;~Location: The stimulation electrodes were attached to the left and right sides of the neck under the outer margin of the sternocleidomastoid muscle 1/3; The reference electrodes were attached to the surface of both pectoralis major muscles.~Treatment frequency: 30 at a time, Bid, until withdrawal/death/for 4 weeks."
89080490|NCT05629819|No Intervention|conventional group|"conventional respiratory therapy and pulmonary rehabilitation, including airway management, early activity, and respiratory muscle training.~No intervention"
89080491|NCT02735005|Experimental|SMAF assessment|"Face to face interview for the Functional Autonomy Measurement System (SMAF) tool questionnaire For disabled patients living at home, the Social SMAF questionnaire is used in addition.~Data related to care consumption of each enrolled patients are collected too."
89080492|NCT02739217|Experimental|PBI-4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
89080493|NCT02739373|Experimental|BMS-986189|Specified Dose on Specified Day
89080494|NCT02739373|Placebo Comparator|Placebo|Specified Dose on Specified Day
89080495|NCT02738983|Experimental|Bioradiotherapy|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day) with concurrent radiotherapy to a total radiation dose of 60-66 Gray (Gy).
89080496|NCT02739139|Placebo Comparator|Placebo|Placebo
89080497|NCT02739139|Experimental|AlphaBrain|AlphaBrain(TM)
89080498|NCT02739061|Active Comparator|cognitive behavioral group therapy|cognitive behavioral group therapy
89080499|NCT02739061|Active Comparator|drug therapy|drug therapy
89080500|NCT02739061|Active Comparator|The combination therapy|cognitive behavioral group therapy and drug therapy
89080501|NCT02746003|Other|Managed Aquifer Recharge water|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control at different times.
89080502|NCT02746003|Other|Control|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control arms at different times.
89080503|NCT02745925|Experimental|normal-weight|normal-weight women
89080504|NCT02745925|Experimental|obesity|obese women
89080505|NCT04374253|Experimental|Group 1|Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 116 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).
89080506|NCT04374253|Experimental|Group 2|Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
89080507|NCT02738905|Experimental|Rifaximin|Participants will receive study drug for a period of 7 days.
89080508|NCT02738827|Other|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.
89080509|NCT02738749|Other|ICD group|Adult patients with newly implanted ICD devices for primary prevention will be enrolled. At baseline, 3-, 6-, 9-, and 12-month followup visit, the medial information and blood samples will be collected.
89080510|NCT02738671||Type 1 Diabetes Mellitus|These T1DM patients have late diabetes onset.(latent autoimmune diabetes in adult, LADA)
89080511|NCT02738671||Type 2 Diabetes Mellitus|A subgroup of these T2DM patients are obesity patients who will have the bariatric surgery. These obese T2DM subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain MRI at baseline and 6 months after their surgery.
89080512|NCT02738671||Control|A subgroup of these non-diabetic people are obesity patients who will have the bariatric surgery. These obese subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain fMRI at baseline and 6 months after their surgery.
89080513|NCT02738437|No Intervention|control|Control Group receiving standard treatment
89080514|NCT02738437|Active Comparator|intervention group|Intervention Group receiving the standard treatment and the kryptonite-bone cement
89080515|NCT02734459|Experimental|tobramycin and dexamethasone ophthalmic test ointment|The test drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in one eye before the cataract surgery.
89080516|NCT02734459|Active Comparator|TobraDex® ointment|The reference drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in another eye before the cataract surgery.
89080517|NCT02745613|Experimental|Family history of T2D|The participants will undergo 8 weeks of combined exercise
89080518|NCT02745613|Experimental|No Family history of T2D|The participants will undergo 8 weeks of combined exercise
89080519|NCT02745691||A. Surgery|A.1 Surgery alone and/or before any adjuvant therapy A.2 Surgery (late effects)
89080520|NCT02745691||B. Radiochemotherapy|B.1 Chemotherapy alone B.2 Radiotherapy alone B.3 Sequential radiochemotherapy B.4 Concurrent radiochemotherapy
89080521|NCT02745691||C. Targeted therapy|C.1 Targeted therapy alone C.2 Targeted therapy in combination with any other therapy
89080522|NCT02745691||D. Immunotherapy|Any new immunotherapy for lung cancer
89080523|NCT02745769|Experimental|Ramucirumab + Merestinib|Ramucirumab intravenously (IV) on day 1 and day 15 in combination with merestinib orally once a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.
89080524|NCT02745769|Experimental|Ramucirumab + Abemaciclib|"Ramucirumab IV on day 1 and day 15 in combination with abemaciclib orally twice a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.~On June 21st 2017 the Ramucirumab + Abemaciclib arm was cancelled with no participants enrolled."
89080525|NCT02738281||Rett Syndrome|This is a prospective natural history study examining the phenotypic variations of individuals with mutations in MECP2 or meeting the diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome. The overwhelming majority will be female, but males meeting diagnostic criteria will be included. No interventions are planned.
89080526|NCT02738281||MECP2 Duplication|This is a prospective natural history study examining the phenotypic variations of individuals with MECP2 duplications. The majority are expected to be males, but females expressing a duplication will be included. No interventions are planned.
89080527|NCT02738281||RTT related disorders|This is a prospective natural history study examining individuals, both females and males who do not meet criteria for Rett syndrome, but have a mutation in MECP2, CDKL5, or FOXG1. No interventions are planned.
89080528|NCT04370041|Experimental|Dokimos Plus aortic valve implantation|Dokimos Plus aortic valve implantation in all included patients.
89080529|NCT05629663|Experimental|AR program group|participants in the AR group were guided by AR-based instructions and requested assistance with the head-mounted device.
89080530|NCT03636607|Experimental|Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
89080531|NCT03636607|Experimental|Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
89080532|NCT02737969||TEE/Angio fusion software|Patients planned to undergo a transcatheter-based structural heart disease procedure that utilizes TEE and fluoroscopic guidance
89080533|NCT02734303||Potentially Exposed NM Residents|residents of the state of New Mexico (NM) potentially exposed to radioactive fallout fromthe Trinity nuclear test conducted in 1945
89080534|NCT02734225|Experimental|EXPERIMENTAL|Functional recovery Balance training
89080535|NCT02734225|Active Comparator|CONTROL|Functional recovery Balance training Dynamometric Platform training
89080536|NCT02745223|Experimental|PresbiDrops (CSF-1)|Participants self-administered PresbiDrops (CSF-1), 1 drop in each eye each morning for 2 weeks.
89080537|NCT02745223|Placebo Comparator|Placebo|Participants self-administered placebo, 1 drop in each eye each morning for 2 weeks.
89080538|NCT02737813|Experimental|Isobaric Marcaine|Isobaric Marcaine 2.2 mL for spinal block
89080539|NCT02737813|Active Comparator|Hyperbaric Marcaine|Hyperbaric Marcaine 2.2 mL for spinal block
89080540|NCT03630913|Experimental|Tagged axillary metastatic node|"Patients undergo axillary sonography assessment routinely performed to seek suspicious nodes. A cytological examination (biopsy is optional) of the suspicious node is performed.~The involved node is then tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC."
89080541|NCT02745379|Experimental|BFPSC+|The group receives a combination (DFDBA)+buccal fat pad derived stem cells BFPSC and PRF for sinus augmentation
89080542|NCT02745379|Active Comparator|BFPSC-|The group receives a combination of demineralized freeze-dried bone allografts DFDBA (lacking any cells) and PRF for sinus augmentation
89080543|NCT02737735|Experimental|Chemotherapy combined with compound herbal medicine|Standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks combined with compound Chinese herbal medicine for 2 years，which include 15 kinds of Chinese herbs:Thunberg fritillary bulb,antimutangenic ,cimicifuga foetida,astragalus,pinellia ,Radix Ophiopogonis ,Solanum nigrum,Hedyotis diffusa,Prunella vulgaris ,cordate houttuynia,Herba Patriniae,dried orange peel ,Codonopsis,Wolfiporia extensa,Coix seed,Rhizoma Alismatis.
89080544|NCT02737735|Active Comparator|Chemotherapy|The therapy of standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks
89080545|NCT02737657||Cohort 1|Participants who are already receiving Canagliflozin and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as the part of study.
89080546|NCT02737657||Cohort 2|Participants who are already receiving any sulphonylurea and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as a part of study.
89080547|NCT02738515|Active Comparator|Group 1|Scaling and Root Planing (SRP) with 0.75% BORIC ACID GEL for treating furcation defect
89080548|NCT02738515|Placebo Comparator|Group 2|Scaling and Root Planing (SRP) with PLACEBO GEL for treating furcation defect.
89080549|NCT02744599|Experimental|Device prompting|
89080550|NCT02744599|No Intervention|Control|Patients receive standard of care
89080551|NCT00636415|Experimental|A|G1 patients received morphine intra-articular route G2 patients received bupivacaine without epinephrine.
89080552|NCT02733835|Experimental|Remifentanil|Remifentanil Patient Controlled Analgesia
89080553|NCT02737423|Experimental|vitamin D|single IM dose 600,000 IU of cholecalciferol
89080554|NCT02737345||Waiting list|Patients on the liver transplant waiting list
89080555|NCT05629507|Experimental|Virtual Reality|In the virtual reality arm, patients will use a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and High Definition audio stereo.
89080556|NCT05629507|No Intervention|Narrative Medicine|In narrative medicine arm, patients will express their subjective experience regarding to the chemotherapy through writing. The experience will be written in free form by the patient and will cover both the cognitive, emotional and perceptual aspects. A nurse will always be available to guide the patient in the activity of expressing cognitive, emotional and perceptual contents.
89080557|NCT05629507|No Intervention|Standard Care|In control arm, patients will be free to choose different activities during the infusion of chemotherapy, such as conversation with nurses, doctors, trainees, reading, writing, watching television, listening to music or videos on their smartphone.
89080558|NCT02737267|Experimental|Moderately high protein diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 40% of the energy derived from carbohydrates, 30% of the energy derived from protein and 30% of the energy derived from fat
89080559|NCT02737267|Placebo Comparator|Low fat diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 60% of the energy derived from carbohydrates, 18% of the energy derived from protein and 22% of the energy derived from fat
89080560|NCT02744911|Experimental|Telemedicine group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device via the internet using the telemedicine application. Also includes speech-language pathologists providing treatment via the telemedicine application.
89080561|NCT02744911|Active Comparator|In person group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device in person. Also includes speech-language pathologists providing treatment in person.
89080562|NCT02733679|Experimental|Ataxia Telangiectasia|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
89080563|NCT02733679|Active Comparator|Healthy controls|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
89080564|NCT02736877|Experimental|Lumera Microscope with OCT RESCAN|In the group microscope coupled to OCT, patients will undergo corneal surgery using the Lumera Microscope WITH RESCAN OCT - ZEISS. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
89080565|NCT02736877|Active Comparator|Conventional Microscope|The control group will undergo corneal transplant with conventional microscope without coupled OCT. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
89080566|NCT02695147||TAVI via Subclavian approach|Any TAVI procedure using any valve type performed via the subclavian approach
89080567|NCT02695147||TAVI via Direct Aortic approach|Any TAVI procedure using any valve type performed via the direct aortic approach
89080568|NCT02744443|Experimental|Leucine|Leucine supplementation (10 g/d)
89080569|NCT02744443|Placebo Comparator|Placebo|Placebo supplementation (alanine, 10 g/d)
89080570|NCT02732353|Active Comparator|Minced beef|Minced beef
89080571|NCT02732353|Experimental|Hydrolyzed beef|Hydrolyzed beef
89080572|NCT02731963|Experimental|Mechanical bowel preparation|80 Patients who received mechanical bowel preparation with 4 packets of polyethylene glycol in 4 liters of water, 4 hours before intervention.
89080573|NCT02731963|No Intervention|No mechanical bowel preparation|81 Patients who received clear liquid diet 1 day before intervention.
89080574|NCT02731807|Experimental|Dose A, B, C, D, E|All participants will receive all doses throughout the course of the study.
89080575|NCT02731807|Experimental|Dose D, E, C, B, A|All participants will receive all doses throughout the course of the study.
89080576|NCT02731807|Experimental|Dose C, D, E, A, B|All participants will receive all doses throughout the course of the study.
89080577|NCT02731807|Experimental|Dose E, D, C, B, A|All participants will receive all doses throughout the course of the study.
89080578|NCT02744521|Experimental|Symptom based screening intervention|
89080579|NCT02744521|No Intervention|control|
89080580|NCT04189705|Experimental|MCT-SR|Drug: MCT-SR 2 times/day for 2 weeks
89080581|NCT04189705|Active Comparator|Mucosta Tab.|Drug: Mucosta Tab. 3 times/day for 2 weeks
89080582|NCT04109677||SHE player|Female player in the top Swedish handball league
89080583|NCT04109677||Handbollsligan player|Male player in the top Swedish handball league
89080584|NCT02731651|Active Comparator|Open Hysterectomy|Open hysterectomy was performed with taking one of the ovaries at the beginning and the other ovary was removed at the end of the surgery.
89080585|NCT02731651|Active Comparator|LaparoscopicAssistedVaginalHysterectomy|Surgery in Group 2 (LAVH): Laparoscopic Assisted Vaginal Hysterectomy was performed with taking one of the ovary at the beginning of the procedure and the other ovary was removed at the end of the surgery.
89080586|NCT02744131|Active Comparator|OCP|Arm 1: oral contraceptive pill, combination pill of ethyl estradiol 20 micro gram with Cyproterone acetate.
89080587|NCT02744131|Active Comparator|Metformin|Arm 2: Metformin . Oral insulin sensitising drug in the dose of 1500gms daily.
89080588|NCT02731885|Experimental|Fasted Conditions|50mg of ABX464 (two 25mg capsules) /Fasted
89080589|NCT02731885|Experimental|Fed Conditions|50mg of ABX464 (two 25mg capsules) /Fed
89080590|NCT05468749|Experimental|CTP-543 Treatment|
89080591|NCT02731495|Experimental|EGCG|Participants were randomly divided based on age, sex and severity of TBI in two groups. Randomization lists was computer-generated by a statistician and participants, project managers and employees at the clinic are completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients received EGCG supplement was in the form of 400 mg oral capsules with a purity of 80% catechin. EGCG powder of each capsule was dissolved in 10 ml deionized water and given to patients via gavage (1 capsule per day) for a week.
89080592|NCT02731495|Placebo Comparator|Placebo|Placebo group only received 10 ml of deionized water via gavage for a week.
89080593|NCT02731573|Experimental|Treatment arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.
89080594|NCT02731573|Other|Control arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.
89080595|NCT02733523|Experimental|"Program Sentirnos bien"|"The intervention Program Sentirnos bien is based around a group dynamic, held once a week during 3 months, aimed at:~Promoting the uptake of self-care healthy habits~Promoting social capital at individual level:~Promoting health literacy"
89080596|NCT02733523|No Intervention|Control arm|The control arm will receive no intervention. Once the trial is finished, i.e. after the last follow-up evaluation, this arm will receive the intervention (waiting-list approach).
89080597|NCT02743975|Experimental|Treatment group|Bevacizumab-800CW
89080598|NCT02743663||Wheezing subjects|Two study visits will be completed with wheezing subjects. The baseline visit will be completed within a 5 day window from the child's discharge from the emergency department. The follow-up visit will be completed 3 months after the baseline visit. At both visits, participants will provide a nasal swab and urine sample, complete three breathing tests: multiple-breath washout, forced oscillation technique, and Spirometry. In addition, at the follow-up visit, children will have an allergy skin test done, a nasal brush to collect epithelial cells and provide a blood sample. Whole blood will be used for basophil activation test (BAT). Children age 4+ will also complete post-bronchodilator testing using Salbutamol to capture information about bronchodilator response.
89080599|NCT02743663||Healthy cohort|One study visit will be completed with healthy participants. At this visit, three breathing tests will be performed: multiple-breath washout, forced oscillation technique, and spirometry. As well, an allergy skin test will be performed at the visit.
89080600|NCT02731417|Experimental|Urinary retention-group 1|For women with post partum urinary retention designated for experimental treatment.
89080601|NCT02731417|Active Comparator|Urinary retention-group 2|For women with post partum urinary retention designated for current departmental protocol treatment.
89080602|NCT02731339|Experimental|Women with Urinary incontinence|
89080603|NCT02731339|Experimental|Women without Urinary incontinence|
89080604|NCT02733211|Experimental|Closed Loop System|MD-Logic automated insulin delivery system - all subjects wearing the study system during nights over 4 weeks
89080605|NCT02733211|Active Comparator|Sensor augmented pump therapy|Sensor augmented pump therapy - all subjects are using sensor augmented pump therapy over 4 weeks
89080606|NCT02743585|Experimental|Rapid diagnostic arm|"Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) AND FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen will be performed.~The Interventions to be administered are the rapid diagnostic tests: FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen.~Subjects will be recruited 8am-3pm daily, weekdays only. Results of the BCID and Rosco test will be communicated to the managing physicians by phone in real-time."
89080607|NCT02743585|No Intervention|Standard of care (control)|Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) will be used. FilmArray BCID and Rosco Diagnostica ESBL and carbapenemase screen will NOT be performed. Subjects will be recruited 8am-3pm daily, weekdays only.
89080608|NCT02733445||dasatinib cohort|Patients with CML receiving dasatinib
89080609|NCT02733445||nilotinib cohort|Patients with CML receiving nilotinib
89080610|NCT05629273||Children treated with continuous renal replacement therapy in the intensive care unit.|"Children treated with CRRT in the ICU due to AKI stage ≥1 (according to KDIGO) and/or ≥2 organ failures. The aim is to evaluate their long term renal function and establish the frequency of chronic kidney disease. Nephrology follow up will be done by a pediatric nephrologist for children living in the Stockholm area or have ongoing care at Karolinska University Hospital.~Due to high mortality in this group of patients and the fact that many patients are referred to Karolinska University Hospital from other regions in Sweden, a substantial number of patients will be lost to follow-up. The investigators will therefore conduct a register-based study of all children who received CRRT due to AKI and/or MOF at Karolinska University Hospital from 2008-2021. Data regarding mortality, cause of death and diagnosis of chronic renal disease will be collected from the Swedish National Patient Register and National Cause of Death Register."
89080611|NCT02731261|Experimental|Experimental|
89080612|NCT02731261|No Intervention|Control|
89080613|NCT02731027||Healthy Controls|
89080614|NCT02731027||Participants with Spinal Cord Injury|
89080615|NCT02731105|Active Comparator|Arm 1|Acnatac® Gel on left face and Epiduo® Gel on right face once daily for three weeks
89080616|NCT02731105|Active Comparator|Arm 2|Epiduo® Gel on left face and Acnatac® Gel on right face once daily for three weeks
89080617|NCT02743429|Experimental|Long term infusion of ch14.18/CHO|10 day continuous Infusion of ch14.18/CHO.
89080618|NCT05454553|Experimental|Patients with left sided breast cancer who are planned for|"one of the following heart sparing techniques :~DIBH radiotherapy~IMRT"
89080619|NCT02730949|Experimental|1 g D-chiro-Inositol + 400 mcg Folic Acid|1 g D-chiro-Inositol + 400 mcg folic acid once daily
89080620|NCT02730949|Active Comparator|400 mcg folic|400 mcg folic acid only once daily
89080621|NCT04205929|Placebo Comparator|Placebo group|Placebo (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
89080622|NCT04205929|Experimental|Curcumin group|Curcumin 600 mg (oral) once daily for 30 days to be started following 3 consecutive days of bleeding
89080623|NCT03856645|Experimental|OKG-0301 0.012% w/v|
89080624|NCT03856645|Experimental|OKG-0301 0.03% w/v|
89080625|NCT03856645|Placebo Comparator|Vehicle Control|
89080626|NCT02695069|Experimental|All Participants|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
89080627|NCT04190797|Experimental|Experimental|Photobiomodulation + patiente controled anaethesia (PCA) group (G1): patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
89080628|NCT04190797|Active Comparator|Control|Placebo + PCA group (G2): patients undergoing knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve blockade (femoral nerve and obturator nerve). With conventional analgesia and with the PCA apparatus.
89080629|NCT02743195|Other|Polyphenol/prebiotic blend|Nutritional Supplement. Active ingredients include: Inulin, Fructooligosaccharides, Polyphenol blend of anthocyanin sources--Blueberry extract, Black Currant extract, Black Rice extract. Participants will be instructed to consume one sachet of powder product every morning with breakfast by mixing into beverage or food of choice.
89080630|NCT02743039|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
89080631|NCT02743039|No Intervention|Control Standard of CAP|No assignment to participate in the CareerAdvance® program, but given community referrals and resources
89080632|NCT02731183|Experimental|FMT|Patients included will receive standard FMT, and then will be followed up for 8 weeks.
89080633|NCT00636493|Experimental|Vein Occlusion Eye|Eye with retinal vein occlusion receiving fluocinolone acetonide sustained drug delivery device
89080634|NCT02742961||Peripheral nerve block|Intervention arm. Participants who receive a peripheral nerve block identified through submission of an appropriate physician billing code
89080635|NCT02742961||No peripheral nerve block|Control arm. Participants who do not receive a peripheral nerve block identified through lack of a submission of an appropriate physician billing code
89080636|NCT02730637|No Intervention|Standard care|Patients with elevated biomarkers receive a standard treatment.
89080637|NCT02730637|Active Comparator|Interventional care|Patients in the interventional population receive an early nephrologist consultation which deliberates with attending doctor on preventing measures according to AKI-KDIGO recommendations.
89080638|NCT02730559|Experimental|Intervention Group|Group A (Parent-adolescent dyads)
89080639|NCT02730559|Active Comparator|Control Group - Active Comparator|Group B (Adolescents only)
89080640|NCT02730481|Experimental|ORAXOL|"Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
89080641|NCT05423353|Active Comparator|Paraffin Bath Therapy|Paraffin bath therapy is a physical therapy method that can create a temperature increase of 7.5 °C in the joint capsule and 4.5 °C in the muscle.
89080642|NCT05423353|Active Comparator|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment that involves delivery of shock waves to injured soft tissue to reduce pain and promote healing.
89080643|NCT02733055|Experimental|subjects|participant undergoing posturographic evaluation
89080644|NCT02732977|Other|expert system|System for predicting patients heart failure, that can predict response to a personalized treatment from the analysis of a set of data (images, physiological data , treatment outcomes ) .
89080645|NCT02732821||Gastric Per Oral Endoscopic Myotomy|All patients presenting with Gastroparesis will undergo Per oral endoscopic gastric myotomy
89080646|NCT02742727|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
89080647|NCT02730091|Active Comparator|Letrozole or anastrozole|Letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
89080648|NCT02730091|Experimental|Vinorelbine + Anastrozole or letrozole|Oral vinorelbine 50 mg (1 soft capsule of 30 mg and 1 soft capsule of 20 mg) three times a week every ( Monday, Wednesday and Friday) before lunch and letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
89224928|NCT06113614|Experimental|Photobiomodulation Group|The shoulder brace (Cosmedical, Mauá, SP, Brazil) contains 159 red LEDs and 159 infrared LEDs interspersed. The PBM group (standard physical therapy combined with active PBM). Participants will apply PBM at home daily for 10 minutes using a device containing 318 light-emitting diodes (LEDs), with 159 LEDs at 660 nm (28.5 mW; 12 J/cm2; 17 J per LED) and 159 LEDs at 850 nm (23 mW; 10 J/cm2; 14 J per LED). PBM and physical therapy sessions (30 minutes, twice a week) will be conducted over 12 weeks.
89224929|NCT06113614|Sham Comparator|Control Group|In the control group (standard physical therapy combined with simulated PBM), participants will receive an identical device to the active one, but only the light from the activation plug and the sound will be triggered when they press the button, while the internal LEDs will remain off.
89224930|NCT06111781|Active Comparator|Stereotactic body radiotherapy|SBRT Though a range of doses are delivered nationally for IR prostate cancer, the most common regimen is 7.25 Gy- 8.00 Gy x 5 fractions, given over 2 weeks.
89224931|NCT06111781|Active Comparator|Relugolix and SBRT|SBRT and Relugolix SBRT along with 30 days of total relugolix (study drug) will be used. Relugolix starting 14 days to 17 days prior to the first treatment.
89224932|NCT06111547|Experimental|Cohort 1: TAK-279 30 mg|Participants will receive a single dose of TAK-279 30 milligram (mg) oral tablet on Day 1 followed by Day 6 to Day 19 once daily under fasted condition.
89224933|NCT06111547|Experimental|Cohort 2: TAK-279 60 mg|Participants will receive a dose of TAK-279 60 mg (2*30mg) oral tablets on Day 1 followed by Day 6 to Day 19 once daily under fasted condition.
89224934|NCT06111547|Placebo Comparator|Cohort 1 and 2: Placebo 30 mg or 60 mg|Participants will receive TAK-279 30 mg or 60 mg (2*30mg) matching placebo oral tablets on Day 1 followed by Day 6 to Day 19 once daily under fasted condition.
89224935|NCT06111313|Experimental|Focal Therapy lattice extreme ablative dose (FTLEAD), RT Only, Arm A|Participants in this group will receive the FTLEAD treatment only and will be followed for up to 5.5 years.
89224936|NCT06111313|Experimental|Focal Therapy lattice extreme ablative dose (FTLEAD), uSTADT, Arm B|Participants in this group will receive the FTLEAD treatment and ultra short-term androgen deprivation therapy (ADT) and will be followed for up to 5.5 years.
89224937|NCT06111313|Experimental|Lattice extreme ablative dose followed by hypofractionated RT (HypoLEAD), Arm C|Participants in this group will receive LEAD RT followed by moderately hypofractionated RT (HypoLEAD) and standard of care androgen deprivation therapy and will be followed for 5.5-8 years.
89224938|NCT06111313|Experimental|Lattice extreme ablative dose followed by hypofractionated RT (HypoLEAD), uSTADT, Arm D|Participants in this group will receive LEAD RT with ultra short-term ADT followed by moderately hypofractionated RT (HypoLEAD) and standard of care ADT and will be followed for 5.5-8 years.
89224939|NCT06109155|Active Comparator|High dose tranexamic acid + high ACT level|high dose tranexamic acid: 50mg/kg ACT level: > 600 sec
89224940|NCT06109155|Active Comparator|High dose tranexamic acid + low ACT level|high dose tranexamic acid: 50mg/kg ACT level: 400~ 600 sec
89224941|NCT06109155|Active Comparator|Low dose tranexamic acid + low ACT level|Low dose tranxeamic acid: 20mg/kg ACT level: 400~ 600 sec
89224942|NCT06109155|Placebo Comparator|Low dose tranexamic acid + high ACT level|Low dose tranxeamic acid: 20mg/kg ACT level: > 600 sec
89224943|NCT06108050|Experimental|Part A1 Dose Exploration: JZP898 monotherapy|
89224944|NCT06108050|Experimental|Part A2 Dose Exploration: JZP898 in combination with pembrolizumab|
89224945|NCT06108050|Experimental|Part B Combination Expansion: JZP898 in combination with pembrolizumab|
89224946|NCT06106919||dienogest|
89224947|NCT06106919||GnRH agonist|
89224948|NCT06106919||GnRH antagonist|
89224949|NCT06106477|Experimental|Intermittent Fasting|Enrolled subjects are expected to start the study intervention after completion of definitive therapy and within three months of starting AET.
89224950|NCT06105775|Experimental|Beetroot Juice|70 ml of a nitrate-enriched beetroot extract juice, containing 400mg of nitrate, once daily for 154 consecutive days.
89224951|NCT06105775|Placebo Comparator|Placebo Juice|70 ml formulation administered once daily, designed to have a similar taste, smell, and texture to the nitrate-enriched beetroot extract juice, 154 consecutive days.
89224952|NCT06105723|Experimental|Path-HA care|A 14-week care initiative comprising two phases is provided, which are the 2-week ICOPE-based personalized care planning phase, and the 12-week healthy aging empowerment phase.
89224953|NCT06105723|No Intervention|Control|No care intervention will be provided.
89224954|NCT06105008|Experimental|Disitamab Vedotin + Toripalimab|Disitamab Vedotin（RC48-ADC）with Toripalimab （JS001）arm
89224955|NCT06105008|Active Comparator|Disitamab Vedotin|Disitamab Vedotin（RC48-ADC） arm
89224956|NCT06104917|Experimental|High Dose Maolactin|Maolactin 500mg per day - 2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day
89224957|NCT06104917|Experimental|Low Dose Maolactin|Maolactin 250mg per day - 1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day
89224958|NCT06104917|Placebo Comparator|Maltodextrin|Placebo capsule - 2 capsules containing Maltodextrin per day
89224959|NCT06101823|Active Comparator|OpSCF|OpSCF, 600 mg, subcutaneously, every two weeks x 14 weeks
89224960|NCT06101823|Placebo Comparator|Placebo|Matched placebo, subcutaneously, every two weeks x 14 weeks
89224961|NCT06101823|Active Comparator|Open Label Extension|Subjects may choose to continue in an Open Label Extension (OLE) phase if they complete the randomized phase. All subjects regardless of treatment assignment in the randomized phase will receive OpSCF, 600 mg every 4 weeks for up to 36 weeks.
89224962|NCT06100913|Experimental|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|Healthy adults who are at no risk for exposure to Ebola Virus and are not prior recipients of an Ebola vaccine receive a single dose of recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP).
89224963|NCT06100471||case|Patients with endometriotic adnexal pathology
89224964|NCT06100471||control|Patients with non endometriotic adnexal pathology
89224965|NCT06100471||analytical control|Patients with no gynecological pathology, not undergoing surgery
89224966|NCT06099288|Experimental|Home-Based Video and Motivational Interviewing Intervention|The intervention will be delivered in English or Spanish by a trained CHW and consists of three home-based visits with tailored print materials, text-messages delivered 2x/week, followed by monthly tailored print materials and phone calls during the last three months of the intervention. For in-home visits, the CHW will deliver a Motivational Interviewing session based on scripts developed in the R34. For phone calls, parents will receive a 30-minute Motivational Interviewing phone call to check in on goals and barriers and reinforce earlier concepts. For text messages, parents will be sent two times/week messages related to objectives targeted during that month's visit, such as parents setting good examples and giving children autonomy in eating. For print materials, parents will receive printed materials, highlighting nutrition and parental feeding guidance.
89224967|NCT06099288|Active Comparator|Read Educate and Develop Youth (READY) Comparison|As done in the R34, the comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education (Refs). Families in the comparison arm will receive the same intervention components as the intervention arm, but these will be focused on child reading rather than nutrition. Parents will send a video of themselves reading with a child, receive 3 home visits and 48 text-messages as well as newsletters for each visit. Instead of receiving cooking materials during the second home visit, they will receive books to read with their children.
89224968|NCT06099275||Preeclampsia|People with preeclampsia will be recruited at the time of diagnosis or suspected diagnosis of preeclampsia, according to accepted definitions of preeclampsia,2 nulliparous, singleton pregnancy, ≥ 20 weeks' gestation, without any preexisting cardiovascular, hepatic, or respiratory problems, no preexisting uterine abnormality including benign tumors, or placental adhesive disorder, not in labor, prior to treatment for preeclampsia, body mass index ≤ 40 kg/m2, age 18 to 50 years. Preeclampsia with severe features will be defined using the American College of Obstetrics and Gynecology definition
89224969|NCT06099275||Healthy Normotensive|Healthy pregnant people will be defined as American Society of Anesthesiologists (ASA) Classification II with no significant medical or surgical illness, nulliparous (first pregnancy beyond 20 weeks' gestation), non-smokers, singleton pregnancy with no uterine abnormalities and normally defined placentation. They will not be receiving any vasoactive medication including salbutamol or thyroid replacement hormones or have ruptured membranes.
89224970|NCT06098118|Experimental|Decision Aid|Participants will receive the adapted MyMammogram decision aid that includes environmental risk information.
89224971|NCT06097663|Experimental|Treatment Sequence 1|Treatment Sequence 1
89224972|NCT06097663|Experimental|Treatment Sequence 2|Treatment Sequence 2
89080649|NCT02730013|Experimental|Square Stepping Exercise|Square-Stepping Exercise (SSE) Intervention Participants in this group will attend a square-stepping exercise intervention 60 minutes: 5 minute for attendance, 5-10 minute warm-up 40-45 minute SSE and 5-10 minute cool-down, on two days a week for a duration of 12 weeks.
89080650|NCT02730013|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
89080651|NCT02742805|Experimental|High Dose Vitamin D|Participants receive high dose of Vitamin D (4,000 IU/day) in addition to standard of care dose of Omalizumab.
89080652|NCT02742805|Active Comparator|Low Dose Vitamin D|Participants receive low dose of Vitamin D (400 IU/day) in addition to standard of care dose of Omalizumab.
89080653|NCT03204643|Experimental|BH-VPN|A bundle of usual care components applied consistently and completely, plus access to mental health trained patient navigators and navigation services.
89080654|NCT03204643|No Intervention|Usual Care|The standard intervention (Control - Usual Care) is given in this population. May contain some of the BH-VPN components.
89080655|NCT02729779|Experimental|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
89080656|NCT02729779|Active Comparator|Aerobic Group|The Aerobic Group will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
89080657|NCT02729857|Experimental|Familial hypercholesterolemia|Subjects diagnosed with familial hypercholesterolemia receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
89080658|NCT02729857|Active Comparator|Healthy|Subjects with no chronic diseases receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
89080659|NCT02732743|Other|Food Supplement Physiomanna® Baby|Dosage: 1g/kg body
89080660|NCT02732431|Other|trisomy 21|Parents will complete two sleep symptom questionnaires (PSQ-SRBD and CSHQ) and children will be evaluated by a paediatric pulmonologist and allergist with skin allergy test. An Ear, Nose and Throat specialist will complete two questionnaires (CAS-15 and SCR) carrying a nasopharyngoscopy. Then, children will perform an overnight polysomnography in the Department of Paediatric Functional Investigations of University Hospital in Nice.
89080661|NCT02742259||Beta Cutoff|Assay
89080662|NCT02742259||Pivotal|Assay
89080663|NCT02729623|Experimental|Single CannaHALER dose 10 ± 0.1 mg|Single dose 10 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
89080664|NCT02729623|Experimental|Single CannaHALER dose 15 ± 0.1 mg|Single dose 15 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
89080665|NCT02729623|Experimental|Single CannaHALER dose 20 ± 0.1 mg|Single dose 20 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
89080666|NCT02729623|Experimental|Single CannaHALER dose 25 ± 0.1 mg|Single dose 25 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
89224973|NCT06097663|Experimental|Treatment Sequence 3|Treatment Sequence 3
89224974|NCT06097663|Experimental|Treatment Sequence 4|Treatment Sequence 4
89224975|NCT06097663|Placebo Comparator|Treatment Sequence 5|Treatment Sequence 5
89224976|NCT06097559||Clinical Outcomes in a Receptive Endometrium|"Enrolled patients that according to the ERA® report are receptive.~The only additional intervention that patients will undergo, apart from those already scheduled for their ART, is the collection of an endometrial biopsy and endometrial fluid.~No drugs will be administered as per the study."
89224977|NCT06097559||Clinical Outcomes in a Non-receptive Endometrium|"Enrolled patients that according to the ERA® report have a displaced WOI and are non-receptive.~The only additional intervention that patients will undergo, apart from those already scheduled for their ART, is the collection of an endometrial biopsy and endometrial fluid.~No drugs will be administered as per the study."
89224978|NCT06097078||Eso-SPONGE®|endoluminal vacuum therapy to prevent anastomotic leakage after esophagectomy due to esophageal cancer
89224979|NCT06093490||Absence Seizure|Age 4-12, Typical Absence Seizure captured during hyperventilation
89224980|NCT06093490||Control Group|Age 4-12, Control Group without seizure activity during hyperventilation
89224981|NCT06089889|Experimental|Group 1|Group 1 will receive ice application as intervention 3 minutes before venous puncture.
89224982|NCT06089889|Experimental|Group 2|Group 2 will be control group, without ice application.
89224983|NCT06088381|Experimental|Intermediate Risk Experimental Observation|"Requires the following criteria:~Pathological T1-3 N1-2 with negative surgical margins~Absent or microscopic extracapsular extension(ECE) (≤1mm)~ctDNA positive pre-operatively and negative post-operatively~This group will undergo observation on the experimental arm of the study. They will be monitored for toxicity, Quality of Life (QoL) and outcomes evaluation. Suspected locoregional recurrence (LRR) based on physical examination, imaging or increasing ctDNA will undergo completion of workup at the discretion of the University of Maryland Head and Neck tumor board. LRR will be offered salvage treatment based on recommendations from multi-disciplinary discussion. Salvage therapy could include surgical resection (with or without adjuvant treatment), and definitive RT (with or without chemotherapy)."
89224984|NCT06082167|Experimental|Zanzalintinib + Pembrolizumab|Subjects with R/M HNSCC will receive zanzalintinib + pembrolizumab
89224985|NCT06082167|Placebo Comparator|Zanzalintinib-Matched Placebo + Pembrolizumab|Subjects with R/M HNSCC will receive zanzalintinib-matched placebo + pembrolizumab
89224986|NCT06079281|Placebo Comparator|Placebo Group|During the Randomized Evaluation Period, the placebo group will receive placebo on Day 1, followed by once every 2 weeks (q2w) via SC injection for 24 weeks. Participants will enter the OLE Period and receive bodyweight dependent doses of either 20mg, 35mg, or 50mg of ALXN1850 and continue q2w dosing with ALXN1850 for up to 132 weeks.
89224987|NCT06079281|Experimental|ALXN1850 Group|Starting at Day 1 of the Randomized Evaluation Period, the ALXN1850 group will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once q2w via SC injection, for 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.
89224988|NCT06075264|Active Comparator|Artesunate ointment|Artesunate formulated as topical ointment, 40% Four 5-day cycles of artesunate ointment every 2 weeks
89224989|NCT06075264|Placebo Comparator|Placebo ointment|Placebo ointment Four 5-day cycles of placebo ointment every 2 weeks
89224990|NCT06075043|Experimental|AND017 Dose A three times weekly|
89224991|NCT06075043|Experimental|AND017 Dose B three times weekly|
89224992|NCT06075043|Experimental|AND017 Dose C three times weekly|
89224993|NCT06075030|Experimental|AND017 Dose A three times weekly|
89224994|NCT06075030|Experimental|AND017 Dose B three times weekly|
89224995|NCT06075030|Experimental|AND017 Dose C three times weekly|
89224996|NCT06074549||Open Label|DynamX Novolimus-eluting Coronary Bioadaptor System
89224997|NCT06071182|Experimental|Task-oriented therapy|Traditional physiotherapy for 30 minutes a day, twice a week for 4 weeks (Passive upper extremity Normal Joint Movements, 3-way and 1 set of 10 repetitions passive stretches for the shoulder (bilateral), 2-way, 1 set of 10 repetitions passive stretches at the elbow level) + 2 times a week a day Fruit ninja game on tablet in 20 minutes
89224998|NCT06071182|Sham Comparator|Sham-controlled|Same time traditional therapy + 5 minutes sham intervention
89225002|NCT06070597|Experimental|Arm 1: Iclepertin treatment+ Placebo to Moxifloxacin|Placebo to moxifloxacin (Day 1) + Iclepertin (Day 1-12) + Placebo to moxifloxacin (Day 13
89225003|NCT06070597|Experimental|Arm B1: Iclepertin Placebo treatment + Moxifloxacin|Moxifloxacin (Day 1) + Placebo to iclepertin (Day 1-12) + Placebo to moxifloxacin (Day 13) - Arm B1
89225004|NCT06070597|Experimental|Arm B2: Iclepertin Placebo treatment + Placebo to Moxifloxacin|Placebo to moxifloxacin (Day 1) + Placebo to iclepertin (Day 1-12) + Moxifloxacin (Day 13) - Arm B2
89225005|NCT06069726|Experimental|Pre-Surgery Atezolizumab|80 patients with rGBM who are eligible for surgical debulking will be treated with one dose of atezolizumab prior to resection. Resected tissue will be used to pathologically confirm recurrence, and tumor tissue will be analyzed by whole exome sequencing (WES). Anticipating that40 patients with low TMB and 40 with high TMB will be treated. All treated subjects will receive post-operative atezolizumab until progression, unacceptable toxicity, death or withdrawal of consent. Post-atezolizumab survival will be compared between low vs high TMB arms to determine if low TMB associates with longer survival after atezolizumab
89225006|NCT06068985|Experimental|PHESGO™-Based Neoadjuvant Therapy for HER2-Positive Early Breast Cancer|This is a single-arm phase II neoadjuvant study using PHESGO™. Participants will receive three cycles of neoadjuvant PHESGO™, with a specific dosage regimen. After three cycles, participants will be reevaluated based on their PET-CT response. PET-CT response is defined as a ≥40% reduction in SUVMax without metabolic progression in non-target lesions. Responders will receive 5 additional cycles of PHESGO™ before surgery. Non-responders will exit the study, following institutional guidelines. Local surgery follows 8 cycles. Adjuvant therapy varies based on pCR status: 1 year of PHESGO™ for pCR; T-DM1 for 14 cycles or investigator's choice chemotherapy plus 10 additional adjuvant cycles of PHESGO™ for non-pCR cases.
89080667|NCT04190719|Experimental|Paprika group|Patients coming for elective major surgery will participate to Paprika program
89080668|NCT04190719|No Intervention|Historical group|Patients previously operated with same characteristics
89080669|NCT02690389|No Intervention|Control|standard procedure is used
89080670|NCT02690389|Sham Comparator|Flumazenil only group|flumazenil is given
89080671|NCT02690389|Active Comparator|control with acupuncture|control with acupuncture
89080672|NCT02690389|Active Comparator|control with acupuncture and flumazenil|control with acupuncture and flumazenil
89080673|NCT03838861|Active Comparator|Control|Standard follow-up in doctors setting
89080674|NCT03838861|Experimental|Intervention|Nurse-led follow-up with focus on empowerment and need assessment by use of ePROMS
89080675|NCT02732197||Sedation (S)|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
89080676|NCT02732197||No sedation (NS)|Parturients who did not receive any sedative agent after the spinal anesthesia performance.
89080677|NCT02729935|Experimental|Parecoxib|40 mg of intravenous parecoxib (DYNASTAT )30 min before surgery
89080678|NCT02729935|Placebo Comparator|Placebo|An equal volume of saline
89080679|NCT02742415|Experimental|Cancer patients receiving hand massage|Caring Hand massage will be provided to the outpatients undergoing chemotherapy
89080680|NCT02742337||Test|Newly diagnosed female patients with rheumatoid arthritis who have not previously used a disease modifying anti-rheumatic drug.
89080681|NCT02742337||Control|Female patients not having a diagnosis of rheumatoid arthritis and who have not previously used a disease modifying anti-rheumatic drug.
89080682|NCT02721667|No Intervention|Enhanced Usual Care|"Participants receive a home BP monitor, are taught how to measure home BP and are encouraged to take BP readings to appointments with their providers. In addition, they will be reminded to perform a home BP series each quarter for study outcome purposes, which will encourage self-monitoring.~Home BP readings will be teletransmitted for data collection purposes but neither participants nor providers will have access to the these readings. High BP levels that trigger safety alerts to research personnel are the only exception - participants and their primary care providers will be made aware of these."
89080683|NCT02721667|Active Comparator|Telemonitoring and Case Management|"Home BP series mean, trends and individual readings will be generated for use by the case manager. Participants in this arm will each be assigned a pharmacist case manager who holds full prescribing privileges and who will:~Administer health behaviour modification counselling, teach BP self-monitoring, and monitor medication adherence;~Review telemonitored health portal BP summaries and make medication regimen adjustments according to guideline-concordant study protocol;~Fax a summary of these adjustments to the participant's primary care provider (to make them aware of treatment changes); and~Facilitate communication between participants and providers."
89080684|NCT02729389|Experimental|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
89080685|NCT02729389|Experimental|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
89080686|NCT02729233|Other|patients receiving biopsies|UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE).
89080687|NCT02729467|Experimental|Panel 1|Participants will receive a single 250 milligram (mg) dose of JNJ-53718678 on Day 1 and 200 mg itraconazole once a day on Days 4 to 11 along with a single 250-mg dose of JNJ-53718678 on Day 9.
89225007|NCT06067984|Experimental|Arm A|Evaluate the efficacy and safety of a digital therapeutic as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
89225008|NCT06067737|Experimental|High-dose psilocybin + buprenorphine|High-dose psilocybin (30 mg) session following standard-of-care outpatient buprenorphine induction
89225009|NCT06067737|Active Comparator|Very low-dose psilocybin + buprenorphine|Very low dose psilocybin session (1 mg) following standard-of-care outpatient buprenorphine induction
89225010|NCT06066424|Experimental|Dose Escalation|"Participants who are enrolled in Dose Escalation, Participants will be assigned to a dose level of TROP2- CAR-NK cells based on when you join this study. Up to 5 dose levels of TROP2-CARNK cells will be tested. At least 3 participants will be enrolled at each dose level.~The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of TROP2-CAR-NK cells is found.~Participants who are enrolled in the Dose Expansion, Participants will receive TROP2-CAR-NK cells at the recommended dose that was found in the Dose Escalation."
89225011|NCT06066424|Experimental|Dose Expansion Cohort 1|"Participants who are enrolled in Dose Escalation, Participants will be assigned to a dose level of TROP2- CAR-NK cells based on when you join this study. Up to 5 dose levels of TROP2-CARNK cells will be tested. At least 3 participants will be enrolled at each dose level.~The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of TROP2-CAR-NK cells is found.~Participants who are enrolled in the Dose Expansion, Participants will receive TROP2-CAR-NK cells at the recommended dose that was found in the Dose Escalation."
89225012|NCT06066424|Experimental|Dose Expansion Cohort 2|"Participants who are enrolled in Dose Escalation, Participants will be assigned to a dose level of TROP2- CAR-NK cells based on when you join this study. Up to 5 dose levels of TROP2-CARNK cells will be tested. At least 3 participants will be enrolled at each dose level.~The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of TROP2-CAR-NK cells is found.~Participants who are enrolled in the Dose Expansion, Participants will receive TROP2-CAR-NK cells at the recommended dose that was found in the Dose Escalation."
89225013|NCT06066008|Experimental|group 1|IVT administration of a single low dose ZM-01 injection
89225014|NCT06066008|Experimental|group 2|IVT administration of a single high dose ZM-01 injection
89225015|NCT06063213||Liver Transplant Group|Patients <1 month post-surgery for liver transplant only.
89225016|NCT06063213||Liver-Kidney Transplant Group|Patients <1 month post-surgery for simultaneous kidney-liver transplant only.
89225017|NCT06062966|Experimental|Treatment arm|
89225018|NCT06061991|Experimental|Intervention group|Mobile instant messaging-based lifestyle intervention
89225019|NCT06061991|Active Comparator|Control group|Brief advice on GDM prevention
89225020|NCT06060899|Active Comparator|Standard pneumoperitoneum pressure|Laparoscopic liver resection performed in standard (14mmHg) pneumoperitoneum pressure
89080688|NCT02729467|Experimental|Panel 2|Participants will receive a single 500-mg dose of JNJ-53718678 on Day 1; a single 600-mg dose of rifampicin along with a single 500-mg dose of JNJ-53718678 on Day 4 and 600 mg rifampicin once daily on Days 5 to 11 along with a single 500-mg dose of JNJ-53718678 on Day 9.
89080689|NCT02727205|Experimental|Single Arm|One-half (½) of the test patch and one-half (½) of the reference patch (Rotigotine Transdermal System) was applied daily to the same site for each product over a 21 day period followed by a 14 day rest phase and a 48 hour challenge phase.
89080690|NCT02721433|Active Comparator|4 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
89080691|NCT02721433|Active Comparator|12 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
89080692|NCT02726893||patients undergoing colonoscopy|patients undergoing colonoscopy were observed in terms of the bowel preparation quality which is measured by Boston Bowel Preparation Scale (BBPS).
89080693|NCT02729155|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
89080694|NCT02729155|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
89080695|NCT02729155|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
89080696|NCT02729155|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
89080697|NCT02721199||Prospective Cohort|Neural Respiratory Drive Automated EMGpara assessment
89080698|NCT02721043|Experimental|Personalized Genome Vaccine 001|"PGV-001 (peptides + Poly-ICLC)~Peptides: 100mcg per peptide per dose.~Poly-ICLC (Hiltonol®, Oncovir): 1.4mg (0.7mL, 2mg/mL)"
89080699|NCT02721121|Active Comparator|circumferential pulmonary vein isolation|circumferential pulmonary vein isolation
89080700|NCT02721121|Experimental|Linear ablation in addiction to pulmonary vein isolation|Linear ablation in addiction to pulmonary vein isolation
89080701|NCT02729311|Experimental|Group 1|Paired PLIÉ Program, immediate start
89080702|NCT02729311|Other|Group 2|Paired PLIÉ Program, delayed start
89080703|NCT02729077||Increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry. Patients in this arm will be especially evaluated for hypoxemia and other complications.
89080704|NCT02729077||Not increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry.
89080705|NCT02728999|Other|Group A|Steep Trendelenburg
89080706|NCT02728999|Experimental|Group B|Decreased Trendelenburg
89080707|NCT02727049|Experimental|injured athlete for OMM|Participating athletes who sustain an injury will receive standard of care with the Intervention osteopathic manipulative medicine (OMM)
89080708|NCT02727049|No Intervention|injured athlete no OMM|Participating athletes who sustain an injury will receive standard of care withOUT osteopathic manipulative medicine (OMM)
89080709|NCT02720887||pregnant woman|Patient to receive an amniocentesis for medical reasons other than study and who will have a measure of nanoparticles load
89080710|NCT02728921|Active Comparator|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.
89080711|NCT02728921|Experimental|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight
89080712|NCT02728843|Experimental|Deferiprone 300 mg|One-half of a 600 mg tablet of deferiprone twice a day, for a total daily dosage of 600 mg
89080713|NCT02728843|Experimental|Deferiprone 600 mg|One 600 mg tablet of deferiprone twice a day, for a total daily dosage of 1200 mg
89080714|NCT02728843|Experimental|Deferiprone 900 mg|One and a half 600 mg tablets of deferiprone twice a day, for a total daily dosage of 1800 mg
89080715|NCT02728843|Experimental|Deferiprone 1200 mg|Two 600 mg tablets of deferiprone twice a day, for a total daily dosage of 2400 mg
89080716|NCT02728843|Placebo Comparator|Placebo|Depending on dosage cohort, either one half-tablet, one tablet, one and a half tablets, or two tablets of placebo, twice a day
89080717|NCT02726503|Experimental|Treatment Arm|
89080718|NCT02720965|Experimental|Electronic pump|Continuous nerve blocks Remote-controlled perineural local anesthetics delivery
89080719|NCT02720965|No Intervention|single injection|single injection
89080720|NCT02720731||children|aged from 1 to 18 years with motor disorder
89080721|NCT02720731||adults|aged from 18 to 80 years with motor disorder
89080722|NCT02728765|Active Comparator|auto CPAP|Each patient will be interviewed by the physician on duty and invited to participate in the overnight hospital based auto continuous positive airway pressure (CPAP) titration study for 1 night and then commencement of auto CPAP treatment for 6 months.
89225021|NCT06060899|Experimental|Low pneumoperitoneum pressure|Laparoscopic liver resection performed in low (10mmHg) pneumoperitoneum pressure
89225022|NCT06057883|Experimental|Probiotic arm|All participants will be given the active probiotic product as this is a single arm, open-label study.
89225023|NCT06057337|Experimental|"Families with Pride (Familias con Orgullo)"|Participants in this group will receive the Families with Pride (Familias con Orgullo) intervention. The intervention consists of seven multi parent group sessions, three multi adolescent group sessions, and four family sessions (parents participant in a total of 11 sessions, adolescents participate in a total of seven sessions) that will be delivered by a facilitator to the parent-child dyad across 12 weeks.
89225024|NCT06057337|No Intervention|Community Practice|In this condition, participants will not receive an intervention, only the standard of care services for up to 12 weeks.
89225025|NCT06056687|Experimental|Alpha Lipoic Acid Group|ALA 600 mg once daily
89225026|NCT06056687|Placebo Comparator|Placebo Group|the second group on placebo once daily
89225027|NCT06055920|Active Comparator|FlowTriever|Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.
89225028|NCT06055920|Active Comparator|Anticoagulation|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
89225029|NCT06055608|Experimental|(Group 1): Belatacept+Sirolimus group|Participants in this group will receive antithymocyte globulin (ATG) + steroid taper + belatacept + (tacrolimus bridge, day 0-14) with conversion to sirolimus (day 30 +/-14 days)
89225030|NCT06055608|Active Comparator|(Group 2): Tacrolimus + Mycophenolate Mofetil (MMF) group|Participants in this group will receive anti-thymocyte globulin (ATG) + steroid taper + tacrolimus + MMF
89225031|NCT06055088|Experimental|exercise with massage ball|The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week. A detailed exercise brochure will be given to the exercise group. Patients in the massage ball group will be given a massage ball to be used in exercises.
89225032|NCT06055088|Experimental|exercise with stress ball|The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week. A detailed exercise brochure will be given to the exercise group. Patients in the stress ball group will be given a stress ball to be used in exercises
89225033|NCT06055088|No Intervention|control|No intervention will be applied to the patients in the control group during the follow-up period, only data collection forms will be applied.
89225034|NCT06052813|Experimental|200mg QD|The starting dose cohort(200mg QD) where accelerated titrated dose-escalation method is applied, a patient will initially receive a single dose BN104 on Day 1 of Cycle 0 (3 days prior to Day 1 of Cycle 1) to evaluate the concentration of BN104 up to 72 hours after administration and the safety of single dose of BN104. Then the patient begins continuous treatment with BN104 200 mg QD on Day 1 of Cycle 1 by every 28-day treatment cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
89225035|NCT06052813|Experimental|200mg BID|After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
89225036|NCT06052813|Experimental|400mg BID|After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
89225037|NCT06052813|Experimental|600 BID|After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
89080723|NCT02728765|Placebo Comparator|Subtherapeutic CPAP|Following detection of obstructive sleep apnea (OSA), each patient randomized to this arm will receive the same CPAP education, mask fitting and short auto CPAP trial for acclimatization but their auto CPAP device will be set at a subtherapeutic level of 4 cmH20 for use at home. The patients randomized to both arms will receive the same general education about OSA, sleep hygiene, avoidance of alcohol, and weight reduction if appropriate.
89080724|NCT02720497|Experimental|60-minute Prolonged Exposure|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
89080725|NCT02720497|Active Comparator|90-minute Prolonged Exposure|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
89080726|NCT05372107|Experimental|Group 1|One drop of 0.001% AG-80308, two times daily to both eyes for 3 months
89080727|NCT05372107|Experimental|Group 2|One drop of 0.03% AG-80308, two times daily to both eyes for 3 months
89080728|NCT05372107|Experimental|Group 3|One drop of 0.1% AG-80308, two times daily to both eyes for 3 months
89080729|NCT05372107|Experimental|Group 4|One drop of 0.03% AG-80308, new formulation, two times daily to both eyes for 3 months
89080730|NCT02726737|Experimental|sodium bicarbonate|0.7 mL of 8.4% sodium bicarbonate & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
89080731|NCT02726737|Active Comparator|Non-sodium bicarbonate|Sterile distilled water & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
89080732|NCT02720575|Active Comparator|A|50,000 IU of crystalline D2 in 5 capsules.. Vitamin D2 in its natural state consumed orally via capsule
89080733|NCT02720575|Active Comparator|B|50,000 IU of crystalline D3 in 5 capsules.. Vitamin D3 in its natural state consumed orally via capsule
89080734|NCT02720575|Active Comparator|C|50,000 IU of vitamin D2 from vitamin D2 yeast in 5 capsules. Vitamin D generated in yeast. Acts as a comparator to the yeast in bread.
89080735|NCT02720575|Active Comparator|D|50,000 IU of vitamin D2 from yeast cell walls in 5 capsules. Yeast cell walls rich in Vitamin D. Acts as a comparator to the yeast in bread.
89080736|NCT02720575|Experimental|E|50,000 IU of vitamin D2 from 2 slices of bread made from bread. Bread raised with yeast rich in vitamin D. Main experimental arm.
89080737|NCT02720575|Experimental|F|50,000 IU of vitamin D2 from 2 slices of bread. Bread raised with yeast and yeast cell walls rich in vitamin D.
89080738|NCT02720341|Experimental|ARMin|Therapy on ARMin robotic device
89080739|NCT02726425|Experimental|Second Life Participants|Half of participants will receive the Diabetes Self Management Medical Group Visits intervention while meeting in the virtual world (Second Life platform)
89080740|NCT02726425|Active Comparator|Face-to-Face Participants|The other half of the participants will receive the Diabetes Self Management Medical Group Visitsintervention while meeting face-to-face in person at Boston Medical Center.
89080741|NCT02726191|Experimental|Posit Science|
89080742|NCT02726191|Experimental|Lumosity|
89080743|NCT02728609||Blue towel: vacuum pack device|Trauma subjects undergoing temporary abdominal closure with vacuum pack technique
89080744|NCT02728609||ABThera abdominal closure|Trauma subjects undergoing temporary abdominal closure with the commercially available ABThera vacuum device
89080745|NCT02728453|Experimental|Empagliflozin|25 mg/d empagliflozin + matching glimepiride placebo for 24 weeks.
89080746|NCT02728453|Active Comparator|Glimepiride|2 or 4 mg/d glimepiride+ matching empagliflozin placebo for 24 weeks.
89080747|NCT02728687|Experimental|Mannitol and menthol cream|Mannitol and menthol cream (Water, Mannitol, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the menthol cream will be applied to the participant's feet. Whether the mannitol and menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
89225038|NCT06052813|Experimental|800 BID|After completion of DLT evaluation for the first dose cohort (200 mg QD), patients will begin to receive twice daily (BID) dosing frequency in each 28-day treatment cycle for the subsequent dose cohorts for which conventional 3+3 design is used until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first.
89080748|NCT02728687|Active Comparator|Menthol cream|Cream containing menthol (Water, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the mannitol and menthol cream will applied to the participant's feet. Whether the menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
89080749|NCT02720263|Experimental|Double-Blind ASP4345 Multiple Dose Levels|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered under fasting conditions. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions.
89080750|NCT02720263|Placebo Comparator|Double-Blind Placebo Multiple Dose|Matching placebo capsules will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, matching placebo capsules will be administered with food. On days 2-6 and 8-13, matching placebo will be administered under fed conditions.
89080751|NCT02720263|Experimental|Open-Label ASP4345|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered with food. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions. This is an optional cohort where subjects will be enrolled to further characterize pharmacodynamics in the event a higher sample size is necessary to determine changes in electrophysiological biomarkers.
89080752|NCT02726269|Active Comparator|CLA (Clarithro+Lanso+Amoxi)|Clarithromycin 500 mg bid, Lansoprazole 30 mg bid and Amoxicillin 500 bid, tablets of oral administration, during 10 days.
89080753|NCT02726269|Experimental|PLA (Panto+Levoflox+Azithro)|Pantoprazole 80 mg od, Levofloxacin 500 mg od and Azithromycin 500 mg od, tablets of oral administration, during 10 days.
89080754|NCT02720029|Experimental|pH/impedance monitor|
89080755|NCT02728375|Experimental|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 45 minutes,three times per week for sixteen weeks
89080756|NCT02728375|Active Comparator|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength. The exercises will be performed 45 minutes, three times per week for sixteen weeks
89080757|NCT02719951|Experimental|autistic patients|[18F]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
89080758|NCT02719951|Experimental|FXS patients|[18F]FPEB PET imaging MRI Biological samples
89080759|NCT02719951|Experimental|Healthy subjects|[18F]FPEB PET imaging MRI Biological samples
89080760|NCT02719717|Experimental|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
89080761|NCT02728219|Experimental|hepatectomy|Comparison of Treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion
89080762|NCT02728219|Active Comparator|TACE|
89080763|NCT02728297|Experimental|Staged ETS|Video-assisted endoscopic sympathicotomy from level of T3 to level of T12 on one side
89080764|NCT02694289|Other|Metformin|Continue Metformin while admitted to hospital
89080765|NCT02694289|Other|Subcutaneous (sliding scale) Insulin|Discontinue Metformin upon admission and be placed on sliding scale subcutaneous insulin treatment while admitted to hospital
89080766|NCT02728063|Experimental|Single arm|Supplementation with Lactibiane Tolerance
89080767|NCT02719873||control group|the group with normal BMI
89080768|NCT02719873||study group|The group with the BMI more than 24.9 kg per meter square to study the impact of maternal obesity in pregnancy outcome
89225039|NCT06052228||Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
89225040|NCT06051994||AI-guided VA ablation|"This is a prospective observational multicenter registry. Patients presenting for a VT ablation at Rush will be screened for inclusion/exclusion criteria and will be included in the study appropriately. The EP specialist conducting the ablation and/or the electrophysiology fellows involved in the procedure will be responsible for patients screening and inclusion. Further data completion (pre-ablation diagnostic procedures, baseline characteristics, ablation data, periprocedural period before discharge home) will be extracted from EPIC and from the study center's Cardiac Mapping System's hard drive.~Follow-up data will be collected from any in-person and virtual clinic visits as per standard of care within 12 months after the index ablation procedure. Follow-up data will also be collected by chart review from routine in-person and remote device interrogations of their ICD devices also conducted as standard of care."
89225041|NCT06051864|Active Comparator|Active VeNS|The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
89225042|NCT06051864|Placebo Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
89225043|NCT06050681|Experimental|Mindfulness Intervention|Participants will engage with a mobile application to complete 21 sessions lasting approximately 11 minutes of mindfulness training over 6 weeks.
89225046|NCT06049680|Other|Single arm SMOFlipid® (lipid injectable emulsion)|Investigational drug: SMOFlipid® (lipid injectable emulsion).
89225047|NCT06048406|Experimental|Intervention|The intervention group will receive a monthly health education intervention focused on influenza vaccination literacy for 5 months.
89225048|NCT06048406|No Intervention|Control|The control group will continue with their routine school health education for 5 months.
89080769|NCT02727985|Experimental|Pharmacist weaning schedule|The Neuromodulation clinic pharmacist will develop a weaning schedule for these patients. Schedules will be individualized taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
89080770|NCT02727985|No Intervention|Self/Family Physician weaning schedule|Patients will wean off their opioids by themselves or with their family physician without the assistance of a prepared schedule.
89080771|NCT02728141|Placebo Comparator|Water|Newborn infants with ID numbers ending in odd numbers offered 2ml distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
89080772|NCT02728141|Active Comparator|Sucrose|Newborn infants with ID numbers ending in even numbers offered 2 ml 25% sucrose in distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
89080773|NCT02719795|Experimental|Ropivacaine|Ropivacaine hydrochloride injection； Generic name：Naropin； Dosage form：Liquid、Injectable formulation； Dosage：105mg；30ml； Frequency：Once.
89080774|NCT02719795|Placebo Comparator|Normal saline|Medical Normal saline Generic name：Normal saline； Dosage form：Liquid、Injectable formulation； Dosage：30ml； Frequency：Once.
89080775|NCT02719561|Experimental|Fatigue intervention|Fatigue Intervention is to be co-designed by participants, and likely to include education, energy conservation and activity promotion. Participants will also decide the name of the Fatigue Intervention
89080776|NCT02727673||healthy volunteers|matched group
89080777|NCT02727673||hepatitis cirrhosis|negative group
89080778|NCT02727673||hepatocellular carcinoma|patients with primary HCC
89080779|NCT02726347|Active Comparator|Smokers between the ages of 19-80|current smokers between the ages of 19 and 80
89080780|NCT02726347|Active Comparator|elderly individuals (over age 50)|elderly individuals, defined as subjects age 50 years or older, without a history of frequent infections, COPD, or asthma
89080781|NCT02726347|Active Comparator|COPD subjects|COPD subjects between the age of 19 and 80, without history of recurrent bacterial infections.
89080782|NCT02726347|Active Comparator|Asthmatics subjects|Asthmatics between the ages of 19 and 80
89080783|NCT02726347|Active Comparator|Subjects with recurrent bacterial infections|Individuals between the age of 19 and 80 who have a history of frequent bacterial infections and are being evaluated for humoral immunodeficiency
89080784|NCT02726035|Experimental|Group 1 A-ABAB|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 1 will receive oral naltrexone 50 mg daily during weeks 5-7 (3 weeks). They will switch to placebo for weeks 8-10, then return to naltrexone for weeks 11-13, then placebo for weeks 14-16 (i.e., A-ABAB double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
89080785|NCT02726035|Experimental|Group 2 A-BABA|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 2 will receive oral placebo once daily during weeks 5-7. They will then be switched to oral naltrexone 50 mg daily for weeks 8-10, then return to placebo for weeks 11-13, then naltrexone for weeks 14-16 (i.e., A-BABA double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
89080786|NCT02719405|Placebo Comparator|Amino Acid Formula|
89080787|NCT02719405|Active Comparator|EHCF|Extensively Hydrolyzed Casein Formula
89080788|NCT02719405|Active Comparator|EHCF + LGG|Extensively Hydrolyzed Casein Formula + Lactobacillus GG
89080789|NCT02725957|Experimental|Trehalose 9%|Single dose administration of Trehalose 9% for IV infusion.
89080790|NCT02725957|Placebo Comparator|Saline 0.9%|Single dose administration of 0.9% saline in the same volume and duration as Treatment Arm 1 (9% trehalose)
89080791|NCT02719483|Active Comparator|rESWT + traditional conservative therapy|Radial extracorporeal shock wave therapy (rESWT) performed with the Swiss DolorClast device (EMS Electro Medical Systems, Nyon, Switzerland) plus traditional conservative therapy.
89080792|NCT02719483|Other|Traditional conservative therapy|Traditional conservative therapy alone.
89080793|NCT02719249||Men with ESRD on dialysis or transplant|
89080794|NCT05130385||Diabetic Retinopathy|Patients with various degree of diabetic retinopathy
89080795|NCT05130385||Artery and vein occlusion|Patients with history of artery or vein occlusion (central or branch artery)
89080796|NCT05130385||Glaucoma|Patients with history of glaucoma (open-angle glaucoma, chronic angle closure glaucoma)
89080797|NCT05130385||Optic nerve neuropathy|Patients with history of various optic nerve neuropathies
89080798|NCT05130385||Hereditary retinal diseases|Patients with history of various retinal dystrophies
89080799|NCT05130385||Retinal detachment|Patients history of retinal detachment
89080800|NCT05130385||Age related macular degeneration|Patients with history of age related macular degeneration
89080801|NCT05130385||Retinal changes from arterial hypertension|Patients with history of arterial hypertension
89080802|NCT05130385||Uveitis|Patients with history of uveitis intermedia and/or posterior and/or pan-uveitis
89080803|NCT05130385||Healthy|Healthy age matched control subjects
89080804|NCT02725723|Experimental|Subject after epidural injection|Subjects are patients from the clinic who have been diagnosed with Lumbar spinal stenosis and determined eligible for receiving steroidal epidural injection for pain management
89080805|NCT02727595|Experimental|CyclaPlex Implant|Implant device for reduction of the inter metatarsal angle (IMA) without osteotomy.
89080806|NCT02727517|Active Comparator|Early (≤ 60 seconds) cord clamping|Early (≤ 60 seconds) cord clamping
89080807|NCT02727517|Active Comparator|Delayed cord clamping|Delayed (≥ 180 seconds) cord clamping
89080808|NCT02719093|Experimental|recombinant FSH|recombinant FSH 150UI daily
89080809|NCT02727439|Experimental|Sedentary Subjects|Healthy lean sedentary subjects.
89080810|NCT02727439|Experimental|Athletes|Active athletes.
89080811|NCT02725255|Experimental|Papaya seed porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
89080812|NCT02725255|Active Comparator|Albendazole and Plain porridge|Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)
89080813|NCT02725255|Placebo Comparator|Plain porridge|arm receiving 300ml plain porridge daily (without papaya seeds)
89080814|NCT02718859|Active Comparator|irreversible electroporation (IRE)|Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy
89080815|NCT02718859|Experimental|IRE & NK cells|Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells
89080816|NCT00636727|Active Comparator|1|arthrocentesis
89080817|NCT00636727|Active Comparator|2|arthroscopy
89080818|NCT00636727|Active Comparator|3|arthroplasty
89080819|NCT02727361|Experimental|Cholinergic striatal imaging|Cholinergic striatal imaging (IRM and TEP) to compare the intensity of the binding of cholinergic tracer
89080820|NCT02727127||Healthy Volunteers|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
89080821|NCT02727127||Bipolar Patients|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
89080822|NCT02719015|Experimental|rAd.CD40L + Pembrolizumab|"The dose escalation phase will include rAd.CD40L dose escalation and increase in the number of injected sites/lesions. Once patients tolerate dose level 1 (1 injection site and 1x1011vp-MTD) in Dose Escalation cohort, Expansion cohort will open with same maximum number of injection sites at maximum tolerated dose from Dose Escalation cohort.~All participants receive same dosage of Pembrolizumab in both phases."
89080823|NCT02727283|Experimental|Cohort 1|Subjects will receive 1 placebo and 3 escalating doses in one of the four treatment periods. The planned dose range is 10 mg to 200 mg. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
89080824|NCT02727283|Experimental|Cohort 2|Cohort 2 will proceed after completion of the treatment periods in Cohort 1. Subjects assigned to Cohort 2 will participate in up to 4 dosing periods which include up to 2 escalating doses and placebo in Periods 1 and 2, and a pilot food effect in Periods 3 and 4. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
89080825|NCT02725333|Other|Shoulder Stabilization|Anteroposterior and superoinferior translations were assessed in patients, before and after shoulder stabilization, through a dedicated patient-specific measurement technique based on optical motion capture and computed tomography.
89080826|NCT02718937|Experimental|BTA-C585|BTA-C585 100 mg oral capsule
89080827|NCT02718937|Placebo Comparator|Placebo|Matching placebo capsule
89080828|NCT04189237|Experimental|electroacupuncture|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of two times per week for six weeks, for a total of twelve times.~Acupoint selection: needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints."
89080829|NCT04189237|No Intervention|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of two times per week for six weeks, for a total of twelve times.
89080830|NCT02725489|Experimental|Part 1 Cohort 1: 1x10^6 cells Vigil|The first part will be a safety run-in comprised of 2 cohorts that will use a 3 + 3 design to determine the Vigil dose in Part 2. Cohort 1 will receive a low dose of Vigil (1x10^6 cells/intradermal (ID) injection) in combination with durvalumab (1500 mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
89080831|NCT02725489|Experimental|Part 1 Cohort 2: 1x10^7 cells Vigil|Cohort 2 will receive Vigil at 1x10^7 cells/ID injection and durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
89080832|NCT02725489|Experimental|Part 1 Cohort -1: 1x10^5 cells Vigil|If needed, Cohort -1 will be used which will receive Vigil at 1x10^5 cells/ID injection and Durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
89080833|NCT02718781|Experimental|Talk and leaders|This group will comprise of health talk and regular contact with community leaders.
89080834|NCT02718781|Experimental|Talk, leaders and equipment|This group will comprise of health talk and regular contact with community leaders. Moreover, a home-based equipment (handgrip) will be delivered to them
89080835|NCT02718781|Active Comparator|Talk|This group will comprise of a health talk only.
89080836|NCT02716519|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks
89080837|NCT02716519|Active Comparator|Standard Card|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
89080838|NCT02716831|Experimental|Counseling & Acceptance-based Therapy|Nutritional Counseling & Acceptance-based Therapy (N-CAAT) incorporates acceptance-based behavioral strategies and nutritional counseling designed to encourage willingness to tolerate distress and the ability to pursue chosen values in an adaptive manner despite distressing internal experiences. In addition to these skills, a principal focus of the treatment will be on identifying, practicing, and achieving behavioral goals, such as normalization of eating, reduction of maladaptive dietary restraint and restriction, and elimination of compensatory behaviors.
89080839|NCT02716831|Active Comparator|Cognitive Therapy for Eating Disorders|Participants in the Cognitive Behavioral Therapy for Eating Disorders (CBT) condition will receive 20-sessions of standard CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn and published in his book Cognitive Behavioral Therapy and Eating Disorders.
89080840|NCT02339233|Experimental|Epidural Stimulator|Eligible participants will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord
89080841|NCT04124263|Experimental|Medication Time Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
89080842|NCT04124263|Experimental|Educational Short Messages|70 hypertensive patients registered for access to medications that will additionally receive text messages at the times indicated in the prescription for use of each indicated medication, in addition to educational information.
89080843|NCT02718547|Experimental|Participants receiving Combigan drops in order to reduce IOP|All of the Participants in this study will be instructed to instill combigan eye drops twice daily in one eye (randomly chosen)
89080844|NCT02725099|Active Comparator|Oral Ticagrelor|
89080845|NCT02725099|Experimental|Chewing Ticagrelor|
89080846|NCT02718703|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
89080847|NCT02325427|Experimental|real tDCS|Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
89080848|NCT02325427|Sham Comparator|sham tDCS|Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
89080849|NCT02325427|No Intervention|no stimulation|Subjects will not received any intervention.
89080850|NCT02724865|Active Comparator|Oral appliance therapy; Somnodent®|Somnodent is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
89080851|NCT02724865|Active Comparator|Oral appliance therapy; Herbst®|Herbst is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
89080852|NCT01225211|Placebo Comparator|Cohort 1: Placebo|Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).
89080853|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).
89080854|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).
89080855|NCT01225211|Placebo Comparator|Cohort 2 and 3: Placebo (HO and HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).
89225049|NCT06047691|Experimental|Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD|AIM-CBCT for PTSD is an abbreviated, intensive, multi-couple group version of cognitive-behavioral conjoint therapy for PTSD, an evidence-based treatment for PTSD delivered in a conjoint format.
89225050|NCT06047691|Active Comparator|Prevention and Relationship Education Program|PREP is an evidence-based relationship education program delivered in a multi-couple group format.
89225051|NCT06046430||Frozen Shoulder Group|The sample of the study will consist of patients who applied to Harran University Hospital and were diagnosed with frozen shoulder.
89225052|NCT06046430||Healthy Group|Healthy volunteers similar to the patient group in gender and age factors.
89225053|NCT06046222|Experimental|NS-229|Self-administer NS-229 in consecutive 28 weeks.
89225054|NCT06046222|Placebo Comparator|Placebo|Self-administer matching placebo in consecutive 28 weeks.
89080856|NCT01225211|Experimental|Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
89225055|NCT06044636|Active Comparator|Digi-physical breastfeeding counceling|"Interventions: Digi-physical breastfeeding counseling~At discharge from the maternity ward: contact with lactation consultant (breastfeeding support and care) via the support hotline with chat as soon as questions or problems arise. The hotline will be available during the whole project period.~After discharge from the maternity ward: pediatric nurse from Child Health Care Unit (CHC) will contact families and make a home visit (physical or digital), giving extended lactation advice and support. Additional home visits if needed.~After discharge until one year after childbirth: the possibility of getting into contact with specialized lactation consultant/nurse at lactation counseling units if needed.~Intervention type: Chatt via Application Alltid Öppet owned by Region Stockholm.~The intervention group will follow current healthcare routines in the Region Stockholm and will get access to an evidence-based information package about breastfeeding from pregnancy week 20."
89225056|NCT06044636|No Intervention|Usual care with physical visits|Title: Usual care with physical visits The control group will follow current healthcare routines in the Region Stockholm and will get access to an evidence-based information package about breastfeeding from pregnancy week 20.
89225057|NCT06042257|Active Comparator|Guanfacine Hydrochloride Immediate Release|Eligible participants will receive GIR for up to 8 weeks. The treatment period will consist of study product administration from day 0 through day 56 with a masked dose-escalation period from day 0 through day 49.
89080857|NCT01225211|Experimental|Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
89080858|NCT01225211|Experimental|Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
89080859|NCT01225211|Experimental|Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
89080860|NCT01225211|Placebo Comparator|Cohort 4: Placebo|Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).
89080861|NCT01225211|Experimental|Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h|Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).
89080862|NCT02685709|Experimental|Run-in phase|Oral octreotide capsules
89080863|NCT02685709|Experimental|RCT phase - Oral|Oral octreotide capsules
89080864|NCT02685709|Active Comparator|RCT phase - Injectables|Injectable somatostatin analogs (octreotide or lanreotide)
89080865|NCT02685709|Experimental|Combination phase (sub-study)|Octreotide capsules plus cabergoline
89080866|NCT02265367|Experimental|Levomilnacipran|In the first three week period levomilnacipran is evaluated whereas in the second three week period placebo is evaluated
89080867|NCT02265367|Experimental|Placebo|In the first three week period placebo is evaluated whereas in the second three week period levomilnacipran is evaluated
89080868|NCT02718469|Experimental|Ebola Vaccine - low dose|Low Dose Zaire Ebola Vaccine
89080869|NCT02718469|Experimental|Ebola Vaccine - mid dose|Mid Dose Zaire Ebola Vaccine
89080870|NCT02718469|Experimental|Ebola Vaccine - high dose|High Dose Zaire Ebola Vaccine
89080871|NCT02718469|Placebo Comparator|Placebo|Placebo
89080872|NCT02716363|Experimental|Device : Rotablator|We compare in-hospital and long-term efficacy or safety of elective Rotational Atherectomy versus bailout Rotational Atherectomy and low-volume operator versus high-volume operator in patients with severe calcified lesions treated.
89080873|NCT02716285|Experimental|Ileocolonic release peppermint oil|Colon-targeted-delivery capsule containing 182mg of Peppermint Oil, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
89080874|NCT02716285|Experimental|Small intestinal release peppermint oil (Tempocol®)|Enteric-coated capsule containing 182mg of Peppermint Oil that release the oil in the small intestine, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
89080875|NCT02716285|Placebo Comparator|Placebo|Capsule containing microcrystalline cellulose, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
89080876|NCT02725021|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
89080877|NCT02725021|No Intervention|Control group|
89080878|NCT01224821|Experimental|Tositumomab and Iodine I-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
89080879|NCT02684851|Placebo Comparator|Placebo|Inactive
89080880|NCT02684851|Active Comparator|Tranexamic|Tranexamic acid: anti-fibrinolytic agents
89080881|NCT01224431|Experimental|Buffered lidocaine J-tip|Needleless injection of buffered lidocaine prior to lumbar puncture versus placebo (Normal saline)
89080882|NCT01224431|Placebo Comparator|Normal saline J-tip|Needleless injection of normal saline (placebo) prior to lumbar puncture versus use of buffered lidocaine
89225058|NCT06042257|Placebo Comparator|Placebo|Eligible participants will receive Placebo for up to 8 weeks.The treatment period will consist of study product administration from day 0 through day 56 with a masked dose-escalation period from day 0 through day 49.
89225059|NCT06041555||ISRAR Cohort|All patient treated with the LINAC UNITY MRI radioguided radiotherapy for a prostate, kidney cancer, cervix, head and neck cancer or glioblastoma.
89080883|NCT02724943|Experimental|TX CORD Intervention|TX CORD Intervention. The intervention entailed: (1) BMI screening, (2) Next Steps brief counseling materials for the healthcare provider, (3) a 3-month intensive Mind Exercise Nutrition Do It! and Coordinated Approach To Child Health (MEND/CATCH) phase, which included the Mind Exercise Nutrition Do it! ( MEND) programs for preschool (ages 2-5) and school-aged (ages 6-12) children coupled with adapted CATCH activities, and (5) a 9-month transition MEND/CATCH Transition phase, which offered monthly reinforcement sessions for parents and children, and twice weekly Young Men's Christian Association (YMCA) sports for children. Community Health Workers (CHWs) serve as program liaisons and assist in delivering all intervention group sessions as well as tracking families. Electronic Health Record (EHR) changes supported the screening and Next Steps delivery.
89080884|NCT02724943|Active Comparator|Brief Clinic Comparison|Next Steps brief clinical intervention. The comparison program was a 12-month clinic-based program conducted at twelve partner healthcare clinics and entailed (1) EHR changes to support childhood obesity clinical visits; (2) BMI screening, (3) Next Steps brief counseling materials for the healthcare provider, and (4) Next Steps self-paced booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity.
89080885|NCT02716129|Active Comparator|Group 1|Morphine group
89080886|NCT02716129|Active Comparator|Group 2|Morphine plus Nalbuphine group
89080887|NCT01223183|Active Comparator|isotonic saline then hypertonic saline|Subjects inhaled nebulized isotonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized 7% hypertonic saline on study day 2.
89080888|NCT01223183|Active Comparator|hypertonic saline then isotonic saline|Subjects inhaled nebulized 7% hypertonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized isotonic saline on study day 2.
89080889|NCT02718391|Experimental|Arm A: Autologous Dendritic Cell vaccine|Daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days starting from the second day after each vaccine dose. Vaccine doses will be given intradermally in two sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis.The first dose (WK1) will consist of freshly prepared vaccine, whereas for all the further doses cryopreserved aliquots will be utilized. The remaining 5 doses will be administered every 4 weeks to complete six months of therapy (six vaccines).
89080890|NCT02718391|No Intervention|Arm B: follow up|Arm B: Patients will undergo laboratory and clinical assessment, tumor re-staging, blood collection for immunological biomarkers every 12 weeks until relapse.
89080891|NCT02718313||Intraventricular conduction delay|Transthoracic echocardiography will be performed to investigate whether the patients have the cardiac disease or not. The transthoracic echocardiography will be performed after the induction of general anesthesia and before the start of surgery.
89080892|NCT02718235||Overall survival HCCIS low risk|HCCIS 2 points
89080893|NCT02718235||Overall survival HCCIS medium risk|HCCIS 1 point
89080894|NCT02718235||Overall survival HCCIS high risk|HCCIS 0 point
89080895|NCT02920333|Experimental|tDCS+ rehab training|tDCS will be applied 10 days, followed by conventional rehab training. Anodal stimulation will be conducted at the intensity of 2 mA and last for 20 minutes over the affected primary motor cortex of cortical representation of the tibialis anterior muscle.
89080896|NCT02920333|Experimental|rTMS+ rehab training|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
89080897|NCT02920333|Sham Comparator|sham tDCS+ rehab training|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
89080898|NCT02724553|Other|Vertical orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the vertical position during routine cataract surgery
89080899|NCT02724553|Other|Horizontal orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the horizontal position during routine cataract surgery
89080900|NCT02718079|Experimental|Standard medical therapy with Plasma Exchange|Plasma Exchange will be performed for consecutive days. Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
89080901|NCT02718079|Active Comparator|Standard medical therapy alone|Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
89080902|NCT02717923|Experimental|Maintenance Treatment|A single arm of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil based standard chemotherapy plus cetuximab.
89080903|NCT02724475|Experimental|LA group|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated.
89080904|NCT02724475|Experimental|3D-CRT group|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times.
89080905|NCT02716207|Experimental|Maximal tolerated dose with CyberKnife|SBRT will be delivered in 5 fractions within 1 to 2 weeks by the following schedule: Doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5 with BED10 in correspondence to 59.5 Gy, 65.6 Gy, 72 Gy, 78.6 Gy, 85.5 Gy, 92.6 Gy respectively while meeting with normal tissue constraints. A minimum of three patients will be included for each dosage level. And an interval is four weeks between each dose level. In case patient presents III/IV GI toxicity, three additional patients will be included at the same dose level. The Maximal Tolerated Dose will be defined as the dose for which at least 2 patients in 3, or at least 3 patients in 9, will present with a limiting toxicity.
89080906|NCT02716051|Experimental|MRI|Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.
89080907|NCT02716051|Active Comparator|PET|At day 1 , in the morning, patient will undergo an PET analysis
89080908|NCT02717845|Experimental|CT scan Ellipse|New medical device for high tibial osteotomy
89080909|NCT02717845|Active Comparator|CT scan Tomofix|Established medical device for high tibial osteotomy
89080910|NCT02715973|Experimental|Nutritional Supplement|"Diet Counseling (Energy=200 kcal/kg/day, (present weight) protein =3-4 gm/kg/day)~Nutritional supplement (Providing extra 40 kcal/kg/day)"
89080911|NCT02715973|Active Comparator|Standard nutritional treatment|"Diet counselling only (Energy=200 kcal/kg/day (present weight) protein =3-4 gm/kg/day).~Standard nutritional treatment"
89080912|NCT02724397|Experimental|Experimental group|(White endoscopy and then LCI/BLI) The patients will be evaluated by Standard White Light and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI).
89080913|NCT02724397|Active Comparator|Control group|(LCI/BLI then white endoscopy) The patients will be evaluated by Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy.
89080914|NCT02717533||blood volume|dry weight adjusted according to ideal blood volume obtained from absolute blood volume measurement (Daxor)
89080915|NCT02715817|Active Comparator|Virtual Rehabilitation - VR|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
89225060|NCT06039371|Active Comparator|Cohort Ia (testosterone cypionate, carboplatin)|Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
89225061|NCT06039371|Active Comparator|Cohort Ib (testosterone cypionate, carboplatin)|Patients continue to receive ADT per standard of care and receive carboplatin IV on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
89225062|NCT06039371|Experimental|Cohort Ic (testosterone cypionate, carboplatin)|Patients continue to receive ADT per standard of care and receive testosterone cypionate IM and carboplatin IV on day 1 of cycle 1. Patients then receive testosterone cypionate IM and carboplatin IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
89225063|NCT06039371|Active Comparator|Cohort IIa (testosterone cypionate, etoposide)|Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
89225064|NCT06039371|Active Comparator|Cohort IIb (testosterone cypionate, etoposide)|Patients continue to receive ADT per standard of care and receive etoposide PO QD on days 1-14 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
89225065|NCT06039371|Experimental|Cohort IIc (testosterone cypionate, etoposide)|Patients continue to receive ADT per standard of care and receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of cycle 1. Patients then receive testosterone cypionate IM on day 1 and etoposide PO QD on days 1-14 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. All patients undergo a biopsy, blood sample collection, bone scan and CT scan throughout the study.
89225066|NCT06038903||EFA group|This group for exploratory factor analysis (EFA)
89225067|NCT06038903||CFA group|This group for confirmatory factor analysis (CFA)
89225068|NCT06038630|Active Comparator|Transfusion and Phlebotomy Patients|Individuals receiving treatment for their blood hemoglobin levels or are a healthy volunteer who is planning to donate blood.
89225069|NCT06038630|Active Comparator|Oxygen Administration Patients|Individuals diagnosed with a chronic blood clot in their lungs and are planning on having surgery to remove it (CTEPH), or have an interstitial lung disease (ILD), or have dyspnea, or are a healthy volunteer.
89225070|NCT06038630|Active Comparator|Acute or Chronic Pulmonary Embolism Patients|Individuals recently diagnosed with a blood clot in their lungs.
89225071|NCT06038136|No Intervention|Standard of Care Neuro Checks|If a patient is randomized to the control group, they will continue to have neuro-checks conducted every 2-4 hours as ordered by the primary team, as per standard of care on the acute stroke service.
89225072|NCT06038136|Experimental|Absence of Neuro Checks|If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
89225073|NCT06033196|Experimental|Tocilizumab Group|Subject in this group will receive ACTEMRA(R) (Tocilizumab) ,(six injections over 20 weeks) plus standard triple maintenance immunosuppression of Tacrolimus, Mycophenolate Mofetil, corticosteroids
89225074|NCT06033196|Placebo Comparator|Placebo Group|Subject in this group will receive placebo for Tocilizumab (sterile normal saline) plus standard triple maintenance immunosuppression of Tacrolimus, Mycophenolate Mofetil, corticosteroids
89225075|NCT06029972|Experimental|Tilpisertib Fosmecarbil Dose A|"Blinded Treatment Phase:~Participants will receive tilpisertib fosmecarbil Dose A for up to 12 weeks. An efficacy assessment will be performed at Week 12.~• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52.~Non-responder Treatment Phase:~• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose A for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug."
89080916|NCT02715817|Active Comparator|Conventional Therapeutic Exercises - CTE|A program of conventional therapeutic exercises (G1) for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1: 30 minutes of upper limb PNF diagonal exercise (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes of scapula PNF diagonal exercise (anterior and posterior elevation); b) protocol 2: 20 minutes of lower limb PNF diagonal exercise (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes of pelvis PNF diagonal exercise (anterior and posterior depression), and 10 minutes gait cycle training;
89080917|NCT02715817|Experimental|VR and CTE|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
89080918|NCT02717689|Experimental|Biomarker arm|Biomarker based adjustment of corticosteroid dose.
89080919|NCT02717689|No Intervention|Standard care|The subject's corticosteroid dose will be adjusted based upon asthma symptom control and lung function
89080920|NCT02717065|Experimental|Characterization, Audiovisual|"Characterization: Tinnitus characterization tools (Minimal Masking Level, Tinnitus Functional Index, Tinnitus Handicap Inventory, and Subjective rating scale) are assessed in an individual over time to determine baseline variability.~Audiovisual: The individual will watch a series of silent videos of a person speaking, both with and without a tone matched to their tinnitus as well as videos of a still face with and without the matched tone."
89080921|NCT02694367||Recurrent miscarriage group|Women with previous history of RM, defined as two or more consecutive miscarriages
89080922|NCT02694367||Control group|Women with no history of RM
89080923|NCT02715739||All participants|
89080924|NCT02715661|Active Comparator|Coronary artery disease|those with a diagnosis of coronary artery disease having been hospitalized for a cardiac event. The intervention is six-month interval of exercise .
89225076|NCT06029972|Experimental|Tilpisertib Fosmecarbil Dose B|"Blinded Treatment Phase:~Participants will receive tilpisertib fosmecarbil Dose B for up to 12 weeks. An efficacy assessment will be performed at Week 12.~• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52.~Non-responder Treatment Phase:~• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose B for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug."
89225077|NCT06029972|Experimental|Tilpisertib Fosmecarbil Dose C|"Blinded Treatment Phase:~Participants will receive tilpisertib fosmecarbil Dose C for up to 12 weeks. An efficacy assessment will be performed at Week 12.~• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose C for up to Week 52.~Non-responder Treatment Phase:~• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose B for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved clinical response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve clinical response at Non-responder Treatment Phase Week 12 will discontinue study drug."
89230138|NCT00050011|Experimental|Zoledronate delayed-start|In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronate 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
89080925|NCT02715661|Active Comparator|Metabolic Syndrome|Metabolic Syndrome patients are defined by having Systolic Blood Pressure (SBP)>130 and/or Diastolic Blood Pressure (DBP)>85 mmHg and any two of the following criteria: Abdominal obesity (waist circumference >102cm in males;>88cm in females), Fasting triglycerides > 1.695 mmol/L, Low HDL cholesterol: Males < 1.04 mmol/L; Females < 1.29 mmol/L, Fasting glucose >5.60 mmol/L. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
89080926|NCT02715661|Active Comparator|Health Control|Control individuals will have no diagnosis of cardiac, vascular, metabolic, inflammatory or neurological disease, and have not been on any medication for such conditions in the past 12 months. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
89225078|NCT06029972|Placebo Comparator|Tilpisertib Fosmecarbil Placebo|"Blinded Treatment Phase:~Participants will receive tilpisertib fosmecarbil placebo for up to 12 weeks. An efficacy assessment will be performed at Week 12.~• Participants who achieve clinical response will receive tilpisertib fosmecarbil Dose C for up to Week 52.~Non-responder Treatment Phase:~• Participants who do not achieve clinical response at Week 12 will discontinue the Blinded Treatment Phase and have the option to enter into the Non-responder Treatment Phase. Participants will receive tilpisertib fosmecarbil Dose A for another 12 weeks. An efficacy assessment will be performed at Week 12 of the Non-responder Treatment Phase. Participants who achieved Clinical Response will receive tilpisertib fosmecarbil Dose B for up to Week 52. Participants who do not achieve Clinical Response at Non-responder Treatment Phase Week 12 will discontinue study drug."
89225079|NCT06029452||ATTRwt-CM and non-amyloid heart failure patients|
89225080|NCT06026228|Placebo Comparator|Control group|The control group will receive daily a placebo capsule per os at mealtime (just before or after) for a period of 6 months
89225081|NCT06026228|Experimental|Experimental group|The experimental group will receive daily per os one capsule of BioGaia® Gastrus probiotic (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) dosed at 108 colony forming units (CFU)/day (distributed by the laboratory PEDIACT France), taken at mealtime (just before or after) for a period of 6 months
89225082|NCT06026111|Experimental|Group A: High-Intensity Interval Training|"10 Participants will complete study procedures as follows:~Baseline clinic visit with assessments.~36 virtual sessions of exercise intervention, 3 x weekly.~Post-intervention clinic visit with assessments."
89225083|NCT06026111|Experimental|Group B: Moderate-Intensity Continuous Training|"10 Participants will complete study procedures as follows:~Baseline clinic visit with assessments.~36 virtual sessions of exercise intervention, 3 x weekly.~Post-intervention clinic visit with assessments."
89225084|NCT06026111|No Intervention|Group C: Usual Care|"10 Participants will complete study procedures as follows:~Post-intervention clinic visit with assessments.~Participants will be asked to maintain their baseline exercise behavior and will be offered to participate in the HIIT exercise program upon the completion of post-intervention assessments after the initial 12 weeks."
89225085|NCT06024109||SYMMCORA®|Barbed suture SYMMCORA® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
89225086|NCT06024109||V-Loc®|Barbed suture V-Loc® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
89225087|NCT06021795|Experimental|Intervention|Treatment using a customized sound audio track delivered via standard commercially available bone conduction headsets
89225088|NCT06020898|Experimental|Sodium valproate group|Within 3 days after admission, 20mg/kg sodium valproate will be given daily. Specifically, 400mg sodium valproate will be infused within 5 minutes, followed by intravenous drip with 1mg/kg/h.
89225089|NCT06020898|Placebo Comparator|Placebo group|Within 3 days after admission, normal saline will be given daily in the same way.
89225090|NCT06020183|Experimental|Hybrid Hyrax|these patents will be treated using Four mini-screws supported hyrax
89225091|NCT06020183|No Intervention|untreated control group|Ethically ,these patents will be treated at the end of the study using the same appliance used for the experimental group
89225092|NCT06019000|Active Comparator|CYR-064 dose 1|Treatment with nasal solution of CYR-064 twice a day for 24 weeks. CYR-064 will be self-administered by patients.
89225093|NCT06019000|Experimental|CYR-064 dose 2|Treatment with nasal solution of CYR-064 twice a day for 24 weeks. CYR-064 will be self-administered by patients.
89080927|NCT04860817|Experimental|Target CD7 CAR-T cells|Three dose levels will be evaluated. The CAR-T cells will be administered with Cytoxan and fludarabine.
89080928|NCT02717221|Experimental|18F-MPG:EGFR+|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
89080929|NCT02717221|Experimental|18F-MPG:post-TKI EGFR+|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study.
89080930|NCT02717221|Experimental|18F-MPG:post-chemo EGFR+|Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
89080931|NCT02717221|Experimental|18F-MPG:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
89080932|NCT02717221|Experimental|18F-MPG:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
89080933|NCT02717221|Experimental|18F-MPG:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
89080934|NCT02715895|Experimental|Friso|Friso formula feeding
89080935|NCT02715895|Experimental|Wyeth|Wyeth formula feeding
89080936|NCT02715895|Active Comparator|Breast milk|Breast milk feeding
89080937|NCT02717299|Experimental|Sensor Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The surgeon will use this data to intraoperatively align the knee according to the indications of the data.
89080938|NCT02717299|Placebo Comparator|Surgeon Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The computer displaying the data will be turned away from the surgeon, so that he is not able to use the sensor data, and must balance the knee with feel and visual estimation of balance.
89080939|NCT04189315|Experimental|Group 1 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 36 weeks.
89080940|NCT04189315|Experimental|Group 2 Asfotase Alfa|Participants will be administered asfotase alfa per approved dose for 12 weeks and then asfotase alfa at a lower dose for 24 weeks.
89080941|NCT02724163|Active Comparator|Mitoxantrone|"Course 1~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2, 3 and 4 (total 4 doses).~Cytarabine:100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).~Course 2~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2 and 3 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
89080942|NCT02724163|Experimental|Liposomal daunorubicin|"Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.~Course 1~Liposomal daunorubicin: 80 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).~Course 2~Liposomal daunorubicin: 60 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
89080943|NCT02724163|Experimental|Gemtuzumab Ozogamicin Dose Finding Study|"Cohort 1: 1x3mg/m2 IV infusion over 2hours on day 4.~Cohort 2: 2x3mg/m2 IV infusion over 2hours on day 4 and day 7.~Cohort 3: 3x3mg/m2 IV infusion over 2hours on days 4, 7 and 10."
89080944|NCT02724163|Active Comparator|High dose cytarabine|Two courses of Cytarabine: 3 g/m2 12 hourly by IV infusion over 4 hours on days 1, 3 and 5 (total 6 doses).
89080945|NCT02724163|Experimental|Fludarabine & cytarabine|"Two courses of:~Fludarabine: 30 mg/m2 daily by IV infusion over 30 minutes on days 1-5 inclusive (total 5 doses).~Cytarabine: 2 g/m2 daily by IV infusion over 4 hours on days 1-5 inclusive (total 5 doses).The cytarabine infusion should be started 4 hours after the start of the fludarabine infusion"
89225094|NCT06019000|Placebo Comparator|Placebo|Treatment with Placebo nasal solution for 24 weeks. CYR-064 will be self-administered by patients.
89225095|NCT06018428|Experimental|Experimental: ADX-914|200mg dose of ADX-914 administered via injection under the skin every 2 weeks for a total of 24 weeks.
89225096|NCT06018428|Placebo Comparator|Placebo Comparator|ADX-914 matched placebo administered via injection under the skin every 2 weeks for a total of 24 weeks.
89225097|NCT06018350|Experimental|Intervention|"Clinicians in this arm will be trained to conduct the adherence intervention in general rheumatology clinic with all follow up patients with a chronic rheumatic disease.~Patients seen by these clinicians will contribute to the outcome data collection."
89225098|NCT06018194||Low FFR|Invasive FFR <= 0.80
89225099|NCT06018194||High FFR|Invasive FFR > 0.80
89225100|NCT06015620||Patients with morbid obesity undergoing metabolic surgery (Mini gastric bypass)|The patients undergoing mini gastric bypass surgery for morbid obesity and its different comorbidities like type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, hypothyroidism and chronic venous hypertension.
89225101|NCT06014827|Experimental|Treatment (BgRT/SBRT)|"Patients continue to receive osimertinib PO QD in the absence of unacceptable toxicity. Patients undergo BgRT/SBRT every other day for 5 treatments. Patients then continue to receive osimertinib and are monitored via imaging. If additional progression is found, patients may receive additional BgRT/SBRT therapy. Treatment continues in the absence of > 5 sites of progression, unacceptable toxicity, or the stopping of osimertinib for more than 4 weeks.~Patients undergo CT scan or PET/CT scan and blood sample collection throughout the study."
89225102|NCT06013423|Experimental|Arm I (myeloablative UCBT)|See detailed description.
89225103|NCT06013423|Experimental|Arm II (myeloablative UCBT)|See detailed description.
89225104|NCT06013111|Experimental|Anti-CEA-CAR-T cell infusion|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10^7 CAR-T cells/kg, 1×10^7 CAR-T cells/kg, and 3×10^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.The patients will receive lymphocyte clearance therapy with cyclophosphamide and fludarabine before the infusion.
89225105|NCT06007547|Experimental|Prophylactic Surfactant via Minimally Invasive Technique|Infants randomized to prophylactic surfactant treatment will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg as soon as possible after delivery (within 15 minutes).
89225106|NCT06007547|Active Comparator|Rescue Surfactant via Minimally Invasive Technique|The control group will be given surfactant will receive a dose of poractant alfa (Curosurf) administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA), at a dosage of 200 mg/kg if their fiO2 reaches a threshold of ≥30% within the first 48 hours of life.
89080946|NCT02724163|Active Comparator|Myeloablative conditioning|"Busulfan Area Under the Curve (AUC) 70-100mg/L x hr by IV infusion over 3 hours, given 12 hourly on days -10 to -7 (8 doses).~Cyclophosphamide 50mg/kg/day by IV infusion over 1 hour, on days -5 to -2 (4 doses)."
89080947|NCT02724163|Experimental|Reduced intensity conditioning|"Busulfan AUC60-65mg/L X hr by IV infusion over 3 hours, given 12 hourly on days -5 to -2 (8 doses).~Fludarabine 30mg/m2/day by IV infusion over 30 minutes on days -8 to -3 (6 doses)."
89080948|NCT02724007||All participants|
89080949|NCT02723851||Acute MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
89080950|NCT02723851||Non-MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
89080951|NCT02717377|No Intervention|Uninterrupted sitting|Subjects remained seated all day except to rise from the chair to void.
89080952|NCT02717377|Active Comparator|Sitting + one bout of activity|Subjects remained seated all day, except to rise from the chair to void, and to perform one bout of 30-minutes moderate-intensity walking. Physical activity was performed at 0800, after measures of vitals and basal questionnaire assessments, but before breakfast.
89080953|NCT02717377|Experimental|Sitting + microbursts of activity|Subjects rose from the seated position every hour for 6-hours from 0910 to 1430 to complete 5-minute bouts of moderate-intensity walking, yielding a total activity time of 30-minutes.
89080954|NCT02486965|Experimental|training group|"The training program consists of three sessions of 45 minutes of physical activity per week for 2 years. During the first 6-9 months, two individual workouts, supervised by a physiotherapist and a session in Living.~Depending on the capacity and exercise tolerance of the patient, patients realize the second phase of training until 2 years of the study: three exercise sessions from 45 to 60 minutes per week of which group session led by a professor of Adapted Physical Activity (APA) and 2 autonomous sessions.~Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms"
89080955|NCT02486965|Placebo Comparator|control group|A training program supervised by physical therapists and teachers in Adapted Physical Activity, identical to the active program in its follow-up, but the intensity of the sessions is lower than that of the training group
89080956|NCT02723539|Experimental|MBN-101|MBN-101: a suspension of 150, 375, or 600 microgram (µg)/milliliter (mL) (w:v) BisEDT drug particles in suspension in 3% methylcellulose / 0.5% polysorbate 80 / 10 millimole (mM) sodium chloride / 10 mM sodium phosphate.
89080957|NCT02723539|Placebo Comparator|Vehicle|MBN-101 diluent (placebo): 3% methylcellulose / 0.5% polysorbate 80 / 10 mM sodium chloride / 10 mM sodium phosphate
89080958|NCT02723617|Other|MED 0.5|
89080959|NCT02723617|Other|MED 2.5|
89080960|NCT02723617|Other|MED 5.5|
89080961|NCT02723617|Other|AAD 2.5|
89080962|NCT02902003|No Intervention|Control|Not eligible for program services
89080963|NCT02902003|Active Comparator|Empowering Families|"These couples will be eligible to participate in the Empowering Families program."
89080964|NCT02715427|Active Comparator|Conventional care|"Preoperative consultation Information support conventional perioperative No bowel preparation~Day before surgery Normal diet until midnight No carbohydrate loading Premedication with anxiolytic~Operative day Conventional general anaesthesia Classic management perfused volumes Conventional use of drains at the operative site Standard nasogastric drainage Conventional analgesia protocol~Postoperative time Mobilization from J1 Progressive refeeding Progressive removal of venous, arterial and urinary catheters. Gradual recovery of the usual treatment from J1 Breathe physiotherapy depending on the clinical course No stimulation of intestinal transit"
89080965|NCT02715427|Experimental|Enhanced recovery|"Preoperative consultation Specific information about the enhanced rehabilitation No bowel preparation Immunonutrition for the 7 preoperative days~Day before surgery Minimal preoperative fasting No premedication Carbohydrate loading~Operative day Optimized general anesthesia Reduced volumes perfused Limiting use of drains at the operative site Reduced doses of morphine Local anesthetic usage No standard use of nasogastric drainage~Postoperative time Stimulation mobilization from D0 Refeeding on demand  from D0 Early removal of venous, arterial and urinary catheters. J1 recovery from the majority of the usual treatment Breathe physiotherapy from D0 to D5 Ileus prevention by chewing gum"
89080966|NCT02715349|Experimental|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
89080967|NCT02715349|No Intervention|Control|Family and patient do not receive psychoeducation, but still receive standard hospital services for schizophrenia.
89080968|NCT02715505|Experimental|HSC835|HSC835 is an expanded umbilical cord blood product used during single umbilical cord blood transplantation
89080969|NCT02716909|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
89080970|NCT02716909|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
89080971|NCT02723695|Experimental|Patients|Surgery (cochlear implantation)
89080972|NCT02723695|Active Comparator|Controls|Asymptomatic subjects
89080973|NCT02723461|Active Comparator|pulsatile oxytocin|Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
89080974|NCT02723461|Active Comparator|continuous oxytocin|Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
89080975|NCT02715037||Acute tonsillitis|Patients referred to the tertiary care center with severe acute tonsillitis but without peritonsillar cellulitis, infectious mononucleosis, or abscess formation.
89080976|NCT02715037||Peritonsillar cellulitis|Patients referred to the tertiary care center with severe acute tonsillitis and peritonsillar cellulitis but without abscess formation.
89080977|NCT02715037||Infectious mononucleosis|Patients referred to the tertiary care center with acute tonsillitis and biochemical or serological signs of infectious mononucleosis but without abscess formation.
89080978|NCT02715037||Controls|Patients treated for conditions not related to the throat and without signs or symptoms of recent throat disease.
89080979|NCT02723227|Experimental|Financial Coaching & Social Service Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
89080980|NCT02723227|Active Comparator|Social Services Referral|Enrollment provides for access to referrals to social services.
89080981|NCT02716597|Experimental|25% Albumin|25% albumin 75 grams IV over 1 hour once.
89080982|NCT02716597|Placebo Comparator|Placebo|0.9% normal saline 200mL IV over 1 hour once.
89080983|NCT04857619||Retrospective|Patients who are diagnosed with HER2-positive unresectable or mBC and have received at least 1 LOT in the advanced setting will be included. Approximately a total of 570-830 patients will be enrolled in the study.
89080984|NCT02715193|Experimental|REMD-477 Treatment A|Administered as a single SC dose in subjects with Type 1 Diabetes
89080985|NCT02715193|Placebo Comparator|Matching placebo|Administered as a single SC dose in subjects with Type 1 Diabetes
89080986|NCT01223027|Experimental|Dovitinib + best supportive care (BSC)|Patients randomized to the dovitinib treatment arm received 500 mg of dovitinib orally on 5 days on/2 days off dosing schedule.
89080987|NCT01223027|Active Comparator|Sorafenib + BSC|Patients in the sorafenib control arm received400 mg of sorafenib (2 x 200 mg tablets) orally taken twice daily.
89080988|NCT02714959|Experimental|Proleukin|Proleukin (subcutaneous injection) 1.5 MIU/day from day 1 to 5 at W1 3 MIU/day from day 1 to day 5 at W3, W6, and W9
89080989|NCT02714647|Experimental|Experimental|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on accuracy over speed prior to practicing the motor task. Participants will also have extended deadlines (750 ms) throughout the task to ensure an accuracy preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
89080990|NCT02714647|Sham Comparator|Control|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on speed over accuracy prior to practicing the motor task. Participants will also have short deadlines (250 ms) throughout the task to ensure a speed preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
89080991|NCT02714725|Placebo Comparator|Control group (Group C)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus normal saline infusion
89080992|NCT02714725|Active Comparator|Group Dexmedetomidine (Group DEX)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus dexmedetomidine infusion 0.5 mcg/kg/hr
89080993|NCT01015287|Experimental|Non pre-treatment|A placebo oral loading dose is given at the time of diagnosis and a 60 milligrams (mg) oral loading dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.
89080994|NCT01015287|Experimental|Split Loading Dose|A 30 mg oral loading dose of prasugrel is given at diagnosis and a 30 mg oral dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days
89080995|NCT02714803|Experimental|Connective tissue massage group|Connective tissue massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
89080996|NCT02714803|Active Comparator|Classic massage group|Classic massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
89080997|NCT02714803|Sham Comparator|Sham massage group|Sham massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
89080998|NCT04028713|Active Comparator|Standard dosing group|Patients will continue to receive adalimumab according to the standard dosing schedule.
89080999|NCT04028713|Experimental|Dose tapering group|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
89081000|NCT04772365|Experimental|Treatment group A|
89081001|NCT04772365|Placebo Comparator|Treatment group B|
89081002|NCT02714491|Active Comparator|Music|Erigo + Music: During each stepping verticalization session the patient receives auditory stimulation (earphones) with previously preferred music
89081003|NCT02714491|Active Comparator|Metronome|Erigo + Metronome: During each stepping verticalization session the patient receives auditory stimulation (earphones) with a metronome (rhythmic with the stepping movement)
89081004|NCT02714491|Active Comparator|Silence|Erigo + Silence: During each stepping verticalization session the patient does note receive any auditory stimulation.
89081005|NCT02714179|Active Comparator|Group Preemptive (Group PE),|Group I: i.V. paracetamol 1 g (100 ml) was given 30 min before induction of anesthesia.
89081006|NCT02714179|Active Comparator|Group Preventive (Group PV),|Group II: i.V. paracetamol 1 g (100 ml) was given before the end of surgery.
89081007|NCT02714413|Placebo Comparator|Sucrose 50g + placebo|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
89081008|NCT02714413|Experimental|Sucrose 50g + D-allulose 2.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
89081009|NCT02714413|Experimental|Sucrose 50g + D-allulose 5.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
89081010|NCT02714413|Experimental|Sucrose 50g + D-allulose 7.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
89081011|NCT02714413|Experimental|Sucrose 50g + D-allulose10.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
89081012|NCT01015131|Experimental|All Participants|18F-FLT-PET imaging
89081013|NCT02714101|Experimental|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
89081014|NCT02714023|Active Comparator|Normal Saline|Patients were randomized to receive normal saline as an irrigation solution during appendectomy.
89081015|NCT02714023|Active Comparator|Sterile Water|Patients were randomized to receive sterile water as an irrigation solution during appendectomy.
89081016|NCT02714023|No Intervention|No irrigation used|Patients who do not receive any irrigation at time of operation.
89081017|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
89081018|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
89081019|NCT02723383|Experimental|BACLOFEN|patient will receive baclofen caps
89081020|NCT02723383|Placebo Comparator|PLACEBO|patient will receive placebo caps (lactose)
89081021|NCT02723149|Experimental|Approach Avoidance Training Condition|The AAT group will push away the joystick from marijuana pictures 90% of the trials and pull towards the marijuana pictures 10% of the trials.
89081022|NCT02723149|Sham Comparator|Sham Condition|The sham group will undergo the same procedures, except the ratio for marijuana pictures will be 50% push and 50% pull.
89081023|NCT02722915|Experimental|fMRI Neurofeedback up-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
89081024|NCT02722915|Experimental|fMRI Neurofeedback down-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
89081025|NCT05269537||Study Group|Cardiac output will be measured at baseline using transthoracic echocardiography. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl. Crystalloid coload 1000 mL will be administered: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection. Cardiac output will be measured at 10 minutes after intrathecal injection, immediately after delivery, at 1 hour after intrathecal injection. Cesarean delivery will be performed. Intravenous ephedrine will be administered to correct hypotension. After delivery, 10 units of oxytocin in 500 ml Ringer acetate will be administered over 30 minutes.
89081026|NCT02722993|Active Comparator|Probiotics|
89081027|NCT02722993|Placebo Comparator|Placebo|
89081028|NCT01222715|Experimental|Arm I (vinorelbine tartrate, cyclophosphamide, bevacizumab)|Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
89081029|NCT01222715|Experimental|Arm II (vinorelbine tartrate, cyclophosphamide, temsirolimus)|Patients receive vinorelbine tartrate and cyclophosphamide as in arm I. Patients also receive temsirolimus IV over 30-60 minutes on days 1, 8, and 15.
89081030|NCT02723071|Experimental|Cohort A: Ocrelizumab 200 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 200 milligram per square meter (mg/m^2) given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
89081031|NCT02723071|Experimental|Cohort B: Ocrelizumab 375 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 375 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
89081032|NCT02723071|Experimental|Cohort C: Ocrelizumab 375/750 mg/m^2|Participants will receive first infusion of ocrelizumab 375 mg/m^2 followed by 7 infusions of 750 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
89081033|NCT02722759|Other|hemoglobin measurement arm|"In this arm hemoglobin measurement is done by four different devices~device Radical-7 for non-invasive measurement of SpHb~device HemoCue for taking capillary and venous blood for measurement of HcHb~device ABL 800 for measurement of BGAHb~device Siemens ADVIA for measurement of labHb~For measurement of haemoglobin by the devices the following interventions have to be done:~venous or arterial puncture (routine)~capillary puncture~placing of the Radical 7 sensor"
89081034|NCT02722681||Symptomatic spinal lipoma patients|Spinal lipoma patients undergoing surgery due to symptomatic lipoma. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intraoperatively and usually discarded, some will be kept for research.
89081035|NCT02722681||Asymptomatic spinal lipoma patients|Spinal lipoma patients who remain asymptomatic. Routine blood and urine samples will be taken as part of routine clinical care, some will be kept for research.
89081036|NCT02722681||Non-lipoma spinal conditions|Patients undergoing spinal surgery for a non-lipoma related condition. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intra-operatively and usually discarded, some will be kept for research.
89081037|NCT02722447|Active Comparator|Rivaroxaban|Rivaroxaban 20 mg od for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks and 20 mg od for 3 weeks)
89081038|NCT02722447|Experimental|Placebo|Placebo for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks followed by 20 mg od for 3 weeks)
89081039|NCT01222403|Experimental|Fluad|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
89081040|NCT01222403|Experimental|Vantaflu_aTIV|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
89081041|NCT02722369|Active Comparator|Control Arm|"IV carboplatin AUC5 (area under curve) on Day1~IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3"
89081042|NCT02722369|Experimental|Investigational Arm|"IV gemcitabine 1200mg/m2 on Day 1 and Day 8~IV carboplatin AUC5 on Day 1~Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)"
89081043|NCT04657393|Active Comparator|Alternative Ventilation Rate|ventilation is performed at 20 breaths/min
89081044|NCT04657393|Active Comparator|Conventional Ventilation Rate|ventilation is performed at 10 breaths/min
89081045|NCT02722291|Experimental|presbyopia|All participants perform all exams under 3 conditions, that is baseline, with out pinhole glasses, and with multiple pinhole glasses
89081046|NCT02694211|Experimental|Intervention group ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
89081047|NCT02694211|No Intervention|Control group|No intervention, business as usual
89081048|NCT02694133|Experimental|Aphasia group|Aphasia
89081049|NCT01222247|Active Comparator|Betamethasone|A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart
89081050|NCT01222247|Placebo Comparator|Placebo|A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
89081051|NCT01014975|Experimental|20 mg Plasmin (Human)|20 mg of Plasmin (Human)
89081052|NCT01014975|Experimental|40 mg Plasmin (Human)|40 mg of Plasmin (Human)
89081053|NCT01014975|Experimental|80 mg Plasmin (Human)|80 mg of Plasmin (Human)
89081054|NCT02713555|Experimental|Roux-en-Y Gastric Bypass group|Morbidly obese patients with type 2 diabetes mellitus will be examined before and after the Roux-en-Y Gastric Bypass procedure
89081055|NCT02713555|Experimental|Gastric sleeve group|Morbidly obese patient with type 2 diabetes Mellitus will be examined before and after the Gastric Sleeve procedure
89081056|NCT02713555|No Intervention|Method /control group|Healthy normal weight participants matched by age and gender to the intervention study will be examined with the same methods as the intervention groups and serve as participants in a method study and as a metabolic normal reference group.
89081057|NCT00628173|Experimental|1|patients with refractory glaucoma who were candidate for AGV implantation allocated in superior site
89081058|NCT00628173|Experimental|2|patients with refractory glaucoma who were candidate for AGV implantation allocated in inferior site
89081059|NCT04299477|Experimental|Patients with periodontitis and osteoporosis|Group 1 : Patients who have periodontitis and osteoporosis prescribed with bisphosphonates
89081060|NCT04299477|Experimental|Systemically healthy patients with periodontitis|Group 2: Patients who have no systemic diseases but diagnosed as periodontitis
89081061|NCT04299477|No Intervention|Systemically and periodontally healthy individuals|Group 3: Healthy controls
89081062|NCT03982537|Experimental|Nature's Blend N-Acetyl-L-Cysteine 600 mg with Chemotherapy|The treatment with NAC will be given twice daily for at least 10 days with the goal to cover the window of opportunity time between the treatment decision for CRT and the beginning of treatment (usually 14-21 days).
89081063|NCT03982537|Other|Standard of Care Chemotherapy (CONTROL)|Patients will receive definitive or adjuvant concurrent chemotherapy and radiotherapy as per standard of care
89081064|NCT05260593|Experimental|Group A (Vit. B12 Phonophoresis group)|Patients in group (A) will receive phonophoresis with Vitamin B12. Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
89081065|NCT05260593|Placebo Comparator|Group B (Placebo-Phonophoresis with Vitamin B12)|Patients in group (A) will receive placebo phonophoresis with Vitamin B12 gel. Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 gel will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
89081066|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 1 Test 1|Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
89081067|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 2 Test 2|Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
89081068|NCT02713477|Placebo Comparator|Placebo - Reference 1|Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
89081069|NCT02713477|Other|Insulin glargine (Lantus) - Reference 2|Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition
89081070|NCT01221623|Experimental|AA4500|collagenase clostridium histolyticum
89081071|NCT01221623|Placebo Comparator|Placebo|Placebo
89081072|NCT02722213|Experimental|Mindfulness-Based Stress Reduction|"The intervention is an 8-week Mindfulness-Based Stress Reduction (MBSR) course, with 8 weekly 2.5-hour group sessions, and 1 all-day (6.5 hours) retreat, taught per standard protocol in a group setting. The course includes instruction and practice of meditation, breathing techniques, gentle yoga and Tai Chi poses, with shared discussion, brief readings and home practice between sessions. Participants will continue with usual care and receive standard educational materials on healthy lifestyles and stress management.~Note: This study will recruit patients eligible for exercise-based cardiac rehabilitation (CR). Randomization to either MBSR or control (no MBSR) condition will occur within two strata (CR; no CR) will occur based on current enrollment in CR at time of study enrollment."
89081073|NCT02722213|No Intervention|Control (No MBSR)|"Those randomized to the control condition will continue with usual care and receive standard educational materials on healthy lifestyles and stress management. At the end of the study control participants will receive a compact disc and workbook on MBSR.~Note: This study will recruit patients who are eligible for traditional exercise-based cardiac rehabilitation (CR). Randomization will be stratified based on whether or not patients are actively enrolled in CR at the time of the study. Within each stratum, participants will be randomized to either the intervention (MBSR) or control (no MBSR) condition."
89081074|NCT02693587||Misodel group in Holbæk|Misodel for induction of labour in Holbæk
89081075|NCT02693587||Angusta group in Roskilde and Næstved|Angusta for induction of labour in Roskilde and Næstved
89081076|NCT01014585|Placebo Comparator|1|Placebo tablets administered orally twice daily
89081077|NCT01014585|Experimental|2|Milnacipran tablets administered orally twice daily
89081078|NCT02722135|Experimental|Volasertib|
89081079|NCT00611143|Experimental|1|Atorvastatin group
89081080|NCT00611143|No Intervention|2|Control group
89081081|NCT01221233|Experimental|NMES AND Stabilization Exercises|Neuromuscular Electrical Stimulation and Lumbar Stabilization Exercises
89081082|NCT01221233|Active Comparator|Moist Heat AND Stabilization Exercises|Moist Heat and Lumbar Stabilization Exercises
89081083|NCT04300569||Patients and Caregivers: Overall Population|"Overall population of this study will include both patients with ISWRD associated with AD-D, AD-D with CVD, and/or VaD, and care givers of patients. Patients and caregivers will undergo all study procedures. Caregivers may care either for a patients who undergo all study procedure (including interview) as well for patients who do not undergo any study procedures but give consent or assent for the use of their medical records in the study (non-interviewed patient)."
88816172|NCT02437890|Experimental|ALX-0061 75 mg q4w|"ALX-0061 75 mg every 4 weeks (q4w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46."
89081084|NCT04488393||Pregnancies with multiple gestations|
89081085|NCT02713165|Experimental|Raisins Enhanced Diet|Participants will be provide with a Raisin Enhanced Diet over a short term period of time.
89081086|NCT02712619|Experimental|metformin 250mg|metformin 375/250 mg
89081087|NCT02712619|Experimental|metformin 1000mg|metformin 1000/1000 mg
89081088|NCT00611221|Active Comparator|1|Massage therapy by a regulated massage therapist
89081089|NCT00611221|Active Comparator|2|Massage by anyone else, eg. husband, nurse, doula
89081090|NCT02722057||Cohort 1 - Interventional|The Interventional cohort will not be utilized.
89081091|NCT02722057||Cohort 2 - Non Interventional|A Non-Interventional Cohort comprising pediatric (<18 years of age) and adult R117H-CFTR patients treated with commercially-available Kalydeco.
89081092|NCT02722057||Cohort 3 - Historical|A Historical Cohort comprising data from an earlier time period for pediatric (<18 years of age) and adult patients with the R117H-CFTR mutation who have never been exposed to Kalydeco and matched on age, gender, and lung function to patients in the Non-Interventional Cohort.
89081093|NCT01220609|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89081094|NCT02713087|Active Comparator|Ephedrine|
89081095|NCT02713087|Active Comparator|Phenylephrine|
89081096|NCT02722603|Experimental|gabapentin / placebo tramadol|gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.
89081097|NCT02722603|Active Comparator|tramadol / placebo gabapentin|tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.
89081098|NCT00611377||1|
89081099|NCT02712853||Autism Spectrum Disorder (ASD)|"Age at enrollment: 18 months to 6 years with established DSM-5 diagnosis of autism spectrum disorder. Exclusion criteria include:~wards of the state syndromic autism (attributed to a known genetic mutation) active periodontal infection active upper respiratory infection"
89081100|NCT02712853||Control|"Age 18 months to 6 years without autism spectrum disorder (may have typical development or developmental delay without autism - as defined by negative MCHAT-R or negative ADOS-II evaluation)~Exclusion criteria include:~wards of the state active periodontal infection active upper respiratory infection"
89081101|NCT02712697|Experimental|WM Group|Shentong Granules, two packs, bid, P.O., 48weeks; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
89081102|NCT02712697|Placebo Comparator|Hormone Group|Placebo ; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
89081103|NCT02708563|Experimental|Immediate intubation|These infants will have immediate endotracheal suctioning after delivery. They will then have resuscitation per Neonatal Resuscitation Program guidelines.
89081104|NCT02708563|Experimental|Immediate resuscitation|These infants will have immediate resuscitation per the Neonatal Resuscitation Program guidelines without endotracheal suctioning.
89081105|NCT02708797|Other|Migraine with aura Patients|Patients with migraine with aura will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
89081106|NCT02708797|Other|Controls|Control group with healthy volunteers will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
89081107|NCT02708719|Other|Pulmonary rehabilitation|multimodal pulmonary Rehabilitation program (3 weeks Duration)
89081108|NCT01220297|Experimental|Carmustine Etoposide Cyclophosphamide|Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
89081109|NCT01220297|Experimental|FTBI + Cyclophosphamide|FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
89081110|NCT02721901|Experimental|iEAT Manual Intervention|Caretakers of 10 children will be randomized to participate in the integrated Eating Aversion Treatment (iEAT) intervention. iEAT is a technology-based manual which aims to increase the child's food consumption.
89081111|NCT02721901|Active Comparator|Control group|Caretakers of 10 children will be randomized to participate in the control group. Participants assigned to the control group will be able to receive the iEAT treatment after the study ends.
89081112|NCT02888015|Other|Upper extremity exercise|Five upper extremity exercises will be provided to each of the 10 participants to complete on a daily basis. Exercises included shoulder flexion, elbow flexion/extension, shoulder abduction, internal/external rotation
89081113|NCT02712775|Experimental|Minocycline|Experimental group will receive an infusion of minocycline, the investigational drug, through a needle in a vein in the arm at the dose of 200 mg at 1 h prior to transplantation and 100 mg 12 h and 24 h after transplantation. In addition, the donated liver will be flushed with 200 mg minocycline 1 h prior to transplantation.
89081114|NCT02712775|Placebo Comparator|Saline|Placebo group will receive an infusion of saline, a placebo, through a needle in a vein in the arm according to the same schedule. In addition, the donated liver will be flushed with saline 1 h prior to transplantation.
89081115|NCT01219985|Experimental|Investigation arm|"standard and respiratory-gated PET acquisitions  for patients included in the trial."
89081116|NCT04318847|Experimental|Ondransetron|Administration of ondansetron
89081117|NCT04318847|No Intervention|Habitual Clinical Practice|Habitual Clinical Practice
89081118|NCT02721823|Experimental|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
89225107|NCT06004921|Experimental|Cohort 1 - AB801 Dose A|Participants will receive a single dose of AB801 or placebo
89081119|NCT02721823|Active Comparator|control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.
89081120|NCT02691221|Other|Participants with previous suicide attempt or ideation|Participants will complete daily tasks assigned for completion through a downloaded application on their mobile device and completing six 2-hour long outcome assessment sessions including rater-lead scales over the course of six months.
89081121|NCT02721745|Experimental|Natural Fatigue|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
89081122|NCT02721745|Experimental|tDCS anodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
89081123|NCT02721745|Experimental|tDCS cathodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
89081124|NCT02721745|Experimental|tDCS sham|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
89081125|NCT02721745|Experimental|inhibitory TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
89081126|NCT02721745|Experimental|Sham TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
89081127|NCT02721511|Experimental|Furosemide injection solution 8mg/mL|8mg/mL (total dose=80mg) of furosemide injection solution administered subcutaneously as 30mg over the first hour and then as 12.5 mg per hours over the subsequent 4 hours.
89081128|NCT02708329|Active Comparator|CTO coronary angioplasty +T-provisional stenting|Coronary angioplasty using T-provisional stenting in patients with bifurcational lesion in Chronic total occlusion segment.
89081129|NCT02708329|Experimental|CTO coronary angioplasty + Mini-crush stenting|Coronary angioplasty using Mini-crush stenting in patients with bifurcational lesion in Chronic total occlusion segment.
89081130|NCT02708407|Experimental|Peritoneal Dialysis Group|These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
89081131|NCT02708407|No Intervention|Control Group|These participants will continue to receive standard HF care.
89081132|NCT02712463||Participants with Schizophrenia|This is an observational study. Data will be collected from the medical records of participants diagnosed with schizophrenia and who had been on oral antipsychotics for at least one year and thereafter have been switched to Long Acting Injectable atypical antipsychotics for at least one year.
89081133|NCT02712307|Experimental|5 days|Phenoxymethylpenicillin 800 mg x 4 for 5 days
89081134|NCT02712307|Active Comparator|10 days|Phenoxymethylpenicillin 1000 mg x 3 for 10 days
89081135|NCT02708251|Experimental|glyceryl trinitrate cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL glyceryl trinitrate cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
89081136|NCT02708251|Experimental|lidocaine cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL lidocaine creamwill be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
89081137|NCT02708251|Placebo Comparator|placebo cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine.1 mL placebo cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
89081138|NCT02708173|Experimental|One dose Vaccine in aged 18-60 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 18-60 years old.
89081139|NCT02708173|Experimental|One dose Vaccine in aged 3-17 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 3-17 years old.
89081140|NCT00611611||1|SLE
89081141|NCT00611611||2|healthy controls
89081142|NCT04188925|Experimental|Group A|True LA with EA
89081143|NCT04188925|Sham Comparator|Group B|Sham LA with EA
89081144|NCT03906643|Experimental|HS-201|HS-201 will be administered intravenously as a single dose
89081145|NCT01218659|Experimental|Migalastat|Participants received 150 mg migalastat orally QOD during the 18-month randomized treatment period and the optional 12-month OLE period. Participants received an inactive reminder capsule on alternate days during both treatment periods.
89081146|NCT01218659|Active Comparator|ERT|Participants received ERT (either agalsidase alfa or agalsidase beta) as prescribed by the participant's treating physician and administered in accordance with the approved prescribing information during the 18-month randomized treatment period. Participants were required to be given >80% of the currently labeled dose and regimen during the 18-month randomized treatment period. During the optional 12-month OLE period, participants received 150 mg migalastat orally QOD. Participants received an inactive reminder capsule on alternate days during the OLE.
89081147|NCT02712229|Experimental|CONNECT Intervention|At clinics randomized to the CONNECT intervention, oncology nurses will be selected by a nurse advisory panel to receive standardized primary palliative care training. A multi-step deployment strategy will be employed to orient oncologists and implement CONNECT processes. CONNECT nurses will administer CONNECT to enrolled patients and caregivers. An intervention fidelity monitoring and maintenance plan will be implemented to ensure high quality and consistent delivery of the intervention.
89081148|NCT02712229|No Intervention|Usual Care Control|At clinics randomized to Usual Care, enrolled patients and caregivers will continue to receive supportive oncology care according to usual practice.
89081149|NCT05172037|Active Comparator|Novaferon|Inhaled Novaferon, given 20 ug BID, daily for 7 days
89081150|NCT05172037|Placebo Comparator|Placebo|Inhaled saline (placebo), given BID, daily for 7 days
89081151|NCT02708017|Active Comparator|S-TAP block|ultrasound guided bilateral subcostal TAP block
89081152|NCT02708017|Active Comparator|P-TAP block|ultrasound guided bilateral Posterior TAP block
89081153|NCT00612625|Experimental|GLP-1|A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)
89081154|NCT00612625|Experimental|Saline|A graded glucose infusion together with a continuous infusion of saline
89081155|NCT02712073||patients undergoing colonoscopy|
89081156|NCT00612001|Experimental|dendritic cell vaccine|
89081157|NCT02711761|Experimental|15 cm|The depth of guide wire will be 15 cm from puncture site of skin prior to tissue dilation during central venous catheterization
89081158|NCT02711761|Experimental|17.5 cm|The depth of guide wire will be 17.5 cm from puncture site of skin prior to tissue dilation during central venous catheterization
89081159|NCT02711761|Active Comparator|20 cm|The depth of guide wire will be 20 cm from puncture site of skin prior to tissue dilation during central venous catheterization
89225108|NCT06004921|Experimental|Cohort 2 - AB801 Dose B|Participants will receive a single dose of AB801 or placebo
89081160|NCT02711917|Experimental|SP1- sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
89081161|NCT02711917|Experimental|SP2- Sevoflurane MAC 0.75|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen.Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
89081162|NCT02711917|Experimental|SP3 -Sevoflurane MAC 1.0|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 1.0. Propofol infusion is started to keep BIS between 40-60.
89081163|NCT02711917|Experimental|SP4- Sevoflurane MAC 0.5|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
89081164|NCT02711917|Experimental|SP5- Sevoflurane MAC 0.75|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
89081165|NCT02711917|Experimental|SE1- Sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
89081166|NCT02711917|Experimental|SE2- Sevoflurane 0.75|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
89081167|NCT02711917|Experimental|SE3- Sevoflurane MAC 1.0|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
89081168|NCT02707783||Bioresorbable vascular scaffold (BVS) implantation|Patients with un/stable angina that require coronary revascularization undergoing the BVS implantation
89081169|NCT02711449|Experimental|Methylprednisolone|125 mg Methylprednisolone intravenously approximately 30 minutes prior to skin incision
89081170|NCT02711449|Placebo Comparator|Placebo|0.9% Saline intravenously approximately 30 minutes prior to skin incision
89081171|NCT02707705|Experimental|: Auricular Acupuncture (needle patch) group A|Needle patch: Patients receiving the auricular acupuncture protocol with needles inserted on adhesive tape.
89081172|NCT02707705|Placebo Comparator|Needle-free patch: group P.|Patients who received the auricular acupuncture protocol with adhesive tape without needles.
89081173|NCT02707705|No Intervention|No intervention: group C|Patients without any device or intervention.
89081174|NCT00612079|Experimental|2|Healthy volunteers with high sensory gating levels.
89081175|NCT00612079|Experimental|1|Healthy volunteers with low sensory gating levels.
89081176|NCT00940498|Experimental|1|PF-05212384 (also known as PKI-587)
89081177|NCT03820531|Experimental|Suspected mucinous pancreas cyst|In all pancreas cysts > 15mm and/or pancreas duct dilatation > 5mm in patients who are fit for surgery EUS-guided pancreas cyst fluid aspiration is conducted. In cyst fluid CEA and lipase examination, cytology and Next Generation Sequencing is performed. After that, the pancreas cyst will be resected and histopathologically analysed.
89081178|NCT02711527|Active Comparator|Acupunture group A|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total) Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation , all needles will be retained for 30 minutes."
89081179|NCT02711527|Active Comparator|Acupunture group B|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total). Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes."
89081180|NCT05115721||Pre-ductal SpO2|
89081181|NCT05115721||Post-ductal SpO2|
89081182|NCT02850718|Experimental|Period 1: Sublingual wafer|Subjects receive receive a single dose of 50 mg sublingual sildenafil followed by plasma sampling for 14 hours.
89081183|NCT02850718|Active Comparator|Period 2: Oral comparator|Subjects receive a single dose of 50 mg oral sildenafil (Viagra) followed by plasma sampling for 14 hours.
89081184|NCT02693353||Study Group|Patients with diagnosed epiretinal membrane undergoing cataract surgery.
89081185|NCT02693353||Control Group|Patients without epiretinal membrane undergoing cataract surgery.
89081186|NCT02707393|Experimental|single arm|Fludarabine intravenous - daily dose: 40mg/sqm on day -7, -6, -5, -4; Thiotepa intravenous - daily dose: 2 x 5mg/kg on day -3; Melphalan intravenous - daily dose: 140/mg/sqm on day - 2; ATG intravenous - dose according to local standards on day -3, -2, -1; bone marrow or peripheral blood stem cells of an HLA identical sibling or matched unrelated donor on day 0; GvHD propyhlaxis with Mycophenolate Mofetil and Cyclosporine A
89081187|NCT02711605|Experimental|Unilateral UltraShape treatment|One side of the chest (left or right breast) will be treated with the UltraShape focused ultrasound device, while the opposite will serve as an untreated control.
89081188|NCT02711605|Experimental|Bilateral UltraShape treatment|Both sides of the chest (right and left breasts) will be treated with the UltraShape focused ultrasound device.
89081189|NCT00940342|Experimental|Treated and Relapsed - Group 1|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
89081190|NCT00940342|Experimental|Treated and High-Risk for Progression - Group 2|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
89081191|NCT00940342|Experimental|70 Years of Age and Refused Chemo - Group 3|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
89081192|NCT02707549|Active Comparator|Normal Saline Group|the patients included in this group will receive normal saline solution (0.9% sodium chloride) during surgery and in the first 24 hours after ICU admission.
89081193|NCT02707549|Experimental|Balanced Crystalloid Solution Group|the patients included in this group will receive balanced crystalloid solution during surgery and in the first 24 hours after ICU admission.
89081194|NCT00936910|Experimental|Antifungal lock-treated patients|Intestinal failure and other patients with poor IV access and central line fungal-related infections will receive intravenous systemic antifungal therapy plus the instillation of Ambisome locks into the infected catheter.
89081195|NCT02707627||Laser Therapy|Participants will receive laser therapy for the treatment of their hypertrophic burn scars. Laser treatment decisions will be tailored to meet the needs of the patient.
89081196|NCT02707315|Experimental|A|"Chemotherapy:~Gemcitabine 1000 mg/m2 weekly x 3 on 28 day cycle~Radiation:~25 Gy over 5 fractions~Surgery:~surgical resection of pancreas~treatment plan:~1 cycle of chemotherapy, followed by stereotactic radiosurgery, followed by an additional 6 cycles of chemotherapy or surgical resection"
89081197|NCT00604942|Experimental|Achalasia|Long vs Short Myotomy repair of Achalasia
89081198|NCT00604942|Experimental|Dysphagia control|Conservative Management
89081199|NCT00604942|Experimental|GORD for surgery|Partial vs Full Fundoplication repair
89081200|NCT00604942|Experimental|GORD not for surgery|esomeprazole 40 mg vs no esomeprazole
89081201|NCT02711683||DL-3-n-butylphthalide group|using DL-3-n-butylphthalide treatment in patients with mild to moderate AD already receiving donepezil
89081202|NCT02711683||donepezil group|only using donepezil treatment in patients with mild to moderate AD
89081203|NCT02854618|Experimental|Everolimus treatment|
89081204|NCT00603694||1|(Experimental group): Receiving > 2 Gy SRS to left hippocampus (n=10)
89081205|NCT00603694||2|(Low-dose control group): Receiving < 0.5 Gy SRS to left hippocampus (n=10)
89081206|NCT00603694||3|(High-dose control group): Receiving whole brain PCI (n=10)
89081207|NCT04266808|Experimental|An interactive telehealth monitoring and biofeedback system|Participants in this group will receive feedback of pressure relief maneuvers and wheelchair propulsion activity. Feedback for pressure relief will include information during the activity to identify adequate duration and magnitude of pressure relief activity, reminders of when the next pressure relief is due, and daily aggregate information regarding the number of successful pressure relief maneuvers performed.
89081208|NCT04266808|Sham Comparator|Education Control|Participants will receive education on the importance and recommended frequency of pressure relief maneuver for prevention of pressure ulcer/injury and on the importance and recommended amounts of physical activity for health.
89081209|NCT05079061|Active Comparator|Misoprostol group|At delivery of baby, routine uterotonics (syntometrine 1ml intramuscular or syntocinon 5 units intravenous bolus followed by 40 units in 500ml normal saline infusion over 4 hours in women contraindicated for syntometrine) will be given as routine practice, and sublingual misoprostol will be given to women in misoprostol group.
89081210|NCT05079061|No Intervention|Control group|At delivery of baby, routine uterotonics (syntometrine 1ml intramuscular or syntocinon 5 units intravenous bolus followed by 40 units in 500ml normal saline infusion over 4 hours in women contraindicated for syntometrine) will be given as routine practice, and no additional sublingual misoprostol will be given to women in control group.
89081211|NCT00605800||1|normal healthy volunteers
89081212|NCT00605800||2|Patients undergoing major liver resections
89081213|NCT02707081|Placebo Comparator|Placebo control group|Saline was given both intraperitoneally and intravenously during caesarean section
89081214|NCT02707081|Active Comparator|Intraperitoneal instillation group|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure with intravenous normal saline in a volume equivalent to that used in intravenous lidocaine group as placebo to ensure blinding.
89081215|NCT02707081|Active Comparator|Intravenous injection group|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding
89081216|NCT02711371||Cannabis Dependence|Cannabis dependent individuals according to DSM 4 criteria, aged 18-40 years
89081217|NCT02711371||Healthy|Healthy controls, socio-demographically matched
89081218|NCT02707237|Other|Verbal counseling|Parents with threatened delivery will receive verbal counseling only
89081219|NCT02707237|Other|Verbal, pictorial, written counseling|Parents with threatened delivery will receive verbal counseling supplemented with pictorial and written information
89081220|NCT00605098|Active Comparator|1|
89081221|NCT00605098|Experimental|2|
89081222|NCT04310215|Experimental|Microfracture + CARTISTEM®|CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.
89081223|NCT04310215|Active Comparator|Microfracture|Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.
89081224|NCT00603772|Experimental|1|Safety when exposed to sunlight
89081225|NCT02707003||AZ PACU|Observation of standard of care with capnography blinded
89081226|NCT02707003||TWH PACU|Observation of standard of care with capnography blinded
89081227|NCT02706613|Other|Face to Face Pulmonary Rehabilitaton|6 week incremental pulmonary rehabilitation (PR) programme. Participants will attend 12 sessions over the 6 week period. The components of the PR programme will include an exercise programme. Education sessions will also be provided and include anatomy of the lungs and what is COPD, anxiety and depression, self management, managing breathlessness, medications and treatments, managing exacerbations of COPD and chest infections, clearing sputum and the Active Cycle of Breathing Technique, nutrition, pacing, smoking cessation. Participants on the face to face arm will also be instructed to carry out the pulmonary rehabilitation exercises an additional three times a week at home.
89081228|NCT02706613|Active Comparator|Online Pulmonary Rehabilitation|Those randomised to receive the online programme will be given log-in details and a password, and instructions to begin the 6 week programme at home. The online programme mirrors the conventional face-to-face PR programme and the exercise and educational components are given by means of instructional videos. Participants will be instructed to exercise five times a week. Participants in the online arm will receive during the PR course telephone contact to record any adverse or serious adverse events.
89081229|NCT00605332|Experimental|1|Investigative Device (Crux Biomedical IVC Filter) will be evaluated for its ability to capture thrombus for the prevention of pulmonary embolism.
89081230|NCT02706769|Active Comparator|Paracetamol|Participants will take blinded Paracetamol (as they were taking before entering the study)
89081231|NCT02706769|Placebo Comparator|Placebo|Participants will take blinded Paracetamol
89081232|NCT05044117|No Intervention|Clinical observation|The standard treatment followed by clinical observation.
89081233|NCT05044117|Experimental|Metronomic capecitabine|The standard treatment followed by a maintenance therapy with capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year.
89081234|NCT05031715|Experimental|Dietary supplement|Berberine Phytosome
89081235|NCT05029609|Other|Group A|Group A will receive nasal Foralumab Dose 1 daily for 14 days (n=9) or placebo (n=3)
89081236|NCT05029609|Other|Group B|Group B will receive nasal Foralumab Dose 2 tiw for 14 days (n=9) or placebo (n=3)
89081237|NCT05029609|Other|Group C|Group C will receive nasal Foralumab Dose 3 daily for 14 days (n=9) or placebo (n=3)
89081238|NCT05029609|Other|Group D|Group D will receive nasal Foralumab Dose 4 daily for 14 days (n=9) or placebo (n=3)
89081239|NCT02693197|Experimental|Cohort 1:T-817MA|Mild hepatic impairment subjects
89081240|NCT02693197|Experimental|Cohort 2:T-817MA|Healthy subjects matched to subjects in Cohort 1
89081241|NCT02693197|Experimental|Cohort 3:T-817MA|Moderate hepatic impairment subjects
89081242|NCT02693197|Experimental|Cohort 4:T-817MA|Healthy subjects matched to subjects in Cohort 3
89081243|NCT02693197|Experimental|Cohort 5 :T-817MA|Severe hepatic impairment subjects
89081244|NCT02693197|Experimental|Cohort 6:T-817MA|Healthy subjects matched to subjects in Cohort 5
89081245|NCT02711293|Experimental|ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard plus enhanced nutrition counseling.
89081246|NCT02711293|Experimental|ART home delivery + no enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard counseling.
89081247|NCT02711293|Experimental|No ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home to provide enhanced nutrition counseling. Participants will not receive ART home delivery.
89081248|NCT02711293|No Intervention|Standard of care|Participants in this arm receive facility-based ART care and no enhanced nutrition counseling. They receive community health worker visits as per the standard of care in Dar es Salaam.
89081249|NCT03961165|Experimental|Treatment arm|1mL 20 mg/mL butylscopolamine bromide i.v.
89081250|NCT03961165|Placebo Comparator|Placebo|1mL 9mg/mL NaCl
89081251|NCT02706457||cohort 2012 - 2014|all patients admitted for > 48 hours on the Intensive Care Unit in 2012, 2013 and 2014
89081252|NCT02706535|Experimental|Part 1 Cohort 1|Subjects will receive a single dose of GSK525762 10 mg on Day 1 followed by 200 mg Itraconazole two times a day (BID) on Day 3. On Day 4 to Day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On Day 7 subjects will receive a single dose of GSK525762 5 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
89081253|NCT02706535|Experimental|Part 1 Cohort 2|Subjects will receive a single dose of GSK525762 10 mg on day 1 followed by 200 mg Itraconazole BID on day 3. On day 4 to day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On day 7 subjects will receive a single dose of GSK525762 5 mg or GSK525762 10 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
89081254|NCT02706535|Experimental|Part 2|Subjects will receive a single dose of GSK525762 10 mg on day 1. From day 3 to 17 inclusive, subjects will receive a single dose of 600 mg rifampicin in fasting conditions. On day 18 subjects will receive single dose of GSK525762 either 20 or 30 mg along with 600 mg dose of rifampicin. On day 19 subjects will receive a single dose of rifampicin 600 mg.
89081255|NCT02711059|Active Comparator|parathyroidectomy|change in insulin resistance
89081256|NCT02711059|No Intervention|control|the study participant will be examined parallel with the active comparator
89081257|NCT02706223|Experimental|Pharmacist Led|This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists
89081258|NCT02706223|Experimental|Nurse Led|This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses
89081259|NCT02706379|Experimental|Local cerebral oxygen saturation|use NIRS technical to detect local cerebral oxygen saturation of both sides of brain
89081260|NCT03960073|Experimental|MitoQ|20mg daily oral dose of MitoQ
89081261|NCT03960073|Placebo Comparator|Placebo|Oral TTP placebo
89081262|NCT02706301|Experimental|Telephone-Based Coping Skills Training (CST)|The CST condition will receive 5 sessions of a cognitive behavior theory-based protocol that teaches coping skills (e.g., relaxation, activity pacing/planning, cognitive restructuring) relevant to managing pain as well as psychological distress.
89081263|NCT02706301|No Intervention|Standard care control|The standard care control condition will receive resources and referrals related to survivorship health. This information will be provided to the participant during their initial survivorship care consult.
89081264|NCT02710825|Experimental|Osteopathic treatment|
89081265|NCT02710825|Placebo Comparator|Simulated osteopathic treatment|
89081266|NCT00612781|Other|A|
89081267|NCT00612781|Other|B|
89081268|NCT00612157|Active Comparator|OSA CPAP|
89081269|NCT00612157|Placebo Comparator|Placebo|
89081270|NCT00940108|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
89081271|NCT00940108|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
89081272|NCT02710903|Experimental|Healthy with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with probing depths (PD) ≤4mm, no evidence of inter proximal clinical attachment loss (CAL), and <20% of sites with bleeding on probing (BOP).
89081273|NCT02710903|Experimental|Periodontal Disease with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
89081274|NCT02710903|Experimental|Healthy with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with PD ≤4mm, no evidence of interproximal CAL, and <20% of sites with BOP.
89081275|NCT02710903|Experimental|Periodontal Disease with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
89081276|NCT05265403||Below knee amputees|Adult, unilateral trans-tibial amputees (amputation is below the knee and only on one side) who will wear and test our prototype prosthetic feet
89081277|NCT04256044||Observational|Observational
89225109|NCT06004921|Experimental|Cohort 3 - AB801 Dose C|Participants will receive a single dose of AB801 or placebo
89225110|NCT06004921|Experimental|Cohort 4 - AB801 Dose D|Participants will receive a single dose of AB801 or placebo
89230139|NCT00661427|Active Comparator|Cetuximab 500 mg/m^2|Cetuximab 500 mg/m^2 IV over 2 hours every other week
89225111|NCT06003699|Experimental|Mindfulness training group|Participants will receive 4 weeks of mindfulness-based training and then continue to have access to the mindfulness training exercise throughout the second training interval.
89225112|NCT06003699|Active Comparator|Wait-list Control Group|Participants will not receive 4 weeks of mindfulness-based training during the first training interval; they will receive 4 weeks of mindfulness training during the second training interval.
89225113|NCT06000670|Experimental|knee osteoarhritis|patients with grade 2 and above chondromlacia as well as all grades of osteoarhtritis
89225114|NCT06000072|Experimental|Telerehabilitation|Telerehabilitation sessions including core exercises
89225115|NCT06000072|Active Comparator|Video-based|Core exercises by watching pre-recorded videos
89225116|NCT05999149|Experimental|Arm A|Camrelizumab Plus Chemotherapy and Famitinib
89225117|NCT05999149|Active Comparator|Arm B|Camrelizumab Plus Chemotherapy
89225118|NCT05998304|Experimental|[14C] Yiqibuvir|Eligible healthy male subjects received a single oral 600 mg (radioactivity of 100µCi) dose of [14C] Yiqibuvir
89225119|NCT05998135|Experimental|Treatment (atovaquone)|Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study.
89225120|NCT05997914|Experimental|Intervention - Patient Videos|Videos of African Americans currently taking anticoagulation talking about their experiences with using anticoagulation or blood thinners and successfully navigating setbacks occurring with use including bleeding, falls, strokes, and affording the medications.
89225121|NCT05997914|No Intervention|Control - Informational Videos (not patients)|Informational videos about anticoagulation and blood thinners presented by experts or actors.
89225122|NCT05995171||Esophageal atresia arm|Patient with esophageal atresia
89225123|NCT05995171||control arm|Patient without esophageal atresia
89225124|NCT05993104||Retrospective observational|Retrospective observational arm recruiting >50 participants, utilising data already collected as part of standard clinical care.
89225125|NCT05993104||Prospective single-arm|Prospective single-arm recruiting 20 participants undergoing AcQMap guided ablation.
89225126|NCT05993104||Feasibility study|Feasibility study recruiting 10 participants.
89225127|NCT05989451|No Intervention|Treatment as Usual (TAU)|Treatment-as-usual (TAU) is a naturalistic treatment condition as delivered in current daily practice by psychiatrists in the medical services in Taiwan. TAU typically includes prescription and monitoring of antidepressant and/or anxiolytic medication, psychological treatment (this may include empathic listening and/or supportive counselling, psychoeducation, etc), or a combination of both. Patients in the TAU condition already receiving any of the aforementioned treatments are informed they will continue to receive as usual the services received before enrollment in the study.
89225128|NCT05989451|Experimental|Transdiagnostic Adapted DBT plus TAU|The modified DBT protocol, developed by the principal investigator and co-investigators, which will be offered in an individual therapy format. It consists of 12 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual (Linehan 2015), retaining the essence of DBT (Linehan 1993), and remain dialectically focused. Each session focuses on specific skills within that content of modules.
89225129|NCT05988567|Placebo Comparator|Placebo candy|
89225130|NCT05988567|Experimental|melon and oil olive pressed candy|
89225131|NCT05988554|Placebo Comparator|Placebo sachet|
89225132|NCT05988554|Experimental|Hibiscus sabdariffa extract and collagen products|
89225133|NCT05985473|Other|Professionally active adults with a moderate hearing loss|
89225134|NCT05984992|Experimental|SRN-001|
89225135|NCT05984992|Placebo Comparator|Placebo|
89225136|NCT05984199|Experimental|Morphologic Disease: Cohort 1|VCAR33 Dose Level 1
89225137|NCT05984199|Experimental|Morphologic Disease: Cohort 2|VCAR33 Dose Level 2
89225138|NCT05984199|Experimental|Morphologic Disease: Cohort 3|VCAR33 Dose Level 3
89225139|NCT05984199|Experimental|MRD Positive: Cohort 1|VCAR33 Dose Level 1
89225140|NCT05984199|Experimental|MRD Positive: Cohort 2|VCAR33 Dose Level 2
89225141|NCT05984199|Experimental|MRD Positive: Cohort 3|VCAR33 Dose Level 3
89225142|NCT05984069||Patients on etiologies|Patients over 18 admitted in ICU for all etiologies with mechanical ventilation over 5 days or length of stay in ICU over 10 days will be included
89225143|NCT05983770|Experimental|Investigative|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
89225144|NCT05983770|Active Comparator|Comparator|Tacrolimus administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter
89225145|NCT05983692|Experimental|Mg Wire group|Intervention: Magnesium-based wire as braiding suture to braid the tendon graft.
89225146|NCT05983692|No Intervention|control group|2-0 vicryl suture as control, size and length matched Mg wire
89225147|NCT05981456|Experimental|Flipped Educational Model|Giving the subject of patient safety education with the flipped education model
89225148|NCT05981456|Active Comparator|Traditional Educatıonal Model|Giving the subject of patient safety education with the traditional education model
89225149|NCT05979389|Experimental|Bicalutamide|50 mg capsule administered orally once daily for 6 months
89225150|NCT05979389|Placebo Comparator|Placebo|Matching placebo capsule administered orally once daily for 6 months
89225151|NCT05978908|Experimental|SAD study in Healthy adult participants|A total of 24 healthy adult participants will be enrolled, and then sequentially allocate to 3 planned dose cohorts (A1-A3): 4 mg, 8 mg and 16 mg, respectively.
89225152|NCT05978908|Placebo Comparator|Placebo|Placebo
89081278|NCT04971655|Experimental|Music therapy group|When individuals with diabetes apply to diabetes education after their polyclinic examination, music therapy will be applied in addition to routine monitoring and applications throughout the education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered as options to the individuals in the intervention group and will be listened to throughout the process. During the training, the selected music will be played over the loudspeaker. Before the training, this group; Patient Description Form and Spielberger State-Trait Anxiety Scale will be applied. After the training, Visual Analogue Scale and State Anxiety Scale will be applied.
89081279|NCT04971655|No Intervention|Control group|When individuals apply to diabetes education after their polyclinic examinations, routine monitoring and application will be made throughout the education. Before the training, this group; Patient Description Form and Spielberger State-Trait Anxiety Scale will be applied. After the training, Visual Analogue Scale and State Anxiety Scale will be applied.
89081280|NCT05383066||those with anti-angiogenesis combined with PD-1/PD-L1 therapy|This study includes patients with advanced liver cancer who can benefit from anti-angiogenesis combined PD-1/PD-L1 treatment and observes the relationship between overall survival and their therpay.
89081281|NCT04267432|Placebo Comparator|Placebo|Placebo
89081282|NCT04267432|Experimental|TCI633|Testing product
89081283|NCT04267432|Active Comparator|Type 2 collagen|Known drug for OA
89081284|NCT04970173||1|patients taking very low-volume 1L-PEG plus ascorbate (plenvu) for open access colonoscopy
89081285|NCT04970173||2|patients taking low-volume 2L-PEG plus ascorbate (moviprep) for open access colonoscopy
89081286|NCT04267354|Experimental|Arm cycling|Participants will perform arm cycling using a table-top arm cycler. Cadence and resistance of the exercise will be determined as per each individual's tolerance. All exercise will be supervised by the neuromuscular specialist physio, to ensure it is completed safely. Participants will be able to have plenty of breaks during the assessments.
89081287|NCT05382988|Experimental|Experimental Group|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
89081288|NCT05382988|No Intervention|Control Group|No additional intervention was performed
89081289|NCT05379868|Active Comparator|Posterior column osteotomy|Apical 3-5 posterior column osteotomies in addition to standard treatment
89081290|NCT05379868|Placebo Comparator|No osteotomies|Standard treatment
89081291|NCT02710747|Experimental|Genetic Group|Dose (mg/week) = [5.6044 - 0.02614 × Age [in years] + 0.0087 × Height [cm] + 0.0128 × Weight [kg] - 0.8677 × VKORC1 A/G -1.6974 × VKORC1 A/A - 0.5211 × CYP2C9 *1/*2 - 0.9357 × CYP2C9 *1/*3 - 1.0616 × CYP2C9 *2/*2 - 1.9206 × CYP2C9*2/*3 - 2.3312 × CYP2C9 *3/*3 - 0.1092 × Asian race - 0.5503 × amiodarone ]2
89081292|NCT02710747|No Intervention|Control Group|Dose for the first three days after operation will be 4.5mg/d.
89081293|NCT05382832|Experimental|A1 Group SCS|Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting two weeks after the SCS implant
89081294|NCT05382832|Experimental|A1 Group Botox|Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting two weeks after the SCS implant
89081295|NCT05382832|Placebo Comparator|B1 Group SCS|Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting two weeks after the SCS implant
89081296|NCT05382832|Placebo Comparator|B1 Group Saline|Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting two weeks after the SCS implant
89081297|NCT05382832|Experimental|A2 Group SCS|Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting at the 28th week of clinical trial investigation
89081298|NCT05382832|Experimental|A2 Group Botox -after washout period|Botox Injection and the SCS Internal Pulse Generator turned on in sham-mode. Starting at the 28th week of clinical trial investigation
89081299|NCT05382832|Placebo Comparator|B2 Group SCS|Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting at the 28th week of clinical trial investigation
89081300|NCT05382832|Placebo Comparator|B2 Group Saline -after washout period|Placebo Injection and Internal Pulse Generator turned on in the high-frequency working mode. Starting at the 28th week of clinical trial investigation
89225153|NCT05978804|Experimental|Active tDCS on the DLPFC + Cognitive Intervention(s)|Participants will receive active tDCS on DLPFC + Cognitive Intervention(s) first and then receive only active tDCS Intervention after a three-month washout period.
89225154|NCT05978804|Experimental|Active tDCS on the DLPFC only|Participants will receive active tDCS on the DLPFC-only intervention first and then receive active tDCS + Cognitive Intervention(s) after a three-month washout period.
89225155|NCT05978622||Dexamethasone Intravitreal Implant (DEX-I)|Dexamethasone 700 μg intravitreal implant (DEX-I) administered according to general clinical practice.
89225156|NCT05977660||With chronic ankle instability (CAI)|Participations with CAI diagnosed by a medical doctor
89225157|NCT05977660||control (without CAI)|Participations without CAI who didn't have any ankle injury 2 years before the study recruitment
89225158|NCT05976698|Experimental|Intervention order: 10 μg LSD - 20 μg LSD - Placebo|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be 10 μg LSD - 20 μg LSD - Placebo. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: active+placebo; 2. visit: active+active, 3. visit: placebo+placebo."
89225159|NCT05976698|Experimental|Intervention order: 10 μg LSD - Placebo - 20 μg LSD|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be 10 μg LSD - Placebo - 20 μg LSD. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: active+placebo; 2. visit: placebo+placebo, 3. visit: active+active."
89225160|NCT05976698|Experimental|Intervention order: 20 μg LSD - 10 μg LSD - Placebo|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be 20 μg LSD - 10 μg LSD - Placebo. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: active+active; 2. visit: active+placebo, 3. visit: placebo+placebo."
89225161|NCT05976698|Experimental|Intervention order: 20 μg LSD - placebo - 10 μg LSD|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be 20 μg LSD -placebo - 10 μg LSD. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: active+active; 2. visit: placebo+placebo, 3. visit: active+placebo."
89225162|NCT05976698|Experimental|Intervention order: placebo - 10 μg LSD - 20 μg LSD|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be placebo - 10 μg LSD - 20 μg LSD. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: placebo+placebo; 2. visit: active+placebo, 3. visit: active+active."
89225163|NCT05976698|Experimental|Intervention order: placebo - 20 μg LSD - 10 μg LSD|"Each subject will participate in 3 x 5 h study sessions separated by at least 7 days.~Order of drug administration will be placebo - 20 μg LSD - 10 μg LSD. Vials will contain either 10μg (Active) or 0 μg LSD (Placebo). Thus, participants will be administered two vials on each study visit. 1. visit: placebo+placebo; 2. visit: active+active, 3. visit: active+placebo."
89225164|NCT05965544|Active Comparator|Group PreS|The block will be applied in the preoperative period
89225165|NCT05965544|Active Comparator|Group PostS|The block will be applied in the postoperative period
89225166|NCT05961033||study|Individuals in the first group to be included in the study group will be included in a virtual reality-based exercise program for half an hour a day, 5 days a week for a total of 4 weeks, in addition to routine electrotherapy programs for half an hour a day, 5 days a week for a total of 4 weeks. These individuals will be able to play the games saved in the Oculus Quest 2 SG system in the virtual environment, thanks to the three-dimensional glasses and handpiece that can be worn on the head.
89225167|NCT05961033||control|Individuals who receive traditional electrotherapy and exercise program
89225168|NCT05958017|Experimental|reSET Group|Participants in this group will use the reSET mobile app for 12 weeks.
89225169|NCT05958017|Other|Standard of Care Group|Participants in this group will receive standard of care treatment for 12 weeks.
89225170|NCT05957718|Experimental|TKTX Group|In this group, We will use TKTX cream as a local anesthesia
89081301|NCT00936598|Experimental|zolpidem|Participants randomized to the zolpidem (intervention) group will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women > or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
89081302|NCT00936598|Placebo Comparator|sugar pill|Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
89081303|NCT01025817|Experimental|Everolimus (EVR) & low dose of tacrolimus|Everolimus (EVR) and tacrolimus treatment arm: Therapeutic drug monitoring of everolimus and tacrolimus was mandatory throughout the study. From Day 5 onwards, the everolimus 0.75 mg b.i.d. dose was increased if the trough level was < 3 ng/mL, or reduced if the trough level was > 8 ng/mL. Tacrolimus was initiated according to local practice. In this treatment arm, the tacrolimus dose was adjusted from Day 3 onwards, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From Month 2 until Month 6, the target tacrolimus trough level was 3 ng/mL to 6 ng/mL. After Month 6, the tacrolimus dose was adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL.
89081304|NCT01025817|Active Comparator|Mycophenolate mofetil & standard dose tacrolimus|Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.
89081305|NCT02710513|Experimental|Beta-glucans|2 months run-in period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of normal pasta) + 2 months intervention period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of functional pasta providing 3 g of beta-glucans/day)
89081306|NCT00939640|Experimental|Dietary intervention|Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
89081307|NCT05264545|Other|Single Arm|There are no arms in the study, it is a non randomized, controlled study
89081308|NCT02872155|Experimental|Oral hydratation|
89081309|NCT02872155|Active Comparator|Endovenous hydratation|
89081310|NCT00605956|Experimental|1|NatrOVA Creme Rinse - 1% Spinosad
89081311|NCT00605956|Experimental|2|NatrOVA Vehicle - no Spinosad
89081312|NCT00605956|Placebo Comparator|3|Blank Patch
89225171|NCT05957718|Placebo Comparator|Control Group|In this group, we will use a Vasalin as Placebo
89225172|NCT05953584|Experimental|Etavopivat|Participants will receive Etavopivat 400 mg once daily (QD) orally.
89230140|NCT00661427|Active Comparator|Cetuximab 750 mg/m^2|Cetuximab 750 mg/m^2 IV over 3 hours every other week
89225173|NCT05953584|Experimental|Etavopivat with HU|Participants will receive Etavopivat 400 mg QD orally in combination with HU. The dose of HU (mg/kg) will be stable (no more than a 20% change in dosing except for weight-based changes) during the study, in the opinion of the Investigator.
89225174|NCT05953428|Experimental|Opioid Sparing Anesthesia Protocol|The OSA protocol will include boluses of dexmedetomidine and ketamine at anesthesia induction, followed by a ketamine infusion that will continue until PACU discharge. Another bolus of ketamine will be administered upon surgical incision and another dexmedetomidine bolus will be given at surgical closure to reduce the use of opioids.
89225175|NCT05953428|Other|Opioid Based Anesthesia Protocol|The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
89225176|NCT05951296|Experimental|Leramistat|Leramistat once daily
89225177|NCT05951296|Placebo Comparator|Placebo|Placebo comparator
89225178|NCT05947136|Experimental|Intervention group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective), specific and proactive referrals will be made systematically after each detection visit according to the level of risk, estimated on the basis of decision trees (management guide) and via the dedicated PASCA network of healthcare professionals, to initiate early treatment and follow-up where necessary.
89225179|NCT05947136|Active Comparator|Control group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring forwarded to the referring onco-haematologists, so that they can initiate their own management.
89225180|NCT05944601||Healthy controls|Elderly people without cognitive impairment or subjective cognitive decline.
89081313|NCT02710357|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
89081314|NCT02710357|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 4 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
89081315|NCT02871999|Active Comparator|Control group|This group receives normal treatment after surgery,with no acupuncture.
89081316|NCT02871999|Experimental|Experimental group|This group receives acupuncture therapy besides normal treatment after surgery. The acupuncture therapy starts after 24 hours of surgery, 1 time a day, 30 minutes every time, until the fifth day.
89081317|NCT05382676||Visual Function|automated vision measured by EyeSwift®Pro-ESP100
89081318|NCT01218113|Experimental|3D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of the HIV Vaccine 732462 at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
89081319|NCT01218113|Experimental|2D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 2 doses of the HIV Vaccine 732462 at Weeks 0 and 4 and one dose of placebo (saline solution) at Week 28, administered intramuscularly in the deltoid of the non-dominant arm.
89081320|NCT01218113|Placebo Comparator|Control Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of placebo (saline solution) at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
89081321|NCT05264467|No Intervention|Control|
89081322|NCT05264467|Experimental|PRF|
89081323|NCT02871453|Experimental|Acupuncture combined rehabilitation|"Scalp acupuncture treatment~Rehabilitation treatment"
89081324|NCT02871453|Experimental|Rehabilitation|Rehabilitation treatment
89081325|NCT00605410|Active Comparator|1|
89081326|NCT00605410|Placebo Comparator|2|
89081327|NCT02710201|No Intervention|Control|No feedback on progress of other participants.
89081328|NCT02710201|Experimental|Descriptive Social Norm|Average physical activity of other participants in study conveyed to this group.
89081329|NCT02710201|Experimental|Descriptive-plus-Injunctive Social Norm|Average physical activity of other participants in study and message of approval or disapproval (depending on how one is faring compared to others) conveyed to this group.
89081330|NCT04300881|Experimental|Treatment|Eplerenone
89081331|NCT04300881|No Intervention|Control|
89081332|NCT04203940|Active Comparator|Cyanoacrylate|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue (Histoacryl®).
89081333|NCT04203940|Active Comparator|Suture|mesh fixation was done with polypropylene 2/0 sutures
89081334|NCT00603850||1|Intermediate AMD Patients
89081335|NCT03873493|Experimental|Venetoclax + Ibrutinib|Participants received 400 mg venetoclax orally once a day after a 5-day ramp-up and 420 mg ibrutinib orally once a day for up to 2 years or until progressive disease, intolerability, or they became eligible for stem cell transplantation after achieving complete remission.
89081336|NCT05264311|Experimental|EG: Exercise Group|Pilates exercise program (1 h x 2 sessions per week x 2 months)
89081337|NCT05264311|No Intervention|CG: Control Group|Usual lifestyle
89081338|NCT05264233|Active Comparator|Meal rich in coconut oil|Participants will be asked to consume a breakfast (0 minute) and lunch (330 minute) rich in coconut oil
89081339|NCT05264233|Active Comparator|Meal rich in butter|Participants will be asked to consume a breakfast (0 minute) and lunch (330 minute) rich in butter
89081340|NCT05264233|Active Comparator|Meal rich in vegetable oil|Participants will be asked to consume a breakfast (0 minute) and lunch (330 minute) rich in vegetable oil
89081341|NCT00611689|Experimental|A|Imatinib and PTK/ZK222584
89081342|NCT05264077|Experimental|Dexmedetomidine|Inj.Dexmedetomidine(precidex ) 200mcg/2ml Given to participants in infusion form for 24 hours
89081343|NCT05264077|Experimental|Midazolam|Inj.midazolam 5mg/ml given to participants in infusion form for 24 hrs
89081344|NCT03757819|Experimental|Before Walking tDCS first then SHAM|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
89081345|NCT03757819|Experimental|During Walking tDCS first then SHAM|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
89081346|NCT04866901|Experimental|Slow-Paced Breathing (SPB)|Participants will first be provided with a brief overview of the science of breathing and benefits for autonomic regulation. Then, participants will receive specific practice instruction and guided breathing at a rhythm of 6 breaths/min (4-6 count) via auditory tones. Each participant will be encouraged to breathe as comfortably and effortlessly as possible, while keeping the lungs moving in accordance with the audio guidance. The accompanying training and daily instruction reminder will emphasize the importance of following the specific rhythm of breathing, without regard to thoughts or inner experience. A soft but firm tone of voice will be employed to minimize likelihood of relaxing effects, while maintaining similarity to the tone of voice used in the other conditions.
89081347|NCT04866901|Experimental|Mindfulness (M)|Procedures are based on Berghoff et al., providing a brief history of mindfulness practices, definitions, instructions for practice, common challenges, and recommendations. An audio recording will then guide the mindfulness practice. Specific to this study, in order to further distinguish the three conditions, the guided audio recording will emphasize the importance of attending to the quality of experience while not changing or attending to breathing patterns.
89081348|NCT04866901|Experimental|Yogic Breathing (SPB+M)|Information from the other two conditions will be synthesized with the aim of eliciting attention to the same breathing instruction used for SPB, while also observing the quality of experience during the practice, as conducted for M.
89081349|NCT00612391|Experimental|Lateral, Minimally Invasive Approach|Lateral, Minimally Invasive Approach in GT fractures treated operatively (plates and screws)
89081350|NCT00612391|Active Comparator|Deltopectoral approach:|Deltopectoral approach for GT fracture treated operatively
89081351|NCT02709811|Experimental|electrochemotherapy|
89081352|NCT04216147|Experimental|PNE group|Patients received 4 sessions, separated one week between them. The treatment consisted the application of a galvanic current through an acupuncture needle (0,30x30mm). The approach were performed with a transverse axis with a needle in plane, being superficial and deep interface of medium nerve the target tissue. The parameters will be 2 mA (milliamps), 10 seconds, 3 impacts (3: 3: 3).
89081353|NCT04216147|Experimental|Surgery group|Patients received surgery for median nerve release.
89081354|NCT05261035|Experimental|stretching exercises group|Pregnant women with RLS were instructed to perform stretching exercises daily for one week
89081355|NCT05261035|Active Comparator|Thermotherapy group|Pregnant women with RLS were instructed to apply warm water immersion of their legs daily for one week.
89081356|NCT04848805||liver recipients with hepatocellular and cohlangiocarcinoma diagnosis|liver recipients
89081357|NCT04841005|Experimental|Square-Step Exercise group|Square-step exercise for 8 weeks will be applied under the supervision of a physiotherapist.
89081358|NCT04841005|Experimental|Strengthening Exercise Group|Strengthening exercise for 8 weeks will be applied under the supervision of a physiotherapist.
89081359|NCT02709733|Experimental|VR Motivation Training|Weekly training sessions with a VR motivation treatment 1 hour per week for 8 weeks.
89081360|NCT02709421||Indomethacin Group|"All the patients with high risks of PEP received administration of one single dose of 100mg rectal indomethacin after ERCP.~Patients were considered high risk of PEP if they met one of the following criteria: clinical suspicion of sphincter of Oddi dysfunction, a history of PEP, pancreatic sphincterotomy, precut sphincterotomy, ≥8 cannulation attempts, cannulation time≥10 minutes; pneumatic dilatation of an intact biliary sphincter, ≥3 inadvertent pancreatic duct cannulation, opacification of pancreatic acini, or the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush or forceps."
89081361|NCT00939484|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89081362|NCT01010217|Experimental|Haploidentical related|Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day
89081363|NCT01010217|Experimental|1 Antigen Mismatch Related or Unrelated|Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.
89081364|NCT01010217|Experimental|Matched Unrelated Donor (MUD)|Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide
89081365|NCT00605488|Experimental|1|Pet Scan
89081366|NCT04268212|Experimental|Bitter Melon|The participants were asked to consume 100 ml of bitter melon juice 15 minutes prior to the 75-g oral glucose intake. Participants drank the juice within 5 minutes. Participants remained seated throughout the following 2 hours.
89081367|NCT04268212|Experimental|Exercise|Participants performed 30 minutes of treadmill walking at 65% of the age-predicted maximum heart rate. The exercise started 15 minutes after the 75-g oral glucose intake.
89081368|NCT00604006|Experimental|Group A|
89081369|NCT00604006|Placebo Comparator|Group B|
89081370|NCT00604084|Experimental|Ivermectin|Non-pregnant, non-breastfeeding, taller than 90cm and 5 years or older
89081371|NCT00604084|Experimental|Permethrin|Pregnant, breastfeeding, children under 90cm or under 5 years old
89081372|NCT02691052||Pts receiving nab-paclitaxel/gemcitabine|Patients with metastatic pancreatic cancer undergoing a firstline therapy with nab-paclitaxel and gemcitabine will be asked to fill in an EORTC QLQ-C30 questionnaire and an additional questionnaire on worries about quality of life impairments every 4 weeks. No further intervention.
89081373|NCT05379478||Unvaccinated, COVID naive|Volunteers with no history of COVID-19 or vaccination. This is an observational study with no intervention
89081374|NCT05379478||Unvaccinated, Convalesced|Volunteers with a history of COVID-19 infection but no COVID-19 vaccination. This is an observational study with no intervention
89081375|NCT05379478||Vaccinated|Volunteers with a history of COVID-19 vaccination. This is an observational study with no intervention
89081376|NCT04267042|Active Comparator|Budesonide via Mucosal Atomization Device (MAD)|"Patients in this arm will administer budesonide using a mucosal atomization device (MAD, Wolfe-Tory Medical, Salt Lake City, UT) once a day at least 5 times a week for 6 months postoperatively. The MAD atomizes the medication into particles from 30-100 um in size thus increasing the surface area for drug absorption.~Budesonide is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the MAD syringe."
89081377|NCT04267042|Active Comparator|Budesonide via nasal saline irrigation (INSI)|"Patients in this arm will administer impregnated budesonide in nasal saline irrigation (INSI) using a NeilMed squeeze bottle (NeilMed Pharmaceuticals, Santa Rosa, California) once a day at least 5 times a week for 6 months postoperatively.~Budesonide is provided in nebules (1mg/2cc).Patients will place two nebules of budesonide into the 240mls of saline."
89081378|NCT04266652|Experimental|Autogenous bone block|the monocortical block grafts were harvested from the retromolar region (i.e. linea oblique) by using of rotating (i.e. carbide burs)
89081379|NCT04266652|Experimental|Tooth block|In the first group, a second mucoperiosteal flap was elevated to surgically remove the respective wisdom tooth. After its removal and during the same surgery, the crown was decapitated at the cemento -enamel junction using a rotating carbide bur under gentle sterile saline cooling and the exposed pulp was preserved. The separated tooth root was adapted to match the size and shape of the defect area. To improve ankylosis between the graft and the defect site, the layer of cementum at the respective downward aspects of the root was carefully removed using a diamond bur until the underlying dentin was entirely exposed
89225181|NCT05944601||Subjective cognitive decline|Individuals presenting cognitive complains that are not confirmed by neuropsychological testing.
89225182|NCT05944601||patients with MCI due to AD|Patients with Mild Cognitive Impairment with abnormal spinal fluid test for amyloid beta protein.
89225184|NCT05941507|Experimental|LCB84 monotherapy|IV infusion Q3W
89225185|NCT05941507|Experimental|LCB84 + anti-PD-1|IV infusion Q3W
89225186|NCT05935930|Active Comparator|Group P (n=22)|Propofol group
89225187|NCT05935930|Active Comparator|Group S (n=22)|Sevoflurane group
89225188|NCT05934110|Experimental|EMP16-120/40|EMP16 120 mg orlistat/40 mg acarbose (referred to as EMP16-120/40), 80 participants.
89225189|NCT05934110|Active Comparator|MR orlistat|MR orlistat 120 mg, 80 participants.
89225190|NCT05934110|Active Comparator|Conventional orlistat|Conventional orlistat 120 mg, 80 participants.
89225191|NCT05934110|Experimental|EMP16-60/20|EMP16 60 mg orlistat/20 mg acarbose (referred to as EMP16-60/20), 40 participants.
89225192|NCT05934110|Placebo Comparator|Placebo|Placebo, 40 participants
89225193|NCT05933239|Other|Patients diagnosed with non-small cell lung cancer (NSCLC), planned for standard-of-care surgery|
89225194|NCT05933122|Sham Comparator|"Cohort called elsewhere"|cohort without specific care by a sexologist
89225195|NCT05933122|Experimental|"Cohort called here"|cohort with an intervention by a sexologist
89225196|NCT05931549||Patients in treatment for severe anorexia nervosa|Treatment as usual.
89225197|NCT05931549||Age matched healthy controls|No treatment.
89225198|NCT05930665|Experimental|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin for 4 to 6 cycles, followed by Maintenance with Cadonilimab and Bevacizumab
89225199|NCT05930483|Experimental|Baseline (instructions, video, tape, scale, accelerometer)|Participants receive written instructions and website link to an instructional video along with supportive materials including measuring tape, Aria WiFi-enabled scale, and Actigraph accelerometer to be worn for 7 days at baseline. Patients also undergo blood sample collection at baseline.
89225200|NCT05930483|Experimental|Stage I, Arm I (¡Vida!)|Participants participate in the online ¡Vida! program consisting of 26 health education online sessions, dietary modifications, and home-based exercise sessions on study. Participants receive supportive materials consisting of a Fitbit Aria scale, a Fitbit Luxe (or latest device), the Fitbit app, and access to the Cook for Your Life website on study. Patients also undergo blood sample collection on study.
89225201|NCT05930483|Experimental|Stage I, Arm II (¡Vida!, lifestyle sessions)|Participants participate in the online ¡Vida! program consisting of 26 health education online sessions, dietary modifications, and home-based exercise sessions on study. Participants receive supportive materials consisting of a Fitbit Aria scale, a Fitbit Luxe (or latest device), the Fitbit app, and access to the Cook for Your Life website on study. Participants also attend remote lifestyle health education sessions on study. Patients also undergo blood sample collection on study.
89225202|NCT05930483|Experimental|Stage II, Arm III (¡Vida!, lifestyle sessions)|Participants receive interventions as in arm II.
89081380|NCT01217957|Experimental|Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 1.68 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
89081381|NCT01217957|Experimental|Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.23 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.23 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
89081382|NCT01217957|Experimental|Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.97 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.97 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
89081383|NCT01217957|Experimental|Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 3.95 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 3.95 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
89081384|NCT01217957|Experimental|Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone|In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
89081385|NCT00939094|Experimental|A|
89081386|NCT00939094|Placebo Comparator|B|
89081387|NCT04297371||CTD with RVH|The diagnosis of CTD was made based on the clinical classification criteria. The RVH patient was diagnosed by an echocardiography demonstration (later confirmed by CMR) of a hypertrophic RV (maximal end-diastole RV wall thickness >4 mm) due to CTD.
89081388|NCT04297371||CTD without RVH|The diagnosis of CTD was made based on the clinical classification criteria.The subjects were enrolled as having non-RVH if their RV wall thickness was ≤ 4 mm (later confirmed by CMR).
89081389|NCT04297371||Control group|The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
89081390|NCT01217801|Experimental|Ondansetron (ODFS)|single dose of Ondansetron Orally Dissolving Filmstrip 8 mg
89081391|NCT01217801|Active Comparator|Zofran (ODT)|Single dose of Zofran (Ondansetron) ODT Orally Disintegrating Tablets 8 mg
89081392|NCT04157413||Stunted Group|A comparative cross sectional study will compare stunted group and non-stunted group on amino acid intake, blood amino acid and intestinal permeability. Stunted group is defined as children who have LAZ <-2 SD
89081393|NCT04157413||Non-stunted Group|Non-stunted group will be those with LAZ >= 0.5 SD matching by age and sex with stunted group. Other criteria will be similar. No Intervention will be given to the groups in this proposed protocol.
89081394|NCT00935818|Active Comparator|varenicline and buproprion SR|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
89081395|NCT00935818|Placebo Comparator|varenicline and placebo|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
89081396|NCT01216319|Experimental|Nipple Reconstruction Cylinder|
89081397|NCT00607516|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
89081398|NCT00607516|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
89081399|NCT04804345||The aprotinin group,|all patients receiving a first infusion 1M KIU before surgical incision followed by a steady dose of 250 000 KIU/h with an additional dose of 1M KIU added to the cardiopulmonary bypass unit.
89081400|NCT04804345||The tranexamic acid group|all patient receiving tranexamic acid following each local center standarded protocol
89081401|NCT00936208||Essential hypertensive men and women|
89081402|NCT02709265|Experimental|Cohort 1|amikacin/fosfomycin (30/12 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
89081403|NCT02709265|Experimental|Cohort 2|amikacin/fosfomycin (60/24 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
89081404|NCT02709265|Experimental|Cohort 3|amikacin/fosfomycin (90/36 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
89081405|NCT02709265|Experimental|Cohort 4|amikacin/fosfomycin (90/36 mg) delivered via the PARI LC Sprint Nebulizer (single dose)
89081406|NCT02709265|Experimental|Cohort 5|amikacin/fosfomycin (Dose and Nebulizer to be chosen based on results from Cohorts 1 - 4)
89081407|NCT02709499|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
89081408|NCT02709499|Experimental|6J LLLT|The Laser radiation will be made with 4J by spot
89081409|NCT01216163|Experimental|Treatment A|
89081410|NCT01216163|Active Comparator|Treatment B|
89081411|NCT01216163|Placebo Comparator|Treatment C|
89081412|NCT05260411|Experimental|AK102 regimen 1|
89081413|NCT05260411|Experimental|AK102 regimen 2|
89081414|NCT05260411|Placebo Comparator|Placebo|
89081415|NCT05260255|Experimental|vitamin D supplementation|add on vitamin D2 ( calciferol ) 40,000 IU/wk for 12 weeks
89081416|NCT05260255|Placebo Comparator|placebo|add on placebo for 12 weeks
89081417|NCT00612469|Placebo Comparator|NaF|Sodium fluoride application
89081418|NCT00612469|Experimental|V3|Topical application of 3% vancomycin
89081419|NCT00612469|Experimental|V10|Topical application of 10% vancomycin
89081420|NCT00612469|Active Comparator|CHX|Topical application of 1% chlorhexidine
89081421|NCT00933244|Other|High Dose Vitamin D3|"Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days."
89081422|NCT00933244|Other|Low Dose Vitamin D3|"Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.~Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days."
89081423|NCT00933244|Placebo Comparator|Placebo|"Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days."
89081424|NCT02709187|Experimental|RT group|combination dose of Candesartan and Rosuvastatin and DP-R208 in order
89081425|NCT02709187|Experimental|TR group|DP-R208 and combination dose of Candesartan and Rosuvastatin in order
89230141|NCT00049543|Experimental|Arm I (gefitinib)|Patients receive gefitinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
89230142|NCT00049543|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
89225203|NCT05930483|Experimental|Stage II, Arm IV (¡Vida!, lifestyle sessions, coaching)|Participants participate in the online ¡Vida! program consisting of 26 health education online sessions, dietary modifications, and home-based exercise sessions on study. Participants receive supportive materials consisting of a Fitbit Aria scale, a Fitbit Luxe (or latest device), the Fitbit app, and access to the Cook for Your Life website on study. Participants also attend remote lifestyle health education sessions and receive 14 30-minute individualized telephone health coaching sessions. Patients also undergo blood sample collection on study.
89225204|NCT05930483|Experimental|Stage II, Arm V (¡Vida!, lifestyle sessions, coaching)|Participants receive interventions as in arm IV.
89225205|NCT05930483|Experimental|Stage II, Arm VI (¡Vida!, lifestyle sessions, coaching, food))|Participants participate in the online ¡Vida! program consisting of 26 health education online sessions, dietary modifications, and home-based exercise sessions on study. Participants receive supportive materials consisting of a Fitbit Aria scale, a Fitbit Luxe (or latest device), the Fitbit app, and access to the Cook for Your Life website on study. Participants also attend remote lifestyle health education sessions and receive 14 30-minute individualized telephone health coaching sessions and receive a bag of groceries each month on study. Patients also undergo blood sample collection on study.
89225206|NCT05924997|Experimental|Interventional arm|
89225207|NCT05919511||At risk for GVHD|Equal or Greater than 18 years old post alloSCT
89225208|NCT05918861|Experimental|Dalcetrapib|Dalcetrapib 600 mg (two 300 mg tablets) orally once daily
89225209|NCT05918861|Placebo Comparator|Placebo|Matching dalcetrapib placebo tablets (2 tablets) orally once per day
89225210|NCT05918640|Experimental|Ewing Sarcoma|The first part of this study is a standard 3+3 design to test the safety, tolerability and pharmacokinetic profile of lurbinectedin administered on a day 1, 4 schedule in patients with FET-fusion tumors.
89225211|NCT05918055|Experimental|Phase I- Dose escalation of KPT-8602 for HR-MDS|Inqovi for 5 days, followed by escalating doses of KPT-8602
89225212|NCT05918055|Experimental|Phase II- Dose expansion for HR-MDS|Inqovi for 5 days, followed by RP2D/Phase II dose of KPT-8602
89225213|NCT05901298|Experimental|Mobile Application|"My Breastfeeding Guide mobile nursing application, which was developed based on Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model."
89225214|NCT05901298|No Intervention|Standart Care|Standard antenatal and postnatal care from health care providers.
89225215|NCT05894356||Men undergoing sperm DNA fragmentation test|Men presenting at the clinic for infertility evaluation
89225216|NCT05887466|Experimental|Low Dose Group|"IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~Study group : 6 subjects~Dosage: 3.15X10^6 cells/body (6 tracks in total, 52.5X10^4 cells per track)"
89225217|NCT05887466|Experimental|High Dose Group|"IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~Study group : 6 subjects~Dosage: 6.30X10^6 cells/body (6 tracks in total, 105X10^4 cells per track)"
89225218|NCT05886842||Test-retest|A group of 19 patients will be tested using the 30 seconds Sit-to-stand and Timed up and go tests. Each test will be repeated 3 times and the best score will be used. There is going to be 3 days waiting period before the re-tests.
89225219|NCT05884372|Experimental|Denosumab+Eldecalcitol|Denosumab (subcutaneous injection 60mg/6 months) combined with ELD (oral 0.75μg/day) for 12 months.
89225220|NCT05884372|Active Comparator|Denosumab+Native Vitamin D+Calcium|Denosumab (subcutaneous injection 60mg/6 months) combined with native vitamin D (oral 800IU/day) and Calcium (oral 600mg/day) for 12 months.
89225221|NCT05879614|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
89225222|NCT05878769|Experimental|Open-Label Extension|Eligible participants from parent studies GB43311 and GB44332 will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W) until the end of the study
89225223|NCT05876351|Experimental|Eculizumab|Participants will receive Eculizumab in a single dose vial.
89225224|NCT05874986|Other|Training group|Resistance training
89225225|NCT05869786|Experimental|Virtual Reality Group|Participants in both groups will receive a conventional rehabilitation program. Participants in the virtual reality group will receive virtual reality-mediated upper extremity rehabilitation for 3 weeks, 5 sessions per week, each session lasting 30 minutes (450 minutes in total). In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves. 3 different games will be intervened for 10 minutes each, totaling 30 minutes per day.
89225226|NCT05869786|Active Comparator|Control Group|Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist. Participants in both groups will receive a conventional rehabilitation program.
89225227|NCT05868148||Shoulder iD device implant|Adult patients who have reached skeletal maturity, with a functional deltoid muscle, and massive and non-repairable rotator cuff tear within one or more indications and zero contraindications who will receive the Shoulder iD Primary Reversed Glenoid device to replace the shoulder joint.
89225228|NCT05867888|Active Comparator|Control group|conventional physical therapy program (Instructions, Ice application, Deep tissue massage, Stretching exercises, Joint mobilization and isometric exercises).
89225229|NCT05867888|Experimental|Experimental group 1|Shock wave therapy + Conventional physical therapy.
89225230|NCT05867888|Experimental|Experimental group 2|Low level laser therapy + Conventional physical therapy.
89225231|NCT05867121|Experimental|Cohort A: NSCLC|Participants with NSCLC will receive RO7496353, and atezolizumab, given as an intravenous (IV) infusion at an assigned dose on Day 1 of each 21-day cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.
89081426|NCT02708953|Experimental|Treatment (thoracic manipulation)|Patients in the initial manipulation group will attend physical therapy two sessions per week for 3 weeks for a total of 6 sessions. Each treatment session will last for a total of 15 minutes. After the initial manipulation group receives 3 weeks of treatment they will wait for 1-week, be retested, and then crossover into the other group.
89081427|NCT02708953|Active Comparator|Wait-list (thoracic manipulation)|When individuals are assigned to the wait-list control group they will serve as the control for 3 weeks while the initial manipulation group receives treatment. After serving as the wait-list control condition for 3 weeks, this group will then return for testing and will receive the manipulation package as described below at 4 weeks.
89081428|NCT04262830||All Study Participants|This is an observational study where all study participants are within a single group.
89081429|NCT00930046|Active Comparator|Ropivacaine group|Patients in this group will receive ropivacaine via the wound catheter for the first 48hrs after surgery
89081430|NCT00930046|Placebo Comparator|Normal Saline Group|Will receive an infusion of normal saline for 48hrs post-operatively via the wound catheter.
89081431|NCT05244031|Active Comparator|Superficial ESP|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
89081432|NCT05244031|Active Comparator|Control group|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
89081433|NCT05155306|Experimental|Tfasted|T: Test Treatment fasted: under fasted conditions
89081434|NCT05155306|Experimental|Tfed|T: Test Treatment fed: under fed conditions
89081435|NCT05155306|Experimental|Rfasted|R: Reference Treatment fasted: under fasted conditions
89081436|NCT05155306|Experimental|Rfed|R: Reference Treatment fed: under fed conditions
89081437|NCT04262752|Experimental|chronically constipated people|Adults with chronic constipation due to either neurogenic bowel dysfunction (NBD) as consequence of a neurogenic condition such as Multiple sclerosis or Parkinson Disease, or to unkwon origin (Idiopathic No-NBD)
89081438|NCT03823651|Experimental|Patient|These are patients undergoing hematopoetic stem cell transplant. Patients will complete Interval training, undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
89081439|NCT03823651|Experimental|Caregiver|These are the assigned caregivers for transplant patients. Caregivers will undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
89081440|NCT04712071|Experimental|Ketamine|40 minutes intravenous infusion of 0.5 mg/kg ketamine.
89081441|NCT02708875|Experimental|Mixed Meal Challenge|Participants will consume a liquid mixed meal (~300 calories - fat, carbohydrate, and protein) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
89081442|NCT02708875|Active Comparator|Glucose Challenge|Participants will consume a glucose challenge (50g glucose) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
89081443|NCT00609388|Active Comparator|A|Group A receives an intraportal Tacrolimus-infusion, ATG Induction, Tacrolimus and Steroids.
89081444|NCT00609388|Placebo Comparator|B|Group B receives a placebo-Saline solution (0.9%)-Infusion, ATG induction, Tacrolimus and Steroids.
89081445|NCT02709031|Active Comparator|Cicletanine|Patients will take escalating doses of cicletanine
89081446|NCT02709031|Experimental|Cicletanine + magnesium|Patients will take escalating doses of cicletanine; patients will in addition take magnesium
89081447|NCT05233111|Placebo Comparator|Treatment as Usual|Participants in the Treatment as Usual (TAU) group will not receive Prolonged Exposure therapy, but will instead receive the standard clinical treatment received by all persons with spinal cord injury (SCI) at the rehabilitation facility. TAU participants will complete questionnaires/interviews at 1, 3, and 6 months from Baseline.
89081448|NCT05233111|Experimental|Brief Prolonged Exposure|Experimental: Brief Prolonged Exposure Participants will receive Brief PE. Subjects in the Brief Prolonged Exposure (BPE) intervention group will additionally receive 3 total therapy sessions, each lasting about 60 minutes spaced about 1-7 days apart. Sessions include education about common reactions to trauma, breathing retraining, identification of self-care tasks and prolonged (repeated) imaginal exposure to trauma memories. Any missed sessions will be made up by scheduling multiple sessions in subsequent weeks. Individuals in the BPE group will complete a screener and then survey questionnaires/ interviews at 1, 3, and 6 months from Baseline.
89081449|NCT04262674|Experimental|Cognitive-motor training|Simultaneous cognitive-motor training (i.e. exergame) and strength training
89081450|NCT04262674|No Intervention|Control|Passive control group
89081451|NCT02887937||Breast Mass 4a-cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
89081452|NCT02887937||Breast Mass 4a- non cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-non cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration..
89081453|NCT02887937||Breast Mass 4b|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4b breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
89225232|NCT05867121|Experimental|Cohort B: GC|Participants with GC will receive RO7496353, nivolumab, and oxaliplatin, given as an IV infusion at an assigned dose on Day 1 of each 21-day cycle along with either capecitabine or S-1, orally, twice daily on Days 1 to 14 of each cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.
89081454|NCT02887937||Breast Mass 4c|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4c breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
89081455|NCT00606112|Placebo Comparator|1|
89081456|NCT00606112|Placebo Comparator|2|
89081457|NCT00606112|Placebo Comparator|3|
89081458|NCT00606112|Placebo Comparator|4|
89081459|NCT05232955||GTS patient group|Cohort of adult GTS patients, males and females, age range 18 to 50 years
89081460|NCT05232955||Control group|Cohort of healthy control subjects, males and females, age range 18 to 50 years
89081461|NCT00606190|Active Comparator|Retrograde brain perfusion|Pt may be randomized to retrograde brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
89081462|NCT00606190|Active Comparator|Antegrade brain perfusion|Pt may be randomized to antegrade brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
89081463|NCT04168957|Experimental|Oraxol|Subjects in KX-ORAX-008 will begin treatment at the last oral paclitaxel dose they received in Study KX-ORAX-007.
89081464|NCT00935584|Other|PACE Study|"The study utilized a quasi-experimental pre-post intervention design. The intervention provided was physician education to improve EMR use and communication.~Physician training in patient-centered EMR use was developed. The conceptual model of patient-centered communication will provide the underlying framework for the training aimed at improving physicians interviewing and communication skills."
89081465|NCT05201443|Experimental|Diode Laser|At baseline, diode laser is applied to one group.
89081466|NCT05201443|Active Comparator|Titanium curettes|At baseline, titanium curettes are used to both of the groups
89081467|NCT00612547||Observation|Children under the age of five years (2 months to 5 years) residing in the zone covered by the community-based service provider throughout the entire follow-up period
89081468|NCT04266262|Experimental|High-Intensity interval training (HIIT)|
89081469|NCT04266262|Experimental|High-intensity resistance training (HIRT)|
89081470|NCT04266262|No Intervention|Usual care (UC)|Provision of Cancer Care Ontario's physical activity guidelines for cancer survivors
89081471|NCT00606268|Experimental|1|1.0 mg/kg
89081472|NCT00606268|Experimental|2|1.5 mg/kg
89081473|NCT05342935|Experimental|IDA treatment|Each subject will be treated with his prescribed manual PD for 14 days, followed by a treatment period of 14 days with the investigational IDA system, and concluding with additional 14 days of treatment with the manual PD.
89081474|NCT04262518|Other|Outcomes4Me App Users|This cohort will download and use the Outcomes4Me mobile app for breast cancer.
89081475|NCT04264624|Experimental|Guided Biofilm Therapy with Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the adjunctive treatment, he/she will also receive subgingival biofilm removal with Perioflow combined with Erythritol powder at sites with PD≥ 5 mm, including the experimental sites, prior to subgingival biofilm removal with USD.
89081476|NCT04264624|Active Comparator|Guided Biofilm Therapy without Perioflow|The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the control treatment, all teeth present will receive the application of disclosing agent, full-mouth supragingival and intra-sulcular biofilm removal with Airflow at sites with PD up to 4 mm, full mouth supra gingival calculus removal with USD, and subgingival biofilm removal with USD at sites with PD> 4 mm, including the experimental sites, as required.
89081477|NCT05342779|Active Comparator|Group A will undergo stripping of great saphenous vein. .|
89081478|NCT05342779|Active Comparator|Group B will undergo treatment by radiofrequency ablation.|
89081479|NCT04266184|Experimental|Kinesio tape (KT)|Abdominal and symphisis pubis supported lumbopelvic KT will be applied. This group will also receive the same educational program with the control group.
89081480|NCT04266184|Active Comparator|Pelvic belt (PB)|A narrow and flexible adjustable pelvic belt will be used in high position (just under the spina iliaca anterior superior). This group will also receive the same educational program with the control group.
89081481|NCT04266184|Other|Control group|This group will receive a 1-hour educational program composed of neuroscience education and ergonomic training.
89081482|NCT04188691|Experimental|vaccine group 1|vaccine produced by NVSI , Specification: GI.1 / GII.4 (low), 0.5ml / dose
89081483|NCT04188691|Experimental|vaccine group 2|vaccine produced by NVSI , Specification: GI.1 / GII.4 (middle), 0.5ml / dose
89081484|NCT04188691|Experimental|vaccine group 3|vaccine produced by NVSI , Specification: GI.1 / GII.4 (high), 0.5ml / dose
89081485|NCT04188691|Placebo Comparator|Normal saline|（0.5ml / dose）produced by NVSI
89081486|NCT04188691|Placebo Comparator|Aluminum adjuvant|（0.5ml / dose）produced by NVSI
89081487|NCT04264546|Experimental|Experimental Adult Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
89081488|NCT04264546|Experimental|Experimental Children Group - High dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of high dosage investigational sIPV Intervention: Biological: one-dose regimen of high dosage investigational sIPV
89081489|NCT04264546|Experimental|Experimental Infant Group - High dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV Intervention: Biological: Three-dose regimen of high dosage investigational sIPV
89081490|NCT02691208|Experimental|Group I Kinesiotherapy|women with pain treated with a predefinided exercises protocol of 30 minutes.
89081491|NCT02691208|Experimental|Group II Acupuncture|women with pain treated with a predefinided exercises protocol of 30 minutes followed by 30 minutes of acupuncture, used in predefined points
89081492|NCT01215851|Experimental|TMC207|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide placebo administered once daily
89081493|NCT01215851|Experimental|TMC207 and pyrazinamide|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day
89081494|NCT01215851|Experimental|PA-824 and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin placebo (matched to moxifloxacin tablets) administered once daily
89081495|NCT01215851|Experimental|PA-824 and moxifloxacin and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin administered once daily as 400mg tablets
89081496|NCT01215851|Active Comparator|Rifafour e-275 mg|Rifafour e-275 administered once daily with each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol and dose by weight as follows: 30kg-37kg received 2 tablets/day; 38kg-54kg received 3 tablets/days; 55kg-70kg received 4 tablets/day; > or = 71kg received 5 tablets/day
89081497|NCT01215851|Experimental|TMC207 and PA-824|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus PA-824 administered once daily as 200mg tablets
89081498|NCT05378698|No Intervention|Healthy arm|Healthy controls
89081499|NCT05378698|Active Comparator|Tralokinumab|Patients with AD
89081500|NCT00613093|Active Comparator|Patients with glioblastoma multiforme|
89081501|NCT00613093|Active Comparator|Patients with Anaplastic Glioma|
89081502|NCT04638205||Suicide attempt cases|Adolescents and young adults who attempted suicide between 7 and 30 days prior the inclusion
89081503|NCT04638205||Non-suicidal controls|Adolescents and young adults without history of suicide attempt or ideation
89081504|NCT00933166|Experimental|Lotrafilcon A|Investigational contact lens worn in both eyes for three months
89081505|NCT03696277|Experimental|Stereotactic ablative body radiation (SABR)|SAbR will be used to treat all sites of measurable metastases. New sites of metastasis will be treated if deemed appropriate by both medical and radiation oncologists with SAbR.
89081506|NCT00607750|Placebo Comparator|1|
89081507|NCT00607750|Experimental|ATG003|
89081508|NCT04262050|Experimental|TMS + tDCS group|
89081509|NCT04262050|Experimental|sham TMS + tDCS group|
89081510|NCT04262050|Experimental|tDCS group|
89081511|NCT04262050|Experimental|TMS group|
89081512|NCT05271955|Experimental|Experimental|Children receiving the usual care plus intensive use of e-GOLIAH (experimental group)
89081513|NCT05271955|Active Comparator|Control|Children receiving only the usual treatment (control group).
89081514|NCT00609544|Experimental|1|
89081515|NCT00609544|Placebo Comparator|2|
89081516|NCT04908475|Experimental|Arm 1: Risankizumab|Participants will receive risankizumab Dose A in Period A and Period B.
89081517|NCT04908475|Experimental|Arm 2a: Apremilast/Risankizumab|Participants will receive apremilast Dose A in Period A followed by risankizumab Dose A in Period B.
89081518|NCT04908475|Active Comparator|Arm 2b: Apremilast|Participants will receive apremilast Dose A in Period A and Period B. Non-responders at Week 28 and Week 40 will be offered to receive risankizumab Dose A.
89081519|NCT04261816||Operating room extubation group|extubation in the operating room immediately following liver transplantation
89081520|NCT04261816||ICU extubation group|extubation in the ICU following liver transplantation
89081521|NCT05127070||Behavioural science and implementation research|"The investigators will recruit adult health care professionals, senior hospital managers and parents/carers of neonates. Approximate sample sizes in each country are as follows:~Zimbabwe: ~80 Healthcare Professionals ; ~20 Carers/ parents of newborn babies and ~10 Hospital administrators/ managers.~Malawi: ~40 Healthcare Professionals (~10 HCPs per focus group discussion); ~10 Carers/ parents of newborn babies and ~10 Hospital administrators/ managers.~Total participants for new data collection: 180 (this number is likely to be much lower if there is limited staff turnover at neonatal units and if HCPs agree to participate in multiple research activities)."
89081522|NCT05127070||Cost data|A time-use survey will be conducted with a small sample of Healthcare professionals at all 3 hospitals where the Neotree is implemented (sample size ~30) to measure time spent for different activities/procedures carried out on or for a patient.
89225233|NCT05867121|Experimental|Cohort C: PDAC|Participants with PDAC will receive RO7496353, and atezolizumab, given as an IV infusion at an assigned dose on Days 1 and 15 of each 28-day cycle along with nab-paclitaxel, and gemcitabine, also given as an IV infusion on Days 1, 8, 15 of each 28-day cycle until unacceptable toxicity or symptomatic deterioration attributed to disease progression.
89225234|NCT05866705||Cancer|Individuals living with cancer
89081523|NCT05127070||Neonatal admissions at Hospital sites where Neotree is implemented in Zimbabwe and Malawi|"The investigators will record routine clinical admission, discharge and microbiological data for all newborns admitted to the newborn care units using the NeoTree as a replacement to paper-based forms. Individual-level patient data will be collected on all neonates admitted for care at Sally Mugabe Central (Oct 2019 to April 2022) and Chinhoyi Provincial Hospitals (Oct 2020 to April 2022) Zimbabwe, and Kamuzu Central Hospital (Oct 2019 to April 2022), Malawi. Given typical admission rates, this equates to a sample size ~12,000 babies in Zimbabwe and ~ 4000 babies in Malawi.~Data will be collected from February 2019 to the end of the study, to explore trends over time and also include measures of quality newborn care."
89081524|NCT05127070||Comparative case-fatality rates in units using NeoTree and representative control sites|The investigators will collect outcome data from neonatal clinical records at two additional representative hospital sites in Zimbabwe over a 6 month period (sample size ~1200), to inform our sample size calculation for a full evaluation at scale in the future. Individual level data will be collected retrospectively from Bindura Provincial Hospital and Parirenyatwa Hospital (1/4/2021 to 01/10/2021 or beyond depending on sample size).
89081525|NCT05127070||Clinical validation sub-study|The sample size for our diagnostic sub-study has been calculated using sepsis as the index diagnosis. Assuming sensitivity and specificity of 92% (lower 95% CI: 84%) >222 babies would need to be diagnosed with sepsis over five months, during which ~>2000 babies will be admitted with sepsis across sites (Sally Mugabe Central Hospital, Zimbabwe and Kamuzu Central Hospital, Malawi). If necessary, the investigators will continue to collect data throughout the duration of the study until our sample size is achieved. These data will be collected as part of the routine Neotree data collection.
89081526|NCT04611139|Experimental|SP-2577 Plus Pembrolizumab|
89081527|NCT00935272|Experimental|Treatment|Restylane® Treatment
89081528|NCT00935272|No Intervention|Non-Treatment|Non-Treatment Arm
89081529|NCT04570501|Experimental|Angiotensin (1-7)|Participants receive treatment for 7 days.
89081530|NCT04570501|Placebo Comparator|Placebo|Participants receive treatment for 7 days.
89081531|NCT00631306||Bottle number 615|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
89081532|NCT00631306||Bottle number 429|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
89081533|NCT04114747|Experimental|Starting at high blood pressure|Patients in this arm are randomized to have high target blood pressure at MAP 80-90 mmHg during the first recordings, thereafter they will receive low blood pressure target 60-70 mm Hg
89081534|NCT04114747|Experimental|Starting at low blood pressure|Patients in this arm are randomized to have low target blood pressure at MAP 60-70 mmHg during the first recordings, thereafter they will receive high blood pressure target 80-90 mm Hg
89081535|NCT00607906|Experimental|Subjects receiving treatment in cohort A1|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 5 milligrams, 15 milligrams, 50 milligrams, or 100 milligrams.
89081536|NCT00607906|Experimental|Subjects receiving treatment in cohort A2|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 100 milligrams, 200 milligrams, 300 milligrams, or 400 milligrams.
89081537|NCT00607906|Experimental|Subjects receiving treatment in cohort A3|Eligible subjects will receive oral immediate release capsules of SB-756050 with a dose of 150 milligrams. Subjects will also receive oral modified release capsules of SB-756050 with doses of 150 milligrams, 300 milligrams, or 400 milligrams.
89081538|NCT00607906|Experimental|Subjects receiving treatment in cohort A4|Eligible subjects will receive SB-756050 in this additional cohort.
89081539|NCT00607906|Experimental|Subjects receiving treatment in cohort B1|Eligible subjects will receive oral modified release capsules of SB-756050 with doses of 50 milligrams, 150 milligrams or 400 milligrams. Subjects will also receive immediate release oral capsules of SB-756050 with a dose of 150 milligrams.
89081540|NCT02692963|Experimental|BCG vaccination|
89081541|NCT02692963|No Intervention|Control|
89081542|NCT04266106|Placebo Comparator|Placebo Comparator|
89081543|NCT04266106|Experimental|probiotic|
89225235|NCT05866705||Care Partner|Care partner for someone who is living with cancer
89225236|NCT05865678||5-10 years post cancer treatment; male; age at diagnosis 18-30|
89081544|NCT04264468||response group and the non-response group|Received neoadjuvant chemotherapy according to the routine clinical diagnosis and treatment, and evaluated the clinical efficacy once every two cycles of chemotherapy. According to the clinical efficacy, the patients were divided into the neoadjuvant chemotherapy response group and the non-response group (evaluation standard RECIST1.1).
89081545|NCT05198791|Experimental|Eplerenone|Patients with MINOCA and an index of microvascular resistance (IMR) greater than or equal to 25 will be randomised to receive eplerenone (starting dose 25 mg, uptitrated to 50mg after two weeks) for six months or standard of care and research protocol study visits. Patients who are screened, give informed consent but are not randomized will enter a followup registry.
89081546|NCT05198791|Sham Comparator|Standard of care|Patients with MINOCA and an index of microvascular resistance (IMR) greater than or equal to 25 will be randomised to receive eplerenone (starting dose 25 mg, uptitrated to 50 mg after two weeks) for six months or standard of care and research protocol study visits. Patients who are screened, give informed consent but are not randomized will enter a followup registry.
89081547|NCT04261660||fresh|NO INTERVENTION
89081548|NCT04261660||Frozen embro transfer natural|NO INTERVENTION
89081549|NCT04261660||Frozen embro transfer hormonal|NO INTERVENTION
89081550|NCT01010061|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
89081551|NCT01010061|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
89081552|NCT01010061|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
89081553|NCT00609700||1|Historical group: patients treated with Ringer's Lactate solution after severe burn injury
89081554|NCT00609700||2|Actual group: patients treated with Ringer's Acetate solution after severe burn injury
89081555|NCT00607984|Experimental|single|
89081556|NCT00609778|Experimental|1:Mechanical CPR with LUCAS|A Mechanical device that provides chest compressions
89081557|NCT00609778|Active Comparator|2 Manual CPR|Manual chest compressions
89081558|NCT05143801|Active Comparator|No mask temperate|Participant exercised in room temperature environment not wearing a surgical face mask
89081559|NCT05143801|Experimental|Mask temperate|Participant exercised in room temperature environment while wearing a surgical face mask
89081560|NCT05143801|Active Comparator|No mask hot|Participant exercised in a hot environmental temperature not wearing a surgical face mask
89081561|NCT05143801|Experimental|Mask hot|Participant exercised in a hot environmental temperature while wearing a surgical face mask
89081562|NCT00929734|Experimental|Rosuvastatin|
89081563|NCT00929734|Placebo Comparator|Placebo|
89081564|NCT05378542|Active Comparator|1. group|participants will receive information about cervical cancer with the developed mobile application.
89081565|NCT05378542|No Intervention|2. group|No Intervention: control group (non-education) Routıne care
89081566|NCT01013883||systolic dysfunction|patients having left ventricular systolic dysfunction on echocardiography
89081567|NCT01013883||distolic heart failure|patients with clinical heart failure and preserved LV systolic dysfunction
89081568|NCT00609856|Active Comparator|1|Pioglitazone
89081569|NCT00609856|Active Comparator|2|Insulin glargine
89081570|NCT05116813|Experimental|Dipraglurant TID|
89081571|NCT04527757||Paediatric patients with inhalation induction|The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
89081572|NCT04527757||Paediatric patients with intravenous induction|The measurement will begin after the patient's arrival at the operating theatre, after the control of the documentation and beginning of the vital signs monitoring. The measurement will be terminated at the occurence of the first ETCO2 wave, after securing the airway with laryngeal mask or orotracheal intubation. For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O). For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
89081573|NCT00613249|Experimental|A|
89081574|NCT00613249|Experimental|B|
89081575|NCT00613249|Placebo Comparator|C|
89081576|NCT01009983|Experimental|Arm 1|Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.
89081577|NCT04474795|Experimental|Staff - Educational training|Nurses, community health workers, and others involved in maternal healthcare
89081578|NCT00628485|Experimental|Low Stimulation|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation."
89081579|NCT00628485|Experimental|High Stimulation|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions."
89081580|NCT00628485|Placebo Comparator|Control Group|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises.
89081581|NCT04471363||Cancer Specific Exercise Education|This subsample of participants will watch an audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
89081582|NCT04471363||Control|All participants will be asked to indicate their exercise knowledge, self-efficacy, beliefs and intentions.
89081583|NCT04297215|Placebo Comparator|Control group|This group will receive therapeutic clothing without antimicrobial agents
89081584|NCT04297215|Active Comparator|Chitosan group|This group will receive antimicrobial therapeutic clothing based on chitosan
89081585|NCT04297215|Active Comparator|Silver group|This group will receive antimicrobial clothing based on silver.
89081586|NCT04850989|Experimental|Virtual reality exposure therapy|Participants were allowed to choose one of two themes. For both themes, each scene was developed to be more anxiety-provoking as the VRE progressed. Greater anxiety-inducing scenes had interviewers and other actors who displayed less compassionate, friendly, humorous, and pleasant verbal and non-verbal behaviors and demeanors to elicit elevated anxiety (Carless & Imber, 2007). Also, a virtual therapist was embedded within the VRE. It functioned to coach the participant through each distinct scene by orienting and prompting them to the exposure therapy task(s), continually conveying core principles of exposure therapy, and repeating the instructions if the participant was not responsive within five seconds. Each scene started with a paused video, during which participants were oriented by the virtual therapist to the context.
89081587|NCT04850989|No Intervention|Waiting list|Participants started treatment 2-4 weeks post-randomization.
89081588|NCT02873091|Active Comparator|CEI|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of CEI: 10 ml/h, beginning immediately after the initial dose
89081589|NCT02873091|Active Comparator|PIEB 1|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil.The basal infusion of PIEB1: 5 ml per 30 min, beginning 30 min after the initial dose
89081590|NCT02873091|Active Comparator|PIEB 2|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of PIEB2: 10 ml per 60 min, beginning 60 min after the initial dose
89081591|NCT03905083|Experimental|Exercise rehab|Investigators aim to evaluate how exercise training may provide beneficial effects on the skeletal muscle and/or pulmonary vasculature in select subjects with pulmonary arterial hypertension, scleroderma or mixed connective tissue disease or patients with exercise pulmonary arterial hypertension
89081592|NCT03905083|No Intervention|No exercsie rehab|Some participants will not be assigned to do exercise rehab so we would be using them as a control arm to intervention group
89225237|NCT05865678||5-10 years post cancer treatment; male; age at diagnosis 31-50|
89225238|NCT05865678||5-10 years post cancer treatment; male; age at diagnosis 51-70|
89225239|NCT05865678||5-10 years post cancer treatment; male; age at diagnosis 70+|
89225240|NCT05865678||5-10 years post cancer treatment; female; age at diagnosis 18-30|
89225241|NCT05865678||5-10 years post cancer treatment; female; age at diagnosis 31-50|
89225242|NCT05865678||5-10 years post cancer treatment; female; age at diagnosis 51-70|
89225243|NCT05865678||5-10 years post cancer treatment; female; age at diagnosis 70+|
89225244|NCT05865678||11-20 years post cancer treatment; male; age at diagnosis 18-30|
89225245|NCT05865678||11-20 years post cancer treatment; male; age at diagnosis 31-50|
89225246|NCT05865678||11-20 years post cancer treatment; male; age at diagnosis 51-70|
89225247|NCT05865678||11-20 years post cancer treatment; male; age at diagnosis 70+|
89225248|NCT05865678||11-20 years post cancer treatment; female; age at diagnosis 18-30|
89225249|NCT05865678||11-20 years post cancer treatment; female; age at diagnosis 31-50|
89225250|NCT05865678||11-20 years post cancer treatment; female; age at diagnosis 51-70|
89225251|NCT05865678||11-20 years post cancer treatment; female; age at diagnosis 70+|
89225252|NCT05865678||21-30 years post cancer treatment; male; age at diagnosis 18-30|
89225253|NCT05865678||21-30 years post cancer treatment; male; age at diagnosis 31-50|
89225254|NCT05865678||21-30 years post cancer treatment; male; age at diagnosis 51-70|
89225255|NCT05865678||21-30 years post cancer treatment; male; age at diagnosis 70+|
89225256|NCT05865678||21-30 years post cancer treatment; female; age at diagnosis 18-30|
89225257|NCT05865678||21-30 years post cancer treatment; female; age at diagnosis 31-50|
89225258|NCT05865678||21-30 years post cancer treatment; female; age at diagnosis 51-70|
89225259|NCT05865678||21-30 years post cancer treatment; female; age at diagnosis 70+|
89225260|NCT05865678||30 years + post cancer treatment; male; age at diagnosis 18-30|
89225261|NCT05865678||30 years + post cancer treatment; male; age at diagnosis 31-50|
89225262|NCT05865678||30 years + post cancer treatment; male; age at diagnosis 51-70|
89225263|NCT05865678||30 years + post cancer treatment; male; age at diagnosis 70+|
89225264|NCT05865678||30 years + post cancer treatment; female; age at diagnosis 18-30|
89225265|NCT05865678||30 years + post cancer treatment; female; age at diagnosis 31-50|
89225266|NCT05865678||30 years + post cancer treatment; female; age at diagnosis 51-70|
89225267|NCT05865678||30 years + post cancer treatment; female; age at diagnosis 70+|
89225268|NCT05864274|No Intervention|OBSERVATION|PATIENTS WILL PARTICIPATE IN THE NEUROPSYCHOLOGY EVALUATION BUT WILL NOT USE THE COGNITIVE MOBILE TRAINING APPLICATION.
89225269|NCT05864274|Experimental|MOBILE COGNITIVE TRAINING APP|These patients will undergo neuropsychology evaluation and use the cognitive mobile training application
89225270|NCT05864235|Active Comparator|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
89225271|NCT05864235|Experimental|Goal Support (GS)|Each week for 6-weeks, GS group participants will compete identical weekly text message assessments to the control group and receive further prompts and tailored feedback and support focused on weekly drinking limit goal commitment & confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
89225272|NCT05864235|Experimental|GS + Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will compete identical weekly text message assessments and feedback to GS plus additionally will receive weekly motivation and strategies to enlist peer support during drinking episodes.
89225273|NCT05861349||Patients with CTS|Patients referred to the Electromyographic Laboratory of the Department of Neurology at the Jagiellonian University Medical College, Cracow, Poland with symptoms suggestive of CTS (numbness of the hand, present or accentuated in the night, reduced hand dexterity) with CTS confirmed in NCS or US.
89225274|NCT05861349||Healthy controls|Subjects referred to the Electromyographic Laboratory of the Department of Neurology at the Jagiellonian University Medical College, Cracow, Poland for investigation towards tetany, with no or only weak signs of tetany in electromyography.
89225275|NCT05859165|Experimental|Nutren Diabetes group|Product Replacement phase: 1-5 days, tube-feeding, 25kcal/kg/day Formal intervention phase:7 days, tube-feeding, 25kcal/kg/day
89081593|NCT04298775|Active Comparator|spinal anesthesia with morphine|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine + 200 mcg of Morphine
89081594|NCT04298775|Active Comparator|spinal anesthesia without morphine + peripheral nerve block|This patients received subarachnoid anesthesia with 20 mg of Hyperbaric Bupivacaine and peripheral nerve block with 0.2 to 0.375% Ropivacaine, in a volume of 20 to 30 mL.
89081595|NCT01215227|Experimental|Preladenant 2 mg|Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 2 mg in this extension study. Participants will receive preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
89081596|NCT01215227|Experimental|Preladenant 5 mg|Participants who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
89081597|NCT01215227|Experimental|Preladenant 5 mg (on placebo in parent study)|Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 will receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
89081598|NCT01215227|Experimental|Preladenant 10 mg|Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 10 mg in this extension study. Participants will receive preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
89081599|NCT01215227|Active Comparator|Rasagiline 1 mg|Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 will continue to receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
89081600|NCT01215227|Active Comparator|Rasagiline 1 mg (on placebo in parent study)|Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 will receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
89081601|NCT05429957|Experimental|Muscle Energy Technique|Muscle Energy Technique of Iliopsoas, Piriformis, Quadratus Lumborum and Erector Spinae muscle
89081602|NCT05429957|Experimental|Aerobic Exercises|aerobic exercises (walking on the treadmill)
89081603|NCT01009515|Experimental|Chemotherapy Combination|Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.
89081604|NCT01214915|Experimental|Anagrelide Hydrochloride|
89081605|NCT04297527|Experimental|Conventional Physiotherapy Group|Group I (18 subjects) received 15 sessions of Conventional Physiotherapy program (CPP) 5 times per week.
89081606|NCT04297527|Experimental|Mulligan Mobilization Group|Mulligan Mobilization was administered 9 sessions (3 days a week, for 3 weeks). .
89081607|NCT04297527|Experimental|Conventional Physiotherapy plus Mulligan Mobilization Group|Conventional Physiotherapy (15 session) plus Mulligan Mobilization Programme (9 session) were applied in this group. CP were applied 5 days a week and CP+MM 3 days a week for 3 weeks.
89081608|NCT02873013||Prostate Cancer|About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.
89081609|NCT01009281|Experimental|AIN457|
89081610|NCT01009203|Experimental|Temsirolimus and Erlotinib|Erlotinib (Tarceva) at 150 mg by mouth daily + Temsirolimus (Torisel) at 15 mg intravenously weekly. Each cycle is comprised of 28 days
89081611|NCT01009047|Experimental|Paliperidone extended-release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 milligram (mg) for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
89081612|NCT01009047|Active Comparator|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
89081613|NCT04205097|Placebo Comparator|Moderate NMB group|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
89081614|NCT04205097|Experimental|Deep NMB group|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2~4 mg/kg
89081615|NCT04205253||Study|The first group is the study group. Patients aged 20 years or older and were to undergo suspension laryngoscopy procedure were eligible for inclusion in this group. Tongue areas were measured twice by submental USG. The first measurements (TA1) were done immediately after endotracheal intubation before introducing the rigid direct laryngoscope, whereas the second measurements (TA2) were done after the SL procedure and after removing the rigid direct laryngoscope just before extubation.The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
89081616|NCT04205253||Control|The second group was the control group, which included patients who did not need SL and any head and neck procedures.The tongue areas of these patients were measured twice by submental USG as in the study group. The TA1 measurements were done immediately after endotracheal intubation, whereas the TA2 measurements were done at the end of the surgical procedure just before extubation. The difference between TA2 and TA1 (i.e., TA2-TA1) were used to define the occurrence of tongue edema as study group.
89081617|NCT04297059|Experimental|Intervention group|Implementation of Ajyal Salima intervention to promote healthy eating and encourage physical activity in Lebanese school-children.
89081618|NCT04297059|No Intervention|Control group|Group of students not receiving any intervention
89081619|NCT04300725|No Intervention|Verbal Counseling|Patients in one study arm receive only verbal counseling prior to their induction of labor.
89081620|NCT04300725|Experimental|Video Counseling|Patients in other study arm will receive verbal + video counseling prior to their induction of labor.
89081621|NCT04300491||Beneficiaries of suspension walking|
89081622|NCT04300491||Non-Beneficiaries of suspension walking|
89081623|NCT04296669|Experimental|Full desk allocation|All children within this classroom received a sit-stand stand
89081624|NCT04296669|Experimental|Partial desk allocation|six sit-stand desks were provided in this classroom. Children were rotated between these desks and traditional desks
89081625|NCT04296669|No Intervention|Control|Traditional classroom furniture was used
89081626|NCT01025193|Experimental|Belimumab|Belimumab will be administered intravenously at a dose of 10mg/kg on days 0, 14, 28 and every 28 days for up to 52 weeks to normalize alloantibody levels in sensitized patients awaiting kidney transplantation. Subjects who are not able to undergo transplantation before the end of the treatment period will have final follow-up evaluation 8 weeks after the last dose of belimumab is administered.
89081627|NCT01025037|Other|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement at the rotator cuff repair site
89081628|NCT01214837|Experimental|MenACWY3|Subjects received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
89081629|NCT01214837|Experimental|MenACWY4|All the subjects received a 3-dose primary series at 2, 4 and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
89081630|NCT01214837|Placebo Comparator|Routine Vaccines|Subjects received routine vaccines only, including PCV-13, at 2, 4 and 6 months of age and a toddler dose at 12 months of age.
89081631|NCT01024959|Experimental|PCA3 Assay|
89081632|NCT01008423|Experimental|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
89081633|NCT01008423|Placebo Comparator|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
89081634|NCT02872077|Active Comparator|Auricular Acupuncture|Study subjects randomized to this group will receive auricular acupuncture: the investigator will evaluate the infant using an ear point locator to determine active sites, and will place acupuncture needles in the active sites found in one ear. Acupuncture sites will be alternated every 3 days between right and left ear.
89081635|NCT02872077|No Intervention|Control|The subjects randomized to the control group will have NO interventions, and will continue to receive routine care for NAS, pharmacologic and non-pharmacologic, per NICU protocol.
89081636|NCT04296825|Placebo Comparator|P|Patients received cow milk for 4 consecutive weeks (two times per day, 10 gram each time).
89081637|NCT04296825|Active Comparator|CA|Patients received camel milk with Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
89081638|NCT04296825|Experimental|C|Patients received camel milk for 4 consecutive weeks (two times per day, 10 gram each time).
89081639|NCT04296825|Experimental|A|Patients received Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).
89081640|NCT00628563||1|Asthma patients
89081641|NCT01012947|Experimental|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
89081642|NCT01012947|Experimental|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
89081643|NCT01012947|Experimental|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
89081644|NCT01012947|Experimental|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
89081645|NCT01012947|Experimental|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
89081646|NCT00627627|Experimental|1|IPI-504
89081647|NCT04296513||High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white-light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.
89081648|NCT04296513||High-definition magnification with digital chromoendoscopy.|The subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
89081649|NCT03832153||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
89081650|NCT03832153||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
89081651|NCT00614263||Blinded Group|SEDline output is unknown to anesthesiologist.
89081652|NCT00614263||Unblinded Group|SEDline output is known to anesthesiologist.
89081653|NCT04735861|Experimental|Combination Arm|Sintilimab 200mg iv., q3w, up to 2 years; Bevacizumab 15mg/kg iv., q3w, up to 22 cycles. Treatment is given until confirmed progression, death, unacceptable toxicity, or any other protocol-specified criterion for withdrawal, whichever occurs first.
89081654|NCT04395859||Patients treated with IVT before COVID19 pandemia|Treatment started at least 6 months before the French confinement for COVID19 (15th march 2020)
89081655|NCT02693275|Other|Quotient® System iPad Test|The Quotient® System iPad Test is a test specifically designed to provide clinicians with objective measures in ability to maintain seated stillness, sustained attention to a monotonous task and inhibiting incorrect impulsive responses. The attention task with motion analyses provides a number of objective measures for detailed assessment of the subject's movements and attentiveness.
89081656|NCT03717571||Control group|age and sex matched healthy control persons
89081657|NCT03717571||isolated tear|patients with isolated complete supraspinatus muscle tear
89081658|NCT03717571||combined tear|patients with complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear
89081659|NCT03685747|Experimental|Vancomycin|A single 20 mg/kg intraperitoneal dose in 1-liter of 7.5% icodextrin solution of vancomycin will be administered. Sparse blood sampling will be obtained during an overnight 12-hour dwell and during the exchange period.
89081660|NCT04154839||Atopic dermatitis group|Number of subjects in atopic dermatitis group 0 - < 6 years : 50 subjects 6 - <12 years : 50 subjects 12 - <18 years : 50 subjects Adult (>= 18 years) : 150 subjects Total no. of cases: 300 cases
89081661|NCT04154839||Control group|>= 40 yrs : 150 subjects
89081662|NCT00614341|Active Comparator|1, 2|"Pulse MedRelief SE 55~Continuous MedRelief SE 55"
89081663|NCT02692573|Experimental|prone|Prone positioned after delivery
89081664|NCT02692573|Active Comparator|supine|Supine positioned after delivery
89081665|NCT04327921|Experimental|peer navigation social support for smoking cessation|36 HIV-positive smokers will have a 30-minute session with the study nurse to discuss smoking cessation. They will also discuss the importance of social support for quitting and the role of a Peer Navigator. Those participants who set a quit date will choose medication/s in collaboration with the nurse and/or physician. The Peer Navigator will be introduced and will reinforce adherence to medication. The Peer Navigator will ensure that the patient picks up the medication, and will help to manage side effects via physician/nurse consultation. The Peer Navigator will provide social support for quitting via weekly phone calls for 12 weeks.
89081666|NCT04327921|Active Comparator|Standard Condition|36 HIV-positive smokers will receive standard care. Participants will meet for a 30-minute session with a study nurse. They will receive counseling based on the 5A's. The nurse will ask about current smoking habits, advise the participant to quit, assess readiness to quit, and assist by providing resources (community programs, Quit line phone number). The nurse will calculate Lung Age which will serve as a motivation tool to encourage smokers to quit. Those willing to set a quit date will be instructed to call their physician for cessation medication and will provided with the National Cancer Institute self-help pamphlet. Those participants not willing to set a quit date will be instructed to contact their physician when they are ready.
89081667|NCT03586687|Active Comparator|20 mg Triamcinolone with 3cc of 1% Lidocaine|20mg Triamcinolone with 3cc of 1% Lidocaine
89081668|NCT03586687|Active Comparator|40 mg Triamcinolone with 3cc of 1% Lidocaine|40mg Triamcinolone with 3cc of 1% Lidocaine
89081669|NCT03586687|Active Comparator|80 mg Triamcinolone with 3cc of 1% Lidocaine|80mg Triamcinolone with 3cc of 1% Lidocaine
89081670|NCT04324099||Conduct disorder|children and adolescents with CD
89081671|NCT04324099||Autism-Spectrum disorder|children and adolescents with ASD
89081672|NCT04324099||typically developing adolescents|typically developing adolescents
89081673|NCT03584737||Symptomatic for bacterial sinusitis|Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
89081674|NCT01214603|Experimental|LY2090314|"Cohort 1: 40 milligrams (mg) LY2090314 administered on Days 1, 8, and 15 of a 28-day cycle for at least two (2) 28-day cycles. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met.~Due to a protocol amendment on September 2010, the study added 2 additional treatment schedules/cohorts. Cohort 2: 40 mg dose given on Days 1, 5, and 9 of a 21-day cycle. Cohort 3: 40 mg dose given on Days 1, 5, 9, and 12 of a 21-day cycle. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met."
89081675|NCT02692729|Experimental|supraumbilical transverse|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis. Above the panniculus, the fatty tissues are not particularly thick. A transverse opening of the aponeurosis and of the parietal peritoneum was done. Then the approach to the lower uterine segment was easy. A Ricard retractor was put in place.
89081676|NCT02692729|Active Comparator|pfannenstiel|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
89081677|NCT02692807|Active Comparator|Hip arthroscopy surgical procedures (HIPARTI Study)|Surgery is performed under general anaesthesia. Traction and joint access is controlled by fluoroscopy. A diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented. Any labral, chondral and bony pathology (cam or pincer) is treated. Labrum may be debrided, sutured, detached and refixed if needed to treat a pincer lesion. Labrum is secured with suture anchors. Pincer and cam resection is performed using an arthroscopic burr. Cartilage lesions maybe left untreated or treated with debridement or microfracture.
89081678|NCT02692807|Placebo Comparator|Sham surgery (HIPARTI Study)|The same arthroscopic procedures as stated above are preformed, but no surgical interventions related to Cam, Pincer, or labral tear are performed, only diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented.
89225276|NCT05859165|Active Comparator|Fresubin Diabetes group|Product Replacement phase: 1-5 days, tube-feeding, 25kcal/kg/day Formal intervention phase:7 days, tube-feeding, 25kcal/kg/day
89081679|NCT02692807|Active Comparator|Prospective Cohort (HARP Study)|Those that are not willing to be included in the RCT (HIPARTI Study), will be asked if they are willing to be included in the prospective cohort, or ongoing in countries were ONLY the surgery is performed (Australia). They will sign an informed concent and will undergo surgical interventions as part of usual care. Outcomes collected and follow-ups will be the same as for the RCT (HIPARTI).
89081680|NCT04308889|Active Comparator|Without Supplementation|No planned dietary supplementation
89081681|NCT04308889|Experimental|With Supplementation|The subject will take 4 capsules (1gram each) of Lovaza daily at 8pm, starting the evening before blister induction and continuing until the second blister fluid has been removed.
89081682|NCT01212185|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin.
89081683|NCT01212185|Experimental|intranasal oxytocin spray|Twice daily intranasal oxytocin spray
89081684|NCT00613717|Experimental|a|pre- and early postnatal iron
89081685|NCT00613717|Experimental|b|iron prenatal only
89081686|NCT00613717|Experimental|c|iron early postnatal only
89081687|NCT00613717|Active Comparator|d|no iron pre- or postnatal
89081688|NCT03626233||Vascular group|Pregnant women with vascular pathology
89081689|NCT03626233||Control group|"Pregnancy without any vascular complication~Delivery before or after 37 weeks of gestation (GW)~In case of delivery after 37GW: birth by cesarean delivery"
89081690|NCT04424797|Experimental|Prone Positioning|Prone positioning
89081691|NCT04424797|Other|Supine Positioning|Supine Positioning
89081692|NCT03369301||Gammanorm|Patients on Gammanorm per standard of care
89081693|NCT03369301||Other Subcutaneous Immunoglobulin|Patients on subcutaneous immunoglobulin treatments other than Gammanorm
89081694|NCT00614419|Active Comparator|1|The Lichtenstein tension-free hernioplasty with polypropylene mesh
89081695|NCT00614419|Experimental|2|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
89081696|NCT03229915|Active Comparator|PTSD|Will receive Cognitive Processing Therapy
89081697|NCT03229915|Active Comparator|Trauma-exponsed control|Will receive Cognitive Processing Therapy
89081698|NCT03229915|No Intervention|no trauma healthy control|Scanned twice (13 weeks apart) without any intervention
89081699|NCT05345431|Other|The control group|Treating with balloon dilation or stent implantation only,
89081700|NCT05345431|Experimental|The EDN group|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation.
89081701|NCT05345275||pain assessments|In the study, primarily the pain assessment data of children were collected. In these pain assessments, assessments of the child, mother, nurse and an independent observer were taken. Simultaneously, a video recording of the child's facial expressions was made.
89081702|NCT01995175|Other|Overall Group|Newborn subjects followed up for Lower Respiratory Tract Infections (LRTI) symptoms from birth until they are 2 years of age and for incidence of wheeze and asthma up to 6 years of age.
89081703|NCT03611101|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection
89081704|NCT03611101|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection
89081705|NCT03611101|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection
89081706|NCT03611101|Placebo Comparator|Placebo|Administered by subcutaneous injection
89081707|NCT05345119||Sirolimus|Treatment with sirolimus for 12 weeks, given as a second-line treatment
89081708|NCT05345119||Methylprednisolone|Treatment with methylprednisolone for 12 weeks, given as a second-line treatment
89081709|NCT03529123|Experimental|Tested Drug|Insulin glargine/lixisenatide fixed ratio combination (FRC)
89081710|NCT03529123|Active Comparator|Control Drug|Insulin glargine (Lantus®)
89081711|NCT04074187|Experimental|Caplacizumab|Eligible study participants will receive caplacizumab in addition to standard of care such as daily plasma exchange (PE) and corticosteroid treatment (mandatory), immunosuppressive treatment (if needed)
89081712|NCT02670031||Newly Diagnosed Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
89081713|NCT02670031||Well-Controlled Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
89081714|NCT02670031||Resistant Essential Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
89081715|NCT03128905|Active Comparator|Colchicine|Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.
89081716|NCT03128905|Experimental|Prednisone (corticoids)|Patients assigned to this group will receive Prednisone : Cortancyl 20mg.
89081717|NCT00613795|Active Comparator|1|Lactobacillus
89081718|NCT00613795|Placebo Comparator|2|placebo
89081719|NCT02430181|Experimental|lonafarnib - I|lonafarnib 200 mg BID; n=3
89081720|NCT02430181|Experimental|lonafarnib - II|lonafarnib 300 mg BID; n=3
89081721|NCT02430181|Experimental|lonafarnib - III|lonafarnib 100 mg TID; n=3
89081722|NCT02430181|Experimental|lonafarnib/PEG IFN-a - I|lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3
89081723|NCT02430181|Experimental|lonafarnib/PEG IFN-a - II|lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3
89081724|NCT02430181|Experimental|lonafarnib/PEG IFN-a - III|lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=2
89081725|NCT02430181|Experimental|lonafarnib/ritonavir|lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3
89081726|NCT03511729||A single exposure to general anesthesia|Participants who have surgery under general anesthesia (without anesthesia/surgery before)
89081727|NCT03511729||Multiple exposures to general anesthesia|Participants who have surgery under general anesthesia (had anesthesia/surgery before)
89081728|NCT03100591|Experimental|14C-radiolabelled ACT-132577|On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state
89081729|NCT04148365||Paediatric Uveitis|Patients with Uveitis below the age of 18 years.
89081730|NCT00613873||1|Women participating in a community based mammography or cervical screening program will also participate in colonoscopy screening. Participation will be measured by stating an interest in colorectal cancer screening and then following through with colonoscopy screening. Furthermore we will assess whether those complying with colonoscopy will also recommend colonoscopy screening for their spouses or household members.
89081731|NCT00614653|Experimental|Bevacizumab, Erlotinib + Capecitabine|Bevacizumab intravenous (IV) every 2 weeks at 5 mg/kg, Erlotinib 100 mg orally (PO) daily + Capecitabine 400 mg/m2 PO twice daily (BID) only on days of radiation. Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy.
89081732|NCT05344729|Experimental|TQB3616 Capsule- Fasted+ TQB3616 Capsule- After meal|Subjects in Arm A will take TQB3616 capsules under fasting and fed state in Cycle 1 and Cycle 2, respectively
89081733|NCT05344729|Experimental|TQB3616 Capsule- After meal + TQB3616 Capsule- Fasted|Subjects in Arm B will take TQB3616 capsules in Cycle 1 and Cycle 2 under fasting state, respectively
89081734|NCT03909451|Experimental|Dose 1|Sotagliflozin dose 1, once daily for 8 days
89081735|NCT03909451|Experimental|Dose 2|Sotagliflozin dose 2, once daily for 8 days
89081736|NCT03909451|Placebo Comparator|Placebo|Placebo, once daily for 8 days
89081737|NCT03463135|Experimental|SAR439794 [PE SLIT + GLA)]|GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
89081738|NCT03463135|Experimental|Placebo for GLA + SLIT PE|Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
89081739|NCT03463135|Placebo Comparator|Placebo for GLA + Placebo for SLIT PE|Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks
89081740|NCT04148131||Group 1, 0-5 months old|Children which is Obstetric brachial plexus palsy and 0-5 months old age have Naracas type 2 lesion.
89081741|NCT04148131||Group 2, 6-24 months old|Children which is Obstetric brachial plexus palsy and 6-24 months old age have Naracas type 2 lesion.
89081742|NCT04148131||Group 3, 25-36 months old|Children which is Obstetric brachial plexus palsy and 25-36 months old age have Naracas type 2 lesion.
89081743|NCT03596125|Experimental|N-acetylcysteine (NAC)|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
89081744|NCT03596125|Placebo Comparator|Placebo|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
89081745|NCT02118727|Active Comparator|Memantine|Up to 20 mg memantine taken by mouth twice a day for 36 weeks
89081746|NCT02118727|Placebo Comparator|Placebo|Up to 2 placebo tablets taken by mouth twice a day for 36 weeks
89081747|NCT05343637|Experimental|RT234 - Cohort 1|Participants will receive RT234 as 0.2 mg and 0.6 mg
89081748|NCT05343637|Experimental|RT234 - Cohort 2|Participants will receive RT234 as 0.6 mg and 1.2 mg
89081749|NCT05343637|Experimental|RT234 - Cohort 3|Participants will receive RT234 as 1.2 mg and 2.4 mg
89081750|NCT03776227|Experimental|Sotagliflozin Test|One tablet of sotagliflozin administered orally under fasting conditions
89081751|NCT03776227|Active Comparator|Sotagliflozin Reference|Two tablets of sotagliflozin administered orally under fasting conditions
89081752|NCT03745495||Group 1|300 To determine the effect of HIVST on PrEP uptake among older adolescent MSM and TGW
89081753|NCT03745495||Group 2|300 To determine the effect of HIVST on retention of older adolescent MSM and TGW in HIV service
89081754|NCT03369613|Active Comparator|MRI - HC tDCS|Healthy controls in Phase 1 transcranial electrical stimulation set to direct current
89081755|NCT03369613|Active Comparator|MRI - HC tACS|Healthy controls in Phase 1- transcranial electrical stimulation set to alternating current
89081756|NCT03369613|Active Comparator|MRI - CD tCDS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to direct current
89081757|NCT03369613|Active Comparator|MRI - CD tACS|Cervical dystonia in Phase 1 transcranial electrical stimulation set to alternating current
89081758|NCT03369613|Active Comparator|Phase II - Stim|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is active
89081759|NCT03369613|Sham Comparator|Phase II - Sham|Cervical dystonia in Phase 2 transcranial electrical stimulation setting is sham
89081760|NCT00614809|Experimental|1|non-randomized open-label uncontrolled phase II trial
89081761|NCT03562741|Experimental|Fecal Microbiota Transplantation|Subjects receive intervention of stool transplanted to the colon via colonoscopy.
89081762|NCT01752907|Experimental|General Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a general chemotherapy side effects education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
89081763|NCT01752907|Experimental|Bone Pain Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a bone pain education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
89081764|NCT00614731|Experimental|ID immunizations (100 mcg)|Participants will receive a total of two 100 mcg intradermal (ID) KLH carrier-protein immunizations with 1 mg/ml KLH per immunization. Immunizations will be given 21 days apart at Visits 5 and 6.
89081765|NCT00614731|Experimental|Scarification by 3 jabs|Participants will receive two scarification immunizations by 3 jabs containing 20 mg/ml of KLH carrier-protein. The immunizations will occur 21 days apart at Visits 5 and 6.
89081766|NCT00614731|Experimental|ID immunizations (250 mcg)|Enrollment will begin after the safety data for Groups 1A and 2A have been reviewed. Participants in this group will receive two 250 mcg ID KLH vaccinations containing 10 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
89081767|NCT00614731|Experimental|Scarification by 15 jabs|Enrollment will begin after the safety data from groups 1A and 2A has been examined. Participants in this group will receive a total of two scarification immunizations by 5 needles used to administer 15 jabs, each containing, 20 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
89081768|NCT02692261|Active Comparator|Hyalossᵀᴹ matrix|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution used for maxillary sinus augmentation
89081769|NCT02692261|Active Comparator|Apatos alone xenograft|Each sinus was filled with 1 gr xenograft (with or without Hyaluronic Acide) for maxillary sinus augmentation
89081770|NCT03181087|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)
89081771|NCT02704663|Experimental|Transumbilical route|Transumbilical removal of benign adnexal masses via laparoscopy.
89081772|NCT02704663|Active Comparator|Lateral abdominal route|Lateral transabdominal removal of benign adnexal masses via laparoscopy.
89081773|NCT02526355|Experimental|Mobile based Intervention|Mobile based Intervention (Learning Through Play Plus) comprised of both LTP and CBT
89081774|NCT02526355|No Intervention|Waiting List Control|Waiting List Control group will receive no intervention, but intervention will be offered to interested participants at the end of the study
89081775|NCT03439189|Experimental|Emricasan 5mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
89081776|NCT03439189|Experimental|Emricasan 25mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
89081777|NCT03439189|Experimental|Emricasan 50mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
89081778|NCT03439189|Placebo Comparator|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
89081779|NCT01211483|Experimental|Part A: U3-1287 (high dose) + Erlotinib|U3-1287 (high dose) intravenously (IV) every three weeks (Q3W) + Erlotinib 150 mg/day orally (PO) until cancer gets worse, side effects become unacceptable or participant withdraws consent
89081780|NCT01211483|Experimental|Part B: U3-1287 (low dose) + Erlotinib|U3-1287 (low dose) IV Q3W + Erlotinib 150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
89081781|NCT01211483|Placebo Comparator|Part B: Placebo + Erlotinib|Placebo matching U3-1287 IV Q3W + Erlotinib150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
89081782|NCT00615823|Active Comparator|1|Atorvastatin group: receive atorvastatin 10 mg daily in addition to supportive care
89081783|NCT00615823|Placebo Comparator|2|Placebo group: receive matching placebo in addition to supportive care.
89081784|NCT02704195|Active Comparator|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
89081785|NCT02704195|Experimental|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
89081786|NCT02699281|Experimental|Ultra-micronized Palmitoylethanolamide|Ultra-micronized Palmitoylethanolamide 600 mg twice a day
89081787|NCT02699281|Placebo Comparator|Placebo|Placebo tab twice a day
89081788|NCT02699359|Experimental|HS-1000 recording|Study participants will receive HS-1000 ICP readings for a continuous 16 minute interval in a 30 degree supine position. Recordings will be obtained in one session. When possible, these recordings will be obtained at their initial examination and all follow-up visits. Sports Medicine staff will coordinate the HS-1000 device earplug insertion and recordings so as not to interfere with, nor marginally delay the patient's normal, routine clinical evaluation.
89081789|NCT00615979||Miniature echo machine|Diagnostic capabilities Wireless transfer
89081790|NCT02704507|Experimental|Topical steroid|Topical retinoid plus topical steroid applied daily to half of the face for 4 weeks, followed by 4 weeks of topical tretinoin. Patients will be randomized to which side receives the topical steroid.
89081791|NCT02704507|Placebo Comparator|Topical emollient|Topical retinoid plus topical emollient applied daily to the opposite half of the face for 4 weeks, followed by 4 weeks of topical tretinoin.
89081792|NCT02699203|Experimental|High-carbohydrate meal|High carbohydrate breakfast meal consisting of oatmeal and berries.
89081793|NCT02699203|Experimental|Low-carbohydrate meal|Low carbohydrate breakfast meal consisting of eggs and avocado.
89081794|NCT02155231||previous enrolled|
89081795|NCT02155231||New Enrolled|
89081796|NCT01210001|Experimental|BI 10773 low dose|BI 10773 tablets once daily
89081797|NCT01210001|Experimental|BI 10773 high dose|BI 10773 tablets once daily
89081798|NCT01210001|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
89081799|NCT02699047|Experimental|Fish oil|3.6 g/day of the encapsulated fish oil (2 capsules/day) providing 1.55 g/d of the n-3 polyunsaturated fatty acids (EPA and DHA) during 9 weeks
89081800|NCT02699047|Placebo Comparator|Control group|3.2 g/day of the olive oil (2 capsules/day) without n-3 polyunsaturated fatty acids
89081801|NCT00624455|Active Comparator|1|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
89081802|NCT00624455|Placebo Comparator|2|Placebo
89081803|NCT01127659|Active Comparator|diabetes with HH-active|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
89081804|NCT01127659|No Intervention|diabetes with normal testosterone|Eugonadal subjects with diabetes. They will not be treated
89081805|NCT01127659|Active Comparator|obese with HH-active|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
89081806|NCT01127659|No Intervention|obese with normal testosterone|Eugonadal non-diabetic obese subjects. They will not be treated
89081807|NCT01127659|Placebo Comparator|Diabetes with HH-placebo|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.
89081808|NCT01127659|Placebo Comparator|Obese with HH-placebo|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.
89081809|NCT01209689|Experimental|Tocilizumab 4 mg/kg|Patients received tocilizumab 4 mg/kg intravenously every 4 weeks for 24 weeks.
89081810|NCT01209689|Experimental|Tocilizumab 8 mg/kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
89081811|NCT01209689|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks for 24 weeks.
89081812|NCT02698969|Experimental|Sugammadex|patients enrolled who will receive sugammadex 2 mg*kg-1 at the end of surgery
89081813|NCT02698969|Active Comparator|Nestigmine, Atropine|patients enrolled who will receive neostigmine 50 mcg*kg-1 and atropine 15 mcg*kg-1 at the end of surgery
89081814|NCT01688869||Mild TBI|Patients who have been diagnosed with a mild brain injury.
89081815|NCT00848731|Experimental|iNO|gaseous NO is delivered by facemask
89081816|NCT01209143|Experimental|Vismodegib + rosiglitazone|Participants received rosiglitazone 4 mg orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
89081817|NCT01209143|Experimental|Vismodegib + oral contraceptive|Participants received the oral contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
89081818|NCT00614965|Experimental|1|IC
89081819|NCT00614965|Experimental|2|PC
89081820|NCT02692183||Parkinson Disease (PD) tremor patients|Patients with PD before and after MRI guided Focused ultrasound thalamotomy
89081821|NCT02692183||Essential tremor (ET) patients|Patients with ET before and after MRIFocused ultrasound guided thalamotomy
89081822|NCT02703883|Experimental|Body Weight Support|Treatment protocol consisted of 18 training sessions on the BWST, three times a week, every session included three sets of six minutes of locomotion with rest intervals of 2 min of rest.
89081823|NCT02703805|Experimental|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors.
89081824|NCT02703805|Active Comparator|Standard YMCA membership|A 12 week standard YMCA membership.
89081825|NCT02703961|Experimental|experimental|"concurrent and adjuvant chemotherapy with cisplatin and docetaxel combined radical radiotherapy.~During external beam radiotherapy: cisplatin 60mg/m2, d1,d22; docetaxel 60mg/m2, d1,d22.~After external beam radiotherapy: cisplatin 75mg/m2, d43,d64;~The patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.~docetaxel 75mg/m2, d43,d64."
89081826|NCT02703961|Other|control|"standard chemoradiotherapy with weekly cisplatin.~Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29.~Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy."
89081827|NCT02703649|Experimental|Single dose|Single 20 mg dose of Letrozole on day 3 of the menstrual cycle.
89081828|NCT02703649|Active Comparator|Daily dose|Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
89081829|NCT02703571|Experimental|Advanced or metastatic solid tumors|Patients in the Phase I portion of the study who have advanced or metastatic solid tumors
89081830|NCT00615355|Other|Body location|Different body locations receive specific treatments
89081831|NCT00615355|Active Comparator|Control|Treatment with narrow-band UVB
89081832|NCT02703727||OAC|Patients on oral anticoagulation therapy (OAC) will receive a pharmacists led medication review with a focus on anticoagulation therapy (extended polymedication check)
89081833|NCT02703415|Active Comparator|Bupivacaine|caudal Bupivacaine
89081834|NCT02703415|Active Comparator|Tramadol|caudal Tramadol
89081835|NCT02703181|Experimental|Cohort 1(600 mg Epelsiban or placebo[every 8 hours])|Each subject will receive 200 mg of epelsiban administered TID (every 8 hours) (total daily dose of 600 mg) or a matching placebo administered every 8 hours.
89081836|NCT03297697||Arm 1: Lymphotrack|-Patients will be treated with frontline chemotherapy per the treating physician's discretion. Collection of the pre-treatment tumor biopsy to identify the tumor-specific clonotype and peripheral blood samples at various time points for assessment of minimal residual disease using the LymphoTrack MRD assay. The results of these studies will be performed in batches and therefore will not be available to patients and clinicians to make clinical decisions.
89081837|NCT04215835|Experimental|study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
89081838|NCT04215835|Placebo Comparator|control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
89081839|NCT01023789|Experimental|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation in the treatment of coronary artery disease
89081840|NCT02702947|Experimental|Prunus Domestica|Prunus domestica extract capsules, 100mg, BD
89081841|NCT02703103|Experimental|Standard cardiopulmonary resuscitation|standard CPR (30:2) according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
89081842|NCT02703103|Experimental|asynchronous cardiopulmonary resuscitation|asynchronuos CPR according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
89081843|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II
89081844|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II
89081845|NCT01208207|Experimental|etoricoxib 90 mg/etoricoxib 90 mg|The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II
89081846|NCT01208207|Active Comparator|naproxen 1000 mg/naproxen 1000 mg|The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II
89081847|NCT02703025|Experimental|GCB 70 administered group|Green coffee bean extract capsule 500mg, BD
89081848|NCT03292471|Experimental|Inhibitory only|Inhibitory 1Hz rTMS will be applied continuously for 1200 pulses (20 minutes) 5 days per week across 2 weeks (10 sessions total).
89081849|NCT03292471|Experimental|Excitatory primed|The inhibitory sequence described above will be preceded for each session by priming stimulation which will consist of intermittent 6-Hz rTMS applied in 5 second trains with 25 second intervals between trains for a total 600 pulses (10 minutes).
89081850|NCT05420285|Experimental|Dapagliflozin|Dapagliflozin is taken orally, once daily at the dosage of 10 mg during 6 months.
89081851|NCT01012713|Experimental|Open-Label Treatment|All patients will receive treatment with Clobex Spray, Vectical Ointment, and Excimer Laser
89081852|NCT02702713|Active Comparator|Dairy BEF + egg placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Dairy BEF + 1 portion of Egg placebo + 1 portion of Bakery placebo
89081853|NCT02702713|Active Comparator|Egg BEF + dairy placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg BEF + 1 portion of Dairy placebo + 1 portion of Bakery placebo
89081854|NCT02702713|Active Comparator|Bakery BEF + dairy placebo + egg placebo|200 subjects consuming every day for 12 weeks: 1 portion of Bakery BEF + 1 portion of Dairy placebo + 1 portion of Egg placebo
89081855|NCT02702713|Placebo Comparator|All placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg placebo + 1 portion of Dairy placebo + 1 portion of Bakery placebo
89081856|NCT00628329||1|
89081857|NCT00628329||2|
89081858|NCT02698813|Experimental|UCMSCs-HA|Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).
89081859|NCT02698813|Active Comparator|Control|Procedure: Transdermal injection of hyaluronic acid only.
89081860|NCT04205331||obese patients|compare between ultrasonography and conventional clinical methods of airway assessment prior to induction of anesthesia correlating it to the Cormack-Lehane scoring system after induction of anesthesia in obese patients
89081861|NCT02702635|Experimental|All Subjects|All recruited subjects
89081862|NCT02871531|Experimental|Pneumatic retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy
89081863|NCT02871531|Experimental|Vitrectomy|Patients with retinal detachment allocated to vitrectomy
89081864|NCT02702791|Experimental|Intervention|Telecoaching - feasible goal setting and feedback to enhance patient's motivation and commitment - in addition to pulmonary rehabilitation.
89081865|NCT02702791|Other|Usual care|includes only general advices regarding physical activity.
89081866|NCT02702557|Other|Elastic Band Exercises|Unsupervised Elastic band exercises performed once a day until the patient is discharged from the hospital. One exercise for the upper extremity (row exercise level 1-3) and one exercise for the lower extremity (knee extension level 1-3). The two exercises are both performed as 3 sets of 10 repetitions.
89081867|NCT02702323|Experimental|Apatinib & TACE|Apatinib 500mg tablet by mouth per day, until disease progression, combined with TACE therapy one times every 4-6 weeks.
89081868|NCT02702323|Active Comparator|TACE|TACE therapy one times every 4-6 weeks.
89081869|NCT01007253|Other|FF/PL, PL/OLO, FF/OLO, PL/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and~placebo (PL) nasal spray and PL eye drops (PL/PL)."
89081870|NCT01007253|Other|PL/OLO, FF/OLO, PL/PL, FF/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~placebo (PL) nasal spray and PL eye drops (PL/PL), and~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)."
89081871|NCT01007253|Other|FF/OLO, PL/PL, FF/PL, PL/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~placebo (PL) nasal spray and PL eye drops (PL/PL),~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO)."
89081872|NCT01007253|Other|PL/PL, FF/PL, PL/OLO, FF/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~placebo (PL) nasal spray and PL eye drops (PL/PL),~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO)."
89081873|NCT02702167|Experimental|High-frequency rTMS|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
89081874|NCT02702167|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
89081875|NCT02702167|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
89081876|NCT02691949|Experimental|Mycophenolate mofetil standard|mycophenolate mofetil 250mg 2# twice per day (BID)
89081877|NCT02691949|Experimental|Mycophenolate sodium low|mycophenolate mofetil 250mg 1# twice per day (BID)
89081878|NCT02698501|Experimental|MEDI9929|MEDI9929 is a human monoclonal antibody immunoglobulin IgG2λ directed against TSLP. MEDI9929 binds with human TSLP and prevents its interaction with thymic stromal lymphopoietin receptor (TSLPR).
89081879|NCT02698501|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP.
89081880|NCT02702245|Placebo Comparator|Placebo comparator: Control|OGTT without thylakoids.
89081881|NCT02702245|Experimental|Experimental: Thylakoids 5 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 5 g. Intervention: OGTT at one occasion.
89081882|NCT02702245|Experimental|Experimental: Thylakoids 10 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 10 g. Intervention: OGTT at one occasion.
89081883|NCT04296747|Experimental|Induction therapy|patients would accept toripalimab combined with chemotherapy as induction therapy, then radical treatment(surgery or chemoradiotherapy) according to whether the tumor could be resectable or the evaluation result according to RECIST1.1. Ones with PD after induction therapy will enter survival follow-up directly
89081884|NCT04298931||Patients undergoing open abdominal surgery|
89081885|NCT02686879|No Intervention|Natural progession|Following the natural progression of axial growth and refractive error.
89081886|NCT02686879|Experimental|Anisohyperopes - intervention eye|The more hyperopic eye will be fitted with a centre-near multifocal contact lens
89081887|NCT02686879|Experimental|Hyperopes|Both eyes will be fitted with centre-near multifocal contact lenses.
89081888|NCT02686879|Experimental|Anisohyperopes - fellow eye|The less hyperopic eye will be fitted with a single vision contact lens if required.
89081889|NCT04296591||study group|The study group consisted of late preterm cases(34-37 weeks of gestation) and
89081890|NCT04296591||control group|the control group consisted of term cases (<37 weeks of gestation).
89081891|NCT01006707|Other|Ondansetron, then Placebo|Some participants received ondansetron pretreatment during the second session, and then placebo during the third session.
89081892|NCT01006707|Other|Placebo, then Ondansetron|Some participants received placebo pretreatment during the second session, and then ondansetron pretreatment during the third session.
89081893|NCT02698657|Experimental|ASP5094 Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of ASP5094. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
89081894|NCT02698657|Placebo Comparator|Placebo Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of Placebo. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
89081895|NCT04298385||Individuals with oblique proximal phalanx fractures of finger|Traction orthosis and exercise
89081896|NCT04216615||patients with preoperative anxiety|
89081897|NCT04216615||patients without preoperative anxiety|
89081898|NCT04296279|Active Comparator|"Part A - Low Dose"|"Part A vaccinees in the low dose arm will receive the lower dosing (20 μg FMP014 per 0.5 mL ALFQ) approximately 2 weeks prior to each vaccination. Vaccination to be delivered on 0,1,2 month."
89081899|NCT04296279|Active Comparator|"Part A - High Dose"|"Part A vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,2 month."
89081900|NCT04296279|Active Comparator|"Part B - Standard Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 4,5,6 month."
89081901|NCT04296279|Active Comparator|"Part B - Delayed Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
89081902|NCT04296279|Active Comparator|"Part B - Delayed Fractional Dose"|"Part B vaccinees in the high dose arm will receive the lower dosing (40 μg FMP014 per 1.0 mL ALFQ) approximately 2 weeks prior to each vaccination.~Vaccination to be delivered on 0,1,6 month."
89081903|NCT04296279|No Intervention|Control|Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.
89081904|NCT00616057|Placebo Comparator|B|Maltodextrin, non digestible carbohydrate
89081905|NCT00616057|Experimental|A|fructans, non digestible carbohydrates fermented in the caeco-colon
89081906|NCT04296201|Experimental|Treatment in the face area|5 female subjects will receive treatment in the face area
89081907|NCT04296201|Experimental|Treatment in the buttocks area|5 female subjects will receive treatment in the buttocks area
89081908|NCT04296201|Experimental|Treatment in the abdominal region|5 male subjects will receive treatment in the abdominal region
89081909|NCT00615511|Placebo Comparator|placebo|Approximately one third of subjects
89081910|NCT00615511|Experimental|Pregnenolone|
89081911|NCT04215133|Experimental|İnspiratory muscle training group|
89081912|NCT04215133|Experimental|Calf muscle training group|
89081913|NCT04215133|No Intervention|Control|
89081914|NCT02702089||IAPE|Intersphincteric AP excision
89081915|NCT02702089||HP|Hartmann's procedure
89081916|NCT01006629|Experimental|palivizumab|palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections
89081917|NCT04215055|Active Comparator|study group|Group I (study group); children receiving intraoral injection of local anasethia using the vibration assisted syringe.
89081918|NCT04215055|Active Comparator|control group|Group II (control group): children receiving intraoral injection of local anasethia using the standard syringe.
89081919|NCT04214977|Experimental|group S|Patients in group S had spinal anesthesia in the sitting position under complete aseptic technique through a standard mid-line approach. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
89081920|NCT04214977|Experimental|group L|Patients in group L received standard general anesthesia. Proper (weight-based) classic laryngeal mask airway was then blindly inserted.
89081921|NCT02701933|Other|Ketamine-Saline|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, ketamine is administered on the first assessment and placebo (saline) is administered on the second assessment.
89081922|NCT02701933|Other|Saline-Ketamine|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, placebo (saline) is administered on the first assessment and ketamine is administered on the second assessment.
89081923|NCT04295967||1|presence of recurrence of urothelial carcinoma
89081924|NCT04295967||2|absence of recurrence of urothelial carcinoma
89081925|NCT01012323|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 weeks (17 infusions) or 4 weeks (13 infusions) for 1 year.
89081926|NCT02871765|Experimental|education group|In education group, each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department by researchers. Three months later, participants in the education group received a follow-up phone call in order to clarify any questions related to the brochure. All participants completed posttest at 6-month follow-up.
89081927|NCT02871765|No Intervention|control group|The control group received the brochure only.
89081928|NCT02870751|Experimental|ST-only ETEC strain TW11681 or TW10722|Oral inoculum of several doses of bacteria to establish range to achieve diarrhea attack rate in around 70% of volunteers.
89081929|NCT01011933|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood and archived tumor tissue samples are collected for biomarker studies.
89081930|NCT02549209|Experimental|Investigational Treatment|"Subjects with no prior therapy:~Pembrolizumab administered at 200 mg~Paclitaxel administered at 175mg/m2~Carboplatin administered at an AUC of 6~Subjects with prior external beam radiation therapy (XRT) and/or platinum-based chemotherapy must initiate paclitaxel and carboplatin at a reduced dose:~Pembrolizumab administered at 200 mg~Paclitaxel administered at 135mg/m2~Carboplatin administered at an AUC of 5"
89081931|NCT03405883||RIF (women with repeated implantation failure)|Transfer of at least 5 good quality embryos in IVF or ICSI cycles, without achieving pregnancy
89081932|NCT03405883||NF (normal fertile women)|Spontaneous conception or conception after max 9 IUI cycles
89081933|NCT03278587|Active Comparator|Community-based screening|
89081934|NCT03278587|Active Comparator|Cataract camp program|
89081935|NCT03278587|Active Comparator|Community health worker program|
89081936|NCT03278587|No Intervention|No intervention|
89081937|NCT02698267|Experimental|BIIB074|Administered orally on Day 1 and Day 11
89081938|NCT01011465|Experimental|Oxytocin|One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol
89081939|NCT01011465|Placebo Comparator|Placebo|The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray
89081940|NCT01011465|Experimental|Social Support|Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks
89081941|NCT01011465|Placebo Comparator|No Social Support|Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.
89081942|NCT01011465|Other|Female Gender|Effects of oxytocin and social support are examined among women versus men
89081943|NCT01011465|Other|Male Gender|Consider effects of oxytocin and social support in men versus women
89081944|NCT02701855||Hypertension and progressive MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
89081945|NCT02701855||Hypertension and stable MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
89081946|NCT02701855||Hypertension, without MCI|60 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
89081947|NCT04294485|Experimental|Experimental group|Physical therapy intervention Efficacy of electrostimulation intervention combined with lower limbs exercise.
89081948|NCT04294485|No Intervention|Control group|Participants will no receive physical therapy intervention
89081949|NCT02494141|Experimental|Curcumin|25/mg/kg per day for 1 year.
89081950|NCT02494141|Placebo Comparator|Placebo|Equivalent placebo for 1 year.
89081951|NCT01011387|Other|NPWT system|Negative pressure wound therapy
89081952|NCT02701621|Active Comparator|MIRT Group|Individuals underwent Multidisciplinary Intensive Rehabilitation Treatment. It consists of 4 weeks of physical therapy in a hospital setting with four daily sessions for five days and one hour of physical exercise on the sixth day.The duration of each session is about one hour. The first session comprises cardiovascular warm-up activities, relaxation and muscle-stretching. The second session includes aerobic exercises and the use of different devices: a stabilometric platform, treadmill plus, crossover, cycloergometer. The third is a session of occupational therapy. The last session includes one hour of speech therapy. The rehabilitation program can also include: robotic-assisted walking training, virtual reality training and meetings with a Psychologist.
89081953|NCT02701621|Experimental|MIRT-AT|"Patients underwent land-based therapy in association with aquatic therapy, three times per week for four weeks.~The land-based activities included the second and the third session of MIRT.~The water sessions were divided in 3 phases:~i) Warm Up Exercises. This phase lasted 10 minutes and comprised walking performances.~ii) Central session Training. This phase lasted 30-45 minutes and comprised trunk mobility exercises in standing position and sitting on a floating device, static and dynamic exercises. The successive balance training exercises comprised: maintaining balance with closed eyes; balance control with one leg resting on a step; postural control changing the support base.~iii) Cool-down. This phase lasted 5 minutes and comprised general stretching exercises and gentle walking."
89081954|NCT02698345||K-POP|Patients with isolated popliteal artery disease undergoing endovascular therapy using drug-eluting balloon (In.PACT Admiral, Medtronic)
89081955|NCT02701465|Experimental|Intervention group|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
89081956|NCT02701465|Active Comparator|Control group|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
89081957|NCT01011309|Experimental|LEISH-F2 + MPL-SE vaccine|Recombinant three antigen Leishmania polyprotein + MPL-SE adjuvant
89081958|NCT01011309|Active Comparator|Sodium stibogluconate (SSG)|20 mg/kg/day IV for 20 days
89081959|NCT04214821|Active Comparator|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89081960|NCT04214821|Active Comparator|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89081961|NCT04214821|Active Comparator|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89081962|NCT04214821|Active Comparator|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection
89081963|NCT04214821|Active Comparator|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89081964|NCT04214821|Active Comparator|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89081965|NCT04214821|Active Comparator|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89081966|NCT04214821|Active Comparator|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89081967|NCT01011153||All Dermatologists|
89081968|NCT00615667|Experimental|tacrolimus(fk506) treatment|tacrolimus(fk506) treatment
89225277|NCT05858671|Experimental|Fenugreek Seed Tea|Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval. The rationale for choosing the dose and intervention time course were based on the previous studies where metabolic effects have been detected. Literature reports from 12 human studies on diabetic and pre-diabetic subjects gave doses of fenugreek seed ranging from 1 to 100g/day, with the median treatment dose being 6.3g/day, to the participants; the intervention time course ranged from 1 week to 3 years, with the median treatment time being 60 days. The dose and duration in this study was designed as being similar to these studies where metabolic effects have been detected and where participant burden will not be too onerous.
89225278|NCT05858671|Placebo Comparator|Black Tea|Control group: A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval. Black tea is a type of fermented tea that has been found to possess much less cardioprotective and lipid profile improving effect compared to green tea due to the different manufacture process. Consumption of black tea has been found not associated with a reduced risk of coronary heart disease in the United Kingdom. Therefore, we propose to use black tea as control tea for this study.
89081969|NCT00615043||TURBT group|Subjects undergoing transurethral resection of bladder tumor or other transurethral biopsy procedure who agree to provide bladder tissue specimens
89081970|NCT04295655|Experimental|Global Exercise Group|all patients received the Control Group treatment added to global exercise treatment. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises. The number of repetitions was adapted to the subject's response taken into account the perceived dyspnea and fatigue during the exercise performance.
89081971|NCT04295655|Experimental|Functional Electrostimulation Group|"all patients received the Control Group treatment plus neuromuscular stimulation therapy (SEFAR Rehab X2, DJO France S.A.S., France) on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
89081972|NCT04295655|Active Comparator|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy.
89081973|NCT02697955|Experimental|Bupivacaine-epinephrine|10 mL of 5 mg/mL bupivacaine with 5 μg/mL epinephrine = 50 mg bupivacaine and 50 μg epinephrine
89081974|NCT02697955|Placebo Comparator|Placebo|10 ml normal saline water (sodium chloride solution, 0,9%)
89081975|NCT04294329|Experimental|Group Quadratus lumborum block with bupivacaine|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine where a solution of 0.25% bupivacaine 0.2 ml /kg (lean body weight) is used on each side with care not to exceed the toxic dose.
89081976|NCT04294329|Placebo Comparator|Group Quadratus lumborum block with saline|After induction of anesthesia a QLB (quadratus lumborum block) will be performed by using ultrasound machine.A volume of 0.2ml/kg normal saline will given for each side.
89081977|NCT00615121||arteries from PAD patients|peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease
89081978|NCT00615121||arteries from Free Fib transfers|peripheral arteries from patients without evidence of peripheral arterial occlusive disease
89081979|NCT02871609||Patients with longterm ureteral stent|
89081980|NCT02701309||Non-invasive Iron detection|Children between 9months and 5years will be recruited for a non-invasive iron measurement on the lower lip. This study is focusing on the feasability of a non-invasive detection method. There is no intervention planed. The device is tested once for 3-5 Minutes.
89081981|NCT03250507|Active Comparator|Bupivacaine|Patients will receive a TAP block with 60 mL 0.25% bupivacaine. this group will not receive Liposomal bupivacaine
89081982|NCT03250507|Active Comparator|Liposomal bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL saline.~this group will not receive bupivacaine. they receive only liposomal bupivacaine."
89081983|NCT03250507|Experimental|Liposomal bupivacaine and bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL 0.25% bupivacaine.~this group will receive the mixture of Liposomal bupivacaine and bupivacaine."
89081984|NCT00997893|Experimental|Estradiol/Medroxyprogesterone Acetate|1 mg/d oral Estradiol pill and 0 mg/d oral placebo pill for 12 weeks, followed by 10 mg/d oral medroxyprogesterone acetate (MPA) pill, for 10 days.
89081985|NCT00997893|Experimental|Soy Phytoestrogen|55 mg/twice daily oral Novasoy®/Soy Phytoestrogen pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
89081986|NCT00997893|Placebo Comparator|Placebo|0 mg tablet/twice daily oral placebo pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
89081987|NCT02697877||Patients with known or suspected coronary artery disease.|Patients with known or suspected coronary artery disease undergoing clinically ordered stress cardiac magnetic resonance imaging.
89081988|NCT04214665|Experimental|Test/Reference|Single dose of test tablet in period I. Followed by single dose of reference tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
89081989|NCT04214665|Experimental|Reference/Test|Single dose of reference tablet in period I. Followed by single dose of test tablet in period II. First and second dose administration will be separated by a washout period of at least 5 days.
89081990|NCT02870673|Active Comparator|Injection of Shincort 0.5 ml and Xylocaine 0.5ml mixture|"In the first week of recruitment, this group will receive the local injection around the distal wrist crease with mixture of Shincort Inj(10mg/ml) 0.5 ml and xylocaine(20mg/ml) 0.5 ml only one time.~The ultrasound-guided procedure is performed by the orthopedic physician."
89081991|NCT02870673|Experimental|sham electroacupuncture|"In this group, the participants receive acupuncture treatment and only 2 minutes electrical stimulation.~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant. After 2 minutes, the stimulator will turn off spontaneously and the participant will not be informed.~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
89081992|NCT02870673|Experimental|electroacupuncture|"In this group, the participants receive acupuncture treatment and 20 minutes electrical stimulation.~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant.~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
89225279|NCT05856773|Active Comparator|Arm A - Standard Fractionation|"50-50.4 Gy (RBE) in 25-28 daily fractions of 1.8-2.0 Gy (RBE) plus a Tumor Bed Boost (for intact breast) of 10 Gy (RBE) in 4-5 daily fractions of 2-2.5 Gy (RBE)~**Additional boost of 10-20 Gy (RBE) in 2-2.5 Gy (RBE) fractions to clinically involved lymph nodes or chest wall/scar allowed at the treating physician's discretion**"
89225280|NCT05856773|Other|Arm B - Hypofractionation|"40.05 Gy (RBE) in 15 daily fractions of 2.67 Gy (RBE) plus a Tumor Bed Boost (for intact breast) of 10 Gy (RBE) in 4-5 daily fractions of 2-2.5 Gy (RBE)~**Additional boost of 10-20 Gy (RBE) in 2-2.5 Gy (RBE) fractions to clinically involved lymph nodes or chest wall/scar allowed at the treating physician's discretion**"
89225281|NCT05855668|Other|Alcohol Use Disorder|Participants will be treated with 12 weeks of CBT for AUD (group therapy) and have the option to receive evidence-based pharmacotherapy for AUD guided by a pharmacotherapy algorithm.
89225282|NCT05855668|Other|Cannabis Use Disorder|Participants will be treated with 12 weeks of CBT + motivational enhancement therapy for CUD (group therapy).
89225283|NCT05853068||Patients on non-invasive ventilatory support to IMV|Patients with AHRF treated with non-invasive ventilatory support [for the purpose of this study we included High-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), and non-invasive ventilation (NIV)] who required endotracheal intubation and invasive mechical ventilation.
89225284|NCT05853055|Experimental|Post-COVID-19 (respiratory training and monitoring)|Post-COVID-19 patients allocated to this arm get an additional respiratory training added to their conventional rehabilitation program. Patients will train twice daily for the length of their rehabilitation stay. An incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA) will be used to complete training sessions of 15 mins each.
89225285|NCT05853055|No Intervention|Post-COVID-19 (control and monitoring)|Patients receive the same therapeutical interventions as the Post-COVID19 respiratory training arm excluding respiratory training.
89225286|NCT05853055|No Intervention|Cancer-related fatigue (monitoring)|Patients are treated according to the respective rehabilitation program not including respiratory training.
89225287|NCT05852353|Experimental|Single arm longitudinal assessment|Single arm longitudinal assessment of the feasibility of a digital pediatric bladder health patient education curriculum. The intervention consists of 7 videos that can be viewed over a 4-week time period. Impact on the study objectives will be measured using a longitudinal pre-post intervention study design.
89225288|NCT05852262|Experimental|High Dose Cephalexin|The intervention is high-dose cephalexin (1000mg PO QID) for seven days
89225289|NCT05852262|Active Comparator|Standard Dose Cephalexin|The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days
89081993|NCT02701231|Sham Comparator|Sham control|Subjects will receive one cycle of treatment of sham low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
89081994|NCT02701231|Experimental|Low-frequency Rotating Magnetic Therapy|Subjects will receive one cycle of treatment of low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
89081995|NCT02701075|Experimental|MC5-A Scrambler Therapy|MC5-A Scrambler Therapy is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a no pain message to the central nervous system. Electrodes are placed on dermatomes that correspond to the area of pain. Patient is treated for 30 minutes and given up to 10 treatment sessions.
89081996|NCT02701075|Sham Comparator|MC5-A Scrambler Therapy Sham Device|The MC5-A Scrambler Therapy Device will be used as an active sham device in this randomized double blind study. Participants assigned to this arm will not receive active therapy.
89081997|NCT04294017||patients|participants undergoing a diagnostic laparoscopy and have a histologically confirmed Endometriosis
89081998|NCT04294017||controls|participants undergoing a diagnostic laparoscopy where no evidence of Endometriosis could be found
89081999|NCT00615745|Experimental|Single Arm|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
89082000|NCT04216069|Experimental|Total 12 regimen group|This group will use the following procedure: Colgate Ultrasoft toothbrush, Colgate Total 12 toothpaste and Plax Mouthwash.
89082001|NCT04216069|Experimental|Tooth brushing alone group|This group will use Colgate Ultrasoft toothbrush and Colgate Cavity Protection toothpaste.
89082002|NCT02697721|Experimental|Powerful Tools for Caregivers|A 6-week psycho-educational program
89082003|NCT02697721|Other|Control group, delayed intervention|Control group with delayed intervention
89082004|NCT04215367|Experimental|High phenolic EVOO intake|Patients with CLL consumed before their meals, 40 ml/day of EVOO rich in oleocanthal and oleacin for 6 months,
89082005|NCT04215367|Experimental|No High phenolic EVOO intake|Patient's history were recorded for third and sixth month before dietary the intervention, taking into consideration that the patients did'nt consume high phenolic EVOO.
89082006|NCT02697799|Experimental|High-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a high-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
89082007|NCT02697799|Experimental|Mid-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a mid-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
89082008|NCT02697799|No Intervention|No modified recruitment strategy|Subjects in this group will receive consent form without a modified recruitment strategy for research participation in the parent study.
89082009|NCT02700607|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
89082010|NCT02700607|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
89082011|NCT04782739||Description of PMTCT service provision and uptake at healthcare facilities|Aggregated data will be collected from all 1560 public healthcare facilities in Zimbabwe on key indicators including antenatal testing and treatment of HIV and syphilis, and management of HIV-exposed and HIV-positive infants. Data will be collected from March 2015 (5 years prior to the pandemic) to the end of the study, to explore trends over time.
89082012|NCT04782739||Neonatal admissions at Harare Children's Hospital|Individual-level patient data will be collected on all neonates admitted for care at Harare Children's Hospital, including on patient characteristics, clinical status at presentation and outcomes. Data will be collected from February 2019 to the end of the study, to explore trends over time.
89082013|NCT04782739||Qualitative study|Qualitative study of 20 pregnant/lactating women accessing routine PMTCT services and 10 community healthcare workers from the Mabvuku and Kuwadzana Polyclinics. The estimated enrolment of 30 participants given in the study design section above refers to participants from this group only.
89082014|NCT04215913||Normal lung tissue|Normal lung tissue from PSC patients
89082015|NCT04215913||PSC tissues|PSC tissues from PSC patients
89082016|NCT04215913||Metastasis tissues|Metastasis tissues from PSC patients
89082017|NCT02697643|Experimental|BHCDS-based recommendations|The Experimental condition will use the BH-CDS tool and receive tailored recommendations in addition to treatment as usual.
89082018|NCT02697643|Placebo Comparator|Non-tailored recommendations|The Control condition will use the BH-CDS tool and receive non-tailored recommendations in addition to treatment as usual.
89082019|NCT05324839|Experimental|score 1 before injection|We injected 1-5 u of BoNTA into score 1 crow's feet lines before being included
89082020|NCT05324839|Experimental|score 2 before injection|2-6 u of BoNTA into score 2 crow's feet lines
89082021|NCT05324839|Experimental|score 3 before injection|3-10 u of BoNTA into score 3 crow's feet lines
89082022|NCT05324839|Experimental|score 4 before injection|5-15 u of BoNTA into score 4 crow's feet lines.
89082023|NCT02700685|Experimental|Pycnogenol|"Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.~Subjects < 30 kg body weight: 20 mg Pycnogenol/day Subjects >= 30 kg body weight: 40 mg Pycnogenol/day"
89082024|NCT02700685|Placebo Comparator|Placebo|Placebo treatment (identical capsules containing excipients only)
89082025|NCT02700685|Active Comparator|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release. Subjects < 30 kg body weight: 20 mg methylphenidate once per day Subjects >= 30 kg body weight: 30 mg methylphenidate once per day
89082026|NCT02700763|Experimental|[18F]dabrafenib molecular imaging|A [18F]dabrafenib PET scan will be performed at baseline (7 days or less before the start of treatment with oral dabrafenib).
89082027|NCT04188613|Experimental|HFJV|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. The patient was extubated, and the jet ventilator catheter was inserted to trachea and ventilation will be start.
89082028|NCT04188613|Active Comparator|ETT|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed through the vocal cords.
89082029|NCT04188613|Active Comparator|LMA|In preparation for the percutaneous tracheotomy, the patient was covered in a sterile fashion. Endotracheal tube (ETT) was removed and laryngeal mask airway device inserted.
89082030|NCT00616291|Experimental|Group I|MHC Class I binding peptide at 1000 mcg
89082031|NCT00616291|Experimental|Group II|MHC Class II binding peptide at 1000 mcg
89082032|NCT00616291|Experimental|Group III|Combination MHC Class I and II binding peptide at 1000 mcg each
89082033|NCT03151681|Experimental|Propranolol pill + mismatch memory reactivation|Prediction-error will be incorporated into each treatment sessions.
89082034|NCT03151681|Experimental|Propranolol pill + standard memory reactivation|
89082035|NCT03151681|No Intervention|Waitlist|
89082036|NCT02700373|Experimental|PDC-APB|"PDC-APB Intra-Muscular (IM)~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
89082037|NCT02700373|Placebo Comparator|Placebo|"Placebo~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
89082038|NCT04215445|Active Comparator|Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
89082039|NCT04215445|Active Comparator|Non-Proteinuric diabetic CKD|Tab.empagliflozin 25mg once daily for 28 days
89082040|NCT01032265|Active Comparator|Web-based treatment|Web-based treatment with information (including life style), PFMT, elements of CBT and regular mail contact with an urotherapist
89082041|NCT01032265|Active Comparator|Pamphlet treatment|Information (including life style), and PFMT exercises.
89082042|NCT00951457|Experimental|Overall study|"Dose escalation phase:~Days -3, -2, -1: 3 - 10 - 30 mg Alemtuzumab s.c.~Treatment phase:~Bendamustine 70 mg/m2 i.v. on d1 + d2 repeat every 28 days for 4 cycles~Alemtuzumab 30 mg s.c. 3x per week (days 1, 3, 5) continuously in parallel with chemotherapy cycles for a maximum of 16 weeks"
89082043|NCT05324527|Experimental|Hand Massage Group|After the researcher and the children in study group sat on a chair facing each other, hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
89082044|NCT05324527|No Intervention|Control group|The control group will be received routine treatment and care in the unit.
89082045|NCT02691871|Experimental|Apatinib + Docetaxel|Low, medium or high dose of Apatinib (days 3-19, q3w) and Docetaxel (60 mg/m2, day 1, q3w)
89082046|NCT02700217|Experimental|Spinal Anaesthesia|2.5ml of heavy 0.5% Bupivacaine, 400mg of Diamorphine (Spinal Anaesthesia) & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
89082047|NCT02700217|Active Comparator|Rectus Sheath Injection|50ml of 0.25% I-Bupivacaine max 2mg/kg (IV block Anaesthesia) injected into rectus sheath bilaterally & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
89082048|NCT00616369||1|"I:~For those patients who have had blood samples drawn as a result of participating in current protocol, Identification of Genetic Markers for Primary Pulmonary Hypertension study (X980515002), we would like to use their previously obtained blood and continue to draw samples (12mL; less than 3 tablespoons) ONLY if they change disease therapies.~For those patients who participated in Pulmonary Arterial Hypertension (PAH) Database study (X030403017), these participants will also sign a consent form to participant in this new trial. We would like to use the previously obtained data from the X030403017 in part with this study.~As for the X980515002 expired patients, we would like to use the previously obtained data ONLY in part for this study that was collected as a result of the X980515002 study."
89082049|NCT00616369||2|"II:~Group 2: After signing a consent form, these participants will have a 12mL (less than 3 teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. With each disease therapy change, the blood draws (12mL samples) will begin again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits."
89082050|NCT02690467|Experimental|Insupen G34x3,5mm|Needle for insulin pen 3,5 mm long and with a diameter of 34 gauge
89082051|NCT02690467|Active Comparator|Insupen G32x4mm|Needle for insulin pen 4 mm long and with a diameter of 32 gauge
89082052|NCT02705833||Population with R/M SCCHN|Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) patients diagnosed between 01July2013 and 30June2014, alive or deceased, at the time of data collection
89082053|NCT02700139|Experimental|Aspheric lens|An aspheric lens which is supposed to slow myopic progression in children by unique asphericity (proprietary information)
89082054|NCT02700139|No Intervention|Single vision spheric/toric lenses|Control: single vision spheric/toric lenses
89082055|NCT02699827|Active Comparator|Magnesium sulphate group|Patients will receive epidural levobupivacaine hydrochloride + magnesium sulphate
89082056|NCT02699827|Placebo Comparator|Placebo group|Patients will receive epidural levobupivacaine hydrochloride + saline 0.9%
89082057|NCT02700061|Experimental|Induced Constraint Therapy - ICT|Physical rehabilitation with Induced Constraint Therapy as part of the occupational therapy. Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
89082058|NCT02700061|Experimental|Robotic occupational therapy|Physical rehabilitation with Robotic occupational therapy. Robotic Occupational Therapy three times a week for twelve weeks.
89082059|NCT02705989|Placebo Comparator|Single Ascending Dose (SAD)|Single ascending dose of BMS-986195 or Placebo matching BMS-986195
89082060|NCT02705989|Placebo Comparator|Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195
89082061|NCT02705989|Placebo Comparator|Japanese-Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage
89082062|NCT02705989|Experimental|Relative Bioavailability with Food Effects (Open Label)|
89082063|NCT00616447|Experimental|1|
89082064|NCT00616447|Sham Comparator|2|
89082065|NCT05323747||Radiation with Hydrogel Spacer|Males at least 18 years of age, who will be undergoing radiation therapy with a hydrogel spacer in place.
89082066|NCT02706067|Experimental|Orlistat|Participants will receive intermittent orlistat for up to 4 years, with the dose determined according to body weight changes.
89082067|NCT04215757|Experimental|Intervention group|"Patient received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.~For L4 radiculopathy Saphenous nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%) For S1 radiculopathy Sural nerve block with 1.5ml of 2% lignocaine diluted to 10ml (0.3%)"
89082068|NCT04215757|Placebo Comparator|Control group|"Patients received one or two peripheral nerve blocks at a maximum according to their involvement in the operation theatre, with full ASA monitoring under all aseptic precautions.~For L4 radiculopathy Saphenous nerve block with 10ml distilled water For L5 radiculopathy Deep peroneal nerve block/posterior tibial nerve block with 10ml distilled water For S1 radiculopathy Sural nerve block with10ml distilled water"
89082069|NCT02699905||Sepsis|Patients with the diagnosis of sepsis or septic shock
89082070|NCT02699905||Control|Healthy control with no evidence of active infection, or recent infection in the past 4 weeks.
89082071|NCT02699671||acute myocardial infarction|
89082072|NCT00615277|Active Comparator|1|1: omega-3 fatty acid supplement
89082073|NCT00615277|Placebo Comparator|2|2: olive oil
89082074|NCT05323201|Experimental|fhB7H3.CAR-T cells|In phase I study , 9 enrolled patients diagnosed with advanced liver cancer will receive one-time transhepatic arterial infusion of fhB7H3.CAR-Ts at the doses of 1×10^6/kg, 3×10^6/kg and 5×10^6/kg, 3 patients for each dose. To further confirm the therapeutic efficacy, in phase II study, 6 enrolled patients will receive an optimal dose (balancing effectiveness and toxicity) of fhB7H3.CAR-Ts.
89082075|NCT02905825|Experimental|Indication for Helicobacter pylori testing|Walk in basis: any pediatric subjects with indication for Helicobacter pylori testing will be enrolled if they meet study eligibility criteria and will perform stool test and urea breath test within a week of each other.
89082076|NCT01208051|Experimental|Arm A (cediranib maleate)|Patients receive cediranib maleate 30 mg PO QD on days 1-28. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89082077|NCT01208051|Experimental|Arm B (cediranib maleate plus lenalidomide thru April 10, 2015)|Patients receive cediranib maleate 30 mg PO and lenalidomide 15 mg PO on days 1-21. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. NOTE: As of April 10, 2015, patients assigned to this arm are discontinued lenalidomide and continued on cediranib alone.
89082078|NCT00616837|Active Comparator|Standard consultation|Standard care in orthopaedic outpatient clinic
89082079|NCT00616837|Experimental|Telemedicine consultation|Orthopaedic care in outpatient clinic by use of telemedicine.
89082080|NCT04214197|Other|Crisaborole|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
89082081|NCT04214275|Experimental|intervention group|standard care and participated in a pulmonary rehabilitation program
89082082|NCT04214275|No Intervention|control group|received standard care after coronary artery bypass graft
89082083|NCT05322889|Experimental|Intervention with Telmisartan|"Telmisartan (open), 80 mg daily p.o. (after run-in phase with 40 mg for 7 days).~for 12 weeks"
89082084|NCT04214431|Experimental|Mindfulness-Based Childbirth Education|Women in the experimental group received eight week mindfulness-based childbirth education program delivered one class each week.
89082085|NCT04214431|No Intervention|Control group|Women in the control group received standardized care.
89082086|NCT02705677||Rett syndrome|This is a biobanking project for individuals with mutations in MECP2 or meeting diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome in order to identify other genetic factors such as X-chromosome inactivation or genetic background that may explain the variations noted in these individuals, including those with the same MECP2 mutation. No interventions are anticipated.
89082087|NCT02705677||MECP2 Duplication disorder|This is a biobanking project for individuals with MECP2 duplications to understand the difference in the size of the duplication and the potential impact of other genes in the duplicated segment. No interventions are anticipated.
89082088|NCT02705677||Rett-related disorders: CDKL5, FOXG1|This is a biobanking project for individuals with mutations in MECP2, CDKL5, and FOXG1 to understand the interplay of mutations in these individuals and the resultant phenotypic expression; for example, individuals with mutations in MECP2 but not meeting diagnostic criteria for Rett syndrome or individuals with mutations in CDKL5 or FOXG1 who may or may not meet diagnostic criteria for atypical Rett syndrome. No interventions are anticipated.
89082089|NCT05322811||Participants|Adults patients with neurological disorder
89082090|NCT02705521|No Intervention|Treatment as usual group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). They will be assessed for progression and be provided with a home exercise program. Range of motion in their shoulder will be collected on a weekly basis using the MIRA technology. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
89082091|NCT02705521|Experimental|Treatment as usual plus Exergames group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). Rather than use a home exercise program patients will be provided with a laptop computer and kinect sensor. they will use the new technology to play 'Exergames' each program will be tailored to the patients progress and patients can play the system as often as they wish. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
89082092|NCT00616915|Other|1|Wellbutrin SR switched to Wellbutrin XL
89082093|NCT01207583||healthy children after vaccination|healthy children after vaccination
89082094|NCT01207427|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally twice daily (BID) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
89082095|NCT01207427|Experimental|ADL5945 0.1 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.1-milligrams (mg) ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
89082096|NCT01207427|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-mg ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
89082097|NCT05410223|Experimental|study group|14-days therapy of Yolk antibody and ilaprazole, clarithromycin/amoxicillin/furazolidone, doxycycline, bismuth
89082098|NCT05410223|Active Comparator|control group|14-days therapy of ilaprazole, clarithromycin/amoxicillin/furazolidone, doxycycline, bismuth
89082099|NCT05410223|Experimental|the case group|14-days therapy of Yolk antibody and ilaprazole, clarithromycin/amoxicillin/furazolidone, doxycycline
89082100|NCT05410223|Active Comparator|the control group|14-days therapy of ilaprazole, clarithromycin/amoxicillin/furazolidone, doxycycline, bismuth
89082101|NCT04713553|Experimental|Arm 1|30-microgram dose of US manufactured drug substance (Lot 1)
89082102|NCT04713553|Experimental|Arm 2|30-microgram dose of US manufactured drug substance (Lot 2)
89082103|NCT04713553|Experimental|Arm 3|30-microgram dose of US manufactured drug substance (Lot 3)
89082104|NCT04713553|Experimental|Arm 4|30-microgram dose of EU manufactured drug substance (Lot 4)
89082105|NCT04713553|Experimental|Arm 5|20-microgram dose of US manufactured drug substance (corresponding to Arm 1, 2 or 3 lot)
89082106|NCT04713553|Experimental|Booster 1: BNT162b2|30-microgram dose
89082107|NCT04713553|Experimental|Booster 2: BNT162b2.B.1.351|30-microgram dose
89082108|NCT01206101|Experimental|Liraglutide|
89082109|NCT01206101|Placebo Comparator|Liraglutide placebo|
89082110|NCT01205165|Experimental|Adefovir Dipivoxil 10mg|All enrolled subject were enrolled to adefovir dipivoxil 10mg arm.
89082111|NCT02705443||Tissue w/ Thermographic Anomaly|"Visibly undamaged tissue with anomaly identified by the thermographic image~No intervention~Standard of care"
89082112|NCT02705443||Tissue w/o Thermographic Anomaly|"Visibly undamaged tissue with no anomaly identified by the thermographic image~No intervention~Standard of care"
89082113|NCT02705443||Tissue w/ Visible Anomaly|"Visibly damaged tissue~No intervention~Standard of care"
89082114|NCT04214509||PD + LRRK2|Patients with LRRK2-associated Parkinson's syndrome
89082115|NCT04214509||no PD + LRRK2|Participants with LRRK2-mutations but without Parkinson's symptoms
89082116|NCT04214509||no PD + no LRRK2|Participants without mutations and without Parkinson's symptoms
89082117|NCT04214509||PD+ other than LRRK2|Parkinson patients with mutations in other genes than LRRK2
89082118|NCT04214509||PD+ no LRRK2|Patients with idiopathic Parkinson's disease
89082119|NCT02705053|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 2)|The subjects' Sensor-Augmented Pump Open-Loop Care for the second week of the study before any adjustments to pump settings, using a CGM and Insulin Pump.
89082120|NCT02705053|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on CGM glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device. Algorithmic adjustment of carbohydrate ratios prior to closed-loop initiation, and continued basal rate and carbohydrate ratio algorithmic optimization during closed-loop use will occur.
89082121|NCT01204775|Experimental|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
89082122|NCT01204775|Placebo Comparator|Placebo|Placebo matching saxagliptin tablet
89082123|NCT02705131|Experimental|Balance Chiropractic Therapy(BCT)|patients are in the sitting position and receive the Balance Chiropractic Therapy(BCT) .1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.The patients will received BCT 1 time every other day, 20min each time. a total of 10 times in 20 days.
89082124|NCT02705131|Active Comparator|Traction Therapy(TT)|patients will receive the Traction Therapy(TT):The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
89082125|NCT02844907|Experimental|Hyperglycemic clamp + Exendin (9-39)|During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM. Participants will receive an infusion of the GLP-1 receptor antagonist Exendin (9-39) between the 60-120 minute time-points of the clamp. The amount of Ex-9 infused will be 750 pmol/kg/min for 60 minutes.
89082126|NCT02844907|Experimental|Dexamethasone|Subjects will be asked to take 4 mg once daily between Visit-2 and Visit-3.
89082127|NCT00628719|Experimental|1|a single dose of 10 mg/kg of liposomal amphotericin B
89082128|NCT00628719|Active Comparator|2|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
89082129|NCT00616993|Placebo Comparator|2|Vehicle
89082130|NCT00616993|Experimental|1|Difluprednate
89082131|NCT02870361|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
89082132|NCT02870361|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
89082133|NCT00997035|Active Comparator|Oral Voriconazole|
89082134|NCT00997035|Placebo Comparator|Placebo|
89082135|NCT01204697|Experimental|A|
89082136|NCT01204697|Experimental|B|
89082137|NCT02705209|Active Comparator|Treatment|
89082138|NCT02705209|Placebo Comparator|Control|
89082139|NCT01001325|Experimental|Seasonal influenza vaccination|Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification
89082140|NCT01001325|Placebo Comparator|Placebo|0.5 mL normal saline
89082141|NCT04141813||"Pilgrims doing the Camino de Santiago (any route)"|"In the present study we utilized the Ultreya dataset. The Ultreya study is an online longitudinal study aimed at evaluating the effects of the pilgrimage on the Way of Saint James on mental health and wellbeing (www.estudiocamino.org). This pilgrimage involves hundreds of paths around Europe with a common termination at Santiago de Compostela (Spain), and it was one of the most important Christian pilgrimages during the Middle Ages. Currently, it is walked by thousands of people (>300,000 per year)."
89082142|NCT02968459|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord MSCs
89082143|NCT02968459|Placebo Comparator|Placebo-Controlled Group|1ml of 0.9% saline
89082144|NCT02870595|Active Comparator|Parallel lidocaine injection|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
89082145|NCT02870595|Sham Comparator|Parallel|In the sham comparator, the device will be placed on the skin, but not turned on. Digit block anesthesia will progress in usual fashion as with active comparator, except without the vibratory device engaged.
89082146|NCT02704975|Experimental|Rehabilitation and Dry Needling|Standard Rehabilitation Protocol following shoulder stabilization surgery and Dry Needling to the Shoulder girdle 1 time a week for 4 weeks between weeks 4 and 8 post operatively
89082147|NCT02704975|Active Comparator|Rehabilitation|Standard Rehabilitation Protocol following shoulder stabilization surgery alone
89082148|NCT01203917|Other|1|gefitinib 250mg tablet
89082149|NCT02704741|Experimental|all subjects|"Eligible subjects will undergo 3 treatments in 4±1 weeks interval on the Vagina (External/Vulva and Internal/Vagina) with the CO2RE device according to study protocol.~Subject will return for to 5 follow-up (FU) visits: 1 week ± 2 days post first treatment visit and 1, 3, 6 and 12 months after last (third) treatment (± 2 weeks).~Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit at the clinic."
89082150|NCT02704819|Experimental|Non-specialist doctor +DSS|"Patients allocated to +DSS group will receive the following intervention:~V1: appointment with a non-specialist doctor with the support of the DSS~V2: appointment with an overseeing expert~V3: DSS Customised Vestibular Physiotherapy~V4: follow-up visit with the overseeing expert"
89082151|NCT02704819|Active Comparator|Non-specialist doctor -DSS|"Patients allocated to -DSS group will receive the following intervention:~V1: appointment with a non-specialist doctor without the support of the DSS~V2: appointment with an overseeing expert~V3: Standard Physiotherapy Practice~V4: follow-up visit with the overseeing expert"
89082152|NCT04318379|Experimental|Low dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of low dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
89082153|NCT04318379|Experimental|High dose group|Chronic HCV patients. Fifteen subjects will receive 1.0 ml of high dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
89082154|NCT04213651||Diabetes Mellitus|Patients with diabetes mellitus
89082155|NCT04213495||Patients undergoing anesthesia in Czech Republic|Patients undergoing anesthesia in Czech Republic in the selected period from the confirmed Anesthesia Center
89082156|NCT02688517||Ancillary-Correlative (genomic analysis)|Previously collected tissue samples are analyzed for the presence of mutations via next generation sequencing. Patients may also undergo collection of blood samples for analysis of circulating cell-free DNA and circulating tumor cells.
89082157|NCT04318223|Experimental|single-arm study following a Simon's two-stage optimal design|Single-arm study with the primary objective of assessing the efficacy and safety of palbociclib in combination with fulvestrant (Faslodex) in women with HR+, HER2-negative metastatic breast cancer, regardless of their menopausal status, whose disease has progressed after prior treatment with AI plus a CDK4/6 inhibitor.
89082158|NCT04318457||Brochoscopy|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during bronchoscopy will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
89082159|NCT04318457||ERCP|20 ASA Class II-III, aged 20-80 adult patients who require moderate sedation during ERCP will be enrolled into this study. The moderate sedation will be performed only after patients' inform consents and approval of the institutional ethics committee. Patients with conditions such as neurological disorders, hearing impairment, history of habitual sedative medication and alcoholism will be excluded from this study.
89082160|NCT02704897|Experimental|Intervention Arm|"Wound assessment tool - delivered via a smartphone. A link will be sent to participants on discharge, which can be accessed at any point should they have concerns about their wound.~They will also be sent the tool at 3 additional time-points."
89082161|NCT02704897|No Intervention|Control Arm|Normal Post-operative Care
89082162|NCT01202903|Experimental|Omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 mL vial that was designed to deliver 150 mg of omalizumab for subcutaneous administration upon reconstitution with 1.4 mL sterile water for injection. The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
89082163|NCT01202903|Placebo Comparator|Placebo|The placebo was the same mixture of inactive excipients, in quality and quantity, as those used for the drug product. The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
89082164|NCT01001169|Experimental|GSK2340274A_F1 6M-9Y GROUP|Healthy male or female Japanese children, between and including 6 months to 9 years of age, who received two doses of GSK2340274A vaccine (formulation 1), administered intramuscularly into the deltoid region of the arm (intramuscularly into the anterolateral part of the thigh for subjects below 12 months of age at the entry of the study), according to 0, 21-day schedule. Within this group, enrolment of subjects was stratified by age into two subgroups, from 6 to 35 months and from 3 to 9 years.
89082165|NCT01001169|Experimental|GSK2340274A_F2 10Y-17Y GROUP|Healthy male or female Japanese children, between and including 10 to 17 years of age, who received two doses of GSK2340274A vaccine (formulation 2), administered intramuscularly into the deltoid region of the arm, according to 0, 21-day schedule.
89082166|NCT01202747|Experimental|LipiFlow Treatment|Treatment with LipiFlow device
89082167|NCT04213339|Experimental|Kegal Exercises|
89082168|NCT04213339|No Intervention|Control|
89082169|NCT04213573|Experimental|Group 1: topical application of silver diamine fluoride|38% silver diamine fluoride liquid
89082170|NCT04213573|Active Comparator|Group 2: topical application of MI varnish.|MI Varnish:5% sodium fluoride varnish which also contains RECALDENT™* (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate
89082171|NCT05154175||Ottobock helmet|Infants treated with an Ottobock helmet
89082172|NCT04395027|No Intervention|Usual care|These patients will not have their iatrogenic septal defect closed.
89082173|NCT04395027|Experimental|Device|These patients will have their iatrogenic septal defect closed after the mitral intervention is completed.
89225290|NCT05851859|Experimental|Complementary respiratory training to cardiac coherence (CC)|"The  intervention  group will benefit from a complementary respiratory training to CC during 6 months in addition to the usual care procedure."
89225291|NCT05851859|No Intervention|Usual care procedure in the event of Long COVID|"The  control  group will follow a usual care procedure in the event of Long COVID"
89082174|NCT04294173|Experimental|video group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the experimental group in the classroom setting. Video presentation including powerpoint presentation and tracheostomy care skill application will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained by the researchers to the video group students in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be watched by the video-assisted teaching method, and the video of tracheostomy care The videos will be sent to students via e-mail. A two-day warning message will be sent to the students from the WhatsApp group to watch the video by the researchers. A week later, students will be invited to the basic skills laboratory for tracheostomy care.
89225292|NCT05848713|Experimental|Therapeutic-Dose Heparin|Participants randomized to the investigational arm will receive a pragmatic strategy of therapeutic-dose low molecular-weight heparin (LMWH) or unfractionated heparin (UFH) administered daily for up to 14 days or until hospital discharge, whichever occurs first. Participants should start receiving study drug as soon as possible following randomization.
89082175|NCT04294173|No Intervention|demonstration group|Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the control group in the classroom setting. Powerpoint presentation will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained to the control group students by the researchers in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be taken to the basic skills laboratory and tracheostomy care will be performed on the dummy by the researchers using the demonstration method. Then, students will be given the output of the powerpoint presentation and asked to study the lecture notes for a week. A two-day warning message will be sent by the researchers to students from the WhatsApp group to study. A week later, students will be invited to the basic skills laboratory to practice tracheostomy care.
89082176|NCT02869659|Active Comparator|Control/Delayed Weight Loss Group|"Control/Delayed Weight Loss Group: (18 weeks) Participants randomized to the delayed weight loss intervention (n=100) will serve as a no-weight loss control to the weight loss group during the first 18 weeks of the study. During the control (18 weeks) phase these participants will receive a monthly phone call visit from staff to maintain contact and interest in the study. At the end of the initial 18 weeks participants will complete all follow up assessments prior to being offered the opportunity to participate in a weight loss program.~No outcome data will be collected at the end of the delayed weight loss phase."
89082177|NCT02869659|Experimental|Weight Loss Group|"Weight Loss group: Phase 1 (18 wks): Participants assigned to this group will undergo a dietary intervention for the first 18 weeks of the study.~This level of weight loss will be achieved through the combination of a partial meal replacement (MR) program and individual and group nutrition/behavioral counseling. Participants will be provided with and asked to consume 4 Medifast® MR per day.~Phase 2 (8 wks): After completion of the active weight loss phase, participants in this group will attend bimonthly group meetings to discuss increasing their activity.~Phase 3 (26 wks): After completion of phase 2, participants will be called monthly for 26 weeks and then asked to return for a maintenance visit at the end of the 52 weeks from study start."
89082178|NCT04210063|Experimental|IMT Intervention|During the first month, participants will be in a month-long control wash in period where no intervention will be provided. During the second month, participants will be in a 4-week daily IMT intervention period. During the third month, participants will be in a month-long efficacy period with no intervention provided.
89082179|NCT02870439|Experimental|patients with at least 20% of wounded burns body|
89082180|NCT02870439|Experimental|patients with at least 5% of wounded burns body|
89082181|NCT02870439|Experimental|patients with post-surgical wounds with skin resection|
89082182|NCT04209751||Children with summer diarrhea|Children aged 0 to 16 years with diarrhea
89082183|NCT00618709|Experimental|Cohort 1|ATX-101 (1 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
89082184|NCT00618709|Experimental|Cohort 2|ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
89225293|NCT05848713|No Intervention|Usual Care|Participants randomized to the control arm will receive usual care thromboprophylactic dose anticoagulation according to local practice. To ensure adequate separation between the study groups, the dose of heparin/LMWH used in the usual care arm should not equal more than half of the approved therapeutic dose for that agent according to local VTE treatment protocols.
89225294|NCT05847504|Experimental|mSTARS|mHealth-supported Skills Training for Alcohol-Related Suicidality, or mSTARS, is an intervention that combines a cognitive-behavioral skills training intervention in emotion regulation skills with a post-discharge mobile health (mHealth) app that encourages application of these skills to real life.
89225295|NCT05845918|Experimental|PRISEM CEP (in-person)|The Cognitive Empowerment Program (CEP) is an in-person lifestyle intervention program in which participants participate in individual or group-based activities that address cognitive, physical, social, and functional independence, education, and well-being goals.
89225296|NCT05845918|Experimental|PRISEM Remote|PRISEM Remote is a remote-based lifestyle intervention program in which participants will attend 17 core online sessions via Zoom from the evidence-based Diabetes Prevention Program curriculum with remaining post-core sessions to reinforce strategies and activities introduced in the core program for the duration of 6 months.
89225297|NCT05845814|Experimental|Arm A: Coformulated favezelimab/pembrolizumab plus EV|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) as an intravenous (IV) infusion on Day 1 of every 3-week cycle for up to ~2 years (35 cycles) and EV at 1.25 mg/kg, administered as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision.
89225298|NCT05845814|Experimental|Arm B: Coformulated vibostolimab/pembrolizumab plus EV|Participants will receive coformulated vibostolimab/pembrolizumab (200 mg/200 mg) as an IV infusion on Day 1 of every 3-week cycle, for up to ~2 years (35 cycles) and EV at 1.25 mg/kg, administered as an IV infusion on Days 1 and 8 of every 3-week cycle until disease progression, intolerable toxicity, or investigator decision.
89225299|NCT05845814|Active Comparator|Arm C: Pembrolizumab plus EV|Participants will receive 200 mg pembrolizumab as an IV infusion on Day 1 of every 3-week cycle for up to ~2 years (35 cycles) and EV at 1.25 mg/kg, administered as an IV infusion on Days 1 and 8 of every 3-week cycle, until disease progression, intolerable toxicity, or investigator decision.
89225300|NCT05845710|Experimental|Neuroguard IEP Direct System|The Neuroguard IEP® 3-in-1 Direct Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP Direct System) is a combination self-expanding carotid artery stent, nitinol embolic protection filter, and post-dilation balloon. Neuroguard IEP Direct System is used with the Neuroguard Direct Access Kit which includes the Flow Redirection System.
89225301|NCT05843370||High SVI|Participants reside in neighborhood zip code clusters that rank at the top of the social vulnerability index (most vulnerable)
89225302|NCT05843370||Low SVI|Participants reside in neighborhood zip code clusters that rank at the bottom of the social vulnerability index (least vulnerable)
89225303|NCT05843357||Observed group|No intervention will be administered on behalf of the project. The participants will be tested using ALBA and PICNIR (non-invasive) cognitive tests, and further sFAQ-CZ and GDS-CZ questionnaires will be administered. Questionnaires FAQ-CZ and MBI-C-CZ will be distributed to participants´ caretakers.
89225304|NCT05841095|Active Comparator|ISA104|
89225305|NCT05841095|Placebo Comparator|Placebo|
89225306|NCT05839847|Experimental|NPU|Participant will be presented with a series of images (cues) and sounds. Three conditions will occur - a no shock (N), predictable shock (P), and unpredictable shock (U). In P, shocks will only occur with the cue. In U, shocks will happen at any time. Participants will be told which condition they are in throughout the task. Startle sounds will occur throughout. 3 Study visits will occur - identical conditions for the participant, testing 2 brain regions and 1 sham visit.
89225307|NCT05839847|Experimental|NPU-c|Participants will be presented with a moving line. When the line reaches a certain point - an event will occur. This event will either be a painful shock or a monetary reward. Startle sounds will occur throughout. 3 study visits will occur - identical conditions for the participant, testing 2 brain regions and 1 sham visit.
89225308|NCT05837117||Patient's Perspective|Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic. Participants may choose to complete the questionnaire electronically (via email link), in-person, or over the phone, whichever you prefer. Your demographic information (such as age, gender, ethnicity, marital status, and cancer diagnosis) will be collected from your medical record. Some of this information may also be asked of you during the questionnaire.
89225309|NCT05828173|Experimental|LithiX Coronary Hertzian Contact Intravascular Lithotripsy Treatment|
89225310|NCT05827861|No Intervention|Usual Care|Standard care in which the participant will receive their health screening results using the format used by Health Promotion Board guidelines and a link to a publicly-available website with information on how to manage the risk of heart disease
89225311|NCT05827861|Experimental|HeartAge only|Participants will be directed to HeartAge, a risk assessment tool available online. Then, they will be directed to a publicly-available website with information on how to manage the risk of heart disease
89082185|NCT00618709|Experimental|Cohort 3|3 subgroups in Cohort 3: 3a: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 3b: ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 3c: ATX-101 (2 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
89082186|NCT00618709|Experimental|Cohort 4|3 subgroups in Cohort 4: 4a: ATX-101 (8 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 4b: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 4c: ATX-101 (4 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
89082187|NCT00620269|Experimental|study arm 1|Induction (with Erlotinib X 3 cycles) -> CCRT with Erlotinib (X 2 cycles) -> continue Erlotinib (X 6 cycles)
89082188|NCT00620269|Experimental|study arm 3|Induction (IP X 3 cycles) -> CCRT with IP (X 2 cycles)
89082189|NCT00620269|Active Comparator|control arm|CCRT with IP (X 2 cycles) -> consolidation IP (X 3 cycles)
89082190|NCT00620269|Experimental|study arm 2|Induction (Erlotinib X 3 cycles) -> CCRT with IP (X 2 cycles) -> recurrence -> Erlotinib (until PD)
89082191|NCT04213417|Experimental|Bobath therapy plus Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the Bobath therapy was applied to the affected side of the body and lower extremity for 60 minutes in each session.
89082192|NCT04213417|Active Comparator|Bobath therapy|Both groups were treated with the Bobath therapy as a neurodevelopmental therapy.
89082193|NCT00618865|Experimental|1|omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)
89082194|NCT00618865|Placebo Comparator|2|Placebo (olive oil ethyl esters)
89082195|NCT04213183||development dataset 01|Slit-lamp and retinal fundus images collected from Department of Hepatobiliary Surgery of the Third Affiliated Hospital of Sun Yat-sen University.
89082196|NCT04213183||development dataset 02|Slit-lamp and retinal fundus images collected from Affiliated Huadu Hospital of Southern Medical University.
89082197|NCT04213183||development dataset 03|Slit-lamp and retinal fundus images collected from Nantian Medical Centre of Aikang Health Care.
89082198|NCT04213183||test dataset 01|Slit-lamp and retinal fundus images collected from Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University.
89082199|NCT04213183||test dataset 02|Slit-lamp and retinal fundus images collected from Huanshidong Medical Centre of Aikang Health Care.
89082200|NCT00617617|Experimental|A|Dietary Supplement: Prevastein HC®
89082201|NCT00617617|Placebo Comparator|B|Placebo
89082202|NCT05104957|Experimental|Dynamic tape|Experimental group will use a special dynamic tape on the lumbar extensor muscles
89082203|NCT05104957|Sham Comparator|Paper tape|Control group will use a paper tape on the lumbar extensor muscles
89082204|NCT04212637|Experimental|Healthy Volunteers|MRI exam
89082205|NCT04212637|Experimental|Parkinson patient|MRI exam
89082206|NCT04212403|Active Comparator|Control|The control groups receives antimicrobial prophylaxis (AMP) as recommended by the guidelines.
89082207|NCT04212403|No Intervention|Treatment group|The treatment group receives no AMP.
89082208|NCT02052193|Experimental|Dabrafenib|Dabrafenib 150mg BID orally
89082209|NCT02052193|Active Comparator|Vemurafenib|Vemurafenib 960mg orally BID
89082210|NCT00617695|Experimental|1|
89082211|NCT00617695|Placebo Comparator|2|
89082212|NCT02704585|Other|Nellcor|Connection to Nellcor pulse oximeter for measuring oxygen saturation after birth
89082213|NCT02704585|Other|Masimo|Connection to Masimo pulse oximeter for measuring oxygen saturation after birth
89082214|NCT00619021|Experimental|Cohort 1|Patient receives gemcitabine 600 mg/m^2.
89082215|NCT00619021|Experimental|Cohort 2|Patient receives gemcitabine 800 mg/m^2.
89082216|NCT00619021|Experimental|Cohort 3|Patient receives gemcitabine 1000 mg/m^2.
89082217|NCT00619021|Experimental|Cohort 4|Patient receives gemcitabine 1200 mg/m^2.
89082218|NCT00620347|Experimental|Single arm|Single arm (sunitinib arm) until PD, unacceptable toxicity, patients refused
89082219|NCT01918735|Experimental|Group/dose level 1a|25 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
89082220|NCT01918735|Placebo Comparator|Group/dose level 1b|Matching placebo for Group/dose level 1a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
89082221|NCT01918735|Experimental|Group/dose level 2a|75 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
89225312|NCT05827861|Experimental|HeartAge and HOPE Platform|Participants will be directed to HeartAge, a risk assessment tool available online. Then, they will be led to download the HOPE-CVD mobile app, an evidence-based behaviour change platform.
89082222|NCT01918735|Placebo Comparator|Group/dose level 2b|Matching placebo for Group/dose level 2a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
89082223|NCT01918735|Experimental|Group/dose level 3a|200 mg GWP42006 oral solution (single dose) followed by an intravenous administration of 5 mg GWP42006 after the oral dose
89082224|NCT01918735|Placebo Comparator|Group/dose level 3b|Matching placebo for Group/dose level 3a
89082225|NCT01918735|Experimental|Group/dose level 4a|400 mg GWP42006 oral solution
89082226|NCT01918735|Placebo Comparator|Group/dose level 4b|Matching placebo for Group/dose level 4a
89082227|NCT01918735|Experimental|GWP42006 1, 2, or 3 times daily|Subjects will receive the selected dose of GWP42006 once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
89082228|NCT01918735|Placebo Comparator|Placebo 1, 2, or 3 times daily|Subjects will receive placebo once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
89082229|NCT04213105|Experimental|QL1206|QL1206 injection (60mg) by subcutaneous injection once on the first day
89082230|NCT04213105|Active Comparator|Prolia®|Prolia® injection (120mg) by subcutaneous injection once on the first day
89082231|NCT01887301|Active Comparator|Group 1: mild hepatic impairment|Mild hepatic impairment: eight patients of Child-Pugh Grade A (Score 5-6). All patients received Sativex treatment.
89082232|NCT01887301|Active Comparator|Group 2: Moderate hepatic impairment|Moderate hepatic impairment: eight patients of Child-Pugh Grade B (Score 7-9). All patients received Sativex treatment.
89082233|NCT01887301|Experimental|Group 3: Pugh Grade B (Score 7-9).|Severe hepatic impairment: eight patients of Child-Pugh Grade C (Score 10-15). All patients received Sativex treatment.
89082234|NCT01887301|Active Comparator|Group 4: Control group|Control Group: eight healthy subjects matched with respect to age (±10 years), weight (±10% body mass index [BMI]) and sex to the severe or most severe evaluable patients. All patients received Sativex treatment.
89082235|NCT00618085|Experimental|1|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the experimental group will receive 2 instruction DVD's introducing them to motor imagery practice, taking 35 minutes in total. The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to help incorporate motor imagery within the therapy. Thereafter the therapist will help the patient use motor imagery as part of their normal treatment. The total amount spent on motor imagery during therapy sessions will be 6.5 hours in 6 weeks."
89082236|NCT00618085|Active Comparator|2|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the control group will receive 2 DVDs for 35 minutes in total. These will show background information on their condition, explaining the importance of practice of activities, and on the principles of motor learning and phased movement which underlie most therapy.The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to control for attention. The total amount the physiotherapist and occupational therapist spend with the patients should be the same in both groups."
89082237|NCT00996801|Placebo Comparator|Placebo|Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
89082238|NCT00996801|Experimental|MK-5442 5 mg|Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
89082239|NCT00996801|Experimental|MK-5442 7.5 mg|Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
89082240|NCT00996801|Experimental|MK-5442 10 mg|Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
89082241|NCT00996801|Experimental|MK-5442 15 mg|Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
89082242|NCT00996801|Active Comparator|Alendronate 70 mg|Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
89082243|NCT00619333|Other|1|
89082244|NCT02692027|Active Comparator|Standard of care|Standard of care in Lesotho. ART-initiation after at least two clinic visits for pre-ART counseling and monthly follow-up visits at the clinic thereafter.
89082245|NCT02692027|Experimental|Same-day ART initiation with less frequent follow-up visits|Proposition of same-day ART initiation with less frequent follow-up visits thereafter.
89082246|NCT04212871|Experimental|watch mukbang|"In the online study, participants were assigned to watch a ramen mukbang, by Yuka Kinoshita (https://youtu.be/ArPaid2Iuck, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a hotpot mukbang by Alun (https://youtu.be/QCTOo9UGZD8, accessed: 2018-11-29)."
89082247|NCT04212871|Experimental|watch another food content video|"In the online study, participants were assigned to watch a donut mukbang, by Yuka Kinoshita (https://youtu.be/ntMT2y0MgHk, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a hotpot cooking show by the Cat's kitchen (https://youtu.be/EH5Ei-sMP60, accessed: 2018-11-29)."
89082248|NCT04212871|Placebo Comparator|watch a non-food content video|"In the online study, participants were assigned to watch a silent documentary introducing the Palace Museum by China Central Television (CCTV) (https://youtu.be/hWnm1BQOTZY, accessed: 2018-10-12).~In the in-person study, participants were assigned to watch a video introducing Cornell University is used for the non-food content video (https://youtu.be/GuM8vTq0jd4, accessed: 2018-11-29)."
89082249|NCT04924621|Experimental|THRIVE group|Patients in group T received mask ventilation(oxygen concentration: 100%, flow rate: 6L /min, head height: 30°) for 5 minutes, and then THRIVE device (device model: Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.) was set 100% oxygen, flow rate 30L /min, temperature 34℃.
89082250|NCT04924621|Placebo Comparator|Control group|The Control Group will receive mask ventilation (oxygen concentration: 100%, flow rate: 6L /min, head height: 30°) for 5 minutes
89082251|NCT00619411|Experimental|I|
89082252|NCT04293705|Experimental|regular TOPS group|Patients are required to perform the regular TOPS program, composed of 10 core sessions and other eventual supplementary sessions. In addition, biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim to monitor patients' activities on problem-solving related to the TOPS program contents and the problem solving process in real life. The program has a specific focus on problem-solving, executive functions, behavioral strategies and social skills.
89082253|NCT04293705|Active Comparator|modified TOPS group|Patients are required to perform the modified TOPS program, composed of 10 sessions focused only on health and wellness contents. Thus, this program does not include contents on problem-solving, executive functions, behavioral strategies and social skills, representing a low cognitively simulating activity. Biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim of monitoring training adherence and discuss the program's contents.
89082254|NCT04211467||Depression|Patients who have been diagnosed with depression
89082255|NCT00996489|Experimental|Coaptite|
89082256|NCT04295343||Patients with suspicious of rectosigmoid endometriosis|
89082257|NCT04212949|Experimental|Repetitive transcranial magnetic stimulation following TESI|Active repetitive transcranial magnetic stimulation will be performed to the patients with lumbar radiculopathy who receive transforaminal epidural steroid injection.
89082258|NCT04212949|Active Comparator|Transforaminal epidural steroid injection|Transforaminal epidural steroid injection will be applied to the patients with lumbar radiculopathy.
89082259|NCT02187601|Experimental|CLD with MPBA and BID|Chronic Liver Disease (CLD) patients of all degrees will be offered to be tested on the MPBA (multi purpose breath analyzer) and BID (BreathID) on a walk- in basis with , proving they meet inclusion/exclusion criteria.
89082260|NCT02187601|Experimental|HV with MPBA and BID|Healthy volunteers (HV) with no known liver disease will undergo the breath test with the MPBA and the BID before and after substrate ingestion.
89082261|NCT00628797|Other|A UVA1 B no UVA1|half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
89082262|NCT00628797|Experimental|A UVA1|
89082263|NCT00618241|Experimental|A|"Group A: day 1-5 Raltegravir 400 mg oral BD (twice daily). Lamotrigine one oral dose 100 mg on day 4. Wash-out 6-31. Followed by one oral dose Lamotrigine 100 mg on day 34.~5 days Raltegravir 400 mg oral BD. Lamotrigine one oral dose 100mg on day 34."
89082264|NCT00618241|Active Comparator|B|"Group B: day 4 Lamotrigine one oral dose on day 4. Wash-out day 6-28 followed by Raltegravir 400 mg oral BD day 29-33. One dose Lamotrigine 100 mg oral on day 32.~One dose Lamotrigine 100 mg oral."
89082265|NCT04213027|Active Comparator|SSLF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Sacrospinous ligament fixation (SSLF) .
89082266|NCT04213027|Active Comparator|ISFF-CSI|native tissue repair procedure with conventional surgical instruments in Chinese apical prolapse female patients randomized to Ischial spinous fascia fixation (ISFF)
89082267|NCT00619567|Experimental|Cognitive Stimulation|Subjects will be given Internet access to the Smartbrain cognitive stimulation program. They will complete exercises for ~30 minutes, at least three times per week, for a period of 24 weeks.
89082268|NCT00619567|No Intervention|Control|"These individuals will receive usual care during the 24 week follow-up period."
89082269|NCT04212715|Experimental|Experimental arm|SABR 35Gy/5 to prostate, up to 50Gy/5 to MR nodule, and 25Gy/5 to pelvic nodes and SVs
89082270|NCT04211623|Active Comparator|Constraint induced movement therapy group|Constrained on more affected side for three hours.
89082271|NCT04211623|Active Comparator|Bimanual activities group; BIM training|Set of bimanual activities performed.
89082272|NCT00618397|Experimental|Arm 1|Ketamine will be administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to in PICU patients that meet eligibility criteria.
89082273|NCT04857151|No Intervention|control|Control
89082274|NCT04857151|Experimental|App based mindfulness program (ABMP)|Participants in this group will participate in App based mindfulness program (ABMP)
89082275|NCT04211779|Experimental|Real tDCS and Exercise|tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and active tDCS intervention at the same time.
89082276|NCT04211779|Sham Comparator|Sham tDCS and Exercise|Sham tDCS (tDCS - TCT Research Limited, Hong Kong) / Exercise Group in which will receive the active intervention of aerobic exercise training and sham tDCS intervention at the same time.
89082277|NCT04211779|Other|Exercise|Exercise group in which will receive the active intervention of aerobic exercise training no tDCS intervention.
89082278|NCT00618475|Experimental|Treatment|Individual cognitive behavioral therapy (CBT)
89082279|NCT00618475|Other|Wait-list control|Individual cognitive behavioral therapy (CBT) after 3 month wait-list period
89082280|NCT04211545|Experimental|Administration of CC-92480 and Rabeprazole|Test Formulation CC-92480 and Reference Formulation will be administered orally at 1.6 mg. Rabeprazole will be administered orally at 40 mg.
89082281|NCT00620581|Placebo Comparator|Paroxetine 10mg;paroxetine 20mg; Placebo|
89082282|NCT01739569|Experimental|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
89082283|NCT01739569|No Intervention|Habitual meals|Dietary treatment with habitual diet
89082284|NCT04211311|Experimental|FES-legcycling with voluntary arm-work|FES-legcycling combined with arm ski-ergometer or arm-cycling
89082285|NCT01000311|Experimental|MenACWY-CRM + Routine Vaccines|"Infants received 3 doses of MenACWY-CRM at 2, 4 and 6 months as a infant series vaccination and a toddler dose at 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months."
89082286|NCT01000311|Experimental|Routine Vaccines|"Infants received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months.~In addition subjects were offered a dose of MenACWY-CRM at 18 months as a benefit of participating in this study. However, blood was not drawn for immunogenicity analysis after this dose."
89082287|NCT04211701|Experimental|Connective Tissue Massage|Connective tissue massage will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions, respectively. The treatment will be administered for four weeks, five days a week.
89082288|NCT04211701|Experimental|Classical Massage|Classic massage will be applied to the lower back and upper back, respectively, while the patient is lying in the prone position. The treatment will be administered for four weeks, five days a week.
89082289|NCT04209439|Active Comparator|ultrasound guided erector spinae plane block|30 ml %0.25 ultrasound-guided erector spinae plane block at the level of T8
89082290|NCT04209439|Active Comparator|Dexketoprofen-trometamol|intravenous 50 mg dexketoprofen-trometamol
89082291|NCT04212559||NPV group|Patients who had treated in pulmonary rehabilitation unit with NPV
89082292|NCT01555411||No treatment|
89082293|NCT01003899|Experimental|afatinib (BIBW 2992)|patient to receive afatinib(BIBW 2992) po QD in an open-label manner
89082294|NCT04160377|Experimental|melancholic depression|patients with melancholic depression undergo the treatment of Fluvoxamine
89082295|NCT04160377|Experimental|non-melancholic depression|patients with non-melancholic depression undergo the treatment of Fluvoxamine
89082296|NCT04150393|Experimental|MaaT033 treatment|A Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule
89082297|NCT04142203||23 h surgery|Adult patients who were treated in 23 h surgical unit
89082298|NCT01000155|Experimental|Vorinostat|Patients received vorinostat in a pulsed fashion, once a day for 3 consecutive days every week to a maximum dose of 400 mg per dose (1200 mg/wk), for 12 to 16 weeks at the maximum dose. The first 3 patients were enrolled in an intrapatient dose escalation schedule of 100 mg/d, then 200 mg/d, each for 3 consecutive days a week for 4 weeks, and then 400 mg/d, 3 consecutive days per week for 16 weeks. The last 2 patients were enrolled to receive 400 mg/d, 3 consecutive days per week for 12 weeks, without an initial dose escalation.
89082299|NCT00621595|Active Comparator|1|Fasting
89082300|NCT00318487|Experimental|Bilateral sinus augmentation|
89082301|NCT00999921|Experimental|Tamoxifen|10 mg once daily from 5th day to 25th day of menstrual cycle for 3 months
89082302|NCT00999921|Experimental|Evening Primrose Oil|1000 mg daily for 3 months
89082303|NCT02869581||Patients with diagnosis of Pancreatic neoplasms|
89082304|NCT00620737|Experimental|Active Arm|Active Treatment
89082305|NCT00620737|Placebo Comparator|Control Arm|Placebo treatment
89082306|NCT02869347|Active Comparator|Conestat alfa|Intravenous injection of Conestat alfa, for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U (2 vials, each diluted in 14ml sterile water).
89082307|NCT02869347|Placebo Comparator|Sodium chloride 0.9%|Intravenous injection of sodium chloride 0.9%.
89082308|NCT00621673|Other|Arm 1|
89082309|NCT05008393|Placebo Comparator|Placebo|Patients will receive placebo orally once daily for 10 days.
89082310|NCT05008393|Experimental|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 orally once daily for 10 days.
89082311|NCT05008393|Experimental|PJS-539 Dose 2|Patients will receive PJS-539 dose 2 orally once daily for 10 days.
89082312|NCT02869503||Patients with colorectal cancer diagnosis|
89082313|NCT04210921|Experimental|Treatment group|"In the treatment group, the Park needle with a real acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi (feeling of needle sensation refers to tenseness around the needle felt by the practitioner and numbness, distension, soreness, and heaviness around the point felt by the patient), and needles will be stimulated manually at least 10 s, then the needles will be retained for 30 minutes."
89082314|NCT04210921|Placebo Comparator|Control group|In the control group, the Park sham needle will instead of the real needle. It is retractile and adopts the sleeve type blunt needle design. When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin. The sham needle may be manipulated by lifting, thrusting or twirling as the real one, but it will not insert into the skin authentically.
89082315|NCT01002573|Experimental|ibuprofen|Ibuprofen, 10 mg/kg
89082316|NCT01002573|Active Comparator|Acetaminophen|Acetaminophen, 10mg/kg
89082317|NCT00620893|Active Comparator|1|1. PEG-400 based artificial tear
89082318|NCT00620893|Active Comparator|2|2. Systane
89082319|NCT04211233|Active Comparator|Invasive subdural arm|Implantation of invasive subdural electrode in patients after surgical treatment of acute subdural hematoma
89082320|NCT04211233|Sham Comparator|Standard treatment arm|Patients with acute subdural hematoma who underwent surgical Treatment and receive Standard medical treatment
89082321|NCT00999687|Experimental|Indigo naturalis extract in oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
89082322|NCT00999687|Placebo Comparator|Olive oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
89082323|NCT04211077||Group 1|Occurrence of a SA according to PMSI
89082324|NCT04211077||Group 2|Occurrence of accidental opioid analgesics overdose according to PMSI code
89082325|NCT04211077||Group 3|Controls : Absence of SA and accidental opioid analgesics overdose
89082326|NCT02871063||High altitude ARDS|ARDS diagnosed at altitudes greater than 1500 meters above sea level
89082327|NCT02871063||Sea level ARDS|ARDS diagnosed at altitudes below 1500 meters above sea level
89082328|NCT04293315|No Intervention|Control|This is the usual care arm. Healthcare workers will provide people with the Fecal Occult Blood Test (FOBT) and information about risk to develop CRC and the importance of early detection.
89082329|NCT04293315|Experimental|Intervention|The same as the Control Arm plus the primary care team of the PCCs will be trained and participate in 8 improvement cycles.
89082330|NCT04293549||rhNGF group|Therapeutic contact lens use was discontinued during the duration of the study. Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment. Changes in the corneal epithelium and stroma were evaluated by slit lamp biomicroscopy and photo documentation of the cornea after fluorescein staining.
89082331|NCT04293549||control comparator group|control comparator group was matched for age and gender and underwent assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline.
89082332|NCT02691715|Experimental|Endometrial saline plus curettage|5 cc saline infused to the endometrial cavity and aspirated. Then routine endometrial curettage performed for same participant.
89082333|NCT02691715|Active Comparator|Endometrial curettage|Only routine endometrial curettage performed
89082334|NCT00996333|Experimental|Gemzar, Taxotere, Xeloda|"Gemcitabine, Docetaxel, Capecitabine:~Gemzar intravenously on Day 4 and 11 Taxotere intravenously on Day 4 and 11 Xeloda tablet taken orally every day for 14 days"
89082335|NCT00621829|Active Comparator|1|"High susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
89082336|NCT00621829|Active Comparator|2|"Low susceptibility ALOX5 gene polymorphisms. Low susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
89082337|NCT00621907|Experimental|1|patient who received levobupivacaïne
89082338|NCT00621907|Placebo Comparator|2|patient who received placebo
89082339|NCT04717219||Severe CAVD with atherosclerosis|Participants with severe CAVD and significant atherosclerosis
89082340|NCT04717219||Severe CAVS without atherosclerosis|Participants with severe CAVD without significant atherosclerosis
89082341|NCT04717219||Moderate CAVD with atherosclerosis|Participants with mild or moderate CAVD and significant atherosclerosis
89082342|NCT04717219||Moderate CAVD without atherosclerosis|Participants with mild or moderate CAVD without significant atherosclerosis
89082343|NCT04717219||Healthy controls|Healthy controls without CAVD and without a history of atherosclerotic cardiovascular events, current typical complaints of angina pectoris or intermittent claudication and overt heart failure (NYHA class III/IV).
89082344|NCT04717219||Controls with bicuspid aortic valve stenosis|Controls with bicuspid aortic valve stenosis, without a history of atherosclerotic cardiovascular events, current typical complaints of angina pectoris or intermittent claudication.
89082345|NCT01349101|Experimental|Myeloablative HSCT|Myeloablative Hematopoietic Stem Cell Transplantation (HSCT): Patients will receive myeloablative transplants or nonmyeloablative transplants depending on their disease type.
89082346|NCT01349101|Experimental|Reduced Intensity HSCT|Reduced Intensity Hematopoietic Stem Cell Transplantation (HSCT): Patients who have received a previous transplant, patients who have received dose limiting radiation, and patients with a DLCO <45% will receive the reduced intensity conditioning regimen.
89082347|NCT02870049|Experimental|Inreach strategy|This consists of a community health worker-delivered in clinic education regrading CRC screening with a fecal immunochemical test (FIT) kit, and telephone reminders.
89082348|NCT02870049|Experimental|Outreach strategy|This consists of mailed invitations to complete screening with an enclosed fecal immunochemical test (FIT) kit and telephone reminders.
89082349|NCT02870049|Experimental|Both Inreach and Outreach strategies|This is a combination of the above two strategies: Inreach and Outreach combined.
89082350|NCT02870049|Active Comparator|Usual care|Usual care in the clinic using the fecal immunochemical test (FIT) kit.
89082351|NCT04295109|Active Comparator|Fentanyl group(group F)|Fentanyl citrate injection, specification: 10mL: 0.5mg / piece (production unit: niching chang rendu Pharmaceutical Co., Ltd., valid period: 48 months) For group F patients,0.5mg fentanyl was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
89082352|NCT04295109|Experimental|Oxycodone group(group O)|Oxycodone hydrochloride injection, specification: 1mL: 10mg / branch (production unit: HAMOL LIMITED, valid period: 60 months) For group O patients,30mg oxycodone was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
89082353|NCT04295109|Experimental|Butorphanol group(group B)|Butorphanol tartrate injection, specification: 1 mL: 1 mg / branch (production unit: Jiangsu henryi Pharmaceutical Co., Ltd., valid period: 24 months); For group B patients,10mg butorphanol was mixed with saline to a total volume of 100mL; continuous infusion was set to 2mL/h, a bolus dose of 3mL, and a lockout interval of 15 minutes
89082354|NCT00620971|Experimental|1|NC/Avastin->DG/Avastin
89082355|NCT00620971|Experimental|2|DG/Avastin
89082356|NCT04673773|Experimental|Feasibility / A massive open course|"The online MOOC contains eight units which cover the following topics (Understanding low back pain (LBP), Physical activity and exercise in relation to LBP, Psychological factors, Sleep / nutrition, Management of LBP at the workplace, Communication with health care, Other issues related to LBP). Each unit will include short factual texts, short videos (2-5mins) with older workers (aged 55+ years) with low back pain and professional experts, as well as knowledge tests. The complete MOOC will take 2-3 hours to complete. It would be possible to complete the MOOC at one time however users will be recommended to complete two units per week over a month period.~The mobile game is designed to encourage participation with the MOOC by providing feedback on engagement with the MOOC, presentation of quizzes to test knowledge gained on the MOOC, as well as feedback on clinical markers of their condition e.g. Mood, pain, physical activity levels."
89082357|NCT00995865|Active Comparator|High dose|
89082358|NCT00995865|Active Comparator|Mid Dose|
89082359|NCT00995865|Placebo Comparator|Placebo|NaCl Injectable 0.9%
89082360|NCT04210531|Experimental|BJ supplementation|Acute beetroot juice (BJ) supplementation
89082361|NCT04210531|Placebo Comparator|PLA supplementation|Acute placebo (PLA) supplementation
89082362|NCT04223661|Experimental|Frailty score 1|"Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
89082363|NCT04223661|Experimental|Frailty Score 2 or above|"Starting dose of lenalidomide in frail subjects (frailty score of 2 or higher) will be 5 mg day 1-21 of 28 day cycle, and escalate to 10 mg.~All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial."
89082364|NCT04220853|Experimental|Septoplasty|The patients indicated for septoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
89082365|NCT04220853|Experimental|Turbinoplasty|The patients indicated for turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
89082366|NCT04220853|Experimental|Septoplasty and turbinoplasty|The patients indicated for septoplasty and turbinoplasty will be included in this arm. The patients will undergo rhinomanometry and acoustic rhinometry after the surgery.
89082367|NCT04210453|Placebo Comparator|Control group|Participants in this group are administered IV normal saline.
89082368|NCT04210453|Experimental|Vitamin C group|Participants in this group are administered IV vitamin C diluted in normal saline.
89082369|NCT00622141|Active Comparator|A|Day 1: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg 7-day washout period will follow. Day 8: take generic GPO squinavir/Norvir
89082370|NCT00622141|Active Comparator|B|Day 1: take generic GPO squinavir/Norvir 7-day washout period will follow. Day 8: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg
89082371|NCT04210765|Active Comparator|Clomiphene citrate group 1|Clomiphene citrate dose 50mg/day for 5 days starting on cycle day (2-4).
89082372|NCT04210765|Active Comparator|Clomiphene citrate group 2|Non-responsive to ovulation induction with Clomiphene Citrate with dose:50mg/day; and treated with dose:100mg/day in the succeeding cycle for 5 days, starting on cycle day (2-4).
89082373|NCT00622219|Experimental|Drug Testing|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
89082374|NCT00622219|No Intervention|Control|Adolescents randomized to the control condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated) but will not be called for drug tests.
89082375|NCT05662267||Islet-after-kidney group|"Patients with type 1 diabetes with a kidney transplant received or not an islet transplantation after kidney transplantation. As soon as they received an islet transplantation, they belong to the Islet-after-kidney group."
89082376|NCT05662267||Kidney alone group|"Patients with type 1 diabetes with a kidney transplant who did not receive an islet transplantation belong to the  Kidney alone group ."
89082377|NCT04210609|Experimental|VHT treatment|Patients will be treated with VHT for 55 minutes at a minimum frequency of 2 times per week
89082378|NCT00621283|Experimental|1|Drug + MR with MRCP
89082379|NCT00138853|Active Comparator|Tantalum knee|Tantalum Tibial component, uncemented
89082380|NCT00138853|Active Comparator|Titanium Knee|Titanium Tibial Component, screw fixed
89082381|NCT00995709|Experimental|AIN457C 300 mg every 2 week dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks
89082382|NCT00995709|Experimental|AIN457C 300 mg monthly dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e
89082383|NCT00995709|Placebo Comparator|Placebo|Placebo was administered in 2 s.c. injections every 2 weeks
89082384|NCT02697097||Control Arm Group|Participants aged 18-30, Male and Female (10 participants each). Control group must have normal range of movement and no evidence of femoro-acetabular impingement (FAI) on clinical examination (negative impingement test, no symptoms). Other exclusions for Control Group include previous surgery to hip joint/s, history of arthritis, family history of FAI, patients who have had symptoms of hip pain in the preceding 1 year or may have other conditions which may affect the hip joint or hip muscle strength including neurological conditions or muscular dystrophy.
89082385|NCT02697097||FAI Arm Comparison Group|Participants aged 18-30, Male and Female (10 participants each). Participants with femoro-acetabular impingement as diagnosed clinically and on radiological imaging for the comparison group (MRI).
89082386|NCT00629031|Active Comparator|2|Paromomycin for 21 days @ 11mg/kg
89082387|NCT00629031|Experimental|1|Paromomycin for 14 days @ 11mg/kg
89082388|NCT04295265|Experimental|Smartphone|Receive daily whatsapp/ SMS message remind the drug intake.
89082389|NCT04295265|No Intervention|Control|receive instruction to take the medication at recruitment
89082390|NCT00621361|Experimental|1|
89082391|NCT00621361|Active Comparator|2|Etoposide + Cisplatin
89082392|NCT04208581|Experimental|Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive Yiqi Huoxue Huatan granule in addition to Western medicine.
89082393|NCT04208581|Placebo Comparator|Placebo Yiqi Huoxue Huatan granule plus Western medicine|Patients in this arm will receive placebo Yiqi Huoxue Huatan granule in addition to Western medicine.
89082394|NCT02696863||filling a questionnaire and interview|"The questionnaire is tracking occupational carcinogens. It consists of 30 questions , fills an average of 3 minutes and includes three response categories: yes, no and do not know. A questionnaire will be added social and professional issues.~Interviews will be conducted with the patient to identify obstacles and facilitating elements"
89082395|NCT04208425|Experimental|Project Personality|The web-based growth mindset intervention, called Project Personality, is delivered entirely via Qualtrics and takes approximately 30 minutes to complete. All intervention activities are self-administered by youth and delivered in a web-based format, including illustrations and audio-recordings of text. Intervention content is designed to maximize relevance for youths experiencing symptoms of depression, including excessive sadness and hopelessness.
89082396|NCT04208425|Active Comparator|Sharing Feelings Intervention|The Sharing Feelings Intervention is delivered entirely via Qualtrics, is self-administered by youth, and takes approximately 30 minutes to complete. It is structurally similar to the growth mindset intervention, but it is designed to mimic supportive therapy (ST). The goals of the ST intervention is to encourage youths to identify and express feelings to close others; the intervention does not teach or emphasize specific skills or beliefs. In previous clinical trials, ST has resulted in significantly fewer reductions in youth internalizing problems compared to cognitive-behavioral and growth mindset interventions.
89082397|NCT04208269|Active Comparator|Postcard campaign|
89082398|NCT04208269|Active Comparator|Provider-only intervention|
89082399|NCT04208269|Active Comparator|Patient and provider intervention|
89082400|NCT04208269|No Intervention|Standard care|
89082401|NCT05368051||long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
89082402|NCT02648113|Experimental|Restrictive transfusion strategy|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
89082403|NCT02648113|Experimental|Liberal transfusion strategy|Transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL.
89082404|NCT02641873|Experimental|BBI608 + FOLFIRI +Bevacizumab|
89082405|NCT00998985|Experimental|400 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo
89082406|NCT00998985|Experimental|600 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo
89082407|NCT00998985|Experimental|800 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo
89082408|NCT00998985|Experimental|400 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo
89082409|NCT00998985|Experimental|600 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo
89082410|NCT00998985|Experimental|800 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo
89082411|NCT00998985|Experimental|200 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo
89082412|NCT00998985|Experimental|100 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo
89082413|NCT00998985|Experimental|50 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo
89082414|NCT00998985|Experimental|200 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo
89082415|NCT00998985|Experimental|100 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo
89082416|NCT00998985|Experimental|50 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo
89082417|NCT00998985|Experimental|30 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo
89082418|NCT00998985|Experimental|10 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo
89082419|NCT05240391|Active Comparator|Arm receiving 20% Human Albumin|20% Human albumin given intravenously over 4 hours
89082420|NCT05240391|Experimental|Arm receiving Midodrine|Tablet Midodrine 2.5 mg - 3 tablets thrice daily orally starting just before paracentesis
89082421|NCT00628953|Experimental|1|
89082422|NCT00628953|Placebo Comparator|2|
89082423|NCT04295031||DM2 without renal disease|patients with type 2 diabetes with normal renal function
89082424|NCT04295031||DM2 with renal impairment|patients with type 2 diabetes with impaired renal function
89082425|NCT04294953|Active Comparator|Group (I) (D) : (Duloxetine group)|
89082426|NCT04294953|Placebo Comparator|Group (II) (P): (placebo group)|
89082427|NCT04293861|Experimental|HYMOVIS Arm|A treatment cycle consists of two injections administered at one week interval. For the purpose of this study, two treatment cycles of two injections of HYMOVIS® at baseline and 6 months will be performed per patient at V1 (Day 0), V2 (Day 7), V5 (Day 180) and V6 (Day 187).
89082428|NCT02869815||ICG+Methylene Blue|"ICG+Methylene Blue:~Sentinel Lymph Node (SLN) identification and resection using dual tracer technique with the sub-areolar injection of ICG+Blue dye, before surgery."
89082429|NCT04293081|Active Comparator|chlorpheniramine maleate group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to chlorepheniramine maleate group (A)
89082430|NCT04293081|Placebo Comparator|placebo group|A total of 45 adult patients undergoing FESS procedure for sinusitis with postoperative nasal packing. Written informed consent will be obtained from all patients before randomization. Patients will be assigned to placebo group (A)
89082431|NCT00995553|Experimental|Cognitive Remediation|A 48-session working memory focused cognitive remediation program is conducted. Training tasks have been selected from 3 software programs, PSS CogRehab, BrainTrain, and custom made N-back tasks.
89082432|NCT00995553|Placebo Comparator|Computer Skills|This is a 48-session, time matched comparison group in which participants practice keyboarding skills and the fundamentals of Microsoft Office Word, Powerpoint, and Excel programs.
89082433|NCT04293003|Experimental|Fasting|6-hour morning fasting
89082434|NCT04293003|Experimental|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
89082435|NCT04293003|Experimental|Mediterranean|Consumption of a Mediterranean breakfast
89082436|NCT04295187||Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
89082437|NCT04295187||Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
89082438|NCT02868723|No Intervention|Control; standard of care|All the subjects enrolled in this arm will receive counseling as the usual standard of care by the stroke neurologists. These will include procedures and guidelines as approved by American Heart Association (AHA), follow up and guidance as offered by Hamad General Hospital's policies.
89082439|NCT02868723|Active Comparator|Intervention; Lifestyle counselling: Behavioural|Subjects in this group will receive a more detailed guidance on rigorous management of stroke and will be provided assistance from a stroke trained nurse and pharmacist additional to the counseling offered by the Stroke Neurologist.
89082440|NCT02869269||Early stage|patients who diagnosed as TNM stage 1 and 2
89082441|NCT02869269||Late stage|patients who diagnosed as TNM stage 3 and 4
89082442|NCT04291833|Active Comparator|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
89082443|NCT04291833|Active Comparator|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
89082444|NCT04291833|Placebo Comparator|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
89082445|NCT02868801|Placebo Comparator|Placebo|placebo, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
89082446|NCT02868801|Experimental|Pregabalin SR tablet 165mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
89082447|NCT02868801|Experimental|Pregabalin SR tablet 330mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
89082448|NCT02868801|Experimental|Pregabalin SR tablet 660mg/day|2pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
89082449|NCT00991887|No Intervention|No Radiation Therapy (XRT)|This group will not receive radiation therapy after surgery.
89082450|NCT00991887|Active Comparator|Radiation Therapy (XRT)|Radiotherapy will be administered no later than 72 hours postoperatively.
89082451|NCT01002339|Experimental|Tacrolimus with rapid steroid withdrawal|Basiliximab induction. Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
89082452|NCT01002339|Active Comparator|Tacrolimus with steroids minimization|Basiliximab induction.Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
89082453|NCT01002339|Experimental|CsA with steroid minimization|Basiliximab induction. Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
89082454|NCT01002105|Experimental|Baclofen|The study was a double-blind, placebo-controlled, randomized trial comparing 50 mg/day of baclofen to placebo over 12 weeks, in addition to a low-intensity psychosocial intervention program, with 26-week and 52-week follow-up observations.
89082455|NCT01002105|Other|Psychosocial intervention|Intervention of the addition of placebo to low-intensity psychosocial intervention program. This was the control group
89082456|NCT02605993|Experimental|Cohort 1|"During the Treatment Period, participants were administered ravulizumab 1400 milligram (mg) on Day 1, ravulizumab 1000 mg on Day 15 and Day 29, and then ravulizumab 1000 mg every 4 weeks for 7 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kilograms (kg), 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
89082457|NCT02605993|Experimental|Cohort 2|"During the Treatment Period, participants were administered ravulizumab 2000 mg on Day 1, ravulizumab 1600 mg on Day 22 and Day 43, and then ravulizumab 1600 mg every 6 weeks for 4 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
89082458|NCT02605993|Experimental|Cohort 3|"During the Treatment Period, participants were administered ravulizumab 1600 mg on Day 1 and Day 15, ravulizumab 2400 mg on Day 29, and then ravulizumab 2400 mg every 8 weeks for 3 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
89082459|NCT02605993|Experimental|Cohort 4|"During the Treatment Period, participants were administered ravulizumab 3000 mg on Day 1, ravulizumab 5400 mg on Day 29, and then ravulizumab 5400 mg every 12 weeks for 2 doses.~During the Extension Period, participants were administered ravulizumab 5400 mg every 12 weeks for up to 5 years."
89082460|NCT00995085|Experimental|Metadoxine SR|Metadoxine is a pyrolate salt of Pyridoxine
89082461|NCT02867787|Experimental|Botox arm|intramuscular injection of botulinum toxin
89082462|NCT02868489|Experimental|Proprietary Blend - LactoWise®|After being randomized into two groups, the assigned experimental group, prior to surgery and after consenting, will be asked to complete the Gastrointestinal Quality of Life Index. In addition the experimental group will be given their supply of LactoWise®. They will be required to take 1 capsule per day (300 mg of bacillus coagulans and galactomannans at 4.5 billion live cells) at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
89082463|NCT02868489|Placebo Comparator|Control|For the control group, prior to surgery and after consenting to enroll in the study participants will also be asked to complete the Gastrointestinal Quality of Life Index. Participants of the control group will be administered their supply of a matching placebo. They will be required to take 1 capsule per day at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
89082464|NCT04209049|Experimental|Normal renal function|All subjects will receive one dose of NNC0174-0833.
89082465|NCT04209049|Experimental|Mild renal impairment|All subjects will receive one dose of NNC0174-0833.
89082466|NCT04209049|Experimental|Moderate renal impairment|All subjects will receive one dose of NNC0174-0833.
89082467|NCT04209049|Experimental|Severe renal impairment|All subjects will receive one dose of NNC0174-0833.
89082468|NCT02868645|Experimental|Patients with bone fibrous dysplasia|Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
88816173|NCT02437890|Experimental|ALX-0061 150 mg q4w|"ALX-0061 150 mg every 4 weeks (q4w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
89082469|NCT02868645|No Intervention|Control subjects|Control subjects will have no intervention
89082470|NCT00136123|Experimental|Implants|
89225313|NCT05827861|Experimental|HeartAge, HOPE Platform, and Genetic Risk Communication|Participants will be directed to HeartAge, a risk assessment tool available online. Then, they will be led to download the HOPE-CVD mobile app, an evidence-based behaviour change platform. Additionally, participants will also receive a report of their genetic risk of CVD.
89225314|NCT05827133||Individuals implanted with Clareon® Vivity® or Vivity® Toric Intraocular Lenses (IOLs)|
89082471|NCT04208893|Experimental|Aerobic training only|The aerobic training intervention will include 60 minutes/session, 3 times/week for 12 weeks at an intensity of 65% - 85% of participants' heart rate reserve (HRR), as determined by the CPET. Patients will be asked to wear a fitness-tracking device to monitor their heart rate response and in order to comply with the prescribed training intensity. All training sessions will start with a 10-minute warm up, 40-minute aerobic interventions, and ends with 10-minute of cool down. One study doctor will be on call during in-hospital training. Onsite supervised aerobic interventions will include play-based activities, whereas home-based aerobic activities will include stationary bikes and exercise activities that would target desired heart rate ranges. Home exercise equipment will be provided.
89082472|NCT04208893|Experimental|Combined aerobic and strength training|Participants in this group will perform a combination of aerobic and strength training activities for 60 minutes/session, 3 times/week for 12 weeks. Aerobic activities for this group will be similar to Arm 1. Strength training will be based on participant's individual assessment findings and developmental status. Resistance level will be set at approximately 50% of the patient maximal load and increased by 3 pounds (or the next level of resistance band) once the patient is able to perform 30 repetitions. Closed kinetic chain exercises such as pushups, squats, and lunges will be made more challenging by the addition of weight or change in body position. Training sessions will include a 10-minute warm up, 40-minute aerobic and strength exercises, and a 10-minute cooldown.
89082473|NCT00603733|Experimental|Pentasa® modified extended release|5-ASA (5-Aminosalicylate)
89082474|NCT00603733|Active Comparator|Pentasa®|5-ASA (5-Aminosalicylate)
89082475|NCT02478151|Experimental|OrganOx Metra|OrganOx Metra Device
89082476|NCT02471911|Experimental|All subjects|"All subjects will receive KPT-330 (selinexor) on days -5 and -3 starting one week before RICE chemotherapy is started. Once chemotherapy starts, selinexor will be given on days 1, 3, and 5 of each chemotherapy cycle.~RICE chemotherapy will consist of Rituximab, ifosfamide, carboplatin, etoposide, and dexamethasone."
89082477|NCT02323321|Experimental|OCS Preservation|OCS Preservation and Assessment
89082478|NCT00622375|Experimental|1|
89082479|NCT02239861|Experimental|TAA-Specific CTLs|"4 different dosing schedules will be evaluated. 2 to 4 patients will be evaluated on each dosing schedule. The first 2 patients on each dose level will be staggered by 4 weeks (which starts when the first infusion is given, Day 0). No subjects between the ages of 2-18 will be enrolled to a dose level on this protocol, until an adult has been enrolled to and treated on that dose level on one of the protocols being conducted under this same IND. Each patient will receive 2 injections at the same dose,14 days apart: The expected volume of infusion will be 1 to 10 cc.~Dose Level One:~Day 0 and 14: 5 x 10^6 cells/m^2~Dose Level Two:~Day 0 and 14: 1 x 10^7 cells/m^2~Dose Level Three:~Day 0 and 14: 2 x 10^7 cells/m^2~Dose Level Four:~Day 0 and 14: 4 x 10^7 cells/m^2"
89082480|NCT02691559|Active Comparator|maternal inflammation group|Amniotic fluid analysis by blood gas device: evaluate the possible association between maternal inflammation and amniotic fluid pH two groups will be designed. One group will consist of infants born to mothers with infection/inflammation whereas the control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
89082481|NCT02691559|Active Comparator|normal pregnancy group|Amniotic fluid analysis by blood gas device: The control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
89082482|NCT02691325|Experimental|Part A (Sequence 1) - Placebo, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 matching placebo (one inhalation) in treatment period 1, and single dose of GSK2269557 200 microgram (mcg) (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
89082483|NCT02691325|Experimental|Part A (Sequence 2) - GSK2269557 100 mcg, Placebo|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 matching placebo (two inhalations) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
89082484|NCT02691325|Experimental|Part A (Sequence 3) - GSK2269557 100 mcg, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
89082485|NCT02691325|Experimental|Part B- GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) once daily via the ELLIPTA DPI for 10 days. Doses of GSK2269557 may be modified based on emerging data from Part A.
89082486|NCT02691325|Experimental|Part B- GSK2269557 matching Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo (2 inhalations) once daily via the ELLIPTA DPI for 10 days.
89082487|NCT02691325|Experimental|Part C- GSK2269557 200 mcg with and without activated charcoal|Subjects will receive a single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) via the ELLIPTA DPI with activated charcoal in one treatment period and without ingestion of activated charcoal in another treatment period. The washout period between each dosing day will be at least 14 days. Dose of GSK2269557 may be modified based on emerging data from Part A.
89082488|NCT02689687|Experimental|Intervention|All participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.
89082489|NCT00621439|Experimental|I|Receives 1 dose of Pegylated Interferon
89082490|NCT00621439|Placebo Comparator|II|Receives placebo
89082491|NCT00622453||Registry of Arrhythmias|Screening of individuals with myotonic muscular dystrophy to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events.
89082492|NCT02689765|Experimental|Anthocyanins|Volunteers will be randomised double blinded into 'Anthocyanins' groups(n=60 per group)and given twice daily two capsules of either 80 grams of Anthocyanins, which corresponds a mixture of fresh blue berries and blackcurrants.The total duration of this trial was 24wk.
89082493|NCT02689765|Placebo Comparator|Control|A daily intake of 320mg Placebo to instead of treatment of Anthocyanins.
89082494|NCT00622531||BNP Open|Subjects treated based on clinical assessment and knowledge of BNP values
89082495|NCT00622531||Control|Subjects treated based on clinical assessment alone
89082496|NCT05661877|Experimental|DengueAid intervention group|The participants in this arm would be given the DengueAid mobile app which can be downloaded through Google Play
89082497|NCT05661877|Active Comparator|MyHealth website control group|The participants in this arm would be required to use the MyHealth dengue website
89082498|NCT04631107|Other|Sequence ABC|AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B), then Placebo (C).
89082499|NCT04631107|Other|Sequence ACB|AD109 Dose 1- 75 mg (A), then Placebo (C) then AD109 Dose 2- 37.5 mg (B)
89082500|NCT04631107|Other|Sequence BAC|AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A), then Placebo (C)
89082501|NCT04631107|Other|Sequence BCA|AD109 Dose 2- 37.5 mg (B), then Placebo (C), then AD109 Dose 1- 75 mg (A)
89082502|NCT04631107|Other|Sequence CAB|Placebo (C), then AD109 Dose 1- 75 mg (A), then AD109 Dose 2- 37.5 mg (B)
89082503|NCT04631107|Other|Sequence CBA|Placebo (C), then AD109 Dose 2- 37.5 mg (B), then AD109 Dose 1- 75 mg (A)
89082504|NCT02691481|Active Comparator|Oatmeal breakfast|consuming 200 kcal of plain cooked oatmeal for breakfast
89082505|NCT02691481|Active Comparator|Glucerna formula|consuming 200 kcal of Glucerna shake for breakfast
89082506|NCT02691481|Active Comparator|Ultra Glucose Control formula|consuming 200 kcal of Ultra Glucose Control shake for breakfast
89082507|NCT01449409|No Intervention|Usual care|
89082508|NCT01449409|Experimental|Real-time asthma care outreach|
89082509|NCT00622609|Experimental|Subjects receiving GSK249320A|Eligible subjects will receive escalating doses of GSK249320A in cohort 1 to 6 with a starting dose of 0.04 milligrams/kilograms up to the maximum dose of 25 milligrams/kilograms, administered as a slow intravenous infusion over 1 hour on Day 1.
89082510|NCT00622609|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of sodium chloride in cohort 1 to 6, administered as a slow intravenous infusion over 1 hour on Day 1.
89082511|NCT04187287|Active Comparator|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will be given for 3 weeks, 1 days in a week. Moreover 10-12 minutes cold pack will apply for every session.
89082512|NCT04187287|Active Comparator|Deep Friction Massage|Deep Friction Massage treatment will be given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
89082513|NCT04208737|No Intervention|control group|"3 FRC measurements will be perforemed, whereby : First measurement; after aneshesia induction and intubation. Second measurement; after pneumoperitoneum Third measurement; end of the operation~After the operation,Postoperative Room Air Test (RAT) will be applied."
89082514|NCT04208737|Experimental|study group|"5 FRC measurements will be performed We will apply recruitment maneuver two times to patients with 30cmH2O pressure for 15 seconds .~First Recruitment maneuver will be applied after the fşrst measurement of FRC following intubation Second Recuitment maneuver will be applied at the end of operation~First FRC measurement after anesthesia induction and intubation. Second FRC measurement after first recruitment maneuver Third FRC measurement; after pneumoperitoneum Fourth FRC measurement before second recruitment maneuver Fifth FRC measurement after second recruitment maneuver and at the end of operation"
89082515|NCT05661799|Experimental|Intervention Group|The proposed intervention consists of one hour of adapted physical activity per week for 12 weeks, led by a professional. In addition to this intervention, the intervention includes two 15-minute sessions, one before and one after the session. At the end of each session, a PA challenge and a positive reinforcement exercise will be proposed. The participants will have a week to try to achieve these. In addition to these two 15-minute sessions, participants will benefit from a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different topics related to diabetes.
89082516|NCT05661799|Active Comparator|Control group|The proposed intervention consists of one hour of adapted physical activity per week for 12 weeks, led by a professional.
89082517|NCT04548037||Patients with transient global amnesia|
89082518|NCT04548037||Healthy volunteers|
89082519|NCT04325737|Experimental|SEP-363856|
89082520|NCT04325737|Placebo Comparator|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
89082521|NCT00457873|Experimental|A|0.9% saline in 5% dextrose (intravenous)
89082522|NCT00457873|Active Comparator|B|0.45% saline in 5% dextrose (intravenous)
89082523|NCT02689375|Experimental|Patients to receive spinal cord stimulator|
89082524|NCT02697565|Experimental|Train-the-Trainers Arm|Intervention Arm receives the Healthy Caregivers- Healthy Children Toolkit (healthy lifestyle role modeling intervention) via a nutritional gate keeper. The toolkit reinforces center health and activity policy standards.
89082525|NCT02697565|Other|Attention Control Arm|Control Arm that receives an attention control safety curriculum.
89082526|NCT04208191|No Intervention|Control - Women|Participants who delivered or received family planning services at a facility that was not implementing a QI project on PCC
89082527|NCT04208191|Experimental|Intervention - Women|Participants who delivered or received family planning services at a facility that was implementing a QI project on PCC
89082528|NCT04208191|No Intervention|Control - Provider|Provider working in a facility that is not implementing a QI project on PCC
89082529|NCT04208191|Experimental|Intervention - Provider|Provider working in a facility that is implementing a QI project on PCC
89082530|NCT02697409|Experimental|Intervention group|The intervention group receives two school-based modules taking less than two hours each delivered by medical students in the schools.
89082531|NCT02697409|No Intervention|Control group|
89082532|NCT02697331|Active Comparator|progesterone|74 patients will receive progesterone pessary 200mg twice daily
89082533|NCT02697331|Placebo Comparator|Placebo|74 patients will receive placebo
89082534|NCT02697175|Experimental|Live Video-Colposcopy|Women are able to observe their colposcopic examination in real-time watching a flat screen in front of them
89082535|NCT02697175|Active Comparator|No Live Video-Colposcopy|Women are not able to observe their colposcopic examination in real-time
89082536|NCT04187911|Experimental|Intervention - Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. DDP aims to treat trauma-related problems and Attachment Disorders over about 20 1-hour sessions using the core communication techniques of Playfulness, Acceptance, Curiosity and Empathy (PACE)
89082537|NCT04187911|Active Comparator|Control - Services as Usual (SAU)|SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise.
89082538|NCT04278625||Cyanotic CHD|Cyanotic congenital heart disease (CHD) patients presenting for Fontan palliation.
89082539|NCT04278625||Acyanotic CHD|Acyanotic congenital heart disease (CHD) patients presenting for repair via median sternotomy.
89082540|NCT02689141|Experimental|Bendamustine + Ofatumumab + Ibrutinib|Bendamustine: 70mg/m² i.v. Ofatumumab: 1000 mg i.v. Ibrutinib: 420 mg po
89082541|NCT00622687|Active Comparator|A|low dose iloprost therapy 0.5 ng/kg x min
89082542|NCT00622687|Active Comparator|B|high-dose therapy
89082543|NCT04432051|Placebo Comparator|GRUP Control|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis.
89082544|NCT04432051|Active Comparator|GRUP Ultrasonography|The daily respiratory system examination of COVID-19 patients who are hospitalized in the intensive care unit is performed and the necessary mechanical ventilation applications are performed by evaluating the arterial blood gas analysis. However, the lung of the patient will be evaluated by ultrasound and the position to use the lung capacity most appropriately will be given.
89082545|NCT02687659|Experimental|Study group using TEMIS system|using TEMIS system during physical exercises: walking, biking, running
89082546|NCT05662735|Active Comparator|Non-absorbable sutures|The hiatal hernia was corrected performing laparoscopic surgery. Primary repair of the hernia was done with non-absorbable sutures
89082547|NCT05662735|Active Comparator|Non-absorbable sutures and a TiMESH®|The hiatal hernia was corrected performing laparoscopic surgery. Primary repair of the hernia was done with non-absorbable sutures and a TiMESH® to reinforce the repair.
89082548|NCT02691403|Sham Comparator|Placebo QL block|30 ml single shot QL block with saline 0.9%
89082549|NCT02691403|Active Comparator|Active QL block|30 ml single shot QL block with 0.25% levo-bupivacaine
89082550|NCT02685319|Experimental|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
89082551|NCT04184713|Experimental|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
89082552|NCT04184713|Active Comparator|Control group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement
89082553|NCT00995007|Active Comparator|Group 2|Sequential Group (carboplatin followed by vandetanib)
89082554|NCT00995007|Active Comparator|Group 1|Combo Group (both drugs together)
89082555|NCT00639847|No Intervention|group 1|this is the standard of care control group. The control group will be instructed to return to their regular physicians for routine follow up at a time to be specified by the physician.
89082556|NCT00639847|Active Comparator|Group 2|Group 2 will receive routine home visits from nurses provided by a home health care agency.
89082557|NCT00639847|Active Comparator|Group 3|In-home asthma management program (AMP) provided by respiratory therapists. The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
89082558|NCT02685475||Diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
89082559|NCT02685475||Non-diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
89082560|NCT04105621||Drug addicts|This group included drug addicts lived in drug rehablitation center.
89082561|NCT04105621||Healthy population|We recruited the healthy participants from the Westlake N-of-1 Trials for Macronutrient Intake (NCT04125602) as healthy control
89082562|NCT00639925|Experimental|Phase I study|
89082563|NCT00994461|Experimental|Celecoxib|
89082564|NCT00994461|Active Comparator|Loxoprofen|
89082565|NCT00994461|Placebo Comparator|Placebo|
89082566|NCT02685553|Experimental|1|Use of NIR
89082567|NCT04185961|Experimental|EVERA-RAPHA with 60mmHG|EVERA-RAPHA apply 15 minutes with 60mmHG every day for 4 weeks
89082568|NCT04185961|Experimental|EVERA-RAPHA with 100mmHG|EVERA-RAPHA apply 15 minutes with 100mmHG every day for 4 weeks
89225315|NCT05823532|Experimental|Infliximab|Subjects will be stratified by sex and randomized prior to this visit in preparation for the infusion. Vitals and safety labs will be drawn at this visit as well as urine testing for drugs of abuse and pregnancy testing for all biological females. Patients will receive breakfast followed by a double-blinded infusion of infliximab (5mg/kg body weight) in the GCSTA Clinical Research Center at Emory University Hospital. The infusion will last 3 hours, and subjects will be monitored during the infusion and for one hour after completion for the possible development of anaphylaxis, which occurs in less than 1% of patients receiving an initial dose of infliximab
88812815|NCT01831622|Experimental|Behavioral|"Cognitive testing of participants. Asterisk applies for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before computer-testing.*~Case Report Form (CRF), ASRS and Wechsler Adult Intelligence Scale (WAIS) subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*~Day 2:~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention (opposite of Day 1), and wait 60 minutes before computer-testing.*~CRF 3, ASRS and Edinburgh Handedness Inventory (EHI).~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
89225316|NCT05823532|Placebo Comparator|Placebo|Subjects will be stratified by sex and randomized prior to this visit in preparation for the infusion. Vitals and safety labs will be drawn at this visit as well as urine testing for drugs of abuse and pregnancy testing for all biological females. Patients will receive breakfast followed by a double-blinded infusion of saline in the GCSTA Clinical Research Center at Emory University Hospital. The infusion will last 3 hours, and subjects will be monitored during the infusion and for one hour after completion for the possible development of anaphylaxis, which occurs in less than 1% of patients receiving an initial dose of infliximab
89225317|NCT05820620|Placebo Comparator|Control group|No intervention + Patient Control Analgesia (PCA)
89225318|NCT05820620|Experimental|QLB group|QLB group Block will be applied + Patient Control Analgesia (PCA)
89225319|NCT05820620|Experimental|TAP group|TAP Block group will be applied + Patient Control Analgesia (PCA)
89225320|NCT05819021||SAINT® Stimulation|All participants will receive 10 treatments per day for 5 days (M-F) of SAINT® stimulation therapy.
89225321|NCT05818540|Experimental|Eclipse novel mask|Human subjects will use the Eclipse CPAP interface for 60 days for a total of 6 hours per night.
89225322|NCT05818540|Active Comparator|Traditional CPAP mask|Human subjects will use the ResMed P-10 CPAP interface for 60 days for a total of 6 hours per night.
89225323|NCT05813873|Experimental|Triflow|Use of Triflow device and exercise regime
89225324|NCT05813873|Active Comparator|Control|Only exercise regime
89225325|NCT05810870|Experimental|Cohort A|"MEN1611 orally (PO) 48 mg twice daily (BID) (2 intakes of 3x16 mg capsules, for a total daily dose of 96 mg MEN1611 free-base) during each 21-day cycle combined with eribulin mesylate 1.4 mg/m2 (equivalent to eribulin 1.23 mg/m2 when expressed as a free base) administered intravenously (IV) over 2 to 5 minutes on days 1 and 8 of every 21-day cycle (CXD1 and CXD8).~A run-in phase for safety and tolerability of MEN1611 in combination with eribulin will be conducted after the first 2 cycles on the first 3 patients. Upon Steering Committee agreement the cohort A will be expanded up to N=14 (11 additional patients).~Patients will receive treatment until disease progression, unacceptable toxicity, death, discontinuation from the study treatment for any other reason, withdrawal of consent, or study termination.~Cohort B will be run only if there will be positive finding in Cohort A, defined as ≥ 6 patients (42.9%) with CB (CR or PR) among 14 recruited patients."
89225326|NCT05810870|Experimental|Cohort B|"Stage I (N =7): MEN1611 monotherapy 48 mg PO BID (2 intakes of 3x16 mg capsules, for a total daily dose of 96 mg MEN1611 free-base) during each 21-day cycle.~After 2 cycles, ORR will be determined per RECIST v1.1 criteria:~Patients experiencing CR or PR will continue with MEN1611 monotherapy.~Patients experiencing stable disease (SD) will continue with MEN1611 monotherapy or will be treated with MEN1611 plus eribulin mesylate 1.4 mg/m2 (1.23 mg/m2 eribulin free base), IV on CXD1 and CXD8, under investigator's decision.~An interim analysis will assess the viability of this part of the trial. Cohort B will be stopped for futility if no responders (no CR or PR) are observed among the 7 patients included.~Stage II: same as stage I with 7 additional patients (total N=14).~Patients will receive treatment until disease progression, unacceptable toxicity, death, discontinuation from the study treatment for any other reason, withdrawal of consent, or study termination."
89225327|NCT05808764|Experimental|Risdiplam|Participants will receive risdiplam once daily for 28 days.
89225328|NCT05807139|Experimental|Placebo 1st visit|stage 1: Placebostage 2: 2x50 mg/day spironolactonestage 3: 2x100 mg/day spironolactonestage4: 2x200 mg/day spironolactone
89225329|NCT05807139|Experimental|Placebo 2nd visit|stage 1: 2x50 mg/day spironolactonestage 2: Placebostage3: 2x100 mg/day spironolactonestage 4: 2x200 mg/day spironolactone
89225330|NCT05807139|Experimental|Placebo 3rd visit|stage1: 2x50 mg/day spironolactonestage 2: 2x100 mg/day spironolactonestage 3: Placebostage4: 2x200 mg/day spironolactone
89225331|NCT05807139|Experimental|Placebo 4th visit|Stage1: 2x50 mg/day spironolactoneStage 2: 2x100 mg/day spironolactonestage 3: 2x200 mg/day spironolactonestage 4: Placebo
89225332|NCT05805501|Experimental|Arm A (Tobemstomig + Axitinib)|Participants will receive intravenous (IV) tobemstomig every three weeks (Q3W) on Day 1 of each 21-day cycle. Participants will also receive oral (PO) axitinib twice daily (BID).
89225333|NCT05805501|Experimental|Arm B (Tobemstomig + Tiragolumab + Axitinib)|Participants will receive IV tobemstomig followed by IV tiragolumab Q3W on Day 1 of 21-day cycle. Participants will also receive axitinib PO BID.
89225334|NCT05805501|Active Comparator|Control Arm (Pembrolizumab + Axitinib)|Participants will receive IV pembrolizumab Q3W on Day 1 of each 21-day cycle. Participants will also receive axitinib PO BID.
89225335|NCT05805189|Experimental|Heliostar group A|In this group the achievement of isolation of the pulmonary veins is evaluated with one shot tecnology Heliostar, multielecrode radiofrequency ballon catheter guided by the impedance level measured in the veins
89225336|NCT05805189|Active Comparator|Carto Group B|In this group the achievement of isolation of the pulmonary veins is evaluated with classic method guided by fluoroscopy
89225337|NCT05804266|Experimental|POEM with conventional precoagulation|POEM with conventional precoagulation
89225338|NCT05804266|Experimental|POEM with underwater precoagulation|POEM with underwater precoagulation
89225339|NCT05800665|Experimental|Stage 1: Dose Escalation|Participants will receive RO7656594 administered at a specified dose on specific days in each 28-day cycle. The dose will be increased in successive cohorts until a study-specific threshold is reached.
89225340|NCT05800665|Experimental|Stage 2: Expansion|Participants will receive RO7656594 at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD).
89225341|NCT05800392|Experimental|Experimental|DEC103: The participants will take 02 (two) pills of the sublingual formulation and 01 (one) pill of the oral one, 1 hour prior the IUD insertion.
89225342|NCT05800392|Placebo Comparator|Placebo|PLACEBO DEC103: The participants will take 02 (two) pills of the placebo sublingual formulation and 01 (one) pill of the placebo oral one, 1 hour prior the IUD insertion.
89225343|NCT05799092|Experimental|Invasive approach group|Invasive coronary angiography will be performed as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA..
89225344|NCT05799092|Active Comparator|Non-invasive approach group|Usual care of non-invasive ischemia testing (exercise electrocardiography [ECG], stress echocardiography by exercise or pharmacologic agent, nuclear test including SPECT or PET, stress cardiac magnetic resonance [MR]) will be performed as next diagnostic step in symptomatic patients with non-high risk obstructive CAD on CCTA.
89225345|NCT05798585|Experimental|US-guided ESP block + sham US-guided TPV block|ESP block will be performed with local anesthetic under US guide; instead TPV block with physiological solution
89225346|NCT05798585|Sham Comparator|sham US-guided ESP block + US-guided TPV block|ESP block will be performed with physiological solution under US guide; instead TPV block with local anesthetic
89225347|NCT05797805|Experimental|Tegavivint single agent dosing regimen|Tegavivint as monotherapy
89225348|NCT05797805|Experimental|Tegavivint plus pembrolizumab combination dosing regimen|Tegavivint in combination with pembrolizumab
89225349|NCT05797610|Experimental|RO7434656|Participants will receive subcutaneous (SC) doses of RO7434656 on Days 1, 15, and 29 followed by once every 4 weeks until Week 105. After Week 105, participants may continue blinded treatment or enter open-label treatment until up to 1 year after the date at which the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.
89225350|NCT05797610|Placebo Comparator|Placebo|Participants will receive SC doses of RO7434656 matching placebo on Days 1, 15, and 29 followed by once every 4 weeks until Week 105. After Week 105, participants may continue blinded treatment or enter open-label treatment until up to 1 year after the date at which the last participant completes the Week 105 assessment, withdraws, or is discontinued from the study.
89230143|NCT03955393||LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|Twenty patients candidates to radical nephrectomy and extended lymphadenectomy for clinical T4 cancers (clinical Nany) or renal masses with evidence of lymphadenopathies at preoperative CT scan (clinical Tany N1) or larger tumor (clinical Tany Nany and max diameter>10 cm). RCC candidates to surgery will receive a single intravenous infusion of 18F-FAZA. Surgery will be scheduled within 1 week after infusion. PET and CT scanning of the abdomen will be planned before surgery.
89082569|NCT00993915||Main group|Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications
89082570|NCT04174911|Experimental|BOL-DP-o-08|BOL-DP-o-08
89082571|NCT04174911|Placebo Comparator|Placebo|Placebo
89082572|NCT01202591|Experimental|AZD4547 + exemestane|Safety run-in: AZD4547 plus exemestane
89082573|NCT01202591|Experimental|AZD4547 + fulvestrant|A Randomised phase IIa: AZD4547 plus fulvestrant
89082574|NCT01202591|Placebo Comparator|Placebo + fulvestrant|Randomised phase IIa: Matching placebo plus fulvestrant
89082575|NCT00639067||1|"Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
89082576|NCT00639067||2|"Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
89082577|NCT00639067||3|"Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
89082578|NCT00639067||4|"Apparently healthy individuals having no signs and symptoms of lung carcinoma.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
89082579|NCT02687503|Other|Daily dose of probiotic|All children enrolled into the study will receive a daily dose of probiotic
89082580|NCT01202279|Active Comparator|Mucinex D|Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days
89082581|NCT01202279|Placebo Comparator|Placebo|Placebo given bid with a full glass of water for 7 days
89082582|NCT03877315|Active Comparator|Stemmed|Subjects operated with stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.
89082583|NCT03877315|Active Comparator|Non-Stemmed|Subjects operated with stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.
89082584|NCT02687347|Experimental|study arm|low dose methadone (1-10mg daily)
89082585|NCT02687347|Active Comparator|control arm|low dose morphine (1-10 mg/day)
89082586|NCT01201967|Experimental|Collaborative care|Study care manager provides education and coordinates treatment between study psychiatrist, patient, and primary medical physician. This occurs in the hospital and by phone after discharge. Care manager may also provide phone-based therapy.
89082587|NCT01201967|Placebo Comparator|Usual care|Patient's physicians are informed of diagnosis of depression/anxiety disorder
89082588|NCT02687425|Experimental|pioglitazone|The patients under the long-term treatment of imatinib mesylate acquire pioglitazone additionally.
89082589|NCT02537665|Other|incidence of bleeding|the effect of the epidural catheter filled with heated or normal saline before inserting into epidural on the incidence of bleeding.
89082590|NCT02537665|Placebo Comparator|inserting time of catheter|record the time from beginning of catheter inserting to completing the placement of the catheter.
89082591|NCT02687269|Experimental|Ranolazine|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, Ranolazine at a dose of 375 mg twice daily.
89082592|NCT02687269|Placebo Comparator|Placebo|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, placebo twice daily.
89082593|NCT02689297|Other|group A|Mouthwash (chlorine dioxide 12ml two times per day, for three weeks)
89082594|NCT02689297|Other|group B|Small toothbrush for tongue cleaning two times per day for three weeks
89082595|NCT04186741||HBO Group|Patients already recieving hyperbaric oxygen therapy for treatment of other medical conditions requiring it as in diabetic foot , cerebral infarctions
89082596|NCT04185805|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
89082597|NCT04185805|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
89082598|NCT03758755|Experimental|BFR Therapy|This group will undergo physical therapy exercises per the standard of care, with the addition of Blood Flow Restriction (BFR) utilizing a wide pressure cuff. BFR exercises will be initiated two weeks post-op, and continued for 16 weeks.
89082599|NCT03758755|Active Comparator|No BFR|This group of patients will undergo physical therapy exercises per the current standard of care after their ACL reconstruction without BFR
89082600|NCT01201811|Experimental|Single-Arm|Azacitidine 75 mg/m^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles
89082601|NCT02685241||General population|General population
89082602|NCT04186897|Experimental|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
89082603|NCT04186897|Sham Comparator|No occlusal reduction|Occlusal surfaces kept intact. No actual occlusal reduction..
89082604|NCT05400785|Active Comparator|Active CRM|
89082605|NCT05400785|Sham Comparator|Sham CRM|
89082606|NCT05392127|Experimental|single arm|SHR0302 Tablets + probe drugs (Midazolam Maleate Tablets + Warfarin Sodium Tablets+ Omeprazole Enteric Capsules+ Repaglinide Tablets) + Vitamin K1 Tablets
89082607|NCT02687113|Other|CT/US fusion|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.~Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
89082608|NCT02685163|Experimental|Antioxidant Ice-cream|Natural antioxidant Ice-cream
89082609|NCT02685163|Placebo Comparator|Control Ice-cream|Natural control ice-cream
89082610|NCT00638599|Experimental|1|LMA® is placed after anesthesia induction till the end of operation
89082611|NCT00638599|Active Comparator|2|Standard tracheal tube is inserted after anesthesia induction till the end of operation
89082612|NCT00640003|Experimental|1|
89082613|NCT00640003|Experimental|2|
89082614|NCT04185727|No Intervention|Standard of Care (SOC)|Therapy control group
89082615|NCT04185727|Experimental|Standard of Care (SOC) + strength training|Strength training intervention as add on to therapy
89082616|NCT04185649|Experimental|BAT8001 for injection|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
89082617|NCT04185649|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
89082618|NCT01201265|Experimental|Overall Participants|Participants received a combination therapy of bevacizumab with gemcitabine plus carboplatin.
89082619|NCT02686957||women closed|"This cohort will include women who underwent repair for obstetric fistula at three fistula repair hospitals in Guinea and who had a closed fistula at hospital discharge.~no intervention will be done."
89082620|NCT04318301||ACEI/ARB|COVID-19 patients with hypertension who had previously taken ACEI/ARB for antihypertensive treatment
89082621|NCT04318301||non ACEI/ARB|COVID-19 patients with hypertension who had not previously taken ACEI/ARB for antihypertensive treatment
89082622|NCT00624533|Active Comparator|A|Primary Health Care Conventional Physiotherapy Treatment (based in electrotherapy)
89082623|NCT00624533|Experimental|B|Group B was treated with the GDS Method (muscular and articular chains physiotherapy method)
89082624|NCT04105075||Patients with COPD and obesity|Patients consented to have a blood sample taken
89082625|NCT04105075||Normal body weight patients with COPD|Patients consented to have a blood sample taken
89082626|NCT04246801|Experimental|Clobetasol propionate|"Clobetasol propionate (Clobetasol propionate ophthalmic nanoemulsion 0.05%)~First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage of one drop four (4) times a day during 14 days."
89082627|NCT04246801|Placebo Comparator|Vehicle|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage of one drop four (4) times a day during 14 days.
89082628|NCT02686567|Active Comparator|with TDT|with TDT
89082629|NCT02686567|Active Comparator|without TDT|without TDT
89082630|NCT01200797|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89082631|NCT00638677|Placebo Comparator|1|Sorbitol tablet
89082632|NCT00638677|Placebo Comparator|2|Xylitol tablet
89082633|NCT00638677|Active Comparator|3|Xylitol + BB12 tablet
89082634|NCT02686723|Experimental|ACL injury|Subjects who has ACL injury repaired and who were allowed to return to sport
89082635|NCT02686723|Active Comparator|Healthy subjects|Subjects who has never been injured in ACL and who practice sports with cutting task (soccer, handball)
89082636|NCT01200485|Experimental|Rasburicase Alone|Rasburicase by vein on Day 1 (0.15 mg/kg or a flat dose of 3 mg) as a single dose, plus as needed dosing (until day 5), during cycle 1 (21 day cycle).
89082637|NCT01200485|Experimental|Arm A (Rasburicase)|Participants randomized to Rasburicase (0.15 mg/kg) by vein on day 1 plus as needed dosing (until day 5) during Cycle 2.
89082638|NCT01200485|Experimental|Arm B (Allopurinol)|Participants randomized to Allopurinol (300 mg/day) by vein each day on Days 1-5 of Cycle 2.
89082639|NCT02688907|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
89082640|NCT02686645|Experimental|Fecal Microbiota Therapy|Vancomycin 125 mg po qid for 7 days or metronidazole 500 mg po tid for 7 days pre-treatment. Loperamide 4 mg po after morning prep and 2 mg post treatment. The route of administration fecal microbiota will be by retention enema via a rectal tube.
89082641|NCT04318067|Experimental|Sleep problems i Attention Deficit Hyperactivity Disorder|Children age 6 to 12 years having ADHD and Sleeping problem will be treated with Melatonin 3 mg one a day (before bedtime)
89082642|NCT04185181|Active Comparator|virtual reality|
89082643|NCT04185181|Active Comparator|propreoceptive neuromuscular facilitation|
89082644|NCT01200407||Filipino Hypertensive patients|Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec
89082645|NCT04186975||Low-risk pregnant women|Normal cohort: this cohort consists of pregnancies which are not at risk. Data are recorded during the normal checkup happening as part of the usual care pathway
89082646|NCT04186975||High-risk pregnant women|Risk cohort: this cohort consists of pregnancies at risk and which are regularly recorded for the purpose of fetal surveillance. Specifically, the investigators recruit pregnancies with intra uterine growth restricted fetuses for this study.
89082647|NCT02685085|Experimental|Misoprostol|in this group misoprostol 25 ug will be administrated for induction of labor every 6 hours
89082648|NCT02685085|Experimental|Foley's catheter|In this group foley's catheter 30 cc will be used for induction of labor
89082649|NCT02685085|Experimental|Combined|Both misoprostol 25 ug and foley's catheter will be used for induction
89230144|NCT00048997|Experimental|Prophylactic cranial irradiation (PCI)|Radiation therapy
89082650|NCT02688595|Experimental|Seldinger|Use a 23 gauge introducer needle for ultrasound-guided central venous catheterization
89082651|NCT02688595|Experimental|Modified Seldinger|Use a 22 gauge Angiocath Plus catheter for ultrasound-guided central venous catheterization
89082652|NCT01200329|Experimental|Gemcitabine + Busulfan + Melphalan|Gemcitabine 2775 mg/m2 by vein over about 3 hours on days -8 and -3. Busulfan 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient. AUC 4,000 by vein over about 3 hours on days -8 to -5. Melphalan 60 mg/m2 by vein over about 30 minutes on days -3 and -2. Palifermin 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2. Infusion of stem cells on Day 0.
89082653|NCT04185493||CCTA Cohort|Consecutive patients with suspected coronary artery disease and low/intermediate pre-test probability
89082654|NCT04186273|Sham Comparator|Donor Site Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
89082655|NCT04186273|Experimental|Donor Site Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested).
89082656|NCT04186273|Experimental|Donor Site Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the donor site wound (from where the skin graft skin harvested)
89082657|NCT04186273|Sham Comparator|Skin Graft Wound, Vehicle|A vehicle moisturizing cream base applied to a bisected area of the skin grafted wound site.
89082658|NCT04186273|Experimental|Skin Graft Wound, FS2 0.25|A moisturizing cream base containing 0.25%w/w of FS2, applied to a bisected area of the skin grafted wound site.
89082659|NCT04186273|Experimental|Skin Graft Wound, FS2 0.5|A moisturizing cream base containing 0.50%w/w of FS2, applied to a bisected area of the skin grafted wound site.
89082660|NCT01199939|Experimental|ETR + DRV/rtv|Darunavir 800mg once daily orally for 48 weeks,Etravirine 400mg once daily orally for 48 weeks,Ritonavir 100mg once daily orally for 48 weeks
89082661|NCT02688439|Active Comparator|Leg in a neutral position|Sciatic nerve block, with leg kept in a neutral position after anesthesia (control group)
89082662|NCT02688439|Experimental|Leg raised 30°|Sciatic nerve block, with leg raised 30° by placing the back of the foot over a support placed on the OR table and maintained in that position for 15 min
89082663|NCT02688439|Experimental|Distal tourniquet placed on the lower part of the leg|Sciatic nerve block, and distal tourniquet placed on the lower part of the leg (upper part of the tourniquet being about 4-6 inches from the ankle) with the leg in a neutral position.
89082664|NCT02688361|Experimental|Fluimucil® (reference) then Acetylcysteine (test) 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Acetylcysteine (test).
89082665|NCT02688361|Experimental|Acetylcysteine (test) 2% solution then Fluimucil® (reference)|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Fluimucil® (reference).
89082666|NCT02686489|Experimental|Heated humidification (HH)|Addition of water vapor (molecular water) to the inspired gas of spontaneously breathing tracheostomy patients.
89082667|NCT02686489|Active Comparator|Cool bland aerosol (LVN)|Addition of particulate water to the inspired gas of spontaneously breathing tracheostomy patients.
89082668|NCT01199861|Experimental|Fingolimod|Participants received Fingolimod 0.5 mg capsules orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
89082669|NCT01199861|Placebo Comparator|Placebo|Participants received placebo tablets orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
89082670|NCT03196219|Experimental|Arm 1: Open-Enrollment Multiple Dose C16G2 Varnish|Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.
89082671|NCT03196219|Experimental|Arm 2A: Single-Blind C16G2 Varnish|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish applications over 7 days (Days 0, 2, 5 & 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
89082672|NCT03196219|Placebo Comparator|Arm 2B: Single-Blind Placebo|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive Placebo applications over 7 days (Days 0, 2, 5 & 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
89082673|NCT03196219|Experimental|Arm 3: Open-Enrollment Single Dose C16G2 Varnish|If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.
89082674|NCT02684929|Experimental|vegan|Vegan subjects interveinted with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
89082675|NCT02684929|Active Comparator|omnivor|Omnivorous subjects iterveined with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
89082676|NCT05398211|Experimental|Preferred Recorded Music (PRM)|The Preferred Live Music (PLM) aims to elicit participants' responses from live music and the ensuing musical and non-musical interactions with the music therapist (MT). In the PLM intervention, preferred songs performed live on guitar or electronic keyboard will be played by a credentialed MT. When appropriate participants may also play percussion instruments offered to them. Elements of improvisation will be incorporated to allow for active engagement by the participants, and to provide opportunities for musical and non-musical attunement to emerge.
89230145|NCT00048997|Other|Observation|Observation
89230146|NCT01092481|Active Comparator|FOLFOX_12 or CAPOX_8|6 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
89230147|NCT01092481|Experimental|FOLFOX_6 or CAPOX_4|3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
89082677|NCT05398211|Experimental|Preferred Live Music (PLM)|The Preferred Recorded Music (PRM) intervention aims to detect responses directly attributable to the music. Participants listen to pre-recorded preferred originally-published versions of music accessed by Spotify music-streaming service and played through loud-speakers. The MT will only start the music, and otherwise not be present during the interventions to ensure the minimal direct interaction with the participants.
89082678|NCT02684773||Incentre Nocturnal Hemodialysis|These are patients who converted to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week) from conventional hemodialysis (4 hours/session, 3 sessions/week) at the inception of this study and are eligible for the long-term follow-up phase of the study.
89082679|NCT02684773||Conventional Hemodialysis|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elected to remain on this dialysis schedule at the inception of this study and are eligible for the long term follow-up phase of the study.
89082680|NCT00640081|Active Comparator|D|Intermittent chemotherapy plus intermittent cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period off all therapy, with reintroduction of the same chemotherapy and cetuximab regimen for a further 12 weeks after initial progression off treatment
89082681|NCT00640081|Experimental|E|Intermittent chemotherapy plus continuous cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period of withdrawal of the chemotherapy, but continued weekly cetuximab monotherapy (maintenance cetuximab), with reintroduction of the same chemotherapy regimen to the cetuximab for a further 12 weeks after initial progression off chemotherapy treatment
89082682|NCT01199705|Experimental|IgPro20|
89082683|NCT02688127|Experimental|tranexamic acid group|tranexamic acid given as 1 gram intravenous dose dilute in 500 cc of ringer lactate 20 minute before cesarean section
89082684|NCT02688127|Placebo Comparator|placebo group|the control group will receive 500 cc of ringer lactate 20 minute before cesarean section
89082685|NCT02686333|Experimental|Meditation Intervention Arm|10-15 minute meditation practices (brief silent meditations, guided meditations, body scans, gentle arm movement exercises). Before each session, the interventionist will perform a brief check in, and may discuss the patient's experience with them for 1-2 minutes after the intervention. Patients will be encouraged to practice the techniques at home between sessions. Patients will also be offered literature on mental health promotion.
89082686|NCT02686333|No Intervention|Control Group (No Meditation Exposure)|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as Usual in the dialysis setting.
89082687|NCT02688283|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
89082688|NCT02688283|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
89082689|NCT02688283|Placebo Comparator|White-bread|45g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
89082690|NCT04185571|Experimental|PEPA membrane|PEPA membrane is an adsorbant synthetic copolymer (Poly Ester Poly Arylate)
89082691|NCT04185571|No Intervention|non adsorbent membrane|Comparison with non adsorbent membrane used in routine
89082692|NCT02686255||Children 0-18 months post heart surgery|complete blood count for all children 0-18 months going through cardiac surgery
89082693|NCT01199471||Chinese Patients Requiring Surgery with Anesthesia|Chinese patients 18 to 70 years of age, meeting the American Society of Anesthesiologists (ASA) Physical Status Class 1 (normal healthy), Class 2 (mild systemic disease), or Class 3 (severe systemic disease), who underwent surgery requiring general anesthesia (sevoflurane) administered per local Prescribing Information and endotracheal intubation or laryngeal mask airway (LMA).
89082694|NCT04185025|Experimental|CeraVe Moisturising Lotion|
89082695|NCT04185025|Active Comparator|Half Mu ceramide body milk|
89082696|NCT04295239|Experimental|MRI|Pre-operative AND post-operative MRI
89082697|NCT02688205||Shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
89082698|NCT02688205||Without shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
89082699|NCT04136665|Experimental|Physical Activity Adapted program|
89082700|NCT02684695||Group A|Patients with enthesitis-related arthritis
89082701|NCT02684695||Group B|Patients with other forms of juvenile idiopathic arthritis (extended oligoarticular JIA and polyarticular JIA)
89082702|NCT04184947||SGLT2i|Patients who received new prescription of a SGLT-2 inhibitor
89082703|NCT04184947||GLP-1RA|Patients who received new prescription of a GLP-1 receptor agonist
89082704|NCT04186507||Prelaminary group|To confirm that Li+ is detectable in sweat .
89082705|NCT04186507||Spectrophon LTD biosensors for Li+ detection in sweat|In this group will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat
89082706|NCT02684383|Experimental|rDEN3∆30 vaccine|Participants will receive the rDEN3∆30 vaccine at Day 0.
89082707|NCT02684383|Placebo Comparator|Placebo|Participants will receive placebo at Day 0.
89082708|NCT04186351|Experimental|Encounter notification service|For participants randomized to the intervention group, their encounter information stored in the eHRSS will be provided to the SCHSA via the automated notification service. Healthcare professionals of the SCHSA would access the electronic health record and provide caring support and services via telephone calls during the 12-month study period.
89082709|NCT04186351|No Intervention|Usual care service|For participants randomized in the control group, no notification will be sent to the SCHSA. Usual care service will be provided during the 12-month study period. In addition, each control participant will receive placebo phone calls at least once every three months (e.g., the calls could be about greeting and general checking).
89082710|NCT00638833|Active Comparator|A|Memantine 30 mg/day
89082711|NCT00638833|Placebo Comparator|B|Placebo
89082712|NCT01198145|Experimental|Arm I: Sulfasalazine|Patients receive oral sulfasalazine twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
89082713|NCT01198145|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
89082714|NCT02684539|Experimental|tilt table Erigo®|observation of physiological parameters, tilting table with onset of syncope
89082715|NCT02687737|Experimental|Exercise|The participants will have the following tests performed: Maximum Expiratory Pressure (MEP), insertion of a fine-wire electromyography (EMG) electrode into the mid-line base of the tongue, will complete swallowing tasks and breathing tasks under Videofluoroscopy (fluoroscopy on only during the actual task)
89082716|NCT02686099|Experimental|SternaLock 360|Sternal closure performed with SternaLock 360 as a primary closure system
89082717|NCT02686099|Active Comparator|Wire Cerclage|Sternal closure performed with standard wire cerclage as a primary closure system
89082718|NCT02688049|Experimental|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients receive NeuroRegen scaffold with mesenchymal stem cells transplantation after spinal cord injury.
89082719|NCT02688049|Experimental|NeuroRegen scaffold/neural stem cells transplantation|Patients receive NeuroRegen scaffold with neural stem cells transplantation after spinal cord injury.
89082720|NCT02687893|Experimental|Aerobic Exercise Week|Subjects will complete 45 minutes of aerobic exercise twice during a 7 day period. Exercise will be graded based on the participant's relative capacity determined at the screening visit. Each exercise session will be followed by 60 minutes of monitored resting recovery.
89082721|NCT02687893|Experimental|Resistance Exercise Week|Subjects will complete 45 minutes of anaerobic exercise twice during a 7 day period. Each exercise session will be followed by 60 minutes of monitored resting recovery.
88812816|NCT01831622|Experimental|fMRI-arm|"Asterisk applies only for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before MRI testing.*~CRF 2, Adult ASRS and WAIS subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment to ensure the patients have not been withheld from medication for too long while keeping blind.*~Day 2 (after 14 - 40 days):~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before testing (opposite of Day 1).*~CRF 3, ASRS and EHI.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
89082722|NCT02687893|No Intervention|No Exercise Week|Subjects will perform no exercise during this week.
89082723|NCT04317677|Other|Babies hospitalized in the pediatric sleep unit|
89082724|NCT01197911|Experimental|Mild impairment|
89082725|NCT01197911|Experimental|Moderate impairment|
89082726|NCT01197911|Experimental|Normal HF|
89082727|NCT01197755|Experimental|Dosing Regimen A|Oral Treatment
89082728|NCT01197755|Experimental|Dosing Regimen B|Oral Treatment
89082729|NCT01197755|Placebo Comparator|Dosing Regimen C|Oral Treatment
89082730|NCT01179048|Experimental|Liraglutide|
89082731|NCT01179048|Placebo Comparator|Placebo|
89082732|NCT00603265|Experimental|ADL5859|2 x 50 milligrams (mg) ADL5859 capsules administered orally once in the morning and once in the evening for 28 days
89082733|NCT00603265|Active Comparator|Duloxetine|2 x 30 mg duloxetine capsules administered orally once in the morning and 2 placebo capsules filled with lactose administered orally once in the evening for 28 days
89082734|NCT00603265|Placebo Comparator|Placebo|2 placebo capsules filled with lactose administered orally once in the morning and once in the evening for 28 days
89082735|NCT02686177|Experimental|1: Liraglutide|Liraglutide 1,2 mg once daily subcutaneous injection for 1 month (4 weeks)
89082736|NCT02686177|Active Comparator|2: Add on oral antidiabetic medication|Metformin or sulfonylurea depending on monotherapy
89082737|NCT04010227|Experimental|Acceptance and Commitment Therapy|Patients and caregivers in the ACT arm learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).
89082738|NCT04010227|Active Comparator|Education/Support|Patients and caregivers in the education/support arm discuss their cancer-related concerns and receive education on services available in their medical center and community.
89082739|NCT02885298||Supine intubations (0-10 degrees)|Intubations performed with patient positioned 0-10 degrees. Patient supine.
89082740|NCT02885298||Inclined (11-44 degrees)|Intubations performed with 11-44 degrees of elevation.
89082741|NCT02885298||Upright (45 degrees or greater)|intubations performed with patient elevated to 45 degrees or greater
89082742|NCT00639613||1|Patients with type 2 diabetes
89082743|NCT00639613||2|Healthy subjects
89082744|NCT02686021|Experimental|Metamizole and Ibuprofen|all patients (n=42) will receive metamizol and ibuprofen in one session. In the other session half will receive metamizol and placebo (n=21) and the other half will receive ibuprofen and placebo. The order will be randomized (balanced).
89082745|NCT02686021|Active Comparator|Metamizole and Placebo|"This is one of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
89082746|NCT02686021|Active Comparator|Ibuprofen and Placebo|"This is the second of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
89082747|NCT02886390|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
89082748|NCT02886390|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
89082749|NCT02685787|Experimental|Psychosocial Intervention|Every caregiver in this arm will be assigned to a permanent counselor.
89082750|NCT02685787|Active Comparator|Educational Intervention on AD|The caregiver enrolled in this arm will not be assigned to a counselor but will participate to group sessions on AD education.
89082751|NCT04186039|Experimental|Congenital diaphragmatic and parietal malformations|Patients with fetal magnetic resonance imaging as part of their usual medical care, for fetal / placental indications of diaphragmatic hernia, omphalocele or gastroschisis.
89082752|NCT01158534|Experimental|Arm I|Patients receive oral celecoxib twice daily and recombinant interferon alpha-2b subcutaneously, once daily, 5 times a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89082753|NCT02687971|Active Comparator|Thermotherapy alone|"Local heat will be applied using a Localized Current Field radio-frequency generating device manufactured by Thermo-Med Technologies, Inc. A wand with 2 electrodes is connected to the main housing by a thin wire. The electrodes are applied to the skin. We will use electrodes 6 mm long, separated by 4 mm. One single session at the site of the lesion(s) at 50°C for 30 applications will be used. Depending on the size of the lesion, more than one application may be administered."
89082754|NCT02687971|Experimental|Thermotherapy plus Miltefosine|"In addition to receiving one single session of thermotherapy as described above, subjects will receive oral miltefosine two or three capsules a day, which is the equivalent of 100 to 150mg respectively for 21 days. Miltefosine capsules will be taken after breakfast, lunch and dinner, in other words, after food.~The daily dose of miltefosine will depend on the weight of each patient. According to dosage instructions if the patient is taking the miltefosine twice a day, it must be taken in the morning and night (dose of 100mg/Kg/day). Whereas if the patient is taking miltefosine three times a day, it must be taken in the morning, noon and night (dose of 150mg/Kg/day)."
89082755|NCT02685631||Observational/data registry collection|Patients receiving Yttrium-90 resin microspheres as part of care
89082756|NCT00638911||Patients with hypertention|
89082757|NCT02683213|Active Comparator|Fluoxetine|One capsule Fluoxetine 20mg once daily for 6 months.
89082758|NCT02683213|Placebo Comparator|Placebo|One matching capsule placebo once daily for 6 months.
88812817|NCT04380818|Active Comparator|Control group|a control group only receive pharmacological treatment
89082759|NCT04185103||Sacubitril-Valsartan cohort|Patients with left systolic disfunction (left ventricle ejection fraction<40%) heart failure and diagnosed with grade II heart failure that have been treated with an ACE or ARA II+betablocker at stable doses during the last 4 weeks and after being evaluated by the cardiologist start Sacubitril-Valsartan treatment.
89082760|NCT04033939|Experimental|HSK3486-01|Randomized to receive HSK3486 (0.016mg/kg,0.064mg/kg )as a single IV injection. HSK3486-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
89082761|NCT04033939|Placebo Comparator|Placebo-01|Randomized to receive placebo (0.016mg/kg,0.064mg/kg )as a single IV injection. placebo-01 was blinded.(2 HSK3486-01: 1 Placebo-01)
88812818|NCT04380818|Experimental|Experimental group|an experimental group will receive low-dose lung irradiation
89082762|NCT04033939|Experimental|HSK3486-02|Randomized to receive either HSK3486（0.128mg/kg,0.192mg/kg,0.288mg/kg,0.432mg/kg,0.540mg/kg,0.648mg/kg,0.810mg/kg) as a single IV injection. HSK3486-02 was open-label.(5 HSK3486-02: 1 propofol-02)
89082763|NCT04033939|Active Comparator|Propofol-02|Randomized to receive propofol (2.5mg/kg) as a single IV injection. Propofol-02 was open-label.(5 HSK3486-02: 1 propofol-02)
89082764|NCT02685943|Experimental|CAMS treatment|Psychotherapy using the Collaborative Assessment and Management of Suicidality framework
89082765|NCT02685943|Active Comparator|Treatment as usual|Ordinary treatment for suicidal patients
89082766|NCT00639691|Experimental|1|
89082767|NCT02684149|Experimental|A|Relational touch before the first arterial puncture and the second arterial puncture without relational touch
89082768|NCT02684149|Experimental|B|First arterial puncture without relational touch and relational touch before the second arterial puncture
89082769|NCT02684071|Experimental|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
89082770|NCT01158378|Active Comparator|DuraSeal Dural Sealant System|
89082771|NCT01158378|Experimental|Adherus Dural Sealant System|
89082772|NCT04184011||SRT for keloid scars|Individuals who are voluntarily scheduled to be treated at one of the participating study sites with SRT (SRT-100™, SRT-Vision™ or SRT-100+™) for the treatment of one or more recurrent keloids.
89082773|NCT04183855|Experimental|control|no supplement will be provided on the day of the experiment
88812819|NCT01448447|Experimental|Sole method|patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS
89082774|NCT04183855|Experimental|Generation UCAN|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
89082775|NCT04183855|Experimental|Mirexus PhytoSpherix|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
88812820|NCT01448447|Experimental|Boost|patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS
88812821|NCT05312294|Experimental|FLU-M w/o/p|Volunteers were vaccinated with a single dose of the Flu-M vaccine (without preservative) intramuscularly in a dose of 0.5 mL.
88812822|NCT05312294|Experimental|FLU-M w/p|Volunteers were vaccinated with a single dose of the Flu-M vaccine (with preservative) intramuscularly in a dose of 0.5 mL.
89082776|NCT01158222|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
89082777|NCT02682979||Geriatric patients|100 consecutive geriatric patients admitted in the Emergency Department of the Brugmann Hospital, Horta site, from 01/04/2015.
89082778|NCT02886780|Experimental|Concentrated Exposure Treatment (cET)|Please refer to:Havnen, A., Hansen, B., Öst, L.-G. & Kvale, G. Concentrated ERP delivered in a group setting: An effectiveness study. Journal of Obsessive Compulsive and Related Disorders 3, 319-324 (2014)
89082779|NCT02886780|Active Comparator|Self-help|"The self-help condition (SH):~Foa, E.B. & Kozak, M.J. Mastery of obsessive-compulsive disorder: Client workbook, (Graywind Publications, New York, 1997)."
89082780|NCT02886780|No Intervention|Wait list|
89082781|NCT02684305|Experimental|Administration of Propess|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:~1.Administration of Propess for additional 24 hours."
89082782|NCT02684305|Experimental|Intravenous oxytocin infusion + balloon|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:~2. Intravenous oxytocin infusion combined with intracervical balloon administration, inflated with 60cc of saline."
89082783|NCT02885376|Experimental|Dentoxol|Dentoxol® is a proprietary mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. Subjects will use Dentoxol® mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
89082784|NCT02885376|Placebo Comparator|Placebo|The placebo rinse will be identical in color, taste and consistency as the Dentoxol rinse and will be packaged in identical bottles with the same labels. Subjects will use placebo mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
89082785|NCT02940769|Experimental|light glasses|Study subjects will wear light glasses
89082786|NCT02940769|Sham Comparator|sham glasses (placebo)|Study subjects will wear sham glasses
89082787|NCT04315584|Experimental|Diagnostic|Study subjects will receive 18FDG via an IV before undergoing one PET/CT scan over 60 minutes. They will then receive an IV injection of Gadovist for contrast before undergoing a multiparametric MRI scan. Subjects will also receive (18)F-FDOPA via an IV before undergoing another PET/CT scan over 60 minutes.
89082788|NCT02683993|Experimental|Stone breaking|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with low frequency parameters.
89082789|NCT02683993|Experimental|Stone dusting|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with high frequency parameters.
89082790|NCT02683291|Active Comparator|Tacrolimus + Mycophenolate|"The investigators wil be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720 mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due to possible side effects of the drug.~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
89082791|NCT02683291|Experimental|Tacrolimus + Sirolimus|"The investigators will be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day (adjusted serum levels at 4-8 ng/ml throughout the study period).~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
89230148|NCT01097161|Experimental|Speech treatment on prosodic basis|Patients receive 20 therapy sessions over a course of 3 months, with one double session per week.
89230149|NCT01097239|Experimental|High Intensity Focused Ultrasound|Transrectal High Intensity Focused Ultrasound (HIFU) treatment of the PelvicTumour
89082792|NCT02685865|Active Comparator|FCSEM Stent|WON is first identified using EUS and punctured using a 19 gauge needle. 10 ml of fluid is aspirated and sent for gram stain and culture with sensitivities. Using a catheter-based stent delivery system with a 15mm AXIOS stent mounted onto it is inserted into the echoendoscope, and introduced into the WON cavity so that the stent lies within both the WON and enteric lumen. The stent is then deployed so that one flange of the stent is located within the WON cavity and the other flange is located within the enteric lumen.
89082793|NCT02685865|Active Comparator|Plastic Stents|WON is first identified using EUS, and punctured using a 19 gauge needle. 10 ml of the WON fluid is aspirated and sent for gram stain and culture with sensitivities. A 0.025 or 0.035 inch guidewire is inserted into the WON through the fine needle aspiration (FNA) needle. A transmural tract is created using an Endoscopic Retrograde Cholangiopancreatography(ERCP) catheter (with the use of a needle knife catheter ± cautery if needed), and then dilated using a 12-13.5-15mm Controlled Radial Expansion (CRE) balloon to a maximum size of 15mm if technically possible. Two or three 7 French plastic stents are inserted through the transmural tract into the WON cavity.
89082794|NCT02685397|Active Comparator|LHRH agonist + Enzalutamide|Subjects will receive LHRH agonist in combination with the new generation of hormonal therapy (enzalutamide, 40mg)
89082795|NCT02685397|Experimental|LHRH agonist + Enzalutamide + SBRT|Subjects will receive LHRH agonist in combination with the new generation of hormone therapy (enzalutamide, 40mg) plus the additional SBRT treatment
89082796|NCT02682745|Experimental|R-T1-T2|First period: administration of reference drug, Second period: administration of test drug l, Third period : administration of test drug ll
89082797|NCT02682745|Experimental|R-T2-T1|First period : administration of reference drug, Second period : administration of test drug ll, Third period : administration of test drug l
89082798|NCT02682745|Experimental|T1-T2-R|First period : administration of test drug l, Second period : administration of test drug ll, Third period : administration of reference drug
89082799|NCT02682745|Experimental|T1-R-T2|First period : administration of test drug l, Second period : administration of reference drug, Third period : administration of test drug ll
89082800|NCT02682745|Experimental|T2-R-T1|First period : administration of test drug ll, Second period : administration of reference drug, Third period : administration of test drug l
89082801|NCT02682745|Experimental|T2-T1-R|First period : administration of test drug ll, Second period : administration of test drug l, Third period : administration of reference drug
89082802|NCT01197521|Experimental|Dosing Regimen A|Oral Treatment
89082803|NCT01197521|Experimental|Dosing Regimen B|Oral Treatment
89082804|NCT01197521|Placebo Comparator|Dosing Regimen C|Oral Treatment
89082805|NCT02683915||Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
89082806|NCT02683915||Non-cooled group|Infants in the non-cooled group received the current standard of care and will be placed under radiant heaters or in incubators, which are servo-controlled according to the abdominal skin temperature to maintain the rectal temperature at 37.0± 0.2°C.
89082807|NCT02683837|Active Comparator|Standard practice|"Remifentanil infusion guided by usual clinical signs (heart rate, blood pressure).~Pupillometry blindly recorded. Anesthesia maintenance with sevoflurane."
89082808|NCT02683837|Experimental|Pupillometry|Remifentanil infusion guided by changes in pupillary diameter. Anesthesia maintenance with sevoflurane.
89082809|NCT02002507||park bench position|Comparing jugular venous flow in supine and park bench position in neurosurgical patients requiring their surgery in park bench position
89082810|NCT02002507||prone position|Comparing the jugular venous flow in the supine and prone position in patients requiring their surgery to be done in the prone position.
89082811|NCT01157676|Active Comparator|Open cystectomy|Open cystectomy performed using an incision made just above or at the level of umbilicus to the pubic symphysis.
89225351|NCT05797311|Experimental|PNF Group|"After classical physiotherapy consisting of 40 minutes of hot pack, TENS, US and Exercise (a set of stretching exercises including Wand and Codman pendulum exercises) was applied by an experienced Physiotherapist, additional PNF exercises were performed once a day, 5 times a week by the same Physiotherapist in the cases in the PNF group. It will be applied for a total of 3 weeks (Total of 15 sessions).~PNF contract-relax to subscapularis and internal rotators (7 Sec of contraction and 15 Sec of relaxation in external rotation, 5 repetitions) Followed by facilitation of D2 Flexion patterns for 5 repetitions.~PNF all scapular patterns with Rhythmic initiation and repeated contractions Technique ."
89225352|NCT05797311|Other|Stabilization Group|"After classical physiotherapy consisting of 40 minutes of hot pack, TENS, US and Exercise (a set of stretching exercises including Wand and Codman pendulum exercises) was applied by an experienced Physiotherapist, stabilization exercises were performed by the same Physiotherapist once a day, 5 times a week, for a total of 5 times a week. It will be applied for 3 weeks (Total of 15 sessions).~scapular stabilization exercises~stabilization exercise for the shoulder joints.~In all the exercises, the subjects maintained the position for 10 seconds, and they took a rest for 3 seconds. Ten repetitions was considered one set, and the subjects conducted three sets. A break of 3 minutes was given between each set."
89225353|NCT05797233|Experimental|1/Conditioning chemotherapy plus CAR T-cells dose escalation|Escalating dose of anti-CD19 and anti-CD20 CAR T- cells/kg + conditioning chemotherapy
89225354|NCT05797233|Experimental|2/Conditioning chemotherapy plus CAR T-cells expansion phase|MTD dose or Optimal dose of Anti-CD19 and anti-CD20 CAR T- cells/kg + conditioning chemotherapy
89225355|NCT05795439|Experimental|Intervention Group|The Intervention group arm of participants will be asked to attend weekly online classes on nutrition and health and to follow a low-fat, vegan diet for 16 weeks.
89225356|NCT05795439|No Intervention|Control Group|The Control group arm of participants will be asked to maintain their regular, pre-study diet.
89225357|NCT05793060|Active Comparator|Group A (n=30)|Dexmedetomidine group
89225358|NCT05793060|Active Comparator|Group B (n=30)|Dexamethasone group
89225359|NCT05790811|Experimental|patient-oriented video|A patient-oriented video with the goal of instructing patients about the maneuvers needed to make specific diagnoses of the hand and wrist. Wording was changed so that it was more patient friendly and text was added to the screen.
89225360|NCT05790811|Active Comparator|physician-oriented training video|A physician-oriented video with the goal of instructing physicians on the maneuvers needed to make specific diagnoses of the hand and wrist.
89225361|NCT05784844|Active Comparator|Meropenem Arm|Patients who meet inclusion criteria may be randomized to meropenem (routine standard of care) dose according to local dosing guidelines to include the use of extended-infusions and adjustments to account for renal function. Duration will be managed by the primary team.
89225362|NCT05784844|Active Comparator|Micafungin Arm|Patients who meet inclusion criteria may be randomized to micafungin dosed as 150mg intravenously every 24 hours according to local dosing guidelines. Duration will be managed by the primary team.
89225363|NCT05783310|Experimental|Psychoeducation Intervention|The intervention group will receive six sessions of a psychoeducation intervention delivered face-to-face
89225364|NCT05783310|No Intervention|Control group|No psychoeducation intervention will be given
89225365|NCT05782712||Syncope|patients referred for syncope evaluation
89225366|NCT05782712||No syncope|Subjects without syncope
89225367|NCT05782647|Experimental|Cuffless BP monitoring|Investigational device Omron HeartGuide® 6410T
89225368|NCT05782647|Active Comparator|Beat-to-beat BP monitoring|Continuous finger BP monitoring (Finometer®, Finapres Medical Systems, Enchede, The Netherlands, and Task Force® monitor, CNSystem, Graz, Austria), based on the photoplethysmographic volume clamp method
89225369|NCT05782491|Experimental|Treatment Arm|Patient in cardiogenic shock listed for Impella 5.5 placement who meets study inclusion criteria
89225370|NCT05777863|Experimental|High-intensity group|The high-intensity group receives a supervised multidomain lifestyle intervention consisting of weekly group meetings. During the weekly group meetings, information and exercises are provided, and participants are able to exchange experiences and advice with other group members.
89225371|NCT05777863|No Intervention|Low-intensity group|The low-intensity group only receives access to general lifestyle-related health information through biweekly leaflets, which are provided through e-mail.
89225372|NCT05776225||Experimental study arm|All enrolled patients in this single arm study will receive a RHC.
89225373|NCT05775445||Group 1 (significant CAD, low risk factors)|"Evidence of significant CAD~a. Coronary angiogram or CT coronary angiogram with documented stenosis >=50% in left main or >=70% in major epicardial vessel or major branches (LAD, LCX, RCA)~AND all of the following~Age </= 45 for males and </= 50 for females~Absence of diabetes mellitus~Absence of tobacco use~No prior CVA or PAD"
89225374|NCT05775445||Group 2 (minor CAD, high risk factors)|"No evidence of significant CAD~a. Coronary angiogram or CT coronary angiogram with <50% stenosis in major blood vessel/branch~No prior history of clinical CAD, PAD or CVA~with one of the~Age >65 with~Diabetes mellitus >5years; or~End Stage Renal Failure (ESRF), regardless of duration or~Framingham risk score > 10%~Diabetes >10 years~End Stage Renal Failure (ESRF) > 5 years~Age >80"
89225375|NCT05775445||Group 3 (signifcant CAD, high risk factors)|"1. Evidence of significant CAD with one of the following:~age>65~Diabetes mellitus~End Stage Renal Failure (ESRF)~Framingham risk score >10%"
89230150|NCT03955315|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells)
89225376|NCT05775445||Group 4 Control group|"1. No evidence of significant CAD and all of the following:~Age <55 for males, <65 for females~Absence of diabetes mellitus~Absence of CKD~Absence of tobacco use"
89225377|NCT05774678|Experimental|Group 1 (preoperative radiation hypofractionated)|Participants will receive the standard number of radiation treatment doses
89225378|NCT05774678|Experimental|Group 2 (preoperative radiation conventionally fractionated)|Participants will receive the standard number of radiation treatment doses
89225379|NCT05773157|Other|Receive Online Modules|All participants receiving the same online modules intervention.
89225380|NCT05772715|Active Comparator|Orthosis group|
89225381|NCT05772715|Experimental|Orthosis + exercise group|
89225382|NCT05772338|Experimental|BNP105 (25 + 25 + 15)|Up to six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops.
89225383|NCT05772338|Placebo Comparator|Placebo|Up to six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops.
89225384|NCT05770908|Experimental|Multimedia animation videos plus paper-based therapeutic exercise program|
89225385|NCT05770908|Active Comparator|Paper-based therapeutic exercise program|
89225386|NCT05765721|Experimental|intervention group|Patients in this group will receive a 8-week family-based frailty self-management program including: (1) one 20-30 minute individual consultation (teaching how to join the family-based frailty self-management program by using poster); (2) provided self-management booklet; (3) provided family-based frailty self-management program video through Line group meeting, once per two weeks ; (4) individual consultation through telephone follow-up once per week for 8 weeks
89225387|NCT05765721|No Intervention|Control group|Patients in this group maintain their daily life activities, and there is no intervention given.
89225388|NCT05763875|Experimental|Inclisiran|Inclisiran s.c and Placebo p.o
89225389|NCT05763875|Active Comparator|Ezetimibe|Placebo s.c. and Ezetimibe p.o.
89225390|NCT05763875|Placebo Comparator|Placebo|Placebo s.c. and Placebo p.o.
89225391|NCT05759156|Active Comparator|Tranexamic Acid|
89225392|NCT05759156|Placebo Comparator|Normal Saline|
89225393|NCT05758883||IC-8 Apthera intraocular lens (IOL) Group|Patients previously enrolled in the IC-8 Apthera IOL Investigational Device Exemption (IDE) study (G180075) and implanted with the IC-8 Apthera IOL.
89225394|NCT05755256|Experimental|Probiotic|The product contains the probiotic strain and no other ingredients.
89225395|NCT05755256|Placebo Comparator|Placebo|The control product is a placebo with the same characteristics of appearance and packaging as the tested product.
89225396|NCT05753319||Physiotherapy group|Intervention group with assessment and early physiotherapy
89225397|NCT05753319||Control group|control group without assessment and physiotherapy in the emergency department
89225398|NCT05751369|Active Comparator|Education Only|Treatment as usual with brief videos and weblink
89225399|NCT05751369|Experimental|TECW+|Education plus motivational enhancement
89225400|NCT05747456|Experimental|IPN-21-SENSE Treatment Group|Subjects randomized (5:1 ratio) to receive an initial treatment with IPN-21-SENSE Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.
89225401|NCT05747456|Other|No-Treatment Control Group, then Delayed Treatment with IPN-21-SENSE|No-Treatment for the first 6-month, then subjects will receive a delayed treatment with IPN-21-SENSE Crosslinked Hyaluronic Acid Gel up to 8mL, based on the PI's assessment, in combination with the aesthetic goal of the subject, then an optional touch-up treatment session 4 weeks later, up to 4mL.
89225402|NCT05745129||Treatment cohort|"Surgical vs conservative treatment.~Surgery procedures are based on the NOMESCO Classification of Surgical Procedures (NCSP). Conservative treatment includes all non-surgical treatment methods such as pharmaceutical treatment, physical medicine and physiotherapy modalities (information, patient education, exercise, manual therapy etc), cognitive-behavioural therapy, multidisciplinary treatment, acupuncture, and others (e.g. chiropractic treatment, homeopathy, naprapathy, osteopathy). The results will be described for important spinal subgroups (specific diagnoses, nerve-root affections, and non-specific conditions)."
89230151|NCT03955315|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
89230152|NCT03955315|Sham Comparator|Sham|Sham needle puncture (outside disc)
89082812|NCT01157676|Active Comparator|Robotic assisted radical cystectomy|Robotic assisted Radical Cystectomy (RARC) is accomplished by a robot assisted laparoscopic approach.
89082813|NCT02680873|Other|SASI bypass|sleeve gastrectomy done and gastro-ileum anastomosis 2.5 meter from the ileocecal valve . the anastomosis is less than 3cmm in diameter . the concept to push undigested food early to the ileum to stimulate intestinal hormones secretion to control diabetes .
89082814|NCT04183543|Experimental|Pulsed Electromagnetic Field Therapy|Study participants will receive 20 minutes of PEMFs (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
89082815|NCT04183543|Sham Comparator|Sham Therapy|Study participants will receive 20 minutes of placebo treatment (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
89225403|NCT05743114|Experimental|Sleep Onset Latency Crossover|Arm 1 is a crossover arm in which participants receive one block of active stimulation (experimental) and a second block in which the device is worn and actively recording, but not delivering phase-locked auditory stimulation (sham). The order of blocks is randomized for each participant.
89082816|NCT02680951|Experimental|Dose Level 1|"Study participants #1 - #6 receive dose level 1 of dasatinib (60/mg/m2/day) in addition to the standard treatment, for up to 2 courses. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
89082817|NCT02680951|Experimental|Dose Level 2|"Study participants # 7 - # 12 receive dose level 2 of dasatinib (80/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 1 did not experience intolerable side effects. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
89082818|NCT02680951|Experimental|Dose Level 3|"Study participants # 13 - # 18 receive dose level 3 of dasatinib (100/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 2 did not experience intolerable side effects. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
89082819|NCT02680717|Active Comparator|Treatment 1|Calcipotriene 0.005% ointment
89082820|NCT02680717|Active Comparator|Treatment 2|Clobetasol 0.05% ointment
89082821|NCT02680717|Active Comparator|Treatment 3|Tacrolimus 0.1% ointment
89082822|NCT05663983||AIEOP|This is a National Association for the treatment of pediatric patients with hematological or oncological disease
89082823|NCT05663983||FIL|This is a National Association that brings together many centers with particular attention to the treatment of adult lymphomas
89082824|NCT04182529|Experimental|Photoneuromodulation Therapy|In this study low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800 will be used. The United States Food and Drug Administration (FDA) has approved this type of device as imposing insignificant risk (FDA-cleared for home treatment, 2005). At each visit, LED clusters will be applied simultaneously for 20 minutes on the Fp1, Fp2 and Pz regions according to the International 10-20 system (Homan, Herman and Purdy, 1987) (energy density, 13 Joules/cm2 [J/cm2] per each LED cluster head placement). The total LED treatment time per visit was 20 minutes.
89082825|NCT04182529|Sham Comparator|Control Group|Subject will not be given any active stimulation
89082826|NCT02680795|Experimental|Wild Type UGT1A1|Cohort A: Open for Enrollment Wild Type UGT1A1, Belinostat IV
89082827|NCT02680795|Experimental|Heterozygous UGT1A1*28|Cohort B: Closed For Enrollment Heterozygous UGT1A1, Belinostat IV
89082828|NCT02680795|Experimental|Homozygous UGT1A1*28|Cohort C: Open For Enrollment Homozygous UGT1A1, Belinostat IV
89082829|NCT00640237|Experimental|1|Arm 1 - the patients will receive two large doses of vitamin D.
89082830|NCT00640237|No Intervention|2|Arm 2 - the patients vitamin D status will be checked during the hospitalization and they will receive the recommendation to treat the vitamin D deficiency in the out-patient department.
89082831|NCT02683759|Active Comparator|Treatment Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:
89082832|NCT02683759|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
89082833|NCT02682589|Active Comparator|Open surgery|Patients undergo open CME. A standard midline incision carefully protected is made through the abdominal wall and the abdominal cavity is explored. A colectomy with CME is performed with the removal of the afflicted colon and its accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia.
89082834|NCT02682589|Experimental|Laparoscopic surgery|Patients undergo laparoscopic CME. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with carbon dioxide to allow access and visualization. The abdominal cavity is explored. A colectomy with CME is performed using laparoscopic-assisted techniques. A 6-8cm midline auxiliary incision is made for specimen extraction and anastomosis.
89230153|NCT00035815|Active Comparator|IGF-1|Insulin like growth factor, type 1 will be given 0.05 mg per kg body weight subcutaneously twice daily
89230154|NCT00035815|Placebo Comparator|Placebo|Placebo arm
89225404|NCT05743114|Experimental|Wake After Sleep Onset|This arm tests active stimulation during sleep onset, as well as additional stimulation if participants wake up during the night. One of 4 possible conditions are randomized for each stimulation even (within subject and within nights): Stimulation locked to alpha peak phase, stimulation locked to alpha trough phase, white noise (active sham), and no sound (control).
89082835|NCT03072433|Active Comparator|Standard of Care|Comparison group will receive the current standard of care. Nurses are instructed to tell mothers about nutrition and water, sanitation and hygiene at any point prior to discharge from hospital. In addition, nurses will tell primary caregivers to play with their children even while they are receiving treatment in a play area with toys available.
89082836|NCT03072433|Experimental|Counseling Intervention Package|Primary caregivers in the intervention group receive group education sessions involving psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene components during a total of four days.
89082837|NCT00991341|Active Comparator|Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
89082838|NCT00991341|Active Comparator|Longer-storage red blood cell units|Red blood cell units stored >= 21 days
89082839|NCT04291989|Experimental|Earlobe and Finger Prick versus venous blood lactate sampling|Compare blood Lactate levels between ear lobe and finger against venous forearm blood sample using the electronic hand held lactate device in hip fracture patients with good cognitive function (AMT >/= 7)
89082840|NCT04291677|Experimental|Intervention group in which musical intervention|Group A: Experimental group in which musical intervention will be applied between the first and the third day of mechanical ventilation.
89082841|NCT04291677|Other|Control group|Group B: Control group with standard treatment without musical intervention.
89082842|NCT04292691|Experimental|Ropivacaine|A cumulative amount of approx. 40ml ropivacaine 0.5% (≙400mg (2x200mg) ropivacaine) is applied immediately before surgery. They are applied in a ring wall 10 cm cranially of the tip of the medial and lateral malleolus (N. peroneus superficialis (N. cutaneus dorsalis medius et intermedius, N. saphenus, N. suralis), as well as sonographically controlled (N. peroneus profundus and N. suralis)
89082843|NCT04292691|Placebo Comparator|Ringer's Lactate|Analog to the Experimental Arm, but the same amount of Ringer (40ml) will be plicated instead Ropivacaine
89082844|NCT00990249|Experimental|Busulfan + Clofarabine + Stem Cell Transplant|"Busulfan test dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.~Clofarabine 40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors.~Stem cell infusion on Day 0."
89082845|NCT02846545|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may enter in an open-label (OL) extension period to receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area).
89082846|NCT02846545|Placebo Comparator|Group 2: Placebo|Participants will receive a matching placebo to golimumab.
89082847|NCT04291755||Checkpoint inhibitor therapy|Patients will be administered a checkpoint inhibitor therapy, including but not limited to pembrolizumab, nivolumab, ipilimumab, and atlizumab, at the standard dosing regimen prescribed by their physician. Stool, blood, and urine samples will be collected from patients prior to start of treatment, and at 4 more timepoints over the next 12 months.
89082848|NCT02869191||blood cultures|Admitted patients in critical care who need blood cultures
89082849|NCT02869191||blood cultures Getafe|Data collection of patients included in study
89082850|NCT04292769|Experimental|Decitabine combined with DC-CIK|Test group: decitabine combined with autologous DC-CIK cells infusion: decitabine 10mg / d, intravenous administration of d-5 to d-1, autologous DC-CIK cells infusion: first course: d1-d3 The second course: d14-d16; the total number of cells is about 5-10 × 109; IL-2: 200,000 IU / d subcutaneous injection, the first course: d0-d4, the second course: d13-d17, every 2 weeks 1 course of treatment, 2 courses in total.
89082851|NCT04292769|Active Comparator|DC-CIK|Control group: autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109; One course: d0-d4, the second course: d13-d17, 1 course every 2 weeks, a total of 2 courses.
89082852|NCT00640939|Active Comparator|A|Topical diclofenac sodium patch
89082853|NCT00640939|Placebo Comparator|B|Topical patch identical in appearance to active comparator
89082854|NCT04291443|Experimental|Upper First Premolar One Side|Heavy force (225 g)
89082855|NCT04291443|Experimental|Upper First Premolar Other Side|Light Force (25 g)
89082856|NCT05663749|Active Comparator|Metformin arm|1000mg for 8 weeks
89082857|NCT05663749|Experimental|Topiramate arm|50mg for 8 weeks
89225405|NCT05742711|Experimental|Treatment Group|The group who have received PENS treatment using PrimaryRelief in addition to Injection paracetamol in a dosage of 15mg/kg every 6th hourly. Break through pain with NRS>4 will be managed with injection tramadol at 1mg/kg followed by 0.5mg/kg after 10mins in cases of persisting pain.
89230155|NCT00662831|Experimental|Active|Active study treatment
89082858|NCT02682433|Experimental|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same position, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
89082859|NCT02682433|Experimental|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same positionabdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
89082860|NCT00990093|Experimental|test intermittent catheter|CH 12 hydrophilic coated catheter
89082861|NCT00990093|Experimental|intermittent catheter|CH 12 hydrophilic coated catheter
89082862|NCT04184167|Active Comparator|intermittent fasting|intermittent fasting before ICSI
89082863|NCT04184167|Placebo Comparator|No intermittent fasting|Usual diet
89082864|NCT02867553|Experimental|Rituximab by intravenous|attack treatment (4 slow intravenous perfusions of rituximab at a dose of 375 mg / m2 on day 1, day 8, day 15 and day 22) and maintenance treatment (intravenous perfusions of rituximab at a dose of 375 mg / m2 every 2 months for 2 years).
89082865|NCT02867553|Active Comparator|multi-field radiotherapy|multi-fields radiotherapy with a dose between 20 and 30 gray and a fractionated dose over 2 at 3 weeks.
89082866|NCT02682199||Whole Brain Radiation|Patients scheduled to receive whole brain radiation with or without chemotherapy/targeted therapy.
89082867|NCT05663671||Crohn's colitis|Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known authentic CC patients.
89082868|NCT05663671||Ulcerative colitis|Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known authentic UC patients.
89082869|NCT05663671||Indeterminate colitis|Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known IC patients (into authentic UC and CC)
89082870|NCT05663671||Diverticulitis|Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known diverticulitis.
89082871|NCT05663671||Ileum|Positive control
89082872|NCT02682277|Active Comparator|Medical device polyglucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
89082873|NCT02682277|Placebo Comparator|Placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
89082874|NCT00909961|Experimental|Zoledronic acid|
89082875|NCT05663593|Experimental|HSK31858|Single or multiple oral doses of HSK31858 Tablet, orally once daily
89082876|NCT05663593|Placebo Comparator|Placebo|Matching placebo Tablet, orally once daily
89082877|NCT02680249|Experimental|CTP-656 Fed, low fat|Single dose of CTP-656 150 mg administered after a low-fat breakfast
89082878|NCT02680249|Experimental|CTP-656 Fasted|Single dose of CTP-656 150 mg administered fasted
89082879|NCT02680249|Experimental|CTP-656 Fed, high fat|Single dose of CTP-656 150 mg administered after a moderate-fat breakfast
89082880|NCT04184557|Experimental|"App Staying Calm in the OR"|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) or Mindfulness Self Compassion (MSC)."
89082881|NCT04184557|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) arm will not download the app until the study is completed.
89082882|NCT00641017|Experimental|1 and 2 - Adults|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
89082883|NCT00641017|Experimental|3A - Seropositive Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
89082884|NCT00641017|Placebo Comparator|3B - Seropositive Children|One dose of 1x10^6 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
89082885|NCT00641017|Experimental|4A - Seronegative Infants and Children|One immunization of 1x10^5 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
89082886|NCT00641017|Placebo Comparator|4B - Seronegative Infants and Children|One dose of 1x10^5 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
89230156|NCT00662831|Placebo Comparator|Placebo|Placebo
89082887|NCT00641017|Experimental|5A - Seronegative Infants and Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
89082888|NCT00641017|Placebo Comparator|5B - Seronegative Infants and Children|One dose of rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
89082889|NCT00642577|Experimental|1|
89082890|NCT00642577|Active Comparator|2|
89082891|NCT02679937|Experimental|Fit4Duty|6-week weight gain prevention group
89082892|NCT02679937|Active Comparator|Nutrition Education|Two, 50 minute educational videos.
89082893|NCT02682121|Placebo Comparator|Placebo|Patients on placebo.
89082894|NCT02682121|Active Comparator|Active drug|Patients on Metformin, 850mg twice daily for 6mos.
89082895|NCT02680405||Atopic Dermatitis|Subjects with Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
89082896|NCT02680405||Non Atopic Dermatitis|Subjects with no Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
89082897|NCT02537587|Active Comparator|Control 1|67g of Control energy bar containing 4g protein, 15g fat, 42g carbohydrate, 2g fiber, and 24g sugar.
89082898|NCT02537587|Active Comparator|Control 2|86g of Control energy bar containing 5g protein, 20g fat, 55g carbohydrate, 3g fiber and 30g sugar
89082899|NCT02537587|Experimental|15/0|Experimental bar with 15% added resistant starch and 0% added protein; 66g portion containing 3g protein, 7g fat, 50g carbohydrate, 10g fiber and 16g sugar
89082900|NCT02537587|Experimental|15/0-LS|Experimental bar with 15% added resistant starch and 0% added protein with reduced sugar; 84g portion containing 4g protein, 8g fat, 55g carbohydrate, 15g fiber and 15g sugar
89082901|NCT02537587|Experimental|15/5|Experimental bar with 15% added resistant starch and 5% added protein; 75g portion containing 9g protein, 7g fat, 52g carbohydrate, 12g fiber and 17g sugar
89082902|NCT02537587|Experimental|10/5|Experimental bar with 10% added resistant starch and 5% added protein; 72g portion containing 10g protein, 8g fat, 49g carbohydrate, 9g fiber and 19g sugar
89082903|NCT02537587|Experimental|10/10|Experimental bar with 10% added resistant starch and 10% added protein; 80g portion containing 17g protein, 7g fat, 49g carbohydrate, 9g fiber and 18g sugar
89082904|NCT02683603|Active Comparator|aerosolised (AS) colistin group|"the intervention was: AS colistin and imipenem. the drug administered was colimycin (colistin) powder 1 million units (MU) by a flakon (Sanofi Winthrop Industry) at the dosage of 4 million units (MU) for 30 minutes 3 times per day for at least 14 days in addition to IV imipenem 1 g three times per day. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland). Inhaled colimycin® requires specific settings of the ventilator to limit turbulence inspiratory flow. The adjustment consisted in a volume controlled mode with a Tidal volume <8 ml / kg, respiratory rate at 12 cycles / min, I / E: 1/1 and an end inspiratory break > 20%."
89082905|NCT02683603|Active Comparator|intravenous (IV) colistin goup|"the intervention was: IV colistin and imipenem. the intravenous (IV) colistin goup received IV colimycin (colistin) as a loading dose of 9 MU during 60 minutes followed by 4.5 million units 2 times per day in addition to IV imipenem 1 g three times per day."
89082906|NCT00641095|Experimental|Fludarabine/Cyclophosphamide/Rituximab|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3 Rituximab 375mgs/m2 day 1 iv infusion~Every 28 days"
89082907|NCT00641095|Active Comparator|Fludarabine/Cyclophosphamide|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3~Every 28 days"
89082908|NCT00984165|Experimental|Donor Lymphocyte Infusion/Radiation|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 1 after radiation (single, 8-Gy fraction to the maximum number of lesions).
89082909|NCT00984165|Active Comparator|Radiation/No Donor Lymphocyte Infusion|Subjects will receive radiation (single, 8-Gy fraction to the maximum number of lesions).
89082910|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Control|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 0.
89082911|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Donor|Healthy subjects who donated lymphocytes for infusion on a treatment Arm.
89082912|NCT02869113|Experimental|Sunscreen agent A + control|Application of control and test product into one of the subjects two eyes.
89082913|NCT02869113|Experimental|Sunscreen agent B + control|Application of control and test product into one of the subjects two eyes.
89082914|NCT02869113|Experimental|Sunscreen agent C + control|Application of control and test product into one of the subjects two eyes.
89082915|NCT00993291|No Intervention|Baseline frequency|Baseline DBS frequency
89082916|NCT02867631|No Intervention|Enhanced control|Regular care as provided by the community based organization from which the convenience sample is recruited with one year of assessments only
89082917|NCT02867631|Experimental|Intervention|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
89082918|NCT01196975|Experimental|GSK2282512A 1 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89082919|NCT01196975|Experimental|GSK2282512A 2 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89082920|NCT01196975|Experimental|GSK2282512A 3 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89082921|NCT01196975|Active Comparator|Victoria Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89082922|NCT01196975|Active Comparator|Yamagata Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89082923|NCT00992589|Experimental|Rabeprazole sodium 5 mg|
89082924|NCT00992589|Experimental|Rabeprazole sodium 10 mg|
89082925|NCT00992589|Placebo Comparator|Placebo|
89082926|NCT01196741|Active Comparator|Saracatinib plus weekly paclitaxel|
89082927|NCT01196741|Placebo Comparator|Placebo plus weekly paclitaxel|
89082928|NCT02868255||Ascites|"30 inflammatory ascites of HCC patients (Collection of human samples ) Ascites will be selected only from HCC patients with an elevated protein level (ie inflammatory ascites) Puncture of ascites will be collected by paracentesis on HCC or ovarian cancer patients during their routine care These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
89082929|NCT02868255||Resections|"30 HCC resections (Collection of human samples ) Fragment of resected HCC will be obtained after surgery and histological analysis will be performed by the anatomo-pathology service These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
89082930|NCT02868255||blood samples|"blood samples (Collection of human samples )will be collected prospectively for complementary functional analysis of peripheral These biological samples are affiliated with the biocollection hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
89082931|NCT00629187|Experimental|1|
89082932|NCT04291287||Triple antithrombotic therapy|patients taking Triple antithrombotic therapy (aspirin and a P2Y12 inhibitor, in addition to either a DOACs or warfarin/acenocumarol)
89082933|NCT04291287||Dual antithrombotic therapy|patients taking Dual antithrombotic therapy (aspirin or P2Y12 inhibitor in addition to either a DOACs or warfarin/acenocumarol)
89082934|NCT04291365|Other|Normal weight|
89082935|NCT04291365|Other|Obesity Class 1|
89082936|NCT04291365|Other|Obesity Class 2|
89082937|NCT04291365|Other|Obesity Class 3|
89082938|NCT00983385|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol immediate release (IR) tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
89082939|NCT02867475|Other|A|Physical activity motivation
89082940|NCT00992511|Experimental|GSK2340272A New 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
89082941|NCT00992511|Experimental|GSK2340272A New 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89082942|NCT00992511|Experimental|GSK2340272A INI 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
89082943|NCT00992511|Experimental|GSK2340272A INI 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the Initial process-manufactured (INI 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89082944|NCT02868177|Experimental|Totum-63|The studied active product is a food supplement formula in shape of capsule which contains Totum-63 (a patented mixture of dry extracts from 5 plants), active ingredient of Valedia
89082945|NCT02868177|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging in which all ingredients are replaced by maltodextrin.
89082946|NCT02868099|Placebo Comparator|Placebo|Subjects received placebo for injection treatment will be administered subcutaneously once a week
89082947|NCT02868099|Experimental|Drug|Subjects received Romiplostim for injection treatment will be administered subcutaneously once a week
89082948|NCT02868021|Placebo Comparator|NO-EX group|Subjects allocated to the No Exercise (NO-EX) group will undergo: Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function and Six-minute walk (SMW) test. Intra-op muscle biopsies.
89082949|NCT02868021|Experimental|EX-BFR group|Subjects allocated to the EX-BFR group will undergo baseline strength testing, Short Physical Performance Battery (SPPB), Numerical pain scale, Six-minute walk (SMW), Self-assessed function, and determination of 1 Repetition Maximum (1-RM). Blood flow restriction exercise, Borg Category Ratio 10 (Borg CR10) scale. Intra-op muscle biopsies.
89082950|NCT02868879||Schizophrenia|
89082951|NCT02868879||Normal controls.|
89082952|NCT02867319|Experimental|age of 18-50 years old|
89082953|NCT02867319|Experimental|age of 7-17 years old|
89082954|NCT02867319|Experimental|age of 2-6 years old|
89082955|NCT02869035|Experimental|Treatment of MDD patients|Treatment of MDD patients with escitalopram
89082956|NCT02869035|No Intervention|Healthy controls|No treatment.
89082957|NCT02869035|Experimental|Shift of treatment for MDD patients|Treatment of MDD patients with duloxetine
89082958|NCT02868957|Active Comparator|Impression data from reference scanner|desktop scanner was used as a reference scanner. According to the data of the manufacturer, the accuracy is less than 20 µm and the scan points more than 100,000.
89082959|NCT02868957|Experimental|Trios|"Trios is a scanner with real time rendering type adopting the confocal principle, and scans the object while showing the scanned area on a screen.~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of Trios intra-oral scanner."
89082960|NCT02868957|Experimental|iTero|"iTero captures teeth and periodontal soft tissue using a red laser beam and parallel confocal imaging technology. This system with a focal depth of 300 can capture up to 100,000 of laser points, and each of such laser points is separated at a 50 mm gap.~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of iTero intra-oral scanner."
89082961|NCT04290819|Experimental|Resistance Training with Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
89082962|NCT04290819|Experimental|Resistance Training with Caffeine|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
89082963|NCT04290819|Experimental|Resistance Training with Caffeine and Creatine Monohydrate|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
89082964|NCT04290819|Placebo Comparator|Resistance Training with Placebo|Participants will go through a 6 week resistance training program (unsupervised), at the facility of their choice. They will be given a program to follow with a 2 day on one day rest split routine as follows: Chest and biceps, legs and core, rest, back and triceps, shoulders and core, rest. This cycle will repeat for the 6 week program.
89082965|NCT02867943||respiratory rate is 10 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
89082966|NCT02867943||respiratory rate is 12 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
89082967|NCT02867943||respiratory rate is 14 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
89082968|NCT02867943||respiratory rate is 16 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
89082969|NCT01196429|Experimental|Treatment (paclitaxel, carboplatin, temsirolimus, docetaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV on days 1 and 8. Treatment repeats every 3 weeks for 6 courses. Patients then receive consolidation therapy comprising temsirolimus IV on days 1, 8, and 15. Treatment repeats every 3 weeks for 11 courses in the absence of disease progression or unacceptable toxicity.~NOTE: * For circumstances in which docetaxel should be substituted for paclitaxel, docetaxel is given IV over 1 hour."
89082970|NCT02887703|Experimental|Sensory Augmentation Group 1|Each subject in Group 1 will undergo 6 weeks of balance training with sensory augmentation followed by 6 weeks of balance training without sensory augmentation.
89082971|NCT02887703|Experimental|Sensory Augmentation Group 2|Each subject in Group 2 will undergo 6 weeks of balance training without sensory augmentation followed by 6 weeks of balance training with sensory augmentation.
89082972|NCT01157364|Other|bimatoprost 20 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
89082973|NCT01157364|Other|bimatoprost 15 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
89082974|NCT01157364|Other|bimatoprost 10 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
89082975|NCT01157364|Other|bimatoprost 6 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
89082976|NCT01157364|Other|bimatoprost 15 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
89082977|NCT01157364|Other|bimatoprost 10 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
89082978|NCT01195415|Experimental|Treatment (vismodegib, gemcitabine hydrochloride)|Patients receive vismodegib PO QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 (beginning in course 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89082979|NCT01195103|Experimental|10 mg/kg Lusedra|10 mg/kg Lusedra initial bolus.
89082980|NCT01195103|Active Comparator|6.5 mg/kg Lusedra|6.5 mg/kg Lusedra initial bolus.
89082981|NCT01195103|Active Comparator|Placebo + Midazolam|Placebo initial bolus with dose of midazolam based on patient's weight
89082982|NCT01194869|Experimental|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
89082983|NCT04317833|Experimental|Dose Escalation SSS17|Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15)
89082984|NCT04317833|Placebo Comparator|Escalation matching Placebo|Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15)
89082985|NCT01177800|Experimental|Infliximab|5 milligram per kilogram (mg/kg) infusion (a fluid or a medicine delivered into a vein by way of a needle) of infliximab administered intravenously (into a vein) at Week 0, 2 and 6 followed by maintenance regimen of 5 mg/kg infliximab at Week 14 and 22. Placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial infusion), matched to infliximab will be given at Week 10, 12 and 16. Total duration of treatment will be 26 weeks.
89082986|NCT01177800|Experimental|Placebo|Placebo infusion, matched to infliximab will be given intravenously at Week 0, 2 and 6. At Week 10, 12 and 16, participants will receive 5 mg/kg infliximab intravenously. Placebo infusion will be again given at Week 14 and 22. Total duration of treatment will be 26 weeks.
89082987|NCT01177722|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)|
89082988|NCT01177722|Experimental|Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)|
89082989|NCT01177722|Experimental|Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)|
89082990|NCT01177722|Active Comparator|Group 4: Active Control|
89082991|NCT02884986|Active Comparator|Etoricoxib|120mg of oral Etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
89082992|NCT02884986|Placebo Comparator|Placebo|120mg of oral Placebo the same amount as the drug administrated one hour prior to spinal anaesthesia induction
89082993|NCT01177410|Placebo Comparator|Placebo|
89082994|NCT01177410|Experimental|Mesalamine Granules 750 mg|
89082995|NCT01177410|Experimental|Mesalamine Granules 1500 mg|
89082996|NCT05264220|Experimental|ACT Matrix|Participants will each receive the ACT Matrix intervention. Participants will be randomised to multiple start dates, producing different baseline durations.
89082997|NCT01156116|Active Comparator|Continuous positive airway pressure|2 weeks of continuous positive airway pressure (CPAP) treatment which includes wearing the CPAP mask for 8 hours each night
89082998|NCT01156116|Placebo Comparator|Placebo|2 weeks of oral administration of a placebo tablet 30min before bedtime
89082999|NCT01155726|Active Comparator|Nelfilcon A, Masked, Unmasked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
89083000|NCT01155726|Active Comparator|Nelfilcon A, Masked, Partially Masked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
89083001|NCT01155726|Active Comparator|Etafilcon A, Masked, Unmasked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
89083002|NCT01155726|Active Comparator|Etafilcon A, Masked, Partially Masked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
89083003|NCT01155570||Humira|Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 80 mg.
89083004|NCT04205916|Experimental|Experimental Group|A total of 50 study subjects (50 eyes) will receive Dextenza dexamethasone intracanalicular insert placed in the lower punctum of their scheduled surgical eye at the time of surgery and will receive intracameral ketorolac during the procedure and 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure.
89083005|NCT04205916|Active Comparator|Control Group|A total of 50 study subjects (50 eyes) will receive topical moxifloxacin 0.5% qid 1 day prior to surgery and for ten days postoperatively, ketorolac 0.5% qid 1 day prior to surgery and for 1 month postoperatively, and prednisolone acetate 1.0% qid starting at the conclusion of cataract surgery for 2 weeks and bid for 2 weeks in their scheduled surgical eye.
89083006|NCT04315428||premature swaddled|the childs in this group will be wrap in a lange (swaddled)
89083007|NCT04315428||premature no swaddled|the childs in this group will be not swaddled
89083008|NCT04315662|Experimental|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
89083009|NCT04315662|Active Comparator|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
89083010|NCT01155024|Other|Traditional Socket First, then DM Socket|Initial fitting of a traditional diagnostic prosthetic socket in first intervention period and initial fitting of a direct manufactured prosthetic socket in the second intervention period
89083011|NCT01155024|Other|DM Socket First, then Traditional Socket|Initial fitting of a direct manufactured prosthetic socket in first intervention period and initial fitting of a traditional diagnostic prosthetic socket in the second intervention period
89083012|NCT01176240|Experimental|Droxidopa|droxidopa active drug
89083013|NCT01176240|Placebo Comparator|Placebo|Placebo matched control
89083014|NCT00988221|Experimental|Tocilizumab 10 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 10 mg/kg intravenously every 4 weeks.
89083015|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
89083016|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing ≥ 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
89083017|NCT00988221|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks.
89083018|NCT02884830|Placebo Comparator|Sham CPAP|Sham continuous positive airway pressure is a CPAP given at too low pressure to have any physiological effect on upper airways patency and on lung volumes
89083019|NCT02884830|Active Comparator|Efficace CPAP|Continuous positive airway pressure is a CPAP given at effective pressure to decrease the work of breathing in COPD patients
89083020|NCT01149096|Active Comparator|Arm I (conventional bone marrow harvest)|Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
89083021|NCT01149096|Experimental|Arm II (filgrastim, bone marrow harvest)|Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
89083022|NCT02867397|Other|Teysuno (S1) in combination with epirubicin and oxaliplatin|
89083023|NCT04291053|Experimental|experimental group|Standard therapy+Huaier granule Huaier granule 20g, po, tid for 2 weeks( or until discharge)
89083024|NCT04291053|No Intervention|control group|standard therapy
89083025|NCT02884518|Experimental|patient group|The patient group recruits subjects diagnosed with first episode psychosis which occurred within 2 years and having been treated with antipsychotics for 1 year. Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity. And patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
89083026|NCT02884518|Other|healthy control group|Screening tests for healthy volunteers included physical examination, vital signs, laboratory will test (hematology, blood chemistry, and urinalysis), and a 12-lead electrocardiograms. A psychiatric interview with the Structured Clinical Interview for text revision of the Diagnostic and Statistical Manual of Mental Disorders -IV(DSM-IV-TR) Axis I disorders, Research Version, Nonpatient Edition (SCID-I/NP) (First et al. 2002) will be conducted. Subjects with any medically significant abnormality on investigations and/or psychiatric disease will be excluded. Also, healthy control group will take a PET scan at 0, 2, 4, 6, and 8 week and clinical scales at baseline.
89083027|NCT02866851|Experimental|Monitoring by Web application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
89083028|NCT01175382|Active Comparator|Behavioral Treatment alone|Behavioral treatment is implemented in 4 clinic visits over a period of 6 weeks, followed by 6 weeks of combined behavioral + drug therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and daily bladder diaries, supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
89083029|NCT01175382|Active Comparator|Drug Therapy (Tolterodine + tamsulosin)|Drug therapy for 6 weeks implemented in a clinic visit with telephone follow-up at 3 weeks, followed by 6 weeks of combined drug + behavioral therapy. Participants in the drug group will receive an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
89083030|NCT01175382|Experimental|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
89083031|NCT01194245|Experimental|Lispro-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
89083032|NCT01194245|Experimental|Aspart-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
89083033|NCT02887547|No Intervention|Control|Control group, with traditional orthodontic mechanics for anterior retraction. Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
89083034|NCT02887547|Experimental|Acceleration|Group with micro-osteoperforation for accelerated tooth movement during anterior retraction, Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
89083035|NCT00979407|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89083036|NCT00979407|Experimental|GSK2340274A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
89083037|NCT01148862|Other|Group A|Group A will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature activated
89083038|NCT01148862|Other|Group B|Group B will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature deactivated
89230157|NCT00788879|Experimental|1|This study arm is located in Brownsville, Texas. This community is exposed to the TSSC media messages as well as may be visited by the lay health workers and see the built environment changes
89083039|NCT02884674|Active Comparator|active Transcranial Magnetic Stimulation|Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, Using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
89083040|NCT02884674|Placebo Comparator|Placebo|Placebo comparator, using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
89083041|NCT02866773|Experimental|PA1:Education sessions, Reminders, Whataps group|The intervention includes Physical activity knowledge enhancement session, Physical activity anti-inertia Reminders , Physical activity ambassadors' electronic communication group.
89083042|NCT02866773|Active Comparator|PA2:Education sessions, Reminders|The intervention includes Physical activity knowledge enhancement session and Physical activity anti-inertia Reminders
89083043|NCT02866773|Active Comparator|PA3:Education sessions, Whataps group|The intervention includes Physical activity knowledge enhancement session and Physical activity ambassadors' electronic communication group.
89083044|NCT02866773|Active Comparator|PA4:Education sessions|The intervention includes Physical activity knowledge enhancement session only.
89083045|NCT02866773|Experimental|HD1:Education sessions, Reminders, Whataps group|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , Health diet ambassadors' electronic communication group.
89083046|NCT02866773|Active Comparator|HD2:Education sessions, Reminders|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , and Health diet ambassadors' electronic communication group.
89083047|NCT02866773|Active Comparator|HD3:Education sessions, Whataps group|The intervention includes Health diet knowledge enhancement session and Health diet ambassadors' electronic communication group.
89083048|NCT02866773|Active Comparator|HD4:Education sessions|The intervention includes Health diet knowledge enhancement session only.
89083049|NCT00975975|Experimental|Basiliximab|Basiliximab will be given by IV on Day +7 post transplant for recipients of matched unrelated cells. Basiliximab will be given by IV on Day +9 post transplant for recipients of matched related cells.
89083050|NCT01193153|Experimental|001|paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
89083051|NCT01193153|Placebo Comparator|002|Placebo monthly by i.m. injection for 15 months
89083052|NCT02867007|Experimental|KHK2455 + Mogamulizumab|"Part 1 (Dose Escalation Part): Will identify the MTD for the KHK2455 monotherapy run-in and for the combination regimen (KHK2455 monotherapy [Cycle 0] followed by KHK2455 +mogamulizumab combination [Cycle 1]).~Part 2 (Expansion Part): Subjects with a selected tumor type will be enrolled and treated with the recommended dose of KHK2455 established in Part 1 in combination with mogamulizumab."
89083053|NCT04289883|Experimental|High molecular weight whey protein-alginate/Calcium alginate|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
89083054|NCT04289883|Experimental|Nano-particulated whey protein/Non-particulated whey protein|"Produced from whey protein with different structures (nano-particulated vs. non-particulated whey proteins and high molecular weight whey protein-alginate coacervates vs. calcium alginate) added cream, sucrose and lactose in order for the products to contain all macronutrients and in equal amounts between the intervention and the control products. Additionally, vanilla flavour (Dr. Oetker vanilla extract) is added in order for the test products to taste similar to koldskål (a well-known Danish food). All test products will be produced in the dairy pilot plant at Department of Food Science at University of Copenhagen prior to performance of the appetite probe days. All test products will have a pH of 4 and will be manufactured from dry (powdered) ingredients and pasteurized cream. They will be kept refrigerated for a maximum of 3 days prior to use and production will be planned accordingly."
89083055|NCT04289727||Group 1|Those with Type 1 Diabetes.
89083056|NCT04289727||Group 2|Those without Type 1 Diabetes.
89083057|NCT04289337|Experimental|Combined probiotics (1)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
89083058|NCT04289337|Experimental|Combined probiotics (2)|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66.
89083059|NCT04289337|Experimental|Combined heat-killed probiotics (1)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus paracasei ET-66.
89083060|NCT04289337|Experimental|Combined heat-killed probiotics (2)|Combined heat-killed Lactobacillus salivarius subsp. salicinius AP-32 and Lactobacillus paracasei ET-66.
89083061|NCT04289337|Experimental|Probiotic metabolites|Combined Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus plantarum LPL28 and Lactobacillus paracasei ET-66 metabolites.
89083062|NCT04289337|Placebo Comparator|Placebo|Does not contain probiotics, heat-killed probiotics and related metabolites.
89083063|NCT02865369||Daclatasvir plus Asunaprevir treatment|Among patients taking Daclatasvir and Asunaprevir combined treatment and having advanced liver fibrosis assessed by transient elastography
89083064|NCT04290585|Experimental|Health Services Research (text message reminder)|Patients receive 1-2 text messages a few weeks before and 1 text message 24 hours before their mammography screening appointment. Patients also receive a phone call reminder as per standard practice.
89083065|NCT01192295|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride (HCl) controlled-release (CR)
89083066|NCT02866929|Active Comparator|Conventional orthodontic treatment|Patients that will receive conventional orthodontics
89083067|NCT02866929|Experimental|Orthodontics with decortication|Patients that will receive orthodontic treatment with selective alveolar decortication
89083068|NCT02866929|Experimental|Orthodontics decortication and Mucograft|Orthodontic treatment, selective alveolar decortication and Mucograft® on the mandibular anterior segment
89083069|NCT02866929|Experimental|Orthodontics and Mucograft®|Patients that will receive orthodontic treatment and Mucograft® on the mandibular anterior segment
89083070|NCT04289181|Experimental|Medically Tailored Meals (MTM)|Participants randomized to the MTM arm will receive MTM for 4 weeks. Meals will be prepared and delivered by Meals on Wheels, a non-profit organization that has been delivering meals to seniors nationwide for decades. Meals on Wheels will deliver 21 complete meals to the patient's home each week. They can accommodate a wide range of patient needs and preferences (e.g., low sodium, gluten-free, no pork products, cultural preferences). Meals on Wheels will contact the patient directly to set up an initial assessment phone call to collect relevant data (e.g., specific patient goals for their HF) and to set up a delivery schedule. Nearing the 4-week mark when meal delivery ends, investigators will check-in with each participant to track progress, assess treatment fidelity and answer any questions. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
89083071|NCT04289181|No Intervention|Usual Care|Patients in this arm will receive usual services offered at Jefferson for patients with HF. This includes regular visits with a HF provider (primary care or cardiology), standard nutrition teaching, medication optimization and post discharge support. During routine office visits, providers reinforce messages about self-management and provide lists of local and national resources related to nutrition and HF self-management. These services follow guideline directed medical therapy. All patients will receive information on community resources (e.g., food pantries, food banks) in the area.
89083072|NCT02865291|Experimental|ForConti device|Use the device up to 12 hours/day for 4 weeks
89083073|NCT04317365|Active Comparator|patients receiving remembering|
89083074|NCT04317365|No Intervention|patients not receiving extra remembering|
89083075|NCT04289103|Experimental|Inolimomab/Leukotac|"Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~Treatment phase - Leukotac will be given up to D28~Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion"
89083076|NCT01154166|Experimental|ReQuip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
89083077|NCT01154166|Placebo Comparator|Placebo|Placebo
89083078|NCT04290195|Experimental|ziv aflibercept patients|20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO
89083079|NCT05656937|Experimental|Oblique orientation|cannulation will be oblique approach
89083080|NCT05656937|Active Comparator|transverse approach|cannulation will be transverse approach
89083081|NCT02865603|Experimental|PAX Good Behavior Game|The intervention is delivered by teachers within the normal school curriculum. Teachers from intervention classes completed 3-day training and were supported by the mentor, who visited their class during the 2016/17 school year and provided counseling via e-mail and phone. During the second year (2017/18) teachers could use the PAX GBG methods, but they did not receive additional support from the mentors.
89083082|NCT02865603|No Intervention|Waitlist control group|Control group continue their normal activities without intervention. After a post-test assessment in spring 2018 the control group teachers will be trained and supported to implement PAX GBG.
89083083|NCT05656859||Study group|Descriptive study
89083084|NCT04289259||Biopsy sample|Tumor mutational burden (TMB) will be assessed on a sample of the biopsy done during standard care of patients.
89083085|NCT04289259||Surgical sample|TMB will be assessed on a sample of the tumor surgical specimen resected during standard care of patients.
89083086|NCT04289259||Biopsy sample + surgical sample|TMB will be assessed both on a sample of the biopsy and a sample of the tumor surgical specimen resected during standard care of patients.
89083087|NCT04313556|Other|Lateral patellar release|Arthroscopic lateral patellar retinacular release
89230158|NCT00788879|No Intervention|2|The control group is located in Laredo. This community is not exposed to the TSSC messages nor does the campaign work to actively change the built environment or use lay health workers to share physical activity and nutrition information.
89225406|NCT05742711|Sham Comparator|Control Group|The group who have received a sham device along with Injection paracetamol in a dosage of 15mg/kg every 6th hourly. Break through pain with NRS>4 will be managed with injection tramadol at 1mg/kg followed by 0.5mg/kg after 10mins in cases of persisting pain.
89225407|NCT05738278|Experimental|Intervention group|After 2 weeks mapping phase, patient-specific HR-informed intervention from week 3.
89225408|NCT05738278|Active Comparator|Control group|After 4 weeks mapping phase, patient-specific HR-informed intervention from week 5.
89225409|NCT05737979||Women undergoing IVF|Women undergoing an antagonist in vitro fertilization cycle using Rekovelle and Menopur for stimulation
89225410|NCT05736107|Experimental|CBL-514 Injection|Participant will receive CBL-514 2 mg/cm² administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to a maximum of 4 treatments.
89225411|NCT05736107|Placebo Comparator|0.9% Sodium Chloride|Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to a maximum of 4 treatments.
89225412|NCT05735899||Core Treatment Group|This is the only group in this study. Participants will receive full standard of care meniscal repair, followed by assessment interventions- ultrasound, MRI, and physical assessment to document healing progress. Participants will return for standard of care post-operative visits with the physician- 6 weeks, 6 months, and 1 year after the operation is performed- at which point the aforementioned interventions will be completed.
89225413|NCT05735236|No Intervention|Control|Participants undergo standard post-operative physical therapy as prescribed by their surgeon.
89225414|NCT05735236|Active Comparator|BFR Cuff|Patients undergo standard post-operative physical therapy as prescribed by their surgeon with the addition of a Blood Flow Restriction (BFR) cuff that is used during their exercises.
89225415|NCT05735041|Experimental|Cognitive digital therapy group|Computer-based cognitive training for 30 minutes at least 5 times a week for 12 weeks; At the end of the 12 weeks, the subjects were randomly divided into two groups. One group continued the training for 12 weeks, at least five times a week for 30 minutes each time, and the other group stopped the training.
89083088|NCT04119531||Patients with insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
89083089|NCT04119531||Patients without insomnia|In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
89083090|NCT05656703|Experimental|Bis Guided light anesthesia|Patients are monitored by bispectral index and held under light anesthesia (BIS level 45 to 60)
89083091|NCT05656703|Placebo Comparator|Standard of Care|Patients receive standard of care anesthesia, BIS monitor was covered with a blind
89083092|NCT02866617|Experimental|Conventional|T1-T2 : VFR constructed on conventional study model T2-T3 : VFR constructed on 3D reconstructed study model
89083093|NCT02866617|Experimental|3D|T1-T2 : VFR constructed on 3D reconstructed study model T2-T3 :VFR constructed on conventional study model
89083094|NCT00624611|Active Comparator|1|Residual pump blood management post aortic cannula removal
89083095|NCT00624611|Experimental|2|Residual pump blood management post aortic cannula removal
89225416|NCT05735041|Active Comparator|Positive control group|Computer-based cognitive training tasks with low or no difficulty variation for 30 minutes at least five times a week for 12 weeks
89230159|NCT00796601|Experimental|Esreboxetine|
89083096|NCT02865213|Experimental|Miniplates + OBA|"The intrusion of posterior teeth using Miniplates + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniplates.~The miniplates are for Jeil Dual top® anchor system, Jeil medical corporation, #702,kolon science valley 2nd, 811, Guro-Dong, Guro-Gu, Seoul, 152-050, Korea. Tel: 82.2.850.3500. Fax: 82.2.850.3537. homepage: www.jeilmed.co.kr/ E-mail: mktg@jeilmed.co.kr"
89083097|NCT02865213|Experimental|Miniscrews + OBA|"The intrusion of posterior teeth using Miniscrews + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniscrews.~The miniscrews are for Denxy ® dental orthodontic products, Denxy technology co, limited . 404,Lihuabuilding,Furongroad, Changsha, Hunan, China. Tel: 0086-731-89717339. Fax: 0086-731-82237315. Homepage: www.denxy-orthodontic.com/email: DENXYDENTALBOSS@126.COM"
89083098|NCT02865213|Experimental|Only OBA|The intrusion of posterior teeth using OBA only will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth only.
89083099|NCT05656079|Experimental|pegylated liposomal doxorubicin；cyclophosphamide；trastuzumab；pertuzumab ；docetaxel|"Pegylated liposomal doxorubicin 35 mg/m2, i.v. d1 +Cyclophosphamide 600 mg/m2 , i.v. d1 +Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg), i.v. d1+Pertuzumab (840 mg loading dose at first day only, then 420 mg), i.v. d1 ； q3w, for 4 cycles followed by Docetaxel 75mg/m2 , i.v. d1+ Pertuzumab 420 mg, i.v. d1+Trastuzumab 6 mg/kg, i.v. d1； q3w, for 4 cycles.~After the completion of adjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab combined with pertuzumab."
89083100|NCT05656079|Active Comparator|Epirubicin；cyclophosphamide f；docetaxel；trastuzumab；pertuzumab|"Epirubicin 90 mg/m2 , i.v. d1 +Cyclophosphamide 600 mg/m2 , i.v. d1； q3w, for 4 cycles followed by Docetaxel 75mg/m2 , i.v. d1+Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg), i.v. d1+Pertuzumab (840 mg loading dose at first day only, then 420 mg), i.v. d1； q3w, for 4 cycles.~After the completion of adjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab combined with pertuzumab."
89083101|NCT00975585|Active Comparator|senofilcon A both eyes|soft contact lens worn daily for 2 weeks, with a 2-week replacement regimen.
89083102|NCT00975585|Active Comparator|lotrafilcon B both eyes|soft contact lens worn daily for 4 weeks, with a 4-week replacement regimen
89083103|NCT01181921|Experimental|Galantamine|
89083104|NCT02883894||bullous pemphigoid|Patients with bullous pemphigoid.
89083105|NCT05655923|Placebo Comparator|Group I|ten patients will be subjected to place bone substitute mixed with Olive oil in intra bony defect. ( Control group)
89083106|NCT05655923|Active Comparator|Group II|ten patients will be subjected to place bone substitute mixed with ozonated olive oil in intra bony defect without further application of ozonated oil.
89083107|NCT05655923|Active Comparator|Group III|ten patients will be subjected to place bone substitute mixed with ozonated olive oil in intra bony defect with further weekly application of ozonated olive oil until third week
89083108|NCT02867241|Experimental|Intervention|"Motivational interviews (3 visits) + supportive phone calls~Feedback of child hair nicotine levels~Feedback of home air quality (PM2.5)~New Media (Website and/or Facebook with information and parental forum)"
89083109|NCT02867241|Other|Control Regular|This group will get no intervention during the study period. Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
89083110|NCT02867241|Other|Control Expanded|This group will get no intervention during the study period. However, participants will fill out a detailed questionnaire on parental perceptions of exposure and risk, as well as questions on social norms, self-efficacy, and knowledge Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
89083111|NCT02867085||Group 1 (MDS group)|
89083112|NCT02867085||Group 2 (control group)|
89083113|NCT04317443||Super-Mini Percutaneous Nephrolithotomy|Patients undergo SMP
89083114|NCT04317443||Extracorporeal Shock Wave Lithotripsy|Patients undergo ESWL
89083115|NCT01174446|Experimental|BAX 326|Recombinant factor IX (rFIX)
89083116|NCT01174446|Active Comparator|BeneFIX|Recombinant Factor IX (rFIX)
89083117|NCT00932698|Experimental|Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2|Ixazomib 0.24 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).
89083118|NCT00932698|Experimental|Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2|Ixazomib 0.48 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).
89083119|NCT00932698|Experimental|Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2|Ixazomib 0.8 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).
89083120|NCT00932698|Experimental|Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2|Ixazomib 1.2 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).
89083121|NCT00932698|Experimental|Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2|Ixazomib 1.68 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).
89083122|NCT00932698|Experimental|Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).
89083123|NCT00932698|Experimental|Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2|Ixazomib 2.23 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).
89225417|NCT05733208|Experimental|Remote ischemic preconditioning|Transient ischemic ischemia consisting of 5-minute ischemia followed by 5-minute perfusion will occur on the upper arm
89225418|NCT05733208|Sham Comparator|Sham-remote ischemic preconditioning|Transient ischemic ischemia will not actually occur on the upper arm
89230160|NCT00796601|Placebo Comparator|Placebo|
89083124|NCT00932698|Experimental|Relapsed and Refractory Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).
89083125|NCT00932698|Experimental|Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after >=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).
89083126|NCT00932698|Experimental|Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after >=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).
89083127|NCT00932698|Experimental|Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).
89083128|NCT00978627|Experimental|IDegAsp OD|
89083129|NCT00978627|Active Comparator|IDet|
89083130|NCT01181609|Experimental|1|
89083131|NCT01154010|Active Comparator|Active Device|"ActiPatch, a device that emits a low frequency energy called pulsed electromagnetic field (PEMF), will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids."
89083132|NCT01154010|Placebo Comparator|Placebo Device|Patients wear the PEMF placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
89083133|NCT02866305|Experimental|HRCT with bullae, treatment conservative|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
89083134|NCT02866305|Experimental|HRCT no bullae, treatment conservative|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
89083135|NCT02866305|Experimental|HRCT with bullae, treatment VATS.|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
89083136|NCT02866305|Experimental|HRCT no bullae, treatment VATS.|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
89083137|NCT04261426|Experimental|IVIG therapy+ standard care|
89083138|NCT04261426|Placebo Comparator|Standard care|
89083139|NCT04264078|Experimental|anti-CD7 UCAR-T cells|After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD7 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
89083140|NCT00608218||Artist|
89083141|NCT01174368|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
89083142|NCT02884050|Experimental|Topiramate|single, 100mg oral dose of topiramate
89083143|NCT02884050|Placebo Comparator|Placebo|matched inactive placebo
89083144|NCT00609934|Experimental|Sorafenib and palliative radiotherapy|
89083145|NCT00608296||1|Study subjects on lithium
89083146|NCT00608296||2|study subjects on quetiapine
89083147|NCT01147926|Placebo Comparator|Placebo|Placebo
89083148|NCT01147926|Active Comparator|Prucalopride|1 milligram (mg) or 2 mg
89083149|NCT05115136|Experimental|Doxepin|25mg PO one time
89083150|NCT05115136|Active Comparator|Diphenhydramine|50mg PO one time
89083151|NCT00975507|Experimental|1|ProQuad™ (V221) + Placebo Followed by ProQuad™
89083152|NCT00975507|Active Comparator|2|M-M-R™ II + VARIVAX™
89083153|NCT00625014|Experimental|1|Healthy men
89083154|NCT04083339|Experimental|AT-001 High dose|The total daily doses will be of 3g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 3g/day of AT-001 is capable of producing the maximum inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
89083155|NCT04083339|Experimental|AT-001 Low Dose|The total daily doses will be of 2g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 2g/day of AT-001 is capable of producing a sufficient inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
89083156|NCT04083339|Placebo Comparator|Placebo Comparator|Placebo capsules will be used as comparator
89083157|NCT01147848|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks
89083158|NCT01147848|Active Comparator|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks
89083159|NCT00610090|Experimental|Treatment - UniFit AAA Stent Graft|
89083160|NCT00606658|Other|Oil dripping therapy|Single Arm
89083161|NCT02864823|Experimental|Perichondrium|Perichondrium Autografts
89083162|NCT00929656|Experimental|Real rTMS|Real rTMS + unimanual paretic UE training
89083163|NCT00929656|Active Comparator|Sham rTMS|Sham rTMS + unimanual paretic UE training
89083164|NCT02866539|Active Comparator|Polyherbal capsule|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
89083165|NCT02866539|Placebo Comparator|Placebo|Placebo will contain an inert substance
89083166|NCT04261270|Experimental|ASC09F+Oseltamivir|
89083167|NCT04261270|Experimental|Ritonavir+Oseltamivir|
89083168|NCT04261270|Experimental|Oseltamivir|
89083169|NCT00977613|Other|life style counseling|Treated stage 2 and 3 colorectal cancer patients were counseled to exercise at least to the equivalent of 18 metabolic hours per week and were assessed over 6 months.
89083170|NCT01152996|Experimental|Vortioxetine|Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.
89083171|NCT04265716|Active Comparator|L. reuteri|Topical administration of ointment with L. reuteri DSM17938, rubbed into skin twice per day
89083172|NCT04265716|Placebo Comparator|Placebo|Rubbed into skin twice per day
89083173|NCT00606736||patients|subjects with right ventricular outflow tract arrhythmia
89083174|NCT00606736||control|subjects ,age match,healthy
89083175|NCT00608452||1|
89083176|NCT00624936|Experimental|Vidaza and Velcade|Vidaza 75mg/m2 IV over 30 min daily on days 1-7 This dose is the same for all dose levels. Velcade will be given immediately after Vidaza is completed at one of the following dose levels: 1, 2, 3, 4
89083177|NCT00979953|Experimental|ADL5859|One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days
89083178|NCT00979953|Experimental|ADL5747|One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days
89083179|NCT00979953|Active Comparator|Oxycodone CR|"One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4~One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14"
89083180|NCT00979953|Placebo Comparator|Placebo|Four placebo capsules administered orally BID for 14 days
89083181|NCT05086198|Experimental|Mindfulness-based intervention (MBI)|A 8-week mindfulness-based intervention. From 15 to 30 minutes of practice per session, three times/week through audio guided meditations.
89083182|NCT05086198|Active Comparator|Physical exercise (PE)|A 8-week physical exercise intervention. From 15 to 30 minutes of practice per session, three times/week through workout videos.
89083183|NCT05086198|No Intervention|Wait list (WL)|The participants will continue their work activity as usual. This arm will receive one of the two previous interventions once the study finished.
89083184|NCT01181531|Active Comparator|Traditional Vitamin D Therapy|
89083185|NCT01181531|Experimental|Cinacalcet|
89083186|NCT01152450|Experimental|Tiotropium daily dose q.d.|two actuations delivered via Respimat® inhaler
89083187|NCT01152450|Experimental|Tiotropium half daily dose b.i.d.|two actuations delivered via Respimat® inhaler
89083188|NCT01152450|Placebo Comparator|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
89083189|NCT05085262||Mild Disease|Those assessed as an outpatient or discharged from the emergency department and never admitted elsewhere based on patient history
89083190|NCT05085262||Moderate Disease|Those admitted but never requiring transfer to ICU or similar advanced care setting
89083191|NCT05085262||Severe Disease|Those requiring admission to ICU or other advanced care settings (i.e. other Level 2 beds)
89083192|NCT05085262||Control Group|Those with a negative COVID-19 and no history of COVID-19
89083193|NCT00610246|Experimental|Sorafenib and Radiation|Eligible patients (not candidates for curative treatment) will have measurable lesions in the anatomic thorax, abdomen or pelvis (any histology) amenable to palliative radiation treatment (30 Gy in 10 fractions). Patients receive sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. If full oral dose (400 mg po bid) is reached in a given cohort (dose level three) then an additional dose level will open where sorafenib treatment (400 mg bid) is extended following radiation for a total of eight weeks.
89083194|NCT04265560|Experimental|Progressive Resistance Training|"The intervention group will receive 8 weeks of Progressive Resistance Training (PRT), twice a week, in addition to usual care. An upper limb functional goal will be identified through discussion with the researcher and the participant. PRT will be individually tailored to target two muscle groups and will be chosen in order to develop strength to progress towards the participants functional goal.~The chronic spinal cord injury exercise guideline parameters will be applied (3 sets of 8-10 repetitions, 1-2 mins rest between sets). Participants will be inducted to their PRT programme and will then independently complete the 8 week programme. During each of the following sessions, assistance for set up of equipment and/or limb position will be given by the researcher and/or the participants family, friend or carer, once they have been trained. PRT sessions will be recorded in a diary to monitor sets and repetitions completed, and intensity (visual analogue scale (VAS))."
89083195|NCT04265560|No Intervention|Usual care only|Participants will continue with their usual care, consistent with standard National Health Service (NHS) care in this population. Usual physiotherapy care is provided, up to 2 times per day, 4 to 5 days per week, each lasting up to 90 minutes. Physiotherapists provide a combination of group exercise and one to one function-orientated physiotherapy sessions to improve balance, general muscle strength, wheelchair and/or transfer skills.
89083196|NCT01181141|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery
89083197|NCT01181141|Active Comparator|Enoxaparin sodium|Enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
89083198|NCT01173120|Experimental|Abatacept Combination Product (ACP)|Participants from the long-term period of study NCT00559585 who enrolled in the ACP substudy switched to administration of subcutaneous (SC) abatacept via the ACP for the duration of the substudy. Abatacept was administered SC using the ACP by the participant or caregiver on Substudy Day 1 and at weekly intervals thereafter. The ACP was a pre-filled liquid product device delivering 125 mg abatacept/device (125 mg/mL).
89083199|NCT05332691|Experimental|Hypertrophic Obstructive Cardiomyopathy|Transapical beating-heart septal myectomy for the patient with hypertrophic obstructive cardiomyopathy.
89083200|NCT00977379|Active Comparator|WBRT Followed by Standard of Care|Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system [CNS] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).
89083201|NCT00977379|Experimental|WBRT+Capecitabine Followed by Capecitabine Maintenance|Participants will receive 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) concurrent with capecitabine 825 milligrams per square meter (mg/m^2) orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by capecitabine 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2, one week after completion of WBRT and continuing until the halting of capecitabine for any reason (CNS or extra-cranial progression, unacceptable toxicity, withdrawal of participant consent or death).
89083202|NCT04263844|Active Comparator|Dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine 1 mcg/kgBB thirty minutes before induction
89083203|NCT04263844|Active Comparator|Midazolam|subject will receive premedication with intranasal midazolam 0,1 mg/kgBB thirty minutes before induction
89083204|NCT01180985|Other|galyfilcon A prototype/comfilcon A|The galyfilcon A prototype lenses are worn during first period and comfilcon A lenses worn during second period. Each period consists of daily lens wear for one week.
89083205|NCT01180985|Other|comfilcon A/galyfilcon A prototype|The comfilcon A lenses are worn during first period and galyfilcon A prototype lenses worn during second period. Each period consists of daily lens wear for one week.
89083206|NCT00610324|Experimental|1|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
89083207|NCT00610324|Active Comparator|2|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
89083208|NCT01147536|Experimental|HSPPC-96 Vaccine|Participants will receive up to 8 administrations of HSPPC-96 25 µg intradermally over 3 months (4 weekly doses, followed by 4 bi-weekly doses [at Weeks 14, 15, 16, 17 19, 21, 23, and 25 in Part 1a and at Weeks 1-4, 6, 8, 10, 12 in Part 1b). Participants will remain untreated with HSPPC-96 for the initial 3-month period in Part 1a for immune monitoring blood draw.
89083209|NCT01154088|Experimental|Group A|
89083210|NCT01154088|Experimental|Group B|
89083211|NCT01154088|Active Comparator|Group C|
89083212|NCT02864901|Experimental|KSL-W 30 mg|3 times per day over 4 treatment days
89083213|NCT02864901|Placebo Comparator|Chewing Gum Placebo|3 times per day over 4 treatment days
89083214|NCT04288791|Experimental|Equia Forte Fil|
89083215|NCT04288791|Experimental|Zirconomer Improved|
89083216|NCT04260724|Active Comparator|TMS group|Transcranial magnetic stimulation for four weeks
89083217|NCT04260724|Sham Comparator|Sham group|sham coil stimulation for four weeks (Although the sound of sham coil is the same to that of real TMS during intervension, no stimulation is applied. )
89083218|NCT04313322|Experimental|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
89083219|NCT02884128|Experimental|PEP02 + 5-FU/LV|The initial starting dose of PEP02 is 60 mg/m2, and was escalated by increments of 20 mg/m2 between dose levels. 5-FU and LV were given as 24-hour infusion via an implanted central venous catheter, with dose fixed at 2000 mg/m2 and 200 mg/m2, respectively. PEP02 was administered on Day 1; 5-FU/LV was started after the end of PEP02 infusion on Day 1 and also on Day 8.
89083220|NCT00629343|Experimental|Treatment|
89083221|NCT02864745|Experimental|Early rehabilitation arm|These patients will receive very early (<48 hours after ICU admission), protocolised, intensive rehabilitation, which will include functional electrical stimulation-assisted cycle ergometry.
89083222|NCT02864745|Active Comparator|Standard-of-care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
89083223|NCT01180049|Active Comparator|temsirolimus (Torisel) 175mg weekly x 3, then 75mg weekly|
89083224|NCT01180049|Active Comparator|temsirolimus (Torisel) 75mg weekly|
89083225|NCT01147458|Experimental|PF-04191834 followed by placebo|PF-04191834 600 mg BID dose followed by matched placebo plus naproxen placebo.
89083226|NCT01147458|Experimental|Placebo followed by PF-04191834|Placebo followed by 600 mg BID dose of PF-04191834 plus naproxen placebo.
89083227|NCT01147458|Experimental|PF-04191834+Naproxen followed by Naproxen|PF-04191834 600 mg BID + Naproxen 500 mg BID followed by Naproxen 500 mg BID plus PF-04191834 placebo
89083228|NCT01147458|Experimental|Naproxen followed by PF-04191834+Naproxen|Naproxen 500 mg BID followed by PF-04191834 600 mg BID + Naproxen 500 mg BID
89083229|NCT01172808|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
89083230|NCT01172808|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
89083231|NCT01172808|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
89083232|NCT01172808|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
89083233|NCT04315194||clarithromycin-naproxen-oseltamivir|Efficacy of clarithromycin-naproxen-oseltamivir combination therapy vs. oseltamivir alone for hospitalised paediatric influenza patients
89083234|NCT01151280|Experimental|WallFlex Biliary Fully Covered Stent|All eligible patients entered into the study will be treated with a WallFlex Biliary Fully Covered Stent
89083235|NCT01149486|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
89083236|NCT01149486|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
89083237|NCT02551315||Type 2 diabetics, no fractures|Postmenopausal women and men with T2DM, without prevalent fragility fractures (longitudinal follow-up)
89083238|NCT02551315||Type 2 diabetics, prevalent fractures|Postmenopausal women and men with T2DM, with prevalent fragility fractures
89083239|NCT02551315||Controls, no fractures|Age and sex-matched non-diabetic controls, without fragility fractures (longitudinal follow-up)
89083240|NCT02551315||Controls, prevalent fractures|Age and sex-matched non-diabetic controls
89083241|NCT00601705|Experimental|Epirubicin, Oxaliplatin and Fluorouracil|
89083242|NCT02680093||Cervical length in pregnant women.|"Pregnant Women beyond the date of birth in conservative monitoring and prenatal follow-up. will be followed while coming to routine monitoring.~physiological parameter of cervical length will be measured as the differential predictor to determine their due date."
89083243|NCT01179737|Experimental|Nilotinib|Participants in cohort 1 were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days. Participants in cohort 2 were assigned to receive nilotinib 300 mg during 168 days
89083244|NCT01179737|Placebo Comparator|Placebo|Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.
89083245|NCT02679859|Experimental|B-type natriuretic guided medical therapy optimisation|B-type natriuretic guided medical therapy optimisation
89083246|NCT02679859|No Intervention|Normal medical management|
89083247|NCT05664529||healthy children aged 6-36 months|120 healthy children with or without any feeding difficulties reported by the mothers will be included. A 20-minute videotaped feeding session will be evaluated by Chatoor Feeding Scale to examine mother-infant relationship during feeding.
89083248|NCT03125083|Experimental|skin-restricted lupus (SRL) patients|Role of inflammation in psychiatric disorders in patients with cutaneous lupus
89083249|NCT00641173|Experimental|1|paroxetine v placebo
89083250|NCT00641173|Placebo Comparator|2|placebo
89083251|NCT05664373|Active Comparator|extraoraly de-epithelialized free gingival graft in combination with CAF|Epithelium will be removed after harvesting the graft by using the blade. By using the blade the epithelium will be separated from the connective tissue.
89083252|NCT05664373|Experimental|intraoraly de-epithelialized free gingival graft in combination with CAF|The epithelium will be removed prior to harvesting the graft from the palate. By using a diamond bur the epithelium will be removed until the connective tissue is exposed on the whole area of the intended graft size. Thereafter, the graft will be harvested.
89083253|NCT02679703|Experimental|High voltage|The applied parameters of high voltage electrical stimulation are medium voltage of 100 volts, an increase in the course of the session, frequency of 10 Hz, with application in the donor areas of thigh or scalp for 40 minutes, 25% above of level engine daily until complete epithelialization, and removal of the dressing type rayon.
89083254|NCT02679703|Experimental|Neuromuscular transcutaneous electrical stimulation (TENS)|10 Hz, 40 min, 200 μs and 25% above of motor level
89083255|NCT02679703|Experimental|Control Group|There will be no intervention
89230161|NCT00796679|Experimental|1|paricalcitol
89230162|NCT00796679|Placebo Comparator|2|placebo
89230163|NCT02554643|Experimental|Diet & Soccer|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Soccer training, 3 times a week, during 12 weeks"
89083256|NCT02681965|Experimental|LEAN|Participants randomized to the weight loss program will initially receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity. Written instructions in the LEAN book will include recording daily diet and exercise in the logs. At the end of the study, participants will return, via a stamped addressed envelope, the logs to the study office so compliance can be assessed.
89083257|NCT02681965|No Intervention|Waitlist Control|Participants randomized to the waitlist control study arm will be mailed the six-month questionnaires, which will include reporting of weight. On return of the 6-month questionnaires each woman will be provided with the entire weight loss program packet.
89083258|NCT00929110|Experimental|Glycopyrronium bromide 50 μg|Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89083259|NCT00929110|Placebo Comparator|Placebo to glycopyrronium bromide|Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89083260|NCT00929110|Active Comparator|Tiotropium 18 μg|Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89083261|NCT00922519||1|
89083262|NCT00640549|Placebo Comparator|2|
89083263|NCT00640549|Active Comparator|1|
89083264|NCT02683369|Experimental|Iron Supplement|Participants will consume one tablet of Blood Builder®/Iron Response®, once per day, every day, for 8 weeks.
89083265|NCT01147068|Experimental|PanBlok 135µg No Adjuvant|135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
89083266|NCT01147068|Experimental|PanBlok 45µg No Adjuvant|45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
89083267|NCT01147068|Experimental|PanBlok 45µg and GLA 1.0µg, SE 2%|45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
89083268|NCT01147068|Experimental|PanBlok 15µg and GLA 1.0µg, SE 2%|15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
89083269|NCT01147068|Experimental|PanBlok 7.5µg and GLA 1.0µg, SE 2%|7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
89083270|NCT01147068|Experimental|PanBlok 3.8µg and GLA 1.0µg, SE 2%|3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
89083271|NCT01147068|Placebo Comparator|Placebo|0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
89083272|NCT02683135|Active Comparator|High-carbohydrate diet|
89083273|NCT02683135|Experimental|Low-carbohydrate diet|
89083274|NCT02683135|Experimental|Low-carbohydrate diet with post-meal walking|
89083275|NCT00640627|Experimental|A|
89083276|NCT00640627|Placebo Comparator|B|
89083277|NCT01146912|Experimental|Text message vaccine reminders|Receipt of text message vaccine reminders
89083278|NCT01146912|Active Comparator|automated phone call from clinic|Receipt of automated phone call from clinic
89083279|NCT00641251|Active Comparator|1|intensive medical management
89083280|NCT00641251|Active Comparator|2|Roux-en-Y gastric bypass with intensive medical management
89083281|NCT02682043|Experimental|Toy car|The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.
89083282|NCT02679547||Appendicitis|The patients with appendicitis
89083283|NCT02679547||Control|The participants without appendicitis
89083284|NCT00641953|Experimental|A|IMX-150 (0.3%) 0.5 g topically BID each foot
89083285|NCT00641953|Experimental|B|IMX-150(0.6%) 0.5 g topically BID to each foot
89083286|NCT00641953|Placebo Comparator|C|Placebo 0.5 g topically BID to each foot for 4 weeks
89083287|NCT02681887|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 12 weeks
89083288|NCT02681887|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
89083289|NCT01134042|Experimental|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
89083290|NCT01134042|Active Comparator|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
89083291|NCT01134042|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks
89083292|NCT02681419|Active Comparator|Needle fenestration|Needle fenestration
89083293|NCT02681419|Active Comparator|Suture wick|suture wick using 10-0 vicryl
89083294|NCT00642031|Experimental|Triciribine|Triciribine 15 mg/m^2 intravenous (IV) Weekly Over 1 Hour On Days 1, 8, and 15.
89083295|NCT01179347|Experimental|tiotropium|2 inhalations once daily delivered with Respimat® inhaler
89083296|NCT01179347|Placebo Comparator|placebo|2 inhalations once daily delivered with Respimat® inhaler
89083297|NCT04182295|Experimental|real acupuncture-full disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
89083298|NCT04182295|Experimental|real acupuncture-partial disclosure|Participants in this group will be given real acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
89083299|NCT04182295|Sham Comparator|sham acupuncture-full disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and fully disclosed sham acupuncture information in the informed consent (i.e., fake acupuncture).
89083300|NCT04182295|Sham Comparator|sham acupuncture-partial disclosure|Participants in this group will be given sham acupuncture once a day for three consecutive days including the very first visit and partially disclosed sham acupuncture information in the informed consent (i.e., different kind of acupuncture).
89083301|NCT04182139|Experimental|30 seconds and %50 intensity stretching|The participants in this group performed an 30 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
89083302|NCT04182139|Experimental|30 seconds and %75 intensity stretching|The participants in this group performed an 30 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
89083303|NCT04182139|Experimental|30 seconds and %100 intensity stretching|The participants in this group performed an 30 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
89083304|NCT04182139|Experimental|60 seconds and %50 intensity stretching|The participants in this group performed an 60 seconds, %50 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
89083305|NCT04182139|Experimental|60 seconds and %75 intensity stretching|The participants in this group performed an 60 seconds, %75 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
89083306|NCT04182139|Experimental|60 seconds and %100 intensity stretching|The participants in this group performed an 60 seconds, %100 intensity static stretching exercise. 3 repetitive static stretching exercises did to hamstring muscles on the dominant side.
89083307|NCT01146288|Experimental|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
89083308|NCT01146288|Experimental|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
88812823|NCT05311982|Active Comparator|DLPFC-L F3 (Block A)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A)
89083309|NCT02683057||IPAQ HIgh|Excessive physical activity:IPAQ quantifying the activity physical according vigorous intensity activities at least 3 days per week adding a minimum total physical activity of at least 1500MET-minutes / week or 7 or more days any combination of walking, moderate intensity or vigorous intensity activities a total minimum of physical activity of at least 3,000 MET-minutes / week
89230164|NCT02554643|Experimental|Diet & Running|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Running training, 3 times a week, during 12 weeks"
89230165|NCT02554643|Active Comparator|Diet|Nutritional Intervention (Diet) once a week, during 12 weeks
89083310|NCT02683057||IPAQ Moderate|Ideal Physical activity: IPAQ quantifying the activity physical according 3 days or more of vigorous intensity physical activity at least 20 minutes per day or 5 or more days of moderate intensity and / or walk at least 30 minutes per day or 5 or more days of any combination of walking, moderate-intensity activity and activity vigorous intensity for a total minimum of physical activity of at least 600 MET-minutes / week.
89083311|NCT02683057||IPAQ Low|IPAQ quantifying the activity physical according Insufficient physical activity: Individuals who can not put on the criteria of the above categories.
89083312|NCT01146054|Experimental|SBRT and Gemzar|Before stereotactic Body Radiotherapy (SBRT) 3-5 gold fiducials are placed by endoscopic ultrasound or CT guidance. A simulation FDG-PET/CT (Fludeoxyglucose (18F) - Positron emission tomography/Computerized tomography) scan will be used for treatment planning purposes (standard free-breathing CT and respiratory-correlated 4-D (4 dimensional) pancreatic protocol CT). Patients are treated by either respiratory gated (Trilogy, Elekta, Novalis) or by respiratory tracking (CyberKnife). SBRT is delivered in 5 fractions of 6.6 Gy by LINAC-based or CyberKnife based radiotherapy over a five-day period. Gemcitabine, cycles should resume/start up to 4 weeks following SBRT on a 3-week on, 1-week off schedule. Initial follow up is at 4, 6, 9 and 12 months and then for years 2-5 is every 3-6 months.
89083313|NCT00640705|Active Comparator|A|Topical diclofenac sodium patch
89083314|NCT00640705|Placebo Comparator|B|Topical patch identical in appearance to active comparator, except without diclofenac sodium
89083315|NCT02353585||Intracranial hemorrhage|Intracranial hemorrhage occuring in patients on novel oral anticoagulants (NOAC) or vitamin-K antagonists
89083316|NCT02353585||Acute ischemic stroke|Acute ischemic stroke occuring in patients on novel oral anticoagulants (NOAC) or vitamin K antagonists (VKA)
89083317|NCT01145898||Glaucoma patients|Patients with Glaucoma
89083318|NCT02681653|Active Comparator|Statin|Atorvastatin, 40 mg for 7 days in patients of septic shock admitted to ICU
89083319|NCT02681653|Placebo Comparator|Placebo|Matched placebo, 40 mg for 7 days in patients of septic shock admitted to ICU
89083320|NCT04181983|Experimental|Personalized exercise program|A home-based personalized exercise program using a smartphone app
89083321|NCT04181983|Active Comparator|Active Control WHO guidelines|A standard exercise program based upon WHO guidelines
89083322|NCT04181983|No Intervention|Control|No exercise program
89230166|NCT00662363|Experimental|Lubiprostone and placebo Senna|Lubiprostone (Amitiza) 24 µg po BID given with meals for 6 days with two tabs placebo Senna at noon
89083323|NCT04315116|Experimental|Treament|Subjects receiving a single oral dose of pyrotinib maleate and wash-out for 6 days, then receiving Loperamide 4 mg bid from day 7 to day 13, with a single oral dose of pyrotinib maleate coadministered on day 10 .
89083324|NCT02679391||A|69 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2011. All post weight loss. , 96% female, BMI by the time of operation 26, mean age 41 (SD 9.5). Their mean weight loss in BMI units: 17.8 (SD 5.12).
89083325|NCT02679391||B|70 consecutive operated patients by plastic surgeons at Karolinska University Hospital 2010-2012. All post weight loss. 86% female, BMI by the time of oepration 26, mean age 38.6 (SD 11.4). Their mean weight loss in BMI units: 17.4 (SD 4.8).
89083326|NCT02679391||C|70 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2013-2014. All post weight loss. 90% female, BMI by the time of operation 26, mean age 46.8 (SD 10.1). Their mean weight loss in BMI units: 16.3 (SD 5.11)
89083327|NCT02886078|Experimental|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
89083328|NCT02886078|Active Comparator|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
89083329|NCT04183933|Active Comparator|Pilates Exercise Group|Pilates exercises will given for 6 weeks, 3 days in a week.
89083330|NCT04183933|Active Comparator|Combined Exercise group|Combined exercises will given for 6 weeks, 3 days in a week.
89083331|NCT02883114|Experimental|single cohort|single dose of PF-06648671 in period 1 and 14-day dose of itraconazole plus single dose of PF-06648671 in period 2
89083332|NCT00640783|Experimental|1|Mediterranean diet
89083333|NCT00640783|Active Comparator|2|Control diet
89083334|NCT04183387|Experimental|Simvastatin and standard treatment|40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis
89083335|NCT04183387|No Intervention|standard treatment|conventional treatment of uveitis
89083336|NCT01133418|Experimental|Cognitive Training|Computerized Progressive Attention Training
89083337|NCT01133418|Sham Comparator|Non-progressive cognitive training|Children in the control condition will participate in the same tasks as children in the Intervention arm. They will experience the same number of blocks and trials of training as the intervention group. Further, their training will be conducted by the same set of trainers and for the same amount of time as the intervention group. However, children in the control group will remain at the lowest level for each CT task throughout training irrespective of performance.
89083338|NCT02679313|Experimental|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit).
89083339|NCT04314804|Experimental|Smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
89083340|NCT04314804|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
89083341|NCT02678065|Experimental|InPact Admiral|Patients treated with the InPact Admiral balloon for popliteal lesions
89083342|NCT04183153|Experimental|Healthy Arm|
89083343|NCT00625092|Experimental|Hyperthermic Treatment|Patients receiving combination of hyperthermic intraperitoneal chemotherapy (HIPC) with oxaliplatin plus intraperitoneal 5-Fu and intraperitoneal leucovorin with peritoneal metastases.
89083344|NCT00931918|Active Comparator|RCHOP|RCHOP [rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
89083345|NCT00931918|Experimental|Vc-RCHOP|Vc-RCHOP [bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: bortezomib (VELCADE ®) 1.3 mg/m^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
89083346|NCT04183075|Experimental|FontActiv Superprotein/Hypercaloric Fiber|Full Nutritional Supplement
89083347|NCT04183075|Active Comparator|Carbohydrates and C Vitamin|Nutritional Supplement
89083348|NCT00642109|Other|TVT|Tension-free Vaginal Tape (TVT)
89083349|NCT00642109|Other|TOT|Transobturator Tape outside-in (TOT Monarc)
89083350|NCT00642109|Other|TVT-O|Transobturator Tape inside-out (TVT-O)
89083351|NCT02681575|Experimental|Cog-Fun A|Metacognitive-Functional occupational therapy intervention (Cog-Fun - A) includes enhancing self awareness in occupational context, acquiring executive strategies and skills and implementation across multiple occupational domains.
89083352|NCT04260490||Cases|"Cases will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected.~Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
89083353|NCT04260490||Controls|"Controls selected after stratification on department of residence, sex and age of the cases and who give a written informed consent to participate.~Controls will be interviewed using a standardized questionnaire. Blood samples will be taken for standard and specific analyses in both cases and controls. Samples for chlordecone and other Persistent organic Polluants (POPs) tests will be collected. Blood samples will be collected for the biobank of Guadeloupe for further studies on genetic susceptibility markers and their links with pesticide exposure."
89083354|NCT02679001||RA participants treated with a TNF inhibitor or TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling will be observed.
89083355|NCT02678221|Active Comparator|Sildenafil citrate with Aspirin|will receive sildenafil citrate 20mg ̸ 8hours plus low dose aspirin 150mg/day
89083356|NCT02678221|Other|placebo with Aspirin|will receive placebo plus low dose aspirin 150mg/day
89083357|NCT04033783|Experimental|6MWT - assessor walks behind the patient|In this experimental condition, the assessor walks behind the patient to continuously measure oxygen saturation during the test (recommended procedure)
89083358|NCT04033783|Active Comparator|6MWT - assessor does not walk behind the patient|In this experimental condition, the assessor does not walk behind the patient. The patient carries the pulse oximeter to continuously measure oxygen saturation during the test.
89083359|NCT00641329|Experimental|1|
89083360|NCT00641329|Placebo Comparator|2|
89083361|NCT02681107|Experimental|Single Arm|Single cohort to receive Accelerated Partial Breast Irradiation (APBI) 27Gy in 5 fractions
89083362|NCT01179191|Experimental|morphine sulfate and naltrexone hydrochloride (EMBEDA)|
89083363|NCT01169844|Experimental|AIN457/AIN457 3 mg/kg.|Participants who were treated with secukinumab 2x10 mg/kg during the core study were treated with secukinumab at 3mg/kg infused intravenously every 4 weeks during the extension study, over a total period of 52 weeks.
89083364|NCT01169844|Placebo Comparator|Placebo/AIN457 3 mg/kg.|Participants who were treated with placebo during the core study were treated with secukinumab at 3mg/kg infused intravenously every 4 weeks during the extension study, over a total period of 52 weeks.
89083365|NCT00642421|Experimental|Population A|Based on the dose of their previous Sandostatin-LAR treatment, Population A will receive 10 or 20 mg of C2L-OCT-01 PR at 5-week intervals.
89083366|NCT00642421|Experimental|Population B|Population B, naive patients and patients who have stopped their treatment with prolonged release octreotide for at least 12 weeks, will receive 20 mg C2L-OCT-01 PR at 5-week intervals.
89083367|NCT00642187|Experimental|1|Pulmicort
89083368|NCT00642187|Placebo Comparator|2|Placebo
89083369|NCT05663125|Experimental|LITT with Early Application of Temozolomide|Patients will receive the early use of temozolomide sooner after Laser interstitial thermal therapy (LITT).
89083370|NCT05655533||Adult patients who clinically suspected to have early spondyloarthropathy|"Adult patients who clinically suspected to have early spondyloarthropathy in acute stage.~At least 4 of 5 criteria for inflammatory low back pain have to be fulfilled"
89083371|NCT01132482|Experimental|Sildenafil|Subjects will receive escalating doses of sildenafil
89083372|NCT01132482|Placebo Comparator|Placebo|During the placebo arm, subjects receiving placebo will have sham dose escalation to maintain blinding.
89083373|NCT02678767|Experimental|HIV+ with neurocognitive disorder|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
89083374|NCT02678767|Active Comparator|HIV+ without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
89083375|NCT02678767|Active Comparator|HIV- without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
89083376|NCT02678455|Experimental|TV005 vaccine|Participants will receive one dose of TV005 vaccine at study entry (Day 0).
89083377|NCT02678455|Placebo Comparator|Placebo|Participants will receive one dose of placebo at study entry (Day 0).
89083378|NCT02678845|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
89083379|NCT02678845|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
89083380|NCT00931762|Experimental|Panobinostat|Participants received panobinostat 40 mg, capsules, orally, with or without food, three times a week on Monday, Wednesday, and Friday for up to 6 treatment cycles (each cycle of 28-days) with dose adjustments possible.
89083381|NCT02886455|Experimental|Cohort 4|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin at two different time points (4 and 24 hours).~There are two visits:~Visit 1:~Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 4 hours before being removed~Visit 2: Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 24 hours before being removed"
89083382|NCT00641407|Experimental|1|
89083383|NCT00641407|Active Comparator|2|
89083384|NCT00624689|Experimental|1|Modified formula
89083385|NCT00624689|No Intervention|2|Standard formula
89083386|NCT00624689|No Intervention|3|Breastfed
89083387|NCT02677597|Experimental|Cisplatin Combined With S-1|Cisplatin 75mg/m2 ivgtt d1 S-1 BSA<1.5 50mg bid，BSA≥1.5 60mg bid po d1-14
89083388|NCT02677597|Experimental|Cisplatin Combined With Paclitaxel|Cisplatin 75mg/m2 ivgtt d1 Paclitaxel 175mg/m2 d1 ivgtt 3h
89083389|NCT00606970|Experimental|Intervention group|Seigen Alpha EV Treatment
89083390|NCT00606970|Placebo Comparator|2|Identically packaged placebo packets taken 3x daily for 3 months maximum
89083391|NCT02681029|Experimental|Blastocyst transplantation|The infertile women who underwent intra- uterus transferring of blastocyst from thawed cleavage embryo
89083392|NCT02681029|Placebo Comparator|Control|The infertile women who underwent intra- uterus transferring of thawed cleavage embryo.
89083393|NCT05662969||Low/mid-volume liver transplant centres|
89083394|NCT05662969||High-volume liver transplant centres|
89083395|NCT05372146|Experimental|CHIVA group|43 participants. In the study group patients GSV was punctured 20-25 cm below SFJ. Radiofrequency catheter (ClosureFast) was inserted and positioned at SFJ distally to the superficial iliac circumflex vein. Four cycles were used for one segment below SFJ. After that catheter cooled down to 40C and was extracted. Phlebectomy was performed using Varady hooks after thermal ablation in both groups. All procedures were performed under tumescent anesthesia.
89083396|NCT05372146|Active Comparator|Control group|43 participants. In the controls GSV was punctured at a distal part of a refluxing segment. Catheter was positioned at SFJ and conventional radiofrequency procedure was performed with four cycles below SFJ and two cycles for every next segment. Phlebectomy was performed using Varady hooks after thermal ablation in both groups. All procedures were performed under tumescent anesthesia.
89083397|NCT02882880|Other|Started|Intervention: Treatment with the Luco Hybrid OSA Appliance (LHOA) Group 1, fitted with LHOA Group 2: LHOA removed for 48 hours
89083398|NCT02882880|Active Comparator|Completed|Intervention: The LUco Hybrid OSA APpliance The subjects that actually completed the study in both groups. Group 1 n = 32, in Group 2 n=19
89083399|NCT02677675|Experimental|Intervention (reminder module)|"A reminder module which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants)"
89083400|NCT02677675|No Intervention|Control (standard care)|Control group received standard care only (routine adherence counselling and paper-based appointment scheduling)
89225419|NCT05733143||Symptom high/T2-biomarker low (20 participants)|[ACQ≥ 1.5 FeNO<20 ppb AND blood eosinophil count<150 cells/µL]. During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
89225420|NCT05733143||Symptom low/T2-biomarker high (20 participants)|[ACQ<1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
89225421|NCT05733143||Symptom low/T2-biomarker low (12 participants)|[ACQ<1.5 AND FeNO<20 ppb AND blood eosinophil count<150 cells/µL] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
89225422|NCT05733143||Symptom high/T2-biomarker high (12 participants)|[ACQ≥ 1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.
89225423|NCT05731141||First Degree Relatives|Siblings or parents of patients.
89225424|NCT05731141||Patients|Patients with lymphatic anomalies.
89225425|NCT05720156||Case group: History of ASCVD, on high-intensity statins and initiating PCSK9 inhibitor therapy|History of ASCVD, on high-intensity statins and initiating PCSK9 inhibitor therapy
89225426|NCT05720156||Control group: No history of ASCVD, not on statins or initiating PCSK9 inhibitor therapy|No history of ASCVD, not currently on high-intensity statins or initiating PCSK9 inhibitor therapy
89225427|NCT05710692|Experimental|PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks|PRX-102 1 mg/kg every 2 weeks or PRX-102 2 mg/kg every 4 weeks (available only in the optional extension part)
89083401|NCT04260568||Persistent Postural Perceptual Dizziness|Semi-structured interviews
89083402|NCT00642343|Placebo Comparator|1|Children with severe to profound deafness that have not received any intervention.
89083403|NCT00642343|Active Comparator|2|Children with an unilateral cochlear implant.
89083404|NCT00642343|Active Comparator|3|Children with bilateral cochlear implants.
89083405|NCT00642343|Active Comparator|4|Children who receive their second implant during the duration of the study.
89083406|NCT01178411|Experimental|Tivantinib (Monotherapy or Combination Therapy)|Tivantinib 360 mg will be administered twice daily, orally, with meals, as a monotherapy or in combination with other drug therapies.
89083407|NCT04263688||Immunotherapy effective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
89083408|NCT04263688||Immunotherapy Ineffective|Immunotherapy was applied for 8 weeks to evaluate the efficacy，The efficacy of immunotherapy was evaluated by imaging, and was evaluated according to RECIST 1.1.
89083409|NCT02681263|Experimental|Temocillin|"Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.~Total antibiotic treatment between 10 and 14 days according to local guidelines (up to 21 days in immunosuppressed patients)."
89083410|NCT02675803|Experimental|VAY736|VAY736 active
89083411|NCT02675803|Placebo Comparator|Placebo|VAY736 placebo
89083412|NCT02678611|Experimental|Basis 250|
89083413|NCT02678611|Experimental|Basis 500|
89083414|NCT02678611|Placebo Comparator|Placebo|
89083415|NCT02677519|Experimental|10 mg Aptensio XR|10 mg methylphenidate, extended release
89083416|NCT02677519|Experimental|15 mg Aptensio XR|15 mg methylphenidate, extended release
89083417|NCT02677519|Experimental|20 mg Aptensio XR|20 mg methylphenidate, extended release once daily
89083418|NCT02677519|Experimental|30 mg Aptensio XR|30 mg methylphenidate, extended release
89083419|NCT02677519|Experimental|40 mg Aptensio XR|40 mg methylphenidate, extended release
89083420|NCT02677519|Experimental|50 mg Aptensio XR|50 mg methylphenidate, extended release
89083421|NCT02677519|Experimental|60 mg Aptensio XR|60 mg methylphenidate, extended release
89083422|NCT01145508|Experimental|Arm A (vaccine therapy and chemotherapy)|Patients receive rilimogene-galvacirepvec SC on day 1 of course 1 and fowlpox-PSA-TRICOM vaccine SC on days 15, 29, 43, and 57 of course 1. Beginning on day 85 (day 1 of course 2), patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment with docetaxel and prednisone repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89225428|NCT05708924|Experimental|IP FT538 monotherapy|Level -1: IP FT538 monotherapy 5 x 10^7 cells/dose Level 1: IP FT538 monotherapy 1 x 10^8 cells/dose Level 2: IP FT538 monotherapy 3 x 10^8 cells/dose Level 3: IP FT538 monotherapy 1 x 10^9 cells/dose Level 4: IP FT538 monotherapy 1.5 x 10^9 cells/dose
89225429|NCT05708924|Experimental|IP FT538 + Enoblituzumab|Level 5: IP FT538 at the safe dose (MTD-1) + Enoblituzumab Level 6: IP FT538 at the highest dose (MTD) + Enoblituzumab
89083423|NCT01145508|Active Comparator|Arm B (docetaxel, prednisone)|Patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89083424|NCT02675881|Active Comparator|RFA DSM|Eligible patients who undergo RFA using DSM and separable clustered electrodes.
89083425|NCT02675881|No Intervention|RFA SSM|Historical control group consisted of patients underwent RFA in our institution with single switching mode (SSM) and single/ or multiple clustered electrodes.
89083426|NCT00931528|Experimental|Tadalafil|Tadalafil
89083427|NCT00931528|Placebo Comparator|Placebo|Placebo
89083428|NCT05362812||Patients with systemic lupus erythematosus|Diagnostic Test: Flow cytometry analysis of urine samples. Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and B cell panel with fluorochromes. T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD38, CD279; B cell panel: CD19, CD20, CD27, CD38, CD21, IgD, CXCR5
89083429|NCT04312152|Active Comparator|PMS Placebo|"If body weight is up to 20 kg:~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
89083430|NCT04312152|Active Comparator|ASD Placebo|"If body weight is up to 20 kg:~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
89083431|NCT04312152|Experimental|PMS Active compound|"If body weight is up to 20 kg:~Q10 ubiquinol, 50 mg b.i.d.~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~Q10 ubiquinol, 100 mg b.i.d.~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
89083432|NCT04312152|Experimental|ASD Active compound|"If body weight is up to 20 kg:~Q10 ubiquinol, 50 mg b.i.d.~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (1.05 mg), Vit. B2 (1.2 mg), Niacin (9 mg), Pantothenic acid (4.5 mg), Vit. B6 (1.5 mg), Vit. B12 (4.5 mcg), Folic acid (0.1 mg), Biotin (0.1125 mg)~If body weight is above 20 kg:~Q10 ubiquinol, 100 mg b.i.d.~Vitamin E 30 mg b.i.d.~Multivitamin B complex b.i.d., including Vit. B1 (2.1 mg), Vit. B2 (2.4 mg), Niacin (18 mg), Pantothenic acid (9 mg), Vit. B6 (3 mg), Vit. B12 (9 mcg), Folic acid (0.2 mg), Biotin (0.225 mg)"
89083433|NCT00975195|Experimental|fluticasone high dose|fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate
89083434|NCT00975195|Experimental|fluticasone medium & low doses|fluticasone priopionate medium and high doses; and tiotropium inhalation; and salmeterol xinafoate; and placebo matched to fluticasone priopionate
89083435|NCT00642499|Experimental|1|
89083436|NCT00642499|Placebo Comparator|2|
89083437|NCT00644215|Experimental|1|5-FU injection has been done
89083438|NCT00644215|Experimental|2|Mitomycin drop has been administrated
89083439|NCT01145352||Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).
89083440|NCT01178099|Experimental|Prasugrel|Participants received a single 10 milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants<60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).
89083441|NCT04016545||Treated patients|
89083442|NCT05323188||Subjects|Control pediatric population: no excess of chronic inflammatory or allergic disease compared to the general French population.
89083443|NCT02673463|Experimental|Spironolactone|Spironolactone 25 mg once daily for 2 years
89083444|NCT02673463|Placebo Comparator|Placebo|Matched placebo once daily for 2 years
89083445|NCT00610636|Experimental|1|The patients with secondary resectable colorectal hepatic metastasis undergoing surgery
89083446|NCT00610636|Active Comparator|2|The patients with secondary resectable colorectal hepatic metastasis who underwent continuous chemotherapy
89083447|NCT01169532|Experimental|Treatment (ridaforolimus and vorinostat)|Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89225430|NCT05706922||Polycystic ovary syndrome (PCOS)|"Hormonal screening~Vaginal swab~Fecal sample~Blood samples~Food Frequency Questionnaire"
89225431|NCT05706922||Control group|"Hormonal screening~Vaginal swab~Fecal sample~Blood samples~Food Frequency Questionnaire"
89225432|NCT05703945|Experimental|Training group|Participants benefit from an 8-week training program of muscle strengthening
89225433|NCT05703945|Sham Comparator|Control group|Participants in the control group will be asked to maintain their habits and lifestyle (without training program) for the duration of the study.
88812824|NCT05311982|Active Comparator|tDCS combined in DLPFC-L (F3) and DLPFC-R (F4)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in tDCS combined in DLPFC-L (F3) and DLPFC-R (F4)
89083448|NCT02537353|Placebo Comparator|Group 1|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application of metal clips. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
89083449|NCT02537353|Active Comparator|Group 2|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application adsorption powder, marketed under the name Hemospray. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
89083450|NCT04181671|Experimental|Low Resistance Training Group|The experimental group will receive low resistance blood flow restriction training with 30% of 1 RM.
89083451|NCT04181671|Active Comparator|High Resistance Training Group|Participants of this group will receive High resistance training (80% of 1 RM) without blood flow restriction.
89083452|NCT00928564|Active Comparator|Pudendal Block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
89083453|NCT00928564|Placebo Comparator|Placebo|5ml of saline at each block site
89083454|NCT02883036||Patients with chronic myeloid leukemia|100 adult patients(age>18 years),with chronic myeloid leukemia defined by the World Health Organization(WHO) criteria
89083455|NCT02883036||Healthy volunteers|Healthy volunteers
89083456|NCT00643357|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox® 170 bar)
89083457|NCT00643357|Placebo Comparator|B|50%Oxygen/50% Nitrogen premix
89083458|NCT01177943|Experimental|Atomoxetine Oral Solution|
89083459|NCT01177943|Active Comparator|Atomoxetine Capsule Formulation|
89083460|NCT00608920|Experimental|SPECT lymph node mapping|"Diagnostic pelvic CT~Nuclear tracer injection (Tc-99m) - same time as the ACCULOC seed implantation~CT simulation (2 hours after prostate markers are placed)~SPECT lymphoscintigraphy (first set of images 3-6 hours after injection and second set may be obtained 18-24 hours after injection)"
89083461|NCT01131312|Experimental|Cytology|Referred to colposcopy if cytology is high grade
89083462|NCT01131312|Experimental|Human Papillomavirus (HPV)|Referred to colposcopy if cytology is high grade or HPV +
89083463|NCT01131312|Experimental|Colposcopy|All refer to colposcopy
89083464|NCT04181281||young adult|18 - 40 years old (n=10) Healthy male or female and able to give informed, written consent.
89083465|NCT04181281||older adult|70 years or older (n=10) Healthy male or female and able to give informed, written consent.
89083466|NCT04181281||AKI patients|Admitted patients with AKI stage 3
89083467|NCT02865057||3rd year Residents|3rd year Ob, Gyn Residents
89083468|NCT02865057||4th Year Residents|4th year Ob, Gyn Residents
89083469|NCT04314960|Experimental|CAI subjects|Subjects in this group will receive eight 20-minutes gait training sessions with functional electrical stimulation.
89083470|NCT04178785|Active Comparator|REMIFENATIL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
89083471|NCT04178785|No Intervention|FENTANYL|Prospective, single-center single blind randomized controlled trial. Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio. A blocked randomization scheme will be created using a computer-generated list of random numbers.
89083472|NCT01177787|Active Comparator|zeltiq|Cryolipolysis had been done for 1 hour on ipsilateral thigh fat through Zeltiq machine.
89083473|NCT01177787|Sham Comparator|electrical stimulation|Lipolysis had been done for 30 minutes on controlateral thigh fat through amplitude modulated frequency.
89083474|NCT02864589|Experimental|I-HRT|Internet-delivered habit reversal training
89083475|NCT02864589|Experimental|I-ERP|Internet-delivered exposure and response prevention
89083476|NCT00928486|Experimental|Lenalidomide and Dexamethasone|Lenalidomide 25mg by mouth (PO) once daily (QD) on Days 1-21 of each 28 day cycle; When creatinine (CrCl) clearance <60 mL/min, the initial dose was 10mg and the dose could be increased to 15mg after 2 cycles if the investigator judged therapeutic effect was insufficient and tolerability was acceptable. Dexamethasone 40 mg by PO once QD on days 1-4, 9-12 and 17-20 of each 28 day cycle for the first 4 cycles and Days 1-4 for the remaining cycles beginning at Cycle 5.
89083477|NCT02887391||Conventional Hemodialysis|Control group 4 hours of hemodialysis 3x per week (12 hours hemodialysis/week)
88812825|NCT05311982|No Intervention|Sham (Block C)|The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in tDCS Sham
89083478|NCT02887391||In-Centre Nocturnal Hemodialysis|8 hours of hemodialysis 3x per week (24 hours hemodialysis/week)
89083479|NCT04056117|Experimental|NA (Non-adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the non-adjuvanted investigational product
89083480|NCT04056117|Experimental|A (adjuvanted) - very low dose - infants|Infants receive 3 very low doses of the adjuvanted investigational product
89083481|NCT04056117|Experimental|NA (Non-adjuvanted) - low dose -infants|Infants receive 3 low doses of the non-adjuvanted investigational product
89083482|NCT04056117|Experimental|A (adjuvanted) - low dose - infants|Infants receive 3 low doses of the adjuvanted investigational product
89083483|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the non-adjuvanted investigational product
89083484|NCT04056117|Experimental|A (adjuvanted) - medium dose - infants|Infants receive 3 medium doses of the adjuvanted investigational product
89083485|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose - children|Children receive 3 medium doses of the non-adjuvanted investigational product
89083486|NCT04056117|Experimental|A (adjuvanted) - medium dose - children|Children receive 3 medium doses of the adjuvanted investigational product
89083487|NCT04056117|Experimental|NA (non-adjuvanted) - medium dose-adults|Adults receive 2 medium doses of the non-adjuvanted investigational product
89083488|NCT04056117|Experimental|A (adjuvanted) - medium dose - adults|Adults receive 2 medium doses of the adjuvanted investigational product
89083489|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - infants|Infants receive 3 high doses of the non-adjuvanted investigational product
89083490|NCT04056117|Experimental|A (adjuvanted) - high dose - infants|Infants receive 3 high doses of the adjuvanted investigational product
89083491|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - children|Chilldren receive 3 high doses of the non-adjuvanted investigational product
89083492|NCT04056117|Experimental|A (adjuvanted) - high dose - children|Chilldren receive 3 high doses of the adjuvanted investigational product
89083493|NCT04056117|Experimental|NA (non-adjuvanted) - high dose - adults|Adults receive 2 high doses of the non-adjuvanted investigational product
89083494|NCT04056117|Experimental|A (adjuvanted) - high dose - adults|Adults receive 2 high doses of the adjuvanted investigational product
89083495|NCT04056117|Experimental|MenACWY-Placebo|Adults receive one administration of MenACWY followed by one placebo administration
89083496|NCT04056117|Other|Rabies|Children receive three administrations of Rabies
89083497|NCT04056117|Other|MenACWY-DTaP|Infants receive two administrations of MenACWY followed by DTaP administration
89083498|NCT05655221|Placebo Comparator|Cohort 1|B1344/Placebo:2mg.
89083499|NCT05655221|Placebo Comparator|Cohort 2|B1344/Placebo:5mg.
89083500|NCT05655221|Placebo Comparator|Cohort 3|B1344/Placebo:15mg.
89083501|NCT05655221|Placebo Comparator|Cohort 4|B1344/Placebo:30mg.
89083502|NCT05655221|Placebo Comparator|Cohort 5|B1344/Placebo:45mg.
89083503|NCT05655221|Placebo Comparator|Cohort 6|B1344/Placebo:60mg.
89083504|NCT05655221|Placebo Comparator|Cohort 7|B1344/Placebo:80mg.
89083505|NCT00610792|Experimental|1|
89083506|NCT02677441|Experimental|Conservative management|Conservative management includes a sling for 10 days, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
89083507|NCT02677441|Active Comparator|Surgery|Surgical fixation of ACJD with coracoclavicular and acromioclavicular fixation, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
89083508|NCT00610870|Experimental|1|Atorvastatin group
89083509|NCT00610870|No Intervention|2|Control group
89083510|NCT05655143|Experimental|Balance Training|
89083511|NCT05655143|No Intervention|Control|
89083512|NCT04181593|Experimental|OmegaD|OmegaD Softgels
89083513|NCT04181593|Placebo Comparator|Placebo|Placebo Softgels
89083514|NCT04265326||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
89083515|NCT01168596|Placebo Comparator|sugar pill|Placebo tablet, 1 per day, duration is approximately 12 weeks.
89083516|NCT01168596|Active Comparator|rasagiline|Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.
89083517|NCT02537275|Experimental|wearing contact lense group|normal subjects after wearing tinted/normal contact lenses
89083518|NCT05658419|Active Comparator|control group|immediate implant placement
89083519|NCT05658419|Active Comparator|study group|socket shield immediate implant placement
89083520|NCT02675647|Experimental|Intervention group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the dosage of 340 UI/kg based on ideal body weight of the obese patients.~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on ideal body weight, to maintain this target during the CPB."
89083521|NCT02675647|Active Comparator|Control group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the usual dosage of 300 UI/kg based on total body weight of the obese patients.~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on total body weight, to maintain this target during the CPB."
89083522|NCT05370898|Experimental|Traditional Chinese medicine|On the basis of general symptomatic treatment of caltrate D，patients in experimental group use the traditional Chinese medicine application prescription.
89083523|NCT05370898|Placebo Comparator|Comparator: placebo|On the basis of general symptomatic treatment of caltrate D，patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
89083524|NCT04315805|Experimental|Integrative Yoga Therapy|Integrative Yoga Therapy will be provided by yoga therapist once a week and participants will be encouraged to practice at home once or twice a day.
89083525|NCT04315805|No Intervention|Wait-list Control|Participants in waiting list will serve as control group for the intervention period. After the ftherapy group has received treatment, the same program will be offered to participants in the wait-list control group.
89083526|NCT02677363|Experimental|Older adults|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
89083527|NCT00610948|Experimental|Group 1|Patients receive oral everolimus once daily on days 1-28. Patients also receive leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89083528|NCT00610948|Experimental|Group 2|Patients receive oral everolimus once daily on days 1-28 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89083529|NCT00610948|Experimental|Group 3|Patients receive oral everolimus once daily on days 1-28, leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1, and oxaliplatin IV over 2-4 hours on day 1. Some patients may also receive panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89083530|NCT04206137|Experimental|Group A (PNF rhythmic initiation group )|PNF rhythmic initiation with bilateral asymmetrical upper and lower limb pattern will administered on both sides, there will be 10 repetition and 3 sets for each side, 20 second rest between two sets.
89083531|NCT04206137|Active Comparator|Group B (Swiss ball exercise group)|Swiss ball exercises will be administered. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set.
89083532|NCT04314726|Active Comparator|amelogenins group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. Amelogenins effect was evaluated by applying them only in the test site and comparing healing results with those obtained on the contra-lateral site
89083533|NCT04314726|Placebo Comparator|placebo group|The study involved enrolling 5 periodontitis free patients, to which the extraction of both lower third molars was prescribed. A bone defect at the distal surface of the second molar ≥ 5 mm, had to be present on the intraoral periapical radiography, bilaterally. In this group (control site) the conventional treatment was performed, and healing was ensured only by the simple blood clot
89083534|NCT04178395|Experimental|real tDCS group|Patients allocated to the real tDCS group (11 patients) received one daily session of bihemispheric transcranial direct stimulation and repetitive peripheral stimulation for 5 consecutive days.
89083535|NCT04178395|Sham Comparator|sham group|Patients allocated to the sham tDCS group (9 patients) received sham tDCS + rPNS also daily, for 5 consecutive days.
89083536|NCT04250818||Control Group|Patients with mTNBC who receive chemotherapy only
89083537|NCT04250818||Experimental Group|patients with mTNBC who receive a combination of chemotherapy and Immunotherapy
89083538|NCT01177553|Active Comparator|Surgery Group|"Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.~Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures."
89083539|NCT01177553|Active Comparator|Expectant Management Group|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
89083540|NCT04178239||Chronic Fatigue|MFI score >53 points
89083541|NCT04178239||No Chronic Fatigue|MFI score < 54 points
89083542|NCT04260178|Experimental|Experimental groups|For the experimental group, EBIP was implemented in three stages:(1) hospital training;(2) home visits + training, which includes motivational interventions that facilitate chronic disease self-care and symptom management with nurse-patient cooperation; and (3) telephone follow-ups and assistance. A handbook was developed in line with the relevant literature and input from two specialist physicians (1,17-20). The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior. The trainings sessions were conducted in a hospital seminar room using PowerPoint presentations. Afterward, patients were asked to demonstrate what they learned, and the parts that were not clear were explained again. The training was concluded after deciding for the first home visit appointment. For patients that could not effectively use the handbook, a close relative was included to all steps of the study.
89083543|NCT04260178|Other|Control groups|Control groups were evaluated with an introductory survey form, PFT, BDI, BMI and SCMP-G scales before and after the study. There were no additional interventions to the control group.
89083544|NCT02675413|Experimental|Dimethyl Fumarate|Open label dimethyl fumarate (Tecfidera) at the US approved dose of 120mg BID for 7 days and then 240mg BID thereafter for 12 months.
89083545|NCT02675725||Post cardiac surgery|Patients after cardiac surgery with signs of decreased organ perfusion and the need of fluid therapy.
89083546|NCT00928408||Cinacalcet|
89083547|NCT04179877|Experimental|Individual placement and support|Group of patients receiving IPS to increase workforce participation.
89083548|NCT04179877|No Intervention|Control|Group of patients receiving treatment as usual.
89083549|NCT02675257|Experimental|Cognitive-behavioural group treatment|"Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control.~Interventions:~Diabetes-related affective problems analysis~Goal setting towards improvement of glycaemic control~Diabetes-specific problem-solving therapy~Interventions to increase diabetes treatment motivation~Activation of personal and social resources~Reduction of barriers to self-care/glycaemic control~Cognitive restructuring of diabetes-related problems~Goal definition regarding self-care/glycaemia/well-being"
89083550|NCT02675257|Active Comparator|Treatment-as-usual|"Standard diabetes education.~Interventions:~Health care and specific topics (e. g. blood pressure)~Healthy foods, cooking recommendations, recipes~Sports, activities and exercise~Foot care: exercises, care & control, injuries, neuropathy~Diabetes complications~Social aspects of living with diabetes"
89083551|NCT00928252|Experimental|Received 18F-fluorocholine PET/CT|IV fluorine-18 labeled methylcholine before PET/CT
89083552|NCT02673073|Placebo Comparator|Control_Education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
89083553|NCT02673073|Experimental|Intervention_Diary|All patients will receive patient's information/education booklet on the heart failure including life style modification. In addition, patients also receive a patient's diary for self-recording of 6 parameters: body weight, blood pressure, heart rate, number of remaining pills, degree of pitting edema, and degree of dyspnea.
89083554|NCT02673229|Active Comparator|Collagenase Santyl|Applied topically (2 mm thickness once daily)
89083555|NCT02673229|Sham Comparator|Bacitracin|Applied topically (2 mm thickness) once daily
89083556|NCT00644293|Experimental|1|
89083557|NCT00644293|Experimental|2|
89083558|NCT01177007|Experimental|TheraSphere|
89083559|NCT00930982|Experimental|Ciprofloxacin Inhale (BAYQ3939)|32.5 mg ciprofloxacin hydrated corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice daily
89083560|NCT00930982|Placebo Comparator|Placebo|Inhalation of matching placebo twice a day
89083561|NCT02673307|No Intervention|Controle|The volunteer does not chew gum during the study period
89083562|NCT02673307|Experimental|Chewing gum|The volunteer chews gum during the first 45 min after ingestion of 250 ml water
89083563|NCT02677285||Skin graft|The bioimpedance measurement is done with a purpose built patch that has electrodes in contact with the wound and reference electrodes.
89083564|NCT02677285||Operation wound|The bioimpedance measurement is done with commercial electrodes places in healthy skin surrounding the wound.
89083565|NCT05662891|Experimental|blood flow restriction + Nordic hamstring exercise|
89083566|NCT05662891|Experimental|Nordic hamstring exercise|
89083567|NCT01176773|Experimental|Juvéderm® Ultra Lip Injectable Gel|
89083568|NCT02887625|Experimental|Combination Therapy|pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week
88812826|NCT02214017|Active Comparator|Standard care|Diabetic patients attended usual procedure in the outpatient clinic with regular visits
89083569|NCT02887625|Active Comparator|Insulin Therapy|"insulin glargine (lantus) will be started every morning and the dose will be weekly increase to achieve fasting plasma glucose (FPG) <110 mg/dl.~and Aspart insulin will be started before meals and the dose is adjusted to maintain HbA1c <7.0% and postprandial plasma glucose (PPG) <140 mg/dl"
89083570|NCT04180033|Other|Colonoscopy surveillance in TC survivors|TC survivors treated with platinum-based chemotherapy will be invited to undergo a colonoscopy surveillance.
89083571|NCT02886377||NMOSD-ON|NMOSD-ON included patients who met the established diagnostic criteria for NMO or NMOSD published by Wingerchuk et al,with AQP4 seropositive according to the results of the AQP4-Ab test.
89083572|NCT02886377||MS-ON|MS-ON group patients included typical acute demyelinating ON with brain lesions fulfilling the revised McDonald criteria or clinical isolate syndrome (CIS), with AQP4 seronegative according to the results of the AQP4-Ab test.
89083573|NCT02886377||Healthy controls|Age- and gender- matched healthy controls.
89083574|NCT05662813|Experimental|Almonertinib|Almonertinib 110 mg，orally once a day. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
89083575|NCT02675335|Active Comparator|Sitagliptin|Sitagliptin tablets, 100mg per day, 12 weeks treatment
89083576|NCT02675335|Placebo Comparator|Placebo|Placebo tablets, 1 tablet per day, 12 weeks treatment
89083577|NCT02675101|Active Comparator|Whole nuts|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume a combination of whole almonds and walnut pieces, a total of 110 g per day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Walnuts and almonds will be provided to participants for the duration of the study.
89083578|NCT02675101|Experimental|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 18 g olestra/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Fat free Pringles will be provided to participants for the duration of the study.
89083579|NCT02675101|Placebo Comparator|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 17.4 g oil/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Original Pringles will be provided to participants for the duration of the study.
89083580|NCT00928018|Active Comparator|Sirolimus-Containing Regimen|"The Sirolimus containing arm will consist of the following drugs:~Experimental Arm: tacrolimus + sirolimus + low-dose methotrexate~Tacrolimus: Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Sirolimus:Given as a loading oral dose of 12 mg on day -3, then as a daily maintenance dose of 4 mg starting on day -2.~Methotrexate: Administered by intravenous bolus infusion, per institutional standard, at a dose of 5 mg/m2 on days +1, +3 and +6."
89083581|NCT00928018|Active Comparator|Sirolimus-Free regimen|"There are two choices for the Sirolimus free arm:~Control Arm 1: tacrolimus + methotrexate~Tacrolimus:Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Methotrexate:Administered by intravenous bolus infusion at a dose of 5 mg/m2 on days +1, +3 and +6. For patients receiving stem cells from unrelated donors, an additional dose will be given on day +11.~Control Arm 2: cyclosporine + MMF~Cyclosporine: administered orally at a dose of 6 mg/kg based on ABW bid starting on day -3.~MMF:administered at a dose of 3gm daily orally (or intravenously if the patient cannot tolerate oral administration) divided in 2 or 3 doses (bid or tid) depending on physician preference starting on day 3."
89083582|NCT02672839|Experimental|Period 1 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
89083583|NCT02672839|Experimental|Period 1 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
89083584|NCT02672839|Experimental|Period 2 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
89083585|NCT02672839|Experimental|Period 2 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
89083586|NCT00643435|Experimental|1|These residents receive training provided by standardized patient instructors, in use of self-efficacy enhancing interviewing techniques to support patient health behavior change,
89083587|NCT00643435|Active Comparator|2|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
89083588|NCT00927940|Experimental|Drug Eluting Stent|All patients may have one or two lesions, if the two lesions are located in separate coronary arteries. A patient with one or two lesions treated with stents of diameter 2.5mm - 3.5mm will be designated in this study.
89083589|NCT02677129|Experimental|home-based exercise intervention|"home-based exercise intervention:~Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems."
89083590|NCT02677129|No Intervention|Waiting control group|The wait list control group receives usual care over the study period. Usual care depends on the hospital guidelines as well as oncologists' and physicians' consideration.
89083591|NCT00910117|Experimental|nimotuzumab|nimotuzumab plus PF regimen
89083592|NCT04264936|Experimental|RC48-ADC and JS001|
89083593|NCT04181437|Experimental|NVP-1203-R1|"Drug: NVP-1203-R1~1 tablet, oral dosing"
89083594|NCT04181437|Experimental|NVP-1203-R2|"Drug: NVP-1203-R2~1 tablet, oral dosing"
89083595|NCT04181437|Experimental|NVP-1203-R1 and NVP-1203-R2|Drug: NVP-1203-R1 1 tablet and NVP-1203-R2 1 tablet co-administration(oral dosing)
89083596|NCT04181125||Children with increased femoral anteversion|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
89083597|NCT04181125||Healthy children|After the demographic information, developmental history and gait information were recorded with the Evaluation Form, clinical evaluation was performed; bilateral lower extremity range of motion, flexibility, leg length measurement, and muscle strength measurement and muscular endurance tests (abdominal, back and lower extremity) will be performed. For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) and the Biodex Balance System for computerized evaluation will be used.
89083598|NCT00927862|Active Comparator|Standard IWPC warfarin dosing algorithm|Standard International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm.
89083599|NCT00927862|Experimental|Modified IWPC warfarin dosing algorithm|Modified International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm
89083600|NCT00927862|Other|Historical controls|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records database of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic (PG)-guided cohorts (July 2008 through December 2010). Patients ≥18 years old initiating warfarin therapy with a baseline and at least 1 follow-up international normalized prothrombin time ratio (INR) level between days 3-14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG based.
89083601|NCT02672527|Experimental|TRA|"At Day 1 (D1), premedication with dexamethasone (20 mg) and a 5-HT3 receptor antagonist anti-emetic agent will be intravenously administered 30 minutes prior to trabectedin administration. Trabectedin will be administered through a central venous catheter at a starting dose of 1.5 mg/m² over 24 hours, diluted in at least 500 mL of normal saline solution or of glucose 5% injectable solution.~Each treatment cycle will last 21 days. Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal, or toxicities.~In case of disease progression, the further treatments will be based on investigator's judgement."
89083602|NCT02672527|No Intervention|BSC|"Treatment:~Patients will receive the best supportive care (BSC) in order to alleviate their symptoms and improve their Quality of Life (QoL).~Antineoplastic agents (including surgery, radiotherapy, thermotherapy, chemotherapy, immunotherapy, hormonal treatment or antibodies-based treatments) are prohibited.~Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal.~In case of disease progression, a treatment with trabectedin will be proposed (cross-over). In case of patient refusal, the further treatments will be based on investigator's judgement."
89083603|NCT04263220|Experimental|Prototype exoskeleon 1|The experimental trial will be performed with the prototype exoskeleton
89083604|NCT04263220|Experimental|Prototype exoskeleon 2|The experimental trial will be performed with the prototype exoskeleton
89083605|NCT04263220|Experimental|No exoskeleton|The experimental protocol will be performed without exoskeleton.
89083606|NCT00976989|Experimental|T+P Concomitant Anthracycline-based chemotherapy|5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
89083607|NCT00976989|Experimental|T+P Sequential Anthracycline-based chemotherapy|FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
89083608|NCT00976989|Experimental|T+P Concomitant Non-Anthracycline chemotherapy|Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
89083609|NCT00927784|Sham Comparator|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media alone (placebo).
89083610|NCT00927784|Experimental|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs in sequential cohorts.
89083611|NCT02675023|Experimental|Auto-injector (AI)|M923 administered via AI
89083612|NCT02675023|Experimental|Prefilled syringe (PFS)|M923 administered via PFS
89083613|NCT04290117|Experimental|ACT-Chrono|First Acceptance and Commitment (ACT) training, followed by chronobiological training
89083614|NCT04290117|Experimental|Chrono-ACT|First chronobiological training, followed by ACT training
89083615|NCT04290117|Other|Chrono|First no training, followed by chronobiological training
89083616|NCT04290117|Other|ACT|First no training, followed by ACT training
89083617|NCT02672605|No Intervention|Control|Participant completes a survey measuring abortion stigma prior to receiving the mandatory Pennsylvania State consent for their abortion.
89083618|NCT02672605|Experimental|Investigational|Participant completes a survey measuring abortion stigma after receiving the mandatory Pennsylvania State consent for their abortion.
89083619|NCT02863965||High definition endoscopy and optic enhancement|All the patients underwent routine preparation before the procedure. The detected lesions in high definition endoscopy were observed with optic enhancement mode. The endoscopist was required to give the real-time descriptions of surface pit patterns of the lesions, based on surface pattern classification. After that, biopsy specimens will be obtained respectively by forceps from each detected lesion recorded for histologic diagnosis.
89083620|NCT04260100|Experimental|Intervention Group|
89083621|NCT04260100|No Intervention|Control Group|Routine care group
89083622|NCT04179487||Pregnant Patients with Suspected PE|Pregnant Patients with Suspected pulmonary embolism undergoing low dose CT pulmonary angiogram
89083623|NCT05331352|Experimental|Subjects following a psychotherapy|Domestic violence victims following a psychotherapy 15 subjets Aged from 20 to 55
89083624|NCT05331352|Experimental|Subjects unfollowing a psychotherapy|Domestic violence victims unfollowing a psychotherapy 15 subjects Aged from 20 to 55
89083625|NCT00644371|Experimental|1|
89083626|NCT04963972|Experimental|Arm I (Lucid Lane)|Patients participate in the Lucid Lane therapy program including working with a mental health therapist on mindfulness, CBT, group therapy, and mind-body therapies for 3-9 months or until the tapering off period is complete.
89083627|NCT04963972|Active Comparator|Arm II (standard of care)|Patients receive standard of care post-surgical opioid education.
89083628|NCT02677207|Experimental|JNJ-39393406|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
89083629|NCT02677207|Placebo Comparator|Placebo|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
89083630|NCT02864199|Experimental|Group A: Moderate Renal Impairment|Participants with CrCl 30 to 50 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 micrograms (mcg) via subcutaneous (SC) injection once weekly, in combination with ribavirin, 600 milligrams (mg) orally (PO) daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
89083631|NCT02864199|Experimental|Group B: Severe Renal Impairment|Participants with CrCl <30 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 400 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
89083632|NCT02864199|Experimental|Group C: Hemodialysis/ESRD|Participants requiring hemodialysis will receive 12 weeks of peginterferon alfa-2a, 135 mcg via SC injection once weekly, in combination with ribavirin, 200 mg PO every morning. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
89083633|NCT02864199|Experimental|Group D: Normal Renal Function|Participants with CrCl >80 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 800 to 1200 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
89083634|NCT05911191|No Intervention|Control|Both groups will receive a first session in which they will be instructed to carry out the unsupervised home EBPrehab program, consisting of respiratory training, ventilatory training, strengthening of the respiratory muscles, aerobic endurance exercise through continuous walking, and a series of recommendationss on post-surgical care
89083635|NCT05911191|Experimental|Experimental|Addittionally, a preoperative musculoskeletal and cardiopulmonary rehabilitation program focused on peripheral resistance training, will be implemented in the experimental group
89083636|NCT05911178|Experimental|Early Onset Alzheimer's Disease (EOAD)|"Patients who have been diagnosed with AD according to clinical and biomarker criteria. Early onset AD is considered as having an age of onset of symptoms younger than 65 years.~Age of onset ≤ 65 years"
89083637|NCT05911178|Experimental|Late Onset Alzheimer's Disease (LOAD)|"Patients who have been diagnosed with AD according to clinical and biomarker criteria. Late onset AD is considered as having an age of onset of symptoms older than 65 years.~Age of onset > 65 years"
89083638|NCT05911178|Experimental|Controls|Healthy control subjects will be matched to patients for age and education level.
89083639|NCT05911126|Active Comparator|Group A|(60 participants) will receive two oral tablets of HBB (Buscopan 10 mg, Boehringer Ingelheim) and one capsule of Celecoxib 200 mg (Celebrex 200, Pfizer, USA) simultaneously.
89083640|NCT05911126|Active Comparator|Group B|(60 participants) will receive one oral placebo capsule similar in size, structure, and color to celecoxib and two oral tablets of HBB (Buscopan 10 mg, Boehringer Ingelheim)
89083641|NCT05911126|Active Comparator|Group C|(60 participants) will receive two oral placebo tablets similar in size and color to Buscopan tablet and one capsule of Celecoxib 200 mg (Celebrex ® 200, Pfizer, USA).
89083642|NCT05911087|Experimental|Phase II group 1 :A single 25 μg dose mRNA vaccine SWIM816|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
89083643|NCT05911087|Active Comparator|PhaseII group 2:A single 25 μg dose mRNA vaccine SW-BIC-213|Intervention Name :COVID-19 mRNA vaccine Type :Control Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
89083644|NCT05911087|Experimental|Phase III group 1:A single 25 μg dose mRNA vaccine SWIM816|Intervention Name :COVID-19 mRNA vaccine Type :Investigational Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.5ml; Dosage Level(s) :0.25ml; Route of Administration: injection Intramuscular
89083645|NCT05911087|Active Comparator|Phase III group 2:A single 30 μg dose mRNA Pfizer Bivalent vaccine|Intervention Name :Pfizer Bivalent Vaccine Type :Control Vaccine Dose :Formulation mRNA Unit Dose Strength(s) :0.3μg; Dosage Level(s) :0.3ml;
89083646|NCT05908565|Active Comparator|Aim 1|To examine the impact of demographic matching and supervision intensity on treatment engagement, treatment satisfaction, symptoms, and functioning for students receiving digital therapy. Hypothesis for Main Effect 1: Participants who are matched with Latinx peer coaches will show greater treatment engagement, satisfaction, and improvements in symptom and functioning relative to participants who are not. Hypothesis for Main Effect 2: Participants assigned to peer coaches in standard supervision will show greater treatment engagement, satisfaction, and improvements in symptom and functioning relative to those assigned to coaches in reduced supervision. Hypothesis for Interaction Effect: Students assigned to coaches who are demographically matched and receiving standard supervision will show greater treatment engagement, satisfaction, and improvements in symptom and functioning relative to those in all other conditions.
89083647|NCT05908565|No Intervention|Aim 2|To examine explanatory/intervening variables impacting treatment engagement, treatment satisfaction, symptoms and functioning for students receiving digital therapy. Hypothesis 2: Evidence of mediation will be observed for the following five explanatory/intervening variables: 1) quality of the relationship between the participant and peer coach, 2) the participants' perception of cultural similarity with their coach, 3) the participants' treatment expectancy and treatment credibility, 4) the participants' perception of their peer coach's cultural competence, and 5) the peer coaches' fidelity to the treatment model.
89083648|NCT05908565|No Intervention|Aim 3|To examine the cost-effectiveness of providing standard supervision. Hypothesis 3: Cost-effectiveness analyses will demonstrate that the increased costs incurred by standard supervision relative to reduced supervision will be justified by participants assigned to peer coaches receiving standard supervision experiencing greater improvements in symptoms than those assigned to peer coaches receiving reduced supervision.
89083649|NCT05908539|Experimental|Equipment box (general)|A box of exercise equipment is distributed to community dwelling older adults.
89083650|NCT05908539|Experimental|Equipment box with briefing (general)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment is provided to community dwelling older adults.
89083651|NCT05908539|Experimental|Group-based exercise (general)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment and an 8-week group exercise training program is provided to community dwelling older adults.
89083652|NCT05908539|Experimental|Group-based exercise with behavioral modification (general)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment and an 8-week group exercise training program is provided to community dwelling older adults, following by a 6-week behavioral modification.
89083653|NCT05908539|Experimental|Equipment box (home-bound)|A box of exercise equipment is distributed to home-bound community dwelling older adults.
89083654|NCT05908539|Experimental|Equipment box with briefing (home-bound)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment is provided to home-bound community dwelling older adults.
89083655|NCT05908539|Experimental|Home-based exercise with behavioral modification (home-bound)|A box of exercise equipment is distributed. Verbal briefing of exercise equipment and an 8-week group exercise training program is provided to home-bound community dwelling older adults, following by a 6-week behavioral modification.
89083656|NCT05908513|Active Comparator|NAC treatment|N-acetylcysteine capsule, 600mg/day, oral, 5 years
89083657|NCT05908513|Placebo Comparator|Placebo|Similar chemical structure of NAC but without function
89083658|NCT05908500|Other|Standard CPR Training|Standard CPR training via American Heart Association or American Red Cross provided for 30 minutes during a high school class
89083659|NCT05908500|Active Comparator|CPR Game|Novel CPR game experience CPR training is provided for 30 minutes during a high school class.
89083660|NCT05908370|Experimental|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|
89083661|NCT05908370|No Intervention|Maxillary orthognathic surgery using 2 patient specific osteosynthesis (2-Plates)|
89083662|NCT05908318|No Intervention|Control group|The control group conducts standard preoperative preparation
89083663|NCT05908318|Experimental|olfactory training group|The olfactory training group was performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
89083664|NCT05908305|Active Comparator|Tramadol Addicted Patients|It represents the group of tramadol addicted patients seeking dental care that require dental anesthesia.
89083665|NCT05908305|Active Comparator|Non addicted patients|The group of patients requiring dental care with local anesthesia and who are not addicted to tramadol.
89083666|NCT02672995|Experimental|Single arm dose-escalation|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.~Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
89083667|NCT05908279||PD|Patients with Parkinson's disease
89083668|NCT05908279||Control|Healthy volunteers
89083669|NCT05908266||PD|Patients with Parkinson disease
89083670|NCT05908266||Control|Healthy volunteers
89083671|NCT05908201|Experimental|early time-restricted eating|The Early Time Restricted Eating (eTRE) group will be asked to consume calorie containing food or drinks only between 9am to 5pm, daily. At other times they are to avoid consuming any calorie containing food or drinks.
89083672|NCT05908201|No Intervention|Control|The Control group will follow their usual eating routine.
89083673|NCT05908175|Other|Intervention group|FES-assisted gait training intervention group
89083674|NCT05908162||Patients with sepsis on day 1|
89083675|NCT05908162||Patients with sepsis on day 7|
89083676|NCT05908162||Patients with severe bacterial infection|
89083677|NCT05908162||Patients with severe viral infection|
89083678|NCT05908019|Experimental|Web-based health care program|We aim to develop a PAH web-based health care program, and to evaluate the effects of this program on ameliorating social support, self-care ability and active tolerance, and improving symptom distress, anxiety, depression and quality of life in patients with PAH.
89083679|NCT05908019|No Intervention|Usual care|usual care
89083680|NCT05908006||non-randomized, open-label study|All participants will have the same Laboratory and Diagnostic Assessments and Imaging Procedures.
89083681|NCT05907928|Experimental|Radio-opaque universal adhesive|Radio-opaque universal adhesive
89083682|NCT05907928|Active Comparator|Conventional universal adhesive|Conventional universal adhesive
89083683|NCT05907915|Experimental|laser group|active low level laser therapy and conventional medical treatment.
89083684|NCT05907915|Placebo Comparator|placebo group|placebo laser and conventional medical treatment
89083685|NCT05907902|Experimental|Aspirin|low-dose aspirin, 100 mg once daily, one 100mg tablet
89083686|NCT05907902|No Intervention|standard protocol|standard of care, UIA management according to guidelines.
89083687|NCT05907863|Experimental|Intracardiac echo guided ablation|
89083688|NCT05907863|No Intervention|Standard, electroanatomical mapping system guided ablation|
89083689|NCT05907798|Active Comparator|Group PECS|placing the ultrasound probe in the midclavicular line and in the parasagittal plane, After identifying the second and third ribs by sliding the ultrasound probe caudally, the lower end will be rotated towards the axilla to make the probe parallel to the deltopectoral groove. Combined with the in-plane technique, this rotation provides better extension to the intercostobrachial nerve. The tip of the needle will be inserted into the interpectoral fascial plane (between pectoralis major and minor). The needle will be advanced from the interpectoral fascial plane to the fascial plane between the pectoralis minor and the serratus anterior. 10 mL of local anesthetic (Bupivacaine) will be applied to the PECS I area and 20 mL to the PECS II area.
89225447|NCT05700643|Experimental|Intervention|500 mg cherry supplement
89225448|NCT05700643|Placebo Comparator|Control|Placebo
89230167|NCT00662363|Active Comparator|Senna active plus Lubiprostone Placebo|Senna 2 tabs daily for 6 days at noon and placebo Lubiprostone 1 Cap BID
89225449|NCT05697406|Experimental|Experimental|Participants will receive an injection of 250 mM of hyperpolarized 13-C pyruvate intravenously after standard of care imaging sequences are performed. Then participants will undergo HP-MR imaging.
89225450|NCT05696912|Other|Ex-vivo and In-vitro approach|"Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis.~In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay"
89225451|NCT05696678|Active Comparator|Intrathecal Morphine (Control Group)|Spinal anesthesia with intrathecal morphine and postoperative continuous wound infusion with sterile saline.
89225452|NCT05696678|Active Comparator|Continuous Wound Infusion (Intervention Group)|Spinal anesthesia without intrathecal morphine and postoperative continuous wound infusion with ropivacaine.
89225453|NCT05695521|Experimental|CK0803|"CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously Dose: 100 million Treg cells (fixed dose)~Dose regimen:~Induction: one infusion every 7 days (+/-3) x 4 doses~Consolidation: one infusion every 28 days (+/-3) x 5 doses"
89225454|NCT05695521|Placebo Comparator|Placebo|Excipient
89225455|NCT05695001||No Intervention: Baseline therapy|Basic therapy is the routine practice of an institution for the treatment of patients with acute pancreatitis without signs of infection
89225456|NCT05695001||Experimental: Basic therapy + Efferon CT|Basic therapy is a routine practice of the institution for the treatment of patients with acute uninfected pancreatitis in combination with extracorporeal hemoperfusion (Efferon CT)
89225457|NCT05694988|No Intervention|Baseline therapy|Basic therapy - the routine practice of an institution for the treatment of patients with uninfected acute pancreatitis
89225458|NCT05694988|Experimental|Basic therapy + Efferon CT + HVHF|Basic therapy, which is the routine practice of an institution for the treatment of patients with acute nonseptic pancreatitis in combination with extracorporeal hemoperfusion therapy (Efferon CT) and high-volume hemofiltration (HVHF).
89225459|NCT05694455|Other|Septic Patient Interventions|Septic Patients will have all interventions performed: Urine collection, Passive Leg Raise, Ultrasound and sublingual microscopy
89225460|NCT05694455|Other|Control Patient Interventions|Control patients will have urine collection and sublingual microscopy performed when intubated
89225461|NCT05691218|Active Comparator|Control - Standard Nebulization|
89225462|NCT05691218|Experimental|A-Vibrating mesh Nebulization|
89225463|NCT05691218|Experimental|B-Vibrating mesh Nebulization and High-flow nasal cannula heated and humidified oxygen|
89225464|NCT05686044|Experimental|7.5mg Buntanetap/Posiphen|Buntanetap/Posiphen 7.5mg oral capsule with daily administration for a period of 12 weeks
89225465|NCT05686044|Experimental|15mg Buntanetap/Posiphen|Buntanetap/Posiphen 15mg oral capsule with daily administration for a period of 12 weeks
89225466|NCT05686044|Experimental|30mg Buntanetap/Posiphen|Buntanetap/Posiphen 30mg oral capsule with daily administration for a period of 12 weeks
89225467|NCT05686044|Placebo Comparator|Placebo|Placebo oral capsule with daily administration for a period of 12 weeks
89225468|NCT05685472|Experimental|MEDI5752 monotherapy|
89225469|NCT05683132|Experimental|Trauma-Informed CBT-I|This intervention includes trauma-informed adaptations to standard treatment for insomnia, CBT-I
89225470|NCT05683132|Active Comparator|PTSD Psychoeducation|This intervention includes psychoeducation about PTSD symptoms modeled after usual care in a VA Women's Health Clinic.
89225471|NCT05680142|Active Comparator|Group sCPB|Superficial cervical plexus block, patients who applied sCPB for postoperative pain
89225472|NCT05680142|Active Comparator|Group cESP|Cervical erector spinae plane block, patients who applied cervical ESP block for postoperative pain
89225473|NCT05679362|Experimental|immediate individual treatment (A)|5 online individual sessions
89225474|NCT05679362|Experimental|immediate group treatment (B)|5 online group sessions with other women with PCOS
89225475|NCT05679362|No Intervention|wait-list-control group|The wait-list control group receives no treatment for the first three months, at which point they will cross over to one of the intervention arms (individual treatment A or group treatment B) and start with the intervention.
89225476|NCT05669716||parents of teens who vape|400 parent participants, defined as an adult who identifies as parenting an adolescent aged 13-17 whom they know/suspect is vaping.
89225477|NCT05669716||teens who formerly vaped|Adolescents N=400 (formerly vaped)
89225478|NCT05669716||teens who never vaped|Adolescents N=400 (never vaped).
89225479|NCT05669716||teens who vape|adolescent participants (minor subjects), comprised of N=400 (currently vaping, defined as vaping at least one day in the previous 30-day period
89225480|NCT05665283|Active Comparator|Reference Standard Group|"In Period 1, 32 healthy volunteers will divided evenly and randomly assigned to receive 1 dose of 100 mg capsules from either the test product or reference product.~In Period 2 the same patients in each cohort will cross over and receive 1 dose of the 100 mg from the other group. These healthy volunteers will receive 1 dose from each of the 100 mg capsules manufactured by both processes."
89225481|NCT05665283|Active Comparator|Test Standard Group|"In Period 1, 32 healthy volunteers will divided evenly and randomly assigned to receive 1 dose of 100 mg capsules from either the test product or reference product.~In Period 2 the same patients in each cohort will cross over and receive 1 dose of the 100 mg from the other group. These healthy volunteers will receive 1 dose from each of the 100 mg capsules manufactured by both processes."
89225482|NCT05664477|Experimental|PhytoSERM group|PhytoSERM 50mg tablet composed of the phytoestrogens daidzein, genistein and S-equol, administered orally every day for 24 weeks.
89225483|NCT05664477|Placebo Comparator|Placebo group|Placebo product with identical shape, size and color with absence of daidzein, genistein, and S-equol. Administered orally every day for 24 weeks.
89225484|NCT05658185|No Intervention|No Intervention: Control Group|All patients will be evaluated on 4 occasions: 1) T1: 1st pre-treatment measurement in control and experimental groups; 2) after 10 weeks, T2: 2nd pre-treatment measurement in control and experimental groups; 3) after 10 weeks, T3: 3rd pre-treatment measurement in control and experimental groups, and 1st post-treatment measurement in experimental groups. Between T2 and T3 the patients in the experimental group will receive for 10 weeks the 10 sessions of the psychological treatment protocol; 4) after that, in the following 10 weeks, the control group will receive the 10 sessions of psychological treatment, thus at T4: 1st post-treatment measurement in the control group, and 1st post-treatment follow-up session in the experimental group (during this time, the experimental group does not receive any more treatment sessions, but practices all the psychological management skills installed during the treatment protocol between T2 and T3).
89225485|NCT05658185|Experimental|Experimental Group|All patients will be evaluated on 4 occasions: 1) T1: 1st pre-treatment measurement in control and experimental groups; 2) after 10 weeks, T2: 2nd pre-treatment measurement in control and experimental groups; 3) after 10 weeks, T3: 3rd pre-treatment measurement in control and experimental groups, and 1st post-treatment measurement in experimental groups. Between T2 and T3 the patients in the experimental group will receive for 10 weeks the 10 sessions of the psychological treatment protocol; 4) after that, in the following 10 weeks, the control group will receive the 10 sessions of psychological treatment, thus at T4: 1st post-treatment measurement in the control group, and 1st post-treatment follow-up session in the experimental group (during this time, the experimental group does not receive any more treatment sessions, but practices all the psychological management skills installed during the treatment protocol between T2 and T3).
89225486|NCT05655364|Experimental|Experimental|
89225487|NCT05655364|No Intervention|No intervention|
89225488|NCT05653726|Experimental|Telemonitoring group|Follow-up group by telematic consultations and non-invasive daily telemonitoring of weight, blood pressure, heart rate, peripheral oxygen saturation and electrocardiogram.
89225489|NCT05653726|No Intervention|Control gropu|Usual care follow-up group
89225490|NCT05653466|Experimental|Adaptive spacing, then high-item non-adaptive spacing, then low-item non-adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225491|NCT05653466|Experimental|Adaptive spacing, then low-item non-adaptive spacing, then high-item non-adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225492|NCT05653466|Experimental|High-item non-adaptive spacing, then adaptive spacing, then low-item non-adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225493|NCT05653466|Experimental|High-item non-adaptive spacing, then low-item non-adaptive spacing, then adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225494|NCT05653466|Experimental|Low-item non-adaptive spacing, then high-item non-adaptive spacing, then adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225495|NCT05653466|Experimental|Low-item non-adaptive spacing, then adaptive spacing, then high-item non-adaptive spacing|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225496|NCT05653440|Experimental|Effort-maximized, then accuracy-maximized, then effort-accuracy balanced|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225497|NCT05653440|Experimental|Effort-maximized, then effort-accuracy balanced, then accuracy-maximized|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225498|NCT05653440|Experimental|Accuracy-maximized, then effort-maximized, then effort-accuracy balanced|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225499|NCT05653440|Experimental|Accuracy-maximized, then effort-accuracy balanced, then effort-maximized|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225500|NCT05653440|Experimental|Effort-accuracy balanced, then effort-maximized, then accuracy maximized|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225501|NCT05653440|Experimental|Effort-accuracy balanced, then accuracy-maximized, then effort-maximized|All participants will receive all three naming treatment conditions in a randomized order - this is one possible ordering of those conditions.
89225502|NCT05650996|Experimental|ADL video/Cast Care|ADL/cast care instructional video ADL/cast care handout
89225503|NCT05650996|Active Comparator|Cast Care Video|Cast care instructional video Cast care handout
89225504|NCT05647447|Experimental|Pilot Trial: Osanetant 28 Days|Osanetant 200 mg orally, twice per day for 28 days.
89225505|NCT05647343|Experimental|ATL-001 0.2 mg/kg vs Placebo|Cohort 1: ATL-001 at 0.2 mg/kg or Placebo (depending on randomization) will be administered during 5 days
89225506|NCT05647343|Experimental|ATL-001 0.5 mg/kg vs Placebo|Cohort 2: ATL-001 at 0.5 mg/kg or Placebo (depending on randomization) will be administered during 5 days
89225507|NCT05647343|Experimental|ATL-001 1 mg/kg vs Placebo|Cohort 3: ATL-001 at 1 mg/kg or Placebo (depending on randomization) will be administered during 5 days
89225508|NCT05647343|Experimental|ATL-001 2 mg/kg vs Placebo|Cohort 4: ATL-001 at 2 mg/kg or Placebo (depending on randomization) will be administered during 5 days
89225509|NCT05647343|Experimental|ATL-001 4 mg/kg vs Placebo|Cohort 5: ATL-001 at 4 mg/kg or Placebo (depending on randomization) will be administered during 5 days
89225510|NCT05643209|Other|consecutive patients|20 patients clinically indicated for a endo-epicardial catheter-based mapping procedure for the treatment of ventricular tachycardia/ ventricular fibrillation substrate
89225511|NCT05643118|Experimental|Part A 100 μg/eye/50 μL|study eye treated with 100 μg (94.3 μg free acid) of OLX10212
89225512|NCT05643118|Experimental|Part A 250 μg/eye/50 μL|study eye treated with 250 μg (235.8 μg free acid) of OLX10212
89225513|NCT05643118|Experimental|Part A 500 μg/eye/50 μL|study eye treated with 500 μg (471.5 μg free acid) of OLX10212
89225514|NCT05643118|Experimental|Part A 750 μg/eye/50 μL|study eye treated with 750 μg (707.3 μg free acid) of OLX10212
89225515|NCT05643118|Experimental|Part A 950 μg/eye/50 μL|study eye treated with 950 μg (895.9 μg free acid) of OLX10212
89225516|NCT05643118|Experimental|Part B 750 μg/eye/50 μL|study eye treated with a total of 3 intravitreal injections of 750 μg (707.3 μg free acid) of OLX10212 each 28 days apart
89225517|NCT05643118|Experimental|Part B 950 μg/eye/50 μL|study eye treated with a total of 3 intravitreal injections of 950 μg (895.9 μg free acid) of OLX10212 each 28 days apart
89225518|NCT05641129||Main Cohort|Consecutive adult patients (≥18 years of age) presenting acutely (i.e. unplanned and non-elective presentation to hospital for urgent or emergency reasons) for symptoms of known or unknown colorectal cancer assessed by hospital surgical teams. Patients should be included regardless of operative or non-operative management, and curative or palliative intent.
89225519|NCT05639751|Experimental|PRT3789 Monotherapy|PRT3789 will be administered by intravenous infusion
89225520|NCT05639751|Experimental|PRT3789/Docetaxel Combination|PRT3789 and Docetaxel will be administered by intravenous infusions
89225521|NCT05638841||atrial fibrillation|After radiofrequency ablation of patients with atrial fibrillation
89225522|NCT05635292|Experimental|Tele-CBT|
89225523|NCT05635292|No Intervention|Control|
89225524|NCT05634707|Experimental|Fluoxetine pre-surgery|Patients randomized to the experimental arm will receive fluoxetine at 20 mg/day for 5 days (initiation dose) followed by a maintenance dose of 40 mg/day starting on Day 6 (dose level 1) or 60 mg/day starting on Day 6 (dose level 2).
89225525|NCT05634707|Active Comparator|Temozolomide pre-surgery|Temozolomide pre-surgery (control) arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
89225526|NCT05633667|Experimental|Substudy 01: Zimberelimab (ZIM) + Sacituzumab govitecan-hziy (SG) + Domvanalimab (DOM)|Participants will receive ZIM, SG and DOM until disease progression (PD), unacceptable toxicity, or protocol specified discontinuation criteria are met.
89225527|NCT05633667|Experimental|Substudy 01: ZIM + DOM + Etrumadenant (ETRUMA)|Participants will receive ZIM, DOM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.
89225528|NCT05633667|Experimental|Substudy 01: ZIM + ETRUMA|Participants will receive ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.
89225529|NCT05633667|Active Comparator|Substudy 01: ZIM + Platinum Based Chemotherapy|"Expansion Stage Only: Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Platinum Based Chemotherapy will be cisplatin or carboplatin and pemetrexed (non-squamous histology) or carboplatin, paclitaxel and nabpaclitaxel (squamous histology)."
89225530|NCT05633667|Experimental|Substudy 02: SG + ZIM + ETRUMA|Participants will receive SG, ZIM and ETRUMA until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.
89225531|NCT05633667|Active Comparator|Substudy 02: Either Docetaxel or SG (Monotherapy Only)|Participants will receive either Docetaxel or SG until PD, unacceptable toxicity, or protocol specified discontinuation criteria are met.
89225532|NCT05633667|Experimental|Substudy 03 - ZIM + DOM + Platinum-based Chemotherapy|"Participants will receive ZIM plus DOM and any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology)."
89225533|NCT05633667|Experimental|Substudy 03 - ZIM + Platinum-based Chemotherapy|"Participants will receive ZIM plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology)."
89225534|NCT05633667|Active Comparator|Substudy 03: Nivolumab + Platinum-based Chemotherapy|"Participants will receive nivolumab plus any one of the chemotherapy (choice of chemotherapy is dependent on histology).~Platinum Based Chemotherapy will be carboplatin and pemetrexed (non-squamous histology) or carboplatin and paclitaxel (squamous histology)."
89225535|NCT05630092|Active Comparator|Maximal then Normal Speed Walk Test|Maximal speed walking test (Max_6MWT) followed by normal speed walking test (Nor_6MWT).
89225536|NCT05630092|Active Comparator|Normal then Maximal Speed Walk Test|Normal speed walking test (Nor_6MWT) followed by Maximal speed walking test (Max_6MWT)
89225537|NCT05626790|Experimental|PNF Stretching|All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. In addition to the exercises, three different types of PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.
89225538|NCT05626790|Active Comparator|Prolonged Stretching|"All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.~In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week."
89225539|NCT05622643||Patients with MS|250 patients with MRI, OCT and bio sample
89225540|NCT05622643||Healthy subjects|50 healthy subjects with MRI
89225541|NCT05621746||Participants with Haemophilia A|Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
89225542|NCT05620719|Active Comparator|Clinic-based Cognitive Behavioral Therapy (CCBT)|CCBT provides CBT for posttraumatic headache through 8 face-to-face, in-clinic sessions.
89225543|NCT05620719|Active Comparator|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|TCBT provides 8-sessions of CBT for posttraumatic headache using telemedicine technology rather than attending in-office sessions. Additionally, TCBT includes instructions for each session specific to the mechanics of a telehealth encounter (e.g., asking participant for name, location, and accessible phone number for location in case of technical failure or crisis). All TCBT participants must be enrolled at the MTF or VA from which they were recruited, and the treatment facility will be notified that they are receiving TCBT in case a crisis arises and needs to be managed by the site.
89225544|NCT05620719|Active Comparator|Treatment As Usual|Participants will continue to engage in clinical care as usual for 8 weeks. Research staff will call the TAU participants weekly to assess for adverse events. Research staff at each site will be trained on standardized assessment of usual care activities using forms adapted from our single-site trial.
89225545|NCT05619692|Experimental|SAGE-718|Participants will receive 1.2mg of SAGE-718 orally once daily for the first 6 weeks Days 1 to 42 [±2 days], followed by 0.9 mg of SAGE-718 for the remainder of the Treatment period up to Day 84 Visit [±7 days].
89230168|NCT02555033|Experimental|M-RT|Machine-based resistance training. Exercising 'traditional' machine-based resistance training.
89083690|NCT05907798|Active Comparator|Group SA|It will be positioned to stand at the head of the patient or to one side of the patient and to see the ultrasound screen easily. High-frequency linear probe and 80 mm blunt-tipped needle will be placed cauda-cranially or cranially-caudal with in-plane technique. The injection site is found by placing the ultrasound probe under the clavicle in a parasagittal manner and counting from the second rib. By moving the probe laterally towards the mid or posterior axillary line, the serratus anterior muscle is seen as a layer of muscle over the anechoic shadow of the rib. It extends over the latissimus dorsi serratus anterior muscle and appears thicker and more prominent in the posterior axillary line. 30 mL of local anesthetic (bupivacaine) will be administered to the fascial plane by advancing the needle superficially or deeply into the serratus anterior muscle.
89083691|NCT05907798|Sham Comparator|Group K (Control group)|The patient, who was taken to the operating table with his consent, will be monitored. ECG monitoring, SpO2 monitoring, invasive artery monitoring will be performed. General Anesthesia will be applied(Induction with 2 mg/kg propofol, 0.6mg/kg rocuronium bromide, 2µcg/kg fentanyl, 2MAC sevoflurane + 40% air mixture and maintenance with 2L/min) Routine coronary artery bypass grafting surgery will be performed without any peripheral blocking and LIMA blood flow will be measured.
89083692|NCT05907772||Recipients with preoperative PIVKA-II≤240mAU/mL|
89083693|NCT05907772||Recipients with preoperative PIVKA-II>240mAU/mL|
89083694|NCT05907642|Experimental|Prune|During the first 3 days of taking the prunes, 60 g (6 pieces of prune) were consumed per day, and if there were no symptoms corresponding to the safety endpoints for 3 days, the amount was increased to 100 g per day thereafter. Prunes were consumed twice, half each in the morning and afternoon, and the total intake period was 18 days.
89083695|NCT05907642|Placebo Comparator|No-prune|No intervention was provided to the control group, and all normal diets were allowed except for prunes during the study period, for 18 days.
89083696|NCT05907603|Experimental|Research Development 13(RD13)-02 cell infusion|drugs use generic name : RD13-02 CAR-T cell injection ; dosage form : Cell injection ; dosage : 2×10^8 CAR+ T cells ; frequency : Once.
89083697|NCT05907590||Patients with Fibromyalgia|Patients with fibromyalgia diagnosed using the ACR criteria (American College of Rheumatology, Wolfe et al., 2010; 2016).
89083698|NCT05907590||Healthy Controls|Healthy controls will consist of people who experience few physical complaints in daily life. The healthy controls will thus be screened for inclusion using the CSD (Checklist for Symptoms in Daily life; Walentynowicz, et al., 2018). Only volunteers with a score of 75 or lower on this questionnaire will be included
89083699|NCT05907577||Disease cohort|Observational, no interventions
89083700|NCT05907577||Control cohort|Observational, no interventions
89083701|NCT05907538||Patients with functional disorder (FD)|Patients with fibromyalgia diagnosed using the ACR criteria (American College of Rheumatology, Wolfe et al., 2010; 2016) Patients with chronic fatigue syndrome diagnosed using the CDC criteria (Centers for Disease Control and Prevention; Fukuda et al., 1994)
89083702|NCT05907538||Patients with stress related syndromes (SRS)|Patients with overstrain and burnout according to the multidisciplinary guidelines for overstrain and burnout in primary care from the Dutch Society of Occupational Medicine (NVAB, 2011)
89083703|NCT05907538||Healthy controls|Healthy controls will consist of people who experience few physical complaints in daily life. The healthy controls will thus be screened for inclusion using the CSD (Checklist for Symptoms in Daily life; Walentynowicz, et al., 2018). Only volunteers with a score of 75 or lower on this questionnaire will be included
89083704|NCT05907499|Experimental|Arm A|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
89083705|NCT05907499|Active Comparator|Arm B|The hematologic growth factors (granulocyte-colony stimulating factor, thrombopoietin receptor agonists, recombinant human erythropoietin)
89083706|NCT05907486|Experimental|Arm A|Modified BUCY conditioning regimen: busulfan (3.2mg/kg, day-7 to day -5), cytarabine (2g/m2, day -8), cyclophosphamide (1.8g/m2, day -4 to day -3), followed by stem cells infusion; N-acetyl-cysteine (Zambon Pharma, Hainan, China) : 8g/d (>=45kg); 200mg/kg.d (<45kg), intravenously for at least 4 hours, day -9 to day +45.
89083707|NCT05907486|Active Comparator|Arm B|Modified BUCY conditioning regimen: busulfan (3.2mg/kg, day-7 to day -5), cytarabine (2g/m2, day -8), cyclophosphamide (1.8g/m2, day -4 to day -3), followed by stem cells infusion.
89083708|NCT05907408||Steatosis|Patients with non-alcoholic fatty liver disease presenting exclusively with steatosis, without fibrosis or inflammation
89083709|NCT05907408||Steatohepatitis|Patients with non-alcoholic fatty liver disease presenting with steatosis and degree >1 of liver fibrosis
89083710|NCT05907382|Experimental|JMKX003002 SAD experimental group|Participants will be randomized into 5 cohorts to receive single oral dose of JMKX003002 on Day 1. The doses in each cohort will be escalated based on the safety and pharmacokinetics (PK) / Pharmacodynamics (PD) data of the previous cohort.
89083711|NCT05907382|Experimental|JMKX003002 MAD experimental group|Participants will be randomized into 2 cohorts to receive orally twice -daily of JMKX003002 for 7 consecutive days. The second cohort will be escalated based on the safety and pharmacokinetics (PK)/ Pharmacodynamics (PD) data of the previous cohort.
89083712|NCT05907382|Experimental|JMKX003002 FE experimental group|Participants will receive 3 Sequence regimens, with a washout period between treatments.
89083713|NCT05907382|Placebo Comparator|Placebo in Cohorts 1 to 5|Participants in Cohorts 1 to 5 will receive single oral dose of matching placebo on Day 1.
89083714|NCT05907382|Placebo Comparator|Placebo in 2 Cohorts|Participants in 2 Cohorts will receive orally twice -daily of matching placebo for 7 consecutive days.
89083715|NCT05907330|Experimental|CU104|CU104 100 mg three capsules a day .
89083716|NCT05907330|Placebo Comparator|Placebo|Placebo three capsules a day.
89225546|NCT05619692|Placebo Comparator|Placebo|Participants will receive placebo-matching capsule once daily orally throughout the treatment period for up to Day 84.
89230169|NCT02555033|Experimental|M-IRT|Machine-based instability resistance training; a similar training program with exercise-machines, but with additional unstable devices placed between participant and exercise-machine or floor respectively.
89230170|NCT02555033|Experimental|F-IRT|Free weight instability resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
89230171|NCT04887155|Active Comparator|Cognitive behavioral therapy (CBT)_no app|
89083717|NCT05907265|Experimental|Immersive Virtual Reality group|"The intervention will be group-based, with 5 participants per group, and will consist of a total of 24 sessions of 60 minutes. These 24 sessions are organized over 12 weeks, 2 sessions per week. The sessions will consist of a group program of multimodal stimulation using immersive MK360 technology to train cognitive, emotional, and physical areas.~Each session will have a different content, although they will follow the following outline:~Welcome and awareness of the here and now.~Mindfulness techniques~Cognitive stimulation~Physical activation~Feedback and end of session.~The visual material used for each session will be specific and adapted to the group."
89083718|NCT05907265|Active Comparator|Active Comparator: Active control program|In paper or pdf format, patients in the active control group will receive guidelines for physical and cognitive stimulation to do autonomously at home. Patients in the active control group will receive guidelines for cognitive and physical stimulation and meditation exercises in paper or pdf format, to be done independently at home. They will be encouraged to do physical exercises, meditation, and cognitive activities two times a week.
89083719|NCT05907187|Experimental|Twalet Deba Group|Participants will receive cervical cancer prevention education, and provide self-administered vaginal or cervical specimens and provide specimens of plants, plant-products or herbs most commonly used in the intravaginal cleansing practice of twalet deba. Total expected participation is about 30 days.
89083720|NCT05907109|Experimental|Intervention|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.
89230172|NCT04887155|Experimental|Cognitive behavioral therapy (CBT) with mobile app|
89230173|NCT00792857|Experimental|CTAP201 Injection at dose a|CTAP201 at dose a
89083721|NCT05907109|No Intervention|Control Group - Standart of Care|"The control group receives basic guidelines on child development, nutrition, and breastfeeding provided by the Brazilian Ministry of Health, in addition to standard of care cardiac pediatric follow-up visits.~Infants will receive outcome developmental evaluations within a 42-month follow-up clinic."
89083722|NCT05907083||Adult CBCT Scan|CBCT Radiation
89083723|NCT05906992|Experimental|CT-P53|CT-P53(Ocrelizumab)
89083724|NCT05906992|Active Comparator|US-Ocrevus|US-licensed Ocrevus(Ocrelizumab)
89083725|NCT05906992|Active Comparator|EU-Ocrevus|EU-approved Ocrevus(Ocrelizumab)
89083726|NCT05906966||CHILDREN|BORN FROM IN VITRO FERTILIZATION OF CRYOPRESERVED OOCYTES
89083727|NCT05906901|Placebo Comparator|Control Group|The investigator will perform a cranial listening technique.
89083728|NCT05906901|Experimental|Suboccipital muscles inhibition|The investigator will perform a suboccipital muscles inhibition technique.
89083729|NCT05906823||benign pleural effusion|Patients with benign pleural effusion.
89083730|NCT05906823||malignant pleural effusion patients with bad prognosis|The OS time of malignant pleural effusion patients is<1 year.
89083731|NCT05906823||malignant pleural effusion patients with good prognosis|The OS time of malignant pleural effusion patients is ≥1 year.
89083732|NCT05906758|Active Comparator|Immediate intervention arm|Immediate angiography will be performed within 24 hours of enrollment. Omnipaque contrast will be administered. Serum creatinine will be collected on enrollment, within 6 hours before coronary angiography, and at 24h, 48h and 1-week after the angiography, as expected in common practice. Pre- and post-hydration administration will be at the discretion of the treating physician. In case percutaneous coronary intervention is indicated it will be schedule for 7 days after angiography.
89083733|NCT05906758|Placebo Comparator|Delayed intervention arm|Delayed angiography will be performed after kidney function stabilizes.
89083734|NCT05906680||Ulcerative Colitis (UC)|Patients with ulcerative colitis undergoing endoscopy and biopsies-collection according to the standard of care. First diagnosis for UC, treatment naive patients (≥18 and <40 years), with no previously documented gastrointestinal infections. Furthermore, clinical and endoscopic evaluation (Mayo score≥2).
89083735|NCT05906680||Crohn's Disease (CD)|Patients with Crohn's disease undergoing endoscopy and biopsies-collection according to the standard of care. First diagnosis for CD, treatment naive patients (≥18 and <40 years), with no previously documented gastrointestinal infections. Furthermore, clinical and endoscopic evaluation (Harvey-Bradshaw score≥5 and overall Simplified Endoscopic Score (SES-CD)> 2).
89083736|NCT05906680||No UC and CD|Subjects undergoing endoscopy and biopsies-collection according to the standard of care (≥18 and <40 years) (for example patients in screening for colorectal cancer disease). Subjects not affected by UC or CD according to the previously reported clinical and endoscopic evaluation criteria.
89083737|NCT05906667|Experimental|Intervention Group|All participants assigned to the experimental group (walking)
89083738|NCT05906654|Experimental|Intervention Group|Participants engage in walking and conversational reminiscence three times per week
89083739|NCT05906576|Experimental|Infliximab|Infliximab for the treatment of Crohn's disease in children
89083740|NCT05906563|Active Comparator|melatonin loaded nanoparticle (test group)|13 patients will be treated with melatonin loaded nanoparticle gel as adjunct to scaling and root planning .it will be applied once weekly for four weeks.
89083741|NCT05906563|Active Comparator|melatonin and metformin loaded nanoparticle (test group)|13 patients will be treated with melatonin and metformin loaded nanoparticle gel as adjunct to scaling and root planning .It will be applied once weekly for four weeks.
89083742|NCT05906563|Placebo Comparator|placebo gel (control group)|13 patients will be treated with placebo gel as adjunct to scaling and root planning .It will be applied once weekly for four weeks.
89083743|NCT05906563|Other|no gel (control group)|13 patients will be treated with only scaling and root planning ..
89083744|NCT05906550|Experimental|Intervention group|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy.
89083745|NCT05906550|Active Comparator|Control group|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume <500mL/min, or when clinical signs of flow dysfunction are present.
89083746|NCT05906537|Experimental|Phase Ia (Dose Escalation Phase)+Phase Ib (Dose Expansion Phase)|Several dose levels are planned for Phase1a and administered every 2 weeks.The dose of SKB410 for injection in Phase 1b is selected based on the Phase 1a.
89083747|NCT05906524|Experimental|Phase 1：KD6001+Tislelizumab|KD6001 combined with Tislelizumab in patients with solid tumors（hepatocellular carcinoma, esophageal squamous cell carcinoma, MSI-H or dMMR solid tumors are preferentially included）
89083748|NCT05906524|Experimental|Phase 2：KD6001+Tislelizumab±Bevacizumab|KD6001 combined with Tislelizumab±Bevacizumab in patients with advanced HCC
89083749|NCT05906498|Active Comparator|mix acetylcysteine with vitamin E|Standard treatment for mild psoriasis, plus N acetyl cysteine (600 mg a day) oral effervescent sachet,30 minutes before breakfast Plus, vitamin E (1000 mg) daily, oral soft gelatin capsule for 8 weeks
89083750|NCT05906498|Active Comparator|acetylcysteine|Standard treatment for mild psoriasis, plus N acetyl cysteine (600 mg a day) oral effervescent sachet, 30 minutes before breakfast, for 8 weeks
89083751|NCT05906498|No Intervention|standard treatment alone|Standard treatment for mild psoriatic patients (topical steroid and salicylic acid
89083752|NCT05906485|Experimental|Experimental Group: fNIRS Neurofeedback-VR Training Group|The experimental group will receive 16 sessions of training, 1 hour each, conducted twice per week over a period of 8 weeks. A classroom setting will be stimulated using VR and participants will be asked to complete some academic-related tasks during the stimulated lessons. The sensor on the neurofeedback device worn by the participants will detect changes in the blood oxy-hemoglobin level in brain cortical tissue and feedback to the participants via visual images or auditory sounds from the computer. Through practice, participants will learn to manipulate their attention, presumably by altering brain activities.
89083753|NCT05906485|Active Comparator|Active Control Group: Computerized Cognitive Training Group|The computerized cognitive training group will receive 16 sessions of training, 35 minutes each, conducted twice per week over a period of 8 weeks. Participants will be asked to complete a set of computerized tasks using Cogmed, a digital training programme which is proven to enhance working memory and attention level in children.
89083754|NCT05906485|Other|Waitlist Control Group|The waitlist control group will not receive any intervention until the intervention arms complete their training. Depending on the availability, either the fNIRS Neurofeedback-VR Training or the Computerized Cognitive Training will be offered to this group.
89083755|NCT05906472|Experimental|Feeds continued|Enteral feeds are continued up until time of tracheostomy.
89083756|NCT05906472|Other|Feeds withheld|Enteral feeds are withheld at least 6 hours prior to time of tracheostomy.
89083757|NCT05905796|Experimental|Brain Health Intervention|Calculate eRADAR scores using EHR data to identify eligible individuals Invite eligible individuals for brain health assessment visit Enter results of brain health assessment visit into EHR Provide summary of results and recommended next steps to the Primary Care Physician and participant
89083758|NCT05905796|No Intervention|Usual Care|Usual care Individuals who meet eligibility criteria will receive usual care.
89083759|NCT05904639|Experimental|Pre-study|Baseline or pre-study arm
89083760|NCT05904639|Experimental|Cross-over arm|Intervention arm
89083761|NCT05903911|Experimental|Trans Care Intervention|
89083762|NCT05903911|No Intervention|Waitlist Control|
89083763|NCT05902156|Experimental|DiaPaDeSS intervention group|DiaPaDeSS will be introduced to participants with type 2 diabetes during face-to-face interviews. The DiaPaDeSS intervention group will have access to all the contents of the DiaPaDeSS, which includes the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires. During the follow-up period, the participants in the DiaPaDeSS intervention group will take DiaPaDeSS messages once a week and be reminded to use the education program. The DiaPaDeSS will be asked to use it for three months on daily and weekly inputs. During the follow-up period, the participants can contact the researcher via 24/7 on the DiaPaDeSS. Participants in the DiaPaDeSS intervention group will also receive routine patient education and hospital follow-ups.
89083764|NCT05902156|Active Comparator|Control Group|DiaPaDeSS will be introduced to participants with type 2 diabetes in the control group during face-to-face interviews. The control group will have access to only these fields self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format. Participants in the DiaPaDeSS group will also receive routine patient education and routine hospital follow-up during the three-month follow-up period..
89230174|NCT00792857|Experimental|CTAP201 Injection|CTAP201 at dose b or dose c
89230175|NCT00792857|Active Comparator|Doxercalciferol at dose a|Active at dose a
89522924|NCT00092989|Experimental|Montelukast 7 mg|Participants receive montelukast 7 mg intravenously (IV) until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
89083768|NCT05901584|Experimental|Cadonilimab (AK104) combined with chemotherapy|Cadonilimab(10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab(10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle
89083769|NCT05900765|Experimental|Zimberelimab combined with or without AVD sequential radiotherapy|"Combination therapy： Subjects received Zimberelimab 240mg Q3W 2 cycle.~According to the results of PET/CT evaluation:~CR: Additional 2 cycles of Zimberelimab (4 cycles of Zimberelimab monotherapy in total); PR: 2 cycles of Zimberelimab+ AVD therapy (only PR patients combined with AVD). Subjects who did not achieve a Partial Response (PR) or Complete Response (CR) in their initial or subsequent efficacy evaluations, and whose potential for benefit was deemed unlikely by the investigator, were discontinued from the study.~Radiotherapy treatment period (patients with CR/PR): Sequentially radiation therapy 20-30Gy."
89083770|NCT05896358||Bariatric naive|patients with obesity who have not undergone bariatric surgery in the past
89083771|NCT05896358||Post Bariatric|patients with obesity who have undergone bariatric surgery in the past and have experienced weight regain or insufficient weight loss
89230176|NCT00792857|Active Comparator|Doxercalciferol|Active at dose b or dose c
89083772|NCT05892510|Placebo Comparator|Placebo|Intra-arterial bolus of placebo (0.9% Sodium Chloride solution) representing standard of care (no intra-arterial thrombolytic treatment).
89083773|NCT05892510|Experimental|Intra-arterial tenecteplase injection at the completion of thrombectomy|intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion or in direct contact with the residual thrombus
89083774|NCT05887414||Surgery|Patients who chose to receive surgery as treatment for their appendicitis.
89083775|NCT05887414||Antibiotics|Patients who chose to receive antibiotics as treatment for their appendicitis.
89083776|NCT05886270|Experimental|Participants|This arm consists of 300 homes of low-income families with children < 7 years of age who are referred from two of GHHI's currently active programs, DSS Foster Care Homes Program, and Amerigroup Maryland Asthma Program.
89083777|NCT05871853||Pre-implementation group|Women delivering during an eight month period, before the intervention is implemented.
89083778|NCT05871853||Post-implementation group|Women delivering during an eight month period, after the intervention is implemented.
89083779|NCT05871164||Patient to be treated for a tumor of the pancreas|Patient to be treated for a tumor of the pancreas by ultrasound-guided radiofrequency with a fine needle, with Indication of pancreatic radiofrequency validated in a Multidisciplinary Consultation Meeting
89083780|NCT05866718|Active Comparator|Self-Compassionate Touch Intervention Alone|All participants will receive the self-compassion intervention after completing their baseline assessment, which will contain the same instructions used in the initial study (see NCT05199779).
89083781|NCT05866718|Experimental|Self-Compassionate Touch Intervention Plus Habit Formation Tools|SCT+HABITS participants will receive the abovementioned procedures, and will also receive evidence-based tools for forming habits.
89083782|NCT05833490|Experimental|Sensory-based priming|Participants will receive rPMS at 10% above motor threshold with the coil placed on the Tibialis Anterior muscle belly. rPMS parameters will be: 40 trains, intermittently (3) seconds on, (19) seconds off, with an intensity ~10% above motor threshold.
89083783|NCT05833490|Sham Comparator|Sham Priming|Participants will receive sham rPMS at a very low intensity with the coil placed on the dorsal part of the foot. rPMS parameters will be: 40 trains, intermittently (3) seconds on, (19) seconds off, with an intensity at 5% of maximum stimulator output.
89083784|NCT05831800|Other|Wearable bioimpedance sensor|
89083785|NCT05806593|Experimental|Intervention (Get Back pilot)|"The intervention includes 5 core sessions (video call) and 5 booster sessions (telephone) over 12 weeks (1 week before until 11 weeks after surgery). All sessions will be led by a physiotherapist. The focus of each core session (1-5) is as follows:~To establish the patient as an active, equal partner in the treatment and to formulate a shared health plan according to person-centred care.~To reduce the threat value of postoperative pain and increase the patient's knowledge about the biopsychosocial nature of pain and positive effects of physical activity.~To detect barriers for postoperative physical activity and to support the patient to gradually start increasing physical activity.~To increase approach behavior for physical activity and reduce avoidance behavior by confronting fears and move towards personal goals.~To support the patient to independently continue with activity progress towards long term health and to formulate a maintenance plan."
89083786|NCT05806593|No Intervention|Control (standard physiotherapy)|The control group will follow standard physical therapy, meaning physical therapy as it is provided at each recruiting site when undergoing surgery due to spinal stenosis. As this may differ substantially between clinical sites nationally, data on frequency of physical therapy and the content of the physical therapy sessions during the study period will be collected as a control variable weekly from the control group.
89083787|NCT05802589|Active Comparator|Control Group (no peripheral block applied)|No peripheral block was applied to this group and it was accepted as the control group. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
89083788|NCT05802589|Active Comparator|Lumbar Erector Spinae Plane Block (L-ESPB) Group|Lumbar erector spinae plane block was applied to this group under ultrasound guidance. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
89083789|NCT05802589|Active Comparator|Pericapsular Nerve Group Block (PENGB) Group|Pericapsular nerve group block was applied to this group under ultrasound guidance. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
89083790|NCT05760807|Experimental|Intranasal oxytocin|Participants will receive oxytocin by intranasal spray under clinician supervision (1 insufflation equating to an active dose of 24 IU) twice daily (i.e., 48 IU per day), delivered over 7 days of a residential inpatient withdrawal admission.
89083791|NCT05746442|Active Comparator|Standard Care Group|Participants will receive brief advice and education materials to quit smoking along with brief weekly assessments to be completed on a smartphone. They will also receive a 8 week supply of of nicotine replacement therapy in the form of nicotine patches.
89083792|NCT05746442|Experimental|Automated Messaging Treatment Group|Participants will receive brief advice and education materials to quit smoking, along with brief weekly assessments and an interactive phone-based treatment program delivered on a smartphone. They will also receive a 8 week supply of of nicotine replacement therapy in the form of nicotine patches.
89083793|NCT05736874|Experimental|Arm C - Fluticasone|Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.
89083794|NCT05736874|Placebo Comparator|Arm C - Placebo|Placebo is a self-administered inhaled agent. Participants will self-administer 1 blister of placebo once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the placebo through the mouthpiece.
89083795|NCT05710380|Experimental|All Participants (Single Arm)|All participants in this trial will be provided with routine instructions and precaution information before starting the magnetic resonance (MRI) scan. After the MRI, participants will undergo an MRI-guided fusion biopsy of the prostate as ordered by their doctor. During this prostate MRI-guided fusion biopsy, the research team will obtain tissue from up to two additional biopsy targets selected by the Risk Map DSS tool. Ultimately, the clinical radiologist will make the final decision on the targets to be biopsied.
89083796|NCT05699655|Experimental|Tislelizumab combined with apatinib and oxaliplatin plus S1|
89083797|NCT05699655|Active Comparator|oxaliplatin plus S1|
89083798|NCT05697042|Experimental|MY-Skills Mobile|8-week intervention merging yoga and self-management offered via secure remote tools including Zoom (video-conferencing software), Canvas (education software), and Qualtrics (survey software) that can be accessed via a computer or tablet. Each participant will have an initial yoga therapy individual session prior to start of group yoga. Group yoga is offered synchronously via Zoom two times per week for 60 minutes (120 minutes per week). The self-management content is delivered primarily through asynchronous tools that include educational videos, facilitated discussion boards, and interactive activities for goal setting, monitoring goals, and problem-solving practice. Self-management content is reiterated during the bi-weekly synchronous sessions, discussed as a group, and mantras are carried through both practices.
89083799|NCT05695079|Active Comparator|No cooling intervention (control)|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
89083800|NCT05695079|Experimental|Fan generating low airflow|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
89083801|NCT05695079|Experimental|Fan generating high airflow|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
89083802|NCT05687500|Experimental|Glibenclamide oral|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
89083803|NCT05683184|Other|Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
89083804|NCT05683184|Other|Opioid Use Disorder|Patients diagnosed with opioid use disorder
89083805|NCT05680064|No Intervention|Control|Patients who are routinely followed up will be included in the control group. At the end of 15 days, all patients will come to the second interview. The same data collection methods will be repeated after 15 days.
89225547|NCT05618834|Experimental|PPCI Arm|The ALF/PCH assigned as treatments will receive the four steps of PPCI including, stakeholder engagement and facility goal development, environment and policy assessment, staff education, and ongoing mentorship/motivation and support over a period of six-months by a research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care. The RNF will work with an identified internal/facility champion monthly to implement the four steps of PPCI.
89083806|NCT05680064|Experimental|Gum-Chewing Group|In the gum-chewing group, routine follow-up and additional gum-chewing training will be given (at least 10 minutes 4 times a day, preferably before meals and with sugar-free gum). Patients in the Gum Chewing Group will chew gum as recommended for 15 days. At the end of 15 days, all patients will come to the second interview. The same data collection methods will be repeated after 15 days. In the study, the chewing gum group will chew Vivident Xylit Full Fresh Mint Flavored Liquid Filled Sugar-Free Sweetener Gum. The contents of the gum; Sweeteners (Xylitol, Sorbitols, Mannitol, Maltitols, Aspartame, Acesulfame-K), Gum Yeast, Stabilizer (Glycerol), Flavorings, Natural Mint Flavoring, Maltodextrin, Starch, Emulsifiers (E473, Soy Lecithin), Green Tea Extract, Consistency Enhancers (Cellulose Gum, Xanthan Gum), Coconut Oil, Antioxidant (E321), Brightener (Carnauba Wax), Colorant (E133). There is no allergen warning.
89083807|NCT05680064|Experimental|Tongue, lip, chin exercise group|In the tongue, lip and chin exercise group, patients who are routinely followed up and who will be given additional tongue, lip and jaw exercises training (at least 10 minutes 4 times a day and preferably before meals) will take place. Patients in Tongue, Lip, Chin Exercise Group will do the tongue, lip and chin exercises as recommended for 15 days. At the end of 15 days, all patients will come the second interview. The same data collection methods are repeated after 15 days. content of the training to be given to the tongue, lip and chin exercise group and the exercise brochure to be given to the patients T.C. Oral-Motor Exercises Brochure published by the Ministry of Health Istanbul Provincial Health Directorate, Basic Evaluation Principles in Treatment Movements book and Specialist. It was determined and prepared in line with the recommendations of physiotherapist İbrahim ÖZDEMİR.
89083808|NCT05676073|Experimental|SHEN26 dose 1|SHEN26 capsule 200mg. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
89083809|NCT05676073|Experimental|SHEN26 dose 2|SHEN26 capsule 400mg. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
89083810|NCT05676073|Placebo Comparator|SHEN26 placebo|Placebo matching the SHEN26 capsule. 10 oral doses twice daily (after breakfast and dinner; Q12h±2h).
89083811|NCT05675163|Placebo Comparator|Placebo|matched dose of sunflower oil
89083812|NCT05675163|Experimental|Vitamin K2 low dose|333 μg/d Vitamin K2 (MK-7)
89083813|NCT05675163|Experimental|Vitamin K2 high dose|666 μg/d Vitamin K2 (MK-7)
89083814|NCT05672589|Experimental|Relaxed rotational thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients bleed.
89225548|NCT05618834|Active Comparator|PPCI-Staff Education Only Arm|The ALF/PCH assigned as controls will receive PPCI-staff education only (EO). The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
89225549|NCT05618678|Active Comparator|Infection Control Training|Nursing homes randomized to this arm of the study receive CDC guidelines and evidence based information on infection prevention prevention and control. Nursing home staff implement these standard in everyday resident care. Additionally, nursing home staff are invited to participate in Extension for Community Healthcare Outcomes (ECHO) sessions via real-time interactive videoconferencing software to support the implementation of the CDC guidelines and evidence-based practices.
89225550|NCT05618678|Experimental|DIGNITY Intervention|Nursing homes randomized to this arm of the study receive an evidence based risk assessment and care planning protocol for supporting decision making and aging in dementia for autonomy (DIGNITY). Nursing home staff use this manual to implement risk assessment and care planning for resident preferences that they perceive to carry a risk to the resident's health and/or safety. In addition nursing home staff participate in Extension for Community Healthcare Outcomes (ECHO) sessions via real-time interactive videoconferencing software to support the implementation of the DIGNITY protocol.
89225551|NCT05615870|Active Comparator|Intervention Group (Active Filter)|"The intervention group will use two Winix 5500-2 HEPA filtration units (Appendix A) (https://winixamerica.com/product/5500-2/). One will be placed in the child's sleep space and one will be placed in another common room with both units running continuously on the high (i.e., level 3 / second from highest) setting. Each unit is 8.2 x 15.0 x 23.6 inches, and verified for a 360 sq. foot room. If a home is too small to accommodate 2 Winix units (for example, a single room residence'), one Winix unit may be used for the study. Additional features beyond HEPA and carbon filter, include plasmawave technology to reduce volatile organic compounds and odors. The plasmawave feature will be turned off to avoid ozone production."
89225552|NCT05615870|Sham Comparator|Control Group (No Filter)|The control group will use identical-appearing Winix 5500-2 units and identical setup procedures as described above, but with no HEPA or carbon filters.
89225553|NCT05611853|Experimental|3.5mg/kg|Will be administered by intravenous infusion every 3 weeks on D1
89225554|NCT05611853|Experimental|4.2mg/kg|Will be administered by intravenous infusion every 3 weeks on D1
89225555|NCT05611853|Experimental|5.0mg/kg|Will be administered by intravenous infusion every 3 weeks on D1
89225556|NCT05609643||Rinvoq|Participants will receive Rinvoq as prescribed by their physician according to local label.
89225557|NCT05607342|Experimental|Pilot Trial: Osanetant 28 Days|Pilot Trial: A single dose level (200mg twice daily, oral) will be provided for men with prostate cancer undergoing curative intent surgery. Men will undergo serum testing at baseline, days 2, 3, 7, 14, and 28 as well as 6 weeks post-treatment in order to evaluate efficacy. All men enrolled will be subject to the same study procedures and assessments, regardless of completion of the study protocol, and analysis will occur via intent-to-treat principles.
89225558|NCT05606965|Experimental|mRNA-1010 (Age Group 18-50 years)|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
89225559|NCT05606965|Active Comparator|Egg-based Quadrivalent Influenza Vaccine (Age Group 18-50 years)|Participants will receive a single dose of egg-based quadrivalent influenza vaccine by IM injection on Day 1.
89225560|NCT05606965|Active Comparator|Adjuvanted Quadrivalent Influenza Vaccine (Age Group 65-80 years)|Participants will receive a single dose of adjuvanted quadrivalent influenza vaccine by IM injection on Day 1.
89225561|NCT05606965|Active Comparator|Inactivated Influenza Vaccine (Age Group 65-80 years)|Participants will receive a single dose of inactivated influenza vaccine by IM injection on Day 1.
89225562|NCT05606965|Experimental|mRNA-1010 (Age Group 65-80 years)|Participants will receive a single dose of mRNA-1010 by IM injection on Day 1.
89225563|NCT05606887|Experimental|Intervention|In addition to completing 3 surveys over the course of 6 months, participants in the intervention arm will be asked to wear a wearable device (FitBit Charge 5), complete texting-based ecological momentary assessments to gauge real-time feelings of stress, and receive bi-weekly personalized data dashboards to report back their data.
88812827|NCT02214017|Experimental|Telemedicine group|After initial check-up in the outpatient dept. medical treatment, control of blood glucose, blood pressure, lipids, and education was executed via videotelephone in the telemedicine group. A videotelephone, TandBerg E20, in the telemedicine group was delivered and serviced by the Danish Tele Company, TDC.
88812828|NCT01550705|Experimental|Isoniazid|Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.
89083815|NCT05672589|Active Comparator|Standard coagulation tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed
89083816|NCT05655156|Experimental|Multiple Knee Ligament Injuries|"Sub-groups of n=7 incurring ligament reconstruction using OrthoPureXT in the following anatomical locations:~Posterior cruciate ligament (PCL)~Anterior cruciate ligament (ACL)~Posteromedial corner including the medial collateral ligament (MCL)~Posterolateral corner including the lateral collateral ligament (LCL)"
89083817|NCT05636449|Active Comparator|Group Suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block after the surgery
89083818|NCT05636449|Active Comparator|Group Periarticular Infiltration Group|A local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
89083819|NCT05616793|Experimental|Dose Group 1|Single, unilateral subretinal administration of a low dose of OPGx-001 to adult participants at least 18 years of age
89083820|NCT05616793|Experimental|Dose Group 2|Single, unilateral subretinal administration of an intermediate dose of OPGx-001 to adult participants at least 18 years of age
89083821|NCT05616793|Experimental|Dose Group 3|Single, unilateral subretinal administration of a high dose of OPGx-001 to adult participants at least 18 years of age
89083822|NCT05605067||Cases|Participants will self-select into the study. All enrolled will meet study specific criteria and be considered cases.
89083823|NCT05601843|Experimental|TENS Arm|Participants randomized to receive treatment with TENS in addition to standard care.
89083824|NCT05601843|No Intervention|Control Arm|Participants randomized to not receive treatment with TENS. These participants receive standard care only.
89083825|NCT05596786|Experimental|Rituximab|
89083826|NCT05596786|Placebo Comparator|Placebo|
89083827|NCT05582707|Experimental|MIPS + Pioglitazone|20 Subjects will undergo MIPS for evacuation of ICH using the BrainPath access device plus perioperative pioglitazone for 3 weeks
89083828|NCT05582707|No Intervention|MIPS Alone|This trial will compare it's subjects to subjects who have previously undergone MIPS for evacuation of ICH using the BrainPath access device as part of the ENRICH trial (NCT02880878). These subjects will be enrolled at an ENRICH trial site independent of our Institution. Deidentified patient information from 20 subjects in this group, who will be matched to those in the ENRICH-PLUS group, will be provided to the principal investigator for comparison of outcomes.
89083829|NCT05571306|Experimental|Intervention|Receives a three month intervention.
89083830|NCT05571306|No Intervention|Care as usual|This arm is given care as usual provided at a General Practice in Denmark.
89083831|NCT05566392||Coronavirus disease (COVID)|Pediatric patients who was diagnosed as COVID
89083832|NCT05566392||Healthy|Pediatric participants who hadn't been diagnosed COVID before
89083833|NCT05564611|Experimental|ADL-018|150 mg single dose Lyophilized vial
89083834|NCT05564611|Active Comparator|US-Licensed XOLAIR|150 mg single dose Lyophilized vial
89225564|NCT05606887|No Intervention|Control|Participants randomized to this arm will receive digital surveys over the course of 6 months (one at baseline, one at 3 months, and one at 6 months). These surveys will be the same as the intervention arm and will ask questions related to burnout, anxiety, depression, PTSD, and stress.
89225565|NCT05591053|Experimental|ActivSight Group|Patients undergoing esophagectomy with ActivSight (n=70)
89225566|NCT05588700|Active Comparator|Control group|
89225567|NCT05588700|Experimental|Intervention group|
89225568|NCT05588154||Cohort 1|Healthy volunteers who will donate blood, and/or bone marrow and may donate other samples
89225569|NCT05588154||Cohort 2|Healthy volunteers who will donate stool samples only
89225570|NCT05587439||Germline EGFR Mutations|Individuals known to carry or at risk for carrying germline EGFR mutations (e.g., T790M, R776G/H/X, V769M, V834L, V843I, P848L, and others that will be identified). Patients with lung cancer with a somatic EGFR mutation prior to the initiation of treatment or who are found to have a suspected germline EGFR mutation via ctDNA analysis are also eligible.
89225571|NCT05587439||Germline Non-EGFR Mutations|Individuals known to carry or at risk for carrying non-EGFR germline mutations (e.g., HER2, BRCA2, MET, YAP1, and others that will be identified). Patients with lung cancer with a somatic variant suggestive of a possible hereditary lung cancer risk are also eligible.
89225572|NCT05587439||Family History Or Multiple Primaries Or Multi-Focal Non-Small Cell Lung Cancer NSCLC|"Individuals and families with history of lung cancer where no pathogenic germline variant has been identified, but ascertained through history of one or more of the following:~Multi-generational or first-degree relative with lung cancer~Personal history of multiple primary lung cancers or other neoplasms~Multi-focal lung cancer"
89225573|NCT05584384|Experimental|Active group|The investigators aim for six sessions of anodal stimulation over the right primary motor area contralateral to the orofacial pain (C3 or C4 in 10-20 EEG system) with cathode above the frontal area ipsilateral to the orofacial pain (Fp1 or Fp2) using HDCstim by Newronika S.r.l., Italy. The therapy will be administered over two weeks (Mon, Wed, Fri) to ensure a washout period of 48 to 72 hours between applications. The current of 2 mA will be delivered via silicone electrodes inserted into saline (0.9%) filled cellulose sponges, anode 5x5cm, cathode 6x8cm, for 20 minutes with 20 seconds of both ramp-up and ramp-down. An International 10-20 EEG system will be used to determine the stimulation location, and dedicated EEG caps will be used to ensure consistency between applications.
89225574|NCT05584384|Placebo Comparator|Sham group|The sham (placebo) will be administered using the same devices with a preprogrammed sham protocol (using HDCprog by Newronika S.r.l., Italy) of 20 minutes to be virtually indistinguishable from the active stimulation.
89225575|NCT05583591|Active Comparator|Combined cataract surgery with Hydrus microstent|
89225576|NCT05583591|Active Comparator|Combined cataract surgery with iStent Inject W|
89225577|NCT05583227|Experimental|Tezepelumab Low Dose|Tezepelumab subcutaneous injections, in accessorised pre-filled syringes
89225578|NCT05583227|Experimental|Tezepelumab High Dose|Tezepelumab subcutaneous injections, in accessorised pre-filled syringes
89225579|NCT05583227|Placebo Comparator|Placebo|Placebo subcutaneous injections, in accessorised pre-filled syringes
88812829|NCT01831700|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
88812830|NCT01831700|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
89083835|NCT05559164|Experimental|Anti-HER2 targeted therapy + Lipitor 40mg daily|Participants will receive Lipitor 40 mg PO daily while receiving anti-HER2 therapy.
89083836|NCT05553405|No Intervention|Baseline [11C]PBR28 PET Scan|Subjects will complete a 120-minute baseline [11C]PBR28 PET scan.
89083837|NCT05553405|Experimental|Post-Intralipid Infusion [11C]PBR28 PET Scan|Subjects will complete a second 120-minute [11C]PBR28 PET scan 4 hours after Intralipid Infusion
89083838|NCT05544760|No Intervention|Control|"Placement into the intervention vs. control group is random, but dependent upon multisensory integration performance. Meaning, older adults who are enrolled and screened with good integration abilities on the CatchU test (aka: VSI + (good) integrators), (VSI = visual-somatosensory integration) will not be placed in either the intervention or control group since better visual-somatosensory integration performance has been linked to better cognitive and motor outcomes. These participants will be included in examination of additional study aims not related to the intervention.~VSI - (poor) integrators, will be randomly assigned into either the intervention or control group to test the beneficial effect of the CatchU intervention.~Participants in the Control arm will be monitored every two months via telephone surveys to determine falls history, but will not receive the CatchU intervention."
89083839|NCT05544760|Experimental|CatchU Intervention|"Placement into the intervention vs. control group is random, but dependent upon multisensory integration performance.~VSI - (poor) integrators, will be randomly assigned into either the intervention or control group to test the beneficial effect of the CatchU intervention. Participants in the Intervention arm will be monitored every two months to determine falls history, but will also receive the CatchU intervention which consists of physicians relaying individualized recommendations from the CatchU physician report to the participant, as well as providing the participant with falls intervention referrals and falls counseling."
89083840|NCT05543083|Experimental|Cognitive-Behavioral Therapy followed by Exercise Training|6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions followed by a 6-week exercise training intervention of 6 weekly 1-hour group sessions
89083841|NCT05543083|Active Comparator|Exercise Training followed by Cognitive-Behavioral Therapy|6-week exercise training intervention of 6 weekly 1-hour group sessions followed by a 6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions
89083842|NCT05543083|Active Comparator|Exercise Training Only|6-week exercise training intervention of 6 weekly 1-hour group sessions followed by an additional 6-week exercise training intervention of 6 weekly 1-hour group sessions
89083843|NCT05543083|Active Comparator|Cognitive-Behavioral Therapy Only|6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions followed by an additional 6-week cognitive-behavioral therapy intervention of 6 weekly 1-hour group sessions
89083844|NCT05526768|Experimental|VITLS Device|The remote monitoring device (VITLS) will be placed onto the chest of consented patients in a manner that will not interfere with standard in-patient monitoring devices. Subjects will simultaneously be monitored with conventional inpatient methods per the unit routine. The providers caring for participating patients will be blinded to the data being collected by the remote monitoring system and no patient care decisions will be made based on the remote monitoring system. The remote monitoring device will automatically monitor and store the data for each subject by subject ID number. Once at least 6, but up to 72 hours of data have been recorded, the investigational device will be removed. Researchers will then retrospectively obtain the corresponding data from the current standard of care inpatient monitoring devices.
89225580|NCT05579197|Experimental|Lower limbs robotic intervention|"The intervention administered in this arm is a lower limb robotic intervention using the device Myosuit. The intervention includes:~An enrollment (session1), in which a clinical and psychological evaluation is performed for the assessment of the inclusion criteria~A baseline evaluation (session2), in which a functional evaluation is performed both with and without the device~Training sessions (sessions 3-9), these are the actual training sessions in which walking, sit to stand, balance and stairs climbing tasks are performed with the device on~Final evaluation (session 10), in which a final functional, clinical, and psychological assessment is performed~The sessions are performed 3 times per week, with a duration of 45 minutes, with the expection of the assessement ones, session 1, 2 and 10, that have a duration of 1h, 2h and 3h, respectively."
89225581|NCT05573919|Experimental|VivAer Patients|These patients will undergo the VivAer procedure, which involves the use of a stylus to deliver radiofrequency heating to the nasal sidewall to reshape the tissue. This will be done to resolve the patients' nasal obstruction. They will have PNIF measurements taken and will complete symptom assessment questionnaires before and after the VivAer procedure.
89225582|NCT05572437|No Intervention|Control Group|Patients randomized to the control group will be assessed for preoperative anxiety using the APAIS scale in the preoperative room and assessment of insomnia using the ISI scale both in the PACU and on the 1st day in the hospital ward. Pain assessment will be measured using the VAS scale in the PACU and on the first day on the hospital ward.
89225583|NCT05572437|Experimental|Intervention Group|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-surgery room, during surgery and in the PACU.
89225584|NCT05568784||Healthy Participants|Patients without pre-existing lower extremity injury that may inhibit response to testing
89225585|NCT05568784||Participants with Knee Arthroscopy|Patients who have recently suffered knee injury that required arthroscopic surgery
88812831|NCT01531439|Active Comparator|Naloxone infusion 0.5 mcg/kg/hr|
88812832|NCT01531439|Experimental|Naloxone 2.5 mcg/kg/hr|Naloxone infusion 2.5 mcg/kg/hr
88812833|NCT01831778||all women|women receiving mammography at one of 6 mammography registries across the country.
88812834|NCT01832012|Active Comparator|Video refresher|Group 3, received 7 minute video refresher prior to examination.
89083845|NCT05511701|Active Comparator|Usual Care|with paper-based guidelines used by community health workers (CHW) and providers
89083846|NCT05511701|Experimental|Intervention|with central data management system linking digital mHealth screening tool for CHWs, electronic appointment scheduling, point of care testing (POCT) for lipids, clinical decision support for medication initiation, and a SMS reminder system for adherence to medications and life-style changes
89083847|NCT05494177||Premium monovision|Patients will undergo to implantation of an extended depth of field intraocular lens in the dominant eye and a trifocal diffractive intraocular lens in the non-dominant eye.
89083848|NCT05494177||Bilateral trifocal diffractive implantation|Patients will undergo to bilateral implantation of trifocal diffractive lenses.
89083849|NCT05487261|Experimental|Sacubitril and valsartan combination|Patient receive: 1 bottle with Sacubitril/Valsartan tablets and 2nd bottle with placebo to enalapril.
89083850|NCT05487261|Active Comparator|Enalapril|Patient receive: 1 bottle with placebo to Sacubitril/Valsartan and 2nd bottle with enalapril.
89083851|NCT05479240|Experimental|short-range radiotherapy sequential Tislelizumab combined with chemotherapy|
89083852|NCT05479240|Experimental|short-range radiotherapy combined with chemotherapy|
89083853|NCT05454462|Experimental|KM-001 0.3%|KM-001 0.3% cream will be applied to the affected area twice daily for 4 consecutive weeks.
89083854|NCT05454462|Experimental|KM-001 1%|KM-001 0.3% cream will be applied to the affected area twice daily for 4 consecutive weeks.
89083855|NCT05454462|Placebo Comparator|Vehicle arm|Vehicle cream will be applied to the affected area twice daily for 4 consecutive weeks.
89083856|NCT05449457|No Intervention|Layered Closure|One half of the wound will have a cutaneous layer of sutures (2 layers), as is standard of care, while the other half of the wound will have an additional layer of 2-octyl cyanoacrylate (3 layers).
89083857|NCT05449457|Experimental|Layered Closure with 2-Octyl Cyanoacrylate|One half of the wound will have a cutaneous layer of sutures (2 layers), as is standard of care, while the other half of the wound will have an additional layer of 2-octyl cyanoacrylate (3 layers).
89083858|NCT05447247|Experimental|Acupuncturing Ba Liao point under ultrasound guidance|
89083859|NCT05447247|Experimental|Conventional acupuncture|
89083860|NCT05442684|Experimental|Ad5-nCoV/O group|
89083861|NCT05442684|Experimental|Ad5-nCoV/O-IH group|
89083862|NCT05442684|Active Comparator|mRNA-based COVID-19 vaccine group|
89083863|NCT05435859|Experimental|Electrocorticography (ECoG) recording during Speech Tasks|Participants listened to 25-minute Speech Tasks while ECoG signals for neural activity was recorded during their intraoperative procedure or inpatient hospitalization at the University of California, San Francisco (UCSF).
89083864|NCT05434936|Other|Collection|There is only one arm of the study, all patients enrolled will have surgery in which the attempt will be made to collect ovarian tissue.
89083865|NCT05431114||Shoulder patients|Participants who presents with glenohumeral instability.
89083866|NCT05566496||Tourette|Age less than 18 years old Diagnosed as Tourette syndrome or chronic tic disorders No other neuropsychiatric disorders
89083867|NCT05566496||Healthy|Age less than 18 years old No other neuropsychiatric disorders
89083868|NCT05415735|Experimental|SMART Program|The Stress Management and Resiliency Training (SMART) Program is a multimodal mind-body and cognitive skills-based program that teaches participants a variety of different approaches for reducing their physiologic stress response. The program is delivered virtually (online) for 1.5 hours once a week for 8 weeks.
89083869|NCT05380388|Experimental|Malaria Vaccine|PvRII/Matrix-M month 0, month 1, month 6
89083870|NCT05380388|Other|control|HBV vaccine month 0, month 1, month 6
89083871|NCT05374616||Individuals with TANGO2 deficiency|Individuals with TANGO2 deficiency known to have disease causing variants in TANGO2
89083872|NCT05370157|Experimental|TeamTRACS (Team Training in Roles, Awareness, Communication, and Support)|CACs randomized to the intervention condition (n = 4) will participate in TeamTRACS. CACs will receive an implementation guide to assist in preparing for and maximizing the impact of training.
89083873|NCT05370157|No Intervention|Waitlist Comparison|CACs randomized to the waitlist comparison (n = 2) will participate in TeamTRACS approximately 4 months after CACs in the intervention condition.
89083874|NCT05365334|Experimental|low-intensity continuous exercise|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
89083875|NCT05365334|Experimental|moderate-intensity continuous exercise|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
89083876|NCT05365334|Experimental|high-intensity interval exercise|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
89083877|NCT05365113|Active Comparator|Continuous positive airway pressure (CPAP) then extended sigh|"Patients assigned to this group will receive a CPAP ARM (40cmH2O during 50 seconds), followed by a 10-minute pause corresponding to a period of return to basal state.~Then an ARM by extended sigh (e-sigh) also 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure).~Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
89083878|NCT05365113|Active Comparator|extended sigh then continuous positive airway pressure (CPAP)|"Patients assigned to this group will receive an ARM by extended sigh (e-sigh) during 50 seconds (driving pressure at 10cmH2O and successive PEEP levels at 10, 15, 20, 25 and 30cmH2O, with respiratory frequency fixed at 30/min in controlled pressure), followed by a 10-minute pause corresponding to a period of return to basal state.~Then they receive a CPAP ARM (40cmH2O during 50 seconds). Hemodynamic (blood pressure, cardiac output, stroke volume) and ventilatory measurements will be performed the last 10 seconds of each recruitment maneuver."
89083879|NCT05364957|Other|control (PEC dietary hygiene)|Diet and exercise alone (control)
89083880|NCT05364957|Experimental|Experimental (BIG + PEC dietary hygiene)|Intragastric balloon combined with diet and exercise (active)
89083881|NCT05358106|Active Comparator|AntiBKV neutralising antibody|AntiBKV infused i.v. over 30 minutes. Infusion parameters may be adjusted to bodyweight so that infusion rate does not exceed 60mg/kg per hour. AntiBKV will be administered as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2 (100, 500, 1000 or 2000 mg).
89083882|NCT05358106|Placebo Comparator|Placebo|Solution containing no active excipients, infused i.v. over 30 minutes as a single infusion in Part 1 or as 4 infusions administered 4 weeks apart in Part 2.
89083883|NCT05356949|Experimental|Intervention|The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
89083884|NCT05332444|Experimental|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
89083885|NCT05332444|Active Comparator|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
89083886|NCT05328570|Experimental|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
89083887|NCT05323825|Experimental|Experimental group|The content of the package is 100 g and should be consumed once a day for 8 weeks.
89083888|NCT05323825|Placebo Comparator|Control group|The content of the package is 100 g and should be consumed once a day for 8 weeks.
89083889|NCT05314491||Multigen Plus CCK|
89083890|NCT05314491||Multigen Plus CCK in combination with AMF TT cones|
89083891|NCT05291481|Experimental|CAPAS Youth Parenting Intervention|11-week CAPAS-Youth culturally adapted intervention
89083892|NCT05291481|No Intervention|Wait-list control|Participants allocated to this condition receive the intervention until all assessments are completed for both arms in each cohort
89083893|NCT05290740|Active Comparator|group A|
89083894|NCT05290740|Active Comparator|group B|
89083895|NCT05269186|Experimental|Virtual reality|Virtual reality session performed before the planning CT scan
88812835|NCT01832012|Experimental|Video refresher and hands-on practice|Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin.
88812836|NCT01832012|No Intervention|No intervention|Group 2
89083896|NCT05269186|No Intervention|Normal care|Normal care without intervention
89083897|NCT05254197||Retrospective cohort|The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 1998, and who have had MR re-examination after first MR exam because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. It is practically impossible to obtain informed consent from patients of this retrospective cohort, and consent was waived by the Institutional Review Board. Target population of this retrospective cohort is 1,500 tumors.
89225586|NCT05568524|Active Comparator|Control|The training program for the control group consists of a telerehabilitation with traditional moderate-to-high load (60%-80% 1RM) exercises (the same as the intervention group sans BFR), utilizing elastic bands. This program for the control group will be conducted in an in-home real-time audio and video style and supervised by a physiotherapist.
89083898|NCT05254197||Prospective cohort|The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since February 2022, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed primary intracranial neoplasms of CNS WHO grade 2 or lower and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. The cohort will consists of patients who agree to participate with written consent. Target population of this prospective cohort is 1,500 tumors.
89083899|NCT05241665||Group 1|
89083900|NCT05241665||Group 2|
89083901|NCT05234554|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
89083902|NCT05234554|Placebo Comparator|Vehicle Ophthalmic Solution|
89083903|NCT05233800|Experimental|Voice-Activated Smart Speaker Program|Faster Asleep
89083904|NCT05233800|Active Comparator|Website|Faster Asleep Website
89083905|NCT05231655||Bladder Cancer|
89083906|NCT05231655||Kidney Cancer|
89083907|NCT05231655||Melanoma|
89083908|NCT05231655||Sarcoma|
89083909|NCT05231655||Glioblastoma|
89083910|NCT05231655||Head and Neck Cancer|
89083911|NCT05214378|Experimental|Treatment Arm|The investigators will test an alternative pattern of sacral root stimulation in individuals who are already implanted with the device. Study participants will act as their own controls.
89083912|NCT05212311|Active Comparator|Group A (Control group)|Group A (n=27) will receive a conventional physical therapy program only for 5 weeks in the form of Splinting, Ultrasound and Exercises.
89083913|NCT05212311|Experimental|Group B (Chitosan phonophoresis group)|Patients in group B (n=27) will receive phonophoresis with chitosan nanoparticles. Patients will also receive the conventional physical therapy program: in the form of Splinting, Ultrasound and Exercises. Session will be applied 3 times per week for a total of 5 weeks.
89083914|NCT05201404|Experimental|Namodenoson (CF102)|Namodenoson 25 mg orally BID, until disease progression or unacceptable adverse events
89083915|NCT05201404|Placebo Comparator|Placebo|Matching placebo orally BID, until disease progression or unacceptable adverse events
89083916|NCT05179837|Experimental|Optical coherence tomography (OCT) probe|After consent, the endoscopist will perform a standard of care colonoscopy. If a polyp is found, then OCT will be used to image that polyp. Patients with polyps, regardless of number found, will have either one tubular adenoma (NICE type 2) imaged OR one hyperplastic polyp (NICE type 1) imaged. If no polyps are found, then one area of normal mucosa will be imaged. If on the rare chance a malignant appearing colonic tumor (NICE type 3) is found, this and no other polyps will be imaged with OCT.
89083917|NCT05176353|Experimental|VAP diagnostic stewardship|
89083918|NCT05159752|Experimental|Afamelanotide|
88812837|NCT03214874|Active Comparator|Demadex 20mg Tablet|Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients
89083919|NCT05130762||General Cohort|All patients who receive a VAD as standard of care in combination with needle-free connectors. A BD PureHub™ Disinfecting Cap will be placed on each eligible needle-free connector and all attachments/removals incl. reason for change will be documented up to 45 days post-enrollment date.
89083920|NCT05126381||Smoker with taking levamlodipine besylate tablets|The subjects are allowed to smoke during the time taking levamlodipine besylate tablets.
89083921|NCT05126381||Non-smoker with taking levamlodipine besylate tablets|The subjects are not allowed to smoke during the time taking levamlodipine besylate tablets.
89083922|NCT05126381||Smoker with taking metformin sustained-release tablets|The subjects are allowed to smoke during the time taking metformin sustained-release tablets。
89083923|NCT05126381||Non-smoker with taking metformin sustained-release tablets|The subjects are not allowed to smoke during the time taking metformin sustained-release tablets.
89083924|NCT05124561|Experimental|Experimental group|6500 participants, Ad5-nCoV-IH, single dose, nebulized inhalation
89083925|NCT05124561|Placebo Comparator|Placebo group|6500 participants, placebo, single dose, nebulized inhalation
89083926|NCT05115890|Experimental|Exercise training|Patients with HFpEF will participate in the 8 weeks of supervised, two-legged, knee extensor exercise training for 3 days per week. Each exercise session will involve a 5-min warm-up and a 5-min cool-down, and exercise intensity will range between 40%-90% of maximal work rate. Maximal work rate will be re-assessed every two weeks.
89083927|NCT05085561|Active Comparator|REC-994 200 mg|REC-994 200 mg po once daily (QD) (1 200 mg REC-994 tablet, 1 matching placebo tablet)
89083928|NCT05085561|Active Comparator|REC-994 400 mg|REC-994 400 mg po QD (2 200 mg REC-994 tablets)
89083929|NCT05085561|Placebo Comparator|Placebo|Matching Placebo po QD (2 matching placebo tablets)
89083930|NCT05078892||Adolescents (12-17)|Adolescents 12-17 with Turner Syndrome
89083931|NCT05078892||Parents of Adolescents (12-17)|Parents of Adolescents (12-17)with Turner Syndrome
89083932|NCT05078892||Young Adults (18-25)|Young Adults (18-25)with Turner Syndrome
89083933|NCT05071586|Experimental|Children diagnosed with stroke/brain bleed|Male and females aged 8 to 21 with established diagnosis of stroke/brain bleed who are US residents.
89083934|NCT05056987|Other|TOTAL30, then AOHP|Lehfilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. The lehfilcon A contact lenses will be worn for approximately 28 days. The senofilcon A contact lenses will be worn for approximately 14 days. Lenses will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
89083935|NCT05056987|Other|AOHP, then TOTAL30|Senofilcon A contact lenses worn first, with lehfilcon A contact lenses worn second, as randomized. The senofilcon A contact lenses will be worn for approximately 14 days. The lehfilcon A contact lenses will be worn for approximately 28 days. Lenses will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
89083936|NCT05053035|Experimental|AL001|AL001 every 4 weeks
89083937|NCT05053035|Placebo Comparator|Placebo|Placebo every 4 weeks
89083938|NCT05051046|Experimental|Hypnosis|
89083939|NCT05051046|No Intervention|General anesthesia|Common practice
89083940|NCT05044533||Cohort 1|Participants with atrial fibrillation (AF) experiencing a bleed
89083941|NCT05043441|Experimental|Acceptance and commitment therapy (ACT) group|10 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
89083942|NCT05043441|Sham Comparator|Psychoeducation control group|Care as usual with psychoeducation materials provided
89083943|NCT05023096|Active Comparator|Menthol+Tobacco|Menthol+Tobacco - where both menthol and tobacco flavored liquids for electronic nicotine delivery systems are available to choose from
89083944|NCT05023096|Experimental|Tobacco|Tobacco - where only tobacco flavored liquid is available for electronic nicotine delivery systems
89083945|NCT05023096|Experimental|Unflavored|Unflavored - where only unflavored liquid is available for electronic nicotine delivery systems
89083946|NCT05014555||Group A Non-biologic Group|Participants on treatment regimen of mesalamine monotherapy or thiopurine monotherapy, or corticosteroids.
89083947|NCT05014555||Group B Anti-TNF Group|Participants on treatment regimen of maintenance montherapy of infliximab (at least 8 every 8 weeks), golilumamb (at least monthly), adalimumab (at least every 2 weeks), or certolizumab (at least monthly), or combination therapy of anti-TNF therapy as described above along with either 15mg of methotrexate or azathiprine at least 1.0mg/kg or 6MP 0.5mg/kg.
89083948|NCT05014555||Group C Ustekinumab Group|Participants on treatment regimen of ustekinumab monotherapy or combination therapy with methotrexate or azathioprine.
89083949|NCT05014555||Group D Vedolizumab Group|Participants on vedolizumab monotherapy or combination therapy with methotrexate or azathioprine.
89083950|NCT05014009|Experimental|FIFA11+ and multidirectional training (MD)|Participants in the MD group will take part in an 8-week NMT intervention known to reduce the risk of sports injury and expected to improve COD movement strategies.
89083951|NCT05014009|Active Comparator|FIFA11+ and linear sprint training (LS)|Participants in the LS group will take part in an 8-week NMT intervention, which is known to reduce the risk of sports injury but is unlikely to improve COD movement strategies and is expected to improve linear sprint performance.
89083952|NCT05006417|Experimental|Participants with R-CECS|Botox to be injected under standard palpatory technique into the affected lower leg compartment.
89083953|NCT05001152|Experimental|Ozanimod|A maximum of 10 healthy adult participants (i.e., sensory panelists) will complete a maximum of 20 taste assessment days, with at least 4 panelists required to evaluate the taste characteristics of ozanimod on each taste assessment day.
89083954|NCT05000632|Experimental|Smoke Free SafeCare (SFSC)|Providers randomized to this group will receive additional SFSC training and will disseminate SFSC program to families who report having a smoker in the home.
89083955|NCT05000632|Active Comparator|Standard SafeCare|Providers randomized to this group will disseminate the Standard SafeCare program to families who report having a smoker in the home.
89083956|NCT04999956|Experimental|dynamic navigation|Dental implant placement using a dynamic navigation system
89083957|NCT04999956|Sham Comparator|freehand|Dental implant placement using freehand technique
89083958|NCT04999306|Experimental|Hypnosis group|"the sessions will be conducted following the same dynamics and the same exercises (safe place, reification, anchoring): introduction of the session (conversational hypnosis in order to probe the patient's perceptions of his or her illness and fatigue, discussion of myths and realities); induction with the creation of a safe place that will be used for each session; visualization; deepening of the trance with work on metaphors (reification technique); making specific suggestions on sensations of fatigue, on regaining energy; then instruction for self-hypnosis or anchoring."
89083959|NCT04999306|Experimental|CBT group|"This program will work specifically on the psychosocial determinants of fatigue.~The first session will be patient education on cancer-related fatigue. S2 will address the concept of perceived control and allow the patient to understand what factors accentuate this condition. S3 will allow the patient to work on the emotions associated with cancer and will be complemented by a hypnosis audio. S4 will address the notion of social support and how the patient can learn to delegate or ask for help. S5 will address the notion of coping strategies, the patient will then be able to identify what he/she puts in place, what is productive and what is not. Finally, the S6 will be a synthesis session that will allow to come back to the points that deserve to be deepened."
89083960|NCT04979078|Experimental|Experimental group|The experimental group receives 9 sessions of photobiomodulation therapy (3x/week for 3 weeks).
88812838|NCT03214874|Experimental|ER Torsemide 20mg Tablet|ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period
89083961|NCT04978636|Active Comparator|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The investigator will investigate the effect of continuous low tidal volume ventilation with hyperoxia avoidance (using FiO2 of 0.21) on PPCs and 30-day mortality compared to low-tidal volume ventilation (with FiO2 of 0.21) or apnea during CPB, and during the sub-study.
89083962|NCT04978636|Active Comparator|Continuous low tidal volume ventilation with using FiO2 of 1.0|The investigator will investigate the effect of low tidal volume lung ventilation with hyperoxia avoidance (FiO2 of 0.21) on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or apnea during CPB, and during the sub-study.
89083963|NCT04978636|Active Comparator|Apnea|The investigator will investigate the effect of apnea during on PPCs and mortality compared to hyperoxic low-tidal volume ventilation (with FiO2 of 1.0) or hyperoxia avoidance (FiO2 of 0.21) during CPB, and during the sub-study..
89083964|NCT04967391|Experimental|Tumescence During STSG Harvest|Prior to the split thickness skin graft (STSG) harvest, the tumescence technique will injection of 100-150 mL normal saline with 1:500,000 epinephrine injected into a deep dermal thigh tissue plane with 18-gauge spinal needle on a 60 mL syringe.
89083965|NCT04967391|No Intervention|No Intervention|"Patients randomized to no tumescence will have their free flap donor site reconstructed with a split thickness skin graft (STSG) harvested at 0.0175 inches using the dermatome to obtain a graft from the thigh."
89083966|NCT04930653|Experimental|Treatment (ECP, mogamulizumab)|Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CR)/PR after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
89083967|NCT04922268|Active Comparator|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
89083968|NCT04922268|Experimental|External focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
89083969|NCT04902170|Experimental|study group|Highly myopic patients with vitreoretinal disease requiring pars plana vitrectomy. The 30mm (shaft length) vitrectomy probe (25 gauge) would be used in the surgery.
89083970|NCT04902170|Active Comparator|control group|Highly myopic patients with vitreoretinal disease requiring pars plana vitrectomy. The 27mm (shaft length) vitrectomy probe (25 gauge) would be used in the surgery.
89083971|NCT04889079||Adolescent females, aged 15-18|Adolescents females aged 15-18, who selected a contraceptive implant to prevent pregnancy.
89083972|NCT04889079||Adolescent females, aged 19-24|Adolescents females aged 19-24, who selected a contraceptive implant to prevent pregnancy.
89083973|NCT04881487|Experimental|Additional stereotactic body radiation therapy|SBRT in addition to standard of care.
89083974|NCT04881487|No Intervention|Standard of care|Treatment according to current clinical practice.
89083975|NCT04874402|Active Comparator|Prepectoral approach|Immediately following mastectomy, participants will undergo prepectoral reconstruction approach. Intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities. Participants will be evaluated at 6 time points during the study.
89083976|NCT04874402|Experimental|Partial subpectoral approach|Immediately following mastectomy, participants will undergo partial subpectoral reconstruction approach. Intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities. Participants will be evaluated at 6 time points during the study.
89083977|NCT04841057|Experimental|Standard BP limb length|50 cm BP limb length
89083978|NCT04841057|Experimental|Medium BP limb length|100 cm BP limb length
89083979|NCT04841057|Experimental|Long BP limb length|150 cm BP limb length
89083980|NCT04839679|Active Comparator|Standard of Care Mayo Clinic booklet|Subjects will receive the standard Mayo Clinic educational booklet in preparation for clinically indicated radiation therapy treatment
89083981|NCT04839679|Experimental|Culturally Oriented Education|Subjects will receive a culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner in addition to the standard Mayo Clinic booklet
89083982|NCT04839549|Experimental|Dextenza (Intracanalicular ) 0.4mg|Dextenza for the treatment of Ocular Rosacea
89083983|NCT04839549|Active Comparator|Fluoromethalone .01%|Fluoromethalone .1% BID for 2 weeks then once daily for 2 weeks for the treatment of Ocular Rosacea
89083984|NCT04837404|Other|ultrasound guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Ultrasound guided femoral access will be used.
89083985|NCT04837404|Other|fluoroscopy guided femoral access|Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Fluoroscopy guided femoral access will be used.
89083986|NCT04836221|Experimental|Intervention|Will receive mHealth support for comorbidity and support from a Community Health Worker by phone
89083987|NCT04829292|Experimental|Open treatment|Supportive therapy followed by CBT
89083988|NCT04826185|Experimental|IMB-1018972 200mg|
89083989|NCT04826185|Placebo Comparator|Placebo|
88812839|NCT02504268|Experimental|Combination Therapy: Abatacept + Methotrexate|Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
89083990|NCT04812314|Experimental|Exercise|"This exercise prescription represents a common or conventional form of physical activity (e.g., moderate/brisk walking). If assigned to this group, participants will perform 45 minutes of moderate intensity continuous steady-state exercise at 70% maximal heart rate (HRmax) to expend 250 calories 4 days per week."
89083991|NCT04812314|Experimental|No exercise|Subjects assigned to this group are to remain sedentary (no planned physical exercise) throughout the duration of the study.
89083992|NCT04794569|Experimental|Tinzaparin|initial 3-week lead-in course of low molecular weight heparin (tinzaparin 175 units/Kg sc daily) followed by a direct oral anticoagulant (rivaroxaban 20mg po daily) for at least 3 months
89083993|NCT04794569|Active Comparator|Rivaroxaban|Direct oral anticoagulant only (rivaroxaban 15mg po BID for 3 weeks followed by rivaroxaban 20mg po daily ) for at least 3 months
89083994|NCT04787042|Experimental|Phase 1a, Dose Escalation|"In the Phase 1a monotherapy study, the starting dose of ST-067 will be 30 μg/kg, with a total of 7 dose level cohorts planned.~The starting dose for the IV infusion monotherapy dosing will be 60 µg/kg.~Patients will be treated every week with ST-067 in all cohorts. The DLT period is 28 days after the initial dose of ST-067. According to the mTPI schema initially there will be 3 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. Up to 12 patients will be treated at the RP2D."
89083995|NCT04787042|Experimental|Phase 2, Expansion|Phase 2 will enroll patients aged 18 years or older diagnosed with the following solid tumors: melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and microsatellite instability-high (MSI-Hi) tumors at the RP2D.
89083996|NCT04787042|Experimental|Phase 1a, Dose Escalation, ST-067 SC + Obinutuzumab Pre-treatment|"Patients will be treated every week with ST-067 in all cohorts. The DLT period is 28 days after the initial dose of ST-067. According to the mTPI schema initially there will be 3 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design.~The starting dose for ST-067 with obinutuzumab pre-treatment will be 120µg/kg. Obinutuzumab will be administered at 1000 mg daily via IV infusion on 2 consecutive days, with the first dose given at least 7 days prior to first dose of SC ST-067."
89083997|NCT04787042|Experimental|Phase 1 combination therapy|Phase 1 dose escalation in combination with pembrolizumab will start at a dose of 30 µg/kg of ST-067 and 200 mg every 3 weeks of pembrolizumab. Patients will be treated every week with ST-067 and every three weeks with pembrolizumab. The MTD will be determined based on the mTPI design.
89083998|NCT04779931|Experimental|Convoy-Pal Intervention|Intervention participants will be sent Convoy-Pal equipment and materials. The equipment can simply be removed from the box, plugged in, and turned on to start. Research staff will provide technical support as needed during the trial. Convoy-Pal is 12-week intervention that uses the Routinify platform to deliver self-management tools and palliative care resources in the participants' home. The platform includes a tablet, charging stand, and smart watch, with additional options for mobile phone access and a website portal.
89083999|NCT04779931|Active Comparator|Waitlist Control|Participants will complete baseline assessments and will be recontacted at 11 weeks to complete follow up assessments at week 12. Participants will receive a $25 gift card for each assessment ($50 total). If they would like to try the intervention at that time, we will send them Convoy-Pal equipment and materials. They will then have 12 weeks to use the tool.
89084000|NCT04737577|Experimental|Supramarginal resection (intervention arm)|Planned resection beyond the Gadolinium (GAD)-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
89084001|NCT04737577|Other|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
89084002|NCT04725903|Experimental|Treatment (proton beam therapy)|Patients undergo conventionally fractionated proton beam therapy daily on Monday-Friday directed to the prostate, pelvic lymph nodes, and para-aortic lymph nodes. Patients may receive an optional high-dose rate brachytherapy boost. Androgen deprivation therapy is required.
89084003|NCT04697810|Experimental|Namodenoson|Namodenoson capsules orally 25 mg every 12 hours for 36 weeks
89084004|NCT04697810|Placebo Comparator|Placebo|Matching placebo capsules orally 25 mg every 12 hours for 36 weeks
89084005|NCT04682301||Observational (focus group, interview)|"AIM I: Participants attend a focus group over 1-1.5 hours providing feedback on refining potential methods of SDM.~AIM II: Participants receive the SDM intervention developed in Aim I and provide feedback. Participants may attend a telephone interview over 45 minutes 1 month later."
89084006|NCT04679194|Experimental|Mana 312|"Mana 312 is administered intravenously (IV) within 30 minutes in either an inpatient or outpatient setting; either a central or peripheral IV line may be used. Each cycle of administration of Mana 312 will be 28 days.~Subjects not experiencing dose-limiting toxicity (DLT) following their initial dose may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses"
89084007|NCT04672720|Experimental|Adding l-carnitine to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. In the experimental group, the women will receive 3 tablet of L-carnitine daily (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) from day 2 of the previous menstrual cycle until pregnancy test day.
89084008|NCT04672720|Placebo Comparator|Adding placebo to controlled ovarian stimulation antagonist protocol|The controlled ovarian stimulation procedure in all the study participate will be same by using a flexible regimen of GnRH antagonist with E2 priming. The patients in the control group will receive 3 placebo tablets in similar way for 8 weeks.
89084009|NCT04647448||Healthy volunteers|Participants with no known cardiovascular disease
89084010|NCT04647448||Chest pain|Patients with symptoms of chest pain, undergoing elective coronary artery CT
89084011|NCT04631042||impulsive compulsive|Individuals between 6 and 80 years of age with a wide range of impulsivity/compulsivity behaviors - ranging from normal to mildly/extremely impaired.
89084012|NCT04629417|Experimental|Injured Worker Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre for a work-related shoulder injury as part of the Working Condition Program.
89084013|NCT04629417|Active Comparator|OHIP (funded) Patient Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre as part of the Shoulder Program.
89084014|NCT04624178|Experimental|Rucaparib in combination with Nivolumab|"One treatment cycle will consist of 28 days. Patients will receive rucaparib at 600 mg, orally, twice daily, continuously for 28 days. They will receive 480mg of nivolumab intravenously on day 1 of every four-week cycle. This is the recommended phase II dose of the combination therapy. Re-staging scans will be performed every 8 weeks.~Treatment will be repeated until the patient develops progressive disease or unacceptable toxicity or for a maximum duration of 26 cycles as long as patients are receiving benefit from treatment, have not had disease progression, met any criteria for study withdrawal and are tolerating therapy."
89084015|NCT04595448||Patients|Patients suffering from moderate tricuspid valve regurgitation
89084016|NCT04595448||Controls|Cardiovascular healthy, age, gender and weight matched controls.
89084017|NCT04576338||College Students|The cohort consists of Black and White college students at a university in a southeastern state in America.
89084018|NCT04563338|Experimental|Arm A (Liver Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
89084019|NCT04563338|Experimental|Arm B (Lung Cancer)|"Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks~Bevacizumab: 15 mg/kg, intravenously (IV), every 3 weeks"
89084020|NCT04563338|Experimental|Arm C (Lung Cancer)|Atezolizumab: 1200 mg, intravenously (IV), every 3 weeks
89084021|NCT04562610|Active Comparator|Group A: All oral pre-operative analgesics|"Group A patients will be administered the following medications in the preoperative holding area:~Acetaminophen 1,000 mg by mouth prior to operation~Celecoxib 200mg by mouth prior to operation~Tranexamic acid 2 grams by mouth prior to operation~Gabapentin 600mg by mouth prior to operation"
89225587|NCT05568524|Experimental|BFRT|The BFR training program for the intervention group consists of elbow flexion and extension, and knee extension exercises performed with low load (elastic bands; equivalent to 30% 1RM) and concurrent BFR (upper limb 50% AOP; lower limb 60% AOP). Subjects will perform 4 sets (30, 15, 15 and 15 reps) of each exercise with 30 s rest between sets and 5-minute rest between exercises.
89225588|NCT05565378|Active Comparator|Pembrolizumab Monotherapy|Participants will be administered an intravenous (IV) infusion of pembrolizumab as monotherapy in a fixed dose.
89225589|NCT05565378|Experimental|Dostarlimab Monotherapy|Participants will be administered an IV infusion of dostarlimab as monotherapy in a fixed dose.
89225590|NCT05565378|Experimental|Substudy 1A|Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of belrestotug in a fixed dose (Dose A).
89225591|NCT05565378|Experimental|Substudy 1B|Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of belrestotug in a fixed dose (Dose B).
89225592|NCT05565378|Experimental|Substudy 1C|Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of belrestotug in a fixed dose (Dose C).
89225593|NCT05565378|Experimental|Substudy 2|Participants will be administered an IV infusion of dostarlimab in a fixed dose followed by an IV infusion of belrestotug along with IV infusion of GSK6097608 in a fixed dose.
89225594|NCT05560009||Observational (18F-DOPA PET/MRI)|Patients receive 18F-DOPA IV and undergo PET/MRI over 60 minutes before standard of care radiotherapy and/or before standard of care surgery.
89225595|NCT05559866|Active Comparator|Control Group: ESG|Subjects will undergo ESG utilizing approved device alone
89225596|NCT05559866|Experimental|Treatment Group: ESG + HAPC|Subjects will undergo ESG as approved and on-label while also utilizing Hybrid APC approved and on-label.
89225597|NCT05559671|Experimental|HZ/su Vaccine, then Placebo|During the initial 24-week period (Period 1), participants will receive HZ/su injection at week 0 and week 8. During the second 24-week period (Period 2), participants will receive placebo saline injection at week 24 and week 32.
88812840|NCT02504268|Active Comparator|Methotrexate treatment|Methotrexate at least 15mg per week tablet or capsule orally
88812841|NCT02504268|Placebo Comparator|Abatacept Placebo|Placebo for Abatacept subcutaneous injection once per week
88812842|NCT02504268|Placebo Comparator|Methotrexate Placebo|Placebo to match Methotrexate capsule orally once per week
89084022|NCT04562610|Active Comparator|Group B: Intravenous agents|"Group B patients will receive:~Acetaminophen (Ofirmev) 1,000mg intravenous prior to operation~Celecoxib 200mg by mouth prior to operation~Tranexamic acid 2grams intravenous at start of operation~Gabapentin 600 mg by mouth prior to operation"
89084023|NCT04558957|Experimental|FLEBOGRIF|Interventions will be performed using Flebogrif catheter.
89084024|NCT04554511||Training cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
89084025|NCT04554511||Validation Cohort|Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020.
89084026|NCT04524910||mCNV patients|Adult Canadian patients diagnosed with myopic choroidal neovascularization (mCNV) and naïve for anti-VEGF treatment
89084027|NCT04518917|Other|Parkinson disease plus dementia|Participants will have a diagnosis of Parkinson disease plus dementia.
89084028|NCT04506424|Experimental|CT-Based Program for First Year of CI Use|"The Flat Panel CT scan will take place after a CI has been implanted and prior to the CI device activation.~The CI device will be activated using a CT-based program. The participant may continue to use this program for 1 year. Speech and music perception abilities will be monitored at regular intervals (approx. at 1, 3, 6, and 12 months post-activation).~After the 1 year of experimental program use, the participant may be switched over to a program that uses only the clinical default settings for 1 month; after which the participant will again complete the speech and music test battery.~At the end of the 13 month study the participant may choose whether to use the CT-based program or the clinical default program moving forward."
89084029|NCT04505501|Experimental|N-803|N-803 at 6mcg/kg every 3 weeks for 3 doses plus ART (n=10)
89084030|NCT04505501|No Intervention|Control|ART alone (n=5)
89084031|NCT04486586|Experimental|Active tDCS plus Speech-Language Therapy first|Active tDCS will be applied at the beginning of 45 minutes speech-language therapy session and then participant will be switched to sham tDCS after a washout period.
89084032|NCT04486586|Sham Comparator|Sham plus Speech-Language Therapy first|Sham will be applied at the beginning of 45 minutes speech-language therapy session and then participant will be switched to an active tDCS after a washout period.
89084033|NCT04465955|Experimental|NGM621 Treatment Group A (every 4 weeks)|NGM621 single intravitreal (IVT) injection
89084034|NCT04465955|Experimental|NGM621 Treatment Group C (every 8 weeks)|NGM621 single IVT injection
89084035|NCT04465955|Sham Comparator|Sham Group B (every 4 weeks)|Sham single IVT injection
89084036|NCT04465955|Sham Comparator|Sham Group D (every 8 weeks)|Sham single IVT injection
89084037|NCT04457193||post-ablation Barrett's patients|The patients with known prior diagnosis of histologically-confirmed Barrett's esophagus with or without dysplasia who have documentation of complete remission of Barrett's esophagus by endoscopy and histology after endoscopic ablation
89084038|NCT04450368||Cases with Air Trapping|20 COPD patients with lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
89084039|NCT04450368||Cases without Air Trapping|20 COPD patients without lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC [FRC/TLC])
88812843|NCT01832168|Other|Control|Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.
89084040|NCT04450368||Healthy Controls|Non COPD patients and non-smokers
89084041|NCT04444895|Experimental|Lanadelumab|Rollover participants from SHP643-303 (NCT04206605) will receive 300 milligram (mg) of lanadelumab solution in prefilled syringe subcutaneously (SC) for 26 weeks once every 2 weeks (Q2W) or once every 4 weeks (Q4W) if well controlled during SHP643-303 (NCT04206605) with up to 13 doses.
89084042|NCT04410653|Experimental|Arm 1 (KRASwt PDAC)|
89084043|NCT04410653|Experimental|Arm 2 (IMA)|
89084044|NCT04410653|Experimental|Arm 3 (other)|
89084045|NCT04377087|Experimental|Olaparib|Olaparib dosed at 300mg orally twice daily, started when CA125 rises by two-fold of nadir value.
89084046|NCT04342611||Observational (Patients under the care of TA Oncologist)|Latino patients with advanced cancer as defined in the inclusion criteria
89084047|NCT04341779|Experimental|Intervention arm|Point-of-care adherence testing and Point-of-care viral load testing
89084048|NCT04341779|No Intervention|Standard-of-care arm|No adherence testing and lab-based viral load testing
89084049|NCT04322994|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
89084050|NCT04322994|Experimental|Intervention|"Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-4L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.~Intervention: Device: High-flow nasal cannula"
89084051|NCT04319367|Active Comparator|Arm A|ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion followed by intensively monitored Antiretroviral Treatment Interruption (ATI)
89084052|NCT04319367|Placebo Comparator|Arm B|ART plus placebo infusion followed by an ATI (control arm). On re-starting ART, participants will receive immediate dual LS bNAbs and then a second ATI 24 weeks after bNAb infusion.
89084053|NCT04286776|Experimental|Direct Electrical Stimulation|Stimulation will be applied concurrently with the task, if applicable, and stimulation trials will be interleaved with sham trials, where no stimulation is delivered.
89084054|NCT04272996|Other|surgery alone|craniotomy for SDH evacuation
89084055|NCT04272996|Active Comparator|Surgery plus embolization|surgery for evacuation of SDH followed by embolization of middle meningeal vessel
89084056|NCT04258436|Active Comparator|Group 1-Block Arm|Group1 will receive an ultra-sound guided serratus anterior block after induction of general anesthesia
89084057|NCT04258436|No Intervention|Group 2-No Block Arm|Group 2 will not receive a serratus block after induction of general anesthesia
89084058|NCT04257214|No Intervention|Treatment as usual|Those randomized to treatment as usual will receive standard treatment from one of four FQHC sites.
89084059|NCT04257214|Active Comparator|Office based CBT|Those randomized to Cognitive Behavioral Treatment will receive cognitive behavioral treatment (CBT) along with standard treatment from the FQHC.
89084060|NCT04257214|Active Comparator|CRS/CPS|Those randomized to certified recovery specialist(CRS)/peer support specialist(CPS) will receive a CRS/CPS along with standard treatment from the FQHC.
89084061|NCT04257214|Active Comparator|CBT+CRS/CPS|Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.
89084062|NCT04252859|Experimental|All Participants|"One session of [18F]FES PET/CT Imaging - COMPLETED~Up to three imaging sessions:~[18F] FES-PET/CT exam,~Optional [18F]FDG PET/CT scan and~Optional follow-up [18F] FES-PET/CT exam."
89084063|NCT04247711|Experimental|OTCH|OTCH is based on OTNY, a Coordinated Specialty Care program for people with first-episode psychosis. The program is implemented by a multidisciplinary team, who provide coordinated, evidence-based services based on the interests, needs, and preferences of each participant.
89084064|NCT04247711|Placebo Comparator|Usual FEP services|This is generally provided in mental health outpatient clinics which serve a population enrolled in the public health care system.
89084065|NCT04246476|Experimental|Self cueing|People living with Parkinson disease and controls walking with self-generated rhythmic cues.
89084066|NCT04246476|Active Comparator|External cueing|People living with Parkinson disease and controls walking to external rhythmic cues (i.e., music).
89084067|NCT04205838|Experimental|Prevention (anakinra, CAR T-cell therapy)|Patients receive standard lymphodepleting therapy including fludarabine and cyclophosphamide on days -5 to -3, then receive axicabtagene ciloleucel CAR T-cell infusion. Patients with clinical evidence of ICANS of any grade, or CRS >= grade 3 receive anakinra SC every 6-12 hours for 12-36 doses over 9 days in the absence of unacceptable toxicity.
89084068|NCT04170543|Experimental|Group 1|MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).
89084069|NCT04170543|Experimental|Group 2|MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).
89084070|NCT04170543|Experimental|Group 3|MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).
89084071|NCT04170543|Experimental|Group 4|MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).
89084072|NCT04170543|Placebo Comparator|Group 5|Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).
89084073|NCT04163016|Experimental|Pharmacokinetics Sampling|"This study will include pregnant women who have decided to continue treatment with commercial certolizumab pegol (CZP) in accordance with their treating physician prior to participating in the study. Study participants will be responsible for obtaining and administering commercially available CZP under the care of their physician and according to the locally approved product label.~From all study participants blood samples will be drawn for pharmacokinetics during the study."
89084074|NCT04161391|Experimental|TPX-0046|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0046.~The food-effect sub-study determines the effect of food on a dose of TPX-0046 at the RP2D dose level.~The Phase 2 part of the study will determine the safety, tolerability, PK, and preliminary efficacy in specific cohorts.~Phase 2 Cohorts:~Cohort I (NSCLC + RET fusion, RET TKI Therapy Naive)~Cohort II (NSCLC + RET fusion, RET TKI Therapy Pre-treated)~Cohort III (MTC + RET mutation, RET TKI Therapy Naive)~Cohort IV (MTC + RET mutation, RET TKI Therapy Pre-treated)~Cohort V (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Naive)~Cohort VI (advanced/metastatic tumor with RET fusion or mutation, RET TKI Therapy Pre-Treated)"
89084075|NCT04147013|Experimental|Celecoxib Group|Patients will receive the interventional drug for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.
89084076|NCT04147013|Placebo Comparator|Control Group|Patients will receive the placebo for 7 days post endoscopic sinus surgery. These patients will also receive a prescription for tramadol (50 mg PO Q6H PRN x 10 tablets), to be used as needed for breakthrough pain. Patients will also be permitted to take acetaminophen for breakthrough pain as needed and will be encouraged to use acetaminophen prior to narcotic usage. Finally, they will be prescribed a nasal saline rinse, which is to be started on postoperative day one.
89084077|NCT04121182|Experimental|Nursing home with On-line training|"25 randomized residents will be included by nursing home Half of the institutions (randomized too) will benefit from an on-line training on the prevention and management of resident lung diseases"
89084078|NCT04121182|Active Comparator|Nursing home with usual practice|This group of Institutions continue their usual practice (routine care) and will not benefit from training during the study period.
89084079|NCT04111900|Experimental|Sleep/Circadian Friendly|initiation of sleep/circadian rhythm friendly intervention the first night spent in MICU after enrollment until patient transfers/discharges, ceases participation, or meets exclusion criteria.
89084080|NCT04111900|No Intervention|Usual Care|Usual care within intensive care unit
88812844|NCT01832168|Experimental|AmnioFix|Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.
89084081|NCT04084717|Experimental|ROS1 Rearrangement|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.
89084082|NCT04084717|Experimental|MET-activating Mutation (exon 14)|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.
89084083|NCT04084717|Experimental|MET-amplification|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.
89084084|NCT04079868|Experimental|Bone Health Service arm|Interventional arm
89084085|NCT04079868|No Intervention|Usual care (control) arm|"This arm represents a no practice management support control group."
89084086|NCT04061070|Sham Comparator|No Intervention with the mix threalose plus polyphenols|The patients allocated in this arm will not treated with a mix of threalose plus polyphenols
89084087|NCT04061070|Active Comparator|Intervention with the mix threalose plus polyhenols|The patients allocated in this arm will treated with a mix of threalose plus polyphenols
89084088|NCT04039841|Other|Motor imagery evaluation|cohort study
89084089|NCT04029922|Experimental|Part A- Dose Escalation|"Part A- Dose Escalation in patients with previously treated advanced HER2-positive solid tumors.~The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
89084090|NCT04029922|Experimental|Part B- Dose Expansion|"Part B - Dose Expansion in previously treated HER2-positive breast, GEA and other HER2-positive solid cancers~Part B will include 3 expansion groups: Group B1 (Breast Cancer) will begin enrolling while Part A is being conducted following the completion of Cohort 7 and Subsequent cohort of subjects in group B1 may enroll into higher doses that are tolerated in Part A. Group B2 (GEA) and Group B3 (Other HER-2 positive solid cancer groups) will begin enrollment after the MTD or RP2D is determined in Part A.~The assigned dose level of MT-5111 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e., on day 1, day 8 and day 15 of each cycle)."
89084091|NCT04020575|Experimental|Dose Escalation|"Dose escalation or de-escalation is tested in cohorts of 3 patients each using standard 3+3 dose-finding."
89084092|NCT04020575|Experimental|Luminal|Dose Expansion - 15 patients will be enrolled with luminal (hormone receptor positive, HER2 negative) metastatic breast cancer.
89084093|NCT04020575|Experimental|HER2+|Dose Expansion - 15 patients will be enrolled with HER2+ metastatic breast cancer.
89084094|NCT04020575|Experimental|Triple Negative|Dose Expansion - 15 patients will be enrolled with triple negative metastatic breast cancer.
89084095|NCT04007510|Experimental|EPI-CAL mHealth data network|"This arm of the study involves the use of the mobile health technology (app) to measure outcomes within an early psychosis (EP) program."
89084096|NCT04007510|Experimental|DUP Evaluation|A subset of individuals will participate in interviews to validate a tool to determine the duration of untreated psychosis in community settings
89084097|NCT03991819|Experimental|Phase 1|"Cycle 1 = 28 days and Cycle 2 and Future Cycles = 21 days~Binimetinib, by mouth (orally): Level 1: 45 mg, twice a day, continuously; Level -1: 30 mg, twice a day, continuously; Level -2: 30 mg, twice a day, for Days 1-14 of each cycle only~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 8 of Cycle 1, then Day 1 of Cycle 2 and future cycles."
89084098|NCT03991819|Experimental|Phase 1b|"All Cycles = 21 days~Binimetinib, by mouth (orally), at the best dose found in Phase 1 of the study, twice a day, continuously.~Pembrolizumab, by vein (intravenously), at a dose of 200 mg on Day 1 of every cycle."
89084099|NCT03919552|Experimental|Carboplatin|Patients receive carboplatin (AUC 4 on day 1) every three weeks
89084100|NCT03919552|Active Comparator|Cisplatin|Patients receive cisplatin (75mg/m2 on day 1) every three weeks
89084101|NCT03900845|Experimental|Environmental Chamber|All participants will wear all three study prostheses in an environmental chamber set at 35 degrees Celsius and 50% relative humidity.
89084102|NCT03900845|Experimental|Field Measurements|All participants will wear all three study prostheses in their home, work, and community environments for two weeks.
89084103|NCT03897595||Mpact cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
89084104|NCT03877757||Family Planning Elevated Contraceptive Access Clinics Program|This group consists of community clinics who apply and are accepted for FPE CAP membership during the Family Planning Elevated initiative. These clinics will receive the intervention and will provide monthly service delivery data to the FPE evaluation team.
89084105|NCT03877757||Control Clinics|This group consists of non-participating community clinics matched on clinic size, geography, and client populations who are not interested in participating in the initiative but are willing to provide monthly service delivery data to the FPE evaluation team.
89084106|NCT03758950|Placebo Comparator|Placebo|Once daily inhaled placebo
89084107|NCT03758950|Active Comparator|Mometasone|Inhaled Mometasone Furoate 220 mcg DPI
89084108|NCT03751371|Experimental|Walking Training with the HWA Device|Training with HWA device
89084109|NCT03751371|Other|Usual Care|Usual Care
89084110|NCT03738410|Active Comparator|Control Arm|The control arm will receive standard of care.
89084111|NCT03738410|Experimental|Mobile Health Messaging Arm|The Mobile Health Messaging Arm will receive standard of care, as well as the mobile health intervention. The mHealth intervention includes psycho-educational messaging as well.
89084112|NCT03738410|No Intervention|Focus Group Arm|The results of the focus groups will contribute to the wording and design of the intervention.
89225598|NCT05559671|Experimental|Placebo, then HZ/su Vaccine|During the initial 24-week period (Period 1), participants will receive placebo saline injection at week 0 and week 8. During the second 24-week period (Period 2), participants will receive HZ/su injection at week 24 and week 32.
89225599|NCT05555862|Experimental|Artesunate suppositories|Four 5-day cycles of artesunate suppositories
89225600|NCT05555862|Placebo Comparator|Placebo suppositories|Four 5-day cycles of placebo suppositories
89225601|NCT05555251|Experimental|Phase I -Dose escalation|Dose escalation study of BI-1607 combined with trastuzumab in HER2+ advanced or metastatic solid tumors.
89225602|NCT05555251|Experimental|Phase 2a - Expansion cohorts|Dose expansion study of BI-1607 combined with trastuzumab in cohort 1: HER2 positive locally advanced or metastatic HER2+ breast cancer and cohort 2: metastatic gastric or gastroesophageal junction adenocarcinoma
89225603|NCT05551741|Experimental|Cohort 1|IBC-Ab002 low dose or placebo
89225604|NCT05551741|Experimental|Cohort 2|IBC-Ab002 mid low dose or placebo
89225605|NCT05551741|Experimental|Cohort 3|IBC-Ab002 mid dose or placebo
89225606|NCT05551741|Experimental|Cohort 4|IBC-Ab002 mid high dose or placebo
89225607|NCT05551741|Experimental|Cohort 5|IBC-Ab002 high dose or placebo
89225608|NCT05550064|Experimental|Intervention arm|"Evidence-based intervention for SCC, previously evaluated in a cluster randomized trial (doi:10.1111/1471-0528.16754) The intervention for prepartum SCC will consist of four different parts, adjusted to suit pregnant women with emphasis on immediate start when applicable:~An educational video presenting available contraceptive methods~4 Key questions concerning how to deal with a new pregnancy, reproductive life plan, and additional health benefits from using contraception.~A tiered effectiveness chart of available contraceptives~A box of contraceptive models"
89225609|NCT05547984|Experimental|Dual Mobility Cup|dual mobility articulation
89225610|NCT05547984|Active Comparator|Standard Acetabular component|standard articulation with polyethylene + vitamin E inlay and metal head
89225611|NCT05546580|Experimental|Active arm|iadademstat and gilteritinib
89225612|NCT05544344|Experimental|Intervention|Subjects receive an intervention with 4 components: establishing a working alliance with a health coach, completing an online inventory to assess personal wellness in eight life areas, developing a Restart plan that includes personalized life goals, and follow-along with a health coach to address barriers to goal attainment and to reinforce achievement.
89225613|NCT05544344|Active Comparator|Services as Usual|Subjects receive mental health services as usual.
89225614|NCT05541913|No Intervention|Control Grup|After acceptance of the child's admission to the ward, parents will be asked to complete the Beck Anxiety Scale. Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again after the discharge training given routinely in the service. Control grup will be called on the postoperative 4th day after discharge and asked to fill in the Beck Anxiety Scale and Health Care Satisfaction Scale.
89225615|NCT05541913|Experimental|Intervention Grup|After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
89225616|NCT05541822|Experimental|Cohort 1: ABN401|Subjects will receive ABN401 800 mg, monotherapy, administered orally once daily in 21-day cycles
89225617|NCT05536297|Experimental|Avacincaptad pegol 2 mg|Avacincaptad pegol 2 mg administered monthly from Month 1 to Month 17
89225618|NCT05534620|Experimental|Treosulfan and Fludarabine|Participants will receive treosulfan 10 gram per square meter (g/m^2), intravenous (IV) infusion, given over 2 hours once daily on three consecutive days (day -4 to day -2), followed by fludarabine, 30 milligram per square meter (mg/m^2) IV infusion once daily on 5 consecutive days (days -6 to -2), preceding allogeneic haematopoietic stem cell transplantation (alloHSCT) on Day 0.
89225619|NCT05529849|Experimental|TCMCB07|once daily subcutaneous injection
89225620|NCT05529849|Placebo Comparator|Placebo|once daily subcutaneous injection
89225621|NCT05528861|Experimental|Lirentelimab (AK002)|Subjects in this arm will receive lirentelimab (AK002) administered subcutaneously.
89225622|NCT05528861|Placebo Comparator|Placebo|Placebo
89225623|NCT05526781||Clareon® monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
89225624|NCT05526326||Post-Approval Transplant Recipient cohort|Adult liver transplant recipients who are transplanted with an OrganOx metra® perfused DBD or DCD donor liver according to the approved indication and matching eligibility criteria
89084113|NCT03658538|Active Comparator|Active Treatment|The active treatment arm will receive two portable active HEPA air cleaners as well as 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).
89084114|NCT03658538|Sham Comparator|Control Arm|Homes in the control group will receive Sham air cleaners that have the internal HEPA filter removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status. The control arm will not receive phone based motivational interviewing to support a home smoking ban and SHS reduction, they will receive only smoking cessation counseling.
89084115|NCT03657368|Experimental|Low tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 6 ml/ kg predicted body weight, and PEEP = 5 cm water (H2O).
89084116|NCT03657368|Experimental|Low tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 6 ml/kg predicted body weight, and PEEP = 8 cm H2O.
89084117|NCT03657368|Experimental|High tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 5cm H2O.
89084118|NCT03657368|Experimental|High tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 8cm H2O.
89084119|NCT03645590|Experimental|Stroke Ready Community intervention|We divided the Flint community into four quadrants. We will focus our workshops and posters on one quadrant, but not exclusively, moving quadrants every 6 months over the course of two years.
89084120|NCT03641456|Experimental|VRD for Followed by VR|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22; oral lenalidomide 25mg on days 1 to 21; and oral dexamethasone 40mg on days 1, 8, 15 and 12 of a 28-day cycle.Patients are allowed to proceed to stem-cell transplantation after four cycles of VRD at the discretion of the treating physician.Two months after hematologic recovery, nonprogressive patients are to receive consolidation therapy comprising two cycles of VRD.Patients who do not proceed to stem-cell transplantation receive more two induction cycles after obtaining maximum response but no less than six cycles totally. Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib 1.3mg/m2 on days 1 and 15 and lenalidomide on days 1 to 21 at the dose level of 10mg.
88812845|NCT00904826|Experimental|Eculizumab|The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks. Subjects will receive therapy for a total of 12 months.
88812846|NCT01532453|Active Comparator|Standard Sun Protection Measures|Detailed information on standardised sun protection measures and application of self-provided sunscreen products. The Investigator may decide on an individual reimbursement of patient's expenditure (out of the centre's budget).
89084121|NCT03639688|Placebo Comparator|Left-sided threading|Patients intubated with fiberoptic bronchoscope by threading the tube on the left labial commissure
89084122|NCT03639688|Active Comparator|Right-sided threading|Patients intubated with fiberoptic bronchoscope by threading the tube on the right labial commissure
89084123|NCT03572660|Other|BMMNC intervention arm|Bone marrow derived mononuclear cells and G-CSF
89084124|NCT03564626|No Intervention|Control Group|Standard of care counseling and discharge instructions per local hospital policy. Standard of care follow up phone calls and visits at baseline and at 30 days. Follow-up will be for 30 days
89084125|NCT03564626|Experimental|Health IT +/- Scheduled Follow Up|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline, scheduled at 15 days and at 30 days. In addition, scheduled phone calls will be performed at days 7 and 21.Follow-up will be for 30 days
89084126|NCT03492671|Experimental|Chemotherapy and SBRT|"Pre-Operative Chemotherapy: Within 28 days of study enrollment, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of four 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.~Post-Operative Chemotherapy: Within 5-10 weeks after surgery, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of two 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.~Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy."
89084127|NCT03442322|Active Comparator|transdisciplinary approach|The transdisciplinary approach that is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability
89084128|NCT03442322|Active Comparator|multidisciplinary approach|The multidisciplinary approach that is problem-based and draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
89225625|NCT05524571|Experimental|Batoclimab|Participants will be administered batoclimab 680 mg SC weekly for 12 weeks followed by 340 mg SC weekly for 12 weeks.
89225626|NCT05524571|Placebo Comparator|Placebo|Participants will be administered matching placebo SC weekly for 24 weeks.
89225627|NCT05524467||Haemodialysis Patients|Only one data collection timepoint per patient is planned. Eligible and consenting patients will be asked to complete several PROs and one questionnaire, and their respective medical charts will be assessed retrospectively
89084129|NCT03439852|Experimental|Light to Moderate Physical Activity/Sedentary behavior|The telephone counseling plus group cohesion intervention is designed to increase Light-to-Moderate intensity physical activity (LMPA) and reduce Sedentary time (ST). The 12-wk intervention includes group discussions during 3 regular monthly club meetings when clubs' accumulated milestones for LMPA/ST min/wk will be identified and future cumulative club goals for PA/ST set. In addition, each member will receive 12 weekly personalized phone calls from health coaches who will use motivational interviewing to set individualized LMPA/ST goals setting, reduce barriers, and facilitate social support for LMPA/ST change.
89084130|NCT03439852|No Intervention|Delayed Treatment/Healthy Aging|Delayed Treatment (DT) / Healthy Aging materials Condition is for 12 weeks and participants receive 12 phone calls using a previously developed contact-matched protocol that uses mailed healthy aging information and telephone calls to assess symptom ratings. After the initial 12 weeks they then receive the LMPA/ST intervention
89084131|NCT03401385|Experimental|Dose Escalation - All Participants|All participants enrolled in the dose escalation part
89084132|NCT03401385|Experimental|Dose Expansion - All Participants|All participants enrolled in the dose expansion part
89084133|NCT03355300|Experimental|Cannabidiol Oral Solution|Cannabidiol Oral solution, dose as assigned in INS-17-103.
89084134|NCT03350529|Experimental|Localised PC prior to RP|MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, index lesion(s) within prostate and if possible with 5mm angular extension (imaging based healthy tissue marginal) to both sides from the tumour boundary in transverse plane and 5 mm in coronal plane. The ablative effect is aimed to reach prostate capsule by heating the control boundary (3 mm from capsule) to temperature 57 °C. The focal approach is intended to be radical as for index lesion.
89084135|NCT03350529|Experimental|Symptomatic locally advanced PC|MRI guided transurethral HIFU ablation is targeted to main prostatic malignant tumour squeezing and/or invading the prostatic urethra and/or bladder neck. The approach is intended to be palliative.
89084136|NCT03350529|Experimental|Locally recurrent PC after EBRT|"MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, local recurrent index lesion(s) within and/or surrounding prostate and if possible with 5 mm angular extension to either side from the tumour boundary in transverse plane and 5 mm in coronal plane. The approach is intended to be focal and salvage.~The whole-gland HIFU ablation approach will be considered in case of extensive organ confined recurrent prostate cancer (positive biopsies for malignancy from extensive/multiple area in prostate and/or extensive/multiple lesion(s) at baseline MRI) to cover whole prostate."
89084137|NCT03350529|Experimental|Symptomatic BPH|MRI guided transurethral HIFU ablation is targeted to adenomas of the prostate. The HIFU sector encompasses bilateral (anterolateral) transitional zones between bladder neck and verumontanum (colliculus seminalis).
89084138|NCT03333031|Experimental|HS-196|HS-196 will be administered intravenously as a single dose
89084139|NCT03332056|Active Comparator|Belladonna and Opium (B&O) suppository|A single belladonna and opium suppository, dose-weight calculated, administered immediately following patient positioning prior to instrumentation. The pharmacologically active ingredients that are present in the belladonna extract consist of atropine and scopolamine. Opium is compound drug that is composed of 20 alkaloids. The principle alkaloid that derives the majority of its effect is its morphine content and acts as a narcotic analgesic by increasing the pain threshold or the magnitude of stimulus required to evoke pain.
89084140|NCT03332056|Placebo Comparator|Placebo Suppository|placebo suppository
89084141|NCT03255434|Active Comparator|Folfox 4|Standard FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin 85mg/m²
89084142|NCT03255434|Experimental|Folfox 4 LBM|Adapted FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin allocated according to lean body mass (LBM)
89084143|NCT03188081||Cohort A|Adult RA patients followed up according to local clinical practice only at the hospital wards
89084144|NCT03188081||Cohort B|Adult RA patients followed up according to local clinical practice at the Hospital wards and additionally at their home through a support program
89084145|NCT03136393|Active Comparator|Control|Community based antenatal counselling
89084146|NCT03136393|Experimental|Intervention|Community based dietary counselling
89084147|NCT03115359|Experimental|Mindfulness Meditation|Mindfulness Meditation intervention, adjunctive to usual care for opioid-treated chronic low back pain.
89084148|NCT03115359|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
89084149|NCT03093350|Experimental|TAA-Specific CTLs|Patients receiving TAA-specific CTLs as therapy for breast cancer.
89084150|NCT03087903|Experimental|150 mg of Grape Seed Extract (GSE)|150 mg of GSE twice daily in the form of 75 mg capsule of Leucoselect Phytosome preparation.
89084151|NCT03074045|Experimental|Test|LCS16 (Low-dose LNG IUS)
89084152|NCT03074045|Active Comparator|Reference|COC (Yarina)
89084153|NCT02982564|Experimental|Low Intensity Exercise|Participants engage in low intensity endurance exercise.
89084154|NCT02982564|Experimental|Moderate Intensity Exercise|Participants engage in moderate intensity endurance exercise.
89084155|NCT02948543|Experimental|Treatment (Arm B):Intravesical BCG + MM|"Induction (weekly x 9); and followed by Maintenance (monthly x 9) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study.~Dosage of Mitomycin (MM) fixed at 40mg per instillation."
89084156|NCT02948543|Other|Treatment (Arm A): Intravesical BCG|"Induction (weekly x 6); and followed by Maintenance (monthly x 10) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study."
89084157|NCT02925780|Experimental|Resin infiltration|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated using the resin infiltrant Icon (DMG, Germany). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
89084158|NCT02925780|Active Comparator|Microabrasion|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated by microabrasion using the microabrasive material Opalustre (Ultradent, USA). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
89084159|NCT02901041|Experimental|Zonisamide & Computerized Psychotherapy|Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.
89084160|NCT02901041|Active Comparator|Placebo & Computerized Psychotherapy|Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.
89084161|NCT02840227|Experimental|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
89084162|NCT02840227|Experimental|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous PCA opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
89084163|NCT02797964|Experimental|Open label|
89084164|NCT02717403|Experimental|Facebook + Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website and the Facebook page on the internet about rheumatoid arthritis. Patients assessed at three and six months after baseline via email self response electronic questionnaires.
89084165|NCT02717403|Experimental|Educational Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website on the internet about rheumatoid arthritis. Content includes the following: (i) a learning center; (ii) relevant links to other evidence-based web pages; (iii) news released by major rheumatology and dermatology organizations/societies; and (iv) chronic disease management strategies. Participants assessed at three and six months after baseline via email self response electronic questionnaires.
89084166|NCT02717403|Experimental|Pilot Testing Group|Participants access the Educational Website and Facebook page about rheumatoid arthritis for a period of one week. After 1 week, research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
89084167|NCT02705508|Experimental|PEG group|Treatment PEG dosages were as follows: days 1 and 8,30min intravenous infusion of 1000mg/m2 gemcitabine;day1,4h intravenous infusion of 100mg/m2 etoposide,day1-3,deep intramuscular injection of 2500U/m2 Pegaspargase at three different sites.The regimen was repeated every 3 weeks.Stage IE/IIE patients underwent four cycles induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved-field radiation (IFRT) dose was 50-56 Gy.Stage IIIE/IVE patients were given for a maximum of six cycles.
89084168|NCT02673398|Experimental|Treatment (neratinib)|Patients receive neratinib 240mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89084169|NCT02547987|Experimental|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV on Day 1 of each 21 day cycle for 6 cycles
89084170|NCT02523040|Experimental|Lenalidomide|"After the screening procedures confirm participation in the research study.~- Lenalidomide Oral, Daily for 21 days of each cycle"
89084171|NCT02513199|Experimental|Participants with HCC|Participants with HCC with a lesion greater than 3 cm treated with TACE/SBRT combination
89084172|NCT02440672|Other|Device:JOURNEY™ II CR Total Knee System (J II CR TKS)|Subjects having TKA with JOURNEY™ II CR Total Knee System
89084173|NCT02396043|Experimental|Modifed BFM-95|All patients received induction phase 1 and phase2, followed by the protocol M, reinduction phase 1 and phase2, and maintenance (mercaptopurine 50 mg/m2 daily and methotrexate [MTX] 20 mg/m2 weekly, both orally) for up to a total therapy duration of 24 months. Response to treatment was evaluated on day 33 and at the end of induction in Modifed BFM-95.Sufficient response was defined as at least 70% tumor regression, less than 5% BM blasts, and no CNS disease on day 33 and complete remission detected by PET / CT at the end of induction.For patients with insufficient response at day 33 or at the end of induction treatment was to be intensified according to the high-risk branch of trial ALL-BFM95, with local radiotherapy (30 Gy) and allogeneic blood stem-cell transplantation.
89084174|NCT02258919|Experimental|Decompressive craniectomy and best medical treatment|Decompressive craniectomy and best medical treatment
89084175|NCT02258919|Active Comparator|Best medical treatment|Best medical treatment
89084176|NCT02232191|Active Comparator|Nonoperative|Pneumococcal vaccine (Pneumovax-23) will be administered within 72 hours of injury. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
89084177|NCT02232191|Active Comparator|Angioembolization|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after embolization. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
89084178|NCT02232191|Active Comparator|Splenectomy|Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after splenectomy. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.
89084179|NCT02143752||Mindfulness|Smokers enter a Mindfulness Training for Smokers course
89084180|NCT02143752||Quit Line|Smokers attempt smoking cessation with the help of the Wisconsin Tobacco Quit Line
89084181|NCT02141828|Experimental|EPZ-5676|EPZ-5676 Dose escalation and expansion cohorts
89084182|NCT02015871|Experimental|Degarelix|
89084183|NCT02000050|Experimental|Single Arm|"Neoadjuvant therapy: FOLFOX4 2 cycles + Tomotherapy + FOLFOX4 2 cycles~Surgery~Adjuvant therapy: FOLFOX4 8 cycles~TME (Total Mesorectal Excision)"
89084184|NCT01800214||Alzheimer's disease (AD)|
89084185|NCT01800214||Vascular Cognitive Disorders (VCD)|
89084186|NCT01800214||Lewy Body Disease (LBD)|
89084187|NCT01800214||Frontotemporal Dementia (FTD)|Behavioral-variant Frontotemporal Dementia (bvFTD) Language-variant Frontoemporal Dementia including Semantic dementia (SD) and Progressive non-fluent aphasia (PNFA) Corticobasal degeneration (CBD) Progressive supranuclear palsy (PSP)
89084188|NCT01800214||Mild Cognitive Impairment (MCI)|
89084189|NCT01800214||Cognitively Normal (CN)|
89084190|NCT01800214||Small Vessel Disease -Neurodegenerative (SVD)|
89084191|NCT01800214||Subjective Cognitive Complaints (SCC)|
89084192|NCT01765491|Experimental|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy.
89084193|NCT01765491|Active Comparator|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy.
89084194|NCT01684150|Experimental|EPZ-5676 Extension cohort|
89084195|NCT01273610|Experimental|Lapatinib and trastuzumab|Patients receive lapatinib ditosylate PO QD and trastuzumab IV once weekly OR once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89084196|NCT01165762|Experimental|Immune Tolerance, Kidney transplantation|Induction of immune tolerance in Haplotype matched living donor kidney transplantation.
89084197|NCT00999804|Experimental|24-week arm|Participants will receive 24-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
89084198|NCT00999804|Active Comparator|12-week arm|Participants will receive 12-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
89084199|NCT00797888|Experimental|Telephonic|Tailored telephonic intervention to improve HbA1c for participants in the diabetes registry
89084200|NCT00797888|Active Comparator|Standard registry|People with diabetes who are in the A1c registry may receive letters from the DOHMH to promote improved A1c and also give lists of bronx resources for healther foof and activites
89084201|NCT00349869|Experimental|1|8-week yoga program
89084202|NCT00349869|No Intervention|2|Usual care control
89084203|NCT00130221|Experimental|chlorhexidine gluconate (CHG)|daily skin cleansing with no-rinse, 2% CHG-impregnated cloths (Sage)
89084204|NCT00130221|Active Comparator|Soap & Water|bathing daily with bar soap (Dial Corp., Scottsdale, AZ) warm water, and cotton washcloths
89084205|NCT00052884|Experimental|Amifostine, Melphalan, and Stem Cell Reconstitution|Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2
89084206|NCT00005095||High Risk for Ovarian Cancer|Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
89084207|NCT00005095||Suspected or diagnosed gynecological condition|Women who are planning to undergo surgery for their gynecological condition
89084208|NCT00005095||Control Group|Healthy subjects with no history of cancer and at general risk.
89084209|NCT00002514|Experimental|Transplant|Allogeneic (if donor) or Autologous (if no donor) bone marrow transplant
89084210|NCT00002514|Active Comparator|Conventional Consolidation/Maintenance|Consolidation/Maintenance Therapy
89084211|NCT00001503||1/All Patients|Patients who were previously enrolled on a CCR protocol and need follow-up by CCR Investigators.
89084212|NCT05448469|Active Comparator|general anesthesia+ bilateral US guided erector spinae plane block|General anesthesia plus ultrasound guided erector spinae plane block with 20 ml bupivacaine 0.2% at T9
89084213|NCT05448469|Active Comparator|general anesthesia+ bilateral US guided paravertebral block|General anesthesia plus bilateral US guided paravertebral block with 7 ml bupivacaine 0.2% at T8 and T10
89084214|NCT05448469|Active Comparator|general anesthesia|general anesthesia plus conventional analgesia
89084215|NCT00607282|Placebo Comparator|Placebo|normal control group
89084216|NCT00607282|Experimental|Udenafil|oral administration of placebo for Udenafil (Dong-A Pharmaceutical co., Ltd, Seoul, Korea)
89084217|NCT02674789|Experimental|Exercise day|Behavioral intervention: 90min bike ergometer test at 70% of VO2max. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
89084218|NCT02674789|No Intervention|Non exercise day (Rest day)|No exercise protocol. Estimating daily variation of magnesium concentration. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
89084219|NCT00609310|Experimental|I|Flavonoid treatment
89084220|NCT02674867|Experimental|Early treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART before 6 months-of-age (early treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
89084221|NCT02674867|Other|Late treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART after 24 months-of-age (late treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
89084222|NCT04265248|Experimental|Virtual Reality|"The subjects will use Fulldive VR as the first degree of difficulty where only tilt movements are necessary, for the second degree of difficulty the game VR Ocean Aquarium 3D will be used, where bending, extension and rotation movements will be integrated, also introducing a sensory element to integrate the sound of the sea.~For these patients to perform the same work as group 2, the physiotherapist will have to count and control in each exercise the number of movements that the patient performs so as not to exceed the proposed dose in the active comparator group (3 sets of 10 repetitions of each exercise)."
89084223|NCT04265248|Active Comparator|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
89084224|NCT02864433||Controls for non-cholera diarrhea cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
89084225|NCT02864433||Non-cholera diarrhea cases|- Cases of acute watery diarrhea that present for healthcare at the study sites, but that test negative for cholera
89084226|NCT02864433||Controls for cholera cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
89084227|NCT02864433||Cholera cases|- Those with cholera-related diarrhea who present to healthcare at the study sites.
89084228|NCT00643591||Observational|Patients with a primary glioblastoma
89084229|NCT05437705|Experimental|Neuromodulation using the optimal rTMS stimulation frequency|Through manipulation of brain state with a negative-affect task and using fMRI as the feedback signal, we aim to fine-tune repetitive Transcranial Magnetic Stimulation (rTMS) delivery to maximally impact the desired brain states in awake behaving study participants in a highly individualized manner (Visit 3: TMS/fMRI). The optimal rTMS stimulation frequency will be tested in a 3-day rTMS neuromodulation intervention.
89084230|NCT05437705|Active Comparator|Neuromodulation using the least optimal rTMS stimulation frequency|We will compare the results of the optimal rTMS frequency neuromodulation with a separate 3-day neuromodulation session using the least optimal rTMS frequency, as determined by Visit 3: TMS/fMRI.
89084231|NCT00927472|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
89084232|NCT00927472|Active Comparator|Nix Creme Rinse|Nix applied to scalp for 10 minutes
89084233|NCT00643747|Experimental|A|Injection of vector
89084234|NCT00642733|Experimental|1|
89084235|NCT02672371|Experimental|active eMNS|Subjects with receive active eMNS for 20 minutes.
89084236|NCT02672371|Sham Comparator|sham eMNS|Subjects with receive sham eMNS for 20 minutes.
89225628|NCT05523635||Gamma 4|Subjects in the clinical investigation will undergo placement of the Gamma4 Nailing System, according to the approved Instructions for Use and Operative Technique Manual
89225629|NCT05523583||Patients newly diagnosed with lung cancer or head & neck cancer|Patients newly diagnosed with lung cancer or head & neck cancer (International Classification of Diseases 10: C76, C34) who undergo front-line treatment and who had at least one episode of smoking within the past 30 days before diagnosis
89225630|NCT05523375|Experimental|Intensive Lifestyle Intervention|"The intervention arm receives a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Obesity Guidelines, delivered remotely using eHealth technology, by trained health coaches embedded in the Digital Medicine Group in the Ochsner Health System. The intervention includes remote sessions with the health coach using evidence-based components such as the use of portion control and various behavioral strategies .Patients in the Intervention arm attend weekly sessions in the first six months, followed by monthly sessions for the remaining 18 months."
89225631|NCT05523375|No Intervention|Usual Care|Patients in the usual care arm will receive their normal, usual care from their primary care team.
89225632|NCT05520515|Experimental|Aquatic training plus health education group|Aerobic exercise training program in the aquatic environment twice a week plus health education program once a week
89225633|NCT05520515|Experimental|Land training plus health education group|Aerobic exercise training program in the land environment twice a week plus health education program once a week
89225634|NCT05520515|Active Comparator|Health education group|Health education program once a week
89225635|NCT05518422|Experimental|Oral Bosentan|
89225636|NCT05517668|Active Comparator|N-acetylcysteine (NAC) only (Control)|Patients randomized to Control group will receive placebo (D5W) in addition to N-acetylcysteine. Study participants will receive study drug (fomepizole or placebo) throughout the study.
89225637|NCT05517668|Experimental|N-acetylcysteine (NAC) and Fomepizole (4-MP) (Study)|Patients randomized to Study group will receive fomepizole (diluted in D5W) in addition to N-acetylcysteine. Study participants will receive study drug (fomepizole or placebo) throughout the study. If randomized to Study group, the infusion of the study medication should be initiated as soon as feasible but no later than 24 hours after the commencement of acetylcysteine therapy.
89225638|NCT05515705|Experimental|EUS-NS +|EUS with the navigation system first on, then off
89225639|NCT05515705|Experimental|EUS-NS -|EUS with the navigation system first off, then on
89225640|NCT05515705|No Intervention|EUS group|EUS alone
89225641|NCT05513586|Experimental|TAK-771|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive SC infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution.
89225642|NCT05511987|Active Comparator|Madela THOPAZ Suction Pump|Digital chest tube drainage systems utilize sensors to objectively quantify the size of air leaks as well as adjust the amount of suction applied to the pleural cavity in order to maintain a constant negative pressure(4). Studies in the adult population have showed that using a digital system allows for objective criteria regarding when it is safe to remove the chest tube and thus decreased time of chest tube drainage. This has also translated into decreased length of stay and cost(2, 6-8). Early data suggests that these same benefits may apply to pediatric patients, however a prospective randomized trial comparing the two systems has not been performed(9, 10).
89230177|NCT00796913|Active Comparator|Stop of medication after remission|"After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in:~Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487."
89084237|NCT00927394|Experimental|Combination Therapy: Aliskiren + Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 weeks. Forced titrated to: 2 tablets of Aliskiren 150 mg + 2 capsules of Valsartan 160 mg daily for 6 weeks
89084238|NCT00927394|Active Comparator|Monotherapy: Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day) for 8 weeks. 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 2 weeks. Forced titrated to: 2 capsules of Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 6 weeks.
89084239|NCT04179253|Other|Unexplained infertility|"The patient was placed in the dorsal lithotomy position. Normal saline was used for uterine distension connected to the inflow channel on the sheath with intravenous tubing. The tip of the hysteroscope was positioned in the vaginal introitus, the labia being slightly separated with fingers. The vagina was distended with saline.~The uterine cavity was systematically explored by rotating the fore-oblique scope in order to identify any anomaly in the uterine walls and/or the right and left tubal ostia. At this stage it was crucially important to avoid lateral movements as much as possible to reduce patient discomfort to a minimum. After that, the scope was removed Finally the evaluation and the data that had been found were written in details by the surgeon. Operative intervention was done if needed. Any complication in the form of pain, bleeding, vasovagal attack and perforation, were registered in the patient sheet."
89084240|NCT02676661||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
89084241|NCT02676661||peri-implant disease|The subjects who suffered from peri-implant disease.
89084242|NCT05014126|Experimental|Pain, Stress, & Emotions Class|No active or placebo comparator will be used. This is a single-arm study design.
89084243|NCT00643825|Active Comparator|A: prolonged adj TMZ|
89084244|NCT00643825|Other|B : Stop and Go|Rechallenging patients with TMZ at relapse
89084245|NCT04178863|Active Comparator|lataprost|latanoprost use
89084246|NCT04178863|Active Comparator|timolol|timolol group
89084247|NCT05329636|Placebo Comparator|Placebo FMT capsules|Glycerol and saline solution will be pipetted into commercially available acid-resistant hypromellose capsules (DRCaps, Capsugel) (650 μL), which will be closed and then secondarily sealed. Capsules will be stored frozen at -80°C (-112°F). Patients will swallow 30 frozen capsules on two consecutive days. Capsules look exactly the same as FMT capsules
89084248|NCT05329636|Experimental|FMT capsules|Fecal matter solution (feces, glycerol and saline solution) will be pipetted into commercially available acid-resistant hypromellose capsules (DRCaps, Capsugel) (650 μL), which will be closed and then secondarily sealed. Capsules will be stored frozen at -80°C (-112°F). Patients will swallow 30 frozen capsules on two consecutive days.
89084249|NCT05329636|Experimental|FMT enemas|patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema/ Fecal matter solution (feces(25 gr of stool , glycerol and saline solution) will be stored at 50 ml tubes frozen at -80°C (-112°F).
89084250|NCT04264858|Experimental|Treatment group|Immunoglobulin of cured patients
89084251|NCT04264858|Placebo Comparator|Control group|γ-Globulin
89084252|NCT04178473|Active Comparator|total abdominal hysterectomy|Total abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
89084253|NCT04178473|Active Comparator|subtotal abdominal hysterectomy|subtotal abdominal hysterectomy at the time of sacrocolpopexy operation for uterovaginal prolapse
89084254|NCT00976911|Active Comparator|Chemotherapy|Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 milligrams per square meter (mg/m^2) as a 1-hour intravenous (IV) infusion on Days 1, 8, 15, and 22 every 4 weeks (q4w) OR topotecan 4 mg/m^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m^2 dose could have been administered over 30 minutes on Days 1-5 every 3 weeks [q3w]) OR pegylated liposomal doxorubicin (PLD) 40 mg/m^2 as a 1 milligram per minute (mg/min) infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices.
89084255|NCT00976911|Experimental|Chemotherapy + Bevacizumab|Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion. Depending on chosen chemotherapy, pre-medication was implemented according to local practices. The chosen chemotherapy was combined with bevacizumab 10 milligrams per kilogram (mg/kg) IV every 2 weeks (q2w; or bevacizumab 15 mg/kg q3w if used in combination with topotecan 1.25 mg/m^2 on Days 1-5 on a q3w schedule). The initial bevacizumab infusion was over 90 minutes, with subsequent infusions over 60 minutes and then 30 minutes, as tolerated.
89084256|NCT04177927|Experimental|endtidalcarbondioxide monitoring group|The patients performed gastrointestinal endoscopy will be monitored with Capnostream 20p / Coviden for etCO2 (End tidal CO2), RR (Respitarory rate), SpO2 and PR (heart rate).
89084257|NCT04177927|Active Comparator|Control Group|Rutine monitorization will be performed to control group of patients.
89084258|NCT05336968|Active Comparator|Triamcinolone acetonide - Ropivacaine - Normal Saline|"Subject would receive:~Triamcinolone acetonide, 40 mg/mL. 1 mL Ropivacaine 0.2%, 2 mL Saline 0.9% 1 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
89084259|NCT05336968|Experimental|Ketorolac - Ropivacaine - Normal Saline|"Subject would receive:~Ketorolac 30 mg/mL, 1 mL Ropivacaine 0.2%, 2 mL Saline 0.9% 1 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
89084260|NCT05336968|Experimental|Triamcinolone acetonide - Ketorolac - Ropivacaine|"Subject would receive:~Triamcinolone acetonide, 40 mg/mL Ketorolac 30 mg/mL, 1 mL Ropivacaine 0.2%, 2 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization"
89084261|NCT04178161|Experimental|Treated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.~Treatment side receives laser treatment of the sweat glands."
89084262|NCT04178161|No Intervention|Untreated side|"Two regions are designated on the upper back. Randomized to treatment and control sides.~Control side is untreated."
89084263|NCT02674555|Experimental|ASP8273|Two Parts - Part A: 14C-radio labeled; Part B: non radio labeled (optional)
89084264|NCT00934648|Experimental|1|
89084265|NCT00643903|Experimental|1|Participants will receive five individual sessions of coping effectiveness training.
89084266|NCT00643903|Active Comparator|2|Participants will receive standard care and one delayed group workshop of coping effectiveness training.
89084267|NCT04178083||Laparoscopic Sacrohysteropexy,|"Under general anesthesia,laparoscopic approach is used to enter the abdomen.Following this, visceral peritoneum is held with forceps from the point where the sacro-uterine ligaments adhere to the uterus.~cut with unipolar scissors to the sacrouterin ligaments approximately 2-4 cm in the midline a transverse incision is made and the posterior wall of the cervix is reached. Approx. 10-15 x2 cm polypropylene mesh 5 mm trocar is inserted into the abdomen with the help of grasper and one end three points with 2/0 non-absorbable prolene sutures in the midline cervix Intracorporeal suture technique.~After the sacral promontorium on peritona about 2 The transverse incision is made to the normal anatomical position and the appropriate mesh length is determined and the other end is fixed to the area prepared on the sacral promontorium at 3 points with 2-0 prolene. Bleeding reperitonization according to intracorporeal suture technique with 2/0 vicry"
89084268|NCT04178083||Modified Laparoscopic Lateral Suspension|A 10 cm diameter trocar is passed through a 1 cm infraumbical incision. In addition, two 5 mm diameter trocar are placed on 4 cm on both sides of the spinal iliac crest, and a 5 mm diameter trocar is placed laterally in the rectus muscle at the left lateral level of the umbilicus. A Prolene network of 25 cm in length is prepared. Dissection of the uterine cavity is performed to expose a mustache. The bottom of the web is secured by suturing the web in the midline and sides of the web with 2-0 prolene. The left and right modified lateral ports are then removed by moving under the bottom of the planet with the help of the planet until the isthmus reaches the bottom of the round ligament. The lateral ports are again slid onto the mesh, placed and sutured with peritoneal 2-0 vicryil, the mesh ends are cut at the skin level and the procedure is terminated.
89084269|NCT04178083||Laparoscopic Pectopexy|"First, the peritoneal layer on the top and side of the bladder opens parallel to the round ligament toward the right pelvic sidewall.~The iliopectineal ligament is then located under the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medially of the outer iliac vein.~iliopectineal (Cooper) ligament exposing a segment of approximately 3-4 cm is formed.~After completion of the dissections, the ends of the mesh are sutured to both iliopectineal ligaments by intracorporeal suture using nonabsorbable sutures. The middle of the net is fixed with three sutures to the lower anterior segment of the uterus. The peritoneum on the mesh is sutured with an absorbable suture material."
89084270|NCT01175213|Experimental|SC/IGSC, 10% with rHuPH20 followed by SC of IGSC, 10% (safety)|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of SC of IGSC, 10% only (safety follow-up)
89084271|NCT01175213|Experimental|SC/IGSC, 10% with rHuPH20 followed by IV of IGSC, 10% (safety|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of intravenous (IV) administration of IGSC, 10% only (safety follow-up)
89084272|NCT01175213|Experimental|IV treatment with IGSC, 10% only|Partial efficacy (trough levels of immunoglobulin G [IgG] only) and safety of intravenous (IV) administration of IGSC, 10% only. This was for participants enrolled in the study who had anti-rHuPH20 andibody titer from study160603
89084273|NCT02865837|Experimental|ARM 1|
89230178|NCT00796913|No Intervention|Medication for 2 yrs after remission|See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
89230179|NCT00796913|Experimental|Se-yeast 200 Microgr/day + arm A|Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.
89084274|NCT04287699|Experimental|labor dance group|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment.The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
89084275|NCT04287699|No Intervention|Control group|Only routine practices were performed with the control group, and data were recorded as in the experimental groups.
89084276|NCT00644449|Experimental|1|
89084277|NCT00644449|Experimental|2|
89084278|NCT04287777|Experimental|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
89084279|NCT04287777|Active Comparator|Mupirocin ointment|Topical administration of Mupirocin ointment 20mg/g TID for 7 days.
89084280|NCT04287777|Placebo Comparator|Placebo|Topical administration of Placebo (ointment) TID for 7 days
89084281|NCT04180657||Patients with protein C deficiency|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
89084282|NCT04180657||Healthy controls|Patient and control group are compared regarding ghrelin, growth hormone levels and appetite, and no other intervention is made.
89084283|NCT02676583|Active Comparator|Billateral tonsil fossa closure|tonsillectomy
89084284|NCT02676583|Active Comparator|No closure of tonsil fossa|tonsillectomy
89084285|NCT02676583|Active Comparator|Unilateral tonsil fossa closure|tonsillectomy
89084286|NCT00642889|Experimental|High Dose|150-200mg/day
89084287|NCT00642889|Experimental|Low dose|50-100mg/day
89084288|NCT00642889|Placebo Comparator|Placebo|
89084289|NCT00629655||1|healthy people, male
89084290|NCT00629655||2|male patients with cerebral infarction, chronic stage
89084291|NCT03920163|Active Comparator|Control|Stable , penetrating trauma patients undergoing laparotomy who receive standard post operative care
89084292|NCT03920163|Experimental|ERATS|Stable penetrating trauma patients undergoing laparotomy who receive enhanced recovery measures post operatively .
89084293|NCT00974259|Experimental|pBrO2 and ICP management|Treatment protocol based on pBrO2 and ICP values.
89084294|NCT00974259|Active Comparator|ICP management|Treatment protocol based on ICP values only.
89084295|NCT04177615|Experimental|Thromboectomy and rTPA|use thromboectomy and rtpa for patient with basilar artery occlusion stroke in 24 hour
89084296|NCT04177615|No Intervention|rTPA( recombinant tissue plasminogen activator )|use rtpa for patient with basilar artery occlusion stroke in 24 hour
89084297|NCT00927082|Experimental|PEG-IFN 90mcg 24 Wks|Participants received Pegasys (Pegylated interferon alfa-2a [PEG-IFN]) 90 micrograms (mcg) subcutaneously (SC) once a week for 24 weeks in Study WV19432 and entered follow-up (FU) Study MV22430.
89084298|NCT00927082|Experimental|PEG-IFN 180mcg 24 Wks|Participants received PEG-IFN 180 mcg SC once a week for 24 weeks in Study WV19432 and entered FU Study MV22430.
89084299|NCT00927082|Experimental|PEG-IFN 90mcg 48 Wks|Participants received PEG-IFN 90 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
89084300|NCT00927082|Experimental|PEG-IFN 180mcg 48 Wks|Participants received PEG-IFN 180 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
89084301|NCT02672137|Experimental|knowledge translation|knowledge translation 12-month multi-facet intensive knowledge translation measures that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
89084302|NCT02672137|No Intervention|Usual care|no intervention
89084303|NCT02864511|Experimental|Intervention group|
89225643|NCT05511987|Active Comparator|Atrium Dry Suction Control Water Seal Chest Drain|there are several limitations to this analog system. First, although the system can manually be set to a certain negative pressure, the actual pressure experienced by the patient varies dependent on the amount of fluid in the tube and the level of the device relative to the patient(2). This leads to inconsistency of pleural pressure which has been associated with an increased incidence of prolonged air leak(2). Second, the analog system relies on a water chamber where bubbles are visualized to indicate an air leak. Air leaks are a common cause of increased duration of chest tube drainage and subsequent length of stay(3). There is high interobserver variability in the subjective measurement of air leaks when using the analog system thus exacerbating the amount of time the chest tube remains in the patient as well as the length of stay(4, 5).
89084304|NCT04287933|Active Comparator|Drain|
89084305|NCT04287933|No Intervention|No drain|
89084306|NCT02674243|Experimental|Iodopovidone group|Patients who will be randomized for using iodopovidone solution for pleurodesis.
89084307|NCT02674243|Active Comparator|Talc group|Patients who will be randomized for using Talc for pleurodesis.
89084308|NCT04256200|Active Comparator|Dienogest|Deinogest (Visanne) 2mg/day orally for 24 weeks
89084309|NCT04256200|Active Comparator|Oral Contraceptive Pills|Oral contraceptive pill (Yasmin, 0.03mg Ethinyl Estradiol and 3mg Drospirenone) orally daily for 24 weeks
89084310|NCT05294029||All subjects with neuromotor disability|
89084311|NCT04246840||Study group|15 adult patients who underwent allogenic hematopoietic stem cell transplantation (HSCT) for severe combined immunodeficieny 15 to 45 years ago
89084312|NCT04246840||Control group|15 age-matched healthy individuals
89084313|NCT02676817||Group 1|Group 1 (n=70) = UC in remission regardless of the medication that allowed remission nor taken by the patient (Mayo' sub-score 0 or 1) and who require colonoscopy regardless of the study according to current guidelines (screening for dysplasia, monitoring during treatment etc).
89084314|NCT02676817||Group 2|Group 2 (n=30) = Active UC (Mayo' sub-score 2 or 3) requiring adalimumab and for whom a rectosigmoidoscopy will be performed 8 to 12 weeks after starting therapy, according to current French guidelines and routine practice. Eight weeks after the treatment is the minimum time necessary to evaluate the effects of this treatment according the current practice in France. Then, investigators chose in our study to assess the effects in the group 2 at 8 weeks. All the 30 patients in group 2 will receive adalimumab and they will be anti-TNF naïve patients.
89084315|NCT04265014|Active Comparator|Goal-directed fluid treatment|"Fluid management will be performed according to SVV and CI monitoring. When patients have SVV>10%, 250 cc crystalloid will be administered and when SVV fell below 10% during 30-minute monitoring standard (5 mL/kg/hr) crystalloid infusion continues. If SVV continues above 10%, a second fluid bolus of 250 cc colloid (minifluid challenge) will be administered.~If the desired SVV level can not be reached, the Hct values will be examined. Blood replacement will be performed when Hct<30% in patients with coronary artery disease (CAD) and when Hct<25% for other patient groups. If the desired SVV level can not be reached in spite of blood replacement products, if CI will be below 2.5 L/min/m2 vasopressor will begun. If SVV will be at normal values with CI below 2.5 L/min/m2, inotrop will begun."
89084316|NCT04265014|Active Comparator|liberal fluid treatment|"Fluid management will be performed according to MAP, HR and urine output.~If peroperative urine amounts will be <0.5 mL/kg/hr during two-hour monitoring, with MAP<65 mmHg, HR>100/min for at least 30 minutes and CVP falls 20% compared to basal values, the same anesthesiologist will begin additional fluid replacement of 5 mL/kg/hr based on clinical experience.~Blood product replacement will be provided at Hct<30% for those with coronary artery disease and at Hct<25% for other patients."
89084317|NCT02674009||laBCC Participants|Participants with laBCC who received at least one dose of Vismodegib in routine clinical practice for 32 months (between 02 Aug 2013 and 31 Mar 2016).
89084318|NCT05329558||Healthy Controls|
89084319|NCT05329558||Patients with ART without MRONJ|
89084320|NCT05329558||Patients with oral ART with MRONJ|
89084321|NCT05329558||Patients with intravenous ART with MRONJ|
89084322|NCT00976677|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes (with or without bevacizumab IV over 30-90 minutes) on day 1. Patients also receive placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive placebo (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
89084323|NCT00976677|Experimental|Arm II|Patients receive paclitaxel and carboplatin (with or without bevacizumab) as in arm I. Patients also receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive erlotinib hydrochloride (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
89084324|NCT05329480|Experimental|Creatine Monohydrate Supplementation|Blinded subjects are instructed to ingest 20g of creatine monohydrate for 7 days divided into 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).
89084325|NCT05329480|Placebo Comparator|Maltodextrin Supplementation|Blinded subjects are instructed to ingest 20g of maltodextrin for 7 days divided into 4 dosages of 5g each that should be taken with water or other liquids throughout the day (breakfast, lunch, afternoon and evening).
89084326|NCT05329480|No Intervention|Control|Participants in the control group do not receive a supplement (creatine or placebo) to ingest over the 7 day period.
89084327|NCT02674087||Expectant women|
89084328|NCT04179331|Experimental|Neurotensin|
89084329|NCT04179331|Experimental|Saline|
89084330|NCT02674165|Experimental|Intervention|"The pregnancy prevention intervention to be tested is an adaptation of Becoming a Responsible Teen (BART), an evidence-based (proven to work by research) HIV prevention curriculum designed primarily for African American adolescents, ages 14-18, in community-based settings.~The culturally-adapted version HART consists of nine sessions, lasting about 2 hours each, and includes interactive group discussions and role plays that are -performed by adolescents. Unlike BART, one PTSD awareness session has been added to address what happens to people who have been exposed to mental trauma and natural disasters."
89084331|NCT02674165|No Intervention|Control or nutrition|Nutrition/fitness curriculum will teach students about ingredients in food that are good for the body and will keep it in good health
89084332|NCT04288167|Experimental|Patients with suspected brain injury|This arm will consist of up to 30 pediatric patients who entered the Emergency Room and who are suspected of having mild traumatic brain injury. Two sample sets will be collected within the first 10 hours from the injury.
89084333|NCT04288167|Active Comparator|Healthy controls|This arm will consist of up to 30 healthy control subjects, the samples of whom will be compared to the samples of brain injury patients (Arm 1). One sample set will be collected from healthy children without any known brain injury.
89084334|NCT00642967|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Participants will receive subcutaneous methoxy polyethylene glycol-epoetin beta every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
89084335|NCT00926536|Experimental|C-arm CT + DSA as needed'|In the group of subjects randomized in this group, the image guidance component of the procedure will be conducted by the acquisition of 3D CT-like images during a trans-hepatic arterial injection of iodinated contrast agent for road mapping the tumor feeding vessels and supplemented by DSA as needed by the operating physician as imaging guidance for planning tumor(s) treatment approach.
89084336|NCT00926536|Active Comparator|DSA only|In the group of subjects randomized in this group, present standard of care, i.e DSA imaging only will be used by the operating physician to map out the tumor vessels and used for treatment approach. Additional 3D CT-like images will be obtained, but only used if the operator cannot perform adequate planning using DSA alone.
89084337|NCT02864043|Other|EGD with NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe following standard of care endoscopy
89084338|NCT04287231|Experimental|Dual-tDCS & PT|Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about 1 hours). Current intensity is fixed at 2 mA and current will flow continuously. Physical therapist will give an intervention program for lower limb performence.
89084339|NCT04287231|Active Comparator|Sham-tDCS & PT|Sham tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere, current intensity will be 2mA (sham mode). Physical therapist will give an intervention program for lower limb performence.
89084340|NCT00607360|No Intervention|Standard Drug Court|Participants received standard services from drug court
89084341|NCT00607360|Experimental|Drug Court plus Therapeutic Workplace|Participants receive standard drug court services plus therapeutic workplace intervention
89084342|NCT02865993|Other|Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
89084343|NCT02865993|Other|No Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
89084344|NCT02865759|Experimental|Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, in a brochure and at a website. The practice is described as spending 15 minutes every day from gestational week 28 to get to know the fetal movement pattern. The fetus must be awake when she practice Mindfetalness and the woman is suggested to lay on her left side when she observe the fetal movements. In the brochure as well at the website the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek health-care without unnecessary delay.
89084345|NCT02865759|No Intervention|Routine Care|No activities will take place in the antenatal clinics randomized to routine care.
89084346|NCT00923260|Experimental|Roux-en-Y Gastric Bypass/Omentectomy|Laparoscopic Roux-en-Y Gastric Bypass with omentectomy
89084347|NCT00923260|Active Comparator|Roux-en-Y Gastric Bypass alone|
89084348|NCT04180735||Perforation|Perforation
89084349|NCT04180735||No perforation|No perforation
89084350|NCT04256278|Experimental|Intervention Group|
89084351|NCT04256278|Placebo Comparator|Control Group|
89084352|NCT04287543|Experimental|Melatonin group|Patients with PD who will receive 25 mg of melatonin gel at 12 hours a day and half an hour before sleeping for 12 months
89084353|NCT04287543|Placebo Comparator|Placebo group|Patients with PD who will receive 25 mg of placebo gel at 12 hours a day and half an hour before sleeping for 12 months
89084354|NCT02676505||1|"Group (I)(Coached group):~It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds."
89084355|NCT02676505||2|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth.
89084356|NCT04287387|Experimental|Glucophage group|
89084357|NCT04287387|Experimental|Acarbose group|
89084358|NCT04287387|Experimental|Sitagliptin group|
89084359|NCT04287387|Experimental|Dapagliflozin group|
89084360|NCT04287387|Experimental|Pioglitazone group|
89084361|NCT04287387|Experimental|Glimepiride group|
89084362|NCT00644527|Experimental|1|Listening to one of two different specific music programs (Group A), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
89084363|NCT00644527|Experimental|2|Listening to one of two different specific music programs (Group B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
89084364|NCT00644527|Sham Comparator|3|Control I (Group C) : Listening 30 min in the morning and 30 min in the evening to unspecific music (Mozart) over 5 weeks.
89084365|NCT00644527|No Intervention|4|Control II (Group D): Waiting list. - Each 50% of the subjects will be assigned randomly to either Group A (arm 1) and B (arm 2) after 5 weeks of waiting time.
89084366|NCT04287153|Experimental|Croytherapy on abdomen and saddlebags|Six (6) to 10 applicators (application area of 17 cm X 6 cm) are applied on the dorsal side (back, waist, saddlebags) for 45 minutes and then on the ventral side (belly) for 45 minutes, with adjustments according to the size of the participant. The temperature applied with the device is variable (-10°c to -7°C).
89084367|NCT00644605|Active Comparator|Arm 1|
89084368|NCT00644605|Active Comparator|Arm 2|
89084369|NCT00644605|Active Comparator|Arm 3|
89084370|NCT00644605|Placebo Comparator|Arm 4|
89084371|NCT02865681|Active Comparator|Conventional IVF|Conventional ovarian stimulation consist of ovarian stimulation with daily gonadotropins injections daily starting in the early follicular phase (cycle day 3). The final maturation of oocytes will be induced with the standard hCG trigger when at least two follicles reached 18 mm or greater. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
89084372|NCT02865681|Experimental|IVF protocol using nasal gonadotropins|Instead of injectable gonadotropins, nasal human menopausal gonadotropins (hMG; menopur) and oral clomiphene citrate and/or oral letrozole starting in the early follicular phase (cycle day 3). When at least two follicles reached 18 mm or greater, Synarel (Nafarelin) will be used instead of the injectable HCG trigger. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
89084373|NCT00644137|Experimental|A|pregabalin 300mg/day given in conjunction with smoking cigarettes.
89084374|NCT00644137|Experimental|2|cigarettes given in conjunction with pregabalin
89084375|NCT04286997|Experimental|GRAIL population|patients are treated with 20 sessions of GRAIL rehabilitation, associated to 20 traditional physiotherapy sessions (1+1 a day, during a period of 30 days)
89084376|NCT04286997|Active Comparator|traditional population|subjects are treated with 40 sessions of traditional physiotherapy (2 a day, during a period of 30 days)
89084377|NCT02672059||Peripheral Neuropathy|Patients with peripheral neuropathy (observational study, no interventions)
89084378|NCT04256356|Active Comparator|Infants born by CS-fed fermented formula at double dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 4,6 g per 100g of powder (group fed with double dosage of fermented matrix compare trial FERCT15)
89084379|NCT04256356|Active Comparator|Infants born by CS-fed fermented formula at triple dosage|Infants born by CS-fed formula milk with fermented matrix at dosage of 6,9 g per 100g of powder (group fed with triple double dosage of fermented matrix compare trial FERCT15)
89084380|NCT04256356|Placebo Comparator|Infants born by CS-fed standard formula|Infants born by CS-fed formula milk without fermented matrix
89084381|NCT04256356|Other|Infants born by CS-breastfed|Infants born by cesarean section fed with mother milk during were the reference group
89084382|NCT02864121|Experimental|arm 1|all patients included in IDAHO study
89084383|NCT04177537||Pre-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work with traditional therapies selected from one rehabilitation facility
89084384|NCT04177537||Post-Low Intensity Continuous Ultrasound Treatment|Retrospective analysis of pain alleviation, range of motion and ability to return to work after treatment with low-intensity continuous ultrasound (LICUS) in conjunction with traditional therapies selected from one rehabilitation facility
89084385|NCT00934102|Active Comparator|Lotrafilcon A|Lotrafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
89084386|NCT00934102|Active Comparator|Narafilcon A|Narafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
89084387|NCT00934102|Active Comparator|Galyfilcon A|Galyfilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
89084388|NCT05587153||Observational study in parturient who will be recruited for the study|this study will include the eligible parturient who will be assessed by perfusion index and by positional hemodynamic changes.
89084389|NCT03760419|Experimental|Intervention Arm|The antibiotic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive usual care and all treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
89084390|NCT03760419|No Intervention|Control Arm|No experimental decision support will be provided to those randomized to the control arm. All children will receive usual care and treatment will not be restricted or altered in any way by the study.
89084391|NCT00910195|Experimental|CPAP before Bi-Level-APAP|receiving CPAP treatment during the first night and then Bi-level-APAP treatment during second night
89084392|NCT00910195|Experimental|Bi-Level-APAP before CPAP|receiving Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
89084393|NCT04285905|Active Comparator|Enhanced standard of care|"Access to Fast Track TB Clinic~Information leaflet for primary male partner"
89084394|NCT04285905|Active Comparator|Group 2|"Access to Fast Track TB Clinic~Information leaflet for primary male partner~Female participant sputum collection from male partners"
89084395|NCT04285905|Active Comparator|Group 3|"Access to Fast Track TB Clinic~Information leaflet for primary male partner~Female participant sputum collection from male partners~Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
89084396|NCT04285905|Active Comparator|Group 4|"Access to Fast Track TB Clinic~Information leaflet for primary male partner~Female participant sputum collection from male partners~Female partner delivered oral HIV self-testing kits for primary male partner"
89084397|NCT04285905|Active Comparator|Group 5|"Access to Fast Track TB Clinic~Information leaflet for primary male partner~Female participant sputum collection from male partners~Female partner delivered oral HIV self-testing kits for primary male partner~Voucher for financial incentive (MKW 5000) that can be collected by the male partner upon attendance at the Fast Track Clinic"
89084398|NCT04203784||Meropenem treated patients|
89084399|NCT04203784||Piperacillin treated patients|
89084400|NCT02671825|Experimental|PUR0217a|PUR0200 formulation 1
89084401|NCT02671825|Experimental|PUR0228a|PUR0200 formulation 2
89084402|NCT02671825|Experimental|PUR0228b|PUR0200 formulation 3
89084403|NCT02671825|Experimental|PUR0228c|PUR0200 formulation 4
89084404|NCT02671825|Experimental|PUR0230c|PUR0200 formulation 5
89084405|NCT02671825|Active Comparator|Reference Product 1|Reference Product formulation with active charcoal
89084406|NCT02671825|Active Comparator|Reference Product 2|Reference Product without active charcoal
89225644|NCT05509894||Participants receiving Ngenla|Participants receiving Ngenla according to label
89225645|NCT05509725|Experimental|Intervention|Participants in this group will be randomized to receive probiotic formulation for the following 8 weeks.
89225646|NCT05509725|Placebo Comparator|Control|Participants in this group will be randomized to receive placebo for the following 8 weeks.
89225647|NCT05509023|Experimental|ADX-914|
89225648|NCT05509023|Placebo Comparator|Placebo|
89225649|NCT05505110|Active Comparator|Intervention Group|Vaginal Seeding
89225650|NCT05505110|Sham Comparator|Control Group|Sterile Swab
89225651|NCT05501093||Diabetic patients|Diabetic patients who plan to undergo bariatric surgery
89225652|NCT05501093||Normo-glycemic (non-diabetic) patients|Non-diabetic patients who plan to undergo bariatric surgery
89225653|NCT05500066||Aequalis Flex Revive Shoulder System|Commercially available shoulder system available in both anatomic and reversed configurations.
89225654|NCT05498480|Experimental|Cohort 1: Relatlimab Dose 1 + Nivolumab|
89225655|NCT05498480|Experimental|Cohort 2: Relatlimab Dose 2 + Nivolumab|
89225656|NCT05496348||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label
89225657|NCT05485376|Experimental|Early Pulmonary Artery Catheter|If you are in the experimental group a PAC will be placed within 6 hours of randomization and within 24 hours of presentation with ADHF-CS.
89225658|NCT05485376|No Intervention|No or delayed Pulmonary Artery Catheter|If you are in the control group, a PAC will not be placed during hospitalization or may be placed 48 hours after randomization into the study. Placement of a PAC within 48 hours is only permitted for emergencies.
89225659|NCT05485051|Experimental|Chlorhexidine baths|All patients in the cluster randomized to the intervention arm will receive baths using a 2% chlorhexidine digluconate solution with surface-active agents during the intervention period. All other infection control and cleaning procedures will be performed according to the current practice in each center.
89225660|NCT05485051|Active Comparator|Usual baths|All patients in the cluster randomized to the intervention arm will receive baths using soap and water according to the current practice in each center during the intervention period. All other infection control and cleaning procedures will be performed according to the current practice in each center.
89225661|NCT05483010|Experimental|Atorvastatin|"Choice of statin is at the discretion of the treating physician and may depend on insurance approval.~Atorvastatin dosing starts at 80 mg once daily.~In the absence of disease progression or intolerable side effects, patients may receive up to 12 months of treatment.~If a patient switches statins due to toxicity, treatment time is still limited to 12 months total (ie, if a patient receives 6 months of atorvastatin and switches to rosuvastatin, the duration of rosuvastatin will be no more than 6 months)."
89225662|NCT05483010|Experimental|Rosuvastatin|"Choice of statin is at the discretion of the treating physician and may depend on insurance approval.~Rosuvastatin dosing starts at 40 mg once daily.~In the absence of disease progression or intolerable side effects, patients may receive up to 12 months of treatment.~If a patient switches statins due to toxicity, treatment time is still limited to 12 months total (ie, if a patient receives 6 months of atorvastatin and switches to rosuvastatin, the duration of rosuvastatin will be no more than 6 months)."
89225663|NCT05481970|Active Comparator|Dexmedetomidine group|Group A , Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
89225664|NCT05481970|Placebo Comparator|Opioid group|In group (B) (OBA) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
89225665|NCT05480995|Experimental|18F-fluorofuranylnorprogesterone PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
89084407|NCT04256122||Responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.~Patient treated with adjuvant MMC or BCG that did not experience recurrence for at least 42 months after TURBT~Patients are tumor-free at the moment of the analysis"
89084408|NCT04256122||Non responder patients|"Patients with NMIBC at first diagnosis, pTa/pT1 (primary tumors) treated with MMC or BCG after TURBT will be selected from the institutional patient registry.~o Patient treated with adjuvant MMC or BCG that experienced recurrence in the first 24 months after TURBT."
89084409|NCT04176367|Experimental|Test: Nicergoline manufactured in China|
89084410|NCT04176367|Active Comparator|Reference: Nicergoline manufactured in Italy|
89084411|NCT04259476|Active Comparator|group A|WIll be given low dose perioperative ketamine infusion, as well as a ketamine bolus at start of surgery.
89084412|NCT04259476|Placebo Comparator|group B|will be given normal saline infusion and bolus at start of surgery.
89084413|NCT04177147|Experimental|Clinical decision support via alert tool|Clinicians received access to the electronic alert tool, which automatically displayed patients' risk of hypoglycemia.
89084414|NCT04177147|No Intervention|Usual care|Clinicians did not receive access to the electronic alert tool.
89084415|NCT04255732|Other|Extent of retinal periphery area viewing|For the 30 patients fundus photography will be performed using two ultra-wide-field imaging systems.
89084416|NCT04177459|Experimental|Health promoting dialogue in addition to treatment as usual|Health promoting dialogues in addition to follow-up from primary and secondary health care, and from schools, which is individually customized due to fatigue and other symptoms present.
89084417|NCT04177459|Active Comparator|Treatment as usual|Follow-up from primary and secondary health care, and from Schools, which is individually customized due to fatigue and other symptoms present..
89084418|NCT00970281|Experimental|10 mg Olanzapine|
89084419|NCT00970281|Placebo Comparator|Placebo|
89084420|NCT00643045|Experimental|1|Low dose (50-100mg/day)
89084421|NCT00643045|Experimental|2|High dose (150-200 mg/day)
89084422|NCT00643045|Placebo Comparator|3|
89084423|NCT04203706|Experimental|Normal-weight subjects|
89084424|NCT02670733||high responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, intracranial pressure (ICP) increases above the median for the study population.
89084425|NCT02670733||low responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, the level of intracranial pressure (ICP) increases below the median for the study population.
89084426|NCT00976209|Experimental|Phenylephrine Hydrochloride Extended Release Tablets, 30 mg|
89084427|NCT00976209|Active Comparator|Phenylephrine Hydrochloride Immediate Release Tablets, 10 mg|
89084428|NCT05275465|Experimental|HH-006|
89084429|NCT05275465|Placebo Comparator|Placebo|
89084430|NCT02862639|Experimental|injection of viscosupplementation and corticosteroid|experimental group
89084431|NCT02862639|Active Comparator|injection of corticosteroid|control group
89084432|NCT04177069||Visucomplex Plus monotherapy|Patients with early dry AMD will be treated with Visucomplex Plus monotherapy.
89084433|NCT04177069||anti-VEGF drug plus Visucomplex Plus|Dry or wet AMD patients under treatment with a stable dose of an anti-VEGF drug, Visucomplex Plus will be added-on, upon physician decision.
89084434|NCT03746301||Treatment|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions.
89084435|NCT00925990|Experimental|CTS-1027 + ribavirin|Study drug plus ribavirin
89084436|NCT00925990|Experimental|CTS-1027 + placebo|Study drug plus placebo for ribavirin
89084437|NCT02670655|Experimental|Group A (short-time iontophoresis group)|Group A was treated with iontophoresis-assisted AFL-PDT with a short incubation time (2 h)
89084438|NCT02670655|Active Comparator|Group B (short-time conventional group)|Group B was treated with conventional AFL-PDT with a short incubation time (2 h)
89084439|NCT02670655|Active Comparator|Group C (long-time conventional group)|Group C was treated with conventional AFL-PDT with a standard incubation time (3 h)
89084440|NCT04176991|Experimental|CTI-1601|
89084441|NCT04176991|Placebo Comparator|Placebo|
89084442|NCT03744351|Other|Healthy volunteer|"45 subjects~A single visit"
89084443|NCT03744351|Other|Clinically Isolated Syndrome|• 35 subjects
89084444|NCT03744351|Other|Non-MS patients with neurological inflammatory disease|• 30 subjects
89084445|NCT03744351|Other|MS patients (remitting or progressive untreated)|"30 untreated remittent patients~30 progressive untreated patients"
89084446|NCT01131078|Experimental|Bevacizumab + Irinotecan + Capecitabine (1000 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle. Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice daily (Day 2 to 15). Cycle length was 3 weeks consisting of 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
89084447|NCT01131078|Experimental|Bevacizumab + Capecitabine (1250 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle in combination with capecitabine administered orally at 1250 mg/m^2 twice daily (Day 1 to 14). Cycle length was 3 weeks with 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
89084448|NCT01131078|Experimental|Bevacizumab + Capecitabine (650 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 Week cycle in combination with capecitabine administered orally at 650 mg/m^2 twice daily (Day 1 to 21). Cycle length was 3 weeks with 3 weeks of capecitabine treatment without interruptions. Participants received the same regimen until unacceptable toxicity, PD, or participant withdrawal.
89084449|NCT04094545||Nasopharyngeal carcinoma(NPC)|The patients (1) were diagnosed with NPC; 2)18< Age <75.
89230180|NCT02554175|Experimental|the target propofol concentration|patients were allocated to 1 of 6 groups of predefined propofol target Ce for induction, namely, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 µg.mL-1.Propofol was administered to achieve target propofol Ce.
89084450|NCT04094545||Health adults|(1) 18< Age <75, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; None of the patients had rhinitis or used any antibiotics during the three months last 3 months.
89225666|NCT05479344|Experimental|Contextual Behavioural Intervention Based on Meaning and Connection|The current intervention involves the identification of strengths (the first week, 90 minutes of intervention), the perception of the meaning in life (the second week, 90 minutes of intervention), the learning of strategies to develop plan (the third week, 90 minutes of intervention), and the understanding of emotion regulation strategies (the fourth week, 90 minutes of intervention).
89225667|NCT05479344|Other|Waiting list group|The waiting list group will receive the same intervention at the end of the 3-month follow-up test.
89225668|NCT05477875|Experimental|Oral cannabinoid|Oral cannabinoid
89225669|NCT05477875|Active Comparator|Oral codeine/acetaminophen|Oral codeine-acetaminophen for controlling pain
89225670|NCT05477563|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive a single infusion of CTX001 through a central venous catheter.
89225671|NCT05471622|Experimental|Intervention|The lead case manager and covering provider on the inpatient care team for participants in this group will receive a message from the research team identifying their patient as appropriate for home palliative care and will be asked to refer their patient for these services.
89225672|NCT05471622|No Intervention|Usual Care|Participants in this group will receive usual care upon discharge from the hospital. Their clinical team will not be notified that they are appropriate for home palliative care services, but they may still be referred for those services if their clinicians feel their patient will benefit.
89225673|NCT05469009|Experimental|Infusion plus Exablate BBBO Treatment|Intravenous infusion of Aducanumab or Lecanemab every 2-4 weeks (per standard of care) followed by blood brain barrier opening by FUS.
89225674|NCT05462106|Placebo Comparator|Placebo for Study Part 1 (Prodromal AD)|Prodromal AD participants receive placebo at predefined time points over 48 weeks
89225675|NCT05462106|Experimental|ACI-24.060 at Dose A|Prodromal AD participants receive dose A of ACI-24.060 at predefined time points over 48 weeks
89225676|NCT05462106|Experimental|ACI-24.060 at Dose B (Optional)|Prodromal AD participants receive dose B of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
89225677|NCT05462106|Experimental|ACI-24.060 at Dose C (Optional)|Prodromal AD participants receive dose C of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
89225678|NCT05462106|Experimental|ACI-24.060 at Dose D (Optional)|Prodromal AD participants receive dose D of ACI-24.060 at predefined time points over 48 weeks. This arm is optional.
89225679|NCT05462106|Placebo Comparator|Placebo for Study Part 2 (Down syndrome)|Participants with Down syndrome receive placebo at predefined time points over 74 weeks
89225680|NCT05462106|Experimental|ACI-24.060 at Dose X|Participants with Down syndrome receive dose X of ACI-24.060 at predefined time points over 74 weeks. Dose X will be a dose already tested in Study Part 1.
89225681|NCT05462106|Experimental|ACI-24.060 at Dose Y (Optional)|Participants with Down syndrome may optionally receive a dose Y of ACI-24.060 at predefined time points over 74 weeks.
89225682|NCT05459701|Placebo Comparator|group (A) for controlled (placebo).|25 patients will recieve placebo for 6 months.
89225683|NCT05459701|Active Comparator|group (D) for Dapagliflozin.|25 patients will recieve 10 mg Dapagliflozin daily for 6 months.
89225684|NCT05458765|Active Comparator|F/TAF|daily oral tablet
89225685|NCT05458765|Active Comparator|F/TDF|daily oral tablet
89225686|NCT05450731|Experimental|cardiac rehabilitation intervention group|Participants assigned to the intervention group will participate in pre-post assessments and a 12-week supervised exercise based cardiac rehabilitation program at a designated local Pulse Heart Institute Cardiac Rehabilitation program.
89225687|NCT05450731|No Intervention|control group|Participants assigned to the control group will participate in pre-post assessments and will maintain usual care and current activity levels.
89225688|NCT05449691|Active Comparator|Biological Matrix|Participants will undergo immediate breast reconstruction using biological matrix and implant
89225689|NCT05449691|Experimental|Synthetic Mesh|Participants will undergo immediate breast reconstruction using synthetic mesh and implant
89230181|NCT00789269|Experimental|1|rhubarb
89230182|NCT00789269|Placebo Comparator|2|
89230183|NCT00789347||1|Healthy volunteers
89230184|NCT00789347||2|Patient with neuropathic pain
89230185|NCT00789347||3|patients without neuropathic pain
89225690|NCT05447923|Experimental|Screening (FIT, education, questionnaire, patient navigation)|Participants receive free FIT tests in conjunction with education on colorectal cancer screening. Participants undergo self-collect FIT and mail the sample to Mayo Clinic Lab for processing. Participants also complete a questionnaire about colorectal cancer screening and healthcare. Participants receive FIT test results through Mayo Clinic nursing support and participants with a positive test are followed up by a patient navigator to discuss next steps and consultation with a gastroenterologist to review their results.
89225691|NCT05445635|Experimental|Iriscope|
89225692|NCT05445635|Active Comparator|EBUS|
89225693|NCT05445635|Experimental|Combined Iriscope + EBUS|
89225694|NCT05441618||Lyoplant®|Lyoplant® is a pure collagen implant obtained from bovine pericardium. The membrane is used for the replacement and extension of connective tissue structures in neurosurgery.
89225695|NCT05440734|Experimental|Melatonin|2 mg oral tablet, melatonin slow release formulation, 1x 60 min before bedtime for 15 days
89225696|NCT05440734|Placebo Comparator|Placebo|2 mg oral tablet, 1x 60 min before bedtime for 15 days
89225697|NCT05436249|Other|Real time neurofeedback with task|Participants will undergo a real-time fMRI scan during which two distinct tasks will be performed.
89225698|NCT05436249|Other|Overt tapping and/or motor imagery practice|Participants will undergo an overt tapping task at baseline. Participants are assigned to a group where they will then perform respective motor and/or imagery tasks at home for 3 weeks.
89225699|NCT05431712||DSA+|Patients with pre-transplantation detected donor-specific antibodies, with Luminex Single Antigen Bead analysis.
89225700|NCT05431712||PRA+|Immunized controls without DSAs pre-transplantation, with equal peak PRA levels and donor/recipient age as the DSA+ group.
89225701|NCT05431712||PRA-|Non-immunized controls without DSAs pre-transplantation, with a peak PRA of less than 6%, with equal donor/recipient age as the DSA+ group.
89225702|NCT05429632|Experimental|3mg mocravimod arm|3 mg of mocravimod orally once per day for 12 months
89225703|NCT05429632|Experimental|1mg mocravimod arm|1 mg of mocravimod orally once per day for 12 months
89225704|NCT05429632|Placebo Comparator|Placebo arm|placebo orally once per day for 12 months
89225705|NCT05422235|Other|Control Group|Subjects in this group will be asked to continue their routine medical treatment for 24 weeks.
89225706|NCT05422235|Experimental|Aerobic Exercise|In order to determine the exercise capacity of subjects, submaximal exercise test will be performed.Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
89225707|NCT05422235|Experimental|Aerobic Exercise+ Foot-Related Exercises|In addition to walking training specific to the subject in the 2nd group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Participants will be followed for 24 weeks.
89225708|NCT05419388|Experimental|Low dose every three weeks (Q3W)|Participants will receive RO7247669 Q3W until loss of clinical benefit, unacceptable toxicity, or a maximum of 24 months.
89225709|NCT05419388|Experimental|High dose Q3W|Participants will receive RO7247669 Q3W until loss of clinical benefit, unacceptable toxicity, or a maximum of 24 months.
89225710|NCT05416151|Other|Arm 1, Test: freeze-dried B. lactis|
89225711|NCT05416151|Other|Arm 2, Control: freeze-dried maltodextrin|
89084451|NCT03738501|Experimental|Chest physiotherapy with SET|Chest physiotherapy will be provided by a single physiotherapist not involved in outcomes assessment. Airway clearance technique will be Slow Expiratory Technique (SET). SET is a slow modulation of airflow in order to remove bronchial secretions within infants lungs. Experimental group will also benefit for standard medical and non-pharmacological care (e.g Standard Treatment)
89084452|NCT03738501|Active Comparator|Standard treatment|Medical treatment, health education for parents, rhinopharyngeal clearance using isotonic saline solution, advices.
89084453|NCT04180501|Experimental|SRS sequential sintilimab|
89084454|NCT04286061|Experimental|Experimental group|Each session will last 1 or 2 minutes, with one intervention being carried out a week, over a period of 4 weeks. Prior to the start of training, the instrument-assisted soft tissue mobilization technique will be performed
89084455|NCT04286061|No Intervention|Control group|Players included in the control group will follow their usual training routine.
89084456|NCT02670499|Experimental|GAP-FLEX|Study Device will be used up to 6 times per day for up to 6 minutes to aid in the recovery and improve the degree of flexion from TKR
89084457|NCT02670499|Active Comparator|CPM|Control Device will be used up to 2 hours per day for up to 3 times per day to aid in the recovery and improve the degree of flexion from TKR and be compared to the Study Device
89084458|NCT04180345||Validation of the questionnaire|Items reduction, ajustment and psychometric validation of the questionnaire
89084459|NCT02671903|Active Comparator|Pacemaker: AV optimised, His pacing|Subjects will remain in this arm for 6 months before being crossed-over. See below intervention details.
89084460|NCT02671903|No Intervention|No pacing|Subjects will remain in this arm for 6 months before being crossed-over. The pacemaker will be programmed to VVI 30 bpm. Dynamic AV delay will be programmed off throughout the study.
89084461|NCT01167582|Experimental|Liberal Transfusion Strategy|Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.
89084462|NCT01167582|Experimental|Restrictive transfusion strategy|"Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.~Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension."
89084463|NCT03695445||Peripheral Norepinephrine|Patients who will undergo surgery with need for vasopressor support.
89084464|NCT04080583||Usual Care|People with a chronic lung condition who are physically inactive
89225712|NCT05412095||Cardiology patient|Patient requiring cardiac surgery with bypass
89084465|NCT04204551|Experimental|PD-TR|"Intervention~exercise, dose: two cycles of 12-week HIIT program (three times a week) separated with 3 months break~& conventional physical therapy"
89084466|NCT04204551|Active Comparator|PD-NTR|conventional physical therapy
89084467|NCT04204551|No Intervention|Healthy Controls|healthy controls without any kind of therapy
89084468|NCT04177303|Active Comparator|Metformin|Patients will continue with their standard insulin therapy and will additionally receive orally metformin 2gr/day.
89084469|NCT04177303|Placebo Comparator|Placebo|Patients will continue with their standard insulin therapy and will additionally receive placebo
89225713|NCT05412095||Pneumology patient|Patient requiring lung surgery with resection of at least one lobe
89225714|NCT05407129|No Intervention|Usual care|This arm is the usual care arm of parents and providers who are randomized to proceed with usual care and are not given the family safety reporting intervention.
89230186|NCT00793013|Experimental|ARDS Net Low Tidal Volume|
89225715|NCT05407129|Experimental|Experimental: Intervention arm|This arm is the intervention arm of parents and providers who are randomized to the family safety reporting intervention on the study units.
89225716|NCT05401799|Active Comparator|Conventional Upper Extremity Neuroeducation|74 patients will receive the standard occupational therapy sessions that they would normally receive during their IRF stay. UE neuroeducation sessions are typically focused on improving strength and mobility of the upper arm. Clinicians will not be given instructions on how to run their sessions, however they will not be allowed to use BURT. Other devices that would normally be used during neuro-educational sessions (including X-cite, electrical stimulation and RT-300) will be allowed for use in this group. The therapists will track the activity, level of assistance and time provided in a tracking sheet, as well as document any adverse events that may occur
89225717|NCT05401799|Experimental|BURT Upper Extremity|As part of routine therapy, 74 patients will receive up to 5 sessions per week of BURT UE therapy in place of conventional neuro re-education. Patients in this arm of the study will receive any conventional therapy during the remainder of their treatment sessions. When using BURT, therapists will track the activity, level of assistance and time provided in a tracking sheet, as well as document any adverse events that may occur.
89225718|NCT05399108|Experimental|The Novel Lateral Approach|In this arm, the catheterization of the internal jugular vein is done with ultrasound guidance displaying the vein on its short axis using a lateral approach and in-plane technique. The catheterization is done according to the newest international recommendations for good clinical practice.
89225719|NCT05399108|Active Comparator|The Conventional Approach|In this group catheterization of the jugular internal vein is done by conventional approach with ultrasound guidance using displaying on its short axis and using the out-of-plane technique.
89225720|NCT05388357|Experimental|AI -guided PCI|based on AI-QCA measurement, a drug eluting stent of an appropriate size is inserted and then high-pressure balloon dilatation is additionally actively performed in all patients.
89225721|NCT05388357|Active Comparator|OCT-guided PCI|In the OCT group, the size of the stent is determined using intravascular optical coherence tomography, and balloon dilatation is additionally performed if necessary.
89225722|NCT05385536||Guidance clinical pathway|Sites will be provided a standardized infrastructure and process for collecting and reporting of urine test results including unique lab requisitions that contain the option to order Guidance® UTI, Standard Urine Culture (SUC), and Urine Analysis (UA) along with a protocol for results notification.
89225723|NCT05385536||Traditional clinical pathway|Sites will employ their current standard clinical care practices for suspected UTI, including Standard Urine Culture (SUC), Urine Analysis (UA), and Guidance® UTI testing as per current reporting practices. Providers at these facilities will have the option to order any diagnostic test they deem appropriate.
89225724|NCT05377905|Experimental|Microneedle Array Doxorubicin (MNA-D)|Immunocompetent and immuno-incompetent subjects will receive the MNA-D patch on 4 subsequent visits for a 20 minute time period at each application and will include patients who have competent immune systems with cSCC meeting all other inclusion/exclusion criteria and patients considered immuno-incompetent post transplant with cSCC meeting all other inclusion/exclusion criteria.
89225725|NCT05377749|Experimental|FACT intervention|Families Addressing Cancer Together (FACT) intervention plus questionnaires
89225726|NCT05377749|No Intervention|Wait-list control condition|Participants assigned to the waitlist control condition only complete questionnaires during the study period. After they have completed their 6-week study activities, they will receive access to the FACT intervention.
89225727|NCT05377658|Experimental|AK104+albumin-bound paclitaxel+carboplatin|Participants receive 3 cycles of AK104 in combination with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy prior to surgery; followed by surgery; followed by adjuvant AK104 for 9 cycles.
89225728|NCT05372549|Other|Oncology preservation|
89225729|NCT05372549|Other|Social (elective) preservation|
89225730|NCT05366881||Cases|Cases will include participants with newly diagnosed, treatment-naive cancer at the time of enrollment.
89225731|NCT05366881||Controls|Controls will include participants without known cancer at the time of enrollment.
89225732|NCT05364411|Experimental|HYDRA-protons|group 1, n=25, run at HollandPTC
89225733|NCT05364411|Active Comparator|Conventional fractionated proton therapy|group 2, n=25, run at HollandPTC
89225734|NCT05364411|Experimental|HYDRA-photons|group 3, n=25 run at Erasmus MC
89225735|NCT05364411|Active Comparator|Conventional fractionated photon therapy|group 4, n=25 run at Erasmus MC
89225736|NCT05358431|Experimental|participants|Patients fulfilling the El Escorial criteria for probable or definite ALS with a C9orf72 mutation or asymptomatics being a first-degree to a person carrying a C9orf72 mutation or Healthy controls
89225737|NCT05357586|Experimental|Transdiagnostic cognitive behavioral therapy|Transdiagnostic cognitive behavioral therapy
89225738|NCT05356117|Experimental|Resistance Training (RT) and Protein Supplementation (PS)|"Participants will be randomly assigned to the Resistance Training (RT) and Protein Supplementation (PS) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week with daily protein supplementation for the duration of their chemotherapy with a maximum of 16-weeks of exercise. Exercises will be tailored to the participants' fitness levels.~Sessions will last ~60 minutes including 5-minute warm-up and 5-minute cool-down.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions."
89230187|NCT00793013|Experimental|APRV Ventilation|
89230188|NCT00789425|Active Comparator|1|a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
89084470|NCT04177225||Patients with normal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their normal left ventricular diastolic function.
89084471|NCT04177225||Patients with abnormal diastolic function|Patients undergoing scheduled surgical procedures requiring general anesthesia and invasive arterial pressure and advanced cardiac function monitoring. A trans thoracic ultrasound examination of cardiac function will be performed before induction of general anesthesia . In the operating room, the anesthesia care team will place all of the standard intra-operative monitors and then induce general anesthesia. After induction, the ultrasound examination will be repeated and the planned additional intra-operative monitors will be placed. The arterial catheter will be attached to a FloTrac/EV1000 monitor that will be used to guide fluid management during the procedure. The sensitivity and specificity of SVV to predict the response of cardiac output to intravenous fluid administration will be assessed in this patient group distinguished by their abnormal left ventricular diastolic function.
89084472|NCT01167426|Active Comparator|20 mg/0.5 mL Glatiramer Acetate|Participants received once daily subcutaneous administration of 20 mg glatiramer acetate as 20 mg/1.0 mL utilizing autoject 2 for glass syringe for two weeks (Period 1), followed by 20 mg/0.5 mL utilizing the autoject 2 device for four weeks (Period 2).
89084473|NCT04204785|No Intervention|Pre-Education|Patient and Anesthesiologist participants completing surveys prior to OR staff education sessions.
89084474|NCT04204785|Experimental|Post-Education|Patient and Anesthesiologist participants completing surveys after OR staff education sessions.
89084475|NCT04286919|Active Comparator|ExRx#1: Physical Activity Guidelines|ExRx#1 uses the Frequency, Intensity, Time, and Type or FITT principle of exercise prescription to prescribe the Physical Activity Guidelines for Americans which is a weekly goal of 150-minutes of moderate intensity aerobic physical activity plus 2 days of muscle strengthening physical activity. ExRx#1 communicates the ultimate goal of the physical activity guidelines for Americans using an image adopted from the physical activity guidelines website that depicts the weekly goal. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the physical activity guidelines ultimate weekly goal by providing a weekly prescription of Frequency, Intensity, Time, and Type of physical activity that accomplishes meeting the physical activity guidelines weekly goal.
89084476|NCT04286919|Experimental|ExRx#2: Heat Map|ExRx#2 uses the heat map image published in the 2018 Physical Activity Guidelines Advisory Committee Scientific Report that communicates the dose-response relationship between increased physical activity and improved health to prescribe the message that all physical activity across all Frequencies, Intensities, Time bouts and Types (FITT) counts towards health. ExRx#2 is founded in the Integrated Behavior Change Theory and emphasizes that all physical activity matters regardless of FITT as depicted by the heat map image. There are 12 weeks of exercise guidelines that will progress participants from being physically inactive to meeting the ExRx#2 heat map ultimate weekly goal of moving more throughout the day across all intensities in order to achieve optimal health as represented by the deep green color on the bottom right of the heat map image.
89084477|NCT02862873|Experimental|Ondansetron|
89084478|NCT02862873|Placebo Comparator|Saline solution|
89084479|NCT02671513|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen.
89084480|NCT02671669|Active Comparator|Usual Care (UC)|
89084481|NCT02671669|Active Comparator|Movn application (MVN)|
89225739|NCT05356117|Experimental|Resistance Training (RT)|"Participants will be randomly assigned to the Resistance Training (RT) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week. Exercises will be tailored to the participants' fitness levels.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions."
89230189|NCT00789425|Placebo Comparator|2|Placebo (starch) + 1000 mg of calcium per day.
89230190|NCT00793091|Active Comparator|1|
89230191|NCT00793091|Placebo Comparator|2|
89084482|NCT03814005|Experimental|Control Arm (Normal Renal and Hepatic Function)|Pevonedistat 20 milligram per square meter (mg/m^2), infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
89084483|NCT03814005|Experimental|Renal Arm (Severe Renal Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day1 through Day7 or Day1 through Day5, and on Days 8-9 in combination with pevonedistat 15 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies and docetaxel 75 mg/m^2 OR carboplatin AUC4, infusion, intravenously, once along with paclitaxel 135 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 15 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
89084484|NCT03814005|Experimental|Mild Hepatic Arm (Mild Hepatic Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies, and carboplatin AUC4, infusion, intravenously, once along with paclitaxel 135 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 20 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
89225740|NCT05356117|Active Comparator|Attention Control (AC)|"Participants will be randomly assigned to the Attention Control (AC) group and receive instruction on a home-based, 3 days a week stretching program.~Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions.~The attention control group will be given the option to participate in the exercise intervention after their treatment is completed, with a cap of a 16-week period."
89225741|NCT05353296|Experimental|Culturally adapted digital cognitive behavioral therapy for insomnia (CBT-I) (Somryst)|Somryst is an FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) program that has been translated and culturally adapted for Spanish speakers. Group will have access to this culturally-adapted Somryst, along with the usual care provided by their primary care provider, and will be provided a sleep hygiene brochure during group assignment.
89230192|NCT00789503|Experimental|Bread fortified with vitamin D3 and calcium|
89084485|NCT03814005|Experimental|Moderate Hepatic Arm (Moderate Hepatic Impairment)|Pevonedistat 20 mg/m^2, infusion, intravenously, once, on Day 1 of Part A in participants with hematologic malignancies or solid tumors, followed by a washout period of approximately 4 to 7 days, further followed by azacitidine 75 mg/m^2, injection, subcutaneously in Cycle 1 or subcutaneously or intravenously in Cycle 2 and subsequent cycles, once on Day 1 through Day 7 or Day 1 through Day 5, and on Days 8 and 9 in combination with pevonedistat 10 mg/m^2, infusion, intravenously, once, on Days 1, 3, and 5 in each 28-day treatment cycle in participants with hematologic malignancies, and carboplatin AUC4, infusion, intravenously, once along with paclitaxel 90 mg/m^2, infusion, intravenously, once on Day 1 in combination with pevonedistat 10 mg/m^2, infusion, intravenously, on Days 3 and 5 in each 21-day treatment cycle in participants with solid tumors until symptomatic deterioration or PD, discontinuation for any reason, study stopped by the sponsor, or up to 12 cycles.
89084486|NCT04087681||Elderly 60+ preferably those with increased risk of IED|Study participants are aged 60 years or older in stable health, preferably with a history of urinary tract infection in the previous 10 years.
89084487|NCT02676115|Active Comparator|Control Group|Standard Post Operative Skin Care
89084488|NCT02676115|Experimental|Treatment Group|Medipore Tape will be applied to ACL reconstruction Incision
89084489|NCT02863887|Experimental|Weight loss intervention|Churches randomized to the intervention condition will receive the community health coach delivered church based intervention for 6 months followed by 6 months of weight maintenance.
89084490|NCT02863887|Experimental|Delayed Treatment Control Group|Churches in the delayed treatment control condition will receive information on various health topics relevant to African Americans, such as strokes, lupus, sickle cell, etc. via text message during the first six months. Participants in this group will not receive any behavioral strategies designed to alter weight, physical activity, or diet during this time. They will receive the community health coach delivered church based weight loss intervention after 6 months.
89084491|NCT05552131|Experimental|Coronary lithotripsy catheter system + drug-eluting stent|
89084492|NCT02668471|Experimental|Ultrasound guided|Radial artery catheters will be placed with the assistance of bedside ultrasound.
89084493|NCT02668471|Active Comparator|traditional method|Radial artery catheters will be placed by the palpation technique only.
89084494|NCT02668549||Patients with Opioid dispensings|Patients receiving two or more opioid dispensings within 18 months
89084495|NCT02668549||Patients with Diuretic dispensings (neg control)|Patients receiving two or more Diuretics dispensings within 18 months will serve as negative control
89084496|NCT04175353|Experimental|Dairy snack|Drink high in milk protein, 250 ml
89084497|NCT04175353|Active Comparator|Orange juice|Regular orange juice, 250 ml
89084498|NCT04175353|Experimental|Berry snack 1|Bilberry-blackcurrant purée, 139 g
89084499|NCT04175353|Experimental|Berry snack 2|Lingonberry purée, 122 g
89084500|NCT04175353|Active Comparator|Berry soup|Bilberry soup, 250 ml
89084501|NCT04175743|Experimental|200 mg CT-044 HCl or Placebo|200 mg of CT-044 HCl administered every 8 hours vs placebo
89084502|NCT04175743|Experimental|400 mg CT-044 HCl or Placebo|400 mg of CT-044 HCl administered every 8 hours vs placebo
89084503|NCT04175743|Experimental|600 mg CT-044 HCl or Placebo|600 mg of CT-044 HCl administered every 8 hours vs placebo
89084504|NCT04016233|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, each with 3 douches. Sequence A will be 3 sequential doses of TFV douche; Sequence B will be one dose of TFV douche followed by 2 sequential non-medicated douches; Sequence C will be 2 sequential non-medicated douches followed by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by various specimen collections over 8 days according to individual sampling schedule assigned to each participant. Specimens will be collected on Days 1, 2, 4, and 8 post sequence administration.
89084505|NCT04175899|Experimental|POCCP (Pharmacist-led Oral Chemo Care Program)|"Intervention Group :~Subjects undergo structured intensified pharmaceutical care program (POCCP) led by oncology experienced pharmacist (run alongside oncologist patient review at the clinic or daycare) in addition to Current Standard Best Care (SBC)"
89084506|NCT04175899|No Intervention|SBC (Current Standard Best Care)|"Control Group :~Subjects undergo usual procedure which is Current Standard Best Care (SBC) for oral chemotherapy treatment which includes pre-chemotherapy review by doctor and prescribing of chemotherapy and supportive medications according to patient's chemotherapy protocol at each visit. Subsequently the patients will collect their prescribed oral medications at the ambulatory pharmacy counter according to the standard procedure of medication dispensing which includes prescription screening, medication filling, double checking, dispensing and counselling at the pharmacy counter as per usual practice of pharmaceutical care of patients."
89084507|NCT02671591|Experimental|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP. The control condition is a one-hour, theory-based, one-to-one session that will help YBMSM think more about using condoms consistently and correctly with every sex partner.
89084508|NCT02671591|Active Comparator|control|"This condition will include the provision of free condoms and lubricants - selected from a buffet of condoms and lubricants designed to offer men a broad selection of high quality products that can optimize the fit and feel of condoms during sex."
89084509|NCT02671747|Experimental|Pilot workshop|Participants attend intervention. No control arm
89084510|NCT04033471|Active Comparator|MI|Bupivacaine 0.25% + midazolam 5mg in total volume 10m1
89084511|NCT04033471|Active Comparator|MM|Bupivacaine 0.25% + midazolam 5mg and morphine 5mg in total volume 10ml
89084512|NCT04033471|Active Comparator|MO|bupivacaine 0.25% + morphine 5 mg in total volume 10 ml
89084513|NCT02670421|Active Comparator|Face to face Heart SMART program|Stress management program presented in a face to face meeting of 90-100 minutes with daily printed program instructions to follow over the next 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
88812847|NCT01532453|Experimental|MD-3511356|Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).
89084514|NCT02670421|Active Comparator|Online Heart SMART program|Stress management program in the form of 10- minute videos completed weekly by participant on-line for 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
89084515|NCT02671279|Other|Low calorie diet|Dietary intervention group
89084516|NCT02671201||Group A|Theoretical training will be scheduled for 2 hours with lectures in basics of emergency ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 4 hours.
89084517|NCT02671201||Group B|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 3 hours.
89084518|NCT02671201||Group C|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound.
89084519|NCT02668081|Experimental|Endoscopic papillary balloon dilation|For EPBD group, after selective cannulation of the common bile duct by the catheter, cholangiography will be performed to confirm the diagnosis of bile duct pathology. A 0.025-0.035-inch guidewire will then be inserted into the bile duct through the catheter. A dilating balloon (The controlled radial expansion (CRE) balloon dilation catheter, CRE balloon 5.5 cm (centimeter) in length, 1-1.2 cm/1.2-1.5 cm/1.5-2.0 cm in diameter) will be passed via the pre-positioned guidewire into the bile duct. Using fluoroscopic and endoscopic guidance, the balloon will be inflated with contrast medium up to the optimal size and duration (normally 5min (minutes)) after the waist on the balloon disappeared according to the patients' condition and tolerance.
89084520|NCT02668081|Active Comparator|Endoscopic sphincterotomy|"For EST group,endoscopic sphincterotomy(EST) will be done as large as possible with a pull type sphincterotome (The TRUEtome, Biliary sphincterotomy sphincterotome, Single-use sphincterotome CleverCut2V)~Other interventions: surgical intervention, endoscopic stenting, percutaneous transhepatic cholangiogram with balloon dilation"
89084521|NCT02670577||stage I or II HR-positive, HER2-negative|"Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive & HER2 negative~& Axillary lymph node status: 0-3 involved"
89084522|NCT02670577||HER2+|"Histologically proven invasive T1a or T1b breast cancer~& Hormone receptor negative or positive~& HER2 positive~& Axillary lymph node status: 0-1 involved"
89084523|NCT02670577||Triple Negative|"Histologically proven invasive T1a or T1b breast cancer~& Hormone receptor negative~& HER2 negative~& Axillary lymph node status: 0-1 involved"
89084524|NCT02670577||Neoadjuvant|Stage I or II patients receiving neoadjuvant therapy.
89084525|NCT00910351|Experimental|Arm 1|
89084526|NCT02671357||ERAMIP with EEN|Minimally invasive pancreaticoduodenectomy (MIPD) with stented pancreatic-gastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES). All patients are submitted to an ERAS trajectory with EEN
89084527|NCT02671123|Active Comparator|Coronary PCI with OCT with Co-Registration|Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance with the use of the Co-Registration software tool after stent implanted.
89084528|NCT02671123|Placebo Comparator|Coronary PCI with OCT without Co-Registration|"Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance without the use of the Co-Registration software tool after stent implanted.~I"
89084529|NCT04174729|Experimental|Hand strength|"The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength. The tests were performed in two sessions lasting 1 hour each. The volunteers used the devices: door handle, tap, door pull handle, switch and door key to quantify hand strength.~In the first session, the volunteers performed the movements 3 times in each device of daily living activities with the right limb, with a 1-minute rest interval between the 3 measurements. The entire procedure performed in the session was repeated again after 30 minutes to verify the reliability and reproducibility of the Intra-evaluator test. The Inter-rater test was repeated after 7 days by the second rater to analyze reliability between the rater."
89084530|NCT02670265|Active Comparator|Parenteral nutrition|Active Comparator: Olimel peri 2.5% ® 1l/d (700 kcal/d) (Baxter GmbH, Unterschleißheim, Germany)
89084531|NCT02670265|Placebo Comparator|Isotonic fluid|Isotonic fluid 1l/d (E153, Berlin-Chemie AG, Berlin, Germany)
89084532|NCT00645463|Experimental|Group A|
89084533|NCT00645463|Experimental|Group B|
89084534|NCT04175587|Experimental|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Induction: a) RIF: 60 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR; Consolidation: a) RIF: 60 mg/kg daily, in a 4-week on 4-week off regimen for four cycles in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles
89084535|NCT04175587|Other|Arsenic trioxide Plus Retinoic Acid|Induction: a) Arsenic trioxide: 0·15 mg/kg daily until CR, b) ATRA: 25 mg/m² daily until CR Consolidation: a) Arsenic trioxide: 0.15mg/kg daily, in a 4-week on 4-week off regimen for four cycles b) ATRA: 25 mg/m² daily, in a 2-week on 2-week off regimen for seven cycles Expected Efficacy: Oral RIF plus ATRA is not inferior to intravenous arsenic trioxide plus ATRA for achieving 2-year EFS.
89084536|NCT02668159|Experimental|Fish peptide|
89084537|NCT02668159|Experimental|Vitamin D|
89084538|NCT02668159|Experimental|Fish peptide + Vitamin D|
89084539|NCT02668159|Placebo Comparator|Control|
89084540|NCT02670109|Experimental|Unique|"Patients will receive a high dose chemotherapy regimen, consisting in the administration of three medications: Carmustine (BCNU) 300mg/m2 or Busulfan 16 mg/kg (according to availability), Cyclophosphamide 80mg/kg, and Carboplatin 1400/m2.~Then they will undergo an Autologous Hematopoietic Stem Cell Transplantation."
89084541|NCT02670187|Experimental|GLS-5300|GLS-5300 at 0.67 mg DNA/dose
89084542|NCT02670187|Experimental|GLS-5300 at 2 mg DNA/dose|GLS-5300 at 2 mg DNA/dose
89230193|NCT00789659|Experimental|VAC dressing|The patients whose postoperative wound will be dressed with a negative pressure (V.A.C.) dressing.
89084543|NCT02670187|Experimental|GLS-5300 at 6 mg DNA/dose|GLS-5300 at 6 mg DNA/dose
89084544|NCT00922636|Active Comparator|Methylphenidate|Extended-release methylphenidate 18 milligrams per day (mg/day) to 54 mg/day, based on weight, given once daily (QD) and orally (po) as a capsule for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
89084545|NCT00922636|Placebo Comparator|Placebo|
89084546|NCT00922636|Experimental|LY2216684 (0.1 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
89084547|NCT00922636|Experimental|LY2216684 (0.2 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
89084548|NCT00922636|Experimental|LY2216684 (0.3 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
89084549|NCT02667925|Experimental|Intervention arm|Patients will receive an intraperitoneal chemotherapy (cisplatin) combined to a radiotracer (nanocis) in order to assess the intraperitoneal distribution of the chemotherapy
89084550|NCT02669719|Experimental|chemotherapy followed dendritic cells|pemetrexed and carboplatin chemotherapy followed dendritic cells infusion from Cycle 3
89084551|NCT02669719|Active Comparator|chemotherapy|pemetrexed and carboplatin chemotherapy only
89084552|NCT02667847||Preoperative patients|Preoperative patients were asked to verbally rate their anxiety 1=on a scale from 0-10 and 2=using the new smiley scale
89084553|NCT00644761|Other|Treatment Arm 1|Adefovir dipivoxil 10 mg once daily with tacrolimus or cyclosporine for 14 days
89084554|NCT05330728|Experimental|Massage group|Suggestions for lifestyle changes + abdominal massage will be performed.
89084555|NCT05330728|Active Comparator|Taping group|Suggestions for Lifestyle Changes + Kinesio taping will be performed.
89084556|NCT05330728|Other|Control group|Suggestions for lifestyle changes will be performed.
89084557|NCT00645073|Active Comparator|A|
89084558|NCT00645073|Active Comparator|B|
89084559|NCT04259008|Active Comparator|Standard neonatal trace elements|"Parenteral nutrition containing 5 mCg/kg/day manganese from Multitrace-4 Neonatal."
89084560|NCT04259008|Experimental|Manganese-free neonatal trace elements|"Parenteral nutrition containing the same trace element doses as Multitrace-4 Neonatal minus manganese."
89084561|NCT04258930|Active Comparator|Group A: Aluminum sulphate and calcium acetate drying soaks|Group A will receive 10 minute soaks every 8 hours with a solution prepared with aluminum sulphate and calcium acetate powder (Domeboro® (Advaita Pharmaceuticals, México)) diluted in 500 ml of clean cold water.
89084562|NCT04258930|Experimental|Group B: Topical sterile silicone gel for wounds|Group B will receive topical silicone sterile gel for wounds (Stratamed gel®, (Stratapharma, Switzerland)) applied every 8 hours.
89084563|NCT04258930|Experimental|Group C: Hydrocolloid dressing|Group C will apply an extra thin hydrocolloid dressing to all the open areas (Duoderm Extra Thin® (Convatec, USA)) with dressing changes every 48 to 72 hours depending on the amount of wound exudate.
89084564|NCT02669875|Active Comparator|Serelaxin|IV infusion of serelaxin (RLX030) for 2 hours
89084565|NCT02669875|Placebo Comparator|Placebo|IV infusion of placebo (20mM sodium acetate pH5) matched to serelaxin for 2 hours
89084566|NCT04176289|Active Comparator|PPI-guided pain therapy|At the end of anesthesia a PPI targeted opioid pain therapy will be performed by gradual administration of piritramid in 3 mg steps up to a PPI score ≤ 3.
89225742|NCT05353296|Active Comparator|Minimally Enhanced Usual Care (mEUC)|Usual care by their primary care provider and a sleep hygiene brochure. Group will continue their typical standard care with their primary care provider, which may include pharmacotherapy. In addition, we will provide a sleep hygiene brochure during group assignment.
89225743|NCT05349422|Experimental|Intervention Group|
89225744|NCT05349422|No Intervention|Usual Care Group|Usual Care Clinical Decision Support (CDS) Tools
89225745|NCT05347927||Test group|will receive water resistante padding and a cast
89225746|NCT05347927||Control group|will receive traditional non-water resistante padding and cast
89225747|NCT05347446|Active Comparator|Hybrid ESD|Hybrid ESD is a modified ESD technique that uses snare-assisted resection as part of the procedure. With hybrid ESD, a circumferential mucosal incision followed by limited submucosal dissection is performed. Following this, a snare is placed around the lesion, slowly closed to allow resection by traversing the submucosal space
89225748|NCT05347446|Active Comparator|Non-Hybrid ESD|A partial or complete circumferential mucosal incision will be performed to expose the submucosa around and underneath the polyp. Endoscopic resection will then proceed via conventional ESD, submucosal tunneling or pocket technique.
89225749|NCT05346042||Confirmed Covid-19|All adult COVID-19 patients and health care workers tested positive in the 7 participating hospitals identified between the end of February 2020 and December 2021.
89225750|NCT05334615||Acute COVID-19|"Hospital admission for management of symptoms related to COVID-19. Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission.~Age ≥18 years."
89225751|NCT05334615||Incidental COVID-19|"Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2.~Age ≥18 years."
89225752|NCT05334615||Acute influenza|"Hospital admission for clinical management of symptoms related to influenza. Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission.~Negative testing for SARS-CoV-2. Age ≥18 years."
89225753|NCT05330975|Experimental|Part A: mRNA-1345 + Placebo|Single injection of mRNA-1345 and placebo, administered intramuscularly (IM), one in each arm on Day 1.
89225754|NCT05330975|Experimental|Part A: mRNA-1345 + Afluria® Quadrivalent|Single injection of mRNA-1345 and Afluria® quadrivalent, administered IM, one in each arm on Day 1.
89225755|NCT05330975|Active Comparator|Part A: Afluria® Quadrivalent + Placebo|Single injection of Afluria® quadrivalent and placebo, administered IM, one in each arm on Day 1.
89225756|NCT05330975|Experimental|Part B: mRNA-1345 + Placebo|Single injection of mRNA-1345 and placebo, administered IM, one in each arm on Day 1. An additional injection of mRNA-1273.214, administered on Day 29.
89225757|NCT05330975|Experimental|Part B: mRNA-1345 + mRNA-1273.214|Single injection of mRNA-1345 and mRNA-1273.214, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.
89225758|NCT05330975|Active Comparator|Part B: mRNA-1273.214 + Placebo|Single injection of mRNA-1273.214 and placebo, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.
89225759|NCT05330975|Experimental|Part C: mRNA-1345|Single injection of mRNA-1345 administered IM on BD Day 1.
89225760|NCT05329649|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.
89225761|NCT05326477|Other|Standard-of-care behavioral weight loss treatment|6-months of group-based behavioral weight loss treatment following the Centers for Disease Control and Prevention Prevent T2 curriculum.
89225762|NCT05326386|No Intervention|Control|Via the Way to Health platform, all participants will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.
89225763|NCT05326386|Experimental|Intervention|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
89225764|NCT05321459||Comatose patients in intensive care unit|Patient admitted in the intensive care unit (ICU) for post cardiac arrest (CA) coma, persistent for at least 3 days after CA.
89225765|NCT05319015|Experimental|Treatment Arm|Patients receive neoadjuvant lenvatinib (20 mg PO daily) for 12 weeks and pembrolizumab (200 mg IV every 3 weeks for four doses) prior to surgical resection of locally advanced RCC with IVC tumor thrombus. Following surgery, patients will receive adjuvant pembrolizumab (200 mg IV every 3 weeks for up to thirteen doses).
89225766|NCT05315349|Experimental|Patient requiring cardiac surgery for myocardial revascularization|
89225767|NCT05315297|Experimental|PEMF device|
89225768|NCT05315297|Sham Comparator|Sham PEMF device|
89225769|NCT05312892|Placebo Comparator|Placebo|Subjects will received 2 weeks of capsules containing placebo.
89225770|NCT05312892|Active Comparator|Amlodipine|Subjects will received 2 weeks of capsules containing amlodipine.
89225771|NCT05312892|Experimental|Moxonidine|Subjects will received 2 weeks of capsules containing moxonidine.
88812848|NCT05311514|Experimental|Allogeneic Platelet Lysate eye drops 50%|Patients with ocular chronic severe graft versus host disease receive 50% allogeneic Platelet Lysate in the form of eye drops 6-8 times a day
89084567|NCT04176289|No Intervention|Non-PPI-guided pain therapy|The amount of administered piritramid in the OR will be left to the discretion of the anesthesiologist attending the participant.
89084568|NCT02671045||A - Genomic profile by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified and the patient/physician agree to receive the targeted therapy
89084569|NCT02671045||B - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified. However, the patient does not receive the targeted therapy.
89084570|NCT02671045||C - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and no actionable target has been identified.
89084571|NCT02671045||D - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified and the patient/physician agrees to receive the targeted therapy.
89084572|NCT02671045||E - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified. However, the patient does not receive targeted therapy.
89084573|NCT02671045||F - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target NOT has been identified.
89084574|NCT02671045||G - No genomic profiling|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has not been sent for genomic profiling.
89084575|NCT01175135|Experimental|PF-02545920 5 mg|
89084576|NCT01175135|Experimental|PF-02545920 15 mg|
89084577|NCT01175135|Placebo Comparator|Placebo|
89084578|NCT01175135|Active Comparator|Risperidone 3 mg|
89084579|NCT02667613|Experimental|HABIT-ILE|HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
89084580|NCT02667613|Active Comparator|Control|A two weeks period of usual customary care.
89084581|NCT00645541|Experimental|Axillary Reverse Mapping (ARM)|
89084582|NCT02667769|Other|Fasting day without any food|Complete fasting: On a fast day under this Protocol no solid food may be eaten unless it is solid, medically prescribed part of a bedtime snack just before falling asleep (which must sometimes be to prevent nocturnal hypoglycaemia with injection of basal insulin before going to sleep) , Otherwise, the patient have ad libitum access to mineral water and unsweetened tea (possibly a fluid intake restriction should be considered for other diseases).
89084583|NCT02667769|Other|Fasting day with calorie- & carbohydrate-free food|During a fasting day for this protocol, patients may calories in unlimited quantity and (with calorie-free dressing) Take carb food like tomatoes, cucumbers, lettuce to be, both during meal periods and in between, if desired.
89084584|NCT02667691|Experimental|SODB Dimpless-caloric restriction|This arm receives daily two capsules of SODB Dimpless 40mg containing 480 UI of superoxide dismutase (SOD), associated with a moderate caloric restriction.
89084585|NCT02667691|Placebo Comparator|Placebo-caloric restriction|This arm receives daily two capsules Placebo containing excipients only, associated with a moderate caloric restriction.
89084586|NCT05098561|Experimental|Music treatment group|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
89084587|NCT05098561|No Intervention|Control Group|No music treatment will be used. Standard pain and comfort measure only.
89084588|NCT02669641|Experimental|Steatosis|Patients with diagnosed steatosis in treatment with combination Silimarin, Phyllanthus Niruri and Choline
89084589|NCT02886221|Other|HV patients|patients with symptomatic Hallux Valgus treated my Reverdin-Isham Osteotomy
89084590|NCT02669485|Experimental|ICG|Administering indocyanine green during surgery and the use of ICG fluorescence imaging to assess bowel perfusion during surgery
89084591|NCT00922480|Active Comparator|2|Losartan group
89084592|NCT00922480|Active Comparator|1|Fimasartan 60mg, 120mg
89084593|NCT04174885|Other|AF epicardial ablation|Patient with persistent AF will receive an epicardial ablation.
89084594|NCT02886143|Experimental|Active Voiding Trial (instillation of sterile saline)|Patients randomized to receive an active voiding trial will have the bladder filled with 250-400 cc of sterile saline (or until the bladder was full) via the lumen of the urinary catheter before the urinary catheter is removed. The patient will then be immediately assisted to void. Physician teams will follow a standardized algorithm for the management of urinary retention arising during the study.
89084595|NCT02886143|Active Comparator|Passive Voiding Trial|For patients randomized to receive a passive voiding trial, the urinary catheter will be removed, the bladder will fill with urine naturally, and the patient will be assisted to void when he or she reports the urge. To ensure uniformity in the intervention, all voiding trials in the study will be supervised by an experienced nurse who will ensure that the protocol is followed.
89084596|NCT04258618|Active Comparator|CBT-I (Cognitive Behavioral Therapy for Insomnia) with TMS|
89084597|NCT04258618|Other|rTMS (repetitive Transcranial Magnetic Stimulation)|Subjects will be getting Transcranial Magnetic Stimulation as part of their standard of care.
89225772|NCT05312164||Candidates for PCI|Patients undergoing diagnostic cardiac catheterization/PCI.
89225773|NCT05310422|Experimental|Tivanisiran sodium ophthalmic solution|
89084598|NCT02669563|Experimental|Stage 1|"Subjects (n = 4 to 10) will be injected once with 20 mCi of [13N]ammonia and receive a 20 minute PET scan. They will then be injected once with 6.5 mCi of one of the two new drugs under study, [18F]4F-MHPG or [18F]3F-PHPG, and receive a 60 minute PET scan.~On a second visit to the clinic, subjects will be injected once with 6.5 mCi of [18F]3F-PHPG or [18F]4F-MHPG (whichever was not used for the first visit) and receive a 60 minute PET scan."
89084599|NCT02669563|Experimental|Stage 2|"Subjects (n = 20 to 26) will be injected with 20 mCi of [13N]ammonia and receive a 20 minute PET scan.~They will then be injected once with 6.5 mCi of [18F]4F-MHPG or [18F]3F-PHPG (whichever was chosen based on Stage 1 of the study) and receive a 60 minute PET scan. On a second visit to the clinic, subjects will be injected once with 20 mCi of [11C]HED and receive a 40 minute scan."
89084600|NCT04963036|Experimental|Entropy and NOL-Guided Goal Directed Anesthesia|
89084601|NCT04963036|Active Comparator|Standard of Care Group (Entropy and blinded NOL)|
89084602|NCT02537119|Experimental|Dynamic massage therapy|Rubbing on hamstrings combined with articular movement
89084603|NCT02537119|Active Comparator|Massage therapy|Rubbing on hamstrings
89084604|NCT04083391||CAI group|assessment had been done to this group that include patients with ankle sprain injury from more than one year and complain with repetitive injuries, giving way and instability feelings
89084605|NCT04083391||non injured ankle group|assessment had been done to this group that include control participants had not injured their ankle before and matched with CAI in age, gender, dominant side
89084606|NCT04255420|Experimental|SPG Block|Sphenopalatine ganglion block using cotton-tipped applicators soaked in 1% lidocaine will be performed.
89084607|NCT04255420|Active Comparator|Standard Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg.
89084608|NCT00973479|Experimental|Group I: Placebo + Methotrexate (MTX)|Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
89084609|NCT00973479|Placebo Comparator|Group II: Golimumab + Methotrexate (MTX)|Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
89084610|NCT04174183|Experimental|Prevena (right side) - Dry dressing (left side)|
89084611|NCT04174183|Experimental|Prevena (left side) - Dry dressing (right side)|
89084612|NCT04174495||Obese patients followed at Nancy University Hospital|
89084613|NCT04315493|Experimental|A|
89084614|NCT04315493|Experimental|B|
89084615|NCT04173871|Experimental|Intervention|Intervention group
89084616|NCT04173871|No Intervention|Control|Control group
89084617|NCT02862483|Experimental|Experimental|Tamsulosin 0.2mg and Tadalafil 5mg
89084618|NCT02862483|Active Comparator|Comparator|placebo for Tamsulosin 0.2mg and Tadalafil 5mg
89084619|NCT01173653|Placebo Comparator|Standard EM Smoking Cessation Info|Patients discharged from ER receive pamphlet re: smoking cessation
89084620|NCT01173653|Active Comparator|Patients contact 1-800-QUIT-NOW before leaving ED|Prior the patient leaving the ED, the PI will assist the patient with contacting 1-800-QUIT-NOW, who will help patient to quit smoking.
89084621|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% healthy|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Healthy volunteers
89084622|NCT02667535|Experimental|Isosorbide Mononitrate 0.5% anal fissure|Isosorbide Mononitrate gel 0.5% - 2g Anorectal usage Once daily Participants with anal fissure
89084623|NCT02667535|Experimental|Isosorbide Mononitrate 1.0% anal fissure|Isosorbide Mononitrate gel 1.0% - 2g Anorectal usage Once daily Participants with anal fissure
89084624|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% anal fissure|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Participants with anal fissure
89084625|NCT04284735|Other|Controls|Patients with RA and without ILD
89084626|NCT04284735|Other|Cases|Patients with RA and ILD
89084627|NCT05657951||Normal eyes|
89084628|NCT02667145|Experimental|Intervention|Self care program focusing on the assistive device, For 4 weeks (1 to week lasting 90 minutes).
89084629|NCT02667145|No Intervention|Control group|receive only a brochure with orientations of joint protection.
89084630|NCT04316819|Experimental|Packed Promise Demonstration Benefits|Treatment households (n=2,143) received one food box per eligible child, per month, delivered to the household, which contained (1) shelf-stable foods, including 6 protein-rich items, 2 dairy items, 4 grain foods, 4 cans of fruit, and 12 cans of vegetables; (2) a nutrition education handout (e.g., a recipe); and (3) a $15 Fresh Check for frozen or fresh fruits and vegetables that participants could redeem at any of 38 Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)-authorized stores or farmers' markets in the study counties.
89084631|NCT04316819|No Intervention|Control Group|Control households (n=2,607) did not receive the treatment benefits but still could participate in other available nutrition assistance programs.
89084632|NCT04286841||Neoadjuvant immunotherapy|
89084633|NCT00645151|Experimental|High Risk|
89084634|NCT00645151|Experimental|Low Risk|
89084635|NCT00645151|Experimental|Medium Risk|
89084636|NCT00645229|Experimental|Arm A|
89084637|NCT01172873|Active Comparator|DCS + Exposure and Response Prevention|Participants in this arm receive 10 twice-weekly 60-minute sessions of Exposure and Response Prevention (E/RP) therapy and 50mg of D-Cycloserine immediately after each therapy session. D-Cycloserine is only administered on days in which therapy sessions are held.
89084638|NCT01172873|Active Comparator|E/RP alone (no DCS administration)|Participants in this arm received twice-weekly 60 minute sessions of E/RP alone for a total of 10 sessions.
89084639|NCT02886299|Active Comparator|Fenofibrate group|Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week).
89084640|NCT02886299|Active Comparator|Simvastatin group|Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days after the dialysis session (3 times per week).
89225774|NCT05310422|Placebo Comparator|Vehicle ophthalmic solution|
89225775|NCT05310279|Experimental|Active video gaming|Participants will engage in 6 weeks of active video gaming (AVG), 2x/week
89225776|NCT05309642|Active Comparator|ICR Arm|On 2 non-consecutive days per week, participants in the ICR (5:2 diet) group will be instructed to consume 500 kcal/day for women and 600 kcal/day for men.
89225777|NCT05309642|Placebo Comparator|Soc Arm|The SoC group will receive 80% of standard calorie (1,200-1,500 kcal/day or reducing 500-1000 kcal/day from standard calorie).
89225778|NCT05306756|Active Comparator|Fetal Blood Sampling (FBS)|"Fetal capillary blood samples will be collected in heparinised tubes and analysed in the delivery suite using the locally available gas analyser. The result of the first technically reliable sample, or the lowest reliable sample if multiple samples are tested, will be interpreted and acted upon according to the protocol, taking account of the clinical circumstances and the stage of labour:~pH ≥7.25 normal, continue and if indicated repeat in 60 minutes; pH 7.21-7.24 borderline, repeat in 30 minutes; pH ≤ 7.20 abnormal, deliver."
89225779|NCT05306756|Active Comparator|digital Fetal Scalp Stimulation (dFSS)|"The examiner will stimulate the fetal scalp digitally with the index and middle finger over a period of 30-60 seconds.The CTG will be observed over a 5-10 minutes interval after the dFSS and if a fetal heart rate acceleration (>15 bpm for 15 seconds) is observed the test will be considered normal. If there is an episode of normal variability (5-25 bpm) but there is no clear acceleration, the test will be considered borderline. If there is no FHR acceleration and no episode of normal variability with ongoing abnormal features, the test should be interpreted as abnormal in the same way as an abnormal FBS result.~FHR acceleration normal, if indicated repeat in 60 min; Uncertain acceleration/ normal variability borderline, repeat in 30 minutes; No Acceleration/ongoing abnormal features abnormal, deliver."
89225780|NCT05305820|Experimental|Intervention|"Exercise: The exercise training program was designed to improve physical fitness prior to surgery and for a 6-week period after surgery once deemed fit.~Nutrition: The nutritional arm consists of nutritional intervention tailored to the outcome of the nutritional screening.Participants will be asked to take part in a dietary food recall system called Foodbook24, and based on their dietary needs will be supported in nutritional optimisation."
89225781|NCT05305820|No Intervention|Control|This group will receive standard oncological care and will receive no formal education of exercise or nutritional intervention.
89225782|NCT05304975|Active Comparator|intervention|"Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline and review study visits.~The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise resource that has been designed for older adults.~Cognitive stimulation will be delivered using Brain HQ®, a computer based cognitive training platform, which utilises visuospatial and auditory games to enhance attention, mental processing speed, learning, memory, and low mood.~Participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary.~The 4-month active intervention will be followed by a 2-month self-directed consolidation phase and all participants will be left to their own initiative for a further 3 months"
89225783|NCT05304975|Other|control|this will be routine management of the diabetes condition as per current recommended practice
89225784|NCT05296902||SILKAM®|SILKAM® is a non-absorbable sterile suture material made from braided silk fibrils. It is available either undyed (white) or dyed black with hematein and is coated with refined paraffin wax or beeswax.
89225785|NCT05296889||Ennovate® Cervical|Alll patients which were treated with the Ennovate® Cervical system in accordance with the indications given in the instructions for use
89225786|NCT05296707|Experimental|Inspiratory muscle training group|Threshold IMT was given this group. Applied for 7 days 6 weeks.
89225787|NCT05296707|Active Comparator|Used routine medicine group|Followed 6 weeks
89225788|NCT05296707|Active Comparator|Control Group|Health children
89225789|NCT05295498|Experimental|Active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 6 sessions (three sessions in two consecutive days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
89084641|NCT02667379|Other|Diagnostic skin testing|Diagnostic skin testing with cat dander samples on volar forearms.
89084642|NCT00645619||1|Patients with pure viral pneumonia
88812849|NCT05311514|Active Comparator|Allogeneic Platelet Lysate eye drops 20%|Patients with ocular chronic severe graft versus host disease receive 20% allogeneic Platelet Lysate in the form of eye drops 6-8 times a day
89084643|NCT00645619||2|Patients with viral pneumonia along with secondary bacterial pneumonia
89084644|NCT00645619||3|Patients with significant bacterial pneumonia
89084645|NCT00645619||4|Patients with congenital heart disease undergoing cardiopulmonary bypass who have no pneumonia
89084646|NCT04174807||Cohort|
88812850|NCT01448525|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
89084647|NCT05261659|Experimental|TMR group|Patients will receive a sound while they receive a positive feedback for their performance of exposure therapy (ET). They will also receive the sound during REM sleep.
89084648|NCT05261659|Active Comparator|Control group|Patients will not receive a sound while they receive a positive feedback for their performance of exposure therapy (ET). They will receive the same sound as the experimental group during REM sleep under the same conditions.
89084649|NCT06332040|Experimental|Gentamicin|14.4 mg gentamicin dissolved in 30 mL 0f 0.9% saline administered BID
89084650|NCT06332040|Placebo Comparator|Placebo|30 mL of 0.9% saline administered BID
89084651|NCT06332014|Experimental|Prolia|Participants will receive Prolia every six months (Q6M)
89084652|NCT06332001||Experimental Group|Patients in this group receive the music and interaction interventions
89084653|NCT06332001||Control Group|Patients in this group receive a standard care condition (no music)
89084655|NCT06331975|Other|Radiomic signature|Assessment of radiomic signature and tumor genetic profile at baseline
89084656|NCT06331962|Experimental|remote home-based exercise therapy group|"Location and Frequency: Four times per week at the individual's own home. Exercise Duration: Eight weeks (subject to adjustments based on actual progress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistance training, sensory exercises.~Note: The participant will receive a customized exercise plan based on their capabilities, including guidelines and exercise instructions (exercise names, required equipment, movement sequences, repetitions, precautions)."
89084657|NCT06331962|Active Comparator|supervised exercise therapy group|"Exercise Location and Frequency: Physiotherapy Center (twice a week) and individual's home (twice a week).~Exercise Duration: Eight weeks (subject to adjustments based on actual progress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistance training, sensory training exercises. The home-based exercise training content is partially the same as the remote home-based exercise group."
89084658|NCT06331962|Other|regular care group|Perform regular care for eight consecutive weeks. After the tracking period ends (8 weeks), provide home-based education on resistance exercises, cardiovascular endurance exercises, and sensory training exercises.
89084659|NCT06331949|Experimental|Experimental Group|In addition to midwifery care, training content, training videos and brochure-supported training on NST will be provided. The NST device will be inserted and, to be standard, 5 minutes after the procedure begins, the volume of the fetal heart sound coming from the device will be increased during the NST recording and the fetal heart sound will be ensured to continue. The pregnant woman who will be transferred will rest for about 2 minutes.
89084660|NCT06331949|No Intervention|Control Group|No additional applications will be made
89084661|NCT06331936|Experimental|Intervention arm|The intervention arm aims at improving children's emotional regulation skills.
89230194|NCT00797069|Active Comparator|standard nutritional product|Standard nutritional product not specific for diabetes
89084662|NCT06331936|No Intervention|Control Arm|The control arm participants will not receive any interventions.
89084663|NCT06331923|Experimental|CGM group|Participants who receive continuous glucose monitoring (CGM) during the perioperative period. Glucose monitoring should be continued until the 7th day after surgery or discharge.
89084664|NCT06331923|No Intervention|Control group|Perioperative blood glucose monitoring was performed according to institutional treatment guidelines.Glucose monitoring should be continued until the 7th day after surgery or discharge.
89084665|NCT06331910|Experimental|insulin eye drop|
89084666|NCT06331884|Placebo Comparator|Placebo|
89084667|NCT06331884|Active Comparator|AK1967 3 mg/kg/body weight|
89084668|NCT06331884|Active Comparator|AK1967 6 mg/kg/body weight|
89084669|NCT06331884|Active Comparator|AK1967 12 mg/kg/body weight|
89084670|NCT06331871|Experimental|Ultrasound-guided percutaneous nerve stimulation (US-PENS) and physiotherapy protocol.|Ultrasound Guied Percutaneus Electrical Nerve Stimulation on the suprascapular nerve and axillary nerve, along with a manual physical therapy protocol in patients with pain and lack of function after a shoulder surgery.
89084671|NCT06331871|Active Comparator|Physiotherapy protocol.|Only a physiotherapy protocol based on available evidence, applied to patients with pain undergoing shoulder surgery.
89084672|NCT06331858|Active Comparator|Study group|The study group received hip device-assisted concentric abductor strengthening (HDACAS) program in addition to knee device-assisted concentric flexor-extensor strengthening (KDACFES) program.
89084673|NCT06331858|Active Comparator|Control group|The control group received only KDACFES program
89084674|NCT06331845|Experimental|intermittent systematic chemotherapy group|Patients diagnosed with wmNPC (more than five metastatic lesions) by histopathology are assigned to receive ISC following SC. Typically, SC(GP) was administered once every three weeks, with a maximum of six courses. Following this, ISC (TS1) was administered to extend the chemotherapy interval, once every 6-8 weeks, until widely progressive disease (WPD: defined as more than five progressive lesions), treatment intolerance, or patient refusal.
89084675|NCT06331819||Patients|Patients referred for sleep study by in-lab polysomnography to enrolled hospitals.
89084676|NCT06331806|Other|Evaluation of myocardial fibrosis|Echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
89084677|NCT06331793|Experimental|Active AlgoCare|An active AlgoCare device (that emits a pulsed radio frequency electromagnetic field at 27.1 MHz) will be placed over the surgical dressing using a plaster or bandage for six days.
89084678|NCT06331793|Placebo Comparator|Non-active AlgoCare|A non-active AlgoCare device (that doesn't emit pulsed radio frequency electromagnetic field) will be placed over the surgical dressing using a plaster or bandage for six days.
89084679|NCT06331780|Experimental|Closed-field Aberrometer|Objective refraction at different distances with Shack-Hartmann Aberrometer
89084680|NCT06331767|Experimental|mSYNC|mHealth psychosocial-behavioral intervention
89084681|NCT06331754|Experimental|Technology-enabled blood pressure management|The intervention will consist of a technology-enabled remote hypertension management program. Participants will be given a cellular blood pressure (BP) cuff and patients with heart failure and chronic kidney disease stage 3b-5 will be given a scale also. Patients will undergo a series of protocolized software-driven medication initiation and titration steps until they reach a blood pressure target of systolic blood pressure < 130 mmHg and diastolic blood pressure < 80 mmHg. Patients will be subsequently monitored for up to 12 more months. If their blood pressure increases, they can re-enter active management.
89084682|NCT06331754|No Intervention|No intervention|Patients meeting inclusion care undergoing usual care in control clinics.
89084683|NCT06331741|Other|The 1st group|ACL reconstruction + collagen membrane
89084684|NCT06331741|Other|The 2nd group|ACL reconstruction (control)
89084685|NCT06331741|Other|The 3rd group|Hallux Rigidus + collagen membrane
89084686|NCT06331728|Experimental|IGNX001|Participants will receive IGNX001 given as a single subcutaneous dose on Day 1.
89084687|NCT06331728|Placebo Comparator|Placebo|Participants will receive IGNX001 placebo given as a single subcutaneous dose on Day 1.
89084688|NCT06331715|Experimental|TR|Subject will receive Test product palbociclib (125 mg Iclos) followed by reference product (Ibrance Pfizer 125 mg capsules) after 14 days washout
89084689|NCT06331715|Experimental|RT|Subject will receive reference product (Ibrance Pfizer 125 mg capsules) followed by Test product palbociclib (125 mg Iclos) after 14 days washout
89084690|NCT06331702|Experimental|Group 1 (JEV-I and MMR co-administration group)|Participants will receive 1 dose of JEV-I and 1 dose of MMR concurrently on Day 0, with each vaccine administered on a different side of the body, and a second dose of JEV-I 7-10 days later. Blood sampling will be performed on Day 0 and 30 days after the second dose of JEV-I.
89084691|NCT06331702|Active Comparator|Group 2 (JEV-I administered separately)|Participants will receive 2 doses of JEV-I (7-10 days apart). Blood sampling will be performed on Day 0 and 30 days after the second dose of JEV-I.
89084692|NCT06331702|Active Comparator|Group 3 (MMR administered separately)|Participants will receive 1 doses of MMR. Blood sampling will be performed on Day 0 and Day 30.
89084693|NCT06331676|Experimental|Endometriosis|Women with endometriosis who have an indication for gynaecological surgery
89084694|NCT06331676|Active Comparator|Control|Women with no endometrial pathology who have an indication for gynaecological surgery
89084695|NCT06331663|Experimental|Arms|Neurosurgery with fixation
89084696|NCT06331650|Experimental|cadonilimab|
89084697|NCT06331637||Transanal Transection and Single-Stapled anastomosis (TTSS)|Patients will undergo restorative proctectomy with Transanal Transection and Single-Stapled (TTSS) Ileal Pouch-Anal anastomosis (IPAA)
89084698|NCT06331637||Double-stapled anastomosis|Patients will undergo restorative proctectomy with double-stapled Ileal Pouch-Anal anastomosis (IPAA)
89084699|NCT06331624|Experimental|GRI-0621|GRI-0621 (tazarotene) 4.5mg, administered orally once daily (QD)
89084700|NCT06331624|Experimental|Placebo|Placebo 4.5mg, administered orally once daily (QD)
89230195|NCT00797069|Active Comparator|diabetes specific product|Diabetes specific nutritional product
88812851|NCT01448525|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
89084703|NCT06331598|Experimental|Atezolizumab|Participants will be treated with atezolizumab every 4 weeks (Q4W) for 12 cycles (cycle = 28 days). After study treatment discontinuation participants will be followed until disease progression and afterwards, survival follow-up and new anti-cancer therapy will be collected until death (unless the participant withdraws consent, is lost to follow-up or the Sponsor terminates the study).
89084704|NCT06331598|Experimental|Atezolizumab + Tiragolumab|Participants will be treated with atezolizumab and tiragolumab Q4W for 12 cycles (cycle = 28 days). After study treatment discontinuation participants will be followed until disease progression and afterwards, information on survival follow-up and new anti-cancer therapy will be collected until death (unless the participant withdraws consent, is lost to follow-up or the Sponsor terminates the study).
89084705|NCT06331585|Experimental|Experimental arm|"Experimental: LDRT on oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy~LDRT: Patient undergoes LDRT using a medical linear gas pedal (5Gy/5f)~Biopsy: Collect pathological tissues from oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy before LDRT (5Gy/5f) and up to 24h after LDRT"
89084706|NCT06331572||TRD|"age 12-18 years~Meet the diagnostic criteria for MDD according to the DSM-5~HAMD-17 score > 13~currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms <50%)"
89084707|NCT06331572||FEDN-MDD|1. age 12-18 years 2. Meet the diagnostic criteria for MDD according to the DSM-5 2. First-episode and drug-naive 4. HAMD-17 score > 17
89084708|NCT06331572||HC|"age 12-18 years~HAMD-17 score < 7~HCs without a personal history of a mental illness or family history in a first-degree relative"
89084709|NCT06331559|Experimental|SIM0501 mono dose escalation|
89084710|NCT06331559|Experimental|SIM0501 mono dose optimization|
89084711|NCT06331559|Experimental|SIM0501 combination dose escalation|
89084712|NCT06331559|Experimental|SIM0501 combination dose optimization|
89084713|NCT06331546|Experimental|Idiopathic Calcium Oxalate Kidney Stone Patients|Low and High oxalate fixed diets. Soluble oxalate absorption test.
89084714|NCT06331546|Active Comparator|Healthy non-kidney stone forming individuals|Low and High oxalate fixed diets. Soluble oxalate absorption test.
89084717|NCT06331520|Active Comparator|NEO-DXMS GROUP|NEPA(1 capsule, day1, PO)+ Olanzapine(5mg, day1-4, PO)+ dexamethasone(12mg, day1; 8mg day2-4, PO/IV).
89084718|NCT06331520|Active Comparator|HALF-DXMS GROUP|NEPA(1 capsule, day1, PO)+ Olanzapine(5mg, day1-4, PO)+ dexamethasone(6mg, day1, PO/IV)
89084719|NCT06331520|Experimental|NEO GROUP|NEPA(1 capsule, day1, PO)+ Olanzapine(5mg, day1-4, PO).
89084720|NCT06331507|Experimental|CMR in CIED|Patients at Michigan Medicine who come in for cardiac imaging procedures and who have CIEDs.
89084721|NCT06331494|Experimental|Butylphthalide|The Butylphthalide group will receive Butylphthalide Sodium Chloride injection (100ml, twice/day) for the initial 10±3 days, followed by oral Butylphthalide soft capsules (0.2g, triple/day) for day 11±3 to day 180.
89084722|NCT06331494|Placebo Comparator|Placebo|The Placebo group will receive Butylphthalide Placebo injection (100ml, twice/day) for the initial 10±3 days, followed by oral Butylphthalide Placebo soft capsules (0.2g, triple/day) for day 11±3 to day 180.
89084723|NCT06331468|Experimental|Cisplatin with concurrent Intensity Modulated Radiotherapy and Brachytherapy|"Cisplatin two (2) one-time weekly intravenous infusions at 40 mg/m2 (70mg maximum)~IMRT once daily, four fractions per week for 2 weeks 4.56 Gy x 8 fractions~High dose rate Brachytherapy twice per week with a 2-day break in between sessions for a total of four brachytherapy treatments. The dose is 7 Gy x 4 fractions"
89084724|NCT06331455|Experimental|Neoadjuvant NORT-Durvalumab|administration of non-ablative oligofractionated radiation therapy using 12 Gy in 3 fractions in combination with two doses of durvalumab (1500 mg IV) prior to surgery.
89084725|NCT06331442|Experimental|Photodynamic therapy group|Group of participants (n=10) allocated to this group will receive photodynamic therapy which consists of toluidine blue based dye (155 mg/mL) and 660 nm diode laser. Participants will be subjected to this treatment right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
89084726|NCT06331442|Active Comparator|Tricalcium phosphate varnish with 5% NaF group|Group of participants (n=10) allocated to this group will receive tricalcium varnish with 5% NaF which will be applied according to the manufacturer's recommendations. Participants will be subjected to this treatment right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
89084727|NCT06331442|Active Comparator|Chlorhexidine varnish group|Group of participants (n=10) allocated to this group will receive chlorhexidine varnish which will be applied according to the manufacturer's recommendations. Participants will be subjected to this treatment right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
89084728|NCT06331442|No Intervention|Negative control group|Group of participants (n=10) allocated to this group will not receive an intervention.
89522925|NCT00092989|Placebo Comparator|Placebo|Participants receive placebo IV until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
89522926|NCT03388463|Active Comparator|Omeprazole group|Patients received intravenous bolus of 80 mg omeprazole followed by 8mg/h infusion for the whole period of ICU stay.
89084731|NCT06331416|Experimental|Telemonitoring|
89084732|NCT06331416|No Intervention|Standard of care|
89230196|NCT00797069|Experimental|Experimental diabetes specific product|Diabetes specific experimental nutritional product
89230197|NCT00797303|Experimental|1|A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
89084733|NCT06331403|Experimental|Mind-Body Sexual Well-Being Group Intervention|"Participants in the mind-body sexual well-being group intervention arm will participate in 6 weekly group sessions, delivered via videoconferencing, following enrollment. Group sessions will include content related to mind-body medicine (e.g., relaxation, mindfulness, self-compassion) applied to sexual well-being as well as educational information related to women's sexual well-being in cancer survivorship.~Before and after completing the group program, participants will also complete brief self-assessment questionnaires to measure topics including satisfaction with sexuality, coping, loneliness, concern about body image, and stigma."
89084734|NCT06331390|Experimental|intervenition|immortela cosmetic product
89084735|NCT06331390|Placebo Comparator|placebo|nothing
89084736|NCT06331377||Observational|Patients complete questionnaires and undergo blood and tissue sample collection. Patients' medical records are also reviewed.
89084737|NCT06331364|Experimental|Intervention Arm|Clinicians will be asked to use the diagnostic portion of the electronic clinical decision tool (eCDST) on their mobile phones, into which they will enter inputs and receive a diagnostic plan. Point of care (POC) testing as advised by the eCDST will be conducted by either clinical staff or trained research staff. If performed by research staff, results will be delivered on paper within 6 hours of testing to ≥ 2 primary clinicians on the team (including the consultant/ attending-level physician or senior registrar). THK, DGM, and DGH do not have an electronic medical record system. Clinicians will be asked to input the results from diagnostic testing and to follow the treatment recommendations as per the eCDST, but will be advised that the final decision regarding prescription of antimicrobials is entirely at their discretion.
89084738|NCT06331364|No Intervention|Usual Care Arm|"Study staff will inform the treating clinicians to diagnose and treat patients according to usual practice. Clinicians will be able to order routine diagnostic testing as per standard practice.~These tests may include complete blood count, chemistries, C-reactive protein (CRP) testing, erythrocyte sedimentation rate (ESR) testing, blood and sputum cultures, and chest x-ray or chest CT imaging."
89084739|NCT06331351|Placebo Comparator|control group|placebo: 2 times a day, 1 sachet each time.
89084740|NCT06331351|Experimental|Jing Si herbal tea liquid packets group|Jing Si herbal tea liquid packets: 2 times a day, 1 sachet each time.
89084741|NCT06331338|Experimental|New health education:use [Decision Cycle for Person-Centered Glycemic Management ]|It is a person-centered approach to care. Treatment goals and plans should be cotreated with people with diabetes based on their individual preferences, values, and goals.
89084742|NCT06331338|Active Comparator|Traditional diabetes self-management education|It is a educator-centered approach to care.
89084743|NCT06331325|Experimental|Frenotomy procedure|Two C-shaped partial thickness incisions are performed on the two sides of the frenum leaving the underlying periosteum intact. Relocation of the muscle attachment is performed by blunt dissection using a mucoperiosteal elevator. Undermining or separation of the epithelium from the underlying lip mucosa is then performed by blunt dissection to facilitate tension-free suturing. The epithelium is then sutured to the underlying periosteum using three interrupted periosteal sutures and is left to heal by secondary intention.
89084744|NCT06331325|Active Comparator|Frenectomy procedure|Frenectomy group (Control): Two full-thickness incisions are performed apical and coronal to the frenum attachment and extending down to and including the periosteum. Complete excision of all muscle tissues is ensured and then both epithelial edges are approximated using single interrupted sutures achieving primary closure.
89084745|NCT06331312|Experimental|Secukinumab 300mg|All eligible participants will receive secukinumab 300 mg s.c. (2 x 150mg/1mL PFS secukinumab) from baseline and every 4 weeks up to 2 years. The study medication may be modified/adjusted after the initial doses of 300mg s.c. (decreased to 150mg s.c. q4w or increased again from 150mg s.c. q4w to 300mg s.c. q4w) if deemed appropriate by the investigator. Dose modification/adjustment may only occur from Week 24 visit onwards. The modification/adjustment of the study medication will be determined at a site visit.
89084746|NCT06331299|Experimental|UGN-103|Patients will receive UGN-103 once weekly for 6 weeks (a total of 6 doses).
89084747|NCT06331286|Experimental|dulaglutide injection treatment group|0.75mg Subcutaneous injection once a week for 24 weeks
89084748|NCT06331286|Other|diet and exercise guidance treatment|diet and exercise guidance treatment for 24 weeks
89084749|NCT06331273||"HCC patients fulfill Hangzhou criteria and receive LT with No-touch technique"|
89084750|NCT06331273||"HCC patients exceed Hangzhou criteria and receive LT with No-touch technique"|
89084751|NCT06331273||"HCC patients fulfill Hangzhou criteria and receive LT without No-touch technique"|
89084752|NCT06331273||"HCC patients exceed Hangzhou criteria and receive LT withoutNo-touch technique"|
89084753|NCT06331260||Preoperative AFP < 400 ng/mL or PIVKA-II < 200mAU/mL|
89084754|NCT06331260||Preoperative AFP ≥ 400 ng/mL and PIVKA-II ≥ 200mAU/mL|
89084755|NCT06331247|Placebo Comparator|Control arm|Usual medical care (including general dietary advice).
89084756|NCT06331247|Active Comparator|MIND diet intervention arm|Usual medical care (including general dietary advice) plus the MIND diet intervention.
89084757|NCT06331221|No Intervention|Control Condition|5-minute rest period.
89084758|NCT06331221|Active Comparator|Quadriceps_Concentric|40 consecutive maximal concentric contractions of quadriceps at 30º/s from the 90° to 30° of knee flexion
89084759|NCT06331221|Active Comparator|Quadriceps_Eccentric|40 consecutive maximal eccentric contractions of quadriceps at 30°/s from the 30° to 90° of knee flexion
89084760|NCT06331221|Active Comparator|Hamstrings_Concentric|30 consecutive maximal concentric contractions of hamstrings at 30º/s from 30º to 90º of knee flexion
89084761|NCT06331221|Active Comparator|Hamstrings_Eccentric|30 consecutive maximal eccentric contractions of the hamstrings at 30º/s from 90º to 30º of knee flexion
89230198|NCT00800579|Experimental|1|GS-9411 0.6 mg
89230199|NCT00800579|Experimental|2|GS-9411 1.2 mg
89084762|NCT06331208||controls|Subjects without heart failure or pulmonary hypertension undergoing clinically indicated diagnostic evaluation or therapeutic procedure
89084763|NCT06331208||heart failure|Subjects with chronic heart failure due to reduced ejection fraction (EF), undergoing clinically indicated right heart catheterisation (evaluation for left ventricular assist device (LVAD)/transplantation (TX) or other decision)
89084764|NCT06331195|Placebo Comparator|DICA-FH + placebo|Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus placebo of both phytosterol and krill oil during 120 days.
89084765|NCT06331195|Experimental|DICA-FH + phytosterol|Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of phytosterol and placebo of the krill oil during 120 days.
89084766|NCT06331195|Experimental|DICA-HF + krill oil|Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of krill oil and placebo of phytosterol during 120 days.
89084767|NCT06331195|Experimental|DICA-HF + phytosterol + krill oil|Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of phytosterol and 2g/day of krill oil during 120 days.
89522927|NCT03388463|Placebo Comparator|Placebo group|Patients received intravenous omeprazole 40mg bolus dose once daily followed by normal saline infusion.
89522928|NCT03388489|Experimental|Mind-Body Walking|breathing, walking and meditation
89084770|NCT06331169|Experimental|Anlotinib dose escalation + trastuzumab deruxtecan|Various doses of anlotinib (8 mg QD, 10 mg QD, and 12 mg QD) administered during dose escalation to determine the recommended phase 2 Dose (RP2D) + trastuzumab deruxtecan 5.4 mg/kg.
89084771|NCT06331169|Experimental|Anlotinib + trastuzumab deruxtecan combination therapy (dose expansion)|Anlotinib at the RP2D + trastuzumab deruxtecan 5.4 mg/kg combination therapy .
89084772|NCT06331156|Experimental|Co-administration Group|Participants receive 2 doses of HRV PCV-free vaccine co-administered with the first 2 doses of IPV vaccine at Month 0.5 and Month 1.5, followed by the third dose of IPV vaccine administered at Month 2.5.
89084773|NCT06331156|Active Comparator|Staggered Group|Participants receive 2 doses of HRV PCV-free vaccine administered at Day 1 and Month 1, and 3 doses of IPV vaccine administered at Month 0.5, Month 1.5, and Month 2.5.
89084776|NCT06331130||Retrospective cohort|Patients affected by High Grade Seruous Ovarian Cancer with mesenteric infiltration confirmed by diagnostic laparoscopy, from January 2021 to December 2023
89084777|NCT06331130||Prospective cohort|Patients affected by High Grade Seruous Ovarian Cancer with mesenteric infiltration confirmed by diagnostic laparoscopy
89084778|NCT06331117|Experimental|Case group|Multiomics profiling of the RASopathies
89084779|NCT06331104||P27 expression groups|12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
89084780|NCT06331104||ESR1 expression groups|12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
89084781|NCT06331091|Active Comparator|Home exercise|This group performed the same exercises given to comprehensive physiotherapy group at home 3 times a week for 6 weeks.
89084782|NCT06331091|Experimental|Comprehensive physiotherapy|This group received comprehensive physiotherapy (manual therapy, neuromuscular electrical stimulation and exercises) 1 day a week, and did the exercises at home the other 2 days a week for 6 weeks.
89084785|NCT06331065|Experimental|Mindfulness meditation practice group|Group informed about mindfulness meditation and experimenting with an adapted program based on mindfulness meditation (intervention group).
89084786|NCT06331065|Active Comparator|Group without mindfulness meditation practice|Group informed about mindfulness meditation and without experimentation of mindfulness meditation practice (control group).
89522929|NCT03388489|No Intervention|Usual care|maintain their daily activity
89230200|NCT00800579|Experimental|3|GS-9411 2.4 mg
89522930|NCT03388307|Experimental|unilateral laminotomy|patients with lumbar canal stenosis who undergo unilateral laminotomy for bilateral decompression
89522931|NCT03388307|Experimental|decompressive laminectomy|patients with lumbar canal stenosis who undergo decompressive laminectomy
89522932|NCT03388411||Obese children|Children ≥95 ‰ between age 7 and 12 years
89522933|NCT03388411||Non-obese children|5‰< BMI <85 ‰ for children between the ages of 7 and 12 years
89522934|NCT04702529|Experimental|Three treatments to hypertrophic scar with RAP device|RAP treatments will be administered to the scar every +/- 2 weeks for a total of 3 treatments
89522935|NCT03388333||Atrial fibrillation ablation group|Patients undergoing catheter ablation for the treatment of atrial fibrillation.
89522936|NCT03388333||Electrophysiological study group|Patients undergoing a diagnostic electrophysiological study without ablation.
89522937|NCT03388333||Atrial flutter ablation group|Patients undergoing catheter ablation of right atrial flutter at the cavotricuspid isthmus.
89522938|NCT04685993|Experimental|Treatment A|LPCN 1144
89522939|NCT03388151|Active Comparator|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
89225790|NCT05295498|Sham Comparator|Sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
89225791|NCT05288062|Experimental|Cohort A (lenalidomide, dexamethasone)|Patients with smoldering multiple myeloma receive lenalidomide PO QD alone on days 1-14 OR in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 alone or in combination with dexamethasone PO QD on days 1, 8, 15, and 22, or in combination with another drug. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
89225792|NCT05288062|Experimental|Cohort B (lenalidomide, dexamethasone)|Patients with newly diagnosed multiple myeloma receive treatment as in Cohort A.
89225793|NCT05288062|Experimental|Cohort C (lenalidomide, dexamethasone, pomalidomide)|Patients with relapsed or refractory multiple myeloma receive lenalidomide PO QD on days 1-14 in combination with dexamethasone PO QD on days 1, 8 and 15 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22 OR pomalidomide PO QD on days 1-21 in combination with dexamethasone PO QD on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
89225794|NCT05288062|Experimental|Cohort D (lenalidomide, dexamethasone, pomalidomide)|Patients with relapsed multiple myeloma after lenalidomide maintenance receive treatment as in Cohort C.
89225795|NCT05283226|Experimental|NRC-2694-A In Combination with paclitaxel|Patients will receive NRC-2694-A 300 mg orally once daily and paclitaxel 175 mg/m² IV infusion over approximately 3 hours once in 21 days for 6 cycles or more.
89225796|NCT05275231|Experimental|Dyads|This is a pragmatic, pre-post, pilot study. Participants will meet in groups of 12 for the SMA intervention at the conference room at the Emory Family Medicine Center in Dunwoody, Georgia. The intervention will consist of bi-weekly sessions over a 16-week period, with phone check-ins for the remaining weeks. Each session will last 60-90 minutes, and participants will engage in a total of 6 televisit sessions. Sessions will consist of a group-based program for all participants, followed by a personalized care plan, led by a physician. In this dyad-based group, participant's social partner must commit to attend all in-person sessions.
89225797|NCT05275231|Active Comparator|Men Only|This is a pragmatic, pre-post, pilot study. Participants will meet in groups of 12 for the SMA intervention at the conference room at the Emory Family Medicine Center in Dunwoody, Georgia. the intervention will consist of bi-weekly sessions over a 16-week period, with phone check-ins for the remaining weeks. Each session will last 60-90 minutes, and participants will engage in a total of 6 televisit sessions. Sessions will consist of a group-based program for all participants, followed by a personalized care plan, led by a physician. In this group just the participant will receive the intervention.
89225798|NCT05273151|Other|KOS treatment|Treatment with intranasal kinetic oscillation stimulation (KOS)
89225799|NCT05268445|Active Comparator|Chemical angioplasty|Chemical angioplasty using intra-arterial Nimodipin
89225800|NCT05268445|Active Comparator|Chemical and Mechanical angioplasty|Balloon angioplasty for refractory intracranial arterial vasospastic stenosis with a CE Marked device (Neurospeed balloon) or Adjustable remodeling mesh angioplasty for refractory intracranial arterial vasospastic stenosis with a CE Marked device (Comaneci) in association with intra-arterial Nimodipin
89225801|NCT05265728|Experimental|Natalizumab 300 mg|Participants will receive natalizumab 300 mg SC Q4W for 48 weeks.
89225802|NCT05264623|Experimental|TENEO 317 Model 2 excimer laser|
89225803|NCT05261984|Experimental|Former ICU patients|Research subjects with a prior history of ICU treatment within six months.
89225804|NCT05261984|Active Comparator|Age- and sex-matched control group|Research subjects without a prior history of ICU treatment within the last 30 years, age- and sex-matched in a 1:2 ratio to the experimental arm.
89225805|NCT05259033|Experimental|IcoSema|Participants will get once weekly dose
89225806|NCT05259033|Experimental|Semaglutide|Participants will get once weekly dose
89522940|NCT03388151|Active Comparator|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
89084790|NCT06331026|Experimental|TRR|Administration order: PEG-rhGH with new preparation (T), PEG-rhGH with present preparation (R), PEG-rhGH with present preparation (R)
89084791|NCT06331026|Experimental|RTR|Administration order: PEG-rhGH with present preparation (R), PEG-rhGH with new preparation (T), PEG-rhGH with present preparation (R)
89084792|NCT06331026|Experimental|RRT|Administration order: PEG-rhGH with present preparation (R), PEG-rhGH with present preparation (R), PEG-rhGH with new preparation (T)
89084793|NCT06331013|Experimental|CyberKnife SBRT treatment|CyberKnife ultra-hypofractionated SBRT for localized Prostate cancer with dose-escalation to the dominant intraprostatic lesion
89084794|NCT06331000||Adult patients with cystic fibrosis|
89084795|NCT06330961|Experimental|Pain-free participants|Aerobic exercise, Biering-Sorensen test and placebo interventions will be administered to a group of subjects with no past history of low back pain. They will serve as a control group.
89084796|NCT06330961|Experimental|Low back pain patients|Aerobic exercise, Biering-Sorensen test and placebo interventions will be administered to a group of non-specific low back pain patients. They will serve as the primary intervention group.
89084797|NCT06330948|Placebo Comparator|placebo group|Placebo group (50mL/bottle)
89084798|NCT06330948|Experimental|SugarCut® Unripe Guava Fruit Extract|SugarCut® Guava Fruit Extract Group (50mL/bottle, each bottle contains 10g Guava Fruit Extract)
89084799|NCT06330935|Active Comparator|TXA dose A arm|Subjects will receive a 15 mg/kg bolus of Tranexamic acid over 20 minutes followed by 2 mg/kg/hr. infusion over 8 hours. The maximum bolus dose is 1000 mg, the maximum rate of infusion is 50 mg/min, and the maximum total maintenance dose is 1000 mg
89084800|NCT06330935|Active Comparator|TXA dose B arm|Subjects will receive a 30 mg/kg bolus of Tranexamic acid over 20 minutes followed by 4 mg/kg/hr. infusion over 8 hours. The maximum bolus dose is 2000 mg, the maximum rate of infusion is 100 mg/min, and the maximum total maintenance dose is 2000 mg
89084801|NCT06330935|Placebo Comparator|Placebo arm C|Subjects in the placebo group will receive a bolus dose of normal saline over 20 minutes followed by a normal saline infusion over 8 hours (in the same weight-based volume as the other study arms)
89084802|NCT06330922||Group 1: healthy individuals (cross-sectional study)|Typically developed adolescents and young adults will be recruited and measured once within the cross-sectional study.
89084803|NCT06330922||Group 2: mildly affected individuals with cerebral palsy (cross-sectional study)|Mildly affected adolescents and young adults will be recruited and measured once within the cross-sectional study.
89084804|NCT06330922||Group 3: moderately and severely affected individuals with cerebral palsy (cross-sectional study)|"The results of the baseline assessment (T0) of the adolescents and young adults with moderate to severe cerebral palsy will be compared with group 1 and group 2.~After the baseline assessment (T0) also used for the group comparison (see description above), group 3 enters a 12-week control period following daily routines. After the 12 weeks, the individuals will be assessed (T1) and will then start with the 12-week cardiorespiratory fitness training. The final assessment (T2) will terminate study participation of group 3."
89084805|NCT06330909|Experimental|Arm A - IMRT/IGRT/SBRT|"Prostate and seminal vesicles RT with 30 Gy in 6 Gy / fraction; prostate RT with 35 Gy in 7 Gy / fraction including a simultaneous integrated boost (SIB) on the intraprostatic tumour mass (ITM) with 40- 42 Gy in 8 - 8.4 Gy / fraction.~If the boost volume is ≥10 ml and/ or ≥ 1/3 of the prostate, the SIB on the ITM has to be restrained to 40 Gy in 8 Gy / fraction. SBRT will be performed twice a week, with at least 2 days between two RT fractions, 5 fractions in 3 weeks (technique: IMRT/IGRT/SBRT)."
89084806|NCT06330909|Active Comparator|Arm B - IMRT/IGRT|Prostate and seminal vesicles RT with 46.4 Gy in 2.32 Gy per fraction, prostate RT with 60 and 62 Gy in 3 and 3.1 Gy per fraction for unfavorable intermediate-risk and high-risk patients, respectively, 20 fractions, 5 fractions /week, (technique: IMRT/IGRT).
89084807|NCT06330883||Frail|Patients will be evaluated frail if the clinical frailty score is ≥5
89084808|NCT06330883||non-fragile|Patients will be evaluated non-fragile if the clinical frailty score is <5.
89084809|NCT06330870|Experimental|WGS/TME evaluation|This is not intervention clinical trial design. We explore whole genome sequencing and tumor microenvironment evaluation for brain metastasis specimen in breast cancer patients.
89084810|NCT06330857|Experimental|Surgical intervention|Operated with the intervention, ie vaginorectopexy
89084811|NCT06330844|Experimental|Experimental: RBSEF-CCT-MCI|Participants will complete the newly developed RBSE-CCT-MCI training program.
89084812|NCT06330844|Other|Control Group: ME-CCT|Participants will complete the original, ME-CCT training program.
89084813|NCT06330831|Experimental|Intensive, Group Based CIMT|The intensive, group based CIMT program lasted for 3 hours/day x 5 days/week x 4 weeks. Children wore a cast on their non-affected arm for 24 hours/day for 3 weeks. During the last week, the cast was removed to focus on bimanual skills. Occupational therapists ran and were present for every hour of the program. Both physical therapy and speech language pathology cotreated for 1 1/2 hours two times per week and either music, art, or adaptive martial arts occurred 1 hour per week. Interns and volunteers served as intervention assistants to maintain a 2:1 or 1:1 child to therapist/interventionist ratio. The same theme-based lesson plans were used for the 2-3-year-old program and the 4-6-year-old program. Each age group program offered spots for 3-6 children to attend per year except for 2020 when the programs were suspended due to COVID 19 pandemic.
89084814|NCT06330818|Experimental|Moyamoya patients|Newly diagnosed Moyamoya patients who will follow a standardized imaging and biosampling protocol. Possible surgical or conservative treatment will not be influenced by this study.
89084815|NCT06330818|No Intervention|Control group|Healthy patients and patients with intracerebral atherosclerotic disease are used as comparators for the results of biosampling.
89230201|NCT00800579|Placebo Comparator|4|Inhaled volume-matched sterile saline placebo
89230202|NCT00661271|Experimental|Mindfulness-Based Stress Reduction|8-week mindfulness-based stress reduction program with one retreat session
89230203|NCT00661271|Active Comparator|Healthy Topics|8-week health education program with one retreat session - based on a health curriculum developed by McGraw/Hill
89084816|NCT06330805|Experimental|Arm 1 (leuprolide)|Patients receive definitive therapy for prostate cancer with ADT (leuprolide via injection once every 3 months, for a total of 6 months) in the absence of disease progression or unacceptable toxicity and definitive radiotherapy within 90 days of starting ADT. Patients receive gadolinium-based contrast intravenously (IV) and undergo exercise-stress cardiac MRI perfusion and comprehensive exercise physiology testing before starting ADT and at 6 months after starting ADT. Patients also undergo blood and urine sample collection throughout the study, as well as completion of quality-of-life questionnaires.
89084817|NCT06330805|Experimental|Arm 2 (relugolix)|Patients receive definitive therapy for prostate cancer with ADT (relugolix orally once daily for a total of 6 months) in the absence of disease progression or unacceptable toxicity and definitive radiotherapy within 90 days of starting ADT. Patients receive gadolinium-based contrast intravenously (IV) and undergo exercise-stress cardiac MRI perfusion and comprehensive exercise physiology testing before starting ADT and at 6 months after starting ADT. Patients also undergo blood and urine sample collection throughout the study, as well as completion of quality-of-life questionnaires.
89084818|NCT06330792|Other|effect of biomechanical awareness and core stability exercises on mechanical low back pain|
89084819|NCT06330792|Other|effect core stability exercises on mechanical low back pain|
89084820|NCT06330779|Experimental|Yoga-group|8 weeks ,once a week, instructor led trauma-adapted yoga intervention.
89084821|NCT06330779|No Intervention|Controll|Waiting list
89084822|NCT06330766||No preoperative dental screening|No preoperative dental screening in patients undergoing TAVI
89084823|NCT06330766||Mandatory preoperative dental screening|Mandatory preoperative dental screening in patients undergoing TAVI
89084824|NCT06330753|Other|Feasibility and Acceptability of Trauma-informed Care Plans (TICP)|"Per our IRB protocol - Patient participants and clinician participants will be asked (via a survey) to rate their:~Acceptability of the Trauma-informed Care Plan, the Appropriateness of the TICP and the feasibility of the TICP. The intervention is the TICP place in the Electronic Medical Record right below the patient's name (on the Storyboard)."
89084825|NCT06330740|Experimental|Intervention Arm|
89084826|NCT06330740|No Intervention|Control Arm|
89084827|NCT06330727|Active Comparator|Coffee capsule|participants in this arm ingest coffee capsules with 1.8g instant black coffee powder twice daily with breakfast and lunch.
89084828|NCT06330727|Placebo Comparator|Placebo|participants in this arm consume cornstarch capsules (without coffee) twice daily with breakfast and lunch.
89084829|NCT06330701|Experimental|Robotic mini-Percutaneous Nephrolithotomy (PCNL)|"Participants with kidney stones will be enrolled for a robotic-assisted mini-percutaneous nephrolithotomy procedure using the MONARCH Platform, Urology for removal of kidney stones. The MONARCH Platform, Urology enables electro-mechanical articulation and precise control of a flexible ureteroscope and/or a flexible mini-PCNL suction catheter (catheter) for visualization and access to the urinary tract for diagnostic and therapeutic procedures."
89084830|NCT06330675|Experimental|Mobilization 4-h after procedure|Short-term bed-rest (4-h) after CIED implantation
89084831|NCT06330675|Active Comparator|Mobilization day-after procedure|Standard of care with prolungate bed-rest after CIED implantation
89084832|NCT06330662|Experimental|Coronally advanced flap with the hyaluronic acid|The experimental group indicates the surgical intervention using a coronally advanced flap to cover multiple adjacent gingival recessions with the addition of hyaluronic acid intraoperatively (CAF+HA).
89084833|NCT06330662|Other|Coronally advanced flap|The control group refers to surgical intervention using a coronally advanced flap only to cover multiple gingival recessions without the addition of hyaluronic acid (CAF).
89084834|NCT06330649|Experimental|Energy Drink|A commercially available caffeine drink containing 200 mgs of caffeine.
89084835|NCT06330649|Placebo Comparator|Water|This will be 12 fl oz of commercially available water .
89084836|NCT06330636|Experimental|D-Allulose|15g D-Allulose added to a high glycaemic index oat porridge
89084837|NCT06330636|Placebo Comparator|Saccharin|Sodium saccharin (1x 'Sweetex' tablet) added to a high glycaemic index oat porridge
89084838|NCT06330623||Phase 1 Cohort|"These participants will be recruited from:~Previous research studies~COPD nursing ward~Pulmonary rehabilitation"
89084839|NCT06330623||Phase 2 Cohort|These participants will be recruited from the pulmonary rehabilitation service.
89084840|NCT06330610|Experimental|Intermittent enteral nutrition|patients that receive intermittent enteral nutrition.
89084841|NCT06330610|No Intervention|continuous enteral nutrition|patients that receive continuous enteral nutrition
89084842|NCT06330597||Patients admitted to CICU|The study population will be composed of patients admitted to the Coronary Intensive Care Unit (CICU) requiring hemodynamic assessment using pulmonary artery catheter (PAC) as standard of care.
89084843|NCT06330584|Placebo Comparator|Placebo|Total dose of midazolam = 0 mg (no active compound)
89084844|NCT06330584|Active Comparator|Standard of Care (SOC)|Total dose of midazolam = 0.9 mg
89084845|NCT06330584|Active Comparator|Double Dose of Standard of Care (2xSOC)|Total dose of midazolam = 1.8 mg
89084846|NCT06330571|Active Comparator|Molar distalization by aligners without attachment|
89084847|NCT06330571|Experimental|Molar distalization by aligners with attachments|
89084850|NCT06330545|Experimental|Patients with Dupuytren's Contacture|Patients with Dupuytren's Contacture will undergo Collagenase Clostridium Histolyticum injection and release followed by two 5-day courses of radiation therapy separated by 6-8 weeks. They will then be followed for 3 years for recurrence.
89084851|NCT06330532||Patients categorized as having no frailty on the frailty item, assessed by four domains|cognitive, emotional, physical, and nutritional.
89084852|NCT06330532||Patients exhibiting the early signs that may lead to frailty, assessed in four domains|cognitive, emotional, physical, and nutritional.
89084853|NCT06330532||Patients categorized as having frailty on the frailty item, assessed by four domains|cognitive, emotional, physical, and nutritional.
89084854|NCT06330519|Experimental|intraligamentary dexamethazone|
89084855|NCT06330519|Active Comparator|Endo-ice cryotherapy|
89084856|NCT06330519|Active Comparator|Intraoral soft tissue cryotherapy|
89084857|NCT06330519|No Intervention|Inferior Alveolar nerve block only|
89084858|NCT06330506|Experimental|experiment group|The pressure ulcer care package to be prepared by the researchers will be implemented
89084859|NCT06330506|No Intervention|control group|Standard maintenance will be applied
89084860|NCT06330480|Other|Intervention group|This group will be invited for the screening
89084861|NCT06330480|No Intervention|Control group|This group will not be invited for the screening
89084870|NCT06330428|Experimental|Experimental group|Sexuality-based family planning education will be provided through podcasts.
89084871|NCT06330428|No Intervention|Control group|Control
89084872|NCT06330415|Experimental|Intervention group|Unlimited access to the SME tool.
89084873|NCT06330415|No Intervention|Control group|Care as usual by the occupational health service.
89084874|NCT06330402|Experimental|Painful condition|Hypertonic saline injection to the infrapatellar fat pad.
89084875|NCT06330402|Placebo Comparator|Control condition|Isotonic saline injection to the infrapatellar fat pad.
89084876|NCT06330389||COVID-19 Positive and Negative status|Burn injuries with COVID-19 Positive and Negative status underwent surgery
89084877|NCT06330376|Active Comparator|arm 1|Participants randomized to usual care
89084878|NCT06330376|Experimental|arm 2|participants randomize to diaphragmatic breathing (DB) program
89084879|NCT06330363|Experimental|LLLT|The LLLT will be performed using a Cube plus30 (Eltech K-Laser s.r.l., Italy). Settings will be based on manufacturer's guidelines for skin and deep tissue stimulation. The LLLT will take 25 min, with 3x5 min of treatment separated by 5 min of rest. In total 16800 J in form of light energy will be applied (3 x 5600 J). All 4 available wavelength will be used (660, 800, 905 and 970 nm). The randomization procedure to allocate the treated leg will occur via a random-number generator stratified for sex (www.randomization.com) performed by an independent researcher of the research group. During the laser treatment protective goggles (K-Laser Protective Goggles, Eltech K-Laser s.r.l.) need to be worn and will therefore be provided. LLLT will only be applied by trained personal.
89084880|NCT06330363|Sham Comparator|Sham|Sham laser based on the same laser device which emitts only light.
89084881|NCT06330350||Keratinisation disorders|Keratinisation disorders comprise a heterogeneous group characterised by abnormal epidermal differentiation, such as variants of ichthyosis and palmoplantar keratoderma.
89225807|NCT05257031|Experimental|SmofKabiven extra Nitrogen|"The investigational product will be administered in a volume that provides the target caloric intake of 15 kcal/kg BW on Study Day 1 and 20 kcal/kg BW/day on Study Days 2 to 5.~If calories are provided from other sources (e.g., enteral/oral nutrition/oral nutritional supplements or non-nutritional sources including glucose solution for drug dilution or propofol), the dose of the investigational product will be reduced accordingly to avoid calorie overload above the respective daily caloric targets."
89225808|NCT05256069|Experimental|Hypoxia Exposure|Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
89225809|NCT05255900||metyrapone treatment|hypercortisolemic patients taking metyrapone since less than a week (usually 250 mg/day, maximum dose 6000 mg/day)
89225810|NCT05255679|Experimental|Early FES|Receives standard care plus FES cycling in Phase 1 (starting 14 to 21 days after injury and for 3 months) and Phase 2 (from month 3 to month 6 after enrollment).
89225811|NCT05255679|Experimental|Delayed FES|Receives standard care only in Phase 1 (considered Control group in Phase 1), and standard care plus FES cycling in Phase 2 (from month 3 to month 6 after enrollment).
89225812|NCT05255679|No Intervention|Control|Receives standard care only
89225813|NCT05252273||Open-label observational study|This study will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
89225814|NCT05248074|Other|Fasting group|"Period 1 : Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) after an overnight fast~Peroid 2: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) in fed condition. High-fat meal (over 900 kcal)"
89225815|NCT05248074|Other|Fed group|"Peroid 1: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) in fed condition. High-fat meal (over 900 kcal)~Period 2: Single oral administration of ABN401 800 mg (3 x 250 mg + 2 x 25 mg) after an overnight fast"
89225816|NCT05238142|Experimental|MiniMed 780G System|Adult participants with insulin-requiring type 2 diabetes age 18-80 using the MiniMed 780G system for a combined run-in period and study period will be approximately 135 days long.
89225817|NCT05236595||Rare genetic disease individualized drug development screening candidate|Patients with targetable disease-causing genetic alterations will be evaluated on a case by case basis. The research study will utilize biospecimens to determine if an individualized therapeutic may be developed as a possible treatment option. If an individualized therapeutic drug can be developed, a future IND FDA application (n=1) will be filed.
89230204|NCT00922181|Experimental|MWA|Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
89084882|NCT06330350||Skin fragility disorders|Skin fragility disorders comprise a group of inherited blistering diseases, such as variants of epidermolysis bullosa.
89084883|NCT06330350||Ectodermal dysplasias|Ectodermal dysplasias consists of multiple inherited disorders that are characterised by abnormalities of the embryonic ectoderm, such as hair, nails, sweat glands or teeth.
89084884|NCT06330350||Dermato-oncogenetic syndromes|This group are genodermatoses associated with the development of malignancies ((non-)cutaneous), such as basal cell nevus syndrome (BCNS), Birt-Hoog-Dubé syndrome, tuberous sclerosis, etc.
89084885|NCT06330350||Other genodermatoses|In this group genodermatoses are listed that do not fit the other groups as mentioned above, for example albinism and cutis laxa.
89084886|NCT06330350||Health care professionals|This group includes clinical geneticists, dermatologists and other clinicians involved in the care of patients with genodermatoses.
89084887|NCT06330337|Other|TMZ group|Temozolomide（TMZ） was given orally or intravenously 150mg/(m2·d) for 5 days, repeated every 28 days for 6 cycles
89084888|NCT06330337|Other|SMES+ABX+TMZ Group|"Drug:~Oral or intravenous infusion of TMZ 150mg/(m2·d) for 5 days, repeated after 23 days of suspension, a total of 6 treatment cycles. During the TMZ treatment cycle, specific mode electroacupuncture stimulation（SMES） combined with Paclitaxel for Injection (Albumin Bound)（ABX） were used on day 1 and day 8.~ABX： ABX was prepared with 0.9% sodium chloride injection and the dosage required by the patient was calculated at 110mg/mm2. Then the intravenous infusion continues for 30 minutes.~SMES：Immediately after the ABX intravenous infusion began, the patient was placed in a supine position, the skin was routinely disinfected with 75% ethanol, and a stainless steel needle was inserted into GV20 and GV26.Then, the needles are stimulated by using an acupuncture point nerve stimulator with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off)."
89084889|NCT06330324||Keratinisation disorders|Keratinisation disorders comprise a heterogeneous group characterised by abnormal epidermal differentiation, such as variants of ichthyosis and palmoplantar keratoderma.
89084890|NCT06330324||Skin fragility disorders|Skin fragility disorders comprise a group of inherited blistering diseases, such as variants of epidermolysis bullosa.
89084891|NCT06330324||Ectodermal dysplasias|Ectodermal dysplasias consists of multiple inherited disorders that are characterised by abnormalities of the embryonic ectoderm, such as hair, nails, sweat glands or teeth.
89084892|NCT06330324||Dermato-oncogenetic syndromes|This group are genodermatoses associated with the development of malignancies ((non-)cutaneous), such as basal cell nevus syndrome (BCNS), Birt-Hoog-Dubé syndrome, tuberous sclerosis, etc.
89084893|NCT06330324||Other genodermatoses|In this group genodermatoses are listed that do not fit the other groups as mentioned above, for example albinism and cutis laxa.
89230205|NCT00922181|Active Comparator|RFA|Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
89230206|NCT00797381||1|
89230207|NCT00797381||2|
89084896|NCT06330298|Experimental|Experimental condition: Receives T-ScEmo Treatment|Experimental group. Receives T-ScEmo Treatment during the study between T0 and T1
89084897|NCT06330298|No Intervention|Waiting list group: Will be on waiting list instead of treatment|Waiting list group: Will be on waiting list for instead of the treatment for the duration of the treatment between T0 and T1.
89084898|NCT06330285|Experimental|Group 1|e-learning
89084899|NCT06330285|Active Comparator|Group 2|face to face learning
89084901|NCT06330259||Group A|25 younger women, aged 18 to 25 y.
89084902|NCT06330259||Group B|25 less young women, aged 26 to 39 y.
89522941|NCT03838939|Experimental|interventional group|"M3 (group with 3 to 10 patients) Intensification Biotherapy Education Workshops : Subcutaneous injection education and biotherapy management"
89084904|NCT06330233|Sham Comparator|Conventional treatment group|mecobalamin tablets (0.5 mg/dose, 3 times/day) and alpha-lipoic acid tablets (0.2 g/dose, 3 times/day) were administered orally for four weeks in conjunction with the patient's daily treatment (basal medication treatment for patients with combined hypertension and hyperlipidemia).
89084905|NCT06330233|Experimental|Moxibustion 5 minutes group|Moxibustion for 5 minutes per point group: Based on conventional treatment, moxibustion was performed. Selection of acupoints was based on data mining of preferred acupoints, moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 5 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.
89084906|NCT06330233|Experimental|Moxibustion 10 minutes group|Moxibustion for 10 minutes per point group: Based on conventional treatment, moxibustion was performed. Selection of acupoints was based on data mining of preferred acupoints, moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 10 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.
89084907|NCT06330233|Experimental|Moxibustion 15 minutes group|Moxibustion for 15 minutes per point group: Based on conventional treatment, moxibustion was performed. Selection of acupoints was based on data mining of preferred acupoints, moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.
89084908|NCT06330220|Experimental|Aflibercept loading|Administration of 2㎎ intravitreal aflibercept three times monthly after diagnosis
89084909|NCT06330207|Experimental|Intervention|ED providers who will test the clinical decision support tool when prescribing for patients with non traumatic dental conditions
89084910|NCT06330194|Active Comparator|Intervention Group|2nd Generation Automated Insulin Delivery system (Medtronic MiniMed 780G)
89084911|NCT06330194|No Intervention|Control Group|Usual care consisting of participants current insulin-treatment (either multiple daily injection with insulin or traditional insulin pump therapy with manual determination of insulin dosing) and real-time CGM if already used.
89084912|NCT06330181|Active Comparator|Virtual reality (VR) game 1|Participants will be asked to play a virtual reality game twice a day for 10 days.
89084913|NCT06330181|Active Comparator|Virtual reality (VR) game 2|Participants will be asked to play a virtual reality game twice a day for 10 days.
89084916|NCT06330155||Alzheimer's dementia patient and healthy subjects|
89084917|NCT06330142|Other|entire study population|
89084918|NCT06330129|Experimental|Healthy subjects|30 healthy subjects undergo trunk muscle strength assessement using the Pegasus device, with repeated measurements to evaluate repeatability and correlation with both surface electromyography (EMG) and MRI scans of trunk muscles.
89522942|NCT03838939|Placebo Comparator|Control group|"M3 (individual) Intensification Biotherapy Education: Subcutaneous injection education and biotherapy management."
89522943|NCT03388073|Experimental|Berry extract I|Plant-based antioxidant-rich berry-based extract.
89522944|NCT03388073|Experimental|Berry extract II|Plant-based antioxidant-rich berry-based extract.
89522945|NCT03388073|Experimental|Berry extract blend|Blend of plant-based antioxidant-rich berry-based extracts.
89522946|NCT03388073|Placebo Comparator|Placebo|
89522947|NCT03390205||Patients|
89522948|NCT03390205||Controls|
89522949|NCT03797911|Experimental|active resistive capacitive monopolar radiofrequency|"Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): The intervention group will receive the treatment with activated resistive capacitive monopolar radiofrequency system, with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
89084919|NCT06330116|Active Comparator|Oral screen|Strength training of the oral and pharyngeal muscles is performed with an oral screen (OS)(IQoro). The OS is a device that has an effect both on the brain plasticity and a strengthening effect of oral and pharyngeal muscles. (9) The OS is placed pre-dentally behind closed lips. The patient pulls the OS forward in a horizontal direction with strong pressure for 5 to 10 seconds while firmly resisting the pressure with tightened lips. The exercise is repeated three times, with 3 seconds of rest between repetitions, and is performed 3 times per day. Training for 3 months.
89084920|NCT06330116|Active Comparator|Neuromuscular electrical training (NMES)|Strength training of the oral and pharyngeal muscles is performed by an oral device used for 20 minutes every day (eXciteosa). The device gives electrical pulses to the surrounding tissue, mainly the tongue. Training for 3 months.
89084921|NCT06330116|Active Comparator|Group training with an occupational therapist|Strength training of the oral and pharyngeal muscles is performed in group, led by an occupational therapist. Training for 3 months.
89084922|NCT06330103|Active Comparator|LV function from cardiologist|Certified Cardiologist will access and interpreted LV function by used traditional Echocardiography then separate result into three group Preserved LV ejection fraction(EF>50%), mildly reduce ejection fraction(EF40-49%), reduced LV ejection fraction(EF<40%)
89084923|NCT06330103|Experimental|LV function By artificial intelligence|AI will access VDO clips in only parasternal long axis view and separate into three group Preserved LV ejection fraction(EF>50%), mildly reduce ejection fraction(EF40-49%), reduced LV ejection fraction(EF<40%)
89084924|NCT06330090||Design|Behavioural or behavioural with imaging
89084925|NCT06330077|Experimental|Ifenprodil|Ifenprodil : 20mg three time a day (60mg/day). Patients will have an escalation of dose over 48 hours (from Day 1) in order to achieve at the end of the 144 hours (6 days, Day 6) a dose of 60mg/day.
89084926|NCT06330077|Placebo Comparator|Placebo|Placebo of ifenprodil : 20mg three time a day (60mg/day). Patients will have an escalation of dose over 48 hours (from Day 1) in order to achieve at the end of the 144 hours (6 days, Day 6) a dose of 60mg/day.
89084927|NCT06330064|Experimental|Cohort 1: Endometrial Cancer|Participants with recurrent or metastatic endometrial cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
89084928|NCT06330064|Experimental|Cohort 2: Head and Neck Squamous Cell Carcinoma|Participants with recurrent or metastatic head and neck squamous carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
88812852|NCT01654302|Active Comparator|Synera|lidocaine/tetracaine patch with heating component which consists of iron powder, activated carbon, sodium chloride, wood flour, water and filter paper.
89084929|NCT06330064|Experimental|Cohort 3: Pancreatic Ductal Adenocarcinoma|Participants with recurrent or metastatic pancreatic ductal adenocarcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
89084930|NCT06330064|Experimental|Cohort 4: Colorectal Cancer|Participants with recurrent or metastatic colorectal cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
89084931|NCT06330064|Experimental|Cohort 5: Hepatocellular Carcinoma|Participants with recurrent or metastatic hepatocellular carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
89084932|NCT06330064|Experimental|Cohort 6: Adenocarcinoma of esophagus, gastroesophageal junction, and stomach|Participants with recurrent or metastatic adenocarcinoma of esophagus, gastroesophageal junction, and stomach who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
89084933|NCT06330064|Experimental|Cohort 7: Non-squamous non-small cell lung cancer|Participants with recurrent or metastatic non-squamous non-small cell lung cancer who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
89084934|NCT06330064|Experimental|Cohort 8: Urothelial carcinoma|Participants with recurrent or metastatic urothelial carcinoma who were previously treated with 1 or more systemic therapy who received an intravenous infusion of I-DXd 12 mg/kg.
89084935|NCT06330051|Experimental|Improvement intervention|receive the following continuous improvement intervention for 6 months
89084936|NCT06330051|No Intervention|Control group|Only information will be collected.
89084939|NCT06330012|Experimental|Spatial transcriptomic approch|Spatial transcriptomic approch for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
89084940|NCT06329999|Experimental|CMGV regime|Mitoxantrone liposomes，Cytarabine，G-CSF，Venetoclax
89084941|NCT06329986|Experimental|Group A|TAMER lenses are used first for 6 months, followed by SV lenses for 6 months.
89084942|NCT06329986|Experimental|Group B|SV lenses are used first for 6 months, followed by TAMER lenses for 6 months.
89084943|NCT06329973|Experimental|Fruquintinib in combination with Sintilimab and CAPEOX|
89084945|NCT06329947|Experimental|Experimental group|Surufatinib in combination with selpalimab and mFOLFOX6
89084946|NCT06329934|Experimental|the intervention group|Establishment of a hierarchical monitoring and management team, Assessment of pressure injury, Communication, Intervention for pressure ulcer, Rehabilitation training
89084947|NCT06329934|Active Comparator|the control group|timely introduction of the current patient's condition to family members to alleviate their concerns, maintaining appropriate temperature (20 ℃~22 ℃) and humidity (60.0%~70.0%) in the ward, careful observation of vital signs such as heart rate, blood oxygen saturation, and blood pressure in patients, rehabilitation training
89084948|NCT06329921|Active Comparator|Active Comparator: PTT protocol|Patients randomized to this arm will be monitored using the nurse-managed PTT guided protocol. This includes patients on both high- and low-dose heparin protocols.
89084949|NCT06329921|Active Comparator|Active Comparator: anti-Xa protocol|Patients randomized to this arm will be monitored using the pharmacy-managed anti-Xa protocol. This includes patients on both high- and low-dose heparin protocols.
89084950|NCT06329908|Experimental|(Neo-DCVac) combined with immune checkpoint inhibitors (ICIs)|DC cell injection ,1.5 × 10 7/time, subcutaneous multi-point injection in axilla and groin or lymph node injection guided by color Doppler ultrasound in axilla and groin, continuous injection at 0W, 1W, 3W, 5W and 7W for five times as the first immunization cycle. Tumor response was evaluated 2 weeks after the completion of the first immunotherapy cycle, and treatment was continued if the response was evaluated as effective (SD/PR/CR), and every 3 weeks until disease progression or intolerable toxicity or active withdrawal of the patient, whichever came first.ICIs are PD1/PD-L1 inhibitors and continue to be pre-enrollment ICIs of any brand
89084951|NCT06329895|Experimental|Healthy volunteers|"The healthy volunteers will be confined to the clinic throughout the Intervention Period of the study.~The study includes visits during Screening, Intervention, and Follow-up."
89084952|NCT06329882|Active Comparator|control group|patients were on sitagliptin 100mg /day monotherapy
89084953|NCT06329882|Active Comparator|Comparative group|patients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg
89084954|NCT06329869|Experimental|Sacituzumab govitecan|
89084955|NCT06329856||members of the Taiwan Academy of Hospice Palliative Medicine|members of the Taiwan Academy of Hospice Palliative Medicine
89084956|NCT06329856||members of the Taiwan Society of Cancer Palliative Medicine|members of the Taiwan Society of Cancer Palliative Medicine
89084957|NCT06329843||Term-born babies & preterm born babies|"We will collect 300 paired (serum bilirubin and Picterus Jaundice Pro) measurements on eligible neonates >35 weeks' gestation admitted to a well-baby nursery. Of these, 150 paired measurements will be from neonates who have already received phototherapy (either on phototherapy or status/post phototherapy) and had a light-occlusive adhesive skin patch in place. Each subject >35 weeks gestation can have up to 5 measurements during the study.~We will collect 200 paired (serum bilirubin and Picterus) measurements on eligible neonates <35 weeks gestation. Of these, 100 paired measurements will be from neonates who have already received phototherapy (either on phototherapy or status/post phototherapy) and had a light-occlusive adhesive skin patch in place. Each subject <35 weeks gestation can have up to 5 measurements during the study."
89522950|NCT03797911|Placebo Comparator|Inactive resistive capacitive monopolar radiofrequency|"Application of the technique in the control group (inactivated resistive capacitive monopolar radiofrequency therapy): The control group will receive the treatment with inactivated resistive capacitive monopolar radiofrequency system (placebo), with the resistive electrode at the minimum intensity, together with the techniques of conventional physiotherapy treatment (trigger point treatment and myofascial techniques according to the location of pain) and pain education.~The patient will be stretched on the stretcher and the session will last 45 minutes, once a week, for 10 sessions. Ass baseline, after half therapy and after 10 weeks therapy."
89084959|NCT06329817|Experimental|Supine position|
89084960|NCT06329817|Experimental|Semi- fowler position|
89084961|NCT06329804|No Intervention|No Intervention Control|Participants allocated to this group will maintain their usual lifestyle for 4-weeks
89084962|NCT06329804|Experimental|Two Sessions/Week|Participants allocated to this group will complete 4-weeks of isometric handgrip exercise training with a frequency of two sessions/week
89084963|NCT06329804|Active Comparator|Four Sessions/Week|Participants allocated to this group will complete 4-weeks of isometric handgrip exercise training with a frequency of four sessions/week
89522951|NCT03393065|Experimental|intervention group pulmonary congestion|in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.
89522952|NCT03393065|No Intervention|Control group|control group the fluid management will not be LUS guided
89084966|NCT06329778||HBCC providers (no observation)|This group will include 100 purposively selected providers from diverse backgrounds who will each complete the provider questionnaire and will also be asked to recruit one or more families to complete the family survey.
89084967|NCT06329778||HBCC providers (observation)|This group will include 50 purposively selected providers from diverse backgrounds who will each complete the provider questionnaire, be asked to recruit one or more families to complete the family survey, and agree to have their child care setting observed by a field staff member.
89084968|NCT06329778||Families|This group will include up to 166 purposively selected families who will each receive the family survey.
89084969|NCT06329765|Experimental|Exercise with CUped|Participants will exercise with CUped (a motor-assisted, split crank pedaling device) and undergo 50 m of gait training. CUped comprises a left and right pedal; each is attached to the shaft of a motor. There is no mechanical connection between pedals. Participant's feet are secured to the pedals. They are asked to pedal forward and keep the legs 180° out-of-phase. The position of the left and right cranks is monitored. When the phase relationship is not maintained, motors provide torque to assist the lagging limb and resist the leading limb. Motors are under feedback control. Torque is proportional to the magnitude and sign of the error.
89084970|NCT06329752|Experimental|Sciatic Nerve block Arm (Single Arm)|
89084971|NCT06329739||Experimental group|Parkinson's Disease patients with genetic mutation
89084972|NCT06329739||Control group|Parkinson's Disease patients without genetic mutation
89084973|NCT06329726||PD - undergone DBS|Patients with Parkinson's disease treated with DBS of the subthalamic nucleus
89084974|NCT06329726||PD - not undergone DBS|Patients with Parkinson's disease not treated with DBS
89084975|NCT06329713|Active Comparator|Group I|"The patients will be given 10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether. Level of sensory block will be tested by testing with ice from S2 dermatome cephally.~Analgesia will be maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of 0,0625% of bupivacaine and 2 mcg/ml fentanyl every 30 minutes, starting 1 hour after the loading dose. In addition, patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minutes may be administered. Breakthrough pain that requires even further analgesia will be treated with an epidural bolus of 10 ml of 0,1% bupivacain solution."
89084976|NCT06329713|Active Comparator|Group 2|"The patients will be given 10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether. Level of sensory block will be tested by testing with ice from S2 dermatome cephally.~Analgesia will be maintained by programmed intermittant epidural boluses of 15 ml of 0,0625% of bupivacaine and 2 mcg/ml fentanyl once in every hour, starting 1 hour after the loading dose. In addition, patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minutes may be administered. Breakthrough pain that requires even further analgesia will be treated with an epidural bolus of 10 ml of 0,1% bupivacain solution."
89084977|NCT06329700||No post-chemotherapy liver atrophy|Patients treated with systemic chemotherapy, then hepatectomy for colorectal liver metastases. No occurrence of post-chemotherapy liver atrophy as measured by computed-tomography liver volumetry.
89084978|NCT06329700||Yes post-chemotherapy liver atrophy|Patients treated with systemic chemotherapy, then hepatectomy for colorectal liver metastases. Yes, occurrence of post-chemotherapy liver atrophy as measured by computed-tomography liver volumetry.
89084979|NCT06329687|Experimental|Nasal Pump|Tyrvaya nasal pump with additional silicone lubricant
89084980|NCT06329674|Experimental|AJU-A51+A51R2 placebo+A51R3|
89084981|NCT06329674|Experimental|AJU-A51 placebo+A51R2+A51R3|
89084984|NCT06329635|Experimental|Intrathecal Treatment Group|The participants in the IT treatment group will be treated with intrathecal nicardipine injection through EVD or LP draining catheter.
89084985|NCT06329635|Sham Comparator|Control Group|The participants of the control group will receive no intrathecal nicardipine injection through EVD or LP draining catheter.
89084986|NCT06329622|Experimental|Intervention|In the intervention group, low-protein diet (0.6g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 30kcal/kg body weight/day. The intervention will last for 6 months. Then,during the subsequent 3-month observation period, the patients maintain a low-protein diet (0.6g protein/kg body weight/day) with the target energy intake of 30kcal/kg body weight/day.
89084987|NCT06329622|Active Comparator|Control|In the control group, low-protein diet (0.6g protein/kg body weight/day) and the target energy intake of 30kcal/kg body weight/day will be prescribed for 9 months
89084988|NCT06329609|Experimental|Intervention|This arm will receive the study intervention
89084989|NCT06329596|Experimental|Xylitol gum|Participants will receive 6.36grams of daily xylitol; Epic dental gum, 1.06 grams Xylitol per piece of gum; to chew two pieces for 10 minutes after meals, thrice a day.
89084990|NCT06329596|Placebo Comparator|Sorbitol gum|Participants will receive Epic sorbitol-containing gum (0 grams xylitol/day); to chew two pieces for 10 minutes after meals, thrice a day.
89084991|NCT06329583|Other|Diaphragmatic breathing protocol|All patients will undergo the diaphragmatic breathing protocol with high-resolution esophageal manometry.
89084992|NCT06329557|Active Comparator|Survey and Coaching|Individual coaching with a trained patient experience professional (XTEC coach) will occur individually with clinicians 3-4 times over several weeks. The coach will assist participants with improving communication with patients.
89084993|NCT06329557|Active Comparator|Survey and Communication Class|A one-hour communication class will take place during the workday. The class will be offered virtually or in person for a group of clinicians to attend.
89084994|NCT06329557|No Intervention|No Intervention|Surveys only
89084995|NCT06329544|Experimental|Fructose Dietary then Glucose Dietary|Participants that will be randomized to the 12-day isocaloric weight-maintaining high fructose diet, then will change to the 12-day isocaloric weight-maintaining high glucose diet after a 10-day washout period.
89084996|NCT06329544|Experimental|Glucose Dietary then Fructose Dietary|Participants that will be randomized to the 12-day isocaloric weight-maintaining high glucose diet, then will change to the12-day isocaloric weight-maintaining high fructose diet after a 10-day washout period.
88812853|NCT01654302|Placebo Comparator|Inactive Patch|placebo patch identical in appearance and composition (namely, the heating components) to the active patch other than lacking the lidocaine and tetracaine active ingredients.
89084998|NCT06329518|Experimental|Rezafungin|Participants will receive one dose of rezafungin as per current prescribing information.
89084999|NCT06329492|Experimental|Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)|Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) is produced by filtering Platelet Poor Plasma (PPP), a Platelet Rich Plasma byproduct, through a hemoconcentrator filter. (PPP) is frequently used in clinical practice to increase volume of PRP or Bone Marror Aspirate Concentrate (BMAC) injectate, and it is occasionally injected in isolation for some indication
89085000|NCT06329479|Experimental|Multi-modal intervention|Single arm study receiving a multi-modal intervention
89085001|NCT06329466||Observation|"Before starting the application to the adolescents in the study (EFT) group, researcher G.C. Fast and easy application steps will be explained with the demonstration method, supported by visual presentations.~Care will be taken to provide a suitable, clean and airy environment in which the participants will feel comfortable. EFT training and applications will be held during the lunch break so that students do not experience problems such as being late for class or absenteeism. It will be taught in groups of 10-11 people in order to be sure that each participant has learned and to easily confirm the accuracy of the application. Researcher G.C. The participants will be asked to do it to themselves at the same time while they are doing it on themselves to teach the hitting points and application principles."
89085002|NCT06329466||Control|Students in the control group will not receive any intervention during the EFT application. Participants in the control group will have the MAÖKF and MSQ filled before the first session, at the end of the third cycle and at the end of the fourth cycle without the application. In order to eliminate ethical problems that may occur in the control group, EFT application will be taught to the participants in this group after the data collection process of the research is completed.
89085003|NCT06329453||Healthy Individuals|
89085004|NCT06329453||Individuals with neurologic diseases|
89085005|NCT06329453||Individuals with known or suspected autoimmune diseases|
89522953|NCT03388255|Experimental|Polydeoxyribonucleotides|"PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~Follow up period: 3 months after end of active treatment, without study medication."
89522954|NCT03390127|Experimental|Group P|After LMA Supreme™ insertion, PEEP of 7 cmH2O would apply during general anesthesia with mechanical ventilation.
89085010|NCT06329388|Experimental|Treatment - Oral Protein Supplement|Participants in this arm will receive the TruHeight Growth Protein Shake. Each serving consists of two scoops of the supplement powder mixed with 12-16 fluid ounces of water. The regimen is once daily, five times per week, for a duration of six months.
89085011|NCT06329388|No Intervention|Control - No Supplement|Participants in this arm will not receive the oral protein supplement but will continue their regular diet. They serve as a comparison group to evaluate the effects of the TruHeight Growth Protein Shake administered to the treatment group.
89085012|NCT06329362|Active Comparator|Minimal Invasive Implant ridge splitting|Using minimally invasive implant placement in atrophied ridge without mucoperiosteal flap, and specially designed implant shaped expanders.
89085013|NCT06329362|Active Comparator|conventional open flap ridge splitting implantation.|Using the conventional open flap technique with mucoperiosteal elevation to expose the ridge with the use of conventional bone expanders and chisels.
89085014|NCT06329323||Cases- Malignant Ovarian Germ Cell Tumour - Arm 1|Patients with a diagnosis of stage 1a MOGCT. Bloods taken at the following time points: Day 0, then 4 weeks; 6 months; 12 months; 24 months post-operatively
89085015|NCT06329323||Cases - Malignant Ovarian Germ Cell Tumour - Arm 2|Patients with a diagnosis of stage 1b/1c MOGCT. Bloods taken at the following time points: Day 0, then 4 weeks; 6 months; 12 months; 24 months post-operatively OR post-final dose of adjuvant chemotherapy
89085016|NCT06329323||Cases - Malignant Ovarian Germ Cell Tumour - Arm 3|Patients with a diagnosis of stage 2 or higher MOGCT. Bloods taken at the following time points: Day 0, then 4 weeks post-neoadjuvant chemotherapy, then 4 weeks; 6 months; 12 months; 24 months post-operatively
89085017|NCT06329323||Controls - Benign Ovarian Germ Cell Tumour|Bloods taken at the time of diagnosis of BOGCT (single blood test)
89085018|NCT06329323||Controls - No Known Gynaecological Pathology|Single blood test
89085019|NCT06329284|Other|Serum Midkine|
89085022|NCT06328790||Functional Motor Disorder rehabilitation group (FMD)|Patients with FMD (subject to current diagnostic criteria) will undergo experiment 3.
89085023|NCT06328790||Healthy Controls group (HC)|Healthy subjects at least 18 years old will undergo experiment 1.
89085024|NCT06328790||"Organic Motor Disorders group"|"Patients with organic motor disorders (weakness due to peripheral neuromuscular disorders, essential tremor, or idiopathic adult-onset dystonia, all according to current diagnostic criteria) will undergo experiment 2."
89085025|NCT06328790||Functional Motor Disorder group (FMD)|Patients with FMD (subject to current diagnostic criteria) will undergo experiment 1.
89085026|NCT06328738|Experimental|Part 1: ELVN-002 + trastuzumab dose escalation|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
89085027|NCT06328738|Experimental|Part 2A: ELVN-002 + trastuzumab + CAPEOX dose escalation in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on days 1 - 14 of a 21-day cycle. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1 of a 21-day cycle.
89225818|NCT05236062|Experimental|Exercise Group|"Home-based, virtually supervised via Zoom, 3x weekly for 12-weeks aerobic and resistance exercise program~Participants will also undergo four testing visits across 6-month period. Tests will include four blood draws and three body composition scans via a dual-energy x-ray absorptiometry (DXA)."
89225819|NCT05236062|Experimental|Attention control Group|"Home-based, 12-week stretching program only with participants asked not to change their activity behavior.~Participants will also undergo four testing visits across 6-month period. Tests will include four blood draws and three body composition scans via a dual-energy x-ray absorptiometry (DXA)."
89522955|NCT03390127|No Intervention|Group Z|After LMA Supreme™ insertion, PEEP would not apply during general anesthesia with mechanical ventilation.
89522956|NCT03392909|Experimental|Intravenous Gentamicin|Intravenous gentamicin (7.5 mgs/kg) daily for for either 14 days and then stopped or twice weekly for three months and then stopped.
89522957|NCT03388177|Experimental|Treatment as usual + Yoga-based therapy|The yoga-based therapy (YBT) group will receive YBT in addition to treatment-as-usual (TAU). YBT will be administered with a manualized protocol and delivered in a group format consisting of nine weekly sessions of 1,5 hours. Group sessions consist of hatha yoga practices of physical postures, breathing practices, and meditation. Each session has a different theme. The practices will primarily consist of yoga exercises (80%) and meditation (e.g., breathing practices) (20%). Between sessions, participants complete an online module with additional psychoeducation and a practice video to encourage home practice for 30-45 minutes a day. YBT will be delivered by a psychologist who is also a trained yoga teacher.
89522958|NCT03388177|Other|Treatment as usual|The treatment as usual (TAU)-only condition will consist of interventions recommended by the Dutch guidelines for depression. These include the combination of pharmacotherapy (antidepressant medications) and psychotherapy (e.g., cognitive behavioral therapy [CBT], interpersonal psychotherapy). Lentis mental health clinicians will administer TAU. In order to improve ability to interpret study results, the investigators will record frequency, content (e.g., cognitive restructuring), format (group versus individual), and intensity of contact within TAU. Such quantification of TAU will allow us to address alternative explanations (e.g., contact time) in the case of positive results for YBT.
89522959|NCT03392831|Experimental|Peripherally inserted central catheter|The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
89522960|NCT03392831|Active Comparator|Central venous catheter|The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
89522961|NCT05239273|Experimental|Complex Decongestive Therapy (CDT) Group|Phase 1 of CDT will be applied to CDT group. This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue 5 days a week for 3 weeks.
89522962|NCT05239273|Other|Control group|Waiting list will included in control group.
89085028|NCT06328738|Experimental|Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously in 14-day cycles, 4 mg/kg IV cycle 1, day 2 followed by 2 mg/kg IV cycle 1, day 8, 4mg/kg IV cycle 1, day 15, and then one dose of 4 mg/kg every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on day 1 and 15 of a 28-day cycle.
89085029|NCT06328738|Experimental|Part 2C: ELVN-002 + trastuzumab + capecitabine dose escalation in breast cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1250 mg/m2 on days 1 - 14 of a 21-day cycle.
89085030|NCT06328738|Experimental|Part 2D: ELVN-002 + trastuzumab + paclitaxel dose escalation in breast cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Paclitaxel will be administered intravenously at 80 mg/m2 on days 1, 8, and 15 of a 21-day cycle.
89085031|NCT06328738|Experimental|Part 2E: ELVN-002 + trastuzumab + eribulin dose escalation in breast cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Eribulin will be administered intravenously at 1.4 mg/m2 on days 1 and 8 of a 21-day cycle.
89085032|NCT06328738|Experimental|Part 3A: ELVN-002 + trastuzumab dose expansion in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+
89085033|NCT06328738|Experimental|Part 3B: ELVN-002 + trastuzumab dose expansion in breast cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
89085034|NCT06328738|Experimental|Part 3C: ELVN-002 + trastuzumab dose expansion in other solid tumor type 1|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
89085035|NCT06328738|Experimental|Part 3D: ELVN-002 + trastuzumab dose expansion in other solid tumor type 2|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
89085036|NCT06328738|Experimental|Part 3E: ELVN-002 + trastuzumab dose expansion in other solid tumor type 3|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.
89225820|NCT05233774|Placebo Comparator|Placebo|Group 1 will receive four infusions of Placebo on Day 0, Week 4, Week 8, and Week 12.
89522963|NCT03125759||Control|patients without any history of stroke
89085037|NCT06328738|Experimental|Part 4A: ELVN-002 + trastuzumab + CAPEOX dose expansion in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on Days 1 - 14 of a 21-day cycle. Oxaliplatin: will be administered intravenously at 130 mg/m2 on Day 1 of a 21-day cycle.
89085038|NCT06328738|Experimental|Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer|ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously in 14-day cycles, 4 mg/kg IV cycle 1, day 2 followed by 2 mg/kg IV cycle 1, day 8, 4mg/kg IV cycle 1, day 15, and then one dose of 4 mg/kg every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on days 1 and 15 of a 28-day cycle.
89085039|NCT06328374||Healthy community dwelling adults|Healthy adults between the ages of 60-100 with no prior history of neurological, respiratory, or gastrointestinal diseases or swallowing or voice impairments, or history of head and neck surgery, cancer, or radiation to the head or neck will be enrolled in this study.
89085040|NCT06328374||Adults with Alzheimer's Disease and their caregivers|Adults with a diagnosis of Alzheimer's disease and their caregivers will be enrolled in this study.
89085041|NCT06327685|Experimental|Dose Escalation|"Participants will be enrolled in cohorts of size 1-3. Participants will take a combination of Avapritinib and Decitabine. Decitabine will be administered in one of the following forms: I) Decitabine: starting IV dose of 20 mg/m2 on days 1-5 of a 28-day treatment cycle. II) Decitabine/Cedazuridine: starting dose of 35mg/100 mg oral tablet on days 1-5 of a 28-day treatment cycle. The starting dose of Avapritinib for the first cohort of patients will begin at dose level 1 with dose modifications to be made according to a Bayesian design.~Avapritnib Dose levels Level -1: 50mg Level 1: 100mg Level 2: 150mg Level 3: 200mg"
89085042|NCT06327685|Experimental|Dose Expansion|Participants with baseline platelet count (cycle 1, day 1) ≥ 75 x 10^9/L will begin the combination of Avapritinib at the dose determined by the dose-finding portion of the study and decitabine or Decitabine/Cedazuridine will be initiated during the first cycle. Participants with a baseline platelet count between 25 x 10^9/L and 74 x 10^9/L will receive decitabine or Decitabine/Cedazuridine (choice of investigator) as a single-agent for at least the first two cycles. Starting with cycle 3 and continuing with each subsequent cycle, patients will be eligible to receive Avapritinib in combination with decitabine or Decitabine/Cedazuridine if the platelet count on day 1 of the cycle is ≥ 75 x 10^9. If the platelet count is < 75 x 10^9/L on day 1 of the cycle, patient will receive single-agent Decitabine or Decitabine/Cedazuridine. In the absence of clear disease progression, patients will be treated for at least 6 cycles before being judged to have not responded.
89085043|NCT06327659|Active Comparator|Group I|
89085044|NCT06327659|Experimental|Group II|
89085045|NCT06327633|Experimental|Olfactory Training Group|The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 5-min per time, with focus, until the completion of the study. Meanwhile, all patients will also continue on their existing dose and regimen of glucose- lowering schemes throughout the study. Visits at 3-week intervals will be performed to evaluate the blood glucose situation, assess the safety of intervention and confirm the compliance of participants.
89085046|NCT06327633|No Intervention|Control Group|The subjects will maintain the original diet and lifestyle, and also continue on their existing dose and regimen of glucose- lowering schemes throughout the study. Visits at 3-week intervals will be performed to evaluate the blood glucose situation.
89085047|NCT06327568||Case patients|Histological-confirmed high-grade anal intraepithelial neoplasia (AIN2+ and 3+) and invasive cancer; patients with macroscopic anal lesion.
89085048|NCT06327568||Control patients|Histological-confirmed low-grade anal intraepithelial neoplasia (AIN1), and subjects at high-risk for anal cancers, including: Immunocompromised subjects (patients with HIV infection, or taking immunosuppressive drugs, or post-organ transplantation); Men who have sex with men (MSM); Women aged at least 40 years with a history of CIN2+ and/or vulvar cancer; Subjects affected by anal and/or peri-anal localizations of Crohn's disease.
89085049|NCT06327542|No Intervention|Usual Care|Participants will receive care as usual provided through their primary care providers. Usual care includes medical diagnostic evaluation, analgesic drug therapies, recommendations for physical activity, and sometimes referral to specialist physicians or physical therapy. Usual care was chosen as a comparison arm for this study because it is practical and clinically relevant. Participants randomized to usual care will be put on a waitlist and can access group acupuncture or IGMV after their final study visit.
89085050|NCT06327542|Experimental|Group Acupuncture|Participants randomized to acupuncture will receive 12 weeks of acupuncture treatments delivered in a group setting, dosing similar to prior research. Acupuncture point selection and other treatment details will follow responsive manualization, a protocol developed for the largest clinical trial of group acupuncture to date. A licensed acupuncturist experienced with administering group acupuncture treatments will determine each participant's traditional Chinese medicine diagnosis and administer 8-10 acupuncture needles on distal points of participant's body (below the knees, from the elbows to the hands, and on the head). Duration of assessment, needle placement and retention will be 30-45 minutes. Details of acupuncture treatments (e.g., frequency and duration, traditional Chinese medicine diagnosis, number of needles and points used) will be documented in electronic health records.
89085051|NCT06327542|Experimental|Integrative Group Medical Visits (IGMV)|IGMV will consist of a 12-week program that provides education on the biopsychosocial model of pain and multimodal treatments; physical movement; mindfulness training; and peer support. Non-pharmacologic approaches are based on guidelines on chronic pain management; feedback of experts, staff, and patients; and feasibility with the greatest potential to benefit participants. Participants will receive a binder with educational materials.
89085052|NCT06327542|Experimental|Group Acupuncture and IGMV|Both group acupuncture and IGMV. Along with usual care, participants will be offered weekly group acupuncture treatments and integrative group medical visits as described above.
89085053|NCT06327529|Experimental|Bean Variety 1|Enriched with Zinc-67, Iron-57
89085054|NCT06327529|Experimental|Bean Variety 2|Enriched with Zinc-70, Iron-58
89085055|NCT06327529|Experimental|Bean Variety 3|Enriched with Zinc-67, Iron-57
89085056|NCT06327529|Experimental|Bean Variety 4|Enriched with Zinc-70, Iron-58
89085057|NCT06327360||Patients with Pulmonary Fibrosis at the Don Gnocchi Foundation (Milan)|42 patients
89085058|NCT06327360||Patients with Pulmonary Fibrosis at the Policlinico (Milano)|42
89085059|NCT06327360||Patients with Pulmonary Fibrosis at the FIMARP ONLUS|46
89085060|NCT06327152|Active Comparator|Caffeine Group|Infants randomized to receive caffeine will continue to receive caffeine at standard of care maintenance dose of 10-15 mg/kg/day given every 24 hours. The dose will be weight adjusted every 7 days, starting on the day of enrollment. Caffeine will be given enterally, via nasogastric tube or by mouth.
89085061|NCT06327152|Placebo Comparator|Placebo Group|Infants randomized to the placebo group will be given sterile water at an equivalent volume to the volume if caffeine were to be given, using the previous weight-based caffeine dose. The placebo will be given every 24 hours. The dose/volume will be weight adjusted every 7 days, starting on the day of enrollment. The placebo will be given enterally, via nasogastric tube or by mouth.
89085064|NCT06326866||Individuals with A Rh (+) blood group|Individuals with normal hearing and whose blood group was previously determined as A Rh (+) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
89085065|NCT06326866||Individuals with A Rh (-) blood group|Individuals with normal hearing and whose blood group was previously determined as A Rh (-) will be included and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
89085066|NCT06326866||Individuals with B Rh (+) blood group|Individuals with normal hearing and whose blood group was previously determined as B Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
89085067|NCT06326866||Individuals with B Rh (-) blood group|Individuals with normal hearing and whose blood group was previously determined as B Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
89085068|NCT06326866||Individuals with AB Rh (+) blood group|Individuals with normal hearing and whose blood group was previously determined as AB Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
89085069|NCT06326866||Individuals with AB Rh (-) blood group|Individuals with normal hearing and whose blood group was previously determined as AB Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
89085070|NCT06326866||Individuals with O Rh (+) blood group|Individuals with normal hearing and whose blood group was previously determined as O Rh (+) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
89085071|NCT06326866||Individuals with O Rh (-) blood group|Individuals with normal hearing and whose blood group was previously determined as O Rh (-) will be included and and Transient evoked Otoacoustic Emissions (TOAE) and Distortion Product Otoacoustic Emissions (DPOAE) will be performed.
89522964|NCT03125759||Ischemic Stroke|patients with an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction within 72 hours.
89522965|NCT02731157|Experimental|Transfusion with rejuvenated red blood cells (RBCs)|Subjects with sickle cell disease will receive RBCs treated with Rejuvesol®. Scheduled red cell exchanges performed with the last 4 units of the exchange having been incubated with Rejuvesol® solution. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
89522966|NCT02731157|Active Comparator|Transfusion with standard red blood cells|Subjects with sickle cell disease will receive standard RBCs. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
89085075|NCT06326489|Experimental|780G|Patients in this arm will receive a 780G for three months.
89085076|NCT06325943|Active Comparator|Treatment arm|"Rituximab~Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6"
89085077|NCT06325943|Placebo Comparator|Placebo arm|"Placebo~Patients will receive two doses of placebo at two-week interval and one dose of placebo at month 6"
89225821|NCT05233774|Experimental|Lomecel-B Dose 1|Group 2 will receive an infusion of Lomecel-B at a dose of 25 x 10^6 cells (25M) on Day 0, followed by Placebo infusions at Week 4, Week 8, and Week 12.
89522967|NCT03387995||Anterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
89522968|NCT03387995||Middle cerebral artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
89522969|NCT03387995||Posterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
89522970|NCT03387995||Internal carotid artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
89085079|NCT06325878|Experimental|Chronic inflammatory demyelinating polyneuropathy (CIDP)|Single nucleotide polymorphisms (SNPs) of 1000 patients with chronic inflammatory demyelinating polyneuropathy will be genotyped using the Illumina Global Screening Array
89085080|NCT06325878|Experimental|Control Subjects|Single nucleotide polymorphisms (SNPs) of 2500 control subjects without chronic inflammatory demyelinating polyneuropathy will be genotyped using the Illumina Global Screening Array
89085081|NCT06325826||Group 1|
89085086|NCT06325514||normal/variations of normal anatomical landmarks|patients that have normal oral findings or variations of normal anatomical landmarks such as: leukoedema, fordyce granules, linea alba, physiological pigmentations, torus palatinus, torus mandibularis, geographic tongue, fissured tongue
89085087|NCT06325514||low risk referral|patients that needs referral for a low risk of malignant transformation disease, such as: hemangiomas, fibromas, oral apthous ulcers, candidal infections, pemphigus valgaris, petechiae, frictional keratosis, smokers' melanosis.
89085088|NCT06325514||high risk referral|patients that needs referral for a high risk of malignancy or a premalignant disease, such as: oral lichen planus, leukoplakia, erythroplakia, squamous cell carcinoma.
89085089|NCT06325423||MIBC patients who received NAC|Patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy before radical cystectomy or bladder preservation
89085090|NCT06325202|Experimental|current HCL non-user: HCL x 24 months|Hybrid closed loop device over a 24-month period for individuals currently not using a hybrid closed loop device
89085091|NCT06325202|Experimental|current HCL non-user: HCL x 12 months, then HCL x an additional 12 months|Hybrid closed loop device over a 12-month period for individuals currently not using a hybrid closed loop device, and then a hybrid closed loop device for an additional 12 months
89085092|NCT06325202|Experimental|current HCL non-user: HCL x 12 months, then HCL + HARPdoc x 12 months|Hybrid closed loop device over a 12-month period for individuals currently not using a hybrid closed loop device, then a hybrid closed loop device plus HARPdoc education for an additional 12 months
89085093|NCT06325202|Active Comparator|current HCL non-user: Usual Care and My HypoCOMPaSS x 12 months, then HCL x 12 months|Usual Care and My HypoCOMPaSS education over 12 months for individuals currently not using a hybrid closed loop device, then hybrid closed loop device for 12 months
89085094|NCT06325202|Active Comparator|current HCL non-user: Usual Care and My HypoCOMPaSS x 24 months|Usual Care and My HypoCOMPaSS education over 24 months for individuals currently not using a hybrid closed loop device
89085095|NCT06325202|Experimental|current HCL user: HCL x 24 months|Hybrid closed loop device over a 24-month period for individuals currently using a hybrid closed loop device
89085096|NCT06325202|Experimental|current HCL user: HCL x 12 months, then HCL x an additional 12 months|Hybrid closed loop device over a 12-month period for individuals currently using a hybrid closed loop device, and then a hybrid closed loop device for an additional 12 months
89085097|NCT06325202|Experimental|current HCL user: HCL x 12 months, then HCL + HARPdoc x 12 months|Hybrid closed loop device over a 12-month period for individuals currently using a hybrid closed loop device, then a hybrid closed loop device plus HARPdoc education for an additional 12 months
89085098|NCT06325202|Active Comparator|current HCL user: HCL and My HypoCOMPaSS x 12 months, then HCL x 12 months|Hybrid closed loop device and My HypoCOMPaSS education over 12 months for individuals currently using a hybrid closed loop device, then hybrid closed loop device for 12 months
89085099|NCT06325202|Active Comparator|current HCL user: HCL + My HypoCOMPaSS x 12 months, then HCL + My HypoCOMPaSS + HARPDOC x 12 months|Hybrid closed loop device and My HypoCOMPaSS education over 12 months for individuals currently using a hybrid closed loop device, then hybrid closed loop device plus My HypoCOMPaSS eduction + HARPdoc education for 12 months
89085100|NCT06325202|Experimental|current HCL user: HCL + My HypoCOMPaSS x 24 months|Hybrid closed loop device plus My HypoCOMPaSS education over a 24-month period for individuals currently using a hybrid closed loop device
89085101|NCT06324448|Experimental|Primary motor cortex|The anodal electrode is positioned in the primary motor cortex (Cz) and the cathodal electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
89085102|NCT06324448|Experimental|Left dorsolateral prefrontal cortex|The anodal electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathodal electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
89085103|NCT06324292|Active Comparator|conventional denture followed by a digital one|the participants will receive a conventional complete denture followed by a digital one having digital smile design
89085104|NCT06324292|Active Comparator|Digital denture followed by a conventional one|the participants will receive a digital complete denture having digital smile design followed by a conventional one
89085105|NCT06322758|Experimental|ΔP-guided VT group|During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
89085106|NCT06322758|Active Comparator|PBW-guided VT group|The VT will be kept at 6 mL/kg of PBW. If the plateau pressure threshold is reached (30 cm H2O), the VT will be decreased down to a minimal value of 4 mL/kg of PBW.
89085107|NCT06322732||Newborn at or near term|Newborn at or near term (≥ 36 weeks of amenorrhea), considered to be alive at the onset of labor and presenting severe perinatal asphyxia
89085108|NCT06322602|Experimental|Ommaya reservoir placement|Patients undergo Ommaya reservoir placement during standard of care biopsy. Patients then undergo extraction of CSF while on study. Patients may also undergo lumbar puncture while on study. Patients also undergo CT on study.
89085109|NCT06315023||As Treated|All patients that have received the therapy; patients treated within and outside the IFU criteria subgroups; male and female subgroups; and duplex imaging subgroups for arterial and venous observations.
89085110|NCT06315023||Imaging Cohort|Sites that are performing (arterial and venous) duplex ultrasound assessments according to the institution's standard practice will be asked to participate in the DUS imaging cohort. The Imaging sub-study will consist of 55 female and 55 male subjects from these sites. Duplex imaging at 1-, 12-, 24-, and 36-months post-procedure will be collected to assess the endpoints of graft patency and venous thrombus within the vein containing the graft (n=110).
89085111|NCT06314620|Active Comparator|Participants who underwent ICC with normal saline flushing and heparin lock|Participants who underwent intercostal chest catheter with normal saline flushing with heparin lock. Instillation done with 20 mls of Normal Saline flush followed by heparin saline lock, every 6 hours by a three way stopcock.
89225822|NCT05233774|Experimental|Lomecel-B Dose 2|Group 3 will receive four infusions of 25M Lomecel-B on Day 0, Week 4, Week 8, and Week 12.
89225823|NCT05233774|Experimental|Lomecel-B Dose 3|Group 4 will receive four infusions of Lomecel-B at a dose of 100 x 10^6 cells (100M) on Day 0, Week 4, Week 8, and Week 12.
89225824|NCT05233189|Experimental|"With the MOOC Childhood cancer, living well, after"|Quantify the impact of the MOOC's membership on the CCS knowledge about LTFU adapted to the medical history of patients and measure how this MOOC can improve the LTFU care of each CCS.
89225825|NCT05233189|Active Comparator|"Without the MOOC Childhood cancer, living well, after"|Quantify the impact of the MOOC's non-membership on the CCS knowledge about LTFU adapted to the medical history of patients and measure how this MOOC can improve the LTFU care of each CCS.
89225826|NCT05232825|Active Comparator|Ocrelizumab: Intravenous (IV) formulation|Participants will receive the first dose of ocrelizumab IV as two IV infusions given 14 days apart. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between SC doses. Participants will undergo 96 weeks of study treatment.
89225827|NCT05232825|Experimental|Ocrelizumab: Subcutaneous (SC) formulation|Participants will receive the first dose of ocrelizumab SC as one SC injection at a dose which is expected to result in non-inferior exposure to ocrelizumab IV. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between the first and second SC doses, and between subsequent SC doses. Participants will undergo 96 weeks of study treatment.
89225828|NCT05231304||Total Talus Replacement|
89225829|NCT05231304||Total Ankle Total Talus Replacement|
89225830|NCT05231304||Total Ankle Total Talus Replacement + Subtalar Fusion|
89225831|NCT05231304||Total Talus Replacement + Subtalar Fusion|
89225832|NCT05224869|Experimental|Patients with prostate cancer|Patients undergo hydrogel rectal spacer placement on day 1. Within 2 weeks (+/-1 week) after Rectal Spacer placement, patients will be scheduled for CT simulation for external beam treatment planning. Patients will begin the SBRT of 24Gy in 5 fractions within 2 weeks (+/-1 week) from the simulation date. Within 4 weeks (+/-1 week) of last day of SBRT, patients undergo brachytherapy. Patient will return for post-implant CT-based dosimetry analysis 4 weeks (+/- 1 week) post brachytherapy,
89225833|NCT05223335|Experimental|Genotype-Guided Therapy|Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYP2C19*2 or*3 LOF allele carrier will be given prasugrel or ticagrelor monotherapy.
89225834|NCT05223335|Active Comparator|Conventional Therapy|Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that have undergone successful percutaneous coronary intervention (PCI) will be stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYp2C19*2 or*3 LOF allele non-carriers will continue with clopidogrel monotherapy.
89225835|NCT05222789||TAP block|Patients receiving TAP block preoperatively, following routine clinical practice
89225836|NCT05222789||Non-TAP|Patients not receiving TAP block preoperatively, following routine clinical practice
89225837|NCT05219799|Other|Hypoxia Exposure|Men and women will be exposed to isocapnic hypoxia. Participants will wear a mask and systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
89085112|NCT06314620|Active Comparator|Participants who underwent ICC with normal saline flushing without heparin lock|Participants who underwent intercostal chest catheter with normal saline flushing without heparin lock. Instillation done with 20 mls of Normal Saline flush , every 6 hours by a three way stopcock.
89085113|NCT06314308|Experimental|Intervention|Task Specific Training Task-Specific Training (TST) which is the repeated, active practice of a motor skill or activity that is meaningful to an individual with the goal of skill acquisition and retention will be provided over 5 sessions after initial an initial assessment by a physical therapist. Cognitive Behavioral Therapy (CBT) with exposure is a psychotherapeutic intervention that focuses on modifying individuals' thoughts and behavior guided through graded exposure will be guided by a psychologist.
89085114|NCT06313684|Experimental|Comprehensive Hybrid Cardiac Rehabilitation|The 24-week Cardiac Rehabilitation intervention will include evaluation, medical and nurse management, aerobic interval training, resistance exercise, psychosocial support, and education. These will initially be delivered in a health center, transitioning to home in 4 stages.
89085115|NCT06313684|Active Comparator|Exercise and center-based Cardiac Rehabilitation|Cardiac rehabilitation with face-to-face continuous aerobic exercise sessions and resistance exercises.
89085116|NCT06313606|Experimental|Dietary fat with negative control supplement|Dietary fat-containing meal plan with a specific supplement that should not modify fat metabolism
89085117|NCT06313606|Experimental|Dietary fat with positive control supplement|Dietary fat-containing meal plan with a specific supplement that may modify fat metabolism
89522971|NCT03387995||Vertebrobasilar system aneurysms|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
89085120|NCT06312306|Experimental|Transcranial direct current stimulation (tDCS) group|Anodal tDCS applied using a DC stimulator
89085121|NCT06312306|Experimental|pilates based core training group|The Pilates training program will last 30 min per session. The selected exercises will be given to all patients and progressed week-wise
89085122|NCT06312306|Active Comparator|control group|Will receive conventional physiotherapy program
89085123|NCT06308913|Experimental|INCB081776/Pembrolizumab and RT for HNSCC|Cycle 1 of this clinical trial is 56 days in duration to allow for the systematic addition of each agent to the combination regimen. For cycle 2 and all subsequent cycles, the treatment cycle will be 21 days in length.
89522972|NCT03392675|Experimental|Self-monitoring of BF and intervention|Self-monitoring and regulation skills will be provided to mothers at discharge. Aside from daily diaries outlining, infant feeding behaviors and pain, mothers will be instructed to watch several 5-minute video modules to assist with self-management of breast and nipple pain. These videos include: pain neurophysiology; non-pharmacological strategies; common BF issues and intervention; catastrophizing; stress reactivity; deep breathing; guided imagery and support (informational and instrumental). These mothers will also be asked to complete study questionnaires and measures at specified time points.
89522973|NCT03392675|No Intervention|Control|Usual care and asked to complete measures at follow-up time points.
89522974|NCT03387839||Medial-Pivot Knee Prosthesis|
89522975|NCT03387839||Posterior-Stabilized Knee Prosthesis|
89522976|NCT03387839||Cruciate-Stubstituting Knee Prosthesis|
89522977|NCT03392597|Experimental|Brothers as Allie|Brothers as Allies is a strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years by addressing rigid beliefs and norms about masculinity that are harmful to the health, safety, relationships and opportunities of boys and young men. Groups of six to ten boys of similar age and development meet weekly with one or two facilitators for 1.5 to 2 hours for ten or more weeks. Meetings include warm up activities, an opportunity for check-in, experiential activities that address gender relevant topics (e.g., group challenges, games, skits, role plays), and a reflection and group dialogue component.
89522978|NCT03392597|Active Comparator|Programming-as-Usual|Usual programming implemented in afterschool programs.
89522979|NCT04586621|Experimental|Atoldys/ Lexilens - SHAM|
89522980|NCT04586621|Experimental|SHAM- Atoldys/ Lexilens|
89522981|NCT03387605|Active Comparator|Ivabradine|Initiation at dose 5 mg PO x 1 dose and further increased in 12 hours to 7.5 mg PO twice per day if patient is stable with mean BP≥ 60 mmHg, systolic blood pressure ≥ 90 mmHg and HR ≥100 bpm
89522982|NCT03387605|Placebo Comparator|Placebo|Matching placebo given PO twice per day
89522983|NCT03387527|Experimental|Prostate Cancer Decision Aid|The research intervention will be exposure to the screening decision aid. Patients will receive standardized counseling including population based risks and benefits of prostate cancer screening. Then, patients will be given opportunity to review the screening decision aid prior to offering a decision on whether or not to undergo prostate cancer screening. The patient decision aid will be a computer application that generates predicted risks associated with prostate cancer.
89522984|NCT04562363||Low risk of herniation.|Use of any method of suturing, including modified.
89522985|NCT04562363||The average risk of hernia formation|The application of modified methods of closure of laparotomy wound.
89522986|NCT04562363||high risk of herniation|The use of alloplastic methods of closure of laparotomy wound.
89522987|NCT04562363||The presence of eventrations|The use of alloplastic methods of suturing a laparotomic wound in the absence of suppuration.
89522988|NCT03387371|Active Comparator|Ultrasonics & Gracey Curettes|Scaling and root planning is done with ultrasonics and gracey curettes in 24 hours with two visits.
89522989|NCT03387371|Experimental|Ultrasonics & Gracey Curettes & Laser|Scaling and root planning is done with ultrasonics, gracey curettes and Er:YAG laser in 24 hours with two visits.
89522990|NCT04506983|Experimental|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 21, day 28).
89522991|NCT04501211|Other|Patch arm|Transdermal Granisetron patch to be given for application for 24 weeks with 2 weeks on and one week off pattern for a total of 24 weeks
89522992|NCT04465331||patients with knee arthrosis|Painful Knee Osteoarthritis with presence of osteophytes on radiography
89225838|NCT05219591|Other|Polysomnographic night|intermittent application of the EPR technology on CPAP device during step 2, on polysomnographic night of the study.
89225839|NCT05219591|Other|Outpatient CPAP use|Application of EPR technology during outpatient CPAP usage, on steps 3 and 4 of the study
89225840|NCT05219513|Experimental|Parts I-III: Dose-escalation of RO7443904|The dose-escalation of RO7443904 and glofitamab will take place every three weeks (Q3W) with obinutuzumab pre-treatment.
89225841|NCT05219513|Experimental|Part IV: Dose-expansion of RO7443904|Part IV of this study will evaluate selected dose levels of RO7443904 in combination with glofitamab from Parts I-III in a Q3W regimen with obinutuzumab pre-treatment.
89225842|NCT05216406|Experimental|5-HTP|The dietary supplement (100 mg of 5-hydroxytryptophan; CLEANMOOD™) was provided by NURA™ (Irvine, California USA). Subjects were instructed to consume one capsule daily at their convenience for 8 weeks.
89225843|NCT05216406|Placebo Comparator|Control|The placebo consisted of maltodextrin. Subjects were instructed to consume one capsule daily at their convenience for 8 weeks.
89225844|NCT05215756|Experimental|Healthy Subjects|Cold pressor test will be performed 3 times. transcutaneous Vagal nerve stimulation will be administered in the 2nd and 3rd cold pressor tests.
89225845|NCT05214482|Experimental|Phase Ib|Subjects receive AK112 plus AK117 until progression
89225846|NCT05214482|Experimental|Phase II|AK112 + chemotherapy± AK117 until progression; AK117 + chemotherapy;
89225847|NCT05213260|Experimental|intervention group (Flipped Teaching Method Group)|"Flipped classroom for intervention group:~The students allotted to the flipped classroom teaching approach will receive the pre-session learning materials (video access links) three days prior to the clinical case session through their institutional email addresses. Students will be encouraged to complete the assigned tasks before coming to class.~The session will start by reviewing the objectives, discussing the difficult points they have in the preparation materials, and answering any question. They also will be shortly briefed about how the scenario would run. They will have a fixed time to take the cardiovascular history, perform examination, order appropriate investigations, reach a differential diagnosis, and formulate a treatment plan. During the session, the instructor will evaluate these students at each level of clinical case-solving. Finally, post-session survey will be disseminated via email to know the students' perception of the flipped teaching."
89085124|NCT06308653|Experimental|Psilocybin 25 mg|"During the Double-blind Period, participants randomized to receive Psilocybin 25 mg will receive a single dose administered orally as a capsule and taken with water, along with the Set and Setting (SaS) Protocol.~The Set and Setting (SaS) Protocol includes preparatory meetings with two Facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two Facilitators, and 4 hours of post-dose integration sessions with Facilitators. During the dosing session, participants are encouraged to wear eyeshades and listen to a curated playlist on headphones."
89085125|NCT06308653|Active Comparator|Psilocybin 5 mg|"During the Double-blind Period, participants randomized to receive Psilocybin 5 mg will receive a single dose administered orally as a capsule and taken with water, along with the Set and Setting (SaS) Protocol.~The Set and Setting (SaS) Protocol includes preparatory meetings with two Facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two Facilitators, and 4 hours of post-dose integration sessions with Facilitators. During the dosing session, participants are encouraged to wear eyeshades and listen to a curated playlist on headphones."
89085126|NCT06308653|Placebo Comparator|Inactive Placebo|"During the Double-blind Period, participants randomized to receive inactive placebo will receive a single dose of Microcrystalline Cellulose (MCC) 25 mg administered orally as a capsule and taken with water, along with the Set and Setting (SaS) Protocol.~The Set and Setting (SaS) Protocol includes preparatory meetings with two Facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two Facilitators, and 4 hours of post-dose integration sessions with Facilitators. During the dosing session, participants are encouraged to wear eyeshades and listen to a curated playlist on headphones."
89085127|NCT06308653|Other|Long-Term Follow-Up|"After the initial 6-week Double-blind Period, all participants will proceed to a 1-year Follow-up Period. Participants will be followed via in-clinic visits and telephone visits during which clinic staff will assess changes in MDD symptom severity and safety measures including concomitant medications, adverse events (AEs), and suicidal ideation and behavior.~Participants will also engage in group psychosocial support sessions, including psychoeducation, throughout this period.~Participants may also be eligible to receive open-label re-administration(s) of Psilocybin 25 mg under the Set and Setting (SaS) Protocol if re-administration eligibility criteria are met."
89085128|NCT06307483||Taichi group|Participants in the Tai chi group were regular Tai chi practitioners who had practiced Tai chi for at least 3 months, at least three times a week for at least 30 minutes each time.
89085129|NCT06307483||Exercise group|The subjects in the exercise group had regular exercise habits, and insisted on non-Tai chi exercise for at least 3 months, at least three times a week, at least 30 minutes each time.
89085130|NCT06307483||Control group|The subjects in the control group were people without long-term exercise habits.
89085131|NCT06304662|No Intervention|Control Group|The control group (CG) that is not going to undergo treatment, which will be evaluated in the pre and post phase of the study. Participants assigned to this group will receive general advice on the positive effects of regular physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
89085132|NCT06304662|Experimental|Experimental Group|The experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the ERFS, for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 30-45 min per session. Once the intervention is finished, a final evaluation will be used again to see if there is a difference or not with the results obtained at the beginning.
89085133|NCT06304259|Active Comparator|Control|participants will receive standard root canal treatment with final flush of normal saline at the room temperature after cleaning and shaping and before obturation.
89085134|NCT06304259|Experimental|Submucosal cryotherapy infiltration|participants will receive Submucosal infiltration injection of 1 mL cryo-treated saline maintained at a temperature of 2 to 5°C before the normal local anaesthetic routine.
89085135|NCT06304259|Experimental|Intracanal cryotherapy|participants will receive root canal treatment with final flush of cold saline maintained at a temperature of 2 to 5°C
89522993|NCT03125993|Experimental|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
89085138|NCT06302114|Experimental|Athletes in overhead sports|15 years and older elite overhead athletes (swim, tennis, basketball,volleyball) were included in the study.
89085139|NCT06298474|Experimental|Experimental, BRAIN Programming|PLWD in the Experimental Group will be invited to use the BRAIN intervention twice per week for 3 months. Each session is expected to last 20-30 minutes. The BRAIN app will initially recommend activities for each PLWD based upon his/her background/interests/preferences, which will be collected when the PLWD first enrolls in the study. After the initial sessions, the BRAIN app will use AI to recommend new activities for subsequent sessions. These recommendations will be based upon the AI's rating of the relative success or failure of the activities initially provided to the PLWD.
89085140|NCT06298474|No Intervention|Control: Standard Programming / Care|PLWD in the Control Group will participate in standard care / programming for 3 months.
89085141|NCT06295744|Experimental|WBI with SIB|
89085142|NCT06294249|Experimental|Laser-induced Incision|The Biolase Epic 10 diode laser device (Biolase, USA) with 940 nm wavelength, 10 W of max output power, 20 KHz of pulse repetition rate, and continuous pulse mode was used.
89085143|NCT06294249|Active Comparator|Punch Incision|The soft tissue Osstem punch (South Korea) was used.
89085144|NCT06282458|Experimental|Semaglutide and Enobosarm 3 mg QD by mouth (E3G) daily|"Approximately 30 subjects will be dosed with semaglutide injected once-weekly and enobosarm 3 mg QD by mouth (E3G) daily for approximately 112 days. Semaglutide dose escalation will occur as follows:~Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg~From Day 112 to Day 196, patients will continue to receive 3 mg enobosarm QD by mouth and will discontinue the semaglutide."
89085145|NCT06282458|Experimental|Semaglutide and Enobosarm 6 mg QD by mouth (E6G) daily|"Approximately 30 subjects will be dosed with semaglutide injected once-weekly and enobosarm 6 mg QD by mouth (E3G) daily for approximately 112 days. Semaglutide dose escalation will occur as follows:~Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg~From Day 112 to Day 196, patients will continue to receive 6 mg enobosarm QD by mouth and will discontinue the semaglutide."
89085146|NCT06282458|Placebo Comparator|GLP-1 receptor agonist and Placebo QD by mouth (PG) daily|"Approximately 30 subjects will be dosed with semaglutide injected once-weekly and placebo QD by mouth (PG) daily for approximately 112 days. Semaglutide dose escalation will occur as follows:~Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg~From Day 112 to Day 196, patients will continue to receive placebo QD by mouth (PG) and will discontinue the semaglutide."
89522994|NCT03126071|Experimental|Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)|Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
89522995|NCT03126071|Experimental|Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)|Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
89522996|NCT03392285||Internal fixation|Patients above 65years old with an undisplaced femoral neck fractures treated with primary internal fixation with screws.
89522997|NCT03392285||Hip arthroplasty|Patients above 65years old with a displaced femoral neck fractures treated with primary hip arthroplasty.
89522998|NCT03392207||Health Care Professionals|Health care professionals receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
89522999|NCT03392207||Elderly|Elderly (age 60 or more) receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
89523000|NCT03387293|Experimental|LGI-LII Breakfast|Low glycemic index, low insulin index (LGI-LII) breakfast as a test meal
89523001|NCT03387293|Experimental|LGI-HII Breakfast|Low glycemic index, high insulin index (LGI-HII) breakfast as a test meal
89523002|NCT03392129|Experimental|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week, 40 minutes each session) of treatment with the Ai Chi Method and educational interventions in relation to asthma.
89523003|NCT03392129|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
89085157|NCT06278909|Experimental|Active stimulation|"Trigeminal nerve stimulation will occur by placement of electrodes (1.25 silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, New York, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 milliampere (mA). Active stimulation will occur at 120 Hz with a 250 μs pulse width and with a duty cycle of 30 seconds on to 30 seconds off."
89085158|NCT06278675|Experimental|Experimental group|Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.
89085159|NCT06278675|No Intervention|Control group|Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.
89523004|NCT03387215|Experimental|10 mg ITI-214|Single oral dose
89523005|NCT03387215|Experimental|30 mg ITI-214|Single oral dose
89523006|NCT03387215|Experimental|75 mg - 150 mg ITI-214|Single oral dose
89523007|NCT03387215|Placebo Comparator|Placebo|Single oral dose
89523008|NCT03392051|Experimental|Clopidogrel Dosing|Multiple doses of Clopidogrel to obtain pharmacokinetic information.
89523009|NCT03392051|Experimental|Clopidogrel in combination with ISIS 681257|Multiple doses of clopidogrel administered with 2 doses of ISIS 681257 at 2 individual timepoints to obtain pharmacokinetic information.
89523010|NCT03391895|Active Comparator|Control Group|Patients in this group will receive a home based exercise program. Home based exercise program includes deep diaphragmatic breathing exercises, resistive local expansion exercise on the collapsed areas in scoliosis concave sides, dynamic lumber stabilization, strengthening of inter scapular muscles, posture and stretching exercises once a day for 8 weeks. One of the exercise sessions was supervised by physiotherapist each week.
89523011|NCT03391895|Experimental|Training Group|In addition to home based exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in our clinic per week, other sessions will be performed at home.
89523012|NCT03386981||1|Professional athletes: Professional athletes belonging to different discipline
89085165|NCT06271954||control|(1) Understanding the content of the questionnaire. (2) Healthy adolescents aged 15 to less than 18 years and healthy adults aged 18 to 24 years.
89085166|NCT06271954||experimental|(1) Understanding the content of the questionnaire. (2) Adolescents aged 15 to less than 18 years and adults aged 18 to 24 years. (3) Diagnosed with major depressive disorder, anxiety disorder, attention deficit hyperactivity disorder (ADHD), or adjustment disorder according to DSM-5.
89085167|NCT06271629||Insomnia Severity index Grade 0&1|administered the Insomnia Severity Index (Korean validated version) to patients with Low Anterior Resection Syndrome (LARS) and divided them into two groups based on the severity grade.
89085168|NCT06271629||Insomnia Severity index Grade 2&3|administered the Insomnia Severity Index (Korean validated version) to patients with Low Anterior Resection Syndrome (LARS) and divided them into two groups based on the severity grade.
89085169|NCT06269913|Experimental|Iron/yeast complex (FeSC)|Iron Supplement
89523013|NCT02520167|Experimental|Dietary and Lifestyle Counseling|Women randomized to the intervention group will meet with a dietary counselor for 15 minutes at every prenatal appointment. They will receive a dietary and lifestyle curriculum based on the Diabetes Prevention Program curriculum (11 lessons) with one additional lesson providing prenatal breastfeeding education. They will also have access to a private online Facebook page for additional education and peer group support.
89085177|NCT06269510|Experimental|Enhanced usual care (EUC)|Eligible participants randomized will be given this for stage 1 of treatment (three months) and stage 2 (three months) if participants engaged in alcohol treatment during the first stage of treatment.
89085178|NCT06269510|Experimental|ENGAGE-ALD application (app)|Eligible participants randomized to this arm will be given this for stage 1 (three months) of treatment and stage 2 (three months) if participants engaged in alcohol treatment during the first stage of treatment.
89085179|NCT06269510|Experimental|ENGAGE-ALD app then Treatment Facilitation Bundle|Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized and assigned to the Treatment Facilitation bundle for stage 2 (three months).
89085180|NCT06269510|Experimental|Enhanced usual care then Treatment Facilitation Bundle|Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized and assigned to the Treatment Facilitation bundle for stage 2 (three months).
89085181|NCT06269510|Experimental|ENGAGE-ALD app then Enhanced usual care|Eligible participants randomized to this arm will be given this for stage 1 (three months) of treatment. Participants that are non-responders (did not engage in alcohol treatment) will be re-randomized to the EUC arm stage 2 (three months).
89085182|NCT06269510|Experimental|Enhanced usual care then Enhanced usual care|Eligible participants randomized to this arm will be given this for stage 1 of treatment (three months). Participants that are non-responders (did not engage in alcohol treatment) will be rerandomized to the Enhanced usual care arm stage 2 (three months).
89085183|NCT06266546|Experimental|Intervention|Prophylactic TXA arm
89085184|NCT06266546|No Intervention|Control|Data collected retrospectively from patients undergoing the same procedure one year prior to the study initiation
89085185|NCT06262334|Experimental|The Fade to Fitness Program|
89085186|NCT06259786||Nocturnal Bruxism|The Quality of Life (The Pediatric Quality of Life Inventory - PedsQL), Postural Changes (New York Posture Analysis - NYPA), Cervical Proprioception (CROM Device), Mandibular Movement Capacity (Maximum Mouth Opening - The Caliper and Excursions- The Linear Rule) will be evaluated.
89085187|NCT06259786||Healthy Group|The Quality of Life (The Pediatric Quality of Life Inventory - PedsQL), Postural Changes (New York Posture Analysis - NYPA), Cervical Proprioception (CROM Device), Mandibular Movement Capacity (Maximum Mouth Opening - The Caliper and Excursions- The Linear Ruler) will be evaluated.
89085188|NCT06256159|Other|Patients with incomplete spinal cord injury|
89523014|NCT02520167|No Intervention|Standard of Care|Usual prenatal care consists of regular clinical appointments, pregnancy ultrasounds, and recommendations to use prenatal multivitamins, eat a balanced diet, and remain physically active. Women with a pre-pregnant body mass index > 30 complete early glucose screening (as early as possible after presentation at the clinic) to detect pre-existing diabetes, and all women undergo routine gestational diabetes screening at 24-28 weeks. Women who test positive for pre-existing diabetes or gestational diabetes are referred to a registered dietitian.
89085193|NCT06252753||unresectable hepatocellular carcinoma (uHCC)|unresectable hepatocellular carcinoma (uHCC)
89085194|NCT06252753||advanced biliary tract cancer (aBTC)|advanced biliary tract cancer (aBTC)
89085195|NCT06251960|Experimental|socket preservation with completely demineralized dentin graft.|
89085196|NCT06251960|Experimental|socket preservation with partially demineralized dentin graft.|
89085197|NCT06249438|Experimental|C-CAR168|Autologous C-CAR168 administered by intravenous (IV) infusion
89225848|NCT05213260|No Intervention|Control group (Traditional Method Group)|This group of students, included 20 participants, will be briefed by the instructors for 30 minutes immediately before the clinical skill session about the clinical case which will include: history taking, examination, investigations, diagnosis, and treatment plan. Following that, there will be time for practice and discussion amongst the students on a high-fidelity manikin. Of note, these students will not receive any pre-session teaching material as the intervention group.
89225849|NCT05209984|Experimental|Experimental drug (Sibutramine IR 15mg / Topiramate XR 75mg)|ADF1 Group Eurofarma drug association of sibutramine IR 15mg / topiramate XR 75mg
89225850|NCT05209984|Experimental|Experimental drug (Sibutramine IR 15mg / Topiramate XR 100mg)|ADF2 Group Eurofarma drug association of sibutramine IR 15mg (Sibus®) Topiramate XR 100mg from Eurofarma Laboratórios S.A..
89225851|NCT05209984|Active Comparator|Sibus (Sibutramine 15mg)|SIB Group Sibutramine 15mg
89225852|NCT05209984|Placebo Comparator|Placebo Group|Placebo Group
89225853|NCT05207033|Active Comparator|Unregulated ad condition|This arm will include exposure to unregulated e-cigarette ads or ads as they appear in modern media.
89225854|NCT05207033|Experimental|Regulated ad condition|This arm will include exposure to regulated e-cigarette ads or ads where we have taken out the appealing features.
89225855|NCT05205967||Patients who received the Galleri® test.|
89225856|NCT05205733|No Intervention|In-Clinic Semen Analysis Testing|Men needing semen analysis for infertility work-up.
89225857|NCT05205733|Experimental|No in-clinic semen analysis testing|Men needing semen analysis for infertility work-up.
89225858|NCT05203822|Experimental|Tepotinib then Itraconazole|Participants received a single oral dose of Tepotinib 500 milligrams (mg) on Day and Day 12 under fed condition followed by single oral dose of itraconazole 200 mg on Days 8 to 11 and Days 13 to 18. On Day 12, participants received a single dose of 200 mg itraconazole simultaneously with a single dose of 500 mg Tepotinib.
89225859|NCT05200871||Adult patients|Adult patients (at least 18 years old) with FSGS or IgAN located in each of the six countries
89225860|NCT05200871||Adult patient care-partners of adult patients|Adult care-partners (paired with adult patients) (at least 18 years old) of adult patients with FSGS or IgAN located in each of the six countries
89225861|NCT05200871||Adult patient care-partners of pediatric/adolescent patients|Adult parents/care-partners (paired with adult patients) (at least 18 years old) of pediatric/ adolescent patients with FSGS or IgAN located in each of the six countries
89225862|NCT05196113|Experimental|sipIT|Participants receive education and a digital tool to monitor their fluid intake and remind them when they have lapsed in regular fluid intake.
89225863|NCT05196113|No Intervention|Control|Participants receive usual care (i.e., education about fluid intake guidelines and encouragement to meet those guidelines).
89225864|NCT05194345|Experimental|Autism Eats nutrition intervention|Autism Eats intervention lessons (10 lessons + 2 booster sessions) integrate ASD-specific feeding strategies such as repeated exposures, food chaining, and making regular mealtime routines and behaviorally-focused nutrition content and activities utilizing goal setting, healthy meal planning, monitoring progress, strategies to overcome barriers, and creating healthy home food environment. The early intervention (EI) providers will be trained to implement the lessons. EI providers are well-trained to use personalized intervention and coaching approach in their EI services, which will be applied to Autism Eats activities as well. Each intervention lesson will take 25-30 minutes within one hour EI services, and parent-child dyads will participate in the intervention as part of their regular EI services. The Autism Eats lesson manual will be provided to the EI providers and the parent handbook will be distributed to the parent participants.
89225865|NCT05194345|Active Comparator|We Can! enhanced usual care control|Enhanced usual care (EUC) control group materials are from the evidence-based materials that are already developed and available online (in both English and Spanish): https://www.nhlbi.nih.gov/health/educational/wecan/index.htm. We will download one to two handouts and email early intervention providers to distribute them to parent-child dyads. Materials will be distributed each week for 10 weeks and additional monthly handouts for two months after the first 10 weeks (parallel to the intervention schedule).
88816174|NCT02437890|Experimental|ALX-0061 150 mg q2w|"ALX-0061 150 mg every 2 weeks (q2w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
89085198|NCT06249321|Experimental|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin [70 mg per square meter of body surface area], irinotecan [130 mg per square meter], leucovorin [200 mg per square meter], and fluorouracil [2000 mg per square meter] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2~6 cycles of chemotherapy.
89085199|NCT06248619|Experimental|Teprotumumab|Teprotumumab administered SC
89085200|NCT06248619|Placebo Comparator|Placebo|Placebo for teprotumumab administered SC
89085202|NCT06245889|Experimental|Neoadjuvant therapy|4 cycles of paclitaxel/carboplatin/pembrolizumab
89085203|NCT06242756|Experimental|Bladder catheterization|Patients placed in the catheterized group will have an indwelling catheter placed after anesthetic has been administered. It would be removed at 12 hours post Cesarean section.
89085204|NCT06242756|No Intervention|Non-use of bladder catheterization|Participants in the non-catheterized group would be encouraged to empty their bladders just prior to transfer to the operating room where they will undergo surgery without an indwelling catheter.
89085205|NCT06241833||PPI group|Patients receiving PPI concomitant with dual antiplatelet therapy after PCI for AMI
89085206|NCT06241833||no PPI group|Patients receiving dual antiplatelet therapy only after PCI for AMI
89523015|NCT03386903|Experimental|Ture acupuncture group|After recruiting, patients are assigned to the ture acupuncture group by randomization,and then receive ture acupuncture treatment. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
89523016|NCT03386903|Placebo Comparator|Sham acupuncture group|After recruiting, patients are assigned to the sham acupuncture group by randomization,and then receive sham acupuncture stimulation. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
89085209|NCT06237790||Gene Therapy Group|The study will recruit gene therapy patients who are definitely diagnosed with autosomal recessive deafness 9 (DFNB9).
89085210|NCT06237790||Cochlear Implant Group|The study will recruit cochlear implant patients with congenital deafness.
89085211|NCT06237049|Experimental|BNT162b2 (Omi XBB.1.5)/RIV and placebo|Participants will receive a single injection combination of BNT162b2 (Omi XBB.1.5) and RIV and normal saline placebo
89085212|NCT06237049|Experimental|BNT162b2 (Omi XBB.1.5) and RIV|Participants will receive BNT162b2 (Omi XBB.1.5) and RIV
89085213|NCT06237049|Active Comparator|BNT162b2 (Omi XBB.1.5) and placebo|Participants will receive BNT162b2 (Omi XBB.1.5) and normal saline placebo
89085214|NCT06237049|Active Comparator|RIV and placebo|Participants will receive RIV and normal saline placebo
89085215|NCT06232252|Experimental|Dose group (DG) 1 (very low dose)|
89085216|NCT06232252|Experimental|Dose group (DG) 2 (low dose)|
89085217|NCT06232252|Experimental|Dose group (DG) 3 (medium dose)|
89085218|NCT06232252|Experimental|Dose group (DG) 4 (high dose)|
89085219|NCT06231810|Experimental|Stimulus magnitude|Differing levels of tactile stimulus will be applied
89085220|NCT06231381|Active Comparator|HB0034|Subjects will be given a single intravenous infusion of HB0034 on D1.
89085221|NCT06231381|Placebo Comparator|Placebo|Subjects will be given a single intravenous infusion of placebo on D1.
89085222|NCT06231108||Case Group|"In the Single Group, three different taping applications will be performed."
89085223|NCT06230328||Cohort 1|Patients with early tumors at diagnosis (BCLC 0, A or B)
89085224|NCT06230328||Cohort 2|Pacientes com tumores avançados ao diagnóstico (BCLC C ou D)
89085225|NCT06230055|Experimental|intrathecal chemotherapy through Ommaya reservoir in combination with systematic chemotherapy|Intrathecal chemotherapy through Ommaya reservoir: MTX, 10-12mg, q3w. Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), or iribrin(1.4mg/m2, d1,8, q3w, iv).
89085226|NCT06230055|Active Comparator|systematic chemotherapy|Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), or iribrin(1.4mg/m2, d1,8, q3w, iv).
89523017|NCT03386903|No Intervention|Healthy group|Healthy subjects without intervention except scanned brain image by MRI at the baseline.
89523018|NCT04167371|Experimental|Biofeedback|
89523019|NCT04167371|Placebo Comparator|Placebo|
89523020|NCT03386825||Regorafenib_DoT<4 months|DoT < 4 months
89523021|NCT03386825||Regorafenib_4 months ≤ DoT < 12 months|4 months ≤ DoT < 12 months
89523022|NCT03386825||Regorafenib_DoT ≥ 12 months|DoT ≥ 12 months
89085233|NCT06222632|Experimental|MIND diet|The MIND group will consume the MIND diet for 12 weeks.
89085234|NCT06222632|Experimental|MIND plus FB|The MIND plus FB intervention will consist of eight sessions.
89085235|NCT06222632|Other|Usual Care|The routine care group will be instructed to perform daily activities as usual
89523023|NCT03386747|Experimental|Home Visiting Group|Intervention: Home visits to improve parenting behaviors
89085239|NCT06219005|Experimental|Emergency Medicine attending physicians and residents|
89085240|NCT06218511|Experimental|Single arm|single-arm open-label
89085241|NCT06218381|Experimental|Image Exposure Arm|This within-subjects design study will have all participants view three types of exposure during fMRI scanning: VBE to combat images, VBE to masked everyday scenes (control), and conscious visible exposure to the same images (control).
89085242|NCT06216860|Experimental|Interventional group / Laughter yoga|"The data of the pre-intervention study will be recorded with Personal Information Form, Five Dimensional Mindfulness Scale and Skovholt Professional Resilience and Self-Care Inventory.~The application will be done for 8 weeks, 1 day a week. Post-intervention data will be collected with Five Dimensional Mindfulness Scale and Skovholt Professional Resilience and Self-Care Inventory and Post Laughter Yoga Evaluation Form."
89085243|NCT06216860|No Intervention|Control group|"The control group did not take part in the laughter yoga program. As a pre-test, the data of the study will be recorded with Personal Information Form, Five Dimensional Mindfulness Scale and Skovholt Professional Resilience and Self-Care Inventory. As the post-test, 8 weeks after the pre-test, the data of the study will be collected with the Five Dimensional Mindfulness Scale and Skovholt Professional Resilience and Self-Care Inventory."
89085244|NCT06215118|Experimental|Part 1 Dose Escalation|Non-randomized elranatamab plus iberdomide
89085245|NCT06215118|Experimental|Part 2 Dose Randomization|Randomized elranatamab plus iberdomide
89085246|NCT06212505||Adults patients with severe hemophilia A (FVIII<2%)|"Adults patients with severe hemophilia A (FVIII<2%) who are:~on prophylaxis with FVIII concentrates after a washout period of 48h for SHL FVIII molecules and at least 4 days for EHL FVIII~or receive on demand FVIII treatment without any FVIII treatment since 48h for SHL FVIII molecules and since 4 days for EHL FVIII"
89085247|NCT06211049|Experimental|Vitex agnus-castus BNO 1095 (20 mg)|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e., 113 days in case of a 28-day menstrual cycle).
89085248|NCT06211049|Placebo Comparator|Placebo|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e., 113 days in case of a 28-day menstrual cycle).
89085249|NCT06209138|Experimental|CO2 laser assisted dermabrasion and 5FU film|
89085250|NCT06209138|Active Comparator|CO2 laser assisted dermabrasion and saline|
89085251|NCT06208462|Experimental|Combined treatment group|"Preoperative treatment 3 weeks is a course of treatment HAIC (GEMOX) chemotherapy~It is performed within one week after the identification of ICC~Day 1 HAIC (GEMOX) Oxaliplatin 85mg/m2 + Gemcitabine 800mg/m2 Adebrelimab: Day 3 Adebrelimab 1200mg i.v. Lenvatinib 2# qd~Evaluation every 2 courses, up to 4 courses.~Liver resection: It is performed within 1 month after preoperative treatment.~Postoperative treatment: Day 1-14 Capecitabine 1200mg B.I.D."
89085252|NCT06206421|Experimental|Fezolinetant|Participants will receive fezolinetant once daily for 52 weeks.
89085253|NCT06206421|Experimental|Placebo|Participants will receive matching placebo once daily for 52 weeks.
89523024|NCT03386747|Experimental|Center based parenting group|Intervention: Center based parenting groups
89085255|NCT06197984||Patients with acute cholangitis|Patients admitted to the hospital due to acute cholangitis and undergoing ERCP will be selected. Bile specimens will be obtained after cannulation through the sphincterotome before the therapeutic intervention.
89085256|NCT06196866|Active Comparator|Control group|Participants carry out daily routine activities and/or receive standard physiotherapy for the whole 24 weeks of the trial, 1 session/week with a time of 45 minutes/session.
89085257|NCT06196866|Experimental|Exergaming group 1|Participants receive Nintendo Ring Fit Adventure exergaming intervention for 12 weeks, 1 session/week with a time of 45 minutes/session + Control group intervention.
89085258|NCT06196866|Experimental|Exergaming group 2|Participants receive Nintendo Wii Fit exergaming intervention for 12 weeks, 1 session/week with a time of 45 minutes/session + Control group intervention.
89085259|NCT06196671|Experimental|Oncolytic virus plus PD-1 inhibitor|"H101 intratumorally injection starts at day 1.~Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.~After two cycles of treatment, Camrelizumab will be administered alone at 200 mg i.v. every 3 weeks from cycle 3 until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.~The following treatment will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline."
89085260|NCT06195878|Experimental|CPAP Therapy|Participants who are diagnosed with moderate-to-severe sleep related breathing disorders (SRBDs) will undergo a 4-month trial of Continuous positive airway pressure (CPAP) therapy.
89085261|NCT06193629|Experimental|Lang Qingata|Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
89085262|NCT06193629|Placebo Comparator|placebo group|Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use。
89085263|NCT06191744|Experimental|Arm A: Epcoritamab + Lenalidomide and Rituximab (R2)|Participants will receive epcoritamab in combination with R2 during the 120 week study duration.
89085264|NCT06191744|Experimental|Arm B: Chemoimmunotherapy (CIT) Option A|Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) [G-CHOP]/ rituximab (R)-CHOP during the 120 week study duration.
89085265|NCT06191744|Experimental|Arm B: Chemoimmunotherapy (CIT) Option B|Participants will receive CIT Option B (G and bendamustine (Benda) [G-Benda]/R-Benda during the 120 week study duration.
89085266|NCT06191744|Experimental|Arm C: Lenalidomide and Rituximab (R2)|Participants will receive lenalidomide and rituximab (R2) during the 120 week study duration.
89523025|NCT03386747|No Intervention|control group|The rest of pregnant women and their children who will not receive the intervention
89085269|NCT06177639||Adult (≥18 years) cohort|Adults that may or may not have eye pathology
89085270|NCT06177639||Minor cohort|Infant/child undergoing clinically-indicated examination that may or may not have eye pathology. We will not enroll inpatient pre-term infants or neonates. The youngest age at enrollment will be 30 days adjusted age using the NICH NRN Web-based Adjusted Age Calculator.
89085271|NCT06173895|Experimental|LY3454738 (Test Formulation)|
89085272|NCT06173895|Experimental|LY3454738 (Reference Formulation)|
89085273|NCT06171412|Experimental|Glu-COACH|The experimental group will receive ESOC plus peer-mentoring support from a peer of the same cultural identity (Glu-COACH) and access to a private social media group for all Black and Latinx teens to improve the initiation and maintenance of CGM (Dexcom)
89085274|NCT06171412|Active Comparator|Enhanced standard-of-care (ESOC)|This group will receive ESOC including additional training and support on CGM beyond routine clinical practice.
89085275|NCT06170333|Experimental|8% sulphur and A. vera soap and ketoconazole 2% shampoo|"Twenty-one patients will be given the combination of 8% sulphur and A. vera soap applied to the entire body surface (excluding face), left on for five minutes and then washed off. This was applied twice daily for four weeks.~Along with the soap or placebo, patients will receive 2% ketoconazole shampoo, left on for five minutes and then washed off. This was applied thrice weekly for a week"
89085276|NCT06170333|Active Comparator|Bland soap and ketoconazole 2% shampoo|"Twenty-one patients will be given bland soap applied to the entire body surface (excluding face), left on for five minutes and then washed off. This was applied twice daily for four weeks.~Along with the soap or placebo, patients will receive 2% ketoconazole shampoo, left on for five minutes and then washed off. This was applied thrice weekly for a week."
89523026|NCT04446767|Experimental|Bioptron light therapy and medical care|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks plus medical care in the form of Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
89085278|NCT06165614|Experimental|Artesunate vaginal inserts/ pessaries|Artesunate vaginal inserts/pessaries are used as a treatment for cervical precancerous lesions.
89085285|NCT06161025|Experimental|Part A: R-DXd 4.8mg/kg Q3W|Participants will be randomized to receive intravenous R-DXd administered at a dose of 4.8 mg/kg every 3 weeks (Q3W).
89085286|NCT06161025|Experimental|Part A: R-DXd 5.6 mg/kg Q3W|Participants will be randomized to receive intravenous R-DXd administered at a dose of 5.6 mg/kg every 3 weeks (Q3W).
89085287|NCT06161025|Experimental|Part A: R-DXd 6.4 mg/kg Q3W|Participants will be randomized to receive intravenous R-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).
89085288|NCT06161025|Experimental|Part B: R-DXd RP3D Q3W|Participants will be randomized to receive intravenous R-DXd administered at the Recommended Phase 3 Dose (RP3D) every 3 weeks (Q3W).
89085289|NCT06161025|Active Comparator|Part B: Investigator's Choice|Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), gemcitabine, or topotecan.
89085290|NCT06160375|Other|Group (P)|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
89085291|NCT06160375|Other|Group (E)|the patient will be in the lateral position, by using US (Esaote MyLabSeven/ Esaote S.p.A, Genoa, Italy) a linear multifrequency 12 L probe and a 20-gauge 100 mm peripheral nerve block needle (Stimupleks Ultra 360 30°-BRA-04892510-01/B. Braun Melsungen AG, Hessen, Germany), the one-sided truncal block will be performed. The transverse process was visualized by placing the probe approximately 3 cm lateral to the spinous process of the T5 vertebrae for ESPB. When the needle advances in the craniocaudal direction with an angle of 30-40° and touched the transverse process, the presence of blood and/ or air will be checked by aspiration. Hydro-dissection was performed with 2-3 mL isotonic saline and 20 mL 0.25% bupivacaine (Marcaine 0.5%, 5 mg/mL) will be injected by observing that the erector spinae muscle (ESM) separates from the transverse process.
89085292|NCT06159673|Experimental|ACP-204 30 mg|Administration once daily at approximately the same time of day, with or without food
89085293|NCT06159673|Experimental|ACP-204 60 mg|Administration once daily at approximately the same time of day, with or without food
89085294|NCT06159673|Placebo Comparator|Placebo|Administration once daily at approximately the same time of day, with or without food
89085295|NCT06150443|Experimental|Group 1 - OMT Only|Osteopathic manipulative treatment will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. The cervical spine will also be treated, with particular attention to the C5-7 levels, all the way to the wrist and hand as the physician sees fit based on the findings of the osteopathic structural exam.
89085296|NCT06150443|Active Comparator|Group 2 - OMT + Conservative Treatment|Will receive Osteopathic manipulative treatment in addition to conservative treatment. Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical and Occupational therapy will be excluded from the conservative therapy regimen. Osteopathic manipulative treatment will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. The cervical spine will also be treated, with particular attention to the C5-7 levels, all the way to the wrist and hand as the physician sees fit based on the findings of the osteopathic structural exam.
89085297|NCT06150443|Active Comparator|Group 3 - Conservative Treatment Only|Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical and Occupational therapy will be excluded from the conservative therapy regimen.
89085300|NCT06146101|Experimental|Phase 2 Investigational Product - IHL-42X Low dose|IHL-42X (2.5 mg dronabinol + 125 mg acetazolamide), one capsule self-administered once daily every night approximately 1 hour prior to bed for 4 weeks.
89085301|NCT06146101|Experimental|Phase 2 Investigational Product - IHL-42X High dose|IHL-42X (5 mg dronabinol + 250 mg acetazolamide), one capsule self-administered once daily every night approximately 1 hour prior to bed for 4 weeks.
89085302|NCT06146101|Placebo Comparator|Phase 2 Placebo|One capsule self-administered once daily every night approximately 1 hour prior to bed for 4 weeks.
89085303|NCT06146101|Experimental|Phase 3 Investigational Product - IHL-42X|IHL-42X (dose will be identified based on the safety and efficacy results in Phase II), one capsule self-administered once daily every night approximately 1 hour prior to bed for 52 weeks.
89085304|NCT06146101|Active Comparator|Phase 3 Comparator - Reference Listed Drug/Dronabinol|One capsule of dronabinol (equivalent dose strength to that in the IHL-42X optimal dose strength) self-administered once daily every night approximately 1 hour prior to bed for 3 months then IHL-42X (optimal dose) one capsule self-administered once daily every night approximately 1 hour prior to bed for the remaining 9 months.
89085305|NCT06146101|Active Comparator|Phase 3 Comparator - Reference Listed Drug/Acetazolamide|One capsule of acetazolamide (equivalent dose strength to that in the IHL-42X optimal dose strength) self-administered once daily every night approximately 1 hour prior to bed for 3 months then IHL-42X (optimal dose) one capsule self-administered once daily every night approximately 1 hour prior to bed for the remaining 9 months.
89085306|NCT06146101|Placebo Comparator|Phase 3 Placebo|One capsule self-administered once daily every night approximately 1 hour prior to bed for 52 weeks.
89085309|NCT06144749|Experimental|Ascending Multiple Dose|Drug: HBI-002 (oral liquid carbon monoxide drug product)
89085310|NCT06142513||Grup I|Subjects with obesity hypoventilation syndrome (30 < body mass index < 45 kg/m2)
89085311|NCT06142513||Grup II|Age and sex-matched obese subjects (30 < body mass index < 45 kg/m2) with low risk of obstructive sleep apnea (STOP-BANG score < 3)
89085312|NCT06137144|Experimental|Module 1: Part A (Dose Escalation) and Part B (Dose Expansion/Optimization)|"In Part A, participants with Relapsed/Refractory classical Hodgkin Lymphoma (cHL) will take AZD3470 tablets orally until PD, unacceptable toxicity, or withdrawal of consent.~In Part B, adult and adolescent participants with r/r cHL will take AZD3470 tablets orally until PD, unacceptable toxicity, or withdrawal of consent."
89085313|NCT06136533||Obesity Hypoventilation Syndrome Group|Individuals diagnosed with OHS over the age of 18 years who met the inclusion criteria and who were followed up by Istanbul University Faculty of Medicine, Department of Chest Diseases
89085314|NCT06136533||Obesity Hypoventilation Syndrome with Sarcopenic Obesity group|Individuals over the age of 18 years with a diagnosis of OHS and sarcopenic obesity who met the inclusion criteria and who were followed up by Istanbul University Faculty of Medicine, Department of Chest Diseases.
89085315|NCT06134999|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
89085316|NCT06134999|Placebo Comparator|Placebo Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7.
89085317|NCT06134180|Experimental|CONFIDENCE AI|Participants will attend the 4-week CONFIDENCE-AI Program. This program will include attending 4 group-based sessions delivered by videoconference. Each session will last approximately 1.5 hours each and will cover topics such as how to budget, accessing community resources to displace the out-of-pocket costs of caregiving, asking for help, and more. Participation will be supplemented by access to a digital app to support engagement, such as through text messaging and resources navigation support.
89085318|NCT06132399|Active Comparator|Commercial non-immersive virtual reality group (CVR)|Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan).
89085319|NCT06132399|Experimental|Gamified, fully immersive and stroke-specific virtual reality group (RESET)|The RESET virtual reality software will be integrated in the META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US).
89085320|NCT06132399|Active Comparator|Usual care (UC)|3 session/week of 90 minutes of physical therapy and occupational therapy.
89085321|NCT06128629|Experimental|NTLA-2001|Single intravenous (IV) infusion of NTLA-2001
89085322|NCT06128629|Placebo Comparator|Placebo|Single IV infusion of normal saline
89085323|NCT06127472|Other|ASD trained|Periods in the SWTD after receiving training in detection and diagnosis of ASD.
89085324|NCT06127472|Other|ASD training - control|Periods in the SWTD before receiving training in detection and diagnosis of ASD.
89085325|NCT06127472|Other|PE program|Periods in the SWTD after receiving the PE program.
89085326|NCT06127472|Other|PE program - control|Periods in the SWTD before receiving the PE program.
89085327|NCT06126341||Participant Cohort 1|Relapse/refractory multiple myeloma/RRMM patients less than 70 years of age.
89085328|NCT06126341||Participant Cohort 2|Relapse/refractory multiple myeloma/RRMM patients 70 years of age or greater
89085329|NCT06126341||Physician Group 1: Primary Myeloma Therapy|Physicians in this group refer for cellular therapy but do not perform the infusions.
89085330|NCT06126341||Physician Group 2: CAR Enabled|These physicians can order and infuse CAR T cells but not stem cells.
89085331|NCT06126341||Physician Group 3: HCT and CAR Enabled|These physicians can order and infuse stem cells and CAR T cells
89085332|NCT06123715|Experimental|Intervention|Preoperative Vitamin C capsules
89085333|NCT06123715|Placebo Comparator|Placebo|Preoperative placebo capsules
89085334|NCT06119529|Experimental|Part A: LY3872386|Single doses of LY3872386 administered either intravenously (IV) or subcutaneously (SC) in healthy participants.
89085335|NCT06119529|Experimental|Part B: LY3872386|Multiple doses of LY3872386 administered either IV or SC in participants with atopic dermatitis.
89085336|NCT06119529|Experimental|Part C: Prednisone|Prednisone administered orally in healthy participants.
89085337|NCT06119529|Placebo Comparator|Placebo|Placebo administered either IV or SC.
89085344|NCT06117449||Patients going on insulin therapy|
89085345|NCT06117449||patients going on oral antidiabetic drugs|
89085346|NCT06115681||Cohort 1|Patients with unresectable locally advanced or metastatic differentiated liposarcoma (DDLPS) who received at least one line of systemic antineoplastic treatment by the end of cohort identification period (index date = start date of first line (1L) treatment).
89225866|NCT05189847||Patients with MFA|Patients with MFA confirmed by ultrasound examination, ABI or using clinical and medical history data.
89085347|NCT06115681||Cohort 2|Patients with DDLPS who have not initiated 1L systemic antineoplastic treatment by the end of cohort identification period (index date = date of initial DDLPS diagnosis during cohort identification period). Patients initiated 1L treatment afterwards or patients received adjuvant and/or neoadjuvant therapy only through follow-up will be included in Cohort 2.
89085348|NCT06112678|Experimental|Sequence 1|Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 4: CKD-348(6) - A single oral dose of 1 tablet under fasting condition
89085349|NCT06112678|Experimental|Sequence 2|Period 1: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
89523027|NCT04446767|Active Comparator|medical care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
89523028|NCT03386669|Experimental|F-18 AV-45 THK-5351|F-18 AV-45 THK-5351 imaging
89523029|NCT03416543||Puncture|Patient with RA or gout or osteoarthritis and performing a puncture. The aim is evaluate the cellular composition of synovial fluid then evaluate the response to a new BI-specifiC Antibody Towards Dendritic Cells.
89523030|NCT04446533|Experimental|Hydrogen Peroxide and Hyaluronic acid (BMG0703)|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
89085356|NCT06107413|Experimental|ABBV-400+Fluorouracil, Folinic Acid, and Bevacizumab (FFB) A|Participants will receive escalating ABBV-400 in combination with FFB on dose schedule A as part of the safety lead in, during the 3 year study duration.
89085357|NCT06107413|Experimental|ABBV-400+FFB B|Participants will receive escalating ABBV-400 in combination with FFB on dose schedule B as part of the safety lead in, during the 3 year study duration.
89085358|NCT06107413|Experimental|ABBV-400+FFB A Low|Participants will receive ABBV-400 in combination with FFB at the low dose determined in the safety lead in on dose schedule A as part of the dose optimization, during the 3 year study duration.
89085359|NCT06107413|Experimental|ABBV-400+FFB A High|Participants will receive ABBV-400 in combination with FFB at the high dose determined in the safety lead in on dose schedule A as part of the dose optimization, during the 3 year study duration.
89085360|NCT06107413|Experimental|ABBV-400+FFB B Low|Participants will receive ABBV-400 in combination with FFB at the low dose determined in the safety lead in on dose schedule B as part of the dose optimization , during the 3 year study duration.
89085361|NCT06107413|Experimental|ABBV-400+FFB B High|Participants will receive ABBV-400 in combination with FFB at the high dose determined in the safety lead in on dose schedule B as part of the dose optimization, during the 3 year study duration.
88816175|NCT02437890|Experimental|ALX-0061 225 mg q2w|"ALX-0061 225 mg every 2 weeks (q2w).~***~Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46."
89085362|NCT06107413|Experimental|FFB+Irinotecan (Standard of Care [SOC])|Participants will receive SOC during the 3 year study duration.
89085363|NCT06106945|Experimental|AZD0305 monotherapy|"Module 1:~Phase Ia: Dose Escalation Phase Ib: Dose Expansion/Optimization AZD0305 will be prescribed at specified dose levels."
89085364|NCT06106191|Experimental|Mindfulness based stress reduction (MBSR) program|Participants will be enrolled in a 8-week mindfulness clinical pain program + Primary Care Provider (PCP) Usual Care.
89085365|NCT06106152|Experimental|Fixed-dose in patients with advanced lung cancer|WTX212A injection Fixed-dose in advanced lung cancer patients
89085366|NCT06106152|Experimental|Combined Study in patients with advanced lung cancer|Fixed-dose WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer
89085367|NCT06105931|Experimental|Young adults with T1D who have a body mass index <25 kg/m2|Young adults with T1D who have a body mass index <25 kg/m2 will have: abdominal MRI, hyperinsulinemic-euglycemic clamp wtih stable isotope tracer, DEXA scan and a High Fat Mixed Meal Tolerance Test.
89085368|NCT06105632|Experimental|Arm A|PF-07220060 to be taken by mouth as a tablet in combination with fulvestrant (a solution for injection)
89085369|NCT06105632|Active Comparator|Arm B|"Investigator's choice of therapy of either:~Fulvestrant alone (a solution for injection), or~Everolimus in combination with exemestane, both a tablet to be taken by mouth."
89523031|NCT04446533|Active Comparator|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
89085371|NCT06102681|No Intervention|control group|Patients who are in the control group will receive standard clinical care and these patient will be stand up 1. day after operation.
89085372|NCT06102681|Experimental|experimental group|Patients who are in the experimental group will receive standard clinical care and they will stand up 8. hours after operation.
89085373|NCT06097728|Experimental|Volrustomig + Carboplatin + pemetrexed|Volrustomig in combination with carboplatin plus pemetrexed
89085374|NCT06097728|Active Comparator|Investigator's choice of standard care|The investigator's choice of nivolumab plus ipilimumab or platinum plus pemetrexed chemotherapy for participants with epithelioid histology, and nivolumab plus ipilumab for participants with non-epithelioid histology.
89085379|NCT06094413|Experimental|Multicomponent Training Intervention|Subjects in the intervention group will attend two standardized group-based sixty-minute sessions per week in the outpatient medical center and will be asked not to change their current physical activity regimen during the 8-week duration of the study.
89085380|NCT06094413|No Intervention|Control Group|Subjects in the control group will be asked to not change their current level of physical activity during the 8-week duration of the study.
89085381|NCT06093893|Experimental|Dexmedetomidine group|Participants randomized into this group will be given Dexmedetomidine to lower their blood pressure during jaw surgery.
89085382|NCT06093893|Experimental|Nicardipine group|Participants randomized into this group will be given Nicardipine to lower their blood pressure during jaw surgery.
89085383|NCT06093893|Experimental|Labetalol group|Participants randomized into this group will be given Labetalol to lower their blood pressure during jaw surgery.
89085386|NCT06091410|Experimental|C group|concomitant administration of COVID-19 booster and quadrivalent influenza vaccination
89085387|NCT06091410|Placebo Comparator|S group (COVID-19 vaccine only)|separate administration of influenza vaccination followed by COVID-19 booster 4 weeks later
89085388|NCT06091410|Placebo Comparator|S group (influenza vaccine only)|separate administration of influenza vaccination followed by COVID-19 booster 4 weeks later
89085389|NCT06091254|Experimental|Odronextamab|"Part 1 is a safety run-in. All participants will receive odronextamab.~In part 2 participants will be randomly assigned in a 1:1 ratio to receive odronextamab followed by odronextamab maintenance."
89085390|NCT06091254|Active Comparator|Rituximab + Investigator's Choice Chemotherapy|Part 2 only, participants will be randomized 1:1 to receive rituximab in combination with chemotherapy followed by rituximab maintenance.
89085391|NCT06083519|Sham Comparator|White Noise|Participants listened to white noise for 24 minutes
89085392|NCT06083519|Experimental|LUCID Music|Participants listened to music chosen from the VIBE app with theta auditory beat stimulation for 24 minutes
89085393|NCT06081153|Experimental|Evolocumab|Evolocumab is the drug that will be administered in this study. It will be administered as a 140mg subcutaneous injection every 14 days for 5 weeks (for a total of 3 doses).
89085394|NCT06081153|Placebo Comparator|Placebo|This arm is a matching placebo that will be administered in the same fashion as the study drug if the patient is randomized to placebo.
89085395|NCT06080789|Experimental|RABI-767 plus Standard-of-Care|Single-dose 125 mg RABI-767 plus standard-of-care
89085396|NCT06080789|No Intervention|Standard-of-Care Only|No Intervention, Standard-of-Care Only
89085397|NCT06075147||naïve nAMD|Treatment-naive patients with nAMD
89085398|NCT06075147||pretreated nAMD|Pretreated patients with nAMD
89085399|NCT06075147||naïve DME|Treatment-naïve patients with DME
89085400|NCT06075147||pretreated DME|Pretreated patients with DME
88816176|NCT02560779|Experimental|Carotuximab (TRC105) and Sorafenib|Carotuximab (TRC105) in combination with standard dose Sorafenib.
89085401|NCT06073470||ADHD GROUP|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
89085402|NCT06073470||TD GROUP|Typically development controls without lifetime diagnosis with ADHD
89085404|NCT06065059|Experimental|Single Agent Dose Escalation|Participants with BRCA 1/2 mutant or HRD+ solid tumors will receive escalating doses of TNG348 to estimate the MTD
89085405|NCT06065059|Experimental|Combination Dose Escalation|Participants with BRCA 1/2 mutant or HRD+ solid tumors will receive escalating doses of TNG348 in combination with olaparib to estimate the MTD
89085406|NCT06065059|Experimental|Single agent dose expansion in breast cancer|Participants with BRCA 1/2 mutant breast cancer will receive TNG348 at the identified RP2D
89085407|NCT06065059|Experimental|Single agent dose expansion in ovarian cancer|Participants with BRCA 1/2 mutant ovarian cancer will receive TNG348 at the identified RP2D
89085408|NCT06065059|Experimental|Combination therapy dose expansion in breast cancer|Participants with BRCA 1/2 mutant breast cancer will receive TNG348 in combination with olaparib at the identified RP2D
89085409|NCT06065059|Experimental|Combination therapy dose expansion in ovarian cancer|Participants with BRCA 1/2 mutant ovarian cancer will receive TNG348 in combination with olaparib at the identified RP2D
89085410|NCT06065059|Experimental|Combination therapy dose expansion in pancreatic or prostate cancer|Participants with BRCA 1/2 mutant pancreatic or prostate cancer will receive TNG348 in combination with olaparib at the identified RP2D
89085411|NCT06065059|Experimental|Combination therapy dose expansion in HRD+ advanced or metastatic solid tumors|Participants with HRD+ advanced or metastatic solid tumors will receive TNG348 in combination with olaparib at the identified RP2D
89085412|NCT06058793|Experimental|Brigimadlin treatment|
89085413|NCT06058039|Experimental|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA-335140 tablet at a dose of 80 mg QD
89085414|NCT06058039|Placebo Comparator|Placebo|Placebo participants will receive matching placebo tablet once daily
89085415|NCT06058013|Experimental|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA- 335140 tablet at a dose of 80 mg once daily (QD)
89085416|NCT06058013|Placebo Comparator|Placebo|Placebo participants will receive matching placebo tablet once daily.
89085417|NCT06056791|Experimental|Cohort 1: 1 x 10^8 INKmune|"In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~In Cohort 1, the initial planned dose is 1 x 10^8 INKmune;~In Cohort 2, the weekly dose will increase to 3 x 10^8 INKmune;~In Cohort 3, the weekly dose will increase to 5 x 10^8 INKmune.~In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination."
89085418|NCT06056791|Experimental|Cohort 2: 3 x 10^8 INKmune|"In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~In Cohort 1, the initial planned dose is 1 x 10^8 INKmune;~In Cohort 2, the weekly dose will increase to 3 x 10^8 INKmune;~In Cohort 3, the weekly dose will increase to 5 x 10^8 INKmune.~In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination."
89085419|NCT06056791|Experimental|Cohort 3: 5 x 10^8 INKmune|"In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~In Cohort 1, the initial planned dose is 1 x 10^8 INKmune;~In Cohort 2, the weekly dose will increase to 3 x 10^8 INKmune;~In Cohort 3, the weekly dose will increase to 5 x 10^8 INKmune.~In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:~Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination."
89085420|NCT06055049|Experimental|Kinesio Taping (n=28)|"Kinesio taping certified researcher Y.S. It will be implemented by. Kinesio Taping will be applied to the study group participants during three menstrual cycles. Kinesio taping will be done face to face by the researcher in the laboratory. The participants were given the Mcgill Pain Scale Short Form, Menstruation Symptom Scale, Perceived Stress Scale, Pittsburgh Sleep Quality Index and World Health Organization Quality of Life Scale-Short Form (WHOQOL-BREF-TR)  immediately after the third cycle and the fourth cycle without treatment. will be applied. The follow-up of the implementation process will be recorded with the MSF and KBIF prepared by the researcher.~Kinesio tapes will be applied to the sacral area with 100% tension twice a week, starting from the first start of menstruation. It will continue like this until the end of the 3rd period of menstruation."
89085421|NCT06055049|Placebo Comparator|Sham Taping (n=28)|"Sham taping (fake or tensionless kinesio taping) will be applied to students in the placebo group. The quality of the kinesio tape used in sham taping will be the same. Mcgill Pain Scale Short Form, Menstruation Symptom Scale, Perceived Stress Scale, Pittsburgh Sleep Quality Index and World Health Organization Quality of Life Scale-Short Form (WHOQOL-BREF-TR) administered to participants in the placebo group before the first session ) will be refilled at the end of the third cycle and at the end of the fourth cycle without treatment. In order to eliminate the ethical problems that may occur in the control group, kinesio taping will be applied to the participants in this group after the data collection process of the research is completed.~Kinesio tapes will be applied to the sacral area without tension, twice a week, starting from the first start of menstruation. This situation will continue until the end of the 3rd menstrual period."
89085422|NCT06054217|Experimental|Study Cohort 1|Participants who were previously enrolled, dosed, and completed approximately 43 days of TID EV administration. Participants are crossed over to receive BID administration of EV for approximately 43 additional days.
89085423|NCT06054217|Experimental|Study Cohort 2|Participants are randomized to receive BID administration of EV for approximately 85 days.
89085424|NCT06054217|Experimental|Study Cohort 3|Participants are randomized to receive TID administration of EV for approximately 85 days
88816177|NCT01138514|Active Comparator|Clindamycin 1%/Benzoyl Peroxide 5%|
88816178|NCT01138514|Active Comparator|Reference Product|
89085429|NCT06048133|Experimental|Arm A|Quemliclustat (AB680), zimberelimab (AB122), gemcitabine, and cisplatin in subjects with untreated advanced BTC. Quemliclustat IV: Day 1, 15, and 29 of each cycle; Zimberelimab IV: Day 1 and 22 of each cycle; Gemcitabine IV: Day 1, 8, 22 and 29 of each cycle; Cisplatin IV: Day 1, 8, 22 and 29 of Cycles 1-4 only.
89085430|NCT06046417|Experimental|Fully automated rapid insulin-and-pramlintide delivery system (8 μg/u)|Insulin aspart/ insulin lispro and pramlintide fully automated delivery system with no meal announcement. Ratio of 1 unit of insulin for 8 μg of pramlintide.
89085431|NCT06046417|Experimental|Fully automated rapid insulin-and-pramlintide delivery system (10 μg/u)|Insulin aspart/ insulin lispro and pramlintide fully automated delivery system with no meal announcement. Ratio of 1 unit of insulin for 10 μg of pramlintide.
89085432|NCT06046417|Active Comparator|Rapid automated insulin-and-placebo delivery system with carbohydrate-matched boluses|Insulin aspart/ insulin lispro and saline placebo hybrid automated delivery system with meal announcement. Participants must input the carbohydrate content of their meals to inform the insulin bolus doses based on their pre-programmed insulin-to-carbohydrate ratios.
89085433|NCT06043713|Experimental|Treatment (FHA11KRASG12V-TCR)|Patients undergo leukapheresis prior to treatment and receive lymphodepletion chemotherapy with either cyclophosphamide IV and fludarabine IV on days -6, -5, -4, and -3 or bendamustine IV on days -4 and -3 at the discretion of the treating clinician and/or PI. Patients then receive FHA11KRASG12V-TCR IV on day 0. Patients may receive an additional FHA11KRASG12V-TCR IV infusion as soon as 28 days or up to 1 year after the first infusion. Patients undergo ECHO or MUGA during screening. Patients also undergo CT, PET or MRI as well as blood sample collection and a tissue biopsy throughout the trial.
89085434|NCT06042478|Experimental|Remibrutinib|Participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 52 weeks.
89085435|NCT06042478|Placebo Comparator|Placebo to remibrutinib|Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w.
89085436|NCT06042478|Placebo Comparator|Placebo to omalizumab|Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d.
88816179|NCT01138514|Placebo Comparator|Vehicle|
89085437|NCT06042478|Active Comparator|Omalizumab|participants will receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d. for 52 weeks.
89085441|NCT06039865|Experimental|Immediate Intervention|Participants will be provided with a consumer wearable immediately after randomization to wear for 4 weeks.
89085442|NCT06039865|Other|Waitlist control|Participants will receive usual care from the sleep center for 6 weeks and then be provided with a consumer wearable to wear for 4 weeks.
89085443|NCT06034483|Experimental|Pelvic Floor Exercise Training|progressive pelvic floor muscle training for 8 weeks
89085444|NCT06034483|Active Comparator|Patient/Individual Education|Individual/patient education includes menopause, sexual health, pelvic floor health and lifestyle issues.
89085445|NCT06031402|Experimental|Early endoscopy group|Intervention of endoscopy is within 12 hours after admission
89085446|NCT06031402|Active Comparator|Delayed endoscopy group|Intervention of endoscopy is within 12-24 hours after admission
89085447|NCT06029439|Experimental|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA-335140 tablet at a dose of 80 mg once daily (QD) during a 52-week treatment period.
89085448|NCT06029426|Experimental|NMRA-335140 80 milligrams (mg) once daily (QD)|Participants will receive a NMRA- 335140 tablet at a dose of 80 mg once daily (QD)
89085449|NCT06029426|Placebo Comparator|Placebo|Placebo participants will receive matching placebo tablet orally, once daily. Participants who complete the study may be eligible to participate in a separate 52-week open-label long term study.
89085450|NCT06027320|Experimental|Brain Health Education Arm|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
89085451|NCT06027320|Other|Alzheimer Disease Education Arm|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
89085452|NCT06023095|Experimental|LY3502970|LY3502970 administered orally
89085453|NCT06023095|Placebo Comparator|Placebo|Placebo administered orally
89085454|NCT06022068|Experimental|Rapamycin|Sirolimus tablets will be administered orally, 7 mg once per week during 26 weeks
89085455|NCT06020573|Other|Intraoperative detection of light signals during electrosurgical breast cancer resection|Participants undergo electrosurgical breast cancer resection while light signals are detected intraoperatively
89085456|NCT06019884|Experimental|Intraoral camera, no prevention specified|
89085457|NCT06019884|Experimental|Intraoral camera, prevention specified|
89085458|NCT06019884|Experimental|Smartphone camera, no prevention specified|
89085459|NCT06019884|Experimental|Smartphone camera, prevention specified|
89085460|NCT06019845|Experimental|Treatment|Magnetic Interventional Ablation Catheter (MAGiC™)
89225867|NCT05189847||Patients with a history of established isolated coronary artery disease|The criterion for inclusion of patients in the present study is the diagnosed ischemic heart disease.
89085464|NCT06018610|Experimental|Intervention Group|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group. Patients will be re-evaluated 3 days after the completion of the interventions.
89085465|NCT06018610|Active Comparator|Control Group|The control group will receive conventional rehabilitation practices (in and out of bed strengthening exercises, for 3 days).
89085468|NCT06015282|Experimental|Investigational aQIVc group|
89085469|NCT06015282|Active Comparator|licensed QIV1 group|
89085470|NCT06015282|Active Comparator|licensed QIV2 group|
89085471|NCT06012591|Other|WHO Standard implementation|
89085472|NCT06009432|Experimental|Intervention Group|In addition to the program given to the control group, the study group will be given proprioceptive neuromuscular facilitation exercise as previously described (Smedes et. al., 2021). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
89085473|NCT06009432|Active Comparator|Control Group|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises activities of daily living recommendations.
89085474|NCT06009419|Experimental|Intervention Group|In addition to the program given to the control group, the dual task program will be progressively given to the study group as previously described (Silsupadol et al., 2006). These applications will be explained to the patients or their relatives face-to-face in the clinical environment after the initial evaluation and then sent and followed up by telerehabilitation method and patients will always have access to programs and education. In addition, both groups will be told that they can contact the researcher upon request.
89085475|NCT06009419|Active Comparator|Control Group|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises activities of daily living recommendations.
89085476|NCT06009380|Experimental|Intervention Group|In addition to the program given to the control group, the dual task program will be given to the study group progressively as previously stated (Silsupadol et al., 2006). These applications will be explained to the patients or their relatives face-to-face in the clinical environment after the initial evaluation and then sent and followed up by telerehabilitation method and patients will always have access to programs and education. In addition, both groups will be told that they can contact the researcher upon request.
89085477|NCT06009380|Active Comparator|Control Group|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises activities of daily living recommendations.
89085478|NCT06009354|Experimental|Intervention Group|The study group will receive multi-component training in addition to the usual practices. In the multi-component training content, self-massage applications performed by the patient's relatives, joint range of motion applications for the extremities, respiratory training, issues to be considered in activities of daily living, training on the use of assistive devices and training on methods of coping with pain kinesiophobia will be given to the patient's relatives through a video.
89085479|NCT06009354|Active Comparator|Control Group|The control group will receive the usual post-operative applications (elevation, rest, cold application, stretching).
89225868|NCT05188469|Experimental|EG-COVID-003|"Subjects will receive one single IM vaccination, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~Component Description (per dose):~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
89085480|NCT06009341|Experimental|Intervention Group|In this study, the intervention group will be given comprehensive training in addition to standard conservative follow-up (pain spasm pain cycle, pain does not always mean that there is a problem, tissue repair, fall prevention, lower extremity classical massage, muscle relaxation relaxation methods, respiratory control), while the control group will be followed only with conservative treatment applications (muscle strengthening, stretching). The applications will be performed with 10 repetitions each day.
89085481|NCT06009341|Active Comparator|Control Group|The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given.
89085482|NCT06008301|Experimental|Consent for the entire study|Participants with a newly diagnosed breast cancer and recommended for enhanced imaging will be randomly assigned to either CEM or MRI and take the State-Trait Anxiety Inventory (STAI) before and after imaging.
89085483|NCT06008301|Active Comparator|Consent only for the STAI|Participants with a newly diagnosed breast cancer and recommended for enhanced imaging but who cannot or choose not to be randomly assigned to CEM or MRI but they consent to take the State-Trait Anxiety Inventory (STAI) before and after imaging.
89085484|NCT06007638|Experimental|LY3876602|Single ascending doses of LY3876602 administered intravenously (IV).
89085485|NCT06007638|Placebo Comparator|Placebo|Placebo administered IV.
89085486|NCT06006325|Experimental|Electroacupuncture (EA)|"The acupoints were Deqi, and the electroacupuncture stimulator was connected and energized."
89085487|NCT06006325|Sham Comparator|Sham electroacupuncture (SHAM-EA)|"No Deqi operation was performed on non-acupuncture points, and the electroacupuncture stimulator was connected and not energized."
89085488|NCT06003153|Other|GLUCOSE-MGH Study|"Day 1: Mixed meal tolerance test~Day 3-15: 7mg Rybelsus, once daily~Day 16: 1 dose of 7mg Rybelsus, Mixed meal tolerance test in the presence of Rybelsus"
89230208|NCT00661193|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89085489|NCT06001762|Experimental|Abemaciclib|"Study procedures will be conducted as follows:~Cycles 1 - 24~Days 1 - 28 of 28-day cycle: Predetermined dose of Abemaciclib 2 x per day.~Endocrine therapy 1 x per day.~In clinic visits with blood tests, questionnaires, and assessments:~Day 1 of Cycles 1, 2, and 3~Day 15 of Cycles 1 and 2~Every three cycles after Cycle 3 Day 1.~End of treatment visit with blood tests, questionnaires, assessments, and stool sample collection."
89085490|NCT05999864|Experimental|Intervention Group|In addition to the program given to the control group, proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
89085491|NCT05999864|Active Comparator|Control Group|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises activities of daily living recommendations.
89085492|NCT05997238|Placebo Comparator|Placebo|LIA preparation was administered without triamcinolone. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
89085493|NCT05997238|Experimental|Low dose triamcinolone|Add 20mg triamcinolone to the LIA preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
89085494|NCT05997238|Experimental|Moderate dose triamcinolone|add 40mg triamcinolone to the LIA preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
89085495|NCT05997238|Experimental|High dose triamcinolone|add 80mg triamcinolone to the LIA preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
89085496|NCT05996744|Experimental|Obeldesivir (ODV)|"Participants will receive ODV for 5 days. The ODV dose to be administered in each cohort based on age and weight as follows:~Cohort 1: ODV, tablets, 350 mg twice daily (BID)~Cohort 2: ODV, tablets, 175 mg BID~Cohorts 3-7: ODV doses will be determined based on available PK data."
89085497|NCT05995873|Sham Comparator|treatment|Half of the participants will receive sham. Treatment will be 2 times a week for 4 weeks, then once a week for 20 weeks and then a followup 1 week later. The sham device is identical to the active device except that it has foil over the LED.
89085498|NCT05995873|Experimental|Active treatment|Participants in this group will receive a 4-minute unilateral transcranial photobiomodulation treatment.
89085499|NCT05995769|Experimental|High Dose (25mg)|PEX010 (Oral Psilocybin), 25mg; single dose administered 24hrs prior to first of 5 weekly MET sessions
89085500|NCT05995769|Active Comparator|Low dose (1mg)|PEX010 (Oral Psilocybin), 1mg; single dose administered 24hrs prior to first of 5 weekly MET sessions
89085501|NCT05995340|Experimental|ELAPR002f Injectable Gel|Participants will receive 3 treatments of ELAPR002f injectable gel into the cheek area on each side of the face.
89085502|NCT05995340|Other|Saline Control|Participants will receive 3 treatments of Saline Control into the cheek area on each side of the face.
89085503|NCT05994248|Experimental|Non-Absorbable Synthetic Mesh|Subjects randomized to the non-absorbable synthetic mesh arm will undergo the procedure (umbilical hernia repair) to receive Marlex mesh.
89085504|NCT05994248|Active Comparator|Absorbable Synthetic Mesh|Subjects randomized to the absorbable synthetic mesh arm will undergo the procedure (umbilical hernia repair) to receive Enform mesh.
89085505|NCT05993585|Experimental|CRT Group|CRT group: We will include patients with symptomatic heart failure (LV ejection fraction <35% on TTE, NYHA II-IV) and an RV pacing percentage of >40%, thus meeting ESC Criteria for CRT upgrade.
89085506|NCT05993585|Active Comparator|Control Group|Control group: patients with an existing dual chamber pacemaker and with preserved ejection fraction
89085507|NCT05992077|Experimental|Therapeutic phase|Children and adolescents confirmed with active HCV infection (positive HCV RNA) during the screening phase will be referred to a specific consultation in Kantha Bopha hospital and in the National Pediatric Hospital for treatment after evaluation of liver disease. Patients with a weight > 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks. For all children and adolescents, residual plasma concentrations (trough concentrations) of the drugs will be assessed after 2 weeks of treatment.
89085508|NCT05988632|Experimental|Insulin, Then Placebo|There will be one single administration of intranasal human insulin (80IU) before alcohol self-administration. After a one week washout period, there will be one single intranasal administration of placebo (saline, 0.9% solution) before alcohol self administration.
89085509|NCT05988632|Experimental|Placebo, Then Insulin|There will be one single intranasal administration of placebo (saline, 0.9% solution) before alcohol self administration. After a one week washout period, there will be one single administration of intranasal human insulin (80IU) before alcohol self-administration.
89085514|NCT05987124|Experimental|Defibrotide|7.1.1 HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought (see 7.2 for definition of response) (Maximum of 4 dose levels) (7.1.2):
89085515|NCT05986786|Experimental|AVT06 (proposed aflibercept biosimilar) PFS|IVT injection with a PFS containing the proposed aflibercept biosimilar AVT06
89085516|NCT05985915|Experimental|Ianalumab Monthly|ianalumab 300 mg s.c. monthly
89085517|NCT05985915|Experimental|Ianalumab 3 Monthly|ianalumab 300 mg s.c. every three months
89085518|NCT05983302|Experimental|Platelet-Rich Plasma-Fibrin Glue|The first intervention group (group A) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing platelet-rich plasma-fibrin glue intervention for 8 weeks.
89085519|NCT05983302|Experimental|Repairing Gel|The second intervention group (group B) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing repairing gel intervention for 8 weeks. The components of repairing gel are vitamin A - vitamin C - vitamin B3 - glycine amino acid. - ethanol - collagen - citric acid - glycerin - malic acid - urea - carboxymethyl cellulose - Sodium alginate - Benzoic acid - Allantoin - Bromelain - Methylene blue - Violet dimethyl sulfoxide . The formulation is patented. (PCT, IR108458)
89085520|NCT05983302|Experimental|Platelet-Rich Plasma-Fibrin Glue and Repairing Gel|The third intervention group (group C) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing the repairing gel with approved wound healing components and platelet-fibrin glue for 8 weeks.
89085521|NCT05983302|Experimental|Classical wound irrigation (control)|For 10 patients with chronic wounds, only classical wound irrigation by normal saline (0.9%) will be continued for 8 weeks.
89085522|NCT05982054|Other|bone marrow injection|injection of autologous concentrated bone marrow cells under ultrasound and fluoroscopy guide after core decompression
89085523|NCT05976243|Experimental|Remibrutinib, symptomatic dermographism group|Remibrutinib oral twice daily in participants with symptomatic dermographism
89085524|NCT05976243|Placebo Comparator|Placebo, symptomatic dermographism group|Placebo oral twice daily, symptomatic dermographism
89085525|NCT05976243|Experimental|Remibrutinib, cold urticaria group|Remibrutinib oral twice daily, cold urticaria
89085526|NCT05976243|Placebo Comparator|Placebo, cold urticaria group|Placebo oral twice daily, cold urticaria
89085527|NCT05976243|Experimental|Remibrutinib, cholinergic urticaria group|Remibrutinib oral twice daily, cholinergic urticaria
89085528|NCT05976243|Placebo Comparator|Placebo, cholinergic urticaria|Placebo oral twice daily, cholinergic urticaria
89085529|NCT05970887|Experimental|C group|Concomitant administration of bivalent mRNA COVID-19 booster and quadrivalent influenza vaccination
89085530|NCT05970887|Placebo Comparator|S group (COVID-19 vaccine only)|separate administration of influenza vaccination followed by bivalent BA.4/BA.5 mRNA booster ≥4 weeks later
89225869|NCT05188469|Experimental|EG-COVID-001|"Subjects will receive one single IM vaccination, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~Component Description (per dose):~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
89085531|NCT05970887|Placebo Comparator|S group (influenza vaccine only)|separate administration of influenza vaccination followed by bivalent BA.4/BA.5 mRNA booster ≥4 weeks later
89085532|NCT05967624|Experimental|Teleconsultation group|Eligible children managed by urban paramedic teams responding to 911 calls in the prehospital setting to support a future trial of clinical efficacy.
89085533|NCT05966662|Experimental|Single-Arm|Subjects with de novo, calcified coronary artery lesions presenting with stable, unstable, or silent ischemia that are suitable for percutaneous coronary intervention (PCI).
89085534|NCT05964335|Experimental|NAL ER 27 mg|BID
89085535|NCT05964335|Experimental|NAL ER 54 mg|BID
89085536|NCT05964335|Experimental|NAL ER 108 mg|BID
89085537|NCT05964335|Placebo Comparator|Placebo|Placebo, tablets BID
89085538|NCT05959278|Experimental|Group 1 - Vestibular rehabilitation - initially supported by the app|First two and a half weeks - conventional vestibular rehabilitation supported by an app Second two and a half weeks - conventional vestibular rehabilitation without an app
89085539|NCT05959278|Experimental|Group 2 - Vestibular rehabilitation - initially without the support of the app|First two and a half weeks - conventional vestibular rehabilitation without an app Second two and a half weeks - conventional vestibular rehabilitation supported by an app
89085540|NCT05959096|Experimental|LY3437943 (Part A)|LY3437943 administered subcutaneously (SC) in either thigh, upper arm, or abdomen
89085541|NCT05959096|Experimental|LY3437943 (Part B)|LY3437943 administered intravenously (IV)
89225870|NCT05188469|Experimental|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
89085542|NCT05958134||Diagnosed with diffuse large B-cell lymphoma, and classified regarding the cell of origin|Retrospective data collection will be carried out from the medical records of the participants included in the study. Will be held description of the epidemiological profile and pathological staging of diffuse large B-cell lymphoma conditions (DLBCL/LDGCB), imaging profiling, together with first-line treatment used in subgroups of germinal center or activated B-cell, in patients followed in Brazilian reference cancer treatment centers, within the last 6 years (between 2017 and 2022).
89085543|NCT05958121|Experimental|Dose escalation/de-escalation (Phase Ia)|Dose-Finding of IMA402 (Phase Ia)
89085544|NCT05958121|Experimental|Dose extension (Phase Ib)|IMA402 monotherapy extension cohorts based on maximum tolerated dose (MTD) and/or recommended doses for extensions (RDEs) (Phase Ib)
89085545|NCT05958121|Experimental|Dose extension (Phase II)|Selected ISEC investigated on MTD/RDEs based on a manageable/favorable safety profile and initial signs of anti-tumor activity (Phase II)
89085547|NCT05952167|Placebo Comparator|Placebo mechanical cervical traction|
89085548|NCT05952167|Experimental|Mechanical cervical traction|
89085549|NCT05951777|Experimental|Treatment|Autologous Adipose Derived Mesenchymal Stem Cells
89085550|NCT05951777|Placebo Comparator|Placebo|Normal Saline
89085551|NCT05951725|Experimental|Experimental vaccine group A，3 months old|4 doses of DTcP vaccine (0.5 ml) on Day 0 and Month 1,2,15~21
89085552|NCT05951725|Active Comparator|Control vaccine group B，3 months old|4 doses of DTaP vaccine (0.5 ml) on Day 0 and Month 1,2,15~21
89085553|NCT05951725|Active Comparator|Control vaccine group C，3 months old|4 doses of DTaP-IPV-Hib vaccine (0.5 ml) on Day 0 and Month 1,2,15~21
89085554|NCT05951725|Experimental|Experimental vaccine group D，2 months old|4 doses of DTcP vaccine (0.5 ml) on Day 0 and Month 1,2,16~22
89085555|NCT05951725|Active Comparator|Control vaccine group E，2 months old|4 doses of DTaP-IPV-Hib vaccine (0.5 ml) on Day 0 and Month 1,2,16~22
89085556|NCT05951725|Experimental|Experimental vaccine group F，2 months old|4 doses of DTcP vaccine (0.5 ml) on Day 0 and Month 2,4,16~22
89085557|NCT05949905|Experimental|Precontemplation, Contemplation, Preparation, Action, and Maintenance-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Precontemplation Stage of Change.
89085558|NCT05949905|Experimental|Contemplation-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Contemplation Stage of Change.
89085559|NCT05949905|Experimental|Preparation-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Preparation Stage of Change.
89085560|NCT05949905|Experimental|Action-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Action Stage of Change.
89085561|NCT05949905|Experimental|Maintenance-based intervention|The intervention that would consider the Processes of Change that people use when they would be in the Maintenance Stage of Change.
89085564|NCT05947058|Experimental|Arthroplasty|A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. We recommend surgeons consider a total hip arthroplasty for younger active, independent participants; conversely, a hemiarthroplasty is recommended for more frail, lower-demand participants. Similarly, cemented arthroplasty for older adult participants is also recommended. The surgical approach and the use of post-operative hip precautions will be determined by the treating surgeon.
89085565|NCT05947058|Active Comparator|Internal Fixation|Based on the fracture displacement eligibility criteria, minimal or no reduction is expected during the surgical procedure. However, the treating surgeon will be allowed to perform fracture reduction maneuvers if desired. Fixed angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. If using multiple cancellous screws, an inverted triangle or similar screw pattern is recommended. Fixed angle devices, such as a sliding hip screw (with or without an anti-rotation screw) or newer multi-screw fixed angle devices will also be permitted. Internal fixation constructs combining cancellous screws and fixed angle devices will be permitted.
89085566|NCT05945108||Non-muscle-invasive bladder cancer or Muscle-invasive bladder cancer|"Defined as:~T1 tumor and/or high-grade lesion (G3) and/or presence of CIS (Carcinoma in situ).~Multifocal relapsed tumor and with at least one large lesion (diameter ≥ 3 cm);~Or:~-Diagnosis of early muscle-invasive urothelial bladder carcinoma."
89085567|NCT05938777|Experimental|Non-Stage-Matched Intervention|The proposed arm would be non-Stage-matched that involves using different Processes of Change as strategies to enhance engaging in regular physical exercise.
89085568|NCT05938634|Experimental|Precontemplation|The intervention that would involve the Processes of Change that people use when they would be in the Precontemplation Stage of Change.
89085569|NCT05938634|Experimental|Contemplation-based intervention|The intervention that would involve the Processes of Change that people use when they would be in the Contemplation Stage of Change.
89085570|NCT05938634|Experimental|Preparation-based intervention|The intervention that would involve the Processes of Change that people use when they would be in the Preparation Stage of Change.
89085571|NCT05938634|Experimental|Action-based intervention|The intervention that would involve the Processes of Change that people use when they would be in the Action Stage of Change.
89085572|NCT05938634|Experimental|Maintenance-based intervention|The intervention that would involve the Processes of Change that people use when they would be in the Maintenance Stage of Change.
89085573|NCT05937152|Experimental|Eptinezumab Group|Subjects diagnosed with diabetic polyneuropathy (DPN) will receive 2 infusions of eptinezumab during the 24 week-long placebo-controlled treatment period.
89085574|NCT05937152|Placebo Comparator|Placebo Group|Subjects diagnosed with diabetic polyneuropathy (DPN) will receive 2 infusions of placebo during the 24-week long placebo-controlled treatment period.
89085575|NCT05937152|Experimental|Open-label Eptinezumab Group|At the end of the placebo-controlled treatment period, all participants will have the option to continue into the 24-week long active study treatment period and will receive 2 infusions of eptinezumab.
89085576|NCT05936619|Experimental|Mind Extender (MindEx)|MindEx consists of two Neuroport Multi-Port Arrays, described in detail in the intervention description. Each NeuroPort Multi-Port Array comprises two electrode arrays implanted into human brain tissue, for a total of four electrode arrays. These will be in 1) prefrontal cortex, a brain area involved in scene comprehension, action selection, and error signaling, 2) premotor cortex, a brain area involved in planning ongoing and upcoming actions, 3) posterior parietal cortex, a brain area involved in processing sensory-to-motor transformations during movements, and 4) primary motor cortex, responsible for controlling movement. The pair of electrode arrays in each NeuroPort Multi-Port Array connect to a single percutaneous pedestal attached to the skull during a surgical procedure. Following recovery from the surgical placement, subjects will participate in study sessions up to 5 times a week. They will learn to use thought to control applications on a computer, a laptop, or a tablet.
89085577|NCT05931874|Experimental|Exp Condition 1|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + MVPA Specific Mindfulness Training + Buddy
89085578|NCT05931874|Active Comparator|Exp Condition 2|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + MVPA Specific Mindfulness Training
89085579|NCT05931874|Active Comparator|Exp Condition 3|Research participant receives the Core Intervention + E-Coach + Buddy
89085580|NCT05931874|Active Comparator|Exp Condition 4|Research participant receives the Core Intervention + E-Coach
89085581|NCT05931874|Active Comparator|Exp Condition 5|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training + Buddy
89085582|NCT05931874|Active Comparator|Exp Condition 6|Research participant receives the Core Intervention + E-Coach + General Mindfulness Training
89085583|NCT05931874|Active Comparator|Exp Condition 7|Research participant receives the Core Intervention + E-Coach + MVPA Specific Mindfulness Training + Buddy
89085584|NCT05931874|Active Comparator|Exp Condition 8|Research participant receives the Core Intervention + E-Coach + MVPA Specific Mindfulness Training
89085585|NCT05931874|Active Comparator|Exp Condition 9|Research participant receives the Core Intervention + General Mindfulness Training + Buddy
89085586|NCT05931874|Active Comparator|Exp Condition 10|Research participant receives the Core Intervention + General Mindfulness Training
89085587|NCT05931874|Active Comparator|Exp Condition 11|Research participant receives the Core Intervention + MVPA Specific Mindfulness Training + Buddy
89085588|NCT05931874|Active Comparator|Exp Condition 12|Research participant receives the Core Intervention + MVPA Specific Mindfulness Training
89085589|NCT05931874|Active Comparator|Exp Condition 13|Research participant receives the Core Intervention + General Mindfulness Training + MVPA Specific Mindfulness Training + Buddy
89085590|NCT05931874|Active Comparator|Exp Condition 14|Research participant receives the Core Intervention + General Mindfulness Training + MVPA Specific Mindfulness Training
89085591|NCT05931874|Active Comparator|Exp Condition 15|Research participant receives the Core Intervention + Buddy
89085592|NCT05931874|Active Comparator|Exp Condition 16|Research participant receives the Core Intervention
89225871|NCT05188469|Experimental|B: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
89225872|NCT05188469|Experimental|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
89225873|NCT05184296|Experimental|cohort 1|Participants taking VA-ECMO during the period of study are referred to as cohort 1
89225874|NCT05184296|No Intervention|cohort 2|Patients receiving only conventional therapy without ECMO belong to cohort 2
89225875|NCT05181982||Intervention Group|Patients being treated at the FIT hospital (Pfalzklinikum) between January 2020 and December 2023
89225876|NCT05181982||Control group|Patients being treated in standard care (control hospitals) in the German federal state Rheinland-Pfalz
89225877|NCT05181657|Experimental|LinkUP Active intervention|"The counselor will present basic evidence-based COVID-19 information on SARS-CoV-2 biology and epidemiology, testing and the safety and efficacy of available COVID-19 vaccines. The counselor will also address COVID-19 misinformation (e.g., that COVID is no worse than the flu), and COVID-19 disinformation (e.g., that COVID vaccines include a tracking device).~The LinkUP active intervention combines education, motivational interviewing (MI), problem-solving, and ongoing support from peer counselors. Through an open discussion with one of OnPoint's peer counselors who are trained in MI, the counselor will present evidence-based COVID-19 information. Next, the counselor will attempt to identify the participant's concerns about COVID-19 and vaccination in an attempt to tip their decisional balance."
89225878|NCT05181657|Placebo Comparator|LinkUP Control Condition (didactic intervention)|As described above, the control condition is a one-way sharing of COVID-19 information presented by an OnPoint counselor. The counselor will be instructed to answer any questions the participant may have but will not engage in motivational interviewing counseling. The same educational materials used in the LinkUP intervention module will be used for this session and it will be completed within 45 minutes.
89225879|NCT05180825|Experimental|Trametinib experimental arm|the experimental arm will be Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
89225880|NCT05180825|Active Comparator|Vinblastine control arm|the control arm will be the weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
89225881|NCT05179928|Active Comparator|Group E (n=30)|Erector Spinae Plane Block
89225882|NCT05179928|Active Comparator|Group R (n=30)|Rectus Sheath Block
89225883|NCT05175794||Cohort 1|Participants that test positive for Mycobacterium tuberculosis (M.tb) with rifampicin resistance will be enrolled in Cohort 1 (n=880).
89225884|NCT05175794||Cohort 2|Participants that test positive for M.tb that are rifampicin susceptible with isoniazid mono-resistance will be enrolled in Cohort 2 (n=400).
89225885|NCT05174312|Experimental|Reprieve Decongestion Management System|Subjects randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
89225886|NCT05174312|Active Comparator|Optimal Diuretic Therapy|Sites will consider best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC) for patients randomized to control arm of the trial.
89225887|NCT05168943|Active Comparator|Group N (n=30)|Continuous Epidural Anesthesia using Nylon (Polyamide) Epidural Catheter
89225888|NCT05168943|Active Comparator|Group P (n=30)|Continuous Epidural Anesthesia using Polyurethane Epidural Catheter
89225889|NCT05163314|Experimental|Soticlestat|Participants with DS and LGS will receive:Participants weighing <45kg:Soticlestat,mini-tablets,titrated from lower dose level(60mg to 140mg) to higher dose(100mg to 200mg) twice daily(BID),based on body weight,orally/via enteral feeding tubes including but not limited to nasogastric(NG)-tube,gastrostomy tube(G-tube),MIC-KEY button,upto 2 weeks in Titration Period. Will continue to receive dose they are on at end of Titration Period,for approximately 4 years in Maintenance Period.Dose will be tapered down to lower dose(not less than lowest dose level based on weight)every 3 days until study drug is discontinued(upto 1week) in Taper Period.Participants weighing ≥45kg/adults:Soticlestat mini-tablets/tablets with starting dose of 200mg BID followed by 300mg BID,up to 2 weeks in Titration Period.Will continue to receive 300mg BID for approximately 4 years in Maintenance Period.Dose will be tapered down upto 100mg every 3 days until study drug is discontinued(up to 1 week) in Taper Period.
89225890|NCT05157581||Sezary Syndrome|15 subjects with Sezary Syndrome will comprise the single arm of this study
89225891|NCT05156151|Other|Stromal lenticule implantation for management of herpetic stromal keratitis|"The thickness of the herpetic stromal scar in the cornea is calculated in microns in OCT. Based on that extraction is performed using SMILE, a new lenticular stromal pocket is placed in the same volume. AS-OCT evaluated the corneal topography, glass-corrected best visual acuity (BSCVA) measurements and electron microscopy. Postoperative complications were monitored during the follow-up period.~During the three year follow-up period, no signs of recurrence or infections were detected in this patient."
89225892|NCT05155085|Experimental|Lirentelimab (AK002) SC 300 mg|Subjects in this arm will receive 7 doses of 300 mg of lirentelimab (AK002) administered subcutaneously every 2 weeks.
89225893|NCT05155085|Other|Placebo|Placebo
89225894|NCT05154929|Other|Control arm|Participants in the control group will be provided a smartwatch and home blood pressure monitor. They will also be provided with general instructions on how to download and install a physical activity and diet regulation applications (apps) available to the general public. They will still be asked to perform the blood pressure monitoring at regularly scheduled time periods, but do not receive the intervention components notifications in myBPmyLife app developed for the experimental group.
89225895|NCT05154929|Experimental|Dietary plus physical activity JITAI|Participants in the experimental group will be provided a smarthwatch and home blood pressure monitor. They will then receive the myBPmyLife app that includes push notifications to promote increased physical activity and improve low sodium food choices. The app also provides goal setting for weekly step count and information on low-sodium food choices, as well as feedback on achieving the goals using a dashboard with visualization tools within the mobile application.
89085593|NCT05924984|Experimental|perforator localization|CT and color Doppler ultrasound were used to locate the perforating branch of the descending branch of the lateral circumflex femoral artery, and the position of the perforator was compared with real perforator respectively during the operation.
89085594|NCT05919329|Experimental|Cohort 1: CRPC|Patients with CRPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.
89085595|NCT05919329|Experimental|Cohort 2: CSPC|Patients with CSPC will receive 18F-DCFPyL PET prior to start of therapy (standard of care), then again 8 days and 28 days after initiation of hormonal therapy.
89085596|NCT05916560|Experimental|LY3437943 (Normal Hepatic Function)|LY3437943 administered subcutaneously (SC).
89085597|NCT05916560|Experimental|LY3437943 (Severe Hepatic Impairment)|LY3437943 administered SC.
89085598|NCT05916560|Experimental|LY3437943 (Moderate Hepatic Impairment)|LY3437943 administered SC.
89085599|NCT05916560|Experimental|LY3437943 (Mild Hepatic Impairment)|LY3437943 administered SC.
89085600|NCT05914441||Thrombotic thrombocytopenic purpura patients|Including all patients enrolled in the study
89085604|NCT05906368|Sham Comparator|Conventional Care|Patients are wearing both a conventional blood pressure cuff and the ClearSight finger cuff blood pressure monitoring system. Only measures from the conventional blood pressure cuff are sent/received by the clinical staff in the central and local nursing and anesthesia staff areas. The ClearSight monitoring system data is collected but not used by the clinical staff team for hypotensive monitoring.
89085605|NCT05906368|Experimental|ClearSight Monitoring|Patients are wearing both a conventional blood pressure cuff and the ClearSight finger cuff blood pressure monitoring system. Measures from BOTH the conventional blood pressure cuff and ClearSight monitoring system are sent/received by the clinical staff in the central and local nursing and anesthesia staff areas. ClearSight monitoring will add additional information regarding hypotensive events for clinical staff to respond to.
89085607|NCT05900141|Experimental|Pelacarsen (TQJ230)|open-label pelacarsen 80 mg
89085608|NCT05899985|Other|Single Arm|Eligible subjects will undergo their normal standard of care treatment pathway with the added interventions described below.
89085609|NCT05899725|Active Comparator|Cohort 1: severe CIP with the treatment of corticosteroids|severe CIP with the treatment of corticosteroids
89085610|NCT05899725|Experimental|Cohort 2: severe CIP with the treatment of corticosteroids and Ruxolitinib|severe CIP with the treatment of corticosteroids and Ruxolitinib
89085613|NCT05893147|Active Comparator|De-escalation VS No De-escalation|
89085614|NCT05893147|Active Comparator|Oral beta-lactams VS Oral Non-beta-lactams|
89085615|NCT05893147|Active Comparator|Central vascular catheter retention VS Central vascular catheter replacement|
89085616|NCT05893147|Active Comparator|Cephalosporin VS Carbapenem for low risk AmpC organisms|
89085617|NCT05893147|Active Comparator|Routine follow-up blood culture VS No routine follow-up blood culture|
89085618|NCT05891496|Experimental|Study intervention period 1|Participants will receive either semaglutide or placebo matched to semaglutide once-weekly subcutaneous (s.c.) injections for 12 weeks as an add on therapy to standard of care. Participants initially received 0.25 milligram (mg) once weekly and the dose was then escalated once in 4 weeks until the maintenance dose (1.0 mg) was reached: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 12).
89085619|NCT05891496|Placebo Comparator|Study intervention period 2|All participants will receive 1.0 mg semaglutide s.c. injections once weekly for 52 weeks during study intervention period 2 as an add-on therapy to standard of care. Participants randomised to semaglutide s.c. 1.0 mg during study intervention period 1 remained on 1.0 mg target maintenance dose for 52 weeks from weeks 12-64. Participants initially randomised to placebo during study intervention period 1 will receive semaglutide s.c. in dose escalation fashion for 8 weeks (0.25 mg from weeks 12-16 and 0.5 mg from weeks 16-20) followed by a maintenance period from weeks 20-64 at dose 1.0 mg.
89085620|NCT05891340|No Intervention|Control|Preoperative exercise, alcohol and smoking cessation are recommended to patients.
89085621|NCT05891340|Active Comparator|Intervention|Respiratory muscle exercise (two times a day) and walking (5000steps/day) are recommended to the patients preoperatively.
89085622|NCT05889468|Active Comparator|Treatment Group|The treatment group will be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission. Patients will be scheduled for a 4-6 week postpartum clinic appointment, which is standard for these patients outside of this proposal.
89085623|NCT05889468|Placebo Comparator|Placebo Group|The control group will receive a 6-week supply of placebo medication from the Investigational Pharmacy prior to discharge. The placebo will be identically appearing to the 81 mg aspirin. Patients will be scheduled for a 4-6 week postpartum clinic appointment, which is standard for these patients outside of this proposal.
89085624|NCT05887999|Experimental|LY3532226|
89085625|NCT05887999|Placebo Comparator|Placebo|
89085626|NCT05887492|Experimental|Dose Escalation|Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD
89085627|NCT05887492|Experimental|Dose Expansion in NSCLC with KRAS Mutation|Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab
89085628|NCT05887492|Experimental|Dose Expansion in NSCLC with KRAS Wild type|Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab
89085629|NCT05887492|Experimental|Dose Expansion in Advanced or Metastatic Solid Tumors|Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab
89085630|NCT05885555|Experimental|Single-arm|All eligible participants will receive ianalumab at the same dose.
89085631|NCT05884645||Patients undergoing endotracheal intubation|Patients across all ages undergoing endotracheal intubation.
89085632|NCT05882058|Experimental|Dose group 1|
89085633|NCT05882058|Experimental|Dose group 2|
89085634|NCT05880810|Experimental|Continuous Glucose Monitoring|Subjects admitted to the Advanced Care at Home program (home hospital) will have the continuous glucose monitor sensor placed for up to 10 days to monitor and dose insulin.
89085635|NCT05880810|No Intervention|Control Arm (Standard of Care)|Subjects admitted to the Advanced Care at Home program (home hospital) will continue with standard of care glucose monitoring (capillary glucose levels checked via glucometer), insulin dosing, and DM treatment during the 10 day period.
89085638|NCT05878938|Experimental|NNC0365-3769 (Mim8) PPX|Participants will receive Mim8 prophylaxis (PPX) subcutaneous (s.c.) injection using a prefilled fixed dose DV3407-C1 pen-injector.
89085639|NCT05877924|Experimental|NBL-020|"Dose increasing study: The initial dose for the dose escalation study is 0.1 mg/kg administered once every 3 weeks (Q3W), with a pre-set maximum escalation dose of 30 mg/kg Q3W.~Dose expansion study: Based on the results of the dose escalation study, the dosage for the dose extension study will be determined through joint discussion between the sponsor and the investigators."
89085640|NCT05872230|No Intervention|Control|Patient receives standard postoperative care with no percussion therapy.
89085641|NCT05872230|Experimental|PACU percussion|Patient receives percussion therapy in the PACU immediately after surgery.
89085642|NCT05872230|Experimental|Postoperative appointment percussion|Patient receives percussion therapy in the office on the day of follow up.
89085643|NCT05872230|Experimental|Both PACU and Postop appointment percussion.|Patient receives percussion therapy in the PACU and receives percussion therapy in the office on the day of follow up.
89085644|NCT05867667|Experimental|Cardiac Rehabilitation to Improve Breast Cancer Outcomes|12 weeks of Cardiac Rehab
89085649|NCT05865886|Experimental|BI 1291583 group|
89085650|NCT05865886|Placebo Comparator|Placebo group|
89085651|NCT05858515|Placebo Comparator|Placebo|These participants will receive placebo for 24 weeks (6 mo)
89085652|NCT05858515|Experimental|Intervention #1|These participants will receive baricitinib 4 mg daily for 24 weeks
89085653|NCT05858229|Experimental|Treatment|Patients will receive RP1 via direct intratumoral (IT) injection into superficial cutaneous solid tumors to assess the safety and tolerability as well efficacy of RP1 treatment. The primary efficacy population is up to 12 evaluable patients with resectable CSCC.
89085654|NCT05857384|Active Comparator|Comparator Arm A- Reference Listed Drug/Marinol|dronabinol 5 mg, two capsules of 2.5 mg administered on an empty stomach once only in the study period
89085655|NCT05857384|Active Comparator|Comparator Arm B-Reference Listed Drug/Taro Acetazolamide|250 mg acetazolamide, one tablet administered on an empty stomach once only in the study period
89085656|NCT05857384|Experimental|Investigational Product Arm C-IHL42X Fasted|IHL-42X (5 mg dronabinol, 250 mg acetazolamide), one capsule administered on an empty stomach once only in the study period
89085657|NCT05857384|Experimental|Investigational Product Arm D-IHL42X Fed|IHL-42X (5 mg dronabinol, 250 mg acetazolamide), one capsule administered after food once only in the study period
89085658|NCT05852184||CMUH|Adult patients who receive maintenance hemodialysis through an arteriovenous (AV) fistula or AV graft access at CMUH.
89085659|NCT05852184||AUH|Adult patients who receive maintenance hemodialysis through an arteriovenous (AV) fistula or AV graft access at AUH.
89085660|NCT05852184||SKC-Central|Adult patients who receive maintenance hemodialysis through an arteriovenous (AV) fistula or AV graft access at SKC-Central.
89085663|NCT05845619|Experimental|Pilot|
89085664|NCT05845619|No Intervention|Controls - prospectively enrolled|
89085665|NCT05845619|No Intervention|Controls - abstracted from records|
89085666|NCT05845593||Group 1|Adult male and female patients with a clinical diagnosis of SLE or incomplete lupus
89085667|NCT05844007|Experimental|High School Students: Remote Delivery|Remote delivery of trauma-informed yoga session for high school students
89085668|NCT05844007|Experimental|High School Students: Face-to-Face Delivery|Face-to-face delivery of trauma-informed yoga session for high school students
89085669|NCT05844007|Experimental|Teachers: Remote Delivery|Remote delivery of trauma-informed yoga session for teachers
89085680|NCT05841979|Experimental|group-based therapy|Group therapy delivered via moodlifters
89085681|NCT05841979|Experimental|physical activity|Physical Activity and Exercise
89085682|NCT05841979|Experimental|nature experience|Nature Experiences
89085683|NCT05841979|No Intervention|self-monitoring|Placebo control
89085684|NCT05838690|No Intervention|Pre-Intervention Phase|NICU Patients who are intubated without the PINS Bundle.
89085685|NCT05838690|Active Comparator|Post-intervention Phase|NICU Patients who are intubated after unit implementation of the PINS Bundle
89085686|NCT05838378|Experimental|Pictorial warnings|Participants randomized to this group will view pictorial cigarillo warnings.
89085687|NCT05838378|Active Comparator|FDA text-only warnings|Participants randomized to this group will view FDA text-only warnings.
89085688|NCT05838378|Active Comparator|Surgeon General text-only warnings|Participants randomized to this group will view Surgeon General text-only warnings.
89085689|NCT05838300|Experimental|Warm humidified CO2|
89085690|NCT05838300|Active Comparator|Dry CO2|
89085691|NCT05834842|Experimental|Behavioral: Online Intervention Unisalud|Participants in this group will receive 9 sessions of a multi-component intervention focused on the reduction of the consumption of ultra processed foods, symptoms of anxiety, depression and stress and the increase of physical activity.
89085692|NCT05834842|No Intervention|No Intervention: Waiting List group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 9 sessions will receive the intervention.
89225896|NCT05150483||Patients with de novo acute hypoxemic respiratory failure|We will consider for inclusion patients presenting in the emergency department with de novo acute hypoxemic respiratory failure (AHRF). De novo AHRF is defined as the requirement of oxygen flow rate of 5 liters per minute or more to maintain SpO2 of 90% or more in a patient who does not receive long term oxygen therapy.
89225897|NCT05150210|Experimental|SP Surgical System|Pulmonary lobectomy and thymectomy procedures will be performed by da Vinci SP Surgical System.
89225898|NCT05147103|Experimental|Duration Trials|Six different durations (three intermittent and three continuous) of LIFU application will be tested across six study sessions. Response recorded using TMS and EMG.
89225899|NCT05142462||EUROSCUP Fixe|120 patients who received EUROSCUP Fixe
89225900|NCT05140330|Experimental|Intervention|7 ALAPAGE sessions over 2 months and 1 evaluation session at 3 months
89225901|NCT05140330|Other|Control|3 evaluation sessions over 2 months and 1 session at 3 months
89225902|NCT05140148|Placebo Comparator|Placebo|placebo pill, twice daily
89225903|NCT05140148|Active Comparator|Amantadine|100 mg amantadine twice daily, or if 65 years or older once daily
89085693|NCT05829447|Experimental|GI-EYE endoscope with inflated ballon (Interventional arm)|all individuals receive colonoscopy examination with G-EYE 760R colonoscopes; once the cecum is reached the balloon is inflated, and the endoscope is withdrawn with the inflated balloon; the colonoscopy is performed with the support of the CADEYE system for polyp detection in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination.
89085694|NCT05829447|No Intervention|G-EYE endoscope with deflated balloon (Control arm)|all subjects receive colonoscopy with G-EYE 760R colonoscope but the balloon remains deflated for the entire procedure; the colonoscopy is performed with the support of the CADEYE system for polyp detection in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination
89085695|NCT05825131||Retrospective and prospective observational study of patients living with MPS IIIC|Cohort 1: These participants will be a part of the retrospective and prospective Natural History Study, including the C-RARE video assessments. In clinic visits will include: neurocognitive, developmental and behavioral clinical outcome assessments as well as biochemical sample analysis, imaging measures and retrospective medical record review. Participants will record daily living activities through the C-RARE app on their mobile device.
89085696|NCT05825131||Remote video recording study and retrospective medical chart review of patients living with MPS IIIC|Cohort 2: These participants will not attend in clinic visits. They will be a part of the C-RARE and retrospective medical chart review analysis. 35 patients with a confirmed diagnosis of MPS IIIC from English, Spanish and Portuguese speaking households will be recruited for this portion of the study.
89085697|NCT05825131||Retrospective medical chart review of MPS IIIC patients either living or deceased|Cohort 3: Deceased or living medical record analysis only of patients with MPS IIIC. Living patients will not be participating in cohort 1 clinical study or cohort 2 C-RARE study.
89085701|NCT05822518|No Intervention|conventional protocol group|patients who are enrolled in conventional pre and post operative routine preparation for surgery protocol.
89085702|NCT05822518|Active Comparator|immune enhancing nutrition protocol group|patients who are enrolled in pre and post operative routine preparation for surgery protocol plus immune enhancing nutrition administration pre and post operatively.
89085703|NCT05818865|Other|device (CLG)|"The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity."
89085706|NCT05810987|Experimental|ELMs and virtual SP encounters|A virtual communication curriculum featuring electronic learning modules (ELMs) and skills sessions with standardized patients (SPs) along with coaching feedback.
89085707|NCT05810987|Active Comparator|ELMs alone|A virtual communication curriculum featuring electronic learning modules (ELMs) only.
89085708|NCT05810025|Experimental|FHIR-Enhanced RealRisks|Participants will self-administer FHIR-enhanced RealRisks with access to risk communication games, family history pedigree and modules on chemoprevention and genetics testing, if relevant to them based on their risk and family history. The investigators are interested in gaining short-term feedback on patient activation and other patient reported outcomes, which will be assessed before and within 2 weeks after using RealRisks.
89085709|NCT05800587|Experimental|Platinum doublet plus immunotherapy (IO)|
89085710|NCT05800587|Experimental|Platinum doublet with or without a VEGFi|
89085711|NCT05800587|Experimental|Single agent chemotherapy with or without a VEGFi|
89085712|NCT05799612|Experimental|Dose Escalation/Deescalation|Participants will receive up to 3 doses of the vaccine (each vaccine is given 2 weeks apart). The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen
89085713|NCT05795738|No Intervention|Control group|regular kindergarten education
89085714|NCT05795738|Experimental|Chinese characters-based visual-motor program|visual perceptual motor activities using Chinese characters as activity materials.
89085715|NCT05795738|Experimental|traditional visual-motor training program|visual perceptual motor activities using commercial or self-designed toys and pencil-paper sheets as activity materials.
89225905|NCT05130073||Observational (PET/CT, medical data review, follow-up)|Patients undergo PET/CT at baseline and at 3 months post therapy completion. Patients' medical records are received. Patients are followed up for 5 years.
89085716|NCT05795179|Experimental|Physiological Stress|Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to a physiological stress group and complete the corresponding stress task. For the physiological stress group, this task is the Cold-Pressor Task (CPT), a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
89085717|NCT05795179|Experimental|Social Stress|Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to the social stress group and complete the corresponding stress task. For the social stress group, this task is the Trier Social Stress Test (TSST), a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
89085718|NCT05795179|Active Comparator|Physiological Non-Stress|Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to the physiological non-stress group and complete the corresponding stress task. For the physiological non-stress group, participants will continuously submerge their hand and forearm in warm water for 3 minutes. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
89085719|NCT05795179|Active Comparator|Social Non-Stress|Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to the social stress group and complete the corresponding stress task. For the social non-stress group, participants will be asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
89085720|NCT05793866|Experimental|BUTEYKO RESPIRATORY TECHNIQUE APPLIED GROUP|This group consists of children between the ages of 7 and 12 who are being treated for asthma. Children with written and verbal consent from their families will be filled with a personal information form, asthma control test and quality of life scale for children. The standard care and treatment of the asthmatic child included in the experimental group will be continued without any intervention. The child included in this group will be taught the Buteyko Breathing Technique (BST) via a smart phone, and the training video will be watched and taught. The training video will be watched on the official site that explains BST in a practical way. The video will be downloaded to the phone of the child or parent using a smartphone at home, for researchers to apply later at home. The participant will continue to apply this technique at home for 10 minutes in addition to his treatment when he needs a bronchodilator in the morning and evening for 4 weeks.
89085721|NCT05793866|No Intervention|GROUP WITH STANDARD CARE AND TREATMENT|This group consists of children aged 7-12 years with asthma who continue to receive standard care and treatment. Children with written and verbal consent from their families will be filled with a personal information form, asthma control test and quality of life scale for children. Asthma control test and quality of life scale for the child with asthma will be administered to the participant who continues the standard treatment and care for 4 weeks. After the research data are collected, the children in the control group will be shown a video explaining the BST in a practical way.
89085722|NCT05792358|Experimental|Wet cupping arm|This arm is the interventiom group and will receive three consecutive sessions of wet cupping therapy once a month.
89085723|NCT05792358|No Intervention|Control arm|This arm is the control group and will not receive any intervention other than the routine medications
89085724|NCT05789524|Experimental|Part 1 - Cohort 1: SerpinPC|Participants will receive SerpinPC 1.2 mg/kg SC Injection QW for 24 weeks after a minimum of 12 weeks of a prospective observation period.
89085725|NCT05789524|Experimental|Part 1 - Cohort 2: SerpinPC|Participants will receive SerpinPC 1.2 mg/kg SC Injection Q2W for 24 weeks after a minimum of 12 weeks of a prospective observation period.
89085726|NCT05789524|Experimental|Part 1 - Cohort 3: SerpinPC|Participants will receive SerpinPC 1.2 mg/kg SC Injection Q4W for 24 weeks after a minimum of 12 weeks of a prospective observation period.
89225906|NCT05128903|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive Translocation Protein (TSPO) Positron Emission Tomography (PET) for longitudinal, quantitative assessment of brain neuroinflammation following whole brain radiation therapy.
89225907|NCT05126992||AZD1222|at least one dose of AZD1222
89225908|NCT05126992||comparator 1|concurrent unvaccinated
89225909|NCT05126992||comparator 2|historical controls
89225910|NCT05126992||comparator 3|"active comparators*~*Feasibility of the active comparator analysis will be assessed prior to conducting the analysis to ensure comparability between groups"
89085727|NCT05789524|Experimental|Part 2 - SerpinPC (Dose-confirmatory phase)|After a minimum of 24 weeks of prospective observation, participants will receive SerpinPC at dose of 1.2 mg/kg Q2W for 24 weeks in Part 2, unless the Interim Analysis (IA) shows a greater benefit-risk profile with either the 1.2 mg/kg QW or Q4W treatment regimens.
89085728|NCT05789524|Experimental|Part 3 - SerpinPC (Extension phase)|After completion of dosing in Part 1 or Part 2, participants will continue treatment with SerpinPC at the dose of SerpinPC selected for Part 2 in a 24-week extension phase (Part 3).
89085729|NCT05787977|Experimental|Interventional Group|Treadmil Training with visual feedback and rhythmic Auditory Cue
89085730|NCT05787977|No Intervention|Control Group|No intervention
89085731|NCT05787860|Active Comparator|Ruxolitinib Cream|Participants will receive topical ruxolitinib 1.5% cream
89085732|NCT05787860|No Intervention|Healthy Control Subjects|Age- and gender-matched healthy control subjects
89085733|NCT05785390|Experimental|Active Drug Treatment|Phase IIa - Dose escalation. 3g cohort and 4.8g cohort run simultaneously, followed by a 6 g cohort. Administered in 600 g capsules of NP-101 for a total daily dose of 3g, 4.8g and 6g adminstered BID. Administered for 14 days.Establish MTDD Phase IIB - Continue study with MTDD as established above.
89085734|NCT05785390|Placebo Comparator|Placebo|As above, except dosed with matching placebo capsules.
89085735|NCT05783102|Experimental|KINDER Intervention|KINDER is a 9-week psychoeducational intervention.
89085736|NCT05782088|Experimental|Single Piezocision|
89085737|NCT05782088|Experimental|Repeated Piezocision|
89085738|NCT05778864|Experimental|LY3473329 (Control)|LY3473329 administered orally to participants with normal renal function
89085739|NCT05778864|Experimental|LY3473329 (Mild Renal Impairment)|LY3473329 administered orally to participants with mild renal impairment
89085740|NCT05778864|Experimental|LY3473329 (Moderate Renal Impairment)|LY3473329 administered orally to participants with moderate renal impairment
89085741|NCT05778864|Experimental|LY3473329 (Severe Renal Impairment)|LY3473329 administered orally to participants with severe renal impairment
89085742|NCT05778864|Experimental|LY3473329 (End-Stage Renal Disease)|LY3473329 administered orally to participants with end-stage renal disease
89085744|NCT05776004|Experimental|CAL02 with Standard of Care|CAL02 (a mixture of 2 liposomal components, both empty, unilamellar, liposomes) will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. CAL02 infusions will be administered over a 1 -2 hour period.
89085745|NCT05776004|Placebo Comparator|Placebo|Placebo will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. Placebo will be prepared and administered following the same infusion protocol as CAL02. Placebo infusions will be administered over a 1 to 2 hour period.
89085746|NCT05767034|Experimental|Secukinumab 300 mg|randomized in 1:1:1 ratio every 4 weeks
89085747|NCT05767034|Experimental|Secukinumab 150 mg|randomized in 1:1:1 ratio every 4 weeks
89085748|NCT05767034|Placebo Comparator|Placebo to secukinumab|randomized in 1:1:1 ratio every 4 weeks
89085749|NCT05766046|Experimental|Standard arm|Volunteers with a negative baseline LDCT will repeat LDCT after the first screening with an annual interval (according to guidelines)
89085750|NCT05766046|Experimental|Risk-based arm|Volunteers with a negative baseline LDCT will repeat LDCT after the first screening with an interval of two years.
89085751|NCT05764291|Experimental|FIT-TEENS|Participants in the intervention group will receive access to a digital behaviour change intervention (FIT-TEENS). Participants will need to complete 10 self-paced online modules and activities over a period of 10 weeks.
89085752|NCT05764291|No Intervention|Wait-list control|Participants in the waitlist-control group will be required to continue their usual physical activities. At the end of 10 weeks, they will also receive access to FIT-TEENS intervention.
89085753|NCT05758545|Active Comparator|COMS One device|"The COMS One device is reusable (the component can be used on multiple subjects and is cleaned between uses). The COMS One device is the housing unit for the user controls, displays and functions including embedded software, lithium-ion battery, optical (LEDs) and a magnetic stimulation coil.~The COMStouch is a sterile single-use component. The COMStouch provides a base and sterile barrier for the COMS One device.~The COMSfix component is a self-adhesive single-use strap used to hold the COMS One device and COMStouch components in place during treatment."
89085754|NCT05758545|Sham Comparator|Sham device|"The sham device is reusable (the component can be used on multiple subjects and is cleaned between uses). The sham device is the housing unit for the user controls, displays and functions including embedded software, lithium-ion battery, optical (LEDs) and a magnetic stimulation coil.~The COMStouch is a sterile single-use component. The COMStouch provides a base and sterile barrier for the sham device.~The COMSfix component is a self-adhesive single-use strap used to hold the sham device and COMStouch components in place during treatment."
89085755|NCT05756413|Experimental|SDT|Pregnant mothers will be randomly assigned to either an experimental group (Group 1) where mothers will receive autonomy-supportive messages informed by the SDT or a control group (Group 2) where mothers will receive the same oral health care messages delivered using a neutral style. All mothers will be exposed to oral health messages - one during pregnancy, one later when their child is 12 months of age, and one when their child is 24 months of age. Three months after receiving the oral health messages at each time point, mothers will be sent a follow-up booster message.
89085756|NCT05756413|Other|Control|Pregnant mothers will be randomly assigned to either an experimental group (Group 1) where mothers will receive autonomy-supportive messages informed by the SDT or a control group (Group 2) where mothers will receive the same oral health care messages delivered using a neutral style. All mothers will be exposed to oral health messages - one during pregnancy, one later when their child is 12 months of age, and one when their child is 24 months of age. Three months after receiving the oral health messages at each time point, mothers will be sent a follow-up booster message.
89085757|NCT05748483|Experimental|Atogepant|Participants will receive atogepant in double-blind period. From Week 25, eligible participants will receive atogepant in open-label period.
89085758|NCT05748483|Active Comparator|Topiramate|Participants will receive topiramate in double-blind period. From Week 25, eligible participants will receive atogepant in open-label period.
89085759|NCT05738291|Experimental|MRD part: BI 1839100 dose group 1|Multiple rising dose (MRD)
89085760|NCT05738291|Experimental|MRD part: BI 1839100 dose group 2|Multiple rising dose (MRD)
89085761|NCT05738291|Experimental|MRD part: BI 1839100 dose group 3|Multiple rising dose (MRD)
89085762|NCT05738291|Experimental|MRD part: BI 1839100 dose group 4|Multiple rising dose (MRD)
89085763|NCT05738291|Experimental|MRD part: BI 1839100 dose group 5|Multiple rising dose (MRD)
89085764|NCT05738291|Placebo Comparator|MRD part: Placebo matching BI 1839100|
89085765|NCT05738291|Experimental|DDI part|Drug-Drug Interaction (DDI)
89085766|NCT05736549|Experimental|B-LB in left knee and B-DEX-MPA in right knee|"Participants in this arm will receive B-LB in their left knee and B-DEX-MPA in their right knee.~Nerve block with (B-LB): A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.~Nerve block with (B-DEX-MPA): A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively."
89085767|NCT05736549|Experimental|B-LB in right knee and B-DEX-MPA in left knee|"Participants in this arm will receive B-LB in their right knee and B-DEX-MPA in their left knee.~Nerve block with (B-LB): A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.~Nerve block with (B-DEX-MPA): A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively."
89085768|NCT05736471||Test Group|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
89085769|NCT05729009||heart transplantation|
89085770|NCT05725135||Males|Propofol total intravenous anaesthesia (TIVA) will be used for both induction and maintenance of anaesthesia. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using automated closed-loop anesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
89085771|NCT05725135||Females|Propofol total intravenous anaesthesia (TIVA) will be used for both induction and maintenance of anaesthesia. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using automated closed-loop anesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesi
89085772|NCT05724628|Experimental|Operative Arm|Operation (laparoscopic appendectomy) will be performed to remove appendix.
89085773|NCT05724628|Experimental|Non-Operative Arm|No operation will be performed, and instead, will receive intra-venous (IV) antibiotics, transitioned to by mouth (oral) antibiotics
89085774|NCT05722847||Low risk|Subjects will be considered low risk if they have non-small cell histology, a length of hospital stay <= 8 days, no or low comorbidity, no emergency department use or hospitalization in the 6 months prior, no wheelchair requirement when hospital discharge, or other than Black and/or Hispanic race.
89085775|NCT05722847||High risk|Subjects will be considered high risk if they have small cell histology, a length of hospital stay > 8 days, high comorbidity, emergency department use or hospitalization in the 6 months prior, prescription of a wheelchair when hospital discharge, or Black and/or Hispanic race.
89085778|NCT05715671|Experimental|Esketamine for induction 0.15mg/kg and maintenance 0.15mg/kg/h|
89085779|NCT05715671|Experimental|Esketamine for induction 0.3mg/kg and maintenance 0.3mg/kg/h|
89085780|NCT05715671|No Intervention|No esketamine|
89085783|NCT05711706|Experimental|Su Jok Application|"I. Interview: One Day Before Surgery:~II. Interview: Post-Surgery - After Transfer to the Clinic III. Interview: Postoperative Day 1 IV. Interview: Postoperative Day 2 V. Interview (Post-Operative Day 10"
89085784|NCT05711706|No Intervention|Standard care|"I. Interview: One Day Before Surgery:~II. Interview: Post-Surgery - After Transfer to the Clinic III. Interview: Postoperative Day 1 IV. Interview: Postoperative Day 2 V. Interview (Post-Operative Day 10"
89085785|NCT05702541|Other|LID223194 MF, then AOHG MF|Lehfilcon A multifocal contact lenses worn first, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product will be worn in both eyes for 2 days in a daily wear modality. CLEAR CARE will be used for daily cleaning and disinfection.
89085786|NCT05702541|Other|AOHG MF, then LID223194 MF|Lotrafilcon B multifocal contact lenses worn first, followed by lehfilcon A multifocal contact lenses, as randomized. Each product will be worn in both eyes for 2 days in a daily wear modality. CLEAR CARE will be used for daily cleaning and disinfection.
89085787|NCT05702229|Experimental|Substudy 1|Volrustomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
89085788|NCT05702229|Experimental|Substudy 2|Rilvegostomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
89085789|NCT05702229|Experimental|Substudy 3|AZD0901 plus volrustomig and 5-fluorouracil or capecitabine
89085790|NCT05702229|Experimental|Substudy 4|AZD0901 plus rilvegostomig and 5-fluorouracil or capecitabine
89085791|NCT05702229|Experimental|Substudy 5|AZD7789 plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
89085792|NCT05702229|Experimental|Substudy 6|AZD0901 plus AZD7789 and 5-fluorouracil or capecitabine
89085793|NCT05700994|Experimental|PEER-CM|Peer-facilitated contingency management (PEER-CM).
89085794|NCT05700994|Active Comparator|Standard of Care|Standard of care contingency management.
89085796|NCT05692180|Experimental|Benralizumab|Patients will receive Benralizumab as an active solution via a subcutaneous (SC) injection.
89085797|NCT05692180|Placebo Comparator|Placebo|Patients will receive a matching solution of the placebo via SC injection.
89085798|NCT05687097||Individuals without sleep apnea after spinal cord injury|No significant sleep apnea is defined as an apnea-hypopnea index (AHI) < 5 events per hour of sleep
89085799|NCT05687097||Individuals with mild sleep apnea after spinal cord injury|Mild sleep apnea is defined as an apnea-hypopnea index (AHI) ≥ 5 events per hour of sleep, but an AHI <15 events.
89085800|NCT05687097||Individuals with moderate sleep apnea after spinal cord injury|Mild sleep apnea is defined as an apnea-hypopnea index (AHI) ≥ 5 events per hour of sleep but an AHI <15 events.
89085801|NCT05687097||Individuals with severe sleep apnea after spinal cord injury|Severe sleep apnea is defined as an apnea-hypopnea index (AHI) > 30 events per hour of sleep.
89085802|NCT05685602|Experimental|Treatment (CA-4948, gemcitabine, nab-paclitaxel)|Patients receive CA-4948 orally (PO), gemcitabine intravenously (IV), and nab-paclitaxel IV on study. Patients undergo magnetic resonance imaging (MRI), computed tomography (CT) scan, positron emission tomography (PET) scan, and/or x-ray imaging throughout the trial. Patients also undergo tumor biopsies and blood sample collection during screening and on study.
89085803|NCT05685238|Experimental|Arm 1|Participants entering from the multiple ascending dose (MAD) part of study NN7769-4513. In part 1, participants will receive Mim8 prophylaxis (PPX) once every two weeks (Q2W) with subcutaneous (s.c.) administration using enhanced cartridge for 26 weeks. In part 2, participants will receive Mim8 PPX once-weekly (QW), Q2W or once-monthly (QM) with s.c. administration using enhanced cartridge or DV3407 pen-injector once it is approved.
89085804|NCT05685238|Experimental|Arm 2|Participants entering from study NN7769-4514 or NN7769-4516. In part 1, participants will receive Mim8 PPX QW or QM with s.c. administration using DV3407 pen-injector for 26 weeks. In part 2, participants will receive Mim8 PPX QW, Q2W or QM with s.c. administration using DV3407 pen-injector.
89085805|NCT05677451|Experimental|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks.
89085806|NCT05677451|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2)
89085807|NCT05677113|Experimental|QBECO|QBECO is an SSI formulated from inactivated E. coli bacteria that is specifically designed to target pathologies of the gastrointestinal (GI) tract and related organs, such as the liver. This trial will test the hypothesis that in patients undergoing resection of colorectal liver metastases (CRLMs), perioperative treatment with QBECO will attenuate the postoperative immune suppression and will improve progression-free survival (PFS).
89085808|NCT05677113|Placebo Comparator|Placebo|A placebo is a liquid that looks like the study drug, but contains no medication.
89085809|NCT05675449|Experimental|Part 1 Dose Escalation|Non randomized Elranatamab plus Carfilzomib and Dexamethasone
89085810|NCT05675449|Experimental|Part 2A Dose Escalation|Non randomized Elranatamab plus Maplirpacept
89085811|NCT05675449|Experimental|Part 2B Dose Randomization|Randomized dose level Elranatamab plus Maplirpacept
89085826|NCT05667662|Experimental|PUR1900 40 mg|4 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
89085827|NCT05667662|Experimental|PUR1900 20 mg|2 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) and 2 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
89085828|NCT05667662|Placebo Comparator|Placebo|4 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.
89523032|NCT04446533|Placebo Comparator|Placebo product|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
89085830|NCT05666349|Experimental|Niraparib and re-irradiation (re-RT)|"Patients will be treated with IMRT-based re-RT for a total dose of 35 Gy in 10 daily fractions over approx. 2 weeks. Patients will take niraparib daily from the first day of re-RT until documented progression or discontinuation due to unacceptable treatment-related toxicity or any other cause (whichever occurs sooner).~Patients will be recruited in cohorts of 3. Following the completion of each dosing cohort and once the patients have completed the dose limiting toxicity (DLT) assessment window, the independent data monitoring committee (IDMC) will review the data for each patient. In conjunction with the statistical recommendations from the continual reassessment method (CRM), the IDMC will advise whether the dose for the next cohort should be escalated, de-escalated or stay at the current niraparib dose."
89085831|NCT05666167|Experimental|Exercise Initiation and Maintenance with Text Messaging and Booster Sessions|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
89085832|NCT05666167|Active Comparator|Exercise Initiation and Maintenance with Text Messaging alone|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging alone.
89523033|NCT03386591|Experimental|Mucosal Atomization (1 administration)|One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)
89523034|NCT03386591|Experimental|Mucosal Atomization (2 administrations)|Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart
89085835|NCT05663892|Experimental|Investigational Population (Group 1) - Trans women living with HIV|"Trans women living with HIV, taking:~Biktarvy~Oral 17(Beta)-Estradiol"
89085836|NCT05663892|Active Comparator|Comparator Population (Group 2) - Cis Women Living with HIV|"Cis women living with HIV, taking:~-Biktarvy"
89085837|NCT05663892|Active Comparator|Comparator Population (Group 3) - Trans Women Living without HIV|"Trans women living without HIV, taking:~-Oral 17(Beta)-Estradiol"
89523035|NCT03386591|Experimental|Narcan 2mg|One Intranasal administration of 2 mg naloxone using Narcan nasal spray
89523036|NCT03386591|Experimental|Narcan 4mg|One Intranasal administration of 4 mg naloxone using Narcan nasal spray
89085840|NCT05662423|Active Comparator|Expressive Writing about Childbirth|Subgroup of participants will write about their recent childbirth.
89085841|NCT05662423|Placebo Comparator|Neutral Writing|Subgroup of participants will write about neutral daily events.
89523037|NCT03386591|Experimental|Intramuscular auto injector|One Intramuscular administration of 2 mg naloxone using Evzio auto-injector
89085844|NCT05653219|Experimental|Treatment arm 1|Participants will receive eltrombopag and ianalumab lower dose
89085845|NCT05653219|Experimental|Treatment arm 2|Participants will receive eltrombopag and ianalumab higher dose
89085846|NCT05653219|Placebo Comparator|Treatment arm 3|Participants will receive eltrombopag and placebo
89225911|NCT05123014|Other|ReLex Smile surgery|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery We used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with adenoviral keratitis.
89225912|NCT05120648||Immediate enrollment|
89225913|NCT05120648||Wait-list controls|
89225914|NCT05117515||Uni-Graft KDV Patch|
89225915|NCT05115058|Other|ReLex Smile module|"VisuMax femtosecond laser created the stromal pocket with a diameter 7.60 mm and cap thickness set to 120 μm from corneal surface and with a small opening - 2 mm superior incision at 90° and side cut angle 50°. The pocket was dissected using a blunt spatula.~The patients were followed up for one year with distance, intermediate, and near visual acuity, slit lamp, corneal topography, anterior segment optical coherence tomography. Uncorrected near visual acuity at 35 cm increased from J7 to J2 in 8 eyes operated on, from J8 to J2 in 7 eyes, and from J6 to J2 in 6 eyes. Uncorrected intermediate visual acuity ranged from J4 to J5 at 70 cm, and uncorrected distance visual acuity remained binocular at 20/20. The patients reported satisfaction while reading a book, looking at the phone, and using a computer. No discomfort was observed from the lights while driving at night."
89225916|NCT05109351|Experimental|Participating to Boost Meal Participation|Intervention group will receive marketing and communication strategies developed by researchers, community organizations, parents, school nutrition directors, and other school stakeholders.
89225917|NCT05109351|No Intervention|Control|Usual care.
89085852|NCT05652179|Experimental|Stellate ganglion block|For patients in Group S, left SGB was performed after the first TEE examination. The patient's head was tilted to the right. A high-frequency probe (6-13 MHz) was placed between the C6 and C7 transverse processes to obtain the best image of the longus colli muscle. After iodine disinfection, a 22-G atraumatic needle for peripheral nerve blocks (B. Braun Melsungen AG, Melsungen, Germany) was used to puncture the site posterior to the left carotid artery and on the surface of the longus colli muscle via an in-plane technique. Then,5 mL of 0.375% ropivacaine hydrochloride injection was administered provided that no blood, cerebrospinal fluid, or gas was suctioned out
89085853|NCT05652179|No Intervention|Control|Patients in Group C did not undergo the SGB procedure.
89085854|NCT05646797|Experimental|ASP2074 Dose Escalation (Part 1)|Participants will be assigned to sequentially or in parallel escalating dose/regimen cohorts of ASP2074 in three parts (Part A, B and C). Part B and Part C will be opened sequentially based upon sponsor review of emerging data.
89085855|NCT05646797|Experimental|ASP2074 Dose Expansion (Part 2) Colorectal Adenocarcinoma|Participants will receive ASP2074 with dose/regimen selected from dose escalation (Part 1).
89085856|NCT05646797|Experimental|ASP2074 Dose Expansion (Part 2) Esophageal or GEJ Adenocarcinoma|Participants will receive ASP2074 with dose/regimen selected from dose escalation (Part 1).
89085857|NCT05646797|Experimental|ASP2074 Dose Expansion (Part 2) Pancreatic Adenocarcinoma|Participants will receive ASP2074 with dose/regimen selected from dose escalation (Part 1).
89085858|NCT05646667|Experimental|Interscalene with erector spinae plane block group|Patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and ultrasound guided erector spinae plane block at thoracic (T2) using 10 ml of bupivacaine 0.5%.
89085859|NCT05646667|Experimental|Interscalene group|Patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
89085860|NCT05645536|Experimental|TOL2506|TOL2506 in combination with standard endocrine therapy (Tamoxifen & Aromatase Inhibitors)
89085861|NCT05644951|Experimental|Hot AXIOS system|Hot AXIOS system (20 mm diameter stent)
89085862|NCT05644561|Experimental|Ravulizumab Intravenous (IV) Infusion|All participants will receive a weight-based loading dose of ravulizumab IV on Day 1, followed by weight-based maintenance dose of ravulizumab on Day 15 and once every 8 weeks (q8w) thereafter for participants weighing ≥ 20 kg, or once every 4 weeks (q4w) for participants weighing < 20 kg, for a total of 122 weeks of treatment.
89085863|NCT05644054|Experimental|Treatment (THC) - session 1|Patients will attend two sessions in a crossover design, where they will receive one of the drugs in a randomized sequence at each session.
89085864|NCT05644054|Placebo Comparator|Placebo - session 2|Patients will attend two sessions in a crossover design, where they will receive one of the drugs in a randomized sequence at each session.
89085867|NCT05640752|Experimental|ESC strategy|ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL <15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
89085868|NCT05640752|Experimental|NICE strategy|According to NICE strategy, subjects with nonanginal chest pain and normal ECG are classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG are classified into high risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
89085869|NCT05639530|Experimental|:treated with different doses of single intravitreal injections of IBI333|"Biological: IBI333 Dose 1 IBI333 of single IVT injections，~Biological: IBI333 Dose 2 IBI333 of single IVT injections"
89085870|NCT05639530|Experimental|treated with different doses of multiple intravitreal injections of IBI333|"Biological: IBI333 Dose 3 IBI333 of multiple IVT injections，~Biological: IBI333 Dose 4 IBI333 of multiple IVT injections"
89085871|NCT05639114|Experimental|Ianalumab s.c. monthly|Ianalumab s.c. monthly
89085872|NCT05639114|Experimental|Ianalumab s.c. quarterly|Ianalumab s.c. quarterly
89085873|NCT05639114|Placebo Comparator|Placebo s.c. monthly|placebo s.c. monthly
89225925|NCT05104268|Active Comparator|Standard Therapy|Subjects will then be randomized into two groups. The Standard Therapy Group will continue their usual therapy with oral topical agents for oral mucositis.
89225926|NCT05104268|Experimental|Bocaliner|Participants that are randomized to the Bocaliner Group will place Bocaliner™ inside of their mouth for 5 minutes and fill out the Initial Bocaliner™ Questionnaire. They will then continue all original therapy for oral mucositis, including oral topical treatments and general hygiene, and will place the Bocaliner™ device inside of their mouth and hold it in place up to 40 minutes as instructed after each topical treatment.
89225927|NCT05101161|Experimental|Bidirectional Neurofeedback|
89225928|NCT05098834|Experimental|PICU and PCICU Patients|Patients younger than 17 years of age receiving mechanical ventilation for an acute respiratory illness will be approached to participate prior to initiation of an ERT for clinical purposes.
89225929|NCT05097534|Active Comparator|iDSMES|"Eligible study subjects randomized to the intervention arm will receive:~A. Intensive Diabetes Self-Management, Education, and Support (iDSMES). Participants will be enrolled in groups in a virtual or in-person setting with their lifestyle coach, in this one-year educational program B. Services addressing Social Determinants of Health All study subjects will have their data collected at time points around baseline, 6 months and 12 months from consenting including glycemic control, hypertension management, dyslipidemia management, prevention or management of complications, healthcare outcomes, lifestyle change outcomes, patient-centeredness outcomes, Secondary diabetes self-management behaviors, self-efficacy in managing diabetes, diabetes distress, and Morisky Green Levine Medication Adherence Scale."
89225930|NCT05097534|Placebo Comparator|Standard of Care|Eligible study subjects randomized to the intervention arm will receive standard of care offered to patients with diabetes.
89225931|NCT05095207|Experimental|Participants with Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer|Abemaciclib in Combination with Bicalutamide
89225932|NCT05091931||Guidance® UTI pathway (standard lab workflow)|Guidance® UTI pathway with antibiotic sensitivity and microbial testing results available to ordering provider within 48 hours of lab receipt. Includes confirmation by the clinical lead that the ordering provider has acted upon results as soon as they are made available. The lab will follow current workflows in terms of result reporting. Treatment based on local standard clinical antibiotic selection with or without empiric therapy.
89085874|NCT05623709||COPD and SRBD prescribed NIV or CPAP|"Group 1a: (n=55) Adults with a SRBD and COPD who are newly prescribed NIV treatment within the study period.~Group 1b: (n=55) Adults with a SRBD and COPD who are newly prescribed CPAP treatment within the study period."
89085875|NCT05623709||COPD controls not prescribed CPAP or NIV|Group 2: COPD controls without a SRBD: (n=55) Adults with COPD who undergo sleep diagnostic testing and who are not recommended to start CPAP or NIV
89085877|NCT05618067|Experimental|Training|
89085878|NCT05618028|Experimental|ABBV-525 Dose Escalation|Participants will receive escalating doses of ABBV-525 until doses for optimization are determined, as part of an approximately 64 month study period.
89085879|NCT05618028|Experimental|ABBV-525 Dose Optimization|Participants will receive one of two doses of ABBV-525 until the recommended phase 2 dose (RP2D) is determined, as part of an approximately 64 month study period.
89085880|NCT05618028|Experimental|ABBV-525 Dose Expansion|Participants will receive the RP2D dose of ABBV-525, as part of an approximately 64 month study period.
89085881|NCT05616741|Experimental|Treatment group|Cerebri biofeedback and Cerebri headache diary
89085882|NCT05616741|Other|Waitlist control group|Only Cerebri headache diary
89085883|NCT05616039|Active Comparator|Control Group (Standard liver surgery)|In this group, tumour/s, resection margin identification, and the type and number of liver resections will be based on naked eye examination, palpation, and intraoperative ultrasound. All the intra-operative findings will be recorded on a pre-designed proforma, and these details include the type of surgical approach (open, laparoscopic, and hand-assisted), if it is an open operation the type of incision, the location, number and size of tumour/s, relationship of the tumour/s to inflow and outflow of the liver, duration of surgery, and estimated blood loss. Post-operatively histology of the resected specimen including resection margin status will be recorded.
89085884|NCT05616039|Experimental|Intervention Group (I-FIGS)|Patients will receive intravenous indocyanine green(ICG) injection (0.03-0.05mg/kg) 2-4 hours before surgery. ICG comes in crystal form in 25mg dose. It will be diluted with 25ml of water, and the required dose as per the weight of the patient will be prepared freshly and given at least 2-4 hours before surgery. The surgical planning will be carried out as per the standard approach using the naked eye and IOUS. As for standard surgery, all intra-operative findings will be recorded on the proforma that contains the details that need to be collected. Once this is all recorded, ICG cameras will be switched on, and the additional findings (additional lesions detected, additional resections carried out) and change to surgical plan (change to the line of parenchymal transection) will be noted. Post-operatively histology of the resected specimen including resection margin status will be recorded.
89085885|NCT05615844|Experimental|Antibiotic Cement Bead Pouch|"The antibiotic cement bead pouch involves placing temporary non-absorbable antibiotic-laden cement beads into the open fracture wound and sealing the wound with a large occlusive dressing for prophylaxis against bacteria.~The antibiotic beads used will be prepared intraoperatively by the surgical team. The bead recipe will be comprised of a ratio of 2 grams of vancomycin, 2.4 grams of tobramycin, and 40g (one bag) of PMMA cement. The beads will be handmade and approximately 10-mm in diameter. The number of beads placed in the wound will be at the discretion of the treating surgeon based on recipient wound size. As commonly practiced, the antibiotic beads may be exchanged for new beads at each subsequent irrigation and debridement surgery. The number of beads, the number of replaced beads, and the removal of the antibiotic beads will be recorded."
89085886|NCT05615844|Active Comparator|Negative Pressure Wound Therapy (NPWT)|"The NPWT system is a sealed dressing placed over the open fracture wound that includes an occlusive plastic wound dressing connected to a vacuum pump, tubing, and a canister to collect fluid. The pump creates a vacuum seal and exerts negative pressure on the wound to remove fluid and maintain a sealed environment. NPWT promotes wound healing through four primary mechanisms: 1) wound shrinkage or macrodeformation; 2) microdeformation at the foam-wound surface interface; 3) fluid removal; and 4) stabilization of the wound environment.~125 mmHg continuous negative pressure is the recommended NPWT device setting; however, the treating surgeon will be allowed to adjust these settings as clinically necessary.~The frequency and timing of NPWT changes will also be at the surgeon's discretion but is expected to primarily coincide with the timing of repeat debridement, typically every 24-72 hours until definitive management has occurred."
89085887|NCT05613517||Healthy individual|Healthy individual without eye disorder.
89085888|NCT05611346|No Intervention|Therapeutic education program|
89085889|NCT05611346|Experimental|Therapeutic education program and Hypnosis|
89085890|NCT05610618|Experimental|Healthy adults|A single group of healthy adults will undergo all experimental conditions (within subject design)
89085896|NCT05599789|Experimental|Pembrolizumab in Combination with Plinabulin and Docetaxel|Pembrolizumab in Combination with Plinabulin and Docetaxel
89085897|NCT05593952|Experimental|Dual task|"The dual task will be self-regulated and will consist of subtracting 3 by 3 from 100, and performing the maximum number of repetitions possible.~exercise with dual task + usual treatment;"
89085898|NCT05593952|Active Comparator|Single task|exercise without dual task + usual treatment.
89085899|NCT05587881||donor with vaccine, patient without vaccine|Patients don' t receive COVID-19 vaccine before allo-HSCT but whose donors receive one dose or more doses COVID-19 vaccine(s) before stem cell collection.
89085900|NCT05587881||donor without vaccine, patient with vaccine|Patients receive one dose or more doses COVID-19 vaccine(s) before allo-HSCT but whose donors don't receive COVID-19 vaccine before stem cell collection.
89085901|NCT05587881||donor with vaccine, patient with vaccine|Patients receive one dose or more doses COVID-19 vaccine(s) before allo-HSCT and whose donors also receive one dose or more doses COVID-19 vaccine(s) before stem cell collection.
89085902|NCT05587881||donor without vaccine, patient without vaccine|Patients don' t receive COVID-19 vaccine before allo-HSCT and whose donors also don't receive COVID-19 vaccine before stem cell collection.
89085903|NCT05582265|Experimental|Neoadjuvant Tislelizumab + Reduction of Cycles of Chemotherapy (Arm A)|"Neoadjuvant therapy ( 3 cycles ) ： Cycle1（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1; Cisplatin (IV), dose=75 mg/m2, or Carboplatin (IV), AUC=5, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Cycle2、3（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1.~Following surgical resection, high risk participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Low risk participants receive 200 mg Tislelizumab Q3W plus radiotherapy as adjuvant therapy."
89085904|NCT05582265|Experimental|Neoadjuvant Tislelizumab + Chemotherapy (Arm B)|"Neoadjuvant therapy ( 3 cycles ) ： Cycle1、2、3（Cycle length: 21 days）：Tislelizumab (IV), dose= 200mg, day=1; Cisplatin (IV), dose=75 mg/m2, or Carboplatin (IV), AUC=5, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Following surgical resection, high risk participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Low risk participants receive 200 mg Tislelizumab Q3W plus radiotherapy as adjuvant therapy."
89085905|NCT05582265|Other|Up-front Surgery (Arm C)|Following surgical resection, high risk participants receive chemoradiotherapy as adjuvant therapy. Low risk participants receive radiotherapy as adjuvant therapy.
89085906|NCT05580666|Experimental|Oral Azithromycin 250 mg once daily|Active Azithromycin tablet
89085907|NCT05580666|Placebo Comparator|Oral matching placebo, once daily|Matching placebo tablet
89085910|NCT05567952|Experimental|nirmatrelvir plus ritonavir for 5 days|Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days
89085911|NCT05567952|Other|placebo plus ritonavir for 5 days|placebo (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days
89523038|NCT04446689|Active Comparator|Biofeedback|The intervention group will develop an activity with self-monitoring called Cardiovascular Biofeedback or Cardiac Frequency Variability (CFV). This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph. This photoplethysmograph verifies blood flow alterations through an optical method. Cardiac frequency oscillations may be estimated both by the quantity of blood infrared lights absorbed or reflected, and by variations in blood volume and pressure. Captured physiological signs will be recorded during ten minutes by the Software Emwave Pro Plus®, which is adapted to biofeedback training.
89085914|NCT05564377|Experimental|EAY191-A2 (Cohort 1, Arm A)|Cohort 1, Arm A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
89085915|NCT05564377|Experimental|EAY191-A2 (Cohort 2, Arm B)|Cohort 2, Arm B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
89085916|NCT05564377|Experimental|EAY191-A2 (Cohort 2, Arm C)|Cohort 2, Arm C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
89085917|NCT05564377|Experimental|EAY191-A2 (Cohort 3, Arm D)|Cohort 3, Arm D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
89085918|NCT05564377|Experimental|EAY191-A3 Combo Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)|Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
89085919|NCT05564377|Experimental|EAY191-A3 Monotherapy Cohort 1 (binimetinib)|Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
89085920|NCT05564377|Experimental|EAY191-A6 Arm I (RAS/RAF/MEK/ERK mutations)|Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or a FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.
89085921|NCT05564377|Experimental|EAY191-A6 Arm II (RAS/RAF/MEK/ERK mutations)|Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated
89085922|NCT05564377|Experimental|EAY191-E4 (taxane therapy)|Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression.
89085923|NCT05564377|Experimental|EAY191-E5 Cohort I Arm A (sotorasib, panitumumab)|Patients receive sotorasib PO QD on days 1-28 and panitumumab intravenously IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
89085924|NCT05564377|Active Comparator|EAY191-E5 Cohort I Arm B (sotorasib)|Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
89085925|NCT05564377|Experimental|EAY191-E5 Cohort II (sotorasib)|Patients receive combination therapy as in EAY191-E5 Arm A.
89085926|NCT05564377|Experimental|EAY191-N2 Cohort I (Arm I) (NF1 mutations)|Patients receive fulvestrant IM and binimetinib PO throughout the trial. Patients also undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
89085927|NCT05564377|Experimental|EAY191-N2 Cohort I (Arm II) (NF1 mutations)|Patients receive fulvestrant IM throughout the trial. Patients who progress on fulvestrant alone are asked to reaffirm their willingness to enroll in cohort II. Patients not willing to transition to cohort II continue further therapy as clinically indicated. Patients undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
89085928|NCT05564377|Experimental|EAY191-N2 Cohort II (NF1 mutations)|Patients receive fulvestrant IM and binimetinib PO throughout the trial. If the patient progressed on fulvestrant, the loading dose of fulvestrant is omitted. Patients undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
89085929|NCT05564377|Experimental|EAY191-N4 Arm I (RAS pathway mutations)|Patients receive selumetinib PO and olaparib PO on study. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
89085930|NCT05564377|Active Comparator|EAY191-N4 Arm II (RAS pathway mutations)|Patients receive selumetinib PO on study. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.
89225933|NCT05091931||Guidance® UTI pathway (modified lab workflow)|Guidance® UTI pathway with antibiotic sensitivity and microbial testing results reporting to a clinical lead specialist at the urology office within 14 hours of lab receipt. Includes confirmation by the clinical lead that the ordering provider has acted upon results as soon as they are made available. Treatment based on local standard clinical antibiotic selection with or without empiric therapy.
89085931|NCT05564377|Active Comparator|EAY191-N5 Arm I (neratinib maleate)|Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
89085932|NCT05564377|Experimental|EAY191-N5 Arm II (neratinib maleate,palbociclib)|Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
89085933|NCT05564377|Experimental|EAY191-S3 (activating AKT mutation)|Patients receive paclitaxel IV and ipatasertib PO on study. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up.
89085934|NCT05563870|Active Comparator|Endoscopic Drainage Arm|Patients randomized to this arm will undergo biliary stenting only
89085935|NCT05563870|Experimental|COMBO-RFA Arm|Patients randomized to this arm will undergo same-session endoluminal radiofrequency ablation followed by biliary stenting
89085936|NCT05558059||Cohort 1|"16 preterm infants undergoing ROP screening to optimize methods to acquire and process beside infant perifoveal vascular imaging and assess rigor and reproducibility.~The visits in the ICN (Intensive Care Nursery) will occur between 32 and 43 weeks post menstrual age at the time of ROP screening exams. Study visits will include, but are not limited to:~Ocular examination~OCT imaging of retinal microanatomy~OCTA imaging of retinal microvasculature~Medical and ocular history~Adverse event documentation"
89085937|NCT05557045|Experimental|Dose Exploration (Part A): JZP815|Participants will receive JZP815 with a starting dose of 20 mg twice daily (BID).
89085938|NCT05557045|Experimental|Expansion (Part B): JZP815|Participants with advanced or metastatic solid tumors who will receive JZP815 at the RP2D established in Dose Exploration (Part A).
89085939|NCT05555108|Experimental|ACTCOM-I Intervention|
89085940|NCT05555108|Active Comparator|Standard CBT-I Intervention|
89085941|NCT05552508|Experimental|Benralizumab|Participants will receive 3 doses of benralizumab having a strength of 30 mg subcutaneously once every 4 weeks (Week 0, Week 4, and Week 8).
89085942|NCT05551325|No Intervention|Control|Usual ICU care.
89085943|NCT05551325|Experimental|Chronobundle|The chronobundle will include bright daytime light, time-restricted intermittent feeding, enhanced exercise/mobility, and overnight sleep promotion.
89085944|NCT05550220|Experimental|Modified Cuff Leak Test|"The subject was placed in a semi-recumbent position.~The subjects were placed in volume assist-control mode with the following parameters:~respiratory rate 15 breaths/min~original oxygen concentration~PEEP 0 cm H2O~the VT was set according to the subject's stable VT in the previous ventilator mode~inspiratory flow was set at 30 L/min with square waveform Positive cutoff value of the air leak volume was 116 mL and the air leak ratio was 0.32."
89085945|NCT05550220|Active Comparator|Usual Cuff Leak Test|"The subjects were placed in volume assist-control mode with the following parameters:~respiratory rate was adapted to patient comfort~original oxygen concentration and PEEP~the VT about 8ml/Kg IBW~inspiratory flow was set at 60 L/min with square waveform Positive cutoff value of the air leak volume was 110 mL and the air leak ratio was 0.15."
89085948|NCT05543538|Placebo Comparator|multimedia audio-visual program|
89085949|NCT05543538|Experimental|multimedia audio-visual and experiential learning programmes|
89085950|NCT05543538|Experimental|multimedia audio-visual and teachers' personal demonstration and experiential learning|
89085951|NCT05539989|Experimental|VPM1002 Vaccine Arm|Participants stratified by HIV and M.tb sensitization status.
89085952|NCT05539989|Experimental|BCG Vaccine Arm|Participants stratified by HIV and M.tb sensitization status.
89085953|NCT05539989|Placebo Comparator|Placebo Arm|Participants stratified by HIV and M.tb sensitization status.
89085954|NCT05538130|Experimental|Monotherapy Dose Escalation (Phase 1a)|Participants will receive PF-07799544
89085955|NCT05538130|Experimental|Phase 1b Substudy B Combination Dose Escalation|Participants will receive PF-07799544 and PF-07799933
89085956|NCT05538130|Experimental|Phase 1b Substudy B Combination Dose Expansion|Participants will receive PF-07799544 and PF-07799933
89085957|NCT05538130|Experimental|Phase 1b Substudy C Combination Dose Expansion|Participants will receive PF-07799544 and PF-07799933
89085958|NCT05537519|Experimental|Open Label Arm|
89085959|NCT05521945|Experimental|Intermittent Fasting Group|eight hours eating window and 16 hours for fasting among healthy population
89085960|NCT05521945|Active Comparator|Customized Dietary group|Customized diet plan according to participants' calorie intake and according to their respective Body Mass Index
89085961|NCT05521945|Placebo Comparator|Control group|Normal routine diet
89085962|NCT05516836|Experimental|Multicomponent exercise program + Telemedicine|"The multicomponent exercise program lasted 6 weeks with sessions twice a week for a total of 12 sessions. It will have a duration of forty minutes in which the first five and the last five will be performed at a constant load of 5% of its maximum load corresponding to the warm-up and return to calm. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed.~A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence"
89085963|NCT05516836|Active Comparator|Multicomponent exercise program|"The multicomponent exercise program lasted 6 weeks with sessions twice a week for a total of 12 sessions. It will have a duration of forty minutes in which the first five and the last five will be performed at a constant load of 5% of its maximum load corresponding to the warm-up and return to calm. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed."
89085964|NCT05515523|Experimental|a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF)|a single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF) for the treatment of knee Post Traumatic Osteoarthritis (PTOA)
89085966|NCT05507164|Other|Temporo-masseteric Nerve Block Administration|Non-randomized administration of the TMNB injection (unilateral) followed by bite force distribution and surface EMG assessment of the temporalis and masseter muscles on the side of the injection
89085967|NCT05493852||FARAPULSE Pulsed Field Ablation System|Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation.
89085968|NCT05489575|Experimental|Active CPAP (Daytime Study)|CPAP at 8, 10, or 12 cm H2O is applied for up to 2 hours while supine and awake.
89085969|NCT05489575|Sham Comparator|Sham CPAP (Daytime Study)|Sham CPAP is applied for up to 2 hours while supine and awake.
89085970|NCT05489575|Experimental|Active CPAP (Overnight Study)|CPAP at 8, 10, or 12 cm H2O is applied for up to 9 hours during the night.
89085971|NCT05489575|Sham Comparator|Sham CPAP (Overnight Study)|Sham CPAP is applied for up to 9 hours during the night.
89085972|NCT05489575|Active Comparator|Sleeping in a head-up tilt position (Overnight Study)|Sleeping with the bed tilted head-up by 10 degrees for up to 9 hours during the night.
89085973|NCT05479474|Experimental|Platelet rich plasma treatment arm|After consent in obtained, the patient will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.
89085974|NCT05474651||Questionnaires assessed expectant fathers who quit smoking|"Participants who met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).~Males ≥18 years old;~The wife has given birth, the newborn is live, and the number of days of birth is less than or equal to 28 days;~Self-reported smoking at least 1 cigarette per day on average for at least 1 month in the past 1 year;~Self-reported that they had quit smoking during their wife's pregnancy on purpose, and maintained it for at least 24 hours;"
89085977|NCT05462379|No Intervention|Standard treatment|10 patients: Pelvic Chemoradiotherapy
89085978|NCT05462379|Experimental|Ovarian Graft|10 patients: Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
89523039|NCT04446689|No Intervention|activity without self monitoring|"The placebo group will develop an activity without self monitoring. In order to keep blindness between the groups the activities will be processed by an electronic device - the on line app Jigsaw Puzzles. This app consists of a puzzle with different levels of difficulties, and is played in a tablet.~Each participant will be performing in the study during four weeks, with two encounters each week (total: four weeks). While the participant will be performing its activity he/she will be monitored by the researchers through CFV (Cardiac Frequency Variability) - with no visualization of the computer monitor.~The control group will answer the research protocol in two moments (D1 and D8), to evaluate"
89523040|NCT04446455|Experimental|Functional Power + Cognitive Training|Training sessions began with approximately 30 minutes of cognitive training using a desktop computer followed by 40 minutes of functional power training.
89085981|NCT05446467|Experimental|Pembrolizumab+cisplatin + 5-fluorouracil|Pembrolizumab+ cisplatin+ 5-fluorouracil+ surgery+ adjuvant treatment+ pembrolizumab maintenance
89085985|NCT05440617||Subjects Treated with Gonadotoxic therapy|Subjects who have planned to undergo OTC for gonadotoxic therapy based on current standard of care.
89085986|NCT05432791|Experimental|Arm 1 (olaparib, temozolomide)|Patients receive temozolomide PO QD on days 1-7 of each cycle and olaparib PO BID on days 1-7 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI and/or bone scans throughout the trial. Patients also undergo collection of blood samples throughout the trial.
89085987|NCT05432791|Active Comparator|Arm 2 (trabectedin, pazopanib)|Patients receive trabectedin IV continuously over 24 hours on day 1 of each cycle or pazopanib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI and/or bone scans throughout the trial. Patients also undergo TTE or MUGA on study and as clinically indicated, as well as collection of blood samples throughout the trial.
89085988|NCT05432336||Complex ocular infections (COI)|All patients with an COI (endophtalmitis or hospitalized keratitis)
89085989|NCT05432323||Adolescents|
89085990|NCT05427214|Experimental|Halcyon 4.0 imaging|Patients planning to receive radiation therapy to the head and neck/brain, thorax, abdomen, or pelvis will undergo imaging on the Halcyon 4.0 system. Patients will return for a minimum of 2 sessions over 9 weeks, with a cumulative total of 10 images being collected.
89085991|NCT05424926||Patients|Patients
89085992|NCT05424315|Active Comparator|Intervention Group|Participants will receive Dapagliflozin 10mg once daily.
89085993|NCT05424315|Placebo Comparator|Control Group|Participants will receive a glucose tab once daily.
89085994|NCT05421065|Experimental|Psilocybin Group (Arm 1)|receives individual psychotherapy sessions plus a (25 mg) psilocybin session.
89085995|NCT05421065|Active Comparator|Ketamine Group (Arm 2)|receives individual psychotherapy sessions plus a (200 mg) ketamine session with open-label access option at the end of their study involvement.
89085996|NCT05419960||Patients|Patients between the ages of 12-20 years with a diagnosis of Osteogenesis Imperfecta of any type and followed by a physician at the Centre de Référence des Maladies Rares des maladies osseuses constitutionnelles (CRMR OI) of Hôpital Necker-Enfants malades.
88812854|NCT03215186||Cataract children|All children in this group were diagnosed as congenital cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
89085997|NCT05419895|Experimental|Families with children enrolled in BCW with suspected diagnosis of autism|Post-consent, families with children between 16-33 months will receive a link to complete the EAC Developmental History Survey on REDCap and a link to complete parent/caregiver questionnaires about developmental and/or adaptive information. Then, the family will be assigned to a clinician for the autism assessment and scheduled their assessment and feedback session (one week later).
89085998|NCT05412810||Oxygen exposures|mechanically ventilated patients with atleast 1.5 hours of FiO2 exposure of 50% or more
89085999|NCT05399459|Experimental|Rimegepant 25 mg|Single dose of 25 mg orally disintegrating tablet of rimegepant
89086000|NCT05399459|Experimental|Rimegepant 75 mg|Single dose of 75 mg orally disintegrating tablet of rimegepant
89086001|NCT05399459|Placebo Comparator|Placebo|Matching placebo tablet
89086002|NCT05373784|Experimental|FMT cohort|This will be a single-arm pilot study of patients with uncomplicated diverticulitis. All subjects enrolled as recipients will undergo FMT via colonoscopy.
89523041|NCT04446455|Active Comparator|Functional Power Training|Training sessions began with 40 minutes of functional power training.
89086004|NCT05371054|Experimental|1/Phase 1: Arm 1 Dose Escalation|VVIP-VIP152 and venetoclax at escalating doses with prednisone at fixed doses to determine the MTD and RP2D of VIP152 and venetoclax
89086005|NCT05371054|Experimental|2/Phase 2: Arm 2 Dose Expansion|VVIP- VIP152 and venetoclax at the RP2D with prednisone at fixed doses
89086006|NCT05368558|Experimental|Cariprazine|Participants will receive cariprazine Dose A daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.
89086007|NCT05368558|Placebo Comparator|Placebo|Participants will receive placebo daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.
89086008|NCT05359003|Experimental|Arm 1: Exercise Intervention|Participants in this arm will undergo a 12-week physical activity program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps).
89086009|NCT05359003|No Intervention|Arm 2 Control|Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks.
89086010|NCT05357118|Experimental|One arm|The study is an one-arm pre- and post-design.
89086011|NCT05353439|Experimental|Treatment (tazemetostat, pembrolizumab, topotecan)|Patients receive tazemetostat PO BID on days 1-21, pembrolizumab IV over 30 minutes on day 1, and topotecan IV over 30 minutes on days 1-5. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study and may also undergo biopsy and collection of blood on study.
89086012|NCT05335070|Experimental|Temporo-masseteric Nerve Block (TMNB) Injection with Local Anesthetic|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the side/s of lower wisdom molar extraction/s
89086013|NCT05333458|Experimental|Arm I (atezolizumab, selienexor)|Patients receive atezolizumab IV over 30-60 minutes on day 8 of cycle 1, and then on day 1 of subsequent cycles. Patients also receive selinexor PO QW on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy at baseline, cycle 1 day 8 and cycle 3 day 1, CT and MRI at baseline, end of cycle 2, and every 2 cycles thereafter, and collection of blood samples throughout the study.
89086014|NCT05333458|Experimental|Arm II (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I. Patients also undergo biopsy at baseline and cycle 3 day 1, CT and MRI at baseline, end of cycle 2, and every 2 cycles thereafter, and collection of blood samples throughout the study.
89086015|NCT05330988|Experimental|Real|Randomly selected participants will receive 20 min. of anodal transcranial direct current stimulation to the the top of their heads. The current will slowly be ramped up over 30 secs.
89086016|NCT05330988|Sham Comparator|Sham|Randomly selected participants will receive 20 min. of sham transcranial direct current stimulation to the top of their heads. Sham stimulation is accomplished by turning on the device and slowly increasing and subsequently decreasing the amount of current to zero. This occurs over 30 secs.
89086017|NCT05330689|Active Comparator|Sample group 1|Sample of subjects with primary osteoarthritis of the knee
89086018|NCT05330689|Active Comparator|Sample group 2|Sample of subjects with primary osteoarthritis of the knee
89086019|NCT05330689|Active Comparator|Sample group 3|Sample of subjects with primary osteoarthritis of the knee
89086020|NCT05330689|Active Comparator|Sample group 4|Sample of subjects with primary osteoarthritis of the knee
89086021|NCT05330689|Placebo Comparator|Sample group 5|Sample of subjects with primary osteoarthritis of the knee
89086022|NCT05330325|Experimental|Somapacitan|Participants will receive Somapacitan for 156 weeks
89086023|NCT05330325|Active Comparator|Norditropin®|Participants will receive Norditropin® for 52 weeks (main phase) and Somapacitan for 104 weeks (extension phase)
89086024|NCT05321160|Experimental|Group E|1ug· kg-1 dexmedetomidine and 0.01mg·kg-1 atropine was administered intravenously. 0.25mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
89523042|NCT03391817|Active Comparator|Intervention arm|Fecal transplant from a thin donor
89523043|NCT03391817|Placebo Comparator|Placebo arm|Fecal transplant made from patients own feces
89086025|NCT05321160|Active Comparator|Group S|1ug· kg-1 dexmedetomidine and 0.01mg·kg-1 atropine was administered intravenously. 4% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anesthesia by mask inhalation and 2-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained.
89086026|NCT05321082|Experimental|BI 1015550 low dose|
89086027|NCT05321082|Experimental|BI 1015550 high dose|
89086028|NCT05321082|Placebo Comparator|Placebo|
89086029|NCT05321069|Experimental|BI 1015550 low dose|
89086030|NCT05321069|Experimental|BI 1015550 high dose|
89086031|NCT05321069|Placebo Comparator|Placebo|
89086032|NCT05318313||Telerehabilitation only|Participants choose to have all of their physical therapy provided virtually throughout the length of the study
89086033|NCT05318313||In-person only|Participants choose to have all of their physical therapy provided in-person throughout the length of the study
89086034|NCT05318313||Hybrid 1|The TR PT evaluation and follow-up visits in the initial 6 weeks will be performed via Zoom software and subsequent follow-up visits will switch to in person after 6 weeks
89086035|NCT05318313||Hybrid 2|The PT evaluation and follow-up visits in the initial 6 weeks will be performed in person and will switch to TR via Zoom software after 6 weeks
89086036|NCT05317416|Experimental|Arm A - Part 1|Elranatamab
89086037|NCT05317416|Active Comparator|Arm B - Part 1|Lenalidomide
89086038|NCT05317416|Active Comparator|Arm B - Part 2|Lenalidomide
89086039|NCT05317416|Experimental|Arm C - Part 2|Elranatamab
89086040|NCT05310838|Experimental|Behavioral Activation for First Episode Psychosis|Patients will receive BA for FEP in individual session format provided by the PI based on a manual adapted for this study.
89086041|NCT05310838|Active Comparator|Treatment at Usual|Patients randomized to TAU will receive typical clinic care offered beyond psychiatric services.
89086042|NCT05306418|Experimental|Mim8|52-week treatment period with a part 1 and part 2, where all participants receive Mim8 prophylaxis
89086043|NCT05305846|Experimental|TENA-PROTO2|Investigational device. Late prototype
89086044|NCT05305547|Experimental|S-217622|S-217622 will be administered orally for 5 days.
89086045|NCT05305547|Placebo Comparator|Placebo|Placebo matching to S-217622 will be administered orally for 5 days.
89086046|NCT05304377|Experimental|Phase 1a Dose Escalation|ELVN-001 administered in 3+3 dose escalation
89086047|NCT05304377|Experimental|Phase 1b Dose Expansion at recommended dose level 1|ELVN-001 administered at the recommended dose in CML without T315I mutations
89086048|NCT05304377|Experimental|Phase 1b Dose Expansion at recommended dose level 2|ELVN-001 administered at a different recommended dose in CML without T315I mutations
89086049|NCT05304377|Experimental|Phase 1b expansion arm in T315I mutated CML|ELVN-001 administered at the recommended dose for CML with T315I mutation
89086050|NCT05300035|Active Comparator|bNAbs|ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).
89086051|NCT05300035|Placebo Comparator|Placebo|ART plus placebo (saline solution) at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).
89086052|NCT05297864|Experimental|Niraparib Treatment|Patients will be treated with individualized starting dose of Niraparib.
89086053|NCT05294991|Experimental|Wellness app intervention #1|Participants assigned to this group will be asked to engage with the app a minimum of 10 minutes per day (70 minutes per week), at any time of day they choose for at 8-week period. There is a recommended program to follow for the 8-week period, but participants are also welcome to engage with other features and content within the app.
89523044|NCT03391739|Experimental|Arm 1|CART-19 cells treat
89086054|NCT05294991|Active Comparator|Wellness app intervention #2|Participants assigned to this group will be asked to engage with the app a minimum of 10 minutes per day (70 minutes per week), at any time of day they choose for at 8-week period. There is a recommended program to follow for the 8-week period, but participants are also welcome to engage with other features and content within the app.
89523045|NCT03386279|Other|Sequence 1|Sequential allocation to PF-04965842 600 mg (oral, single dose), placebo (oral, single dose), and moxifloxacin 400 mg (oral, single dose)
89225934|NCT05091931||Traditional clinical pathway|Local standard clinical practice pattern for UTI testing (e.g., urine analysis, urine culture and sensitivities or molecular testing as available). Treatment based on local standard clinical antibiotic selection with or without empiric therapy
89086055|NCT05294120|Experimental|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided RadIation Therapy|"If eligible, patients will undergo pretreatment RCM/OCT imaging, followed by RT.~Six weeks after the completion of RT, patients will undergo post-treatment assessment with RCM/OCT and biopsy. If residual carcinoma is detected on the biopsy, surgical excision of the BCC will be performed. If no residual carcinoma is detected on the biopsy, the patient will be monitored for clinical evidence of recurrence for up to 3 years."
89086056|NCT05290064|Experimental|1/UPF HH, UPF HL, UNF LL, UPF LL|Four diets in the order specified
89086057|NCT05290064|Experimental|2/ UPF HL, UPF LL, UPF HH, UNF LL|Four diets in the order specified
89086058|NCT05290064|Experimental|3/ UPF LL, UNF LL, UPF HL, UPF HH|Four diets in the order specified
89086059|NCT05290064|Experimental|4/ UNF LL, UPF HH, UPF LL, UPF HL|Four diets in the order specified
89086060|NCT05286736||Early (untreated) Parkinson's Disease|Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria.
89086061|NCT05286736||Healthy Controls|Age- and sex-matched healthy controls.
89086062|NCT05283720|Experimental|Arm 1: Dose Escalation|Participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) will receive escalating doses of subcutaneous (SC) epcoritamab in combination with oral lenalidomide in 28 day cycles.
89086063|NCT05283720|Experimental|Arm 2: Dose Escalation|Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.
89086064|NCT05283720|Experimental|Arm 3: Dose Escalation|Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles.
89086065|NCT05283720|Experimental|Arm 4: Dose Escalation|Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
89086066|NCT05283720|Experimental|Arm 5: Dose Escalation|Participants with R/R follicular lymphoma (FL) will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
89086067|NCT05283720|Experimental|Arm 6A: Dose Escalation|Participants with R/R mantle cell lymphoma (MCL) will receive escalating doses of SC epcoritamab in combination with oral ibrutinib in 28 day cycles.
89086068|NCT05283720|Experimental|Arm 6B: Dose Escalation|Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
89086069|NCT05283720|Experimental|Arm 7: Dose Escalation|Participants with newly diagnosed treatment-naïve MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
89086070|NCT05283720|Experimental|Arm 1: Dose Expansion|Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral lenalidomide in 28 day cycles.
89086071|NCT05283720|Experimental|Arm 2: Dose Expansion|Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.
89086072|NCT05283720|Experimental|Arm 3: Dose Expansion|Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles.
89086073|NCT05283720|Experimental|Arm 4: Dose Expansion|Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
89086074|NCT05283720|Experimental|Arm 5: Dose Expansion|Participants with R/R FL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
89225935|NCT05090150|No Intervention|Best clinic practices|Participants start with best clinic practices and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in their original arm)
89086075|NCT05283720|Experimental|Arm 6: Dose Expansion|Participants with R/R MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib in 28 day cycles.
89086076|NCT05283720|Experimental|Arm 7: Dose Expansion|Participants with newly diagnosed treatment-naïve MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
89225936|NCT05090150|Experimental|Best clinic practices plus lottery incentives|Participants start with best clinic practices plus lottery incentives and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in the original arm)
89086077|NCT05282134|Experimental|Wet cupping therapy|The intervention group will undergo 3 successive wet cupping therapy (WCT) sessions once in a month throughout 3 months (On 0, 30, and 60 days. Cups will be held for 5 minutes on the 5 regions of the C7 cervical spine (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupoint) and bilateral T6-8 lateral spine (BL44-46) points, which are recommended areas for headache, Then, these areas where the blood supply has increased will be drawn with a sterile lancet and the cup will be applied again and left for 10 minutes, and then the cups will be removed and the accumulated blood will be cleaned.
89086078|NCT05282134|Experimental|Acupuncture|Acupuncture application will be done by manually needling selected acupuncture points specific to the disease twice a week for 4 weeks. After the needles are placed, they will be manipulated to create a feeling of de-qi and left for 20 minutes.
89086079|NCT05282134|No Intervention|Control|Control group will not receive any intervention
89086080|NCT05276973|Experimental|Treatment (paclitaxel, carboplatin, ipatasertib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive ipatasertib PO QD until 24 hours before surgery in the absence of disease progression or unacceptable toxicity.
89086081|NCT05275439|Experimental|SL-172154|Patients will receive intravenous administration
89086082|NCT05275439|Experimental|SL-172154 + Azacitidine|Patients will receive intravenous administration of SL-172154 and Azacitidine.
89086083|NCT05275439|Experimental|SL-172154 + Azacitidine + Venetoclax|Patients will receive intravenous administration of SL-172154 and Azacitidine plus oral venetoclax.
89086084|NCT05275439|Experimental|Part D-Previously untreated HR-MDS 1:1:1 Randomization|"Previously untreated MDS patients with or without TP53 mutation will be randomized to receive the following:~3 mg/kg SL-172154 + Azacitidine~1 mg/kg SL-172154 + Azacitidine~Azacitidine Monotherapy"
89086085|NCT05269446||STEMI patients|STEMI: patients diagnosed with ST-segment elevation myocardial infarction
89086086|NCT05269446||SA or NSTEMI patients|SA: patients diagnosed with stable angina
89086087|NCT05269446||Healthy subjects|Patients with suspected coronary artery disease, but coronary angiography (CAG) indicates no obvious coronary stenosis
89086088|NCT05256771|Active Comparator|Arm A: Full Treatment Arm (Laser + EMS + RF/PEMF)|Arm A: Three (3) diode laser treatments treatments at days 0, 28 and 56 (±2 days). Subjects will also receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
89086089|NCT05256771|Active Comparator|Arm B: EMS/RF Arm (EMS + RF/PEMF)|Arm B: Subjects will receive bi-weekly electrical muscle stimulation and pulsed electromagnetic fields/vacuum assisted radio frequency treatments at days 0, 14, 28, 42 and 56 (±2 days).
89086090|NCT05256771|Active Comparator|Arm C: EMS Arm (EMS only)|Arm C: Subjects will receive weekly electrical muscle stimulation treatments at days 0, 7, 14, 21, 28 and 35 (±2 days).
89086091|NCT05253339|Active Comparator|Standard administration method|"Drug: Cefoxitin, Device: not applicable (standard method)~Two grams of cefoxitin (JW Pharmaceutical Co., Ltd., Seoul, South Korea) was dissolved in 50 mL of normal saline and administered for about 10 min before skin incision."
89225937|NCT05090150|Experimental|Randomized from best clinic practices to smart lockers|Second randomization into community ART through the use of smart lockers
89225938|NCT05090150|Experimental|Randomized from best clinic practices to home delivery|Second randomization into home ART delivery
89086092|NCT05253339|Experimental|Target controlled infusion (TCI)|"Drug: Cefoxitin, Device: TCI Syringe pump~Two grams of cefoxitin were dissolved in 50 mL of normal saline to give a concentration of 40 mg/mL. Before skin incision, cefoxitin was infused with a TCI syringe pump (Pilot Anesthesia 2, Fresenius vial, France), which was connected to a personal computer by an RS232c cable and controlled with TCI software (Asan pump, version 2.1.3; Bionet Co. Ltd., Seoul, Korea, http://www.fit4nm.org/download, last accessed: 27 August, 2012). Target concentrations of total concentrations were set to 80 μg/mL."
89086093|NCT05243719|Experimental|Treatment Options 1, 2, 3, 4, 5|Participants will fall into 1 of 5 treatment options dependent on the treatment received (ADP101 or placebo) during the parent study and their tolerance of the treatment regimen during the parent study.
89523046|NCT03386279|Other|Sequence 2|Sequential allocation to PF-04965842 600 mg (oral, single dose), moxifloxacin 400 mg (oral, single dose), and placebo (oral, single dose)
89523047|NCT03386279|Other|Sequence 3|Sequential allocation to placebo (oral, single dose), PF-04965842 600 mg (oral, single dose), and moxifloxacin 400 mg (oral, single dose).
89086096|NCT05233436|Experimental|Part 1A Dose Escalation Monotherapy|Participants will receive PF-07265028 at escalating dose levels.
89086097|NCT05233436|Experimental|Part 1B Dose Escalation Combination|Participants will receive PF-07265028 at escalating dose levels in combination with sasanlimab fixed dose
89086098|NCT05233436|Experimental|Part 2A Dose Expansion Combination (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
89086099|NCT05233436|Experimental|Part 2A Dose Expansion Combination (UC)|Participants with urothelial cancer (UC) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
89086100|NCT05233436|Experimental|Part 2A Dose Expansion Combination (Gastric/GEJ)|Participants with gastric/gastroesophageal junction cancer (Gastric/GEJ) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
89086101|NCT05233436|Experimental|Part 2A Dose Expansion Combination (NSCLC)|Participants with non small cell lung cancer (NSCLC) will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
89086102|NCT05233436|Experimental|Part 2A Dose Expansion Combination (selected tumor types)|Participants with selected tumor types will receive PF-07265028 in combination with sasanlimab at the recommended dose from Part 1B
89086103|NCT05233436|Experimental|Part 2B Dose Expansion Monotherapy (selected tumor types)|Participants with selected tumor types will receive PF-07265028 single agent at the recommended dose from Part 1A.
89086104|NCT05230628|Experimental|Active TENS|Active will be performed with using a TENS device with an ear clip attached to the tragus of the right ear (which is innervated by auricular branch of the vagus nerve) at 25 Hz, 200ms at a current just below discomfort threshold.
89086105|NCT05230628|Sham Comparator|Sham TENS|Sham TENS will be performed to the ear lobe, which is devoid of vagal innervation.
89086106|NCT05217927|Experimental|Rimegepant 75mg Orally Disitegrating Tablet (ODT)daily dosing|"Double-blind Treatment Phase: Rimegepant 75 mg ODT dosed daily~Open-Label Extension Phase:~Rimegepant 75 mg ODT dosed daily"
89086107|NCT05217927|Experimental|Rimegepant 75mg Orally Disintegrating Tablet (ODT)every other day dosing|Double-blind Treatment Phase: Rimegepant 75 mg ODT every other day dosing alternating with matching placebo
89086108|NCT05217927|Placebo Comparator|Placebo comparator dosing|Double-blind Treatment Phase: matching placebo dosed daily
89086109|NCT05215353|Experimental|Music Therapy (MT)|MT is a non-pharmacological, evidence-based intervention, in which board-certified music therapists engage patients in personally tailored experiences with music to achieve therapeutic goals. Patients will receive a workbook with materials for each session These experiences range from music-guided relaxation to more active forms of musical engagement, including singing and improvising music.
89086110|NCT05215353|Active Comparator|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) is an evidence-based, nonpharmacological intervention delivered by licensed mental health providers. Informed by the cognitive behavior model of anxiety, CBT focuses on the relationship between thoughts, behaviors, and emotions and how thoughts and behaviors can exacerbate or reduce anxiety.
89086111|NCT05215275|Experimental|MICT to HIIT|participants will receive moderate-intensity continuous training lasting 8 weeks, and then exchange to high-intensity interval training lasting 8 weeks, with 8 weeks rest insert to two different modalities of exercise.
89086112|NCT05215275|Experimental|HIIT to MICT|participants will receive high-intensity interval training lasting 8 weeks, and then exchange to moderate-intensity continuous training lasting 8 weeks, with 8 weeks rest insert to two different modalities of exercise.
89086113|NCT05196815|Experimental|The Royal Wolverhampton NHS Trust- New Cross Hospital|
89086114|NCT05195281|Experimental|Repetition of EUS-FNA or FNB for RNA extraction|
89086115|NCT05187273|Experimental|intervention|
89086116|NCT05187273|No Intervention|control|
89086117|NCT05175040|Experimental|Prophylactic manual rotation|Prophylactic manual rotation involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation.
89086118|NCT05175040|Sham Comparator|Sham rotation|Sham rotation involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation.
89225939|NCT05090150|Experimental|Randomized from best clinic practices plus lottery incentives to smart lockers|Second randomization into community ART through the use of smart lockers
89225940|NCT05090150|Experimental|Randomized from best clinic practices plus lottery incentives to home delivery|Second randomization into home ART delivery
89086119|NCT05172245|Experimental|Dose Escalation (ipatasertib, cisplatin, radiation therapy)|Patients receive ipatasertib PO QD or Monday, Wednesday, and Friday depending on dose level on days 1-28 of each cycle. Patients also receive cisplatin IV weekly on day 1 of cycle 1, weeks 1-4 and day 1 of cycle 2, weeks 1-3 for 7 doses. Patients undergo RT daily (Monday-Friday) for 35 fractions during weeks 1-7. Treatment repeats every 28 days for a total of 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT, CT, or MRI during screening, follow-up, and as clinically indicated. Patients undergo blood sample collection on trial.
89086120|NCT05172245|Experimental|Dose Expansion (ipatasertib, cisplatin, radiation therapy)|Patients receive ipatasertib PO MTD on days 2-28 or 3-28 of cycle 1 and 1-28 of subsequent cycles. Patients also receive cisplatin IV weekly on day 1 of cycle 1, weeks 1-4 and day 1 of cycle 2, weeks 1-3 for 7 doses. Patients undergo RT daily (Monday-Friday) for 35 fractions during weeks 1-7. Treatment repeats every 28 days for a total of 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT, CT, or MRI during screening, follow-up, and as clinically indicated. Patients undergo blood sample collection and tumor biopsy on trial.
89086121|NCT05161481|Experimental|Avenciguat (BI 685509), dose group 1|
89086122|NCT05161481|Experimental|Avenciguat (BI 685509), dose group 2|
89086123|NCT05161481|Placebo Comparator|Placebo|Placebo
89086124|NCT05159050|Experimental|Intraperitoneal paclitaxel-loaded tumor penetrating microparticles (TPM)|Paclitaxel-loaded tumor penetrating microparticles (TPM), dose escalation starting at 50 mg/m^2 instilled in the peritoneal cavity at study start and again 6-8 weeks after the first TPM treatment.
89086125|NCT05155787|Experimental|Group with neurofeedback training|The neurofeedback training system records the brain waves from the subject and converts the original brain wave signal into frequency energy through spectrum analysis. The system will help the subject to find self relax method for producing more alpha waves. Each person will arrange training three times a week for four weeks.
89086126|NCT05155787|Sham Comparator|Group with shame neurofeedback training|In the shame group, the system is not feedback to the actual wave. Each person will arrange training three times a week for four weeks.
89086127|NCT05153122|Experimental|Investigational SenseGuard Device|Patients undergo SG monitoring at least twice daily before and after receiving treatment.
89523048|NCT03386279|Other|Sequence 4|Sequential allocation to placebo (oral, single dose), moxifloxacin 400 mg (oral, single dose), and PF-04965842 600 mg (oral, single dose)
89523049|NCT03386279|Other|Sequence 5|Sequential allocation to moxifloxacin 400 mg (oral, single dose), PF-04965842 600 mg (oral, single dose), and placebo (oral, single dose)
89086131|NCT05149885|Experimental|Investigational SenseGuard Device|"Subjects with suspected diagnosis of Asthma and eligible for MCT will be recruited to the study.~The MCT procedure will be performed as usual, with the addition of SG measurements after each spirometry for each Methacholine dose."
89086132|NCT05149326|Experimental|Experimental arm|
89086133|NCT05149326|Placebo Comparator|Control arm|
89086134|NCT05143840|Experimental|Asciminib|"Asciminib 80mg taken orally once a day starting cycle 1 day 1 for up to 24 months during the single agent asciminib phase.~Patients who have not achieved MR4.5 after 24 months will be given a low dose tyrosine kinase inhibitor (low-TKI). There will be three options of low-TKIs to be given at the investigator's discretion."
89225941|NCT05088356|Experimental|Arm A1: Matched related/matched unrelated donor transplantation (closed)|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:.~Fludarabine (160 mg/m2)~Melphalan (50 mg/m2)~TBI (4Gy)~All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus."
89523050|NCT03386279|Other|Sequence 6|Sequential allocation to moxifloxacin 400 mg (oral, single dose), placebo (oral, single dose) and PF-04965842 600 mg (oral, single dose)
89225942|NCT05088356|Experimental|Arm B: Haploidentical transplantation (closed)|"Subjects without an identified matched related or matched unrelated donor will receive a haploidentical transplantation with reduced intensity preparative conditioning:~-. Fludarabine (160 mg/m2)~Melphalan (100 mg/m2~TBI (4Gy)~Patients will receive GVHD prophylaxis with post-transplant cyclophosphamide and tacrolimus."
89523051|NCT03391661|Experimental|Chronic Pain and the Brain|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes / their brains.
89225943|NCT05088356|Experimental|Arm A2: Fully matched (8/8) related/unrelated donor transplantation|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:~Fludarabine (160 mg/m2)~Thiotepa (10 mg/kg)~TBI (4Gy)~All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus."
88812855|NCT03215186||Healthy children|All children in this group were healthy and without cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
89523052|NCT03391661|Placebo Comparator|Health Behavior Control|This 15 to 20-minute exercise is designed as a control condition that has face validity as helpful and that relates to health. Thus, patients are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections).
89523053|NCT03391583|Experimental|Standard of Care plus Education|Educational material will be provided at three time points along with the current standard of care provided in tertiary health care setting
89086135|NCT05142384|Experimental|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later."
88812856|NCT01832558|Experimental|Eplerenone|Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily
88812857|NCT01832558|Placebo Comparator|Placebo|Placebo additionally to standard ACE-inhibition with enalapril 20mg daily
88812858|NCT01551095|Experimental|PEGJ|Patients in this arm will receive self-propelled balloon PEGJ tube.
88812859|NCT01832636|Active Comparator|Alanyl-Glutamine 3g/d|Alanyl-Glutamine orally 3g/day for 10 days
89523054|NCT03391583|No Intervention|Standard of Care|Current standard of care provided in tertiary health care setting
89523055|NCT03386201|Experimental|Intravenous methylene blue|
89086136|NCT05142384|Active Comparator|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies.
89086137|NCT05130580|Experimental|Arm I (educational materials, enhanced consult, decision aid)|Patients receive newly-developed educational materials about breast reconstruction and attend an enhanced consultation visit with their plastic surgeon to discuss options for breast reconstruction surgery, during which a decision aid application containing a customized presentation of possible breast reconstruction outcomes is presented. At the end of the consultation visit, patients complete questionnaires about decision-making and psychological well-being. Within 4-6 weeks and 3-6 months after beginning the reconstruction process, patients also complete questionnaires about satisfaction with their breasts, body image, and psychological well-being, and undergo two-dimensional (2D) and 3D imaging of the torso.
89086138|NCT05130580|Active Comparator|Arm II (educational materials, standard of care consultation)|Patients receive newly-developed educational materials about breast reconstruction and attend a standard of care consultation visit with their plastic surgeon to discuss options for breast reconstruction surgery. At the end of the consultation visit, patients complete questionnaires about decision-making and psychological well-being. Within 4-6 weeks and 3-6 months after beginning the reconstruction process, patients also complete questionnaires about satisfaction with their breasts, body image, and psychological well-being, and undergo 2D and 3D imaging of the torso.
89086139|NCT05128539|Experimental|JS001(Toripalimab)+JS002|
89086140|NCT05126277|Experimental|Arm 1 - ianalumab s.c. q4w|ianalumab s.c. q4w in addition to standard of care (SoC)
89086141|NCT05126277|Experimental|Arm 2 - ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
89086142|NCT05126277|Placebo Comparator|Arm 3 - placebo s.c. q4w|Placebo s.c. q4w in addition to SoC
89086143|NCT05125068|Experimental|Arm A|AT-1501 10mg/kg Arm A will receive 10 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions.
89086144|NCT05125068|Experimental|Arm B|AT-1501 5mg/kg Arm B will receive 5 mg/kg of AT-1501 every 3 weeks for up to 93 weeks for a total of 32 infusions
88812860|NCT01832636|Active Comparator|Alanyl-Glutamine 6g/d|Alanyl-Glutamine orally 6g/day for 10 days
89086145|NCT05120310|Experimental|Intervention|"Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge).~- Calm Coaching for sleep Subsample (N=100): A random subsample of eligible participants, based on their ISI scores, will be invited to use the Calm Coaching for Sleep Program (using Healthie platform)."
89086146|NCT05120310|Other|Waitlist Control|"Participants will be instructed to not participate in any mindfulness meditation activities for eight weeks. The research team will send the participant study instructions. At the end of eight weeks participants will be given access to the Calm app and will be able to schedule one live 20-minute coaching session with a Calm Coach.~- Calm Coaching for sleep Subsample (N=100): A random subsample of eligible participants, based on their ISI scores, will be invited to use the Calm Coaching for sleep Program. The Calm Coaching for sleep program is administered by Calm for six weeks."
89086147|NCT05120154|Experimental|Intervention|Access to all the CAPACITI module materials, provided on a learning management system. The intervention group will also receive the CAPACITI program with module facilitation, namely high-facilitation and expert coaching in the coverage of module materials in four live webinars (bimonthly for the 2 month duration of the module = 4 webinars).
89086148|NCT05120154|Active Comparator|Control|Access to all the CAPACITI module materials, provided on a learning management system. The control group will not receive module facilitation (i.e., will entail self-directed learning).
89086149|NCT05119374|Experimental|Investigational SenseGuard Device|All subjects use SenseGuard Device for twice daily monitoring of respiratory parameters.
89086150|NCT05116462|Experimental|Sintilimab|"Neoadjuvant Treatment period: up to 3 cycles of sintilimab plus platinum-based chemotherapy prior to surgery.~adjuvant Treatment period: Subjects will receive 1 cycle of sintilimab plus platinum-based chemotherapy, and then receive sintilimab therapy after surgery until disease recurrence, unacceptable toxicity, receiving new anti-tumor therapy, withdrawal of informed consent (ICF), lost to follow-up or death, or other conditions that require treatment discontinuation (whichever occurs first). The maximum duration of postoperative treatment with either sintilimab or placebo is 13 cycles."
89086151|NCT05116462|Placebo Comparator|Placebo|"Neoadjuvant Treatment period: up to 3 cycles of placebo plus platinum-based chemotherapy prior to surgery.~adjuvant Treatment period: Subjects will receive 1 cycle of placebo plus platinum-based chemotherapy, and then receive placebo therapy after surgery until disease recurrence, unacceptable toxicity, receiving new anti-tumor therapy, withdrawal of informed consent (ICF), lost to follow-up or death, or other conditions that require treatment discontinuation (whichever occurs first). The maximum duration of postoperative treatment with either sintilimab or placebo is 13 cycles."
89086152|NCT05111353|Experimental|Arm 1: Vaccine given after neoadjuvant chemotherapy and surgery|"The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, 22, 50, and 78 beginning approximately 1 month after surgery. Day 1 should begin approximately 1 month after surgery."
89086153|NCT05111353|Experimental|Arm 2: Vaccine given after neoadjuvant chemotherapy but before surgery|"The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, and 22 during the chemotherapy holiday, and Days 50 and 78 post-operatively. Optimal timing for Day 1 is 1 week after end of chemotherapy, but Day 1 may be given up to 3 weeks after end of chemotherapy."
89086154|NCT05108519||Observational (medical records review)|Patients' medical records are reviewed.
89086155|NCT05103423|Experimental|Treatment group 1|
89086156|NCT05103423|Experimental|Treatment group 2|
89086157|NCT05103423|Placebo Comparator|Placebo|
89086158|NCT05098119|Experimental|Sintilimab+ Carboplatin + Nab-paclitaxel|"Neoadjuvant therapy (the total cycles of the treatment is 3) ：~Cycle1（Cycle length: 21 days）： Sintilimab (IV), dose= 200mg, day=1; Carboplatin (IV), dose=300mg/m2, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Cycle2、3（Cycle length: 21 days）： Sintilimab (IV), dose= 200mg, day=1.~Adjuvant therapy（will be dictated by surgical pathology and occurs after standard of care surgery）：~Sintilimab will be given intravenously once every 3 weeks for up to 1 year if participant is considered high-risk based on surgical pathology（high risk features：positive margins or extracapsular extension).~These doses of Sintilimab will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
89086159|NCT05095649|Experimental|Regulatory T-cell enriched infusion|The doses of Regulatory T-cell enriched infusion will be 2x10^6 cells/kg
89086160|NCT05090540||Transcatheter Edge to Edge Repair|TEER procedure is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of MV. If the use of one MitraClip device does not result in sufficient reduction in mitral regurgitation, a second MitraClip device may be used to reduce MR optimizing the procedure.
89086161|NCT05090540||Mitral Valve Replacement|Mitral-valve replacement includes complete preservation of the subvalvular apparatus to avoid dilation of the left ventricle over time. The technique of preservation, type of prosthetic valve implanted, and technique of suture placement has been chosen according to the preference of the surgeons. In SMR due to ischemic cardiomyopathy, CABG operation(Revascularization) is required
88812861|NCT01832636|Active Comparator|Alanyl-Glutamine 12g/d|Alanyl-Glutamine orally 12g/d for 10 days
89086162|NCT05090540||Restrictive Mitral Annuloplasty|RMA may be performed with the use of complete rigid or semi-rigid annuloplasty ring which has been downsized for the annulus diameter. Since patients who received RMA have coronary artery lesions, a CABG operation is useful to ensure favorable remodeling of the left ventricle.
89086163|NCT05090540||Restrictive Mitral Annuloplastie Plus Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SVR). The SVR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation. In patients who received SVR due to ischemic cardiomyopathy CABG operation is required
89086164|NCT05082740||Women with a family history of breast cancer|This women are register to the Family History Risk and Prevention clinic and have taken part in the original FH-Risk study. These women will be given the opportunity to learn of their revised breast cancer risk estimate.
89086165|NCT05081557||Participants Receiving Upadacitinib|Participants receiving upadacitinib for atopic dermatitis.
89086166|NCT05081167|Experimental|REL-1017|A 75 mg REL-1017 loading dose (three 25 mg REL-1017 tablets) will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 25 mg REL-1017.
89086167|NCT05081167|Placebo Comparator|Placebo|Three tablets of matching placebo will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 1 placebo tablet.
89086168|NCT05081024||Observational (biospecimen collection, medical record review)|Patients undergo collection of blood samples at baseline (before any neoadjuvant therapy), every 2 months while undergoing TNT, and then every 3 months for up to 3 years after completion of TNT. Patients' medical records are also reviewed. Patients may undergo collection of tissue sample if an archival tissue sample is not available.
89086169|NCT05067595|Experimental|Arm I (upper FMT)|Patients receive upper FMT capsules PO over 2 days. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
89086170|NCT05067595|Experimental|Arm II (Lower FMT)|Patients undergo lower FMT via colonoscopy on day 0. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
89086171|NCT05067595|Experimental|Arm III (upper FMT, fiber supplementation)|Patients receive upper FMT capsules PO over 2 days. Patients receive fiber supplementation PO while on study. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
89086172|NCT05067595|Experimental|Arm IV (Lower FMT, fiber supplementation)|Patients undergo lower FMT via colonoscopy on day 0. Patients receive fiber supplementation PO while on study. Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.
89086174|NCT05063552|Active Comparator|Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
89225944|NCT05088356|Experimental|Arm A3: Fully (8/8) matched related/unrelated donor transplantation|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:~Fludarabine (160 mg/m2)~Thiotepa (5 mg/kg)~TBI (2-3 Gy).~All enrolled subjects will receive GVHD prophylaxis with single-agent tacrolimus."
89086175|NCT05063552|Experimental|Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
89086176|NCT05063552|Experimental|Phase II, Arm C (Bevacizumab, Atezolizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
89086177|NCT05063552|Experimental|Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study.
89086178|NCT05063552|Experimental|Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)|Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
88812862|NCT01832636|Placebo Comparator|Glycine 12.5g/d|Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
89086179|NCT05053971|Experimental|Treatment (entinostat, ZEN003694)|"PHASE I RUN-IN PERIOD: Patients receive ZEN003694 PO QD during days -14 to 1. Patients also undergo core needle biopsy within 30 days prior to starting therapy.~PHASE II RUN-IN PERIOD: Patients receive ZEN003694 PO QD or entinostat PO QW during days -14 to 1 based on the order to which they are enrolled to the study (e.g. every other patient starts by taking ZEN003694 alone for 14 days). Patients also undergo core needle biopsy within 30 days prior to starting therapy.~PHASE I & II COMBINATION TREATMENT: Patients receive entinostat PO QW on days 1, 8, 15, and 22, and ZEN003694 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo core needle biopsy on day 1 of cycle 1, and on day 1 of cycle 14."
89086180|NCT05046600||All Products listed in Descriptions|Biocomposite™ or PEEK PushLock, DX SwiveLock SL, Headless Compression Screws, Tenodesis Screw (Biocomposite and PEEK), Corkscrew® Titanium (Nano and Micro-Corkscrew), DynaNite Nitinol Staples
89086182|NCT05038124|Experimental|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction. Active sparing of the intended surgical approach will be incorporated into the radiation plan by creating an avoidance structure. Surgical stabilization will proceed within 1 week of completion of radiotherapy. Pathologic specimens will be obtained intraoperatively via existing surgical access for histologic and molecular analysis. An optional research MRI with perfusion will be performed within 30 days prior to radiation simulation and within one-week after radiation therapy using 3T scanner. If patients receive radiation simulation at a non-MSK Manhattan site, MRI with Perfusion will not be performed.
89086183|NCT05037617|Experimental|Intervention site (Foothills Medical Centre): Continuation of Oxytocin|Participants in this arm will receive a blinded vial of oxytocin once a patient is found to be >= 6 cm dilated.
89086184|NCT05037617|Placebo Comparator|Intervention site (Foothills Medical Centre): Discontinuation of oxytocin|Participants in this arm will receive a blinded vial of saline solution once a patient is found to be >= 6 cm dilated.
89086185|NCT05030337|No Intervention|Manual oxygen control|Standard ventilation with inspired oxygen concentration adjusted manually as per unit's protocol.
89086186|NCT05030337|Other|Closed-loop automated oxygen control|Ventilation with Oxygenie software (closed-loop automated oxygen control system), adjusted by clinical staff as necessary
89086187|NCT05029882|Experimental|Part 1 (Monotherapy Dose Escalation)|Participants with advanced solid tumors will receive escalating doses of ABBV-400.
89086188|NCT05029882|Experimental|Part 2i (wtEGFR Non-Small Cell Lung Cancer [NSCLC])|Participants with non-squamous wtEGFR NSCLC will receive ABBV-400 at the Recommended Phase 2 dose (RP2D).
89086189|NCT05029882|Experimental|Part 2ii (mutEGFR NSCLC)|Participants with non-Squamous mutEGFR NSCLC will receive ABBV-400 at RP2D.
89086190|NCT05029882|Experimental|Part 2iii (Squamous NSCLC)|Participants with squamous NSCLC will receive ABBV-400 at RP2D.
89086191|NCT05029882|Experimental|Part 3 (Gastroesophageal Adenocarcinoma/Gastroesophagel Junct|Participants with gastroesophageal adenocarcinoma will receive ABBV-400 at the RP2D.
89086192|NCT05029882|Experimental|Part 4 (Colorectal Cancer)|Participants with Colorectal Cancer (CRC) will receive ABBV-400 at the RP2D and various dose levels for dose optimization.
89086193|NCT05029882|Experimental|Part 5 (MET Amplification)|Participants with mesenchymal-epithelial transition proto-oncogene (MET) amplification will receive ABBV-400 at the RP2D and various dose levels for dose optimization.
89086194|NCT05029882|Experimental|Part 6 (MET Mutation)|Participants with MET mutation will receive ABBV-400 at the RP2D and various dose levels for dose optimization.
89086195|NCT05029882|Experimental|Part 7a (Combination Dose Escalation)|Participants with CRC will receive escalating doses of ABBV-400 in combination with bevacizumab.
89086196|NCT05029882|Experimental|Part 7bi (Combination Dose Optimization Low Dose)|Participants with CRC will receive the low dose determined in the dose escalation arm (Part 7a) of ABBV-400 in combination with bevacizumab.
89086197|NCT05029882|Experimental|Part 7bii (Combination Dose Optimization High Dose)|Participants with CRC will receive the high dose determined in the dose escalation arm (Part 7a) of ABBV-400 in combination with bevacizumab.
89086198|NCT05029882|Experimental|Part 7biii (Combination Comparator)|Participants with CRC will receive trifluridine/tipiracil (TAS-102) in combination with bevacizumab.
89086199|NCT05021393|Experimental|Intervention Group|The intervention group will receive the services from a clinical pharmacist and the existing standard care available in the medical oncology ward.
89086200|NCT05021393|No Intervention|Control Group|The standard care includes the current existing care provided to patients in the hospital. In addition, it includes all the available medical and non-medical services except the service provided by the clinical pharmacist.
89086201|NCT05000216|Experimental|Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086202|NCT05000216|Experimental|Cohort A, Arm A2: BNT162b2 + Continue IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086203|NCT05000216|Experimental|Cohort A, Arm A3: Ad26.COV2.S + Continue IS (MMF or MPA)|Arm closed, effective protocol version 3.0. Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086204|NCT05000216|Experimental|Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
88812863|NCT01449305|Experimental|Nanoone Woman Underwear|"Nanoone negative ion of textiles, which is health material specifically designed for human body, in short distance and long time to produce negative ion, the human body really needed, it can neutralize free radical in the human body."
89086205|NCT05000216|Experimental|Cohort A, Arm A5: BNT162b2 + Withhold IS (MMF or MPA)|Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
89086206|NCT05000216|Experimental|Cohort A, Arm A6: Ad26.COV2.S + Withhold IS (MMF or MPA)|Arm closed, effective protocol version 3.0. Adult participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Janssen COVID-19 vaccine booster (1 dose), per protocol instruction.
89086207|NCT05000216|Experimental|Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086208|NCT05000216|Experimental|Cohort B, Arm B2: BNT162b2 + Continue IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086209|NCT05000216|Experimental|Cohort B, Arm B3: Ad26.COV2.S + Continue IS (MTX)|Arm closed, effective protocol version 3.0. Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086210|NCT05000216|Experimental|Cohort B, Arm B4: Moderna mRNA-1273 + Withhold IS (MTX)|Adult Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
89086211|NCT05000216|Experimental|Cohort B, Arm B5: BNT162b2 + Withhold IS (MTX)|Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster, per protocol instruction.
89086212|NCT05000216|Experimental|Cohort B, Arm B6: Ad26.COV2.S + Withhold IS (MTX)|Arm closed, effective protocol version 3.0. Adult participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Janssen COVID-19 vaccine booster (1 dose), per protocol instruction.
89086213|NCT05000216|Experimental|Cohort C, Arm C1: Moderna mRNA-1273 + Continue IS (B cell depletion therapy)|Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086214|NCT05000216|Experimental|Cohort C, Arm C2: BNT162b2 + Continue IS (B cell depletion therapy)|Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086215|NCT05000216|Experimental|Cohort C, Arm C3: Ad26.COV2.S + Continue IS (B cell depletion therapy)|Arm closed, effective protocol version 3.0. Adult participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086216|NCT05000216|Experimental|Cohort D, Arm D1: Ad26.COV2.S + Withhold IS (MMF or MPA)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
89086217|NCT05000216|Experimental|Cohort D, Arm D2: Alternative mRNA Vaccine + Withhold IS (MMF or MPA)|Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of an alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
89086218|NCT05000216|Experimental|Cohort D, Arm D3: Moderna mRNA-1273 + Withhold IS (MMF or MPA)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
89086219|NCT05000216|Experimental|Cohort E, Arm E1: Ad26.COV2.S + Withhold IS (MTX)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
89086220|NCT05000216|Experimental|Cohort E, Arm E2: Alternative mRNA Vaccine + Withhold IS (MTX)|Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of an alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
89086221|NCT05000216|Experimental|Cohort E, Arm E3: Moderna mRNA-1273 + Withhold IS (MTX)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
89086222|NCT05000216|Experimental|Cohort F, Arm F1: Ad26.COV2.S + Withhold IS (B cell depletion therapy)|Arm closed, effective protocol version 4.0. Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after receiving a dose of the Janssen COVID-19 vaccine, per protocol instruction.
89086223|NCT05000216|Experimental|Cohort F, Arm F2: Alternative mRNA Vaccine + Withhold IS (B cell depletion therapy)|Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the alternative COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
89086224|NCT05000216|Experimental|Cohort F, Arm F3: Moderna mRNA-1273 + Withhold IS (B cell depletion therapy)|Adult participants who previously received the Janssen COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction. Beginning with version 6.0 of the protocol, bivalent versions of the mRNA vaccines, Moderna and Pfizer-BioNTech COVID-19 vaccines, replaced original monovalent versions.
89086225|NCT05000216|Experimental|Cohort D, Arm D4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (MMF or MPA)|Adult participants who previously received an mRNA vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction.
89086226|NCT05000216|Experimental|Cohort E, Arm E4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (MTX)|Adult participants who previously received an mRNA vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction.
89086227|NCT05000216|Experimental|Cohort F, Arm F4: Monovalent [B.1.351] CoV2 preS dTM-AS03 + Withhold IS (B cell depletion therapy)|Adult participants who previously received an mRNA vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Sanofi-GSK COVID-19 vaccine, per protocol instruction
89086228|NCT05000216|Experimental|Cohort A, Arm A1P: Moderna mRNA-1273, Bivalent + Continue IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086229|NCT05000216|Experimental|Cohort A, Arm A2P: BNT162b2, Bivalent + Continue IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086230|NCT05000216|Experimental|Cohort A, Arm A4P: Moderna mRNA-1273, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
89086231|NCT05000216|Experimental|Cohort A, Arm A5P: BNT162b2, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
89086232|NCT05000216|Experimental|Cohort B, Arm B1P: Moderna mRNA-1273, Bivalent + Continue IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Moderna COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89225945|NCT05088356|Experimental|Arm C1:7/8 mismatched related/unrelated donor transplantation (closed)|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:~Fludarabine (160 mg/m2)~Thiotepa (10 mg/kg)~TBI (4 Gy) All enrolled subjects will receive GVHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF)."
89225946|NCT05088356|Experimental|Arm C2: 7/8 mismatched related/unrelated donor transplantation|"Subjects will receive reduced intensity preparative chemotherapy conditioning for a matched related/ unrelated donor transplant:~Fludarabine (160 mg/m2)~Thiotepa (5 mg/kg)~TBI (2-3 Gy)~All enrolled subjects will receive GVHD prophylaxis with tacrolimus and ruxolitinib."
89225948|NCT05086510|Active Comparator|Sinus Rhythm|This group will undergo mapping during sinus rhythm to identify and ablate late potentials that may be incriminated in the tachycardia circuit.
89225949|NCT05086510|Active Comparator|Right ventricular extrastimulus pacing group|This group will undergo mapping during right ventricular single extrastimulus pacing to identify and thus ablate potentials that might have been masked during sinus rhythm.
89225950|NCT05083390|Experimental|norUrsodeoxycholic acid 1500 mg/day|3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1500 mg
89225951|NCT05083390|Experimental|norUrsodeoxycholic acid 1000 mg/day|3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1000 mg
89225952|NCT05083390|Placebo Comparator|Placebo to norUrsodeoxycholic acid|3 film-coated tablets once daily for 72 weeks containing placebo to norUrsodeoxycholic acid
89225953|NCT05078203|Experimental|Exercise|36 minutes of exercise
89225954|NCT05078203|Placebo Comparator|Rest|36 minutes of rest
89225955|NCT05075824|Experimental|Crovalimab|Participants will receive a loading series of Crovalimab comprised of an intravenous (IV) loading dose on Day 1, followed by weekly Crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance SC dosing will begin at Week 5 and will continue every 4 weeks (Q4W) thereafter for a total of 48 weeks of treatment.
89225956|NCT05075824|Placebo Comparator|Placebo|Participants will receive matching Placebo administered by IV infusion and SC injection over the same duration as Crovalimab, for a total of 48 weeks of treatment.
89225957|NCT05071131|Active Comparator|Inulin|15 grams inulin per day for 7 days, followed by 30 grams inulin per day for 28 days
89225958|NCT05071131|Placebo Comparator|Placebo|15 grams maltodextrin per day for 7 days, followed by 30 grams maltodextrin per day for 28 days
89225959|NCT05064709|Experimental|CCM Group (CCM ON)|CCM therapy will be turned on in 2/3 of the subjects for the entire duration of the study.
89225960|NCT05064709|Sham Comparator|Sham Group (CCM OFF)|CCM therapy will be turned off in 1/3 of the subjects for the first 18 months of the study. After 18 months, CCM therapy will be turned on for the rest of the study duration.
89225961|NCT05064436|Experimental|Part A - Healthy Participants|
89225962|NCT05064436|Experimental|Part B - Participants with MS|
89225963|NCT05064293|Other|Control Arm|"Data will be collected at baseline and 6-month follow-up from the standardized instruments and automated sources for all eligible subjects randomized to the control arm.~Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider.~Study clinicians will document clinically relevant information from their assessment in a telephone encounter and route these to the child's KP primary care provider in Epic as well as the site navigator.~Control arm participants do not receive navigation."
89225964|NCT05064293|Experimental|Navigation Arm|"6-months of telephonic support from a mental health (MH) navigator to promote early access, engagement, coordination, and personalization of mental health treatment and services as soon as early symptoms of mental health problems are detected in children.~The navigator model and implementation to be tested include:~Automated identification of early symptoms for children~Virtual collection of self-reported, standardized assessment scores~Psychologists interpreting assessment scores and providing feedback to families and PCPs~Trained clinicians serving as MH navigators to conduct family outreach, engage them in MH care, and coordinate with and between clinicians for up to 6-months~Up to 4 video-based behavioral health sessions with the MH navigator, as needed, while barriers to initiation of ongoing mental health services can be explored and addressed over the 6-month period."
89225965|NCT05064124||CADDIE|Participants will have a colonoscopy with the assistance of the CADDIE device characterisation AI system
89225966|NCT05064124||Control group|Participants will have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system
89225967|NCT05061888|Active Comparator|Food Waste Intervention Group|This group will receive an intervention on food waste management and fruit and vegetable replacement to increase diet quality while avoiding an increase in calories. Both groups will obtain free fruit and vegetable boxes and will use the FoodImage app to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
89225968|NCT05061888|Placebo Comparator|Stress Management Control Group|This group will receive an intervention on Stress Management and will be intensity matched to the treatment group. Both groups will obtain free fruit and vegetable boxes and will use FoodImage to record food acquisition (Shop), food prep (Prep), intake (Eat) and waste (Toss) for approximately 3 (24 hour) days; ideally including 1 weekend date.
89086233|NCT05000216|Experimental|Cohort B, Arm B2P: BNT162b2, Bivalent + Continue IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086234|NCT05000216|Experimental|Cohort B, Arm B4P: Moderna mRNA-1273, Bivalent + Withhold IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Moderna COVID-19 vaccine, per protocol instruction.
89086235|NCT05000216|Experimental|Cohort B, Arm B5P: BNT162b2, Bivalent + Withhold IS (MTX)|Pediatric participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after receiving an additional dose of the Pfizer-BioNTech COVID-19 vaccine booster, per protocol instruction.
89086236|NCT05000216|Experimental|Cohort C, Arm C1P: Moderna mRNA-1273, Bivalent + Continue IS (B cell depletion therapy)|Pediatric participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Moderna COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086237|NCT05000216|Experimental|Cohort C, Arm C2P: BNT162b2, Bivalent + Continue IS (B cell depletion therapy)|Pediatric participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive an additional dose of the Pfizer-BioNTech COVID-19 vaccine and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
89086238|NCT05000216|Experimental|Cohort D, Arm D1P: BNT162b2, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
89086239|NCT05000216|Experimental|Cohort D, Arm D2P: Moderna mRNA-1273, Bivalent + Withhold IS (MMF or MPA)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
89086240|NCT05000216|Experimental|Cohort E, Arm E1P: BNT162b2, Bivalent + Withhold IS (MTX)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
89086241|NCT05000216|Experimental|Cohort E, Arm E2P: Moderna mRNA-1273, Bivalent + Withhold IS (MTX)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease, will withhold their immunosuppressive medications (IS) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
89225969|NCT05057429|Experimental|Bioelectric Dressing on the Right Armpit and Standard Gauze Dressing on the Left Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the right armpit and will receive the standard gauze dressing for up to 8 weeks on the left armpit.
89225970|NCT05057429|Experimental|Bioelectric Dressing on the Left Armpit and Standard Gauze Dressing on the Right Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the left armpit and will receive the standard gauze dressing for up to 8 weeks on the right armpit.
89225971|NCT05056545|Experimental|PPFP Intervention|The study team will train government clinic staff in ANC, L&D, IV, or postpartum services to promote and provide the PPFP intervention at the selected facilities. Community Health Workers (CHW) and 'Happy Clients' will be trained as PPFP promotional agents. Video-based PPFP promotions will be shown at the intervention facilities. If interested in PPFP, women will be referred to the facility by their CHW.
89225972|NCT05056545|No Intervention|Standard of Care|Currently, no systematic PPFP training, promotional, or service delivery activities are regularly taking place at the selected facilities. The team will compare the intervention with historical records from the facilities applying intervention and compare
89225973|NCT05056363|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 45 minutes.
89225974|NCT05056363|Experimental|Training Group|In addition to conventional home based traditional scoliosis exercises, patients in this group will also receive core stabilization exercise training for 45 minutes, 5 times in a week for 8 weeks. Every two sessions will be supervised in a clinic per week.
89225975|NCT05048459|Active Comparator|Standard surveillance|This surveillance approach involves the participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
89225976|NCT05048459|Experimental|Telemedicine surveillance (tele-surveillance)|Tele-surveillance involves the participant staying at home while their healthcare providers follow their condition and give them the care they need. They can communicate with their healthcare team through face-to-face video conferencing on their desktop computer, laptop, smart phone, or tablet. They can also communicate with their healthcare team by phone.
89225977|NCT05034432|Experimental|Intra-Op Prophylactic VT ablation|Subjects will get ablation procedure as needed if they were determined to be refractory to medical antiarrhythmic control should undergo catheter-based electrophysiology study and ablation on LVAD support
89225978|NCT05034432|Active Comparator|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
89225979|NCT05031325|Experimental|Endoscopic submucosal dissection with Purastat|To compare of the risk of bleeding after endoscopic submucosal dissection, after ESD, application of Purastat gel (not a drug but a device with CE mark) with a catheter of a gel on the resected area to cover the whole surface of mucosal resection.
89225980|NCT05031325|No Intervention|Comparative arm without Purastat|After endoscopic submucosal dissection (ESD) and hemostasis, if the patient is randomized in the comparative group, no gel will be applied on the resected area that will remain like this without intervention (common practice)
89225981|NCT05022810|Experimental|Test Drug|Participants will receive a single oral dose of either New Paracetamol Oral Suspension (24 mg/ml) or Panadol B&I Oral Suspension (24 mg/ml paracetamol) on Day 1 (Period 1) and Day 4 (Period 2) under fasting conditions as per the randomization schedule. A wash out period of at least 72-hour will be maintained between each treatment period.
89225982|NCT05022810|Active Comparator|Reference Drug|Participants will receive a single oral dose of either New Paracetamol Oral Suspension (24 mg/ml) or Panadol B&I Oral Suspension (24 mg/ml paracetamol) on Day 1 (Period 1) and Day 4 (Period 2) under fasting conditions as per the randomization schedule. A wash out period of at least 72-hour will be maintained between each treatment period
89225985|NCT05016791|Active Comparator|Active|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider. In addition, participants in this arm shall be loaned an Apple Watch device and undergo an education session to familiarise themselves with the study recording schedule and how to perform recordings.
89225986|NCT05016791|No Intervention|Control|Participants shall receive standard care and follow-up as provided by their clinical care provider. Heart rhythm monitoring tests shall be performed as per their clinical care provider.
89225987|NCT05006027||Percutaneous coronary intervention using a 7-Fr thin wall sheath via the snuffbox approach|patients with coronary artery disease who planned to perform PCI using 7-Fr thin wall sheath via the snuffbox approach
89225988|NCT04998019|Experimental|PositiveLinks|Participants from clinics randomized to PL will get the patient smartphone app; clinic staff will receive the provider portal and provider smartphone app, the provider online LMS (learning management system), and the research assistant will use the administrative website to enroll participants. Patients randomized to PL will use it for 12 months or more; they can opt to use it as long as it is available during the study(access depending on enrollment date).
89225989|NCT04998019|No Intervention|Usual Care|Participants from clinics randomized to Usual Care (UC) will receive usual clinic retention and medication adherence support services for 12M. Based on site assessments, and descriptions from the clinics, the UC condition ranges from having no ancillary support to only case management, to Ryan White funding and comprehensive services (adherence support, patient navigation, mental health, substance abuse, dental services and food banks)
89086242|NCT05000216|Experimental|Cohort F, Arm F1P: BNT162b2, Bivalent + Withhold IS (B cell depletion therapy)|Pediatric participants who previously received the Moderna COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Pfizer-BioNTech COVID-19 vaccine, per protocol instruction.
89086243|NCT05000216|Experimental|Cohort F, Arm F2P: Moderna mRNA-1273, Bivalent + Withhold IS (B cell depletion therapy)|Pediatric participants who previously received the Pfizer-BioNTech COVID-19 vaccine and who are taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will continue to take their prescribed BCDTs without alterations in schedule and dosing. Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX) before and after receiving a dose of the Moderna COVID-19 vaccine, per protocol instruction.
89086244|NCT04995419|Experimental|Enfortumab Vedotin 1.25 mg/kg|Participants received 1.25 milligrams per kilogram (mg/kg) of body weight enfortumab vedotin by intravenous (IV) infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first. Participants who had intense PK Sampling were enrolled in PK Cohort.
89086245|NCT04975919|Experimental|Treatment (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO QD on days 1-10. Patients who achieve CR/CRi during consolidation/maintenance may receive decitabine and cedazuridine PO QD on days 1-5. Patients also receive venetoclax PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89086246|NCT04969341||Screening (survey, medical record review)|Patients complete survey over 20 minutes consisting of validated and piloted items related to cost and convenience barriers in lung cancer screening, personal financial and lung cancer risk perception questions, and the Telehealth Satisfaction and Usefulness questionnaire. Patients also have their medical records reviewed retrospectively.
89086247|NCT04962360|Experimental|Nutritional standardized supplementation formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake.
89086248|NCT04962360|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
89086249|NCT04962334|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
89086250|NCT04962334|Placebo Comparator|Placebo|Low caloric formula (Powder added to waster) without added vitamins and minerals
89086251|NCT04961658|Experimental|Treatment Arm - Dose Cohort 1|Participants will receive a single dose of GEM00220 at 15 million cells
89086252|NCT04961658|Experimental|Treatment arm - Dose Cohort 2|Participants will receive a single dose of GEM00220 at 60 million cells
89086253|NCT04961658|Experimental|Treatment arm - Dose Cohort 3|Participants will receive a single dose of GEM00220 at 150 million cells
89086254|NCT04961658|Experimental|Treatment arm - Dose Cohort 4|Participants will receive two doses of GEM00220 at 150 million cells each, seperated by 24 hours
89086255|NCT04945213|Experimental|Biperiden|Drug: Biperiden 5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
89086256|NCT04945213|Placebo Comparator|Placebo|"Placebo~1 mL of sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 mL of 0,9% saline - every 6 hours for 10 consecutive days - IV"
89086257|NCT04941898||TAK-660 15-50 international units per kilograms (IU/kg)|Participants will receive TAK-660 15-50 IU/kg slow intravenous injection every 8- 24 hours until the bleeding is resolved or wound healing.
89086258|NCT04935957|Other|Non-interventional. Open Label.|GLUCUBE system performance in the monitoring and measurement of the blood glucose compared to the standard glucometer (blood capillary glucometer - Bayer Contour®Next).
89086259|NCT04934722|Experimental|Pembrolizumab + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab intravenously (IV) every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
89086260|NCT04934722|Placebo Comparator|Placebo + Enzalutamide + ADT|Starting on Day 1 of each 21-day cycle, participants receive placebo IV Q3W for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a LHRH agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
89086261|NCT04930094|Experimental|Secukinumab 300 mg|Secukinumab 300 mg s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a specified 26-week prednisone taper regimen. After the 26-week prednisone taper, participants will continue to receive placebo to prednisone until Week 52.
89086262|NCT04930094|Placebo Comparator|Placebo|Placebo to secukinumab s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Placebo will be given in combination with a specified 52-week prednisone taper regimen.
89086263|NCT04930094|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4. Secukinumab will be given in combination with a specified 26-week prednisone taper regimen. After the 26-week prednisone taper, participants will continue to receive placebo to prednisone until Week 52.
89523056|NCT03386123|Experimental|Cognitive Behaviour Therapy for Insomnia (CBTi)|"A standard CBTi programme for the treatment of primary insomnia, with six, 2 hour, group sessions over eight weeks. There will be minor adaptations for tinnitus, including making specific reference to tinnitus and psycho-education about tinnitus. Every session concludes with provision of a homework task and a sleep diary to complete over the next week. The CBTi course will be supported by providing participants with a CD with some relaxation exercises and a booklet that covers the information given in the session.~CBTi includes: Sleep restriction, stimulus control, Sleep hygiene, Relaxation training, Paradoxical intention, Cognitive therapy: Targeting unhelpful beliefs about sleep and worry, Behavioural experiments: Testing unhelpful beliefs and adjusting sleep related behaviour."
89086268|NCT04925167|Experimental|argatroban group|Patients received argatroban for anticoagulation during V-V ECMO.
89086269|NCT04925167|Active Comparator|UFH group|Patients received UFH for anticoagulation during V-V ECMO.
89086270|NCT04920656||Breast cancer patients|All adult patients with a confirmed diagnosis of breast cancer, aged 18 or older at time of cancer diagnosis, will be invited to participate.
89086273|NCT04903080|Experimental|Treatment (HER2 CAR T cells), Phase I Arm|Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0. Treatment repeats every 8 to 12 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
89086274|NCT04903080|Experimental|Treatment (HER2 CAR T cells), Surgical Arm|Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0 followed by surgical tumor resection 4-6 weeks following HER2 CAR T cell infusion. Treatment repeats every 8 to 15 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
89086275|NCT04899921|Experimental|Ipilimumab + Nivolumab + Troriluzole [Phase I dose level 1]|Phase I dose level 1 participants received nivolumab 1 mg/kg and ipilimumab 3 mg/kg intravenously (IV) on day 1 of each 21-day cycle and the original starting troriluzole dose of 140 mg orally in the morning as well as 280 mg orally in the evening every day of each 21-day cycle. Participants were treated until disease progression or unacceptable toxicity.
89086276|NCT04899921|Experimental|Ipilimumab + Nivolumab + Troriluzole [Phase II]|"Participants will be randomly assigned and receive:~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Troriluzole self-administered at a predetermined dose orally twice a day~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Troriluzole self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
89086277|NCT04899921|Experimental|Ipilimumab + Nivolumab + Placebo [Phase II]|"Participants will be randomly assigned and receive:~12 Week Induction Phase: Nivolumab at pre-determined dose followed by ipilimumab at predetermined dose every 3 weeks, with 21 consecutive days defined as a treatment cycle. Placebo self-administered at a predetermined dose orally twice a day~36 Week Maintenance Phase: Nivolumab will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Placebo self administered at a predetermined dose orally twice a day. No ipilimumab will be given in the maintenance phase."
89086278|NCT04899921|Experimental|Ipilimumab + Nivolumab + Troriluzole [Phase I dose level 2]|Phase I dose level 2 participants received nivolumab 1 mg/kg and ipilimumab 3 mg/kg intravenously (IV) on day 1 of each 21-day cycle and troriluzole 140 mg twice per day orally. Participants were treated until disease progression or unacceptable toxicity.
89086279|NCT04899921|Experimental|Ipilimumab + Nivolumab + Troriluzole [Phase I dose level 3]|Phase I dose level 3 participants received nivolumab 1 mg/kg and ipilimumab 3 mg/kg intravenously (IV) on day 1 of each 21-day cycle and troriluzole 140 mg/day orally. Participants were treated until disease progression or unacceptable toxicity.
89086280|NCT04893785|Experimental|Cabozantinib and Temozolomide|"All patients will receive:~Cabozantinib 40 mg os QD~Temozolomide 100 mg/m2/day seven days followed by seven days of stop (regimen one week on / one week off)."
89086281|NCT04893460|Experimental|Intervention|All participants will use the CoQuit App for Smoking Cessation
89086286|NCT04884360|Experimental|Group A: Olaparib tablets 300 mg oral twice daily (n=280).|Participants in Group A will receive olaparib tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.
89086287|NCT04884360|Placebo Comparator|Group B: Placebo tablets 300 mg oral twice daily (n=140)|Participants in Group B will receive matching placebo tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.
89086288|NCT04877249|Experimental|Gait training for stroke|
89086289|NCT04877249|Active Comparator|Gait training for healthy|
89086290|NCT04869553|Experimental|ABC's arm|The 3 pain managements are in the ABC's order.
89086291|NCT04869553|Experimental|BCA's arm|The 3 pain managements are in the BCA's order.
89086292|NCT04869553|Experimental|CAB's arm|The 3 pain managements are in the CAB's order.
89086293|NCT04868539|Experimental|Sleep Restriction with Extended Duration Artificial Light at Night (ALAN)|In the Sleep Restriction Group with Extended Duration Artificial Light At Night (ALAN) first, the sleep episodes will be shortened to 5 hours, centered at the same time as the baseline sleep (with bedtime 2.5 hours later and wake time 2.5 hours earlier).
89086294|NCT04868539|Experimental|Sleep Restriction without Extended Duration Artificial Light at Night (ALAN)|In the Sleep Restriction group without Extended Duration ALAN, the sleep episodes will be shortened to 5 hours as in the ALAN Condition (centered at the same time as the baseline sleep with bedtime 2.5 hours later and wake time 2.5 hours earlier), but the participant will remain sitting in bed in near darkness (< 1 lux) for the 2.5 hours before and after the 5-hour sleep episode, such that their exposure to room lighting and activity (14 hours/day) will remain similar to that in the Baseline condition.
89086295|NCT04864834|Experimental|SOK583A1 (40 mg/mL)|Intravitreal (IVT) administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
89086296|NCT04864834|Active Comparator|Eylea EU (40 mg/mL)|"IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.~EU: European"
89086297|NCT04861519||adult subjects who underwent a clinically indicated invasive coronary angiography|adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions.
89086298|NCT04854213|Other|Liquid biopsy|Blood samples for liquid biopsy
89086299|NCT04845685|Experimental|CGM Patients|Subjects with diabetes mellitus or medication induced diabetes that have been admitted to the hospital after a surgery for organ transplantation or scheduled for organ transplant surgery will be fitted with a CGM monitor to monitor glucose levels during hospitalization
89086300|NCT04844021|Experimental|Nudge|"Clinics randomized to the Nudge condition will receive the EHR prompt only. The investigators will add default language to the standard Well Child Visit workflow to serve as a reminder and allow for tracking of S.A.F.E. Firearm implementation. The clinician will be asked to denote whether the program was delivered (e.g., whether conversation around firearm storage was conducted, whether cable firearm lock was offered) to the parent during the visit. This EHR prompt will remain turned on from active implementation through the sustainment period."
89225990|NCT04997096|Experimental|Exercise|"Participants randomized to one of two groups with 2:1 ratio: exercise (n=20)~- Aerobic and Resistance Exercise for 16 weeks"
89225991|NCT04997096|Active Comparator|Attention Control|"Participants randomized to one of two groups with attention control (n=10).~-Attention Control for 16 weeks home-based stretching"
89225992|NCT04995822||EUROSTEM femoral stem|All patients who received EUROSTEM femoral stem whatever the version (cemented or cementless)
89225993|NCT04993638||EUROSCUP MOBILE cementless|107 who received cementless version of EUROSCUP MOBILE
89225994|NCT04993638||EUROSCUP MOBILE cemented|40 who received cemented version of EUROSCUP MOBILE
89225995|NCT04990323|Experimental|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen (Preferred: Clo/Flu/Bu90, Alternative: MIDI)~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
89225996|NCT04987723|Other|AF + HFrEF cohort|"Left Ventricular Ejection Fraction (LVEF) < 50% by echocardiogram during routine screening or within 12 months prior to enrolment day. The echo must have been performed >3 weeks after optimisation of HF and rate control therapies, otherwise repeat imaging will be performed after this has been achieved~With~NYHA functional status II-III at the enrolment visit."
89225997|NCT04987723|Other|AF + symptoms cohort|"Left Ventricular Ejection Fraction (LVEF) > 50% by echocardiogram during routine screening or within 12 months prior to enrolment day~With~modified European Heart Rhythm Association symptom classification 2b-4."
89225998|NCT04987060|Other|Intrastromal Fresh Human Lenticule Implantation|The aim of this study is to investigate the effect of intrastromal fresh corneal lenticule implantation using Smile module surgery after PK with primary objective to increase visual acuity by reducing irregular astigmatism according to high K values. The stromal pocket diameter was 8 mm, 2mm super incision, 140-µm cap thickness and fresh lenticular implantation is performed.
89225999|NCT04987021|Experimental|Nucleus Smart App with Remote Assist Custom Sound Pro 6.3|Remote Assist Custom Sound Pro 6.3 to enable clinicians to use the App to remotely to program the recipients sound processors.
89226000|NCT04975997|Experimental|Daratumumab in combination with Iberdomide and dexamethasone - Dose 1|Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.
89226001|NCT04975997|Experimental|Daratumumab in combination with Iberdomide and dexamethasone - Dose 2|
89226002|NCT04975997|Experimental|Daratumumab in combination with Iberdomide and dexamethasone - Dose 3|
89226003|NCT04975997|Active Comparator|Daratumumab in combination with dexamethasone and bortezomib|Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone
89226004|NCT04974892||low dose aspirin|high-risk women given LDA at ≤16 weeks.
89226005|NCT04974892||Non responders to low dose aspirin|high-risk women who have not responded to LDA and have gone on to develop PE.
89226006|NCT04974086|Experimental|CDS Tool Evaluation|All participants will receive intervention and feasibility, acceptability, and usability of intervention will be assessed from each participant cohort group.
89226007|NCT04970992|Experimental|Dose escalation and cohort expansion Q1W|DZ-002 treatment once every week
89226008|NCT04967287|Experimental|MyopiaX|MyopiaX treatment
89226009|NCT04967287|Active Comparator|Myopia control spectacles|Clinically validated treatment to control myopia
89226010|NCT04961996|Experimental|Arm A: Giredestrant|
89226011|NCT04961996|Active Comparator|Arm B: Endocrine Therapy of Physician's Choice|
89226012|NCT04961996|Experimental|Substudy: Giredestrant + Abemaciclib, Then Giredestrant|In this substudy, participants will receive giredestrant in combination with abemaciclib for up to 2 years. Participants will continue with giredestrant monotherapy for an additional 3 years in order to complete a total of 5 years on study treatment.
89226013|NCT04958265|Experimental|Crovalimab|Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.
89226014|NCT04956549|Experimental|Physical Activity|150 minutes of physical activity weekly
89226015|NCT04956549|Experimental|Successful Aging|Low intensity activity program and a healthy aging educational component
89226016|NCT04955743|Experimental|Cohort 1: Melanoma|Participants who are melanoma (PD-1/PD-L1-experienced)
89226017|NCT04955743|Experimental|Cohort 2: Renal Cell Carcinoma|Participants who are Renal Cell Carcinoma (PD-1/PD-L1 experienced).
89226018|NCT04954222||COVID19 long haulers|Individuals that have been diagnosed with COVID19 and continue to have lingering symptoms associated with COVID19
89226019|NCT04954222||COVID19 no residual symptoms|Individuals that have been diagnosed with COVID19 and do not have lingering symptoms that are associated with COVID19
89226020|NCT04950075|Experimental|INBRX-109|IV every three weeks
89086301|NCT04844021|Experimental|Nudge+|This arm consists of Nudge as described above, as well as facilitation. Facilitation (i.e., external support delivered by health system employees not employed within the clinic site) will be offered for 12 months to each clinic, in keeping with other implementation trials. The investigators will use a train-the-trainer model to train facilitators at both health systems to ensure they achieve facilitator core competencies with an eye toward implementation of S.A.F.E. Firearm. The role of the facilitator is to engage with study clinics, to assist each clinic in setting change and performance goals around the implementation of S.A.F.E. Firearm, and to troubleshoot implementation barriers.
89086303|NCT04838288|Experimental|Change from Prograf to Envarsus|All participants will be switched from Prograf to Envarsus
89086304|NCT04837352||Multiple sclerosis patients|Patients with multiple sclerosis over 18 years old who have already started a long-term treatment and consent to participate to the study
89086305|NCT04819100|Experimental|Selpercatinib|Selpercatinib administered orally.
89086306|NCT04819100|Placebo Comparator|Placebo|Placebo administered orally.
89086307|NCT04804839|Experimental|First research arm (Combined group)|Combined group with 8 weeks of pelvic floor muscle training, knack maneuver and lifestyle recommendations.
89086308|NCT04804839|Experimental|Second research arm [PFMT (including knack maneuver) group]|Only 8-week PFMT (including knack maneuver)
89086309|NCT04804839|Active Comparator|Third research arm (PFMT alone group)|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
89086310|NCT04799275|Experimental|Arm I (oral azacitidine, R-miniCHOP)|Patients receive CC-486 PO for 7 days prior to cycle 1. Patients then receive CC-486 PO on days 8-21. Treatment repeats every 21 days for cycles 1-5 in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for cycles 1-6 (6 cycles total) in the absence of disease progression or unacceptable toxicity.
89226021|NCT04950075|Placebo Comparator|Placebo|IV every three weeks
89226022|NCT04945018|Experimental|HS-001 Low dose|HS-001 Low dose Administration
89226023|NCT04945018|Experimental|HS-001 High dose|HS-001 High dose Administration
89086311|NCT04799275|Active Comparator|Arm II (R-miniCHOP)|Patients receive rituximab IV (or SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89086312|NCT04793646|Active Comparator|N-acetylcysteine syrup|Thirty pSS patients
89086313|NCT04793646|Placebo Comparator|Placebo syrup|Thirty pSS patients
89086314|NCT04786210|Experimental|Site A of keloid scar|One half of keloid scarring on a single subject
89086315|NCT04786210|Experimental|Site B of keloid scar|One half of keloid scarring on a single subject
89086316|NCT04782830|Experimental|placebo|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
89086317|NCT04782830|Active Comparator|Standard treatment|Either midodrine or atomoxetine at their regular dose.
89086318|NCT04781140|Placebo Comparator|Placebo|Placebo, qd
89086319|NCT04781140|Experimental|SPN-812|SPN-812, qd
89086320|NCT04780880||Youth football players|Young footballers aged 10-16 training and playing for a Polish football club.
89086321|NCT04779151|Experimental|1.A - Urothelial Bladder Cancer|
89086322|NCT04779151|Experimental|1.B - Gastric or gastro-esophageal junction adenocarcinoma|
89086323|NCT04779151|Experimental|1.C - Head and Neck Cancer|
89086324|NCT04779151|Experimental|1.D - Biliary Tract Cancer and pancreatic ductal adenocarcinoma (PDAC)|
89086325|NCT04779151|Experimental|1.E - Others: any histology, excepted breast cancer, prostate cancer or serous ovarian cancer|
89086326|NCT04779151|Experimental|Cohort 2 - Platinum-sensitive urothelial bladder cancer|
89086327|NCT04779151|Experimental|Cohort 3 - Clear Cell Renal Cell Carcinoma|
89086328|NCT04754698|Other|Patients with rheumatic diseases|CoronaVac 2-dose schedule with 21-28-day interval and a booster dose (third dose of CoronaVac) 6 months after the primary vaccination
89086329|NCT04754698|Other|Patients with PLWHA|CoronaVac 2-dose schedule with 21-28-day interval
89086330|NCT04754698|Other|Healthy controls|CoronaVac 2-dose schedule with 21-28-day interval and a booster dose (third dose of CoronaVac) 6 months after the primary vaccination
89086331|NCT04752033|Experimental|Morphine|Subjected to sequential up and down dose titration using biased coin method in parallel with the hydromorphone arm
89086332|NCT04752033|Experimental|Hydromorphone|Subjected to sequential up and down dose titration using biased coin method in parallel with the morphine arm
89086333|NCT04751409|Experimental|Group 1, Arm I (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years consisting of restaging with CT-chest and imaging of the primary site.
89086334|NCT04751409|Experimental|Group 1, Arm II (limited follow-up)|Patients undergo limited follow-up every 6 months for 2 years consisting of restaging with either CT-chest or CXR and imaging of the primary site.
89086335|NCT04751409|Experimental|Group 2 (intense follow up)|Patients undergo intense follow-up every 3 months for 2 years as in Group 1, Arm I.
89086336|NCT04748159|Experimental|Infants in prone position|The purpose of this intervention study is to evaluate short-term effects (within one hour) of prone positioning on vital signs in infants under 12 months of age with acute RSV bronchiolitis.
89086337|NCT04742101|Experimental|S65487 with azacitidine|
89086338|NCT04741230|Experimental|Gebauer Lenticule|Gebauer Lenticule implant device
89086339|NCT04736667||Subjects fail screening for TMVI|Subjects with symptomatic mitral valve disease who after referral for TMVI, are deemed not to be candidates for TMVI.
89086340|NCT04730622||Fragility fracture|Patients who are candidates for hip replacement surgery (endo- and arthroplasty).
89086341|NCT04726033|Experimental|Dose level 1 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu
89086342|NCT04726033|Experimental|Dose level 2 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 8mg of unlabelled TLX592 (mass dose of 10mg).
89086343|NCT04726033|Experimental|Dose level 3 of 64Cu-TLX592|Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 18mg of unlabelled TLX592 (mass dose of 20mg).
89086344|NCT04726033|Experimental|Confirmation of optimal 64Cu-TLX592 dose|"Based on the result of Groups 1-3, the optimal dose and imaging timepoints will be selected to treat 3 patients with higher tumour burden (≥10 metastatic sites and/or visceral disease as detected on a 68Ga-PSMA-11 or 18F-DCFPyl PSMA PET/CT scan).~Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 0, 8 or 18mg of unlabelled TLX592."
89086345|NCT04711252|Experimental|AZD9833 + palbociclib|The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (1 mg, PO, once daily)
89086346|NCT04711252|Active Comparator|Anastrozole + palbociclib|The patients will recieve Anastrozole (1 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)
89086348|NCT04703842|Experimental|SRD-001|3E13 or 4.5E13 vg; one-time intracoronary infusion
89086349|NCT04703842|Placebo Comparator|Placebo|One-time intracoronary infusion
89086351|NCT04688164|Experimental|REL-1017|A 75 mg REL-1017 loading dose (three 25 mg REL-1017 tablets) will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 25 mg REL-1017 in addition to their ongoing antidepressant.
89086352|NCT04688164|Placebo Comparator|Placebo|Three tablets of matching placebo will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 1 placebo tablet in addition to their ongoing antidepressant.
89086353|NCT04685304|Experimental|PGx-guided care|Pharmacogenetic results (e.g., CYP2D6, CYP2C9) and a pharmacist consultation will be provided to their primary care provider. This consultation note (PharmD consult) will aid primary care providers in the interpretation and application of PGx results in prescribing decisions. The ultimate prescribing decision is at the discretion of the primary care provider and patient.
89226024|NCT04943328|Other|TrendHip®|
89226025|NCT04940078|Experimental|Part A: Cagrilintide and semaglutide in separate syringes|Participants will up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks treatment with cagrilintide and semaglutide administered as separate injections. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination). Followed by a 38 days follow-up period.
89226026|NCT04940078|Experimental|Part A: Cagrilintide and semaglutide combined in DV3384 device|Participants will be up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks of treatment with cagrilintide and semaglutide administered using the DV3384 manual syringe. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination. Followed by a 38 days follow-up period.
89226027|NCT04940078|Experimental|Part B: Cagrilintide and semaglutide combined in DV3384 device|Participants will receive a single injection of Cagrilintide 0.25 mg/semaglutide 0.25 mg using the DV3384 manual syringe followed by a 28 days follow-up period.
89226028|NCT04938362||Brain abscess patients with cognitive dysfunction and/or fatigue|This group of patients experience cognitive dysfunction and/or fatigue after brain abscess.
89226029|NCT04938362||Brain abscess patients without cognitive dysfunction and/or fatigue|This group of patients does not experience cognitive dysfunction and/or fatigue after brain abscess.
89226030|NCT04934839|Experimental|Patients with osseointegrated prostheses|Patients with an osseointegrated prosthesis following a lower limb amputation
89226031|NCT04934839|Experimental|Patients with socket prostheses|Patients with a socket-mounted prosthesis following a lower limb amputation
89226032|NCT04930406||Historical control group|
89226033|NCT04930406||Intervention group|
89226034|NCT04927442||Covid-19 patients|Patients, male or female, 18 to 65 years old, who tested positive for COVID-19 (PCR or rapid test) =5 days before enrollment.
89226035|NCT04925427|Experimental|Case Management and Peer Recovery|Participants in the CM/PRC + OEND arm will receive one year of service delivery. During the initial intake interview the CM will identify primary, secondary, and tertiary barriers to treatment initiation and completion, then create an action plan tailored to each client. PRCs with lived SUD or incarceration experience will address recovery barriers, while CMs will focus on service barriers. Where beneficial and desired by the clients, PRCs will accompany clients to provider and select service appointments to promote engagement and retention. CM/PRC teams will provide OEND upon community re-entry. The teams will provide follow-up phone calls and home visits to facilitate service linkages. Contact frequency will depend on clients' individual barriers (e.g., transportation, homelessness), but will include at least weekly in-person or telephone check-ins for first six months, reduced to monthly check-ins after that.
89086354|NCT04685304|Active Comparator|Standard care|"Care for study subjects will occur without PGx results at the discretion of the study subject, their primary care provider.~After the active participation ends (i.e. after the three month follow up is complete), PGx results and a PharmD consult will be provided similar to the PGx-guided arm."
89086355|NCT04673942|Experimental|PART 1: Dose Escalation Safety Run-In (Enrollment Completed)|Subjects will be treated with AdAPT-001 as a single injection, one time.
89086356|NCT04673942|Experimental|PART 2: Dose Expansion Single-Agent (Enrollment Completed)|6 subjects will be enrolled in the Lead In Cohort. A Safety Analysis will be performed after 6 subjects have received at least 24 doses. Upon Safety team review as a continuous reassessment of safety, an additional 19 subjects may be enrolled. All subjects in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.
89086357|NCT04673942|Experimental|PART 3: Expansion|Up to 45 subjects will be enrolled in the expansion cohort to receive either AdAPT-001 on Days 1 and 15 of 28-day cycles or AdAPT-001 on Days 1 and 15 plus a checkpoint inhibitor of 28-day cycles.
89086358|NCT04673942|Experimental|Phase 2|Approximately 55 to 80 subjects with advanced solid tumors including sarcoma to receive either AdAPT-001 on Days 1 and 15 of 28-day cycles or AdAPT-001 on Days 1 and 15 plus a checkpoint inhibitor of 28-day cycles..
89226036|NCT04925427|Placebo Comparator|Naloxone-Only|Participants randomized to the Usual care + OEND condition will be trained on naloxone administration by research staff at the time of randomization. Upon community re-entry,they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
89086359|NCT04673448|Experimental|Treatment (niraparib, dostarlimab)|Patients receive niraparib PO QD on days 1-28 of cycle 1. Beginning cycle 2, patients receive niraparib PO QD on days 1-21 and dostarlimab intravenously (IV) on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 6, patients receive niraparib PO QD on days 1-42 and dostarlimab IV on day 1. Cycles repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
89086360|NCT04665245||COVID-19 Positive Patients|The study only includes one cohort: COVID-19 positive patients. Enrollees will not receive any therapeutic intervention; participants will simply report their temperature and any symptoms experienced twice per day for 10 days.
89086361|NCT04653454|Experimental|CGM Patients|Patients with diabetes mellitus admitted to the hospital and using a CGM will be encouraged to continue to use these devices in inpatient setting. The device alarms of high or low glucose levels will be communicated to the nursing staff.
89086362|NCT04649242|Active Comparator|BHV3000 (active drug)|BHV3000 (rimegepant) 75 mg or 50 mg ODT
89086363|NCT04649242|Placebo Comparator|Placebo|Matching 75 mg or 50 mg ODT placebo
89086364|NCT04647214||Bimatoprost intracameral implant (DURYSTA) 10μg|Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.
89086365|NCT04646226|Experimental|fistula surgically placed|Randomized group to have surgically placed fistula for permanent hemodialysis access
89086366|NCT04646226|Active Comparator|graft surgically placed|Randomized group to have surgically placed graft for permanent hemodialysis access
89086367|NCT04644952||Observational (medical record review)|Patients' medical records are reviewed retrospectively.
89086368|NCT04644575|Experimental|Arm A: Previously treated in BIVV001 study|This arm includes all participants who have completed the previous phase 3 studies on BIVV001, as well as participants who have completed Arm B or Arm C of this study rolling over in Arm A, and participants who will have completed any future BIVV001 study who will be proposed to continue BIVV001 treatment. Participants in this arm will continue receiving BIVV001 prophylaxis treatment once-weekly (QW) for a total of 100 exposure days (EDs) cumulative from the parent study and this study. Participants will have the opportunity to continue in this study for up to 4 years, unless BIVV001 is commercially available in their applicable participating country.
89086369|NCT04644575|Experimental|Arm B: Newly initiated (China Only) in BIVV001|This arm includes Chinese participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) for 52 weeks. After 52 weeks of treatment in this arm B, participants will be able to roll into arm A.
89086370|NCT04644575|Experimental|Arm C: Newly initiated in BIVV001 with planned major surgery|This arm includes participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) and will undergo planned major surgery after at least 6 initial EDs with BIVV001, and within 26 weeks from Day 1. After 52 weeks of treatment in arm C, participants will be able to roll into arm A.
89523057|NCT03386123|Active Comparator|Standard Audiological Care (SAC)|"A group intervention that fits with reported audiological treatment of people with tinnitus and significant sleep impairment. This involves psycho-education about tinnitus, habituation, sleep and sleep hygiene. Relaxation will be advised and information provided. A bedside sound generator, as used in routine clinical practice will be provided. Information will be based on standard advice given by hearing therapists/audiologists and will not include specific psychological techniques which are not part of SAC. The group will be generally supportive.~SAC tends not to involve repeated meetings; after the initial session, there will be one follow up session 8 weeks later. Follow up will allow for question and answer, and reports on what has been useful. Both sessions will last for 2 hours"
89523058|NCT03386123|Placebo Comparator|Sleep Support Group (SSG)|"Participants will meet in a group, which will offer equivalent contact with therapists and a supportive group milieu as CBTi. It will focus on the potential benefits of a supportive group and will not include specific advice.~Participants will complete 2-week sleep diaries as baseline and outcome measures at the four time-points, which will be checked within the session to ensure that participants know how to complete them correctly. The SSG will meet in a group for six sessions, over eight weeks, each of 2 two hours duration."
89523059|NCT03391505|Experimental|Treatment Group 1|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
89086374|NCT04620382|Active Comparator|Midodrine|Single oral dose of midodrine (5-10mg) combined with sham abdominal compression
89086375|NCT04620382|Experimental|Abdominal Compression|Abdominal compression (up to 40 mmHg) combined with a placebo pill
89226037|NCT04919122||Patients with metastatic renal cell cancer (mRCC) with no prior systemic therapy for mRCC|This is an observational cohort.
89523060|NCT03391505|Experimental|Treatment Group 2|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
89523061|NCT03391505|Placebo Comparator|Control Group|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
89523062|NCT03298217|Other|Bronchiolitis patients sverity|In patients with bronchiolitis mWCAS / 3-5 : Measurement of the peak tidal inspiratory flow (PTIF)
89523063|NCT03391349||Group I|GROUP I: 35 generalized severe chronic periodontitis subjects without type II diabetes mellitus and systemically healthy.
89523064|NCT03391349||Group II|GROUP II: 35 generalized severe chronic periodontitis subjects diagnosed with type II diabetes mellitus.
89523065|NCT03268811|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.
89523066|NCT03391271|Experimental|photobiomodulation therapy (PBMT)|During photobiomodulation therapy (PBMT) or low-level laser therapy, visible and/or (near)-infrared laser light is used at the affected area to improve tissue repair and thereby promote functional recovery of peripheral nerves
89523067|NCT03391271|Placebo Comparator|Placebo group|No PBMT
89523068|NCT03385967|Active Comparator|ropivacaine only|0.5% ropivacaine
89086376|NCT04616560|Experimental|Treatment (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 35 cycles in the absence of disease progression or unacceptable toxicity.
89086381|NCT04591275|Experimental|CMAB807|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
89086382|NCT04591275|Active Comparator|Prolia®|60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily
89086383|NCT04589611|Experimental|Phase I single amobarbital/Gel-One dose|Phase I: An open label study of 3 patients will be done. If no dose limiting toxic (DLT) side effects occur, then an additional 3 patients will be done. If no DLT events occur, the study will proceed to Phase II.
89086384|NCT04589611|Active Comparator|Phase IIa Part 1 amobarbital/Gel-One dose|20 subjects will be randomized to amobarbital/Gel-One single dose.
89086385|NCT04589611|Placebo Comparator|Phase IIa Part 1 Placebo|10 subjects will be randomized to amobarbital/Gel-One single dose.
89086386|NCT04589611|Active Comparator|Phase IIa Part 2 amobarbital/Gel-One dose|20 subjects will be randomized to one dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
89086387|NCT04589611|Placebo Comparator|Phase IIa Part 2 placebo|20 subjects will be randomized to one dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
89086388|NCT04587323||Group 1:|Group 1: COVID-19 + inpatients who did not require mechanical ventilation (25 patients);
89086389|NCT04587323||Group 2:|Group 2: COVID-19 + inpatients who required mechanical ventilation (25 patients).
89086390|NCT04587323||Group 3:|Group 3: COVID-19 + inpatients with no preexisting cardiovascular disease (25 patients)
89086391|NCT04587323||Group 4:|Group 4: COVID-19 + inpatients with preexisting cardiovascular disease (25 patients).
89523069|NCT03385967|Active Comparator|ropivacaine with dexmedetomidine|25ml of 0.5%ropivacaine with 0.25mcg/kg of dexmedetomidine
89086393|NCT04567355|Experimental|Migraine Manager|The Migraine Manager portal intervention is comprised of 16 modules that are assigned in an individually tailored manner to participants based on their answers to a brief assessment battery. Once assessments are completed, a treatment plan consisting of recommended modules is automatically generated for patient and parent guidance, and the user is directed to the list of recommended modules. Participants will also complete online daily diaries for eight weeks.
89086394|NCT04567355|No Intervention|Attention Control|Participants in this arm will complete the online daily diaries for eight weeks (i.e., equal time as the Migraine Manager arm) through the portal but will be restricted from receiving intervention content; they will also receive equal number of communications via the portal as the Migraine Manager arm. Data from migraine daily diaries will not be available to AC participants or their clinicians as this would likely be used clinically and lead to contamination of the control arm resulting from varying levels of intervention across participants based on their data.
89086395|NCT04560010|Experimental|Tranexamic Acid Injection (TXA)|Subjects scheduled to undergo TSA (anatomic and reverse) will receive TXA before surgical incision and 3 hours later.
89086396|NCT04560010|No Intervention|No Tranexamic Acid Injection (TXA) given|Subjects scheduled to undergo TSA (anatomic and reverse) will receive no TXA.
89086397|NCT04557956|Active Comparator|Arm I (tazemetostat) phase II|Patients receive tazemetostat PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients may crossover to Arm II after completion of radiation therapy. Patients undergo tumor biopsy, CT scan, and MRI throughout the study.
89086398|NCT04557956|Experimental|Arm II (tazemetostat, dabrafenib, trametinib) phase I/phase II|Patients receive tazemetostat orally PO BID, dabrafenib PO BID, and trametinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy, CT scan, and MRI throughout the study.
89086399|NCT04543695|Active Comparator|adjuvant chemotherapy group|concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)
89086400|NCT04543695|Experimental|consolidation chemotherapy group (CNCT group)|concurrent chemoradiotherapy → consolidation chemotherapy → TME (CNCT group)
89086401|NCT04543695|Experimental|induction chemotherapy group (INCT group)|induction chemotherapy → concurrent chemoradiotherapy →TME ( INCT group).
89086402|NCT04525014|Experimental|RRx-001, Temozolomide and Irinotecan|
89086403|NCT04507113|Experimental|Lumbar radiculopathy|Patients with acute lumbar radiculopathy (less than 3 months of evolution)
89086404|NCT04502563|Experimental|Active arm|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
89086405|NCT04502563|Sham Comparator|Control|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
89086406|NCT04502225|Experimental|Elevation of the whole bed (tilt)|Tilt of the whole bed so that the participant's head is raised by 9 and/or 12 inches.
89086407|NCT04502225|Experimental|Elevation of the trunk|Elevation of the trunk by tilting just the head of the bed so that the participant's head is raised by 9 and/or 12 inches.
89086408|NCT04502225|Experimental|Elevation of the whole bed (tilt) - In home|Tilt of the whole bed so that the participant's head is raised by 8 inches.
89086409|NCT04502225|Experimental|Elevation of the trunk - In home|Elevation of the trunk by raising the head 8 inches on a wedge pillow.
89086410|NCT04495725|Placebo Comparator|Voucher for a Discounted Placebo Product|Voucher for a Discounted Placebo Soft-Gel Capsule Product
89086411|NCT04495725|Experimental|Voucher for a Discounted High THC:Low CBD Product|Voucher for a Discounted 4.3mg THC/0.7mg CBD Soft-Gel Capsule Product
89086412|NCT04495725|Experimental|Voucher for a Discounted Equal THC:CBD Product|Voucher for a Discounted 2.5mg THC/2.5mg CBD Soft-Gel Capsule Product
89086413|NCT04495725|Experimental|Voucher for a Discounted Low THC:High CBD Product|Voucher for a Discounted 0.2mg THC/4.8mg CBD Soft-Gel Capsule Product
89086414|NCT04483206|Experimental|Treatment (Melphalan-based autologous transplant)|Patients receive high dose (100 mg/m2) melphalan IV over 30 minutes on day -3 and PK-directed melphalan IV over 30 minutes on day -1 to achieve set cumulative melphalan exposure levels. Patients then undergo stem cell infusion on day 0.
89086415|NCT04471337|Experimental|Arm A: Moderately impaired renal function|Participants with moderately impaired renal function will receive multiple doses of BAY1817080.
89086416|NCT04471337|Experimental|Arm B: Normal renal function matched to Arm A|Participants with normal renal function matched to Arm A will receive multiple doses of BAY1817080.
89086417|NCT04471337|Experimental|Arm C: End stage renal disease on dialysis|Participants with ESRD requiring dialysis will receive single dose of BAY1817080.
89086418|NCT04471337|Experimental|Arm D: Normal renal function matched to Arm C|Participants with normal renal function matched to Arm C will receive single dose of BAY1817080.
89086419|NCT04459052|Other|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 500 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered). Oral NAC will be taken for approximately 6 ±3 months.
89086420|NCT04459052|Other|Waitlist Control Cohort|Standard of Care Treatment for approximately 6 ±3 months.
89086421|NCT04453072|Experimental|Supportive Care (app, scales, coaching, questionnaire)|Patients receive an iPhone with W8Loss2Go app, a body scale and a digital food scale to weigh themselves and food daily. Patients interact with coaches via text messages for 4 days weekly and receive weekly 15 minute phone calls for appointment reminders, emotional support, progress discussion, and follow up on items discussed in a prior visit or phone call. Patients also have telemedicine interviews with the coach lasting 60 minutes at 2 and 4 months to elicit both positive and negative impacts on weight management and to identify barriers such as emotional eating, displacement behaviors, poor coping skills to life stressors, and social challenges. Patients who opt to extend the intervention until month 12 attend an additional telemedicine meeting with the coach. Patients also complete questionnaires over approximately 1.5 hours.
89086422|NCT04451980||HIV+ non-diabetics|HIV-infected participants with hemoglobin A1c (HbA1c) <5.7% or fasting glucose <100 mg/dl.
89086423|NCT04451980||HIV+ pre-diabetics|HIV-infected participants with HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dl.
89086424|NCT04451980||HIV+ diabetics|HIV-infected participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
89086425|NCT04451980||HIV-negative diabetics|HIV-negative participants with HbA1c >=6.5% or fasting glucose >=126 mg/dl or on anti-diabetic medications.
89086426|NCT04439266|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
89086427|NCT04439253|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89086428|NCT04438382|Experimental|Arm A (infliximab)|Patients receive infliximab IV on day 1 followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive an additional dose of infliximab IV on day 14 at the discretion of the treating physician.
89086429|NCT04438382|Experimental|Arm B (intravenous immunoglobulin therapy)|Patients receive intravenous immunoglobulin therapy IV over 2-5 days per institutional guidelines followed by prednisone taper IV or PO for 4-6 weeks in the absence of disease progression or unacceptable toxicity.
89086430|NCT04432571|Active Comparator|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC)
89086431|NCT04432571|Experimental|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT)
89086432|NCT04432571|Experimental|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV)
89086433|NCT04432571|Experimental|E-NAV/SOC-OIC|Electronic Navigation/SOC-OIC
89086434|NCT04432571|Experimental|E-NAV/CCT|E-Nav/Conditional cash transfer
89086435|NCT04432571|Experimental|E-NAV/IP-NAV|E-Nav/In-Person Peer Navigation
89086436|NCT04431479||Observational (questionnaire, biospecimen, chart review)|Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months after starting index treatment, and at start of a new systemic treatment. Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment, or at a treatment change visit if new therapy has not started.
89086437|NCT04417777||Polynesian patient|Patient with dilatation of idiopathic bronchi
89086438|NCT04417777||Relatives of polynesian patient|Healthy
89086439|NCT04406272|Experimental|Before and After Surgery|"VB-111 will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
89086440|NCT04406272|Experimental|After Surgery|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovering from surgery (within 28-35 days after surgery), participants will receive intravenous VB-111 every 6 weeks. Participants evidencing disease progression may initiate bevacizumab at a pre-determined dose as needed for supportive care and will continue with VB-111 infusions every 6 weeks until tumor growth is evidenced a two consecutive time points."
89086441|NCT04406272|Experimental|After Surgery Standard of Care|"Placebo (IV solution with no medicine) will be administered intravenously at a pre-determined dose at 14-28 days prior to surgery.~Upon recovery from surgery, participants will receive standard of care treatment every 6 weeks until tumor growth is evidenced a two consecutive time points."
88812864|NCT02476422|Experimental|Dilcofenac potassium + placebo to Ibuprofen|Single dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
89086449|NCT04397679|Experimental|Treatment (radiation therapy, temozolomide, chloroquine, TTF)|"Patients undergo 30 fractions of 3D CRT or Intensity-modulated radiation therapy (IMRT) and receive temozolomide by mouth (PO) and chloroquine PO daily from day 1 for the duration of radiation therapy up to day 49. Treatment continues in the absence of disease progression or unacceptable toxicity.~ADJUVANT TREATMENT: Beginning 4 weeks after the last day of radiation therapy, patients receive temozolomide PO QD on days 1-5 and chloroquine PO daily on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients demonstrating continued benefit may continue to receive temozolomide and chloroquine for up to 12 cycles. Patients also undergo TTF therapy over 18 hours or longer per day."
89086450|NCT04384484|Experimental|Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)|"Part 1 consists of a non-randomized safety run-in period evaluating the study drug for the first 20 participants.~Participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m^2 Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m^2 Q3W for up to 6 additional cycles."
89086451|NCT04384484|Experimental|Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)|Randomized participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m^2 every Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m^2 Q3W for up to 6 additional cycles.
89086452|NCT04384484|Active Comparator|Part 2: Standard Immunochemotherapy (R-GemOx)|Randomized participants will receive R-GemOx consisting of rituximab, gemcitabine and oxaliplatin as a standard immunochemotherapy treatment on Day 1 or Day 2 of each cycle for up to 8 cycles, where 1 Cycle is 2 weeks. R-GemOx will be administered via an intravenous infusion of rituximab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2 every 2 weeks (Q2W) for up to 8 cycles.
89086455|NCT04363073|Experimental|Anaabella|Milk will be expressed using Annabella breast pump.
89086456|NCT04363073|Active Comparator|Control pump|Milk will be expressed using a control breast pump.
89086457|NCT04350892|Active Comparator|Roux-en-Y Gastric Bypass Surgery|
89086458|NCT04350892|Active Comparator|Sleeve Gastrectomy Surgery|
89086459|NCT04350892|Active Comparator|Very Low Calorie Diet|
89086461|NCT04333732|Experimental|M-M-R II ®|Education and surveillance plus M-M-R II ® Single dose, 0.5 mL subcutaneous injection of M-M-R II ®
89086462|NCT04333732|Placebo Comparator|Placebo|Education and surveillance plus placebo Single dose, 0.5 mL subcutaneous injection of 0.9% saline
89086463|NCT04333641||small AAA patients|all patients with small AAA
89086464|NCT04333576|Placebo Comparator|Double-Blind: Placebo|Participants will receive double-blind placebo on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months.
89086465|NCT04333576|Experimental|Double-Blind: Elagolix|Participants will receive double-blind Elagolix on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months.
89086466|NCT04333576|Experimental|Double-Blind: Elagolix + COC|Participants will receive double-blind elagolix in combination with COC (combined oral contraceptive) on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC for 15 months. Participants will be followed-up for up to 12 months.
89086467|NCT04329624|Active Comparator|Levosimendan|Patients receive a continuous infusion of 12.5mg solved in 50mL Levosimendan for up to 24 hours. Infusion will be started with surgical skin incision.
89086468|NCT04329624|Placebo Comparator|Placebo|Patients receive a continuous infusion containing a placebo solved in 50mL for up to 24 hours. Infusion will be started with surgical skin incision.
89086469|NCT04301934|Active Comparator|Vaginal Estrogen Therapy Group|Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly
89086470|NCT04301934|Experimental|Laser Therapy Group|Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.
89086471|NCT04287075||Surgery|Participants who elect to undergo surgery for the treatment of their chronic, neuropathic pain
89086472|NCT04287075||Non-surgery|Participants who elect to not have surgery for the treatment of their chronic, neuropathic pain
89086473|NCT04285567|Experimental|VEN + G|Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
89086474|NCT04285567|Active Comparator|FCR/BR|Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
89086475|NCT04276376|Experimental|Cohort 1A-D|"Molecularly selected cohorts that harbor DNA repair deficiency, defined as bi-allelic loss-of-function alteration (mutation and/or deletion) in at least one of the following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, PALB2, RAD51C, RAD51D, FANCA, NBN, RAD51, RAD54L.~1.A - Non-Small Cell Lung Cancer~1.B - Urothelial Bladder Cancer~1.C - metastatic Castration Resistant Prostate Cancer~1.D - others: any histology, excepted breast cancer or serous ovarian cancer"
89086476|NCT04276376|Experimental|Cohort 2A-C|Platinum-sensitive disease 2.A - Non-Small Cell Lung Cancer 2.B - Urothelial Bladder Cancer 2.C - Gastric or gastro-esophageal junction adenocarcinoma
89086477|NCT04276376|Experimental|Cohort 3|Metastatic Castration Resistant Prostate Cancer (mCRPC)
89086478|NCT04276376|Experimental|Cohort 4|Clear Cell Renal Cell Carcinoma
89086479|NCT04271228|Experimental|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
89086480|NCT04268667|Experimental|Upper cervical spine manipulation group|Spinal thrust joint manipulation on the atlantoaxial joint
89086481|NCT04268667|Active Comparator|Cervicothoracic spine manipulations group|Different spinal thrust joint manipulations on the thoracic spine (T6), mid-cervical spine (C3-C4) and cervicothoracic junction (C7-T1).
89086482|NCT04250727|Experimental|3mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 3mg nicotine concentration.
89086483|NCT04250727|Experimental|6mg Nicotine Concentration|15 participants will be randomly assigned to receive ZYN Pouches with 6mg nicotine concentration.
89086484|NCT04248829|Experimental|Lazertinib + Gefitinib-matching placebo|Lazertinib (240 mg or 160 mg orally, once daily) plus Gefitinib-matching placebo (250 mg orally, once daily) in accordance with the randomization schedule
89086485|NCT04248829|Active Comparator|Gefitinib + Lazertinib-matching placebo|Gefitinib (250 mg orally, once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally, once daily) in accordance with the randomization schedule
89086486|NCT04237077|Experimental|"Group with telephone coaching program ."|subjects aged 75 years or more living at home, with telephone coaching program
88812865|NCT02476422|Active Comparator|Ibuprofen + placebo to diclofenac potassium|Single dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
89086487|NCT04237077|Active Comparator|"Group without telephone coaching program."|subjects aged 75 years or more living at home, without telephone coaching program
89086488|NCT04229004|Active Comparator|Gemcitabine combined with nab-paclitaxel|The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted as long as drug dosing and modification guidelines are followed.
89086489|NCT04229004|Active Comparator|mFOLFIRINOX|Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion
89086490|NCT04229004|Experimental|pamrevlumab (FibroGen)|"Arm is closed to recruitment.~Experimental: Pamrevlumab in combination with gemcitabine/nab-paclitaxel.~Participants enrolled to this treatment arm will receive treatment with pamrevlumab in combination with gemcitabine and nab-paclitaxel.~Gemcitabine and nab-paclitaxel are FDA approved therapies for metastatic pancreatic cancer and will be supplied or obtained according to local clinical study agreements and in accordance with local guidelines."
89086491|NCT04229004|Experimental|Canakinumab and Spartalizumab|"Arm is closed to recruitment.~Canakinumab and Spartalizumab in Combination with Nab-Paclitaxel and Gemcitabine.~Participants enrolled to this treatment arm will receive treatment with Canakinumab and Spartalizumab in combination with nab-paclitaxel and gemcitabine."
89086492|NCT04229004|Experimental|Experimental: SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.~All four agents (SM-88, methoxsalen, phenytoin, and sirolimus) should be dosed with approximately 240 mL (8 fl. oz.) of water in the morning. All four agents should be taken together consistently. SM-88 used with MPS should ideally be taken approximately 1 hour before or 2 hours after a meal."
89086493|NCT04225039|Experimental|Cohort A|Subjects in this arm (N=16) receive a single priming dose of both INCMGA00012 (500mg) and INCAGN01876 (300mg) prior to stereotactic radiosurgery (SRS), then undergo SRS (8 Gy x 3 fractions). Following SRS, INCMGA00012 (500mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) are resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
89086494|NCT04225039|Experimental|Cohort B sub-arm #1|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 (500mg) + INCAGN01876 (300mg) + SRS. Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (500 mg IV every 4 weeks) and INCAGN01876 (300mg IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
89086495|NCT04225039|Experimental|Cohort B sub-arm #2|Subjects in this arm (N=8) receive neoadjuvant immunotherapy INCMGA00012 + INCAGN01876 (without SRS). Subjects then undergo surgery. Postoperatively, the immunotherapy combination of INCMGA00012 (IV every 4 weeks) and INCAGN01876 (IV every 2 weeks) is resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.
89086496|NCT04218370|Active Comparator|Conventional|Thrice-weekly intermittent dialysis until pre-specified criteria for recovery are met
89086497|NCT04218370|Experimental|Conservative|Conservative dialysis strategy--dialysis prescribed only when specific metabolic or clinical indications are met. These indications are: blood urea nitrogen >112 mg/dL (40 mmol/L; blood potassium concentration >6 mmol/L; blood potassium concentration >5.5 mmol/L despite medical treatment; arterial blood gas pH <7.15, or in the absence of an available blood gas, serum bicarbonate <12 mmol/L, acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate >5 L/min or equivalent via face mask/tracheostomy mask to maintain SpO2 >95% or requiring FiO2 >50% in patients with tracheostomy already on invasive or non-invasive mechanical ventilation and despite diuretic therapy; clinician judgement
89086498|NCT04209738||Eurythmy Therapy (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified therapist: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by an eurythmy manual and an exercise video. This complements the regular care.
89086499|NCT04209738||Tai Chi (performed as part of the ENTAiER main study)|In group sessions á 5 patients with a qualified teacher: In the first 3 months 2 times a week, in the second 3 months once a week. Recommendation to practice at home at least 3 days a week (optimal to practice daily). They are supported by a Tai Chi manual and a practice video. This complements the regular care.
89086500|NCT04209738||Standard Care|"Brochure with detailed description of different evidence-based measures for fall prevention, created for the specific age group (Gleichgewicht & Kraft - Trittsicher durchs Leben https://www.trittsicher.org/files/trittsicher_bzga_sturzpraevention_2015-11-23.pdf) and recommendation to visit the family doctor and discuss fall prophylaxis with him."
89086501|NCT04198571||Zinforo Treated|Only those Adults treated with this treatment for CAP or cSSTi
89086502|NCT04194645|Placebo Comparator|SRD: Placebo matching BI 474121 oral solution (OS)|This arm comprises all placebo treated participants of the single rising dose (SRD) part treated with an oral solution (placebo treated participants of the two lowest dose group (DG)s). Participants receiving placebo were equally distributed across dose groups. A single dose of BI 474121 matching placebo powder for oral solution was administered after an overnight fast together with 240 milliliter (mL) of water to participants who were in a standing position.
89086503|NCT04194645|Placebo Comparator|SRD: Placebo matching BI 474121 tablet (T)|This arm comprises all placebo treated participants of the SRD part treated with a tablet (placebo treated participants of the five upper DGs). Participants receiving placebo were equally distributed across dose groups. A single dose of BI 474121 matching placebo tablet was administered after an overnight fast together with 240 mL of water to subjects who were in a standing position.
89086504|NCT04194645|Experimental|SRD: 0.25 milligram (mg) BI 474121 - OS|A single dose of 0.25 mg BI 474121 was solved in 0.5 mL of water and was administered after an overnight fast together with 240 mL of water to participants who were in a standing position.
89086505|NCT04194645|Experimental|SRD: 1 mg BI 474121 - OS|A single dose of 1 mg BI 474121 was solved in 2mL of water and was administered after an overnight fast together with 240 mL of water to participants who were in a standing position.
89086506|NCT04194645|Experimental|SRD: 2.5 mg BI 474121 - T|A single dose of 2.5 mg BI 474121 was administered as 1 uncoated 2.5 mg tablet after an overnight fast together with 240 mL of water to participants who were in a standing position.
89086507|NCT04194645|Experimental|SRD: 5 mg BI 474121 - T|A single dose of 5.0 mg BI 474121 was administered as 2 uncoated 2.5 mg tablets after an overnight fast together with 240 mL of water to participants who were in a standing position.
89086508|NCT04194645|Experimental|SRD: 10 mg BI 474121 - T|A single dose of 10.0 mg BI 474121 was administered as 1 uncoated 10.0 mg tablet after an overnight fast together with 240 mL of water to participants who were in a standing position.
89086509|NCT04194645|Experimental|SRD: 20 mg BI 474121 - T|A single dose of 20.0 mg BI 474121 was administered as 2 uncoated 10.0 mg tablets after an overnight fast together with 240 mL of water to participants who were in a standing position.
89086510|NCT04194645|Experimental|SRD: 40 mg BI 474121 - T|A single dose of 40.0 mg BI 474121 was administered as 4 uncoated 10.0 mg tablets after an overnight fast together with 240 mL of water to participants who were in a standing position.
89086511|NCT04194645|Experimental|BA: BI 474121 10 mg as: OS fasted (Reference (R)) / T fasted (T2) / T fed (T1)|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (Reference (R)), in period 2 as 1 uncoated tablet with 240 mL of water after an overnight fast (Test 2 (T2)) and in period 3 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (Test 1 (T1)). Between periods was a wash-out period of at least 7 days.
89086512|NCT04194645|Experimental|BA: BI 474121 10 mg as: R / T1 / T2|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (R), in period 2 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1) and in period 3 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2). Between periods was a wash-out period of at least 7 days.
89086513|NCT04194645|Experimental|BA: BI 474121 10mg as: T2 / R / T1|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2), in period 2 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (R) and in period 3 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1). Between periods was a wash-out period of at least 7 days.
89086514|NCT04194645|Experimental|BA: BI 474121 10mg as: T2 / T1 / R|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2), in period 2 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1) and in period 3 as oral solution solved in 20 mL water with 240 mL of water after an overnight fast (R). Between periods was a wash-out period of at least 7 days.
89086515|NCT04194645|Experimental|BA: BI 474121 10mg: T1 / R / T2|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1), in period 2 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (R) and in period 3 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2). Between periods was a wash-out period of at least 7 days.
89086516|NCT04194645|Experimental|BA: BI 474121 10mg: T1 / T2 / R|Participants received a single dose of 10.0 mg BI 474121 in each period, in period 1 as 1 uncoated tablet in fed conditions after a high-fat / high-caloric breakfast with 240 mL of water (T1), in period 2 as 1 uncoated tablet with 240 mL of water after an overnight fast (T2) and in period 3 as oral solution solved in 20 mL of water with 240 mL of water after an overnight fast (R). Between periods was a wash-out period of at least 7 days.
89086517|NCT04193865||Extracorporeal Life Support with Renal Replacement Therapy|"This cohort will include all subjects receiving extracorporeal life support with concurrent continuous renal replacement therapy.~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each participants's CRRT course."
89086518|NCT04193865||Renal Replacement Therapy|"This cohort will include all subjects receiving continuous renal replacement therapy (no extracorporeal life support).~Two blood samples and one ultrafiltration sample will be obtained for the study protocol twice per day (every 12 hours) for the duration of each patient's CRRT course."
89086519|NCT04188548|Experimental|Dose Escalation LY3484356|LY3484356 given orally.
89086520|NCT04188548|Experimental|Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI|LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
89086521|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E3: LY3484356|LY3484356 given orally.
89086522|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus|LY3484356 and everolimus given orally.
89086523|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib|LY3484356 and alpelisib given orally.
89086524|NCT04188548|Experimental|Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib|LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
89086525|NCT04188548|Experimental|Part D: Dose Expansion: LY3484356 +/- Abemaciclib|LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.
89086526|NCT04188548|Experimental|Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab|LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.
89086527|NCT04188288|Experimental|Neurofeedback|Three imaging (fMRI) sessions of experimental feedback.
89086528|NCT04188288|Other|Control feedback|Three imaging (fMRI) sessions of control feedback.
89086529|NCT04182633|Experimental|Group A - Treatment Group|This group will receive vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota for 2 days at high dose, then intestinal microbiota for 12 weeks at a maintenance dose
89086530|NCT04182633|Placebo Comparator|Group B - Control Group (Miralax only for 1 day)|This group will receive placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota for 2 days at high dose, then placebo intestinal microbiota for 12 weeks at a maintenance dose
89523070|NCT03391037||Intervention|diagnostic criteria for volume assessment were heart rate (HR), mean arterial blood pressure (MABP), central venous pressure (CVP), and urine output hourly (UOP) in ml/hr. During period of hypovolemia, all enrolled patients had left IJV scanned (T0) and measured by one anesthesiologist experienced in point-of-care ultrasound. This point-of-care anesthesiologist is not involved in the anesthetic management of the patient and blinded to the volume status of the patient values. Hypovolemic patients were given a fluid bolus in the form of ringer acetate 5 ml / Kg. Ultrasonic and hemodynamic measurements are reassessed 10 minutes (T 10) after the fluid resuscitation.
89523071|NCT03131531||Hodgkin lymphoma|
89086533|NCT04179032|Experimental|Belimumab 200 mg|Participants with Systemic Lupus Erythematosus were administered with Belimumab 200 milligram per milliliter (mg/mL) subcutaneous (SC) injection. The dosing frequency was based on body weight. Participants who weigh more than or equal to 50 kilograms were administered every week, who weigh between 30 to less than 50 kg were administered every 10 days and who weigh less than 30 kg were administered every 2 weeks.
89086534|NCT04177498|Experimental|Treatment (rigosertib sodium)|Patients receive rigosertib sodium either oral or IV over a 52 week period. Patients will take oral rigosertib continuously for a total of three weeks, every four-week cycle (three weeks on, one week off drug). For IV, rigosertib is administered as a 72-hr continuous infusion on Days 1, 2 and 3 of a 2-week cycle for the first eight 2-week cycles, then on Days 1, 2 and 3 of a 4-week cycle thereafter.
89086535|NCT04176159|Experimental|Motor imagery and task-oriented training group|Two modules. A first module of motor imagery. A second module of task-oriented training and the incorporation of collective activities.
89086536|NCT04176159|No Intervention|Usual school routines group|Children continue with the usual school routine. Once the study is completed and the corresponding measurements have been made, the subjects included in this group will be subjected to the same program detailed in the intervention, to not deprive them of their benefits.
89523072|NCT03131531||Non-Hodgkin lymphoma|
89523073|NCT03131531||Myeloma|
89523074|NCT03390959|Experimental|Proprioceptive Training|The group participates in proprioceptive training that promotes sensory integration.
89523075|NCT03390959|Other|Control Group|The group continues in their daily lives with phone monitoring.
89523076|NCT03390881|Experimental|Fasting condition|Effects of cumulated negative energy balance (fasting over 480 min) on breath acetone changes
89523077|NCT03390881|Active Comparator|Sugar condition|Effects of sugar consumption on breath acetone changes
89523078|NCT03390881|Active Comparator|Fat condition|Effects of fat consumption on breath acetone changes
89523079|NCT03390803||patients with hemifacial spasm|
89523080|NCT03390803||healthy control subjects|
89523081|NCT03390647|Experimental|Cohort A1|Japanese participants will receive a single oral dose of E6130 on Day 1 and Day 7 administered in the specified order (fasted/fed or fed/fasted) to evaluate the food effect.
89523082|NCT03390647|Experimental|Cohort B1|Caucasian participants will receive a single oral dose of either E6130 or placebo on Day 1.
89523083|NCT03390647|Experimental|Cohorts A2-A4|Japanese participants will receive multiple oral doses of E6130 or placebo on Days 1 to 5, administered in a randomized, dose-ascending manner.
89523084|NCT03125837||general anesthesia|Digital photographs of the face of each patient undergoing general anesthesia with endotracheal intubation
89523085|NCT03390179||diabetes|Patient with non insulin diabetes
89523086|NCT03390179||control|Patient without diabete
89523087|NCT02732015|Experimental|Arm I (rolapitant hydrochloride)|"Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
89523088|NCT02732015|Active Comparator|Arm II (fosaprepitant dimeglumine)|"Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
89523089|NCT03093701|Experimental|Group 1|TLC399 (ProDex) 0.36mg DSP with 100 mM PL
89523090|NCT03093701|Experimental|Group 2|TLC399 (ProDex) 0.6 mg DSP with 100 mM PL
89523091|NCT03093701|Experimental|Group 3|TLC399 (ProDex) 0.6 mg DSP with 50 mM PL
89523092|NCT03093701|Experimental|Group 4|TLC399 (ProDex) 0.84 mg DSP with 50 mM PL
89523093|NCT03789461|Experimental|Fecal Microbiota Transplantation|FMT infusion
89523094|NCT03048461|Experimental|Platelet Rich Plasma|Participants will receive intradermal injections autologous PRP to an area (100cm2) of alopecia on the scalp.Two treatments will be performed 3 months apart
89523095|NCT03048461|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of sterile normal saline to an area (100cm2) of alopecia on the scalp. Two treatments will be performed 3 months apart
89523096|NCT03708419|Experimental|Optimal diet|Participants will follow a diet for a total duration of 12 weeks, optimal for their metabolic phenotype. For participants with muscle insulin resistance (MIR) this will be a diet high in monounsaturated fatty acids, for participants with liver insulin resistance (LIR) this will be a diet high in protein and fiber and low in fat.
89086537|NCT04172532|Experimental|Phase I (hypofractionated radiation therapy, M3814)|Patients in Phase I undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
89086538|NCT04172532|Experimental|Phase II Group I (hypofractionated radiation therapy M3814)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
89086539|NCT04172532|Placebo Comparator|Phase II Group II(hypofractionated radiation therapy, placebo)|Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.
89086542|NCT04164082|Experimental|Treatment (pembrolizumab, gemcitabine hydrochloride)|"INDUCTION: Patients receive pembrolizumab IV over 25-40 minutes on day 1 of cycles 1-4. Patients also receive gemcitabine hydrochloride intravesically on days 1, 8 and 15 of cycles 1 and 2. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning cycle 5, patients with no evidence of disease after induction receive pembrolizumab IV over 25-40 minutes and gemcitabine intravesically on day 1. Treatment repeats every 3 weeks for 12 cycles in the absence of disease progression or unacceptable toxicity."
89086543|NCT04162665|Experimental|Pre-operative adaptive short course radiation therapy|Consenting and eligible patients will receive adaptive short course radiation therapy (SCRT) (25 Gy at in 5 fractions), followed by standard of care total neoadjuvant chemotherapy followed by standard of care gastrectomy or esophagogastrectomy. The recommended SOC chemotherapy options are CAPOX, FOLFOX, or FLOT, but any SOC total neoadjuvant chemotherapy may be given at the discretion of the treating medical oncologist after consultation with the study chair. Patients who are not able to complete their full total neoadjuvant therapy regimen prior to surgery may complete chemotherapy postoperatively at the discretion of the treating physician.
89086544|NCT04135703|Experimental|Risk Prevention Services +Housing|Opioid and related prevention services including Strengths-Based Outreach and Advocacy (SBOA), MI, HIV risk and suicide prevention (CTSP) as well as rental and utility assistance for 6 months.
89086545|NCT04135703|Experimental|Risk Prevention Services Only|Opioid and related prevention services including Strengths-Based Outreach and Advocacy (SBOA), MI, HIV risk and suicide prevention (CTSP).
89086546|NCT04126031|Experimental|Part A, Cohorts 1-3|Single dose pharmacokinetics. This arm will include three age cohorts.
89086547|NCT04126031|Experimental|Part B, Cohorts 1-3|Multi-dose pharmacokinetics. This arm will include three age cohorts.
89086548|NCT04117347|Experimental|Light therapy A via the Re-Timer®|-15 minutes/day
89086549|NCT04117347|Experimental|Light therapy B via the Re-Timer®|-30 minutes/day
89086550|NCT04117347|Experimental|Light therapy C via the Re-Timer®|-60 minutes/day
89086551|NCT04115540|Experimental|TENS penile nerve stimulation group|"The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum). Participants will be able to use the device prior to sexual activity (immediately before sexual encounter for 10 minutes or daily for up to 14 days prior) to prime their system or during sexual activity. Each participant will use the device these three separate ways for 6 weeks each (total of 18 weeks of use)."
89086552|NCT04093323|Experimental|Treatment (IFNA2, rintatolimod, celecoxib, alphaDC1 cell based treatment)|Patients receive recombinant interferon alpha-2 IV over 30 minutes, rintatolimod IV over 2.5 hours, and celecoxib PO BID on days 1-3. Beginning cycle 2, patients also receive alpha-type-1 polarized dendritic cells ID on day 1. Treatment repeats every 3 weeks up to 4 cycles in the absence of disease progression or unacceptable toxicity. At 12 weeks, patients with progressive disease may switch to ipilimumab with or without a PD-1/PD-L1 inhibitor and patients with a complete response CR, PR, or stable disease SD may switch to a PD-1/PD-L1 inhibitor or best alternative care.
89086553|NCT04083781|Experimental|Arm 1: No prophylaxis|Haemophilia A with inhibitors (HAwI) and haemophilia B with inhibitors (HBwI) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension part, patients in arm 1 will receive daily concizumab subcutaneous (s.c., under the skin) injections.
89086554|NCT04083781|Experimental|Arm 2: Concizumab prophylaxis|HAwI and HBwI patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
89086555|NCT04083781|Experimental|Arm 3: Concizumab prophylaxis|The HAwI and HBwI patients enrolled into the concizumab phase 2 trial (NN7415-4310) at time of transfer will be offered enrolment into this trial. It is required that these patients are on concizumab prophylaxis up until enrolment into the trial. These patients will continue concizumab prophylaxis.
89086556|NCT04083781|Experimental|Arm 4: Concizumab prophylaxis|Patients previously on prophylaxis with by-passing agents and on-demand patients who are screened at a timepoint where the required number of patients in arms 1 and 2 have been randomised. These patients will, if eligible, be enrolled into the trial and will initiate concizumab prophylaxis at visit 2a (week 0).
88812866|NCT01832714||mTBI|Subjects who undergo an mTBI event
88812867|NCT01832714||Control|Subjects who do not undergo an mTBI
88812868|NCT01832792|Experimental|Self-help|In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
89086557|NCT04082429|Experimental|Arm 1: No prophylaxis (PPX)|Haemophilia A (HA) and haemophilia B (HB) patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis. In the extension phase, this group will receive treatment with concizumab.
88812869|NCT01832792|Other|Waiting List|One third of participants will be allocated to a treatment waiting list, after which they will be randomised to one of the other two arms.
89086558|NCT04082429|Experimental|Arm 2: Concizumab prophylaxis|HA and HB patients, previously treated on-demand, will be randomised 1:2 to no prophylaxis versus concizumab prophylaxis.
89086559|NCT04082429|Experimental|Arm 3: Concizumab prophylaxis|The HA patients enrolled into the concizumab phase 2 trial NN7415-4255 (explorer 5) will be offered enrolment into this arm.
89086560|NCT04082429|Experimental|Arm 4: Concizumab prophylaxis|"Arm 4 will include patients previously on prophylaxis with factor products with a minimum of 24 weeks observation in NN7415-4322 (explorer 6) (at least 30 HA and 30 HB patients).~In addition, arm 4 will also include: 1) Patients who were randomised to arms 1 and 2 before the treatment pause. 2) HA patients who were in NN7415-4255 (explorer 5) at the time of the treatment pause, and who have now completed explorer 5. 3) On demand patients included after arms 1 and 2 are closed."
89086561|NCT04073706|Experimental|TH BSO with SNB|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG)+/- Methylene Blue Dye (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.
89086562|NCT04073706|Active Comparator|TH BSO without retroperitoneal node dissection|Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.
89086563|NCT04071366|Experimental|Part 1: Open Label Itacitinib Once Daily|During Part 1, all participants receive itacitinib 200mg once daily (open label) for 30 days. The study population will include participants receiving any approved IEC for an approved indication.
89086564|NCT04071366|Experimental|Part 2: Double-Blind Itacitinib Twice Daily|During Part 2, participants will be randomized to receive itacitinib 200mg or placebo twice daily for 30 days. The study population also includes participants who are receiving Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.
89086565|NCT04071223|Experimental|Arm A (radium Ra 223 dichloride, cabozantinib s-malate)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1 of cycles 1-6 and cabozantinib S-malate PO QD on days 1-28 of every cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89086566|NCT04071223|Active Comparator|Arm B (cabozantinib s-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89086567|NCT04068181|Experimental|Cohort 1 - Locally Recurrent/Metastatic - Primary Resistance|"Includes participants who received anti-PD1 therapy in the locally recurrent/metastatic setting and experienced a best overall response of disease progression or stable disease prior to confirmed disease progression.~Participants will receive talimogene laherparepvec at an initial dose of up to 4.0 mL of 10^6 plaque-forming units (PFU)/mL on Day 1. Subsequent doses of up to 4.0 mL of 10^8 PFU/mL will be administered every 3 weeks for up to 35 cycles in total. Participants will also receive pembrolizumab at a dose of 200 mg every 3 weeks for up to 35 cycles."
89086568|NCT04068181|Experimental|Cohort 2 - Locally Recurrent/Metastatic - Acquired Resistance|"Includes participants who received anti-PD-1 therapy in the locally recurrent/metastatic setting and experienced confirmed disease progression following a complete or partial response on anti-PD-1 therapy.~Participants will receive talimogene laherparepvec at an initial dose of up to 4.0 mL of 10^6 plaque-forming units (PFU)/mL on Day 1. Subsequent doses of up to 4.0 mL of 10^8 PFU/mL will be administered every 3 weeks for up to 35 cycles in total. Participants will also receive pembrolizumab at a dose of 200 mg every 3 weeks for up to 35 cycles."
89226038|NCT04916002|Experimental|Vidutolimod and cemiplimab for cutaneous squamous cell carcinoma (CSCC) (A1)|Participants who have not received prior systemic therapy for metastatic or locally and/or regionally advanced unresectable CSCC and who are not eligible for curative radiation will receive vidutolimod intratumoral(ly) (IT) and cemiplimab intravenous (IV) according to the treatment schedule until a reason for treatment discontinuation is reached.
88812527|NCT03726307|Experimental|DCreg: 0.5 million cells/kg+SOC|"N=3 participants will receive 0.5 (± 0.1) million cells/kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
89086569|NCT04068181|Experimental|Cohort 3 - Adjuvant Setting -Disease Free Interval < 6 months|"Includes participants who received anti-PD-1 therapy in the adjuvant setting and experienced confirmed disease progression following a disease-free interval of < 6 months after starting the adjuvant anti-PD-1 therapy.~Participants will receive talimogene laherparepvec at an initial dose of up to 4.0 mL of 10^6 plaque-forming units (PFU)/mL on Day 1. Subsequent doses of up to 4.0 mL of 10^8 PFU/mL will be administered every 3 weeks for up to 35 cycles in total. Participants will also receive pembrolizumab at a dose of 200 mg every 3 weeks for up to 35 cycles."
89086570|NCT04068181|Experimental|Cohort 4 - Adjuvant Setting -Disease Free Interval ≥ 6 months|"Includes participants who received anti PD-1 therapy in the adjuvant setting and experienced confirmed disease progression following a disease-free interval of ≥ 6 months after starting the adjuvant PD-1 inhibitor.~Participants will receive talimogene laherparepvec at an initial dose of up to 4.0 mL of 10^6 plaque-forming units (PFU)/mL on Day 1. Subsequent doses of up to 4.0 mL of 10^8 PFU/mL will be administered every 3 weeks for up to 35 cycles in total. Participants will also receive pembrolizumab at a dose of 200 mg every 3 weeks for up to 35 cycles."
89086571|NCT04058756|Experimental|PDR001|All subjects in all combination will be entered in one arm
89086572|NCT04058158|Experimental|Treatment Sequence I|Subjects who are randomised to initially receive SB12 will be switched to receive Soliris® at Week 26
89086573|NCT04058158|Experimental|Treatment Sequence II|Subjects who are randomised to initially receive Soliris® will be switched to receive SB12 at Week 26
89086574|NCT04048824|Experimental|Inhibitory Learning-Based Exposure|Participants will receive exposure therapy aimed at increasing inhibitory learning.
89086575|NCT04048824|Active Comparator|Habituation-Based Exposure|Participants will receive exposure therapy aimed at reducing fear responding.
89086576|NCT04047472|Experimental|Brolucizumab 6 mg|
89086577|NCT04047472|Active Comparator|Aflibercept 2 mg|
89086578|NCT04027946|Experimental|Mesothelin Expressing Non-Small Cell Lung Cancer Participants|LMB-100 + Pembrolizumab
89086579|NCT04023669|Experimental|A: prexasertib + cyclophosphamide|"Stratum A: Participants receive combination treatment with cyclophosphamide given intravenously (IV) on days 1 and 15 and prexasertib given intravenously (IV) on days 2 and 16. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. They may also receive growth therapy support with filgrastim or peg-filgrastim.~Note: Only if absolutely necessary, cyclophosphamide may be given on day 16 and prexasertib may be given on day 17."
89086580|NCT04023669|Experimental|B: prexasertib + gemcitabine|"Stratum B: Participants receive combination treatment with gemcitabine given intravenously (IV) on days 1 and 15 and prexasertib given intravenously (IV) on days 2 and 16. Cycles repeat every 28 days for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity. They may also receive growth therapy support with filgrastim or peg-filgrastim.~Note: Only if absolutely necessary, gemcitabine may be given on day 16 and prexasertib may be given on day 17."
89086581|NCT04007744|Experimental|Treatment (sonidegib, pembrolizumab)|Patients receive sonidegib PO QD on days 1-8, and pembrolizumab IV over 30 minutes on day 8. Treatment repeats every 21 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89086582|NCT04004611|Experimental|Open Label (OL) Induction Period: 5 milligram per kilogram (mg/kg) Miri intravenous (IV)|Participants (≤40 kg weight) received 5 mg/kg mirikizumab given as an IV infusion every 4 weeks (Q4W) on weeks 0, 4, 8 for 12 weeks.
89086583|NCT04004611|Experimental|Open Label Induction Period: 10 mg/kg Miri IV|Participants (≤40 kg weight) received 10 mg/kg mirikizumab given as an IV infusion Q4W on weeks 0, 4, 8 for 12 weeks.
89086584|NCT04004611|Experimental|Open Label Induction Period: 300 mg Miri IV|Participants (>40 kg weight) received 300 mg mirikizumab given as an IV infusion Q4W on weeks 0, 4, 8 for 12 weeks.
89086585|NCT04004611|Experimental|Open Label Maintenance Period: 50 mg Miri subcutaneous (SC)|Participants (≤20 kg weight) who were responders to mirikizumab at week 12 in induction received 50 mg subcutaneously (SC) Q4W from week 12 through week 48 or until loss of response was confirmed.
89086586|NCT04004611|Experimental|Open Label Maintenance Period: 100 mg Miri SC|Participants (>20 to ≤40 kg weight) who were responders to mirikizumab at week 12 in induction received 100 mg SC Q4W from week 12 through week 48 or until loss of response was confirmed.
89086587|NCT04004611|Experimental|Open Label Maintenance Period: 200 mg Miri SC|Participants (>40 kg weight) who were responders to mirikizumab at week 12 in induction received 200 mg SC Q4W from week 12 through week 48 or until loss of response was confirmed.
89086588|NCT04004611|Experimental|Open Label Maintenance Period: Non-Responders: 10 mg/kg Miri IV/ 50 mg Miri SC|Participants (≤40 kg) who were non responders to miri at Week 12 in induction received 10 mg SC Q4W for 12 weeks or discontinued after repeat induction, and then received 50 mg miri (≤20 kg weight) SC Q4W through week 48 or until loss of response was confirmed.
89086589|NCT04004611|Experimental|Open Label Maintenance Period: Non-Responders: 10 mg/kg Miri IV/100 mg Miri SC|Participants (≤40 kg) who were non responders to miri at week 12 in induction received 10 mg SC Q4W for 12 weeks or discontinued after repeat induction, and then received 100 mg miri (>20 to ≤40 kg weight) SC Q4W through week 48 or until loss of response was confirmed.
89086590|NCT04004611|Experimental|Open Label Maintenance Period: Non-Responders: 300 mg Miri IV /200 mg Miri SC|Participants (>40 kg) who were non responders to miri at week 12 in induction received 300 mg SC Q4W for 12 weeks or discontinued after repeat induction, then received 200 mg miri SC Q4W through week 48 or until loss of response was confirmed.
89086591|NCT03969004|Experimental|Cemiplimab|
89086592|NCT03969004|Placebo Comparator|Placebo|
89086593|NCT03942081|Experimental|Ulcer Measurement and Photo Group|Diabetic patients with foot ulcers being seen in clinic.
89086594|NCT03942081|No Intervention|Healthy Control Group|Patients without foot ulcers being seen in the clinic.
89086595|NCT03931291|Experimental|Experimental arm: APR-246 + azacitidine|APR-246 and azacitidine maintenance therapy will continue for a maximum of 12 cycles
89086596|NCT03922724|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
89086597|NCT03922724|Experimental|2/IOC Arm|Immunosuppression Only Conditioning, plus allogeneic HCT with GVHD prophylaxis
89086598|NCT03922724|No Intervention|3/Donor Arm|Donors for Recipients in Arm 1, Arm 2, Arm 4, or Arm 5
89086599|NCT03922724|Experimental|4/mRIC Arm|modified Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
89086600|NCT03922724|Experimental|5/ATL-RIC Arm|modified Reduced Intensity Conditioning Arm for ATL patients, plus allogeneic HCT with GVHD prophylaxis
89523097|NCT03708419|Experimental|Suboptimal diet|Participants will follow a diet for a total duration of 12 weeks, suboptimal for their metabolic phenotype. For participants with liver insulin resistance (LIR) this will be a diet high in monounsaturated fatty acids, for participants with muscle insulin resistance (MIR) this will be a diet high in protein and fiber and low in fat.
89523098|NCT02938325||No intervention: General Anesthesia|"Thirty patients undergoing elective surgery under general anesthesia who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the surgery, patients will be questioned for awareness under anesthesia by Modified Brice Questionnaire.~There will be no intervention. Patients will be anesthetized with general anesthesia as they were supposed to be for their elective surgery. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
89086603|NCT03919773|Active Comparator|Treatment IVIG Arm|IVIG (Gammunex-C) infusion (0.4 gm/kg) every week for 4 weeks, then every 2 weeks for 8 weeks (12 weeks total).
89086604|NCT03919773|Placebo Comparator|Treatment Albumin Arm|albumin infusion (0.4 gm/kg) every week for 4 weeks then every 2 weeks for 8 weeks (12 weeks total) during
89086608|NCT03874026|Experimental|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
89086611|NCT03848299|Experimental|Experimental: Single Arm|All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.
89086612|NCT03835663||Patients with non erosive reflux|Patients with symptoms of reflux but no evidence of oesophagitis or Barretts oesophagus on endoscopy.
89086613|NCT03835663||Patients with erosive reflux|Patients with symptoms of reflux with evidence of oesophagitis or Barretts oesophagus on endoscopy.
89086614|NCT03835663||Patients with no reflux|Patients with healthy oesophago-gastric mucosa and no symptoms of reflux.
89086615|NCT03819153|Experimental|Semaglutide|Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
89086616|NCT03819153|Placebo Comparator|Placebo|Participants are to receive placebo (semglutide) for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
89086617|NCT03816163|Experimental|zolbetuximab +nab-paclitaxel + gemcitabine|Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
89086618|NCT03816163|Active Comparator|nab-paclitaxel + gemcitabine|Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
89086619|NCT03788837|Experimental|intravenous Ilomedin|a first dose of Ilomedin of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h
89086620|NCT03788837|Placebo Comparator|Intravenous Placebo|Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h
89086621|NCT03764540|Experimental|Cabazitaxel plus prednisone|"Cabazitaxel: Single-dose vial, containing a total of 60 mg of cabazitaxel expressed as anhydrous and solvent-free basis, per 1.5 mL of solution. Cabazitaxel will be administered by IV route Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).~Prednisone will be administered by oral route"
89086622|NCT03764540|Active Comparator|Docetaxel plus prednisone|"Docetaxel is formulated in polysorbate 80 and commercially available as 80 mg/2.0 mL single-dose vials with accompanying diluent (13% ethanol in water for injection) for IV use.~Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).~Prednisone will be administered by oral route"
89086623|NCT03754790|Experimental|Fitusiran|Participants will be administered fitusiran as a subcutaneous injection once monthly or every other month for up to 48 months post initiation of modified IMP dose/frequency or until fitusiran becomes commercially available, whichever comes first.
89086624|NCT03747484|Experimental|Treatment (TCR-T cells, avelumab or pembrolizumab)|Approximated 5-7 days prior to receiving FH-MCVA2TCR T-cells, patients receive interferon gamma administered at the FDA-approved dosing of 50mcg/m2, 3 times weekly for a total of 4 weeks. Patients receive FH-MCVA2TCR T-cells IV over 60-120 minutes. Beginning 14 days after receiving FH-MCVA2TCR T-cells, patients also receive standard of care avelumab IV over 1 hour every 2 weeks for 1 year or pembrolizumab IV over 30 minutes every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease may then receive an additional cycle of FH-MCVA2TCR T-cells.
89086625|NCT03747484|Experimental|Treatment 2 (TCR-T cells, avelumab or pembrolizumab)|Approximated 5-7 days prior to receiving FH-MCVA2TCR T-cells, patients receive interferon gamma administered at the FDA-approved dosing of 50mcg/m2, 3 times weekly for a total of 4 weeks. Patients receive FH-MCVA2TCR T-cells IV over 60-120 minutes. Beginning 14 days after receiving FH-MCVA2TCR T-cells, patients also receive standard of care avelumab IV over 1 hour every 2 weeks for 1 year or pembrolizumab IV over 30 minutes every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease may then receive an additional cycle of FH-MCVA2TCR T-cells.
89086626|NCT03740529|Experimental|Phase I Dose Escalation (Pirtobrutinib Monotherapy)|Dose Escalation and determination of MTD; multiple dose levels of pirtobrutinib to be evaluated
89086627|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 3|CLL/SLL patients with no prior therapy.
89086628|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 1|Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
89086629|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 4|CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
89086630|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 2|CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
89086631|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 5|WM patients treated with a prior BTK inhibitor-containing regimen.
89086632|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 6|MZL patients treated with a prior BTK inhibitor-containing regimen.
89226039|NCT04916002|Experimental|Vidutolimod and cemiplimab for CSCC (A2)|Participants who have progressed while receiving a programmed cell death protein 1 (PD-1)-blocking antibody or within 12 weeks of discontinuation of PD-1 blocking antibody for metastatic or locally and/or regionally advanced unresectable CSCC, will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89226040|NCT04916002|Experimental|Vidutolimod and cemiplimab for Merkel cell carcinoma (MCC) (B1)|Participants who have not received prior systemic therapy for metastatic or locally and/or regionally advanced unresectable MCC will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89226041|NCT04916002|Experimental|Vidutolimod and cemiplimab for MCC (B2)|Participants who have progressed while receiving a PD-1-blocking antibody or within 12 weeks of discontinuation of the PD-1 blocking antibody, will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89226042|NCT04916002|Experimental|Vidutolimod and cemiplimab for triple negative breast cancer (TNBC) (C1)|Participants who have not received prior therapy with immune checkpoint inhibitors (iCPIs) and who must have previously received treatment with sacituzumab govitecan (all advanced or metastatic TNBC participants), with trastuzumab deruxtecan [human epidermal growth factor receptor 2 (HER2)-low participants] and with adenosine diphosphate ribose polymerase (PARP) inhibitor [for BReast CAncer gene (BRCA)] for TNBC will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89226043|NCT04916002|Experimental|Vidutolimod and cemiplimab for TNBC (C2)|Participants who have previously received treatment with sacituzumab govitecan (all advanced or metastatic TNBC participants), with trastuzumab deruxtecan (HER2-low participants) and with PARP inhibitor (for BRCA) and who have progressed while receiving a PD-1-blocking antibody or within 12 weeks of discontinuation of a PD-1 blocking antibody for advanced or metastatic TNBC, will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89226044|NCT04916002|Experimental|Vidutolimod and cemiplimab for basal cell carcinoma (BCC) (D)|Participants who have not received prior hedgehog pathway inhibitor therapy, or prior anti-PD-1/programmed cell death ligand 1 (PD-L1) therapy and who do not wish to receive or who are not candidates for a hedgehog inhibitor, for metastatic or locally and/or regionally advanced unresectable BCC and will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89226045|NCT04916002|Experimental|Vidutolimod and cemiplimab for non-small cell lung cancer (NSCLC) (E)|"Participants with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%] based on a prior PD-L1 result as determined by College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA) (or equivalently licensed) lab, with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or ros oncogene 1 (ROS1) aberrations, and who have not received prior anti-PD-1/PD-L1 therapy and are amenable to IT therapy and do not wish to receive chemotherapy.~Note: this cohort is not conducted in Europe"
89226046|NCT04916002|Experimental|Vidutolimod and cemiplimab for recurrent/metastatic Oropharynx Squamous Cell Carcinoma (OPSCC) (F)|Participants with PD-L1 combined positive score (CPS) ≥ 1, based on a prior PD-L1 result and human papillomavirus (HPV)-positive disease based on a prior result, who have not received prior systemic therapy for recurrent/metastatic disease. Participants will receive vidutolimod IT and cemiplimab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
89226047|NCT04915924|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
89226048|NCT04914234|Active Comparator|Group A (n=30)|Atenolol group
89226049|NCT04914234|Active Comparator|Group M (n=30)|Metoprolol group
89086633|NCT03740529|Experimental|Phase 2 (Pirtobrutinib Monotherapy) Cohort 7|Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late phase studies of pirtobrutinib may be eligible to enroll in this cohort Diffuse large B-cell lymphoma (DLBCL) is excluded. MCL without prior BTK inhibitor treatment is excluded. Patients enrolling to Cohort 7 must have received one or more prior therapies or have no available approved therapy with demonstrated clinical benefit with the exception of untreated Richter's transformation, which is allowed.
89086634|NCT03740529|Experimental|Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm A|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax
89086635|NCT03740529|Experimental|Phase 1b Dose Expansion (Pirtobrutinib Combination Therapy) Arm B|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of pirtobrutinib in combination with venetoclax and rituximab
89086636|NCT03740529|Experimental|Phase 1 Dose Expansion (Pirtobrutinib Monotherapy)|Patients to receive the recommended Phase 2 dose of pirtobrutinib
89523099|NCT02938325||No intervention: Sedation|"Fourty patients undergoing elective cardiac catheterization under conscious sedation who will be monitored with standard ASA, BIS and EEG for comparisons. In recovery unit, at the end of the procedure, patients will be questioned for awareness under sedation by Modified Brice Questionnaire.~There will be no intervention. Patients will be anesthetized with sedation as they were supposed to be for their elective cardiac catheterization. The EEG during the anesthesia will be assessed afterwards, and patients will be asked about their memory from the surgery."
89086638|NCT03719755|Active Comparator|50% dextrose|Cystoscopic distention of 40 cc of 50% dextrose plus 300 cc of normal saline washout
89086639|NCT03719755|Placebo Comparator|Normal Saline|Cystoscopic distention media of normal saline.
89086640|NCT03716726|Experimental|Intervention-WE CARE|"The WE CARE SDoH Screening Survey will be given at all visits by the front desk staff to all parents of Sickle Cell Anemia patients who present to the pediatric hematology clinic. They will also be provided the Family Resource Book.~Clinical team members (i.e. medical assistants and providers) will be trained to review the WE CARE Social Determinants of Health survey at visits and to provide community resource information sheets to parents with needs. The completed surveys will be scanned into the electronic health record (EHR)."
89086641|NCT03716726|Experimental|Control-Standard of Care|Standard of care for pediatric patients with sickle cell anemia will be delivered.
89086642|NCT03711214|Active Comparator|pSS patients|We will evaluate 40 patients with pSS (EULAR/ACR Classification Criteria, 2016) of both sexes before and after periodontal disease treatment.
89086643|NCT03711214|Active Comparator|Healthy individuals|We will evaluate 40 healthy controls before and after periodontal disease treatment.
89086644|NCT03709680|Experimental|Phase 2 Arm A|Palbociclib in combination with irinotecan and temozolomide.
89086645|NCT03709680|Experimental|Phase 1|Palbociclib in combination with temozolomide and irinotecan and/or with topotecan and cyclophosphamide.
89086646|NCT03709680|Active Comparator|Phase 2 Arm B|Irinotecan and temozolomide alone.
89086647|NCT03709680|Experimental|Phase 1 Tumor specific cohort - Neuroblastoma|Palbociclib in combination with topotecan and cyclophosphamide.
89086648|NCT03699956|Experimental|Arm 1|"RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks~Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
89086649|NCT03699956|Active Comparator|Arm 2|"Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
89086650|NCT03681028|Other|Individualized therapy|Study treatment for a given patient will consist of a regimen chosen from agents implicated in critical molecular signaling pathways and/or from signature-based predictions of drug efficacy. All agents are listed in the current pharmacopoeia for human use, but will differ amongst individual subjects. The study treatment will consist of up to 4 FDA approved drugs that have known dosing. This study is not only looking at 4 drugs. It is selecting up to 4 drugs per patient but the drugs chosen can be any FDA-approved drug. Therefore, it is not possible to pre-specify the medications.
89086651|NCT03670615|Experimental|Exercise and tDCS|Patients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
89086652|NCT03670615|Other|Exercise Education and tDCS|Patients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
89086653|NCT03670615|Other|Exercise and Sham tDCS|Patients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
89086654|NCT03644667|Experimental|Tocilizumab + Standard of Care Triple IS|"Tocilizumab plus standard of care triple immunosuppression (IS). Heart transplant recipients will receive tocilizumab (Actemra®) plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~a calcineurin inhibitor (tacrolimus),~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
89086655|NCT03644667|Placebo Comparator|Placebo + Standard of Care Triple IS|"Placebo plus standard of care triple maintenance immunosuppression (IS). Heart transplant recipients will receive placebo plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~a calcineurin inhibitor (tacrolimus),~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
89086656|NCT03625037|Experimental|Epcoritamab|Epcoritamab will be administered by subcutaneous injections in cycles of 28 days.
89086657|NCT03620500||Children with Cochlear Implants|Children with sensory neural hearing loss who undergo cochlear implantation will be monitored to see if balance develops normally in this population
89086658|NCT03607266||Group I (Ibuprofen)|Ibuprofen Group will receive 800 mg iv ibuprofen in 100 cc of isotonic solution within 30 min before the procedure
89086659|NCT03607266||Group D (Dexketoprofen|Dexketoprofen Group will receive 50 mg iv dexketoprofen in addition to 100 cc of isotonic solution within 30 min before the procedure
89086660|NCT03607266||Placebo Group|will receive 100 cc of isotonic solution within 30 min before the procedure
89086661|NCT03547973|Experimental|Cohort 1: Sacituzumab Govitecan-hziy|Participants with urothelial cancer (UC) previously treated with platinum-based and/or checkpoint inhibitors (CPIs) will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle.
89086662|NCT03547973|Experimental|Cohort 2: Sacituzumab Govitecan-hziy|Participants with UC who are ineligible for platinum-based therapy and failed therapy with previous immune CPI therapy will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle.
89086663|NCT03547973|Experimental|Cohort 3: Sacituzumab Govitecan-hziy + Pembrolizumab|Participants who have had progression or recurrence of UC following a platinum-containing regimen in the metastatic setting, or progression or recurrence of UC within 12 months of completion of platinum-based therapy as neoadjuvant or adjuvant therapy will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle and pembrolizumab at the standard approved dose (200 mg) only on Day 1 of a 21-day cycle. Lower doses of sacituzumab govitecan-hziy may be tested based on dose-limiting toxicities (DLTs) observed to determine the Recommended Phase 2 Dose (RP2D) of sacituzumab govitecan-hziy in combination with pembrolizumab.
89086664|NCT03547973|Experimental|Cohort 4: Sacituzumab Govitecan-hziy + Cisplatin + Avelumab (Dose Escalation Phase)|Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles. Based on DLTs observed, two additional lower doses may be tested to determine RP2D of sacituzumab govitecan-hziy in combination with cisplatin. If premature termination of 1 agent occurs due to toxicity, the other agent may be continued to complete up to 6 cycles of therapy. For participants who have not progressed, maintenance therapy will begin with infusions of avelumab 800 mg every 2 weeks beginning on Cycle 1, Day 1 and every 2 weeks thereafter and sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days.
89086665|NCT03547973|Experimental|Cohort 4: Sacituzumab Govitecan-hziy + Cisplatin + Zimberelimab (Dose Expansion Phase)|Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles. If premature termination of 1 agent occurs due to toxicity, the other agent may be continued to complete up to 6 cycles of therapy. For participants who have not progressed, maintenance therapy will begin with infusions of sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days and zimberelimab 360 mg every 3 weeks (Day 1 of a 21-day cycle).
89086666|NCT03547973|Experimental|Cohort 5 (Arm 1): Sacituzumab Govitecan-hziy + ZIM|"Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle).~Upon completion of the safety lead-in, participants will receive SG 10 mg/kg IV on Days 1 and 8 of a 21-day cycle followed by ZIM 360 mg IV, Q3W (Day 1 of a 21-day cycle) until PD, unacceptable toxicity, or loss of clinical benefit. participants who must discontinue 1 agent may continue the other until PD, unacceptable toxicity, or loss of clinical benefit."
89086667|NCT03547973|Experimental|Cohort 5 (Arm 2): Avelumab|"Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle).~Upon completion of the safety lead-in, participants will be randomized to receive avelumab 800 mg IV Q2W until PD, unacceptable toxicity, or loss of clinical benefit."
89086668|NCT03547973|Experimental|Cohort 5 (Arm 3): ZIM|"Participants in Cohort 5 will have completed 4 to 6 cycles of gemcitabine (GEM) + cisplatin therapy without PD prior to study entry. The safety lead-in will be conducted, in 6 to 8 participants (treated with SG 10 mg/kg IV on Day 1 and Day 8 of a 21-day cycle + ZIM 360 mg IV every 3 weeks on a 21-day cycle).~Upon completion of the safety lead-in, participants will be randomized to receive ZIM 360 mg IV Q3W (Day 1 of a 21-day cycle) until PD, unacceptable toxicity, or loss of clinical benefit."
89086669|NCT03547973|Experimental|Cohort 6 (Arm 1): Sacituzumab Govitecan-hziy|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease. Treatment may be discontinued at any time, but participants will continue to be followed for tumor response until progression is documented, and alternate therapy is initiated. If participants discontinue therapy before evidence of radiologic progression, imaging should continue until radiologic progression is documented, if feasible.
89086670|NCT03547973|Experimental|Cohort 6 (Arm 2): Sacituzumab Govitecan-hziy + ZIM|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG in combination with ZIM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease. The standard approved dose of SG will be used in combination with ZIM. Treatment may be discontinued at any time, but participants will continue to be followed for tumor response until progression is documented or alternate therapy is initiated. If participants discontinue therapy before evidence of radiologic progression, imaging should continue until radiologic progression is documented, if feasible.
89086671|NCT03547973|Experimental|Cohort 6 (Arm 3): Sacituzumab Govitecan-hziy + ZIM + Domvanalimab|Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and SG in combination with ZIM and DOM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease.
89086672|NCT03547973|Experimental|Cohort 6 (Arm 4): Carboplatin + Gemcitabine|"Upon completion of the safety lead-in, participants in Cohort 6 will be randomized and CARBO in combination with GEM will be administered in cisplatin-ineligible participants who have never received therapy in the metastatic setting or for unresectable locally advanced disease.~Participants without disease progression as assessed by the investigator after completion of 4 to 6 cycles of therapy may continue with maintenance therapy (avelumab 800 mg every 2 weeks) until loss of clinical benefit."
89086673|NCT03541291|Experimental|SMART-SYNC LM03|All participants
89086674|NCT03539952|Active Comparator|Penicillamine arm|Patients randomized to penicillamine during the postrandomisation and 1st extension period
89086675|NCT03539952|Experimental|Trientine arm|Patients randomized to TETA 4HCl during the postrandomisation and 1st extension period
89086676|NCT03529019|Experimental|Nutritional Supplement|Administration of Ensure Surgery Immunonutrition Shake and ensure Enlive Advanced Nutrition Shake.
89086677|NCT03519048|Active Comparator|Conventional follow-up|clinical examination with nasofibroscopy every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter. Low Dose Chest CTscan every year in patients with tobacco consumption history of > 20 pack-year. Panendoscopy plus CT-scan are performed in case of clinical symptoms or abnormal clinical exam.
89086678|NCT03519048|Experimental|Intensive follow-up strategy|adding to the conventional follow-up strategy , an annual head&neck and thoracic injected CT-scan and Lugol upper gastrointestinal endoscopy (the first performed 12 months after inclusion), annual whole body PET-CT (the first at 6 months after inclusion). These 3 exams are performed every year during 3 years after inclusion (i.e. 3 CT-scan, 3 digestive endoscopies and 3 PET-CT per patient). Clinical follow up will be conducted as in the conventional follow up group and panendoscopy or bronchoscopy will be performed if needed. After 3 years, patients will be followed by conventional follow-up.
89086679|NCT03515460|Experimental|sugar oral load|oral ingestion of a high carbohydrate meal
89086680|NCT03515460|Experimental|fat oral load|oral ingestion of a high fat meal
89086681|NCT03515460|Experimental|sugar and fat oral loads|oral ingestion of a high carbohydrate and fat meal
89086682|NCT03504774|Experimental|Cashew or Shrimp Oral Immunotherapy|Participants, ages 7 to 55 years, inclusive, with an allergy to Cashew or Shrimp.
89086683|NCT03499249|Experimental|N-Acetylcysteine Treatment|Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
89086684|NCT03482297|Experimental|Automated Abdominal Binder|Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the automated abdominal binder combined with placebo pill t.i.d The automated abdominal binder will be placed during the morning orthostatic trial on the active/sham binder study day. The binder will inflate automatically (~40 mmHg) every time the participant stands up throughout the study day.
89086685|NCT03482297|Sham Comparator|Sham binder|Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the sham binder combined with placebo pill t.i.d. The sham binder will be placed during the morning orthostatic trial on the active/sham binder study day. The sham binder will inflate automatically (~5 mmHg) every time the participant stands up throughout the study day.
89086686|NCT03480776|Active Comparator|Acetylsalicylic Acid (ASA)|
89086687|NCT03480776|Sham Comparator|Placebo|
89086688|NCT03459846|Experimental|Arm 1: Durvalumab/Placebo|Durvalumab 1500 mg intravenous (IV) every 4 weeks (q4w) starting on week 1 day 1/Placebo orally (PO) twice a day (BID) starting on week 1 day 1.
89086689|NCT03459846|Experimental|Arm 2: Durvalumab/Olaparib|Durvalumab 1500 mg IV q4w starting on week 1 day 1/Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
89086690|NCT03455855|Experimental|treated with the Jetstream System|It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Jetstream System.
89086691|NCT03414021||Thyroid Diseases|SPECT-CT Scan
89086692|NCT03414021||Heart Diseases|SPECT-CT Scan
89086693|NCT03414021||Bone Diseases|SPECT-CT Scan
89086694|NCT03414021||Brain Diseases|SPECT-CT Scan
89086695|NCT03414021||Kidney Diseases|SPECT-CT Scan
89086696|NCT03412409|Experimental|RIC regimen|"Old patients or those have high comorbidity burden without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
89086697|NCT03405311|Active Comparator|Palpation|The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
89086698|NCT03405311|Experimental|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device.
89086699|NCT03404960|Experimental|Arm A|Niraparib + Nivolumab
89086700|NCT03404960|Experimental|Arm B|Niraparib + Ipilimumab
89086701|NCT03370614||IBS Group|Participants will complete initial baseline and follow up IBS evaluations and questionnaires. Pre and Post FDG-PET-MR scans will be conducted to evaluate changes at baseline and approximately 2 months after dietary and nutritional counseling.
89086702|NCT03370614||Healthy Control Group|Participants will complete initial baseline evaluations and questionnaires. Participants will also receive a FDG-PET-MR scan.
89086703|NCT03361033||Medulloblastoma|Participants who are survivors of pediatric medulloblastoma and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
89086704|NCT03361033||Other Brain Tumors|Participants who are survivors of other pediatric brain tumors (excluding medulloblastoma and craniopharyngioma), who have not been treated with craniospinal irradiation (CSI), and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
89086705|NCT03312556|Placebo Comparator|Placebo pill or patch or sham CPAP|Placebo pill or patch or sham CPAP
89086706|NCT03312556|Active Comparator|CPAP (continuous positive airway pressure)|Continuous positive airway pressure during the night
89086707|NCT03304678|Other|Treatment with sirolimus|Lymphangioleiomyomatosis (LAM) is a cystic lung disease characterized by proliferation of cells with mutations in the tuberous sclerosis complex (TSC) which leads to activation of the mTORC pathway.
89086709|NCT03290079|Experimental|Pembrolizumab & Lenvatinib treatment|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks, in addition to 20 mg Lenvatinib by mouth every day of each 3 week cycle. Estimated average length of treatment per participant: 4 months.
89086710|NCT03287362|Experimental|ST-arm|one-third of the patients is randomized to schema therapy
89086711|NCT03287362|Active Comparator|CBT-arm|one-third of the patients is randomized to cognitive behavioral therapy
89086712|NCT03287362|Placebo Comparator|IST-arm|one-third of the patients is randomized to individualized supportive therapy
89086713|NCT03286335|Experimental|Proton Radiation|"Radiation therapy will be delivered typically five (5) days per week on weekdays~Proton Radiation dose be determine by histology"
89086714|NCT03215511|Experimental|Cancer participants <12 years|A Rolling-6 dose escalation design will be used. The starting dose for participants age < 12 years will be 25% below the highest dose level cohort divided by 1.73 m^2 cleared by the Safety Review Committee (SRC) for subjects age 12 years and older.
89086715|NCT03215511|Experimental|Cancer participants ≥12 years|A 3+3 dose escalation design will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study, enrolling 3 to 6 participants per cohort with a starting dose level of 100 mg twice daily (BID).
89523100|NCT02938325||No Intervention - Awake Volunteers|EEG and BIS will be recorded in twenty volunteers, for 10 minutes, in supine position, while their eyes are closed. This recording will be utilized as for positive control for recall.
89086718|NCT03172858|Experimental|Intracervical Balloon Catheter Group|"The intracervical balloon catheter will be passed through the cervix either with a speculum exam or by a digital exam. Then the catheter balloon will be filled with 80 cc of sterile fluid. The catheter will be pulled to tension and taped to the patient's leg.~Patients will have the option to IV pain medication at the time of intracervical balloon placement. The intracervical balloon will remain in place for 6 hours unless it falls out spontaneously. At the 6 hour mark, a vaginal exam will assess if the intracervical balloon has pulled through the cervix or if it needs further tension. The intracervical balloon will remain in place a maximum of 12 hours. After a maximum of 12 hours in place the intracervical balloon will be removed and oxytocin will be started per protocol."
89523101|NCT02922881|Experimental|Ulcerative Colitis Diet|Participants will receive a structured 12-week diet with a step down phase.
89523102|NCT03702257|Other|Bronchial fibroscopy|Bronchial fibroscopy with trans-bronchial biopsies
89086719|NCT03172858|Active Comparator|Immediate low-dose oxytocin infusion group|At our institution the policy for oxytocin infusion is to start at a low dose of 2mu/min and to increase by 2mu/min at 15 to 20 minute intervals based on how often uterine contractions are occuring. A specific order from a physician is required to increase the oxytocin dose above 20 mu/min. Oxytocin will be titrated per usual protocol.
89086720|NCT03136835|Experimental|Pilot|Maternal Hyperoxygenation (4L/min via nasal prongs)
89086721|NCT03125902|Placebo Comparator|Placebo and Paclitaxel|Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
89086722|NCT03125902|Experimental|Atezolizumab and Paclitaxel|Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
89086723|NCT03124355|Experimental|Placebo pill with vagal/sham stimulation|Patients will receive a single oral dose of placebo sugar pill, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
89086724|NCT03124355|Experimental|Pyridostigmine with vagal/sham stimulation|Patients will receive a single oral dose of pyridostigmine pill 30 mg, and 1.5-2 hours later they will have two tilt table tests: one with vagal stimulation and one with sham vagal stimulation
89086725|NCT03124355|Experimental|Galantamine with vagal/sham stimulation|Patients will receive a single oral dose of galantamine pill 8 mg, and 1.5-2 hours later they will have two tilt table tests:one with vagal stimulation and one with sham vagal stimulation
89086726|NCT03064126|Experimental|RANGER™ Paclitaxel Coated Balloon|"RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure.~Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon."
89086727|NCT03064126|Active Comparator|Standard Balloon Angioplasty|Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.
89086728|NCT03053687|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
89086729|NCT03053687|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
89086730|NCT03042988|Experimental|Heat Stress|Passive heat-stress using a commercial heating pad applied on the trunk
89086731|NCT03042988|Sham Comparator|Control (Non-heating)|Commercial heating pad applied on the trunk but turned off
89086732|NCT03032601|Active Comparator|N-acetyl Cysteine Cohort|Intravenous N-acetyl Cysteine - 50mg in 200ml of D5W over one hour 1 x per week Oral N-acetyl Cysteine - 1 500mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
89086733|NCT03032601|No Intervention|Control Cohort|Standard of Care Treatment
89086734|NCT03028311|Other|Treatment (angiography, yttrium Y-90 radioembolization)|"The first 2 patients enrolled receive standard of care diagnostic and treatment during 2 visits for approximately 6 hours each within 2-4 weeks. During the first visit, patients undergo diagnostic angiography with embolization of potential hepatoenteric collaterals, receive technetium Tc-99m albumin aggregated as a surrogate to the therapy microspheres via catheter, and undergo planar imaging. During the second visit, patients undergo a second angiography and receive yttrium Y 90 resin microspheres via arterial microcatheter. Patients then undergo single-photon emission computed tomography-computed tomography (SPECT-CT) Bremsstrahlung imaging.~All subsequent patients enrolled undergo the same previously described diagnostic and treatment during 1 visit over about 8 hours."
89086735|NCT02944682|Experimental|Liquefied petroleum gas cookstove|Participants randomized to the experimental arm will receive a liquefied petroleum gas (LPG) cookstove and 18-month supply of LPG.
89523103|NCT02520245|Experimental|Open-Label|
89523104|NCT02864303|Other|Patients with Alzheimer disease|Saliva samples were collected on this patients
89523105|NCT03390023||Hispanic Women|Hispanic women who have been pregnant within the past 5 years.
89086736|NCT02944682|No Intervention|Control|Participants in the control group will not receive a liquefied petroleum gas (LPG) stove and will continue using traditional cooking methods (open fire or traditional stoves), or the cooking method of their choice. Control households will receive compensation based on a uniform set of trial-wide principles, customized to each site based on formative research.
89086737|NCT02941263||Affected Participants|Participants with unilateral or bilateral GA associated with atrophic AMD.
89086738|NCT02929589|Experimental|Opioid naïve patients-Group A|"Group A: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.~."
89086739|NCT02929589|Experimental|Non-Opioid naïve patients-Group C|Group C: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, in addition to their preferred opioid medication prescription.
89086740|NCT02929589|Placebo Comparator|Opioid naïve patients-Group B|Group B:Subjects will be prescribed 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
89086741|NCT02929589|Experimental|Non-Opioid naïve patients-Group D|Group D: Subjects will be prescribed or advised to continue to take only their preferred current oral opioid prescription (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, or transdermal fentanyl).
89086742|NCT02897063|Experimental|Droxidopa and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
89086743|NCT02897063|Experimental|Midodrine and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.
89086744|NCT02874677|No Intervention|Control|Routine activities
89086745|NCT02874677|Experimental|Experimental|Effort reeducation program : 3 sessions of 20 minutes per week during 6 weeks
89086746|NCT02870738|Active Comparator|Pelvic Floor Physical Therapy|One hour of pelvic floor physical therapy twice weekly for 8 weeks
89086747|NCT02870738|Active Comparator|Bladder Instillations|Bladder instillation of lidocaine, kenalog, heparin sulphate, and bicarbonate twice weekly for 8 weeks
89086748|NCT02819037|Experimental|Gas chromatography and stool analysis|gas chromatography and stool analysis for detection of malabsorption
89086749|NCT02811679|Experimental|Blinatumomab|Blinatumomab will be administered as a continuous IV infusion through a central venous catheter for a 42 day cycle. Blinatumomab will start with a 7 day infusion at 9mcg/d. If no dose limiting toxicity (table 6.1) after 7 days, the dose will be escalated to 28 mcg/d for 7 additional days. If no dose limiting toxicity (table 6.1) after 14 days, blinatumomab will be infused at a target dose of at 112mcg/d for 28 days. Subjects will be restaged after a 6 week treatment free period by PET CT. All subjects without disease progression will receive an additional 4 week cycle starting at the target dose of 112 mcg/d.
89086750|NCT02807480|Experimental|Exposure-based therapy|Participants will complete 10, 90-minute sessions of Exposure-based therapy, conducted using a group format. Each group will include 8-12 participants. Exposure-based therapy seeks to increase abilities to manage anxiety through repeated practice in facing the situations or thoughts that are the focus of worry or fear. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
89523106|NCT03390023||Close Family Member|Close family member of participants in Group 1 - Hispanic Women.
89086751|NCT02807480|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen negative mood. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
89086752|NCT02759835|Experimental|Tyrosine Kinase Inhibitor Naïve Epidermal Growth Factor Receptor *mutated Non Small Cell Lung Cancer|"Cohort 1 - Osimertinib followed by LAT followed by osimertinib. Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for participants without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.~*including germline T790M mutation"
89086753|NCT02759835|Experimental|EGFR mutated NSCLC Progressed on prior 1st/2nd Generation EGFR TKI therapy &acquired T790M Mutation|Cohort 2 - Osimertinib followed by LAT followed by osimertinib. Participants may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, or radiofrequency ablation.
89086754|NCT02759835|Experimental|Epidermal Growth Factor Receptor mutated Non Small Cell Lung Cancer Progressed on Osimertinib|Cohort 3 - LAT followed by Osimertinib. Participants may undergo 1 of 3 local ablative procedures after initial progression on Osimertinib: surgery, radiotherapy, radiofrequency ablation. The starting dose of Osimertinib will be 80 mg per day for participants without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline. Single daily dose of Osimertinib until progression.
89086755|NCT02738645||pneumonia in RICU|The patients admit in RICU because of pneumonia.
89086756|NCT02725060|Experimental|Autonomic and Antibody Assessments|"On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case:~Posture study with blood samples for autoantibody testing~24-hour heart rhythm and blood pressure monitoring~autonomic function tests~Quantitative Axonal Sudomotor Reflex Testing~Total blood volume assessment~Pharmacologic testing with phenylephrine~Pharmacologic testing with isoproterenol~Cardiac output with rebreathing~Assessment of splanchnic capacitance~Microneurography"
89086757|NCT02693990|Experimental|Grade II (Atypical) Meningiomas, STR|Patient will be treated at the starting dose of Intensity Modulated Proton Therapy (IMPT) which is pre-determined.
89086758|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, GTR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
89086759|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, STR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
89086760|NCT02689466||cervical dystonia|clinically documented cervical dystonia (focal cervical or segmental with neck involvement) established by history and physical/neurological examination, at least 18 years old.
89086761|NCT02689466||healthy volunteers|age and sex matched healthy volunteers, at least 18 years old.
89086762|NCT02673333|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
89086763|NCT02669160|Experimental|Experimental|Group of communicating CP children receiving a 30 minutes daily session of verticalization with a motorized orthosis reproducing walking movement (PS Innowalk)
89086764|NCT02669160|Other|Control|Group of communicating CP children receiving a 30 minutes daily session of verticalization with their conventional passive stander.
89086765|NCT02650804|Experimental|BPM31510 plus gemcitabine|"BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.~Cycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21."
89086766|NCT02633943||Subjects with Transfusion-Dependent β-Thalassemia|Subjects treated with ex vivo gene therapy product in an applicable bluebird bio-sponsored clinical trial who agree to participate in this long-term follow-up study
89523107|NCT03385889|Experimental|Cervical Spine Mobilization Group|Subjects with cervicogenic headache who will be assigned to cervical spine mobilization group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
89086767|NCT02595762||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
89086768|NCT02567136||Amyotrophic Lateral Sclerosis|Patients with ALS
89086769|NCT02567136||Healthy Controls|Healthy control volunteers
89086770|NCT02545868|Experimental|Group A: OCR + Vaccines|Participants will receive dual infusion of OCR 300 milligrams (mg) on Day 1 and then on Day 15, and then participants will further receive immunization course (TT-containing adsorbed vaccine, 23-PPV either unboosted or boosted with 13-PCV, influenza vaccine, and repeated administration with KLH) at 12 weeks post-OCR treatment until Week 24. Participants who complete the 24-week immunization study period will have the option for retreatment with a single infusion of 600 mg OCR on Day 169 and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
89086771|NCT02545868|Other|Group B: Vaccines (Optional OCR in Extension)|Participants will receive immunizations (TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH) on Day 1 until Week 12 of the immunization period.
89086772|NCT02538991|Experimental|Bulkamid|
89086773|NCT02538991|Active Comparator|Tension-free Vaginal Tape|
89086774|NCT02517125|Experimental|Patients with head and neck cancer|
89086775|NCT02465268|Experimental|pp65-shLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
89086776|NCT02465268|Experimental|pp65-flLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
89086777|NCT02465268|Placebo Comparator|unpulsed PBMC and Saline|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
89086778|NCT02450851||Undiagnosed disorders|Patients with rare, undiagnosed disorders.
89086779|NCT02429557|Experimental|Abdominal compression and placebo pill|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
89086780|NCT02429557|Sham Comparator|Sham abdominal compression and placebo|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
89086781|NCT02429557|Experimental|Abdominal compression and midodrine|Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and midodrine 2.5-10 mg PO given 1 hour before the second head up tilt
89086782|NCT02429557|Active Comparator|Sham abdominal compression and midodrine|Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and midodrine 2.5-10mg PO given 1 hour before the second head up tilt
89086783|NCT02423057|Experimental|1|TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
89086784|NCT02397200|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
89086785|NCT02397200|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals.
89086786|NCT02322840|Experimental|Transcatheter Mitral Valve Replacement (TMVR) Implant|Twelve TMVR Implant
89086787|NCT02273362|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 7 days (depending on the date of surgery, treatment range may be 5-14 days).
89086788|NCT02232399|Active Comparator|Milrinone|In this arm the patients will receive Milrinone as an inotrope agent. Concentration: 0.2 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.4 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 48 μg / kg
89086789|NCT02232399|Experimental|Levosimendan|In this arm the patients will receive Levosimendan as an inotrope agent. Concentration: 0.05 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.1 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 12 μg/kg
89086790|NCT02171884||Group E1|Singletons born following ART via IVF/ICSI (short culture)
89086791|NCT02171884||Group EC1|Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo
89086792|NCT02171884||Group T1|Singletons conceived naturally
89086793|NCT02171884||Group E2|Singletons born following ART with IVF/ICSI (prolonged culture)
89086794|NCT02141074|Experimental|50 EDs (exposure days)|
89086795|NCT02043964|Experimental|tears and cerebro-spinal fluid sampling|
89523108|NCT03385889|Experimental|Cervical Spine Manipulation Group|Subjects with cervicogenic headache who will be assigned to cervical spine manipulation group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
89523109|NCT03385889|No Intervention|Control Group|No intervention. Subjects in this groups will wait for 5 minutes between pre- and post-testing of dependent variables.
89086798|NCT01962948|Experimental|Phase 1: 100 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
89086799|NCT01962948|Experimental|Phase I: 125 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
89086800|NCT01962948|Experimental|Phase I: 150 mg/m2 ganetespib, 80 mg/m2 paclitaxel|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2.
89523110|NCT03389945|Active Comparator|25G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 25 gauge spinal needle.
89523111|NCT03389945|Experimental|27G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 27 gauge spinal needle.
89523112|NCT03385811||Medical Professionals|no intervention, only questionnaire survey
89523113|NCT03385733|Experimental|Inspiratory muscle training group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with %30 MIP at home.
89523114|NCT03385733|No Intervention|control group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with 9 cmH2O pressure at home.
89523115|NCT03537833||"PPI-positive or test group"|Patients treated with PPI
89523116|NCT03537833||"PPI-negative or control group"|Patients not treated with PPI
89086801|NCT01962948|Experimental|Phase II: MTD/MED of ganetespib, 80 mg/m2 paclitaxel|Paclitaxel IV given over 1 hour at 80 mg/m2 days 1, 8 and 15 of a 28-day cycle. PLUS ganetespib IV at MTD/MED from Phase I on days 1, 8 and 15 of a 28-day cycle.
89086802|NCT01950624||Down syndrome cohort|Individuals who have a diagnosis of complete trisomy 21, translocation down syndrome and Mosaic Down syndrome
89086803|NCT01897571|Experimental|Phase 1|Patients in the Phase 1 portion of the study.
89086804|NCT01897571|Experimental|Phase 2 Group 1: Tazemetostat in R/R FL with Mutant EZH2|Patients with R/R FL with mutant EZH2 treated with tazemetostat as a single agent in Phase 2 of the study.
89086805|NCT01897571|Experimental|Phase 2 Group 2: Tazemetostat in R/R FL with Wild-Type EZH2|Patients with R/R FL with wild-type EZH2 treated with tazemetostat as a single agent in Phase 2 of the study.
89086806|NCT01897571|Experimental|Phase 2 Group 3: Tazemetostat in R/R DLBCL|Patients with R/R DLBCL treated with tazemetostat as a single agent or tazemetostat in combination with prednisolone in Phase 2 of the study.
89086807|NCT01853826|Experimental|afatinib|Patients will receive afatinib once daily
89086808|NCT01732523||No treatment|No intervention
89086809|NCT01623167|Experimental|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 6
89086810|NCT01623167|Experimental|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 3
89086811|NCT01623167|Experimental|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18months, and receive eltrombopag day 1 to month 6
89086812|NCT01623167|Experimental|Extrension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
89086813|NCT01578109|Experimental|Treatment (sorafenib tosylate and transplant)|Patients receive sorafenib tosylate PO BID beginning at least 30 days after completion of induction therapy and/or transplant and no more than 120 days after transplant continuing for up to 2 years after transplant in the absence of disease progression or unacceptable toxicity.
89086814|NCT01559935|Experimental|Car-BiRD Therapy|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
89523117|NCT03439085|Experimental|Treatment (INO-3112, durvalumab)|Patients receive DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 IM and via electroporation at 1, 3, 7, and 12 weeks and durvalumab IV at 4, 8, and 12 weeks. Starting week 12, cycles repeat every 8 weeks for DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and every 4 weeks for up to 13 doses of durvalumab in the absence of disease progression or unacceptable toxicity.
89523118|NCT03389867|Experimental|Male Sexual Health Formulation|Kaempferia parviflora extract 100mg daily
89086818|NCT01196702||CVID|Patients with common variable immunodeficiency
89086819|NCT01196702||CVID and granulomatous disease|Patients with CVID complicated with granulomatous inflammation
89086820|NCT01196702||CVID and bronchiectasis|Patients with CVID complicated by bronchiectasis
89086821|NCT01196702||Control on Immunoglobulin|Patients on immunoglobulin long-term who do not have an immunodeficiency
89086822|NCT01196702||Control bronchiectasis|Controls with bronchiectasis not caused by a known immunodeficiency
89086823|NCT01196702||Control with granulomatous disease|Control patients with Crohn's Disease as this is a disease that causes granulomatous inflammation.
89086824|NCT01196702||Healthy Controls|
89086825|NCT01081262|Experimental|Arm I (carboplatin and paclitaxel)|Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
89086826|NCT01081262|Experimental|Arm II (oxaliplatin and capecitabine)|Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
89086827|NCT01081262|Experimental|Arm III (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
89086828|NCT01081262|Experimental|Arm IV (oxaliplatin, capecitabine, bevacizumab)|Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.
89086829|NCT01071941|Experimental|Group 1|The first subjects will receive a single infusion of rRp450. Subsequent subjects will receive rRp450 as four doses administered every 1-2 weeks.
89086830|NCT00889733|Experimental|IP Cisplatin|Patients with epithelial ovarian cancer who have undergone optimal debulking surgery receive IP Cisplatin with IV Paclitaxel.
89086835|NCT00740870|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
89086836|NCT00701909|Active Comparator|Morphine plus Ketamine, then Morphine plus Saline (placebo)|During the first wound care procedure, patients received morphine 0.05 mg/kg (a maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK). Then, during the second wound care procedure, patients received morphine 0.1 mg/kg (a maximum dose of 8 mg) plus saline (MS).
89086837|NCT00701909|Placebo Comparator|Morphine plus Saline (placebo), then Morphine plus Ketamine|During the first wound care procedure, patients received morphine 0.1 mg/kg (a maximum dose of 8 mg) plus saline (MS). Then, during the second wound care procedure, patients received morphine 0.05 mg/kg (a maximum dose of 4mg) plus ketamine 0.25 mg/kg (MK)
89086842|NCT00381680|Active Comparator|Regimen A: Standard vincristine dosing|See detailed description.
89086843|NCT00381680|Experimental|Arm B: Randomized High Dose Vincristine regimen|See detailed description. Closed to accrual as of 09/2010).
89086844|NCT00342732||non-diabetic volunteers|non-diabetic volunteers aged 18-65 who are healthy as determined by medical history, physical examination, and laboratory tests
89086845|NCT00018057|Experimental|Active|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the control invention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
89086846|NCT00018057|Placebo Comparator|Control|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the control invention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
89111029|NCT02796729|Experimental|dynamic glucose enhanced MRI after D-glucose injection|"IV catheter preparation: Catheter will be placed in one arm. Fasting glucose levels measured with a glucometer using a 1-2 mL sample of blood. Only participants with normal fasting blood glucose levels (70-125 mg/dL) will proceed with the study. First IV catheter will monitor blood glucose every 10 min after bolus injection until it returns to normal. Second IV catheter is placed on the opposite arm for glucose infusion and GBCA (gadobutrol) infusion.~Glucose infusion protocol: Occurs when the participant is in the MRI. Bolus injection of hospital grade 25g of 50% dextrose solution over 1 min is to increase blood glucose concentrations to about 3-4 times the normal level. Blood glucose levels should return to normal levels within 30 to 60 min.~GBCA infusion protocol: Occurs when the participant is in the MRI; approximately 20 min after glucose infusion. Standard intravenous bolus injection of 0.1mM/kg of gadobutrol (Gadovist) at an injection rate of 5 mL/sec."
89111030|NCT00760747|Experimental|Slow Switching Group|Slow Switching Group (switch from full stimulant dose to atomoxetine, 1.2 mg/kg/day, orally (PO), during 10 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
89111031|NCT00760747|Experimental|Fast Switching Group|Fast Switching Group (switch from full stimulant dose to atomoxetine 1.2 mg/kg/day, PO, during 2 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
89111032|NCT02802891||Recruitment group|"Group of individuals (aged 6 to 18 years old) recruited for the JOIN project. Consent was obtained from legal guardians for individuals under 18.~Exclusion criteria:~Individuals who refused to partake in the clinical assessment, despite the legal guardians consent.~Individuals who provided an insufficient amount of sample (ex: low volume of EBC)"
89111033|NCT02802579|Active Comparator|A: standard protocol|Standard dual-source computed tomography coronary angiography protocol
89111034|NCT02802579|Experimental|B: enhanced protocol|enhanced dual-source computed tomography coronary angiography protocol
89111035|NCT02802579|Experimental|C: enhanced obesity protocol|enhanced obesity-mode dual-source computed tomography coronary angiography protocol
89111036|NCT02794467|Experimental|Epelsiban 75 mg|Approximately 24 subjects will receive 75 mg of epelsiban three times a day (TID) via oral administration
89111037|NCT02794467|Experimental|Epelsiban 200 mg|Approximately 24 subjects will receive 200 mg of epelsiban TID via oral administration
89086847|NCT00925600|Placebo Comparator|Placebo|Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
89086848|NCT00925600|Experimental|Denosumab|Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.
89086849|NCT02666287|Experimental|Sequence 1|"Each subject will receive all the 9 treatment regimens in the following order: A,G/B/F/C,H/E/D,I with a washout period of 7 days between each treatment period administered via the ELLIPTA inhaler. Where Treatment A= BAT/FF 900/300 microgram (mcg) (3 inhalations of 300/100 mcg).~Treatment B= BAT 900 mcg (3 inhalations of 300 mcg) concurrently with FF (lactose) 300 mcg (3 inhalations of 100 mcg) from separate inhalers.~Treatment C= BAT 900 mcg (3 inhalations of 300 mcg). Treatment D= FF (lactose) 300 mcg (3 inhalations of 100 mcg). Treatment E= FF (magnesium stearate [MgSt]) 300 mcg (3 inhalations of 100 mcg). Treatment F= FF/VI 300/75 mcg (3 inhalations of 100 mcg/25 mcg). Treatment G= 7-day repeat doses: BAT/FF 300/100 mcg (1 inhalation). Treatment H= 7-day repeat doses: BAT 300 mcg (1 inhalation). Treatment I= 7-day repeat doses: FF (lactose) 100 mcg (1 inhalation)."
89086850|NCT02666287|Experimental|Sequence 2|Each subject will receive all the 9 treatment regimens in the following order: B/C,H/A,G/D,I/F/E with a washout period of 7 days between each treatment period.
89086851|NCT02666287|Experimental|Sequence 3|Each subject will receive all the 9 treatment regimens in the following order: C,H/D,I/B/E/A,G/F with a washout period of 7 days between each treatment period.
89086852|NCT02666287|Experimental|Sequence 4|Each subject will receive all the 9 treatment regimens in the following order: D,I/E/C,H/F/B/A,G with a washout period of 7 days between each treatment period.
89086853|NCT02666287|Experimental|Sequence 5|Each subject will receive all the 9 treatment regimens in the following order: E/F/D,I/A,G/C,H/B with a washout period of 7 days between each treatment period.
89086854|NCT02666287|Experimental|Sequence 6|Each subject will receive all the 9 treatment regimens in the following order: F/A,G/E/B/D,I/C,H with a washout period of 7 days between each treatment period.
89086855|NCT02668861|Experimental|Vitamin D+Budesonide Nasal Spray|Vitamin D 4000IU/day for 8 weeks + Budesonide Nasal Spray 128ug/d for 8 week
89086856|NCT02668861|Placebo Comparator|placebo+Budesonide Nasal Spray|Placebo for 8 weeks + Budesonide Nasal Spray128ug/d for 8 week
89086857|NCT05330650|Active Comparator|Triclosan coated suture|
89086858|NCT05330650|Active Comparator|Non coated suture|
89086859|NCT02668705|No Intervention|Human RA|A sham research informed consent form will be explained by a research assistant
89086860|NCT02668705|Experimental|ECA|A sham research informed consent form will be explained by an ECA (embodied conversational agent as presented on a touch screen computer)
89086861|NCT02668705|Experimental|ECA + Human RA|A sham research informed consent form will be explained by an ECA and then questions will be answered by a research assistant
89086862|NCT04255888|Active Comparator|Thick periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
89086863|NCT04255888|Active Comparator|Thin periodontal phenotype|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
89086864|NCT00968253|Experimental|Phase I: RAD001 + Combination Chemo|"Optimal dose finding of Everolimus (RAD001) beginning dose 5 mg + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Cytarabine (Ara-C) during Cycles 2, 4, 6, & 8.~First chemotherapy combination Hyper-CVAD = Cyclophosphamide, Vincristine, Adriamycin (doxorubicin), and Dexamethasone; Second chemotherapy combination Methotrexate and Ara-C."
89086865|NCT00968253|Experimental|Phase II: MTD RAD001 + Combination Chemo|MTD dose of Everolimus + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Ara-C during Cycles 2, 4, 6, & 8.
89086866|NCT04258540|Experimental|Intervention group|The intervention group received a yoga course for 12 weeks, two times a week. Each yoga class was 1.25 hr in duration.
89086867|NCT04258540|Active Comparator|Control group waitlist|The control group were on a waitlist during the period of measurements, and received the same yoga course after all measurements had been completed.
89086868|NCT00646009|Experimental|1|budesonide/formoterol
89086869|NCT00646009|Active Comparator|2|fluticasone/salmeterol
89086870|NCT00646009|Active Comparator|3|albuterol
89086871|NCT00646087|Experimental|Ketamine (6K)|6K: 6 ketamine injections (0.5 mg/kg of ketamine) every other day for 12 days
89086872|NCT00646087|Active Comparator|Ketamine/Placebo (2K4P)|2K4P = two active ketamine injections(2K) and four placebo (saline) injections over 12 days.
89086873|NCT04255576|Experimental|Experimental: JMT103|Eligible subjects will receive JMT103 at a dose of 2 mg/kg SC Q4W with a loading dose of 2 mg/kg SC on study days 8 and 15.
89086874|NCT02668315|Experimental|Cohort 1|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 1.0-4.9 x 10E5/kg and TNC superior or equal to 2.0 x 10E7/kg
89086875|NCT02668315|Experimental|Cohort 2|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.5-4.9 x 10E5/kg and TNC superior or equal to 1.5 x 10E7/kg
89086876|NCT02668315|Experimental|Cohort 3|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.25-4.9 x 10E5/kg and TNC superior or equal to 1.25 x 10E7/kg
89086877|NCT05309434|Experimental|Study group with standing coach|The team performs the simulated CPR with the coach standing next to the defibrillator
89086878|NCT05309434|Experimental|study group with mobile coach|The team performs the simulated CPR with the coach free to move around the simulation room
89086879|NCT05309434|No Intervention|control group without coach|The team performs the simulated CPR without the coach
89086880|NCT04175197||Study Cohort|Subjects with symptoms of intermittent claudication and/or critical limb ischemia (Rutherford Class 2-3-4-5-6) with angiographic evidence of femoropopliteal-below-the-knee arterial occlusion or stenosis
89086881|NCT02862405||Patients with loss of central vision|Patients coming in ophthalmic consultation will be selected for the study. The diagnosis of this disease is based on clinical examination, and imaging of the retina.Patients with only loss of central vision will be selected.
89086882|NCT02862405||Patients with loss of peripheral vision|Patients coming in ophthalmic consultation will be selected for the study. Patients with loss of peripheral vision will be selected on the bases of presence of tunnel vision.
89086883|NCT02862405||Control group|Patients without loss of vision.
89086884|NCT04258696|Active Comparator|Gingival retraction by ultrapak retraction cord|
89086885|NCT04258696|Experimental|Gingival retraction by diode laser|
89086886|NCT05180565|Experimental|Colovac|Patients receive Colovac device during colorectal surgery
89086887|NCT04255498|Experimental|Etanercept|50 MG/ML Prefilled Syringe (once a week for 4 weeks)
89086888|NCT04255498|Experimental|Mifepristone|(300 mg once a day for 7 days) will follow the etanercept.
89086889|NCT00645775|Placebo Comparator|1|Compare active to placebo
89086890|NCT04255264||Study patients|Obese subjects scheduled to undergo abdominoplasty surgery are included. These are later classified according to metabolic status.
89086891|NCT04258384||Patient|The study included individuals whose native language is Turkish, who are literate, over the age of 18, diagnosed with rheumatoid arthritis, without cognitive impairment and communication problems, and who want to participate in the study.
89086892|NCT00964743|Experimental|Intrathecal DepoCyt and Oral Sorafenib|This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
89086893|NCT04992871||Patient population|Children, adolescents and adults diagnosed with cerebral palsy who are born, treated or living in Switzerland
89086894|NCT04258774|Active Comparator|Healthy Adults|
89086895|NCT04258774|Active Comparator|Adults diagnosed with vascular pathology of the brain|
89086896|NCT02537041|Other|healthy volunteers|to obtain normal values diastolic myocardial stiffness references. The objective will be to confirm the increase with age in myocardial stiffness assessed by elastography in healthy subjects.
89086897|NCT02537041|Other|diastolic Heart Failure|older patients with isolated diastolic HF (EF> 45%, 60-80 years, n = 20) and infiltrative cardiomyopathy restrictive-type amyloidosis (n = 20) . The objective will be to study the results of elastography on two separate clinical types of IC diastolic well identified.
89111038|NCT02794467|Placebo Comparator|Placebo|Approximately 24 subjects will receive a matching placebo TID via oral administration
89111039|NCT02796417|Experimental|Rehacop group|Cognitive rehabilitation
89111040|NCT02796417|Active Comparator|Control group|Occupational activities
89111041|NCT02796495|Experimental|Operation of hand prosthesis with direct nerve stimulation|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in one or two amputees:~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~TIME-4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~Sensorized Hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~Prosthetics sensorized hand for amputees DLR/HIT Hand II (Wessling Robotics)~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand~The EPIONE Psychophysical Testing Platform software for stimulator control"
89111042|NCT00760669||Participants Receiving Infiximab|Participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA) receiving infliximab injection will be observed.
89111043|NCT02802267|Experimental|inecalcitol|Two tablets of Inecalcitol 2mg each (total 4mg) taken orally every other day.
89111044|NCT02802267|Placebo Comparator|placebo|Two tablets of placebo 2mg each (total 4mg) taken orally every other day
89111045|NCT02794623|Experimental|Cochlear Implant Recipients|
89111046|NCT04235049|No Intervention|In prison treatment arm|Of patients who achieved SVR, 100 inmates will be enrolled for long-term monitoring for re-infection after they have completed treatment. Patients will be seen every 6 months to test for reinfection, however they will not be subject to any medical or behavioral interventions through the study team. Limited opioid agonist therapy may be available as per the standard practice of the DOC, however syringe exchange and other harm reduction services will not be accessible to inmates, per DOC policy.
89111047|NCT04235049|Active Comparator|Community Linkage - Rapid Initiation Arm|The rapid initiation group will receive HCV medication immediately upon release from prison/jail.
89111048|NCT04235049|Active Comparator|Community Linkage - Clinic-Based Initiation Arm|The group will receive medication after attending first ANCHOR clinic visit.
89111049|NCT04235049|No Intervention|In prison - Retrospective Review|a retrospective review of de-identified available data provided by the DOC for all patients previously treated with DAAs through standard of care in the DOC will be reviewed for rates of SVR.
89111050|NCT02802189|Experimental|exercise and INIT group|The first group (experimental) followed the exersice programme in combination with the integrated neuromuscular inhibition technique (INIT).
89111051|NCT02802189|Active Comparator|exercise group|"The protocol for this group was identical to the previous group with the sole difference that the application of INIT was not included.~At the end of the exercise programme, relaxing breathing exercise and gentle stretching was applied for 15 min"
89111052|NCT02796339|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at the dosage of 2.8g daily. Patients with active disease will be administered with supplements for 3 months, whereas patients in remission will be administered with supplements for 6 months.
89111053|NCT02796339|Placebo Comparator|Placebo|This arm of patients will receive placebo . Patients with active disease will be administered with placebo for 3 months, whereas patients in remission will be administered with placebo for 6 months.
89111054|NCT02796183|Other|Diabetic macular edema|Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
89111055|NCT02796105|Experimental|Progevera|Progevera 10 mg
89111056|NCT02796105|Active Comparator|Orgalutran|Orgalutran 0.25 mg
89111057|NCT02794701||people with silicosis|
89111058|NCT02794545|Experimental|Recent infection patient|The patient who infected with HIV-1 and screened out by P24 ELISA, and they would receives early cART course.
89111059|NCT02795949|Experimental|Antipseudomonal beta-lactam antibiotic|"Ampicillin 2g IV/6h~Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h~Cefuroxime 750-1000 mg IV/8h~Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h~Amoxicillin/clavulanate 1000/125 mg IV/8h~Ciprofloxacin 400 mg IV/12h~Ertapenem 1-2g/24h."
89111060|NCT02795949|Active Comparator|De-escalation(short-spectrum antibiotic)|"Piperacillin/tazobactam 4/0.5 g IV/8h~Meropenem 1-2 g IV/8h~Imipenem 0.5 g IV/6h - 1g IV/6h~Aztreonam 1-2 g IV/8h~Ceftazidime 1-2 g IV/8h~Cefepime 2 g IV/8-12h"
89111061|NCT00769483|Experimental|Phase I, Arm A|MK-0646 + Gemcitabine
89111062|NCT00769483|Experimental|Phase I, Arm B|MK-0646 + Gemcitabine + Erlotinib
89111063|NCT00769483|Experimental|Phase II, Arm A|Gemcitabine + Erlotinib
89111064|NCT00769483|Experimental|Phase II, Arm B|MK-0646 + Gemcitabine + Erlotinib
89111065|NCT00769483|Experimental|Phase II, Arm C|Gemcitabine + Erlotinib
89111066|NCT02794389|Experimental|N-acetyl cysteine|1200mg for 2 days 2400mg for 7 days
89111067|NCT02794389|Placebo Comparator|Placebo|Magnesium stearate capsules
89111068|NCT02601703|Experimental|Tacrolimus Ointment 0.1%|
89111069|NCT02601703|Active Comparator|Protopic® ointment, 0.1%|
89111070|NCT02601703|Placebo Comparator|Placebo of Tacrolimus Ointment|
89086898|NCT02537041|Other|systolic Heart Failure|"elderly patients with heart failure with impaired ejection (<45%) fraction, but no segmental dysfunction.~The evaluation of myocardial stiffness by elastography in all these patients will be compared to conventionally ultrasound and biological parameters currently used for diagnosis of elderly's diastolic HF"
89086899|NCT02862327|Active Comparator|intravenous dexamethasone|intravenous injection of 8mg (2ml) of dexamethasone during regional anesthesia
89086900|NCT02862327|Placebo Comparator|intravenous placebo|intravenous injection of 2ml of NaCl 0.9% during regional anesthesia
89086901|NCT04945720|Experimental|Hepatic artery infusion chemotherapy（HAIC） plus Durvalumab|The therapeutic scheme was modified FOLFOX6 regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), leucovorin (200 mg/m2 from hour 3 to 5 on day 1) and Fluorouracil (400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours). All chemo-drugs were given by HAI.Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
89086902|NCT02666365|Active Comparator|Bolus infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a bolus infusion
89086903|NCT02666365|Active Comparator|Continuous Infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a continuous infusion
89086904|NCT03423303|Experimental|Screening arm|Invitation to prostate cancer screening and questionnaires.
89086905|NCT03423303|No Intervention|Control arm|Registry-based follow-up and a questionnaire.
89086906|NCT00645385||MRS of the neural system|MRS to study epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism.
89086907|NCT02862093|Active Comparator|Deep rTMS|The intervention consisted of deep rTMS of dorsolateral prefrontal cortex through the Brainsway Deep TMS System using an H-shaped coil . The motor threshold was measured by delivering a single pulse to the motor cortex. The site of stimulation was located 5.5 cm anterior to the point at which maximum stimulation of the abductor pollicis brevis muscle was reached. Each patient received a total of 12 rTMS sessions (three sessions per week): 20 trains per session at an intensity of 100% of the motor threshold, 50 pulses per train at a frequency of 10 Hertz, an inter-train interval of 15 seconds.
89086908|NCT02862093|Placebo Comparator|Placebo|The sham stimulation consisted of rTMS sessions without an effective instrument operation.
89086909|NCT02666443|Placebo Comparator|Control (C)|Control intervention (no dexamethasone)
89086910|NCT02666443|Experimental|Peri-neural (N)|Peri-neural Dexamethasone 1 mg
89086911|NCT02666443|Experimental|Intravenous|Intravenous Dexamethasone 1 mg
89086912|NCT00925522|Experimental|Therapy Cool Path Duo Cardiac Ablation System|All patients who are eligible receive cardiac ablation procedure for Ischemic Ventricular Tachycardia
89086913|NCT01130532|Active Comparator|2.5 milligram (mg) titrated to 5 mg Tadalafil|2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks
89086914|NCT01130532|Active Comparator|5 mg Tadalafil|5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks
89086915|NCT01130532|Placebo Comparator|Placebo|for 12 weeks
89086916|NCT04258306|Active Comparator|Resveratrol|180 mg natural Resveratrol (Polygonum cuspidatum 98%) deriving from galenic preparation from the IRRE pharmacy - Istituto Riuniti based in Cannara in via Vittorio Emanuele II 23.
89086917|NCT04258306|Experimental|REVIFAST|180 mg of Revifast® (mixture of resveratrol from Polygonum cuspidatum extract Siebold & Zucc. Root supported on Magnesium hydroxide).
89086918|NCT04284501||Study|children with Migraine headache
89086919|NCT04284501||Control|Healthy children
89086920|NCT04253158|Experimental|Educational standard|The aim of this arm is to increase knowledge about alcohol and other drug use.
89086921|NCT04253158|Experimental|Educational standard and Harm prevention|The aim of this arm is to increase knowledge about alcohol and other drug use and increase intentions for the use of harm prevention strategies.
89086922|NCT04253158|Experimental|Educational standard and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use and shift alcohol-related expectancies.
89086923|NCT04253158|Experimental|Expectancies and Harm prevention|The aim of this arm is shift alcohol-related expectancies and increase intentions to use harm prevention strategies.
89086924|NCT04253158|Experimental|Educational standard and Normative perceptions|The aim of this arm is to increase knowledge about alcohol and other drug use and correct erroneous alcohol-related normative perceptions.
89086925|NCT04253158|Experimental|Normative perceptions and Harm prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions and increase intentions to use harm prevention strategies.
89086926|NCT04253158|Experimental|Educational standard, Normative Perceptions, and Expectancies|The aim of this arm is to increase knowledge about alcohol and other drug use, correct erroneous alcohol-related normative perceptions, and shift alcohol-related expectancies.
89086927|NCT04253158|Experimental|Normative perceptions, Expectancies, and Harm Prevention|The aim of this arm is to correct erroneous alcohol-related normative perceptions, shift alcohol-related expectancies, and increase intentions to use harm prevention strategies.
89086928|NCT04912804||COVID-19 Patient|Patient discharged from a conventional short-stay hospitalization unit.
89086929|NCT02668237|Experimental|Experimental group|The intervention for this group will be the use of a OptiPAC. A molecular technique and urinary tests will be performed to test a panel of infectious agents : the results will allow the children to benefit from an adapted treatment.
89086930|NCT02668237|Active Comparator|Control Group|The children will benefit from the usual care : an antibiotic prevention treatment.
89086931|NCT04856800|Experimental|Whey|Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). 20 g of whey protein will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
89086932|NCT04856800|Placebo Comparator|Placebo|The placebo will be ingested 30 min. prior to breakfast from diagnosis of GDM (around week 28) and until delivery.
89086933|NCT00646711|Experimental|Sequence Group I|Depakote Delayed Release/Depakote Sprinkle
89086934|NCT00646711|Experimental|Sequence Group II|Depakote ER
89086935|NCT04255186|Experimental|Thermal CRMRF|"9 sessions in 3 week of Thermal CRMRF: The power of the RFCR equipment in this intervention will be 35 VA in capacitive method (10% of the maximum power of the equipment) and 30 W in the resistive method (15% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessiones a week).~In Thermal CRMRF it will be necessary to adapt to the patient's thermal sensitivity"
89086936|NCT04255186|Experimental|Subthermal CRMRF|9 sessions in 3 week of Subthermal CRMRF: The power of the RFCR equipment in this intervention will be 7 VA in capacitive method (2% of the maximum power of the equipment) and 4 W in the resistive method (2% of the maximum power of the equipment) in 3 week (3 sessions a week on alternate days) + 15 sessions in 3 week of exercise protocol (5 sessions a week).
89086937|NCT04255186|Sham Comparator|Sham CRMRF|9 sessions in 3 week of sham stimulation: The application will be carried out in the same way as in the experimental groups, but in this case the manufacturer will introduce a simulated stimulation protocol so that the device does not emit current + 15 sessions in 3 week of exercise protocol (5 sessiones a week).
89086938|NCT00646243||1 Heart Failure|216 consecutive consenting patients with refractory heart failure candidate to cardiac resynchronization therapy by clinical and electrocardiographic criteria
89086939|NCT00646243||2 Healthy subjects|120 healthy subject includes defined as absence of history and symptoms of any cardiovascular disease, normal physical examination and ECG.
89086940|NCT00972777|Experimental|Besifloxacin|0.6% ophthalmic suspension
89086941|NCT00972777|Placebo Comparator|Vehicle|
89086942|NCT04254874|Experimental|Abidol hydrochloride|Standard symptomatic support therapy (SMT) plus abidol hydrochloride(0.2g, 3 times a day).
89086943|NCT04254874|Experimental|Abidol Hydrochloride combined with Interferon atomization|Interferon(PegIFN-α-2b) atomization was added(45ug, add to sterile water 2ml, twice a day) on the basis of group I.
89086944|NCT02667223|Experimental|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
89086945|NCT02667223|Active Comparator|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered subcutaneously to healthy volunteers
89086946|NCT02667223|Experimental|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
89086947|NCT02667223|Experimental|Cohort 5: bococizumab 450 mg + rHUPH20|bococizumab 450 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
89086948|NCT02667223|Experimental|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to subjects with hypercholesterolemia receiving a statin
89086949|NCT02883660||Cases|"patients who had empirically defined increased AEs on one of the specified antidepressants (SSRIs/ SNRIs). This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
89086950|NCT02883660||Controls|"patients who did not have empirically defined increased AEs with an index antidepressant (one of the specified SSRIs/ SNRIs) AND were nonresponders to that antidepressant. This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
89086951|NCT02882724|Experimental|Exercise training|
89086952|NCT02882724|Experimental|Control|Control group did not do any exercise training.
89086953|NCT00918736|Experimental|hyaluronate injection|All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
89086954|NCT02666053|Experimental|Treatment A|Single BMS-663068 tablet under fasted conditions
89086955|NCT02666053|Experimental|Treatment B|Single BMS-663068 tablet with a high fat meal
89086956|NCT02666053|Experimental|Treatment C|Single BMS-663068 tablet after a single famotidine tablet under fasted conditions
89086957|NCT04067635||Conservative Arm|Participants are followed by the research team conservatively. Participants in this arm may choose to undergo any valvular intervention at the discretion of their treating clinical team.
89226050|NCT04913311||Observational (biospecimen collection, standard treatment)|Patients undergo collection of blood, stool and saliva samples at baseline. Patients will also have a 6 minute walk and standard of care pulmonary function test at baseline. Patients receive standard of care treatment consisting of concurrent chemoradiation from baseline up to week 10 and immune checkpoint inhibitors from week 10-62. Patients also undergo the collection of blood, stool, saliva and No BAL sample is collected at week 10. During the course of treatment, patients also complete routine tests and procedures to monitor for side effects per standard of care including CT within 4 weeks, lung function tests including home spirometry TIW from week 10-62, bronchoscopy and/or a nasal wash to check for viral infection. Patients also complete questionnaires about symptoms and quality of life QW for weeks 1-10, BIW during weeks 10-62.
89226051|NCT04913220|Experimental|Cohort A: Melanoma|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
89226052|NCT04913220|Experimental|Cohort B: cutaneous squamous cell carcinoma (CSCC)|SAR444245 and cemiplimab administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
89226053|NCT04904588|Experimental|Regimen A (MAC: busulfan and fludarabine, PBSC HCT)|"Patients receive:~Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3~Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0."
89226054|NCT04904588|Experimental|Regimen B (MAC: Fludarabine and TBI; PBSC HCT)|"Patients receive:~Fludarabine (90 mg/m2 total dose) IV on days -7 to -5~Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
89226055|NCT04904588|Experimental|Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)|"Patients receive:~Fludarabine (120-180 mg/m2 total dose) IV on days -6 to -2~Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
89226056|NCT04904588|Experimental|Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)|"Patients receive:~Fludarabine (120-180 mg/m2 total dose) IV on days -7 to -3~Melphalan (100-140 mg/m2) IV on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
89226057|NCT04904588|Experimental|Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)|"Patients receive:~Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Cyclophosphamide (29-50 mg/kg) IV on days -6 and -5~TBI (200 cGy) on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
89226058|NCT04904588|Experimental|Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)|"Patients receive:~Busulfan (dosed by age and weight per institutional standards to target goal pharmacokinetic (PK) in range noted in protocol.) on days -6 to -3~Cyclophosphamide (100 mg/kg total dose) IV on days -2 and -1~Patients receive a bone marrow (BM) graft infusion from a mismatched unrelated donor on Day 0."
89226059|NCT04904588|Experimental|Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)|"Patients receive:~Cyclophosphamide (100 mg/kg total dose) IV on days -5 and -4~TBI (1200 cGy total dose) on days -3, -2 and -1~Patients receive a BM graft infusion from a mismatched unrelated donor on Day 0."
89226060|NCT04897243||Multidisciplinary model of care|The Chronic Viral Illness Service at the Glen hospital of the MUHC will provide care with a multidisciplinary assessment, according to local current standard practice. Each newly-referred patient at the CVIS will be first received by a dedicated nurse, who then orients referral to a physician and/or a social worker and/or a pharmacist.
89226061|NCT04897243||Physician-only model of care|The Jewish General Hospital will provide care as per current local standard practice. Each newly-referred patient will be assessed by a clinician. Blood tests will be performed by central laboratory nurses who are not part of the HIV clinic.
89226062|NCT04896372|Experimental|ACT intervention|The ACT condition (comprehensive of standard care) comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and a psychological intervention based on ACT combined with a standard psychological assessment and support to the hospitalization.
89226063|NCT04896372|Other|Standard care|The TAU comprises a three-week in-hospital multidisciplinary rehabilitation program for weight loss and the standard psychological assessment and support to the hospitalization
89226064|NCT04895709|Experimental|Part 1A: BMS-986340 Dose Escalation|
89226065|NCT04895709|Experimental|Part 2A: BMS-986340 Dose Expansion|
89226066|NCT04895709|Experimental|Part 1B: BMS-986340 + Nivolumab Dose Escalation|
89226067|NCT04895709|Experimental|Part 2B: BMS-986340 + Nivolumab Dose Expansion|
89226068|NCT04895709|Experimental|Part 1C: BMS-986340 + Docetaxel Dose Escalation|
89226069|NCT04894110|Experimental|EO2002 treatment - Group 1|
89226070|NCT04894110|Active Comparator|EO2002 treatment - Group 2 - low dose|
89226071|NCT04894110|Active Comparator|EO2002 treatment - Group 2 - mid dose|
89226072|NCT04894110|Active Comparator|EO2002 treatment - Group 2 - high dose|
89226073|NCT04892186|Experimental|Myo-inositol|30 women with resistance insulin or glucose intolerance will receive myo-inositol 2g + folic acid 200mcg, orally, twice a day for 6 months.
89226074|NCT04892186|Active Comparator|Metformin|30 women with resistance insulin or glucose intolerance will receive metformin 850 mg, orally, twice a day for 6 months
89226075|NCT04890652|Other|Risky drinkers|All participants will receive the same 4 week intervention.
89226076|NCT04886999|Experimental|Inhaler A CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator."
89226077|NCT04886999|Active Comparator|Inhaler B CHF1535 100/6 µg pMDI|"Active ingredient: Fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg.~Excipients: HFA-134a, Ethanol anhydrous, Hydrochloric acid. Presentation: Canister containing 120 doses plus actuator"
89226078|NCT04886115|Experimental|Eccentric pedalling group at 15 rpm|
89226079|NCT04886115|Experimental|Eccentric pedalling group at 60 rpm|
89226080|NCT04886115|Active Comparator|Control|
89226081|NCT04884035|Experimental|Administration of CC-220 with R-CHOP-21|CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
89086958|NCT04067635||Surgical Arm|Participants have already elected upfront to undergo surgical repair (at least, mitral annuloplasty) with their treating clinical team, just prior to enrollment into this study.
89086959|NCT04257838||Piperacillin-Tazobactam or Meropenem Cohort|Patients hospitalized for sepsis or septic shock that are treated with Piperacillin-Tazobactam or Meropenem and meet all the inclusion criteria and none of the exclusion criteria.
89086960|NCT01172639|Other|CoBRA classic high risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Sulfasalazine 2g tablet by mouth, daily for 40 weeks~Prednisone tablet by mouth, weekly step down scheme 60 - 40 - 25 - 20 - 15 - 10 mg daily for 6 weeks, followed by 7.5mg daily till week 28, then further tapered down to stop at week 32"
89086961|NCT01172639|Other|CoBRA slim high risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
89086962|NCT01172639|Other|CoBRA avant-garde high risk group|"Methotrexate 15mg tablet by mouth, weekly for 40 weeks (continued for entire trial if randomized to Methotrexate monotherapy at week 40)~Leflunomide 10mg tablet by mouth, daily for 40 weeks (continued for entire trial if randomized to Leflunomide monotherapy at week 40)~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
89086963|NCT01172639|Other|CoBRA slim low risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
89086964|NCT01172639|Other|Tight Step Up low risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~No oral steroids allowed during the first year of the trial"
89086965|NCT01144182|No Intervention|Current Best Practice (CBP)|CBP received no intervention and only current best practices for inpatient HF care.
89086966|NCT01144182|Active Comparator|Quality improvement program (QIP)|Comprehensive quality improvement program (QIP) intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
89086967|NCT00646789|Experimental|1|MK0633
89086968|NCT01225562|Experimental|1|Oral Treatment
89086969|NCT01225562|Experimental|2|Oral Treatment
89086970|NCT01225562|Placebo Comparator|3|Oral Treatment
89086971|NCT04203628|Experimental|Prospective cohort|"Any child with presumptive TB will be proposed to participate in the study.~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies.~For children identified from the routine practice, the nurse will collect 2 respiratory samples (sputum or GA) in consecutive children with presumptive TB to be tested using Ultra as done in routine care, record symptoms and refer the child for clinical exam and for chest X-ray. For the purpose of the study, 2 stool samples will be collected to be tested with Ultra. In addition, for study purpose the two respiratory samples will be tested with Mycobacterial culture as this test is not routinely prescribed for TB diagnosis in the study sites"
89086972|NCT04203628|Experimental|Enrichment cohort|"Any child with presumptive TB and a positive Xpert result from one respiratory sample (NPA, IS or GA) will be proposed to participate in the study.~If the child is enrolled in the TB-Speed SAM or HIV studies, the study nurse will collect 2 stool samples then collect information about the clinical examination, chest X-ray, HIV-testing and the mycobacterial culture results as soon as they are available, from the data collected in the TB-speed records since all these procedures are already performed in these studies~For children identified from the routine care, once enrolled, samples collected as routine practice will be tested with mycobacterial culture in addition to Xpert. If needed an additional respiratory sample will be collected (sputum or GA) and tested with Mycobacterial culture. The nurse will also record symptoms, refer the child for clinical exam and for chest Xray, and collect stool samples. HIV-testing will be offered for children with unknown HIV-status"
89086973|NCT02665819||Pediatric cancer women survivors|Women diagnosed for a cancer between 01/01/87 and 31/12/99 before the age of 15 years old living in Rhône-Alpes, will incur a blood taking for DNA tests (hormone tests) to see their fertility capacity.
89086974|NCT00925288|Active Comparator|Regular schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,2,6 months
88812870|NCT03214484|Active Comparator|electronc tablet|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
89086975|NCT00925288|Experimental|Modified Schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,3,6 months
89086976|NCT04174573|Experimental|Group therapy only (GTO)|Patients in GTO group will receive structured group therapy programme
89086977|NCT04174573|Experimental|Group therapy with tDCS (GT-tDCS)|Patients in this group will receive group therapy along-with tDCS intervention
89086978|NCT01143714|Active Comparator|A|
89086979|NCT01143714|Placebo Comparator|B|
89086980|NCT04800757|Experimental|individual (Brief Motivational Intervention)|
89086981|NCT04800757|Experimental|Group (Group Problem Solving)|
89086982|NCT04800757|Placebo Comparator|Standard of Care|
89111071|NCT02790489|Experimental|Valedia|Dose 1 : 2,5 g (4 capsules) Valedia per day during 4 weeks Dose 2 : 5 g (8 capsules) Valedia per day during 4 weeks 2 weeks (wash-out period) between the 2 doses
89111072|NCT04098913|Experimental|Reduced screen-based media use|Reducing recreational screen-based media use for a period of 2 weeks.
89111073|NCT04098913|No Intervention|Control group|Participants are asked to continue their habitual screen-based media use.
89226082|NCT04884035|Experimental|Administration of CC-99282 with R-CHOP-21|CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
89226083|NCT04884035|Experimental|Administration of CC-220 with polatuzumab-R-CHP|CC-220 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment
89226084|NCT04884035|Experimental|Administration of CC-99282 with polatuzumab-R-CHP|CC-99282 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment
89226085|NCT04879628|Experimental|Intravenous (IV) SAR441344|SAR441344 IV
89226086|NCT04879628|Placebo Comparator|IV Placebo|Placebo IV
89226087|NCT04879628|Experimental|Subcutaneous (SC) SAR441344|SAR441344 SC
89226088|NCT04879628|Placebo Comparator|SC Placebo|Placebo SC
89226089|NCT04877756|Experimental|Arm A 2.0 mg/cm OLX10010 biweekly|Arm A- half the scar treated with 2.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
89226090|NCT04877756|Experimental|Arm B 5.0 mg/cm OLX10010 biweekly|Arm B- half the scar treated with 5.0 mg/cm of OLX10010 biweekly, other half treated with OLX Placebo
89226091|NCT04877756|Experimental|Arm C 2.0 mg/cm OLX10010 weekly|Arm C- half the scar treated with 2.0 mg/cm of OLX10010 weekly, other half treated with OLX Placebo
89226092|NCT04876729|Experimental|Otago Exercise Program|An individualized Otago Exercise Program will be delivered by community health representatives (CHR) in participants homes. There will be 10 home visits over a 12 month period.
89226093|NCT04876729|No Intervention|Education|The control group will receive education on fall risk reduction. This will be delivered by the CHR with 6 home visits over 12 months
89226094|NCT04861259|Experimental|Crovalimab|Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] C5 SNP (Single Nucleotide Polymorphism) Cohort - participants with documented C5 polymorphism.
89226095|NCT04860479||Infants: 28 days - 12 month|inguinal sonoanatomy
89226096|NCT04860479||small children: 13 months - 36 months|inguinal sonoanatomy
89226097|NCT04860479||preschool age: 37 months - 72 months|inguinal sonoanatomy
89226098|NCT04860479||school age: 73 months - 9 years|inguinal sonoanatomy
89226099|NCT04860479||Preadolescant: >9 years - 12 years|inguinal sonoanatomy
89226100|NCT04860479||Adolescants: >12 years - 18 years|inguinal sonoanatomy
89226101|NCT04860336||Pregnant women less than or equal to 14w0d gestation|
89226102|NCT04858698|Experimental|Reduced fluoroscopy arm|Patients exposed to 20 seconds or less of fluoroscopy to implant a single chamber device with aid of ultrasound / echocardiography.
89226103|NCT04858698|Active Comparator|Conventional arm|Patients exposed to more than 20 seconds of fluoroscopy to implant a single chamber device with/without the aid of ultrasound / echocardiography.
89226104|NCT04853758|Active Comparator|Sacubitril/Valsartan|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan.
89226105|NCT04853758|Active Comparator|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril.
89226106|NCT04840121|Active Comparator|Study Group - AdhesioRT|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the study group will proceed with frozen embryo transfer cycle according window of implantation determined by AdhesioRT.
89226107|NCT04840121|Active Comparator|Control Group - Standard of Care|Prior to frozen embryo transfer, participants will proceed with the AdhesioRT test. Participants randomized in the control group will proceed with the first frozen embryo transfer cycle as per standard of care. In the event of unsuccessful implantation (negative serum pregnancy test), participants will proceed with subsequent frozen embryo transfer cycle according to window of implantation determined by AdhesioRT.
89226108|NCT04837820|Experimental|Acupuncture|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
89226109|NCT04837820|Placebo Comparator|Sham Acupuncture (SA)|The intervention will consist of 10 acupuncture sessions over 10 weeks using the standardized, semi-fixed protocol.
89226110|NCT04837820|Experimental|Wait-List Control|During the 26-week waiting period, the CRC will contact patients in the WLC group at the same frequency as the acupuncture groups with respect to data collection. Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians. WLC patients will be compensated with real acupuncture treatments after Week 26 (end of study).
89226111|NCT04837053|Experimental|Intervention cluster|EKIT tool
89226112|NCT04837053|Active Comparator|Control Cluster|routine care
89226113|NCT04835805|Experimental|Belvarafenib Monotherapy|Twice daily (BID), continuous dosing.
89226114|NCT04835805|Experimental|Belvarafenib Plus Cobimetinib|Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase.
89226115|NCT04835805|Experimental|Belvarafenib Plus Cobimetinib Plus Nivolumab|Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus nivolumab IV infusion every 4 weeks (Q4W) in a run-in phase followed by an expansion phase
89226116|NCT04832958|Experimental|Radioguided surgery|"68Ga-PSMA PET/MRI acquisition~99mTc-PSMA-I&S intravenous injection the day before surgery~99mTc-PSMA-I&S SPECT/CT imaging~99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations~Robot-assisted ePLND followed by RP~99mTc-PSMA-RGS to detect an increased count rate in the prostatic fossa after removal of the primary tumor~Histopathological examination~Monitoring of adverse events and perioperative outcomes after surgery"
89226117|NCT04823650||Ages 3-5|COHORT A and B
89226118|NCT04823650||Ages 6-11|COHORT A and B
89226119|NCT04823650||Ages 12-17|COHORT A and B
89226120|NCT04823585|Placebo Comparator|subcutaneous injections of placebo|Subcutaneous injections of placebo (physiological sodium chloride solution) once per month for 16 weeks. A total of 4 injections.
89226121|NCT04823585|Experimental|subcutaneous injections of Mepolizumab 100 mg|Subcutaneous injections of Mepolizumab 100 mg once per month for 16 weeks. A total of 4 injections.
89226122|NCT04821349|Other|Single arm study|Standard reading Group vs AI-assisted reading Group
89226123|NCT04821271|Experimental|1|Individuals in Arm 1 will receive daily double-blinded TS-161 for three weeks during Test Session 1 and daily double-blinded placebo for three weeks during Test Session 2.
89226124|NCT04821271|Experimental|2|Individuals in Arm 2 will receive daily double-blinded placebo for three weeks during Test Session 1 and daily double-blinded TS-161 for three weeks during Test Session 2.
89226125|NCT04819893||Women giving birth prematurely|Delivery before 29 WA
89226126|NCT04819893||Women giving birth at term|Childbirth between 39WA and 31WA+6 days
89226127|NCT04819269|Active Comparator|Tivanisiran sodium ophthalmic solution|
89226128|NCT04819269|Placebo Comparator|Vehicle ophthalmic solution|
89226129|NCT04817839|Experimental|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
89226130|NCT04817839|Experimental|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
89226131|NCT04814628|Experimental|healthy volunteer subject|"A single healthy volunteer subject will participate in the study as a model of a pregnant woman in the third trimester of pregnancy, with a functional respiratory capacity reduced by 20% thanks to elastic restraints performed under the control of functional respiratory explorations.~8 obstetric anesthesiologists will participate in the 4 scenarios;"
89226133|NCT04802057|Experimental|SAR445088|Repeat dose of SAR445088
89226134|NCT04793893|Experimental|Treatment of residual hypermetropia refraction after LASIK|"The main problem at young patients post - LASIK after one year is residual hypermetropic refractive errors (especially accommodation problem) The method used in Eye Hospital is treatment with implantation of human fresh corneal lenticule (min. -1.50D) taken from myopic patients in post - LASIK patients with residual hypermetropic refractive error (min. +1.0D).~The flap of LASIk is lifted,cleaned and then the lenticule gently inserted.The lenticule was positioned according the K2 values when is astigmatism residual refractive error.In cases where is not astigmatism the lenticule was positioned in central position under the flap."
89226135|NCT04792502|Experimental|Planned Therapy|
89226136|NCT04791969|Experimental|Naltrexone with ecological momentary intervention|Naltrexone Hydrochloride, 50 mg., intermittent with ecological momentary assessment (EMA)
89226137|NCT04791969|Placebo Comparator|Placebo with ecological momentary intervention|Placebo, intermittent with ecological momentary assessment (EMA)
89226138|NCT04790344|Experimental|Treatment Arm|All study subjects belong to Treatment Arm, which is receiving investigational LUX-Dx ICM device.
89226139|NCT04789304|Placebo Comparator|Placebo / Placebo + Midazolam|Placebo matching BI 1595043. Patients included in the placebo arm corresponding to dose group 3, also received Midazolam.
89086983|NCT04257916|Experimental|Experimental group|"The intervention by kinesiotape will be done with the player in supine position with the foot in dorsal flexion, anchoring the strip below the sole of the foot without tension, adding 50-70% tension until internal and external malleolus, and ending without tension. Another strip will be placed under the external malleolus, anchoring the bandage and following the talus (50-70% tension), leaving the scaphoid bulge free, surrounding the plant without tension and leaving the 5th metatarsal free. The bandage continues on the peroneal-astragalin ligament and the external malleolus (50-70% tension), until the tendon without tension. In the end we will surround the internal malleolus to the Achilles tendon without tension, ending with the same tension in the external malleolus and the neck of the talus.~The myofascial technique and strength training will be the same in both groups."
89086984|NCT04257916|Active Comparator|Control group|"The myofascial technique will be carried out by positioning the caudal hand of the physiotherapist in the astragalin and heel region, and the cranial hand in the middle foot. With a tibiotarsal traction, the foot will be everted, performing a shear in the astragalin zone, using a combined and slow technique.~All players will warm up for 10 minutes on tape, at a speed of 7 km / h without inclination. The strength work was carried out with an isoinertial machine (Space Whell) with intervalic methodology: 20 -10, with 4 series and doing three exercises: Squat, Lunges and Deadlift. One minute breaks will be made between sets."
89086985|NCT04920682|Active Comparator|Group M (reversion with moderate neuromuscular blockade)|Administration of neostigmine 60 mcg/kg and atropine 30 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)> 0.4.
89086986|NCT04920682|Active Comparator|Group S (reversion with superficial moderate neuromuscular blockade)|Administration of 0.9% saline solution (SF) when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)> 0.4.
89086987|NCT04920682|Active Comparator|Group N (two-step reversal of neuromuscular blockade)|Administration of neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)> 0.4 .
89086988|NCT04920682|Placebo Comparator|Group P (placebo)|Administration of 0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)> 0.4.
89086989|NCT04174339|Experimental|camrelizumab plus apatinib and POF|Participants will receive camrelizumab in combination with apatinib plus POF until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89086990|NCT00972543|Active Comparator|Raptiva|Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
89086991|NCT00972543|Placebo Comparator|Placebo|Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
89086992|NCT04173481|Experimental|Rood's Group|Rood's sensory motor training along with CIMT
89086993|NCT04173481|Active Comparator|Conventional Physical Therapy Group|Conventional Physical Therapy including Proprioceptive Neuromuscular Facilitation technique.
89086994|NCT00925132|Experimental|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
89086995|NCT02862015|Experimental|Oncothermia|Patients with oncothermia treatment and palliative chemotherapy
89086996|NCT02862015|Active Comparator|Control|Patients with palliative chemotherapy only
89086997|NCT00646867|Experimental|1|Experimental
89086998|NCT00646867|Placebo Comparator|2|Placebo
89086999|NCT04254718|Experimental|Digital Storytelling|Legacy intervention via digital story for NICU parents
89087000|NCT02664805|Active Comparator|LEO 124249 ointment|Twice daily cutaneous application for 8 weeks
89087001|NCT02664805|Placebo Comparator|LEO 124249 ointment vehicle|Twice daily cutaneous application for 8 weeks
89087002|NCT04285593|Experimental|Experimental group|"Each session will last 10 minutes, taking place two days a week, over a period of four weeks. The intervention will take place at the beginning of the training session.~The players included in the experimental group will perform an exercise protocol with Bulgarian squats."
89087003|NCT04285593|No Intervention|Control group|The players included in the control group will continue with their usual warm-up routine.
89087004|NCT04245904||proffesional basketball player|
89087005|NCT04245904||sedentary control|
89087006|NCT01143402|Experimental|Arm I (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are unable to be treated with temozolomide may be treated with dacarbazine IV every 3 weeks (with approval from the Principal Investigator). Patients who experience disease progression may crossover to arm II.
89087007|NCT01143402|Experimental|Arm II (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89087008|NCT00646945|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)
89087009|NCT00646945|Placebo Comparator|B|50% oxygen/50% Nitrogen premix
89087010|NCT01171625|Other|CEP Aortic Bioprothesis, model 3300TFX|
89087011|NCT00629889|Active Comparator|Levetiracetam|Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year
89087012|NCT00629889|Active Comparator|Pregabalin|Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year
89087013|NCT04898686|Active Comparator|Probiotic group|daily use of a probiotic chewable for 8 weeks
89087014|NCT04898686|Placebo Comparator|Placebo group|daily use of the placebo chewable for 8 weeks
89087015|NCT04066855||Chronic Kidney Disease (CKD)|patients diagnosed as CKD
89087016|NCT04066855||Renal transplant|recipients of renal transplantation
89087017|NCT04257604||Perampanel|Participants with partial-onset seizures, with or without secondary generalization will receive perampanel tablets as add-on therapy according to the approved summary of product characteristics (SmPC) after the baseline visit as part of the clinical practice and will be observed after 3 months (visit 1), 6 months (visit 2), and 12 months (final visit).
89087019|NCT04315259|Experimental|Laser activated irrigation|conventional root canal treatment was done , 2.5% sodium hypochlorite was used and was activated by 980 nm with a repeated pulse mode using a pulse duration of 5 s and a pulse interval of 0.2 ms. The laser irradiation will be delivered for 1 minute into the canal up to 1 mm short of the working length, with circling movements from the apical part moving towards the coronal part (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100)
89087020|NCT04315259|Experimental|Soft tissue laser application|"Endodontically treated teeth by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices.~Application of the laser probe was applied to both the buccal and lingual mucosae overlying the apices of the target tooth. Total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) The laser unit used in this study used was a diode laser (Lite Medics 1.00Watt serial number 148 Ver.SwvM. 150VS108VT.100) of wavelength 980nm and Max power 15WCW Class IV Laser Product"
89087021|NCT04315259|No Intervention|conventional root canal|conventional root canal treatment with irrigation of sodium hypochlorite 2.5% with no laser intervention
89087022|NCT04849936||evaluation of fecal biomarkers|comparison of the biomarker levels between different gastrointestinal diseases
89087023|NCT00630045|Experimental|1|2~3 cycles of neoadjuvant chemotherapy before resection of liver metastasis
89087024|NCT00630045|Active Comparator|2|no neoadjuvant chemotherapy, resect the liver metastasis directly
89087025|NCT04315103|Experimental|the combined-injection group|patients received a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP
89087026|NCT04315103|Active Comparator|the one-injection group|patients received a single injection of 3 ml PRP
89226140|NCT04789304|Experimental|15 mg BI 1595043|15 milligram (mg) BI 1595043. Dose group 1.
89226141|NCT04789304|Experimental|30 mg BI 1595043|30 mg BI 1595043. Dose group 2.
89226142|NCT04789304|Experimental|60 mg BI 1595043 + Midazolam|60 mg BI 1595043 + Midazolam. Dose group 3.
89226143|NCT04774952|Experimental|RMC-5552|RMC-5552 for IV administration
89226144|NCT04772079|Experimental|Active treatment deucravacitinib standard dose|
89226145|NCT04772079|Experimental|Active treatment deucravacitinib half-standard dose|
89226146|NCT04772079|Placebo Comparator|Placebo|
89226147|NCT04766814||Patient Group|10 women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation.
89226148|NCT04766814||Control Group 1|10 healthy women subjects between the ages of 50-80 year
89226149|NCT04766814||Control Group 2|10 healthy women subjects between the ages of 20-30 years
89226150|NCT04756063|Experimental|Ascorbic Acid (AA)|The first intravenous dosage of 1500mg of AA in 100mL of normal saline (NS) will be administered after induction of general anesthesia and invasive line placement prior to surgical incision. An identical dosage will be delivered approximately every 6 hours for the first 48 hours, for a total of 8 doses
89226151|NCT04756063|Placebo Comparator|Placebo|The first intravenous dosage of placebo (100 mL of NS) will be administered after induction of general anesthesia and invasive line placement prior to surgical incision. An identical dosage will be delivered approximately every 6 hours for the first 48 hours, for a total of 8 doses
89226152|NCT04747314|Experimental|Antidepressant (AD)|Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks. Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months.
89226153|NCT04747314|Experimental|Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment. Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months.
89226154|NCT04747314|Experimental|Antidepressant (AD) + Enhanced Fear Avoidance Rehabilitation (EFAR)|Subjects will receive a combination of antidepressant medication and physical therapy for 8 months, in addition to their current opioid prescription and weaning guidelines, if applicable. No re-randomization will be done in this treatment group.
89226155|NCT04747314|Experimental|AD -> EFAR|"Subjects will be randomly assigned to receive the antidepressant medication for 4 months under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks.~Non-responders determined at the end of 4 months will be re-randomized to continue receiving AD or EFAR for another 4 months. Those re-randomized to receive EFAR for another 4 months will receive a combination of antidepressant medication and physical therapy, in addition to their current opioid prescription and weaning guidelines, if applicable."
89226156|NCT04747314|Experimental|EFAR -> AD|"Subjects will be randomly assigned to receive 8 1-hour physical therapy sessions, pain education, and motivational messaging via Vivify app for 4 months, in addition to their current opioid prescription and weaning guidelines, if applicable. Trained physical/occupational therapists will determine the activities as part of the treatment.~Non-responders determined at the end of 4 months will be re-randomized to continue receiving EFAR or AD for another 4 months. Those re-randomized to receive AD for another 4 months will be under the care of a nurse practitioner and psychiatrist, in addition to their current opioid prescription and weaning guidelines, if applicable. Dosage change and side effects are mitigated by check-in visits (virtually or in-person) every 4 weeks."
89226157|NCT04745871|Experimental|Intervention|All patients with prostate cancer undergo PSMA PET/CT as part of the trial in addition to standard methods (abdo-pelvic MRI and a bone scan).
89087027|NCT02861859|Placebo Comparator|Placebo Comparator|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4).~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle,), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4)."
89087028|NCT02861859|Active Comparator|Olanzapine|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO, OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4).~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4)."
89087029|NCT00910507|Experimental|Exercise counseling|Each participant in the experimental group receives exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
89087030|NCT00910507|Active Comparator|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
89087031|NCT05657795|No Intervention|Manual oxygen control|Standard ventilation with inspired oxygen concentration adjusted manually as per unit's protocol.
89087032|NCT05657795|Other|Closed-loop automated oxygen control (Oxygenie, SLE 6000)|Ventilation with Oxygenie software (closed-loop automated oxygen control system), adjusted by clinical staff as necessary
89087033|NCT00910585|Experimental|Active coaching|Telephone and in person coaching
89087034|NCT00910585|Active Comparator|Usual care|Return to PCP for usual care
89087035|NCT04317209|Experimental|SHR0410 low dosage|
89087036|NCT04317209|Experimental|SHR0410 medium dosage|
89087037|NCT04317209|Experimental|SHR0410 high dosage|
89087038|NCT04317209|Placebo Comparator|Placebo|
89087039|NCT04255654|Experimental|Brief Intervention|There is only 1 intervention for this study. They will have the brief intervention completed on them. There is no control group.
89087040|NCT00647023|Experimental|A|
89087041|NCT05657717|Experimental|Intervention|Manukamed - 100% sterile manuka honey
89087042|NCT05657717|No Intervention|Control|No intervention was given. Participants receive standard wound care of the tympanic membrane which includes 0.3% Ofloxacin otic ear drops which were used twice a day for 5 days.
89087043|NCT00924898|Experimental|Acute HIV Treatment Group|Single arm, open label study in which all participants received the same study treatment with efavirenz, emtricitabine, and tenofovir DF
89087044|NCT01167192|Experimental|Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation|"Cisplatin 75 mg/m^2 IV every 21 days for 4 cycles or Carboplatin AUC 6 IV every 21 days for 4 cycles.~Radiation beginning cycle 2 day 1 daily for 5-6 weeks 45-50 Gy.~Recommended mastectomy~Recommended adjuvant chemotherapy~-doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for 14 days for 4 cycles followed by paclitaxel 175 mg/m2 for 14 days for 4 cycles)"
89087045|NCT00646321|Experimental|1|budesonide/formoterol
89087046|NCT00646321|Active Comparator|2|budesonide
89087047|NCT00647101|Experimental|Latanoprost group|
89087048|NCT01166958|Active Comparator|Daily teriparatide (Forteo)|
89087049|NCT01166958|Active Comparator|Monthly cycles of teriparatide followed by raloxifene|
89087050|NCT04827316||Patients undergoing clinically indicated CCTA|Patients undergoing clinically indicated CCTA
89087051|NCT01170221|Experimental|TR-701 FA|TR0-701 FA 200 mg tablets once a day for six days followed by 4 days of placebo
89087052|NCT01170221|Active Comparator|Linezolid|Linezolid 600 mg tablets oral twice a day for 10 days
89087053|NCT04849624||ICU COVID-19 patients|COVID-19 patients that are admitted into the ICU and fulfilled the eligibility criteria
89087054|NCT04849624||ICU non-COVID-19 patients|Non-COVID-19 patients that are admitted into the ICU matched with ICU COVID-19 patients that are recruited and fulfilled the eligibility criteria
89087055|NCT04254640|Experimental|C-CAG|cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.
89087056|NCT01166646|Experimental|Halobetasol Proprionate Lotion 0.05%|Subjects randomized to receive lotion
89087057|NCT01166646|Active Comparator|Halobetasol Proprionate Cream 0.05%|Subjects randomized to receive cream
89087058|NCT04203394|Experimental|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
89087059|NCT04203394|Experimental|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
89087060|NCT00647179||1|Patients recently diagnosed with acromegaly
89087061|NCT04909840|Experimental|dental floss|Instructions of oral hygiene with toothbrush plus dental floss
89087062|NCT04909840|Active Comparator|without dental floss|Individuals who will use only toothbrush
89087063|NCT01129284|Experimental|Acthar gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
89087064|NCT00647257|Active Comparator|A|
89087065|NCT00647257|Placebo Comparator|B|
89087066|NCT04033393|Experimental|Game based dual-task training group|Participants in dual-task training group will execute game based dual-task training with treadmill, 3 times per week for 8 weeks
89087067|NCT04033393|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training, 3 times per week for 8 weeks
89087068|NCT01166568|Experimental|Implantation-Non Randomized|Subjects are not participants in the randomized sub-study. PresView Scleral Implants surgical placed in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
89087069|NCT01166568|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. PresView Scleral Implants surgical placed in the eye(s)Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
89087070|NCT01166568|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have PresView Scleral Implants surgically placed in the eye(s) and become part of the overall study experimental group.
89087071|NCT02664727|Experimental|Heavy drinkers|The effects of acute exercise in heavy drinkers. Participants will cycle on ergometer for 30 min at 50-60% of Heart Rate Reserve (HRR).
89087072|NCT02664727|Experimental|Alcoholic patients|The effects of acute exercise in alcoholic patients. Participants will cycle on ergometer for 30 min at 55-60% of Heart Rate maximal (HRmax).
89087073|NCT02666989|Active Comparator|open placebo|8 weeks of open placebo treatment
89087074|NCT02666989|No Intervention|waitlist group|4 weeks of waiting list followed by 4 weeks of open placebo treatment
89087075|NCT04742179|Experimental|Experimental group|The children belonging to the classes of the school complex undergoing the maintenance intervention.
89087076|NCT04742179|No Intervention|Control group|The children belonging to the classes of the school complex that will not undergo the maintenance intervention.
89087077|NCT01166178|Experimental|Zoledronic Acid|Participants received zoledronic acid infusion in addition to calcium and vitamin D
89087078|NCT01166178|Placebo Comparator|Placebo|Participants received placebo to zoledronic acid infusion in addition to calcium and vitamin D
89087079|NCT00646477|Experimental|A|Phase 1 : manual Phase 2 : automatic Descent rate pressure : slow
89087080|NCT00646477|Experimental|B|Phase 1 : manual Phase 2 : automatic Descent Rate Pressure : fast
89087081|NCT00646477|Experimental|C|Phase 1 : automatic Phase 2 : manual Descent rate pressure : slow
89087082|NCT00646477|Experimental|D|Phase 1 : automatic Phase 2 : manual Descent Rate Pressure : fast
89087083|NCT00924820|Experimental|Bevacizumab|Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.
89087084|NCT01225172|Experimental|BMS-754807|
89087085|NCT01225172|Experimental|BMS-754807 + letrozole|
89087086|NCT02665039|Experimental|Vinflunine + gemcitabine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~280 mg/m2 in patients with GFR 40-60 ml/min~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
89087087|NCT02665039|Active Comparator|Carboplatin + gemcitabine|"Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
89087088|NCT02665663|Other|healthy volunteers|"Constitution of a control group consisting of 20 healthy volunteers, matched for age and sex to establish a normal pressure force of the language depending on the age and sex value"
89087089|NCT02665663|Other|Patients with Amyotrophic Lateral Sclerosis|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis (ALS), included at diagnosis of the disease on clinical and electromyographic arguments addressed in speech pathology consultation without a complaint swallowing.
89087090|NCT02665663|Other|patients with Amyotrophic Lateral Sclerosis and swallowi|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis ( ALS) and swallowing disorders clinically objectified in the ENT consultation.
89087091|NCT04844086|Experimental|Infusion RPM CD19-mbIL15-CAR-T cell|"In this study, anti-CD19 autologous chimeric antigen receptor T-cells infusion produced by rapid personalized manufacture are used to treat patients with relapsed/refractory Advanced Lymphoid Malignancies.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to RPM CD19-mbIL15-CAR-T cell infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
89087092|NCT00647335||1|Women with diagnosis of PCOS
89087093|NCT05329870||Normal Colonoscopy and Normal qFIT|Normal colonoscopy and qFIT <10 micrograms haemoglobin
89087094|NCT05329870||Normal Colonoscopy and Raised qFIT|Normal colonoscopy and qFIT >=10 micrograms haemoglobin
89087095|NCT01143324||MAST™ procedure|
89087096|NCT04172935|Experimental|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal working distance as measured before intervention.
89087097|NCT04172935|No Intervention|Control Group|Will be deferred to receive spectacles as above, after the 4 weeks evaluation period.
89087098|NCT04254016|Experimental|Non-randomized single-arm of HIBISTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted on the administration of Hibiscus-Stevia drink at a dose of 4 mg / kg / day / for Stevia and 4 g / day for Hibiscus for a period of 8 weeks and after meals."
89087099|NCT02665585|Experimental|C-Guard carotid stent|Carotid stenting procedure by C-Guard stent implantation (InspireMD, Boston, MA, USA)
89087100|NCT02665585|Active Comparator|Wallstent carotid stent|Carotid stenting procedure by Wallstent implantation (BostonScientific, Marlborough, MA, USA)
89087101|NCT01224782||Chronic Kidney Disease, Secondary Hyperparathyroidism|All eligible participants with chronic kidney disease stage 3 and 4 and secondary hyperparathyroidism treated with Zemplar (paricalcitol) capsules according to the local marketing authorization
89087102|NCT04252924||students|medical student, dental medicine student, pharmacy student, nursing student, physiotherapy student, dietetics student, kinesiology student, biomedical laboratory techniques student, biomolecular science student, psychology student, economy student, student of maritime sciences
89087103|NCT02883816|Experimental|cystic fibrosis|assessment of lung function in newborns screened for cystic fibrosis
89087104|NCT00647413|No Intervention|1|
89087105|NCT00647413|Experimental|2|expert system intervention on smoking behaviour + feedback of a biomarker
89087106|NCT00647491|Experimental|20 mg|20 mg adalimumab eow
89087107|NCT00647491|Experimental|40 mg|40 mg adalimumab eow
89087108|NCT00647491|Experimental|80 mg|80 mg adalimumab eow
89087109|NCT00647491|Placebo Comparator|Placebo|Placebo eow
89087110|NCT04253704|Experimental|2% IDL lotion|The left arm of each subject was used for the test material hydrating lotion (IDL).
89087111|NCT04253704|Placebo Comparator|Control lotion|The right arm of each subject was used for control lotion lacking the IDL component.
89087112|NCT04252456|Other|standard chemotherapy for advanced colorectal cancer|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.
89087113|NCT01224158|Experimental|PR-009577 Toothbrush|Experimental Power Toothbrush
89087114|NCT01224158|Active Comparator|PR-000172 Toothbrush|Flat trimmed Manual Toothbrush
89087115|NCT02665351|Active Comparator|Peramivir 300mg Q12H|Peramivir 300 mg, administered intravenously, twice daily (every 12 hours)
89087116|NCT02665351|Active Comparator|Peramivir 600mg Q24H|Peramivir 600 mg, administered intravenously, once daily (every 24 hrs)
89087117|NCT02666911|Experimental|4D Ultrasound|4D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury. The same patients will be imaged with both 2D and 4D transducers.
89087118|NCT02666911|Active Comparator|2D ultrasound|2D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury.The same patients will be imaged with both 2D and 4D transducers.
89087119|NCT04253860|Experimental|TENS|Transcutaneous electrical neurostimulation will be applied for 30 minutes three times a week during 90 days
89087120|NCT04253860|Sham Comparator|Sham|A sham comparator will be applied for 30 minutes three times a week during 90 days. The device does not emit electrical impulses
89087121|NCT01129128|Active Comparator|Echinacea preparation 1|Commercially available Echinacea purpurea product
89087122|NCT01129128|Active Comparator|Echinacea preparation 2|Commercially available Echinacea purpurea product
89087123|NCT01129128|Placebo Comparator|Placebo|Inert liquid that is similar in appearance and taste to the active Echinacea products
89087124|NCT01222520|Experimental|Telmisartan and amlodipine FDC|once a daily
89087125|NCT01222520|Active Comparator|Telmisartan monotherapy|once a daily
89087126|NCT04252222|Experimental|VL3|Tracheal intubation with VL3 videolaryngoscope
89087127|NCT05312424|Placebo Comparator|Placebo|Placebo group: subject will take one pill (150 mg olive oil) after breakfast and another pill (150 mg olive oil) after dinner
89087128|NCT05312424|Active Comparator|Low GG|LOW GG group: subject will take one pill (150 mg olive oil) after breakfast and another pill (150 mg GG) after dinner
89087129|NCT05312424|Active Comparator|High GG|HIGH GG group: subject will take one pill (150 mg GG) after breakfast and another pill (150 mg GG) after dinner
89087130|NCT02888210|Experimental|MD-15|Investigational intraocular lens
89087131|NCT04172233|Experimental|Phase I: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0 and 4 by subcutaneous injection
89087132|NCT04172233|Experimental|Phase I: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0 and 4 by subcutaneous injection
89087133|NCT04172233|Experimental|Phase I: AK101 270 mg|Biological: AK101 AK101 270 mg on Week 0 and 4 by subcutaneous injection
89087134|NCT04172233|Placebo Comparator|Phase I: Placebo|Biological: Placebo Placebo on Week 0 and 4 by subcutaneous injection
89087135|NCT04172233|Experimental|Phase II: AK101 45 mg|Biological: AK101 AK101 45 mg on Week 0, 4 and 16 by subcutaneous injection
89087136|NCT04172233|Experimental|Phase II: AK101 90 mg|Biological: AK101 AK101 90 mg on Week 0, 4 and 16 by subcutaneous injection
89087137|NCT04172233|Experimental|Phase II: AK101 135 mg|Biological: AK101 AK101 135 mg on Week 0, 4 and 16 by subcutaneous injection
89087138|NCT04172233|Placebo Comparator|Phase II: Placebo to AK101|Drug: Placebo Placebo on Week 1 and 4 by subcutaneous injection, and then AK101 on Week 12 16 by subcutaneous injection
89087139|NCT01221350|Experimental|Lipoic acid|Lipoic acid 600 mg oral dose (two 300 mg capsules) once daily in the morning during 60 days
89087140|NCT01221350|Placebo Comparator|Placebo|Placebo (two placebo capsules) orally once daily in the morning during 60 days
89087141|NCT02665429|No Intervention|Control|Providers who are subject only to the routine implementation of clinical practice guidelines without additional experimental intervention
89087142|NCT02665429|Experimental|Intervention|"Providers who are subject to routine clinical practice guideline implementation AND receive provider's own individual prescribing data profile intervention (Individual prescribing data profile and self-assessment)"
89087143|NCT00646633|Active Comparator|Acupuncture & educ|Patients will receive a total of 8 acupuncture treatments. In each of the first four sessions, they will also receive patient education.
89087144|NCT00646633|No Intervention|2. Standard care|Patients in the control arm will continue to receive standard care from their physician.
89087145|NCT00647569|Experimental|A|No previous major abdominal surgery
89087146|NCT00647569|Experimental|B|Previous major abdominal surgery
89087147|NCT00647647|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
89087148|NCT00647647|Active Comparator|2|Lamisil® Tablets 250 mg
89087149|NCT01221272|Experimental|Ranolazine/Placebo|Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
89087150|NCT01221272|Experimental|Placebo/Ranolazine|Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
89087151|NCT00647725|Active Comparator|I|Active phrase analgesia
89087152|NCT00647725|Active Comparator|II|Latent phrase analgesia
89087153|NCT02665897||Eclampsia|pregnant women with eclampsia will be diagnosed by the occurrence of seizures on top of preeclampsia.
89087154|NCT02665897||severe preeclampsia|pregnant women with severe preeclampsia will be diagnosed according to blood pressure ≥160/110 mmHg with proteinuria detection by boiling method +3,+4.
89087155|NCT02665897||healthy|matched normotensive pregnant women.
89087156|NCT01220414|Active Comparator|Men|
89087157|NCT01220414|Active Comparator|Women|
89087158|NCT01128894|Experimental|albiglutide|weekly albiglutide subcutaneous injection
89087159|NCT01128894|Active Comparator|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
89087160|NCT01128816|No Intervention|Standard HF therapy|Subjects will receive optimal standard therapy for heart failure conforming to national guidelines as determined by the referring cardiologist
89087161|NCT01128816|Active Comparator|Standard therapy for HF + ASV|Subjects will receive treatment with Adaptive Servo Ventilation in addition to optimal standard therapy for heart failure conforming to national guidelines, as determined by the referring cardiologist
89087162|NCT01220180||Epilepsy|
89087163|NCT01220180||Neuropathic Pain|
89087164|NCT01220180||Fibromyalgia|
89087165|NCT01220024|Experimental|2, 5x5cm bupivacaine collagen sponges|collagen sponges
89087166|NCT01220024|Placebo Comparator|2, Placebo collagen sponges|Placebo collagen sponges
89087167|NCT01128738|Active Comparator|GSK1358820|Onabotulinum toxin type A
89087168|NCT01128738|Placebo Comparator|Placebo|Placebo
89087169|NCT00625248||no anthithrombotic|procedures where there were no antithrombotics
89087170|NCT00625248||Antithrombotic - continued|patients who are on antithrombotics
89087171|NCT00625248||Discontinued Antithrombotic|Patients who were on antithrombotics but have been discontinued
89087172|NCT01143090|Experimental|Open Label|Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.
89087173|NCT05125146|Active Comparator|Pharmacotherapy|Trazodone is the treatment of choice for insomnia and participants allocated to the pharmaceutical intervention group will be prescribed trazodone as a regular treatment for the duration of the study. Participants on trazodone will also visit the psychiatrist every month to ensure their wellbeing is protected, the quality of the data is maintained, the conduct of the trial is in compliance with the approved protocol, and other regulatory requirements. Trazodone is the routine practice for insomnia and is covered through most patients' healthcare. However, if the patient does not have coverage for trazodone, they will be provided financial compensation to offset the cost.
89087174|NCT05125146|Experimental|e-CBTi|The e-CBTi modules will involve guiding participants to develop constructive and balanced strategies that would help to handle sleep problems. The e-CBTi program is based on the idea that insomnia is caused by thoughts and behaviours that can be changed. The modules aim to adjust negative thinking so patients can think about and adapt to the events that are happening to them, allowing them to adjust their behaviour and thoughts to be more realistic. Continuing, the modules are designed to help patients with insomnia deal with inaccurate thoughts about sleep and negative sleep behaviours, change their lifestyle practices that negatively affect their sleep, and improve relaxation skills to improve healthy sleep patterns. More specifically, the focus of the program is on addressing and exploring the concept of sleep, sleep habits, sleep hygiene, bedtime worries, negative thoughts, and thought examination.
89087175|NCT01165554|Experimental|[18F] Flutemetamol|
89087176|NCT01218308|Experimental|FluLaval® Quadrivalent Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of FluLaval® Quadrivalent vaccine at Day 0 and, if unprimed, 2 doses of FluLaval® Quadrivalent vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
89087177|NCT01218308|Active Comparator|Havrix Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of Havrix™ vaccine at Day 0 and, if unprimed, 2 doses of Havrix™ vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
89087178|NCT02887976|Experimental|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid)
89087179|NCT01165320|Experimental|Participants with Esophageal Candidiasis|Candida infection is strongly suspected based on clinical symptoms and the participant's clinical course, white moss (plaque) is observed on the esophageal mucosa, and therapy via intravenous infusion is judged to be suitable for the present episode of esophageal candidiasis. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 7 and 28 days, respectively.
89226158|NCT04745026|Experimental|GWP42003-P 10 mg/kg/day|Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive 5 milligrams per kilogram per day (mg/kg/day) GWP42003-P for 1 week and then 10 mg/kg/day GWP42003-P for 11 weeks.
89087180|NCT01165320|Experimental|Participants with Invasive Candidiasis|Candida infection is strongly suspected based on the presence of refractory fever not responding to an antibiotic agent, or clinical symptoms at the site of disease, or the participant's clinical course. In addition, at least 1 of the following criteria must be met: 1) Candida infection is strongly suspected based on radiographic imaging findings and positive serological test for fungus, 2) yeast is observed by direct microscopy or histopathological test of tissue biopsied from the site of disease, or 3) Candida species are observed by culture test of specimens sampled from the site of disease. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 56 days, respectively.
89087181|NCT01165320|Experimental|Participants with Aspergillosis|Aspergillus infection is strongly suspected based on clinical symptoms and the participant's clinical course, and characteristic radiographic imaging findings are observed. In addition, at least 1 of the following criteria must be met: 1) risk factors predisposing to an Aspergillus infection, 2) positive serological test for Aspergillus, 3) acute-branching mold with separated hyphae are observed by direct microscopy or histopathological test, or 4) Aspergillus species are observed by culture test. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 84 days, respectively.
89087182|NCT01217606|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
89087183|NCT01217606|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
89087184|NCT05463146|Experimental|Deep breathing excercises|Deep breathing is known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
89087185|NCT05463146|Experimental|Deep breathing excercise and progressive muscle relaxation|PMR involves participants actively contracting muscles to create tension and progressively releasing it. This routine is repeated until participants acquire complete relaxation
89087186|NCT05460962|Experimental|Deep breathing excercises|is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
89087187|NCT05460962|Experimental|Deep breathing excercise and progressive muscle relaxation|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
89087188|NCT01128114|Experimental|Quetiapine XR|Quetiapine fumarate (Seroquel XR)
89087189|NCT05458544|Experimental|[177Lu]Ludotadipep 3.7 GBq|If investigators observed one or no DLT in 6 patients at the 3.7 GBq dose level, the study can advance to the Phase 2a part of the trial after the safety review committee (SRC) review.
89087190|NCT01217060|Experimental|Docetaxel + 5-FU + Radiation + Surgery|Docetaxel 20 mg/m2 given by vein (IV) once a week up to 5 1/2 weeks. Dexamethasone 10 mg IV 30 minutes prior to weekly Docetaxel. 5-FU 300 mg/m2 IV, continuously for 96 hours 5 days a week for about 5 1/2 weeks. Radiation 50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks. Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
89087191|NCT04816669|Experimental|Lyophilized SDV|
89087192|NCT04816669|Experimental|Frozen liquid MDV (control for lyo SDV)|Control for lyophilized SDV
89087193|NCT04816669|Experimental|Frozen-liquid with LNP size at the upper end of specification|
89087194|NCT04816669|Experimental|RTU|
89087195|NCT04816669|Experimental|Frozen liquid MDV (given as third dose following a primary series of lyophilized BNT162b2)|Additional vaccine dose, using the frozen-liquid formulation, offered to participants who originally received 2 doses of the lyophilized formulation of BNT162b2
89087196|NCT01165242|Experimental|Group A|Subjects were vaccinated with vaccine GSK134612 Lot A
89087197|NCT01165242|Experimental|Group B|Subjects were vaccinated with vaccine GSK134612 Lot B
89087198|NCT01165242|Active Comparator|Group C|Subjects were vaccinated with Menactra®
89087199|NCT01170065|Experimental|BIBF 1120 low qd|Low dose BIBF 1120 once daily
89087200|NCT01170065|Experimental|BIBF 1120 low bid|Low dose BIBF 1120 twice daily
89087201|NCT01170065|Experimental|BIBF 1120 medium bid|Intermediate dose BIBF 1120 twice daily
89087202|NCT01170065|Experimental|BIBF 1120 high bid|High dose BIBF 1120 twice daily
89087203|NCT04174417|Active Comparator|systolic blood pressure (SBP)|Systolic blood pressure (SBP) for group 1 patients 80-90 mmHg
89087204|NCT04174417|Active Comparator|mean blood pressure (MBP)|Mean blood pressure (MBP) for group 2 patients 50-65 mmHg
89087205|NCT02885844|Experimental|INVERTED VISION|inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
89087206|NCT02885844|Active Comparator|NORMAL VISION|During normal vision trials, subject's field of view will be restricted by goggles without lenses (see below) in order to be equivalent to the inverted vision one.
89087207|NCT00966693|Experimental|Treatment (lenalidomide, thalidomide, dexamethasone)|"Participants receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Participants also receive dexamethasone PO QD on days 1-4, 9-12, and 17-20 of courses 1-2, and days 1, 8, 15, and 22 of subsequent courses. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Participants who have stable or responding disease to treatment receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants may receive dexamethasone at the discretion of the investigator."
89087208|NCT01215968|Placebo Comparator|Placebo|"Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5.~Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
89087209|NCT01215968|Experimental|LY2189265|"Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5.~1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
89087210|NCT02663713|Experimental|Ticagrelor|Ticagrelor 60 mg twice daily
89087211|NCT02663713|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily
89226159|NCT04745026|Placebo Comparator|Placebo|Participants will be stratified based on their age (6 to 11 years old, 12 to 17 years old), use of antipsychotics (on versus off), and region (North America versus Rest of the World) and will be randomized to receive matching placebo for 12 weeks.
89226160|NCT04744883|Experimental|SMT plus placebo/naloxone|Participants are randomly assigned to an 8 week SMT treatment group conducted by certified physical therapists. Immediately before and after the treatment sessions along with midway through the treatment (after 4 sessions), participants will undergo the placebo/naloxone administration intervention to assess mechanisms of SMT or MT-related changes.
89087212|NCT02664649|Experimental|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
89087213|NCT02664649|Active Comparator|Standard of care|VKA or Antiplatelet therapy
89087214|NCT02664493|Experimental|SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.~Methylprednisolone 0.5 g daily for 3 days will be administered in (Steroid pulse therapy) SPT group."
89087215|NCT02664493|No Intervention|non-SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.~Steroid pulse therapy (SPT) will not be applied and no additional treatment will be added in non-SPT group"
89087216|NCT00963807|Experimental|Treatment|Patients receive docetaxel IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo FDG PET/CT, FLT PET/CT, and thoracic CT at baseline and the end of cycles 1 and 2 and then undergo surgery.
89087217|NCT01142466|Experimental|Rebif (3x44 mcg) Group|
89087218|NCT01142466|No Intervention|No treatment Group|
89087219|NCT02663635|Other|Single Arm|
89087220|NCT00648505|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
89087221|NCT00648505|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
89087222|NCT01215734|Active Comparator|High-Dose Trivalent Inactivated Influenza Vaccine|Forty adult hematopoetic stem cell transplant recipients at least 6 months post transplant will receive high dose trivalent influenza vaccine
89087223|NCT01215734|Active Comparator|Standard dose Trivalent Inactivated Flu Vaccine|Twenty Adult stem cell transplant recipients at least 6 months post transplant will receive standard dose trivalent influenza vaccine.
89087224|NCT04172311|Experimental|Modified Atkins Diet|"Modified Atkins Diet administration~Carbohydrates will be restricted to 10 grams per day.~Recipes will be provided to be prepared from easy home available foods, to have 2.5 gram per meal. Along with this, a list of carbohydrate free foods will be provided.~Fats intake will be actively encouraged. Protein intake will be unrestricted.~Medications will be changed to carbohydrate free preparations.~A multivitamin and calcium supplementation will be added."
89087225|NCT04172311|Active Comparator|Levetiracetam|Levetiracetam will be started at a dose of 10 mg/kg/day in two divided doses and increased to 20 mg/kg/day after 1 week. Syrups will be used in children younger than 5 years of age, and tablets will be used in children > 5 years of age. Further dose titration will be done as per the seizure control, in 10 mg/kg/day increments in 2 weekly intervals, to a maximum of 60mg/kg/day.
89087226|NCT01169987||Participants Treated with Adalimumab|Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment is initiated. All medications will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
89087227|NCT02863185|Experimental|Pitavastatin group|Use of 2mg or 4mg Pitavastatin
89087228|NCT02863185|Active Comparator|Atorvastatin group|Use of 10mg or 20mg Atorvastatin
89087229|NCT01215422||children intubated with Glidescope|children intubated with Glidescope
89087230|NCT01215422||children intubated with DCI|children intubated with DCI
89087231|NCT04315025|Active Comparator|Conditioned Medium (CM)|a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar
89087232|NCT04315025|Active Comparator|UC-MSC + NaCl|1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar
89087233|NCT04315025|Active Comparator|UC-MSC+CM|1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar
89087234|NCT02664571|Other|ACA with isolated hemosiderosis|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with isolated hemosiderosis.~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
89087235|NCT02664571|Other|ACA with lobar hematoma(s)|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with lobar hematoma(s).~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
89087236|NCT02664571|Other|Alzheimer's without ACA|"This group is composed of Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy (ACA).~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
89087237|NCT02664571|Other|Healthy volunteers|"This group is composed of healthy volunteers.~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
89087238|NCT00972153|No Intervention|No device used|
89087239|NCT00972153|Sham Comparator|Device attached, not activated|
89087240|NCT00972153|Experimental|Device deployed and activated|
89087241|NCT04736485|Experimental|FLOT regimen plus Spartalizumab|"Standard FLOT regimen~Docetaxel 50 mg/m² IV infusion on D1~Oxaliplatine 85 mg/m² IV infusion on D1~Leucovorin 200 mg/m² IV infusion on D1~Fluorouracile 2600 mg/m² 24 h IV infusion on D1~with Spartalizumab PDR001 Patients will received the fixed dose of 400 mg per IV infusion on D1 every four weeks (q4w) for 2 pre-operative cycles (8 weeks) and 2 post-operative cycles (8 weeks)"
89087242|NCT00647881|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
89087243|NCT00647881|Active Comparator|2|Paxil CR™ Tablets 25 mg
89087244|NCT02861625||Group A|letter of condolence offering to the reliable person a post-death consultation with the reference physician (sent between J15 and J30 post death)
89087245|NCT02861625||Group B|no intervention, i.e without a letter of condolence proposing a consultation with the reference physician
89087246|NCT04174261|Experimental|Ticagrelor - Remote Ischemic Preconditioning|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
89087247|NCT04174261|Other|Ticagrelor - Control|Ticagrelor 180mg loading dose, and 90mg b.i.d thereafter. BP-cuff uninflated around the non-dominant arm
89087248|NCT04174261|Active Comparator|Clopidogrel - Remote Ischemic Preconditioning|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. 3 cycles of 5-minute ischemia/5-minute reperfusion using a BP cuff around the non-dominant arm
89087249|NCT04174261|Other|Clopidogrel - Control|Clopidogel 300mg loading dose, and 75mg q.d. thereafter. BP-cuff uninflated around the non-dominant arm
89087250|NCT00971997|Experimental|Lispro 50/50|
89087251|NCT04171609|Experimental|Cancer survivors|Adult survivors of any kind of cancer (except for minor skin cancer) are eligible to participate
89087252|NCT00910741|Experimental|Nanoplatin|"Nanoplatin (NC-6004) had to be administered once every 3 weeks, on Day 1, Day 22 and Day 43 etc.~Gemcitabine had to be administered to every patient 2 times on Day 1 and Day 8 every 3 weeks after the infusion of Nanoplatin (NC-6004)."
88812528|NCT03726307|Experimental|DCreg: 1.2 million cells/kg+SOC|"N=3 participants will receive 1.2 (± 0.2) million cells/kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
89087253|NCT02863731|Experimental|Alternating postures: first day|Alternating body postures on the first day of measurement. Sitting body posture on the second day of measurement.
89087254|NCT02863731|Experimental|Alternating postures: second day|Alternating body postures on the second day of measurement. Sitting body posture on the first day of measurement.
89087255|NCT02863731|No Intervention|Control group|Sitting body posture on both days of measurement.
89087256|NCT02863497|Active Comparator|Mindfulness Intervention|For those randomly selected to receive mindfulness-based sex therapy, they will be asked to participate in four sessions of group therapy, over a period of 2 months. Sessions will occur in a conference room at St. Paul's Hospital. Part of the protocol of the Mindfulness - based sex therapy is that they will have a diary to be filled in. This diary will not be collected at the end of the therapy, as it is for the participant to keep. The group facilitators will be collecting session attendance.
89087257|NCT02863497|No Intervention|No Intervention|For those who are not in the intervention group they will simply be asked to fill the initial questionnaire and the 3 month post questionnaire. They will not participate in any other questionnaires.
89087258|NCT00647959|Experimental|1|Doxycycline Tablets, 150mg
89087259|NCT00647959|Active Comparator|2|Adoxa Tablets 150 mg
89087260|NCT00648583|Experimental|1|Ondansetron Tablets 24 mg
89087261|NCT00648583|Active Comparator|2|Zofran® Tablets 24 mg
89087262|NCT04284579|Experimental|time for cannulation|intravenous cannulation after sevoflurane induction
89087263|NCT02882334|Experimental|Finger individuation training|Finger Force Manipulandum
89087264|NCT02882334|Active Comparator|control|conventional physiotherapy
89087265|NCT02664259|Experimental|UTB-VBN-EBUS group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
89087266|NCT02664259|Active Comparator|UTB-VBN-EBUS-X-ray group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
89087267|NCT00630123||1|Electroconvulsive Therapy (ECT): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
89087268|NCT00630123||2|Transcranial Magnetic Stimulation (TMS): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
89087269|NCT04285749|Experimental|Fluvastatin|"Participants will receive Fluvastatin for 2 weeks.~RNA-sequencing and gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision."
89087270|NCT03809481|Experimental|Danaparoid Sodium|Subjects will receive danaparoid via IV infusion for at least 7 days then transition to a VKA. IV loading bolus injection of 2250 U, followed by 400 U/h for 4 hours, then 300 U/h for 4 hours, then a maintenance infusion of 150-200 U/h.
89087271|NCT03809481|Active Comparator|Argatroban|Subjects will receive argatroban 2 microgram/kg/min as a continuous infusion, titrated to an aPTT that is 1.5 to 3.0 x initial baseline value, but not exceeding 100 seconds.
89087272|NCT00649129|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
89087273|NCT00649129|Active Comparator|2|Ditropan XL® Tablets 10 mg
89087274|NCT01127646|Experimental|Atomoxetine|Participants received 25-80 milligrams (mg) of atomoxetine orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 25-80 mg of atomoxetine orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 25-80 mg of atomoxetine orally, once daily for 1-5 days.
89226161|NCT04744883|Experimental|MT plus placebo/naloxone|Participants are randomly assigned to an 8 week MT treatment group conducted by certified clinical therapists. Immediately before and after the treatment sessions along with midway through the treatment (after 4 sessions), participants will undergo the placebo/naloxone administration intervention to assess mechanisms of SMT or MT-related changes.
89226162|NCT04731649|Experimental|Sex Education + Standard Care|The experimental arm will receive the FTT + intervention
89226163|NCT04731649|No Intervention|No Education + Standard Care|The control arm will not receive the FTT + intervention
89226164|NCT04730843|Experimental|Part A dose escalation|ES102 will be escalated in patients with advanced solid tumors.
89226165|NCT04730843|Experimental|Part B expansion|Subjects with advanced non-small cell lung cancer, advanced esophageal squamous cell carcinoma, other advanced solid tumors (such as nasopharyngeal carcinoma, cervical cancer, gastrointestinal tumors, other reproductive system tumors, etc.) will be treated with ES102 at the RP2D.
89226166|NCT04727619|Experimental|Experimental|Participants who participated in the SLEEP program.
89226167|NCT04727619|No Intervention|Control|Participants who did not participate in the SLEEP program.
89226168|NCT04727359||FIT64b model project|Patients being treated in FIT64b model project at UKT
89226169|NCT04727359||Standard care|Patients being treated in standard care (control hospitals)
89226170|NCT04725656|Active Comparator|Active arm, low concentration (18 mg/mL) nicotine salt e-liquids|
89226171|NCT04725656|Active Comparator|Active arm, high concentration (59 mg/mL) nicotine salt e-liquids|
89226172|NCT04725656|Other|Control group|Receive only smoking cessation counseling
89226173|NCT04720625|Experimental|Adapt2Quit|These participants will receive Adapt2Quit motivational messaging and quitline facilitation messaging for 6 months.
89226174|NCT04720625|Active Comparator|Control|These participants will receive quitline facilitation-only messaging for 6 months.
89226175|NCT04719156|Other|ICG use followed by SPY-PHI imaging.|Participants will be injected with 2.0mg/kg of ICG dye to access tumor margin using Stryker SPY imaging technology.
89226176|NCT04718974|Experimental|"intervention  Call for life- mHealth tool with standard of care for PLHIV"|"The system has options to either use interactive voice response or short message service and the user has to make a choice, get a secret pin code which ensures privacy to end user.~The mHealth tool/system offers personalised pill reminder calls, health tip messages, clinic appointment reminders and remote symptom reporting"
89226177|NCT04718974|No Intervention|"Standard of care usual care"|"Standard~• Care and support for people living with HIV, and the first line ART regimen is based on the Apr 2018, consolidated guidelines for prevention and treatment of HIV in Uganda (MoH, 2018), and will also follow the healthcare services package for PLHIV including the Adult Care and Treatment Package."
89226178|NCT04716309|Active Comparator|VLP|Open reduction and volar locking plate
89226179|NCT04716309|Active Comparator|CRPP|Closed reduction and percutaenous K-wires/pins
89226180|NCT04712422||Healthy participants|At least 25 healthy participants aged from 18 to 50 years old. Participants will be excluded if pregnant.
89226181|NCT04712422||Pathologic group|At least 22 participants with diagnosis of Myotonic Dystrophy 1.
89226182|NCT04712097|Experimental|M + Len (Arm A)|Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
89087275|NCT01127646|Active Comparator|Osmotic-release oral system methylphenidate|Participants received 18-54 mg of osmotic-release oral system (OROS) methylphenidate orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 1-5 days.
89087276|NCT02660047|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
89087277|NCT02660047|Placebo Comparator|Liraglutide - Placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dose: same as Liraglutide~Duration: 26 weeks"
89087278|NCT04285437|Experimental|massage|neonates are massaged by their mother during the first 2 months after birth.
89087279|NCT04285437|No Intervention|control|neonates are not massaged.
89087280|NCT00648661|Experimental|1|Escitalopram Oxalate Tablets 20 mg
89087281|NCT00648661|Active Comparator|2|Lexapro® Tablets 20 mg
89087282|NCT05367414|Experimental|aromatherapy|In addition to routine medical treatment, massage with diluted tea tree oil was applied to the individuals in this group.
89087283|NCT05367414|Placebo Comparator|placebo|Individuals in this group were provided massage with sweet almond oil in addition to routine medical treatment.
89087284|NCT05367414|No Intervention|control|Individuals in this group received only routine medical treatment.
89087285|NCT04284111||Children with myopia|"A total of 1,000 children from 8 hospitals in China is required to undergo ophthalmic examinations and complete questionnaires at baseline and~1yr after wearing ortho-k lenses."
89087286|NCT04171687|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
89087287|NCT04171687|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and Tegoprazan 50mg tablet once daily for 7 days
89087288|NCT04171687|Experimental|Clopidogrel 75 mg + RAPA113|Oral administration of clopidogrel 75 mg tablet and RAPA113 tablet once daily for 7 days
89087289|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device and myringotomy|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty, and myringotomy
89087290|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty only (no myringotomy)
89087291|NCT03556215|Experimental|No effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and airy middle ear (without otitis media with effusion), Eustachian tube dilatation device, no myringotomy
89087292|NCT00648817|Placebo Comparator|Group 1|"Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the first 14 days of the study.~Tenofovir DF placebo tablet QD for the last 14 days of the study."
89087293|NCT00648817|Active Comparator|Group 2|"Tenofovir DF placebo tablet QD for the first 14 days of the study.~Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the last 14 days of the study."
89087294|NCT02664025|Active Comparator|simulation group|Interns will carry out 10 VE on a simulator
89087295|NCT02664025|No Intervention|Control group|Interns who will not perform any simulated VE
89087296|NCT02862717||Hemodialysis (HD)|HD patients in MOH dialysis centres notified to NRR.
89087297|NCT02862717||Continuous ambulatory peritoneal dialysis (CAPD)|CAPD patients in MOH dialysis centres notified to NRR.
89087298|NCT02663557||non-hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP<140 mmHg; 2. Systolic blood pressure-coefficient variation (SBP-CV) < Median SBP-CV
89087299|NCT02663557||non-hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP< 140 mmHg; 2. SBP-CV > Median SBP-CV
89087300|NCT02663557||hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV < Median SBP-CV
89087301|NCT02663557||hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV > Median SBP-CV
89087302|NCT04284033|Experimental|Standard then Extended Infusion Set|Participants will start with wearing the standard infusion set for up to 7 days, then switch to the Extended Wear infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
89087303|NCT04284033|Experimental|Extended then Standard Infusion Set|Participants will start with wearing the Extended Wear infusion set for up to 7 days, then switch to the standard infusion set for up to 7 days, then repeat the cycle for a total of 4 weeks
89087304|NCT02663479|Experimental|Cardiopressin|A 5 capsule proprietary blend of herbal extracts and nutrients
89087305|NCT02663479|Placebo Comparator|Placebo|A 5 capsule placebo matched in color and size to the Experimental supplement
89087306|NCT02663401|No Intervention|Control|Control situation in campus cafeterias where no labelling of food is proposed
89087307|NCT02663401|Experimental|Front-of-pack labelling (5-CNL)|Introduction of the 5-CNL front-of-pack nutrition label on shelf display tags for every food and beverage sold in the campus cafeteria. Communication campaigns accompanying the introduction of the label
89087308|NCT02862561|Experimental|Precision Cell Immunotherapy|"Precision Cells combined with Chemotherapy treatment: Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood. Precision Cells：once per 3 weeks with a total of three periods."
89087309|NCT02862561|Active Comparator|Chemotherapy|"Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood."
89087310|NCT02663323|Experimental|MeRes100 - BRS|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
89087311|NCT01215188|Experimental|V114 Aluminum-adjuvanted|Four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
89087312|NCT01215188|Experimental|V114 Non-adjuvanted|Four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
89087313|NCT01215188|Active Comparator|Prevnar 13®|Four IM doses at 0.5 mL of Prevnar 13® at 2, 4, 6, and 12 to 15 months of age.
89087314|NCT04285281|Experimental|Gabapentin|Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
89087315|NCT04285281|No Intervention|Control group|Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
89087316|NCT02663245|Experimental|Intervention 1|Diabetes specific consultation + multicomponent intervention aimed at professionals and patients
89087317|NCT02663245|Experimental|Intervention 2|Multicomponent intervention aimed at professionals and patients minus the diabetes specific consultation.
89087318|NCT02663245|No Intervention|Control group|No intervention. Data of the control groups will be retrieved from the SIDIAP.
89087319|NCT00629733|Experimental|Ro-14|
89087320|NCT02659657|Experimental|Interleukin-2 interventions|Patients with standard risk hematologic malignancies undergoing an unmodified haploidentical HCT will be eligible. Once patients achieved neutrophil engraftment will be given IL-2, 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days).
89087321|NCT02861547||Traumatic brain injury|
89087322|NCT02659891|Active Comparator|Group 1 (Treatment)|Intravenous immune globulin (IVIg; Privigen®) 1g/kg monthly for 2 months with immunosuppression reduction.
89087323|NCT02659891|Placebo Comparator|Group 2 (Control)|Placebo infusion monthly for 2 months with immunosuppression reduction
89087324|NCT02863341|Experimental|naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
89087325|NCT02863341|No Intervention|naive Wait-list Control arm|
89087326|NCT02863341|Experimental|non-naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
89087327|NCT02863341|No Intervention|non-naive Wait-list Control arm|
89226183|NCT04712097|Experimental|R + Len (Arm B)|Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)
89087328|NCT02659735|Experimental|Panel 1: Treatment ADBC|Participants will receive Treatment A (600 milligram [mg] JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 1; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 2; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 3; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
89087329|NCT02659735|Experimental|Panel 1: Treatment BACD|Participants will receive Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 1; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 2; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 3; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
89087330|NCT02659735|Experimental|Panel I: Treatment CBDA|Participants will receive Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 1; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 2; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 3; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
89087331|NCT02659735|Experimental|Panel I: Treatment DCAB|Participants will receive Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 1; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 2; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 3; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
89087332|NCT02659735|Experimental|Panel 2: Treatment EFG|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
89087333|NCT02659735|Experimental|Panel 2: Treatment FGE|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
89087334|NCT02659735|Experimental|Panel 2: Treatment GEF|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
89087335|NCT02659735|Experimental|Panel 2: Treatment GFE|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
89087336|NCT02659735|Experimental|Panel 2: Treatment FEG|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
89226184|NCT04712097|Experimental|M + Len (US Extension Arm C)|Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
89087337|NCT02659735|Experimental|Panel 2: Treatment EGF|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
89087338|NCT04283799|Experimental|The new HMF group|Very preterm infants tolerating 80mL/kg/day of enteral feeding for >24 hours are started to receive the new human milk fortifier. Study procedure is from the first day of full-strength fortification feeding to the 21th days of that.
89087339|NCT04283799|No Intervention|Other HMF group|This group is a historical control group using the other HMF. Infants with similar gestational age, birth weight, feeding start time and length of hospitalization are enrolled into the control group.
89087340|NCT04286763||Hilar stricture|Bile duct Stricture (corresponding to E3, E4 and E5 from of Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
89087341|NCT04286763||Low level Stricture|Bile duct Stricture (corresponding to E1 and E2 from Strasberg. -According to the classification proposed by Strasberg of operative bile duct injuries).
89087342|NCT00648193|Experimental|1|Paroxetine hydrochloride 40 mg tablet
89087343|NCT00648193|Active Comparator|2|Paxil® 40 mg Table
89087344|NCT04283721|No Intervention|No Video|These patients will not see the educational video on epidural/spinal analgesia and will receive the usual Irish standard of care.
89087345|NCT04283721|Experimental|Antenatal Video|These patients will see the educational video on epidural/spinal analgesia only at the antenatal classes.
89087346|NCT04283721|Experimental|Labour Video|These patients will see the educational video on epidural/spinal analgesia only at the beginning of labour.
89087347|NCT04283721|Experimental|Video Twice|These patients will see the educational video on epidural/spinal analgesia twice (during antenatal classes and at the beginning of labour).
89087348|NCT01215032|Experimental|Metformin|This is the only arm of this phase 2 open label study
89087349|NCT02659579|Experimental|The Reader Organisation's Shared Reading Programme|In the Reader Organisation's Shared Reading Programme, parents and children will attend The Reader Organisation's weekly shared reading programme for 8 weeks. The programme consists of two different modules. Parents will attend 'Magical Storytimes' with their children, in which a collection of shared book reading sessions are led by a project worker. Parents will also attend sessions on their own ('Stories for you and Yours') in which they will be informed how to choose books and read interactively with their child.
89087350|NCT02659579|Active Comparator|Shared Reading control|In the Shared Reading control parents and children will attend a weekly shared reading group at a library for 8 weeks where parents/children will read in a shared reading group which will be coordinated by a group facilitator.
89087351|NCT00962247|Experimental|Sedentary; usual, 25% reduced, 50% reduced|The initial 3 weeks of the study, children were asked to maintain their usual targeted sedentary behaviors (TV, video game, computer use) measured by a television reduction device (TV Allowance). The following 3 weeks children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 25% from the usual sedentary condition using a television reduction device (TV Allowance). The final 3 weeks of the study, children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 50% from the usual sedentary condition using a television reduction device (TV Allowance)
89087352|NCT02659423||Green Dot BIC 1|"Bystander Intervention Components Clusters will include at least a component of Green Dot.~E.g. Comparisons will be made across schools that have Green Dot versus those that don't have Green Dot. (BIC 1)"
89087353|NCT02659423||Online BIC 2|"Bystander Intervention Components Clusters will include at least a component of online bystander training.~E.g. Comparisons will be made across schools that have online bystander training versus those that do not. (BIC 2)"
89087354|NCT02659423||Alternative programs BIC 3|"Bystander Intervention Components Clusters will include at least a component of Green Dot.~E.g. Comparisons will be made across schools that have alternative program versus those that do not. (BIC 3)"
89087355|NCT02663089|Experimental|[14C]-GSK961081 IV+GSK961081 inhalation; [14C]-GSK961081 oral|On Day 1 of Treatment Period 1, after an overnight fast of at least 8 hours, each subject will receive [14C] GSK961081 4 micrograms (mcg) by IV infusion over 1 hour. Within 5 minutes after the start of infusion, subjects will take 1200 mcg non-radiolabelled GSK961081 by inhalation. After Treatment Period 1, there will be a washout of at least 2 weeks. On Day 1 of Treatment Period 2, after an overnight fast of at least 8 hours, each subject will take 200 mcg [14C]-GSK961081 as an oral solution.
89087356|NCT02663167|Experimental|Internet-delivered Cognitive-Behavioral Therapy|
89087357|NCT02664103|Experimental|SAR439281(Cohort 1)|Regimen 1: one full-dose tablet containing capecitabine and cyclophosphamide, given BID without interruption
89087358|NCT02664103|Experimental|SAR439281(Cohort 2)|Regimen 2: two tablets containing capecitabine and cyclophosphamide, given OD without interruption
89087359|NCT02664103|Experimental|SAR439281(Cohort 3)|Regimen 3: one tablet containing capecitabine and cyclophosphamide, given OD without interruption
89087360|NCT02663011||5YR boy|
89087361|NCT02663011||5YR girl|
89087362|NCT02663011||4YR boy|
89087363|NCT02663011||4YR girl|
89087364|NCT02663011||3YR boy|
89087365|NCT02659345|Experimental|Art Therapy|The art therapy intervention will be executed by an art therapist at the Cancer Center. The same art therapy practices that are utilized in daily practice will be employed in this study. The intervention will include assessment of patient's needs and goals in addition to utilization of various art modalities. Sessions will conclude with processing of the art and supportive counseling as appropriate. Pilot testing of the intervention has been performed informally at Maroone Cancer Center with positive feedback provided by patients and their support systems to the physicians, nurses, and art therapist. Change in pain, emotional distress, depression, adn anxiety will be measured by the emotions thermometer.
89087366|NCT00918580|Experimental|1|
89087367|NCT02663869||HIV Aging-Young|200 patients
89087368|NCT02663869||HIV Aging-Old|200 patients
89087369|NCT02663869||controls|1200 patients
89087370|NCT02662855|Active Comparator|Control|WHO-recommended therapies, mainly symptomatic and supportive treatments. Briefly: body fluid management (intravenous or oral, depending on patient status), balanced nutrition (including glucose, electrolytes, vitamin, et al.), preventing intravascular volume depletion, correcting profound electrolyte abnormalities, avoiding the complications of shock, defervesce, anti-diarrheal, acesodyne, anti-anxiety. For patients with positive Plasmodium detection or bacterial infection, apply artemether-lumefantrine or antibiotics respectively. Details refer to 'Manual for the care and management of patients in Ebola Care Units/Community Care Centres, Interim emergency guidance' and 'Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the Front-line Health Worker' by WHO.
89087371|NCT02662855|Experimental|Treatment|WHO-recommended therapies plus oral administration of Favipiravir
89087372|NCT00648271|Experimental|1|Metoprolol Tartrate Tablets 25 mg
89087373|NCT00648271|Active Comparator|2|Lopressor® Tablets 50 mg
89087374|NCT04170127|Experimental|Right side of the maxilla|the right side of the maxilla
89087375|NCT04170127|No Intervention|Left side of the maxilla|left side of the maxilla
89087376|NCT00648349|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
89087377|NCT00648349|Active Comparator|2|Aciphex® Delayed-Release Tablets 20 mg
89226185|NCT04704934|Experimental|Trastuzumab deruxtecan|Participants who will be randomized to receive a 6.4 mg/kg intravenous (IV) dose of trastuzumab deruxtecan once every 3 weeks on Day 1 of each 21-day cycle.
89226186|NCT04704934|Active Comparator|Ramucirumab + paclitaxel|Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle.
89523119|NCT02581709|Experimental|Countering cognitive impairment|Each participant will complete neuropsychological assessments at baseline (prior to chemotherapy) and after chemotherapy. Patients identified as experiencing cognitive decline measured using Reliable Change Index on at least one cognitive function measure from before until after chemotherapy will be offered the intervention. Participants in the interventions will complete a neuropsychological assessment after completion of the intervention. Questionnaires to assess other non-cognitive factors e.g. quality-of-life will be administered at the end of chemotherapy to all participants and after the intervention to participants in the intervention.
89523120|NCT02554331|Experimental|Patients RBD|Patients RBD subject to FP-CIT single-photon emission computed tomography and Neuropsychological evaluation and Gait recording with sensors
89226189|NCT04692012|Other|FRESH CORNEAL LENTICULE IMPLANTATION|The aim of this study is to investigate the effect of fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
89226190|NCT04691297|Experimental|Escape|The ESCAPE program provides 8 counseling sessions over the phone, provides nicotine replacement therapy at no cost, and education about lung screening
89523121|NCT02554331|Other|controls healthy volunteers|controls healthy volunteers subject to Neuropsychological evaluation and Gait recording with sensors
89523122|NCT01999595|Experimental|High frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
89523123|NCT01999595|Experimental|Low frequency TENS with large pads|"TENS=transcutaneous electrical nerve stimulation~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 10 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
89523124|NCT01999595|Experimental|High frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation~High frequency TENS was a 80 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
89226191|NCT04691297|Experimental|Standard Care|The usual care program will include 1 counseling session, nicotine replacement therapy at no cost referral and enrollment in quitworks and an educational brochure about lung cancer screening
89226192|NCT04682704|Experimental|Frequency 20Hz; amplitude 1mA below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
89226193|NCT04682704|Active Comparator|Frequency 5Hz; amplitude 1mA below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
89226194|NCT04682704|Active Comparator|Frequency 20Hz; amplitude 50% below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
89226195|NCT04682704|Active Comparator|Frequency 5Hz; amplitude 50% below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
89087378|NCT04253938|Other|Education|"Visit 1 - Parent/Caregiver will complete a questionnaire about breastfeeding/formula feeding practices and food insecurity. The questionnaire includes a nutrition history, asking how much formula is consumed, number of times they are breastfed per day, what types and amounts of solid foods are consumed, and if vitamins and/or iron drops are given (including frequency and amount). After the questionnaire, the participant will be asked to demonstrate how they typically prepare infant formula. Finally, the PI or designee will provide a brief education about appropriate feeding practices as recommended by the AAP. This will include appropriate formula preparation methods, use of juice, introduction of cow's milk and solids, as well as basic nutrition information.~Visit 2 - If the family returns for a clinic visit again before the child turns 1 year of age, the same procedures as Visit 1 will be performed, including reinforcement of education."
89087379|NCT00649207|Experimental|1|"This is an open label study; therefore, there are no numbered/labeled study arms.~This is a dose escalation study, ABT-888 dose will be escalated in conjunction with two schedules of whole brain radiation therapy (WBRT). Subjects may be treated WBRT for 3 weeks (15 days) or 2 weeks (10 days)."
89087380|NCT02662621|Other|ill patient|Patient with a cancer disease
89087381|NCT02662621|Other|Healthy volunter|Subject without any cancer pathology
89087382|NCT02663947||ultrasound group|ultrasonographic measure for optic nerve sheath diameter
89087383|NCT00920686|Experimental|NXN-188|NXN-188, 600 mg, PRN
89087384|NCT00920686|Active Comparator|sumatriptan succinate 100 mg|Sumatriptan, 100 mg, PRN
89087385|NCT00920686|Placebo Comparator|placebo|matching, PRN
89087386|NCT00648427|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
89087387|NCT00648427|Active Comparator|2|Paxil CR™ Tablets 25 mg
89087388|NCT02656225|Experimental|Ejiao compound|The participants in experimental group receive Ejiao compound (20ml, twice daily) orally for 4 weeks.
89087389|NCT02656225|Active Comparator|Niferex|The participants in control group receive Polysaccharide Iron Complex(Niferex)(150mg per tablet, once daily) orally after breakfast over 4 weeks.
89087390|NCT04253470||cleavage stage embryo|embryo which is on day 2 or 3
89087391|NCT04253470||blastocyst embryo|embryo which is on day 5
89523125|NCT01999595|Experimental|Low frequency TENS with small pads|"TENS=transcutaneous electrical nerve stimulation~Low frequency TENS was a 3 Hz TENS delivered via a pair of electrodes with the size of 5 cm x 2.5 cm~Dosage: same as electrical density using a standardized pad size (5cm x 5cm) with comfortable intensity"
89087392|NCT02662543||Hospitalized AGE patients|Children less than 18-years-old hospitalized due to acute gastroenteritis to seven Estonian hospitals participating in this study
89087393|NCT04170751|Experimental|group N|In group N, 16 mcg / cc of norepinephrine was infused to patients.
89087394|NCT04170751|Experimental|group V|In group V, 0.4 unit / cc of vasopressin was infused to patients.
89087395|NCT04865536|Active Comparator|Cohort 1 TBI-223 1800 mg, fasting|1800 mg, fasting
89087396|NCT04865536|Active Comparator|Cohort 1 TBI-23 1800, fed|TBI-23 1800, fed
89087397|NCT04865536|Placebo Comparator|Cohort 1 Placebo, fed|Placebo, fed
89087398|NCT04865536|Placebo Comparator|Cohort 1 Placebo fasting|Placebo fasting
89087399|NCT04865536|Active Comparator|Cohort 2 TBI-223, 2400mg,fed|2400mg,fed
89087400|NCT04865536|Active Comparator|Cohort 2 TBI-223, 2400 mg fasting|2400 mg fasting
89087401|NCT04865536|Placebo Comparator|Cohort 2 Placebo, fed|Placebo, fed
89087402|NCT04865536|Placebo Comparator|Cohort 2 Placebo, fasting|Placebo, fasting
89087403|NCT04865536|Active Comparator|Cohort 3 3000mg, fed|3000mg, fed
89087404|NCT04865536|Placebo Comparator|Cohort 3 placebo, fed|placebo, fed
89087405|NCT02662465|Experimental|mucositis grade 1, laser 660|Group 1 will include patients with oral mucositis grade 1. Sera used wavelength of 660nm, power 100mW and lluencia of 4 J / cm².
89087406|NCT02662465|Experimental|mucositis grade 2, laser 660|Group 2 included patients with oral mucositis grade 2. Sera used with a wavelength of 660nm, power 100mW and lluencia of 8 J / cm².
89226196|NCT04681729|Experimental|Dupilumab|Dose regimens, on top of regular or as needed non-sedating H1-antihistamine
89087407|NCT02662465|Experimental|mucositis grade 3, laser 790|Group 3 included patients with oral mucositis grade 3 Sera used laser diode AsGaAl operating in continuous mode, with a wavelength of 790 nm, power of 100mW and fluency of 8 J / cm².
89087408|NCT02659111|Experimental|High-intensity physical exercise, HIFE|
89087409|NCT02659111|Active Comparator|Physical training advice|
89087410|NCT02656147|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
89087411|NCT02656147|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
89087412|NCT02656147|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
89087413|NCT04170049|Experimental|Behavioral: The sensory stimulative activity interventions|
89087414|NCT02659267|Experimental|Interventions Group=|Group of change behavior including physical activity and healthy eating habits promotion.
89087415|NCT02659267|No Intervention|Control Group=|Group that will not receive the VAMOS program as intervention, only participate in the Health Academy Program Activities.
89087416|NCT02659033|Active Comparator|ceftriaxone|healthy volunteer who receive ceftriaxone
89087417|NCT02659033|Active Comparator|cefotaxime|healthy volunteer who receive cefotaxime
89087418|NCT04170595|Experimental|GB221,2mg/kg|Coprelotamab Injection, 2 mg/kg, Single dose,
89087419|NCT04170595|Experimental|GB221,6mg/kg|Coprelotamab Injection, 6 mg/kg, Single dose,
89087420|NCT04170595|Active Comparator|Herceptin,6mg/kg|Trastuzumab Injection, 6 mg/kg, Single dose,
89087421|NCT04170595|Experimental|GB221,8mg/kg|Coprelotamab Injection, 8 mg/kg, Single dose,
89087422|NCT04170595|Experimental|GB221+ Capecitabine|Multiple dose groups
89087423|NCT04170595|Active Comparator|Herceptin+Capecitabine|Multiple dose groups
89087424|NCT04511533|Experimental|Treatment Arm|The recommended dosage of dacomitinib is 45 mg taken orally once a day at approximately the same time each day, until disease progression, participant refusal/lost to follow-up, or unacceptable toxicity occurs.
89087425|NCT00648973|Experimental|1|Diphenhydramine 50 mg
89087426|NCT00648973|Experimental|2|Diphenhydramine 25 mg
89087427|NCT00648973|Active Comparator|3|Pseudoephedrine 120 mg
89087428|NCT00649909||Observation|Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c >8%.
89087429|NCT02662309|Experimental|MPDL3280A|Patients receive 2x 3-weekly cycles of MPDL3280A (one infusion on the first day of each cycle) prior to cystectomy surgery.
89087430|NCT02658955|Experimental|Short stitch|Patients in which abdominal wall is closed by short stitch technique
89087431|NCT02658955|No Intervention|Large stitch|Patients who didn't receive properly closure according with the protocol
89087432|NCT02655835|Experimental|Internet Mindfulness Meditation Intervention|Six-week internet mindfulness meditation training program including handouts and daily guided meditations
89087433|NCT02655835|Experimental|Access|Written information handouts on mindfulness meditation and access to guided daily meditations
89087434|NCT02662075|Experimental|E-cigarette/tobacco Smoking Exposure|
89087435|NCT02661919|Experimental|Emfit mattress sensor|
89087436|NCT04032691|Experimental|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
89087437|NCT02658799|Experimental|diclofenac potassium|"Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.~To promote compliance, each patient was recalled monthly."
89087438|NCT02658799|Active Comparator|placebo|"or placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (placebo) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.~To promote compliance, each patient was recalled monthly."
89087439|NCT02536885|Experimental|Liberal group|During the surgery, blood pressure of the patients will be maintained within ± 25% of the patient's normal blood pressure.
89087440|NCT02536885|Experimental|Restrictive group|During the surgery, blood pressure of the patients will be maintained within ± 10% of the patient's normal blood pressure.
89087441|NCT02655757|Active Comparator|Sitagliptin|Sitagliptin 100mg QD
89087442|NCT02655757|Placebo Comparator|Placebo|Placebo
89087443|NCT02661841|Experimental|LI-Guided Therapy|One hundred and fifty chronic heart failure patients treated based on guidelines and LI-Guided Therapy.
89087444|NCT02661841|Active Comparator|Control|One hundred and fifty chronic heart failure patients treated based on guidelines only.
89087445|NCT02661763||Schoolchildren in Zambia|Schoolchildren in grades 7-12 in fifteen randomly selected schools in Lusaka area
89087446|NCT01214720|Experimental|1|
89087447|NCT02655991|Experimental|Telephone Case Monitoring|Telephone care management augmenting treatment as usual
89087448|NCT02655991|Active Comparator|Treatment as Usual|Case management, psychotherapy, and pharmacotherapy as usual
89087449|NCT02655913|Experimental|vitamin C+ mEHT+ supportive care|"Patients will be allocated into 3 Vitamin C infusion dosage groups:~1g/kg.d,1.2g/kg.d,1.5g/kg.d;3 times a week for 8 weeks(25 infusions);concurrent with Modulated Electro-Hyperthermia (mEHT): 150W x 60 min/session,3 times a week for 8 weeks (25 sessions);together with supportive care."
89226197|NCT04681729|Placebo Comparator|Matched Placebo|Placebo, on top of regular/as needed non-sedating H1-antihistamine
89087450|NCT02655913|Placebo Comparator|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
89087451|NCT00649285|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
89087452|NCT00649285|Active Comparator|2|Macrobid® Capsules 100 mg
89087453|NCT04318574|Experimental|Interventional|Balance, Agility, Strengthening Exercise (BASE) class intervention - a 6-week exercise class to determine the change in balance performance, fear of falling and self-efficacy
89087454|NCT02661685|Experimental|autologous IKDC-like cell|Received autologous IKDC-like cells
89087455|NCT04169269|Active Comparator|Enoxaparin|enoxaparin injectable, 40 milligram subcutaneous injection daily for 20 days
89087456|NCT04169269|Active Comparator|Rivaroxaban|rivaroxaban oral 10 milligram tablet daily for 20 days
89087457|NCT02655367|Experimental|Milled followed by flaked oats|Participant consumes test meal consisting of porridge made from milled oats on study day 1, followed by porridge made from flaked oats on study day 2
89087458|NCT02655367|Experimental|Flaked followed by milled oats|Participant consumes test meal consisting of porridge made from flaked oats on study day 1, followed by porridge made from milled oats on study day 2
89087459|NCT02661529|Active Comparator|Transesophageal Echocardiogram|Patients undergoing an Transesophageal Echocardiogram (TEE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
89087460|NCT02661529|Active Comparator|Transthoracic Echocardiogram|Patients undergoing an Transthoracic Echocardiogram (TTE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
89087461|NCT02661373|Experimental|Treatment Arm|Participants will receive SJ733, an investigational drug developed at St. Jude Children's Research Hospital, and cobicistat.
89087462|NCT00649051|Experimental|1|Metolazone Tablets 2.5 mg
89087463|NCT00649051|Active Comparator|2|Zaroloxyn® Tablets 2.5 mg
89087464|NCT02536573|No Intervention|Control|Intraoperative fluoroscopy of the hip is used to visually estimate the acetabular cup angle and make any necessary adjustments.
89087465|NCT02536573|Experimental|Radlink Surgical Positioning System|Fluoroscopic image of the hip joint is imported into the Radlink Surgical Positioning software. The software calculates a target cup position using bony landmarks, and the surgeon matches the cup to the target.
89087466|NCT02655289|Experimental|Modulated TENS|
89087467|NCT02655289|Placebo Comparator|Placebo TENS|
89087468|NCT04169971|Experimental|Music group|Will receive music during the operation conducted under spinal anaesthesia
89087469|NCT04169971|No Intervention|Control group|Will not receive music during the operation conducted under spinal anaesthesia
89087470|NCT02661607|Other|Point of care echocardiography after central venous catheter|Point of care echocardiography plus chest radiography
89087471|NCT04170829|Experimental|Group 1 (n=6)|will be administered ChAdOx1 MERS: 5 x 109 vp ChAdOx1 MERS
89087472|NCT04170829|Experimental|Group 2 (n=9)|will be administered ChAdOx1 MERS: 2.5 x 1010 vp ChAdOx1 MERS
89087473|NCT04170829|Experimental|Group 3 (n=9)|will be administered ChAdOx1 MERS: 5 x 1010 vp ChAdOx1 MERS
89087474|NCT02655211|Active Comparator|CO2-CO2-Med|Participants will receive two blocks of CO2 laser treatment, followed by one block of usual care.
89087475|NCT02655211|Active Comparator|Med-CO2-CO2|Participants will receive one block of usual care, followed by two blocks of CO2 laser therapy.
89087476|NCT02655211|Active Comparator|CO2-Med-CO2|Participants will receive one block of CO2 laser therapy, one block of usual care, and finally one more block of CO2 laser therapy.
89087477|NCT02655211|Active Comparator|PDL-PDL-MED|Participants will receive two blocks of PDL laser therapy, followed by one block of usual care.
89087478|NCT02655211|Active Comparator|Med-PDL-PDL|Participants will receive one block of usual care, followed by two blocks of PDL laser therapy.
89087479|NCT02655211|Active Comparator|PDL-Med-PDL|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
89087480|NCT02655211|Active Comparator|PDL-CO2-Med|Participants will receive one block of PDL laser therapy, followed by one block of CO2 laser therapy, followed by one block of usual care.
89087481|NCT02655211|Active Comparator|CO2-PDL-Med|Participants will receive one block of CO2 laser therapy, followed by one block of PDL laser therapy, followed by one block of usual care.
89087482|NCT02655211|Active Comparator|Med-PDL-CO2|Participants will receive one block of usual care, followed by one block of PDL laser therapy, followed by one block of CO2 laser therapy.
89087483|NCT02655211|Active Comparator|Med-CO2-PDL|Participants will receive one block of usual care, followed by one block of CO2 laser therapy, followed by one block of PDL laser therapy.
89226198|NCT04679857|Experimental|UC|Total Knee Arthroplasty with an ultracongruent insert
89087484|NCT02655211|Active Comparator|PDL-Med-CO2|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of CO2 laser therapy.
89087485|NCT02655211|Active Comparator|CO2-Med-PDL|Participants will receive one block of CO2 laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
89087486|NCT02655445|Active Comparator|Mini-craniotomy|"Intervention: Bone flap > 30mm and replaced, placement of Jackson-Pratt drain~A linear incision located over the biggest bulk of the hematoma is made. Dura is opened and a wide opening of the pseudomembrane is done. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
89087487|NCT02655445|Active Comparator|Twist Drill Craniostomy|"Intervention: twist drill burr hole <5mm, placement of Integra basket-type drain~A stab incision to the scalp is made, at the approximate location of the thickest diameter of hematoma. The twist-drill hole <5mm is placed obliquely to the surface of the skull, at an angle of about 45° until perforation of the dura. No irrigation is performed. A basket-type drain (Integra) is placed in the subdural space and tunneled underneath the skin"
89087488|NCT02655445|Active Comparator|Burr Hole Craniostomy|"Intervention: 2 Burr Holes >5mm and <30mm, placement of Jackson-Pratt drain~First burr hole at the site of maximal diameter, second anterior and superior to that point. The scalp incisions are so planned that they can be incorporated into a craniotomy if necessary. Visible membranes are opened with a sharp hook until the pia is visualized. Gentle irrigation is performed and continued until the returning liquid is clear. Two burr holes are placed to facilitate drainage. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
89087489|NCT00649987|Experimental|1|Albuterol Sulfate Extended-Release Tablets 8 mg
89087490|NCT00649987|Active Comparator|2|VoSpire® ER Tablets 8 mg
89226199|NCT04679857|Active Comparator|PS|Total Knee Arthroplasty with posterior stabilized design
89226200|NCT04678336|Experimental|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
89087491|NCT04169035|Experimental|Odon device|The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assiste vaginal birth. Odon trained practitioner available to assist the birth.
89087492|NCT04169035|Active Comparator|Forceps or ventouse|"The practitioner providing the woman's care in labour determines that she requires an assisted vaginal birth, and there is no obstetric indication for an alternative method of assisted vaginal birth.~The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth."
89087493|NCT01142232|Experimental|Melphalan with lenalidomide|Melphalan will be given on Day -2 and Day -1. Lenalidomide will be given from Day -7 to Day +2.
89087494|NCT04169659|Experimental|Kyphoplasty with Titanium spheres|Patients treated with kyphoplasty with baloons and insertion of titanium microspheres inside the body vertebra.
89087495|NCT04169659|Active Comparator|Kyphoplasty with Polymethylmethacrilate|Patients treated with Kyphoplasty with baloons and insertion of Polymethylmetacrylate inside the body vertebra.
89087496|NCT02655133|Active Comparator|Pentaglobin®|Patients will receive Immunoglobulins IgGAM (Pentaglobin®) at dosage of 250 mg/kg IV (5 mL/kg) per day (rate of 0.4 mL/kg/h), for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®).
89087497|NCT02655133|Placebo Comparator|Physiologic Solution|Patients will receive physiologic solution (NaCl 0.9%) at a dosage of 5 ml/Kg per day for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®)
89087498|NCT02536807|Experimental|Hyaluronan|Hyaluronan gel injection
89087499|NCT02536807|Placebo Comparator|Control|Control placebo gel injection
89087500|NCT02883738|Experimental|upper limb tremor|
89087501|NCT04395547|Placebo Comparator|Placebo|
89087502|NCT04395547|Experimental|JointAlive™|
89087503|NCT02660671|Active Comparator|Usual care|Email outreach
89087504|NCT02660671|Experimental|Active choice|Email outreach + active choice
89087505|NCT02660671|Experimental|Financial incentive + Active choice|Email outreach + active choice + financial incentive
89087506|NCT02536495|Experimental|Treatment (docetaxel, selinexor)|Patients receive docetaxel IV on day 1 and selinexor PO BID on days 1, 3, 7, 9, 13, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89087507|NCT02536417|Active Comparator|Treatment arm: melatonin|melatonin 0.5 mg as treatment, to be given daily at bedtime
89087508|NCT02536417|Placebo Comparator|Placebo arm|Sugar pill identical in appearance to the melatonin 0.5 mg tablets used in treatment arm
89087509|NCT01140906|Placebo Comparator|Placebo|
89087510|NCT01140906|Experimental|Vortioxetine: 15 mg|
89087511|NCT01140906|Experimental|Vortioxetine: 20 mg|
89087512|NCT01140906|Other|Duloxetine: 60 mg|Active Reference
89087513|NCT00650065|Experimental|1|Cetirizine HCl Tablets 10 mg
89087514|NCT00650065|Active Comparator|2|Zyrtec® Tablets 10 mg
89087515|NCT02654821|Experimental|TCR treatment|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
89087516|NCT02882412||patient group|
89087517|NCT04170439|Other|clomiphene plus metformin plus N acetyle cysteine|Women who will receive clomiphene citrate plus metformin plus n acetyle cysteine
89087518|NCT04170439|Other|clomiphene plus metformin plus chromium|Women who will receive clomiphene plus metformin plus chromium
89087519|NCT04170439|Other|clomiphen citrate plus metformin|Women who will receive clomiphene plus metformin
89087520|NCT05188092|No Intervention|Control|Routine fluid deresuscitation in which fluid withdrawal is started and continued at the discretion of the treating physician.
89087521|NCT05188092|Active Comparator|Intervention|Deresuscitation is guided by lung ultrasound observations.
89087522|NCT02660515|Active Comparator|ORIF|The operation has to be performed within 3 weeks after the initial trauma. According to the current standard, antibiotic prophylaxis (Cefazoline, 1000 milligram intravenous) will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis and the arteria radialis. After the fracture site is exposed, the fracture will be reduced and an appropriate volar locking plate will be positioned. The type and brand of the plate are at discretion of the treating surgeon. When a dorsal approach is deemed necessary the distal radius will be approached between the third and fourth dorsal extensor tendon compartments. To evaluate the quality of articular reduction, fluoroscopic images will be obtained. Wound closure will be performed using standard techniques.
89087523|NCT02660515|Active Comparator|ORIF with additional wrist arthroscopy|Surgery will be performed by a certified trauma surgeon, with experience in wrist arthroscopy. A delay of minimal 5 days before performing arthroscopy is mandatory to enable visualisation due to the organisation of the hematoma. During wrist arthroscopy, the forearm will be positioned upright and in neutral position, the elbow flexed by 90° and axial traction of 4-6 kg will be performed. Four portal entrees are created by superficial stab incisions and blunt preparation through the joint capsule; one midcarpal radiair and one midcarpal ulnar portal and the 3-4 and 6-R portal. A shaver is used for removal of fracture haematoma and osteocartilaginous debris. Cartilage damage will be graded using the Outerbridge classification system. With the 1 mm hook probe assessment of the quality of reduction and ligamentous injuries (TFCC, scapholunate and lunotriquetral) will be performed. Wound closure will be performed using standard techniques.
89087524|NCT02883504|Experimental|Echocardiography|
89087525|NCT02660593|Experimental|SanGrow|Patients will be given SanGrow Decoction 150 ml per day for 3 months.
89087526|NCT00962091|Experimental|Dose Escalation|A single dose of alisertib 15 mg, oral solution (OS) was administered on Day 1, followed by alisertib 40 mg, powder-in-capsule (PIC), orally, twice a day (BID) on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, was administered on Cycle 2 Day 1 followed by alisertib 40 mg on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Subsequent cycles, alisertib 40 or 50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
89087527|NCT00962091|Experimental|Part A: Relative Bioavailability OS/PIC (Sequence A)|A single dose of alisertib 25 mg, OS, administered on Day 1, followed by alisertib 40 mg PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, administered on Cycle 2 Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles, alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
89523126|NCT01999595|Placebo Comparator|Control TENS|"TENS=transcutaneous electrical nerve stimulation~Control TENS was the application of electrical stimulation via skin with no current"
89087528|NCT00962091|Experimental|Part A: Relative Bioavailability PIC/OS (Sequence B)|A single dose of alisertib 50 mg, PIC, orally administered on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 25 mg, OS, once on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles followed by alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in Cycle 3, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
89087529|NCT00962091|Experimental|Part B: OS Food Effect Fed/Fasted (Sequence A)|Alisertib 35 mg (35 mg = relative bioavailability estimate in Part A as dose of OS that was calculated to yield the area under the concentration time curve of a 50-mg PIC dose): A single dose of alisertib 35 mg oral solution (OS), in fed state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 35 mg administered, OS, in fasted state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg, PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted, based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
89226201|NCT04676009|Experimental|Exercise arm :|"Patient randomized to the Exercise arm will receive physical activity recommendations at inclusion and nutritional assessment will be carried out during the first and last treatment cure. Patients will receive an acute physical exercise just before immunotherapy and chemotherapy infusion.They will have a home walking program and will have to wear an activity tracker during the 3 months of intervention.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3)."
89523127|NCT01999595|Sham Comparator|Sham TENS|"TENS=transcutaneous electrical nerve stimulation~Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told that the TENS was turn-on whether you feel it or not"
89523128|NCT01964807|Experimental|Cigarette smokers|Will smoke 1 cigarette, National Institute of Drug Abuse (NIDA) test type with 16.6 mg nicotine; 1 cigarette, NIDA test type with <0.45 mg nicotine; perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
89087530|NCT00962091|Experimental|Part B: OS Food Effect Fasted/Fed (Sequence B)|A single dose of alisertib 35 mg, OS, in fasted state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 2 Day 1 alisertib 30 mg, OS administered in fed state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
89087531|NCT00962091|Experimental|Part C: ECT Food Effect Fed/Fasted (Sequence A)|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 40 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Cycle 3 onwards, participants were administered alisertib 40 mg BID ECT on Days 1-7 with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
89087532|NCT00962091|Experimental|Part C: ECT Food Effect Fasted/Fed (Sequence B)|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 mg, ECT, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2, a 23-day cycle. Cycle 3 onwards participants were administered alisertib 40 mg BID ECT on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
89087533|NCT02660437|Active Comparator|Effect of PR in MCI-group|Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of MCI-Group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR). Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques.
89087534|NCT02660437|Placebo Comparator|Effect of PR in control-group|"Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of control-group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR).~Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques."
89087535|NCT01163916||Patients with RA, PsA and AS|Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) prescribed adalimumab as part of Routine Clinical Care in Russia.
89087536|NCT00649363|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
89087537|NCT00649363|Active Comparator|2|Zofran ODT® Tablets 8 mg
89087538|NCT04285203|Experimental|Educational Video|Participants were exposed to 2 educational videos in addition to standard of care education.
89087539|NCT04285203|No Intervention|Standard of Care|Participants received standard of care education.
89087540|NCT02654899|Experimental|Part 1_Cohort 1_Active;|Single ascending dose of PF-06815345
89087541|NCT02654899|Placebo Comparator|Part 1_Cohort 1_Placebo;|Single dose of placebo
89087542|NCT02654899|Experimental|Part 1_Cohort 2_Active|Single ascending dose of PF-06815345
89087543|NCT02654899|Placebo Comparator|Part 1_Cohort 2_Placebo|Single dose of placebo
89087544|NCT02654899|Experimental|Part 2|Single dose of solid dosage formulation (test) versus liquid dosage formulation (reference) of PF-06815345
89226202|NCT04676009|No Intervention|Control arm|"Patients will receive physical activity recommendations at inclusion and a nutritional assessment will be carried out during the first and last treatment cure. They will receive the usual care and standard treatment protocol (immunotherapy and chemotherapy).~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place 40 min before the administration of treatments (1), just before the administration of treatments (2) and 12 hours after the start of treatment (3)."
89226203|NCT04671862|Experimental|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~1 Treatment pre radiotherapy~3 treatments weekly during radiotherapy"
89226204|NCT04668001|Experimental|Near-Infrared Transcranial Photobiomodulation (tPBM-NIR)|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
89087545|NCT02654743|Experimental|SF|"Sulforaphane (SF) will be administered in an approximate dosage of 1 µmol SF/lb (2.2 kg µmol/kg) body weight. This dosage roughly approximates the dosage that was used in the Singh et al, (2014; PNAS) clinical trial of sulforaphane in male adolescents and adults with autism. The sulforaphane will be supplied as glucoraphanin (GR)-enriched broccoli seed extract tablets (manufacturing details follow). Each active tablet will contain 125 mg broccoli seed extract (containing 37 µmol GR, which is equivalent to about 15 µmol SF), 50 mg dried broccoli sprouts (a source of myrosinase, the enzyme that converts GR to SF), 15 mg ascorbic acid, 55.90 mg microcrystalline cellulose, and other minor GRAS excipients used for tablet forming.~The total dose per day will depend of study participants' body weight."
89087546|NCT04314258|Experimental|Drinking Moringa oleifera tea|The experimental group will drink twice daily 2 tea bags of Moringa oleifera tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.
89087547|NCT04314258|No Intervention|Drinking plain water|The control group will receive instructions to consume 200 ml of plain water twice daily for a period of 4 weeks.
89087548|NCT02862795|Other|HPV detection in anal canal samples|
89087549|NCT04168723|Experimental|Group A-MD1003|Group A=32 subjects Placebo for MD1003 on Day -1. Daily dose of 1200 mg of MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Day 9
89087550|NCT04168723|Active Comparator|Group B-Moxifloxacin|"Subjects in Group B will be further randomized to Subgroups B1 and B2 in a ratio of 1:1.~Subgroup B1: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Moxifloxacin 400 mg on Day 1 and Placebo for moxifloxacin on Day 9 Subgroup B2: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Moxifloxacin 400 mg on Day 9"
89087551|NCT04168801|Experimental|Early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, if he did not have them, then receives diet indicated between 16 and 24 hours after admission.
89087552|NCT04168801|Active Comparator|Usual oral refeeding|usual oral refeeding (UOR) Once the attending physician decided according to his clinical judgment to restart the oral feeding
89087553|NCT00649441|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
89087554|NCT00649441|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
89087555|NCT01122576|Experimental|Crystalens AO|Eligible subjects to undergo small incision cataract surgery and were implanted with the Crystalens AO bilaterally.
89087556|NCT01122576|Active Comparator|ReSTOR|Eligible subjects to undergo small incision cataract surgery and were implanted with the ReSTOR IOL bilaterally.
89087557|NCT01122576|Active Comparator|Tecnis Multifocal IOL|Eligible subjects to undergo small incision cataract surgery and were implanted with the Tecnis Multifocal IOL bilaterally.
89087558|NCT02660203|Experimental|forced expiration|2 daily sessions of forced expiration on ipsilateral decubitus from day 1 after surgery until chest tube removal
89087559|NCT02660203|No Intervention|control|No session of forced expiration
89087560|NCT02654665|Experimental|Liraglutide|Liraglutide will be administered once daily by subcutaneous injection at a starting dose of 0.6 mg, increasing at 0.6 mg/week increments to a maximum of 3.0 mg over the next 6 weeks, as tolerated.
89087561|NCT02654665|Active Comparator|Bariatric Surgery|Subjects will have outcomes measured within 28 days before surgery. Post-operative management and frequency of follow-up visits will be decided by the bariatric surgeon. Study visits for biochemical and endothelial function testing; MRI and liver biopsy and / or fibroscan will follow the same schedule as that of the lifestyle and liraglutide arms. Target weight loss for the first 26 weeks post-surgery is at least 30% of excess body weight.
89226205|NCT04668001|Placebo Comparator|Sham Transcranial Photobiomodulation (tPBM-Sham)|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
89226206|NCT04665271|Experimental|Immediate Treatment - Zemedy App|Participants will be given immediate access to the Zemedy app for IBS.
89087562|NCT02654665|Active Comparator|Diet modification and exercise|Exercise will be used to induce and maintain weight loss in a 26-week Weight Management Program. Each subject will follow an aerobic exercise prescription of moderate intensity (60-75% maximum heart rate) to expend 2000-3000 kcal/week, lasting 30-60 minutes each session (over 5-7 sessions). Subjects will be instructed by sports trainers, compliance reviewed and adjusted if necessary to maintain the targeted total energy expenditure to produce weight loss of at least 7% over 26 weeks.
89087563|NCT02654509|Experimental|EEE vaccine|Eastern Equine Encephalitis Vaccine will be administered as primary doses of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area and booster doses of 0.1 mL given intradermally in the volar aspect of the forearm. The primary series will be administered on Days 0 and 26-35 with a booster at 6 months. Titers will be collected 28-35 days after the second primary vaccine is < 1:40, the subject will receive a booster dose 28- 90 days of obtaining the titer result.
89087564|NCT04168333|Active Comparator|T101 Group|"The study will consist of 2 cohorts:~Single Dose (SD) Cohort:~9 chronic hepatitis B patients will be enrolled and be divided into 3 groups, with 3 patients in each group.~Multiple Dose (MD) Cohort:~18 chronic hepatitis B patients will be enrolled and be divided into 2 groups, with 9 patients in each group."
89087565|NCT04168333|Placebo Comparator|Placebo Group|"The study will consist of 2 cohorts:~Single Dose (SD) Cohort:~3 chronic hepatitis B patients will be enrolled in this group.~Multiple Dose (MD) Cohort:~6 chronic hepatitis B patients will be enrolled in this group."
89087566|NCT02654431||Breast Cancer patients|Breast cancer patients
89087567|NCT02654431||women with breast cancer|women with breast cancer
89087568|NCT02654431||Cancer patients|Cancer patients
89087569|NCT04167865|No Intervention|Control group|All patients will be instructed to wear the device for 1 hours for 12 weeks after being instructed on how to use the vacuum bell. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
89226207|NCT04665271|Active Comparator|Active Control - Education and Relaxation Training App|Participants will be given access to a education and relaxation training app. After 8 weeks they will then be crossed over to the Zemedy app.
89226208|NCT04660344|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
89226209|NCT04660344|Placebo Comparator|Arm B: Placebo|Placebo will be administered intravenously on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
89226210|NCT04644731||Pediatric patients who require fluid removal|Pediatric patients who require fluid removal with the Aquadex™ System per local standard of care
89226211|NCT04642729|Other|ReLex Smile surgery|The myopic lenticule after Relex Smile surgery is put into BBS solution for 10 min. Under topical anesthesia, Using VisuMax Femtosecond Laser.
89226212|NCT04642729|Other|fresh corneal lenticule implantation|Using VisuMax Femtosecond Laser we make intrastromal pocket incision 2-3 mm in periphery of cornea (Because the macular dystrophy is in the center more progressive) and 150 µm deep to put fresh corneal lenticule. After one month using VisuMax we create a flap using autologous serum with purpose to remove more dead keratocytes and adding live keratocytes with aim to regenerate the metabolism of cornea.
89226213|NCT04632628|Experimental|NiteCAPP: Online Cognitive Behavioral Therapy for Insomnia|This is a pilot trial with one treatment condition (CBT-I).
89226214|NCT04632043|Active Comparator|Early intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 >92%) for at least 48 hours will undergo intubation.
89226215|NCT04632043|Active Comparator|Delayed intubation|Patients with COVID-19 suffering from severe acute hypoxemic respiratory failure (defined as the need for non-rebreather mask or high flow nasal oxygen with setting FiO2 of at least 90% or non-invasive mechanical ventilation to maintain a SpO2 >92%) for at least 48 hours will continue to receive non-rebreather mask, high-flow nasal oxygen or non-invasive mechanical ventilation in an attempt to avoid intubation.
89226216|NCT04630574||Patients with Huntington's disease|Each patient is seen in the framework of his annual follow-up consultation, for an evaluation of his speech with the computerized tool MonPaGe.
89226217|NCT04629105|Active Comparator|Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.
89226218|NCT04629105|Placebo Comparator|Cohort (SARS-CoV-2): Arm 2 (Placebo)|Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.
89226219|NCT04629105|Active Comparator|Cohort 2 (Flu): Arm 3 (LMSCs)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.
89087570|NCT04167865|Active Comparator|Exercise Group|In addition to the applications to the control group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PE. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
89087571|NCT02658643|Experimental|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
89087572|NCT02658643|Active Comparator|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
89087573|NCT02658721|Experimental|lidocaine+adjunct tramadol|In the first group (LDC+TRA group), IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation.
89087574|NCT02658721|Experimental|lidocaine+systemic tramadol|In the second group (LDC+SysTRA group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation.
89087575|NCT02658721|Active Comparator|lidocaine|In the third group (LDC group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL.
89087576|NCT00965523|Experimental|Eribulin Mesylate|
89226220|NCT04629105|Placebo Comparator|Cohort 2 (Flu): Arm 4 (Placebo)|Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo.
89087577|NCT02652013|Experimental|40 patients with multiple sclerosis|The study sample will consist of 40 patients with multiple sclerosis. MS patients and control subjects will be recruited on the Rennes (Centre Hospitalier Universitaire and Pôle de Médecine Physique et de Réadaptation Saint-Hélier) and Angers sites (Centre Hospitalier Universitaire) participating in COGNISEP project
89087578|NCT02652013|Other|40 healthy subjects|All the performance of the 40 MS patients will be compared to 40 control subjects matched in age, gender and sociocultural level. Subjects with a history of neurological and psychiatric condition or substance abuse will be excluded from the study. Control subjects will receive an honorary as a token for their time.
89087579|NCT00629967|Active Comparator|A|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
89087580|NCT00629967|Active Comparator|B|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
89226221|NCT04628793|Experimental|Cohort 1|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
89226222|NCT04628793|Experimental|Cohort 2|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
89226223|NCT04628793|Experimental|Cohort 3|Single dose administration of PF-07258669 and placebo; Within a cohort, participants will receive 3 doses of PF-07258669 and 1 dose of placebo.
88812529|NCT03726307|Experimental|DCreg:2.5 to 5.0 million cells/kg+SOC|"N=8 participants will receive 25 to 5.0 million cells /kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
89226224|NCT04624113|Experimental|Phase I: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend on dose level assigned~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
89226225|NCT04624113|Experimental|Phase 2: Tazemetostat + Pembrolizumab|"Cycle 1 over 5 weeks (35 days). Subsequent cycles over 3 weeks (21 days).~Tazemetostat tablet twice per day Days 1-35 of Cycle 1, then Days 1-21 of subsequent cycles. Dose of tazemetostat will depend of recommended phase 2 determined in Phase I portion of study.~Pembrolizumab 200mg intravenous Day 15 of Cycle 1, then Day 1 of subsequent cycles."
88812530|NCT03696017||Group 1|Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using opioids (40 patients per group).
89087581|NCT04283643|Experimental|Healthy Human Subjects|Healthy human subjects will complete study procedures in the research lab at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation.
89087582|NCT04283643|Experimental|Acute Pain Patients|Acute Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
89087583|NCT04283643|Experimental|Chronic Pain Patients|Chronic Pain Patients will complete study procedures in the hospital or clinic at UVA. They will complete pain-related behavioral questionnaires and undergo experimental pain testing for temperature and laser stimuli for real and control conditions of brain stimulation, as well as rate their ongoing pain.
89087584|NCT02861703|Experimental|Online lifestyle intervention|"A weekly psychosocial intervention (Online Lifestyle Intervention) delivered in an online group format, to promote positive changes in physical (eating habits, physical activity) and mental health (body image, self-esteem, self-efficacy)."
89087585|NCT02861313|Experimental|CM LOC attachment|CM LOC attachment other names: resin matrix attachment
89087586|NCT02861313|Active Comparator|ball attachment|ball attachment other names metallic ball attachment
89087587|NCT02654353|Other|Group A: stepwise ablation|Stepwise ablation of persistent atrial fibrillation (conventional treatment arm) In this arm, patients will be treated with the conventional stepwiese ablation approach
89087588|NCT02654353|Active Comparator|Group B: sequential substrate ablation|Sequential substrate ablation of persistent atrial fibrillation (novel procedure) In this arm, patients will undergo an ablation procedure that consist of PVI, cardioversion, linear ablation and atrial fibrillation re-induction after blocked lines, followed by electrogram-guided ablation
89087589|NCT01122264|Experimental|Tadalafil on demand|10 milligrams (mg) or 20 mg on demand
89087590|NCT01122264|Experimental|Tadalafil once a day|5 mg or 2.5 mg once a day
89087591|NCT01122264|Active Comparator|Sildenafil Citrate|50 mg, 100 mg, or 25 mg on demand
88812531|NCT03696017||Group 2|Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using benzodiazepines (BZD) (40 patients per group).
89087592|NCT04311294|Active Comparator|ANS-6637 Low Dose|200mg ANS-6637 (2 tablets)
89087593|NCT04311294|Active Comparator|ANS-6637 High Dose|600mg ANS-6637 (2 tablets)
89087594|NCT04311294|Placebo Comparator|Placebo|0mg matched placebo (2 tablets)
89087595|NCT04265131|Experimental|Experimental group|art therapy is delivered on top of treatment as usual (TAU). TAU means that individual verbal therapy takes place on a regular basis, whereby the frequency varies depending on the severity of the eating disorder and the patient's request for help. Cognitive-behavioral therapy is provided with elements of dialectical behavioral therapy, and there is also the possibility of family or couple counseling by a family-based therapist.
89087596|NCT00920218|Experimental|GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
89087597|NCT00920218|Experimental|GSK 1437173A F2 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
89087598|NCT00920218|Experimental|Placebo-GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
89087599|NCT00920218|Placebo Comparator|Placebo Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
89087600|NCT02861235|Experimental|1. stress thallium-201 tomoscintigraphy|
89087601|NCT02861235|Experimental|2. stress technetium-99m tomoscintigraphy 1|
89087602|NCT02861235|Experimental|3. stress technetium-99m tomoscintigraphy 2|
89087603|NCT02861235|Experimental|4. stress technetium-99m tomoscintigraphy 3|
89087604|NCT02861235|Experimental|5. rest thallium-201 tomoscintigraphy|
89087605|NCT02861235|Experimental|6. rest technetium-99m tomoscintigraphy|
89087606|NCT00649519|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
89087607|NCT00649519|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
89087608|NCT02654275|Active Comparator|Proprioceptive Intervention|Strength training on a non-stable surface
89087609|NCT02654275|No Intervention|No Proprioceptive Intervention|Conventional strength training
89087610|NCT02882256|Experimental|Intervention|Patients will receive video discharge instructions in addition to standard written discharge instructions.
89087611|NCT02882256|No Intervention|Control|Patients will receive standard written discharge instructions.
89087612|NCT02652091||Interferon beta-1b|Patients diagnosed with relapse-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are injecting Betaseron via the Betaconnect device.
89087613|NCT00625560|Experimental|A|entecavir 1.0 mg QD
89087614|NCT00625560|Active Comparator|B|lamivudine 100 mg QD
89087615|NCT02654197||H.pylori positive children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
89087616|NCT02654197||H.Pylori negative children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
89087617|NCT02651857|Experimental|Endoscopy exploratory single arm|
89226226|NCT04612556||late-onset severe eosinophilic asthma and fixed obstruction|Patients with late-onset severe eosinophilic asthma and fixed obstruction will be administered Mepolizumab (100 MG), subcutaneusly every 30 days
89087618|NCT04167709|Experimental|Allocated CHS nurses|Primary and secondary baseline data are collected from the allocated CHS nurses before the study starts. The CHS nurses are then given the educational intervention and afterwards primary and secondary outcomes are collected again.
89087619|NCT04310982||Health Adults|Forty-nine healthy participants (30 females, 19 males) completed the test-retest protocol with 7 days between tests. Participants were; 23,58±2,65 years of age, 62,9±10,08 kg of weight and 168,76±8,31 cm of height. Participants included in the study did not have any musculoskeletal, neurological or other pathology potentially affecting their gait and jump performance.
89087620|NCT02651935|Experimental|Intellivent ASV|Patients in this arm will be ventilated with Intellivent ASV. Intellivent ASV is an automatic close loop ventilation mode. FiO2 setting will be automatically adjusted according to patients SpO2 and minute volume will be automatically adjusted according to patients EtCO2.
89087621|NCT02651935|No Intervention|PCV+PSV|PCV+PSV is a conventional ventilation strategy of pressure controlled ventilation PCV) and pressure support ventilation (PSV).In this arm, FiO2, pressure control levels, respiratory frequency and all the ventilator settings will be manually adjusted by the physicians in charge.
89087622|NCT04311138|Experimental|Experimental group|Experimental group receive a 10-wk diversified community-based reablement service.
89087623|NCT04311138|Active Comparator|Control group|Control group receive a 10-wk multicomponent training.
89087624|NCT00650455|Active Comparator|Arm 2|
89087625|NCT00650455|Placebo Comparator|Arm 3|
89087626|NCT00650455|Active Comparator|Arm 1|
89087627|NCT02654041|Experimental|Hypothyroxinemia induced patients|Combined T3 and Methimazole treatment will be administered. This experimental treatment will be administered adjunct to standard oncological treatment for newly-diagnosed GBM patients e.g. radiation followed by Temozolomide.
89087628|NCT02651779|Active Comparator|Closed reduction and plasterimmobilisation|The control group will be treated with closed reduction and cast immobilization. This will take place under local anaesthesia by means of a haematoma block with 20 cc Lidocaine 1%. Closed reduction will be preferably performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilizing wrist and hand in the reduced position. Additional radiographs will be performed to verify the success of the reduction. After this has been confirmed, the wrist will be immobilized initially in a split plaster and later changed into a circular cast for five to six weeks immobilization in total.
89111074|NCT04234191|Experimental|Rapid Micro-Induction|On Day 1, participants will receive 0.5mg bup/nx sublingually (SL) every 3 hours (Q3H) - total daily dose of 4mg. On Day 2, they will receive 1mg bup/nx SL Q3H - total daily dose of 8mg. On Day 3, they will receive 8mg bup/nx SL once and 1-4mg bup/nx SL Q3H as needed (PRN) for withdrawal symptoms and/or craving and/or pain - maximum daily dose of 32mg. Afterwards, their day 3 total dose will be consolidated to once daily dosing - maximum daily dose of 32mg. On Days 1 and 2, participants will concurrently receive 1-48mg hydromorphone orally, intravenously, subcutaneously, or intramuscularly (PO/IV/SC/IM) Q1 to 3H PRN for withdrawal symptoms and/or craving and/or pain, titrated to effect (start at lower end of dosing range). Hydromorphone will be discontinued on Days 3 onwards.
89087629|NCT02651779|Other|Open reduction and internal plate fixation|The surgery will be performed by a certified trauma surgeon. According to the current standard treatment protocol, antibiotic prophylaxis will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis muscle and the radial artery. After the fracture site is exposed, the fracture will be reduced and provisionally fixed under fluoroscopy with K-Wires/reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Fracture reduction and screw placement will be confirmed by radiographic images. Additionally, fixation can be supported by a dorsal plate or radial column plate. This will be at discretion of the surgeon and depends on the fracture configuration and the position of the fragments. Wound closure will be performed at the discretion of the surgeon using standard techniques.
89087630|NCT02658409|Experimental|GC3106(quadrivalent)|0.5ml, intramuscular, a single dosing
89087631|NCT02658409|Active Comparator|Fluarix™tetra Syringe Inj.(Quadrivalent)|0.5ml,intramuscular,a single dosing
89087632|NCT02653807|Experimental|mobilization with movement|MWM at the talocrural joint during active weight bearing ankle dorsiflexion with the belt
89087633|NCT02653807|Active Comparator|osteopathic mobilization|passive mobilization of the talo-crural joint
89087634|NCT01121562|Experimental|Sunitinib arm|
89087635|NCT04169425||Group 1|patients who underwent to laparoscopic TME, with elective diverting ileostomy for rectal cancer
89087636|NCT04169425||Group 2|patients who underwent to laparoscopic TME, without elective diverting ileostomy for rectal cancer
89087637|NCT02658253|Experimental|Group A1:Primvac 20 µg +alhydrogel|"Group A1: 3 European volunteers 0.5 ml intramuscular injection: 20 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
89087638|NCT02658253|Experimental|Group A2:Primvac 20 µg +GLA-SE|Group A2: 3 European volunteers 0.5 ml intramuscular injection:20 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
89087639|NCT02658253|Experimental|Group B1:Primvac 50 µg +alhydrogel|"Group B1: 6 European volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
89087640|NCT02658253|Experimental|Group B2:Primvac 50 µg +GLA-SE|Group B2: 6 European volunteers 0.5 ml intramuscular injection:50 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
89087641|NCT02658253|Experimental|Group C1:Primvac 50 µg +alhydrogel|"Group C1: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
89087642|NCT02658253|Experimental|Group C2: Primvac 50 µg +GLA-SE|"Group C2: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 2.5 µg GLA-SE~Vaccination schedule: D0, D28 and D56"
89087643|NCT02658253|Placebo Comparator|Group C3: Placebo|"Group C3: 5 African volunteers 0.5 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56"
89087644|NCT02658253|Experimental|Group D1:Primvac 100 µg +alhydrogel|"Group D1: 10 African volunteers 0.6 ml intramuscular injection: 100µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
89087645|NCT02658253|Experimental|Group D2: Primvac 100 µg +GLA-SE|"Group D2: 10 African volunteers 0.6 ml intramuscular injection: 100 µg Primvac+ 2.56 µg GLA-SE~Vaccination schedule: D0, D28 and D56"
89087646|NCT02658253|Placebo Comparator|Group D3: placebo|"Group D3: 5 African volunteers 0.6 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56"
89087647|NCT04308252||Pharmaco-resistant epilepsy (PRE)|Pharmaco resistant patients are defined by seizures despite adequate dosing of ≥2 anticonvulsant drugs.
89087648|NCT04308252||Pharmaco-sensitive epilepsy (PSE)|Pharmaco-sensitive patients are defined by no seizures for 6 months.
89087649|NCT04308252||Sibling control|Sibling of the of the PRE study participants.
89087650|NCT02651623|Experimental|Sertraline|Maximum dose of 400 mg/day (200 mg BID given at approximately 12 hours apart) sertraline, dose titrated from a starting single dose (QD) of 50 mg in the morning on Day 1 followed by BID doses administered on Days 2 through 14 (Day 14 morning dose only) will be administered
89087651|NCT02651623|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
89087652|NCT02651623|Placebo Comparator|Drug - Placebo|placebo - placebo administered on Days 1 through 14
89087653|NCT04167475|Experimental|Probiotic capsule|The participants consume one probiotic capsule a day for 8 weeks
89087654|NCT04167475|Placebo Comparator|Placebo capsule|The participants consume one placebo capsule a day for 8 weeks
89087655|NCT01121484|Experimental|desvenlafaxine succinate sustained-release|
89087656|NCT01121484|Placebo Comparator|Placebo|
89087657|NCT00650221|Experimental|1|
89087658|NCT00650221|Active Comparator|2|
89087659|NCT01169675|Experimental|BIBW 2992 low dose|patient receives low dose tablet BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
89087660|NCT01169675|Experimental|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
89087661|NCT01169675|Experimental|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
89087662|NCT01169675|Experimental|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
89087663|NCT01169675|Experimental|BIBW 2992 medium dose 6 day|patient receives medium BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
89087664|NCT01169675|Experimental|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
89087665|NCT00650533|Experimental|1|Glimepiride Tablets 1 mg
89087666|NCT00650533|Active Comparator|2|Amaryl® Tablets 1 mg
89087667|NCT02653729|Experimental|Espidone, Olepra, Donu & C.B.T|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days
89087668|NCT02653729|Active Comparator|Espidone, Olepra & Donu|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night
89087669|NCT02881866|Active Comparator|Air Hunger|"Previous studies have shown that inhaled furosemide relieves 'air hunger'.~Each volunteer has 3 mists per visit. The mists are either in the order of Furosemide-Saline-Furosemide or Saline-Furosemide-Saline. The furosemide mist is 40mg (10mg/ml) nebulised and the saline mist is 4ml nebulised.~Induced air hunger (hypercapnia with constrained ventilation) is the active comparator and will be the type of breathlessness induced, before and after each mist inhalation on one day. ."
89087670|NCT02881866|Experimental|Work Effort|Induced sense of breathing effort (raised ventilation with external resistive load) is the 'experimental arm' and will be the type of breathlessness induced, before and after each mist inhalation on the other day. .
89087671|NCT00924664|Experimental|Tanezumab 20 mg|
89087672|NCT00924664|Experimental|Tanezumab 10 mg|
89087673|NCT04314869|Experimental|Recipient|Patient with absolut uterine factor will undergo uterus transplantation.
89087674|NCT02653651|Active Comparator|Ketamine|Ketamine infused at 0.1 mg/kg/hour
89087675|NCT02653651|Experimental|Lidocaine|Lidocaine infused at 1 mg/kg/hour
89087676|NCT02653651|Placebo Comparator|Placebo|An equal volume of saline
89087677|NCT02653573|Experimental|Intervention|Telephone health coaching over 3 months with supporting education materials.
89087678|NCT02887469|Active Comparator|Intermittent bolus group|"<<Within 6hr>>~Moderately Severe : 3% saline 2ml/kg over 20min *1 (unknown bwt 100ml)~Severe :3% saline 2ml/kg over 20min *2 (unknown bwt 100ml)~<additional treatment> Repeat 3% saline 2ml/kg over 20min at every sample time point (at 1/6hr) till Na 5-9 mmol/L inc from initial Na and sx relief~<<During 6-24hr>>~- Moderately Severe or Severe~: Repeat 3% saline 2ml/kg over 20min at every sample time point(at 12/18/24hr) till Na 5-9 mmol/L inc from initial Na and sx relief~<<During 24-48hr>>~Moderately Severe or Severe : Repeat 3% saline 2ml/kg over 20min at every sample time point (at 30/36/42/48hr) till Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief"
89087679|NCT02887469|Active Comparator|slow continuous infusion group|"<<Within 24hr>>~- Moderately Severe: 3% saline 0.5ml/kg/hr (unknown bwt 25ml/hr)~- Severe: 3% saline 1ml/kg/hr (unknown bwt 50ml/hr)~Infusion protocol modification as below by Na at every sample time point (at 1/6/12/18/24 hr)~If Na 5-9 mmol/L inc from initial Na and sx relief : stop 3% saline infusion regardless of △ Na~if △ Na inc <0.5mmol/hr or △ Na inc <3mmol/6hr : add 0.25ml/kg/hr, restart 0.5ml/kg/hr if previously stopped~if △ Na inc ≥0.5mmol/hr or △ Na inc ≥ 3mmol/6hr~: maintain infusion rate~<<During 24-48hr>>~- Moderately Severe and Severe~Infusion protocol modification as below by Na at every sample time point (at 30/36/42/48hr)~If Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief~: stop 3% saline infusion regardless of △ Na~if △ Na inc <1.5mmol/6hr~: add 0.25ml/kg/hr or restart 0.25ml/kg/hr if previously stopped~if △ Na inc ≥ 1.5mmol/6hr~: maintain infusion rate"
89087680|NCT05376839|Experimental|Group 1: Cedirogant|Participants will receive cedirogant once daily.
89087681|NCT05376839|Experimental|Group 2: Cedirogant|Participants will receive cedirogant once daily.
89087682|NCT05376839|Experimental|Group 3: Cedirogant|Participants will receive cedirogant once daily.
89087683|NCT05376839|Experimental|Group 4: Cedirogant|Participants will receive cedirogant once daily.
89087684|NCT02651311|Experimental|Block|"ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg.~Fentanyl in postanesthesia care unit(PACU), Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4."
89087685|NCT02651311|Placebo Comparator|No block|Fentanyl in PACU, Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4.
89087686|NCT04168177|Active Comparator|control group|
89087687|NCT04168177|Active Comparator|ESP Group|
89087688|NCT02653261|Experimental|Tranexamic Acid|Tranexamic Acid (TXA): bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
89087689|NCT02653261|Placebo Comparator|Placebo|An equal volume of saline
89087690|NCT04252378|Experimental|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and external intercostal muscle near 5th rib.
89087691|NCT04252378|Active Comparator|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
89226227|NCT04607733|Experimental|Mirikizumab - Prefilled Syringe|2× 1mL (total 200 milligrams (mg) mirikizumab) administered by subcutaneous injection (SC) via a prefilled syringe (PFS)
89226228|NCT04607733|Experimental|Mirikizumab - Autoinjector|2× 1mL (total 200 milligrams (mg) mirikizumab) administered by subcutaneous injection (SC) via an autoinjector (AI)
89226229|NCT04605549|Experimental|CIN-107 for dosing at 2, 4, or 8 mg (QD)|"Patients will be provided with an initial dose of CIN-107 and start once daily (QD) dosing of CIN-107 tablets at 2 mg. At Visit 4, CIN-107 dose may be up-titrated to 4 mg QD if the patient has tolerated dosing of CIN-107 at 2 mg and the blood pressure (BP) records indicate minimal hypotension risk.~At Visit 5, CIN-107 dose may be up-titrated to 8 mg QD if the patient has tolerated dosing of CIN-107 at 4 mg."
89087692|NCT02657941|Experimental|Motivational group|psycho-education program inspired by motivational interviewing and behavioral psychotherapy
89087693|NCT02657941|Active Comparator|educational group|exclusively informative psycho-education program
89087694|NCT02653339|Experimental|Qufeng Shengshi Fang and Loratadine|Qufeng Shengshi Fang is a traditional Chinese medicine form 8 kinds of herbs. Loratadine is the second generation antihistamines, after converted into its active metabolite Carrie period (carebastine), its antihistamines and allergy effect has been demonstrated in vitro and in vivo tests, also received data from clinical trials.
89226230|NCT04599088|Experimental|Brain functional MRI with simplified urodynamics|Females with urgency urinary incontinence
89226231|NCT04596540|Experimental|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 6 infusions
89226232|NCT04596540|Experimental|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 6 infusions
88812532|NCT03696017||Group 3|Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using BZD/opioid (40 patients per group).
89087695|NCT02653339|Active Comparator|Loratadine|Loratadine (INN) is a second-generation H1 histamine antagonist drug used to treat allergies. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.Loratadine is marketed by Schering-Plough[needs update] under several trade names (e.g., Claritin) and also by Shionogi in Japan. It is available as a generic drug and is marketed for its nonsedating properties. In a version named Claritin-D or Clarinase, it is combined with pseudoephedrine, a decongestant; this makes it useful for colds, as well as allergies but adds potential side effects of insomnia, anxiety, and nervousness.
89087696|NCT00649597|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
89087697|NCT00649597|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
89087698|NCT02653105|Experimental|OLFM4|Patient have a blood test every 6 months at the same time of the clinical exam planned in the following. The OLFM4 will be dose in the blood sample and the rate of OLFM4 compared to the result of imaging.
89087699|NCT02657785|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
89087700|NCT02653027|Experimental|Lumacaftor Ivacaftor|Subjects will get an OGTT before and after starting the combination therapy lumacaftor-ivacaftor.
89087701|NCT04168255|Other|Retinal detachment|Retinal detachment with proliferative vitreoretinopathy and inferior breaks
89087702|NCT02651077||Case Group|38 women with severe and deep endometriosis, aged 18 to 45 years old and hospitalized at Nantes University Hospital for surgical indication of endometriosis lesions ablation.
89087703|NCT02651077||Control Group|38 women aged 18 to 45 years old without suggestive signs of endometriosis
89087704|NCT02652793|Experimental|Experimental|All participants will switch their current antiretroviral regimen to a boosted atazanavir and lamivudine once daily.
89087705|NCT02650687||Elective Non Cardiac Surgical Patients|65 years of age and older
89087706|NCT00650611|Active Comparator|Low-Dose Ziprasidone|
89087707|NCT00650611|Active Comparator|High-Dose Ziprasidone|
89087708|NCT00600067|Experimental|1|
89087709|NCT00600067|Placebo Comparator|2|
89087710|NCT02650609|Experimental|Methylprednisolone|"Methylprednisolone will be supplied as powder and stored in capsules containing 16 mg with lactose as excipient.~Capsules will be administered orally in the morning, during breakfast with a glass of water.~Dose is adapted according to the weight of the patient (1mg/kg):~<60 kg: 3 pills of 16 mg/day~60-80kg: 4 pills of 16 mg/day~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
89087711|NCT02650609|Placebo Comparator|Placebo|"Placebo capsules will only contain lactose. Capsules will be administered orally in the morning, during breakfast with a glass of water.~Dose is adapted according to the weight of the patient (1mg/kg):~<60 kg: 3 pills of 16 mg/day~60-80kg: 4 pills of 16 mg/day~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
89087712|NCT02652871|Experimental|LY2510924 + Idarubicin + Cytarabine|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients. On Day 8, LY2510924 administered after bone marrow aspiration and/or biopsy is performed.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.~Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.~Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
89087713|NCT00650299|Experimental|1|Alprazolam Extended-release Tablets 3 mg
89087714|NCT00650299|Active Comparator|2|Xanax XR® Tablets 3 mg
89087715|NCT00970593|Placebo Comparator|OAP-189|
89087716|NCT00970593|Placebo Comparator|2|
89087717|NCT04167553|Experimental|HM15136|
89087718|NCT04167553|Placebo Comparator|Placebo|
89087719|NCT02657395|Experimental|PriMatrix|Use of PriMatrix as a substitute for a subepithelial connective tissue graft under a coronal positioned flap for root coverage.
89087720|NCT04168411|Experimental|Symptomatic treatment group|The patients were allocated to wear a double layered elasticated bandage for treatment 5th metatarsal base fractures (Zone 1).
89226233|NCT04596540|Placebo Comparator|Placebo|IV infusion of Normal Saline every 28 days for a total of up to 6 infusions
89226234|NCT04591587|Active Comparator|Smile Group|Twenty patients (20) underwent SMILE surgery (first group)
89226235|NCT04591587|Active Comparator|Lenticule Group|Twenty patients (20) underwent lenticule implantation (second group)
89226236|NCT04591184|Experimental|Active Covigenix VAX-001|Dose-ranging, 2 dose levels. 24 subjects receiving active i.m. vaccine
89226237|NCT04591184|Placebo Comparator|Placebo|Placebo injection. 12 subjects receiving placebo
89226238|NCT04585035|Experimental|Dose escalation of D-1553 monotherapy|Phase 1a will evaluate up to 7 sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.
89226239|NCT04585035|Experimental|Dose combination of D-1553 with other therapies|Phase 1b will determine the MTD of D-1553 in combination treatment in subjects with advanced or metastatic NSCLC, CRC and other solid tumors. There are multiple groups in Phase 1b for different tumor types and treatment combinations to evaluate safety, MTD and RP2D.
89226240|NCT04585035|Experimental|Phase 2 of D-1553 monotherapy and combination therapies|The Phase 2 portion is a multi-arm, parallel, open label study to evaluate the efficacy of D- 1553 single agent and combination treatments in subjects with advanced or metastatic solid tumors with KRas G12C mutation. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose.
89226241|NCT04585009|Experimental|Cohort1:GSK3923868 50 micrograms (mcg)/ Placebo/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/Placebo/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
89226242|NCT04585009|Experimental|Cohort 1:GSK3923868 50 mcg/ 100 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/Placebo in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
89226243|NCT04585009|Experimental|Cohort 1:GSK3923868 50mcg/ 100mcg/ 250mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
89226244|NCT04585009|Experimental|Cohort 1:Placebo / GSK3923868 100 mcg/ GSK3923868 250 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 100 mcg/GSK3923868 250 mcg in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
89226245|NCT04585009|Experimental|Cohort 2:Placebo / GSK3923868 1000 mcg/ GSK3923868 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: Placebo/GSK3923868 1000 mcg/GSK3923868 3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
89087721|NCT04168411|Active Comparator|Cast group|The patients were given a below-knee cast for treatment 5th metatarsal base fractures (Zone 1).
89087722|NCT02861469||Main carers|Individual semi-structured interviews
89087723|NCT02861469||General practitioners|Individual semi-structured interviews
89087724|NCT04168099|Experimental|Cefotaxime|Cefotaxime intravenous
89087725|NCT04168099|Active Comparator|Gemifloxacin|Oral Gemifloxacin
89087726|NCT04283877|Experimental|Methylphenidate|30 mg methylphenidate, 60 minutes before testing
89087727|NCT04283877|Placebo Comparator|Control|30 mg of lactose pill, 60 minutes before testing
89087728|NCT00962013|Other|Restoration® Modular|All subjects were enrolled into a single arm and received the Restoration® Modular Revision Hip System to replace the femoral portion of a failed previous implant.
89087729|NCT02650375|Experimental|Metatinib Tromethamine|
89087730|NCT02652715|Experimental|Basic science (Salvia hispanica seed)|Patients receive Salvia hispanica seed PO QD for 12 weeks.
89087731|NCT04283487|Experimental|Fructans solution|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody.The fructans solution used in this study is 500 ml water containing 40g fructans
89087732|NCT04283487|Active Comparator|Glucose solution|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a positive control in this study. The glucose solution used in this study is 500 ml water containing 40g glucose.
89087733|NCT04283487|Placebo Comparator|Saline solution|The saline solution does't contain any sugar and used in this study is 500ml 0.9% normal saline.
89087734|NCT02657317|Experimental|FORT-A|"has been labeled FORT-A. FORT-A is provided on an outpatient basis and includes 12 daily group pain management and physical therapy sessions spanning three weeks. Group interventions are supplemented by individual psychotherapy, biofeedback, and case staffings. CBT sessions were decreased in favor of CAM components. FORT-A participants will receive 270 minutes (4½ hours) of intervention a day for 12 days over 3 weeks."
89087735|NCT02657317|Active Comparator|VA Treatment As Usual|"Treatment As Usual (TAU) represents usual VA Care based on as usual appointments and referrals from VA providers. TAU can include active medical interventions, psychosocial intervention, and other rehabilitation strategies."
89087736|NCT04283331|Experimental|Bandage Contact Lens + Proparacaine|The eye that receives a bandage contact lens soaked in proparacaine.
89087737|NCT04283331|No Intervention|Bandage Contact Lens WITHOUT Proparacaine|The eye that receives a bandage contact lens (standard of care).
89087738|NCT02657473|Active Comparator|TIS 300mg once daily|Tobramycin inhalation solution (TIS) 300mg once daily for at least 9 months and up to 12 months
89087739|NCT02657473|Placebo Comparator|Placebo once daily|Saline 0.9% inhalation solution 300mg once daily for at least 9 months and up to 12 months
89087740|NCT04281459|Experimental|SCT 4/7|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with short cycle scheme of 4 consecutive days on and 3 days off treatment
89087741|NCT04281459|Active Comparator|Control|Patients receiving 3-drug antiretroviral therapy containing rilpivirine with standard scheme of 7 days per week of treatment
89087742|NCT02652637|Experimental|Mechanical and oral antibiotic bowel preparation|Mechanical bowel preparation using PEG, neomycin 2g p.o. (single-dose), and metronidazole 2g p.o. (single dose) are given the day before surgery.
89087743|NCT02652637|No Intervention|No bowel preparation|No mechanical bowel preparation or oral antibiotics.
89087744|NCT02861079|Experimental|Propess with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix
89087745|NCT02861079|Active Comparator|Propess vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
89087746|NCT02652403|Active Comparator|Complete conventional dentures|Complete dentures fabricated by conventional technique.
89087747|NCT02652403|Active Comparator|Complete simplified dentures|Complete dentures fabricated by simplified technique
89087748|NCT02861157|Experimental|TX Condition: Planet T1D Intervention|Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Youth participants will then receive a mobile phone preloaded with the Planet T1D app and a brief orientation to the app and associated website. Participants in the TX condition will receive immediate access to the Planet T1D application and website following the orientation session and will have four months to freely use the application. The TX group will be provided with a mobile phone for the full 2-months of the study.
89087749|NCT02861157|No Intervention|CO Condition: Treatment-As-Usual|A national sample of type 1 diabetes participants will be recruited through a partnership with Medikidz Ltd. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet T1D app and website but will receive email reminders to complete surveys online at each time point.
89087750|NCT00649675|Experimental|1|Meloxicam Tablets 15 mg
89087751|NCT00649675|Active Comparator|2|Mobic® Tablets 15 mg
89087752|NCT04283565|No Intervention|Strategy 1: Usual practice|No systematic screening of asymptomatic AOMI and routine management of FRCV.
89087753|NCT04283565|Experimental|Strategy 2: Motivationnal interviewing|No systematic screening of asymptomatic AOMI and management of CVRF by a motivationnal interviewing.
89087754|NCT04283565|Experimental|Strategy 3: Systematic screening of AOMI by BPI measurement|Systematic screening of AOMI by BPI measurement and routine management of FRCV.
89087755|NCT04283565|Experimental|Strategy 4: Both strategies|Systematic screening of AOMI by BPI measurement and management of CVRF by a motivationnal interviewing.
89087756|NCT02652559|Experimental|Home initiation|Home initiation of long-term NIV will be compared with standard in-hospital initiation. NIV at home will be titrated by a specialised nurse of our home mechanical ventilation centre (HMV) on transcutaneously measured gas exchange and respiratory electromyography and will be adjusted with the use of telemedicine.
89087757|NCT02652559|Active Comparator|Inhospital initiation|Inhospital initiation of NIV is standard care and in the study will be set as the control arm.
89087758|NCT02860923|Experimental|Exenatide|Treatment with exenatide at the initial dose of 5 µg x 2/day (subcutaneously administered) during 4 weeks, and treatment with 10 µg x 2/day during 5 months.
89087759|NCT02860923|Placebo Comparator|Placebo|Patients will be maintained on placebo (injected subcutaneously, twice a day) with the same dose and frequency than exenatide arm.
89087760|NCT02861001|Active Comparator|bronchoscopic guidance|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
89087761|NCT02861001|Experimental|tube mounted camera guidance|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
89087762|NCT04168021|No Intervention|Group 90 individuals, baseline assessment before intervention|Baseline Cognitive status assessment
89087763|NCT04168021|Experimental|Remote ischemic condition of the brain|Intermittent claudication induction on a daily basis for 1 month
89087764|NCT04168021|No Intervention|Late cognitive assessment|Late cognitive status assessment 6 months later
89087765|NCT02862951||Term pregnancy (>37 weeks gestation)|Term pregnancy (>37 weeks gestation)
89226246|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ Placebo/ 3000 mcg|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/Placebo/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
89226247|NCT04585009|Experimental|Cohort 2:GSK3923868 500 mcg/ 1000 mcg/ Placebo|Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/Placebo. There will be at least 10 days of wash-out period between doses for each participant.
89226248|NCT04585009|Experimental|Cohort 2:GSK3923868 500mcg/ 1000mcg/ 3000mcg|Healthy participants will receive single ascending doses of GSK3923868 in the planned treatment sequence: GSK3923868 500 mcg/1000 mcg/3000 mcg. There will be at least 10 days of wash-out period between doses for each participant.
89226249|NCT04585009|Experimental|Cohort 3: Participants receivings repeated doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
89226250|NCT04585009|Experimental|Cohort 4: Participants receiving repeat doses of GSK3923868|Healthy participants will receive planned repeat doses of 3000 mcg (six capsules) GSK3923868 daily for 14 days
89226251|NCT04585009|Experimental|Cohort 5: Participants receiving repeat doses of GSK3923868|Participants with stable asthma will receive a planned repeat dosing of 3000 mcg (six capsules) GSK3923868 daily for 7 days
89226252|NCT04581408|Experimental|Orkambi|"Generic name: Lumacaftor/Ivacaftor~Dosage form: tablet~Dosage: each tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor~Frequency: two tablets twice a day."
89226253|NCT04560998|Experimental|Semaglutide|Semaglutide given in addition to standard-of-care treatment
89226254|NCT04560998|Placebo Comparator|Placebo (semaglutide)|Placebo given in addition to standard-of-care treatment
89226255|NCT04559802|Experimental|Transmucosal (Non-Submerged)|Flaps will be adapted to the healing abutments for a trans-mucosal healing up on closure
89226256|NCT04559802|Active Comparator|Submerged|Flaps will be advanced to achieve primary wound closure.
89226257|NCT04557735|Experimental|Ravulizumab plus Best Supportive Care|Participants will receive ravulizumab plus Best Supportive Care as background therapy.
89226258|NCT04549467|Experimental|Dolutegravir + lamivudine|Dolutegravir 50 mg, 1 tablet QD plus lamivudine 300 mg, 1 tablet QD
89226259|NCT04549467|Active Comparator|Dolutegravir + emtricitabine/tenofovir (FTC/TDF)|Dolutegravir 50 mg, 1 tablet QD plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
89226260|NCT04545242|Active Comparator|Dexamethasone (low dose)|Dexamethasone: 6 mg/iv/day during 10 days.
89226261|NCT04545242|Active Comparator|Dexamethasone (moderate dose)|Dexamethasone: 20 mg/iv/ daily from day of randomization (day 1) during 5 days, followed by 10 mg/iv/ daily from Day 6 to Day 10 of randomization.
89226262|NCT04544618|Experimental|Intervention group|Participants will be exposed to a virtual reality simulation of the operating room environment for a minimum of ten minutes.
89226263|NCT04544618|No Intervention|Treatment as usual group|Participants will receive standard of care with no additional intervention aside from information received at their surgical oncology appointment and optional preoperative education classes (available to all patients).
89087766|NCT04032769|Experimental|Modified strategy MODS|"the threshold of D-dimer will depend on the YEARS rule (MODS strategy):~If all the three items of YEARS are negative (i.e. No hemoptysis, No clinical sign of deep venous thrombosis and PE is not the most likely diagnosis), then the threshold of D-dimer will be raised at 1000 ng/ml.~If at least one item of YEARS is positive, then the threshold will remain unchanged (>500 ng/ml for patients aged < 50 and > agex10 for patients aged 50 and over).~A positive result of D-dimer and the absence of other obvious cause for PE will mandate a CTPA, or V/Q scan if CTPA is contra-indicated.~A negative result of D-dimer will rule out PE."
89087767|NCT04032769|No Intervention|Control group|All included patients will be tested with D-Dimer, threshold for ordering a CTPA as usual
89087768|NCT00970359|Experimental|pts with thyroid cancer with and without BRAF mutation|Patients receive selumetinib orally (PO) twice daily (BID) for 4 weeks. Within 1 month, patients with adequate RAI uptake may receive 131I per standard of care and continue selumetinib until 2 days following 131I.
89087769|NCT01121406|Experimental|BI 6727|Patients receive BI 6727 infusion every 3 weeks
89087770|NCT01121406|Active Comparator|Cytotoxic|At the investigator discretion, patient will receive one of the following cytotoxics: topotecan, paclitaxel, gemcitabine or liposomal doxorubicin
89087771|NCT02650141|Experimental|ziyinxiehuo Granules|Children of ziyinxiehuo granules group will be treated with chinese herbal granules,3 times a day, for 6 months.
89087772|NCT02650141|Active Comparator|zishenqinggan Granules|Children of zishenqinggan granules group will be treated with chinese herbal granules, 3 times a day, for 6 months.
89087773|NCT02657239|Experimental|MOVE UP Intervention|Subjects will participate in a healthy lifestyle weight management intervention focused on healthy eating and increasing physical activity
89087774|NCT02652325|Active Comparator|povidone-iodine|
89087775|NCT02652325|Active Comparator|3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP swabs|
89087776|NCT02652325|Placebo Comparator|Saline|
89087777|NCT00960687|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered 30 minutes after the initiation of a standard breakfast.
89087778|NCT00960687|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered 30 minutes after the initiation of a standard breakfast.
89087779|NCT00920140|Experimental|Phase I|"The proposed treatment schedule of GSK1120212 is continuous daily dosing. At the initiation of dosing, a loading dose will be given prior to starting continuous dosing (maintenance dose).~Alterations to the dose and schedule will be based on emerging PK, PD, and tolerability data. The goal will be to define a regimen that is well tolerated and provides adequate PK and PD. This will be the recommended Phase II schedule."
89087780|NCT00920140|Experimental|Phase II|A dose determined by Phase I to further evaulate the safety profile, PK, PD, and clinical activity of GSK1120212.
89087781|NCT00649753|No Intervention|A|
89087782|NCT00649753|Experimental|B|
89087783|NCT00649753|Experimental|C|
89087784|NCT00649753|Experimental|D|
89087785|NCT01120782|Active Comparator|etafilcon A toric new lens/etafilcon A toric lens|The lens worn first is a new etafilcon A toric contact lens and the lens worn second is a marketed etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
89087786|NCT01120782|Active Comparator|etafilcon A toric lens/etafilcon A toric new lens|The lens worn first is a marketed etafilcon A toric contact lens and the lens worn second is a new etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
89087787|NCT02650297|Experimental|CDT and pneumatic compression pump|combined decongestive therapy consists of the pressure of bandage, manual lymphatic drainage, and exercises that increase the flow of lymph and skin care are used. Intermittent pneumatic pump is not as a part of CDT, but it can be used as an adjunct method. This device according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk.
89087788|NCT02650297|No Intervention|not CDT and pneumatic compression pump|Patients in the control group received no treatment for lymphedema but were placed on the waiting list for CDT as soon as possible after the 8 weeks follow-up period.
89087789|NCT04203862|Experimental|1|Single administration of low dose NPC-22
89087790|NCT04203862|Experimental|2|Single administration of low/middle dose NPC-22
89087791|NCT04203862|Experimental|3|Single administration of middle dose NPC-22
89087792|NCT04203862|Experimental|4|Single administration of middle/high dose NPC-22
89087793|NCT04203862|Experimental|5|Single administration of high dose NPC-22
89087794|NCT04203862|Experimental|6|Single administration of placebo dose NPC-22
89087795|NCT01120626|Active Comparator|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
89087796|NCT01120626|Placebo Comparator|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
89087797|NCT04252534|Active Comparator|Repetitive electromagnetic stimulation|Group 1 consists of 20 RP patients (40 eyes) who received combined rEMS with PRP. In this group, patients received rEMS for 30 minutes before subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
89087798|NCT04252534|Active Comparator|Platelet rich plasma|Group 2 consists of 20 RP patients (40 eyes). In this group, patients received only subtenon PRP injections. In this group, 3 loading doses were applied at 3-week intervals. Then 2 booster dose were applied at 6-month intervals.
89087799|NCT04252534|No Intervention|Natural course|Group 3 consists of 20 RP patients (40 eyes). Patients in this group did not accept any interventional application and were only followed up. The
89087800|NCT00650377|Experimental|1|Finasteride Tablets 5 mg
89087801|NCT00650377|Active Comparator|2|Proscar® Tablets 5 mg
89087802|NCT05115370||Patients with an inflammatory disease taking immune-suppressing medication|
89087803|NCT02649985|Experimental|Relapsing-Remitting Multiple Sclerosis|"Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, at least one gadolinium enhancing lesion on a MRI within 12 months of enrollment, or at least one new FLAIR bright lesion on MRI within 6 months of enrollment.~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
89087804|NCT02649985|Experimental|Progressive Multiple Sclerosis|Subjects meeting the definition for SPMS/PPMS (Primary Progressive Multiple Sclerosis) by International Panel Criteria and who have demonstrated deterioration in EDSS score in last 1 year.
89087805|NCT02649985|Active Comparator|Alzheimer's Disease|Subjects meeting the definition for probable AD based on NINDS-ADRDA criteria. In terms of severity of disease, the investigators will select subjects with mild AD, as defined by Mini-Mental Status Examination (MMSE) score of 20-26.
89087806|NCT02649985|Other|Healthy Control|This group will serve as non disease population.
89087807|NCT02649985|Experimental|Multiple Sclerosis Ocrelizumab|"Subjects who have been prescribed Ocrelizumab by their treating MS neurologist but have not yet started the first Ocrelizumab infusion.~Subjects will undergo two separate visits for [F-18]PBR06 PET scans, once before starting Ocrelizumab and the second visit 3 months after completion of the initial Ocrelizumab doses."
89087808|NCT04242784||Spoke Hospital|Patients that undergo the Code Stroke process at Spoke Hospitals
89087809|NCT04242784||Hub Hospital|Patients that undergo the Code Stroke process at Hub Hospitals
89087810|NCT04242784||Transfer|Patients that undergo the Code Stroke process at a Spoke Hospital and transfer to the Hub Hospital
89087811|NCT02650063|Experimental|DE-117 ophthalmic solution|
89087812|NCT02649751|Experimental|Group 1|"200 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
89087813|NCT02649751|Experimental|Group 2|"400 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
89087814|NCT02649751|Experimental|Group 3|"400 mg roscovitine (8) or (4) placebo twice daily for cycles of 7 days (4 days on and 3 days off)"
89087815|NCT04252300|Experimental|Healthy subjects_Period 1|Healthy adults from USA receive a single dose of rosuvastatin (interaction drug) in Period 1.
89087816|NCT04252300|Experimental|Healthy subjects_Period 2|The healthy adults from Period 1 receive both rosuvastatin + BAY1817080 in Period 2.
89087817|NCT02649595|Other|Red Cross respite care|A 2 week free stay at a Red Cross respite center after hospitalization.
89087818|NCT02649595|No Intervention|Streets/communal programmes|Homeless being discharged from hospital to the streets and communal programmes.
89087819|NCT04256746|Placebo Comparator|Boiled Rice|63 g of raw rice was cooked.
89087820|NCT04256746|Experimental|Boiled Rice+0.37 gr extract|63 g of raw rice was cooked and 0.37 gr mulberry fruit powdered extract added and mixed
89087821|NCT04256746|Experimental|Boiled Rice+0.75 gr extract|63 g of raw rice was cooked and 0.75 gr mulberry fruit powdered extract added and mixed
89087822|NCT04256746|Experimental|Boiled Rice+1.12 gr extract|63 g of raw rice was cooked and 1.12 gr mulberry fruit powdered extract added and mixed
89087823|NCT04256746|Experimental|Boiled Rice+1.50 gr extract|63 g of raw rice was cooked and 1.50 gr mulberry fruit powdered extract added and mixed
89087824|NCT04256746|Placebo Comparator|Rice porridge|60 g of rice porridge was rehydrated with 300 ml boiling hot water
89087825|NCT04256746|Active Comparator|Rice porridge+1.50 gr extract|60 g of rice porridge was rehydrated with 300 ml boiling hot water and 1.50 gr mulberry fruit powdered extract added and mixed
89087826|NCT04167319||Paclitaxel|Patients scheduled to receive paclitaxel as part of their standard treatment
89087827|NCT04167319||Oxaliplatin|Patients scheduled to receive oxaliplatin as part of their standard treatment
89087828|NCT04256668|Active Comparator|good embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with normal embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal fertilization rate >50% and normal blastocyst development rate >50%).
89087829|NCT04256668|Active Comparator|poor embryo development in assisted reproduction|20 infertile men treated with assisted reproduction with poor embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal or slightly reduced fertilization rate <50% and low or absent blastocyst development (0 or only 1 blastocyst).
89087830|NCT04256668|Placebo Comparator|natural conception|20 previously infertile men, normal history, normal genital status, normal sperm count, DNA fragmentation rate <20% (as given by TUNEL) and achieving pregnancy naturally (without medical intervention).
89087831|NCT02649517|Other|chronic inflammation|All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy.
89087832|NCT00924508|Experimental|Patch + cream, patch alone, cream alone|This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% cream and hydrogel patch (occlusion), the second treated with cream alone, and the third treated with occlusion alone.
89087833|NCT00650923|Experimental|Arm 1|See Detailed Description
89087834|NCT01139658||All comers|
89087835|NCT02649205||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
89087836|NCT04256590||Study|Patients aged 16 years or younger who were to undergo adenoidectomy surgery were eligible for inclusion in this group. Tongue surface areas were measured twice by submental USG.The first measurements (TSA2) were done immediately after endotracheal intubation but before insertion and placement of the tongue depressor. The second measurements (TSA1) were done after adenoidectomy surgery and after removal of the tongue depressor but just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue swelling.
89087837|NCT04256590||Control|This group included patients aged 16 years or younger who did not need adenoidectomy surgery and any head and neck procedures. Tongue surface areas of the patients were measured twice by submental USG as in the study group. TSA1s were done immediately after endotracheal intubation, and TSA2s were done at the end of the surgical procedure just before extubation. The difference between TSA2 and TSA1 (i.e., (TSA2-TSA1) was used to defined the occurrence of tongue edema.
89087838|NCT00637858|Placebo Comparator|1|
89087839|NCT00637858|Active Comparator|2|Lyc-o-Mato 5mg
89087840|NCT00637858|Active Comparator|3|Lyc-o-Mato 15mg
89087841|NCT00637858|Active Comparator|4|Lyc-o-Mato 30mg
89087842|NCT00637858|Active Comparator|5|Lycopene capsules (non Lyc-o-mato) 15 mg
89087843|NCT04167241||Patients submitted to right pneumonectomy or bi-lobectomy|Consecutive, elective surgical patients submitted to right pneumonectomy or bi-lobectomy
89087844|NCT02649127|Experimental|Imaginal Therapy Only|The imaginal exercise of exposure therapy will be manualized (Rothbaum, Foa & Hembree, 2007) and adapted with the permission of Dr. Foa for combat-related stress disorders (Peterson, Cigrang & Riggs, 2008). While traditional exposure therapy includes both imaginal exposure and in vivo exposure, this study will use only the imaginal exposure components. Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes.
89087845|NCT02649127|Experimental|Exercise Only|The aerobic exercise regimen will be standardized according to the American College of Sports Medicine recommendations: frequency of a minimum of 5 sessions per week, at a vigorous intensity [>60% of oxygen uptake reserve (VO2R)], time of 20-25 minutes per exercise session. To determine the exercise heart rate intensity, the Karvonen formula for heart rate reserve will be used. The mode of exercise will be purposeful walking or jogging. The goal of the exercise is not training, but rather to keep the participant's heart rate >60% of their individually-determined heart rate reserve.
89087846|NCT02649127|Experimental|Imaginal Therapy & Exercise Combined|Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes. Participants will exercise listening to their tape at least 5-times/week outside of scheduled unit Physical Training. Participants will wear the heart rate monitor to record their exercise activity.
89226264|NCT04544098|Experimental|PRRT with 177Lu-DOTATATE|Patients will undergo a routine 68Ga-DOTATATE PET/CT. Patients with sufficient tumor uptake will be offered therapy with 177Lu-DOTATATE. The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration.
89087847|NCT02649127|Active Comparator|Nurse-led Self-Care|The Self-Care Group will use written materials that outline the benefits of thinking about problems the individual is facing as well as the benefits of exercise, however doing the two activities together will not be advocated as part of the material. A fact sheet prepared by the National Center for PTSD, Returning from the War Zone: A Guide for Military Personnel as well as a list of coping strategies and self-care behaviors adapted from the National Center for PTSD guide, Self-Care and Self-Help Following Disasters, will be used to guide the discussion. The research nurse will meet with the participant five times over 8-weeks at weeks 1, 2, 4, 6, and 8 to encourage use of the self-care fact sheet and assess the participant for safety.
89087848|NCT04251598|Experimental|Education group|"Only I am Protecting my Child From the Sun program was given."
89226265|NCT04533503||HF-OCT imaging|Enrolled subjects who meet lesion-specific eligibility criteria and undergo HF-OCT imaging
89230209|NCT00661193|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89230210|NCT00800813||open, laparoscopic, or robotic-assisted lap|Patients will also be assessed for penile length and the presence of Peyronie's Disease at these specified times.
89230211|NCT00793481||Diagnostic tool|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
89087849|NCT04251598|Experimental|Education + SMS group|"The I am Protecting my Child From the Sun program was given. After the program, an SMS message was sent on Wednesday and Saturday for 12 weeks. A total of 25 SMS messages were sent to remind the subject and applications."
89087850|NCT04251598|No Intervention|Control group|"No attempt was made by the researcher during the study. Only data collection was carried out. At the end of the research, the I am Protecting my Child From the Sun program was given.."
89087851|NCT02657161|Active Comparator|Group A|"Comparator vaccine RABIPUR®~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
89087852|NCT02657161|Experimental|Group B|"PIKA Rabies vaccine~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
89087853|NCT02657161|Experimental|Group C|"PIKA Rabies vaccine with an accelerated regimen~Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)"
89087854|NCT01139580|Experimental|Calcipotriene Foam|Calcipotriene Foam 0.005%,
89087855|NCT01139580|Placebo Comparator|Vehicle Foam|Vehicle Foam
89087856|NCT02657083|Experimental|Glucose control using DreaMed MD-AID|In this group the subjects use a closed loop system (DreaMed Substance Administration Device) that combines glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™), which provides real-time interstitial glucose values, with a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) and computer algorithm, which directs insulin delivery in response to glucose sensor data.
89087857|NCT02657083|Active Comparator|Glucose control using SAP|In this group the subjects use a standard treatment (Sensor Augmented Pump), characterised by glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™) which provides real-time interstitial glucose values and a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) without computer algorithm decisions.
89087858|NCT04686760|Experimental|Nitroglycerin solution|
89087859|NCT04686760|No Intervention|standard solution|
89087860|NCT04312698|Experimental|Experimental Group 1|
89087861|NCT04312698|Placebo Comparator|Comparator Group 1|
89087862|NCT04312698|Placebo Comparator|Comparator Group 2|
89087863|NCT04251832|Experimental|Ultrasound guided percutaneous lavage with STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using sodium thiosulfate 25 %: a volume of 1 mL of sodium thiosulfate will be prepared in a syringe and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. At the end of the procedure 1 mL (250 mg) of thiosulfate will be injected inside the calcific deposit. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.~Only a single procedure will be performed and the outcomes measured after 1 week, 1 month and 3 months."
89087864|NCT04251832|Active Comparator|Ultrasound guided percutaneous lavage without STS|"Ultrasound guided percutaneous lavage with a single needle technic. A total of 10 mL of lidocaine 1% will be injected in the subcutaneous tissues, the subacromial bursa and over the surface of the calcific deposit. A 21 G pediatric spinal needle will be used for the procedure to prevent needle clogging by calcific debris. When backflow of calcific material could be identified in the syringe, lavage of the deposit will be performed using of saline solution and successive propulsion and aspiration will be performed. The procedure will be repeated until the backflow becomes clear. Finally, 1.5 mL of methylprednisolone will be injected in the SAB.~Only a single procedure will be performed and the outcomes measured after 1week, 1month and 3months"
89087865|NCT04312464||Discharged group|The individual which is defined as patient discharged from hospital
89087866|NCT04312464||Dead group|The individual which is defined as patient with all-cause death
89087867|NCT02656927|Experimental|Yoga Condition|
89087868|NCT02656927|Placebo Comparator|Wait-list Control Condition|
89087869|NCT04251988|No Intervention|Standard of Care (No VR) Randomization|Patients will receive standard of care during catheterization, which includes caregiver presence in the room and Child Life Specialists in the room, if desired, and does not include virtual reality.
89087870|NCT04251988|Experimental|VR Randomization|Patients will receive virtual reality in addition to standard of care.
89087871|NCT04312776||Patients infected with CA-MRSA|It is an observational study, no interventions to any of the two study arms.
89087872|NCT04312776||Healthy people without any infection|It is an observational study, no interventions to any of the two study arms.
89087873|NCT02656849|Experimental|BAY 1000394|"After the screening procedures confirm eligibility to participate in the research study:~Each treatment cycle lasts 4 weeks.~Participants will take the study drug orally at predetermined times and dosage per cycle."
89230212|NCT03872531||Cohort 1|Includes age group 3-5 with a cap at 20 subjects. This is a retrospective, observational study
89230213|NCT03872531||Cohort 2|Includes age group 6-10 with a cap at 30 subjects. This is a retrospective, observational study
89087874|NCT04313010|Experimental|Regenerative endodontics therapy with PRF|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. Only the apex 1/3 of the root canal need to be filled with blood. PRF was injected into the root canal to a level below the CEJ, then wait for 10-15min to coagulate.
89087875|NCT04313010|Active Comparator|Regenerative endodontics therapy with BC|In the procedures of regenerative endodontics therapy, K-files were intentionally used to violate the periapical tissues via overinstrumentation up to 2-3mm past the apical foramen to induce bleeding. The adequate blood need to be full with canal space and below the CEJ, then wait for 10-15min to coagulate.
89087876|NCT05252260|Experimental|Diode Laser|Vestibuloplasty operation was performed via diode laser
89087877|NCT05252260|Other|Diode laser + Low-level laser therapy|Vestibuloplasty operation was performed via diode laser and following low-level laser therapy was applied
89087878|NCT05252260|Active Comparator|Conventional surgery|Vestibuloplasty operation was performed via scalpel
89087879|NCT05252260|Other|Conventional surgery + Low-level laser therapy|Vestibuloplasty operation was performed via scalpel and following low-level laser therapy was applied
89087880|NCT02536729||Oral Sodium Phosphate - Normal preparation|Oral sodium phospate exposure with special diet (Liquid)
89087881|NCT02536729||Oral Sodium Phosphate - Modified preparation|Oral sodium phospate exposure with special diet (Liquid), but the participant can normally lunch the day before the test
89087882|NCT02536729||polyethylene glycol + Electrolytes|polyethylene glycol + Electrolytes exosure with special diet (Liquid)
89087883|NCT02656771|Active Comparator|Echo Bi-Metric THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.~It is a relatively new implant that is now in routine clinical use. The stem uses many of the features of the known and used Integral® and Bi-Metric® hip stems while integrating new design features to further enhance clinical performance such as a reduced neck geometry to allow for increased ROM and decreased risk of neck impingement, a polished neck designed to reduce debris should impingement occur and a polished bullet-shape distal tip to reduce distal stresses."
89087884|NCT02656771|No Intervention|Bi-Metric Porous Primary THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.~It was introduced in 1984 and have shown good clinical results and excellent stem survival in register studies"
89087885|NCT02883582|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA)with or without ICS)+ hydrogen/ oxygen inhaled
89087886|NCT02883582|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
89087887|NCT02656537|Experimental|EnSite™ HD Grid Catheter AF/AT Mapping|
89087888|NCT00917644|Other|Reference|80 mg atorvastatin tablets
89087889|NCT00917644|Experimental|Test|New 80 mg atorvastatin tablets
89087890|NCT02649283|Other|Breast symmetrisation with OrbiSymm|Standard surgical intervention of up to 30 patients including placement of the OrbiSymm device
89087891|NCT02649283|Other|Breast symmetrisation without device|Standard surgical intervention of up to 30 patients without the Orbix device; only routine reduction/symmetrisation intervention
89087892|NCT01137786|Active Comparator|IOPAMIDOL 370|
89087893|NCT01137786|Active Comparator|IODIXANOL 320|
89087894|NCT00631774|Active Comparator|1|a meal replacement program with Glucerna SR on top of the exchange-diet plan
89087895|NCT00631774|Active Comparator|2|an caloric-matched exchange-diet plan only.
89087896|NCT00625170|Active Comparator|1|Healthy men
89087897|NCT00625170|Active Comparator|2|Healthy men with a positive family anamneses of schizophrenia
89087898|NCT00599755|Experimental|Gem/Cis or Gem/Carbo|
89087899|NCT04251364|Experimental|Acetazolamide|Oral acetazolamide (250 mg/day) intake for 9 months
89087900|NCT04251364|Experimental|Atorvastatin|Oral atorvastatin (40 mg/day) intake for 9 months
89087901|NCT04251364|Placebo Comparator|Placebo|Oral placebo pill (daily) intake for 9 months
89087902|NCT00637260|Experimental|A|
89087903|NCT00637260|Sham Comparator|B|
89087904|NCT02648425|Experimental|Regimen A / Amended Regimen A|"Regimen A: Cisplatin + 5-fluorouracil~ASLAN001 daily in combination with:~Cisplatin 80 mg/m2 IV infusion for 1 day and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks for up to 6 cycles.~Or~Amended Regimen A: Cisplatin + 5-fluorouracil + leucovorin~ASLAN001 daily in combination with:~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks for up to 6 cycles."
89087905|NCT02648425|Experimental|Regimen B|"Regimen B: Cisplatin + capecitabine~ASLAN001 daily in combination with:~Cisplatin 60-80 mg/m2 IV infusion on Day 1 and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks for up to 6 cycles."
89087906|NCT00637338|Experimental|PF-04603629|The dose range initially planned is 3 mg up to 70 mg, although the specific doses administered may be modified based on emerging study data.
89087907|NCT00637338|Placebo Comparator|Placebo|
89087908|NCT00625482|Active Comparator|Boys 1|OPV as usual
89087909|NCT00625482|Experimental|Boys 2|OPV plus BCG
89087910|NCT00625482|Active Comparator|Girls 1|OPV as usual
89087911|NCT00625482|Experimental|Girls 2|OPV plus BCG
89087912|NCT02648503|Experimental|Deep neuromuscular block|PTC=1-2
89087913|NCT02648503|Active Comparator|Moderate neuromuscular block|TOF=1-2
89087914|NCT04787614||Home-based providers|Individuals who provided paid care for children under the age of 13 in a residential setting as of 2019
89087915|NCT04787614||Center-based providers|Providers who cared to children ages 0 through 5 years of age (not yet in kindergarten) in a non-residential setting as of 2019
89087916|NCT04787614||Center-based workforce|Individuals employed in center-based child care programs working directly with children in classrooms as of 2019
89087917|NCT02536261||Withdrawal group|Withdrawal observation after reaching the withdrawal standard
89087918|NCT02536261||Continue treatment group|Continue treatment obsevation after reaching the withdrawal standard
89087919|NCT04250896|Other|Control|Control group will receive standard child care in health units plus exposure to EsIAN (Strategy of Integral Attention to Nutrition)
89087920|NCT04250896|Experimental|Intervention|Intervention group will receive SMS messages sent through a cell pone in addition to the control group receive (standard child care in health units plus exposure to EsIAN)
89087921|NCT05253508|Experimental|Healthy human participants|ring-block anaesthesia with lidocaine in one of the two visits
89087922|NCT04524130|Experimental|Lidocaine and Ketamine|Participants in this arm will receive intra-operative lidocaine and ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
89087923|NCT04524130|Active Comparator|Lidocaine|Participants in this arm will receive only intra-operative ketamine infusion as adjunctive drugs for pain control. All medication is dosed based on calculated lean body weight (LBW) by Janmahasatian formula.
89087924|NCT04524130|Placebo Comparator|Placebo|Participants in this arm will receive normal saline, same volume as lidocaine and ketamine.
89087925|NCT00600613|Experimental|1|Patients going for treatment of liver metastases with radiation therapy.
89087926|NCT00649831|Active Comparator|Group 2|
89087927|NCT00649831|Active Comparator|Group 1|
89087928|NCT05251870|Experimental|Intranodal TolDCB29 (low dose)|Two administrations of 5 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
89087929|NCT05251870|Experimental|Intranodal TolDCB29 (intermediate dose)|Two administrations of 10 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
89087930|NCT05251870|Experimental|Intranodal TolDCB29 (high dose)|Two administrations of 15 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
89087931|NCT05251870|Experimental|Intranodal TolDCB29 (recommended dose)|Two administrations of the recommended dose of autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). The recommended dose will be advised by the data safety monitoring board after data review of the first three arms. This cohort will consist of nine patients.
89087932|NCT05117944|Experimental|Drama|Students in the intervention group will act as the patient and act out the case given to them. Nursing care to be provided by a professional nurse to the student who will play the role of the patient in line with the case content includes helping the patient (student) eat, perform personal hygiene (oral care, etc.), dress and move. The case content will not be shared with the students in advance, and the student will not need to make any preliminary preparations. However, ten minutes before the start of the practice, the situations that are expected to be portrayed as the patient specified in the case will be explained to the students. The skills laboratory will be used as three separate patient rooms (with two or three patients), in which students in the role of inpatient will receive care from a professional nurse. Each student will experience the patient role only once.
89087933|NCT05117944|No Intervention|Control|Students in the control group will fill in the datasheet, Altruism Scale and Empathy Scale simultaneously with the intervention group, without any intervention, and then the Altruism Scale and Empathy Scale at the 1st and 3rd months.
89087934|NCT02648659|Experimental|triple with clarithromycin|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin bid for 2 weeks
89087935|NCT02648659|Experimental|triple with metronidazole|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Metronidazole 500mg tid for 2 weeks
89087936|NCT02648659|Experimental|quadruple|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin 500mg bid, Metronidazole 500mg tid for 2 weeks
89087937|NCT04567888|Active Comparator|Happify Teens|Happify Teens is a digital well-being intervention that can be accessed via mobile application or web browser
89087938|NCT04567888|No Intervention|Waitlist Control|Waitlist Control Condition
89087939|NCT01125930|Placebo Comparator|Vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
89087940|NCT01125930|Active Comparator|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
89087941|NCT02656615|Experimental|Abiraterone|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
89087942|NCT05253430||D1 lymph node dissection (LND)|Patients with gastric cancer that underwent curative surgery with gastrectomy and D1 lymph node dissection
89087943|NCT05253430||D2 lymph node dissection (LND)|Patients with gastric cancer that underwent curative surgery with gastrectomy and D2 lymph node dissection
89087944|NCT03946579|Other|Patient treated by adjuvant therapy|Self questionnaires of sexual health and quality of life (FSFI, QLQ-C30, BR23, ELD 15, HADS, GDS 15, BIS, FACIT)
89087945|NCT05031988||University Students|To assess the determinants of physical activity and mental health among university students during and after Covid-19 lockdown.
89087946|NCT00651235|Experimental|B|In combination therapy,the maximal dose of Losartan is 100 mg/day for adult and 50 mg/day for children. 50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children
89087947|NCT00651235|Active Comparator|A|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
89087948|NCT04015219|Experimental|Treatment Arm|PROKERA SLIM + Standard of Care
89087949|NCT04015219|Active Comparator|Control Arm|Standard of Care
89087950|NCT02648269|Experimental|SEL-110|Single intravenous dose of SEL-110
89087951|NCT02648269|Experimental|SEL-212|Single intravenous dose of SEL-110 plus SEL-037 (pegsiticase)
89087952|NCT02648269|Experimental|SEL-037|Single intravenous dose of SEL-037 (pegsiticase)
89087953|NCT00918346|Experimental|Tafluprost 0.0015% preserved formulation|
89087954|NCT00918346|Experimental|Tafluprost 0.0015% unpreserved formulation|
89087955|NCT02649361|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89087956|NCT02649361|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89087957|NCT02648815|Active Comparator|Percutaneous catheter drainage group|Percutaneous catheter drainage (PCD) of necrotic tissue and pathological collections formed during acute pancreatitis
89087958|NCT02648815|Active Comparator|Abdominal paracentesis evacuation group|Abdominal paracentesis drainage (APD) of peritoneal fluid during acute pancreatitis
89087959|NCT00913978|Active Comparator|Group 1: VitaHeat|Patients in group one will be warmed perioperatively with the VitaHeat mattress and IV fluid warmers once they are in the operating room.
89087960|NCT00913978|Active Comparator|Group 2: Bair Hugger|Patients in group two will be warmed perioperatively with the upper body bair hugger and IV fluid warmers once they are in the operating room.
89087961|NCT02648893|Experimental|MBFC-Exp|The MBFC-Exp (Multiple biofortified food crops - Experimental) arm will consume meals based on biofortified food crops.
89087962|NCT02648893|Active Comparator|MBFC-C|The MBFC-C (Multiple biofortified food crops - Control) arm will consume the same meals based on non-biofortified (commercially available) food crops.
89087963|NCT02649049||Patients with NAFLD|Patients with NAFLD are the cases.
89087964|NCT02649049||control group|Healthy people without NAFLD are controls.
89087965|NCT04687540|Placebo Comparator|Study day 1 (study visit 1)|Baseline measurements (pre-intervention) are obtained on study visit 1.
89087966|NCT04687540|Active Comparator|Study day 21 (study visit 2)|Post-intervention measurements: Participants will be under the influence of tocilizumab, which was injected at the end of study visit 1.
89087967|NCT01137474|Experimental|Dapagliflozin, 10 mg|Oral tablets administered as 10 mg once daily for up to 12 weeks
89087968|NCT01137474|Placebo Comparator|Placebo-matching dapagliflozin|Oral tablets administered once daily in the morning
89087969|NCT01137474|Experimental|Dapagliflozin, 2. 5 mg|Oral tablets administered as 2.5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
89087970|NCT01137474|Experimental|Dapagliflozin, 5 mg|Oral tablets administered as 5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
89087971|NCT02648191|Experimental|Active stimulation|
89087972|NCT02648191|Sham Comparator|Inactive stimulation|
89087973|NCT04791436||Mild Illness|Recovered COVID-19 patients who experienced a mild clinical course
89087974|NCT04791436||Moderate Illness|Recovered COVID-19 patients who experienced a moderate clinical course
89087975|NCT04791436||Severe Illness|Recovered COVID-19 patients who experienced a severe clinical course
89087976|NCT02647879||Hepatitis C infected|All patients diagnosed with hepatitis C in Iceland
89087977|NCT04790188|Experimental|Experimental intervention first.|Participants randomized to receive the nootropic first.
89087978|NCT04790188|Placebo Comparator|Experimental intervention second.|Participants randomized to receive the placebo first
89087979|NCT02648737|Experimental|Cognitive Behavioural Therapy (CBT)|Patients who will receive CBT plus clinical monitoring will receive 10 weekly individual sessions (60-75 minutes), tailored to the preferences and needs of each patient. In each session, a registered psychologist will address specified aspects of (coping with) anxiety and related concerns with a specific focus on behaviour and thoughts associated with anxiety.
89087980|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status. Patients who receive clinical monitoring only will be given the option to receive CBT once the trial is completed.
89087981|NCT02645305|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be transfused into 20 COPD patients.
89087982|NCT04609696|Experimental|Part 1: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 1 formulation under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
89087983|NCT04609696|Experimental|Part 1: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 1 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
89087984|NCT04609696|Experimental|Part 1: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 1 formulation under fed conditions. Period 3: Danicopan as the PIC 1 formulation under fasted conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
89230214|NCT03872531||Cohort 3|Includes age group 11-15 with a cap of 30 subjects. This is a retrospective, observational study
89230215|NCT03872531||Cohort 4|Includes age group 16-20 with a cap of 20 subjects. This is a retrospective, observational study
89230216|NCT03872531||Cohort 5|Includes age group 21-30 with a cap at 20 subjects. This is a retrospective, observational study
89087985|NCT04609696|Experimental|Part 2: Sequence 1|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 2 formulation under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fasted conditions. Period 3: Danicopan as a tablet under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
89087986|NCT04609696|Experimental|Part 2: Sequence 2|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as the PIC 2 formulation under fasted conditions. Period 2: Danicopan as a tablet under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fed conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
89087987|NCT04609696|Experimental|Part 2: Sequence 3|"Participants will receive danicopan once each period as a single oral dose under fasted or fed conditions as follows:~Period 1: Danicopan as a tablet under fed conditions. Period 2: Danicopan as the PIC 2 formulation under fed conditions. Period 3: Danicopan as the PIC 2 formulation under fasted conditions.~There will be a washout period of at least 5 days between each danicopan dosing."
89087988|NCT01168973|Experimental|Ramucirumab + Docetaxel|
89087989|NCT01168973|Placebo Comparator|Placebo + Docetaxel|
89087990|NCT00631462|Experimental|1|
89087991|NCT03918109|Experimental|OTO-313|
89087992|NCT03918109|Placebo Comparator|Placebo|
89087993|NCT04187430||Retrospective group|
89087994|NCT04187430||Prospective group|
89087995|NCT02648035||Subcutaneous Tocilizumab|Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.
89087996|NCT04311372|Experimental|Educational session+Material+Videos (Group 1)|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
89087997|NCT04311372|Active Comparator|Educational session+Material ONLY (Group 2)|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
89087998|NCT04744012||unique group|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
89087999|NCT02644993|Experimental|Proton beam therapy|
89088000|NCT00652561|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
89088001|NCT00653497|Experimental|1|Community-based aquatic exercise program (Arthritis Foundation Aquatics Program). Two classes per week, 45-60 minutes in duration.
89088002|NCT00653497|No Intervention|2|Usual care; abstention from initiation of new exercise programs. Invited to participate in Arthritis Foundation Aquatics Program after study completion.
89088003|NCT03206437|Experimental|Mindfulness-Based Stress Reduction|This group will take the 8 week MBSR course within 4 weeks of their first testing visit. When the course is finished they will come in for their second testing visit. The course meets once a week in person for 2.5 hours and participants are expected to do practices at home.
89088004|NCT03206437|Other|Waitlist|The wait-list group will not participate in the MBSR course within 4 weeks of their first testing visit. They will wait 8-16 weeks and come on for a second testing visit. After their data is collected they will be offered an MBSR course to take.
89088005|NCT01124916|Active Comparator|Laparoscopic Abdominal Sacrocolpopexy (LASC)|Women assigned to this cohort will receive standard laparoscopic abdominal sacrocolpopexy (LASC)
89088006|NCT01124916|Experimental|Robotic Assisted Laparoscopic (RASC)|Women assigned to this cohort will receive robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)
89088007|NCT00631618|Experimental|Suntinib|Suntinib
89088008|NCT02647801|Experimental|Mindfulness intervention|The experimental group comes to weekly laboratory meetings and practices mindfulness. Participants also fill out self-report questionnaires which assess self-control and mindfulness.
89088009|NCT02647801|No Intervention|Control group|The control group comes to weekly laboratory meetings and fills out self-report questionnaires which assess self-control and mindfulness. No mindfulness training is carried out.
89088010|NCT04777630||Patients with low vision who experience Charles Bonnet hallucinations|No intervention, observation of neuroimaging and questionnaires
89088011|NCT04777630||Patients with low vision who do not experience Charles Bonnet hallucinations|No intervention, observation of neuroimaging and questionnaires
89088012|NCT04714060|Experimental|cohort 1|2.5 mg/kg UB-621 group
89088013|NCT04714060|Experimental|cohort 2|5 mg/kg UB-621 group
89088014|NCT04431778|Experimental|Ethosuximide|Patients with chronic peripheral neuropathic pain
89088015|NCT04431778|Placebo Comparator|Placebo|Patients with chronic peripheral neuropathic pain
89088016|NCT05252650||regional block|epidural / peripheral nerve block
89088017|NCT05252650||intravenous|intravenous analgesia
89088018|NCT05252572|Experimental|Treatment of CLL1-positive Hematological Malignancies|Administration of CLL1 CAR T-cells A dose levels of 2-8*10E6/kg are administrated for each subject.
89088019|NCT00631384|Experimental|1|Women to be asked to bring husbands for couple VCT
89088020|NCT00631384|Active Comparator|2|Women to receive individual VCT
89088021|NCT05252494|Experimental|animal assisted therapy group|Animal assisted therapy group will watch aquarium fish while bloodletting prosedure.
89088022|NCT05252494|No Intervention|Control Group|Control group will not watch aquarium fish while bloodletting prosedure.
89088023|NCT02691130|Experimental|A: M-001 0.5mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine~Two administrations of non adjuvanted M-001, 0.5mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
89088024|NCT02691130|Experimental|B: M-001 1.0mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine~Two administrations of non adjuvanted M-001, 1.0mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
89088025|NCT02691130|Placebo Comparator|C: Saline & H5N1 influenza vaccine|"Biological/Vaccine: Two saline administrations followed by H5N1 influenza vaccine~Two administrations of saline followed by 3mcg Alum/H5N1 influenza vaccinated intervals of 19-23 days"
89088026|NCT00916006|Experimental|PEP005 gel|PEP005 gel, 0.015% applied once daily for three consecutive days
89088027|NCT00916006|Placebo Comparator|Vehicle gel|Vehicle gel applied once daily for three consecutive days
89088028|NCT04606186|Active Comparator|Lactobacillus reuteri Prodentis®-lozenges|
89088029|NCT04606186|Placebo Comparator|Placebo-lozenges (BioGaia)|
89088030|NCT04701814|Active Comparator|group A (controlled group)|received passive range of motion (PROM)/ active assisted range of motion (AAROM)/ active range of motion (AROM) exercises, strengthen of rotator cuff, biceps, shoulder and scapular muscles, ultrasound (5 min. - 1.5 W/c.m2 - 1 MHZ), electrical stimulation ( interferential bipolar technique for 20 min. on shoulder joint). This treatment was repeated three times per weeks with 24 hours rest for 3 weeks.
89088031|NCT04701814|Active Comparator|group B(Study group)|All patients in group B received biomechanical scapular mobilization with movement and motor learning and traditional methods.
89088032|NCT04589572|Experimental|XLIF - group|
89088033|NCT04589572|Active Comparator|PLIF - Group|
89088034|NCT04669132|Experimental|Olanzapine + Netupitanto + Palonosetron|Olanzapine 5 mg/day d 0-4 + Netupitanto 300 mg/day d 1 + Palonosetron 0.56 mg/day d 1;
89088035|NCT04701346|Experimental|Low SAA diet|Dietary intervention
89088036|NCT04701346|Active Comparator|High SAA diet|Dietary intervention
89088037|NCT01168349||Cohort|
89088038|NCT00915772|Experimental|Linagliptin + metformin bid|Linagliptin low dose + metformin 500 mg, bid
89088039|NCT00915772|Experimental|Linagliptin+ metformin bid|Linagliptin low dose + metformin 1000 mg bid
89088040|NCT00915772|Active Comparator|Metformin bid|Metformin 1000 mg bid
89088041|NCT04363606|Experimental|"Non-fatigued patients who have been in intensive care units"|
89088042|NCT04363606|Experimental|"Fatigued patients who have been in intensive care units"|
89088043|NCT04363606|Experimental|patients who have not been in intensive care units|
89088044|NCT00632086|Experimental|1|Single oral dose of 325 mg aspirin administered as PA32540
89088045|NCT00632086|Experimental|2|aspirin core
89088046|NCT00632086|Active Comparator|3|active
89088047|NCT00912964|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once a day for 12 weeks.
89088048|NCT00912964|Experimental|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.
89088049|NCT00912964|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.
89088050|NCT02647957|Experimental|Group A|Hospital using Code Stroke
89088051|NCT02647957|No Intervention|Group B|Hospital not using Code Stroke
89088052|NCT02641639|Active Comparator|Fosbretabulin tromethamine|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and CA4P
89088053|NCT02641639|Placebo Comparator|Placebo|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and placebo
89088054|NCT02647723|Experimental|Oral supplement for pregnant women|450 mg/daily of DHA beginning at 10-16 weeks of gestation through the end of pregnancy
89088055|NCT02647723|Placebo Comparator|Sugar pill|450 mg/daily of sugar pill beginning at 10-16 weeks of gestation through the end of pregnancy
89088056|NCT02647567|Experimental|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
89088057|NCT02647567|Placebo Comparator|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
89088058|NCT00651469|Experimental|Arm 1|
89088059|NCT00651469|Placebo Comparator|Arm 2|
89088060|NCT02647489|Experimental|1A - 20 µg PAMVAC + Alhydrogel|The study participant will get 20 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
89088061|NCT02647489|Experimental|2A - 20 µg PAMVAC + GLA-SE|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
89088062|NCT02647489|Experimental|3A - 20 µg PAMVAC + GLA-LSQ|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
89088063|NCT02647489|Experimental|4A - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
89088064|NCT02647489|Experimental|5A - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
89088065|NCT02647489|Experimental|6A - 50 µg PAMVAC + GLA-LSQ|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
89088066|NCT02647489|Experimental|1B - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
89088067|NCT02647489|Experimental|2B - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
89088068|NCT02647489|Experimental|3B - 100 µg PAMVAC + Alhydrogel|The study participant will get 100 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
89088069|NCT02647489|Experimental|4B - 100 µg PAMVAC + GLA-SE|The study participant will get 100 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
89088070|NCT02647489|Placebo Comparator|5B - Placebo|The study participant will get Placebo (physiological saline solution) administrated three times with each time 28 days interval (day 0-28-56)
89088071|NCT00653575||1|Women who report a history of childhood sexual abuse
89088072|NCT00653575||2|Women who do not report a history of childhood sexual abuse
89088073|NCT02641171||Entire Cohort|This is an observational/validation study and there is no intervention involved. Exhaled air samples, blood samples, and fecal samples will be obtained.
89088074|NCT00910897|Active Comparator|Velcade-Dexamethasone|
89088075|NCT00910897|Active Comparator|Velcade-Thalidomide-Dexamethasone|
89088076|NCT00913744|Experimental|Ocriplasmin|
89088077|NCT00913744|Sham Comparator|Sham injection|
89088078|NCT00651547|Experimental|1|
89088079|NCT00651547|Active Comparator|2|
89088080|NCT00651547|Active Comparator|3|
89088081|NCT02647411||Projeto Boa Visão|Review of records between 1995 and 2000, in totality of 16.806 patients between 2 and 40 years old
89088082|NCT02647411||Projeto Olhar Brasil|Review of records between March and September 2014, in totality of 163 patients between 6 and 18 years old
89088083|NCT04589260|Experimental|TD-1058|"Part A (SAD): 6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of TD-1058~Part B (MAD): 6 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of TD-1058~Part C (IPF subjects): 8 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of TD-1058~Part D (Healthy Subjects): 6 subjects (1 cohort) will receive a single dose of TD-1058. After receipt of initial dose, subjects will recieve infusion of radiolabeled TD-1058 microtracer."
89088084|NCT04589260|Placebo Comparator|Placebo|"Part A (SAD): 2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive a single dose of placebo~Part B (MAD): 2 out of 8 subjects per cohort (up to 4 cohorts) will be randomized to receive multiple dose of placebo~Part C (IPF subjects): 4 out of 12 subjects per cohort (up to 2 cohorts) will be randomized to receive multiple dose of placebo"
89088085|NCT02641327||Internal ward|Patients hospitalized in Internal Medicine unit with unstable blood pressure that need regulation/ stabilization of their blood pressure (e.g., CHF, post surgical, hypotension or Hypertension patients, patients with kidney failure, heart disease, stroke)
89088086|NCT02641327||ICU|Patients hospitalized in intensive care with arterial line that allow continuous blood pressure measurement
89088087|NCT02644759|Experimental|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
89088088|NCT00912808|Experimental|Donepezil|
89088089|NCT00912808|Placebo Comparator|Sugar Pill|
89088090|NCT02647333|Experimental|Omega-3 fatty acid|Omega-3 fatty acids for 8 weeks, dosage are 3 and 4 g/day for women and men, respectively.
89088091|NCT02647333|Experimental|Omega-6 fatty acid|Omega-6 fatty acids for 8 weeks, dosage are 20 and 27 g/day for women and men, respectively.
89088092|NCT02641405|Experimental|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
89088093|NCT02641405|Placebo Comparator|Placebo|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
89088094|NCT02647255|Experimental|PE and methylprednisolone pulse|Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange >7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
89230217|NCT03872531||Cohort 6|Includes age group 31-40 with a cap at 20 subjects. This is a retrospective, observational study
89088095|NCT02647255|Active Comparator|Methylprednisolone pulse|Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
89088096|NCT04415086|Sham Comparator|Group A|Participants will receive the standard of care treatment
89088097|NCT04415086|Active Comparator|Group B|Participants will receive the standard treatment and convalescent plasma in a volume of 200ml (150-300ml)
89088098|NCT04415086|Active Comparator|Group C|Participants will receive the standard treatment and convalescent plasma in a volume of 400ml (300-600ml)
89088099|NCT04329442|Experimental|PrEP Received|Participants will be provided with a free 30-day supply of PrEP.
89088100|NCT04414228|Active Comparator|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
89088101|NCT04414228|Active Comparator|ProAQT in guiding goal-directed hemodynamic therapy|Subjects randomized to the GDT group will be managed according to the ERAS algorithm utilizing ProAQT variables (mean arterial pressure, stroke volume variation and cardiac index) If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If mean arterial pressure is < 70 mmHg and/or cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of < 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
89088102|NCT00960531|Experimental|ACC-001 (3mcg) + QS-21|ACC-001 (3mcg) + QS-21
89088103|NCT00960531|Experimental|ACC-001 (10mcg) + QS-21|ACC-001 (10mcg) + QS-21
89088104|NCT00960531|Experimental|ACC-001 (30mcg) + QS-21|ACC-001 (30mcg) + QS-21
89088105|NCT00632164||1|Cervical adjustments
89088106|NCT00632164||2|Thoracic adjustments
89088107|NCT02640937||Orthopaedic device related infections|"Inclusion Criteria:~infections after fracture fixation or prosthetic joint surgery~Affected bone or joint: Long bones of the lower extremity; hip joint, knee joint;~Bacterial growth of S. epidermidis at the site of interest~Written consent~Age: 18 and older"
89088108|NCT00653653||Group A|Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.
89088109|NCT04280367||Comparator group|Specific learning disorders group
89088110|NCT04280367||neuro-developmental complexed group|Group of neuro-developmental complexe of learning
89088111|NCT04280367||Complexed with anxiety|Disorders in learning with anxiety
89088112|NCT02859909|Experimental|2 day treatment schedule|Patients will receive a dosage of 1 g/kg bw per day of BT595 for 2 consecutive days
89088113|NCT02859909|Experimental|5 day treatment schedule|Patients will receive a dosage of 0.4 g/kg bw per day of BT595 for 5 consecutive days
89088114|NCT00652639|Experimental|A|Subjects received the kali formulated products under fasting conditions
89088115|NCT00652639|Active Comparator|B|Subjects received the Roche formulated products under fasting conditions
89088116|NCT02858271|Experimental|AKB-9778|Single dose of [14C]-radiolabeled subcutaneous (SC) injection of AKB-9778 in the morning of Day 1
89088117|NCT02859987|Active Comparator|Landmark Technique|Blinded method for catheter placement
89088118|NCT02859987|Experimental|Ultrasound-guided Technique|Use sonography for catheter placement
89088119|NCT02644915|Experimental|study group|"Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
89088120|NCT02644915|Placebo Comparator|control group|"100ml 0.9%%NaCl solution,but without edaravone, will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
89088121|NCT00960375|Experimental|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
89088122|NCT00960375|Active Comparator|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide test at the start of each group meeting. StSST groups provide education about smoking and support for quitting.
89088123|NCT00651703|Experimental|1|
89088124|NCT00651703|Experimental|2|
89088125|NCT00651703|Experimental|3|
89088126|NCT00651703|Experimental|4|
89088127|NCT00632242|Experimental|TTP Remission Cohort 1|Patients will receive a total dose of 0.47 mg/kg of ARC1779 over 4 hours to achieve a target plasma concentration of 6 mcg/mL
89088128|NCT00632242|Experimental|TTP Remission Cohort 2|Patients will receive a total dose of 1.67 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 6 mcg/mL
89088129|NCT00632242|Experimental|TTP Remission Cohort 3|Patients will receive a total dose of 3.34 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 12 mcg/mL
89088130|NCT00632242|Experimental|Acute TTP Cohort 4|Patients will receive up to a total dose of 40.78 mg/kg of ARC1779 for ≤ 14 days to achieve a target plasma concentration of 12 mcg/mL
89088131|NCT00632242|Experimental|vWD-Type2b Cohort 5|Subjects will receive either ARC1779, desmopressin or a combination of ARC1779 and desmopressin in a 3-period crossover design. The maximum dose of ARC1779 will be 0.47 mg/kg to achieve a target plasma concentration of 6 mcg/mL.
89088132|NCT02644837|Active Comparator|i-Gel and AuraGain|"In this arm of the crossover study, patients will undergo insertion of Ambu AuraGain laryngeal mask airway and iGel and will undergo initial management with the iGel. Primary and Secondary outcomes will be assessed. The initial device will be removed and subsequent Airway management will then be undertaken with the Ambu AuraGain and the same outcomes will be assessed.~Interventions with both devices will be~Insertion of the laryngeal mask airway~Assessment of ease of insertion~Ability to perform positive pressure ventilation~Measurement of OLP~Fibreoptic assessment with Ambu A-scope~Ability to insert nasogastric tube~Record number of manipulations~An assessment of device related trauma"
89088133|NCT02644837|Active Comparator|AuraGain and i-Gel|"In this arm of the crossover study, patients will undergo insertion of the Ambu AuraGain laryngeal mask airway and i-Gel and will undergo initial management with the Ambu AuraGain.. Primary and Secondary outcomes will be assessed. Airway management will then be undertaken with the iGel device and the same outcomes will be assessed.~Interventions with both devices will be~Insertion of the laryngeal mask airway~Assessment of ease of insertion~Ability to perform positive pressure ventilation~Measurement of OLP~Fibreoptic assessment with Ambu A-scope~Ability to insert nasogastric tube~Record number of manipulations~An assessment of device related trauma"
89088134|NCT02964585|Active Comparator|Active Arm|100 mg of Canagliflozin for 16 weeks
89088135|NCT02964585|Placebo Comparator|Placebo Arm|Placebo for 16 weeks
89088136|NCT00637936|Active Comparator|1|Group 1 is given 30% oxygen during and 2 hours after surgery
89088137|NCT00637936|Active Comparator|2|Group 2 is given 80% during and 2 hours after surgery.
89088138|NCT02644603|Experimental|Enhanced Recovery After Surgery|Patients underwent ERAS protocol
89088139|NCT02644603|No Intervention|Conventional Treatment|Patients underwent conventional treatment
89088140|NCT02640703|Active Comparator|morning vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 am
89088141|NCT02640703|Active Comparator|evening vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 pm
89088142|NCT02640859||Normal cohort|Normal cohort for biobank
89088143|NCT02646943||Cohort of patients with chronic chagas cardiomyopathy|"We have established a prospective cohort of 1,959 patients with chronic Chagas cardiomyopathy (CCC) to evaluate if a clinical prediction rule based on electrocardiogram (ECG), Brain Natriuretic Peptide (BNP) levels and other biomarkers can be useful in clinical practice.~The study is being conducted in 21 cities of the northern part of Minas Gerais state in Brazil, and includes a follow up of at least two years. The baseline evaluation included collection of socio-demographic information, social determinants of health, health-related behaviours, comorbidities, medicines in use, history of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life, blood sample collection and ECG."
89088144|NCT00630279|Placebo Comparator|1|
89088145|NCT00630279|Experimental|2|
89088146|NCT00630279|Experimental|3|
89088147|NCT00630279|Experimental|4|
89088148|NCT03850522|Experimental|Vaccination|Vaccination with PD-L1 peptide
89088149|NCT02640781|Experimental|covered stent|newly designed covered stent group
89088150|NCT02640781|Active Comparator|uncovered stent|currently used uncovered stent group
89230218|NCT03872531||Cohort 7|Includes age group 41 and over with a cap at 35 subjects. This is a retrospective, observational study
89230219|NCT00800969|Other|all patients|all patients with Adenocarcinoma
89230220|NCT00801047|Experimental|1|Epidural group
89230221|NCT00801047|Active Comparator|2|Remifentanil iv PCA
89230222|NCT00801203|Experimental|1|Induced Reflex Cough Test (IRCT) followed by Voluntary Cough Test (VCT)
89088151|NCT00651781|Experimental|1|"Phase I:3 dose levels Cytarabine (200 mg/m2- 500 mg/m2-1000 mg/m2) with scheme Flag-Ida in combination with Velcade until determinate the appropriate dose.~Phase II:~Fludarabine, Cytarabine and Idarubicin in combination with 2 times per week of Velcade administration. Each 28-day treatment, patients will be evaluated, and in absence of disease progression or unacceptable toxicity, patients will start second cycle with Bortezomib in monotherapy two times per week followed by a 10 days rest period. That is, patients who response with acceptable toxicity will receive the combined sequential scheme twice (as induction and consolidation)."
89088152|NCT04166617|Active Comparator|Conventional therapy|Conventional physical therapy for upper limb in stroke patients
89088153|NCT04166617|Experimental|Leap motion plus conventional therapy|Leap motion plus conventional physical therapy for upper limb in stroke patients
89088154|NCT02646787|Experimental|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
89088155|NCT02646787|Experimental|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
89088156|NCT02646787|No Intervention|Control|No intervention during the subject's standard wound care session
89088157|NCT02646865|Experimental|Self-Compassion Enhanced Cognitive-Behavioral Therapy|Group Cognitive-Behavioral Therapy for social anxiety enhanced with exercises targeting self-compassion
89088158|NCT02646865|Active Comparator|Cognitive-Behavioral Therapy|Standard Group Cognitive-Behavioral Therapy for social anxiety
89088159|NCT00957801|Active Comparator|Testosterone injection|Testosterone enanthate given as a single 100 mg Intramuscular (IM) injection
89088160|NCT00957801|Active Comparator|Testosterone gel|Testosterone topical gel (Androgel 1%) 10 mg administered daily for seven days
89088161|NCT00957801|Active Comparator|Testosterone injection and Medrol 6 day dose pack|Testosterone enanthate given as a single 100mg Intramuscular (IM) injection. Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
89088162|NCT00957801|Active Comparator|Medrol 6 day dose pack|Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
89088163|NCT02640469|Active Comparator|Chlorhexidine with water rinse|This is a traditional method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
89088164|NCT02640469|Experimental|Chlorhexidine without water rinse|This is an experimental method of disinfection. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
89088165|NCT02640469|Active Comparator|Chlorhexidine + sterillium hand rub|This is a standard method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
89088166|NCT02640391||Quiescent UC|Patients with quiscent UC who will undergo colonoscopy for surveillance or mucosal healing check up
89088167|NCT02646709|Experimental|Ketamine 1|Ketamine 1 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
89088168|NCT02646709|Experimental|Ketamine 1.5|Ketamine 1.5 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
89088169|NCT02646709|Experimental|Ketamine 2|Ketamine 2 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
89088170|NCT00651859|Experimental|1|Bimatoprost 0.01% Ophthalmic Solution
89088171|NCT00651859|Experimental|2|Bimatoprost 0.03% Ophthalmic Solution
89088172|NCT00651859|Placebo Comparator|3|Bimatoprost Vehicle Ophthalmic Solution
89088173|NCT02955823|Experimental|1 arm for all patient: Ritux-Dexame-Lena|Rituximab-Dexamethasone-Lenalidomide
89088174|NCT02644447|Experimental|HUC-MSCs Transplantation|
89088175|NCT02644447|Experimental|HUC-MSCs with Injectable Collagen Scaffold Transplantation|
89088176|NCT02646631|Experimental|Usual Treatment|
89088177|NCT02646631|Experimental|MORE|
89088178|NCT02646631|Active Comparator|MORE + MI|
89088179|NCT02535793|Other|laboratory workers with symptoms in presence of drosophila|
89088180|NCT00957723|Other|Triathlon® CR Total Knee System|Participants receive the Triathlon® CR Total Knee System
89088181|NCT02646397|Experimental|Fosinopril,benidipine combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus benidipine (4/8 mg）once daily for 6 months.
89088182|NCT02646397|Experimental|Fosinopril,hydrochlorothiazide combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus hydrochlorothiazide (12.5/25 mg）once daily for 6 months.
89088183|NCT00653731|Experimental|Snoezelen ©|
89088184|NCT00653731|Experimental|Reminiscence|
89088185|NCT00653731|Experimental|10 min activation|
89088186|NCT00653731|Active Comparator|Talk|
89088187|NCT02646553||Children refered to the obesity clinic.|All children refered to the obesity clinic for examination and optionally treatment are invited.
89088188|NCT04204395|Experimental|Experimental group|"When complete the admission process, the caregiver will give a peanut ball to perform, besides the routine health brochure.~The participants will be at independent compartment."
89088189|NCT04204395|No Intervention|Control group|Take the routine health brochure. The participants will be at independent compartment.
89088190|NCT02640079|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy aimed at reducing pain catastrophizing.
89088191|NCT02859831||with construction work|
89088192|NCT02859831||without construction work|
89088193|NCT00652015||1|Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
89088194|NCT00652015||2|Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
89230223|NCT00801203|Experimental|2|Voluntary Cough Test (VCT) followed by Induced Reflex Cough Test (IRCT)
89088195|NCT04279353|Experimental|Mindfulness Based Intervention|Participants was asked to answer PSS-10 questionnaire to measure their stress level, then they received Mindfulness Based Intervention program for 4 weeks and did the PSS-10 test again after 4 weeks.
89088196|NCT00653809||A, 1, I|Caucasian women without preeclampsia or PIH, delivering their first child
89088197|NCT00653809||A, 1, II|Caucasian women with preeclampsia or PIH, delivering their first child
89088198|NCT00653809||A, 2, I|African-american women without preeclampsia or PIH, delivering their first child
89088199|NCT00653809||A, 2, II|African-American women with preeclampsia or PIH, delivering their first child
89088200|NCT00653809||B, 1, I|Caucasian women without preeclampsia or PIH, delivering at least their second child
89088201|NCT00653809||B, 1, II|Caucasian women with preeclampsia or PIH, delivering at least their second child
89088202|NCT00653809||B, 2, I|African-american women without preeclampsia or PIH, delivering at least their second child
89088203|NCT00653809||B, 2, II|African-american women with preeclampsia or PIH, delivering at least their second child
89088204|NCT04282863|Active Comparator|robotic-assisted laparoscopic myomectomy (RM)|After randomization, participants who are assigned to the robotic-assisted laparoscopic myomectomy (RM) agree to receive RM.
89088205|NCT04282863|Placebo Comparator|Conventional laparoscopic myomectomy (LM)|After randomization, participants who are assigned to the Conventional laparoscopic myomectomy (LM) agree to receive LM.
89088206|NCT00652795|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
89088207|NCT00652795|Active Comparator|B|Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.
89088208|NCT03778021|Experimental|Intervention Group|"Intervention schools receive a raised bed school garden and a curriculum of healthy eating and gardening lessons.~3rd and 4th grade students in the intervention group received the curriculum and exposure to the school garden during the academic school year (2019-20)~Behavioral Gardening Exposure: Assistance provided with planting and maintaining the school garden~Healthy Eating and Gardening Curriculum: 14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season."
89088209|NCT03778021|No Intervention|Comparison Group|"For the comparison group schools, no program was provided in school year (2019-2020).~After the trial, and the follow-up evaluation, in school year 2020-2021 comparison schools received delayed intervention components as follows: School gardens were created during the 2020-2021 school year (subject to delays due to pandemic restrictions). Curriculum materials were supplied to the school for use by teachers as they saw fit, after pandemic restrictions were lifted."
89088210|NCT00911170|Placebo Comparator|Placebo|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2, and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus placebo subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
89088211|NCT00911170|Placebo Comparator|Pegfilgrastim|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2 and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus pegfilgrastim 6 mg administered as a single subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
89088212|NCT02644213|Experimental|research arm|"12 young, healthy civilian volunteers will participate in this study. The experiment will take place in a dome room.~The experiment will be performed according to the protocol of using CAREN and MOTEK systems:~CAREN high (Computer Assisted Rehabilitation Environment) which screens virtual scene in the dome.~MOTEK (Motek Medical©, the Netherlands) which is a two track treadmill (for each leg) placed on a rotatable platform.~each subject will undergo the same experiment protocol."
89088213|NCT00910975|Active Comparator|Standard of care|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment is given for 24, 48 or 72 weeks depending on the time point (week 4, 12 or 24) when HCV RNA becomes undetectable by the Cobas Taqman assay. If HCV RNA has not declined 2 logs by week 12 or is detectable at week 24, treatment is stopped.
89088214|NCT00910975|Experimental|Tailored treatment|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment duration is flexible, 24-72 weeks, depending on the time point when the HCV RNA level is calculated to be 1 copy/mL. If the decline between day 14 and 28 is poor, treatment is stopped after 5 weeks.
89088215|NCT04165057|Active Comparator|Group OMT|Optimal muscle tension management
89088216|NCT04165057|No Intervention|Group Control|Conventional anesthetic management
89088217|NCT00653887|Active Comparator|A|biofeedback (active group)
89088218|NCT00653887|Placebo Comparator|B|discussion about digestive tract (placebo group)
89088219|NCT01167881|Experimental|BI 10773 dose plus metformin|Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily
89088220|NCT01167881|Active Comparator|Glimepiride 1-4 mg plus metformin|Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.
89088221|NCT02646085|Experimental|Intervention|C11 Methionine positron emission tomography (PET/CT) studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 10 millicuries of C11 Methionine will be injected intravenously. Approximately 60 minutes following tracer injection, the patient will be positioned on a Siemens Biograph PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first with while the patient is free breathing. PET will be acquired at 3 minutes per bed position using the 3D mode, approximately 6-7 bed positions. C11 Methionine PET/CT imaging will take less than 60 minutes.
89088222|NCT02639767|Experimental|pemetrexed/cisplatin with pleural IMRT|This is a single institution phase I study of pemetrexed/cisplatin given concurrently with pleural intensity modulated radiation therapy (IMRT) in patients with unresectable malignant pleural mesothelioma (MPM). All patients will receive pleural intensity modulated radiation therapy (IMRT). Patients will be enrolled in cohorts of 3-6 at each dose level of pemetrexed/cisplatin, and dose escalation will proceed in a standard 3+3 fashion until the maximum tolerated dose (MTD) is identified.
89088223|NCT04296136||High risk of mortality|Adult patients admitted to the hospital medicine service with a high risk of mortality
89088224|NCT04296136||High risk of mortality (pre-implementation)|Adult patients admitted to the hospital medicine service with a high risk of mortality
89088225|NCT02646241|Experimental|unroofing biopsy|
89088226|NCT02646241|Active Comparator|EUS-FNB|
89088227|NCT02639689|Experimental|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
89088228|NCT04829344|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
89088229|NCT04829344|Placebo Comparator|Placebo|Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
89088230|NCT04166305||Drug responders|60 patients are drug responders
89088231|NCT04166305||Drug resistant|60 patients are drug resistant
89088232|NCT04166305||The control|The control consists of 60 Age and gender matched healthy individual with negative past and family history of epilepsy and febrile convulsion.
89088233|NCT04522960|Experimental|Patients with dementia or mild cognitive impairment due to AD|Dementia or MCI due to AD according to NIA-AA research criteria.
89088234|NCT04522960|Active Comparator|Healthy volunteers|Age-and-gender matched healthy controls.
89088235|NCT00960063|Experimental|Temozolomide+Irinotecan+Robatumumab|Participants receive temozolomide 100 mg/m^2/day intravenously (IV) on Days 1-5 PLUS irinotecan 10 mg/m^2/day IV on Days 1-5 and Days 8-12 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
89088236|NCT00960063|Experimental|Vincristine+Doxorubicin+Cyclophosphamide+Robatumumab|Participants receive vincristine 2 mg/m^2 (maximum 2 mg) IV on Day 1 PLUS cyclophosphamide 1200 mg/m^2 IV on Day 1 PLUS doxorubicin hydrochloride 75 mg/m^2 IV continuously over 48 hours PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
89088237|NCT00960063|Experimental|Ifosfamide+Etoposide+Robatumumab|Participants receive ifosfamide 1800 mg/m^2 per day IV PLUS etoposide 100 mg/m^2 per day IV on Days 1-5 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
89088238|NCT02646319|Experimental|Treatment (nanoparticle albumin-bound rapamycin)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
89088239|NCT00653965|Experimental|1|Rosuvastatin
89088240|NCT00653965|Active Comparator|2|Atorvastatin
89088241|NCT02646163|Experimental|REP 2055|Treatment with REP 2055
89088242|NCT00959907|Active Comparator|BoNT A1 (4U)|BoNT A1 (4U): Botulinum toxin A (Dysport®)4 units
89088243|NCT00959907|Active Comparator|BoNT-A2 (2U)|BoNT-A2(2U): Botulinum toxin A (Botox®) 2 units
89088244|NCT00912340|Experimental|Trastuzumab|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab and hormone therapy.
89088245|NCT00912340|Experimental|Everolimus|Patients receive everolimus PO daily and continue their most recent hormone therapy. Patients achieving disease progression receive trastuzumab IV over 30-90 minutes once every 3 weeks in combination with everolimus and hormone therapy.
89088246|NCT00912340|Experimental|Trastuzumab and everolimus (ARM REMOVED)|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and everolimus PO daily while continuing to receive their most recent hormone therapy.
89088247|NCT02639845||Patients Prescribed Eye Drops|Patients who are scheduled to receive prescription eye drops due to complications such as cataract surgery, glaucoma, retina surgery, or eye-related condition.
89088248|NCT01167257|Experimental|Experimental arm|"Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation~Liposome encapsulated botulinum toxin A'"
89088249|NCT01167257|Placebo Comparator|Control arm|"Normal saline 50 mL in single intravesical instillation~Normal saline instillation'"
89088250|NCT01119846|Experimental|Part A|Part A (Cohort 1) is a single-blind, randomized, placebo-controlled, 5-period crossover in which drug naïve T2DM subjects will receive escalating doses of GSK1292263 in each of 3 periods and placebo and open-label sitagliptin in the other 2 periods. The sequence will be randomized, but will maintain the low, medium and high dose order for GSK1292263.
89088251|NCT01119846|Experimental|Part B|Part B (Cohort 2) is a single-blind, randomized, 2-period study in which T2DM subjects will receive a single dose of GSK1292263, fasted or fed.
89088252|NCT01119846|Experimental|Part C|Part C (Cohort 3, optional Cohort 4) is a single-blind, randomized, placebo-controlled, 5-arm study of 14 days of dosing with GSK1292263, placebo or open-label sitagliptin. An optional Cohort 4 may be enrolled to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1292263 when dosed in a BID regimen.
89088253|NCT03775525|Experimental|Experimental: monotherapy|GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.
89088254|NCT03775525|Experimental|Experimental: Combination with Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer|GZ17-6.02 given orally twice daily x 21 day schedule in combination with Capecitabine 825 mg/m2 orally twice daily for 14 days x 21 day schedule.
89088255|NCT03775525|Experimental|Experimental: Combination with Capecitabine in Metastatic Colorectal Cancer|GZ17-6.02 given orally twice daily x 21 day schedule in combination with Capecitabine 850 mg/m2 orally twice daily for 14 days x 21 day schedule.
89088256|NCT04235530||VAS and DVAS|To measure the pain score of patients after surgery
89088257|NCT05657327||Group with postoperative complications|Postoperative complications such as pancreatic fistula, postoperative bleeding and delayed gastric emptying
89088258|NCT05657327||Group without postoperative complications|No postoperative complications such as pancreatic fistula, postoperative bleeding and delayed gastric emptying
89088259|NCT00654043|Experimental|A|Subjects received Par formulated products under fed conditions
89088260|NCT00654043|Active Comparator|B|Subjects received Roche formulated products
89088261|NCT02816632|Experimental|healthy volunteers|
89088262|NCT04167007|Active Comparator|Group I|Gemcitabine at 1000 mg/m²
89088263|NCT04167007|Active Comparator|Group II|Oxaliplatin at 85 mg/m² ; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) and 5-FU 2400 mg/m²
89088264|NCT01167179|No Intervention|comparison group|Usual care Participants in the comparison group receive the usual care which consists of a 5 year medical routine control schedule based on the national guidelines, and - if appropriate - involvement of the dietician and the speech language therapist.During years one to five the routine control appointments are planned at a minimum of every 2, 3, 4, 6 and 12 months respectively. Most patients who undergo a total laryngectomy have additional contact with an oncology nurse during their 6-8 weekly medical control visits at the outpatient clinic for approximately the first year of follow-up. All other head and neck cancer patients have no structured follow-up contact with an oncology nurse.
89088265|NCT01167179|Experimental|nurse-led consultation|"Interventional care Year 1 follow-up: 2-monthly medical control visit + 30 minute nursing consultation, to a minimum of 6 in year 1. No restrictions with regard to cancer stage, site or treatment modality.~Intervention consist of standardised nursing consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. Goals: helping patients (and their partners) cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship."
89088266|NCT04345120|Experimental|SY-008-6mg/d|2mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，12mg/d.
89230224|NCT00801281|Active Comparator|R-CVP|Standard arm 1. R-CVP - Rituximab, Cyclophosphamide, Vincristine, Prednisone 2
89230225|NCT00801281|Experimental|R-CHOP|Study arm 2. R-CHOP - Rituximab, Cyclophosphamide, Hydroxyldaunorubicine (doxorubicin), Oncovin (vincristine), Prednisone 1
89088267|NCT04345120|Experimental|SY-008-12mg/d|4mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8. The researchers will decide whether to move on to the next stage，18mg/d.
89088268|NCT04345120|Experimental|SY-008-18mg/d|6mg TID. The subjects were given the drug for the first time before breakfast in D1, and then continued to take the drug daily until dinner in D7, and left after PD sample collection and safety assessment before breakfast in D8, and then the test will be terminated.
89088269|NCT04345120|Placebo Comparator|SY-008 matching placebo|Oral administration of the same number of tablets in the corresponding test group.
89088270|NCT02951455|Experimental|CD-LC|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Licensed Clinician (LC).
89088271|NCT02951455|Experimental|CBP- LC|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Licensed Clinician (LC)
89088272|NCT02951455|Experimental|QLW- LC|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life Wheel, Licensed Clinician (LC)
89088273|NCT02951455|Experimental|CD & CBP- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
89088274|NCT02951455|Experimental|CD & QLW- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
89088275|NCT02951455|Experimental|QLW & Capacity Building ProjectCBP- LC|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks. Licensed Clinician (LC)
89088276|NCT02951455|Experimental|QLW & CD & CBP-LC|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
89088277|NCT02951455|Experimental|LC|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes.Licensed Clinician (LC)
89088278|NCT02951455|Experimental|CD- PF|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Peer Facilitator (PF)
89088279|NCT02951455|Experimental|CBP- PF|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Peer Facilitator (PF)
89088280|NCT02951455|Experimental|QLW-PF|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life wheel, Peer Facilitator (PF)
89088281|NCT02951455|Experimental|CD & CBP- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions. Peer Facilitator (PF)
89088282|NCT02951455|Experimental|CD & QLW- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
89088283|NCT02951455|Experimental|QLW & CBP- PF|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks.Peer Facilitator (PF)
89088284|NCT02951455|Experimental|CD & QLW & CBP- PF|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
89088285|NCT02951455|Experimental|PF|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes. Peer Facilitator (PF)
89088286|NCT04237636||Patients with post-operative AKI|"Patients developing acute kidney injury (AKI) following heart valve replacement surgery.~AKI was classified according to the KDIGO definition[10]. Stage-1 AKI: increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.5μmol/l) or increase to more than or equal to 150% to 200% (1.5≤x<2) from baseline within 7 days. Stage-2 AKI: Increase in serum creatinine to more than 200% to 300% (2≤x<3) from baseline. Stage-3 AKI: Increase in serum creatinine to more than 300% (3≤) from baseline (or serum creatinine of more than or equal to 4.0 mg/dl (≥ 353.6μmol/l) or when the patient commenced RRT."
89088287|NCT04237636||Patients without post-operative AKI|Patients with normal kidney function (without acute kidney injury (AKI)) following heart valve replacement surgery
89088288|NCT02639611|Active Comparator|Immediate Post Operative Acupuncture Treatment|
89088289|NCT02639611|Active Comparator|Acupuncture Treatment After 6 Weeks of Recovery|
89088290|NCT01167023|Experimental|7.5 mg Prasugrel|Participants were to receive 7.5 milligrams (mg) of prasugrel orally, once daily if they weighed ≥60 kilograms (kg) and if pharmacodynamic (PD) measures indicated that the 5-mg prasugrel dose did not produce a steady-state PD response equivalent to inhibition of platelet activation (IPA) ≥25%. Because these criteria were not met, no participants received 7.5 mg of prasugrel.
89088291|NCT01167023|Placebo Comparator|Placebo|
89088292|NCT01167023|Experimental|5 mg Prasugrel|
89088293|NCT04273126|Experimental|Intervention|This arm consists of approximately 8-10 modules lasting approximately one hour and consisting of psychoeducation and core components including communication, problem solving, goal setting, and dealing with stress, tailored to families with experiences of homelessness and parental substance use.
89088294|NCT00654121|Active Comparator|1|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
89088295|NCT00654121|No Intervention|2|
89088296|NCT04336852|Experimental|Arm 1|
89088297|NCT03484117|No Intervention|Treatment as Usual|Participants in this arm will receive bilingual written materials on healthy living with HIV at the baseline visit. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants.
89230226|NCT00801359|Active Comparator|BSSplus|
89230227|NCT00801359|Experimental|Ringer|
89088298|NCT03484117|Experimental|Community Health Worker|Participants in the intervention arm will receive 5 one-on-one sessions over 24 weeks with a Spanish-speaking CHW. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants
89088299|NCT01166945|Placebo Comparator|Short Course|Short course (5 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination and placebo for next 9 days.
89088300|NCT01166945|Active Comparator|Long Course|Long course (14 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination given orally for 14 days.
89088301|NCT02639533|Experimental|Pregabalin|Pregabalin 150 mg PO single dose
89088302|NCT02639533|Placebo Comparator|Placebo|Placebo (a pill of same physical characteristics as the one used for the experimental arm, containing starch) PO single dose
89088303|NCT02885987|No Intervention|Standard Colonoscopy|AmplifEYE will not be used.
89088304|NCT02885987|Experimental|Colonoscopy with AmplifEYE|AmplifEYE accessory device will be attached to the colonoscope prior to starting the procedure
89088305|NCT02646007|Experimental|BM-MSC|Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienböck's disease.
89088306|NCT02885675||ARDS|
89088307|NCT02885675||Healthy control|
89088308|NCT02639377|Experimental|Chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
89088309|NCT02639377|Placebo Comparator|Placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
89088310|NCT02639455|No Intervention|Athlete group|Participants wo regularly exercise and are student athletes.
89088311|NCT02639455|No Intervention|Non-exercise group|Participants who are not student athletes.
89088312|NCT02639455|Experimental|Exercise group|Participants are not student athletes but commit to modest exercise for 5 weeks as part of this study.
89088313|NCT00910000|Experimental|Dose Level 1A|"Vorinostat: 200 mg taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 100 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
89230228|NCT00801437||Xalacom treatment|patients with primary glaucoma
89088314|NCT00910000|Experimental|Dose Level 2A|"Vorinostat: 300mg, taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
89088315|NCT00910000|Experimental|Dose Level 1B|"Vorinostat: 200mg, taken orally twice a day for days 1-3 and days 8-10 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
89088316|NCT00910000|Experimental|Dose Level 1C|"Vorinostat: 200mg, taken orally twice a day for days 1, 2, 8 and 9 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
89230229|NCT00797615|Placebo Comparator|Alternative Intervention|12-week alternate intervention program focused on building self-esteem and social self-efficacy
89088317|NCT00910000|Experimental|Dose Level 1D|"Vorinostat: 300mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
89088318|NCT00910000|Experimental|Dose Level 2D|"Vorinostat: 400mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
89088319|NCT02885909|Active Comparator|Insulin protocal with CGM|Insulin protocal with continue glucose monitor
89088320|NCT02885909|Active Comparator|Insulin protocal|Insulin protocal with convential glucose monitor
89088321|NCT02885909|No Intervention|Convential treatment|Convential insulin treatment and glucose monitor
89088322|NCT02700945|Active Comparator|Reveal LINQ™ Insertable Cardiac Monitor|Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
89088323|NCT02700945|No Intervention|Control Arm|Subjects randomized to the control arm will be followed per site specific standard of care.
89088324|NCT05657171||PCOS +GINGIVITIS|FEMALE PATIENTS WITH PCOS AND GINGIVITIS ON CPA/EE DRUG REGIMEN
89088325|NCT00652873|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fed conditions
89088326|NCT00652873|Active Comparator|B|Subjects received the reference product, Dostinex under fed conditions
89088327|NCT02887235|No Intervention|Standard of Care (SOC) Meals|Patient assigned in this arm will receive standard of care nutritional services including nutrition consult, evaluation, and as needed follow-ups.
89088328|NCT02887235|Active Comparator|Medically tailored meals|Patient assigned in this arm will receive home delivered, medically tailored meals (HDMTM) in addition to the standard nutritional care.
89088329|NCT00652171|Active Comparator|1|17 Patients - Mean age of 26 years old, 14 female and 3 male - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
89230230|NCT00797615|Active Comparator|Active Intervention|12-week intervention program focused on dietary intake and physical activity
89088330|NCT00652171|Placebo Comparator|2|17 Patients - 11 females and 6 males mean age of 29 years old - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
89088331|NCT01119768|Active Comparator|Esomeprazole 8 weeks treatment|20 mg q.d. (quaque die) once a day dosing for 8 weeks
89088332|NCT01119768|Active Comparator|Esomeprazole 2 Weeks Treatment|20 mg q.d. (quaque die) once a day dosing for 2 weeks
89088333|NCT04281303||Endoscopic vertical gastroplasty|Proof-of-concept study that will prospectively include a number of patients undergoing endoscopic vertical gastroplasty + lifestyle modifications to evaluate the effect of this technique in an adult population with obesity and NASH cirrhosis
89088334|NCT02885831||A - Abduction splintage|Treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients.
89088335|NCT02885831||B - Surveillance|No treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients
89088336|NCT02859363||Young stroke|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing for the 26 common Fabry mutation types in Taiwan.
89230231|NCT00797693|Experimental|Vaginal Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
89088337|NCT02656953|Experimental|VDU lenses|VDU lenses provide a clear vision of the intermediate zone at a distance of approximately 70 centimeters, which is closer than distant vision at a distance of more than 2 meters (e.g. driving), but further than near vision at a distance of 40 centimeters (e.g. reading), so the computer screen is seen clear without the need for excessive focusing effort or bad postures. In this study Zeiss® Officelens Plus lenses with a Silhouette® frame were used.
89230232|NCT00797693|Experimental|Oral Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
89230233|NCT00797771|Experimental|A|"Adi insulin pump users"
89088338|NCT02656953|Active Comparator|Progressive lenses|Progressive lenses or multifocal lenses provide a continuous range of focal power between near and far distances.Progressive lenses have some lens power for the intermediate zone as well, but this zone might not be large enough for comfortable and ergonomic computer work. In this study Zeiss® Multifocal Precision Plus lenses with a Silhouette® frame were used.
89230234|NCT00797849|Active Comparator|1|Wear prosthetics laminated with Farabloc surrounding the liner. If not wearing prosthetics, subject needs to wear Farabloc sock or glove over shrinker.
89088339|NCT01165307|Active Comparator|Medical Therapy|Subjects will be prescribed monthly packets of Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills. Subjects who are unable to tolerate oral contraceptive pills or are unwilling to take oral contraceptive pills will be prescribed naproxen sodium pills. The latter will be administered as follows; 500mg with onset of menses, then 250mg three times daily for the duration of the menses (or maximum of five days).
89088340|NCT01165307|Active Comparator|Radiofrequency Endometrial Ablation|Subjects will undergo NovaSure® radiofrequency endometrial ablation within 4 weeks of randomization. The procedure will occur at any time during the menstrual cycle, without endometrial pre-treatment. Endometrial thinning will be carried out using suction curettage in 50% of the cases included in the ablation group. Random assignment for this treatment will be included in the overall randomization plan.
89088341|NCT02639143|Experimental|ticagrelor|Ticagrelor, 180 mg, oral administration. followed by 90 mg bid
89088342|NCT02639143|Active Comparator|Clopidogrel|Clopidogrel 600 mg loading dose taken orally, followed by 75 mg qd.
89088343|NCT02536027|Experimental|septic AKI patients|septic AKI patients requiring CVVH
89088344|NCT02645773|Experimental|Pre-laser|non-ablative laser Laser Pre-wounding low dose laser Pre-wounding medium dose laser Pre-wounding high dose
89088345|NCT02645773|Experimental|Immediate-laser|non-ablative laser Laser low dose - immediate after wounding Laser medium dose - immediate after wounding Laser high dose - immediate after wounding
89088346|NCT02645773|Experimental|Post-laser|non-ablative laser Laser low dose - post wounding Laser medium dose - post wounding Laser medium dose - post wounding
89088347|NCT02645773|No Intervention|Control|Untreated control wound
89088348|NCT02644057|Active Comparator|M-group|Will be given milrinone as an intravenous infusion at 0.2-0.6 mcg/kg/min for a maximum period of 72 hours and adjusted based on creatinine clearance measured by cockcroft-gault equation. It would be titrated based on hemodynamic response , urine output and at the discretion of the treating physician
89088349|NCT02644057|Active Comparator|D-group|Will be given dobutamine as an intravenous infusion at a maximum rate of 20 mcg/kg/min depending on patient tolerance and would adjusted based on hemodynamic response, urine output and at the discretion of treating physician
89088350|NCT00960999|Experimental|Single-fraction SBRT (34 Gy)|Single-fraction stereotactic body radiation therapy (SBRT) of 34 Gy
89088351|NCT00960999|Experimental|Multiple-fraction SBRT (48 Gy)|Multiple-fraction stereotactic body radiation therapy (SBRT) given in four daily 12 Gy fractions for a total dose of 48 Gy
89088352|NCT00654277|Experimental|A|Subjects received Kali formulated products under fasting conditions
89088353|NCT00654277|Active Comparator|B|Subjects received GlaxoSmithKine product under fasting conditions
89088354|NCT01124838|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by every other week (eow) dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 to 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
89088355|NCT01124838|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses eow starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
89088356|NCT02639221|Experimental|PXT002331|
89088357|NCT02639221|Placebo Comparator|Placebo|
89088358|NCT00959751|Experimental|NXN-188 600 mg|3 x 200 mg capsules, PRN
89088359|NCT00959751|Placebo Comparator|Placebo|3 x 0 mg capsules, PRN
89088360|NCT00630435|Experimental|1|
89088361|NCT00630435|Experimental|2|
89088362|NCT00630435|Experimental|3|
89088363|NCT00630435|Active Comparator|4|
89088364|NCT02858193|Experimental|1.35 g SCMC- lys powder|1.35 g of SMC L-lysine monohydrate salt powder for solution
89088365|NCT02858193|Experimental|Fluifort® syrup|Fluifort® syrup 90 mg SCMC-lys/mL
89088366|NCT02858115||one lung ventilation lung|patients requiring one lung ventilation lung resection.
89088367|NCT00630591|Experimental|Standardized Materials Group|
89088368|NCT00630591|Experimental|Independent Tailored Intervention|
89088369|NCT00630591|Experimental|Partner-Assisted Tailored Intervention|
89088370|NCT02581215|Experimental|Arm A: Experimental Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~Arm A will receive ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks."
89088371|NCT02581215|Placebo Comparator|Arm B: Placebo Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were ramucirumab"
89088372|NCT04282941|Experimental|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
89088373|NCT04282941|Experimental|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
89088374|NCT04280913||COVID-19 patients|Hospitalized patients with COVID-19
89088375|NCT04282707|Experimental|Endoscopic closure|Prospectively collected patients for gastric ESD and would undergo closure of defect
89088376|NCT04282707|Other|Historical control|Historical control of patients who underwent gastric ESD
89088377|NCT00910858|Experimental|10 mg Lenalidomide|"Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure.~During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 10 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment."
89088378|NCT00910858|Experimental|15 mg Lenalidomide Non-del 5q|Following the enrollment of the first 25 patients into the Monotherapy Phase, a second group of 15 patients with low- or intermediate-1-risk MDS not associated with a del 5q (non-del 5q) cytogenetic abnormality were enrolled to receive 15 mg of lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 15 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.
89088379|NCT02859285|Active Comparator|Estradiol vulvar cream|"The estradiol cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
89088380|NCT02859285|Placebo Comparator|Placebo cream|"The placebo cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
89088381|NCT04260412|Experimental|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO membrane, then dialysis for 4 weeks with MCO membrane and increased fiber intake
89088382|NCT04260412|Active Comparator|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
89088383|NCT02859051|No Intervention|control|No intervention
89088384|NCT02859051|Experimental|robot|Humanoid robot interacts with child, teaching breathing and coping strategies.
89088385|NCT00598975|Active Comparator|NKTR-102 100 mg/m2 + Cetuximab|"NKTR-102 100 mg/m2 + Cetuximab Arm~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
89088386|NCT00598975|Active Comparator|NKTR-102 125 mg/m2 + Cetuximab|"NKTR-102 125 mg/m2 + Cetuximab Arm~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
89088387|NCT00957021|Other|Triathlon® PS Total Knee System|Triathlon® PS Total Knee System
89088388|NCT01124604|Experimental|Tapentadol Hydrochloride|
89088389|NCT01124604|Placebo Comparator|Placebo|
89088390|NCT00909844|Experimental|Triptorelin|
89088391|NCT02645695|Active Comparator|routine pulmonary rehabilitation|routine pulmonary rehabilitation consisted of position giving technique
89088392|NCT02645695|Active Comparator|chest wall vibration technique|chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours.
89088393|NCT00652249||Extraventricular Drainage/Pressure|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
89088394|NCT02882568|Other|investigational|Blood test for Inflammatory and immunological analysis during acute sepsis phase and one month later
89088395|NCT00654433|Experimental|I|
89088396|NCT01124448|Experimental|Lactobacillus salivarius PS2|Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
89088397|NCT01124448|Active Comparator|Lactobacillus salivarius PS2B|Lactating women without mastitis (n=15)
89088398|NCT02643745|Experimental|Nephrology Intervention|Nephrology intervention before surgery:
89088399|NCT02643745|No Intervention|Standard of Care|No nephrology intervention before surgery (standard of care)
89088400|NCT02638909|Experimental|ceritinib|Phase II, single-arm study of oral ceritinib in adult patients with ALK and ROS1 activated gastrointestinal malignancies
89088401|NCT01124292|Experimental|Able-bodied subject with piercing|Able-bodied subjects who already have tongue piercing.
89088402|NCT01124292|Experimental|Able-bodied subject without piercing|Able-bodied subjects who willing to receive a tongue piercing for this study.
89088403|NCT01124292|Experimental|Subjects with spinal cord injury|Persons with mobility limitations requiring power wheel chair, able to move tongue, able to follow simple commands, and have some experience with computers. All participants willingly received a mid-line tongue piercing.
89088404|NCT02645539|Experimental|Single Arm|All patients are treated with the intravascular ventricular assist system (iVAS).
89088405|NCT02638675|Experimental|Wellness program, accelerometer, incentives|During the intervention period (weeks 1 to 12), intervention participants will be eligible to earn daily reward points contingent on step count goal achievement. Intervention participants will earn 100 reward points (i.e. $1) for each day that specific step count goals are reached. During weeks 13 to 24, participants will no longer receive daily reward points for completing specific step count goals.
89088406|NCT02638675|Active Comparator|Wellness program and accelerometer|During the 24 week trial, control participants will receive no additional incentives when step count goals are reached.
89088407|NCT02638753|Active Comparator|Education|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology.
89088408|NCT02638753|Experimental|Education combined with hypnosis|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology combined with hypnosis.
89088409|NCT02643589|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
89088410|NCT02643589|Active Comparator|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
89088411|NCT02643901|Experimental|Ic-GW003 150ug/kg 4-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
89088412|NCT02643901|Experimental|Ic-GW003 300ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
89088413|NCT02643901|Experimental|Ic-GW003 500ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
89088414|NCT02643901|Experimental|Ic-GW003 650ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
89088415|NCT02643901|Experimental|Ic-GW003 850ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
89088416|NCT04309422||Overexpression of PDL1|Overexpression of PDL1
89088417|NCT04309422||Absence of overexpression of PDL1|Absence of overexpression of PDL1
89088418|NCT02645383|Active Comparator|PASCAL group|Patients undergone PASCAL laser photocoagulation
89088419|NCT02645383|Active Comparator|Conventional group|Patients undergone conventional laser photocoagulation
89088420|NCT02881944|Experimental|Low FODMAP (modified healthy) Diet|Low FODMAP diet for 3 weeks. Veterans will be provided a diet containing foods low in FODMAP.
89088421|NCT02881944|Experimental|High FODMAP (typical healthy) Diet|High FODMAP diet for 3 weeks. Veterans will be provided a typically healthy diet following US Dietary Guidelines, containing foods high in FODMAPs
89088422|NCT00652405|Experimental|treatment A|four weeks of white wine consumption (25g alcohol/day; ~2.5 standard drinks)
89088423|NCT00652405|Placebo Comparator|Treatment B|Four weeks of water
89088424|NCT02643823|Experimental|hUC-MSC + DMARDs|Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.
89088425|NCT02643823|Active Comparator|DMARDs|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up.
89088426|NCT02638831|Experimental|Ketorolac Tromethamine|Ketorolac 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
89088427|NCT02638831|Active Comparator|Ketoprofen|Ketoprofen gel 2.5% for external application. Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
89088428|NCT01136772|Experimental|Paliperidone palmitate|Intramuscular injections of paliperidone palmitate 39-234 mg every month
89088429|NCT01136772|Active Comparator|Haloperidol decanoate|Intramuscular injections of haloperidol decanoate 25-200 mg every month
89088430|NCT00909532|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
89088431|NCT00909532|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
89088432|NCT02882490|Experimental|Parent training (PT)|The PT arm receives a 10-week therapist-guided behavioral group treatment. The treatment is based on existing literature for training parents in child behavior management skills (Barkley 1999). Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
89088433|NCT02882490|Experimental|Supportive Therapy (ST)|The ST arm receives a 10-week supportive group treatment. Parents are invited to discuss relevant problems that have occurred during the previous week. A therapist moderate the discussion but does not provide information about the behavioral techniques included in the PT group. Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
89088434|NCT04312308||Non-Small Cell Lung Cancer Treated with Atezolizumab|Patients with Non-Small Cell Lung Cancer Treated with Atezolizumab
89088435|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis treatment
89088436|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis treatment
89088437|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype CC|THERANOVA 400 dialyzer prototype CC in hemodialysis treatment
89088438|NCT02377570|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis treatment
89088439|NCT01136382|Experimental|1|Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)
89088440|NCT01136382|Placebo Comparator|2|Placebo pMDI 2 inhalations bid
89088441|NCT04772326||PrEP patients undergoing follow-up at Tourcoing hospital|
89088442|NCT00912028|Active Comparator|senofilcon A|contact lens
89088443|NCT00912028|Active Comparator|lotrafilcon B|contact lens
89088444|NCT00912028|Active Comparator|balafilcon A|contact lens
89088445|NCT00912028|Active Comparator|methafilcon A|contact lens
89088446|NCT00912028|Active Comparator|vifilcon A|contact lens
89088447|NCT00632008|Experimental|1|SBG
89088448|NCT00632008|Placebo Comparator|2|
89088449|NCT04071730|Experimental|Immulina Dietary Supplementation|Immulina Dietary Supplementation - 200 mg capsules; 800 mg/day; 2 (200 mg) capsules given by mouth in the morning and 2 (200 mg) capsules given by mouth in the evening for 4 weeks duration
89088450|NCT04071730|Placebo Comparator|Placebo|Placebo - inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 4 weeks duration
89088451|NCT02731729|Experimental|ipilimumab and nivolumab|For patients in the combination arm, nivolumab will first be administered intravenously at a dose of 1 mg/kg of body weight over a period of 60 minutes, once every 3 weeks for four doses. Thirty minutes after the completion of each nivolumab infusion, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes.
89088452|NCT02731729|Experimental|ipilimumab|In the ipilimumab monotherapy group, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes once every 3 weeks for four doses.
89088453|NCT02645461|Active Comparator|Riluzole|Riluzole 50 mg twice daily in ALS patients
89088454|NCT02645461|Experimental|PEA plus Riluzole|Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
89088455|NCT00632320||S, 1, A|group (success or failure), case number, measurement method
89088456|NCT00654589|Experimental|deferasirox|
89088457|NCT02645227|Active Comparator|Group 1|Open flap debridement (OFD)
89088458|NCT02645227|Active Comparator|Group 2|OFD with Platelet rich fibrin (PRF)
89088459|NCT02645227|Active Comparator|Group 3|OFD with PRF and 1.2% Rosuvastatin
89088460|NCT00652483|Experimental|1|Brimonidine ophthalmic solution 0.1%
89088461|NCT00652483|Active Comparator|2|Brimonidine ophthalmic solution 0.2%
89088462|NCT01119066|Experimental|Total Body Irradiation, Thiotepa and Cyclophosphamide|Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
89088463|NCT01119066|Experimental|Busulfan, Melphalan and Fludarabine|Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)
89088464|NCT01119066|Experimental|Clofarabine, Melphalan and Thiotepa|Clofarabine (20mg/m2/ day x 5) (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
89088465|NCT01119066|Experimental|Melphalan, Fludarabine and Thiotepa|Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
89088466|NCT00910624|Experimental|BOC + PEG/RBV|Participants who enrolled within 2 weeks after the last dose of PEG/RBV in previous protocol received boceprevir (BOC) + peginterferon/ribavirin (PEG/RBV) for up to 44 weeks followed by 24 weeks post-treatment follow-up. Participants who did not enroll within 2 weeks after the last dose of PEG/RBV in previous protocol received PEG/RBV for 4 weeks followed by BOC + PEG/RBV for up to 44 weeks, with 24 weeks post-treatment follow-up.
89088467|NCT00654667|Placebo Comparator|2|Placebo
89088468|NCT00654667|Experimental|Experimental 1|Resveratrol
89088469|NCT04164511||Patients with post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy and receiving 2 daily ice creams for 2 weeks after surgery. Standard analgesic therapy available.
89088470|NCT04164511||Patients without post-tonsillectomy ice cream|Pediatric patients undergoing tonsillectomy, not receiving any ice cream for 2 weeks after surgery. Standard analgesic therapy available.
89088471|NCT04066738|Other|Patients with myocardial scar|Patient with previous STEMI resulting in myocardial scar, elected to CRT implant
89230235|NCT00797849|Sham Comparator|2|Wear prosthetics laminated with sham material surrounding the liner. If not wearing prosthetics, subject needs to wear sock or glove over shrinker.
89088472|NCT05095428|Experimental|PARTS|The Program for Alleviating and Resolving Trauma and Stress (PARTS) Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
89088473|NCT05095428|Active Comparator|NBSR-T|The Nature Based Stress Reduction for Trauma Survivors (NBSR-T) Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
89088474|NCT04063150|Active Comparator|IPV at 14 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 14 weeks and 9 months of age.
89088475|NCT04063150|Active Comparator|IPV at 6 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 6 weeks and 9 months of age.
89088476|NCT04063150|Active Comparator|fIPV ID at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
89088477|NCT04063150|Active Comparator|fIPV ID at 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
89088478|NCT04063150|Active Comparator|fIPV IM at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
89088479|NCT04063150|Active Comparator|fIPV 0.1mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
89088480|NCT04063150|Active Comparator|fIPV 0.2mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.2 mL) of IPV at 14 weeks and 9 months of age.
89088481|NCT02645071|Experimental|Physical activity|The experimental arm is a 15-20 min interactive session, which aims to reduce participants' sedentary behavior and increase physical activity by increasing their motivation, self-efficacy, and knowledge of different types of easy exercises.
89088482|NCT04165681|Experimental|Limbix Spark|A 5 week mobile + virtual reality CBT-based program
89088483|NCT01123980|Experimental|BIAsp 30|0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
89088484|NCT01123980|Active Comparator|Insulin glargine|0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
89088485|NCT04037800|Experimental|SFUR-RARP|Patients in which RARP with sustainable functional urethral reconstruction (SFUR) is performed.
89088486|NCT04037800|Active Comparator|Standard RARP|Patients in which standard RARP is performed.
89088487|NCT02676973|Active Comparator|Sacral Colpopexy|Sacral Colpopexy performed via open, robotic, or laparoscopic procedure.
89088488|NCT02676973|Active Comparator|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair: Sacrospinous Ligament Suspension (SSLS) and Uterosacral Ligament Suspension (USLS)
89088489|NCT02676973|Active Comparator|Apical Transvaginal Mesh Repair|Uphold™ LITE
89088490|NCT04015648|Experimental|Group 1|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10^9 vp vaccination intramuscularly.
89088491|NCT04015648|Experimental|Group 2|Volunteers will receive standalone dose of ChAdOx1 Zika 2.5 x 10^10 vp vaccination intramuscularly.
89088492|NCT04015648|Experimental|Group 3|Volunteers will receive standalone dose of ChAdOx1 Zika 5 x 10^10 vp vaccination intramuscularly.
89088493|NCT02643511|Experimental|Prostate biopsy,Hemiablative focal Brachytherapy|This is a non-randomized, Phase II study examining the efficacy in terms of postimplant dosimetry (primary endpoint) as well as the secondary endpoints of QOL changes, toxicity, local control with post-treatment biopsy outcomes and comparison with historical whole-gland cohorts in men with early stage low volume prostate cancer treated with hemiablative focal brachytherapy
89088494|NCT02859207|Experimental|Cohort 1|Participants with mild hepatic impairment (Child-Pugh class A).
89088495|NCT02859207|Experimental|Cohort 1C|Healthy participants (control) matched to participants in Cohort 1.
89088496|NCT02859207|Experimental|Cohort 2|Participants with moderate hepatic impairment (Child-Pugh class B)
89088497|NCT02859207|Experimental|Cohort 2C|Healthy participants (control) matched to participants in Cohort 2
89088498|NCT02859129|Experimental|Rosuvastatin|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
89088499|NCT02859129|Experimental|Epanova®|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13)
89088500|NCT02859129|Experimental|Epanova® + Crestor®|Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24
89088501|NCT02859129|Active Comparator|Vascepa®|Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20).
89088502|NCT04164823|Experimental|Medical Taping|"Medical taping will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).~Patients will be taped for four days. It will start at the beginning of pain associated to the menstruation."
89088503|NCT04164823|Active Comparator|Analgesic self-medication (OTC)|"Participants will use the usual analgesic self-treatment for primary dysmenorrhea.It will start at the beginning of pain associated to the menstruation.~They will note the treatment indicating the analgesic and the dosage in a calendar."
89088504|NCT03976336|Experimental|Berberine|
89088505|NCT03976336|Placebo Comparator|Identical Placebo|
89088506|NCT04164589|Placebo Comparator|Control|The Neuro-Adaptative Regulation will be carried out in the regime of switched off power supply in vulvo-perineal and sacral area.
89088507|NCT04164589|Experimental|Experimental|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacarl area.
89088508|NCT02857959|Experimental|single dose benzathine penicillin G.|single dose benzathine penicillin G.
89088509|NCT02857959|Active Comparator|three doses of benzathine penicillin G.|three doses of benzathine penicillin G.
89088510|NCT00632398|Active Comparator|Attention control (reading)|Caregivers read to patients from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks.
89088511|NCT00632398|Experimental|Touch, Caring and Cancer DVD program|Caregivers apply the instruction of the Touch, Caring and Cancer DVD program for patients for recommended 20 minutes at least 3 times per week for 4 weeks.
89088512|NCT00654979|Experimental|Single arm|SafeFlo IVC Filter
89088513|NCT02643433|Experimental|MR and JE coadministration group|Infants aged 8 months are vaccinated measles-rubella combined vaccine (MR) and Japanese Encephalitis alive vaccine (JE) in different sites at same time.
89088514|NCT02643433|Active Comparator|MR administration alone group|Infants aged 8 months are vaccinated measles-rubella combined vaccine alone
89088515|NCT00632476|Placebo Comparator|A|Participants will receive a placebo capsule throughout pregnancy.
89088516|NCT00632476|Active Comparator|B|Participants will receive a vitamin C capsule throughout pregnancy.
89088517|NCT00632476|No Intervention|C|A group of non-smoking pregnant women will not receive placebo or vitamin C.
89088518|NCT04164745|Experimental|Experimental: Anlotinib plus Pembrolizumab|
89088519|NCT00655213|Active Comparator|1|AAISafeR mode programming
89088520|NCT00655213|Active Comparator|2|DDD with long AV Delay programming
89088521|NCT00655213|Active Comparator|3|DDDAMC mode programming
89088522|NCT00655213|Other|4|AAISafer mode programming in non randomized patients
89088523|NCT01198522|Other|Therapy of L19IL2 and Gemcitabine|Dose escalation study. Part A) Gemcitabine dose escalation. Part B) L19IL2 dose escalation.
89088524|NCT02638285|Experimental|HCG group|HCG group
89088525|NCT02638285|Experimental|LH group|LH group
89088526|NCT02638285|Experimental|clomiphene citrate|clomiphene citrate
89088527|NCT04201210|Experimental|Experimental Arm|Patients with no matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the experimental arm
89088528|NCT04201210|Active Comparator|Control Arm|Patients with a matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the control arm
89088529|NCT01134250|Experimental|F16IL2 in combination with paclitaxel|
89088530|NCT03751774|Experimental|MAMAACT|Training of midwives in intercultural communication. A 6 hours course and 2 one hour booster sessions. Distribution of health education materials on warnings signs of pregnancy and health system navigation to pregnant women during antenatal care visits.
89088531|NCT03751774|No Intervention|Control|Care as usual
89088532|NCT03414268|Experimental|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
89088533|NCT03414268|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
89088534|NCT01118520|Active Comparator|perindopril|ACE inhibitor blood pressure lowering agent
89088535|NCT01118520|Active Comparator|amlodipine|calcium channel blocker blood pressure lowering agent
89088536|NCT01118520|Placebo Comparator|placebo|inactive substance identical in appearance to the othe two comparators
89088537|NCT03744832|Experimental|Point of Care Testing|"Point of care testing using the Alere i™ Strep A assay for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. If test is positive, patients will be started on antibiotics prior to discharge from the ED. If test is negative, patients will not be started on antibiotics.~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
89088538|NCT03744832|Active Comparator|Standard Care|"Conventional testing using a standard bacterial throat culture for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. Patients will be discharged with a post-dated prescription and will be contacted in approximately 3 days if their culture results are positive to fill/take the antibiotics.~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
89088539|NCT01135992|Experimental|IGlar/IDeg|
89088540|NCT01135992|Experimental|IDeg 3TW|
89088541|NCT03734770|Active Comparator|Subcutaneous progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
89088542|NCT03734770|Active Comparator|Vaginal progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
89088543|NCT00959049|Experimental|Afluria Cohort A|Age 6 months to < 3 years
89088544|NCT00959049|Experimental|Afluria Cohort B|Age 3 to < 9 years
89088545|NCT00959049|Experimental|Afluria Cohort C|Age 9 to < 18 years
89088546|NCT00959049|Active Comparator|Fluzone Cohort A|Age 6 months to < 3 years
89088547|NCT00959049|Active Comparator|Fluzone Cohort B|Age 3 to < 9 years
89088548|NCT00959049|Active Comparator|Fluzone Cohort C|Age 9 to < 18 years
89088549|NCT00956943|Active Comparator|21mg transdermal nicotine + placebo patch|21mg transdermal nicotine + placebo patch
89088550|NCT00956943|Experimental|42mg transdermal nicotine|42mg transdermal nicotine
89088551|NCT00958893|Experimental|25 mg Proellex|25 mg Proellex daily
89088552|NCT01135914|Experimental|Combination Therapy|Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
89088553|NCT01135914|Experimental|Ranibizumab Monotherapy|Participants received ranibizumab intravitreal injection therapy only
89088554|NCT01135914|Active Comparator|Laser Monotherapy|Participants received Laser photocoagulation therapy only
89088555|NCT04281927||Atrial fibrillation|Patients with presumed atrial fibrillation will undergo monitoring with the device and Holter ECG.
89088556|NCT04281927||Sinus rhythm|Patients with presumed sinus rhythm will undergo monitoring with the device and Holter ECG.
89088557|NCT04281927||Sinus rhythm and frequent extrasystoles|Patients with presumed sinus rhythm and frequent extrasystoles will undergo monitoring with the device and Holter ECG.
89088558|NCT02858973|Experimental|Q203|Q203 tablets
89088559|NCT02858973|Placebo Comparator|Placebo|Placebo tablets
89088560|NCT04282005|Experimental|surgery group|Fourteen patients who meet study criteria will be assigned to the study group and will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
89088561|NCT04282005|Active Comparator|lifestyle and diet|Fourteen patients matched to the surgery group for age, gender, BMI, diabetes status, and NALFD score will undergo additional lifestyle interventions, dietary counselling and or meal replacement by a dietician aimed at inducing at least a 5-7% weight reduction, prior to their surgery (while on the waiting list for surgery).
89088562|NCT02860611||Type 1 Diabetes|Patients with type 1 diabetes
89088563|NCT02860611||Type 2 Diabetes|Patients with type 2 diabetes
89088564|NCT02860611||Control|Healthy volunteers
89088565|NCT04280679|Other|Arm of patient treated by HIFU|Compression bandages
89088566|NCT00907738|Experimental|Vorinostat|
89088567|NCT04282161|Experimental|Axys EX device|
89088568|NCT01123356|Experimental|Oratumumab and Lenalidomide|"Single arm, non randomized study~Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.~Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.~Treatment to be administered for up to 6 cycles"
89088569|NCT02858817|Experimental|51,200 PfSPZ|Three injections of 51,200 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
89088570|NCT02858817|Experimental|150,000 PfSPZ|Three injections of 150,000 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
89088571|NCT02858817|Placebo Comparator|Placebo|Three injections of NaCl 0,9% solution under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
89088572|NCT02883192|Experimental|ondansetron|ondansetron
89088573|NCT02883192|Placebo Comparator|Placebo|Placebo
89088574|NCT04280835|Experimental|Group Psychoeducation that Focused on Social Skill Development|The Psychoeducation program that focused on social skill development, consists of 8 sessions, one day a week, each lasting an average of 60 Minutes. Psychoeducation was conducted in three groups and each of them consisted of eight patients.
89088575|NCT04280835|No Intervention|Control Group|No intervention was performed on the patients in the control group, and routine follow-up (arranging treatment by the doctor, answering the patient's and family's questions about treatment) continued in the polyclinic.
89088576|NCT02883270|Experimental|RAGT treatment group|Robotic-assisted gait training （RAGT）is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation after some neuropathy. The investigators use LokoHelp for training, which is provided to the feet and the patient actively controls the knee and hip joints. The participants of RAGT treatment group receive 30 min conventional rehabilitation and 30 min robotic-assisted gait training daily for 8 weeks.
89088577|NCT02883270|Placebo Comparator|controls|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
89088578|NCT02860455|Other|SpCO and COHb measurement|"SpCO measurement (Experimental) : Non invasive pulse CO-oximetry will be carried out in all patients simultaneously with venous blood sampling for standard laboratory blood gas analysis, at time of prehospital management by emergency medical services~COHb measurement (Active comparator) : Blood carboxyhemoglobin testing will be carried out in all patients"
89088579|NCT00908596|Experimental|Gadoxetic acid disodium (Primovist/Eovist, BAY86-4873)|Participants received Primovist at a dose of 0.025 mmol/kg body weight (BW) intravenously.
89088580|NCT05143593|Experimental|the experiment group|early adjustment of antibiotics is guided by results of SSBD
89088581|NCT05143593|No Intervention|control group|early adjustment of antibiotics is guided on the results of conventional culture
89088582|NCT02590120|Active Comparator|Enteral nutrition product : product A|Administration during 16 hours.
89088583|NCT02590120|Active Comparator|Enteral nutrition product : product B|Administration during 16 hours.
89088584|NCT02860533|Experimental|Blood pressure measurement|six repetitive blood pressure measurements with iPhone and conventional oscillometric cuff device during stress testing will be performed
89088585|NCT01118052|Experimental|Treatment (EGEN-001)|Patients receive intraperitoneal EGEN-001 on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89088586|NCT02860377|Active Comparator|stranger's voice|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
89088587|NCT02860377|Experimental|maternal voice|At the end of surgery, patients were stimulated to wake up by recorded maternal voice, which was recorded before the operation.
89088588|NCT03394534|Experimental|CGA group|
89088589|NCT03394534|No Intervention|Treatment as Usual|
89088590|NCT04277949|Experimental|Erbium laser|All participants will receive Erbium laser treatment on their right post-auricular region
89088591|NCT04277949|Experimental|DNA repair enzyme|All participants will apply topical DNA repair enzymes on their left post-auricular region
89088592|NCT00632554|Experimental|1|prednisolone therapy for three months
89088593|NCT00632554|Active Comparator|2|prednisolone therapy for six months
89088594|NCT01123200|Other|Brain Computer Interface In-Home Use|
89088595|NCT02857803|Experimental|Virtual Reality|The Virtual Reality group will perform personalised activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
89088596|NCT02857803|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalised to their deficits and generated automatically through a Task Generator.
89088597|NCT02857803|Active Comparator|Conventional Therapy|The Conventional Therapy group will perform the activities offered by the public health system, which are motor-focused.
89088598|NCT05054088||Cohort 1|Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with symptoms compatible with SARS-CoV-2 infection.
89088599|NCT05054088||Cohort 2|Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with symptoms compatible with SARS-CoV-2 infection.
89088600|NCT03335722|Active Comparator|Active TDCS and Fluency Intervention|Participants will receive 1-milliamp (mA) tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes a day for five consecutive days. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
89088601|NCT03335722|Sham Comparator|Sham TDCS and Fluency Intervention|Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes a day for five consecutive days. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
89088603|NCT00955617|Experimental|Dotarem / Gadovist|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Dotarem in period 1 then with Gadovist in period 2
89088604|NCT00955617|Experimental|Gadovist / Dotarem|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Gadovist in period 1 then with Dotarem in period 2
89088605|NCT05462860|Experimental|Suprathel® dressing|The Suprathel® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use
89088606|NCT05462860|Active Comparator|Standard of Care|The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.
89088607|NCT04277871|Experimental|The intervention group|The intervention group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The intervention group attended on-site group practice sections and performed individual home-based practice.
89088608|NCT04277871|Active Comparator|The comparison group|The comparison group received an educational section and related educational materials. The educational section involved two sub-sections: a discussion section and an abbreviated practice section. The comparison group performed individual home-based practice only.
89088609|NCT05331898|Experimental|Education Group|increase the rational drug use of the parents.
89088610|NCT05331898|No Intervention|control|PARENTS CANNOT USE RATIONAL MEDICATION ON THEIR CHILDREN
89088611|NCT03082209|Experimental|Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab|Participants with KRAS-mutant CRC are administered with ABBV-621 in combination with bevacizumab plus FOLFIRI
89088612|NCT03082209|Experimental|Chemotherapy combination: ABBV-621+FOLFIRI|Participants with RAS-mutant CRC who have received one prior line of therapy will be administered ABBV-621 in combination FOLFIRI.
89088613|NCT03082209|Experimental|Dose Optimization: ABBV-621 + Venetoclax for AML|Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.
89088614|NCT03082209|Experimental|Dose Optimization: ABBV-621 Monotherapy for AML|Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.
89230236|NCT00793559|Active Comparator|terlipressin bolus|1 mg of terlipressin received one time only
89088615|NCT03082209|Experimental|Dose Optimization: ABBV-621 + Venetoclax for DLBCL|Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.
89088616|NCT03082209|Experimental|Dose Optimization for Pancreatic Cancer|Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).
89088617|NCT03082209|Experimental|Dose Optimization for KRAS-mutant CRC|Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.
89088618|NCT03082209|Experimental|Dose Escalation|ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).
89088619|NCT05423860||dementia|Patients with a diagnosis of dementia
89088620|NCT05423860||Prostate cancer|patients with a diagnosis of prostate cancer
89088621|NCT05423860||breast cancer|Patients with a diagnosis of breast cancer
89088622|NCT05423860||Normal|Patients without a diagnosis
89088623|NCT05423860||tramatic brain injury|patients with a diagnosis of traumatic brain injury
89088624|NCT02224144|Experimental|Vitamin D3 plus Calcitriol|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU daily for 12 months~1 pill of Rocaltrol (calcitriol) 0.5 mcg daily for 12 months"
89088625|NCT02224144|Placebo Comparator|Vitamin D3 plus Placebo|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU per day for 12 months~1 pill of placebo (sugar pill) per day for 12 months"
89088626|NCT00958347|Other|Omnifit HA Hip Stem|Participants underwent total hip replacement surgery using the Omnifit HA Hip Stem.
89088627|NCT05419180|Other|stiripentol|
89088628|NCT04281615|Experimental|Intervention (Generic Message)|Receives promotional materials that feature a generic messaging approach.
89088629|NCT04281615|No Intervention|Control (Threshold Message)|Receives promotional materials that use traditional, threshold messages.
89088630|NCT02857647|Experimental|The experimental group|"Participants who will assigned to the experimental group will be asked to watch an information video of 30 minutes 1-2 weeks prior to the surgery date.~n=100."
89088631|NCT02857647|No Intervention|The control group|"Participants who will assigned to the control group will receive standard care and will not asked to watch a videotaped lecture prior to the surgery.~n=100."
89088632|NCT02067052||Advanced vulvar cancer|Patients with advanced-stage tumors.
89088633|NCT02067052||Early-stage vulvar cancer|Patients with early-stage tumors
89088634|NCT05418712|Placebo Comparator|Placebo|Participants will receive placebo matched to VX-150.
89088635|NCT05418712|Experimental|VX-150|Participants will be randomized to receive a single dose of one of different dose levels VX-150.
89088636|NCT04280289|Experimental|Cannabidiol extract|"10 healthy subjects (5 female, 5 male), will be enrolled into the study. Each subject will receive a single CBDE dose delivering 2.5 mg/kg CBD, after consumption of a standardized meal.~Nine (9mL) of blood for PK analysis, at each of the following timepoints: 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the study drug administration.~Urine will be collected at the following timepoints: Predose, 0-4 hrs, 4-8 hrs, 8-12 hrs, 12-24 hrs, 24-36 hrs, 36-48 hrs, and 48-72 hrs for PK analysis"
89088637|NCT03302728|Experimental|Lenalidomide & brentuximab vedotin|Brentuximab vedotin 1.8mg/Kg Lenalidomide 15 mg
89088638|NCT03866044||Parkinson's Disease (PD)|"Patients with Parkinson's Disease meeting the following criteria:~Inclusion criteria:~Aged 18 or more.~Clinically established or probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of other neurologic or psychiatric disease~Pacemaker or other implanted electronic devices~Claustrophobia"
89088639|NCT03866044||Healthy participants|"Healthy participants age- and sex-matched to the PD group.~Inclusion criteria:~Age- and sex-matched to PD group (aged 18 or more)~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of neurologic or psychiatric disease~Pacemaker or other implanted electronic devices~Claustrophobia"
89088640|NCT05331742||vaccinated|patient between age 18 and above who have received a complete dose of coronavirus disease vaccine patient who has been admitted to critical care unit due to corona virus disease infection
89088641|NCT05331742||unvaccinated|patients between age 18 and above who has been admitted to critical care unit due to coronavirus disease infection and admitted to critical care unit
89088642|NCT03863236|Active Comparator|regular diet|The control group (group 1) will continue their regular diet.
89088643|NCT03863236|Active Comparator|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support two weeks before the operation and the nutritional support will continue 10 days after the operation.
89088644|NCT00958191|Other|Trident® X3 Polyethylene Insert|Participants who received the Trident® X3 Polyethylene Insert.
89088645|NCT05322382|Experimental|Single|Subjects undergo an interventional procedure and non-invasive measurements of SpO2.
89088646|NCT03832972||Women using birth control|
89088647|NCT03832972||Women not using birthcontrol|
89088648|NCT03051477|Experimental|Helixor® M|Advanced solid tumors
89088649|NCT03125356|Experimental|Diet Soda|Subjects will be asked to consume a diet soda three times daily for eight weeks.
89088650|NCT05314114|Experimental|No Axillary Surgery|No axillary surgery including SLNB
89088651|NCT02860299|Experimental|Citrate lock|
89088652|NCT02860299|Active Comparator|Heparin lock|
89088653|NCT02858505|Active Comparator|27 mg elemental iron group|received 27 mg elemental iron once daily starting at 12 weeks until 36 weeks
89088654|NCT02858505|Active Comparator|54 mg elemental iron group|received 54 mg elemental iron once daily starting at 12 weeks until 36 weeks
89088655|NCT05313100|Active Comparator|Smokers|The patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking were included in the smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used.
89088656|NCT05313100|Sham Comparator|Nonsmokers|The patients who never smoked were included in the non-smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used.
89088657|NCT00960843|Active Comparator|Conventional Adjustment Group|Subject whose band adjustments will be made via conventional standard of care (e.g., volume, hunger).
89088658|NCT00960843|Active Comparator|Intraband Pressure Arm|Subjects whose band adjustments will be guided by intraband pressure readings.
89088659|NCT04281693|Experimental|Screening participants|
89088660|NCT02860143||studying ventilation during sedation|Comparing ventilation during sedation with capnography
89088661|NCT02860221|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
89088662|NCT02860221|Experimental|Topical epinephrine|Topical epinephrine
89088663|NCT02860221|Active Comparator|Control|No epinephrine
89088664|NCT02860065|Experimental|CPC-201|combination of solifenacin and high doses of donepezil
89088665|NCT04274829||PTMC|Patients with papillary microcarcinoma of the thyroid
89088666|NCT02857881|Experimental|Evolutive keratoconus|
89088667|NCT02857569|Experimental|Experimental IT Arm|"ipilimumab: 0.3mg/kg IT injection every 3 weeks until complete response, eradication of all injectable sites, disease progression or toxicity, for a maximum of 4 doses (to compare back to back to IV standard of care and marketing authorization).~nivolumab: 1mg/kg, IV injection every 3 weeks during IT ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IT ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
89088668|NCT02857569|Active Comparator|Standard Arm|"ipilimumab: 3mg/kg, IV injection every 3 weeks for a maximum of 4 doses as per standard of care and marketing authorization.~nivolumab: 1mg/kg, IV injection every 3 weeks during IV ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IV ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
89088669|NCT04164667|Active Comparator|Self-Guided|Participant's do not receive text message direction from the VA Annie Text Messaging System. Participant's create their own method for accomplishing app-based exercise and mindfulness practice without detailed instructions.
89088670|NCT04164667|Experimental|Directed Messaging|Participant's receive text message directions from the ANNIE VA messaging system. The directed messaging system provides text message details of the participant's app-based meditation and exercise instructions.
89088671|NCT04164355||Patients undergoing Tadalafil|Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months
89088672|NCT04164355||Control Group|Healthy controls without previous surgery of radical prostatectomy.
89088673|NCT01605253|Active Comparator|Eszopiclone|The total study duration is 16 weeks, with subjects taking 3mg eszopiclone at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
89088674|NCT01605253|Placebo Comparator|Placebo|The total study duration is 16 weeks, with subjects taking placebo at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
89088675|NCT04164433|Experimental|Workplace-based HIV Self-Testing|"i. Explain the procedure of conducting HIVST & interpret HIV self- test result to the user.~ii. Demonstrate how to perform the self-test and how to interpret the self-test result.~iii. Provide appointment card including information on linkage for HIV prevention services and further testing for diagnosis among those with a reactive self-test. Participants with a non-reactive self-test will be referred to HIV prevention services.~iv. Provide a toll free number for continued consultation"
89088676|NCT04164433|No Intervention|Workplace-based standard HIV Testing Services (HTS)|Standard of care following the HIV testing algorithm .
89088677|NCT00655135|Placebo Comparator|1|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received placebo administered intravenously to patients on Day 1 and Day 29.
89088678|NCT00655135|Experimental|2|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 0.5 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
89088679|NCT00655135|Experimental|3|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 2 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
89088680|NCT02643121||children with sepsis, SIRS|Data will be collected and analyzed from childrens with SIRS or septic state who will be admitted to the Department of Anesthesia and Intensive Care of the University Children´s Hospital Brno, Czech Republic. Infections, sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome (MODS) will be defined according to commonly used criteria - by International pediatric sepsis consensus conference.
89088681|NCT02643121||control group, healthy children|The samples children undergoing elective surgery will be used as a controls, i.e. samples from patients without signs of infection.
89088682|NCT04163965|Other|Patients having a pacemaker|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology. Simultaneously standard routine ECG measurements will take place.
89088683|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
89088684|NCT02643277|Experimental|Mobile phone text messaging|The intervention will receive text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring. The messages provide tips and suggestions, and positive reinforcement or encouragement, for improving lifestyle behaviors and compliance with therapy.
89088685|NCT02635945|Experimental|PBF-680 10 mg|2 capsules: PBF-680, 5 mg capsules for oral administration (excipient: 76 mg microcrystalline cellulose).
89088686|NCT02635945|Placebo Comparator|Placebo|2 capsules: Placebo to PBF-680, as 95.12 mg microcrystalline cellulose capsules.
89088687|NCT04162249||Conventional ablation (CONTROL GROUP)|"Pulmonary veins ablation.~Anterior aspect: power 30 W, catheter dragging (30 s per point).~Posterior aspect: point-by-point ablation using 30 W/30 s applications. If esophageal temperature measured with two independent esophageal probes exceeded 49 ºC radiofrequency settings were modified to 20 W/ 60 s and the number of radiofrequency applications minimized in areas with esophageal temperature rise.~Al procedures were performed with continuos intracardiac echo image and esophageal temperature monitoring."
89230237|NCT00793559|Experimental|terlipressin drip|
89088688|NCT04162249||High-power and short-duration ablation|"Pulmonary veins ablation.~Subgroup 50W: power 50 W, application duration ≤ 30 s, target lesion index: LSI ≥ 5 or Ablation Index ≥ 350 (posterior wall) or ≥400 (anterior wall).~Subgroup 60W: power 60 W, application duration 7-10 s, contact force ≥5 g.~Subgroup 70W: power 70 W, application duration 9 s, contact force ≥5 g.~Intracardiac echo was not used. Esophageal temperature probes were used only in 6 patients in the subgroup 50W."
89088689|NCT04164043|Experimental|Recreational Therapy Wellness Recovery Program Group|All participants will enter a baseline data collection period for two weeks. They will then participate in a 12-week community-based Recreational Therapy (RT) Wellness Recovery Program (WRP) for individuals with Parkinson's disease (WRP).
89088690|NCT00955305|Active Comparator|Arm A (CPB)|Patients receive carboplatin intravenously (IV) over 30 minutes, paclitaxel IV over 3 hours, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab may continue in the absence of disease progression or unacceptable toxicity.
89088691|NCT00955305|Experimental|Arm B (CPB+cixutumumab)|Patients receive carboplatin, paclitaxel, and bevacizumab as in Arm A. Patients also receive cixutumumab (IMC-A12) IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab and cixutumumab may continue in the absence of disease progression or unacceptable toxicity.
89088692|NCT02635789|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
89088693|NCT02635789|Placebo Comparator|Placebo gel|Placebo gel is matched ingredient with NPC-12G gel
89088694|NCT02635711|Experimental|Adapted Taekwondo training|An adapted TKD training regime which was developed by our research team [16] will be used in this study. This training programme is designed to train balance control, eye-hand coordination and facilitate skeletal development for children with DCD. The high-impact striking techniques (e.g., punching and blocking) incorporated in the programme may stimulate bone growth [15]. Subjects who are assigned to the TKD training group will attend a weekly 1-h session of TKD training that will be held at the University of Hong Kong for 12 weeks. All TKD training sessions will be conducted by a qualified World Taekwondo Federation black belt coach.
89088695|NCT02635711|Active Comparator|Control|Subjects who are assigned to the DCD-control group will receive no TKD training during the study period. Instead, they will participate in jogging exercise daily (one hour per day) for 12 weeks. Participants will be encouraged to jog to school or other places every day, as appropriate. Pedometers will be used to monitor their exercise level and enhance habitual physical activity. The pedometer count (steps per day) will be documented in a log book by the parents. Signed log books will be returned to our research personnel after the intervention period. In addition, children with DCD in this group will receive an adapted TKD training menu and 12 training/demonstration sessions immediately after the follow-up testing is completed.
89088696|NCT00655291|Placebo Comparator|A|
89088697|NCT00655291|Experimental|B|
89088698|NCT02857725|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were considered for SPF testing.
89088699|NCT00656695|Experimental|1|taking Iminoral
89088700|NCT00656695|Active Comparator|2|taking Neoral
89088701|NCT02858427|Experimental|depressed with suicide attempt (SA)|elderly depressed patients with a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
89088702|NCT02858427|Experimental|depressed without a history of SA|elderly depressed patients without a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
89088703|NCT02642887|Experimental|The test group|This group included 30 recession defects treated with mTA + SCTG
89088704|NCT02642887|No Intervention|The control group|This group included 30 recession defects treated with cTT + SCTG
89088705|NCT02637817||Control Group|Neonates with no evidence of brain lesions on conventional MRI.
89088706|NCT02637817||Patients Group|Neonates with PWML diagnosed by conventional MRI.
89088707|NCT04204083|Other|Monovisc|
89088708|NCT04271865|Other|therapy induced anemia for HCV treated patients|"Four types of interventions:~Educational to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits~Provision of Dates : Dates fruit intake for all the anaemic patients~Recipe book~Model kitchen for all patients having Hemoglobin lower than normal hemoglobin levels; less than 13.2 grams (g) of hemoglobin per deciliter (dL) of blood for men and less than 11.6 for women."
89088709|NCT00598585|Experimental|sidenafil|sidenafil
89088710|NCT00598585|Placebo Comparator|placebo|placebo
89088711|NCT04271553|No Intervention|Control|Patient will undergo standard workflow for elective surgical admissions.
89088712|NCT04271553|Experimental|Video|In addition to standard workflow, will also receive the intervention bundle which consists of a cartoon video and sets of activity sheets
89088713|NCT00653107|Experimental|A|Stent followed by 3 brachytherapy fractions
89088714|NCT00653107|Active Comparator|B|3 fractions of brachytherapy
89088715|NCT02635243|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
89088716|NCT02635243|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
89088717|NCT02635243|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
89088718|NCT00953667|Experimental|Niacin and Endotoxin|All subjects are expected to have the same interventions- Niacin and Endotoxin.
89088719|NCT04274439|Experimental|Internet-Based Pain Education and Exercise|"Patients allocated to the intervention group will receive a login and password for individual access to the website designed for the study. The content of this intervention will include videos and animations based on pain education, physical activity promotion and general exercises. The pain education component will be based on the E-pain intervention developed by Reis et al (2017), which includes nine main features: (1) acceptance, (2 and 3) education about pain, (4) sleep hygiene, (5) recognizing stress and negative emotions, (6) increasing positive coping in lifestyle, (7) exercises, (8) communication and (9) relapse prevention. The exercise component will include general exercises aiming to improve strength, flexibility, control and coordination.~Patients in this group will also receive weekly text messages and a health coaching over the telephone. The text messages will include information on the benefits of exercises, motivation, and positive messages about dealing with pain."
89088720|NCT04274439|Active Comparator|Online Booklet|The patients allocated to the control group will have access to an online booklet containing general information about self-management of chronic pain, including pain education, advice on healthy lifestyle and sleeping habits and promotion of exercises. They will also receive one phone call at week 4 and text messages once a week during the study period.
89088721|NCT02812173|Active Comparator|suprapubic tube ex 2 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 2th day after the surgery
89088722|NCT02812173|Active Comparator|suprapubic tube ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 5th day after the surgery
89088723|NCT02812173|Active Comparator|transurethral catheter ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a transurethral catheter, which was withdrawn on the 5th day after the surgery
89088724|NCT00630669|Active Comparator|1|Rubber band ligation
89088725|NCT00630669|Active Comparator|2|Bipolar coagulation
89088726|NCT02857335|Other|study group|patients with benign intracranial hypertension ages 8-16 years
89088727|NCT02857491|Experimental|ranibizumab|Intravitreal Injection of 0.5 mg ranibizumabone week before vitrectomy.
89088728|NCT02857491|Sham Comparator|control|Sham intravitreal injection one week before vitrectomy.
89088729|NCT00883129|Experimental|Mycophenolate Arm|Participants will receive oral mycophenolate mofetil for 2 years.
89088730|NCT00883129|Experimental|Cyclophosphamide Arm|Participants will receive oral cyclophosphamide for 1 year, followed by placebo for 1 year.
89088731|NCT02856867|Active Comparator|mFOLFOX6 + Nintedanib|"Patients will receive nintedanib in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).~Dose modification of nintedanib and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
89088732|NCT02856867|Placebo Comparator|mFOLFOX6 + Placebo|"Patients will receive placebo in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).~Dose modification of placebo and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
89088733|NCT00630513|Experimental|E|3 days regimen with Ertapenem
89088734|NCT00630513|Active Comparator|AS|3 days treatment with Ampicillin-Sulbactam
89088735|NCT01278927|Active Comparator|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief (10 minute) personalized introduction to the home-based exercise intervention. On Day 30 post hematopoietic cell transplantation (HCT), participants will meet briefly with the same interventionist when possible. To minimize contamination across intervention conditions, participants randomized to Exercise will be provided with only general advice regarding stress management (i.e., to continue using any techniques they currently use to manage stress). The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant.
89088736|NCT01278927|Active Comparator|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief standardized introduction to the self-administered intervention. On Day 30 post HCT, the interventionist will meet with the participant to answer any questions about the intervention, encourage the continued use of stress management techniques as recommended, and monitor for any adverse reactions to use of the techniques. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
89088737|NCT01278927|Active Comparator|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions. On Day 30 post HCT, the same interventionist will meet with the participant briefly to answer any questions about the interventions, encourage the continued use of the interventions as recommended, and monitor for any adverse reactions. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
89230238|NCT00797927|Experimental|1. quetiapine|quetiapine would replace the original conventional antipsychotic agent
89088738|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive a digital video disc (DVD). The interventionist will briefly discuss the topics of the DVD and elicit questions. To minimize contamination across intervention conditions, participants randomized to the control group will be provided with only general advice about exercise and stress management during treatment (i.e., to maintain any usual patterns of exercise to the extent possible and to continue using any techniques they currently use to manage stress).
89088739|NCT02635399|Placebo Comparator|conventional group|Conventional PPPD
89088740|NCT02635399|Experimental|DJ-pexy group|PPPD with additional DJ-pexy to anchor DJ to transverse colon
89088741|NCT02635321||Patients with LGMD 2T|Four patients over 18 years old with genetically verified LGMD 2T.
89088742|NCT04270773|Other|Only arm|Single arm, Receiving treatment
89088743|NCT00905632|Experimental|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
89088744|NCT00905632|Experimental|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
89088745|NCT00905632|Experimental|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
89088746|NCT00905632|Placebo Comparator|Placebo + SOC|Placebo tid +SOC
89088747|NCT01213732|Experimental|L19TNFα plus melphalan|Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).
89088748|NCT05287360|Experimental|Treatment Sequence 1|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 1; Period 2: Formulation 2; Period 3: Formulation 3; Period 4: Formulation 4~There will be a washout period of 5 days between each dosing."
89088749|NCT05287360|Experimental|Treatment Sequence 2|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 2; Period 2: Formulation 4; Period 3: Formulation 1; Period 4: Formulation 3~There will be a washout period of 5 days between each dosing."
89088750|NCT05287360|Experimental|Treatment Sequence 3|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 3; Period 2: Formulation 1; Period 3: Formulation 4; Period 4: Formulation 2~There will be a washout period of 5 days between each dosing."
89088751|NCT05287360|Experimental|Treatment Sequence 4|"Participants will receive rivoceranib on Day 1 of each period as a single dose under fasted conditions as follows:~Period 1: Formulation 4; Period 2: Formulation 3; Period 3: Formulation 2; Period 4: Formulation 1~There will be a washout period of 5 days between each dosing."
89088752|NCT05333770|Experimental|SCI Group|"Complete testing at Baseline, Post, and 6 month follow up. Intervention includes 15 treatment sessions (3-5 times per week) with HF-rTMS & 6 month follow-up. Following HF-rTMS, there will be 30 minutes of arm and hand training. Each session will last for approximately 60 mins.~At baseline, post and 6 months, the following evaluations to evaluate safety and other related measures. These measures include a safety and pain questionnaire, spasticity measurement, a physician or clinician evaluation to determine motor and sensory neurological level of injury, hand and arm function measurement, evaluation of ability to perform everyday tasks, and measures to determine level of brain function."
89088753|NCT00954447|Experimental|Linagliptin|patient receives a tablet with intended final marketed dose
89088754|NCT00954447|Placebo Comparator|Placebo|patient receives a tablet identical to those containing Linagliptin
89088755|NCT00904150||1 Menstrual migraine|Caucasian women with a current or past history of menstrual migraine (MM = pure menstrual migraine or menstrually-related migraine) attending the City of London Migraine Clinic
89088756|NCT00904150||2 No migraine|Caucasian women with no personal history of migraine
89088757|NCT02692612||Young|
89088758|NCT02692612||Middle-Aged|
89088759|NCT02692612||Old|
89088760|NCT05195320|Experimental|Group Intervention|Participants will attend six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion. These skills are presented in sequence over the course of the intervention so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex. The culmination of developing these skills and participation in a peer group will assist individuals in increasing self-efficacy and overall QOL, well-being and participation. Participants will complete follow-up assessment at 18- and 30-weeks post-intervention.
89088761|NCT05195320|Placebo Comparator|Placebo|Participants will receive no intervention throughout the course of the study; however, the participants will be tested at 18- and 30-weeks participation in the study.
89088762|NCT05186584|Experimental|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|Patients in this group will receive Maitland's Antero-Posterior Mobilization.
89088763|NCT05186584|Experimental|MAITLAND'S LATERAL MOBILIZATION|Patients in this group will receive Maitland's Lateral Mobilization.
89088764|NCT04735744||Prospective cohort|Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that treat patients recovering from COVID-19 in Dutch primary care
89088765|NCT04735744||Retrospective cohort|Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that have been treated patients recovering from COVID-19 in Dutch primary care
89088766|NCT00903760|Experimental|Decitabine + Clofarabine|Drug delivery intravenously (IV) in alternating series of cycles (Decitabine 20 mg/m^2 for 5 days first 3 cycles, then Clofarabine 10 mg/m^2 five days for next 3 cycles), pattern repeats for up to 24 cycles.
89088767|NCT00903760|Experimental|Decitabine|Decitabine 20 mg/m^2 IV daily for 5 days for a total of 24 courses.
89088768|NCT02969512|Experimental|HIPPER|The HIPPER group will receive 12 interactive online modules (~20 minutes each). HIPPER participants will receive email or phone contact (participant preference) to provide them with website portal access consisting of the web address, and simple instructions to access the website using personalized encrypted login information to the site.
89088769|NCT02969512|Active Comparator|OASIS Online Educational Webinars|To provide a comparable level of education, participants in the Online Education group will receive 2 hours of OASIS online educational webinars as per current practice.
89088770|NCT05177614|Experimental|Upper-level multiple micronutrient-fortified bouillon cube|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with six micronutrients
89088771|NCT05177614|Experimental|Lower-level multiple micronutrient-fortified bouillon cube|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with six micronutrients
89088772|NCT05177614|Placebo Comparator|Control (iodine-fortified bouillon cube)|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with one micronutrient
89088773|NCT04165603|Active Comparator|5mg/kg of ICG, 24h before surgery|5mg/kg of indocyanine green, intravenously injection 24 hours before surgery
89088774|NCT04165603|Experimental|1mg/kg of ICG, 24h before surgery|1mg/kg of indocyanine green, intravenously injection 24 hours before surgery
89088775|NCT04165603|Experimental|5mg/kg of ICG, 48h before surgery|5mg/kg of indocyanine green, intravenously injection 48 hours before surgery
89088776|NCT04165603|Experimental|1mg/kg of ICG, 48h before surgery|1mg/kg of indocyanine green, intravenously injection 48 hours before surgery
89088777|NCT02846272|Experimental|Observational cohort|Observing MRI changes in subjects.
89088778|NCT04202536|Experimental|TDF switch to Besifovir Dipivoxil Maleate|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Besifovir Dipivoxil Maleate 183mg daily
89088779|NCT04202536|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
89088780|NCT02817880|Experimental|rTMS (repetitive transcranial magnetic stimulation)|rTMS (repetitive transcranial magnetic stimulation)
89088781|NCT02817880|Experimental|tDCS (transcranial direct-current stimulation)|tDCS (transcranial direct-current stimulation)
89088782|NCT02817880|Experimental|tsDCS (transcutaneous spinal Direct Current Stimulation)|tsDCS (transcutaneous spinal Direct Current Stimulation)
89088783|NCT02794402|Active Comparator|Bydureon|s.c. once Weekly
89088784|NCT02794402|Placebo Comparator|Placebo|s.c. once Weekly
89088785|NCT00883051|Experimental|50 mg Lasmiditan|50 mg lasmiditan administered orally (PO)
89088786|NCT00883051|Experimental|100 mg Lasmiditan|100 mg lasmiditan administered orally (PO)
89088787|NCT00883051|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally (PO)
89088788|NCT00883051|Experimental|400 mg Lasmiditan|400 mg lasmiditan administered orally (PO)
89088789|NCT00883051|Placebo Comparator|Placebo|Placebo administered orally (PO)
89088790|NCT00655447||1|all women having a hysterectomy with oophorectomy
89088791|NCT00655447||2|all women having a hysterectomy without removal of ovaries
89088792|NCT02637739|Experimental|Pregnancy of unknown location|pregnant women of at least 5 weeks by last menstrual period and transvaginal ultrasound did not revealed intra-uterine pregnancy or ectopic pregnancy Intervention: hysteroscope
89088793|NCT00655525|Active Comparator|1|
89088794|NCT00655525|Placebo Comparator|2|
89088795|NCT03395587|Experimental|Experimental intervention|Fluorescence-guided surgery (day 0) Leukapheresis (wk4) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) vaccination with autologous, tumor lysate-loaded, mature dendritic cells (DC) (7x, 2 - 10 x 106 DC each, intradermal injection, weekly wk11-14, wk17, 21, 25)Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)
89088796|NCT03395587|Other|Control intervention|"Standard therapy:~Fluorescence-guided surgery (day 0) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)"
89088797|NCT00903682|Experimental|etravirine|etravirine (ETR TMC125) 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
89088798|NCT00903682|Active Comparator|efavirenz|efavirenz (EFV) 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
89088799|NCT00655603|Experimental|1|10 patients with Type 2 Diabetes Mellitus
89088800|NCT00655603|Experimental|2|10 healthy, matched control participants
89088801|NCT01117428|Experimental|Sym004|
89088802|NCT05223322|Active Comparator|Taking Charge during Treatment (TCT) Intervention|"Taking Charge during Treatment (TCT) Intervention. TCT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Participants will receive Take Charge program binder, 2-4 x weekly text messaging, activity tracker and resistance bands."
89088803|NCT05223322|No Intervention|Control Group|"To ensure scientific rigor allowing us to test causal pathways associated with exercise, women will be randomized to the TCT intervention or control group arm. The control group will not receive the TCT intervention The investigators experience teaches us that to increase the likelihood of retaining control group participants, the investigators must offer some resources. Thus, the investigators will provide the control group with a one-page summary of the American College of Sports Medicine exercise recommendations, and the Take Charge program binder at the completion of the study. Participants will also receive resistance bands and activity tracker at the end of the study. 95 The investigators will also send weekly text messages with supportive content not related to exercise or lifestyle (i.e., a riddle, take a moment to smile today, a picture of a baby animal)."
89088804|NCT04162405||Patients with tinnitus and hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold >30 dB
89088805|NCT04162405||Patients with tinnitus without hearing loss|Patients with tinnitus and average speech-frequency tonal audiogram threshold <30 dB
89088806|NCT02637661||Initial AMI|To study the sensitivity, specificity, positive predictive value, and negative predictive value of different earlobe crease as risk factors of AMI
89088807|NCT02637661||No coronary heart disease|To study the characteristics of earlobe crease
89088808|NCT02715466|Experimental|Gelatine|Balanced gelatine solution
89088809|NCT02715466|Active Comparator|Electrolyte|Balanced electrolyte solution
89088810|NCT00655681|Experimental|A recieveds pamidronate 1mg/kg once|Receives pamidronate 1mg/kg once
89088811|NCT00655681|Placebo Comparator|B: placebo group recieves saline|receives saline injection 10 cc/kg over 4 hours once post operatively
89088812|NCT04187586||Extracorporeal shock wave therapy group|The ESWT group received shock waves with low-energy flux density (0.05-0.30 mJ/mm2). The interval between treatments is a 1-week. To evaluate the effect of ESWT, we reviewed the skin test results (thickness, melanin, erythema, TEWL, sebum, and skin elasticity levels) immediately before ESWT and immediately after the sixth session. And also the ESWT group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
89088813|NCT04187586||conventional therapy without extracorporeal shock wave therapy|Conventional therapy group received the standard treatment, which involved medication, scar lubrication, burn rehabilitation massage therapy, and physical therapy.
89088814|NCT02345356||Standard-of-Care|the standard clinical approach will be followed
89230239|NCT00797927|No Intervention|2. conventional antipsychotics|
89088815|NCT02345356||Genotype-guided|algorithmically guided personalized therapy of warfarin, using a pharmacogenetic model developed in Caribbean Hispanics
89088816|NCT02635477|Experimental|Intervention Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with an actigraphy device that displays an adaptive personalized daily step count goal and audible alerts to increase physical activity
89088817|NCT02635477|Experimental|Control Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with a matching actigraphy device that has a blacked-out screen and does not display step count goals or provide audible alerts (functions in silent monitoring mode only)
89111075|NCT04234191|Active Comparator|Standard Induction|Day 1 is initiated when participants score 11 or above on the Clinical Opiate Withdrawal Scale (COWS), and when they have been abstinent from short-acting opioids for at least 6-12 hours or from long-acting opioids for 24-72 hours. On Day 1, participants will start with 2 or 4mg bup/nx SL. If their COWS score increases, bup/nx will be held. If their COWS score remains the same or decreases, additional dosing can be done in increments of 2mg bup/nx SL every 2 hours (Q2H) as needed (PRN). On Day 2, dosing will be consolidated to once daily dosing. The maximum total daily dose for Day 1 and 2 is 32mg.
89088818|NCT05139550|Experimental|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities Lift can, Lift pencil, Lift paper clip, Stack checkers, Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
89088819|NCT02635087||high risk group|"the miRNA tool predict this group of patients as high risk"
89088820|NCT02707198|No Intervention|Group A|Will receive prescribed antibiotics and will not receive kefir. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
89088821|NCT02707198|Active Comparator|Group B|Will receive prescribed antibiotics and will receive kefir only during hospital stay. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
89088822|NCT02707198|Active Comparator|Group C|Will receive prescribed antibiotics and will receive kefir during hospital stay and for the duration of the prescribed antibiotic regimen for up to a total of 30 days . Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
89088823|NCT04163497|Experimental|Diary reading|
89088824|NCT04163497|No Intervention|No diary reading|
89088825|NCT05208736||5-year nonsurvival or transplantation|Patients who died or underwent liver transplantation within 5 years since admission.
89088826|NCT05208736||5-year transplantation-free survival|Patients who survival without liver transplantation at 5 years since admission.
89088827|NCT02635165|Active Comparator|Surgical treatment with Stracos|The patient was placed in the lateral decubitus position. The procedure involved a curvilinear thoracic incision overlying the center of the fractured segments. The intercostal muscles were dissected off the rib on its superior aspect away from the fracture site, and the fracture was then reduced. The investigators then chose the most suitable Stracos, which is to be found in two available sizes, 6 or 9 claws, according to the length of the fracture. The clip chosen was molded according to the shape of the corresponding rib and the claws were crimped using special pliers on and around the fractured rib.The investigators treated only one rib out of two with Stracos, and as for displaced or comminuted fractures, the adjacent rib was wrapped using vicryl suture on the osteosynthesis rib.
89088828|NCT02635165|No Intervention|Medical treatment|
89088829|NCT01135524|Experimental|BTDS|Buprenorphine transdermal patch
89088830|NCT04165447|No Intervention|No labeling Control|Arm 1 was the Control condition, which did not display the label on any products.
89088831|NCT04165447|Experimental|Within-category labeling|Arm 2 displayed the label on the 20% of products that were lowest in calories per serving within each product category (termed Within-category Labeling, WC).
89088832|NCT04165447|Experimental|Across-category labeling|Arm 3 displayed the label on the 20% of all products that were lowest in calories per serving (termed Across-category Labeling, AC).
89088833|NCT00948675|Experimental|Pemetrexed + Carboplatin + Pemetrexed|Pemetrexed and Carboplatin followed by Pemetrexed
89088834|NCT00948675|Active Comparator|Paclitaxel + Carboplatin + Bevacizumab|Paclitaxel, Carboplatin, and Bevacizumab followed by Bevacizumab
89088835|NCT02850172|Experimental|Walk, eat, & breathe group|"Participants in the experimental group will receive Walk, Eat, & Breathe at initiation of CCRT and ends before curative surgery."
89088836|NCT02850172|No Intervention|Control group|Participants in the control group received usual care.
89088837|NCT02642497|Active Comparator|local ketamine group|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
89088838|NCT02642497|Placebo Comparator|control group|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
89088839|NCT02642497|Active Comparator|systemic ketamine group|Intra-muscular injection of ketamine at a dose of 1 mg/kg before wound closure.
89088840|NCT00911131|Active Comparator|Screening esophagoduodenoscopy (EGD)|"EGD will be performed utilizing conscious sedation. During EGD, the endoscopist will capture pictures of the esophageal body, Z-line, lower esophagus and proximal gastric folds. Grading of esophageal varices will be performed by all investigators using the Italian Liver cirrhosis project.~Patients who are found to have small grade varices and meet the inclusion and exclusion criteria will be enrolled in the study."
89088841|NCT00911131|Active Comparator|Capsule Endoscopy|The capsule endoscope will be swallowed by the participant with 100cc of water and simethicone in the supine position. Recording is done for 2 minute in this position and then the head will be elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient will sip10cc of water and after 15 seconds, they will sit upright and sip water again. They can then walk and resume normal activity for 15 minutes. The videos will be reviewed and graded by a gastroenterologist experienced with capsule endoscopy and will be blinded to the patient's clinical and procedural history as well as the most recent EGD. The varices will be graded using the Given Imaging software that grades varices as no varices (C0), small varices or < 25% of esophageal circumference (C1), and large varices or > 25% of esophageal circumference (C2).
89088842|NCT00911131|Active Comparator|Capsule Endoscopy with abdominal binder|Before swallowing the capsule endoscope, an inflatable girdle is wrapped around the waist above the umbilicus and held in place by a an abdominal binder. The pressure is increased by 10mmHg for 10 minutes. The PillCam ESO is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
89088843|NCT02857257|Experimental|Treatment arm|Only one treatment arm. Patients are allocated under disease condition and later treated with ACHIM. The post-treatment disease progression is monitored.
89088844|NCT00903370|Active Comparator|MVS|All participants will undergo mitral valve surgery with ligation/excision of left atrial appendage.
89088845|NCT00903370|Experimental|Ablation|Participants will undergo mitral valve surgery with ligation/excision of left atrial appendage plus surgical ablation with pulmonary vein isolation or biatrial lesion set.
89088846|NCT04273581|Placebo Comparator|Control group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. placebo：100mg/d，qn，for 14 days.
89088847|NCT04273581|Experimental|Thalidomide group|α-interferon： nebulized inhalation, 5 million U or equivalent dose added 2ml of sterile water for injection, 2 times a day, for 7 days； Abidol, 200mg / time, 3 times a day, for 7 days; Methylprednisolone： 40mg, q12h， for 5 days. thalidomide：100mg/d，qn，for 14 days.
89088848|NCT01110408|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
89088849|NCT01110408|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be dministered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefepime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
89088850|NCT02850328|Other|high-load resistance training for long term space flights|"Short duration electrical will be delivered and the resulting EMG will be recorded. Intensity of electrical stimulation will be progressively increased until we observed a maximal EMG response.~Finally an ultrasound probe (similar to that used for prenatal diagnostic imaging) will be fixed behind your calf in order to visualize muscle."
89088851|NCT00953043|Active Comparator|Lubiprostone|Subjects randomized to this arm received 24 micrograms of lubiprostone per day for three days.
89088852|NCT00953043|Placebo Comparator|Placebo|Subjects randomized to this arm received placebo medication for three days.
89088853|NCT02850484|Active Comparator|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
89088854|NCT02850484|Experimental|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
89088855|NCT02850484|Active Comparator|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
89088856|NCT02854917||Memantine Alone|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine for a period of 28 weeks."
89088857|NCT02854917||Memantine plus Individualized Management of AD|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine plus individualized management of AD for a period of 28 weeks."
89088858|NCT01135134|Experimental|Mometasone furoate nasal spray (MFNS) (50 μg spray device)|"The dose will be as follows:~5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
89088859|NCT01135134|Placebo Comparator|MF placebo nasal spray|"Administration will be as follows:~5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
89088860|NCT02850094|Experimental|Financial Bonuses|For two weeks following enrollment, subjects are monitored via their FitBit accelerometer to monitor their pre-intervention physical activity levels. For a twenty-four week period following the observational period, participants are eligible for financial bonuses based on their increased activity. Participants enroll as teams and are eligible for additional financial bonuses based on their team's performance.
89088861|NCT00948441|Experimental|Group 1|25% ethanol for 12 weeks; wash out period for 4 weeks; heparin lock for 12 weeks
89088862|NCT00948441|Experimental|Group 2|heparin lock for 12 weeks; wash out period for 4 weeks; 25% ethanol lock for 12 weeks
89088863|NCT02849860|Experimental|IDP-121 Lotion|Lotion
89088864|NCT02849782|Experimental|Fampridine responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine responder is a PwMS with an improvement in the judgment of the practitioner."
89088865|NCT02849782|Active Comparator|Fampridine non responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine non responder is a PwMS without any improvement in the judgment of the practitioner."
89088866|NCT00630903|Active Comparator|A|8-MOP + UVA x 24 weeks
89088867|NCT00630903|Active Comparator|B|IFN alone, 2 weeks, 8-MOP + UVA irradiation + IFN, 22 weeks
89088868|NCT02883426|Experimental|Group 1: H3N2v Seronegative Adults: H3N2v LAIV|Participants will receive one dose of H3N2v LAIV on Day 0 (study entry). They will then receive one dose of H3N2v IIV on Day 84.
89088869|NCT02883426|Experimental|Group 2: H3N2v Seropositive Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
89088870|NCT02883426|Placebo Comparator|Group 2: H3N2v Seropositive Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
89088871|NCT02883426|Experimental|Group 3: H3N2v Seronegative Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
89088872|NCT02883426|Placebo Comparator|Group 3: H3N2v Seronegative Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
89088873|NCT02883426|Experimental|Group 4: Children: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
89088874|NCT02883426|Placebo Comparator|Group 4: Children: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
89088875|NCT01238289|Placebo Comparator|Control group|This arm continues with standard care at community clinic
89226266|NCT04530292|Experimental|intervention by a pediatric nurse at the child's home|"The pediatric nurse will visit the patient's home 3 times during the first six months of the discovery of diabetes in children. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit can be organized according to the needs of families.~The pediatric nurse will ensure the implementation of learning in terms of drug therapy (modality of insulin administration, adaptation of insulin doses) and diet, according to the knowledge acquired during the initial hospitalization. She will offer her help to the families to make a connection with the school and after-school activities of the child.~In addition to these visits, the child and his family will come to the hospital as part of the regular medical follow-up: consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes."
89226267|NCT04530292|No Intervention|Classic strategy (for retrospective group)|The child and his family benefited from a consultation with a pediatric nurse at 1 month of the discovery of T1D and had medical consultations with the pediatric diabetologist at the 3rd and 6th month and at 1 year of the discovery of diabetes. The data from this group were collected in a previous study (collection of retrospective data) for children whose parents were in a precarious social situation and whose management was traditional.
89226268|NCT04526938|Experimental|Endovascular repair|Endovascular repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms including those secondary to aortic dissection using a physician-modified endovascular graft.
89226269|NCT04513366|Experimental|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase)~Other Names:~Pegadricase, pegsiticase Drug: SEL-110.36 (0.1 mg/kg) SEL-110.36, ImmTOR"
89226270|NCT04513366|Experimental|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase)~Other Names:~Pegadricase, pegsiticase Drug: SEL-110.36 (0.15 mg/kg) SEL-110.36, ImmTOR"
89226271|NCT04513366|Placebo Comparator|Placebo|Normal saline
89226272|NCT04505553|Experimental|Arm I (acupuncture, acupressure, cryotherapy)|Patients undergo acupuncture during chemotherapy infusion on day 1 and fluorouracil pump disconnect on day 3 of each biweekly chemotherapy infusion over 12 weeks. Patients also undergo self-administered acupressure over 11 minutes daily for 12 weeks and undergo standard of care oral cryotherapy.
89226273|NCT04505553|Active Comparator|Arm II (cryotherapy)|Patients undergo standard of care oral cryotherapy.
89088876|NCT01238289|Experimental|Peer Education|This group receives 8 weeks of peer led self management education classes and subsequent monthly support groups for a total of 10 months
89088877|NCT02849314|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89088878|NCT02849314|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89088879|NCT02849392|Experimental|Pistachio|Pistachio added 20% of kcals to diet
89088880|NCT02849392|No Intervention|No Pistachio|No pistachios in diet (control)
89088881|NCT02857023|Experimental|Cogmed intervention|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
89088882|NCT02857023|Experimental|Cogmed-waitlist control|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
89088883|NCT01207479|Experimental|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
89088884|NCT02849236|Placebo Comparator|Control group|PECS block performed with Saline solution instead of local anesthetic
89088885|NCT02849236|Experimental|PECS group|PECS block performed with Ropivacaine 3.75mg/mL
89088886|NCT02856789||Healthy volunteers (HV)|"HV without any known treatment, without any coagulation trouble and with normal hemostasis results.~FS and TEG will be processed to define the most relevant parameters for normal range and the correlation between both assays.~Tests performed on HV :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)~Specialized hemostasis tests"
89088887|NCT02856789||Patients without coagulation disorder|"Hospitalized patients without coagulation disorder or abnormal hemostasis and hematological results and witout ongoing treatment (mainly anticoagulant treatment). FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.~Tests performed on patients :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)"
89230240|NCT00793637||Surgical|Patients with proximal and/or distal tibial, femoral and/or humeral fractures treated with intramedullary nails and the Angular Stable Locking System(ASLS)
89230241|NCT00801593||Children with JIA|
89226274|NCT04504422|Experimental|Primary motor cortex|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
89226275|NCT04504422|Experimental|Left dorsolateral prefrontal cortex|The anodic electrode is positioned in the left dorsolateral prefrontal cortex (F3) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
89226276|NCT04504422|Experimental|Ventromedial prefrontal cortex|The anodic electrode is positioned in the ventromedial prefrontal cortex (Fpz) and the cathode electrode on the left dorsolateral prefrontal cortex (F4). The current increases to 2.0 mA over a period of 30 seconds, maintains 2.0 mA for 19 minutes, and decreases to 0 mA over 30 seconds.
89226277|NCT04504422|Sham Comparator|Sham stimulation|The anodic electrode is positioned in the primary motor cortex (Cz) and the cathode electrode on the right orbital frontal cortex (Fp2). The current increases to 2.0 mA during first 30 seconds, decreases to 0 mA over 30 seconds, and then stops supplying for 19 minutes.
89226278|NCT04502823|No Intervention|Control Group|"Clinical practice: Management by Doppler and CTG findings.~In women allocated to the control group, the sFlt-1/PlGF result will be blinded to caregivers. Routine Doppler-based clinical care will be used to counsel women. Following the Doppler classification:~Fetuses with an EFW below the 3rd centile or below the 10th centile accompanied by any impaired fetoplacental Doppler, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~Fetuses with an EFW above the 3rd centile without any fetoplacental Doppler abnormality, elective delivery will be recommended at at ≥40 weeks."
89226279|NCT04502823|Experimental|Intervention Group|Management based on sFlt-1/PlGF values
89226280|NCT04491136|Experimental|ACEI/ARB treatment in 6 months/ARNI treatment in next 6 months|"Angiotensin-converting enzyme inhibitor/Angiotensin receptor blockers treatment in the first 6 months~Angiotensin receptor neprilysin inhibitor treatment in next 6 months"
89226281|NCT04489199||Stroke patient|Patient included in the Dijon Stroke Registry.
89226282|NCT04487067|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)
89230242|NCT02554097||EST+LC group|Patients accept the management of endoscopic sphincterotomy and laparoscopic cholecystectomy.
89230243|NCT02554097||LCBDE+LC group|Patients accept the management of laparoscopic common bile duct exploration and laparoscopic cholecystectomy.
89088888|NCT02856789||Patients with coagulation disorders|"Hospitalized patients with coagulation disorders, mainly trauma patients or abnormal hemostasis and hematological results, mainly decreased fibrinogen level . FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.~Tests performed on patients :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)"
89088889|NCT02856711|Experimental|Trauma-informed group|These groups will use the enhanced Centering Pregnancy curriculum.
89088890|NCT02856711|No Intervention|Control group|These groups will use the standard CenteringPregnancy curriculum.
89088891|NCT04368676|Experimental|Sudarshan Kroya Yoga (SKY)|Sudarshan Kriya Yoga (SKY) will be delivered using the Hospital approved Cisco WebEx platform. The online version of SKY will be delivered by at least one certified Canadian SKY teacher, with at least one back up teacher, under the supervision of Ms. Ronnie Newman, Director of Research and Health Promotion, Art of Living Foundation, USA. The online version of SKY for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered.
89088892|NCT04368676|Active Comparator|Health Enhancement Program (HEP)|The Health Enhancement Program (HEP) will be delivered using the Hospital approved Cisco WebEx platform. The online version of HEP for healthcare workers has a total duration of 10.5 hours. This includes 3 interactive online sessions of 2.5 hours each during the first week followed by four weekly follow-up sessions each 30-45 minutes long. For ease of scheduling, multiple time windows will be offered. HEP will be taught by Dr. Paris Lai, co-investigator and senior psychiatry resident.
89088893|NCT01117350|Experimental|Insulin Glargine|"Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study.~The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 < FPG ≤ 100 mg/dL (3.9 < FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation."
89088894|NCT01117350|Active Comparator|Liraglutide|"Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study.~The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment."
89088895|NCT00952731|Experimental|oral placebo, afimoxifene|4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.
89088896|NCT00952731|Active Comparator|tamoxifen citrate, placebo gel)|Placebo gel applied to the breasts daily. 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules).
89088897|NCT04202224|Experimental|Study|Receives pre-emptive analgesia 30min. prior to third molar extraction. NSAID: Ibuprofen 400mg and Acetaminophen 500mg/
89088898|NCT04202224|Placebo Comparator|Placebo|Receives glucose tablets as pre-emptive analgesia 30min. prior to third molar extraction.
89088899|NCT04202224|Active Comparator|Control|Receives no medication prior to third molar extraction.
89088900|NCT02848690|Experimental|Educational Intervention Group|Participants assigned to the educational intervention group will have dietitian consultation to receive a dietary planning based on diet rich of fruits, vegetables, low fat, low processed foods and high nonfat dairy. During six months they will have monthly dietitian appointments including educational sessions to stimulate sodium restriction and enhance to follow the dietary planning. Each 15 days they will be contacted by phone to reinforce adherence to sodium restriction diet.
89230244|NCT02554097||LTCBDE+LC group|Patients accept the management of laparoscopic transcystic common bile duct exploration and laparoscopic cholecystectomy.
89088901|NCT02848690|Sham Comparator|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
89088902|NCT00947427|Placebo Comparator|Placebo|Placebo solution given by subcutaneous injection on monthly basis for 12 months
89088903|NCT00947427|Experimental|Canakinumab|Subcutaneous injection of canakinumab at dose of 2.0 mg/kg given monthly of 12 months
89088904|NCT04811404|Experimental|Ethyl eicosapentaenoic acid|Ethyl eicosapentaenoic acid will be given at 1G by mouth twice per day
89088905|NCT01116882|Active Comparator|SOS|Patients randomized to the SOS arm are transferred to tertiary hospitals for their PCI procedure.
89088906|NCT01116882|Experimental|Non-SOS|Patients in the non-SOS arm are randomized to stay at the community hospitals for their PCI procedure.
89088907|NCT02054013|Experimental|Prostatic artery embolization|Prostatic artery embolization (PAE) has been suggested as a minimal invasive alternative procedure with rapid recovery and low morbidity
89088908|NCT02054013|Other|Conventional monopolar transurethral prostatectomy|Standard treatment
89088909|NCT02848846|Experimental|Robotic Hand|The two patient enrolled will perform the task requiring the use of the robotic hand.
89088910|NCT02850562|Active Comparator|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
89230245|NCT00793715|Active Comparator|1|Decompressive laparotomy with temporary abdominal closure
89226283|NCT04485104|Experimental|GWP42003-P|"The 52-week treatment period includes a fixed 2-week titration schedule followed by flexible dose optimization.~Day 1: 5 mg/kg/day (2.5 mg/kg twice daily (b.i.d.))~Day 8: 10 mg/kg/day (5 mg/kg b.i.d.)~Day 15 to Week 52: Flexible dosing based on the participant's observed efficacy, safety, and tolerability per the investigator's clinical judgement. Up to a maximum of 20 mg/kg/day (10 mg/kg b.i.d.) for LGS and DS or 25 mg/kg/day (12.5 mg/kg b.i.d.) for TSC, in maximum weekly increments of 5 mg/kg/day (≤ 2.5 mg/kg b.i.d.)."
89226284|NCT04474509|Experimental|FACT Module Engagement|During this module, patients will have the opportunity to increase their motivation to change and encourage the engagement in committed actions, consistent with their life values. Patients are invited to reflect on what is important in their lives, which values make their life worth living, and which actions they could take to live a meaningful life, in accordance with personal values. The use of metaphors and experiential exercises will facilitate the process of exploring personal values, identifying life directions and related behaviors. For example, the 80th Birthday Party metaphor requires participants to imagine there is a party in honor of their birthday and the time comes when people are starting to give speeches and try to answer the question about what they want to hear people at the party say. This exercise help patients in wondering what person they want to be with themselves and others.
89226285|NCT04474509|Experimental|FACT Module Openness|"Participants attending this module are guided to recognize and distancing themselves to stressful thoughts, feelings and sensations. They will learn to read suffering as part of human experience, without self-judgment and self-condemnation. Rather, therapist will encourage the patient's assumption of an open and acceptable approach to internal experiences. Throughout the module, therapist will help patients to reflect on their usual, but ineffective efforts to solve personal problems, and encourage the adoption of new responsive strategies based on acceptance and defusion from personal distress.~An example of metaphor used during the Module is The Passenger on a bus. In this metaphor patient have to imagine to be a driver bus and his every thought is a passenger that gets on and off the bus. This exercise help patients to accept, defuse from, and reduce the power of their thoughts."
89226286|NCT04474509|Experimental|FACT Module Awareness|The module comprises meditation exercises and experiences aimed to learn how to act intentionally with awareness about personal thought and sensations without automatically reacting. Participants are supported to recognize their actions and the context where they occur and learn to choose to respond with action consistent with their values and not automatically. Therapist will propose breathing exercises, body scan and others mindfulness experiences. Participants will be encouraged to sitting comfortably, close the eyes, feel themselves in contact with the present moment they are living, paying attention to their breath, noticing the rhythm and any other aspect of the experience of breathing. Then, the therapist guides the participant's attention on the body, noting any part of their body from the head to feet. Then, the sounds around, any noises that could distract their attention on themselves.
89226287|NCT04473820|Active Comparator|Vapocoolant spray|Patients in this arm will receive vapocoolant spray before IV cannulation.
89226288|NCT04473820|Active Comparator|Lidocaine-Prilocaine cream|Patients in this arm will receive Lidocaine-Prilocaine cream before IV cannulation.
89523129|NCT01964807|Experimental|Nonsmokers|Will undergo secondhand cigarette smoke (SHS) exposure and conditioned, filtered air exposure. Each intervention will last 180 minutes, and each will take place one time, on one of 2 study visits, in random order.
89523130|NCT01964807|Experimental|Smokeless tobacco users|Will use 1 pouch of commercially available moist oral snuff and will chew gum (sham moist snuff). Each intervention will last 30 minutes, and each will take place one time, on one of 2 study visits, in random order.
89226289|NCT04467658||ADHD|
89226290|NCT04467658||NT NeuroTypical|
89226291|NCT04467658||ADHD NOS|
89226292|NCT04467593|Experimental|Cohort A1|Three patients with advanced solid cancer will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15)
89226293|NCT04467593|Experimental|Cohort A2|One patient with advanced solid cancer will receive 3 hyperthermia treatments of 4 hours per treatment. The next patient with advanced solid cancer will receive 3 hyperthermia treatments of 6 hours per treatment.
89226294|NCT04467593|Experimental|Cohort B|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (2 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
89226295|NCT04467593|Experimental|Cohort C|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (4 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
89226296|NCT04467593|Experimental|Cohort D|Three pancreatic cancer patients will be subjected to three hyperthermia treatments (6 hours duration per treatment) alone (1st treatment) or in combination with (2nd and 3rd treatment) Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
89226297|NCT04455503|Experimental|Cohort A: Nivolumab and EVX-02A|EVX-02A administered IM.
89226298|NCT04455503|Experimental|Cohort B: Nivolumab and EVX-02B|EVX-02B administered IM.
89226299|NCT04455503|Experimental|Cohort C: Nivolumab and EVX-02A OR Nivolumab and EVX-02B|The selected delivery methodology either EVX02A or EVX-02B.
89226300|NCT04452149|Placebo Comparator|Observation Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed per standard of care for heart failure management without visibility to the heart failure sensor data. Subjects will transition to the intervention arm after 13 months.
89226301|NCT04452149|Experimental|Intervention Arm|Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed using an integrated device diagnostic-based risk stratification algorithm combined with a clinical medication plan.
89226302|NCT04449497||Bereaved caregivers|Caregivers who, in the past two years,have lost a family member or close friend after a brief or extended period of illness or injury
89226303|NCT04449497||Country experts|Qualified individuals (providers, palliative care experts, policy makers) from countries across the globe with knowledge of the phenomenon of interest-end-of-life care.
89226304|NCT04447313|Experimental|Arm I (ACT)|Participants receive ACT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
89226305|NCT04447313|Active Comparator|Arm II (SBT)|Participants receive SBT telephone coaching over the course of 12 months, calls 1-16 weekly, calls 17-23 biweekly, and calls 24-25 monthly. Call 1 is 30 minutes in duration, while calls 2-25 are each 15-20 minutes in duration.
89226306|NCT04447027|Experimental|1- Experimental Treatment: Dose Escalation|Lenalidomide by oral intake at escalating doses of 5, 10, 15, or 20 mg/day on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle, to determine MTD
89226307|NCT04447027|Experimental|2 - Experimental Treatment: Dose Expansion|Lenalidomide by oral intake at MTD on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle
89226308|NCT04440176|Experimental|Group 1 (MenABCWY 0-, 12-months)|MenABCWY administered at Month 0 and Month 12
89226309|NCT04440176|Experimental|Group 2 (MenABCWY 0-, 36-months)|MenABCWY administered at Month 0 and Month 36
89226310|NCT04439838|Experimental|1 mg BI 1595043|1 mg BI 1595043
89226311|NCT04439838|Experimental|3 mg BI 1595043|3 mg BI 1595043
89226312|NCT04439838|Experimental|6 mg BI 1595043|6 mg BI 1595043
89226313|NCT04439838|Experimental|12 mg BI 1595043|12 mg BI 1595043
89226314|NCT04439838|Experimental|25 mg BI 1595043|25 mg BI 1595043
89226315|NCT04439838|Experimental|50 mg BI 1595043|50 mg BI 1595043
89226316|NCT04439838|Experimental|90 mg BI 1595043|90 mg BI 1595043
89226317|NCT04439838|Experimental|160 mg BI 1595043|160 mg BI 1595043
89226318|NCT04439838|Placebo Comparator|Matching Placebo|Matching Placebo
89226319|NCT04432584|Experimental|Arm A (Crovalimab)|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
89226320|NCT04432584|Active Comparator|Arm B (Eculizumab)|Participants will receive an approved maintenance dose of eculizumab starting on Day 1 and Q2W (every 2 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of study eculizumab treatment, participants will have the option to switch to crovalimab or to discontinue from the study after completion of 10 weeks of safety follow-up.
89226321|NCT04432584|Experimental|Arm C (Crovalimab) (Exploratory)|Participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
89226322|NCT04431024||Cancer patients|Individuals with history of cancer and detected or suspected germline mutation in BAP1 TPDS
89226323|NCT04431024||Relatives of cancer patients|First- or second-degree relatives of a cancer patient (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)
89230246|NCT00793715|Active Comparator|2|Patients who will receive percutaneous puncture with placement of abdominal catheter
89230247|NCT00801671|Active Comparator|1|
89230248|NCT00801671|Sham Comparator|2|
89230249|NCT04045925|Experimental|Taïso practice|6 months of biweekly practice Taïso
89088911|NCT02850562|Experimental|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
89088912|NCT02856477|Experimental|adapted treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
89088913|NCT02856477|Experimental|non-adaptated treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
89088914|NCT04235062|Experimental|Fluid Expansion and Diuretic Challenge|Subject receive intravenous infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution, followed by diuretic challenge with 40mg Furosemide intravenous bolus.
89088915|NCT02848456|Active Comparator|Spinal Manipulation SM|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
89088916|NCT02848456|Active Comparator|Max Voluntary Isometric Contraction MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
89088917|NCT02848456|Active Comparator|SM+MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
89088918|NCT02283255|Active Comparator|Aerobic Exercise Training Group|Aerobic Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months.
89088919|NCT02283255|Active Comparator|Inspiratory Muscle Training Group|Respiratory Training: muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
89088920|NCT02283255|Active Comparator|No Exercise Trainint Group|No Physical Activity: Control group (usual care)
89088921|NCT02848144|Other|Children with infectious shock|Children aged from 1 month to <18 years. In 3 stratified groups : <2 years, 2-8 years, and >8 years. About one third of the patients are expected in each age-group.
89088922|NCT02848144|Other|Control group: healthy children|Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.
89088923|NCT02848300|Experimental|All Participants|Bimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days.
89088924|NCT02848378||Chronic periodontitis group|Subjects who have moderate to severe alveolar bone loss and clinical attachment level (CAL) ≥5 mm and probing depth (PD) ≥6mm in multiple sites of all four quadrants of the mouth but with no evidence of rapid progression
89088925|NCT02848378||Gingivitis group|Subjects who show gingival inflammation that is based on the presence of bleeding on probing (BOP) at >50% of sites in the whole mouth, no clinical and radiographic signs of periodontitis
89088926|NCT02848378||Periodontally healthy group|Subjects who have no sites with PD >3mm and CAL >0 mm, a BOP score of <15% at the examination and no alveolar bone loss.
89088927|NCT00953745|Active Comparator|Depressed Participants|"Subjects with treatment-resistant depression (TRD) will be administered the Hamilton Depression Rating Scale (HAM-D 17) for entry and will receive escitalopram combined with an adjunctive placebo capsule for 8 weeks.~Subjects who fail to respond will continue to receive escitalopram and additionally change to receive a placebo tablet resembling the active augmentation agent Aripiprazole (ARP) for 2 weeks.~Subjects who fail to respond to escitalopram after the 2 phase placebo treatment will enter the ARP augmentation phase of the study and will receive escitalopram augmentation with ARP.~Subjects will have 3 neuroimaging scans: F-DOPA PET, raclopride PET, and functional MRI conducted after 10 weeks of treatment and repeated after 6 weeks of ARP treatment."
89088928|NCT00953745|No Intervention|Control Participants|Non-depressed, age- and sex-matched subjects without a DSM-IV Axis I diagnosis will serve as controls. They will not receive antidepressant, ARP, or any drug augmentation and will be used as quality control to compare the pre-ARP and post-ARP treatment brain images.
89088929|NCT02847910|Experimental|experimental group|device： High-tech disposable tissue suction set for uterine cavity tissue is produced by Xi'an Mejiajia Medical Equipment Company ; The participants will be use the disposable tissue suction set during the induced abortion procedure.
89088930|NCT02847910|Experimental|control group|device： Traditional metal instruments for induced abortion procedure; The participants will be use traditional metal instruments during induced abortion procedure.
89088931|NCT02848066||Gastric Cancer patients|This arm is composed of the gastric cancer patients. It is perfomed a blood sampling to them after the research registration.
89088932|NCT02848066||Cancer-free healthy volunteers|This arm is composed of the cancer-free healthy volunteers. It is perfomed a blood sampling to them after the research registration.
89088933|NCT04202380|Other|Azithromycin 1 day group|Patients will receive Azithromycin 1000mg once orally
89088934|NCT04202380|Other|Azithromycin 5 days group|Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days
89230250|NCT02553785|Experimental|Revivent TC|Surgical treatment of left ventricle using the Revivent TC System
89230251|NCT00794027|Other|Yoga group|Patients with heart failure
89088935|NCT04067674||Septic shock patients|Patients included in this cohort will have blood sampling for measurement of immune related biomarkers (immunophenotyping, functional tests, messenger ribonucleic acid (mRNA), circulating markers) in circulating blood and their associations with relevant clinical outcomes
89088936|NCT02847988|Active Comparator|Neuro-muscular electrical stimulation|"Intervention:Neuromuscular electrical stimulation (NMES)~NMES stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering NMES"
89088937|NCT02847988|Sham Comparator|Sham stimulation|"Intervention: sham stimulation~Sham stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering sham-NMES"
89088938|NCT02167048|Experimental|Normal-dose Psychostimulant, Low-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
89088939|NCT02167048|Active Comparator|Low-dose Psychostimulants, Normal-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
89088940|NCT02167048|No Intervention|No intervention, No intervention|This arm is completely no intervention, and is ONLY for healthy volunteers. We are testing healthy volunteers of the same age to give us an estimate of order effects to help us correct for better performance in the 2nd session due simply to taking the same tests twice (note: the tests are Version A and B).
89088941|NCT02847754|Experimental|A|A patients in arm A carry out daily physical Training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home. exercise tailored isometric physical exercise
89088942|NCT02847754|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min progressive muscle relaxation starting from day one of radiotherapy.
89088943|NCT02075710|Experimental|High sugar/meal feed|Diet high in simple sugar fed as two large meals daily
89088944|NCT02075710|Experimental|High sugar/nibble|Diet high in simple sugar fed as 8 small meals daily
89088945|NCT02075710|Experimental|High fat/meal feed|Diet high in fat fed as two large meals daily
89088946|NCT02075710|Experimental|High fat/nibble|Diet high in fat fed as 8 small meals daily
89088947|NCT02075710|Experimental|High sugar/3 meals a day|Diet high in simple sugar fed as 3 meals a day
89088948|NCT02075710|Experimental|High fat/ 3 meals a day|Diet high in fat fed as 3 meals a day
89088949|NCT02847442|Experimental|Opicapone (BIA 9-1067) 50 mg|Total duration of trial participation and treatment: three months. All subjects will start treatment with 50 mg opicapone (OPC) once daily for a 3-month period in addition to their current treatment with levodopa/dopa decarboxylase inhibitor (L-dopa/DDCI)
89088950|NCT04736602|Experimental|Triptorelin Pamoate 15mg for injection|"Triptorelin will be injected at day 1 and month 3.~If participants are willing to enter extension phase, two additional Triptorelin injections will be given at month 6 and month 9."
89088951|NCT01698658|Experimental|Diagnostic (SoftVue ultrasound tomography)|Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.
89088952|NCT02847676||No previous surgery, adhesions present.|Patients have had no previous abdominal surgery. Inspection shows peritoneal adhesions.
89088953|NCT02847676||No previous surgery, no adhesions present.|Patients have had no previous abdominal surgery. Inspection shows no peritoneal adhesions.
89088954|NCT02847676||Previous surgery, adhesions present.|Patients have had previous abdominal surgery. Inspection shows peritoneal adhesions.
89088955|NCT02847676||Previous surgery, no adhesions present.|Patients have had previous abdominal surgery. Inspection shows no peritoneal adhesions.
89088956|NCT04710706|Active Comparator|Water-alone colonoscopy (water exchange technique)|During water-alone colonoscopy, gas insufflation (air or CO2) is not allowed during the insertion of the colonoscope to the caecum. Instead, water is used to facilitate the passage of the scope to the caecum. On withdrawal, CO2 is permitted.
89088957|NCT04710706|Active Comparator|Water-CO2 hybrid colonoscopy (modified water immersion technique)|During water-CO2 hybrid colonoscopy, the operator has access to both water and CO2. In the left colon, predominately water is used to navigate the sigmoid. Once the splenic flexure is reached, a combination of water and CO2 is used to reach the caecum. On withdrawal, CO2 is permitted.
89230252|NCT00798239|Active Comparator|Control|The control arm is Iliac Crest Autograft
89230253|NCT00798239|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
89230254|NCT00798239|Experimental|Prefix 750|Prefix (AMPLEX) B2A Enhanced Ceramic Granules
89088958|NCT02847208||cystic fibrosis women|It was a cohort of 155 CF women attending the Lyon adult centre. Women attending the CF adult centre in 2014 completed a written questionnaire about their contraceptive choices, frequency of gynaecological follow-up and cervical screening. Other clinical data were collected from the CF adult centre registry.
89088959|NCT01551550|Experimental|GDD & Amniotic Membrane Graft|After GDD implantation, amniotic membrane graft (AmnioGuard™, Bio-Tissue inc, Miami, FL) is used to cover the GDD tube.
89088960|NCT01551550|Active Comparator|GDD & Pericardial Graft|After GDD implantation, a pericardial graft (Tutoplast®, IOP Inc, Costa Mesa, CA) is used to cover the GDD tube.
89088961|NCT01478698|Experimental|Single dose|The first 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled into a dialysate bag and infused for a 4 hour intraperitoneal dwell.
89088962|NCT01478698|Experimental|2 doses|The next 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled twice a day for one day
89230255|NCT00798395|Experimental|Treatment 1|
89226324|NCT04427137|Experimental|Accelerated LFR|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients that have responded to treatment will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
89226325|NCT04424927|Experimental|PRV-015 Low Dose|PRV-015 Low Dose, sterile solution for subcutaneous administration
89226326|NCT04424927|Experimental|PRV-015 Medium Dose|PRV-015 Medium Dose, sterile solution for subcutaneous administration
89226327|NCT04424927|Experimental|PRV-015 High Dose|PRV-015 High Dose, sterile solution for subcutaneous administration
89088963|NCT01478698|Experimental|4 doses|The next 5 consented participants will be administered tPA 10mg + DNase 5mg twice a day for 2 days.
89088964|NCT01478698|No Intervention|control|Any potential participants that have not consented into the intervention arms will be approached to be consented into a non-intervention observational control group. A maximum of 5 participants will be recruited into this control group.
89088965|NCT04968340|Other|• Group 1(conventional c s)|this arm will be exposed to the conventional method of cesserian section which entail introduction of the operator hand below the fetal head during its extraction
89088966|NCT04968340|Other|• Group2(EPO technique)|this group will be exposed to external pop out teqnique which entails support of lower uterine segment without introduction of the obstetrician hand into uterine incision
89088967|NCT04216498||Pre-Transfer Patients aged 10-16 years|
89088968|NCT04216498||Post-Transfer Patients aged 16-25 years|
89088969|NCT04216498||Parents/Guardians of Pre-Transfer Patients|
89088970|NCT00902746|Experimental|NPC-01|Norethisterone, Ethinyl Estradiol
89088971|NCT00632710|Experimental|b|laser
89088972|NCT00632710|Placebo Comparator|a|laser placebo
89088973|NCT01331668||renal allograft donors and recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven
89088974|NCT01199380|Active Comparator|Standard Treatment (ST)|Participants will receive a standard, group smoking cessation treatment equated for contact time, based on the most recent clinical practice guideline for treating tobacco. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will complete between group exercises and will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events. Participants will also receive 8 weeks of the transdermal nicotine patch.
89088975|NCT01199380|Experimental|Behavioral Activation for Smoking|Behavioral Activation Treatment for Smoking (BATS) includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Participants will also receive 8 weeks of the transdermal nicotine patch.
89088976|NCT02847286|Active Comparator|Treatment A|Dapivirine Ring-004 for 28 days
89088977|NCT02847286|Active Comparator|Treatment B|Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
89088978|NCT02847286|Active Comparator|Treatment C|Clotrimazole, 5 g per day for 7 days
89088979|NCT04215874||Dorsal penile nerve block group|"Ultrasound (US) guided dorsal penile nerve block with in plane technique was done.~Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis."
89088980|NCT04215874||Caudal epidural block group|A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed 0.25% bupivacaine at a dose of 0.2 ml/kg was administered.
89226328|NCT04424927|Placebo Comparator|Placebo|Placebo, sterile solution for subcutaneous administration
89226329|NCT04421573|Experimental|BCPHD-D5W with usual care|"Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, and 8 weeks.~All helpful treatment methods already underway are continued. Other new treatment methods are discouraged."
89226330|NCT04421573|Active Comparator|Waiting period with usual care|All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
89226331|NCT04418414|Experimental|Autologous HSCT CD68-ET3-LV gene therapy|G-CSF/Plerixafor mobilization and apheresis will be used for collection of hematopoietic stem cells and subjects will receive transplantation of autologous CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector encoding the human factor VIII gene.
89226332|NCT04417803|Other|diffuse large B-cell lymphoma|
89226333|NCT04417803|Other|follicular lymphoma|
89226334|NCT04417803|Other|Hodgkin's lymphoma|
89226335|NCT04411823|Experimental|Intervention arm|Undergo an upper endoscopy with EndoFLIP at baseline before sleeve gastrectomy
89226336|NCT04403022|Other|Single arm|Colorectal procedure will be performed by da Vinci SP® Surgical System
89226337|NCT04397185|Experimental|Breast Cancer Locator (BCL)|Subject randomized to BCL surgical guidance to perform partial mastectomy
89226338|NCT04397185|Active Comparator|Wire Localization (WL)|Subject randomized to WL surgical guidance to perform partial mastectomy
89088981|NCT00902668|Experimental|Supportive care (lovastatin)|Patients undergo 25-28 fractions of standard whole-breast irradiation followed by a boost to the tumor bed or 10 fractions of accelerated partial-breast irradiation with balloon brachytherapy BID over 5-10 days. Patients also receive lovastatin PO QD for 12 months beginning on day 1 of radiation therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
89088982|NCT02846662|Experimental|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an applicative for smartphones (CONEMO), which encourages them to be more active and to incorporate more activities in their everyday life.~Primary care nurses will train participants to use the CONEMO app, monitor patients' adherence to CONEMO, calling patients when they are non-adherent, and give technical support when necessary. They will be supervised by clinical psychologists.~Primary care teams are informed of participants' depression level and deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication."
89088983|NCT02846662|No Intervention|ENHANCED USUAL CARE|The primary care teams are informed of the participants' depression level and can deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication. This is considered enhanced usual care because the teams are notified about participants' level of depressive symptomatology, which otherwise might go undetected, and then decide about the best way to handle with patients' needs related to their depressive symptomatology.
89088984|NCT02846818|Experimental|Low mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were randomized to usual range MAP (40 to 60 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
89088985|NCT02846818|Experimental|High mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were blindly randomized to intervention group MAP (60 to 80 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
89088986|NCT02846584|Experimental|CD19 or CD20 CAR T cells briging HSCT|lentiviral transfection and transfuse anti-CD19 or anti-CD20 CAR T cells into patients. Six months later, select appropriate patients to transplant hemopoietic stem cells.
89088987|NCT04835038|Experimental|Sodium Bicarbonate Ringer's Injection group|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
89088988|NCT04835038|Active Comparator|Sodium Lactated Ringer's Injection group|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
89230256|NCT00798395|Experimental|Treatment 2|
89230257|NCT00798395|Placebo Comparator|Treatment 3|
89088989|NCT03856918|Experimental|PEEP 3 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 3 cm of water during thoracic surgery.
89088990|NCT03856918|Experimental|PEEP 6 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 6 cm of water during thoracic surgery.
89088991|NCT03856918|Experimental|PEEP 9 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 9 cm of water during thoracic surgery.
89088992|NCT04201912|Placebo Comparator|control patients|Evaluation of Toll like receptor activity from whole saliva obtained from control patients
89088993|NCT04201912|Active Comparator|Periodontal patients without diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients without diabetes
89088994|NCT04201912|Active Comparator|Periodontal patients with diabetes|Evaluation of toll like receptor activity from whole saliva obtained from periodontal patients with diabetes
89088995|NCT02850952|Experimental|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
89088996|NCT03678766|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experimental learning.
89088997|NCT03678766|Experimental|Cognitive Behavior Therapy (CBT)|CBT provides coping skills, self-monitoring, and goal setting.
89088998|NCT02850796|Experimental|Kg-Free|Kg-free is a manualized acceptance, mindfulness & compassionate-based group intervention for women struggling with their weight. It comprises 10 weekly group sessions plus 2 booster fortnightly sessions (31/2months) 2h30 hours each, run in small groups (ranging from 10 to 12 participants).
89088999|NCT02850796|Other|Treatment as Usual (TAU)|nutritional treatment for weight loss in primary care units and Hospitals from Coimbra's district that includes dietary and physical activity support
89089000|NCT04802200||Patients operated from minimally invasive cardiac surgery|Patients operated between December 16, 2019 and june 30, 2021 from minimally invasive cardiac surgery with femoral cannulation for cardiopulmonary bypass in Dijon University hospital and in whom the MANTA device has been used for femoral artery closure
89089001|NCT03630562|Other|Patients with exudative AMD|
89089002|NCT04801030|Experimental|Culturally-appropriate social marketing campaign|Participants will receive a multi-layered, social marketing campaign which is deemed culturally appropriate. This will occur over a 6 month -time period. Rates will be observed at 0, 6, and 12 months.
89089003|NCT04801030|No Intervention|Control Arm 1|Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
89089004|NCT04801030|No Intervention|Control Arm 2|Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
89089005|NCT04202068|Experimental|Ceftriaxone sodium and Sulbactam Sodium for injection|combinations of β-Lactamase inhibitors
89089006|NCT05012644||Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
89089007|NCT05012644||Aromatase inhibitor alone|Aromatase inhibitor alone
89089008|NCT02846506|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with 1 Extended Release (XR) tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin (XR) 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89089009|NCT02846506|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89089010|NCT02846506|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89089011|NCT02846506|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89089012|NCT02846428|Active Comparator|5-Fluorouracil + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of 5-FU + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
89089013|NCT02846428|Experimental|Capecitabine + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of capecitabine + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
89226339|NCT04392622|Experimental|d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
88821338|NCT04447703|Active Comparator|Aim II: Arm I (Genetic Counseling, Genetic Testing)|Patients receive genetic counseling with a certified genetic counselor in-person, by telehealth, or over the phone (according to patient preference). Patients may then undergo genetic testing.
89089014|NCT03568084|Experimental|MEFAP|MEFAP (multicomponent physical activity program) for 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
89089015|NCT03568084|Active Comparator|Control: usual practice|No intervention. Individuals allocated to this arm, will be look after as usual in their health Centers.
89089016|NCT04368130|Experimental|SIGNAL|"Program to explore the feasibility and acceptability of a smartphone-based real-time behavioral anomaly detection system (SIGNAL).~Patients will download the adapted Beiwe app onto their smartphones for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
89089017|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
89089018|NCT00947349|Experimental|BI 201335 NA low TN|patient to receive a capsule containing low dose of BI 201335 NA/Drug for treatment-naive (TN) patients
89089019|NCT00947349|Experimental|BI 201335 NA high TN|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-naive (TN )patients
89089020|NCT00947349|Experimental|BI 201335 NA high TE|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-experienced (TE) patients
89089021|NCT00947349|Placebo Comparator|Placebo in Treatment Naive (TN) Patients|
89089022|NCT02846194|Experimental|brief guided imagery|The study group of our research will go through six Brief Guided Imagery sessions. These sessions will be completed within two months and will last one hour each.
89089023|NCT02846194|No Intervention|control group|
89089024|NCT02844556|Other|SMILE surgery|Small incision lenticule extraction (SMILE) has become a novel and effective method for the correction of myopia and myopic astigmatism. It is a micro-invasive and flapless refractive procedure that has been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
89089025|NCT02844556|Other|FS-LASIK surgery|FS-LASIK surgery is femtosecond laser assisted- conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
89089026|NCT02846116|Active Comparator|lithium disilicate|The intervention will be: Prosthetic crown
89089027|NCT02846116|Active Comparator|Vita suprinity|The intervention will be: Prosthetic crown
89089028|NCT00947193|Experimental|Ataluren Overall Study|Ataluren was provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren was taken 3 times per day, with dosing based on the participant's body weight. The dose level for ataluren was 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening or 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by an interval of 14 days without treatment.
89089029|NCT03425812|Experimental|Non- NSAIDS group|To withdraw NSAIDS therapy
89089030|NCT03425812|Active Comparator|NSAIDS group|To continue NSAIDS therapy
89089031|NCT00947115|Experimental|Cervarix 15-25 years group|Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
89089032|NCT00947115|Experimental|Cervarix 26-45 years group|Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
89089033|NCT00947115|Experimental|Cervarix 46-55 years group|Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
89089034|NCT02845804||Alpine|The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™
89089035|NCT02845960||Experimental group|rapid recovery
89089036|NCT02845960||Controlled group|no rapid recovery
89089037|NCT02844634|Experimental|Immediate doxycycline 100mg PO daily|"Individuals will receive tenofovir/emtricitabine one tablet daily in an open-label fashion.~Subjects are randomized to immediate (12 months duration) doxycycline 100mg PO daily."
89089038|NCT02844634|Active Comparator|Deferred doxycycline 100mg PO daily|Individuals will receive daily tenofovir/emtricitabine one tablet daily and will begin doxycycline 100mg PO daily after 6 months for a total duration of 6 months
89089039|NCT02844478|Active Comparator|SBP ENGLISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in English
89089040|NCT02844478|Experimental|SBP SPANISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in Spanish
89089041|NCT02844166|Experimental|viscoelastic group|viscoelastic surface support
89089042|NCT02844166|Active Comparator|pyramidal foam group|pyramidal foam surface support
89089043|NCT03337906||Participants infected with HIV-1|Persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
89089044|NCT00952419|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
89089045|NCT00952419|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
89089046|NCT00952419|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
89089047|NCT02000037|Active Comparator|Dietary care|Treatment is composed of a dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille).
89089048|NCT02000037|Experimental|IR reflexotherapy + dietary care|"Treatment is composed of :~IR reflexotherapy sessions given by a trained professional ;~dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille)."
89089049|NCT02000037|Experimental|IR Reflexotherapy|Treatment is composed of IR reflexotherapy sessions given by a trained professional.
89089050|NCT00902278|Active Comparator|Flulaval|
89089051|NCT00902278|Active Comparator|Fluvirin|
89089052|NCT00902278|Active Comparator|Fluzone|
89089053|NCT00902278|Active Comparator|Fluarix|
89089054|NCT00902278|Active Comparator|Affluria|
89089055|NCT02854293||Booklet-Question List (BQL) group|76 patients
89089056|NCT02854293||control group|"Conventional palliative management~76 patients"
89089057|NCT02845726||Patients with temporary ureteral stent|Assessment of patients transiently undergoing ureteral stenting.
89089058|NCT02844322|Experimental|Bortezomib|Patients in this group will receive bortezomib+ cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to RCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
89089059|NCT02844322|Experimental|rituximab|Patients in this group will receive rituximab+cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to BCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
89089060|NCT01998633|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
89089061|NCT02845570|Experimental|68Ga-DOTANOC PET/MRI|Comparison between 68Ga-DOTANOC PET/MRI and 18F-FDG PET/MRI scans
89089062|NCT02844400||Adjuvant and Curative Chemotherapy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with adjuvant or curative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
89089063|NCT02844400||Palliative Chemoteraphy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with palliative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
89089064|NCT03097276|Other|Patients who underwent open decompression surgery|
89089065|NCT01987635|Experimental|MEMO 3D anuloplasty ring|MEMO 3D anuloplasty ring
89089066|NCT01987635|Active Comparator|rigid ring|rigid ring
89089067|NCT05337904|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on"
89089068|NCT05337904|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
89089069|NCT02854137|Experimental|Sunscreen / Arm 1|Subjects will be escorted to a separate room for instillation of the test materials. Test materials will be instilled in immediate succession and with a randomized order of presentation. A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the eyes of the subject forming sacs in the conjuntival tissue, apply one test product to one eye.
89089070|NCT02854137|Other|Control|A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the other eyes of the subject forming sacs in the conjuntival tissue, apply control materials to this eye, follow the same procedure, using a new pipet tip or steriled dropper.
89089071|NCT00630981||Intervention group|"Combined psychotherapy and pharmacological treatment~Open single arm 'pilot' clinical trial in patients with dissociative disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan Psychotherapeutic Center in Montreux.~Patients will be interviewed according to the Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered."
89089072|NCT05243134||Study Group|Patients with at least one type of anatomic deformity
89089073|NCT05243134||Control group|Patients without anatomic deformity
89226340|NCT04392622|Experimental|d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
89089074|NCT02854371|Experimental|CLD and LC|Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.
89089075|NCT02845180|Experimental|3 Mo. Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 3 months.
89089076|NCT02845180|Experimental|6 Month Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 6 months.
89089077|NCT02845414|Experimental|Intravenous Infusion of dCD133KDEL|
89089078|NCT02845492|Experimental|Qigong intervention|Qigong meditative exercise intervention meets three times a week for 10 weeks. The qigong group (n=30) will meet at the Women's Medicine Collaborative, Miriam Hospital (146 W. River St., Providence, RI) for Qigong classes. The lesson will be taught by a validated Qi Gong master with over forty years of experience and the interventional protocol will be validated. Two and a half hours of weekly outside personal practice will also be required of participants.
89089079|NCT02845492|Active Comparator|CHIP healthy wellness-exercise class|The Complete Health Improvement Program is a validated set of weekly classes designed to promote gentle exercise and wellness related activities in a supportive group setting led by an experienced trainer.
89089080|NCT00952341|Experimental|Aprepitant (MK-0869)|
89089081|NCT00952341|Placebo Comparator|Standard Therapy|
89089082|NCT02845024|Active Comparator|oral doxycycline|Oral capsules of doxycycline 100 mg were used
89089083|NCT02845024|Placebo Comparator|oral placebo capsule|oral placebo capsule were used
89089084|NCT05242588|Experimental|JS005 150 mg|30 patients will be enrolled in this arm.
89089085|NCT05242588|Placebo Comparator|Placebo 150 mg|10 patients will be enrolled in this arm.
89089086|NCT05242588|Experimental|JS005 300 mg|30 patients will be enrolled in this arm.
89089087|NCT05242588|Placebo Comparator|Placebo 300 mg|10 patients will be enrolled in this arm.
89089088|NCT05242588|Experimental|JS005 450 mg|30 patients will be enrolled in this arm.
89089089|NCT05242588|Placebo Comparator|Placebo 450|10 patients will be enrolled in this arm.
89089090|NCT02852733||Residents in end-of-life situation|"Residents in end-of-life situation the day of the survey, as determined by the physician coordinator of nursing homes (we will use the definition of terminal condition contained in the guide of the CNSA (coding PATHOS - April 2011))."
89089091|NCT02852733||dead residents|dead residents in the quarter preceding the date of the survey
89226341|NCT04392622|Experimental|d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
89089092|NCT02853903|Experimental|Allogenic NK immunotherapy|In this group, the patients will receive more than 4 times of allogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89089093|NCT02853903|Active Comparator|Autogenic NK immunotherapy|In this group, the patients will receive more than 4 times of autogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89089094|NCT04269525|Experimental|pneumonia|According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4), patients enrolled will be divided to serious pneumonia group or critical pneumonia group. All subjects will receive UC-MSCs 3.3 * 107 cell number / 50ml / bag, 3 bags each time. And UC-MSCs will be infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. The efficacy and safety of the treatment, patients' adverse reactions will be monitored.
89089095|NCT05242120||Residents who completed their residency (class 2013,2014 , 2016, 2017)|Residents who completed their residency (class 2013,2014 , 2016, 2017)
89089096|NCT00602277|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5 in course 1, followed by insertion of an IP access port. Beginning in course 2, patients receive wild-type reovirus IV over 60 minutes on days 1-5 and wild-type reovirus IP over 10 minutes on days 1 and 2*. Treatment with IV and IP wild-type reovirus repeats every 28 days in the absence of disease progression or unacceptable toxicity. (phase II closed as of 1/7/2011). NOTE: *Patients receive IP wild-type reovirus on days 2 and 3 in course 3.
89089097|NCT05241964|Experimental|PRP|PRP injection
89089098|NCT01909089|Experimental|Chloroprocaine|Up-down sequential allocation.
89089099|NCT02844790|Experimental|IDegAsp|
89089100|NCT05337358|Active Comparator|Lithium disilicate|The intervention will be: Prosthetic endocrown
89089101|NCT05337358|Active Comparator|Fiber reinforced composite|The intervention will be: Prosthetic endocrown
89226342|NCT04392622|Experimental|d-limonene -8gram|8 gram d-limonene orally, as 4 grams 2 times daily delivered during chemoradiation
88821339|NCT04447703|Experimental|Aim II: Arm II (WBGE, Genetic Couseling, Genetic Testing)|Patients receive a link to the web-based genetic education tool online including all elements of genetic counseling in written modules and in a series of professional videos. Patient may then undergo genetic testing. Patient may cross-over to Arm I to see a genetic counselor.
89089102|NCT02845102|Experimental|Pre-Post Feasibility Testing|The pre-post feasibility testing/ intervention includes the use of tablet technology and cognitive behavioral therapy (CBT) for depression and self-management education for patients with chronic illness and/or chronic pain and depression. The pre-post feasibility testing phase will include 25 subjects. The total duration of pre-post feasibility testing will be 6 weeks upon the retrieval of the RA-CBT tablet and the inclusion of follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview.
89089103|NCT01214642|Experimental|LY2523355 Days 1, 5, 9|LY2523355 administered intravenously on Days 1, 5 and 9, starting dose is 2 milligrams per meter squared (mg/m^2) for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
89089104|NCT01214642|Experimental|LY2523355 Days 1, 8|LY2523355 administered intravenously on Days 1 and 8, starting dose is 8 mg/m^2 for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
89089105|NCT01214642|Experimental|LY2523355 Days 1, 5 + pegfilgrastim|LY2523355 administered intravenously on Days 1 and 5, starting dose is 8 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 6 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
89089106|NCT01214642|Experimental|LY2523355 Days 1, 4 + pegfilgrastim|LY2523355 administered on Days 1 and 4, starting dose is 12 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 5 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
89089107|NCT02856633||Vitaliti System|
89089108|NCT05241652|Active Comparator|Intervention group|Sixteen patients are assigned an IMT exercise program that included inspiratory muscle strengthening exercises thrice a week at a 50% MIP intensity, five sets per time, ten breathing repetitions per set, for an estimated duration of 20 minutes each using Threshold IMT for 12 weeks.
89089109|NCT05241652|Placebo Comparator|Control group|Sixteen patients are assigned an IMT exercise program that included inspiratory muscle strengthening exercises thrice a week at a 10% MIP intensity, five sets per time, ten breathing repetitions per set, for an estimated duration of 20 minutes each using Threshold IMT for 12 weeks.
89089110|NCT02690740|Experimental|open label|"test/retest of a titrated quantitative CPT (TqCPT) with outcomes: CPT-scoring system and correlation with digital photo analysis.~in all patients: 1 Arm = CPT test/re-test, no comparator~No intervention of a new drug (CPT-solution registered (ALK- Abelló, Hørsholm, Denmark));"
89089111|NCT02852499||Mothers|Pregnant women.
89089112|NCT02852499||Fathers|Futur fathers.
89089113|NCT02852499||Children|Children after childbirth.
89089114|NCT04410328|Experimental|Participants receiving Dipyridamole and Aspirin|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally plus standard care. Participants will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally), 2 times daily starting on the day of enrollment for a total of 2 weeks.
89089115|NCT04410328|Other|Participants receiving standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
89089116|NCT01214252||Permacol Patients|Patients who have undergone surgical repair of their abdominal wall defect with Permacol Surgical Implants with at least 12 months follow up.
89089117|NCT02852577|Active Comparator|Clonazepam|Treatment with clonazepam
89089118|NCT02852577|Active Comparator|Paroxetine|Treatment with paroxetine
89089119|NCT05234476|Experimental|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
89089120|NCT05234476|Active Comparator|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
89089121|NCT01214174|Experimental|Dose 1|513ug
89089122|NCT01214174|Experimental|Dose 2|776ug
89089123|NCT01214174|Experimental|Dose 3|1046ug
89089124|NCT04201990|Experimental|treatment group|Camrelizumab, iv, Q3W until progression disease or intolerable toxicity or 2 years Apatinib, po, QD until progression disease or intolerable toxicity or 2 years
89089125|NCT00901342|Experimental|Sipuleucel-T|Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
89089126|NCT00632866|Experimental|1|Active treatment : Hydroxychloroquine
89089127|NCT00632866|Placebo Comparator|2|Placebo
89089128|NCT00901186|Experimental|RFB002|RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.
89089129|NCT00901186|Active Comparator|Laser photocoagulation|At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.
89089130|NCT01213472|Experimental|NY-ESO 1 Group|Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.
89089131|NCT05040880|Experimental|Sequence A|TRTR
89089132|NCT05040880|Experimental|Sequence B|RTRT
89089133|NCT00900796||1|Patients diagnosed with active AS who start anti-TNF therapy according to standard clinical practice.
89089134|NCT01213082|Experimental|24GyE + anti-VEGF|
89089135|NCT01213082|Experimental|16GyE + anti-VEGF|
89089136|NCT01213082|Sham Comparator|Sham Irradiation + anti-VEGF|
89089137|NCT04073290|Active Comparator|Rifaximin and lactulose|Rifaximin 550 milligram b.i.d. combined with lactulose
89089138|NCT04073290|Placebo Comparator|Placebo and lactulose|Placebo b.i.d. combined with lactulose
89089139|NCT05017558||intervention|Measurement of viral load in HIV-1 infected mothers at delivery by POC to optimise post-natal prophylaxis and neonatal diagnosis of children according to the estimated risk of MTCT (high risk:VL at delivery ≥ 1000 copies/mL, low risk: VL at delivery < 1000 copies/mL) in Conakry, Guinea.
89089140|NCT00632788||intervention group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between March 1, 2007 and Oct. 31, 2007
89089141|NCT00632788||control group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between April 1, 2006 and Feb. 28, 2007
89089142|NCT04975828||patients type 2 DM with coronary artery disease and diabetic retinopathy.|
89089143|NCT04975828||patients type 2 DM with coronary artery disease and diabetic neuropathy.|
89089144|NCT04975828||patients type 2 DM with coronary artery disease and diabetic nephropathy|
89089145|NCT04975828||patient type 2 DM with coronary artery disease and non microvascular complications.|
89089146|NCT03936790|Other|Ropi_dosing|The dose of ropivacaine for each parturient is determined by the response of the previous participant to a higher or lower dose according to the sequential distribution algorithm (up-down sequential allocation).
89089147|NCT04782700|No Intervention|Watchful Waiting|The patients randomized to the watchful waiting group will not be prescribed any steroids at the time of randomization.
89089148|NCT04782700|Experimental|Prednisone (Steroid) Taper|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
89089149|NCT03800056||Group 1 APS 1|Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.
89089150|NCT03800056||Group 2 APS2|Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.
89089151|NCT04745884|Experimental|Monitoring|Imaging guided by monitoring results
89089152|NCT05336734|Experimental|Main group|The group underwent a psychotherapy course combining CBT and imagery work. (For full protocol see Prinz et al., 2019)
89089153|NCT00885703|Experimental|Stage 1, Fluconazole 1200mg|Participants receive Fluconazole 1200mg induction dose in Stage 1
89089154|NCT00885703|Experimental|Stage 1, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 1
89089155|NCT00885703|Experimental|Stage 1, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 1
89089156|NCT00885703|Active Comparator|Stage 1, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 1
89089157|NCT00885703|Experimental|Stage 2, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 2
89089158|NCT00885703|Experimental|Stage 2, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 2
89089159|NCT00885703|Active Comparator|Stage 2, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 2
89089160|NCT04554784|Active Comparator|Conventional|Conventional pain treatment.
89089161|NCT04554784|Active Comparator|Bowen|Patients will be referred to Occupational Therapist for Bowen therapy.
89089162|NCT04549480|Experimental|Bosutinib capsule|Bosutinib pediatric capsule to healthy participants
89089163|NCT04549480|Active Comparator|Bosutinib tablet|Bosutinib tablet to healthy participants
89089164|NCT05336578|Experimental|1- PRF|After wisdom tooth extraction PRF located to the extraction socket
89089165|NCT05336578|No Intervention|PRF free|Only surgical procedure of the wisdom tooth extraction is performed
89089166|NCT02642731||Patients for elective TKA|patients with normal or near normal plasma creatinine who come for elective total knee arthroplasty
89089167|NCT02642419|Experimental|Rivaroxaban|
89089168|NCT02642419|Experimental|Rivaroxaban and single antiplatelet drug|
89089169|NCT00901576|Experimental|SPD503|
89089170|NCT00901576|Active Comparator|Concerta|
89089171|NCT00901576|Active Comparator|SPD503 + Concerta|
89089172|NCT00655837|Experimental|1|
89089173|NCT02634931|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
89089174|NCT05336422|Experimental|training on the risks associated with sun exposure|power point on the risks associated with sun exposure
89089175|NCT00655915||Injection Patients|Those patients who receive corticosteroid injections for carpal tunnel syndrome
89089176|NCT02637271|Experimental|Total Meal Replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
89089177|NCT02637271|Active Comparator|Typical Diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
89089178|NCT02637349|Experimental|POST SCP|Patient receives Survivorship Care Plan (SCP) after active treatment ends. It will be discussed with the patient. SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
89089179|NCT02637349|Active Comparator|POST TAU|Patient receives treatment as usual (TAU) after active treatment ends.
89089180|NCT04162093|Experimental|single trough|
89089181|NCT02637193|Experimental|Venlafaxine|Maximum dose of 450 mg/day (225 mg BID given at approximately 12 hours apart) Venlafaxine, dose titrated from a starting single dose (QD) of 75 mg venlafaxine in the morning of Days 1 and 2, followed by BID escalating doses administered on Days 3 through 10, followed by 450 mg/day (BID) on Days 11 through 13, and on Day 14 only the morning dose of 225 mg will be administered, then 3 days (Days 15, 16 and 17) of down titration
89089182|NCT02637193|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
89089183|NCT02637193|Placebo Comparator|Drug -- placebo|Placebo administered on Days 1 through 13 and on Days 15 to 17
89089184|NCT04163575|Experimental|experimental:1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
89089185|NCT04163575|Experimental|experimental:2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
89089186|NCT04163575|Experimental|experimental:3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD22-CAR) targeting CD22.
89089187|NCT00656773|Experimental|1|
89089188|NCT00656773|Active Comparator|2|
89089189|NCT04017559|Experimental|Intervention cohort|All participants were entered into the intervention cohort to receive the Motivational Interviewing intervention
89089190|NCT04165525|Active Comparator|HelixAR Electrosurgical Generator (HEG)|Argon gas and high frequency electrical current ablation device
89089191|NCT04165525|Active Comparator|Conventional Electrosurgical Coagulation (CEC) Systems|Standard Bovie electrosugical device without argon gas
89089192|NCT00656071||1|Control -- postoperative mechanical ventilation patients without ARDS
89089193|NCT00656071||2|Cases -- postoperative mechanical ventilation patients with ARDS
89089194|NCT04163263|Experimental|Cohorts 1-3: BOS-356|Twice daily application of BOS-356 0.1%, 0.4%, and 0.7% gel in Cohorts 1, 2, and 3, respectively
89089195|NCT04163263|Placebo Comparator|Cohorts 1-3: Vehicle|Twice daily application of vehicle gel
89089196|NCT04163263|Experimental|Cohort 4: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
89089197|NCT04163263|Placebo Comparator|Cohort 4: Vehicle|Twice daily application of vehicle gel
89226343|NCT04392622|Experimental|de-escalation dose d-limonene -6gram|6 gram d-limonene orally, as 3 grams 2 times daily delivered during chemoradiation
89089198|NCT04163263|Experimental|Cohort 5: BOS-356|Twice daily application of BOS-356 gel at a dose determined based on safety and tolerability data from Cohorts 1-3
89089199|NCT04163263|Placebo Comparator|Cohort 5: Vehicle|Twice daily application of vehicle gel
89226344|NCT04392622|Experimental|de-escalation dose d-limonene -4gram|4 gram d-limonene orally, as 2 grams 2 times daily delivered during chemoradiation
89226345|NCT04392622|Experimental|de-escalation dose d-limonene -2gram|2 gram d-limonene orally, once daily delivered during chemoradiation
89226346|NCT04392388||SAPRIS-SERO|SAPRIS-SERO enrolls participants from cohorts entitled: Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé.
89226347|NCT04391816||Study Participants|Participants that were previously enrolled in the NIAAA Screening Protocol.
89089200|NCT02634697|Experimental|3RP Intervention Group|"AF Patients will undergo the 3RP intervention which will comprise of the following:~i. One-one-one session: each subject will spend an hour with a clinician to set specific goals for the intervention. They will also answer questionnaires.~ii. ECG monitoring: Enrolled subjects may be monitored with an ECG at some point after the time of consent up to the day of the one-on-one session, and again after completing the 8 weeks.~iii. Weeks 1 - 8: subjects will meet with the clinician/staff member as a group once a week for 1.5 hours each where they will be taught a variety of techniques to elicit the relaxation response as well as other cognitive skills.~At the end of the 4th (mid-point) and 8th (last) weekly session, subjects will answer questionnaires.~iv. 6 month follow up: 3 months after the final 3RP session to answer questionnaires.~v. Subjects will be asked to keep track of their AF episodes during the course of the study."
89089201|NCT02634697|Active Comparator|3RP Waitlist Control Group|The Control Group will wait for 6 months (from the time the Intervention group starts the 3RP intervention) and then will undergo the same study procedures as the intervention group - except for the 6 month follow up.
89089202|NCT00882583|Experimental|Dasatinib/Cetuximab/RT|"In Cohort A , there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.~Cohort A will consist of patients with AJCC stage II (T2N0) and III (T1-2N1) SCCHN of oral cavity, oropharynx, T2N0 hypopharynx, T2N0-1 supraglottic larynx. Treatment will be dasatinib at specific dose level in combination with cetuximab 250mg/m2 IV and radiation therapy (RT) 70Gy at 2Gy/fn."
89230258|NCT00798395|Active Comparator|Treatment 4|
89089203|NCT00882583|Experimental|Dasatinib/Cetuximab/cisplatin/RT|"In Cohort B, there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.~Cohort B will include patients with AJCC stage III (T3N0-1) and IV (T1-4N2-3M0, T4N0-1M0) squamous cell carcinoma of Oral Cavity, Oropharynx, Hypopharynx, and Larynx. Treatment will be daily dasatinib at specific dose level, in combination with q 3 week cisplatin 75mg/m2, weekly cetuximab 250mg/m2 IV and RT 70Gy ( 2gy per fraction)."
89089204|NCT00656149|Active Comparator|Telerehabilitation of hand function|Intervention: for one hour per day participants perform exercise therapy on a home-based tele-rehabilitation workstation, the Rehabilitation Joystick for Computerized Exercise (ReJoyce) with which participants play computer games associated with activities of daily life. A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system. Hand grasp-release is assisted with functional electrical stimulation (FES) triggered voluntarily by the participant with the use of a wireless earpiece with a sensor that detects toothclicks.
89089205|NCT00656149|Active Comparator|Conventional exercise therapy|Intervention: for one hour per day participants perform conventional range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 with the use of the ReJoyce tele-rehabilitation min). A remote therapist coaches each one-hour session A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system.
89089206|NCT00900562|Experimental|Arm 1|Zalypsis (PM00104)
89089207|NCT02634775|Experimental|CKD - no dialysis|Change in treatment strategy: Start on dialysis, transplantation
89089208|NCT02634775|Experimental|Patients on PD|Change in treatment strategy: Change of PD prescription, start on HD, transplantation
89089209|NCT02634775|Experimental|Patients on HD|Change in treatment strategy: Change of HD prescription, transplantation
89089210|NCT02636959|Active Comparator|high volume saline irrigation (HVSI)|High volume nasal spray, NeilMed® Sinus Rinse, is a high saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
89089211|NCT02636959|Active Comparator|low volume saline irrigation (LVSI)|Low volume nasal spray, Salinex Rinse, is a low saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
89089212|NCT04510480||cardiac arrest|"Out of hospital cardiac arrest patients (Historical cohort) from 1st January 2009 and 30th June 2020.~Out of hospital cardiac arrest patients from 1st July 2020 and 31st December 2025."
89089213|NCT04488094|Experimental|Heart transplantation|Patients suspected of having acute heart allograft rejection after heart transplantation will receive a single IV injection of [18F]FSPG
89089214|NCT04488094|Experimental|Liver transplantation|Patients suspected of having acute liver allograft rejection after heart transplantation will receive a single IV injection of [18F]FSPG
89089215|NCT02634619|Active Comparator|Ventral Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
89089216|NCT02634619|Active Comparator|Dorsal Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
89089217|NCT02634541|Active Comparator|DMARD-naive|Sulfasalazine will be given as the initial therapy.
89089218|NCT02634541|Experimental|Post-sulfasalazine|Sulfasalazine contraindicated or not efficient, adalimumab will be given as the initial therapy.
89089219|NCT04475848|Experimental|Part 1: SAD/FE|There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of RO6953958 while fasted. Participants in the fed (FE) cohort will return to receive the same single oral dose of RO6953958 repeated in the fed state.
89089220|NCT04475848|Placebo Comparator|Part 1: SAD placebo|There will be 7 cohorts in this study. In each cohort, participants will receive a single oral dose of a placebo while fasted/fed.
89089221|NCT04475848|Experimental|Part 2: MAD|A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of RO6953958 once daily (QD) for 10 days.
89089222|NCT04475848|Placebo Comparator|Part 2: MAD placebo|A maximum of 5 dose levels are anticipated. For each dose level, a minimum of 8 and a maximum of 16 participants will receive a multiple oral dose of RO6953958 QD for 10 days.
89089223|NCT04475848|Experimental|Part 3: DDI|"RO6953958 will be administered at the maximum dose QD that was tested in the ongoing Part 2 (MAD).~Participants will also be administered midazolam."
89089224|NCT04057651||Hip osteoarthritis waiting for surgery|
89089225|NCT04057651||Knee osteoarthritis waiting for surgery|
89089226|NCT04653142|Experimental|BI 765063 (Part A) and BI 765063 + BI 754091 (Part B)|
89089227|NCT00599521|Experimental|Adapalene lotion 0.1%|
89089228|NCT00599521|Placebo Comparator|Adapalene Lotion vehicle|
89089229|NCT04201678|Active Comparator|CLIA (conventional local anesthesia infiltration) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
89111076|NCT02790567||HIT study group|The HIT study group will include all patients admitted in our surgical intensive care unit (ICU) during the study period if the clinician in charge of the patient suspects the diagnosis of HIT. The HEP score, the 4Ts score, the immuno-diffusion particle gel immunoassay (ID-PaGIA) and the HIT-Ab(PF4-H) test will be done for each patient the day the diagnosis of HIT will be suspected.
89089230|NCT04201678|Active Comparator|EPIAA (Extrapedicular infiltration anesthesia) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
89089231|NCT04201678|Active Comparator|ESP (Erector Spina Plane Block) Group|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 Megahertz (MHz) linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
89089232|NCT03542812|Experimental|Single-dose|"Participants will be enrolled into the two groups, Group 1 (which will consist of 10 participants) and Group 2 (which will consist of 8 participants) in an alternating basis. Both Group 1 and Group 2 participants will receive a single, 150 mg/kg dose of oral L-citrulline. Population PKs will be done for both groups, at up to 3 time points.~Multiple interim time points and following completion of enrollment into Groups 1 and 2, data analysis will be done and results reviewed by the data safety monitoring board (DSMB). After the DSMB review is complete, enrollment into Group 3 will begin."
89089233|NCT03542812|Experimental|Steady-state|To evaluate the tolerability and ability to achieve target trough L-citrulline levels of 100-150 µM, an additional group of 18 infants (group 3) will be given oral L-citrulline doses at intervals over a total of 72 hours. If the participant is not nipple feeding, the dose will be delivered via the participant's indwelling gavage feeding tube. The dose and interval of L-citrulline will be based on results from the studies that assess pharmacokinetic parameters using a maximum daily dose of 3 g/kg/d. Blood draws for PKs will be done at baseline and prior to last dose of L-citrulline. Urine will be collected to measure nitric oxide metabolites.
89089234|NCT02642263|No Intervention|Oxytocin|Oxytocin 20 IE in 500 ml G Na intravenous infusion over 6 hours (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%), Sintetica-Bioren, Switzerland, after birth of the baby. For blinding purposes a 3ml NaCl 0.9% syringe is administered intravenously after birth of the baby as well.
89089235|NCT02642263|Experimental|Carbetocin|100 mcg of Carbetocin, Ferring, Switzerland, as iv administration after birth of the baby. For blinding purposes an intravenous infusion of 500 ml G Na (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%) is administered over 6 hours.
89089236|NCT02231398||Women who participated in nuMoM2b|
89089237|NCT02637115|Placebo Comparator|Placebo|Placebo corresponds to a solution of Phosphate buffer saline (PBS) and glycerol, that is the carrier used in the 3 other groups receiving the bacteria (active arms)
89089238|NCT02637115|Experimental|Live Akk 9|Live Akkermansia muciniphila (Akk) at the dose of 10exp9 live bacteria (one billion of live bacteria) per day
89089239|NCT02637115|Experimental|Live Akk 10|Live Akkermansia muciniphila (Akk) at the dose of 10exp10 live bacteria (ten billion of live bacteria) per day
89089240|NCT02637115|Experimental|Killed Akk|This group corresponds to Akkermansia muciniphila that have been heat-killed. The initial quantity of bacteria before the heating procedure was of 10exp10 bacteria.
89089241|NCT00779740|Experimental|New Formulation Group|
89089242|NCT00779740|Active Comparator|Old Formulation Group|
89089243|NCT02636803|Experimental|oxfendazole 6 mg/kg|patients receive 6 mg/kg oxfendazole once
89089244|NCT02636803|Experimental|oxfendazole 30 mg/kg|patients receive 30 mg/kg oxfendazole once
89089245|NCT02636803|Experimental|oxfendazole 6 mg/kg 3 times|patients receive 6 mg/kg oxfendazole three times
89089246|NCT02636803|Active Comparator|albendazole 400 mg|patients receive 400 mg albendazole once
89089247|NCT02535871|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
89089248|NCT02535871|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
89089249|NCT02634385|No Intervention|Small Renal Mass|Patient's with a small renal mass will be undergoing embolization prior to laparoscopic partial nephrectomy.
89089250|NCT02634463|Other|Antipsychotic Immunoassay Development Participants|No study agent will be administered as a part of this study. Participants must be on Aripiprazole or Olanzapine, or Paliperidone or Risperidone, orally, daily or long-acting injectable versions, as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for use in the development of antipsychotic immunoassays. Participants may also be on long acting injectable versions of the medication.
89089251|NCT02535403|Experimental|ICBT|14 weeks of internet-based cognitive behavioral therapy with therapist support
89089252|NCT02535403|No Intervention|Wait-list|14 weeks wait-list control
89089253|NCT00882115|Experimental|DEP challenge in subjects consuming BSE|DEP will be administered in nostrils of participants who received BSE intervention by drinking 1 cup of liquid containing 1.25 g BSE daily for 4 days, or without consuming BSE.
89089254|NCT00881959|Experimental|Group 1: Puros Dermis|Experimental treatment group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
89089255|NCT00881959|Active Comparator|Group 2: Alloderm|Control group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
89089256|NCT00653419|Experimental|A|Subjects received the Par formulated product (Buspirone HCl) under fasting conditions
89089257|NCT00653419|Active Comparator|B|Subjects received the Bristol-Myers Squibb formulated product (Buspar) under fasting conditions
89089258|NCT00884377|Active Comparator|Sodium stibogluconate intravenous|20 mg/kg/day Sodium stibogluconate intravenous
89089259|NCT00884377|Experimental|ThermoMed device|ThermoMed device, single heat treatment at 50 degrees Celsius
89089260|NCT00656929|Active Comparator|1|Vitamin D3 50 mcg (2000 IU) daily
89089261|NCT00656929|Placebo Comparator|2|Placebo tablets
89089262|NCT00656383|Active Comparator|1|Client is randomized to receive leg ulcer treatment in the home
89089263|NCT00656383|Active Comparator|2|Client randomized to receive leg ulcer care in the clinic
89089264|NCT04161937|Experimental|Behavioural Intervention|Half of the randomly selected participants will get behavioural intervention based on Diabetes Prevention Program module.The behavioural intervention classed will be administered by trained nurse weekly for 16 weeks.After completion of behavioural intervention both the experimental and control arm will get cafeteria intervention.
89089265|NCT04161937|Experimental|Control|Half of the participants will act as a control and will not receive any form of behavioural intervention.
89089266|NCT00884221|Experimental|Highly Purified Menotrophin|
89089267|NCT00884221|Active Comparator|Recombinant FSH|
89089268|NCT02634229||Diabetic family members|(i) probands negative for GCK/MODY2 , HNF1A/MODY3 genes and HNF4A/MODY1; (ii) dominant inheritance of diabetes (three consecutive affected generations, or two generations with at least 2 diabetic patients in a generation); (iii) Diagnosis of diabetes before age 40 years in at least 3 diabetic family members; (iv) negative testing for anti-GAD and IA2-antibodies; and (v) body mass index < 30 kg/m2 (to avoid inclusion of patients with insulin-resistant type 2 diabetes).
89089269|NCT02634229||Healthy relatives|Healthy subjects whose relationship is relevant for genetic analysis and necessary for the validation step (family cosegregation study)
89089270|NCT02153632|Experimental|240mg amantadine HCl ER tablets|amantadine HCl ER, 240 mg tablets, once daily, 22 weeks
89089271|NCT02153632|Experimental|320mg amantadine HCl ER tablets|amantadine HCl ER, 320 mg tablets, once daily, 22 weeks
89089272|NCT02153632|Placebo Comparator|Placebo Tablets for Amantadine|Placebo, tablets, once daily, 26 weeks.
89089273|NCT03524326|Experimental|Head and Neck Squamous or Cutaneous Squamous Cell Carcinoma|A 3+3 dose de-escalation design for three dose levels of lenvatinib combined with cetuximab will be used. A DLT will be defined as any toxicities of grade 3 or higher (per CTCAE v4 criteria) felt to be possibly, probably, or definitely related to lenvatinib, as well as grade 4 toxcities related to cetuximab, which occurs within 28 days following the first dose of lenvatinib in combination with cetuximab.
89089274|NCT01236430|Active Comparator|Ezetimibe 10mg and Atorvastatin 10mg|Ezetimibe 10mg tablet and Atorvastatin 10mg tablet coadministered
88821340|NCT04439526||Participants with Facial Psoriasis|Participants with moderate facial psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
89089275|NCT01236430|Experimental|10mg Ezetimibe/10mg Atorvastatin|10mg Ezetimibe/10mg atorvastatin combination tablet
89089276|NCT01236430|Active Comparator|Ezetimibe 10mg and Atorvastatin 80mg|Ezetimibe 10mg tablet and Atorvastatin 80mg tablet coadministered
89089277|NCT01236430|Experimental|10mg Ezetimibe/80mg Atorvastatin|Ezetimibe/atorvastatin 10mg/80mg combination tablet
89089278|NCT00726856||Patients|patients with dyslipidemia
89089279|NCT00651274|Experimental|Ezetimibe|
89089280|NCT00651274|Placebo Comparator|Placebo|
89089281|NCT05335330||Group: Pregnant women (first pregnancy)|This group will consist of women in the first trimester of pregnancy. Pregnant women will be evaluated 3 times in total, each measurement being in a different trimester.
89089282|NCT00351988||African American caregivers|African American caregivers for patients with advanced non-small cell lung cancer or breast cancer.
89089283|NCT00351988||Latino caregivers|Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
89089284|NCT00351988||White non-Latino caregivers|White non-Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
89089285|NCT00212836|Experimental|Asenapine|
89089286|NCT00212836|Active Comparator|Olanzapine|
89089287|NCT00805324|Experimental|Arm 1|
89089288|NCT00157924|Experimental|1|1. simvastatin/ezetimibe 10/20mg
89089289|NCT00157924|Active Comparator|2|2. atorvastatin 10mg
89089290|NCT05335642||Patients that had secondary interventions after EVAR|
89089291|NCT05335642||Patients without secondary interventions after EVAR|
89089292|NCT00794794|Experimental|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
89089293|NCT03612466|Experimental|Dose Escalation Arm|"Dose Levels 1-3 will consist of treatment with radiopharmaceutical (153Sm-DOTMP) alone. If the maximally tolerated dose (MTD) has not been reached at Level 3, external beam radiotherapy will be added to each of Levels 4-6. Participants enrolled on Dose Levels 4-6 will be treated with external beam radiotherapy to all radiographically evident sites of disease. If an MTD has not been determined at Level 6, the study will end and Dose Level 6 will be declared the Recommended Phase 2 Dose.~Participants will be given prophylactic / supportive treatment protocols including Calcium Carbonate, mozobil, and neupogen injectable product."
89089294|NCT02842606|Experimental|Fiber-enriched pasta|The participants consume whole wheat pasta with added fiber (fiber 12 g fiber/100 g).
89089295|NCT02842606|Active Comparator|Control pasta|The participants consume pasta made from durum wheat semolina (fiber 2.7g/100g).
89089296|NCT02842684|Experimental|Traumacad software|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise . The recent TraumaCad system ( Brainlab® ) allows adjustment of the scales for each patient and the virtual positioning of implants to simulate the response to the return of geometric hip parameters
89089297|NCT02842684|No Intervention|without digital planning|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise
89089298|NCT00899548||Metastatic breast cancer patients|DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis
89089299|NCT04201366||Sample 1|All participants fulfilling the inclusion criteria.
89089300|NCT04201366||Sample 2|Participants fulfilling the inclusion criteria and reports no neck/shoulder pain at baseline.
89089301|NCT02690818|Experimental|Behavioral intervention arm|"Regularly scheduled medication reminder text messages~Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication.~Standard of care: Monthly reminder call and clinic visit"
89089302|NCT02690818|No Intervention|Control group receiving standard care|Standard of care: Monthly reminder call and clinic visit
89089303|NCT02842528|Experimental|Alcohol-dependent patients|
89089304|NCT02842528|Active Comparator|First-degree relatives of alcohol-dependent probands|
89089305|NCT02842528|Active Comparator|Healthy Controls|
89089306|NCT04201522|Active Comparator|Training intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance
89089307|NCT04201522|Sham Comparator|Sham intervention|The effect of 6-weeks of respiratory training with normocapnic hyperpnoea on exercise tolerance in the training group compared to the sham group.
89089308|NCT02842450||training with typical definitions established + photos|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
89089309|NCT02842450||Training only with definitions|Interns will receive typical definitions of LAP stages
89089310|NCT02844088|Experimental|vaccinated group|evaluation of immunity's level against meningococcus C among people vaccinated in 2002 in Puy-de-Dôme
89089311|NCT02844088|Other|unvaccinate group|Duration of vaccinal immunity, compare vaccinal immunity to possible natural immunity among unvaccinated people
89089312|NCT00899392|Experimental|Electronic Assisted Consent|Standard procedural consent performed by pediatric gastroenterologist plus assistance from computerized emmi module.
89089313|NCT00899392|No Intervention|Control Consent|Standard procedural consent as performed by pediatric gastroenterologists
89089314|NCT02842372||Ectoin Dermatitis Cream 7%|Cream for symptomatic treatment and relief of skin redness and itching experienced with various types of inflammatory dermatoses.
89089315|NCT02842294||irinotecan based chemotherapy|patients having a 1st line doublet chemotherapy including irinotecan
89089316|NCT02842294||oxaliplatin based chemotherapy|patients having a 1st line doublet chemotherapy including oxaliplatin
89089317|NCT02842294||triplet chemotherapy|patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy
89089318|NCT01176604|Experimental|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres via a catheter over 5 minutes on day 0. Patients may receive additional treatments at 4-12 week intervals until all tumors in the liver have been treated in the absence of disease progression or unacceptable toxicity.
89089319|NCT02843932|Experimental|Psychogenic disorders|Psychogenic movement disorders and seizures
89089320|NCT02844010||patients with pneumonia|
89089321|NCT02842138|Experimental|CD19 CAR T cells|A standard dose escalation approach aimed to assess the safety and efficacy of autologous anti-CD19 CAR T cells will be applied.
89089322|NCT02844244|Experimental|training group|Two two-hour training sessions for the participants. It aimed to train lay resident leaders to be peer health promoters. The peer health promoters were taught either to independently implement or to assist social workers to conduct a series of community-based family well-being activities.
89226348|NCT04388839|Experimental|Arm A - First Strike|Participants will receive 42 weeks of conventional doses of vinorelbine, actinomycin D and cyclophosphamide
89089323|NCT02841982|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
89089324|NCT02841982|Active Comparator|IPCA|postoperative IPCA is given alone
89089325|NCT02841826|Other|Group I: IUD without uterine sound group|Transvaginal ultrasound before to intrauterine contraceptive device insertion without uterine sounding.
89089326|NCT02841826|Other|Group II: IUD with uterine sound|Intrauterine contraceptive device inserted by classic method
89089327|NCT00633178|Experimental|Group Interpersonal Therapy (IPT)|Participants will receive group interpersonal therapy.
89089328|NCT00633178|Active Comparator|Treatment as Usual (ETAU)|Participants will receive psychiatric treatment as usual.
89089329|NCT00633178|No Intervention|No Treatment|Participants are healthy and will receive no treatment.
89089330|NCT02841904|Other|CLE|CLE assessed by the pathologist
89089331|NCT02841904|Active Comparator|Biopsy|Histology assessed by the pathologist
89089332|NCT02841514|Experimental|treatment group|the operator will administer the Y10 whitening toothpaste in to the attachable mouthpiece and place it in the subject's mouth and turn on the device RF. After treating the patients for 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
89089333|NCT02841514|Placebo Comparator|placebo group|the operator will administer an off the shelf regular toothpaste in to the attachable mouthpiece and place it in the subject's mouth. At this point the operator will switch on the device but the RF will not be activated. After 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
89089334|NCT04533958|Experimental|HypnoVR Arm|During each Docetaxel infusion, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
89089335|NCT04533958|No Intervention|Control Arm|Patients receive the docetaxel infusions under standard conditions (no medical hypnosis in virtual reality intervention)
89089336|NCT02841592|Active Comparator|Non-rebreather|This group will have a non-rebreather mask applied to the face and they will receive the flush rate oxygen intervention
89089337|NCT02841592|Active Comparator|Bag-valve-mask|With each inspiration from the subject, the ventilation bag will be gently squeezed to provide positive pressure and augment the amount of oxygen that is received by the subject for each breath. This group will receive the flush rate oxygen with assist intervention.
89089338|NCT02841436|Experimental|irreversible electroporation (IRE)|IRE (AngioDynamics, NY) To use 2 to 6 unipolar electrodes in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
89089339|NCT02841358|Other|Psychiatric adults patients presenting psychologic disorders|
89089340|NCT02843698|Experimental|Dexmedetomidine group|Patients will receive either, Dexmedetomidine (Precedex, Hospira, Lake forest, IL, USA) in a dose of (1ug/Kg LBW) bolus followed by 0.5ug/Kg continuous infusion for one hour
89089341|NCT02843698|Placebo Comparator|Control group|Patients will receive normal saline
89089342|NCT00690898|Experimental|Lanreotide autogel 120 mg|
89089343|NCT02841202|Active Comparator|oral contraceptive pills group|healthy women using oral contraceptive pills for only contraception for more than one year was called OCP group
89089344|NCT02841202|No Intervention|control group|The second group was called control group consisting 20 healthy women and using no drug
89089345|NCT02841124|Other|Qualitative research|Semi-structured interviews
89089346|NCT00895414|Experimental|Doxorubicin alone first, then Doxorubicin with Enalapril|Patients receive doxorubicin hydrochloride IV over 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2.
89089347|NCT00895414|Experimental|Doxorubicin with Enalapril first, then Doxorubicin alone|Patients receive doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
89089348|NCT02843464|Experimental|long-term RIPC group|routine treatment + once RIPC/day for a year. Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
89089349|NCT02843464|No Intervention|control group|routine treatment.
89089350|NCT02843620|Placebo Comparator|Placebo|The placebo arm will take a pill each day containing only excipients
89089351|NCT02843620|Experimental|b-2Cool|The b-2Cool arm will take a pill each day containing 40 mg of b-2Cool and excipients
89089352|NCT05334394|Experimental|Mulligan Group|
89089353|NCT05334394|Experimental|Control Group|
89089354|NCT01822288|Experimental|Tibolone group|Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.
89089355|NCT01822288|Active Comparator|Conventional hormone therapy group|Estradiol valerate (E2V) 1mg & medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.
89089356|NCT02843542|Other|Control Group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT)
89089357|NCT02843542|Other|Study group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT) and in addition will also undergo the PET-MR
89089358|NCT02811952||study group|Patients that need that need cystoscopy due to suspicion/known bladder malignancy.
89089359|NCT02811952||control group|Patients that need cystoscopy due to others reasons than malignancy.
89089360|NCT01328626|Experimental|Arm A (CLL/SLL subjects)|Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) subjects
89089361|NCT01328626|Experimental|Arm B (NHL subjects)|Non-Hodgkin lymphoma (NHL) subjects
89089362|NCT02842996||Patient and carer study group|Patients having undergone hip fracture surgery and their care givers.
89089363|NCT02842918|Active Comparator|Spinal Manual Therapy|Supine thoracic spine manipulation located between the levels of T4-T7
89089364|NCT02842918|Sham Comparator|Spinal Range of Motion|Supine thoracic spine sham manipulation located between the levels of T4-T7; identical procedure as the active treatment intervention but without the delivery of high velocity low amplitude thrust
89089365|NCT02840812|Experimental|Renal function impaired|Subject with Severe Impaired Renal Function. Nemonoxacin Malate Capsules 500mg single dose oral
89089366|NCT02840812|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
89089367|NCT01212770|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
89089368|NCT01212770|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
89089369|NCT01212770|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
89089370|NCT01212770|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
89089371|NCT05334316|No Intervention|Usual Care Group|Usual care as determined by the patient's primary team. Initiation and daily dosing of corticosteroid treatment will be based on clinicians' preference and clinicians.
88821341|NCT04439526||Participants with Genital Psoriasis|Participants with moderate genital psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
89089372|NCT05334316|Experimental|Individualized dosing strategy|Biomarker guided corticosteroid use. Initiation of corticosteroid will be recommended based on the an individual treatment rule (ITR) and subsequent dosing of corticosteroid will be recommended based on daily CRP values till CRP <50 mg/L.
89089373|NCT00598273|Experimental|Peginesatide 0.025 mg/kg|
89089374|NCT00598273|Experimental|Peginesatide 0.04 mg/kg|
89089375|NCT00598273|Active Comparator|Darbepoetin Alfa|
89089376|NCT05334238|Experimental|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
89089377|NCT05334238|No Intervention|No Orelabrutinib|no treatment after autologous transplantation
89089378|NCT02842840|Experimental|Patients based intervention|A multifaceted intervention program will use to improve adherence and clinical outcomes in Stroke patients. This intervention focus on behavioral treatment in the patients.
89089379|NCT02842840|Experimental|Family based intervention|Patients and their families will receive a series of educational/motivational interventions.
89089380|NCT02842840|Active Comparator|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 30 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
89111077|NCT02801799|Active Comparator|Infusion group 1|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 12 mL/h. This infusion rate is normal clinical practice when administering a perineural infusion of ropivacaine."
89111078|NCT02801799|Experimental|Infusion group 2|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 60 mL/h. This infusion rate is experimental."
89089381|NCT04161625|Experimental|Safe Step - digital exercise program|"All included participants will receive full access to the Safe Step application and create their own individual program of strength and balance exercises. During 1 year the participants are recommended to exercise at least 30 minutes, 3 times a week and continuously progress their program. In addition they will every month receive an email with general falls prevention information in a short video.~Additional support to promote reach and exercise adherence will be provided in the format of technical support and try-out group exercises throughout the recruitment period."
89089382|NCT02641951|Placebo Comparator|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
89089383|NCT02641951|Active Comparator|Pecs II block|Ultrasound guided Pecs II block
89089384|NCT04163029||preoperative oral care|
89089385|NCT04161703|Experimental|focused ultrasound, diet and exercises|
89089386|NCT04161703|Experimental|diet and exercises|
89089387|NCT02636491|Experimental|investigational device|"MD-Logic-Automated Insulin Delivery System, Version 01.05.02~The device is being used continuously over 60 hours for insulin therapy"
89089388|NCT02636491|Placebo Comparator|MiniMed Paradigm® Veo™ System|"sensor augmented insulin pump~The device is being used continuously over 60 hours for insulin therapy"
89089389|NCT00657007|Placebo Comparator|Placebo|IV infusion over 2 hours
89089390|NCT00657007|Experimental|Belimumab 1 mg/kg|1 mg/kg IV infused over 2 hours
89089391|NCT00657007|Experimental|Belimumab 4 mg/kg|4 mg/kg IV infused over 2 hours
89089392|NCT00657007|Experimental|Beimumab 10 mg/kg|10 mg/kg IV infused over 2 hours
89089393|NCT00657007|Experimental|Belimumab 20 mg/kg|20 mg/kg IV infused over 2 hours
89089394|NCT04318652|Other|Methylprednisolone eye drops|Preservative free steroids methylprednisolone 5% eye drops (prepared by dilution of methyleprednisolone 500mg in 10 ml distilled water (Solu-Medrol, Pfizer company) was prepared and given for all enrolled cases by the following regimen 5 times/day for 5 days with gradual decrease every third day over the following 2 weeks
89089395|NCT04318652|Placebo Comparator|distilled water eyedrops|Distilled water eyedrops instilled 3 times per day for two weeks
89089396|NCT04161547|Experimental|Cohort A1: CSPCHA115 100 mg|"CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days.~Eight subjects will receive CSPCHA115~Two subjects will receive matching placebo"
89089397|NCT04161547|Experimental|Cohort A2: CSPCHA115 200 mg|"CSPCHA115 200 mg or placebo administered orally in the fasted state for 7 days.~Eight subjects will receive CSPCHA115~Two subjects will receive matching placebo"
89089398|NCT04161547|Experimental|Cohort A3: CSPCHA115 400 mg|"CSPCHA115 400 mg or placebo administered orally in the fasted state for 7 days.~Eight subjects will receive CSPCHA115~Two subjects will receive matching placebo"
89089399|NCT04161547|Experimental|Cohort A4: CSPCHA115 600 mg|"CSPCHA115 600 mg or placebo administered orally in the fasted state for 7 days.~Eight subjects will receive CSPCHA115~Two subjects will receive matching placebo"
89089400|NCT02887898|Active Comparator|Carb counting and bolus calculator|Education in carb counting and the use of an automated bolus calculator
89089401|NCT02887898|Placebo Comparator|Carb counting|Education in carb counting and manual calculation of insulin bolus
89089402|NCT02633995||preeclampsia|spinal anaesthesia will be given for cesarean section
89089403|NCT02633995||normotensive|spinal anaesthesia will be given for cesarean section
89089404|NCT02633917|Experimental|Motor control exercises|One group should perform motor control exercises
89089405|NCT02633917|Active Comparator|Standard exercises|the other group should perform standard physiotherapy exercises
89089406|NCT02633683|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
89089407|NCT01211522|Experimental|Haloperidol|Haloperidol
89089408|NCT01211522|Experimental|Ziprasidone|Ziprasidone
89089409|NCT01211522|Placebo Comparator|Placebo|Placebo
89089410|NCT04161469|Other|Group 1|Patients diagnosed with anal fistula treated by laser closure of the tract
89089411|NCT04161469|Other|Group 2|Patients diagnosed with anal fistula treated by laser closure of the tract with an additional surgical technique as the closure of the internal orifice with a purse-string suture using 2-0 polyglactin
89089412|NCT01211288|Active Comparator|HIV negative group|This group contains participants consented to receive implants and identified as negative for HIV
89089413|NCT01211288|Experimental|HIV positive group|This group contains participants consented to receive implants and identified as positive for HIV
89089414|NCT02641795|Experimental|Experimental|Minimally invasive robotic cochlear implantation with custom device
89089415|NCT05404724|Experimental|Treatment group|itraconazole and SHR0302 tablets
89089416|NCT02636257|Experimental|Recessive Spherical Headed Silicone Intubation|The silicone nasolacrimal intubation under nasal endoscopy can restore natural drainage pathway in tears and as an out-patient surgery, it is more simple,cheap and mini-invasive.Recessive Spherical Headed Silicone Intubation is safe,convenient and almost unpainful for no trauma.It has no facial scar and no damage for structure and function of lacrimal duct.Besides,silica gel is non-toxic and nonirritating.Nasal endoscopy handed by otorhinolaryngologist helps intraoperative visualization about anatomy of the nasal cavity,understanding and management of congenital nasolacrimal duct obstruction and is the only method that confirms the correct anatomic position of the catheterization and in real time,avoiding traditionally the blind raking-out wire by the ophthalmologist alone.Compare to the classic DCR,its short therapeutic effects are equal but more convenient and fewer time and money-cost.
89089417|NCT02636257|Other|Dacryocystorhinostomy|Nasolacrimal duct obstruction is common among patients with epiphora,which is seriously affect the quality of life. The treatment principle is to restore or rebuild the lacrimal duct drainage channel. The classic operation type is dacryocystorhinostomy(DCR), which is complex for face-section particularly.After surgery the lacrimal passage can't siphon the tear out physically any more so that it will effect the patients' life.Besides,the operating time,bleeding volume,hospitalization time and total cost for the surgery is higher.
89089418|NCT00656461|Experimental|1|
89089419|NCT02633761|Active Comparator|Group 1|200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours
89089420|NCT02633761|Placebo Comparator|Group 2|placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.
89089421|NCT04161313||Cystic fibrosis|children with cystic fibrosis
89089422|NCT04161313||primary ciliary dyskinesia|children with primary ciliary dyskinesia
89226349|NCT04388839|Experimental|Arm B - Second Strike - Maintenance|Participants will receive conventional doses of Vincristine/Actinomycin D/Cyclophosphamide (VAC) until complete response (CR) for 12-42 weeks and then switch to up to 2 years of vinorelbine/oral cyclophoshamide
89226350|NCT04388839|Experimental|Arm C - Adaptive Therapy|Therapy with VAC that starts and stops based on response, adaptive timing of therapy, with a prolonged time to progression rather than complete remission goal
89226351|NCT04388839|Active Comparator|Arm - D Conventional Therapy|Participants will receive a chemotherapy combination based on published trials. An example would be 42 weeks of VAC but may also include irinotecan, doxorubicin, ifosfamide, etoposide.
89226352|NCT04387474|Experimental|Experimental group|brain-computer interface rehabilitation training and traditional rehabilitation training.
89226353|NCT04387474|Other|Control group|traditional rehabilitation training.
89226354|NCT04384965|Experimental|Accelerated iTBS|In the acute treatment phase, treatment will occur 8 times daily (50 min pause between treatments) on weekdays, until symptom remission is achieved (HRSD-24 score < to 10) or a maximum of 10 working days of daily treatment. In the tapering phase, treatments will be reduced to 2 treatment days per week for 2 weeks and then 1 treatment day per week for 2 weeks (4 weeks total). Patients will then enter the symptom-based relapse prevention phase including virtual check-in with study staff and a treatment schedule based on symptom level according to a modified relapse prevention algorithm that has been developed to prevent relapse after a successful course of ECT (known as the STABLE algorithm). The relapse prevention phase will last a maximum of 6 months.
89226355|NCT04384692|Experimental|Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)|See detailed description.
89226356|NCT04384367|Experimental|Rizatriptan 10mg+ Naproxen 550mg|Rizatriptan 10mg+ Naproxen 550mg
89226357|NCT04384367|Active Comparator|Maxalt 10mg|Rizatriptan10mg
89226358|NCT04384367|Active Comparator|Flanax 550mg|Naproxen 550mg
89226359|NCT04384367|Placebo Comparator|Placebo|Placebo
89226360|NCT04381130|Experimental|EF-009|In both the Phase I and Phase IIa portions of the study, subjects will be evaluated for response every 8 weeks after EF-009 wafer implantation for up to 2 years, by CT, PET/CT or MRI (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be assessed based on the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST v1.1). The total study duration for each subject consists of screening, treatment, and extended follow-up period and survival follow-up period.
89226361|NCT04377555|Experimental|All Participants|Main study participants will be evaluated at baseline, monitored and followed for a 1 year period with the option to participate in a 1 year extension. Participants in the CSF substudy will be followed for two years and will receive two additional doses of 600 mg ocrelizumab at Weeks 48 and 72.
89226362|NCT04374175||Adenocarcinoma group|Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.
89226363|NCT04374175||Control group|Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.
89226364|NCT04370756|Active Comparator|Ex only|Participants will perform 8 weeks of supervised exercise training (EX).
89226365|NCT04370756|Experimental|EX + BR|Participants will perform 8 weeks of supervised exercise training (EX) plus pre-exercise consumption of beetroot juice (BR).
89226366|NCT04360278||Plasma Donors|Persons who have recovered from COVID-19 or have been immunized against SARS-CoV-2 who meet criteria to donate plasma.
89226367|NCT04350463|Experimental|Arm A: SCLC in ICI naïve subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
89226368|NCT04350463|Experimental|Cohort B: SCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
89226369|NCT04350463|Experimental|Cohort C: sqNSCLC in ICI progressor subjects|"CC-90011 will be given orally (PO) at a dose of 40 mg on a once weekly basis in a continuous 28-day cycle.~Nivolumab will be administered intravenously at a dose of 480 mg every 4 weeks per local practice as a 30 minute or a 60-minute infusion as per local practice."
89226370|NCT04349189||Group 1|50 Men and Women with sickle cell disease and VTE
89226371|NCT04349189||Group 2|50 Men and Women with sickle cell disease but no VTE
89226372|NCT04349189||Group 3|50 Men and Women with sickle cell trait
89226373|NCT04349189||Group 4|50 ethnically matched Men and Women without sickle cell disease, sickle cell trait, or VTE
89226374|NCT04347629|No Intervention|Usual Care|Usual clinical care
89089423|NCT04161313||healthy controls|Age-matched healthy volunteers
89089424|NCT02633605||First Sense Breast Exam|
89089425|NCT00883753|Experimental|tocilizumab|Participants received tocilizumab 8 mg/kg intravenous (IV), maximum dose not exceeding 800 mg in a single infusion, every 4 weeks for up to 104 weeks or up to 4 weeks after tocilizumab became commercially available in the respective country whichever occurred first.
89089426|NCT02641717|Experimental|All subjects|All patients enrolled in this study will self-collect a vaginal swab (experimental) then have a physician collected vaginal swab (gold standard)
89089427|NCT04162639|Experimental|One donor|Participants will receive skin allograft from 1 distinct cadavers.
89089428|NCT04162639|Experimental|Two donors|Participants will receive skin allograft from 2 distinct cadavers.
89089429|NCT04162639|Experimental|Three donors|Participants will receive skin allograft from 3 distinct cadavers.
89089430|NCT04162639|No Intervention|Control|Participants will be burned patients with wounds that do not require skin allografts, but are instead reconstructed with their own skin (skin autografts) in a single stage.
89089431|NCT01210664|Experimental|Polyclonal Regulatory T Cells|Patients with Type 1 Diabetes Mellitus will have their regulatory T cells (Tregs) isolated by researchers and receive Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells by infusion
89089432|NCT02633839|Experimental|Adults who smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
89089433|NCT02633839|Experimental|Adults who don't smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
89089434|NCT02636335|Experimental|Bright Light|"8 a.m. study participants will be exposed to Bright Light (4500 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
89089435|NCT02636335|Experimental|Control|"8 a.m. study participants will be exposed to a Control Light Condition (230 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
89089436|NCT02632903|Experimental|Intravenous Zoledronic Acid|Intravenous Zoledronic Acid 0.025mg/kg at baseline and 6 months
89089437|NCT00657397|Experimental|A|Methadone inducted by a primary care physician
89089438|NCT00657397|Active Comparator|B|Methadone inducted (in CSAPA)
89089439|NCT04160611|Experimental|Premedication with Midazolam|Patients will be randomly divided into two groups, control and midazolam. The midazolam group will receive midazolam premedication in such a way that 7.5mg midazolam will be taken orally 30 minutes before the aspiration procedure. Because midazolam causes sedation, the woman will be monitored by midazolam after medical premedication to avoid possible complications and will not be allowed to get out of bed on her own for 30 minutes. After 30 min, all women, both test and control group, will begin aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
89089440|NCT04160611|No Intervention|No Premedication with Midazolam|Women in the control group will undergo aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
89089441|NCT04160299|Experimental|Dance-based exergaming|This will be an intervention-based study with single-group design, where participants will receive VR-based dance training for ten weeks. An anticipated 20 participants with a diagnosis of mild cognitive deficits will be recruited for initial screening
89089442|NCT02535559|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
89089443|NCT02535559|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
89089444|NCT04161001|Experimental|Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan, Amlodipine and Rosuvastatin, Ezetimibe
89089445|NCT04161001|Placebo Comparator|Olmesartan, Rosuvastatin, Ezetimibe|co-administration of Olmesartan and Rosuvastatin, Ezetimibe
89089446|NCT04161001|Placebo Comparator|Amlodpine, Olmesartan|co-administration of Olmesartan, Amlodipine
89089447|NCT02636413|Experimental|LacTEST|0,45 g of gaxilose po, once, per diagnostic test performed.
89089448|NCT02636413|Active Comparator|Hydrogen Breath Test|25 to 50 g of lactose po, once, per diagnostic test performed.
89089449|NCT04160767|Active Comparator|Probiotic|
89089450|NCT04160767|Placebo Comparator|Placebo|
89089451|NCT02633449|Experimental|cognitive behavioral therapy + tDCS|Group cognitive behavioral therapy combined with tDCS
89089452|NCT02633449|Active Comparator|cognitive behavioral therapy + sham-tDCS|Group cognitive behavioral therapy combined with sham-tDCS
89089453|NCT02633449|Placebo Comparator|cognitive behavioral therapy|Group cognitive behavioral therapy only
89089454|NCT02535637||Mothers-Infant|Mothers who were planning to exclusively breastfeed for six months were enrolled into the study along with their infant.
89089455|NCT04162717|Experimental|The Effect of Telephone Symptom Triage Protocols|"Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles.~Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later."
89089456|NCT04162717|No Intervention|Control group|The control group received standard nursing care applied at the hospital
89089457|NCT00911209|Experimental|Intervention|The Intervention group at each session will receive information on Heart healthy diet, lifestyle recommendations and diet and exercise counseling with a dietitian in order to achieve at least 7% weight loss (for example a person weighing 200 pounds will be encourage to lose at least 14 pounds).
89089458|NCT00911209|No Intervention|No Intervention|The standard of care group will receive information on Heart healthy diet at baseline visit and will return to a final visit about 28 weeks later.
89089459|NCT00881569|Experimental|1|CS-7017 tablets twice daily at strength ranging from 0.5 mg to 0.75 mg
89089460|NCT04017481|Experimental|Repetitive stimulating transcranial stimulation (rTMS)|Subjects receive 8 sessions M1 Neuromodulation using rTMS according to the protocol ( 80% resting motor threshold, 10 Hertz; 1000 pulses; 25 trains de 4 seconds con 25 seconds intertrain.
89089461|NCT04017481|Experimental|EEG guided Neurofeedback (NFB)|Subjects receive 8 sessions M1 EEG guided NFB with virtual reality goggles in order to modify the beta rhythm. The sessions have a duration of 20min
89089462|NCT04017481|Experimental|rTMS + NFB|Subjects receive both interventions sequentially
89089463|NCT04017481|No Intervention|No intervention|No interventions, the patient just comes to be evaluated sequentially according to the timing of experimental groups.
89089464|NCT04160143|Experimental|SBRT followed by pulmonary metastasectomy|SBRT+Surgery
89089465|NCT02636179||448 children|Children aged 11-15 years from a historical cohort born after In Vitro Fertilization or Intracytoplasmic Sperm Injection at Hospital Saint Joseph of Marseille
89089466|NCT02636179||1344 children|Children aged 11-15 years born spontaneously schooling in the same geographic area as case
89089467|NCT00657163|Experimental|1|fluoxetine
89089468|NCT00657163|Placebo Comparator|2|Placebo
89089469|NCT04032457|Active Comparator|A1 - SiHyDD to Moist|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
89089470|NCT04032457|Active Comparator|A2 - Moist to SiHyDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
89089471|NCT04032457|Active Comparator|A3 - SiHyDD to OASDD|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of ACUVUE® OASYS 1-Day contact lenses.
89089472|NCT04032457|Active Comparator|A4 - OASDD to SiHyDD|1 week of ACUVUE® OASYS 1-Day contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
89089473|NCT04032457|Active Comparator|A5 - SiHyDD to DT1|1 week of Test SiHyDD contact lenses followed by cross over to 1 week of Alcon DAILIES TOTAL 1® contact lenses.
89089474|NCT04032457|Active Comparator|A6 - DT1 to SiHyDD|1 week of Alcon DAILIES TOTAL 1® contact lenses followed by cross over to 1 week of Test SiHyDD contact lenses.
89089475|NCT04032457|Active Comparator|B1 - HydDD to Moist|1 week of Test HydDD contact lenses followed by cross over to 1 week of 1-DAY ACUVUE® Moist contact lenses.
89089476|NCT04032457|Active Comparator|B2 - Moist to HydDD|1 week of 1-DAY ACUVUE® Moist contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
89089477|NCT04032457|Active Comparator|B3 - HydDD to BioTrue|1 week of Test HydDD contact lenses followed by cross over to 1 week of BIOTRUE ONEday® contact lenses.
89089478|NCT04032457|Active Comparator|B4 - BioTrue to HydDD|1 week of BIOTRUE ONEday® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
89089479|NCT04032457|Active Comparator|B5 - HydDD to AqCom+|1 week of Test HydDD contact lenses followed by cross over to 1 week of DAILIES® AquaComfort PLUS® contact lenses.
89089480|NCT04032457|Active Comparator|B6 - AqCom+ to HydDD|1 week of DAILIES® AquaComfort PLUS® contact lenses followed by cross over to 1 week of Test HydDD contact lenses.
89089481|NCT00657475|Experimental|2|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin low dose (150 UI/Kg).
89089482|NCT00657475|Active Comparator|1|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin Full Dose (300 UI/Kg)
89089483|NCT02636023|Experimental|SPhENo-Cardiograph / ECG|SPhENo-Cardiograph and ECG
89089484|NCT02632981|Active Comparator|chronic periodontitis patients|gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
89089485|NCT02632981|Placebo Comparator|periodontally healthy controls|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
89089486|NCT04160689|Active Comparator|Group 1|Anyridge (Mega'Gen, Korea) 5° conical internal hexed connection
89089487|NCT04160689|Active Comparator|Group 2|Core (Bioimplant, Italy) 35° conical internal hexed connection (screw-vent style)
89089488|NCT02631889|Experimental|Transcollation technology|the use of transcollation technology for hilium dissection during Lung surgery
89089489|NCT02631889|Active Comparator|Traditional Electrocautery|The use of electrocautery for hilium dissection during lung surgery
89089490|NCT00657319||A|
89089491|NCT00881335|No Intervention|control group|
89089492|NCT00881335|Experimental|intervention|Intervention group were given flutter valve mucus clearance devices to do pulmonary function exercise
89089493|NCT02632825|Experimental|Nasal High Flow|NHF will be applied at 8 L/min (AIRVO 2) through (OPT 316) Optiflow nasal cannula interface without supplemental oxygen
89089494|NCT02632825|No Intervention|Control|Control is no NHF intervention
89089495|NCT00657631|Experimental|A|Acceptance and Commitment Therapy will be administered to all subjects.
89089496|NCT00661219|Active Comparator|Arm 1|
89089497|NCT00661219|Placebo Comparator|Arm 2|
89089498|NCT00665665|Experimental|A|
89089499|NCT00665665|Experimental|B|
89089500|NCT00665665|Experimental|C|
89089501|NCT00665665|Experimental|D|
89089502|NCT00665743|Experimental|A|PN400 (naproxen/esomeprazole)
89089503|NCT00665743|Active Comparator|B|naproxen 500 mg
89089504|NCT00665743|Active Comparator|C|naproxen 500 mg
89111079|NCT02801799|Experimental|Infusion group 3|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 300 mL/h. This infusion rate is experimental."
89111080|NCT02801799|Experimental|Infusion group 4|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 600 mL/h. This infusion rate is experimental."
89089505|NCT04156711|Experimental|Remote Ischemic Preconditioning|Remote ischemic preconditioning is carried out before the induction of general anesthesia. All four cycles will be completed before general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg (if systolic blood pressures exceeds 185 mmHg, the cuff will be inflated to at least 15 mmHg above the systolic blood pressure) resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia, the cuff is deflated, and the limb is reperfused for 5 minutes. This cycle is repeated 4 times. Pulse oximetry is performed on the RIPC limb to make sure that the blood flow is completely interrupted during ischemia
89089506|NCT04156711|No Intervention|Control|Will receive no intervention, but will go through same tests at the same time-points (endothelial function measured by reactive hyperemia index, blood samples, Heart rate variability and questionaires)
89089507|NCT02357992|Experimental|Stereotactic Radiotherapy (SRT)|"Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.~50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor."
89089508|NCT00661297|Experimental|Arm 1|
89089509|NCT00661297|Placebo Comparator|Arm 2|
89089510|NCT02842762|Sham Comparator|Non-paced|"cardiac surgery~3D TEE measurements of systolic dyssynchrony~right ventricular epicardial pacemaker lead (off)"
89089511|NCT02842762|Experimental|Paced|"The patient is randomized to the order of measurements taken, and serves as his own control.~cardiac surgery~3D TEE measurements of systolic dyssynchrony~right ventricular epicardial pacemaker lead (on)"
89089512|NCT02690896|Experimental|UCF Behavioral Intervention Group|The intervention group will be the UCF Caregiver Support. Participants will receive a 90 minute group session, once a week, for a period of 6 consecutive weeks.
89089513|NCT02690896|Active Comparator|Community Comparison Group|Comparison group members will come from potential local support groups include, but are not limited to, the support group at the Faith Assembly of God church, the caregiver support group at the First Baptist Church of Orlando, and the caregiver support group at the Alzheimer's and Dementia Resource Center.
89089514|NCT00879775|Experimental|Caffeine|Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour
89089515|NCT00879775|Placebo Comparator|Placebo|Intravenous injections of 100ml of normal saline over 1 hour
89089516|NCT02840344|Experimental|Couples MBSR|"Young breast cancer survivors and their partners take part in an 8-week Couples Mindfulness-Based Stress reduction (C-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor and partner will be asked to watch a video module, together, each week for a total of 8 weeks. The C-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
89089517|NCT02840344|Active Comparator|Individual MBSR|"Young breast cancer survivors take part in an 8-week Individual Mindfulness-Based Stress reduction (I-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor will be asked to watch a video module each week for 8 weeks in a row. The I-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
89089518|NCT00665899|Experimental|Cancer-Focused Relationship Enhancement|Cancer-Focused Relationship Enhancement
89089519|NCT00665899|Experimental|Couple's Cancer Education|Couple's Cancer Education
89089520|NCT00665899|No Intervention|Usual Care|Cancer-Related Community and Internet Resources
89089521|NCT00894790|Experimental|1|
89089522|NCT00894790|Active Comparator|2|
89089523|NCT04156867|Experimental|simple discectomy|traditional simple discectomy
89089524|NCT04156477|Experimental|Ketone ester|Intake of a ketogenic drink.
89089525|NCT04156477|Active Comparator|Isocaloric and -volumetric glucose drink|Intake of a taste matched glucogenic drink.
89089526|NCT04156477|Placebo Comparator|Isovolumetric tap water drink|Intake of a taste matched tap water drink.
89089527|NCT02840110||Post-ACTR|Subjects who have previously been treated with an ACTR T cell product
89089528|NCT00665977|Sham Comparator|A|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
89089529|NCT00665977|Active Comparator|Double Blind Treatment Group 2|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
89089530|NCT00665977|Active Comparator|Double Blind Treatment Goup 1|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
89089531|NCT02840500||Breakthrough Cancer Pain|No intervention (Non-interventional study)
89089532|NCT02631811|Experimental|Supportive /palliative care intervention|patients will be supported by a multidisciplinary palliative specialist team
89089533|NCT02631811|No Intervention|usual medical follow up|patients will be supported by the support care team if asked by the oncologist
89089534|NCT00666055||Group 1|30 post-menopausal HIV-infected women
89089535|NCT00666055||Group 2|12 pre-menopausal HIV-infected women
89089536|NCT02840734|Experimental|Kinesio taping|All subjects wore an eye mask and the taped leg was covered by clothes for preventing subjects and researchers from identifying different tapings due to double-blinding. Subjects layed down on the mat in a supine position with the hip flexed 30º and the knee flexed 60º. Y type tape was applied from a point 10 cm below the anterior superior iliac spine, bisected at the junction between quadriceps femoris tendon and the patella, ending at its inferior side. And another Y type tape was applied from the tibial tuberosity, bisected at the junction between patella tendon and the patella, ending at its superior side. The first 5 cm tape was not stretched and acted as the anchor. I type tapes were applied downward and inward to the superior and inferior meniscus of the patella respectively.
89089537|NCT02840734|Placebo Comparator|Placebo taping|Placebo tapes (3M tape) were applied with same method with Kinesio taping.
89089538|NCT02840734|No Intervention|No taping|In case of the no taping condition, the subject was treated along the same procedure which was closed subject's eyes with eye mask and covered the legs with clothes although applied anything on their legs. It might be able to minimize the error, because the researchers did not realize which condition the subject had.
89089539|NCT02839954|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
89089540|NCT04159285|Experimental|Group CBT|15-week group CBT with a focus on improvement of social interactions by cognitive re-modelling and role plays. Patients may simultaneously receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
89089541|NCT04159285|Experimental|Treatment as Usual|Patients may receive continuation ECT and/or individual psychotherapy and/or take anti-depressive medication.
89089542|NCT02690662|Experimental|Obese with kidney stones|Hypocaloric diet for 3 months
89089543|NCT02631655|Other|device 18FDOPA|impact of device 18F-FDOPA PET on treatment decisions
89089544|NCT02840188||Radius tilt angle|Children 0-16 years of age positive for distal forearm fracture and positive history of goalkeeper's fracture (to catch a ball).
89089545|NCT02840188||Normal control group|Children 0-16 years of age without radius fracture and no history of catching a ball.
89089546|NCT00661375|Experimental|Arm 1|
89089547|NCT04250974|Experimental|electroacupuncture|electroacupuncture at points after surgery
89089548|NCT04250974|Sham Comparator|electroacupuncture non-point|electroacupuncture at non-points after surgery
89089549|NCT04250974|No Intervention|Control group|only oral or injection painkiller were used after surgery
89089550|NCT00911287|Experimental|Single Arm|
89089551|NCT04154527||postpartum women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz) curved linear array ultrasound transducer was used (LOGIQe Ultrasound,General Electric Healthcare, USA) with the ultrasound unit set in B mode."
89089552|NCT04154527||nulliparous women with no pelvic floor disorders|"This group realised a set of 6 abdominal and pelvic floor exercises, with a muscle recruitment of 25% of maximum force.~Exercise A: Pelvic Floor contraction Exercise B: Pelvic Floor and Deep Abdominal muscles contraction Exercise C: Pelvic Floor, Deep Abdominal muscles contraction, and axial Stretching Exercise D: Pelvic Floor, Deep and Superficial Abdominal muscles contraction Exercise E: Abdominal Crunch Exercise Exercise F: Low pressure Abdominal Exercise The correct muscle contraction execution was controlled by superficial pelvic floor and abdominal electromyography.~The bladder base and neck displacement was registered by Transabdominal Ultrasound (TAUS) and Transperineal Ultrasound (TPUS) respectively. To image the bladder base and the bladder neck a 3.5 MHz (megahertz)curved linear array ultrasound transducer was used (LOGIQe Ultrasound,GE eneral Electric Healthcare, USA) with the ultrasound unit set in B mode."
89089553|NCT02837848|Experimental|Coactivation strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
89089554|NCT02837848|Active Comparator|Regular strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
89089555|NCT02631031|Other|morning administration|administration of single oral dose valsartan (160 mg) in the morning
89089556|NCT02631031|Other|evening administration|administration of single oral dose valsartan (160 mg) in the evening
89089557|NCT02839564|Experimental|Adhesiolysis group|Patients underwent laparoscopic adhesiolysis
89089558|NCT02839564|Placebo Comparator|Placebo group|Patients underwent diagnostic laparoscopy alone
89089559|NCT00911365|Placebo Comparator|normal saline|
89089560|NCT00911365|Experimental|autologous mesenchymal stem cells|
89089561|NCT04250272|Experimental|Serratus Anterior Plane Block|Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance. 20ml of 0.375% ropivacaine was slowly injected between the fascia of serratus anterior and latissimus dorsi near 5th rib.
89089562|NCT04250272|Active Comparator|Intercostal Nerve Block|Intercostal Nerve Block was performed just before closing the surgical incision while looking directly at the affected intercostal space. 10ml of 0.375% ropivacaine was delivered evenly at anterior and posterior intercostal spaces from the port site.
89089563|NCT02838160|Experimental|booklet Group|
89089564|NCT02838160|Experimental|Oral presentations group|
89089565|NCT02838160|Experimental|Clinical teaching in bedside Group|
89089566|NCT02839408|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
89089567|NCT02839408|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months.
89089568|NCT02839408|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500mg Azithromycin
89089569|NCT02838082|Experimental|Sleep Hygiene Protocol|Participants in this arm will undergo a 4 week sleep hygiene protocol
89089570|NCT02838082|Active Comparator|Standard of Care Protocol|Participants will undergo 4 weeks of current inpatient standard of care procedures in a rehabilitation facility
89089571|NCT02838004|Experimental|Single arm receiving Mini WELL Ready IOL|IOL implantation for cataract
89089572|NCT05334082|Experimental|FIFA 11+ Group|Teams will replace regular warm-up with the intervention protocol - FIFA11+ injury prevention program - during training sessions
89089573|NCT05334082|No Intervention|Control Group|Teams will maintain regular warm-up during training sessions
89089574|NCT02837614|Active Comparator|Group A (intramuscular dexamethasone)|In Group A patients, 1 ml of dexamethasone (4mg) administered in the deltoid muscle before commencement of surgical procedure
89089575|NCT02837614|Experimental|Group B (submucosal dexamethasone)|In Group B patients, 1 ml of dexamethasone was administered in submucosa after local anesthesia
89089576|NCT02837614|Placebo Comparator|Group C (control)|Group C patients continued without receiving any preoperative medication.
89089577|NCT02839486||vancomycin and cefoxitin pharmacokinetics|This is surgical prophylaxis and cefoxitin/vancomycin have to be administered to each patient of the study, before surgery
89089578|NCT05333536|Experimental|Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of UL and LL with theraband ,10 reps each.Upper limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower Limb: Flexors of hip, Extensors of hip,Plantar flexors.
89089579|NCT05333536|Active Comparator|Control group|control only participates in their yearly swimming trainings.
89089580|NCT00879229|Experimental|Ambrisentan|Participants were randomized to receive ambrisentan treatment at an initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 52 weeks
89089581|NCT00879229|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ambrisentan for 48 weeks, then transition to ambrisentan treatment at the initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 4 weeks.
89089582|NCT02837692|Experimental|Cohort 1|Participants assigned to Cohort 1 group A (elderly non-Asian), group B (young healthy non-Asian) and group C (healthy Japanese) will receive JNJ-42847922 10 mg, 3 hours after completing dinner.
89089583|NCT02837692|Experimental|Cohort 2|Participants assigned to Cohort 2 group A, group B and group C will receive JNJ-42847922 20 mg, 3 hours after completing dinner.
89089584|NCT02837692|Experimental|Cohort 3|Participants assigned to Cohort 3 group A and group C will receive JNJ-42847922 40 mg, 3 hours after completing dinner. Participants in group B will receive JNJ-42847922 40 mg, 3 hours after completing dinner in Period 1, followed by at least 7 days washout period, further followed by JNJ-42847922 40 mg, immediately after completing dinner.
89089585|NCT02837692|Experimental|Cohort 4|Participants assigned to Cohort 4 group B will receive JNJ-42847922 60 or 80 mg, 3 hours after completing dinner.
89089586|NCT04249960|No Intervention|Transition as usual|Young people in this group will receive usual care and transition as usual, they will be our control group.
89089587|NCT04249960|Experimental|Managed transition|Young people in this group will do the managed transition, they will be our experimental group.
89089588|NCT04249570|Experimental|Iodine|gastrostomy feeding tube is coated with a layer of Betadine by aseptic gauze before PEG technique
89089589|NCT04249570|No Intervention|No iodine|gastrostomy feeding tube is not coated with a layer of Betadine by aseptic gauze before PEG technique
89089590|NCT02837770|Active Comparator|Pacebo pill and Diclofenac Eye Drops|Pacebo pill will be administered 4 hours before the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
89089591|NCT02837770|Active Comparator|Oral Diclofenac and Diclofenac Eye Drops|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
89089592|NCT02837770|Placebo Comparator|Pacebo pill and Artificial Tears|Pacebo pill will be administered 4 hours before the IVI and one drop Artificial Tears will be instilled 45' prior to the IVI.
89089593|NCT02837458|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 30 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
89089594|NCT02837458|Sham Comparator|Sham Stimulation|Electrodes are placed over the arm for a 30 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
89089595|NCT00878995|Placebo Comparator|Standard of Care Therapy + Placebo Testosterone|Patients receive standard of care chemotherapy and/or radiation plus placebo testosterone intramuscularly (IM) weekly for 7 weeks.
89089596|NCT00878995|Active Comparator|Standard of Care Therapy + Testosterone|Patients receive standard of care chemotherapy and/or radiation plus testosterone (Testosterone Enanthate 100mg/ml) intramuscularly (IM) weekly for 7 weeks.
89089597|NCT02837536|Active Comparator|Horizontal iCare|In the horizontal iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the horizontal position first and then their IOP measured with the iCare tonometer held in the vertical position.
89089598|NCT02837536|Active Comparator|Vertical iCare|In the vertical iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the vertical position first and then their IOP measured with the iCare tonometer held in the horizontal position.
89089599|NCT04250584|Experimental|Test Device|Novel Mandibular Advancement Device
89089600|NCT04250584|Active Comparator|Predicate Device|Predicate Mandibular Advancement Device
89089601|NCT02837146|Experimental|Tocilizumab (TCZ) + Methotrexate (MTX)|"Induction phase:~From week 0 to week 24, all subjects will receive TCZ and MTX~Maintenance phase:~From week 24 to week 54, all subjects will receive MTX"
89089602|NCT02837068|Experimental|Wheelchair handrail compensator|When a patient sitting on the wheelchair, the physiotherapist put the paralysis upper limb on the handrail compensator and keep the limb in normal position for at least 60 minutes one day.
89089603|NCT02837068|Active Comparator|Ordinary wheelchair|When a patient sitting on the wheelchair, the paralysis upper limb was put on the ordinary handrail for at least 60 minutes one day.
89089604|NCT02837224||Preimplementation: Situate Locate System|Subjects/surgeries performed before implementation of the Situate Detection System.
89089605|NCT02837224||Implementation|Subjects/surgeries performed after implementation of the Situate Detection System.
89089606|NCT00657865|Active Comparator|1|Ramipril
89089607|NCT00657865|Placebo Comparator|2|Placebo
89089608|NCT00661765|Active Comparator|Chantix immediate release tablet formulation|
89089609|NCT00661765|Experimental|Varenicline transdermal delivery system|
89089610|NCT02839252|Experimental|Intervention Group|After the baseline tools have been completed, the child will be given the Iggy Comic Book and trading cards. Parents and their children will then watch a 12-minute Iggy Video. At the completion of the video and prior to going home, the child and parent will complete the same 2 measures on asthma knowledge and self-efficacy. At 1-month after this clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
89089611|NCT02839252|No Intervention|Control Group|After the baseline tools have been completed, the parent and child will go home. At 1-month after the initial study clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
89089612|NCT00657943|Experimental|1M|Metformin + Levemir x1
89089613|NCT00657943|Placebo Comparator|1P|Placebo + Levemir x1
89089614|NCT00657943|Experimental|2M|metformin + NovoMix
89089615|NCT00657943|Placebo Comparator|2P|Placebo + NovoMix
89089616|NCT00657943|Experimental|3M|Metformin + 4x therapy
89089617|NCT00657943|Placebo Comparator|3P|Placebo + 4x therapy
89089618|NCT02837380|Experimental|FF/UMEC/VI|Subjects will receive single combination dose of FF/UMEC/VI 100/62.5/25 mcg via a DPI in the morning for 7 days.
89089619|NCT02837302|Active Comparator|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
89089620|NCT02837302|No Intervention|General nutritional support|General nutritional support
88812871|NCT03214484|Active Comparator|computer|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
89089621|NCT04249804|Experimental|Intrathecal Mg group|45 patients will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine
89089622|NCT04249804|Experimental|IV Mg infusion group|45 patients will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia
89089623|NCT04249804|No Intervention|control|0.5% heavy bupivacaine in the spinal with no additives
89089624|NCT02630797|Placebo Comparator|Blueberry baseline|No blueberry products provided as part of the usual dietary intake
89089625|NCT02630797|Active Comparator|Blueberry Low|One blueberry product per day containing an equivalent of 0.75 cups of fresh blueberries provided as part of usual dietary intake for 42 days
89089626|NCT02630797|Active Comparator|Blueberry Medium|Two blueberry products per day containing an equivalent of 1.5 cups of fresh blueberries provided as part of usual dietary intake for 42 days
89089627|NCT02630797|Active Comparator|Blueberry High|Four blueberry products per day containing an equivalent of 3 cups of fresh blueberries provided as part of usual dietary intake for 42 days
89089628|NCT02836834|Experimental|Dose Escalation Cohort|JS001
89089629|NCT02836834|Experimental|Expanded cohort 1|The subjects of expanded cohort 1 will use repeated doses every 2 weeks like multiple dose cohorts
89089630|NCT02836834|Experimental|Expanded cohort 2|The subjects of expanded cohort 2 will use repeated doses every 2 weeks like multiple dose cohorts
89089631|NCT02631109|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
89089632|NCT02839096|Other|Once Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and placebo in the evening
89089633|NCT02839096|Other|Twice Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and 325mg of ferrous sulfate in the evening
89089634|NCT04156321|Experimental|Intervention|Group I (intervention) will receive 150 gm of Sajna shak/bora (Moringa) added with 25 gm concenstrated dal with 100 gm of rice as mid-morning snack in selected school 5 times a week for 6 months
89089635|NCT04156321|No Intervention|Control arm|Group II (Control) will rice, concenstrated dal and potato vaji. Both groups will receive calorie matched meal (411 kcal)
89089636|NCT02838784|Experimental|Artacent Human Amniotic Membrane|Patients randomized to the Artacent group will receive standard of care (off-loading with a removable cast walker and non-adherent dressings in addition to debridement and use of moisture retentive dressing) and the application of the Artacent amniotic allograft once every two weeks for up to 5 applications or until the ulcer has healed.
89089637|NCT02838784|Active Comparator|Lower Extremity Ulcer Standard of Care|Patients randomized to standard of care will receive off-loading with a removable cast walker and non-adherent dressings (e.g. Adaptic) in addition to debridement and use of moisture retentive dressings. An outer dressing will also be applied.
89089638|NCT02630485|Experimental|Graceful Lifestyle Changes & MYO|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
89089639|NCT02630485|Experimental|Graceful Lifestyle Changes|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
89089640|NCT02630485|Placebo Comparator|Letrozole & MYO|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
89089641|NCT02630485|Placebo Comparator|Letrozole|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
89089642|NCT00666133|No Intervention|2|Women in Group II (standard of care) will receive an 8 mL loading dose containing 4g magnesium sulfate administered manually per standard hospital protocol. The solution will be diluted with normal saline according to standard hospital practice, and given IV over 20 minutes. For women in Group II, the IV loading dose will be followed immediately with 20 mL treatment by IM injection, given as 10 mL (5 g magnesium sulfate) into each buttock. This dose will be followed by 10 mL treatments (5g magnesium sulfate) every four hours, injected into alternate buttock. Treatment will be discontinued when clinically indicated.
89089643|NCT00666133|Experimental|1|Women in Group I (Springfusor® arm) will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4will be administered using the Springfusor® pump. For women in Group I, the administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours for upto 24 hours postpartum.
89089644|NCT04159363|Experimental|Intervention group|Participants in the intervention group will receive an interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage) in addition to routine care provided by the respective hospitals.
89089645|NCT04159363|No Intervention|Control group|Participants in the control group will receive routine care provided by the respective hospitals . The routine care includes normal consultation with their attending physician, information concerning treatment plans, such as surgical procedures and its associated risks, preoperative preparations and postoperative care, treatment after discharge and/or subsequent adjunct therapy if required.
89089646|NCT02632513|Experimental|continuous ultrasonic irrigation|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
89089647|NCT02632513|No Intervention|Syringe irrigation|In the syringe irrigation group, irrigation was done using 27 gauge syringe.
89089648|NCT00661843|Experimental|1|Intervention group: Intervention constitutes of 2 supervised yoga classes per week incorporating gentle Yoga postures, relaxation and meditation sequences In addition: daily home based sessions of yogic relaxation and meditation using a pre-recorded audio CD
89089649|NCT00661843|No Intervention|2|Control in waiting to be crossed over after control phase completed. Participants of this group studied using same objective and subjective outcome measures.
89089650|NCT00879697|Active Comparator|Strength training|Patients who performed strength training. The strength training program was composed by 8 exercises for whole body performed at sub-maximal intensity prescribed according to the patients self-perceived effort
88812872|NCT01450319|Experimental|Cetuximab|
88812873|NCT05310656|Experimental|Mindfulness-based empowerment programme|
89089651|NCT00879697|Active Comparator|Walking training|Patients who performed walking training. The walking training was performed in a treadmill using sub-maximal intensity prescribed based in patients self perceived effort
89089652|NCT04159207||A Longitudinal Study of Inflammatory Pathways in Depression|We target to recruit 80 patients with Major Depression Disorder diagnosis and 80 patients with Major Depression Disorder with suicidal behavior.
89089653|NCT00894556|Experimental|Treatment Sequence A|Rizatriptan - Rizatriptan - Placebo
89089654|NCT00894556|Experimental|Treatment Sequence B|Rizatriptan - Placebo - Rizatriptan
89089655|NCT00894556|Experimental|Treatment Sequence C|Placebo - Rizatriptan - Rizatriptan
89089656|NCT00894556|Other|Baseline Phase|Sumatriptan
89089657|NCT00666367|Active Comparator|1|Vitamin D (D-cure) will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
89089658|NCT00666367|Placebo Comparator|2|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
89089659|NCT01210352|Experimental|CII Drug|Open Label
89089660|NCT00661921|Active Comparator|40 mg AMG 108 Q2W|
89089661|NCT00661921|Active Comparator|150 mg AMG 108 Q2W|
89089662|NCT00661921|Active Comparator|75 mg AMG 108 Q2W|
89089663|NCT00661921|Placebo Comparator|Placebo Q2W|
89089664|NCT04250506|Experimental|Treatment A: Daridorexant 50 mg|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
89089665|NCT04250506|Experimental|Treatment B: Daridorexant 200 mg|Daridorexant (ACT-541468) administered as film-coated tablets (4 x 50 mg) for oral use.
89089666|NCT04250506|Placebo Comparator|Treatment C: Placebo|Placebo administered as tablets (4 x 50 mg) for oral use.
89089667|NCT04250506|Active Comparator|Treatment D: Moxifloxacin 400 mg|Moxifloxacin administered as film-coated tablets for oral use.
89089668|NCT00666445||1|Patients diagnosed with Alzheimer's Disease
89089669|NCT00666445||2|Aged-matched normal controls
89089670|NCT02836912|No Intervention|Regular education|Regular education for COPD, including percussion and posture drainage.
89089671|NCT02836912|Experimental|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group.
89089672|NCT04158973|Experimental|VTE prophylaxis based on bleeding risk assessment|Patients will undergo a bleeding risk assessment to determine their entering VTE prophylaxis. Low bleeding risk patients will have once daily sc LMWH prophylaxis. Intermediate bleeding risk patients will have q 12 h sc low dose unfractionated heparin prophylaxis. High bleeding risk patients will have mechanical prophylaxis. Assigned prophylaxis can be interrupted as clinical judgement requires, e.g., for peri-procedural reasons. When patients are discharged, if they have low risk of bleeding at the time of discharge, whatever their bleeding risk assessment at the time of randomization, will begin 5 mg rivaroxaban prophylaxis (two 2.5 mg tablets) once daily with food, starting on the day of discharge, for 15 days.
89089673|NCT04158973|Active Comparator|Routine VTE prophylaxis in local clinical practice|VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge.
89089674|NCT02836678|Active Comparator|Control group|Ridge splitting, immediate implantand PRF.
89089675|NCT02836678|Experimental|Test group|Ridge splitting, immediate implant, Nanobone with PRF.
89089676|NCT00662077|Experimental|1|Ibandronate + Lifestyle modifications
89089677|NCT00662077|Other|2|Lifestyle modifications
89089678|NCT04250428|No Intervention|Control|Women in the control arm will have (standard) access to antenatal care.
89089679|NCT04250428|Experimental|Demand intervention|Women in this arm will receive a home visit by a study nurse at the beginning of their pregnancy that will inform them regarding the importance of iron and folic acid supplementation as well as malaria prophylaxis.
89089680|NCT04250428|Experimental|Supply intervention|Women in this arm will get a monthly visit by study nurses. Women who did not obtain supplements or malaria prophyllaxis through routine antenatal care services will be directly provided with the supplements and malaria drugs by the study nurse.
89089681|NCT01210118|Experimental|High intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
89089682|NCT01210118|Other|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
89089683|NCT00658099||A|
89089684|NCT00658099||B|
89089685|NCT00658177|Experimental|Arm 1|
89089686|NCT00658177|Placebo Comparator|Arm 2|
89089687|NCT02691104|Experimental|Intervention|"Use of the app and Fitbit alongside 5-7 week pulmonary rehabilitation programme (plus goal-setting help from physiotherapist), and then app and Fitbit plus intermittent contact with physiotherapist for 8 weeks after pulmonary rehabilitation~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
89089688|NCT02691104|Other|Control|"Attend 5-7 week pulmonary rehabilitation programme (usual care) and wear blinded Fitbit during pulmonary rehabilitation and for 8 weeks afterwards~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
89089689|NCT00658255|Experimental|1|
89089690|NCT00658255|Active Comparator|2|
89089691|NCT02838862||Response to Therapy|
89089692|NCT02838862||No therapy response|
89089693|NCT04158661||Tmin-group|"confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG~age ≥ 18 years~thymectomy ≥ three years"
89089694|NCT04158661||T0-group|"confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG~a very long disease history OR~age ≥ 18 years~rejecting a thymectomy or have contraindications for thymectomy"
89089695|NCT04158661||"MGTX-group (historical control group)"|"from MGTX-trial (Randomized Trial of Thymectomy in Myasthenia Gravis)"
89089696|NCT01208870|Experimental|Variety Group|Traditional family based weight control treatment program with components to reduce variety of high energy dense foods incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
89089697|NCT01208870|Experimental|Nutrition Education Control|Traditional family based weight control treatment program, without components from habituation theory incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
89089698|NCT02839018||Central nervous system (CNS) group|n=50 patients with presumed low prevalence of ICU-AW
89089699|NCT02839018||Severe sepsis/shock group|n=50 patients with presumed high prevalence of ICU-AW
89089700|NCT02836210|Active Comparator|Angled incision|Patients in this arm will undergo 27-gauge vitrectomy wound construction using angled (tunnel-like) incisions for trocar entry.
89089701|NCT02836210|Active Comparator|Straight Incision|Patients in this arm undergo 27-gauge vitrectomy wound construction using straight (perpendicular) incisions for trocar entry.
89089702|NCT00880555||Arm 1: Non-Dementia Memory Disorder|Elderly patients with non-dementia memory disorder (mild cognitive impairment)
89089703|NCT00880555||Arm 2: Control|Elderly controls without memory impairment
89089704|NCT00880555||Arm 3: Mild Alzheimer Disease|Patients with mild Alzheimer disease (but preserved routine activities of daily living)
89089705|NCT04249102|Experimental|CGM Group|The study group will be provided with a Continuous Glucose Monitoring system (Guardian Connect from Medtronic).
89089706|NCT04249102|Active Comparator|FGM Group|The control group will be provided with a Flash Glucose Monitoring system (Abbott Diabetes Care).
89089707|NCT00658489|Active Comparator|1|Residents randomized to the promotion of oral health group will receive training consisting of 7 modules (3 on the Bright Futures curriculum and 4 on oral health promotion). They will then enroll 3 patient-child dyads from their practice who present for a well child care visit. Outcomes will be obtained by completing pre- and post-study surveys. Residents will be observed by a faculty preceptor during 3 different patient encounters, and will receive feedback at the end of the 6 month study period.
89089708|NCT00658489|Active Comparator|2|Residents randomized to the prevention of iron deficiency group will complete one web-based module.
89089709|NCT02836288|Experimental|Ketamine|Oral ketamine 1.0 mg/kg mixed with syrup
89089710|NCT02836288|Placebo Comparator|Placebo|Oral placebo (syrup)
89089711|NCT02836288|Experimental|Ketamine after placebo|Optional oral Ketamine 1.0 mg/kg mixed with syrup for patients on placebo arm after 12 week treatment is completed.
89089712|NCT02632435|Other|Peripherally inserted central catheter|PICC line will be inserted for the delivery and duration of chemotherapy.
89089713|NCT02632435|Other|portacath|PORT will be inserted for the delivery and duration of chemotherapy and trastuzumab.
89089714|NCT00658645|Experimental|Bifeprunox|
89089715|NCT00658645|Placebo Comparator|Placebo|
89089716|NCT00658645|Active Comparator|Quetiapine|
89089717|NCT02836132|Active Comparator|Weight Watchers Online|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform.
89089718|NCT02836132|Experimental|Weight Watchers Online + Experience Success|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform. They will also receive 6 months of no-cost access to the Experience Success online platform, with 4 virtual reality scenarios for training in behavioral weight loss skills.
89089719|NCT01208402|Active Comparator|oral long acting beta blocker|oral administration of long acting beta blocker as standard of care on the day of surgery
89089720|NCT01208402|Experimental|Esmolol infusion|given 30 minutes prior to induction up to 12 hours post-op
89089721|NCT04248946|Experimental|MRI stream|"In this stream all patients receive 2 experimental interventions (anodal tDCS and cathodal tDCS) and a sham intervention (sham tDCS). These are delivered in randomised order, ensuring a balanced distribution of participants across possible orders. They will receive 5 sessions per condition (on consecutive days), for a total of 15 sessions.~I. Anodal, cathodal, sham II. Anodal, sham, cathodal III. Cathodal, anodal, sham IV. Cathodal, sham, anodal V. Sham, anodal, cathodal VI. Sham, cathodal, anodal"
89089722|NCT04248946|Experimental|Bedside stream|"In this stream all patients receive 1 experimental interventions (either anodal tDCS or cathodal tDCS) and 1 sham intervention (sham tDCS). These include only 1 session per condition and are delivered in randomised order, resulting in the following possible combinations:~I. Anodal, sham II. Cathodal, sham III. Sham, anodal IV. Sham, cathodal~Participants will be randomly assigned to the above groups ensuring a balanced distribution of participants across them."
89089723|NCT01208324|Active Comparator|Estrogen patch|Vivelle Dot® 0.10 - 0.15 mg/day for 8 weeks
89089724|NCT01208324|Active Comparator|Amino Acids|L-Isoleucine (4.2 g), L-Leucine (6.6 g), L-Lysine (4.8 g), L-Methionine (1.5 g), L-Phenylalanine (6.6 g), L-Threonine (3.0 g), L-Valine (4.8 g)
89089725|NCT01208324|Placebo Comparator|Placebo Patch|Placebo
89089726|NCT01208324|Placebo Comparator|Placebo pills|31.5 g of lactose or microcellulose
89089727|NCT05333848|Experimental|COMBO condition|An interactive stigma content website.
89089728|NCT05333848|Experimental|STIGMA condition|A non-interactive stigma content website.
89089729|NCT05333848|Experimental|INTERACT condition|An interactive non-stigma content website.
89089730|NCT05333848|Placebo Comparator|CONTROL condition|A non-interactive non-stigma content website.
89089731|NCT02838940|Experimental|cesarean in different indications|Women that are about to undergo an elective cesarean in different indications.
89089732|NCT00880399|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
89089733|NCT00880399|Experimental|Orvepitant 30 mg|30 mg/day (low dose)
89089734|NCT00880399|Experimental|Orvepitant 60 mg|60 mg/day (high dose)
89089735|NCT02835898||Test Group|Patients with periodontal disease that need conventional periodontal treatment
89089736|NCT02835898||Control Group|Periodontally-healthy individuals.
89089737|NCT02835976|Experimental|Olesoxime|Participants will receive a single dose of liquid suspension of 14C-labeled olesoxime containing an equivalent of 600 milligrams (mg) of the compound. The total amount of administered radiocarbon will be 93 microcuries (mcCi), or 3.447 megabecquerels (MBq).
89089738|NCT02838706||Elderly with hip fracture|The subjects are patients age ≥ 65 years requiring surgery for a hip fracture
89089739|NCT02836054|Other|Patients with cognitive disorders|lumbar punction + brain MRI
89089740|NCT02836054|Other|Patients without cognitive disorders|lumbar punction + brain MRI
89089741|NCT02835742|Active Comparator|Group1|Treatments for Group 1 include GM-CSF inhalation with 250 mcg/day/body of sargramostim (125 mcg BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
89089742|NCT02835742|Placebo Comparator|Group2|Treatments for Group 2 include placebo inhalation (Placebo BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
89089743|NCT05326360|No Intervention|group C|receive ramosetron i.v. 0.3mg at the end of surgery without additional ramosetron
89089744|NCT05326360|Experimental|group B|receive ramosetron i.v. 0.3mg at the end of surgery with two additional doses of ramosetron at 12- and 24- hour postoperative time points
89089745|NCT05326360|Experimental|group M|receive ramosetron i.v. 0.3mg at the end of surgery followed ramosetron 0.6 mg mix with the patient-controlled analgesia (PCA) regimen
89089746|NCT05325814||Device: Continuous monitoring system|Continuous monitoring system Recruited patients will be continuously monitored with Isansys Lifetouch patch, Nonin WristOx 3150, Isansys wireless blood pressure monitor (Meditech Blue BP-05) and standard monitoring at the post anesthesia care unit
89089747|NCT00666523|Experimental|1|
89089748|NCT00666523|Placebo Comparator|2|
89089749|NCT02838550|Experimental|MOI and PEDOMETER|Accessing to a motivational online intervention and wearing an unblinded pedometer (in order to receive feedback of the steps taken).
89089750|NCT02838550|Experimental|MOI (without PEDOMETER)|Accessing to a motivational online intervention and wearing a blinded pedometer (in order to not receive feedback of the steps taken).
89089751|NCT02838550|No Intervention|CONTROL|Wearing a blinded pedometer (in order to not receive feedback of the steps taken).
89089752|NCT00666601|Experimental|Pilot study|3 subjects, open lable, microdialysis single dose.
89089753|NCT00666601|Experimental|Main Study|12 subjects, open label, single dose of 600 mg.
89089754|NCT01207388|Experimental|Blinatumomab|Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
89089755|NCT02835664|Experimental|Nicotinamide Riboside|Supplementation of Nicotinamide Riboside (Niagen) of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
89089756|NCT02835664|Placebo Comparator|Placebo|Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
89089757|NCT00666991|Experimental|Nanotax, 50 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 50 mg/m2 once every 28 days until progression or unacceptable toxicity
89089758|NCT00666991|Experimental|Nanotax, 82.5 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 82.5 mg/m2 once every 28 days until progression or unacceptable toxicity
89089759|NCT00666991|Experimental|Nanotax, 125 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 125 mg/m2 once every 28 days until progression or unacceptable toxicity
89089760|NCT00666991|Experimental|Nanotax, 175 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 175 mg/m2 once every 28 days until progression or unacceptable toxicity
89089761|NCT00666991|Experimental|Nanotax, 225 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 225 mg/m2 once every 28 days until progression or unacceptable toxicity
89089762|NCT00666991|Experimental|Nanotax 275 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 275 mg/m2 once every 28 days until progression or unacceptable toxicity
89089763|NCT02835430|Experimental|Coronally advanced flap and PRF with DFDBA|Coronally advanced flap and platelet-rich fibrin membrane with demineralized freeze-dried bone allograft.
89089764|NCT02835430|Active Comparator|Coronally advanced flap and PRF without DFDBA|Coronally advanced flap and Platelet-rich fibrin membrane without demineralized freeze-dried bone allograft.
89089765|NCT02835508|Experimental|Treatment A|Participants will receive a single dose of 1 tablet of JNJ-56021927, 60 milligram (mg) on Day 1.
89089766|NCT02835508|Experimental|Treatment B|Participants will receive a single dose of JNJ-56021927, 120 mg (2 tablets*60 mg) on Day 1.
89089767|NCT02835508|Experimental|Treatment C|Participants will receive a single dose of JNJ-56021927, 240 mg (4 tablets*60 mg) on Day 1.
89089768|NCT02838394|Experimental|Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be dry needled; presence of muscle twitching (which would signify appropriate needle insertion) will be documented.
89089769|NCT02838394|Sham Comparator|Sham Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be SHAM dry needled with blunted needles, no actual penetration through the skin will occur.
89089770|NCT00667147|Experimental|A|
89089771|NCT00667147|Experimental|B|
89089772|NCT02835586|Experimental|paclitaxel delivery in femoropopliteal artery|
89089773|NCT04154215|Experimental|Dementia with Lewy Body (DLB) patients|
89089774|NCT00911521|Active Comparator|Vaccine arm|subjects receiving vaccination
89089775|NCT02835352|Experimental|Essential oils then oil massages|Essential oils massages will be done as needed during a period of 7 days, then oïl massages as needed will be done during a follow-up period of 7 days
89089776|NCT02835352|Experimental|Oil then essential oils massages|Oil massages will be done as needed during a period of 7 days, then essential oïl massages as needed will be done during a follow-up period of 7 days
89089777|NCT02630407|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (product name: Hymovis, Fidia Spa, Padova, Italy) the day after ACL reconstruction (after drainage removal)
89089778|NCT02630407|Placebo Comparator|Placebo group|Single injection of 3 ml saline solution the day after ACL reconstruction (after drainage removal)
89089779|NCT04248790|Experimental|Experimental: the mobile App|Participants in the intervention arm will receive access to all the app capabilities. The app features include information on HIV testing locations, sex and PrEP diary and reminder of taking PrEP.
89089780|NCT00667303||1|
89089781|NCT02838238|Experimental|X|Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles
89089782|NCT02838238|Placebo Comparator|Placebo|Placebo, bid, po, d1-14, every 3 weeks for 6 cycles
89089783|NCT00667537|Experimental|Radium-223 chloride|IV administrations of 100 kBq/kg b.w (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization). Two administrations took place with an interval of 6 weeks
89089784|NCT02835040|Experimental|CAP Service|
89089785|NCT02835040|Active Comparator|Usual care|
89089786|NCT01206764|Experimental|RAD001|
89089787|NCT04248400|No Intervention|Control|No intervention
89089788|NCT04248400|Active Comparator|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
89089789|NCT04248400|Experimental|Tai Chi|A 24 weeks Tai Chi training with three 1-hour section per week
89089790|NCT00667927|Other|1|
89089791|NCT02835118|Experimental|Surotomycin 0.5 g|Two oral doses of 0.25 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
89089792|NCT02835118|Experimental|Surotomycin 1 g|Two oral doses of 0.5 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
89089793|NCT02835118|Experimental|Surotomycin 2 g|Two oral doses of 1 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
89089794|NCT02835118|Placebo Comparator|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
89089795|NCT00668005|Experimental|Arm 1|
89089796|NCT00668005|Placebo Comparator|Arm 2|
89089797|NCT02835196||Optical Elastography Assessment of Skin Thickness|
89089798|NCT02835196||Visual Assessment of Skin Thickness|
89089799|NCT05333692|Active Comparator|NEPRO®|
89089800|NCT05333692|Experimental|Fresubin® Protein Energy DRINK|
89089801|NCT04154137||Patients undergoing digestive endoscopy|"All the patients, age ranged from 18 to 90 years, referred to Digestive Endoscopy Outpatients Clinic of the Department of Gastroenterology of the University Hospital Paolo Giaccone of Palermo, Italy"
89089802|NCT00668161|Experimental|1|Exercise
89089803|NCT00668161|No Intervention|2|Control
89089804|NCT00668239|Active Comparator|1|Laser treatment: laser was applied to the macular region according to the modified grid technique in inverted C, preserving 500 μ of the foveolus and avascular zone, with 100μ diameter shots, energy varying from 0.2 to 0.5 joules, with a time of exposure between 0.2 and 0.4 seconds. One hundred and fifty to 200 shots were applied according to the size of the retinal area². ND YAG laser (Crystal Focus (EMERED®) was used
89089805|NCT00668239|Experimental|2|triamcinolone as previously described
89089806|NCT04156009|Experimental|Treatment (+aromatherapy) group|
89089807|NCT04156009|Sham Comparator|Control (-aromatherapy) group|
89089808|NCT00668473||1|Subjects with diffuse scleroderma
89089809|NCT00668473||2|Healthy controls
89089810|NCT00668551||1|Telemedicine care
89089811|NCT00668551||2|Standard of care
89089812|NCT02631499|Experimental|Adjuvant TACE|TACE will be performed 4-6 weeks after hepatectomy in patients with preoperative CTC ≥2 Epirubicin, lipiodol and gelatin sponge articles are used in TACE.
89089813|NCT02631499|No Intervention|Control|no interventions were assigned after hepatectomy
89089814|NCT04156243|Experimental|CD19 CARvac T cells|CD19 CARvac T cells transduced with a lentiviral vector to express
89230259|NCT00801905|Active Comparator|1: Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
88812533|NCT03694756|Other|Pre-biopsy patients|Patients identified by a radiologist at the time of diagnostic evaluation. Once consent is obtained, the TMEM-MRI will be scheduled. After TMEM-MRI, the patient will undergo core biopsy as per usual radiology procedure, with additional FNA at the time of core biopsy (preceding the core biopsy). MenaINV and MenaCalc will be calculated from the FNA material. After the breast biopsy confirms the suspected diagnosis of invasive breast carcinoma, the patient will be referred to breast surgery and a treatment plan devised, as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be also calculated from the specimen obtained at the time of definitive surgery. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
89089815|NCT02630173|Experimental|Non vital teeth with apical radiolucency|Endodontic treatment was performed in non vital teeth with periapical radiolucency. Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 3 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 or #15K-files. Coronal flaring with # 2 and #3 Gates-Glidden drills was done.Calcium hydroxide was filled in the canals with the help of a lentulo spiral.At the second appointment,calcium hydroxide paste was removed and copious irrigation with 3% sodium hypochlorite was followed by 5.0 mL 17% ethylenediaminetetraacetic acid with a final rinse of 5.0 mL of 3% sodium hypochlorite. The canals were obturated with gutta-percha and ZOE sealer.
89089816|NCT02630173|Active Comparator|Vital teeth|Only scaling and root planing will be done in contralateral vital tooth with pocket depth >5mm .Non surgical periodontal treatment in the form of scaling and root planing was provided in minimum of two sessions using ultrasonic scaler (Satelec P5 Booster Suprasson) and hand instruments (Hu-friedy scalers and curettes).
89089817|NCT02632357|Experimental|AS group|Subjects with ULNTT asymmetry > 10°
89089818|NCT02632357|No Intervention|S group|Subjects with ULNTT symmetry
89089819|NCT00658957|Experimental|A|Daily standard wound care and topical application of the gentamicin-collagen sponge twice weekly
89089820|NCT00658957|Placebo Comparator|B|Daily standard wound care and topical application of the placebo sponge twice weekly
89089821|NCT00662467|Active Comparator|1|aspirin and clopidogrel
89089822|NCT00662467|Experimental|2|aspirin, clopidogrel, and warfarin
89089823|NCT00668941|Experimental|1|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a continuous regimen of daily teriparatide (20 mcg subcutaneously) for 48 months, in addition to alendronate. Biopsies will be performed at Week 7 or Month 7.5. The participants will then have the option to be followed while taking alendronate alone for 24-48 months.
89089824|NCT00668941|Experimental|2|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a cyclical regimen of teriparatide, in addition to alendronate. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an aption to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
89089825|NCT00668941|Active Comparator|3|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will continue taking alendronate alone. Biopsies will be performed at Week 7 and then participants in this group will be offered teriparatide as part of Group 2 or 3.
89089826|NCT00668941|Experimental|4|Participants in this group will receive a continuous regimen of teriparatide (20 mcg delivered subcutaneously) daily for 48 months. Biopsies will be performed at Week 7 or Month 7.5. At 24 months the participants will then have the option of taking alendronate and remaining in the study for another 24 months.
89089827|NCT00668941|Experimental|5|Participants in this group will receive a cyclical regimen of teriparatide. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an option to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
89089828|NCT00668941|Active Comparator|6|Participants in this group will take only calcium and vitamin D supplements. Biopsies will be performed at Week 7. Participants will then be offered the standard care for osteoporosis or they may enter the study in Group 4 or 5.
89089829|NCT00894322|Experimental|Cohort 1: Healthy Participants|A single 10-mg dose of exenatide once weekly suspension given to healthy participants via 3 subcutaneous (SC) injections at Day 1.
89089830|NCT00894322|Experimental|Cohort 2: Diabetes Participants|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks.
89089831|NCT00894322|Placebo Comparator|Cohort 2: Diabetes Participants Placebo|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks.
89089832|NCT02631265|Active Comparator|Reduction of insulin basal rate at the time of exercise|
89089833|NCT02631265|Active Comparator|Reduction of insulin basal rate 20 minutes prior to exercise|
89089834|NCT02631265|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
89089835|NCT00662623|Experimental|1|
89089836|NCT00662623|Active Comparator|2|Usual Care (Standard Care)
89089837|NCT00669097|Experimental|TKI258|
89089838|NCT00633412|Experimental|1|20mg Oral tablet daily
89089839|NCT00633412|Experimental|2|40mg Oral tablet daily
89089840|NCT00633412|Active Comparator|3|150mg oral twice daily
89089841|NCT00596635|No Intervention|Control Group|No cranberry capsules administered
89089842|NCT00596635|Active Comparator|One cranberry capsule|1 650mg cranberry capsule daily
89089843|NCT00596635|Active Comparator|Two cranberry capsules|1 650 mg cranberry capsule twice daily (bid)
89089844|NCT00662701|Active Comparator|1|Catheter RF ablation with complete circumferential ablation around the right and PVs, and additional lines between the lower and upper PVs, and towards the mitral valve ring.
89089845|NCT00662701|Active Comparator|2|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
89089846|NCT04159051|Experimental|Combined regional hyperthermia and salvage radiotherapy|
89089847|NCT00662779|Experimental|1|15 mcg arformoterol nebulizer + 1 inhalation of placebo inhalation powder
89089848|NCT00662779|Active Comparator|2|1 inhalation of formoterol fumarate inhalation powder (12 mcg/inhalation) + 2 ml of normal saline nebulizer
89089849|NCT00662779|Placebo Comparator|3|1 inhalation of placebo inhalation powder + 2 ml of normal saline nebulizer
89089850|NCT00669253|Experimental|1|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
89089851|NCT00669253|Active Comparator|2|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods (ultrasonic and manual means)
89089852|NCT00669253|Active Comparator|3|Surgery at baseline for all deep pockets using conventional methods (ultrasonic and manual means)
89089853|NCT02630329|Experimental|vNOTES adnexectomy|Vaginal Natural Orifice Transluminal Endoscopic Surgery
89089854|NCT02630329|Active Comparator|LSC adnexectomy|Laparoscopic adnexectomy
89089855|NCT00911599|Active Comparator|Conserve Total Hip with BFH|CONSERVE® A-Class Total Hip with BFH technology. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
89089856|NCT00911599|Active Comparator|Metal with Polyethylene Liner|Metal on polyethylene total hip replacement. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
89089857|NCT00662935|Experimental|2|the sequence of stimulation begins by OFF
89089858|NCT00662935|Experimental|1|the sequence of stimulation begins by ON
89089859|NCT02630095|Other|Control.|No anticoagulation，just routine follow up.
89089860|NCT02630095|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
89089861|NCT00669487|Experimental|1. GPO-VIR S 1 pill orally every 12 hours|
89089862|NCT00669487|Experimental|2 GPO-VIR Z 1 pill orally every 12 hours|
89089863|NCT00669487|Experimental|3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr|
89089864|NCT00669643|Active Comparator|R-MDT PB|R-MDT PB group: standard/regular treatment recommended by WHO - All patients presenting fewer than 6 skin lesions will receive the standard treatment regimen for paucibacillary patients as the intervention; Intervention - PB 6 doses of rifampicin and dapsone
89089865|NCT00669643|Experimental|U-MDT PB|U-MDT PB group: a unified treatment for all patients - All patients presenting fewer than 6 lesions (WHO PB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - PB 6 doses of rifampicin, clofazimine and dapsone
89089866|NCT00669643|Experimental|R-MDT MB|R-MDT MB group: standard/regular treatment recommended by WHO - All patients presenting 6 skin or more lesions will receive the standard treatment regimen for multibacillary patients as the intervention; Intervention - MB 12 doses of rifampicin, clofazimine and dapsone
89089867|NCT00669643|Experimental|U-MDT MB|U-MDT MB group: a unified treatment for all patients - All patients presenting 6 lesions or more (WHO MB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - MB 6 doses of rifampicin, clofazimine and dapsone
89089868|NCT00669721|Experimental|A|This patients start a run in period with LMWH schedule as hemodialysis circuit anticoagulation. Then they'll undergo hemodialysis with LMWH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to UFH schedule. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
89089869|NCT00669721|Active Comparator|B|The patients randomized to receive UFH will start a run in period with this heparin schedule. Then they'll undergo hemodialysis with UFH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to LMWH. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
89089870|NCT00669799|Experimental|1|clyndamyacin
89089871|NCT00669799|Experimental|2|gentamicin
89089872|NCT04158505||non-interventional study|
89089873|NCT00659347|Active Comparator|1|
89089874|NCT00659347|Placebo Comparator|2|
89089875|NCT00894166|Active Comparator|Nicotine Replacement Therapy Responder|Nicotine Responders
89089876|NCT00894166|Active Comparator|Pre-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Zyban (bupropion) in combination with nicotine patches
89089877|NCT00894166|Active Comparator|Pre-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Chantix (varenicline)
89089878|NCT00894166|Active Comparator|Pre-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to continued use of nicotine patches
89089879|NCT00894166|Active Comparator|Post-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Zyban (bupropion) in combination with nicotine patches
89089880|NCT00894166|Active Comparator|Post-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Chantix (varenicline)
89089881|NCT00894166|Active Comparator|Post-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to continued use of nicotine patches
89089882|NCT00880165|Active Comparator|Arm 1|In-laboratory testing followed by continuous positive airway pressure treatment
89089883|NCT00880165|Active Comparator|Arm 2|Home unattended testing followed by continuous positive airway pressure treatment
89089884|NCT02834650|Experimental|Group 1a|Group 1a comprises healthy volunteers who will complete a Cardiac MRI without contrast. A subset of healthy volunteers will have a repeat MRI at Children's Hospital of Orange County.
89089885|NCT02834650|Experimental|Group 1b|"Group 1b comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test.~A subset of boys with DMD will have a repeat MRI with contrast at Children's Hospital of Orange County."
89089886|NCT02834650|Experimental|Group 2|Group 2 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a repeat MRI scan with contrast at 6 Months.
89089887|NCT02834650|Experimental|Group 3|Group 3 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a genetic testing.
89089888|NCT04032223|Experimental|3D printed metal copings|3D printed primary and secondary metal copings inderctly from 3D printed resin in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
89089889|NCT04032223|Active Comparator|Cast metal copings|Cast metal primary and secondary metal copings in mandibular implant supported telescopic overdenture , Single Implants are placed in the interforaminal region bilaterally .
89089890|NCT00659503|Active Comparator|1|Ciclesonide 200µg
89089891|NCT00659503|Placebo Comparator|2|Placebo
89089892|NCT04248556|Experimental|subjects, 18-59 y, healthy|patch test with investigation product
89089893|NCT00663013|Active Comparator|1|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
89089894|NCT00663013|Active Comparator|2|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
89089895|NCT02834728||Frail elderly people|A group of elderly people hospitalised in medical wards via emergency department
89089896|NCT04158193|Experimental|Acupuncture group|Subjects in the acupuncture group are given acupuncture treatment.
89089897|NCT04158193|Experimental|Sham acupuncture control group|Subjects in the sham acupuncture control group are given non-acupoint shallow acupuncture.
89089898|NCT02834572|Experimental|All About Me|assessment and algorithm to provide participants with a tailored recommendation of their optimal HIV testing approach
89089899|NCT02834572|Active Comparator|Control|HIV testing information
89089900|NCT04158115|Experimental|Entire Spinal Mobilization|Entire Spinal Mobilization( All spinal segment from Co-C1to L5-S1 Moist heat. Soft tissue Mobilization Exercises. (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
89089901|NCT04158115|Active Comparator|Segmental Mobilization|Segmental Mobilization. (All lumbar segment from L1-L2 to L5-S1) Moist heat. Soft tissue Mobilization Exercises (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
89089902|NCT00670189|Experimental|BMS-833923|
89089903|NCT00663091|Experimental|Bacteriophages|
89089904|NCT00670345|Experimental|1|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
89089905|NCT00670345|Placebo Comparator|2|Patients belonging to the control group will receive the same volume of saline infusions.
89089906|NCT04153981|Experimental|Insulin Glargine|Participants received insulin glargine once a day (QD) subcutaneously (SC) with a starting dose of 10 units. Participants self-titrated once or twice weekly until fasting blood glucose level was lowered to <100 milligrams per deciliter (mg/dL). Dose was reduced by 4 units in case of hypoglycemia.
89089907|NCT02631343|Experimental|Intervention KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
89089908|NCT02631343|Other|Control|Routine visits by government health workers
89089909|NCT04153903||Patients with intermediate lesions|Imaging cohort will be performed invasive angiography and optical coherence tomography (or Coronary CT angiography) with FFR(Fractional Flow Reserve) values of the intermediate lesions (50-70% stenosis)
89089910|NCT01165229|Experimental|Zoster vaccine group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
89089911|NCT01165229|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
89089912|NCT00596011|Active Comparator|Polyphenon E Treatment|Polyphenon E, 200 mg epigallocatechin gallate (EGCG) twice a day (BID)
89089913|NCT00596011|Placebo Comparator|Placebo Administration|Matching placebo BID
89089914|NCT04153825|Active Comparator|Active TENS Group|Ten sessions of active conventional TENS and hydrocollator hot-pack.
89089915|NCT04153825|Active Comparator|Active IFC Group|Ten sessions of active interferential current and hydrocollator hot-pack.
89089916|NCT04153825|Sham Comparator|Sham TENS Group|Ten sessions of sham TENS and hydrocollator hot-pack.
89089917|NCT04153825|Sham Comparator|Sham IFC Group|Ten sessions of sham IFC and hydrocollator hot-pack.
89089918|NCT02632201|Experimental|PIK-HER2 cells|PIK-HER2 cells treatment will be performed every 3 weeks with a total of three periods.
89089919|NCT02632201|Active Comparator|DC-PMAT|DC-PMAT treatment will be performed every 3 weeks with a total of three periods.
89089920|NCT00659659|Experimental|1|MEDI-563
89089921|NCT00659659|Experimental|2|MEDI-563
89089922|NCT00659659|Placebo Comparator|4|Placebo
89089923|NCT00659659|Placebo Comparator|5|Placebo
89089924|NCT00670501|Experimental|1|LY333334 40 micrograms/day plus calcium and vitamin D
89089925|NCT00670501|Experimental|2|LY333334 20 micrograms/day plus calcium and vitamin D
89089926|NCT00670501|Placebo Comparator|3|Placebo plus calcium and vitamin D
89089927|NCT02631421||Pulmonary Arterial Hypertension|Clinical diagnosis of pulmonary arterial hypertension
89089928|NCT02631421||Healthy subjects and patients with other causes of PH|Patients referred for right heart catheterization who do not have PAH
89089929|NCT05657093|Active Comparator|Beetroot juice|The swimmers ingested a shot of Beet-It 70 ml beetroot juice (BJ)) 3 hours before undergoing a 2x6x100m crawl intermittent maximal speed performance test.
89089930|NCT05657093|Placebo Comparator|Placebo|The swimmers ingested a shot of Beet-It (70 ml placebo (PL)) 3 hours before undergoing a 2x6x100m crawl intermittent maximal speed performance test.
89089931|NCT04153669|No Intervention|Control|This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.
89089932|NCT04153669|Experimental|Exercise-No NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions."
89089933|NCT04153669|Experimental|Exercise-NMES|"This group will continue with regular visits to the specialist. This visits include recommendations to improve lifestyle.~The exercise protocol includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions. Additionally, this group will receive neuromuscular electrical stimulation (NMES) concomitant to the strength training."
89089934|NCT00663247|Placebo Comparator|B|placebo used as control for comparison with active drug
89089935|NCT00663247|Active Comparator|A|
89089936|NCT02629939|No Intervention|questionnaires|"Questionnaires will be distributed to families of heart patients to test the theoretical knowledge to perform CPR The questionnaires were distributed to internal, cardiology clinics and clinic T by a doctor, Paramedic or medical student. The family will be asked to fill out the questionnaire independently.~The questionnaires will be distributed in Hebrew, Arabic, Russian and English The research questionnaire will include questions about able to perform basic CPR"
89089937|NCT02629939|Experimental|to participate in a short course for learning CPR|": The investigators will offer patients and their relatives to participate in a short course for learning CPR.~Relatives will receive a prescription Containing a proposal for participation in the course~Prescription will be awarded in four places:~-.Family physicians as a suggestion during a routine visit / presentation of cardiac problem~Heart Rehabilitation Institute - cardionegev~Doctors internal medicine department as part of a patient's discharge letter with heart disease~Doctors in cardiology clinic The prescription will be accompanied by several minutes of explanation about the program and its importance The investigators consider the level of responsiveness and participation, find out which arm yielded the highest number of participants (actual turnout of the total prescriptions distributed) And how to expand their activities"
89089938|NCT04158271|Experimental|Prone Position|Evaluation of Techniques for tracheal tube Exchange in prone position
89089939|NCT04158271|Experimental|Laryngeal tube|Evaluation of Techniques for tracheal tube Exchange in patients with laryngeal tube (LT)
89089940|NCT04158271|Experimental|Endotracheal tube Leackage|Evaluation of Techniques for tracheal tube Exchange in critical care patients with a endotracheal tube and a high leackage
89089941|NCT01163747|Active Comparator|Methotrexate|Participants continued to receive their standard dose of methotrexate up to Week 8. From Week 8 participants also received 8 mg/kg tocilizumab intravenously every 4 weeks until Week 20. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
89089942|NCT01163747|Experimental|Tocilizumab + Methotrexate|Participants received 8 mg/kg tocilizumab intravenously at Baseline (Day 1) and every 4 weeks up to Week 20, in addition to their standard dose of methotrexate. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
89089943|NCT00663325|Experimental|1|Lactic acid in small quantity during 21 days
89089944|NCT00659893|Experimental|1|Cohort 1 One 25 cm2 treatment area; on one arm
89089945|NCT00659893|Experimental|2|Cohort 2 One 50cm2 contiguous treatment area; on one arm
89089946|NCT00659893|Experimental|3|Cohort 3 Two 25cm2 treatment areas; one on each arm
89089947|NCT00659893|Experimental|4|Cohort 4 One 25cm2 treatment area; and one 50cm2 contiguous treatment area; one on each arm
89089948|NCT00659893|Experimental|5|Cohort 5 One 75cm2 contiguous treatment area; on one arm
89089949|NCT00659893|Experimental|6|Cohort 6 Two 50cm2 contiguous treatment area; one on each arm
89089950|NCT00659893|Experimental|7|Cohort 7 One 25cm2 treatment area; and one 75cm2 contiguous treatment area; one on each arm
89089951|NCT00659893|Experimental|8|Cohort 8 One 100cm2 contiguous treatment area; on one arm
89089952|NCT02629783|Experimental|Physiotherapy + Corticosteroid injection + Psychomotor therapy|Usual care + intervention
89089953|NCT02629783|Active Comparator|Physiotherapy + Corticosteroid injection|Usual care
89089954|NCT01163279|Experimental|Cognitive Training|
89089955|NCT01163279|Active Comparator|Psychosocial Education|
89089956|NCT04155931||body temperature measurement|The investigators planned to perform prospectively in 80 children with ASA I according to the American Society of Anesthesia (ASA) Anesthesia Risk Scale between 6 months and 7 years of age in both sexes who underwent inguinal hernia, undescended testes and hydrocele surgery
89089957|NCT02629705|Other|Group A|"Placebo intervention~Assessment block (3 days)~Washout-phase of 21-35 days~Carrageenan intervention~Assessment block (3 days)"
89089958|NCT02629705|Other|Group B|"Carrageenan intervention~Assessment block (3 days)~Washout-phase of 21-35 days~Placebo intervention~Assessment block (3 days)"
89089959|NCT00670657|Experimental|1|AmBisome® 2 mg/kg/day in a unique daily IV administration
89111081|NCT02801799|Active Comparator|Infusion group 5|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 1800 mL/h. This infusion rate is normal clinical practice when administering a perineural bolus of ropivacaine."
89226375|NCT04347629|Experimental|Video Decision Aid|The video intervention consists of a video decision aid along with a video declaration (ViDec), which is recorded by the patient. The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
89226376|NCT04322448||Cubital Tunnel Syndrome Patients|Cubital Tunnel Syndrome patients. Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
89226377|NCT04322448||Peroneal Nerve Decompression Patients|Patients with compressive peroneal nerve neuropathy and will undergo a Peroneal Nerve Decompression (PND). Patients will undergo standard of care exams and surgery. During surgery, the surgeon will apply the mechanomyography (MMG) to the targeted nerve immediately prior and post decompression. Subjects will be followed until they are 6 months postop.
89226378|NCT04315285|Active Comparator|Control group|12 sessions of treadmill training with instruction of 'swing your arms'
89226379|NCT04315285|Experimental|Heel-strike group|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
89226380|NCT04315285|Experimental|Big step group|12 sessions of treadmill training with instruction of 'lift your foot up high'
89226381|NCT04315285|Experimental|Internal focus heel-strike|12 sessions of treadmill training with instruction of 'strike the ground with your heel'
89226382|NCT04315285|Experimental|External focus shoe-strike|12 sessions of treadmill training with instruction of 'strike the ground with your shoe-heel'
89226383|NCT04312178|Other|return vaginal self-swab by mail|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail
89226384|NCT04312178|Other|financial incentive mail-back vaginal self-swab|Socially disadvantaged women who have received a vaginal self-swab and have to return it by mail to obtain a cash incentive
89226385|NCT04312178|Other|handing over the vaginal swab to a professional|Socially disadvantaged women who have received a vaginal self-swab and need to report it to a health professional
89226386|NCT04312178|Other|financial incentive the vaginal self-swab to a pro|Socially disadvantaged women who have received a vaginal self-swab and have to report it to a health professional to obtain a cash incentive
89226387|NCT04311632|Experimental|Arm 1|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
89089960|NCT01162499|Experimental|Exendin-(9-39) first, then Vehicle|"After an overnight fast, an intravenous (IV) infusion of Exendin-(9-39) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1). The Exendin-(9-39) dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects.~The next day, all procedures will be repeated except subjects will receive an IV infusion of normal saline (vehicle) over 6 hours."
89089961|NCT01162499|Active Comparator|Vehicle first, then Exendin-(9-39)|"After an overnight fast, an intravenous (IV) infusion of normal saline (vehicle) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1).~The next day, all procedures will be repeated except subjects will receive an IV infusion of Exendin-(9-39) which will be started 1 hour prior to the meal challenge and continue for 5 hours. The dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects."
89089962|NCT04153513|Experimental|Lanolin|
89089963|NCT04153513|Active Comparator|Mother's milk|
89089964|NCT00659971|Experimental|1|PAC113 0,15% mouthrinse
89089965|NCT00659971|Experimental|2|PAC113 0,075% mouthrinse
89089966|NCT00659971|Experimental|3|PAC113 0,0375% mouthrinse
89089967|NCT00659971|Active Comparator|4|Nystatin suspension
89089968|NCT05657015|Experimental|Lepidium sativum|15 participants 15 participants with localized stage II or III, and grade A periodontitis received about 2ml of locally delivered Lepidium sativum in situ gel with scaling and root surface debridement once at the beginning of the study
89089969|NCT05657015|Active Comparator|simvastatin|15 participants with localized stage II or III, and grade A periodontitis received about 1.2% of locally delivered Simvastatin in situ gel with scaling and root surface debridement once at the beginning of the study
89089970|NCT04314479|Experimental|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes
89089971|NCT04314479|Other|Symptom Assessment Only|For participants randomized to the control condition weekly symptom assessment telephone calls will be completed by staff at the University of Arizona Cancer Center Behavioral Measurements Interventions Shared Resource (BMISR). At week 13 an exit interview will be completed by the study coordinator to record participants feedback regarding study intervention, length, coaches, etc… In addition, staff from BMISR will call to repeat all baseline measures with the exception of the demographic questionnaires. Symptom assessment calls will take approximately 15 minutes.
89089972|NCT02887313|Experimental|Locally advanced rectal cancer|Locally advanced rectal cancer receiveing total neoadjuvant treatment
89089973|NCT01206140|Experimental|Arm I (selumetinib and temsirolimus)|Patients receive selumetinib PO twice daily on days 1-28 and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22.
89089974|NCT01206140|Experimental|Arm II (selumetinib)|Patients receive selumetinib as in arm I. Patients who experience disease progression may cross over to arm I.
89089975|NCT01162421|Experimental|Early Adalimumab|Participants in the Early Adalimumab arm will receive adalimumab and methotrexate at Baseline and every other week for study duration.
89089976|NCT01162421|Active Comparator|Standard of Care|Participants in the Standard of Care arm will receive methotrexate and other disease modifying antirheumatic drugs as per local treatment guidelines and study doctor's judgement. Adalimumab may be initiated after a minimum of 6 months.
89089977|NCT05366387|Sham Comparator|Aerosol delivery without intrapulmonary percussive ventilation (Control condition)|"A radiolabelled 99mTc-DTPA aerosol is generated with a jet nebuliser and is inhaled by the subject through a device (connecting tubes, filters) connecting the nebuliser with 1) a mouthpiece and 2) an intrapulmonary percussive ventilation device which is turned off.~Aerosol deposition in fibrotic lung regions is characterized by SPECT imaging."
89089978|NCT05366387|Active Comparator|Aerosol delivery with intrapulmonary percussive ventilation (IPV condition)|"A radiolabelled 99mTc-DTPA aerosol is generated with a jet nebuliser and is inhaled by the subject through a device (connecting tubes, filters) connecting the nebuliser with 1) a mouthpiece and 2) an intrapulmonary percussive ventilation device which is turned on (frequency=1 Hz, pressure to be determined in phase 1 for each patient, in the 5-40 cm H2O range).~Aerosol deposition in fibrotic lung regions is characterized by SPECT imaging."
89089979|NCT01162343||Older Emergency Department Patients|Patients who were 65 years or older from the emergency department were enrolled.
89089980|NCT02885519|No Intervention|Control|Standard treatment and standard vocational rehabilitation
89089981|NCT02885519|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
89089982|NCT02885519|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
89089983|NCT02885441|Experimental|Ketorolac|Ketorolac,10 mg, 3 times daily from time of enrollment until 72 hours from enrollment for up to a maximum of 9 doses, along with the standard medical treatment
89089984|NCT02885441|No Intervention|Control|The standard medical treatment
89089985|NCT04314791||US scan with calculation of the PAI|
89089986|NCT02885597|Experimental|Juanbi group|participants should administrate both Juanbi pill and Methotrexate
89089987|NCT02885597|Placebo Comparator|placebo group|participants should administrate both Juanbi pill placebo and Methotrexate
89089988|NCT01188551|Experimental|dexmedetomidine w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of dexmedetomidine 1mcg/kg given intranasally in OR.
89089989|NCT01188551|Active Comparator|fentanyl w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of fentanyl 2mcg/kg given intranasally in OR.
89089990|NCT01188551|Experimental|dexmedetomidine w/o midazolam|1 dose of dexmedetomidine 1mcg/kg given intranasally in OR without any pre-medication.
89089991|NCT01188551|Active Comparator|fentanyl w/o midazolam|1 dose of fentanyl 2mcg/kg given intranasally in the OR without any pre-medication.
89089992|NCT04316429|Active Comparator|Egg phase:|Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets.
89089993|NCT04316429|Placebo Comparator|Control phase:|The participants will consume a vegan diet for 6 weeks.
89089994|NCT05293379||Patients sensitized in the VACCIPREV program|Patients from 3 vaccination centers who agreed to participate to the VACCIPREV program by using the teleconsultation booth and completing the questionnaires of tobacco dependance and assessment of sleep quality.
89089995|NCT01161407|Placebo Comparator|Placebo|Placebo control for calcium carbonate, given in same capsule form as the calcium carbonate, 3 times per day with meals.
89089996|NCT01161407|Active Comparator|Calcium Carbonate (Phosphate Binder)|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium.
89089997|NCT01161173||Erlotinib|Participants received erlotinib (Tarceva) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics. The recommended daily dose of erlotinib is 150 mg orally once daily.
89089998|NCT01159769|Experimental|Olopatadine 0.2%|1 drop self-administered in each eye once daily in the morning for 7 days
89089999|NCT01159691||Neupro|Routine treatment as per approved label in Europe/ in accordance with the terms of the local marketing authorization for Neupro® transdermal patch.
89090000|NCT02885207|Other|Focal epilepsy of unknown cause|
89090001|NCT05280119|Experimental|Patients benefitting ultrasound examination|This is the only arm of the study. Patients with an indicative clinical picture that leads the clinician to resort to the use of an ultrasound to potentially support the diagnosis will be examined to verify the presence of pleural effusion or intra-abdominal effusion, or to identify basilic vein. The patients will be assessed first with the echOpen device and second witn an ultrasound routinely used in the department. In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
89090002|NCT01157897|Experimental|Cohort 1: 15 μg VMP001|15ug VMP001 per vaccination on days -1 or 0, 28, and 84. P. vivax sporozoite challenge on day 98.
89090003|NCT01157897|Experimental|Cohort 2: 30 μg VMP001|30ug VMP001 per vaccination on days 14, 42, and 84. P. vivax sporozoite challenge on day 98.
89090004|NCT01157897|Experimental|Cohort 3: 60 μg VMP001|60ug VMP001 per vaccination on days 28, 56, and 84. P. vivax sporozoite challenge on day 98.
89090005|NCT01157897|Other|Control|No Vaccinations given for controls. P. vivax sporozoite challenge on day 98.
89090006|NCT04316507|Experimental|Oncologist led genetic counselling and testing|All subjects receive Oncologist Led Genetic Counselling and Testing
89090007|NCT01185821|Experimental|BAF312 10 mg/2 mg|10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
89090008|NCT01185821|Experimental|BAF312 2 mg/2 mg|2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
89090009|NCT01185821|Experimental|BAF312 1.25 mg/2 mg|1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
89090010|NCT01185821|Experimental|BAF312 .5 mg/2 mg|.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
89090011|NCT01185821|Experimental|BAF312 .25 mg/2 mg|.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
89090012|NCT02885285|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
89090013|NCT02885285|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
89090014|NCT02885285|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
89090015|NCT02885285|Active Comparator|No Exercise Class|Subjects randomly selected for the no class group will not participate in the study exercise classes. Subjects will still complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
89090016|NCT00893464|Experimental|IXAZOMIB|
89090017|NCT05318326|Placebo Comparator|Placebo control group|Placebo control group
89090018|NCT05318326|Experimental|Yogliptin 200mg group|Yogliptin 200mg group
89090019|NCT05318326|Experimental|Yogliptin 400mg group|Yogliptin 400mg group
89090020|NCT02834962|Experimental|single bundle ACLR|patients undergo single bundle ACL reconstruction
89090021|NCT02834962|Active Comparator|double bundle ACLR|patients undergo double bundle ACL reconstruction
89090022|NCT02834182|Experimental|Bipolar Disorder patients and Schizophrenic patients|
89090023|NCT02834182|Active Comparator|Healthy Controls|
89090024|NCT00891904|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once weekly in weeks 1-5
89090025|NCT02834338|No Intervention|Laparoscopic surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
89090026|NCT02834338|Active Comparator|Laparoscopic surgery, intervention|activity tracking for autofeedback
89090027|NCT02834338|No Intervention|Open surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
89090028|NCT02834338|Active Comparator|Open surgery, intervention|activity tracking for autofeedback
89090029|NCT02837926|Experimental|women attending for cervical cancer screening|
89090030|NCT02834260|Experimental|ozurdex group|Subconjunctival injection of the absorbable implant of Dexamethasone immediately at the end of penetrating keratoplasty. The injection is made at the 12 O'Clock position is a bubble created by subconjunctival injection of balanced salt solution.
89090031|NCT02834416|Experimental|Group-Supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
89090032|NCT02834416|Experimental|Home-Based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
89090033|NCT02831608|Experimental|Drug: influenza vaccine|Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.
89090034|NCT02831608|Placebo Comparator|Drug: placebo|Saline administered as a deep subcutaneous injection at one occasion per subject.
89090035|NCT01157351|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months
89090036|NCT01157351|Active Comparator|002|aripiprazole flexible dosing as prescribed by the study doctor for 15 months
89090037|NCT01157351|Active Comparator|003|haloperidole flexible dosing as prescribed by the study doctor for 15 months
89090038|NCT01157351|Active Comparator|004|olanzapine flexible dosing as prescribed by the study doctor for 15 months
89090039|NCT01157351|Active Comparator|005|paliperidone flexible dosing as prescribed by the study doctor for 15 months
89090040|NCT01157351|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 15 months
89090041|NCT01157351|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 15 months
89090042|NCT01157351|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 15 months
89090043|NCT02831686|Experimental|Selinexor (KPT-330), Ixazomib, and Dexamethasone|"Patients with relapsed and/or refractory MM will be treated with ixazomib, selinexor, and dexamethasone, all of which will be administered orally.Ixazomib will be given on Days 1, 8, and 15 on a 28 day cycle.~Selinexor will be given twice weekly for three weeks, then there will be 1 week off (Days 1,3, 8,10, 15, 17) This study will follow a 3-by-3 dose escalation design.~Dexamethasone will be given on all days of Selinexor but will also be given on the week off from Selinexor (Days 1, 3, 8, 10,15, 17, 22, 24)."
89090044|NCT02831530|Experimental|Abemaciclib|Patients randomized to the treatment arm will start treatment from 15 days before the surgery (day 1 of the study) to receive the last dose of treatment the day before the surgical procedure (day 14 of the study). Abemaciclib will be taken orally at a dose of 150 mg/ twice a day (Every 12h +/- 2h) on day 1 to day 14. The treatment should be taken in the morning and evening with a big glass of water (250ml) at approximately the same time.
89090045|NCT02831530|No Intervention|No treatment|
89090046|NCT04248478||Fibromiyalgia Patients|Patients diagnosed with fibromyalgia according to 2013 American College of Rheumatology criteria are planned to be included in this arm.
89090047|NCT04248478||Healthy Volunteers|Healthy volunteers are planned to be included in this arm.
89090048|NCT00633490|Experimental|A|
89090049|NCT04247932||Municipal|Individual participants receiving active labor market intervention from municipal providers
89090050|NCT04247932||Non-profit|Individual participants receiving active labor market intervention from non-profit providers
89090051|NCT04247932||Register|Matched sample from register data, no intervention provided
89090052|NCT02834026|Experimental|Intervention|The intervention group held two months of training in hemodialysis a physical therapy protocol with cycle ergometer
89090053|NCT02834026|Experimental|Control|The control group was reassessed after two months of the initial evaluation
89090054|NCT02831452||non-pregnant nulliparous|nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
89090055|NCT02831452||primigravid on 1º trimester|"nulliparous women on her first pregnancy and gestational age until 13 weeks and 6 days.~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
89090056|NCT02831452||primigravid on 2º trimester|"nulliparous women on her first pregnancy and gestational age between 14 weeks and 27 weeks.~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
89090057|NCT02831452||primigravid on 3º trimester|nulliparous women on her first pregnancy and gestational age above 28 weeks. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
89090058|NCT02831374|Experimental|Use of platelet rich plasma (Group A)'|Local anesthesia, surgical extraction of impacted third molar, Preparation of PRP gel, Placing platelet Rich plasma and suturing, Postoperative medication
89090059|NCT02831374|Placebo Comparator|surgical extraction (Group B)|Local anesthesia, surgical extraction of impacted third molar, Suturing, Postoperative medication
89090060|NCT02833870|Experimental|Musical intervention|
89090061|NCT02833870|Experimental|Non-musical (cooking) intervention|
89090062|NCT02833870|Active Comparator|Control with no intervention|
89090063|NCT02833558|Experimental|PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to stop bleeding during ESD.
89090064|NCT02833558|Other|Standard Electrocautery|Control arm where standard electrocautery delivered via the endoscopic knife tip or coag grasper is used to achieve haemostasis during ESD
89090065|NCT02831218|Experimental|QCA and Aspirin alone|
89090066|NCT02831218|Experimental|QCA and Clopidogrel alone|
89090067|NCT02831218|Active Comparator|Imaging guided and Aspirin alone|
89090068|NCT02831218|Active Comparator|Imaging guided and Clopidogrel alone|
89090069|NCT02831140|Other|Common arm : for both groups :|"In preoperative phase~In peroperative phase~In postoperative phase"
89090070|NCT02831140|Experimental|FTR protocol group (A)|"A. Experimental : FTR protocol group :~Early exercises after a thoracic surgery : removing urinary probe and all catheters as well as alimenting ."
89090071|NCT02831140|No Intervention|Control group (B)|Traditional, conventional care group with first get up and alimentation permission in 24 hours at the postoperative.
89090072|NCT02833480|Experimental|Fluticasone group|Advair (fluticasone) 250 mcg to be administered twice daily via Diskus for 12 weeks
89090073|NCT02833480|Experimental|Budesonide group|Symbicort (budesonide) 400 mcg to be administered twice daily via Turbuhaler for 12 weeks
89090074|NCT02833480|Active Comparator|Formoterol group|Oxeze (formoterol) 12 microg to be administered twice daily via Turbuhaler for 12 weeks
89090075|NCT02831296||Affected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy (SMA)~The affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy."
89090076|NCT02831296||Unaffected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger who are not affected with SMA~The unaffected group will undergo the same assessments as the affected group."
89090077|NCT02831296||Unaffected Family Members|"Parents and siblings of any age, without genetic diagnosis of SMA, who have family members enrolled in either of the Affected Infants/Children/Adults cohorts.~The unaffected siblings will undergo the same assessments as the affected group, where age-appropriate. Unaffected parents' participation will be limited to blood sample collection and optional research skin biopsy."
89090078|NCT02831296||Affected Subjects >36 Mos. of Age|"Children and adults >36 months at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy.~The older affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy. Where applicable, these participants will be considered Affected Control Subjects."
89090079|NCT02833636||Successful CTO-PCI group|low ACEF score <1.215 (n = 79), intermediate ACEF score from 1.215 to 1.493 (n=70), and high ACEF score≥1.493 (n=72)
89090080|NCT02833636||Failed/non-attempted CTO-PCI group|low ACEF score<1.215 (n=45), intermediate ACEF score from 1.215 to 1.493 (n=57), and high ACEF score≥1.493 (n=54).
89090081|NCT04201054|Experimental|Fluconazole|Subjects receive a single-dose treatment.Urine samples will be collected after administration (4 fractions: 0-12, 12-24, 24-48, 48-72 hours post-administration).
89090082|NCT04247854|Active Comparator|Probiotic|
89090083|NCT04247854|Placebo Comparator|No intervention|
89090084|NCT01157117|Experimental|Omalizumab/milk OIT|Participants receive blinded omalizumab injections every 2 to 4 weeks through Month 16 and unblinded omalizumab injections thereafter until the Month 28 desensitization oral food challenge (OFC). Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk OFC and discontinue omalizumab injections. If they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
89090085|NCT01157117|Placebo Comparator|Placebo for omalizumab/milk OIT|Participants receive blinded placebo for omalizumab injections every 2 to 4 weeks through Month 16; after unblinding the injections are discontinued. Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk oral food challenge (OFC); if they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
89090086|NCT01157117|No Intervention|Untreated control|Participants did not receive any study intervention but provided regular blood draws at specific study time points to allow mechanistic comparisons with the participants in the other two groups who did receive study intervention.
89090087|NCT04247386|Experimental|PEG-Mizone prep|"The evening before the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 60g Polyethylene Glycol (PEG-4000) with 0.6L Mizone+0.4L water at a rate of 250 ml every 15 min.~On the day of the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 120g Polyethylene Glycol (PEG-4000) with 1.2L Mizone+0.8L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
89090088|NCT04247386|Active Comparator|PEG-ELS prep|"The evening before the colonoscopy: In the PEG-ELS prep group, all the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min.~On the day of the colonoscopy: all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min."
89090089|NCT02833246|Experimental|SMS/MMS text messaging|Patients will be able to tailor their SMS/MMS reminders with respect to when (i.e., what time of day) they wish to receive the reminders, as well as how often the messages are sent (e.g., morning and evening).
89090090|NCT02833246|Active Comparator|usual care|This includes physician and nursing assessment and intervention for any identified AEs. Of note, there is not currently standard follow-up that patients receive from nursing or physician staff while on an OAM treatment. Patients are encouraged to call their physician's office with any questions or changes in their medical status but are not called routinely by MSK staff.
89090091|NCT02885051|Experimental|preterm newborn|Newborns hospitalized in the neonatal or Neonatal Resuscitation unit of Brest University Hospital and born before 36 weeks of gestation who will have recording of skin conductance and heart rate variability.
89090092|NCT02833324|Experimental|Fitbit with ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. In addition to being educated on the importance of postoperative ambulation, this arm will have 5 alarms every day reminding them to ambulate.
89090093|NCT02833324|Active Comparator|Fitbit without ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. Participants will be educated on the importance of postoperative ambulation but will not have ambulation reminder alarms.
89090094|NCT04248088|No Intervention|Educational Control Group|Education provided for optional use
89090095|NCT04248088|Experimental|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly for 6 months
89090096|NCT02833090|Other|Group 1|Control group had biomarkers.
89090097|NCT02833090|Experimental|Group 2|Biomarkers
89090098|NCT02833090|Experimental|Group 3|Biomarkers
89090099|NCT02833090|Experimental|Group 4|Biomarkers
89090100|NCT02833012|Experimental|Group 1|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
89090101|NCT02833012|Experimental|Group 2|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
89090102|NCT02833012|Experimental|Group 3|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
89090103|NCT02833012|Experimental|Group 4|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
89090104|NCT00891202|Experimental|Active|Eliglustat
89090105|NCT00891202|Placebo Comparator|Placebo|Placebo
89090106|NCT02831062|No Intervention|ad lib diet|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients will be asked to continue on their regular diet and the protein and caloric ingestion will be recorded at each visit.
89090107|NCT02831062|Experimental|Low Protein Diet + Ketosteril|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients in this arm will be prescribed a low protein diet (LPD) and +Ketosteril supplementation, containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose). Protein and caloric ingestion will be recorded.
89090108|NCT02830906|Experimental|ramosetron group|Patients received 0.3 mg of intravenous ramosetron before spinal anesthesia and intrathecal morphine
89090109|NCT02830906|Active Comparator|ondansetron group|Patients received 8 mg of intravenous ondansetron before spinal anesthesia and intrathecal morphine
89090110|NCT02832778|Experimental|Stage 1 London|"Stage 1, London:~Phase 1 (2 weeks): tenofovir/emtricitabine or tenofovir/lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily~Phase 2 (12 weeks): tenofovir/emtricitabine or tenofovir /lamivudine or zidovudine/lamivudine) plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)"
89090111|NCT02832778|Experimental|Stage 2 Kampala|Tenofovir/emtricitabine or lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥ 50 kg or rifampicin 450 mg and isoniazid 300 mg if <50kg).
89090112|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Cohort A|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by fluorescence in situ hybridization (FISH) (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
89090113|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Main Cohort|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by FISH (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
89090114|NCT02830984|Experimental|EST+LBD+ENBD group|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
89090115|NCT02830984|Active Comparator|EST+LBD group|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
89090116|NCT02833168||1|Patients with proven neuromuscular disorders known to be potentially associated with significant diaphragmatic weakness, e. g. ALS, myotonic dystrophy type 1, limb-girdle muscular dystrophy, Duchenne and Becker muscular dystrophy. Patients already receiving home ventilatory support will not be included in the study.
89090117|NCT02833168||2|Patient with proven obstructive sleep apnea syndrome prior to CPAP initiation.
89090118|NCT02833168||3|Patients with sleep disorders other than sleep-related breathing disorders, e. g. narcolepsy, hypersomnia, parasomnia or sleep-related movement disorders.
89090119|NCT04247230|Experimental|PET500 (0.1%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.1%) corresponding to a tetracaine total dose of 0.26mg"
89090120|NCT04247230|Experimental|PET500 (0.25%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.25%) corresponding to a tetracaine total dose of 0.65mg"
89090121|NCT04247230|Experimental|PET500 (0.5%)|"Each actuation of the pump spray dispenses 130µl PET500. Two pumps will dispense 260µl as follows:~PET500 (0.5%) corresponding to a tetracaine total dose of 1.3mg"
89090122|NCT04247230|Experimental|PET500 placebo comparator|Each actuation of the pump spray dispenses 130µl PET500 [vehicle only]. Two pumps will dispense 260µl
89090123|NCT04247230|Active Comparator|STUD100 (9.6%)|Each actuation of the pump spray dispenses 130µl, corresponding to a dose of 7.7mg lidocaine. Three pumps will dispense 390µl of a 9.6% solution, delivering a total dose of 23mg lidocaine. UK License Number PL/2294/5000R
89090124|NCT02832934|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
89090125|NCT02832934|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
89090126|NCT04247776|Experimental|Prehab|General nutrition, relaxation, and exercise instructions. Home-based functional exercises, Fitbit goals, and nutrition supplements.
89090127|NCT04247776|Active Comparator|ERAS|Enhanced Recovery After Surgery standard of care plus Fitbit.
89090128|NCT02832700|Active Comparator|Casein glycomacropeptide (CGMP)|During 4 weeks a daily oral intake of CGMP-protein-shake.
89090129|NCT02832700|Placebo Comparator|Placebo|During 4 weeks a daily oral intake of placebo-shake consisting of milk powder.
89090130|NCT02832232|Experimental|Mobilization Group|translational dorsal glide mobilization technique grade III and Protocolized Physiotherapy
89090131|NCT02832232|Experimental|Maintained pressure Group|pressure maintained suboccipital inhibition technique and Protocolized Physiotherapy
89090132|NCT02832232|Other|Control Group|Protocolized Physiotherapy
89090133|NCT02830828||Patients|Patients fulfilling inclusion/exclusion criteria referred to the PI with suspected carpal tunnel syndrome.
89090134|NCT02830828||Controls|"Healthy volunteers fulfilling inclusion/exclusion criteria with no symptoms of carpal tunnel syndrome.~Mid-study, it was elected to also match patients to their own contralateral disease-free hand to act as a control."
89090135|NCT02830516||Lung elastance - transpulmonary pressure|Lung elastance and transpulmonary pressure measured by tidal esophageal pressure variations and by performing a PEEP step
89090136|NCT04247152|Other|Intraoperative Aberrometry vs Preoperative Biometry|Retrospective view of existing chart data.
89090137|NCT02831920|Experimental|Single Arm|every patient undergoes mpMRI and targeted biopsies, CEUS and targeted biopsies and systematic biopsies. Every patient is therefore its own control.
89090138|NCT02830672|Active Comparator|Open surgical release A1 Pulley|
89090139|NCT02830672|Active Comparator|Ultrasound guided close release A1 pulley|
89090140|NCT02832076|Experimental|group a|This arm will receive subcutaneous negative suction drain for the midline wound for 10 days.
89090141|NCT02832076|Active Comparator|group b|This arm will receive closure of the midline wound without a subcutaneous drain.
89090142|NCT02831842||mCRC Participants|Data of mCRC participants who received first-line treatment with bevacizumab-containing regimen or with chemotherapy alone and had KRAS-mutant status and mCRC participants who received first-line treatment with bevacizumab-containing regimen or an anti-epidermal growth factor receptor (EGFR)-containing regimen and had KRAS wild type status, will be collected retrospectively.
89090143|NCT00891046|Experimental|Canakinumab|Canakinumab
89090144|NCT04245982||group (C)|healthy controls group
89090145|NCT04245982||group (P)|periodontitis group
89090146|NCT04245982||group (DP)|diabetes and periodontitis group
89090147|NCT02830048|Experimental|Glibenclamide dose titration|Increasing doses of glibenclamide oral suspension from 0.3mg/day to 6mg/day.
89090148|NCT02830126|No Intervention|Anesthesiology Control Tower Control|Patients managed by anesthesia teams without feedback alerts from the ACT
89090149|NCT02830126|Experimental|Anesthesiology Control Tower Feedback|Patients managed by anesthesia teams with feedback alerts from the ACT
89090150|NCT04245358|Other|Ainara|Ainara is a class II medical device, already marketed in several EU countries. Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
89090151|NCT02829892|Other|Light therapy|Innovative ambient lighting
89090152|NCT02829970|Experimental|SUCCEEDS Program|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will be engaged about personalized alcohol feedback and identify life values and specific activities important to those values.
89090153|NCT02829970|Active Comparator|Living a Healthy College Lifestyle|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will engage in discussion focused on experiences as an emerging adult.
89090154|NCT02828722|Experimental|Controlled light, noise and nutrition|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the nutrition protocol corresponding to the daily rhythm will be applied.
89090155|NCT02828722|Experimental|Controlled light and noise|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the continuous nutrition (in accordance with the clinical trial site's standard practice) will be applied.
89090156|NCT02828722|No Intervention|Control|The treatment of the study subject will be performed based on the clinical trial site's standard practice without environmental simulation or changes in the nutrition protocol.
89090157|NCT04245592|Experimental|Extra Virgin Olive Oil|Women with fibromyalgia will consume Extra Virgin Olive Oil.
89090158|NCT04245592|Experimental|Refined Olive Oil|Women with fibromyalgia will consume Refined Olive Oil.
89090159|NCT02828332|Other|Patient with autism disorder|Interview with a psychologist who do Vineland II (VABS -II) and evaluate Quality of life and comorbidities
89090160|NCT02828566|Experimental|IN ketamine and IV saline|Ketamine, single dose, 10 mg/kg (0.1 mL/kg) of 100 mg/mL solution delivered intranasally using an atomizer and divided to both nares to a maximum of 800 mg (8 mL) AND 0.9% normal saline (NS) 0.02 to 0.03 mL/kg delivered intravenously to a maximum of 2.4 mL
89090161|NCT02828566|Active Comparator|IV ketamine and IN saline|Ketamine, single dose, 1 to 1.5 mg/kg (0.02 to 0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 120 mg (2.4 mL) AND 0.9% normal saline (NS) 0.1 mL/kg delivered intranasally using an atomizer and divided to both nares, to a maximum of 8 mL
89090162|NCT04245046|Experimental|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:~Age: 18-49 years~Weight: 55-105 kg~Height: 163-188 cm~BMI 18.5-29.9 kg/m²"
89090163|NCT02829580|Experimental|Sickle group|Children with major sickle cell syndrome will have an usual Echocardiography
89090164|NCT02829580|Active Comparator|Control group|Children recruited in a previous study and who had an usual Echocardiography
89090165|NCT02828410|Experimental|SBI|Serum bovine immunoglobulin protein isolate (SBI)
89090166|NCT04245124|Experimental|SMART INTERVENTION|N= 81 20 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
89090167|NCT04245124|Experimental|TCR|N= 81 60 HOURS THERAPY IMMEDIATE POST TREATMENT EVALUATION 3 MONTH POST TREATMENT EVALUATION
89090168|NCT04246450|No Intervention|LVEF between 35%-50%, no noninvasive risk factors (NIRFs)|Follow up, no further intervention
89090169|NCT04246450|No Intervention|LVEF between 35%-50%, NIRFs present, noninducible|Follow up, no further intervention
89090170|NCT04246450|Active Comparator|LVEF between 35%-50%, NIRFs present, inducible|All patients in this group will receive an ICD
89090171|NCT04246450|Sham Comparator|LVEF <35%, no NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
89090172|NCT04246450|Sham Comparator|LVEF <35%, NIRFs present, noninducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
89090173|NCT04246450|Sham Comparator|LVEF <35%, NIRFs present, inducible|All patients in this group will receive an ICD, the aim is to compare major arrhythmic event occurrence according to NIRF presence and/or inducibility, and whether risk stratification accuracy can be improved as compared to classic approach of ICDs being offered to all dilated cardiomyopathy patients with LVEF<35%
89090174|NCT04244812|Other|CSAP group|"Participants in the CSAP group will receive examination of laser doppler flowmetry(LDF).~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian"
89090175|NCT04244812|Other|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
89090176|NCT04244812|Experimental|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
89090177|NCT02827864|Experimental|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1 lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
89090178|NCT02827864|Experimental|apply tDCS concurrently|"For the participants in the CON group, sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS.~Similar to the SEQ group, the participants will also practice functional tasks for 30 minutes after MT."
89090179|NCT02827864|Sham Comparator|MT with sham tDCS|For the SHAM group, the training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
89090180|NCT00633568|Active Comparator|A|One course of chemotherapy with cisplatin and docetaxel followed by induction chemoradiotherapy followed by two courses of consolidation chemotherapy
89090181|NCT00633568|Experimental|B|Three courses of induction chemotherapy followed by consolidation chemoradiotherapy
89090182|NCT04246294||Sleep apnea patients|"This group of patients will have been monitored over night with cardiorespiratory monitoring (CRM). CRM enables the physician to establish an Apnea-Hypopnea Index (AHI) which will be used for diagnosis. An AHI > 15 is considered moderate-to-severe sleep apnea, and this is the focus group of patients in the current project.~These patients will be followed for 12 months during continuous positive airway pressure (CPAP) treatment. Adherence to the CPAP treatment will be closely monitored."
89090183|NCT02829658||Psychiatric patients group|Patient groups were composed with: BPD, other PD and assessed Psychologic test
89090184|NCT02829658||Control group|Matched controls (age, sex) composed the 3rd and 4th group (BPD control and other PD control). They were randomly chosen in the health database insurance previously used. They had no intervention.
89090185|NCT02827630|Active Comparator|DH-4|Subjects will use Proteus Discover, the digital health offering (DH) for 4 weeks
89090186|NCT02827630|Active Comparator|DH-12|Subjects will use Proteus Discover, the digital health offering (DH) for 12 weeks
89090187|NCT02827630|Other|Usual Care|Subjects received usual medical care including all normal interventions such as medication titration, adherence counseling, lifestyle coaching, and additional clinic visits per their providers' discretion.
89090188|NCT05216692|Experimental|Experimental group|The foot strengthening protocol will last 4 weeks with 2 sessions per week and is composed of 3 exercises targeting forefoot and midfoot region strength as well as enhancing plyometric capabilities of the foot complex.
89090189|NCT05216692|Active Comparator|Control group|The standard literature foot strengthening protocol will last 4 weeks with 3 sessions per week and is composed of one exercise targeting the strength of the foot medial arch.
89090190|NCT04245826||Low-calorie Sweetened Beverages (LCSBs)|Beverages exclusively using zero-energy (e.g., acesulfame-potassium, aspartame, cyclamate, saccharin, sucralose, advantame, neotame), and /or reduced-energy food additives (e.g., stevia, monk fruit).
89090191|NCT02829736|Active Comparator|Chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard post-operative chest tube.
89090192|NCT02829736|Experimental|No chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
89090193|NCT02829346|Experimental|Peri-articular group|Patients received 750 mg of peri-articular Tranexamic acid (Transamin®; OLIC Thailand Ltd, Bangkok, Thailand; 250 mg/5 mL, 15 cc total volume) injection into the soft tissue around medial capsule (5 ml), lateral capsule (5 ml) and around the quadriceps muscle (5 ml), 10 minutes prior to deflating the tourniquet and wound closure.
89090194|NCT02829346|Active Comparator|Intravenous group|Patients received 750 mg of intravenous tranexamic acid(250 mg/5 ml, 15 cc total volume, keeping within the therapeutic range of 10-15 mg/kg/dose), 10 minutes prior to deflating the tourniquet and wound closure.
89090195|NCT05210764||propofol|General anesthesia is induced and maintained mainly with propofol.
89090196|NCT05210764||sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
89090197|NCT05210764||ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
89090198|NCT00889720|Other|Smoking cessation tratment including varenicline|
89090199|NCT04244500||Influenza|Influenza testing
89090200|NCT02827786|Experimental|Electromagnetic Acoustic Imaging|
89090201|NCT02827552|Other|ARPEGE BioM|N/A (not a randomized study)
89090202|NCT04244734|Active Comparator|Group 1|The control group receives regular treatment in the ICU, which includes muscle strengthening exercises, passive/assisted or active mobilizations, and respiratory physiotherapy with breathing muscle strengthening in a medium load (initially at 40% load from results in MIP).
89090203|NCT04244734|Experimental|Group 2|The experimental group receives a new early rehabilitation program based on a patient's in-bed cycling that allows controlled and adapted training to the patient's situation, along with coordinated exercise with neuromuscular electrostimulation and respiratory physiotherapy with breathing muscle strengthening in a high load (initially at 60% load from results in MIP).
89090204|NCT02880306||RA cohort|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria.
89090205|NCT02880306||Non-RA cohort|Participants who were ≥18 years of age, without a RA diagnosis
89090206|NCT02881788||Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a traumatic brain injury. We are hoping to find patterns that may indicate a TBI in the data we collect.
89090207|NCT02881788||Non-Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a non-trauma related brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as healthy controls.
89090208|NCT02881788||Control|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have not recently sustained any brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as subjects who have had a non-trauma related brain injury.
89090209|NCT02827318|Active Comparator|75g glucose|75g of glucose dissolved in 500ml provided in a clear plastic tumbler.
89090210|NCT02827318|Experimental|75g isomaltulose|75g of isomaltulose dissolved in 500ml provided in a clear plastic tumbler.
89090211|NCT02827318|Placebo Comparator|Sweetened water|500ml water sweetened with sucralose provided in a clear plastic tumbler.
89090212|NCT04309968|Experimental|solid tumors|Experimental: Solid tumors Part 1 - Dose-escalation of SYHA1801 in patients with advanced solid tumors.Daily dosing of SYHA1801 on Days 1 and 4-31 of 28-day cycle. Escalating dose cohorts.
89090213|NCT04309968|Experimental|advanced cancers|Part 2 - Dose-expansion of SYHA1801 in patients with advanced cancers potentially sensitive to BRD4 inhibitor.The dose level and schedule of SYHA1801 of 28-day cycle at the MTD determined in Part 1.
89090214|NCT04244578|Experimental|Active-Sham tDCS|Each tDCS sessions will be delivered for 5 days for a total of non consecutive two weeks. The first session will be active tDCS and two months after, a sham tDCS will follow.
89090215|NCT04244578|Active Comparator|Sham-Active tDCS|"Each tDCS sessions (sham tDCS and active tDCS) will be delivered for 5 days for a total of non consecutive two weeks.~The first session will be sham tDCS and two months after, an active tDCS will follow."
89090216|NCT02828878|Experimental|ApoGraft|ApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4
89090217|NCT05183464||Children with primary hypersomnia|Children with primary hypersomnia, i.e. narcolepsy or idiopathic hypersomnia
89090218|NCT05183464||Children with secondary hypersomnia|Children with a secondary hypersomnia, i.e. caused by sleep deprivation, a psychiatric disorder, sleep fragmentation, circadian delay.
89090219|NCT04244422|Active Comparator|cyst enucleation using piezosurgery|SATLEC ACTEON peizotome 2 was used for bone cutting and separating the cystic lining from the surrounding bone.After complete removal of the cyst, the bony window was replaced back in place and the flap was sutured.
89090220|NCT04244422|Active Comparator|cyst enucleation using conventional surgery|A carbide bur was used to remove the bone to uncover the cyst. A periosteal elevator and a curette were used to aid in the removal of the cystic lesion.
89090221|NCT02827474||Patient Participants|Patient participants will participate in two patient interviews.
89090222|NCT02827474||Physician Participants|Provider participants will participate in one provider interview.
89090223|NCT02827396|Experimental|Psycho-social intervention|Experimental group: The intervention group will get Psycho social Training Intervention which will be developed during the third phase of the study.
89090224|NCT02827396|No Intervention|TAU intervention|Wait-list (controlled) group: The waiting list (control) group will continue getting the general health education (TAU) that is done at disability clinics in the existing sites.
89090225|NCT04243954|Experimental|PCA IV Hydromorphone (continuous dose = 0)|"Intravenous PCA with hydromorphone after successful titration of 24 hours.~The PCA setting:~1) Continuous dose = 0; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
89090226|NCT04243954|Experimental|PCA IV Hydromorphone (continuous dose ≠ 0)|"Intravenous PCA with hydromorphone after successful titration of 24 hours.~The PCA setting:~1) Continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) Bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) Lockout time = 10 minutes; 4) Evaluate once every 24 hours"
89090227|NCT04243954|Active Comparator|Oral Morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
89090228|NCT04244344|Experimental|interventional|"all High fall risk subjects who meet the criteria by STRATIFY Tool"
89090229|NCT02827240|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
89090230|NCT02827240|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
89090231|NCT02827240|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
89090232|NCT02827942|Experimental|Dual therapy|Patients assigned to this group are treated with dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week. The eradication rate attained with this regimen is measured.
89090233|NCT02827942|Active Comparator|Triple therapy|Patients assigned to this group are treated with the triple therapy with vonoprazan 20 mg bid, clarithromycin 200 mg bid and amoxicillin 750 mg bid for 1 week as the first line therapy or the triple therapy with vonoprazan 20 mg bid, metronidazole 250 mg bid and amoxicillin 750 mg bid for 1 week as the second line therapy. The eradication rates attained with these regimens are measured.
89090234|NCT00880087|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
89090235|NCT00880087|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
89090236|NCT02827084|Experimental|Kinesio Taping|Apply the Kinesio Taping with tension in the vatus mediallis
89090237|NCT02827084|Placebo Comparator|Placebo|Apply the Kinesio Taping without tension in the vatus mediallis
89090238|NCT02827084|No Intervention|Control|It will not apply Kinesio.
89090239|NCT00889252|Experimental|K-Lens|Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug
89090240|NCT00889252|Placebo Comparator|Placebo Lens|Placebo lens
89090241|NCT00670813|Experimental|Modafinil (Vigil)|"Modafinil Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives 200 mg of Modafinil each at 12:00, 24:00 and again at 12:00 o' clock"
89090242|NCT00670813|Placebo Comparator|Placebo|"Placebo Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives Placebo at 12:00, 24:00 and again at 12:00 o' clock"
89090243|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F126)|ketoconazole 2% cream (formulation F126) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
89090244|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F012) (Nizoral)|ketoconazole 2% cream (formulation F012) (Nizoral) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
89090245|NCT01110330|Placebo Comparator|Placebo cream|Placebo cream A topical white homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
89090246|NCT00663481|Experimental|1|CoFactor
89090247|NCT00663481|Experimental|2|CoFactor
89090248|NCT00663481|Active Comparator|3|Leucovorin
89090249|NCT04308954|Experimental|Fragile X Syndrome|Adult males aged 18-30 years diagnosed with FXS will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
89090250|NCT04308954|Experimental|Idiopathic Intellectual Developmental Disorder|Adult males aged 18-30 years diagnosed with idiopathic intellectual developmental disorder will undergo a non-invasive F18 FMZ PET/MRI scan to determine GABA(A) receptor density; developmental dynamics of GABA(A) receptor distribution, and structural neuroanatomy and connectional anatomy.
89090251|NCT05016778|Experimental|Treatment Group|This is a open label, single arm clinical trial.
89090252|NCT02881398|Experimental|mHealth|Each participant randomized to a mHealth assessment were evaluated with: (1) structural abnormalities with handheld-echocardiography (Vscan®, General Electric Healthcare); (2) vital signs with smartphone-connected oxymetry and blood pressure monitors (iHealthLabs®); (3) functional assessments on a 6-minute walk test with a trial-axial activity monitor (Ozeri®); (4) cardiac rhythm abnormalities with smartphone-connected- iECG (AliveCor®) and; (5)point-of-care testing with fingerstick B-type natriuretic peptide (Alere). All study participants then underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
89090253|NCT02881398|Active Comparator|Standard-Care|Each participant randomized to a standard-assessment were evaluated with the resource available at the institution including a physical examination,12 lead-ECG, radiographic, laboratory testing as clinically required. All study participants underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
89090254|NCT04243564|Active Comparator|PLMA|The PLMA, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
89090255|NCT04243564|Active Comparator|I-gel|The I-gel, a second generation gastric access SGD, is used as temporary ventilatory device before tracheal intubation. Performance is evaluated.
89090256|NCT05010460|Experimental|Roxadustat|Roxadustat
89090257|NCT05010460|Placebo Comparator|placebo|Placebo has the same appearance with the experimental drug (Roxadustat).
89090258|NCT00596947|Experimental|Prednisone Withdrawal|Participants randomized to the prednisone withdrawal group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was given intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered to participants an inpatient or outpatient for a total of 3 to 5 doses. Participants also began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued indefinitely. The steroids were initially given in the operating room intravenously at time of transplant as Solu-medrol (methylprednisolone)and were then switched to daily oral prednisone doses. The participant's dose of prednisone was rapidly decreased until it was completely eliminated by day 6 post-transplant.
89090259|NCT00596947|Active Comparator|Prednisone Maintenance|Participants randomized to the prednisone maintenance group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was initiated intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered an inpatient or outpatient for a total of 3 to 5 doses. Participants began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued on them indefinitely. The steroids were initially given intravenously in the operating room at time of transplant as Solu-medrol (methylprednisolone) and were then switched to daily oral prednisone tablets. Participants remained on all drugs according to their doctor's standard of care, and the prednisone was not be eliminated.
89090260|NCT04155697|Active Comparator|Hand washing with soap for thirdhand smoke removal|
89090261|NCT04155697|Active Comparator|Ethyl alcohol-based sanitizer for thirdhand smoke removal|
89090262|NCT00663559|Other|1|This study has only one arm with Sunitinib
89090263|NCT04158349|Experimental|Dose Level 0|Dose Level 0: 85 mg/m2 Oxaliplatin IP every 2 weeks
89090264|NCT04158349|Experimental|Dose Level 1|Dose Level 1: 95 mg/m2 Oxaliplatin IP every 2 weeks
89090265|NCT04158349|Experimental|Dose Level 2|Dose Level 2: 105 mg/m2 Oxaliplation IP every 2 weeks
89090266|NCT00660205||operation|Patients with upper gastro intestinal cancer who underwent surgery
89090267|NCT00660205||palliation|Patients with upper gastro intestinal cancer who did not underwent surgery
89090268|NCT00660205||control|Persons with no cancer who accepted to be control with blood samples and flow doppler ultrasound examination of both legs.
89090269|NCT00670891|Experimental|HBOT|HBOT
89090270|NCT00670969||A|People who will have the portable measurement taken first and handheld measurement taken second
89090271|NCT00670969||B|People who will have the handheld measurement taken first and portable measurement taken second
89090272|NCT00888940|Experimental|ecallantide|
89090273|NCT00888940|Active Comparator|Cyklokapron(R)|
89090274|NCT00595621|Active Comparator|MGP-1 ON|Experimental Pacemaker on for 6 weeks
89090275|NCT00595621|Active Comparator|MGP-1 OFF|Experimental Pacemaker on or off for 4 weeks
89090276|NCT02826070|Other|Off-treatment|Patients who had stopped treatment during EFFORT extension study could receive 2-year off-treatment follow-up. All the patients in Part I will be followed up at the interval of 12 weeks. For these patients, if they have hepatitis flare during follow-up, they will be re-treated with telbivudine combined with adefovir for the left study period ( the total study period is 2 years) and followed up at the interval of 12 weeks. Hepatitis flare is defined as HBV DNA>4 Log10 copies/mL with either ALT≥5 times upper limit of normal (ULN) or TBIL≥2×ULN，or 2 ≤ALT ≤5 ×ULN (at two consecutive visits at least 2 weeks apart) and total bilirubin (TBIL) <2×ULN.
89090277|NCT02826070|Other|On-treatment|Patients with continuous treatment during EFFORT extension study will continue treatment, without off-treatment rule in the further extension study. The treatment strategy is depended on the HBV DNA level of each individual, that is, for patients with negative HBV DNA level (defined as HBV DNA <20 IU/mL) will continue their previous treatment strategy; and for patients with positive HBV DNA level (defined as HBV DNA>=20 IU/mL) will receive the combination therapy of telbivudine and adefovir, irrespective of their previous treatment strategy. All the patients in Part II will be followed up at the interval of 24 weeks until they complete the 2-year on-treatment follow-up. Patients will be conducted liver biopsy at the sixth year of treatment. All the patients with telbivudine monotherapy will be switched to telbivudine plus adefovir once confirmed HBV DNA breakthrough developed.
89090278|NCT05090488|Experimental|Received Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
89090279|NCT05090488|Active Comparator|Received Diabetes Education in Group|Diabetes education in group, with trained educator team from primary health care
89090280|NCT00663715||1|Pediatric Patients of ages 11-17
89090281|NCT02826226||obstructive ventilation disorder|patients with known or suspected obstructive ventilation disorder and clinical indication for bronchodilator testing
89090282|NCT00671047||1|SLE subjects with flares in the last 12 months in specific organ systems.
89090283|NCT00671125|Experimental|Ramelteon 8 mg QD|
89090284|NCT00671125|Experimental|Ramelteon 16 mg QD|
89090285|NCT00671125|Placebo Comparator|Placebo|
89090286|NCT04157803|Other|Patient cohort|Patients with polyps> 5mm with suspicion of tubular, tubulovillious or serrated adenomas, found during a videcolonoscopy.
89090287|NCT04196920||Cohort with TNF combination therapy|Cohort with TNF combination therapy (infiximab/adalimumab) with azathiorpine
89090288|NCT04196920||Cohort with anti-TNF combination therapy|Cohort with anti-TNF combination therapy (infiximab/adalimumab) with methotrexate
89090289|NCT04157959|Experimental|SHR4640|SHR4640 dose1 Oral Tablet Day1~Day14 qd,Febuxostat dose2 Oral Tablet Day8 and Day14 qd.
89090290|NCT04157959|Experimental|Febuxostat|Febuxostat dose2 Oral Tablet Day1 and Day14 qd, SHR4640 dose1 Oral Tablet Day8~Day14 qd.
89090291|NCT04243408|Experimental|group 1|
89090292|NCT04243408|Placebo Comparator|group 2|
89090293|NCT02827162||Case D1|Subject having experienced a Virologically confirmed dengue infection, from the first injection until the end of the active phase, excluding Case D3 subjects
89090294|NCT02827162||Case D3|Subject having experienced a Virologically confirmed dengue infection, from 28 days after the third injection until the end of the Active Phase of the proof of concept (PoC) efficacy study
89090295|NCT02827162||Control I|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and belonging to the PoC efficacy study immunogenicity subset
89090296|NCT02827162||Control E|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and not belonging to the PoC efficacy study immunogenicity subset
89090297|NCT02826148|Other|Patients with autism disorder|The RAADS-R scale is a self-administered questionnaire completed by the patient himself assisted by a clinician
89090298|NCT00663949|Active Comparator|A,1,II|patients in this arm takes 25 mg captopril q8h
89090299|NCT00663949|Active Comparator|A,2,II|
89090300|NCT00660361||A|individuals co-infected with HIV-HBV and receiving tenofovir as aprt of their HAART regimen
89090301|NCT00660439|Experimental|A|Treatment group, receives Narrative Exposure Therapy immediately after first assessment. Patients are assessed 1 and 6 months after treatment.
89090302|NCT00660439|No Intervention|B|Waiting list control group, receives no intervention for 3 months after first assessment. A second assessment is then administered and patients receives Narrative Exposure Therapy. Patients are assessed 1 and 6 months after treatment.
89090303|NCT00911677||Open Aortic Repair|Patients 60 years of age and older undergoing open repair of the abdominal aorta
89090304|NCT00888238|Experimental|Sitagliptin/Sitagliptin/Placebo|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
89090305|NCT00888238|Experimental|Sitagliptin/Placebo/Sitaglipitin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
89090306|NCT00888238|Experimental|Placebo/Sitagliptin/Sitagliptin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
89090307|NCT05660356|Experimental|Growth Hormone|Participants will perform daily at-home subcutaneous GH injections after receiving thorough at-home education training provided by a pharmaceutical nurse before and research personnel. The GH will be provided be Pfizer. Starting doses will be 0.2 ug/L and 0.3 ug/L for women taking exogenous oral estrogen.
89090308|NCT05660356|Placebo Comparator|Placebo|Participants will perform daily at-home subcutaneous placebo injections after receiving thorough at-home education training provided by a pharmaceutical nurse before and research personnel. Starting doses will be 0.2 ug/L and 0.3 ug/L for women taking exogenous oral estrogen.
89090309|NCT00595465|Active Comparator|IC51 Batch A|
89090310|NCT00595465|Active Comparator|IC51 Batch B|
89090311|NCT00595465|Active Comparator|IC51 Batch C|
89090312|NCT02825914|Active Comparator|Casein glycomacropeptide (CGMP)|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of CGMP-protein-shake during 12 weeks.
89090313|NCT02825914|Placebo Comparator|Placebo|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of placebo-shake consisting of milk powder during 12 weeks.
89090314|NCT00671281|Experimental|B|This group will be the experimental group which will receive tranexamic acid in oral form three days before and six days after surgery.
89090315|NCT00671281|Placebo Comparator|A|This will be the control group which will take the placebo medication for 3 days before and six days after their functional endoscopic sinus surgery (FESS).
89090316|NCT01205438|Experimental|LY2127399 every 2 weeks|
89090317|NCT01205438|Experimental|LY2127399 every 4 weeks|During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
89090318|NCT01205438|Placebo Comparator|Placebo|
89090319|NCT02825602||Vietnam War Theater Veterans|Vietnam War Theater Veterans are defined for this protocol as those who served in the U.S. Armed Forces on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos between February 28, 1961 and May 7, 1975, inclusive. The investigators based this definition on legal dates of service set forth in 38 Code of Federal Regulations (CFR) 3.2 - Periods of war, but broadened the definition of sites of military service that constituted war zones based on written historical accounts and input from Vietnam Veterans.
89090320|NCT02825602||Blue Water Navy Vietnam Veterans|Blue Water Navy Veterans are defined as Veterans who served aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975 and who never served ashore or on inland waterways of Vietnam.
89090321|NCT02825602||Vietnam era Veterans|Vietnam era Veterans served in locations around the world OTHER than on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos or aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975.
89090322|NCT02825602||Non-military U.S. public|Non-military U.S. public are individuals who were born before 1958, never served in the U.S. military, and are age- and gender-matched (by the study investigators) to Vietnam War Theater Veterans.
89090323|NCT04155229|Experimental|Null setting, forced entry|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at -blank-. This setting required the prescriber to enter a quantity in order to write a prescription."
89090324|NCT04155229|Experimental|5 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 5."
89090325|NCT04155229|Experimental|10 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 10."
89090326|NCT04155229|Experimental|15 tablet default|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at 15."
89090327|NCT04155229|Active Comparator|Status quo default setting|"Each arm sets the default quantity (preset quantity) embedded in the electronic medical record for study opioids.~This arm has a default setting for opioid quantity set at the status quo value for each site (20 for site 1, 12 for site 2)."
89090328|NCT00664183|Experimental|1|
89090329|NCT00664183|Experimental|2|
89090330|NCT00671359|Experimental|after fast|Administration of a single oral dose of 600mg TR-701 to subjects in the fasted state.
89090331|NCT00671359|Experimental|After high fat food|Administration of a single oral dose of 600mg TR-701 to subjects in the fed state.
89090332|NCT04153201|Experimental|Hydroxychloroquine|Patients with primary antiphospholipid syndrome started on hydroxychloroquine while continuing standard care (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents, depending on primary APS subgroup)
89090333|NCT04153201|No Intervention|Standard care|Patients with primary antiphospholipid syndrome continuing standard care only (vitamin K antagonists or direct oral anticoagulants, and/or antiplatelet agents
89090334|NCT04153123|Experimental|Lidocaine with epinephrine|Peribulbar anesthesia with lidocaine and epinephrine
89090335|NCT04153123|No Intervention|Lidocaine without epinephrine|Peribulbar anesthesia with lidocaine
89090336|NCT02825524|Experimental|Endobiliary radiofrequency|
89090337|NCT00671593|Experimental|Experimental inhaled dust mite|All subjects receive the same experimental inhaled challenge interventions
89090338|NCT01104870|Active Comparator|Dose Group 1|UT-15C 0.25 mg twice daily
89090339|NCT01104870|Active Comparator|Dose Group 2|UT-15C 1.25 mg twice daily
89090340|NCT01104870|Active Comparator|Dose Group 3|UT-15C individual Maximum Tolerated Dose
89090341|NCT02887664||Blood test in Mothers of SGA Infants|In mothers of Small for Gestational Age (SGA) Infants, maternal and cord blood test will be performed
89090342|NCT02887664||Blood test in Mothers of AGA infants|In mothers of Appropriate for Gestational Age (AGA) Infants, maternal and cord blood test will be performed
89090343|NCT02825368|Experimental|Homeopathic vaccine group|"Diphtheria (Diphtherinum®), pertussis (Pertussinum®), tetanus (Tetanotxicum®), measles (Morbilinum®) and mumps (Ourlianum®) nosodes.~Two sterile saline injections (0.5ml each, intramuscular and subcutaneous) as placebo."
89090344|NCT02825368|Active Comparator|Conventional vaccine group|"One intramuscular dose of Tdap (tetanus, diphtheria, acellular pertussis)~One subcutaneous dose of MMR (measles, mumps, rubella)~Sugar pellets as placebo."
89090345|NCT02825368|Placebo Comparator|Control group|"Sugar pellets oral dose~Two sterile saline injections (0.5 ml each, intramuscular and subcutaneous) as placebo"
89090346|NCT02632279|Experimental|TRP depleted|TRP depleted protein drink
89090347|NCT02632279|Placebo Comparator|Placebo|Balanced protein drink (+1.21g of TRP)
89090348|NCT02631187|Experimental|Balloon Eustachian Tuboplasty|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
89090349|NCT02881476|Experimental|Allogeneic WJ-MSCs injection|Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
89090350|NCT00664339|Active Comparator|Vaccine|Flu Vaccine
89090351|NCT00664339|Other|Control|Conventional treatment therapy for heart failure
89090352|NCT00664417|Experimental|1|
89090353|NCT00664417|Experimental|2|
89090354|NCT00664417|Experimental|3|
89090355|NCT00664417|Experimental|4|
89090356|NCT00664417|Experimental|5|
89090357|NCT00664417|Experimental|6|
89090358|NCT00664417|Active Comparator|7|
89090359|NCT00664417|Active Comparator|8|
89090360|NCT00664417|Placebo Comparator|9|
89090361|NCT04031755|Experimental|Minocycline versus Placebo|"Phase 1: 4 weeks of daily minocycline 100mg BID dosing~2-week washout period~Phase 2: 4 weeks of daily placebo dosing"
89090362|NCT04031755|Experimental|Placebo versus Minocycline|"Phase 1: 4 weeks of daily placebo dosing~2-week washout period~Phase 2: 4 weeks of daily minocycline 100mg BID dosing"
89090363|NCT01104792|Experimental|Cariprazine|Participants received cariprazine 3.0, 4.5, 6.0, or 9.0 mg orally once a day for 48 weeks.
89090364|NCT01205126|Experimental|OROS Hydromorphone hydrochloride (HCl)|OROS Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
89090365|NCT01205126|Active Comparator|Oxycodone HCl Controlled release (CR)|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
89090366|NCT04155307|Experimental|Detection of anismus in patients with distal constipation|
89090367|NCT00664495|No Intervention|C|Control
89090368|NCT00664495|Active Comparator|DWL|Diet Weight Loss
89090369|NCT00664495|Active Comparator|EWL|Exercise Weight Loss
89090370|NCT00664495|Active Comparator|EWS|Exercise Without Weight Loss
89090371|NCT05137314|Experimental|3 mg/mL PLG0206|administered intraoperatively by local irrigation
89090372|NCT05137314|Experimental|10 mg/mL PLG0206|administered intraoperatively by local irrigation
89090373|NCT02629627|Experimental|cojugated ALC/Leucine+Metformin|Intervention with conjugated linoleic acid/Leucine + 500mg in individuals with METS
89090374|NCT02629627|Active Comparator|Metformin+placebo conjugatedALC/leucine|active comparator with Metformin 500mg + Placebo of ACL/Leucine in individuals with METS
89090375|NCT02629627|Placebo Comparator|Placebo of Metformin|Active comparator with ACL/Leucine + Placebo of Metformin in individuals with METS
89090376|NCT02629627|Placebo Comparator|ACL/Leu placebo|Placebo comparator with ACL/Leu placebo + Metformin placebo in individuals with METS
89090377|NCT00664729|Active Comparator|1|Caloric Restriction
89090378|NCT00664729|Experimental|2|Caloric restriction + Moderate-intensity aerobic exercise
89090379|NCT00664729|Experimental|3|Caloric restriction + Vigorous-intensity aerobic exercise
89090380|NCT00946647|Experimental|Panobinostat + 5-Azacytidine|"In phase I: Panobinostat : Escalating doses starting with 20 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In both phases, dose of 5-Azacytidine was 75 mg/m^2, subcutaneously Daily for Day 1 to Day 7."
89090381|NCT00946647|Active Comparator|5-Azacytidine|"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.~Dose of 5-Azacytidine : 75 mg/m^2 subcutaneously daily from Day 1 to Day 7."
89090382|NCT04310514|Active Comparator|Experimental: glucose - fructose - xylitol - saccharose|"glucose 35 g (500ml of 7% solution);~fructose 35 g (500ml of 7% solution);~xylitol 35 g (500ml of 7% solution);~saccharose 35 g (500ml of 7% solution)"
89090383|NCT04310514|Active Comparator|Experimental: fructose - glucose - saccharose - xylitol|"glucose 35 g (500ml of 7% solution);~fructose 35 g (500ml of 7% solution);~xylitol 35 g (500ml of 7% solution);~saccharose 35 g (500ml of 7% solution)"
89090384|NCT04310514|Active Comparator|Experimental: xylitol - saccharose - glucose - fructose|"glucose 35 g (500ml of 7% solution);~fructose 35 g (500ml of 7% solution);~xylitol 35 g (500ml of 7% solution);~saccharose 35 g (500ml of 7% solution)"
89090385|NCT04310514|Active Comparator|Experimental: saccharose - xylitol - fructose - glucose|"glucose 35 g (500ml of 7% solution);~fructose 35 g (500ml of 7% solution);~xylitol 35 g (500ml of 7% solution);~saccharose 35 g (500ml of 7% solution)"
89090386|NCT00671827||Robotic Gynecologic Surgery|Patients who have undergone or will undergo a robotic-assisted gynecologic procedure.
89090387|NCT00671905|Active Comparator|1|Circumferential PV isolation
89090388|NCT00671905|Active Comparator|2|HF stimulation-guided and anatomic ablation of the main right and left atrial GP.
89090389|NCT00671905|Active Comparator|3|HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by circumferential PV isolation
89090390|NCT02631967|Experimental|Kono anastomosis|Patients receiving Kono anastomosis
89090391|NCT02631967|Experimental|Stapled side-to-side anastomosis|Patients receiving stapled side-to-side anastomosis
89090392|NCT04157491|Experimental|anlotinib and anti PD-1 antibody|
89090393|NCT04157647|Active Comparator|CytoSorb|Patients assigned to this arm group will receive hemadsorption witbhCytoSorb during the surgery and in the next 24 hours after surgery.
89090394|NCT04157647|Sham Comparator|Control|Patients assigned to this arm group will undergo to a normal CPB without the use of any hemoadsorption system.
89090395|NCT02629471|Experimental|response time due to light flashs pulses|light flashing effects on response time to random target appearance
89090396|NCT00946101|Active Comparator|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414- Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of influenza virus type A/California/07/2009.
89090397|NCT00946101|Placebo Comparator|Placebo|Placebo - Placebo was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer
89090398|NCT00664885|Experimental|CSCT|
89090399|NCT00672061|Experimental|Ramelteon 16 mg QD or Placebo QD|
89090400|NCT00672217|Placebo Comparator|Behavioral Placebo Therapy|Behavioral Placebo Treatment
89090401|NCT00672217|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (CBTI)
89090402|NCT00660751|Active Comparator|1|
89090403|NCT00660751|Placebo Comparator|2|
89090404|NCT00664963|Experimental|1|YUKON Sirolimus-eluting Stent
89090405|NCT00664963|Active Comparator|2|YUKON Stent (uncoated)
89090406|NCT00672295|Experimental|Dasatinib, paclitaxel,and carboplatin|Combination of dasatinib, paclitaxel,and carboplatin
89090407|NCT04154995||Long-term ICU patients|Patients with a ICU length of stay of at least 48 hours.
89090408|NCT00665041|Experimental|PR1|
89090409|NCT00665041|Placebo Comparator|PL1|
89090410|NCT04153045|Placebo Comparator|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
89090411|NCT04153045|Experimental|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
89090412|NCT04152655|Active Comparator|Group 1: idebenone|Oral 30 mg fixed dose three times a day x 24-months (90 mg total / day) with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
89090413|NCT04152655|Placebo Comparator|Group 2: placebo|Oral placebo three times a day x 24-months with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
89090414|NCT00672373|Experimental|A|Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
89090415|NCT00672373|Placebo Comparator|B|Matching placebo treatment
89090416|NCT01109940|Experimental|AIN457|
89090417|NCT00595309|Active Comparator|A|
89090418|NCT00665119|Experimental|treatment|Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.
89090419|NCT05113212|Active Comparator|Control arm|patients aﬀected by macular pucker or macular hole, whose internal limiting membrane peeling is performed using a traditional optical microscope (Leica F40)
89090420|NCT05113212|Experimental|Experimental arm|patients aﬀected by macular pucker or macular hole whose internal limiting membrane peeling is performed by 3D heads-up microscopy system (NGenuity 3D)
89090421|NCT00665197|Active Comparator|Protracted Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 30 Gy in 10 fractions of 3.0 Gy"
89090422|NCT00665197|Experimental|Short Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 20 Gy in 5 fractions of 4.0 Gy"
89090423|NCT04309890||Study group|
89090424|NCT00672529|Active Comparator|Intervention Group|
89090425|NCT00672529|Placebo Comparator|Placebo Group|
89090426|NCT02629549|Experimental|OTL38|Dosage calculated by weight of individual
89090427|NCT00672607|Experimental|1|
89090428|NCT00672607|Placebo Comparator|2|
89090429|NCT00665509|Experimental|1|
89090430|NCT00672685|Experimental|1|Omega-3 group without any intervention
89090431|NCT00672685|Experimental|2|Omega-3 combined group (Omega-3 + multi-domain intervention)
89090432|NCT00672685|Experimental|3|Placebo combined group (Placebo + multi-domain intervention)
89090433|NCT00672685|Placebo Comparator|4|Placebo group without any intervention
89090434|NCT00595075|Experimental|1|Ramelteon 8 mg will be given once prior to a 2-hour nap
89090435|NCT00595075|Placebo Comparator|2|Placebo will be given once prior to a 2-hour nap
89090436|NCT00887224|Experimental|Desvenlafaxine succinate sustained release 50 mg|
89090437|NCT00887224|Placebo Comparator|Placebo|
89090438|NCT00672763|Active Comparator|A|Standard corticosteroid treatment PLUS Vitamin D3 (Colecalciferol).
89090439|NCT00672763|Placebo Comparator|B|Standard corticosteroid treatment PLUS placebo (Migliol Oil)
89090440|NCT04154449||Control group.|
89090441|NCT04154449||Surgical group Received intranasal insulin.|
89090442|NCT04154449||Surgical group Received placebo.|
89090443|NCT02629081||Controls & Cases|Controls (participants without heartburn or other GERD symptoms undergoing standard upper endoscopy for the following: anemia, weight loss, diarrhea, and screening for esophageal varices) and Cases (participants with heartburn or other GERD symptoms undergoing standard endoscopy for heartburn or other GERD symptoms.)
89090444|NCT00661063|Experimental|K|drug - ketamine 1% gel
89090445|NCT00661063|Placebo Comparator|P|vehicle gel
89090446|NCT00661063|Experimental|M|association of ketamine and clonidine gel
89090447|NCT00661063|Experimental|C|clonidine gel
89090448|NCT00665587||A = MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation together with MAZE procedure
89090449|NCT00665587||B = non-MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation (without MAZE procedure).
89090450|NCT02629237|Experimental|Multifaceted education group|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
89090451|NCT02629237|No Intervention|control group|Subjects will not be asked to watch education film and not participate in counseling session before and after surgery.
89090452|NCT02825446|Active Comparator|angioplasty tibial arteries|
89090453|NCT02825446|Experimental|radio frequency denervation popliteal artery by the use|"radio frequency denervation popliteal artery Vessix Renal Denervation System Balloon"
89090454|NCT00675883||Prospective|500 patients who will be enrolled in the MS Alliance program will be consented to participate in this study.
89090455|NCT00675883||Retrospective|500 patient chart reviews will be completed for patients who were enrolled in the MS Alliance program between two (2) to three (3) years ago.
89090456|NCT04242706|Active Comparator|Control group|Endotracheal tube with evacuation lumen without Bactiguard coating.
89090457|NCT04242706|Experimental|Experimental group|Endotracheal tube with evacuation lumen with Bactiguard coating.
89226388|NCT04311632|Experimental|Arm 2|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
89226389|NCT04311632|Experimental|Arm 3|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
89226390|NCT04311632|Experimental|Arm 4|TCD601 administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
89226391|NCT04311632|Active Comparator|Arm 5|ATG administered with the contemporary standard of care (SoC) consisting of concentration-controlled tacrolimus (TAC) combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
89090458|NCT00672919|Experimental|Pioglitazone QD|(and stable statin therapy)
89090459|NCT01109316|Active Comparator|Insulin Lispro 2 Day|
89090460|NCT01109316|Experimental|Insulin Lispro 6 Day|
89090461|NCT01109316|Active Comparator|Insulin Aspart 6 Day|
89090462|NCT02825290|Experimental|Study group|hCG (Choriogonadotropin alfa; Ovitrelle 250 mcg) on day of embryo transfer & GnRH-agonist (Triptorelin acetate; Decapeptyl 0.1 mg) after 4 days In addition to the usual progesterone luteal support.
89090463|NCT02825290|No Intervention|Control group|The usual progesterone only luteal phase support.
89090464|NCT00675961|Experimental|1|Behavioral Counseling Intervention (BCI) plus treatment as usual (TAU) (i.e. standard referral to and management by an addictions specialist)
89090465|NCT00675961|Experimental|2|Naltrexone/ Brief Behavioral Compliance Enhancement Treatment (BBCET) plus TAU
89090466|NCT00675961|Experimental|3|BCI + Naltrexone/BBCET plus TAU
89090467|NCT00675961|Active Comparator|4|Treatment as Usual (TAU)
89090468|NCT00887068|Experimental|Azacitidine|Azacitidine 32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
89090469|NCT00887068|No Intervention|No Azacitidine|Standard treatment post allogeneic transplant is supportive care only.
89090470|NCT00941031|Experimental|Induction Single Dose|"Induction with single injection - Single: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12"
89090471|NCT00941031|Experimental|Induction Monthly Dose|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12"
89090472|NCT00941031|Experimental|Induction Early Loading Dose|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12"
89090473|NCT00941031|Placebo Comparator|Placebo Dose|Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12
89090474|NCT04310436|Experimental|Looking down to naval.|Modifying Saccade origin by looking down to naval.
89090475|NCT04310436|Placebo Comparator|Looking up in the air.|Modifying Saccade origin by looking up in the air.
89090476|NCT00886834|Experimental|Misoprostol|Misoprostol 400 micrograms inserted vaginally or buccally, per the participants desire.
89090477|NCT00886834|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
89090478|NCT00880009|Experimental|1|Combination of Bosutinib and Letrozole
89090479|NCT00880009|Active Comparator|2|Letrozole
89090480|NCT04242472|Experimental|SMS group|Nutrition-related SMS messages in addition to standard of care TB treatment with directly observed therapy
89090481|NCT04242472|No Intervention|Control group|Standard care of TB treatment with directly observed therapy alone
89090482|NCT00602433||questionnaire and laboratory biomarker analysis|Subjects with advanced non-small cell lung cancer and take erlotinib as part of their anticancer therapy for at least 3 months. Subjects have had some changes in hair growth, acne or menses (periods) that might be a side effect of erlotinib. Subjects will complete a questionnaire and blood collected for biomarker analysis.
89090483|NCT02827006|Active Comparator|Bone graft|Bone graft from iliac crest as gapfiller
89090484|NCT02827006|Experimental|Calcium phosphate bone cement|CaP bone cement as gapfiller
89090485|NCT00676039|Active Comparator|1|"Crossover Effexor / NOVO-Venlafaxine~Examination of the bioequivalence of Effexor (Wyeth Pharmaceuticals) and NOVO-Venlafaxine (NOVOPHARM).~Both drugs will be given at the dose of 75 mg/day (one capsule per day) for 4 consecutive days. A washout period (corresponding to 10 half-life of the active metabolite desmethylvenlafaxine) will be respected after receiving each medication."
89090486|NCT00676039|Active Comparator|2|"Crossover Celexa/Gen-citalopram~Examination of the bioequivalence of Celexa (Lundbeck, Brand Name) and Gen-Citalopram (Genpharm, Generic). Both drugs will be given at the dose of 40 mg/day (one tablet per day) for 8 consecutive days. A washout period (corresponding to 10 half-life of citalopram) will be respected after receiving each medication."
89090487|NCT01104636||Single group prospective treatment cohort (varenicline)|
89090488|NCT04268511||Caudal epidural block group|Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
89090489|NCT04268511||Pudendal nerve block group|The long axis of the ultrasound probe was positioned on a horizontal line connecting the ischial tuberosity that had been previously located by palpation to the anus. The ischial tuberosity could be easily identified as a hypoechoic area that is bounded superiorly by a hyperechoic line. The probe was then moved medially on the same axis until the rectum appeared as another hypoechoic area.
89090490|NCT04931602||Model A|"Patients will be followed-up at bone, endocrine and rheumatology clinic after discharge depending upon availability of the consultant. Multifaceted risk-factor assessment for identifying patients at risk will be conducted including formal future fracture risk assessment/life style/medication review and fall risk assessment.~Comprehensive laboratory designed package including calcium (Ca), albumin (ALB), phosphate (P), bone alkaline phosphatase (BAP), C terminal peptide of type 1 collagen (CTx), vitamin D (25OHD) and intact parathyroid hormone (iPTH) will be performed at first clinic visit for all patients between 6-8 weeks post fracture. Screening for secondary causes of osteoporosis will be conducted for those identified in need. BMD testing as per guidelines for patients with fragility fractures will be conducted at clinic visit and recorded with risk assessment form (12)."
89111082|NCT02690103|Active Comparator|Group 1|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months. In addition, they are given ribavirin according to their body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
89226392|NCT04255966||Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
89090491|NCT04931602||Model B|All routine intervention except treatment initiation-the responsibility of patient's general practitioner for prevention of secondary fracture. Those included in this intervention arm, will be identified and risk assessment will be performed at hospital admission. Recommendations for the treatment will be made to be initiated by the patient's general physician. Patients will be followed at 6 months on telephone, and a questionnaire related to treatment compliance &/or non-compliance will be filled by the coordinator.
89090492|NCT04931602||Model C|Health education only provided at the time of admission with handover to family physician for follow-up. Patients will be given an appointment to follow-up at community health center of Aga Khan University
89090493|NCT04931602||Model D|Health Education provided. There is no physician contact with the person's general practitioner for prevention of secondary fracture. Education material for the patient have been prepared and will be provided to patient along with counselling by the nurse at the time of discharge
89090494|NCT04157023|Other|Medical Students|Simulator training of 7 patient cases adapted to medical students.
89090495|NCT04157023|Other|Ophthalmologist|Simulator training of 7 patient cases adapted to ophthalmologists.
89090496|NCT04157023|Other|Neurologist/Neurosurgeon/Neonatologist|Simulator training of 7 patient cases adapted to neurologists, neurosurgeons and neonatologists.
89090497|NCT04157257|Experimental|QL-007 +TDF|QL-007 200 mg BID +TDF 300 mg QD
89090498|NCT04157257|Experimental|QL-007 +Entecavir|QL-007 200 mg BID +Entecavir 0.5 mg QD
89090499|NCT04157257|Active Comparator|TDF monotherapy|TDF tablet 300 mg QD
89090500|NCT04157257|Active Comparator|Entecavir monotherapy|Entecavir tablet 0.5 mg QD
89090501|NCT04243174|Other|SMS Messages|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
89090502|NCT02852421|Active Comparator|Multiple injection paravertebral blocks|"Patients in this group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
89090503|NCT02852421|Experimental|Single injection paravertebral block|"Patients in single injection group will receive single injection paravertebral blocks at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections."
89090504|NCT04152811|Active Comparator|Waitlist 1|usual diabetes care
89090505|NCT04152811|Experimental|Intervention 1|6-weeks of cooking matters for diabetes classes
89090506|NCT04152811|Active Comparator|Waitlist 2|usual diabetes care
89090507|NCT04152811|Experimental|Intervention 2|6-weeks of cooking matters for diabetes classes
89090508|NCT02852109||experimental group|patients who was firstly diagnosed as diffuse axonal injury
89090509|NCT02852109||control group|patients negative for magnetic resonance examination with no trauma
89090510|NCT04152889|Experimental|Camrelizumab+chemotherapy|
89090511|NCT00602511|Active Comparator|1|Bortezomib - dexamethasone
89090512|NCT00602511|Experimental|2|Thalidomide - dexamethasone
89090513|NCT02826616|Experimental|Trimetazidine group|Trimetazidine 60 mg 30 min before PCI and 20 mg for 12 months after surgery
89090514|NCT02826616|No Intervention|The control group|placebo 60 mg 30 min before PCI and 20 mg for 12 months after surgery
89090515|NCT00676117|Experimental|1|
89090516|NCT00676117|Active Comparator|2|
89090517|NCT05042986|Experimental|Single Dose Capsule|Single oral dose of 200 mg (100 μCi in 200 mg salt [0.5 μCi/mg as salt], equivalent to 100 μCi in 142 mg active [0.7 μCi/mg as active]) of [14C]-SKI-O-703 containing approximately 100 μCi of [14C]-SKI-O-703 per capsule after an overnight fast.
89090518|NCT02852187|Active Comparator|MOBIS PEEK|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS PEEK Cage
89090519|NCT02852187|Active Comparator|MOBIS II ST|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS II ST Cage
89090520|NCT00676273|Active Comparator|1|TVTO
89090521|NCT00676273|Active Comparator|2|TVTS
89090522|NCT04242160|Experimental|Modified Clamshell Thoracotomy First|Participants randomized to perform the MCT first, then cross over to the perform the alternate LAT.
89090523|NCT04242160|Active Comparator|Left Anterolateral Thoracotomy First|Participants randomized to perform the LAT first, then cross over to the perform the alternate MCT.
89090524|NCT00911755|Other|Laryngoscopy|
89090525|NCT00911755|Other|Videolaryngoscopy|
89090526|NCT02826850|Sham Comparator|Genicular nerves|Neurotomy by radiofrequency of genicular nerves knee guided by fluoroscopy
89090527|NCT02826850|Active Comparator|Saphenous Nerve|Neurotomy of saphenous nerve by radiofrequency on the distal third of the thigh, guided by ultrasound
89090528|NCT04270071|Experimental|Yangxin Shengmai Granules|"Patients were given Yangxin Shengmai granules orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
89090529|NCT04270071|Placebo Comparator|Placebo|"Patients were given Yangxin Shengmai granules simulation orally 14g (1 bag) each time, 3 times daily for 4 weeks. And nitroglycerin tablets are used when angina attack.~For patients who have used drugs such as aspirin, angiotensin-converting enzyme inhibitor, lipid-lowering drugs to treat coronary heart disease before inclusion, they can continue to use the original varieties and doses, without dose adjustment."
89090530|NCT04152733|No Intervention|Control group|Children in the control group receive oxygen via conventional nasal cannula during deep sedation. Oxygen flow is determined to set the fraction of inspired oxygen of 50%.
89090531|NCT04152733|Experimental|High flow (HF) group|Children in the HF group receive oxygen via high flow nasal cannula during deep sedation. Fraction of inspired oxygen is set to 50%.
89090532|NCT02826538|Experimental|patient specific guides|fracture fixation with 3D planning and use of patient-specific instruments
89090533|NCT02826538|Active Comparator|standard procedure|standard procedure of fracture Fixation without 3D planning and without use of patient-specific instruments
89230260|NCT00801905|Placebo Comparator|2: placebo|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
89090534|NCT04152577|Experimental|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
89111083|NCT02690103|Experimental|Group 2|Patients are treated with Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose.
88812534|NCT03694756|Other|Post-biopsy patients|Patients after breast biopsy. Once consent is obtained, patients will undergo TMEM-MRI. The patients will undergo definitive breast surgery and will receive adjuvant treatments as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be evaluated in final surgical specimen. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
88812535|NCT03665116|Experimental|Arginine|L-arginine 1.5 g capsule by mouth, once daily for 6 months
89111084|NCT00760513|Active Comparator|Omega 3 fatty acid (fish oil)|OMACOR (alternative name: Lovaza) 4 grammes daily, oral capsule
89111085|NCT00760513|Placebo Comparator|dummy pill|4 grammes daily, oral capsule (olive oil)
89111086|NCT02689947|Experimental|Restylane Silk|open label no placebo control
89090535|NCT04152577|Active Comparator|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
89090536|NCT02856087|Placebo Comparator|group LR|low dose remifentanil (1 ng/ml of Ce) with normal saline infusion
89090537|NCT02856087|Active Comparator|group HR|High dose remifentanil infusion (4ng/ml of Ce) with normal saline infusion
89090538|NCT02856087|Experimental|group HR-N|remifentanil infusion at 4ng/ml of Ce with naloxone infusion
89090539|NCT02881632||Healthy infants aged 0-2|Healthy infants aged 0-2 year with no respiratory diseases to provide a reference values. A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person.
89090540|NCT02881632||Infants aged 0-1 with Bronchiolitis|Infants admitted to hospital within last 24hrs (AVB participants only). A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person
89090541|NCT00886288||Telmisartan|
89090542|NCT00886288||Telmisartan + hydrochlorothiazide|
89090543|NCT02855931|Experimental|Middle turbinate resection|Resection of one middle turbinate
89090544|NCT02855931|No Intervention|Middle turbinate preservation|Preservation of one middle turbinate
89090545|NCT00676429|Experimental|1|Ziprasidone Hydrochloride oral solution with individual titration from 5 mg to 40 mg per day
89090546|NCT00676429|Placebo Comparator|2|Placebo oral solution
89090547|NCT02880072|Experimental|refeeding syndrome|6 patients with head and neck cancer and refeeding syndrome, 4 different of preparations of phosphate orally
89090548|NCT02880072|Experimental|no refeeding syndrome|6 patients with head and neck cancer without refeeding syndrome, 4 different of preparations of phosphate orally
89090549|NCT02856165|Experimental|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (Fisher&Paykel (F&P), NZ)
89090550|NCT02856165|Active Comparator|Low-flow oxygen therapy|Low-flow oxygen therapy with standard nasal canula
89090551|NCT02629315|Active Comparator|10% neutral buffered formaldehyde|Specimens will be fixed for 24-48hours in 10% neutral buffered formaldehyde and then dissected for lymph nodes.
89090552|NCT02629315|Experimental|Carnoy's solution|Specimens will be fixed for 24-48hours in Carno'ys solution and then dissected for lymph nodes.
89090553|NCT04310046|Other|PCI before TAVI|PCI is performed within 1-45 days before TAVI.
89090554|NCT04310046|Experimental|PCI after TAVI|PCI is performed within 1-45 days after TAVI.
89090555|NCT02855853|Experimental|serious game|
89090556|NCT02855853|Placebo Comparator|control|
89090557|NCT00676507|Experimental|Treatment|Treatment Arm: This course of therapy is Best Support Care (BSC) plus monthly intradermal (ID) injections of Lucanix™ (belagenpumatucel-L) consisting of 25,000,000 cells in a volume of 0.40 mL.
89090558|NCT00676507|Placebo Comparator|Control Arm|Control Arm: This course of therapy is Best Support Care (BSC) plus a placebo injection that consists of 0.15% Intralipid® in solution composed of the cryopreservation formulation minus the gene modified cells and dimethyl sulfoxide (DMSO) in a volume of 0.40 mL.
89090559|NCT02880150|Other|Elite climbers|Elite climbers selected in a national group for their previous performances at high altitude
89090560|NCT02880150|Other|Sea level sportsmen|Control group with similar anthropometric, age, gender and maximal normoxic oxygen consumption that the elite climber group
89090561|NCT01204658|Experimental|10PP-LD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with low doses (LD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD) co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
89111087|NCT04100239|Experimental|Intervention Arm|Open continuous recruitment of participants to trial where all participants begin the study as 'control participants' and at regular 'steps' participants are allocated to next available intervention group and cross from the control to the intervention condition, until all groups have completed the intervention.
89111088|NCT02794233|Experimental|PD patients with implanted DBS|Impedance measurements at different time points.
89090562|NCT01204658|Experimental|10PP-HD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with high doses (HD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD), co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
89090563|NCT01204658|Active Comparator|Synflorix/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Synflorix™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Synflorix™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Synflorix™ and on the right side for Infanrix hexa™.
89090564|NCT01204658|Active Comparator|Prevnar 13/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Prevnar 13™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Prevnar 13™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Prevnar 13™ and on the right side for Infanrix hexa™.
89090565|NCT00951483|Experimental|Intervention Cohort|Patients will undergo baseline psychological and laboratory tests then receive Quetiapine-XR(Seroquel-XR) with flexible dosing at the discretion of the treating physician based on clinical response and tolerability. The dose range will be from 50-300mg. The total duration of the treatment will be 12 weeks.
89090566|NCT00951483|No Intervention|Healthy Control|Participants without major depressive disorder or anxiety are enrolled as a comparison group without intervention.
89090567|NCT01104246|Experimental|Testosterone Transdermal Systems|Testosterone
89090568|NCT00676741||A|
89090569|NCT00676741||B|
89090570|NCT00676741||C|
89090571|NCT01103778|Experimental|Velcade® therapy|Patients with greater than 1gm of proteinuria per day will receive Velcade®.
89090572|NCT02855619|Active Comparator|Martin|A threshold-based IMT is performed like used by Martin in a randomized trial in 2011, in a view of inspiratory strength increase.
89090573|NCT02855619|Active Comparator|Cader|A threshold-based IMT is performed like used by Cader in a randomized trial in 2012, in a view of inspiratory endurance increase.
89090574|NCT02855619|Experimental|EDRIC|A new threshold-based IMT is performed, in a view of both inspiratory strength and endurance increase.
89090575|NCT00673543||1|Pregnant women with insulin requiring diabetes
89090576|NCT00673543||2|Pregnant women without insulin requiring diabetes
89090577|NCT00673621|Experimental|1|
89090578|NCT01103466|Active Comparator|New ostomy appliance (Atlas)|Atlas= new base plate. Due to company confidentiality the product is just called Atlas and this is not short for any other names
89090579|NCT01103466|Active Comparator|SenSura|Commercially available ostomy appliance
89090580|NCT01103466|Active Comparator|Conform 2|Commercially available ostomy appliance
89090581|NCT02627053|Experimental|rivaroxaban|
89111089|NCT04098289||Hysteroscopic septum resection without in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with natural conception (without the use of in vitro fertilization techniques).
89111090|NCT04098289||Hysteroscopic septum resection with in vitro fertilization|Primary infertile women who underwent hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
89111091|NCT04098289||Natural conception, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with natural conception (without in vitro fertilization techniques).
89090582|NCT00945945|Experimental|DLX30-PLA|Per the protocol, patients randomized to the duloxetine group were to receive duloxetine for the entire 13-week acute treatment period. Patients were to start at a 30 mg daily (QD) dose of duloxetine for 1 week, then increase to 60 mg QD of duloxetine for the following 12 weeks. However, due to a study drug labeling error, patients randomized to this group received 30 mg of duloxetine for the initial 1-week, but received placebo instead of receiving 60 mg QD of duloxetine for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as DLX30-PLA throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive 30 mg QD of duloxetine during that week, and that did occur per protocol.
89090583|NCT00945945|Placebo Comparator|PLA-DLX60|Per the protocol, patients randomized to the placebo group were to receive placebo for the entire 13-week acute treatment period. Patients were to start on placebo for the first week, then continue on placebo for the following 12 weeks. However, due to a study drug labeling error, patients in this group received placebo for the initial 1-week, but received 60 mg QD of duloxetine instead of receiving placebo for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as PLA-DLX60 throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive placebo that week, and that did occur per protocol.
89090584|NCT01203956|Experimental|SmartFlex|Use Continuous Airway Pressure device with SmartFlex engaged
89090585|NCT01203956|Active Comparator|Standard|Use Continuous Airway Pressure device without SmartFlex engaged
89090586|NCT04150627|Active Comparator|deep breathing|
89090587|NCT04150627|No Intervention|normal breathing|
89090588|NCT01103232|Experimental|Electrical Muscle Stimulation|Electrical muscle stimulation of the right wrist flexor muscles was applied
89090589|NCT01103232|Sham Comparator|Control|Transcutaneous electrical nerve stimulation was applied
89090590|NCT02627287|Experimental|DV3316 pen-injector|
89090591|NCT02627287|Active Comparator|FlexPen®|
89090592|NCT02853669|Experimental|group (A) lumber plexus block|Ultrasound-guided Lumber plexus Block (30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation.
89090593|NCT02853669|Experimental|Group (B) adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
89090594|NCT00673699||A|Seventy dyspeptic consecutive patients that going upper gastrointestinal endoscopy
89111092|NCT04098289||In vitro fertilization, without hysteroscopic septum resection|Primary infertile women who did not undergo hysteroscopic septum resection and obtained the first pregnancy with the use of in vitro fertilization techniques.
89111093|NCT02790333|Experimental|Tri-Staple reloads|Tri-Staple reloads were used for pancreatic stump texture
89111094|NCT02790333|Active Comparator|traditional reloads|the traditional reloads were used for pancreatic stump texture
88812536|NCT03665116|No Intervention|No Intervention|no supplement for 6 months
88812537|NCT03660852||Before dedicated MRI|
89090595|NCT01112982|Other|Febuxostat Sub-Study|"To analyze the effect of urate-lowering therapy (specifically with febuxostat [Uloric]) on the synovial pannus in the index joint of a subgroup of patients. Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric) and who have a serum urate level of > or = to 9.0, will be treated with febuxostat (Uloric) and their serum urate level will be followed at months 1, 3, 6, and 9. Magnetic Resonance Imaging (with and without gadolinium) of the same index joint will be repeated at month 9 to assess for the presence and degree of synovial pannus. Because initiation of urate-lowering therapy can induce acute attacks of gout, these subjects will also be started on colchicine as a prophylactic (and remain on colchicine for 6 months)."
89090596|NCT01112982|Other|MRI of index joint|"To analyze synovial pannus in the Magnetic Resonance Imaging (with and without gadolinium) of the index joint on Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric)."
89090597|NCT01203878|Experimental|Imiquimod & photodynamic therapy|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light
89090598|NCT01203878|Active Comparator|Imiquimod|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation
89090599|NCT02853825|No Intervention|Wait List Control Group|No interventions given, this is a wait list control group.
89090600|NCT02853825|Experimental|Intervention Group|Receive relationship skill enhancement classes with access to parenting, employment services, and financial services.
89090601|NCT02851953|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
89090602|NCT04151797|Experimental|Medication therapy management|Medication therapy management by pharmacist-led medication review
89090603|NCT01112514|Experimental|ICG Injection|These participants underwent a colonoscopy after having an ICG injection.
89090604|NCT02629003|Active Comparator|[11C]Cimbi-36|"[11C]Cimbi-36~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
89090605|NCT02629003|Active Comparator|[11C]Cimbi-36-5|"[11C]Cimbi-36-5~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
89090606|NCT00625794|Experimental|1|8 weeks or counseling plus 6 weeks of nicotine nasal spray
89090607|NCT00625794|Active Comparator|2|8 weeks or counseling only.
89090608|NCT02853981|Active Comparator|Harmonic scalpel group|group of donors whom will undergo liver transection using harmonic scalpel.
89090609|NCT02853981|Active Comparator|clamp-crush group|group of donors whom will undergo liver transection using Kelly clamp.
89090610|NCT00911911|Experimental|FEC 100 + TAXOTERE|"FEC 100 = Fluoro-uracile + Epirubicin + Cyclophosphamide Fluoro-uracile : 500 mg/m²/cycle Epirubicin : 100 mg/m²/cycle Cyclophosphamide : 500 mg/m²/cyle 1 cycle = 21 days. For a total of 6 cycles or 3 cycles followed by 3 cycles of TAXOTERE~TAXOTERE 100 mg/m²/cycle~1 cycle = 21 days. For a total of 3 cycles following 3 FEC 100"
89090611|NCT01203098|Experimental|DU-176b 30mg once daily|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
89090612|NCT01203098|Active Comparator|Enoxaparin sodium twice daily|Enoxaparin sodium 20mg (=2000IU) / 0.2mL twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
88812538|NCT03660852||After dedicated MRI|
89090613|NCT01203098|Experimental|DU-176b 15mg once daily|DU-176b 15mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
89090614|NCT05032794|Experimental|Unrestricted diet|The participant is not instructed to follow any dietary recommendation before colonoscopy. But only the restriction and fasting required for sedation.
89090615|NCT05032794|Active Comparator|One day low residue diet|"The participant is instructed to follow a low residue diet the day before the colonoscopy.~It will be given a informative document and educated by a nurse."
89090616|NCT00676975|Active Comparator|Traditional Chinese Medicine|Traditional Chinese Medicine 17g herbal extract
89090617|NCT00676975|Placebo Comparator|Traditional Chinese Medicine Placebo|Placebo
89090618|NCT00945555||All participants|Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
89090619|NCT04318184|Experimental|Exercise|Submaximal aerobic exercise protocol
89090620|NCT00673777|Experimental|A|
88812539|NCT03581331|Experimental|acute unilateral vestibular loss|patients with acute unilateral vestibular loss by surgical deafferentation will performed an orthoptic balance
89090621|NCT01108458|Experimental|Pertuzumab plus Erlotinib Hydrochloride|"Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks~Erlotinib hydrochloride 150 mg/day by mouth"
89090622|NCT00633646|Active Comparator|1|low protein diet
89090623|NCT00633646|Active Comparator|2|low protein diet with keto acids
89090624|NCT00633646|Active Comparator|3|high protein diet
89090625|NCT04318262||Patient with Staphylococcus lugdunensis infection|All consecutive patients with S. lugdunensis infection (microbiological and clinical data)
89090626|NCT04318262||Patient with Staphylococcus aureus infection|Patients with S. aureus infection (microbiological and clinical data), matched to the hospital sector for S. lugdunensis infections
89090627|NCT04318262||Patient with other coagulase negative Staphylococcus infection|Patients with CoNS infection (microbiological and clinical data),matched to the hospital sector for S. lugdunensis infections
89090628|NCT02851641||Nasolacrimal duct obstruction|
89090629|NCT04242316|Experimental|Mirror Therapy|Patients performed customized bimanual upper limb exercises with a mirror. They can observe the mirror visual feedback of their non-paretic hand during the movements.
89090630|NCT04242316|Active Comparator|Bilateral arm training|Patients performed customized bimanual upper limb exercises without a mirror.
89090631|NCT00680563|Experimental|1|
89090632|NCT02887508|Experimental|HINTS Intervention|The HINTS intervention consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills related to a specific topic relevant to online partner seeking and transmission risk reduction, including Internet safety and communication, condom negotiation, and serostatus disclosure.
89090633|NCT02887508|Active Comparator|Healthy Living Control|The Healthy Living Control condition consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills to address non-sexual health-related topics particularly relevant to individuals living with HIV, such as nutrition, healthy eating, portion control, exercise and staying active, and stress reduction.
89090634|NCT02851719|Experimental|BF group|24 outpatient sessions of the PFMT (twice a week) using manometric-based BF equipment and daily home PFMT exercises.
89090635|NCT02851719|Active Comparator|PFMT group|24 outpatient sessions (twice a week) of PFMT without BF and daily home PFMT exercises.
89090636|NCT01108068|Experimental|Lithium|patients with OPPG will be treated with lithium for 6 months
89090637|NCT01108068|No Intervention|Unaffected controls|Family members of patients with OPPG will have DXA and pQCT to compare to OPPG patients. These unaffected participants will not receive lithium.
89090638|NCT00680641|Active Comparator|A|Simvastatin 40mg
89090639|NCT00680641|Placebo Comparator|B|Placebo
89090640|NCT01201850|Experimental|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses.
89090641|NCT05660122||Treatment group|patients with gastroesophageal reflux disease
89090642|NCT04980144|Experimental|DQS group|Participants in DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 8 weeks.
89090643|NCT04980144|Active Comparator|HA group|Participants in HA group will be administered one drop of 0.1% Sodium hyaluronate artificial tears (preservative free) six times per day for 8 weeks.
89090644|NCT00951171|Experimental|Cervical occulsion|Insemination Eliptosphere catheter filled with 1cc of air for 15 minutes. H/S Eliptosphere by Copper surgical (U.S. Patent No. 5,624,399)
89090645|NCT00951171|Active Comparator|Standard IUI|Insemination with TOmcat catheter
89090646|NCT00677131|Active Comparator|1|To read the package insert of the drug
89090647|NCT00677131|Active Comparator|2|To read the education information provided by the Pharmacy of NTUH
89090648|NCT00677131|Active Comparator|3|Oral education provided by the pharmacist
89090649|NCT02825056|Active Comparator|Bupivacaine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%).
89090650|NCT02825056|Experimental|Bupivacaine + Morphine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%) and 250 microgram of preservative free Morphine (VERMOR).
89090651|NCT02628691||HCV coinfection with no-to-moderate fibrosis|
89090652|NCT02826772|Experimental|Phase 1 GT0918 level 1|generic name: not applicable dosage form: tablet dosage: oral dosage to be determined dosage frequency: daily dosage duration: 6 months
89090653|NCT04318418||Cases|Patients who developed severe COVID-19 disease (including fatal events)
89090654|NCT04318418||Controls|Infected patients who did not develop severe COVID-19 respiratory disease (including individuals who recovered from the infection)
89090655|NCT00677209|Active Comparator|A|house dust mite allergics will undergo autovaccine immunization
89090656|NCT02824744|Active Comparator|treatment by 2l/min/kg in HFNC|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
89090657|NCT02824744|Experimental|treatment by 3l/min/kg in HFNC|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
89090658|NCT02824900|Experimental|Vibration stimuli to neck|Vibration stimuli to contralesional neck muscles, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
89090659|NCT02824900|Active Comparator|Vibration stimuli to hand|Vibration stimuli to contralesional hand, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
89090660|NCT00674089|Active Comparator|1|Routine Post-partum Care and Vitamin A supplementation (50,000 IU) to the Newborn
89090661|NCT00674089|Placebo Comparator|2|Routine Post-partum Care with Placebo to the Newborn
89090662|NCT01200992|Experimental|EN3348|8 mg mixed with sterile water for injection for a total volume of 50mL
89090663|NCT01200992|Active Comparator|Mitomycin C|40 mg powder will be reconstituted with sterile water for injection to a total volume of 40 mL
89090664|NCT02824666|Experimental|0.5 mg/kg|• Cohort 1: ATI-9242 - Single IV bolus dose of 0.5 mg/kg
89090665|NCT02824666|Experimental|ATI-9242 1.0 mg/kg|• Cohort 2: ATI-9242 - Single IV bolus dose of 1.0 mg/kg
89090666|NCT00674167|Experimental|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel and cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
89090667|NCT00674167|Experimental|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
89090668|NCT00674167|Experimental|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycles.
89090669|NCT02824588|Experimental|Intervention|Working Memory Training
89090670|NCT02824588|Active Comparator|Control|Internet use
89090671|NCT00680719|Active Comparator|1|Family Therapy plus HIV prevention
89090672|NCT00680719|Active Comparator|2|Family Therapy only.
89090673|NCT00912145|Experimental|1|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
89090674|NCT00912145|Active Comparator|2|Alprazolam Tablets, 2 mg, Xanax (The Upjohn Company)
89090675|NCT00680875|Experimental|Intervention|5th and 6th grade students who attend schools randomly assigned to the intervention condition.
89090676|NCT00680875|No Intervention|Usual Curriculum|5th and 6th grade students attending schools randomly assigned to the usual curriculum control condition.
89090677|NCT04243252|Experimental|Intervention Food Pantries|Food pantries will complete online training to help them rank foods by nutritional value and promote those foods to pantry clients; the effect on pantries and their clients will be measured.
89090678|NCT04243252|Active Comparator|Control Food Pantries|Food pantries will continue to operate as usual during the study period; the effect on pantries and their clients will be measured.
89090679|NCT02626975||ACL reconstruction ballooning|"ACL reconstruction with short hamstring tendon autograft~arm ballooning~arm no ballooning"
89090680|NCT04242004|Experimental|DHA group|
89090681|NCT04242004|Placebo Comparator|placebo group|
89090682|NCT04150237||Novices|Medical students
89090683|NCT04150237||Intermediates|Endoscopy (EGD) assisting nurses. No prior self-performed endoscopies
89090684|NCT04150237||Experienced|Medical doctors in medical Gastroenterology or surgery, who have self-performed more than 500 EGD
89090685|NCT02824510|Active Comparator|Patients under insulin pump therapy.|Patients under insulin pump therapy. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart).
89090686|NCT02824510|Active Comparator|Patients under MDI.|Patients under multiple daily injection regimen. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart and glargine or detemir).
89090687|NCT00674245|Active Comparator|Pantoprazole|40 mg once daily for four weeks improves sleep quality in patients with GERD
89090688|NCT00674245|Placebo Comparator|placebo|To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.
89090689|NCT04242082||patients with psoriasis vulgaris only|
89090690|NCT04242082||patients with psoriasis vulgaris and type 2 diabetes mellitus|
89090691|NCT04242082||healthy control|
89090692|NCT00878215|Experimental|Phase 1:Localize Anatomical Points on Liver Surface|-The surgeon will use image-guided surgery equipment to create the mapping with 3-D pictures of the participants liver. Laser range scanning will also be used to take 3-D pictures of the liver surface. The participant will then have planned standard surgery.
89090693|NCT00878215|Experimental|Phase 2: Ceramic bead|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. During the surgery, a ceramic bead will be placed in a pre-operatively determined target location within the tumor using image-guided surgery. Standard surgical procedures will then be used to remove the tumors. Magnetic resonance (MR) images of the resected liver will confirm targeting accuracy.
89090694|NCT00878215|Experimental|Phase 3: Ablative therapy|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. The liver tumors will be ablated using image-guided surgery. Standard surgical procedures will then be used to remove the portion of the liver that has the ablated tumors. The accuracy of the ablation will be confirmed via pathology sectioning.
89090695|NCT00878215|Experimental|Phase 4: Ablative therapy (not liver resection candidates)|-This phase is for patients who otherwise do not qualify to have a portion of their liver to be surgically removed. The surgeon will use image-guidance to create the mapping with 3-D pictures of the liver. The tumors will be ablated using image-guided therapy.
89090696|NCT04243018|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Intervention to improve well-being and reduce the negative effects of shame and self-stigma in a population of adults experiencing homelessness.This will involve participating in two sessions, lasting two and a half hours each, over a period of two weeks. Well-being will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition participants will be provided with an acceptance and commitment training workbook. The workbook will foster core processes of the ACT model through psycho-education, daily exercises, tips and tools.
89090697|NCT04243018|Active Comparator|Peer Support Group|This peer support group will involve discussing themes around experiencing homelessness, shame and stigma and will be facilitated by an experienced peer support group leader.This will involve participating in two sessions, lasting two hours each, over a period of two weeks.
89090698|NCT02628847|Experimental|Drug|Sildenafil citrate 25mg once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
89090699|NCT02628847|Placebo Comparator|control|placebo capsule once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
89090700|NCT00677287|Experimental|A|
89090701|NCT05660902|No Intervention|Control Group|Patients in this group continued their routine medical treatment program without any treatment.
89090702|NCT05660902|Experimental|Intervention Group|Patients in this group continued their routine medical treatment program without any treatment. Moreover, ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes.
89090703|NCT02826460||Liver Transplant Recipients|
89090704|NCT00674401|Active Comparator|1|"In patients with paroxysmal atrial fibrillation: Empirical pulmonary vein antrum circumferential isolation.~In patients with persistent atrial fibrillation: Empirical circumferential PV antrum isolation w/out roof line."
89090705|NCT00674401|Active Comparator|2|"In patients with paroxysmal atrial fibrillation: High frequency sites ablation in the LA.~In patients with persistent atrial fibrillation: A combined approach involving pulmonary vein antrum isolation w/out roof line and high frequency sites ablation"
89090706|NCT02824120|Experimental|Comedy|patients in this group will watch a comedy film that will not exceed 30 minutes
89090707|NCT02824120|Experimental|Documentary|patients in this group will watch a documentary film that will not exceed 30 minutes.
89090708|NCT00677443|Experimental|S-1 and Oxaliplatin|"S-1 and Oxaliplatin~S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks"
89090709|NCT00677443|Active Comparator|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin
89090710|NCT04913584|Experimental|Immediate Intervention|Online Group CBT for PPD. Women in the treatment group will attend an online 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by eight lay-peers.
89090711|NCT04913584|Experimental|Wait-List Controls|Online Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however, they will begin the CBT group 9 weeks after enrolling in the study.
89090712|NCT04259242|Experimental|premenopausal women with periodontitis|Experimental: premenopausal women with periodontitis premenopausal women with chronic periodontitis will be evaluated after SRP for serum bone resorption markers - CTX and inflammatory markers IL-6
89090713|NCT04150003|Experimental|Pulmonary Rehabilitation program|10-weeks structured exercise-based intervention protocol on the restoration of lung blood flow after an acute PE
89090714|NCT04150003|Active Comparator|Usual care|Protocolized usual care for patient suffering PE
89090715|NCT05660824|Experimental|SVF (Stromal vascular fraction)|"Patients will receive a venepuncture to obtain PRP, and a lipoaspirate to obtain SVF. Then an ultrasonographic guided PRP+SVF injection will be performed.~Patients will consecutively receive two monthly PRP injections. Patients in tendinopathies subgroup will besides undergo tendon needling concomitant to each injecetion."
89090716|NCT05660824|Active Comparator|PRP (Platelet-rich plasma)|"Patients will receive a venepuncture to obtain PRP, and a sham lipoaspirate. Then an ultrasonographic guided PRP injection will be performed.~Patients will consecutively receive two monthly PRP injections. Patients in tendinopathies subgroup will besides undergo tendon needling concomitant to each injecetion."
89090717|NCT04150159|Experimental|Fasting Mimicking Diet (FMD) Arm|The ProLon® FMD diet is made up of nut bars, dehydrated soups, tea, olives, kale crackers, electrolyte beverages, and a chocolate crisp bar consumed for 5 days every 30 days for 4 months.
89090718|NCT04150159|Active Comparator|Mediterranean Diet Arm|"The Mediterranean diet is based on the traditional foods that people used to eat in countries like Italy and Greece in the 1960s.~Eat every day: vegetables, fruits, nuts, seeds, legumes, potatoes, whole grains, breads, yogurt, dairy, fish/seafood, herbs, spices and extra virgin olive oil.~Eat three or fewer servings each week: poultry, eggs, cheese.~Eat two or fewer servings each week: red meat, potatoes.~Eat two or fewer servings each week: sweets, sodas, processed meat, refined grains, refined oils and other highly processed foods."
89090719|NCT00677521|Experimental|1|
89090720|NCT00677599|Active Comparator|Intervention A|Experimental arm enriched with flavonoids
89090721|NCT00677599|Placebo Comparator|Intervention B|
89090722|NCT02826304|Active Comparator|VH|Vaginal Hysterectomy for uteri larger than 280gm
89090723|NCT02826304|Active Comparator|LAVH|Laparoscopic assisted vaginal hysterectomy for uteri larger than 280gm
89090724|NCT00674713|Experimental|A|Patients receiving acupuncture at P6 point plus physiological saline solution
89090725|NCT00674713|Active Comparator|B|Patients receiving ondansetron plus sham acupuncture
89090726|NCT00674713|Other|C|Patients receiving ondansetron plus acupuncture at P6 point
89090727|NCT00674713|Placebo Comparator|D|Patients receiving physiological saline solution plus sham acupuncture
89090728|NCT04241380|Active Comparator|Conventional treatment group|Patients in this group will received conventional treatments. Drug: None. Drug: For the high-risk patients, doctors will assess their risk factors and choose continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) if needed. Aspirin 5 mg/kg may be given every eight hours subsequently for 3 months.
89090729|NCT04241380|Experimental|Anti-coagulant treatment|Continuous infusion heparin. Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5mg/kg will be given every eight hours subsequently for three months. Study will follow the intention-to-treat principle.
89090730|NCT02824354|Placebo Comparator|placebo|"The placebo will have the same composition as the active treatment (without the drug substance) and an identical appearance. White, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side."
89090731|NCT02824354|Experimental|Nalmefene|"Drug : 'Nalmefene (Selincro®) 18 mg tablet is a white, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side. It contains 18.06 mg nalmefene (in the form of hydrochloride dihydrate).~Nalmefene must be taken as-needed: on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. If the patient has started drinking alcohol without taking nalmefene, the patient should take one tablet as soon as possible.~The maximum dose of nalmefene is one tablet per day. Nalmefene can be taken with or without food."
89090732|NCT00674869|Experimental|1|pit and fissure sealant on one randomized tooth by pair of permanent molar
89090733|NCT00674869|No Intervention|2|No intervention
89090734|NCT04150315||Coronary bypass with DM type 2|
89090735|NCT04150315||Coronary bypass without DM type 2|
89090736|NCT02823496|Experimental|Arm 1|All subjects are patched with the same product
89090737|NCT00677755|Experimental|Mf+Ms|The women in mifepristone combined misoprostol group (Mf+Ms) received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
89090738|NCT00677755|Experimental|Ms-alone|The control group (Ms-alone) patients were only administered 0.8 mg of misoprostol orally on day 3.
89090739|NCT02628457||Mild Subgroup|patients with supraspinatus tendon retracted upto medial 1/3rd of humerus head and arthroscopic rotator cuff repair done by single row.
89090740|NCT02628457||Moderate Subgroup|patients with supraspinatus tendon retracted between medial 1/3rd of humerus head and glenoid,and arthroscopic rotator cuff repair done by single row.
89090741|NCT02628457||Severe subgroup|patients with supraspinatus tendon retracted beyond glenoid and arthroscopic rotator cuff repair done by single row
89090742|NCT02823418||No neuraxial labor analgesia|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
89090743|NCT02823418||Neuraxial labor analgesia|For patients who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
89090744|NCT04149379|Experimental|Treatment group|One group of 6 patients undergoing 20 sessions of hyperbaric therapy at table 14/90.
89090745|NCT02824042|Experimental|Anetumab ravtansine|The evaluation of multiple ECG parameters and the drug-drug interaction (DDI) potential of anetumab ravtansine parameters when administered alone and together with itraconazole 100 mg oral capsules will be conducted in 2 sequential parts. On Cycle 1 Day 1, anetumab ravtansine will be given alone at a dose of 6.5 mg/kg in Part 1 and Part 2. On Cycle 2 Day 1, anetumab ravtansine will be given together with itraconazole at a dose of 0.6 mg/kg in Part 1, and at a dose of 6.5 mg/kg (planned) in Part 2.
89090746|NCT02628925||Recovery room|10 medical staff working in the recovery room
89090747|NCT02628925||Orthopedic ward|10 medical staff working on the orthopedic ward
89090748|NCT02628301|Active Comparator|Hypercaloric diet|Hypercaloric diet (1.6x REE) for 30 days
89090749|NCT02628301|Placebo Comparator|Normal diet|Normocaloric diet (1.0xREE)
89090750|NCT00675181|Active Comparator|A, 1|A, 1 = Melatonin
89090751|NCT00675181|Placebo Comparator|A, 2|A,2 = Placebo
89090752|NCT04241458|Experimental|BI 706321|
89090753|NCT04241458|Placebo Comparator|Placebo|
89090754|NCT02823808|Experimental|ALO+PIO|Group who takes Alogliptin 25mg+Pioglitazone 15mg, once daily.
89090755|NCT02823808|Active Comparator|GMPD+MET|Group who takes Glimepiride 2mg+Metformin 500mg, once daily.
89090756|NCT02628379||Class 1, 2, or 3 alterations, with targeted therapy|Patients put on targeted therapies matched to specific genomic alterations.
89090757|NCT02628379||Site-specific therapy determined by tissue of origin testing|Patients put on therapy determined by tissue of origin testing (e.g., CancerTYPE ID)
89090758|NCT02628379||Empiric CUP therapy|Patients put on empiric treatment at physician discretion
89090759|NCT04241302|Active Comparator|Free Field Voice test|The examiner will inform the patient to repeat a sequence of Spondee words or a combination of numbers and letters whispered by the examiner initially. The examiner will be standing at the same distances as in the FFCT examination (starting with 2 feet). If the patient fails to hear the whispered voice at 2 feet, the examiner increases the loudness of voice to conversational tone at the same distance. The test is repeated thrice each time with a different set of Spondee words to avoid the patients recognizing the same sequence. If the patient is unable to respond, the examiner moves closer to 6 inches and whispers to the patient, and if no further response, then, conversational voice is used. The patient's free-field threshold is the voice and distance level at which more than 50% correct is obtained.
89090760|NCT04241302|Experimental|Free Field Click Test|The app is designed by our team by a broadband (500-3000 Hz) click sound of 30-40 dB for soft sound/whisper and 60-70dB for loud sound/conversation voice. This app is designed by the Flutter-Dart programming tool and the speaker is produced via hand-held devices of Apple and Android brands. The tone is produced 3 times, with 2 out of 3 answers are considered as the patient's hearing threshold. The examiner stands at the distance of 2 feet away behind the seated patient and a soft sound from the FFCT is tested. The patient is then asked to respond yes or to nod if able to hear the sound. When the patient is unable to answer or no response is received upon thrice testing, the examiner then moves closer to 6 inches to the patient and again the soft sound is tested thrice. Loud sound is then tested if the patient is unable to respond, starting from 2 feet distance for three times. And then, the loud sound is tested at 6 inches of distance if no further response is obtained.
89090761|NCT04151719|Experimental|MNTX 450 mg QD|Participants will receive methylnaltrexone bromide (MNTX) 450 milligrams (mg) (3 tablets of 150 mg each) once daily (QD) orally. Treatment will continue until participant's death or early withdrawal from the study or study termination by the sponsor.
89090762|NCT02823886|Experimental|STEMI patients|
89090763|NCT05299255|Experimental|Utidelone vs placebo|Drug: Utidelone vs placebo in Third-line and above Treatment Extensive Small-cell Lung Cancer
89090764|NCT00912067||hematopoietic stem cell transplantation|
89090765|NCT02823340|Experimental|Fractional Microneedle Radiofrequency Treatment|Fractional Microneedle Radiofrequency Treatment
89090766|NCT02823184||Patients|ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available
89090767|NCT00677989||LA|LA group: patients with perforated appendicitis treated by laparoscopic operation intentionally
89090768|NCT00677989||OA|OA group:patients with perforated appendicitis treated by open approach
89090769|NCT02822482|Experimental|Copanlisib + Cetuximab|All patients will be treated by Copanlisib in association with Cetuximab.
89090770|NCT00678067|Placebo Comparator|Placebo|12 hypercholesterolemic children 3-13 years of age
89090771|NCT00678067|Experimental|DHA+EPA group|12 hypercholesterolemic children 3-13 years of age
89090772|NCT00678067|Experimental|DHA Group|12 hypercholesterolemic children 3-13 years of age
89090773|NCT04239898|Experimental|Red cabbage microgreens|2 cups of fresh red cabbage microgreens per day
89090774|NCT04239898|Experimental|Red beet microgreens|2 cups of fresh red beet microgreens per day
89090775|NCT02822326|Experimental|CD19-CAR-T2 T Cells|The subject's T cells will be modified to those which could identify and kill the tumor cells (CD19+ cells). These CD19-CAR-T2 T cells will be infused over 10-15 minutes on days Day 1, 2 and 3 tentatively according to the response to infusion.
89090776|NCT00675337|Active Comparator|perineum|infants maintained at the level of the perineum until umbilical cord clamping
89090777|NCT00675337|Experimental|abdomen|infants placed on the maternal abdomen prior to cord clamping
89090778|NCT04152265|Other|No Intervention: Current screening practice.|Patients will be asked to complete the Food Frequency Questionnaire (FFQ) and the questionnaire about The World Health Organization Quality Of Life (WHOQOL-BREF), also and will be collected the demographic and anthropometric data
89090779|NCT04152265|Experimental|Experimental: Sequential screening strategy|People aged between 50-65, will take part in the study. Patients, which will take in a screening colonoscopy, will be divided into two groups according to the result obtained. The first group, will be constitute the patients with a positive test result, while the second group (control) will be constitute the patients with the negative test result. In addition, from the Subjects the samples of blood and faeces will be collected.
89090780|NCT02822404|Experimental|Urinary and blood sample|Urinary and blood samples for cystatin C dosage
89090781|NCT02822248|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89090782|NCT00675493||A|
89090783|NCT04240990|Experimental|Prospective cohort|Children included in the cohort will all be in the same arm. The patients will benefit from standard-of-care TB diagnosis with additional diagnostic methods.
89090784|NCT02627131|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
89090785|NCT02821936|Experimental|Parametric Imaging|"one parametric PET at the inclusion and one at 42 Gray after the beginning of radiotherapy.~Two PET scans at 3 months and one year after inclusion"
89111095|NCT04096105|Experimental|CC-93538 in Japanese subjects|Twenty-four Japanese subjects will be randomized into 1 of 2 dose levels in a 1:1 fashion so that 12 subjects will receive a 180 mg or 360 mg dose via SC injection.
89523131|NCT01964807|Experimental|e-cigarette users|Will use one electronic cigarette with 18 mg/ml nicotine, one electronic cigarette with no nicotine, and will perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.
89523132|NCT02317289|Experimental|Detection of freezing|freezing parkinsonian patients
89523133|NCT02263235|Experimental|Group 1|60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
89523134|NCT02263235|Experimental|Group 2A|20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
89523135|NCT02263235|Experimental|Group 2B|30 patients (15 probable AD, 15 neurological disease without cognitive degradation)
88812540|NCT03499795|Experimental|VGX-3100|Adult participants who were HIV negative with histologically confirmed anal or anal/peri-anal HSIL associated with HPV-16 and/or 18, received four 6 mg doses of VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 40 followed immediately by EP using the CELLECTRA™ 5PSP device.
89523136|NCT01441115|Experimental|ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer|ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer
89523137|NCT02006147|Experimental|TLC399 (Group 1)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
89523138|NCT02006147|Experimental|TLC399 (Group R1)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
89523139|NCT02006147|Experimental|TLC399 (Group 2)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
89523140|NCT02006147|Experimental|TLC399 (Group 3)|TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
89523141|NCT03385499|Other|negative control group|blood additional samples on negative control group
89523142|NCT03385499|Other|positive control group|blood additional samples on positive control group
89523143|NCT03385499|Other|seroconversion group|blood additional samples on seroconversion group
89523144|NCT03380741||Group1|Tumour present on histology and MRI following biopsy/LLETZ
89523145|NCT03380741||Group 2|Tumour absent on MRI following biopsy/LLETZ
89523146|NCT03380741||Group 3|Tumour recurrence present at the vaginal vault on MRI
89523147|NCT03380741||Group 4|Tumour recurrence absent at the vaginal vault on MRI
89523148|NCT03380741||Group 5|Normal cervix at colposcopy
89523149|NCT03385187|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a Type IV sleep monitor.
89523150|NCT03385109||Senhance Treated|All patients enrolled who go on to have a surgery in which the Senhance system is used
89523151|NCT03380663|Active Comparator|RIC - Healthy|Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
89523152|NCT03380663|Active Comparator|RIC - HF|Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
89523153|NCT03380663|Active Comparator|BFRE - Healthy|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
89090786|NCT04239664|Experimental|Acceptance Based Telephone Support (ABS+UC)|One face-to-face session to be informed of the group they have been randomised into and Acceptance Based Support, followed by five 30-minute telephone sessions of Acceptance Based Support. Usual care continues as normal.
89090787|NCT04239664|No Intervention|Usual Care (Control Group) (UC)|One face to face session to be informed of the group they have been randomised into and encouraged to ask any questions, and will be informed they will be contacted again in 8 weeks. Usual care continues as normal.
89090788|NCT04240834|Experimental|LD group|Low-dose Aspirin(50mg qd) + Ticagrelor( 90mg bid) for 12 months
89090789|NCT04240834|Active Comparator|Control group|Regular Aspirin(75mg qd) + Ticagrelor(90mg bid) for 12 months
89090790|NCT01200758|Active Comparator|Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
89090791|NCT01200758|Experimental|Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
89226393|NCT04255784|Experimental|Active iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days. Each session will deliver 1800 pulses of active iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
88812541|NCT03496987|No Intervention|Manual Drainage|Patients undergo drainage of pleural fluid via manual (syringe) system
88812542|NCT03496987|Experimental|Vacuum Bottle Drainage|Patients undergo drainage of pleural fluid via a vacuum bottle system (evacuated cylinder)
88821342|NCT04439201|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
88812543|NCT03456804|Experimental|Treatment ESK981|Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
88812544|NCT03456700|Experimental|Treatment (auranofin, sirolimus)|Participants receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
89230261|NCT00658541|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
88812545|NCT03401450|Active Comparator|ACB within true AC with bupivacaine|The patients will receive an ultrasound-guided single injection adductor canal block with 20 mL of 0.5% bupivacaine
89090792|NCT02823106|Experimental|Verapamil and Citicoline|10mg of verapamil in 10 cc of normal saline and 1000mg of citicoline in 10cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
89090793|NCT02823106|Placebo Comparator|Placebo|The control group will receive saline only.
89090794|NCT02821858|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) 50 milligram (mg) (n=8) or placebo (n=2) on Day 1.
89090795|NCT02821858|Experimental|Panel 1: Treatment B|Participants will receive ODV 100 mg (n=8) or placebo (n=2) on Day 1.
89090796|NCT02821858|Experimental|Panel 1: Treatment C|Participants will receive ODV 300 mg (n=8) or placebo (n=2) on Day 1.
89090797|NCT02821858|Experimental|Panel 2: Treatment D|Participants will receive AL-335 400 mg (n=8) or placebo (n=2) on Day 1 of Period 1. Each treatment period will be separated by a washout period of 7 days.
89090798|NCT02821858|Experimental|Panel 2: Treatment E|Participants will receive AL-335 800 mg (n=8) or placebo (n=2) on Day 1 of Period 2. Each treatment period will be separated by a washout period of 7 days.
89090799|NCT02821858|Experimental|Panel 2: Treatment F|Participants will receive AL-335 1,200 mg (n=8) or placebo (n=2) on Day 1 of Period 3. Each treatment period will be separated by a washout period of 7 days.
89090800|NCT04240600|Experimental|Hyperproteic, hypercaloric formula|Each patient will receive 2 bottles per day of Supportan DKN during the hospital stay (nutritional contribution: 600 kcal and 40 g of protein).
89090801|NCT04240600|Active Comparator|Standard formula|Each patient will receive 2 cans or bottles per day of Fresubin® Original DRINK (nutritional contribution: 474.2 kcal and 17.6 g of protein).
89090802|NCT00876343|Experimental|1|Fixed dose
89090803|NCT00876343|Experimental|2|Titration dose
89090804|NCT00876343|Placebo Comparator|3|Placebo
89090805|NCT02822014|Other|FDG-PET/CT arm|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients. We correlated evolution of FDG uptake with clinical evolution of patients.
89090806|NCT04151641|Experimental|Sequence 1|
89090807|NCT04151641|Experimental|Sequence 2|
89090808|NCT02627989||Diflucortolone valerate (Nerisona/Texmeten)|Adult patients with atopic dermatitis switching from diflucortolone-valerate fatty ointment to ointment (water/oil emulsion) during autumn/ winter (Nov to Feb) or spring/ summer (May to Aug)
89090809|NCT02822170|Experimental|IV amino acids and in-bed cycle ergometry|"Beginning within 96 hours of ICU admission, participants will receive the following combined intervention:~IV amino acids (15% solution) delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day.~In-bed cycle ergometry exercise delivered in 45-minute sessions 5 days per week according to a detailed specific protocol that includes a safety check and gradual increases in resistance if the participant is actively cycling."
89090810|NCT02627209|Active Comparator|serum angiotensin converting enzyme|spectrophotometric assay
89090811|NCT02627209|Active Comparator|serum lysozyme|radial immunodiffusion
89090812|NCT00675649|Experimental|001|
89090813|NCT00675649|Placebo Comparator|002|
89090814|NCT00633724|Experimental|1|
89090815|NCT01107912|Experimental|5 milligrams (mg) prasugrel|
89090816|NCT01107912|Active Comparator|10 mg prasugrel|
89090817|NCT01107912|Active Comparator|75 mg clopidogrel|
89090818|NCT01200524|Experimental|AZD2423, 20mg|
89090819|NCT01200524|Experimental|AZD2423, 150 mg|
89090820|NCT01200524|Placebo Comparator|Placebo|Tablet to match the 20 mg and 50 mg AZD2423 active tablet
89090821|NCT00678145|Experimental|Healthy|Healthy individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
89090822|NCT00678145|Experimental|Type 1 Diabetes|T1D individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
89090823|NCT04239742|Experimental|18F-PSMA PET/CT and 18F-Fluciclovin PET/CT|patients undergo an 18F-PSMA PET/CT scan and an 18F-Fluciclovin PET/CT scan, within a time frame of two weeks.
89090824|NCT02626741|Experimental|meal replacement group|the participants receive a meal replacement plus life style modification
89090825|NCT02626741|Experimental|control group|the participants receive life style modification only.
89090826|NCT04317950|Other|Vojta group|All participants were properly instructed and signed an informed consent previous to the interventions. They were comfortably laid down on their back with eyes open, wearing the EEG cap and electromyography electrodes during the intervention. They were asked to remain relaxed and still during the whole process. After a first minute of resting, the experimental group received a continuous reflex locomotion stimulus during the next 8 minutes.
89090827|NCT04317950|Sham Comparator|Control group|On the contrary, the control group received a continuous sham stimulus during the next 8 minutes.
89090828|NCT02879916|Placebo Comparator|Placebo|NaCl 0.9% 3ml perineural stellate ganglion injection
89090829|NCT02879916|Active Comparator|Stellate ganglion block|Levobupivacaine 3ml perineural stellate ganglion injection
89090830|NCT02690506|Placebo Comparator|Group C|Oral placebo pill was administered 2 hours before anesthesia
89090831|NCT02690506|Active Comparator|Group P|Oral pregabalin 150 mg was administered 2 hours before anesthesia
89090832|NCT02626663||aHUS|atypical Hemolytic Uremic Syndrome
89090833|NCT02626663||TTP|Thrombotic thrombocytopenic purpura
89090834|NCT02626663||MAHA|other microangiopathic hemolytic anemias
89090835|NCT04310280|Experimental|Topical insulin glargine|The wound surface is treated locally with glargine insulin injected sub-dermal in a daily matter for 7 days. Allocation is randomized.
89090836|NCT04310280|Placebo Comparator|0.9% saline solution|The wound surface is treated with conventional wound care in a daily matter for 7 days. Allocation is randomized.
89111096|NCT04096105|Experimental|Administration of CC-93538 in Caucasian subjects|Twenty-four Caucasian subjects will be matched to Japanese subjects by weight (± 20%) and receive a 180 mg or 360 mg dose via SC injection
88812546|NCT03401450|Active Comparator|ACB proximal to true AC with bupivacaine|The patients will receive an ultrasound-guided single injection femoral triangle block with 20 mL of 0.5% bupivacaine
89111097|NCT02790099|Experimental|Rectus sheath block only|Patient will be given surgical rectus sheath block postoperatively with 40ml of bupivacaine (2.5mg/mL) and 0.1ml of normal saline will be injected intrathecally at time of spinal anaesthesia.
88812547|NCT03356483|Experimental|Psilocybin|Psilocybin (0.25mg/kg)
88812548|NCT03356483|Placebo Comparator|Niacin|Niacin (250mg)
88812549|NCT03347084|Active Comparator|Excitation|Excitation Paradigm: LIFUP excites the activity of hippocampal neurons.
88812550|NCT03347084|Active Comparator|Inhibition|Inhibition Paradigm: LIFUP inhibits the activity of hippocampal neurons.
88812551|NCT03326063|Active Comparator|Ifetroban|Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.
88812552|NCT03326063|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo for 4 weeks.
89090837|NCT02822872||infertile couples|"couples addressing IVF treatment due to known infertility will fill questionnaire in order to assess their stress level (as mentioned above), after filling the questionnaire scalp hair sample will be taken to assess chronic cortisol secretion.~during the IVF treatment the stress level will be assessed every 3 month by using the same system (in order to find match between the stress level and cortisol secretion with the fertility treatment"
89090838|NCT04151407|Experimental|601 dose level 1 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
89090839|NCT04151407|Experimental|601 dose level 2 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once
89090840|NCT04151407|Experimental|601 dose level 3 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once
89090841|NCT04151407|Experimental|601 dose level 4 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
89226394|NCT04255784|Sham Comparator|Sham iTBS|Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days, using a sham coil that reproduces auditory and tactile sensations of stimulation and has an identical external appearance. Each session will deliver 1800 pulses of sham iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / ~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
89226395|NCT04223115|Experimental|Digitalized CBT intervention with phone coaching|Participants receive weekly sessions of internet-based CBT, including telephone coaching
89226396|NCT04223115|Active Comparator|Psychoeducation about depression|Participants receive psychoeducative material about depression in digitalized form.
89090842|NCT04151407|Experimental|601 dose level 5 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(3.75mg), Vitreous injection, injection once;
89090843|NCT04151407|Experimental|601 dose level 6 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously.
89090844|NCT04151407|Experimental|601 dose level 7 treatment|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously.
88812553|NCT03324984|Experimental|1% Chloroprocaine (PF)|1% Chloroprocaine is an ester-linked local anesthetic with the shortest duration of action of all local anesthetics.
88812554|NCT03324984|Active Comparator|0.75% bupivacaine|0.75% bupivacaine is a amino-amide anesthetic local anesthetic. It is hyperbaric in nature due to addition of dextrose.
89090845|NCT04824118||Group 1: Gestation less than 10 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
89090846|NCT04824118||Group 2: Gestation 10-14 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
89090847|NCT04824118||Group 3: Gestation 14-20 weeks|Blood tests and urine sample at baseline and 10-14 days after mifepristone administration
89090848|NCT04824118||Group 4: Non-pregnant controls|Blood tests at baseline only.
89090849|NCT02627911|Other|Usual System (open-loop)|"In open loop, the patient will be provided with its usual pump and a CGM. To estimate rest and physical activity in patients being sedentary situation ( Centers : Caen, Nancy & Strasbourg) or in situations of physical activity ( Centers : CHSF Marseille and Besancon ) , the usual system will be complemented by an accelerometer  ActiGraph  and a  ActiHeart  heart rate monitor."
89090850|NCT02627911|Experimental|DIABELOOP System (closed-loop)|In the closed loop, the patient's pump will be replaced by the Diabeloop system consisting of insulin pump Cellnovo driven by remote control augmented by Diabeloop software and connected to the CGM.
89090851|NCT04239586|Experimental|Sulfonylurea treatment group|Increasing doses of sulfonylurea class of drug to see whether insulin treatment can be reduced in dose or stopped.
89090852|NCT02628613|Active Comparator|Paclitaxel plus Epirubicin|Paclitaxel plus Epirubicin for 4 cycles, paclitaxel 80 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
89090853|NCT02628613|Experimental|Vinorelbine plus Epirubicin|Vinorelbine plus Epirubicin for 4 cycles, vinorelbine 25 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
89090854|NCT04239352||healthy pregnant women|"Blood samples taken from 40 healthy pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.~this group will be the control group."
89090855|NCT04239352||preeclamptic pregnant women|"Blood samples taken from 40 preeclamptic pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method.~this group will be the study group."
89090856|NCT02627833||Subject Group|Patients suffering from Bronchiolitis Obliterans
89090857|NCT02627833||Control Group|Age and sex matched control group
89090858|NCT01100034||1|pediatric patients with plaque psoriasis on etanercept
89090859|NCT02822560|Active Comparator|pEVAR|percutaneous femoral access using a suture-mediated closure system
89090860|NCT02822560|Active Comparator|open femoral access|cutdown to femoral artery and surgical closure
89090861|NCT00675805|Active Comparator|Group I|IVIG infusion with filter
89090862|NCT00675805|Placebo Comparator|Group II|IVIG infusion without filter
89090863|NCT02880930|Experimental|Vitamin D supplement (Cholecalciferol)|Participants will be given oral Fultium-D3 drops (Internis) contain 400 IU cholecalciferol/day for a period of 3 months. Daily vitamin D3 supplementation dose will be increased to 1,000 IU for an additional 3 months if plasma 25(OH)D still below 75 nmol/L.
89090864|NCT04770766||Staff observation|Doctor-in-training and non-medical practitioner volunteers
89090865|NCT04770766||Patient questionnaires|Patients attending the Emergency Department of one of six NHS trusts participating in the research as a case study
89090866|NCT04770766||Case study NHS Trusts|NHS organisations with an Emergency Department participating as a case study site
89090867|NCT04770766||All England NHS Trusts|NHS Trusts whose Emergency Department (n=183) records data is held by NHS Digital and will be provided anonymously/without individual patient consent (these anticipated hundreds of thousands of records are not included in the enrolled patient numbers)
89090868|NCT04770766||Patient interviews|Patients attending the Emergency Department of one of six NHS trusts participating in the research as a case study and volunteering to take part in an interview following completion of the patient questionnaire
89090869|NCT04770766||Staff interviews|Staff working in the Emergency Department of one of six NHS trusts participating in the research as a case study and volunteering to take part in an interview
89090870|NCT04770766||Stakeholder interviews|Senior NHS clinicians, managers, commissioners and lay representatives with roles and interests in the non-medical practitioner workforce
89090871|NCT04148833|Experimental|LDE-Paclitaxel|Paclitaxel carried by a lipid nanoparticle (LDE-Paclitaxel)
88812555|NCT03276481||Multiple Myeloma|Participants with multiple myeloma undergoing autologous hematopoietic cell transplantation (HCT) after a high dose melphalan conditioning regimen
89090872|NCT04148833|Placebo Comparator|LDE-Placebo|Lipid nanoparticle (LDE)
89090873|NCT04926246|Experimental|Part 1: R1-T2-T4-T1-T3|
89090874|NCT04926246|Experimental|Part 1: T1-T4-T2-T3-R1|
89090875|NCT04926246|Experimental|Part 1: T2-T1-T3-R1-T4|
89090876|NCT04926246|Experimental|Part 1: T3-R1-T1-T4-T2|
89090877|NCT04926246|Experimental|Part 1: T4-T3-R1-T2-T1|
89090878|NCT04926246|Experimental|Part 2: R2-T7-T6-T5|
89090879|NCT04926246|Experimental|Part 2: T5-T6-T7-R2|
89090880|NCT04926246|Experimental|Part 2: T6-T5-R2-T7|
89090881|NCT04926246|Experimental|Part 2: T7-R2-T5-T6|
89090882|NCT04926246|Experimental|Part 3: R3-T10-T9-T8|
89090883|NCT04926246|Experimental|Part 3: T8-T9-T10-R3|
89090884|NCT04926246|Experimental|Part 3: T9-T8-R3-T10|
89226397|NCT04217005|Experimental|experimental group|amputees or diabetics receiving intervention
89226398|NCT04213885|Experimental|Pulsed Accelerated|30mW, 5 sec, 5 sec off, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
89226399|NCT04213885|Active Comparator|Conventional|9mW continuous, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea
89226400|NCT04203160|Experimental|Phase 1 and Phase 2, Arm A (investigational)|On Day 1 and Day 8 of each 3-week cycle, patients will receive CPI-613 + gemcitabine and cisplatin. Patients may continue gemcitabine, cisplatin and CPI-613 for up to 2 years in absence of disease progression or unacceptable toxicity.
89226401|NCT04203160|Active Comparator|Phase 2, Arm B (standard of care)|On Day 1 and Day 8 of each 3-week cycle, patients will receive gemcitabine and cisplatin. Patients may continue gemcitabine and cisplatin for up to 2 years in absence of disease progression or unacceptable toxicity.
89226402|NCT04199702|Other|Same day discharge|
89226403|NCT04187053|Experimental|Conventional mechanical therapy with aPDT adjunct|Traditional non-surgical mechanical debridement along with antimicrobial photodynamic therapy will be done at implant sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. The dye will be applied topically confined to the epithelialized space surrounding the implant fixture and will not be internalized. After 5 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the implant using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
89226404|NCT04187053|Sham Comparator|Conventional mechanical therapy with sham aPDT treatment|"Control group will have conventional mechanical instrumentation of implant site with Sham aPDT treatment with saline and non-light emitting laser"
89226405|NCT04184895|Experimental|ASP2390 Low Dose (Cohort 1)|Participants will receive a low dose of ASP2390 once weekly for a total of 12 doses. After all participants in cohort 1 complete 4 doses of treatment, the overall safety and tolerability of the dose will be evaluated by the Dose Escalation Committee (DEC).
89226406|NCT04184895|Placebo Comparator|Placebo Low Dose (Cohort 1)|Participants will receive a low dose of matching Placebo once weekly for a total of 12 doses.
89226407|NCT04184895|Experimental|ASP2390 High Dose (Cohort 2)|Participants will receive a high dose of ASP2390 once weekly for a total of 12 doses. The dose for cohort 2 may be adapted after the DEC evaluates emergent safety and tolerability data.
89226408|NCT04184895|Placebo Comparator|Placebo High Dose (Cohort 2)|Participants will receive a high dose of matching Placebo once weekly for a total of 12 doses.
89226409|NCT04160065|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Exposure Escalation:~The first 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection); 3/3 patients recruited.~The second 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 2 time points 7 days apart (28-day follow-up post last injection); 1/3 patients recruited.~The third 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 3 time points 7 days apart (28-day follow-up post last injection); recruitment pending.~Cohort Expansion:~The remaining 11 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 3 time points 7 days apart (28-day follow-up post last injection); recruitment pending."
88812556|NCT03275857|Other|Cisplatin|
88812557|NCT03267810|Experimental|Active TENS|Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
88812558|NCT03267810|Sham Comparator|Sham TENS|Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.
88812559|NCT03209583||Congenital Heart Disease|subjects have CHD and arrhythmias being treated with an implanted pacing device.
89090885|NCT04926246|Experimental|Part 3: T10-R3-T8-T9|
88812560|NCT03196245||Pregnant women|Pregnant women undergoing influenza vaccination or acutely infected with influenza
88812561|NCT03191578|Experimental|RUTI® injection|
88812562|NCT03191578|Placebo Comparator|Sodium Chloride 0.9% injection|
89090886|NCT02821546|Placebo Comparator|standard hydration|Patients underwent first-time ERCP to receive standard fluid hydration with Lactated Ringer's solution at a rate calculated by the Holliday-Segar method given peri-procedurally starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
89090887|NCT02821546|Active Comparator|aggressive hydration|Patients underwent first-time ERCP to receive aggressive fluid hydration with Lactated Ringer's solution at a rate of 150 ml/hr starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
89090888|NCT02821702|Experimental|Post surgery and embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
89090889|NCT02821702|Active Comparator|Control group|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
89090890|NCT02821702|Active Comparator|Post surgery with accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
89090891|NCT02821702|Active Comparator|Post surgery without accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
89090892|NCT02821702|Active Comparator|Normal Vaginal Delivery - no suspected accreta|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
89090893|NCT00876265|Experimental|Belotero|
89090894|NCT00876265|Active Comparator|Zyplast|
89090895|NCT04308018|Active Comparator|S1|Caudal end of the instrumentation at S1
89090896|NCT04308018|Active Comparator|S2alar-iliac|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
89090897|NCT02690350|Experimental|Cohort 1 U3-1784 2.5 mg/kg|U3-1784 (2.5 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
89090898|NCT02690350|Experimental|Cohort 2 U3-1784 3.75 mg/kg|U3-1784 (3.75 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
89090899|NCT02690350|Experimental|Cohort 3 U3-1784 5.6 mg/kg|U3-1784 (5.6 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
89090900|NCT02879838||Occupational Asthma|
89090901|NCT02879838||Work Aggravated Asthma|
89090902|NCT02879838||Non-Work-Related Asthma|
89090903|NCT02821468|Experimental|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochoride 1,500mg
89090904|NCT02821468|Experimental|Control|Untreated arm
89090905|NCT04964622|Other|nurofen|sodium ibuprofen 1 tablet (256) 30 minutes before treatment administered once (oral)
89090906|NCT04964622|Placebo Comparator|placebo|starch tablet 30 minutes before treatment administered once (oral)
89090907|NCT04769050||First-line patients|First-line treatment of HER2-positive metastatic breast cancer patients
89090908|NCT04769050||Second-line patients|Second-line treatment of HER2-positive metastatic breast cancer patients
89090909|NCT04309656|Experimental|Panel 1: Pretomanid after meal|Each participant will receive four single-dose treatments. Panel 1 will receive a meal before dosing.
89090910|NCT04309656|Experimental|Panel 2: Pretomanid after fast|Each participant will receive four single-dose treatments. Panel 2 will fast before dosing.
89090911|NCT02821624|Experimental|Cohort 1|G1T38 or placebo
89090912|NCT02821624|Experimental|Cohort 2|G1T38 or placebo
89090913|NCT02821624|Experimental|Cohort 3|G1T38 or placebo
89090914|NCT02821624|Experimental|Cohort 4|G1T38 or placebo
89090915|NCT02821624|Experimental|Cohort 5|G1T38 or placebo
89090916|NCT02821624|Experimental|Cohort 6|G1T38 or placebo
89090917|NCT02821624|Experimental|Cohort 7|G1T38 or placebo
89090918|NCT02821624|Experimental|Cohort 8|G1T38 or placebo
89090919|NCT02821624|Experimental|Cohort 9 - Food Effect|G1T38
89090920|NCT02821624|Experimental|Cohort 10|G1T38 or placebo
89090921|NCT02821624|Experimental|Cohort 11|G1T38 or placebo
89090922|NCT02821624|Experimental|Cohort 12|G1T38 or placebo
89090923|NCT02879058|No Intervention|Without Ultrasound|Laparoscopic or robotic myomectomy will be performed without aid of intraoperative contact ultrasonography
89090924|NCT02879058|Experimental|With Ultrasound|Laparoscopic or robotic myomectomy will be performed with aid of intraoperative contact ultrasonography
89090925|NCT02881164|Experimental|Low glycemic index breakfast|Low glycemic index breakfast (GI=45)
89090926|NCT02881164|Active Comparator|High glycemic index breakfast|High glycemic index breakfast (GI=80)
89090927|NCT02821390|Active Comparator|Nepafenac 0.1% Eye Drops|One drop of Nepafenac 0.1% Eye Drops will be instilled to the eye's cul de sac prior to the intravitreal injection.
89090928|NCT02821390|Placebo Comparator|Artificial Tears|One drop of Artificial Tears will be instilled to the eye's cul de sac prior to the intravitreal injection.
89090929|NCT02821312|Active Comparator|Active in Group A1~A7|In each of Groups A1 to A7, 8 subjects will receive DA-8010.
89090930|NCT02821312|Placebo Comparator|Placebo in Group A1~A7|In each of Groups A1 to A7, 2 subjects will receive placebo.
89090931|NCT02821312|Active Comparator|Active in Group B1~B4|In each of Groups B1 to B4, 8 subjects will receive DA-8010.
89090932|NCT02821312|Placebo Comparator|Placebo in Group B1~B4|In each of Groups B1 to B4, 2 subjects will receive placebo.
89090933|NCT02821078|Experimental|Participants|"In addition to the standard clinical MR protocol, 2 added sequences:~4D flow imaging sequence~standard 2D-PhaseContrast at portal trunk level as reference"
89090934|NCT04240132|Experimental|Adherence to hand hygene|The face-to-face interview will be held in an appropriate empty room in the intensive care unit (ICU) in a time schedule suitable for the healthcare workers. The researchers will provide training to healthcare workers working in the ICU in accordance with the World Helath Organization (WHO) Hand Hygiene Guidelines. One day training on nursing interventions related to enteral feeding treatment will be provided to nurses and their questions will be answered. At the end of the each training, trainees will be given a data collection form to assess the effectiveness of the training.
89090935|NCT02821234|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE <85%) with 10 days actigraphy occurred in the last 2 months
89090936|NCT02821234|Experimental|Control group|Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)
89090937|NCT02820922||Orthopedic emergency surgery|Patients of all ages who have undergone emergency orthopedic surgery The analysis of medical data with regard to age, sex, the American Society of Anesthesiologists (ASA) score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
89090938|NCT02822638||STEMI PATIENT Cohort|STEMI PATIENT Cohort
89090939|NCT00633958|Experimental|18F-FLT|All subjects will receive 18F-FLT prior to PET imaging.
89090940|NCT02820688|Active Comparator|Concentrated|Infraclavicular nerve block under guidance of ultrasonography will be performed using an undiluted solution of 45mg bupivacaine and 180mg prilocaine (bupivacaine 0.25% and prilocaine 1%, 18mL in total) to patients in this group
89090941|NCT02820688|Active Comparator|Diluted by 33%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 33% (bupivacaine 0.167% and prilocaine 0.66%, 27mL in total) to patients in this group
89090942|NCT02820688|Active Comparator|Diluted by 50%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 50% (bupivacaine 0.125% and prilocaine 0.5%, 36mL in total) to patients in this group
89090943|NCT02818816|Experimental|Brimonidine Tartrate 0.2% (2mg/mL)|One (I) drop of brimonidine tartrate 0.2% (2mg/mL) will be placed in the randomized eye preoperatively thirty minutes before robotic-assisted radical laparoscopic prostatectomy (RALP)
89090944|NCT02818816|Placebo Comparator|Carboxymethylcellulose Eye Drops|One drop of Carboxymethylcellulose eye drops will be placed in the randomized eye half an hour before RALP
89090945|NCT02820610|Active Comparator|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
89090946|NCT02820610|Active Comparator|Magnesium sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
89090947|NCT02820610|Placebo Comparator|Control group|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
89090948|NCT04751266||Patients with MIRPE|first minimally invasive repair of pectus excavatum
89111098|NCT02790099|Active Comparator|Intrathecal morphine group|0.1mg preservative free morphine will be injected intrathecally at time of spinal anesthesia and 40ml of normal saline will be injected as rectus sheath block.
88812563|NCT03141567||Outpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
89090949|NCT02820532|Other|Tracking|The volunteers will be placed on the treatment couch. Their respiratory motion will be measured and the treatment couch will be moved accordingly. During the couch motion experiment the heartbeat, the skin humidity, the respiratory characteristics and the pupil motion will be additionally measured.
89090950|NCT02820766||Journey II BCS Knee|Physical Therapy Observational
89090951|NCT02820766||All Other Posterior Stabilized Knees|Physical Therapy Observational
89111099|NCT02790099|Active Comparator|Both intervention|Patient will be given 0.1mg preservative free morphine intrathecally at time of spinal anaesthesia and surgical rectus sheath block with 40ml of bupivacaine (2.5mg/ml).
89111100|NCT04100005||Crohn's disease|Patients who have been diagnosed with Crohn's disease
89090952|NCT04745728|Active Comparator|cyclophosphamide and prednisone|"Prednisone will be given at 1mg/kg/d p.o. and will be tapered after 2 months and discontinued over a 6-12 month period.~Cyclophosphamide will be given at 1-2mg/kg/d p.o. with a target accumulated dose of 12g.~Azathioprine or mycophenolate mofetil are optional which could be given for a short period of time (<6 months）after discontinuation of cyclophosphamide if patients do not remit at 6 month."
89090953|NCT04745728|Active Comparator|Rituximab|"Rituximab 1000mg I.V. on Day1 and at 6 month. After 6 months, in patients with response but without complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be given on the 15th day after each Rituximab infusion if CD19+ B cell count>5/ul on the 15th day.~Calcineurin inhibitors (CNI) are optional but should be tapered after 6 months and discontinued after 9 months."
88812564|NCT03141567||Inpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
88812565|NCT02947035|Experimental|Low Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
89090954|NCT05659186|Experimental|Treatment Cohort|Tislelizumab administration on day 1, and Anlotinib continuous administration from days 1 to 14， every three weeks Radiotherapy
89090955|NCT01107444|Experimental|LY2181308 + Docetaxel|"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.~Docetaxel: 75 milligrams/square meter (mg/m^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."
89090956|NCT01107444|Active Comparator|Docetaxel|Docetaxel: 75 milligrams/square meter (mg/m^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.
89090957|NCT04238806|Active Comparator|Desflurane Continuous|In Group 1 of 60 patients, desflurane inhalational agent was administered continuously during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg. For maintenance, in Group 1 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% during the whole surgical procedure and intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 1 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
89090958|NCT04238806|Active Comparator|Desflurane Intermittent|In Group 2 of 60 patients, desflurane inhalational agent was administered intermittently during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg/kg. For maintenance, in Group 2 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% before and after the cardiopulmonary bypass procedure as intermittently with the addition of intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 2 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.
89090959|NCT02820454|Experimental|AGuIX and radiotherapy|"Patients receive a single intravenous injection of AGuIX on day 1. Then patients undergo a whole brain radiation therapy, 5 days a week in weeks 1-2. The first radiotherapy session will be performed 4 hours after AGuIX injection.~Five dose escalation cohorts : 15 mg/kg, 30mg/kg, 50mg/kg, 75mg/kg and 100 mg/kg"
89090960|NCT05659108||CONTROL|stimuli with traditional CPR education per half-year
89090961|NCT05659108||TREATMENT|stimuli with blended CPR education per half-year
89090962|NCT02878824||HK-Children|This is a group of typically-developing children ages 7-12 years old who are of Chinese ethnicity, born and raised in Hong Kong (n=32).
89090963|NCT02878824||FHK-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity; either born, migrated and/or raised in Hong Kong (n=32).
89090964|NCT02878824||FU-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in an urban area in the Philippines (n=32).
89090965|NCT02878824||FR-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in a rural area in the Philippines (n=32).
89090966|NCT04627558||stroke patients, balance assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
89090967|NCT02820376|Other|All patients|"Differential renal function assessment by 4D CT:~All patients will undergo both CT and SPECT assessment of differential renal function; each patient will be his own comparator"
89090968|NCT00876187|Experimental|Tanezumab 20 mg IV|
89090969|NCT00876187|Experimental|Tanezumab 10 mg IV|
89090970|NCT00876187|Experimental|Tanezumab 5 mg IV|
89090971|NCT00876187|Active Comparator|Naproxen|
89090972|NCT00876187|Placebo Comparator|Placebo|
89090973|NCT04238884|Experimental|Experimental group|Based on the genetic study carried out and the patient's characteristics (age, weight, indication), the Pharmacogenetics Unit of the University Hospital La Paz will indicate the dose to be administered based on the therapeutic individualization protocol guided by pharmacogenetics.
89090974|NCT04238884|Active Comparator|Control group|No information will be provided and procedure will be carried out according to normal clinical practice, with clinical monitoring by the doctor in charge.
89090975|NCT01102374|Experimental|High Dose Vitamin D|100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
89090976|NCT01102374|Active Comparator|Standard Dose Vitamin D|12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
89090977|NCT05658640|Experimental|Sub-study D|"Trametinib + dexamethasone + cyclophosphamide and cytarabine.~Each cycle lasts 28 days.~Cycle 1: Trametinib is given orally continuously once a day in tablets or oral formulation depending on the age and weight of the patient. Dexamethasone is given intravenously (IV)/orally on days 1 to 5. Cyclophosphamide is given IV on day 3. Cytarabine is given IV in two blocks of 4 days each one week apart from day 5.~Cycle 2 and subsequent cycles: Trametinib is given orally continuously once a day in tablets or oral formulation depending on the age and weight of the patient. Dexamethasone is given intravenously (IV)/orally on days 1 to 5. Cyclophosphamide is given IV on day 1. Cytarabine is given IV in two blocks of 4 days each one week apart from day 3.~Patients in dose level -1, receive only 1 block of cytarabine per cycle.~All patients receive age adapted intrathecal chemotherapy."
89090978|NCT04238572|Experimental|Audiovisual distraction device|Audiovisual distraction device, analgesia nociception index monitoring, remifentanil added to local anesthesia technique
89090979|NCT04238572|Active Comparator|Active comparator group|Analgesia nociception index monitoring, remifentanil added to local anesthesia technique
89090980|NCT02880696|Experimental|Test (Regular)|Regular stimulation sequence & DCS
89090981|NCT02880696|Active Comparator|Control (Random)|Random stimulation sequence & DCS
89090982|NCT04693702||Age-related Macular Degeneration|
89090983|NCT04693702||Diabetic Macular Edema|
89090984|NCT01106976||Group 1 Parkinson disease subjects|Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.
89090985|NCT02818504|Experimental|Repeatability and reproducibility study|"Monitoring of system (Wize MIrror) measurements with changes in environmental conditions (fasting state, light, temperature)"
89090986|NCT02818504|Experimental|Validation study|"Longitudinal monitoring of cardiometabolic risk factors through an user---friendly, unobtrusive, personalized system for lifestyle self---management (the Wize Mirror)"
89090987|NCT02818270|Experimental|Drug depositions|Aerosol drug deposited delivered on the inhaled and exhaled filters and protective filters were evaluated. Salbutamol and Acetylcysteine were delivered by a jet nebulizer through a mechanical ventilator.
89090988|NCT02879760|Experimental|Ad/MAGEA3, MG1-MAGEA3 and pembrolizumab|"Ad-MAGEA3 prime will be administered as a single IM dose on Day 1 at 2 x 10e11 VP.~MG1/MAGEA3 boost will be administered IV on Day 15 and Day 18 by 5 cohorts: Cohort 1: Days 15 & 18 at 1x 10e10 pfu.~Cohort 2: Days 15 & 18 at 1x 10e11 pfu. Cohort 3: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 4: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 5: Day 15 at 3x 10e11 pfu; Day 18 at 3 x 10e12 pfu. Pembrolizumab will be administered IV every 3 weeks starting on Day 22."
89090989|NCT02818348|Experimental|DRV cohort|Darunavir/Cobicistat 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
89090990|NCT02818348|Experimental|ETR cohort|Etravirine 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
89090991|NCT04308876|Experimental|Manual therapy and strengthening exercises|Manual therapy and strengthening exercises were applied totally 15 sessions for 5 weeks 3 times a week in hospital by physiotherapist.
89090992|NCT04308876|Active Comparator|Strengthening exercises|Patients in this group performed the strengthening exercises given to the experimental group on their own at home with experimental group at the same time, frequency and dose.
89090993|NCT00634192|Experimental|1|
89090994|NCT00634192|Experimental|2|
89090995|NCT02626897|Other|Sarcoidosis - GENEActiv device first|Six patients start with the GENEActiv wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the ActiGraph GT3X device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
89090996|NCT02626897|Other|Sarcoidosis - ActiGraph device first|Six patients start with the ActiGraph GT3X wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the GENEActiv device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
89090997|NCT02879214|Experimental|SIDE cervical trial|To Maximal downstage locally advanced squamous cell cervical cancer before minimal invasive surgical resection. The SIDE study is to use both RT dose escalation to the biological target defined by PET and Chemo dose escalation composited with two drugs to achieve maximal reduction of tumor burden, providing feasibility of minimal invasive surgical resection.
89090998|NCT04238182|Active Comparator|wet cupping|smokers in this group will receive single wet cupping session
89090999|NCT04238182|Active Comparator|dry cupping|smokers in this group will receive single dry cupping session
89091000|NCT02627755|Active Comparator|Glide group|Device: Glidescope® use
89091001|NCT02627755|Experimental|Glide+aScope group|Device: combined use of two airway devices Glidescope® + aScope®
89091002|NCT02817724|Active Comparator|m-Health group|BENECA System: The m-health group will use the BENECA app for 8 weeks.
89091003|NCT02817724|Experimental|Integral Group|BENECA System and Supervised-occupational therapy program: The integral groups will use the BENECA app and they will receive a face-to-face occupational therapy rehabilitation program for 8 weeks.
89091004|NCT00681421|Experimental|A|
89091005|NCT00684463|Experimental|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent
89091006|NCT02817490||Patients with hypermobility type Ehlers-Danlos Syndrome|Patients with hypermobility type Ehlers-Danlos Syndrome participating to one out of the three patient education sessions included in the study.
89091007|NCT02817490||Caregivers|Caregivers participating to one out of the three patient education sessions included in the study.
89091008|NCT02817568||Aggressive Periodontitis (case)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention.(Drawing Blood)
89111101|NCT02790177|Experimental|HiB|This group will receive the compound for the reduction of adhesions
89226410|NCT04155073|Experimental|COPD/smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking, quitting smoking, and respiratory symptoms, 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit, and if needed, 3) a home spirometry test with instructions on how to video themselves completing a lung functioning test via the device within an additional e-visit.
89226411|NCT04155073|Active Comparator|Treatment as Usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
89226412|NCT04154332||Healthy Controls|
89226413|NCT04154332||Preeclampsia Group|
89226414|NCT04153721|Experimental|Digital Solution|The proposed digital solution aims to improve the patient's preparation for his colorectal surgery and follow his rehabilitation after surgery, by reinforcing his compliance with existing protocols and enriching it with complementary practices
89226415|NCT04145466|Experimental|Fat responders (1)|receiving high-fat diet
89226416|NCT04145466|Experimental|Carbohydrate responders (1)|receiving high-fat diet
89226417|NCT04145466|Experimental|Fat responders (2)|receiving high-carbohydrate diet
88812566|NCT02947035|Experimental|High Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
89091009|NCT02817568||Healthy (Control)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention. (Drawing Blood)
89091010|NCT00678457|Experimental|ondansetron/olanzapine|"ondansetron (4 μg/kg b.i.d.)~olanzapine (9 μg/kg)"
89091011|NCT00678457|Placebo Comparator|placebo|placebo
89091012|NCT02817646||Intensive care patients|Patients admitted to the intensive care unit for 4 days or more with a computed tomography scan made for clinical reasons early during intensive care stay and who receive enteral and/or parenteral nutrition as per hospital protocol
89091013|NCT00678613|Placebo Comparator|1, Primary prophylaxis|"Patients with liver cirrhosis with ascites having ascitic fluid protein <1 gm/dl will be included in this arm.~They will be randomized between probiotics and placebo."
89091014|NCT00678613|Active Comparator|2, secondary prophylaxis|"Patients with liver cirrhosis with ascites having history of prior SBP will be included in this arm.~They will be randomized between probiotics and norfloxacin."
89091015|NCT02817334|Experimental|indocyanine green|"As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.~Intervention: Drug: indocyanine green"
89091016|NCT02626429|Experimental|Active, Young Adult Famale|Participants will complete a bout of exercise and then consume a randomly assigned amino acid intake prior to measuring whole body 13CO2 excretion and phenylalanine oxidation.
89091017|NCT02817412|Experimental|Go/No-Go Training|In the go/no go training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. They are told to press response keys as quickly as possible to indicate the side of presentation (go-trials). On half of the trials, the rectangular frame surrounding the image is not solid but hatched, which is a signal for them to withhold their response (no-go trials). This training is divided into 4 blocks of 50 trials.
89091018|NCT02817412|Experimental|Stop-Signal Training|In the stop signal training, participants are shown images in either a dark blue or light gray border. They are told to press the space bar as quickly as possible when the border is blue (go trials) and to withhold a response when the border is gray (no-go trials). This training is divided into 20 blocks of 32 trials.
89091019|NCT02817412|Experimental|Dot-Probe Training|In the dot-probe training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. Immediately after the images disappear, a small dot probe appears in the location of one of the images. Participants are told to press response keys as quickly as possible to indicate whether a visual probe appeared behind the left or right image during the trials. The probe appears in the location occupied by a high-calorie food image 10% of the time and in the location occupied by a low-calorie food image 90% of the time. This training is divided into 6 blocks of 40 trials.
89091020|NCT02817412|Placebo Comparator|Generic Training|In the generic training, participants complete a generic go/no-go training that uses images of flowers and office supplies instead of the images of high-calorie and low-calorie food images. This generic go/no go training is identical in duration and contact time to the go/no-go food training.
89091021|NCT00681499||malignant|eg. hepatocellular carcinoma, colorectal liver metastases
89091022|NCT00681499||benign|eg. liver cysts, traumatic liver injuries, adenoma etc
89091023|NCT04579432|Experimental|Training Group|
89091024|NCT04579432|No Intervention|Control Group|
89091025|NCT00678769|Experimental|Group A (temsirolimus on days 15 and 22 course 1)|Patients receive temsirolimus IV over 30 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
89091026|NCT00678769|Experimental|Group B (cixutumumab on days 15 and 22 of course 1)|Patients receive cixutumumab IV over 60 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
89091027|NCT00678769|Experimental|Group C (temsirolimus on days 1, 8, 15, and 22)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
89111102|NCT02790177|Placebo Comparator|Normal saline|This group will just receive normal saline to ensure blinding.
89111103|NCT04100083|Active Comparator|Group 1|Patients taking 50mg Spironolactone
88812874|NCT01552343|Experimental|Female - Desmopressin 25 μg|Female participants took 1 tablet of 25 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
89091028|NCT02817022|Other|developmentally supportive care|enrolled neonates will be provided routine supportive care as per existing NICU protocols. This will be carried out in the initial 6 months (0-180 days) of study commencement. This group will serve as control group (group A). During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care(DSC). DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. This group will be designated as group B
89091029|NCT04146883|Experimental|Post procedural antibiotics treatment|This group was treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin) and post procedural oral prophylactic antibiotics
89091030|NCT04146883|No Intervention|Pre procedural antibiotics treatment only|This group was only treated with pre-procedural (pacemaker or ICD implantation) prophylactic once intravenous antibiotics (cefazolin 1000mg or else if allergy to cefazolin).
89091031|NCT02817256|Active Comparator|Group A, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.~Ergocalciferol 300,000 IM - Every 3 months Oral Vitamin B12 tablets daily (500mcg) Calcium /D Tab 600-200mg Centrium -1 Tablet Daily~Mineral:~Iron preparation - Daily (47mg)"
89091032|NCT02817256|Active Comparator|Group B, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.~Centrium - 1 Tablet daily Ergocalciferol 50000 IU once every two weeks Vitamin B12 1000mcg IM every three months Calcium /D Tab 600-200mg~Minerals:~Iron preparation - Daily (47mg)"
89091033|NCT00681577|Experimental|A|
89091034|NCT02817100|Experimental|BAY1817080|Study Part 1: Dose 1 to 7 of BAY1817080 (increasing dose levels; redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]); Study part 2: Dose 1 to 4 of BAY1817080 together with an American breakfast (increasing dose levels; redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
89091035|NCT02817100|Placebo Comparator|Placebo|Study Part 1: Placebo Dose 1 to 7 of BAY1817080; Study Part 2: Placebo Dose 1 to 4 of BAY1817080
89091036|NCT00684697|Placebo Comparator|1|low iron dose
89091037|NCT00684697|Active Comparator|2|intermediate iron dose
89091038|NCT00684697|Experimental|3|High Iron dose
89091039|NCT02816944|Experimental|EUS-guided laser ablation for refractory neoplasms|
89091040|NCT00678847|Placebo Comparator|B|
89091041|NCT00678847|Active Comparator|A|
89091042|NCT02816866|Experimental|empowered primary care model|"patients receive an individualized prescription for survivorship care prepared by a cancer survivor specialist to be implemented by the primary care doctor"
89091043|NCT02816866|Experimental|specialty survivor clinic|patient attends a specialty survivor clinic at Yale for survivorship care
89091044|NCT00684853|Active Comparator|1|
89091045|NCT00684853|Active Comparator|2|
89091046|NCT02816554|Experimental|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1.0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12days
89091047|NCT02816554|Experimental|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
89091048|NCT02816554|Experimental|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
89091049|NCT02816554|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
89091050|NCT02816476|Experimental|Daratumumab|Patient will receive Daratumumab every week for the first 2 cycles then every 2 weeks from cycle 3 through cycle 6.
89091051|NCT00678925|Active Comparator|1|Choline supplement given from 18-weeks pregnancy through 90 days postpartum
89091052|NCT00678925|Placebo Comparator|2|Placebo capsules given from 18 weeks pregnancy through 90 days postpartum
89091053|NCT00875485|Experimental|Twinrix Adult Group|Subjects received 2 doses of Twinrix™ Adult intramuscularly according to a 0, 6 month schedule in the primary study
89091054|NCT00875485|Experimental|Twinrix Junior Group|Subjects received 3 doses of Twinrix™ Junior (= half dose Twinrix™ Adult) intramuscularly according to a 0, 1, 6 month schedule in the primary study
89091055|NCT04572802||control group|Coronary heart disease population: after coronary angiography, Gensini score was used to evaluate the severity of coronary artery occlusion, and then compared with the population of type 2 diabetes complicated with coronary heart disease
89091056|NCT04572802||experimental group (course of disease <5 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).Retrospective examination of patients' data, recording patients' laboratory tests and drug use, taking blood to measure orphanin, and evaluating the severity of coronary artery occlusion with Gensini score.
89091057|NCT04572802||experimental group(course of disease 5-10 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 5-10 years).
89091058|NCT04572802||experimental group(course of disease10-20 years)|Type 2 diabetes complicated with coronary heart disease (course of disease 10 -20years).Finally, the data were obtained to evaluate the relationship between the course of diabetes and the severity of coronary heart disease, as well as the relationship between the course of diabetes and OFQ in patients' blood.
89091059|NCT04237870|Active Comparator|Active treatment|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS repeat twice with 15 min interval. Treatment will be applied in central suleus.
89091060|NCT04237870|Sham Comparator|Sham treatment|Sham rTMS will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
89091061|NCT00684931|Experimental|1|patients with Attention Deficit Disorder with or without Hyperactivity
89091062|NCT00684931|Sham Comparator|2|healthy volunteer without Attention Deficit Hyperactivity Disorder
89091063|NCT04238104||sea level|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center of sea level were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
89091064|NCT04238104||altitude <1000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude less than 1000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
89091065|NCT04238104||altitude 1000-2000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 1000-2000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
89091066|NCT04238104||altitude 2000-3000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 2000-3000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
89091067|NCT04238104||altitude 3000-4000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 3000-4000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
89091068|NCT04238104||altitude 4000-5000|Pulse oximetry was performed between 6 and 72 hours after delivery (measured and recorded at 6, 12, 24, 48 and 72 hours respectively). Using Masimo Radical-7 (Irvine, CA, USA) to measure. All measurements at the medical center with the altitude between 4000-5000 metres were performed by the well-trained investigator. All major CHD infants will be measured the POX by the same way during the whole study period.
89091069|NCT04147117|Experimental|Pessary Group|"A pessary certified is inserted through the vagina with the woman in recumbent position and is placed around the cervix.~Correct placement of the pessary is assessed by ultrasound. Patients on the pessary group are specially awarded about adverse symptoms and the need of immediate report in case of pain, bleeding and symptomatic contractions.~The pessary is not removed when symptoms of infection occur after pessary insertion, but appropriate treatment is given.~The pessary is removed at 37 weeks of pregnancy. Indications for pessary removal before 37 weeks are: active vaginal bleeding, premature labor not responding to tocolysis or severe patient discomfort."
89091070|NCT04147117|No Intervention|Control group|Current management for the follow-up of these women in the PBPC.
89091071|NCT00679003|Experimental|1|Social learning and cognitive behavioral therapy (SLCBT)
89091072|NCT00679003|Active Comparator|2|Education and support (ES)
89111104|NCT04100083|Active Comparator|Group 2|Patients taking 100mg Spironolactone
89111105|NCT04100083|Active Comparator|Group 3|Patients taking 200mg Spironolactone
89111106|NCT02794155|Experimental|Test Group|HDV Insulin Lispro subcutaneous, pre-prandial dosing, 26 week treatment period
89091073|NCT04547140|Experimental|Liquid Alpha1-Proteinase Inhibitor + Standard Medical Treatment|Participants received the first intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) 120 milligrams per kilogram (mg/kg), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8 (second dose was not mandatory and was given at the principal investigator's [PI] discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.
89091074|NCT04547140|Placebo Comparator|Placebo + Standard Medical Treatment|Participants received IV infusions of 0.9% normal saline of commensurate volume to that of liquid alpha1-proteinase inhibitor as placebo on Day 1 and Day 8 (Day 8 was not mandatory and was given at the PI's discretion). Participants also received all standard of care interventions while hospitalized, from Day 1 to Day 29.
89091075|NCT00679159|Experimental|1|24 children (5 x 10^7pfu)
89091076|NCT00679159|Experimental|2|36 infants (2.5 x 10^7pfu)
89091077|NCT00679159|Experimental|3|36 infants (5 x 10^7 pfu)
89091078|NCT00679159|Experimental|4|36 infants (1 x 10^8pfu)
89091079|NCT00679159|Placebo Comparator|5|36 infants (Prevenar vaccine)
89091080|NCT04237714|Experimental|IBI-based automated support|Internet-based intervention with automated support by the system. It consistes in phone text messages twice a week for users. The content of the messages focuses on motivating and reminding users to complete the activities proposed in the program and reviewing the treatment contents. Additionally an automatic email is send if participants have not access the program for a week. The program also provides continuous feedback to users through transversal tools.
89091081|NCT04237714|Experimental|IBI-plus human support|In this condition, the participants receive automated support explained above and additionally human support for a maximum of 5 minutes that consist in a weekly phone call provided by a psychologist. The content of phone calls is related with resolve questions or doubts about the use and clinical content of the IBI and also motivating and reminding the importance to complete activities in the program.
89091082|NCT04237714|No Intervention|Control group|Waiting list control group.
89091083|NCT04146103|Experimental|Experimental arm|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally, for 3 months.
89091084|NCT05654038|Experimental|Target CD19 UCAR-NK cells|Subjects who meet the enrollment conditions will receive intravenous infusion of anti-CD19 UCAR-NK Cells within 1 week after hematopoietic stem cell infusion.
89091085|NCT00685009||1|Women from the Women's Health Initiative study taking estrogen hormone therapy
89091086|NCT00685009||2|Women from the WHI study taking estrogen plus progesterone hormone therapy
89091087|NCT00685009||3|Women from the WHI study taking placebo
89091088|NCT02816086|No Intervention|Standard care|The study participants receives standard care in the ward, this does not include a pharmacist.
89091089|NCT02816086|Experimental|Intervention|Interdisciplinary collaboration structure
89091090|NCT00679237|Active Comparator|Multifactorial intervention|Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
89091091|NCT00679237|No Intervention|Control|no intervention
89091092|NCT02816164|Active Comparator|Neupogen for 5 days|Neupogen injection for 5 days
89226418|NCT04145466|Experimental|Carbohydrate responders (2)|receiving high-carbohydrate diet
89226419|NCT04131686||Control sites|Group of patients receiving standard treatment for symptomatic acute rhinosinusitis
89226420|NCT04131686||Test sites|Group of patients receiving NAC inhalation in addition to standard treatment for symptomatic acute rhinosinusitis
89226421|NCT04130022|Other|Fasted Children|
89091093|NCT02816164|Active Comparator|Neupogen for 7 days|Neupogen injection for 7 days
89091094|NCT02816164|Active Comparator|Neupogen for 10 days|Neupogen injection for 10 days
89091095|NCT02816320||Inpatient stays|All patients who were hospitalized in participating hospitals in France during the study period were eligible for inclusion.
89091096|NCT00681733|Experimental|A|Pioglitazone
89091097|NCT00681733|Active Comparator|B|Pentoxifylline
89091098|NCT02816008|Experimental|Cognitive rehabilitation group|Cognitive rehabilitation training with RGS in the clinic.
89091099|NCT02816008|Active Comparator|Passive control group|Passive/conventional cognitive training at home.
89091100|NCT04151329|Experimental|2.4mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box, 2.4mg/kg IV infusions
89091101|NCT04151329|Experimental|3.6mg/kg of BAT8001|Drug:BAT1306 100mg/4ml/box, 200mg IV infusions ,BAT8001 100mg/box,3.6mg/kg IV infusions
89091102|NCT02815774|Active Comparator|health volunteers|this group patients were given SP2086 50mg only one time.
89091103|NCT02815774|Active Comparator|mild renal insufficiency|this group patients were given SP2086 50mg only one time.
89091104|NCT02815774|Active Comparator|moderate renal insufficiency|this group patients were given SP2086 50mg only one time.
89091105|NCT02815774|Active Comparator|severe renal insufficiency|this group patients were given SP2086 50mg only one time.
89091106|NCT02815774|Active Comparator|end-stage renal insufficiency|this group patients were given SP2086 50mg only one time.
89091107|NCT00679315|Experimental|Alpha blocker|alfuzosin hydrochloride XL 10mg
89091108|NCT00679315|Placebo Comparator|Placebo|Placebo
89091109|NCT02626351|Experimental|Receiving/ received QI intervention|A clinic which is presently receiving the Intensive Phase of the QI intervention, or is in the Maintenance Phase
89091110|NCT02626351|Active Comparator|Not yet received QI intervention|A clinic which has not yet received the QI intervention
89091111|NCT00679393|Other|Fix|Open reduction internal fixation of severely comminuted calcaneal fracture (Sanders IV)
89091112|NCT00679393|Other|Fuse|Primary subtalar fusion of severely comminuted calcaneal fractures (Sanders IV).
89111107|NCT02794155|Active Comparator|Control Group|Insulin Lispro subcutaneous, Pre-prandial dosing, 26 week treatment period
89111108|NCT03798015||mitral valve surgery|outcome of mitral valve surgery (stroke yes or no)
89226422|NCT04124406||Adults Prescribed Cologuard|Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.
89226423|NCT04121364|Experimental|Tetranite|All patients enrolled in study will receive the dental adhesive with a dental implant. The robustness of the dental implant stability will be assessed at various time points.
89226424|NCT04111991|Active Comparator|Usual Care|Usual care in the NCH Complex Concussion Clinic
89226425|NCT04111991|Experimental|Usual Care + C-STEP|Usual care in the NCH Complex Concussion Clinic, plus 4 weekly sessions of C-STEP
89091113|NCT02820220||Patient/patient attendants|"Study subjects will be females.~Age at enrolment should be more than 18 years.~Attending Department of Paediatrics OPD/emergency/well-baby clinics/immunisation clinics OR Department of Gynaecology and Obstetrics OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.~Written informed consent to participate in the study."
89091114|NCT02820220||Students,nursing|"Pursuing Bsc Nursing(in their final year) or intern of college of nursing LHMC~Written informed consent to participate in the study"
89091115|NCT02820220||In-service nurses|"Posted in Department of Paediatrics indoor/OPD/well-baby clinics/immunisation clinics or Department of Gynaecology and Obstetrics indoor/OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.~Written informed consent to participate in the study."
89091116|NCT04189042||Parkinson Group|Patients with Parkinson's Disease (Hoehn and Yahr stage 1-4)
89091117|NCT04189042||Healthy Control|Healthy People
89091118|NCT02816242|Experimental|intervention|teaching anatomy by concept map
89091119|NCT02816242|Sham Comparator|placebo|teaching anatomy by traditional method
89091120|NCT04692298|Other|Pulse|Participants will consume kidney beans, lentil, pinto beans, black-eyed pea, chickpea
89091121|NCT02820142||Bacteremia with Sepsis group|Patients aged 20 years or older with a diagnosis of bacteremia will be eligible for inclusion in the study.
89091122|NCT02815930||HCUs|Newly incident seniors with annual total healthcare expenditures in the top 5% of Ontarians
89091123|NCT02815930||Non-HCUs|Seniors with annual total healthcare expenditures below the top 5% of Ontarians
89091124|NCT04238962|Experimental|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
89091125|NCT04238962|Active Comparator|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
89091126|NCT01098474|Experimental|SB692342 2 dose Group|Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.
89091127|NCT01098474|Experimental|SB692342 1 dose Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.
89091128|NCT01098474|Active Comparator|Control Menjugate Group|Subjects received three doses of the control Menjugate™ vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.
89091129|NCT01098474|Experimental|SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group|"Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomintantly with the last two doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered instramuscularly in the right arm, on a 0, 1, 2 months schedule.~All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose."
89091130|NCT01098474|Experimental|SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
89111109|NCT02790255|Experimental|Cold air|Subjects to be seated in an airtight chamber at an ambient temperature between 16 to 20 degrees Celsius for 1 hour.
89111110|NCT02790255|Experimental|Cold water|Subjects to be seated in an airtight chamber at an ambient temperature of 24 degrees Celsius, with their hands and feet fully immersed in cold water for 5 minutes.
88812567|NCT02818426|Experimental|UCPVax|"UCPVax is a therapeutic cancer vaccine composed of two peptides called UCP2 and UCP4 derived from telomerase combined with Montanide ISA 51 VG as adjuvant.~The two peptides UCP2 and UCP4 will be emulsified in Montanide ISA 51 and injected subcutaneously in separate sites (one site per peptide), at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination every 8 weeks for 12 months."
88812568|NCT02797561||Tandem lesion evaluated by FFR|
89091131|NCT01098474|Active Comparator|Control Tritanrix + Prevnar + Polio Sabin Group|Subjects received three doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
89091132|NCT04238026|Experimental|Distal radial artery approach|Puncture in the snuff box area of the arm with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
89091133|NCT04238026|Active Comparator|Proximal radial artery approach|Puncture in the ventral side of the arm (2 cm proximal to the styloid apophysis) with through and through technique, advancement of a wire and placement of an hydrophilic sheath introducer.
89091134|NCT00633802|Placebo Comparator|2|
89091135|NCT00633802|Experimental|1|
89091136|NCT04460248|Experimental|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|
89091137|NCT02819986|Experimental|Progressive Goal Attainment Program|10 one hour weekly therapy sessions focused on behavioural interventions
89091138|NCT02878902||Before implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2012 to December 31, 2013"
89091139|NCT02878902||Post implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2014 to December 31, 2015"
89091140|NCT02819830|Experimental|Intervention group|"Participants, who have been randomly assigned to the intervention group, will take part in a six-week supervised exercise training programme. This programme takes place in a rehabilitation gymnasium. The exercise programme consists of two group sessions per week (scheduled for evenings, after typical working hours, approximately 12 patients per session). Each session lasts for approximately 70 minutes and includes a 5 minute warm up, 30 minutes of aerobic cycling exercise, 30 minutes of strength training, and a 5 minute cool down.~Participants will also perform a 30 minute walk each weekend as part of the intervention."
89091141|NCT02819830|No Intervention|Control group|Participants who have been randomly assigned to the control group will not undertake the exercise intervention. These participants are instructed to maintain their usual lifestyle.
89091142|NCT02820064|Other|only one arm|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
89091143|NCT00876733||HIV treatment|
89091144|NCT04425538|Experimental|Infliximab|All patients enrolled into this trial will be assigned to the Infliximab arm. Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.
89091145|NCT04309344|Experimental|RF|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage
89091146|NCT04309344|Active Comparator|Control|The mechanical shaver is used to remove superficial fibrillations.
89091147|NCT02879526|Experimental|C-CPT|
89091148|NCT02819674||early-onset hypertension|early-onset hypertension patients recruited in Chinese multiple centers
89091149|NCT02815306|Experimental|Brace goup|The infants who were brace group treated by braces which were designed and made by us.
89091150|NCT04309032|Experimental|Bladder fill|Retrograde bladder filling of 250cc of 0.9% normal saline for irrigation prior to removal of foley catheter
89091151|NCT04309032|No Intervention|No bladder Fill|no filling prior to removal of foley catheter
89091152|NCT04690582|Active Comparator|Treatment As Usual|Participants will receive cognitive processing therapy (CPT) for PTSD combined with a self-guided safety plan. As a recommended standard care practice with suicidal patients, the combination of CPT and safety plan represents treatment as usual. The safety plan will be assigned during the first therapy session.
89091153|NCT04690582|Experimental|Crisis Response Plan (CPT+CRP)|Participants will receive cognitive processing therapy (CPT) for PTSD combined with a collaborative crisis response plan (CRP). The CRP includes many of the same elements as the safety plan (i.e., warning signs, self-management strategies, sources of social support, crisis services), but is created collaboratively by the patient with active input of their clinician rather than being self-guided. The CRP also includes a section focused on the participant's reasons for living, an addition that has been shown to increase positive emotional states (e.g., hope, optimism) and lead to faster reductions in suicidal intent. The CRP will be collaboratively created during the first therapy session.
89091154|NCT02878980|Experimental|Arm I (exercise intervention)|Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum.
89091155|NCT04145167||Medical Treatment|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by medical therapy only, for any clinical/angiographic/instrumental indication.
89091156|NCT04145167||Percutaneous intervention|This group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by percutaneous intervention (CTO-PCI), as indicated by the heart-team.
89091157|NCT04145167||Surgical treatment|This group will include all patients with a diagnose of coronary chronic total occlusions (generally not isolated) who will be treated by means of coronary artery by-pass grafting (CABG), as indicated by heart-team decision.
89111111|NCT04234581|Experimental|Lysulin|Participants will be randomly allocated in blocks for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) per os with breakfast, lunch and dinner.
89226426|NCT04111770|Experimental|IVUS guided PCI|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
89226427|NCT04111770|Active Comparator|QCA guided PCI|QCA will be used to determine lesion characteristics
89226428|NCT04103879|Experimental|ECT-001-Expanded CB|"Patients will receive a myeloablative conditioning regimen.~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)."
89226429|NCT04098744|Experimental|Artesunate vaginal insert|Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.
89226430|NCT04098744|Placebo Comparator|Placebo vaginal inserts|Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4.
89226431|NCT04096417|Experimental|Treatment (pemigatinib)|Patients receive pemigatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89226432|NCT04096274|Experimental|LOCI (Intervention)|In clinics assigned to the LOCI condition, executives and first-level leaders will receive leadership training and coaching to support implementation of the OQ-A system. In addition, leaders and clinicians in this condition will receive training and technical assistance to implement the OQ-A measurement-based care system.
89226433|NCT04096274|Active Comparator|Training and Technical Assistance only (Control)|In clinics assigned to the control group, leaders and clinicians will receive training and technical assistance to implement the OQ-A measurement-based care system. In addition, to support enrollment in this condition, leaders in this condition will be offered access to general web-based leadership seminars.
89226434|NCT04095689|Experimental|Experimental|docetaxel chemotherapy and pembrolizumab plus IL-12 gene therapy.
89226435|NCT04092257|Experimental|VIA and thermocoagulation|Participants will undergo same day VIA and thermocoagulation
89226436|NCT04086485|Experimental|1/Lu-177-DOTATATE + Olaparib escalation|Lu-177-DOTATATE and escalating doses of olaparib to determine the maximum-tolerated dose (MTD)
89226437|NCT04086485|Experimental|2/Lu-177-DOTATATE + Olaparib fixed dose|Lu-177-DOTATATE and olaparib at the MTD
89226438|NCT04086056||Children with craniosynostosis|Children with craniosynostosis who will be operated in prone position.
89226439|NCT04081350|Active Comparator|10 µg/kg LY3471851|Participants received subcutaneous (SC) injection of 10 microgram per kilogram (μg/kg) LY3471851 every 2 weeks for a treatment period of 12 weeks.
89226440|NCT04081350|Active Comparator|12 µg/kg LY3471851|Participants received subcutaneous injection of 12 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
89226441|NCT04081350|Active Comparator|24 µg/kg LY3471851|Participants received subcutaneous injection of 24 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.
89226442|NCT04081350|Placebo Comparator|Placebo|Participants received subcutaneous injection of placebo every 2 weeks for a treatment period of 12 weeks.
88812875|NCT01552343|Placebo Comparator|Female - Placebo|Female participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
89226443|NCT04081233|Experimental|Early surgical stabilization|This arm will include early surgical stabilization (within 72 hours of admission) in addition to the usual care received for patients with multiple rib fractures. Usual care will involve pain management.
89226444|NCT04081233|Active Comparator|Usual care|This arm will be usual care only. Usual care will include pain managment.
89226445|NCT04080531|Experimental|Arm I (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
89226446|NCT04080531|Experimental|Arm II (trivalent influenza vaccine, Prevnar)|Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.
89226447|NCT04078555|Experimental|ENERGI-F703 GEL|topical application on target venous leg ulcer, twice daily
89226448|NCT04078555|Placebo Comparator|ENERGI-F703 GEL matched vehicle|topical application on target venous leg ulcer, twice daily
89226449|NCT04078282|Experimental|Active treatment group|Patients will meet in a joint consultation with their family physician and a psychiatrist for evaluation. Then it follows three treatment sessions with the family physician before a new joint consultation with the psychiatrist. The intervention ends with three more treatment sessions with the family physician.
89226450|NCT04078282|Active Comparator|Control group|Patients belonging to family physicians who constitute the control group will be assessed and given treatment according to usual care. This may include treatment by the family physician, medication, referrals to specialized care.
89226451|NCT04068727|No Intervention|Control|
89226452|NCT04068727|Experimental|Clinical Pharmacist Intervention|
89226453|NCT04067011|Experimental|Group 1:Ciprofloxacin + AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.~Group 1 will concomitantly receive ciprofloxacin."
89226454|NCT04067011|Experimental|Group 2: Doxycycline +AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.~Group 2 will concomitantly receive doxycycline."
89226455|NCT04067011|Experimental|Group 3: AV7909|Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
89226456|NCT04064242|Experimental|CMK389|CMK389
89226457|NCT04064242|Placebo Comparator|Placebo|Placebo
89226458|NCT04062396|Active Comparator|Eurosets REMOWELL 2 oxygenator|
89226459|NCT04062396|Active Comparator|LivaNova INSPIRE oxygenator|
89226460|NCT04054557|Active Comparator|Arm I (Standard of Care office Visits)|Participants receive standard of care office visits approximately every 3 months (± 2 weeks) for one year.
89226461|NCT04054557|Experimental|Arm II (Standard of Care Office Visits, survey, telehealth)|Patients receive standard of care as in Arm I and 4 automated electronic surveys every 3 weeks (+/- 1 weeks) for a total of 18 electronic surveys over one year. Patients who report severe or very severe side effects, or stopping or are thinking about stopping their ET will have a follow up encounter with a research coordinator.
89226462|NCT04054557|Experimental|Arm III (Smart Pill Bottle, messaging)|Patients receive a wireless smart pill bottle that performs daily time-specific reminders to open the pill bottle and take the medication. Additional messages are triggered by the pill bottle when non-adherence is indicated (lack of bottle opening or no change in remaining pills), as well as when medication is skipped.
89226463|NCT04053816|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below 3.6 mEq/L.
89091158|NCT04420156||i-ROP cohort|Premature infants who are at risk of retinopathy of prematurity(ROP) at participating study sites. As standard of care, babies who are born less than 31 weeks gestational age or less than 1500 grams are routinely screened for ROP. Families are approached to participate in this study where finding from babies' eye exams and associated retinal images along with demographic and other health data are collected and coded with unique identifier. No intervention is administered. The ROP exams and images obtained are done as a standard of care and would be performed even if there is no consent provided.
89091159|NCT02627521|Experimental|PRU Guided CABG|Timing of CABG surgery within 24 hours of reaching a normalized platelet function (NPF). NPF defined as a PRU value >235 or a PRU value between >170 and <235 for two consecutive days as documented by VerifyNow assay.
89091160|NCT02627521|Active Comparator|CABG per standard of care|Timing of CABG per standard of care
89091161|NCT02627599||Chronic Obstructive Pulmonary Disease|"More than 12 million adults are diagnosed with COPD~COPD is the 3rd leading cause of death in the U.S.~Breathing difficulty is the major reason patients seek medical attention~COPD patients requiring hospitalization are associated with higher costs~Oximetry is an important tool for assessing need for Long-Term Oxygen Therapy~LTOT has been proven to improve survival and quality of life~Patients provided with a breath responsive variable bolus oxygen conserving device:~support increased activity~improve quality of life~increase functional capability~reduce portable oxygen source utilization~maintain and/or improve oxygen saturation"
89091162|NCT02815228|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89091163|NCT00681967|Experimental|Cohort 1|post operative combination of gefinib and RT
89091164|NCT00681967|Experimental|Cohort 2|combination of gefitinib with RT and Chemotherapy in non operated patients
89091165|NCT00685321|Experimental|1|deep TMS treatment
89091166|NCT00685321|Sham Comparator|2|inactive treatment
89091167|NCT04239118|Experimental|Applications of autoplasma, enriched with platelets and|Endoscopic applications of autoplasma, enriched with platelets and granular sorbent aseptisorb-A in bleeding gastroduodenal ulcers
89091168|NCT04239118|Other|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents.
89091169|NCT04139941||Individuals with known or unknown HCV status|
89091170|NCT04192396||RIF patients|Repeated implantation failure patients
89091171|NCT04192396||Oocyte/embryo donation program|Patients awaiting for oocyte/embryo-donation recipient patients
89091172|NCT02815150|Experimental|Treatment group|Preoperative oral carbohydrate drink: patients drink 5% glucose solution 250ml 2-3 hours before surgery.
89091173|NCT02815150|No Intervention|Control group|Patients undergo 6-8 hours of preoperative fasting.
89091174|NCT02814994|Experimental|tidal volume guided by respiratory system compliance|effects of tidal volume guided by respiratory system compliance on mortality in patients suffering from ARDS
89091175|NCT02814994|Experimental|low tidal volume|Ventilated patients with low tidal volume
89091176|NCT00875017|Experimental|Meal + Lanthanum|
89091177|NCT00875017|Active Comparator|Meal + Sevelamer|
89091178|NCT00875017|No Intervention|Meal Only|
89091179|NCT00875017|No Intervention|Fasting|
89091180|NCT02819362||Prospective cohort - MRI|Patients with pathological nipple discharge
89091181|NCT00679705|Experimental|1|Ritodrine (Pre-Par)
89226464|NCT04053816|Active Comparator|Tight control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
89091182|NCT00679705|Experimental|2|Atosiban (Tractocile)
89091183|NCT00679705|Placebo Comparator|3|Placebo
89091184|NCT04672486|Experimental|Intervention Arm|Participants will be offered an online problem-solving intervention that is delivered through a smartphone app (called POD Adventures) with telephone-based guidance from a lay counsellor. The app teaches problem-solving skills through interactive animated vignettes and personalized action plans, with encouraging prompts and feedback offered through an in-app guide character. In addition, methods of gamification are used to model and practice complementary coping strategies (e.g., relaxation) and enhance engagement. Participants will use the app remotely (i.e., from their home) in their own time.
89091185|NCT04672486|No Intervention|Usual Care|Participants randomized to the control arm will be provided with usual care. This will consist of information and contact details about local mental health service providers and two recently established government provided/affiliated helplines: (i) Manodarpan, a student mental health helpline supported by the Ministry of Human Resource Development; and (ii) a 24/7 mental health helpline (KIRAN) supported by the Social Justice and Empowerment Ministry. The same information will be provided to participants in the intervention arm.
89091186|NCT04140019||NSTEMI|
89091187|NCT04237948|Active Comparator|physical therapy plus REAL tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.~Real Cerebellar tDCS will be applied for 10 days of time."
89091188|NCT04237948|Placebo Comparator|physical therapy plus SHAM tDCS|"Patients will be undergo a rehabilitation treatment during hospitalization consisting in 60 minutes of physical rehabilitation for 4 weeks.~Sham Cerebellar tDCS will be applied for 10 days of time."
89111112|NCT04234581|Placebo Comparator|Placebo|Subjects will be instructed to take two tablets of placebo per os with breakfast, lunch and dinner.
89091189|NCT00685633|Active Comparator|Arm A|Patients are observed without treatment in weeks 1-12. Patients with a prostate-specific antigen (PSA) rise of > 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks.
89091190|NCT00685633|Active Comparator|Arm B|In weeks 1-12, patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of > 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks.
89091191|NCT04206670|Experimental|In-Home Technology System|Participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over a six month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter).
89226465|NCT04053634|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
89091192|NCT04206670|Other|Waiting Control|Participants will be assigned a date for receiving and installing the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) six months after they enter the study. During that six-month period, questionnaires (e.g., health and well-being) will be administered 3 times (at the start of the study and every 3 months thereafter). At the end of the six-month period, participants will receive and install the full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) in their homes. Remote assistance will be provided to help with the installation. Sensors, warnings, messaging, and social networking features will be activated remotely. Participation will extend over an additional six-month period with questionnaires (e.g., health and well-being) administered 2 times (every 3 months following installation).
89091193|NCT00685711|Placebo Comparator|1|Placebo intradermal n = 2 with each dose level of Cat-PAD.
89091194|NCT00685711|Experimental|2|Intradermal injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 12 nmol may be administered to an additional cohort of 6 subjects.
89091195|NCT00685711|Placebo Comparator|3|Placebo subcutaneous n = 2 with each dose level of Cat-PAD.
89091196|NCT00685711|Experimental|4|Subcutaneous injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12, 20 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 20 nmol may be administered to an additional cohort of 6 subjects.
89091197|NCT00682045||T-SPOT.TB positive|T-SPOT.TB positive patients
89091198|NCT04371952|Experimental|Doxycycline 100mg|Doxycycline capsule containing 2 tablets doxycycline 100mg over-encapsulated. Doxycycline is given at 200 mg once a day and administered per os during 2 weeks
89091199|NCT04371952|Placebo Comparator|Doxycycline placebo|Doxycycline Placebo capsule 200 mg, containing 1 capsule of a marketed placebo = RODAEL placebo ( lactose, 380 mg / capsule). Doxycycline placebo is given once a day and administered per os during 2 weeks
89091200|NCT04145089|Active Comparator|C-Mac intubation|Intubation with C-MAC video laryngoscopy
89091201|NCT04145089|Active Comparator|Glidescope intubation|Intubation with Glidescope video laryngoscopy
89091202|NCT00679861|Experimental|3|A practitioner delivered counselling and an expert system intervention is implemented in practices allocated to this arm
89091203|NCT00679861|Experimental|1|A practitioner delivered counselling intervention was implemented in practices allocated to this arm
89091204|NCT00679861|Experimental|2|A computer expert system intervention was implemented in practices allocated to this arm
89226466|NCT04053634|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
89091205|NCT02814760||Pre-intervention group (Control group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.~Patients of this group are included before the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
89091206|NCT02814760||Post-intervention group (Training course group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.~Patients of this group are included after the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
89091207|NCT00875797|Active Comparator|parentral glutamine|parenteral glutamine given in central venous line in dose up to 30 g par day
89091208|NCT00875797|Experimental|entral glutamine|enteral glutamine given through gastric tube in a dose up to 30 g per day
89091209|NCT04144621||Normal SDF|Couples with male partners having SDF lower than 20% using TUNEL assay
89091210|NCT04144621||Abnormal SDF|Couples with male partners having SDF greater than 20% using TUNEL assay
89091211|NCT04337476|Experimental|mother's song|At the suggestion of the music therapist, the mothers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
89091212|NCT04337476|Experimental|father's song|At the suggestion of the music therapist, the fathers of each child will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
89091213|NCT04337476|Experimental|singing of the music therapist|Music therapist will record two lullabies sung by themselves; lullabies will be part of traditional classical literature. The songs will be recorded and loaded on a simplified digital software to modify any background noise or pauses. The recording will be inserted in the usb / sd flash drive used directly by the PAL device. During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit
89091214|NCT04337476|No Intervention|No singing|Control group (not subjected to musical stimulation- no singing). During the entire hospital stay, newborn babies will receive standard care in use in the neonatal intensive care unit.
89091215|NCT02626195|Experimental|nutritional support program apply|Preoperative nutritional support program is given for 5 or more days preoperatively by nutritional support program.
89091216|NCT02626195|No Intervention|historical control group|Historical control group is that did not receiving
89091217|NCT02814214||ECG+IEGM|Surface ECG and intracardiac electrogram recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy settings
89091218|NCT00685789|Experimental|Acupuncture with Deqi|Needles were inserted and manipulated manually using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation of soreness, numbness, fullness, aching, cool, warmth, heaviness and radiating sensation (Deqi) occurred. The needles were retained for 30 min.
89091219|NCT00685789|Active Comparator|Acupuncture without Deqi|Needles were simply inserted and retained for 30 min, without any other stimulation.
89091220|NCT04329832|Experimental|Hydroxychloroquine|
89091221|NCT04329832|Active Comparator|Azithromycin|
89091222|NCT02626273|Experimental|intervention group|an intervention group who will undergo the management program combining physical activity and restrictive diet at Tza Nou Medical House for 10 months
89091223|NCT02626273|Other|a control group|a control group who will not undergo any intervention
89091224|NCT00679471||Pre-Term|Infants born pre-term with birthweight less than 1KG
89091225|NCT00679471||Full-Term Infants|Well infants who are born full-term
89091226|NCT04049071||Case|Cases are patients that are prescribed tocilizumab as escalation therapy for relapsing/refractory GCA
89091227|NCT04049071||Control|Controls are those that are prescribed an alternative escalation therapy (not tocilizumab) for relapsing/refractory GCA.
89091228|NCT04237246|Experimental|Once daily Tacrolimus (Advegraf)|
89091229|NCT00680095|Experimental|A|AN2690 Solution, 2.5%
89091230|NCT00680095|Experimental|B|AN2690 Solution, 7.5%
89091231|NCT00680095|Experimental|C|AN2690 Solution, 5.0%
89091232|NCT00680095|Active Comparator|D|AN2690 Solution, Vehicle
88812876|NCT01552343|Experimental|Male - Desmopressin 75 μg|Male participants took 1 tablet 75 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
88812877|NCT01552343|Placebo Comparator|Male - Placebo|Male participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
89091233|NCT00680095|Active Comparator|E|Sodium Lauryl Sulfate, 0.5%
89091234|NCT04237168||DLBCL patients|newly diagnosed DLBCL (de novo, all ages) patients treated with RCHOP (first-line treatment regimen)
89091235|NCT00685867|Experimental|1|Rapid detection
89091236|NCT00685867|Other|2|Enhanced infection control
89091237|NCT02814604|Experimental|Traffic Light|"Participants in this group will download an app which features the nutrition information of the selected product in a multiple coloured traffic light format (i.e. the traffic light system shows a coloured round indicator for each of saturated fat, sugar, and sodium; shaded red (high), amber (medium) or green (low), according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
89091238|NCT02814604|Experimental|Health Star Rating System|"Participants in this group will download an app which features the nutrition information of the selected product in a form of 0-5 stars to provide an overall healthy rating. The Health Star Rating provides a rating for all products and products not meeting the criteria still carry the symbol (with no colored stars). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
89091239|NCT02814604|No Intervention|Control|Participants in this group will only see the Nutrition Facts Table (as it appears on the product's package) when the product is scanned in the app.
89091240|NCT02814604|Experimental|High-in Warning Label|"Participants in this group will download an app which features the nutrition information of the selected product in a 'high-in' warning label format (i.e. stop signs for each of saturated fat, sugar, and sodium; according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
89091241|NCT00686023|Active Comparator|1|DHS fixation
89091242|NCT00686023|Active Comparator|2|IMN fixation
89091243|NCT02814136|Active Comparator|WACA|wide area circular ablation
89091244|NCT02814136|Active Comparator|EWACA|extra-wide area circular ablation
89091245|NCT00682201||1|Healthy pregnant women
89091246|NCT02814058|Experimental|Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
89091247|NCT02814058|Experimental|Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
89091248|NCT00680173|Active Comparator|A|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin achieve a sustained virological response
89091249|NCT00680173|Active Comparator|B|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin did not achieve a sustained virological response
89091250|NCT04293016|Active Comparator|Support as usual|
89091251|NCT04293016|Experimental|Problem Solving therapy|
89091252|NCT04293016|Experimental|ICU diary|
89091253|NCT00682279|No Intervention|This is a single-arm, dose escalation|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
89091254|NCT02811484|Other|Group 1|Insulin titration and behavioral therapy.
89091255|NCT02811484|Placebo Comparator|Group 2|Exenatide-LAR plus Dapagliflozin placebo, basal insulin titration, and behavioral therapy.
89091256|NCT02811484|Experimental|Group 3|Exenatide-LAR plus Dapagliflozin, basal insulin titration, and behavioral therapy.
89091257|NCT00686101||1|Normal control subjects (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, who are not actively trying to quit smoking at the time of the interview, and who must be free from Axis I psychotic disorder.)
89091258|NCT00686101||2|Subjects with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, and who are not actively trying to quit smoking at the time of the interview.)
89091259|NCT00686179|Experimental|1|Escalating doses of AZD3480 during 6 days
89091260|NCT00686179|Experimental|2|Repeated doses of AZD3480 during 6 days
89091261|NCT00686179|Placebo Comparator|3|Placebo during 6 days
89091262|NCT00686179|Active Comparator|4|Placebo during 5 days, active day 6
89111113|NCT02801955||tumor marker|serum CEA and CA 19-9 levels in patients with curative gastrectomy preoperatively and peritoneal CEA and CA 19-9 levels in patients taken at the beginning of curative gastrectomy via sampling of peritoneal washing aspirate
89111114|NCT02793843|Active Comparator|Ondansetron|
89111115|NCT02793843|Experimental|Ondansetron+ dexamethasone|
89091263|NCT04139707|Experimental|Caring4Dementia Group|The experimental group will receive Careing4Dementia downloadable on their smartphone or tablet. Caring4Dementia will tell and show caregivers of a person living with dementia how to 1) manage difficult behaviors, 2) deal with refusal, 3) deal with tensions and 4) manage work-life demands. The app is self-administered and self-paced and contains surveys referring to the outcome measurements tools used in the study. The intervention will be for 30 days without any restriction or limitation in terms of timing, location or frequency of use.
89091264|NCT04139707|Active Comparator|White Paper Group|The White Paper group will receive a white paper on the principles of communicating efficiently with persons living with dementia.
89091265|NCT04139707|No Intervention|Control Goup|The control group will not receive any intervention.
89091266|NCT02813902|Active Comparator|Heliocare|240 mg administered orally daily
89091267|NCT02813902|Placebo Comparator|Sugar pill|a sugar pill matching the Heliocare tablet in look and weight will be administered orally daily
89091268|NCT00922597||Group 1|
89091269|NCT02811172||Healthy pregnant women|Healthy pregnant women
89091270|NCT02811172||Risk pregnant women|Hypertensive, obese and diabetic women
89091271|NCT04151173|Experimental|aspiration/electrocoagulation|
89091272|NCT04151173|Active Comparator|cystectomy|
89091273|NCT02627365|Experimental|Individualized, interactive SMS|Individualized, interactive SMS intervention plus Standard care. Messages sent automatically using the Text-IT system.
88812878|NCT02475564|Placebo Comparator|placebo|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 1 pill of placebo (starch)
89091274|NCT02627365|No Intervention|Standard care|Standard care according to Kenyan guidelines, including clinic-based adherence education and counseling.
89091275|NCT02813746||Obese non smoker vs Normoweight non smoker|Endometrial fluid (EF) will be obtained from non-smokers normo-weight and obese patients in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. They will be classified following the guidelines of the obesity classification system by the World Human Organization (WHO). Patients will be subjected to a fitness program during a year with the aim to achieve a weight reduction to normal values (19-24.9 kg/m2). The modifications in the miRNAs expression will be studied. After the weight loss, new EF will be collected from these patients.
89091276|NCT02813746||Normoweight smoker vs Normoweight non-smoker|EF will be obtained from non-smokers and smokers normo-weight in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. Smokers patients will be urge to give up smoking during at least one year. After this time, new samples will be collected to determine if the non-exposition to this contaminant could exert any effect in the miRNAs signature. A regular control will be done in this group of patients to ensure that they have not been exposed to tobacco in 12 months. Professional support will be given in the same centre of the study to help the patient to accomplish its objective.
89091277|NCT00874939|Experimental|PBO→MK-7.5→DON→MK-25|Treatment by single oral dose with Placebo (PBO) in the first crossover period; MK-0249 7.5 mg (MK-7.5) in the second crossover period; Donepezil 5 mg (DON) in the third crossover period; and MK-0249 25 mg (MK-25) in the fourth crossover period.
89091278|NCT00874939|Experimental|MK-7.5→PBO→MK-25→DON|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 25 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
89091279|NCT00874939|Experimental|DON→MK-25→PBO→MK-7.5|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
89091280|NCT00874939|Experimental|MK-25→DON→MK-7.5→PBO|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Placebo in the fourth crossover period.
88812879|NCT02475564|Experimental|resveratrol|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 40mg of resveratrol
89091281|NCT00874939|Experimental|PBO→MK-25→MK-7.5→DON|Treatment by single oral dose with Placebo in the first crossover period; MK-0249 25 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
89091282|NCT00874939|Experimental|MK-7.5→DON→PBO→MK-25|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Donepezil 5 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
89091283|NCT00874939|Experimental|DON→MK-7.5→MK-25→PBO|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and Placebo in the fourth crossover period.
89091284|NCT00874939|Experimental|MK-25→PBO→DON→MK-7.5|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Placebo in the second crossover period; Donepezil 5 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
89091285|NCT00874939|Experimental|PBO→DON→MK-25→MK-7.5|Treatment by single oral dose with Placebo in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
89091286|NCT00874939|Experimental|MK-7.5→MK-25→DON→PBO|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Donepezil 5 mg in the third crossover period; and Placebo in the fourth crossover period.
89091287|NCT00874939|Experimental|DON→PBO→MK-7.5→MK-25|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 7.5 mg in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
89091288|NCT00874939|Experimental|MK-25→MK-7.5→PBO→DON|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; Placebo in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
89091289|NCT04268836|Experimental|Treatment arm|Patients will be treated by the Optimal Acuity Clear-K Low Vision Aid System.
89091290|NCT00634348|Active Comparator|Aripiprazole|
89091291|NCT00634348|Active Comparator|Ziprasidone|
89091292|NCT00680329||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
89091293|NCT02811016|Experimental|budesonide 200|inhaled budesonide 200 µg bid
89091294|NCT02811016|Experimental|budesonide 800|inhaled budesonide 800 µg bid
89091295|NCT02811016|Placebo Comparator|placebo|inhaled placebo bid
89091296|NCT00686413|Experimental|1|
89091297|NCT00686413|Experimental|2|
89091298|NCT02810860|Other|Open Label|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
89091299|NCT04144309|Active Comparator|True acupuncture group|12 sessions of acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
89091300|NCT04144309|Placebo Comparator|Sham acupuncture group|12 sessions of sham acupuncture treatment (SE+SA) will be given twice a week for 6 weeks after randomization, followed by once a month for 3 months, for a total of 15 sessions of treatments.
89091301|NCT05592262|Experimental|Treatment group A|
89091302|NCT05592262|Experimental|Treatment group B|
89091303|NCT00690313|Active Comparator|Arm 1|Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
89091304|NCT00690313|Active Comparator|Arm 2|Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
89091305|NCT02626585|No Intervention|Control|Control group (n=20): Following removal of nasal cast on postoperative first week, no additional taping was applied to this group.
89091306|NCT02626585|Experimental|2-weeks of PRT|2-weeks of PRT (n=17): Following removal of nasal cast on postoperative first week, 2 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 3rd week).
89091307|NCT02626585|Experimental|4-weeks of PRT|4-weeks of PRT (n=20): Following removal of nasal cast on postoperative first week, 4 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 5th week).
89091308|NCT04144543|Experimental|White Noise|"The white noise used in our study is a fragment called Bebeğiniz ağlamasın-2 from Kolik album of Buzuki Orhan Osman, which was used in similar studies (Balci, 2006; Karakoc & Turker, 2014; Kucukoglu et al., 2016).Since the white noise is a continuously monotonous sound, which is in the form of a hum, it resembles the sounds in mother's womb (Balci, 2006)."
89091309|NCT04144543|Experimental|Facilitated Tucking|Facilitated tucking is the procedure of holding the baby's arms and legs in a flexed position close to the midline of the torso, and the baby is able to move his/her extremities during this procedure (Caglayan, 2011).
89091310|NCT04144543|Experimental|White Noise+Facilitated Tucking|Both applications performed together.
89091311|NCT04237324|Experimental|NAFL group|One side of the patient face has been therapied by 1565nm fiber nonablative fractional laser(Lumenis Co., Yokneam, Israel).
89091312|NCT04237324|Active Comparator|FMR group|Another side of the patient face has been therapied by FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
89091313|NCT02813434|Experimental|Florbetapir|
89091314|NCT04139863|Other|aMMP-8 chairside test|Test group. The aMMP-8 chairside mouth rinse test is performed for the test group.It identifies adolescents with poor oral hygiene at risk for subclinical periodontitis without detectable and visible manifestations of the illness, such as periodontal deepened pockets.
89091315|NCT04139863|No Intervention|No test|The other group is control group. No test administered.
89091316|NCT02810782|Experimental|Phenobarbital|Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
89091317|NCT02810782|Active Comparator|Chlorpromazine|Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
89091318|NCT02810782|Active Comparator|Morphine|Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
89091319|NCT02626117|Active Comparator|CAF+ SCTG+ laser depithelialisation|CAF + SCTG and Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium.
89091320|NCT02626117|Sham Comparator|CAF+SCTG+ sham laser depithelialisation|CAF+ SCTG+ sham LASER deepithelialisation was applied to remove the sulcular epithelium.
89091321|NCT02810626|No Intervention|Control|Control Group (surgical standard of care): Subjects 18 years and younger diagnosed with a pediatric brain tumor, and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
89091322|NCT02810626|Other|Interventional|Interventional Group (involvement of all BrightMatter™ products): Subjects 18 years and younger diagnosed with a pediatric brain tumor and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol and will be sent to the interventional technology (BrightMatter Bridge) for quality control. The QC'ed images will then be sent to a pre-operating planning software (BrightMatter Plan) for planning the surgical approach. Surgery will be carried out with guidance from the exported plan and the intra-operative neuro-navigation software, BrightMatter Guide, with the use of post-processing DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
89091323|NCT00686491||1|Triathletes
89091324|NCT00686491||2|Cold air athletes
89091325|NCT00686491||3|Swimmers
89091326|NCT00686491||4|Other sports elite athletes
89091327|NCT00686491||5|Control subjects
89091328|NCT00875563|Experimental|1|Zenith(R) Fenestrated AAA Endovascular Graft
89091329|NCT02884661||Hospitalization in Cardiology department|Patients cared by the Cardiology department
89091330|NCT02884661||Hospitalization in Geriatric unit|Patients cared by the Geriatric unit
89091331|NCT00690391||Surgical observation|patients with cancer in a palliative setting and in need of surgical interventions
89091332|NCT01155869|Experimental|XR-NTX|Depot naltrexone (Vivitrol) 380 mg. IM monthly
89091333|NCT01155869|Active Comparator|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
89091334|NCT05635006||Training group|70% of the participants were randomly divided into training groups to train the learning performance of the machine
89091335|NCT05635006||Validation group|15% of the participants were randomly divided into validation groups to enhance the learning performance of the machine and avoid over fitting
89091336|NCT05635006||Test group|15% of the participants were randomly divided into test groups to test the learning performance of the machine and draw research conclusions
89091337|NCT02810470|Experimental|Cream appreciation tests|
89091338|NCT02810470|Experimental|Beverages appreciation tests|
89091339|NCT00690469||Observational (biomarker analysis)|"Participants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology.~Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available.~For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened."
89091340|NCT02810314|Experimental|Clinical measures|MS patients recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works for each group and all MS patients will also complete a comprehensive neuropsychological battery including cognitive and behavioural tests of interest in MS
89091341|NCT02810314|Other|Control measures|Healthy participants recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works
89091342|NCT02810158||Patients with suspected OSA|Persons with clinical suspicion of obstructive sleep apnoea syndrome (OSA)
89091343|NCT02625493||study population|All patients who underwent elective coronary procedures belonged to the one group, they received standard care without any additional interventions, but were asked to fill in a questionnaire.
89091344|NCT02625649||RYGB|RYGB-operated type 2 diabetic patients
89091345|NCT02625649||non-RYGB|non-RYGB-operated type 2 diabetic controls
89091346|NCT00690547||Test Group|
89111116|NCT02793687|Experimental|Mexidol|"Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.~The use of the study drug is held with basic therapy."
89091347|NCT02809924|Experimental|Simulation-based just-in-time training|Viewing a short video showing the neonatal glottis of similar gestational age to the patient that is being intubated followed by practice on a mannequin (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada) with supervision and feedback from a senior provider (low fidelity simulation).
89091348|NCT02809924|Active Comparator|Video training|5 minutes video regarding endotracheal intubation
89091349|NCT00690625|Experimental|A|MyoRx cream
89091350|NCT00690625|Placebo Comparator|B|Placebo cream, same composition as experimental cream, without Omega 3 fatty acid
89091351|NCT02813512|Experimental|GXNPC1|Three subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and four standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), European Stroke Scale (ESS), European Stroke Motor Subscale (EMS), Barthel Index, MMSE and Gait analyses at 1 month, 3 months, and 6 months after treatment.
89091352|NCT00687037|Experimental|I|Cetylpyridinium chloride during 21 days.
89091353|NCT02810002|Experimental|DEFINITE-REGULATOR|Training with DEFINITE-REGULATOR experiment infantry boots manufactured by Brill Industries, Rishon LeZion, Israel
89091354|NCT02810002|Active Comparator|modified Belleville 390 TROP|Standard issue infantry boot
89091355|NCT02625415|Experimental|Vitamin B6|Topical application of B6 cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
89091356|NCT02625415|Placebo Comparator|Placebo|Topical application of B6 Placebo cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
89091357|NCT02809768|Experimental|Avatrombopag plus fluconazole|Part A: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, fluconazole (400-mg) will be administered once daily on Days 1 to 16, and a single dose of avatrombopag (20-mg) on Day 7 in Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
89111117|NCT02793687|Placebo Comparator|Placebo|"Sequential therapy as follows: Placebo (i.v. solution) for 10 days followed by placebo 1 tablet three times a day for 8 weeks.~The use of a placebo is held with basic therapy."
89226467|NCT04052971|Experimental|Escalation phase|"Drug: ABN401~Route of Administration: Oral~The study will follow a single patient cohort approach for the first 3 regular dose levels followed by classic 3+3 design. The starting dose is 50mg QD."
89226468|NCT04052971|Experimental|Expansion phase|"Drug: ABN401~Route of Administration: Oral~Once the maximum tolerated dose (MTD) or highest escalation cohort has been reached, or notable efficacy has been observed at a given dose level, a decision as to Recommended Phase 2 dose (RP2D) will be determined. Up to 40 patients with Non-Small Cell Lung Cancer Harboring c-MET Dysregulation will be recruited."
89226469|NCT04047797|Experimental|Treatment (ixazomib, rituximab)|Patients receive ixazomib by mouth on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of cycle 1. Beginning in cycle 3, patients receive rituximab Intravenous over 4-8 hours on day 1. Treatment repeats every 28 days up to cycle 12 in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue to receive ixazomib indefinitely in the absence of disease progression or unacceptable toxicity.
89226470|NCT04044768|Experimental|Autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) SPEAR™ T cells|
89226471|NCT04039971|Active Comparator|Tendon-Bone Graft|Participants receive the Quadriceps Tendon Tendon-Bone Graft technique during ACL reconstruction.
89226472|NCT04039971|Active Comparator|All-Soft-Tissue Graft|Participants receive the Quadriceps Tendon All-Soft-Tissue Graft technique during ACL reconstruction.
89226473|NCT04034264||Afebrile close contact|Lived in the same household or worked in the same enclosed workspace daily with a febrile enrollee at the time they got sick with a known highly morbid and/or transmissible pathogen.
89226474|NCT04034264||Febrile patient|Patients between 2 months and 65 years old who present with fever, or diagnosed with a highly morbid and/or transmissible pathogen by clinically validated tests.
89226475|NCT04019275|Experimental|ENGAGE|The intervention blends social learning, guided discovery, and skill training to promote community participation after stroke. The intervention is delivered in a group format and comprises group learning activities and individual action planning activities that address barriers to community participation after stroke.
89226476|NCT04018040|Experimental|Intervention Group|Patients will follow a lacto-ovo vegetarian diet for an 8 week period. patients will be provided with a lacto-ovo vegetarian food box delivery service with fresh ingredients and recipes to cover four dinners per week.
89226478|NCT04012723|Experimental|MY01 Device|"Device: MY01 Device~Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure"
89226479|NCT04011722|Experimental|Portico™ NG (Navitor) valve, FlexNav™ Delivery System|Portico ™ NG (Navitor) valve implantation with the new generation Portico NG (Navitor) valve (23mm, 25mm, 27mm and 29mm sizes), and the second-generation FlexNav Delivery system (small and large), Portico™ NG (Navitor) Loading System(s) (small and large).
89091358|NCT02809768|Experimental|Avatrombopag plus itraconazole|Part B: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, itraconazole (200-mg) will be administered twice daily on Day 1 and 200-mg once daily on Days 2 to 16. A single dose of avatrombopag (20-mg) will be administered on Day 7 of Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
89091359|NCT02809768|Experimental|Avatrombopag plus rifampin|Part C: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, rifampin (600-mg) will be administered once daily on Days 1 to 16. In order to avoid a food-effect on rifampin absorption, each dose will be administered 1 hour before participants consume a meal. On Day 7 of Treatment Period 2, rifampin (600-mg) and avatrombopag (20-mg) will be administered 1 hour before meal and 30 minutes after starting meal consumption.
89091360|NCT02813278|Experimental|simo decoction and acupuncture with vitamin B1|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection for 5 days or until flatus.
89091361|NCT02813278|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection for 5 days or until flatus.
89091362|NCT02813278|No Intervention|empty control|Patients only receive best support care.
89091363|NCT04138849|Experimental|BBT-877 Low Dose|
89091364|NCT04138849|Experimental|BBT-877 Mid Dose|
89091365|NCT04138849|Experimental|BBT-877 High Dose|
89091366|NCT04138849|Placebo Comparator|Placebo|
89091367|NCT00690703|Experimental|1|Treatment
89111118|NCT02801487|Experimental|CIRT with concurrent chemo arm|Treated with carcon ion radiotherapy along with concurrent chemotherapy (Cisplatin 40mg/m^2, weekly).
89091368|NCT04237090|Active Comparator|Diphenhydramine + placebo|"Diphenhydramine 50 mg intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion.~Lactose tablet 100 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water."
89091369|NCT04237090|Experimental|Cetirizine + placebo|"Cetirizine tablet 10 mg per os given 30 minutes before the paclitaxel infusion.with a 180 milliliters glass of water.~1 milliliter of sodium chloride 0,9 percent intravenous given in a 50 milliliters bag of sodium chloride 0.9 percent, with famotidine, 30 minutes before the paclitaxel infusion. 15 minutes infusion."
89091370|NCT00690781|Experimental|Casein Pulse|"casein is the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
89091371|NCT00690781|Experimental|Casein Spread|"casein is the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
89091372|NCT00690781|Experimental|MSP Pulse|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
89091373|NCT00690781|Experimental|MSP Spread|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
89091374|NCT00682669|Experimental|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
89091375|NCT00682669|Active Comparator|HLC|A Healthy Living Course (HLC) consisting of an 8-week program of lectures and discussion on health-related topics.
89091376|NCT00682747|Experimental|HBO|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen)
89091377|NCT00682747|No Intervention|non HBO|
89091378|NCT00682825|Experimental|1|Bispectral index-guided protocol
89091379|NCT00682825|Active Comparator|2|End-tidal anesthetic gas-guided protocol
89091380|NCT02809612|Experimental|Internet-based intervention|"Patients randomized to the internet-based intervention will be given access to the information in the internet-based platform directly after randomization. During the first 6 weeks, information will be offered in a structured way, with a theme changing weekly. After this time-point, the patients will have the possibility to navigate through all information. The platform encompasses internet-based training including information on the disorder, psycho-education and information of simple self-implemented intervention strategies cope with vulvodynia and ameliorate dyspareunia. The platform will also include videos where team members will describe their role in treating patients with the disorder, but also short videos from former patients willing to share their individual stories."
89091381|NCT02809612|No Intervention|Control group|Patients randomized to the control group through the platform will immediately be informed about the fact that there is available information and resources on the internet and that they will be called for a visit to the physiotherapist-midwife at due time, according to the present guidelines of care followed in the respective clinic (Uppsala, Falun, Gävle).
89091382|NCT00682903|Experimental|1|This arm will benefit from the nonstop measure of the subcutaneous glucose during the hospitalization and the week on returning to the place of residence,
89091383|NCT00912379||hemoglobin determination|ICU and emergency unit patients
89091384|NCT02809378|Experimental|Sevoflurane|anesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
89091385|NCT02809378|Experimental|sevoflurane, remifentanil, and propofol|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
89091386|NCT02809378|Experimental|Sevoflurane, remifentanil, propofol, and palonosetron|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
89091387|NCT00683059|Experimental|Nab-paclitaxel|
89091388|NCT02813122||with x-ray|patients underwent bariatric surgery and underwent x-ray
89091389|NCT02813122||without x-ray|patients underwent bariatric surgery and did not underwent x-ray
89111119|NCT04234503|Experimental|Ethics Quarter|Nurse managers perform 12 educational packages in web-page www.etiikanvartti.fi.
89111120|NCT04234503|No Intervention|Standard organisational ethics structures|Nurse managers continue in their standard organisational ethics structures
89091390|NCT01185353|Experimental|1 mg LY3009104 once daily|Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
89091391|NCT01185353|Experimental|2 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
89091392|NCT01185353|Experimental|4 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
89091393|NCT01185353|Experimental|8 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
89091394|NCT01185353|Placebo Comparator|Placebo once daily|Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
89091395|NCT01185353|Experimental|2 mg LY3009104 twice daily|(Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
89091396|NCT02809300|Experimental|ankylosing spondylarthritis|
89091397|NCT04237402|Other|Intra individual|Before and after pregnancy, hair follicles will be analysed
89091398|NCT00683137|Active Comparator|Arm 1|
89091399|NCT00683137|Active Comparator|Arm 2|
89091400|NCT00683137|Active Comparator|Arm 3|
89091401|NCT02809456|Experimental|Nicorandil|Beginning 4-6 weeks during radiation therapy, patients receive nicorandil is given during radiotherapy interval, 5mg each time, 3 times daily oral. Treatment repeats after completion of radiation therapy in the absence of disease progression or unacceptable toxicity.
89091402|NCT02809456|Active Comparator|observation|regular radiotherapy as our protocol
89091403|NCT05576740||natural cycle|In this group, women have a natural menstrual cycle, not intervened by exogenous hormones. The interventions performed in this group are the same as in the other groups.
89091404|NCT05576740||artificial cycle|In this group, women with an artificial menstrual cycle, i.e. women using hormonal contraception, oral or vaginal, are selected. The interventions carried out in this group are the same as in the other groups.
89091405|NCT05576740||natural cycle with deficient luteal phase|In this group, women have a natural menstrual cycle, with a low progesterone level during the luteal phase, and are not intervened by exogenous hormones. The interventions performed in this group are the same as in the other groups.
89091406|NCT04139473|Active Comparator|Hepaticojejunostomy|Patients undergo right lobe living donor liver transplantation will receive hepaticojejunostomy
89091407|NCT04139473|Active Comparator|Duct-to-duct anastomosis|Patients undergo right lobe living donor liver transplantation will receive duct-to-duct anastomosis
89091408|NCT04139629|Other|antibody positive (CAT+)|patients found positive for one of the assayed antichlamydial antibodies
89091409|NCT04139629|Other|antibody negative (CAT-)|women with negative antichlamydia antibody test
89091410|NCT04222894|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 12 weeks
89091411|NCT04222894|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 12-week study period.
89091412|NCT00687349|Experimental|Intervention Arm|The training program will assign resident or NP student to a rotation. They will be receiving the educational intervention during 8 half-day sessions.
89091413|NCT00687349|No Intervention|Control Arm|Resident or NP student is assigned to usual education.
89091414|NCT02813044|Experimental|TIVA group|Anesthesia is maintained with propofol during surgery
89091415|NCT02813044|Active Comparator|inhalation anesthesia group|Anesthesia is maintained with sevoflurane during surgery
89091416|NCT02625883||Survivors|Patients with out-of-Hospital resuscitation and return of spontaneous circulation. Structured interview for quality of life (questionnaire) one year after resuscitation.
89091417|NCT04236778|Experimental|Cohort 1|Cohort 1 received oral vancomycin followed by a single dose of VE303.
89091418|NCT04236778|Experimental|Cohort 2|Cohort 2 received oral vancomycin followed by a single day of 5 doses of VE303.
89091419|NCT04236778|Experimental|Cohort 3|Cohort 3 received oral vancomycin followed by a single day of 10 doses of VE303.
89091420|NCT04236778|Experimental|Cohort 4|Cohort 4 received oral vancomycin followed by 5 days of 10 doses daily of VE303.
89091421|NCT04236778|Experimental|Cohort 5|Cohort 5 received oral vancomycin followed by 14 days of 10 capsules daily of VE303
89091422|NCT04236778|Experimental|Cohort 6|Cohort 6 received 21 days of 10 doses daily of VE303
89091423|NCT04236778|Experimental|Cohort 7|Cohort 7 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
89091424|NCT04236778|Experimental|Cohort 8|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
89091425|NCT04236778|Experimental|Cohort 9|Cohort 8 received oral vancomycin followed by 10 doses of VE303 daily for 2 days, followed by 2 doses of VE303 daily for 3 days
89091426|NCT04236778|Placebo Comparator|Vancomycin only|This cohort only received oral vancomycin.
89091427|NCT00687427||A|Group A - 25 individuals or more, that start occupational therapy and agree to participate in the research.
89091428|NCT00687427||B|Group B- 25 individuals or more, half a year after hand injury that were treated in occupational therapy at the same institute.
89091429|NCT00687427||C|Group C - 25 individuals or more, a year after hand injury that were treated in occupational therapy at the same institute
89091430|NCT01098240|Experimental|Active Treatment|CP-601,927
89091431|NCT01098240|Placebo Comparator|Placebo|Placebo
89091432|NCT02812888||Hyperthyroid Patients|Patients with hyperthyroidism
89091433|NCT02812888||NC group|Normal control subjects
89091434|NCT00922675|Experimental|Postconditioning|Active arm:Postconditioning protocol before routine PCI/stenting of an occluded coronary artery
89091435|NCT00922675|Other|Control|Control arm: Routine PCI/stenting of an occluded coronary artery without postconditioning
89091436|NCT04149028|Experimental|PRP injection|injection of PRP inside ovary by the assistance of laparoscopy
89091437|NCT02809222|Other|Patients with MDS at diagnosis|The intervention, specific to the study, is to take blood samples on patients with MDS at diagnosis. A quality of life questionnaire will also be used to monitor patients
89091438|NCT02809222|Other|Patients with MDS in treatment|The intervention, specific to the study, is to take blood samples on patients with MDS receiving treatment. A quality of life questionnaire will also be used to monitor patients
89091439|NCT02809222|Other|Healthy volunteers|The intervention, specific to the study, is to take blood samples on patients healthy volunteers.
89091440|NCT04139785|Experimental|Intervention|Guided Cognitive Behavioural Therapy based app
89091441|NCT04139785|No Intervention|Care as usual|Care as usual
89091442|NCT02812966|Active Comparator|Lutonix DCB|Lutonix 035 Drug coated Balloon PTA Catheter
89091443|NCT02812966|Active Comparator|IN.PACT DCB|IN.PACT Admiral Paclitaxel-Coated PTA Balloon Catheter
89091444|NCT00687661|Active Comparator|1|Arm #1 will include patients randomized to receive bisphosphonate therapy for 24 months.
89091445|NCT00687661|Placebo Comparator|2|Arm #2 will include patients randomized to receive placebo therapy for 24 months
89091446|NCT02809534|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89091447|NCT02809144|Other|Nerve block|One novel nerve block combination
89091448|NCT02808988|Active Comparator|group A|periodontal phase 1 therapy consisted of scaling and root planning, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
89091449|NCT02808988|Active Comparator|group B|periodontal phase 1 therapy consisted of scaling and root planning, no bisphosphonate therapy,gingival crevicular fluid collection
89091450|NCT02808988|Active Comparator|group C|no periodontal phase 1 therapy, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
89091451|NCT02808988|Active Comparator|group D|no periodontal phase 1 therapy, no bisphosphonate therapy,gingival crevicular fluid collection
89091452|NCT04139551||1XXX Denono PD|Newly diagnosed unmedicated PD patients
89091453|NCT04139551||2XXX Mild /Moderate PD|Early to moderate stage PD patients well controlled on medication(typically fewer than 8 years since diagnosis)
89091454|NCT04139551||3XXX Advanced PD|Advanced PD patients (typically greater than 8 years duration)
89091455|NCT04139551||4XXX DBS patients|PD patients with deep brain stimulation systems
89091456|NCT04139551||5XXX PSP patients|PSP patients
89091457|NCT04139551||6XXX Healthy Controls|Age-frequency matched healthy controls
89091458|NCT02625805|Experimental|Participants diagnosed with ADD/ADHD|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
89091459|NCT02625805|Experimental|Healthy participants|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
89091460|NCT01098162||Vimpat®|Routine treatment in accordance with the local marketing authorization for Vimpat® added to one Baseline antiepileptic drug.
89091461|NCT00687895|Experimental|1|training in clinical algorithm plus microscopy
89091462|NCT00687895|Experimental|2|clinical algorithm
89091463|NCT00687895|No Intervention|3|Control
89091464|NCT02808910|Experimental|Salt nudge|The following changes will be made in the cafeteria: Salt will be placed in a corner of the buffet, rather than on each dining table. Other spices, without sodium, will be provided on the table. A sign will be placed on the table that nudges participants to try the other spices. Food in the buffet that is high in salt will be labeled with a negative-appearing symbol, and food in the buffet that is low in salt will be labeled with a positive symbol.
89091465|NCT02808910|Experimental|Vegetable nudge|The following changes will be made in the cafeteria: Names of the vegetable dishes in the buffet will be made more attractive. Signs will be placed with reminders to eat more vegetables. Signs will be placed with a visual indication of the percentage of a meal that should consist of vegetables.
89091466|NCT02808910|Experimental|Portion size nudge|The following changes will be made in the cafeteria: Smaller plates will replace the regular plates. Verbal and visual nudges to reduce portion size will be given. Utensils for self-serving calorie-dense foods in the buffet will be smaller than normal.
89091467|NCT02808910|Experimental|Combined nudge|All three nudges are combined in this intervention.
89091468|NCT02808910|No Intervention|Control groups|No changes are made to the cafeteria, compared to the pre-study situation. One control group participates after each of the nudges to control for effects of time of the year.
89091469|NCT00688051|Experimental|1|
89091470|NCT00688129|Experimental|KITS Program|The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
89091471|NCT00688129|No Intervention|Services as usual|
89091472|NCT00688207|Experimental|Rosiglitazone|An open-label, single, oral dose of 4mg of rosiglitazone in the morning under fasted conditions
89091473|NCT02880462|Active Comparator|high dose sulforaphane|The goal of the study is to investigate whether adding high doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
89091474|NCT02880462|Active Comparator|low dose sulforaphane|The goal of the study is to investigate whether adding low doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
89091475|NCT02880462|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
89091476|NCT00688285|Active Comparator|1|education and automated clinical alerts
89091477|NCT00688285|Active Comparator|2|education session alone
89091478|NCT05576506||Deep learning algorithm group|After the patient has passed the screening, a routine colonoscopy will be performed, and the target tissue with suspected inflammation or neoplasia will be biopsied. The clinical investigators use the hyperspectral microscope to collect image information of the biopsy tissue in the endoscopy room. After collecting information, biopsy specimens will be routinely processed and sent for pathological diagnosis.
89091479|NCT00688363|Experimental|1|No blood-glucose self-control, no HbA1c
89091480|NCT00688363|Experimental|2|Blood-glucose self-control, no HbA1c
89091481|NCT00688363|Experimental|3|No blood-glucose self-control, HbA1c
89091482|NCT00688363|Experimental|4|Blood-glucose self-control, HbA1c
89091483|NCT02812654|Experimental|Doxorubicin, Ifosfamide, radiotherapy|Doxorubicin 75mg/m2 (cycle 1,2 and 3), ifosfamide 9 g/m2 (cycle 1 and 3) and radiotherapy: 25 Gy / 5 x 500 cGy/day, beginning at Cycle2/Day1. The surgery will performed after 4-6 weeks from cycle 3. The remain viable cells in surgical specimen will be analyzed and if it accounts less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1.
89091484|NCT00690859||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
89091485|NCT02809066|Experimental|Interventional group|8-week follow- up with dietary sufficient calcium intake
89091486|NCT02809066|No Intervention|Control group|8-week follow- up with no specific diet
89091487|NCT01097694|Active Comparator|Imatinib mesylate|Group on active imatinib treatment
89091488|NCT01097694|Placebo Comparator|Placebo|Group on Placebo treatment
89091489|NCT02808754|No Intervention|Usual Care|Patients in the usual care arm will undergo CEA without RIPC.
89091490|NCT02808754|Experimental|Remote Ischemic Preconditioning|Patients in the RIPC arm will undergo CEA with RIPC.
89091491|NCT00688675||Treated GERD pts|Previously diagnosed GERD patients on treatment in Switzerland
89091492|NCT00688831|Experimental|A|AZD1305 solution for iv infusion
89091493|NCT00688831|Placebo Comparator|B|NaCl solution for iv infusion
89091494|NCT02808832|Experimental|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
89091495|NCT02808832|No Intervention|Usual care|Usual care
89091496|NCT00688987|Active Comparator|1|Subjects with AI will be randomized to each of three doses of hydrocortisone for 4 months on each dose.
89091497|NCT00688987|Active Comparator|2|isocaloric diet
89091498|NCT02808676|Experimental|Exercises+CognitiveTraining+Vitamin D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks."
89091499|NCT02808676|Experimental|Exercises+CognitiveTraining+Placebo D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks."
89226480|NCT04011722|Experimental|Navitor Titan Valve|Navitor Titan Valve (35mm) implantation with the large FlexNav Delivery system and Navitor Loading System - LG+.
89226482|NCT04007523|No Intervention|Usual Care Group|Usual care per surgical ward standards
89226483|NCT04007523|Experimental|HELP Support System|This arm will receive the HELP Support System intervention only
89226484|NCT04007523|Experimental|Family Support System|This arm will receive the Family Support system intervention only
89226485|NCT04007523|Experimental|Combined Support Systems|Participants randomized to this arm will receive both HELP- and family-based support system interventions
89226486|NCT04002401|Experimental|Axicabtagene Ciloleucel and Rituximab Combination|Participants will receive rituximab 375 mg/m^2, once on Day -5 along with conditioning chemotherapy (fludarabine 30 mg/m^2 over 30 minutes and cyclophosphamide 500 mg/m^2 over 60 minutes) once on Days -5 to -3, followed by axicabtagene ciloleucel 2 x 10^6 anti-cluster of differentiate 19 (CD19) chimeric antigen receptor (CAR) T cells/kg once on Day 0 and additional rituximab 375 mg/m^2 of 5 doses, once every 28 days starting from Day 21 up to Day 133.
89226487|NCT04000880|Experimental|Project 1: Diet-Exercise|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
89226488|NCT04000880|Experimental|Project 2: Exercise-Diet|Participants will receive and participate in web-based sessions that focus on diet for 6 months, followed by exercise for another 6 months. Participants will be encouraged to track their diet and weight for the first 6 months and to log their data in the intervention website, during the second 6 months they will be asked to log their physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
89226489|NCT04000880|Experimental|Project 3: Combined Diet and Exercise|Participants will receive the diet and exercise content simultaneously in combined web-based sessions. Participants will receive and participate in web-based sessions that focus on diet and exercise for 12 months. Participants will be encouraged to track their diet, weight and physical activity data (minutes and step counts). Tailored feedback and goal recommendations will be provided through the website. Participants will also receive access to resources for relevant behavioral topics. All participants will be invited to participate in the secret Facebook group for the project (though participation is optional).
89226490|NCT04000724|Experimental|Text+Step|The TechStep Text+Step messaging intervention is a six-month technology-based culturally competent theory-based text messaging intervention that sends three automated text messages to participants daily to reduce HIV risk and increase PrEP uptake and adherence.
89226491|NCT04000724|Experimental|WebApp+Step|The TechStep WebApp+Step website intervention is a six-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV sexual risk reduction and PrEP uptake and adherence.
89226492|NCT04000724|Experimental|Information|The Information/No Step intervention includes nothing more than access to a website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
89226493|NCT03997448|Experimental|Abemaciclib and Pembrolizumab|Abemaciclib 150mg days 1-21, and Pembrolizumab 200mg IV, Day 1
89226494|NCT03993717||Three to six months post-transplant Group|Subjects in this arm will receive the SHINGRIX vaccine three to six months after kidney transplant
89226495|NCT03993717||Twelve to thirty-six months post-transplant Group|Subjects in this arm will receive the SHINGRIX vaccine twelve to thirty-six months after kidney transplant
89226496|NCT03986034|Experimental|Relapsed/Refractory CLL pts|Ages 18 and older
89226497|NCT03964090|Experimental|1|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
89091500|NCT02808676|Experimental|Exercises+Control CogTraining+Vitamin D3|Exercises will combine aerobic+resistance training. Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc.). Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks
89111121|NCT02801565|Experimental|GH AQ|Controlled ovarian stimulation in the middle of the corpus (D21 days) of the previous menstrual cycle to use recombinant Human Growth Hormone Injection（rhGH） Injection 15IU/5mg/3mL/cartridge, 5IU per day, Subcutaneous injection after 20:00 until the HCG trigger day.
89091501|NCT02808676|Experimental|Exercises+Control CogTraining+Placebo D3|Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
89091502|NCT02808676|Placebo Comparator|Placebo exercise+Control Cog+Placebo D3|This will be the comparator arm with control/placebo activities.
89091503|NCT04138459||Qualitative exploration|Ten community mental health service users will be interviewed with their most important mental health worker to explore how recovery orientation of services affects roles and collaboration.
89091504|NCT02878746|Experimental|Robotic mirror therapy|For 30 min per day for two weeks (10 sessions)
89091505|NCT02878746|Active Comparator|Conventional mirror therapy|For 30 min per day for two weeks (10 sessions)
89091506|NCT00683371|Active Comparator|1|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery
89091507|NCT00683371|Placebo Comparator|2|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery.
89091508|NCT04308798|Experimental|Control group|No surgical glove changing during total knee arthroplasty procedure
89091509|NCT04308798|Experimental|Treatment 1 group|Changing surgical glove after draping and before cementation during total knee arthroplasty procedure
89091510|NCT04308798|Experimental|Treatment 2 group|Changing surgical glove before cementation during total knee arthroplasty procedure
89091511|NCT02808520||Hodgkin-lymphoma|Children and adolescents aged 10-18 years
89091512|NCT04138693|Experimental|Cohort 1: 2 x 2.0 g G-PUR® oral suspension|
89091513|NCT04138693|Experimental|Cohort 2: 1 x 2.0 g G-PUR® oral suspension|
89091514|NCT04138693|Placebo Comparator|Cohort 3: Placebo oral suspension|
89091515|NCT02812498|Experimental|Teleconsultation|Teleconsultation for patients affected by type 1 diabetes mellitus
89091516|NCT02812498|Other|Control|Standard visit in outpatient clinic for the same type of patients
89091517|NCT00689065|Experimental|CALAA-01|
89091518|NCT00690937|Experimental|1 ECS|Low dose treatment
89091519|NCT00690937|Experimental|2 ECS|High dose treatment
89091520|NCT00690937|Active Comparator|3 Colesevelam|Active control treatment
89091521|NCT00690937|Placebo Comparator|4 Placebo|Placebo matched to low dose treatment
89091522|NCT00690937|Placebo Comparator|5 Placebo|Placebo matched to high dose treatment
89091523|NCT01102140|Active Comparator|POMx|15 subjects will received 1000 mg of oral POMx for 12 weeks.
89091524|NCT01102140|Placebo Comparator|Control- sugar Pill|15 subjects will receive a matching sugar pill for 12 weeks.
89091525|NCT02690116|Experimental|Qigong/Tai Chi Easy|The Qigong/Tai Chi Easy (QG/TCE) intervention has been standardized, manualized, and has a formal training program for instructors from the Institute of Integral Qigong and Tai Chi (IIQTC).
89091526|NCT02690116|Sham Comparator|Sham Qigong|This active control group uses a gentle movement intervention, with similar types of movements with the same energy expenditure, but without the meditative states and breath focus as QG/TCE (validated in the pilot study using the Meditative Movement Inventory).
89091527|NCT02690116|Active Comparator|Educational Support|The Recovery Support Group will consist of a classroom-style intervention, designed to educate, engage interaction, and maintain participation and attention over 8 weeks. This group will include readings/discussions specific to breast cancer, and social interaction facilitation.
89091528|NCT02812810|Experimental|active rTMS|
89091529|NCT02812810|Placebo Comparator|placebo rTMS|
89226498|NCT03964090|Experimental|2|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib Days 1-10 (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
89091530|NCT02879370|Experimental|TICRANT|Transanal Inspection and management of low ColoRectal Anastomosis
89091531|NCT04139239||Patients with disorders of consciousness|
89091532|NCT02808442|Experimental|UCART19|
89091533|NCT00683527|Experimental|1|Starting oral iron at day 14 of life (Early Iron group)
89091534|NCT00683527|No Intervention|2|No iron supplementation till 60 days of life (Control group)
89091535|NCT02808598|Experimental|Clinical Trials Education Program|Breast Cancer Clinical Trials Education program is offered to women in the experimental arm. This program was designed to promote increased clinical trials literacy among African American and Hispanic American women. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among these two groups of women who are traditionally underrepresented in breast cancer clinical trials.
89111122|NCT02793765|Experimental|Docetaxel & Sipuleucel-T|75 mg/m2 docetaxel IV over 1-hour every 21 days x 6 cycles; 28 day rest then Sipuleucel-T IV over 1-hour every 14 days for 3 doses
89111123|NCT02793609|Other|Outpatient group|After insertion of double balloon induction catheter of labor, women are discharged overnight to home. Intervention is to let patient to go home.
89111124|NCT02793609|Other|Inpatient group|After insertion of double balloon induction catheter of labor, women are observed in the prenatal ward. Intervention is to observe women in the ward.
89091536|NCT02808598|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of African American and Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
89091537|NCT04138225||Healthy|Healthy participants are those without IBS, IBD or any other gastrointestinal disorder
89091538|NCT04138225||Irritable bowel syndrome (IBS)|Participants with Rome IV diagnosed IBS
89091539|NCT04138225||Inflammatory bowel disease (IBD)|Patients with IBD - either ulcerative colitis (UC) or Crohn's disease (CD)
89091540|NCT00634426||1|De novo surgical cohort
89091541|NCT00634426||2|Nonoperative treatment cohort
89091542|NCT00634426||3|Secondary surgical treatment cohort
89091543|NCT00683683|Other|Cooling|Cardiac arrest patients will be cooled to 32-34°C within 6 hours of ED arrival
89091544|NCT00683761|Experimental|1|
89091545|NCT02812732|Other|Intervention|Providers at each clinic will receive the intervention (DOSE HPV) on a rolling basis. Vaccination rates will be compared pre- and post-intervention at each clinic, and changes in rates will be compared across clinics.
89091546|NCT00912457|Experimental|Donepezil|Donepezil-treated sleep apnea patients
89091547|NCT00912457|Placebo Comparator|Placebo|Placebo-treated sleep apnea patients
89226499|NCT03960333||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
89091548|NCT02808286|Experimental|Hybrid|"The hybrid emotion-focused treatment consists of 10-15 individual 1/1,5 hour sessions. It includes the following stages (examples of methods in parathesis)~Stage I. Analysis of emotions and pain (Validation, Compassion, Chain analysis, Values & goals).~Stage II. Developing skills (Dialectics, Self-validation, Self-compassion, emotion regulation skills).~Stage III. Exposure training (Exposure for emotionally sensitive stimuli, exposure in vivo for avoided movements).~Stage IV. Maintenance (Identifying key elements, Planning for flare-ups)."
89091549|NCT02808286|Active Comparator|internet Cognitive Behavior Therapy (iCBT)|CBT pain treatment, delivered via the internet consists of 8, weekly, modules and includes topics such as pain education, pain coping strategies (e.g. pacing), relaxation, cognitive restructuring, problem solving, stress and sleep management, conflict resolution. Patients read materials included in each module and do homework tasks on which they report back to the therapist via the internet. The therapist gives written feedback and guidance after each module. See reference for details.
89226500|NCT03960333||Overweight/Obese|Overweight/Obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
89091550|NCT04139161|Experimental|Q-Factor Intervention|Participants will progress through three increasing Q-Factors for each cycling workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated.
89091551|NCT04139083||TVM group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with TVM
89091552|NCT04139083||LSC mesh suspension group|Women with mainly uterine prolapse stage II or greater as defined by the POP-Q staging system treated with LSC mesh suspension
89091553|NCT04200586|Experimental|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground
89091554|NCT02807974|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
89091555|NCT02807818|Experimental|Nurse home visits|Nurse biweekly home visit.
89091556|NCT02807818|No Intervention|Usual care|Usual care.
89091557|NCT04120168||DMD and Pompe Disease Cohort|The aim of this study gropu was to determine the frequency of Duchenne muscular dystrophin in boys and adolescents with unexplained transaminase elevation for at least 3 months and in late onset Pompe disease in girls and boys and to determine the demographic and clinical characteristics of these patients.
89091558|NCT00874549|Active Comparator|Group 1: Menomune Day 0|Participants received a single dose of Menomune® vaccine on Day 0.
89091559|NCT00874549|Experimental|Group 2: Menactra® Day 0 x 2|Participants received two single-dose injections of Menactra® vaccine on Day 0
89091560|NCT00874549|Experimental|Group 3: Menactra® Day 0 and 14|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14
89091561|NCT00874549|Experimental|Group 4: Menactra® Day 0 and 28|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.
89091562|NCT02807740|Experimental|Virtual Reality|Patients will be treated with a virtual reality rehabilitation program
89091563|NCT02807740|Other|Conventional Rehabilitation Program|Patients will be treated with a conventional rehabilitation program.
89091564|NCT00689377||1|Subjects of either sex, any race, with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus
89091565|NCT02812108||HARET|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
89091566|NCT02807896||pancreatic cancer|pancreatic cancer 88
89091567|NCT02807896||bile duct cancer|bile duct cancer 101
89091568|NCT02807896||stomach cancer|stomach cancer 9
89091569|NCT02807896||colon cancer|colon cancer 5
89091570|NCT02807896||normal group|normal group 29
89091571|NCT04116268||Obesity|BMI >23kg/m2
89091572|NCT04116268||Control|BMI 18-22.9kg/m2
89091573|NCT02812264|Experimental|API App|use of API weight loss mobile application for 12 months, plus fitness tracker and scale.
89091574|NCT02812264|Active Comparator|Attention Control|use of non-API app for weight loss over 12 months, plus fitness tracker and scale.
89091575|NCT02812030||aflibercept in real world|Patients receiving aflibercept for diabetic macular oedema at Bristol Eye Hospital or Gloucestershire Hospitals NHS Foundation Trust
89091576|NCT02625103|Experimental|Clozapine|treatment as usual: administration of clozapine between 9 and 12 pm. Blood sampling 10 -14 hours post drug administration
89091577|NCT02807662|Experimental|Experimental|Intervention mothers receive adapted Seeking Safety intervention delivered by prenatal care advocate over 8 sessions
89091578|NCT02807662|No Intervention|No intervention|Treatment as usual mothers receive usual services of a prenatal care advocate
89091579|NCT01155479|Experimental|Preladenant 2 mg|Preladenant 2 mg oral tablet and placebo for rasagiline taken in the morning (AM) followed by preladenant 2 mg oral tablet taken in the evening (PM) for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
89091580|NCT01155479|Experimental|Preladenant 5 mg|Preladenant 5 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 5 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
89091581|NCT01155479|Experimental|Preladenant 10 mg|Preladenant 10 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 10 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
89091582|NCT01155479|Placebo Comparator|Placebo|Placebo for preladenant and placebo for rasagiline taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).
89091583|NCT01155479|Active Comparator|Rasagiline|Rasagiline 1 mg oral capsule and placebo for preladenant taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
89091584|NCT04138303|Experimental|Exercise Only Group (EX)|Participants will only receive the exercise protocol without nutrition education or counseling and instructed to continue to consume their regular diet.
89091585|NCT04138303|Experimental|Exercise with CR-LC Group|Participants will receive the exercise protocol and CR-LC Diet regimen.
89091586|NCT04138303|Experimental|Exercise with Ancestral Diet (AD) Group|Participants will receive the exercise protocol and AD regimen.
89091587|NCT02807584|Experimental|ELECT|Adhesive Foam Dressing
89091588|NCT04031131|Active Comparator|Intervention Arm|topical anaesthetic gel and lubricating gel
89091589|NCT04031131|Placebo Comparator|Control Arm|lubricating gel alone
89091590|NCT04186858||Symptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Symptomatic group where cell samples will be collected from the front surface of the subject's eyes.
89091591|NCT04186858||Asymptomatic|Based on the score of the questionnaire, eligible subjects will be placed in the Asymptomatic group where cell samples will be collected from the front surface of the subject's eyes.
89091592|NCT00683839|Experimental|2|"Dental practitioners provide the following intervention:~5As plus nicotine replacement therapy The 5As consist of: Ask, Advise, Assess, Assist and Arrange."
89091593|NCT00683839|No Intervention|1|Usual Care Control: Patients receive treatment as usual.
89091594|NCT02807272|Experimental|Tipifarnib, Oral|Single arm
89091595|NCT02811796||angio-based FFR estimation|The investigators will include all patients receiving successful coronary stent implantation. In these patients the investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
89091596|NCT04138771|Experimental|Eligible patients for AI test|Device: an artificial intelligence system for postoperative management of cataract patients. These patients are enrolled in primary healthcare units and the AI clinic at Zhongshan Ophthalmic Center.
89091597|NCT01155323|Active Comparator|etafilcon A/omafilcon A|etafilcon A contact lenses will be worn during the first week and omafilcon A contact lenses will be worn during the second. Lenses were replaced daily
89091598|NCT01155323|Active Comparator|omafilcon A/etafilcon A|omafilcon A contact lenses will be worn during the first week and etafilcon A contact lenses will be worn during the second. Lenses were replaced daily.
89091599|NCT02807194|Experimental|general anesthesia|'lumbar disc herniation'
89091600|NCT02807194|Experimental|spinal anesthesia|'lumbar disc herniation'
89091601|NCT00912535|Active Comparator|Quetiapine extended release tablet|Quetiapine orally at a flexible dose fo 50-300mg/day according to the judgment by the investigator for 8 weeks, as adjunct to the same antidepressant at the same dose.
89091602|NCT00912535|Placebo Comparator|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
89091603|NCT02811718|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
89091604|NCT02811718|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
89091605|NCT04313777|Experimental|VR therapy group|Cardiac rehabilitation supplemented by VR therapy
89091606|NCT04313777|Active Comparator|Control Group|Cardiac rehabilitation supplemented by Schultz Autogenic Training
89091607|NCT00689455||1|Primary care population
89091608|NCT02811874|Experimental|diabetes education|Four community health workers receive a one-month diabetes education program (intervention group, patients n= 62)
89091609|NCT02811874|Active Comparator|education in other areas|Four community health workers receive an education course in other health issues (control group, patients n= 56).
89091610|NCT02625727|Experimental|hyaluronic acid group|hyaluronic acid injection
89091611|NCT02625727|Active Comparator|hyaluronic acid and corticosteroid group|hyaluronic acid combined corticosteroid injection
89091612|NCT02884739||schizophrenia|
89091613|NCT02884739||chronic psychiatric disorder other than schizophrenia|
89091614|NCT00691171||1|GERD: Patients with established diagnoses of GERD based on ICD-9 codes
89091615|NCT00691171||2|Atypical GERD: Patients without an established diagnosis of GERD with atypical symptoms that could be due to GERD (e.g., asthma)
89091616|NCT00691171||3|Chronic NSAID users: Patients using chronic NSAIDs who are at increased risk of GI complications (defined as previous diagnosis of peptic ulcer disease; age 75 or older; or concomitant use of corticosteroids, anticoagulants, or aspirin)
89091617|NCT01155167|Placebo Comparator|Placebo|
89091618|NCT01155167|Experimental|Topical dilator|
89091619|NCT02807038|Experimental|Lung function test|Pregnant women performed one spirometry at each trimester of pregnancy
89091620|NCT04141111|Experimental|CGM intervention|Underwent intervention defined by the intermittent use of a continuous glucose monitoring (CGM) device.
89091621|NCT02811406|Experimental|Receives IV albumin infusion|IV albumin 20% 50 mL for every 1L of ascitic fluid drained
89091622|NCT02811406|Placebo Comparator|Do not receive IV albumin infusion|No IV albumin infusion
89091623|NCT00691249|Experimental|1|Resistant starch type 4-Raw
89091624|NCT00691249|Experimental|2|Resistant starch type 4-Raw
89091625|NCT00691249|Experimental|3|Resistant starch type 4-Cooked
89091626|NCT00691249|Experimental|4|Resistant starch type 4-Cooked
89091627|NCT00691249|Placebo Comparator|5|Shredded wheat
89523154|NCT03380663|Active Comparator|BFRE - HF|Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
89523155|NCT03380663|Active Comparator|TRT - Healthy|Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
89091630|NCT01106586|Experimental|Stribild|
89091631|NCT01106586|Active Comparator|ATV/r + FTC/TDF|
89091632|NCT02884583|Experimental|Pulmonary function test|Patients hospitalized for Oral Food Challenge realize pulmonary function test
89091633|NCT00683995|Experimental|1|KW-2246 (fentanyl citrate)
89091634|NCT02884817|Experimental|Listerine prof.gum.ther|"The test solution was the commercially available mouthwash product EOELA that contains essential oils and ELA in 21.6% alcohol (Listerine Professional Gum Therapy®, Johnson & Johnson,USA).~Intervention; Rinsing 30 sec with test solution twice daily for 21 days"
89091635|NCT02884817|Placebo Comparator|21.6% hydroalcoholic|"a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%.~Intervention: Rinsing 30 sec with placebo comparator twice daily for 21 days"
89091636|NCT02884817|Sham Comparator|Plain sterile water|"Plain sterile water.~Intervention: Rinsing 30 sec with sham comparator twice daily for 21 days"
89091637|NCT02806804|Experimental|one dose test vaccine|One dose of quadrivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
89091638|NCT02806804|Experimental|one dose commercially available trivalent influenza vaccine|One dose of trivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
89091639|NCT02806804|Experimental|One dose quadrivalent influenza virus vaccine|One dose of quadrivalent influenza virus vaccine (trivalent influenza virus vaccine added to a new influenza B component) will be randomly given in aged 3-60 years old.
89091640|NCT04138537|Other|Acromegaly group|CCCRC test and OB volume results
89091641|NCT04138537|Other|Control Group|CCCRC test and OB volume results
89091642|NCT02811562|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in manikin using fiberoptic bronchoscope
89523156|NCT03380663|No Intervention|Control - Healthy|No intervention.
89523157|NCT03380663|No Intervention|Control - HF|No intervention.
89091643|NCT02811562|Experimental|fiberoptic bronchoscope with pentax-airwayscope|Tracheal intubation in manikin using fiberoptic bronchoscope with pentax-airwayscope
89091644|NCT04137991|Experimental|Nol-Guided Analgesia Group|In the Nol-Guided Analgesia Group remifentanil effect site concentration will be adapted to maintain the NOL-index between 10 and 25 throughout the anesthetic.
89091645|NCT04137991|Active Comparator|Standard Analgesia Group|Remifentanil titration in the Standard Analgesia Group will be left at the anesthesiologists discretion (i.e., guided by heart rate, blood pressure, and experience).
89091646|NCT04031365|Experimental|Acupuncture and Cognitive Behavioral Therapy|Participants will receive four sessions of a brief acupuncture therapy in addition to a brief cognitive behavioral therapy.
89091647|NCT04031365|Active Comparator|Cognitive Behavioral Therapy|Participants in this group will receive a brief cognitive behavioral therapy in addition to four telephone follow-ups.
89091648|NCT01155011|Experimental|MIPARC intervention|"Eleven Continuing Care Retirement Communities were randomized to either the MIPARC intervention or an attention-control condition. The intervention focused on increasing light to moderate PA.~The MIPARC study intervenes on four levels: individual (pedometer self monitoring, educational materials and monthly counseling calls, support), interpersonal (monthly group educational sessions and peer mentoring), environment (walking signage prompts, tailored environmental resources, step counts)and policies (review of on-site activity opportunities and walkability, recommendations for policy change and peer led advocacy)to increase the activity levels of residents.~For the first 3 months, intervention participants will engage in either a group educational session, phone counseling call, or a peer led session, on a rotating basis."
89091649|NCT01155011|Active Comparator|Health Education Control|The control group received an active health education intervention. The education curriculum will involve both lectures and mailed materials. The lectures were delivered to match the MIPARC intervention schedule. Sessions included information on general health and healthy aging. Physical activity was not discussed in these sessions but participants received information on the benefits of PA. Control participants also received health check phone calls to match the individual attention paid to participants in the MIPARC intervention sites.
89091650|NCT00689689|Active Comparator|Fully Coated Prodigy Stem (AML)|Total hip arthroplasty with fully coated prodigy stem (AML)
89091651|NCT00689689|Active Comparator|Cemented Endurance Hip Stem|Total hip arthroplasty with cemented Endurance hip stem component
89091652|NCT00689767|Experimental|A|This arm will receive the coated stent
89091653|NCT00689767|Active Comparator|B|This arm will receive a bare metal stent
89091654|NCT04313465|No Intervention|Control (Routine Care)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a cardiac troponin blood test upon admission to the Emergency Department. Participants will then have a repeat cardiac troponin blood test in 3 hours.
89091655|NCT04313465|Experimental|Intervention (Immediate Discharge)|Participants will undergo risk stratification using the T-MACS decision aid, which includes a troponin blood test upon admission to the Emergency Department. Participants will then be discharged.
89091656|NCT02806648|Experimental|Palbociclib|Palbociclib
89091657|NCT02878434||Study group|
89091658|NCT02878434||control group|
89091659|NCT04138147|Active Comparator|Superficial cervical plexus with auriculotemporal nerve blocks|
89091660|NCT04138147|Experimental|Cervical retrolaminar with auriculotemporal nerve blocks|
89091661|NCT04071808||Coronary angiography group|In diabetic patients without symptoms of myocardial ischemia, coronary angiography showed no stenosis or stenosis less than 75%.
88812569|NCT02764762|Experimental|Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)|In Triple Combination Therapy Phase, vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2, 6, 14 and 22, with adalimumab 160 mg subcutaneously (SC), once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34. In Monotherapy Phase, vedolizumab 300 mg IV infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.
89091662|NCT04071808||Coronary angiographic stent implantation group|Coronary angiographic stenosis was more than 75% in diabetic patients without myocardial ischemia symptoms, and coronary stents were implanted.
89091663|NCT04307784|Experimental|Vitamin D3 alone Group|Treated with VD3 (50.000 IU/week)
89091664|NCT04307784|Experimental|Omaga-3 alone Group|Treated with (1000 mg) wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
89091665|NCT04307784|Experimental|Vitamin D3 and Omega-3 Combination, Group|Treated with 50.000 IU VD3 per week and 1000 mg wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.
89091666|NCT04307784|Experimental|Control Group|No intervention was given.
89091667|NCT00689845|Experimental|Cohort 1|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1. Patients also receive oral prednisolone on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89091668|NCT00689845|Experimental|Cohort 2|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, oral prednisolone on days 1-5, and filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
89091669|NCT00689845|Experimental|Cohort 3|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV and doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; methotrexate IV on days 8, 36, and 64; vincristine IV on days 8, 22, 36, 50 ,64, and 78; bleomycin IV on days 22, 50, and 78; and oral prednisolone on days 1-84, followed by a taper.
89091670|NCT00689845|Experimental|Cohort 4|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV on days 1, 29, and 57; doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; etoposide phosphate IV on days 15, 16, 43, 44, 71, and 72; vincristine IV and bleomycin IV on days 8, 22, 36, 50, 64, and 78; and oral prednisolone on days 1-84, followed by a taper.
89226501|NCT03960333||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance who have been recently prescribed Metformin and have a Body Mass Index (BMI) ≥ 85th percentile for age/sex (n=20) will be recruited. Participants in this cohort will be asked to complete a two study visits approximately 6 months apart.
89226502|NCT03950414|Experimental|Tier 1|3 participants enrolled at dose level 5x10^3 cells/kg of CMV viral specific T-cells
89226503|NCT03946839||ICU Survivors|sepsis/septic shock Patients with high risk of cognitive impairment who discharge from ICU
89091671|NCT00689845|Experimental|Cohort 5|Patients receive rituximab IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1; vindesine IV and bleomycin IV on days 1 and 5; oral prednisone on days 1-5; methotrexate intrathecally on day 2; and G-CSF SC on days 6-13 for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of 4 courses of R-ACVBP, patients receive consolidation therapy comprising high-dose methotrexate IV, rituximab IV, ifosfamide IV, etoposide phosphate IV, and cytarabine SC according to protocol GELA LNH03-2B.
89091672|NCT00624767|Experimental|1|Insulin Nasal Spray
89091673|NCT00624767|Active Comparator|2|NovoLog
89091674|NCT04200820|Experimental|Trampoline|The participants will jump on a mini-trampoline for 30 seconds and then will have a 30 seconds break. This will be repeated 16 times. This resulted in a cumulative total intervention time of 8 minutes.
89091675|NCT04205981|Experimental|Aerobic exercise|Exercise intervention. The experimental group increased their energy expenditure according to American College of Sports Medicine and WHO-based physical activity recommendations for all adults to promote clinically significant weight loss and for additional health benefits: 300 min of moderate-intensity aerobic training throughout the week (WHO, 2010; Swift et al. 2014). Participants underwent five 60 min moderate-intensity cycling sessions per week for a period of 8 weeks, 40 sessions in total. Each session involved 5 min of warm up at 40 Watts, cycling for 50 min at a speed that increased their HR to a target HR obtained at 50-60% of peak VO2, and a 5 min of cool down at 40 Watts.
89091676|NCT04205981|No Intervention|Control|. In the control group, participants did not undergo any intervention and were instructed to maintain their regular physical activity and diet regime for 8 weeks.
89091677|NCT02806492|Experimental|Patient for cardiac surgery|All patient undergo the 5 different intervention in a randomised matter.
89091678|NCT02884895|Experimental|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
89091679|NCT02884895|Active Comparator|Direct Laryngoscopy|Direct Laryngoscopy
89091680|NCT02806258|Active Comparator|Arm A|6-8 cycles of Primary systemic therapy using anthracycline and/or taxane based regimens, according to their physician's preference and center policy
89091681|NCT02806258|Experimental|Arm B|The patients will receive 3D conformal or other modality (eg IMRT, VMAT) APBI during their PST sequence. APBI will be planned sequentially between the Primary systemic therapy cycles, 2 weeks after the 3rd/6 or the 4th/8 cycle of PST.
89091682|NCT00691405|Experimental|A1|Arformoterol 5 mcg BID for 14 days
89091683|NCT00691405|Experimental|A2|Arformoterol 15 mcg BID for 14 days
89091684|NCT00691405|Experimental|A3|Arformoterol 25 mcg BID for 14 days
89091685|NCT00691405|Placebo Comparator|A4|Placebo inhalation solution BID for 14 days
89091686|NCT00691405|Experimental|B1|Arformoterol 15 mcg QD for 14 days
89091687|NCT00691405|Experimental|B2|Arformoterol 25 mcg QD for 14 days
89091688|NCT00691405|Experimental|B3|Arformoterol 50 mcg QD for 14 days
89091689|NCT00691405|Placebo Comparator|B4|Placebo inhalation solution QD for 14 days
89091690|NCT01106430|Experimental|Lisdexamfetamine Dimesylate|
89091691|NCT01106430|Active Comparator|Atomoxetine Hydrochloride|
89091692|NCT02804698|Experimental|Meta Salud Diabetes-Intervention|"Attend the thirteen weekly educational classes and physical activity group (prior physician approval) that are part of the Meta Salud Diabetes program.~Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.~Respond to a survey about your nutrition and physical activity habits on three separate occasions (at the start of the 13-week program, just after you finish the program, and nine months after you finish the program).~You may also be invited to participate in a follow-up interview, where you will be asked about your experience during and after the Meta Salud Diabetes program."
89091693|NCT02804698|No Intervention|Meta Salud Diabetes-Comparison Group|"Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.~Respond to a survey about your nutrition and physical activity habits on three separate occasions (you will answer the first survey as soon as you finish reading and agree to participate by signing this form, the second survey will be three months from now, and the third survey will be 12 months from now)."
89091694|NCT01154231||Nonacog Alfa (Genetical Recombination)|
88812570|NCT02666547|Other|68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs|Active Comparator: 68Ga-NODAGA-RGD radiotracer All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT or a 18F-FET PET/CT
89091695|NCT02806180|Experimental|Single-Operator|For the 'Single Operator Ultrasound Guided IV placement' arm the RN operator will use the ultrasound probe to identify the target vein, and continue to hold and adjust the probe while placing the IV.
89091696|NCT02806180|Experimental|Dual-Operator|For the 'Dual Operator Ultrasound Guided IV placement' arm the RN operator will use the US to identify the target vein, at which time the study coordinator will hold the ultrasound probe in position. The RN operator will then place the IV.
89091697|NCT00684151||1|Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at least 3 months
89091698|NCT02804776|Experimental|Gefitinib|Gefitinib 250mg oral daily will be given for 4 weeks prior to surgery
89091699|NCT01154153|Placebo Comparator|Placebo|"placebo during the screening phase and~placebo during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
89091700|NCT01154153|Experimental|TAA-AQ|"placebo during the screening phase and~TAA-AQ (Nasacort AQ) during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
89091701|NCT02806102||High-risk|"Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors:~Age ≥ 65 years~Diabetes mellitus requiring medication~Documented history of a second prior presumed spontaneous MI (>1 year ago)~Documented history of angiographic evidence of multivessel coronary artery disease~Chronic, non-end stage renal dysfunction"
89091702|NCT02806102||Low-risk|Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors
89091703|NCT00691561|Experimental|1|Participants receive HIV counseling and testing and 8 intervention sessions to assist them with reducing unsafe sexual behaviors.
89091704|NCT00691561|No Intervention|2|Participants receive HIV counseling and testing only.
89091705|NCT00684229|Active Comparator|Regional anesthesia and analgesia|Regional anesthesia and analgesia (either epidural or paravertebral anesthesia).
89091706|NCT00684229|Active Comparator|general anesthesia followed by opioid analgesia|Subjects randomized to arm 2 will receive general anesthesia followed by opioid analgesia.
89091707|NCT02887001|Other|BMO|
89091708|NCT04236622||Health|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
89091709|NCT04236622||Peri-implantitis|For each patient we evaluated the Probing Depth (PD), measured in mm, and the following dichotomous variables: plaque index (absent or present), gingival index (absent or present), occurrence of annual maintenance (absent or present), tooth position (anterior or posterior) and the patient's smoking habit (absent or present).
89091710|NCT00690001||1|HIV-1 infected patients in Taiwan
89091711|NCT04313387||Control group - Normal eyes (CG)|"• Control group - Normal eyes (CG): 351 eyes without KC of 351 patients who underwent LASIK or photorefractive keratectomy (PRK), stable after at least 18 months of follow-up, without any changes in the posterior elevation at the 18-month Pentacam in relation to the preoperative exam (surgeries performed in 2012-2018). Our objective topographic criteria were: both eyes with a KISA% index of less than 60%, Kmax of 47.2 D or less, and I-S difference of less than 1.45 D. Because no truly established tomographic parameter(s)/cut-off(s) for differentiating normal from keratoconus suspect eyes exist, we adapted our classification for normal eyes to the recent publication by Ambrósio et al. by adding the criterion of overall subjective normal topography and tomography examinations based on the evaluation of experienced refractive surgeon (GCAJ). Only one eye was randomly selected for further statistical analysis."
89091712|NCT04313387||Very assimetric ectasia with normal topography|• Very assimetric ectasia with normal topography group (VAE-NT G): 88 eyes of 88 patients with very asymmetric ectasia with normal topography (VAE-NT) in one eye and frank ectasia (VAE-E) in the fellow eye. The inclusion criteria followed previous studies (28, 32, 33) Eyes in this group with insufficient topographic findings to meet diagnostic criteria for keratoconus, and following features normal-appearing cornea on slit-lamp biomicroscopy, keratometry, retinoscopy. These cases were the less affected eye (fellow eye) of a keratoconic patient was included if the following criteria were met: KISA% index of less than 60%, I-S difference of less than 1.45 D, and Kmax of 47.2 D or less (ie, same topographic criteria as in normal eyes, except than in normal eyes, both eyes of the patient met the criteria). These patients can be considered with corneas highly susceptible to ectasia.
89091713|NCT04313387||Keratoconus group (KCG)|• Keratoconus group (KCG): 148 patients (one eye each) with bilateral clinical KC. The KCG included one eye randomly selected from 148 patients with keratoconus; one eye was randomly included per patient to avoid selection bias related to the use of both eyes from the same patient. The inclusion criteria were the same as for VAE-E, except that both eyes of the patient met the ectasia criteria.
89091714|NCT02804620|Experimental|PLEASED|The PLEASED intervention arm will receive peer leader who is patients with diabetes that has been gone through our trainings. Also, they will receive three free health screenings (baseline, 3 months, 12 months) and monetary compensation for their time and effort.
89091715|NCT02804620|No Intervention|Wait List|The wait list will receive three free health screening (at baseline, 3months, 12 months) and monetary compensation for their time and effort.
89091716|NCT00690079|Experimental|AZD1386|7 groups receiving a specified volume of the active component AZD1386 at different points of time.
89091717|NCT00690079|Placebo Comparator|Placebo|7 groups receiving a specified volume of placebo at different points of time
89091719|NCT02805712|Active Comparator|Control|Participant will receive usual care for Heart Failure patients, which include standard written material on Advanced Care planning and supportive cardiology/palliative care consult if ordered by attending.
89091720|NCT02805712|Experimental|Verbal Information and Discussion|Participants will participate in a guided goals of care conversation and the support of a Palliative Care Social Worker who is working closely with the patients' primary cardiology team. Social worker has ongoing clinical review of participants with a Palliative Care physician who will provide a full medical consult if appropriate.
89091721|NCT00874237|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
89091722|NCT00874237|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
89091723|NCT00874237|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
89091724|NCT00874237|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
89091725|NCT00874237|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
89091726|NCT00874237|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
89091727|NCT02805946|Other|intravenous followed by oral|"Start with posaconazole IV 300mg BID on the first day. Posaconazole will be infused over a period of 90 minutes.~Days 2-7 patients will receive posaconazole IV 300mg QD.~Days 8-12 patients will receive posaconazole PO 300mg QD.~Days 13-16 patients will receive posaconazole PO 200mg QD.~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
89091728|NCT02805946|Other|oral followed by intravenous|"Start with posaconazole PO 300mg BID on the first day.~Days 2-7: patients will receive posaconazole PO 300mg QD.~Days 8-12: patients will receive posaconazole IV 300mg QD. Posaconazole will be infused over a period of 90 minutes.~Days 13-16 patients will receive posaconazole IV 200mg QD.~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
89091729|NCT05544604|Active Comparator|group 1: active primary motor cortex stimulation|active tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the pain for 20 minute duration for five sessions in five consecutive days (one session /day)
89091730|NCT05544604|Sham Comparator|group 2 : sham primary motor cortex stimulation|sham tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds.
89091731|NCT05544604|Active Comparator|group 3 : active insula stimulation|active tDCS (2 mA) targeting the insula of the contralateral side of the pain for 20 minute duration for five sessions in five consecutive days (one session /day)
89091732|NCT05544604|Sham Comparator|group 4 : sham insula stimulation|sham tDCS over the insula in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds.
89091733|NCT04139005|Experimental|Awareness-Connection|
89091734|NCT04139005|Experimental|Awareness-Insight|
89091735|NCT04139005|No Intervention|Wait list|
89091736|NCT01153841|Experimental|Synflorix Group|Subjects receiving Synflorix™(GSK 1024850A) co-administered along with Infanrix hexa™.
89091737|NCT01153841|Active Comparator|Control Group|Subjects receiving Infanrix hexa™ vaccine alone.
89091738|NCT02804386|Experimental|treatment|Sofosbuvir, 400 mg OD for 6 months
89226504|NCT03946839||Healthy Control|The control group have to be medically and cognitively healthy. These individuals are recruited from the community and all attempts will be made to match them on age,sex and education to individuals recruited for groups of ICU Survivors.
89091739|NCT02805868|Experimental|Treatment (siltuximab)|Patients receive siltuximab IV over 60 minutes on day 1. Patients also undergo bone marrow biopsy and aspiration at baseline and at the end of treatment (within 30 days of last siltuximab dose) or as clinically indicated. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are responding after 6 courses may receive additional siltuximab treatment for up to 1 year at the discretion of the study doctor.
89091740|NCT00691639||1|Patients who are or were participants in any Alcon AL-3789 study.
89091741|NCT02805634|Experimental|Multiple sclerosis|Patients with multiple sclerosis, followed by Dr Dachy within the CHU Brugmann Hospital.
89091742|NCT02805634|Other|Control group|Control group without neurological pathology
89091743|NCT02690038|Experimental|Intervention Arm 1: Treatment|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
89091744|NCT02690038|Active Comparator|Intervention Arm 2: Control|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
89091745|NCT00691795|Experimental|CLONIDINE|Participants randomized to this arm of the study receive 75 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
89091746|NCT00691795|Experimental|FENTANYL|Participants randomized to this arm of the study receive 75 micrograms fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
89091747|NCT04136821|Placebo Comparator|Placebo|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
89091748|NCT04136821|Experimental|Oceanix™|Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
89091749|NCT02805556|Experimental|Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529|Single oral dose of BMS-663068 followed by Single intravenous dose of [13C]BMS 626529
89091750|NCT00694291|Experimental|1|Sorafenib 400 mg orally twice daily
89091751|NCT00694291|Placebo Comparator|2|Placebo
89091752|NCT04100902|Active Comparator|Odactra 12-sq HDM sublingual tablet|House Dust Mite, sublingual tablet
89091753|NCT04100902|Placebo Comparator|Placebo sublingual tablet|Placebo, sublingual tablet
89091754|NCT01153763|Other|All patients|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
89091755|NCT00691873|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
89091756|NCT00691873|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
89091757|NCT02805322|Experimental|Temporal Temperature Measurement|Infrared Temporal Temperature Measurement using the ARC InstaTemp MD in three different age groups with a specified percentage reporting as febrile.
89091758|NCT02805322|Active Comparator|Tympanic and/or Sublingual Temperature|"Tympanic and/or Sublingual Temperature Measurement using one or both of two widely used reference clinical thermometers in three different age groups with a specified percentage reporting as febrile.~Choice between Tympanic and/or Sublingual is determined based on standard of care in study site~Reference Thermometer 1 - Covidien Genius 2 Tympanic Thermometer~Reference Thermometer 2 - Welch Allen SureTemp Plus Sublingual Thermometer"
89091759|NCT05538052|Active Comparator|2% lidocaine|The first group will receive intraligamentary injections of 2% lidocaine with 1: 80 000 epinephrine. The injections will be administered using a pressure-type syringe (Osung Deosy, Pearland, Tx, USA) and 30 gauge short needles (Septojet needles, Septodont).
89091760|NCT05538052|Experimental|2% lidocaine plus tramadol hydrochloride|The second group will receive intraligamentary injections of 2% lidocaine with 1:80 000 epinephrine plus tramadol hydrochloride (50 mg, 1:1 v/v ratio). The injections will be administered using a pressure-type syringe (Osung Deosy, Pearland, Tx, USA) and 30 gauge short needles (Septojet needles, Septodont).
89091761|NCT05538052|Experimental|tramadol hydrochloride|The second group will receive intraligamentary injections of tramadol hydrochloride (25mg/ mL). The injections will be administered using a pressure-type syringe (Osung Deosy, Pearland, Tx, USA) and 30 gauge short needles (Septojet needles, Septodont).
89091762|NCT05298475|Experimental|Statin-only group|The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn).
89091763|NCT05298475|Experimental|Low-dose PCSK9 inhibitor group|The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn) and 1 injection of PCSK9 inhibitor once a month SC.
89091764|NCT05298475|Experimental|Normal-dose PCSK9 inhibitor group|The patients in this group are treated with medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn) and 1 injection of PCSK9 inhibitor twice a month SC.
89091765|NCT02884505||Patients with Hypersomnolence|Patients referred for polysomnography and multiple sleep latency test
89226505|NCT03941093|Experimental|Arm A|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
89226506|NCT03941093|Placebo Comparator|Arm B|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
89091766|NCT02805400|Other|Neurocognitive performance|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
89091767|NCT05355233|Experimental|bebo concept|it is a technique to deal urinary incontinence
89091768|NCT05355233|Experimental|diaphragmatic breathing|breathing technique to strengthen core muscles
89091769|NCT02805166|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
89091770|NCT02621671|Experimental|Arm 1: Cognitive Interviews|"Participants will complete several survey items, view 1 of 8 disease risk pictures (selected at random), and then complete further survey questions.~Participants will then be recorded giving their opinions on the remaining 7 disease risk pictures which depict the hypothetical risk of disease.~The entire visit will take no more than 90 minutes with no follow-up.~The first 10-20 participants will be randomized to this arm."
89091771|NCT02621671|Experimental|Arm 2: Experimental survey|"Participants will be randomly assigned by GfK's computer to one of the 12 experimental conditions.~After completing questions about information seeking and physical activity, the participants will read a short scenario that describes the purpose of a risk assessment tool and ask them to imagine that they had just entered their information into such a tool.~Participants will see whichever risk ladder corresponds to the experimental condition to which they were assigned.~The hypothetical display will be consistent with a display generated for an individual whose risk profile includes risk increasing and decreasing factors, but does not engage in the recommended amount of physical activity."
89091772|NCT04316351|Experimental|Toripalimab + Pemetrexed + Anlotinib|
89091773|NCT02805244|Experimental|JTZ-951, 14C-JTZ-951|Single oral administration on Day 1; 10 mg JTZ-951, 100 μCi of 14C-JTZ-951
89091774|NCT00694447|Experimental|Real acupuncture|Real acupuncture
89091775|NCT00694447|Sham Comparator|Sham acupuncture|Sham acupuncture
89091776|NCT02884349|Experimental|RoM assessment|All patients recruited to the study.
89091777|NCT02625337|Active Comparator|Pembrolizumab mono|Pembrolizumab monotherapy
89091778|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib short|Pembrolizumab combined with a short scheme of dabrafenib+trametinib
89091779|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib intermediate|Pembrolizumab combined with an intermediate scheme of dabrafenib+trametinib
89091780|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib long|Pembrolizumab combined with a long scheme of dabrafenib+trametinib
89091781|NCT04236310|Experimental|SHR6390+Anastrozole+Pyrotinib+Trastuzumab±Ovarian Suppression|
89091782|NCT00694525||1|Women in this group will have 21-OHD CAH.
89091783|NCT00694525||2|Women in this group will be healthy controls and will not have 21-OHD CAH.
89091784|NCT04134949|Experimental|CBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
89091785|NCT04134949|Experimental|MCBT|consists of eight weekly treatment sessions of 45 to 60 minutes.
89091786|NCT02804308|No Intervention|Group Control with breast cancer and without breast cancer|Stretching exercises, lasting 40 minutes each session, 2 times a week for nine months
89091787|NCT02804308|Experimental|Combined Training with breast cancer and without breast cancer|Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training.
89091788|NCT02805088|Experimental|Bipolar Disorder patients|
89091789|NCT02805088|Experimental|Schizophrenia patients|
89091790|NCT02805088|Experimental|Healthy Volunteers|
89091791|NCT02621515|Experimental|Nivolumab|All patients in this trial will receive treatment with nivolumab for 24 months. Treatment will be discontinued if confirmed disease progression has been demonstrated, if unacceptable toxicity or intercurrent illness prevents further treatment, and when informed consent is withdrawn. After discontinuation of treatment, follow-up will start. Duration of follow-up depends on survival of patients, with a maximum of 24 months. Therefore the end of this study is determined as 24 months after the last patient in this trial has started follow-up, has died, withdraws consent or is lost to follow-up for a different reason
89091792|NCT00912613|No Intervention|Discussion with nurse|Brief discussion with ICU follow-up nurse about the patients' critical illness
89091793|NCT00912613|Experimental|ICU Diary|Receipt of ICU Diary at 1 month post critical illness
89091794|NCT02803918|Experimental|Lixisenatide|Administration of 3 ascending repeated doses of lixisenatide once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
89091795|NCT02803918|Placebo Comparator|Placebo|Administration of 3 ascending repeated doses of matching placebo once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
89091796|NCT04138069|Experimental|PLB+Aerobic Bicycling|Pursed Lip Breathing + Aerobic Bicycling
89091797|NCT04138069|Active Comparator|Aerobic Bicycling|Only Aerobic bicycling
89091798|NCT04022356|Experimental|Connected soles|Number of steps recorded by the soles (activation per smartphone)
89091799|NCT04022356|Active Comparator|Gold Standard|Number of steps counted by two observers viewing the film
89091800|NCT02621593|Experimental|Treatment of dry eye secondary to MGD|Intervention: Treatment of dry eye symptoms secondary to MGD with the M22-IPL system
89091801|NCT04236466|Experimental|hyrax group|cleft lip and palate patients with hyrax appliance
89091802|NCT04236466|Experimental|haas group|cleft lip and palate patients with haas appliance
89091803|NCT00692107|Active Comparator|1|68 Gy
89091804|NCT00692107|Experimental|2|78 Gy
89091805|NCT02805010|Experimental|Subcutaneous(SC) Abatacept|
89091806|NCT02805010|Placebo Comparator|Placebo|
89091807|NCT02621437|Experimental|Intervention group (osteopathy)|Patients will have three sessions of osteopathy and 6 phone questionnaires.
89091808|NCT02621437|Other|control group|Patients will have 6 phone questionnaires.
89091809|NCT02621281|Active Comparator|cold storage|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
89091810|NCT02621281|Active Comparator|Kidney Transporter machines|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
89091811|NCT02803996|Active Comparator|Part A- Single Dose- 400 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
89091812|NCT02803996|Active Comparator|Part A- Single Dose- 600 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
89091813|NCT02803996|Placebo Comparator|Part A-Single Dose-Placebo|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
89091814|NCT02803996|Active Comparator|Part B-Multiple Dose-400 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
89091815|NCT02803996|Active Comparator|Part B-Multiple Dose-600 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
89091816|NCT02803996|Placebo Comparator|Part B-Multiple Dose-Placebo|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
89091817|NCT04136431|Experimental|Intervention group|
89091818|NCT04136431|Placebo Comparator|Control group|
89091819|NCT02800954|Experimental|multiple myeloma group|case group = patients with multiple myeloma
89091820|NCT02800954|Experimental|MGUS group|monoclonal gammopathy of undetermined significance
89091821|NCT02800954|Other|healthy control group|control group = healthy subjects
89091822|NCT02800564|Experimental|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months plus interactive voice response systems (IVRS) and monthly open community meetings.
89091823|NCT02800564|Experimental|Passive mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months
89091824|NCT04236232||Patients who will be diagnosed as Subclinical Hypothyroidism|50 pt who will be diagnosed as Subclinical Hypothyroidism by elevated level of TSH (TSH: >4.5 mu/l) and normal T4
89091825|NCT04236232||Patients with normal thyroid function|50 pt with normal thyroid function (TSH &T4)
89091826|NCT02803762|Experimental|Investigational: [14C] Pacritinib|All enrolled subjects are checked in the day before drug administration. Following at least a 10-hour fast (not including water), each subject will receive an oral dose of 400 mg [14C]pacritinib (containing 100 μCi radioactivity).
89091827|NCT00871741|Experimental|GSK2202083A GROUP|Subjects in this group were to receive three doses of GSK2202083A vaccine at 3, 5 and 11 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
89091828|NCT00871741|Active Comparator|INFANRIX + MENJUGATE GROUP|Subjects in this group were to receive three doses of Infanrix™ hexa vaccine at 3, 5 and 11 months of age, and two doses of Menjugate® vaccine at 3 and 5 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
89226507|NCT03925038|Active Comparator|Treatment as Usual|Participants will receive psychotherapy (treatment as usual).
89091829|NCT02800408|Experimental|Whole grain high-BCX maize|Whole grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
89091830|NCT02800408|Experimental|Refined grain high-BCX maize|Refined (degermed) grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
89091831|NCT02800408|Placebo Comparator|Whole grain white maize|Whole grain, white maize (low in beta-cryptoxanthin) will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
89091832|NCT02800720|Experimental|Meditation Awareness Training|"Target Intervention Arm:~8-week meditation intervention"
89091833|NCT02800720|Active Comparator|Cognitive Behavioural Therapy for Groups|"Active Comparator Arm:~8-week CBT-based intervention"
89091834|NCT02625025|Experimental|Low pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Low Pression Pneumoperitoneum (8 mm Hg)
89091835|NCT02625025|Experimental|Standard pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Standard Pression Pneumoperitoneum (12 mm Hg)
89091836|NCT00692263|Experimental|A|Escitalopram - tramadol
89091837|NCT00692263|Experimental|B|Placebo - tramadol
89091838|NCT00692263|Experimental|C|placebo - placebo
89091839|NCT00694759|Active Comparator|A|Pioglitazone will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
89091840|NCT00694759|Active Comparator|B|Metformin will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
89226508|NCT03925038|Experimental|Augmented Care|Participants will receive augmented psychotherapy which includes use of an electronic media dashboard as part of treatment.
89091841|NCT00694759|Placebo Comparator|C|Placebo will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
89091842|NCT02803840|Other|Experimental|DLBCL patients with indication for palliative radiotherapy
89091843|NCT00694837|Experimental|B|
89091844|NCT02800252|Placebo Comparator|Control Group|Full-mouth periodontal debridement and placebo
89091845|NCT02800252|Active Comparator|Test 1|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
89091846|NCT02800252|Active Comparator|Test 2|omega-3 plus aspirin before periodontal therapy
89091847|NCT02621359|Experimental|Quadruple therapy|Nitazoxanide (500mg bid), Levofloxacin (500 mg once daily), Omeprazole (40 mg bid) and doxycyclin (100 mg twice daily) were prescribed for 14 days.
89091848|NCT01152437|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
89091849|NCT01152437|Active Comparator|Cetuximab|Patients receive cetuximab intravenously once a week, every week
89091850|NCT02800174|Experimental|Smart nitinol stent implantation group|The Smart nitinol stent system was used (import product registration number YZB/USA 0115-2008; Nitinol stent system, trade name SMART Control). The stent system comprises a self-expanding stent and a delivery system. The self-expanding stent is composed of a nickel titanium alloy and the ends of the stent are equipped with tantalum radiopaque markers. The Smart nitinol stent system is sterilized with ethylene oxide gas and is intended for single use only.
89091851|NCT02800174|Active Comparator|Antiplatelet drug group|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
89091852|NCT04137913|Experimental|Music Group|Individuals in the music group will complete two assessment visit (pre-intervention and post-intervention). After their baseline visit, they will participate in a 6-week group music class, scheduled for 2 hours a day, 3 days a week. The daily music workshops will be led by a musician associated with the Rice Shepherd School of Music. Each week will be carefully scaled in difficulty, with the workshops becoming progressively more sophisticated. For instance, the first week's listening will focus on short and more familiar works such as instrumental etudes and folk songs. Gradually, the instructor will build towards symphonic movements, as well as more unfamiliar and experimental music. The course will culminate in creating a final composition.
89091853|NCT04137913|No Intervention|Non-music group|Individuals in the non-music group will complete two assessment visits separated by 2-3 months. They will be asked not to participate in any other music-related courses during the time they are enrolled in the study. At the end of participation, participants will be given resources to seek out music classes.
89091854|NCT02800330|Other|Arm A (e.g. sequence phase A-B-C)|In this arm patients will use regorafenib alone in the first cycle (treatment A), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib with esomeprazole 3 hours before (treatment C)
89091855|NCT02800330|Other|Arm B (e.q. sequence phase C-B-A)|In this arm patients will use regorafenib with esomeprazole 3 hours before (treatment C), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib alone (treatment A),
89091856|NCT01151579|Active Comparator|Levalbuterol 0.63|Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.
89091857|NCT01151579|Active Comparator|Levalbuterol 1.25|Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.
89091858|NCT00694915|Experimental|Mw|Mycobacterium w
89091859|NCT00694915|Active Comparator|BCG|bacillus Calmette-Guerin (BCG)
89091860|NCT02800096|Active Comparator|Gambling Internet intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
89091861|NCT02800096|Experimental|Gambling Internet intervention + MoodGYM|The G+MH intervention condition will consist of the G-only intervention and an online intervention for depression and anxiety. The mental health intervention chosen is MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
89091862|NCT02799940||Computed tomography in acute respiratory distress syndrome|The lung on computed tomography (CT) in patients with acute respiratory distress syndrome (ARDS) has revealed a heterogeneous pattern of lung injury, with areas of normal lung interspersed with altered regions: ground-glass opacification and consolidation among the most frequent. It has been performed quantitative assessments of ARDS by means of CT, thus enabling a correlation of such pathologic details with physiologic, clinical parameters and with patient outcomes. Therefore, the primary objective of the study is to determine the correlation between the extent of oxygenation (PaO2/FiO2) and the degree of consolidation (total CO) in the CT. The secondary objectives are to determine: the correlation between the driving pressure, ventilator variables and the total CO; the independent variables associated with total CO; differences in the CT with respect to the total lung-disease score (total CO plus total value of ground-glass opacification) between survivors and nonsurvivors.
89091863|NCT00694993|Experimental|Subjects receiving GSK1004723 + placebo in cohort I and II|Eligible subjects will receive GSK1004723 nasal spray with single doses of 50 micrograms, 100 micrograms, 200 micrograms, 500 micrograms and 1000 micrograms. Subjects will also receive placebo nasal spray.
89091864|NCT00694993|Experimental|Subjects receiving GSK1004723 200 micrograms in cohort III|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 200 micrograms given once daily for 14 days.
89091865|NCT00694993|Experimental|Subjects receiving placebo in cohort III|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
89091866|NCT00694993|Experimental|Subjects receiving GSK1004723 1000 micrograms in cohort IV|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 1000 micrograms given once daily for 14 days.
89091867|NCT00694993|Experimental|Subjects receiving placebo in cohort IV|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
89091868|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Needle|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via epidural needle followed by catheter placement.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
89230262|NCT00658541|Active Comparator|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
89091869|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Catheter|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via the epidural catheter administration following catheter placement.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
89091870|NCT02803450|Active Comparator|Low Volume, High Concentration via Epidural Catheter|"Standard of Care Epidural Administration Epidural loading: Participants will receive 10ml of 0.125% bupivacaine with fentanyl 2mcg/ml in 5 ml increments 5 minutes apart via the epidural catheter following epidural catheter placement, per standard of care.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.0625% bupivacaine with 2mcg/ml fentanyl. The infusion rate will be set at 10ml/hr basal rate and 4ml every 15 minutes on demand with lockout of 26ml/hr.~For inadequate analgesia: One additional 5ml boluses of the standard 0.125% bupivacaine with 2mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
89091871|NCT00692497|Active Comparator|1|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
89091872|NCT00692497|No Intervention|2|Patients in the control group are randomised to use the regular patient pathway prior to day case outpatient surgery. All these patients are referred to the surgical outpatient clinic. At the outpatient clinic patients are examined by a surgeon and indications for surgery is decided by the surgeon. If indicated, patients are then referred to outpatient surgery and the surgical procedure is performed several weeks after the examination.
89091873|NCT02803528|Experimental|Biodentine|The exposed area of the pulp is going to be covered with Biodentine.
89091874|NCT02803528|Active Comparator|MTA|The exposed area of the pulp is going to be covered with MTA
89091875|NCT04136041|Experimental|Smartphone Application|Participants watch a video using the Smartphone Application displaying positive word stimuli.
89091876|NCT04136041|No Intervention|No Intervention|No Intervention.
89091877|NCT01097616|Experimental|Suvorexant HD|Drug
89091878|NCT01097616|Experimental|Suvorexant LD|Drug
89091879|NCT01097616|Placebo Comparator|Placebo|Placebo Comparator
89091880|NCT02799628|Active Comparator|intervention|"Give the physical therapy of low back pain educational video + therapist introduction and recommendation video, at the first time of clinic visit.~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
89091881|NCT02799628|Placebo Comparator|placebo|"Give the physical therapy of low back pain educational video, at the first time of clinic visit.~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
89091882|NCT00695071|Active Comparator|A|
89091883|NCT02799550|Experimental|allogeneic CART-19|infusions of allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
89091884|NCT04137679|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
89091885|NCT04137679|Active Comparator|Neoadjuvant Radiochemotherapy followed by surgery|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
89091886|NCT02621125|Experimental|Fertilix|Fertilix supplementation
89091887|NCT02621125|Placebo Comparator|Placebo|Placebo
89091888|NCT02803606||hypothermia|Preterm neonates less than 32 weeks of gestational age admitted at birth to the Neonatal Medicine unit
89091889|NCT00695227|Experimental|Screening for Barrett's Esophagus|
89091890|NCT02799394|Experimental|Activity modification, exercises and gradual return to sport|
89091891|NCT00692575|Experimental|1: Experimental|Problem-solving, education based telephone counseling.
89091892|NCT00692575|Sham Comparator|2: No intervention|Standard of care control group
89091893|NCT02803294|Experimental|Aortic Stenosis/regurgitation|Transcatheter aortic valve replacement
89091894|NCT02803216|Experimental|standard triple region|The patients in this group were given 10-day standard triple therapy.
89091895|NCT02803216|Active Comparator|standard triple region +2-week TCM|The patients in this group were given 10 days of standard triple therapy + 2-week Xiang-sha-liu-jun decoction.
89091896|NCT02803216|Active Comparator|standard triple region +4-week TCM|The patients in this group were given 10days of standard triple therapy + 4-week Xiang-sha-liu-jun decoction.
89091897|NCT02624635|Active Comparator|Manual Therapy|The treatment for this group will be manual therapy.
89226509|NCT03922100|Experimental|NMS-03592088|"Phase I Dose Escalation~Schedule A - Starting dose of 20 mg/day~Schedule B - Starting dose of 120 mg/day~Only one dose level open for enrollment except EU backfill cohorts.~Phase II Dose Expansion (Exploratory) - (EU)~Recommended Phase II Dose (RP2D) of NMS-03592088 in Phase 1~Cohort 1: Patients who have failed standard of care including venetoclax and gilteritinib based therapies~Cohort 2: Patients who have failed standard of care"
89226510|NCT03920007|Experimental|ATSN-101|ATSN-101 single dose according to an ascending dose design (dose escalation phase) or ATSN-101 single dose (dose expansion phase)
89226511|NCT03916276|Active Comparator|Cognitive Therapy (CT) Condition|Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain.
89226512|NCT03916276|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
89226513|NCT03916276|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
89226514|NCT03903224|Active Comparator|Combined PECS II and TTP blocks (PT)|"Modified Pectoralis block (PECS II) : Using ultrasound we proceed to inject 10 ml of bupivacaine 0.25% between the pectoral muscles and 10 ml under Pmm above the serratus muscle.~Transversus Thoracic Plane block : 10 mL bupivacaine (0.25%) is injected between the transversus thoracic muscle and the internal intercostal muscle between the third and fourth left ribs connecting at the sternum."
89226515|NCT03903224|Active Comparator|Erector Spinae Block (E)|Using ultrasound an echogenic 22-G block needle is inserted in-plane in a cranial-to-caudal direction until contact is made with the T5 transverse process. A total of 30 bupivacaine 0.25% is then injected while seeing the fluid lifting the erector spinae muscle off.
89226516|NCT03878979|Experimental|Newly diagnosed SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of a newly diagnosed SCCHN.
89226517|NCT03878979|Experimental|Reccurence of SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of SCCHN which has recurred.
89226518|NCT03873363|Experimental|PS|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
89226519|NCT03873363|Active Comparator|CR|Implantation of a cruciate retaining Total Knee Arthroplasty.
89226520|NCT03872401|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injection once every 2 weeks (Q2W).
89226521|NCT03872401|Experimental|Evolocumab 140 mg Q2W|Participants will receive 140 mg evolocumab by subcutaneous injection Q2W.
89226522|NCT03866187|Experimental|Group A1_Step A|Subjects aged 18-65 years receive one dose of each of the study vaccines, Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation at Day 1, Modified Vaccinia Ankara HBV vaccine (MVA-HBV) low dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169.
89226523|NCT03866187|Active Comparator|Group A2_Step A|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 low dose formulation, one dose each at Days 1, 57, 113 and 169.
89226524|NCT03866187|Placebo Comparator|Group A3_Step A|Subjects aged 18-65 years receive four doses of placebo, one dose each at Days 1, 57, 113 and 169.
89091898|NCT02624635|Experimental|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip.
89091899|NCT04308408|Active Comparator|Mexican Guideline Daily Allowance (GDA)|Guideline Daily Amounts (GDA) is a purely numerical and reductive labeling system, indicates the grams and percentages (according to the guideline-based daily intakes) per portion of kilocalories, saturated fats, other fats, sugars, and sodium, with no specific judgement, opinion or recommendation.
89091900|NCT04308408|Experimental|Ecuador's Multiple Traffic Light (MTL)|Multiple traffic light labels, an interpretive nutrient-specific FOP label, use the typical traffic light colors (green, yellow/amber, red) and text descriptors to indicate the high, medium, or low content of total fat, sugar and salt.
89091901|NCT04308408|Experimental|Chilean Warning Labels in Red|Warning Labels (WL), another nutrient-specific interpretive FOP labelling scheme, include 'high in' symbols for products that exceed limits of energy, sodium, sugar and saturated fat.
89091902|NCT02799316|Other|rheumatic disease with HBs-ag positive|• HBV core antibodies testing. • Real time PCR testing.
89091903|NCT04015999|Experimental|Intervention arm|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
89091904|NCT04015999|Active Comparator|Control arm|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
89091905|NCT04936932|Active Comparator|Standard|1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec
89091906|NCT04936932|Active Comparator|Slow|1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec
89091907|NCT02803372|Experimental|Intervention group|In addition to routine monitoring, invasive LiDCOrapid is used to monitor mean arterial pressure (MAP), stroke volume variation (SVV) and cardiac index (CI). Intraoperative goal-directed circulatory management is performed, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery.
89091908|NCT02803372|Active Comparator|Control group|Routine monitoring is performed, which includes invasive blood pressure and urine output. Intraoperative routine circulatory management is performed, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h.
89091909|NCT00695383|Experimental|1|
89091910|NCT00695383|Active Comparator|2|
89091911|NCT02803684|Experimental|Single arm|Whole cohort
89091912|NCT02620969||Patients on haemodialysis|During a midweek session of a patient on haemodialysis, blood and dialysate sampling is performed at different time points.
89091913|NCT02799238|Active Comparator|Radiotherapy in combination with Temozolomide (TMZ)|radiotherapy combined with TMZ treatment followed by adjuvant TMZ
89091914|NCT02799238|Experimental|ALECSAT + Radiotherapy in combination with TMZ|3 doses of ALECSAT /4 weeks followed by ALECSAT every 3 months
89091915|NCT00692653|Experimental|P4|Participant uses P4 program before meeting with his clinician to discuss treatment options.
89091916|NCT00692653|No Intervention|Usual care+|Usual care plus participant is directed to reputable websites highly rated in research literature to learn more about prostate cancer treatments.
89091917|NCT02798926||with the use of a polyethylene bag|
89091918|NCT02798926||without the use of a polyethylene bag|
89091919|NCT02620813|No Intervention|No Acne|Healthy subjects without acne between the ages of 15-45
89091920|NCT02620813|Experimental|Acne Subjects on Topical Tretinoin Treatment|Subjects with acne before and after topical retinoid therapy
89091921|NCT02620813|Experimental|Acne Subjects on Systemic Isotretinoin Treatment|Subjects with acne before and after isotretinoin therapy
89091922|NCT02799004||Patients in acute pain|
89091923|NCT02803060|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89091924|NCT00695461|Experimental|1|Receives Lactobacillus plantarum 299v in an oatmeal drink, at a concentration of 10(9) colony-forming-units/ml, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
89091925|NCT00695461|Placebo Comparator|2|Receives oatmeal drink, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
89091926|NCT02798848|Experimental|Assistive technology: tablet computer|iPad tablet computers
89091927|NCT02798848|Active Comparator|Standard optical low vision devices|standard optical devices including magnifiers, telescopes, CCTV
89091928|NCT00692731||Active|Tea catechin sport beverage
89091929|NCT00692731||Control|Control beverage
89091930|NCT02624401|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion.
89091931|NCT02624401|Experimental|Propofol|Intravenous propofol using target controlled infusion.
89091932|NCT02624401|Experimental|S-ketamine|Intravenous S-ketamine using target controlled infusion.
89091933|NCT02624401|Experimental|Sevoflurane|Inhalational sevoflurane using target controlled inhalation.
89091934|NCT02624401|Placebo Comparator|Placebo|Intravenous saline.
89091935|NCT02624557|Experimental|Moderate hepatic impairment group|Subjects with moderate hepatic impairment with Child-Pugh score 7 - 9
89091936|NCT02624557|Experimental|Severe hepatic impairment group|Subjects with severe hepatic impairment with Child-Pugh score 10 - 15
89091937|NCT02624557|Experimental|Matching healthy control group|Subjects with apparent normal liver function matched to the hepatic impairment subjects by sex, race, age, and weight.
89091938|NCT02802748|Experimental|Metronomic Vinorelbine + Letrozole|"Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks~Letrozole: 2.5mg daily, for 3 weeks"
89091939|NCT02802748|Active Comparator|Letrozole alone|Letrozole: 2.5mg daily, for 3 weeks
89091940|NCT02802748|Active Comparator|Metronomic Vinorelbine alone|Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
89091941|NCT00695617|Experimental|A|citrate first
89091942|NCT00695617|Experimental|B|no anticoagulation first
89091943|NCT02798614|Active Comparator|10-day cast|Removal of plaster cast 10 Days after reduction
89091944|NCT02798614|No Intervention|1-month cast|Removal of plaster cast 1 month after reduction
89091945|NCT04115176||smokers + periodontitis|Individuals clinically diagnosed with chronic periodontitis that smoke recruited for this group.
89091946|NCT04115176||nonsmoker + periodontitis|Individuals clinically diagnosed with chronic periodontitis that don't smoke recruited for this group.
89091947|NCT02620891|Active Comparator|experimental group|Using helium oxygen mixture
89091948|NCT02620891|No Intervention|matched group|Using air oxygen mixture
89091949|NCT02798692|Active Comparator|Low dose HB-101 group|Intervention:Three administrations of a low dose of HB-101
89091950|NCT02798692|Active Comparator|Medium dose HB-101 group|Intervention:Three administrations of a middle dose of HB-101.
89091951|NCT02798692|Active Comparator|High dose HB101 group|Intervention:Three administrations of a high dose of HB-101.
89091952|NCT02798692|Placebo Comparator|Placebo group|Intervention:Three administrations of placebo (diluent)
89111125|NCT02793531|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
89091953|NCT02620735|Active Comparator|Exercise Only|Participants receive 12-weeks PA training (1x/week - 60 min) group sessions with a CEP/RKin, and a progressively structured home-based exercise program based on the American College of Sports Medicine (ACSM) guidelines.It combines aerobic-resistance exercise with flexibility training, and progresses towards increased in intensity and improved fitness. The goal is at least 150 min/week of moderate-intensity aerobic activity. Participants are also asked to complete 3-5 additional home-based sessions of aerobic, and resistance activities each week. Initial intensity is based on the performance of the exercises during a group session and is self-monitored via the 10-point rating of perceived exertion, with a prescribed training zone of 4-7.
89111126|NCT02793531|Experimental|Cancer subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
89111127|NCT02793453|Other|Diseased|Patients suffering of moderate to severe chronic periodontitis
88812571|NCT02627508|Experimental|Pregnenolone (up to 500 mg per day)|"Twice daily intake of orally administered Pregnenolone will occur on a schedule as described below.~Weeks 1 and 2: 30mg twice daily (total 60mg per day)~Weeks 3 and 4: 60mg twice daily (total: 120mg per day)~Weeks 5 and 6: 90mg twice daily (total: 180mg per day)~Weeks 7 and 8: 150mg twice daily (total: 300mg per day)~Weeks 9 and 10: 210mg twice daily (total: 420mg per day)~Weeks 11 to 14: 250mg twice daily (total: 500mg per day)"
89091954|NCT02620735|Experimental|Exercise + iMOVE|Participants will receive the same exercise program at the Exercise Only group + 1) one-on-one telephone-based counselling (10 x 30-minute telephone: weeks 1, 2, 3, 4, 5, 6, 8, and 12 (during the exercise program) and at weeks 20,28 (post-exercise program booster sessions)); 2) supportive software on smart-phone devices (the HealthCoach program), 3) use of Fit-bit and corresponding software. The iMOVE intervention was designed to enhance sustained behavior change. The theoretical constructs employed are based on promoting motivation and establishing: a) exercise self-efficacy, b) social support for exercise and c) positive exercise-induced feelings during the acute intervention (12 weeks) and post-exercise program period (6 months).
89091955|NCT02798770||Stroke Center Basel|
89091956|NCT04235452||Epileptic myoclonus|Juvenile Myoclonic Epilepsy and Progressive Myoclonic Epilepsy
89091957|NCT04235452||Non-epileptic myoclonus (secondary)|Post hypoxic myoclonus, Post ischemic stroke myoclonus, Hepatic, Chronic kidney disease, and Drug induced myoclonus
89091958|NCT01151345|Experimental|diltiazem|
89091959|NCT02802904|Experimental|Palm olein IV 64|Palm olein IV 64, n= 15, 4 weeks intervention
89091960|NCT02802904|Experimental|Cocoa butter|Cocoa butter, n= 15, 4 weeks intervention
89091961|NCT02802904|Experimental|Virgin olive oil|Virgin olive oil, n= 15, 4 weeks intervention
89091962|NCT02798302|Active Comparator|Non rebreather|
89091963|NCT02798302|Active Comparator|Bag valve mask without leak|
89091964|NCT02798302|Active Comparator|Bag valve mask with simulated mask leak|
89091965|NCT02798146|Other|hormonal levels|Blood samples are collected for analysis of LH, E2, hCG and progesterone.
89091966|NCT02802670|Experimental|GDC-0810|GDC-0810 300-mg dose administered as oral solution, containing approximately 100 microcuries of [14C]-labeled GDC-0810.
89091967|NCT02802826|Experimental|Tailored Exercise Prescription|"Participants will have a discussion on the 'My Exercise Prescription' booklet on the benefits of increasing levels of physical activity. They will be encouraged to read this in more detail and guided through its completion. The participant will receive an exercise prescription using the Pre-Intervention Assessment Tool (PIAT) and following discussion with the participant on a realistic and achievable starting point.~The booklets provided will guide participants through the exercise programme which is a graduated walking-based activity intervention. Both booklets provide participants with a suggested starting point for walking distance per week based on their PIAT score as well as motivational and behaviour change strategies to encourage participation."
89091968|NCT02802826|No Intervention|Standard Care|No sham or placebo conditions will be used in the study. At visit 1 standard care participants will be given the Standard Care Information Sheet and asked to simply continue with standard care.
89091969|NCT02798068|Active Comparator|Solu - Medrol|Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration
89091970|NCT02798068|Placebo Comparator|Placebo|NaCl 0,9% 100ml IV once single administration
89091971|NCT02802358||Hip fracture|Patients with a hip fracture due to an accidental fall
89091972|NCT02802358||Wrist fracture|Patients with a wrist fracture due to an accidental fall
89091973|NCT02802436|Experimental|Extraction with socket graft and GEM21|"Intervention - Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Test site (active arm) will be injected with Bioactive Agent (PDGF - Platelet derived growth factor). At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd.~Bioactive agent - GEM21S (Growth factor enhanced matrix) Dosage - one cup containing 0.5 cc of ß-TCP particles (0.25 to 1.0 mm); and one syringe containing a solution of 0.5 mL rhPDGF-BB (0.3 mg/mL)"
89091974|NCT02802436|Other|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Normal saline will be used and no growth factor to maintain the volume in control sites
89091975|NCT02797912||CF children and young people|Observational study involving clinical procedures: lung function testing, respiratory muscle strength testing, body composition analysis & exercise tolerance.
89091976|NCT02802280|Other|Cardiovascular risk in HCV patients|"Intervention:~The only intervention to be carried out along the study will consist of a complete evaluation of cardiovascular risk of HCV patients both at baseline (pre-treatment) and after HCV treatment, through performing different tests (see below)~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied at different times before and after the end of the treatment.~The participation in the study will not influence neither the indication to treat nor the treatment used.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
88812572|NCT02627508|Placebo Comparator|Placebo|Placebo
88812573|NCT02521363|Experimental|Upfront Breast Surgery|Patients will have the microdevice implanted prior to breast surgery, in the absence of neoadjuvant chemotherapy
89091977|NCT04235842|No Intervention|Control Group (CG)|The CG will receive the standard indications routinely provided by the hospital which consists in information about practice of regular physical activity according to World Health Organization. A leaflet with illustrations and indications will be provided and will be explained by the principal investigator.
89091978|NCT04235842|Experimental|Moderate-intensity continuous exercise training group (GMICT)|The GMICT will be submitted to a physical exercise program in which the aerobic component will be a moderate-intensity continuous exercise training, performed at 60% of the heart rate reserve, two days a week, for 30 minutes.
89091979|NCT04235842|Experimental|High-intensity interval training exercise group (GHIIT)|The GHIIT will be will be submitted to a physical exercise program in which the aerobic component will be a high-intensity interval exercise training, performed in a protocol consisted of four one-min sprint at 90% of the heart rate reserve, alternated with one-min rest (at week 1) and progressing until reach 10 bouts of one-min sprint alternated with one-min rest.
89091980|NCT00593827|Active Comparator|Arm 1|ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest
89091981|NCT00593827|Active Comparator|Arm 2|ixabepilone 40 mg/m^2 every 3 weeks
89091982|NCT02797834||Patients Endometrial Fluid|"Endometrial fluid samples from healthy and fertile women in their natural cycles, with ages ranging from 18 to 35 years, normal karyotype, negative for HIV, HBV, HCV and RPR, BMI ranging from 18 to 30 Kg/m2 (both included) and regular menstrual cycle (3-4/28-30 days).~This unique assignment group will be divided into 5 subgroups attending to the moment of the menstrual cycle in which the patient could be classified: phase I (days 0-8), phase II (days 9-14), phase III (days 15-18), phase IV (days 19-24) and phase V (days 25-30)."
89091983|NCT02797756||Case|CC/GER+ presence of chronic cough and presence of GER evidenced by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
89091984|NCT02797756||Control|CC/GER- presence of chronic cough and absence of GER by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
89091985|NCT02802202||Fibromyalgia|Individuals who met the criteria for a diagnosis of FM based upon the ACR diagnostic criteria.
89091986|NCT02802202||Myofascial Pain Syndrome|Individuals with a diagnosis of MPS that does not meet the American College of Rheumatology (ACR) diagnostic criteria for FM.
88812574|NCT02521363|Experimental|Neoadjuvant Therapy|Patients will have the device placed and retrieved on a core biopsy the following day, then receive neoadjuvant chemotherapy prior to definitive breast surgery.
88812575|NCT02340962|Experimental|Group I|200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin
88812576|NCT02340962|Experimental|Group II|400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin
89091987|NCT02802202||Control|Individuals with no current or prior diagnosis consistent with MPS or FM.
89091988|NCT00692809||1|HIV+ve+LTBI (n=100)
89091989|NCT00692809||2|HIV+ve+clinical TB (n=50)
89091990|NCT00692809||3|HIV-ve+clinical TB (n=15)
89091991|NCT00692809||4|Normal control (n=15)
89091992|NCT02797600||ARM I|Woman residing in Appalachian counties who have prevalent invasive cervical cancer. Invasive cervical cancer cases participants will include women previously and currently treated for ICC during the past 10 years. Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. Biological samples will be collected during a scheduled visit with the research staff.
89091993|NCT02797600||ARM II|Woman residing in Appalachian counties who are newly diagnosed with invasive cervical cancer(ICC). Newly diagnosed with ICC, and currently being treated for ICC. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected during a scheduled clinic visit.
89091994|NCT02797600||ARM III|Healthy controls (women without a diagnosis of any type of cancer. Healthy controls will be women who are coming into one of the participating clinic or physician practice for a routine Pap test. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected at the time of the clinical Pap smear.
89091995|NCT04135105||Normal hearing group|Right-handed, normal hearing, no reported neurological disorders
89091996|NCT04136119||healthcare professionals|doctors, pharmacists and dieticians who are involved in prescribing vitamins and micronutrients to critically ill patients
89091997|NCT02797366|Other|Proton radiotherapy|Proton radiation therapy daily (Monday through Friday) for 4-8 weeks. This is a single arm study.
89091998|NCT00692887||1|Subjects diagnosed as new CNV or treated CNV
89091999|NCT02801890|Experimental|AD-MSC|The patients with ultra filtration failure (UFF) underwent AD-MSC injection.
89092000|NCT02801890|Placebo Comparator|Placebo|The patients with ultra filtration failure (UFF) underwent Placebo injection.
89092001|NCT02801812||Systemic Lupus Erythematosus|patients ≥18 years diagnosed SLE upon classification according to 2012 SLICC criteria and disease onset ≥16 years.
89092002|NCT02801812||Healthy controls|subjects ≥18 years fulfilling the definition proposed in the protocol.
89092003|NCT00695851|Experimental|1|15 mg/m2 weekly of PCK3145
89092004|NCT00695851|Experimental|2|7.5 mg/m2 twice per week of PCK3145
89092005|NCT02797210|Experimental|Sham then Active Stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then active rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
89092006|NCT02797210|Experimental|Active then Sham Stimulation|Active repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then sham rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
89092007|NCT02624323|Experimental|Axillary catheterization|Real-time ultrasound-guided axillary vein catheterization, in plain technique.
89092008|NCT02624323|Experimental|Jugular catheterization|Real-time ultrasound-guided jugular vein catheterization, out of plain technique.
89092009|NCT02796820|Experimental|Huaier Granule|Huaier Granule will be administrated from 4 to 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
89092010|NCT02796820|No Intervention|Regular follow-up observation|Regular follow-up observation after surgery.
89092011|NCT04135885|Experimental|Intervention group|Intervention group: patients took 7 days of folic acid tablets before surgery (0.3mg/d for children aged 1-3, 0.4mg/d for children aged 4~5 years, dissolved in 20ml brown sugar water.)
89092012|NCT04135885|Experimental|Placebo group|Placebo group: The patient received the same dose of brown sugar water for 7 days before surgery. Folic acid dose selection is based on the maximum daily intake of children（tolerable upper intake levels，UL）
89092013|NCT02801968|Experimental|Tap block|Tap block with ropivacaine 2 mg/kg at the end of cesarean delivery. Postoperative analgesia with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
89092014|NCT02801968|Active Comparator|control group|Postoperative analgesia after cesarean delivery with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
89092015|NCT00696865|Experimental|1|
89092016|NCT00696865|Placebo Comparator|2|
89092017|NCT02802046||FFR≦0.8|FFR is a score of 0 to 1, FFR < 0.75, has proved almost always accompanied by myocardial ischemia.
89092018|NCT02802046||FFR>0.8|FFR > 0.80 almost never associated with myocardial ischemia.
89092019|NCT02620657||Non interventional study|The patients with advanced NSCLC who have the medical records from Jan 1st 2014 to Dec 31st 2014 will be recruited .
89092020|NCT02801734|Experimental|Intervention|"Participants in the EQUIP intervention group will individually receive four face-to-face sessions with a palliative care nurse.~For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate."
89092021|NCT02801734|No Intervention|Control|For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate.
89092022|NCT02624011|Experimental|Physical inactivity|Study arm consisting of 7 days of habitual physical activity followed by 7 days of step reduction and exercise cessation.
89111128|NCT02793453|Other|Healthy|Healthy Patients not suffering of any periodontal disease a
89111129|NCT02793219|Experimental|Sipuleucel-T then Docetaxel|Sipuleucel-T IV over 1-hour every 14 days for 3 doses; 28 day rest; 75 mg/m2 docetaxel IV over 1-hour every 21 days for 6 cycles
89092023|NCT02796898|Experimental|Treated Group|"SM88 is a combination therapy consisting of 4 agents. One agent, the tyrosine isomer will be increased in each of 2 dose cohorts as follows:~Cohort 1:~Tyrosine isomers - 230 mg qd~Phenytoin - 50 mg qd.~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd~Cohort 2:~Cohort 2 has increasing tyrosine isomer from q.d. to b.i.d.~Expansion Cohort:~The optimum dose will be expanded in 2nd stage of the study to 30 subjects."
89092024|NCT00693043|No Intervention|Standard anesthesia group|Patients randomized to arm 1 received standard of care anesthesia for pleuroscopy. Duration of the procedure will be recorded. Pain management will be monitored prior to, intraoperatively and at the end of the procedure.
89092025|NCT00693043|Experimental|Lidocaine Group|Patients randomized to arm two will receive a reduced topical dose of lidocaine of 2mg/kg and additional lidocaine 3mg/kg infused into the pleura cavity. Duration of procedure will be monitored from the time initial dose of intradermal lidocaine until the start of surgical wound closing, pain scale will be administered prior to the procedure and at the end of the procedure. Lidocaine serum levels will be monitored at 30, 60, and 120 minutes after initial intradermal administration of lidocaine.
89092026|NCT04235296|Active Comparator|control group|epidermal growth factor
89092027|NCT04235296|Experimental|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
89092028|NCT02624167|Active Comparator|NW-3509A|Patients will start on NW-3509A 15 mg BID and be up-titrated to 20mg, and 25mg BID dependent on tolerability.
89092029|NCT02624167|Placebo Comparator|Placebo|Patients will receive matching placebo BID
89092030|NCT02796976|No Intervention|healthy older active|only cross-sectional
89092031|NCT02796976|No Intervention|healthy older sedentary|only cross-sectional
89092032|NCT02796976|Active Comparator|older sedentary at risk|cross-sectional and training or control condition
89092033|NCT02620501|Placebo Comparator|Placebo|Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD
89092034|NCT02620501|Experimental|Experimental|Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD
89092035|NCT02796742||Group MSSA|
89092036|NCT02796742||Group MRSA|
89092037|NCT02796742||Group PVL-negative strains|
89092038|NCT02796742||Group PVL-positive strains|
89092039|NCT00693121|Placebo Comparator|Placebo|Identical capsule to amantadine hydrochloride active intervention, administered twice daily x 14 days
89092040|NCT00693121|Active Comparator|Amantadine|Amantadine hydrochloride 100mg capsule administered twice daily x 14 days
89092041|NCT02796586|Placebo Comparator|Individual Contraceptive Counseling|Performed by a medical provider and planned to simulate a typical clinic visit addressing contraception.
89092042|NCT02796586|Experimental|Group Contraceptive Counseling|Performed by a bicultural study staff member who speaks the primary languages of participants and had been formally trained in contraception counseling.
89092043|NCT04134793||Sinus group|Six-month follow-up, by holter ECG record，the patients keep normal sinus after atrial fibrillation radiofrequency ablation.
89092044|NCT04134793||atrial fibrillation recurrence group|Six-month follow-up, by holter ECG record，the patients again suffer from atrial fibrillation after atrial fibrillation radiofrequency ablation.
89092045|NCT02801500|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
89092046|NCT02801500|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
89092047|NCT02801344|Experimental|Normal protein intake|participants will receive the controlled-diet containing 0.8 g protein /kg/day and the test drink containing 0.14 g protein/kg/d.
89092048|NCT02801344|Experimental|Moderate protein intake|participants will receive the controlled-diet containing 1.20 g protein /kg/day and the test drink containing 0.40 g protein/kg/d.
89092049|NCT02801344|Experimental|High protein intake|participants will receive the controlled-diet containing 1.83 g protein /kg/day and the test drink containing 1.03 g protein/kg/d.
89092050|NCT02796430||Mechanically ventilated patients|Ease of use will be assessed by analysing the time needed to start indirect calorimetry measurement, and results of indirect calorimetry measurements by both the new indirect calorimeter and the currently used calorimeters at each study center.
89092051|NCT00696007|Experimental|1|A neoadjuvant chemotherapy (gemcitabine and cisplatin) regimen administered before surgery-nephroureterectomy for upper tract TCC
89092052|NCT00696007|Other|2|A retrospective cohort group (approximately 60 subjects) identified from an institutional cancer registry who have undergone a nephroureterectomy alone over the past five years
89092053|NCT02796508|Experimental|Non-action video game training|Experimental: Non-action video game training 16 1-hour training sessions with 10 non-action video game training selected games from Lumosity.
89092054|NCT02796508|Active Comparator|Non-cognitive video game training|Active Control: Non-cognitive social video game training 16 1-hour training sessions with non-cognitive video game training with social games from The Sims.
89092055|NCT02624089|Experimental|Ropivacaine Group|This group will receive nebulized ropivacaine 0.5% based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered once at the onset of pneuomoperitoneum during appendectomy.
89092056|NCT02624089|Placebo Comparator|Placebo group|This group will receive placebo (normal saline) based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered at the onset of pneuomoperitoneum during appendectomy.
89092057|NCT02624089|No Intervention|Non-enrolled group|This group will not receive either intervention (ropivicaine) or placebo (normal saline), but will have primary and secondary endpoints evaluated.
89092058|NCT02801422||Cannabis Dependence|ages 18-40
89092059|NCT02801422||Healthy control subjects|socio-demographically matched
89092060|NCT02624245|Experimental|Experimental: Conventional Physical Therapy|Strength, this arm will receive hip and knee muscle strengthening with and without weight bearing.
89092061|NCT02624245|Active Comparator|Movement control training|Movement control training, this arm will receive movement control training associated to muscle strengthening.
89092062|NCT02796196||Supportive care (monitoring device, medical chart review)|Data including demographics, type of HCT (e.g., allogeneic or autologous), preexisting physical conditions (e.g., chronic joint injury), CRF, steroid use data, ECOG and KPS scores are collected from patients' medical charts at time of enrollment. Patients are prescribed participation in a primarily self-directed physical activity program which encourages them to spend 6 hours out of bed daily and to perform 30 minutes of light-to-moderate daily aerobic activity. Patients who are able to maintain independent mobility undergo physical therapist assessment 2 times a week until hospital discharge. Patients wear a physical activity monitoring device and daily activity and sleep data are collected continuously during hospital LOS.
89092063|NCT00696943|Experimental|18F-ML-10,|Pre-treatment baseline and post treatment follow-up 18F ML-10 PET/CT sessions.
89092064|NCT02796040|Experimental|patients with ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
89092065|NCT02796040|Other|patients without ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
89092066|NCT00693199|Experimental|1|
89092067|NCT00693199|Active Comparator|2|
89092068|NCT00693199|Experimental|3|
89092069|NCT02795962|Active Comparator|Transfer to an Endovascular Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be directly transferred to the nearest Endovascular Center bypassing the Local Stroke Center.
89092070|NCT02795962|No Intervention|Transfer to the Local Stroke Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be transferred to the Local Stroke Center as done accordingly with the current stroke code protocol.
89092071|NCT02623777|Experimental|AXOS as first intervention|AXOS as first intervention
89092072|NCT02623777|Experimental|SCFA as first intervention|SCFA as first intervention
89092073|NCT04135651|Experimental|Paralaryngeal pressure|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
89092074|NCT04135651|Active Comparator|Cricoid pressure|During the induction of anesthesia, cricoid pressure is applied by 30N force with three fingers.
89092075|NCT02796118|Experimental|ASP2151 Low dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
89092076|NCT02796118|Experimental|ASP2151 High dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
89092077|NCT02796118|Experimental|ASP2151 Low dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
89092078|NCT02796118|Experimental|ASP2151 High dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
89092079|NCT02796118|Placebo Comparator|Placebo in non-elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
89092080|NCT02796118|Placebo Comparator|Placebo in elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
89092081|NCT02795884|Experimental|Intercalation arm|"Intercalation phase (Duration: 3wks x 4 cycles = 12 wks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Erlotinib 150mg D8-21 q3wks~Maintenance phase (Duration: 1 year) Erlotinib 150mg D1-28"
89092082|NCT02795884|Active Comparator|Chemotherapy alone arm|Duration: 3wks x 4 cycles = 12 wks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3wks
89092083|NCT02795728|Experimental|Experimental arm|Fuji type VII is a GIC based sealant with an additional property of high fluoride release
89092084|NCT02795728|Active Comparator|Resin based sealant|Helioseal F is a resin based sealant
89092085|NCT02800798||High risk for OSA|High risk OSA defines as Stop-bang score ≥ 3
89092086|NCT02800798||Low risk for OSA|Low risk OSA defines as Stop-bang score < 3
89092087|NCT02795572|Experimental|Intervention Group|The intervention group will receive a daily dose of Vitamin D 2000 IU, Vitamin B6 100 mg, Vitamin B12 100 mcg and Omega-3 Fatty Acids 2700 mg [900 mg TID (600 mg EPA, 300 mg DHA)].
89092088|NCT02795572|No Intervention|Reference Group|Reference group will receive usual care.
89092089|NCT02795650|Experimental|Experimental arm|Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.
89092090|NCT02795650|Active Comparator|Control|Investigators are allowed to chose the best option of standard treatment for patients.
89092091|NCT02800876||asymptomatic not ruptured aneurysm|Patients with asymptomatic not ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
89092092|NCT02800876||symptomatic not ruptured aneurysm|Patients with symptomatic aortic aneurysms greater than 3 cm who received a clinical indicated CT
89092093|NCT02800876||symptomatic ruptured aneurysm|Patients with symptomatic ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
89092094|NCT02800876||patients with small aneurysms|Patients with small aortic aneurysms approximately 5.5 cm, ruptured and not ruptured, who received a clinical indicated CT
89092095|NCT02795494||Perthes Group|Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline.
89092096|NCT02795494||Fracture Control Group|Participants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline.
89092097|NCT02801188|Placebo Comparator|Bupivacaine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
89092098|NCT02801188|Active Comparator|Mixture of bupivacaine and dexmedetomidine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye and 1 ug/kg of dexmedetomidine
89092099|NCT04236076|Experimental|PulseHaler™|Patients will receive PulseHaler for home treatment
89092100|NCT04236076|Sham Comparator|Sham PulseHaler - CONTROL group|Patients will receive Sham device for home treatment
89092101|NCT04235920||Impaired Cognition|First group was cognitively impaired test with MoCA score of 25 or less.
89092102|NCT04235920||Preserved cognition|The second group was cognitively preserved with MoCA score of higher than 25.
89092103|NCT02795260|Experimental|ESAT6-CFP10 in the right arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of BCG immunization :ESAT6-CFP10 in the right arm and TB-PPD in the left arm concomitantly,according to a randomisation scheme.
89092104|NCT02795260|Experimental|ESAT6-CFP10 in the left arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of Bacillus Calmette - Guerin immunization :ESAT6-CFP10 in the left arm and TB-PPD in the right arm concomitantly,according to a randomisation scheme.
89092105|NCT02801032|Active Comparator|Active Treatment|Tadalafil 20 mg Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
89092106|NCT02801032|Placebo Comparator|Control|Placebo Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
89092107|NCT05442190|Experimental|SGX302 (Ointment with 0.25 % Hypericin)|SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
89092108|NCT05442190|Placebo Comparator|Placebo (Ointment without Hypericin)|Placebo ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
89092109|NCT02795416|Experimental|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
89111130|NCT02801721|Active Comparator|Stimulation|Stimulation group received psycho social stimulation. In the stimulation there were anemic and non anemic children. All anemic children received iron(syrup) supplementation.
89092110|NCT02790658|Other|Grumixama Juice|"Juice of grumixama purple fruit (Eugenia brasiliensis Lam.), which is good source of anthocyanins and ellagitannins. It was made with filtered water and sanitized fruits, with a blender. It was administered in single dose of 0.97 mg of anthocyanins and of 4.71 mg of ellagitannins per mL of juice. Which volunteers ingested 10 mL of juice per each Kg body weight.~The metabolomic approach of plasma and urine samples following acute intake of grumixama juice was done by the collection of blood samples and urine, following the intake of grumixama juice."
89092111|NCT02795026|Active Comparator|Manual therapy|Intervention to be administered is manual therapy with myofascial release of trigger points for pelvic floor muscles, pelvis and abdominal musculature.
89092112|NCT02795026|Active Comparator|Dry needling & manual therapy|Intervention to be administered is Trans-perineal trigger point dry needling, done externally to target the trigger points in the pelvic floor muscles along with dry needling of the pelvis and abdominal musculature.Manual therapy will only be used in areas difficult to reach with the acupuncture needles.
89092113|NCT02689960|Other|vaginal administration first|Intervention first visit: vaginal administration of 100mg prednisone suppository, Intervention second visit: rectal administration of 100mg prednisone suppository
89092114|NCT02689960|Other|rectal administration first|Intervention first visit: rectal administration of 100mg prednisone suppository, Intervention second visit: vaginal administration 100mg prednisone suppository
89092115|NCT01150097|Experimental|Everolimus + reduced tacrolimus|Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.
89092116|NCT01150097|Experimental|Tacrolimus elimination|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.
89092117|NCT01150097|Active Comparator|Tacrolimus control|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.
89092118|NCT02790190|Experimental|Individualized Adaptive radiotherapy|GTV dose per fraction will be 2.2-2.4 y per fraction for 20 fractions and PTV dose per fraction will be 2.0 Gy per fraction.Perform PET/CT before radiotherapy and at 36 Gy for treatment response assessment and adaptive plan.Adaptive plan treated at 2.2-3.8 Gy per fraction for GTV and 2.0 Gy for PTV in the final 10 fractions.
89092119|NCT02790190|No Intervention|Conventional radiotherapy|2 Gy per fraction for all patient,perform PET/CT before radiotherapy and at 40 Gy for treatment response assessment .Continue treatment to a total dose of 60 Gy.
89092120|NCT02794948|Experimental|Chinese Medicine intervention|Chinese medicine HuYang Yang Kun Formula 1 capsule every time per day for 3 day per month, DHEA(dehydroepiandrosterone) placebo 1 sack every time, twice a day for three months
89092121|NCT02794948|Active Comparator|Western intervention|DHEA(dehydroepiandrosterone) 1 sack every time twice a day for three months. Chinese medicine formula granules placebo 1 capsule every time per day for 3 day per month.
89092122|NCT01149863|Experimental|Plerixafor 17 hours prior to apheresis|Dosing of plerixafor will occur at 3PM (1500 hours).
89092123|NCT02794792|Active Comparator|Metformin and placebo|Participants will receive daily dosage of Metformin and Placebo as single tablets.
89092124|NCT02794792|Experimental|Metformin and Ipragliflozin|Participants will receive daily dosage of Metformin and Ipragliflozin (2 dose strengths) as single tablets.
89092125|NCT02794792|Other|Metformin, placebo and Ipragliflozin|Participants will receive daily dosage of Metformin, placebo and Ipragliflozin (1 dose strength) as single tablets.
89092126|NCT01149473|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
89092127|NCT01149473|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
89092128|NCT02790268||Lens Subluxation|Pediatric eyes with lens subluxation undergoing Cionni Ring Bag fixation with in-the-bag IOL Implantation
89092129|NCT00872989|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.
89092130|NCT00872989|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89092131|NCT02794714|Experimental|deep neuromuscular blockade|Rocuronium will be administered to achieve PTC 1-2 throughout surgery.
89092132|NCT02794714|Active Comparator|moderate neuromuscular blockade|Rocuronium will be administered to achieve TOFC 2 throughout surgery
89092133|NCT00625001||1|Women with Turner syndrome
89092134|NCT00625001||2|Healthy control women
89092135|NCT02790112|Other|GnRHas - Not GnRHas patients|Compared long term outcome of treated and untreated patients with idiopathic central precocious puberty : hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
88812577|NCT02309645|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
88812578|NCT02309645|Other|Sutures Only|Subjects randomized to control will receive additional dural repair sutures as deemed necessary by the surgeon to attempt to achieve a watertight closure.
89092136|NCT02790112|Other|GnRHas - controls patients|Compared long term outcome of treated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
89092137|NCT02790112|Other|Not GnRHas - Controls patients|Compared long term outcome of untreated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
89092138|NCT04234750|No Intervention|control group|no intervention
89092139|NCT04234750|Experimental|experimental group|mesenchymal stem cell conditioned medium-derived pleiotropic factor
89092140|NCT01148771|Experimental|Ertapenem 1 gram intravenous (IV) 5 minute bolus|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 5 minute IV bolus.
89092141|NCT01148771|Active Comparator|Ertapenem 1 gram IV 30 minute infusion|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 30 minute infusion (i.e., the standard dose).
89092142|NCT02794636||IFN Treatment|Adult (age ≥ 18 years) patients identified as having stage III melanoma and no other primary or secondary cancer who initiated treatment with IFN between 1/1/2007 and 12/31/2011. Patients are required to have continuous pharmaceutical benefit enrollment for 180 days before (pre-index) and after (post-index) IFN initiation and no evidence of treatment with systemic chemotherapy during the pre- or post-index period
89092143|NCT01148693|Active Comparator|gentamicin|adding 10mg gentamicin to every 10 ml of contrast media
89092144|NCT01148693|Placebo Comparator|Placebo|Identical placebo
89092145|NCT00693355|Experimental|1|sodium butyrate
89092146|NCT00693355|Placebo Comparator|2|NaCl
89092147|NCT02620111|Experimental|Whey protein high leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein high in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
89092148|NCT02620111|Active Comparator|Whey protein normal leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein normal in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
89092149|NCT02883959|Experimental|music therapy|Music therapy
89092150|NCT02883959|No Intervention|control arm|No music
89092151|NCT04234828||Patients referred for an overnight in-lab PSG|Simultaneous assessment of SAS with Withings Sleep Device and overnight PSG
89092152|NCT00696085|Other|I|Pregnant women are recruited and screened for alcohol use using a validated alcoholism screening questionnaire. Those who screen positive are then entered into the next phase of the study.
89092153|NCT02794558|Experimental|Treatment Arm|Subjects in this arm are treated once with MRgFUS device
89092154|NCT00693433|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89092155|NCT02794090|Active Comparator|Usual care, individual visits|Usual care according to regular treatment routines at the clinic during 18 months. The Child and parent(s) at regular visits to the nurse at the clinic.
89092156|NCT02794090|Active Comparator|Telephone coaching|Intervention: Telephone consultation each months except for summer holidays during 18 months. The treating nurse communicated with one of the parents.
89092157|NCT05414422|Experimental|PCN-101 30 mg|PCN-101 30 mg
89092158|NCT05414422|Experimental|PCN-101 60 mg|PCN-101 60 mg
89092159|NCT05414422|Placebo Comparator|Placebo|Placebo
89092160|NCT00872599|Placebo Comparator|Placebo, then fenofibrate|Randomized study of fenofibrate versus placebo during high salt diet
89092161|NCT00872599|Placebo Comparator|Fenofibrate, then placebo|Randomized study of fenofibrate versus placebo during high salt intake.
89092162|NCT04233658|Placebo Comparator|Placebo|
89092163|NCT04233658|Experimental|Cynara Scolymus|
89092164|NCT00693511|Experimental|Circuit Training|Participants received CT exercise training two times per week for approximately 60-90 min per session for 16 wk
89092165|NCT00693511|Experimental|Circuit training + motivational interviewing|Participants in the CT + MI group received the same CT classes but also received four individual MI and four group MI sessions throughout the 16-wk program by two trained research staff
89092166|NCT00693511|No Intervention|Control|No intervention
89092167|NCT00693589|Active Comparator|R|Rosuvastatin treatment for 6 weeks and after that combined treatment with rosuvastatin and vitamin supplementation for additional 6 weeks
89092168|NCT00693589|Active Comparator|V|Vitamin supplementation with folic acid, vitamin B12 and B6 for 6 weeks and after that combined treatment with vitamin supplementation and rosuvastatin
89092169|NCT04233736|Active Comparator|Treatment group|
89092170|NCT04233736|Sham Comparator|Control group|
89092171|NCT02620267|Experimental|tDCS Stimulation|Each subject will receive all three types of stimulation on separate days- anodal, cathodal, and sham stimulation
89092172|NCT02794168|Experimental|VAS203 (Ronopterin)|Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg
89092173|NCT02794168|Placebo Comparator|Saline|Intravenous infusion of physiological saline over 48 hours
89092174|NCT02793934||1st phase|"In the 1st phase of the study the staff of the medical organizations continue to work in the familiar old scheme, but using the set of scales."
89111131|NCT02801721|No Intervention|No stimulation|No stimulation group did not receive any stimulation. In the no stimulation group there were anemic and non anemic children. All anemic children received iron (syrup) supplementation
88812579|NCT02272634|Experimental|Treatment A|Multiple oral YPL-001 80 mg doses (1 x 80 mg tablet + 1 x 1 YPL-001 80 mg matching placebo tablet) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
89092175|NCT02793934||2nd phase|"In the 2nd phase, medical organizations will start to work on a new model with the implementation of problem-oriented multidisciplinary approach and the use of modern rehabilitation technologies. There is planning to use clearly defined criteria for transfer from stage to stage, developed by the professional community. When doctors will be trained program ICF-reader will have an opportunity to establish a rehabilitation diagnosis on the basis of the ICF, and the option for ICF assessment using rating scales."
89092176|NCT01148537|Experimental|BTDS|Buprenorphine transdermal patches 5, 10, 20, and 2 * 20 mcg/h.
89092177|NCT01148537|Placebo Comparator|Placebo TDS|Matching placebo transdermal patches 5, 10, 20 and 2 * 20.
89092178|NCT01148537|Active Comparator|Moxifloxacin|Moxifloxacin hydrochloride 400 mg tablets
89092179|NCT02794324|Experimental|Voluntary deep-inspiratory breath hold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
89092180|NCT02794324|Active Comparator|Active-breathing-controlled deep-inspiratory breathhold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
89092181|NCT02794324|Active Comparator|Prone treatment|Stage 1B: Optimised supine DIBH vs prone position
89092182|NCT02794012||At-Risk Rheumatoid Arthritis subjects|
88812580|NCT02272634|Experimental|Treatment B|Multiple oral YPL-001 160 mg doses (2 x 80 mg tablets) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
89092183|NCT02794012||Early Rheumatoid Arthritis subjects|
89092184|NCT02794012||Healthy Controls|
89092185|NCT02794012||Non-Rheumatoid Arthritis Autoimmune Controls|
89092186|NCT02789722|Experimental|Yerba Mate Extract 750 mg|Yerba Mate Extract - Capsules: daily dose of 2.250 g, distributed in 3 doses of 750 mg, for 28 days.
89092187|NCT02789722|Placebo Comparator|Placebo|Starch - Capsules: 3 times daily for 28 days.
89092188|NCT02793778|Experimental|CROWN|CROWN: A nutritionally based therapy with a high protein content, formulated as a powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
89092189|NCT02793778|Placebo Comparator|CROWN Placebo|Placebo: An appearance and volume matched formulated powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
89111132|NCT02801409|Active Comparator|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
89092190|NCT02793544|Active Comparator|Regimen A (RIC: Flu/Cy/TBI)|"Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2~Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5~Total Body Irradiation (TBI) 200cGy on Day -1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
89092191|NCT02793544|Active Comparator|Regimen B 2a (FIC: Bu/Cy)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)~Cyclophosphamide 50mg/kg/day IV on Days -2,-1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
89092192|NCT02793544|Active Comparator|Regimen B 2b (FIC: Bu/Flu)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)~Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
89092193|NCT02793544|Active Comparator|Regimen C (FIC: Cy/TBI)|"Cyclophosphamide 50mg/kg/day IV on Days -5,-4~Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
89092194|NCT02793388|Active Comparator|Supervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure. Supervision of primaquine is done on alternate days at home (attended by a home visitor) or at the health centre.
89092195|NCT02793388|Active Comparator|Unsupervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure for self administration.
89092196|NCT02793310|Active Comparator|DMEK|The intervention group will receive cornea transplantation by DMEK
89092197|NCT02793310|Active Comparator|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
89092198|NCT02689882|Experimental|pharmacokinetic study|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
89092199|NCT02789644|Experimental|Ursodeoxycholic acid 400mg|Day 1: Ursodeoxycholic acid 400mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
89092200|NCT02789644|Experimental|Ursodeoxycholic acid 800mg|Day 1: Ursodeoxycholic acid 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
89092201|NCT04234594|Experimental|QL1203|Participants only receive QL1203, 6mg/kg on Day 1.
89092202|NCT04234594|Active Comparator|Vectibix®|Participants only received Vectibix®，6 mg/kg on Day 1.
89092203|NCT02789488|Other|Furocyst|Furocyst one caps BID
89092204|NCT02793076|Experimental|Bollywood Dance|Bollywood dance is a routine that doubles as both physical and mental exercise.
89092205|NCT03806608|Experimental|Crestal|Implants were placed with the implant-abutment interface(IAI) at the level of the the alveolar ridge
89092206|NCT03806608|Experimental|Subcrestal|Implants were placed with the implant-abutment interface(IAI) 1 mm below the level of the alveolar ridge
89092207|NCT01148459|Experimental|Group A|Infants enrolled to this group will receive 3 doses of the experimental vaccine.
89092208|NCT01148459|Active Comparator|Group B|Infants enrolled to this group will receive 3 doses of the rabies comparator vaccine.
89092209|NCT02789254|Experimental|Experimental: FLYSYN|IV infusion over a 3-hr duration
89092210|NCT03913234|Experimental|Combination of Letrozole, Trastuzumab with Ribociclib|Phase IB (dose escalation of ribociclib with fixed dose of letrozole and Ribociclib) Phase II (ribociclib of RPIID with fixed dose of letrozole and ribociclib)
89092211|NCT02792842|Experimental|ART-123 (3-day ART)|
89092212|NCT02792842|Experimental|ART-123 (1-day ART)|
89092213|NCT02792842|Placebo Comparator|Placebo|
89092214|NCT02792764||Port|Subjects receiving chemotherapy through a port
89092215|NCT02792764||Peripheral Intravenous (PIV) Lines|Subjects receiving chemotherapy through a peripheral IV
89092216|NCT02792998|Experimental|IW-1701|IW-1701 tablets administered orally in multiple ascending dose.
89092217|NCT02792998|Placebo Comparator|Placebo|Matching placebo tablets administered orally.
89092218|NCT02792920|Other|CoCr-EES|
89092219|NCT02792608|Experimental|Mindfulness-based Therapy|5 week, manual-based group MBI treatment for depression
89092220|NCT02792686|Experimental|ABX464|50, 100, 150 or 200 mg once a day / Single Administration
89092221|NCT02792374||Dental patients group|Psychological measurement is done when they refer to a dental clinic.
89092222|NCT02792374||Control group|Psychological measurement is done when they refer to a dental clinic.
89092223|NCT02792530|Other|arm 1|Unuric hemodialytic patients who accumulate above 2.5 (4%) in intradialytic intervals before the nutritional intervention.
89092224|NCT02792296|Experimental|Daily measurement|This arm will be asked to use the Project: EVO Monitor once a day for four weeks..
89092225|NCT02792296|Experimental|Multiple times per day measurement|This arm will be asked to use the Project: EVO Monitor at least once per day and six times over the day every three days for four weeks.
89092226|NCT02792296|Experimental|Weekly measurement|This arm will be asked to use the Project: EVO Monitor once a week for eight weeks.
89092227|NCT02791984|Experimental|Fluid challenge with 250 ml of Ringer Lactate|
89092228|NCT02789332|Active Comparator|Paclitaxel with Carboplatin (PwCb)|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (37 patients) followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
89092229|NCT02789332|Experimental|Paclitaxel with Olaparib (PwO)|"paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (65 patients)~followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery."
89092230|NCT02792140|No Intervention|Baseline|reporting of dreams
89092231|NCT02792140|Experimental|Naltrexone|daily administration of 50mg Naltrexone, reporting of dreams
89092232|NCT02792140|Placebo Comparator|Placebo|daily administration of Placebo, reporting of dreams
89092233|NCT04234282|No Intervention|Control Group|The control group will receive a 30-minute class on knee osteoarthritis diagnosis, prognosis, various treatment options, and will conclude with a question and answer session. This will account for the 30 minute face to face time provided in the treatment group
89092234|NCT04234282|Experimental|Manual Physical Therapy|The treatment group will receive one 30-minute session of orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment. The manual therapy and exercises are tailored to the individual based on their limitations and restrictions.
89092235|NCT02791750||Observational|Patients followed for a medical consultation in the Institut de Cancérologie de Lorraine at 5 years of the beginning of an adjuvant hormonal therapy.
89092236|NCT04234516|Active Comparator|Buprenorphine|Sublingual buprenorphine-naloxone films
89092237|NCT04234516|Active Comparator|Morphine|Oral morphine sulphate tablets
89092238|NCT02791672||Same Day Discharge|Following a Latissimus Dorsi flap reconstruction patients will be offered discharge at 24 hours. Patients successfully discharged within 24 hours of their surgery will be included in the cohort group.
89092239|NCT02789566|Experimental|Regimen|Primaquine (PQ) 30 mg base single dose
89092240|NCT02791360|Other|MRI evaluation|Patient pretreated for brain tumor and witness
89092241|NCT00872521|Experimental|bortezomib; doxorubicin; dexamethasone|PAD induction Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1 4 8 & 11) Doxorubicin 20 mg/m2 i.v. (D1 & 4) Dexamethasone 20 mg p.o. (D1 2 4 5 8 9 11 & 12)
89092242|NCT04234438|Active Comparator|Before application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa Before subliminal micropulse laser application
88812581|NCT02272634|Placebo Comparator|Treatment C|Multiple oral matching placebo (2 x 1 YPL-001 80 mg matching placebo tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days.
89092243|NCT04234438|Active Comparator|After application|32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa After 12 months subliminal micropulse laser application
89092244|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Patients with clinical suspicion for CTEPH, scheduled for SPECT
89092245|NCT02791126||Heart Failure|"Patients presented to hospital with a primary diagnosis of Heart Failure or are attending a hospital clinic for management of Heart Failure within 6 months of an episode of decompensated heart failure, which either resulted in a hospital admission (primary diagnosis) or was treated in out-patient clinic.~Cardiovascular Magnetic Resonance and Echocardiogram will be performed."
89092246|NCT02790814|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
89092247|NCT02790814|Active Comparator|Hand-held fetoscope|Intermittent fetal heart rate monitoring
89092248|NCT00693667|Placebo Comparator|A|Placebo
89092249|NCT00693667|Active Comparator|B|250 mg active ingredient
89092250|NCT00693667|Active Comparator|C|500 mg active ingredient
89092251|NCT00693667|Active Comparator|D|750 mg active ingredient
89092252|NCT02791048|Experimental|Experimental Group|Music therapy for up to 45 minutes twice a week for three weeks, in addition to usual care from the hospice multidisciplinary team.
89092253|NCT02791048|No Intervention|Control Group|Usual care only from the hospice multidisciplinary team. The dose and frequency of usual care will be as deemed appropriate by the hospice practitioner in charge of their treatment.
89092254|NCT00697021|Active Comparator|1|Patients who suffered acute STEMI and were treated by PPCI and by Aspirin 100mg and Plavix 75mg and showed on treatment platelet over-reactivity observed by TEG system on the 5th day after admission to ICCU
89092255|NCT00697021|Other|2|Patients who suffered acute STEMI and were treated by PPCI and recieved by Aspirin 100mg and Plavix 75mg and showed platelet inhibition observed by TEG system on the 5th day after admission to ICCU
89092256|NCT02790892|Other|Art therapy - pre and post test measures|20 young adults aged 15-24 years with diabetes (10 with type 1 diabetes and 10 with type 2 diabetes) receiving 12 weeks of group art therapy. Participants serve as their own controls.
89092257|NCT02620345|Experimental|Dydrogesterone M/ Women Pregnancy|"Reducing the size of fibroids with medication~Drug: Dydrogesterone M 15mg/Fibroids/Women Pregnancy~Dosage:~1tablet/24 hours/day/ (when seeing fibroids to 4 weeks after postpartum). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day~The lost in size of fibroids throughout pregnancy after 48 weeks."
89092258|NCT02620345|Experimental|Dydrogesterone M/ Reproductive Age|"Reducing the size of fibroids with medication~Drug: Dydrogesterone M 15mg/Fibroids/Reproductive Age~Dosage:~1tablet/24 hours/day/24 weeks ( from discovered fibroids through 24 weeks). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day~The lost in size of fibroids after 24 weeks."
89092259|NCT02790970|Experimental|PReDicT Test|To determine whether use of the PReDicT Test to direct antidepressant treatment results in an increased proportion of depressed patients showing a response to treatment at week 8
89092260|NCT02790970|Placebo Comparator|Treatment as usual|Treat patients as usual without using the predict test to determine treatment.
89092261|NCT02623543|Experimental|OrthoK|OrthoK lenses will be prescribed for subjects randomly and followed for 2yrs throughout wearing the lenses. There will be an enrollment appointment, dispense appointment, 1-day, 1-week, 1-month, 6-month, 12-month, and 24-month follow-ups.
89092262|NCT02623543|Placebo Comparator|Control|Subjects in the randomly assigned control will continue to wear their glasses throughout the 2yr follow-up period. There will be an enrollment appointment, 6-month, 12-month, and 24-month follow-ups.
89092263|NCT00696163||A|
89092264|NCT02790502|Other|Intervention|Intervention Group
89092265|NCT02790580|Active Comparator|Dose-dense doxorubicin/cyclophosphamide|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after doxorubicin/cyclophosphamide
89092266|NCT02790580|Experimental|Dose-dense doxorubicin/cyclophosphamide + sunitinib|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide, Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0), Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)
89092267|NCT00693823|Active Comparator|1|Femoral-popliteal surgical bypass with prosthetic graft
89092268|NCT00693823|Active Comparator|2|Interventional angioplasty and placement of an ePTFE covered stent graft within the femoral-popliteal artery as an endoluminal bypass percutaneously
89092269|NCT02788864|Active Comparator|Arterakine|Active drug: Arterakine (DHA/piperaquine) one tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinin; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
89092270|NCT02788864|Placebo Comparator|Placebo|Placebo (visually matched to Arterakine for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
89092271|NCT05298787|Experimental|SAD - 2mg/kg or placebo IV infusion|Single IV infusion
89092272|NCT05298787|Experimental|SAD - 10mg/kg or placebo IV infusion|Single IV infusion
89092273|NCT05298787|Experimental|SAD - 40mg/kg or placebo IV infusion|Single IV infusion
89092274|NCT05298787|Experimental|MAD - 2mg/kg or placebo IV infusion|IV infusion given every 8 hours over 3 days for a total of 9 doses
89092275|NCT05298787|Experimental|MAD - 10mg/kg or placebo IV infusion|IV infusion given every 8 hours over 3 days for a total of 9 doses
89092276|NCT05298787|Experimental|SAD - 120mg/kg or placebo IV infusion|Single IV infusion
89092277|NCT05298787|Experimental|MAD - 40mg/kg or placebo IV infusion|IV infusion given every 8 hours over 3 days for a total of 9 doses
89092278|NCT04137055|Experimental|ZSP0678-10mg (single dose)-Cohort 1|ZSP0678/Placebo 10mg
89092279|NCT04137055|Experimental|ZSP0678-30mg (single dose)-Cohort 2|ZSP0678/Placebo 30 mg Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.
89092280|NCT04137055|Experimental|ZSP0678-60mg (single dose)-Cohort 3|ZSP0678/Placebo 60mg Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.
89092281|NCT04137055|Experimental|ZSP0678-120mg (single dose)-Cohort 4|ZSP0678/Placebo 120mg Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.
89092282|NCT04137055|Experimental|ZSP0678-180mg (single dose)-Cohort 5|ZSP0678/Placebo 180mg Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.
89092283|NCT04137055|Experimental|ZSP0678-240mg (single dose)-Cohort 6|ZSP0678/Placebo 240mg Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.
89092284|NCT04137055|Experimental|ZSP0678-320mg (single dose)-Cohort 7|ZSP0678/Placebo 320mg Enrollment into Cohort 7 will begin upon assurance of safety for Cohort 6.
89092285|NCT04137055|Experimental|ZSP0678 (food effect)-Cohort FE|"Period 1: Group A and Group B receive ZSP0678/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2: Group A and Group B receive ZSP0678/Placebo under the fed or fasting condition ,respectively on Day8.~Enrollment into Cohort FE will begin upon assurance of safety for Cohort 4."
89092286|NCT04137055|Experimental|ZSP0678 Dose1 (multiple doses)-Cohort 8|ZSP0678/Placebo Dose1 will be administrated according to the results of Cohort 2&3
89092287|NCT04137055|Experimental|ZSP0678 Dose2 (multiple doses)-Cohort 9|ZSP0678/Placebo Dose2 will be administrated according to the results of Cohort 3&4
89092288|NCT04137055|Experimental|ZSP0678 Dose3 (multiple doses)-Cohort 10|ZSP0678/Placebo Dose3 will be administrated according to the results of Cohort 4&5
89092289|NCT02788786|Experimental|chlorhexidine|0.12% w/v chlorhexidine oral rinse; 15ml, twice-daily, for 12 weeks
89092290|NCT02788786|Experimental|cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride oral rinse; 15ml, twice-daily, for 12 weeks
89092291|NCT02788786|Active Comparator|Salt and Water|Salt and water based oral rinse; 15ml, twice-daily, for 12 weeks
89092292|NCT02788786|No Intervention|No oral rinse|No rinse provided in this group
89092293|NCT00693901|Experimental|1|Parks will be assigned to the community-based participatory research condition.
89092294|NCT00693901|Active Comparator|2|Parks will be assigned to the director-only condition.
89092295|NCT00693901|No Intervention|3|Parks will be assigned to the control condition and will receive no intervention.
89092296|NCT03668236|Experimental|Fluid restriction group|"No IV fluids unless one of the extenuating circumstances occur; then, IV fluid may be given in measured amounts:~In case of severe hypoperfusion or severe circulatory impairment defined by either:~Lactate≥4 mmol/L~MAP<50 mmHg (with or without vasopressor/inotrope)~Mottling beyond the kneecap (mottling score >2) OR~Urinary output<0.1 mL/kg bodyweight/h, but only in the first 2hrs after randomisation~A bolus of 250-500 ml of IV crystalloid solution may be given followed by re-evaluation~In case of overt fluid losses (e.g. vomiting, large aspirates,…) IV fluid may be given to correct for the loss, but not above the volume lost.~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:~Correct dehydration or electrolyte deficiencies~Ensure a total fluid input of 1L per 24hrs~IV fluids may be given as carrier for medication, but the volume should be reduced to the lowest possible"
89092297|NCT03668236|Active Comparator|Standard-care|"There will be no upper limit for the use of either IV or oral/enteral fluids. In particular:~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
89092298|NCT02623465|Experimental|Part A:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin once in each of 3 periods
89092299|NCT02623465|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
89092300|NCT02623465|Experimental|Part B:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin with each meal for 14 days
89092301|NCT02623465|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
89092302|NCT04232800|Experimental|Riboflavin|Participants in this group will receive 100mg riboflavin TID during study participation.
89092303|NCT04232800|Placebo Comparator|Placebo|Participants in this group will receive inert placebo capsules TID during study participation.
89092304|NCT01148225|Other|Adalimumab|Participants received open label (OL) adalimumab 40 mg by subcutaneous (SC) injection every other week (eow) until the final visit.
89092305|NCT02623387|Active Comparator|Standard Paravertebral Block|Patients receiving a conventional paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered using anatomical landmarks
89092306|NCT02623387|Active Comparator|Ultrasound Guided Paravertebral Block|Patients receiving paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered under ultrasound guidance
89092307|NCT02788240|Experimental|Peg GCSF with standard medical therapy|
89092308|NCT02788240|Active Comparator|Placebo with standard medical therapy|
89092309|NCT02788162|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89092310|NCT04134715|Experimental|PF-06826647 alone then OC alone then OC+PF-06826647|In Period 1 (Period 1 is 2 days), participants will receive a single dose of PF-06826647 600 mg on Day 1. Period 2 (Period 2 is 14 days) will immediately follow Period 1 without any washout. In Period 2, the participants will receive OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet, orally starting from Period 2 Day 1 until Period 3-Day 16 (Period 3 is 17 Days). Period 3 will immediately follow Period 2 with no washout. In Period 3 on Day 1, the participants will receive a single dose of PF-06826647 600 mg. On Day 2 in Period 3, PF-06826647 will not be dosed. From Day 3, the participants will receive PF-06826647 600 mg QD for 14 days followed by OC in the form of 1 PORTIA (EE and LN) or equivalent tablet.
89092311|NCT00694057|Placebo Comparator|Placebo|Placebo capsules BID
89092312|NCT00694057|Experimental|Active|HE3286 10 mg (5 mg BID)
89092313|NCT02884115|Active Comparator|Retreatment group|Serofast early syphilis cases retreated with three doses benzathine penicillin
89092314|NCT02884115|No Intervention|Control group|Absence of any retreatment
89092315|NCT00696319|Experimental|1|Arm 1 will go through a rehabilitation protocol with perturbation training exercises.
89092316|NCT00696319|Experimental|2|Arm 2 will go through a rehabilitation protocol with traditional exercises for balance and stability training.
89111133|NCT02801409|Experimental|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
89111134|NCT00907296|Placebo Comparator|Placebo|Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.
89092317|NCT01190891|Active Comparator|Manual Physical Therapy|The orthopaedic manual physical therapy (OMPT) intervention approach used in this study will be based on an impairment model. The physical therapist providing the intervention will address the impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients will receive procedures tailored to their specific impairments. Procedures will include mobilizations and manipulations of the joint and soft-tissues.
89092318|NCT01190891|Active Comparator|Corticosteroid Injection (Subacromial)|Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL
89092319|NCT00871975|Experimental|Urodynamics + Tetra|All patients were recruited to the same arm and receive Urodynamics testing as part of the routine diagnostic work-up, plus the Tetra-NIRS intervention.
89092320|NCT00694213|Experimental|1|
89092321|NCT00694213|Experimental|2|
89092322|NCT00694213|Experimental|3|
89092323|NCT00694213|Placebo Comparator|4|
89092324|NCT04134403|Experimental|Arm 1: Intervention|Arm will be those that are randomized to receive usual care plus hydrocortisone, thiamine and ascorbic acid.
89092325|NCT04134403|No Intervention|Arm 2: Usual care|Arm will be those that are randomized to receive usual care alone.
89092326|NCT01190813|Active Comparator|Levodopa/Carbidopa|Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
89092327|NCT01190813|Placebo Comparator|Placebo|Oral placebo tid
89092328|NCT03641326|Experimental|Participants With Primary Gliosarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
89092329|NCT03641326|Experimental|Participants With Secondary Gliosarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
89111135|NCT00907296|Experimental|Romosozumab 70 mg: 2 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
89092330|NCT03641326|Experimental|Participants With Primary Central Nervous System (CNS) Sarcoma|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest. Participants will be given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
89092331|NCT03721510|Active Comparator|Group 1A|HIV-uninfected volunteers receiving one IV infusion
89092332|NCT03721510|Active Comparator|Group 1B|HIV-uninfected volunteers receiving one IV infusion
89092333|NCT03721510|Active Comparator|Group 2|HIV-infected volunteers on ART receiving three or six IV infusions
89092334|NCT02788942|No Intervention|Umbilical|The cholecystectomy material will be removed from umbilical port as usual. This will be control group. Port site infection rates will be measured.
89092335|NCT02788942|Experimental|Epigastric|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured.
89092336|NCT04313309|Experimental|Support Group|This is the only group in the study consisting of patients with chronic musculoskeletal pain who are receiving the Integrative Yoga Therapy Program
89092337|NCT00870727|Experimental|Arm 1. Aripiprazole oral product|Participants will receive Aripiprazole oral product with a minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
89092338|NCT00870727|Placebo Comparator|Arm 2. Placebo oral capsule|Participants will receive matching (identical in size and appearance to study drug) placebo oral capsules over 8-weeks of treatment.
89092339|NCT03707782||Individuals with immune deficiencies|aged 18 years or older and have an immune deficiency
89092340|NCT03707782||Family members|aged 18 years or older and are related to a person who has an immune deficiency
89092341|NCT02787928|Experimental|Intrathecal Dilaudid|This will be a prospective up/down dosage study. After obtaining informed consent, eligible participants will be part of an up/down dose titration study. This first phase of our study will be conducted using intrathecal (spinal) hydromorphone to determine an appropriate dose range for our study population. Study drug dose will initially be 40 mcg. The only deviation from the current standard of care will be that patients will be given hydromorphone intrathecally instead of morphine. The rest of the care provided will be standard of care and per current practices at VCU labor and delivery floor.
89092342|NCT02617069|Experimental|Group 1 (Cardiac surgery+botulinum toxin)|All patients underwent conventional cardiac surgery. After the main stage of the surgery botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
89111136|NCT00907296|Experimental|Romosozumab 70 mg: 3 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
89111137|NCT00907296|Experimental|Romosozumab 70 mg: 4 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.
88812582|NCT02026388||Primary Hyperoxaluria|Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.
88812583|NCT02026388||Dent Disease|Diagnosis of Dent Disease, or a family member of someone with this diagnosis.
88812584|NCT02026388||Cystinuria|Diagnosis of Cystinuria, or a family member of someone with this diagnosis.
88812585|NCT02026388||APRT deficiency|Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.
89092343|NCT02617069|Active Comparator|Group 2 (Cardiac surgery+placebo)|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
89092344|NCT02788630|Experimental|Intervention group|Arm: Experimental: Intervention group Field workers trained in sleep hygiene counseling will advice the mothers randomly allocated to the intervention group. The intervention will be delivered at the child household and will include information on: Normal sleep behaviors during the first year of life; ideal conditions to promote sleep onset like environmental improvements that ensure restful sleep (no screen media, low noise and light); calming naptime routines and avoiding stimulating or stressing children just before naptime; practices that promote child self-regulation of sleep, including putting infants to sleep drowsy but awake; and how to handle nighttime awakenings. A booklet with the intervention content to aid the mother in implementing the intervention will be used.
89111138|NCT00907296|Experimental|Romosozumab 140 mg: 2 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
88812586|NCT01366404||FFR|Patients who had FFR measurement
88812587|NCT01007357|Other|Body MRI healthy volunteers|Body MRI to optimize sequences in healthy individuals and in disorder subjects
88812588|NCT00788125|Experimental|Dasatinib with Ifosfamide, Carboplatin, Etoposide|
88812589|NCT00606463|Experimental|(Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
89092345|NCT02788630|No Intervention|Control group|Mothers randomly allocated to the control group will be visited at home following the same schedule as the intervention group. The control group will receive a written material describing the advantages of breastfeeding over maternal and child health. No advice in relation to child sleep hygiene will be delivered to the mothers from the control group.
89092346|NCT02619877|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
89092347|NCT02619877|Active Comparator|Standard therapy|Standard therapy for patients with diabetic foot ulcer
89092348|NCT02788552|Active Comparator|Acute Symptomatic WKS- 300mg|Thiamine Hydrochloride 300mg daily (i.e. 100mg 3 times/day) for 5 days
88812590|NCT00554437|Experimental|1|Intermediate-intensity, community-based, multifactorial falls intervention
89092349|NCT02788552|Active Comparator|Acute Symptomatic WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 5 days
89092350|NCT02788552|Active Comparator|Acute Symptomatic WKS - 1500mg|Thiamine Hydrochloride 1500mg daily (i.e. 500mg 3 times/day) for 5 days.
89092351|NCT02788552|Active Comparator|High-risk subclinical WKS- 100mg|Thiamine Hydrochloride 100mg once daily for 3 days.
89092352|NCT02788552|Active Comparator|High-risk subclinical WKS- 300mg|Thiamine Hydrochloride 300mg (i.e. 100mg 3 time/day) for 3 days
89092353|NCT02788552|Active Comparator|High-risk subclinical WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 3 days.
89092354|NCT04135339|Experimental|Group A. Eccentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
89092355|NCT04135339|Experimental|Group B. Concentric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
89092356|NCT04135339|Experimental|Group C. Isometric exercise.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
89092357|NCT04135339|No Intervention|Group D. Control.|15 subjects with a latent myofascial trigger point in the medial gastrocnemius muscle.
89092358|NCT01147055|Experimental|1|There should be at least 14-day washout period between treatment A and B.
89092359|NCT00696397||A|adult men and women between 18 and 50 years of age with atopic dermatitis
89092360|NCT03705754|Active Comparator|Tattoo arm|Tattoo will be placed by endoscopic submucosal injection of carbon black suspension
89092361|NCT03705754|No Intervention|Control arm|Tattoo will not be placed but case will follow standard procedure
89092362|NCT02623231|Experimental|escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
89092363|NCT02623231|Placebo Comparator|placebo|Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
89092364|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 1: 0.5mg CVL-936|Oral suspension/solution
89092365|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo|Matching Placebo; Oral suspension/solution
88812591|NCT00554437|Active Comparator|2|Occupational therapist home safety evaluation
89092366|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 2:TBD mg CVL-936|Oral suspension/solution
89092367|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
89092368|NCT04232878|Active Comparator|Active Comparator: Group 1 Period 3:TBD mg CVL-936|Oral suspension/solution
89092369|NCT04232878|Placebo Comparator|Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
89092370|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 1:TBD mg CVL-936|Oral suspension/solution
89092371|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
89092372|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 2:TBD mg CVL-936|Oral suspension/solution
89092373|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
89092374|NCT04232878|Active Comparator|Active Comparator: Group 2 Period 3:TBD mg CVL-936|Oral suspension/solution
89092375|NCT04232878|Placebo Comparator|Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
89092376|NCT04232878|Active Comparator|Active Comparator: Group 3: TBD mg CVL-936|Oral suspension/solution
89092377|NCT04232878|Placebo Comparator|Placebo Comparator: Group 3: TBD mg Matching Placebo|Matching Placebo; Oral suspension/solution
89092378|NCT02623153|Active Comparator|capecitabine and oxaliplatin|capecitabine of 1000 mg/m2, orally administered twice a day on days 1-14 and oxaliplatin at 130 mg/m2on day 1, as intravenous 2 h infusion
89092379|NCT02623153|Experimental|S1, oxaliplatin and docetaxel|S1 of 40 mg/m2, orally administered twice a day on days 1-14,oxaliplatin 130 mg/m2 and docetaxel 40 mg/m2on day 1 as intravenous
89092380|NCT04316195||Patient admitted for an acute traumatic spinal cord injury|
89092381|NCT02616913|Experimental|R,R-monatin|150 mg single dose
89092382|NCT02616913|Active Comparator|Moxifloxacin|400 mg tablet single dose
89092383|NCT02616913|Placebo Comparator|Placebo|placebo single dose
89092384|NCT02884037||1|Rifaxmin group
89092385|NCT02884037||2|placebo group
89092386|NCT00912847||JHC|AFP > 20 ng/ml and USG positive
89092387|NCT00912847||Non JHC|patient without AFP > 20 or USG negative
89092388|NCT04233502|Experimental|Melatonin|Slenyto® 1 mg / 5 mg prolonged release Melatonin tablets (pink and yellow) film coated 3 mm in diameter,
89226525|NCT03866187|Experimental|Group B1_Step B|Subjects aged 18-65 years receive one dose of each of the study vaccines, ChAd155-hIi-HBV high dose formulation at Day 1, MVA-HBV high dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at Day 169.
89226526|NCT03866187|Active Comparator|Group B2_Step B|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 high dose formulation, one dose each at Days 1, 57, 113 and 169.
89226527|NCT03866187|Active Comparator|Group B3_Step B|Subjects aged 18-65 years receive two doses of placebo, one each at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation at Day 169.
89226528|NCT03866187|Experimental|Group C1_Step C|Subjects aged 18-65 years receive one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 1 and the 3 following doses of MVA-HBV high dose formulation co-administered with HBc-HBc-HBs/AS01B-4 high dose formulation at Day 57, 113 and Day 169.
89226529|NCT03866187|Active Comparator|Group C2_Step C|Subjects aged 18-65 years receive two doses of placebo at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 169.
89226530|NCT03853707|Experimental|Arm A (ipatasertib, carboplatin, paclitaxel)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89226531|NCT03853707|Active Comparator|Arm B (ipatasertib and carboplatin)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89226532|NCT03853707|Experimental|Arm C (ipatasertib, capecitabine, atezolizumab)|Patients receive ipatasertib PO QD on days 1-21, capecitabine PO BID on days 1-7 and 15-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89226533|NCT03850899||Cases|Heavy drinkers with alcoholic hepatitis
89226534|NCT03850899||Controls|Heavy drinkers without significant liver disease
89226535|NCT03850899||Donor|Healthy non-drinkers
89226536|NCT03850678|Experimental|Hearing Aid|Group of participants with hearing loss. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels, while manipulating different hearing aid parameters and also without the provision of amplification, will be assessed.
89226537|NCT03850678|No Intervention|Normal Hearing|Group of participants with normal hearing that serve as a reference group. Subjects will complete a questionnaire that asks relevant questions about their medical and developmental history and educational level. Participants will be screened for a potential cognitive impairment using the Montreal Cognitive Assessment Basic (MOCA-B). Working memory span will be assessed using the reading span test. Each subject will undergo a routine audiological examination, including audiometric testing and tympanometry. The ability of the subjects to detect different frequencies and to repeat speech presented at a variety of levels will be assessed.
89226538|NCT03845166|Experimental|XL092 Single-Agent Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 3-6 subjects in a standard 3 plus 3 design."
89226539|NCT03845166|Experimental|XL092 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).
89226540|NCT03845166|Experimental|XL092 + Atezolizumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
89226541|NCT03845166|Experimental|XL092 + Atezolizumab Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), metastatic castration-resistant prostate cancer (mCRPC), and colorectal cancer (CRC).
89226542|NCT03845166|Experimental|XL092 + Avelumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
89226543|NCT03843918|Experimental|LAE001+ADT|LAE001+ADT
89226544|NCT03840967|Other|Niraparib|
89226545|NCT03825757|Experimental|Primaspan tablet 250 mg|Primaspan tablet 250 mg (Acetyl salicylic acid): 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
89226546|NCT03825757|Placebo Comparator|Placebo tablet|Placebo Oral Tablet: 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
89226547|NCT03817021|Experimental|All Factors On|Nutrition and Physical Activity Self-Assessment of Childcare (Core NAP SACC) will be turned on ECE Provider intervention will be turned on Parent intervention will be turned on Child intervention will be turned on
89226548|NCT03817021|Experimental|NAP SACC on/ECE on/Parent on|Core NAP SACC will be turned on ECE Provider intervention will be turned on Parent intervention will be turned on Child intervention will be turned off
89226549|NCT03817021|Experimental|NAP SACC on/ECE on/Child on|Core NAP SACC will be turned on ECE Provider intervention will be turned on Parent intervention will be turned off Child intervention will be turned on
89226550|NCT03817021|Experimental|NAP SACC on/ECE on|Core NAP SACC will be turned on ECE Provider intervention will be turned on Parent intervention will be turned off Child intervention will be turned off
89226551|NCT03817021|Experimental|NAP SACC on/Parent on/Child on|Core NAP SACC turned on ECE Provider intervention turned off Parent intervention turned on Child intervention turned on
89226552|NCT03817021|Experimental|NAP SACC on/Parent on|Core NAP SACC turned on ECE Provider intervention turned off Parent intervention turned on Child intervention turned off
89226553|NCT03817021|Experimental|NAP SACC on/Child on|Core NAP SACC turned on ECE Provider intervention turned off Parent intervention turned off Child intervention turned on
89092389|NCT04233502|Placebo Comparator|Placebo melatonin|Placebo melatonin will be identical in appearance (pink and yellow) and formulation to active Slenyto® tablets, but will contain no active melatonin.
89092390|NCT02616679||Cognitively Normal|Participants will be deemed cognitively normal based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
89092391|NCT02616679||Amnestic Mild Cognitive Impairment (aMCI)|Participants will be deemed aMCI based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
89092392|NCT01146665|Experimental|Computer-based PAF|Standard medical care followed by computer-based personalized assessment feedback (PAF).
88812592|NCT00890162|Active Comparator|Omalizumab|Subjects will receive two doses of Omalizumab while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
88812593|NCT00890162|Placebo Comparator|Placebo|Subjects will receive two doses of placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
89092393|NCT01146665|Sham Comparator|Computer-based sham|Standard medical care followed by a computer-based sham.
89092394|NCT00696475|Experimental|1|Diazoxide equivalent dose
89092395|NCT00696475|Experimental|2|Diazoxide equivalent dose
89092396|NCT00696475|Experimental|3|Diazoxide equivalent dose
89092397|NCT00696475|Placebo Comparator|4|
89092398|NCT03628066|Experimental|Arm 1|"Oncotype DX Breast recurrence score on diagnostic tissue~Daily Letrozole for 24 weeks + Palbociclib daily for 24 weeks + Goserelin weekly for 24 weeks"
89092399|NCT02616757|Active Comparator|Simple Bone Cyst Patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline and once annually for 2 years.~There will also be optional blood samples taken o measure bone alkaline phosphatase."
89092400|NCT02616757|Active Comparator|Fracture patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at future follow-up visits as clinically indicated or at a one year follow-up visit.~There will also be optional blood samples taken to measure bone alkaline phosphatase."
89111139|NCT00907296|Experimental|Romosozumab 140 mg: 3 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
89111140|NCT00907296|Experimental|Romosozumab 140 mg: 4 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.
89092401|NCT02616757|Placebo Comparator|Health volunteers|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at a one year follow-up visit.~There will also be optional blood samples taken to measure bone alkaline phosphatase."
89092402|NCT00625079|Placebo Comparator|Pre-transplant placebo|There are two placebo comparators.... one for the group of patients with resting PAH and another for the group of patients with exercise PAH
89092403|NCT00625079|Experimental|Pre-transplant sildenafil|There are two active comparators, one group with resting PAH and another with exercise PAH, both receiving drug.
89092404|NCT00625079|No Intervention|Pre-transplant no PAH-specific therapy|this group of patients has no evidence for either resting or exercise PAH but will be followed without specific drug intervention
89092405|NCT02788084||B cell Non-Hodgkin Lymphoma|18 years of age or older with new diagnosis of non-Hodgkin lymphoma with FFPE specimen demonstrating enough tissue for elucidation of lymphoma specific variant and immunoglobulin clonotype, willing to provide baseline and follow up bloodwork to look for presence of variant and clonotype.
89092406|NCT00912769||subvastus approach/ midvastus approach|subvastus: vastus medialis oblique was not cut during operation midvastus: vastus medialis oblique was cut during operation
89092407|NCT00912769||Cybex|Knee extension/ flexion isometric and isokinetic performance of all cases were tested using Cybex
89226554|NCT03817021|Experimental|NAP SACC on|Core NAP SACC turned on ECE Provider intervention turned off Parent intervention turned off Child intervention turned off
89092408|NCT02788318||diagnostic of SUDEP|patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause (diagnosis of SUDEP). Brain samples and skin samples are collected.
89092409|NCT02788318||Control 1|Subjects with a known epilepsy, whose death is linked to a specific cause. Brain samples and skin samples are collected.
89092410|NCT02788318||Control 2|Subjects without known pathological history, remained victims of unexplained sudden unexpected death (SUDEP) after all investigations and for which a heart rhythm disorder is suspected in first intention. Brain samples and skin samples are collected.
89092411|NCT02619721|Experimental|Sacral Neuromodulation is on|Sacral Neuromodulation is on as soon as implantation
89092412|NCT02619721|Placebo Comparator|Sacral Neuromodulation is off|Sacral Neuromodulation is off after implantation
89092413|NCT04133389|Experimental|Growth Mindset of Personality|Experimental intervention
89092414|NCT04133389|Placebo Comparator|Growth Mindset of Athletic Ability|Control intervention
89092415|NCT02787616||Rosacea Group|
89092416|NCT02787616||Non-Rosacea Group|
89092417|NCT02787772|Experimental|Elective Hernia Repair|Elective abdominal wall hernia surgery was performed in randomized cirrhotic patients.
89092418|NCT02787772|No Intervention|Clinical follow up|"Cirrhotic patients were kept in clinical follow up concerning their abdominal wall hernia.~If a complication occured at the hernia site (such as skin rupture, bowel strangulation,..) the patient underwent emergency hernia repair."
89092419|NCT02616835|Experimental|theta-burst TMS|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
89092420|NCT02616835|Sham Comparator|sham theta-burst TMS|Sham protocol for theta-burst transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
89092421|NCT01145885|Experimental|BI 6727|BI 6727 cycles in every 21 days
89092422|NCT02787538|Experimental|US-ANSWER-2 decision aid|The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option.
89092423|NCT02787538|Active Comparator|Control group (Online medication guide)|The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.
89092424|NCT02616991|Experimental|Cohort|computed tomography venography
89092425|NCT02786992|Active Comparator|Misoprostol + Oxytocin|400 ug sublingual misoprostol + 10 IU Oxytocin IVI
89092426|NCT02786992|Active Comparator|Carbetocin|100 ug Carbetocin IV
89092427|NCT02617303|Experimental|OTAGO'S program arm|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive OTAGO'S exercise program during three months, followed by adherence phase. Falls and fractures will be quarterly followed during 15 months.
89092428|NCT02617303|Active Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. Normal medical treatment will be provided by family physicians and nurses. Falls and fractures will be quarterly followed during 15 months.
89092429|NCT02884193|Experimental|Brief Cooling (Quick Icing)|Group receiving the application of cold on the ventral side of the dominant forearm for 30 seconds, using the technique of ice beakers dynamically.
89092430|NCT02884193|Active Comparator|Prolonged Cold|"Group receiving the intervention of ice bag for a period of 5 and a half minutes from 1 minute, on the ventral side of the dominant forearm"
89092431|NCT02884193|Sham Comparator|Control|"Group receives a placebo application through an ice bag empty. The bag will be applied from 1 minute to 6 and a half minutes, as the group of prolonged cold"
89092432|NCT02787460|Experimental|Behavioral Text Messages|Couples assigned to a treatment group will receive weekly behavioral theory-based messages encouraging them to attend the sessions.
89092433|NCT02787460|No Intervention|Simple Reminder Text Messages|"Couples in the control group will receive simple reminder text messages that include the date, time, and location of their next group session"
89092434|NCT04232644|Active Comparator|Treatment A|crushed d-amphetamine IR tablets
88812594|NCT02504424|Experimental|AeroForm Tissue Expander|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
88812595|NCT01433081|Active Comparator|Magnesium sulfate infusion|Administration of magnesium suflate
88812596|NCT01433081|Placebo Comparator|Placebo|.9 normal saline infusion
89092435|NCT04232644|Experimental|Treatment B|manipulated ADAIR IR capsules
89092436|NCT02622529||Screening through Questionnaires|All of the patients within this single existent Arm will receive the questionnaires.
89092437|NCT03557788|Experimental|Rifaximin|Patients who receive PO Rifaximin 500mg TDS for 2 weeks. All patients will receive treatment to evaluate the effect of the intervention. This is a single-arm study.
89092438|NCT04133155||nab-P + GEM|Nab-paclitaxel plus gemcitabine
89092439|NCT01190267|Experimental|Asenapine|All enrolled participants receive open-label asenapine 2.5 mg twice daily (BID) on Day 1-3, which is increased to 5.0 mg BID on Day 4 (dose can be increased earlier at the investigator's discretion). Asenapine dosing is flexible for the remainder of the 26-week open-label drug administration period, and can be adjusted to either 2.5 mg or 5.0 mg BID at the investigator's discretion, based on tolerability and/or symptomatology.
89092440|NCT02622763|Experimental|10 millions dose|a total of 10 millions tolerogenic dendritic cells
89092441|NCT02622763|Experimental|100 millions dose|a total of 100 millions tolerogenic dendritic cells
89092442|NCT02787382|Experimental|Pregnant women with CMV infection|"An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography)."
89092443|NCT02787382|Experimental|Pregnant women with suspected CMV infection|"The healthy women from the group will serve as controls. An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography). As the control group-Newborns found to be negative for CMV will serve as control group."
89092444|NCT03279874||German dentists|Dentists who are working in dental offices in Germany
89092445|NCT00869089|Experimental|CC-10004|"CC-10004 treament:~30mg,oral medication, BID, for 24 weeks (60mg total DAILY)"
89092446|NCT01190189|Experimental|Cervarix Group|Healthy female subjects who received control vaccine in the primary study HPV-015 (NCT00294047), were administered three doses of Cervarix vaccine intramuscularly, according to a 0,1,6-month schedule.
89092447|NCT04232488|Experimental|Angiography performed using distal radial artery|Patients undergoing coronary angiography with or without intervention using distal radial artery ('snuff box') as a vascular access
89092448|NCT04232488|Active Comparator|Angiography performed using proximal radial artery|Patients undergoing coronary angiography with or without intervention using proximal radial artery as a vascular access
89092449|NCT02616367|Experimental|liposomal bupivacaine Periarticular injection|Will consist of 100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL liposomal bupivacaine 30 mL normal saline).
89092450|NCT02616367|Active Comparator|Ropivacaine Periarticular Injection|Will consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine
89092451|NCT05347264|Experimental|massage gun|15 to 20 minutes along with hot pack.
89092452|NCT05347264|Experimental|transverse friction massage|15 to 20 minutes along with hot pack.
89092453|NCT04200040|Experimental|treatment group|"OrienX010 will be administered once every two weeks by intratumoral injection. The treatment dose , depends on the patient's tumour size, The maximum dose of OrienX010 in at each treatment , the expected accumulated dose in 10 mL. The investigator should be confirmed the injectable tumor size and adequate dose within 24 hours prior to treatment.~OrienX010 treatment will be continuous and extend from first dose of study medication until to complete response, clinical related progression disease (PDr), untolerated toxicities, lost to follow up, death or meet end of treatment criteria."
89092454|NCT04200040|Active Comparator|Control group|Dacarbazine will be administered once every three weeks by intravenous 1000mg/square meter. Dacarbazine treatment will be continuous and extend from first dose of study medication until to progression disease (PD), untolerated toxicities, lost to follow up, death or meet end of treatment criteria.
89092455|NCT00871117|Experimental|Kinrix + M-M-R II + Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II and Varivax each, subcutaneously in the deltoid of the right upper and lower arm, respectively.
89092456|NCT00871117|Active Comparator|Kinrix + M-M-R II -> Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II, subcutaneously in the deltoid of the right upper arm. At Day 30 they received one dose of Varivax subcutaneously in the deltoid region of the right upper arm.
89092457|NCT04232722|Experimental|Sorafenib + arsenical|After enrollment, the patients received oral treatment at sorafenib 200mg bid continuous and realgar-indigo naturalis formula preparation at 60mg/kg tid p.o, d1-14, q4w
89092458|NCT02787070|Active Comparator|Primaquine supervised|14 days of supervised primaquine treatment (0.5mg/kg/day).
89226555|NCT03812562|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive standard of care yttrium Y 90 glass microspheres IV. Within 1-2 weeks of completing of yttrium-90 treatment, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. If imaging shows adequate FLR and at least stable disease, patients will undergo resection within 2 weeks after the last dose of nivolumab. Patients who do not complete resection due to feasibility and have progressed or have evidence of high-risk explant may continue to receive nivolumab IV every 2 weeks for up to 1 year.
89226556|NCT03812224|Experimental|Erenumab|Participants were to receive erenumab 70 mg once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
89226557|NCT03812224|Placebo Comparator|Placebo|Participants were to receive placebo to erenumab once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
89226558|NCT03809624|Experimental|Single Agent Escalation|INBRX-105 will be escalated in patients with locally advanced or metastatic solid tumors.
89092459|NCT02787070|Active Comparator|Primaquine unsupervised|14 days of unsupervised primaquine treatment (0.5mg/kg/day).
89092460|NCT02622685|Experimental|DWP10292|"Drug: DWP10292 DWP10292 tablets, oral administration, multiple administration~Arms: DWP10292"
89092461|NCT02622685|Placebo Comparator|DWP10292 Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations~Arms: Placebo"
89092462|NCT02622685|Experimental|Ursodeoxycholic acid (UDCA)|"Drug: Ursodeoxycholic acid (UDCA) UDCA tablets, oral administration, multiple administrations~Arms: Ursodeoxycholic acid (UDCA)"
89092463|NCT02622685|Placebo Comparator|Ursodeoxycholic acid (UDCA) Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations~Arms: Placebo"
89092464|NCT02622607|Experimental|ZOL|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 months for 12 months.
89092465|NCT02622607|No Intervention|Control|No investigational treatment
89092466|NCT02622841|Experimental|BLEND|Combination of stereotactic bodyradiotherapy and surgical stabilization within 48 hours for the treatment of unstable spinal metastases.
89092467|NCT02622451|Other|Youth Behavioral Intervention|Teen Intervene
89092468|NCT02622451|Other|Parent Education|Everyday Parenting
89092469|NCT02619565|Other|Blood samples if evolution of the disease|blood samples at Day 0 and also if there is an evolution of the disease
89092470|NCT03181750|No Intervention|Control|Patients and caregivers randomized to this arm will receive a packet of educational materials in English or Spanish. These materials are written at 5-6th grade reading level. The materials focus on advance care planning, pain and symptom management, and hospice care.
89092471|NCT03181750|Experimental|Patient Navigator Intervention Group|Patient and caregivers randomized to this arm will receive the same packet of educational materials. They will also receive at least 5 visits from a bicultural bilingual patient navigator. The navigator will utilize a annualized visit guide manual to lead discussions on advance care planning, pain and symptom management, and hospice care.
89092472|NCT02616445|Placebo Comparator|MAD Study|
89092473|NCT02616445|Placebo Comparator|Fed-Fasted|
89092474|NCT02616445|Experimental|CSF|
89092475|NCT02622373||Birth Between 23-32 Weeks Gestation|Babies born between 23-32 weeks of gestational age will have their body composition determined using PEA POD Infant Body Composition System at 34 weeks, 36 weeks and 40 weeks of corrected age.
89092476|NCT02622373||Birth Between 34-36 Weeks Gestation|Babies born at 34 weeks and 36 weeks of gestational age will have their body composition measured using PEA POD Infant Body Composition System as soon as they are off parenteral nutrition and receiving full enteral nutrition.
89092477|NCT02622373||Birth at Term|Body composition will be measured using PEA POD Infant Body Composition System in this group will be obtained prior to discharge.
89092478|NCT02787226|Active Comparator|TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after total shoulder arthroplasty (TSA).
89092479|NCT02787226|Active Comparator|Reverse TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after reverse total shoulder arthroplasty (TSA).
89092480|NCT02787226|Active Comparator|TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after TSA.
89092481|NCT02787226|Active Comparator|Reverse TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after reverse TSA.
89092482|NCT00697567|Experimental|Group A|HSV seropositive subjects
89092483|NCT00697567|Experimental|Group B|HSV seronegative subjects
89092484|NCT00697567|Experimental|Group C|HSV seropositive subjects
89092485|NCT00697567|Experimental|Group D|HSV seronegative subjects
89092486|NCT02787148|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy for Major Depression
89092487|NCT02787148|No Intervention|Waitlist group|Waitlist group to control for repeated physiological measures and fluctuations over time
89092488|NCT02616289|Experimental|Emollient|Topical emollient (Sun Flower seed oil) in addition to routine standard of care for severe acute malnutrition.
89092489|NCT02616289|No Intervention|Control|Routine Standard of care only for severe acute malnutrition.
89092490|NCT03421756|Experimental|Non Myeloablative regimen (Alemtuzumab)|Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.
89092491|NCT00870103|Experimental|Vigadexa eye drops|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
89092492|NCT02619487|Experimental|8-12 years old, parent receiving text|text message to parent only
89092493|NCT02619487|Active Comparator|13-18 years old, parent receiving text|text message to parent only
89092494|NCT02619487|Active Comparator|13-18 years, both receiving text|Text message to parent and adolescent
89092495|NCT02619487|No Intervention|No text|No text will be sent
89092496|NCT03365752|Experimental|Chloroprocaine|
89092497|NCT03365752|Active Comparator|Mepivacaine|
89092498|NCT03365752|Active Comparator|General Anesthesia|
89092499|NCT02622217|Experimental|Sleep deprived|Participants undergo a simulation session after an on call night
89092500|NCT02622217|No Intervention|Rested|Participants undergo a simulation session after a night of normal sleep at home
89092501|NCT04133467||Group SB|Scalp block performed with Levobupivacaine 0.125% (total dose 2 mg/kg) in combination with intraoperative intravenous acetaminophen (15 mg/kg if body weight >10Kg, 7 mg/kg if body weight < 10 kg).
89092502|NCT04133467||Group ST|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg
89092503|NCT02619643|Experimental|Primed PAS 1A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
89092504|NCT02619643|Experimental|Unprimed PAS 1B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
89092505|NCT02619643|Sham Comparator|Sham PAS|A single session of sham paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied
89092506|NCT02619643|Experimental|Primed PAS 2A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
89092507|NCT02619643|Experimental|Unprimed PAS 2B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
89092508|NCT02619643|Experimental|Primed PAS 1C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
89092509|NCT02619643|Experimental|Primed PAS 2C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
89092510|NCT04232410||OSA Pcrit-DISE|Patients diagnosed with OSA and eligible for non-CPAP treatments
89226559|NCT03809624|Experimental|Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
89226560|NCT03809624|Experimental|Expansion Cohort Melanoma|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
89226561|NCT03809624|Experimental|Expansion Cohort PD-L1 Positive Basket|Patients with gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
89226562|NCT03809624|Experimental|Expansion Cohort Nasopharyngeal or Oropharyngeal Carcinoma|Patients with head and neck squamous cell carcinoma (NPC or OPC) will be treated with single-agent INBRX-105 at either the MTD or RP2D.
89226563|NCT03809624|Experimental|INBRX-105 Escalation in Combination with Pembrolizumab|INBRX-105 will be escalated in combination with Pembrolizumab in pateitns with locally advanced or metastatic solid tumors.
89226564|NCT03809624|Experimental|Combination Expansion Cohort Non-small Cell Lung Cancer|CPI relapsed/refractory patients will be treated with INBRX-105 in combination with Pembrolizumab.
89226565|NCT03809624|Experimental|Combination Expansion Cohort Melanoma|CPI relapsed/refractory patients will be treated with INBRX-105 in combination with Pembrolizumab.
89226566|NCT03809624|Experimental|Combination Expansion Cohort Cohort PD-L1 Positive Basket|CPI-relapsed/refractory patients with head and neck squamous cell carcinoma, gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-105 in combination with Pembrolizumab.
89226567|NCT03809624|Experimental|Combination Expansion Cohort CPI Naive Non-small Cell Lung Cancer|CPI naive patients (PD-L1 IHC between 1 and 49%) will be treated with INBRX-105 in combination with Pembrolizumab.
89226568|NCT03809624|Experimental|Combination Expansion Cohort CPI Naive HNSCC|CPI naive patients (PD-L1 IHC >50%) will be treated with INBRX-105 in combination with Pembrolizumab.
89226569|NCT03799003|Experimental|ASP1951 Monotherapy Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1951.Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
89226570|NCT03799003|Experimental|ASP1951 Monotherapy Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in a monotherapy or combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable.
89226571|NCT03799003|Experimental|ASP1951 Optional Monotherapy Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
89226572|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Escalation|The combination escalation cohort will evaluate escalating dose levels of ASP1951 in combination with a fixed dose of pembrolizumab. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
89226573|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in the combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable. Once the high dose RP2D and schedule of ASP1951 in combination with pembrolizumab has been determined, expansion cohorts may be opened to enroll participants with NSCLC (all PD-L1 status), NSCLC PD-L1 high, SCCHN and cervical cancer (if any of these tumor specific expansion cohorts are not already opened). Also, low dose cohorts of ASP1951 in combination will be opened in NSCLC (all PD-L1 status), SCCHN and cervical cancer for further evaluation of response and safety and establishing a possible low dose RP2D based on clinical and biomarker activity.
89111141|NCT00907296|Experimental|Romosozumab 210 mg: 2 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
89111142|NCT00907296|Experimental|Romosozumab 210 mg: 3 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
89111143|NCT00907296|Experimental|Romosozumab 210 mg: 4 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.
89226574|NCT03799003|Experimental|ASP1951 plus pembrolizumab Optional Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
89092511|NCT02785666|Experimental|Treatment and behavioural intervention:|"Treatment intervention: Patients with a replicating GT 1 and/or 4 HCV infection without or with cirrhosis will be treated with grazoprevir/elbasvir (100mg/50mg) for 12 weeks. GT 1a infected patients with baseline RAV's and GT 4 infected patients with a history of prior HCV treatment failure without or with cirrhosis will be treated with the same regimen for 16 weeks, in combination with weight-adjusted ribavirin.~Behavioural Intervention: Participants with inconsistent condom use with occasional partners will receive the behavioral Intervention and in addition standard of care written and oral information on prevention of HCV reinfection. Study participants with consistent condom use or those reporting inconsistent condom use with occasional partners but not willing to participate in the intervention will receive standard of care written and oral information on prevention of HCV reinfection only"
89092512|NCT01145417|Experimental|Pregabalin (Lyrica)|
89092513|NCT02622139|Experimental|Multispectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography (MSOT) for the evaluation of disease activity in inflammatory bowel diseases (IBD)
89092514|NCT04232332|Experimental|3.75μg (pre test)|Single dose
89092515|NCT04232332|Experimental|7.5μg|Single dose
89092516|NCT04232332|Placebo Comparator|15μg single dose|Intramuscular injection once
89226575|NCT03796559|Experimental|Magseed marker|Magseed marker deployed percutaneously, prior to patient undergoing neo-adjuvant chemotherapy (NAC), under ultrasound guidance to mark a lymph node intended for selective surgical removal post NAC.
89226576|NCT03786016|Experimental|8-Days in an Isolation, Confinement Unit|Subjects will spend 7-night/8-day in an isolated and confined unit with up to 3 other subjects.
89226577|NCT03778229|Experimental|osimertinib + savolitinib|osimertinib + savolitinib
89226578|NCT03778229|Placebo Comparator|placebo + savolitinib|placebo + savolitinib
89092517|NCT04232332|Placebo Comparator|30μg single dose|Intramuscular injection once
89092518|NCT04232332|Placebo Comparator|45μg single dose|Intramuscular injection once
89092519|NCT04232332|Placebo Comparator|60μg single dose|Intramuscular injection
89092520|NCT04232332|Placebo Comparator|75μg single dose|Intramuscular injection
89092521|NCT04232332|Placebo Comparator|90μg single dose|Intramuscular injection once
89092522|NCT04232332|Placebo Comparator|30μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
89092523|NCT04232332|Placebo Comparator|45μg multiple dose|The dosage will be adjusted according to the actual situation of the trial
89092524|NCT02622061||PCD Subjects|Participants 5 and older with PCD.
89092525|NCT02622061||Healthy Subjects|Participants 5 and older without any pulmonary disease.
89092526|NCT04135183|Experimental|Comprehensive evaluation group|The effectiveness of initial treatment and the next treatment plan were determined based on the CAP guidelines of Chinese Thoracic Society (CTS) or Infectious Diseases Society of America/American Thoracic Society(IDSA/ATS). The evaluation process was independently evaluated and documented by at least two clinicians. In case of disagreement, the final determination shall vote on the majority of votes.
89092527|NCT04135183|Experimental|PSI evaluation group|The changes of PSI scores and serum CRP were used to evaluate the therapeutic effects. If both PSI scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of PSI scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both PSI scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
89092528|NCT04135183|Experimental|Expand-CURB evaluation group|The changes of Expand-CURB scores and serum CRP were used to evaluate the therapeutic effects. If both Expand-CURB scores and CRP suggest that treatment is effective, the initial treatment will be maintained. If either of Expand-CURB scores or serum CRP suggest that treatment is effective, the initial treatment can be maintained, but need to be reviewed in the next 3-5 days. If both Expand-CURB scores and serum CRP suggest that the treatment is failed, the initial treatment should be changed. The change of initial treatment is not limited to antibiotics, but also include using glucocorticoid, ICU admission, mechanical ventilation according to the patients' condition.
89092529|NCT04135183|No Intervention|Prospective observational group|Patients' Expand-CURB scores, PSI scores and serum CRP before and after 3-5 days of initial treatment will be recorded. And the initial treatment, whether the initial treatment was changed 3-5 days of initial treatment and the final outcomes (ICU admission, 30-day mortality, average length of stay) will be recorded.
89092530|NCT02785276|Experimental|Ropivacaine infusion|Following the insertion of the 2mm fenestrated catheter, the wound catheter will be connected to the 270mL AutoFuser Pain Pump. The intraperitoneal infusion with ropivacaine (0.2%) at 4 mL/hour will start immediately and continue for 68 hours post-operatively uninterrupted.
89092531|NCT02785276|Placebo Comparator|Placebo infusion|In the same manner as described for the ropivacaine infusion arm, 0.9% Normal Saline will be administered over 68 hours.
89092532|NCT02883881||No eye rubbing|
89092533|NCT02883881||with eye rubbing|
89092534|NCT00696553|Active Comparator|B1|Nutrition
89092535|NCT00696553|Experimental|B2|Nutrition plus Exercise
89092536|NCT04316039|Experimental|RT+TMZ|
89092537|NCT04316039|Active Comparator|RT|
89092538|NCT04199416|Experimental|mRehab app|Participants randomized to the intervention group will be given the mRehab app free of charge to perform self-management of their knees in their homes.
89092539|NCT04199416|Sham Comparator|Sham app|Participants randomized to the control group will receive a sham app free of charge to perform self-management of their knees in their homes.
89092540|NCT00697645|Sham Comparator|1|Patients with stroke will be treated with usual stroke care and sham TMS will be applied
89092541|NCT00697645|Experimental|2|Deep TMS applied over the motor strip in patients with stroke in addition to usual stroke care.
89092542|NCT02786680|Experimental|stroop test in condition DBS off|Condition 1 : On Med /Off Stim
89092543|NCT02786680|Active Comparator|stroop test in condition DBS on|Condition 2 : On Med /On Stim
89092544|NCT01144715|Experimental|Hand Mentor Therapy|Use of the Hand Mentor (TM) Stroke Therapy Device at home for 8 weeks
89092545|NCT01144715|Active Comparator|Control|Self administered home therapy program
89092546|NCT00696631|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
89092547|NCT00696631|Placebo Comparator|Placebo|matching placebo tablets
89092548|NCT04198324|Active Comparator|Entire fold uterine closure|The uterus will be sewn with full fold locked sutures that pass through myometrium and endometrium.
89092549|NCT04198324|Experimental|Non-endometrial uterine closure|The uterus will be sewn with locked sutures that pass through myometrium without endometrium.
89092550|NCT02615977|Experimental|Intervention|"In the verum treatment condition, i.e. Zooming Joystick Task, 90% of all alcohol-related pictures appear in the landscape format and hence are trained to be pushed away."
89226579|NCT03773159||Patients|Patients with von Willebrand disease or major constitutional thrombopathy or patients on antiplatelet drugs
89092551|NCT02615977|Placebo Comparator|Placebo Intervention|In the placebo condition, i.e. Zooming Joystick Task (Placebo), alcohol picture are as often pushed away as pulled towards the subject.
89092552|NCT01189487|Experimental|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV
89092553|NCT02621905|Active Comparator|Sporanox|100 mg
89092554|NCT02621905|Experimental|Lozanoc|50 mg
89092555|NCT02785198|No Intervention|Control group|A control group receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
89092556|NCT02785198|Experimental|Passive training group|An Intervention group doing passive exercise for 8 weeks in knee extensor machine, and receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
89092557|NCT04134247|Experimental|PD-1 combined with chemotherapy|21 days every cycle, assessment after 3-cycle
89092558|NCT04134247|Active Comparator|chemotherapy|21 days every cycle, assessment after 3-cycle
89092559|NCT04232098|No Intervention|Thermoneutral|thermoneutral condition
89092560|NCT04232098|Experimental|Feet heated|Hot water up to ankles
89092561|NCT04232098|Experimental|Calf heated|Hot water up to top of calves
89092562|NCT01106352|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m^2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
88812597|NCT00890396||Active Follow-up|An active follow-up involved the performance of many of the laboratory tests and procedures done during BABY HUG clinical trials study. These included, but not limited to, serial laboratory parameters that were not part of routine clinical care such as Hgb F levels, pitted cell count, Howell-Jolly Body determination, a liver-spleen scan, diethylenetriaminepentaacetic acid (DTPA) glomerular filtration rate (GFR) measurement, creatinine clearance, Cystatin C, urine concentrating ability, transcranial Doppler, and neuropsychological testing.
89092563|NCT01106352|Active Comparator|Docetaxel|Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
89092564|NCT04045639||Intervention arm|The AF risk prediction algorithm will be run on patient records within the Egton Medical Information Systems (EMIS) data base, in order to identify patients at risk of developing AF
89092565|NCT04045639||Control arm|Patients may be diagnosed with AF through routine clinical practice only
89092566|NCT01144403|Experimental|Rituximab|Rituximab, 375 milligram per meter square (mg/m^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).
89092567|NCT03071926|Experimental|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks
89092568|NCT02619331|Experimental|Atopic volunteers|Allergy tests will be performed in allergic patients with rhinoconjunctivitis and allergy test reading measured following two different methodologies. 1) test reading based on conventional wheal and flare measurement (wheal diameter in mm, CWFM), 2) test reading based on high speed laser doppler imaging (HS-LDI). Both type of tests reading will be compared.
89092569|NCT03061552|Experimental|IVCD arm|IVCD-assisted determination of target post-dialysis weight
89092570|NCT03061552|No Intervention|conventional arm|conventional determination of target post-dialysis weight
89092571|NCT02883647||retreatment|"Patients with HBV DNA > 2000 IU/ml and ALT ≥ 5×ULN;~Patients with HBV DNA > 2000 IU/ml and 2×ULN < ALT ≤ 5×ULN, but have clinical symptoms.~Intervention: Patients of this group will receive Entecavir 0.5mg/d or Tenofovir 300mg/d again."
89092572|NCT02883647||non-retreatment|"Patients with HBV DNA ≤ 2000 IU/ml;~Patients with HBV DNA > 2000 IU/ml and ALT ≤ 2×ULN;~Patients with HBV DNA > 2000 IU/ml and 2×ULN < ALT ≤ 5×ULN, but have no clinical symptoms."
89092573|NCT02621827|Experimental|Non-pregnant, non-lactating (NPNL)|"NPNL women are age and parity matched to pregnant women. Each NPNL women is studied twice, approximately 3 months apart.~At each study period the participant receives (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3."
89226580|NCT03773159||Controls|Blood donors at the French blood establishment in Burgundy Franche-Comté
89092574|NCT02621827|Experimental|Pregnant/Lactating|Pregnant women receive (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3. The same women are followed-up in lactation to repeat the same protocol.
89092575|NCT02615899|Active Comparator|Matched|Administer Targeted (specific) balance exercise interventions
89092576|NCT02615899|Active Comparator|Mismatched|Administer Untargeted (non-specific) balance exercise interventions
89092577|NCT02703922|Other|GCA suspicion|A first screening is performed using color Doppler ultrasound. In case of negative results, patients undergo TAB.
89092578|NCT00625157|Experimental|1|
89092579|NCT00625157|Placebo Comparator|2|
89092580|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 5 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
89092581|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 2 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
89092582|NCT00868231|Experimental|Aclidinium 400 μg bid|Aclidinium bromide 400 μg twice-daily by inhalation
89092583|NCT00868231|Active Comparator|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily by inhalation
89092584|NCT00868231|Placebo Comparator|Placebo|Placebo
89092585|NCT04231864|Experimental|Treatment (durvalumab, epacadostat)|Patients receive durvalumab intravenously (IV) over 1 hour on day 1 and epacadostat orally (PO) twice a day (BID) on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression who are benefiting from treatment in the opinion of the principal investigator may continue durvalumab and epacadostat for up to an additional 12 months from the initiation (or re-initiation) of treatment on study.
89092586|NCT02786524|No Intervention|Standard of Care|Patients randomized to this arm receive standard symptom management care by their primary gynecologic oncologist and complete the NCCN distress thermometer and ESAS-r at each visit, every 3-4 weeks.
89226581|NCT03768349|Experimental|PET/CT Ga-68 PSMA|Ga-68 labeled PSMA-11 (or PSMA-HBED-CC) PET/CT
89092587|NCT02786524|Experimental|Symptom Management and Supportive Care|Patients randomized to this arm are referred to a specialized symptom management and supportive care clinic and seen within two weeks. Patients will be seen in follow-up as recommended by the symptom management providers, and at each visit they will complete the ESAS-r and NCCN distress thermometer and return their responses either in person or by mail to the study team in a pre-addressed postage paid envelope.
89226582|NCT03768349|Experimental|PET/CT F-18 Labeled PSMA 1007|F-18 Labeled PSMA 1007 PET/CT
89226583|NCT03761173||FlowTriever|Mechanical thrombectomy for pulmonary embolism
89226584|NCT03761173||Conservative Therapy Sub-Study|Anticoagulation medication for pulmonary embolism (as directed by treating physician)
89092588|NCT02883803|Experimental|MSC|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line.
89092589|NCT02883803|Sham Comparator|Placebo|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 250 ml albumin 4%, infused for 30 minutes in central venous line.
89092590|NCT00698347||M2a-Magnum™ Hip System|Patients who received the M2a-Magnum™ Hip System
89092591|NCT04130581|Experimental|TMS|Six 30-pulse trains of 20 Hz repetitive Transcranial Magnetic Stimulation to left primary motor cortex hand area, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
89092592|NCT04130581|Sham Comparator|Sham|Six 30-pulse trains of 20 Hz repetitive sham Transcranial Magnetic Stimulation above, but not in contact with, the head, separated by 60 seconds, repeated at 0, 24, 48, and 72 hours post-immobilisation.
89092593|NCT02614573|Experimental|The study population|The clinical phases of this study will be held in the nursing home (EHPAD; principal building + 2 annexes) of Pont-Saint-Esprit, located in France. Patients are elderly dependents treated by anti-vitamin K for more than 6 months.
89092594|NCT02614495|Experimental|Surufatinib|300mg once-daily
89092595|NCT01143077|Experimental|Lurasidone Open-Label Arm A|
89092596|NCT01143077|Experimental|Lurasidone Open-Label Arm B|
89092597|NCT01143077|Experimental|Lurasidone Open-Label Arm C|
89092598|NCT02786446|Active Comparator|Lidocaine gel|20 grams Lidocaine gel 2 % will be applied to corresponding lumber area of the patients 30 minutes before undergoing ESWL for renal stone.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
89092599|NCT02786446|Active Comparator|Naproxen Sodium|Oral Naproxen sodium 550 mg will given to patients 45 minutes before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
89092600|NCT02786446|Active Comparator|Lidocaine Gel and Naproxen Sodium|Oral Naproxen sodium 55o mg and locally applied 2 % lidocaine gel to patients before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
89092601|NCT02618941|Experimental|AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/adjuvanted
89092602|NCT02618941|No Intervention|Control|Untreated control group
89092603|NCT02784964|Experimental|Elixcyte 8mL|ADSC 6.4*10^7 cells, allogeneic injection, one time injection on Day 1
89092604|NCT02784964|Active Comparator|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc., one time injection on Day 1
89092605|NCT02784964|Experimental|Elixcyte 4mL|ADSC 3.2*10^7 cells, allogeneic injection, one time injection on Day 1
89092606|NCT02784964|Experimental|Elixcyte 2mL|ADSC 1.6*10^7 cells, allogeneic injection, one time injection on Day 1
89092607|NCT02619019|Active Comparator|Dexamethasone group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
89092608|NCT02619019|Active Comparator|Pethidine group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
89092609|NCT02619019|Placebo Comparator|Control group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
89092610|NCT02615587||AF patients in Denmark / Cohort 1|"The base population of AF patients for diagnosis and health care utilization / resource use will be identified in the National Patient Registry. For a given period of time (2000-2013, both years inclusive) all patients with a hospital contact (admission, outpatient visit or ER visit) and for whom AF was the primary or secondary diagnosis code will be identified.~Further Data sources used:~Registry of Medicinal Product Statistics: for determining the individuals' use of prescription medicine DREAM database: for investigation of sickness benefit and productivity loss Statistics Denmark's databases: on social services from municipalities Cause of Death Registry: AF-patients or controls who died during the study period (2000-2013) Danish Civil Registry: used for identification of controls, holds information about age, gender"
89226585|NCT03743610|Experimental|Effect of heart rate training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining >65% max heart rate during room air based maximal peak work.
89226586|NCT03743610|Experimental|Effect of saturation of oxygen training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%.
89226587|NCT03743610|Active Comparator|Effect of optimized training in simulated altitude|Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude.
89226588|NCT03743610|Placebo Comparator|Effect of placebo training in non-simulated altitude|Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude.
89226589|NCT03741673|Experimental|Group I (pre-operative SRS)|Patients undergo SRS within 30 days of randomization followed by surgery within 30 days. Patients may undergo additional SRS if disease returns after treatment.
89226590|NCT03741673|Active Comparator|Group II (post-operative SRS)|Patients undergo surgery within 30 days of randomization followed by standard of care SRS within 30 days. Patients may undergo additional SRS if disease returns after treatment.
89226591|NCT03740542|Active Comparator|Esophagectomy with Pyloroplasty|Esophagectomy with Pyloroplasty
89226592|NCT03740542|Experimental|Esophagectomy without Pyloroplasty|Esophagectomy without Pyloroplasty
89226593|NCT03740256|Experimental|Treatment Phase|"Seven dose levels will be evaluated using the BOIN design. Cohorts of size 3 will be enrolled at each dose level until 9 evaluable patients have been studied at a single dose. Each patient will receive an intratumoral injection of CAdVEC alone or combined with an injection of HER2.CAR.T cells 3 days later (Day 4), according to the following dose levels.~Dose Level 1 CAdVEC = 5.00E+9 HER2 specific CAR-T cells = 0~Dose Level 2 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 0~Dose Level 3 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 1.00E+06~Dose Level 4 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+06~Dose Level 5 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+07~Dose Level 6 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+07~Dose Level 7 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+08"
89226594|NCT03732521|Experimental|Intervention group|educational therapy
89226595|NCT03732521|No Intervention|Control group|usual clinical practice
89226596|NCT03725592|Active Comparator|Standard Treatment|Receives arsenic removal device and written instructions and phone calls on how to use the device (Arsenic Removal Device)
89226597|NCT03725592|Experimental|Intensive Education|Receives the Standard Treatment plus in-person visits and phone calls for follow-up (Community Participatory Arsenic Mitigation)
89226598|NCT03711448|Active Comparator|Control group|
89226599|NCT03711448|Experimental|Experimental group|
89226600|NCT03708159|Experimental|active tDCS + mindfulness meditation|Participants randomized to this group will receive active tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
89226601|NCT03708159|Sham Comparator|sham tDCS + mindfulness meditation|Participants randomized to this group will receive sham tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
89226602|NCT03685305|Experimental|Hypocaloric diet with hunger reduction strategy|Participants will be prescribed a hypocaloric diet with additional instructions to promote hunger reduction. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
89226603|NCT03685305|Active Comparator|Hypocaloric diet without hunger reduction strategy|Participants will only be prescribed a hypocaloric diet. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
89226604|NCT03685110||CoreHip|Clinical and Radiological Data of 300 patients of a Standard Patient Population, who are treated with CoreHip Total Hip Arthroplasty for Indications according to the Instructions for Use (IfU) with a five year follow Up
89226605|NCT03677986|No Intervention|Usual Care|Participants in this group will be referred to receive office-based buprenorphine treatment
89111144|NCT03787251|Experimental|experimental group|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
89092611|NCT02786368|Other|Control group|For year one, this arm will receive no intervention. Usual agriculture production and income will be assessed monthly for one year. Additionally, every season (twice yearly), household food security and usual dietary intake of woman of reproductive age (WRA) and their child aged 6-59 mo will also be collected. After one year of implementation, this group will be offered the Enhanced Homestead Food Production package fully subsidized, as well as training on nutrition, WASH, gender and business/marketing.
89092612|NCT02786368|Experimental|EHFP group|Households will receive training and inputs for an Enhanced Homestead Food Production (EHFP) package. Participants will also receive educational components through inter-personal behavioural change communication on nutrition (Essential Nutrition Actions), Water Sanitation and Hygiene (WASH), gender, and business/marketing.
89092613|NCT02615821|Experimental|Affective Mental Contrasting|"Before the goal formation or mental contrasting activities, participants will receive information about the affective benefits of exercising (e.g. regular physical activity has been shown to reduce stress, physical activity is enjoyable), and related research support including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit affective judgements. Specifically, the affective condition will include the additional prompts Why might you find exercise to be enjoyable, pleasant, exciting, or fun? for eliciting outcomes, and Why might you find exercise to be unenjoyable, unpleasant, boring, or miserable? for eliciting obstacles."
89092614|NCT02615821|Active Comparator|Instrumental Mental Contrasting|"Before the goal formation or mental contrasting activities,participants will receive information about the instrumental benefits of exercising (e.g., regular physical activity reduces the risk of developing cancer) and related research support, again including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit either instrumental judgements. Specifically, the instrumental conditions will include the prompts Why might you find exercise to be useful, advantageous, beneficial, or important? for eliciting outcomes, and Why might you find exercise to be unimportant, useless, inconvenient, or detrimental? for eliciting obstacles."
89092615|NCT02615821|Active Comparator|Standard Mental Contrasting|In the standard condition, the space where the affective and instrumental benefits of physical activity were listed in the instrumental and affective conditions, will be left blank in the standard condition, and no additional prompting questions will be given, allowing for the idiosyncratic identification of obstacles and outcome.
89092616|NCT04307160||Group I|Patients ≤ 5 years of age
89092617|NCT04307160||Group II|Patients ≥ 7 years of age
89092618|NCT02956798|Experimental|Stereotactic ablative body radiation (SABR)|Stereotactic ablative body radiation (SAbR) to all sites of measurable metastases (≤3) will be treated by SAbR. New sites of metastasis will be evaluated for continued treatment if deemed appropriate by both medical and radiation oncologists with SAbR.
89092619|NCT02947516|Active Comparator|Percutaneous liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo a percutaneous liver biopsy per standard protocol.
89226606|NCT03677986|Experimental|Video DOT+|Participants in this group will be referred to receive office-based buprenorphine treatment and will receive financial incentives for taking their daily buprenorphine dose.
89092620|NCT02947516|Experimental|EUS-guided liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo an endoscopic ultrasound procedure per standard protocol. The liver will be identified, and Color Doppler imaging prior to needle puncture will confirm lack of significant vascular structures within the needle path. Liver biopsies using up to 1-2 passes from the left hepatic lobe using a transgastric approach and up to 1-2 passes from the right hepatic lobe using a transduodenal bulb approach will be performed. The participant will be observed in the recovery unit for up to 60 minutes after the EUS-LB, and discharged if no pain or signs of complication.
89092621|NCT01096446|Experimental|Higher Infusion|Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
89092622|NCT01096446|Other|Standard Infusion|Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
89092623|NCT00864721|Experimental|Sunitinib Malate|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
89092624|NCT05308420|Active Comparator|PENG block|"Patients scheduled for primary total hip arthroplasty after receiving spinal anesthesia will undergo pericapsular nerve group (PENG) block.~Postoperative multimodal analgesia with paracetamol, etoricoxib and oxycodone"
89092625|NCT05308420|Active Comparator|Intrathecal morphine|"Patients scheduled for primary total hip arthroplasty will receive spinal anesthesia with local anesthetic and morphine administered intrathecally. After onset of spinal anesthesia a sham PENG block will be performed.~Postoperative multimodal analgesia with paracetamol, etoricoxib and oxycodone."
89092626|NCT04132921||Patients with AKI|Patients with AKI after joint replacement
89092627|NCT04132921||Patients without AKI|Patients without AKI after joint replacement
89092628|NCT02897050|Experimental|T+mCX followed by FEC|Docetaxel 75mg/m2, iv, d1 + CTX 50 mg/d, po, d1-d21 + capecitabine 1200mg/m2/d, po, d1-d21 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
89092629|NCT02897050|Active Comparator|T followed by FEC|Docetaxel 100mg/m2, iv, d1 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
89092630|NCT02619097|Experimental|0.08mg/kg|Pegol-sihematide injection, 0.08mg/kg, single-dose
89092631|NCT02619097|Experimental|0.2mg/kg|Pegol-sihematide injection, 0.2mg/kg, single-dose
89092632|NCT02619097|Experimental|0.33mg/kg|Pegol-sihematide injection, 0.33mg/kg, single-dose
89092633|NCT02619097|Experimental|0.5mg/kg|Pegol-sihematide injection, 0.5mg/kg, single-dose
89092634|NCT02619097|Experimental|0.7mg/kg|Pegol-sihematide injection, 0.7mg/kg, single-dose
89092635|NCT01095666|Experimental|Group 1|
89092636|NCT01095666|Experimental|Group 2|
89092637|NCT01095666|Experimental|Group 3|
89092638|NCT04132765||Patients with cerebral palsy|Patients with cerebral palsy at between the ages of 4-16 years and at Gross Motor Function Classification Levels of 3,4,5
89092639|NCT04231474||Demographic and clinical features of the patients|Number of patients Time from injury to hospitalization Time from injury to urodynamic evaluation Duration of hospitalization
89092640|NCT04231474||Comparison of urodynamic outcomes|Treatment options in patients with level SCI : cervical, thoracical and lumbar spinal cord injury
89092641|NCT02615431||MitraClip Intervention|the influence of MitraClip on Apnoea Asleep
89092642|NCT05338840|Experimental|MULLIGAN|ROTATIONAL MOVEMENT
89092643|NCT05338840|Experimental|Medial gapping technique|Medial gapping technique
89092644|NCT02618863|Active Comparator|1 , cricoid pressure|30 male
89092645|NCT02618863|Active Comparator|2,cricoid pressure|30 female
89092646|NCT05302180|Experimental|Synchronous online group|The synchronous online pain neuroscience education program (EducaDor program) will be held in groups at until 12 participants, at 10 weekly synchronous meetings on the Whereby® platform.The professional will conduct each synchronous meeting with dialogued exhibition class using multimedia material shared on the computer screen
89092647|NCT05302180|Experimental|Asynchronous group|Participants allocated in the asynchronous group will receive the interactive e-book at the beginning of the program and ten videos (one per week) with the same topics of synchronous online EducaDor program sent on their smartphone devices and e-mail, in addition to usual care. Before receiving the materials, users will participate in an individual or group synchronous meeting of up to 12 participants on the Whereby® platform to receive a guidance for the use of interactive e-book and access to videos over the 10 weeks. The videos were previously developed and tested in another clinical trial.
89092648|NCT05302180|Active Comparator|E-book group|Participants allocated to this group will receive the interactive e-book of EducaDor program in their smartphone devices and e-mail, in addition to usual care. Before receiving the e-book, the users will also participate in an individual or group synchronous meeting of up to 12 participants on the Whereby® platform to receive a guidance for the use of interactive e-book over the 10 weeks.
89092649|NCT01100658|Active Comparator|Methylphenidate|Administered 1 capsule each day for 1 week, .3 mg/kg dose.
89092650|NCT01100658|Placebo Comparator|Placebo|Administered 1 capsule each day for 1 week.
89092651|NCT02618785|Experimental|Hyoscine|The experiment group receive Hyoscine 10 mg 2 tablets by mouth before hysterosalpingography procedure
89092652|NCT02618785|Placebo Comparator|Placebo|The control group receive placebo by mouth before hysterosalpingography procedure
89092653|NCT02618707||Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
89092654|NCT05276908|Experimental|mTLIP10|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
89092655|NCT05276908|Experimental|mTLIP20|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
89092656|NCT02785978|Experimental|Parkinson Disease Patients Group #1|PD patients with programmed levodopa challenge
89092657|NCT02785978|Experimental|Parkinson Disease Patients Group #2|PD patients without programmed levodopa challenge
89092658|NCT02785978|Experimental|Healthy volunteers|Healthy volunteers
89092659|NCT02786056|Experimental|Lung MRI examination|
89092660|NCT02786212|Experimental|dexmedetomidine|Patients receiving intraoperative dexmedetomidine infusion. Infusion duration: from 10 minutes after anesthetic induction to the end of surgery.
89092661|NCT02786212|Placebo Comparator|control|control group, receiving same volume of normal saline infusion.
89092662|NCT05273710|Other|Zinc absorption study|Zinc absorption is determined from each of 3 test meals in all subjects.
89092663|NCT02784808||Biologic DMARDs|Participants who received biologic DMARDs as per standard of care were included in this arm.
89092664|NCT02784808||Non-biological DMARDs|Participants who received non-biologic DMARDs as per standard of care were included in this arm.
89092665|NCT02784652|Experimental|RT & Zoledronic acid|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions, Zoleronic acid: every 4 weeks, 6 times, 4.0 mg iv
89092666|NCT04231630|Other|Observational Case|1 infant will be enrolled as an observational case. Will receive an exclusive human milk diet at home.
89092667|NCT02784730|Experimental|Iterative PICC placement|New PICC placement at each chemotherapy cycle (removed after treatment administration)
89092668|NCT02784730|Active Comparator|Long term implantable device|Port-a-cath inserted prio first chemotherapy cycle and maintained throughout the study
89092669|NCT02786290|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
89092670|NCT04231552|Experimental|Chemotherapy and PD1 inhibitor|CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
89092671|NCT02785744||Patients receiving DEXA Scan|Gaucher patients referred for dual energy X-ray absorptiometry (DEXA scan), who were found to have T-score <-1.0.
89092672|NCT01100502|Experimental|Brentuximab vedotin|brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
89092673|NCT01100502|Placebo Comparator|Placebo|placebo every 3 weeks by IV infusion
89092674|NCT02784418|Active Comparator|PCI of CTO|Intervention: PCI of CTO (Chronic Total Occlusion Percutaneous Coronary Intervention) Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. CTO PCI patients will receive blinded clopidogrel 75 mg daily for 6 months.
89226607|NCT03661255|Experimental|PC CARES Intervention|Experimental: PC CARES Intervention Participants will attend 1-7 sessions of the PC CARES curriculum, either virtually or in-person. Investigators will collect data from this group at baseline, after each session they attend, and at follow-up.
89226608|NCT03661255|No Intervention|No intervention|This group will not attend the PC CARES sessions. Investigators will collect data from this group at baseline and follow-up
89226609|NCT03655132|No Intervention|Waitlist Control Group|Veterans in the waitlist control will be provided with a list of common pain resources at the Bedford VAMC.
89226610|NCT03655132|Experimental|VACT-CP Group|Veterans randomized to VACT-CP will receive 7 online-module based weekly sessions of treatment via personal computer or provided tablet with wireless accessibility at the Bedford VAMC.
89226611|NCT03651830|Experimental|Prosthetic Foot Emulator|The Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how individual patients will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
89226612|NCT03651830|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
89226613|NCT03646123|Experimental|Part A: A+AVD|Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
89226614|NCT03646123|Experimental|Part B: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
89226615|NCT03646123|Experimental|Part C: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
89226616|NCT03635073|Experimental|Soticlestat|Treatment: Soticlestat, tablets orally twice daily at optimized dose, titrated in up to 2 weeks of Dose Optimization Period, followed by Maintenance Period, which lasts until development is stopped by the sponsor, or the product is approved for marketing, or at any time at the discretion of the sponsor.
89226617|NCT03622775|Experimental|Treatment (daratumumab)|Beginning 60-120 days after transplant, participants receive daratumumab IV over 4-8 hours on days 1, 8, 15 and 22 of courses 1 and 2 and days 1 and 15 of courses 3-6, then on day 1 of subsequent courses. Courses repeat every 28 days for 3 years in the absence of disease progression or unacceptable toxicity.
89226618|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza®|"Group A:~4 grams Lovaza®, 2 grams twice a day (BID). 2 grams by mouth daily, AM and PM 8,000 mgs CUR Curcumin C3 complex® tablets, divided into 2 doses. 4 grams by mouth, twice a day, AM and PM."
89226619|NCT03598309|Active Comparator|Curcumin C3 complex® +Lovaza® +Placebo|"Group B:~2 grams Lovaza®, 1 gram twice a day, AM and PM. 4,000 mgs CUR Curcumin C3 complex® tablets, 2,000 mgs twice a day, AM and PM.~1 placebo capsule twice a day, AM and PM."
89226620|NCT03598309|Active Comparator|Placebo only|Placebo: Two matching placebo capsules twice a day (BID), taken by mouth, AM and PM
89226621|NCT03597503|Experimental|Flexible dose of SPN-810|Subjects treated with flexible dose of SPN-810
89226622|NCT03597503|Placebo Comparator|Placebo|Subjects treated with Placebo
89092675|NCT02784418|Sham Comparator|Sham Procedure|"Intervention: Sham procedure Subjects will be blinded to randomization assignment using a combination of conscious sedation and sensory isolation (e.g., blindfold and noise isolation). Control subjects will only undergo a Sham procedure, wherein they will undergo bilateral arterial access, without angiography or PCI being performed. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. Sham group will receive blinded placebo clopidogrel for 6 months."
89092676|NCT02784340|Active Comparator|IV dexamethasone|40 women received 16 mg Dexamethasone IV drip.
89092677|NCT02784340|Active Comparator|Local dexamethasone|40 women received 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
89092678|NCT02784340|Placebo Comparator|placebo|Placebo in the form of IV fluids 500 cc saline infusion
89092679|NCT02785822|Active Comparator|Fostipur|
89092680|NCT02785822|Experimental|Meriofert|
89092681|NCT02878512|Active Comparator|PCNL under General Anesthesia|Patients were premedicated with Inj. Atropine 0.06 mg intramuscularly half an hour prior to surgery, IV ranitidine 1mg kg-1, IV ondansetron 0.08mg kg-1 IV midazolam 0.02mg kg-1 and Pentazocine 0.3 mg/kg. Anaesthesia was induced with IV Thiopentone sodium 3-5 mg kg-1 and Vecuronium 0.1mg kg-1.and then intubated. Anaesthesia was maintained on 50 %:50% nitrous oxide and oxygen, vecuronium and propofol infusion . At the end of the surgery postoperative analgesia was given with IV tarmadol and local nfiltration with 0.25% bupivacaine at the surgical site. Patients were reversed with IV glycopyrrolate 0.008mg kg-1 and IV neostigmine 0.06mg kg-1 and extubated.
89092682|NCT02878512|Experimental|PCNL under Segmental epidural Anesthesia|epidural space was located at T12 -L1 or L1-L2 space .The epidural catheter was inserted cephalad 5 cm upwards in the epidural space (tip approximately at T8 to T9). and test dose of 3 ml of 2% Adrenalized Lignocaine was administered..loading dose of 0.5% Bupivacaine, approximately 8 to 10 ml was injected epidurally with regular negative aspiration to block T6- T12 segments, if desired level was not achieved then additional dose of 1 to 1.5 ml 0.5% bupivacaine per spared segment was given to achieve the desired level.Motor blockade of the lower limbs was checked and noted before lithotomy, before prone and at the end of the surgery using Bromage scale. After two segment regression of sensory level epidural top up with 1/4th of initial dose 2 to 3 ml of 0.5% Bupivacaine was given. At the end of the surgery 8ml of 0.125% Bupivacaine was administered for postoperative analgesia and the catheter was removed.
89092683|NCT02784184||1 year follow-up group|1 year follow-up group including 6 measurements
89092684|NCT02784184||40 days diaper study subgroup|"Subgroup of the 1 year follow-up group including 15 girls undergoing daily measurement of urinary hormone excretion"
89092685|NCT04847856|Experimental|List of health centers that randomly allocated to receive the intervention|The intervention was structured Diabetes self-care information, education, and communication (IEC) delivered to the participants at the selected primary health care center level. The Information, education, and communication intervention were delivered by relevant and trained health animators working in chronic care clinics. The intervention was composed of sessions and the participants were planned to attend five structured sessions on diabetes self-care at months: 1, 2, 3,4,5&6. Besides, the participants were provided with a single-page checklist with a to-do list of activities and simple advice that covering the various aspects of diabetes self-care.
89092686|NCT04847856|No Intervention|List of health centers that randomly allocated to receive routine care|The comparators were type II diabetic patients of both genders attending the selected primary health care centres that receiving routinely provided diabetic care including advice from the health care providers. Participants were interviewed at the start of the trial to collect the baseline data about self-care with measurements of blood glucose level, serum cholesterol level, blood pressure, BMI, and waist circumference. At the end of the trial, the sam participants were interviewed to collect end-line data and similar measurements.
89092687|NCT04306614|Experimental|Capillary technique|
89092688|NCT04306614|Placebo Comparator|Suction technique|
89092689|NCT04231006|Experimental|Single arm|Single arm
89092690|NCT01094886|Experimental|001|Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
89092691|NCT04231240||Adult cardiac surgery with normothermia|
89092692|NCT04231240||Adult cardiac surgery with hypothermia|
89092693|NCT04231240||Pediatric cardiac surgery with normothermia|
89092694|NCT04231240||Pediatric cardiac surgery with hypothermia|
89092695|NCT04231240||Adult cardiac surgery without cardiopulmonary bypass|
89092696|NCT02784028|Experimental|SGM-101|6 dose levels of SGM-101 (5mg/patient, 7.5mg/patient, 10 mg/patient, 12.5mg/patient , 15 mg/patient - 24 h prior surgery and 15 mg/patient - 48h prior surgery
89092697|NCT02782234|No Intervention|not contract management|monthly follow-up phone or family visit completed as regulation, and instruct them proper healthy training.
89226623|NCT03593590||Ocrelizumab|Participants with relapsing or primary progressive MS receiving ocrelizumab under routine clinical care.
89226624|NCT03589703|Active Comparator|T-APA|Patients with active points related to cLBP. Will receive acupressure within the two zones for cLBP located on the front and back of the ear and three points known for alleviating stress and pain.
89226625|NCT03589703|Active Comparator|NT-APA|"The same procedure for APA will be applied but the tapes/seeds will be placed on five different ear points, comprising mouth, stomach, duodenum, internal ear, and tonsil.~These points are chosen for the non-target ear points of APA treatment for two reasons. First, they are distinct from the zones of the ear (and the points therein) associated with the lower back, and correspond to body regions in which the participant is usually pain-free. Second, they are equivalent in number to those points used in the APA treatment group."
89226626|NCT03589703|Other|Enhanced Educational Control Group (CG-2)|Participants in the enhanced educational control group will be given the cLBP educational booklet and visit the office weekly for assessment (i.e., blood draws and questionnaires), which is the same schedule as that for the APA groups.
89226627|NCT03589547|Experimental|Durvalumab and SBRT|"Durvalumab 10mg/kg x 1 day, dose #1 to occur > 3 weeks and <7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).~SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors~Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)"
89226628|NCT03568630||New Onset Diabetes/High-Risk Prediabetes|"Must meet one of the following criteria:~New onset type 2 diabetes diagnosed within the past 3 years, defined as Hemoglobin A1c ≥ 6.5%*, fasting blood glucose >126mg/dL confirmed on a subsequent day or as diagnosed by a physician~High-risk pre-diabetes: Hemoglobin A1c >6.3% or A1c >6.0% with fasting blood glucose >110 or 2 hour oral glucose tolerance test between 140-200mg/dL; subjects who have been on metformin <3 years are eligible"
89226629|NCT03568630||Pancreatic Cystic Neoplasm/Pancreatitis|"Must meet one of the following criteria:~Pancreatic cystic neoplasm for which resection, endoscopic ultrasound or serial imaging has been recommended~Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist"
89226630|NCT03568630||Inherited Risk|"Must meet one of the following criteria:~Two or more blood relatives with PDAC (includes 1st-3rd degree relatives as defined in Table 2)~One 1st degree relative with PDAC diagnosed before age 60~Germline mutation associated with a higher than average risk of PDAC including but not limited to the following: Hereditary breast and ovarian cancer syndromes BRCA1, BRCA2, PALB2 Hereditary nonpolyposis colon cancer (Lynch) syndrome MLH1, MSH2, MSH6, PMS2 Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome CKDN2a, p16 Peutz-Jeghers syndrome STK11 Ataxia-telangiectasia ATM Juvenile polyposis syndromes SMAD4, BMPR1A Li Fraumeni TP53 Cystic fibrosis and unaffected carriers CFTR~Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC"
89226631|NCT03564288|Experimental|Dose Escalation Cohort|To identify the recommended phase 2 dose (RP2D) of SKI-G-801 in patients with relapsed or refractory AML (Acute Myeloid Leukemia)
89226632|NCT03564067|Other|tDCS + cCBT|After baseline assessments are complete, participants will be provided with a tDCS device (Soterix Medical tDCS mini-Clinical Trials system (mini-CT)), which is deactivated until a code is provided by the research staff. Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
89230263|NCT00048061|Active Comparator|Ibandronate 2.5 mg|Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
89230264|NCT00048061|Experimental|Ibandronate 50/50 mg|Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
89226633|NCT03554317|Experimental|Bipolar Androgen Therapy + Nivolumab|All participants must have a rising PSA and/or radiographic progression and prior treatment with at least one novel androgen receptor (AR) targeted therapy (i.e. abiraterone acetate, enzalutamide). Up to one taxane agent for metastatic castration-resistant prostate cancer is permitted. Patients will be treated with testosterone cypionate 400mg IM every 4 weeks for a lead-in period of 12 weeks. After the lead-in period, all patients will be treated with nivolumab 480mg IV every 4 weeks and maintained on testosterone cypionate 400mg IM every 4 weeks. Treatment [with a minimum drug exposure of 12 weeks] will be continued until PSA progression (PCGW3 criteria) or clinical/radiographic progression (whichever comes first), or until unmanageable toxicity requiring drug cessation.
89226634|NCT03548285|Experimental|patient with low risk|"Low-risk is defined by:~Planning target volume (PTV) less than 10 cc, AND~No reported smoking within 1 month from registration~Radiation Therapy will be delivered twice per week for 5 fractions (total 42.5 Gy)"
89226635|NCT03548285|Experimental|patient with moderate risk|"Moderate-risk is defined by:~Planning target volume (PTV) greater than or equal to 10 cc, OR~Smoking within 1 month from registration (no more than 1 pack per day)~Radiation Therapy will be delivered daily for 16 fraction (total 58.08 Gy)"
89226636|NCT03537963|Other|Pre-Intervention Qualitative Interviews|Hematopoietic cell transplant (HCT) survivors, caregivers and clinicians will participate in this part of the study. HCT survivor participants will be asked to nominate and provide contact information for the person who was their primary caregiver before, during, or after their HCT hospitalization. All participants will be asked to participate in either an in-person or telephone interview that will last approximately 1 hour. The interview will be digitally audio-recorded and will ask questions on the trajectory of sleep disturbance in HCT recipients and strategies to manage common barriers to quality sleep, as well as discuss the planned intervention for sleep disturbance in HCT survivors.
89226637|NCT03537963|Experimental|mHealth Stepped-care Intervention|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention, post-intervention questionnaire and interview.
89226638|NCT03537963|Active Comparator|Educational Control Condition|For HCT survivors randomized to this group: Baseline survey, followed by Educational Control intervention, post-intervention questionnaire and interview.
89226639|NCT03537963|Experimental|mHealth Stepped-care Intervention + virtual reality relaxation|For HCT survivors randomized to this group: Baseline survey, followed by mHealth Stepped-care intervention + virtual reality relaxation component, post-intervention questionnaire and interview.
89226640|NCT03536793||Pancreatic cysts|Samples (urine, serum, whole blood and cystic fluid) will be taken from 50 patients with pancreatic cysts on follow-up. These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM). Some of the cystic fluid and the whole blood sample will either be analysed at the University of Hull or a commercial laboratory for proteomic and genomic data. Collection will occur on the same day of the participants' routinely indicated procedure.
89226641|NCT03536793||Pancreatic cancers|Samples (urine and serum) will be taken from 50 patients diagnosed with pancreatic cancer (resectable and non-resectable). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
89226642|NCT03536793||Benign hepatopancreatobiliary conditions|Samples (urine and serum) will be taken from 80 age- and gender-matched control patients - 20 patients with acute pancreatitis and a non-resolving pseudocyst, 20 undergoing cholecystectomy for stones, 20 undergoing cholecystectomy for inflammation and 20 patients undergoing investigations for dyspepsia (normal control subgroup). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
89226643|NCT03512132||control|
89226644|NCT03512132||T1D with normal albumin levels|
89226645|NCT03512132||T1D with macroalbuminuria|
89226646|NCT03512132||T1D with microalbuminuria|
89226647|NCT03512132||T1D with microalbuminuria and statins|
89226648|NCT03511196|Experimental|Adaptive ADT+ Standard of Care|Participants will undergo 12-16 weeks of GnRH analog, along with 8-12 weeks of combinational therapy with GnRH analog and abiraterone plus prednisone. 14 participants who achieve >75% PSA decline after the run-in period will be enrolled. GnRH analog and abiraterone will be stopped after study enrollment. PSA and testosterone level will be measured every 4 weeks during the run-in period, then every 6 weeks after study enrollment. Imaging studies with CT and bone scan will be performed at the time of study enrollment and these will be considered baseline scans. Study treatment will be restarted if participant's PSA reaches 2 fold or higher of his baseline PSA. Selection of treatment will be based on participant's testosterone level.
89226649|NCT03498001|Experimental|Patients|
89226650|NCT03477396|Experimental|Treatment (ribociclib, aromatase inhibitor)|Participants receive ribociclib orally PO QD on days 1-21 and aromatase inhibitor per treating investigator's discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89226651|NCT03476954|Experimental|Respiratory impedance monitoring session|
89226652|NCT03475888|Active Comparator|Group A|Patients who have undergone a successful percutaneous CTO recanalization
89226653|NCT03475888|Active Comparator|Group B|Patients who have undergone a failed percutaneous CTO recanalization or have an untreated CTO
89226654|NCT03475186|Experimental|Ramipril|Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).
89226655|NCT03459287|Experimental|INTERCEPT (test)|The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician.
89226656|NCT03459287|Active Comparator|Conventional (Control)|The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and administered intravenously. The Control RBC components will be handled and labeled in a manner so as to maintain blinding. Dose and schedule of RBC transfusions will be determined by the treating physician.
89226657|NCT03458611|Experimental|Group A|In period 1 group A will receive the active intervention and in period 2 they will receive the placebo intervention.
89226658|NCT03458611|Experimental|Group B|In period 1 group B will receive the placebo intervention and in period 2 they will receive the active intervention.
89226659|NCT03458546|Experimental|Roflumilast and R-CHOP|
89226660|NCT03442231||Journey™ UNI Unicompartmental Knee System|Subjects previously received knee replacement
89226661|NCT03439891|Experimental|Part 1: Dose Escalation|Participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dose.
89226662|NCT03439891|Experimental|Part 2: Child Pugh B Expansion (sorafenib, nivolumab)|Participants receive sorafenib on days 1-28, and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89226663|NCT03439345|Experimental|Fenofibrate 145 mg|Name: fenofibrate; Form: tablet; Dosage: 145 mg; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
89226664|NCT03439345|Placebo Comparator|Placebo Oral Tablet|Name: placebo; Form: tablet; Dosage: not applicable; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
89226665|NCT03414905||Aspira Catheter & Drainage System|"Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1~The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output"
89226666|NCT03393832||Oral Care with Mother's Milk|All infants admitted to the Texas Children's Hospital NICUs who have mother's milk available will receive oral care with mother's milk.
89226667|NCT03393832||Oral Care with Sterile Water|Infants will receive oral care with sterile water when mother's milk is not available.
89226668|NCT03374670|Experimental|Cohort 1|Zimura dosage 1 + Eylea 2 mg
89226669|NCT03374670|Experimental|Cohort 2|Zimura dosage 2 + Eylea 2 mg
89226670|NCT03373045||Cohort of US adults with severe asthma|To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
89226671|NCT03364153|Experimental|Cohort 1|Zimura dose group
89226672|NCT03364153|Sham Comparator|Cohort 2|Sham dose group
89226673|NCT03360201|Experimental|Intervention: Tuko Pamoja|The intervention, Tuko Pamoja, is delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. The content and structure has been adapted in both content and implementation model based on formative research in this context. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection.
89226674|NCT03351712|Active Comparator|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Gold Standard Intervention + Activity Tracker WITHOUT Feedback (Medical Rehabilitation, Motivational Support and Psycho-Education) During the in-patient phase, participants will participate in the intensive four-week hospital-based and medically-managed rehabilitation program for weight reduction. All patients will be placed on a hypocaloric nutritionally balanced diet tailored to the individual after consultation with a dietitian. Furthermore, they will receive nutritional counseling provided by dietitians, have physical activity training provided by physiotherapists and motivational support with elements of psycho-education provided by physicians trained and informed by psychologists-psychotherapists.
89226675|NCT03351712|Experimental|Gold Standard Intervention and Activity Tracker WITH Feedback|In this experimental condition, will be provided the same rehabilitation program for the 4-weeks in-patient phase. In addition, for these subjects will be implemented a Stepped Protocol using wearable devices / activity trackers to collect information about daily physical activity and providing meaningful and informative feedbacks. The additional procedure starts during the in-patients phase, delivering and explaining the use of the wearable devices. In this meeting, longer than the one previously described for the control condition, experimenters provide information, set individualized goals and explain feedbacks which will be delivered after ending in-patients phase by the electronic wearable devices.
89226676|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|In this experimental condition, the subjects followed the normal medical rehabilitation program described above for the first experimental condition. For the out-patient phase the ACT intervention includes monthly 30 minutes skype-telephone sessions. The ACT-based interventions includes different processes: 1) Acceptance, that involves the active awareness of difficult private experiences without attempts to control or avoid unpleasant emotions. 2) Mindfulness, refers to engaging in present moment experience and adopting an open and curious attitude. 3) Defusion: Participants will be encouraged to defuse from thoughts and feelings by turning attention toward the 'noticing-self', instead of becoming attached to thoughts and 'run' through life on 'auto-pilot'. 4) Values and Commitment: encouraging participants to live in accordance with their values, participants can engage in meaningful activities despite experiencing unwanted emotions/ sensations.
89226677|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITH Feedback|ACT-Based Intervention and Activity Tracker WITH Feedback (Combining ACT and Behavioral Change) In the last experimental condition, obese individuals will follow the same rehabilitation program in the in-patients phase of the Behavioral Change condition, with the addition of the brief ACT intervention of 4 45-minutes sessions for a total amount of 3 hours one-to-one therapy sessions, exactly as in the ACT condition. In the out-patient phase of 16 weeks, each participant receive feedback from activity tracker following the same stepped protocol but message and feedbacks are informed by ACT therapist, including Value-based goal setting, prompt for including defusion from difficult thoughts, mindfulness cues and a set of ACT-consistent metaphors and messages.
89226678|NCT03345095|Experimental|Experimental Arm|Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
89226679|NCT03345095|Active Comparator|Standard Arm|Radiotherapy + Temozolomide followed by adjuvant Temozolomide
89226680|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
89092698|NCT02782234|Experimental|Contract management|In accordance with the contract content, researchers and participants should manage and maintain the liquid balance of the participants. Signed doctors and nurses should undergo the follow-up phone or family visit on time, instruct them proper healthy training, and provided necessary information data. By telephone, SMS, wechat, remind and urge the participants to take the lifestyle and behavior regulate in the contract. Participants should supervise and manage the fluid unbalance (Edema, hypertension, heart failure, and fluid imbalance of intake and output etc.), and feedback the Management and supervision to researchers according to contract.
89092699|NCT01094808|Experimental|Pregabalin 75 mg|Subjects randomized to this arm received a single dose of pregabalin 75 mg orally
89092700|NCT01094808|Experimental|Pregabalin 200 mg|Subjects randomized to this arm received a single dose of pregabalin 200 mg orally
89092701|NCT01094808|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo medication orally
89092702|NCT02007226||Spinal Cord Injury|Chronic SCI (Duration of Injury >5 years)
89092703|NCT00864253|Experimental|ABI-007|Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
89092704|NCT00864253|Active Comparator|Dacarbazine|Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
89092705|NCT02782312|Experimental|ICS+LABA Group|Seretide 250，inhalation，twice daily，one year
89092706|NCT02782312|Active Comparator|Control Group|routine therapy for one year
89092707|NCT01094730|Other|galyfilcon A prototype/marketed galyfilcon A|The galyfilcon A prototype lens worn daily for 12-16 days during the first period then the marketed galyfilcon A lens worn daily for 12-16 days during the second period.
89092708|NCT01094730|Other|marketed galyfilcon A/galyfilcon A prototype|The marketed galyfilcon A lens worn daily for 12-16 days during the first period then the galyfilcon A prototype lens worn daily for 12-16 days during the second period; during each period.
89092709|NCT02783872||Loss of control|30 overweight or obese (BMI≥85th %ile) youth endorsing loss of control eating within the past 3 months
89092710|NCT02783872||Overweight control|30 overweight or obese controls without any history of loss of control eating
89092711|NCT02783872||Normal-weight control|15 normal-weight controls without any history of loss of control eating
89092712|NCT04229758|Experimental|1 week|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
89092713|NCT04229758|Experimental|2 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
89092714|NCT04229758|Experimental|4 weeks|Time to delay the initiation of anticoagulation is determined at randomization. Patients will be randomized to initiate anticoagulation 1 week, 2 weeks, or 4 weeks following injury.
89092715|NCT04307706|Experimental|Intervention group|''Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group
89092716|NCT04307706|No Intervention|Control group|Only data collection was carried out. No attempt was made by the researcher during the study.
89092717|NCT04230538|Experimental|DJO Walker|Application of DJO Walker
89092718|NCT04230538|Active Comparator|Traditional plaster cast|Application of traditional plaster cast
89092719|NCT02783794|Experimental|BP-C1|Patients randomized to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
89092720|NCT02783794|Placebo Comparator|Placebo|Patients randomized to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
89092721|NCT00698425|Experimental|1: 0 mA-min (0 mA for 4 min)|Ocular iontophoresis 0 mA-min (0 mA for 4 minutes)
89092722|NCT00698425|Experimental|2: 4 mA-min (2 mA for 2 min), + polarity|Ocular iontophoresis 4 mA-min (2 mA for 2 minutes), positive polarity
89092723|NCT00698425|Experimental|3: 5 mA-min (2.5 mA for 2 min), +|Ocular iontophoresis 5 mA-min (2.5 mA for 2 minutes), positive polarity
89092724|NCT00698425|Experimental|4: 6 mA-min (3 mA for 2 min), + polarity|Ocular iontophoresis 6 mA-min (3 mA for 2 minutes), positive polarity
89092725|NCT00698425|Experimental|5: 7 mA-min (3.5 mA for 2 min), +|Ocular iontophoresis 7 mA-min (3.5 mA for 2 minutes), positive polarity
89092726|NCT00698425|Experimental|6: 8 mA-min (4 mA for 2 min), + polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), positive polarity
89092727|NCT00698425|Experimental|7: 7 mA-min (3.5 mA for 2 min), -|7 mA-min (3.5 mA for 2 minutes), negative polarity
89092728|NCT00698425|Experimental|8: 8 mA-min (4 mA for 2 min), - polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), negative polarity
89092729|NCT00698425|Experimental|9: 20 mA-min (4 mA for 5 min), +|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), positive polarity
89092730|NCT00698425|Experimental|10: 20 mA-min (2 mA for 10 min), +|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), positive polarity
89092731|NCT00698425|Experimental|11: 20 mA-min (4 mA for 5 min), -|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), negative polarity
89092732|NCT00698425|Experimental|12: 20 mA-min (2 mA for 10 min), -|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), negative polarity
89092733|NCT00698425|Experimental|13: 0 mA-min (0 mA for 10.5 min)|Ocular iontophoresis 0 mA-min (0 mA for 10.5 minutes)
89092734|NCT00698425|Experimental|14: 13.5 mA-min (4.5 mA for 3 min), +|Ocular iontophoresis 13.5 mA-min (4.5 mA for 3 minutes), positive polarity
89092735|NCT00698425|Experimental|15: 15 mA-min (5 mA for 3 min), +|Ocular iontophoresis 15 mA-min (5 mA for 3 minutes), positive polarity
89092736|NCT00698425|Experimental|16: 16.5 mA-min (5.5 mA for 3 min), +|Ocular iontophoresis 16.5 mA-min (5.5 mA for 3 minutes), positive polarity
89092737|NCT00698425|Experimental|17: 18 mA-min (6 mA for 3 min), +|Ocular iontophoresis 18 mA-min (6 mA for 3 minutes), positive polarity
89092738|NCT00698425|Experimental|18: 19.5 mA-min (6.5 mA for 3 min), +|Ocular iontophoresis 19.5 mA-min (6.5 mA for 3 minutes), positive polarity
89092739|NCT00698425|Experimental|19: 20 mA-min (7 mA for 3.84 min), +|Ocular iontophoresis 20 mA-min (7 mA for 3.84 minutes), positive polarity
89092740|NCT02614417||Polysomnography|Patients undergo an one-night in-hospital polysomnography to diagnose sleep-disordered breathing
89092741|NCT05342506|Experimental|Cohort 1|Study subjects: Patient with cervical carcinoma
89092742|NCT05342506|Experimental|Cohort 2|Study subjects: Patient with ovarian cancer
89092743|NCT05342506|Experimental|Cohort 3|Study subjects: Patient with malignant trophoblastic tumor
89092744|NCT05242198|Other|Rectus sheath block group (Group R)|Patients who underwent rectus sheath block
89092745|NCT05242198|Other|Control group (Group C)|The patients that did not apply any fascial plane block
89092746|NCT04230616|Active Comparator|Conventional total knee arthroplasty|conventional total knee arthroplasty with standard intramedullary alignment guide
89092747|NCT04230616|Active Comparator|NAVIO total knee arthroplasty|NAVIO assisted total knee arthroplasty
89092748|NCT04230850|Active Comparator|Mildly Impaired Group|This group will consist of participants with 35-50 degrees of lumbar flexion.
89092749|NCT04230850|Active Comparator|Moderately Impaired Group|This group will consist of participants with 20-34 degrees of lumbar flexion.
89092750|NCT04230850|Active Comparator|Highly Impaired Group|This group will consist of participants with less than 20 degrees of lumbar flexion.
89092751|NCT00638092|Experimental|Iodine|This is the hypothetical active arm
89092752|NCT00638092|Placebo Comparator|Placebo|this is the hypothetical placebo
89092753|NCT04230772|Experimental|Natural Orifice Specimen Extraction Surgery|Natural orifice specimen extraction surgery will performed in patients assigned to this group.
89092754|NCT04230772|Active Comparator|Traditional Robotic-assisted Surgery|Traditional robotic-assisted surgery will performed in patients assigned to this group.
89092755|NCT05342272|Experimental|GUM Hydral Moisturizing Gel|One group of 20 patients receiving GUM® Hydral® Moisturizing Gel (test group): they were be instructed to apply during a 28 days treatment period 1 to 2 cm of gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary.
89092756|NCT05342272|Active Comparator|Biotene Oral Balance Gel|One group of 20 patients receiving Biotene® Oral Balance Gel (control group): they were be instructed to apply during a 28 days treatment period 1 to 2 cm of gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary.
89092757|NCT04230460|Placebo Comparator|0% THC/ 0% CBD|
89092758|NCT04230460|Experimental|THC (5-10% [37.5 mg]) / Low CBD (<1% [2.5 mg])|
89092759|NCT04230460|Experimental|THC (>10% [62.5 mg]) / Low CBD (<1% [2.5 mg])|
89092760|NCT04230460|Experimental|0.065% BAC|
89092761|NCT02783638|Experimental|YHD1119 (Pregabalin 300mg)|YHD1119 (Pregabalin 300mg)
89092762|NCT02783638|Active Comparator|Lyrica (Pregabalin 150mg)|Lyrica (Pregabalin 150mg)
89092763|NCT04229524|Experimental|angiographic intervention group|Enrolled patients will undergo thoracoscopy combined with a three-incision esophageal carcinoma radical mastectomy and two-field (chest-abdomen) lymph node dissection.Quantitative assessment of blood supply in the gastic conduit was performed using fluoroscopy before esophagogastric anastomosis.
89092764|NCT04229524|No Intervention|control group|The same surgical method as the experimental group.The only difference is that the position of the gastic conduit anastomosis is determined based on the experience of the doctor.
89092765|NCT02783326|Experimental|COPD Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
89092766|NCT02783326|Active Comparator|Control Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
89092767|NCT02782000|Experimental|Long-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 6 months.
89092768|NCT02782000|Active Comparator|Short-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 3 months.
89092769|NCT04230070|Experimental|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
89092770|NCT04230070|Active Comparator|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
89092771|NCT02782078|Other|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
89092772|NCT01293682|Experimental|Calcitriol|Calcitriol 45mcg/week
89092773|NCT05342116|No Intervention|Fasting Arm|Patient will fast at least 6 hours prior to endoscopy
89092774|NCT05342116|Active Comparator|Water Arm|Patient will drink 400 ml of water 2 to 4 hours prior to endoscopy
89092775|NCT05342116|Experimental|CHO Arm|Patient will drink 400 ml of Preload 2 to 4 hours prior to endoscopy
89092776|NCT02782936|Experimental|Baseline|Randomised baseline without and with gas mask.
89092777|NCT02782936|Experimental|Induced Hypoxemia|Randomised hypoxemia: i. without gas mask; ii. with gas mask; and iii. correction with FreeO2 and gas mask.
89092778|NCT02782936|Experimental|Effort|Randomised effort without and with gas mask
89092779|NCT02782858|Experimental|Dose 1 GNbAC1|Monthly IV repeated dose
89092780|NCT02782858|Experimental|Dose 2 GNbAC1|Monthly IV repeated dose
89092781|NCT02782858|Experimental|Dose 3 GNbAC1|Monthly IV repeated dose
89092782|NCT02782858|Placebo Comparator|Placebo|Monthly IV repeated dose
89092783|NCT00864097|Experimental|Tanezumab 10 mg + diclofenac|IV tanezumab 10 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
89092784|NCT00864097|Experimental|Tanezumab 5 mg + diclofenac|IV tanezumab 5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
89092785|NCT00864097|Experimental|Tanezumab 2.5 mg + diclofenac|IV tanezumab 2.5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
89092786|NCT00864097|Placebo Comparator|IV placebo + diclofenac|IV placebo to match tanezumab every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
89092787|NCT04230226|Active Comparator|Pre-workout and Post-workout Product|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
89092788|NCT04230226|Placebo Comparator|Study Placebo|non-caloric powder mixed with water consumed within 30 minutes prior to exercise and within 15 minutes post exercise
89092789|NCT02782624|Experimental|Treatment A: Empagliflozin|5 mg bid
89092790|NCT02782624|Experimental|Treatment B: Empagliflozin|10 mg qd
89092791|NCT02781766|Other|One arm: patients with severe haemophilia A on prophylaxis|Patients with severe haemophilia A (FVIII < 1 IU/dl), currently on prophylactic therapy , having the same prophylaxis regimen in the last six months, aged between 2 (with a body weight ≥12.5 kg ) and 45 years , with adequate venous access, having patient's diary or equivalent regularly completed and able to give informed consent
89092792|NCT02781688|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks.
89092793|NCT00887536|Active Comparator|Group 1: TAC then pegfilgrastim|docetaxel, doxorubicin, cyclophosphamide, and pegfilgrastim/filgrastim
89092794|NCT00887536|Active Comparator|Group 2: TC|docetaxel and cyclophosphamide
89092795|NCT00887536|Experimental|Group 3: TC + bevacizumab|docetaxel, cyclophosphamide, and bevacizumab
89092796|NCT02614339|Experimental|metformin|
89092797|NCT02614339|Active Comparator|control|
89092798|NCT00697333|No Intervention|A|Irradiation of all tumor manifestations detectable by CT and/or positron emission tomography using fluoro-deoxy-glucose including a part of eventual atelectasis and the whole affected lymph node stations by 60 - 74 Gy/2Gy) irradiation of elective lymph node stations up to 50 Gy/2 Gy
89092799|NCT00697333|Experimental|B|Irradiation of all tumor manifestations detectable by positron emission tomography using fluoro-deoxy-glucose including the whole affected lymph node stations by 60 - 74 Gy/2Gy
89092800|NCT04132687|Other|autologous blood patch|autologoust blood patch therapy
89092801|NCT02618395|Experimental|Treatment A|
89092802|NCT02618395|Experimental|Treatment B|
89092803|NCT02618395|Experimental|Treatment C|
89092804|NCT01183013|Active Comparator|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily
89092805|NCT01183013|Active Comparator|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily
89092806|NCT01183013|Active Comparator|Pioglitazone 45 mg|Pioglitazone Capsules 45 mg once daily
89092807|NCT01183013|Active Comparator|Linagliptin 5mg|Linagliptin 5mg Tablets once daily
89092808|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 15 mg|Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily
89092809|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 30 mg|Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily
89092810|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 45 mg|Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily
89092811|NCT04129801||Prospective analysis|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).~Evaluation of Muscle Strength was used The Biodex Multi-joint System 3 dynamometer (Biodex Medical Systems, Inc., Shirley, New York, USA) to measure isokinetic extension (Ext) and flexion (Flex) MVC torques for both legs."
89092812|NCT02618629|Experimental|14C-Z-215|
89092813|NCT04132609|Active Comparator|Cognitive Bias Intervention|Complete cognitive bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
89092814|NCT04132609|Placebo Comparator|Control|Complete standard attentional bias intervention task during methadone clinic visit 3x/wk for 4 weeks.
89092815|NCT04132531||Normal weight control|Individuals who are generally healthy and have a body mass index less than 25 kg/m^2.
89092816|NCT04132531||Bariatric Surgery Group|Individuals electing to undergo bariatric surgery (generally with a body mass index between 35 and 40 kg/m^2 with an additional co-morbidity such as type 2 diabetes, or individuals with a body mass index greater than 40 kg/m^2) and who are willing to participate for 2 visits, one before and one after surgery. The intervention in this group is bariatric surgery.
89092817|NCT02615197|Active Comparator|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014).
89092818|NCT02615197|Experimental|Dialectical Behavior Therapy + DBT Prolonged Exposure protocol|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014) plus an adapted version of Prolonged Exposure therapy for PTSD.
89092819|NCT04229212|No Intervention|No drainage|No drainage
89092820|NCT04229212|Experimental|Drainage|a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed
89092821|NCT02618473|No Intervention|seloken|"In seloken arm, patients performs the cardiac CT procedure regarding the national scan guidelines, ande receive 5-10 intravenous seloken, until heart rate below 60 beats pr minit is achieved."
89092822|NCT02618473|Experimental|non-seloken|"Patients randomized to non-seloken, do not receive any medication."
89092823|NCT00634660|Active Comparator|0.001 mg/kg|One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.
89092824|NCT00634660|Active Comparator|0.003 mg/kg|One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.
89092825|NCT00634660|Active Comparator|0.01 mg/kg|One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.
89092826|NCT00634660|Active Comparator|0.03 mg/kg|One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.
89092827|NCT00634660|Active Comparator|0.1 mg/kg|One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.
89092828|NCT00634660|Active Comparator|0.3 mg/kg|One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.
89092829|NCT00634660|Active Comparator|1.0 mg/kg|One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.
89092830|NCT00698503||M2a- 38™ Hip System|
89092831|NCT02886767|Experimental|skin-to-skin contact (SSC)|Experimental: a daily skin-to-skin contact (SSC) at least 15 minutes in length
89092832|NCT02886767|No Intervention|Control: hospital routine care|As the hospital routine. Allow the father to visit the neonate, touching the neonate
89092833|NCT00922753|Active Comparator|BiPAP6 assisted preoxygenation|
89092834|NCT00922753|Active Comparator|BiPAP4 assisted preoxygenation|
89092835|NCT00922753|Active Comparator|Standard preoxygenation (VS)|
89092836|NCT05141500|Experimental|Healthy adult participants|All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors
89092837|NCT02618239|Experimental|Healthy subjects|Bimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks
89092838|NCT05341102|Experimental|LY3556050 (Part 1)|Participants will receive single ascending doses of LY3556050 orally.
89092839|NCT05341102|Experimental|Placebo (Part 1)|Participants will receive placebo orally.
89092840|NCT05341102|Experimental|LY3556050 (Part 2)|Participants will receive multiple ascending doses of LY3556050 orally.
89092841|NCT05341102|Experimental|Placebo (Part 2)|Participants will receive placebo orally.
89092842|NCT02615041|Experimental|1 g by bolus injection|1 g of meropenem with bolus injection every 8 h regimen
89092843|NCT02615041|Experimental|1 g by 3 h infusion|1 g of meropenem with 3 h infusion every 8 h regimen
89092844|NCT02615041|Experimental|2 g by 3 hinfusion|2 g of meropenem with 3 h infusion every 8 h regimen
89092845|NCT04229602|Experimental|Venlafaxine Hydrochloride Sustained-Release Capsules|During the study session, healthy subjects will be administered a single dose of Hydrochloride Sustained-Release Capsules 75 mg under Fed conditions.
89092846|NCT04229602|Active Comparator|Active Comparator: EFEXOR® XR|During the study session, healthy subjects will be administered a single dose of EFEXOR® XR 75mg under Fed conditions.
89092847|NCT05298163|Experimental|Intervention Group|Drug: Calcitriol The intervention group will be given calcitriol at a dose of 0.25 mcg/day for six months in the form of capsules that have been marked and numbered. The drugs will be taken through the RSCM pharmacy once a month during visit and the allocation will be given using drug labels that are sealed and packaged identically.
89092848|NCT05298163|Active Comparator|Placebo Group|Drug: Placebo oral The placebo drug will be given for six months in the form of capsules that have been marked and numbered. The drugs will be taken through the RSCM pharmacy once a month during visit and the allocation will be given using drug labels that are sealed and packaged identically.
89092849|NCT05133232|Experimental|SynPhNe physio-neuro platform|Subjects will receive 15 to18 sessions of training at 60 minutes each on the use of the SynPhNe physio-neuro platform, for over the course of 4 weeks, outside of their conventional occupational therapy in accordance to a study protocol.
89092850|NCT05133232|No Intervention|Conventional occupational therapy|Subjects will receive conventional occupational therapy (OT) only.
89092851|NCT01141283|Experimental|BTDS|Buprenorphine transdermal patch
89092852|NCT05340946|Experimental|Group (G)|received general anaesthesia followed by IV patient-controlled analgesia (IV PCA).
89092853|NCT05340946|Experimental|Group (F)|received spinal anaesthesia followed by continuous ultrasound guided femoral never block once the anaesthesia-induced motor block resolved.
89092854|NCT00863707|Placebo Comparator|Placebo|Matching intravenous (IV) bolus injection
89092855|NCT00863707|Experimental|Regadenoson|0.4 mg/5 mL intravenous bolus injection
89092856|NCT05340634|Active Comparator|Oral Contraceptive|Drospirenone 4 mg once a day for 6 months
89092857|NCT05340634|Experimental|Oral Contraceptive + Food supplement Metionac|Drospirenone 4 mg once a day and Metionac twice daily (200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 Vitamin B6) for 6 months
89092858|NCT05340634|Other|Food supplement MetioNac|Metionac twice daily (200 mg S-adenosylmethionine, 100 mg N-acetylcisteine, 75 mg alpha lipoid acid and 0,65 Vitamin B6) for 6 months
89092859|NCT02886689||1|patients will be those receiving any biotherapy
89092860|NCT02886689||2|patients will be those not receiving biotherapy : non indication, refusal, contraindication.
89092861|NCT05367479|Active Comparator|Cefazolin|standard of care as a pre-operative antibiotic given with 60 minutes of incision before gastric bypass surgery. given intravenous as a single dose, weight based.
89092862|NCT05367479|Active Comparator|Clindamycin|also standard of care alternative as a pre-operative antibiotic given with 60 minutes of incision before gastric bypass surgery. given intravenous as a single dose, weight based.
89092863|NCT02614105|Experimental|Pelvic floor muscle training|Participants in the pelvic floor muscle training group will receive group exercise sessions (1 hour) at the physiotherapy out-patient department of the hospital once a week for 16 weeks with guidance from an experienced pelvic floor physiotherapist. The group exercise sessions will focus on pelvic floor muscle training, relaxation and breathing techniques. Participants in the pelvic floor muscle training group will also receive an individually adapted pelvic floor muscle training program for daily home use.
89092864|NCT02614105|Experimental|Cough-suppression|Participants in the cough-suppression group will receive a group education session with general information about cough-suppression therapy and advice about how to distinguish between unproductive and productive cough to enable them to perform airway clearance techniques when required. In addition, participants will receive one to two individual sessions (30-60 minutes) of cough-suppression therapy tailored to the individual needs based on symptoms and underlying disease activity
89092865|NCT02614105|Experimental|Control group|Participants in the group will receive guidance and instruction in terms of correct contraction of the pelvic floor muscles at clinical assessment. Control group participants will receive brief written information about pelvic floor muscle training and cough-suppression therapy, but no other form of regular follow-up or intervention throughout the intervention period.
89092866|NCT02780830|Experimental|AZD2014 plus Ibrutinib Combination|AZD2014 and ibrutinib will be dosed together in the morning under fasting conditions. When possible, the morning doses of AZD2014 and ibrutinib should be taken at approximately the same time each day. The morning doses must be taken in a fasted state (water to drink only) from at least 2 hours prior to the dose to at least 1 hour post dose. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
89092867|NCT02613793||Preterm pre-eclampsia (cases)|Pregnant patients diagnosed with pre-eclampsia prior to 35 weeks gestation
89092868|NCT02613793||Pregnant patients (controls)|Age- and gestation-matched pregnant patients who are not suffering with pre-eclampsia, hypertensive disease or any other neuropsychiatric condition
89092869|NCT04187807|Experimental|Melatonin 5mg|Melatonin 5mg, every 24 hours for 14 days
89092870|NCT04187807|Placebo Comparator|Placebo|Starch based placebo, every 24 hours for 14 days
89092871|NCT02780752|Active Comparator|Oral hymecromone 400mg po three times per day|Participants will be administered oral hymecromone 400mg po three times per day (1200 mg)
89092872|NCT02780752|Active Comparator|Oral hymecromone 800 mg po three times per day (2400 mg)|Participants will be be administered oral hymecromone 800 mg po three times per day (2400 mg)
89092873|NCT02780752|Active Comparator|Oral hymecromone 1200 mg three times per day (3600 mg)|Participants will be administered oral hymecromone 1200 mg three times per day (3600 mg)
89092874|NCT02781298|Experimental|New Infant Cereal|amount ingested according to pediatricians recommendations
89092875|NCT02781298|Active Comparator|Multicereals Infant Cereal|amount ingested according to pediatricians recommendations
89092876|NCT04132297|Experimental|Virtual Asthma Academy Training + Telehealth Visit Group|Participants will receive the Asthma Academy Training virtually. One week after the virtual training, participants will be scheduled to complete a Telehealth visit via zoom through their smart phones or computers.
89092877|NCT04132297|Experimental|Virtual Asthma Academy Training|Participants will receive the virtual Asthma Academy Training via zoom through their smart phones or computers.
89092878|NCT01094184|Experimental|Bevacizumab 10 mg/kg Q2W|Participants will receive bevacizumab at a dose of 10 milligrams per kilogram (mg/kg) every 2 weeks (Q2W) as intravenous infusion along with paclitaxel every week (Q1W) or docetaxel every 3 weeks (Q3W) as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
89092879|NCT01094184|Experimental|Bevacizumab 15 mg/kg Q3W|Participants will receive bevacizumab at a dose of 15 mg/kg Q3W as intravenous infusion along with paclitaxel Q1W or docetaxel Q3W as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
89092880|NCT00697879|Experimental|1|Oral, once daily administration of CHR-3996 to determine safety and tolerability
89092881|NCT02780908|Experimental|Hypoxia at rest and exercise|The participants will perform a resting test, hypoxia sensitivity test and a graded exercise test to voluntary exhaustion in normoxic condition ((HYPO; FiO2=0.120 corresponding to terrestrial altitude of approx. 4000 m)
89092882|NCT02780908|Placebo Comparator|Normoxia at rest and exercise|The participants will perform a resting test and a graded exercise test to voluntary exhaustion in normoxic condition ((NORM; fraction of inspired oxygen (FiO2)=0.209, placebo)
89092883|NCT01134731|Experimental|paliperidone|dose escalation , levels 1-5 daily dosing ranged from 1-5mg
89092884|NCT01134731|Active Comparator|lithium|dose escalation, level 1-5 daily dosing 300-1500mg
89092885|NCT01134731|Placebo Comparator|placebo|1-5 placebo capsules
89092886|NCT04132063||Generic levetiracetam|
89092887|NCT05340556|Experimental|sRPL patient|sRPL with an older brother and at least one child prior to diagnosis
89092888|NCT05340556|Experimental|Brother or child to the sRPL patient|An older brother (with at least same biological mother) og child to the sRPL patient
89092889|NCT04127071|Active Comparator|Surgical I&D Procedure|The abscess cavity will be evaluated thoroughly with ultrasonography. The site will be prepared and draped. The skin surface will be infiltrated with local anesthetic with a 25-gauge needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Incision of the skin surface with a number 11-blade scalpel will be performed over the largest area of infection; the incision will be extended into the abscess cavity. A blunt instrument will then be used to break up internal loculations if present. Repeated instrumentation through the initial incision or extension of the original incision will be performed if needed. Lastly, iodoform packing will be inserted through the incision into the cavity. The decision to send the abscess contents for microbiological culture and susceptibility analysis will be at the discretion of the treating clinician.
89092890|NCT04127071|Experimental|Ultrasound-guided Needle Aspiration Procedure|The abscess cavity will be evaluated thoroughly with US. The site will be prepared and draped. The skin surface and anticipated needle track will be infiltrated with local anesthetic with a 25g needle. The treating clinician may provide ultrasound-guided regional anesthesia for procedural analgesia at their discretion. Under direct US-guided visualization, a 14g 2in steel needle attached to a 40mL syringe will be advanced into the abscess cavity with manual negative pressure. The needle tract will be extended obliquely 2-3 cm between the skin and abscess to prevent fistulization. Purulent material will be aspirated until no further purulence can be aspirated. Multiple aspiration attempts on the initial visit will be permitted to maximally drain the abscess cavity. Additionally, irrigation of the abscess cavity with sterile saline will be permitted to break up internal loculations if present, as has reported previously for trunk and breast abscesses.
89092891|NCT02781220||Qualifying participants|All consented IDEAS trial participants will have additional data collected: visual and semi-quantitative software aided amyloid PET scan interpretation, care partner questionnaires and documented provider diagnosis, diagnostic confidence, and management plan following the IMPACT design
89092892|NCT01141205|Experimental|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
89092893|NCT01141205|Placebo Comparator|Saline|Saline
89092894|NCT02618317|Active Comparator|Heparin Lock Solution|Patients on Heparin 1,000 U/ml locking solution, administered at the end of each dialysis session during a 15-week period .
89092895|NCT02618317|Experimental|Trissodium Citrate 30%|Patients on trissodium citrate 30% locking solution, administered at the end of each dialysis session during a 15-week period .
89092896|NCT02618317|Experimental|Minocycline-EDTA 30 mg/ml - 3 mg/ml|Patients on Minocycline 30 mg/ml/EDTA 3 mg/ml locking solution, administered at the end of each dialysis session during a 15-week period.
89092897|NCT02781376|Experimental|CHICA-OSA|Two clinics will be randomized to receive the advanced CHICA-OSA computer decision support system designed to support PCPs in evidence-based identification and management of pediatric OSA. This module includes a snoring identification component (received by the control group).
89092898|NCT02781376|Other|Control|Two clinics will be randomized to receive a control computer decision support system module that automates screening for snoring and alerts the PCP, but does not provide any additional guidance on evidence-based diagnosis or management.
89092899|NCT02614963|Experimental|Clostridium Butyricum group|Irritable bowel syndrome patients treated with Clostridium Butyricum
89092900|NCT02614963|Placebo Comparator|Placebo group|Irritable bowel syndrome patients treated with placebo
89092901|NCT01140503|Experimental|apremilast|apremilast 20mg bid
89092902|NCT02689726|Experimental|GTL001 + Aldara, 5% imiquimod cream|2 doses, 6 weeks apart, GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination
89092903|NCT00863317|Experimental|montelukast sodium|4mg granules PO QD for 14 days
89092904|NCT00863317|Placebo Comparator|Placebo|Sucrose granules PO QD for 14 days
89092905|NCT02883413|Experimental|CRT +Teach the Parent|The Teach the Parent (TtP) addition to CRT is designed to increase parental understanding of their adolescents' thinking styles. We hypothesize that by doing so, parents will be more likely to challenge eating disorder behaviors and be less likely to accommodate behavioral symptoms of the eating disorder (e.g., make something low-fat for dinner because it will be easier). In this arm, adolescents will explain what they learned during CRT and walk their parents though at least 4 tasks during each TtP session. Parents and child will not be permitted to speak about the eating disorder during these sessions. TtP sessions will occur 3-4 times during hospitalization and will be guided by the adolescent.
89092906|NCT02883413|Active Comparator|CRT + Family Fun Time|In order to assess for any non-specific effects of spending non-eating disorder driven time with family, adolescents in the CRT+ Contact Control condition will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). We refer to this condition as CRT + Family Fun Time (CRT+FFT). Adolescents will be asked to complete a series of fun tasks (some standardized, some are choice driven) with their parents. During these sessions, they will not be permitted to discuss CRT or the eating disorder.
89092907|NCT02883413|No Intervention|Treatment as Usual (TAU)|Adolescents in this condition will not receive any additional treatment. They will have a standard hospital stay with all normal contact with health professionals.
89092908|NCT01200368|Experimental|1|Experimental
89092909|NCT01200368|Active Comparator|2|Active comparator
89092910|NCT01200368|Active Comparator|3|Active comparator
89092911|NCT00697957|No Intervention|2|Control group
89092912|NCT00697957|Experimental|1|Exercise
89092913|NCT04125121|Active Comparator|Sevoflurane-Propofol|"Session one: Sevoflurane as maintenance anaesthetic during general anaesthesia.~Session two: Propofol as maintenance anaesthetic during general anaesthesia."
89092914|NCT04125121|Active Comparator|Propofol-Sevoflurane|"Session one: Propofol as maintenance anaesthetic during general anaesthesia.~Session two: Sevoflurane as maintenance anaesthetic during general anaesthesia."
89092915|NCT02618083|Experimental|retinal detachment|color Doppler ultrasound of the eye
89092916|NCT01079130|Experimental|Indacaterol 18.75 µg|"Indacaterol 18.75 µg once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
89092917|NCT01079130|Experimental|Indacaterol 37.5 µg|"Indacaterol 37.5 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
89092918|NCT01079130|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
89092919|NCT01079130|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
89092920|NCT01079130|Active Comparator|Salmeterol|"Salmeterol 50 µg twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
89092921|NCT01079130|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
89092922|NCT05341570|Experimental|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BPI-21668 administered, once daily (QD).
89092923|NCT05341570|Experimental|Dose Expansion|Oral tablets administered at MTD/RP2D. Each treatment cycle will be 28 days in duration with BPI-21668 administered, once daily (QD).
89092924|NCT02689414|Experimental|Remote ischaemic preconditioning|Four episodes of 5 minutes of ischaemia are performed. Between all the episodes there is a 5-minute period of reperfusion.
89092925|NCT02689414|Sham Comparator|Control to RIPC|Four episodes of 5 minutes during which the pressure in the cuff is equal to venous pressure are performed. Between all the episodes there is a 5-minute pause.
89092926|NCT01078974|Experimental|pomalidomide, dexamethasone, rituximab|"Drug: pomalidomide Taken orally once a day~Drug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15~Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15"
89092927|NCT04307082|Experimental|Ibrexafungerp|Oral [14C]-Ibrexafungerp Single Dose
89092928|NCT02877576|Experimental|Epileptic patient|micro-electrode recordings interventions: Implantation of mixed intracerebral electrodes Face detection Face individualization
89092929|NCT02878200|Experimental|reactive treatment|Household members; defined as those sharing the same sleeping area, in the intervention villages, will be treated with a full course of dihydroartemisinin-piperaquine (DHAP)
89092930|NCT02878200|No Intervention|standard care|In control villages, no household treatment will be done
89092931|NCT05340088||Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
89092932|NCT05340088||Patients who underwent RIRC for 4-6 weeks after DJ stent placement for passive dilatation|Patients who underwent RIRC for 4-6 weeks after DJ stent placement for passive dilatation
89092933|NCT02780518|Experimental|Airvo|All patients scheduled for elective microlaryngeal surgery under general anaesthesia and subglottic high frequency jet ventilation
89092934|NCT04306770|Active Comparator|Intervention|OPTIMUM Programme
89092935|NCT04306770|No Intervention|Control|Treatment as usual
89092936|NCT00869557|Experimental|Stribild|
89092937|NCT00869557|Active Comparator|Atripla|
89092938|NCT02878356|Active Comparator|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
89092939|NCT02878356|Active Comparator|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
89092940|NCT02878356|Active Comparator|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
89092941|NCT02780596|Experimental|Items1;3|Caregiver is randomly assigned to receive screening items 1 and 3. Item 1: Does CHILD NAME often wake one or more times during the night? Item 3: Do you think CHILD NAME's sleep is a problem?
89092942|NCT02780596|Experimental|Items1;4|Caregiver is randomly assigned to receive screening items 1 and 4. Item 1: Does CHILD NAME often wake one or more times during the night? Item 4: Does you think CHILD NAME has a sleep problem?
89092943|NCT02780596|Experimental|Items1;5|Caregiver is randomly assigned to receive screening items 1 and 5. Item 1: Does CHILD NAME often wake one or more times during the night? Item 5: Do you have any concerns about CHILD NAME's sleep?
89092944|NCT02780596|Experimental|Items2;3|Caregiver is randomly assigned to receive screening items 2 and 3. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 3: Do you think CHILD NAME's sleep is a problem?
89092945|NCT02780596|Experimental|Items2;4|Caregiver is randomly assigned to receive screening items 2 and 4. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 4: Does you think CHILD NAME has a sleep problem?
89092946|NCT02780596|Experimental|Items2;5|Caregiver is randomly assigned to receive screening items 2 and 5. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 5: Do you have any concerns about CHILD NAME's sleep?
89092947|NCT02780596|Experimental|Items3;5|Caregiver is randomly assigned to receive screening items 3 and 5. Item 3: Do you think CHILD NAME's sleep is a problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
89092948|NCT02780596|Experimental|Items4;5|Caregiver is randomly assigned to receive screening items 4 and 5. Item 4: Does you think CHILD NAME has a sleep problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
89230265|NCT00048061|Experimental|Ibandronate 100 mg|Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
89092949|NCT02877420|Experimental|Non-Technical Skills Training Curriculum|This group will receive 4 hours of small-group and hands-on sessions and 1 hour of didactic NTS sessions. Participants will watch a video that demonstrates ideal endoscopic performance. They will use the E-NTS Checklist during the integrated scenario training. This checklist targets NTS. The group will be given 7 hours of expert-assisted instruction on the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (6 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist who will demonstrate techniques, answer questions and provide individualized performance feedback with a focus on NTS. The last three hours on the high fidelity simulator will be an integrated scenario (IG) featuring standardized patient (SP) and standardized nurse (SN). Feedback will be given after each IG by the instructor, SP and SN. Participants can view the E-NTS Checklist before and after each case.
89226681|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
89226682|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
89226683|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
89226684|NCT03316560|Experimental|Group 1: Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 1 of rAAV2tYF-GRK1-RPGR study drug.
89226685|NCT03316560|Experimental|Group 2: Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug.
89226686|NCT03316560|Experimental|Group 3 and Group 4 Phase 1/2 Dose Escalation|Group 3 male subjects at least 18 y/o and Group 4 male subjects at least 6 y/o treated with Dose 3 of rAAV2tYF-GRK1-RPGR study drug.
89226687|NCT03316560|Experimental|Group 5 Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug.
89226688|NCT03316560|Experimental|Group 6 Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 6 of rAAV2tYF-GRK1-RPGR study drug.
89226689|NCT03315871|Experimental|1/combination therapy (closed December 2018)|Prostvac + CV301+ MSB0011359C
89226690|NCT03315871|Experimental|2/combination therapy + surveillance (closed)|Surveillance followed by Prostvac + CV301 then Prostvac + CV301 + MSB0011359C
89226691|NCT03315871|Experimental|3/combination vaccine therapy +/- surveillance|Surveillance as needed followed by Prostvac + CV301
89226692|NCT03310489|Experimental|Digitalized cognitive-behavioral intervention|
89226693|NCT03310489|Active Comparator|Psychoeducation about anxiety|
89226708|NCT03294759|Experimental|Bio-ACL (Amion)|Intervention: ACL Autograft Reconstruction with Amion Collagen Scaffold. Stem Cells isolated from bone marrow aspirate from distal femur will be injected inside the Amion Collagen Scaffold.
89226709|NCT03294759|Active Comparator|Control|Intervention: Normal ACL Autograft Reconstruction with either patella or hamstring autograft will be performed in the control group.
89226710|NCT03283254|Experimental|Practical Resources for Effective Postpartum (PREPP)|A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.
89092950|NCT02877420|Active Comparator|Conventional Simulation Training Group|This group will receive 4 hours of small-group and hands-on sessions on colonoscopy theory from an expert endoscopist. The core curriculum is designed on the basis of the American Society for Gastrointestinal Endoscopy colonoscopy curriculum and an endoscopic training textbook. This curriculum has been shown to be effective when compared to self-regulated learning on the simulator. The sessions will be interlaced with eight hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and on the high-fidelity VR simulator (7 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist. The expert will demonstrate techniques, answer questions and provide feedback on global performance. Feedback, in the form of performance metrics, will be provided by the simulator upon completion/failure of each module.
89092951|NCT01200290|Experimental|LY2127399|
89092952|NCT02781142|Experimental|Motor imagery training|Persons with multiple sclerosis
89092953|NCT02781142|No Intervention|Control group|Persons with multiple sclerosis
89092954|NCT02781142|No Intervention|Healthy controls|Healthy participants
89092955|NCT04131985|Experimental|Erector spina block|"After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).~All anesthesia procedure will be the same as control group"
89092956|NCT04131985|No Intervention|Control|There were no intervention. All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1-2μg/kg, propofol 2 - 4 mg/kg and rocuronium 0.6 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCO2≈ 35-40 mmHg. Anesthesia was maintained using remifentanil 0.05-0.1 mcg/kg/min and propofol 80-100 mcg/kg/min via total intravenous micro pump until the surgery was completed. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria.Tramadol 100 mg i.v. will be used before 15 min end of surgery and 20 mL of 25% bupivacaine will be infiltrated to the trochar sites at the end of the surgery. Patient control analgesia device will administer all patients.
89092957|NCT02618005|Experimental|LcS group|Consuming probiotic capsule
89092958|NCT02618005|No Intervention|Control group|
89092959|NCT02781064|Active Comparator|Atorvastatin 20mg|Atorvastatin to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
89092960|NCT02781064|Placebo Comparator|Placebo - Microcrystalline Cellulose|Placebo to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
89092961|NCT04205682|Experimental|Cannabidiol (CBD)|Drug: Cannabidiol (day 1: 1200 mg (800 mg BD); day 2-4: 800 mg (400 mg BD); day 5: placebo BD).
89092962|NCT04205682|Placebo Comparator|Placebo|Drug: Placebo (days 1-5: placebo matched BD)
89092963|NCT01134263|Experimental|CYD Dengue Vaccine Phase III Lot 1|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1),Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
89092964|NCT01134263|Experimental|CYD Dengue vaccine - Phase III Lot 2|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
89092965|NCT01134263|Experimental|CYD Dengue vaccine - Phase III Lot 3|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
89092966|NCT01134263|Experimental|CYD Dengue vaccine - Phase II Lot|Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
89092967|NCT01134263|Placebo Comparator|Placebo|Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
89092968|NCT00626184|Placebo Comparator|A|Placebo
89092969|NCT00626184|Active Comparator|B|Active study Drug: ALV003
89092970|NCT00634738|Experimental|one|
89092971|NCT02780440||Control Group|Subjects will participate in standard occupational therapy rehabilitation protocol plus a traditional home based exercise program.
89092972|NCT02780440||Experimental Group 1|Subjects will participate in standard rehabilitation protocol plus unimanual home based mirror therapy program
89092973|NCT02780440||Experimental Group 2|Subjects will participate in standard rehabilitation protocol plus bimanual home based mirror therapy program.
89092974|NCT01199822|Experimental|Olaratumab|
89092975|NCT05158816||COVID-19 patients|COVID-19 patients admitted to the ICU
89092976|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 1 Group|Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.
89092977|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 2 Group|Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.
89092978|NCT00866359|Active Comparator|A. Apremilast|
89092979|NCT00866359|Placebo Comparator|B. Placebo Comparator|
89092980|NCT00634816||Chemotherapy recipients|Subjects who have undergone chemotherapy will receive DXA scan
89092981|NCT04317014||cases|early puberty girls of Han Chinese
89092982|NCT04317014||controls|normal development girls of Han Chinese
89092983|NCT02780986|Active Comparator|Female entertainment worker intervention group|The intervention program for the female EE workers aims to increase STI/HIV prevention knowledge and develop their condom negotiation and application skills so as to increase condom use with both casual and paid partners. It consists of a total of 4 sessions: 2 on-site and 2 online sessions. For each on-site session, groups of 4 to 5 female EE workers will be gathered. The 2 on-site sessions would be delivered by peer educators. The 2 online sessions would be conducted via phone and other modes of network communication (e.g. SMS message or WhatsApp message) depending on the preference of each participant. In addition, all the intervention materials and video demonstrations will also be uploaded onto the web portal for the participant to access during their free time.
89092984|NCT02780986|No Intervention|Female entertainment worker control group|"The female EE workers in the control group will receive the same number of 2 onsite and 2 online sessions but covering healthy eating and physical activity.~The following gives a summarised breakdown and content of each session:~Session 1 (on-site immediately after baseline survey, 10 minutes):~The peer educator will share information on healthy eating and physical activity using the educational pamphlets from the Health Promotion Board (HPB) with the participants.~Session 2 (online 1-2 weeks after baseline survey, 5 minutes):~The peer educator will share an app on healthy eating with the participants.~Session 3 (online 3-4 weeks after baseline survey, 5 minutes):~The peer educator will share an app on physical activity with the participants.~Session 4 (onsite during follow-up survey, 10 minutes):~The peer educator will reinforce information on healthy eating and physical activity based on the educational pamphlets from HPB with the participants."
89092985|NCT02780986|Active Comparator|Heterosexual men intervention group|The intervention program for heterosexual men patronising EEs will be a holistic non disease-centric, non-stigmatising and non-judgemental program addressing sexual well-being, avoidance of casual and paid sex if possible and safe sex such as condom use.
89092986|NCT02780986|No Intervention|Heterosexual men control group|There will be a simultaneous programme on healthy eating and physical activity at the control site at Tanjong Pagar. Health promoters will go around Tanjong Pagar and distribute pamphlets and brochures developed by the HPB on healthy eating and physical activity to the heterosexual men who step into or out of the EEs there. These health promoters have been trained to give simple health advice on healthy eating and physical activity if the heterosexual men wish to find out more information.
89092987|NCT01199198|Experimental|Tolvaptan Group|Tolvaptan Group: Starting dose 15 mg by mouth once a day for 14 days.
89092988|NCT01199198|Placebo Comparator|Placebo Group|Placebo Group: Placebo by mouth once a day for 14 days.
89092989|NCT01095978||Acute upper respiratory tract diseases, bronchitis, pneumonia|
89092990|NCT02617927||Vedolizumab Cohort|"Group 1a Mothers exposed to Vedolizumab at any time during pregnancy (and up to 3 months prior to last menstrual period [LMP], if this information is available).~Group 1b Infants born to Group 1a patients."
89092991|NCT02617927||Anti-TNF Agents Cohort|"Group 2a Patients with IBD who were exposed to anti-TNFs at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).~Group 2b Infants born to Group 2a patients."
89092992|NCT02617927||Conventional therapy only Cohort|"Patients with IBD who were exposed to conventional therapy only any time during pregnancy (and up to 3 months prior to LMP, if this information is available).~• Group 3b Infants born to Group 3a patients."
89092993|NCT01134107|Experimental|Insulin Lispro 6 Day (6D)|
89092994|NCT01134107|Active Comparator|Insulin Aspart 6 Day (6D)|
89092995|NCT04046965||Region XI Head Start children and families|children (800) parents (800) classrooms/teachers (80) program directors (22) center directors (37)
89092996|NCT01199042|Other|BiPAP autoSV Advanced Device|Positive airway pressure device
89092997|NCT02780674|Active Comparator|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
89092998|NCT02780674|Placebo Comparator|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
89092999|NCT05339620|Experimental|mop group|a group of patients with a class 2 divsion 1 dental malocclusion, overjet greater than 9 mm, extraction of upper first premolars planned, and it has been 3 months post extraction and before canine retraction is commenced.
89093000|NCT05339620|Active Comparator|mop group ( same)|a group of patients with a class 2 divsion 1 dental malocclusion, overjet greater than 9 mm, extraction of upper first premolars planned, and it has been 3 months post extraction and before canine retraction is commenced.
89093001|NCT01198574|Experimental|Iron group|
89093002|NCT01198574|Experimental|Vitamin A group|Vitamin A group
89093003|NCT01198574|Experimental|Iron and Vitamin A group|Iron and Vitamin A group
89093004|NCT01198574|Experimental|Placebo group|Placebo group with folic acid
89093005|NCT01198028|Experimental|Treatment (erlotinib)|Participants receive erlotinib PO QD in the absence of disease progression or unacceptable toxicity.
89093006|NCT02780362|Experimental|A Test|Test drug (Prodactariv)1 tablet contains 60 mg Daclatasvir
89093007|NCT02780362|Active Comparator|B Reference|Reference drug (Clatazev) 1 tablet contains 60 mg Daclatasvir
89093008|NCT01197950|Active Comparator|Manual Acupuncture|Manual stimulation
89093009|NCT01197950|Experimental|Electro Acupuncture|Electrical and manual stimulation
89093010|NCT01197950|No Intervention|Standard care|No acupunture
89093011|NCT01092780|Experimental|MK-7288 10mg/Pbo/MK-7288 20mg/Modafinil|Participants received single doses of study drug in the following order: MK-7288 10 mg in Treatment Period 1, Placebo (Pbo) in Treatment Period 2, MK-7288 20 mg in Treatment Period 3 and Modafinil 200 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
89093012|NCT01092780|Experimental|MK-7288 20mg/MK-7288 10mg/Modafinil/Pbo|Participants received single doses of study drug in the following order: MK-7288 20 mg in Treatment Period 1, MK-7288 10 mg in Treatment Period 2, Modafinil 200 mg in Treatment Period 3 and Placebo in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
89093013|NCT01092780|Experimental|Modafinil/MK-7288 20mg/Pbo/MK-7288 10mg|Participants received single doses of study drug in the following order: Modafinil 200 mg in Treatment Period 1, MK-7288 20 mg in Treatment Period 2, Placebo in Treatment Period 3 and MK-7288 10 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
89093014|NCT01092780|Experimental|Pbo/Modafinil/MK-7288 10 mg/MK-7288 20mg|Participants received single doses of study drug in the following order: Placebo in Treatment Period 1, Modafinil 200 mg in Treatment Period 2, MK-7288 10 mg in Treatment Period 3 and MK-7288 20 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
89093015|NCT05338138||the standard blind technique for Central venous catheter insertion into the internal jugular vein.|using the blind experience based technique without imaging guidance
89093016|NCT05338138||ultrasound guided technique for Central venous catheter insertion into the internal jugular vein.|using real time ulrasound guidance
89093017|NCT04228744|Experimental|Bilateral surgical implantation of DBS system|All the participants will receive bilateral surgical implantation of DBS system to VIC and NAc. The experimenter will active the DBS system and adjust the parameters for all the participants after surgery.
89093018|NCT05338684|Experimental|diagnostic catheter intervention then therapeutic if indicated|
89093019|NCT04306302|Experimental|Medium-dose ExPEC10V or Placebo: Group 1|Participants will be randomized to receive a single intramuscular (IM) injection of medium dose of ExPEC10V or Placebo on Day 1.
89093020|NCT04306302|Experimental|High-dose ExPEC10V or Placebo: Group 2|Participants will be randomized to receive a single IM injection of high dose (based on safety assessment through Day 15 postvaccination of medium dose) of ExPEC10V or Placebo on Day 1.
89093021|NCT02779504||Agluna treated METS|Patient implanted with Agluna treated METS
89093022|NCT02779504||Untreated METS|Patient implanted with untreated METS
89093023|NCT01092546|Experimental|Arm 1|
89093024|NCT02779348|Experimental|Nebicapone plus warfarin|BIA 3-202 200 mg tid + Warfarin 25 mg
89093025|NCT02779348|Experimental|Warfarin|Warfarin 25 mg
89093026|NCT02877264|Experimental|Vapendavir Capsule, 264 mg|Vapendavir phosphate salt administered orally as a single dose of two 132 mg hard gelatin capsules
89093027|NCT02877264|Experimental|Vapendavir Tablets, 264 mg|Vapendavir free base tablets containing 264 mg of vapendavir
89093028|NCT02877264|Experimental|Vapendavir Oral Suspension, 264 mg|Vapendavir free base as a 24 mg/mL oral suspension
89093029|NCT02779582|Experimental|Progesterone|Oral micronized progesterone, 300 mg po daily, taken as three capsules daily before sleep for three months
89093030|NCT02779582|Placebo Comparator|Placebo|Placebo, each taken as three capsules daily before sleep for three months
89093031|NCT01197794|Experimental|AZD1981 10 mg|AZD1981 10 mg
89093032|NCT01197794|Experimental|AZD1981 40 mg|AZD1981 40 mg
89093033|NCT01197794|Experimental|AZD1981 100 mg|AZD1981 100 mg
89093034|NCT01197794|Experimental|AZD1981 400 mg|AZD1981 400 mg
89093035|NCT01197794|Experimental|AZD1981 80 mg|AZD1981 80 mg
89093036|NCT01197794|Experimental|AZD1981 200 mg|AZD1981 200 mg
89093037|NCT01197794|Placebo Comparator|Placebo|
89093038|NCT04307316|Experimental|ACBT group|Active cycle breathing technique
89093039|NCT04307316|Active Comparator|Conventional treatment group|Conventional treatment group
89093040|NCT02779426|Experimental|Text Message Intervention + Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution as well as daily text messages with information about atopic dermatitis and treatment reminders. 1-2 times/week they will receive a message asking if they were able to complete their treatments in the last day. They will respond with 1=yes, 2=no, 3= I have questions about the treatment. Those who respond with 3 will be sent the contact information for the office. No other communications will be sent through text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
89093041|NCT02779426|No Intervention|Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution. They will not receive text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
89093042|NCT04228198||Radical cystectomy|Patients with histologically confirmed diagnosis of bladder cancer undergoing radical cystectomy surgery at 28 Urology departments in Italy
89093043|NCT04317638||breastfed group|Infants on exclusive breast feeding for the first 6 months of life and their mothers
89093044|NCT04317638||formula fed group|Infants on exclusive formula feeding for the first 6 months of life
89093045|NCT04317638||mixed fed group|Infants on mixed feeding (formula & breast feeding) and their mothers
89093046|NCT04307472|No Intervention|Control|Control arm will receive no intervention.
89093047|NCT04307472|Experimental|Clinician nudge|"The clinician nudge using an active choice intervention in the electronic health record will be delivered to the clinician during the patient's visit. This will be through a Best Practice Advisory that describes the guideline criteria for which the patient is eligible for statin therapy, provides pre-selected options for a statin with alternative options.~The clinician nudge using monthly peer comparison messages will be sent as an inbox message through the electronic health record. Clinicians will be told what percent of their eligible patients have been prescribed a statin and how that compares to peer clinicians at Penn Medicine."
89093048|NCT04307472|Experimental|Patient nudge|The patient nudge will be a text message. Patients with a visit scheduled with their primary care clinician will be identified and sent this text 72 hours before their scheduled visit. The text will remind them of the visit, inform them of their eligibility for a statin, describe the benefits and risks of statin therapy, and ask the patient to discuss statin therapy with their primary care clinician during the visit.
89093049|NCT04307472|Experimental|Clinician Nudge and Patient Nudge|The clinician nudge and patient nudge will be implemented.
89093050|NCT02780050|No Intervention|chest compression before physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.~2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). Researchers record subject's chest compression depth and rate in 1st chest compression."
89093051|NCT02780050|Experimental|after core muscle activation using physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.~After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 2nd chest compression."
89093052|NCT00634894|Experimental|Femara|
89093053|NCT00634894|Placebo Comparator|Placebo|
89093054|NCT02779270|Experimental|BAY987518|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
89093055|NCT02779270|Active Comparator|Sunscreen control|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
89093056|NCT02779894|No Intervention|Hospital group|Patients referred to the sleep unit and randomized to Hospital group. Participants will be diagnosed in the hospital either by Polysomnography , Respiratory Polygraphy or one night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the titration and adjustment of patient's will be accomplished at the hospital. This patient's will be monitored during 3 months of the study at the hospital.
89093057|NCT02779894|Other|ICT group|Patients referred to the sleep unit and randomized to intervention group. Participants will be diagnosed at home by 3 night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the adjustment will be performed at the CPAP supplier center, titration will be performed at home and patient's compliance and treatment will be controlled via remote. During the 3 months of the study patient's will be controlled via phono/video conferences and with a platform designed for the study.
89093058|NCT04228900|Experimental|Intervention group|Drug review and tailored nutritional supply.
89093059|NCT04228900|No Intervention|Control group|"Follow-up by home nurse service and family physician as usual."
89093060|NCT01078662|Experimental|1|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator. Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions.
89093061|NCT04227886||Good response|TRG of 0-1 is defined as good response.
89093062|NCT04227886||Poor response|TRG of 2-3 is defined as poor response.
89093063|NCT04227886||Light toxicity|No grade 3-4 toxicities occur during neoadjuvant therapy.
89093064|NCT04227886||Heavy toxicity|Grade 3-4 toxicities occur during neoadjuvant therapy.
89093065|NCT02200978|Active Comparator|ATO and chemotherapy|"Induction:~ATRA 25mg/m2 d1-CR ≯42 days; ATO 0.16mg/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20 mg (1-3 years), or 30 mg ( > 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① ATO 0.16mg/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance."
89093066|NCT02200978|Experimental|RIF and chemotherapy|"Induction:~ATRA 25mg/m2 d1-CR ≯42 days; RIF 0.135/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20mg (age 1-3 years), or 30mg (age > 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① RIF 0.135/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance treatment."
89093067|NCT02779192|Active Comparator|SPI-1005 200 mg|200 mg SPI-1005, capsule, bid, po, x7d
89093068|NCT02779192|Active Comparator|SPI-1005 400 mg|400 mg SPI-1005, capsule, bid, po, x7d
89093069|NCT02779192|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, bid, po, x7d
89093070|NCT05020210||Sivelestat Sodium group|Patients treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
89093071|NCT05020210||Conventional treatment group|Patients not treated with Sivelestat Sodium/Normal Saline after the diagnosis of ARDS
89093072|NCT04227808|Experimental|Lenvatinib Arm|Experimental: Participants will be given lenvatinib (12 mg/d for body weight≥60kg, 8 mg/d for body weight < 60kg) for 12 months until disease recurrence or intolerance AEs or death.
89093073|NCT04963426|Experimental|Intervention arm|"The intervention consists of interactive workshops that will be facilitated by WHO and trained local personnel and involve students, teachers and local authorities. In the workshops, the Global Accelerated Action for the Health of Adolescents (Global AA-HA!) approach will be used to:~identify adolescent health needs through exploring the collected baseline data;~assess policies and practices already in place;~identify gaps and needs for action to improve health. A menu of actions will be identified, prioritized, implemented and monitored."
89093074|NCT04963426|No Intervention|Control arm|The schools in the control arm will not participate in any intervention and continue 'as usual' after the baseline surveys.
89093075|NCT01091454|Experimental|Treatment (cisplatin and brostallicin)|Patients receive cisplatin IV over 2 hours on day 1 and brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89093076|NCT01140347|Experimental|Ramucirumab DP and BSC|
89093077|NCT01140347|Placebo Comparator|Placebo and BSC|
89093078|NCT02779114|Other|Control group|After 1:1:1 randomization patients in the control group receive their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during 12 months of the study.
89093079|NCT02779114|Other|Reduction group 1|Patients in reduction group 1 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
89093080|NCT02779114|Other|Reduction group 2|Patients in reduction group 2 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study. If they are still in remission they will discontinue their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
89093081|NCT04227964|Experimental|Periodontal regeneration|Periodontal regeneration consisting of papilla preservation flaps, application of FDA approved CE marked periodontal regenerative devices, tooth splinting and root canal treatment as required.
89093082|NCT04227964|Active Comparator|Extraction and tooth replacement|Tooth extraction and replacement with a dental implant or a fixed partial denture following healing and reconstruction of the extraction area. Choice based on standard of practice.
89093083|NCT02779036|Experimental|Task-oriented Exercise|Structured, progressive, task-oriented, home exercise program
89093084|NCT02779036|Active Comparator|Usual Care|Usual Physiotherapy Care
89093085|NCT02878278|Experimental|Chidamide BIW|Chidamide is given 30mg,5mg/pill,twice a week, for at least 6 weeks
89093086|NCT02878278|Experimental|Chidamide QD|Chidamide is given 10mg,5mg/pill, everyday,for at least 6 weeks.
89093087|NCT02883101|Active Comparator|Pulmonary rehabilitation group|"Participants randomised to the PR group will receive exercise training and regular instruction in self-management of ACT along with standard care. Patients will be enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine and Sleep disorders, All India Institute of Medical Sciences.~The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one will be at home. The patient will be asked to maintain a personal log recording the date, time, duration and type of exercise performed to ensure compliance, and these will be regularly reviewed and monitored.~The Rehabilitation Programme will include the following:~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
89093088|NCT02883101|No Intervention|Standard care group|"Candidates randomized to the standard care group will receive standard care for bronchiectasis according to current guidelines. These participants will receive instruction and review of airway clearance therapy (ACT). Each participant will be provided with written information about bronchiectasis and education regarding self-management of the condition. Participants who have not been previously instructed in any ACT will be taught the active cycle of breathing technique. These participants will not receive any supervised exercise training."
89093089|NCT05209126|Experimental|Beetroot supplementation|One serving 140 mL of beetroot juice (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
89093090|NCT05209126|Placebo Comparator|Placebo supplementation|One serving 140 mL of beetroot juice placebo (0.08 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
89093091|NCT02877108||Adasuve|These patients will receive Adasuve for treatment of agitation.
89093092|NCT02877108||Haloperidol/Lorazepam|These patients will receive haloperidol/lorazepam for treatment of agitation.
89093094|NCT04227652|Experimental|Aggressive treatment strategy|The antipyretic strategy was initiated immediately upon increase of the temperature above 38.3°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
89093095|NCT04227652|Experimental|Conservative treatment strategy|The antipyretic strategy was initiated only after the body temperature exceeded 39.5°C. The antipyretic strategy consisted of administration of ibuprofen (per-orally or into the nasogastric tube, or rectal administration in the form of a suppository) in therapeutical dose, alway supplemented with physical cooling in cases when the temperature exceeded 39.5°C. The body temperature was measured in the urinary bladder.
89093096|NCT02883569|Active Comparator|HIVD-OP|open or endoscopic discectomy
89093097|NCT02883569|Experimental|HIVD-NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
89093098|NCT02883569|Active Comparator|LSS w/o instability -OP|decompression, instrumentation and fusion
89093099|NCT02883569|Experimental|LSS w/o instability -NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
89093100|NCT02883569|Active Comparator|LSS w/ instability - OP|decompression, instrumentation and fusion
89093101|NCT02883569|Experimental|LSS w/ instability - NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
89093102|NCT02883569|Active Comparator|No intervention group|exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
89093103|NCT02883569|Experimental|Intervention group|epidural block, epidural adhesiolysis
89093104|NCT04306224|Experimental|IMC-002|Dose escalation will follow the traditional 3+3 design.
89093105|NCT02883023|Experimental|Electrosclerotherapy|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will be treated with electrosclerotherapy
89093106|NCT02883023|Active Comparator|Intralesional bleomycin injections|One region of interest in the capillary malformation will be treated with intralesional bleomycin injections without electroporation
89093107|NCT02883023|No Intervention|No treatment|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will not be treated.
89093108|NCT02778958|Experimental|ibuprofen and morphine|iv ibuprofen 800 mg infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
89093109|NCT02778958|Active Comparator|paracetamol and morphine|iv paracetamol 1 gram infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
89093110|NCT01197560|Experimental|Lenalidomide|Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
89093111|NCT01197560|Active Comparator|Investigators Choice|"One of the following:~Gemcitabine, Oxaliplatin, Rituximab, or Etoposide"
89093112|NCT04227418||Mental Health|
89093113|NCT04227418||Psychiatric|
89093114|NCT04228666|Experimental|HB-adMSCs|HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10^8 total HB-adMSC cells.
89093115|NCT04196140|Experimental|Treatment|All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm.
89093116|NCT05199142|Experimental|SDI-118|SDI-118 capsule self-administered orally once daily (QD) for 17 days.
89093117|NCT05199142|Placebo Comparator|Placebo|Placebo capsule self-administered orally once daily (QD) for 17 days.
89093118|NCT05320978||patients undergoing minimally invasive pylor-preserving pancreaticoduodenectomy|Adult patients aged 20 years or older and who underg minimally invasive pylor-preserving pancreaticoduodenectomy
89093119|NCT05315362|Experimental|Intervention group - intradermal vaccination with patch|Participants will receive 20 µg of mRNA-1273 vaccine through the intradermal route using a solid micro needle delivery system
89093120|NCT05315362|Active Comparator|Control group - intramuscular vaccination with standard needle|Participants will receive 20 µg of mRNA-1273 vaccine through the intramuscular route
89093121|NCT02778568|Experimental|Resistance Training|Patients performed resistance exercises
89093122|NCT02778568|Active Comparator|Control|Patients who performed flexibility exercise
89093123|NCT04227496|Active Comparator|Noise1|A sound will be played while moving a body part through range of motion
89093124|NCT04227496|Active Comparator|Noise2|A sound (different from Noise 1) will be played while moving a body part through range of motion
89093125|NCT04227496|No Intervention|No noise|No sound will be played while moving a body part through range of motion
89093126|NCT01133405|Experimental|LY2886721 Part 1: Cohort A/B|Single (7 milligram (mg), 15 mg, 25 mg, 35 mg) doses of LY2886721 administered orally in up to three of three study periods
89093127|NCT01133405|Placebo Comparator|Placebo Part 1: Cohort A/B|Single dose in up to 1 period
89093128|NCT01133405|Experimental|LY2886721 Part 2: Cohort C|Single 10 mg dose of LY2886721, dose determined by Part 1
89093129|NCT01133405|Experimental|LY2886721 Part 2: Cohort D|Single 35 mg dose of LY2886721, dose determined by Part 1
89093130|NCT01133405|Placebo Comparator|Placebo Part 2: Cohort C/D|Single dose
89093131|NCT02779816|Experimental|Intervention (pen device)|Subjects will use the pen device when using their commercially available insulin pens
89093132|NCT02779816|No Intervention|Control|Subjects will use the commercially available insulin pens only (no adaptive pen device).
89093133|NCT01196078|Experimental|1|
89093134|NCT01196078|Active Comparator|2|
89093135|NCT01078584||Hypertensive Participants|Hypertensive diabetics and non-diabetics, with or without isolated systemic hypertension and/or renal dysfunction, who were naïve to trandolapril or on trandolapril within past 30 days.
89093136|NCT05314660|Experimental|Silver diamine fluoride group|Application of 38% SDF.
89093137|NCT05314660|Experimental|Atrumatic restorative technique|
89093138|NCT05314660|Experimental|Ultra conservative treatment (UCT)|
89093139|NCT05314036|Experimental|Acute Postprandial Blood Sampling|Two-hour postprandial blood sampling following administration of a standardized test meal
89093140|NCT01133171|Experimental|Dashboard Plus Nurse|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling plus a computerized dashboard intervention.
89093141|NCT01133171|Experimental|Nurse Alone|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling.
89093142|NCT01133171|No Intervention|Control|Patients randomized to this group were followed retrospectively to collect data on their primary care visits and laboratory results and past medical history over the 12 month study period. They had no contact with study personnel and did not receive any type of intervention.
89093143|NCT05311462||Weight-loss success with history of weight cycling|High-protein diet for three months
89093144|NCT05311462||Weight-loss failure with history of weight cycling|High-protein diet for three months
89093145|NCT01195844||Brazilian Children With Rotavirus Gastroenteritis|Brazilian children under 5 years of age who have diarrhea attributed to rotavirus located in 4 hospitals from 4 different Brazilian regions
89093146|NCT02883725||Esophageal atresia|
89093147|NCT04920292|Experimental|Single Dose of 100mg Oxfendazole versus Placebo|8 participants will receive a single oral dose of 100mg of oxfendazole. 2 participants will receive a single oral dose of placebo.
89093148|NCT04920292|Experimental|Single Dose of 400mg Oxfendazole versus Placebo|8 participants will receive a single oral dose of 400mg of oxfendazole. 2 participants will receive a single oral dose of placebo.
89093149|NCT04920292|Experimental|Multiple Doses of 400mg Oxfendazole versus Placebo|"8 participants will receive multiple oral doses of 400mg of oxfendazole on 5 consecutive days.~2 participants will receive multiple oral doses of placebo on 5 consecutive days."
89093150|NCT02779972||60's decade|60's decade Echo stress test
89093151|NCT02779972||70's decade|70's decade Echo stress test
89093152|NCT02779972||80's decade|80's decade Echo stress test
89093153|NCT04312685|Active Comparator|Prometra Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refills 1-3) and will be compared to 3 months retrospectively collected pain scores (VAS, ODI and Global Pain Scale Assessments) and drug doses prior to peristaltic pump explant.
89093154|NCT04312685|No Intervention|Retrospective records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
89093155|NCT02779738|Experimental|Merestinib Fasted|Single dose of merestinib administered in fasted state in one of three periods
89093156|NCT02779738|Experimental|Merestinib Standard Meal|Single dose of merestinib administered with a standard meal in one of three periods
89093157|NCT02779738|Experimental|Merestinib High-Fat Meal|Single dose of merestinib administered with a high-fat meal in one of three periods
89093158|NCT04227262|No Intervention|the control group|Group (a) control group received traditional physical therapy program.
89093159|NCT04227262|Experimental|the study group|group (b) study group received the same traditional physical therapy program in addition to mirror therapy three times / weak for three successful months.
89093160|NCT01132547|Experimental|Arm I cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
89093161|NCT01132547|Placebo Comparator|Arm II placebo|Patients receive an oral placebo twice daily for 8 weeks.
89093162|NCT01194830|Active Comparator|Linagliptin|1 Tablet PO QD
89093163|NCT01194830|Placebo Comparator|Placebo|1 Tablet PO QD
89093164|NCT05074888|Experimental|Prospekta|Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15 minutes before eating or drinking), keep the tablets in the mouth, without swallowing, until completely dissolved.
89093165|NCT05074888|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Prospekta scheme.
89093166|NCT02778646||MINAP Audit|Individuals within this group are those that have been admitted into a United Kingdom (UK) based hospital following a major cardiac event. The FH status of individuals within this group is unknown.
89093167|NCT02778646||BCIS Audit|Individuals within this group are those who have undergone percutaneous coronary intervention in the United Kingdom (UK). The FH status of individuals within this group is unknown.
89093168|NCT04228510||Study group|ST elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention who will be followed up in Assiut University hospital.
89093169|NCT02778334|No Intervention|patients who return home|
89093170|NCT02778334|Experimental|patients who continued hospitalization in rehabilitation|
89093171|NCT02778178|Experimental|TAP block with ropivacaine|Bilateral single shot TAP block under ultrasound guidance: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
89093172|NCT02778178|Placebo Comparator|TAP block with placebo|Placebo administration: bilateral single shot TAP block under ultrasound guidance: 20 mL saline 0.9%, per side
89093173|NCT04228432|Experimental|Patients with breast cancer treated by adjuvant hormonotherapy|
89093174|NCT01194440|Experimental|Arm I - IV Zoledronic Acid Prophylaxis|Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
89093175|NCT04228588|Experimental|Mepolizumab|Mepolizumab 100mg, SC, every 4 weeks
89093176|NCT04823052|Placebo Comparator|Placebo|One capsule, twice a day
89093177|NCT04823052|Active Comparator|Sulindac (HLX-0201), dose strength 1|One capsule, twice a day
89093178|NCT04823052|Active Comparator|Sulindac (HLX-0201), dose strength 2|One capsule, twice a day
89093179|NCT04823052|Active Comparator|Gaboxadol (HLX-0206)|One capsule, twice a day
89093180|NCT05048992|Active Comparator|ELDOA method|Twenty (20) patients will be treated with ELDOA method
89093181|NCT05048992|Active Comparator|Post-facilitation stretching|Twenty (20) patients will be treated with Post-facilitation stretching technique.
89093182|NCT05258500|Experimental|Ghostly|The first arm consists of a strength training program incorporated in the Ghostly game that will be given to the patient to be completed without supervision of the therapist as an added exercise program to their conventional therapy.
89226711|NCT03283254|Active Comparator|Enhanced Treatment as Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring
89226712|NCT03281291||R012-20 Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20 of study NCT03276962.
89226713|NCT03281291||R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38 of study NCT03276962.
89226714|NCT03281291||Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38 of study NCT03276962.
89226715|NCT03281291||Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32 of study NCT03276962.
89226716|NCT03281291||Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2 of study NCT03276962.
89226717|NCT03265574|Experimental|Intervention|
89226718|NCT03265574|No Intervention|Standard care|
89226719|NCT03236428|Experimental|Daratumumab|Daratumumab will be administered by IV infusion weekly during cycles 1 and 2 Daratumumab will be administered by IV infusion every other week during cycles 3 through 6 Daratumumab will be administered by IV infusion monthly during cycles 7 through 20
89226720|NCT03235232|Experimental|BREMEN eye drops|1 drop in affected eye(s), each 12 hours for 8 weeks.
89226721|NCT03235232|Active Comparator|Combigan®|1 drop of Combigan® in affected eye(s), each 12 hours for 8 weeks.
89226722|NCT03225664|Experimental|Treatment (trametinib, pembrolizumab)|Patients receive trametinib PO QD 14 days prior to cycle 1 and days 1-10 of each course (10 days on, 11 days off). Beginning in cycle 2, participants also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89226723|NCT03213834|Active Comparator|Thoracoscopy Arm|Consisting of chest thoracoscopy
89226724|NCT03213834|Active Comparator|Fibrinolytic Therapy Arm|Consisting of chest fibrinolytic therapy
89226725|NCT03198533|Active Comparator|Triathlon PA|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
89226726|NCT03198533|Active Comparator|Triathlon Pressfit|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
89226727|NCT03179904|Experimental|Cohort A (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28, paclitaxel IV over 1-96 hours on days 1, 8, and 15, and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and optionally every 21 days after 3 cycles and paclitaxel is discontinued. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity. Patients also undergo ECHO and CT or MRI at screening and on study and undergo collection of blood samples and biopsy on study.
89226728|NCT03179904|Experimental|Cohort B (TVB-2640, trastuzumab, endocrine therapy)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28 and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and optionally every 21 days after 3 cycles and paclitaxel is discontinued. Patients also continue endocrine therapy of either anastrozole PO QD, exemestane PO QD, fulvestrant IM on days 1 and 14 of cycle 1 and day 1 of subsequent cycles, or letrozole PO QD. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity. Patients also undergo ECHO and CT or MRI at screening and on study and undergo collection of blood samples and biopsy on study.
89226729|NCT03165734|Experimental|Pacritinib 200 mg BID|To receive pacritinib 200 mg twice daily (BID) orally, at the same time of day, with or without food
89093183|NCT05258500|Experimental|Blood flow restriction and Ghoslty|The second intervention arm incorporates blood flow restriction into the conventional therapy using the Smart Cuffs PRO system (Smart Tools, USA). Additionally, these participants will receive additional exercises added to their conventional therapy using the Ghostly game
89093184|NCT05258500|Active Comparator|Control|The control group will not be given the Ghostly game as additional exercises to complete after their conventional therapy, but will receive instructions for a strength training program targeting the same muscles as both intervention groups.
89093185|NCT00951015|Experimental|10 mg GSK1349572|subjects will receive GSK1349572 10mg once daily blinded to dose
89093186|NCT00951015|Experimental|25mg GSK1349572|subjects will receive GSK1349572 25mg once daily blinded to dose
89093187|NCT00951015|Experimental|50mg GSK1349572|subjects will receive GSK1349572 50mg once daily blinded to dose
89093188|NCT00951015|Other|efavirenz control|efavirenz will serve as the internal control arm
89093189|NCT01139021|Experimental|B246_12_M12|Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.
89093190|NCT01139021|Experimental|B246_12M13|Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.
89093191|NCT01139021|Experimental|B13_15_27|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.
89093192|NCT01139021|Experimental|B12_14_26|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.
89093193|NCT01139021|Experimental|B_24_26|Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
89093194|NCT01139021|Experimental|B12M13|Subject was randomized in group B13_15_27 but treated as group B12_M13.
89093195|NCT02777866|Experimental|1: Bupivacaine 0.5%|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
89093196|NCT02777866|Placebo Comparator|2: 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs, who will be infiltrated in the total thickness of the abdominal wall with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound.
89093197|NCT00626262|Experimental|1|20mg oral
89093198|NCT00626262|Experimental|2|20mg IV
89093199|NCT02876796|Experimental|50 mg GS-0976 (Cohort 1)|"Sequence 1:~Period 1 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 2:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution"
89226730|NCT03165734|Active Comparator|Physician's Choice (P/C) therapy|The Physician's Choice (P/C) therapy (limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must be selected prior to randomization.
89226731|NCT03133780|Active Comparator|Ketamine|Patients will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
89226732|NCT03133780|Active Comparator|Midazolam|Patients will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
89226733|NCT03115983|Experimental|LimiFlex|Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
89226734|NCT03115983|Active Comparator|Fusion|Transforaminal lumbar interbody fusion with concomitant posterolateral fusion with pedicle screw instrumentation
89226735|NCT03113500|Experimental|Treatment (CHEP-BV)|"INDUCTION: Patients receive cyclophosphamide IV and doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (or for up to 5 cycles for patients who received 1 cycle of CHOP-like or CHP-BV therapy prior to induction, per investigator's discretion) in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy, post-consolidative radiation therapy, or after completing induction cycle 6 (cycle 5 for patients who qualify for receiving 5 cycles of CHEP-BV instead of 6), patients with objective response (complete response or partial response) receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
89226736|NCT03088514|Experimental|NITRATE-LVH intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 months
89226737|NCT03088514|Placebo Comparator|NITRATE-LVH placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
89226738|NCT03088514|Experimental|NITRATE-CBP intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 month
89226739|NCT03088514|Placebo Comparator|NITRATE-CBP placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
89226740|NCT03085758|Experimental|Treatment Arm A|Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)
89226741|NCT03085758|Experimental|Treatment Arm B|Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)
89226742|NCT03085758|Placebo Comparator|Control group|Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)
89226743|NCT03071406|Active Comparator|Arm A: Nivolumab + Ipilimumab|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.
89226744|NCT03071406|Active Comparator|Arm B: Nivolumab + Ipilimumab + SBRT|Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.
89226745|NCT03059940|Experimental|Quitline (QL) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider. Participants given shared decision making and discussion about screening with the LDCT provider.~Participants referred to the Quitline for counseling and NRT (nicotine patch). Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
89226746|NCT03059940|Experimental|Quitline-Rx (QL-Rx) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~LDCT provider and patient discuss options for pharmacotherapy.~Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
89226747|NCT03059940|Experimental|Integrated Care (IC) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,"
89226748|NCT03053622|Experimental|Mirikizumab Test Subcutaneous (SC) 1|250 mg mirikizumab test formulation given as a single injection SC in healthy participants
89226749|NCT03053622|Experimental|Mirikizumab Test SC 2|250 mg mirikizumab test formulation given as two injections given SC in healthy participants
89226750|NCT03053622|Experimental|Mirikizumab Test Intravenous (IV)|250 mg mirikizumab test formulation given as an infusion into the vein in healthy participants
89226751|NCT03053622|Active Comparator|Mirikizumab Reference|250 mg mirikizumab reference formulation given as three injections subcutaneous (SC) in healthy participants
89226752|NCT03047837|Placebo Comparator|Placebo|placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID) for 12 months
89226753|NCT03047837|Experimental|Metformin|placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID), for 12 months
89226754|NCT03047837|Experimental|Aspirin|active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID), for 12 months
89226755|NCT03047837|Experimental|Apirin plus Metformin|active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID), for 12 months
89226756|NCT03037515|Active Comparator|Intravenous Tranexamic Acid|The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.
89226757|NCT03037515|Active Comparator|Oral Tranexamic Acid|The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.
89226758|NCT03033589|Active Comparator|Adductor Canal Nerve Block|One hour prior to procedure, subject to receive 20 mL of 0.5% ropivacaine injected into the sheath of the saphenous nerve at the adductor hiatus. Ultrasound guidance utilized for appropriate localization of the targeted nerve sheath for local infiltration. No nerve stimulators to be utilized during or after the procedure.
89226759|NCT03033589|Active Comparator|Femoral Nerve block|One hour prior to procedure, subject to receive 30 mL of 0.5% ropivacaine injected into the nerve sheath of the femoral nerve at the level of the femoral triangle. Ultrasound guidance utilized for appropriate localization of the targeted nerve sheath for local infiltration. No nerve stimulators to be utilized during or after the procedure.
89226760|NCT03022188||Observational|Observational
89226761|NCT03009786||Elderly institutionalized subjects or outpatients|
89226762|NCT02998580|Active Comparator|Convential Sequential Bilateral rTMS|"LFR followed by HFL.~1 Hz stimulation of the right DLPFC for 600 pulses followed by 10 Hz stimulation of the left DLPFC for 3000 pulses (4 seconds on 26 seconds off for 75 trains). Treatment will occur 5 times per week for 4 to 6 weeks."
89226763|NCT02998580|Experimental|Bilateral Theta Burst Stimulation|"cTBS followed by iTBS.~continuous theta burst stimulation (cTBS) of the right DLPFC for 600 pulses followed by intermittent theta burst stimulation (iTBS) of the left DLPFC for 600 pulses. Treatment will occur 5 times per week for 4 to 6 weeks."
89226764|NCT02991677|Other|control|This is an attention control group with regular contact by study staff.
89226765|NCT02991677|Experimental|aerobic exercise|Aerobic exercise intervention is for 12 weeks 3 times weekly with training on site.
89226766|NCT02991677|Experimental|resistive training|Intervention is for 12 weeks 3 times weekly with training on site.
89226767|NCT02979522|Experimental|Phase 1: Brentuximab Vedotin 48 mg/m^2 + AVD|Brentuximab vedotin 48 mg/m^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and dacarbazine 375 mg/m^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.
89093200|NCT02876796|Experimental|200 mg GS-0976 (Cohort 2)|"Sequence 3:~Period 1 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 4:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution"
89093201|NCT02876796|Experimental|20 mg GS-0976 (Cohort 3)|"Sequence 5:~Period 1 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 6:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution"
89093202|NCT04980820|Experimental|FFP2|This arm starts with a FFP2 mask and switches to a FFP3 mask.
89093203|NCT04980820|Experimental|FFP3|This arm starts with a FFP3 mask and switches to a FFP2 mask.
89093204|NCT02876562|Experimental|root coverage with collagen matrix|evaluation of root coverage achieved by collagen matrix in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
89093205|NCT02876562|Active Comparator|root coverage with connective tissue graft|evaluation of root coverage achieved by connective tissue graft in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
89093206|NCT02779660|Experimental|RIPC-Group|After randomization patients will undergo 3 sessions of RIPC (Remote ischemic preconditioning) intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
89093207|NCT02779660|Placebo Comparator|Control-Group|After randomization patients will undergo 3 sessions of sham-intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
89093208|NCT01193660|Experimental|Umbilical Cord Blood & Erythropoietin & Rehabilitation|Allogenic umbilical cord blood infusion, erythropoietin injection & active rehabilitation
89093209|NCT01193660|Active Comparator|Erythropoietin & Rehabilitation|Erythropoietin injection, active rehabilitation
89093210|NCT01193660|Placebo Comparator|Only Rehabilitation|Active rehabilitation
89093211|NCT02778022|Experimental|Immediate PriCARE|Parent-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
89093212|NCT02778022|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual.
89093213|NCT04306068|Experimental|Experimental group|Athletes included in the experimental group will perform a plyometric exercise protocol. Each session will consist of a 4-station circuit with 1 minute rest between each station and 30 seconds between sets
89093214|NCT04306068|No Intervention|Control group|Athletes included in the control group will follow their usual warm-up routine.
89093215|NCT02777788|Active Comparator|chemotherapy|"Eligible subjects will be treated with platinum-doublet 2 cycles chemotherapy:pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin. Each cycle was 21-days.~Dosage:pemetrexed i.v.500mg/m2 d1 ; docetaxel i.v.75mg/m2 d1 ; gemcitabine i.v.1250 mg/m2 d1,d8 ; paclitaxel i.v.175mg/m2 d1 ; vinorelbine i.v.25mg/m2 d1,d8; carboplatin i.v.area under curve (AUC) 5 d1 ；cis-platinum i.v.75mg/m2 d1（or divided into 3days）；nedaplatin i.v.80mg/m2 d1."
89093216|NCT02777788|Experimental|TCM combined chemotherapy|TCM：JinFuKang plus XingZaoRuanJian, chemotherapy will be the same. JinFuKang po.tid.30ml d6-d21 XingZaoRuanJian po.tid.30ml d6-d21
89093217|NCT02856009|Experimental|patient|
89093218|NCT01076166||Children with lower respiratory tract infection|Thai children with lower respiratory tract infections on Klacid Granules for Oral Suspension
89093219|NCT02777710|Experimental|Combination Pexidartinib-Durvalumab|"DURVALUMAB (MEDI4736): therapeutic Class anti-PD-L1 mAb, given IV every 4 weeks at a fixed dose of 1500mg, AstraZeneca~PEXIDARTINIB (PLX3397): therapeutic Class Kinase inhibitor targeting CSF1-R, Flt3 and Kit. Administered daily as split dose regimen, orally. Five dose-levels possible in dose escalation part: 400mg 5 days on 2 days off (intermittent schedule), 400 mg, 600 mg, 800 mg or 1000 mg.~In this combination trial, Pexidartinib should be taken first and the Durvalumab IV infusion should be scheduled 1 hour after the Pexidartinib morning dose."
89093220|NCT02776150||MGIT liquid culture+drug sensitivity test|MGIT: The bactec MGIT 960 system is non-radiometric. It uses MGIT media and patented sensors, making efficient use of advanced fluorometric technology, which permits highly accurate detection of O2 consumption without sharps. Automated quality control is performed continuously to ensure precise and reliable operation. Results are provided as positive/negative and numerical growth units.
89093221|NCT02776150||Xpert-MTB/RIF|xpert-MTB/RIF: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System. A sputum sample is collected from the patient with suspected TB. The sputum is mixed with the reagent that is provided with the assay, and a cartridge containing this mixture is placed in the GeneXpert machine. All processing from this point on is fully automated.The test simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours.
89111145|NCT03787251|Active Comparator|Control group|"The chemotherapeutic drug chosen by the investigator (if not used in the previous treatment regimen, it cannot be selected).~The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient decease. If the adverse event grade 3 and above Or non-hematologic toxicity of grade II and above appeared, allowing the dose to be lowered twice."
89093222|NCT02776150||probe melting curve detection|Probe-based fluorescence melting curve analysis (FMCA) is a powerful tool for mutation detection based on melting temperature generated by thermal denaturation of the probe-target hybrid, which performed for Mycobacterium tuberculosis's drug resistant monitor. The method was explored two dual-labeled, self-quenched probes, TaqMan and shared-stem molecular beacons, in their ability to conduct FMCA. Both probes could be directly used for FMCA and readily integrated with closed-tube amplicon hybridization under asymmetric PCR conditions. Improved flexibility of FMCA by using these probes was illustrated in three representative applications of FMCA: mutation scanning, mutation identification and mutation genotyping, all of which achieved improved color-multiplexing with easy probe design and versatile probe combination and all were validated with a large number of real clinical samples.
89093223|NCT01193582|Experimental|Group 1|
89093224|NCT01193582|Experimental|Group 2|
89093225|NCT01193582|Experimental|Group 3|
89093226|NCT01193582|Experimental|Group 4|
89093227|NCT00602901|Experimental|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
89093228|NCT00602901|Experimental|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
89093229|NCT00602901|Active Comparator|Usual Medical Care|Usual medical care - (Celebrex, Aleve, Bextra, Naproxen)
89093230|NCT00945477|Experimental|Advanced prostate cancer, treatment, pazopanib|Pazopanib
89093231|NCT02777398|Experimental|Trans-Quadrant Channel Surgery|Patients in the experimental arm (experimental group, i.e. microsurgery through trans-Quadrant channel pathway) will be operated using Quadrant channel system. All the tumor resection will be operated through the Quadrant channel with assistance of microsurgical techniques.
89093232|NCT02777398|Active Comparator|Conventional Open Surgery|Patients in the active comparator arm (control group, i.e. conventional open surgery) will be operated using the conventional open surgery. All the tumor resection will be operated directly with conventional procedures. More posterior structures of spine will be removed.
89093233|NCT01135719|Active Comparator|Wavefront guided LASIK/PRK|Wavefront-guided LASIK/PRK
89093234|NCT01135719|Active Comparator|Wavefront optimized LASIK/PRK|Wavefornt optimized LASIK/PRK
89093235|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 500 mg|Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.
89093236|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 850 mg|Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.
89093237|NCT01076088|Active Comparator|Metformin 500 mg|Metformin 500 mg twice daily for 24 weeks.
89093238|NCT01076088|Active Comparator|Metformin 850 mg|Metformin 850 mg twice daily for 24 weeks.
89093239|NCT01076088|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
89093240|NCT01076088|Placebo Comparator|Placebo|Matching placebo tablets for 24 weeks.
89093241|NCT05021458|Experimental|Group A|Ten patients will be treated with Gong's mobilization.
89093242|NCT05021458|Active Comparator|Group B|Ten patients will be treated with SNAGs
89093243|NCT02776462||Potential Traumatic Brain Injury|This group will consist of people admitted to the ER, Trauma Bay, or Neurosurgery for potential traumatic brain injury.
89093244|NCT02776384||chronic heart failure|patients who are diagnosed with chronic heart failure with either preserved or reduced ejection fraction
89093245|NCT02777632||HCV patients following living donor liver transplantation|single infection episode group
89093246|NCT02777632||patients following living donor liver transplantation|recurrent Infections episode group
89093247|NCT02777320|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
89093248|NCT02777320|Experimental|Ibuprofen group|Second Group: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
89093249|NCT04226560|Experimental|41% Silicone hydrogel Soft contact lenses (SHSCL)|Healthy adult males or females age ≥20-45 years of age
89093250|NCT04226560|Active Comparator|ACUVUE® VITA™|Healthy adult males or females age ≥20-45 years of age
89093251|NCT01193348|Experimental|Eculizumab|
89093252|NCT00945321|Active Comparator|1|aprepitant 165 mg
89093253|NCT00945321|Active Comparator|2|aprepitant 185 mg
89093254|NCT00945321|Experimental|3|fosaprepitant 150 mg
89093255|NCT00945321|Experimental|4|aprepitant with food
89093256|NCT02776228|Experimental|benzodiazepine|The patient which will be in the Experimental arm (after randomization) will receive 0.25 mg of Brotizolam (short acting benzodiazepine) for six weeks from the day of discharge.
89093257|NCT02776228|Placebo Comparator|placebo|The patient which will be in the placebo arm (after randomization) will receive placebo for six weeks from the day of discharge.
89093258|NCT04990492|Experimental|Paper Baseline|Half of the participants will complete the GAD 7 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 on the Mirror device equipped with Amazon Alexa.
89093259|NCT04990492|Experimental|Alexa Baseline|The other half of the participants will complete the GAD 7 on the Mirror device equipped with Amazon in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 in the traditional paper format.
89093260|NCT00631215|Experimental|1|Healthy Adults
89093261|NCT00945243|Other|Treatment|Treatment of cervical DDD with the Zero-P device
89093262|NCT01192412|Active Comparator|'Less tight' control.|The diastolic blood pressure (dBP) treatment goal is 100 mmHg.
89093263|NCT01192412|Active Comparator|'Tight' control.|The diastolic blood pressure (dBP) treatment goal is 85 mmHg.
89093264|NCT04226092|Experimental|Subjects with atopic dermatitis|
89093265|NCT04226092|Experimental|Control subjects|
89093266|NCT04868578|Experimental|PPI|the patient take PPI caps
89093267|NCT04868578|Placebo Comparator|PPI placebo|The patient take PPI placebo
89093268|NCT02777164|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
89093269|NCT01192178|Active Comparator|FLOVENT™ DISKUS™ 100 mcg|FLOVENT™ DISKUS™ 100 mcg is an inhaled corticosteroid indicated in the US for maintenance treatment of asthma as prophylactic therapy in patients 4 years and older.
89093270|NCT01192178|Experimental|ADVAIR™ DISKUS™ 100/50 mcg|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a corticosteroid and a long acting beta2 adrenergic agonist indicated for; maintenance treatment of asthma in patients 4 years of age and older.
89093271|NCT02777008|Experimental|CTP-543 Single Dose|Single oral dose
89093272|NCT02777008|Experimental|CTP-543 Multiple Dose|Multiple oral dose for 7 consecutive days
89093273|NCT02855775|Experimental|Bevacizumab|Bevacizumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
89093274|NCT02855775|Experimental|Trastuzumab|Trastuzumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
89093275|NCT02775994|Experimental|Treatment Arm|Single dose of Canakinumab 4mg/kg
89093276|NCT02855385||Patient group|This are patients who have current or previous history of rectal bleeding
89093277|NCT02855385||General Practitioner group|This are General practitioner who are in public or private hospitals who treat patients with rectal bleeding
89093278|NCT01192100|Experimental|Breakfast Skipping|Breakfast skipping serves as the baseline/control arm since the participants habitually skip breakfast (i.e., skip breakfast at least 5 times/week). Thus, during the week prior to and including the testing day, the participants will continue to skip breakfast each morning.
89093279|NCT01192100|Experimental|Normal Protein Breakfast Meals|For 7 days, the participants will consume normal protein breakfast meals each morning. These meals will consist of cereal-based foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 15% protein (13 g of dietary protein), 65% CHO, and 20% fat.
89093280|NCT01192100|Experimental|Protein-rich Breakfast Meals|For 7 days, the participants will consume protein-rich breakfast meals each morning. These meals will consist of home-cooked foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 40% protein (35 g of protein), 40% CHO, and 20% fat.
89093281|NCT04193566|Active Comparator|Dapagliflozin|"Patients in the active arm will be treated with dapagliflozin 50 mg once on site for visit 2 and once at home on the evening before visit 3.~Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf."
89093282|NCT04193566|Placebo Comparator|Placebo|"Patients in the placebo arm will be treated with placebo once on site for visit 2 and once at home on the evening before visit 3.~Placebo drug:~The composition equals the composition of Forxiga® - just with the active ingredient omitted. Active drug and placebo are similar in appearance and smell."
89093283|NCT02776930||Return to Duty after Rehab from Injury|Patients deemed healthy enough to return to full duty without any restrictions after completing a course of rehabilitation for a lumbar/thoracic spine or lower extremity injury.
89093284|NCT00869401|Experimental|Group 1 (Phase II) dasatinib + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only dasatinib post cycle 8 until progressive disease, unacceptable adverse events or refusal.
89093285|NCT00869401|Active Comparator|Group 2 (Phase II) placebo + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only placebo post cycle 8 until progressive disease, unacceptable adverse events or refusal.
89093286|NCT04226482|Active Comparator|New Device|Laparoscopic appendectomy will be done using new ultrasonic shears.
89093287|NCT04226482|Experimental|Used Device|Laparoscopic appendectomy will be done using reprocessed ultrasonic shears.
89093288|NCT04823104|Experimental|Intervention group with home visitation|pregnant women who are included in this group will be assigned an intervention by home visitation for pregnancy follow-up
89093289|NCT04823104|No Intervention|control group without home visitation|pregnant women will be free to choose their pregnancy follow-up without home visitation
89093290|NCT02776072||dimethyl fumarate (DMF)|Participants who initiated DMF during the specified time period
89093291|NCT02776072||glatiramer acetate (GA)|Participants who initiated GA during the specified time period
89093292|NCT02776072||teriflunomide|Participants who initiated teriflunomide during the specified time period
89093293|NCT02776072||fingolimod|Participants who initiated fingolimod during the specified time period
89093294|NCT01076010|Experimental|Sorafenib crossover to tivozanib.|The subjects who failed sorafenib (had Response Evaluation Criteria in Solid Tumors [RECIST] - defined progressive disease) on the parent protocol AV-951-09-301 will be offered tivozanib hydrochloride on Protocol AV- 951-09-902.
89093295|NCT01076010|Experimental|First line tivozanib.|The subjects who were randomized to tivozanib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability in Protocol AV-951-09-301.
89093296|NCT01076010|Active Comparator|First line sorafenib.|The subjects who were randomized to sorafenib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability were to be offered long-term access to sorafenib.
89093297|NCT02775838|Experimental|kidney transplantation|Intravenous injection of Indocyanine Green in patients receiving kidney transplantation
89093298|NCT04122391||control|team will work in OR with volume of 85 dB
89093299|NCT04122391||intervention|team will work in OR with volume of 100 dB
89093300|NCT02776852|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89093301|NCT00698659||patients on anti-VEGF therapy|"This study aims to assess the pharmacodynamic effects of anti-VEGF therapy. The following groups of patients will be approached:~Those who are starting on anti-VEGF therapy (such as but not limited to bevacizumab, sunitinib, and sorafenib) as part of routine clinical management or on clinical studies~All patients must be aged aged ≥ 21 years All patients must have a signed written informed consent prior to study enrollment. A separate consent will be obtained from patients already involved in a clinical study using anti-VEGF treatment.~Patients with a known allergy to intravenous contrast used in fluorescein and indocyanine green angiography will be exempt from these investigations but will undergo other study assessments."
89093302|NCT02775604|Other|Home-Based Video|GoPro Camera
89093303|NCT02775604|Other|Paper Checklist|Homeowner Print Checklist
89093304|NCT04305990|Experimental|Demand-driven delivery followed by free-flow delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a demand-driven delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
89093305|NCT04305990|Experimental|Free-flow delivery followed by demand-driven delivery|Participants will inspire 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes followed by inspiration of 100% oxygen through their nose with the gas delivery device set to a free-flow delivery setting through a nasal hood for 2 minutes.
89111146|NCT02789865|Active Comparator|Antibiotic therapy group|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
89111147|NCT02789865|Experimental|ERAT group|The patients will receive emergent endoscopic retrograde appendicitis therapy (ERAT).
89226768|NCT02979522|Experimental|Phase 2: Brentuximab Vedotin 48 mg/m^2 + AVD|Brentuximab vedotin 48 mg/m^2 (A), intravenous infusion, once on Days 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and dacarbazine 375 mg/m^2 (AVD), intravenous infusion, once on Days 1 and 15 of each 28-day cycle for up to 6 cycles.
89226769|NCT02971761|Experimental|Treatment (pembrolizumab, enobosarm)|Patients receive pembrolizumab IV over 30 minutes on day 1 and enobosarm PO QD on days 1-21. Courses repeat every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
89226770|NCT02943746|Active Comparator|Control Group (Standard Protein Diet)|"Infants will receive a standard feeding regimen which consists of mother's own milk or donor human milk (DHM) with DHM derived fortifier.~Once daily, a 24 hour batch of human milk is prepared for each infant (standard practice). A 2.5 mL sample will be analyzed for calories, protein, fat, and carbohydrates. Based on the amount of protein in the milk, fortification of feeds with donor human milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day of protein. Data will be recorded for milk analysis, nutrition, and infant growth.~The diet will be continued until approximately 35 to 36 weeks postmenstrual age at which point a DXA scan will be performed.~A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed.~Anthropometrics: weekly weight, length, and head circumference by trained research nurse."
89226771|NCT02943746|Experimental|Intervention Group (High Protein Diet)|"The intervention group will receive the same standard feeding regimen with the addition of extra milk fortification to give a high protein diet.~Human milk will be prepared and analyzed in the same method as the control group. Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.~The diet will be continued until approximately 35 to 36 weeks PMA at which point a DXA scan will be performed.~Infants will have 3 sets of labs. A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed.~Anthropometrics: weekly weight, length, and head circumference by trained research nurse."
89226772|NCT02922777|Experimental|BGB324 in combination with docetaxel|The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
89226773|NCT02915575|Other|Control Arm (usual care)|Participants will be discharged as per usual ward discharge protocols.
89226774|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
89226775|NCT02911103|Experimental|Active|single arm study
89226776|NCT02906007|Experimental|Bedaquiline (BDQ)|Participants will receive bedaquiline (BDQ) once a day for 2 weeks. For the next 22 weeks, participants will take BDQ 3 times a week on Monday, Wednesday, and Friday.
89226777|NCT02887820|Other|Pilot Arm|All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.
89226778|NCT02884271||cardiac arrest group|patients who develop intraoperative cardiac arrest
89226779|NCT02884271||without cardiac arrest group|patients who don't develop intraoperative cardiac arrest
89226780|NCT02881320|Experimental|Cohort 1 (12 to < 18 years of age and weight ≥ 35 kg)|"Part A: Participants will participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive the adult strength B/F/TAF FDC through Week 48.~Part B: Following confirmation of BIC PK data from Cohort 1 Part A, participants will receive the adult strength B/F/TAF through Week 48."
89226781|NCT02881320|Experimental|Cohort 2 (6 to < 12 years of age and weight ≥ 25 kg)|"Part A: Participants will participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive the adult strength B/F/TAF FDC through Week 48.~Part B: Following confirmation of BIC PK data from Cohort 2 Part A, participants will receive the adult strength B/F/TAF FDC through Week 48."
89226782|NCT02881320|Experimental|Cohort 3 (≥ 2 years of age and weight ≥ 14 to < 25 kg)|"Part A: Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive the low dose B/F/TAF FDC tablet through Week 48.~Part B: Following confirmation of BIC PK data from Cohort 3 Part A, participants will receive the low dose B/F/TAF FDC tablet through Week 48."
89230266|NCT00048061|Experimental|Ibandronate 150 mg|Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
89230267|NCT00802139|Experimental|venoferrum group|
89093306|NCT02614651|Experimental|The study population|"The study population consists of subjects with a concentric constriction of the visual field (retinitis pigmentosa, glaucoma) whose motor capacity allows the use of a computer keyboard with one hand. Subjects are recruited on a voluntary basis, from information disseminated to professionals in the rehabilitation of functional low vision and patient associations, in the Ophthalmology Service of the University Hospital of Nimes and within the ARAMAV Institute.~Intervention: Find visual comfort threshold related to light intensity~Intervention: Find the size of the visual field~Intervention: Effectiveness of brightness control~Intervention: Performance of color correction~Intervention: Vuzix Wrap 1200DX virtural reality glasses"
89093307|NCT04225780|Experimental|Treatment of low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group and low-dose IL-2 is defined as 1 million IU per day subcutaneously.
89093308|NCT04225780|Placebo Comparator|Treatment of ganciclovir|If patients are eligible, which CMV-DNA are more than 10^3 copies, it will be randomly distributed in ganciclovir treatment group.
89093309|NCT04816864|Active Comparator|ECANS started from the right vagus nerve|superior ECANS and ultrasonography guided inferior ECANS
89093310|NCT04816864|Active Comparator|ECANS started from the left vagus nerve|superior ECANS and ultrasonography guided inferior ECANS
89093311|NCT02877966|Experimental|Arm A|Amixea- patented stoechiometrical mixture of EAA & AA
89093312|NCT02877966|Placebo Comparator|Arm B|Placebo
89093313|NCT04226014||Patients with echo-endoscopic ultrasound of the pancreas|Patients requiring endoscopic ultrasound of the pancreas were included in the cohort.
89093314|NCT02618161|Experimental|Arm A|HDR Brachytherapy single dose of 15 Gy followed by EBRT of 46 Gy in 23 fractions and Androgen deprivation therapy 6 months to 3 years, (sequencing of HDR followed by EBRT)
89093315|NCT02618161|Active Comparator|ARM B|External Beam Radiotherapy (EBRT) of 46 Gy in 23 fractions, followed by single dose of HDR brachytherapy of 15 Gy boost and Androgen deprivation therapy 6 months to 3 years (timing of HDR Brachytherapy Treatment is changed compared to ARM A)
89093316|NCT04226404|Experimental|CSD1905-11|Subjects will be assigned to flavor variant CSD1905-11 of 4.8% ENDS products based on their preferred flavor.
89093317|NCT04226404|Experimental|CSD1905-12|Subjects will be assigned to flavor variant CSD1905-12 of 4.8% ENDS products based on their preferred flavor.
89093318|NCT04226404|Experimental|CSD1905-13|Subjects will be assigned to flavor variant CSD1905-13 of 4.8% ENDS products based on their preferred flavor.
89093319|NCT04226404|Experimental|CSD1905-14|Subjects will be assigned to flavor variant CSD1905-14 of 4.8% ENDS products based on their preferred flavor.
89093320|NCT04226404|Experimental|CSD1905-15|Subjects will be assigned to flavor variant CSD1905-15 of 4.8% ENDS products based on their preferred flavor.
89093321|NCT04226404|Experimental|CSD1905-16|Subjects will be assigned to flavor variant CSD1905-16 of 4.8% ENDS products based on their preferred flavor.
89093322|NCT04226404|Experimental|CSD1905-17|Subjects will be assigned to flavor variant CSD1905-17 of 4.8% ENDS products based on their preferred flavor.
89093323|NCT00698113|Active Comparator|1|This group receives the massage intervention for a period of six weeks. Children and parents are asked to journal weekly for the six week period.
89093324|NCT00698113|No Intervention|2|The control group does not receive any massage intervention during the initial six weeks of the study. The children are asked to journal during this six week period.
89093325|NCT01075152|Experimental|Earlier HIV Therapy|HIV therapy initiated at 7-13 days of cryptococcal meningitis diagnosis. HIV therapy consisting of a nucleoside with lamivudine and efavirenz.
89093326|NCT01075152|Active Comparator|Deferred HIV Therapy|"HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/- 1 week).~HIV therapy consisting of a nucleoside with lamivudine and efavirenz."
89093327|NCT02775526|Active Comparator|TOT|TOT
89093328|NCT02775526|Active Comparator|TVT|TVT
89093329|NCT02775526|Active Comparator|Burch colposuspension|Burch colposuspension
89093330|NCT02775682||patients with epilepsy|
89093331|NCT02775682||normal individuals without epilepsy|
89093332|NCT04134637|Experimental|PIFB group|"For carrying out PIFB bilaterally the skin on either side of the sternum will be prepared with povidone iodine solution. Then a linear ultrasound probe will be placed on the right and left sides at 2 cm from the sternal body.~A 22 gauge, 4 inch needle will be advanced until contacting the 4th costal cartilage following the lower edge of US probe, directing the tip from the bottom of the sternum and positioning the needle tip between the pectoralis major and the external intercostal muscles. Group A will receive twenty milliliters of a solution of 0.25% bupivacaine plus epinephrine (5 mcg/ml). Boluses of 5 ml are introduced to perform hydrodissection of the interfascial plane."
89093333|NCT04134637|No Intervention|control group|the block will not be given
89226783|NCT02881320|Experimental|Cohort 4 Group 1 (≥ 2 years of age and weight ≥ 14 to < 25 kg)|"Due to Cohort 3 Part A Intensive PK evaluation at Week 2 with the low dose B/F/TAF FDC tablet, participants will not participate in an Intensive PK evaluation at Week 2.~Participants will receive B/F/TAF FDC tablets for oral suspension (TOS) once daily through Week 48."
89226784|NCT02881320|Experimental|Cohort 4 Group 2 (≥ 1 month of age and weight ≥ 10 to < 14 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.
89226785|NCT02881320|Experimental|Cohort 4 Group 3 (≥ 1 month of age and weight ≥ 6 to < 10 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.
89226786|NCT02881320|Experimental|Cohort 4 Group 4 (≥ 1 month of age and weight ≥ 3 to < 6 kg)|Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.
89230268|NCT00802139|Active Comparator|Bolgre group|
89230269|NCT00802217|Active Comparator|Cohort 1|Civamide liquid filled softgel capsule 5 mg
89230270|NCT00802217|Active Comparator|Cohort 2|Civamide liquid filled soft gel capsules 2 x 5 mg
89093334|NCT04225702||Group Aspirin|The elderly patients who using Aspirin at least three months before operation were in the Group Aspirin
89093335|NCT04225702||Group Control|The elderly patients who not using Aspirin before operation were in the Group Control
89093336|NCT04133857|Active Comparator|Group A|undergo HIIT first then SSMIT protocol
89093337|NCT04133857|Active Comparator|Group B|undergo SSMIT first then HIIT protocol
89093338|NCT02877186|Experimental|Diet Soda|Consumption of diet soda three times daily for one week
89093339|NCT02877186|Placebo Comparator|Carbonated Water|Consumption of plain, unsweetened, carbonated water three times daily for one week
89093340|NCT04225858|Experimental|Omission of sentinel lymph node biopsy|No surgical axillary staging (i.e. sentinel lymph node biopsy) will be performed.
89111148|NCT02789865|Active Comparator|Appendectomy group|The patients will receive laparoscopic appendectomy according to standard routines.
89093341|NCT02617849|Experimental|Pembrolizumab, Carboplatin, Paclitaxel|Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
89093342|NCT01078116||Patients with Rheumatoid Arthritis|Eligible rheumatoid arthritis patients treated with adalimumab according to the approved Summary of Product Characteristics (SmPC) in European Union
89093343|NCT02775448|Experimental|Diet + exercise + Carduus marianus 6cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 6cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
89093344|NCT02775448|Experimental|Diet + exercise + Carduus marianus 12cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 12cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
89093345|NCT02775448|Experimental|Diet + exercise + Carduus marianus 30cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 30c, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
89093346|NCT02775448|Placebo Comparator|Diet + exercise + placebo|Diet (1600 cal/day) + aerobic exercise (30 min daily) + placebo (87°alcohol), 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
89093347|NCT00950859|Experimental|GSK1349572 Cohort I|Single Arm, Cohort I
89093348|NCT00950859|Experimental|GSK1349572 Cohort II|Single Arm, Cohort II
89093349|NCT02775292|Experimental|Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 TCR PBMC IV on day 0.~NIVOLUMAB: Patients receive nivolumab IV over 60 minutes on day 0 or 1. Treatment repeats every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.~NY-ESO-1(157-165) PEPTIDE PULSED DC: Patients receive NY-ESO-1(157-165) peptide pulsed DC ID on days 1, 14, and 28.~LOW DOSE ALDESLEUKIN ADMINISTRATION: Patients receive aldesleukin SC BID for 7 days beginning on day 1 for a maximum of 14 doses."
89111149|NCT02793297|Experimental|refined wheat crisp bread|refined wheat crisp bread was served as part of a complete standardized breakfast
89111150|NCT02793297|Experimental|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread was served as part of a complete standardized breakfast
89093350|NCT00862849|Experimental|Insulin Lispro, Regular Human Insulin, rHuPH20|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C).~Intervention A: a single, subcutaneous (SC) injection of 0.15 units per kilogram (U/kg) insulin lispro with 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase (rHuPH20)~Intervention B: a single, SC injection of 0.15 U/kg regular human insulin (RHI) with 3.75 ng/kg rHuPH20~Intervention C: a single, SC injection of 0.15 U/kg insulin lispro alone~There was a washout period of 3 to 14 days between interventions.~The treatment sequence (ABC, ACB, BAC, BCA, CAB, or CBA) was repeated once so that each participant received up to 6 injections."
89093351|NCT01090050|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Sumatriptan/Naproxen Sodium will treat daily with 1 tablet Sumatriptan 85mg / Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Sumatriptan/Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue.
89093352|NCT01090050|Active Comparator|Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Naproxen Sodium will treat daily with 1 tablet Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Naproxen Sodium will be provided with 14 tablets of Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue.
89093353|NCT02776618|Experimental|Polyglactin 910|One half of excision site will be randomly assigned superficial closure with polyglactin 910 suture
89093354|NCT02776618|Experimental|poliglecaprone 25|One half of excision site will be randomly assigned superficial closure with poliglecaprone 25
89093355|NCT00944229|Active Comparator|1 Drug Treatment - LOVAZA|Drug Treatment - LOVAZA 4 gm q24 for 8 weeks
89093356|NCT00944229|Placebo Comparator|2 placebo|Placebo 4 capsules q24 for 8 weeks
89093357|NCT02775370|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
89093358|NCT00698893|Experimental|Group A|
89093359|NCT00698893|Experimental|Group B|
89093360|NCT04225468|No Intervention|Treatment As Usual (TAU)|No intervention will be administered.
89093361|NCT04225468|Experimental|Opioid Exposure Reduction Program 1 (OERP1)|Participants will engage in a brief, educational intervention at their pre-surgery appointment approximately 2-3 weeks before ACL reconstruction surgery.
89093362|NCT04225468|Experimental|Opioid Exposure Reduction Program 2 (OERP2)|"Participants will engage in the same intervention as OERP1, but those in OERP2 will also receive a 5-minute booster intervention session 3 days after surgery."
89093363|NCT02855307|Active Comparator|Unannounced exercise|The target blood glucose of the algorithm will be as usual. A pre-meal full insulin bolus will be given.
89093364|NCT02855307|Active Comparator|Announced exercise with pre-meal full bolus|The target blood glucose of the algorithm will be increased and a pre-meal full bolus will be given
89093365|NCT02855307|Active Comparator|Announced exercise with reduced insulin bolus|The target blood glucose of the algorithm will be increased and the pre-meal insulin bolus will be reduced by 33%.
89093366|NCT01077960|Experimental|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
89093367|NCT04269369|Experimental|Group A|Dosage according to French guidelines
89093368|NCT04269369|Experimental|Group B|Dosage according to literature
89093369|NCT02776696|Experimental|Advanced HybridClosed Loop System (AHCL)|Advanced Hybrid Closed Loop System (AHCL) - all subjects wearing the study system during 36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3 or 5 days in a camp setting and 21 days at home during segment 4.
89093370|NCT02776696|Experimental|Hybrid Closed Loop System (HCL)|"Hybrid Closed Loop System (HCL) - all subjects wearing the study system during:~36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3"
89093371|NCT02776540|Active Comparator|900 mg Clopidogrel|67 patients will receive 12 tablets clopidogrel ( each 75 mg) as total 900 mg each patient
89093372|NCT02776540|Active Comparator|600 mg Clopidogrel|67 patient will receive 8 tablets clopidogrel (each 75 mg) as total 600 mg each patient and 4 tablets placebo to receive 12 tablets as total
89093373|NCT02776540|Placebo Comparator|400 mg Aspirin|67 patients will receive 4 tablets Aspirin ( each 75 mg) as total 300 mg for each patient and 8 tablets placebo to receive 12 tablets as total
89093374|NCT00944697|Placebo Comparator|Tablets|A placebo tablet to match the active reference treatment
89093375|NCT00944697|Active Comparator|Tablet|Oxycodone Naloxone tablets
89093376|NCT01077804||Varivax vaccinated children|Children who are members of Kaiser Permanente Medical Care Program (KPMCP) and who received a first dose of the varicella vaccine, Varivax, in 1995 between the ages of 12 and 23 months.
89093377|NCT00603057||Lung Cancer Imaging Patients|Adult patients (>18 years of age)with histologically confirmed or clinically diagnosed lung cancer who require radiation therapy, with or without surgery and with or without chemotherapy.
89093378|NCT02772796|Experimental|SENS-218|2 x 10 mg administered once on Day 1.
89093379|NCT00626652|Experimental|1|
89093380|NCT02775136|Experimental|HS-1000 recording|Non-invasive measurements duration with HS-1000 device will be for at least 30 minutes and up to 1 hour of aggregate recording either continuously in the event the patient's clinical condition allows it or in separate recording iterations in the event patient's condition will not allow continuous recording. For each patient, there may be several monitoring intervals from three times a day and up to as long as the patient undergoes brain monitoring, per the discretion of the investigator, patient and/or family members.
89093381|NCT02878122||Patients with epithelial ovarian cancer|Cancer treatment
89093382|NCT04878172|Experimental|TempSure Firm Day 0 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 0 (within 24 hours after treatment).
89093383|NCT04878172|Experimental|TempSure Firm Day 10 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 10 (+/- 3 days) after treatment.
89093384|NCT04878172|Experimental|TempSure Firm Day 20 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 20 (+/- 3 days) after treatment.
89093385|NCT04878172|Experimental|TempSure Firm Day 30 Biopsy Group|Subjects will undergo abdominal surgery after an abdominal treatment with TempSure Firm at day 30 (+/- 7 days) after treatment.
89093386|NCT04306926|Experimental|TQB2450+SBRT|SBRT three days before TQB2450.
89093387|NCT04807348|Experimental|Chiglitazar sodium 32mg QD+metformin|Chiglitazar 32mg qd+metformin
89093388|NCT04807348|Experimental|Chiglitazar sodium 48 mg QD+metformin|Chiglitazar 48 mg qd+metformin
89093389|NCT04807348|Placebo Comparator|placebo+metformin|placebo+metformin
89093390|NCT01075074|Active Comparator|Ropivacaine 0.05%|Subject received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side
89093391|NCT01075074|Placebo Comparator|Normal Saline|Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.
89093392|NCT01075074|Active Comparator|Ropivacaine 0.25%|Subjects received a bilateral transversus abdominis plane block using 15cc of 0.25% ropivacaine on each side
89093393|NCT04224922|Experimental|single-arm|weekly paclitaxel at a dose of 80mg/m² in combination with weekly carboplatin (AUC=2), for 12 weeks, followed by 4 cycles of dose dense epirubicin at a dose of 90 mg/m² and cyclophosphamide at a dose of 600 mg/m² every 2 weeks (plus Long acting GCSF at day 2) administrated preoperatively in locally advanced operable stage II and III triple negative breast cancer
89093394|NCT00626418|Placebo Comparator|1|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
89093395|NCT00626418|Active Comparator|2|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
89093396|NCT02877030|Experimental|Test control group|Start the sensorimotor exercises protocol with video game immediately after the first evaluation
89093397|NCT02877030|Active Comparator|Control test group|Start of sensorimotor exercises with video game protocol after ten weeks
89093398|NCT02877030|No Intervention|comparison group|No intervention
89093399|NCT02877888|Experimental|drug fluoride varnish /strength 22600ppm|intervention: drug :fluoride varnish 22600ppm topical application every 6 months for a total period of 2 years
89093400|NCT02877888|No Intervention|placebo comparator|placebo:use of routine dental advice
89093401|NCT02772640|Active Comparator|Arm I: R+E morning->evening|Rosuvastatin and Ezetimibe morning or evening administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the morning (8:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the evening hours (20:00).
89093402|NCT02772640|Active Comparator|ARM II: R+E evening->morning|Rosuvastatin and Ezetimibe evening or morning administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the evening (20:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the morning hours (8:00).
89093403|NCT02877342||Pre-intervention|All injured patients arriving by ambulance (to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving without notification buy ambulance service
89093404|NCT02877342||Post-Intervention|All injured patients arriving by ambulance, and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving with and without notification by the ambulance service using the pre-hospital notification application.
89093405|NCT02877810|Experimental|Telemedicine|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telemedicine, a live, interactive, audiovisual teleconferencing system, from a pediatric critical care physician.
89093406|NCT02877810|Active Comparator|Telephone|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telephone, from a pediatric critical care physician..
89093407|NCT02772484|Experimental|HS-1000 recording|The recording session should be performed in a quiet environment with no disturbance to the patient for a total of up to 60 minutes.
89093408|NCT02876952|Active Comparator|Attention Control Group (AC)|Moderate to high- intensity physical activity and Mediterranean Diet recommendations
89093409|NCT02876952|Experimental|HV-HIIT|"Supervised high volume and high intensity interval training exercise group with Mediterranean Diet recommendations.~High-intensity [heart rate (HR) values up to second ventilatory threshold (VT2) to peak intensity] interval training and high-volume increasing gradually from 20 to 40 min and alternating high and moderate [HR values between first ventilatory threshold (VT1) and VT2] intensities at different protocols."
89093410|NCT02876952|Experimental|LV-HIIT|"Supervised low volume and high intensity interval training exercise group with Mediterranean Diet recommendations.~High-intensity (HR values up to VT2 to peak intensity) interval training and low-volume (20 min) alternating high and moderate (HR values between VT1 and VT2) intensities at different protocols."
89093411|NCT02772406|Experimental|Experimental group|(With LCI endoscopy and 1 month later with white light endoscopy) The patients will be evaluated by Linked Color Imaging and 1 month later evaluated by White Light endoscopy
89093412|NCT02772406|Active Comparator|Control group|(With white light endoscopy and 1 month later with LCI endoscopy) The patients will be evaluated by White Light endoscopy and 1 month later evaluated by Linked Color Imaging
89093413|NCT02772718|Experimental|Part 1 - single dose|Cohorts A, B, and C
89093414|NCT02772718|Experimental|Part 2 - multiple doses|Cohort 1
89093415|NCT00866281|Experimental|30 mg/m^2 bid|Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m^2 bid cohort was 60 mg/m^2.
89093416|NCT00866281|Experimental|60 mg/m^2 bid|Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m^2 bid through oral route. The total daily dose in 60 mg/m^2 bid cohort was 120 mg/m^2.
89111151|NCT02793297|Experimental|unfermented rye crisp bread|Unfermented rye crisp bread was served as part of a complete standardized breakfast
89093417|NCT02772016|Experimental|Intervention group|Patients in the treatment group received daily 15 g oral Colla corii asini(Shandong Dong-E E-Jiao Co., Ltd) in powder form for 4 consecutive weeks. The dosage was adjusted to 10 g per day for 6 consecutive weeks if patients encounter any of the following side effects: swollen gums, dry or sore throat, ulcers in oral cavity.
89093418|NCT02772016|No Intervention|Control group|Patients in control groups do not receive any intervention.
89093419|NCT04225000|Active Comparator|Exercise Group|Hip & Knee Exercises
89093420|NCT04225000|Experimental|Mobilization Group|Tibiofemoral joint anterior-posterior mobilization combined Hip & Knee Exercises
89093421|NCT04121611|Experimental|Optical coherence tomography confirmed residual thrombus|Early antithrombotics
89093422|NCT04121611|No Intervention|Optical coherence tomography confirmed no residual thrombus|Best medical management
89093423|NCT04175080||Control|
89093424|NCT04175080||HFpEF group|
89093425|NCT04175080||Hypertensive group|Patients in which the results of BNP/NT-proBNP did not confirm the diagnosis of HFpEF were classified as hypertensive group.
89093426|NCT02617615|Experimental|MB-110|oral hard-gel capsule formulation. One dose strength, 25 mg of MB-110, will be filled into the #00 hard-gel capsule.
89093427|NCT02617615|Placebo Comparator|Placebo|in the same #00 hard-gel capsules.
89093428|NCT02772250|Active Comparator|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by a investigator at 15:00-17:00 on the day before colonoscopy.
89093429|NCT02772250|Experimental|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
89093430|NCT02614885||Prophylactic Mastectomy|Females undergoing prophylactic mastectomy with RFA performed on the excised tissue.
89093431|NCT02772172|Active Comparator|GuideMia surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in GuideMia program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
89093432|NCT02772172|Active Comparator|Control surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in control program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
89093433|NCT02772094|Experimental|Single arm, open-label|"Experimental:~ADCTA-G total 10 doses, each dose (30+/-5 millions autologous dendritic cells plus 6+/-0.5 millions 100Gy-irradiated short-term cultured autologous GBM tumor cells) divided in 2 halves for subcutaneous injection into both axillar areas, in a course of 6 months (sequential series of weekly injections 4 times, bi-weekly injections twice; then monthly injections 4 times.~Experimental: ADCTA-G total 10 doses, each dose (similar fore-mentioned numbers of 5:1 ratio of autologous dendritic cells and irradiated short-term cultured autologous GBM tumor cells) divided into 2 injections administered subcutaneously in both axillar areas, in a course of 8 months (sequential series of bi-weekly injections 4 times, then monthly injections 6 times)."
89093434|NCT02771860|Active Comparator|Experimental: denosumab|50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks denosumab 60mg sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks. Calcium and vit D supplementation will be installed at baseline.
89093435|NCT02771860|Placebo Comparator|Comparator|"50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks placebo sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks.~Calcium and vit D supplementation will be installed at baseline"
89093436|NCT02771782|Experimental|BCG|Subjects are vaccinated with BCG vaccine (SSI) alone, 0,1ml intradermal
89093437|NCT02771782|Experimental|TDaP-IPV|Subjects are vaccinated with TDaP-IPV vaccine (Boostrix Polio) vaccine alone, 0,5ml intramuscular
89093438|NCT02771782|Experimental|BCG+TDaP-IPV|Subjects are vaccinated with BCG vaccine (SSI) (0.1ml intradermal) and TDaP-IPV vaccine Boostrix Polio (0.5ml intramuscular) simultaneously
89093439|NCT02771392|Experimental|Tetracaine Group|Patients with he primary diagnosis of corneal abrasion will be treated with ophthalmic tetracaine. Tetracaine will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of preservative-free, undiluted 1% tetracaine hydrochloride (a total of 1.5 mL or approximately 50 drops will be provide to avoid overuse). Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
89093440|NCT02771392|Placebo Comparator|Normal Saline Group|Patients with the primary diagnosis of corneal abrasion will be treated with normal saline eye drops. Normal saline will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of normal saline. Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
89093441|NCT02771470|Experimental|Probiotic|Microbial composition using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
89093442|NCT02771470|Placebo Comparator|Placebo|Microbiota modulation using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
89093443|NCT02696746||Pain related conditions|Subjects with painful or painless conditions (observational study, no interventions)
89093444|NCT02771704|Experimental|Silver diamine fluoride|Intervention: Silver diamine fluoride will be applied in vivo on carious dentine lesions
89093445|NCT02771704|Experimental|Potassium iodide|Potassium iodide will be applied in vivo on carious dentine lesions.
89093446|NCT02771704|Experimental|Chlorhexidine|Chlorhexidine will be applied in vivo on carious dentine lesions
89093447|NCT02771704|Experimental|Silver diamine fluoride+Potassium iodide|Silver diamine fluoride and potassium iodide mixture will be applied in vivo on carious dentine lesions
89093448|NCT02771704|Experimental|Saline|Sterile physiological saline will be applied in vivo on carious dentine lesions
89093449|NCT02771548||Anterior Cruciate Ligament Reconstruction|Those who have undergone unilateral anterior cruciate ligament reconstructive surgery in the Sports Surgery Clinic.
89093450|NCT02771548||Control|Healthy volunteers with no previous knee injury, no current lower limb injuries and take part in regular multidirectional team sports.
89093451|NCT02771314|Experimental|AZD9291|AZD9291
89093452|NCT02771002||septic shock patients|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until normalisation of lactate sonographic assesment of perfusion of solid organs once within 24h after admission
89093453|NCT02771002||patients rewarming after cardiac surgery|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until extubation
89093454|NCT02771002||healthy volunteers|measurements of peripheral perfusion including capillary refill time and peripheral perfusion index in ambient temperature and after cooling of extremity
89093455|NCT02771158|Experimental|midodrine|randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation
89093456|NCT02771158|Placebo Comparator|placebo|randomization to placebo control
89093457|NCT02770924|Experimental|AT LISA TRI TORIC|All patients will be undergo to phacoemulsification with IOL implantation bilateral
89093458|NCT02770924|Experimental|AT LISA TRI|All patients will be undergo to phacoemulsification with IOL implantation bilateral
89093459|NCT02770534||Sickle patients in steady state|Well sickle cell patients attending the outpatient clinic
89093460|NCT02770534||Sickle cell patients admitted in crisis|Inpatients with acute vaso-occlusive crisis
89093461|NCT02770534||Sickle patients on transfusion program|Sickle patients managed on a regualar transfusion program
89093462|NCT02770534||Sickle patients on Hydroxycarbamide|Sickle cell patients managed on hydroxycarbamide and on a stable dose for at least 3 months
89093463|NCT02770534||Health controls|Well age and race matched individuals without a known diagnosis of sickle cell anaemia
89093464|NCT02770768|Active Comparator|Flibanserin|"Drug: Flibanserin~8 weeks~100mg once daily at bedtime"
89093465|NCT02770768|Placebo Comparator|Placebo|Drug: Matching Placebo Matching placebo capsules taken in same amount of pills as the active medication (for 8 weeks once daily at bedtime)
89093466|NCT01077258||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
89093467|NCT02770690|Experimental|spray|apply the ethyl chloride spray before propofol injection
89093468|NCT02770690|Active Comparator|lidocaine|apply the lidocaine 0.5 mg/kg under the touniquette state before propofol injection
89093469|NCT02770690|Placebo Comparator|placebo|apply the saline before propofol injection
89093470|NCT04754542||Discontinuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to discontinue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
89093471|NCT04754542||Continuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to continue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
89093472|NCT02770378|Experimental|Temozolomide combined with 9 repurposed drugs|"After enrollment, the subject goes into the induction cycle, which lasts 35 days. The induction cycle consists of a drug-by-drug addition and up-dosing process.~Hereafter, the subject will enter the treatment cycles (up to 12). During the induction cycle and the first 2 treatment cycles, regimen adjustments (dropping of certain drugs, dose modification of certain drugs) may be executed to accommodate to the patients' individual toxicity reactions that may occur during this period."
89093473|NCT02770456|Experimental|High dose fish oil|Women will be offered 4 capsules per day containing fish oil
89093474|NCT02770456|Experimental|Low dose fish oil|Women will be offered 4 capsules per day containing mixed fish oil and olive oil
89093475|NCT02770456|Placebo Comparator|Control|Women will be offered 4 capsules per day containing olive oil
89093476|NCT02770222|Experimental|Part 1, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. There is a washout period of 14 to 21 days between the two periods.
89093477|NCT02770222|Experimental|Part 1, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. They also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. During the second period (Treatment A) they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
89093478|NCT02770222|Experimental|Part 2, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin.There is a washout period of 14 to 21 days between the two periods.
89093479|NCT02770222|Experimental|Part 2, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin. During the second period (Treatment A), they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
89093480|NCT02770144|Experimental|Financial Coaching & Social Services Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
89093481|NCT02770144|Active Comparator|Access to Referrals to Social Services|Enrollment provides access to referrals to social services to meet basic needs.
89093482|NCT00943917|Experimental|ITCA 650 20 mcg/day|
88812598|NCT00890396||Passive Follow-up|A passive follow-up involved the abstraction of clinical data from the medical record. Results of physical examinations and laboratory tests performed as part of routine clinical care were recorded.
88812599|NCT01399229||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
89093483|NCT00943917|Experimental|ITCA 650 40 mcg/day|
89093484|NCT00943917|Active Comparator|Exenatide Injection|
89093485|NCT00943917|Experimental|ITCA 650 20/20|
89093486|NCT00943917|Experimental|ITCA 650 20/60|
89093487|NCT00943917|Experimental|ITCA 650 40/40|
89093488|NCT00943917|Experimental|ITCA 650 40/80|
89093489|NCT00943917|Experimental|Ex Inj/ITCA 650 40|
89093490|NCT00943917|Experimental|Ex Inj/ITCA 650 60|
89093491|NCT02769988||Project SHARE|
89111152|NCT05332782||M-TEER|Patients with primary mitral regurgitation undergoing mitral valve transcatheter edge-to-edge repair.
89230271|NCT04808141|Experimental|Digital Rehabilitation|Home-based rehabilitation with a digital biofeedback system
88812600|NCT01399229||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
89093492|NCT04780620|Experimental|Parent Intervention Group|The parent intervention group will undergo 8 weekly, manualized group sessions, with between 6 and 10 parent participants. Sessions are structured and follow an agenda including check-in and review of home practice, discussion of a skill or strategy, and review and assignment of home practice. Group sessions are held weekly for 1.5 hours and include both didactic, discussion, and practice elements, as well as assigned home practice.
89093493|NCT04780620|No Intervention|Usual Care Group|Parents in the usual care condition will be involved in their adolescent's care as is standard in our clinical program. With adolescent consent, parents are invited to participate in a single, 2-hour orientation session for parents/caregivers that provides information about depression, as well as the role of sleep, diet, and exercise in improving mood. Based on adolescent preference, parents can also attend regular psychiatric appointments with their adolescent, in which they will receive further information about depression and may receive and provide information about their adolescent's depression symptoms and response to psychosocial and pharmacological interventions. This control condition will allow us to determine whether the parent intervention is more effective than a relevant clinical alternative.
89093494|NCT02876250|Experimental|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
89093495|NCT02876250|Placebo Comparator|Control|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
89093496|NCT02769910|Other|Cowhage|Cowhage is used to induce non-histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hours and Qutenza Demo Patch.
89093497|NCT02769910|Other|Histamine|Histamine is used to induce histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hour and Qutenza Demo Patch.
89093498|NCT02876484|Experimental|Placebo|"Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.~25 ml water"
89093499|NCT02876484|Experimental|Chenodeoxycholic Acid|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Chenodeoxycholic acid (1250 mg) mixed in 25 ml yoghurt
89093500|NCT02876484|Experimental|Colesevelam|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
89093501|NCT02876484|Experimental|Colesevelam x 2|plus (on another study day) 3,75 g colesevelam administered the evening before the experiment. Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
89093502|NCT02851485|Experimental|GLPG1972 600 mg oral solution fasted|600 mg GLPG1972 administered as oral solution after overnight fasting
89093503|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fasted|600 mg GLPG1972 administered as oral tablet after overnight fasting
89093504|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fed|600 mg GLPG1972 administered as oral tablet after a high-fat high-calorie breakfast
89093505|NCT04779372|Experimental|Group of dCBT-I|participants will receive 6-week smartphone-based dCBT-I from a Wechat applet
89093506|NCT04779372|Sham Comparator|Group of sleep education|Patients will receive sleep health education like the advices getting from common sleep clinic by the same applet as the group of CBT-I in smartphone
89093507|NCT02696668|Active Comparator|modified FaME|Participants in the modified FaME group will receive a 16 weeks falls rehabilitation programme which will be tailored and progressed according to their abilities and their needs by the physiotherapist / instructor providing the rehabilitation at the hospital.
89226787|NCT02881320|Experimental|Open-Label Extension|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive adult strength B/F/TAF FDC, low dose B/F/TAF FDC, or B/F/TAF FDC TOS (based on age and weight) until it becomes available for use according to the participant's age and weight or the product becomes accessible to participants through an access program.
89226788|NCT02859753|Experimental|RFA|
89226789|NCT02859753|Active Comparator|MCT|
89226790|NCT02852213|Experimental|Single treatment arm|Single-stage dose-escalation, open-label safety study of AAV2-hAADC delivered by image-guided convection-enhanced delivery bilaterally into the substantia nigra pars compacta and the ventral tegmental area of pediatric patients with AADC deficiency. Primary aim is to determine the dose for future studies based on safety, biomarkers of pharmacological activity of AADC and clinical outcomes. Cohort 1 (3 subjects) will receive a single low dose of AAV2 hAADC. The total AAV2-hAADC dose will be infused via MR guided infusion into 4 sites in both the left and right SNc and VTA. Dose intervals will be 90 days between the first 3 subjects. Cohort 2 dose (4 subjects) will be determined by Cohort 1 results. Following Cohort 2, Cohort 3/4 will be dose and divided divided by age. Cohorts 3/4 will receive the same dose by MR guided infusion to 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 (24-47mo old) will have same vector concentration and lower volume of infusion than Cohorts 3/4
89226791|NCT02846376|Experimental|Group A - Nivolumab|"Nivolumab for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~Dose level 1: 1 mg/kg~Dose level 2: 3 mg/kg"
89226792|NCT02846376|Experimental|Group B - Ipilimumab|"Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~Dose level 1: 0.3 mg/kg~Dose level 2: 1.0 mg/kg~Dose level 3: 3.0 mg/kg"
89226793|NCT02846376|Experimental|Group C - Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~Dose level 1: 0.3 mg/kg~Dose level 2: 0.6 mg/kg~Dose level 3: 1.0 mg/kg"
89226794|NCT02830594|Experimental|Treatment (pembrolizumab, RT)|"INITIAL TREATMENT: Patients undergo palliative external beam RT daily. On day 1, patients undergo the first RT fraction and then receive pembrolizumab intravenously (IV) over 30 minutes. Cycles repeat every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.~SECOND PHASE: Patients who achieve a complete response, stop study treatment, and then experience radiographic disease progression may be eligible for the second phase at the discretion of the investigator if no cancer treatment was administered since the last dose of pembrolizumab and trial eligibility safety parameters are met. Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity."
89226795|NCT02827877|Experimental|Treatment (trastuzumab, copper Cu 64-DOTA-trastuzumab PET)|Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 cycles of trastuzumab and pertuzumab.
89226796|NCT02823769|Experimental|SI-R21204 resin composite|Fillings made with a new dental filling material
89226797|NCT02823769|Active Comparator|Nanohybrid resin composite|Fillings made with nanohybrid resin composite (Clearfil Majesty)
89226798|NCT02822092||Patients with Psychotic Disorders taking Risp. or Arip.|Risperidone or aripiprazole will be administered. Subjects will start risperidone 1 mg qhs or 5mg qhs aripiprazole; on day 4 the daily dose will be increased to 2 mg risperidone or 10mg aripiprazole and to 3 mg risperidone or 15mg aripiprazole at day 7. The target dose is 3 mg risperidone or 15 mg aripiprazole daily but patients who remain psychotic can be increased to 4 mg risperidone or 20mg aripiprazole at week 4; 5 mg risperidone or 25 mg aripiprazole at week 6 and 6 mg risperidone or 30 mg aripiprazole at week 8. Study Psychiatrists will be able to increase faster if symptoms don't improve as well as decrease for side effects. These dose ranges conform with standard clinical practice and are within the FDA approved dosing ranges for schizophrenia, and schizoaffective disorder. Subjects advance in the risperidone titration schedule until they respond or develop dose-limiting side effects.
89226799|NCT02822092||Healthy Volunteers|Healthy Volunteers will participate in MR imaging, Electroencephalogram , and cognitive testing.
89226800|NCT02821767||Participants|subjects with diagnosed or undiagnosed ocular conditions and/or their first-degree relatives
89226801|NCT02806882|Experimental|Ceftaroline fosamil|600mg 1 hour intravenous infusion ZINFORO
88812601|NCT01399229||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
89093508|NCT02696668|Experimental|Multisensory|Participants in the multisensory group will receive balance exercises training which will be tailored and progressed to their abilities and needs.
89093509|NCT02769598||ANI Index for Hospitalized children|"Each child will be registered upon arrival in the service and for a period of 24 hours. Registration will finish at the end of 24 hours or when the patient is discharged from the service. A FLACC scale (Face, Legs, Activity, Cry, Consolability scale) will be performed at the patient's input and then once every 4 hours corresponding to the patient's baseline. A FLACC scale will then be performed at each painful episode of the patient and 30 minutes after the end of production of analgesic treatment corresponding to the post-treatment painful condition of the patient.~A measurement of blood pressure will be performed at each pain rating by the patient assisted by the nurse."
89093510|NCT02769676|Experimental|3-week visit|Participants randomized to this arm will receive an additional visit at 3-weeks postpartum
89093511|NCT02769676|Active Comparator|usual care|Participants randomized to this arm will receive usual postpartum care, including the standard timing for a postpartum visit.
89093512|NCT02876094|Experimental|Open-label|All patients will be treated at each dose of oral once daily celecoxib (40, 80 and 160 mcg/kg) for a period of two weeks, for a total of 6 weeks (42 days) of treatment.
89093513|NCT02769364||Participants treated with eribulin for at least 7 months|
89093514|NCT04257903||Occlusal Splint Therapy|The data of patients who previously received occlusal splint therapy were evaluated. Participants in the study received occlusal splint therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received occlusal splint therapy as part of routine medical care, and a researcher studied the effect of occlusal splint therapy.
89093515|NCT04257903||Low-Level Laser Therapy|The data of patients who previously received Low-Level Laser Therapy were evaluated. Participants in the study received Low-Level Laser Therapy, but the investigator did not assign this intervention specifically to the study participants. Participants received Low-Level Laser Therapy as part of routine medical care, and a researcher studied the effect of Low-Level Laser Therapy.
89093516|NCT00603135|Experimental|A|
89093517|NCT02769754|Placebo Comparator|Control|In the control group (group A) no additional treatment will be applied after performing the usual surgical hemostasis.
89093518|NCT02769754|Experimental|Hemopatch|Hemopatch will be apply in the treatment group (group B), once the standard surgical hemostasis is achieved
89093519|NCT02769286|Experimental|Osimertinib in cohort 1|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA
89093520|NCT02769286|Experimental|Osimertinib in cohort 2|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring T790M which were detected from circulating tumor DNA
89093521|NCT02855073|Experimental|ReJoinTM Group|Subjects in this Group will receive ReJoinTM injections on day 1 and day 22, and Sodium Hyaluronate injection on day 8 and day 15.
89093522|NCT02855073|Active Comparator|Sodium Hyaluronate Group|subjects in this group will receive Sodium Hyaluronate injections on day 1, 8, 15, 22.
89093523|NCT01077024|Experimental|Smoking-cessation treatment + substance treatment as usual|
89093524|NCT01077024|No Intervention|Substance-treatment as usual|Treatment as usual is outpatient stimulant-dependence treatment as typically provided by the participating site.
89093525|NCT02769130|Experimental|Losartan|"Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins.~Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year."
89093526|NCT02768896|No Intervention|Baseline|Patients will walk naturally with EEG measuring brain waves
89093527|NCT02768896|Experimental|Visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
89093528|NCT02768896|Experimental|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
89230272|NCT04808141|Active Comparator|Conventional rehabilitation at an outpatient clinic|
88812602|NCT01434641|Other|low-dose stress MPI SPECT|Patients will receive a low-dose stress/high-dose rest protocol. Subject results are compared to archived patients undergoing a standard protocol./
88812603|NCT01400477|Experimental|DMXB-A-SR|Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR), 3-2, 4 dimethoxybenzylidene anabaseine sustained release (GTS-21)
88812604|NCT01400477|Placebo Comparator|Arm #2: Placebo Comparator|Inert capsule to resemble active drug.
89093529|NCT02768896|Experimental|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
89093530|NCT02853357|Sham Comparator|Control|The control group includes randomized participants that will receive a sham manipulation. Participants will also complete the standard set of core strengthening exercises.
89093531|NCT02853357|Experimental|Manipulation|The manipulation group includes randomized participants that will receive a thoracic spine thrust manipulation. Participants will also complete the standard set of core strengthening exercises.
89093532|NCT02769208|Active Comparator|Group A: Pre-Filter Only Intervention|Subjects in Group A start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which both the HEPA and ESP are removed, leaving only a pre-filter. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
89093533|NCT02769208|Active Comparator|Group B: Pre-filter + HEPA Intervention|Subjects in Group B start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which the ESP is removed, leaving a pre-filter + HEPA combination. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
89093534|NCT02769052|Active Comparator|Follow-up/Treatment - Control Group|Composed of two phases of 8 weeks each (follow-up - treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
89093535|NCT02769052|Active Comparator|Treatment Group|Composed of one phase of 8 weeks (treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
89093536|NCT04257669||Iron sufficient|Haemoglobin ≥120g/L Serum ferritin > 20μg/L
89093537|NCT04257669||Non-anaemic iron deficient|Haemoglobin ≥120g/L Serum ferritin ≤ 20μg/L
88812605|NCT01401023|Experimental|Clostridium difficile Patient|Open non-comparative trial
89093538|NCT04257669||Iron deficient anaemic|Haemoglobin <120g/L Serum ferritin ≤ 20μg/L
89093539|NCT04257669||Anaemic without iron deficiency|Haemoglobin <120g/L Serum ferritin > 20μg/L
89093540|NCT02768740|Active Comparator|200 mg group|Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
89093541|NCT02768740|Experimental|300 mg group|Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
89093542|NCT01089582||AD patients|
89093543|NCT02768974|Experimental|OPRX-106 2 mg|Open label, 1:1 randomization ration (up to 10 subjects)
89093544|NCT02768974|Experimental|OPRX-106 8 mg|Open label, 1:1 randomization ration (up to 10 subjects)
89093545|NCT02851095|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with two Extended Release (XR) tablet of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D of (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and 1 metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with 2 metformin (XR) tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89093546|NCT02851095|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89093547|NCT02851095|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89093548|NCT02851095|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89093549|NCT04224532|Experimental|Group P|Pneumoperitoneum is induced before reverse Trendelenburg position.
89093550|NCT04224532|Experimental|Group RT|Pneumoperitoneum is induced after reverse Trendelenburg position.
89093551|NCT02876874||the patients group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
89093552|NCT02876874||the health group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
89093553|NCT02768818|Experimental|Intervention|Probiotic VIVOMIXX™
89093554|NCT02768818|Placebo Comparator|Control|Placebo
89093555|NCT02876016|Experimental|awake brain surgery|Exploration of the cortical area of the brain awake surgery
89093556|NCT02768506||Gastric bypass|Subjects submitted to gastric bypass
89093557|NCT02768506||SADI-S|Subjects submitted to SADI-S
89093558|NCT00862459|Experimental|Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg body weight (BW) of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
89093559|NCT00862459|Experimental|Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
89093560|NCT00862459|Experimental|Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
89093561|NCT01074450|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
89093562|NCT01074450|Active Comparator|2|Mirapex® 0.25 mg Tablets
89093563|NCT02768428|Experimental|Video-Audio Media|watching the entire video in 15 mins
89093564|NCT02768428|No Intervention|Handbooks|study the hand book in 15 mins
89093565|NCT00603369|Experimental|1|13 session group intervention including sexual health information, affect management skills, cognitive monitoring, and communication skills training.
89093566|NCT00603369|Active Comparator|2|2 session group intervention including sexual health information training.
89093567|NCT04297566||Crohn disease's patients|Crohn's disease patients seen in gastroenterology consultation or coming in day hospital for treatment
89093568|NCT02853279|Experimental|Interval exercise training|Supervised exercise training undertaking interval exercise twice per week for 30 min each visit over 12 weeks.
89093569|NCT02853279|Active Comparator|Continuous exercise training|Supervised exercise training undertaking continuous exercise twice per week for 30 min each visit over 12 weeks.
89093570|NCT02768116|Experimental|ATP technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of non-left-main bifurcation lesion.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
89093571|NCT02768116|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Provisional T stenting technique in the treatment of non-left-main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
89093572|NCT02768272|Experimental|Epidural analgesia|Randomized allocation to receive patient controlled epidural analgesia or programed intermittent epidural boluses
89093573|NCT02768272|Experimental|Epidural technique|Randomized allocation to be punctioned a conventional epidural or a combined spinal-epidural technique
89093574|NCT04269681|Experimental|High Flow Nasal Cannula Arm|Participants will receive HFNC if they have no delirium and signs of ARF. The device is supposed to be used continuously in the nose with some changes in flow and/or temperature according to tolerance. There is no crossover to the standar of care arm.
89093575|NCT04269681|Active Comparator|Standard respiratory support|Participants will receive standard of care with low flow oxygen catheter or mask initially. If there is any sign of clinical deterioration NIV can be offered if tolerated by the patient. There will be no cross over with HFNC arm.
89093576|NCT00635284|Experimental|ABI-009|
89093577|NCT02854839|No Intervention|The Control Group|Patients will be randomized 1:1 to the control group and the treatment group. Patients who had allocated control group will not receive adjuvant treatment.
89093578|NCT02854839|Experimental|The Treatment Group (MG4101)|Patients will be randomized 1:1 to the control group and the treatment group. The treatment group will receive 6 times of MG4101(allogeneic natural killer cells) on week 0, 1, 2, 5, 6, 7.
89093579|NCT02768350|Experimental|Control group|All of the participants in control group will be treated with conventional treatment for 3 days, The conventional treatments consist of: (1) Passive chest mobilization, (2) Positioning, (3) Side lying (good lung down), (4) Vibration. The conventional treatment consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
89093580|NCT02768350|Experimental|Experimental group|All of the participants of the experimental group will be treated with ventilator hyperinflation technique (VHI) for 3 days. Tidal volume will increase from baseline (100% VT) to the tidal volume target at 1.5 times (150% VT). At this level, patients will receive six breathes and in each breathe will be sustained for 5 second (6 hyperinflation breathe per set); expiratory VT will return to baseline after each breath. Four sets of hyperinflation breathing will be used. After this, VT will decrease to baseline and patients have a 60 second for rest between hyperinflation set. The ventilator hyperinflation technique (VHI) consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
88812606|NCT01401101|Experimental|PTSD Care Management (PCM)|PCM has six intervention components: 1) patient education, 2) patient screening and written feedback of screening information to primary care clinicians, 3) clinician education on practice guidelines , 4) structured feedback between primary care and mental health clinicians, 5) continuity of patient care, and 6) a resource guide detailing available community services where the FQHC has established reciprocal referrals. All of the intervention components will be implemented through the CM, except for the clinician education component, which will combine onsite and online continuing medical education (CME)-accredited sessions.
89093581|NCT04131595|Experimental|MVA-BN-WEV Dose 1|Subjects in treatment Group 1 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 107 Inf.U in 0.5 mL.
89093582|NCT04131595|Experimental|MVA-BN-WEV Dose 2|Subjects in treatment Group 2 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 108 Inf.U in 0.5 mL
89093583|NCT04131595|Experimental|MVA-BN-WEV Dose 3|Subjects in treatment Group 3 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 2 x 108 Inf.U in 2 x 0.5 mL
89093584|NCT00699049|Placebo Comparator|Alpha blocker and placebo|
89093585|NCT00699049|Experimental|Alpha blocker and solifenacin|
89093586|NCT04131283|Experimental|Epinephrine effect throught keratinized ginigva|1 mg/ml epniephrine vs physiologocal saline
89093587|NCT04131283|Experimental|Epinephrine effect throught gingival sulcular epithelium|1 mg/ml epniephrine vs physiologocal saline
89093588|NCT04224454||Primary Sjögren's syndrome|111 consecutive patients with primary Sjögren's syndrome (European-American 2002 criteria)
89093589|NCT02767960||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
89093590|NCT02767960||NSTEMI group|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTEMI,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
89093591|NCT02767960||UAP group|The study population consists of 30 patients with unstable angina pectoris (UAP, n = 30). They will all undergo coronary angiography for the diagnosis of acute coronary syndrome. The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
89093592|NCT02767960||control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group.
89093593|NCT02617693|Other|Standard of care|
89093594|NCT02617693|Experimental|Life style intervention|
89093595|NCT02696980|Experimental|Rescue|Intervention: Positive expiratory pressure (PEEP) 10 will be applied after the administration of methacholine
89093596|NCT02696980|Experimental|Prophylaxis|Intervention: Positive expiratory pressure (PEEP) 10 will be applied during the administration of methacholine
89093597|NCT02696980|Placebo Comparator|No PEEP|Intervention: Positive expiratory pressure (PEEP) 0 will be applied during the administration of methacholine
89093598|NCT02767648||cholestasis|infant suffering from cholestasis proteomic urine analysis
89093599|NCT00943761|Experimental|Vaniprevir 300 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 300 mg twice daily (b.i.d.) in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
89093600|NCT00943761|Experimental|Vaniprevir 600 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 600 mg b.i.d. in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
89093601|NCT02617771|Active Comparator|Vit D|Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
89093602|NCT02617771|No Intervention|Control|
89093603|NCT02696590|Experimental|MS patients injectable Vitamin D3|MS patients who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
89093604|NCT02696590|Experimental|MS patients orally Vitamin D3|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
89093605|NCT02696590|Active Comparator|Healthy groups Injectable Vitamin D3|who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
89093606|NCT02696590|Active Comparator|Healthy groups Vitamin D3 orally|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
89093607|NCT02617459|Experimental|Levobetaxolol eye drops|Levobetaxolol eye drops 5ml/25mg per bottle
89093608|NCT02617459|Active Comparator|Betaxolol eye drops|Betaxolol eye drops 5ml/12.5mg per bottle
89093609|NCT02854995|Other|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce.
89093610|NCT02854995|Other|preputioplasty with intralesional injection of triamcinolone|(ii) preputioplasty with intralesional injection of triamcinolone: longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile.
88812607|NCT01401101|Placebo Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition consists of only the clinician education and patient screening without written feedback.
89093611|NCT04192786|Experimental|Treatment Group 50 Hz|
89093612|NCT04192786|Experimental|Treatment Group 100 Hz|
89093613|NCT04192786|Active Comparator|Control Group|
88812608|NCT01515995|Experimental|Magnesium sulfate group|15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
89093614|NCT02696512|Experimental|IBRF ACP/MCP Group 1|The Treatment group will be receiving a combination of pharmaceuticals (polypharmacy using FDA-approved products) and nutraceuticals (Nutraceutical supplementation) and median nerve stimulation (MNS)
89093615|NCT02696512|Other|Standard of Care Group 2|Standard of Care only
89093616|NCT00949533|Experimental|Standard Dose|Oseltamivir capsule will be administered orally at a dose of 75 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 milligrams/ milliliter [mg/mL]) based on their body weight with a starting dose of 30 mg BID to a maximum dose of 75 mg BID; for 5 days.
89093617|NCT00949533|Active Comparator|Double Dose|Oseltamivir capsule will be administered orally at a dose of 150 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 mg/mL) based on their body weight with a starting dose of 60 mg BID to a maximum dose of 150 mg BID; for 5 days.
89093618|NCT02767414|Experimental|Respirio Flu Test and eLab Flu Test|"Upper respiratory tract samples from participants will be tested with:~Respirio Flu Test; eLab Flu Test; and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)"
89093619|NCT02767258|Active Comparator|Sham Comparator: Eye drop|Eye drop LACRIBELL® - two drops each eye, two times a day, after eye cleansing.
89093620|NCT02767258|Experimental|VIDISIC® GEL|Ocular gel VIDISIC® GEL applied two times a day at the lower palpebra from medium line to the lateral border.
89093621|NCT04224376|No Intervention|Conventional rehabilitation|Normal postoperative treatment protocol with physiotherapy after ACL surgery
89093622|NCT04224376|Experimental|Serious Gaming|In the training group each patient was additionally provided with a GenuSport knee trainer device (prototype plus tablet with software application) with the active knee extension training program for 6 weeks. Other postoperative treatment was identical.
89093623|NCT02854761|Experimental|SC administration|Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months
89093624|NCT02854761|Experimental|IM administration|Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months
89093625|NCT00866047|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
89093626|NCT01706692||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
89093627|NCT01706692||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
89093628|NCT01706692||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
89093629|NCT01706692||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
89093630|NCT01706692||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
89093631|NCT01706692||Fumaric acids|Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
89093632|NCT01706692||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
89093633|NCT01706692||Other anti-psoriatic systemic treatments|e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed
89093634|NCT02767336|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
89093635|NCT02617537|Experimental|BAY86-5300|Patients suffering from dysmenorrhea, treated with Yaz
89093636|NCT02617537|Placebo Comparator|Placebo|Patients suffering from dysmenorrhea,treated with placebo
89093637|NCT02767180||Critical care survivors|Former ICU-patients recruited six months to three years after discharge from the ICU
89093638|NCT02767180||Matched controls|Control patients who have not been critically ill, matched for age and sex.
89093639|NCT04719442|Experimental|BHF-LC|To test an innovative implementation strategy, four communities will be assigned to pilot test the packaged PWMI and training materials when coupled with a learning collaborative facilitation strategy and sustainability action planning process to support PWMI adoption, implementation, and sustainability (BHF-LC).
89093640|NCT04719442|Active Comparator|BHF-Program Only|Four other communities will be assigned to receive the packaged PWMI and training program only.
89093641|NCT00869323|Experimental|Treated Patients|This group includes patients receiving Bortezomib and Rituximab for post-transplant lymphoproliferative disorders (PTLD).
89226802|NCT02782104|Experimental|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
89226803|NCT02776735|Experimental|Sarilumab|Participants will receive one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants will receive the selected dose regimen once this is identified. Sarilumab will be given during 12-week core treatment phase followed by an extension treatment phase (144 weeks for approximately 72 patients enrolled in dose-finding and second portions and 84 weeks for approximately 28 patients enrolled in third portion)
89226804|NCT02774746|Active Comparator|35-week delivery group|Subjects to be delivered at 35 0/7 weeks through 35 6/7 weeks.
89226805|NCT02774746|Active Comparator|38-week delivery group|Subjects to be expectantly managed to spontaneous delivery, delivered by 38 0/7 weeks through 38 6/7 weeks.
89226806|NCT02770131||Group 1|To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).
89226807|NCT02755610|Experimental|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
89226808|NCT02755610|No Intervention|Control|Standard care
89226809|NCT02738606|Experimental|Group I (surgery, chemotherapy)|Patients undergo hepatectomy and receive chemotherapy at the discretion of treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
89226810|NCT02738606|Active Comparator|Group II (chemotherapy)|Patients receive chemotherapy at the discretion of the treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
89226811|NCT02728830|Experimental|Pembrolizumab|"Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appropriate by their treating physician.~If subject's disease does not get worse following standard of care chemotherapy, they will receive pembrolizumab in the maintenance setting every three weeks for up to a year.~If subject's disease returns after completing a year of pembrolizumab and they have not had adverse reactions to pembrolizumab they may be eligible to continue receiving pembrolizumab for an additional year in the second course phase."
89226812|NCT02704234|Experimental|Active Acupuncture|Active Acupuncture 2 times per week for 5 weeks
89226813|NCT02704234|Placebo Comparator|Placebo|Placebo Acupuncture 2 times per week for 5 weeks
89226814|NCT02694874|Experimental|Rosiglitazone|Participants will receive rosiglitazone 0.045mg/kg/dose twice daily dosing, for 4 days
89226815|NCT02694874|Placebo Comparator|Placebo|Participants will receive placebo (grounded placebo powder) at a dose of 0.045mg/kg/dose twice daily for 4 days
89226817|NCT02681302|Experimental|All Participants|"Ipilimumab 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22~Nivolumab 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26"
89226818|NCT02654171|Experimental|AK0529|Subjects will receive single or multiple doses of AK0529 at different dose levels within different cohorts.
88812609|NCT01515995|Active Comparator|Normal Saline group|15 mg albuterol in 22 ml of normal saline solution via nebulizer over one hour
89226819|NCT02654171|Placebo Comparator|Placebo|Patients who are randomized to the control arm within each cohort will receive the corresponding placebo to AK0529.
89226820|NCT02651948|Experimental|Transperineal prostate biopsy (TPB)|Transperineal prostate biopsy MRI-guided
89226821|NCT02651948|Active Comparator|Transrectal prostate biopsy (TRB)|Transrectal prostate biopsy echo-guided
89226822|NCT02629107||Healthy Volunteers|Healthy volunteers, age 18-34.
89226823|NCT02624869|Experimental|Evolocumab|Participants receive 420 mg evolocumab administered by subcutaneous injection every 4 weeks (QM) for up to 80 weeks.
89226824|NCT02601417|No Intervention|Control|Group which considers both blood culture and bile culture for antibiotics choice
89226825|NCT02601417|Experimental|Trial|Group which considers only blood culture and ignore bile culture for antibiotics choice. Patients in this arm would undergo bile culture but ignore the result when choosing antibiotics
89226826|NCT02590393|Experimental|Nicotine + NNTAs|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain tobacco extract with nicotine + NNTAs in a vehicle of propylene glycol and vegtable glycerin, with tobacco or menthol flavor matched to each participant's preference. The yields of nicotine and NNTAs will be in the range of typical commercial cigarettes.
89226827|NCT02588651|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg intravenously (IV) once every 3 weeks
89226828|NCT02573779||Infants fed mother's own milk|Infants fed >50% mother's own milk with enteral feeding.
88812610|NCT01436045|Experimental|Insulin glulisine|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
88812611|NCT01436045|Placebo Comparator|Saline|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
89093642|NCT02775058||patients|The subjects enrolled in this CI just received dental grafting by the device under evaluation and in any case will be subject to the same procedures foreseen for this CI for the dental implant surgery.
89093643|NCT02767102|Experimental|Red wine with Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be enriched with 10 ng mL-1 MLT (MLT+) and used as experimental wine.
89093644|NCT02767102|Placebo Comparator|Red wine without Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be used as placebo treatment (PLC).
89093645|NCT02774902|Experimental|TAK-438 40 mg + Clarithromycin 500 mg|TAK-438 40 mg, tablets, orally once on Days 1 and 8 along with clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.
89093646|NCT04662970|Experimental|Device programming|according to different settings from the SyncAV algorithm
89093647|NCT02766946|Experimental|Mechanical Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Mechanical Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
89093648|NCT02766946|Active Comparator|Non-invasive Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Non-invasive Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
89093649|NCT02766946|Active Comparator|Spontaneous Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Spontaneous Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
89093650|NCT02766868|Experimental|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
89093651|NCT02774824||CABG patients from protocol 003-03|"Patients who will agree to be followed for an additional 9 months, which include:~2 phone calls at 6 and 9 months after coronary artery bypass graft surgery~1 clinic visit at 12 months after coronary artery bypass graft surgery ( 64-slice or better MDCT angiography)"
89093652|NCT02774434|Experimental|JM-105|Within 15 minutes of each ordered blood sample 2 TcB measurements will be performed using the JM-105 on the sternum and forehead. Subject's participation will end after a 10 day period.
89093653|NCT02767024|Experimental|Sodium Nitroprusside|Dose titration will start at 25 μg/min and increased by 25 μg every 5 minutes to maximal dose of 400 μg/min while maintaining SBP ≥ 90 mmHg. Every 5 minutes, the Pulmonary Capillary Wedge Pressure (PCWP), SBP will be measured. If PCWP > 16 mmHg while maintaining SBP ≥ 90 mmHg, the investigator will proceed to titrate dose with the goal to achieve the target of PCWP ≤ 16 mmHg and Cardiac Index (CI) > 2.2 L·min-1·m-2, or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
89093654|NCT02767024|Active Comparator|Dobutamine|Dose titration will start at 2.5 μg/kg/min and increased to doses of 5, 7.5 and 10 μg/kg/min (maximal dose). Every 30 minutes, the investigator will collect Pulmonary Artery (PA) blood samples for PA sat measurement to calculate Cardiac Output (CO) and CI by Fick. If CI ≤ 2.2 L·min-1·m-2, the investigator will proceed to titrate dose until CI > 2.2 L·min-1·m-2 or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
89093655|NCT02766790|Placebo Comparator|Placebo|Placebo taken once daily in the morning and once daily in the evening
89093656|NCT02766790|Active Comparator|TA-65MD 100 units Dose|TA-65MD 100 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
89093657|NCT02766790|Active Comparator|TA-65MD 250 units Dose|TA-65MD 250 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
89093658|NCT02766790|Active Comparator|TA-65MD 500 units Dose|TA-65MD 500 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
89093659|NCT02766790|Active Comparator|TA-65MD 250 units a.m. and p.m. Dose|Two TA-65MD 250 units capsules; one of them will be taken in the a.m. and one of them will be taken in the p.m.
89093660|NCT02774200|Experimental|test group|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
89093661|NCT02766712|Experimental|CA 1st Half of lesion|During each of the 15 pre-specified lesions, pacing will be initiated at a 500ms cycle length from a catheter in the coronary sinus or right ventricle prior to the start of the lesion. Pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Weckebach behavior continues, the pacing catheter will be moved to the right ventricle, which and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
89093662|NCT02766712|Experimental|CA 2nd Half of Lesion|During each of the 15 pre-specified lesions, pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Wenckebach behavior persists, the pacing catheter will be moved to the right ventricle and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
89093663|NCT01192022|Active Comparator|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
89093664|NCT01192022|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
89093665|NCT02766634|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
89093666|NCT02766634|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
89093667|NCT04857190|Active Comparator|Group DS (n=40)|Parker Flex-it Directional Stylet group
89093668|NCT04857190|Active Comparator|Group MS (n=40)|Conventional Malleable Stylet group
89093669|NCT02774044|Experimental|Cadisurf (goat lung surfactant extract)|Neonates in the intervention group will be intratracheally administered 100 mg/kg of GLSE (CADISURF®).
89093670|NCT02774044|Active Comparator|Survanta (Beractant)|
89093671|NCT00635206|Active Comparator|1|Auto M series device set to Bi Flex
89093672|NCT00635206|Active Comparator|2|Set to standard CPAP
89093673|NCT02766556|Active Comparator|arm 1|received ISB with 8mL of ropivacaine with 100 μg (1ml) of dexmedetomidine
89093674|NCT02766556|Placebo Comparator|arm 2|received ISB with 8mL of ropivacaine with 1ml of normal saline
89093675|NCT02774356||Native Chinese speakers|
89093676|NCT02774356||Native English speakers without experience of a tonal language|
89093677|NCT01191944|Experimental|pramipexole Extended release|subjects will receive 0.375mg once a day to 4.5mg once a day depending on investigator's judgement
89093678|NCT01191944|Active Comparator|pramipexole Immediate release|subjects will receive 0.125mg three times a day to 1.0mg three times a day depending on investigator's judgement
89093679|NCT02774512|Experimental|Nilotinib|A specific colonoscopy is performed in order to take biopsy for biological studies to determine the ZAK-0 expression status. Then the patient receives nilotinib orally at the dose of 800 mg/day (400 mg twice a day) for 7 days. The patient is scheduled for surgery the morning after the last take of the nilotinib (12 hours). When the colectomy is performed, the surgeon collects different tumoral samples which are immediately delivered to the laboratory.
89093680|NCT04224844|Active Comparator|Erector spinae plane block group (Group 1)|Patients will receive erector spinae plane block in addition to intravenous patient-controlled analgesia device containing tramadol.
89093681|NCT04224844|Active Comparator|Control group (Group 2)|Control group will receive only intravenous patient-controlled analgesia device containing tramadol.
89093682|NCT02773888|Experimental|HS-1000 recording|ICP readings will be recorded in parallel from both the invasive ICP monitor, and HeadSense's non-invasive ICP monitor. Each recording session will be done until an aggregate of at least 30 minutes worth of quality data is collected, depending on the patient's clinical condition. For each patient, two recording sessions will be completed for 30-60 minutes each for 120 minutes total.
89093683|NCT04223908||FCS|patient with genetically documented familial chylomicronemia syndrome
89093684|NCT04223908||MCS|patient with genetically or phenotypically documented multifactorial chylomicronemia syndrome
89093685|NCT01191788|Experimental|Group CBT|Clients received up to 16 sessions of group CBT for depression
89093686|NCT01191788|Active Comparator|Comparison|Treatment as Usual comparison condition
89093687|NCT00940875|Experimental|1|
89093688|NCT00940875|Active Comparator|2|
89093689|NCT02774122|Active Comparator|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
89093690|NCT02774122|Experimental|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
89093691|NCT02851017|Experimental|Exergaming group (XBOX Kinect|Kinect™ exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total).
88812612|NCT01519271|Placebo Comparator|Placebo Patch|
89093692|NCT02851017|Experimental|Traditional gym based exercise group|Traditional gym based (TGB) exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total). Those in the TGB group performed exercises that were matched for sequence, intensity, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading as required in the Kinect™ group.
89093693|NCT05656274|Experimental|JS1-1-01|JS1-1-01 25mg，50mg，100mg，150mg
89093694|NCT05656274|Placebo Comparator|Placebo|placebo 25mg，50mg，100mg，150mg
89093695|NCT02773810|Experimental|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
89093696|NCT02766010|Experimental|group A TensorTip|Male or female, age > 18
89093697|NCT04317560|Active Comparator|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
89093698|NCT04317560|Experimental|Arthrocentesis plus i-PRF injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. Only the second needle was removed without removing the first needle inserted. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
89093699|NCT04192708|Experimental|DV-ICNB group|intercostal nerve block under direct vision
89093700|NCT04192708|Experimental|UG-ICNB group|intercostal nerve block under ultrasound guidance
89093701|NCT04192708|Experimental|PV group|thoracic paravertebral block under ultrasound guidance
89093702|NCT05655728|Active Comparator|Metformin intervention treatment group|
89093703|NCT05655728|Placebo Comparator|The placebo treatment group|
89093704|NCT02773654||Healthy Volunteers|Asymptomatic subjects: subjects without complaints or history of shoulder pain or obvious movement abnormalities.
89093705|NCT02773654||Symptomatic Volunteers|Symptomatic subjects: subjects with shoulder pain who have active range of motion beyond 120° of elevation.
89093706|NCT02887430|Experimental|intervention|Participants will be received 8 sessions of foot reflexology therapy, 30 minutes each (2 sessions per week of 4 weeks) and low back pain standard care
89093707|NCT02887430|No Intervention|control|participants will be received standard care in general practice
89093708|NCT00940485|Experimental|Peginterferon alfa-2a + entecavir|Participants received PEGASYS® (peginterferon alfa-2a)180 micrograms (mcg) subcutaneously once weekly for 48 weeks, plus entecavir 0.5 milligram (mg) orally once daily for 8 weeks.
89093709|NCT00940485|Active Comparator|Entecavir|Participants received entecavir 0.5 mg orally once daily for 48 weeks.
89093710|NCT02696356|Experimental|Cohort 1|0.1mg GRN-1201
89093711|NCT02696356|Active Comparator|Cohort 2|1.0mg GRN-1201
89093712|NCT02696356|Experimental|Cohort 3|3.0mg GRN-1201
89093713|NCT05655650||Normal cognition|75 subject without any of the following: subjective memory complaint and cognitive impairment base on cognitive assessments
89093714|NCT05655650||Subjective Cognitive Disorder|75 subjects without cognitive impairment based on cognitive cognitive assessments but with subject memory complaint
89093715|NCT05655650||Mild Cognitive Impairment|75 subjects with both subjective memory complaints and mild cognitive impairment base on cognitive assessments
89093716|NCT05655650||Dementia|75 subjects with both subjective memory complaints and moderate to severe cognitive impairment base on cognitive assessments
89093717|NCT02765932|Active Comparator|Placebo Therapy|Dummy Movements
89093718|NCT02765932|Experimental|Psychosensory Therapy|Will involve touch technique, havening.
89093719|NCT05655416|Other|Lower limb varicose vein|
89093720|NCT02854683|Experimental|Normal Saline|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
89093721|NCT02854683|Experimental|Oral rehydration solution|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
89093722|NCT04317248|Experimental|MSDCV immune therapy combined with radical surgery therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time before the first time of MSDCV immune therapy
89093723|NCT04317248|No Intervention|Radical surgery therapy|Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time
89093724|NCT04317248|Experimental|MSDCV immune therapy combined with TACE therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: the first time of TACE therapy must perform before the first time of MSDCV immune therapy， then perform when necessary according to subjects condition
89093725|NCT04317248|No Intervention|TACE therapy|Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: perform when necessary according to Subjects condition
89093726|NCT04317248|Experimental|MSDCV immune therapy combined with targeted agents therapy|Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
89093727|NCT04317248|No Intervention|Targeted agents therapy|Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition
89093728|NCT02773342||Pathological findings in chest CT|
89093729|NCT05655338|Experimental|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The patients received antimicrobial photodynamic therapy after non-surgical periodontal treatment
89093730|NCT05655338|Experimental|SYSTEMIC ANTIBIOTICS|The patients received systemic antibiotics after non-surgical periodontal treatment
89093731|NCT00943605|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
89093732|NCT00943605|Experimental|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
89093733|NCT02765620||drug|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
89093734|NCT02765620||radiation|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
89093735|NCT05655260|Experimental|p53 abn subtype and nonendometrioid carcinomas|p53 abn stage I-II MI (myometrial invasion) >0%; MMR-D/NSMP nonendometrioid stage I-II MI >0%
89093736|NCT05655260|Experimental|MMR-D molecular subgroup|MMR-D stage IA-B grade 1-2, substantial LVSI; MMR-D stage IA grade 3, substantial LVSI; MMR-D stage IB grade 3; MMR-D stage II grade 1-3;
89093737|NCT05655260|Experimental|NSMP molecular subgroup|NSMP stage IA-B grade 1-2, substantial LVSI; NSMP stage IA grade 3, substantial LVSI; NSMP stage IB grade 3; NSMP stage II grade 1-3;
89093738|NCT00604149||1|case of out-of-hospital cardiac arrest
89093739|NCT00604149||2|cases of MI
89093740|NCT00604149||3|controls without coronary disease
89093741|NCT02773420|Experimental|HET application arm|Patients with grade I-II internal hemorrhoids will undergo HET application
89093742|NCT05655104||Couplet Care group and their historical controls|"Postintervention group: All parents enrolled in 2022-23 are classified into this group. They receive the intervention Couplet Care.~Pre-intervention group: All parents enrolled in 2018-19 are treated as controls. They did not receive the intervention Couplet Care."
89093743|NCT00604227|Experimental|1|high altitude exposure
89093744|NCT02772874||Urge-predominant|All subjects who report fecal incontinence that is primarily urge-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
89093745|NCT02772874||Passive-predominant|All subjects who report fecal incontinence that is primarily passive-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
89093746|NCT00603603|Experimental|80% inhaled oxygen-non-rebreather|10 liters of oxygen via non re-breather mask during cesarean section and up to two hours post-operatively
89093747|NCT00603603|Active Comparator|30% inhaled oxygen-nasal cannula|2 liters of oxygen via nasal cannula (standard of care) during cesarean section only
89093748|NCT01132313|Experimental|2|4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
89226829|NCT02573779||Donor milk fed infants|Infants fed <50% mother's own milk (and thus >50% donor human milk) with enteral feeding.
89226830|NCT02565498|Other|Preoperative Radiation Therapy (Arm A)|Preoperative intensity modulated radiation therapy followed by surgery
89226831|NCT02565498|Experimental|Postoperative Radiation Therapy (Arm B)|Surgery followed by postoperative intensity modulated radiation therapy
89226832|NCT02531932|Active Comparator|Carboplatin alone|AUC 4 every 3 weeks as an IV infusion
89226833|NCT02531932|Experimental|Carboplatin + Everolimus|Carboplatin AUC 4 every 3 weeks IV infusion plus daily oral everolimus 5mg pill
89226834|NCT02504853||Affected Genetic|Have a suspected genetic or congenital disorder potentially associated with food allergy or related condition, as determined by the principal investigator (PI) or associate investigators (AIs).
89226835|NCT02504853||Affected Non-Syndromic Food|Individuals with a clinical history of immediate hypersensitivity reaction to foods and sensitized to food allergen(s) as evidenced by SPT or allergen-specific IgE testing.
89226836|NCT02504853||Allergic GI Disease|Individuals with a diagnosis or clinical suspicion of eosinophilic esophagitis (EoE), as determined by the principal investigator (PI) or associate investigators (AIs).
89226837|NCT02504853||Unaffected Relative / Healthy Volunteer|Unaffected relatives are relatives of affected; unaffected by food allergy or the genetic condition under study. Healthy volunteers are not related to affected and serve as controls.
89226838|NCT02475434|Experimental|Cream Supplement group|Infants randomized to the cream supplement group will receive an exclusive HM-based diet with the addition of a HM-derived cream caloric supplement.
89226839|NCT02475434|No Intervention|Control Group|Infants randomized to the Control group will receive the standard regimen of an exclusive HM-based diet (no cream supplement).
89226840|NCT02444741|Experimental|Group I, Phase I (pembrolizumab + SBRT)|Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT, PBRT, or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
89226841|NCT02444741|Experimental|Group I, Phase II (pembrolizumab + SBRT)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV on day 1 and SBRT on days 44-47 or IMRT, PBT, or 3D-CRT on days 43-61. Treatment with pembrolizumab repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
89093749|NCT01132313|Experimental|1|4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
89093750|NCT01132313|Experimental|3|16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
89093751|NCT01132313|Experimental|4|28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
89093752|NCT01132313|Experimental|5|40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
89093753|NCT01132313|Experimental|6|28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
89093754|NCT01132313|Experimental|7|28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
89093755|NCT01132313|Experimental|8|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
89093756|NCT01132313|Experimental|9|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
89093757|NCT01132313|Experimental|10|24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
89093758|NCT01132313|Experimental|11|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
89093759|NCT01132313|Experimental|12|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
89093760|NCT02765308||Healthy volunteers|healthy age matched with cases volunteers as controls
89093761|NCT02765308||Uveitis with raised IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure
89093762|NCT02765308||Uveitis with with normal IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure
89093763|NCT00422565|Experimental|Endeavor|Zotarolimus-eluting stent
89093764|NCT00422565|Active Comparator|Cypher|Sirolimus-eluting stent
89093765|NCT00422565|Active Comparator|Taxus|Paclitaxel-eluting stent
89093766|NCT02773108||Hospitalized|Hospitalized psychiatric patients
89093767|NCT02773108||Daily hospital|
89093768|NCT02773108||Outpatients|
89093769|NCT04316936|Experimental|Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg|Omidria (= ketorolac + phenylephrine) and intracanalicular dexamethasone insert (punctal plug)
89093770|NCT04316936|Experimental|Omidria + Dexycu|Omidria (= ketorolac + phenylephrine) and intraocular dexamethasone suspension
89093771|NCT04316936|Active Comparator|Omidria + Prednisolone Acetate 1%|Omidria (= ketorolac + phenylephrine) and topical prednisolone acetate ophthalmic drops
89093772|NCT02772952|Other|Control Group|a control group whose intervention will be to review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
89093773|NCT02772952|Experimental|Experimental Group|Experimental group whose intervention will be a Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program.
89093774|NCT02850627|Experimental|Tongguan capsule|Tongguan capsule (0.5 g tid. for 6 months)
89093775|NCT02850627|Placebo Comparator|placebo capsule|same volume/day of placebo capsule (0.5 g tid. for 6 months)
89093776|NCT02765386|Experimental|Cochlear Implant Recipients|Newly implanted cochlear implant recipients with post-implantation acoustic hearing.
89093777|NCT02850861|Experimental|The experimental group|In this group, the condylar reductor was applied in the surgical treatment of mandibular condylar fractures.
89093778|NCT02850861|No Intervention|The control group|In this group, traditional surgical instruments were applied in the surgical treatment of mandibular condylar fractures.
89093779|NCT00861757|Placebo Comparator|Placebo|
89093780|NCT00861757|Experimental|2.5 mg Tadalafil|
89093781|NCT00861757|Experimental|5.0 mg Tadalafil|
89093782|NCT00861757|Active Comparator|0.2 mg Tamsulosin|
89093783|NCT02762734|Experimental|MEDIA|"The patient will benefit of the usual care with additional text message (SMS or mail or other new media). The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt."
89093784|NCT02762734|No Intervention|CLASSIC|The patient will benefit of the usual care.
89093785|NCT02850783|Experimental|SLN identification with 89-zirconium-nanocoll|Submucosal injection of 2.5 mBq, 0.4 ml 89-Zirconium-Nanocoll and subsequently SLN identification
89093786|NCT00604305|Active Comparator|Acrysof|Routine monofocal IOL
89093787|NCT00604305|Active Comparator|Acuity's AIOL|Accomodaing IOL
89093788|NCT05657756|Other|Atracrium group|
89093789|NCT05657756|Other|Rocoronium group|
89093790|NCT01131455|Active Comparator|Fusion+ACP+Autograft|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus, external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with dissection through the capsule and penetration to the joint. Standard debridement of the gutters, tibia osteophyte, tibia-talor joint resection and autograft preparation will be performed in the joint. Depending on randomization of the subject, (Autologous concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and reduced.
89093791|NCT01131455|Active Comparator|Fusion + ACP +DBM|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). Depending on the randomization of the subject, (Autologous Concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
89093792|NCT01131455|No Intervention|Standard-Fusion +Autograft only|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with blunt dissection through the capsule and penetration to the joint. Depending on the randomization of the subject, ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
89093793|NCT02765542|Experimental|Automated phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
89093794|NCT05657600||Video-based yoga group|The pranayama (respiration), asana (poses), yoga exercises and meditation were given to by means of video at home for 6 weeks (2days/week) as 12 sessions, and 60 min.
89093795|NCT05657600||Face-to-face yoga group|The pranayama (respiration), asana (poses), yoga exercises and meditation were given to face to face at Volunteer Training and Consultation Centre for 6 weeks (2days/week) as 12 sessions, and 60 min.
89093796|NCT05657600||physical exercise|The exercises for respiration, muscle strengthening, stabilization, and flexibility were given face-to-face at Volunteer Training and Consultation Centre for 6 weeks (2days/week) as 12 sessions, and 60 min.
89093797|NCT02762812|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
89093798|NCT02762812|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
89093799|NCT05657522|Experimental|Rapid Molar Intruder|Patients in this group will undergo the interventional procedure, which is the application of the rapid molar intruder appliance. This will help in correcting the open bite.
89093800|NCT05657522|No Intervention|Untreated Control Group|Patients in this group will be monitored without any active treatment.
89093801|NCT02762890|Experimental|Deep neuromuscular blockade|Rocuronium will be administered continuously to achieve post-tetanic count 1-2 during surgery.
89093802|NCT02762890|Active Comparator|Moderate neuromuscular blockade|Rocuronium will be administered continuously to achieve Train-of-four 1-2 during surgery.
89093803|NCT00698191|Experimental|1|
89093804|NCT01138007|Experimental|323U66 SR 150 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening throughout the treatment phase.
89093805|NCT01138007|Experimental|323U66 SR 300 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening during the first week of the treatment phase. At the second week, 323U66 SR 300mg cohort is up-titrated to a daily dose of 323U66 SR 300 mg, administered as 323U66 SR 150 mg tablet twice daily in the morning and in the evening, and the same daily dose is maintained to administer until the end of the treatment phase.
89093806|NCT01138007|Placebo Comparator|Placebo cohort|323U66 SR placebo tablet is orally administered twice daily throughout the treatment phase.
89093807|NCT04223128|Active Comparator|Magnesium sulfate group(M)|Participants in group (M) will receive 50 mg/kg MgSO4 in 100 ml isotonic saline intravenous (I.V) over 20 minutes prior to induction of general anesthesia by 30 minutes then ultrasound guided TAPblock after closure of the abdomen
89093808|NCT04223128|Active Comparator|Dexamethasone group(D)|participants in group (D) will receive 2 mg Dexamethasone in 100 ml isotonic saline IV then ultrasound guided TAPblock after closure of the abdomen
89093809|NCT04223128|Placebo Comparator|Placebo group(C)|participants in group (C) will receive 100 ml isotonic saline IV (placebo) by the same route and over the same duration as control then ultrasound guided TAPblock after closure of the abdomen
89093810|NCT05375864|Experimental|Paracetamol absorption test|
89093811|NCT02613715|Experimental|Blackberry juice with 12% ethanol|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml alcohol beverage (38%) and 17 g sugar.
89093812|NCT02613715|Experimental|Blackberry juice|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml water and 17 g sugar.
89093813|NCT02762968|Placebo Comparator|Placebo|Placebo capsules similar to the experimental treatments.
89093814|NCT02762968|Experimental|HMB|HMB capsules providing 3 g of calcium HMB per day.
89093815|NCT02762968|Experimental|HMB + BC30|Capsules providing 3 g calcium HMB per day plus Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
89093816|NCT02613559|Experimental|TK001 0.1mg|Injection:single Intravitreal Injection
89093817|NCT02613559|Experimental|TK001 0.5mg|Injection:single Intravitreal Injection
89093818|NCT02613559|Experimental|TK001 1.0mg|Injection:single Intravitreal Injection
89093819|NCT02613559|Experimental|TK001 2.0mg|Biological: TK001 Injection:single Intravitreal Injection
89093820|NCT02613559|Experimental|TK001 2.5mg|Biological: TK001 Injection:single Intravitreal Injection
89093821|NCT02613559|Experimental|TK001 3.0mg|Injection:single Intravitreal Injection
89093822|NCT02762656|Active Comparator|Lidocaine|Patients will receive Lidocaine drip during spine surgery
89093823|NCT02762656|Placebo Comparator|Placebo|Patients will receive placebo during spine surgery
89093824|NCT05657210||KRAS wildtype|
89093825|NCT05657210||KRAS codon 12 mutation|
89093826|NCT05657210||KRAS codon 13 mutation|
89093827|NCT05657210||KRAS codon 61 mutation|
89093828|NCT02764996|Experimental|Acupuncture for Migraine|Acupuncture treatments will be subject dependent, and points could include the N point (on scalp); various auricular points to include Shen Men, Point Zero, thalamus and Omega-2; body points to include Liver 2, Liver 3, Gall Bladder 20, bladder 10; and surface release over tense areas in the neck or shoulders
89093829|NCT05657132|Experimental|Costus paste|Costus paste used as an intracanal medication for decreasing the number of enterococcus faecalis present in the necrotic root of the primary molar
89093830|NCT05657132|Active Comparator|metapaste|metapaste used as an intracanal medication for decreasing the number of enterococcus faecalis present in the necrotic root of the primary molar
89093831|NCT02765152|Active Comparator|Conventional Physical Therapy|Usual therapy: joint mobility exercises, stimulating joint movement of the main active components of the upper limb; major muscle groups stretching, especially in the affected muscles by tone impairment; manual resistance training according to the degree of the patient's muscle strength, prioritizing the functional specificity of the upper limb, so the majority of the exercises will be held in open chain; motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks.
89093832|NCT02765152|Experimental|discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
89093833|NCT02765152|Experimental|rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
89093834|NCT01131299|Active Comparator|Alpha cyclodextrin first then placebo|Randomized subjects will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks. After the one week washout, the subjects will receive 2 tablets orally of placebo (three times a day for 12-14 weeks).
89093835|NCT01131299|Placebo Comparator|Placebo first then Alpha cyclodextrin|Participants will receive 2 tablets orally of placebo (three times a day for 12-14 weeks). The subjects will have a one-week washout. After the washout, the participants will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks.
89093836|NCT02762422|Experimental|Phlebotomy plus normal saline|Four serial phlebotomy procedures followed by infusion of normal saline
89093837|NCT02762422|Experimental|Phlebotomy plus intravenous iron|Four serial phlebotomy procedures followed by infusion of intravenous iron sucrose
89093838|NCT02762422|Placebo Comparator|Sham Phlebotomy|Four serial sham phlebotomy procedures followed by infusion of normal saline
89093839|NCT04316858|Active Comparator|Water|Water will be used as solvent for sodium phosphate
89093840|NCT04316858|Active Comparator|Zero calorie carbonated drink|Zero calorie carbonated drink will be used as solvent for sodium phosphate
89093841|NCT02614807|Experimental|Intervention|All recruited patients will receive a standard endorsement of lower fluid intake (<1.5 Litres/day) by a hypertension nurse and physician and an additional treatment consisting of a bottle (237 ml) of Nepro (a low sodium, low potassium content protein supplement) a day (supply for 4 weeks will be provided).
89093842|NCT04555720|Experimental|Interdisciplinary Care|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participant's doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
89093843|NCT04555720|No Intervention|Standard of Care|If assigned to standard of care, group participants will have a normally scheduled visit with neurologist.
89093844|NCT04119895|Experimental|NMES and exercise|Neuromuscular electrical stimulation and core stabilization exercise
89093845|NCT04119895|Sham Comparator|Sham NMES and exercise|Sham neuromuscular electrical stimulation and core stabilization exercise
89093846|NCT02764840|Experimental|experimental group isokinetic dynamometer (GEDI)|Isokinetic Biodex System Pro 4
89093847|NCT02764840|Experimental|experimental group elastic tube (GETE)|elastic tube brand LEMGRUBER 203
89093848|NCT00637325|Experimental|A|"In the maintenance study:~ARM A: maintenance of trastuzumab~In the 2nd line study:~ARM A: trastuzumab plus chemotherapy treatment"
89093849|NCT00637325|No Intervention|B|"In the maintenance study:~ARM B: interruption of trastuzumab treatment~In the 2nd line study:~ARM B: chemotherapy alone"
89093850|NCT02762344||ACT < 150 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal below 150 sec
89093851|NCT02762344||ACT between 150 and 249 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal between 150 and 249 sec
89093852|NCT02762344||ACT >= 250 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal above 250 sec
89093853|NCT04316780||Nintedanib until 0 day - 2 days before transplant|Nintedanib taken until 0 - 2 days before receiving transplant
89093854|NCT04316780||Nintedanib until 3 days - 28 days before transplant|Nintedanib taken until 3-28 days before receiving transplant
89093855|NCT04316780||Nintedanib until > 28 days before transplant|Nintedanib taken until more than 28 days before receiving transplant
89093856|NCT04316780||Pirfenidone until 0 day - 1 day before transplant|Pirfenidone taken until 0 - 1 day before receiving transplant
89093857|NCT04316780||Pirfenidone until 2 days - 28 days before transplant|Pirfenidone taken until 2-28 day before receiving transplant
89093858|NCT04316780||Pirfenidone until > 28 days before transplant|Pirfenidone taken more than 28 days before receiving transplant
89093859|NCT02764684|Experimental|HIV-infected patients|Probiotics (lactobacillus rhamnosus)
89093860|NCT02764450|Experimental|Astralis 10 HPM|Polymerization High-power mode: 1300 mW/cm2 for 10 s
89093861|NCT02764450|Experimental|Astralis 10 RM|Polymerisation regular mode: 650 mW/cm2 for 20
89093862|NCT04663282|Experimental|INS068|Intervention: Drug: INS068 injection
89093863|NCT04663282|Active Comparator|IDeg|Intervention: Drug: insulin Degludec
89093864|NCT02764606||Patients with a non-small cell lung cancer|Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).
89093865|NCT01130597|Experimental|patiromer|spironolactone + patiromer
89093866|NCT02762188|Experimental|wet ARMD patients|Patients with the wet form of ARMD who receive or have received in the past anti VEGF intra vitreal injections. Diagnosis of wet ARMD is made based on clinical data-visual acuity, fundus presence of subretinal fluid and/or haemorrhage and/or hard exudates, fundus photographs -color and red free, optical coherence tomography (SD-OCT), fluorescein angiography and indocyanine green angiography showing the presence and activity of subretinal neovascularisation.
89093867|NCT02761876|Experimental|Intervention (Participatory education)|Participatory education
89093868|NCT02761876|No Intervention|Control|Delayed participatory education
89093869|NCT02696278|Experimental|Hummus and vegetables|Children will receive a lesson about vegetables and hummus and vegetables as part of their daily snack.
89093870|NCT02696278|Experimental|Vegetables only|Children will receive a lesson about vegetables and vegetables as part of their daily snack.
89093871|NCT00939003|Experimental|Adalimumab|
89093872|NCT00939003|Placebo Comparator|Placebo|
89093873|NCT00939003|Experimental|Open-label Adalimumab|
89093874|NCT01188668|Experimental|Aripiprazole + Desvenlafaxine SR|
89093875|NCT02882945||Group A|150 healthy blood donors without a family history of diabetes mellitus
89093876|NCT02882945||Group B|200 cases of type 2 DM without complications (group B), there were 62 males and 108 females, aged 29-53, with an average age of 42 ± 9 years
89093877|NCT02882945||Group C|120 cases of type 2 DM with macroangiopathy complication (group C), there were 70 males and 50 females, aged 40-53, with an average age of 47 ± 6 years. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD
89093878|NCT04524286||Public - Childbearing Women|Childbearing women living in three deprived areas in a city in the South of England.
89093879|NCT04524286||Staff - Midwives|Midwives working in caseloading teams providing continuity of care to women living in three deprived areas in a city in the South of England.
89093880|NCT04192084|Experimental|Traumatic amputations of the digits|we will perform microvascular partial toe transfer for patients with traumatic amputations of one or more digits
89093881|NCT01130051|Experimental|Colcrys® 0.6 mg intact tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
89093882|NCT01130051|Experimental|Colcrys® 0.6 mg tablet on applesauce|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
89093883|NCT05301998|Other|Study Group|"Measurements of elasticity and thickness will be performed for each of the 200 patients.~Among the 200 patients, 10 will have a breast MRI in 3 different positions"
89093884|NCT00865189|Experimental|Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)|In this arm, participants will undergo 3 phases of treatment. During the Phase 1, participants will receive induction chemotherapy with 6 two-week cycles of bevacizumab + Folfox-4 (5-FU + oxaliplatin + folinic acid) for 12 weeks followed by a treatment-free interval of 3 to 4 weeks. The Phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (intravenous [IV] infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The Phase 3 will be surgery involving a radical rectal excision using the total mesorectal excision (TME) technique.
89093885|NCT00865189|Experimental|Arm B (Bevacizumab, Chemoradiotherapy)|In this arm, participants will receive the Phase 2 and Phase 3 treatments only. The phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (IV infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The phase 3 will be surgery involving a radical rectal excision using the TME technique.
89093886|NCT02762032|Active Comparator|Arm 1|15 subjects will be randomized to receive PrimaVie Herbal Supplement 125 mg to take twice daily for 14 weeks.
89093887|NCT02762032|Active Comparator|Arm 2|15 subjects will be randomized to receive PrimaVie Herbal Supplement 250 mg to take twice daily for 14 weeks.
89093888|NCT02762032|Placebo Comparator|Arm 3|15 subjects will be randomized to receive placebo (control supplement) to take twice daily for 14 weeks.
89093889|NCT02764372|Experimental|Serious games|The experimental group received Serious Games-based upper extremity therapy through Kinect
89093890|NCT02764372|Active Comparator|Exergames|The control played the same amount of time with commercial exergames of the Wii
89093891|NCT02852889||fluid responders|Patients whose stroke volume index increase by >10% in response to a 500-ml fluid bolus was defined as fluid responders.
89093892|NCT02852889||fluid non-responders|Patients whose stroke volume index increase by <10% in response to a 500-ml fluid bolus was defined as fluid non-responders.
89093893|NCT04311905|Experimental|Laser activated irrigation LAI|Diode Laser activated irrigation
89093894|NCT04311905|Placebo Comparator|conventional root canal treatment|mock LAI , conventional root canal treatment 2.5% sodium hypochlorite
89093895|NCT00697489|Active Comparator|1|unique surgery
89093896|NCT00697489|Active Comparator|2|Double surgery
89093897|NCT02764216|Experimental|EMI group|Elective mucosal irradiation
89093898|NCT00698269||A|
89093899|NCT00698269||B|
89093900|NCT00698269||C|
89093901|NCT01182194|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
89093902|NCT01182194|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
89093903|NCT02761798||Automated Mobile Interactive Audiometer, Test Retest|Each participant will act as his/her own control. The iPad audiogram will be compared to the audiogram in sound booth or to a second iPad audiogram.
89093904|NCT02761798||Automated Mobile Interactive Audiometer, Validation.|iPad testing will be compared to conventional audiometry in the sound booth.
89093905|NCT02761798||Automated Mobile Interactive Audiometer, Speech Recognition|Testing with NU-6 word lists will be conducted by the iPad and by an audiologist in the sound booth.
89093906|NCT02761798||Automated Mobile Interactive Audiometer, Cochlear Implant|Participants with cochlear implants will be tested using iPad against conventional audiometry (warble tone) in the sound booth.
89093907|NCT04133779||Group A (MS)|"Age 18-55 years;~Unisex patients diagnosed with MS according to McDonald criteria and successive relapse (38, 39), and subjects with CIS;~Course of the disease: RR-SP-PP-CIS;~Disease duration (starting from diagnosis): from 1 month to 25 years for subjects with RR, SP, and PP; a maximum of 5 years for subjects with CIS;~Not in clinical relapse (at least 30 days after the last clinical relapse);~Subjects treated or non-treated with immunomodulatory and immunosupressive drugs;~Signature of the informed consent."
89093908|NCT04133779||Group B (HC)|"Age 18-55 years;~Absence of significant diseases and lack of familiarity with MS, ie health check-ups (HC);~Signature of the informed consent.~The subjects included in this group could be, for example, unrelated relatives or spouses of those affected by MS or other diseases in the study, or linked to these by affinity restrictions (such as, the father-in-law with the son-in-law, the husband with his wife's brother, etc.) or accompanying persons or operators of other centres."
89093909|NCT04133779||Group C (OND)|"Aged 18-55 years;~Subjects with other non-inflammatory neurodegenerative disease (OND), for example Parkinson, ALS, ataxy.~Signature of the informed consent."
89093910|NCT04133779||Group D (ONDi)|"Age 18-55 years;~subjects suffering of other inflammatory neurodegenerative diseases (ONDi), for example optical neuromielitys, ADEM, encephalitis, neuro lupus, neurological complications of systemic autoimmune diseases;~Signature of the informed consent."
89093911|NCT02764294|Active Comparator|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
89093912|NCT02764294|Active Comparator|Stress Ball Group|"Stress ball group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
89093913|NCT02764294|Active Comparator|DVD Group|DVD group was watched a DVD of their choice (documentaries, interesting and amazing videos, comedies) on a ceiling-mounted monitor positioned at a comfortable distance to the participant.
88812613|NCT01519271|Active Comparator|Exelon Patch (rivastigmine transdermal system)|
88812614|NCT01401257|Experimental|PXT3003 Low dose|Oral Liquid formulation, 1/100, bid, 12 months
89093914|NCT02764294|No Intervention|Control Group|Participants received usual care from health professionals. They didn't receive any intervention.
89093915|NCT04131205||Minimal Hepatic Encephalopathy|Patients with hyperammonemia and minimal hepatic encephalopathy
89093916|NCT04131205||Control|Healthy controls
89093917|NCT05381571|Experimental|Reminiscence-based physical therapy|Participants will use the reminiscence-based technology (jDome BikeAround) for 10-minute sessions for three times per week during the 12 week study enrolment period.
89093918|NCT02764060|Experimental|Tongue scraper|In this group the subjects are explained how to use a plastic loop-formed tongue cleaner (Halita® tongue cleaner (Dentaid, Spain)) to clean their tongues.
89093919|NCT02764060|Experimental|Toothbrush|In this group the subjects are explained how to use a toothbrush (Oral-B® Indicator® medium tooth brush) to clean their tongues.
89093920|NCT01181726|Experimental|Investigational Test Product|Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
89093921|NCT01181726|Active Comparator|Reference Listed Drug|Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets
89093922|NCT01137071|Experimental|Monoclonal antibody hu3S193|Monoclonal antibody hu3S193 will be administered to 51 patients at the dose of 30mg/m2 every other week (total of 12 infusions) for a total of 23 weeks.
89093923|NCT00603681|Experimental|T|Test product
89093924|NCT00603681|Active Comparator|C|Reference product
89093925|NCT00699127|Experimental|1|The group that will have lecture of information regarding infants in NICU.
89093926|NCT00699127|No Intervention|2|The group that will not have lecture of information regarding NICU hospitalization
89093927|NCT02763904|Experimental|Intensive nutritional counseling|Dietary counseling + energy dense oral nutritional supplements
89093928|NCT02763904|Active Comparator|Dietary counseling|Dietary counseling
89093929|NCT02853045|Experimental|period with drug (trade name) then period with generic|Period of 6 weeks.
89093930|NCT02853045|Experimental|period with generic then period with drug (trade name)|Period of 6 weeks.
89093931|NCT04131049|Experimental|Carbohydrate Counting|The insulin doses of the breakfasts were calculated according to carbohydrate counting.
89093932|NCT04131049|Experimental|Food Insulin Index|The insulin doses of the breakfasts were calculated according to food insulin index.
89093933|NCT00603759|Active Comparator|1|
89093934|NCT00603759|Placebo Comparator|2|
89093935|NCT04130815|Active Comparator|Slow/Deep/Large|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration
89093936|NCT04130815|Active Comparator|Slow/Deep/Small|Slow/deep breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
89093937|NCT04130815|Active Comparator|Fast/Shallow/Large|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with large droplet size over a 10-15 minute duration.
89093938|NCT04130815|Active Comparator|Fast/Shallow/Small|Fast/shallow breathing pattern will be targeted while inhaling furosemide with nebulizer set to deliver 4ml of a 10mg/ml solution of furosemide with small droplet size over a 10-15 minute duration.
89093939|NCT02761564|Experimental|ScVO2 group|Anemia (<9g/dL) requiring blood transfusion Measure of ScvO2 : ScVO2 is measured using the central venous catheter placed in the superior vena cava. Transfusion is performed if the ScVO2 is inferior or equal to 65%.
89093940|NCT02761564|Other|Control group|Anemia (<9g/dL) requiring blood transfusion : Transfusion is performed following national guidelines for red blood cell transfusion
89093941|NCT02763982||G1|High or normal left ventricular ejection fraction
89093942|NCT02763982||G2|Moderate left ventricular ejection fraction
89093943|NCT02763982||G3|Reduced left ventricular ejection fraction
89093944|NCT04312061|Experimental|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
88812615|NCT01401257|Experimental|PXT3003 Intermediate dose|Oral Liquid formulation, 1/50, bid, 12 months
89093945|NCT04312061|Placebo Comparator|placebo|oral placebo tablet given 1 hour before LNG-IUD insertion
89093946|NCT02852811|Other|group education|To measure improvement of menopause symptoms and depression all participating women answered a baseline questionnaire and a follow-up questionnaire four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
89093947|NCT02852811|No Intervention|control group|The control group did not obtain any group education or any other intervention. Women answered at baseline questionnaire and four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
89093948|NCT00860743|No Intervention|Arm 1|"We plan to study 10 males and 10 females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep."
89093949|NCT00860743|Experimental|ANTIOXIDANT COCKTAIL|We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness and sleep following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.
89093950|NCT04317170|Experimental|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia.
89093951|NCT04317170|No Intervention|No Music|Patients will undergo their routine procedure without being played music.
89093952|NCT02761720||MyPennMedicine (MPM)|Participants assigned to this arm downloaded only the MyPennMedicine mobile app.
89093953|NCT02761720||MPM and Ginger iO|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app.
89093954|NCT02761720||Lottery|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app. They were also given a lottery incentive if they completed 70% of the daily mood ratings.
89093955|NCT04311593||group 1|control group with normal platelet count
89093956|NCT04311593||group 2|patients with acute ITP
89093957|NCT04311593||group 3|patients with chronic ITP
89093958|NCT01186796|Experimental|Fulvestrant|
89093959|NCT05383131|Experimental|HEC585 and Pirfenidone|period 1 - Pirfenidone X mg, TID; period 2 - HEC585 X mg, QD; period 3 - Pirfenidone X mg, TID + HEC585 X mg, QD.
89093960|NCT05383131|Experimental|HEC585 and Nintedanib|period 1 - Nintedanib X mg, BID; period 2 - HEC585 X mg, QD; period 3 - Nintedanib X mg, BID + HEC585 X mg, QD.
89093961|NCT02763670|Other|Interventional|PRETICARD patient care management
89093962|NCT02763670|Other|Control|"Heterogenous as usual patient care management."
89093963|NCT04119817|Experimental|Mucosave® capsules|60 healthy volunteers taking 400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day after dinner before going to bed.
89093964|NCT04119817|Placebo Comparator|Placebo|40 healthy volunteers taking capsules of placebo for a period of 8 weeks, once a day after dinner before going to bed.
89093965|NCT04269057||HFpEF|heart failure patients with preserved ejection fraction who using ARNI
89093966|NCT04269057||HFrEF|heart failure patients with reduced ejection fraction who using ARNI
89093967|NCT01136915|Active Comparator|IOPAMIDOL injection 370|
89093968|NCT01136915|Active Comparator|Iodixanol 320|
89093969|NCT02761486|Active Comparator|Aspirin|The subjects will receive 325 mg of aspirin once a day for 6 weeks followed by a 6-week washout.
89093970|NCT02761486|Placebo Comparator|Placebo|The subjects will receive placebo once a day for 6 weeks followed by a 6-week washout.
89093971|NCT02617225||DHaAL Intervention|The group receives standard Ailment-free Life (DHaAL) DHaAL intervention
89093972|NCT02617225||DHaAL +CFSS Intervention|This group received the standard DHaAL intervention and additional support under another UNICEF program named Child Friendly School System (CFSS).
89093973|NCT02617225||Control|This group receive the standard / business-as-usual support from the Education Department, but does not receive DHaAL or CFSS Interventions.
89093974|NCT04268589|No Intervention|control group|routine study
89093975|NCT04268589|Experimental|virtual reality group|Three days a week, 2 times a day, 15 minutes in the morning and in the evening for 9 days in total
89093976|NCT02882789|Experimental|LCB01-0371 200mg|LCB01-0371 IV 200 mg
89093977|NCT02882789|Experimental|LCB01-0371 400mg|LCB01-0371 IV 400 mg
89093978|NCT02882789|Experimental|LCB01-0371 800mg|LCB01-0371 IV 800 mg
89093979|NCT02617381|Experimental|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
89093980|NCT00940017|Experimental|1|
89093981|NCT01129583|Experimental|Botulinum Toxin|100 U injected into biceps, 100 U into brachialis
89093982|NCT01129583|Placebo Comparator|Saline|100 U injected into biceps, 100 U into brachialis
89093983|NCT00848497|Active Comparator|Testim® + Viagra®|Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night
89093984|NCT00848497|Placebo Comparator|Placebo Testim® + Viagra®|Placebo Testim® gel once daily + Viagra® 25 mg tablet every night
89093985|NCT02763592|Experimental|Lidocaine|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
89093986|NCT02763592|Placebo Comparator|placebo|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
89093987|NCT04268043|Experimental|flexible laryngeal airway|
89093988|NCT04268043|Experimental|proseal laryngeal mask airway|
89093989|NCT02763748|Experimental|Laparoscopic surgery|Laparoscopic endoscopy combined surgery. This is a kind of traditional surgical method.
89093990|NCT02763748|Experimental|laparoscopic and endoscopic|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
89093991|NCT02763748|Experimental|Single-arch laparoscopic and endoscopic|Single-arch LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
89093992|NCT04268355|Experimental|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers
89093993|NCT00857623|Experimental|1|
89093994|NCT00857623|Placebo Comparator|2|
89093995|NCT04312607||Philadelphia chromosome positive|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
89093996|NCT04312607||Philadelphia chromosome negative|according to PCR detection of BCR-ABL gene CD26 expression on stem cells
89093997|NCT02761096|Experimental|Study group|The acupuncture intervention will start no more than 48 hours after craniotomy and will be given once a day for 6 days (a total of 6 sessions within 8 days). It will be given in addition to conventional treatments. All interventions will be performed by one Korean Medicine doctor with over 5 years of working experience with a college education of 6 years. This doctor will be trained in the study protocol before the start of the trial.
89093998|NCT02761096|Other|Control group|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery.
89093999|NCT01185782|Experimental|SJ-0021 group|
89094000|NCT01185782|Active Comparator|Purified pituitary gonadotropin group|
89094001|NCT04119349|Experimental|Counseling|Women are given extra 15-minute counseling on the pros and cons of all different methods for prenatal testing including no testing at all
89094002|NCT04119349|No Intervention|Standard care|Women receiving standard care by means of counseling
89094003|NCT02761174|Active Comparator|Brimonidine (Mirvaso cream)|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face (control) and 0.5 g of brimonidine (Mirvaso cream) to the randomized side of the face.
89094004|NCT02761174|Other|IPL+air-cooling|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face and IPL+air-cooling (control) are thereby compared to IPL+air-cooling+brimonidine (Mirvaso cream).
89094005|NCT01129115|Active Comparator|Nonexercise control group|
89094006|NCT01129115|Experimental|Aerobic Exercise Group 1|
89094007|NCT01129115|Experimental|Aerobic Exercise Group 2|
89094008|NCT01129115|Experimental|Aerobic Exercise Group 3|
89094009|NCT04119583|Experimental|U-shape Automatic Electric Toothbrush|
89094010|NCT04119583|Active Comparator|Usual home toothbrushing procedure|
89094011|NCT04119583|No Intervention|No toothbrushing|
89094012|NCT04119583|Active Comparator|Conventional Electric Toothbrush|
89094013|NCT04222738|Experimental|Non-randomized single-arm of GINOFF1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted on the administration of Zingiber officinale Roscoe extracts, at a daily dose of 2g/day (equivalent overall daily dose of extract in simple powdered form) for a period of 6weeks. The extracts were given as capsules, either one capsule three times per day (1 capsule x 3 / day) and after meals. Each capsule contains 399mg of pure Zingiber officinale Roscoe extracts."
89094014|NCT04119661|Experimental|Max-i-Probe|
89094015|NCT04119661|Active Comparator|NaviTip|
89094016|NCT04315922||Severe Ischemic Stroke|Severe Stroke as defined by inclusion criteria
89094017|NCT04315922||Mild Ischemic Stroke|Mild Stroke as defined by inclusion criteria
89094018|NCT04315922||Transient Ischemic Attack|Transient Ischemic Attack as defined by inclusion criteria
89094019|NCT04312217|Active Comparator|Medical clowning|Preoperative medical clown exposure
89094020|NCT04312217|No Intervention|Control|Normal preop care
89094021|NCT04116307|Experimental|Polymethylsiloxane|Polymethylsiloxane (Enterosgel) is given 3 x 10 g for the initial two days, and 3 x 5 g for the next three days.
89094022|NCT04116307|Active Comparator|Lactobacillus reuteri|Probiotic Lactobacillus reuteri (BioGaia) is given 3 x 20 drops (which means 3 x 400,000.000 CFU) per day for five days.
89094023|NCT02763436|No Intervention|"Group immediate cord clamping (ICC)"|The cord will be clamped within the first minute after birth, afterwards the newborn will be placed on the mothers chest/abdomen. This corresponds to the present routine approach in Graz.
89094024|NCT02763436|Active Comparator|"Group physiological based cord clamping (PBCC)"|"The newborn will be placed on mother's chest/abdomen with intact cord. After the newborn has established stable breathing efforts (continuous regular breathing pattern and SpO2 values >25th percentile from Dawson et al reference range for oxygen saturation -minute 2>58%, minute 3>67%, minute 4>76%) the cord is clamped. This will need 2 - 4 minutes."
89094025|NCT04311359||Group/Cohort|Brain Oedema induced by drugs reported to the FAERS database from inception till first quarter of 2019
88812616|NCT01401257|Experimental|PXT3003 High dose|Oral Liquid formulation, 1/10, bid, 12 months
88812617|NCT01401257|Placebo Comparator|Placebo|Oral Liquid formulation, bid, 12 months
89094026|NCT02882555|Experimental|Children|"12 concentrations of caspaicin are administered: - 0.6, 1.2, 2.4, 4.8, 9.8, 19.5, 39, 78.1, 156.2, 312.5, 625, 1250 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline~At least 1-hour-interval (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
89226842|NCT02444741|Experimental|Group II, Phase I (pembrolizumab + IMRT, PBRT or 3D-CRT)|Patients who exhibit a lung lesion of size or location not amenable to SBRT, but amenable to WFRT receive pembrolizumab as in Group I and either IMRT, PBRT, or 3D-CRT in 15 fractions total on days 1-19 concurrent with pembrolizumab administration.
89226843|NCT02444741|Experimental|Group II, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV as in Group I without XRT. At the first planned efficacy evaluation (5 weeks), patients exhibiting PD are treated with SBRT concurrent with the remaining cycles of pembrolizumab. In the event that lesion size has progressed to the point where the attending physician no longer considers SBRT safe, then the patient will be salvaged with IMRT, PBRT, or 3D-CRT and analyzed as part of the fourth treatment group.
89226844|NCT02444741|Experimental|Group III, Phase II (pembrolizumab + IMRT, PBRT, or 3D-CRT)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I and IMRT, PBRT, or 3D-CRT on days 43-61.
89226845|NCT02444741|Experimental|Group IV, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I without XRT. The decision on when to start XRT will be assessed first at week 5 (after the second dose of pembrolizumab). If a patient has PD based on irRC then XRT will be delivered after the third dose of pembrolizumab, while patients with SD or PR will not start XRT and will continue to be followed. These patients will then have follow up CT scans 5 weeks after course 3 and then approximately every 3 months for the remainder of the trial; any patient at this point with PD will then have XRT delivered with the sixth dose of pembrolizumab.
89226846|NCT02444741|Experimental|Group V, Phase II (low dose radiation therapy)|Patients with lesions amenable to SBRT or WFRT receive pembrolizumab IV as in Group I. Patients also receive either IMRT, PBRT, or 3D-CRT in 15 fractions to the primary lesions and low dose radiation therapy to other lesions on days 43-61 or SBRT in 4 fractions to primary lesions and low dose radiation therapy to other lesions on days 44-47.
89226847|NCT02423070||Cohort 1|Heart and Lung Transplant patients
89226848|NCT02422147||Ablation of PCL|Patients with pancreatic cysts will undergo ablation using alcohol under EUS-guidance
88812618|NCT01402115|Experimental|Polycan|Polycan 150mg for 12 weeks
88812619|NCT01402115|Placebo Comparator|Placebo|Placebo 15mg for 12 weeks
89094027|NCT02882555|Active Comparator|Adults|"As reference for more precise assessment of effects of development.~12 concentrations of caspaicin are administered: 0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline~At least 1-hour-interval (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
89094028|NCT02761018|Experimental|Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
89094029|NCT02761018|Experimental|Fitness Tracker with Group Participation|will use a fitness tracker and will be able to see other member's daily and weekly results
89094030|NCT04119427|Experimental|Test Group|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
89094031|NCT04119427|Placebo Comparator|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
89094032|NCT02763358|Other|Bites and Steps displayed|All subjects will be assigned to one arm-daily bites and steps displayed on Bite Counter device
89094033|NCT00699361|Experimental|1|Measurement before Pantoprazole application
89094034|NCT00699361|Experimental|2|Measurements after Pantoprazole application
89094035|NCT01185704|Experimental|Day 1 protocol|
89094036|NCT01185704|Experimental|Day 7 protocol|
89094037|NCT01128959|Experimental|Intravenous Carbamazepine (IV CBZ)|
89094038|NCT04222582|Active Comparator|Active tDCS|"Administration of a 2 milliamp (mA) current delivered via two scalp electrodes for 20 minutes (ramp-in + ramp-out periods, 30s total) 2 times per day for 5 consecutive days, >3 hour interval between sessions, for a total of 10 tDCS sessions.~tDCS will be administered with a constant current regulator (NeuroConn DC-Stimulator Plus®, Germany) using 2 saline-soaked sponge electrodes applied over the scalp. Using the 10-20 international EEG system for tDCS electrode placement, the anode will be positioned midway between F3 and Fp1 (left DLPFC) and the cathode midway between T3 and P3 (left TPJ)."
89094039|NCT04222582|Sham Comparator|Sham tDCS|Administration of 2mA tDCS for 30 seconds followed by 19.5 minutes of no current via two scalp electrodes for 20 min (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.
89094040|NCT04222582|Other|Open-label Active tDCS|Subjects who have received sham tDCS will be given the option to subsequently receive 10 sessions of open-label active tDCS (2X/day for 5 consecutive days) with >3 hours interval between sessions, for a total of 10 tDCS sessions.
89094041|NCT04222582|No Intervention|Healthy Control|Healthy volunteers will complete the same questionnaires, EEG recording procedures, and neuroimaging scans as the schizophrenia patient group, but will not undergo tDCS.
89094042|NCT04119739|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
89094043|NCT04119739|Active Comparator|Ibuprofen|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
89094044|NCT04119739|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
89094045|NCT00625235|Other|1|High Carbohydrate diet
89094046|NCT00625235|Other|2|High Protein diet
89094047|NCT04206098||Sex|Male/Female
89094048|NCT02763514|Active Comparator|DHA-enriched oil|3 g PronovaPure 150:500 EE EU
89094049|NCT02763514|Active Comparator|EPA-enriched oil|3 g PronovaPure 500:200 EE EU
89094050|NCT02763514|Placebo Comparator|Placebo|3 g Olive oil
89094051|NCT00859573|Active Comparator|1. Modafinil|
89094052|NCT00859573|Placebo Comparator|2: Placebo|Placebo
89094053|NCT04312295|Experimental|ACP-SCT program|The ACP simulation-based communication training (ACP-SCT)program was designed 12 hours (4hours/week) workshop for nephrology nurses.
89094054|NCT04312295|No Intervention|Without ACP-SCT program|The control group only gives the ACP simulation-based communication training program handbook.
89094055|NCT02887118||Common arm|Children with sickle cell anemia will be included. Blood samples of all the included patients will be collected during a day-hospitalization for a planned chek-up. For all these patients the number of dense erythrocytes will be evaluated
89094056|NCT02760940|Experimental|Oral liposomal iron treatment|Oral liposomal iron - 28 mg per day over 8 weeks
89094057|NCT01136291|Other|physical exercise|exercise on obese and overweight pregnant women, routine prenatal care and nutritional counseling
89094058|NCT01136291|No Intervention|no exercise|Routine prenatal care and nutritional counseling. No exercise
89094059|NCT02763280|Experimental|Ginseng extract 1g|Ginseng extract 1g
89094060|NCT02763280|Experimental|Ginseng extract 3g|Ginseng extract 3g
89094061|NCT02763280|Placebo Comparator|Placebo|Placebo
89094062|NCT02758444|Active Comparator|Micronutrient Powder (MNP) + 15 mg Zn|1 sachet of Micronutrient Powder (MNP) + 15 mg Zn will be added to a single meal on study day 8
89094063|NCT02758444|Active Comparator|MNP + 10 mg Zn|1 sachet of MNP + 10 mg Zn will be added to a single meal on study day 8
89094064|NCT02758444|Active Comparator|MNP + 5 mg Zn|1 sachet of MNP + 5 mg Zn will be added to a single meal on study day 8
89094065|NCT02758444|Placebo Comparator|MNP without Zn|1 sachet of MNP without Zn will be added to a single meal on study day 8
89226849|NCT02415621|Other|Abiraterone Acetate Therapy|Study schedule involves stopping FDA Approved abiraterone after participants achieve a good PSA response (50% or more decline of pre-abiraterone PSA) and then restarting abiraterone after their PSA reaches the level of pre-abiraterone PSA.
89226850|NCT02414789|Experimental|SRM / MS-MS|
89226851|NCT02407405|Experimental|1|Selumetinib 50 mg BID daily
89226852|NCT02401685|Experimental|Adjuvant therapy alone|Women in this arm will have adjuvant therapy but no treatment to their armpit after surgery. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
89226853|NCT02401685|Active Comparator|Adjuvant therapy plus axillary treatment|Women in this arm will have adjuvant therapy plus treatment to their armpit after surgery. Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
89226854|NCT02397083|Experimental|Arm I (LIUD)|Patients continue treatment with the LIUD for up to 9 months in the absence of disease progression or unacceptable toxicity.
89226855|NCT02397083|Experimental|Arm II (LIUD, everolimus)|Patients continue treatment with the LIUD and receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
89226856|NCT02396134|Experimental|Arm I (CMVpp65-A*0201 peptide vaccine)|Patients receive CMVpp65-A*0201 peptide vaccine SC on days 28 and 56 after HCT.
89226857|NCT02396134|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC on days 28 and 56 after HCT.
89094066|NCT02760784||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
89094067|NCT02760784||Control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
89094068|NCT01185548|Experimental|Tasisulam and Tolbutamide|"Three study periods and continued access to tasisulam every 28 days (except Period 1 which was tolbutamide only and lasted 4 days) until disease progression:~Period 1: 500 milligram (mg) tolbutamide administered on Day 1.~Period 2: 500 mg of tolbutamide and individualized tasisulam dose [based on area under the curve albumin-corrected threshold (AUCalb)]. The AUCalb is a surrogate marker for unbound tasisulam, and this dosing approach represents the maximum level of unbound tasisulam which may be achieved clinically, administered on Day 1.~Period 3: Individualized tasisulam dose (based on AUCalb) administered on Day 1 and 500 mg tolbutamide administered on Day 4."
89094069|NCT01128569|Placebo Comparator|Placebo|Placebo Inhaler
89094070|NCT01128569|Active Comparator|inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)|ICS/LABA inhaler
89094071|NCT01128569|Active Comparator|ICS|ICS inhaler
89094072|NCT02696044|Experimental|Participants aged 0 months to 3 years|Participants will receive 4 grams of triheptanoin per kilogram of body weight daily.
89094073|NCT02696044|Experimental|Participants aged 4 to 6 years|Participants will receive 3 grams of triheptanoin per kilogram of body weight daily.
89094074|NCT02696044|Experimental|Participants aged 7 to 9 years|Participants will receive 2.5 grams of triheptanoin per kilogram of body weight daily.
89094075|NCT02696044|Experimental|Participants aged 10 to 14 years|Participants will receive 2 grams of triheptanoin per kilogram of body weight daily.
89094076|NCT02696044|Experimental|Participants aged 15 to 20 years|Participants will receive 1.5 grams of triheptanoin per kilogram of body weight daily.
89094077|NCT02696044|Experimental|Participants aged 21 years and older|Participants will receive 1.2 grams of triheptanoin per kilogram of body weight daily.
89094078|NCT04582942|Placebo Comparator|PEG (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will only be PEG.
89094079|NCT04582942|Experimental|PEG+lactulose (low-risk patients and high-risk patients)|The dosing regimen of low-risk patients and high-risk patients will be PEG combined with lactulose.
89094080|NCT02883179|Active Comparator|lidocaine injection|5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to avoid intravascular injection.
89094081|NCT02883179|Experimental|lidocaine-prilocaine cream|5-g dose of Lidocaine-prilocaine cream will be applied to the intact tissue around each tear for 5 minutes before suturing
89094082|NCT02758366|Experimental|Doxorubicin|"Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.~At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)~At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).~At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).~Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day."
89094083|NCT05125601||Patients with bilateral deafness|Patients aged 2 to 10 years with bilateral deafness, wearing an amplifier device and / or a cochlear implant.
89094084|NCT00637403|Active Comparator|I|Megestrol acetate concentrated suspension in subjects with normal renal function
89094085|NCT00637403|Experimental|II|Megestrol acetate concentrated suspension in subjects with mild renal impairment
89094086|NCT00637403|Experimental|III|Megestrol acetate concentrated suspension in subjects with moderate renal impairment
89094087|NCT00637403|Experimental|IV|Megestrol acetate concentrated suspension in subjects with severe renal impairment
89094088|NCT00637403|Experimental|V|Megestrol acetate concentrated suspension in subjects with end stage renal disease
89094089|NCT02758288||New Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a new treatment protocol, prospective data collection approach
89094090|NCT02758288||Standard Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a traditional standard of care protocol, retrospective data collection approach
89094091|NCT01128413|Experimental|Fluid Optimization (FO)|"Cheetah NICOM® (non-invasive cardiac output monitoring) Passive Leg Raise Testing (PLRT) that demonstrates a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) will receive a 500ml normal saline bolus. NICOM® PLRT with SVI or CI <15% will receive a saline lock. If bolused, NICOM® PLRT will be performed within 10 minutes after the bolus with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements. If saline locked, NICOM® PLRT will be performed every 30 minutes with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements.~Additionally, USCOM®, IVC Ultrasound collapsibility, CURVES Questionnaire, and repeat lactate measurements will be performed."
89094092|NCT01128413|Active Comparator|Routine Care (RC)|Patients randomized to receive routine ED care will receive IV fluid administration per the treating clinicians discretion. The Cheetah NICOM®PLRT, USCOM®, IVC Ultrasound collapsibility, and CURVES Questionnaire will be performed and repeat lactate measurements will only be revealed to the routine care arm if they are used as part of the provider's routine care.
89094093|NCT02760628|Experimental|The First Twenty (TF20)|Participants in TF20 will be provided an online wellness program focused on fitness and nutrition tailored to firefighters. TF20 is interactive and involves health coaching.
89226858|NCT02393924||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
89226859|NCT02393859|Active Comparator|High Risk Consolidation 3 (HC3) Chemotherapy|One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m^2/day intravenous [IV] on Days 1-6), vincrisitne (1.5 mg/m^2/day IV on Days 1 and 6), daunorubicin (30 mg/m^2 IV over 24 hours on Day 5), methotrexate (1 g/m^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m^2 IV for 1 hour on Days 2-4), and pegylated [PEG]-asparaginase (1000 U/m^2 IV for 2 hours or intramuscularly [IM] on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m^2 IV or IM every 48 hours for a total of 6 doses).
89226860|NCT02393859|Experimental|Blinatumomab|15 μg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
89226861|NCT02391324|Experimental|Lokomat (LOK)|Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
89226862|NCT02391324|Experimental|Gait focused physical therapy (fPT)|Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
89226863|NCT02391324|Experimental|LOK + fPT|Two 50-minute sessions per week. Children will receive both the LOK and the fPT protocols (content as described above for each) for the duration of the 8 to 10 week intervention phase. These will be given as two sessions of LOK one week alternating with two sessions of fPT the next week. The fPT will build on motor learning principles because the activities will allow the child to practice motor skills in a variety of different activities. Techniques focusing on body structure changes will be prohibited.
89226864|NCT02391324|No Intervention|Maintenance therapy|Consists of maintenance therapy and a weekly email from the centre's research assistant to monitor any co-interventions. Maintenance may include range of motion/stretching and basic isometric strength home program as well as up to 10 minutes per day of exercise bicycle or treadmill or general walking practice.
89226865|NCT02379429||1/Participants|Adults with biopsy-proven or suspected urothelial cancer who require diagnostic or therapeutic intervention
89226866|NCT02379429||2/Healthy Volunteers|Healthy volunteers from whom blood, saliva and urine samples are easily obtainable.
89226867|NCT02365766|Experimental|Arm A - Phase 1b Dose Finding Cohort:|Cisplatin-eligible subjects will receive pembrolizumab at starting dose of 200mg (dose level 0), and/or 120mg (dose level -1) in combination with gemcitabine and cisplatin. The MTD will be the highest pembrolizumab dose level in combination with gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Once the MTD is established, this portion of the study will close and the phase II will open to cohorts I and II at the recommended phase II dose (RP2D).
89226868|NCT02365766|Experimental|Arm B - Phase II Cohort I:|Cisplatin-eligible subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days) . Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. Note: the last dose of pembrolizumab falls on what would be day 8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
89226869|NCT02365766|Experimental|Arm C - Phase II Cohort II:|Cisplatin-ineligible subjects receive gemcitabine every week every 28 days for 3 cycles. Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. NOTE: due to the timing of gemcitabine cycles every 4 weeks, and every 3-week dosing of pembrolizumab, there are two doses of pembrolizumab given during cycle 2: D1 and D22. Additionally, the last dose of pembrolizumab falls on what would be D8 of a 4th 'chemo' cycle; however gemcitabine is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
89226870|NCT02216032|Experimental|Treatment Group|We will deliver the TMW Curriculum to 106 Treatment families. The TMW Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.
89226871|NCT02216032|Other|Control Group|We will deliver a Nutrition Curriculum to 100 Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.
89226872|NCT02205034|Active Comparator|first arm|4IU of oxytocin every other day
89226873|NCT02205034|Active Comparator|second arm|4 IU of oxytocin daily
89226874|NCT02205034|Active Comparator|third arm|4 IU of oxytocin twice daily
89226875|NCT02192021|Experimental|Micro needle array-Doxorubicin (MNA-D)|MNA-D application for all subjects
89226876|NCT02158208||Patients with HD|
89226877|NCT02158208||Controls|
89226880|NCT02115503||Cohort 1|Cohort 1 will consist of those having primarily Class I antibody development post-transplant
89226881|NCT02115503||Cohort 2|Cohort 2 will include those having primarily Class II antibody development post-transplant
89226882|NCT02115503||Cohort 3|Cohort 3 will consist of the remaining subjects that have a mix of Class I and II antibodies.
89226883|NCT02103140|Experimental|Facility-Based Exercise Intervention|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
89226884|NCT02103140|No Intervention|Control|After baseline testing, the control group will be asked to maintain their current daily activities and exercise habits for the duration of the study (6 months). The control group will have measurements at the same time periods as the participants in the intervention arm through the completion of the study. Participants will be seen for follow-up at 3 and 6 months (study completion). The participants in the control group will receive the same incentives as those in the intervention arms (gift cards). Since the women in the control group are obese, with components of metabolic syndrome, and at relatively high risk for breast cancer, we are providing healthy lifestyle information to the group, via text messages.
89226885|NCT02103140|Experimental|Home-Based Exercise Intervention|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
89226886|NCT02085772|Experimental|Patients with pre-conceptional obesity|
89226887|NCT02080741|Other|Type A behaviour profile|
89226888|NCT02080741|Other|Type B behaviour profile|
89226889|NCT02077335|Experimental|HDR brachytherapy monotherapy|Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.
89226890|NCT02048189|Other|Intensified multiple injections|
89226891|NCT02048189|Other|Pumps|
89226892|NCT02045563||Patients with type-1 diabetes|
89226893|NCT02045563||Patients with type-2 diabetes|
89226894|NCT02045563||Volontaires sains|
89226895|NCT02042573|Other|Depressive patients treated with rTMS|
89226896|NCT02042573|Other|Depressive patients treated with SSRI|
89226897|NCT02042573|Other|Controls|
89226898|NCT02019849||Plasmafit® Total Hip Arthroplasty|
89226899|NCT02016924|Experimental|Cohort 1: Part A and Part B|Participants ages 12 to <18 years old will receive cobicistat 150 mg with either ATV or DRV plus background regimen (BR). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
89226900|NCT02016924|Experimental|Cohort 2 (Group 1)|"After Protocol Amendment 9, Cohort 2 weight range will be modified to ≥ 25 to < 40 kg.~Group 1 will be the current weight/age range for Cohort 2, participants aged 6 to <12 years old and ≥ 25 to < 35 kg. They will receive cobicistat (co) 150 mg and emtricitabine/tenofovir alafenamide (F/TAF) 20/25 mg with either ATV or DRV."
89226901|NCT02016924|Experimental|Cohort 2 (Group 2)|"After Protocol Amendment 9, Cohort 2 weight range will be modified to ≥ 25 to < 40 kg.~Group 2 will be the new weight range for Cohort 2, participants aged 6 to <12 years old and ≥ 35 to < 40 kg. They will receive cobicistat (co) 150 mg and emtricitabine/tenofovir alafenamide (F/TAF) 20/25 mg with DRV"
89226902|NCT02016924|Experimental|Cohort 3|Participants ages ≥ 2 years old will receive cobicistat 90 mg and F/TAF 120/15 mg with either ATV or DRV.
89226903|NCT02016924|Experimental|Cohort 4 (Group 1)|Participants age ≥ 4 weeks old weighing 14 to < 25 kg will receive cobicistat tablet for oral suspension (TOS) 90 mg, once daily and F/TAF TOS 120/15 mg, once daily with either ATV or DRV or lopinavir boosted by ritonavir (LPV/r). Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, minimum age and weight for DRV is ≥ 3 years and ≥ 15 kg; participants receiving LPV/r will not receive cobicistat TOS.
89226904|NCT02016924|Experimental|Cohort 4 (Group 2)|Participants age ≥ 4 weeks old weighing 10 to < 14 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 60/7.5 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
89226905|NCT02016924|Experimental|Cohort 4 (Group 3)|Participants age ≥ 4 weeks old weighing 6 to < 10 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 30/3.75 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
89226906|NCT02016924|Experimental|Cohort 4 (Group 4)|Participants age ≥ 4 weeks old weighing 3 to < 6 kg will receive cobicistat TOS 30 mg (twice daily) and F/TAF TOS 15/1.88 mg, once daily with either ATV or LPV/r. Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, respectively; participants receiving LPV/r will not receive cobicistat TOS.
88812620|NCT01436279|Experimental|Mifepristone + misoprostol|Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
89226907|NCT02016924|Experimental|Cohort 5 (Group 1)|Participants ages ≥ 4 weeks old weighing ≥ 10 to < 14 kg will receive F/TAF TOS 60/7.5 mg, once daily with the third unboosted drug.
89226908|NCT02016924|Experimental|Cohort 5 (Group 2)|Participants ages ≥ 4 weeks old weighing ≥ 6 to < 10 kg will receive F/TAF TOS 30/3.75 mg, once daily with the third unboosted drug.
89226909|NCT02016924|Experimental|Cohort 5 (Group 3)|Participants ages ≥ 4 weeks old weighing ≥ 3 to < 6 kg will receive F/TAF TOS 15/1.88 mg, once daily with the third unboosted drug.
89226910|NCT02004028|Experimental|VS-6063 (defactinib)|Administered orally (BID) for 12, 21 or 35 days (+/- 2 days)
89226911|NCT01950975|Other|Parents|2 parents of child
89226912|NCT01950975|Other|infant|
89226913|NCT01950754|Other|depressive patients|
89226914|NCT01950754|Other|nondepressed controls|
89226915|NCT01921062|No Intervention|Control|Patients allocated to the control group only receive standard treatment.
89226916|NCT01921062|Experimental|Motor imagery|Patients allocated to this arm perform kinesthetic motor imagery during the immobilisation period.
89226917|NCT01911195|Active Comparator|Control Group: Cognitive Testing|Control arm will receive cognitive testing only without undergoing general anesthesia
89226918|NCT01911195|Experimental|ISOFLURANE- Experimental Arm|Experimental arm will receive cognitive testing before and after general anesthesia
89226919|NCT01909102|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
89226920|NCT01909102|Active Comparator|Usual care|Usual care is based on current guidelines for the long-term multi-disciplinary rehabilitation and prevention of cardiac patients.
89226921|NCT01907425|Other|Pre-natal Patient|
89226922|NCT01785641|Experimental|ceftazidime+ciprofloxacin|2 synergistic antibiotics(ceftazidime IP and ciprofloxacin po for gram negative bacterial peritonitis)
89226923|NCT01785641|Active Comparator|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
89226924|NCT01785641|Experimental|cefazolin+gentamicin|cefazolin IP and gentamicin IP for gram positive bacterial peritonitis
89226925|NCT01785641|Active Comparator|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
89226926|NCT01772771||Ancillary-correlative (biospecimen collection, chart review)|Patients' previously collected tissue samples are analyzed. Patients may also undergo collection of blood, saliva or buccal samples for analysis. Patients' medical records are reviewed.
89226927|NCT01760226|Experimental|DA-EPOCH-R for DLBCL, PTLD & PMBCL|"Minimum of 6 cycles (cycle=3 weeks), possibly 8. Dosages of the drugs will be determined by the subject's weight and height for cycle 1. Thereafter, the dosages of some drugs will be adjusted up or down for the next cycle, dependent on the blood tests results.~DA-EPOCH-R for 2 cycles then two more cycles of DA-EPOCH-R. If complete response (CR), then DA-EPOCH-R for more 2 cycles. If no CR, DA-EPOCH-R for 4 more cycles."
89226928|NCT01712490|Experimental|A + AVD|A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
89226929|NCT01712490|Active Comparator|ABVD|ABVD consists of doxorubicin 25 mg/m^2, bleomycin 10 units per square meter (units/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
89226930|NCT01698840|Experimental|Investigational Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Investigational Nutrition group will receive vitamin D drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
89226931|NCT01698840|Placebo Comparator|Routine Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Routine Nutrition group will receive placebo drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
89226932|NCT01592968|Experimental|Arm I (SRS)|Patients undergo SRS on day 1.
89226933|NCT01592968|Experimental|Arm II (WBRT)|Patients undergo WBRT 5 days per week (7 days per week for inpatients) for 2 weeks.
89226934|NCT01563731|Other|SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l|Highest SBP target. Higher LDL-C target. Control arm
89226935|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l|"Intermediate SBP target. Higher LDL-C target~."
89226936|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l|Lowest SBP target. Higher LDL-C target
89226937|NCT01563731|Active Comparator|SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l|Highest SBP target. Lower LDL-C target.
89226938|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l|Intermediate SBP target. Lower LDL-C target.
89226939|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C < 1.8 mmol/l|Lowest SBP target. Lower LDL-C target.
89226940|NCT01525966|Experimental|Treatment (carboplatin and nab-paclitaxel)|Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once weekly. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89094094|NCT02760628|Placebo Comparator|Life Simple Seven (LS7)|Participants assigned to the LS7 arm will be directed to a website that contains information about health and wellness from the American Heart Association that was developed for the general population. No health coaching is present and the site is not tailored for the fire service.
89094095|NCT01185080|Experimental|1. AZD8848|20 μg AZD8848 three times weekly
89094096|NCT01185080|Placebo Comparator|2. Placebo|Placebo three times weekly
89094097|NCT01185080|Experimental|3. AZD8848 and placebo|60 μg AZD8848 once weekly and placebo twice weekly
89094098|NCT00625313|Experimental|HMY Model YA-60BB IOL|Patients receiving a Hoya HMY Acrylic Foldable Intraocular Lens.
89094099|NCT02882399|Experimental|Shortystrap|
89094100|NCT04498156||CKD-Patients|Cohort consisting of adult patients with a known diagnosis of type 2 diabetes and evidence of chronic kidney disease (CKD)
89094101|NCT04498156||Physicians treating CKD|Cohort consisting of licensed general practitioners, endocrinologists and nephrologists who are currently treating patients with both chronic kidney disease (CKD) and type 2 diabetes
89094102|NCT02760550||never smokers|who have never smoked at all
89094103|NCT02760550||ex-smokers|formerly smokers but currently do not smoke at all
89094104|NCT02760550||current smokers|current smokers who, at the time of the survey, smoke any tobacco product either daily or occasionally. Social smokers fall into this category and are defined as those who smoke less than one cigarette per week or smoke only in some occasions
89094105|NCT01128179|Experimental|Lanthanum carbonate|
89094106|NCT01128179|Placebo Comparator|Placebo|
89094107|NCT02883257|Experimental|Cognitive Behavioral Therapy|"20 individual 60-minute appointments over the course of 16 weeks~Consistent with Beck, Rush, Shaw, and Emery (1979)"
89094108|NCT01181102|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
89094109|NCT01181102|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg (=2000IU) 0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
89094110|NCT02757820|Active Comparator|LMA classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
89094111|NCT02757820|Active Comparator|I-gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
89094112|NCT02757820|Active Comparator|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
89094113|NCT00858637|Experimental|1 MCI-196|
89094114|NCT00858637|Placebo Comparator|2 Placebo of MCI-196|
89094115|NCT00858637|Active Comparator|3 Simvastatin|
89094116|NCT00858637|Placebo Comparator|4 Placebo of Simvastatin|
89094117|NCT04221646|Experimental|Thighs circumference reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied simultaneously.
89094118|NCT04221646|Experimental|Saddlebags fat thickness reduction|The subjects will be enrolled and treated once per week. Both legs will be treated consecutively. The therapy will be applied consecutively too.
89094119|NCT02760394|Active Comparator|Treated group|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
89094120|NCT02760394|Other|Control group|Following 2 months of follow up the group will be crossed over to receive the same treatment as the treated group
89094121|NCT04221334|Active Comparator|Experimental Toothbrush 1|1. A connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
89094122|NCT04221334|Active Comparator|Experimental Toothbrush 2|2. A non-connected power toothbrush; brushed twice daily (morning and evening) for two (2) minutes, with Colgate Cavity Protection Toothpaste; Oral.
89094123|NCT00699439|Active Comparator|A|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the paper-based flow-chart will be printed out to place on the chart.
89094124|NCT00699439|No Intervention|B|If a patient is identified as having an asthma exacerbation by the Bayesian Network, and assigned to the control group, no flow-chart will be printed out.
89094125|NCT02760316|Experimental|AZD9567 oral suspension of 10 mg|Participants will receive oral supension of 10 mg dose strength
89094126|NCT02760316|Experimental|AZD9567 oral suspension of 20 mg|Participants will receive oral suspension of 20 mg dose strength
89094127|NCT02760316|Experimental|AZD9567 oral suspension of 40 mg|Participants will receive oral suspension of 40 mg dose strength
89094128|NCT02760316|Experimental|AZD9567 oral suspension of 80 mg|Participants will receive oral suspension of 80mg dose strength
89094129|NCT02760316|Active Comparator|Prednisolone oral capsules of 20 mg|Participants will receive oral capsules of 5 mg dose strength
89094130|NCT02760316|Experimental|AZD9567 oral suspension of 125 mg|Participants will receive oral suspension of 125 mg dose strength
89094131|NCT02760316|Experimental|AZD9567 oral suspension of 155 mg|Participants will receive oral suspension of 155 mg dose strength
89094132|NCT02760316|Active Comparator|Prednisolone oral capsules of 5 mg|Participants will receive oral capsules of 5 mg dose strength
89094133|NCT02760316|Active Comparator|Prednisolone oral capsules of 40 mg|Participants will receive oral capsules of 5 mg dose strength
89094134|NCT00858403|Experimental|Treatment with Dasatinib|Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing. This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.
89094135|NCT02760472|Active Comparator|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
89094136|NCT02760472|Experimental|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
89094137|NCT00858247|Experimental|Vitamin D3-low dose|Vitamin D3 400 IU capsule, one capsule daily for 12 weeks.
89094138|NCT00858247|Experimental|Vitamin D3-high dose|Vitamin D3 2000 IU capsule, one capsule daily for 12 weeks.
89094139|NCT04222348|Experimental|Metformin|850-2550 mg every 24h.
89094140|NCT04222348|Active Comparator|Insulin Detemir|Individual doses according to glycemic controls.
89094141|NCT04222114|Experimental|Catumaxomab group|
89094142|NCT04222114|Active Comparator|IC group|IC group is defined as the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
89094143|NCT02757976|Active Comparator|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging
89094144|NCT02757976|Experimental|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
89094145|NCT00838435|Experimental|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
89094146|NCT02760160|Other|Reconstituted grape powder|Open grape powder pouch and pour contents into volumetric measuring device. Add approximately 180 mL of water to container with grape powder. Stir for a minimum of 30 seconds and ingest.
89094147|NCT02757664|Active Comparator|Shock wave plus eccentric exercises|Shock wave therapy associated with eccentric exercises rehabilitation program.
89094148|NCT02757664|Placebo Comparator|Placebo plus eccentric exercises|Placebo associated with eccentric exercises rehabilitation program.
89094149|NCT02757742||Non-ischemic cardiomyopathy|Non-ischemic cardiomyopathy patients with baseline cardiac magnetic resonance LVEF≤35%
89094150|NCT02757508|Active Comparator|Control|Vitamins/minerals-200 mg premix
89094151|NCT02757508|Experimental|Group 1|Vitamins/minerals + Milk Protein (8.75 g)-the milk protein is a skim milk powder with the sugar lactose.
89094152|NCT02757508|Experimental|Group 2|Vitamins/minerals + Milk/plant Protein (8.75g)-the milk protein is a skim milk protein powder and the plant protein is a rice protein concentrate and the sugar lactose.
89094153|NCT02757508|Experimental|Group 3|Vitamins/minerals + Milk Protein (4.38g)-the milk protein is a skim milk protein powder with the sugar lactose.
89094154|NCT02760082||Semi-structured interviews|20 participants (anticipated)
89094155|NCT02760082||Questionnaire survey|400 respondents (anticipated)
89094156|NCT02760082||Focus group interviews|3-5 focus group interviews (anticipated)
89094157|NCT04435678|Other|birch pollen allergy|"106 patients with suspicion of birch pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
89094158|NCT04435678|Other|grass pollen allergy|"106 patients with suspicion of grass pollen allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
89094159|NCT04435678|Other|house dust mite allergy|"148 patients with suspicion of house dust mite allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)"
89094160|NCT04435678|Other|cat allergy|"106 patients with suspicion of cat allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and a skin prick test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
89094161|NCT04435678|Other|bee venom allergy|"106 patients with suspicion of bee venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
89094162|NCT04435678|Other|vespid venom allergy|"106 patients with suspicion of vespid venom allergy will be included in the study. For routine diagnosis, blood samples will be taken to determine total IgE and specific IgE and an intradermal test will be performed.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
89094163|NCT04435678|Other|non-allergic individuals|"148 non-allergic individuals will be included in the study. They should have no symptoms that could be related to inhalant allergy or Hymenoptera venom allergy, negative skin test results and undetectable IgE levels.~Left over blood samples will be used to perform the additional allergy test (ALEX² test using the MAX 45k automated laboratory system)."
89094164|NCT02759848||with history of TB|
89094165|NCT02759848||without history of TB|
89094166|NCT02757196|Experimental|Rituximab plus methylprednisolone|Combination therapy with rituximab （1000mg IV day1, week 3, week 17 , and week 19）plus short-term methylprednisolone (1mg/kg, oral or IV; reduce to 50% of base dose at week 4, then reduce 8mg every 1 week until stopped).
89094167|NCT02757196|Active Comparator|Methylprednisolone|standard dose methylprednisolone alone (1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks).
89094168|NCT04403698|Experimental|24 weeks|Subject receiving alendronate treatment for 24 weeks (n = 20)
89094169|NCT04403698|Experimental|48 weeks|Subject receiving alendronate treatment for 48 weeks (n = 20)
89094170|NCT02759770||ARDS|ARDS patients after cardiac surgery
89094171|NCT02759770||non-ARDS|non-ARDS patients after cardiac surgery
89094172|NCT02759770||propective group|patients of cardiac surgery including ARDS and non-ARDS patients
89094173|NCT02759926|Active Comparator|Denatonium benzoate intragastric|1 µmol/kg bodyweight (10mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
89094174|NCT02759926|Active Comparator|Quinine hydrochloride intragastric|10 µmol/kg bodyweight (100mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
89094175|NCT02759926|Placebo Comparator|Tap water intragastric|An equal amount of tap water was administered as a bolus into the stomach through a nasogastric feeding tube.
89094176|NCT02759926|Active Comparator|Denatonium benzoate intraduodenal|1 µmol/kg bodyweight (10mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
89094177|NCT02759926|Active Comparator|Quinine hydrochloride intraduodenal|10 µmol/kg bodyweight (100mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
89094178|NCT02759926|Placebo Comparator|Tap water intraduodenal|An equal amount of tap water was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
89094179|NCT02759536|Experimental|Boronophenylalanine and IHNI-based BNCT|
89094180|NCT04221256|Experimental|Administration of SSRI|Participants will be administered either 5, 10 or 20mg of SSRI escitalopram prior to paired associative stimulation.
89094181|NCT04221256|Placebo Comparator|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
89094182|NCT00838201|Experimental|Arm 1|
89094183|NCT02695888|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
89094184|NCT02695888|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
89094185|NCT02757118|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
89094186|NCT02757118|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
89094187|NCT00837967|Experimental|First Symbicort, then Terbutaline|Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
89094188|NCT00837967|Experimental|First Turbuhaler, then Symbicort|Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,
89094189|NCT02759614|Experimental|Bevacizumab and Erlotinib|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
89094190|NCT02759614|Active Comparator|Erlotinib|Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
89094191|NCT02757040|Experimental|Ibrutinib combined with As2O3|Ibrutinib combined with As2O3
89094192|NCT02757040|Active Comparator|Ibrutinib|Ibrutinib only
89094193|NCT00635440|Active Comparator|A|
89094194|NCT00635440|Sham Comparator|B|
89094195|NCT02756884|Experimental|LoFU and aADSC|Low Frequency Ultrasound LFUS will be delivered in a non-sterile manner using a custom modified LFUS combined imaging/therapy probe. Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area after the administration of the low frequency ultrasound
89094196|NCT02756884|Active Comparator|Adipose Derived Stem Cells|Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area without the administration of the low frequency ultrasound
89094197|NCT02759224|Other|Arm A (Lafutidine and Irsogladine maleate --> BRI-1501)|Subjects of Arm A take Lafutidine and Irsogladine maleate Individual tablets at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm A take a BRI-1501 tablet at 36th day
89094198|NCT02759224|Other|Arm B (BRI-1501 --> Lafutidine and Irsogladine maleate)|Subjects of Arm B take a BRI-1501 tablet at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm B take Lafutidine and Irsogladine maleate Individual tablets at 36th day
89094199|NCT02756806|Experimental|Picosecond Q-switched Laser|Treatment with investigational wavelengths of the Cutera enlighten laser for tattoo removal.
89094200|NCT02756728|Active Comparator|HDM+ASCT|Standard of care; High dose Melphalan + Autologous Stem Cell Transplantation
89094201|NCT02756728|Experimental|BI-505|Biweekly infusions of BI-505 in addition to High dose Melphalan + Autologous Stem Cell Transplantation
89094202|NCT02759068|Experimental|patients behavior|Behavior (motor reaction) to stimuli (sounds and odors)
89094203|NCT02759068|Active Comparator|healthy volunteers behavior|Behavior (motor reaction) to stimuli (sounds and odors)
89094204|NCT00638170|Active Comparator|A|Cranberry juice
89094205|NCT00638170|Placebo Comparator|B|Placebo juice
89094206|NCT02759302||Patients with LGMD2N|Five patients over 18 years old with genetically verified LGMD2N
89094207|NCT00635518|Other|I, Intervention|
89094208|NCT04586920|Experimental|LY3509754 - Part A|Escalating doses of LY3509754 administered orally
89226941|NCT01487928|Experimental|Human Milk Cream Group|For infants randomized to the human milk cream group, the human milk (either mother's own or donor) being provided to the infant will be tested each time a new container is used to prepare feedings. The test will be for the caloric content of the milk using a commercially available device provided for this purpose. If the caloric level falls below 20 kcal/oz for any test, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. The amount added will be calculated to the nearest mL rounding down for 0.1-0.4mL and up for 0.5-0.9 mL to avoid imprecision due to the measuring device used in the nutrition preparation area.
89094209|NCT04586920|Placebo Comparator|Placebo - Part A|Placebo administered orally
89094210|NCT04586920|Experimental|LY3509754 plus Itraconazole - Part B|LY3509754 and Itraconazole administered orally
89094211|NCT04586920|Placebo Comparator|Placebo plus Itraconazole - Part B|Placebo and Itraconazole administered orally
89094212|NCT04586920|Experimental|LY3509754 plus Midazolam - Part C|Multiple doses of LY3509754 administered orally. Some participants will also receive midazolam orally.
89094213|NCT04586920|Placebo Comparator|Placebo plus Midazolam - Part C|Multiple doses of placebo administered orally. Some participants will also receive midazolam orally.
89094214|NCT04586920|Experimental|LY3509754 (Japanese) - Part D|Multiple doses of LY3509754 administered orally to Japanese participants
89094215|NCT04586920|Placebo Comparator|Placebo (Japanese) - Part D|Placebo administered orally to Japanese participants
89094216|NCT02756494||Ischemic Stroke in Young Adults|Patients between 18 and 45 years of age with a first ever ischaemic stroke are eligible for this study from the Department of Beijing Chaoyang Hospital between January 1, 2016 and December 31, 2016. All patients were defined as a sudden loss of global or focal cerebral function that persisted with a probable vascular cause for 24h and confirmed by brain CT or MRI.
89094217|NCT02756494||matched control subjects|The age-, sex-, and time of enrollment-matched control cohort was randomly identified after eliminating the study subjects and those who had been given a diagnosis of any stroke at any time.
89094218|NCT02758990|Experimental|Predictions: BMI vs. Broccoli|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094219|NCT02758990|Experimental|Predictions: BMI vs. Caffeine|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094220|NCT02758990|Experimental|Predictions: BMI vs. Coffee|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094221|NCT02758990|Experimental|Predictions: BMI vs. Spinach|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094222|NCT02758990|Experimental|Predictions: BMI vs. Vitamin A|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094223|NCT02758990|Experimental|Predictions: BMI vs. Vitamin C|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094224|NCT02758990|Experimental|Predictions: Headache vs. Vitamin B6|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094225|NCT02758990|Experimental|Predictions: Headache vs. Vitamin C|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094226|NCT02758990|Experimental|Predictions: Headache vs. Nicotinamide|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094227|NCT02758990|Experimental|Predictions: Headache vs. Axon Eyewear|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094228|NCT02758990|Experimental|Predictions: Rhinitis vs Broccoli|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094229|NCT02758990|Experimental|Predictions: Rhinitis vs Caffeine|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094230|NCT02758990|Experimental|Predictions: Rhinitis vs Chocolate|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094231|NCT02758990|Experimental|Predictions: Rhinitis vs Coffee|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094232|NCT02758990|Experimental|Predictions: Rhinitis vs Vitamin A|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094233|NCT02758990|Experimental|Predictions: Insomnia vs Axon Eyewear|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094234|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin A|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094235|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin E|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094236|NCT02758990|Experimental|Predictions: Insomnia vs Nicotinamide|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094237|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin D3|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094238|NCT02758990|Experimental|Predictions: Joint pain vs Broccoli|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094239|NCT02758990|Experimental|Predictions: Joint pain vs Caffeine|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094240|NCT02758990|Experimental|Predictions: Joint pain vs Coffee|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
88812621|NCT01436279|Active Comparator|Osmotic dilators|Placed 20-24 hours prior to procedure
89094241|NCT02758990|Experimental|Predictions: Joint pain vs Spinach|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
89094242|NCT02756416|Experimental|ASL MRI and MRA|All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.
89094243|NCT02758912|Experimental|arm 1, Cardionat®|oral intake of study drug capsules at a dose of 1 g per day for 3 weeks.
89094244|NCT02758912|Experimental|arm 2, Cardionat®|oral intake of study drug capsules at a dose of 2 g per day for 3 weeks.
89094245|NCT02758756|Active Comparator|Massage|Subjects assigned to Arm 1 will receive two massage treatments approximately two weeks apart.
89094246|NCT02758756|Experimental|Two Reiki Tx|Subjects assigned to Arm 2 will receive two Reiki treatments approximately two weeks apart.
89094247|NCT02758756|Experimental|Four Reiki Tx|Subjects assigned to Arm 3 will receive four Reiki treatments approximately 1 week apart.
89094248|NCT02756104|Other|Volunteers|Healthy People on each collecting blood for phenotyping Tcells
89094249|NCT02756104|Other|Patients with ALS|"Patients with ALS deficient or not in Vitamin D on each collecting blood for phenotyping Tcells.~The patients who are deficient in Vitamin D will have supplementation in vitamin D"
89094250|NCT02755870|Experimental|CNM-Au8|"CNM-Au8 is an orally administered, clean-surface gold nanocrystal suspension drug. It is atomically clean-surface elemental nanocrystals, free of any residual surface chemicals or surface-capping agents.~CNM-Au8 15, 30, 60, 90mg as an oral suspension"
89094251|NCT02755870|Placebo Comparator|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
89094252|NCT02756026|Experimental|Micronutrient supplementation|"On day 3, all mothers are given a commercial multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).~On day 4, all mothers are given two commercial multiple micronutrient supplements (Nutri-Fem) manufactured by Thorne, containing twice the Recommended Dietary Intake (RDA)."
89094253|NCT02755714|No Intervention|No Atrovent ®|NO INTERVENTION: The patient will not receive Ipratropium bromide spray (MDI) 20 μg ,(Atrovent ®) prior to CLE testing
89094254|NCT02755714|Experimental|Atrovent ®|INTERVENTION: Ipratropium bromide spray (MDI) 20 μg (Atrovent ®) prior to CLE testing
89094255|NCT02755792|Experimental|Calligraphy Training|This group receives a Chinese calligraphy training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
89094256|NCT02755792|Active Comparator|iPad Training|This group receives an iPad training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
89094257|NCT02758678||1-patients with operating tumor|"1- 23 patients with operating tumor; In 1 group the specimens of blood will be collected day before surgery and 1-2 month after surgery. Will be collected: histopathology outcomes - type carcinoma, tumore volume and before surgery: morphology and coagulation system. Will be assessed correlation between mentioned above factors and concentration of P-selectin.~Will be compared concentration of P-selectin in 3 groups of patients.~Serum separation and Raman spectroscopy analysis. A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
89094258|NCT02758678||2-patients with advanced desease.|"2- ten patients with advanced and metastatic disease who received palliative RT (RT - radiotherapy);~In 2 group - the specimens of blood we collected before palliative treatment-radiotherapy. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens.The Raman spectra (RS) assessed as above"
89094259|NCT02758678||3-patients with inoperable disease|"In group 3 - the specimens of blood we collected before radical treatment and one month after completion treatment. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned above factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
89094260|NCT02758522|Active Comparator|Once-daily insulin|60% of total dose of insulin as NPH insulin in the once-daily regimen was administered subcutaneously before breakfast. Also, 40% in rapid insulin before meals (every 8 hours).
89094261|NCT02758522|Active Comparator|Twice-daily insulin|60% of total dose of insulin as NPH insulin in the twice-daily regimen it was given before breakfast and before dinner. Also, 40% in rapid insulin before meals (every 8 hours).
89094262|NCT02758522|Active Comparator|Triple-daily insulin|60% of total dose of insulin as NPH insulin in the triple daily regimen it was administered before each meal. Also, 40% in rapid insulin before meals (every 8 hours).
89094263|NCT02758600|Experimental|LVEF < 45%|Patients with left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
89094264|NCT02758600|Experimental|LVEF > 45%|Patients without left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
89094265|NCT00942357|Experimental|Arm I (cisplatin, radiation therapy, paclitaxel, carboplatin)|Patients receive cisplatin IV on days 1 and 29. Patients also undergo radiation therapy QD, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89094266|NCT00942357|Active Comparator|Arm II (paclitaxel and carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89094267|NCT02755402|Experimental|Rapid evaluation|Transient elastography, Xpert HCV Viral load, medical and nurse visits
89094268|NCT02755480|Experimental|ultralow dose research|"An Ultralow Dose Thoracic Computed Tomography scan will be added to the standard of care Low dose CT scan.~The image quality of the ultralow dose CT will be compared to the Low dose thoracic Computed Tomography."
89094269|NCT02755324|Experimental|Intervention|Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae
89094270|NCT02755558|Experimental|Low energy density, small portion|Low milk energy density and small portion size
89094271|NCT02755558|Experimental|Low energy density, large portion|Low milk energy density and large portion size
89094272|NCT02755558|Experimental|High energy density, small portion|High milk energy density and small portion size
89094273|NCT02755558|Experimental|High energy density, large portion|High milk energy density and large portion size
89094274|NCT02752828|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
89094275|NCT02752828|Active Comparator|insulin glargine|"Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
89094276|NCT02755636|Experimental|PCPHC intervention|PCPHC intervention during 6-month intervention period plus study assessments at baseline, 6, and 12 months
89094277|NCT02755636|Active Comparator|Usual care|Usual primary care plus study assessments at baseline, 6, and 12 months
89094278|NCT02753062|Experimental|bendamustine, rituximab|Bendamustine plus subcutaneous Rituximab treatment of 6 cycles. Rituximab 1400mg subcutaneous over 5mins on day 1 and bendamustine 120mg/m2 + NS 500mL iv over 1hour on day 1 and 2.
89094279|NCT02752672||Psoriasis|Psoriasis patients treated with dithranol
89094280|NCT02752672||Non-Psoriasis|Non-Psoriasis patients undergoing surgery for skin lesions. Tumor-adjacent skin is collected for control purposes.
89094281|NCT00939783|Experimental|Dimebon 20 mg TID|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
89094282|NCT02752594|Experimental|probiotic|2 mg of probiotic powder mixed in 10 ml of distilled water
89094283|NCT02752594|Placebo Comparator|placebo|10 ml of distilled water
89094284|NCT02755246|Experimental|Polyamine supplementation|750 mg polyamine-rich plant extract per day
89094285|NCT02755246|Placebo Comparator|Placebo|750 mg potato starch per day
89094286|NCT04220710||Marker selection group|Methalation detection of circulating free DNA and FFPF samples from pathologically confirmed patients with ovarian endometriosis(30 cases), ovarian cancer (30 cases)and other benign ovarian tumors (30 cases)will be performed to select markers for ovarian endometriosis diagnosis.
89094287|NCT04220710||Marker validation group|The selected markers will be validated in patients with ovarian cysts (300 cases )found by ultrasound. The diagnosis accuracy of the markers will be evaluated by comparing with the pathological diagnosis.
89094288|NCT02755168|Other|External Pop-Out Cesarean Section|
89094289|NCT02755168|Other|Classic technique|
88812622|NCT02210195|Active Comparator|Experimental: aprepitant 125 mg/day|125 mg aprepitant daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
89094290|NCT04221100|Placebo Comparator|Control|Participants will review the 500 chest radiographs without the assistance of xrAI
89094291|NCT04221100|Experimental|Treatment|Participants will review the 500 chest radiographs with the assistance of xrAI
89094292|NCT02755012||Longitudinal|155 women enrolled in 2nd or 3rd trimester of pregnancy, and seen again, with their infant, at 0-6 wk postpartum, and 4-6 mo postpartum
89094293|NCT02755012||Early Postpartum|60 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
89094294|NCT02755012||Later Postpartum|56 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
89094295|NCT04289740|Experimental|cognitive-bahavioral therapy|Trasdiagnotic cognitive-behavioral group therapy: The psychological interventions will be manualized. Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period.
89094296|NCT04289740|Active Comparator|relaxation therapy|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
89094297|NCT02754700|Experimental|Biofeedback Hip|Hip focused biofeedback with neuromuscular training
89094298|NCT02754700|Experimental|Biofeedback Knee|Knee focused biofeedback with neuromuscular training
89094299|NCT02754700|Active Comparator|Neuromuscular Training|Neuromuscular Training component
89094300|NCT04220788|Experimental|Enhanced pharmacist service|The advanced care group will be undergo a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA) with the pharmacist
89094301|NCT04220788|Active Comparator|Usual care|Patients in the usual care arm will receive their usual care which they will obtain care from their doctor,nurse and pharmacist where appropriate
89094302|NCT02752360|Experimental|BSA Group|Patients accept the management of Biodegradable Stenting Anastomoses for reconstruction in the surgery of Intestinal Anastomosis
89094303|NCT02752360|Experimental|DHS Group|Patients accept the management of Double-layer Hand Sutures for reconstruction in the surgery of Intestinal Anastomosis
89094304|NCT00635596|Experimental|I|
89094305|NCT04527796||rehabilitation|All included patients get an pre-intervention and a post intervention analysis
89094306|NCT02752204|Other|Stage 1|AZD 2014 oral tablets will be given to patients
89094307|NCT02752204|Other|Stage 2|AZD 2014 oral tablets and rituximab infusion will be given to patients
89094308|NCT04220398|Experimental|NCHT Group|Neoadjuvant chemotherapy combined with hormone therapy, Radical Prostatectomy (RP)+ extended lymph node dissection
89094309|NCT04220398|Active Comparator|NHT Group|Neoadjuvant hormonal therapy, radical Prostatectomy (RP)+ extended lymph node dissection.
89094310|NCT04220398|Other|RP Group|Radical Prostatectomy (RP)+ extended lymph node dissection alone.
89094311|NCT02752126|Active Comparator|Standard Palliative Radiation|Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.
89094312|NCT02752126|Experimental|Esophageal Sparing IMRT|Patients on the experimental arm will receive esophageal-sparing intensity-modulated radiotherapy, with the same dose(s) as in the standard arm.
89094313|NCT04220944|Experimental|Locoregional therapies combined with Anti-PD-1 antibody|Percutaneous microwave ablation combined with simultaneous TACE was performed. Sintilimab will be initiated on day 3-7 after the first locoregional therapies. Sintilimab will be administered every three weeks (200mg fixed dose IV) until disease progression for up to one year.The second locoregional procedure will be repeated according to the enhanced CT images.
89094314|NCT04221022|Active Comparator|Light physical activity (Group 1)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into Light Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
89094315|NCT04221022|Active Comparator|Moderate physical activity (Group 2)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into moderate Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
89094316|NCT04221022|Active Comparator|Vigorous physical activity (Group 3)|Female collegiate students were assessed by using Academic stress scale questionnaire, Cohen Perceived stress Scale and rapid assessment of physical activity (RAPA) to determine physical activity level and academic stress. They were assigned into vigorous Physical activity. Each subject in first group completed 6 weeks of exercise sessions which aimed to cope up academic stress among female collegiate students. Each subject was evaluated for changes in symptoms in each week.
89094317|NCT02754622||Observational Group|"2hours before planned physical rehabilitation patients will have their regular ventilator changed to the study ventilator by an ICU Consultant and patients will be clinical stable for 30mins prior to the start of the planned physical rehabilitation.~Intended physical rehabilitation as planned will continue without change. This session will be observed by a member of the research team to ensure accurate documentation of the exact timing of performance of the physical rehabilitation activity.~Patients will also undergo an assessment by the Medical Research Council Sum-score and maximal inspiratory pressure (all part of routine physiotherapy assessment).~Following the physical rehabilitation session, the patient to rate their perceived exertion then patients will also undergo ultrasound assessment of peripheral skeletal muscle architecture.~Patients return to their original ventilator after 30mins by an ICU Consultant."
89094318|NCT02752516|Experimental|Anlotinib|
89094319|NCT02751892|Experimental|Active Lifestyle Programme|Supervised exercises for 3 months and motivational interviewing to facilitate physical activity behaviour change. Supervised exercise sessions took place twice per week for the first four weeks. This was tapered off to once per week for the second four weeks. During the last month of the intervention participants continued with the exercise at home and were encouraged to achieve 150min of moderate to vigorous PA per week.
89094320|NCT02751892|No Intervention|Standard Care|Received usual care. Was offered the intervention after the completion of the study.
89094321|NCT02754466|Experimental|Deep dentin lesions|Subjective vs objective criteria in selective excavation of carious lesions Group 1: selective carious dentin excavation using subjective criteria (standard protocol in Dentistry) Group 2: selective carious dentin excavation using objective criteria (polymer burs) All restorations performed using high-viscosity glass-ionomer.
89094322|NCT02754466|Experimental|Shallow and medium depth dentin lesion|Glass-ionomer vs Bulk fill composites in the ART approach All cavities excavated using hand-instruments only (ART approach) Group 1: restorations using high-viscosity glass-ionomer Group 2: restorations using self-etch adhesive and bulk fill composite
89094323|NCT02754232|Active Comparator|Telemedical training|Patients in the intervention group will receive telemedical training 21 times, three times weekly for seven weeks. During the first three weeks the regional physiotherapists will be responsible for the training. Municipal occupational -and physiotherapists will manage the last four weeks' training.
89094324|NCT02754232|No Intervention|The usual training or no training|Patients in the control-group will receive no telemedical training. They will be discharged to the municipal sphere with a rehabilitation plan, where they have the possibility to receive training.
89094325|NCT04220632|Experimental|Itacitinib+corticosteroids|Itacitinib administered in combination with corticosteroids
89094326|NCT02751970|Active Comparator|3 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of a primer and subsequently an adhesive resin.
89094327|NCT02751970|Experimental|2 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of an adhesive/primer step.
89094328|NCT02751970|Active Comparator|2 step SE & Dental restoration|Dental restoration with etching the dental substrates with acidic primer, followed by the application of adhesive resin.
89094329|NCT02751970|Experimental|1 step SE & Dental restoration|Dental restoration with etching and infiltrate the dental substrates with acidic primer/adhesive system.
89094330|NCT02752438||Survived|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation and survived.
89094331|NCT02752438||Death|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation but died.
89094332|NCT00939627|Placebo Comparator|Arm I (cetuximab and placebo)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral placebo twice daily on days 1-21.
89094333|NCT00939627|Experimental|Arm II (cetuximab and sorafenib tosylate)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral sorafenib tosylate twice daily on days 1-21.
89094334|NCT02752282|Sham Comparator|Control Video|Participants in this study arm will be assigned to watch a short educational video about new pap screening guidelines for women. Intervention: Cancer Screening Guidelines.
89094335|NCT02752282|Active Comparator|Intervention Video|Participants in this group will be assigned to watch a short educational video providing anticipatory counseling on their LNG-IUS' side effects and expected changes in bleeding. Intervention: Anticipatory Counseling
89094336|NCT05382741|Experimental|DURVALUMAB + REGORAFENIB|"Durvalumab 1500 mg (120-minute IV infusion) every 28 days, Regorafenib 90 mg/die orally once daily for 21 days in a 28-day cycle.~Treatment will be administred up to 1 year."
89094337|NCT05382741|No Intervention|CONTROL ARM|"Observation (follow-up).~Crossover to the experimental arm is allowed in case of relapse."
89094338|NCT05090007||mTBI|A TBI is caused by a bump, blow, or jolt to the head that disrupts the normal function of the brain. Not all blows or jolts to the head result in a TBI.
89094339|NCT05090007||HC|Healthy controls
89094340|NCT02754076|Experimental|AX 250|In Part 1, patients will receive up to 3 escalating doses of AX 250 (30, 100 and 300 mg) via ICV infusion every week until the maximum tolerated tested dose (MTTD) is established. In Part 2, patients will receive weekly doses of AX 250 via ICV infusion that will continue for 48 weeks at the MTTD established in Part 1.
89094341|NCT05381415||Patients with COPD|"Patients with COPD diagnosis (VEMS/FVC after bronchodilatation <0.7) will be enrolled in a stable state of disease, diagnosed from at least 12 months [GOLD].~Each patient will be studied during three visits. In the first visit it will be established the patient eligibility. Furthermore, the patient will be able to familiarize with the experimental procedure. Chronic inhalation therapy will be suspended 24 (long action) and 8 (short action) hours before the second and third visit. If a patient is on tiotropium bromide, it will be required to be suspended 7 days before the visit.~During the second and third visit, which will be scheduled 30 days one from another, the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR or FRC, in a random order. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique."
89094342|NCT04220476|Active Comparator|ARM 1 - Letrozole and Palbociclib|Patients randomized to arm 1 will start standard Letrozole followed by Palbociclib at day 21.
89094343|NCT04220476|Active Comparator|ARM 2 - Letrozole and Palbociclib + I-SBRT|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions.
89094344|NCT00937833|Experimental|Urethrovesical Sling|Surgisis Male Sling placed at the time of prostatectomy
89094345|NCT00937833|Active Comparator|Control|Prostatectomy
89094346|NCT02695810|Experimental|Dapagliflozin|Dapagliflozin, 10 mg per day
89094347|NCT02695810|Active Comparator|Metformin|Metformin, 2 x 850 mg per day
89094348|NCT02695810|Active Comparator|Exercise|Exercise, interval training
89094349|NCT02695810|No Intervention|Control|No intervention
89094350|NCT04204161|Experimental|CAR-T19/CAR-T22|CAR-T19/CAR-T22 (autologous T cells transduced with CD19 / 22 CAR-ζ/4-1BB vector) will be administered to children with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity.
89094351|NCT02753764|No Intervention|Normal control|Health volunteers will be recruited as an additional control group.
89094352|NCT02753764|Other|Corticosteroid sensitive (CS) asthmatics|After the initial visit, asthmatics will be given oral prednisone for 1 week and patients will return for the spirometer assessment. Patients will be defined as CR if <10% improvement in FEV1 % predicted is observed and as CS in >12% improvement in FEV1% predicted is observed.
89094353|NCT02753764|Active Comparator|Corticosteroid resistant (CR) asthmatics active|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
89094354|NCT02753764|Placebo Comparator|Corticosteroid resistant (CR) asthmatics placebo|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
89094355|NCT05382429|Experimental|OWHTO|open wedge high tibial osteotomy group For the open wedge high tibial osteotomy group, Those who were randomly assigned to the OWHTO group, OWHTO Surgical procedure will be performed.
89094356|NCT05382429|Experimental|CWHTO|closing wedge high tibial osteotomy group For the closing wedge high tibial osteotomy group, hose who were randomly assigned to the CWHTO group, CWHTO Surgical procedure will be performed
89094357|NCT02695654||Chronic pain in knee osteoarthritis|Ultrasound guided single shot Adductor canal block with 0,25% Levobupivacaine 14 ml and 100 mcg Clonidine
89094358|NCT02751736|Experimental|Intervention|"2 g sachet (CJLP 243) once a day for 3 weeks~10 billion lactic acid bacteria(lactobacillus plantarum CJLP243), maltodextrin, glucose(anhydrous)"
89094359|NCT02751736|Placebo Comparator|Control|"2g sachet (near identically appearing placebo) once day for 3 weeks~maltodextrin, glucose(anhydrous)"
89094360|NCT02751658|Other|patients in the Otorhinolaryngology|patients in the Otorhinolaryngology department realization of a levy into the mouth swab on the day of admission to hospital and the day of release
89094361|NCT00635674|Experimental|Group I - compliant|CPAP use for more than 4 hr/night
89094362|NCT00635674|Active Comparator|Group 2-noncompliant|CPAP for less than 4 hr/night
89094363|NCT02696122|Experimental|Local Group|Local infiltration under general anesthesia via laryngeal mask
89094364|NCT02696122|Experimental|Spinal Group|Spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine
89094365|NCT02751346||Patients with Pain|Patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
89094366|NCT02751346||Patients without Pain|Patients without pain age and gender matched to patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
89094367|NCT02753608|Sham Comparator|No ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients without clinical signs of VAP
89094368|NCT02753608|Experimental|Ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients displaying clinical signs of VAP
89094369|NCT01135511|Experimental|Treatment 1|
89094370|NCT01135511|Experimental|Treatment 2|
89094371|NCT01135511|Experimental|Treatment 3|
89094372|NCT01135511|Placebo Comparator|Treatment 4|
89094373|NCT01135511|Active Comparator|Treatment 5|
89094374|NCT02753140|Experimental|RT concurrent with cetuximab|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy.To observe the curative effect of the treatment of the cetuximab
89094375|NCT02753140|Experimental|RT concurrent with TP|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy. To observe the curative effect of concurrent radiotherapy and chemotherapy
89094376|NCT02753218|Experimental|Midazolam and LEO 32731|
89094377|NCT02752984||PICC insertion|Peripherally Inserted Central Catheter insertion
89094378|NCT05429554||group 1|patients will be treated with DPP4 inhibitor + metformin
89094379|NCT05429554||control|patients will be treated with metformin without DPP4 inhibitor.
89094380|NCT04220164||Dyslipidemic patients|Patients who meet the criteria of high-risk category according to 2017 Taiwan Lipid Guideline for High-Risk Patients have a abnormal serum LDL-C level
89094381|NCT05429398|Experimental|Linperlisib +Camrelizumab 200mgQ3w|Linperlisib will be administrated orally from 40mgQD, 60mgQD to 80mgQD in sequence during dose excalation part and a selected dose in dose expansion part,for 21 consecutive days as a treatment cycle; Camrelizumab will be administrated intravenously 200mg every 3 weeks in all patients just before the administration of Linperlisib.
89094382|NCT04220086|Experimental|Pediatric massage|Children with ASD will receive pediatric massage for 12 weeks.
89094383|NCT04220086|Sham Comparator|Waitlist control|Waitlist control
89094384|NCT04220086|Other|Healthy Control|15 healthy controls (age- and sex- matched with ASD patients) will be recruited. All of them will receive clinical evaluations, EEG and fNIRS detection.
89094385|NCT05429086|Active Comparator|group remimazolam|"The initial dose of remimazolam was 0.2mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score ≤3), the gastroscopy will begin; If MOAA/S score > 3 point, additional administration of remimazoalm will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was >3 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after gastroscopy: In order to maintain a certain degree of sedation after gastroscopy , the evaluator decides when to administer additional drugs.~remimazolam supplemental administration: the supplemental dose was 2.5 mg , bolus"
89094386|NCT05429086|Active Comparator|group propofol|"The initial dose of propofol was 2mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score ≤3), the gastroscopy will commence. If subjects' MOAA/S score > 3 point, additional administration of propofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was >3 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after gastroscopy: In order to maintain a certain degree of sedation after gastroscopy , the evaluator decides when to administer additional drugs.~Propofol supplemental administration: the supplemental dose was 0.5mg/kg, bolus."
89094387|NCT05429086|Experimental|group remimazolam combined propofol|"The initial dose of remimazolam was 0.1 mg/kg, combined propofol 0.5mg/kg, and the infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score ≤3), the gastroscopy will begin. If subjects' MOAA/S score > 3, additional administration of propofol will be allowed. If the MOAA/S score was >3 after 3 consecutive times of addition, sedation was failure, and the study was recorded and quit. Maintenance of sedation after gastroscopy: In order to maintain a certain degree of sedation after gastroscopy, the evaluator decides when to administer additional drugs.~supplemental administration: the supplemental dose was remimazolam 2.5 mg,single dose, bolus. There is no permission to use propofol , unless the MOAA/S score still > 3 after five consecutive dosing supplement"
89094388|NCT04219930||epileptic children|fifty patient with epilepsy
89094389|NCT04219930||Healthy controls|thirty healthy control
89094390|NCT00638248|Active Comparator|1|Desmoteplase 90µg/kg BW
89094391|NCT00638248|Active Comparator|2|Desmoteplase 125 µg/kg BW
89094392|NCT00638248|Placebo Comparator|3|Placebo
89094393|NCT04219306|Experimental|Machine alert|These cardiac suspected cardiac arrest will have had an alert generated by the machine learning model in addition to standard Emergency Medical Services response.
89094394|NCT04219306|No Intervention|Usual care|These suspected cardiac arrests will receive standard Emergency Medical Services response.
89094395|NCT04219150|Experimental|Electrical cardiometry (EC)|
89094396|NCT04219150|Experimental|"Fluid and Catheter Treatment Trial FACTT Lite"|
89094397|NCT04468204|Experimental|SinuSonic Device|SinuSonic device used for 1 min three times a day for 8 weeks.
89094398|NCT04468204|Sham Comparator|Sham|Sham SinuSonic device used for 1 min three times a day for 8 weeks.
89094399|NCT04219462|Active Comparator|study group|twenty men receive extracorporeal shock wave (ESWT) twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura +sildenafil 5mg once daily for 3 months.
89094400|NCT04219462|Sham Comparator|control group|twenty men will receive sham treatment underwent identical therapy with Extracorporal shock wave therapy (ESWT) application with a similar appearance and sound as the active low intensity extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
89094401|NCT04219852||"bariatric surgery group"|Women between 18 and 50 years, who undergone bariatric surgery at the University Hospital of Reims.
89094402|NCT04219384||Critical-illness related cardiac arrest (CIRCA)|Those experiencing a critical illness-related cardiac arrest in a participating adult, general ICU
89094403|NCT04467736|No Intervention|Control|No further treatment after alveolar ridge preservation
89094404|NCT04467736|Active Comparator|Test|In case the test group comes out, instructions for the daily application of hyaluronic acid (Gengigel Forte©) will be given. Hyaluronic acid will be administered by the patient 3 times per day during 7 days.
89094405|NCT04218994|Experimental|Group A|Subjects instructed on flossing technique.
89094406|NCT04218994|No Intervention|Group B|No instructions for flossing provided. Subjects asked to continue their normal oral hygiene care.
89094407|NCT05428228|Experimental|TP1|Participants will be administered TP1 during one of the experimental visits.
89094408|NCT05428228|Experimental|TP2|Participants will be administered TP2 during one of the experimental visits.
89094409|NCT05428228|Placebo Comparator|Placebo|Participants will be administered placebo during one of the experimental visits.
89094410|NCT04219228||Students in urban counties|All first-grade students in urban counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
89094411|NCT04219228||Students in rural counties|All first-grade students in rural counties will undergo anthropometry and ophthalmic examination, and be required to complete questionnaires and wear wearable devices to collect environmental information and daily activities.
89094412|NCT00624728|Experimental|A|
89094413|NCT01184846|Experimental|IgPro10|10% liquid formulation of human immunoglobulin (IgPro10). IgPro10 will be administered by IV infusion as one induction dose of 2 g/kg body weight (bw), followed by seven 3-weekly maintenance doses of 1 g/kg bw.
89094414|NCT01180400|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
89094415|NCT01180400|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
89094416|NCT04316000||A - Removal of the Subepithelial Tumour|The subephitelial tumour is successfully removed by endoscopic band ligation without resection.
89094417|NCT04316000||B - Non Removal of the Subepithelial Tumour|The subephitelial tumour is not successfully removed due to various reasons (size >15-mm, not technical success,...).
89094418|NCT04316000||C - Not Observed or Benign Subepithelial Tumour|The subephitelial tumour is not observed or is a benign entity, which does not require further interventions for these patients.
89094419|NCT01180244|Active Comparator|Active treatment|Subjects in this group will receive the noninvasive cortical stimulation signal from the treatment device
89094420|NCT01180244|Placebo Comparator|Placebo group|Subjects in this group will be provided the same experience as those in the active treatment arm, but will not receive the noninvasive cortical stimulation signal from the treatment device
89094421|NCT01191086|Experimental|Open-label USL255|Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day
89094422|NCT04316312|Experimental|Inspiratory muscle training group|
89094423|NCT01088412||Treated|Participants treated with somatropin for improvement of growth
89094424|NCT01088412||Untreated|Untreated participants with presence or history of neoplastic disease evaluated for endocrine or growth disorder or with any SHOX deficiency related disorder
89094425|NCT04198714|Experimental|Pudendal block|9cc of 0.25% Marcaine + 1cc of 40mg/mL triamcinolone. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
89094426|NCT04198714|Sham Comparator|Sham injection|10cc normal saline. 5cc will be injected transvaginally in the area of the pudendal nerve on each side.
89094427|NCT00635752|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy (TF-CBT)
89094428|NCT00635752|Active Comparator|2|Participants will receive sessions of treatment as usual (TAU)
89094429|NCT04218916|Experimental|Rhodiola Rosea Capsule|
89094430|NCT04218916|Placebo Comparator|Placebo Capsule|
89094431|NCT05383924|Active Comparator|postplacental IUD (PP-IUD) insertion|patients will have immediate postplacental IUD insertion
89094432|NCT05383924|Active Comparator|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit
89094433|NCT04297098||Asthmatic patients|
89094434|NCT04297098||Allergic patients|
89094435|NCT04297098||Control group|
89094436|NCT04948840|Other|Group A|Patients with early grade ≥2 radio-induced epidermis Intervention : blood sample
89094437|NCT04948840|Other|Group B|Patients with early grade 0-1 radiation-induced epidermis Intervention : blood sample
89094438|NCT04948840|No Intervention|Group C|Patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
89094439|NCT04948840|No Intervention|Group D|Patients without late pathologic radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years) No intervention : Blood sample already collected from another study and patients agree to use their blood sample for another research
89094440|NCT04948840|No Intervention|Group E|Control group : patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes.
89094441|NCT05318560|Active Comparator|Local anesthetic injection|Patients will be injected with lidocaine and given upper trapezius muscle stretching exercises. Lidocaine injection 2cc 2% will be administered to all patients using a 26 gauge, 0.45x13 mm disposable sterile needle to the affected trigger point.
89094442|NCT05318560|Active Comparator|Ozone injection|Ozone injection will be performed on patients and upper trapezius muscle stretching exercises will be given. 8 cc of oxygen/ozone gas at a concentration of 15 µg/mL will be injected into the trigger point.
89226942|NCT01487928|No Intervention|Control Group|For infants randomized to the Control group, human milk and human milk derived fortifier will be provided according to the institutional standard of care and there will be no use of the milk analysis (mother's own or donor), which is typical for the vast majority of neonatal intensive care units.
89094443|NCT05318560|Active Comparator|Stretching exercise|Patients will be given a home program that includes upper trapezius muscle stretching exercises. Upper trapezius stretching exercises will be performed twice a day for at least 15 seconds, ten sets each time, for three weeks, with one hand on the patient's back and the other hand holding the side of the head and tilting it to the side until a slight tension is felt. The exercises will be explained in the text, visual and verbal forms with the exercise form.
89094444|NCT04171258|Experimental|Botulax®|
89094445|NCT04171258|Active Comparator|Botox®|
89094446|NCT04165564||Group 1 - Screening|Participants in this group will be 55-77 years old and currently smoke or were former smokers with 30 pack-years or more (and quit less than 15 years ago)
89094447|NCT04165564||Group 2 - Incidental|Participants in this group will be > 45 years old and currently smoke or were former smokers with 10 pack-years or more (and quit less than 15 years ago)
89094448|NCT05247814||Patients admitted to interdisciplinary polypharmacy consultation service|Patients admitted to the Interdisciplinary Polypharmacy Consultation Service of the Department of Geriatric's University Outpatient Clinic in cooperation with the Institute of Clinical Pharmacology
89094449|NCT02695576|Experimental|Surgery|Lumbar fusion surgery Physiotherapy Cognitive behavioral therapy
89094450|NCT02695576|Active Comparator|Non-surgery|Physiotherapy Cognitive behavioral therapy
89094451|NCT01086384|Experimental|Fluticasone furoate/GW642444|
89094452|NCT01086384|Experimental|fluticasone furoate|
89094453|NCT00635986|Experimental|A|group 1 (n = 14) patients received 5 mL of a 100 mcg Fentanyl solution in saline without preservative by the epidural route and 2 mL saline intravenously. Group 2 (n = 15) patients received 5 mL saline by the epidural route and 2 mL (100 mcg) Fentanyl intravenously
89094454|NCT04866784|Experimental|High Sensation TENS|"Active TENS is delivered for 30mins at a frequency of 100 Hz and pulse duration of 100μsec using the EMPI Select TENS unit (calibrated using an oscilloscope prior to study). The intensity will be increased until patients feel a maximally strong but comfortable sensation to ensure an analgesic effect."
89094455|NCT04866784|Placebo Comparator|Low Sensation TENS|Placebo TENS parameters will be identical to Active TENS (100 Hz and 100 μsec), but a novel placebo TENS unit, previously tested and validated will be used (Rakel et al., 2010). The placebo device provides a current for 30sec and ramps off over 15sec to zero output. An indicator light remains on so it appears to the subject that the unit is still producing current. This unit has demonstrated nearly 100% blinding of investigators such that the investigator applying the TENS is unable to distinguish between the active and the placebo unit; approximately ~50% of subjects are successfully blinded using this unit.
89094456|NCT04866784|No Intervention|No Treatment Control|The No Treatment Control includes application of TENS electrodes identical to the other 2 conditions, but the unit remains off. This condition will control for potential effects of repeat testing and any placebo effect.
89094457|NCT01127633|Experimental|Solanezumab|
89094458|NCT01127633|Placebo Comparator|Placebo|
89094459|NCT04799626||Treatment|The use of antimicrobial agents depends on the clinical practice.
89094460|NCT02751112|Experimental|Couple donor / recipient|"Each couple will be treated the same way :~An additional blood sample of the donor will be taken prior GCSF mobilization. This blood sample will then be analyzed via Predictor's kit, by the immunology laboratory of the hospital where the graft will be done.~Whatever the result given by the Predictor' kit, the graft will be done for the recipient patient. No change will be done on the usual graft process."
89094461|NCT00636064|Placebo Comparator|A|
89094462|NCT00636064|Experimental|B|
89094463|NCT00636064|Experimental|C|
89094464|NCT01122173|Experimental|Robotic catheter manipulation, Ablation|To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.
89094465|NCT02751034|Experimental|Neuramis® Deep Lidocaine|Neuramis® Deep Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
89094466|NCT02751034|Active Comparator|Restylane® PERLANE-L|Restylane® PERLANE-L Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
89094467|NCT02750878|No Intervention|Control group|Participants will receive only the standard verbal TOT surgical consent counseling.
89094468|NCT02750878|Other|Intervention group|Participants will receive the standard verbal TOT surgical consent counseling plus a handout describing their surgical intervention
89094469|NCT04217668|Experimental|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day.
89094470|NCT01127165|Experimental|Zonisamide Low Dose Group|
89094471|NCT01127165|Experimental|Zonisamide High Dose group|
89094472|NCT02750722|Experimental|Cycling in combination with Flutter® therapy|Participants perform 30 minutes of moderately intense cycling exercise in 4-min intervals at 75% of their maximal heart rate and interspersed with 2-min resting periods during which 6-8 breathing maneuvers are performed with the Flutter®.
89094473|NCT02750722|Active Comparator|Cycling without Flutter® therapy|Participants perform 30 minutes of continuous moderately intense cycling exercise at 75% of their maximal heart rate without additional Flutter® breathing maneuvers.
89094474|NCT01126619||Anti-TNF|Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor (anti-TNF) agent prior to enrollment according to national approved indications and reimbursement guidelines.
89094475|NCT02750644||High-risk|Patients with atherosclerotic carotid disease with (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
89226943|NCT01483079||Former preterm infants|A cohort of infants less than or equal to 1250 grams birth weight that received donor human milk products in the NICU will be recruited and followed. Some infants recruited will be from a previously studied population of very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.
88812623|NCT02210195|Placebo Comparator|Placebo 125mg/d|Matched placebo pill given daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
89094476|NCT02750644||Standard-risk|Patients with atherosclerotic carotid disease without (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
89094477|NCT00941733|Experimental|Drug Eluting Balloon|Intervention: IN.PACT Amphirion™
89094478|NCT00941733|Active Comparator|Standard PTA|Intervention: Standard PTA
89094479|NCT04278508|Active Comparator|Group A|P < 10.0 ng/ml with increasing P dosage from 800 mg to 1200 mg daily from the FET day.
89094480|NCT04278508|Active Comparator|Group B|P < 10.0 ng/ml without change in drug regimen.
89094481|NCT04278508|Active Comparator|Group C|P ≥ 10.0 ng/ml without change in drug regimen.
89094482|NCT04454242|Experimental|L-EMST|"At 30% of the maximum expiratory pressure (MEP), 25 breaths, 7 days / week, a total of 8 weeks will be trained once a day with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 30% of the new measurement."
89094483|NCT04454242|Active Comparator|H-EMST|"In 60% of the maximum expiratory pressure (MEP), 25 breaths a day, 7 days / week, a total of 8 weeks will be trained with a 1-minute rest cycle in 5 breaths.~Patients will be invited to control every 2 weeks. MEP measurements will be repeated and the training value will be adjusted in 60% of the new measurement."
89094484|NCT05382351|Experimental|Entecavir group|Patients receive treatment with entecavir
89094485|NCT05382351|Experimental|Entecavir and Tenofovir Amibufenamide group|Patients will receive the treatment of entecavir combined with tenofovir amibufenamide
89094486|NCT04218760|Experimental|Isosorbide mononitrate|Cases and controls both receive one tablet Imdur® 60 mg (isosorbide mononitrate) on the study day and have 3 sets of blood samples drown.
89094487|NCT02750488|Experimental|BAY987517|All subjects are patched with the same product
89094488|NCT00604539|Experimental|1|Chondroitin sulphate
89094489|NCT00604539|Placebo Comparator|2|
89094490|NCT02750254|Experimental|Arm 1: Azacitidine|"Treating physician must choose from one of these conditioning regimens (will be given per standard of care)~fludarabine and fractionated total body irradiation (Flu/FrTBI)~fludarabine and busulfan (Flu/Bu4)~fludarabine, cyclophosphamide, and single dose total body irradiation (Flu/Cy/sdTBI)~fludarabine and melphalan (Flu/Mel)~reduced-intensity fludarabine and busulfan (Flu/Bu2)~G-CSF from Day -5 through Day -1 per standard of care~On Day 0, the allograft will be infused per standard of care.~Azacitidine will be administered on Day +1 and +2 post-stem cell transfusion days~Cyclophosphamide on Days +3 and +4 post-transplant"
89094491|NCT00941655|Experimental|Surgery + HIPEC + Systemic Chemotherapy|"Surgery -gastric resection, metastasectomy, and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes. Leucovorin 20 mg/m^2 IV and Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours."
89094492|NCT00941655|Experimental|Systemic Chemotherapy Alone|Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours.
89094493|NCT00605787|Active Comparator|Single group|Single group all treated similarly, outcome evaluated as changes within individuals during intervention
89094494|NCT00939393|Active Comparator|FESS in OR with or without balloons|Functional Endoscopy Sinus Surgery
89094495|NCT00939393|Active Comparator|Balloon sinuplasty in physician office|Balloon Sinuplasty in physician office using Acclarent devices
89094496|NCT05382273||Use of T-Break Guide: None|Participants who reported not using the T-Break Guide (intervention)
89094497|NCT05382273||Use of T-Break Guide: Some|"Participants who reported using the T-Break Guide some"
89094498|NCT05382273||Use of T-Break Guide: A lot|"Participants who reported using the T-Break Guide a lot"
89094499|NCT04441996|Experimental|Therapeutic plasma exchange (TPE)|Participants with COVID-19-associated hyperviscosity randomized to receive therapeutic plasma exchange (TPE).
89094500|NCT04441996|Active Comparator|Standard of care|Participants with COVID-19-associated hyperviscosity randomized to receive standard of care treatment.
89094501|NCT04267965||Group A|Patients who have been successfully operated on with total parathyroidectomy for symptomatic secondary hyperparathyroidism and their PTH levels are below 72 pg/dL within one week after surgery.
89094502|NCT04267965||Group B|Patients who have had regular dialysis and their iPTH levels are around 500 pg/dL
89094503|NCT05380869|Other|Point-of-care test Procalcitonin for LRTI|Diagnostic study, a POCT-PCT is done in all included patients
89094504|NCT02750020||never smokers|Around 1667 never smokers will be required to answer a questionnaire via telephone.
89094505|NCT02750020||ex-smokers|Around 1667 ex-smokers will be required to answer a questionnaire via telephone.
89094506|NCT02750020||current smokers|Around 1667 current smokers will be required to answer a questionnaire via telephone.
89094507|NCT04190836|Experimental|Self-Managed Exercise Strategy|
89094508|NCT00936117|Experimental|Posaconazole|Posaconazole 200 mg (liquid) by mouth 3 times per day.
89094509|NCT04218682|Experimental|Immediate Game Use|AYACS randomly assigned to this arm will immediately play the Shadow's Edge Game following enrollment for a duration of 7 weeks. Following the designated 7-week game-play period, they will continue to have access to the game. They will continue to receive all usual care health care throughout and following the study.
89094510|NCT04218682|No Intervention|Wait-List Comparison Group|AYACS randomly assigned to this arm will begin to play the Shadow's Edge game 7 weeks following enrollment. They will continue to receive all usual health care throughout and following the study.
89094511|NCT04267653|Active Comparator|lactoferrin|Oral bovine lactoferrin (bfl) 100 mg once daily on empty stomach
89094512|NCT04267653|Active Comparator|ferrous sulfate|Oral ferrous sulfate 3-6 mg/kg of elemental iron/day in divided doses
89094513|NCT04267653|Active Comparator|combined|combined therapy (both lactoferrin and ferrous sulfate)
89094514|NCT00604071||1|subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV
89094515|NCT04088500|Experimental|Nivolumab + Ipilimumab (combination)|Nivolumab + Ipilimumab (combination) Q3W for 4 doses
89094516|NCT05379153|Experimental|Arm I (vaginal fractional CO2 laser therapy)|Patients undergo vaginal fractional CO2 laser therapy over 20-30 minutes every 6 weeks for 3 treatments in the absence of disease progression or unacceptable toxicity.
89094517|NCT05379153|Sham Comparator|Arm II (placebo)|Patients undergo placebo procedure over 20-30 minutes every 6 weeks for 3 treatments in the absence of disease progression or unacceptable toxicity.
89094518|NCT04218214||LIFE-DM Group|The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and microfinance loans of 2 million VND. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union.
89094519|NCT05379075|Experimental|Female students of Chen Taichi training based on Relaxation guidelines|"Relaxation theory is different from coordination. It only focuses on relaxing the body and mind to an extreme level. Previously, masters of Taichi described or taught it as relax or let nature take its course. This explanation may lead to ignoring it since it is against intuition. Pavel explained the relaxation method as mastering muscle tension. The critical point of Pavel's book is the viewpoint of canceling the stretch reflection. The present study applied this viewpoint to judge the extent and rotation degree when practicing taichi. In other words, students will be taught this skill to relax their bodies when the tension comes out from low posture movements. The relaxation skills also include dropping the control of the body, exhale when stretching, moving like a string puppet without muscle power, steps like cats, and three-line relaxation method. Duration:12 weeks. Frequency: 3 times per week. Time length: 90min+60min×2"
89094520|NCT05379075|Experimental|Male students of Chen Taichi training based on Relaxation guidelines|"Relaxation theory is different from coordination. It only focuses on relaxing the body and mind to an extreme level. Previously, masters of Taichi described or taught it as relax or let nature take its course. This explanation may lead to ignoring it since it is against intuition. Pavel explained the relaxation method as mastering muscle tension. The critical point of Pavel's book is the viewpoint of canceling the stretch reflection. The present study applied this viewpoint to judge the extent and rotation degree when practicing taichi. In other words, students will be taught this skill to relax their bodies when the tension comes out from low posture movements. The relaxation skills also include dropping the control of the body, exhale when stretching, moving like a string puppet without muscle power, steps like cats, and three-line relaxation method. Duration:12 weeks. Frequency: 3 times per week. Time length: 90min+60min×2"
89094521|NCT05379075|Active Comparator|Female students of Chen Taichi training based on Coordination guidelines|"Coordination theory is also called three in one. It mainly guides exercisers to practice Taichi by integrating the mind, movements, and breathing in a unity state. Students in this group will be taught how to integrate the three requests according to the principles. The principles are Waist axis, Movements softy and slowly, Inspiratory contraction and Expiratory stretch. The training will be conducted on the warming-up time by practicing a single movement and the club time by practicing a learned routine.~Duration:12 weeks. Frequency: 3 times per week. Time length: 90min+60min×2"
89094522|NCT05379075|Active Comparator|Male students of Chen Taichi training based on Coordination guidelines|"Coordination theory is also called three in one. It mainly guides exercisers to practice Taichi by integrating the mind, movements, and breathing in a unity state. Students in this group will be taught how to integrate the three requests according to the principles. The principles are Waist axis, Movements softy and slowly, Inspiratory contraction and Expiratory stretch. The training will be conducted on the warming-up time by practicing a single movement and the club time by practicing a learned routine.~Duration:12 weeks. Frequency: 3 times per week. Time length: 90min+60min×2"
89094523|NCT02750098|Experimental|Diabetic patients|Diabetic patients planned to undergo elective cataract surgery
89094524|NCT01082874|Experimental|Active Clonidine and Active ASA|
89094525|NCT01082874|Experimental|Active Clonidine and Placebo ASA|
89094526|NCT01082874|Experimental|Placebo Clonidine and Active ASA|
89094527|NCT01082874|Placebo Comparator|Placebo Clonidine and Placebo ASA|
89094528|NCT04009408|Experimental|EMST therapy|Participants use the EMST device as per study protocol, set to 50% of the patient's maximal expiratory pressure, as measured by handheld manometer.
89094529|NCT04009408|Sham Comparator|Sham EMST therapy|Participants use a sham EMST device that has the spring removed as per study protocol, with no significant airflow resistance.
89094530|NCT00933543|Experimental|Visonac cream with PDT|Active treatment, Light dose 37 J/cm2.
89094531|NCT00933543|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 J/cm2.
89094532|NCT02749942|Active Comparator|AutoRIC: Remote Ischemic Conditioning|Daily cuff treatment of arm with 4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG of pressure) on top of standard care.
89094533|NCT02749942|Sham Comparator|AutoRIC: Sham device treatment|Daily sham device treatment of arm, 4 cycles of 5 minute (0 mmHG of pressure) on top of standard care. No ischemia induced.
89094534|NCT00607503|Experimental|1|
89094535|NCT04264533|Experimental|VC|12g Vitamin C+sterile water for injection; total volume: 50ml. 12ml/h; infusion pump；q12h.
89094536|NCT04264533|Placebo Comparator|Sterile water for injection|50ml water for injection. 12ml/h; infusion pump; q12h.
89094537|NCT02750176|Experimental|CERCT|Closed chain exercises
89094538|NCT01082328|Experimental|Kuvan®|
89094539|NCT02749864||A: Age 20-34 yr|No intervention Cohort of subjects aged 20-34 years old.
89094540|NCT02749864||B: Age 35-49 yr|No intervention Cohort of subjects aged 35-49 years old.
89094541|NCT02749864||C: Age 50-79 yr|No intervention Cohort of subjects aged 50-79 years old.
89094542|NCT03796000||colonoscopy: obese and smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
89094543|NCT03796000||colonoscopy: obese and non-smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
89094544|NCT03796000||colonoscopy: lean and smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
89094545|NCT03796000||colonoscopy: lean and non-smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
89094546|NCT03796000||gastroscopy: obese and non-smoker undergoing bariatric surgery|"6 small tissue samples of the gastric corpus and 6 of the Duodenum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample~1cm long piece of the jejunum, which is usually disposed during bariatric surgery."
89094547|NCT03796000||gastroscopy: lean and non-smoker|"6 small tissue samples of the gastric corpus and 6 of the Duodenum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
89094548|NCT02749786|Other|Control Group|Participants who do not have rosacea (control group)
89094549|NCT04218058|Active Comparator|study (ultrasound guided closed reduction of zygomatic arch))|reduction of zygomatic arch guided by ultrasound
89094550|NCT04218058|Active Comparator|control (open reduction of zygomatic arch)|open reduction of zygomatic arch through coronal incision
89094551|NCT04217434|Experimental|Group 300µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 300 µm fibre length will be used in continuous contact mode at a power setting of 1.5 to 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
89094552|NCT04217434|Experimental|Group 300µm in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline].LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes, 300 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 - 3 W. Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
89094553|NCT04217434|Experimental|Group 400µm in continous contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
89094554|NCT04217434|Experimental|Group 400µm in pulsed contact mode|"Diode LASER (A.R.C Fox , Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®[ 2% lignocaine in 1:80000 adrenaline.LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes , 400 µm fibre length will be used in pulsed contact mode at a power setting of 1.5 t 3 W. • Simultaneously, increase in temperature on site will be recorded using FLUKETM 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain. Post operative instructions will be given."
89094555|NCT04217512|Active Comparator|Standard hydration alone|Cisplatin with standard hydration
89094556|NCT04217512|Active Comparator|Pantoprazole high dose|Cisplatin with standard hydration with pantoprazole 1.6 mg/kg
89094557|NCT04217512|Active Comparator|Pantoprazole Low dose|Cisplatin with standard hydration with pantoprazole 0.6 mg/kg
89094558|NCT02749708|Experimental|Dose level 1|IRX5183 50 mg daily
89094559|NCT02749708|Experimental|Dose level 2|IRX5183 75 mg daily
89094560|NCT03632434|Experimental|tDCS|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
89094561|NCT04217980|Experimental|Lung ultrasonography (LUS) group|Group 1: Lung ultrasonography is performed as the main (first) pulmonary image test
89094562|NCT04217980|Active Comparator|Chest X ray (CXR) group|Group 2: Chest X ray is performed as main (first) pulmonary image test
89094563|NCT01079988|Experimental|Cyclosporin|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
89094564|NCT01079988|Experimental|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
89094565|NCT01079988|Experimental|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
89094566|NCT01079988|Experimental|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
89094567|NCT01079988|Experimental|Systemic corticosteroids/methotrexate|"Corticosteroid starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%.~Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks."
89094568|NCT04172194||PT Group|patients with hepatocellular carcinoma treated by percutaneous thermoablation alone
89094569|NCT04172194||PT+TAC group|patients with hepatocellular carcinoma treated by pecutaneous thermoablation comined in a single session with trans-arterial chemoembolization
89094570|NCT02876718||Rivaroxaban, BAY59-7939|It is a single-arm study in which only patients who switched from a VKA to a NOAC treatment will be included.
89094571|NCT04217122|Experimental|Strawberry intervention group|Participants consume two packages of 13 g of standard strawberry powder in the morning and afternoon/evening per day for 4 weeks
89094572|NCT04217122|Placebo Comparator|Placebo group|Participants consume two packages of 13 grams placebo powder in the morning and afternoon/evening for 4 weeks.
89094573|NCT01074216|Experimental|vitamin D, vitamin D3|This is a Phase II study involving Stage IV colorectal cancer patients with serum vitamin D deficiency, to determine the ability to correct vitamin D deficiency and to maintain serum vitamin D levels (25-hydroxy vitamin D) once achieved.
89094574|NCT02749474||Pregnant women diagnosed with cancer|Any pregnant woman diagnosed with any cancer within 6 weeks prior to their last menstrual period, or up to 6 months after the end of their pregnancy can be enrolled.
89094575|NCT04218136||patient with head and neck cancer|Patients treated by standard treatment and have a minimum of 4 blood samples.
89094576|NCT01079832|Experimental|Arm I: CyberKnife Radiosurgery|Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
89094577|NCT02749630|Experimental|Healthy Volunteer|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
89094578|NCT02749630|Experimental|Ulcerative Colitis|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
89094579|NCT02749630|Experimental|Crohn's Disease|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
89094580|NCT03209128||Irradiation prophyllactique cérébrale|
89094581|NCT04788342||Patients with and without left ventricular systolic dysfunction|Patients with different pathologies of the cardiovascular system (coronary artery disease, hypertension, valvular heart disease, heart failure) will be performed pulse wave recording using a CardioQvark cardiomonitor and echocardiography.
89094582|NCT02749318|Experimental|Experimental Group|Consented patients who complete the initial Experimental Group Questionnaire, receive a prophylaxis, have the IL-1 genetic test for risk of severe periodontitis performed, their dental records monitored for 18 months post-enrollment, and answer a Study Completion Questionnaire 18 months post-enrollment.
89094583|NCT02749318|No Intervention|Usual Care Group|Consented patients who complete the initial Usual Care Group Questionnaire, receive a prophylaxis and have their dental records monitored for 18 months post-enrollment.
89094584|NCT03199144|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy delivering 30 Gy in 5 fractions over 9 days
89094585|NCT04306536|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
89094586|NCT04306536|No Intervention|Control group|Best local diet
89226944|NCT01463072|Experimental|Treatment (nab-paclitaxel)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89094587|NCT04304664|Experimental|Mindfulness- Based Intervention (MBI)|In MBI arm, patients received mindfulness- based intervention, a psychological mind- body intervention, focusing on stress reduction,. the intervention was led by a licensed clinical therapist and mindfulness specialist, who was trained in MBSR at Bangor University.
89094588|NCT04304664|No Intervention|Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 10-weeks waiting period. At the end of that period received the exact intervention as the study group.
89094589|NCT00636142|Active Comparator|1|Infliximab
89094590|NCT00636142|Placebo Comparator|2|Placebo
89094591|NCT04305522|Experimental|Probiotic 1 group|A commercially-available multi-strain probiotic with added magnesium and vitamin B6
89094592|NCT04305522|Experimental|Probiotic 2 group|A multi-strain probiotic
89094593|NCT04305522|Placebo Comparator|Placebo group|Identical placebo
89094594|NCT02499562|Experimental|Hydronidone(180mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 2 capsules each time; with co-administration of placebo capsule, three times a day, 2 capsules each time, namely the daily dose of the investigational product is 180mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
89094595|NCT02499562|Experimental|Hydronidone(270mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 3 capsules each time; with co-administration of placebo capsule, three times a day, 1 capsules each time, namely the daily dose of the investigational product is 270mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
89094596|NCT02499562|Experimental|Hydronidone(360mg) & Entecavir|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 4 capsules each time; namely the daily dose of the investigational product is 360mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
89094597|NCT02499562|Experimental|Entecavir & Placebo(360mg)|placebo capsule 30mg/capsule placebo capsule, three times a day, 4 capsules each time. The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
89094598|NCT02877654|Experimental|Irritable Bowel Syndrome|
89094599|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program (Youth Empowerment Seminar, YES!) will be offered to at risk youth participating in programs or resources offered by Youth Opportunities Unlimited. The YES! program will be taught in two phases: (1) an active learning phase which consists of four consecutive days (3 hrs/day) of SEL skills taught in a multi-modality interactive format as well as SKY training, and (2) a reinforcement phase which involves weekly follow up sessions (75-90 mins each) for the 7 weeks following the active phase. Two certified instructors from the Art of Living Foundation (Spencer Delisle and Mark Frye) will deliver this training under supervision of Ronnie Newman (RN). After the initial 4 day training, participants will be asked to practice SKY daily for 20-25 minutes in addition to attending the weekly follow up sessions.
89094600|NCT04304430||Dapagliflozin|Patients who initiated a new therapy with dapagliflozin
89094601|NCT04304430||DPP-4i|Patients who initiated a new therapy with a DPP-4i
89094602|NCT04216966|Placebo Comparator|Control group|This group did not undergo any instrumentation.
89094603|NCT04216966|Experimental|Gracey Curette group|Teeth under this group were subjected to debridement with Gracey curette .
89094604|NCT04216966|Experimental|After Five group|Teeth under this group were subjected to debridement with After 5 curette .
89094605|NCT04216966|Experimental|Mini Five group|Teeth under this group were subjected to debridement with Mini Five curette .
89094606|NCT02875002|Experimental|All subjects|Subjects have relapsed and refractory aggressive B- and T-cell lymphomas and will receive both Belinostat and Volasertib.
89094607|NCT02749396||IFN-β / Cohort 1|Exposure to IFN-β only
89094608|NCT02749396||IFN-β + other MSDMDs / Cohort 2|Women with MS exposed to IFN-β regardless of exposure to other MSDMDs
89094609|NCT02749396||No MSDMDs / Cohort 3|Women with MS exposed with no exposure to any MSDMDs
89094610|NCT02749396||No IFN-β + other MSDMDs / Cohort 4|Women with MS exposed to IFN-β exposure regardless of exposure to other MSDMDs
89094611|NCT02749396||Other MSDMDs / Cohort 5|Women with MS exposed to other MSDMD only excluding IFN-β or glatiramer acetate (Copaxone) or dimethyl fumarate (Tecfidera)
89094612|NCT02749396||Control / Cohort 6|Women from the general population without MS
89094613|NCT04305132||Depression|Subjects with depression treated with electroconvulsive therapy
89094614|NCT04305132||Healthy|Healthy subjects
89094615|NCT00627120|Experimental|1|1mg dose group
89094616|NCT00627120|Experimental|2|10mg dose group
89094617|NCT00627120|Experimental|3|100mg dose group
89094618|NCT00627120|Experimental|4|200mg dose group
89094619|NCT00627120|Experimental|5|400mg dose group
89094620|NCT00627120|Experimental|6|800mg dose group
89094621|NCT02749162|Placebo Comparator|Group A|After the spinal anesthesia regressed, the investigators performed a single shot femoral block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
89094622|NCT02749162|Active Comparator|Group B|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg and 4 mg dexamethasone phosphate. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
89094623|NCT02749162|Active Comparator|Group C|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg+ lidocaine 1% 200 mg and 8 mg dexamethasone phosphate.After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
89094624|NCT02874612||Young Adults with Type 1 Diabetes Mellitus|All YA (ages 18-24) who are seen in the Cincinnati Children's Hospital Medical Center Diabetes Clinic and have recently (< 4 months) completed the Transition Readiness assessment tool as part of their standard clinical care is eligible for the study.
89094625|NCT02041234|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
89094626|NCT02041234|Active Comparator|Best Medical Treatment|"Anti-diabetic medications provided (Mono- or Combination- therapy):~Incretin analogues: Liraglutide up to 3 mg daily Or DPP-4 Inhibitors: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily Xenical: Up to 120 mg tds SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily Participants will also take lipids & BP medications according to standard of care."
89094627|NCT04305210|Experimental|F-18-PMPBB3|F-18-PMPBB3 imaging
89094628|NCT04305210|Experimental|18F-florbetapir|18F-florbetapir (AV45) imaging
89094629|NCT04305288||Gemox|The patients received conventional chemotherapy Gemox
89094630|NCT04305288||mFOLFIRINOX|The patients received chemotherapy modified FOLFIRINOX
89226945|NCT01266642|Experimental|Arm I (HF-WBI)|Patients undergo HF-WBI comprising external beam RT 5 days a week for approximately 3 weeks.
89226946|NCT01266642|Active Comparator|Arm II (CF-WBI)|Patients undergo CF-WBI comprising external beam RT 5 days a week for approximately 5 weeks.
89226947|NCT01218854|Experimental|B-NASS|Block assisted needle angle selection system
89226948|NCT01218854|Experimental|L-NASS|laser assisted needle angle selection system
89226949|NCT01218854|Experimental|MD-NASS|mobile-device assisted needle angle selection system
89226950|NCT01204983||Observational|"This is a quality improvement project to evaluate the current standard of care of nutritional management for very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.~There is no randomization, there are no control subjects, and therefore there is no probability of group assignment."
89226951|NCT01176006|Active Comparator|Group A|10/10 HLA Matched Related or Unrelated Donor Transplant
89226952|NCT01176006|Active Comparator|Group B|9/10 HLA Matched Related or Unrelated Donor Transplant
89226953|NCT01176006|Other|Group C|Donor (closed)
89226954|NCT01176006|Other|Group D|Family Interview (closed)Participation in research interview
89226955|NCT01176006|No Intervention|Group E|Patient and caregiver psychosocial and QOL assessments during HSCTParticipation in interview and questionnaires
89226956|NCT01154920|Experimental|PCC Group + RT|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT)
89226957|NCT01154920|Experimental|PCC Group + RT + Chemotherapy|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT) + Chemotherapy
89226958|NCT01154920|Experimental|C-TPF Group + RT|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT)
89226959|NCT01154920|Experimental|C-TPF Group + RT + Chemotherapy|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT) + Chemotherapy
89226960|NCT01109394||1/Cohort 1|Adult or Pediatric subjects, with any malignancy, pre-malignancy, suspected malignancy, family history of malignancy, or without malignancy undergoing surgery or well visit.
89226961|NCT01109394||2/Cohort 2|Human samples, specimens and data collected on IRB approved protocols that are now closed
89226962|NCT01109394||3/Cohort 3|Parent/caregiver of a participating pediatric or adult subject who is being treated for, or who has previously been treated for any form of pediatric cancer.
89226963|NCT01038193||aSAH patients|Cognitive assessment
89226964|NCT01034670|Experimental|endoscopy arm|imaging performed in conjunction with the regularly scheduled endoscopy during which the newer imaging techniques will be used to detect premalignant conditions. includes wide field fluorescence, microscopy, Raman spectroscopy and/or ultrasound.
89226965|NCT00950001|Experimental|Arm I (SRS)|Patients undergo stereotactic radiosurgery to the surgical cavity within 30 days of the craniotomy.
89226966|NCT00950001|No Intervention|Arm II (observation)|Patients undergo clinical observation after craniotomy.
89226967|NCT00947531|Experimental|Cerebrolysin|
89226968|NCT00947531|Placebo Comparator|0.9% Saline Solution|
89226969|NCT00941473|Active Comparator|Epidural Steriod Injection|This study focuses on the changes in bone mineral density over time of the cohort previously described in the inclusion criteria (post-menopausal white women)
89226970|NCT00923507||Patients|Patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstr(SqrRoot)(Delta)m macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL).
89226971|NCT00881920|Experimental|Kappa CD28 T cells for B-CLL|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
89226972|NCT00881920|Experimental|Kappa CD28 T cells for B-cell lymphoma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
89226973|NCT00881920|Experimental|Kappa CD28 T cells for myeloma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
89226974|NCT00855036||Renal Injury|All patients who have a discernable injury to the renal parenchyma on CT scan from blunt trauma
89226975|NCT00766584||PROOF cohort|This cohort is the same than the PROOF study (NCT00759304). Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and were eligible if aged 65 at the inclusion date in the PROOF study
89226976|NCT00673335|Experimental|Treatment arm|Letrozole, 1 tablet
89226977|NCT00673335|Placebo Comparator|Placebo|Comparator, 1 tablet
89226978|NCT00630032|Active Comparator|Docetaxel|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)
89094631|NCT04217824|Active Comparator|karydakis flap|An asymmetric elliptical excision is performed, defective tissues between the lower and upper ends are removed until they reach healthy borders. The wound edge is then mobilized and the flap is slid over the corresponding wound edge by suturing to the fascia and the skin to the appropriate wound layers. Thus, the gluteal groove is lateralized. Subcutaneous tissue and skin are closed.
89094632|NCT04217824|Active Comparator|limberg flap|Rhomboid excision and pilonidal sinuses together with damaged tissue. On the right side of the patient, the intact skin is shifted to the medial area where the tissues are removed without tension. Thus, the defective part and gluteal groove are corrected.
89094633|NCT02749006|Active Comparator|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) daily for four weeks. The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
89094634|NCT02749006|Sham Comparator|Sham rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
89094635|NCT01072344|Experimental|Chamomile Extract|Pharmaceutical grade oral chamomile extract.
89094636|NCT01072344|Placebo Comparator|Placebo|Pharmaceutical grade lactose monohydrate.
89094637|NCT02695732|Experimental|Carvedilol|Carvedilol，6.25mg-12.5mg/d,oral,6-36 months
89094638|NCT02695732|Active Comparator|endoscopy|endoscopy，every 4 weeks until eradication of varices
89094639|NCT02751268|Placebo Comparator|Control|placebo for the realization of infraorbital and infratrochlear block
88812624|NCT01436435|Experimental|Jetstream Atherectomy System|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention including Atherectomy utilizing the Jetstream Atherectomy System with or without adjunctive therapy.
88812625|NCT00836888|Experimental|Cohort|
88812626|NCT02262026|Experimental|FHP; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
89094640|NCT02751268|Active Comparator|Ropivacaine|ropivacaine for the realization of infraorbital and infratrochlear block
89094641|NCT02748772|Active Comparator|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Two Anti-angiogenesis Drugs（Endostar and Thalidomide） Combined With Chemotherapy for the patients of Advanced Colorectal Cancer
89094642|NCT02748772|Placebo Comparator|Pure chemotherapy（Xelox）|chemotherapy alone for the patients of Advanced Colorectal Cancer
89094643|NCT02750956||Group 1|Periodontal healthy individuals
89094644|NCT02750956||Group 2|Patients with chronic periodontitis
89094645|NCT02750956||Group 3|the same patients in group 2 after they had been treated with scaling and root planing (SRP) were considered as Group 3.
89094646|NCT02748850|Active Comparator|leukemia patients|Patients with acute leukemia and / or refractory anemia with excess blasts and comprising a number of blasts in the blood greater than 5% device.
89094647|NCT02748850|Placebo Comparator|apheresis patients|patients with non-myeloid hematological malignancy
89094648|NCT02747056|Experimental|Autism spectrum disorder studyA part1|The subjects will perform clinical, psychological and neuropsychological assessment. the subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
89094649|NCT02747056|Experimental|Autism spectrum disorder studyA part2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
89094650|NCT02747056|Other|Control adults Study A, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
89094651|NCT02747056|Other|Control adults Study A, part 2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
89094652|NCT02747056|Experimental|Autism spectrum disorder Study B, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
89094653|NCT02747056|Experimental|Autism spectrum disorder Study B, part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements.
89094654|NCT02747056|Other|Control adults, Study B part 1|The subjects will perform clinical, psychological and neuropsychological assessment.The subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
89094655|NCT02747056|Other|Control adults, Study B part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements
89094656|NCT01071954|Experimental|Romiplostim|Participants received romiplostim administered by subcutaneous injection once a week. The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of between 50 x 10^9/L and 200 x 10^9/L.
89094657|NCT02748538||Face Down|To posture in the face down position for the first 24 hours following surgery.
89094658|NCT02748538||Position to Support the Break|The head is positioned so that the retinal breaks (which caused the retinal detachment) are positioned at the highest point of the eye and well supported by the intra-ocular gas bubble left within the eye at the completion of surgery.
89094659|NCT02746978|Active Comparator|Peer directed education|A revised education approach that focuses on problem solving discussions delivered by peers and grounded clinical information is compared to traditional approach of didactic clinician-driven education lectures
89094660|NCT02746978|Other|Patient Engagement Portal|A patient-owned portal to manage injury information is maintained in real-time by patients and families and shared with other care providers after inpatient rehabilitation discharge.
89094661|NCT04216888|Experimental|Open label|Open label intranasal ketamine
89094662|NCT02746744|Experimental|Rituximab|Infusion of Mabthera/Rituximab every 6 months
89094663|NCT02746744|Active Comparator|Dimethyl Fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
89094664|NCT02746744|Sham Comparator|Sodium Chloride solution|Sham infusion with sodium chloride solution for the Tecfidera/Dimethyl Fumarate arm every 6 months (so that the examining physician will be blinded)
89094665|NCT02748304|Placebo Comparator|control|just follow up after liver resection in HCC patients
89094666|NCT02748304|Active Comparator|sorafenib|use sorafenib after liver resection in HCC patients
89094667|NCT02748304|Active Comparator|sorafenib and aspirin|use sorafenib and aspirin after liver resection in HCC patients
89094668|NCT02748382|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline) higher chloride albumin (5% Octalbin)
89094669|NCT02748382|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate) lower chloride albumin (5% Plasbumin)
89094670|NCT02748460||Patients treated with Esmya|Any patient who was confirmed as receiving one dose of Esmya
89094671|NCT02746666|Experimental|Intervention|Under pharmacist's behavioral intervention
89094672|NCT02746666|No Intervention|Control|No pharmacist's behavioral intervention
89094673|NCT02746900|Experimental|Cervical cerclage|After the woman is placed in the dorsal lithotomy position and the bladder is emptied with a urinary catheter to reduce the chance of bladder injury, surgical preparation with Betadine will be performed. Breisky retractors and Sims retractors will be used to exposure the entire cervix. Sponge ring forceps will be used to optimized visualization of the cervix and provide the necessary countertraction at the suture entry and exit sites. McDonald technique will be performed placing 4-6 bites circumferentially around the cervix. Only one stitch will be used. The suture will be places as high as feasible
89094674|NCT02746900|No Intervention|No intervention|Bed rest will be not recommended.
89094675|NCT04216654||Group(A)|52 cases of type 2 diabetic patients.They have +ve Serum antibody and Stool antigen specific for Helicobacter pylori.
89094676|NCT04216654||Group(B)|36 cases of type 2 diabetic patients. They have +ve Serum antibody and -ve Stool antigen-specific for Helicobacter pylori.
89094677|NCT04216654||Group(C)|112 cases of type 2 diabetic patients. They have -ve Serum antibody and Stool antigen-specific for Helicobacter pylori.
89094678|NCT02748148|Experimental|Medication therapy management|Medication therapy management service that is enhanced by the incorporation of pharmacogenomics and medication risk mitigation factor technology
88812627|NCT02262026|Experimental|FHP; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
89094679|NCT02746432|No Intervention|Control group|Routine intra operative saline infusion to be administered.pre-operation and timed assessment lab set to be obtained.
89094680|NCT02746432|Experimental|Intervention group.Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin (Human regular insulin) ) infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
89094681|NCT02746354|Experimental|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
89094682|NCT02746354|No Intervention|Usual care|
89094683|NCT02747992||PECS 0|receiving paravertebral block
89094684|NCT02747992||PECS 1|receiving paravertebral block and blocks targeting pectoral musculature
89094685|NCT02746276|Other|Ceftriaxone and metronidazole|Pharmacokinetic study of ceftriaxone and metronidazole in malnourished children
89094686|NCT05629936|Other|digital intervention|Digital intervention
89094687|NCT02747602|Experimental|Group ABC|AC-1204, caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast
89094688|NCT02747602|Experimental|Group BCA|caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast, AC-1204
89094689|NCT02747602|Experimental|Group CAB|caprylic triglyceride high fat breakfast, AC-1204, caprylic triglyceride oil standard breakfast
89094690|NCT02745964|Experimental|LMA supreme|Anesthesia is maintained using LMA supreme during surgery.
89094691|NCT02745964|Active Comparator|I-gel|Anesthesia is maintained using I-gel during surgery.
89094692|NCT02746042|Experimental|Sinupret extract coated tablets|"Sinupret extract coated tablets: one tablet three times a day orally during the 16-week treatment phase.~There will be no dose change during the trial."
89094693|NCT02746042|Placebo Comparator|Placebo coated tablets|Placebo coated tablets: One tablet three times a day orally during the 16-week treatment Phase.
89094694|NCT02748226||Retrospective cohort|This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals.
89094695|NCT02748226||Prospective cohort|This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals.
89094696|NCT02747680|Other|type 1 diabetes|type 1 diabetes >5 years duration Well controlled (a1c <7.5%)
89094697|NCT02747680|Other|healthy controls|healthy controls
89094698|NCT02746198|Experimental|Verum|2 bottles (á 65ml) of a probiotic dairy drink consumed daily for 6 weeks
89094699|NCT02746198|Placebo Comparator|Placebo|2 bottles (á 65ml) of a dairy drink containing chemically acidified milk without bacterial strains consumed daily for 6 weeks
89094700|NCT02745886|Experimental|Metformin group|Metformin 0.85 twice daily for 6 months
89094701|NCT02745886|No Intervention|Standard diet group|
89094702|NCT02745886|Other|CR group|Calorie restriction diet will be given to this group.
89094703|NCT02747446|Experimental|Honey|added sugar: diet with 25% acacia honey
89094704|NCT02747446|Experimental|Fructose:glucose mixture|added sugar: Diet with 25% energy as a fructose:glucose mixture
89094705|NCT02747446|No Intervention|control|no intervention: Diet with 45% starch and no honey or added sugars
89094706|NCT02745652|Experimental|pulsed electromagnetic field (PEMF)|patients in this group received the pulse electromagnetic field with frequency 50 Hz and intensity 80 gauss for 30 min.The patient was in sitting position, while the forearm was rested on the bed inside the solenoid in supination position
89094707|NCT02745652|Experimental|Therapeutic ultrasound (US)|Pulsed mode US was applied over the volar surface of the forearm (the carpal tunnel area) 15 min per session with a frequency of 1 MHz and intensity of 1.0 W/cm2
89094708|NCT02747524|Experimental|Vita Mamba|Nutrient fortified peanut butter paste for 26 weeks.
89094709|NCT02747524|No Intervention|Control|
89094710|NCT02747290|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
89094711|NCT02747368|Other|Wet age related macular degeneration|Ocusweep system is compared to results of conventional devices.
89094712|NCT02745808|Experimental|HUC-MSCs|Intracavernous injection of 15 million HUC-MSCs.
89094713|NCT02745808|Experimental|Injectable Collagen Scaffold + HUC-MSCs|Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.
89094714|NCT02747134|Experimental|Emotion Regulation and Mindfulness skills|A 10 week intervention including emotion regulation and mindfulness skills from dialectical behavioral therapy (DBT) was delivered.
89094715|NCT02747134|Active Comparator|Psychoeducation|Psychoeducation consisted of 5 session in which basic information about depressive symptoms and how to prevent depression relapse was given.
89094716|NCT02745574|Experimental|Combined maneuver|Combined maneuver: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm dihydrogen monoxide (H2O). The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
89094717|NCT02745574|Experimental|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
89094718|NCT02745574|No Intervention|Control group|CO2 was removed by passive exsufflation through the port site.
89094719|NCT02745496|Other|TRUS Biopsy|Standard of Care Treatment
89094720|NCT02745496|Other|TRUS/FUSION Biopsy|Interventional Treatment
89094721|NCT02745730|Active Comparator|Glucose|Shake sweetened with glucose
89094722|NCT02745730|Active Comparator|Fructose|Shake sweetened with fructose
89094723|NCT02745730|Experimental|Sucralose|Shake sweetened with sucralose
89094724|NCT02745730|Experimental|Allulose|Shake sweetened with allulose
89094725|NCT02742142|Placebo Comparator|control|Distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) was painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.In addition, instructions on oral hygiene (OHI) tailored to the individual's condition was given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) was provided. The OHI and provision of toothpaste will be repeated at 6-month intervals.
89094726|NCT02742142|Experimental|silver diammine fluoride|the subjects received the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution was painted onto the exposed tooth root surfaces. This treatment was repeated after 12 and 24 months.
89094727|NCT02742064||MDD-Single Episode|1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime.
89094728|NCT02742064||MDD-Recurrent|1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime.
89094729|NCT02742064||Bipolar Disorder|1. Subjects who have been diagnosed with bipolar disorder in their lifetime.
89094730|NCT00636298|Experimental|A|Single arm treatment with combination of cetuximab and bevacizumab
89094731|NCT05629624|Experimental|Chickpea based RUSF|Locally produced ready to use supplementary food (RUSF), 50 g/packet contains 204 kcal energy). Two packets of RUSF provided for consumption at a rate of 50-100 kcal/kg/day till the child's weight for height returns to normal (WHZ >-1SD) or for maximum 3 months.
89094732|NCT05629624|Experimental|E-RUSF|Enhanced Ready to use therapeutic feeds (E-RUSF), 50-100 kcal/kg/d daily until for anthropometric recovery (WHZ > - 1SD) is achieved or for maximum 3 months then E-SQLNS will be given till the end of 2 years follow-up.
89094733|NCT05629624|No Intervention|Well-nourished children|Well-nourished children at 1 year of age (WLZ/WHZ score >-1 SD). No nutritional or psychosocial intervention. Only follow-up.
89094734|NCT05629624|Experimental|Outcome reference group|3 year olds previously untreated MAM children (WHZ <-2 and ≥-3 z-score, and/or MUAC <12.5 and ≥11.5 cm) and free from any acute illness will be used as the outcome reference group.
89094735|NCT02741908|Experimental|Fixed diet plan|Patients received a fixed diet plan to assist in the choice of foods aimed at changing eating behavior. Dietary intake was evaluated by using 3 nonconsecutive 24-hour dietary recalls collected at each visit. Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
89094736|NCT02741908|Experimental|Calorie counting diet|Patients underwent a calorie counting diet, in which each patient has received a table list with equivalent points for food and drinks, and was instructed to record all daily food or drink intake and calculate the total score of points consumed (1 point = 3.6 calories). They were allowed to eat any food but were limited to the recommended amount of points (or calories equivalents). Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
89094737|NCT02745340|Active Comparator|Acetate|
89094738|NCT02745340|Experimental|Citrate|
89094739|NCT02745106|Experimental|PADN treatment|"Procedure/Surgery: Right heart catheterization, Radiofrequency pulmonary artery denervation using following devices:~Ablation catheter~Carto 3, Carto RMT, Stereotaxis~Swan-Ganz catheter"
89094740|NCT02745106|Sham Comparator|Control (Sham)|"Procedure: Right heart catheterization~Using following device:~- Swan-Ganz catheter"
89094741|NCT02741752|Experimental|test group|decortication group
89094742|NCT02741752|No Intervention|control|without decortication
89094743|NCT02695264|Experimental|HS-1000 recording|ICP readings will be recorded from both the invasive and HeadSense non-invasive ICP monitor for an aggregate of 30 minutes. During the recording sessions, a webcam will take periodic snapshots of the ICP monitor and/or bedside monitor picturing the ICP values and other clinical parameters that are displayed on screen, with a focus on blood pressure and heart rate (HR). Recording sessions will be done until an aggregate of at least 30 minutes of data are collected, depending on the patient's clinical condition. Recording sessions may be repeated over several days until the 30 minute target is reached.
89094744|NCT02741830||Uterosacral ligament suspension (USLS)|This group of patients underwent the procedure of native tissue vaginal reconstructive surgery using uterosacral ligament suspension for pelvic organ prolapse.
89094745|NCT02741830||Robotic sacrocolpopexy (RSC)|This group of patients underwent the reconstructive pelvic surgery of robotic sacrocolpopexy using synthetic mesh.
89094746|NCT02745262||Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
88812628|NCT02262026|Experimental|FHP; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
89094747|NCT02745262||Non Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
89094748|NCT02741674||Roux-en-y gastric bypass (RYGB)|"Adults and children ages 12 ≤79 years at time of surgery~Had a primary (not revision) Roux-en-y gastric bypass from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
89094749|NCT02741674||Adjustable gastric banding (AGB)|"Adults and children age 12 ≤79 years at time of surgery~Had a primary (not revision) adjustable gastric banding procedure from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
89094750|NCT02741674||Sleeve gastrectomy (SG)|"Adults and children age 12 ≤79 years at time of surgery~Had a primary (not revision) sleeve gastrectomy from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
89094751|NCT02695186||A/IM alone|Patients with intestinal metaplasia who undergo gastroscopy and blood sample analysis
89094752|NCT02695186||B/IM and MS|Patients with intestinal metaplasia and metabolic syndrome who undergo gastroscopy and blood sample analysis
89094753|NCT02695186||C/Healthy controls|Healthy controls without intestinal metaplasia or metabolic syndrome who undergo gastroscopy and blood sample analysis
89094754|NCT02744950|Active Comparator|Intermediate/complex repair|This arm will have closures of scalp defects with deep and superficial suture placement.
89094755|NCT02744950|Experimental|Pulley stitches|This arm of the study will have only pulley stitches to close the entire defect.
89094756|NCT02695108|Experimental|classical approach for neck pain|patients in this arm received classical approaches for neck pain. Cervical manual therapy was performed on patients in this arm and they were also instructed to to perform cervical endurance, strength and stretching exercises. Rehabilitation period was lasted for 6 weeks. Pain, quality of life and scapular kinematics were assessed before and after rehabilitation program.
89094757|NCT02695108|Experimental|scapular exercise on neck pain|patients in this arm received cervical manual therapy and cervical exercises too. Apart from cervical manual therapy and cervical exercises,patients also performed scapular stabilization exercise targeting trapezius, serratus anterior and rhomboid muscles. Rehabilitation period was lasted for 6 weeks. The same assessment parameters was conducted on this arm too.
89094758|NCT02744716|Experimental|non-balloon group|with aspirin
89094759|NCT02744716|Experimental|balloon group|with aspirin and intrauterine balloon
89094760|NCT02744716|No Intervention|control group|without aspirin and intrauterine balloon
89094761|NCT02741362|Experimental|ADSC arm|Single intravenous administration of Stromal Vacsular Fraction (SVF) cells soinating Adipose Derived Stem Cells (ADSC) 6 week baseline data prior to the injection of ADSC will be collected. 6 week, 3 months and 6 months follow up data will be compared against baseline.
89094762|NCT00837811|Experimental|LY2127399|
89094763|NCT02744794|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
89094764|NCT02744872|Active Comparator|Felodipine|Tablet Felodipin 10 mg x 1 daily
89094765|NCT02744872|Placebo Comparator|Placebo|Identical placebo once daily
89094766|NCT02741206|Active Comparator|High Risk PTSD Group 1|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
89226979|NCT00630032|Experimental|Ixabepilone|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);
89226980|NCT00609791|Experimental|nab-paclitaxel|
89226981|NCT00569140|No Intervention|1|E10030
89226982|NCT00544830|Experimental|Treatment (androgen therapy, radiation therapy)|"ADT: Patients not currently on ADT receive goserelin acetate SC or leuprolide acetate via injection once every 4 or 12 weeks and bicalutamide PO QD. Treatment repeats every 12 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients already receiving ADT at the time of enrollment continue treatment until they have received 36 weeks of therapy.~RADIATION THERAPY: Patients achieving PSA normalization after initiation of androgen deprivation therapy undergo intensity-modulated radiation therapy daily for 2-7 weeks during or after completion of androgen deprivation therapy."
89226983|NCT00534430|Experimental|Busulfan, FTBI and VP16|IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant
89226984|NCT00492050|Experimental|Bortezomib + Rituximab|Bortezomib 1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).
89226985|NCT00456963|Experimental|Diet, exercise and Enalapril|one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
89226986|NCT00456963|Active Comparator|Diet, Exercise and Losartan|one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
89226987|NCT00456963|Placebo Comparator|Diet, exercise and Placebo|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
89226988|NCT00418821|Experimental|Laronidase|Mothers treated with laronidase who intended to breastfeed their infants while receiving laronidase and their infants who were breastfeed while the mothers were receiving laronidase.
89226989|NCT00353782||Dyslipidemia|Dyslipidemia
89226990|NCT00177268||CTCL, atopic dermatitis, eczema|Those subjects with cutaneous t-cell lymphoma and Sezary syndrome, atopic dermatitis, or eczema may participate as appropriate with the potential for blood, tissue or urine sampling.
89226991|NCT00073801||Chronic Pelvic Pain and Endometriosis|Women with chronic pelvic pain and endometriosis found at study surgery
88812629|NCT02262026|Experimental|FHP; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
89094767|NCT02741206|Active Comparator|High Risk PTSD Group 2|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
89094768|NCT02741206|Experimental|Low Risk PTSD Control|Twenty additional women, who are at lower risk and thus not eligible for randomization, will also receive one psycho-education session and usual care (control group 2).
89094769|NCT02744638|Experimental|probiotic yoghurt & Arilin|probiotic yoghurt, 2 units (125 g), containing living strains of L.crispatus, L.gasseri, L.rhamnosus, L.jensenii, each in a concentration of 1 x 107 CFU/ml product for 4 weeks Two yoghurts are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
89094770|NCT02744638|Placebo Comparator|chemically acidified milk & Arilin|chemically (H3PO4) acidified milk (125g) without bacterial strains. Two products are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
89094771|NCT02744560|Experimental|patients|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
89094772|NCT00703417||1|Healthy post-menopausal women
89094773|NCT00703417||2|Diabetic without fracture
89094774|NCT00703417||3|Diabetic with fracture
89094777|NCT02744404||POC EID|Point of Care Early Infant Diagnosis qualitative technologies (Alere q) will be implemented. Sample collection and testing will happen in the same location within the health care facility.
89094778|NCT02744404||Laboratory-based testing|Conventional laboratory-based testing using the Abbott m2000 technology will continue to be used per standard of care in Malawi. Dried blood spot samples will be collected at health care facilities and transported within the national network to centralized laboratories for testing.
89094779|NCT02744326|Experimental|Text message reminder group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive text message reminders to attend or schedule a follow-up outpatient referral.
89094780|NCT02744326|No Intervention|Usual Care group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive the usual standard of care.
89094781|NCT02740894||targeted therapy|according to national healthy policy, targeted therapy is the optional therapy
89094782|NCT02740894||traditional chemotherapy|according to national healthy policy, chemotherapy is the first line treatment.
89094783|NCT00857389|Experimental|Thio-Clo-Bu with Allo SCT|"Pre-transplant conditioning regimen:~Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF~Post haploidentical stem cell transplant participants:~Cyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses."
89094784|NCT02741050|Experimental|Tailored Physical Activity Intervention|Intervention group will receive Spanish-language physical activity print intervention based on SCT and Transtheoretical Model, (TTM) that emphasizes behavioral strategies for increasing activity levels.
89094785|NCT02741050|Active Comparator|Standard of Care Control Group|Control group will receive standard of care through the Family Medicine clinic as well as monthly questionnaires on topics other than physical activity (e.g. diet) to complete.
89094786|NCT03873376|Experimental|Opt-in|Receive offer to order self-sampling kit
89094787|NCT03873376|Experimental|Opt-out|Receive self-sampling kit unsolicited
89094788|NCT03873376|Experimental|Control|Receive open reminder to be screened by physician
89094789|NCT02744482|Experimental|Risedronate|Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.
89094790|NCT02744482|Placebo Comparator|Placebo|Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.
89094791|NCT02744248|Active Comparator|IOP Injection|Participants will receive 1 injection of the IOP at Days 1,once time.
89094792|NCT02744248|Placebo Comparator|0.9% normal saline|Participants will receive 1 injection of 0.9% normal saline at Days 1,once time.
89094793|NCT01071798||Main Analysis Set|Participants who received at least one cycle of rituximab
89094794|NCT02744170|Experimental|COPD patients with delivery order 1, 2, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
89226992|NCT00073801||Chronic Pelvic Pain and No Endometriosis|Women with chronic pelvic pain and NO endometriosis found at study surgery
88812630|NCT02262026|Experimental|FHP; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
89094795|NCT02744170|Experimental|COPD patients with delivery order 2,3, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
89094796|NCT02744170|Experimental|COPD patients with delivery order 3, 2, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
89094797|NCT02744170|Experimental|COPD patients with delivery order 1, 3, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
89094798|NCT02744170|Experimental|COPD patients with delivery order 2, 1, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
89094799|NCT02744170|Experimental|COPD patients with delivery order 3, 1, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
89094800|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^9 vp/dose|Participants administered MRKAd5 HIV-1 gag vaccine 1x10^9 viral particles (vp)/dose (V520), on Day 1, Week 4, and Week 26.
89094801|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^10 vp/dose|"Participants were to be administered MRKAd5 HIV-1 gag 1x10^10 vp/dose (V520) on Day 1, Week 4, and Week 26.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in the group MRKAd5 HIV-1 gag 1x10^10 vp/dose."
89094802|NCT00857311|Experimental|Placebo|Participants administered placebo to MRKAd5 HIV-1 gag vaccine (V520) on Day 1, Week 4, and Week 26.
88812631|NCT02262026|Experimental|FHP; placebo, then 125mg AZD0530,then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
89094803|NCT00857311|Sham Comparator|Open Label Tetanus and Diptheria Toxoids Adsorbed|"Participants were to be administered open label tetanus and diptheria toxoids adsorbed (Td) at Day 1 only.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in this group."
89094804|NCT05629000||Carotid artery stenosis|patient with carotid artery stenosis
89094805|NCT04118881|Experimental|treatment group|The treatment group was given intradermal needling at ear acupoints: cardia (CO3), stomach (CO4), sympathetic (HX4)
89094806|NCT04118881|Sham Comparator|control group|The control group was given intradermal needling at ear acupoints: spiral area (HX7 and HX8).
89094807|NCT02875626|Experimental|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
89094808|NCT02744014|Experimental|Early intervention group|The program starts with a 30-days training course led by course instructor Wim Hof and supervised by the research team. The mindset & physical therapy based on the Wim Hof Method includes breathing techniques, training of mindset and concentration, and gradual cold exposure.
89094809|NCT02744014|Other|Late intervention group|This group will receive the same training with a delay of 60-90 days, serving initially as control.
89094810|NCT02874768|Experimental|dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
89094811|NCT02874768|Active Comparator|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
89094812|NCT04118647|Experimental|Wu-Chu-Yu tang|
89094813|NCT04118725|Experimental|Muscular explorations|Pulmonary function test and diaphragmatic electromyography
88812632|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
89094814|NCT05629312|Experimental|Maxillary expansion|"All included patients (in all arms) present (at least one) maxillary canine impaction.~Patients in this arm present also lack of space in the upper jaw and are treated with maxillary expansion"
89094815|NCT05629312|Experimental|Extraction of deciduous canines|"All included patients (in all arms) present (at least one) maxillary canine impaction.~Patients in this arm present also lack of space in the upper jaw and are treated with extraction of deciduous canines"
89094816|NCT05629312|No Intervention|No intervention|"All included patients (in all arms) present (at least one) maxillary canine impaction.~Patients in this arm present also lack of space in the upper jaw and no intervention is performed"
89094817|NCT05629312|No Intervention|Control|"All included patients (in all arms) present (at least one) maxillary canine impaction.~Patients in this arm do not present lack of space in the upper jaw and no intervention is performed"
89094818|NCT00857233|Experimental|Memantine|
89094819|NCT05628922|Experimental|Early Responders|those with undetectable plasma EBV DNA after first cycle of induction chemotherapy (GP regimen)
89094820|NCT05628922|Experimental|Intermediate Responders|those with detectable plasma EBV DNA after first cycle of induction chemotherapy (GP regimen), and undetectable plasma EBV DNA at completion of induction chemotherapy
89094821|NCT05628922|Experimental|Late Responders|those with detectable plasma EBV DNA after first cycle and at completion of induction chemotherapy (GP regimen)
89094822|NCT02740426|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
89094823|NCT02740426|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
89094824|NCT00856999|Experimental|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
89094825|NCT02743624|Other|Pressure Support Titration|The analysis of the diagnostic accuracy of the breathing pattern variables, P 0.1 and the rate of tracheal muscle relaxation.
89094826|NCT02743546|Experimental|Dose Optimization:Participant with Certain B-Cell Malignancies|Participants with certain B-cell malignancies (diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], or follicular lymphoma [FL]) will receive rising doses of intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met. Dose escalation will continue until the recommended phase 2 dose or maximum tolerated dose is reached.
89094827|NCT02743546|Experimental|Dose Expansion: Participants with DLBCL|Participants with DLBCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
89094828|NCT02743546|Experimental|Dose Expansion: Participants with FL|Participants with FL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
89094829|NCT02743546|Experimental|Dose Expansion: Participants with MCL|Participants with MCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
89094830|NCT02743546|Experimental|Dose Expansion: Participants with CLL|Participants with chronic lymphocytic leukemia (CLL) will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
89094831|NCT00699595||Term pregnant women|Healthy women scheduled for elective Cesarean section.
89094832|NCT01071252|Experimental|AIN457 1x25mg|
89094833|NCT01071252|Experimental|AIN457 3x25mg|
89094834|NCT01071252|Experimental|AIN457 3x75mg|
89094835|NCT01071252|Experimental|AIN457 3x150mg|
89094836|NCT01071252|Placebo Comparator|Placebo|
89094837|NCT02743234|Experimental|FMT|Fecal microbiota transplantation (FMT) following 4-10 days of vancomycin 125 mg x 4, using cryopreserved feces from a healthy anonymous donor
89094838|NCT02743234|Active Comparator|Fidaxomicin|10 days fidaxomicin 200 mg x 2 daily
89094839|NCT02743234|Active Comparator|Vancomycin|10 days vancomycin 125 x 4 daily
89094840|NCT02740270|Experimental|Arm A|
89094841|NCT02740270|Experimental|Arm B|
89094842|NCT00856843|Active Comparator|Polyethylene glycol 3350 based bowel preparation|Polyethylene glycol 3350 based bowel preparation
89094843|NCT00856843|Experimental|BLI800|BLI800
89094844|NCT02875782|Experimental|DM intervention|Subjects will receive a patient-centered motivational intervention with two components: (1) the stage-matched smoking cessation intervention and (2) the relationship between smoking and diabetic complications. All subjects will receive a self-help cessation manual with DM components and take the exhaled carbon monoxide test. The total counseling process will take about 20 minutes. Three consecutive (3-, 6- and 12-month) follow ups will be conducted. Also, the counselor will further the progress of their action plan and barriers encountered in the behavioral change process as well as engage them in the process, enhance their self-efficacy, and identify individual barriers and facilitators.
89094845|NCT02875782|Placebo Comparator|Control group|Subjects will receive usual care provided at the DM clinic. All subjects will receive a self-help cessation manual and take the exhaled carbon monoxide test. Counselor will give follow-up calls to the patients to assess their smoking status and other health-related lifestyle practices. Three consecutive (3-, 6- and 12-month) follow ups will be conducted with all participants. The total counseling process will take about 20 minutes.
89094846|NCT02740348|Experimental|ZocDoc Assistance|Research assistant sets up follow-up appointment for subject using ZocDoc.
89094847|NCT02740348|Active Comparator|ZocDoc Information|Research assistance provides subject with written information about ZocDoc.
89094848|NCT02740348|No Intervention|Usual Care|ED staff gives written and verbal discharge instructions to subject.
89094849|NCT02743156|Active Comparator|angiography-guided PCI|angiography-guided percutaneous coronary intervention
89094850|NCT02743156|Experimental|IVUS-guided PCI|intravascular ultrasound guided percutaneous coronary intervention
89094851|NCT02743390|Active Comparator|TNF-alpha inhibitor drug|Infliximab infusion (TNF-α inhibitor, 3 mg/kg, 250mL)
89094852|NCT02743390|Placebo Comparator|Placebo drug|Saline infusion (250mL)
89094853|NCT00856609|Active Comparator|Exenatide|10 micrograms subcutaneously twice
89094854|NCT00856609|Placebo Comparator|Placebo|Twice daily
89094855|NCT02743000||Women ages 18-35|Women ages 18-35 who do and do not engage in binge eating will be included in the study
89094856|NCT02739958|Active Comparator|Propofol group|Patients receive only intravenous anesthetics
89094857|NCT02739958|Placebo Comparator|Isoflurane group|Patients receive isoflurane /fentanyl anesthesia
89094858|NCT02739802|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
89094859|NCT02739880|Experimental|The study population|"The study population consists of postmenopausal patients (more than 2 years and less than 10 years) with a body mass index <35 with sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness.~Intervention: Intra-mucosal Injections of Cross-linked Hyaluronic Acid"
89094860|NCT01071096|Active Comparator|OnabotulinumtoxinA|Minimum dose of 155 international units (U) OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
89094861|NCT01071096|Placebo Comparator|Saline|155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
89094862|NCT02742844|Experimental|APZ2 application|Topical, single application of APZ2; 500000 cells per square cm;
89094863|NCT02739646|Experimental|Females|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
89094864|NCT02739646|Experimental|Males|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
89094865|NCT02739568|Experimental|Pitolisant (BF2.6449|Histamine H3 receptor H3R antagonist/ inverse agonist
89094866|NCT02739568|Placebo Comparator|Placebo|Placebo
89094867|NCT02742688|Experimental|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|
89094868|NCT02742688|Placebo Comparator|Placebo|
89094869|NCT02742610|Experimental|Mindfulness with Contingency Management|The intervention (MSI-CM) will involve two individual pre-quit in-person sessions and two post-quit phone counseling sessions, a series of brief mindfulness trainings that will be delivered via smartphone, that prompts participants to practice a mindfulness exercise five times a day while abstinent during the 2-week incentivized abstinence period (using CM) plus an additional 2 weeks (without CM) following the participant's target quit date. The MSI-CM participants will be asked to provide CO video via smartphone twice daily with monetary incentives provided (CM). Participants will receive monetary incentives contingent on each confirmed CO level (less than 7 ppm) for the CM period. We will use CM as an adjunct strategy to enhance the efficacy of mindfulness training.
89094870|NCT02742610|Active Comparator|Active Control|Participants assigned to the control group will receive two individual pre-quit in-person sessions and two post-quit phone counseling sessions, similar to the MSI-CM except for mindfulness introduction/discussion. Participants in the control group will receive the same monetary incentives on average as the participants in the MSI-CM for submitting CO videos, regardless of CO levels (non-abstinent contingent), during the 2-week post-TQD period. Each participant in the group (the non-contingent CO group) will be yoked to a single participant (selected randomly with stratification) in the MSI-CM. The yoked participant receives the same amount of monetary incentives as his or her matched participant in the contingent CO (MSI-CM) group.
89094871|NCT02739724|Active Comparator|Classic laparoscopy|Patients will undergo laparoscopy surgery with classic laparoscopy technic.
89094872|NCT02739724|Experimental|Laparoscopy single port access|Patients will undergo laparoscopy surgery by single port access technic.
89094873|NCT00856375|Experimental|NKTR-102|NKTR-102 IV every 3 weeks
89094874|NCT00856375|Active Comparator|irinotecan|irinotecan IV every 3 weeks
89094875|NCT02739490|No Intervention|Group control|It does not perform any kind of guided exercise.
89094876|NCT02739490|Experimental|Core Training Group|The training was distributed in four positions defined ventral plank, side plank left, right side board and bridge semiflexion knees, respectively. With time isometric contraction of 30 seconds repeated four times with rest 30 seconds between repetitions. During 10 sessions distributed twice weekly.
89094877|NCT01070784|Experimental|1|
89094878|NCT01070784|Active Comparator|2|
89094879|NCT00837577|Experimental|Sitagliptin/Sitagliptin|
89094880|NCT00837577|Experimental|Placebo/Sitagliptin|
89094881|NCT02742220|Experimental|Isometric Handgrip Training Group|Experimental group will perform home-based unilateral handgrip exercise and will be recommended to increase daily physical activity levels.
89094882|NCT02742220|Sham Comparator|Control Group|Control group will be recommended to increase daily physical activity levels.
89094883|NCT02742298|Other|QMUS|All patients will undergo serial quantitative muscle ultrasound.
89094884|NCT02742298|Other|EIM|All patients will undergo serial electrical impedance myography measures.
89094885|NCT01070550||Cohort|Participants chronically infected with the hepatitis C virus including Genotypes 1 to 6.
89094886|NCT02742376|Other|Soft surface|A soft sponge used for physiotherapy is placed on the floor along a path,
89094887|NCT02742376|Other|Floor|The subject will walk on the floor.
89094888|NCT02742376|Other|Shoes|Special shoes (Kyboot) with air cushions that are meant to relieve pressure will be used.
89094889|NCT02739178|Experimental|GSF Sanitation intervention|This arm will receive the GSF sanitation intervention, a community-level sanitation intervention
89094890|NCT02739178|No Intervention|Comparator|This arm will receive the GSF intervention in 2017 or later.
89094891|NCT04189900|Experimental|Triptorelin|The subjects in this group receive a single dose treatment. Biologic sample collection (urine) from 48 hours pre-administration to 48 hours post administration.
89094892|NCT00848107|Experimental|Treprostinil|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).
89094893|NCT02739334|Experimental|ENRICH|The intervention will integrate the Play and Learning Strategies (PALS) program, a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler with Coordinated Approach To Child Health (CATCH), a behaviorally-based school health promotion program based on Social Cognitive Theory (SCT) to increase opportunities for healthy eating and activity.
89094894|NCT02739334|Active Comparator|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
89094895|NCT02739256|Experimental|voiding trial 4 hours post-op|
89094896|NCT02739256|Active Comparator|voiding trial post-op day 1|
89094897|NCT04030741|Active Comparator|Meronem and flagyl|Children in Non-operative treatment (group A) Children in non-operative treatment group will be given intravenous meropenem (10 mg/kg/dose x IV x TDS) and metronidazole (20 mg/kg/day divided into 3 doses) for at least 48 hours. Once the child starts tolerating oral intake and becomes clinically improved, the treatment will be changed to oral ciprofloxacin (20 mg/kg/day) divided into 2 divided doses) and metronidazole (20 mg/kg/day divided into 3 doses for another 8 days.
89094898|NCT04030741|Active Comparator|Surgery (appendectomy)|"Children in group B: appendectomy will b done and post operative single dose of antibiotics.~discharge after 24hour and Follow up after 1 week."
89094899|NCT03689140|Experimental|App-only|The intervention will consist of participants will only use a smoking cessation app
89094900|NCT03689140|Experimental|Telemedicine counseling only|The intervention will consist of participants will only use telemedicine counseling
89094901|NCT03689140|Experimental|App + telemedicine counseling|The intervention will consist of participants will only use a smoking cessation app + telemedicine counseling
89094902|NCT03689140|No Intervention|Usual Care|The participants will continue with usual care
89094903|NCT04298632|Experimental|Youth-only|Only the youth receives the education program
89094904|NCT04298632|Experimental|Family enhanced|A parent and the youth both receive the education program
89094905|NCT04298632|No Intervention|Control|neither parent, nor youth receives the education program
89094906|NCT00636376|Experimental|1|Single arm--no randomization. All subjects enrolled will have vitals collected and three ultrasounds at different levels of head of the bed elevations.
89094907|NCT02736760|Experimental|Daylight photodynamic therapy (PDT)|"One intervention in the daylight photodynamic therapy arm:~Daylight photodynamic therapy using Methylaminolevulinate (MAL) will be performed five times within 18 months (visits 1-5). In the PDT group the patients will apply a chemical sunscreen (SPF 50+) to the whole face and other light-exposed, unprotected areas of the skin. After at least 15 minutes a lesion preparation of AKs (removal of crusts) will be performed and methylaminolevulinate (MAL) will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours."
89094908|NCT02736760|Active Comparator|Cryosurgery|In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. In the control group, cryosurgery will be performed using liquid nitrogen spray in each AK lesion; this will be done at visit 1 and, if necessary, also at visits 2-5. At visits 2-6, the efficacy of the treatment will be evaluated by the observer by documenting all existing and newly appearing AKs in the face.
89226993|NCT00073801||Healthy Volunteers|Women without no chronic pelvic pain and no symptoms of endometriosis
89094909|NCT02736838|Experimental|Phase I|Interventions: Different positions will be applied to subjects to measure preipheral tissue oxygenation, pressure, and changes in microvascular flow. Subjects will be placed up to 4 hours in each of the standard positions for the experiment: supine decubitus (SD) right lateral decubitus (RLD), left lateral decubitus (LLD). SD measurements will be made at 0, 30 and 45 degrees of inclination to bed. RLD and LLD positions will be evaluated with a body inclination of 30 and 90ª. The subjects will lie down on a memory foam mattress for an articulated bed, as are commonly used at home, residential or hospital care. Between the subject and the mattress will be inserted the pressure measuring surface. Measurements in each position will be made during intervals of 0-4 hours in the same position (SD-RLD-LLD) in each of the inclinations of the bed (0º, 30°, 45 °) or body (30º, 90º), respectively.
89094910|NCT00856297|Experimental|MenACWY-CRM|Subjects received one primary dose of MenACWY-CRM conjugate vaccine in the parent study and were followed for persistence in the present study.
89094911|NCT00856297|Active Comparator|Licensed comparator|Subjects received one primary dose of a quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier in the parent study and were followed for persistence in the present study at 5 years postvaccination.
89094912|NCT00856297|Other|Naive|Subjects who were age-matched to the other study groups and had not received any previous meningococcal vaccinations.
89094913|NCT00856297|Experimental|MenACWY-CRM/MenACWY-CRM|Subjects received one primary dose of the MenACWY-CRM conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
89094914|NCT00856297|Experimental|Licensed comparator/MenACWY-CRM|Subjects received one primary dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
89094915|NCT02875470|Experimental|Intensiv Perio Set|Root planing with diamond burs
89094916|NCT02875470|Active Comparator|Gracey curette|Root planing with Gracey curettes
89094917|NCT02738944|Active Comparator|Integrated Care|Telepsychiatry Collaborative Care
89094918|NCT02738944|Active Comparator|Referral Care|Telepsychiatry Enhanced Referral
89094919|NCT04304898||Single Group Assignment|Intervention group without a control group
89094920|NCT02875938|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
89094921|NCT02736604|Experimental|Air anesthesia|air will be used as carrier agent for maintenance of anesthesia
89094922|NCT02736604|Active Comparator|Nitrous Oxide anesthesia|nitrous oxide will be used as carrier agent for maintenance of anesthesia
89094923|NCT02613013|Active Comparator|single LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
89094924|NCT02613013|Experimental|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure
89094925|NCT04304976|Experimental|Training with ROBERT® Passive|Training performed with ROBERT® in passive mode, resulting in active assistive training.
89094926|NCT04304976|Experimental|Training with ROBERT® Active|Traning performed with ROBERT® in Active mode, resulting in active resistive training.
89094927|NCT02738710|Experimental|transumbilical wound|transumbilical incision
89094928|NCT02738710|Active Comparator|infra umbilical wound|infra umbilical incision
89094929|NCT04296084||healthy individuals|Volunteer healthy individuals who are between the ages of 20-40 and who do not have any medical condition to affect gait or arm swing.
89094930|NCT02611921|Experimental|Crossover Group: Ketamine verses Placebo|"Phase 1: Two ascending doses of intranasal ketamine~Two week washout~Phase 2: Two doses of placebo"
89094931|NCT02611921|Experimental|Crossover Group: Placebo verses Ketamine|"Phase 1: Two doses of placebo~Two week washout~Phase 2: Two ascending doses of intranasal ketamine"
89094932|NCT02736448|Experimental|Arm Lu-PRRT-Cap|Arm Lu-PRRT-Cap: oral low dose of capecitabine in association with Lu-PRRT (at 3.7 Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
89094933|NCT02736448|Experimental|Arm Lu-PRRT|Arm Lu-PRRT: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
89094934|NCT00701077|Experimental|1|3,4-Di-amino-Pyridine : a single 20 mg dosing
89094935|NCT00701077|Placebo Comparator|2|
89094936|NCT00703651|Experimental|1|
89094937|NCT00703651|Experimental|2|
89094938|NCT00703651|Active Comparator|3|
89094939|NCT01046136|Active Comparator|Mucinex|
89094940|NCT01046136|Placebo Comparator|placebo|
89094941|NCT02736682|Experimental|Single dose antibiotic|2g of intra venous Ceftriaxone and 500 mgs Intra venous metronidazole is administered to the mothers as a Single dose pre-operative30-60 minutes before surgery.
89094942|NCT02736682|Active Comparator|multiple dose antibiotic.|Multiple doses of IV Ceftriaxone 1g and metronidazole 500mgs given to the mother during surgery there after Ceftriaxone 1g every day for 3 days and IV metronidazole 500 mgs every 8 hours for 3 days.
89094943|NCT02736292|Experimental|participant|
89094944|NCT02874690|Placebo Comparator|Placebo|Placebo pill received
89094945|NCT02874690|Experimental|Methylphenidate|
89094946|NCT02736214|Experimental|Lifestyle counseling|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
89094947|NCT02736214|No Intervention|Control group|The control group answered a baseline questionnaire in the waiting room and received standard care.
89094948|NCT05298007|Active Comparator|real stimulation|Participants will receive active tDCS once daily for two weeks. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. Fourteen2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes each day over 14 consecutive sessions.
89094949|NCT05298007|Sham Comparator|sham stimulation|Participants will receive sham tDCS once daily for two weeks. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
89094950|NCT02738242|Experimental|Novus system users|Sixteen (16) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be recruit for this study and will receive the Novus system for daily use.
89094951|NCT02738632|Experimental|Telmisartan/Amlodipine+Hydrochlorothiazide|Telmisartan/Amlodipine combination drug and Hydrochlorothiazide
89094952|NCT02738632|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide
89094953|NCT01070394|Experimental|LDX Treatment|Eligible participants received 12 weeks of open-label treatment. Those on treatment prior to baseline underwent a 7-day (for amphetamine or methylphenidate) or 28-day (for atomoxetine or other medications) washout period prior to initiating LDX treatment. The starting dose was 30mg/day, which could be titrated up by 20mg/day during visits 2-6 (for a maximum dose of 70mg/day). At discretion of investigator, the dose could be down-titrated by 20mg/day during visits 4-6. Once the dose was optimized (after visit 6), the dose was maintained for 8 weeks.
89094954|NCT00836953|Experimental|Study Group|Participants received 2 doses of Fluzone® vaccine
89094955|NCT02736058|Experimental|Participants|the included pregnant females will undergo trans-abdominal sonography as well as trans-vaginal sonography , to diagnose the abnormal placentation and the results will be compared to the intra- operative as well as the pathological examination of the specimen.
89094956|NCT00703807|Experimental|1|Daily oral RAD001 for 21 days in combination with oral topotecan on days 1-5 of a 21 day cycle
89094957|NCT00699829||1|Mohs' micrographic surgery (MMS)
89094958|NCT00699829||2|Conventional surgery
89094959|NCT02738554|Other|Treatment cessation arm|Cessation of treatment as according to European Association for the Study of the Liver Guidelines for chronic hepatitis B
89094960|NCT00701233|Active Comparator|2|Corticosteroid injection into Carpal Tunnel
89094961|NCT00701233|Active Comparator|1|Botulinum toxin injection into Carpal Tunnel
89094962|NCT03645694|Experimental|SSA|Individuals with memory concerns in the experimental arm received the prototype facial recognition technology, which included a smartphone and smartwatch. The smartphone was equipped with facial recognition software application; the smartwatch communicated information with the smartphone. Persons with memory concerns and their family care partners were given a demonstration on how to utilize the technology.
89094963|NCT03645694|No Intervention|Control|Control participants did not receive the technology; at the conclusion of follow-up, all controls were offered the technology to use.
89094966|NCT01070316|Experimental|Everolimus|Subjects will be administered study drug if they meet study criteria after 4 weeks of baseline phase. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily.
89094967|NCT02737774|Experimental|Icotinib and Pemetrexed/Carboplatin|"Icotinib: Icotinib for 18 weeks, 125mg Tid，PO. Chemotherapy: pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.~Then continue with Icotinib, 125mg Tid，PO. until disease progression."
89094968|NCT02735590|Experimental|Open-label 3HP|Participants in the Treatment Arm will receive high dose INH (15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg) with Pyridoxine supplementation (25mg), and Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months. Dispensing of IP and Directly Observed Treatment (DOT) field visits in Treatment Arm participants will be performed by staff members not involved in TB symptom screening or investigation. Participants receiving 3HP who develop symptoms of hepatotoxicity will be evaluated by an Investigator.
89094969|NCT02735590|No Intervention|Baseline Screening; Active Surveillance|Adult volunteers living in TB hyperendemic communities of South Africa will be consented and screened. Individuals with HIV infection and conditions likely to affect the performance of the COR assay, or the safety and/or efficacy of the 3HP investigational regimen, will not be enrolled. Active surveillance for TB disease (Observation Arm), including regular symptom screening and symptom-targeted TB investigation (all participants) will be conducted on this Arm.
89094970|NCT04168606||Cases with placental abruption|"Cases of placental abruption included in our study will be clinically defined and will not be only diagnosed by histological examination.~All cases will be reviewed by an experienced obstetrician in order to confirm the diagnosis."
89094971|NCT05626348|Experimental|Methotrexate(MTX)+Iguratimod(IGU)|"Drug: Iguratimod（IGU），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Methotrexate(MTX)，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response.~For RA patients with naive or csDMARDs-IR"
89094972|NCT05626348|Experimental|Adalimumab+Methotrexate(MTX)|"Drug: Adalimumab，40mg, iH,q2w, once two weeks (q2w) prescribed at the beginning and adjusted due to patient response.~Drug: Methotrexate(MTX)，7-10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response.~For RA patients with csDMARDs-IR"
89094973|NCT05626348|Experimental|Iguratimod(IGU)+Leflunomide(LEF)+Hydroxychloroquine(HCQ)|"Drug: Iguratimod（IGU），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~Drug: Leflunomide(LEF)，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response.~Drug: Hydroxychloroquine(HCQ)，200mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response.~For RA patients with csDMARDs-IR"
89094974|NCT02737696|Active Comparator|Control|Participants in this group will have access to Drug Enforcement Administration's website (JustThinkTwice.gov). The JustThinkTwice website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz. Youth in this group will be informed that they will be prompted (by email and phone; described below) when the next online survey is available to complete. Youth will be asked to use this website for 30 minutes, twice per week (for a total of 60 minutes per week) for about 3-4 weeks.
89094975|NCT02737696|Experimental|Experimental|"Participants assigned to the Web-based prescription opioid prevention for adolescents will immediately (post-group assignment) be asked to start completing modules. All youth can choose to access modules in any order. Youth will be encouraged to complete 1-2 modules per login, 2x/week (about 30 mins. minimum per login to parallel the manner in which other evidence-based prevention programs have been provided to youth. We do not plan to place an artificial constraint on module access but will encourage youth to use the flexible, web- based tool in a manner that is most useful to them. In our experience providing online interventions, we expect that most youth will complete all 9 modules within 3-4 weeks."
89094976|NCT02738320|Experimental|Intervention|Intervention patients will receive access to NHCPlus when discharge to a nursing home from the hospital is expected.
89094977|NCT02738320|No Intervention|Usual Care|Control patients will receive the usual care when discharge to a nursing home from the hospital is expected.
89094978|NCT02737384|Experimental|Treatment|
89094979|NCT03512392|Experimental|Conservative fluid and deresuscitation|"Fluid restriction (avoidance of maintenance intravenous fluid and minimisation of drug diluent volumes)~Daily assessment of eligibility for deresuscitation for 3 days (eligible if oedema in more than 1 site and cumulative fluid balance > 2 litres)~Deresuscitation to target negative daily fluid balance of 1 to 3 litres:~5mg Indapamide daily (enteral) 100mg Spironolactone daily (enteral) 0.5mg/kg furosemide once (intravenous, max 40mg) 2.5-20mg/hr furosemide infusion titrated to effect OR continuous renal replacement therapy with fluid removal"
89094980|NCT03512392|Active Comparator|Usual care|Usual care at the discretion of the treating team
89094981|NCT02737540||Major depressive episode|This study population consists of patients over 60 years of age with or without a personal history of suicide attempts, hospitalized in the Nîmes University Hospital psychiatry department or the Sophoras clinic for a major depressive episode.
89094982|NCT02737540||Healthy subjects|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts will be recruited.
89094983|NCT02735434|Experimental|Internet-based ACT|Brief clinical psychiatric assessment to determine eligibility (video-based).
89094984|NCT02735434|Active Comparator|Internet-based discussion forum|Brief clinical psychiatric assessment to determine eligibility (video-based).
89094985|NCT02737228|Experimental|CG200745 PPA|CG200745 PPA plus Gemcitabine and Erlotinib
89094986|NCT01126541|Experimental|A|1000 mg IV rituximab
89094987|NCT01126541|Experimental|B|2 x 1000 mg IV rituximab
89094988|NCT02737150|Active Comparator|Self-expandable valve under local anesthesia|CoreValve Evolut R valve under local anesthesia with conscious sedation
89094989|NCT02737150|Active Comparator|Self-expandable valve under general anesthesia|CoreValve Evolut R valve under general anesthesia
89094990|NCT02737150|Active Comparator|Balloon-expandable valve under local anesthesia|Edwards Sapien 3 valve under local anesthesia with conscious sedation
89094991|NCT02737150|Active Comparator|Balloon-expandable valve under general anesthesia|Edwards Sapien 3 valve under under general anesthesia
89094992|NCT02736916|Experimental|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
89094993|NCT02736916|Active Comparator|Conventional PCI|LD-SCLC patients with Conventional PCI
89094994|NCT02735356|Experimental|Treatment (itraconazole and placebo)|Patients apply itraconazole topically BID and placebo topically BID for 12 weeks.
89094995|NCT00625469|Experimental|treatment with bosentan|patients with resting or exercise induced PAH receive bosentan in a randomized open label fashion
89094996|NCT00625469|No Intervention|PAH group with no therapy|patients with resting or exercise PAH get randomized to receive no specific therapy
89094997|NCT00625469|No Intervention|No PAH and no therapy|patients with no evidence of either resting or exercise PAH receive no intervention but are followed until lung transplantation
89094998|NCT04311125|Active Comparator|total hip arthroplasty via the mini posterior approach|total hip arthroplasty via the mini posterior approach. This approach was first described by Kocher and Langenbeck and later modified by Gibson in 1950. There is a convex incision centered on the posterior rim of the major trochanter. The incision follows the curve of the buttock and at the height of the posterior lip of the major trochanter, it is peripherally oriented along the posterior outer surface of the femur. The major gluteus is divided along the muscle fibers. Guiding sutures are inserted into the tendon mass of the hip rotor muscles just prior to their origin on the major trochanter and dissected to expose and subsequently retract the posterior hip capsule.
89094999|NCT04311125|Active Comparator|THR via the anterior approach without traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 [7]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
89095000|NCT04311125|Active Comparator|THR via the anterior approach with a traction table|The anterior approach is a modification of the classic Smith- Peterson anterior hip approach as described by Berend et al in 2009 [7]. This approach utilizes the intermuscular plane between the tendon fascia lata and the sartorius muscle, and laterally repairs the fibers of the rectus femur to expose and enclose the anterior pubic joint. A surgical traction table may be used during surgery.
89095001|NCT00637481|Experimental|Arm I (lower dose atorvastatin calcium)|Participants receive oral atorvastatin once daily for 3 months.
89095002|NCT00637481|Experimental|Arm II (atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm I) once daily for 3 months.
89095003|NCT00637481|Experimental|Arm III (higher dose atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm II) once daily for 3 months.
89095004|NCT00637481|Other|Arm IV (no intervention)|Participants do not receive treatment. Participants undergo blood sample collection and fine needle aspiration of breast tissue at baseline and at 3 months for correlative biomarker studies.
89095005|NCT00637559|Experimental|1|40mg twice daily
89095006|NCT00637559|Experimental|2|40mg three times daily
89095007|NCT00637559|Experimental|3|20mg three times daily
89095008|NCT02736994|Other|Immersion in water|water
89095009|NCT02736994|Active Comparator|Immersion in water + cleansing tablet|Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
89095010|NCT02736994|Experimental|Immersion in water with PIP|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium)
89095011|NCT04310969|Experimental|treatment group|Patients are treated every two weeks for a total of three times. Forceful expression of the meibomian glands is followed after each therapy.
89095012|NCT04310969|Sham Comparator|control group|Forceful expression of the meibomian glands only for patients.
89095013|NCT04310969|Active Comparator|active control group|LipiFlow® treatment is used as an active comparator.
89095014|NCT05577208|Experimental|renal denervation|Renal denervation shall be performed by echo-guided catheterization of the femoral artery, and subsequent cannulation of the renal arteries with a guide catheter. A renal denervation catheter shall be advanced through the guide catheter to the distal portion of the artery. The procedures shall be aimed to deliver as many radiofrequency applications as possible, 0.5 cm apart, intended duration of 60 sec, to all four quadrants of the renal arteries and main branch vessels with > 3 mm diameter.
89095015|NCT04311047|Experimental|USPIO-enhanced MRI|Ferumoxtran-10 contrast will be intravenously administered 24-36 before performing an MRI scan. The MRI scan will be discussed with the surgeon prior to resection. Findings on MRI will be compared to pathology.
89095016|NCT05553730|Experimental|Intervention Group|Older adults randomly sorted into intervention group will receive six months of intervention after registration.
89095017|NCT05553730|No Intervention|Control Group|Older adults randomly sorted into Control group will not receive six months of intervention after registration.
89095018|NCT00836875|Experimental|1|Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).
89095019|NCT02732314|Experimental|Investigational OTC Cream|Investigational OTC Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
89095020|NCT02732314|Placebo Comparator|Placebo Cream|Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
89095021|NCT02732314|Active Comparator|Cosmetic Eczema Cream|Cosmetic Eczema Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
89095022|NCT02732314|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 4 weeks to atopic dermatitis lesions and then on any new lesions that appear for 4 weeks and as directed by the study doctor.~Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, anywhere the patient would apply their ordinary body moisturizer except atopic dermatitis lesions."
89095023|NCT01125917|Experimental|BTDS|Buprenorphine transdermal patch
89095024|NCT02734966|Experimental|arm 1|lower dose： Magnesium Isoglycyrrhizinate injection 100mg OD for 4 weeks
89095025|NCT02734966|Experimental|arm 2|higher dose：Magnesium Isoglycyrrhizinate injection 200mg OD for 4 weeks.
89095026|NCT02734966|Active Comparator|Tiopronin Injection|Tiopronin Injection 200mg OD for 4 weeks
89095027|NCT00847561|Experimental|Family-based CBT|Family-based CBT. Participants will receive family-based cognitive behavioral therapy. Families in this group will learn about how to identify the signs and symptoms of anxiety, ways to cope with anxiety, relaxation techniques, and problem-solving skills. They will participate in 8, one-hour sessions, once/week with trained clinicians and 3 monthly booster sessions to reinforce what they learned.
89095028|NCT00847561|Placebo Comparator|Information Monitoring|Information Monitoring. Participants will receive a packet of information about anxiety. Participants in this group will be called monthly to monitor symptoms of anxiety.
89095029|NCT05569837|Experimental|Regular meal pattern|Participants will follow a regular meal pattern for 14 days
89095030|NCT05569837|Experimental|Irregular meal pattern|Participants will follow an irregular meal pattern for 14 days
89095031|NCT01121549||Aromasin|All patients included in the study
89095032|NCT02732002|Experimental|OCBRA group.|This group of patients will follow the proposed methodological approach for work related injuries rehabilitation.
89095033|NCT00847405|Experimental|1|
89095034|NCT00847405|Active Comparator|2|
89095035|NCT04118413|Experimental|Erector spinae plane block|Erector spinae plane block will be administrated to this group at end of the surgery under spinal anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively and sheduled paracetamol will be given.
89095036|NCT04118413|No Intervention|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine and sheduled paracetamol. No block will be performed.
89095037|NCT02734654|No Intervention|Control group|patients do not receive remote preconditioning prior to lung lobectomy
89095038|NCT02734654|Experimental|RIPC group|patients receive remote preconditioning prior to lung lobectomy
89095039|NCT02881931||Pre-Manifest HDGEC Participant|
89095040|NCT02881931||Early-Manifest HDGEC Participant|
89095041|NCT02881931||Corresponding HDGEC participant Companion|
89095042|NCT02731846|Experimental|FF/UMEC/VI (100/62.5/25 mcg) + placebo|Subjects will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg delivered via single ELLIPTA inhaler ('closed' triple) and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
89095043|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg|Subjects will receive FF/VI (100 mcg/25 mcg) and UMEC 62.5 mcg delivered via two ELLIPTA inhaler ('open' triple) once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
89095044|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + placebo|Subjects will receive FF/ VI (100 mcg/25 mcg) delivered via single ELLIPTA inhaler and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
89095045|NCT00836095|Other|Supreme LMA|"Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
89095046|NCT00836095|Active Comparator|Proseal LMA|"Proseal is a multiple use, variant of the laryngeal mask airway.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
89095047|NCT05564455|Active Comparator|SRK-T Formula for Prediction of refraction|To compare post-operative refractive outcome with Sanders Retzlaff Kraff theoretical (SRK T) and Kane formulae for intraocular lens (IOL) power calculation in cataract patients
89095048|NCT05564455|Active Comparator|Kane Formula for Prediction of refraction|To compare post-operative refractive outcome with Sanders Retzlaff Kraff theoretical (SRK T) and Kane formulae for intraocular lens (IOL) power calculation in cataract patients
89095049|NCT02731924||Ultrasound for Appendicitis|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected appendicitis
89095050|NCT00701467||Observation|
89095051|NCT00701545||1|Patients with von Willebrand disease treated with Humate P® ivr in Canada
89095052|NCT02731768|Active Comparator|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively. They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
89095053|NCT02731768|Experimental|Social support-enhanced|Participants will receive the same intervention components as the Standard group, as well as two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
89095054|NCT02694484|Other|Healthy volunteers|For healthy volunteers corresponding to the inclusion criteria it will be taken them Blood and stool samples : a blood sample during the inclusion visit and if they are seropositive for the CMV, it will be taken them another blood sample and they will give a stool sample for the following visit
89095055|NCT04248712|Experimental|Treatment Group|Participants receive Famotidine 40 mg tab twice daily by mouth and Loratadine 10 mg tab once daily by mouth for 12 weeks.
89095056|NCT04248712|Placebo Comparator|Placebo Group|Participants receive Famotidine placebo tablet matching Famotidine orally twice daily for 12 weeks, and Loratadine placebo tablet matching Loratadine orally daily for 12 weeks.
89095057|NCT02734732|Active Comparator|Ciprofloxacin|T. Ciprofloxacin 750mg, single dose immediately prior to prostate biopsy
89095058|NCT02734732|Active Comparator|Trimethoprim/Sulfamethoxazole|Trimethoprim/Sulfamethoxazole 160mg/800mg immediately prior to prostate biopsy
89095059|NCT00835237|Experimental|Boostrix Group|Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)
89095060|NCT00835237|Active Comparator|Decavac Group|Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)
89095061|NCT02731378|Experimental|EPO plus sustained iron dextran|Group 1, EPO treatment at the original dose plus IV iron dextran 200 mg every three weeks (Q3W) for 15 weeks
89095062|NCT02731378|Experimental|EPO plus aggressive iron dextran|Group 2, EPO treatment at the original dose plus IV iron dextran 100 mg, twice a week (BIW) for five weeks
89095063|NCT02731378|Active Comparator|Double EPO|Group 3, the control group, doubling the EPO dose without preplanned iron supplementation
89095064|NCT02731456|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude.
89095065|NCT04118335|Experimental|Intervention Group|The individuals in the intervention group were asked to gargle with 5 ml black mulberry syrup three times a day after meals and wait average one minute in the mouth and then swallow, in addition to the standard practice of the clinic. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. The patients were followed for 15 days. The 15-day period is consistent with the duration of mucositis healing in the literature. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
89095066|NCT04118335|No Intervention|Control Group|Standard procedures of the clinic were applied to control group. According to the standard practice of the clinic, mucositis treatment was performed by nystatin and/or benzidamine hydrochloride to the patients with the request of the physician. Follow-up and evaluation of patients who were discharged early were performed by home visits and made a phone call everyday.
89095067|NCT02731534|Experimental|Z-213|
89095068|NCT02731534|Active Comparator|Saccharated Ferric Oxide|
89095069|NCT04115917|Experimental|Schocket Scleral Depressor|Scleral Depression with Schocket Scleral Depressor
89095070|NCT04115917|Active Comparator|Cotton Tipped Applicator|Scleral Depression with Cotton Tipped Applicator
89095071|NCT02734420|Experimental|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs; Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up: Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
89095072|NCT02734420|Experimental|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette; Follow up; Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
89095073|NCT04117867||Intraoperative hypotension|
89095074|NCT02731066|Experimental|High pro, carbo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
89095075|NCT02731066|Experimental|Standard pro, carbo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
89095076|NCT02731066|Experimental|High pro, placebo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
89095077|NCT02731066|Experimental|Standard pro, placebo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
89095078|NCT04118257|Experimental|Fruit Juice|Participants consumed 2 bottles of 100% fruit juice daily for 3 weeks.
89095079|NCT04118257|Experimental|Soda|Participants consumed 2 cans of caffeine-free Coca Cola daily for 3 weeks.
89095080|NCT04118257|Other|Water|Participants consumed 2 bottles of water daily for 3 weeks.
89095081|NCT01072500|Active Comparator|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
89095082|NCT01072500|Active Comparator|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
89095083|NCT00704275|Experimental|A|0.05% cyclosporin
89095084|NCT00704275|Active Comparator|B|Refresh
89095085|NCT02734342|Experimental|Exercise, Kinesiophobia and Knee Osteoarthritis|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. During the hour, participants will complete a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improve aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted.
89095086|NCT00847015|Experimental|Gemcitabine, Cisplatin, and Sunitinib|This is a phase II study of GCS (Gemcitabine, Cisplatin, and Sunitinib) as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.
89095087|NCT04302792|No Intervention|Stage 1: Interviews and focus group sessions|"Group A: Cancer patients (requiring or have required texture-modified foods and/or experiencing or have experienced taste&smell alterations in the last 12 months) will be required to attend a one-hour online interview.~Group B: Relatives of cancer patients (requiring texture-modified foods and/or experiencing taste&smell alterations) will be required to attend a 2-hour online focus group session.~Group C: Healthcare professionals with a minimum of a year's experience with oncological patients that require texture-modified foods and/or have taste & smell alteration will be required to attend a 2-hour online focus group session.~A food diary will be given to Group A and B to complete for 7-days prior to their session. Topics to be discussed during the interview and the focus group sessions will include the food requirements of cancer patients, the barriers of the current food products, possible solutions to these requirements if any and their expectations towards new food solutions."
89095088|NCT04302792|Experimental|Stage 2: Texture-modified foods for cancer patients|The study will involve conducting a tasting trial over a 2-weeks period where participants will be required to consume a maximum of three 3D printed texture-modified food based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
89095089|NCT04302792|Experimental|Stage 3: Taste-optimised foods for cancer patients|The study will involve conducting a home test over a one-month period where participants will be required to consume taste-optimised products based on the findings from Stage 1 and evaluate the food product by completing a structured questionnaire. Key questions areas covered by the questionnaire include appetite, sensory characteristics of the product (taste, flavour, mouthfeel/texture and smell), liking and acceptability, purchase intent and best place to buy the products; questions will involve rating scales as well as qualitative comments.
89095090|NCT00704431|Experimental|darapladib|darapladib
89095091|NCT02734186|Experimental|Sh|Mono infected with Schistosoma haematobium
89095092|NCT02734186|Experimental|ShMp|Coinfected with Schistosoma haematobium andMansonella perstans
89095093|NCT00704509|Experimental|Bifeprunox|
89095094|NCT00704509|Placebo Comparator|Placebo|
89095095|NCT00704509|Active Comparator|Quetiapine|
89095096|NCT02730910|Experimental|Purple Wheat Crackers|Bran-enriched purple wheat wholegrain crackers served in 120 g portion.
89095097|NCT02730910|Experimental|Purple Wheat Granola Bars|Bran-enriched purple wheat wholegrain granola bars served in 160 g portion.
89095098|NCT02734030||Control Group|"Knee pain-free females with no history of lower limb injuries serving as a control group.~."
89095099|NCT02734030||Anterior Knee Pain Group|Females with anterior knee pain syndrome were enrolled in this group.
89095100|NCT02730832|Experimental|Patients with schizophrenia|
89095101|NCT02733952|Active Comparator|tranexamic acid|"bolus intravenous injection of tranexamic acid 10mg/kg (maximum1g) 15 min before incision followed by continuous infusion of 1mg/kg/h dissolved in 1L of saline for 10 h (maximum~1 g/10 h)"
89095102|NCT02733952|Active Comparator|Pericervical Tourniquet|The tourniquet method will be used where the urinary bladder will be dissected downwards from the lower uterine segment, and then a perforation will be made in the posterior leaflet of the broad ligament bilaterally at the level of uterine isthmus. A tourniquet (using 16- inch Foley catheter) will be passed through the perforation encircling the uterine arteries bilaterally. The Fallopian tubes and the ovaries will be carefully excluded from the line of the tourniquet to avoid direct compression and necrosis. The tourniquet will be released intermittently (at about 30 minutes interval) during the surgery and ﬁnally removed after the repair of the uterus
89095103|NCT02694796|Experimental|Intervention|The 'Physical activity program after a balneotherapy' intervention involves providing a workshop during a balneotherapy about physical activity and use of automated physical activity program including website, mobile app and connected devices, and after the balneotherapy, the access to the automated program during 12 months.
89095104|NCT02694796|No Intervention|Control|Patients included in the control arm will receive a booklet including informations about physical activity recommendations and practice.
89095105|NCT05435170|Experimental|Treatment sequence AB|Participants will receive linerixibat in fed state (Treatment A) in period 1 followed by linerixibat in fasted state (Treatment B) in period 2. The washout period will be of at least 7 days.
89095106|NCT05435170|Experimental|Treatment sequence BA|Participants will receive linerixibat in fasted state (Treatment B) in period 1 followed by linerixibat in fed state (Treatment A) in period 2. The washout period will be of at least 7 days.
89095107|NCT02733640|Active Comparator|Pantoprazole|Drug: Pantoprazole 40 mg once-daily
89095108|NCT02733640|Experimental|Ranitidine|Drug: Ranitidine 150 mg twice-daily
89095109|NCT02730520||Immuno-allergology patients|Patients followed within the Immuno-Allergology Service of the CHU Brugmann Hospital, who received an allergy assessment between 01/01/2015 and 31/12/2015. At least 1400 dermis will be analyzed. The allergens tested include: dermatophagoides pteronyssinus (DEPT), dermatophagoides farinae (DPF), blomia, cat, dog, cockroach, orchardgrass, timothy grass, alder, hazel,birch, olive tree, cypress, ash, latex, aspergillus, alternaria, cladosporium, peanut, hazel.
89095110|NCT02730676||Electronic Cigarette #1|VUSE® Original Digital Vapor Cigarettes (29 mg nicotine)
89095111|NCT02730676||Electronic Cigarette #2|VUSE® Menthol Digital Vapor Cigarettes (29 mg nicotine)
89095112|NCT02733562||Binge eaters|Classificated preoperatively
89095113|NCT02733562||Volume eaters|Classificated preoperatively
89095114|NCT02733562||sweet eaters|Classificated preoperatively
89095115|NCT02733562||snack eaters|Classificated preoperatively
89095116|NCT00855595|Experimental|Azelaic acid (Finacea, BAY39-6251) plus Doxycycline (Oracea)|Participants received topical azelaic acid gel 15% twice daily and doxycycline 40 mg once daily for 12 weeks
89095117|NCT00855595|Active Comparator|Metronidazole (Metrogel) plus Doxycycline (Oracea)|Participants received topical metronidazole 1% gel once daily and doxycycline 40 mg once daily for 12 weeks
89095118|NCT05434858|Experimental|Patient at high risk for gout due to elevated serum urate concentrations (≥ 8 mg/dL)|"Patients at high risk for gout due to elevated serum urate concentrations (≥ 8 mg/dL) will be included.~The participants included will be followed for a period of 60 months, with an initial visit, a final visit as well as an additional visit in case of suspicion of gout.~The presence of symptoms suggestive of gout will be evaluated during regular contact with the participants: a telephone call every 6 months as well as a postal or electronic mail every 3 months. Participants will be asked to contact the investigator if new symptoms or relevant medical events occur.~Blood (32.5 ml maximum) and urine (4 ml) samples will be taken from participants who have given their specific consent for a biological collection with a particular genetic aim."
89095119|NCT02733718|Other|Group 1: no enteral feeding|intervention: NIRS (near-infrared spectroscopy)
89095120|NCT02733718|Other|Group 2: Feeding is reduced by %50|intervention: NIRS (near-infrared spectroscopy)
89095121|NCT02733718|Other|Group 3: Feeding will be continued|intervention: NIRS (near-infrared spectroscopy)
89095122|NCT05433532|Experimental|Azacitidine，Venetoclax，and Flumatinib Regimen|See Detailed Description.
89095123|NCT00855439|Experimental|Exenatide|Subjects will take exenatide by subcutaneous injection twice daily for 18 months
89095124|NCT00855439|Active Comparator|glargine|Subjects will take 1 daily injection of insulin glargine for 18 months.
89095125|NCT01064856|Experimental|Double-blind (DB) Adalimumab|Adalimumab 40 mg subcutaneous (SC) injection every other week (eow) up to Week 12 in double-blind period.
89095126|NCT01064856|Placebo Comparator|Double-blind Placebo|Placebo subcutaneous (SC) injection every other week (eow) up to Week 12 in the double-blind period.
89095127|NCT01064856|Experimental|Double-blind Adalimumab / Open-label Adalimumab|Adalimumab 40 mg SC injection eow up to Week 12 in double-blind period and from Week 12 to Week 156 in open-label period.
89095128|NCT01064856|Placebo Comparator|Double-blind Placebo / Open-label Adalimumab|Placebo SC injection every other week (eow) up to Week 12 in the double-blind period; adalimumab 40 mg subcutaneous injection eow from Week 12 to Week 156 in the open-label period.
89095129|NCT02730442|Experimental|Single dose F901318 with fluconazole|AUC0-t for F901318 will be assessed before and after 5 days of treatment with fluconazole oral
89095130|NCT02733874|Experimental|test group|Compound Clobetasol Propionate Ointment
89095131|NCT02733874|Active Comparator|control group|Calcipotriol Betamethasone Ointment
89095132|NCT02730364|Experimental|Theraflu night powder|Participants will receive a single dose (1 sachet) of Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
89095133|NCT02730364|No Intervention|No Treatment|Participants in this arm will not receive any medication
89095134|NCT02730052|Active Comparator|Omron 9200T without Telemonitoring|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
89095135|NCT02730052|Experimental|Omron 9200T plus Telemonitoring|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
89095136|NCT00846391|Experimental|MK8245 5 mg b.i.d.|MK8245
89095137|NCT00846391|Experimental|MK8245 50 mg b.i.d.|MK8245
89095138|NCT00846391|Placebo Comparator|Placebo|Placebo
89095139|NCT00636454|Active Comparator|1|This group will serve as the control group and will receive only the care usually given to OA patients.
89095140|NCT00636454|Experimental|2|This group will take part in the 10-session treatment program that will teach patients cognitive and behavioral skills to cope with pain.
89095141|NCT01042392|Active Comparator|Ramipril|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal): At visit 4, part of patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
89095142|NCT01042392|Experimental|Aliskiren|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal ): At visit 4, part of the patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
89095143|NCT01042392|Placebo Comparator|Placebo to Ramipril|In period III (double-blind withdrawal ): At visit 4, part of patients from Ramipril arm received placebo to Ramipril for 1 day. The study ended at visit 5 (48 hours later than visit 4).
89095144|NCT01042392|Placebo Comparator|Placebo to Aliskiren|In period III (double-blind withdrawal ): At visit 4, part of the patients from Aliskiren arm received placebo to Aliskiren for 1 day. The study ended at visit 5 (48 hours later than visit 4).
89095145|NCT00704665|Placebo Comparator|2|Placebo
89095146|NCT00704665|Experimental|A|10ug/kg/day or 25/ug/kg/day
89095147|NCT02694952|Active Comparator|FAV-Africa|FAV-Africa infusion at enrollment, and then at two and six hours after enrollment, if necessary. To be given as unblinded rescue dose at twelve hours if fourth dose of antivenom necessary.
89095148|NCT02694952|Experimental|EchiTabPlus-ICP|EchiTabPlus-ICP infusion at enrollment, and then at two and six hours after enrollment, if necessary.
89095149|NCT00913315|Experimental|tolterodine + tamsulosin|
89095150|NCT00913315|Active Comparator|tamsulosin + placebo|
89095151|NCT00701857|Experimental|Pemetrexed, Cisplatin, Radiation Therapy|Concomitant Pemetrexed and CDDP Plus Radiation Therapy
89095152|NCT02733484|Experimental|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
89095153|NCT02733484|Placebo Comparator|Placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
89095154|NCT02694640|Experimental|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
89095155|NCT02694640|Experimental|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
89095156|NCT02694640|Experimental|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
89095157|NCT02733328||AKI Patients|Patients with AKI
89095158|NCT02733328||Non-AKI Patients|Patients without AKI
89095159|NCT05420272||Pes planus|Evaluation group- Trunk performance and endurance lower extremity biomechanics
89095160|NCT05420272||Control group healthy|Trunk performance and endurance lower extremity biomechanics
89095161|NCT02729662|Other|Patients with ADPKD|This analysis set consists of patients whose at least 2 TKV data are available both before and after taking tolvaptan.
89095162|NCT03195244|No Intervention|Observation|
89095163|NCT03195244|Active Comparator|One-on-one Aquatic Therapy|
89095164|NCT03195244|Experimental|Group Aquatic Therapy|
89095165|NCT03194854|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
89095166|NCT03194854|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
89095167|NCT02733250|Other|Pembrolizumab + Nab-Paclitaxel|"Phase I will determine the recommended Phase II dose (RP2D) of nab-paclitaxel when given in combination with pembrolizumab. Escalation for nab-paclitaxel will be conducted following a 3+3 design. First cohort of 3 patients will receive nab-paclitaxel on Days 1 and 8 at a dose of 100 mg/m2 intravenous (IV) in combination with pembrolizumab at 200 mg IV every 3 weeks. If no dose limiting toxicities (DLT) occur, the dose of nab-paclitaxel will be escalated to 100 mg/m2 on Days 1, 8 and 15 every 3 weeks. The dose of pembrolizumab will remain the same. If no DLTs occur, dose level 2 will be defined as the RP2D. In the Phase II, pembrolizumab will be administered at 200 mg IV every 3 weeks and nab-paclitaxel will be administered at the RP2D."
89095168|NCT02733094|Experimental|Open-label|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 2 weeks until week 32.
89095169|NCT02729584||Normal weight|
89095170|NCT02729584||Obese|
89095171|NCT03188068|Active Comparator|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
89095172|NCT03188068|Active Comparator|Sirolimus plus prednisolone|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.~Prednisolone was administered 2 mg/kg administered once daily. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks."
89095173|NCT03304600|Experimental|Active stimulation|10 sessions (1 per day during 2 week) of active tDCS stimulation
89095174|NCT03304600|Sham Comparator|Sham Stimulation|10 sessions (1 per day during 2 week) of sham stimulation
89095175|NCT02729506|Active Comparator|Arm A|"Intervention:~Yttrium-90 Transarterial Radioembolization~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.~Patients must not be less than 18 and not more than 80 and can be either gender.~Patients must have a performance status of ECOG score equal to or less than 2.~Child-Pugh's A or Early B, score 8 and above"
89095176|NCT02729506|Active Comparator|Arm B|"Intervention:~Trans-arterial chemo-embolization using Drug-eluting beads~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.~Patients must not be less than 18 and not more than 80 and can be either gender.~Patients must have a performance status of ECOG score equal to or less than 2.~Child-Pugh's A or Early B, score 8 and above"
89095177|NCT02732782|Experimental|Isometric exercise|Isometric exercise (90% maximum voluntary contraction (MVC), 12 weeks, 4 times a week, 5 sets of 4 repetitions a 3 seconds)
89095178|NCT02732782|Active Comparator|Eccentric exercise|"Eccentric training (Alfredson approach, 12 weeks, 2 sets per day with extended and two sets per day with bended knee, 15 repetitions per set)"
89095179|NCT02732782|No Intervention|Control|Control, no intervention
89095180|NCT02729428||Exercise trained young adults|Exercise trained young adults between the age of 18-35 years.
89095181|NCT02729428||Sedentary young adults|Sedentary young adults between the age of 18-35 years.
89095182|NCT02729428||Exercise trained older adults|Exercise trained older adults between the age of 55-75 years.
89095183|NCT02729428||Sedentary older adults|Sedentary older adults between the age of 55-75 years.
89095184|NCT02732548|Active Comparator|NPWT Only|Study subjects who are randomized to the control arm will be treated with Negative Pressure Wound Therapy (NPWT) and additional standard care treatments. No cellular or acellular biological tissue scaffold will be allowed for subjects in this study arm for the first 6 weeks of the study. Subjects who are randomized to this arm and who do not experience at least a 50% surface area reduction of the study wound by the 6 week study visit will have the option to cross over into the NPWT + MIRODERM treatment arm.
89095185|NCT02732548|Experimental|NPWT + MIRODERM|Subjects in this arm will receive NPWT and standard care, plus application(s) of the MIRODERM product.
89095186|NCT03303664|Experimental|IMPROVE Protocol|The intervention is composed of 4 parts: 1) a multidisciplinary team that recommends, develops, approves, monitors the components of the intervention and training? 2) monitoring of medication sedation risk using established scale 3) restriction of medication dispensing via enhanced technology 4) health professional training on multimodality pain management including complementary and alternative therapies.
89095187|NCT03303664|No Intervention|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
89095188|NCT02729272|Experimental|Ultrasonic ESD|Laparoscopic colpotomy by ultrasonic ESD (Harmonic Synergy Hook Blade; Ethicon Endo-Surgery) during total laparoscopic hysterectomy.
89095189|NCT02729272|Active Comparator|Monopolar ESD|Laparoscopic colpotomy by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany) during total laparoscopic hysterectomy.
89095190|NCT02732470|Experimental|Qi Gong|The effect of Qi Gong training on quality of life in patients with systemic lupus erythematosus
89095191|NCT03170362|Experimental|Intervention group|Pharmacogenetic test results will be provided to the provider within 72 hours of randomization in order to facilitate choice in selecting antidepressants.
89095192|NCT03170362|No Intervention|Delay results group|The comparator arm will not receive results at the time of randomization but will get results after the 24 week assessment (thus the results are delayed).
89095193|NCT02732158|Experimental|Nutrition Products|Two servings per day of the sachet study product mixed with water; 1 carotenoid capsule per day
89095194|NCT02727166|Experimental|Inulin 8 g/d|Mixture of oligo- and polysaccharides composed of fructose units connected by β (2→1) links with a total number of fructose and glucose units ranging between 2 and 70.
89095195|NCT02727166|Placebo Comparator|maltodextrine 8 g/d|
89095196|NCT03112408|Experimental|FORWARD (Axe 1)|
89095197|NCT03112408|Experimental|BACKWARD (Axe 1)|
89095198|NCT03112408|Experimental|CONTROL (Axe 1)|
89095199|NCT03112408|Experimental|ADAPTATION (Axe 2)|
89095200|NCT03112408|Experimental|CONTROL (Axe 2)|
89095201|NCT02727088|Active Comparator|Pulpectomy : root canal treatment|Pulpectomy : ablation of the whole dental pulp, preparation and filling of the whole root canal system
89095202|NCT02727088|Experimental|Pulpotomy : Conservative pulp management|Pulpotomy : ablation of the coronal part of the pulp
89095203|NCT02727010||mothers with motor impairment due to a rare disease|20 Women with motor impairment due to a rare disease
89095204|NCT02727010||mothers with motor impairment not related to a rare disease|controls, 20 women with motor impairment not related to a rare disease
89095205|NCT02728960|Experimental|Traumatic Brain Injury|Documented history of Traumatic Brain Injury
89095206|NCT02728960|Active Comparator|Normal Controls|No prior history of concussion, TBI, blast exposure, stroke, or other major neurological disorder
89095207|NCT02728960|Active Comparator|Sequence Development Volunteers|
89095208|NCT02728882|Experimental|single arm|"Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days，the first day,the fourth day,the seventh day,28 days,31 days,34 days.~Duration:Total seven times."
89095209|NCT01064310|Experimental|pazopanib followed by sunitinib|800mg pazopanib orally for 10 weeks followed by 50mg sunitinib orally for 10 weeks
89095210|NCT01064310|Experimental|sunitinib followed by pazopanib|50mg sunitinib orally for 10 weeks followed by 800mg pazopanib orally for 10 weeks
89095211|NCT00627276|Experimental|Arm I|Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
89095212|NCT00627276|Placebo Comparator|Arm II|Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.
89095213|NCT02726854|Experimental|Apatinib|Patients will be offered with Apatinib (850mg daily,orally)until their disease have progressed.
89095214|NCT04724928|Active Comparator|Non-metastatic MIBC|No signs of extra-pelvic metastasis on conventional imaging (abdominopelvic and thoracic CT/MRI) and 18F-FDG-PET-CT's
89095215|NCT04724928|Experimental|Oligo-metastatic MIBC on 18F-FDG-PET-CT|No signs of extra-pelvic metastasis on conventional imaging (abdominopelvic and thoracic CT/MRI) but presence of ≤ 3 metastasis on 1 or both 18F FDG PET-CT 's
89095216|NCT04724928|Experimental|Poly-metastatic MIBC on 18F-FDG-PET-CT|No signs of extra-pelvic metastasis on conventional imaging (abdominopelvic and thoracic CT/MRI) but presence of > 3 metastasis on 1 or both 18F FDG PET-CT 's
89095217|NCT02728570|Experimental|Low Flavonoids then High Flavonoids|Participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks.
89095218|NCT02728570|Experimental|High Flavonoids then Low Flavonoids|Participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks.
89095219|NCT02728492|Experimental|Quisinostat 8 mg & Paclitaxel & Carboplatin|Quisinostat 8 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
89095220|NCT02728492|Experimental|Quisinostat 10 mg & Paclitaxel & Carboplatin|Quisinostat 10 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
89095221|NCT02728492|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|Quisinostat 12 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
89095222|NCT02728492|Experimental|Quisinostat 8 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 8 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
89095223|NCT02728492|Experimental|Quisinostat 10 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 10 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
89095224|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
89095225|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1250 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1250 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
89095226|NCT02726776|Experimental|Suspension without prior climbing|Free Suspension in a harness after baseline measurements and without prior climbing
89095227|NCT02726776|Experimental|Suspension with prior climbing|Free Suspension in a harness after baseline measurements and after climbing in moderate intensity for 10 minutes
89095228|NCT02726152|Experimental|Polymer clips|Patients will be randomised to polymer clips for closure of the appendiceal stump
89095229|NCT02726152|Active Comparator|Endoloops|Patients will be randomised to endoloops for closure of the appendiceal stump
89095230|NCT02726308|Active Comparator|Dexamethasone Group|I.V. Dexamethasone 5 mg just before induction plus intra-operative 10 ml/kg Ringer's lactate solution.
89095231|NCT02726308|Active Comparator|Dexamethasone and super-hydration Group|I.V. Dexamethasone 5 mg just before induction of anesthesia plus intraoperative 30 ml/kg Ringer's lactate solution
89095232|NCT02728414|Experimental|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
89095233|NCT02728414|Other|placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
89095234|NCT01037244|Placebo Comparator|Placebo|
89095235|NCT01037244|Experimental|Udenafil 50 mg|
89095236|NCT01037244|Experimental|Udenafil 100 mg|
89095237|NCT01037244|Experimental|Udenafil 150 mg|
89095238|NCT00833989|Placebo Comparator|PLACEBO|
89095239|NCT00833989|Experimental|ACTIVE|
89095240|NCT02728180|Experimental|Xingnaojing and standard care|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
89095241|NCT02728180|Active Comparator|Standard care only|Subjects will receive guidelines-based standard care only.
89095242|NCT02873832||MPS|
89095243|NCT02873832||Control|
89095244|NCT02728024||A|Complete the questionnaires with personal aid
89095245|NCT02728024||B|questionnaires are completed by patients alone
89095246|NCT02726230|Experimental|Ananya Intervention|"Strengthen enumeration and mapping of areas to ensure reach of front line workers (FLWs: auxiliary nurse midwives- ANMs; community health workers- ASHAs; anganwadi workers- AWWs).~Convene monthly FLW meetings to build skills and get trained in job kits to increase the quantity and quality of household visits.~Train FLWs on communication skills and use of mobile kunji, a job-aid tool, to improve FLWs' communication with households.~A mass media campaign inclusive of street theatre, tv and radio, and a mobile van.~Community mobilization linking mass media efforts with self-help groups.~Quality improvement activities at public health facilities.~Facility-based skills training to staff delivering infants to improve quality of care"
89095247|NCT02726230|No Intervention|Control Condition|standard of care public health services in India
89095248|NCT02727946|Other|optimal resuscitation|This group of multiple trauma patients will be resuscitated with crystalloids, analgesics, blood products as needed. Then follow up of the difference between arterial and venous CO2 to difference between arterial and venous oxygen tension, serum lactate, renal function, other organ affection along over the short hospital stay period
89095249|NCT01037088|Experimental|Mild dose cannabis|3.53% THC by weight
89095250|NCT01037088|Experimental|Low dose cannabis|1.29% THC by weight
89095251|NCT01037088|Placebo Comparator|Placebo cannabis|placebo marijuana
89095252|NCT02727790|Experimental|PES Treatment|Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System
89095253|NCT02727790|No Intervention|Control|Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System
89095254|NCT04189120|Active Comparator|Thoracic epidural analgesia (TEA)|Under full aseptic conditions and wearing sterile gloves while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine, then an 18-G Epidural needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal or IV injection. After negative response, 15 ml of 0.25% epidural bupivacaine will be injected and the patient will be turned to the supine position.
89111153|NCT02793141||ICU Nosocomial Pneumonia|Nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ward patients (= or > 48 hours after hospital admission) that due to deterioration are subsequently admitted to ICU or nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ICU patients (= or >48 hours after hospital admission) or ventilator-associated pneumonia with onset = or > 48 hours after intubation. No intervention will be administered.
89095255|NCT04189120|Active Comparator|Ultrasound-guided superficial serratus plane block (SSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. The muscles will be identified easily overlying the fifth rib, the latissimus dorsi , teres major and serratus muscles . A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle beneath the latissimus dorsi. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected
89095256|NCT04189120|Active Comparator|Ultrasound-guided deep serratus plane block (DSPB)|Under full aseptic conditions, the patient is placed in lateral position with the diseased side up, sterile field is established with a povidone iodine solution, and the linear transducer 8-12 MH (sonosite M-turbo ; Inc., Bothell, WA, USA) is covered by a disposable sterile cover and will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the fifth rib is identified in the mid-axillary line. A skin wheal of 1% lidocaine will be made 1 cm away from the lateral edge of the transducer thorough which the needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane between the posterior border of the serratus anterior muscle and the corresponding surface of the rib. Under continuous ultrasound guidance 30 ml of 0.25% bupivacaine will be injected deep to the serratus muscle separating the serratus anterior muscle from the external intercostal muscle.
89095257|NCT02725996|Experimental|curative therapy+NK infusion|Adjuvant adoptive immune therapy using NK cell 4 times after curative therapy
89095258|NCT02725996|Other|curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation[RFA]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
89095259|NCT02725762|Experimental|Photobiomodulation Treatment|Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
89095260|NCT02725762|Sham Comparator|Sham Treatment|Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
89095261|NCT02727712|Experimental|TPVB T2/3+T5/6+GA|the group A of patients has been received bilateral thoracic paravertebral block (TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4), before general anesthesia management
89095262|NCT02727712|Experimental|TPVB T3/4+GA|the group Bof patients has been received bilateral thoracic paravertebral block (TPVB 3/4) by ropivacaine(0.3%,10ml*4), before general anesthesia management Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
89095263|NCT02727712|Placebo Comparator|GA|group C under control (without TPVB)program Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
89095264|NCT04118101|Active Comparator|ESPB group|A total of 25 ml bupivacaine 0.5% willbe injected into the ESP.
89095265|NCT04118101|Placebo Comparator|Control group|The ESPB will not be performed.
89095266|NCT01042236|Experimental|Arm 1|
89095267|NCT02725918|Experimental|Pem mono|Patients in arm B will receive pemetrexed (500 mg/m2, d1) every 3 weeks until PD or intolerable toxicities.
89095268|NCT02725918|Active Comparator|Pem+Cis|Patients in arm A will receive 4 cycles of cisplatin (75 mg/m2, d1) and pemetrexed (500 mg/m2, d1) every 3 weeks, those without disease progression (PD) and being tolerable judged by investigator will continue single-agent pemetrexed (500 mg/m2, d1) every 3 weeks as maintenance until progression or intolerable toxicities.
89095269|NCT02727634|Other|Postoperative elective CABG patients|Patients included for coronary artery bypass graft (CABG) surgery, secondary to ischaemic heart disease.
89095270|NCT02725606|Active Comparator|Pegylated Recombinant Human G-CSF|100ug/kg 6 subjects (2 subjects per GW003 cohort)
89095271|NCT02725606|Experimental|GW003 300ug/kg|6-8 subjects
89095272|NCT02725606|Experimental|GW003 650ug/kg|6-8 subjects
89095273|NCT02725606|Experimental|GW003 850ug/kg|6-8 subjects
89095274|NCT02725684||Glioblastoma|Observational study, no intervention
89095275|NCT02725450|Experimental|Motor Imagery + Psychomotor Battery of fine motor skills|Application of Motor Imagery together with normal practice improves fine motor skills in disabled individuals.
89095276|NCT02725294||COPD patients|Veterans with COPD who are cared for at VA Puget Sound Health Care System (Seattle, WA) or VA Eastern Colorado (Denver, CO) who are at high risk for a COPD exacerbation based on an exacerbation treated with prednisone or antibiotics in the year preceding enrollment.
89095277|NCT02725294||Informal Caregiver for COPD patients|Informal caregiver (ie. family member, friend, etc.) for the patient with COPD who is participating in the COPD patients cohort.
89095278|NCT00592501|Experimental|Proton/Photon Radiotherapy, Cisplatin, Fluorouracil|
89095279|NCT02727556|Experimental|Functional dyspepsia patient|Visual stimuli of food and non-food images will be presented to patients. Non-food images include positive, neutral, negative emotional pictures.
89095280|NCT02727556|Experimental|Healthy|Visual stimuli of food and non-food images will be presented to participants. Non-food images include positive, neutral, negative emotional pictures.
89095281|NCT03097666|Other|C2 Cryoballoon Swipe Ablation System|C2 Cryoballoon Swipe Ablation System
89095282|NCT02727400||advanced maternal age|Infertile women due to advanced maternal age
89095283|NCT02727400||Young patients|women under 35 undergoing infertility treatments
89095284|NCT02721628|Experimental|Epi-keratoplasty Group|Epi-keratoplasty Group: Reversible keratoplasty performed with only the removal of corneal epithelium of the host cornea. A donor graft is transplanted on the recipients' eye locating on the Bowman's layer.
89095285|NCT02721628|Active Comparator|Collagen Cross-Linking Group|Collagen Cross-Linking: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
89095286|NCT02721472|Other|sickle cell disease patients|Sickle cell disease patients included in the study and Plasma DNA levels will be analyzed and compared in patients with a reactive hyperaemia index (RHI) < 1.67 (endothelial dysfunction) assessed by Endo-PAT 2000 versus those recorded in patients with a RHI ≥ 1.67 (no endothelial dysfunction).
89095287|NCT02721394|Experimental|Researcher Implemented FCT|Children receive functional communication training. Assessment and initial intervention sessions are completed by the researcher and family carers are trained to continue the intervention at home.
89095288|NCT02721394|Experimental|Family Carer Implemented FCT 1|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher in person.
89095289|NCT02721394|Experimental|Family Carer Implemented FCT 2|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher via videoconferencing and support from a family carer assistant in person.
89095290|NCT01040832|Experimental|Cetuximab plus EMD 1201081|
89095291|NCT01040832|Active Comparator|Cetuximab monotherapy|
89095292|NCT02721550|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-4 Cisplatin:20 mg/m²,d1,week 1-4 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T40Gy/20f,week 1-4"
89095293|NCT02721238|Active Comparator|Resuscitation with 30ml/kg plasmalyte|
89095294|NCT02721238|Experimental|Resuscitation with 20% Albumin|
89095295|NCT02721004||Rheumatoid arthritis participants|Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
89095296|NCT04302090|Experimental|pain level changes according to the use of the Winner flow|"each included patient will experience :~a period of consecutive spontaneous uterine contractions without using the regulated expiration mouthpiece~a period of consecutive uterine contractions managed by the regulated expiration method using the Winner flow"
89095297|NCT04304196|Experimental|TEMPO|These patients and caregivers will be able to access the TEMPO modules and will receive technical support to use it effectively. Patients will receive usual care throughout the study.
89095298|NCT04304196|Active Comparator|Control|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
89095299|NCT02832856|Placebo Comparator|Control|"Control group members will receive a job readiness curriculum entitled Beginning to Work it Out (BWIO) that assists at-risk youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
89095300|NCT02832856|Experimental|Full Relationship Smarts Curriculum|This group receives the behavioral intervention of the healthy relationship education in the form of the full, 12-lesson RS+ curriculum over approximately 12 weeks.
89095301|NCT02832856|Experimental|Abridged Relationship Smarts Curriculum|"This group receives the behavioral intervention of the healthy relationship education in the form of the summary 8-lesson version of the RS+ curriculum - as well as four lessons on career planning and job readiness over approximately 12 weeks."
89095302|NCT02720770|Experimental|norditropine simplex|
89095303|NCT02733406|Other|Target Controlled Infusion|This group of patients will have their anaesthesia induced with Target Controlled Infusion (TCI)
89095304|NCT02733406|Other|Velocity Controlled Infusion|This group of patients will have their anaesthesia induced with Velocity Controlled Infusion (VCI)
89095305|NCT02720926|Experimental|TKI258 combined with Xeloda/Oxaliplatin|TKI258 200 mg once a day (OD) 5 days on/2 days off Capecitabine (Xeloda) 2000 mg/m2 bid d1-14 Oxaliplatin 130mg/m2 d1 q21days
89226999|NCT00001467||Blood relatives|blood related family members of proband
89227000|NCT00001467||Proband|person initially ill/studied/diagnosed
89095306|NCT00854581|Experimental|Induction (Up to Day 21)|"For one cycle, up to Day 21. All participants are enrolled to induction therapy phase, then move to the maintenance therapy phase if they achieve complete response (PR) or partial response (PR). Participants who achieve a clinical CR at Day 14 response assessment will go on to Part 1 maintenance therapy. Patients who achieve a PR will receive 7 more days of induction therapy and then go on to Part 1 Maintenance Therapy.:~Zidovudine:~Days 1-2: 1.5 grams intravenously (IV) twice daily~Days 3-21: 1.5 grams IV twice daily~Interferon alfa-2b (IFN):~5 10 million units (mu) intravenously twice daily"
89095307|NCT00854581|Experimental|Part 1 Maintenance (Up to Day 60)|"From Treatment Day 14 or 21 to start of Month 3 (Day 60). Study participants move on to Part 1 Maintenance Therapy only if they achieve complete response (CR) or partial response (PR) after induction therapy. Restaging and molecular evaluation of disease at start of Month 3:~Zidovudine: 600 mg orally twice daily in all phases of Maintenance Therapy~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly~Participants then proceed to Part 2 maintenance."
89095308|NCT00854581|Experimental|Part 2A Maintenance (Up to 12 Months)|"Participants achieving a CR with undetectable clonal disease. Participants will receive therapy for as long as response is maintained:~Zidovudine: 600 mg orally twice daily~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly"
89095309|NCT00854581|Experimental|Part 2B Maintenance (Up to 12 Months)|"Participants achieving a CR with minimal residual disease (by multiplex PCR) or PR in Part 1:~Zidovudine: 600 mg or 300 mg orally twice daily, per protocol~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly, per protocol~Valproic acid, 250 mg orally twice daily, per protocol"
89095310|NCT02720458|Experimental|Standardized hypnotic taper and self-help program|
89095311|NCT02720458|Active Comparator|Standardized hypnotic taper only|
89095312|NCT02720614|Experimental|Hypofractionated radiation/chemotherapy|"Hypofractionated radiation：Patients receive accelerated hypofractionated radiation: three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, completed within 4.6 weeks.~Chemotherapy: Regimen 1 is as follows: vinorelbine (NVB) was administered by intravenous infusion at a dose of 25 mg/m2 on day 1 (d1) and day 8 (d8), and carboplatin (CBP) is administered at a concentration-time curve (AUC) of 5 mg/ml on d8. This treatment was repeated every 28 days. One cycle of chemotherapy is performed concurrently with the radiotherapy.~Chemotherapy: Regimen 2 is as follows: paclitaxel at 30 mg/m2 and cisplatin at 20 mg/m2 (TP) are administrated every week for 5 weeks continuously."
89095313|NCT02720380|Experimental|Buteyko|Children in the intervention group will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
89095314|NCT02720380|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
89095315|NCT00833911|Experimental|Tramadol Contramid® OAD|
89095316|NCT02720146||Artificital tear|The epitheliotrophic ability in cell and animal model
89095317|NCT02720146||Human peripheral serum|The epitheliotrophic ability in cell and animal model
89095318|NCT02720146||Human platelet lysate|The epitheliotrophic ability in cell and animal model
89095319|NCT02719756|Experimental|Metformin & Dapagliflozin|Metformin stable dose tablets and Dapagliflozin 10 mg tablets by mouths, once daily in morning for 3 months
89095320|NCT02719756|Active Comparator|Metformin up-titration|Metformin tablets up-titration by mouths, for 3 months
89095321|NCT02719678|Experimental|Intervention group|Invitation to up to three general health checks over a 10-year period
89095322|NCT02719678|No Intervention|Control group|Control group
89095323|NCT01125293|Experimental|Phase I Stage A Level 1|"Combination of everolimus & rituximab for 6 cycles:~Everolimus 5 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
89095324|NCT01125293|Experimental|Phase I Stage A Level 2|"Combination of everolimus & rituximab for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
89095325|NCT01125293|Experimental|Phase I Stage B Level 1|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 5 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle (1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
89227001|NCT00001379|Experimental|1|Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the designated schedule, as tolerated. Patients continue taking interferon for 1 year beyond CR. Patients who progress may crossover to receive EPOCH-R.
89095326|NCT01125293|Experimental|Phase I Stage B Level 2|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
89095327|NCT01125293|Experimental|Phase I Dose Expansion|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
89095328|NCT01125293|Experimental|Phase II|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
89095329|NCT02702986|Experimental|imILT of pancreatic cancer|10 patients suffering from LAPC will be submitted to immunostimulating interstitial laser thermotherapy (imILT) in a single-arm setting
89095330|NCT02719912|Experimental|Valve Replacement|Mitral valve replacement
89095331|NCT05111483|Experimental|Tupler's technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~Repositioning with diastasis rehab splint :~Protect the connective tissue~Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~Diastasis safe exercises program to maintain the gains"
89095332|NCT05111483|Experimental|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~Tie a scarf around abdomen while performing exercises~Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~Respiratory rehabilitation manoeuvre"
89095333|NCT02719834||Acetaminophen, then placebo|Participants in this group will receive acetaminophen for the first four weeks, then placebo for the next four weeks.
89095334|NCT02719834||Placebo, then acetaminophen|Participants in this group will receive placebo for the first four weeks, then acetaminophen for the next four weeks.
89095335|NCT04311203|Experimental|Mental Health First Aid Intervention|Two-day MHFA training provided by MHFA England. Organisations will raise awareness of the presence of MHFA in the workplace, with delivery of MHFA by trained members to participants in the workplace.
89095336|NCT04311203|No Intervention|Control|A brief consultation from MHFAE on the promotion of mental health and well-being in the workplace.
89095337|NCT02719600|Experimental|Down Syndrome Group|Group with Down Syndrome
89095338|NCT02719600|Active Comparator|Typical Development Group|Control group with typical development
89095339|NCT02719288|Experimental|CLARIX® CORD 1K|Applied in addition to standard of care tendon repair surgery.
89095340|NCT02719288|No Intervention|Standard of care tendon repair surgery only|
89095341|NCT02719210|Experimental|High Volume Plasma Exchange with Standard Treatment|
89095342|NCT02719210|Active Comparator|Standard Treatment|"Standard Treatment is defined as anti raised Intra-cranial pressure~Elective positive pressure ventilation in hepatic encephalopathy grade 3 or 4 and in those with features of raised ICP (Intra-cranial pressure).~Mannitol~Hypertonic 3% Saline"
89095343|NCT02719132|Experimental|Arm 1|Arm 1 - therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks (Treatment Regimen 1) followed by metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks (Treatment Regimen 2)
89095344|NCT02719132|Active Comparator|Arm 2|Arm 2 - metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks (Treatment Regimen 2) followed by therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks (Treatment Regimen 1)
89095345|NCT02719054|Experimental|stimulation|Cognitive behavioral therapy for mother and play stimulation for children aged 6 to 12 months
89095346|NCT02719054|No Intervention|Mother child dyad|
89095347|NCT02718976|Experimental|Shamrock guided by US/MR image fusion|Use of US/MR image fusion guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
89095348|NCT02718976|Other|Shamrock guided by US|Use of US guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
89095349|NCT02718664|No Intervention|A (fasting)|Fasting condition
89095350|NCT02718664|Experimental|B (fed)|Fed condition (test meal)
89095351|NCT02718742|Experimental|Treatment (nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89095352|NCT02718508|No Intervention|Standard Care|All enrolled adolescents will continue to receive standard trauma center care, a brief intervention during their hospitalization by a trauma center social worker which is required by institutional policy.
89095353|NCT02718508|Experimental|Standard Care plus e-Parenting Group|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
89095354|NCT02718430|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
89095355|NCT02718274|No Intervention|Control|Standard of care.
89095356|NCT02718274|Active Comparator|Self-testing|Community-Based Distribution Agents (CBDAs) in the HIV Self-Testing (HIVST) Arm villages will be trained to provide HIVST services as well as reproductive health services.
89095357|NCT02718274|Active Comparator|Self-testing + home HIV care home initiation|CBDAs will be trained to provide HIV Self-Testing plus offer home assessment and HIV care initiation (first assessment and first 14 days of HIV care medications), with this additional intervention aimed at facilitating linkage into care.
89095358|NCT02717884|Experimental|TCP, ATRA, Cytarabine|"Phase I part:~The rolling-six phase I design will be used to determine the MTD of TCP in combination with fixed-dose of ATRA and with fixed-dose AraC in patients with AML/MDS.~Intervention: Four dose levels of TCP (20 mg, 40 mg**, 60 mg**, 80 mg** on days 1-28) will be examined in combination with ATRA (45 mg/m2 on days 10-28) and with fixed-dose AraC (40 mg on days 1-10) in the first cycle. In case of dose-limiting toxicity (DLT) on the starting level 1 of 20 mg a de-escalation to dose level of 10 mg (level -1) will be investigated.~**TCP dose will be slowly increased to achieve the necessary dose level and slowly tapered off at the end of treatment"
89095359|NCT02718196|Experimental|Application Users|English-speaking parents of children ages 6-24 months who are interested in starting sleep training within the next month.
89095360|NCT04100512|Active Comparator|Incentive spirometry|Each patient will be instructed on how to use the respiratory therapy device, either IS or OPEP, by research personnel and respiratory therapists. Participants will be instructed to record their compliance with the RT protocol in their respective patient diaries. Patient diaries will be collected upon discharge for analysis.
89095361|NCT04100512|Experimental|Oscillating Positive Expiratory Pressure Device|Each patient will be instructed on how to use the respiratory therapy device, either IS or OPEP, by research personnel and respiratory therapists. Participants will be instructed to record their compliance with the RT protocol in their respective patient diaries. Patient diaries will be collected upon discharge for analysis.
89095362|NCT02717572|Experimental|FDG-PET/CT and FDG-PET/MR|"10 mCI fludeoxyglucose IV bolus approximately 60 minutes before first PET/CT~Immediately following PET/CT scan, the participant will be moved to PET/MR scanner~The scans will take place at baseline and also one more time point between Day 1 and Day 7. There needs to be at least 24 hours between the baseline and repeat imaging"
89095363|NCT05041192|Experimental|Synaquell Group|Subjects will receive the dietary supplement, Synaquell, twice-daily during the hockey season.
89095364|NCT05041192|Placebo Comparator|Placebo Group|Subjects will receive the placebo twice-daily, during the hockey season.
89095365|NCT02717806|Experimental|PATHway|"Patients allocated to the PATHway intervention will be given a 4 week run-in period as an outpatient to get acquainted with the system. During this run-in period, the PATHway system will also be installed in each participant's home. They will be provided with a training manual and a quick set up guide for getting started with PATHway in the home.~After this 4 week run-in period, the PATHway system will be set up for each individual patient including a patient specific exercise prescription. The patient will then exercise with the PATHway platform for 6 months."
89095366|NCT02717806|No Intervention|Usual care|Patients randomized to the control group will receive usual care.
89095367|NCT01121393|Experimental|Arm A BIBW 2992|Patients receive a tablet of BIBW 2992 daily until progression or unacceptable toxicity
89095368|NCT01121393|Active Comparator|Arm B Chemotherapy|Patients receive Gemcitabine and Cisplatin, maximum is 6 courses
89095369|NCT02717338|Experimental|Competence|Participants will be assigned to review our donor coping website.
89095370|NCT02717338|Experimental|Autonomy|Participants will be assigned to receive a brief telephone interview.
89095371|NCT02717338|Experimental|Relatedness|Participants will be asked to join a closed Facebook group for one month.
89095372|NCT02717338|Experimental|Competence + Autonomy|Participants will be assigned to the web site review, followed by the brief telephone interview.
89095373|NCT02717338|Experimental|Competence + Relatedness|Participants will be assigned to the web site review, followed by the one-month Facebook group membership.
89095374|NCT02717338|Experimental|Autonomy + Relatedness|Participants will be assigned to the brief telephone interview, followed by the one-month Facebook group membership.
89095375|NCT02717338|Experimental|Competence + Autonomy + Relatedness|Participants will be assigned to the web site review, brief telephone interview, and one-month Facebook group membership.
89095376|NCT02717338|No Intervention|Treatment-as-Usual Control|Participants will receive the standard communications that New York Blood Center has with all first-time donors.
89095377|NCT02717260|Sham Comparator|Sham transcranial noise stimulation|subjects are stimulated 3 times with sham transcranial random noise stimulation (tRNS) (Starstim) with a 30 seconds offset
89095378|NCT02717260|Active Comparator|1 Active transcranial random noise stimulation|subjects are stimulated 1 time with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes and 2 times with sham tRNS
89095379|NCT02717260|Active Comparator|3 Active transcranial random noise stimulation|subjects are stimulated 3 times with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes
89095380|NCT02882477|Experimental|Deferiprone and Acetylcystein|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200 mg divided in 2 doses 5 months duration
89095381|NCT02882477|Experimental|Deferiprone and Acetylcystein with Sitagliptin and Metformin|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200mg divided in 2 doses PO Januet 50/500 if BW < 30kg and 50/850 if BW> 30kg *2/D 5 months duration
89095382|NCT04081168|Active Comparator|Stereotactic Body Radiotherapy|Patients included will undergo Stereotactic Body Radiotherapy (SBRT) of hepatic metastases.
89095383|NCT04081168|Active Comparator|Microwave Ablation|Patients included will undergo Microwave Ablation (MWA) of hepatic metastases.
89095384|NCT02716792|Experimental|Ibandronate 15-Minute Infusion|Participants will receive ibandronate IV infusions over a 15-minute interval.
89095385|NCT02716792|Active Comparator|Ibandronate 60-Minute Infusion|Participants will receive ibandronate IV infusions over a 60-minute interval.
89095386|NCT02716636|No Intervention|Fast placement|Placement of the tenaculum quickly and without avoiding ratchet
89095387|NCT02716636|Experimental|Slow placement of the tenaculum|Placement of the tenaculum over a 7-10 second time frame and not allowing the tenaculum to ratchet audibly.
89095388|NCT02694016|Experimental|Remote ischemic preconditioning|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis and a preoperative lower leg remote ischemic preconditioning(RIPC) phase.
89095389|NCT02694016|No Intervention|Control group|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis
89095390|NCT02359318|Experimental|Resin infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the no infiltration and de-bonding arm. The teeth that are included in this intervention arm are treated by resin infiltration using Icon (DMG, Germany) according to the manufacturers´ instruction. This is followed by bonding of new brackets (Gemini metal brackets, 3M Unitek). These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
89095391|NCT02359318|Placebo Comparator|No infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the resin infiltration and de-bonding arm. The teeth that are included in this intervention arm are left untreated new brackets (Gemini metal brackets, 3M Unitek) are bonded. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
89095392|NCT02359318|Other|Control and de-bonding|"Patients with brackets and without white spots are included in this group. After removal of the old brackets, new brackets (Gemini metal brackets, 3M Unitek) are bonded again. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
89095393|NCT02716558|Experimental|Moisture tolerant resin sealant|Moisture resistant sealant (wet bond sealant)
89095394|NCT02716558|Active Comparator|ART sealant|Glass inomer based sealant
89095395|NCT02716402|Other|Cyanotic congenital heart disease|Patients who previously have been examined with cerebral MRI and V/Q SPECT/CT will be re-examined with cerebral MRI and V/Q SPECT/CT
89095396|NCT02716480|Experimental|Mobility Coaching|"45 patients undergoing bariatric surgery received a monthly mobility coaching session of 20 to 30 min by phone during 6 months."
89095397|NCT02716480|Experimental|Diet Coaching|"45 patients undergoing bariatric surgery received a monthly diet coaching session of 20 to 30 min by phone during 6 months."
89095398|NCT04964596|Active Comparator|a colonoscopy as surveillance exam|patients will undergo Colonoscopy, finding will be documented. Findings of colonoscopy will be documented and treated according to the institutional standards. Study participation for patients ends after the colonoscopy and follow-up of pathology results and complication assessment.
89095399|NCT04964596|Active Comparator|undergoing a FIT as surveillance exam|if the FIT test is positive: patients will have subsequent colonoscopy within 3 months. Findings of FIT testing and if positive the colonoscopy will be documented and participation in the study will end after that. Findings of the FIT test and colonoscopy will be treated according to the institutional standards. If FIT test is negative patient will leave the study and will have a follow up with a colonoscopy or FIT test in 1 to 2 years outside of this study.
89095400|NCT04964596|Active Comparator|undergoing CT colonography as surveillance exam|If CTC is positive: patients will have subsequent colonoscopy within 3 months. Findings will be documented and participation in the study will end there. Findings of the colonoscopy will be addressed according to our institution's guidelines. If CTC is negative for polypoid lesions patient will leave the study and will have a follow up 5 years after with either a CTC or colonoscopy.
89095401|NCT04964284|Experimental|rhTSH group|Patients received thyroid hormone suppression therapy (Euthyrox) . rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
89095402|NCT04964284|Experimental|Thyroid hormone withdrawal group|After randomization, patients with thyroid hormone withdrawal therapy(i.e. Stop taking thyroid hormone for 14 days, and then monitor the level of thyroid-stimulating hormone every week). When TSH>30mU/L, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
89095403|NCT02716168|Experimental|Video consultation|Video consultation between cancer patient, general practitioner and oncologist at the start of chemotherapy treatment
89095404|NCT02716168|No Intervention|usual care|Usual care. The patients General Practitioner will receive standard discharge summary and ambulant notes from the oncologist specialist
89095405|NCT04896346||Previous Treatment: Biologic StrataGraft Skin Tissue|"This consists of areas that were treated with Stratagraft Skin Tissue under a previous clinical study STRATA2016.~No new interventions will occur."
89095406|NCT04896346||Previous Treatment: Autograft Comparator|"This consists of areas that were treated with autograft comparator under a previous clinical study STRATA2016.~No new interventions will occur."
89095407|NCT02716090|Experimental|Dalap Duo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel cream. Apply the product on the areas affected by acne once a day in the evening for 84 days.
89095408|NCT02716090|Active Comparator|Epiduo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel. Apply the product on the areas affected by acne once a day in the evening for 84 days.
89095409|NCT02715778||Adult Participants|
89095410|NCT02715778||Child Participants|
89227002|NCT00001379|Experimental|2|EPOCH-R every 3 weeks for up to 6 cycles, based on response.
89095411|NCT02715934|Experimental|Glucose to Goal|Three diabetes educators will be assigned to the Glucose to Goal/experimental arm. The educators will each identify two primary care practices of mid to large size to participate in the Glucose to Goal intervention. Patients will not be formally recruited or enrolled. Rather, information documented in the electronic medical record system will be extracted to evaluate patient-level outcomes. Based on a random sampling of mid to large size primary care practices in study communities, an estimated 2,200 patients with diabetes per study group will meet eligibility criteria for DSME referral.
89095412|NCT02715934|Other|Control Group|Two usual care diabetes educators will each identify three primary care practices of mid to large size to include in the control arm and participate in the usual care intervention. Uneven group assignment accounts for the amount of time (one day equivalent/per week) that the intervention diabetes educators will devote to each primary care practice versus the full-time availability of the usual care diabetes educators to see patients at the outpatient, hospital-based program. Like the experimental arm, an estimated 2,200 patients with diabetes will meet eligibility criteria for DSME referral. Patients will not be formally recruited or enrolled into the control arm; data will be extracted from the electronic medical record system to evaluate patient-level outcomes.
89095413|NCT01227616|Experimental|Ferumoxytol|Intravenous (IV) iron
89095414|NCT01227616|Active Comparator|IV Iron Sucrose|Intravenous (IV) iron
89095415|NCT02715544|Experimental|Intervention group|The group will receive healthy lifestyle intervention
89095416|NCT02715544|Active Comparator|control group|Other: physical activity and dietary guidelines
89095417|NCT04189276|Active Comparator|Group1|T101+ETV(Entecavir) /TDF(Tenofovir)
89095418|NCT04189276|Active Comparator|Group2|T101+ETV/TDF
89095419|NCT04189276|Active Comparator|Group3|ETV or TDF
89095420|NCT04189276|Active Comparator|Group4|Peg-IFNα-2b+ETV/TDF
89095421|NCT00956488|Experimental|supported treadmill ambulation training|
89095422|NCT02714998|Active Comparator|Methotrexate only|Single dose of systemic Methotrexate administered to 55 patients.
89095423|NCT02714998|Active Comparator|Salpingectomy only group|Laparoscopic unilateral salpingectomy performed to 61 patients.
89095424|NCT02714998|Active Comparator|Salpingectomy following Methotrexate|15 patients underwent laparoscopic unilateral salpingectomy following unsuccessful single dose of methotrexate administration.
89095425|NCT00765310|Active Comparator|Lipoic Acid|600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)
89095426|NCT00765310|Placebo Comparator|Placebo|Placebo two caps every morning on empty stomach
89095427|NCT02715154|Active Comparator|Dexmedetomidine 0.5 µg/kg/h|Solution containing 5 µg/mL of dexmedetomidine was continuously infused by 0.5 μg/kg in 10 min, followed with 0.1 ml/kg/hr continuous infusion until the closure of the abdominal.
89095428|NCT02715154|Placebo Comparator|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal.
89095429|NCT02715232|Experimental|Female-to-Males|Female-to-Male Transsexuals receiving Testosterone treatment
88812633|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
89095430|NCT02715232|Experimental|Male-to-Females|Male-to-Female Transsexuals receiving Estradiol and Anti-androgen treatment
89095431|NCT02715232|No Intervention|Female Controls|Female Controls receiving no intervention
89095432|NCT02715232|No Intervention|Male Controls|Male controls receiving no intervention
89095433|NCT02714608|Experimental|Ginsenoside H dripping pills|Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
89095434|NCT02714608|Experimental|Ginsenoside H dripping pills+Placebo|Drug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
89095435|NCT02714608|Placebo Comparator|Placebo|Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
89111154|NCT02591706|Active Comparator|Dental implant (C1)|"Internal Conical Connection: The C1 has a six-position cone index, except for the C1 narrow platform that has a four-position cone index. The conical connection is 2.00mm in depth, with a 12° cone. As a result of our meticulous manufacturing process a perfect fit between the implant and the abutment is achieved, eliminating micro-movements and minimizing bone resorption.~Patient will be randomly assigned to one of the two groups after flap opening."
89095436|NCT00643864|Other|Mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same therapist who performed the pretests."
89095437|NCT02693860|Experimental|huJ591 followed by 89Zr-J591|Subjects will receive two infusions of unlabeled huJ591 on days 1 and 15 (+/- 1 day). 89Zr-J591 will be administered on day 22 (+/- 1 day) and 5-8 days later. PET/CT will be performed followed by repeat imaging of the prostate. Radical prostatectomy with or without lymph node dissection is performed 2 to 4 weeks after the second dose of J591.
89095438|NCT02721160|Experimental|Nutrition PBF|45 health centres are assigned to this group. The intervention consists in a performance based financing scheme applied to nutrition services.
89095439|NCT02721160|No Intervention|Control|45 health centres are in the control group. Health centres in this group are not incentivized, but they receive an equivalent funding to the one received by the intervention group. The main difference is that this payment is not based on their own performance.
89095440|NCT02714686|Experimental|Radio Mass Media Family Planning Campaign|Clusters receive a three-year mass media campaign on family planning in an attempt to reduce cognitive barriers to contraception
89095441|NCT02714686|No Intervention|Control group|
89095442|NCT02714842|Experimental|Radiolabelled Diclofenac tablet A|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
89095443|NCT02714842|Experimental|Radiolabelled diclofenac tablet B|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
89095444|NCT02714842|Active Comparator|Voltaren|Single dose of enteric coated diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
89095445|NCT02714842|Experimental|Radiolabelled diclofenac tablet C|Single dose of delayed release diclofenac sodium (25 mg) tablet radiolabelled with 4 MBq 99mTc
89095446|NCT02714530|Experimental|Radiotherapy combined with erlotinib|Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
89095447|NCT02714530|Active Comparator|Radiotherapy alone|Radiotherapy 3 Gy x 10 alone
89095448|NCT02714452|Other|Intervention|Person-centred care
89095449|NCT02714452|No Intervention|Control|Conventional care
89095450|NCT02714296|Active Comparator|Group Nutridrink 200ml|50 patients: two days before the investigation is assigned to a diet with the use of specialized clinical nutrition Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
89095451|NCT02714296|Active Comparator|Group Nutridrink compact protein|two days before the study is assigned diet with the addition of specialized clinical nutrition Nutridrinc compact protein 125 ml 2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
89095452|NCT02714296|No Intervention|Group control|only diet without receiving specialized nutrition
89095453|NCT02714374|Experimental|GL-ONC1|Cohort 3, 5, 7, 8, 9
89095454|NCT02714140|Experimental|Group A: More preferred Existing + Common|Group A participants will be offered the common option and 3 currently available testing options that are targeted at the distribution of preferences among participants.
89095455|NCT02714140|Experimental|Group B: More preferred Enhanced + Common|"Group B participants will be offered the common option and 3 preference-informed enhanced testing options, which include combinations of features that may not yet be available in the study area."
89095456|NCT02714140|Active Comparator|Group C: Less preferred + Common|Group C participants will be offered the common option and 3 predicted less-preferred options. With the common option being the best option in Group C, this group is effectively a non-PB-HCT comparison group.
89095457|NCT02713906|Experimental|X-Ray Knee Guide group|Total knee arthroplasy using Materialise X-Ray Knee Guides
89095458|NCT02713984|Experimental|HER2 positive cancers|Patients with relapsed and refractory cancer of HER2 expression will be treated with anti-HER2 CAR-T cells
89095459|NCT02713672|Experimental|Intervention group|Psychiatric patients with a CYP2D6 or CYP2C19 PM or IM genotype, using antidepressants or antipsychotics metabolized by CYP2D6 or CYP2C19
89095460|NCT02713672|No Intervention|Control group|Psychiatric patients with a CYP2D6 or CYP2C19 EM genotype using antidepressants or antipsychotics
89095461|NCT02713750||HIV female adolescents|sexually active, HIV-infected female adolescents, 12-24 years old who are aware of their HIV status
89095462|NCT04000906|Experimental|Experimental Arm|Pressurized intraperitoneal aerosol chemotherapy (PIPAC) administration of Nab paclitaxel and cisplatin
89095463|NCT00636766|Experimental|1|
89095464|NCT02713360|Experimental|Cognitive therapy|The intervention consists of 3 steps. 1: Consultation with a nurse that aims of identifying what the anxiety consist of and how the patient experiences his or her life situation with an ICD. A plan is made to structure the treatment. 2: Participation in an individualized intervention based on anxiety type specific protocols. 3. The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
89095465|NCT02713360|No Intervention|Usual care|The control group will receive usual care which consists of control of ICD, disease control and treatment, and at one of the sites an offer of a group information meeting where experiences and events with ICD are discussed. The meeting takes place at Rigshospitalet every other month.
89095466|NCT02713282|Experimental|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq.) up to 525 mg eq. based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
89095467|NCT02713516|Experimental|Single Arm|The children in this study will have a single visit. During this visit the child and their parent will be introduced to the virtual reality (VR) system. The child will interact with the VR system and after they have finished, they will be asked questions about their experience with the VR system.
89095468|NCT02713048||Acute coronary syndrome culprit coronary lesion|
89095469|NCT02713048||Stable obstructive coronary artery disease|
89095470|NCT02713048||Non-obstructive coronary artery disease|
89095471|NCT00611182||1|Patients with Pulmonary Fibrosis
89095472|NCT00611260|Experimental|Meditation Cohort|25 patients will be given instruction in vipassana meditation. Vipassana meditation is thought to reduce the incidence of atrial and ventricular arrhythmias in patients with congestive heart failure, and improve their overall psychological profile.
89095473|NCT00611260|Active Comparator|Standard Care|25 patients will receive current standard of care to manage their congestive heart failure, implanted cardiac devices, and psychological health.
89095474|NCT02712970||stage-I|Single pit in the midline, no lateral extension. Pit-picking technique will be performed.
89095475|NCT02712970||Stage-II|>1 pits in the midline, no lateral extension. Pit-picking and Bascom cleft lift techniques will be performed.
89095476|NCT02712970||Stage-III|Midline pit/pits plus lateral extension in one direction. Bascom cleft lift technique will be performed.
89095477|NCT02712970||Stage-IV|Midline pit/pits plus lateral extension in both directions. Rhomboid excision with the Limberg Flap will be performed.
89095478|NCT02712970||Stage-R|Recurrent PSD following any type of treatment. Other flap techniques such as V-Y advancement flap, Z-Plasty will be performed.
89095479|NCT03987568|Experimental|Diagnostic (MRI biospecimen collection)|Patients undergo MRI over 15 minutes before standard of care surgery. Patients also undergo collection of blood samples during MRI and at the time of surgery.
89095480|NCT02693782|Placebo Comparator|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
89095481|NCT02693782|Active Comparator|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
89095482|NCT00611338|Active Comparator|Standard of Care, Wait-List Control|Participants received standard medical care, which in most clinics included informational brochures provided by physicians and clinic staff. Participants were given HIV prevention information and materials in English and Spanish and were provided referrals for services. Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the wait-list control participants participated in the Trauma + HIV group arm.
89095483|NCT00611338|Active Comparator|HIV Prevention|Eight, 90 minute group sessions. Three of the sessions focused on health education (e.g., medication adherence, nutrition, exercise) and five focused on HIV prevention skills (e.g., condom skills, communication, social support). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the participants in this arm were given the option to receive the 3 trauma-focused sessions from the Trauma + HIV group arm.
89095484|NCT00611338|Active Comparator|HIV Prevention plus Trauma|The same format as the HIV Prevention arm with eight, 90 minute group sessions. The participants received the same five HIV prevention skills sessions along with three sessions that focused on reducing trauma-related stress (e.g., breathing training, relaxation exercises, grounding exercises, coping, trauma-related triggers). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months.
89095485|NCT02712580|Active Comparator|First investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light."
89095486|NCT02712580|Active Comparator|Second investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light."
89095487|NCT02712580|Placebo Comparator|ES Wetling W200 with white light|Placebo device - 'ES Wetling W200 Placebo with white light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
89095488|NCT02712580|Placebo Comparator|ES Wetling W200 with red light|Placebo device - 'ES Wetling W200 Placebo with red light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
89095489|NCT00611416|Experimental|1|Active treatment A
89095490|NCT00611416|Experimental|2|Active treatment B
89095491|NCT00611416|Experimental|3|Active treatment C
89095492|NCT00611416|Active Comparator|4|Positive control
89095493|NCT00611416|Placebo Comparator|5|Placebo
89095494|NCT02712658|Active Comparator|terbutaline|terbutaline is administered by injection (0.25-0.5 mg Bricanyl, AstraZeneca diluted in 9 ml isotonic saline)
89095495|NCT02712658|Placebo Comparator|Placebo|placebo is administered as isotonic saline (10 ml)
89095496|NCT02712736|Other|Survey respondents|The patients who consent to participate will be sent home from the clinic with a survey to complete and return via mail in a provided addressed, stamped envelope. The survey consists of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant, cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy, and questions regarding complementary and alternative medicine use.
89095497|NCT00611494|Active Comparator|A|MMF
89095498|NCT00611494|Active Comparator|B|EC-MPS
89095499|NCT02712502||Study group (OG).|"50 patients c and acute exacerbation of chronic bacterial rhinosinusitis in the study group (OG).~The treatment regimen in the study group.~Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
89095500|NCT02712502||Control group (CG).|"50 patients c and acute exacerbation of chronic rhinosinusitis in the control group (CG).~The treatment regimen of the control group. Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
89095501|NCT02712346|Experimental|Treatment|Ambrisentan 5 mg PO daily
89095502|NCT02712346|Placebo Comparator|Placebo|One inactive pill PO daily
89095503|NCT02712190|Experimental|Low - High frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 250/min and respiratory rate 500/min
89095504|NCT02712190|Experimental|High - Low frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 500/min and respiratory rate 250/min
89095505|NCT02712268|Other|After introduction of the checklist|Review of medications of all consecutive admitted patients during the study period using a checklist
89095506|NCT02712034|Placebo Comparator|Medication-assisted treatment (MAT)|Patients will receive standard medication-assisted treatment (MAT) as prescribed by their health care provider.
89095507|NCT02712034|Experimental|MAT + A-CHESS|Patients in the MAT + A-CHESS arm will receive MAT as described plus the A-CHESS recovery support system via a smartphone.
89095508|NCT02711722|Active Comparator|PScli1|Patients are ventilated in Pressure support (PS) according to the Clinical settings for 30min.
89095509|NCT02711722|Active Comparator|NAVAcli|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to match to respiratory muscle unloading reached with PScli1. Patients are ventilated in NAVAcli for 30min.
89095510|NCT02711722|Active Comparator|NAVA40%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 40% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA40% for 30min.
89095511|NCT02711722|Active Comparator|NAVA60%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 60% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA60% for 30min.
89095512|NCT02711722|Active Comparator|PScli2|Patients return to PS ventilation, according to the Clinical settings as in PScli1 for 30min.
89095513|NCT02711566|Active Comparator|Sensorimotor training|"Patients in this arm were assigned to the 'Physioassistant: Haptic training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation.~All participating centers used the exact same apparatus and experimental set-up."
89095514|NCT02711566|Experimental|Haptic training|Patients in this arm were assigned to the 'Physioassistant: Sensorimotor training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation. All participating centers used the exact same apparatus and experimental set-up.
89095515|NCT02711488|Experimental|Intervention group|Combine primary prevention activities at the school level with secondary prevention at the household level
89095516|NCT02711488|No Intervention|Control group|No intervention
89095517|NCT02711176|Experimental|Tavanex & Nexium & Tinafas|"Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days"
89095518|NCT02711176|Active Comparator|Lanzol & Klacid &Iramox|Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days
89095519|NCT02711098|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
89095520|NCT02711098|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
89095521|NCT00611650|Experimental|Arm I|Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
89095522|NCT00611650|Placebo Comparator|Arm II|Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
89095523|NCT02711332||Degree of Haemolysis|Each subject will have four capillary blood sampling on different fingers. A reference venous blood sampling will be conducted.
89095524|NCT00636844||Group A|Patients receiving chemotherapy (anthracycline and/or adjuvant trastuzumab) for the first time
89095525|NCT02711020|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy delivered in individual format.
89095526|NCT02711020|Experimental|Personal Construct Therapy|Personal Constructs Therapy delivered in individual format.
89095527|NCT02710942|Experimental|SPHERE intervention|It is a comprehensive self-guided Internet-based cognitive-behavioral therapy (CBT) that includes three components: (1) the myWHI diary. (2) 30 multi-media learning topics that the user is encouraged to go through in a sequential way. The topics contain education information and teach strategies to cope better with their headaches.
89095528|NCT02710942|Experimental|PRISM intervention|It is a targeted self-guided Internet-based CBT intervention. PRISM was built upon the myWHI diary, an electronic headache diary. PRISM helps users discover their headache triggers by analyzing the inputted diary data using association rule mining. Once one or multiple headache triggers are identified the application uses an algorithm to provide the user with a few personalized recommendations to help them to cope with these triggers. The algorithm is based on the opinion of clinical experts (e.g., medical health professionals, psychologists). The user chooses recommendations to follow and sets goals in the application to follow them. To support the process, the application checks in with users about their goals and tracks goal completion.
89095529|NCT02710942|No Intervention|Usual care|Participants can continue doing what they usually do to deal with their migraines.
89095530|NCT02710708|Experimental|Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)|Chinese women between 18 and 45 years old inclusive (smokers not older than 35 years old) requesting oral contraception who have no contraindication to YAZ will be recruited for the study. Women who underwent surgical or medical abortions will also be recruited.
89095531|NCT02710552|Active Comparator|Three antihypertensive Drugs|Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine
89095532|NCT02710552|Active Comparator|Two antihypertensive drugs|Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
89095533|NCT02710396|Experimental|Cohort 1|Subjects will receive single agent pembrolizumab 200 mg IV will be administered every 3 weeks for up to 2 years.
89095534|NCT02710396|Experimental|Cohort 2|Subjects will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of nab-paclitaxel and carboplatin administered with cycles 1 and 2.
89095535|NCT02710396|Experimental|Cohort 3|Subject will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of pemetrexed and carboplatin administered with cycles 1 and 2.
89095536|NCT04564768|Experimental|Intervention group|Online Mindfulness-Based Cancer Recovery
89095537|NCT04564768|No Intervention|Control group|Treatment as usual
89095538|NCT02710318|Experimental|Immunization Alert on|Children with visits seen when the immunization alert is on
89095539|NCT02710318|No Intervention|Immunization Alert off|Children with visits seen when the alert is off
89095540|NCT02710162|Experimental|Screening|Participants enrolled will have the following test: Micro Mouth Pressure Meter, reflexive cough testing (with capsaicin used in blocks), lingual strength and endurance trials using the Iowa Oral Performance Instrument, Electrical Impedance Myography of the tongue, Pulmonary Function Testing, and a Videofluoroscopic Swallowing Study. In addition, the patient will complete the following surveys: Swallowing Related Quality of Life Questionnaire (SWAL-QOL), Eating Assessment Tool-10 (EAT-10), Functional Oral Intake Scale (FOIS), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS), and the Communicative Effectiveness Survey (CES).
89095541|NCT02709928|Experimental|TD-0714|Capsule formulation
89095542|NCT02709928|Placebo Comparator|Placebo|Capsule formulation
89095543|NCT02710006|Experimental|SonoHysteroAVC|Three-dimensional sonohysterography is the first point for uterine cavity volume estimation, and it is going to be performed in all participants. The investigators are going to fill the uterine cavity twice by saline solution during single sonohysterography procedure, and acquise the volumetric datasets of uterus for offline analysis. The 3D dataset containing the entire uterine cavity will by analyzed using a personal computer and/or the ultrasound machine with specific softwere.
89095544|NCT04497610||Positive TeraSystem test|Patients having positive PCR tests will undergo TeraSystem test
89095545|NCT04497610||Negative TeraSystem test|Patients having negative PCR tests will undergo TeraSystem test
89095546|NCT02709850|Placebo Comparator|Cohorts A, D: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
89095547|NCT02709850|Experimental|Cohorts A, D: IONIS ANGPTL3-LRx 20 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 20 milligrams (mg) subcutaneously on Day 1.
89095548|NCT02709850|Experimental|Cohorts A, D: IONIS ANGPTL3-LRx 120 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 120 mg subcutaneously on Day 1.
89095549|NCT02709850|Placebo Comparator|Cohorts B, C: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
89095550|NCT02709850|Experimental|Cohorts B, C: IONIS ANGPTL3-LRx 40 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 40 mg subcutaneously on Day 1.
89095551|NCT02709850|Experimental|Cohorts B, C: IONIS ANGPTL3-LRx 80 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 80 mg subcutaneously on Day 1.
89095552|NCT02709850|Placebo Comparator|Cohorts AA-DD: Placebo|Participants received IONIS ANGPTL3-LRx-matching placebo subcutaneously once per week for 6 weeks.
89095553|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 10 mg|Participants received IONIS ANGPTL3-LRx 10 mg subcutaneously once per week for 6 weeks.
89095554|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 20 mg|Participants received IONIS ANGPTL3-LRx 20 mg subcutaneously once per week for 6 weeks.
89095555|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 40 mg|Participants received IONIS ANGPTL3-LRx 40 mg subcutaneously once per week for 6 weeks.
89095556|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 60 mg|Participants received IONIS ANGPTL3-LRx 60 mg subcutaneously once per week for 6 weeks.
89095557|NCT02709772|Active Comparator|Provider Alert|This arm is the intervention arm. This arm will receive the Electronic Record Alert.
89095558|NCT02709772|No Intervention|No Provider Alert|This arm is the control arm.
89095559|NCT02709304|Placebo Comparator|Standard Gel|Standard gel not containing local anesthetic used to insert urinary catheters.
89095560|NCT02709304|Experimental|Lidocaine Gel|lidocaine containing gel uses to insert urinary catheters
89095561|NCT04189666|Active Comparator|Group R: patients receive Rivastigmine patch|receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative
89095562|NCT04189666|Active Comparator|Group M: patients receive Melatonin patch|receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative
89095563|NCT00937521|Other|1|Vaccine candidate formulation I
89095564|NCT00937521|Other|2|Vaccine candidate formulation II
89095565|NCT00937521|Other|3|Vaccine candidate formulation III
89095566|NCT00937521|Other|4|Vaccine candidate formulation IV
89095567|NCT00937521|Other|5|Vaccine candidate formulation V
89095568|NCT00937521|Other|6|Vaccine candidate formulation VI
89095569|NCT00937521|Other|7|Control
89095570|NCT00937521|Other|8|Vaccine candidate formulation I with antipyretic
89095571|NCT02709460|Experimental|Lateral occlusion|Women included in this arm is randomized to lateral occlusion of the uterine artery
89095572|NCT02709460|Active Comparator|cervical occlusion|Women included in this arm is randomized to occlusion of the uterine artery at cervical entry
89095573|NCT02709382|Experimental|FEP-TAZ|Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)
89095574|NCT02708992|Experimental|Cefixime/Azithromycin|Eight participants will receive three oral doses of 800 mg cefixime (q 8 hours) on Day 1, followed by three oral doses of 800 mg cefixime (q 8 hours)+ one oral dose of 1000 mg azithromycin (with first dose of cefixime) on day 10
89095575|NCT02709070|Active Comparator|resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
89095576|NCT02709070|Experimental|highly-purified CTL|Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective participants who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Participants in the immunotherapy group received a number up to 5×10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. Participants were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving resection, followed by 6-9 treatments during 6 months to 2 years after receiving resection.
89095577|NCT00604773||delirious patients|minimal one positive CAM-ICU score during ICU admission
89095578|NCT00604773||non-delirious patients|without any positive CAM-ICU scores during ICU admission
89095579|NCT02709148|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
89095580|NCT05380791||IEM in patients with GERD with normal MRS contraction|Esophageal motility determined by high resolution esophageal manometry and multiple rapid swallow (MRS) tests
89095581|NCT05380791||IEM in patients with GERD with abnormal MRS contraction|Esophageal motility determined by high resolution esophageal manometry and multiple rapid swallow (MRS) tests
89095582|NCT00606099|Experimental|1|telbivudine
89095583|NCT00606099|Active Comparator|2|adefovir dipivoxil
89095584|NCT02708602||β2AR Arg16Arg (AA group)|People with β2AR Arg16Arg genotype.
89095585|NCT02708602||β2AR Arg16Gly (AG group)|People with β2AR Arg16Gly genotype.
89095586|NCT02708602||β2AR Gly16Gly (GG group)|People with β2AR Gly16Gly genotype.
89095587|NCT02708602||β2AR Gln27Gln (CC group)|People with β2AR Gln16Gln genotype.
89095588|NCT02708602||β2AR Gln27Glu (CG group)|People with β2AR Gln27Glu genotype.
89095589|NCT02708602||β2AR Glu27Glu (GG group)|People with β2AR Glu27Glu genotype.
89095590|NCT00935883|Placebo Comparator|Saline|Randomized patients in the drusen or the GA cohort will receive placebo saline infusions as a comparator
89095591|NCT00935883|Active Comparator|Eculizumab|Randomized patients in the drusen or the GA cohort will receive active treatment with eculizumab
89095592|NCT02708446|Active Comparator|Sublingual misoprostol|200mg mifepristone + 400mcg sublingual misoprostol q3h
89095593|NCT02708446|Active Comparator|Buccal misoprostol|200mg mifepristone + 400mcg buccal misoprostol q3h
89095594|NCT02708056|Other|Sugammadex, Bridion|Drug were given intravenously by a anesthesiologist at the end of surgery
89095595|NCT04426708|Experimental|Mild hepatic impaired subjects (A)|Mild hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
89095596|NCT04426708|Experimental|Moderate hepatic impaired subjects (B)|Moderate hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
89095597|NCT04426708|Experimental|Healthy volunteers (C)|Matched healthy volunteers: to receive a single dose of HMS5552 ( 25mg ) tablet orally
89095598|NCT05305209|Experimental|Intervention group|They will receive the k-laser treatment with the k-laser Cube Plus 30 device
89095599|NCT05305209|Placebo Comparator|Control Group|They will receive a sham treatment with the k-laser Cube Plus 30 device turned off
89095600|NCT05378919|Active Comparator|Arm A (Control): Radiotherapy + fluorouracil|Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy) , then 6-8 weeks after chemoradiation, surgery, followed by adjuvant chemotherapy for 4-6 months, either Folfox4 or fluorouracil, depending on the center's choice.
89095601|NCT05378919|Experimental|Arm B (Experimental): Chemotherapy with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4) regimen|"Neoadjuvant CT FOLFOX4, 8 cycles (ca. 4 months; each cycle = 2 weeks):~oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles)."
89095602|NCT00607581|Experimental|1|"The participants receive up to 9 28-day cycles of~cyclophosphamide: 500 mg orally on days 1, 8, 15;~lenalidomide: 15 mg orally on days 1-21;~dexamethasone: 40 mg orally on days on days 1, 8, 15, 22."
89095603|NCT02707900|Experimental|Vorinostat + AGS-004|"Vorinostat (VOR) 400 mg PO - two paired doses at Step 2 (Enrollment) - Only participants demonstrating an in vivo response to the 2nd of the paired VOR doses will proceed to the AGS-004 manufacturing and treatment in Steps 3 through 7.~Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal (ID) injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses."
89095604|NCT05380479|Experimental|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night. This group will consist of 40 patients with anorexia in advanced cancer patients.
89095605|NCT05380479|Active Comparator|Megestrol Acetate|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night This group will consist of 40 patients with anorexia in advanced cancer patients.
89095606|NCT02707822||kidney or liver transplantation|Renal or liver transplant recipients with tacrolimus as immunosuppressive drugs.
89095607|NCT00936975|Experimental|18F-Fluoride PET|Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. Dasatinib was administered under a concurrent protocol and was not considered part of the intervention on this protocol
89095608|NCT00604929|Experimental|1|
89095609|NCT04410718||The intensive care unit cohort|Patients (with or without diabetes) with COVID-19 admitted to the intensive care unit
89095610|NCT04410718||The hospitalisation cohort|Patients with diabetes and COVID-19 admitted to the medical ward
89095611|NCT02707510|Experimental|Intervention Arm|Patients in the intervention group will be provided with all programmatic materials (including copies of power point presentations, copies of reading texts, and audio CDs) and classes will be held in group format, with a maximum of 9 participants per group. Classes will meet weekly, in a group, and at a set time. All classes will be facilitated jointly by the two Co-PIs. All participants will complete surveys before class, during class, at the end of class, 1 month after the end of class, 6 months after the end of class and 1 year after the end of the class. Additionally, those randomized to the intervention group will be asked to attend a 1 time focus group 1 week after the end of the class.
89095612|NCT02707510|No Intervention|Control Arm|Patients in the control group will be asked to complete surveys at: baseline, 6 weeks after baseline (T1), and 1 month after T1. After T1, the control group will off study and will be permitted to attend the next available GRACE course.
89095613|NCT02707354|Experimental|Probe based confocal laser endomicroscopy (Cellvizio)|intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console.
89095614|NCT04335682|Active Comparator|Darolutamide (DARO)|Patients will take DARO at a dose of 600 mg (300 mg ×2 tablets) by mouth twice daily beginning on Day 1, of Week 1. Patients will take DARO throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
89095615|NCT04335682|Active Comparator|Enzalutamide (ENZ)|Patients will take ENZ at a dose of 160 mg PO once daily (QD), beginning on Day 1, of Week 1. Patients will take ENZ throughout planned treatment period or withdrawal of consent or progression of disease requiring change in therapy.
89095616|NCT02707120|Experimental|PRGF-Endoret eye-drops|
89095617|NCT02707120|Active Comparator|Artificial tears eye-drops|
89095618|NCT02706808|Experimental|resistance starch for CKD|- Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
89095619|NCT02706808|Experimental|cross-over period|intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
89095620|NCT02693470|Other|single-arm study|"50 patients with severe psoriasis who received Stelara(ustekinumab) at 0 and 1 month. The investigators check microparticles level at baseline and 4 months later.~50 patients without psoriasis: the microparticles are checked at baseline."
89095621|NCT02706574||Isolated Traumatic Brain Injury|This group will present to our Level 1 Trauma Center with a Traumatic Brain Injury and no other associated injuries. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
89095622|NCT02706574||Isolated Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient with no injury to their head. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
89095623|NCT02706574||Combined Traumatic Brain Injury and Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient that had injuries to both their head and body. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
89095624|NCT02706574||Healthy, Uninjured Controls|This group will consist of subjects that have not been exposed to any major trauma in the previous 12 months. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
89095625|NCT00936897|Active Comparator|Ibandronate|Ibandronate 150mg PO QM (tablet)
89095626|NCT00936897|Experimental|Denosumab|denosumab 60mg Subcutaneous Q6M (pre-filled syringe)
89095627|NCT02706418|Other|Clinical Massage Therapy|
89095628|NCT00607659||Chlamydia Positive|Adolescent females, 11-21 years old, evaluated for pelvic examinations or STI screening will be asked to participate in this study. Participants are being asked to give us permission to collect:additional cervical or vaginal swabs, rectal swabs, blood draws where three tablespoons of blood, a urine pregnancy test, and a comprehensive health history. You may be asked to provide a urine specimen at the initial visit instead of having a cervical swab. The study team will obtain a cervical swab when you come back for your follow-up appointments. If your culture is positive for Chlamydia, you will be asked attend 3 additional follow-up appointments after 3 months, 6 months, 1 year, 2 years, and 3 years .
89095629|NCT00607659||Control/Chlamydia Negative|Some participants with negative cultures will be included in this study as a control group. The same specimens, exams and blood draws will apply for those subjects with visits at 3 months, 6 months, 1 year, 2 years, and 3 years
89095630|NCT02706340||Vaginal delivery|Women who have had a copper IUD placed within 10 minutes of a vaginal delivery of at least 34 weeks 0 days gestation.
89095631|NCT02706340||Cesarean delivery|Women who have had a copper IUD placed within 10 minutes of a cesarean delivery of at least 34 weeks 0 days gestation.
89095632|NCT02706496||young adults (20-35yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
89095633|NCT02706496||middle age(45-60yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
89095634|NCT02706496||elderly(65-74yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
89095635|NCT04266561|Other|lap. recurent inguinal hernia repair|After induction of general anesthesia, the patient was placed supine in Trendelenburg's position. Insertion of the main umbilical port. Laparoscopic hernia repair was done by intracorporeal insertion of purse string technique with some modifications
89095636|NCT02706184|Experimental|Intervention|Patients receive E. coli Nissle suspension
89095637|NCT02706184|Placebo Comparator|Control|Patients receive placebo
89095638|NCT00606255||A|Active training group: Electronic Pill-Boxes with SMS service 1/week, training material provided
89095639|NCT00606255||B|Passive training group: Electronic Pill-Boxes ,Training material provided
89095640|NCT00606255||C|Usual treatment group: Electronic Pill-Boxes, maintain current treatment method
89095641|NCT04264689|Active Comparator|thoracic epidural|thoracic epidural will be done before induction of general anesthesia
89095642|NCT04264689|Experimental|serratus anterior block|ultrasound guided serratus anterior block will be done after induction of general anesthesia
89095643|NCT04264689|Experimental|erector spinae block|ultrasound guided erector spinae block will be done after induction of general anesthesia
89095644|NCT05265676|Experimental|Cohort 1 - AB treatment sequence|"Period 1 - Test Product (A): Enoxaparin Sodium pre-filled syringe BP 40 mg/0.4 ml of Venus Remedies Limited, India.~Period 2 - Reference Product (B): 'Clexane®' (Enoxaparin Sodium pre-filled syringe; 40 mg/0.4 ml) of Sanofi, Germany."
89095645|NCT05265676|Experimental|Cohort 2 - BA treatment sequence|"Period 1 - Reference Product (B): 'Clexane®' (Enoxaparin Sodium pre-filled syringe; 40 mg/0.4 ml) of Sanofi, Germany.~Period 2 - Test Product (A): Enoxaparin Sodium pre-filled syringe BP 40 mg/0.4 ml of Venus Remedies Limited, India."
89095646|NCT00606333|Experimental|Investigational arm|Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
89095647|NCT00606333|Active Comparator|Control Arm|Subjects randomized to treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
89095648|NCT04264611|Experimental|Short Foot Exercise Group|The group that received the short foot exercise
89095649|NCT04264611|Experimental|Towel Curl Exercise Group|The group that received the towel curl exercise
89095650|NCT04264611|No Intervention|Control Group|The group that received no exercise
89095651|NCT05265130|Experimental|YQFM group|YQFM 5.2g in 0.9% Normal Saline 250ml IV, about 40 drops per min, once a day.
89095652|NCT05265130|Placebo Comparator|Placebo group|0.9% Normal Saline 250ml IV, about 40 drops per min.
89095653|NCT02691117|Experimental|Garlic concentrate|Garlic gel concentrate- once a day topical application
89095654|NCT02693626|Experimental|intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per day for the time leading up to the quit day and the following 12 weeks.~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
89095655|NCT02693626|No Intervention|No cessation message intervention|Control group participants only will receive one text message every week, thanking them for being in the study, providing study center contact details, and reminding them of the time until their free month at the end of follow up. Another one to two messages will be sent per week until the end of the 24 week. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points.
89095656|NCT02693626|Experimental|Not intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per week for the time leading up to the quit day and the following 12 weeks.~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
89095657|NCT04266405|Placebo Comparator|Placebo drink|
89095658|NCT04266405|Experimental|Collagen and Zhuyin Drinks|
89095659|NCT05264662|Active Comparator|Open label Adacel|"Tdap (Adacel) ADACEL (0,5 ml) should be administered as an injection by the intramuscular route.~Re-dosing with ADACEL can be used to boost immunity to diphtheria, tetanus and pertussis at 5- to 10-year intervals.~ADACEL may be administered to pregnant women during the second and third trimester to provide passive protection to infants against pertussis."
89095660|NCT05264662|No Intervention|control|Infants born to unvaccinated mothers.
89095661|NCT00606411|Active Comparator|Topiramate|Study medication arm, 25-300mg of Topiramate
89095662|NCT00606411|Placebo Comparator|Placebo|Placebo arm of study, 25-300mg of sugar pill
89095663|NCT04158310||Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
89095664|NCT04158310||Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD.
89095665|NCT00631293|Experimental|1|administration of lactisole
89095666|NCT00631293|Placebo Comparator|2|administration of placebo
89095667|NCT00612196|Experimental|1|
89095668|NCT00612196|Experimental|2|
89095669|NCT00612196|Experimental|3|
89095670|NCT00612196|Experimental|4|
89095671|NCT00612196|Experimental|5|
89095672|NCT00612196|Experimental|6|
89095673|NCT00612196|Experimental|7|
89095674|NCT00612196|Experimental|8|
89095675|NCT00612196|Experimental|9|
89095676|NCT00612196|Placebo Comparator|10|
89095677|NCT00607737|Experimental|1|insulin detemir
89095678|NCT00607737|Placebo Comparator|2|saline
89095679|NCT05264428|Experimental|Experimental group|Participants need to drink honey every day for four weeks.
89095680|NCT05264428|Placebo Comparator|Control group|Participants need to drink water every day for four weeks.
89095681|NCT05264272||Prospective Study|HBV/HDV positive individuals
89095682|NCT05264272||Retrospective Study|patients positive for anti-HDV
89095683|NCT01120691|Experimental|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
89095684|NCT01120691|Active Comparator|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
89095685|NCT01120691|Active Comparator|open-label tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
89095686|NCT00612274|Experimental|1|sirolimus, tacrolimus and short course methotrexate
89095687|NCT05263882|Other|single arm|"Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
89095688|NCT02725138|Experimental|Probiotic|subjects will be treated with probiotic containing Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
89095689|NCT02725138|Placebo Comparator|Placebo|subjects will be treated with placebo without Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
89095690|NCT05261230|Experimental|Vedic Counselling Group|Vedic Counselling was given by trained and experienced therapists
89095691|NCT05261230|Active Comparator|Usual Care Group|Standard psychosocial care delivered by psychologists.
89095692|NCT05261152|Experimental|Probiotic group|Capsules are containing S. boulardii and were administered twice daily (250 mg). The administration of investigated product started within 30 min before the first dose of the antibiotic and continued for 21 days.
89095693|NCT05261152|Placebo Comparator|Placebo group|Capsules are containing placebo and were administered twice daily. The administration of investigated product started within 30 min before the first dose of the antibiotic and continued for 21 days.
89095694|NCT05260996|Experimental|Pilot Group|
89095695|NCT05260996|No Intervention|Control Group|
89095696|NCT02724904|Experimental|Allogeneic Stem Cell Transplantation|Patients will undergo reduced intensity conditioning (fludarabine and thiotepa) followed by fully matched related or unrelated allogeneic stem cell transplantation. Afterwards, patients will receive standard post-transplant care (Methotrexate).
89095697|NCT00935493|Experimental|Guanfacine 0.1 mg po qhs|
89095698|NCT00935493|Experimental|Guanfacine 0.5 mg po qhs|
89095699|NCT00935493|Placebo Comparator|Placebo po qhs|
89095700|NCT05380245|Experimental|Treatment Voriconazole (alone), then Voriconazole + Clarithromycin.|On Day-1, Group-A participants first received Voriconazole (alone) (Dose: 400mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral). After a washout period of two weeks. Then, on Day-16 they received Voriconazole (Dose: 400mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral) along with Clarithromycin (Name of medication of Intervention Formulation: Tablet Klaricid, Dose: 500mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral).
89095701|NCT05380245|Experimental|Treatment Voriconazole + Clarithromycin, then Voriconazole (alone).|On Day-1, Group-B participants first received Voriconazole (Dose: 400mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral) along with Clarithromycin (Name of medication of Intervention Formulation: Tablet Klaricid, Dose: 500mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral).After a washout period of two weeks. Then, on Day-16 they received Voriconazole (alone) (Dose: 400mg, Dosage form: Tablet, Frequency: Once (OD), Duration of administration: Single Dose, Kind of administration: Oral).
89095702|NCT03856996|Experimental|Group 1: Stable CH505TF gp120 + GLA-SE|Participants in Group 1 will receive 100 mcg of Stable CH505TF gp120 admixed with 10 mcg of GLA-SE by intramuscular (IM) injection at Months 0, 2, and 6.
89095703|NCT03856996|Experimental|Group 2: Transient CH505TF gp120 + GLA-SE|Participants in Group 2 will receive 100 mcg of Transient CH505TF gp120 admixed with 10 mcg of GLA-SE by IM injection at Months 0, 2, and 6.
89095704|NCT05378685|Active Comparator|Oral|Infants in this group are endotracheally intubated through their mouth.
89095705|NCT05378685|Active Comparator|Nasal|Infants in this group are endotracheally intubated through their nose.
89095706|NCT03853252|Other|Skin biopsy|
89095707|NCT02724826|Experimental|Qigong therapy|The qigong treatment was done according to medical qigong, and is a way of affecting and directing qi (energy) for medical benefit. Each qigong practice included body posture adjustment, gentle movement, meditation, relaxation, breathing regulation practices and massage. The qigong was practiced in groups of ten to 15 participants. Each qigong session started with information about the philosophy and a general warm-up with soft movements and 14 selected qigong exercises according to the Biyun method.
89095708|NCT02724826|Active Comparator|Exercise therapy|Exercise therapy was carried out individually, adjusted for each participant. A physiotherapist instructed the participant with focused on the cervical and shoulder/thoracic regions. Each training session included stationary bicycle for ten minutes, 40 minutes of dynamic exercises. These exercises consisted of active movements in all neck directions and muscle exercises aimed to maintain/increase circulation, endurance and strength. The load at the muscle exercises was to achieve between 30 and 70% of maximum muscle capacity and was gradually increased as endurance and strength were gained.
89095709|NCT00605241|Other|GSK598809|Drug
89095710|NCT04266171|Experimental|CGMS Diet Education|
89095711|NCT04266171|Active Comparator|Conventional Diet Education|
89095712|NCT00935259|Experimental|Simvastatin 40 mg first, then placebo|Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks
89095713|NCT00935259|Placebo Comparator|Placebo first, then simvastatin 40 mg once daily|Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks
89095714|NCT02937766|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)
89095715|NCT02937766|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)
89095716|NCT02724748|Experimental|Educational intervention|Beside usual care the intervention will encourage collaborative practices between staff, patients and family members to adopt more human patient-centred approach on the unit. The intervention is designed to impact on treatment culture and thereby treatment practices on the study wards.
88812634|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
89095717|NCT02724748|No Intervention|Treatment as usual|Wards allocated to comparison wards continue with their usual care. No restrictions on how nursing staff works in these wards, although participation in corresponding projects is not supported.
89095718|NCT05260450|Experimental|Group A (Long-pulsed group)|Nail clippings allocated to group A received laser treatment with a 1064 nm Nd:YAG-laser. They received one treatment with laser settings: pulse duration 10 ms, spot size 3 mm, fluence 40-50 J/cm2, number of laser pulses 100 /cm2.
89095719|NCT05260450|Active Comparator|Group B (Short-pulsed group)|Nail clippings allocated to group B received laser treatment with a 1064 nm Nd:YAG-laser. They received one treatment with laser settings: pulse duration 0.3 ms, spot size 3 mm, fluence 40 J/cm2, number of laser pulses 100 /cm2.
89095720|NCT00606567|Active Comparator|1-treatment|remote monitoring with carelink every 3 months
89095721|NCT00606567|No Intervention|2- control|device interrogations in clinic every 3 months
89095722|NCT04267419||healthy Control|MDA and NO in saliva
89095723|NCT04267419||keratosis|MDA and NO in saliva
89095724|NCT04267419||leukoplakia|MDA and NO in saliva
89095725|NCT04267419||Oral lichen Planus|MDA and NO in saliva
89095726|NCT04267419||oral Squamous cell carcinoma|MDA and NO in saliva
89095727|NCT00606645|Experimental|1|XmAb2513
89095728|NCT02724670|Other|Radiation|IGRT 5x 2Gy/week, total dose: 78 Gy
89095729|NCT04267341||Mild Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 1-2
89095730|NCT04267341||Moderate Stage Parkinson's Disease Patients|Modified Hoehn and Yahr stage 2.5-3
89095731|NCT04267341||Healthy Control|Healthy People
89095732|NCT05260372||Lung transplantation recipients|Recipients aged 18 to 65 years old undergoing lung transplantation at Fondazione IRCCS Ospedale Policlinico Milano undergoing quantification of donor-derived cell-free DNA on serial plasma samples
89095733|NCT04264377||Healthy|26 healthy subjects
89095734|NCT04264377||Asthma|26 subjects with asthma
89095735|NCT05260294|Active Comparator|18 Gauge Tuohy group|In the 18G group, all CESIs were performed utilizing the fluoroscopy only method when the needle was navigated from the skin toward the epidural space under contralateral oblique fluoroscopy, and the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK).
89095736|NCT05260294|Active Comparator|25 Gauge Tuohy group|In the 25G group, all CESIs were performed utilizing the fluoroscopy only method when the needle was navigated from the skin toward the epidural space under contralateral oblique fluoroscopy, and the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK).
89095737|NCT00606723|Experimental|1|"Group I: Relapsed AML-patients with blast cell reduction to <20% before the second course of induction therapy. These patients will receive conventional SCT.~Group II: Patients with non response to frontline treatment of AML, patients with blast cells <20% before the second course of induction therapy who do not achieve a second remission and relapsed AML-patients with blast cells >=20% before the second course of induction therapy. If these patients have a matched donor (MSD/MD) they will receive SCT with FLAMSA.~Group III: Patients who are eligible for Group II but have no matched donor. These patients will receive SCT from a haploidentical donor."
89095738|NCT03826576|Experimental|Intervention Group|Intervention group will receive a Multicomponent Intervention.
89095739|NCT03826576|No Intervention|Control Group|Control group will not receive any kind of intervention, only it will receive information about AMED criteria and allergens of food.
89095740|NCT00607971|Experimental|1|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
89095741|NCT02724436|Experimental|TACE|transcatheter arterial chemoembolization
89095742|NCT02724436|Experimental|TACE+radioembolization|TACE plus radioembolization with Y-90: 100
89095743|NCT01120379||XV-LTF cohort|
89095744|NCT02724358|Experimental|TACE|iodized oil (5ml) + Pirarubicin (20mg)
89095745|NCT02724358|Experimental|Rg3|20mg, BID, maintained though Month 12
89095746|NCT02724358|Experimental|TACE + Rg3|the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE.
89095747|NCT02724358|Experimental|Control|standard liver protective therapy
89095748|NCT05260138|Experimental|The intervention group|received all basic routine care in addition to regular position change and gentle body massage
89095749|NCT05260138|Active Comparator|The control group|received the conventional NICU care
89095750|NCT00608049|Experimental|1|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/high GI, and low carbohydrate/low GI
89095751|NCT00608049|Experimental|2|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/low GI, and low carbohydrate/high GI
89095752|NCT00608049|Experimental|3|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/high GI, and low carbohydrate/low GI
89095753|NCT00608049|Experimental|4|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/low GI, and low carbohydrate/high GI
89095754|NCT00608049|Experimental|5|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/high GI, and high carbohydrate/low GI
89095755|NCT00608049|Experimental|6|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/low GI, and high carbohydrate/high GI
89095756|NCT00608049|Experimental|7|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/high GI, and high carbohydrate/low GI
89095757|NCT00608049|Experimental|8|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/low GI, and high carbohydrate/high GI
89095758|NCT05259748|Experimental|intervention group|At the beginning, personal information form, behavioural change stage diagnosis form and healthy lifestyle scale II were applied. 6-week psychoeducation, consisting of 6 modules, based on the Transtheoretical model, was applied to the intervention group. Finally, posttests were applied after the psychoeducation.
89095759|NCT05259748|No Intervention|control group|At the beginning, personal information form, behavioural change stage diagnosis form and healthy lifestyle scale II were applied. No interventions were applied to the control group. It was contacted with the control group three times, two face to face and one via phone. In the third and final meeting, when the intervention group's sessions are completed, posttests were applied again to the control group.
89095760|NCT02724202|Experimental|Open Label|All subjects will receive induction oral curcumin 500 mg twice per day for 2 weeks. Patients will continue on curcumin at same dose for an additional 6 weeks while being treated with 3 cycles of 5FU.
89095761|NCT04265859|Experimental|Depressed|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
89095762|NCT04265859|Other|Healthy Control|Participants in this group will be randomized to receive either the CBT training (n=10) or Mindfulness training (n=10).
89095763|NCT01120067|Experimental|Intensive Treatment|Intensive 3 week treatment for pain and PTSD. This includes elements of Cognitive Processing Therapy and CBT for Chronic Pain
89095764|NCT01120067|Experimental|Treatment as Usual|Treatment as Usual. Participants are eligible for all treatment services as needed except for treatment of pain or PTSD
89095765|NCT02724280|Active Comparator|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
89095766|NCT02724280|Placebo Comparator|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
89095767|NCT05282043|Experimental|post COVID-19 group|In this group cases, who were infected with COVID-19 and had at least 12 weeks after diagnosis, will be allocated. Those should have no symptoms of COVID-19 such as fever, cough, ageusia, anosmia, diarrhea, arthralgia, myalgia, sore throat, headache, chest pain.
89095768|NCT05282043|Active Comparator|healthy control group|In this group cases, who were not infected with COVID-19 will be allocated.
89095769|NCT00605397|Experimental|1|breast cancer pt receiving trastuzumab therapy will undergo two complete PET studies.
89095770|NCT00605397|Experimental|2|breast cancer pt receiving trastuzumab therapy will undergo one complete PET studies
89095771|NCT00625547|Experimental|1|
89095772|NCT00625547|Experimental|2|
89095773|NCT05241340|Experimental|Open arm|All patients will receive study interventions (sasanlimab and SBRT) and standard-of-care radical cystectomy.
89095774|NCT04265469|Experimental|Patients with diabetics get mobile education|Patients with diabetics get mobile education
89095775|NCT04265469|No Intervention|Patients with diabetics|Patients with diabetics
89095776|NCT05240326|Active Comparator|exercise training group|Clinical pilates exercises
89095777|NCT05240326|Sham Comparator|control training group|Relaxation exercises
89095778|NCT02881853|Experimental|Part A1|XmAb7195 for IV infusion; dose level 1; 4 once-weekly doses
89095779|NCT02881853|Experimental|Part A2|XmAb7195 for SC injection; dose level 1; 4 once weekly doses
89095780|NCT02881853|Experimental|Part A3|XmAb7195 for SC injection; dose level 2; 4 once weekly doses
89095781|NCT02881853|Experimental|Part A4|XmAb7195 for SC injection; dose level 3; 4 once weekly doses
89095782|NCT02881853|Experimental|Part A5|XmAb7195 for SC injection; dose level 4; 4 once weekly doses
89095783|NCT02881853|Experimental|Part B6|XmAb7195 or placebo for SC injection; dose level 5; 4 once-weekly doses
89095784|NCT02881853|Experimental|Part B7|XmAb7195 or placebo for SC injection; dose level 6; 4 once-weekly doses
89095785|NCT02881853|Experimental|Part B8|XmAb7195 or placebo for SC injection; dose level 7; 4 once-weekly doses
89095786|NCT02881853|Experimental|Part B9|XmAb7195 or placebo for SC injection dose level 8; 4 once-weekly doses
89095787|NCT02724046|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
89095788|NCT02724046|Active Comparator|Household prophylaxis|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
89095789|NCT02724046|Active Comparator|Village prophylaxis|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
89095790|NCT02724124|Experimental|static stretching|group of 11 volunteers (gSS)
89095791|NCT02724124|Experimental|warm up -|group of 11 volunteers (gWU)
89095792|NCT02724124|Experimental|static stretching + warm up|(group of 11 volunteers - SS+WU)
89095793|NCT02724124|Experimental|warm up+static stretching|(group of 11 volunteers - WU+SS)
89095794|NCT02724124|Other|Control Group|No intervention - athletes rested
89095795|NCT00608127|Experimental|1|Single arm open label
89095796|NCT04265547|Experimental|Intervention Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Participants in the intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion.
89095797|NCT04265547|No Intervention|Control Arm|Mother-daughter pairs will partake in an educational session at the baseline visit, which will cover topics on reading product labels, cleaning habit, and cooking methods for reducing environmental exposures. Educational materials will be adapted from the Environmental Protection Agency (EPA) and other accredited sources. Participants will also be introduced to free resources for consumer product safety information, such as the Detox Me phone application. Mother-daughter pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy (OS) measurement, and questionnaire completion. Control arm participants will be offered the chemical-free products, cleaning supplies, and air filter at this time.
89095798|NCT01124045|Experimental|DUREZOL|Difluprednate ophthalmic emulsion, 0.05%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
89095799|NCT01124045|Active Comparator|PRED FORTE|Prednisolone acetate ophthalmic suspension, 1.0%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
89095800|NCT04265391|Experimental|Snakehead fish cookies|Subjects who were given intervention of snakehead fish cookies during the study period
89095801|NCT04265391|Placebo Comparator|Standard cookies|Subjects who were in control group and received standard cookies
89095802|NCT00608283||Live Kidney Donors|People who are going to donate a kidney at one of the three transplant centers from August 2007 until June 2011
89095803|NCT01123889|Active Comparator|control|corticosteroid injection into subacromial space
89095804|NCT01123889|Experimental|experimental|patients will receive an injection of platelet rich plasma into the subacromial space
88812635|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
88812636|NCT02262026|Active Comparator|FHN; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
89095805|NCT05226208||Women with not severe labour pain|Group 1 included 282 patients (pain level ≥7 mm according to the VAS).
89095806|NCT05226208||Women with severe labour pain|Group 2 included 84 patients (pain level ≤ 6 mm using the VAS).
89095807|NCT05379543||ICU-Severely ill group|Patients requiring transfer to the intensive care unit (ICU), and presenting with severe symptoms (dyspnea, respiratory rate ≥30/min, blood oxygen saturation ≤93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio <300, or lung infiltrates >50% within 24 to 48 hours)
89095808|NCT05379543||ICU-Critically ill group|Patients requiring transfer to the ICU, and presenting with respiratory failure, septic shock, multiple organ dysfunction, or failure)
89095809|NCT05379543||Mildly ill group|Patients presenting with fever, mild to moderate respiratory symptoms, and with or without imaging presentations of pneumonia
89095810|NCT05379543||Healthy control group|Healthy volunteers, matched for gender and age, without any signs or evidence of COVID-19 infection
89095811|NCT02723968|Other|Continuous glucose monitoring system|OGTT followed by continuous glucose monitoring system and finally IGTT and HbA1C dosage
89095812|NCT00606879|Experimental|Single arm|
89095813|NCT00605631|Experimental|1|
89095814|NCT00605631|Active Comparator|2|
89095815|NCT00605631|Other|3|
89095816|NCT02723890|Experimental|Tyto Device|examination with Tyto device carried out by a nurse and sent online to the principle and co-investigators for remote analysis.
89095817|NCT02723656|Active Comparator|Proactive mailed care coordination|
89095818|NCT02723656|Active Comparator|Proactive telephone care coordination.|
89095819|NCT05192512|Experimental|TQB2928 injection|weekly intravenous (IV) infusions for four times (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle
89095820|NCT00934947|Placebo Comparator|Sugar pill|
89095821|NCT00934947|Experimental|Propranolol, Propanolol ER|
89095822|NCT05191810|Experimental|Study Group|Macrogol (PEG 3350, PEG 4000), standard dosage Educational intervention: Recommendation of adequate for age fluid intake plus standard information about non-pharmacological supporting treatment
89095823|NCT05191810|No Intervention|Control Group|Macrogol (PEG 3350, PEG 4000), standard dosage Standard educational information about non-pharmacological supporting treatment
89095824|NCT02723578|Experimental|Pemetrexed and Erlotinib|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and Erlotinib 150 mg PO once daily on days 1-21 every 21 days
89095825|NCT04267263|No Intervention|Delayed Treatment Control group|Participants will receive the treatment after completion of the 3-month follow-up assessment
89095826|NCT04267263|Experimental|Lifestyle group|Participants will receive the treatment immediately
89095827|NCT01123655|Experimental|Arm 1|"The study will have 3 treatment arms each with 10-12 patients who have demonstrated T cell immunity to CII and have an in vitro response to APL A12 at the screening visit. Patients will be randomized to one of the 2 treatment arms (30 micrograms APL A12 or placebo). Each of the 2 treatments will be given for 16 weeks.~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate.~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
89095828|NCT01123655|Experimental|Arm 2|"The next group will receive a higher dose (50 micrograms) and/or placebo (Block 2).~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
89227006|NCT00001174||Healthy Volunteers|Healthy volunteers
89227007|NCT00001174||Patients|Patients with bipolar disorder
89095829|NCT01123655|Experimental|Arm 3|"Block 3 (Arm 3) will include placebo and both doses of APL/A12 to ensure 10-12 patients are enrolled in each arm ( total of approximately 32 subjects) so we will have 24 subjects who complete the 16 weeks of study treatment. Arms 2 and 3 will run simultaneously.~Intervention: Drug treatment will be stopped or interrupted if indicated."
89095830|NCT04189198|Experimental|Articaine group|Patients in this group are assigned to recieve 30 ml of Articaine 2%
88812637|NCT02262026|Active Comparator|FHN; placebo, then 125mg AZD0530, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
89095831|NCT04189198|Experimental|Bupivacaine|Patients in this group are assigned to recieve 30 ml of bupivacaine 0.5%
89095832|NCT00608361|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89111155|NCT02591706|Experimental|Dental implant (V3)|"The unique triangular shape of the coronal portion of the V3 implant results in less titanium and more bone and soft tissue visible in the esthetic zone, for a restorative-driven approach and easier soft tissue management. The V3 provides doctors with a more advantageous starting point; where greater volume of bone and soft tissue is achieved at the onset of implant placement.~Patient will be randomly assigned to one of the two groups after flap opening."
89095833|NCT04311281||Suspected AD|"Participants with suspected AD enrolling in the trial must meet all of the following criteria:~Cognitive deficits do not occur exclusively in the context of a delirium.~Cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia).~There is insidious onset and gradual progression of impairment in one or more cognitive domains.~The participant has documented memory problems in one or more other cognitive domains, such as language, visual-spatial functioning, executive functioning, etc. (Busse et al., 2006)."
89095834|NCT04311281||Suspected CTE / TES|"Required Features:~Persistence of symptoms for longer than 2 years; no other neurologic disorder that is more likely to account for all the clinical features; history of head trauma exposure; progressive course; and at least 1 supportive feature~History of head trauma exposure, typically associated with history of concussion, although may be limited to subconcussive trauma~Head trauma exposure is repetitive in nature~Demonstrated progressive course~Delayed symptom onset~Self-report or observer report of cognitive dysfunction, confirmed with objective cognitive decline documented by results of formal neuropsychological testing. Cognitive decline typically affects more than 1 domain (executive, visuospatial, memory, and language).~Supportive Features (only 1 required):~Emotional dysregulation~Behavioral change~Motor disturbance"
89095835|NCT00934791|Active Comparator|Control Group|Tacrolimus, mycophenolate mofetil, and prednisone
89095836|NCT00934791|Active Comparator|Sirolimus Group|Sirolimus, mycophenolate mofetil, and prednisone
89095837|NCT02882165|Experimental|Intervention arm|Participants receive a comprehensive medical review by a Respiratory Clinical Fellow.
89095838|NCT02882165|No Intervention|Control arm|Participants receive usual care as required via their primary care practice.
89095839|NCT02723812|Experimental|GCFLU® Influenza vaccine (Split virion, Inactivated)|One dose 0.5 mL vaccine GCFLU® administered intramuscularly.
89095840|NCT05268159||Stroke patients|Stroke patients admitted to the Lille Neurological rehabilitation unit after a first-ever hemispheric stroke, assessed at the subacute phase (< 6months)
89095841|NCT02723422|Experimental|Prehabilitation Visit/Increased Physical Therapy post-TAVR|
89095842|NCT02723422|Active Comparator|Control|Standard of care physical therapy post-TAVR
89095843|NCT00605709|Experimental|1|Active Cream 3% ; AM & PM
89095844|NCT00605709|Active Comparator|2|Placebo Cream AM; 3% Active Cream PM
89095845|NCT00605709|Active Comparator|3|Placebo Cream AM; 1.5% Active Cream PM
89095846|NCT00605709|Placebo Comparator|4|Placebo Cream AM & PM
89095847|NCT02882009|Experimental|Gantenerumab + Placebo|Participants will be randomized to receive gantenerumab HCLF and placebo solution via SC injection according to different sequences for the site of administration and different injection speeds.
89095848|NCT00636688|Experimental|1|Behavioral (Lifestyle Counseling)
89095849|NCT00636688|Active Comparator|2|Control group
89095850|NCT00607035|Experimental|A|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
89095851|NCT00607035|Experimental|H|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
89095852|NCT05060081|Experimental|Pilates exercise program group|Pilates exercise program group will perform five exercises.
89095853|NCT05060081|Active Comparator|Traditional plank exercise program group|Traditional plank exercise program group will perform five exercises.
89095854|NCT02723266|Experimental|Intervention|Treatment receives the STOPPING-GDM intervention. Control does not receive the intervention.
89095855|NCT02723266|No Intervention|Control|Control does not receive the intervention.
89095856|NCT00608439|Placebo Comparator|Placebo|Placebo CAST
89095857|NCT00608439|Active Comparator|Centella asiatica selected triterpenes|Active CAST
89095858|NCT02693236|Experimental|adenovirus-transfected autologous DC vaccine plus CIK cells|
89095859|NCT04265313||Head and Neck Cancer patients|Turkish patients diagnosed with Head and Neck Cancer
89095860|NCT02722954|Experimental|Demcizumab and Pembrolizumab|Demcizumab will be administered prior to pembrolizumab
89095861|NCT01119443|Other|Treatment sequence A|V4: PPX ER 1.5mg x 1 fed, V5: PPX ER 0.375mg x 4 fed, V6:: PPX ER 1.5mg x 1 fasted, V5: PPX ER 0.375mg x 4 fasted
89095862|NCT01119443|Other|Treatment sequence B|V4: PPX ER 0.375mg x 4 fed, V5: PPX ER 1.5mg x 1 fed, V6:: PPX ER 0.375mg x 4 fasted, V5: PPX ER 1.5mg x 1 fasted
89095863|NCT04262973|Experimental|experimental group|The experimental group will not only receive six-hour dementia care course, but also a half-day interprofessional education workshop, maintain a six-month interprofessional practice model, and join interprofessional practice experience-sharing conferences.
89095864|NCT04262973|Active Comparator|control group|The control group will only receive six-hour dementia care course.
89095865|NCT00625859|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
89095866|NCT00625859|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
89095867|NCT00625859|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
89227008|NCT01897610|No Intervention|control group|The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.
89095868|NCT00625859|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
89095869|NCT00625859|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
89095870|NCT00625859|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
89095871|NCT02723110||rs78408340 heterozygous carriers|
89095872|NCT02723110||homozygous non-risk allele carriers|
89095873|NCT04262739|Experimental|NYH817G|
89095874|NCT04262739|Experimental|NYH100P|
89095875|NCT04262739|Experimental|NYH817G and NYH100P|
89095876|NCT02691195|Placebo Comparator|group control|group control :Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
89095877|NCT02691195|Experimental|group SPB|group SPB:Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
89095878|NCT02723032|Other|Healthy Subjects and patients|Validation of SpO2 sensor in healthy subjects as a first step. Validation of SpO2 sensor in patients as a second step.
89095879|NCT02722876|Experimental|Contralateral rehabilitation|8-weeks of resistance training of the non-operative limb following ACL reconstruction
89095880|NCT02722876|Placebo Comparator|Placebo flexibility exercise|8-weeks of 'placebo' flexibility training of the upper limb
89095881|NCT04131946|Experimental|Community Intervention Group/Arm 1|"Community navigators will work with local businesses (barber shop, hair salon) to identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT.~Community navigators will attend community events to post the informational flyer and provide education about CRC to community members. At these events, they will identify and screen eligible community members within or near the South Shore community area. The navigator will engage with each potential participant using the attached script. If the participant is interested, the navigator will document the participant's contact information, and assist the participant in obtaining and returning their FIT."
89095882|NCT04131946|No Intervention|Standard of Care (Control) Arm 2|"These procedures are a detailed summary of the existing lay navigation program at Mile Square Health Center (MSHC). These procedures are unrelated to our research, except to demonstrate how the existing navigation program from which we will obtain deidentified data works.~Lay clinic navigator use clinic schedules and walk-ins to identify and screen eligible participants within the Englewood MSHC. The navigator engages with each potential participant using standard scripted language. For interested patients, the navigator documents interest and FIT dispensing as appropriate, and assists the patient in obtaining and returning their FIT.~Lay clinic navigators attend community events as normally scheduled to provide community-based health education and referral to the MSHC. At these events, they identify and screen eligible community members within the Englewood community area."
89095883|NCT03808090|Experimental|Normal Individuals|Normal individuals: no prior history of KS, no obesity, no diabetes
89095884|NCT03808090|Experimental|Calcium Oxalate Kidney Stone Formers|Those individuals that have a high propensity to form calcium oxalate kidney stones
89095885|NCT03808090|Experimental|Type 2 Diabetes|Those individuals that have been diagnosed with type 2 diabetes
89095886|NCT03808090|Experimental|Type 2 diabetic kidney stone formers|Those individuals that have been diagnosed with type 2 diabetes and kidney stones.
89095887|NCT02722642|Experimental|Bronchial basal cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
89095888|NCT02722720|Experimental|Carotid stenting, Transradial approach|Internal carotid artery stenting using transradial arterial approach
89095889|NCT02722720|Active Comparator|Carotid stenting, Transfemoral approach|Internal carotid artery stenting using transfemoral arterial approach
89095890|NCT01111019|Experimental|r-hGH (Saizen®)|
89095891|NCT02883400|No Intervention|SOC-Standard of care|standard of care, nontreatment
89095892|NCT02883400|Experimental|spironolactone|spironolactone
89095893|NCT02722174||BED|Binge Eating Disorder
89095894|NCT02722174||ADHD|Attention Deficit Hyperactivity Disorder
89095895|NCT02722174||SUD, cocaine subtype|Stimulant Use Disorder, cocaine subtype
89095896|NCT02722174||BPD|Borderline Personality Disorder
89095897|NCT02722174||BPD, Cohort 2|Borderline Personality Disorder, Cohort 2
89095898|NCT02722174||HC|Healthy Controls
89095899|NCT01119287|Experimental|Maxidex|Dexamethasone 0.1% ophthalmic suspension, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
89095900|NCT01119287|Experimental|Patanol|Olopatadine hydrochloride 0.1% ophthalmic solution, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
89095901|NCT01119287|Placebo Comparator|Tears Naturale II|Inactive ingredients, used as placebo, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
89095902|NCT02694172|No Intervention|Lean non diabetic|Lean and healthy subjects receiving no intervention
89095903|NCT02694172|Experimental|Overweight non diabetic|fiber rich cereal bars, two bars a day for 4 weeks
89095904|NCT02694172|Experimental|Overweight diabetic|fiber rich cereal bars, two bars a day for 4 weeks
89095905|NCT01110707|Experimental|r-hFSH + r-hLH|
89095906|NCT01110707|Active Comparator|r-hFSH alone|
89095907|NCT03772600|Experimental|Dexcom G6|Use a Dexcom G6 CGM for 36 months
89095908|NCT03772600|No Intervention|FreeStyle Libre|"Keep using their FreeStyle Libre for 6 months. Before the 6 month time point is reached, patients will wear a blinded Dexcom G6 for 28 days, together with their FreeStyle Libre.~Cross-over to Dexcom G6 for 30 months."
89095909|NCT02694250|Other|DTRAX Cervical Cervical Cage with DTRAX Bone Screw|
89095910|NCT01119131|Active Comparator|Arm 1|Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
89095911|NCT01119131|Placebo Comparator|Arm 2|Will be on placebo and 1000mg of calcium.
89095912|NCT00636922|Experimental|Everolimus with 5-azacitidine|Everolimus increasing oral doses days 5-21 each cycle 5-azacitidine 75mg sub cutaneously 7 doses in 21 days
89095913|NCT02722096|Experimental|Axillary block anesthesia|Axillary brachial plexus block anesthesia (with Ropivacaine and Lidocaine) will be performed by anesthetist 30 to 45 minutes before surgery
89095914|NCT02722096|Active Comparator|Local anesthesia|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
89095915|NCT04893538||A|First analysis: Patients with high Lymphocyte count Second analysis: Patients with low International Prognosis Score Third analysis: Patients with high Lymphocyte/monocyte ratio
89095916|NCT04893538||B|First analysis: Patients with low Lymphocyte count Second analysis: Patients with high International Prognostic Score Third analysis: Patients with low Lymphocyte/monocyte ratio
89095917|NCT04862962||Group A: Rosuvastatin /Ezetimibe fixed dose (TREZETE®)|Rosuvastatin /Ezetimibe fixed dose (TREZETE®) Pharmaceutical Form: Tablets Dosage: 10 mg / 10 mg or 20 mg / 10 mg Administration way: Oral
89095918|NCT01118975|Experimental|Pilot Phase - Vornistat 200 to 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and escalating doses of vorinistat (200mg run-up, 300mg, and 400mg 4 days on 3 days off)
89095919|NCT01118975|Experimental|Phase II - Vorinistat 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and vorinostat 400 mg 4 days on 3 days
89095920|NCT02722018|Experimental|Part 1: GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of three Phase III prototype tablets (Prototype 1, 2 or 3) in a crossover fashion.
89095921|NCT02722018|Experimental|Part 2 (Optional): GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of two Phase III prototype tablets (Prototype 4 or 5) in a crossover fashion.
89095922|NCT02722018|Experimental|Part 3: GDC-0810 dose level B - Low Fat Meal/Fasted|Participants will receive a single dose of GDC-0810 dose level B on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal or under fasted condition either as Phase II tablet (with low fat meal) or as the Phase III prototype tablet selected from Parts 1 or 2 (with low fat meal or under fasted conditions), in a crossover fashion.
89095923|NCT04310111|Experimental|EUS-RFA|Patients were placed in the lateral position under deep sedation with supplementary oxygen and electrocardiograph monitoring. The target tumor was identified by EUS, then the biopsy needle stylet was removed and replace with the RFA probe. RF energy was applied for 90-120 seconds at 5 Watts. Wait 1 minute before repositioning the Habib™ EUS RFA needle and repeat procedure as many times as needed to ensure complete ablation of the tumor. EUS-guided celiac plexus neurolysis (EUS-CPN) was performed on patients with intractable upper abdominal pain.
89095924|NCT02721940|Experimental|Treatment group|In the treatment group, patients will be given local injection of enriched autologous mononuclear cells and zoledronic acid into the necrotic area following core decompression by drilling.
89095925|NCT02721940|Experimental|Control group|In the control group, core decompression will be performed, but no treatment will be given.
89095926|NCT04851340|Experimental|Cow's Milk First|Participants in this group will eliminate all cow's milk products during the first 10 days of the study and receive the cow's milk intervention first and then will cross-over to eliminate soy products in the second 10 days of the study and receive the soy milk intervention during the second diet intervention.
89095927|NCT04851340|Experimental|Soy Milk First|Participants in this group will eliminate all soy products during the first 10 days of the study and receive the soy milk intervention first and then will cross-over to eliminate cow's milk products in the second 10 days of the study and receive the cow's milk intervention during the second diet intervention.
89095928|NCT04094350|Experimental|ACF with a seed-and-recruit model|Active case finding with a seed-and-recruit model to be implemented by KHANA. Target group: key populations for TB (people living with HIV, TB contacts, people with diabetes, people who use/inject drugs) and presumptive TB cases
89095929|NCT04094350|Experimental|ACF targeting household and neighborhood contacts|Active case finding targeting household and neighborhood contacts to be implemented by CENAT. Target group: household contacts, immediate neighbors of people diagnosed with TB in the last 2 years, and other presumptive TB cases
89095930|NCT04094350|Experimental|ACF targeting the older population|Active case finding targeting the older population (people aged 55 and older) using mobile screening units to be implemented by CATA. Target group: elderly above age of 55 and other presumptive TB cases
89095931|NCT04094350|No Intervention|Passive case finding|Passive case finding strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
89095932|NCT01110239|Experimental|remote limb preconditioning|Subjects with subarachnoid hemorrhage will undergo escalating times of limb ischemia to determine tolerability and safety. The leg will be made transiently ischemic with application of a blood pressure cuff for up to 3 cycles of 10 minutes.
89095933|NCT02721862|Experimental|Experimental|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking an oral drug (Ursodeoxycholic Acid 250mg) twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
89095934|NCT02721862|Placebo Comparator|Control|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking a placebo, that is dispensed from the pharmacy and having the same color as the ursodeoxycholic acid 250mg, twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
89095935|NCT00612898|Experimental|1|800mg BID apricitabine plus optimised background
89095936|NCT00612898|Active Comparator|2|150mg BID lamivudine plus optimised background
89095937|NCT01118663|Experimental|Acetadote without EDTA|Acetadote EF [Ethylenediaminetetraacetic Acid (EDTA) - Free]
89095938|NCT01118663|Active Comparator|Acetadote|Acetadote [Old formulation containing EDTA]
89095939|NCT02721706|Experimental|CIPA screening tool|Patients are evaluated by CIPA nutritional screening tool
89095940|NCT02721706|No Intervention|usual hospital clinical care|Patients are not subject of CIPA screening tool, and continue the usual hospital clinical care
89095941|NCT02721784|Other|Pre- and Post- Radiotherapy MRI|"mpMRI/VERDICT sequences to be preformed pre- and post- EBRT (external beam radiotherapy) according to the following schedule:~Pre-Androgen Deprivation Therapy 3 weeks before radiotherapy 6 week after starting radiotherapy 6 Months after starting radiotherapy~External Beam Radiotherapy to be given after 3 months of androgen deprivation"
89095942|NCT01118351|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
89095943|NCT00612976||1|Patients with COPD treated with budesonide/formoterol
89095944|NCT04188496|Experimental|PULMONARY FUNCTION TEST (PFT) GROUP|"Thoracic joint Mobilization was applied on Experimental group.~Thoracic Flexion:~Patient sits on the treatment table with arms across the chest and hands on opposite shoulders. Stand facing the patient's left side.~Thoracic Extension:~Performed by asking sits on a treatment chair with arms folded across the chest and hands on opposite shoulders.~Thoracic Segment Rotation:~Performed by asking the patient to lie on left side. Place a pillow under patient's waist to assist left side bending. Position the patient's arms are folded across the chest with hands on opposite shoulders to stabilize the shoulder girdle and minimize movement there."
89095945|NCT04188496|Other|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
89095946|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 50mg bid|Oral tablet for 24 weeks
89095947|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 150mg qd|Oral tablet for 24 weeks
89095948|NCT04034134|Experimental|Jaktinib Hydrochloride Tablets 200mg qd|Oral tablet for 24 weeks
89095949|NCT02693314|Experimental|Jarro-Dophilus EPS® Group|Jarro-Dophilus EPS® (5 billion CFU/capsule) probiotic formulation capsule for 28 days
89095950|NCT02693314|Experimental|Jarro-Dophilus EPS® High Potency Group|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule) probiotic formulation capsule for 28 days
89095951|NCT02693314|Placebo Comparator|Placebo Group|Placebo capsule for 28 days
89095952|NCT02693392|Active Comparator|Control|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up without add-on fenugreek extract.
89095953|NCT02693392|Experimental|Fenugreek|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up with add-on fenugreek extract.
89095954|NCT04175626||Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
89095955|NCT00613054|Experimental|Zactima + Gleevec + Hydrea|
89095956|NCT04687696|Experimental|Post Isometric Relaxation Group|The participants in this group will perform post isometric relaxation stretching in modified cross body position for 6 weeks.
89095957|NCT04687696|Experimental|Isolytic Stretching Group|The participants in this group will perform isolytic stretching in modified cross body position for 6 weeks..
89095958|NCT04687696|Experimental|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position for 6 weeks.
89095959|NCT04167436|Experimental|Prehabilitation|Patients receive multi-modal prehabilitation with exercise three times weekly, protein supplements, vitamin supplements, dietitian consultation and medical optimization prior to surgery. A minimum of four weeks.
89095960|NCT04167436|No Intervention|Standard of Care|Receives standard of care
89095961|NCT00613132|Experimental|1|Pts receiving EIACDs
89095962|NCT00613132|Experimental|2|Pts not receiving EIACDs
89095963|NCT04645498||Metabolism, Inborn Errors|Patient affected by an inherited metabolic disease
89095964|NCT03712852|Active Comparator|PRF+CAF treated patients|The clot collected from the blood samples is pressed through a calibrated compression system into the PRF box the folded membrane is measured and adjusted to 1,5 mm, then transferred on a sterile gauze. A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the PRFs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
89095965|NCT03712852|Active Comparator|SCTG+ CAF treated patients|SCTG is taken from the opposite palate area of gingival defect. The graft is collected with a single incision technique and it is measured and adjusted to 1,5 mm by measuring with a standard caliper.A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the SCTGs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
89095966|NCT03712852|Active Comparator|CAF treated patients|A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the flap is sutured over the enamel in a tension free position.
89095967|NCT00613444|Experimental|LumaCare LC-122M non-coherent light source|"Split Face Comparison. One half of subject's face will receive topical photosensitizer applications followed by LumaCare LC-122M non-coherent light source illumination. Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.~The other half of the face will not receive any treatment and will serve as internal control."
89095968|NCT04558216|Experimental|Vonoprazan single doses / rifampin single doses|Participants will be administered a single oral dose of 20 mg of vonoprazan oral tablets on Day 1 and Day 17. Participants will also be administered single daily doses of 600 mg rifampin oral capsules on Days 3 through 18.
89095969|NCT04132180|Experimental|Early mobilization|
89095970|NCT04132180|Active Comparator|Late mobilization|
89095971|NCT04120870|Active Comparator|Etomidate|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
89095972|NCT04120870|Experimental|Ketamine|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
89095973|NCT01118117|Experimental|Misago™ Self-Expanding Stent System|
89095974|NCT00613210||1|women without contraction at 24-34 weeks of gestation
89095975|NCT00613210||2|women without contractions between 24-34 weeks of gestation with a history of preterm labor
89095976|NCT00613210||3|women with preterm contractions 24-34 weeks of gestation
89095977|NCT00613522||case|Fist ischaemic hemispheric stroke or TIA
89095978|NCT00613522||control|No ischaemic hemispheric stroke or TIA
89095979|NCT04310657|Experimental|Precision therapy|
89095980|NCT04310657|No Intervention|control|
89095981|NCT03747562|Experimental|Experimental group|"Patients randomised to the experimental group will receive a prescription for a gabapentin starting dose of 100 mg three times a day (ter in die, t.i.d) /day per orally, additional to the analgesics according to standard local practices.~Gabapentin dosage may be gradually increased based on individual patient response and tolerability, and as per standard practice in accordance with the drug label. The dose can be further increased in 300 mg/day increments (dose increments of 50% - 100%) every two to three days, up to a maximum dose of 3600 mg/day. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of two weeks, and to reach 3600 mg/day is a total of three weeks."
89095982|NCT03747562|Placebo Comparator|Control group|Patients randomised to the control group will receive a prescription for a matching placebo. The starting dose will be the same as in the experimental group (100 mg three times a day per orally), additional to the analgesics according to standard local practices. Placebo can optionally follow the same dose scheme as described in the experimental arm.
89095983|NCT04510246|Experimental|Intervention|Practitioners randomised to the intervention arm will receive the standard of care surveillance letter if the notification is new. Both new and repeat notifications will receive further enhanced case support during the project if required. Support can be provided at the first phone call, or if accepted and required, in a 12-week period during which the DoH health care worker can do follow-up calls with the GP or directly with the patient to inform the patient and enhance linkage back to their GP. At the end of the 12-week period, a follow-up call we be carried out for the project evaluation.
89095984|NCT04510246|No Intervention|Control|All practitioners randomised to this arm will be contacted by telephone approximately 12 weeks after an HCV notification has been made from the laboratory to the Department of Health.This is not current standard practise and will be performed by the DoH HCV health worker for the project evaluation purpose. At this phone call consent will be sought for the GP to provide information on their clinical management of the notified patient. The details of the clinical management survey are provided as Appendix B. Details provided or missing from the standard DoH surveillance form would be confirmed with the GP at this phone call. Three attempts will be made to contact the practitioner to complete the survey within a 30-day period before they are determined to be unable to be contacted.
89095985|NCT01109849|Active Comparator|weight recovery treatment- monitoring|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the monitoring arm , participants will continue on their ER stimulant 7 days a week and have their weight, height and BMI checked monthly.
89095986|NCT01109849|Active Comparator|behavior therapy|10 week basic parent training, advanced 8 week parent training course. monthly boosters, option for individual parent training sessions, school consultant assigned to each subject
89095987|NCT01109849|Experimental|ER stimulant|daily use of 12 hour extended release methylphenidate product
89095988|NCT01109849|Experimental|weight recovery treatment- caloric supplement|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the caloric supplement arm, participants will continue on their ER stimulant 7 days a week, have their weight, height and BMI checked monthly and be prescribed a 150 kcal caloric supplement to be consumed every evening.
89095989|NCT01109849|Experimental|weight recovery treatment- drug holiday|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the drug holiday arm, participants will only take their ER stimulant on school days a week and have their weight, height and BMI checked monthly.
89095990|NCT04094662|Experimental|Mirogabalin|Mirogabalin 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.
89095991|NCT04094662|Placebo Comparator|Placebo|Placebo (14-weeks)
89095992|NCT01061736|Experimental|Part A: SAR 100 mg qw|Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.
89095993|NCT01061736|Experimental|Part A: SAR 150 mg qw|Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.
89095994|NCT01061736|Experimental|Part A: SAR 100 mg q2w|Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.
89095995|NCT01061736|Experimental|Part A: SAR 150 mg q2w|Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
89095996|NCT01061736|Experimental|Part A: SAR 200 mg q2w|Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
89095997|NCT01061736|Placebo Comparator|Part A: Placebo qw|Placebo (for sarilumab) qw on top of MTX for 12 weeks.
89095998|NCT01061736|Experimental|Part B Cohort 1: Non-selected Doses|Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
89095999|NCT01061736|Experimental|Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
89096000|NCT01061736|Experimental|Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
89096001|NCT01061736|Experimental|Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)|Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
89096002|NCT04083820||Semaglutide s.c. once-weekly|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
89096003|NCT02881463|Experimental|Home Exercise Program|8- week therapeutical exercise program performing at home for women with knee joint osteoarthritis
89096004|NCT02881541|Experimental|Patients having Enhanced Support|"A preoperative consultation with a nurse. This time will be dedicated to the preparation of returning home: explanation of the clinical pathway, realization of postoperative wound care, information on pain management and answer any questions the patient.~A nurse call on D + 1, the day after the operation to ensure the smooth running of returning home, assess postoperative pain, the correct performance of local care, answer questions from the patient, and provide advice to to limit pain .. A reminder to J2 / J3 will be produced at the request of the patient or on FDI initiative if particular difficulties are reported"
89096005|NCT02881541|Experimental|Patients having usual care|no intervention will be made for this group. Patients will receive usual care respecting intern procedure
89096006|NCT04058782||Patients with myocardial|
89096007|NCT01117337|No Intervention|Mesh Non Fixation Group|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed by ant means
89096008|NCT04465162|Experimental|Treatment (radiation therapy)|Patients undergo radiation therapy QD 5 times weekly over 3.5-5 weeks.
89096009|NCT02881385||E5 Esense 10%|PSV mode using E5 ventilator with Esense 10%
89096010|NCT02881385||E5 Esense 30%|PSV mode using E5 ventilator with Esense 30%
89096011|NCT02881385||E5 Esense 50%|PSV mode using E5 ventilator with Esense 50%
89096012|NCT02881385||Servo-I Esense 10%|PSV mode using Servo-I ventilator with Esense 10%
89096013|NCT02881385||Servo-I Esense 30%|PSV mode using Servo-I ventilator with Esense 30%
89096014|NCT02881385||Servo-I Esense 50%|PSV mode using Servo-I ventilator with Esense 50%
89096015|NCT02881385||E5 Esense autocycle|PSV mode using E5 ventilator with Esense Auto cycle
89096016|NCT05033873|Experimental|Group A: Universal Exercise Unit Therapy (UEU)|This experimental group will be given universal exercise unit therapy.
89096017|NCT05033873|Experimental|Group B: Sling Exercise Therapy (SET)|This experimental group will be given sling exercise therapy
89096018|NCT05033873|Other|Group C: Control Group|Control group will be given routine physical therapy
89096019|NCT02874378|Experimental|study group|Dexmedetomidine will be pumped at 0.3μg/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
89096020|NCT02874378|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
89096021|NCT01108523|Experimental|HP828-101|HP828-101 Experimental Formulation
89096022|NCT01035606|Experimental|Goal-oriented Attention Regulation Training|training in goal-directed attention regulation
89096023|NCT01035606|Active Comparator|Education|brain health education
89096024|NCT01035606|Experimental|Technology-assisted Goal-directed Self-Regulation Training|computer-assisted training in goal-directed attention regulation
89096025|NCT01117181|Experimental|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention
89096026|NCT01117181|Placebo Comparator|Placebo|matching placebo and psychosocial intervention
89096027|NCT04302714|Active Comparator|cervical injection|Fluorescent SLN Imaging With Indocyanine Green (ICG), using near-infrared fluorescence imaging, will be used as a dye for SLN mapping. Injections will be performed intraoperative. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room, and 4 mL is injected directly into the cervix. This solution was injected intracervically at 3 and 9 o'clock positions, both submucosally and deep into the cervical stroma. A spinal needle 18-gauce is used to inject the ICG. The 4 mL can be divided into 4 separate injections (1 mL each). The ICG should be injected slowly, at a rate of 5 to 10 seconds per quadrant.
89096028|NCT04302714|Experimental|hysteroscopic injection|hysteroscopy is performed using an operative hysteroscope. Uterine distension is obtained by means of saline solution. Usually, the fluid bag is placed 50 cm above the patient's plane so that the intracavitary pressure does not exceed 40 mm Hg. After visualization of uterine cavity a 22-gauce, 40-mm needle was introduced into the operative port and IGC is injected peritumorally. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room. The injection is performed subendometrially around the lesion, or, if the uterine cavity was totally involved by disease, at 3, 6, 9, and 12 o'clock . The depth of needle placement is modulated by visualizing endometrial elevation during injection.
89096029|NCT02881619|Placebo Comparator|Placebo|Placebo - (inert content)
89096030|NCT02881619|Experimental|Experimental -|400 mg of NAISE etodolac
89096031|NCT04303806|Experimental|Group 1|40 preeclamptic parturient receive 20 mg rosuvastatin orally once daily.
89096032|NCT04303806|Experimental|Group 2|40 preeclamptic parturient receive 40 mg rosuvastatin orally once daily.
89096033|NCT02882087|Experimental|Placebo Comparator|Placebo SC plus MTX. Patients received placebo SC weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
89096034|NCT02882087|Experimental|Experimental: RC18 160 mg plus MTX|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
89096035|NCT04303884|Experimental|Experimental: Pembrolizumab|Chemo-resistant gestational trophoblastic neoplasias treated with pembrolizumab
89096036|NCT05032547|Experimental|Primary Care Online Emotion-Regulation Treatment|The youth component in the experimental condition will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as mindfulness practice and acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective responding to their children's and their own emotions.
89096037|NCT05032547|Active Comparator|Supportive Treatment|The intervention will be delivered in a blended treatment format combining asynchronous therapist-guided online modules (text/videos/audio/messaging function) with a synchronous session delivered over video-link.
89096038|NCT01040130|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
89096039|NCT01040130|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
89096040|NCT01040130|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler
89096041|NCT05012969|Experimental|intervention|HipStop bandage for 12 weeks to prevent dislocation of the hip
89096042|NCT05012969|No Intervention|control|normal procedure after dislocation of hip which is information on movement restrictions
89096043|NCT00932451|Experimental|PF-0231066|
89096044|NCT02874456|Experimental|virus detection|detection of ZIKA virus in blood and sperm
89096045|NCT05297682||singal group|Patients receiving less than two anesthesia in a year
89096046|NCT05297682||repeat group|Patients who received two or more anesthesia in a year
89096047|NCT01108055|Experimental|pazopanib + paclitaxel|"Cycle of 28 days. Pazopanib: 800mg daily~Cycle of 28 days Paclitaxel: 80mg/m2 on days 1,8 and 15"
89096048|NCT00609375|Experimental|I|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
89096049|NCT00609375|Active Comparator|II|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
89096050|NCT01107899|Active Comparator|clopidogrel 600 mg|
89096051|NCT01107899|Active Comparator|prasugrel 60 mg|
89096052|NCT01107899|Experimental|prasugrel 30 mg|
89096053|NCT04264299|Active Comparator|T tube drainage|Closure of common bile duct after choledocholithotomy over T tube
89096054|NCT04264299|Experimental|Primary closure|Primary closure of the common bile duct after choledocholithotomy
89096055|NCT04264299|Experimental|Antegrade stenting|Closure of common bile duct over antegrade biliary plastic stent
89096056|NCT04265157||Early occlusion of hepatoduodenal ligament|Early occlusion of hepatoduodenal ligament during mobilization of the liver of the recipient by using portal vein clamp or occlusive temporary bands.
89096057|NCT04265157||classical occlusion of hepatoduodenal ligament|classical occlusion of hepatoduodenal ligament after mobilization of the liver of the recipient immediately before explantation by suing of portal vein clamp
89096058|NCT01115933|Experimental|XIENCE PRIME SV EECSS|XIENCE PRIME SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System
89096059|NCT01107743||Amlodipine and Atorvastatin Combination Tablet|Subjects taking Amlodipine and Atorvastatin Combination Tablets
89096060|NCT01059864|Experimental|Arm 1|
89096061|NCT01059864|Experimental|Arm 2|
89096062|NCT04310033||Cases|"> 18 years old~Non-opposition of the patient or relatives~Lung, head and neck or colorectal cancer~Non scheduled ICU admission~At least 24 hours of ICU stay~Alive at ICU discharge~Able to answer by phone to quality of life questionary"
89096063|NCT04310033||Controls|"Cancer patients not admitted in ICU, matched with the cases according to~the type of primary cancer~the presence or absence of oncogenic addiction~the setting of anticancer treatment (curative/palliative)~the line of anticancer treatment (none/L1/L2-L3/>L3)."
89096064|NCT04309955|Experimental|modified thoracic drainage group|After surgery, both a chest tube and a pigtail catheter are inserted into the middle and posterior axillary lines of the 7th intercostal space, respectively.
89096065|NCT04309955|No Intervention|traditional thoracic drainage group|After surgery, only a chest tube is inserted into the midaxillary line of the 7th intercostal space, traditionally.
89096066|NCT02880917|Active Comparator|Cognitive training + tDCs-Active|tDCs active left dorsolateral prefrontal cortex (2mA,20 min) and Cognitive training (20min) at the same time.
89096067|NCT02880917|Sham Comparator|Cognitive training+ tDCs-Sham|tDCs Sham dorsolateral prefrontal cortex ((2mA,20 min) and Cognitive training (20min) at the same time.
89096068|NCT01035138|Experimental|Drug: semagacestat|
89096069|NCT03739840|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
89096070|NCT03739840|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
89096071|NCT03739840|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
89096072|NCT03739840|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several placebo tablets to maintain the blinding.
89096073|NCT01035060||Older Adult|Healthy Men and Women Over 70 Years of Age
89096074|NCT01035060||Young Adult|Healthy Men and Women Aged 18-30 Years
89096075|NCT04301700|Experimental|relaxation|The progressive muscle relaxation intervention, designed by Jacobson (1987), will be consist of sessions involving straining and relaxing all muscle groups from head to foot with deep breathing and last for 20 min. The patients will be asked to tense a very muscle group for 5 s and relax after counting up to 10 s while breathing out. In this way, facial, head, neck, shoulders, arms, chest, abdomen, legs, hips, feet and fingers muscles are stretched and relaxed on purpose for relaxing in patients with COPD.
89096076|NCT04301700|Experimental|mindfulness meditation|The research team closely will be following the mindfulness meditation intervention, developed by Kabat-Zinn, Lipworth, and Burney (1985), which is a part of the mindfulness-based stress reduction program. Mindfulness meditation is including interventions such as yoga, body scan, walking meditation, and sitting meditations. In the present study, the researchers will prefer sitting meditation. In this context, the second co-author will want patients to sit up in the chair in an upright and comfortable position. The patients will focus on deep breathing and felled the breath flowing throughout their body during the interventions that will last for 20 min in each session.
89096077|NCT04301700|No Intervention|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
89096078|NCT02875236|Placebo Comparator|Control|Ringer-acetat
89096079|NCT02875236|Active Comparator|Intervention|OctaplasLG®
89096080|NCT01039428|Experimental|HS219|
89096081|NCT01039428|Placebo Comparator|Placebo|
89096082|NCT00613600|Experimental|1|Two 665 mg capsules of glucomannan three times a day for eight weeks
89096083|NCT00613600|Placebo Comparator|2|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
89096084|NCT03962608|Experimental|Yaq-001|Standard medical treatment + Yaq-001 (8 g/ day)
89096085|NCT03962608|Placebo Comparator|Placebo|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
89096086|NCT01034358|Experimental|Human Papillomavirus Vaccine|The Gardasil HPV vaccine was administered in 3 doses: baseline, 2 months, and 6 months.
89096087|NCT04155502||Social media sites.|These participants will be recruited from advertisements posted on social media websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
89096088|NCT04155502||Informational sites|These participants will be recruited from advertisements posted on informational websites. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
89096089|NCT04155502||Dating applications|These participants will be recruited from advertisements posted on dating applications. Participants who complete the baseline assessment will receive a code to order a free HIV self-test kit. Participants will be asked to complete two online follow-up questionnaires at 14-days and 60-days post-baseline. These questionnaires will ask questions related to HIV self-test kit use and PrEP uptake.
89096090|NCT03470818|Experimental|Intervention group|"Preparatory instructional videos (flipped classroom model)~32 participants~Application of a flipped classroom model~Prior to the simulation session, the intervention group will have received the study intervention. This consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
89096091|NCT03470818|Sham Comparator|Control group|"Sham videos~Participants in the control group will also be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility.~This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
89096092|NCT04302402|Active Comparator|Rifaximin|Rifaximin 550mg thrice daily for 14 days Other Name: Normix
89096093|NCT04302402|Placebo Comparator|Placebo|Placebo thrice daily for 14 days
89096094|NCT03935620|Experimental|EMT|After a period of stable baseline performance (3 to 5 sessions) for parents and children the interventionists will apply the EMT Language Intervention.
89096095|NCT04408300|Experimental|Ophthalmological exam|
89096096|NCT03931408|Experimental|Gentamicin|Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of gentamicin mixed with saline, 2 times per day. A formulation derived from 480 mg gentamicin sulfate diluted in 1 L normal saline will be used for instillation. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
89096097|NCT03931408|Placebo Comparator|Placebo instillation (saline alone)|Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of saline alone. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
89096098|NCT03931408|Other|No instillation|Participants will be randomized into one of three groups. In this arm participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
89096099|NCT03398824|Experimental|Treatment arm|Receive metformin HCl
89096100|NCT01033734|Experimental|Single arm|
89096101|NCT03792256|Experimental|Treatment (Palbociclib)|Patients receive Palbociclib 50 mg/m^2 (starting dose with maximum dose of 100 mg) PO (or via NG-tube) once daily on Days 1-21; Intrathecal cytarabine (IT ARAC) age-based dosing on Day 1, Doxorubicin 60 mg/m^2 IV push or infusion over 1-15 min on Day 4; Prednisone or prednisolone 40 mg/m^2 PO divided BID or TID on days 4-31; Vincristine 1.5 mg/m^2 (maximum dose 2 mg) IV push or mini-bag per institutional policy on days 4, 11, 18, and 25; and Pegaspargase 2500 IU/m^2 IV over 1-2 hours on Days 5, and 18. If CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) age-based dosing on days 4, 11, 18, and 25. Patients known to be CNS3 at study entry may receive ITT on Day 1 rather than IT ARAC. If CNS1 and 2 leukemia present, patient receive Methotrexate (IT MTX) age-based dosing on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.
89096102|NCT04301856||CF children treated with CFTR modul|Cystic fibrosis patients under 18 years treated with CFTR modulators according to french health recommendations observational cohort study
89096103|NCT00613288|Experimental|A|
89096104|NCT03711838|Experimental|N-Acetylcysteine|N-Acetylcysteine supplementation: Orally, 40 mg/kg per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 40mg/kg per day in 3 doses (250 ml each).
89096105|NCT03711838|Active Comparator|Placebo|Placebo administration: Orally 750 ml per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 750 ml per day in 3 doses (250 ml each).
89096106|NCT00613678|Active Comparator|1|Exercise + Education: Eight group sessions (8-15 people) during which participants engage in muscular strength and flexibility exercises. In addition, weekly educational lectures on topics germane to osteoarthritis management are included.
89096107|NCT00613678|Experimental|2|Exercise + Activity Strategy Training: 7/8 sessions will be in a group format in which participants engage in muscular strength & flexibility exercises and listen to education lessons on management strategies for osteoarthritis. The remaining session includes a home assessment by an occupational therapist to facilitate adequate participation in daily living and leisure activities.
89096108|NCT03656848|Experimental|QFR-guided PCI group|If the patient is assigned to QFR-guided PCI, QFR is first measured in all coronary arteries with DS% ≥ 50% and ≤ 90%. Then PCI treatment is performed in lesions with QFR ≤ 0.80, and optimal medicine treatment is prescribed to those with QFR > 0.80. It is strongly recommended to select the device size based on the 3D-QCA measurements in this group.
89096109|NCT03656848|Active Comparator|Angiography-guided PCI group|If the patient is assigned to angiography-guided PCI, then the investigator performs PCI according to the stenosis severity based on visual assessment of the angiogram. No other functional tests such as FFR/iFR can be used for further assessment of the lesion before PCI.
89096110|NCT04275778|Active Comparator|Hydroxychloroquine|"Hydroxychloroquine will be prescribed upon confirmation of pregancy at a dosage of 400 mg / day. Either in 2 doses (1 tablet of 200 mg in the morning and 1 tablet of 200 mg in the evening). Or in a single take: 2 tablets of 200 mg.~Treatment will be continueted during the pregnancy and will be stopped at delivery."
89096111|NCT04275778|Placebo Comparator|Placebo group|"Placebo will be prescribed upon confirmation of pregancy at a dosage of 400 mg / day. Either in 2 doses (1 tablet of 200 mg in the morning and 1 tablet of 200 mg in the evening). Or in a single take: 2 tablets of 200 mg.~Treatment will be continueted during the pregnancy and will be stopped at delivery."
89096112|NCT04260880||Test group 1|individuals with mild depression
89096113|NCT04260880||Test group 2|individuals with moderate depression
89096114|NCT04260880||control group|systemically healthy individuals
89096115|NCT04156360||Healthy Volunteers|
89096116|NCT04156360||Patients With Pulmonary Nodule|
89096117|NCT03746314||Supportive Care Leader|A staff member who is knowledgeable about supportive care services for adult oncology patients.
89096118|NCT03746314||Oncology Providers|Physicians, nurses, physicians assistants, nurse practitioners who routinely provide cancer care to adult oncology patients.
89096119|NCT01115855|Experimental|Eplerenone arm|Add on standard heart failure therapy
89096120|NCT01115855|Placebo Comparator|Placebo arm|Add on standard heart failure therapy
89096121|NCT03669094|Active Comparator|L. salivarius V4II-90|Lactobacillus salivarius V4II-90; approximately 1*10E9 colony forming unit (CFU) of L. salivarius V4II-90 in 1 oral capsule per day for 12 weeks.
89096122|NCT03669094|Placebo Comparator|Control group|Placebo supplement in 1 oral capsule per day for 12 weeks.
89096123|NCT03615508|Other|10% phenylephrine|All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.
89096124|NCT05331976||Symptomatic subjects|"Subjects must present with 1 or more signs or symptoms of COVID-19 infection*.~Subjects must have experienced symptom onset within the previous 5 days.~Subject or Subject's legally authorized representative (LAR) is willing and able to provide informed consent. Adult subjects unable to consent will provide assent in addition to LAR's consent.~Subject is ≥ 2 years of age. Subjects 2 ≥ x ≤ 17 will provide assent in addition to parent/legal guardian's consent."
89096125|NCT05331976||Asymptomatic Subjects|"Subject must have been exposed to known SARS-CoV-2 positive or suspected SARS-CoV-2 symptomatic individuals within the previous 5 days.~Subject or Subject's legally authorized representative (LAR) is willing and able to provide informed consent. Adult subjects unable to consent will provide assent in addition to LAR's consent.~Subject is ≥ 2 years of age. Subjects 2 ≥ x ≤ 17 will provide assent in addition to parent/legal guardian's consent."
89096126|NCT05288296|Experimental|Athletes in Taiwan|"In the first year, we would recruit senior high school soccer athletes (n=30) to observe the difference with/without dynamic taping on landing error scoring system under fatigue status. (2x2 cross-over study)~In the second year, we would recruit junior/senior high school and college athlete (n=900) to establish a native model of single-leg and double-leg LESS, then in advanced, confirm the ability to predict ACL injuries.~In the third year, we will focus on high-risk subjects evaluated by LESS and athlete with ACL reconstruction (n=60) to observe the supportive effect of dynamic taping. (2x2 cross-over study)"
89096127|NCT00614068|Experimental|A|Participants will receive 12 sessions of trauma-focused cognitive behavioral therapy over 3 months.
89096128|NCT00614068|Active Comparator|B|Participants will receive 12 sessions of treatment as usual over 3 months.
89096129|NCT05274802|Experimental|Part A1 (Single dose): Cohort A: ALS-4 25mg|Single dose of ALS-4 or placebo before Breakfast
89096130|NCT05274802|Experimental|Part A1 (Single dose): Cohort B: ALS-4 50mg|Single dose of ALS-4 or placebo before Breakfast
89096131|NCT05274802|Experimental|Part A1 (Single dose): Cohort C: ALS-4 100mg|Single dose of ALS-4 or placebo before Breakfast
89096132|NCT05274802|Experimental|Part A1 (Single dose): Cohort D: ALS-4 200mg|Single dose of ALS-4 or placebo before Breakfast
89096133|NCT05274802|Experimental|Part A1 (Single dose): Cohort E: ALS-4 300mg|Single dose of ALS-4 or placebo before Breakfast
89096134|NCT05274802|Experimental|Part A2 (Single dose): Cohort F: ALS-4 50mg|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
89096135|NCT05274802|Experimental|Part B (Multiple dose): Cohort AA: ALS-4 50mg|Multiple dose of ALS-4 or placebo up to two times daily
89096136|NCT05274802|Experimental|Part B (Multiple dose): Cohort BB: ALS-4 100mg|Multiple dose of ALS-4 or placebo up to two times daily
89096137|NCT05274802|Experimental|Part B (Multiple dose): Cohort CC: ALS-4 200mg|Multiple dose of ALS-4 or placebo up to two times daily
89096138|NCT02880995|Experimental|patient group|"50 Drug-naïve patients with first episode psychosis (We anticipate the non-responder rate will be 30% of the patients)~Drug-naïve~Diagnosed as first episode psychosis~The total score of PANSS>70~No co-morbid psychiatric illness (including drug dependence/abuse)~They will also undergo PET scan at the baseline. And the investigators are going to determine treatment response after 6 weeks of treatment with amisulpride. Also they should complete clinical scales at 0, 2, 4, 6, and 8 week."
89096139|NCT02880995|Other|healthy control group|"12 healthy volunteers~No history of psychiatric disorder (including drug dependence/abuse)~No history of physical illness~No contra-indication to scanning~They will also undergo PET scan at the baseline"
89096140|NCT03522064|Experimental|High dose testosterone + Carbolplatin|500mg IM enanthate every 4 weeks in combination with ongoing LHRH agent (unless post-orchidectomy) plus Carboplatin AUC 5
89096141|NCT01115309|Other|XprESS Balloon Device|Sinus dilation
89096142|NCT04310579|No Intervention|Lead-In|Read Rebreathing Reproducibility Assessment
89111156|NCT02793063||BBD Consortium Contact Registrants|Osteogenesis Imperfecta patients who have self-registered at the Brittle Bone Disorders Consortium (BBD) Consortium Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
89096143|NCT04310579|Active Comparator|Part 1 Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) tablets and intravenous (IV) placebo 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day.~Note: Initial doses of oxycodone will be 10 mg, but may be increased to 15 mg if necessary based on criteria specified in protocol. Initial doses of midazolam will be 0.0375 mg/kg but may be increased to 0.075 mg/kg based on criteria specified in protocol."
89096144|NCT04310579|Active Comparator|Part 2 Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
89096145|NCT04188340|Placebo Comparator|control group|using bergamot massage oil apply to GV20, GV24 SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
89096146|NCT04188340|Experimental|test group|using Su-Man formula massage oil ap-ply to GV20, GV24, SP6, HT7 and PC6 acupoints, and massage for 20 times before sleep continuously 28 days
89096147|NCT05244538|Experimental|Virtual Reality Distraction|In the experimental group, patients will benefit from a 20-minute VR. Patients will watch a forest walk in virtual reality while listening to narrations designed to induce relaxation and meditation. If the oocyte retrieval was not completed within 20 minutes, patients will watch the same VR program again.The TCI remifentanil and propofol will be connected to the infusion but will be stopped and titrated if discomfort.
89096148|NCT05244538|Active Comparator|Sedation group|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml.~The concentration of propofol will be adjusted by an effect concentration of 0.5 ug/ml with a maximum of 1.5 ug/ml, in this case according to a 5-point scale~fully awake and oriented~drowsy~eyes closed, responds quickly to verbal commands~eyes closed, aroused only by mild physical stimulation~eyes closed, not aroused by mild physical stimulation) A sedation score of 3 will be the target throughout the procedure."
89096149|NCT05175742|Experimental|40µg PTX-COVID19-B Open-label|Participants, 15 healthy adults 18 to 64 years of age will receive 1 intramuscular (IM) injection of 40µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28.
89096150|NCT05175742|Experimental|40µg PTX-COVID19-B|Participants, 360 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of 40µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28. Participants will receive a placebo dose on Day 21.
89096151|NCT05175742|Active Comparator|Pfizer-BioNTech COVID-19 vaccine|Participants, 190 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of Pfizer-BioNTech COVID-19 vaccine on Day 1, followed by a placebo dose on Days 21. Participants will receive a placebo dose on Day 28.
89096152|NCT03638128|Other|Alternative Medications / Observational|"Participants who received non-denosumab alternative therapy during the study or who were not receiving any medication at baseline.~Alternative osteoporosis medication(s) were determined at the investigator's discretion and per standard of care and local guidelines."
89096153|NCT03638128|Experimental|Denosumab 1 mg/kg Q6M|Participants who received at least 1 dose of 1 mg/kg denosumab administered once every 6 months (Q6M) by subcutaneous injection, but no Q3M denosumab during this study.
89096154|NCT03638128|Experimental|Denosumab 1 mg/kg Q3M|Participants who received at least one dose of 1 mg/kg denosumab administered once every 3 months (Q3M) by subcutaneous injection during this study.
89096155|NCT00614146|Experimental|1|
89096156|NCT00614146|Active Comparator|2|
89096157|NCT03555838|Experimental|Active tDCS|Participants in this arm will receive 20 minutes of 2 mA transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
89096158|NCT03555838|Sham Comparator|Sham tDCS|Participants in this arm will receive 20 minutes of sham transcranial direct current stimulation over the primary motor cortex of the more affected arm prior to robotic training.
89096159|NCT05108194|Experimental|Arm 1: Intervention|Participants (N=50) who endorse insomnia will be followed for 8 weeks. All participants will be asked to download a separate app to passively monitor sleep that will inform the personalized messages. Participants will also be asked to respond to daily prompts in order to validate the passive sleep data. The study includes two phases: (1) a training and validation phase and (2) an intervention phase. During phase 1, participants' sleep habits and other behaviors will be monitored for two weeks in order to validate and optimize the SMS personalized sleep intervention (PSI). In phase 2, participants will be transitioned to the intervention phase of the study.
89096160|NCT03529630|Experimental|Inverted syringe|Participants in this arm will use of the inverted syringe before each breastfeeding starting from the first feed after delivery and continued as long as needed by the mother.
89096161|NCT03529630|No Intervention|Standard of care|Participants in the control group will receive standard medical care as dictated by their obstetricians. Any advice regarding infant nutrition or treatment of inverted nipples will be left to the primary physician, including possible use of the inverted syringe technique. .
89096162|NCT04940026|Experimental|SAR439859|Single oral dose of SAR439859 at Day 1 in fasted condition followed by intravenous administration of [14C]-SAR439859 microtracer 3 hours later, and single oral dose of [14C]-SAR439859 at Day 7 in fasted condition
89096163|NCT03448120|No Intervention|Control Group|The volunteers who will remain in prolonged rest (10 minutes for homeostasis plus 30 minutes of no intervention).
89096164|NCT03448120|Experimental|Acupuncture Group|The volunteers will receive six needles in six acupoints in the non-dominant upper limb for 30 minutes.
89096165|NCT03448120|Experimental|Dry needling Group|The volunteers will receive application of six needles arranged in the non-dominant biceps brachialis for 30 minutes.
89096166|NCT00614224|Experimental|A|Treadmill training group (TAEX)
89096167|NCT00614224|Active Comparator|B|Attention control group (CON)
89096168|NCT04748926|Experimental|Group 1|Participants will receive caplets after fast (treatment A) on Day 1 and caplets after meal (treatment B) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.
89096169|NCT04748926|Experimental|Group 2|Participants will receive caplets after meal (treatment B) on Day 1 and caplets after fast (treatment A) on day 6, and then receive either oral formulation 1 tablets after fast (treatment C) or oral formulation 2 tablets after fast (treatment D) on day 11.
89096170|NCT03261076|Experimental|SERIOUS Intervention|All youth will be juveniles in a residential facility for post-adjudicated youth. They will be recruited into the study as they are being placed in the facility post-adjudication, to ensure that they meet criteria and will be in the facility long enough to complete the program. All qualified youth will be invited to participate in the SERIOUS intervention; once a group of youth are recruited to complete the multiple baseline design and interventionists are free (from running interventions with other participants) to work with the youth, an intervention cycle will begin.
89096171|NCT03221218|Experimental|Enhanced screening-informed letter|Family physicians will receive a letter that includes their patient's screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines for MTBI (2013).
89096172|NCT03221218|No Intervention|Standard letter|Family physicians will receive a letter that includes generic recommendations for managing MTBI based on the Ontario Neurotrauma Foundation clinical practice guidelines (2013). Screening test results will not be provided.
89096173|NCT05345236|Experimental|QL1207|Subjects randomized into QL1207 group will receive QL1207 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
89096174|NCT05345236|Active Comparator|Eylea®|Subjects randomized into Eylea® group will receive Eylea® 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
89096175|NCT02692690|Experimental|before-after|TENS stimulation neck and thigh
89096176|NCT02692534||Cocaine negative|Patients with preoperative urine cocaine negative results
89096177|NCT02692534||Cocaine positive|Patients with preoperative urine cocaine positive results
89096178|NCT04413370||Severe Group|This group of subjects needed a referral to the hospital for further treatments.
89096179|NCT04413370||Mild group|This group of subjects was diagnosed with dry eye but can use artificial tears instead of further treatment.
89096180|NCT04413370||Follow-up group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
89096181|NCT05344768|No Intervention|control group|Patients in the control group will be asked to maintain their usual exercise and eating habits throughout the study. No intervention will be applied.
89096182|NCT05344768|Experimental|moderate continuous aerobic exercise training group|After the warm-up period (5 minutes), 35 minutes of continuous exercise training will be applied at 60% (moderate intensity) of the maximum oxygen consumption (VO2max) value obtained from cardiopulmonary exercise test with a bicycle ergometer. After the exercise training, the patients will be taken to a 5 minute cool-down period.
89096183|NCT05344768|Experimental|high-intensity interval training group|After the warm-up period (5 minutes), the patient will be asked to cycle for 1 minute at a workload of 90% (high intensity) of the VO2max obtained from cardiopulmonary exercise test with a bicycle ergometer, and the patient will be asked to cycle for 2 minutes at a workload of 25% of the VO2max value. This cycle will be repeated 10 times. The patient will then be placed in a 5 minute cool-down period.
89096184|NCT05344768|Experimental|resistance exercise training group|It will be planned as 3 sets of 10 repetitions resistance exercises with 50% of 1 maximum repetition. Exercises will be performed on chest press, pectoral, pulley, hip abductor and adductor, leg press, cable biceps curl, triceps push down, shoulder press, abdominal crunch machines. The program will be created with a rest period of 3 minutes between sets, 10 minutes of stretching before the exercise and 10 minutes of stretching and cooling exercises after the exercise.
89096185|NCT05344768|Experimental|combination of moderate continuous aerobic exercise training with resistance exercise training group|The combination of moderate continuous aerobic exercise training with resistance exercise training will be applied to the patients.
89096186|NCT05344768|Experimental|combination of high-intensity interval training with resistance exercise training|The combination of high-intensity interval training with resistance exercise training will be applied to the patients.
89096187|NCT00613912||A|Ambulant patients with major depression
89096188|NCT05344612|Experimental|CTCA|
89096189|NCT05344612|No Intervention|Standard care|
89096190|NCT00614536||001|
89096191|NCT05344222|Experimental|Photobiomodulation|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
89096192|NCT05344222|Sham Comparator|Sham Photobiomodulation|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
89096193|NCT04333654|Experimental|Hydroxychloroquine|Hydroxychloroquine, loading dose on day 1 followed by a daily maintenance dose during 9 days
89096194|NCT04333654|Placebo Comparator|Placebo|Matching placebo
89096195|NCT01059630|Active Comparator|Bendamustine Alone|Participants will receive bendamustine 120 milligrams per meter square (mg/m^2) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.
89096196|NCT01059630|Experimental|Obinutuzumab + Bendamustine|"Induction phase: Participants will receive bendamustine 90 mg/m^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants will also receive obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.~Maintenance phase: Participants with complete response (CR), partial response (PR) or stable response (SD) then will receive obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurs first)."
89096197|NCT05344144|Experimental|Emotional freedom technique group|Emotional freedom technique group pregnant women who have experienced prenatal loss, who were included in the emotional freedom technique group with randomization method, will be given a counseling program including psychosocial care and emotional freedom technique application in addition to the routine.
89096198|NCT05344144|Experimental|Music group|Music group pregnant women who have experienced prenatal loss, who were included in the music group with randomization method, will be given a counseling program including music application in addition to the routine.
89096199|NCT05344144|No Intervention|Control|control group standard care group
89096200|NCT04314700|Other|OCT imaging and review of excised breast lumpectomy tissue|
89096201|NCT04226170|Active Comparator|treatment|ondansetron + pyridostigmine
89096202|NCT04226170|Placebo Comparator|Placebo|placebo+ pyridostigmine
89096203|NCT05343910|Experimental|Aromatherapy massage group|Experimental: aromatherapy massage group The oil mixture used in this study (1:, 1:, 1: 1, 20cc rosemary, 20cc mint, 20cc ginger, 20cc black pepper), 80% of the mixture obtained from the total 4% (3.2cc) carrier oil (100% almond oil=96.8cc) and then combined with abdominal massage. Before implementing the procedure in the experimental group (n=25), information about what an abdominal and aroma massage is, how long it will take, and how it will be applied was provided to the participants. The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
89096204|NCT05343910|No Intervention|Control group|Individuals in the control group (n=24) did not receive any type of aroma massage application.
89096205|NCT04200976|Experimental|Tele-CABA|Participants who engage in the Tele-CABA intervention.
89096206|NCT04200976|Placebo Comparator|Usual Care|Participants who do not engage in the Tele-CABA intervention during their time in the study. They will be eligible to receive Tele-CABA following completion of the 6-month questionnaires and cognitive assessment (as a courtesy).
89096207|NCT04192240|Experimental|WB Training with external feedback|WB during sit-to-stand with external feedback for 10 minute and then, WB during stepping training with external feedback for 10 minutes. After training, subjects will walk overground for 10 minutes.
89096208|NCT04192240|Active Comparator|WB Training without external feedback|WB during sit-to-stand without external feedback for 10 minute and then, WB during stepping training without external feedback for 10 minutes. After training, subjects will walk overground for 10 minutes.
89096209|NCT05343520|Experimental|Experimental Group|30 pregnant women in the experimental group, pelvic floor muscle exercise was explained in detail and an exercise brochure was given in addition. Pelvic floor muscle exercises were taught by the researcher G.Y. In order for the exercise to be continued or applied correctly, the experimental group was interviewed by phone every 2 weeks. Information was given about continuing pelvic floor muscle exercises beginning from the 30th week of pregnancy until the postpartum 6th week.
89096210|NCT05343520|No Intervention|Control Group|The control group were filled only data collection forms
89096211|NCT04672980|Experimental|RTX-321 Dose Escalation|Phase 1: RTX-321 administered intravenously on Day 1 of each cycle monotherapy dose escalation
89096212|NCT04672980|Experimental|RTX-321 Dose Expansion|Phase 1: RTX-321 administered intravenously on Day 1 of each cycle.
89096213|NCT04143958|Experimental|agalsidase beta|Commercially available agalsidase beta treatment at approved dose and regimen;administered once every 2 weeks as an IV infusion
89096214|NCT04143958|Active Comparator|agalsidase alfa|Commercially available agalsidase alfa treatment at approved dose and regimen; administered once every 2 weeks as an IV infusion
89096215|NCT04303338|Experimental|Masotherapy with neural tension|The investigators are going to massage the patient´s upper limb applying a radial nerve neural tension. In order to the upper limb should be positioned lowering the scapula, elbow extended, internal rotation glenohumeral, forearm pronation, bend and cubital deviation of the wrist, fingers bended and thumb adduction, and finally glenohumeral abduction.
89096216|NCT04303338|Active Comparator|Masotherapy with non-neural tension|The investigators are going to practice a conventional upper limb massage
89096217|NCT04142086|Experimental|Group 1|1 injection of vYF vaccine Dosage 1
89096218|NCT04142086|Experimental|Group 2|1 injection of vYF vaccine Dosage 2
89096219|NCT04142086|Experimental|Group 3|1 injection of vYF vaccine Dosage 3
89096220|NCT04142086|Active Comparator|Group 4|1 injection of YF-VAX
89096221|NCT04643184|Experimental|Management Program|Comanagement program (cardiological-geriatric) to carry out during hospitalization a comprehensive evaluation that allows to know the medical and socio-environmental needs of the patients to plan the required care at home and achieve an effective transition.
89096222|NCT04643184|No Intervention|Usual Care|Usual care during hospitalizacion and discharge.
89227009|NCT01897610|Experimental|Immuncell-LC group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).
89096223|NCT05343442|Experimental|Patients assigned to percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
89096224|NCT02874222||Caucasian|surveys completed by subject n=600, nationally
89096225|NCT02874222||African-American|surveys completed by subject n=200, nationally
89096226|NCT02874222||Asian|surveys completed by subject n=200, nationally
89096227|NCT04150510||Online Survey|Individuals who are willing to participate in this online survey
89096228|NCT05333302|Experimental|CD19 CAR-T cells immunotherapy|After a cycle of lymphodepleting chemotherapy a patient receive locally produced autologous CD19 CAR-T cells
89096229|NCT05343208|Experimental|Cognitive Behavioral Therapy Group|The group received online Cognitive Behavioral Therapy via the My-E-Health. Patients were issued a preTest psychometric assessment and a post therapy assessment using the Burnout Psychometrics provided within the My-E-Health's online ecosystem. All patients were required to validate the accuracy of the assessments during a follow-up of their results.
89096230|NCT05343208|No Intervention|Control Group|The Control Group received no online therapy. Patients were issued a preTest psychometric assessment and a post therapy assessment using the Burnout Psychometrics provided within the My-E-Health's online ecosystem. All patients were required to validate the accuracy of the assessments during a follow-up of their results.
89096231|NCT03456778|Experimental|Platelet-Rich Plasma|Participants with moderate to severe tendinosis receiving ultrasound-guided percutaneous tenotomy with an injection of Platelet-Rich Plasma (PRP) to treat chronic tendinopathy
89096232|NCT03664882|Experimental|Fexofenadine|Fexofenadine, single administration
89096233|NCT03664882|Placebo Comparator|Placebo|Placebo, single administration
89096234|NCT03903016|Experimental|Test (T)|Insulin Lispro (SAR342434), 200 Units/ml, single dose on day 1 of each period
89096235|NCT03903016|Active Comparator|Reference (R)|Insulin Lispro Sanofi® ,100 Units/ml, single dose on day 1 of each period
89096236|NCT03571750|Experimental|Building Stronger Allies Condition|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
89096237|NCT03571750|Placebo Comparator|Health Education Training Condition|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
89096238|NCT03521362|Experimental|MyT1DHero App|Participants in this group will receive use of the MyT1DHero app.
89096239|NCT03521362|Active Comparator|"Other T1D App"|Participants in this group will receive use of a different app with less capabilities.
89096240|NCT03514732|Experimental|Novanuit® Triple Action|2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime.
89227010|NCT01895517|Active Comparator|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
89227011|NCT01895517|Experimental|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
89227012|NCT01890291||Non-treatment Group|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
89096241|NCT03800836|Experimental|Arm A1: Ipat + Atezo + Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096242|NCT03800836|Experimental|Arm A2: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096243|NCT03800836|Experimental|Arm A3: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096244|NCT03800836|Experimental|Arm B1: Ipat + Atezo + Nab-Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096245|NCT03800836|Experimental|Arm B2: Ipat + Atezo + Nab-Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096246|NCT03800836|Experimental|Arm C1: (Ipat + Pacl) (2 weeks) + Atezo|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096247|NCT03800836|Experimental|Arm C2 (Ipat + Pacl) (2 weeks) + Atezo|Expansion (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89227013|NCT01890291||Immuncell-LC Group|Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
89227014|NCT01758692||Able-bodied Controls|"10 controls between the ages of 18 and 65 of either gender; free of cardiovascular disease and/or medication.~An addition 40 controls ages 18-89 of either gender, will perform the non-invasive manipulations only."
89227015|NCT01758692||Spinal Cord Injury|"40 subjects to perform the pharmacological and non-invasive manipulations; between the ages of 18 and 65 years old in stable health for the last 6 months, non-smoker, and level of injury from C1 - S4 for over 1 year and an AIS classification of A, B, C. Free of arrhythmia, hypertension, cardiovascular disease, kidney disease, diabetes, neuropathies, neuromuscular disease, and sulfite allergies or hypersensitivity.~60 subjects to perform the non-invasive manipulations only; between 18-89 years of age in stable condition (>6 months), non-smoker. Level of injury from C1-S4 for over a year with a AIS classification of A, B, or C. No history of diabetes, autonomic neuropathy, parkinson's disease, or acute illness or infection. An additional 30 will perform the non-invasive testing before and after completion of an ambulatory training protocol."
89227016|NCT01572532|Experimental|Intervention Screening and Treatment|"CHWs will collect urine and vaginal samples for all women enrolled. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison. Vaginal specimens will be collected via sterile self-administered vaginal swabs. The women will be instructed by the CHW to insert a Dacron swab ~4-5 cm into the vagina, allow the swab to stand for 15 seconds, and then rotate 360 degrees prior to withdrawal. The CHW will gently roll out the swab onto a plain glass slide and allow to air dry prior to transport to Sylhet field laboratory.~A midstream urine specimen will be obtained for urine culture. The mother will be instructed to separate the labia and collect 20-30mL of midstream urine into a sterile container which will be immediately refrigerated in a cool specimen box."
89227017|NCT01572532|No Intervention|Control Arm|Standard care will be administered, including antenatal and postnatal care. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison.
89227018|NCT01439659|Other|Nutritional Counseling|For 6 months control group receives dietary counseling.
89227019|NCT01439659|Experimental|Daily Supplements|2 capsules (Juice Plus+) twice a day (morning and evening) plus Juice Plus+ Complete drink each evening for 6 months.
89227020|NCT01267448|Active Comparator|Saxagliptin + Metformin XR|Saxagliptin 5 mg + Metformin XR 1000 mg will be automatically titrated weekly in 2 weeks to Saxagliptin 5 mg + Metformin XR 2000 daily for a total duration of 12 weeks.
89227021|NCT01267448|Active Comparator|the Control goup Glipizide XL|The control group will receive Sulphonylurea (Glipizide XL 10mg orally) for a total duration of 12 weeks.
89227022|NCT01265030|Experimental|Sirolimus|"Preoperative sirolimus:~loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligram)~starting 24 hours after the initial loading dose, subjects will receive a dose of 4 milligram/meters2 daily; Per Os (PO), by mouth days 2 through 28"
89096248|NCT03800836|Experimental|Arm D1: (Atezo + Pacl) (2 weeks) + Ipat|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096249|NCT03800836|Experimental|Arm D2: (Atezo + Pacl) (2 weeks) + Ipat|Expansion (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096250|NCT03800836|Experimental|Arm E: Ipat + Atezo|Participants (Cohort 2) will receive Ipatasertib orally daily on Days 1-28 of Cycle 1 (35-day cycle) and on Days 1-21 of subsequent cycles (28-day cycles). Atezolizumab will be administered by IV infusion on Days 8 and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096251|NCT03800836|Experimental|Arm F1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
89096252|NCT03800836|Experimental|Arm F2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
89096253|NCT03800836|Experimental|Arm G1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
89096254|NCT03800836|Experimental|Arm G2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
89096255|NCT03800836|Experimental|Arm H: Ipat + Atezo + Pacl|Participants (Cohort 4) will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
89096256|NCT00932373|Experimental|1|
89096257|NCT03511690|Experimental|Immediate BRCA-Gist Intervention|Participants randomized to immediate BRCA-gist will complete the adapted intervention and immediately complete a baseline survey. They will be asked to complete a second survey two weeks after completion of the first one. BRCA-gist is a web-based tutoring system that emulates one-to-one human tutoring via avatars to communicate risk of BRCA1/2. We estimate a completion time of 90 minutes.
89096258|NCT03511690|Experimental|Delayed BRCA-Gist Intervention|Participants randomized to delayed BRCA-gist will initially complete a baseline survey. Two weeks after completion of that survey, they will complete the adapted intervention and immediately complete a second survey.
89096259|NCT04265235|Experimental|Home-based Exercise Program|12-weeks, remotely monitored home-based exercise program consisting or aerobic and resistance exercise
89096260|NCT03509506|No Intervention|Non-App Group|"The participants will be instructed to continue their daily routine, track their daily steps with a pedometer, and record their daily steps on the Activity Log paper form."
89096261|NCT03509506|Experimental|App Group|The participants will be trained how to use the mobile application (Heart Failure Health Storyline (HFHS)) to track their health status, physical activity, manage their medications schedule, and explore the other features that the application has. Additionally, they will receive a pedometer to track their daily steps and record their data on the mobile application.
89096262|NCT04265001|Active Comparator|Control group|Topical cholrhexidine hydrochloride 125 mg/100 ml available commercially (Hexitol; Arab Drug Company for Pharmaceutical and Chemical Industries, Cairo, Egypt) mouthwash. Topical cholrhexidine hydrochloride mouthwash treatment has been repeated three times per day for one week.
89096263|NCT04265001|Experimental|Hyaluronic acid group (HA group)|Topical hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash (Aftamed; Bioplaxpharma, UK).Topical hyaluronic acid mouthwash treatment has been repeated three times per day for one week.
89096264|NCT03488290|Experimental|LTP Plus TF CBT|LTP Plus TF CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
89096265|NCT03488290|Other|Treatment as Usual|TAU group will receive routine care consisting of routine follow ups
89096266|NCT04263753|Experimental|conservative surgery for bladder in placenta accretta|
89096267|NCT00607347|Experimental|A|The subjects will be undergoing a oral glucose tolerance test.
89096268|NCT00608595|Experimental|Therapeutic Intervention/Celecoxib|Celecoxib
89096269|NCT00614770|Experimental|1|Standard White Light Colonoscopy
89096270|NCT00614770|Experimental|2|High Definition White Light Colonoscopy
89096271|NCT00614770|Experimental|3|Narrow Band Imaging Colonoscopy
89096272|NCT03761134|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
89096273|NCT03761134|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
89096274|NCT03761134|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
89096275|NCT05241717|Experimental|Intervention arm|All study participants will be given the intervention
89096276|NCT01055496|Experimental|Arm 1 (R-CVP)|Subjects in arm 1 will be enrolled in dose escalation cohorts that will initially evaluate an escalating dose of cyclophosphamide in combination with set doses of inotuzumab ozogamicin, vincristine, prednisone, and rituximab.
89096277|NCT01055496|Experimental|Arm 2 (R-GDP)|Subjects in arm 2 will be enrolled in dose escalation cohorts that will initially evaluate escalating doses of gemcitabine and/or cisplatinum in combination with set doses of inotuzumab ozogamicin, dexamethasone, and rituximab.
89096278|NCT03436498|Experimental|SAR341402/NovoLog|SAR341402 will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of SAR341402 as treatment, patient will switch with NovoLog® as treatment.
89096279|NCT03436498|Experimental|NovoLog/SAR341402|Novolog will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of NovoLog® as treatment, patient will switch with SAR341402 as treatment.
89096280|NCT00609453|Experimental|1|Individuals with major depressive disorder receiving therapy
89096281|NCT01055262|Experimental|Heatwrap 1|Experimental heatwrap device for the lower back
89096282|NCT00609531|Experimental|Active|Individuals with an Autism Spectrum Disorder receiving citalopram
89096283|NCT00609531|Placebo Comparator|Placebo|Individuals with an Autistic Spectrum Disorder receiving placebo
89096284|NCT03414736|Experimental|Cohort 1|Daily dose escalation (click-by-click): Starting at dose 1 in the morning with daily increments to dose 2. During the escalation phase, the dose will only be increased if the patient is feeling fine.
89096285|NCT03414736|Experimental|Cohort 2|Weekly dose escalation in 6 escalation steps (7 dose levels): Starting at dose 1 injected in the morning with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
89096286|NCT03414736|Experimental|Cohort 3|Weekly dose escalation in 4 escalation steps (5 dose levels): Starting at dose 3 with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
89096287|NCT04301466|Experimental|Qi Zhi Tong Luo group|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. Each capsule was weighted 0.5g. Qi Zhi Tong Luo capsule (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
89096288|NCT04301466|Placebo Comparator|Placebo group|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
89096289|NCT04264923|Experimental|All patients enrolled|All patients enrolled with receive the HyGIeaCare Prep with a new lab sampling technique to be used on all patients enrolled in the study.
89096290|NCT03406000|Experimental|Insulin glargine (U300)|Self-administered subcutaneously once daily in the morning, at the same time.The initial dose for patients switching from insulin glargine is 80% of the total daily dose of basal insulin agent that was discontinued. Thereafter, insulin glargine (U300) will follow a titration algorithm for dose adjustment.
89096291|NCT02874300|No Intervention|Control|The control arm will comprise the offer of an assessment by a standard community falls prevention service.
89096292|NCT02874300|Other|High intensity supervision arm|high-intensity supervision
89096293|NCT02874300|Other|Moderate intensity supervision arm|Moderate intensity supervision
89096294|NCT04262037|Experimental|HPPV|will receive high frequency positive pressure ventilation during cardiopulmonary bypass at tidal volume 2 ml/kg and respiratory rate 80. Lung ultrasound will be done at the beginning and end of surgery
89096295|NCT04262037|Experimental|CPPV|will receive continuous positive airway pressure of 10 cmH2o during the bypass. Lung ultrasound will be done at the beginning and end of surgery
89096296|NCT04262037|No Intervention|Control|will be disconnected from the ventilation (passive deflation). Lung ultrasound will be done at the beginning and end of surgery.Lung ultrasound will be done at the beginning and end of surgery
89096297|NCT01052844|Placebo Comparator|Control group|"Placebo:~Five and four days before chemotherapy (day -5 and day -4): 1x daily~Three and two days before chemotherapy (day -3 and day -2): 2x daily~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
89096298|NCT01052844|Experimental|Gabapentin|"Gabapentin 300mg:~Five and four days before chemotherapy (day -5 and day -4): 1x daily~Three and two days before chemotherapy (day -3 and day -2): 2x daily~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
89096299|NCT04261881|Active Comparator|Nutraceutical intervention, 5 capsules twice daily.|Participants will consume the nutraceutical blend ATP-Fuel at 5 capsules twice daily.
89096300|NCT04261881|Active Comparator|Nutraceutical intervention, 3 capsules once daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules once daily.
89096301|NCT04261881|Active Comparator|Nutraceutical intervention, 3 capsules twice daily.|Participants will consume the nutraceutical blend ATP-II at 3 capsules twice daily.
89096302|NCT04225546||Patient group|Patients with hemiplegic and diplegic cerebral palsy between 4 - 10 years of age
89096303|NCT04225546||Control group|Healthy volunteer typically developing peers
89096304|NCT05319795|Experimental|Effortful Swallow Maneuver|Adults with a confirmed diagnosis of Parkinson Disease who have radiographically confirmed difficulties with timely airway protection and/or bolus clearance during swallowing. Individuals will complete a 4-week intervention program with two 30-minute sessions of Effortful Swallow (ES) practice daily, 5 days per week.
89096305|NCT04261647|Experimental|Experimental group 1|kinesio- taping technique plus traditional physical therapy program.
89096306|NCT04261647|Experimental|Experimental group 2|Pelvic floor exercise plus traditional physical therapy program.
89096307|NCT04261647|Active Comparator|Control group|traditional physical therapy program in the form of stretching of piriformis, stretching of iliopsoas and clam shell exercise, seat cushioning and seat kitz.
89096308|NCT03679936||Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
89096309|NCT03679936||Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
89096310|NCT03679936||Multiple primary lung cancer group|PET/CT dynamic scan,needle biopsy and gene detection
89096311|NCT03679936||Intrapulmonary metastases group|PET/CT dynamic scan,needle biopsy and gene detection
89096312|NCT00607425||1|Non-small cell lung cancer patients
89096313|NCT00607425||2|Healthy control subjects
89096314|NCT04261803||Familial Hypercholesterolemia children|
89096315|NCT04261803||Control children|
89096316|NCT01049412|Experimental|LY2605541 First, Then Insulin Glargine|Participants received LY2605541 for 8 weeks, followed by insulin glargine for 8 weeks.
89096317|NCT01049412|Active Comparator|Insulin Glargine First, Then LY2605541|Participants received insulin glargine for 8 weeks, followed by LY2605541 for 8 weeks.
89096318|NCT02692378|Active Comparator|Treatment|"Standard haemodialysis treatment thrice weekly (using a standard dialysate containing bicarbonate at a concentration of 35mmols/L) with the addition of oral sodium bicarbonate 500mg capsules for 12 weeks (weeks 5-16 of the study).~The dosage will be titrated to individual blood levels. Starting dose will be 1g twice daily and if predialysis bicarbonate levels remain <22mmols/L the dose will be increased by 0.5g twice daily each week. The maximum dose would be 3g twice daily.~The oral sodium bicarbonate may be withheld on dialysis days, when bicarbonate will be supplemented through the dialysate. This will be assessed on a case by case basis."
89096319|NCT02692378|No Intervention|Control|Standard haemodialysis treatment thrice weekly using a standard dialysate containing bicarbonate at a concentration of 35mmols/L.
89096320|NCT02692456|Active Comparator|Double needle celiac neurolysis (DNCN)|Patients were subjected to CT guided celiac neurolysis using 2 needle antero-crural technique on each side with patient in prone position and both needles will be lateral to the aorta
89096321|NCT02692456|Placebo Comparator|Single needle celiac neurolysis (SNCN)|Patients were subjected to CT guided celiac neurolysis using a single needle antero-crural approach from left side to be just in the front of the aorta near the origin of celiac trunk with patient in lateral position with his left side up then after the injection the patient were kept to his right side up for more homogenous spread of the dye.
89096322|NCT04302480|Experimental|Alternative smoking products (ASP)|
89096323|NCT04302480|Active Comparator|Sugar-sweetened beverages (SSB)|
89096324|NCT02873988||patients with COPD|patients with COPD
89096325|NCT02873988||patients without COPD|patients without COPD
89096326|NCT05494918|Experimental|Dose escalation|It's a dose escalation to identify the Maximum Tolerated dose (MTD) , recommended dose for expansion (RDE) or recommended Phase II dose (RP2D) of JSKN003, guided by the modified ADT design and BOIN design.
89096327|NCT02584426|Experimental|Cefazolin Treatment|Subjects will receive antibiotic treatment with phonophoresis (i.e., hypodermoclysis) during test 1, and will be given standard of care for 8 weeks.
89096328|NCT02584426|No Intervention|Standard of Care Control|Subjects will not receive intervention and will receive standard of care for 8 weeks.
89096329|NCT00934089|Experimental|PF-04217329 + placebo|Active study drug + latanoprost vehicle
89096330|NCT00934089|Experimental|PF-04217329 + latanoprost|Active study drug + latanoprost
89096331|NCT05333068|Experimental|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment
89096332|NCT05333068|Sham Comparator|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)|MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)
89096333|NCT01032174||Azithromycin SR|Acute Bacterial Maxillary Sinusitis
89096334|NCT01032174||Amoxiclav 1000 mg|Acute Bacterial Maxillary Sinusitis
89096335|NCT03344146|Other|Group 1|Intake reminders followed by crossover to no intake reminders
89096336|NCT03344146|Other|Group 2|No intake reminders followed by crossover to intake reminders
89096337|NCT02704936||Male donor|42 samples of semen from male donor attached to a donation program Normal sperm count as WHO 2010.
89096338|NCT02704936||IUI positive pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and have obtained positive pregnancy in any of the first 4 treatments IUI
89096339|NCT02704936||IUI unsuccessful pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and after undergoing maximum 4 cycles have unsuccessfully IUI indication of IVF / ICSI.
89096340|NCT02704780|Active Comparator|400 Microgram Misoprostol|Misoprostol 400 micro-gram dissolved in 20 mL normal saline will be injected in the umbilical vein in the first group
89096341|NCT02704780|Active Comparator|800 Microgram Misoprostol|Misoprostol 800 micro-gram dissolved in 20 mL normal saline will be injected in umbilical cord of the second group
89096342|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Specificity|Specimens collected from normal apparently healthy individuals at low risk for HIV infection will be tested by the investigational HIV test and FDA-licensed HIV test.
89096343|NCT00933933|No Intervention|ARCHITECT HIV Ag/Ab Combo Sensitivity|Specimen with confirmed positive HIV Antigen, HIV-1 antibody, or HIV-2 antibody will be tested by the investigational HIV test.
89096344|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Reactivity|Specimen collected from individuals at risk for HIV infection will be tested by the investigational HIV test.
89096345|NCT02704546|Experimental|Methylphenidate|In experimental days taking MPH, subjects will take 20mg Ritalin® (Novartis AG) in two tablets of 10mg, by swallow 1 hour prior to performing the physical test.
89096346|NCT02704546|Placebo Comparator|Placebo|In experimental days with placebo subjects will be asked to ingest 2 capsules identical to Ritalin® capsules, by swallow 1 hour prior to performing the physical test.
89096347|NCT01032018|Active Comparator|Referred Care|Immediately after the initial post-ACS screening, the participant's physician will be notified in writing if the participant is depressed according to the BDI. Depending upon the physician's own evaluation of the participant, he or she may elect to defer depression treatment, initiate it, or to refer the patient to a mental health specialist.
89096348|NCT01032018|Experimental|Stepped Care|Stepped Care participants will be given a description of the choices available in this arm, including choosing antidepressant medication and/or telephone-based, Problem-Solving Therapy (PST). If the patient is randomized to Stepped Care, their physician will be informed that depression treatment is being provided by the trial. Patients will select their preferred treatment approach. Depression symptoms will be monitored to determine whether the patient is improving relative to his/her baseline score. Relapse monitoring and maintenance therapy will continue for the duration of the study.
89096349|NCT05332912|Experimental|Immediate|Participants will receive 16 weeks of spatial ability experience.
89096350|NCT05332912|Placebo Comparator|Delayed|Participants will receive 8 weeks of verbal ability experience prior to receiving 8 weeks of spatial ability experience.
89096351|NCT04264221|Experimental|Intervention Group|"New management mode intervention: Pharmaceutical care A more recent strategy is pharmaceutical care, where a hospital provides timely patient education, monitoring and management of adverse drug reactions, identifying other drug-related problems, and an evaluation of treatment adherence by a clinical pharmacist. At the first visit, the clinical pharmacist provides a mobile phone number and encourages patients to contact them anytime if they need any consultation on the TB treatment.~Short Message Service and Phone calls daily use of the mobile phone for a TB treatment will support pharmaceutical care. TB patients or family members will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects."
89096352|NCT04264221|No Intervention|No Intervention Group.|Treatment Group included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by World Health Organization and routine treatment group (6 months treatment regimen); Routine health education provided by health care professionals.
89096353|NCT00609687|Other|A|Patients with suspected sarcoid-related posterior segment inflammation with inconclusive clinical exam findings, ancillary testing, and laboratory results
89096354|NCT00614848|Experimental|1|Endeavor Drug Eluting Coronary Stent
89096355|NCT00614848|Active Comparator|2|Driver bare-metal coronary stent
89096356|NCT01031706|Experimental|Hypertonic saline|6% NaCl, 4 ml TID via eFlow
89096357|NCT01031706|Placebo Comparator|Placebo|0.12% x 4ml via eFlow nebulizer
89096358|NCT04260165|Experimental|Proximal Row Carpectomy|
89096359|NCT04260165|Active Comparator|Four-corner fusion|
89096360|NCT00627510||A|all patients consecutively admitted to psychiatric inpatient treatment (naturalistic sample from routine psychiatric hospital intake)
89096361|NCT05484934|Experimental|Implant of acellular NAC graft|The implantation of the NAC acellular graft for regenerative nipple areolar complex
89227023|NCT00901511|Experimental|GM-CSF Group|"Scheduled Baseline WLL: All participants will receive scheduled bilateral WLL at baseline (month 0).~GM-CSF induction treatment: All participants will receive inhaled GM-CSF (250 mcg daily, 7 consecutive days every other week for 12 weeks beginning 1 week after the scheduled baseline WLL).~Washout period: All participants will not receive inhaled GM-CSF treatment for 4 weeks immediately following GM-CSF induction treatment.~GM-CSF maintenance treatment: All participants will receive inhaled GM-CSF (250 mcg daily on days 1 and 3 of every consecutive 14-day period for 6 months beginning 17 weeks after the scheduled baseline WLL).~Unscheduled Rescue WLL: Any participant experiencing progression of aPAP lung disease (defined as the disease progression resulting in respiratory failure (PaO2 at rest <60 mmHg of PaO2 > 60 mmHg at rest AND desaturation <90% at rest OR decline in SpO2 of 5% or more during exercise testing) will receive unscheduled rescue WLL."
89096362|NCT05118243|Active Comparator|Control cracker|All participants eat control crackers, which contain high amounts of GOS (approx. 5g GOS/daily portion of crackers)
89096363|NCT05118243|Active Comparator|Enzyme-treated cracker|All participants eat enzyme-treated crackers, which contain minimal amounts of GOS (less than 1g GOS/daily portion of crackers)
89096364|NCT02873910|Experimental|IQP-AS-119|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
89096365|NCT02873910|Placebo Comparator|Placebo|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
89096366|NCT00927069|Experimental|Group A|Patients who have shown an unsatisfactory response to 3 months of etanercept 50 mg twice a week without dose reduction prior to screening.
89227024|NCT00901511|Other|Control Group|"Scheduled Baseline WLL: All participants will receive a scheduled bilateral WLL at baseline (month 0).~Unscheduled Rescue WLL: Any participant experiencing progression of aPAP lung disease (defined as the disease progression resulting in respiratory failure (defined by a resting PaO2 <60 mmHg or > 60 mmHg and desaturation <90% at rest or decline in SpO2 of 5% or more during exercise testing) will receive unscheduled rescue WLL."
89227025|NCT00534196||Group under operation of brachytherapy|Patients with histologically confirmed adenocarcinoma of the prostate and who are planning to undergo brachytherapy with PI (permanent iodine) or combination of PI with other tratement.
89227026|NCT00500500|Experimental|EGb 761® (Tanakan®)|EGb 761® (Tanakan®)
89227027|NCT00500500|Placebo Comparator|Placebo|Placebo
89227028|NCT00117143|Experimental|Romiplostim|Participants will receive a maximum of 2 administrations of romiplostim by subcutaneous injection, the first on day 1 of the study and the second on day 15 or 22 depending on the participant's platelet count. Romiplostim doses to be tested were 30, 100, 300, and 500 μg.
89227029|NCT00004180|Experimental|Well-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
89227030|NCT00004180|Experimental|De-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
89227031|NCT00004180|Experimental|Myxoid/ round-cell liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
89227032|NCT00004180|Experimental|Pleomorphic liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
89227033|NCT00988494|Experimental|High concentration|DE-105 high concentration
89227034|NCT00988494|Experimental|Low concentration|DE-105 low concentration
89227035|NCT00988494|Placebo Comparator|Placebo|DE-105 placebo
89227036|NCT05347290|Experimental|Lead Apron + Rampart IC, M1128|Consented providers will perform catherization procedures utilizing both lead apron and Rampart system. Radiation will be measured by dosimeters worn by the providers.
89227037|NCT05347290|Experimental|Rampart M1128 IC, Only|Consented providers will perform catherization procedures utilizing only the Rampart system. Radiation will be measured by dosimeters worn by the providers.
89227038|NCT05347290|Active Comparator|Lead Apron Only|This is the control group. Consented providers will perform catherization procedures utilizing only the lead apron and ancillary shields (lead skirt, vest, thyroid collar (all at least 0.5mm Pb) with use of under table lead per lab operating policy and mobile suspended lead-acrylic shield and lead glasses). Radiation will be measured by dosimeters worn by the providers.
89227039|NCT00539994|Experimental|Treatment B|200mg BID retapamulin 5 days
89227040|NCT00539994|Placebo Comparator|Treatment C|200mg BID placebo 5 days
89227041|NCT00539994|Experimental|Treatment A|200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days
89227042|NCT04004676|Active Comparator|Placebo|isocaloric carbohydrate - only containing drink will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
89227043|NCT04004676|Experimental|Ketone_CHO|Ketone - Carbohydrate supplementation will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
89227044|NCT05711550|Experimental|Healthy Subjects: Study 1|This arm corresponds to study 1 (Real Neurofeedback uses only normal frequency band signals ranging from 1 to 35 Hz from the EEG-signal). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
89227045|NCT05711550|Experimental|Healthy Subjects: Study 2|This arm corresponds to study 2 (Real Neurofeedback uses only infra-low frequencies below 0.1Hz from the EEG-signal). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
89227046|NCT05711550|Experimental|Healthy Subjects: Study 3|This arm corresponds to study 3 (normal frequency band & infra-low frequencies are used in Real Neurofeedback). All included participants participate at 2 experimental conditions (Real Neurofeedback, Sham Neurofeedback) at 2 different days in a randomized order. Both, the investigators and the participants are blinded in regard to the intervention they receive at the two experimental visits.
89227047|NCT04005222|Other|SELENIUM|The patients in this group were supplemented with oral selenium at 0.1mg/kg doses twice daily for one month. After selenium supplementation period was completed, AC sampling as described above.
89227048|NCT04005222|Other|MELATONIN|The patients in this group were supplemented with oral melatonin 0.5 mg/kg/day doses twice daily for one month. After supplementation was completed 0.1 cc sampling from AC.
89227049|NCT05711472|Experimental|Experimental|"Intervention Group Three different ball sizes, 55, 65 and 75 cm in diameter, were provided to the pregnant women, and the appropriate ball size was determined according to the height of the participant. In order for the pregnant woman to continue the balance exercises, they were allowed to sit on the round birth ball with their knees and hips at an angle of approximately 90°, with an upright spine. A birth ball of 55 cm was used for women between 150 and 160 cm in height, 65 cm for women between 160 and 170 cm, and 75 cm for women between 170 and 185 cm in height. Exercises with the round birth ball were guided by the researcher and the pregnant women performed the exercises in line with the guide.~These are the movements performed with the round birth ball in 3 different positions: sitting (pelvic rocking movement, forward-backward and right-to-left rocking, forward supported sitting, and springing motion), kneeling, and squatting (ball hugging and pelvic rocking motion)."
89096367|NCT00927069|Experimental|Group B|Patients who showed a satisfactory response to 3 months or more of etanercept 50 mg twice a week followed by a loss of response after dose reduction to 50 mg etanercept once a week prior to screening.
89096368|NCT00927069|Experimental|Group A dose increase at Week 12|Patients in group A who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
89096369|NCT00927069|Experimental|Group B dose increase at Week 12|Patients in group B who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
89096370|NCT01031628|Active Comparator|Arm A|Patients with blood level less than 1100 will continue imatinib 400 mg daily
89096371|NCT01031628|Active Comparator|Arm B|Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
89096372|NCT01031628|Active Comparator|Arm C|Patients with blood level ≥1100 will continue imatinib 400 mg daily
89096373|NCT01031628|Active Comparator|Arm D|Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily
89096374|NCT02704468||CAVI and FGF-21|renal transplant patients for more than 1 month measured FGF-21 and CAVI
89096375|NCT00609843|Experimental|1|
89096376|NCT02691988|Experimental|ICS withdrawal|Guided ICS withdrawal combined with optimization of bronchodilator treatment
89096377|NCT02691988|Active Comparator|Usual care|Optimization of bronchodilator treatment
89096378|NCT01031004|Experimental|narafilcon B|contact lens
89096379|NCT01031004|Active Comparator|etafilcon A|contact lens
89096380|NCT01904656|Experimental|Arm I|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
89096381|NCT01904656|Active Comparator|Arm II|"Participants are exposed to a Healthy Eating Peaches!- media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
89096382|NCT00608673|Experimental|1|Patients in arm one used twice daily pimecrolimus 1% cream on their facial discoid lupus erythematosus lesions for 8 weeks.
89096383|NCT00608673|Active Comparator|2|Twice daily betamethasone valerate 0.1% cream to facial lesions of discoid lupus erythematosus for 8 weeks
89096384|NCT01622062|Experimental|Group 1|"Patients with WHO Category II exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
89096385|NCT01622062|Experimental|Group 2|"Patients with WHO Category III exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
89096386|NCT01622062|Active Comparator|Group 3|"Patients with WHO Category III exposure receive PEP with PVRV using the updated 2-site TRC (2-2-2-0-2) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
89096387|NCT02873676|Experimental|nutritional intervention|This group received multi-dimensional intensive nutritional intervention for 3 month, which included whey (30g/d,plus three times every week ),vitamin D (1000IU) and omega-3 fatty acid (DHA 1200mg and EPA 800mg).
89096388|NCT02873676|Experimental|resistance training program|This group received resistance training program which is made up warm-up exercise, muscle strength training and relaxing.
89096389|NCT02873676|Experimental|lifestyle modification project|This group receive multi-dimensional intensive nutritional intervention and resistance training program.
89096390|NCT02873676|Placebo Comparator|control|This group receive nutritional consulting,which involve dietary pattern modification and protein intake standardization.
89096391|NCT04263519|Active Comparator|Low Serum Level|Stable Blood Tacrolimus of 2-5 ng/ml.
89096392|NCT04263519|Active Comparator|High Serum Level|Stable Blood Tacrolimus of 5.1-10 ng/ml.
89096393|NCT04215718|Active Comparator|fistulotomy group|46 patients with simple anal fistula underwent fistulotomy and marsupialization of wound edges
89096394|NCT04215718|Active Comparator|fistulectomy group|46 patients with simple anal fistula underwent fistulectomy and closure of the wound
89096395|NCT00609921|Active Comparator|1|ARQ197
89096396|NCT04288050||Diabetic subjects under dialysis|Diabetic subjects under dialysis
89096397|NCT02704078|Active Comparator|EBUS-TBNA|Mediastinal lymph node aspiration shall be performed transtracheally.
89096398|NCT02704078|Experimental|EUS-B-FNA|Mediastinal lymph node aspiration shall be performed transesophageally
89096399|NCT00637650|Experimental|B|"Experimental group: patients in whom stone dust was left for spontaneous elimination"
89096400|NCT00637650|Other|A|Control group: Patients in whom all fragments resulting from laser lithotripsy of ureteral stones were actively retrieved
89096401|NCT00637767|Experimental|radio-labelled anti-CD66 monoclonal antibody|Up to 4mg radio-labelled anti-CD66 monoclonal antibody. Plus standard treatment
89096402|NCT00637767|Active Comparator|No IMP - standard treatment|No IMP - standard treatment
89096403|NCT03570190||TAVI patients|elective patients with a diagnosis of sAS and admitted for TAVI attending one of the participating centers for commercially available balloon expandable valve implantation that will be managed by a coordinator
89096404|NCT01280500|Placebo Comparator|Group A - Usual Care Controls|Group A will consist of 20 primary care clinics who are part of the Carolinas Healthcare System network but have not yet adopted the Electronic Medical Record System. These practices do use the same billing databases as the remaining clinics, allowing easy identification of asthma patients and their health services utilization patterns. Data from the billing systems will be used to retrospectively populate a database for these clinics from January 2009 forward.
89096405|NCT01280500|Active Comparator|Group B - EMR Control Practices|There are currently 65 primary care practices within the Carolinas Healthcare System network that have electronic medical record with decision support (EAP)access at baseline. These practices will serve as a second level of control for comparison with the intervention groups. Each of these practices is currently using Cerner PowerChart and at the start of the study and will have access to the asthma decision support tools; an electronically generated Asthma Action Plan (AAP); and a built-in system of population management reports which will be pushed to the practices on an on-going basis to help in patient recall and management. The EAP approach to care has been developed with input from clinicians, hospital administrators, hospital information services personnel, and Cerner consultants.
89096406|NCT01280500|Active Comparator|C Integrated Approach to Care|There are 10 practices within the Carolinas Healthcare System (CHS) network that have already received additional training for improving outcomes for patients with chronic diseases termed the Integrated Approach to Care (IAC). This IAC approach developed by CHS is based on the Chronic Care Model (CCM). The IAC approach includes a heavy emphasis on the use of health information technology that practices receive during the initial EAP rollout.
89096407|NCT01280500|Active Comparator|Group D - Shared Decision Making (SDM)|This approach has great potential for improved patient outcomes and provides an additional step in the successful implementation of patient self-management. The research team will develop the SDM intervention during the first 6 months of the study. In particular, the Shared decision making (SDM) intervention will be designed to be deployed within the 4 large clinics that care for the majority of the community's underserved and disadvantaged patients. The SDM intervention development will be overseen by the study advisory board and actively recruit providers from within the clinics for feedback about the intervention.
89096408|NCT01280500|Active Comparator|School Based Care (SBC)|Activities included: spending individual time with students to assess, treat, and monitor and to educate students in proper asthma management; facilitate access to health care and medicine; and communicate with parents.
89096409|NCT05100849|Experimental|Kinect-based cognitive training|Standard treatment protocol and 14 sessions (biweekly during 30 minutes) of Kinect-based cognitive training inspired by instrumental activities of daily living.
89096410|NCT05100849|Experimental|Tablet-based cognitive training|Standard treatment protocol and 14 sessions (biweekly during 30 minutes) of Tablet-based cognitive training inspired by instrumental activities of daily living.
89096411|NCT01221688|Other|group 2 (cN0)|Patients without proven axillary involved nodes will undergo SLN biopsy and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLN biopsy alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
89096412|NCT01221688|Experimental|group 1 (pN+)|group 1 : patients with proven involved axillary nodes will undergo SLN biopsy and complete level I-II axillary lymphadenectomy.
89096413|NCT00609999|Experimental|Stratum A|Pts not on EIAEDs
89096414|NCT00609999|Experimental|Stratum B|Pts on EIAEDs
89096415|NCT00951652|Experimental|CBT plus supportive listening|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be supportive listening
89096416|NCT00951652|Active Comparator|CBT plus Interpersonal and emotional processing therapy|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be Interpersonal and emotional processing therapy
89096417|NCT00608751|Experimental|IMRT|External beam radiation with 6 MV photons will be delivered in 200 cGy daily fractions, 35 fractions over 7 weeks for a total dose of 7000 cGy.
89096418|NCT00931515|Experimental|NuBac|NuBac device implanted at the L4/5 level
89096419|NCT00931515|Active Comparator|Prodisc-L|Prodisc-L implanted at the L4/5 level.
89096420|NCT02703766|Active Comparator|Lean|"Lean individuals are defined as having body fat content less or equal to 25% in men and less than 35% for women.~Overfeeding induced weight gain and subsequent weight loss"
89096421|NCT02703766|Experimental|Obese|"obese individuals are defined as having body fat content more than 25% in men and more than 35% for women.~Overfeeding induced weight gain and subsequent weight loss"
89096422|NCT00823108|Experimental|1|Glucose-insulin-potassium
89096423|NCT00823108|No Intervention|2|Control
89096424|NCT04259619|Experimental|Low-Level Laser Therapy|During 2-3 days this group receives three low-level laser therapy (LLLT) treatments with the Soft Power Laser carried out by a specially trained breastfeeding consultant.
89096425|NCT04259619|Placebo Comparator|Placebo Therapy|During 2-3 days this group receives three placebo treatments with an identically looking laser, which in contrast submits only red colored light. The therapy is also carried out by a specially trained breastfeeding consultant.
89096426|NCT00627250|Experimental|A|Amantadine 100 mg every morning and 12 noon
89096427|NCT00627250|Placebo Comparator|B|Placebo tablet every morning and 12 noon
89096428|NCT05330949||case group|
89096429|NCT05330949||control|
89096430|NCT04301232||Fast-Track Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Patients who fulfilled criteria of all scoring systems were defined as eligible for PACU by-pass (fast-tracking) and transferred into phase II recovery area in the ward without observation in PACU (Group FT = Fast Track;)
89096431|NCT04301232||PACU Group|After extubation, patients were evaluated using modified Aldrete Scoring System (mASS) , White's Fast- Track Scoring System (WFTSS) and SPEEDS criteria during 15 minutes with 3 min intervals. Ineligible patients were taken into PACU where their treatments were continued until discharge criteria were achieved (Group PACU)
89096432|NCT02692144|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
89096433|NCT02692144|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
89096434|NCT02692144|Placebo Comparator|White-bread|47g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
89096435|NCT04300374||Sevoflurane only|inhalation of sevoflurane during general anesthesia
89096436|NCT04300374||Remifentanil and Sevoflurane|remifentanil infusion and inhalation of sevoflurane during general anesthesia
89096437|NCT02703376|Other|Patients after esophageal surgery|Oral Prednisone for 12 weeks
89096438|NCT04259697|Experimental|Clinical pilates|Exercises will be performed two times per week for twelve weeks.
89096439|NCT04259697|Experimental|Whole body vibration|Exercises will be performed two times per week for twelve weeks.
88812638|NCT03839030|Experimental|MBHP-Educa|Experimental: Intervention Group A novel Mindfulness-based Health Promotion program for Educators for active teachers will be employed. The intervention will be held once a week for 8-weeks, two-hour meetings (16.0-h total). Participants will be encouraged to meditate for 10-30 min/day via audio recording.
89096440|NCT04301388|Experimental|TVCL-based|Monitor progression of labor by shortening of cervix examined by transvaginal cervical length
89096441|NCT04301388|Active Comparator|Conventional-based|Monitor progression of labor by per vaginal exam to detect cervical change
89096442|NCT02873442|Experimental|Precision cells combined with TACE|"Transcatheter Arterial Chemoembolization:~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
89096443|NCT02873442|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
89096444|NCT04261179|Other|Lymphoseek + Nanocoll|Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams
89096445|NCT00610077|Experimental|1|Letrozole
89096446|NCT00610077|Active Comparator|2|Clomiphene citrate
89096447|NCT00823576|Active Comparator|1|"Group witness: one receiving a single bolus of analgesic~Seepage simple person the end of intervention of 200mg of ropivacaïne 0,5 % at the level of zones it"
89096448|NCT00823576|Active Comparator|2|Group catheter: receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
89096449|NCT01028352|Other|Duloxetine|
89096450|NCT03172780|Experimental|Diclofenac Sodium Gel|Diclofenac Sodium Gel, 1%
89096451|NCT03172780|Active Comparator|Voltaren® Gel|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
89096452|NCT03172780|Placebo Comparator|Placebo gel|Placebo gel
89096453|NCT00929643||1|
89096454|NCT05011617|Experimental|MAC group|Electroacupuncture was performed for two consecutive days before surgery (2 daily 30-min sessions) by a licensed acupuncturist at 4.0 mA using an alternating frequency of 2 and 100 Hz (every 1.5 seconds) (LH-202, Huawei, Beijing, China). Acupoints included bilateral Yunmen (LU2), Zhongfu (LU1), Lieque (LU7), and Neiguan (PC6). On the day of surgery, electroacupuncture started upon the completion of a loading dose of dexmedetomidine, was suspended when CPB started (to avoid interference with electrocardiogram recording) and continued until the end of surgery.
89096455|NCT05011617|No Intervention|IGA group|Anesthesia was induced with propofol (2.0-3.5 μg/mL) by target control infusion and 0.3-0.5 μg/kg sufentanil. Tracheal intubation was facilitated by rocuronium (1.0 mg/kg). Anesthesia was maintained using isoflurane at 0.7-1.0 minimal alveolar concentration in a gas mixture of oxygen and air and remifentanil (0.05-0.2 μg·kg-1·min-1) by intravenous injection pump. Sufentanil dose was totally 2.5-4.0 μg/kg. Muscle relaxation was achieved using 1/3-1/4 of the induction dose every 40-60 min based on a train of four. Mechanical ventilation with 80% O2 in air was used. Tidal volume (7-8 mL/kg) and respiratory rate (10-12/min) were adjusted according to PETCO2 to achieve normal ventilation (PETCO2 35-45 mmHg).
89096456|NCT02703298|Experimental|TRX-818|
89096457|NCT04259385|Active Comparator|Calorie/Control Label Condition|Beverages at the concession stand and in the parent survey in this arm will display solely a calorie label.
89096458|NCT04259385|Experimental|Text Warning Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display both a text warning and a calorie label.
89096459|NCT04259385|Experimental|Sugar Graphic Label Condition|Sugary beverages at the concession stand and in the parent survey in this arm will display a sugar graphic warning label depicting the amount of sugar in the product, the same text warning, and a calorie label.
89096460|NCT04261101|Experimental|Block A|Test intervention with questions regarding diabetes and adrenal
89096461|NCT04261101|Active Comparator|Block B|Test intervention with questions regarding thyroid and hypophysis
89096462|NCT03101488|Experimental|KN035|KN035 is to be injected subcutaneously 0.1mg/kg or 0.3mg/kg or 1mg/kg or 2.5mg/kg or 5mg/kg or 10mg/kg weekly until disease progresses or unacceptable tolerability occurs.
89096463|NCT00926367|Experimental|Clinidamycin/ Benzoyl Peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide (BPO).
89096464|NCT00926367|Active Comparator|Benzoyl peroxide and adapalene|Once-daily applications, to the randomized side of the face either left or right, of benzoyl peroxide (BPO) and adapalene
89096465|NCT02703142||Patients after esophagectomy|Endoscopic examinations are performed at 1, 8, and 15 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
89096466|NCT04261023|Experimental|Abatacept|Treatment arm - 125mg sub-cutaneous injection at week 0 and once weekly thereafter for a maximum of 48 weeks
89096467|NCT04261023|No Intervention|Control arm - CCP Next Generation|Observational study cohort - usual care
89096468|NCT05086341|Experimental|My COPD|In addition to usual care, participants in the intervention group will receive a 12-week, twice a week, physiotherapist-supported individualized exercise program and physical activity plan via the eHealth tool My COPD.
89096469|NCT05086341|No Intervention|Usual care|Participants in the control group will receive usual care only. Usual care is recommended to include, but not restricted to, long-acting anticholinergics and long-acting ß2-antagonists with 24-hour duration and support for smoking cessation, PA and exercise, self-management and nutrition.
89096470|NCT01114529|Experimental|Everolimus|Conversion from CNI to everolimus in combination with Myfortic and steroids
89096471|NCT01114529|Active Comparator|Calcineurin inhibitor, Prograf or Neoral|Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids
89096472|NCT00926289|Active Comparator|Telmisartan|Telmisartan 80 mg
89096473|NCT00926289|Experimental|Telmisartan/hydrochlorothiazide|Telmisartan80mg/Hydrochlorothiazide25mg
89096474|NCT02707276|Experimental|Phase 1: Cross-Over, Active LFMS first|Phase 1 crossover: three 20 minute treatments of active low field magnetic stimulation, once per day for three consecutive days during week 1. Then repeat with three 20 minute treatments of sham LFMS, once per day for three consecutive days during week 3.
89096475|NCT02707276|Sham Comparator|Phase 1: Cross-Over, Sham LFMS first|Phase 1 crossover: three 20 minute treatments of sham low field magnetic stimulation, once per day for three consecutive days during week 1. Then repeat with three 20 minute treatments of active LFMS, once per day for three consecutive days during week 3.
88812639|NCT03839030|No Intervention|Control Group|Control Group Teacher education as usual. These participants will participate in teacher training (Neuroscience for Education - Neuro Educa). The Neuro-Educa will be held once a week for 8-weeks, two-hour meetings (16.0-h total).
89096476|NCT02707276|Experimental|Phase 2: Parallel, Active LFMS|Phase 2 parallel: five 20-minute active low field magnetic stimulation treatments, once per day for five consecutive days during week 1.
89096477|NCT02707276|Sham Comparator|Phase 2: Parallel, Sham LFMS|Phase 2 parallel: five 20-minute sham low field magnetic stimulation treatments, once per day for five consecutive days during week 1.
89096478|NCT02699398|Experimental|VR-based therapy|3 weeks of home-based treatment for motor training using a virtual reality rehabilitation setup.
89096479|NCT02699398|Active Comparator|Control|3 weeks of home-based occupational therapy for motor training.
89096480|NCT04309643|Experimental|CTP-543|In Period 1, participants will receive a single oral dose of the combination oral contraceptive (OC) on Day 1. There will be a washout period of 7 days between dosing in Period 1 and the first dose in Period 2. In Period 2, participants will receive twice daily oral doses of CTP-543 for 8 consecutive days with a single dose of the combination OC co-administered on Day 4.
89096481|NCT02881073|No Intervention|Control|"Eligible women at participating centres prior to roll-out of PlGF testing (as per stepped wedge trial design) will be managed according to HSE/Institute of Obstetrician and Gynaecologists' National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia or by NICE guidelines for Management of Hypertension in Pregnancy for those in Northern Ireland."
89096482|NCT02881073|Active Comparator|Maternal plasma PlGF quantification|"Women in the interventional arm will have an additional point of care test performed at the time of enrolment for immediate PlGF quantification. The PlGF measurement will be reported as the absolute value in pg/ml with the following ranges given:~PlGF <12 pg/ml: Very low~PlGF ≥12 and <100 pg/ml: Low~PlGF ≥100 pg/ml: Normal~All hospitals will follow National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia with the additional integration of PlGF results as indicated in the algorithm."
89096483|NCT03208036|Experimental|TDCS|TDCS offered concurrent with working memory focused cognitive training
89096484|NCT03208036|Sham Comparator|Sham|Sham stimulation offered concurrent with working memory focused cognitive training
89096485|NCT00926211|Experimental|Computer-Assisted|Hair harvest using the computer-assisted system
89096486|NCT00926211|Active Comparator|Manual Harvest|Hair harvesting via manual technique
89096487|NCT04310813||Endoscopic urologic patients|Patients with bladder cancer or benign prostate hyperplasia undergoing urologic endoscopic procedures.
89096488|NCT02881229||Women in the Vulvar Specialty Clinic|Information will be collected from all patients presenting with vulvar complaints who have been seen by Dr. Schlosser in the Vulvar Mucosal Specialty Clinic at Northwestern Medical Group.
89096489|NCT03188146||PBC patients with liver biopsy|Ursodeoxycholic acid will be given compliance to the treatment guideline.
89096490|NCT00610233|Active Comparator|A|Urodynamic investigation with deep brain stimulation ON
89096491|NCT00610233|Experimental|B|Urodynamics with deep brain stimulation OFF
89096492|NCT02880839|Experimental|Partial cervical lamina excision group|Patients in the cervical lamina partial excision group underwent partial cervical lamina excision and cervical pedicle screw internal fixation.
89096493|NCT02880839|Experimental|Pipeline-dredge discharge group|Patients in the pipeline-dredge discharge group underwent pipeline-dredge discharge and cervical pedicle screw internal fixation.
89096494|NCT02880839|Experimental|Digital navigation group|Patients in the digital navigation group underwent digital navigation-assisted cervical pedicle placement.
89096495|NCT02699320||"Asymptomatic"|"Asymptomatic meaning patients showed well tolerance to parenteral nutrient (PN) administration and there were no complications occurred within two months (n=7);"
89096496|NCT02699320||CLABSI|with central catheter-related blood stream infections (CLABSI) meaning patients had fever, increased neutrophils, documented positive catheter blood culture but exclude other source of infection (n=5)
89096497|NCT02699320||PNALD|with parenteral nutrient associated liver disease (PNALD), meaning SBS patients showed elevated liver enzymes and bilirubin (n=14).
89096498|NCT02699320||healthy controls|Seven healthy infants who had added complementary were served as controls (n=7).
89096499|NCT04259073|Placebo Comparator|Group C|two capsules filled with sugar
89096500|NCT04259073|Active Comparator|Group P150|two capsules; one of them containing sugar (like the placebo one), the other is the active drug (pregabalin 150 mg)
89096501|NCT04259073|Active Comparator|Group P300|two capsules of pregabalin (150 mg)
89096502|NCT00609063|Experimental|1|Participants will receive atorvastatin for 6 months.
89096503|NCT00609063|Placebo Comparator|2|Participants will receive matching placebo for 6 months.
89096504|NCT02703064|Experimental|Furocyst|Furocyst 500mg capsule, BD
89096505|NCT01114373|Active Comparator|Melatonin|Subjects with mild to moderate essential hypertension will be given 24mg time release melatonin for 4 weeks either before or after exposure to 4 week of placebo with no washout period.
89096506|NCT01114373|Placebo Comparator|Placebo|Subjects with mild to moderate essential hypertension will be given placebo for 4 weeks either before or after exposure to 4 weeks of 24mg daily dose of time release melatonin with no washout period.
89096507|NCT02699476|Active Comparator|Individual + Computer A|Daily activities involve playing one hour of computer games (e.g., hangman, boggle, word scramble, chess; computer cognitive training A (CCA)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
89096508|NCT02699476|Experimental|Individual + Computer B|Daily activities involve playing an alternative set of computer games (computer cognitive training B (CCB)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
89096509|NCT02699476|Active Comparator|Group + Computer B|Daily activities involve group and individual cognitive therapy discussions on health, nutrition, and other topics and computer cognitive training B (CCB).
89096510|NCT00925899|Experimental|Melatonin|20 mg
89096511|NCT00925899|Placebo Comparator|Placebo|
89096512|NCT02601586|Experimental|PR oxycodone|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa placebo 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone : 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
89096513|NCT02601586|Active Comparator|levodopa|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa : 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa : 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
89096514|NCT02601586|Placebo Comparator|Placebo|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa placebo 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
89096515|NCT00609141|Experimental|Treatment (monoclonal antibody therapy)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.
89096516|NCT00615862||AUD+ and AUD-|AUD stands for alcohol use disorders. Patients with alcohol use disorders are assigned the label AUD+. Patients without alcohol use disorders are assigned the label AUD-.
89096517|NCT05330715|Other|Advanced Mobile Stroke Unit|Prehospital treatment of patients with an advanced Mobile Stroke Unit. The advanced Mobile Stroke Unit is an ambulance equipped with a computed tomography scanner, and additional diagnostic devices, such as point-of-care-laboratory and telemedicine to enable the team to diagnose and initiated specialised treatment of emergency patients at the emergency site.
89096518|NCT05330715|Other|Conventional ambulance|Prehospital emergency care with conventional ambulances.
89096519|NCT02702830||Diagnostic (MRI and CPET)|Patients undergo CPET using a one-way breathing mask in 2 separate days 1-2 weeks apart. Patients also undergo MRI before and within 60 seconds after exercising.
89096520|NCT02702908||mPC|Prostate cancer patients with bone metastases (mPC)
89096521|NCT02702908||mCRPC|Patients with castration-resistant prostate cancer with bone metastases (mCRPC)
89096522|NCT00610389|Experimental|1|
88812640|NCT03145688|No Intervention|Control|The control group package will consist of the Canadian 24 Hour Movement Guidelines recommending 60 minutes of moderate to vigorous physical activity per day for children. The guide also contains arguments & information about the benefits of physical activity.
89096523|NCT01114217|Experimental|Ferumoxytol|Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 [NCT01114139]. Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin <11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) <20% at any evaluation visit, (except study termination visit). Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV). The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1. The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.
89096524|NCT01030536|Experimental|CAT-8015 20 microgram per kilogram (mcg/kg)|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
89096525|NCT01030536|Experimental|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
89096526|NCT01030536|Experimental|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
89096527|NCT01030536|Experimental|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
89096528|NCT01030536|Experimental|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
89096529|NCT00615004||1-SSA|All patients receiving first-line depot SSA treatment, with either octreotide-LAR or lanreotide, achieving control of the disease, and with available follow-up after 12 months of treatment.
89096530|NCT00615004||2-Surgery|All patients treated with first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach, who did not require any additional therapy for acromegaly and with available follow-up after 12 months of treatment
89096531|NCT01030458|Experimental|amlodipine plus valsartan|In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.
89096532|NCT01030458|Active Comparator|hydrochlorothiazide plus bisoprolol|In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol
89096533|NCT02692222||PPV|This study will track changes in PPV and CO before and after of volume expansion, which goal is to change the cardiac output.
89096534|NCT02702674|Active Comparator|propranolol plus oxytocin|121 patients who will receive a capsule containing 20 mg propranolol (propranolol plus oxytocin) administrated orally before beginning induction and repeated after 8 hours if no sufficient uterine contractions reached.
89096535|NCT02702674|Placebo Comparator|placebo plus oxytocin|121 control patients who will receive a similar capsule as a placebo (oxytocin plus placebo) before beginning induction.
89096536|NCT02702752|Other|DYNASDY|The study considers changes in SDF-1α levels in response to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease.
89096537|NCT02702752|Active Comparator|Control group|A control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
89096538|NCT01114139|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
89096539|NCT01114139|Placebo Comparator|Placebo|Participants received a total of 2 doses of IV saline (17 mL). The first IV dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose.
89227050|NCT05711472|No Intervention|No Intervention|"Control Group~The followings were administered to the pregnant women in the Control Group after they were admitted to the hospital for delivery:~Information was given about the research,~Written consent was obtained,~Routine practices and care were provided in the delivery room (taking anamnesis, taking vital signs, demonstrating correct breathing techniques, ensuring freedom of movement)~Cervical changes were recorded on the partograph by vaginal examination,~EFM (Electronic Fetal Monitoring) was applied based on doctor's orders,~Fetal Heart Sound (FHS) was listened to every half hour and recorded on the partograph."
89227051|NCT04441710||Caregivers|Staff of university hospitals
89227052|NCT04441710||Primary care caregivers|Population of professional caregivers such as general practitioner or freelance nurse.
89227053|NCT04441710||Patients|
89227054|NCT01563744|Experimental|EGD-assisted colonoscopy prep|2 liters of polyethylene glycol instilled through the channel of the endoscope during EGD when colonoscopy expected the following day. Patients follow a clear liquid diet, then ingest an addition 1 liter polyethylene glycol 4 hours prior to colonoscopy. Patients are also given a tap water enema 1 hour prior to colonoscopy.
89227055|NCT01563744|Active Comparator|Standard Colonoscopy Prep|Split-dose polyethylene glycol (2 liters pm prior to colonoscopy, 1 liter 4 hours prior to colonoscopy)), clear liquid diet, metoclopramide 10 mg IV 30 minutes prior to procedure, tap water enema 1 hr prior to colonoscopy
89227056|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab once weekly|Four weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 8, 15, 22. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
89227057|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab twice weekly|Eight 8 twice-weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 4, 8, 11, 15, 18, 22 & 25. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
89227058|NCT02531191|Experimental|New Tablet Preceding Group|Each subject received an ASP015K small tablet in period 1 and an ASP015K current tablet in period 2 under fasted conditions with 200 mL of water.
89227059|NCT02531191|Experimental|Current Tablet Preceding Group|Each subject received an ASP015K current tablet in period 1 and an ASP015K small tablet in period 2 under fasted conditions with 200 mL of water.
89227060|NCT01087177|Experimental|Exposure to Pedialink CEASE Trained Site|Parents at a practice where the clinicians were trained to address tobacco use through the Pedialink CEASE module.
89227061|NCT01081639|Experimental|Gonal-f|
89227062|NCT01081639|Active Comparator|Puregon|
89227063|NCT01081717||001|golimumab as prescribed
89227064|NCT01081717||002|anti-TNF biologics as prescribed
89227065|NCT01081717||003|non-anti-TNF biologics as prescribed
89227066|NCT01081717||004|systemic non-biological treatments as prescribed
89227067|NCT01081717||005|general population non-treated cohort
89227068|NCT03963973|Experimental|RDN-929|low, medium and high dose of RDN-929 capsules
89227069|NCT03963973|Placebo Comparator|Placebo|Matching placebo capsules
89227070|NCT01085305|Experimental|PCIT|Provision of Parent-Child Interaction Therapy
89227071|NCT01085305|Active Comparator|TAU|Treatment as usual from other therapists in the same clinics
89227072|NCT03811093|Experimental|Care as Usual Group|A randomly selected group of 20 participants who received treatment per the prescribed trial protocol using a fully functional invisa-RED Technology Elite device. Treatment protocol was as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular LLLT protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
89227073|NCT03811093|Placebo Comparator|Sham Group|A randomly selected group of 20 participants who will receive treatment per the prescribed trial protocol using a non functional invisa-RED Technology Elite device. (The sham device will be disabled and will deliver no low laser light energy during therapy.) Treatment protocol is as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
89227074|NCT01087255|No Intervention|Usual Care|Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.
89227075|NCT01087255|Experimental|Electronic Pillbox Monitoring System|Usual care plus receive use of the wireless electronic pillbox and medication monitoring system
89227076|NCT01087411|Experimental|Motivational Interviewing and omega 3|This arm is the group that receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
89227077|NCT01087411|Experimental|Motivational interviewing and placebo|This arm is the group that receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
89227078|NCT01087411|Experimental|Control and omega 3|This arm is the group that does not receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
89227079|NCT01087411|Placebo Comparator|Control and placebo|This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
89096540|NCT02699242|Experimental|Simulator arm|In the Simulation arm group the subjects will be trained on the virtual reality bronchoscopic simulator (ORSIM simulator) for up to 60 minutes as active intervention, before they undertake the 2nd Fiber optic intubations.
89096541|NCT02699242|No Intervention|Control arms|The control arm will be exposed only to the didactic teaching. The subjects will not undergo simulator training before undergoing 2nd fiber optic intubations.
89096542|NCT01027884|Placebo Comparator|Placebo|Placebo 900 mg/day
89096543|NCT01027884|Experimental|Idebenone|Idebenone 900 mg/day
89096544|NCT02699164|Experimental|combine group|"Conventional physiotherapy applied 15 sessions of treatment. In addition to conventional physiotherapy non-surgical spinal decompression therapy applied.~First 10 sessions of treatment non-surgical decompression therapy applied and last 5 sessions spinal stabilization exercise applied."
89096545|NCT02699164|Experimental|conventional physiotherapy|conventional physiotherapy applied 15 sessions of treatment. Conventional physiotherapy consisted hotpack, Transcutaneal Electric Nerve Stimulation(TENS) and Ultrasound Currents. Spinal stabilization exercises applied last five sessions of therapy.
89096546|NCT02699008|Active Comparator|HPR-Ticagrelor row|ACS patients aftergoing PCI treated with clopidogrel and aspirin were included. in the 3-5th day after prescription of clopidogrel, platelet function were tested simultaneously by three methods: Light transmittance aggregometry（LTA）, Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
89096547|NCT02699008|Active Comparator|HPR-Clopidogrel row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
89096548|NCT02699008|Active Comparator|unHPR row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
89096549|NCT03387514|Experimental|18F-DCFPyL whole body PET/CT scan|18F-DCFPyL whole body PET/CT scan at three time-points
89096550|NCT01022580|Active Comparator|Infasurf surfactant (ONY, Inc.)|Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.
89096551|NCT01022580|Sham Comparator|Sham (No Treatment)|"Infants already receiving inhaled nitric oxide will receive Sham (no treatment) doses on study days 0,2,4,6, and 8."
89096552|NCT02698930|Experimental|dexmedetomidine group|
89096553|NCT02698930|Placebo Comparator|Control group|
89096554|NCT02880683|Experimental|Single arm, transvenous cardiac autonomic nerve stimulation|
89096555|NCT04215094||infected group|Intracranial infection were diagnosed according to the Centers for Disease Control (CDC) definitions
89096556|NCT04215094||non-infected group|the postoperative recovery was uneventful with no infection
89096557|NCT02698852|Experimental|BuMA Supreme group|Totally 1000 subjects combined the 220 subjects from randomized controlled trial(RCT) group
89096558|NCT04310501||CKD Patients|"Patients (n=150) with CKD (Stages 1-5 pre-dialysis, undergoing dialysis, kidney transplantation) who fulfil the inclusion criteria from the Nephrology Dept and Renal Transplant Unit of the University Hospital of Ioannina.~Sixty patients will be selected for the pilot study which will include blood and urine tests and specific polymorphism analysis (pharmacogenetic tests)"
89096559|NCT01107353|Active Comparator|First Imipramine Pamoate, then Tofranil-PM|First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)
89096560|NCT01107353|Active Comparator|First Tofranil PM, then imipramine pamoate|First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)
89096561|NCT02702206|Experimental|corticosteroids SASD injection|under US guidance 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
89096562|NCT02702206|Experimental|hyaluronic acid (ARTZ) SASD injection|under US guidance 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
89096563|NCT02702206|Placebo Comparator|normal saline SASD injection|under US guidance 2.5ml normal saline and 0.5ml distilled water and 1ml 1% lidocaine
89096564|NCT01107197|Active Comparator|Isonitrogenous isocaloric formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula isonitrogenous isocaloric to the experimental one
89096565|NCT01107197|Experimental|Enriched nutrition formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula enriched in arginine, zinc and antioxidant oligoelements
89096566|NCT04216186|Active Comparator|Atomoxetine and Coenzyme Q|Atomoxetine and Coenzyme Q
89096567|NCT04216186|Placebo Comparator|Placebo and Atomoxetine|Placebo and Coenzyme Q
89096568|NCT02881697||Obese insulin-resistant subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; insulin-resistant, scheduled for elective bariatric surgery
89096569|NCT02881697||Lean insulin-sensitive controls|Adipose tissue sampling in normal weight patients (BMI < 27kg/m2) aged 18- max. 60 years, males and females; insulin-sensitive, scheduled for elective surgery
89096570|NCT02881697||Obese diabetic subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; diabetic, scheduled for elective bariatric surgery
89096571|NCT02698696|Experimental|ECo program|Objective: to inform the patient about cognitive impairments and their repercussions; to train the patient in problem-solving skills through exercises; to implement strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises, tools (tokens, cards, maps, chessboard) Modules: Psychoeducation, Attention, Memory, Executive Functions, Functional Impairments
89096572|NCT02698696|Experimental|CRT program|Objective: problem-solving skills training through exercises, in order to use strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises Modules: Cognitive Flexibility, Working Memory, Planning
89096573|NCT02698696|Active Comparator|Supportive psychotherapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' cognitive and functional impact, social skills, and the regulation of sleep and daily activities.
89096574|NCT01989598|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.
89096575|NCT04214938|Active Comparator|Hypertonic sea water|The patient was applied intranasal hypertonic sea water (3.5% sodium chloride) before the nasoendoscopy procedure.
89096576|NCT04214938|Active Comparator|Lidocaine|The patient was applied intranasal Vemcaine as TLA (10% lidocaine; AstraZeneca, Södertälje, Sweden) before the nasoendoscopy procedure.
89096577|NCT04214938|Active Comparator|Xylometazoline|The patient was applied intranasal Otrivine (0.1% xylometazoline hydrochloride, GlaxoSmithKline, Brentford, UK ) before the nasoendoscopy procedure.
89096578|NCT04214938|Placebo Comparator|0.9% Sodium chloride|The patient was applied intranasal placebo (0.9% sodium chloride) before the nasoendoscopy procedure.
89096579|NCT02702050|Active Comparator|Conventional treatment group|Conventional treatment group will receive an educational session before commencement of the program. Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises will be provided within a 6-week period (i.e., two sessions per week) to all subjects. No mechanical stimulation will be given.
89096580|NCT02702050|Experimental|Mechanical stimulation group|A 10 minute mechanical stimulation program - 'Mechanical stimulation (LPG system; Cellu M6 Integral I), will be provided after each of the twelve sessions of conventional treatment.
89096581|NCT00615160|Experimental|A|PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)
89096582|NCT00615160|Experimental|B|combined treatment with DTIC 850 mg/m² on day 1 + PTK-ZK 1250 mg flat dose on days 1 to 28
89096583|NCT02702362|Active Comparator|anodal stimulation|"Patients received anodal tDCS (on the precuneus ) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS.~A final CRS-R is performed 5 days after the end of the session to assess the potential long term effects of the tDCS."
89096584|NCT02702362|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed 5 days after the end of the session.
89096585|NCT02702284|Other|Adequate health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
89096586|NCT02702284|Experimental|Adequate health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
89096587|NCT02702284|Other|Limited health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
89096588|NCT02702284|Experimental|Limited health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
89096589|NCT01112579|Experimental|Treatment|
89096590|NCT01112579|Other|Control|
89096591|NCT04215484||P|P (previa) : pregnant women with placenta previa on ultrasound and no suggestive signs of placenta accreta
89096592|NCT04215484||I|I (abnormal placental Invasion) : pregnant women with placenta previa on ultrasound,and suggestive signs of placenta accreta on ultrasound with or without MRI
89096593|NCT04215484||N|N (placenta normally located) : pregnant women without suggestive signs of placenta previa or accreta on ultrasound
89096594|NCT02880605||appropriate in appropriate indications|
89096595|NCT02880605||inappropriate in appropriate indications|
89096596|NCT02880605||appropriate in inappropriate indications|
89096597|NCT02880605||inappropriate in inappropriate indications|
89096598|NCT02698618|Experimental|Ticagrelor|A loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours)
89096599|NCT02698618|Active Comparator|Clopidogrel|A loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg
89096600|NCT02698462|Other|FIT and Questionnaire|Six thousand persons eligible for the national CRC screening program will be selected. They will be selected from four areas that are considered representative of the Netherlands. All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
89096601|NCT02698150||Remote monitoring|Active group of patients undergoing daily remote monitoring using sensors and wearables
89096602|NCT02698150||Control|Control group of patients undergoing standard follow up wth no remote monitoring
89096603|NCT01112267|Experimental|Tramadol Hydrochloride (HCl)/acetaminophen|Participants will receive 1 tablet containing fixed dose of combination of tramadol hydrochloride (HCl) 75 milligram (mg) /acetaminophen Extended Release (ER) 650 mg orally once daily on Days 1 to 3, 1 tablet twice daily (tramadol HCl 150 mg/acetaminophen 1300 mg) on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
89096604|NCT01112267|Placebo Comparator|Placebo|Prticipants will receive 1 tablet matching placebo once daily orally on Days 1 to 3, 1 tablet twice daily on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
89096605|NCT04216030|Experimental|High iron Irish potato|Meal sequence B, IP High Fe
89096606|NCT04216030|Active Comparator|Regular Irish potato|Meal sequence A, OFSP control
89096607|NCT00616096|Experimental|1|
89096608|NCT00925587|Active Comparator|Q2W|Q2W administration of darbepoetin alfa.
89096609|NCT00925587|Active Comparator|QM|QM administration of darbepoetin alfa
89096610|NCT02698306|Experimental|Dexamethasone|Dexamethasone: Dexametasone 4mg tablet every 8/8hs for 3 days
89096611|NCT02698306|Active Comparator|Diclofenac Sodium|Diclofenac Sodium: Diclofenac Sodium 50 mg tablet every 8/8 hs for 3 days
89096612|NCT02698228|Sham Comparator|Standard of Care|Intravenous injection of 0.1mg/kg of morphine. Injection of 5cc of 0.9% normal saline into the subcutaneous tissue of the thigh.
89096613|NCT02698228|Active Comparator|Femoral nerve block|Intravenous injection of 0.1mg/kg of morphine. Injection of 20cc of 0.5% bupivacaine into the fascia iliaca space using standard anatomic landmarks.
89096614|NCT02698228|Active Comparator|Ultra-sound guided femoral nerve block|Intravenous injection of 0.1mg/kg of morphine.Injection of 20cc of 0.5% bupivacaine around their femoral nerve under direct ultrasound guidance
89096615|NCT02698072|Experimental|Exercise and dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).~6 dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using Hong's fast-in and fast-out technique with multiple rapid needle insertion."
89096616|NCT02698072|Active Comparator|Exercise and sham dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).~6 sham dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using a park sham device consists of a base with a hole in the centre and sticky tape on the bottom. From the top of the base extends a double tube, continuing the central hole in the base."
89096617|NCT00616174|Other|1|Active warming with Bair Hugger blanket
89096618|NCT02702128|Active Comparator|Tranexamic acid|1g of Tranexamic acid on 1hour and 1g of tranexamic acid on 8 hours
89096619|NCT02702128|Placebo Comparator|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
89096620|NCT05194683|Experimental|Letter Writing Arm|Relational letter writing intervention
89096621|NCT05194683|No Intervention|Control Arm|No intervention
89096622|NCT00610545|Active Comparator|1|Use Atorvastatin 80mg for 60 days , and the vascular surgery will be made between day-7 and day-60
89096623|NCT00610545|Active Comparator|2|Use Atorvastatin 20 mg for 60 days , and the vascular surgery will be made between day-7 and day-60
89096624|NCT00193414|Experimental|Intervention|Chemotherapy-naïve patients with unresectable stage III/IV NSCLC received pemetrexed 500 mg/m2 IV and gemcitabine 1500 mg/m2 IV every 2 weeks for 8-12 cycles with restaging every 4 cycles. Patients also received supplemental folate/B12 therapy.
89096625|NCT02701972|Experimental|Control and Test|Pre-implantation and Post-implantation of BACE device
89096626|NCT02701816||K-INNOVA|Patients with femoropopliteal artery disease undergoing endovascular therapy using Innova stent (Boston Scientific).
89096627|NCT04260711|Experimental|Discontinuation of DMT|Discontinuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
89096628|NCT04260711|No Intervention|Continuation of DMT|Continuation of first-line disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
89096629|NCT00615628||family members|family members of the proband and father identified
89096630|NCT00610623|Experimental|1|azithromycin iv 300 mg/day
89096631|NCT00610623|Placebo Comparator|2|Placebo
89096632|NCT02701660|Experimental|electronic medication dispenser|An Automatic Tablet Dispensing and Packaging System is used to repack all solid oral prescription medications for each participant into unit-of-dose pouches. Every participant receives a roll with pouches for 14-28 days loaded into a dispenser installed at their homes. The electronic medication dispenser is a remote controlled, electronic medication management aid reminding the patients with acoustic alerts to take their medication.
89096633|NCT04214782|No Intervention|Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images without the help of Artificial Intelligence (AI) algorithm
89096634|NCT04214782|Experimental|AI enabled Transvaginal Ultrasound diagnosis|radiologists interpretTransvaginal Ultrasound images with the help of Artificial Intelligence algorithm
89096635|NCT02697994|Experimental|Sterile Water Injection|Participants randomised to the intervention group received 4 intracutaneous injections of 0.1 ml sterile water into the skin surrounding the Michaelis rhomboid over the sacral area.
89096636|NCT02697994|Placebo Comparator|Dry Injection|Participants in the control group received 4 dry injections in the same region using an insulin needle .
89096637|NCT02697838|Experimental|Experimental: Apatinib plus chemotherapy|
89096638|NCT02697682|Experimental|Intervention|All patients are recieving the treatment.
89096639|NCT02697526|Other|Terumo|Patients in this arm will receive Terumo after catheterization
89096640|NCT02697526|Other|Tensoplast|Patients in this arm will receive Tensoplast after catheterization
89096641|NCT02690428|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
89096642|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea (HU)_1|50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
89096643|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea (HU)_2|50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
89096644|NCT02706106|Experimental|Knee brace with a hole|Patients will be prepared to receive the device of knee brace with a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
89096645|NCT02706106|Placebo Comparator|Knee brace without a hole|Patients will be prepared to receive the device of knee brace without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
89096646|NCT04956705|Experimental|The Model for Improvement|Together with the health care staff at the nursing homes, the project group will identify which strategies to implement in order to increase the number of residents receiving the recommended daily supplements of 20 µg of vitamin D and 800-1000 mg of calcium. The Model for Improvement will be the methodological framework for defining, implementing, and evaluating strategies.
89096647|NCT04260633|No Intervention|Group 1|22-hour tray wear time, DM assisted aligner change frequency
89096648|NCT04260633|Active Comparator|Group 2|22-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
89096649|NCT04260633|Sham Comparator|Group 3|22-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
89096650|NCT04260633|Active Comparator|Group 4|12-hour tray wear time, VPro+ (active), DM assisted aligner change frequency
89096651|NCT04260633|Sham Comparator|Group 5|12-hour tray wear time, VPro+ (inactive), DM assisted aligner change frequency
89096652|NCT02705950|Active Comparator|intrathecal baclofen bolus|In ITB bolus group: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. A 50 µg.
89096653|NCT02705950|Placebo Comparator|placebo|In the placebo group: 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
89096654|NCT04951323|Experimental|Injection of anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Injection of two doses (at Day 1 and Day 21) of the anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
89096655|NCT02705872|Experimental|Programmed intermittent boluses|Epidural analgesia performed with programmed intermittent boluses.
89096656|NCT02705872|Active Comparator|Continuous perfusion|Epidural analgesia performed with a continuous perfusion.
89096657|NCT04215016|Experimental|Humanized anti-CD19 and anti-CD20 dual specific CAR-T cells|
89096658|NCT02706028|Active Comparator|ultrasound group|Patients in the ultrasound group received underwater US therapy to both hands and wrists for 7 minutes with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
89096659|NCT02706028|Sham Comparator|control group|The control group received sham treatment (the ULTRON home OE-302® device was not turned on) during 10 sessions for 7 minutes per session.
89096660|NCT02701504||Sleep apnea group|The patients who are found to have sleep apnea based on the results of the portable sleep study
89096661|NCT02701504||Non sleep apnea group|The patients who are found to have no sleep apnea based on the results of the portable sleep study
89096662|NCT02701426|Experimental|participant|agree to participate to the program combining physical activity and nutritional counseling
89096663|NCT02701426|No Intervention|no participant|disagree to participate to the program
89096664|NCT00615706||1|Asthmatics
89096665|NCT00615706||2|Healthy volunteers (without asthma)
89096666|NCT02700880||Heart failure patients with LifeVest|Subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator
89096667|NCT00930813|Experimental|Lutonix Catheter|Paclitaxel coated Balloon Catheter
89096668|NCT00930813|Active Comparator|Standard uncoated Balloon Angioplasty Catheter|uncoated angioplasty balloon
89096669|NCT05324800|Experimental|Curcuma longa L. extract mixture group|2 times a day, 2 capsule for 1 time, after breakfast and dinner meal (1.6 g/day, Curcuma longa L. extract mixture 1 g/day)
89096670|NCT05324800|Placebo Comparator|placebo group|2 times a day, 2 capsule for 1 time, after breakfast and dinner meal (1.6 g/day, Curcuma longa L. extract mixture 0 g/day)
89096671|NCT04216108|Experimental|23G gauge needle vitrectomy surgery|
89096672|NCT04216108|Experimental|27G gauge needle vitrectomy surgery|
89096673|NCT04215796|Experimental|ReX-C intervention|Subjects use ReX-C to receive CFTR modulators medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
89096674|NCT02700958|Experimental|Remote ischemic preconditioning|Remote Ischemic Preconditioning (RIPC) is performed by inflating blood pressure cuff for 5-minutes at 200 mmHg, or if patients systolic blood pressure is higher than 200 mmHg 20 mmHg above systolic pressure, alternated with 5-minute deflation for 4 times.
89096675|NCT02700958|Sham Comparator|SHAM remote ischemic preconditioning|SHAM Remote Ischemic Preconditioning (RIPC-SHAM) is accomplished by alternating 4 cycles of 5-minute inflation with 5-minute deflation. Blood pressure cuff will be inflated to 10-20 mmHg. RIPC-SHAM is performed with standard blood pressure cuff on upper-arm.
89096676|NCT04250103||patient|patients who receive home health care
89096677|NCT04250103||caregiver|caregivers who take care of patients with home health care
89096678|NCT04215328|Experimental|Mixed-Meal|Ensure Nutrition Shake
89096679|NCT04215328|Placebo Comparator|Electrolyte Solution|Pedialyte Solution
89096680|NCT04258527|Experimental|Patients with advanced malignancies with FGF/FGFR alterations|
89096681|NCT00615238|Experimental|Diet plus continuous bouts|diet-plus-continuous bouts of vigorous aerobic exercise
89096682|NCT00615238|Experimental|Diet plus short bouts|diet-plus-short bouts of vigorous aerobic exercise accumulated throughout the day
89096683|NCT00615238|Experimental|Diet plus moderate lifestyle activity|diet-plus-moderate intensity lifestyle activity accumulated throughout the day
89096684|NCT04946799|Experimental|Low-intensity training combined with blood flow restriction group (LI-BFR)|
89096685|NCT04946799|Active Comparator|High-intensity aerobic exercise group (HI)|
89096686|NCT04946799|Placebo Comparator|Low intensity group (LI)|
89096687|NCT00610779|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
89096688|NCT00610779|Placebo Comparator|2|spray containing placebo.
89096689|NCT02700724|Other|Observation|Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.
89096690|NCT02700724|Other|Immediate Surgery|Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.
89096691|NCT04258371|Experimental|Dapagliflozin Treatment Arm|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
89096692|NCT04258371|Placebo Comparator|Placebo Arm|Placebo Matching Dapagliflozin Tablet for 12 weeks
89096693|NCT00609219|Experimental|EBV specific CTL|autologous EBV specific CTLs
89096694|NCT00930579|Experimental|Metformin|Women with newly diagnosed early invasive breast cancer will receive Metformin
89096695|NCT00609297||Supportive Care|Alive Hospice Patients with Pain
89096696|NCT04257981|Experimental|Experimental group|"Transcranial direct stimulation + virtual related group:~Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp Virtual reality (KVR) is the use of a computer interface involving upper limb activity in pediatric rehabilitation. VR creates an artificial environment, presented to the user through appropriate sensory stimulations."
89096697|NCT04257981|Sham Comparator|Control group|Sham Transcranial direct stimulation Group + virtual related group; The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies.
89096698|NCT04260555|Experimental|TEST|tid PO, DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml
89096699|NCT04260555|Active Comparator|Reference 1|tid PO, Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml
89096700|NCT04260555|Active Comparator|Reference 2|tid PO, Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml
89096701|NCT04260321||AI|Artificial intelligence colonoscopy
89096702|NCT04260321||Control|White light colonoscopy
89096703|NCT02700568|Experimental|axitinib|Patients will receive axitinib.
89096704|NCT00925353|Experimental|lidocaine gel|
89096705|NCT02700646|No Intervention|standard care|Standard care comparison
89096706|NCT02700646|Experimental|inpatient|Inpatient recommendations to parents regarding infant motor activities
89096707|NCT02700646|Experimental|inpatient/outpatient|Inpatient and outpatient recommendations to parents regarding infant motor activities
89096708|NCT02705560|Experimental|Cow´s milk (3.9% fat, pasteurized)|Cow´s milk (3.9% fat, pasteurized) Single dose, 600 ml milk
89096709|NCT02705560|Experimental|Hard, yellow cheese|"Hard, yellow cheese Single dose, 100 g cheese~+ 500 ml water"
89096710|NCT02705560|Active Comparator|Soy based drink|Soy based drink Single dose, 600 ml soy drink (soy drink + plant based cream)
89096711|NCT04203615|Active Comparator|PD patients with real rTMS|Patients will receive real rTMS in a two weeks long sessions (10 sessions).
89096712|NCT04203615|Sham Comparator|PD patients with sham rTMS|Patients will receive sham rTMS in a two weeks long sessions (10 sessions).
89096713|NCT02705482|Experimental|Arm A: MEDI0562 and durvalumab|MEDI0562 and durvalumab
89096714|NCT02705482|Experimental|Arm B: MEDI0562 and tremelimumab|MEDI0562 and tremelimumab
89096715|NCT00615316|Experimental|A|
89096716|NCT00615316|Placebo Comparator|B|
89096717|NCT04215172||macrolides group|"Every patient of this group will be educated and instructed about usage, dosing and side effects of the drug.~Dose: azithromycin 500 mg three times weekly for 6 months. added to the conventional treatment."
89096718|NCT04215172||conventional group|Every patient of this group will receive the conventional treatment.
89096719|NCT02700490|Active Comparator|Specialist|Assessment and treatment of common mental disorders by a clinical psychologist in primary care facilities.
89096720|NCT02700490|Experimental|Enhanced Usual Care|Assessment and treatment of common mental disorders by a general practitioner and nurse practitioner, who have been trained in the WHO mhGap manual, in primary care facilities.
89096721|NCT04260399|Experimental|Lavender Aromatherapy|Passive exposure via an ambient essential oil diffuser to lavender aromatherapy
89096722|NCT04260399|Placebo Comparator|Placebo Aromatherapy|Passive exposure via an ambient essential oil diffuser to saline water aromatherapy
89096723|NCT02705638|Experimental|Rituximab and Lenalidomide|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15, as well as Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
89096724|NCT04877223||CF|Patients with Cystic Fibrosis
89096725|NCT02705170||left ventricle dilatation|The subjects of the investigation will be patients with recent diagnosis of unknown left ventricle dilatation. These subjects received coronary artery angiography as exam suggested by guidelines to discriminate the cause of left ventricle dilatation. In subjects without documentation of coronary artery lesions, the Authors will assess the index of microvascular resistance.
89096726|NCT04260009|Experimental|Phase 1: Brigatinib|Brigatinib tablet or age-appropriate formulation (AAF), orally once daily in 28-day Cycles with reference to adult dose of 90 mg in Week 1 and 180 mg starting in Week 2 based on participant's weight as dose level 1. Participants could receive dose level 2 based on safety and tolerability of dose level 1 in dose escalation phase (Ph).
89096727|NCT04260009|Experimental|Ph 2:Brigatinib (Unresectable/Recurrent ALK+ IMT) Participants|Brigatinib recommended phase 2 dose (RP2D) determined during phase 1, tablet or AAF orally QD in participants with Unresectable/ Recurrent ALK+ IMT for up to 2 years in dose expansion phase.
89096728|NCT04260009|Experimental|Ph 2 :Brigatinib (Relapsed/Refractory ALK+ ALCL) Participants|Brigatinib RP2D determined during phase 1, tablet or AAF orally QD in participants with Relapsed/ Refractory ALK+ ALCL for up to 2 years in dose expansion phase.
89096729|NCT02705092|Experimental|Subliminal priming with subliminal reward stimuli|"This intervention consisted of five presentations [three cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal priming (displayed for 17 ms), and positive words as subliminal reward (displayed for 17 ms)].~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
89096730|NCT02705092|Experimental|Subliminal priming with supraliminal reward stimuli|"This intervention consisted of four presentations [two cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal prime (displayed for 17 ms), and positive words as supraliminal reward (displayed for 150 ms)].~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
89096731|NCT04257825|Other|Initial Off|Individuals were asked to not use their device on weeks 1 and 3 of the study. They were asked to use their device on weeks 2 and 4.
89096732|NCT04257825|Other|Initial On|Individuals were asked to not use their device on weeks 2 and 4 of the study. They were asked to use their device on weeks 1 and 3.
89096733|NCT02700256||Patients undergoing a procedure|Patients will be asked to complete a baseline survey after enrollment. After surgery, enrollees who opt for the email/online access will receive an email upon discharge with a link to the WebCore site. Email will be sent at 9 am on postoperative day (POD) 2 to the email address the patient provided at consent. On post-operative days 2 through 6 the patient will be asked to complete a symptom inventory, they will receive an email with a link to the WebCore website, where they will be able to complete that day's survey. Enrollees who opt for the automated phone calls will complete their surveys via Interactive Voice Response (IVR), which will be automatically set-up to call the patient at 9 am on POD 2. Patients will complete phone surveys daily for 5 days. If the first phone call does not connect to the patient, a second phone call will be made at 10:00am. If the second call is unsuccessful a third & final call for that day will be placed at 11:00am.
89096734|NCT02692066||Healthy Controls|Healthy Children ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) markers of humoral immunity at baseline and 4 weeks post vaccination and 2) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
89096735|NCT02692066||Children with Chronic Liver Disease|Children with chronic liver disease ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) varicella DNA in the blood and saliva at enrollment, 1 week, 2 weeks, 3 weeks, 4 weeks post vaccination 2)markers of humoral immunity at baseline and 4 weeks post vaccination and 3) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
89096736|NCT02691910|Active Comparator|CONCURRENT CHLOROQUINE+PRIMAQUINE|"The infected individuals were treated with the standard chloroquine (CQ)+primaquine(PQ) regimen to malaria caused by Plasmodium vivax.~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 0 of CQ treatment. Total dose, 3.5mg/kg The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
89096737|NCT02691910|Experimental|CHLOROQUINE|"The infected individuals were initially treated with chloroquine (CQ) alone and the primaquine(PQ) was introduced on day 28.~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 28 of CQ treatment. Total dose, 3.5mg/kg.~The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
89096738|NCT05028777||Patients diagnosed with left ventricular thrombus|All patients diagnosed with left ventricular thrombus through different imaging modalities (echocardiography, CT or MRI) and who have been diagnosed and/or treated at the Inselspital or another site of the Insel Gruppe.
89096739|NCT02705248||Group A|(Group A) case group: 40 pregnant females at 6- 13wks presenting with a history of recurrent pregnancy loss (two or more failed clinical pregnancies as documented by ultrasonography or histopathology examination according to the American Society of Reproductive Medicine) (ASRM, 2008).
89096740|NCT02705248||Group B|control group: 40 pregnant females at 6- 13wks with no history of abortion.
89096741|NCT04215250|Active Comparator|Andropulous method|"Andropulous method uses equations to determine the depth of CVC insertion.~For subject with <100 cm in height:~Depth of CVC insertion (cm) = (height (cm)/ 10)-1~For subject with >100 cm in height:~Depth of CVC insertion (cm) = (height (cm)/ 10)-2"
89096742|NCT04215250|Active Comparator|ECG method|change in p wave from ECG
89096743|NCT02705326|Experimental|Opti-Speech|Speech treatment will be guided by Opti-Speech's visual feedback of tongue movement during speech
89096744|NCT02700802|Experimental|Feed1st: Face-to-face provider delivered referral|In this arm of the study, caregivers will receive usual care and a brief face-to-face referral to the Feed1st program delivered by the provider.
89096745|NCT02700802|Experimental|Feed1st: Text message delivered referral|In this arm of the study, caregivers will receive usual care and an automated brief text message referral to the Feed1st program from the health care provider. The text message referral will align as closely as possible with the face-to-face referral.
89096746|NCT02700802|No Intervention|Standard of Care|Usual care includes passive delivery of information from nursing staff about all available food options in the hospital including the self-serve food pantries in the standard Caregiver FYI Admissions Packet.
89096747|NCT02705014|Experimental|treatment group|patients were administered with pulsatile gonadotropin-releasing hormone (GnRH )therapy for 12 months at an interval of 90 minutes.The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L.
89096748|NCT02700178|Experimental|Biofeedback|Participants will be asked to participate in all or a subset of daily activities for wheelchair users. The intervention will consist of visual and/or auditory cues to guide their movement while performing the tasks during one to two sessions.
89096749|NCT02704624|Active Comparator|Vitamin D|Tablets with 50000UI cholecalciferol (vitamin D3) will be administered, weekly, for six months.
89096750|NCT02704624|Placebo Comparator|Placebo|The patients selected to the placebo group will receive inert content tablets without therapeutic effect, weekly, for six months.
89096751|NCT02701114|Active Comparator|Proximal|Proximal Adductor Canal Block
89096752|NCT02701114|Active Comparator|Distal|Distal Adductor Canal Block
89096753|NCT02700100|Experimental|Pulmonary Valved Conduit (PV-001)|Bioabsorbable Pulmonary Valved Conduit (PV-001) implantation through open surgery.
89096754|NCT02701036||sporadic adult onset ataxia|SAOA denotes the non-hereditary degenerative adult-onset ataxia disorders that are distinct from multiple system atrophy (MSA). SAOA is a group of ataxia of unknown etiology characterized by a slowly progressive cerebellar syndrome starting around the age of 50 years. Possibly is accompanied by signs of mild autonomic dysfunction that do not meet the criteria of severe autonomic failure required for a diagnosis of MSA.
89096755|NCT02701036||cerebellar multiple system atrophy|Multiple system atrophy of cerebellar type is a cerebellar syndrome with sporadic onset developing in midlife, with autonomic features of otherwise unexplained bladder dysfunction with or without erectile dysfunction in males, orthostatic hypotension and atrophy of the cerebellum, brainstem, and middle cerebellar peduncles.
89096756|NCT04213846|Experimental|Mobile Alcohol Expectancy Challenge (mAEC)|Participants randomized to the mAEC condition will receive twice daily intervention messages for three weeks and have access to other psycho-educational alcohol information.
89096757|NCT04213846|No Intervention|Assessment-only Control|Participants randomized to the control group will not receive any intervention. They will be an assessment-only control group.
89096758|NCT02700022|Experimental|Alisertib combined with R-EPOCH|Dose escalation will take place within cohorts. Subjects will receive alisertib tablets twice daily in combination with R-EPOCH chemotherapy on days 1 through 5 of each 21-day cycle. The treatment will be given in 6 cycles. The first 3 patients to be enrolled will receive a 20 milligram (mg) dose of alisertib. The dose of alisertib will be increased or decreased as more subjects enter the study. Each dose level will be evaluated for safety and tolerability before the next higher dose is given. The dose levels will be modified until the maximum tolerated dose (MTD) is reached. Once the MTD has been established, enrollment into that cohort will continue with up to a maximum of 24 patients total enrolled into the study.
89096759|NCT02699944|Experimental|CRT sub-optimal responder|Subjects who have had CRT for at least 6 months and who have not responded as well as they could, in their cardiologists opinion. Subjects' ejection fraction are still <50% despite CRT. A ECG Vest Optimization protocol will be utilized as one aspect to determine the best CRT programming for each individual subject.
89096760|NCT02699788|Experimental|Multifunction Cardiogram|non-invasive computerized, multiphase, resting electrocardiogram analysis device
89096761|NCT02699710|Experimental|Part 1: GDC-0853, Rabeprazole (Fasting State)|Participants will receive single dose of GDC-0853 (200 milligrams [mg]) in a crossover design as either the capsule or tablet formulation in the fasted state with the final fixed treatment consisting of the tablet formulation administered in the fasted state after prior administration of rabeprazole (20 mg twice daily [BID]) for 3 days.
89096762|NCT02699710|Experimental|Part 2: GDC-0853, Rabeprazole (Fasting or Fed State)|Participants will receive single dose of GDC-0853 (200 mg) tablet formulation in the fasted or fed state in a crossover design with the final fixed treatment consisting of the tablet formulation administered in the fed state after prior administration of rabeprazole (20 mg BID) for 3 days.
89096763|NCT02699710|Experimental|Part 3: GDC-0853, Methotrexate|Participants will receive single dose of methotrexate (7.5 mg) under fasting conditions on Day 1 (5 mg folic acid will be administered the following day [Day 2]) and then GDC-0853 (200 mg) tablet formulation twice daily (BID) under fasting conditions (an overnight fast for the morning dose and a 2 hour fast for the evening dose) from Days 15 to 20 after washout period from Days 2 to 14. On Day 21, participants will receive single dose of methotrexate (7.5 mg) with single dose of GDC-0853 (200 mg) tablet formulation under fasting conditions, and folic acid (5 mg) will be administered on Day 22.
89096764|NCT00618670|Experimental|1|Home-based program with progressive increases in exercise duration and intensity (i.e., cadence); walking duration will be longer for the home-based group because the intensity of walking will be lower than the graded treadmill walking performed by the supervised group
89096765|NCT00618670|Experimental|2|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes, and progressive increments in exercise intensity from 50 to 70% of exercise capacity
89096766|NCT00618670|Active Comparator|3|Light resistance training without any walking exercise
89096767|NCT05119348|Experimental|Stop coronavirus (STOPCOV)|A fieldworker will deliver the STOPCOV pack and personal protective equipment at baseline. The fieldworker will communicate with intervention households daily, delivering STOPCOV hygiene information.
89096768|NCT05119348|No Intervention|Control|Participants received no additional messaging about managing COVID19 in the household.
89096769|NCT00618904|Experimental|1|Probiotic containing Lactobacillus and Bifidobacterium
89096770|NCT00618904|Placebo Comparator|2|Placebo
89096771|NCT05324722|Experimental|PPCS|Novel intervention
89096772|NCT05324722|Active Comparator|CBS|Cross arm stretch gave to individuals
89096773|NCT05324644|Experimental|Interventional group|32 randomly selected first-year students in the university, who voluntarily agreed to be recruited into the study and smoke and are considering quitting.
89096774|NCT05324644|No Intervention|Control group|32 randomly selected first-year students in the university, who voluntarily agreed to be recruited into the study and smoke and are considering quitting.
89096775|NCT04214704|Experimental|Genteel arm|In the Genteel arm, the subjects exclusively use the Genteel device for the first 12 weeks, and then switch to the conventional method of SMBG for an additional 12 weeks. This arm will use Butterfly Touch Lancets (BTL) throughout the study.
89096776|NCT04214704|Active Comparator|Conventional arm|In the Conventional arm, the subjects use the conventional method of SMBG for the first 12 weeks and then switch to the Genteel device for an additional 12 weeks. This arm will use the lancet and lancing device which they were using prior to randomization to the study.
89096777|NCT03140488|Active Comparator|Lean-Control|"1) Control group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
89096778|NCT03140488|Experimental|Lean-Intervention|"2) Intervention group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
89096779|NCT03140488|Active Comparator|Obese-Control|"3) Control group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
89096780|NCT03140488|Experimental|Obese-Intervention|"4) Intervention group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
89096781|NCT00616408||A|Newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment with LAR
89096782|NCT03093610|Active Comparator|Traditional|The chest tube in the traditional Group will be managed according to the current Guidelines of the investigators' department.
89096783|NCT03093610|Active Comparator|Test group|"The chest tube in the Test Group will constitute the experimental Group. The chest tube will be removed when the fluid production over 24h has reached a weight related threshold."
89096784|NCT05323942|Other|Education and Exercise Therapy Group|Children and their parents were trained about bruxism, parafunctional oral habits, and sleep hygiene education. Therapeutic exercises about head-neck posture, breathing, and relaxation were given for 8 weeks.
89096785|NCT03088150|Active Comparator|Surgical resection|Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.
89227080|NCT00485589|Placebo Comparator|Placebo|Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
89227081|NCT00485589|Experimental|Ocrelizumab 200 mg|Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
89227082|NCT00485589|Experimental|Ocrelizumab 500 mg|Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
89227083|NCT01014273|Active Comparator|Trans-femoral access|Femoral artery PCI access site
89227084|NCT01014273|Active Comparator|Trans-radial access|Radial artery PCI access site
89227085|NCT01018797|Experimental|INTRASTROMAL CORNEAL RING SEGMENT|Eighteen eyes of 18 patients, 8 men and 10 women, with high levels (> 5 diopters [D]) of postkeratoplasty astigmatism were studied in a nonrandomized, retrospective, observational case series. PK was performed to treat keratoconus in 15 patients, corneal scar after trauma in 2 patients, and Fuchs endothelial dystrophy in 1 patient.
89227086|NCT01015599|Experimental|HOP'N After-School Program|After-school program with daily physical activity following CATCH guidelines, daily fruit/vegetable snack, and weekly nutrition and physical activity education based on social cognitive theory.
89227087|NCT00490971|Experimental|Paliperidone ER|
89227088|NCT00490971|Placebo Comparator|Placebo|
89227089|NCT00490971|Active Comparator|Olanzapine|
89227090|NCT00686075|Experimental|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
89227091|NCT00686075|Placebo Comparator|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
89227092|NCT00686075|Experimental|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
89227093|NCT00686075|Placebo Comparator|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
89227094|NCT00686075|Experimental|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
89227095|NCT00686075|Placebo Comparator|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
89227096|NCT00686075|Experimental|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
89227097|NCT00686075|Placebo Comparator|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
89227098|NCT00686075|Experimental|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
89227099|NCT00686075|Placebo Comparator|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
89227100|NCT02562677|Experimental|ACTIVE tNS|TNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally. The study protocol will follow the rational of our previous trials with TNS.
89227101|NCT02563613|Experimental|Physical Exercise (PE)|Physical exercise will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will comprise of a core intervention session on physical exercise, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on healthy diet. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
89227102|NCT02563613|Experimental|Healthy Diet (HD)|Healthy diet will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will include a core intervention session on healthy diet, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on physical exercise. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
89227103|NCT02563613|Placebo Comparator|Wait-list Control (C)|The control group will consist of a tea gathering session at the beginning and 1 month later, followed by a follow-up session at 3 months on physical exercise or healthy diet. The tea gathering sessions will cover topics unrelated to the intervention, such as arts and crafts workshops. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
89227104|NCT00750425|Experimental|1|Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone
89227105|NCT02563457|Experimental|case|diabetic patients who will receive periodontal treatment blood sampling
89227106|NCT02563457|Experimental|control|diabetic patients without periodontal treatment (no periodontal treatment) blood sampling
89227107|NCT00745589|Active Comparator|higher dose sevelamer|first-line higher dose sevelamer hydrochloride
89227108|NCT00745589|Active Comparator|low dose sevelamer|second-line fixed low-dose sevelamer hydrochloride added to calcium carbonate
89227109|NCT00750581|Placebo Comparator|Standard dose group|The infants randomized to the standard dose group will receive indomethacin (0.1 mg/kg) at 24 hr intervals for 5 days. These infants will also receive 5 extra doses of normal saline infusion of similar volume at 12 hrly intervals between the indomethacin schedules to match the Escalating dose Indomethacin Schedule
89227110|NCT00750581|Active Comparator|Escalating dose group|The infants randomized to the Escalating dose group will receive indomethacin started at 0.2 mg/kg/dose every 12 hours for 2 doses with stepwise increment in indomethacin dose by 0.1 mg/kg/dose every 24 hours upto maximum dose of 0.6 mg/kg/dose
89227111|NCT00685763|Experimental|Proton radiation and chemotherapy|"Chemotherapy and Radiation Combination~Proton radiation 59.4 cobalt gray equivalent(CGE) in 33 fx at 1.8 CGE per fx over 7 weeks.~Capecitabine (Xeloda ®) 1,000 mg by mouth approximately every 12 hrs, 5 days/week starting the first day of radiation until the end of radiation, but on radiation days only.~Consolidation Chemotherapy starting 4 weeks after the completion of radiation~Gemcitabine (Gemzar ®) Suggested Regimen - 1,000mg/m2 by IV over 30 minutes once a week for 3 weeks (followed by a week of rest) for 12 total doses."
89227112|NCT00745667|Active Comparator|1|laparoscopic
89227113|NCT00745667|Active Comparator|2|open correction
89227114|NCT00745745|Active Comparator|1|Apical ICD lead placement
89227115|NCT00745745|Experimental|2|Mid-Septal ICD lead placement
89227116|NCT00750659|Experimental|1|Nilotinib treatment
89227117|NCT02561663|Experimental|NWT-03, followed by placebo|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
89227118|NCT02561663|Experimental|Placebo, followed by NWT-03|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
89227119|NCT00098293|Experimental|1|
89227120|NCT00098293|Active Comparator|3|
89227121|NCT00098293|Experimental|2|Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
89227122|NCT04056065|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
89096786|NCT03088150|Experimental|Thermal ablation|Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.
89096787|NCT02691754|Experimental|free paracetamol|the General Practitioners can prescribe paracetamol for free (covered by NHS). Patients can receive monthly dose at the local hospital
89096788|NCT02691754|No Intervention|standard drug prescription|"Paracetamol is not included in the list of drugs than can be prescribed in charge of National Health System by General Practitioners.~The General Practitioners can prescribe other drugs or recommend paracetamol payed by the patient (out of pocket) at the chemistry."
89096789|NCT02691676|Experimental|Plasmalyte|Arm 1: Plasmalyte in 5% glucose infusion solution (PL), manufactured by Baxter Healthcare as slightly alkalizing (Na+ 140; K+ 5.0; Mg2+ 1.5; Cl- 98; acetate 27; gluconate 23)
89096790|NCT02691676|Active Comparator|Ringerfundin|Arm 2: Ringerfundin infusion solution (RF), manufactured by B. Braun as acid-base neutral (Na+ 145; K+ 4.0; Mg2+ 1.0; Ca2+ 2.5; Cl- 127; acetate 24; malate 5.0).
89096791|NCT00616486|Experimental|1|
89096792|NCT00616486|Placebo Comparator|2|
89096793|NCT05318872||ENT cancers|patients with ENT cancer in the active care line for who a surgical resection is planned.
89096794|NCT01106651|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
89096795|NCT01106651|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
89096796|NCT01106651|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
89096797|NCT00637078|Active Comparator|1|Drug: Fix dose combination therapy
89096798|NCT00637078|No Intervention|2|Guidelines based management
89096799|NCT05323162|Experimental|Encapsulated autologous fecal microbiota transplantation|Encapsulated own microbiota to be transplanted from large- to small intestine by oral ingestion
89096800|NCT05323006|Active Comparator|scapular stabilization exercises|the effect of the scapular stabilization exercises on clavicular movement
89096801|NCT05323006|No Intervention|no intervention|no intervention
89096802|NCT04214470||Irritable Bowel Syndrome Patients|Patients with IBS.
89096803|NCT04214314||Control|The control group will continue to receive the integral rehabilitation provided by the center.
89096804|NCT04214314||Experimental|The participants of the experimental group, in addition to the integral rehabilitation of the center will receive the training of the attention through NeuronUp APT. There will be 3 rehabilitation sessions of one hour a week for about a month and a half or two.
89096805|NCT05003609|Active Comparator|Intervention Group|ECMO early rehabilitation is led by a senior physiotherapist who has specialised training in ECMO care and coordinates individualised early physical training from randomisation to day 28 in ICU and liaises with the patient through to hospital discharge. The early rehabilitation intervention involves physical activity, functional retraining, strengthening exercises and mobilisation based on a reproducible, physiological approach.
89096806|NCT05003609|No Intervention|Control Group|The control group will receive standard care from nursing and physiotherapy staff not involved in the early, co-ordinated rehabilitation.
89096807|NCT00625781|Experimental|B2|IGT randomized to treatment
89096808|NCT00625781|No Intervention|B1|"IGT randomized to no treatment"
89096809|NCT02867644|Active Comparator|standard care|
89096810|NCT02867644|Experimental|standard care+conversational hypnosis|
89096811|NCT02880449|Experimental|Intervention|The intervention will be conducted in pre-existing older women's groups based in community centres. The intervention will consist of three educational sessions, encouragement to enlist the support of a partner or 'buddy' (e.g. a spouse, partner or friend), an information pack (containing information on the local area, walking routes, points of interest) and the option of weekly telephone contact. Participants will be given the opportunity to discuss their progress and share feedback with the rest of the group at weekly meetings.
89096812|NCT02880449|No Intervention|Control|Due to the stepped wedge design of the study, one group in each centre will not receive the intervention procedure detailed above until week seven. The control groups shall be given information about the study at baseline and informed that they will receive the intervention 6 weeks later.
89096813|NCT01027650|Experimental|Stage 1 Cohort 1|AGN208397 intravitreal injection 75 ug on Day 1.
89096814|NCT01027650|Experimental|Stage 1 Cohort 2|AGN208397 intravitreal injection 300 ug on Day 1.
89096815|NCT01027650|Experimental|Stage 1 Cohort 3|AGN208397 intravitreal injection 600 ug on Day 1.
89096816|NCT01027650|Experimental|Stage 1 Cohort 4|AGN208397 intravitreal injection 900 ug on Day 1.
89096817|NCT01027650|Experimental|Stage 2 Arm 1|AGN208397 intravitreal injection 600 ug on Day 1.
89096818|NCT01027650|Experimental|Stage 2 Arm 2|AGN208397 intravitreal injection 450 ug on Day 1.
89096819|NCT01027650|Experimental|Stage 2 Arm 3|AGN208397 intravitreal injection 300 ug on Day 1.
89096820|NCT01027650|Active Comparator|Stage 2 Arm 4|Dexamethasone 700 ug intravitreal implant on Day 1.
89096821|NCT02880527||patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis will be used:~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~general practitioners~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
89096822|NCT05322772||children with epilepsy|epilepsy diagnosed clinically EEG
89096823|NCT05322772||children with febrile convulsions|the child has high grade fever from 6 month to 6 years not recurrent duration less than 15 minute or atypical febrile convulsions
89096824|NCT05322772||children with cns infection|"the child has fever, neck, rigidity DCL~+or- CSF analysis"
89096825|NCT05322772||children with electrolyte imbalance, hypoglycemia|abnormal values of electrolyte hypoglycemia
89096826|NCT05322772||children with poisoning|history of ingestion or inhalation of toxic substance
89096827|NCT05322772||children with encephalopathy|the child complains of brain disease or mal function with altered mental status as a complication of primary illness as kidney failure ,cirrhosis, etc.
89096828|NCT05322772||children with trauma|history of trauma imaging study done
89096829|NCT05322772||children with genetic cause|the child has congenital anomaly as chromosomal abnormality, metabolic disease, mitochondrial disease
89096830|NCT05322772||others|children not fulfilling the previous groups
89096831|NCT05000567|No Intervention|Control Group|No intervention.
89096832|NCT05000567|Experimental|Experimental Older group|12 week strength training program: Nordic Hamstring Exercise
89096833|NCT05000567|Experimental|Experimental Younger group|12 week strength training program: Nordic Hamstring Exercise
89096834|NCT04214548||Eczema|Patients diagnosed with eczema
89096835|NCT04309331|Experimental|PKU Motion|amino acid based protein substitute
89096836|NCT00616876|Experimental|1|Study group will receive 1% lactulose in all their feeds (human milk or preterm formula)
89227123|NCT04056065|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
89227124|NCT04055285|Experimental|Sympathetic Renal Denervation|Sympathetic Renal Denervation
89227125|NCT04055285|Active Comparator|Conventional treatment with drug therapy|Conventional drug therapy of resistant hypertension
89227126|NCT00685685|Experimental|Lovastatin 40 mg tablet|A single dose of Lovastatin 40 mg administered after an overnight fast of at least 10 hours.
89227127|NCT00685685|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered after an overnight fast of at least 10 hours.
89227128|NCT01087567|Experimental|Intensive insulin regimen|A weight based, basal bolus will be given for 12 weeks.
89227129|NCT01087567|Active Comparator|Routine Care|Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
89227130|NCT00684671|Experimental|Twinrix Group|Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
89227131|NCT00684671|Active Comparator|Engerix + Havrix Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
89227132|NCT00684671|Active Comparator|HB VAX PRO + Vaqta Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).
89227133|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.2 mg/kg|Participants will receive single subcutaneous (SC) injection of 0.2 mg/kg SHP681 in the abdomen.
89227134|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.5 mg/kg|Participants will receive single SC injection of 0.5 mg/kg SHP681 in the abdomen.
89227135|NCT03859323|Experimental|Single Ascending Dose (SAD): 1 mg/kg|Participants will receive single SC injection of 1 mg/kg SHP681 in the abdomen.
89227136|NCT03859323|Experimental|Single Ascending Dose (SAD): 2 mg/kg|Participants will receive single SC injection of 2 mg/kg SHP681 in the abdomen.
89227137|NCT03859323|Experimental|Single Ascending Dose (SAD): 4 mg/kg|Participants will receive single SC injection of 4 mg/kg SHP681 in the abdomen.
89227138|NCT03859323|Placebo Comparator|Single Ascending Dose (SAD): Placebo|Participants will receive single SC injection of placebo matched to SHP681 in the abdomen.
89227139|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.2 mg/kg|Participants will receive SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
89227140|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.5 mg/kg|Participants will receive SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
89227141|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 1 mg/kg|Participants will receive SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
89227142|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 2 mg/kg|Participants will receive SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
89227143|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 4 mg/kg|Participants will receive SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
89227144|NCT03859323|Placebo Comparator|Multiple Ascending Dose (MAD): Placebo|Participants will receive SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen.
89227145|NCT00750971|Experimental|1|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
89227146|NCT00750971|Active Comparator|2|Best currently available immunosuppressive/immunomodulatory therapy
89227147|NCT00751049|Experimental|PhXA41|
89227148|NCT00751049|Active Comparator|timolol|
89227149|NCT00751985|Experimental|1|Personalized normative feedback (PFI). The PFI was a single-session intervention; it was displayed in a single screenshot and addressed the participant by name. It consisted of a summary of the participant's weekly consumption, a comparison with maximum drinking limits and a graphical comparison of the participant's consumption to the average level in the municipality (gender-specific), followed by information about health and social risks of heavy drinking as well as links for further self-help material and a local alcohol treatment facility.
89227150|NCT00751985|Experimental|2|Self-help material (SHM). The SHM was a single-session intervention and was displayed in a single screenshot. It consisted of information about maximum drinking limits, followed by information about health and social risks of heavy drinking as well as links for further standardized self-help material and a local alcohol treatment facility.
89227151|NCT00751985|Placebo Comparator|3|Control
89227152|NCT03857841|Experimental|20 pmol phospholipid/kg body weight|UNEX-42 administered at 20 pmol phospholipid/kg body weight
89227153|NCT03857841|Experimental|60 pmol phospholipid/kg body weight|UNEX-42 administered at 60 pmol phospholipid/kg body weight
89227154|NCT03857841|Experimental|200 pmol phospholipid/kg body weight|UNEX-42 administered at 200 pmol phospholipid/kg body weight
89227155|NCT03857841|Placebo Comparator|Placebo|Phosphate-buffered saline
89227156|NCT01014429|Experimental|1|
89227157|NCT00500331|Experimental|Arm 1|GSK189075
89227158|NCT00500331|Placebo Comparator|Arm 2|Placebo
89227159|NCT00500331|Other|Arm 3|pioglitazone (active control)
89227160|NCT01015755|Experimental|thirst intervention|
89227161|NCT01019109||Titanium rod|Titanium rods used as a part of PSF construct
89227162|NCT01019109||CoCr Rod|Cobalt Chrome rods used as a part of PSF construct
89227163|NCT00499863|Experimental|Methylphenidate Transdermal System|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
89227164|NCT00499863|Placebo Comparator|2|Daily application of matching MTS Placebo Patch
89227165|NCT04475835|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during PCI
89227166|NCT04475835|Active Comparator|Heparin|Heparin 100U/kg
89227167|NCT01014507|Active Comparator|A|
89227168|NCT01014507|Experimental|B|
89227169|NCT00484185||1|
89227170|NCT00097981|Active Comparator|Thalidomide + dexamethasone|
89227171|NCT00097981|Experimental|Thalidomide + dexamethasone + DOXIL|
89227172|NCT01015911|Experimental|1|SGN-75
89227173|NCT03997149|Experimental|Stress Condition|The stress condition involved the Trier Social Stress Test (TSST), a standardized laboratory stressor designed to elicit psychological stress and cortisol responses. Following the TSST, participants were brought to a separate room, instructed to rest and given the option to eat at their leisure. Books and magazines were included in the room for the participant to utilize.
89227174|NCT03997149|Placebo Comparator|Rest Condition|Participants completed a control condition on a separate day. This condition followed the same sequence of events as the stress condition with the exception that the 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
89227175|NCT01016145|Active Comparator|First generation antipsychotic|Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.
89227176|NCT01016145|Experimental|Second generation antipsychotics|Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone
89227177|NCT03741283|Experimental|Optimisation of nutrition and medication|"N=approx.~65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition."
89227178|NCT03741283|No Intervention|Standard care|N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.
89227179|NCT01016223|Active Comparator|Beclomethasone dipropionate inhaler|
89227180|NCT01016223|Placebo Comparator|Matched inhaler|
89227181|NCT01087645|Experimental|Trial part 1|
89227182|NCT01087645|Experimental|Trial part 2|
89227183|NCT04151121|Experimental|Intervention|The participants will receive MBCT (Mindfulness-Based Cognitive Therapy) as 2-hourly sessions over 8-weeks including a 6-hour session at the end of 6th week. The MBCT will be adapted for chest pain.
89227184|NCT04151121|No Intervention|Control group|These participants will continue to receive any treatment (or no treatment) by their primary care physicians.
89227185|NCT04151017|Experimental|Autologous fibrin glue|
89227186|NCT04151017|Active Comparator|Sutures|
89227187|NCT01019265|Experimental|Norspan patch (Buprenorphine TDS)|
89227188|NCT01019265|Active Comparator|TramadolSR tab (Tridol SR tab)|
89227189|NCT03963661|Experimental|c-SIGHT|SIGHT requires participants to grasp and lift rods with their less impaired arm.
89227190|NCT01087879|Active Comparator|Oral contraceptive pill|9 weeks treatment with contraceptive pill.
89227191|NCT01087879|Active Comparator|Contraception vaginal ring|9 weeks treatment with vaginal ring.
89227192|NCT01087879|Active Comparator|Transdermal contraceptive patch|9 weeks treatment with a transdermal contraceptive patch.
89227193|NCT01019421|Experimental|Lu AE58054|
89227194|NCT01019421|Placebo Comparator|Placebo|
89227195|NCT01085695|Experimental|1|
89227196|NCT01085695|Experimental|2|
89227197|NCT01085695|Experimental|3|
89227198|NCT01085695|Active Comparator|4|
89227199|NCT00572195|Experimental|Evaluation Group (stimulation ON)|Group of subjects that have an RNS® System implanted, completed the RNS® System Pivotal or Feasibility study, and elected to continue to receive RNS® System responsive stimulation for the long term.
89227200|NCT01088035|Experimental|Carboplatin|
89227201|NCT03961477|Active Comparator|IF group|Interferential therpapy
89227202|NCT03961477|No Intervention|Placebo|No intervention
89227203|NCT01085851|Experimental|Dexchlorpheniramine 1% lotion|
89227204|NCT01085851|Active Comparator|Dexchlorpheniramine 1% cream|
89227205|NCT00751127|Active Comparator|Timolol|
89227206|NCT00751127|Experimental|PhXA41|
89227207|NCT00751205|Experimental|Arm 1|
89227208|NCT00751205|Placebo Comparator|Arm 2|
89227209|NCT00572039|Experimental|PST|Problem Solving Treatment (PST)
89227210|NCT00572039|Placebo Comparator|ST|Supportive Therapy (ST)
89227211|NCT00751283|Experimental|1|GRST Peripheral Catheter System
89227212|NCT00752063|Experimental|A|All subjects will receive Sorafenib with Capecitabine and Oxaliplatin
89227213|NCT00751361|Active Comparator|1|Treatment group: Patients receive 10 Rheopheresis treatments within 17 weeks
89227214|NCT00751361|No Intervention|2|No treatment control group
89227215|NCT00684593|Experimental|Navarixin|Navarixin 30 mg administered orally once daily for 28 days.
89227216|NCT00684593|Placebo Comparator|Placebo|Matching placebo to Navarixin administered orally once daily for 28 days.
89227217|NCT00752141|Experimental|1|oral oxybutynin
89227218|NCT00752141|Experimental|2|oxybutynin topical gel
89227219|NCT00752141|Placebo Comparator|3|placebo tablets plus placebo gel
89227220|NCT00752375|Active Comparator|A|Eligible children will be randomized to antibiotic prophylaxis. Children under 3 months will receive amoxicillin 10mg/kg once per day. Children >3months will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component). Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day.
89227221|NCT00752375|Placebo Comparator|B|Eligible children will then be randomized to placebo.
89227222|NCT00751517|Active Comparator|A|Cyclophosphamide
89227223|NCT00751517|Experimental|B|Methotrexate
89227224|NCT00751595|Experimental|ARM A (Tat Protein 7.5 or 30 microg 5X)|Group I: Subjects receiving 5 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 5 intradermal immunization with Tat (30 microg).
89227225|NCT00751595|Experimental|ARM B (Tat Protein 7.5 or 30 microg, 3X)|Group I: Subjects receiving 3 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 3 intradermal immunization with Tat (30 microg)
89227226|NCT00751673||TESS prosthesis|Consecutive series of patients with a TESS prosthesis.
89096837|NCT00616876|Placebo Comparator|2|Control group will receive 1% dextrose placebo in all their feeds (human milk or preterm formula).
89096838|NCT01106027|Experimental|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery. Patients will be given 900 mg of eculizumab on Day 1 post-transplant. Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant.~At week 4, patients will be assessed for donor specific anti-donor human leukocyte antigen (HLA) antibody (DSA). Patients with total DSA normalized values <5000 will stop eculizumab treatment. Patients with total DSA normalized values >5000 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly."
89096839|NCT00616954|Experimental|1|with ATG-F
89096840|NCT00616954|No Intervention|2|control
89096841|NCT00927927|Experimental|SD 0.0002 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0002 mg/kg
89096842|NCT00927927|Experimental|SD 0.0012 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0012 mg/kg
89096843|NCT00927927|Experimental|SD 0.007 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.007 mg/kg
89096844|NCT00927927|Experimental|SD 0.035 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.035 mg/kg
89096845|NCT00927927|Experimental|SD 0.175 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.175 mg/kg
89096846|NCT00927927|Experimental|SD 0.7 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.7 mg/kg
89096847|NCT00927927|Experimental|SD 2.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 2.5 mg/kg
89096848|NCT00927927|Experimental|SD 7.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 7.5 mg/kg
89096849|NCT00927927|Experimental|SD Placebo|Subjects were injected once with placebo
89096850|NCT00927927|Experimental|MD 0.02 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg
89096851|NCT00927927|Experimental|MD 0.3 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg
89096852|NCT00927927|Experimental|MD 1.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg
89096853|NCT00927927|Experimental|MD 1.6 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg
89096854|NCT00927927|Experimental|MD 4.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg
89096855|NCT00927927|Experimental|MD Placebo|Subjects were injected biweekly four times with placebo
89096856|NCT04257513||Healthy controls subjects|Subjects without known family history of HD, or tested negative for the HD expansion mutation.
89096857|NCT04257513||Symptomatic HD subjects|Subjects HD gene expansion carriers who have clinical diagnostic motor symptoms of defined HD, and disease stage I to III.
89096858|NCT04257513||Presymptomatic HD subjects:|Subjects HD gene expansion carriers who not have clinical diagnostic motor features of HD.
89096859|NCT01027416|No Intervention|No Intervention|
89096860|NCT01027416|Active Comparator|Tamoxifen|Tamoxifen 20 mg orally 1x/day for 4 weeks
89096861|NCT04259931||No relapses|Patients with clostridium difficile infections without relapses
89096862|NCT04259931||Relapsing patiens|Patients with clostridium difficile infections with relapses
89096863|NCT04300842||Cancer patient|This project expects to enroll 60 cancer patients and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
89096864|NCT04300842||Healthy population|This project expects to enroll 60 healthy population and their subjective-objective measurements on fatigue, stress, and total steps will be observed.
89096865|NCT05331495|Experimental|Hemoperfusion and CPB and DHCA surgery|The experimental group was treated with hemoperfusion simultaneously with CPB and DHCA.
89096866|NCT05331495|No Intervention|traditional CPB and DHCA surgery|The control group was treated with intraoperative CPB and DHCA surgery.
89096867|NCT02873520|Experimental|Precision Cells combined with Chemotherapy treatment:|Precision cells combined with Chemotherapy treatment: Chemotherapy: once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
89096868|NCT02873520|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
89096869|NCT00923559|Experimental|Mother-Infant Psychoanalytic treatment;MIP|MIP intervention
89096870|NCT00923559|Active Comparator|TAU at Child Health Centres|Regular nurse visits at Child Health Centres according to Swedish infant health care.
89096871|NCT01015638|Experimental|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
89096872|NCT01015638|Active Comparator|Clindamycin phosphate and BPO 2.5% gel|Once Daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel.
89096873|NCT04257591|Experimental|hamstring strengthening|8-week protocol (3 days per week) based on isometric, concentric and excentric exercisesof hamstrings
89096874|NCT04257591|No Intervention|Control|No intervention added to regular training.
89096875|NCT01022502|Active Comparator|refined indigo naturalis ointment|Refined indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
89096876|NCT01022502|Active Comparator|crude indigo naturalis ointment|Crude indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
89096877|NCT04907877|Experimental|Probiotic|NordBiotic ImmunoVir, a mixute of bidido- and lactobacteria administered in a dose of 5 billion once a day for 28 days
89096878|NCT04907877|Placebo Comparator|Placebo|Maltodextrine administered once a day for 28 days
89096879|NCT02872506|Active Comparator|medical treatment by Anti TNF|The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time
89096880|NCT02872506|Active Comparator|ileocecal resection|The surgical treatment group are the patients operated on for the first time by means of ileocecal resection laparoscopic or laparotomy
89096881|NCT00627744|Placebo Comparator|BE 1|Patients in this arm are randomly assigned to treatment with placebo
89096882|NCT00627744|Active Comparator|BE 2|Patients in this arm are randomly assigned to treatment with Sitagliptin
89227227|NCT00685373|Experimental|Canakinumab (ACZ885)|Subcutaneous injection every 8 weeks based on participant's body weight. Body weight >40 kilogram (kg): 150 milligrams (mg) per injection and body weight <= 40 kg: 2 mg/kg per injection. For participants who did not experience sufficient symptomatic relief, an up-titration to the dose and/or more frequent doses were permitted as per protocol.
89227228|NCT02561117|Active Comparator|q8h|Metronidazole given every 8 hours
89227229|NCT02561117|Experimental|q24h|Metronidazole given once daily
89227230|NCT00684515|Experimental|Vorapaxar 2.5 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
89227231|NCT00684515|Experimental|Vorapaxar 1 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
89227232|NCT00684515|Placebo Comparator|Placebo + Aspirin|Placebo oral tablets; once daily for 60 days + Aspirin
89227233|NCT00751751|Experimental|1|oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks
89227234|NCT00751751|Active Comparator|2|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.
89227235|NCT00490815|Experimental|1|
89227236|NCT00490815|Experimental|2|
89227237|NCT01016301|Active Comparator|Pharmacist service,|The pharmacist service consists of medication review, drug treatment discussion with the patient, and a medication report.
89227238|NCT01016301|No Intervention|Control|Usual care
89227239|NCT01014663|Active Comparator|Therapeutic Exercise|
89227240|NCT01014663|Active Comparator|Non-Contact Boxing Training|
89227241|NCT01019499|Active Comparator|berry products|Berry products
89227242|NCT01019499|Placebo Comparator|control products|Control products
89227243|NCT04453137|Active Comparator|Humira 40 mg/mL (Adalimumab Originator)|During the LeadIn Period, patients will receive Humira (initial dose of 80 mg [2 × 40 mg] administered subcutaneously [SC], followed by 40 mg SC given every other week starting 1 week after the initial dose). At Week 12, responsive patients (Psoriasis Area and Severity Index [PASI] ≥ 75 [PASI75]) will be randomly assigned in a 1:1 ratio to either of the following groups for participation in the Double-Blind Switching Module.
89227244|NCT04453137|Active Comparator|IC - Humira 40 mg/mL (Adalimumab Originator)|patients continue to receive Humira 40 mg every other week from Week 12 until Week 26 (8 injections)
89227245|NCT04453137|Experimental|IC - Humira/AVT02 40 mg/mL (Adalimimab Biosimilar)|"patients undergo repeated switches (Sw) of AVT02 and Humira from Week 12 until Week 26:~Sw1-AVT02 (40 mg every other week) for 4 weeks (2 injections),~Sw2-Humira (40 mg every other week) for 4 weeks (2 injections),~Sw3-AVT02 (40 mg every other week) for 8 weeks (4 injections)."
89227246|NCT04453137|Experimental|AVT02 40 mg/mL (Adalimimab Biosimilar)|At Week 28, after the EoS IC visit, responsive patients (PASI ≥ 50 [PASI50]) will be offered to continue with the optional open-label Extension Phase (Weeks 28 to 52). AVT02 40 mg will be administered every other week starting from Week 28 (after completing EoS IC assessments), ending with the final study drug administration at Week 50. The EoS visit is planned for Week 52.
89227247|NCT03855189|Experimental|Mometasone Furoate (MF)|Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
89227248|NCT03855189|Active Comparator|Beclomethasone Dipropionate (BDP)|Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
89227249|NCT03855189|Placebo Comparator|Placebo|Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
89227250|NCT03853551|Experimental|Single|Single arm
89227251|NCT00423670|Active Comparator|Arm 1. PEG +RBV for 48 Wks (Part I)|"Participants treated with PegIntron (1.5 μg/kg, once weekly [QW]) and Ribavirin (800 to 1400 mg/day) for 48 weeks.~Participants with detectable HCV-RNA levels after 24 weeks of treatment had the option of crossing over to receive 24 weeks of PegIntron (1.5 μg/kg, QW), Ribavirin (800 to 1400 mg/day), and boceprevir (800 mg three times daily [TID]) for 24 additional weeks. The participants that crossed over to receive boceprevir formed Arm 8. The total treatment duration was up to 54 weeks."
89227252|NCT00423670|Experimental|Arm 2. PEG + RBV + BOC for 28 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
89227253|NCT00423670|Experimental|Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
89227254|NCT00423670|Experimental|Arm 4. PEG +RBV + BOC for 48 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
89227255|NCT00423670|Experimental|Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
89227256|NCT00423670|Experimental|Arm 6. PEG + RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
89227257|NCT00423670|Experimental|Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), low-dose ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks (Arm 7) during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
89096883|NCT01105091|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
89096884|NCT01105091|Active Comparator|2|Flolan®
89096885|NCT04257435|Active Comparator|Traditional Behavioral Health Treatment|
89096886|NCT04257435|Experimental|Positive Psychological Group Treatment|
89096887|NCT04253301|Experimental|Treatment|Subjects will have the InnoVein Valve implanted
89096888|NCT00628056|Active Comparator|1|
89096889|NCT00628056|Placebo Comparator|2|
89096890|NCT00924729|Active Comparator|Moxifloxacin 0.5% ophthalmic solution|
89096891|NCT00924729|Active Comparator|Besifloxacin 0.6% ophthalmic suspension|
89096892|NCT01099709|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
89096893|NCT01099709|Active Comparator|Original OxyContin® (OXY) 10 mg|Original OxyContin® (OXY) 10 mg x 1 dose
89096894|NCT04257357|Experimental|Exercise group|Eight-week supervised exercise program: Patients in the intervention group receive the same usual care as the patients in the control group. In addition, the patients participate in an eight-week supervised interval training program. Briefly put, the patients are required to participate in at least 16 out of 20 possible training passes over the period of eight weeks. The training consists of a brief warm up followed by 35-50 minutes of interval training on a bicycle. The intensity and duration will increase over time
89096895|NCT04257357|Active Comparator|Control group|"Patients in the control group receive usual care as a minimum. This includes three-five days of hospitalization where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.~It is considered an active comparator as all patients in the control group perform a watt-max cycle ergometer test with VO2 measurement 3 times, and this in it-self can influence patients' activity level."
89096896|NCT01099397||PEAR Participants|All participants eligible for PEAR study. Each participant will be have fasting and oral glucose tolerance test data collected.
89096897|NCT04907019|Experimental|Group-drugs interaction|24 subjects were enrolled in this study. The effects of rifampicin single dose and steady-state on the pharmacokinetics of sy-004 will be analyzed.
89096898|NCT01022424|Experimental|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
89096899|NCT05329857|Experimental|Metformin and Vildagliptin 1000/50 mg Tablet|1 tablet of Metformin and Vildagliptin 1000/50 mg as single-dose administration
89096900|NCT05329857|Active Comparator|EUCREAS® 50/1000 mg Tablet|1 tablet of EUCREAS® 50/1000 mg (each film-coated tablet contains Vildagliptin 50 mg and Metformin hydrochloride 1000 mg) as single-dose administration
89096901|NCT01098851||Obstructive Sleep Apnea|Surgery patients at high risk for Obstructive Sleep Apnea
89096902|NCT01098851||Surgery Patients|Surgery patients at low risk for Obstructive Sleep Apnea
89096903|NCT01026948||Propess and Monica AN24 care package|Women who are eligible and consent to recruitment will receive the Propess and Monica AN24 care package for outpatient induction of labour
89096904|NCT04951089|Experimental|i-gel supraglottic device insertion for oxygenation|i-gel supraglottic device insertion for oxygenation i-gel supraglottic device insertion for oxygenation and ventilation
89096905|NCT04951089|Experimental|Air-Q SP 3G supraglottic insertion for oxygenation|Air-Q SP 3G supraglottic device insertion for oxygenation Air-Q SP 3G supraglottic device insertion for oxygenation and ventilation
89096906|NCT05033652|No Intervention|Standard strategy|
89096907|NCT05033652|Experimental|Warning KD strategy|
89096908|NCT01104779|Experimental|Cariprazine (3-6 mg/day)|Cariprazine once daily fixed-flexible low dose
89096909|NCT01104779|Experimental|Cariprazine (6-9 mg/day)|Cariprazine once daily fixed-flexible high dose
89096910|NCT01104779|Placebo Comparator|Placebo|Placebo
89096911|NCT00918957|Experimental|TIP (Tobramycin Inhalation Powder)|Tobramycin 28 mg powder. The TIP dose of 112 mg twice a day (bis in diem = b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment.
89096912|NCT00918957|Placebo Comparator|Placebo|Placebo 20 mg powder capsules. The dose regimen for the reference product was inhaling the contents of four capsules twice a day (bis in diem = b.i.d.), in the morning and in the evening for 28 days (on treatment), followed by 28 days of no study treatment (off treatment).
89096913|NCT01022268||Infection, inflammation or allergy|"Children presenting via any means to St Mary's Hospital; this would include the A&E department, the general and infectious disease wards and the paediatric intensive care unit.~Children needing blood tests for any clinical reason Children who, in the clinical judgement of the doctor assessing them, have presented because of a condition consistent with an infectious, inflammatory or allergic process"
89096914|NCT01022268||controls|children who do not have an infectious, inflammatory or allergic condition, who anyway require blood tests for clinical reasons
89096915|NCT04308161|Experimental|vitamin D oral gel|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks.~Topical oral Vitamin D gel is prepared with the aid of pharmaceutics department, faculty of pharmacy, Alexandria University. It is prepared by using Cholecalciferol 2ml ampoule (200.000 I.U.) within topical oral gel formulation."
89096916|NCT04308161|Active Comparator|conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Dose: Three times a day for six weeks"
89096917|NCT04308161|Experimental|combination therapy|"Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Symptomatic treatment dose: Three times a day for six weeks"
89096918|NCT04939467|Experimental|Pirfenidone & BLD-0409|Following an overnight fast, subjects will be administered IP in a fixed sequence.
89096919|NCT04939467|Experimental|Nintedanib & BLD-0409|Following an overnight fast, subjects will be administered IP in a fixed sequence.
89096920|NCT01015560|Experimental|treatment|MLN1202 8mg/kg IV Days 1, 15, 29 given as 1 6 week cycle
89096921|NCT02878889|Experimental|Arm 1|S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
89096922|NCT04581174|Experimental|1st degree of hypertrophy according to Camacho|Patients with 1st degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
89096923|NCT04581174|Experimental|2nd degree of hypertrophy according to Camacho|Patients with 2nd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
89096924|NCT04581174|Experimental|3rd degree of hypertrophy according to Camacho|Patients with 3rd degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
89096925|NCT04581174|Experimental|4th degree of hypertrophy according to Camacho|Patients with 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated.
89096926|NCT02879045|Experimental|elasticity Belly® oil|Volunteer's abdomen skin are divided two parts through medioventral line, half of the abdomen skin will apply the elasticity Belly® oil
89096927|NCT04253223|Experimental|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses
89096928|NCT00918879|Experimental|1|Saxagliptin
89096929|NCT00918879|Placebo Comparator|2|
89096930|NCT04874805|Experimental|Major patient admitted to the ICU for COVID|
89096931|NCT01026792|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. For complete responders, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or for 2 courses after complete response criteria are first met. For other patients, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89096932|NCT01026324|Experimental|Treatment (dinaciclib)|Patients receive dinaciclib IV over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
89096933|NCT04300686|Active Comparator|Tocilizumab|This group of 20 TAK cases are prescribed with tocilizumab (Dose: 8mg/kg. qm. ivgtt.) for 24 weeks.
89096934|NCT04300686|Experimental|Adalimumab|This group of 20 TAK cases are prescribed with adalimumab (Dose: 40mg.bim.IH.) for 24 weeks.
89096935|NCT04299282|Active Comparator|CanGaroo|The treatment group will receive a CanGaroo envelope with implantation of a CIED
89096936|NCT04299282|No Intervention|No CanGaroo|The control group will not receive a CanGaroo envelope with implantation of a CIED
89096937|NCT01098539|Active Comparator|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
89096938|NCT01098539|Active Comparator|sitagliptin|albiglutide matching placebo + sitagliptin
89096939|NCT02880215|Experimental|Attention Bias Modification|Behavioral intervention designed to improved negative attention bias.
89096940|NCT02880215|Experimental|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
89096941|NCT02880215|No Intervention|Assessment Only|Assessment only with no active intervention.
89096942|NCT01098461|Active Comparator|albiglutide 15mg weekly|once weekly subcutaneous injection of albiglutide 15mg
89096943|NCT01098461|Active Comparator|albiglutide 30mg weekly|once weekly subcutaneous injection of albiglutide 30mg
89096944|NCT01098461|Active Comparator|albiglutide 30mg every other week|subcutaneous injection of 30mg albiglutide every other week
89096945|NCT01098461|Placebo Comparator|placebo|once weekly subcutaneous injection of placebo to match albiglutide
89096946|NCT01098305|Active Comparator|Varenicline|
89096947|NCT01098305|Placebo Comparator|Placebo|
89096948|NCT00833833|Experimental|Phase 1: 2 mg pomalidomide|Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
89096949|NCT00833833|Experimental|Phase 1: 3 mg pomalidomide|Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
89096950|NCT00833833|Experimental|Phase 1: 4 mg pomalidomide|Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
89096951|NCT00833833|Experimental|Phase 1: 5 mg pomalidomide|Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
89096952|NCT00833833|Experimental|Phase 2: pomalidomide + dexamethasone|Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (determined by age) on days 1, 8, 15, and 22 of each 28-day cycle. The starting dose of dexamethasone was 40 mg for participants who were ≤ 75 years of age and 20 mg for participants who were > 75 years of age. Dose reduction steps for dexamethasone were provided for drug-related toxicities.
89096953|NCT00833833|Experimental|Phase 2: pomalidomide|4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone on days 1, 8, 15, and 22 of each 28-day cycle at the starting dose of 20 or 40 mg depending on age in addition to their current dose of pomalidomide, or to discontinue treatment.
89096954|NCT04308083|Active Comparator|convergent neck|Group A Sweden & Martina Prama (P). Transgingival tapering machined collar, 2.8 mm in height.
89096955|NCT04308083|Sham Comparator|divergent neck|Group B Straumann Tissue Level (TL). Transgingival widening polished collar, 1.8 mm in height.
89096956|NCT02878733||Albumin|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) with any volume of 5% albumin
89096957|NCT02878733||Crystalloid Only|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) without any volume of 5% albumin
89096958|NCT01098071|Experimental|mometasone furoate nasal spray|
89096959|NCT04307771|Experimental|m-health application|a mobile app designed to send reminders for brushing and give information on maintaining oral health
89096960|NCT04307771|Other|Leaflet|This is the control arm. An educational leaflet for maintaining oral hygiene will be given to participants in this arm
89096961|NCT02612545|Active Comparator|ACT|Patients randomized to ACT will receive DHA-PPQ only
89096962|NCT02612545|Experimental|TACT|Patients randomized to TACT will receive DHA-PPQ plus MQ
89096963|NCT02878577||EEG fMRI TBI Mild/Moderate-Severe severity|patient population who suffered a brain trauma (traumatic brain injury, TBI). with a Glasgow Coma Scale between 3-15
89096964|NCT02878577||EEG fMRI Control group|healthy subjects with out a traumatic brain injury
89096965|NCT00704743|Active Comparator|1|Cylindrical cast
89096966|NCT00704743|Active Comparator|2|Modified sugar tong cast
89096967|NCT00704743|Active Comparator|3|Volar dorsal splint
89096968|NCT00699985||1|Behcet's Disease patients that their diagnosis was based on the new International Criteria for Behcet's Disease (ICBD).
89096969|NCT00699985||2|Non-Behcet's Disease patients were patients mimicking BD.
89096970|NCT01097057|Experimental|Treatment (rituximab, etoposide, carboplatin, ifosfamide)|Patients receive rituximab IV on day 1, etoposide IV on days 2-4, carboplatin IV on day 3, and ifosfamide IV on day 3 over 24 hours. Patients also receive G-CSF SC once daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal number of CD34+ cells are collected.
89096971|NCT02612701|Experimental|Cigarettes|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes
89096972|NCT02612701|Experimental|E-cigarettes (nicotine free e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.
89096973|NCT02612701|Experimental|E-cigarettes (low nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.
89096974|NCT02612701|Experimental|E-cigarettes (high nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.
89096975|NCT05065463|Experimental|Cohort 1|Participants with severe renal impairment will receive a single dose of AZD8233 on Day 1.
89096976|NCT05065463|Experimental|Cohort 2|Participants who are healthy will receive a single dose of AZD8233 on Day 1.
89096977|NCT05065463|Experimental|Cohort 3|Participants with ESRD on dialysis will receive a single dose of AZD8233 on Day 1.
89096978|NCT01022112|Experimental|TA-7284-Low|
89096979|NCT01022112|Experimental|TA-7284-Low-middle|
89096980|NCT01022112|Experimental|TA-7284-High-middle|
89096981|NCT01022112|Experimental|TA-7284-High|
89096982|NCT01022112|Placebo Comparator|Placebo|
89096983|NCT04299204|Experimental|Years 1997-2007|Group-1, PCNL was performed in the first 10 years period (Years 1997-2007);
89096984|NCT04299204|Experimental|2008- to the present|The PCNL was performed in the second ten years period from 2008 to the present.
89096985|NCT01096667|Placebo Comparator|Placebo|Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
89096986|NCT01096667|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
89096987|NCT01096667|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
89096988|NCT01096667|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
89096989|NCT01096667|Active Comparator|HCTZ 12.5mg|HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days
89096990|NCT01014624|Experimental|Prasugrel|Prasugrel 10mg administered for 7 days followed by a Washout Period up to 12 days.
89096991|NCT01014624|Active Comparator|Clopidogrel|Clopidogrel 75mg administered for 7 days followed by a 12 day Washout Period up to 12 days.
89096992|NCT01021878|Experimental|icodextrin|glucose sparing alternative dialysis solution
89096993|NCT01021878|Active Comparator|dextrose|dianeal, Control group, standard treatment
89096994|NCT02872428|Experimental|Valproic acid (Depacon)|Valproic acid by IV infusion over one hour
89096995|NCT02872428|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
89096996|NCT02873364|Active Comparator|Vitamin D3 (Low dose)|Daily 600 unites of vitamin D + Cetirizine 10mg twice a day
89096997|NCT02873364|Experimental|Vitamin D3 (High dose)|Daily 4000 unites vitamin D + Cetirizine 10mg twice a day
89096998|NCT02872740|Experimental|Embolization of Left Gastric Artery|These patients will have their left gastric artery embolized
89096999|NCT02872740|Experimental|Embolization of Gastroepiploic Artery|These patients will have their gastroepiploic artery embolized
89097000|NCT02871960|Experimental|Robotic colectomy|Patients undergoing robotic colectomy for colorectal cancer
89097001|NCT02871960|Active Comparator|Laparoscopic colectomy|Patients undergoing laparoscopic colectomy for colorectal cancer
89097002|NCT00628290|Experimental|1|
89097003|NCT00628290|Active Comparator|2|
89097004|NCT04559412|Experimental|Sofusa Enbrel|Enbrel® administered by the Sofusa® DoseConnect™ delivery system
89097005|NCT00854113|Experimental|EGT0001474|Ascending doses of EGT0001474
89097006|NCT00854113|Placebo Comparator|Placebo|Placebo
89097007|NCT02872584||Prednisone|Patients with dermatological conditions requiring high dose long term glucocorticoid treatment
89097008|NCT00704821|Experimental|Stage 1|In Stage 1, PTC299 will be given orally twice a day (BID) each day at about the same time each day for the first 28 days of each cycle. Each cycle will constitute a 4-week (28 days) period followed by a ≥2-week (14-day) washout period. Participants will be assigned to 0.3 milligrams (mg)/kilograms (kg)/dose BID, 0.6 mg/kg/dose BID, or 1.2 mg/kg/dose BID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
89097009|NCT00704821|Experimental|Stage 2|In Stage 2, PTC299 will be given BID or 3 times a day (TID) orally each day at about the same time each day; therefore, 84 (for BID) or 126 (for TID) doses of PTC299 will be delivered during the 6-week (42-day) period in each cycle. Each participant will be assigned to 100 mg/dose BID, 100 mg/dose TID, 120 mg/dose TID, 160 mg/dose TID, or 200 mg/dose TID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
89097010|NCT00704821|Experimental|Stage 3|In Stage 3, PTC299 will be given BID or TID (for total of 42 [for BID] or 63 [for TID] doses) orally about same time per day starting on Day 1 in each 3-week (21-day) cycle. Starting dose will be 1 dose level below maximum tolerated dose (MTD) from Stage 2 or 80 mg/dose BID if 100 mg/dose TID in Stage 2 exceeds MTD. Dose escalation will be based on safety evaluations by Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant. Participants will also receive docetaxel as a 1-hour IV infusion on Day 1 per cycle at starting dose of 75 mg/m^2 with body surface area calculation based on body weight. Dose will be sequentially reduced to 60 and 50 mg/m^2 in participants with a docetaxel-related dose-limiting toxicity (DLT). Participants will be medicated with oral corticosteroids with docetaxel administration. Recommended dose is 8 mg BID dexamethasone for 3 days starting 1 day prior to docetaxel administration.
89097011|NCT00704821|Experimental|Stage 4|In Stage 4, PTC299 will be given orally each day continuously starting on first day of each cycle at about same time per day; so, 42 doses of PTC299 will be delivered for 3 weeks (21-day) in Cycle 1 (BID dosing), and 84 doses will be delivered for 3-weeks (21-day) in Cycle 2 and beyond (TID dosing). For Cycle 1, participants will be assigned to 600, 800, or 1000 mg/dose BID sequentially based on safety evaluations by Sponsor's medical monitor at enrollment. For Cycle 2 and beyond, participants will receive PTC299 160 mg/dose TID. During Cycle 1, Cohort 1 participants will eat a meal containing of ≤15 grams (g) of dietary fat and Cohort 2 participants will eat a meal containing of ≤25 g of dietary fat prior to each dose of PTC299. If ≤2 of 6 participants had experienced DLT during Cycle 1 in either diet plan, then the dose will be escalated to 800 mg BID in Cohort 3 at the optimal diet. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
89097012|NCT00704899|Experimental|2|anti-depressants
89097013|NCT00704899|Experimental|1|physiotherapy
89097014|NCT00845845|Active Comparator|Omega-3-acid ethyl esters (Lovaza)|Participants receive 4 milligrams (mg) daily of omega-3-acid ethyl esters (Lovaza) and dietary counseling for 24 weeks
89097015|NCT00845845|Placebo Comparator|Placebo|Participants receive daily placebo and dietary counseling for 24 weeks
89097016|NCT01104701|Active Comparator|Group A|2 mg exenatide once weekly subcutaneous (SC). This arm is used as a reference arm in the study.
89097017|NCT01104701|Experimental|Group B|Low dose 5 mg exenatide once monthly suspension SC.
89097018|NCT01104701|Experimental|Group C|Medium dose 8 mg exenatide once monthly suspension SC.
89097019|NCT01104701|Experimental|Group D|High dose 11 mg exenatide once monthly suspension SC.
89097020|NCT00833755|Active Comparator|Opioid - Ketamine|This group consists of 16 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
89097021|NCT00833755|Active Comparator|Non-opioid - Ketamine|This group consists of 22 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
89097022|NCT00833755|Placebo Comparator|Opioid - Placebos|This group consists of 18 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
89097023|NCT00833755|Placebo Comparator|Non-opioid - Placebos|This group consists of 23 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
89097024|NCT01021332|Experimental|Total Group|Participants who received at least one dose of open-label fixed dose combination (FDC) treatment
89097025|NCT00704977|Active Comparator|1|Pterygium surgery using alcohol 20% + wound closure by bare sclera technique
89097026|NCT00704977|Active Comparator|2|"Alcohol 20% for pterygium separation + wound closure by sliding flap technique.~The main steps of surgery are described below.Wound closure technique is as follows.~Disection of conjunctiva adjascent to the wound, bringing the dissected conjunctiva to the wound area and suturing by vicril 6/0 sutures"
89097027|NCT00704977|Active Comparator|3|"Alcohol 20 % for pterygium separation + using amniotic membrane and biological glue for wound closure.~The steps of surgery are as described below, wound closure technique is as follows.~Amniotic membrane is applied with its mesenchimal side to conjunctiva and glued by biological glue (main ingradients: calcium and thrombin)"
89097028|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg|olmesartan medoxomil 20mg / amlodipine besylate 5 mg / hydrochlorothiazide 12.5mg
89097029|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg|
89097030|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg|
89097031|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg|
89097032|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg|
89097033|NCT00923091|Experimental|olmesartan/amlodipine 20mg/5mg|olmesartan medoxomil 20mg / amlodipine besylate 5mg
89097034|NCT00923091|Experimental|olmesartan/amlodipine 40mg/5mg|
89097035|NCT00923091|Experimental|olmesartan/amlodipine 40mg/10mg|
89097036|NCT04030819|No Intervention|control group|no intervention
89097037|NCT04030819|Experimental|experimental group|schema therapy
89097038|NCT04115683|Experimental|Intervention Group|
89097039|NCT04115683|Active Comparator|Control Group|
89097040|NCT04299126|Experimental|high absorption pad for blood and pus|High absorption pad for blood and pus with natural antimicrobial agent composes of sericin and chitosan. It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
89097041|NCT04299126|Active Comparator|commercial wound dressing|Commercial wound dressing is gauze dressing impregnated with paraffin, containing 0.5% chlorhexidine acetate (Bactigras). It will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
89097042|NCT00853957|Experimental|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
89097043|NCT00853957|Active Comparator|Amlodipine|Amlodipine 5mg titrated to 10 mg
89097044|NCT04571034|Sham Comparator|Control Group|Healthy adults receiving sham comparator.
89097045|NCT04571034|Experimental|Medium-Intensity Roller Massage|Healthy adults receiving medium-intensity roller massage.
89097046|NCT04571034|Experimental|High-Intensity Roller Massage|Healthy adults receiving high-intensity roller massage.
89097047|NCT01021020|Experimental|1|Colchicine (fasted)
89097048|NCT01021020|Experimental|2|Colchicine (fed)
89097049|NCT01021020|Active Comparator|3|Colchicine/Probenecid (fasted)
89097050|NCT04256187||Healthy group|Caregivers of children who treated with botulinum toxin.
89097051|NCT00833053|Experimental|IFX q 6 weeks|
89097052|NCT00833053|Experimental|IFX + MTX|
89097053|NCT02873130|Experimental|Behavioral: Telepractice Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) through West Chester University's Desire 2 Learn (D2L) software program. Synchronous and asynchronous learning opportunities are provided through D2L over a four week period. The GVPM includes vocal hygiene, vocal education, and vocal training.
89097054|NCT02873130|Experimental|Behavioral: In-person Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) at West Chester University in-person. The GVPM will meet for 2 hours once a week for four weeks. The GVPM includes vocal hygiene, vocal education, and vocal training.
89097055|NCT02873130|Sham Comparator|Behavioral: Telepractice, Vocal Hygiene and Vocal Education|Participants will complete Vocal Hygiene and Vocal Education through West Chester University's Desire 2 Learn (D2L) software program. Asynchronous learning opportunities are provided through D2L over a one week period.
89097056|NCT04299984||Open Conversions|Patients undergoing total or partial endograft explantation for any EVAR complication.
89097057|NCT04299984||SemiConversions|Patients undergoing open or laparoscopic surgery for any EVAR complication (mostly endoleak correction) with complete endograft preservation.
89097058|NCT05329467|Other|Validation|
89097059|NCT04256031||Excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are higher than 30
89097060|NCT04256031||Non-excessive Smartphone Use Group|Participants whose Smartphone Addiction Scale-Short Version scores are 30 or less
89097061|NCT04253067|Active Comparator|Active fCO2 laser treatment|Laser probe will be inserted into the vagina. The laser treatment is delivered at 6 points to the vaginal wall. Delivery begins at the most proximal and the wand is retracted by 1 cm and another row of laser treatment is delivered. The number of levels is determined by vaginal length.
89097062|NCT04253067|Sham Comparator|Sham fCO2 laser treatment|Laser probe will be inserted into the vagina. To prevent the delivery of laser energy, the laser will remain in standby mode during the visit. Keeping the laser in standby mode prevents laser exposure. The treatment will appear to be the same as the active treatment. The machine maintains a low humming noise while in standby mode.
89097063|NCT01020786|Experimental|Pemetrexed + Carboplatin|After four 21-day cycles of Pemetrexed plus Carboplatin treatment, Pemetrexed monotherapy is continued until study discontinuation.
89097064|NCT04241445||novice observers|who have practiced GMA sporadically (def.: < = 2 GMA/week for < = 2 years), have limited experience, and do not use GMA in clinical settings
89097065|NCT04241445||GMA experts|GMA tutors and individuals who have applied GMA regularly (def.: > 2 GMA/week for > 2 years)
89097066|NCT00918645|Experimental|41 Ca|
89097067|NCT04255719|Experimental|Unilateral DBS of the subthalamic nucleus (STN)|To deliver unilateral STN DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral STN DBS. The STN stimulation will be programmed as previous parameter configuration with optimal therapeutic benefits. Participants will be asked to complete a comprehensive set of assessments under unilateral STN stimulation in the off-medication state. 45 minutes after taking regular medication, participants need to complete the second set of assessments in the on-medication state.
89097068|NCT04255719|Experimental|Unilateral DBS of the globus pallidus interna (GPi)|To deliver unilateral GPi DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral GPi DBS. The study protocol is identical to the intervention of unilateral STN DBS but it was done on a different day.
89097069|NCT00922935|Experimental|Cresco early loading|The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) at 10 days of post surgery
89097070|NCT00922935|Experimental|Cresco late loading|"Healing caps will be placed until loading. The minimum waiting time is 4 weeks, but not before try ins to ensure a perfect fit. The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) within 42-56 days (6 to 8 weeks) of surgery."
89097071|NCT00922935|Active Comparator|Straumann system late loading|Straumann components loading at 6-8 weeks post surgery
89097072|NCT01020474|Placebo Comparator|Placebo|
89097073|NCT01020474|Experimental|drug-pregabalin|
89097074|NCT04245891||Control group|boli of ephedrine phenylephrine (45μg/mL-3mg/mL) if the variation of MAP < 20% of baseline (MAP before spinal anaesthesia).
89097075|NCT04245891||Protocol group|continuous infusion of norepinepineprhine at 20 μg/mL, started at 0.05 μg/kg/min. The dosage of norepinephrine was then adjusted to maintain a variation in MAP < 20% of baseline. In case of failure, the use of a control group boli injection was possible.
89097076|NCT02872818|Active Comparator|Control group|Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia
89097077|NCT02872818|Active Comparator|Metformin group|Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days
89097078|NCT02872818|Active Comparator|Medroxyprogesterone acetate group|Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days
89097079|NCT00922779|Experimental|1|
89097080|NCT04286646||Pupil diameter before/after cataract|The investigators measure the pupil diameter before and after (3 months) cataract. Mesopic and photopic conditions
89097081|NCT04205448|Experimental|Exercize group|10 weeks of physical exercise. Testing of strength and balance.
89097082|NCT04205448|No Intervention|Control group|Testing of strength and balance.
89097083|NCT00627822||Ward|Patients in the hospital ward
89097084|NCT00627822||Emergency room|Patients in the emergency waiting room
89097085|NCT00627822||Intensive care unit|Family members of patients admitted to the intensive care unit
89097086|NCT04532892|Placebo Comparator|Placebo|Morning and night tablets with no active ingrédients. Morning and night tablets are different.
89097087|NCT04532892|Experimental|Dietary supplément|Morning and night tablets with active ingrédients. Morning and night tablets are different.
89097088|NCT00924651|Experimental|Standard Care + EXCAP|Personalized exercise prescription
89097089|NCT00924651|No Intervention|Standard Care|Wait list control
89227258|NCT00423670|Experimental|Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I)|"Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with~PegIntron (1.5 μg/kg QW), and ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks."
89227259|NCT03996759||Critically ill patients|Patients admitted in ICU
89227260|NCT01019577|Experimental|Ixabepilone|
89227261|NCT05072535|Experimental|Part 1-Group A|Subjects will receive 200 mg HA121-28 tablet A on Day 1 of the first cycle, followed by tablet B on Day 36 of the second cycle, in the fasted state.
89227262|NCT05072535|Experimental|Part 1-Group B|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle, followed by tablet A on Day 36 of the second cycle, in the fasted state.
89227263|NCT05072535|Experimental|Part 2-Group C|Subjects will receive 200 mg HA121-28 tablet B on Day1 of the first cycle in fasted state, followed by tablet B on Day 36 of the second cycle in the fed state.
89227264|NCT05072535|Experimental|Part 2-Group D|Subjects will receive 200 mg HA121-28 tablet B on Day 1 of the first cycle in the fed state, followed by tablet B on Day 36 of the second cycle in fasted state.
89227265|NCT03996681|Experimental|TACE plus methylcantharidimide tablets|Methylcantharidimide tablets( 75mg po tid) is administered before first TACE 3 days and taken continuously after TACE treatment. Every 6 weeks is a cycle.
89227266|NCT01019655|Experimental|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
89227267|NCT01019655|No Intervention|Control|No intervention other than usual care at the study site
89227268|NCT01019733|Experimental|Patients|Children whom will receive intrathecal autologous stem cells
89227269|NCT00483717|Placebo Comparator|Placebo|Intranasal Placebo
89227270|NCT00483717|Experimental|Ketorolac tromethamine|Intranasal ketorolac tromethamine
89227271|NCT00406354|Experimental|Atomoxetine Fast Titration|0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
89227272|NCT00406354|Experimental|Atomoxetine Slow Titration|0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
89227273|NCT00406354|Placebo Comparator|Placebo|matching placebo daily dose taken orally
89227274|NCT01037842|Active Comparator|Metformin+Mitiglinide|mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
89227275|NCT01037842|Placebo Comparator|Metformin+Placebo|placebo three times a day added to metformin 500 mg three times a day
89227276|NCT01037920|Experimental|Intervention|subjects in the intervention arm will complete a self-affirmation exercise prior to a physician visit
89227277|NCT01037920|Active Comparator|Control|subjects in the intervention arm will complete a sham exercise prior to a physician visit
89227278|NCT00483405|Other|Single Arm Trial|Single Arm Trial
89227279|NCT00483327|Experimental|Megestrol Acetate|80 mg (2 tablets) orally at breakfast, 80 mg at dinner for at least 12 weeks and up to 2 years.
89227280|NCT00684203|Experimental|Vorapaxar 20 mg/1 mg|Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
89227281|NCT00684203|Experimental|Vorapaxar 20 mg/2.5 mg|Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
89227282|NCT00684203|Experimental|Vorapaxar 40 mg/1 mg|Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
89227283|NCT00684203|Experimental|Vorapaxar 40 mg/2.5 mg|Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
89227284|NCT00684203|Placebo Comparator|Placebo|Placebo loading dose + daily placebo maintenance dose + standard of care (Aspirin + Ticlopidine)
89097090|NCT04570410|Experimental|Subgroup1:Patients who can tolerate cisplatin chemotherapy|"GC plus Tislelizumab Participants receive GC (Gemcitabine plus cisplatin), in combination with Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W~Biological: GC GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks"
89097091|NCT04570410|Experimental|Subgroup2:Patients who cannot tolerate cisplatin chemotherapy|"Tislelizumab Participants receive Tislelizumab administered intravenously (IV) every 3 weeks (Q3W) before surgery.Immunotherapy was continued for 6 months after excision of the primary lesion.~Intervention/treatment： Biological: Tislelizumab Tislelizumab IV infusion of 200 mg Q3W"
89097092|NCT04203771|Experimental|Probiotic|Orodispersible tablets containing AB-DENTALAC probiotic formula.
89097093|NCT04203771|Placebo Comparator|Control|Orodispersible tablets without probiotic strains (excipients only).
89097094|NCT00627588|Experimental|Dose Evaluation|To assess the safety and efficacy of up to three dose levels of ProSavin
89097095|NCT00627588|Sham Comparator|Sham element|The potential use of sham comparator to confirm efficacy
89097096|NCT00922623|Experimental|Belotero®|
89097097|NCT01025232|Active Comparator|4 Week Re-treatment|Subjects can receive re-treatment every 4 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Subjects will go no longer than 12 weeks without treatment.
89097098|NCT01025232|Active Comparator|6 Week Re-treatment|Subjects can receive re-treatment every 6 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Every 6 weeks regimen will test potential longer duration of action of 2.0 mg ranibizumab. Subjects will go no longer than 12 weeks without treatment.
89097099|NCT04255485||Short time anesthesia group|Unilateral cochlear implantation,which time of anesthesia is less than 3 hours
89097100|NCT04255485||Long time anesthesia group|Bilateral cochlear implantation, which time of anesthesia is more than 3 hours
89097101|NCT04300452|Active Comparator|Carbetocin group|In the carbetocin group will be administered 100 mcg of carbetocin diluted in 100 cc of N/S 0.9% in a continuous rapid-flow intravenous infusion.
89097102|NCT04300452|Active Comparator|Ergometrin group|In the ergometrine maleate group will be administered intravenously 0.2 mg of the substance slowly in a bolus administration.
89097103|NCT04252599||Control group|
89097104|NCT04252599||Multiple sclerosis group|
89097105|NCT04252599||Multiple sclerosis trunk impairment|
89097106|NCT04252755|Other|EEG Neurofeedback|Within-subjects sessions of EEG neurofeedback
89097107|NCT01025154|Experimental|Clofarabine, Cytarabine + Idarubicin|Induction Cycle: Clofarabine 20 mg/m^2 intravenous (IV) daily for 5 days; Idarubicin 10 mg/m^2 IV daily for 3 days; Cytarabine 1 g/m^2 IV daily for 5 days
89097108|NCT04252833|Experimental|CT-044 600 mg|The dose to be utilized for the evaluation of food effect will be CT-044 600 mg single dose.
89097109|NCT04252911||Anaesthetised patients|50 patients undergoing robotic surgeries under general anesthesia
89097110|NCT04252365|Experimental|arm 1|"Patients with PD-L1 high expression (TPS≥50%) receive Sintilimab injection 200mg i.v. on day 1 every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.~Patients with PD-L1 low or negative expression (TPS<50%) receive Sintilimab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Sintilimab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
89097111|NCT04252365|Active Comparator|arm 2|"Patients with PD-L1 high expression (TPS≥50%) receive Pembrolizumab injection 200mg i.v. on day 1once every three weeks (Q3W). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.~Patients with PD-L1 low or negative expression (TPS<50%) receive Pembrolizumab injection 200mg i.v. in combination with platinum-based chemotherapy every three weeks (Q3W) for 4 cycles. After that, patients receive Pembrolizumab injection on day 1 Q3W during the maintenance phase (Cycle 5 onward). Courses repeat every 21days in the absence of disease progression or unacceptable toxicity."
89097112|NCT04256499||Water load test|Patients experiencing a syndrome of inappropriate antidiuresis who had an acute water load test
89097113|NCT04256499||Control group|Patients who had an acute water load test and who did not experience any water homeostasis anomalies
89097114|NCT04256577||patients proven having (SLE)|20 patients proven to have systemic lupus Erthematosus without renal impairment (eGFR) ≥ 80 ml/min/1.73 m2 and albumin / creatinine ≤ 30 mg/g)
89097115|NCT04256577||patients proven to have (LN) by renal biopsy|Group (2) 25 patients proven to have LN by renal biopsy before starting treatment and after 3 cycle of treatment (eGFR < 80 ml/min/1.73 m2 and albumin/creatinine ratio > 30 mg/g)
89097116|NCT04256577||healthy control|(20) patients healthy control matched in age and sex
89097117|NCT04252443|Other|Nurse|The research population consisted of 190 nurses working in a university hospital. Because all of the nurses in the research population could not be reached, a sample was selected using a simple random sampling method. One hundred twenty-seven nurses were interviewed in the research population, with a 95% confidence interval and a 5% sampling error.
89097118|NCT00832819|Experimental|E7080 (Dose Escalation Cohort)|This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
89097119|NCT00832819|Experimental|E7080 (Expansion Cohort)|Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.
89097120|NCT04820361|Placebo Comparator|Placebo|oral spray
89097121|NCT04820361|Active Comparator|Sativex®|.It contains Δ-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
89097122|NCT00702013||1|
89097123|NCT00702013||2|
89097124|NCT00702013||3|
89097125|NCT00702013||4|
89097126|NCT00702013||5|
89097127|NCT00702013||6|
89097128|NCT00702013||7|
89097129|NCT00702013||8|
89097130|NCT04256655|Experimental|Cohort 1 0.225 g|Randomized to treatment with either CDX-6114 0.225g or matching Placebo
89097131|NCT04256655|Experimental|Cohort 2 0.75g|Randomized to treatment with either CDX-6114 0.75g or matching Placebo
89097132|NCT04256655|Experimental|Cohort 3 2.25g|Randomized to treatment with either CDX-6114 2.25 g or matching Placebo
89097133|NCT05320497|Experimental|Transparent cap-assisted SpyGlass|Add a transparent cap to the end of the SpyGlass choledochoscopy
89097134|NCT00705055||1|Normal Males
89097135|NCT00705055||2|Normal Females
89097136|NCT00705055||3|Abnormal Males
89097137|NCT00705055||4|Abnormal Females
89097138|NCT00853723|Experimental|PTHrP 400 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.
89097139|NCT00853723|Experimental|PTHrP 600 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.
89097140|NCT00853723|Active Comparator|PTH 20 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.
89097141|NCT01104545|Experimental|Panel A - Healthy|Healthy participants receive single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast except for Period 3. Period 3 dose was administered after the ingestion of a high-fat breakfast.
89097142|NCT01104545|Experimental|Panel B - Healthy|Healthy participants receive single oral dose of MK-3614 0.5 mg. 0.75 mg, 0.25 mg twice a day (b.i.d.), 0.25 mg three times a day (t.i.d), or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast
89097143|NCT01104545|Experimental|Panel C - Hypertensive|Hypertensive participants receive single oral dose of MK-3614 0.75 mg. 0.5 mg. 0.75 mg, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing period. All doses were administered after an 8-hour fast
89097144|NCT04117789|Experimental|Therapist-guided ICBT for depression|"Participants will receive internet-delivered CBT with therapist support. The treatment consists of 8 online chapters with interactive features as videos and illustrations, delivered over a maximum of 10 weeks. The treatment has the main focus on behavioral activation.~The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The parent program also consists of eight chapters, including psychoeducation about depression and how to support their adolescent in treatment.~The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support."
89097145|NCT04117789|Experimental|Self-guided ICBT for depression|The self-guided ICBT for depression is identical to the therapist-guided ICBT intervention, however without the therapist support. To ensure patient-safety, there will be clear instructions to the patients and primary caregivers how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
89097146|NCT04117789|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both. The content of TAU and the treatment techniques used, will be monitored.
89097147|NCT00918255|Experimental|Adalimumab 40 mg qwk|Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
89097148|NCT00918255|Experimental|Adalimumab 40 mg eow|Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
89097149|NCT00918255|Placebo Comparator|Placebo|Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.
89097150|NCT04252131|Experimental|Cassia seed|oral administration of Cassia seed (3.0g), once/day for 12 weeks
89097151|NCT04252131|Placebo Comparator|Cassia seed placebo|oral administration of Cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia) for 12 weeks
89097152|NCT04252053|Experimental|Supervised Pilates-Based Core Stability Training Group|In order to detect the effects of pilates-based core stabilization training (PBCST) on isokinetic knee strength and postural sways, individuals with MS will receive pilates-based core stabilization training for 8 weeks and 2 days a week. One educational session will perform to teach basic principles of pilates based training. Individuals in this group will receive treatment at the clinic by physiotherapist supervision. All sessions will be individualized (not group training).
89097153|NCT04252053|Active Comparator|Home exercise group|The home exercise group will perform the same PBCST exercises at home during the same period (8 weeks, 2 days a week) as the brochures prepared for them. Individuals in this group will receive one educational session which includes basic principles of pilates and one session which includes two-week exercise program. Participants will be invited to the clinic every two weeks to ensure the progression of the exercises and the exercise program will be updated.
89097154|NCT01096589|Experimental|Arm 1 - 3M Coban 2|3M Coban 2 - 2 apps/wk
89097155|NCT01096589|Experimental|Arm 2 - 3M Coban 2|3M Coban 2 - 3 apps/wk
89097156|NCT01096589|Experimental|Arm 3 - 3M Coban 2|Arm 3 - 3M Coban 2 - 5 apps/wk
89097157|NCT01096589|Active Comparator|Arm 4 - Comprilan|Comprilan short-stretch bandage 5 apps/wk
89097158|NCT04252521|Active Comparator|metoclopramide+ dexketoprofen trometamol|10 mg metoclopramide+ 50 mg dexketoprofen trometamol
89097159|NCT04252521|Experimental|metoclopramide|10 mg metoclopramide
89097160|NCT04252521|Experimental|dexketoprofen trometamol|50 mg dexketoprofen trometamol
89097161|NCT04819659|No Intervention|Group Control|Without pharyngeal pack insertion
89097162|NCT04819659|Experimental|Group Pharyngeal packing (Group PP)|Pharyngeal pack insertion after endotracheal intubation
89097163|NCT00845065|Placebo Comparator|Arm 1 (Control Arm)|Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by placebo (800 mg three times a day [TID] PO, using placebo matching SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks with 24 weeks post-treatment follow-up.
89097164|NCT00845065|Experimental|Arm 2 (Boceprevir Arm)|"Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by boceprevir (800 mg three times a day [TID] PO, using SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks~with 24 weeks post-treatment follow-up."
89097165|NCT04772001|Experimental|CCRT+Anlotinib|Classical chemoradiotherapy will be conducted by clinical routine method. Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks. Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime and for patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug. Hydrochloride anlotinib will be orally taken daily at a dose level of 12mg for 14 days. Then rest for 7 days and start a new cycles for a total of 3 cycles. First capsule of anlotinib will be taken 7 days before the first radiation.
89097166|NCT00626171|Other|1|Allergen challenge
89097167|NCT00832585|Experimental|Alefacept|"Amevive® has been shown to be a safe and effective agent in the treatment of psoriasis but may prove useful in treating atopic dermatitis at a dose of 15mg IM every week for 12 weeks. Unlike other biologics for the treatment of skin diseases, the use of alefacept is not associated with increased infection, congestive heart failure, demyelinating disorders or lupus- like syndromes."
89097168|NCT00918567|Experimental|Combined therapy|atomoxetine plus behavior therapy
89097169|NCT00918567|Active Comparator|Drug therapy|atomoxetine alone
89097170|NCT04255797|Experimental|experimental group|The experimental group will perform massage in an incubator. The researchers provide a natural plant-based massage oil for the parents.
89097171|NCT05252325|Other|HAL on the right side of the face; HA on the left side of the face|the subjects will receive HAL ( hyaluronic acid +lidocaine)in the right side of the face, HA (hyaluronic acid without lidocaine) in the left side
89097172|NCT05252325|Other|HAL on the left side of the face; HA on the right side|the subjects will receive HA in the right side of the face, HAL in the left side
89097173|NCT04255641||frozen embryos|
89097174|NCT04770051|Experimental|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
89097175|NCT05252091|Experimental|herombopag olamine tablets|
89097176|NCT01024920|Experimental|Nintedanib (BIBF 1120)|Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.
89097177|NCT01024920|Active Comparator|sunitinib|Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.
89097178|NCT00832117|Experimental|Escalation and Expansion|
89097179|NCT02611843|Experimental|Peer-Supported Web CBT|Semi-structured brief sessions conducted weekly for the 12 weeks of study treatment by a certified peer support specialist. Sessions focus on helping participants use the skills they are learning in the Web CBT treatment in their daily lives. Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
89097180|NCT02611843|Experimental|Self-Managed Web CBT|Self-managed Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
89097181|NCT02872272|Experimental|Treatment with Amikacin|Dressing impregnated by administration of amikacin
89097182|NCT02872896|Experimental|ClearSight device|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the ClearSight device second by second throughout surgery.
89097183|NCT02872896|Sham Comparator|Non-ClearSight|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the Non-ClearSight (the clinical team) every 5 minutes throughout surgery.
89097184|NCT02612467|Experimental|Stratified care|Patients are stratified into low, medium, high risk of poor outcome. Stratified care are delivered by special trained physiotherapists according to risk group
89097185|NCT02612467|Active Comparator|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
89097186|NCT04205292|Active Comparator|Dilatation and Evacuation (D&E)|Women in this group will receive an in-patient treatment with Dilatation and Evacuation (D&E) after two doses of Methotrexate .
89097187|NCT04205292|Experimental|hysteroscopic surgery|Women in this group will receive hysteroscopic surgery after two doses of Methotrexate .
89097188|NCT01104311|Experimental|Aggressive BP lowering|Lowering of systolic blood pressure between 110mmHg and 120mmHg during study period
89097189|NCT01104311|Active Comparator|Modest BP lowering|Lowering of systolic blood pressure between 130mmHg and 140mmHg
89097190|NCT02612389|Experimental|MM Intervention taught via DVD|Receive Meditative Movement training via DVD with pre and post interventional testing.
89097191|NCT02612389|No Intervention|MM Intervention Waitlist Control|Testing at same frequency as Meditative Movement interventional subjects.
89097192|NCT04205214|Experimental|Integrative Cognitive Behavioural Therapy Intervention Group|The group receive 12 weekly individual Integrative Cognitive Behavioural Therapy sessions from the principal investigator and Trainee counselling Psychologist. The sessions last up to 60 minutes on a weekly basis. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week intervention.
89097193|NCT04205214|No Intervention|Wait List Control Group|The group do not receive the intervention and are told that they can start the intervention after 12 weeks. The participants in this group are required to complete self-reported questionnaires assessing: anxiety, depression, stress and quality of life. They are also required to attend a scalp assessment and undergo a blood test and medical photography. These assessments occur at the initial assessment prior to beginning the intervention and after the 12-week waiting period. After this 12-week waiting period, they are offered the individual therapy and their data is added to the experimental group data.
89097194|NCT00702247|Experimental|1|
89097195|NCT00831493|Experimental|Vorinostat + Radiation Therapy|Vorinostat starting dose 200 mg orally once daily, Monday to Friday, Weeks 1 to 6; Radiation Therapy Dose of 50.4 Gray (Gy) in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
89097196|NCT00853567|Active Comparator|25 g Proellex|25 mg oral daily dose of Proellex
89097197|NCT00853567|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
89097198|NCT00853567|Placebo Comparator|Placebo|Placebo treatment
89097199|NCT00853489|Experimental|recombinant bone morphogenetic protein 2|The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
89097200|NCT00853489|Active Comparator|Autogenous iliac crest bone graft|Bone will be harvested from the iliac crest and placed in the bone defect.
89097201|NCT00700219||1|Women presenting in preterm labor with intact amniotic membranes
89097202|NCT00705445|Active Comparator|A|This group will not receive any of the intervention supplements. The group will only receive nutritional counselling and education, and treatment provided for any encountered illness according to IMCI guidelines.
89097203|NCT00705445|Experimental|B|"This group will receive micronutrient supplements containing microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid.~This group will also receive Nutritional Counselling and Education and treatment according to IMCI Guidelines for any serious illness."
89097204|NCT00705445|Experimental|C|"This group will receive Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, Folic Acid, and Zinc.~This group will also receive nutritional counselling, education and treatment according to IMCI Guidelines in case of any untoward illness."
89097205|NCT02879981||Pediatric Participants With Acute Bronchitis|Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to Balsamic Bactrim as per the local label will be observed for safety.
89097206|NCT04307693|Experimental|Lopinavir/ritonavir|Lopinavir/ritonavir 200mg/100mg 2 tablets by mouth, every 12 hours for 7-10 days
89227285|NCT04055987|Experimental|Congenitally deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of consonant-vowel-consonant (CVC) combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
89227286|NCT04055987|Experimental|Adventitiously deaf|Prior and post speech training, participants will read aloud a standard paragraph (Rainbow passage), complete a traditional speech test (Goldman Fristoe Test of Articulation - 3) to assess the sounds of the English language in all word positions (initial, medial, final) and read a list of CVC combinations. Individual treatment will be provided once a week for 10 consecutive weeks. Traditional speech intervention with visual biofeedback from the EPG will be used. Auditory feedback will be provided through the participants own cochlear implant.
89227287|NCT01037998|Active Comparator|A|Iressa 250 mg daily treatment plus UFUR twice daily treatment
89227288|NCT01037998|No Intervention|B|Gefitinib 250 mg daily treatment
89227289|NCT00752687|Other|1|Single dose of ABT-072, dose escalation ranging from 10 mg to 320 mg or placebo in healthy volunteers
89227290|NCT00752687|Other|2|HCV positive subjects administered 160mg ABT-072 or placebo, multi-dose, QD
89227291|NCT02561429|Experimental|SPT of histamine|SPT of histamine concentration 1, 5 and 10 mg/ml
89227292|NCT00751907|Experimental|Atorvastatin|40mg Atorvastatin nightly for 4 months
89227293|NCT00751907|Placebo Comparator|Placebo|matching placebo nightly for 4 months
89227294|NCT00752843|Experimental|1|
89227295|NCT00755729|Experimental|OCH|fast from midnight the night before surgery, and consume 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
89227296|NCT00755729|No Intervention|FSD|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
89227297|NCT00752921|Active Comparator|A|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
89227298|NCT00752921|Placebo Comparator|B|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
89227299|NCT00683657|Experimental|Saxagliptin 5 mg + Metformin|
89227300|NCT00683657|Placebo Comparator|Placebo + Metformin|
89227301|NCT00755963|Experimental|1|
89227302|NCT00755963|Experimental|2|
89227303|NCT00755963|Placebo Comparator|3|Placebo
89227304|NCT00752999|Experimental|A|150 mg tablet, oral, twice-a-day
89227305|NCT00752999|Placebo Comparator|B|Placebo tablet, oral, twice-a-day
89227306|NCT00756041|Experimental|TAK-128 100 mg QD|
89227307|NCT00756197|Experimental|Cryo Spray Ablation Group 1|4 cycles of 10 seconds each
89227308|NCT00756197|Experimental|Cryo Spray Ablation Group 2|2 cycles of 20 seconds each
89097207|NCT04307693|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 400mg by mouth, every 24 hours for 7-10 days
89097208|NCT04307693|No Intervention|Control|No lopinavir/ritonavir and hydroxychloroquine
89097209|NCT02878421|Active Comparator|tobacco cigarette|Intervention: tobacco cigarettes min 15/day
89097210|NCT02878421|Active Comparator|e.cigarettes + 16mg nicotine & flavor|Intervention: One flavoured electronic cigarette 16mg nicotine/day
89097211|NCT02878421|Active Comparator|e.cigarettes + 0mg nicotine & flavour|Intervention: One electronic cigarette with flavour +0mg nicotine/day
89097212|NCT02878187||placenta previa|all women managed by conservative surgical techniques during cesarean section after intraoperative hemorrhage due to placenta previa/accreta
89097213|NCT02878187||healthy controls|women delivered by Cesarean for any other indication with no intraoperative hemorrhage or any additional surgical techniques performed during Cesarean
89097214|NCT04307303|Experimental|Abdominal functional electrical stimulation|
89097215|NCT04307303|Sham Comparator|Low dose abdominal functional electrical stimulation arm|
89097216|NCT02879903|Experimental|biofilm tobacco effect|Group smokers - patients will receive periodontal treatment and biofilm will be collected.
89097217|NCT02879903|Experimental|biofilm non smoker effect|Group Non Smokers - patients will receive periodontal treatment and biofilm will be collected.
89097218|NCT04307459||Coronavirus Infection|All patients admitted to the Respiratory Unit with SARS-CoV-2 infection and respiratory failure
89097219|NCT01019694|Experimental|Combivent Respimat 20/100 microgram(mcg)|patient to take 1 inhalation 4 times a day
89097220|NCT01019694|Active Comparator|Combivent CFC-MDI 36/206 microgram-mcg|patient to take 2 inhalations 4 times a day
89097221|NCT01019694|Active Comparator|Atrovent HFA 42 mcg + Albuterol HFA|patient to take 2 inhalations of each 4 times a day
89097222|NCT00831415|Experimental|1|DVS SR
89097223|NCT01095653|Experimental|Group 1|
89097224|NCT01095653|Experimental|Group 2|
89097225|NCT01095653|Experimental|Group 3|
89097226|NCT00913159|Active Comparator|Using HM3 lithotripter|This is an older generation lithotripter
89097227|NCT00913159|Active Comparator|F2 lithotripter|This is a newer generation lithotripter
89097228|NCT00920907|Experimental|Ipilimumab (Process B)|Reference
89097229|NCT00920907|Experimental|Ipilimumab (Process C)|Test
89097230|NCT00705601||1|
89097231|NCT01103141|Active Comparator|Micropuncture|
89097232|NCT01103141|Active Comparator|Standard|
89097233|NCT00700297|Active Comparator|Colchicine|Patients who received Colchicine and went on placebo after 4 months
89097234|NCT00700297|Placebo Comparator|Placebo|Patients who received placebo and went on Colchicine after 4 months
89097235|NCT04307147|Experimental|NX (vinorelbine and capecitabine )|Standard therapy plus NX chemotherapy for 4 cycles, (vinorelbine 25 mg/m² d1,8 and capecitabine 1250 mg/m² d1-14, every 3 weeks)
89097236|NCT04307147|No Intervention|Control group|Standard therapy
89097237|NCT00844831|Experimental|Treatment with lubiprostone|Subjects receive lubiprostone and bacteria is measured before and after
89097238|NCT02878343|Active Comparator|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
89097239|NCT02878343|Active Comparator|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
89097240|NCT02878343|Active Comparator|Incentive and environmental strategies|A combination of incentives and environmental strategies
89097241|NCT02878343|No Intervention|Usual care|Standard employee wellness benefits
89097242|NCT04117633|Active Comparator|Mesh Rectopexy|Using Laparoscopy
89097243|NCT04117633|Active Comparator|Suture Rectopexy|Using Laparoscopy
89097244|NCT00920829|Active Comparator|A118G A/A with Naltrexone|Individuals with the OPRM1 genotype Asn40 are given naltrexone 50 mg after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
89097245|NCT00920829|Placebo Comparator|A118G A/A with Placebo|Individuals with the OPRM1 genotype Asn40 are given Placebo for 16 weeks with Medication Management in 16 weeks
89097246|NCT00920829|Active Comparator|A118G Any G with Naltrexone|Individuals with the OPRM1 genotype Any G (Asp) are given naltrexone 50 mg after 2 days of naltrexone 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
89097247|NCT00920829|Placebo Comparator|A118G Any G with Placebo|Individuals with the OPRM1 genotype Any G (Asp) are given 50 mg naltrexone after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
89097248|NCT04306835|Active Comparator|CPAP + CBT-i|Patients treated simultaneously with CPAP for their OSAS and cognitive behavioral therapy for their insomnia.
89097249|NCT04306835|No Intervention|CPAP only|Patients suffering from OSAS and insomnia, but only treated with CPAP.
89097250|NCT05010876|Experimental|standard care + C1 inhibitor|The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.
89097251|NCT05010876|Experimental|standard care + Icatibant + C1 inhibitor|"The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.~The icatibant will be used in a single injection of 30 mg subcutaneously, preferably in the abdominal region. These doses correspond to the doses usually used in the treatment of conditions in which icatibant is indicated."
89097252|NCT05010876|Placebo Comparator|standard care + placebo|
89097253|NCT04307069|Experimental|Immediate oxytocin infusion|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, she will receive oxytocin for augmentation of labor.
89097254|NCT04307069|Experimental|Expectant management for 24 hours|Once the patient will arrive at the maternity ward with prelabor rupture of membranes, we will wait for spontaneous delivery to occur. After 24 hours of rupture of membranes, the woman will receive oxytocin for augmentation of labor.
89097255|NCT02878265|Placebo Comparator|Vitamin A|A single dose of 20,000IU Vitamin A for the whole study period
89097256|NCT02878265|Active Comparator|Vitamin A and zinc|A single dose of 20,000IU Vitamin A and 10mg of elemental zinc each day for 5 months
89097257|NCT02878265|Active Comparator|Vitamin A , Zinc and Multivitamin|A single dose of 20,000IU Vitamin A , 10mg of elemental zinc each day and 0.5ml/kg multivitamin syrup for 5 months
89097258|NCT00831181|Experimental|Preoperative Chemoradiation|Preoperative Chemoradiation with oxaliplatin/5-FU followed by mesorectal excision and 5-FU / leucovorin (FOLFOX 6)
89097259|NCT01023672|Other|Armodifinil|150-250 mg armodafinil by mouth daily
89097260|NCT04251429|Experimental|Immediate Intervention Group|SHIFT study team provides coaching to Health and Safety Committee to implement a participatory program for increasing committee effectiveness.
89097261|NCT04251429|Other|Delayed Intervention Group|Active Comparator for 2 years: status quo program remains in place with new ongoing data collection. Then experimental intervention as above.
89097262|NCT05252013|Placebo Comparator|Plain Bread|Participants will be attending the Human Nutrition Unit in the morning (day 1), following an overnight fast. Fasted blood samples will be taken and one portion of plain bread (122g) served with 25g of jam will be consumed by the volunteers. The meal will be consumed within 15 minutes and postprandial blood samples will be collected. Participants will be provided with the meals for the rest of the day to take away and for days 2 and 3. In total, they will consume 6 plain bread rolls on days 1, 2 and 3 (2 bread rolls/day).
89097263|NCT05252013|Experimental|Broad bean hull bread|Participants will be attending the Human Nutrition Unit in the morning, following an overnight fast. Fasted blood samples will be taken and one portion of the bean hull bread (155g) served with 25g of jam will be consumed by the volunteers. The meal will be consumed within 15 minutes and postprandial blood samples will be collected. Participants will be provided with the meals for the rest of the day to take away and for days 2 and 3. In total, they will consume 6 bean hull bread rolls on days 1, 2 and 3 (2 bread rolls/day).
89097264|NCT00705835|Experimental|1|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Six patients will start on 50μg rsPSMA +0.5 mg Alhydrogel® Weeks 1,2,3 and 7.
89097265|NCT00705835|Experimental|2|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Eight patients will start on 250μg rsPSMA + 1.0 mg Alhydrogel Weeks 1,2,3 and 7
89097266|NCT01094171|Experimental|Poliorix Group|Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age. All vaccines were administered intramuscularly in the anterolateral side of the left thigh (Poliorix) and the right thigh (Infanrix).
89097267|NCT05251935|Experimental|Foot Muscle Exercise|
89097268|NCT05251935|Active Comparator|Arch Support Insole and One Leg Balance Activities|
89097269|NCT01093625|Experimental|Narafilcon B Contact Lens|Investigational Silicone Hydrogel Contact Lens
89097270|NCT01093625|Active Comparator|Spectacles|
89097271|NCT01023516|Experimental|1|
89097272|NCT01023516|Placebo Comparator|2|
89097273|NCT00844753|Active Comparator|1|Atomoxetine + Parent Management Training
89097274|NCT00844753|Active Comparator|2|Atomoxetine without Parent Management Training
89097275|NCT00844753|Placebo Comparator|3|Placebo + Parent Management Training
89097276|NCT00844753|Placebo Comparator|4|Placebo without Parent Management Training
89097277|NCT02878109||Post-treatment phase group|29 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before and after transarterial chemoembolisation (TACE).
89097278|NCT02878109||Pre-treatment phase group|11 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before treatment (if any).
89097279|NCT05525611|Experimental|Cabergoline|
89097280|NCT05525611|Placebo Comparator|Control|
89097281|NCT04309175|Experimental|Slow-Fast|
89097282|NCT04309175|Experimental|Fast-Slow|
89097283|NCT00830947|Experimental|OrthoAccel Device|Device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
89097284|NCT00830947|Sham Comparator|Sham Device (inactive device)|Sham device will look identical to active devices but will not deliver vibration to the patient.
89227309|NCT00753311|Active Comparator|Rizatriptan|Patients with migraine with and without aura will be enrolled and randomly provided with study drug (rizatriptan 10 mg MLT or placebo, ratio 1:1). Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
89227310|NCT00753311|Placebo Comparator|placebo|Patients who met all the study entry criteria were enrolled and randomly allocated to receive either rizatriptan 10 mg wafer or placebo (ratio 1:1).Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
89227311|NCT00756431|Active Comparator|Screw without HA Coating (Hiploc)|
89227312|NCT00756431|Experimental|Screw with HA Coating (Hiploc)|
89227313|NCT00756587|Active Comparator|I|Group one received feeding by bottle as the standard method of feeding in the NICU
89227314|NCT00756587|Experimental|II|Group 2 received all feeding by cup
89227315|NCT00756743|Experimental|PF-04802540|
89227316|NCT00756743|Placebo Comparator|Placebo|
89227317|NCT00753389||1|
89227318|NCT00756821||SMA cohort|Subjects between the ages of 2-12 years diagnosed with SMA Type I, II, or III.
89227319|NCT00756821||Control cohort|Healthy children between the ages of 2-12 years. These children may be either genetically-related siblings of SMA children (genetically confirmed non-carriers of SMA),or unrelated children.
89227320|NCT00680771||1|Primary Insomnia
89227321|NCT00680771||2|Good Sleepers
89227322|NCT00753467|Experimental|1|IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days
89227323|NCT00753467|Experimental|2|IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days
89227324|NCT00753467|Active Comparator|3|Adefovir dipivoxil monotherapy (10 mg QD) 30 days
89227325|NCT00482703|Experimental|A|
89227326|NCT00482703|Experimental|B|
89227327|NCT00756899||Obese|Chilren with BMI of >95th percentile
89227328|NCT00756899||Non-obese|Children with BMI of <85th percentile
89227329|NCT00757055|Active Comparator|1|Patients on ivabradine titrated to heart rate
89227330|NCT00757055|Placebo Comparator|2|No therapy given
89097285|NCT05524129|Experimental|Interventional (Group I)|It will be a hybrid form of rehabilitation, i.e. home exercises according to brochures in combination with regular visits to the ambulance for check-ups according to a precisely set schedule, the authorized physiotherapist will also contact the patients by phone at regular weekly intervals, thereby maintaining their motivation.
89097286|NCT05524129|Active Comparator|Control (Group II)|These patients will undergo regular rehabilitation only in the outpatient center with the normally indicated frequency visits twice a week for 4 weeks.
89097287|NCT01018992|Placebo Comparator|Placebo|Adult women with DSM-IV defined PTSD will receive matching placebo for 6 weeks
89097288|NCT01018992|Experimental|GSK561679|Adult women with DSM-IV-defined PTSD will receive GSK561679 at a fixed dose of 350 mg/day for 6-weeks
89097289|NCT02872350|Experimental|Premature with necrotizing enterocolitis|
89097290|NCT00917553|Experimental|doxycycline monohydrate|
89097291|NCT00917553|Placebo Comparator|Placebo|Placebo
89097292|NCT04809909|Experimental|Peripheral stimulation of acupuncture points (PSAP)|Two electrode leads will be implanted and connected to an external neurostimulator for electrical stimulation of acupuncture points.
89097293|NCT04809909|Active Comparator|Peripheral nerve field stimulation (PNFS)|Two electrode leads will be implanted and connected to an external neurostimulator for electrical stimulation of the painful area.
89097294|NCT05251857|Experimental|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|The intervention group is the group in which the investigors applied animation education program Intervention: Behavioral: Animation Education Program
89097295|NCT05251857|No Intervention|Standard Clinical Care Applied to Laparoscopic Sleeve Gastrectomy Patients|The control group is the group that receives standard clinical care
89097296|NCT04747509|Experimental|Blackburn exercises|Blackburn exercises and hot pack
89097297|NCT04747509|Active Comparator|Conventional physical therapy|Conventional physical therapy and hot pack
89097298|NCT04255251|Experimental|Intervention group|Subjects in this group will receive Silver Diamine Fluoride around their crown margins every six month for the next 3 years.
89097299|NCT04255251|Active Comparator|Fluoride varnish group|Subjects in this group will receive fluoride varnish around their crown margins every six month for the next 3 years.
89097300|NCT04859439|Experimental|Mild Renal Impairment|Subjects will receive a single dose of 100 mg DBPR108
89097301|NCT04859439|Experimental|Moderate Renal Impairment|Subjects will receive a single dose of 100 mg DBPR108
89097302|NCT04859439|Experimental|Severe Renal function|Subjects will receive a single dose of 100 mg DBPR108
89097303|NCT04859439|Experimental|Kidney failure|Subjects will receive a single dose of 100 mg DBPR108
89097304|NCT04859439|Experimental|Normal Renal function|Subjects will receive a single dose of 100 mg DBPR108
89097305|NCT04855851|Experimental|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|Subjects will receive 6 PAIN NEUROSCIENCE EDUCATION (PNE) sessions and 12 weeks (3 times/week) of STRENGTH TRAINING (ST)
89097306|NCT04855851|Active Comparator|USUAL CARE|The subjects of this group will receive Usual Care. In Spain, the treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients, and recommendation of aerobic and flexibility exercise
89097307|NCT01018680|Placebo Comparator|Placebo|
89097308|NCT01018680|Experimental|Duloxetine|
89097309|NCT04255017|No Intervention|Symptomatic supportive treatment|Symptomatic supportive treatment
89097310|NCT04255017|Experimental|Abidol hydrochloride was added on the basis of group I.|Abidol hydrochloride 0.2g once,3 times a day,2 weeks
89097311|NCT04255017|Experimental|Oseltamivir was added on the basis of group I.|Oseltamivir 75mg once,twice a day,2 weeks
89097312|NCT04255017|Experimental|Lopinavir/ritonavir was added on the basis of group I.|Lopinavir/ritonavir 500mg once,twice a day,2 weeks
89097313|NCT04255173|Experimental|Geriatric osteoporotic patients|We measured different anthropometric and body composition measurements as body weight, BMI, percentage body fat, skeletal muscle index (SMI), ABSI, waist (WC) and hip circumference (HC) in geriatric population to investigate the relation to osteoporosis.
89097314|NCT04255095|Active Comparator|Nasobiliary drainage|
89097315|NCT04255095|Experimental|Naso-pancreatic drainage(negative pressure)|
89097316|NCT04592991|Active Comparator|AAA Group|"Participants with AAA will undergo routine clinical evaluation of AAA including ultrasound and CT and scheduling of open surgical repair as directed by the treating physician. We will record age and tobacco use of participant. If participant has not had a renal function blood test performed within the past 90 days, we will draw approximately 2 teaspoons of blood for a creatinine test. We will also ask the participant's permission to use a contrast dye for the CT portion of the PET-CT scan. If the participant agrees we will additional questions to gauge eligibility to receive the contrast dye.~If available, we would like to collect any discarded AAA tissue from the surgical procedure. This discarded tissue will be kept as part of a Washington University vascular research repository. If the participant agrees to this there will be a separate consent form to sign allowing the collection of the leftover tissue along with some information about medical history."
89227331|NCT04052867|Experimental|Lignocaine group|20 patients undergoing elective laparoscopic donor nephrectomy will be given lignocaine infusion as part of the perioperative pain management.
89227332|NCT04052867|Active Comparator|Control group|20 patients undergoing elective laparoscopic donor nephrectomy will be receiving an equivalent volume of normal saline.
89227333|NCT00757133|Experimental|1|Conventional laparotomy closure
89227334|NCT00757133|Active Comparator|2|Laparotomy closure with mesh augmentation
89227335|NCT00482391|Experimental|AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB|The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is given subcutaneously (SQ) on day # 2 of each AC. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion. Trastuzumab will be administered weekly starting with paclitaxel treatment # 1. Near the completion of all chemotherapy, patients may receive trastuzumab on a q 3-weekly schedule, starting as early as with paclitaxel cycle # 12. The total duration of trastuzumab from beginning to end is 52 weeks. Lapatinib will be given orally at 1000 mg daily, starting with trastuzumab for a total duration of 52 weeks. Hormonal therapy such as tamoxifen or an aromatase inhibitor will be given to patients with hormone receptor positive disease at the physician's discretion. Radiation therapy to the breast or chest is recommended to patients as appropriate.
89227336|NCT00753779|Experimental|1|colesevelam HCl Tablets and simvastatin tablets
89227337|NCT00753779|Placebo Comparator|2|simvastatin and Welchol placebo
89227338|NCT00757289|Experimental|1|PRP injection
89227339|NCT00757289|Active Comparator|2|Corticosteroid Injection
89227340|NCT00757367|Experimental|TI Inhalation Powder|TI Inhalation Powder, single dose, 60 units
89227341|NCT00757523|Active Comparator|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation).
89227342|NCT00757523|Experimental|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation).
89227343|NCT00753857|Experimental|1|Participants received 2 ads for drugs to reduce cardiovascular risk with drug facts boxes second pages.
89227344|NCT00753857|Active Comparator|2|Participants receive the same 2 advertisements for drugs to reduce cardiovascular risk with the standard second page (i.e., brief summary)
89227345|NCT00423046|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals human papillomavirus [HPV]16/18 vaccine 580299 (CervarixTM) at Months 0, 1 and 6 and a dose of placebo at Month 2. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
89227346|NCT00423046|Active Comparator|Gardasil Group|Subjects received 3 doses of Gardasil® (Merck's human papillomavirus [HPV] vaccine) at Months 0, 2 and 6 and a dose of placebo at Month 1. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
89227347|NCT00757679|Experimental|Milnacipran|
89227348|NCT00757679|Placebo Comparator|Placebo|
89227349|NCT00754091|Experimental|1|
89227350|NCT00496587|Experimental|Capecitabine + Gemcitabine + Bevacizumab|Capecitabine 800 mg/m^2 By Mouth Twice Daily On Days 1-21. Gemcitabine 900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15. Bevacizumab 10 mg/kg By Vein On Days 1 and 15.
89227351|NCT00757835|Active Comparator|Travoprost/timolol therapy|treatment with travoprost/timolol fixed combination drops once in the evening for 3 months. 24-hour pressure monitoring.
89227352|NCT00757835|Active Comparator|Latanoprost/timolol therapy|Treatment with latanoprost/timolol fixed combination for 3 months. 24-hour pressure monitoring.
89227353|NCT04052633||Cholangiography success|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative success of cholangiography
89227354|NCT04052633||Cholangiography failure|From January 2018 to August 2018 all consecutive elective and emergency cholecystectomies performed with intraoperative failure of cholangiography
89227355|NCT01038076|Experimental|MedCHEC Tablet Computer & Adherence Care|Patients assigned to the intervention answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates provider and patient reports. Patients may be referred to an Adherence Care Manager on the basis of the reports. In addition, patients will receive standard information about adherence.
89227356|NCT01038076|No Intervention|Adherence Information Only|Patients assigned to the active comparator arm will receive standard information about adherence.
89227357|NCT00757913|Experimental|1|n-3 enriched nutrition
89227358|NCT00757913|Placebo Comparator|2|isocaloric nutrition without n-3 supplement
89227359|NCT01038154|No Intervention|control|Not Receive pravastatin
89097317|NCT04592991|Active Comparator|Aortoiliac Occlusive Disease Group|Participants with non-aneurysmal aortoiliac occlusive disease, will be eligible for the study based on lifestyle limiting claudication (lack of blood flow to muscles causing cramping), pain in the feet or toes at rest, and/or tissue loss (leg or foot ulcers that don't heal or gangrene) that requires aortofemoral bypass. The aortofemoral bypass is not part of this research study.
89097318|NCT01012440|Experimental|Beast cancer subjects|Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods
89097319|NCT00916929|Other|Implantable Cardioverter Defibrillator (ICD)|Impedance Monitoring Feature in an Implantable Cardioverter Defibrillator (ICD).
89097320|NCT00916929|Other|Cardiac Resynchronization Therapy (CRT-D)|Impedance Monitoring Feature in a Cardiac Resynchronization Therapy (CRT-D) device.
89097321|NCT04299750|Experimental|Alveolar Ridge Preservation|Patients in this arm will undergo atraumatic extraction of an hopeless tooth and a socket preservation procedure. Alveolar ridge preservation will be performed using a slow-resorption bone substitute and a collagen membrane that covers the graft.
89097322|NCT04299750|Active Comparator|Natural healing|Patients in this arm will undergo atraumatic extraction of an hopeless tooth. The socket will follow natural healing.
89097323|NCT04299516|Experimental|Two-team SBA|Two-team simultaneous bilateral total knee arthroplasty
89097324|NCT04299516|Active Comparator|Single-team SBA|Single-team simultaneous bilateral total knee arthroplasty
89097325|NCT02872194|Experimental|Suncare agent A + control|Application of control and test product into one of the subjects two eyes.
89097326|NCT02872194|Experimental|Suncare agent B + control|Application of control and test product into one of the subjects two eyes.
89097327|NCT02872194|Experimental|Suncare agent C + control|Application of control and test product into one of the subjects two eyes.
89097328|NCT04298736|Experimental|Bariatric Surgery|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to either laparoscopic Roux-en-Y Gastric Bypass or laparoscopic Sleeve Gastrectomy
89097329|NCT04298736|Active Comparator|Lifestyle Modification|Obese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to guided diet and physical activity.
89097330|NCT00844597|Experimental|Cohort 1 - 0.5 mg/kg/wk|Subjects in this group will receive a 0.5 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
89097331|NCT00844597|Experimental|Cohort 2 - 1.0 mg/kg/wk|Subjects in this group will receive a 1.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
89097332|NCT00844597|Experimental|Cohort 3 - 2.0 mg/kg/wk|Subjects in this group will receive a 2.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
89097333|NCT00844597|Experimental|Cohort 4 - 4.0 mg/kg/wk|Subjects in this group will receive a 4.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
89097334|NCT00844597|Experimental|Cohort 5 - 10.0 mg/kg/wk|Subjects in this group will receive a 10.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
89097335|NCT00844597|Experimental|Cohort 6 - 20.0 mg/kg/wk|Subjects in this group will receive a 20.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
89097336|NCT01017120|Experimental|1|Tazarotene foam, 0.1%
89097337|NCT01017120|Placebo Comparator|2|Vehicle Foam
89097338|NCT04297410|Experimental|Neoadjuvant LuPSMA|
89097339|NCT04298580|Active Comparator|PVB before surgery|
89097340|NCT04298580|Active Comparator|PVB after surgery|
89097341|NCT02872038|Experimental|Treatment|Cefepime intraperitoneal continuous dosing
89097342|NCT02872038|Active Comparator|Control|Cefazolin plus Ceftazidime intraperitoneal continuous dosing
89097343|NCT02871804|Active Comparator|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
89097344|NCT02871804|Experimental|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
89097345|NCT04298424|Experimental|Peer-led|The experimental group will conduct a 4-week peer self-management program and receive the original outpatient routine care.
89097346|NCT04298424|No Intervention|No Peer-led|The control group will only issue a self-management manual and receive the original outpatient routine care.
89097347|NCT01016964|Sham Comparator|Sham Device|Sham device
89097348|NCT01016964|Active Comparator|LLT Device 2009 12 Beams|HairMax LaserComb 2009 model 12 beam
89097349|NCT00627900|Other|BMS|Implantation of a bare metal stent
89097350|NCT00627900|Other|SES|Implantation of a sirolimus-eluting stent
89097351|NCT04299360||standard BIV|the following group describes the effects of the left ventricular stimulation involving a dipole of two electrodes located inside a suitable vessel branch of the coronary sinus (CS). Standard BIV pacing modality can be achieved by either a quadripolar electrode implanted in the CS, of which only two poles will be used for cardiac resynchronization therapy, or by a bipolar electrode equipped with just two electrodes. The latter describes the old technology, requiring a change into typology of generator which has to display an IS-1 connection (due to different distal terminal of the electrode itself), instead of the new one IS-4 connection that has been developed for quadripolar electrodes.
89097352|NCT04299360||MPP BIV|Such modality of left ventricular stimulation requires a dynamic use of the four electrodes located in the proximal segment of the electrocatheter that allows the recruitment of a vast area of the left ventricle. It is limited by the presence of scars on left ventricle surface, or phrenic nerve inadvertent stimulation.
89097353|NCT02996110|Active Comparator|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab
89097354|NCT02996110|Experimental|Nivolumab + Relatlimab|Nivolumab + Relatlimab
89097355|NCT02996110|Experimental|Nivolumab + BMS-986205|Nivolumab + BMS-986205
89097356|NCT02996110|Experimental|Nivolumab + BMS-813160|Nivolumab + BMS-813160 (CCR2/5 dual antagonist)
89097357|NCT04213768|Experimental|Plication|
89097358|NCT04213768|Active Comparator|Resection|
89097359|NCT00916617|Experimental|1|5 mg/week
89097360|NCT04214236|Experimental|ciNPT group|Subjects will receive post-operative incisional wound care by ciNPT (125 mmHg, continuous suction) for the first 7 days after surgery.
89097361|NCT04214236|Sham Comparator|Control group|Subjects will receive post-operative incisional wound care by standard non-adherent surgical dressing (vaseline petrolatum gauze),
89097362|NCT01103063|Experimental|AZCQ|Azithromycin/chloroquine
89097363|NCT01103063|Active Comparator|SP|sulfadoxine-pyrimethamine (Fansidar)
89097364|NCT04214158||Professional Folk Dancers|Individuals who have been actively dancing for at least two years will be included in the study.
89097365|NCT04214158||sedentary|According to the international physical activity questionnaire, individuals with low levels of physical activity will be included in the study.
89097366|NCT02987998|Experimental|Resectable Patients|Chemoradiation (Cisplatin + Etoposide + Pembrolizumab with concurrent radiation). Patients will be assessed for surgery followed by consolidation therapy
89097367|NCT04213378|Experimental|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent restenosis with paclitaxel eluting PTCA balloon
89097368|NCT04213378|Active Comparator|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent restenosis with SeQuent® Please paclitaxel eluting balloon
89097369|NCT02879591|Experimental|Patients with schizophrenia|Patients with schizophrenia
89097370|NCT02879591|Placebo Comparator|Healthy volunteers|Healthy volunteers
89097371|NCT00617032|Active Comparator|1|1x10^10 DRP/mL tgAAC94
89097372|NCT00617032|Active Comparator|2|1x10^11 DRP/mL tgAAC94
89097373|NCT00617032|Placebo Comparator|3|Single dose tgAAC94 placebo
89097374|NCT02877953|No Intervention|Control group|The conventional care was performed for the patients of control group
89097375|NCT02877953|Experimental|Intervention group|the prevention of complications post-TIPS
89097376|NCT04213924|Active Comparator|Group ESPB|Ultrasound-guided erector spinae plane block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
89097377|NCT04213924|Active Comparator|Group NSAII|lidocaine 5% gel and 800 mg ibuprofen intravenously
89097378|NCT02968264||TOF participants|Tetralogy of fallot patients at any age
89097379|NCT01091675|Experimental|etoricoxib|All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
89097380|NCT00620230|Experimental|1|
89097381|NCT00620230|Placebo Comparator|2|
89097382|NCT00617110|Sham Comparator|allergic clean air|subjects with allergic rhinitis will be exposed to clean air followed by LAIV
89097383|NCT00617110|Active Comparator|Allergic diesel|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
89097384|NCT00617110|Sham Comparator|control clean air|Healthy control subjects will be exposed to clean air followed by LAIV
89097385|NCT00617110|Sham Comparator|Control diesel|Healthy control will be exposed to diesel followed by LAIV
89097386|NCT02739412|Experimental|Interleukin-2|IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.
89097387|NCT04213612|Experimental|PLD+CTX+VCR|CTX 1g/m2/d，D1-2 VCR 1.5mg/m2，D1
89097388|NCT01091519||Toviaz(fesoterodine) plus educational materials|
89097389|NCT01091519||Toviaz(fesoterodine) alone|Toviaz(fesoterodine) without additional educational materials
89097390|NCT00620308|Experimental|CD-NP low-dose study drug|
89097391|NCT00620308|Experimental|CD-NP high-dose study drug|
89097392|NCT00620308|Placebo Comparator|Placebo|
89097393|NCT02878031|Experimental|Oral amoxicillin for CI pneumonia|Community management of chest indrawing pneumonia using oral amoxicillin by CHWs
89097394|NCT00572962|Experimental|1|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
89097395|NCT02879669|Experimental|ONCOS-102+cyclophosphamide+pemetrexed/cisplatin (carboplatin)|ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120). Pre-treatment with an i.v. bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78). Patients will also receive pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin (carboplatin) in combination with ONCOS-102.
89227360|NCT01038154|Experimental|Pravastatin|
89097396|NCT02879669|Active Comparator|Pemetrexed/cisplatin (carboplatin)|Patients will be treated with pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 1, and continuing as applicable during the study period of 6 cycles of chemotherapy. Patients will be monitored regularly for immunological assessment (PBMCs) including Month 9 and Month 12 (i.e., after the end of study visit), and will be followed up for survival every 3 months until end of life.
89097397|NCT04213690||Patients with Lupus|Patients who have been diagnosed with Lupus
89097398|NCT05339321|Experimental|SCG101|SCG101 will be given via Intravenous (IV) infusion.
89097399|NCT05339321|Experimental|SCG101 + PD1/PD-L1 checkpoint inhibitor|SCG101 will be given via Intravenous (IV) infusion. The PD-1/PD-L1 checkpoint inhibitor will be given per product label.
89097400|NCT00620386|Experimental|1|Intubation with Bonfils intubating fiberscope
89097401|NCT00620386|Active Comparator|2|Intubation with Macintosh laryngoscopy
89097402|NCT01011738||Cohort|
89097403|NCT00918333|Experimental|Treatment (panobinostat and everolimus)|Patients receive panobinostat PO QD or on days 1, 3, 5, 15, 17, and 19 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89097404|NCT04929730|No Intervention|Control group|Patients with an acute kidney injury in laborytory testing receive usual care. Nephrology co-supervision only on enquiry of the ward physician
89097405|NCT04929730|Other|Interventional group|Patients with an acute kidney injury in laborytory testing receive nephrology co-supervision in hospital and information about the importance of ambulant follow-up care.
89097406|NCT01091363|Experimental|deep cultural arm|deep cultural therapy
89097407|NCT01091363|Active Comparator|standard arm|brief cessation counseling
89097408|NCT04910542|Other|EpI-Net community intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
89097409|NCT04306757|Experimental|FCV|Artificial ventilation will be performed with individualized flow-controlled ventilation (Evone, Ventinova Medical B.V., Eindhoven, the Netherlands) during cardiac surgery until admission to postoperative ICU. Individualisation will be established by compliance guided end-expiratory and peak pressure setting, flow setting will be adjusted to secure normocapnia and I:E Ratio set to 1:1.
89097410|NCT04306757|Active Comparator|PCV|Artificial ventilation will be performed with low tidal volume pressure-controlled ventilation (Primus, Dräger, Lübeck, Germany) during cardiac surgery until admission to postoperative ICU. Peak pressure will be set to achieve a tidal volume of 7ml/kg predicted body weight at a compliance titrated positive end-expiratory pressure. Respiratory rate will be set to maintain normocapnia and I:E ratio set to 1:1.5 except extension of expiration is necessary in order to avoid air trapping.
89097411|NCT00617266|Active Comparator|Arm 1 Control Group|Distribution of pamphlets containing information on the hazards of tobacco
89097412|NCT00617266|Experimental|Arm 2|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
89097413|NCT00617266|Experimental|Arm 3|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
89097414|NCT00617266|Experimental|Arm 4|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
89097415|NCT01090973|Experimental|Oral drug treatment|LBH589 will be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 & 5, then 8, 10 &12, then 15, 17 & 19, then 22, 24 & 26.
89097416|NCT04755933|Experimental|Intervention|An online learning tool, designed to helps parents develop a calm, consistent behaviour management style, whilst learning skills to discourage children's avoidance.
89097417|NCT04755933|No Intervention|Control|The participants in the control arm will not receive access to the online course, but will complete the same sets of questionnaires at each of the timepoints.
89097418|NCT02607904|Experimental|GWP42003-P|"Administered orally, twice daily (morning and evening), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner (i.e., only participants taking placebo in the blinded phase will up-titrate; doses will remain unchanged for those taking GWP42003-P in the blinded phase).~Participants remain on the maintenance dose for the remainder of the 48-week treatment period, until early withdrawal or at an early study conclusion date defined by the sponsor. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found.~Dosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early."
89097419|NCT04604925||Remote patient monitoring for hypertension|RPM Integration: All intervention practices will receive communication by email explaining RPM procedures, ordering, use, and financial implications. We will also present this information at practice meetings. Primary care clinicians at these sites will receive clinical decision support (Epic Best Practice Alert) for patients meeting primary or secondary eligibility criteria. It will be at the discretion of the primary care clinicians when to offer or refer patients to RPM.
89097420|NCT04604925||Usual care|Matching patients from control practices will be selected from remaining Northwestern Medical Group primary care sites and be chosen to provide as sufficiently large number of eligible patients for comparison. These groups will contribute EHR data through the NM EDW but will not have any new procedures put in place
89097421|NCT05295394|Experimental|single arm|dolutegravir 50 mg QD plus lamivudine 300 mg QD
89097422|NCT01090739|Experimental|TOPAS|TOPAS Treatment for Fecal Incontinence
89097423|NCT04916457||group ND|control group without DM non-intervention
89097424|NCT04916457||group VD|"very low-risk group: diabetic patient with no loss of protective sensation(LOPS) and no peripheral artery disease(PAD).~non-intervention"
89097425|NCT04916457||group LD|low-risk group: diabetic patient with LOPS or PAD non-intervention
89097426|NCT04916457||group MD|moderate-risk group: diabetic patient with LOPS + PAD non-intervention
89097427|NCT04916457||group HD|"high-risk group: diabetic patient with LOPS or PAD, and one or more of the following:~history of a foot ulcer~a lower-extremity amputation (minor or major)~end-stage renal disease~non-intervention"
89097428|NCT02871648|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
89097429|NCT02871648|Active Comparator|Fludrocortisone|Subjects will receive 0.1 mg of fludrocortisone (Florinef) on one of three study days.
89097430|NCT02871648|Active Comparator|Epleronone|Subjects will receive 100 mg of epleronone on one of three study days.
89097431|NCT04873024|Experimental|Intervention-first|Participants in this arm will receive the Intervention treatment on the first night, and the control treatment on the second night.
89097432|NCT04873024|Experimental|Control-first|Participants in this arm will receive the Control treatment on the first night, and the Intervention treatment on the second night.
89097433|NCT00637845|Experimental|1|40mg once daily
89097434|NCT00637845|Active Comparator|2|30mg twice daily
89097435|NCT04297878|Experimental|Group A|Taking two SsK12 lozenges at night on days 1, 7 and 14.
89097436|NCT04297878|Active Comparator|Group B|One SsK12 daily at night for 14 days.
89097437|NCT04209712|Experimental|haploid allogeneic NK cell therapy|haploid allogeneic NK cell therapy with chemotherapy
89097438|NCT00628524||1|> 500 consecutive patients with coronary artery disease fulfilling eligibility criteria.
89097439|NCT04284384||HUNT4 70+|All inhabitants of Nord-Trøndelag 70 years of age or older were invited to participate in HUNT4 70+.
89097440|NCT04284384||HUNT Trondheim 70+|All inhabitants of one district in Trondheim 70 years of age or older were invited to participate in HUNT4 70+.
89097441|NCT02497300|Experimental|Spironolactone|Participants will be randomized to spironolactone 25mg daily for the 1st or 2nd 6 week treatment period.
89097442|NCT02497300|Active Comparator|Amiloride|Participants will be randomized to amiloride 5mg daily for the 1st or 2nd 6 week treatment period.
89097443|NCT04254471|Experimental|Dose escalation (AL3810 + carboplatin + etoposide)|Phase II:Participants will receive AL3810 orally in combination with carboplatin and etoposide during the Cycles 1-4 . AL3810 dose escalated form 5mg to 10mg step-up to determine the recommended dose of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
89227361|NCT02560727||colonoscope via of FMT|FMT pathway is colonoscope
89097444|NCT04254471|Experimental|AL3810+ carboplatin + etoposide|Phase III:Participants will receive AL3810(recommended dose will be determined by safety monitoring committee (SMC) in Phase II) orally in combination with carboplatin and etoposide during the Cycles 1-4. Thereafter, participants will receive maintenance AL3810 until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
89097445|NCT04254471|Placebo Comparator|Placebo+ carboplatin + etoposide|Phase III:Participants will receive placebo orally in combination with carboplatin and etoposide during the induction Cycles 1-4. Thereafter, participants will receive maintenance placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent, investigator's consideration, lost follow up, death ,study termination by the sponsor.whichever occurs first.
89097446|NCT04299672|Experimental|Postural reconstruction|"Maximum external rotation of the hip in lower limb elevation and the dorsal flexion of the ankle with flexion of the toes, performed in both lower limbs alternately and independent.~Participant must control breathing. The detail phases of a general intervention are:~PASSIVE displacement of the segment until reaching CRITICAL AMPLITUDE, which corresponds to the light myofascial stress or to the appearance of evoked responses.~ACTIVE MAINTENANCE of the critical amplitude.~WORK BREATHING.~INDUCTIVE ACTIVE APPLICATIONS with movements of great relative amplitude.~FINISHING CRITERIA: reduction or extinction of evoked responses, patient fatigue or execution of the technique for 15 minutes without any of the above premises having been reached."
89097447|NCT00631527|Experimental|Sunitinib Malate, Hormone Ablation + RT|Sunitinib Malate + Hormone Ablation (Leuprolide or Goserelin + Bicalutamide) + Radiation Therapy (RT)
89097448|NCT00620620|Placebo Comparator|Inhaled Placebo|Staccato Placebo
89097449|NCT00620620|Experimental|Inhaled Zaleplon 0.5 mg|Staccato Zaleplon 0.5 mg
89097450|NCT00620620|Experimental|Inhaled Zaleplon 1 mg|Staccato Zaleplon 1 mg
89097451|NCT00620620|Experimental|Inhaled Zaleplon 2 mg|Staccato Zaleplon 2 mg
89097452|NCT00620620|Experimental|Inhaled Zaleplon 4 mg|Staccato Zaleplon 4 mg
89097453|NCT04209556|Placebo Comparator|Placebo|Placebo
89097454|NCT04209556|Experimental|PF-06826647 100 mg once a day (QD)|PF-06826647 100 mg once a day (QD)
89097455|NCT04209556|Experimental|PF-06826647 300 mg QD|PF-06826647 300 mg QD
89097456|NCT04209556|Experimental|PF-06826647 600 mg QD|PF-06826647 600 mg QD
89097457|NCT04209556|Experimental|Open Label Extension, PF-06826647 400 mg QD|PF-06826647 400 mg QD
89097458|NCT00916383|Experimental|Upper Back|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.
89097459|NCT00916383|Experimental|Upper Arm|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.
89097460|NCT00916383|Experimental|Side of Torso|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.
89097461|NCT00617500|Active Comparator|Hormone|
89097462|NCT00617500|Experimental|flower therapy|
89097463|NCT00617500|Experimental|therapeutic touch|
89097464|NCT00617500|Experimental|auriculotherapy|
89097465|NCT04845555||Patients with hemophilia A|Patients suffering from moderate or severe hemophilia A (FVIII <5%) over the age of 12 years.
89097466|NCT04254003|Other|Test, then Control|DT1 Toric contact lenses worn first, followed by AO1DfA contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
89097467|NCT04254003|Other|Control, then Test|AO1DfA contact lenses worn first, followed by DT1 Toric contact lenses, as randomized. Each product will be worn in both eyes for approximately 1 hour.
89097468|NCT04703998|Experimental|Arthroscopic rotator cuff repair and platelet rich plasma|A standard double-row arthroscopic rotator cuff repair will be performed and at the end of the procedure 10 ml of autologous platelet-rich plasma will be placed under direct vision at the tendon-bone interface.
89097469|NCT04703998|Active Comparator|Arthroscopic rotator cuff repair|A standard double-row arthroscopic rotator cuff repair will be performed.
89097470|NCT04209478|Experimental|TAP Block|Cases were assessed transversus abdominis plane block for postoperative analgesia
89097471|NCT04209478|Experimental|QL Block|Cases were assessed quadratus lumborum block for postoperative analgesia
89097472|NCT05252715|Experimental|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 20 µg/dose. Primary vaccination at 0, 1 and 2 months of age, respectively. Booster vaccination at 18 months of age.
89097473|NCT05252715|Active Comparator|Meningococcal A and C Polysaccharide Conjugate Vaccine|Meningococcal A and C Polysaccharide Conjugate Vaccine, 20 µg/dose. Primary vaccination at 0, 1 and 2 months of age, respectively.
89097474|NCT00617578|Experimental|1|programming of VF therapy: ATP (antitachycardia pacing) One Shot ON
89097475|NCT00617578|Active Comparator|2|programming of VF therapy: ATP (antitachycardia pacing) One Shot OFF
89097476|NCT05252637|Experimental|Duplication plus LSC|Laparoscopic duplication of posterior vagina plus mesh placement
89097477|NCT05252637|No Intervention|LSC|Laparoscopic Sacral Colpopexy with mesh placement on posterior vagina
89097478|NCT04209244|Experimental|Fish oil|Eskimo-3 Pure Fish Oil, 10 ml per day (2.6 g EPA+DHA)
89097479|NCT04209244|Placebo Comparator|Placebo|Rapeseed Oil, 10 ml per day
89097480|NCT05251623|Experimental|pedometer|walking with pedometer
89097481|NCT05251623|No Intervention|control|no intervention
89097482|NCT00631605||1|
89097483|NCT00631605||2|
89097484|NCT04209166|Experimental|FAD|the first-episode major depressive disorder with atypical feature
89097485|NCT04209166|Experimental|RAD|the recurrent major depressive disorder with atypical feature who have been medication-free for no less than 2 weeks
89097486|NCT04209166|No Intervention|BD|the depressive episode of bipolar disorder
89097487|NCT04209166|No Intervention|HC|healthy control
89097488|NCT00916305|Experimental|Modified Audio video|Participants will listen to an audio video modified to mimic noise induced hearing loss after one night at a loud club
89097489|NCT00916305|Active Comparator|Unmodified Audio video|Participants will listen to the same music as the other arm, but only the track with unaltered music.
89097490|NCT04253925|Experimental|global postural correction exercises|global postural correction exercises in addition to Kegel exercises
89097491|NCT04253925|Active Comparator|Kegel exercises|only Kegel exercises
89097492|NCT04766008|Experimental|Metformin continuation|
89097493|NCT00916149|Active Comparator|Levetiracetam|12 individuals with epilepsy, 6 of whom experience infrequent focal epileptiform discharges and 6 of whom experience frequent focal discharges. These individuals will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.
89097494|NCT00916149|Active Comparator|Lamotrigine|12 individuals with epilepsy, 6 of whom experience infrequent generalized discharges and 6 of whom experience frequent generalized discharges. These individuals will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.
89097495|NCT00916149|No Intervention|No treatment|15 healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.
89097496|NCT04742920|Other|MMA embolization group|MMA embolization procedure with Onyx™ in addition to standard (surgical/conservative) management
89097497|NCT04742920|Other|Control group|Standard (surgical/conservative) Management alone
89097498|NCT00631761|Experimental|1|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas of the human bladder.
89097499|NCT00631761|Placebo Comparator|2|The control group will be instructed to read a urethrocystoscopy textbook chapter at home
89097500|NCT00620932|No Intervention|Control Group|These patients will continue with whatever routine exercise they already engage in.
89097501|NCT00620932|Experimental|Exercise Arm|These patients will participate in a controlled, supervised exercise program.
89097502|NCT00175162|Active Comparator|Osteopal G bone cement|
89097503|NCT00175162|Active Comparator|Refobacin-Palacos R bone cement|
89097504|NCT00621010|Experimental|Cohort|
89097505|NCT00621088|Active Comparator|Intertan|
89097506|NCT00621166|Other|1|generic lopinavir/ritonavir
89097507|NCT04563832|Other|Control group|standardized respiratory management.
89097508|NCT04563832|Experimental|Experimental group|same program as control group associated with the daily use of a hyperinsufflation technique (2 times per day during15 minutes, 5 days a week, for 2 years)
89097509|NCT04555798|Placebo Comparator|Group A|Group A continue on the same conventional way of management as mentioned above with conventional way of ventilation and broad spectrum antibiotics coverage
89097510|NCT04555798|Active Comparator|Group B|group B who connected to (A-VECMO).with venous access from femoral vien and arterial cannulation using the femoral artery
89097511|NCT04549090||No QL block group|These patients will not be receiving QL block based on their shared decision with their surgeon and anesthesiologist. Patients' pain scores and amount of pain killers will be followed up for 24 hours postoperatively
89097512|NCT04549090||QL block group|These patients will be receiving QL block based on their shared decision with their surgeon and anesthesiologist. Patients' pain scores and amount of pain killers will be followed up for 24 hours postoperatively
89097513|NCT00617812|Experimental|Shan5|
89097514|NCT04515550||Huntington's disease (HD)|people with HD
89097515|NCT04515550||Controls without HD|people without HD
89227362|NCT02560727||Transendoscopic enteral tubing|FMT was performed via TET tube
89227363|NCT00405652|Experimental|Enteric-coated Mycophenolate sodium|Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.
89227364|NCT04052321|Experimental|3D scan arm|This is a single arm study. Patients in this arm will receive a 3D scan just prior to, 2 weeks after, as well as 6 and 12 months after Nuss bar removal.
89227365|NCT01324180|Experimental|VLPD Regimen|Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.
89227366|NCT02560649|Experimental|A:PEG+NUC (HBsAg<200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus nucleoside analogue(NUC):~HBsAg<200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
89227367|NCT02560649|Active Comparator|B:PEG+NUC(HBsAg>200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus+nucleoside analogue(NUC):~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
89227368|NCT02560649|Active Comparator|C:NUC(HBsAg>200IU/ml at week 24)|"nucleoside analogue(NUC):~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
89227369|NCT04052165|Experimental|Glaucoma drainage device in glaucoma patient|GDD is inserted in glaucoma patients
89227370|NCT04052009|Experimental|CT - Group|The conventional training consists of gait training during walking over ground. It includes the standard interventions therapists apply during training over ground. The aim is to achieve as many steps as possible. Three training sessions per week of intensive over ground therapy are planned, and twice a week a therapy with focus of attention isn't walking.
89227371|NCT04052009|Active Comparator|EET - Group|In the end-effector-based training participants undergo gait training in the end-effector device lyra (THERA-trainer). The principle of an end-effector is that the movement is induced at the level of participants feet. Furthermore, participants wear a harness attached to the end-effector lyra for safety purpose and for weight support. Three training sessions per week of intensive over lyra therapy are planned, and twice a week a therapy with focus of attention isn't walking
89227372|NCT04052009|Active Comparator|CETcomb:|The group with the combined training receives 5 sessions of CT and EET each. The pattern of series per week is always either two sessions of CT with one session of EET or vice versa.
89227373|NCT00754403|Experimental|Pioglitazone 30 mg QD + Metformin 1000 mg QD|
89227374|NCT00754403|Active Comparator|Metformin 1000 mg QD|
89227375|NCT00754481|Active Comparator|1|
89227376|NCT00754481|Experimental|2|
89097516|NCT04208932||MDD|major depressive disorder
89097517|NCT04208932||HC|healthy control
89097518|NCT02691364||Healthy|Healthy women
89097519|NCT02691364||Preeclamptic|Pregnant women with preeclampsia
89097520|NCT04208854||VINORELBINA|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
89097521|NCT01090427|Experimental|Ustekinumab Half-standard Dosage|Participants will receive ustekinumab at half the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
89097522|NCT01090427|Experimental|Ustekinumab Standard Dosage|Participants will receive ustekinumab at the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
89097523|NCT01090427|Experimental|Placebo|Participants will receive matching placebo at Week 0 and 4, followed by ustekinumab at half-standard or standard dosage at Weeks 12, 16, 28, and 40.
89097524|NCT04208776|Experimental|Midodrine+Propranolol|
89097525|NCT04208776|Active Comparator|Propranolol|
89097526|NCT02879435|Experimental|bupivacaine|Intervention
89097527|NCT02879435|Placebo Comparator|Placebo|Control
89097528|NCT02879513|Active Comparator|Switch to CEF|Epirubicin 75 mg/m² IV push on day 1 every 3 weeks for 4 cycles. Cyclophosphamide 500 mg/m² IV push on day 1 every 3 weeks. 5-fluoruracil 500 mg/m² IV push on day 1 every 3 weeks.
89097529|NCT02879513|Experimental|Continue the neoadjuvant regimen|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
89097530|NCT02879513|Experimental|Pathological complete response group with chemotherapy|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
89097531|NCT02879513|No Intervention|Pathological complete response group with no chemotherapy|
89227377|NCT02560571|Experimental|all patients|all study patients will undergo ultrasound and blood test
89227378|NCT00758225|Experimental|only one arm|
89227379|NCT00754637||510(k) Inclusion Criteria|Any person meeting the inclusion criteria for the device may be included in this study. These patients tend to be those seeking relief from painful or debilitating knee joint disease.
89097532|NCT00621478|Active Comparator|Cohort 1|"Cohort 1 (preconsented) patients will involve obtaining informed consent from the legally authorized representative of a potential study subject before they present to the ED in SE. Patient assent will be obtained for patients as per local IRB rules. The consent document (enclosed in this application) will inform parents that if their child comes to the ED and qualifies for the study based on study inclusion/exclusion criteria, they will be enrolled.~Patients who cannot be contacted to confirm consent will be enrolled in Cohort 2 (EFIC) as detailed below.~Patients in Cohort 1 will be randomized in a blinded fashion to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
89097533|NCT00621478|Active Comparator|Cohort 2|"Cohort 2 (EFIC) will include patients who appear in the ED with SE and qualify for the study but have not given prior consent. These patients will be enrolled under the EFIC regulations. The parent/guardian will be given the opportunity to object to participation or ask additional questions.~The child will be enrolled (dosed) with study medication under an EFIC. Once the child is stabilized, a research staff member will approach the parent or LAR to obtain informed consent to continue the child's participation in the study. If a parent or LAR refuses continued participation, then no further study procedures will be performed. Safety and data will be collected in accordance with federal regulations.~Cohort 2 will be randomized, like Cohort 1, to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
89097534|NCT00621556|Experimental|1|Drug + MR with MRCP
89097535|NCT04308551|Experimental|Indobufen|200 mg Indobufen, bid po, 90 days
89097536|NCT04308551|Active Comparator|Aspirin|100 mg Aspirin, qd po, 90 days
89097537|NCT04209010||One-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in one stage using silicone implant and acellular dermal matrix.
89097538|NCT04209010||Two-stage group|Immediate implant based breast reconstruction after skin sparing mastectomy in two stages using expander to silicone implant technique.
89097539|NCT04306991|Experimental|Fever|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
89097540|NCT04306991|Experimental|Apyrexia|Auscultation using an electronic stethoscope Measurement of cardiac output using echocardiography
89097541|NCT04212988|Experimental|the trial group|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
89097542|NCT04212988|Placebo Comparator|the control group|In control group patients, only place the probe for NIRS monitor.
89097543|NCT04306913|Active Comparator|Control|
89097544|NCT04306913|Experimental|Esmolol|
89097545|NCT02299414|Experimental|Anti-hypertensive therapy to goal <140/90 mmHg|Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used
89097546|NCT02299414|Active Comparator|No anti-hypertensive unless BP is severe (≥160/105 mmHg|Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used
89097547|NCT02877875|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC;Chorpita & Weisz, 2009), and (2) a youth monitoring and feedback system (MFS).
89097548|NCT02877875|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
89097549|NCT04309097|Experimental|Digital intervention|Participants will have access to a live-streaming App that offers Recess and Exercise Advocate Program (REAP).
89097550|NCT04309097|Active Comparator|Information-only intervention|Participants will have access to health information only.
89097551|NCT01016262|Experimental|MAX-002|
89097552|NCT01016262|Placebo Comparator|Placebo|
89097553|NCT01016262|Active Comparator|Canasa®|
89097554|NCT00621634|Experimental|1|Active treatment with omega-3 fish oil capsules (1 g each capsule, 50% DHA), 6 capsules each day for 12 weeks
89097555|NCT00621634|Placebo Comparator|2|Matching placebo treatment
89097556|NCT05662696|Experimental|Telemonitoring Program for Pregnant Women at High Risk for Preeclampsia in Pakistan|The study intervention includes a telemonitoring program for high-risk pregnant women, which will be delivered using the telemonitoring platform. The trial will administer the telemonitoring program to 50 pregnant women at high risk for preeclampsia. The intervention will enable pregnant women to take daily blood pressure readings at home with a provided Bluetooth-enabled home blood pressure monitor, to report if participants have symptoms, and to receive automated alerts and self-care messages (e.g., instructing patients to repeat blood pressure readings, call a medical officer, visit the emergency department, etc.). A healthcare provider (medical officer) will receive alerts from the telemonitoring system if the patient's blood pressure trends are out of the target or if the patient is reporting symptoms.
89097557|NCT04308629|Experimental|tDCS over PMAs|One session of transcranial direct current stimulation (tDCS) over premotor areas (PMAs)
89097558|NCT04308629|Active Comparator|tDCS over M1|One session of transcranial direct current stimulation (tDCS) over primary motor area (M1)
89097559|NCT00621712|Active Comparator|A|Patients in group A will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
89097560|NCT00621712|Experimental|B|Patients in group B will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
89097561|NCT04308317|Experimental|Tetrandrine Cohort|"After the subjects were enrolled, they were given Tetrandrine 60mg QD for a course of 1 week(Take 6 days, stop using for 1 day)"
89227380|NCT00754715|Experimental|AZD2516|
89097562|NCT04308317|No Intervention|Control Cohort|Treatment according to standard protocols without intervention
89097563|NCT04212208|Experimental|Intervention group|EMLA cream + High-frequency USG probe kept for 15minutes.After 15 minutes IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
89097564|NCT04212208|Active Comparator|Control group|EMLA cream+Low frequency USG probe kept over the cream for 15 minutes. IV cannulation will be done and Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
89097565|NCT04212130|Experimental|Evaluation of environmental cleanliness|"In this study,~fluorescent marking,~microbiological sampling and~BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
89097566|NCT01009554|Experimental|Potassium Oxylate|1.5% potassium oxalate sensitive mouthwash
89097567|NCT01009554|Active Comparator|Sodium Fluoride|Sodium Fluoride Dentifrice
89097568|NCT04211896|Experimental|anlotinib plus nivolumab|
89097569|NCT02012374|Experimental|"Intensive Language Action Therapy (constrained)"|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. Spoken responses are explicitly modeled and encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
89097570|NCT02012374|Experimental|Unconstrained Intensive Language Action Therapy|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. All communicative responses are encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
89097571|NCT04188184|Active Comparator|tranexmic acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
89097572|NCT04188184|Active Comparator|Epinephrine roup|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
89097573|NCT04495218||Patient with a diagnosis of incomplete form of albinism|
89097574|NCT05093764|Other|VIV TAVR with BVF using TCEP|All subjects will receive the intervention.
89097575|NCT01006590|Experimental|1|Saxagliptin 5 mg
89097576|NCT01006590|Active Comparator|2|Metformin 500 -1000 mg
89097577|NCT02010112|Experimental|Initial Diagnosis Cohort|Subjects with clinical indication of H.pylori infection will undergo breath test compared to routine clinical standard of care- endoscopy
89097578|NCT00619138|Active Comparator|1|
89097579|NCT00619138|Active Comparator|2|
89097580|NCT04212832|Active Comparator|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block with 0.5 ml/kg % 0.25 bupivacaine
89097581|NCT04212832|Other|No intervention|Standard Pain Followup and Monitorization
89097582|NCT00621790|Experimental|Fenoldopam|Fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min) for up to 4 days
89097583|NCT00621790|Placebo Comparator|Placebo|Placebo (normosaline), continuous perfusion
89097584|NCT00618124|Experimental|A|
89097585|NCT02252380|Experimental|Transcranial ExAblate System|Transcranial ExAblate System (MRgFUS)
89097586|NCT05067946|Experimental|GX-19N|GX-19N will be intramusculary administered via EP on day 1 and day 29.
89097587|NCT05067946|Placebo Comparator|Placebo|Placebo will be intramusculary administered via EP on day 1 and day 29
89097588|NCT00621868|Experimental|1|Lowest dose
89097589|NCT00621868|Experimental|2|Low-middle dose
89097590|NCT00621868|Experimental|3|High-middle dose
89097591|NCT00621868|Experimental|4|Highest dose
89097592|NCT00621868|Placebo Comparator|5|placebo
89097593|NCT02246374|Experimental|ExAblate Treated Arm|ExAblate Transcranial System subthalamotomy for motor symptoms of Parkinson's Disease.
89097594|NCT02246374|Sham Comparator|ExAblate Sham Treated Arm|ExAblate Transcranial System sham subthalamotomy for motor symptoms of Parkinson's Disease. Sham subjects completing the 4 Month visit may be offered the actual ExAblate subthalamotomy.
89097595|NCT01882660|Experimental|Decitabine treatment|Treatment with decitabine
89097596|NCT05662618|Experimental|Rapamycin coated peripheral balloon catheter|Rapamycin coated peripheral balloon catheter of Bomaian Company.
89097597|NCT05662618|Active Comparator|Drug eluting peripheral balloon catheter|Paclitaxel eluting balloon catheter
89097598|NCT02216500|Experimental|Ketogenic Therapy|Ketogenic Therapy will be administered.
89097599|NCT01001832|Active Comparator|Subcutaneous (SC) abatacept, 125 mg|
89097600|NCT01001832|Active Comparator|Intravenous (IV) abatacept, 125 mg|
89097601|NCT01873456|Experimental|Multifactorial nutritional intervention|dietician, resistance type exercise, dysphagia assessment and treatment
89097602|NCT01873456|No Intervention|usual care|usual care
89097603|NCT01851694|Experimental|GLP-1|The incretin, Glucagon-Like-peptide-1 (GLP-1) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins. (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
89227381|NCT00754715|Placebo Comparator|Placebo|
89227382|NCT02561039|Experimental|Ibandronate IV Infusion|Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.
89097604|NCT01851694|Experimental|GIP|The incretin, Glucose-dependent Insulinotropic Polypeptide (GIP) will be infused into the veins starting 30 minutes prior to initiating the GPA test. This infusion will continue for a total of 90 mins (during the GPA for 230 mg/dL glucose levels) and then this will be stopped. The GPA test will be performed for the 340 mg/dL glucose levels but no incretin will be infused during this part of the test. These data will be compared when the subject repeats the GPA test with a placebo (saline or salt containing solution) infusion.
89097605|NCT01001598|Other|danazol|Subjects with either Fanconi anemia or Dyskeratosis congenita
89097606|NCT04208620|Placebo Comparator|Placebo|Placebo administered subcutaneously
89097607|NCT04208620|Experimental|Cotadutide|Cotadutide administered subcutaneously
89097608|NCT01006356|Experimental|Hydromorphone hydrochloride (HCl) oral osmotic system (OROS)|Hydromorphone HCl OROS 8 milligram (mg) once daily for 2 weeks.
89097609|NCT02192866||Peanut allergic|No intervention(s) to be administered.
89097610|NCT02192866||Other food allergic|No intervention(s) to be administered.
89097611|NCT02192866||Controls|No intervention(s) to be administered.
89097612|NCT04213066|Active Comparator|Control group|This group received eye-hand practice for drawing pictures.
89097613|NCT04213066|Experimental|Grating group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies.
89097614|NCT04213066|Experimental|Random dot group|This group received eye-hand practice for drawing pictures with rotating grating stimuli of various spatial frequencies constructed by random dots of stochastic resonance.
89097615|NCT01089725|Placebo Comparator|Placebo|
89097616|NCT01089725|Experimental|2.5 mg tanezumab SC and placebo IV|
89097617|NCT01089725|Experimental|5 mg tanezumab SC and placebo IV|
89097618|NCT01089725|Experimental|10 mg tanezumab SC and placebo IV|
89097619|NCT01089725|Experimental|10 mg tanezumab IV|
89097620|NCT00622102|Experimental|1|50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
89097621|NCT00622102|Other|2|50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
89097622|NCT00619372|Experimental|B|Low dose OKT3 with GC
89097623|NCT00619372|Experimental|C|Mid dose OKT3
89097624|NCT00619372|Experimental|D|Mid OKT3 dose with GC
89097625|NCT00619372|Experimental|E|High dose OKT3
89097626|NCT00619372|Experimental|F|GC only
89097627|NCT00619372|Experimental|A|Low dose OKT3
89097628|NCT02879279|Experimental|Robotic rehabilitation|In the robotic rehabilitation group, both the distal and the proximal parts of the patients' upper arm will be treated by means of a multi-set of robotic and technological devices, i.e, Amadeo, Pablo, Diego and Motore. The aforementioned systems can be used to perform three-dimensional movements of the shoulder, planar movements of the shoulder and elbow, prono-supination movements of the forearm, flexion-extension movements of the wrist, bimanual movements, and flexion/extension movements of the fingers. A vibratory treatment will be applied, using the Amadeo, to increase the proprioception of the hand. Motor and cognitive tasks, comprising active, passive and active-assistive, will be performed during the treatment. Visual and auditory feedback will be provided to help the patients.
89097629|NCT02879279|Active Comparator|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment. The therapeutic tasks will focus on sensorimotor reprogramming, hypertonus inhibition, functional improvement, including task-oriented exercises. Specifically, patients will perform passive, active and active assisted exercises on the three upper limb joints, to improve joint function, to prevent contractures, to inhibit hypertonus and to improve trophism and motor function.
89097630|NCT02877719||Children from low-income families|Children from low-income families were invited to fill in a set of questionnaires.
89097631|NCT02877719||Children from high income families|Children from high-income families were invited to fill in a set of questionnaires.
89097632|NCT00626015|Experimental|Arm I|Temozolomide, PEP-3-KLH conjugate vaccine, and daclizumab
89097633|NCT00626015|Experimental|Arm II|Temozolomide, PEP-3-KLH conjugate vaccine, and normal saline
89097634|NCT00626015|Experimental|Basiliximab|Patients will receive basiliximab 20 mg IV with vaccine # 1 only and continue with PEP-3-KLH, temozolomide.
89097635|NCT03787498|Experimental|PLX2853|Approximately 30 subjects will be enrolled as part of dose escalation to identify the MTD/RP2D of PLX2853. Up to 6 additional subjects may be enrolled at the MTD/RP2D to further characterize the PK and PDy of PLX2853.
89097636|NCT00618280|Active Comparator|1|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
89097637|NCT00618280|Placebo Comparator|2|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
89097638|NCT01101191|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
89097639|NCT01101191|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
89097640|NCT04212754||Procedure: Emergency surgery for traumatic brain injury|
89097641|NCT02691286||Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI complicated with cardiogenic shock
89097642|NCT02691286||No Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI without cardiogenic shock
89097643|NCT02691520||Taiwan Participants with Treatment Resistant Depression|Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.
89097644|NCT02879357|Experimental|Trained Clinicians|Training in Serious Illness Communication Guide
89097645|NCT02879357|No Intervention|Untrained Clinicians|No training in Serious Illness Communication Guide
89097646|NCT00622258|Experimental|Everolimus|
89097647|NCT01812616|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide in a double-blind manner
89097648|NCT01812616|Placebo Comparator|Placebo and Dose-Intense Temozolomide|Patients will received placebo and Dose-Intense Temozolomide and in double-blind manner
89097649|NCT00618358|Experimental|Vascular Sealant)|
89097650|NCT00618358|Active Comparator|Gelfoam/Thrombin|
89097651|NCT04212676|Experimental|PR+BAT Group|In addition to the PR program, the BAT will be administered to the experimental group by a physiotherapist with 5 years of experience in BAT for 8 weeks.
89097652|NCT04212676|Active Comparator|PR Group|Patients in the control groups will receive a 30-minute Pulmonary Rehabilitation (PR) program every day of the week for 8 weeks.
89097653|NCT01178762|Experimental|Observation|
89097654|NCT03629236|Experimental|GrafixPL|
89097655|NCT03629236|Active Comparator|Control|
89097656|NCT03563560|Experimental|ACM regimen|ACM regimen is for Japanese patients with relapsed or refractory AML.
89097657|NCT03563560|Experimental|A+7+3 regimen|A+7+3 regimen is for Japanese newly diagnosed AML patients.
89097658|NCT01178294|Experimental|OBI-1|Initial dose: 200 U/kg - additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours)
89097659|NCT01799044|Experimental|Irreversible electroporation|Single arm study: Irreversible electroporation of colorectal liver metastasis
89097660|NCT01178138|Other|Prazosin effects on methamphetamine|Randomized placebo controlled trial of prazosin effects on methamphetamine
89097661|NCT04211428||Bipolar Disorder|Patients with bipolar disorder
89097662|NCT00618592|Experimental|CHO|
89097663|NCT00618592|No Intervention|FAST|
89097664|NCT04206254|Experimental|gp96 group|"Patients only receive autologous gp96 vaccination after surgery (do not accept other anti-tumor treatments)~6 times of gp96 vaccination are administered via subcutaneous injection in 25μg doses within 8 weeks after surgery. gp96 is administered once a week."
89097665|NCT04206254|No Intervention|Control group|Patients do not accept any anti-tumor treatmentsafter surgery
89097666|NCT04206410|Experimental|Probiotic|Multistrain probiotic mixture consisting of two Lactobacillus strains (L. rhamnosus and L. acidophilus) and three Bifidobacterium strains (B. longum, B. bifidum and B. lactis) administered for 8 weeks in a dose 1,0E+10/day, 2x sachets/day (5,0E+9/cfu per sachet)
89097667|NCT04206410|Placebo Comparator|Maltodextrin|Placebo - Maltodextrin manufactured with an appearance, taste and packaging (sachets) identical to the probiotic mixture administarted for 8 weeks 2x sachets/day
89097668|NCT05662150|Active Comparator|Questionnaires|Patients with DM1 were asked to complete a questionnaire to rate a 25-item activity scale (DM1-Activ) and the Myasthenia Gravis Activity of Daily Life scale (MG-ADL) to rate their level of functional burden. For the DM1-Activ a score of 40 alludes no impairment and a score of 0 indicates the highest functional burden of physical activity. This scale has proven to be practical, reliable and valid. For the MG-ADL the total score ranges from 0 to 24, a score of 0 denotes no and 24 the highest functional burden. It should be noted that this scale is not adjusted for DM1. The rationale was to gain information about muscle fatigue and consequently the neuromuscular junction.
89097669|NCT05662150|Active Comparator|grip strength via dynamometer|The isometric grip strength was tested by using a dynamometer. The subject will be asked to perform an increasing force against the dynamometer over a period of several seconds.
89097670|NCT05662150|Active Comparator|short exercise test|The subject was asked to contract the ADM muscle as hard as possible in isometric conditions for 10 seconds. CMAP's was recorded 2 seconds after the end of the exercise and then every 10 seconds for 50 seconds.
89097671|NCT05662150|Active Comparator|needle EMG|The electrical myotonia of each examined muscle was scored according to the Streiss and Sun scale.
89097672|NCT02558530|Other|Low carbohydrate diet|Isocaloric diet, <20 g carbohydrates per day
89097673|NCT04208542|Active Comparator|Interventional|Under general anaesthesia, ultrasound guided ESP block will perform at the T5 level with 0.375% ropivacaine 20ml. Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
89097674|NCT04208542|No Intervention|Control|Fentanyl 1 ug/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with fentanyl (10 ug/kg) and palonosetron 0.075mg will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 48 hours. Pain assessment will record 3 months after surgery.
89097675|NCT01190228|Experimental|Group 1: JE-CV Vaccine Booster|Participants previously vaccinated with JE-CV vaccine will receive a booster dose of JE-CV vaccine on Day 0.
89097676|NCT01190228|Experimental|Group 2: JE-CV Vaccine First Dose|JE-CV vaccine naïve participants will receive a single dose of JE-CV vaccine on Day 0.
89097677|NCT01190228|Active Comparator|Group 3: Varicella Vaccine|JE-CV vaccine naïve participants will receive one dose of Varicella vaccine on Day 0.
89097678|NCT01009086|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
89097679|NCT01009086|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
89097680|NCT01009086|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
89097681|NCT05662072|Experimental|Motor imagery|Motor imagery of inspiratory and expiratory exercises, 10 series of 1 minute.
89097682|NCT05662072|Experimental|Action observation|Action observation of inspiratory and expiratory exercises, 10 series of 1 minute.
89097683|NCT05662072|Placebo Comparator|Placebo Observation|Placebo visualization of nature video, 10 minutes.
89097684|NCT01190150|Experimental|0.65 g / 1.3 g tranexamic acid|Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.
89097685|NCT01190150|Experimental|1.3 g / 0.65 g tranexamic acid|Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.
89097686|NCT04211662|Experimental|Intervention Group|Tailored Multidimensional Intervention
89097687|NCT04211662|No Intervention|Control Group|Regarding the control group, the participants will receive a simple educational booklet through one home visit.
89097688|NCT04315688||Tresiba®|Patients with type 2 diabetes
89097689|NCT05210062||Exposure to suxamethonium during ECT|A single group is planned in this study, consisting of patients with a medical indication for ECT for psychiatric pathologies which are resistant to medical treatment (depression, mania, hallucinatory episode in particular).
89227383|NCT02561039|Experimental|Ibandronate PO Tablet|Participants will receive ibandronate, 50 mg PO daily, for 4 months.
89227384|NCT00422734|Placebo Comparator|1|Placebo
89227385|NCT00422734|Active Comparator|2|5 mg tadalafil
89227386|NCT02560415|Experimental|1: Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
89227387|NCT02560415|Active Comparator|2: Comparator|Treatment as usual
89227388|NCT03916198|Experimental|PDRN(polydeoxyribonucleotide)|polydeoxyribonucleotide 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
89227389|NCT03916198|Placebo Comparator|CONTROL(normal saline)|normal saline 3cc at surgery under arthroscopy guidance and 2 weeks after surgery under ultrasound guidance
89227390|NCT00422422|Experimental|Brivaracetam|
89227391|NCT00413374|Other|Enoxaparin|
89227392|NCT00682643|Placebo Comparator|vehicle placebo nasal spray|
89227393|NCT00682643|Active Comparator|fluticasone furoate nasal spray|
89227394|NCT00758381|Experimental|A|"Sorafenib 400 mg po bid, continuously~Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days."
89227395|NCT00758381|Active Comparator|B|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days
89097690|NCT01001520|Placebo Comparator|Placebo (Sugar Pill)|11-day placebo-controlled medication period
89097691|NCT01001520|Active Comparator|Tolcapone|11-day phase, tapered dosing scheduled (Day 1: 100mg three times daily, Days 2-8: 200mg three times daily, Day 9: 200mg twice daily, Day 10: 200mg once daily, Day 11: 100mg once daily); oral dosing; medication is encapsulated by the University of Pennsylvania's Investigational Drug Service (IDS)
89097692|NCT00619840|Active Comparator|1|
89097693|NCT00619840|Placebo Comparator|2|
89097694|NCT04463082|Experimental|Weight category 10-20kg|Pediatric patients with a weight of 10-20kg will be enrolled in this arm.
89097695|NCT04463082|Experimental|Weight category 20-30kg|Pediatric patients with a weight of 20-30kg will be enrolled in this arm.
89097696|NCT04463082|Experimental|Weight category 30-50kg|Pediatric patients with a weight of 30-50kg will be enrolled in this arm.
89097697|NCT02344108|Experimental|Inspire® Upper Airway Simulation System|Subjects meeting inclusion criteria, including sleep study and drug induced sleep endoscopy criteria, will undergo surgical placement of a hypoglossal nerve simulator (Inspire® Upper Airway Simulation System Model 3028 IPG). The simulator will be activated one month after surgery and subjects will undergo repeat sleep study evaluation and device titration at one, two, six and twelve months after implantation. Subjects will be followed for one year to determine safety and efficacy of the device.
89097698|NCT04415658|Experimental|Thyroxine|Intravenous thyroxine infusion
89097699|NCT04415658|Placebo Comparator|Saline Placebo|Intravenous saline infusion
89097700|NCT02871024|Experimental|Intervention arm|Usual care with two sessions of 2-hour hemoperfusion with Toraymyxin in 24 hours apart
89097701|NCT01189604|Placebo Comparator|Arm1 - Placebo|
89097702|NCT01189604|Active Comparator|Arm 2 - ICI35,868 (propofol)|
89097703|NCT01189604|Active Comparator|Arm 3 - ICI35,868 (propofol)|
89097704|NCT01189604|Active Comparator|Arm 4 - ICI35,868 (propofol)|
89097705|NCT01189604|Active Comparator|Arm 5 - ICI35,868 (propofol)|
89097706|NCT01189604|Active Comparator|Arm 6 - ICI35,868 (propofol)|
89097707|NCT01189604|Active Comparator|Arm 7 - ICI35,868 (propofol)|
89097708|NCT02697058|Experimental|Part 1: Safety and PK|BAX2398 in combination with 5-FU/calcium levofolinate
89097709|NCT02697058|Experimental|Part 2: Safety, PK, Efficacy|BAX2398 in combination with 5-FU/calcium levofolinate
89097710|NCT02697058|Active Comparator|Part 2: 5-FU/calcium levofolinate alone|5-FU/calcium levofolinate
89097711|NCT05661994|Experimental|Omega-3 Group|While 1.560 mg/day omega-3 FA supplementation was given to the patients in the omega-3 group for eight weeks, but not in the control group.
89097712|NCT05661994|No Intervention|Control Group|While 1.560 mg/day omega-3 FA supplementation was given to the patients in the omega-3 group for eight weeks, but not in the control group.
89097713|NCT04294602|Experimental|Exercise Program|This group received therapeutic exercises and patient education. For patients to encounter fewer problems and to reduce their problems, some recommendations were made that should be taken into consideration in daily life. These suggestions were given in writing. The exercise program included muscle stretching, massage of painful muscles, guided opening and closing movements, gentle isometric tension exercises against resistance, correction of body posture and relaxation techniques. All exercises were done in 6 repetitions a set, 3 sets a day, 3 days a week, treatment program lasted 4 weeks.
89097714|NCT04294602|Experimental|Low Level Laser Therapy Program|This group received LLLT, therapeutic exercises and patient education in the therapy programs. LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points. The application was applied to MTrP or sensitive points in the mastication and cervical muscles.LLLT program was done in 3 days a week, the treatment program lasted 4 weeks.
89097715|NCT04294602|Experimental|Manual Pressure Release Program|ThisThis group received manual pressure release (MPR), therapeutic exercises and patient education in the therapy programs. MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, MTrPs in the mastication and neck muscle. Applied pressure gradually with finger over the MTrPs until the subject reported a 'moderate but easily tolerable' pain value of 7 out of 10. When the pain value decreased to at least 3 or 4 therapist increased pressure again until discomfort and/or pain appeared again. This process was repeated until there was no MTrP tension/tenderness or 60 s had elapsed. MPR program was done in 3 days a week, the treatment program lasted 4 weeks.
89097716|NCT02696824|Experimental|CBT-AD|Those assigned to the CBT-AD [cognitive behavioral therapy for adherence and depression) condition, will have up to 8 additional sessions delivered by the study clinic nurse. Additionally, those assigned to CBT-AD will have the procedures available to those assigned to ETAU.
89097717|NCT02696824|No Intervention|ETAU|"Participants in both conditions receive usual care plus the following procedures below.~All participant will have the benefit of the psychosocial assessment, and the clinic nurse will provide feedback to the participant and to their clinic doctor about their depression. Additionally, all participants will undergo standard of care second line treatment adherence counseling in the clinic . The clinic doctor will not be restricted in terms of referral or treatment of depression for their patient with respect to antidepressant medications or other interventions available."
89097718|NCT04296786|Experimental|Chidamide plus Sintilimab|Patients in experimental group will receive fixed does of Sintilimab and Chidamide. This regimen is repeated every 21 days. The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment.
89097719|NCT00622414|Experimental|Treatment (ziv-aflibercept)|"PART 1: Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive aflibercept until the maximum tolerated dose (MTD) is determined.~PART 2: Patients receive aflibercept as in part 1 at 150% of the MTD determined in part 1. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
89097720|NCT01008696|Experimental|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
89097721|NCT01008696|Active Comparator|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
89097722|NCT01955980|Experimental|Buparid; Treatment A|Buparid 1mg budesonide/2 ml nebulizer solution
89097723|NCT01955980|Active Comparator|Budes; Treatment B|Budes Nasal Spray 50 µg budesonide/pump
89097724|NCT02870478|Active Comparator|0.01% atropine daily|Nightly dosing of 0.01% atropine
89097725|NCT02870478|Experimental|0.01% atropine twice per week|Atropine dosed twice per week
89097726|NCT00622492||VV-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
89097727|NCT00622492||VA-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
89097728|NCT05661838||non-PPCs group|Patients without PPCs (Pleural effusion, Pulmonary atelectasis, Pulmonary infection)
89097729|NCT05661838||PPCs group|Patients with PPCs (Pleural effusion, Pulmonary atelectasis, Pulmonary infection)
89097730|NCT04296162|Experimental|Single arm|6 cycle of oral vinorelbine or capecitabine combined with trastuzumab (21 days per cycle), followed by sequential single trastuzumab to 1 year
89097731|NCT00619996|Experimental|1|
89097732|NCT02870790|Experimental|treatment|A single open-label arm. All participants receive daily oral pill containing TDF/FTC
89097733|NCT04141228||Patients receiving apixaban|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
89097734|NCT04141228||Patients receiving warfarin|With or without low molecular weight heparin in the inpatient/emergency department (ED) setting
89097735|NCT05028400|Experimental|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
89097736|NCT05661526|Experimental|Bloodpoly board game|Students in the Bloodpoly board game group; In the designated classroom and common time frame and under the supervision of researchers, they will be provided with an average of 50 minutes of board games per day for three days. For this, four groups of five students will be formed and students will be randomly assigned to these groups. Students will then be asked to move on to the four areas where the board game takes place. Four groups will start playing Bloodpoly simultaneously. The game will continue until all questions are finished.
89097737|NCT05661526|Active Comparator|Text-to-speech group|Students in the text-to-speech group; 50 minutes of reading time will be organized per day for three days in the designated classroom and common time and under the supervision of the researchers During the reading time, the content of the topic related to blood transfusion described by the researchers will be given to the students and they will be provided with reading. At the end of the period, the documents given will be taken back by the researchers.
89097738|NCT00622570|Experimental|1|Pentobarbital
89097739|NCT00622570|Active Comparator|2|thiopental
89097740|NCT04208308|No Intervention|Control negative group|Without supplementation
89097741|NCT04208308|Experimental|Experimental negative group I|"Chia seeds supplementation (25 g)~On dose (25g) of chia seeds contains:~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
89097742|NCT04208308|Experimental|Experimental negative group II|"Chia seeds supplementation (15 g)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
89097743|NCT04208308|Experimental|Experimental negative group III|"Combine supplementation: chia seeds and fish oil~Daily dose:~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
89097744|NCT04208308|Experimental|Experimental negative group IV|"Fish oil supplementation~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
89097745|NCT04208308|No Intervention|Control positive group|Without supplementation
89097746|NCT04208308|Experimental|Experimental positive group I|"Chia seeds supplementation (25 g)~On dose (25g) of chia seeds contains:~energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg"
89097747|NCT04208308|Experimental|Experimental positive group II|"Chia seeds supplementation (15 g)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
89097748|NCT04208308|Experimental|Experimental positive group III|"Combine supplementation: chia seeds and fish oil~Daily dose:~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
89097749|NCT04208308|Experimental|Experimental positive group IV|"Fish oil supplementation~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
89097750|NCT01473004|Experimental|Sirspheres, response evaluation|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
89227396|NCT05436119||GrowBaby|All pregnant women presenting at < 19 weeks EGA for prenatal care covered by Molina Health of Nevada MCO will be offered the GrowBaby group nutrition and lifestyle program. Primary and secondary outcomes of those who opt out of the program will be compared to those who opt in. Additionally, all women who develop primary or secondary outcomes in the GrowBaby arm will be compared to those who do not develop primary or secondary outcomes (nested case-control). Outcomes will be compared locally, regionally and nationally within the Medicaid population, as well.
89227397|NCT00754871|Experimental|Arm 1|
89227398|NCT00754871|Experimental|Arm 2|
89227399|NCT00754871|Experimental|Arm 3|
89227400|NCT00754871|Experimental|Arm 4|
89227401|NCT05435807|Experimental|intervention group|Clinical Pilates Exercises+TNE
89227402|NCT05435807|Experimental|control group|Clinical Pilates Exercises
89227403|NCT00421408|Experimental|Protein powder|Participants will receive a protein supplement daily (40 g whey protein supplement).
89227404|NCT00421408|Placebo Comparator|Placebo carbohydrate|Participants will receive a placebo supplement daily (40 g maltodextrin).
89227405|NCT02560337|Experimental|Cabazitaxel|"25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.~Treatment continues until progression or unacceptable toxicity."
89227406|NCT01038388|Experimental|Bortezomib, lenalidomide, dexamethasone, vorinostat|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11; lenalidomide by mouth once a day on days 1-14; dexamethasone by mouth once a day on days 1, 2, 4, 5, 8, 9, 11, and 12; and vorinostat by mouth on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~After 8 courses, patients may receive maintenance therapy comprising lenalidomide by mouth once a day on days 1-21, dexamethasone by mouth once a day on days 1, 2, 8, and 9, and bortezomib IV over 3-5 seconds or subcutaneously on days 1 and 8. Courses may repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89227407|NCT02560259|Active Comparator|Physiotherapy Group|Physiotherapy
89227408|NCT02560259|Placebo Comparator|Conservative group|Conservative treatment
89227409|NCT05435183|Experimental|non-invasive high-frequency oscillatory ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. In the non-invasive high-frequency oscillation ventilation mode, the support pressure is consistent with the non-invasive bi-level positive pressure mode, and the high-frequency airway pressure oscillation driven by the solenoid valve is added during the expiratory phase. The amplitude is about 4cmH2O, and the oscillation frequency is about 8HZ.
89227410|NCT05435183|Active Comparator|Bilevel positive pressure ventilation|Patients were titrated for relevant parameters of non-invasive ventilation the day before the trial. Noninvasive bilevel positive pressure ventilation mode pressure titration follows previous studies.
89227411|NCT04050059|Active Comparator|2% Lidocaine group|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited) skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal anesthesia induction.
89097751|NCT05368792|Experimental|Complex Carbohydrate|"Participants in the intervention group will be instructed to follow standard bowel preparation guidance AND consume two servings of the complex CHO (12.5% maltodextrin) drink (PREcovery®, Enhanced Medical Nutrition, Toronto, Canada) the evening prior to the procedure, and one serving 2-3 hours prior to the colonoscopy. Participants should not consume anything within 2 hours prior to the procedure's start time. One serving consists of one package (50 g maltodextrin) stirred into 400 mL of cold water.~Standard bowel preparation guidance is as follows a split-dose 2L PEG ± bisacodyl (iso-osmolar) solution (Bi-PegLyte®, Pendopharm, Montreal, Canada) taken according to the physician's order. All participants will be instructed to follow a clear fluid diet starting the day before the procedure. Participants will also be verbally instructed to consume 2L of clear liquids the day before their colonoscopy in addition to the PREcovery."
89097752|NCT05368792|No Intervention|Fasting|"The Fasting arm will follow the current standard of care for colonoscopy preparations in Ontario, Canada. This includes fasting from midnight before the procedure and following a PEG bowel preparation~All participants will follow a standard bowel preparation guidance, a split-dose 2L PEG ± bisacodyl (iso-osmolar) solution (Bi-PegLyte®, Pendopharm, Montreal, Canada) taken according to the physician's order. All participants will be instructed to follow a clear fluid diet starting the day before the procedure. Participants will also be verbally instructed to consume 2L of clear liquids the day before their colonoscopy. Participants in the fasting arm will be instructed to not have any oral intake after 00:00 of the day of their colonoscopy."
89097753|NCT00925678|Experimental|1|
89097754|NCT00925678|Placebo Comparator|2|
89097755|NCT00890266|Experimental|Study Arm|Exploratory
89097756|NCT04208152|Active Comparator|anle138b|Dosage: 50 mg and higher Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
89097757|NCT04208152|Placebo Comparator|placebo|Matching placebo Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
89097758|NCT00622804|Other|1|Billroth-II (B-II)reconstruction
89097759|NCT00622804|Other|2|Roux en Y gastrojejunostomy (RY-GJ)
89097760|NCT00622804|Other|3|uncut Roux en Y gastrojejunostomy (uncut RY-GJ)
89097761|NCT05661760||chronic pain osteoarthritis|Patients with chronic pain and disability with osteoarthritis
89097762|NCT04210960||Patients group|50 multiple sclerosis patients
89097763|NCT04210960||Control group|30 normal healthy control
89097764|NCT04211038|Experimental|healthy subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
89097765|NCT04211038|Experimental|COPD subjects|Firstly, increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive. Secondly, do incremental cycle ergometry test with the assisstance of NPPV.
89097766|NCT04187638|Experimental|Olive oil|Participants will receive 30ml/day of olive oil for two weeks
89097767|NCT04187638|Placebo Comparator|Butter|Participants will receive 30g/day of butter also for two weeks.
89097768|NCT04211116||Pediatric patients indicated to CVC insertion|Paediatric patients indicated to central venous line insertion
89097769|NCT02691832|Experimental|research arm|"the trial contains one group which will undergo the described protocol three times:~connected to rectal thermistor and to the double sensor~connected to rectal thermistor, double sensor and cooling system of Icetron Technologies Ltd.~connected to rectal thermistor and to the double sensor integrated into a helmet."
89097770|NCT01176968|Experimental|Eplerenone plus standard of care|
89097771|NCT01176968|Placebo Comparator|Placebo plus standard of care|Matching placebo for eplerenone 25mg film coated tablets.
89097772|NCT04211584|Active Comparator|forearm radial artery access|traditional access (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
89097773|NCT04211584|Active Comparator|anatomic snuffbox access|access in the snuffbox area of the wrist (puncture and cannulation) in the forearm part of the radial artery will be made for further coronary interventions
89097774|NCT02697370|Other|Pharmacokinetic based factor VIII dosage|Patient's routine prophylactic factor VIII concentrate infusion will be given in the morning and the exact time (hours and minutes) and dose recorded. There is no wash out so the date, time and dose of the previous 2 prophylactic doses must be accurately known. Samples will be collected that afternoon, the following morning and the following afternoon. Samples can be taken at any convenient time but the exact time must be recorded. Factor VIII levels will be measured and this pharmacokinetic data will be used to calculate the dose of factor VIII (to be infused on alternate days) required to maintain a predicted factor VIII ≥1.5 IU/dL at all times(this will be rounded up to the nearest full 250 IU vial)
89097775|NCT02691442|Active Comparator|Ropivacaine 0.75%|The investigators administer 5 milliliters of Ropivacaine 0.75% in the inter scalene space
89097776|NCT02691442|Active Comparator|Levobupivacaine 0.5%|The investigators administer 5ml of Levobupivacaine 0.5% in the inter scalene space
89097777|NCT02691442|Active Comparator|Levobupivacaine 0.5% + epinephrin|The investigators administer 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in the inter scalene space
89097778|NCT00622648|Experimental|A|Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)
89097779|NCT00622648|Placebo Comparator|B|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
89097780|NCT04316234|No Intervention|A. Clean Air|Clean air - no vaping was done.
89097781|NCT04316234|Experimental|B. Passive vaping|E-cigarette users were present in an adjacent chamber during both exposures, but only in situation B they were vaping and the vape-polluted air was passed on to the exposure chamber.
89097782|NCT04208386|Experimental|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive single subcutaneous (SC) injection of JNJ-73763989 on Day 1 under fasted condition.
89097783|NCT04208386|Experimental|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
89097784|NCT04208386|Experimental|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive single SC injection of JNJ-73763989 on Day 1 under fasted condition.
89097785|NCT04208386|Experimental|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive SC injection of JNJ-73763989 on Day 1 under fasted condition.
89097786|NCT02886806|Experimental|high risk vascular surgery|Patients scheduled for high risk vascular surgery under automated total closed loop intravenous anesthesia and fluid management
89097787|NCT02687854||Apixaban|Non-valvular atrial fibrillation patients who were initiated on apixaban for stroke prevention
89097788|NCT02687854||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on Vitamin K antagonist for stroke prevention
89097789|NCT03991468|Experimental|NanoZoomer Whole Slide Imaging|All cases will be assessed via Whole Slide Imaging using the Hamamatsu NanoZoomer S360MD Digital Slide Scanner System to assess pathological characteristics of scanned slides.
89097790|NCT03991468|Active Comparator|Glass Slide Light Microscopy|All cases will be assessed via the use of traditional light microscopy to assess pathological characteristics of glass slides.
89097791|NCT01006122|Placebo Comparator|Placebo|
89097792|NCT01006122|Active Comparator|PF-03654746|At the end of the second arm of the study, the patient will have completed the study and have a 7-10 day follow-up visit.
89097793|NCT02687698|Experimental|Ketogenic diet|Patients will be suggested to follow a ketogenic diet for 8 weeks.
89097794|NCT02687698|No Intervention|Control|Usual diet.
89097795|NCT02689570||type 1 diabetic patients|Adult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients had to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria were a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m2.
89097796|NCT02687620||AS patients receiving Anti-TNF treatment|Three hundred and fifty consecutive AS patients fulfilling the modified New York criteria for the classification of AS (5), and with a new anti-TNF agent prescription (either for the first time or switched) in the last two weeks period will be included. Treatment with anti-TNF agents will be in accordance with the regulations of Turkish Social Security Agency (SGK) on the initiation and continuation of anti-TNF agents in AS, as well as ASAS/EULAR recommendations for the management of AS (29, 30).
89097797|NCT00639028|Other|1|Ankle echography
89097798|NCT00639028|Other|2|echography + stress radiography
89097799|NCT00639028|Other|3|stress radiography
89097800|NCT04186156|Experimental|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
89097801|NCT01005966|Other|Run in|Placebo
89097802|NCT01005966|Experimental|Sodium Fluoride Toothpaste|Sodium fluoride toothpaste
89097803|NCT01005966|Active Comparator|Amine Fluoride Toothpaste|Amine Fluoride
89097804|NCT01005966|Other|675ppmf toothpaste|Dose response
89097805|NCT01005966|Active Comparator|Sodium monofluorophosphate/sodium fluoride Toothpaste|Sodium monofluorophosphate/sodium fluoride Toothpaste
89097806|NCT01005966|Placebo Comparator|0 ppmf toothpaste|
89097807|NCT03937960|Active Comparator|Carbohydrate restricted group|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose. It will provide a fixed amount of carbohydrate, and a total calorie goal - with proteins and fats to satiety. During the first two weeks of the intervention, carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day. At week three, additional CHO sources will be added back to the diet prescription including nuts, unsweetened yogurt, and low-glycemic fruits such as apples and berries.
89227412|NCT04050059|Active Comparator|EMLA cream group|In EMLA (Eutectic Mixture of Local Anesthesia- lidocaine 2.5% and prilocaine 2.5%) cream group, EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
89227413|NCT05435105|Experimental|Virtual Reality Group|Watching the cartoon by wearing virtual reality glass to the child during the peripheral intravenous catheterization
89227414|NCT05435105|Experimental|Local Cold-Vibration Group|The local cold-vibration device is placed 5 cm above the area just before peripheral intravenous catheterization
89227415|NCT05435105|No Intervention|Control Group|Routine Care
89227416|NCT00679913|Active Comparator|1|standard pancreatoduodenectomy
89227417|NCT00679913|Active Comparator|2|extended pancreatoduodenectomy
89227418|NCT02560103||Single group|No treatment
89227419|NCT00482001|Experimental|donepezil|donepezil, capsule, 5mg daily once daily for 14 days
89227420|NCT00482001|Placebo Comparator|placebo|placebo (cornstarch), capsule, once daily for 14 days
89227421|NCT00490035|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
89227422|NCT00490035|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
89227423|NCT00490035|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
89227424|NCT00490035|Experimental|Brivaracetam 100 mg/day|Brivaracetam 100 mg/day, 50 mg administered twice a day
89227425|NCT01014897|Experimental|subcortical|Subcortical stroke patients will receive tDCS stimulation and sham in random order
89227426|NCT01014897|Experimental|cortical|subjects will receive active and sham tDCS in random order
89227427|NCT01016535||Children, Health Professionals|
89227428|NCT00404248|Active Comparator|With Enzyme-inducing antiseizure drugs (+EIASD)|"subjects on the +EIASD treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
89097808|NCT03937960|Active Comparator|Standard/Low fat diet group|The control, low-fat diet will contain 55:25:20 %energy from CHO: protein: fat based on the United States Department of Agriculture (USDA) My Plate Daily Food Plan and our groups previous work. For example, an 1800 kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
89097809|NCT00628680|Experimental|AAT-023 (Zuragen Arm)|Active experimental consisting of AAT-023 (Zuragen)solution
89097810|NCT00628680|Active Comparator|Heparin|5000 units diluted with normal saline to the exact catheter lumen volume
89097811|NCT00603382|Placebo Comparator|Placebo|
89097812|NCT00603382|Experimental|GW685698X|
89097813|NCT01176266|Experimental|Asfotase alfa|A total of 6 mg/kg/week of asfotase alfa administered by SC injection (either 1 mg/kg asfotase alfa 6 times per week, or 2 mg/kg asfotase alfa 3 times per week)
89097814|NCT01182428|Experimental|XIENCE V® / XIENCE PRIME™|
89097815|NCT01182428|Active Comparator|CYPHER SELECT|
89097816|NCT00603304|Placebo Comparator|Placebo|Participants will take one 320 mg placebo gelcap daily for 24 weeks one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
89097817|NCT00603304|Active Comparator|Saw Palmetto|Extract of Serenoa Repens 320 mg once daily for 24 weeks (one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
89097818|NCT01176032|Experimental|Aliskiren|"Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
89097819|NCT01176032|Active Comparator|Lostaran|"Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
89097820|NCT02691598|Experimental|Group A|Dexmedetomidine Hydrochloride 4ug/ml；0.05ml/kg.h infusion for 24hours
89097821|NCT02691598|Placebo Comparator|Group B|Normal Saline 0.05ml/kg.h infusion for 24hours
89097822|NCT01008618|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will be continued for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
89097823|NCT01008618|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
89097824|NCT01008618|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
89097825|NCT01001208|Experimental|Etanercept Plus Methotrexate|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received active methotrexate titrated as follows: 7.5 mg per week (3 capsules) for weeks 1 and 2, 10 mg per week (4 capsules) for weeks 3 and 4, and then up to 15 mg per week (6 capsules) or the maximum tolerated dose for the remainder of the 24-week treatment period.
89097826|NCT01001208|Active Comparator|Etanercept Plus Placebo|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received oral placebo that was the same number of capsules per week as the methotrexate dosing regimen.
89097827|NCT04296708|Experimental|ExerCube group|The ExerCube is an immersive fitness game setting that combines innovative soft- and hardware designs with state of-the-art training concepts. The ExerCube has three walls which serve as virtual reality projection screens and haptic interfaces. The ExerCube is a playful physical-cognitive exergame training. The user navigates a virtual environment/reality via whole body exercise. The video game navigates the user and triggers various cognitive functions. The used physical exercises are functionally and elicit the improvement of endurance and strength components. Via different monitoring systems (points and heart rate), the game adapts to the individual abilities and training level to tailor workout intensity. The ExerCube training consists of two sessions a week each session will last about 30 minutes of which 25 minutes will be pure playtime
89097828|NCT04296708|No Intervention|Control group|The control group does not have any additional ExerCube training.
89097829|NCT04296630|Active Comparator|Message #1|This arm will receive one of three social media messages that is preferred by our target population through focus groups that are being conducted as part of a previous study.
89097830|NCT04296630|Active Comparator|Message #2|This arm will receive the second social media message that is preferred by our target population as identified from our previous focus group study.
89097831|NCT04296630|Active Comparator|Message #3|This arm will receive the third social media message that is preferred by our target population as identified from our previous focus group study.
89097832|NCT04296630|Active Comparator|Tailored Arm|This arm will receive social media messages that will be tailored by one of the following variables: gender (men/women), age (younger/older), location (urban/rural), or social economic status (level of education). Testing to be conducted in a previous study will identify the variable that messages are tailored by.
89097833|NCT04295460|Experimental|Dual Therapy|Dolutegravir plus lamivudine
89097834|NCT04295460|Active Comparator|Triple Therapy|Dolutegravir plus TAF/FTC
89097835|NCT02871102|Experimental|Intervention Arm|
89097836|NCT01000974|Experimental|Hiberix Group|Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
89097837|NCT01000974|Active Comparator|ActHIB Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of ActHIB® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The ActHIB® vaccine was administered intramuscularly in the right thigh. The Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
89097838|NCT01000974|Active Comparator|Pentacel Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.
89097839|NCT04295616|Experimental|IPV & active breathing training|"Intrapulmonary Percussive Ventilation (IPV) and active breathing exercises, provided by trained speech and language therapists.~This training will be performed in combination with a multidisciplinary rehabilitation programme."
89097840|NCT04295616|Active Comparator|Active breathing training only|Active breathing training provided by trained speech therapists. This training will be performed in combination with a multidisciplinary rehabilitation programme.
89097841|NCT01004406|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent
89097842|NCT01004406|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
89097843|NCT04210804|Experimental|Omega-3|1gEPA and 1gDHA in 200mls smoothie
89097844|NCT04210804|Placebo Comparator|Placebo|200mls smoothie without EPA or DHA. Looks and tastes identical to omega-3 arm
89097845|NCT04210570|Experimental|Memsorb GA|Memsorb Filter will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
89097846|NCT04210570|Active Comparator|CGA GA|Chemical CO2 absorber (CGA) will be used during general anesthesia (GA), fresh gas flow and ventilator settings are not modified
89097847|NCT04210570|Experimental|Memsorb low-flow|Memsorb Filter will be used during low flow general anesthesia (GA)
89097848|NCT04210570|Experimental|CGA low flow|Chemical CO2 absorber (CGA) will be used during low flow general anesthesia (GA)
89097849|NCT04210570|Experimental|Memsorb laparoscopic surgery|Memsorb Filter will be used during general anesthesia for laparoscopic surgery
89097850|NCT04210570|Experimental|CGA laparoscopic surgery|Chemical CO2 absorber (CGA) will be used during laparoscopic surgery
89097851|NCT01187368|Experimental|Evaheart LVAS (EVA2)|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class III with dyspnea upon mild physical activity or Class IV heart failure.
89097852|NCT01187368|Active Comparator|HeartMate 3 (HM3)|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class III with dyspnea upon mild physical activity or Class IV heart failure.
89097853|NCT00620152|Experimental|1|Low glycemic load diet
89097854|NCT00620152|Active Comparator|2|Low fat diet
89097855|NCT04210648|Experimental|Intervention group|Those who will use the mobile app
89097856|NCT04210648|No Intervention|Non-intervention group|Those who will not use the mobile app
89097857|NCT02687308|Active Comparator|1Retrograde radical prostatectomy RRP|This opem surgical prostatectomy techniques described by Patrick Walsh is made through prostatic dissection, from apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
89097858|NCT02687308|Experimental|2Anterograde radical prostatectomy RRP2A|This opem surgical prostatectomy techniques dissect the prostate, bladder neck and the neurovascular bundle, in an antegrade way, from bladder neck to the apex. With careful bladder neck dissection and preservation, careful nervesparing procedures with meticulous retroprostatic dissection of the posterior layer of Denonvilliers' fascia, and urethrovesical anastomosis performed through a monofilament running suture.
89097859|NCT03900832|Placebo Comparator|PAD without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097860|NCT03900832|Experimental|PAD warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097861|NCT03900832|Placebo Comparator|PAD neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097862|NCT03900832|Experimental|PAD heating suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097863|NCT03900832|Experimental|PAD lower limb warm water immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097864|NCT03900832|Placebo Comparator|Healthy subjects without heating|Subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097865|NCT03900832|Experimental|Healthy subjects warm bath|Subjects will take a warm bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097866|NCT03900832|Placebo Comparator|Healthy subjects neutral bath|Subjects will take a neutral bath. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097867|NCT03900832|Experimental|Healthy subjects heat suit|Whole body heating with the suit will be performed. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097868|NCT03900832|Experimental|Healthy subjects lower limb immersion|Subjects will place their lower legs in warm water. Then, subjects will walk on a treadmill using the Gardner protocol until the patient says they want to stop. BP, HR and NIRS will be continuously measured during Gardner protocol. Skin blood flow, skin temperature and BP will be measured in the supine position before and after the Gardner protocol.
89097869|NCT00639106|Experimental|A|Expander Placement WITH Alloderm
89097870|NCT00639106|Active Comparator|B|Expander Placement WITHOUT Alloderm
89097871|NCT01182350|Experimental|radiation + bevacizumab|"Cohort 1: MGMT-/EGFR-~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles"
89097872|NCT01182350|Experimental|radiation + bevacizumab + erlotinib|"Cohort 2: MGMT-/EGFR+~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
89097873|NCT01182350|Experimental|radiation + bevacizumab + temozolomide|"Cohort 3. MGMT+/EGFR-~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Temozolomide: Administered orally at 90 mg/m2/day continuously during radiation therapy, held through the interim period and then 200 mg/m2/day for 5 days for up to 10 maintenance cycles"
89097874|NCT01182350|Experimental|radiation + bevacizumab + erlotinib + temozolomide|"Cohort 4. MGMT+/EGFR+~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
89097875|NCT04315844|Experimental|balloon|To evaluate the efficacy and security of Ewata combined with a stent device in the treatment of acute ischemic stroke within 8 hours To prove whether the clinical efficacy and safety of Ewata r is not inferior to other guidings.
89097876|NCT05367518|Active Comparator|Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g|Probiotic Streptococcus salivarius K12 Fast Melt Powder (Dose 1: 1 Billion colony forming units /g)
89097877|NCT05367518|Active Comparator|Streptococcus salivarius K12 Fast Melt Powder 100 million colony forming units /g|Group B: Dose 2 Streptococcus salivarius K12 Fast Melt Powder (Dose 2: 100 Million colony forming unit/gram)
89097878|NCT01163474|Experimental|Arm 1 - All study participants|Evaluate video clinic visit prior to Face-to-Face usual care visit
89097879|NCT02886182||group A|pregnants who were positivity for serum HBsAg for more than 6 months and HBeAg , HBV DNA >106IU/mL, alanine aminotransferase (ALT) below 35 IU/mL (ULN=40IU/mL) and no received nucleoside analogue antiviral therapy were enrolled into group A
89097880|NCT02886182||group B|the CHB infection pregnants with undetectable HBVDNA were enrolled into group B(control group)
89097881|NCT00603538|Experimental|CP-751,871|
89097882|NCT03854734|No Intervention|Usual Care|Educational emails about broad health topics to keep control group engaged
89097883|NCT03854734|Active Comparator|Multi-Component Intervention|(1) a community event to raise parental awareness of the importance of vaccination; (2) social marketing to target parents' attitudes and knowledge around vaccinations in the form of educational material
89097884|NCT04545580|Placebo Comparator|Treatment period: Placebo|This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data. Participants will be randomized to 12 weeks of double-blind treatment with matching placebo.
89097885|NCT04545580|Experimental|Treatment period: BAY1817080|This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data. Participants will be randomized to 12 weeks of double-blind treatment with BAY1817080.
89097886|NCT04185766|Placebo Comparator|Placebo (0,5 ml/Kg)|
89097887|NCT04185766|Placebo Comparator|Placebo (1 ml/Kg)|
89097888|NCT04185766|Experimental|Destrogel (0,5 ml/Kg)|
89097889|NCT04185766|Experimental|Destrogel (1 ml/Kg)|
89097890|NCT02537938|Experimental|NGP 555|NGP 555 given once a day for 14 days as a capsule; 100 mg, 200 mg, or 400 mg
89097891|NCT02537938|No Intervention|Placebo|Placebo comparator given once a day for 14 days as a capsule.
89097892|NCT04033900|Experimental|Prewarming|Active warming is allowed prior to surgery with forced-air warming devices
89097893|NCT04033900|No Intervention|No prewarming|Non active warming is allowed before surgery
89097894|NCT00639184|Experimental|1|Home intervention program
89097895|NCT00639184|Active Comparator|2|health education counseling
89097896|NCT02537860|Experimental|Three PVB injections|Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
89097897|NCT02537860|Experimental|Five PVB injections|Patients will receive five PVB injections between T11 and L3.
89097898|NCT02687230|Experimental|Cohort 1|Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
89097899|NCT02687230|Experimental|Cohort 2|Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
89097900|NCT02687230|Experimental|Cohort 3|Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
89097901|NCT04210102|Other|CR + LUS|Patient will be performed first the Chest radiography then the Lung ultrasound.
89097902|NCT04210102|Other|LUS + CR|Patient will be performed first the Lung ultrasound then the Chest radiography
89097903|NCT01163318||Adalimumab 40 mg/0.8 mL syringe for subcutaneous injection|Participants with rheumatoid arthritis who received adalimumab, per approved label
89097904|NCT02885792|Experimental|Debuting and chronic schizophrenia|"ILLNESS HISTORY:~Existing psychiatric and somatic diagnosis and treatment~Charlson co-morbidity~MEASURE OF SOCIAL CONDITIONS~- For example Lubben Social Network Scale-6 and Brief Trauma Questionnaire.~MEASURE OF PSYCHIATRIC CONDITION::~Positive and Negative Syndrome Scale (PANSS)~Clinical Global Impression Scale (CGI)~Columbia Suicide Severity Rating Scale (C-SSRS)~Beck Cognitive Insight Scale~Birchwood Insight Scale~CARDIOVASCULAR MEASUREMENT:~CT Coronary angiography (CT-CAG)~Echocardiography~Heart rate variability (HRV)~Pulmonary function test (PFT)~Toe blood pressure (TBP)~Blood test~Body composition analysis~CT scan of upper abdomen~Cardiovascular magnetic resonance imaging (CMR)~Adipose tissue biopsy"
89097905|NCT02885792|Active Comparator|Matched controls|"CARDIOVASCULAR MEASUREMENT:~CT Coronary angiography (CT-CAG)~Echocardiography~Heart rate variability (HRV)~Pulmonary function test (PFT)~Toe blood pressure (TBP)~Blood test~Body composition analysis~CT scan of upper abdomen~Cardiovascular magnetic resonance imaging (CMR)~Adipose tissue biopsy"
89097906|NCT01162304|Active Comparator|ER Oxycodone vs IR Oxycodone|"Extended release Oxycodone to assess pain relief adverse effects, treatment satisfaction and impact of treatment on health related quality of life.~IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every four hours"
89097907|NCT04515394|Experimental|Tepotinib + Cetuximab|
89097908|NCT04206176|Experimental|Single group crossover|The patients who are on a maintenance dose of clopidogrel 75mg once daily will be transitioned to ticagrelor 45mg twice daily after which they will be tested.
89097909|NCT01175018|Experimental|Anakinra|Anakinra 100 mg injectable subcutaneously daily
89097910|NCT01175018|Placebo Comparator|Placebo|0.67 ml of sodium chloride (NaCl) 0.9% solution
89097911|NCT02685514|Experimental|HIFU Graves|Applying the High intensity Focused Ultrasound treatment to the relapsed Graves' disease Patients.
89097912|NCT04314986|Experimental|AR882 (Dose A)|
89097913|NCT04314986|Experimental|AR882 (Dose B)|
89097914|NCT04314986|Experimental|AR882 (Dose C)|
89097915|NCT04314986|Experimental|AR882 (Dose D)|
89097916|NCT04314986|Placebo Comparator|Placebo|
89097917|NCT02685280|Experimental|DBS for psychiatric disorders patients|Patients on deep brain stimulation for either obsessive-compulsive disorder or major depression, undergoing rechargeable neurostimulator implantation as intervention
89097918|NCT03754972|Experimental|Lumbar spinal stenosis surgery candidate|Patients with lumbar spinal stenosis and spondylolisthesis that have previously consented to surgical treatment. After recording the initial surgical plan, the Sagittal plane shear index (SPSI) will be provided to the surgeon. The surgeon may change the initial surgical plan based on the stability metric.
89097919|NCT01174784|Experimental|Treatment|The Wildcat catheter is a CTO crossing catheter. Subjects will be subjected to crossing with this device.
89097920|NCT02686918|Experimental|consultation by Advanced Practice Nurse.|During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.
89097921|NCT04314440|Experimental|Music therapy|After the initial warm up session music therapy will be delivered three times a week for 15-20 minutes. All babies in the experimental group will be exposed to three weeks of music therapy sessions that is a total of 9 music therapy session prior to discharge from the hospital. The baby will be placed at the bassinet 15 minutes before music therapy begins. The baby will be in the bassinet during music therapy and 15 minutes post music therapy to allow measurement of physiological indicators. If parents are present during music therapy they will not engage in kangaroo care during the music therapy session or when physiological measurements are being taken pre and post music therapy, but can do so at other times.
89097922|NCT04314440|No Intervention|Control|Infants in this group will not receive any music therapy but will receive all other standard care provided to infants at the Regina General Hospital (RGH). All measurements will be carried out for all the infants in this group at the time when observations are carried out for infants in the music therapy group.
89097923|NCT02686996|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (2 tablets twice daily) for 14 weeks
89097924|NCT02686996|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of identical placebo tablets ( 2 tablets twice daily) for 14 weeks
89097925|NCT02687074|Experimental|Intubation rate on 28 days|patients with respiratory failure treat with HFNC or NIV and intubation rate on 28 days
89097926|NCT01174550|Active Comparator|Functional diagnostic tests|Stress Echocardiogram Nuclear Stress Test Exercise Electrocardiogram
89097927|NCT01174550|Active Comparator|Anatomic diagnostic test|Coronary Angiography
89097928|NCT00638326|No Intervention|1|Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
89097929|NCT00638326|Experimental|2|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
89097930|NCT00638326|Active Comparator|3|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel
89097931|NCT04184830|Experimental|tDCS arm|"Active stimulation:~Direct current will be transferred using a pair of saline-soaked surface sponge electrodes (5x7). For anodal stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 minutes, which will result in current density of 0.08 mA/cm².In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
89097932|NCT04184830|Sham Comparator|tDCS sham|"Sham stimulation:~During the sham stimulation a pair of saline-soaked surface sponge electrodes (5x7) will be places on the scalp For sham stimulation of the left DLPFC the anode will be placed over the site of F3, according to the 10-20 international system for electroencephalogram electrode placement. The cathode will be placed over the right supraorbital area. A constant current of 2mA will be applied for 30 seconds.In order to avoid side effects, as a result of electrical transient (e.g. tingling and burning sensation), the current will be ramped for 10 seconds at the beginning and end of stimulation (Nitsche et al., 2008)."
89097933|NCT04187560|Active Comparator|Part A Cohort 1|LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day
89097934|NCT04187560|Active Comparator|Part A Cohort 2|LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day
89097935|NCT04187560|Active Comparator|Part A Cohort 3|LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day
89097936|NCT04187560|Active Comparator|Part A Cohort 4|LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day
89097937|NCT04187560|Active Comparator|Part A Cohort 5|LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day
89097938|NCT04187560|Active Comparator|Part B Cohort 6|LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
89097939|NCT04187560|Active Comparator|Part B Cohort 7|LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
89097940|NCT04187560|Active Comparator|Part B Cohort 8|LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)
89097941|NCT04314674|Active Comparator|%3 HS bolus 3 mL.kg-1|After the head fixation 3 mL.kg-1 %3 hypertonic saline will be administered over the 20 min intravenously.
89097942|NCT04314674|Active Comparator|%3 HS infusion 20 ml/h|After the head fixation 3% hypertonic saline at 20 ml/h infusion rate will be administered during the operation
89097943|NCT04314674|Active Comparator|%20 mannitol 0,6 gr.kg-1|After the head fixation %20 mannitol 0,6 gr.kg-1 will be administered over the 20 min intravenously.
89097944|NCT00639262|Experimental|Cohort 1 - Brain Metastasis|Sorafenib and Radiotherapy
89097945|NCT00639262|Experimental|Cohort 2 - Gliomas|Sorafenib and Radiotherapy, plus Temozolomide
89097946|NCT02886104|Active Comparator|CRLM resection group|Resection of both primary and secondary tumors in SCRLM and resection of MCRLM. Interventions: Simultaneous resection of both primary and secondary tumors in SCRLM and resection of MCRLM.
89097947|NCT02886104|Experimental|CRLM ablation group|"Ablation of CRLM after resection of primary tumor in SCRLM and ablation of MCRLM.~Interventions: Ablation of liver metastasis within 30 days after resection of primary tumor in SCRLM and ablation of MCRLM."
89097948|NCT02689102||ILD patients|ILD patients scheduled for diagnostic bronchoscopy with biopsy and/or broncho-alveolar lavage will undergo additional imagaing with probe based optical techniques.
89097949|NCT02885558|Experimental|L + T-type|8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)
89097950|NCT02885558|Active Comparator|L-Type|8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)
89097951|NCT04185688||Multiple Sclerosis|"Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~Biodex Balance System: Biodex Balance System is used to evaluate limits of stability. The limits of stability test consists of standing on the platform and leaning in eight directions to make a cursor displayed on the system's screen hit a target.~Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
89097952|NCT04185688||Healthy People|Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.
89097953|NCT01008150|Active Comparator|Arm 1: paclitaxel + trastuzumab then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Following paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
89097954|NCT01008150|Experimental|Arm 2: paclitaxel + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
89097955|NCT01008150|Experimental|Arm 3: paclitaxel + trastuzumab + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
89097956|NCT01008150|Experimental|Arm 3 NR: paclitaxel+trastuzumab+neratinib|Non-randomized: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
89097957|NCT02687152|Experimental|Arginase inhibition|N-hydroxyl-nor-L-arginine, i.a. 0.1 mg/min for 120 min
89097958|NCT04186936|Experimental|Treatment Sequence AB|Participants will receive Test Product A (single dose of 2 caplets [Combination caplet with loperamide hydrocloride [HCl] 2 milligram [mg] + simethicone 125 mg]) orally on Day 1 followed by Reference Product B (single dose of 2 Imodium Express tablets-lyophilizate [2*2 mg loperamide HCl] + 6 Espumisan capsules [6*40 mg simethicone]) orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
89097959|NCT04186936|Experimental|Treatment Sequence BA|Participants will receive Reference product B orally on Days 1 followed by Test product A orally on Day 13. A washout period of at least 7 days will be maintained between each treatment.
89097960|NCT01007916|Other|Lotrafilcon B / Habitual|Lotrafilcon B contact lenses worn first, with habitual contact lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
89097961|NCT01007916|Other|Habitual / Lotrafilcon B|Habitual contact lenses worn first, with lotrafilcon B lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
89097962|NCT02689180|Placebo Comparator|Withdraw of furosemide|Withdraw of of 40 or 80 mg of furosemide per day
89097963|NCT02689180|Active Comparator|Maintenance of furosemide|Maintenance of 40 or 80 mg of furosemide per day
89097964|NCT01007838|Experimental|Chronic kidney disease progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
89097965|NCT01007838|Sham Comparator|Chronic kidney disease sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
89097966|NCT01007838|Experimental|Healthy controls progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
89097967|NCT01007838|Sham Comparator|Healthy controls sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
89097968|NCT02686762|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
89097969|NCT02686762|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
89097970|NCT02686762|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
89097971|NCT02689336|Experimental|Erlotinib and Temozolomide|"Erlotinib is an oral drug that will be administered on an outpatient basis at a dose of 85 mg/m^2/dose once a day continuously (every day of a 28-day cycle)~Temozolomide is an oral drug that will be administered on an outpatient basis at a dose of 180mg/m2/dose once a day on Days 1-5 of a 28-day cycle."
89097972|NCT02685592|Experimental|Lentigo maligna patients|All the participants with histologically confirmed lentigo maligna will receive photodynamic therapy three times with 2 weeks' intervals. The borderline of treatment area is delineated with Wood's lamp and hyperspectral imaging system using 5 millimeter margins. Before applying the 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) light sensitizing gel the skin of treatment area is prepared with fractional ablative CO2-laser to enhance absorption. Ameluz® is spread as a 1 millimeter thick layer on the skin. After light sensitizer absorption the treatment area is illuminated with artificial red light (Aktilite CL128 lamp) using a light dose of 90 J/cm2. Finally 4 weeks after the last PDT treatment LM is excised surgically using 5 mm margins.
89097973|NCT04417972|Experimental|SHR7280 dose 1|oral administration for 21days,Phase I
89097974|NCT04417972|Experimental|SHR7280 dose 2|oral administration for 21days,Phase I
89097975|NCT04417972|Experimental|SHR7280 dose 3|oral administration for 21days,Phase I
89097976|NCT04417972|Experimental|SHR7280 dose 4|oral administration for 21days,Phase I
89097977|NCT04417972|Active Comparator|SHR7280 low dose|oral administration for 84days,Phase II
89097978|NCT04417972|Active Comparator|SHR7280 high dose|oral administration for 84days, Phase II
89097979|NCT04417972|Placebo Comparator|Placebo|oral administration for 84days, Phase II
89097980|NCT01007448|Experimental|Bexarotene 150 milligrams (mg)/square meter (m^2)/day|Participants will receive bexarotene 150 mg/m^2/day once daily for 24 weeks.
89097981|NCT01007448|Experimental|Bexarotene 300 mg/m^2/day|Participants will receive bexarotene 300 mg/m^2/day once daily for 24 weeks.
89097982|NCT02686684||Dimethyl Fumarate|MS patients who started treatment with dimethyl fumarate
89097983|NCT02686684||Healthy Control|
89097984|NCT04294056|Experimental|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
89097985|NCT04294056|Active Comparator|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
89097986|NCT02870556|Experimental|EP, Cervical epidural group|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive cervical epidural analgesia in addition to the standard general anesthesia (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) Cervical epidural technique: epidural needle will be inserted at C 6-C7 or C7-T1 under fluoroscopy in prone position, 6 ml of 0.125% bupivacaine and fentanyl 2 mic/ ml will be administered before skin incision followed by 4 ml of the same injectate, will be infused continously for 2 days
89097987|NCT02870556|Active Comparator|GA, General anesthesia|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive standard general anesthesia only (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) in addition to postoperative analgesia through patient controlled intravenous morphine analgesia (PCA), that involve 1 mg continuous infusion and 2 mg boluses with lockout interval 10 min
89097988|NCT00628602|Experimental|Rx Group|BION Therapy Group
89097989|NCT00628602|Placebo Comparator|Control Group|control group
89097990|NCT03538756|Experimental|Baseline Group A--Walkasins On Then Off|"Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits"
89097991|NCT03538756|Experimental|Baseline Group B--Walkasins Off Then On|"Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
89097992|NCT03538756|Experimental|Single Arm Long-Term Follow-up|"During the baseline visit, participants were randomized to two groups that applied to the first visit only. After the baseline visit, community-dwelling participants received Walkasins to wear over the next 52 weeks. They returned for follow-up visits at weeks 2, 6, 10, 26, and 52, during which they repeated the functional measures while wearing their Walkasins and responded to the questionnaires. Between weeks 10 and 26 and 26 and 52, they were contacted periodically to remind them of study requirements and to collect follow-up information regarding health changes, adverse events, pain scores, device usage, and device functioning.~Note: Due to COVID-19 disruptions, some participants were not able to return for all in-person follow-up visits. They completed the patient-reported outcome measures via telephone visits."
89097993|NCT04204824|Experimental|Ultrasound and exercise|This group will receive ultrasound treatment, strengthening exercises and stretching exercises.
89097994|NCT04204824|Active Comparator|Sham Ultrasound and exercise|This group will receive sham ultrasound treatment, strengthening exercises and stretching exercises.
89097995|NCT04186702|Active Comparator|visual acuity letter score|visual acuity letter score is used to compare between the two groups after interventional procedures
89097996|NCT04186702|Active Comparator|macular thickness(CST)|macular thickness(CST)is used to compare between the two groups after interventional procedures
89097997|NCT04187014|Active Comparator|Tranexamic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid are 650 mg each. The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
89097998|NCT04187014|Experimental|Aminocaproic acid|"Will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic tablets are 1000 mg each.The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the aminocaproic acid, a total dose of 6 grams (6 tablets) divided between the 3 administrations (2 gram each, ie 2 tablets of 1000 mg) will be administered."
89097999|NCT02686840|Experimental|sublingual misoprostol|Group A (100 patients): will be treated with sublingual misoprostol
89098000|NCT02686840|Active Comparator|vaginal misoprostol|Group B (100 patients): will be treated with vaginal misoprostol
89098001|NCT00638482|Experimental|1|Hydrochlorothiazide
89098002|NCT00639964|Other|type 1 diabetic pregnant women|type 1 diabetic pregnant women
89098003|NCT00639964|Other|type 2 diabetic pregnant women|type 2 diabetic pregnant women
89098004|NCT00639964|Other|healthy pregnant women|healthy pregnant women with normal glucose tolerance
89098005|NCT02684968|Experimental|Colorectal Surgery with QL block having anesthetic|Bilateral QL catheter with local anesthetic infusion + intravenous patient controlled narcotic medication
89098006|NCT02684968|Placebo Comparator|Colorectal Surgery with QL block having saline|Bilateral QL catheter with normal saline infusion + intravenous patient controlled narcotic medication
89098007|NCT04034290|Experimental|Stage 1 (GamFluVac intranasal drip)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated by intranasal drip
89098008|NCT04034290|Experimental|Stage 1 (GamFluVac with the help of a spray dispenser)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated intranasally with the help of a spray dispenser
89098009|NCT04034290|Experimental|Stage 2 Vaccine|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
89098010|NCT04034290|Placebo Comparator|Stage 2 (Controll Group)|Placebo
89098011|NCT04184596||Stated-Preferences Observational Group|A discrete choice experiment will be conducted with participants with peripheral neuropathic pain in the stated-preferences observational group. The instrument will measure patient preferences for topical versus systemic pain treatment.
89098012|NCT00638560|Experimental|1|"Antioxidant treatment arm:~Vitamin E, 400 IU po, once daily Vitamin C, 1g po, twice daily"
89098013|NCT00638560|Placebo Comparator|2|Control
89098014|NCT02685124|Experimental|Bahia orange juice|250 ml twice daily for 7 days
89098015|NCT02685124|Experimental|Cara Cara orange juice|250 ml twice daily for 7 days
89098016|NCT02685124|Placebo Comparator|Isocaloric control drink|250 ml twice daily for 7 days
89098017|NCT00638638|Experimental|1|"Early Abciximab bolus during prehospital transportation in ambulance 0.25 mg/Kg iv with Heparin 40 UI/kg bolus.~Abciximab placebo bolus and Abciximab infusion 10 µg/Kg/min after coronary angiography and before angioplasty."
89098018|NCT00638638|Experimental|2|"Abciximab placebo bolus during prehospital transportation in ambulance with Heparin 40 UI/kg bolus.~Abciximab 0.25 mg/Kg bolus after coronary angiography and before angioplasty followed by Abciximab infusion 10 µg/Kg/min."
89098019|NCT02684812|Active Comparator|Tranexamic Acid|Eligible subjects are randomly assigned to immediate administration of TXA (1 g i.v.) after a diagnosis of SAH, as confirmed by CT-scan of the brain, continued by continuous infusion of 1 g per 8 hours to a maximum of 24 hours after start of medication. A maximum of 4 g TXA (1 g bolus + 3x 1 g continuous infusion) can be administered to one patient.
89098020|NCT02684812|No Intervention|Control|Standard care
89098021|NCT04185376||group A 200 patients|patients with one or more PFDs significant psychological strain in at least one pelvic floor domain
89098022|NCT04185376||group B 200 patients|patients without any pelvic floor complaints
89098023|NCT02686216|Experimental|F-18 THK-5351|F-18 THK-5351 imaging
89098024|NCT02686294|Experimental|T-R|First period : administration of test drug Second period : administration of reference drug
89098025|NCT02686294|Experimental|R-T|First period : administration of reference drug Second period : administration of test drug
89098026|NCT02688478|Active Comparator|Filtered air|Exposure for 3 hours to filtered air followed by subject specific inhaled allergen challenge
89098027|NCT02688478|Experimental|Phthalate|Exposure for 3 hours to dibutyl phthalate followed by subject specific inhaled allergen challenge
89098028|NCT01004250|Experimental|Study Treatment|
89098029|NCT02688634||Treatment|Participants in this group are randomize to receive post-operative antibiotic of Amoxicillin x7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
89098030|NCT02688634||Non-Treatment|Participants in this group will be randomize to no post-operative antibiotic. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
89098031|NCT00639496|Experimental|1|patients taking NAC 600 mg t.i.d.
89098032|NCT00639496|Placebo Comparator|2|
89098033|NCT04186624|Experimental|Supervised Exercise Program|The exercise program that applied at the hospital includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
89098034|NCT04186624|Active Comparator|Home-based Exercise Program|The home-based exercise program given with a brochure that includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
89098035|NCT04184752||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
89098036|NCT04184752||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
89098037|NCT04184752||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
89098038|NCT02685046|Experimental|Intervention|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
89098039|NCT02684890||Tinnitus patients|Patients with tinnitus lasting over 3 months
89098040|NCT02684890||Non-tinnitus patients|Patients without tinnitus
89098041|NCT01004172|Experimental|carboplatin, bevacizumab, trastuzumab (if HER2+)|"Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.~carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle~bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle~trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only~*8mg/kg loading dose in cycle 1 for some participants~HER-2: human epidermal growth factor receptor 2"
89098042|NCT02688244|Active Comparator|Irrigation|Irrigation of the area with at least 300ml normal saline using the power suction/irrigator
89098043|NCT02688244|Active Comparator|No irrigation|Only suction with the power suction/irrigator without saline attached
89098044|NCT02688322|Experimental|2 g q12 of sulbactam, 1 h infusion|2 g of sulbactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 1 h every 12 h.
89098045|NCT02870400|Experimental|REGN2477|Cohorts 1 - 5 will receive REGN2477
89098046|NCT02870400|Experimental|Placebo|Cohorts 1 - 5 will receive placebo
89098047|NCT02685904|Experimental|ENIA11|25 mg of ENIA11 subcutaneously administered twice weekly
89098048|NCT02685904|Placebo Comparator|Placebo|25 mg of Placebo subcutaneously administered twice weekly
89098049|NCT00638794||Surgical|Patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
89098050|NCT00638794||Observational|Consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications
89098051|NCT03098290||Intermittent Claudication|Mild to severe claudication
89098052|NCT03098290||Ischaemic Rest Pain|
89098053|NCT03098290||Critical Limb Threatening Ischaemia|Ulcers, Necrosis, Gangrene
89098054|NCT04184986||inflammatory bowel disease|100-150 pts with dg. inflammatory bowel disease
89098055|NCT04184986||unspecific GI symptoms|100-150 pts unspecific GI symptoms
89098056|NCT00639652||1. 3D-histology|Nodular, micronodular, or sclerosing BCCs
89098057|NCT00639652||2. Shave excision|Superficial BCCs
89098058|NCT04186234|Experimental|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 35 to 50 Grays in 5 fractions over 5 to 14 days.
89098059|NCT02685748|Experimental|Aspirin & pantoprazole|"Aspirin 1000 mg/pd per os in two doses~Pantoprazole 40 mg/pd per os in two doses for gastric protection"
89098060|NCT02685748|Placebo Comparator|Placebo|"Two pills in the morning and two in the evening~All pills (aspirin, pantoprazole an placebo) will be the same looking- in the same capsules."
89098061|NCT04186312|Experimental|Immediate Treatment|Cognitive-Behavioral Treatment program known as ACCESS
89098062|NCT04186312|Other|Delayed Treatment|Allowed to receive treatment as usual during study, then received ACCESS after delay of two-semesters
89098063|NCT04184440|Placebo Comparator|placebo|corn starch；capsule，2 g/day，2 times/day；3 months
89098064|NCT04184440|Experimental|Cyclocarya paliurus extract|aqueous extract of Cyclocarya paliurus；capsule，2 g/day，2 times/day；3 months
89098065|NCT04184440|Experimental|Cyclocarya paliurus compounds|mixed aqueous extract of Cyclocarya paliurus and other traditional Chinese herbal medicines including Astragalus propinquus Schischkin，Dioscorea oppositifolia L.，Dendrobium nobile Lindl.，Salvia miltiorrhiza Bge. and Inulin；capsule，2 g/day，2 times/day；3 months
89098066|NCT02685982|Experimental|Rhythmic Sensory Stimulation|Participants in this group will undertake 30 minutes of daily Rhythmic Sensory Stimulation, for 5 day per week, for a total of 5 weeks. The stimulation consists of specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range. The intervention is conducted at the participant's home using a portable device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit. This device is a low-voltage consumer product device that has built in low frequency (subwoofer-type) speakers. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration that is synchronized with the relaxing musical track.
89098067|NCT04184908|Experimental|GROUP EXPERIMENTAL|Gel xerostomia Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
89098068|NCT04184908|Placebo Comparator|CONTROL GROUP|Gel placebo Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
89098069|NCT00639730|Experimental|A|This is open-label - all patients are placed on the diet. There is no control or placebo arm.
89098070|NCT02684500||aneurysmal subarachnoid hemorrhage|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) for a aneurysmal subarachnoid hemorrhage in subjects undergoing hypertensive therapy for cerebral vasospasm in SAH, to justify the withholding of enteral nutrition.
89098071|NCT02685670|Experimental|Mixed CD19CAR transfer|All subjects will be infused with αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T cells in equal number
89098072|NCT02684656|Active Comparator|Hemodialysis|Intervention: Patients will be switch to hemodialysis and basal plasma oxalate levels as well as oxalate removal by hemodialysis will be determined after two weeks of treatment.
89098073|NCT02684656|Active Comparator|Hemodiafiltration|Intervention: Patients will be switch back to hemodiafiltration and basal plasma oxalate levels as well as oxalate removal by hemodiafiltration will be determined after two weeks of treatment.
89098074|NCT00640120||1|Asthmatic subjects
89098075|NCT00640120||2|Healthy subjects
89098076|NCT02688010|No Intervention|Control|No specific noise reduction strategies to restrict noise exposure less than 45 dB combined with either continuous bright light or continuous near darkness or unstructured combination of the two during the hospitalization.
89098077|NCT02688010|Experimental|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
89098078|NCT00638872|Experimental|1|PDRN
89098079|NCT00638872|Placebo Comparator|placebo|placebo
89098080|NCT00638950|Placebo Comparator|Placebo|
89098081|NCT00638950|Active Comparator|n-3 LC-PUFA|
89098082|NCT00639808|Placebo Comparator|1|
89098083|NCT00639808|Experimental|2|TZP-101
89098084|NCT02687932|Experimental|LCZ696|LCZ696 for 12 months
89098085|NCT02687932|Active Comparator|Valsartan|Valsartan for 12 months
89098086|NCT00641602|Experimental|1|Nexium
89098087|NCT00641602|Active Comparator|2|Prevacid
89098088|NCT04183972|Experimental|Image collecting Group|An computer algorithm will be developed and evaluated by these image data.
89098089|NCT01161524|Experimental|Perampenal (Core Study)|Participants received perampanel 2 mg per day and up-titrated weekly in 2-mg increments to a target dose range of 8 to 12 mg per day.
89098090|NCT01161524|Placebo Comparator|Placebo (Core Study)|Participants received matching placebo tablets once a day (6 tablets of placebo).
89098091|NCT01161524|Experimental|Perampanel (Extension Phase)|During the Extension Phase, participants previously assigned to perampanel arm (Core Study) continued taking study medication at the dose achieved at the end of the Core Study once daily. Participants previously assigned to a placebo arm (Core Study) started perampanel dose at 2 mg/day and up-titrated weekly in 2-mg increments up to a maximum dose of 12 mg/day.
89098092|NCT02681224|Active Comparator|Active Product with Occlusion|TR987 Gel with Silon Bandage
89098093|NCT02681224|Active Comparator|Active Product without Occlusion|TR987 without Silon Bandage
89098094|NCT02681224|Placebo Comparator|Placebo Gel with Occlusion|Placebo Gel with Silon Bandage
89098095|NCT02681224|Placebo Comparator|Placebo Gel without Occlusion|Placebo Gel without Silon Bandage
89098096|NCT04182646|Experimental|Single arm|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required.
89098097|NCT02683096||SGA Infants|
89098098|NCT02683096||Failed Hearing Screen Infants|
89098099|NCT02680990|Active Comparator|Exercise Education|Distribution of exercise education materials
89098100|NCT02680990|Experimental|Band Together|A strength-training and walking program with or without an exercise partner throughout neoadjuvant therapy.
89098101|NCT04184128||Detrusor underactivity|The DU was defined when the PdetQmax was less than 20 cmH2O, the Qmax was less than 15 mL/s, and the bladder voiding efficiency (BVE) was less than 90 %. BVE = voided volume / (voided volume+ PVR) x 100%.
89098102|NCT04184128||Bladder outlet obstruction|The BOO was defined when the PdetQmax was not less than 40 cmH2O, and the Qmax was less than 12 mL/s.
89098103|NCT04184128||Non-DU/BOO group|Those women without DU or BOO were allocated to the non-DU/BOO group.
89098104|NCT02682940|Other|Usual Care Patients on MDI or CSII|Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
89098105|NCT01000506|Active Comparator|Mepolizumab 750mg|Mepolizumab 750mcg i.v. every 4 weeks
89098106|NCT01000506|Active Comparator|Mepolizumab 250mg|Mepolizumab 250mcg i.v. every 4 weeks
89098107|NCT01000506|Active Comparator|Mepolizumab 75mg|Mepolizumab 75mcg i.v. every 4 weeks
89098108|NCT01000506|Placebo Comparator|Placebo|Placebo saline every 4 weeks i.v.
89098109|NCT02682862|Experimental|Spiolto Respimat|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
89098110|NCT02682862|Active Comparator|Striverdi Respimat|olodaterol 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
89098111|NCT00640198|Active Comparator|Group 1 Memantine|Patients included in this group will receive memantine alone followed by memantine combined with intensive speech-language therapy.
89098112|NCT00640198|Placebo Comparator|Group 2|Patients included in this group will receive placebo alone followed by memantine combined with intensive speech-language therapy.
89098113|NCT04296552|Experimental|12 week lowFODMAP dietary intervention|Patients with IBS-D are enrolled in a 12 week strict lowFODMAP dietary intervention study.
89098114|NCT04293822|Experimental|Study group|Group of 30 patients randomly selected will use topical Cetirizine 1% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
89098115|NCT04293822|Active Comparator|Control group|Group of 30 patients randomly selected will use topical Minoxil 5% gel twice daily over a period of 6 months, where the treatment will be given in identical non-labeled bottles with a code and neither the patients, healthcare provider nor the investigator will know which treatment is given and what the code referred to.
89098116|NCT02680600|Experimental|Study arm|"Cefepime dosing~Blood sampling~Urine sampling~Determination of renal markers~Population pharmacokinetic modeling~Covariate screening~Monte Carlo simulations"
89098117|NCT02680678|Active Comparator|Colloid preload|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) 15 minutes before spinal anesthesia.
89098118|NCT02680678|Active Comparator|Colloid Co-load|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) beginning with spinal anesthesia.
89098119|NCT02680678|Active Comparator|Crystalloid Preload|20 patients each patient receives 20 ml/kg of Ringer's lactate solution 15 minutes before spinal anesthesia.
89098120|NCT02680678|Active Comparator|Crystalloid Co-load|20 patients each patient receives 20 ml/kg of Ringer's lactate solution beginning with spinal anesthesia.
89098121|NCT04182724|Experimental|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib 250 mg p.o. qd Nab-paclitaxel 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
89098122|NCT02680912|Experimental|Warm needle acupuncture|"Warm needle acupuncture (wenzhen; 温针) is where moxa cones are placed on the handle of the needle, after the needle has been inserted. Once lit, heat transmits along the shaft of the needle to the acupuncture point.~Moxa refers to the herb mugwort (Artemisia vulgaris) that is burnt to warm specific parts of the body, including acupuncture points."
89098123|NCT02680912|Active Comparator|Basic needle acupuncture|Basic needle acupuncture is the use of acupuncture needles alone, without other methods of stimulation.
89098124|NCT02682628|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89111157|NCT00816400|Experimental|MEDI-575, 3.0 mg/kg QWk Escalation Phase (Cohort 1)|Single lead-in dose of MEDI-575 at 0.5 mg/kg as a 60-minute intravenous (IV) infusion administered 7 days prior to first dose at 3.0 mg/kg; MEDI-575 administered at 3.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (once every 7 days [QWk]) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89098125|NCT04183816|Experimental|Total cold-water immersion group|"Participants allocated to the TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C. Each Participant was totally immersed in a pool while his/her head and neck remained above water level. The water's temperature was continuously measured by a mercury-in-glass thermometer and maintained at the aforementioned temperature by continuously adding ice blocks.~With respect to depth of immersion, TCWI is more efficient than partial CWI since exposing a larger area of the body is needed for cardiovascular changes to occur (Murray and Cardinale, 2015; Stephens et al., 2016)."
89098126|NCT04183816|Active Comparator|Ice massage group|Participants in the IM group were seated. The investigator in charge of this intervention group applied Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
89098127|NCT04184518|Experimental|Cediranib plus durvalumab|
89098128|NCT02680522|Active Comparator|Control Group|composed of healthy volunteers who underwent training with virtual reality. Exercises with game through virtual reality
89098129|NCT02680522|Experimental|Parkinson's Group|composed of patients with Parkinson's disease and who underwent training with virtual reality. exercises with game through virtual reality
89098130|NCT01174238|Experimental|Arm A|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. In addition patients enrolled in Arm A will also have FLT-PET scans.
89098131|NCT01174238|Experimental|Arm B|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. Patients enrolled in Arm B will not have FLT-PET scans.
89098132|NCT04315532|Active Comparator|Pregnancy Group|"GCF and saliva samples were taken from pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from pregnant periodontal healty individuals baseline and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed for pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
89098133|NCT04315532|Active Comparator|Non-Pregnancy Group|"GCF and saliva samples were taken from non-pregnant gingivitis patients before treatment and after 8 weeks. GCF and saliva samples were taken from periodontal healty individuals baseline and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed for non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken."
89098134|NCT02682472|Experimental|SettleIN|SettleIN - Adjustment to care programme intervention
89098135|NCT00640900|Experimental|Commercial program at center|
89098136|NCT00640900|Experimental|Commercial program over the telephone|
89098137|NCT00640900|Other|Usual care|Weight loss counseling
89098138|NCT02680444|Experimental|Reappraisal-Only Intervention|Participants were instructed to independently practice the Self-Administered Reappraisal-Only Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the positive reappraisal instructions available online. This involved thinking about how one could grow, learn or benefit from the negative event in any way possible.
89098139|NCT02680444|Experimental|Mindful-Reappraisal Intervention|Participants were instructed to independently practice the Self-Administered Mindful-Reappraisal Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the Mindful-Reappraisal instructions available online. This involved thinking about the negative event in an objective, non-judgmental way, then following the Reappraisal-Only instructions, and closing off with a brief mindfulness breathing technique.
89098140|NCT02680444|Active Comparator|Event Recall Active Control|Participants were instructed to independently practice the Self-Administered Event Recall Exercise in the evening for five days. In this condition, participants were only instructed to recall a negative event from that day with no reappraisal exercise.
89098141|NCT02928406|Experimental|Atezolizumab|Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
89098142|NCT01174160|Experimental|vernakalant HCl|vernakalant hydrochloride
89098143|NCT01174160|Placebo Comparator|placebo|placebo
89098144|NCT05663632||group 1 heart failure patients|
89098145|NCT05663632||Group 2 controle|
89098146|NCT04313894|Experimental|Stem Cell Therapia Group|A total of 11 patients with Kellgren-Lawrence grade II-III knee OA who were admitted to the outpatient clinic with knee pain and who had received conservative treatment for a period of 6 months and who had not benefited from it will be taken. Patients will be evaluated 7 (V1-7) during the study period. Patients who comply with the study criteria will be included in the study. The clinical, immunological and radiological efficacy of the treatment and clinical improvement will be evaluated in all follow-up patients at the beginning and at the beginning of the treatment.
89098147|NCT02683798|Active Comparator|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
89098148|NCT02683798|Experimental|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
89098149|NCT04315454|Placebo Comparator|Group A|patients will receive 20 ml of normal saline into interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
89098150|NCT04315454|Experimental|Group B|Patients will receive 20 mg 0.25% Levobupivacaine into the interfascial plane between rhomboids major &erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side.
89098151|NCT02683720|Experimental|ONS1|new product
89098152|NCT02683720|Active Comparator|ONS2|usual care
89098153|NCT02682550||Ctrl|healthy volunteers, sex- and age matched Blood drawing at one time point: 20 ml
89098154|NCT02682550||PT|"polytrauma patients fulfilling the following criteria:~injury severity score ≥25~age ≥ 18 Blood drawing at admission to the emergency room, 8 h, 24h, 48 h, 120 h and 240 h post trauma: 20 ml"
89098155|NCT01161446|Experimental|Home Testing|
89098156|NCT01161446|No Intervention|Standard Testing|
89098157|NCT02680210|Other|cognitive measures and questionnaires|the material of the study will consist of cognitive measures and questionnaires in order to (1) compare the cognitive performances and behavioral manifestations between patients with TBI and volunteers without neurological disorders and (2) to analyze the links between cognitive and behavioural measures in the TBI population
89098158|NCT00641680|Experimental|1|Budesonide
89098159|NCT00641680|Active Comparator|2|Fluticasone propionate
89098160|NCT00641680|Placebo Comparator|3|
89098161|NCT04183582|Experimental|Intervention Group|Single arm group receiving Behavioural Activation, a facilitated self-help programme delivered by trained Health Visitors as six one hour sessions over four weeks.
89098162|NCT04033588|Other|Freedom® Total Knee System|A prospective, multi-centre, non-comparative, post-market clinical follow-up study to evaluate the survivorship, safety and performance of the Freedom® Total Knee System in United Kingdom
89098163|NCT01174004|Experimental|1|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
89098164|NCT01174004|Placebo Comparator|2|placebo, tablet, once daily by mouth for 6 weeks
89098165|NCT02680288|Placebo Comparator|Oral Placebo|Oral inert treatment
89098166|NCT02680288|Experimental|Active Treatment, Low-Dose|Lorcaserin 10 mg, single dose
89098167|NCT02680288|Experimental|Active Treatment, High-Dose|Lorcaserin 20 mg, single dose
89098168|NCT02885402|Experimental|Osteoarthritis patient|
89098169|NCT02885402|Placebo Comparator|Healthy volunteers|
89098170|NCT00909922||Lower Limb Amputees|Unilateral Above knee amputees
89098171|NCT01173692|Placebo Comparator|Placebo|Twice Daily Orally
89098172|NCT01173692|Experimental|Minocycline|100 mg Twice Daily Orally
89098173|NCT00641758|Placebo Comparator|Placebo|
89098174|NCT00641758|Active Comparator|Pycnogenol|
89098175|NCT00640276|Active Comparator|T|Lifestyle modification + active drug(Pitavastatin)
89098176|NCT00640276|Other|C|Lifestyle Modification
89098177|NCT00640354|Experimental|1|Pediatric residents randomized to having an automated external defibrillator
89098178|NCT00640354|Active Comparator|2|Pediatric residents randomized to having a manual defibrillator
89098179|NCT02680132|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
89098180|NCT02680132|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
89098181|NCT02683564|Experimental|BOW015|Infliximab-EPIRUS, 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
89098182|NCT02683564|Active Comparator|Remicade|Remicade (infliximab) , 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
89098183|NCT04104100||Women with nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for <65 year-old women.
89098184|NCT04104100||Women without nocturnal polyuria|Nocturnal polyuria was defined when the proportion of night-time voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of night-time voided volume over 24-hour voided volume was greater than 20% for <65 year-old women.
89098185|NCT01101035|Experimental|Febuxostat|Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.
89098186|NCT01101035|Active Comparator|Allopurinol|Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but <60 mL/min).
89098187|NCT04306679|Experimental|Interventional arm|The intervention, which was aimed to educate children on how to use pain scales and provide reliable pain assessments was based on a two short animation clips, lasting approximately 5 min each, and a short (5 min) guided interaction between the study nurse and the participants, in between the two clips.
89098188|NCT04306679|Other|Control|Children underwent the routine pre-operative preparations, which included a section on pain assessment.
89098189|NCT01100567|Placebo Comparator|Placebo platform|Randomized to stand on placebo platform for 10 minutes/day
89098190|NCT01100567|Active Comparator|Low-magnitude mechanical stimulation|Randomized to stand on LMMS platform 10 minutes/daily
89098191|NCT01160822|Experimental|Part A: Canakinumab|In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.
89098192|NCT01160822|Placebo Comparator|Part A: Placebo|Participants received a single intra-articular injection of canakinumab-matching placebo.
89098193|NCT01160822|Experimental|Part B: Canakinumab|Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
89098194|NCT01160822|Placebo Comparator|Part B: Placebo|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
89098195|NCT01160822|Active Comparator|Part B: Naproxen|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.
89098196|NCT01006980|Experimental|Vemurafenib|
89098197|NCT01006980|Active Comparator|Dacarbazine|
89098198|NCT00887926|Experimental|IMC-EB10 5 milligrams/kilogram (mg/kg)|All participants will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.
89098199|NCT04182178||Gastroesophageal reflux|Laparoscopic total (Nissen) or posterior 270 degree (Toupét) partial fundoplication for the treatment of gastroesophageal reflux disease.
89098200|NCT02679898|No Intervention|Lean Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
89098201|NCT02679898|No Intervention|Overweight/Obese Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
89098202|NCT02679898|Experimental|Unloaded-Whole Body Vibration (WBVT)|Lower-body exercise training on a vibration platform
89098203|NCT02679898|Experimental|Loaded-Whole Body Vibration (WBVT)|Externally loaded lower-body exercise training on a vibration platform
89098204|NCT04296240|Experimental|Neoadjuvant chemotherapy|Oxaliplatin 130mg/m2 d1 and Capecitabine 1250mg/m2 bid1-14 or other fluorouracils, every 21 or 14 days for 2 to 4 cycles, and efficacy evaluation every 2 cycles;
89098205|NCT04391322||Group 1|Healthy participants without lung disease
89098206|NCT04391322||Group 2|Participants with stable cystic fibrosis
89098207|NCT04391322||Group 3|Participants with cystic fibrosis, anticipated to receive treatment with CFTR-modulator therapy. Please note: treatment is determined by your physician as part of your normal therapy plan.
89098208|NCT04205058|Experimental|standard coffee|Hot standard coffee with caffeine (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
89098209|NCT04205058|Placebo Comparator|caffeine-free coffee|Hot caffeine-free coffee (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
89098210|NCT04205058|Sham Comparator|water|Hot water (one 30 mL espresso cup twice a day, from postoperative day one to first bowel movement or postoperative day three).
89098211|NCT04183738|Active Comparator|SOC|darunavir/ritonavir 800/100mg + 2 NRTIs po od
89098212|NCT04183738|Experimental|DOL|darunavir/ritonavir 800/100mg + dolutegravir 50mg po od
89098213|NCT04183738|Experimental|D2N|dolutegravir 50mg + tenofovir + emtricitabine or lamivudine po od
89098214|NCT02870322|Active Comparator|Fruit and Vegetable CSA Prescription|"Study participants randomized to the CSA group will be expected to pick up their weekly CSA box at University Health Services and to commit to using and consuming as much of the produce as they are able. CSA group participants will also be required to attend two cooking and food preparation classes coordinated by Slow Food UW. The classes will teach study participants how to properly clean and prepare the fruits and vegetables from a weekly CSA box, and also offer techniques and show them how to cook the foods in a healthy manner. These classes will also educate study participants on the benefits of eating fruits and vegetables and buying them from local farmers. These two classes will only exist for study participants in this fruit and veggie CSA group. Participants in the CSA group will also be required to take a field trip to the farm providing their CSA share, which will offer the opportunity for participants to gain a better understanding of from where their food comes."
89098215|NCT02870322|Active Comparator|Bikeshare Prescription|"Study participants randomized to the bikeshare group will be expected to use B-cycle bikes for transportation and/or recreation as much as is safe and appropriate. Bikeshare group participants will be required to attend one bicycle use/safety course. This course will introduce the B-cycle program, demonstrate use of the B-cycle station, provide information use of helmets and safety gear, and provide information on the basics of cycling and keeping yourself safe and comfortable while riding in traffic. The study participants in this group will also be required to attend a class on the benefits of exercise, including bicycling, among other forms of physical activity. This class will be offered by the University Health Services Wellness program. B-cycle usage, including estimated distance traveled and frequency of use, will be tracked via the B-cycle Madison website."
89098216|NCT02870322|No Intervention|Control|"Study participants in the control group will receive continued usual care from University Health Services providers, which includes educational brochures on healthy eating and exercising, plus a cash payment. Control group participants are not part of a wait-list group."
89098217|NCT02682160|Other|Use of Protein Assistant|patients can use the Protein Assistant during 2 months to evaluate the quantity of protein's intake.
89098218|NCT04033666|Active Comparator|High Flow nasal cannula|It will be administered as part of the high-flow nasal cannula treatment to reduce the symptoms of acute asthma
89098219|NCT04033666|Active Comparator|NIV noninvasive ventilation|It will be administered as part of the Noninvasive ventilation treatment to reduce the symptoms of acute asthma
89098220|NCT02871414|Experimental|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
89098221|NCT02871414|Experimental|REST - Late Group|Control - No treatment for 7 weeks, then provided 7 weeks of sleep skills education provided in group and one-on-one format
89098222|NCT00641134|Other|A|A:Home-Based exercise program,-at discharge from in-Hospital CR program-, with one reinforcement session each month for the first 6 months.
89098223|NCT00641134|No Intervention|B|Usual care, after CR, consisting of recommendation on usefulness of physical exercise and standard follow-up visits and functional assessment at 6 and 12 months.
89098224|NCT02682082|Experimental|Neurolysis without Bupivacaine|Experimental Group: Endoscopic ultrasound guided celiac plexus Neurolysis without Bupivacaine so only with Absolute Alcohol 20 mL
89098225|NCT02682082|Active Comparator|Neurolysis with Bupivacaine|Endoscopic ultrasound guided celiac plexus Neurolysis with Bupivacaine (0.5% Bupivicaine 20mL + Absolute Alcohol 20 mL)
89098226|NCT02870946|Experimental|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced.
89098227|NCT02870946|Experimental|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
89098228|NCT00640432|Active Comparator|A|
89098229|NCT00640432|Experimental|B|
89098230|NCT02870244|Experimental|Escalating Doses|Three patients will be treated at the first & each subsequent dose level. Patients will be observed for 30 days post T cell infusion. If there was one DLT in the first 3 patients, an additional 3 patients will be treated at that level. If no additional DLTs are observed (for a total of 1 DLT in 6 patients) then the dose will be escalated. If two patients in the first 3 patients at a dose level experience a DLT, the dose will be de-escalated to the previous level & an additional 3 patients will be enrolled at that level if 6 have not yet been treated at that level. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a DLT. If 2 or 3 patients in the first 3 patients experience a DLT at the first dose level, the study will terminate.
89098231|NCT02679664|Experimental|Treatment group|20 mg tablet of rosuvastatin PO once-a-day starting at the time of randomization until the completion of follow-up at 6 months.
89098232|NCT02679664|No Intervention|Control group|Standard medical care only. No rosuvastatin group.
89098233|NCT02871180|Other|With late night snack|At 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten from Type 1 diabetic patients on an intensified conventional treatment regimen.
89098234|NCT02871180|Other|Without late night snack|Not nutrients (No late night snack) were consumed at 10 p.m. from Type 1 diabetic patients on an intensified conventional treatment regimen..
89098235|NCT02679742|Experimental|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program
89098236|NCT02679742|Placebo Comparator|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program
89098237|NCT04295226||Participants in Structured post-stroke follow-up in Malmö|"Consecutive patients with acute ischemic stroke or intracerebral hemorrhage, treated in-hospital at Skåne University Hospital in Malmö and discharged straight to own home.~The intervention consists of a structured follow-up visit, managed by a stroke nurse, 3 months after stroke followed by a multidisciplinary team rounds resulting in an individual treatment plan for stroke-related health problems, and a final follow-up at 12 months"
89098238|NCT02679586|Experimental|Diffusion weighted MRI Group|"All patients will receive a double baseline diffusion weighted MRI (performed on the same day as the Baseline MRI).~Patients participating in Part I will receive another MRI approximately 1 week (day 8-11) after the first dose of Chemotherapy (chemotherapy will be determined by the treating physician and is not assigned as part of this trial).~Patients participating in Part II will receive a single MRI 1-2 weeks after the first dose of Chemotherapy A (chemotherapy will be determined by the treating physician and is not assigned as part of this trial). A second MRI will be repeated within 2 weeks prior to the start of Chemotherapy B."
89098239|NCT04295070|Placebo Comparator|Placebo|Saline (0.9%) delivered intranasally via dropper
89098240|NCT04295070|Experimental|Low dose cohort|CodaVax-RSV delivered intranasally via dropper
89098241|NCT04295070|Experimental|High dose cohort|CodaVax-RSV delivered intranasally via dropper
89098242|NCT02870010|Experimental|non-metastatic hepatocellular carcinoma|"Radiation : Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection~Biological : blood samples (5 ml) will be taken"
89098243|NCT02870712|Experimental|suture directed|The suture of the perineum is headed by obtaining hemostasis by digital compression 5 minutes; If hemostasis is obtained, the perineum will not be sutured. In case of failure of hemostasis, suture of the perineum will be realized.
89098244|NCT02870712|Active Comparator|systematic suture|systematic suture tears following current recommendations
89098245|NCT02537782|Other|Cardiac resynchronisation therapy implantation|Patients with current guideline-based indication for CRT implantation.
89098246|NCT00998400|No Intervention|Clinical Management|Control group
89098247|NCT00998400|Experimental|CBT + WBT|Patients treated with Cognitive-Behavioral Therapy in combination with Well-Being Therapy and lifestyle modification
89098248|NCT00641212|Experimental|1|Budesonide
89098249|NCT00641212|Placebo Comparator|2|
89098250|NCT02869776|Experimental|Rapid finger stick|HIV and HCV testing through rapid finger stick. Behavioral questionnaires will also be administered.
89098251|NCT02869776|Experimental|Standard venipuncture|HIV and HCV testing through venipuncture. Behavioral questionnaires will also be administered.
89098252|NCT04293900||Study cohort|24-hour dietary recall, hand grip strength, accelerometer, International Physical Activity Questionnaire (IPAQ), Patient-reported outcomes survey (NCI-PRO-CTCAE), Pittsburgh Sleep Quality Index (PSQI), Functional Assessment of Cancer Treatment - Lymphoma (FACT-lym), urine sample (optional), fecal sample (optional)
89098253|NCT04183192|Experimental|Arm A: Mepolizumab low dose|Single dose of mepolizumab 3 mg SC
89098254|NCT04183192|Experimental|Arm B: Mepolizumab low intermediate dose|Single dose of mepolizumab 6 mg SC
89098255|NCT04183192|Experimental|Arm C: Mepolizumab high intermediate dose|Single dose of mepolizumab 12 mg SC
89098256|NCT04183192|Experimental|Arm D: Mepolizumab high dose|Single dose of mepolizumab 24 mg SC
89098257|NCT04183192|Experimental|Arm E: Reslizumab low dose|Single dose of reslizumab 0.1 mg/kg IV
89098258|NCT04183192|Experimental|Arm F: Reslizumab intermediate low dose|Single dose of reslizumab 0.2 mg/kg IV
89098259|NCT04183192|Experimental|Arm G: Reslizumab high intermediate dose|Single dose of reslizumab 0.4 mg/kg IV
89098260|NCT04183192|Experimental|Arm H: Reslizumab high dose|Single dose of reslizumab 0.8 mg/kg IV
89098261|NCT04183192|Placebo Comparator|Arm I: Placebo|Single dose of placebo
89098262|NCT00997386|Experimental|busulfan, and melphalan, and alemtuzumab|Three drug regimen using busulfan, and melphalan, and alemtuzumab.
89098263|NCT02394574|Active Comparator|Clean Cookstove|Subjects will use ethanol stoves using bioethanol
89098264|NCT02394574|Other|Traditional Cookstove|Subjects will use traditional firewood or kerosine cookstove and receive education on how to reduce air pollution exposures
89098265|NCT02870088|Active Comparator|Prolonged Sitting|Participants sat on a chair during the trial.
89098266|NCT02870088|Experimental|Breaking Sitting|Participants walked regularly during the trial.
89098267|NCT04182256|Experimental|MS group|In the MS group, the MS grips the HVC through the magnet adsorbed onto the wall of the basin containing the liver. By changing the position of the MS on the wall of the basin, the surgeon is able to expose the surgical field.
89098268|NCT04182256|No Intervention|MA group|In MA group, assistants use vessel forceps to pull the HVC according to the attending's requirements.
89098269|NCT02869620||Patients with thyroid cancer diagnosis|
89098270|NCT02679820|Experimental|PostPlacental IUD insertion|Copper T intrauterine device will be inserted immediately following delivery of the placenta in cases of cesarean section deliveries.
89098271|NCT02679820|No Intervention|Control|IUD will be offered as a method of contraception after puerperium
89098272|NCT02683330|Experimental|Mindfulness-based intervention (MBI)|Participants randomly assigned to the MBI group will receive 8 sessions over an 8-week period. The sessions will last 1 hour and will be held via video-conference through Skype, an online application.
89098273|NCT02683330|No Intervention|Wait-list control (WLC)|Participants randomly assigned to the WLC group will be discouraged from any new mindfulness related activities during the trial. The WLC group will be offered the opportunity to take part in the MBI at the end of the 20-week follow-up.
89098274|NCT00641914|Experimental|1|
89098275|NCT00641914|Placebo Comparator|2|
89098276|NCT02683408|Experimental|diosmiplex|diosmiplex 630 mg BID administered orally
89098277|NCT02683408|Placebo Comparator|placebo|placebo BID administrered orally
89098278|NCT00640588|Experimental|1|Telbivudine
89098279|NCT00640588|Active Comparator|2|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
89098280|NCT05663398|Experimental|Darfen 400|A single oral dose of the test product Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
89098281|NCT05663398|Active Comparator|Nurofen® Forte Express|A single oral dose of the reference product Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
89098282|NCT02683252|Experimental|Normal patients|Patients with normal bone appearance on conventional MR images
89098283|NCT02683252|Experimental|Carpal osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the carpal bones on conventional MR images (hypointensity on T1 weighted sequences, no contrast enhancement).
89098284|NCT02683252|Experimental|Femoral head osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the femoral head on conventional MR images (fat containing signal anomalies with geographic contours in the femoral epiphysis).
89098285|NCT02683252|Experimental|Pseudarthrosis|Patients presenting a non consolidated macroscopic bone fracture for over 6 months (clinical history and imaging findings).
89098286|NCT02683252|Experimental|Compartment syndrome|Patients with a confirmed compartment syndrome on intra-compartment pressure assessement
89098287|NCT02681926||Average force group|A recent tool, called VISITAG, has been developed (and approved by EMEA) for Biosense Webster Navistar Smart Touch catheter in order to allow collection of ablation points with pre-determined characteristics, such as stability of catheter during ablation, mean contact force, drop in impedance. In the Average Force group, the operators decided to use the mean contact force as target parameter indicating a good lesion.
89098288|NCT02681926||Force Time Integral group|In the Force Time Integral (FTI) group, the operators decided to use the FTI as target parameter indicating a good lesion.
89098289|NCT00641992||1|Response to medical treatment
89098290|NCT00641992||2|Failure to medical treatment (surgery or percutaneous resolution)
89098291|NCT00642070||Host|Women with current symptoms of a urinary tract infection
89098292|NCT00640666|Experimental|Physical activity intervention|Behavior change intervention
89098293|NCT00640666|No Intervention|Standard of care with written materials|Written materials
89227429|NCT00404248|Active Comparator|With Non enzyme-inducing antiseizure drugs (-EIASD)|"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
89227430|NCT00421174|Experimental|Etanercept|Etanercept plus corticosteroids
89227431|NCT00421174|Active Comparator|Placebo|Placebo plus Corticosteroids
89227432|NCT00496197|Experimental|1.|Subjects receive anidulafungin IV followed by oral therapy with fluconazole or voriconazole.
89227433|NCT03996993||Hormone Therapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, a positive SOC Axumin scan, and a patients not having received hormonal therapy for a minimum of 3 months, will receive hormonal therapy in the form of Casodex for 2 weeks, followed by Lupron indefinitely. Patients will then receive serial Axumin scans up to 1 year post-therapy.
89230273|NCT03955159|Experimental|Experimental: Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
89230274|NCT03955159|Placebo Comparator|Placebo comparator|The placebo that will be used in the present study is maltodextrin, which is a food supplement based on carbohydrate powder.
89098294|NCT00640744|Other|A|An untreated carotid plaque will be obtained at the first endarterectomy. Atorvastatin 80mg will be administered for 3 months. The contralateral (treated) plaque will be obtained at the second endarterectomy. Hence, each patient will be his/her own control
89098295|NCT02678026|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early).~Women will receive pessary soon after UIC"
89098296|NCT02678026|No Intervention|No intervention|No treatment
89098297|NCT05663008||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis.
89098298|NCT05663008||Amyotrophic lateral sclerosis patients|Individuals from the Irish population (Irish Motorneuron Disease Register) with possible/probable/definitive diagnosis of ALS.
89098299|NCT05663008||Postpoliomyelitis syndrome|Individuals from the Irish population (Irish Motorneuron Disease Register) with postpoliomyelitis syndrome diagnosis.
89098300|NCT05663008||Spinal Muscular Atrophy|Individuals from the Irish population (Irish Motorneuron Disease Register) with spinal muscular atrophy diagnosis.
89098301|NCT02678104|Experimental|Chlorhexidine mouth wash|Tooth extraction. The patients will start using Chlorhexidine mouthwash on 2nd day of extraction twice daily for 7 days.
89098302|NCT02678104|Experimental|Manuka Honey|intra-alveolar application of Manuka Honey after tooth extraction.
89098303|NCT04183036|No Intervention|Small EST combined with EPLBD|
89098304|NCT04183036|Experimental|Large EST combined with ECPP|
89098305|NCT02681536|Experimental|Minidose long protocol|Down-regulation started on day 20 of the previous cycle by GnRH agonist triptorelin (0.5 µg Decapeptyl; Ferring). On the second day of menstruation, when down regulation was confirmed (as evidenced by endometrial thickness <5 mm and/or E2 levels <50 pg/mL) using transvaginal sonography (TVS) by Voluson 730 Pro (GE, Fairfield, CT) apparatus, gonadotropin (Merional; IBSA) was commenced at an initial dose of 300-450 IU/day for the first 5 days followed by individual adjustment in Gn dose according to ovarian response and the dose of Decapeptyl 50µg/day was continued until day of HCG administration.
89098306|NCT02681536|Experimental|microdose flare protocol|OCPs drospirenone /ethinyl estradiol (Yasmin, BAYER) for not less than 21 days before starting ovarian stimulation, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by HMG IM daily (Merional, 75 IU, IBSA) 3 days later. Then the same cycle adjustment was done as the minidose long protocol.
89098307|NCT04183114|Experimental|IP batch MRUK-0317|135 Subjects received Bio Farma's vaccine batch MRUK 0317
89098308|NCT04183114|Experimental|IP Batch MRUK-0417|135 Subjects received Bio Farma's vaccine batch MRUK 0417
89098309|NCT04183114|Experimental|IP Batch 550118|135 Subjects received Bio Farma's vaccine batch MRUK 0417
89098310|NCT04183114|Active Comparator|Control|135 Subjects received SII's MR vaccine batch 012W72230Z
89098311|NCT02681692|Active Comparator|MEI colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system
89098312|NCT02681692|No Intervention|Standard colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) without the assistance of magnetic scope navigation system
89098313|NCT02681692|Active Comparator|MEI colon model Group|"Colonoscopist would be randomized to perform colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part.~All force variation data would be recorded by a image storage device."
89098314|NCT02681692|No Intervention|Standard colon model Group|Colonoscopist would be randomized to perform conventional colonoscopy on a colon model without an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
89098315|NCT00996996|Experimental|open-label, single arm|Tositumomab and Iodine I 131 Tositumomab
89098316|NCT04182568|Experimental|nab-paclitaxel|
89098317|NCT04182568|Active Comparator|Docetaxel|
89098318|NCT02681380|Experimental|Relation learning|Participants of this group will benefit form a specific learning on relation, Balint like. They will have 7 sessions during 3 months.
89098319|NCT02681380|Placebo Comparator|Control group|Participants of this group will have no learning related to relation with patient.
89098320|NCT02870868|Experimental|Slow breathing with exhale greater than inhale|
89098321|NCT02870868|Experimental|Slow breathing with exhale equal to inhale|
89098322|NCT04283682|No Intervention|standard group|Feeding procedures follow clinical nursing practices
89098323|NCT04283682|Experimental|intervention group|At appropriate time to invite mothers of premature infants into the NICU for skin-to-skin and breastfeeding
89098324|NCT04033744|Experimental|PRF (platelet-rich fibrin)|PRF will be used after the extraction of the third molar to prevent periodontal defects to second molar
89098325|NCT04033744|Active Comparator|spontaneous healing|after the extraction of the third molar the socket will be left to heal spontaneously
89098326|NCT00628836|Active Comparator|SE group|surface stimulation
89098327|NCT00628836|Experimental|BE group|BION stimulation
89098328|NCT02679196|Experimental|KA2237|Open label treatment with KA2237
89098329|NCT00641368|Experimental|1|R4Power Program
89098330|NCT00641368|Other|2|Waitlist Control
89098331|NCT00641446|Experimental|1|Pulmicort
89098332|NCT00641446|Active Comparator|2|Varivax
89098333|NCT02677948|Experimental|Pacritinib and Ibrutinib|"Phase I: Patients will receive Pacritinib 100-200 mg twice daily along with Ibrutinib 420mg/day.~Phase II Lead-In: Pacritinib at MTD daily continuous x 2 months followed by Pacritinib at MTD twice daily along with Ibrutinib 420mg/day."
89098334|NCT02869854|Active Comparator|PAP only|This group will follow the referral scheme for three months, and after this period they will leave new blood samples and answer surveys. They will get a new PAP with follow up after another 3 months.
89098335|NCT02869854|Active Comparator|Mindfulness only|Mindfulness. This group will receive a group course in mindfulness during 8 weeks once a week, and with 20 minutes of daily personal training. Three and six months after inclusion they will answer a new set of surveys and fasting blood samples.
89098336|NCT02869854|Experimental|Combination of the two groups|Mindfulness and physical activity prescription. This group will get a combination of the two other groups. PAP will be prescribed during the first meeting and another one after 3 months. During the first 8 weeks once a week they will participate in a mindfulness training group and also preform 20 minutes of daily training. The same surveys as the other groups and fasting blood samples
89098337|NCT02681146|Experimental|Group1|Educational advice + physiotherapist treatment
89098338|NCT02681146|Experimental|Group2|Educational advice + physiotherapist treatment
89098339|NCT02681146|Experimental|Group3|Educational advice + physiotherapist treatment
89098340|NCT02681146|Experimental|Group4|Educational advice + physiotherapist treatment
89098341|NCT02681146|Experimental|Group5|Educational advice + physiotherapist treatment
89098342|NCT02681146|Experimental|Group6|Educational advice + physiotherapist treatment
89098343|NCT02681146|Experimental|Group7|Educational advice + physiotherapist treatment
89098344|NCT02681146|Experimental|Group8|Educational advice + physiotherapist treatment
89098345|NCT02679118|Experimental|Sentire|The patients will undergo their laparoscopic gastric bypass, during the operative period at pre-defined time points, a small amount of gas from the abdomen will be withdrawn and analyzed for the device. The laparoscopic gastric bypass will proceed without interference or effect from the device.
89098346|NCT00641524|Other|treatment|Iron depletion via phlebotomy
89098347|NCT02677636|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
89098348|NCT02677636|Placebo Comparator|Placebo Comparator|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
89098349|NCT05663164|Experimental|Experimental: Vitamin B1|Vitamin B1 (thiamine) 100mg every 6 hours x 3-days
89098350|NCT05663164|Placebo Comparator|Drug: Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
89098351|NCT02677558||CFOP obese|"Transthoracic Echocardiography in pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of greater or equal 40kg/m2 at the time point of inclusion into the study.~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia."
89098352|NCT02677558||CFOP control|"Transthoracic Echocardiography pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of less or equal 30kg/m2 at the time point of inclusion into the study.~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia"
89098353|NCT00643318|Experimental|CyberKnife Stereotactic Radiosurgery|
89098354|NCT02537470|Other|Arm 1|Placebo
89098355|NCT02537470|Experimental|Arm 2|Biphasic remogliflozin etabonate
89098356|NCT02678728|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12hr of aortic cross clamp off
89098357|NCT02678728|Placebo Comparator|Normal saline|IV loading and infusion of same volume of normal saline after induction until 12hr of aortic cross clamp off
89098358|NCT04180072|Experimental|Atezolizumab plus bevacizumab|Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Study treatment will continue until documented tumor progression or occurrence of unacceptable toxicity.
89098359|NCT02678806|Experimental|Postoperative radiotherapy group|Patients hospitalized in Affiliated Tumor Hospital of Guangxi Medical University from 1st November 2017, who were diagnosed as BCLC-A stage hepatocellular carcinoma, accepted hepatocellular carcinoma resection, pathologically confirmed as narrow margin (the closest distance from margin to tumor capsule < 1cm) and microvascular invasion was found in tumor capsule and adjacent tissues junction were selected and received margin postoperative radiotherapy.
89098360|NCT02678806|Active Comparator|Postoperative TACE group|
89098361|NCT02676076|Experimental|CHF 5993 100/6/12.5 µg|"Treatment A:~CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB"
89098362|NCT02676076|Active Comparator|CHF 1535 100/6 µg|"Treatment B :~CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF"
89098363|NCT02537626|Active Comparator|Erchonia ALS Laser|The Erchonia ALS Laser is a mains powered variable hertz laser device made up of five independent red laser diodes mounted in scanner devices and positioned equidistant from each other. Each scanner emits 7.5 milliwatts (mW) ± 1.0 mW 640 nanometers (nm) with a tolerance of ±10 nm of red laser light.
89098364|NCT02537626|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia ALS Laser but does not emit any therapeutic light.
89098365|NCT04181554||DRAM group|The post-partum women with DRAM
89098366|NCT02678650|Experimental|volatile anesthetics group|10min after intubation, begin to sevoflurane wash-in / wash-out operation: sevoflurane administration was interrupted for at least 10 min, by washout with a high fresh gas flow (10 l/min) to achieve a MAC value below 0.2. Following the interruption, sevoflurane was again washed in with a high fresh gas flow (6 l/min) to achieve 1 MAC end-tidal concentration as soon as possible, and repeated twice periods of 10 minutes. Discontinuation of the halogenated agent for at 15 minutes during the last wash out time.
89098367|NCT02678650|Placebo Comparator|propofol intravenous anesthesia group|propofol infusion 3-5μg / kg / h
89098368|NCT04180150|Experimental|TQ-A3334 combined with entecavir|Subjects receive TQ-A3334 (1.2 mg QW) and entecavir (0.5 mg qd) in 24 weeks
89098369|NCT04180150|Placebo Comparator|Placebo combined with entecavir|Subjects receive placebo (0 mg QW) and entecavir (0.5 mg qd) in 24 weeks
89098370|NCT02678338|Experimental|Hu5F9-G4|Dose Escalation: CD47 blocking antibody Hu5F9-G4
89098371|NCT00642226|Active Comparator|1|Grid Laser
89098372|NCT00642226|Experimental|2|Vitrectomy in combination with 20 mg triamcinolone
89098373|NCT02675608||Year 1 Group 1|They are between 18-65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
89098374|NCT02675608||Year 1 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
89098375|NCT02675608||Year 1 Group 3|They are between 18-65 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
89098376|NCT02675608||Year 1 Group 4|They are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
89098377|NCT02675608||Year 1 Group 5|They are between 35-50 years of age, meet the criteria listed above for non-diabetic subjects in Group 1, with the exception of chronic HIV with or without hepatitis B or C infection, and have current medical history of CD4 T-cell counts 300-800.
89098378|NCT02675608||Year 2 Group 1|They are between 18-64 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
89098379|NCT02675608||Year 2 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
89098380|NCT02675608||Year 2 Group 3|If they are between 18-64 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
89098381|NCT02675608||Year 2 Group 4|If they are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
89098382|NCT02678494|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home for 3 months. 3-5 sessions per week initially, then at least once a week. Each session consists of 5-6 blocks of 5 minute training.
89098383|NCT02677402|Experimental|cold water immersion|Participants immersed their lower limbs in water of ~12°C
89098384|NCT02677402|Experimental|contrast water therapy|Participants immersed their lower limbs in water : alternated every 2 min between ~12°C and ~35°C for CWT
89098385|NCT02677402|Experimental|thermo neutral immersion|Participants immersed their lower limbs in water of ~35°C
89098386|NCT02677480|Active Comparator|Test group, probiotic tablets and gel|Test group, probiotic tablets and gel: tablets with probiotic bacteria (10exp8/tablet) and pH-rising components and gel (with probiotic bacteria and pH-rising components) in trays on the teeth once a week.
89098387|NCT02677480|Placebo Comparator|Placebo group, placebo tablets and gel|Placebo group, placebo tablets and gel: placebo tablets without probiotic bacteria and pH-rising components and gel (with no probiotic bacteria but with pH-rising components) in trays on the teeth once a week.
89098388|NCT00996918|Experimental|Bapineuzumab 0.5 mg/kg|bapineuzumab
89098389|NCT00996918|Experimental|Bapineuzumab 1.0 m/kg|bapineuzumab
89098390|NCT02675530|Experimental|healthy control|Healthy controls will receive electrophysiological assessments before and after NMDA antagonist administration.
89098391|NCT04179994|Experimental|Miswak extract-containing toothpaste group|Test group.
89098392|NCT04179994|Active Comparator|Toothpaste containing Potassium Nitrates|Positive control.
89098393|NCT04179994|Placebo Comparator|Placebo group|Toothpaste contains same ingredients of test group except for the active ingredient as negative control.
89098394|NCT04179916|Experimental|Healthy volunteers|Participants between 21 and 25 years, the Faculty of Physical Education and Physiotherapy of the Opole University of Technology Students
89098395|NCT02675374|Experimental|Treatment group|24 patients
89098396|NCT02675374|Placebo Comparator|Control group|24 patients
89098397|NCT05662930||Hypertension + Diabetes Mellitus (HT+DM)|"Patients who fulfilled the following criteria were included in this group:~Using antihypertensive treatment for the last 3 months~Diagnosed with Type 2 Diabetes Mellitus and taking medication for at least 3 months~Being between the ages of 40-65~Being male~Having signed the informed consent form"
89098398|NCT05662930||Hypertension (HT)|"Patients who fulfilled the following criteria were included in this group:~Using antihypertensive treatment for the last 3 months~Being between the ages of 40-65~Being male~Having signed the informed consent form"
89098399|NCT02678260|Experimental|PDR001|PDR001 will be administered i.v. every two weeks until a patient experiences unacceptable toxicity, progressive disease as per irRC and/or treatment is discontinued at the discretion of the investigator or the patient. The treatment period will begin on Cycle 1 Day 1. For the purpose of scheduling and evaluations, a treatment cycle will consist of 28 days. During the study, cohorts of patients will be treated with PDR001 until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
89098400|NCT02677168|Experimental|cNEP|Subjects with OSA will be treated with cNEP (continuous negative external pressure) at home for three weeks
89098401|NCT04181398|Experimental|Baseline high hs-CRP|"Anthropometry:~Actual Height and weight~Calculated BMI from measured weight and height.~Pubertal development (Tanner stage)~Waist circumference~Skin fold measurement (Triceps and Subscapular)~Waist-to-height ratio.~Blood pressure (mean of 3 measurements)~Peripheral arterial tonometry~Questionnaire~Blood sample (hsCRP)"
89098402|NCT04181398|Experimental|Baseline low hs-CRP|"Anthropometry:~Actual Height and weight~Calculated BMI from measured weight and height.~Pubertal development (Tanner stage)~Waist circumference~Skin fold measurement (Triceps and Subscapular)~Waist-to-height ratio.~Blood pressure (mean of 3 measurements)~Peripheral arterial tonometry~Questionnaire~Blood sample (hsCRP)"
89098403|NCT02677012||Arm I (RESOLVE TM)|Patients undergo AFG reconstructive surgery comprising washing and low velocity spinning using a commercially available system that washes the lipoaspirate with lactated Ringer's solution separates non-fat material from the fat with gentle centrifugal force and suction.
89098404|NCT02677012||Arm II (Cytori PureGraft TM)|Patients undergo AFG reconstructive surgery comprising gravity filtration using a commercially available system in which the lipoaspirate is rinsed with lactated RL and the non-fat material is filtered through mesh.
89098405|NCT02677012||Arm III (Coleman technique)|Patients undergo AFG reconstructive surgery comprising standard centrifugation at 3200 rpm for 3 minutes with the resulting oil and aqueous layers discarded.
89098406|NCT02677090|Placebo Comparator|Placebo|Placebo
89098407|NCT02677090|Active Comparator|Dose 1 - Promitor®|Investigational product Dose 1
89098408|NCT02677090|Active Comparator|Dose 2 - Promitor®|Investigational product Dose 2
89098409|NCT02677090|Active Comparator|Dose 3 - Promitor®|Investigational product Dose 3
89098410|NCT04179682|Active Comparator|4-week 2-hours/day CIMT program|a 4-week 2-hours/day constraint program, total 40 hours CIMT, in preschool education.
89098411|NCT04179682|Active Comparator|2-week 4-hours/day CIMT program|one was a 2-week 4-hours/day constraint program, total 40 hours CIMT, in preschool education.
89098412|NCT04179604|Experimental|Levosimemdam|Levosimendan 2.5 mg / ml concentrate for solution for infusion. A 5 ml vial contains 12.5 mg of levosimendan. The concentrate is a clear solution, yellow or orange, for dilution before administration. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
89098413|NCT04179604|Placebo Comparator|Placebo|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
89098414|NCT05277142|Experimental|Group (A)|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
89098415|NCT05277142|Experimental|Group (B)|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks.
89098416|NCT02673580|Other|Open Access telePRO|Intervention: In open access, contact to the outpatient clinic is initiated by the patient by filling in a PRO questionnaire.
89098417|NCT02673580|Other|Standard telePRO|No intervention: In standard telePRO, outpatient follow-up activity is determined by a clinician and patients receive a questionnaire at fixed intervals.
89098418|NCT02675218||Patients with rheumatoid arthritis.|Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.
89098419|NCT02673502|Experimental|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
89098420|NCT02673502|Experimental|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery.
89098421|NCT00643474|Experimental|A|
89098422|NCT00643474|Experimental|B|
89098423|NCT02537704|Experimental|Group Lifestyle Balance Program|"Participants will be assigned to an adaptation of the Group Lifestyle Balance Program, a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.~Additionally, participants will attend at least one monthly visit with a nutritionist (individually).~The lifestyle objectives for participants will be as follows:~To lose 5-10% of initial weight through healthy eating.~To do 150 minutes of physical activity each week."
89098424|NCT02673658|Active Comparator|Motor + problem solving|This method focuses on spontaneous movement (rather than facilitated movement). Self-initiated, functionally directed movement is emphasized. Intervention includes guidance and cues, which gently call the child's attention to the support surface, and a set-up of the environment for small increments of movement so that the child can solve a movement problem. Passive movements are not used. Each small increment of movement to advance sitting skill or other motor skills is paired with a specific object or toy that challenges a cognitive concept for spatial problem solving. In this approach, the parent will adjust toys and supports to encourage changes of position from sitting, to transitions in and out of sitting to crawling or standing, but will not assist the child physically.
89230275|NCT00802295|Active Comparator|standard dosis protocol|Administration of standard dosis of gonadotrophins for ovarian stimulation.
89230276|NCT00802295|Experimental|2|Administration of low dosis of Gonadotrophins for ovarian stimulation
89230277|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with short hamstring|Anatomic anterior cruciate ligament with short hamstring graft
89111158|NCT00816400|Experimental|MEDI-575, 6.0 mg/kg QWk Escalation Phase (Cohort 2)|MEDI-575 administered at 6.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89230278|NCT03954925|Active Comparator|Anatomic anterior cruciate ligament with standard hamstring|Anatomic anterior cruciate ligament with standard hamstring graft
89230279|NCT00802373|Experimental|I|Solifenacin succinate 5/10mg
89230280|NCT00802373|Experimental|II|Tolterodine 4mg
89230281|NCT01092715|Experimental|Mobilization|Spinal mobilization and exercises
89230282|NCT01092715|Active Comparator|Massage|Neck massage and exercises
89230283|NCT03957109|Other|general anesthesia|general anesthesia
89098425|NCT02673658|Active Comparator|Body weight support training|In this approach, infants will be supported physically by their parents to take steps, sit, crawl, or reach, in practice sessions focused simply on the motor skill. Toys or problem solving will not be part of this intervention, but the child will be assisted (lifted by the parent) through movement to improve strength and learn specific movements and new positions. The child will be able to perform as much of the movement as possible, but the parents will initiate the activity if the child does not initiate, and the parent will lift the child passively through the task if the child is unable to move.
89098426|NCT02673346||employees|YKHC employees
89098427|NCT04178356|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, proprioceptive neuromuscular facilitation techniques will be applied for 4 weeks.
89098428|NCT04178356|Active Comparator|Control Group|Conservative treatment of low back pain will be applied for 4 weeks.
89098429|NCT02675140|Experimental|ZENTEL|Children in intervention group 1 was received 400 mg single-dose albendazole administration, by mouth, for once.
89098430|NCT02675140|Experimental|ZENTEL and Vitamin A Soft Capsules|Children in intervention group 2 was received a 200,000 IU vitamin A capsule combined 400 mg single-dose albendazole once initially, by mouth.
89098431|NCT02675140|No Intervention|No drug adminitrated|Children in this Group were received no intervention as control group
89098432|NCT00642538|Experimental|1|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
89098433|NCT00642538|Experimental|2|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
89098434|NCT00642538|Experimental|3|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
89098435|NCT00642538|Placebo Comparator|4|TIP (placebo comparison)
89098436|NCT00642538|Active Comparator|5|10 ug subcutaneous control
89098437|NCT00644254||Resected DPAC|145 consecutive resections for primary ductal pancreatic adenocarcinoma (DPAC)performed between 1998 and 2005.
89098438|NCT02674906|Active Comparator|citrate|A quantity of 20 ml ACD-A per 100 ml of collected blood is used to prevent coagulation in the cell savage process. Pre-prepared ACD-A solutions is available (composition of ACD-A solution used: 22.0 g sodium citrate dehydrate, 24.5 g glucose monohydrate, 8.0 g citric acid monohydrate per 1000 ml of water
89098439|NCT02674906|Active Comparator|heparin|A heparinised saline solution of 25,000 IU of heparin per 1 litre of intravenous normal saline (0.9% NaCl) solution is used with a dosage of 20 ml of solution per 100 ml of collected blood. This type of solution is not commercially available and is made locally. This solution is used in the cell salvage process to prevent coagulation.
89098440|NCT02674672|Experimental|VenaTech Retrievable arm|VenaTech Retrievable arm
89098441|NCT02673268|Experimental|Patients with breast cancer|
89098442|NCT04179214|Experimental|Group I Experimental: thoracic manipulation|The experimental group will receive thoracic manipulation along with conventional pt protocol.
89098443|NCT04179214|Active Comparator|Group II Control|this group of participant will receive Conventional physical therapy protocol
89098444|NCT00643630|Experimental|1|Twice daily topical application
89098445|NCT00643630|Placebo Comparator|2|Twice daily topical application
89098446|NCT01160744|Experimental|IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin|IMC-1121B + Pemetrexed + Carboplatin [Area Under the Concentration Time Curve 6 (AUC 6)] or Cisplatin
89098447|NCT01160744|Active Comparator|Pemetrexed + Carboplatin (AUC 6) or Cisplatin|Pemetrexed + Carboplatin (AUC 6) or Cisplatin
89230284|NCT03957109|Other|spinal anesthesia|spinal anesthesia
89098448|NCT01160744|Experimental|IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin|IMC-1121B + Gemcitabine + Carboplatin [Area Under the Concentration Time Curve 5 (AUC 5)] or Cisplatin
89098449|NCT01160744|Active Comparator|Gemcitabine + Carboplatin (AUC 5) or Cisplatin|Gemcitabine + Carboplatin (AUC 5) or Cisplatin
89098450|NCT02677246|Experimental|Denosumab|Phase 1, 3+3 design with inter-patient dose escalation from 1mg/kg/dose to 2mg/kg/dose, and possibility of a dose de-escalation of 0.5mg/kg/dose, A modification of 3+3 design is implemented to take into account the achievement of bone resorption blockade by Denosumab. CTX is a biologic marker of bone resorption. Provided a decrease of CTX blood level will be observed under the lower limit (2,5th percentile) for age and sex, or under 20% of the pre-treatment level, there will be no reason to continue escalating the dose. This modified 3+3 design prevents exposure of children to dose escalations that would not be needed regarding the medical and biological aims of this trial.
89098451|NCT02673112|Experimental|STEP-mhc + LS|Subjects will be asked to perform exercise at 80% of the heart rate threshold determined using the Balke protocol for 5 minutes greater than their measured minutes of MVPA/day at baseline (Subthreshold exercise program). They will also be given a light stretching protocol (5 stretches). The exercise intervention will last for 6 weeks and will be supported by weekly health coaching.
89098452|NCT02673112|Active Comparator|LS alone|Subjects will be given a light stretching program alone (5 stretches). The exercise program will last for 6 weeks.
89098453|NCT00643708||A|14 cases
89098454|NCT00643708||B|14 cases
89098455|NCT00643708||C|14 cases
89098456|NCT00643708||D|14 Cases
89098457|NCT04181164||HPP-Group|Adults with hypophosphatasia.
89098458|NCT04181164||Control-Group|Healthy control subjects.
89098459|NCT02672800|Experimental|Writing intervention|
89098460|NCT02672800|No Intervention|Control|
89098461|NCT04180774|Experimental|Melanoma Adjuvant|Patients with completely resected stage III or IV melanoma receiving GMV in the adjuvant setting
89098462|NCT04180774|Experimental|Melanoma Therapeutic|Patients with incompletely resected stage III or IV melanoma receiving GMV in the therapeutic setting
89098463|NCT04180774|Experimental|Renal Cell Adjuvant|Patients with completely resected stage III or IV kidney cancer receiving GMV in the adjuvant setting
89098464|NCT04180774|Experimental|Renal Cell Therapeutic|Patients with incompletely resected stage III or IV kidney cancer receiving GMV in the therapeutic setting
89098465|NCT02674828|Experimental|Reinforcement treatment|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
89098466|NCT02674828|Active Comparator|Standard Treatment|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
89098467|NCT01160354|Experimental|Plerixafor 240 mcg/kg + Clofarabine|"Plerixafor 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before hour IV administration of Clofarabine fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).~Phase II: Plerixafor at the highest dose tolerated in Phase I.~Plerixafor was dose-escalated in a 3+3 design, starting at 240 mcg/kg, and proceeding to dose levels of 320 mcg/kg, and 400 mcg/kg."
89098468|NCT00643786|Experimental|A|Oxygène
89098469|NCT00643786|Placebo Comparator|B|Air Médical
89098470|NCT04178512|Active Comparator|group Dexamethasone|Patients will receive 8 mg of dexamethasone(2ml) in addition to 2ml of hyperbaric bupivacaine 0.5% (total volume 4 ml) intrathecal injection.
89098471|NCT04178512|Active Comparator|group Fentanyl|patients will receive 20 microgram fentanyl(diluted in sterile normal saline0.9% to 2ml)in addition to 2ml of hyperbaric bupivacaine 0.5%(total volume 4 ml) intrathecal injection.
89098472|NCT04178512|Active Comparator|group Control|patients will receive 2ml of sterile normal saline0.9% in addition to 2ml of hyperbaric bupivacaine o.5% (total volume 4 ml) intrathecal injection.
89098473|NCT02674360|Active Comparator|SDM Online Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of a web-based SDM online Training (intervention group I). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The SDM online training works on the modeling principle.
89098474|NCT02674360|Active Comparator|Face-to-Face SDM Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of an individualized, context-based SDM individual face-to-face training at the workplace of the participants (intervention group II). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The individual training works on the coaching principle.
89098475|NCT02674360|No Intervention|Control Group|The Control Group receives no SDM Training. All participants of the Control Group will be offered to participate in the SDM Online Training after T2.
89098476|NCT04179292|Experimental|Physiotherapy Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients by physiotherapist for 3 sessions per week. On the other days, it will be implemented as an 8-week home program with 5 sessions per week.
89098477|NCT04179292|Experimental|Home Program|Stretching and strengthening exercises, functional exercises, massage techniques, sensory training and breathing exercises will be applied to the patients as home program. Motivation will be provided by contacting by phone / call once a week for follow-up.
89098478|NCT01160198|Experimental|ferrous bisglycinate chelate 1 OD|ferrous bisglycinate chelate 1 tablet daily
89098479|NCT01160198|Active Comparator|ferrous ascorbate|ferrous ascorbate, 1 tablet daily
89098480|NCT01160198|Experimental|ferrous bisglycinate chelate 2 OD|ferrous bisglycinate chelate 2 tablets daily
89098481|NCT02676934|Experimental|Et group|applying end tidal concentration as a control target for delivery of sevoflurane
89098482|NCT02676934|No Intervention|FGF group|using Fresh gas control for sevoflurane delivery
89098483|NCT05277220||Thermography|
89098484|NCT05351086|Experimental|Inhaled placebo and IV D.H.E. 45 1 mg|
89098485|NCT05351086|Experimental|Inhaled PUR3100 0.5 mg and IV placebo|
89098486|NCT05351086|Experimental|Inhaled PUR3100 1.0 mg and IV placebo|
89098487|NCT05351086|Experimental|Inhaled PUR3100 1.5 mg and IV placebo|
89098488|NCT02885168|Experimental|Shock + Treatment|Patients treated with activated protein C
89098489|NCT02885168|Other|Shock|Patients not treated with activated protein C
89098490|NCT05657002|Active Comparator|accurate problem list, then inaccurate problem list|"in round 1, the participants will use the patient record of patient A, with an accurate problem list and answer the question: can the patient be prescribed Medication X and Y where medication X is a control question and medication Y is related to a contraindicated diagnosis (on problem list)~In round 2, the participants will use the patient record of patient B, with an inaccurate problem list and answer the question: can the patient be prescribed Medication X and Y where medication X is a control question and medication Y is related to medical history (not on problem list)"
89098491|NCT05657002|Active Comparator|inaccurate problem list, then accurate problem list|"in round 1, the participants will use the patient record of patient A, with an inaccurate problem list and answer the question: can the patient be prescribed Medication X and Y where medication X is a control question and medication Y is related to a contraindicated diagnosis (not on problem list)~In round 2, the participants will use the patient record of patient B, with an accurate problem list and answer the question: can the patient be prescribed Medication X and Y where medication X is a control question and medication Y is related to medical history (on problem list)"
89098492|NCT02674594||Patient treated with Dabigatran|
89098493|NCT02674594||Patient treated with Rivaroxaban|
89098494|NCT02674594||Patient treated with Apixaban|
89098495|NCT02674594||Patient treated with Warfarin|
89098496|NCT02674282|Experimental|ACL-injured|ACL injured professional soccer players submitted to ACL reconstruction.
89098497|NCT02674282|No Intervention|Control|Healthy professional soccer players
89098498|NCT02672722|Experimental|Healthy Test Subjects|We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects.
89098499|NCT00643942||1|
89098500|NCT02672878|Experimental|BVS implantation in patients with ISR|
89098501|NCT04099030||Opioid shortage|Patients undergoing laparoscopic cholecystectomy during time of Fentanyl drug shortage
89098502|NCT04099030||Normal Opioid supply (no shortage)|Patients undergoing laparoscopic cholecystectomy during time of normal Fentanyl drug supply
89098503|NCT02673970||observational arm|From start treatment till date of death or date of cure, the patient will be followed for survival and adverse events on pembrolizumab
89098504|NCT01159574|Experimental|all patients|"ClaPd therapy:~Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.~Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day."
89098505|NCT00910156|Active Comparator|Airtraq|
89098506|NCT00910156|Active Comparator|Glidescope|
89098507|NCT00910156|Active Comparator|Macintosh|
89098508|NCT04179058||IPAF patients|IPAF definition according to 2015 ERS/ATS criteria
89098509|NCT04179058||non-IPAF patients|
89098510|NCT01158950|Experimental|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
89098511|NCT01158950|Placebo Comparator|Placebo|Drug: Placebo for tolcapone administered at study visit
89098512|NCT02676856|Experimental|CR group|For the patients in CR group(CR status of AML at microtransplantation), the conditioning regimen is high-dose (HD) Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with long-term course.
89098513|NCT02676856|Experimental|Non-CR group|For the patients in Non-CR group (PR or NR status of AML at microtransplantation), the conditioning regimens include: IAC or HD Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with short-term course.
89098514|NCT00910234|Active Comparator|Drug: rhEpo, low dose|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
89098515|NCT00910234|Active Comparator|Drug: rhEpo, high dose|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
89098516|NCT00910234|Placebo Comparator|Control Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
89098517|NCT04315220|Experimental|Experimental group (Core stability training (CST))|"Core stability training (CST) consists of two levels: level 1- Mat exercises (includes abdominal muscle contraction, bridging,cat stretch,single leg circle and superman) and level 2- Swiss ball exercises (includes abdominal muscle contraction, bridging and squatting by using therapy ball).~There will be three sets of 15 repetitions of each exercises. The first set will consist of 10 seconds hold period, follow by 12 seconds hold in second set and 15 seconds hold in third set respectively. The entire session will last for approximately 30 minutes."
89098518|NCT04315220|Active Comparator|Control group|Will not receive any kind of training.
89098519|NCT05652322|Active Comparator|Group 1|prolonged intravenous loop diuretic treatment - furosemide
89098520|NCT05652322|Experimental|Group 2|Early (48 hrs) change to oral loop diuretic - furosemide - 150% eqivalent iv dose
89098521|NCT05652322|Experimental|Group 3|Early (48 hrs) change to oral loop diuretic - furosemide - 200% eqivalent iv dose
89098522|NCT01172288|Experimental|N-Acetylcysteine|NAC was titrated up to a maximum dose of 2400 mg over the course of 2 weeks. Subjects were assigned 600 mg twice a day for weeks 1-2, and then were assigned 1200 mg twice a day for the remainder of the 12 week study.
89098523|NCT01172288|Placebo Comparator|Placebo|Placebo: Subjects were assigned to take two capsules twice a day for weeks 1-2, and then were assigned 4 capsules twice a day for the remainder of the 12 week study.
89098524|NCT02676622|Experimental|Stem-cell mobilization and Leukapheresis|"Stem-cell mobilisation will be achieved using Cyclophosphamide (CY) 4g/m² (2g/m2 on 2 consecutive days) followed 5 days later by filgrastim (G-CSF) 10 mg/kg injection. This will be done daily until the day before the last day of leukapheresis. The PBSCs will be harvested usually between day +9 and +11 of completing CY.~Leukapheresis will be performed to a target cell dose of 3-8 x106 CD34+ cells/kg Approximately 1 month later patients will undergo HSCT"
89098525|NCT04313816||unique group|patients visiting their family physician
89098526|NCT00644020||Group 1|the Tyroserleutide for injection at the dosage of 3mg/d
89098527|NCT00644020||Group 2|the Tyroserleutide for injection at the dosage of 6mg/d
89098528|NCT00644020||Group 3|the Tyroserleutide for injection at the dosage of 12mg/d
89098529|NCT00644020||Group 4|the placebo group
89098530|NCT04178980|Active Comparator|case|
89098531|NCT04178980|Placebo Comparator|control|
89098532|NCT02674126|Placebo Comparator|Control group|Control group
89098533|NCT02674126|Active Comparator|Maternal sound group|Maternal sound
89098534|NCT04178902|Experimental|Part A: ABBV-467 Dose Escalation|ABBV-467 administered by intravenous (IV) infusion at various doses until a recommended phase 2 dose is determined.
89098535|NCT04178902|Experimental|Part B: ABBV-467 Dose Expansion|ABBV-467 administered by intravenous (IV) infusion at recommended phase 2 dose as identified in Part A.
89098536|NCT02672566|Experimental|Experimental group : enoxaparin|Experimental group will take enoxaparin (4000 Ui / Day) and will benefit from the usual care.
89098537|NCT02672566|Active Comparator|Control group|The control group will only benefit from the usual care.
89098538|NCT02672488|Experimental|Sorafenib and Metformin|Sorafenib 400μg tablet by mouth and Metformin 500mg tablet by mouth with meal, twice per day
89098539|NCT02672488|Active Comparator|Sorafenib Alone|Sorafenib 400μg tablet by mouth, twice per day
89098540|NCT02673892|Experimental|PODS intervention|The PODS intervention is administered during the discharge process which includes discharge teaching. In the acute settings, discharge teaching is provided by a nurse navigator, resident physician, or other members of the care team. In the rehabilitation setting, discharge teaching is provided by a multi-disciplinary team. PODS is used as a useful add-on to the usual discharge teaching process. The PODS form used during the study will be a fillable pdf. Members of the healthcare team will fill it out electronically, then print it out and give the paper to the patient. After the discharge teaching is finished, patients take the completed PODS home with them as a post-discharge reference and guide.
89098541|NCT02673892|No Intervention|Usual Care|Patients randomized to this arm will receive usual discharge care. At UHN, this involves receiving a discharge summary with information pertaining to hospital course including investigations performed and medications used, as well as follow-up care suggested. It is intended to be, unlike PODS, a document for the primary care physician seeing the patient after discharge to refer to. As to discharge instructions provided for the patient, there is no standard procedure and sometimes follow-up instructions are included for the patient. Patient education may or may not be provided to the patient verbally by their nurse, resident, physician, or pharmacist. Moreover, follow-up with the primary care physician may be set up prior to or following discharge with the nurse navigator.
89098542|NCT00644098|Placebo Comparator|Placebo|cellulose and soybean oil
89098543|NCT00644098|Experimental|Intervention|soluble fibre complex and medium chain triglycerides
89098544|NCT02537392|Experimental|Vitamin B Complex and Folic Acid|Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
89098545|NCT02537392|Experimental|Iron and Folic Acid|Daily supplements of iron (60 mg) and folic acid (0.4 mg).
89098546|NCT02537392|Active Comparator|Folic Acid|Daily supplement of 0.4 mg folic acid.
89098547|NCT05613712||Patients|Patients followed by the rheumatology department of the CHU Grenoble Alpes, constituting the SCORIC group
89098548|NCT05613712||Referring physician|Physicians identified as the referring physician for patients in the SCORIC group
89098549|NCT02676700|Active Comparator|Pelvic floor muscle training and Kaatsu|"Participants are instructed in the PFMT program by primary investigator and instructed in Kaatsu training by a research nurse. The Kaatsu training is performed 4 times a week before PFMT. The program includes 2 x 15 knee extensions with partly occlusion of the blood supply to the thigh. Training level is >12 RM. Training is performed sitting on a chair and rubber bands are used to increase resistance. Training adherence and bother with the training is reported in a training diary. At week 6 the research nurse adjusts the training program.~The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.~Training adherence and any bother with the training is reported in a training diary."
89098550|NCT02676700|Active Comparator|pelvic floor muscle training|"Participants perform the same PFMT program as the intervention group. The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.~Training adherence and any bother with the training is reported in a training diary."
89098551|NCT02676544|Experimental|Embosphere microspheres|Embospheres are calibrated microspheres which will be percutaneously delivered intra-arterially via a microcatheter under fluoroscopic guidance to occlude the prostatic arteries.
89098552|NCT04178278|Experimental|Shuttle walking test group|Patients will performed shultte walking test.
89098553|NCT04178278|Active Comparator|Exercise stress test group|Patients will performed exercise stress test.
89098554|NCT04178278|Active Comparator|6 minutes walking test group|Patients will performed 6 minutes walking test.
89098555|NCT00642928|Placebo Comparator|Placebo|
89098556|NCT00642928|Experimental|BF 2.649-5 mg|
89098557|NCT00642928|Experimental|BF 2.649 10 mg|
89098558|NCT00642928|Experimental|BF 2.649 20 mg|
89098559|NCT00642928|Experimental|BF 2.649 40 mg|
89098560|NCT02676232|Experimental|Intervention|Participants in this arm will follow DARWeb: an online psychosocial intervention for children with recurrent abdominal pain and their parents. This is composed by 7 units for parents and 7 units for children, that have been developed from the cognitive-behavioral model, including setting goals, relaxation and distraction techniques, changing maladaptive thoughts and assertive communication training. The team under the program only contact with families for sending reminders and to answer potential technical problems or doubts
89098561|NCT02676232|No Intervention|Control|Participants allocated in this arm will not receive intervention. However, they will be invited to participate once the families allocated to the experimental group complete the program.
89098562|NCT02673814|Experimental|Arm A (durvalumab)|10 mg/kg durvalumab alone every two weeks
89098563|NCT02673814|Experimental|Arm B (bavituximab + durvalumab)|3 mg/kg bavituximab weekly in combination with 10 mg/kg durvalumab every two weeks
89098564|NCT02673814|Experimental|Arm C (bavituximab + durvalumab)|3 mg/kg bavituximab in combination with 10 mg/kg durvalumab both every two weeks
89098565|NCT00644176|Experimental|1|
89098566|NCT00644176|Experimental|2|
89098567|NCT02673424|Active Comparator|FFR-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by FFR-guided strategy.
89098568|NCT02673424|Active Comparator|IVUS-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by IVUS-guided strategy.
89098569|NCT02673736|Experimental|PLX73086|"Part 1: Open-label, sequential PLX73086 dose escalation in approximately 36 solid tumors subjects.~Part 2: Extension cohort at the recommended phase 2 dose (RP2D) of PLX73086 in approximately 30 subjects with histologically confirmed, unresectable, locally advanced or refractory TGCT (including metastatic disease)."
89098570|NCT04178200||1.5 ml Dose|For retrobulbar anesthesia, 1.5 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
89098571|NCT04178200||3 ml Dose|For retrobulbar anesthesia, 3 ml of local anesthetic solution (2% lidocaine, 5% bupivacaine) will be administered to the patients.
89098572|NCT00644410|Active Comparator|1|The number of mesenchymal stromal cells reached after two culture expansion passages.
89098573|NCT00644410|Placebo Comparator|2|Saline
89098574|NCT02537158|Experimental|sorafenib group|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
89098575|NCT02537158|Experimental|TACE group|TACE group patients will accept TACE therapy once at a month after resection.
89098576|NCT02537158|No Intervention|control group|Control group patients will not accept any intervention,except necessary supportive treatment.
89098577|NCT04177420|Experimental|Experiment Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night.
89098578|NCT04177420|Placebo Comparator|Control Group|lay on the FIR-C mattress with cover the FIR-C abdominal pad on abdominal part and Knee part during the sleeping time. The controller will switch on and switch off rotated in each hour for whole night. the FIR-C mattress and the FIR-C abdominal pad is malfunction and it can not produce the FIR-C.
89098579|NCT02676154|Other|Fesoterodine|Open-Label
89098580|NCT02676310|Experimental|Cohort 1: Bimatoprost 0.3% (Formulation B)|0.25 mL of bimatoprost 0.3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
89098581|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation A)|0.25 mL of bimatoprost 1% (Formulation A) applied onto pre-specified area on the scalp once daily for 28 days.
89098582|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation B)|0.25 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
89098583|NCT02676310|Experimental|Cohort 3: Bimatoprost 1% (Formulation B)|1 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
89098584|NCT02676310|Experimental|Cohort 4: Bimatoprost 3% (Formulation B)|1 mL of bimatoprost 3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
89098585|NCT04180618|Experimental|Patients(Care givers)|"1,000 patients(caregivers) are enrolled and use the personal health wallet service.~They fill out questionnaire to evaluate the service~Some of them are invited for an in-depth interview."
89098586|NCT04180618|Experimental|Medical staffs|"12 medical staffs are enrolled and use the personal health wallet service.~After that, they are invited for an in-depth interview."
89098587|NCT04177888|Experimental|Experimental group|Experimental group with 45 participants, received hot pack, which was a single-use pack filled with magnesium sulfate and water, squeezed between the hands to activate the warming effect, applied to the lower back area for 30 minutes followed by 10 minutes rest then again applied for 30 minutes. This procedure was repeated till delivery.
89098588|NCT04177888|No Intervention|Control group|Control group with 46 participants received the hospital routine care that included Entonox inhalation as optional labor pain management.
89098589|NCT00643084|Experimental|1|patients will consume a low residue diet prior to surgery and have no routine bowel preparation
89098590|NCT00643084|Other|2|standard bowel preparation
89098591|NCT02676388|Experimental|Freeze-dried, Capsulized FMT|Patients included will receive bowel lavage and subsequent Freeze-dried, Capsulized FMT, and then will be followed up for 3 months.
89098592|NCT02676388|Experimental|Fresh FMT|Patients included will receive bowel lavage and subsequent Fresh FMT, and then will be followed up for 3 months.
89098593|NCT04177186|Experimental|strength training group|ST group only strength training will be provided.
89098594|NCT04177186|Experimental|strength training with botulinum toxin|BT-ST group, strength training will be provided after the administering Botulinum toxin into the muscle belly guided under Ultra sound imaging.
89098595|NCT02672020|Experimental|patients with adrenal tumor|
89098596|NCT04180384|Experimental|Oraxol (paclitaxel capsules+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
89098597|NCT04180384|Active Comparator|Oraxol (paclitaxel tablets+ HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg tablets~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
89098598|NCT02672254||Shams|Samples without any type of treatment
89098599|NCT02672254||Samples with 1 treatment|These samples will be treated with only one therapy: chemical agents such as cisplatin or other metallic compounds, or with superficial radiotherapy. These results will help us understand the effectiveness of each treatment by itself on cSCC cells.
89098600|NCT02672254||Samples with 2 treatments|These samples will be treated with both, chemical agents followed by superficial radiotherapy. These results will provide us information concerning the effectiveness of both treatments, wich is expected to be enhanced by the concomitant effects.
89098601|NCT04177732|Other|Healthy peri-implant status|Patient with healthy peri-implant status
89098602|NCT04177732|Other|Presence of peri-implant diseases|Patients with presence of peri-implant diseases
89098603|NCT02671942|Active Comparator|roflumilast:250μg|Drug: Roflumilast Roflumilast tablets Roflumilast 250 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
89098604|NCT02671942|Active Comparator|roflumilast:375μg|Drug: Roflumilast Roflumilast tablets Roflumilast 375 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
89098605|NCT02671942|Active Comparator|roflumilast:500μg|Drug: Roflumilast Roflumilast tablets Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
89098606|NCT02671942|Placebo Comparator|placebo|Drug: placebo placebo tablets placebo tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
89098607|NCT00643240|Experimental|111 In-BU-12|111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.
89098608|NCT00644488|Experimental|A1|Active
89098609|NCT02675920||High risk group of HCC|"known high risk group of HCC according to AASLD guideline. And patients whose risk index is equal to or higher than 2.33.~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive).~Patients undergo ultrasonography and LDCT using non-ionic monomer iodinated CT contrast media biannually and the interval between ultrasound and LDCT is within 30 days."
89098610|NCT02671630|No Intervention|Control group|Patients receive only usual hospital care
89098611|NCT02671630|Experimental|Experimental group|Patients receive only usual hospital care and community-based computerized cognitive training program
89098612|NCT02671552|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren protein-type A microspheres IV and then undergo contrast-enhanced ultrasound imaging the morning prior to cryosurgery and at 3-4 months post treatment during Magnetic Resonance Imaging (MRI) or computed tomography (CT) follow up.
89098613|NCT02671006||Patients|Patients with an active Chronic Urticaria according to the EAACI criteria will be included. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
89098614|NCT02671006||Volunteers|Volunteers must no have history of immediate allergy (patients under medical follow up for melanoma in remission for at least 3 months, age (+/- 5 years) and sex matched). Controls should have no history of atopy, urticaria or immediate allergy declared (rhinitis, urticaria, asthma) at the time of the test. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
89098615|NCT00644566|No Intervention|TAU|Treatment as usual. These subjects and their providers were told to pursue treatment services as they normally would do.
89098616|NCT00644566|Experimental|shared care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
89098617|NCT04176328|Experimental|Cystic Fibrosis patients treated with Teicoplanin|Hospitalized male and female patients aged ≥ 18 years, suffering of Cystic Fibrosis.
89098618|NCT04178044|Experimental|GB223-group 1|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg,single dose administration; 2 subjects receive placebo.
89098619|NCT04178044|Experimental|GB223-group 2|21mg/kg
89098620|NCT04178044|Experimental|GB223-group 3|63mg/kg
89098621|NCT04178044|Experimental|GB223-group 4|119mg/kg
89098622|NCT04178044|Experimental|GB223-group 5|140mg/kg
89098623|NCT04175860|Experimental|Intervention group|"Consists of a series of non-pharmacological preventive interventions that will focus on the - transition-discharge-hospital program including individualized non-pharmacological interventions such as dyad characterization, competency assessment, risk assessment, inherent program strategies, and monitoring.~The intervention or program  Hospital Discharge Plan to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes an educational session and weekly telephone follow-up according to the patient's risk characterization."
89098624|NCT04175860|No Intervention|Control group|This group of patients-family caregivers will be carried out the discharge activities that are regularly developed in the second level institution and recorded in a check-sheet and field diary.
89098625|NCT02671396|Experimental|Virtual reality based intervention|Virtual reality based balance training
89098626|NCT02671396|Active Comparator|Conventional intervention|Conventional balance training
89098627|NCT04177342|Active Comparator|fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
89098628|NCT04177342|Experimental|oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
89111159|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Escalation Phase (Cohort 3)|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89098629|NCT02671786|Experimental|Intervention Arm|"Intervention area: Provision of community based health care to severely malnourished children 6 months age in 16 tribal villages by trained semi-literate village health workers.~Treatment of severely malnourished children through MAHAN RUTF & MAHAN Vit-Min mix~Growth monitoring of all children below the age of 5 years~Treatment of associated diseases like Diarrhea, Pneumonia, Malaria, etc.~Management of resistant or relapsed severely malnourished cases by pediatrician.~Intensive behavior change communication of parents of children below the age of 5 years for proper nutrition.~Dose: 46 gms of proteins/kg/day & 100170 calories/kg/day with gradual escalation with micro nutrient supplementation Route: Oral Frequency: 4 times a day Duration: 12 weeks"
89098630|NCT02671786|No Intervention|Control Arm|Control area: In control area, the V.H.W. and supervisor records weight of all under 5 children. They also collect data related to birth, deaths and verbal autopsy.
89098631|NCT00644644||1|monitored
89098632|NCT00644644||2|control
89098633|NCT04016506||Pancreas injury|children with Pancreas trauma
89098634|NCT02668276|Placebo Comparator|Standard NCCN counseling|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment.
89098635|NCT02668276|Experimental|Standard NCCN counseling and Oncotype DX results|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment. The result provided by the Oncotype DX prostate test is called a Genomic Prostate Score (GPS). The GPS provides important information about how aggressive a man's cancer is based on the biology of the man's individual tumor.
89098636|NCT04175158|Experimental|GB222|1mg/kg
89098637|NCT04175158|Active Comparator|Bevacizumab|1mg/kg
89098638|NCT02671318|Active Comparator|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
89098639|NCT02671318|Active Comparator|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
89098640|NCT04086784||3D-printed Cage|Patients undergoing posterior lumbar interbody fusion with 3D-printed Porous Titanium Alloy Cages at the lowest fusion segment
89098641|NCT04086784||Peek Cage|Patients undergoing posterior lumbar interbody fusion with PEEK Cages at the lowest fusion segment
89098642|NCT02668510|Experimental|Platelet Rich Plasma Injection Group|shockwave therapy within standard of care using Ossatron system with intervention injection of platelet rich plasma (PRP) using Arthex system, into the plantar fascia at the calcaneal origin
89098643|NCT02668510|Placebo Comparator|Placebo injection group|shockwave therapy with placebo normal saline injection
89098644|NCT00644722|Active Comparator|1|Single use metallic blades
89098645|NCT00644722|Active Comparator|2|Classic reusable metallic blades
89098646|NCT02668588|Experimental|LF-PB 30 mg|extended release of octreotide
89098647|NCT02668588|Placebo Comparator|Placebo|extended release of placebo
89098648|NCT02668042|Experimental|liveness tissue skin|
89098649|NCT04174690|Experimental|Balance|Volunteers aged from 18 years to over 60 years were selected without compromise. The tests were performed in a single session lasting 1 hour where the volunteers will do the tests on the force platform.
89098650|NCT02671084|Experimental|Sevoflurane Group|Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
89098651|NCT02671084|Placebo Comparator|Control Group|Control Group called group B patients who will not receive sevoflurane. The patient of group B will receive facial mask properly attached to your face into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
89098652|NCT02671162|Placebo Comparator|Wheat|Placebo capsule/ 2 capsule 3 times per day
89098653|NCT02671162|Active Comparator|Fumaria|Fumaria capsule (0.5 mg Fumaria parviflora L.) / 2 capsule 3 times per day.
89098654|NCT04175782|Experimental|ERAS group|A standardized ERAS protocol is applied to the ERAS group based on the latest guidelines. Smoking and alcohol consumption is stopped 4 weeks before the surgery. Preoperative anemia is corrected with intravenous iron supplementation. Prolonged fasting, bowel preparation, and premedication are avoided in this group. Clear fluids are allowed up to 2 h and solids rich in carbohydrate up to 6 h hours prior to induction of anesthesia. Warmed up intravenous fluids are administered to maintain normothermia intraoperatively. This group of subjects receives general anesthesia. Volume and salt overload and drain usage are avoided to the utmost. Intravenous paracetamol is administered for postoperative analgesia before the completion of the surgical procedure. Nasogastric tube placement is avoided and catheters are removed as soon as possible. Nonopioid oral analgesics and NSAIDs are utilized for postoperative pain medication.
89098655|NCT04175782|No Intervention|Control|This group will receive conventional pre-and postoperative care.
89098656|NCT02668120||Cases|Patients with chronic histiocytic intervillositis during pregnancy followed at University Hospital of Lille. Alkaline phosphatase assay was performed during pregnancy and is documented in the medical record. The cases are included retrospectively.
89098657|NCT02668120||Low-risk pregnancy|Patients with a low risk pregnancy followed at University Hospital of Lille and recruited prospectively in prenatal consultation. These patients have no pathological obstetric history.
89098658|NCT02668120||High-risk pregnancy|Patients with severe pregnancy complication (IUGR, Preeclampsia or Death in Utero), but without chronic intervillositis, and hospitalized in the maternal-fetal pathology department of the University Hospital of Lille. They are recruited prospectively.
89098659|NCT04176796|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
89098660|NCT04176796|Experimental|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
89098661|NCT04176484||Survey|Women, 18 years of age or older, who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be given a handout (attached) by clinic staff during routine pre-op counseling informing them that they may be called and asked to participate in a research survey. Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview. Participation will be voluntary and all data collected will be recorded without any identifiers.
89098662|NCT04176484||Operating Room Feasibility|A list of women 25 or older who are scheduled for an abdominal procedure after being seen in the General Surgery clinic will be generated to include MRN, procedure date, and pocedure type. A medical record review will be undertaken of these women and we will collect information about conditions that would facilitate or hinder the ability to perform a salpingectomy. No patient interaction will occur by the study team and all data will be de-identified at the time of collection.
89098663|NCT02667964|Other|Healthy controls|Spiroergometry
89098664|NCT02667964|Other|Patients with T2DM|Spiroergometry
89098665|NCT02667964|Other|Patients with T1DM|Spiroergometry
89098666|NCT05276986|Experimental|DOMS protocol group|DOMS was induced for the trunk muscles with a load equals to 80% of the maximum repetitive voluntary contraction. Pulmonary function parameters, respiratory muscle strength and endurance, exercise capacity, pain, fatigue, and dyspnea perception severity were recorded before DOMS and at the 24th and 48th hours after DOMS.
89098667|NCT00644800|Experimental|Arm A|
89098668|NCT02670616|Experimental|ibrutinib in combination with r-CHOP|Ibrutinib560 mg daily on day 1-21 per each cycle ,Rituximab375 mg/m2, Cyclophosphamide750 mg/m2, doxorubicin 50 mg/m2, vincristine1.4 mg/m2 on day 1; Prednisolone 100mg per day on day 1-5 ,cycle length: 21 days ,Six cycles of treatment
89098669|NCT00996840|Experimental|Cohort 1 - SB-681323 Intravenous 3mg|3mg SB-681323 Intravenous administration, infused over 4 hours
89098670|NCT00996840|Experimental|Cohort 2 - SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
89098671|NCT00996840|Experimental|Cohort 3 - SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
89098672|NCT00996840|Experimental|Cohort 4 - SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
89098673|NCT00996840|Experimental|Combined Placebo|Placebo to match intervention
89098674|NCT04174768|Experimental|Bariatric surgery patients|Bariatric patients undergoing sleeve gastrectomy or Roux-en-Y gastric bypass
89098675|NCT02670694||Rett Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Rett Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
89098676|NCT02670694||Angelman's Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Angelman's Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
89098677|NCT02670694||Prader-Willi Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Prader-Willi Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
89098678|NCT02670694||Control|Siblings of RTT, AS and PW subjects will serve as control subjects.
89098679|NCT00644956|Active Comparator|Arm 1|
89098680|NCT00644956|Active Comparator|Arm 2|
89098681|NCT04175002||Anovulatory PCOS women with a BMI greater than 27|
89098682|NCT04175002||Anovulatory PCOS women with a BMI lower than 25|
89098683|NCT04175002||Healthy fertile women with a BMI greater than 27|
89098684|NCT04175002||Healthy fertile women with a BMI lower than 25|
89098685|NCT04174846|Active Comparator|Treatment of SAM children with RUTF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with standard ready-to-use therapeutic food (RUTF)
89098686|NCT04174846|Experimental|Treatment of SAM children with RUSF|Treatment of severe acute malnutrition (SAM) in children 6-59 months old with ready-to-use-supplementary food (RUSF)
89098687|NCT02670772|Active Comparator|Stavudine|Stavudine 20mg twice daily for 96 weeks
89098688|NCT02670772|Active Comparator|Tenofovir Disoproxil Fumarate|Tenofovir 300mg once daily for 96 weeks
89098689|NCT02667808||Focus Group|Participants with HIV and receiving antiretroviral therapy (ART) will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
89098690|NCT02667808||Questionnaire|Participants with HIV will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
89098691|NCT04277208||Arthroscopic Rotator Cuff Repair|
89098692|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 1|Low FODMAP Oral Nutrition Supplement
89098693|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 2|Low FODMAP Oral Nutrition Supplement
89098694|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 3|Low FODMAP Oral Nutrition Supplement
89098695|NCT02667184|Experimental|FOS Supplement|Supplement containing fructooligosaccharides
89098696|NCT04294992|Experimental|Granisteron group|
89098697|NCT04294992|Active Comparator|Ondansetron group|
89098698|NCT02670460|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left subclavian vein.
89098699|NCT00628914|Experimental|1|Open label escitalopram plus eszopiclone for 8 weeks
89098700|NCT00628914|Other|2|Escitalopram and eszopiclone for initial 4 weeks, then switch to escitalopram and placebo for final 4 weeks.
89098701|NCT00628914|Placebo Comparator|3|Escitalopram plus placebo for 8 weeks
89098702|NCT02670850|No Intervention|Control group|Patients received only routine hospital care
89098703|NCT02670850|Experimental|Intervention group|Patients received regular hospital routine care and model-based intervention program
89098704|NCT02870634|Experimental|Cu(II)ATSM|Cu(II)ATSM capsules, administered orally once daily
89098705|NCT02537236|Experimental|Group one|20 subjects received Therapeutic Lifestyle Changes diet more 1.05 grams of fish oil omega 3 fatty acids
89098706|NCT02537236|Active Comparator|Group two|20 subjects received conventional diet more 1.05 grams of fish oil omega 3 fatty acids
89098707|NCT02537236|Experimental|Group three|20 subjects received Therapeutic Lifestyle Changes diet more 2.10 grams of fish oil omega 3 fatty acids.
89098708|NCT02537236|Active Comparator|Group four|20 subjects received conventional diet more 2.10 grams of fish oil omega 3 fatty acids
89098709|NCT02537236|Placebo Comparator|Group five|20 subjects, control group received conventional diet.
89098710|NCT04174066||SNLGM|70 patients with an SNLGM
89098711|NCT04174066||primary FSH|74 with a primary FSH
89098712|NCT00645580|Experimental|A|
89098713|NCT02666872|Experimental|Motivational interviewing on vaccination|An educational strategy based on motivational interviewing of approximately 15 minutes to promote vaccination, in maternity ward.
89098714|NCT02666872|No Intervention|Brochure about vaccines for infants|Parents in the control group only received a brochure about vaccines for infants. This brochure is given to all fathers and mothers giving birth to the CHUS, participating or not at our study.
89098715|NCT02670304|Experimental|letrozole|letrozole for the first day after ovum picked up at least for 5 days.
89098716|NCT02670304|Active Comparator|aspirin|asprin for the first day after ovum picked up at least for 5 days.
89098717|NCT02671708|Experimental|IDA+BUCY|For intermediate-risk AML undergoing auto-HSCT，IDA+BUCY conditioning regimen was IDA 15mg/m2/day on days -12 and -10；BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
89098718|NCT02671708|Active Comparator|BUCY|"For intermediate-risk AML undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days~-3 and -2."
89098719|NCT00998946|Experimental|Pralatrexate|"Participants received pralatrexate at an initial dose of 30 mg/m^2, as IV push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline on Days 1, 8 and 15 of a 4-week cycle (weekly for 3 weeks with 1 week of rest) until criteria for discontinuation per protocol were met. The initial dose of 30 mg/m^2 may be reduced to 20 mg/m^2 weekly, permitted per protocol defined criteria. If pralatrexate 20 mg/m^2/week was not tolerated, pralatrexate had to be discontinued. Dose re-escalation was not allowed once dose reduction was done.~Participants had dietary supplement of vitamin B12 and folic acid along with pralatrexate. Vitamin B12, given as 1mg IM, within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days post last dose of pralatrexate. Folic acid was given 1mg daily, orally, for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days post last dose of pralatrexate."
89098720|NCT05146180|Experimental|Parametric positron emission computed tomography|
89098721|NCT01158404|Experimental|LY900009|"Dose escalation phase: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Dose confirmation phase: 30 mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
89098722|NCT02670070|Active Comparator|Coadministration of G+R|Coadministration of gemigliptin 50mg and rosuvastatin 20mg
89098723|NCT02670070|Experimental|Combination G/R|Combination of gemigliptin 50mg / rosuvastatin 20mg
89098724|NCT00645034|Active Comparator|Arm 1|
89098725|NCT00645034|Placebo Comparator|Arm 2|
89098726|NCT02885090|Experimental|RTT patient|Blood sampling
89098727|NCT02885090|Experimental|Parents|Blood sampling. To distinguish between inherited polymorphic variants and potentially deleterious new imbalances.
89098728|NCT04173832|Experimental|Tianqi Pingchan Granule Combined With Amantadine|
89098729|NCT04173832|Placebo Comparator|placebo Combined With Amantadine|
89098730|NCT04173910||LPEC/Sellick ultrasound|
89098731|NCT00998790|Experimental|AMS AdVance Sling Group|European Male subjects >40 years old who were implanted with the AMS AdVance Male Sling to treat Stress Urinary Incontinence.
89098732|NCT02537002|Experimental|Cohort 1- PF-05230907 or Placebo|
89098733|NCT02537002|Experimental|Cohort 2- PF-05230907 or Placebo|
89098734|NCT01001988|Experimental|Study group|Participants received a single dose of JE-CV administered in Study JEC02. In Study JEC05 there were yearly visits with blood samples taken for immunogenicity assessment.
89098735|NCT02667340|Experimental|Superstarch|Supplementation with Superstarch before a simulated soccer game
89098736|NCT02667340|Placebo Comparator|Placebo|Supplementation with placebo before simulated soccer game.
89098737|NCT04293354|Active Comparator|Serratus Plane Block|The Serratus plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
89098738|NCT04293354|Sham Comparator|Control|No block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
89098739|NCT02666170|Experimental|therapy with alpha-lipoic acid daily for six months|
89098740|NCT02670148|Experimental|Chiropractic Care (CC)|Participants in the CC group will receive evaluation and treatment (chiropractic manipulative therapy) from a doctor of chiropractic over a 4 week period.
89098741|NCT02670148|No Intervention|Waitlist control group (WC)|Participants allocated to the waitlist control group will not receive any chiropractic treatment during the active study period. These individuals will be scheduled for one additional study visit following allocation. This final study visit will be scheduled 4 weeks after allocation (± 7 days). WC participants are not restricted from receiving any other healthcare during study participation. However, participants in the WC group will be asked not to receive any chiropractic care or spinal manipulation by any other provider during the 4 week intervention period. After WC participants complete the final study visit, they will be offered chiropractic care. This treatment will not be part of the study and no data will be collected at these visits.
89098742|NCT02667262||Extended Release and/or Long-Acting Opioids|
89098743|NCT00645736||1|Single cohort
89098744|NCT02666404|Experimental|Volume Resuscitation|We would like to establish new endpoints for guidance of volume resuscitation by implementing new measurements (body impedance, renal resistive index).
89098745|NCT04072120||R1|"Norwegian citizens aged 45 and above 1.1.1994 - 31.12. 2009 registered in the FS-data during this period.~Sub-sample those attending a cardiovascular health survey who later developed stroke."
89098746|NCT04072120||R2|All Norwegians born in the period 1 January 1940 to 31 December 1959 who survived to 1991.
89098747|NCT04072120||R3|Norwegian citizens aged 45 and above 1.1.2016.
89098748|NCT00646126|Active Comparator|1|1:Active comparator sulfadoxine-pyrimethamine plus artesunate
89098749|NCT00646126|Placebo Comparator|2|2:placebo comparator
89098750|NCT02670226|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
89098751|NCT02670226|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
89098752|NCT02537080|Experimental|Nimodipine group|1 tbl of 30 mg nimodipine will be administered orally with premedication
89098753|NCT02537080|Experimental|Control group|1 tbl of placebo will be administered orally with premedication
89098754|NCT02667496|Experimental|Leukine|"Administered SC in treatment cycles up to 24 weeks~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
89098755|NCT02667496|Placebo Comparator|Placebo|"Administered SC in treatment cycles up to 24 weeks~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
89098756|NCT00645112|Active Comparator|1|
89098757|NCT00645112|Active Comparator|2|
89098758|NCT02666482|Experimental|Stop Smoking SF Web App - baseline|"Online Study 1 will test the data gathering aspects of the proposed web app using a baseline, usual care intervention consisting of a static smoking cessation guide, the Guía para Dejar de Fumar, tested in printed form in the Muñoz et al. (1997) study. The print version of the guide yielded an 11% quit rate at 3 months. The investigators will utilize the content of the guide as the main element of the baseline app, so it will serve to estimate baseline utilization and quit rates when this already tested intervention is provided in a web app format. Participants can join the study online by going to: https://stopsmokingsf.org"
89098759|NCT02667106|Experimental|Single-dose, open label RX0041-2|Active Drug
89098760|NCT02666092||Fish allergy|"51 subjects presenting allergic manifestations after digestive, cutaneous, or respiratory contact with fish will be recruited.~Interventions will include:~A questionnaire on domestic exposure to fish, and on the characteristics of clinical manifestations~A detection of anti-Anisakis and anti-fish antibodies"
89098761|NCT02666092||Control|"51 subjects presenting no allergic manifestations after contact with fish.~Interventions will include:~A questionnaire on domestic exposure to fish~A detection of anti-Anisakis and anti-fish antibodies"
89098762|NCT02669524|Active Comparator|T2D + OGTT + LY2409021|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
89098763|NCT02669524|Placebo Comparator|T2D + OGTT + placebo|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + placebo comparator to the human antagonist of the glucagon receptor.
89098764|NCT02669524|Active Comparator|T2D + IIGI + LY2409021|Type 2 diabetes patients + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
89098765|NCT02669524|Placebo Comparator|T2D + IIGI + placebo|Type 2 diabetes patients + isoglycaemic iv glucose infusion + placebo comparator to the human antagonist of the glucagon receptor.
89098766|NCT02669524|Active Comparator|T2D + MEAL + LY2409021|Type 2 diabetes patients + Standardised liquid meal + the human antagonist of the glucagon receptor.
89098767|NCT02669524|Placebo Comparator|T2D + MEAL + placebo|Type 2 diabetes patients + Standardised liquid meal + placebo comparator to the human antagonist of the glucagon receptor.
89098768|NCT02669524|Active Comparator|CTRL + OGTT + LY2409021|Healthy controls + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
89098769|NCT02669524|Placebo Comparator|CTRL + OGTT + placebo|Healthy controls + 50 oral glucose tolerance test 4 hours + placebo comparator of the human antagonist of the glucagon receptor.
89098770|NCT02669524|Active Comparator|CTRL + IIGI + LY2409021|Healthy controls + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
89098771|NCT02669524|Placebo Comparator|CTRL + IIGI + placebo|Healthy controls + isoglycaemic iv glucose infusion + placebo comparator the human antagonist of the glucagon receptor.
89098772|NCT02669524|Active Comparator|CTRL + MEAL + LY2409021|Healthy controls + Standardised liquid meal + the human antagonist of the glucagon receptor.
89098773|NCT02669524|Placebo Comparator|CTRL + MEAL + placebo|Healthy controls + Standardised liquid meal + placebo comparator of the human antagonist of the glucagon receptor.
89098774|NCT04075708||Case-group|The case group will consist of women diagnosed with PE after 34 weeks of gestation.
89098775|NCT04075708||Control-group|The control group will include 165 participants who were not diagnosed with PE in their pregnancies.
89098776|NCT00996606|Experimental|Tocilizumab in Active RA|Participants with active RA will receive tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions will be given from Baseline to Week 44, and participants will be assessed through Week 48.
89098777|NCT00645814|Placebo Comparator|A|
89098778|NCT00645814|Active Comparator|B|
89098779|NCT00645814|Active Comparator|C|
89098780|NCT02669836|Experimental|Posterior fossa decompression surgery|The bone is surgically removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected
89098781|NCT02669836|Experimental|Dural augmentation surgery|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened. Microsurgical dissection is performed and the dura is sewn closed.
89098782|NCT04174378||GnRH agonist with progestogen support|
89098783|NCT04174378||progestogen support only|
89098784|NCT02669446||Ectoin containing Lozenges|treatment with Ectoin containing lozenges
89098785|NCT02669446||Hyaluronic acid containing lozenges|treatment with hyaluronic acid containing lozenges
89098786|NCT02669446||Saline solution for gargling|Subjects in were requested to gargle with salt water
89098787|NCT00645892|Active Comparator|A|
89098788|NCT00645892|Placebo Comparator|B|
89098789|NCT04293120|Experimental|Training|Training 4 sessions over a one week time period of 180 catches/stops with a medicine ball.
89098790|NCT04174456|Experimental|Olmesartan group|olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month
89098791|NCT04174456|Active Comparator|Valsartan group|valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month
89098792|NCT02869308|Other|Myocardial angioscintigraphy|
89098793|NCT00910390|Placebo Comparator|Slow Freezing|Standard freezing protocol (slow freezing) of preimplantation embryos
89098794|NCT00910390|Experimental|VIT-Irvine|Vitrification with Irvine solution (rapid freezing) of preimplantation embryos
89098795|NCT00910390|Experimental|VIT-Vitrolife|Vitrification (rapid freezing) with Vitrolife solution
89098796|NCT02869698|Experimental|Evaluation of cognitive functions by Spectral Dynamic Imaging|Evaluation of cognitive functions by SDI will be conducted during the exploration SEEG (which usually lasts from 1 to 3 weeks), and started a few days after implantation of intracranial electrodes
89098797|NCT02665936|Active Comparator|group L|Epidural levobupivacaine 0.125% (Chirocaine) in normal saline in a total volume of 10 ml will be administered epidurally in active stage of labor
89098798|NCT02665936|Active Comparator|group LD4|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 4 mg in a total volume 10 ml
89098799|NCT02665936|Active Comparator|group LD8|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 8 mg in a total volume 10 ml
89098800|NCT04292262||AKI|
89098801|NCT04292262||Non AKI|
89098802|NCT02665858|Active Comparator|IIH Patients|Patients diagnosed with Idiopathic Intracranial Hypertension who undergo OCT imaging
89098803|NCT02665858|Active Comparator|Control Group|Patients diagnosed with headache with ruled out Idiopathic Intracranial Hypertension who undergo OCT imaging
89098804|NCT02869386|Experimental|STEMO deployment|STEMO is a specialized stroke ambulance providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
89098805|NCT02869386|Active Comparator|Regular care|Regular prehospital care consists of an ambulance. In suspected life-threatening cases an emergency physician is sent to the emergency scene in parallel.
89098806|NCT02665780|Experimental|Treatment|Periodontal debridement, tongue cleaning, mouth rinsing with 20ml Cetylpyridium Chloride daily for 24 weeks
89098807|NCT02869464||Patients presenting with IA|These patients will undergo an abdominal ultrasound (Imaging - Ultrasound) to test for abdominal aortic aneurysm(s). RNA, DNA testing will be planned on banked samples
89098808|NCT02869464||Patients presenting with AAA|These patients will undergo a non-contrast enhanced magnetic resonance angiogram (MRA) (Imaging - MRA) to test for intracranial aneurysm(s). RNA, DNA testing will be planned on banked samples
89098809|NCT00646360|Experimental|DHA arm|Docosahexonic acid (DHA) (400 mg/day). Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.
89098810|NCT00646360|Placebo Comparator|Placebo arm|Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.
89098811|NCT04293510||group study 1|children and adolescents who diagnosed as lupus patients
89098812|NCT04293510||group study 2|age and sex matched healthy children free from any infection with no family history of immunological diseases
89098813|NCT04174300|Experimental|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
89098814|NCT00995436|Active Comparator|Extraoral anchorage|The intervention is the placement of Headgear, to be worn 100 hours per week
89098815|NCT00995436|Active Comparator|Miniscrews|The intervention is the of miniscrews to supplement anchorage
89098816|NCT00995436|Active Comparator|Nance palatal arch|Anchorage supplemented by Nance palatal arch fixing molars together with an arch
89098817|NCT04173598|Experimental|Intervention Group|An intervention group consisting of a dyad (patient + family carer) benefiting in addition to the usual treatment from the intervention for the family carer.
89098818|NCT04173598|Active Comparator|Control Group|A group consisting of a dyad (patient + caregiver) with usual care (control group)
89098819|NCT02667028||patients receiving PCI|patients receiving percutaneous coronary intervention(PCI)
89098820|NCT04292886|Active Comparator|thin endometrium ,treatment,Tamoxifen|From the 2nd day of the menstrual cycle, the patient took tamoxifen and femoston
89098821|NCT04292886|Placebo Comparator|thin endometrium ,treatment,Vitamin C|From the 2nd day of the menstrual cycle, the patient took Vitamin C and femoston
89098822|NCT02669134|Active Comparator|SonR optimization|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
89098823|NCT02669134|Placebo Comparator|Fixed settings|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming device programming: sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR CRT Optimization programmed Off)."
89111160|NCT00816400|Experimental|MEDI-575, 12 mg/kg QWk Escalation Phase (Cohort 4)|MEDI-575 administered at 12.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89098824|NCT04292418||study group 1|(rejector group )include Paediatric living donor kidney transplant recipients (aged 4-18 years) at least 35 child recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the study group 1 measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test
89098825|NCT04292418||study group 2|the second group (non rejector group ) include Paediatric living donor kidney transplant recipients (aged 4-18 years) recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the studied group at least 35 child measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test in the study group 2
89098826|NCT04292028|Experimental|pilates group|The Pilates group participated in an 8-week clinical Pilates training program
89098827|NCT04292028|Active Comparator|Control group|Control group were given a home-based exercise program
89098828|NCT02869230|Other|Radioguided occult lesion localization|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
89098829|NCT02869230|Experimental|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
89098830|NCT02669290|Experimental|Guided|Guided LV lead placement for CRT.
89098831|NCT02669290|Active Comparator|Non-Guided|Non-guided LV lead placement for CRT.
89098832|NCT02868840|Experimental|Tai Chi group|Tai Chi exercise, twice a week, one hour per session. participated in Tai Chi either while seated or standing upon their comfort level.
89098833|NCT02868840|Active Comparator|Symptom management group|manage stroke symptom through phone and text message along with other rehabilitation therapy.
89098834|NCT02669368|Active Comparator|Standard dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.
89098835|NCT02669368|Active Comparator|Low dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
89098836|NCT02669368|Active Comparator|Low dose Rocuronium + Magnesium Sulfate|Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
89098837|NCT00645268|Active Comparator|Arm 1|
89098838|NCT00645268|Placebo Comparator|Arm 2|
89098839|NCT00645268|Other|Open-Label Arm|
89098840|NCT00646438|Active Comparator|1|strict glucose control (study arm)
89098841|NCT00646438|No Intervention|2|standard insulin treatment (control arm)
89098842|NCT02666014|Active Comparator|Sugammadex group|"Sugammadex 2 mg/Kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation.~The drug is to be diluted with normal saline to make up to 5 ml volume to maintain blinding."
89098843|NCT02666014|Active Comparator|Neostigmine group|"Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg, diluted in normal saline to make up 5 ml total volume to maintain blinding.~Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation for reversal of neuromuscular blockade produced during surgery.~Atropine sulfate-diphenoxylate hydrochloride combination will be an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered."
89098844|NCT02665702|Experimental|Endostar Combined With NVB and DDP|Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
89098845|NCT04173676|Experimental|use of indocyanine green|submucosal injection of ICG is by gastroscopy on the superior and inferior edge of the esophageal tumor,Dose of 0.5mg
89098846|NCT02665546||Case|Patients with diagnosis of LCH based on histopathological or clinical and radiological findings.
89098847|NCT02665546||Controls|Current or ex smokers matched with cases for age, gender and smoking history.
89098848|NCT02665156|Experimental|Robotic Stapled orthotopic neobladder|Intracorporeal stapled neobladder using robotic staplers: Partly stapled orthotopic neobladder: robotic staplers applied to create the neobladder neck and to suture the left side of the posterior aspect of neobladder. Right side of the posterior aspect of neobladder and the anterior aspect of the neobladder hand sewn.
89098849|NCT04173130|Experimental|Injection of botulinum toxin with investigational device|
89098850|NCT04173286||short term antibiotics|< 7 days
89098851|NCT04173286||long terms antibiotics|> 7 days
89098852|NCT00646750|Experimental|1|BEAM preceded by Ybritumomab Tiuxetan (Zevalin)
89098853|NCT00646828||without PHA1|patients without mineralocorticoid receptor mutation
89098854|NCT00646828||PHA 1|patients with a rare disease, pseudohypoaldosteronism type 1, due to heterozygous inactivating mutations of the mineralocorticoid receptor
89098855|NCT00646516|Experimental|1|
89098856|NCT04033198||fourth decade|appendectomy done , appendix send for histopathological examination
89098857|NCT04033198||fifth decade|appendectomy done , appendix send for histopathological examination
89098858|NCT04033198||sixth decade|appendectomy done , appendix send for histopathological examination
89098859|NCT04033198||older than 60 years|appendectomy done , appendix send for histopathological examination
89098860|NCT02665624|Active Comparator|Stewed apricot juice + senna group|68 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. Additional one liter of stewed apricot juice (made with dried apricot) were told to be drunken until 2 h before colonoscopy.
89098861|NCT02665624|Active Comparator|senna alone group|60 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. 1 patient was dropped out due to obstructive sigmoid colon cancer.
89098862|NCT05258266|Experimental|ZX-101A Dose Level A|ZX-101A administered orally at level A once daily in a 28-day cycle
89098863|NCT05258266|Experimental|ZX-101A Dose Level B|ZX-101A administered orally at level B once daily in a 28-day cycle
89098864|NCT05258266|Experimental|ZX-101A Dose Level C|ZX-101A administered orally at level C once daily in a 28-day cycle
89098865|NCT05258266|Experimental|ZX-101A Dose Level D|ZX-101A administered orally at level D once daily in a 28-day cycle
89098866|NCT05258266|Experimental|ZX-101A Dose Level E|ZX-101A administered orally at level E once daily in a 28-day cycle
89098867|NCT02668744|Experimental|Intervention|TX Sprouts
89098868|NCT02668744|Placebo Comparator|Control|Delayed Intervention
89098869|NCT02668900|Experimental|Decision support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
89098870|NCT02668900|No Intervention|Usual care|The control group will not receive the decision support intervention prior to consultation with the physician.
89098871|NCT00910546|Experimental|Implantation of gold marker|CT guided implantation of gold marker into early stage lung tumors. Extra 4DCT scans and fluoroscopies during planning and the 3 fraction radiotherapy course.
89098872|NCT00646594|Experimental|1|budesonide/formoterol
89098873|NCT00646594|Active Comparator|2|fluticasone/salmeterol
89098874|NCT00646984|Active Comparator|1|Standard continuous antiretroviral therapy
89098875|NCT00646984|Experimental|2|CD-4 guided interruption arm
89098876|NCT00646984|Experimental|3|Viral load driven treatment interruption
89098877|NCT00910468||Robot Assisted Laparoscopic Myomectomy|
89098878|NCT00910468||Myomectomy via Laparotomy|
89098879|NCT04173052|Experimental|Infertile Males|It represents the participants, all the participants in the study are infertile.
89098880|NCT04172896|Active Comparator|Intraperitoneal Group|Vaginal intraperitoneal uterosacral ligament suspension group
89098881|NCT04172896|Active Comparator|Extraperitoneal Group|Vaginal extraperitoneal uterosacral ligament suspension group
89098882|NCT02665390|Experimental|treatment|Patients who are medically inoperable peripheral lung cancer will enroll in this study.They will receive percutaneous cryoablation and follow-up according to schedule.
89098883|NCT04172818|Experimental|Patients with diary|Evaluation the psychological impact of a diary on the patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives.
89098884|NCT02668978|Experimental|Hemopatch™|Hemopatch™ sealing hemostat
89098885|NCT02668978|Active Comparator|Control|Standard surgical technique
89098886|NCT00647140|Experimental|1|18F-L6DOPA PET
89098887|NCT04172428||Healthy volunteers|Young healthy volunteers between the ages of 18-55.
89098888|NCT00647218|Experimental|Experimental|
89098889|NCT00994890|Experimental|Tanezumab 2.5 mg|
89098890|NCT00994890|Experimental|Tanezumab 5 mg|
89098891|NCT00994890|Experimental|Tanezumab 10 mg|
89098892|NCT02663830|Experimental|(Sildenafil & clomiphene citrate group)|105 Patients will receive 25 mg sildenafil citrate 6 hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
89098893|NCT02663830|Active Comparator|clomiphene only|105 patients will receive only clomiphene citrate 100mg/day (day 2 to 6) orally (2 tablets at same time daily).
89098894|NCT00910702|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
89098895|NCT02665078||Thoracoscopic Ultrasound|Patients who undergo lobectomy or an anatomical segmental resection for malignant lung tumors will be enrolled in the study. After lung resection, the lung will be evaluated by XLTF-UC180 for localization of the tumor. The ultrasound probe will be put on the lung surface in several different directions to obtain the cross section with maximum diameter. The ultrasound image with size measurement of the tumor will be recorded using an ultrasound scanner (EU-Y0008, OLYMPUS MEDICALSYSTEMS CORP., Tokyo, Japan). After ultrasound evaluation, the specimen will be delivered directory to the pathology laboratory and the actual tumor size and histological diagnosis will be determined. In addition, we will evaluate the differences between US image and pathological morphology using HE slides of lung tumor.
89098896|NCT00648544|Experimental|1|
89098897|NCT00648544|Active Comparator|2|
89098898|NCT00645346|Experimental|1|Subjects will receive either 5, 10 or 20 mcg of the vaccine
89098899|NCT00645346|Placebo Comparator|2|Subjects will receive placebo control
89098900|NCT00647374||1|
89098901|NCT04175314||Case -|Patient presenting one or more periodontal recession more than 1mm of height
89098902|NCT04175314||Control-|Patient presenting no periodontal recession or recession of less than 1 mm of height
89098903|NCT00648622|Experimental|1|Carvedilol Tablets 12.5 mg
89098904|NCT00648622|Active Comparator|2|Coreg® Tablets 12.5 mg
89098905|NCT00994422|Experimental|0.5% ivermectin cream|
89098906|NCT00994422|Placebo Comparator|vehicle control|
89098907|NCT04061434||Cardiac resynchronisation therapy recipients|
89098908|NCT04061434||Other cardiac implantable electronic devices recipients|
89098909|NCT00647452|Experimental|1|Healthy male volunteers
89098910|NCT00647452|Experimental|2|Healthy female volunteers
89098911|NCT00648700|Experimental|1|Levothyroxine Sodium Tablets 300 μg
89098912|NCT00648700|Active Comparator|2|Levothroid® Tablets 300 μg
89098913|NCT04172662|Experimental|Music therapy group|Receive Music therapy in addition to standard treatment
89098914|NCT04172662|No Intervention|Control group|Receive standard treatment
89098915|NCT00648778|Experimental|1|Loxapine Succinate Capsules 25 mg
89098916|NCT00648778|Active Comparator|2|Loxitane® Capsules 25 mg
89098917|NCT00645424|Experimental|Arm A|
89098918|NCT00645424|Experimental|Arm B|
89098919|NCT00645424|Experimental|Arm C|
89098920|NCT04172740|Experimental|Treatment|
89098921|NCT04172350|Experimental|Intervention group: iCareBreast plus routine care|Participants in the intervention group will receive the routine care provided by the hospital (the same as the control group) plus the iCareBreast mobile app, which provides i) pre-surgery education and instructions; ii) post-surgery education, instructions, and recovery plan; iii) positive psychological support; and iv) social support. The total intervention period is 29 days (14 days before surgery, operation day, and 14 days after the surgery).
89098922|NCT04172350|Active Comparator|Control group: Routine care|Participants in the control group will only receive routine care provided by the attending Hospital. Participants being allocated to the control group may freely use the Internet to search for information regarding breast cancer but will not be granted to access the iCareBreast app.
89098923|NCT02664844|Experimental|Obese adolescent|
89098924|NCT02665000|Experimental|Study arm: Structured training programme|"The participants in study arm will undergo 5 days training program in laparoscopic appendectomy using the Box and Wet Trainer as intervention. Each training session will take up to 2 hours. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.~After the above training, they will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and graded based on a validated GOALS scoring system 6. The Primary Outcome will be the difference of the GOALS results between the 2 groups. Secondary outcomes will include OSAT score, patient outcome, residents' feedback score as well as conversion rates to open surgery."
89111161|NCT00816400|Experimental|MEDI-575, 15 mg/kg QWk Escalation Phase (Cohort 5)|MEDI-575 administered at 15.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89098925|NCT02665000|No Intervention|Control arm: non-training|"Participant in study arm will not receive any additional training during the training week. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.~They will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and then graded based on a validated GOALS scoring system 6"
89098926|NCT02663596|Experimental|Vancomycin|Patients with vancomycin mixed in the CRRT solution(s)
89098927|NCT04171336|Experimental|Animal-assisted group therapy|
89098928|NCT00647530|Experimental|Pre&Post Op Chemo|12 weeks of OxFP neuoadjuvantly followed by surgery and 18 weeks of OxFP
89098929|NCT00647530|Experimental|Pre&Post Op Chemo with P-mab|12 weeks of OxFP and panitumumab neuoadjuvantly followed by surgery and 18 weeks of OxFP alone.
89098930|NCT00647530|Active Comparator|Post Op Chemo|surgery followed by 24 weeks of OxFP.
89098931|NCT00647608|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
89098932|NCT00647608|Active Comparator|2|Inderal® LA Capsules 160 mg
89098933|NCT02663440|Experimental|IMRT|Hypofractionated IMRT With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor
89098934|NCT04171180|Active Comparator|Controlled group|Controlled group: budesonide/formoterol(SYM) 160/4.5ug 1 inhalation bid* 3 months (n=250).
89098935|NCT04171180|Experimental|Study group|Study group: SYM 160/4.5ug 2 inhalation bid* 3 months (n=250).
89098936|NCT02660008|Experimental|ZP4207|ZP4207 (peptide analogue of human glucagon) Planned doses: 0.1, 0.3, 0.6, 1.0 mg s.c.
89098937|NCT02660008|Active Comparator|GlucaGen|GlucaGen (native glucagon) Planned doses: 0.5, 1.0 mg s.c.
89098938|NCT02664766|No Intervention|Control condition|Control condition with no intervention. Participants will be recording their daily alcohol consumption. No lifestyle modification during this period.
89098939|NCT02664766|Experimental|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week.
89098940|NCT02664688|Experimental|Lumbar stabilization exercises|Home exercise program to perform daily for 6 months
89098941|NCT02664688|Active Comparator|Flexor Exercises|Home exercise program to perform daily for 6 months
89098942|NCT00649168|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
89098943|NCT00649168|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
89098944|NCT02659774|Experimental|Group A|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
89098945|NCT02659774|Placebo Comparator|Group B|Face to Face counseling (Motivational intervention) + Booklet + SMS
89098946|NCT02659774|Placebo Comparator|Group C|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
89098947|NCT02659774|Placebo Comparator|Group D|Phone counseling (Motivational intervention) + booklet + SMS
89111162|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Escalation Phase (Cohort 6)|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (once every 21 days [Q3Wk]) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89098948|NCT02663206|Other|Botulinum toxin injection|"Drug/Device: Botulinum toxin injection; Endoscopic Botulinum toxin (BTX) injection at lower esophagus; Upper endoscopy with Botulinum toxin injection.~The procedure will be performed as an outpatient basis by an endoscopist. Sedation can be in form of conscious sedation, monitored anesthesia care or general anesthesia. An upper endoscope will be inserted into the patient's mouth and advanced into lower esophagus. Botulinum toxin (Botox@) 100 units 8-10 (25 units/mL) will be injected in 1-ml portion in each of four quadrants about 1 cm above the Z-line (the LES region).~At 1 month follow-up, patients who do not response to the first botox injection (Eckardt score > 3) will receive the second botox injection.~At 3-month follow-up, POEM will be offered as a rescue therapy to both non-responders (Eckardt score > 3 at 3-month follow-up after the procedure) and relapsers (Eckardt score ≤ 3 at 3-month follow-up but becomes > 3 during the follow-up)"
89098949|NCT02663206|Other|peroral endoscopic myotomy|"Procedure/Surgery: peroral endoscopic myotomy.~The procedure will be performed by an endoscopist (gastroenterologist or surgeon). General anesthesia will be started and upper endoscope will be inserted into the patient's mouth and advanced into the stomach. Endoscopic myotomy will be performed. Mucosal entry will then be closed using endoscopic clips or endoscopic suturing.~All patients will recover from their procedures according to standard practice. They will remain nothing per oral (NPO) the night after the procedure and started on intravenous proton pump inhibitors. A gastrografin esophagram will be obtained the next day and if no evidence of leak, the diet will be advanced to a soft diet for two weeks. The patients will be evaluated by study coordinator/PI on a daily basis during their hospitalization."
89098950|NCT02663284|Experimental|Perineural block|Perineural block with Ropivacaine 0.5%
89098951|NCT00647686|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
89098952|NCT00647686|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
89098953|NCT04172272|Active Comparator|Systemic multimodal analgesia only|"In the first group, patients will receive intravenous, systemic, multimodal analgesia: paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
89098954|NCT04172272|Experimental|TAP block only|In the second group there will be patients in who will be given the TAP block. The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacaine in 40 ml bilaterally. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
89098955|NCT04172272|Experimental|Combined TAP block with systemic multimodal analgesia|In the third group there will be patients who will be treated with TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
89098956|NCT02663050|Experimental|Kinesio taping group|only Kinesio taping treatment group
89098957|NCT02663050|Active Comparator|NSAID treatment group|only NSAIDs taking group
89098958|NCT02663050|Active Comparator|Combination treatment group|NSAIDs plus Kinesio taping group
89098959|NCT00648856|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
89098960|NCT00648856|Active Comparator|2|Zoloft® Tablets 100 mg
89098961|NCT01171976|Experimental|TE Ranibizumab 0.5 mg and Laser|On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
89098962|NCT01171976|Experimental|TE Ranibizumab 0.5 mg alone|Patients received ranibizumab intravitreal injection therapy only.
89098963|NCT01171976|Active Comparator|PRN Ranibizumab 0.5 mg|Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.
89098964|NCT00996216|Experimental|Open-label eltrombopag|Open-label eltrombopag with dose titrations to support adequate platelet counts.
89098965|NCT00647764|Experimental|Single Arm|
89098966|NCT00647842|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
89098967|NCT00647842|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
89098968|NCT02662972|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards the sphenopalatine ganglion in the affected side (ipsilateral to the pain)
89098969|NCT04291716|Other|Single Arm|This is a single-arm study. All subjects enrolled in the study will wear the device during stay in the EMU.
89098970|NCT02662894|Experimental|Valsartan 160mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (160mg) + rosuvastatin (20 mg), oral, once daily.
89098971|NCT02662894|Experimental|Valsartan 320mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (320 mg) + rosuvastatin (20 mg), oral, once daily.
89098972|NCT02662894|Active Comparator|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
89098973|NCT02662894|Active Comparator|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
89098974|NCT04291794|Active Comparator|Conventional bolus induction|Hypnotic component of general anesthesia induction will be a single bolus of propofol 2mg/kg followed by turning on sevoflurane 2% at a fresh gas flow of 2L/min.
89098975|NCT04291794|Experimental|Target-controlled induction|Hypnotic component of general anesthesia induction will be target-controlled propofol infusion tritiated to loss of consciousness. Propofol target-controlled infusion will be maintained.
89098976|NCT02662660|Experimental|Port-sites infiltration:Bupivacaine0,25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port. Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
89227434|NCT03996993||Salvage Radiotherapy Cohort|Post-radical prostatectomy patients fitting our inclusion criteria, including rising PSA > 0.1 ng/ml, not concurrently on androgen deprivation therapy (ADT) and/or received ADT in the past 3 months, and a positive SOC Axumin scan, will receive salvage radiation therapy according to the following protocol. External beam radiation therapy will be delivered in the form of high-dose intensity modulated radiation therapy (IMRT). A total prescribed dose of 72 Gy will be delivered in 40 fractions over 8 weeks. For the first 25 fractions, the clinical target volume (CTV) is defined as the residual prostatic bed, plus internal/external iliac nodes. For the subsequent 15 fractions the CTV is defined as the residual prostatic bed plus margin. As part of SOC, the radiation fields will incorporate the Axumin positive areas into treatment planning objectives. Patients will then receive serial Axumin scans up to 1 year post-therapy.
89227435|NCT01019889|Experimental|Placebo|Placebo (encapsulated starch + lactose)
89227436|NCT01019889|Experimental|SCRT(Socheongryong-tang )|encapsulated Socheongryong-tang extract
89227437|NCT01019889|Experimental|YPS (Yeongyopaedok-san)|Encapsulated Yeongyopaedok-san extract
89227438|NCT01015053|Experimental|Regional block|"An ultrasound-guided rectus sheath block will be performed by the regional block anesthesiologist in the regional block arm."
89227439|NCT01015053|Active Comparator|Wound infiltration|"Local wound infiltration will be performed by the surgeon in the wound infiltration arm."
89227440|NCT00495495|Experimental|Ozone treatment|Ozone treatment of randomly selected study tooth for 60 seconds
89227441|NCT00495495|Placebo Comparator|Placebo, no ozone|Placebo treatment (no ozone) of randomly selected study tooth for 60 seconds.
89227442|NCT00404092|Experimental|1st cohort|70mg caspofungin 1x/day
89227443|NCT00404092|Experimental|2nd cohort|100mg caspofungin 1x/day
89227444|NCT00404092|Experimental|3rd cohort|150mg caspofungin 1x/day
89227445|NCT00404092|Experimental|4th cohort|200mg caspofungin 1x/day
89227446|NCT00481767|Active Comparator|Cervarix Group|Healthy female subjects who received 3 doses of Cervarix at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
89227447|NCT00481767|Placebo Comparator|Placebo Group|Healthy female subjects who received 3 doses of placebo at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
89227448|NCT04261491|Experimental|postmenopausal women with chronic periodontitis|postmenopausal women with chronic periodontitis will be evaluated after SRP for serum bone resorption markers- CTX and inflammatory markers IL-6
89227449|NCT00489489|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
89227450|NCT00489489|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
89227451|NCT00489489|Placebo Comparator|Placebo + IFN-β|Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
89227452|NCT00489411|Experimental|Arm I/Group A (Duloxetine then Placebo)|Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
89227453|NCT00489411|Experimental|Arm II/Group B (Placebo then Duloxetine)|Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
89227454|NCT00420784|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
89227455|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
89098977|NCT02662660|Experimental|Epidural analgesia:Levobupivacaine0.125%|"Epidural analgesia consists in the placement of a thoracic epidural catheter inserted at the level T6-T7 and administration of a continuous perfusion of Levobupivacaine 0.125% 6ml/h.~Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours."
89098978|NCT02662660|Active Comparator|Metamizole and Acetaminophen iv|Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
89098979|NCT00628992|Other|1|
89098980|NCT00628992|Active Comparator|2|
89098981|NCT00628992|Active Comparator|3|
89098982|NCT00628992|Active Comparator|4|
89098983|NCT02868606||Historical control group (H)|Winthrop patients with diabetes hospitalized between August 1, 2010 and March 31, 2011
89098984|NCT02868606||Intervention group (I)|Winthrop patients with diabetes hospitalized between August 1, 2011 and March 31, 2012
89098985|NCT02868606||Parallel control group (P-sub-H)|Patients with diabetes hospitalized between August 1, 2010 and March 31, 2011 at 7 control hospitals located in the New York City metropolitan region
89098986|NCT02868606||Parallel control group (I-sub-H)|Patients with diabetes hospitalized between August 1, 2011 and March 31, 2012 at 7 control hospitals located in the New York City metropolitan region
89098987|NCT02659852|Experimental|Side by side group|
89098988|NCT02659852|Active Comparator|Stent in stent group|
89098989|NCT02662738|Active Comparator|A wheat product|A wheat product (containing 2% 13C-universally-labeled wheat) with natural fruit extract added.
89098990|NCT02662738|Placebo Comparator|Control|A wheat product (containing 2% 13C-universally-labeled wheat) without natural fruit extract added.
89098991|NCT02662738|Other|Glucose solution|A solution of 50g glucose of which 2% 13C-universally-labeled glucose (2%) and unlabeled glucose (98%) in 250 mL water.
89098992|NCT00647920|Experimental|40 mg|
89098993|NCT00647920|Placebo Comparator|Placebo|
89098994|NCT02664454|Experimental|Systematic nurse-led GA|Interactive educational seminar for GPs and nurses, and focused on geriatric assessment in primary care combined with Systematic nurse-led GA and dedicated hotline for GPs seeking geriatric advice
89098995|NCT02664454|Experimental|GP-led GA on a case-by-case basis, as decided by the GP|Interactive educational seminar for GPs, and focused on Geriatric assessment in primary care combined with a GP-led GA on a case-by-case basis, as decided by the GP, and a dedicated hotline for GPs seeking geriatric advice
89098996|NCT02664454|No Intervention|No intervention|No educational seminar Usual care
89098997|NCT04172116||long pouch RYGB|Patients with the variation of a long and narrow pouch (hypothesis: slower transit of food)
89098998|NCT04172116||short pouch RYGB|Patients with the variation of a short and wide pouch (hypothesis: faster pouch emptying as compared with long and narrow pouch)
89098999|NCT02662816|Experimental|glutathion|The study will validate the detection and the quantification of glutathione in muscle and liver using 1H MRS
89099000|NCT00830869|Experimental|Part 1: Ixazomib 0.125 milligram per square meter (mg/m^2)|Ixazomib (MLN9708) 0.125 mg/m^2, injection, intravenously (IV), once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
89099001|NCT00830869|Experimental|Part 1: Ixazomib 0.25 mg/m^2|Ixazomib (MLN9708) 0.25 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
89099002|NCT00830869|Experimental|Part 1: Ixazomib 0.5 mg/m^2|Ixazomib (MLN9708) 0.5 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
89099003|NCT00830869|Experimental|Part 1: Ixazomib 1 mg/m^2|Ixazomib (MLN9708) 1 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
89099004|NCT00830869|Experimental|Part 1: Ixazomib 1.33 mg/m^2|Ixazomib (MLN9708) 1.33 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
89099005|NCT00830869|Experimental|Part 1: Ixazomib 1.76 mg/m^2|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
89111163|NCT00816400|Experimental|MEDI-575, 35 mg/kg Q3Wk Escalation Phase (Cohort 7)|MEDI-575 administered at 35.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89099006|NCT00830869|Experimental|Part 1: Ixazomib 2.34 mg/m^2|Ixazomib (MLN9708) 2.34 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study. Once the MTD will be established, participants with NSCLC, Head and Neck Cancer (H&N), Soft Tissue Sarcoma (STC) or Prostate Cancer (PC) will be included in MTD disease expanded cohort. An additional tumor pharmacodynamics expansion cohort (TPEC) will enroll participants with any type of solid tumor that can be biopsied for tissue analysis before and after treatment with ixazomib.
89099007|NCT00830869|Experimental|Part 2:Ixazomib 1.76 mg/m^2-NSCLC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with NSCLC during Part 2 of the study.
89099008|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-H&N|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with H&N during Part 2 of the study.
89099009|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-STC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with STC during Part 2 of the study.
89099010|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-PC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with PC during Part 2 of the study.
89099011|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-TPEC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with various types of solid tumors suitable for biopsy in tumor pharmacodynamic expansion cohort (TPEC) during Part 2 of the study.
89099012|NCT02662504|Experimental|multimodal treatment + intrapleural PDT|"surgery of the MPM: extended pleurectomy/decortication (eP/D)~intra-operative (intrapleural) photodynamic therapy (PDT). Briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~then:~prophylactic chest radiotherapy of surgical scars to prevent tumor seeding (3 x 7 Gray)~adjuvant standard chemotherapy by (cis)platin 75 mg/m2 and pemetrexed 500 mg/m2 up to 6 cycles (1 cycle every 3 weeks), with oral folic acid (400 μg daily) and vitamin B12 (1000 μg Q9W) supplementation"
89099013|NCT00648934|Experimental|1|Topiramate Sprinkle Capsules 25 mg
89099014|NCT00648934|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
89099015|NCT04170868|Other|Video 1|Ten-day exposure to one of two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
89099016|NCT04170868|No Intervention|Video 1 Washout|Ten-day washout period between access to the first and second videos.
89099017|NCT04170868|Other|Video 2|Ten-day exposure to the second of the two randomly assigned psychoeducational videos. Administration of outcome measures pre and post.
89099018|NCT02659228|Placebo Comparator|Control 1 (negative control)|Individuals with a diagnosis of UWS without neural markers of consciousness
89099019|NCT02659228|Active Comparator|Control 2 (positive control)|Individuals with a diagnosis of MCS, who are behaviourally responsive and who present neural markers of consciousness
89099020|NCT02659228|Experimental|Target Population|Individuals with a clinical diagnosis of UWS, but who possess some neurophysiological signatures of conscious awareness
89099021|NCT00844519|Active Comparator|Maraviroc|For subjects assigned to the maraviroc group, subjects will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medication. For subjects on ritonavir, the dose of maraviroc will be 150mg by mouth twice daily.
89099022|NCT00844519|Placebo Comparator|Placebo|
89099023|NCT02664376||Geriatric ward population|Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.
89099024|NCT02659462||patients post Fontan palliation for single ventricular hear|Cardio Pulmonary Exercise Testing
89099025|NCT02659462||Subjects post surgical correction of congenital heart disease|Cardio Pulmonary Exercise Testing
89099026|NCT02659462||Healthy patients|Cardio Pulmonary Exercise Testing
89099027|NCT00702793|Experimental|1|Smoking cessation drug - varenicline
89099028|NCT04170166|Active Comparator|Anterolateral Approach|The randomised group of patients receiving the subacromial steroid injection via an anterolateral approach
89099029|NCT04170166|Active Comparator|Posterior Approach|The randomised group of patients receiving the subacromial steroid injection via a posterior approach
89099030|NCT01171820|Active Comparator|TAXUS® Liberté™|
89099031|NCT01171820|Active Comparator|XIENCE V® EECSS|
89099032|NCT05520229||Pre- Preanaesthesia assessment clinic|Patients who have been to surgery for an elective laparoscopic or open partial intestine from 2014-2017.
89099033|NCT05520229||Post- Preanaesthesia assessment clinic|Patients who have been to surgery for an elective laparoscopic or open partial intestine from 2017 and have attended a preanesthesia clinic.
89099034|NCT02658916|Experimental|Panel 1: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
89099035|NCT02658916|Experimental|Panel 2: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
89099036|NCT02658916|Experimental|Panel 3: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
89099037|NCT02658916|Experimental|Panel 4: BIIB092 (Expansion Panel)|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
89099038|NCT05518747|Experimental|Probiotic|In this group participants will receive non-surgical periodontal treatment at baseline, which will for 12 weeks
89099039|NCT05518747|Placebo Comparator|Placebo|In this group participants will receive non-surgical periodontal treatment at baseline, which will for 12 weeks
89099040|NCT02662426|Experimental|Drugs for experimental group|Lingdancao granules, 4 packs per time (3g/pack), three times per day; analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
89099041|NCT02662426|Active Comparator|Drugs for positive control group|Oseltamivir phosphate capsule (tamiflu), 1 capsule per time (75mg), twice per day; analogous Lingdancao granules, 4 packs per time, three times per day.Drugs must be used on the day of fever and last for five days continuously.
89099042|NCT02662426|Placebo Comparator|Drugs for placebo control group|Analogous Lingdancao granules, 4 packs per time, three times per day, analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
89099043|NCT00994110|Experimental|SOM230|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
89099044|NCT00994110|Placebo Comparator|placebo|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
89099045|NCT04315376|Experimental|Exercise-Diet Group|The participants receive a personal exercise program according to Astrand-rhyming test baseline results, and a hypo-caloric diet intervention
89099046|NCT04315376|Active Comparator|Diet Group|The participants no receive a personal exercise program, only the hypo-caloric diet
89099047|NCT02662348|Experimental|Interleukin-2 Transfusion|Patients receive low-dose Recombinant Human Interleukin-2 SC daily beginning 3 days before the first HER2Bi armed T cell infusions infusion.
89099048|NCT02662348|Experimental|T Cells Transfusion|Patients receive HER2Bi-Armed T Cells IV weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89099049|NCT02868372|Active Comparator|Betadine group|Subcutaneous tissues of cesarean section wounds are swabbed with10% undiluted Povidone Iodine solution without mobbing before closure of subcutaneous tissues
89099050|NCT02868372|No Intervention|No intervention group|No swabbing of subcutaneous tissue of cesarean section wounds
89099051|NCT00629148|Active Comparator|combination chemotherapy|Simultaneous use of Vinorelbine and Capecitabine
89099052|NCT00629148|Experimental|sequential chemotherapy|Sequential use of Vinorelbine and Capecitabine
89099053|NCT02662192|Experimental|Intervention|Exercise + health education + auditory rehabilitation 10 weeks of exercise, interactive health education, socialization and auditory rehabilitation program
89099054|NCT02662192|Active Comparator|Auditory rehabilitation alone|"auditory rehabilitation alone~1 hour of group auditory rehabilitation once a week for 10 weeks"
89099055|NCT00993954|Experimental|Nurse Reduction|Patients randomized to reduction by nurse.
89099056|NCT00993954|Active Comparator|Physician Reduction|Patients randomized to treatment by Emergency Department Physician in traditional ED manner
89099057|NCT02662114||Tresiba®|
89099058|NCT01157234|Active Comparator|Nebivolol|Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
89099059|NCT01157234|Active Comparator|Metoprolol|Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
89099060|NCT04170712||Surgical or High Risk|Patients with confirmed diagnosis of ovarian cancer or suspicious mass or who have a family history or genetic mutation that puts them at high risk fro ovarian cancer.
89099061|NCT02661802|Experimental|Oxygen Supplementation|Two six-minute walk tests, one with oxygen supplementation and another without were performed on different days. During the test with oxygen supplementation the delivery was continuous by mask at 40% and technician walked behind the patient with the oxygen source.
89099062|NCT00991302|Experimental|CAP-IT|"Participants received the modified CAP-IT adherence intervention in addition to standard care.~Modified client adherence profiling and intervention tailoring (CAP-IT): Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)"
89099063|NCT00991302|No Intervention|Standard care|Participants received standard care.
89099064|NCT04170790|Experimental|Healthy volunteer|Day 1: Sildenafil 50 mg single dose Day 2-Day 8: Washout period Day 9-12: Saxagliptin 5 mg Once/day Day 13: Sildenafil 50 mg+ Saxagliptin 5 mg
89099065|NCT02661958|Experimental|S6G5T-3|topical cream
89099066|NCT02661958|Experimental|S6G5T-1|topical cream
89099067|NCT02661958|Active Comparator|S6G5T-5|topical cream
89099068|NCT02661958|Active Comparator|S6G5T-7|topical cream
89099069|NCT02661958|Active Comparator|S6G5T-6|topical cream
89099070|NCT02661958|Placebo Comparator|S6G5T-8|topical cream
89099071|NCT04291872|Experimental|Non-Heated Arm|Proximal cavities were restored with Equia Forte (GC Corporation, Europe) according to manufacturer's orders.
89099072|NCT04291872|Experimental|Heated Arm|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
89099073|NCT04171648|Experimental|Roasted Peanut Group 1|Arm 1 is the arm of participants that will receive the roasted peanut treatment first and then will crossover to the boiled peanut treatment.
89099074|NCT04171648|Experimental|Boiled Peanut Group 1|Arm 2 is the arm of participants that will receive the boiled peanut treatment first then will crossover to the roasted peanut treatment.
89099075|NCT00995670|Experimental|Sevoflurane and Glucose|"Endothelial function will be measured via forearm blood flow (FBF). Subjects may get I/R injury (ischemia) without glucose or sevoflurane (placebo); I/R with glucose only (glucose trial); I/R with sevoflurane only (sevo trial); I/R with glucose and sevoflurane (combo trial). Baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Glucose: 5% dextrose will be infused at 12 ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 1 hr to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent I/R injury.~Sevoflurane: 1 minimum alveolar concentration (MAC) for 20 min (after 1 hr glucose and before I/R) 26 volunteers were studied 67 times in this arm."
89099076|NCT00995670|Experimental|Vitamin C and Glucose|"To determine if vitamin C can restore the impairment of the endothelium (FBF) caused by the glucose (dextrose infusion). All subjects received glucose and I/R injury (ischemia), either with or without vitamin C. Control baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Vitamin C: 1 gm iv bolus injection 5 min before I/R injury 16 volunteers were studied 25 times in this arm."
89099077|NCT00995670|Experimental|Statins and Glucose|"Volunteers ingested a 40 mg simvastatin (statin) pill for the two evenings prior to study day and the morning of the study to determine the effect of simvastatin on modulating the I/R injury during hyperglycemia (high glucose). Volunteers were studied with statin alone and with statin and glucose.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Statin: 40 mg of simvastatin 17 volunteers were studied 31 times in this arm."
89099078|NCT02661724|Experimental|Take Charge Burn - Pain (TCBR-Pain)|The TCBR-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress.
89099079|NCT02661724|No Intervention|Education attention control|The attention group receives an educational materials that is matched to the TCBR-Pain intervention in terms of session length and time on the web-based program. The web-based Education attention condition includes 7 sessions delivered over 7 weeks. The Education Attention Control is education materials commonly employed in rehabilitation centers and has been successfully used in several studies as a comparison to active rehabilitation interventions
89099080|NCT02658838|Experimental|full amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with full amount low molecular weight heparin until they leave hospital.
89099081|NCT02658838|Experimental|half amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with half amount low molecular weight heparin until they leave hospital.
89099082|NCT02658838|Experimental|No low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with no low molecular weight heparin.
89099083|NCT02536534||Patients with PAH and CTEPH|Patients diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and stable on optimal medical therapy who meet the study's eligibility criteria
89099084|NCT00648076|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
89099085|NCT00648076|Active Comparator|2|Depakote ER® Tablets 500 mg
89099086|NCT02868294|Experimental|Patient receiving the Fassier-Duval Nail|Implementation of a telescopic system intramedullary
89099087|NCT00649246||1|"controls:~healthy individuals with no family history of type 1 diabetes"
89099088|NCT00649246||2|"high-risk:~Subjects with islet autoantibodies or high-risk diabetes genes"
89099089|NCT00649246||3|"type 1 diabetes:~subjects with type 1 diabetes"
89099090|NCT02869152|Experimental|Intraoperative sentinel lymph node mapping|Subjects will come to the OR and undergo a flexible sigmoidoscopy after induction of anesthesia and receive separate endoscopic injections of Spot (up to 5 cc), 99mTc-sulfur colloid (up to 0.5 mCi), and Indocyanine green (ICG) (1 ml). Patient will undergo the standard transanal endoscopic surgery (TES) to remove the rectal neoplasm, exposing the lymph node basin. The sentinel node(s) will be identified using a combination of the gamma probe and fluorescence imaging endoscopically, dissected out, and removed through a transanal approach.
89099091|NCT02661568||Population with condition and with exposure|
89099092|NCT00629070|Experimental|ST|Traditional strength training
89099093|NCT00629070|Experimental|VT|Velocity-enhanced training
89099094|NCT00649012|Experimental|1|Pioglitazone HCl Tablets 45 mg
89099095|NCT00649012|Active Comparator|2|Actos® Tablets 45 mg
89099096|NCT02869542||Patients with lymphoma diagnosis|
89099097|NCT04293432||Group/Cohort|Torsade de Pointes induced by drugs reported to the FAERS database from inception till first quarter of 2019 (1990-2019)
89099098|NCT02661334|Placebo Comparator|Placebo|30g white rice flour
89099099|NCT02661334|Experimental|Low dose|5g/day Creatine Monohydrate (25g white rice flour) for 28 days
89099100|NCT02661334|Experimental|Loading dose|Creatine Monohydrate 20g/day (10g white rice flour) for 7 days, followed by maintenance dose of Creatine Monohydrate 5g/day (25g white rice flour) for the remaining 21 days
89099101|NCT02661334|Experimental|High dose|High dose of Creatine Monohydrate 20g/day (10g white rice flour) for the entire 28 day period
89099102|NCT04291248|Experimental|Anlotinib+AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89099103|NCT04291248|Experimental|AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
89099104|NCT04170088|Experimental|Tranexamic acid|"Left side of face of each participant was selected for intradermal Tranexamic acid injections.~generic name : Tranexamic acid Dose : 4mg / ml tranexamc acid diluted with 0.9 % normal saline Frequency : every 2 weekly total 6 doses. Duration : 6 months"
89099105|NCT04170088|Experimental|0.9% Normal saline|Right side of face of each participant was selected for intradermal normal saline injections generic name : Normal Saline Dose : 0.9 % Normal Saline Dose : Frequency : every 2 weekly total 6 doses. Duration : 6 months
89099106|NCT02867670||Transcranial Magnetic Stimulation of Motor Cortex|All study participants will receive real TMS stimulation over the primary motor cortex in order to collect physiological measures which will later be correlated with measures of neuroplasticity. There is NO placebo stimulation.
89099107|NCT02867670||Transcranial Magnetic Stimulation of Language Cortex|All study participants will receive real TMS stimulation over the language cortex and a control site (i.e. vertex). Transient changes in speech production will be recorded and compared to measures of neuroplasticity. There is NO placebo stimulation.
89099108|NCT00648154|Experimental|1|Letrozole Tablets 2.5 mg
89099109|NCT00648154|Active Comparator|2|Femara® Tablets 2.5 mg
89099110|NCT02869074||VWD Spanish Cohort|"Patients with previously diadnosis of VWD from approximately 38-40 different centers from Spain.~Samples from these patients will be analyzed locally, and also centrally for VWF and VWFgene"
89099111|NCT04170010||Conservatively managed group|Individuals with conservatively managed obesity
89099112|NCT04170010||Surgically managed group|Individuals with a past history of bariatric surgery (Roux-en-Y gastric bypass/Sleeve gastrectomy) for the management of obesity
89099113|NCT02664142|Experimental|BIS Group|"BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)~GA induction (Phase 1):~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)~anaesthesia (Phase 2, Phase 3):~hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
89111164|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Expansion Phase|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89111165|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Expansion Phase|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
89099114|NCT02664142|Experimental|Non-BIS Group|"BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)~GA induction (Phase 1):~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)~anaesthesia (Phase 2, Phase 3):~hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
89099115|NCT04291638|Experimental|Remote Caregiver Training|The Remote Caregiver Training arm consists of participation in a 5-hour, videoconferencing-based caregiver training program.
89099116|NCT04291638|Experimental|Remote Caregiver Training + Intensive Treatment|The Remote Caregiver Training + Intensive Treatment arm consists of participation in a 5-hour, videoconferencing-based caregiving training program, followed by participation in the videoconferencing-based intensive group behavioral treatment program.
89099117|NCT02664064|Experimental|online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants receive online curriculum, access to a live health coach, interactive group message forums, and connected weight and activity monitoring devices.
89099118|NCT02664064|No Intervention|Matched Control|A de-identified dataset of control subjects matched on age, gender, prediabetes diagnosis, body mass index, comorbidities and socioeconomic status will be cultivated for comparison to the active intervention arm.
89099119|NCT04291482|Experimental|Intervention arm|The intervention group participants will be assessed with EMA and they will provide daily data regarding their predictors of weight loss outcomes and their adherence to the personal weight loss plan (phase I, month 0-3). Then participants will receive tailored information regarding the most predictive factors relevant to their weight loss trajectories (phase II, month 3-6). The information will be tailored and delivered through emails and text messages.
89099120|NCT04291482|Other|Control arm|Control group participants will receive basic educational weight loss information in a form of educational factual emails and text messages.
89099121|NCT04169854|Experimental|Lidocaine Patch|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked Lidocaine 5% patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
89099122|NCT04169854|Placebo Comparator|Placebo|Surgeons will be asked to mark the planned incisions site 3 days before craniotomy. The masked placebo patch will be applied to cover the insicion mark as well as the head-holders sites within 6:00 P.M. to 6:00 A.M. for 3 consecutive preoperative days.
89099123|NCT02536768|Experimental|Intervention|Minimum package of interventions to improve ART adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
89099124|NCT02536768|No Intervention|Comparison|Standard of care HIV treatment
89099125|NCT02661100|Experimental|CDX-1401 + Poly-ICLC + Pembrolizumab followed by Pembrolizumab|Patients receive CDX-1401, Poly-ICLC and Pembrolizumab for 4 cycles (Q 3 weeks) followed by Pembrolizumab alone (Q 3 weeks) until disease progression.
89099126|NCT00648232|Experimental|A|Participants will receive voluntary brief HIV counseling and testing plus enhanced linkage to care.
89099127|NCT00648232|Experimental|B|Participants will receive voluntary brief HIV counseling and testing plus routine referral to care.
89099128|NCT00648232|Experimental|C|Participants will receive voluntary longer, more detailed HIV counseling and testing plus enhanced linkage to care.
89099129|NCT00648232|Experimental|D|Participants will receive voluntary longer, more detailed HIV counseling and testing plus routine referral to care.
89099130|NCT00648232|Active Comparator|E|Participants who are found to be healthy will receive voluntary brief HIV counseling and testing only.
89099131|NCT00648232|Active Comparator|F|Participants who are found to be healthy will receive voluntary longer, more detailed HIV counseling and testing only.
89099132|NCT00601354|Experimental|Emotion Regulation Group therapy + alli|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program, plus 12 weekly sessions of guided self-help group psychotherapy
89099133|NCT00601354|Active Comparator|Orlistat/alli program meds only|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program alone
89099134|NCT02660866|Placebo Comparator|SMT+APT+Placebo|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy."
89099135|NCT02660866|Active Comparator|SMT+APT+Vorapaxar|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy.~Vorapaxar: Vorapaxar 2.08mg/day"
89099136|NCT04169932|Experimental|CD20 CAR-T|
89099137|NCT04169620|Experimental|variable aquatic Ai Chi|"The 15 patients assigned to the aquatic therapy group (experimental group) received 20 twice-weekly sessions in total, during the same period of time as the control group. These 20 sessions consisted of group sessions lasting 45-minutes.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
89099138|NCT04169620|Placebo Comparator|variable dry land|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
89099139|NCT02663986|Experimental|Organizational Skills Training (OST) Intervention|"To improve children's organizational functioning, OST focuses on four key skills.~Tracking Assignments~Managing Materials~Time Management~Task Planning"
89099140|NCT00853099|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
89099141|NCT00853099|Experimental|Adalimumab 80 mg/40 mg|Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
89099142|NCT00853099|Experimental|Adalimumab 160 mg/80 mg|Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
89099143|NCT00648310|Active Comparator|1|arm 1: Tolterodine 4 mg once daily for 12 weeks
89099144|NCT00648310|Experimental|2|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
89099145|NCT00702871|Active Comparator|1|Arm 1 was given Injection Ranitidine 50mg i.v. 8 hourly for stress ulcer prophylaxis.
89099146|NCT00702871|Active Comparator|2|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
89099147|NCT00700453|Active Comparator|Control 1 Group|Subjects randomized to the Control 1 group will abstain from playing any video games for the entire study participation.
89099148|NCT00700453|Active Comparator|VG1- Control 2 Group|Subjects randomized to the Control 2 group will play a selected violent video game for 60-120 minutes/day during week 2 of the study and will abstain from any video game play during week 3 of the study.
89099149|NCT00700453|Active Comparator|VG1- VG2 group|Subjects randomized for VG1-VG2 group will play 60-120 minutes/day of a violent video game during weeks 2 & 3 of study participation.
89099150|NCT00700453|Active Comparator|VG1-CT group|Subjects randomized to the VG1-CT group will play 60-120 minutes of a selected violent video game during week 2 of the study and play a selected computerized cognitive training program for 60-120 minutes/day during week 3 of the study.
89099151|NCT00992784|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A
89099152|NCT00992784|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine
89099153|NCT00992784|Active Comparator|Fluarix young Group|Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine
89099154|NCT00830167|Placebo Comparator|Placebo|
89099155|NCT00830167|Experimental|Pregabalin|
89099156|NCT02611531|Experimental|Video Module Education (VME)|The RE will provide participants with a tablet device and will demonstrate how to access VME and complete the pre/post e-learning assessments. The RE will provide technical support but will neither participate directly in the education nor help with the self-assessments. The participants will first complete the pre-assessment e-learning tool on the tablet. They will then watch the video instruction that will provide a complete demonstration with verbal instructions on correct inhaler technique. Next the participants will complete the post-assessment e-learning tool. Based on participants' performance, they will be directed to further tailored video-instruction. The cycle of self-assessment and video instruction will continue until sufficient mastery has been achieved.
89099157|NCT02611531|Active Comparator|Teach-To-Goal (TTG)|Participants assigned to the TTG condition will be provided with an intensive, iterative education and evaluation strategy that consists of the following steps.
89099158|NCT00992394|Other|Arm 1|Subjects randomized to arm 1 stop their etanercept treatment on entry into the study and may be retreated by etanercept 50 mg once weekly after medical review and agreement between the subject and the investigator
89099159|NCT00992394|Other|Arm 2|Subjects randomized to arm 2 in which subjects continue on treatment with etanercept at 25 mg once weekly, but with the option to have their drug treatment increased to 50 mg once weekly after medical review and agreement between the subject and the investigator
89227456|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.
89227457|NCT00420784|Placebo Comparator|PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
89227458|NCT00420628|Experimental|Loteprednol/Tobramycin|0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension
89227459|NCT00420628|Placebo Comparator|Vehicle|Vehicle
89227460|NCT03993808|Experimental|Educational/behavioral support for hypertension self efficacy|On-site monitoring of pulse, blood pressure, weight, and surveys, at Months 0,1,3,6; Four educational sessions to address: 1) basics about blood pressure (BP); 2) training in home BP monitoring with personal Omron 10 device; 3) information about Dietary Intervention to lower Systemic Blood Pressure (DASH) eating plan, recipes and cooking demonstrations; 4) education about BP medication adherence. Interventions occur on the background of Carter Burden Network's implementation of a DASH-congruent menus for congregant meals for all seniors attending the sites, including those not enrolled in the protocol.
89227461|NCT00489255|Experimental|Trimethobenzamide (Tigan®)|
89227462|NCT00489255|Placebo Comparator|Inactive substance|
89227463|NCT00413218|Experimental|Isavuconazole (ISA)|Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.
89227464|NCT00413218|Active Comparator|Caspofungin (CAS)/Voriconazole|Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.
89227465|NCT02303392|Experimental|Treatment (selinexor, ibrutinib)|Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89227466|NCT03994042|Experimental|Mental imagery neurofeedback training|Complete intervention with mental imagery neurofeedback training. Patients recruited by physioterapists who underwent baseline evaluations with clinical tests, fMRI and EEG measurements. Patients will after intervention perform clinical tests, fMRI, and EEG measurements to evaluate outcomes of intervention.
89227467|NCT00420316|Experimental|Rotarix Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
89227468|NCT00420316|Placebo Comparator|Placebo Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
89227469|NCT03993886|Other|Arm 1|Adult (≥ 18 years of age) ambulatory patients diagnosed with heart failure and/or undergoing cardiac management.
89227470|NCT03993886|Other|Arm 2|Adult (≥ 18 years of age) patients undergoing chronic hemodialysis.
89227471|NCT03993886|Other|Arm 3|Adult (≥ 18 years of age) patients (i) implanted with the CardioMEMS HF device and (ii) diagnosed with heart failure and/or undergoing cardiac management.
89227472|NCT03993886|Other|Arm 4|Adult (≥ 18 years of age) patients diagnosed with heart failure and/or undergoing cardiac management.
89227473|NCT01038466||CHAT trial participants|CHAT trial participants whose data was used in the final data analysis for the CHAT study
89099160|NCT04291170|Experimental|QDASH|Completing the tasks on the QuickDASH
89099161|NCT04291170|Active Comparator|KOOSJR|Completing the tasks on the KOOSJR
89099162|NCT00829933|Experimental|1|DU-176b low dose
89099163|NCT00829933|Experimental|2|DU-176b intermediate dose
89099164|NCT00829933|Experimental|3|DU-176b high dose
89099165|NCT00829933|Active Comparator|4|Warfarin
89099166|NCT01170962|Experimental|Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
89099167|NCT01170962|Experimental|Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
89099168|NCT01170962|Experimental|Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
89099169|NCT01170962|Experimental|Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
89099170|NCT01170962|Experimental|Arm 5: Placebo plus peginterferon alfa-2a and ribavirin|(prior partial responders only)
89099171|NCT00843193|Experimental|GSK679586|Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
89099172|NCT00843193|Placebo Comparator|PLACEBO|Subjects will receive three, once monthly intravenous administration of saline, according to randomization
89099173|NCT00829621|Active Comparator|75 mmHg suction|IVAC suction 75 mmHg
89099174|NCT00829621|Experimental|125 mmHg suction|IVAC suction 125 mmHg
89099175|NCT01157078|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
89099176|NCT01157078|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
89099177|NCT00591721|Experimental|Energy conservation education|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles
89099178|NCT00591721|Other|Wait list control|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles.
89099179|NCT04117399|Experimental|IMT group|Inspiratory muscle training + aerobic exercice
89099180|NCT04117399|Active Comparator|Control group|aerobic exercice
89099181|NCT01156844|Experimental|Indacaterol 37.5 µg (twice a day)|"Indacaterol 37.5 µg twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89099182|NCT01156844|Experimental|Indacaterol 75 µg (once a day)|"Indacaterol 75 µg once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89099183|NCT01156844|Experimental|Indacaterol 150 µg (every other day)|"Indacaterol 150 µg every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 µg inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89099184|NCT01156844|Placebo Comparator|Placebo|"Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89099185|NCT00853021|Experimental|Bevacizumab and Aldesleukin|
89099186|NCT00913237|Experimental|1|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
89099187|NCT00913237|Active Comparator|2|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
89099188|NCT01156532||Adalimumab Treatment in Participants with Psoriasis|Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate.
89099189|NCT02884856||Females observers (F)|those with female gender characteristics
89099190|NCT02884856||Male observers (M)|those with male gender characteristics
89099191|NCT00843115||Observational|This study was non-interventional and simply followed for 3 months patients initiating a treatment with donepezil
89099192|NCT01156376|Experimental|PO-019|Formula 12027-019 Mouthwash
89099193|NCT01156376|Experimental|PO-020|Formula 12027-020 Mouthwash
89099194|NCT01156376|Active Comparator|PO-116-A|Cool Mint Listerine
89099195|NCT00700531|Experimental|1|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on the Gambro HCO 1100 dialysers
89099196|NCT00700531|Active Comparator|2|Patients receive standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
89099197|NCT00829387|Experimental|Behavioral|Cognitive behavioral therapy - Ten sessions of individual treatment delivered by a doctoral level psychologist.
89099198|NCT00829387|Active Comparator|Educational|Diabetes Education - Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator
89099199|NCT00705913|Active Comparator|1|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)
89099200|NCT00705913|Active Comparator|2|
89099201|NCT01156142|Experimental|Arm I|Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
89099202|NCT01156142|Placebo Comparator|Arm II|Patients receive placebo oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.
89099203|NCT00842257|Experimental|Panitumumab|Panitumumab administered by a central line infusion on days 1 and 15 of each 4 week cycle.
89099204|NCT05603377|Other|study group|
89099205|NCT00706069|Experimental|1|Vinorelbine oral plus Capecitabine
89099206|NCT00700609|Experimental|1|"Attachment Based Family Therapy (ABFT)~ABFT developed by Dr. Guy Diamond and colleagues is a brief, 12 week, manualized family-based intervention."
89099207|NCT00700609|Active Comparator|2|"Treatment as usual (TAU)~No attempt is made to standardize TAU. Regular clinical staff will provide mental health services."
89099208|NCT02884622|Other|CF patients|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added and blood sampling will be collected for this study
89099209|NCT04188002|Other|Control - Fruit and Vegetable|Participants in this arm will receive usual care.
89099210|NCT04188002|Other|Physical Activity Intervention|Participants in this arm will be encouraged via tailored newsletters and email/or text reminders to improve diet and physical activities.
89099211|NCT00852475|Placebo Comparator|MUFA|Assignment to monounsaturated enriched diet with exercise. This represents the MUFA MOVE! program
89099212|NCT00852475|Active Comparator|PUFA|Assignment to polyunsaturated enriched diet with exercise. This represents the PUFA MOVE! program
89099213|NCT01155284|Experimental|Sitagliptin and Lansoprazole|Sitagliptin 50mg co-administered with Lansoprazole 30mg. Subjects age 11-17 years at Visit 2 will take 1 capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 capsules of each once daily
89099214|NCT01155284|Placebo Comparator|Placebo|Sitagliptin Placebo and Lansoprazole placebo capsules will be administered. Subjects age 11-17 years at Visit 2 will take 1 placebo capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 placebo capsules of each once daily
89099215|NCT00852397|Experimental|Apixaban 2.5 mg|
89099216|NCT00852397|Experimental|Apixaban 5.0 mg|
89099217|NCT00852397|Placebo Comparator|Placebo|
89099218|NCT00841321|Active Comparator|Arm 1|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to take the intervention or placebo.
89099219|NCT00841321|Placebo Comparator|Arm 2|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to receive the placebo.
89099220|NCT00986232|Experimental|1|ProQuad (low dose)
89099221|NCT00986232|Experimental|2|ProQuad (middle dose)
89099222|NCT00986232|Experimental|3|ProQuad (high dose)
89099223|NCT00986232|Active Comparator|4|M-M-R II + PUVV
89099224|NCT00852241|Experimental|Restalyne and Perlane|One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
89099225|NCT02612233|Active Comparator|Pregabalin|Pregabalin 150mg ON week 1 increased to Pregabalin 300mg ON weeks 2-11 then decrease to Pregabalin 150mg ON week 12 then STOP
89099226|NCT02612233|Active Comparator|Duloxetine|Duloxetine 30mg ON week 1 increase to Duloxetine 60mg weeks 2-11 then decrease to Duloxetine 30mg ON week 12 then STOP
89099227|NCT02612233|Placebo Comparator|Placebo|1 capsule ON week 1- increase to 2 capsules ON week 2-11 then decrease to 1 capsule ON week 12 then STOP.
89099228|NCT01169636|Experimental|Panobinostat MTD + ICE|Phase 1: Escalating Panobinostat dose with routine ICE Chemotherapy
89099229|NCT01169636|Experimental|ICE Chemotherapy|Phase 2: Routine ICE Chemotherapy (Ifosfamide, Carboplatin, + Etoposide)
89099230|NCT01169636|Experimental|Panobinostat + ICE|Phase 2: Panobinostat with ICE Chemotherapy
89099231|NCT00706225|Experimental|1|Bazedoxifene and Conjugated Estrogens (BZA & CE)
89099232|NCT00703105|Experimental|Autologous Dendritic Cell Vaccination|DC vaccination with 1 x 10(6th) tumor lysate or WT1 and MUC1 peptide and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals(6 weeks)
89099233|NCT00706303|Active Comparator|1 Intervention group|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
89099234|NCT00706303|No Intervention|2|Usual care. The control group will receive usual care, as decided by their GP and or hospital consultant, and the patient themselves (e.g., NHS 24 helpline). They will be asked to complete diary cards and receive telephone follow up calls as an attention control, similar to the intervention group.
89099235|NCT04117009|Experimental|Remifentanil 2 ng/mL|Following baseline echocardiographic evaluation, Remifentanil (ultiva at a concentration of 20 micg/ml) infusion will be started at a rate to reach a target plasma level of 2 ng/mL. A target Controlled Infusion pump will be used to infuse the study drug. Once the target drug concentration is reached (which is expected to reach around 10-15 minutes), the final echocardiographic examination will be performed.
89099236|NCT04117009|Experimental|Baseline|Baseline transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure and study drug infusion begins.
89099237|NCT04117243|Active Comparator|Tranexamic group|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision).
89099238|NCT04117243|Active Comparator|Misoprostol group|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision.
89099239|NCT04117243|Active Comparator|oxytocin only group|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby
89099240|NCT01169558|Experimental|Bevacizumab|Bevacizumab will be administered in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum until disease progression or study completion.
89099241|NCT00700687|Experimental|1|PA32540
89099242|NCT00700687|Experimental|2|PA32540 and celecoxib
89099243|NCT00700687|Active Comparator|3|aspirin and celecoxib
89099244|NCT00706459||1|Patients with lumbar back pain scheduled for back surgery.
89099245|NCT00706459||2|Patients with degenerative disease without classic discogenic back pain
89099246|NCT00706459||3|Normal control without back pain.
89099247|NCT00706459||4|Post Surgical discectomy patients
89099248|NCT00706459||5|disc specimens
89099249|NCT04314908|Experimental|Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0."
89099250|NCT04314908|Experimental|Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at point 0 and sonic activation assisted irrigation will be applied."
89099251|NCT04314908|Experimental|Non Apical enlargement|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point."
89099252|NCT04314908|Experimental|Non Apical enlargement + Sonic Activation Assisted Irrigation|"Routine retreatment procedure will be performed at working length according to the apex locator at 1mm shorter than 0 point and sonic activation assisted irrigation will be applied."
89099253|NCT02884778|Experimental|NoL index in response to stimulation|"There is only one arm in this study. The intervention is not a drug, but it is the stimulus applied to the patient such as intubation and a standardized electrical stimulus applied on the forearm of the anesthetized patient. There are several stimuli that are the so-called interventions and the NoL index and the classical vital signs (heart rate, mean blood pressure, BISspectral index) are registered in response to these stimuli in an observational manner."
89099254|NCT00840463|Active Comparator|1|
89099255|NCT00840463|Placebo Comparator|2|
89099256|NCT00703183|Experimental|1|ACU-4429
89099257|NCT00703183|Placebo Comparator|2|matching placebo
89099258|NCT00706693|Active Comparator|Glucose|BD glucose tablets (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
89099259|NCT00706693|Active Comparator|Fructose|Fruit to Go (TM) is taken PO in response to a hypoglycemic event by participants randomized to this arm
89099260|NCT00706693|Active Comparator|Sucrose|Skittles (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
89099261|NCT01168856||Cohort|
89099262|NCT02613325|Experimental|Arm 1: fPAM imaging & Single cell PAM imaging|"fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.~When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.~Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.~To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged"
89099263|NCT00700765||A|
89099264|NCT02611999|No Intervention|Control|Physicians in this Arm received only a paper memo with a list of common imaging tests and procedures.
89099265|NCT02611999|Experimental|Single Price|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
89099266|NCT02611999|Experimental|Paired Inside/Outside Prices|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
89099267|NCT04030897|Active Comparator|Online Programs + Information/Psychoeducation/Referral (IPR)|"Includes 2 online, one-session programs (one for youths; one for parents) and Primary Care-based IPR. The 30-min, self-administered YOUTH PROGRAM includes: An introduction to the brain and a lesson on neuroplasticity; Testimonials from older youths who describe their views that traits are malleable, due to the brain's plasticity; Further stories by older youths, describing times when they used growth mindsets to persevere during social/emotional setbacks; Study summaries noting how/why personality can change; And an exercise in which youths write notes to younger students, using scientific information to explain people's capacity for change. In the 15-min Qualtrics-based PARENT PROGRAM, parents read 2 scientific passages on (1) the notion that emotions are flexible in youth and adults, and (2) that failure promotes personal growth. After each passage, parents write a persuasive summary of its main arguments, directed to fellow parents who may benefit from the information."
89099268|NCT04030897|Placebo Comparator|Information/Psychoeducation/Referral (IPR; usual care control)|Information, Psychoeducation and Referral (IPR) represents usual care in the Stony Brook University Hospital's Pediatric Primary Care Division. Families of a youth with elevated MD symptoms during a PC visit receive a folder containing informational materials about the nature of depression and referrals to providers in their area. All families in this study will receive PC-based IPR.
89099269|NCT04117165|Experimental|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from chronic inflammatory rheumatism, in particular, rheumatoid arthritis. Prescription of bDMARD or their biosimilars is possible.
89099270|NCT04117165|Active Comparator|Patient Current care|Current care of patients with rheumatoid arthritis, based on the recommendations of the French Society of Rheumatology. Prescription of bDMARD or their biosimilars is possible.
89099271|NCT00828451|Experimental|Preterm Infants for EGF Profiles|Premature infants born at < 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of [5,5,5-2H3]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.
89099272|NCT04042987||Historical Control Group|Retrospective chart review
89099273|NCT04042987||Prospective QIP Group|Participants that meet eligibility criteria will be prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption.
89099274|NCT00839917|Experimental|ProQuad™|
89099275|NCT00839917|Active Comparator|M-M-R™ II and Varivax™|
89099276|NCT00839527|Active Comparator|metformin + glimepiride + pioglitazone + albiglutide placebo|Metformin + glimepiride + pioglitazone + matching albiglutide placebo
89099277|NCT00839527|Experimental|metformin + glimepiride + pioglitazone placebo + albiglutide|Metformin + open-label glimepiride + pioglitazone matching placebo + albiglutide
89099278|NCT00839527|Active Comparator|met + glimepiride + pioglitazone placebo + albiglutide placebo|metformin + open-label glimepiride + pioglitazone placebo + albiglutide placebo
89099279|NCT00706771|Active Comparator|Sodium bicarbonate|sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
89099280|NCT00706771|Active Comparator|Sodium chloride|sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
89099281|NCT04031053||Intensive Pharmacokinetic Group|After receiving the first dose of ITZ, a single blood sample will be collected 12-hours post-dose. On Day 7, the blood will be collected for intensive PK study. After 7 days of combined ITZ + EFV, a blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. An identical set of intensive PK blood samples will be drawn 2 weeks after initiating the EFV based regimen.
89099282|NCT04031053||Trough Level Group|On Days 7 and 14, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. After initiating an EFV based regimen, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose on Days 7 and 14.
89099283|NCT00707083|Active Comparator|Standard- or Intermediate-Risk Maintenance Arm I|Patients receive oral mercaptopurine and oral methotrexate on days 1-56, dexamethasone IV on days 1-5 and 29-33, vincristine IV on days 1 and 29, and methotrexate IT on day 50. Treatment repeats every 8 weeks for up to 8 (girls)-11 (boys) courses.
89099284|NCT00707083|Experimental|Standard- or Intermediate-Risk Maintenance Arm II|Patients receive oral mercaptopurine once daily on days 8-28 and 36-56; oral methotrexate once on days 8,15, 22, 36, 43, and 50; dexamethasone IV on days 1-5 and 29-33; and vincristine IV on days 1 and 29. Patients also receive methotrexate IT on day 1, every 8 weeks, for 8 courses.
89099285|NCT05500261|Experimental|0.8 μg/kg intranasal dexmedetomidine|Intranasal administration of 0.8 μg/kg dexmedetomidine
89099286|NCT05500261|Experimental|1.5 μg/kg intranasal dexmedetomidine|Intranasal administration of 1.5 μg/kg dexmedetomidine
89099287|NCT05500261|Experimental|2.0 μg/kg intranasal dexmedetomidine|Intranasal administration of 2.0 μg/kg dexmedetomidine
89099288|NCT04116931|Experimental|clopidogrel-600 mg-12h|clopidogrel 600 mg loading dose (LD) 12 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
89099289|NCT04116931|Experimental|clopidogrel-600 mg-24h|clopidogrel 600 mg loading dose (LD) 24 hours after the last maintenance dose（MD） of ticagrelor followed by 75 mg MD daily
89099290|NCT04116931|Experimental|clopidogrel-75 mg-12h|clopidogrel 75 mg maintenance dose(MD) 12 hours after the last MD of ticagrelor
89099291|NCT04116931|Experimental|clopidogrel-75 mg-24h|clopidogrel 75 mg maintenance dose（MD) 24 hours after the last MD of ticagrelor
89099292|NCT00600886|Experimental|Pasireotide LAR|Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.
89099293|NCT00600886|Active Comparator|Octreotide LAR|Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.
89099294|NCT00649324|Experimental|1|Hydrochlorothiazide Tablets 50 mg
89099295|NCT00649324|Active Comparator|2|Hydrochlorothiazide Tablets 50 mg
89099296|NCT00648388|Experimental|1|Cilostazol Tablets 100 mg
89099297|NCT00648388|Active Comparator|2|Pletal® Tablets 100 mg
89099298|NCT02658760|Experimental|Bupivacaine|30cc of 0.25% bupivacaine
89099299|NCT02658760|Active Comparator|Dexmedetomidine and bupivacaine|30cc of 0.25% bupivacaine and 2mg/kg dexmedetomidine
89099300|NCT02536690|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 1 mg/kg and will be adjusted as described in summary.
89099301|NCT02536690|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary.
89099302|NCT02536690|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by midazolam 0.03 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.~Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary."
89099303|NCT02660632|Placebo Comparator|Thoracic epidural analgesia (TEA)|Patients who will be subjected for midline laparotomy, will receive epidural analgesia through an inserted thoracic epidural catheter before induction of general anesthesia
89099304|NCT02660632|Active Comparator|Rectus sheath catheter block|After insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected on each side, then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
89099305|NCT00649090|Active Comparator|Exemestane group|
89099306|NCT00838903|Experimental|albiglutide + metformin|Albiglutide + metformin + placebo sitagliptin + placebo glimepiride
89099307|NCT00838903|Active Comparator|sitagliptin + metformin|Sitagliptin + metformin + placebo albiglutide + placebo glimepiride
89099308|NCT00838903|Active Comparator|glimepiride + metformin|Glimepiride + metformin + placebo albiglutide + placebo sitagliptin
89099309|NCT00838903|Active Comparator|metformin + placebo|Metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride
89111166|NCT02792985|Experimental|Multisensory stimulation protocol|The Experimental group will follow an intervention protocol.
89099310|NCT02660398|No Intervention|Controls|Our control group will consist of an observational cohort of 40 patients in whom we will make quantitative assessments of the Train-of-four ratio (TOF ratio). This is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
89099311|NCT02660398|Other|Intervention|The intervention consists of a protocol for intraoperative management of neuromuscular blockade with rocuronium and reversal with neostigmine. A train-of-four count of 4 at the thumb will be confirmed prior to administration of an adjusted dose of neostigmine. TOF ratio is measured in the same manner as for the Control group, it is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
89099312|NCT00648466|Experimental|1|Sumatriptan Succinate Tablets 100 mg
89099313|NCT00648466|Active Comparator|2|Imitrex® Tablets 100 mg
89099314|NCT04170322|Experimental|thin pvc gasrtric calibration tube|thin pvc gastric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy.
89099315|NCT04170322|Active Comparator|thick silicone gastric calibration tube|thick silicone gastrric calibration tube is inserted after intubation to release gas from the stomach, then moved in correct position to help surgeon construct a sleeve gastrectomy
89099316|NCT00649402|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
89099317|NCT00649402|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
89099318|NCT00649480|Experimental|1|BALSALAZIDE DISODIUM CAPSULES, 750 MG
89099319|NCT00649480|Active Comparator|2|COLAZAL® Capsules 750 mg
89099320|NCT02656108|Experimental|omiited controlled cord traction|neither controlled cord traction nor fundal pressure will be applied. The placenta will be delivered physiologically and signs of placental separation will be awaited
89099321|NCT02656108|Active Comparator|controlled cord traction|the cord will be held in one hand and the other hand will be placed just above the woman's pubic boneto stabilize the uterus during cord traction
89099322|NCT02656342|Experimental|250 mg DCS|64 patients receive 250 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
89099323|NCT02656342|Experimental|100 mg D-Cycloserine|64 patients receive 100 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
89099324|NCT02656342|Active Comparator|Placebo|32 patients receive placebo two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
89099325|NCT04116385||Cancer surgery patients|Adult subjects (18 years or older) undergoing an oncologic surgical procedure.
89099326|NCT02656186|Experimental|Single-arm pretest-posttest|In this study, the subjects served as their own controls. Subjects who were eligible based on inclusion criteria first entered into a 2-week pre-intervention period, during which they received nutrition counseling to keep their routine dietary habits. This was followed by an intervention period, during which an oral nutritional supplement was used over a period of 2 weeks.
89099327|NCT04169464|Other|group I|A group of HCV infected patients treated with DAA therapy including Sofospovir
89099328|NCT02656030|Experimental|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise 2 times/week, 6 weeks duration
89099329|NCT02656030|Experimental|cranio-cervical flexion exercise|cranio-cervical flexion exercise 2 times/week, 6 weeks duration
89099330|NCT02656030|Active Comparator|usual care|Usual care 2 times/week, 6 weeks duration
89099331|NCT00650416|Experimental|1|Carvedilol Tablets 12.5 mg
89099332|NCT00650416|Active Comparator|2|Coreg® Tablets 12.5 mg
89099333|NCT00649948|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
89099334|NCT00649948|Active Comparator|2|Glucophage XR 500 mg
89099335|NCT04254328|Experimental|Nintendo Wii Fit|Nintendo Wii Fit group work program; 13 exercises in 5 groups including 3 yoga exercises, 3 balance exercises, 2 aerobic, 2 training plus exercises and 3 muscle-workout will be done respectively. Patients in this group will exercise for 8 weeks, 3 days in a week and 40-50 minutes of exercise within resting interval.
89099336|NCT04254328|Experimental|Respiratory|Respiratory training group participants' will do deep breathing exercise against resistance of 30% of intraoral pressure. This exercise will be applied for 8 weeks, each day of the week, twice in a day for 15 minutes and 4-5 normal breaths after 4-5 deep breaths. Each week, intraoral pressure will be measured and new training intensity values will be determined.
89099337|NCT04254328|No Intervention|Control|Patients in the control group will not be included in any exercise program, but all groups will be advised of walking in order to increase physical activity level.
89099338|NCT04167982|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid(ALA) cream for 30min. A repeat treatment was administered once weekly for a maximum of 5 times. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and after treatment.
89099339|NCT04167982|Active Comparator|conventional-dose isotretinoin group|Patients in the conventional-dose isotretinoin group were given oral isotretinoin 0.5 mg/kg daily for 6 months, and the cumulative dose was 90 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
89099340|NCT04167982|Active Comparator|low-dose isotretinoin group|Patients in the low-dose isotretinoin group were given oral isotretinoin 0.2 mg/kg daily for 6 months, and the cumulative dose was 36 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.
89099341|NCT02651974|Active Comparator|Control condition|A control invitation letter similar to the previous standard (non-incentive) invitation with slight wording and grammatical improvements will be mailed to patients randomly assigned to this group.
89099342|NCT02651974|Active Comparator|Cost condition|A control invitation letter with the addition of one line informing participants of the average value of the KIT procedure will be mailed to patients randomly assigned to this group.
89099343|NCT02651974|Active Comparator|Cost/Future condition|An invitation letter with the average value of the KIT procedure and a sentence assuring participants that should a follow-up test be requested, it will also be provided free of charge will be mailed to patients randomly assigned to this group.
89099344|NCT00649558|Experimental|1|Pioglitazone HCl Tablets 45 mg
89099345|NCT00649558|Active Comparator|2|Actos® Tablets 45 mg
89099346|NCT02658604||Home visit by pharmacist|Patients of participating pharmacies age 65 or older, who are on 5 or more chronic prescription medications, and who have a need for, and agree to, a home visit by a pharmacist for a medication review.
89099347|NCT02658682|Experimental|ABM +|Attention Bias Modification
89099348|NCT02658682|Sham Comparator|ABM -|Sham Attention Bias Modification
89099349|NCT04169308|Experimental|Experimental: Restylane-L® Filler injection|
89099350|NCT02658526||control|children without anesthesia / surgery
89099351|NCT02658526||anesthesia|children with anesthesia for diagnostic reason
89099352|NCT02658526||surgery|children with anesthesia / surgery
89099353|NCT02655718|Other|Patients with ACS|Patients with ACS who underwent coronary angiography within 72 hours from the onset of disease. In identifying nonobstructive coronary atherosclerosis , patients underwent cardiac contrast MRI.
89099354|NCT02651896||HypoIGRT|"Low Risk (T1-T2a, Gleason score 6, and PSA < 10 ng/mL)~Intermediate Risk (T1-T2c, Gleason 7, and PSA 10-20 ng/mL)~High Risk (T3 - 4 , Gleason 8-10, and/or PSA > 20 ng/mL) Neoadjuvant hormone therapy is allowed on groups 2 and 3"
89099355|NCT02658370|Experimental|animated home-based exercises (Wii-fit)|using the Wii game console by Nintendo
89099356|NCT02658370|Active Comparator|conventional home-based exercise program|by using a compilation with 31 exercises especially for rheumatoid arthritis patients
89099357|NCT00650494|Experimental|1|Valacyclovir Hydrochloride Tablets 1000mg
89099358|NCT00650494|Active Comparator|2|Valtrex® Tablets 1000 mg
89099359|NCT02655874|Experimental|Six-monthly influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and 180
89099360|NCT02655874|Active Comparator|Annual influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and an active-comparator (Tetanus-diphtheria-pertussis) at day 180
89099361|NCT00828139|Experimental|Arm I (ziv-aflibercept, topotecan hydrochloride)|Patients receive ziv-aflibercept IV over 1 hour on day 1 and topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive ziv-aflibercept IV on day 1 and topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89099362|NCT00828139|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89099363|NCT02655796|Experimental|Moderate/High Risk|Participants assessed as moderate/high risk of falling according to the CDC Algorithm for Fall Risk Assessment
89099364|NCT02655796|Experimental|Low Risk|Participants assessed as low risk of falling according to the CDC Algorithm for Fall Risk Assessment
89099365|NCT04222192|Sham Comparator|Conventional Epidural application|Epidural catheter insertions with conventional (anatomical landmarks use) method
89099366|NCT04222192|Active Comparator|Paramedian sagittal application|Epidural catheter insertions with real time ultrasound guided Paramedian sagittal approach
89099367|NCT04222192|Active Comparator|Transverse Interlaminar application|Epidural catheter insertions with real time ultrasound guided Transverse Interlaminar approach
89099368|NCT04169386|Experimental|AK102 75mg|AK102 75mg
89099369|NCT04169386|Experimental|AK102 150mg|AK102 150mg
89099370|NCT04169386|Experimental|AK102 300mg|AK102 300mg
89099371|NCT04169386|Experimental|AK102 500mg|AK102 500mg
89099372|NCT04169386|Placebo Comparator|Placebo|Matching placebo
89099373|NCT02658214|Experimental|Cohort 1|ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)
89099374|NCT02658214|Experimental|Cohort 2|Small-cell lung cancer (SCLC)
89099375|NCT02658214|Experimental|Cohort 3|Triple-negative breast cancer (TNBC)
89099376|NCT02658214|Experimental|Cohort 4|Triple-negative breast cancer (TNBC)
89099377|NCT02658214|Experimental|Cohort 5|Gastric/gastro-esophageal junction (GEJ)
89099378|NCT02658214|Experimental|Cohort 6|Pancreatic ductal adenocarcinoma (PDAC)
89099379|NCT02658214|Experimental|Cohort 7|Esophageal squamous cell carcinoma (ESCC)
89099380|NCT05492461||Swiss Physicians|A group of approximately 10'000 physicians practicing in the cantons of Basel-Stadt, Basel-Landschaft, Aargau, Lucerne, Graubünden, Ticino and Vaud.
89099381|NCT05492461||General population of Switzerland|A group of 10,000 people from the general population including the three language regions (German, Italian, and French)
89099382|NCT04169230|Experimental|Citalopram|Single acute oral dose 20 mg Citalopram (tablet encapsulated in opaque capsule)
89099383|NCT04169230|Placebo Comparator|Placebo|Single acute oral dose Lactose Placebo (tablet encapsulated in opaque capsule)
89099384|NCT02655952|Experimental|Foxy-5|"Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly for three weeks.~There will be a maximum of 8 dose cohorts. Cohorts 1-4 will be conducted in the United Kingdom and Denmark whereas cohorts 5-8 will only be conducted in Denmark. As doses in cohort 1 and 2 have been investigated in the previous phase I study, cohorts 1+2 and 3 can be run in parallel with dose escalation approved by the DSMB at all times.~DK+UK: Cohort 1: 0.8 mg/kg DK+UK: Cohort 2: 1.3 mg/kg DK+UK: Cohort 3: 1.8 mg/kg DK+UK: Cohort 4: 2.3 mg/kg DK only: Cohort 5: 3.0 mg/kg DK only: Cohort 6: 4.0 mg/kg DK only: Cohort 7: 5.3 mg/kg DK only: Cohort 8: 7.0 mg/kg"
89099385|NCT02655640||Lupus|Characteristics of patients with Systemic Lupus Erythematosus. No interventions will be administered. Patients will be asked to complete questionnaires.
89099386|NCT02655640||Scleroderma|Characteristics of patients with Systemic Sclerosis. No interventions will be administered. Patients will be asked to complete questionnaires.
89099387|NCT02658058|Active Comparator|Landmark technique|As intervention, patients in this group are administered landmark guided midline spinal anesthesia.
89099388|NCT02658058|Experimental|Ultrasound-guided paramedian technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided paramedian technique using parasagittal oblique view
89099389|NCT02658058|Experimental|Ultrasound-guided midline technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided midline technique using transverse median view
89099390|NCT02655484|Other|COPD patients|Oxygen was delivered to the face mask by a tube at a constant rate (5L/min) to keep the fingertip oxygen saturation at 90% or above. Ventilatory assistance was delivered using a BiPAP® Vision® ventilator (Respironics, Murrysville, Pennsylvania, USA) in BiPAP mode applied via a tightly fitting full face mask (Curative, Suzhou, China). A symptom-limited cycle exercise test was performed while assisted by non-invasive ventilation (NIV). All measurements were recorded at inspiratory pressure of 14 cmH2O, expiratory pressure of 4 cmH2O during rest and exercise. Breathing pattern, mean exhalation flow, mean plateau exhalation valve flow, the mean inspiratory fraction of CO2 (tidal FiCO2) reinsufflated from the circuit between the mask and the exhalation valve was measured for each breath.
89099391|NCT02651506|Experimental|Electromagnetic Navigation Bronchoscopy|
89099392|NCT02651506|Active Comparator|Transthoracic Needle Biopsy|
89099393|NCT04201756|Experimental|Afatinib|
89099394|NCT02651350|Experimental|Methylprednisolone|Participants will receive methylprednisolone from week 0 through week 48 study visit in combination with standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) in the first 12 weeks. Participants will then be followed until week 72 study visit.
89099395|NCT02651350|Active Comparator|Standard Treatment|Participants will only receive standard treatment (namely,routine liver protection drugs) including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72 study visit.
89099396|NCT02658292|Active Comparator|NAFT900|NAFT900 (Naftifine hydrochloride foam, 3%)
89099397|NCT02658292|Placebo Comparator|Vehicle|Vehicle Foam
89099398|NCT02657824||measuring ejection fraction|ejection fraction in an acute dyspneic patients
89099399|NCT02655328|Experimental|athlete under asthma treatment|athlete suffering from asthma blood sample urine sample
89099400|NCT04169152||Internal hemorrhoids and rectal prolapse|Participants were treated with Cap-assisted endoscopic sclerotherapy (CAES).
89099401|NCT04168840||Patient undergoing general anesthesia with intubation|Patient undergoing general anesthesia with intubation We will explore clinical airway parameters and external ultrasound parameters of the airway
89099402|NCT02655172|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
89099403|NCT02655172|Active Comparator|Control group|healthy patients who will perform cognitive tasks
89099404|NCT02657980|Experimental|YBand(YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (total of 10 applications)
89099405|NCT02657980|Sham Comparator|Sham-Yband(YDT-201N)|sham-tDCS application 5 days a week for 2 weeks (total of 10 applications)
89099406|NCT04168996|Experimental|rib fracture patients group|Individualized discharge planning in rib fracture patients with different severity of lung injury
89099407|NCT04168996|No Intervention|Control group|Patients included in control group received standard conservative treatment during hospitalization
89099408|NCT00650572|Experimental|ARRY-380|
89099409|NCT02651038|Experimental|Micafungin|Micafungin is administered per clinical need and the pharmacokinetic parameters are analyzed
89099410|NCT02657902||Gamma 3 Nail|Fractures that were treated with a Gamma 3 nail
89099411|NCT02657902||Gamma 3 Nail + U-Blade|Fractures that were treated with a Gamma 3 nail and additional with antirotation U-blade lag screws.
89099412|NCT02536924|Experimental|Waiting room intervention plus TAU|The treatment group will receive waiting room intervention plus treatment as usual.
89099413|NCT02536924|Experimental|Only TAU.|The control group will receive only treatment as usual.
89099414|NCT02657746|No Intervention|usual care|Usual care comprises existing services for hypertension control in the community without any additional training
89099415|NCT02657746|Experimental|multi-component interventions|: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
89099416|NCT02657668|Experimental|Treatment Group|Emotion focused therapy: EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
89099417|NCT02657668|No Intervention|Control Group|Control group: For control group interactions to be effective in therapeutic outcomes, the psycho-educational group was assigned as control group. The Psycho-educational group was conducted in four sessions (without pretest and posttest sessions). They became familiar with etiology and role of psychological factors in IBS, without any psychotherapy. Eight members were removed (because of being absent more than three sessions).
89099418|NCT04033042|Experimental|Protocol 1|RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.
89099419|NCT04033042|Experimental|Protocol 2|"RSP-21 Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 41 days.~One group of subjects will receive training in the use of the device the other will not. Both groups will receive the instructions for use."
89099420|NCT02650882|Placebo Comparator|placebo|Placebo group (PG) Nine athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a fixed load at 15% MIP, placebo protocol.
89099421|NCT02650882|Experimental|Experimental|Experimental group (EG) Ten athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a progressive load at 60%, 70% and 80 % of MIP.
89099422|NCT00838513|Experimental|eculizumab|
89099423|NCT04032886|Experimental|classic kinesio tape|this group will receive mechanical correction tape with classic tape plus exercise.
89099424|NCT04032886|Experimental|performance kinesio tape|this group will receive mechanical correction tape with performance tape plus exercise.
89099425|NCT04032886|Other|control|this group will receive only exercise.
89099426|NCT02536222|Experimental|Reactive case investigation : FT/FDA with DHA-PQ|All consenting household members eligible to receive DHA-PQ and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHA-PQ. If no one in the household tests RDT positive then no one in the household will receive DHA-PQ.
89099427|NCT02536222|No Intervention|No Intervention: Standard of Care (Control)|The standard of care arm will have the standard of care offered by the Ministry of Health which applies to all arms. This includes available mosquito net coverage and passive case detection of individuals seeking treatment from a health provider at a health post or community.
89099428|NCT00649636|Experimental|1|Fluoxetine Capsules 40 mg
89099429|NCT00649636|Active Comparator|2|Prozac Pulvules 40 mg
89099430|NCT04030663|Active Comparator|papaverine|
89099431|NCT04030663|Active Comparator|nitroglycerine|
89099432|NCT04030663|Placebo Comparator|xlyocaine|
89099433|NCT02654938|Experimental|Mobilan (M-VM3)|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Investigational Drug Product
89099434|NCT02654938|Placebo Comparator|Placebo|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Placebo (Glucose 5%)
89099435|NCT00700921|Experimental|Active Drug (Lovastatin)|
89099436|NCT00700921|Placebo Comparator|Placebo (inactive comparator)|
89099437|NCT00600106|Active Comparator|Hormone replacement therapy|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
89099438|NCT00600106|Placebo Comparator|Placebo|1mg placebo
89099439|NCT04168918|Experimental|Group Psychological Intervention|One topic will be discussed at each of the six sessions using some principles from cognitive behavioral therapy and psychoeducation.
89099440|NCT04168918|No Intervention|Treatment-as-usual|Participants will receive their usual care which involves being seen by a mental health professional (psychologist, psychiatrist/resident in psychiatry, or mental health nurse).
89099441|NCT02650726|Placebo Comparator|control group|The participants in this group are instructed to consume placebo capsules every day during the trial period.
89099442|NCT02650726|Experimental|treatment group|The participants in this group are instructed to consume anthocyanin capsules every day during the trial period.
89099443|NCT00850993|Experimental|Cohort 1: Stannsoporfin 1.5 mg/kg|Participants receive a single dose of 1.5 mg/kg by intramuscular (IM) injection, along with PhotoTherapy (PT) if and when needed.
89099444|NCT00850993|Experimental|Cohort 2: Stannsoporfin 3.0 mg/kg|Participants receive a single dose of 3.0 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
89099445|NCT00850993|Experimental|Cohort 3: Stannsoporfin 4.5 mg/kg|Participants receive a single dose of 4.5 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
89099446|NCT00850993|Placebo Comparator|Cohort 4: Placebo|Participants receive a single dose of placebo (sterile saline solution) by IM injection, along with PT if and when needed.
89099447|NCT04168762|Experimental|TUMS and Sham Group|During the subjects two visits they will receive a TUMS stimulation and a sham (placebo) stimulation at both visits.
89099448|NCT04168762|Experimental|TUMS or Sham Group|During the subjects first of two visits they will receive either a TUMS stimulation or a sham (placebo) stimulation and at the second visit they will receive the other.
89099449|NCT02650570||Head/Neck Cancer|Subjects diagnosed with advanced (stages III or IV), persistent (recurrence within 6 months) or recurrent head and neck squamous cell carcinoma (HNSCC)
89099450|NCT02650570||Healthy Control|Healthy controls age matched to the Head/Neck cancer group.
89099451|NCT02657512|Experimental|Arm A|"Period  rivaroxaban alone~Washout period (at least 6 days)~Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 5 hours after rivaroxaban administration"
89099452|NCT02657512|Experimental|Arm B|". Period  rivaroxaban and activated charcoal 5 hours after rivaroxaban administration~Washout period (at least 6 days)~Period  rivaroxaban alone~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration"
89099453|NCT02657512|Experimental|Arm C|". Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration~Washout period (at least 6 days)~Period  rivaroxaban alone"
89099454|NCT00818779|Experimental|Aliskiren|Aliskiren 150-300 mg once daily
89099455|NCT00818779|Active Comparator|Amlodipine|5-10 mg amlodipine once daily
89099456|NCT02654548|Experimental|PCOS women and babies|Sebum output using Sebutape on post-partum PCOS women and new born babies.
89099457|NCT02654548|Active Comparator|Non-PCOS women and babies|Sebum output using Sebutape on post-partum non-PCOS women and new born babies.
89099458|NCT02657278|Other|Symptomatic Peripheral arterial disease|Patients scheduled to undergo surgery or angioplasty of the iliofemoral segment for intermittent claudication.
89099459|NCT00850759|Experimental|virtual reality|street-crossing training in a virtual pedestrian environment
89099460|NCT00850759|Active Comparator|computer and video|exposure to training in pedestrian safety via computer software, internet games, and television videos
89099461|NCT00850759|Active Comparator|streetside training|one-on-one training in street-crossing skills by an adult, at a streetside location
89099462|NCT00850759|No Intervention|no-contact control|no-contact control group.
89099463|NCT02650492|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
89099464|NCT00827827|Experimental|Arm 1|Participants in this group undergo lower-extremity strength training on three pneumatic resistance machines (Keiser Leg Press, Keiser Leg Extension, and Keiser Leg Curl). Training sessions happen 3 times per week (M,W,F) and last approximately 45 minutes to 1 hour. Participants in this group exercise each limb individually to account for the large discrepancies in strength between legs in stroke survivors.
89099465|NCT00827827|Active Comparator|Arm 2|Participants in this group receive equal exposure to study staff compared with the experimental ST group (approximately 45 minutes to 1 hour 3 times per week). Exercise sessions for this group involve a full battery of active and passive...upper and lower body...stretching and range of motion exercises performed on raised padded tables.
89099466|NCT02654704||Healthy Young Adults|Healthy young adults aged 18-25. Vaccination in all cohorts/groups.
89099467|NCT02654704||Asthma Young Adults|Young adults aged 18-25 with asthma. Vaccination in all cohorts/groups.
89099468|NCT02654704||Immunocompromised Young Adults|"Young adults aged 18-25 that are immunocompromised (e.g. following treatment for leukemia).~Vaccination in all cohorts/groups."
89099469|NCT02654704||Healthy Older Adults|Healthy older adults aged 55+ Vaccination in all cohorts/groups.
89099470|NCT02654704||Asthma Older Adults|Older adults 55+ with asthma. Vaccination in all cohorts/groups.
89099471|NCT02654704||Immunocompromised Older Adults|"Older adults aged 55+ that are immunocompromised (e.g. following treatment for leukemia).~Vaccination in all cohorts/groups."
89099472|NCT02650336||CIN proup|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
89099473|NCT02650336||control group|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
89099474|NCT00649714|Experimental|1|Zonisamide Capsules 100 mg
89099475|NCT00649714|Active Comparator|2|Zonegran® Capsules 100 mg
89099476|NCT02654392|Placebo Comparator|placebo|This group will receive isoenergetic carbohydrate (corn syrup) supplement daily for 5 weeks
89099477|NCT02654392|Other|Polyunsaturated fatty acid group|This group will receive a plant essential fatty acid food supplement, Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils, containing a 2.5:1 omega-6 to omega-3 ratio (1.5 g per 70kg body mass plus an additional 0.5 g on exercise days)
89099478|NCT02654158||Low-dose of Fuganlin Oral Liquid|"oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
89099479|NCT02654158||High-dose of Fuganlin Oral Liquid|"oral~less than 1 years old: 10mL each time and three times a day~1~3 years old: 20mL each time and three times a day~4~6 years old: 20mL each time and four times a day~7~12 years old: 20mL each time and five times a day"
89099480|NCT02657122|Experimental|TD-1473 for SAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
89099481|NCT02657122|Placebo Comparator|Placebo for SAD|2 of out 8 subjects per cohort will be randomized to receive placebo
89099482|NCT02657122|Experimental|TD-1473 for MAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
89099483|NCT02657122|Placebo Comparator|Placebo for MAD|2 of out 8 subjects per cohort will be randomized to receive placebo
89099484|NCT00600028|Experimental|Experimental: Thalidomide, then placebo|Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.
89099485|NCT00600028|Experimental|Experimental: Placebo, then Thalidomide|Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.
89099486|NCT02650102|Experimental|antipsychotics|This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.
89099487|NCT02650102|No Intervention|health control|This group was treated with no invention
89099488|NCT02657044|Active Comparator|EMR|In the EMR-arm, endoscopic resection will be performed using the (p)EMR technique.
89099489|NCT02657044|Active Comparator|ESD|In the ESD-arm, endoscopic resection will be performed using the (h)ESD technique.
89099490|NCT02650180|Other|Soberlink Cellular Device|Soberlink Cellular Device: a Breath Alcohol Analyzer
89099491|NCT02653924|Active Comparator|silk suture|silk suture
89099492|NCT02653924|Active Comparator|vicryl suture|vicryl suture
89099493|NCT02653924|Active Comparator|nylon suture|nylon suture
89099494|NCT02653924|Active Comparator|polypropylene suture|polypropylene suture
89099495|NCT00650884|No Intervention|1|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CONTROL PATIENTS will only be treated with Standard of Care during this 12 week trial, but will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch after completion of this study.
89099496|NCT00650884|Experimental|2|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). EXPERIMENTAL PATIENTS will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
89099497|NCT00650884|Other|3|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CROSS-OVER patients will be initially treated only with Standard of Care, and after six weeks, they will be Crossed-Over and fit with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
89099498|NCT00910780|Active Comparator|Staying on Risperdal|
89099499|NCT00910780|Active Comparator|Risperdal switched to Abilify|
89099500|NCT00910780|Active Comparator|Staying on Zyprexa|
89099501|NCT00910780|Active Comparator|Zyprexa switched to Abilify|
89099502|NCT02649712|Active Comparator|Unilateral stent|Patients undergo placement of unilateral biliary stent on day 1.
89099503|NCT02649712|Active Comparator|Bilateral stents|Patients undergo placement of bilateral biliary stents on day 1.
89099504|NCT02656888|Experimental|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
89099505|NCT02656888|Placebo Comparator|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
89099506|NCT02656966|Active Comparator|Auricular acupuncture + standard therapy|Patients, who will wish acupuncture, will receive this intervention, in addition to standard therapy
89099507|NCT02656966|No Intervention|Standard therapy alone|Patients who do not wish acupuncture will be asked if they will fill in the study questionnaire
89099508|NCT02656810|Experimental|Sequence A|Single subcutaneous injection of two teriparatide products (PF708 and Forteo)
89099509|NCT02656810|Experimental|Sequence B|Single subcutaneous injection of two teriparatide products (Forteo and PF708)
89099510|NCT02536612|Experimental|Lottery|"Conditional economic incentive (CEI) lotto arm participants will get a chance to win a type of lottery or lotto ticket with a 50% chance of winning each time: (a) if they come back to the clinic and are still using a modern contraception method after 3 months (including IUD, injectable contraceptive, or implant); (b) if they come back to the clinic and are still using modern contraception after 6 months; and (c) if they come back to the clinic at 6 months and they don't have a new curable STD (such as syphilis).~They will also will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months."
89099511|NCT02536612|Active Comparator|No Lottery|Participants in the Control (No CEI Lotto) group will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months; they will NOT have a chance to win a lottery even if they are still using a modern contraception and are free of new curable STDs.
89099512|NCT02649478|Experimental|Fluticasone / Salmeterol|"fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler (LOMI) inhaler device twice a day by inhalation throughout the study"
89099513|NCT02649478|Active Comparator|Advair Diskus 100/50|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
89099514|NCT02649478|Placebo Comparator|placebo inhaler|placebo inhaled powder twice a day by inhalation throughout the study
89099515|NCT00650962|Active Comparator|CPR first|Compression First (CF)
89099516|NCT00650962|Active Comparator|Analysis First|Rhythm analysis first
89099517|NCT02653612|Experimental|Experimental Arm|This cohort will receive the contrast agent
89099518|NCT04167592|Active Comparator|Benzydamine Hydrochloride Group|Subjects who were allocated in benzydamine group would gargle with 15 of ml benzydamine hydrochloride 0.15% before sedation started.
89099519|NCT04167592|Placebo Comparator|Control Group|Subjects who were allocated in control group would gargle with 15 ml of water before sedation started.
89099520|NCT02656732|Experimental|coronally advanced flap with amnion chorion membrane|coronally advanced flap was reflected and amnion chorion allograft membrane was placed under the flap as a guided tissue regeneration barrier.
89099521|NCT02656732|Active Comparator|subepithelial connective tissue graft|coronally advanced flap was reflected and subepithelial connective tissue graft was harvested from the palate and placed under the flap.
89099522|NCT04168294||sedation group|Patients undergo sedative esophagogastroduodenoscopy (EGD) and are intravenous injected propofol in bolus
89099523|NCT04168294||control group|patients undergo conventional EGD
89099524|NCT02653534|Experimental|Intervention Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
89099525|NCT02653534|No Intervention|Control|Routine visits by government health workers
89099526|NCT02656576|Other|patient with suspected lesions of the tonsillar region|patients will have a tonsil biopsy and a smear
89099527|NCT04167202|Experimental|Hydrogen-rich water|Six 30-min ankle baths with hydrogen-rich water (one hydrotherapy every 4 hours)
89099528|NCT04167202|Active Comparator|RICE protocol for acute injury|RICE protocol include: (1) rest, (2) ice packs every 20 min every 3 hours (total of 8 sessions), (3) compression with elastic bandage for 24 h, and (4) leg elevation at all possible times of the injured area above the level of the heart
89099529|NCT02649244|Experimental|The Family Caregiver Training Program|The experimental group received a 2 hour intervention training on activities of daily throughout the early, middle, and late stages of dementia including communication, eating/feeding, nutrition, bathing, grooming, dressing, toileting, and transferring.
89099530|NCT02649244|No Intervention|Standard Care|The control group received a 1 1/2 hour training, however the information was based on what has been deemed standard care by the Alzheimer's Association.
89099531|NCT02653378|Active Comparator|DIET ARM|A 25% energy depletion (daily for 3 days) induced by reducing the amount of energy intake that would otherwise keep the individual in energy balance.
89099532|NCT02653378|Active Comparator|EX ARM|A 25% energy depletion (daily for 3 days) induced by performing aerobic exercise at 50% of V02max.
89099533|NCT04168138|Experimental|Newly diagnosed AML in elderly patient|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when WBC>20*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
89099534|NCT02653222|Experimental|Renal sympathicolysis|"The patient will have:~Ambulatory Blood Pressure Monitoring~Magnetic Resonance Angiography~Blood test~Renal sympathicolysis~Ambulatory Blood Pressure Monitoring~Magnetic Resonance Angiography"
89099535|NCT00651196||1|Type 1 diabetics
89099536|NCT00651196||Healthy controls|Healthy age and sex matched controls
89099537|NCT02656498|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
89099538|NCT02656498|Experimental|MCI Subjects|MCI Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
89099539|NCT02656498|Experimental|AD Subjects|AD Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
89099540|NCT02656498|Experimental|Subjects with other neurodegenerative disease|Subjects with other neurodegenerative disease will receive an IV injection, [18F]THK-5351 at baseline.
89099541|NCT02653066|No Intervention|Control|Participant is recruited via usual avenues including flyers and physician referral. This includes participants who received a HealtheRx with advertisement for phone survey but did not call in based on advertisement.
89099542|NCT02653066|Experimental|Intervention with consent form|After completing survey, participant in HealtheRx+ group receives $5 bill with their survey check and blank registry consent form.
89099543|NCT02653066|Experimental|Intervention with return of consent form|After returning signed consent form, participant in HealtheRx++ group is mailed $5 bill.
89099544|NCT00649870|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
89099545|NCT00649870|Active Comparator|2|Valtrex® Tablets 1000 mg
89099546|NCT02536144|Experimental|MCCES|Magnetic -controlled capsule endoscopy system (MCCES) is a robot system that the capsule would be swallowed to observe the mucosa of the human alimentary canal especially the colon under the control of the magnetic-manipulator.
89099547|NCT02536144|Active Comparator|Colonoscopy|Colonoscopy has now been in use for many years to visualize and diagnose abnormalities of the colon and it is the gold standard for detecting colorectal lesions.In this study,the additional utility of the colonoscopy is to monitor the movement of the Magnetic -controlled capsule endoscopy.
89099548|NCT02649400||Diastolic Heart Failure|Women with diastolic heart failure and previous coronary artery disease
89099549|NCT04167280|Active Comparator|Ipratropium bromide|20mcg bronchodilator inhaler
89099550|NCT04167280|Placebo Comparator|placebo|matching bronchodilator inhaler
89099551|NCT02652910|Experimental|IL-2 programmed CD19.CAR-T cells|Administrated with IL-2 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
89099552|NCT02652910|Experimental|IL-7/IL-15 programmed CD19.CAR-T cells|Administrated with IL-7/IL-15 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
89099553|NCT04167046||Control|Patients in this group did not receive an erector spinae block. Data are obtained retrospectively (years 2017 and 2018).
89099554|NCT04167046||Erector spinae block|Patients in this group receive an erector spinae block. Data will be obtained prospectively.
89099555|NCT02652832|Active Comparator|Depression Electroconvulsive therapy|40 patients with major depression receiving a mean of 12 sessions of Electroconvulsive therapy
89099556|NCT02652832|Active Comparator|Depression active repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
89099557|NCT02652832|Sham Comparator|Depression sham repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of sham 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
89099558|NCT02652832|Active Comparator|Schizophrenia active transcranial magnetic stimulati|40 patients with schizophrenia and predominant negative symptoms receiving 20 sessions of intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
89099559|NCT02652832|Sham Comparator|Schizophrenia sham transcranial magnetic stimulation|patients with schizophrenia and predominant negative symptoms receiving 20 sessions of sham intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
89099560|NCT02652832|Active Comparator|Schizophrenia active transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
89099561|NCT02652832|Sham Comparator|Schizophrenia sham transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of sham transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
89099562|NCT02652832|No Intervention|Healthy volunteers|80 healthy volunteers receiving no stimulation
89099563|NCT02652988|Active Comparator|Active-tDCs|17 patients will receive Active-tDCS intervention (2mA, 30 min) at home.
89099564|NCT02652988|Sham Comparator|Sham-tDCS|17 patients will receive Sham-tDCS intervention (2mA, 30 min) at home.
89099565|NCT04166968|Sham Comparator|Control Group|neuromotor training and placebo stimulation
89099566|NCT04166968|Experimental|Group 1|neuromotor training and cathodal stimulation over the unaffected hemisphere
89099567|NCT04166968|Experimental|Group 2|neuromotor training and anodal stimulation over the affected hemisphere
89099568|NCT02648854|Other|Group 1|<Group 1> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition)
89099569|NCT02648854|Other|Group 2|<Group 2> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition)
89099570|NCT02649010|Active Comparator|Group A|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
89099571|NCT02649010|Active Comparator|Group B|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
89099572|NCT04281160||Clinical Metric|Patients and healthy controls were evaluated by expert raters with standard clinical metrics of neurologic function.
89099573|NCT04281160||Mobile Activity Metric|Patient performed mobile activity
89099574|NCT02652598|Experimental|Open-Label|Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
89099575|NCT02648776||Estazolam|Exposure to sedative-hypnotic drugs; Patients who have taken estazolam for at least one week before the first date of enrollment
89099576|NCT02648776||Lorazepam|Exposure to sedative-hypnotic drugs; Patients who have taken lorazepam for at least one week before the first date of enrollment
89099577|NCT02648776||Diazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Diazepam for at least one week before the first date of enrollment
89099578|NCT02648776||Alprazolam|Exposure to sedative-hypnotic drugs; Patients who have taken Alprazolam for at least one week before the first date of enrollment
89099579|NCT02648776||Flunitrazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Flunitrazepam for at least one week before the first date of enrollment
89099580|NCT02648776||Zolpidem|Exposure to sedative-hypnotic drugs; Patients who have taken Zolpidem for at least one week before the first date of enrollment
89099581|NCT02648776||Zopiclone|Exposure to sedative-hypnotic drugs; Patients who have taken Zopiclone for at least one week before the first date of enrollment
89099582|NCT02648776||Control Group|Patients not taking any of the included or any other anxiety-hypnotic agents
89099583|NCT02648464|Experimental|Hydroxychloroquine|Hydroxychloroquine 300 mg tablet by mouth daily for 6 months. Patients under the weight of 60 kg: hydroxychloroquine 300 mg tablet daily for 5 days per week for 6 months.
89099584|NCT02648464|Placebo Comparator|Placebo|Placebo tablet by mouth daily for 6 months. Patients under the weight of 60 kg: placebo tablet daily for 5 days per week for 6 months.
89099585|NCT02648542|Active Comparator|CAS vs. tDCS|Assess the efficacy of compensatory auditory stimulation (CAS) versus transcranial direct current stimulation (tDCS)
89099586|NCT02648542|Sham Comparator|Combined CAS+tDCS vs. Sham|Assess the efficacy of combined compensatory auditory stimulation (CAS) + transcranial direct current stimulation (tDCS) versus sham stimulation
89099587|NCT02652754|Other|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
89099588|NCT02652520|Experimental|Kidney transplantation|HEMO2Life® use in organ preservation solution. Grafts removed and transplanted locally within the 6 kidney transplant centers participating in the study will be preserved with Hemo2life.
89099589|NCT02645110|Experimental|MC Hand soap|For bacterial removal trial: Hand washing with the tested soap following bacterial application
89099590|NCT02645110|Sham Comparator|Water|For bacterial removal trial: Hand washing with tap water alone following bacterial application
89099591|NCT02645188|Experimental|Experimental|Cueing
89099592|NCT02645188|No Intervention|Control|
89099593|NCT02645032|Experimental|Test group|Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).
89099594|NCT02645032|Active Comparator|Comparator group|"Biological/Vaccine:~One dose of Typhim Vi® will be administrated intramuscularly at 1st dose (Day 0).~One dose of VAXIGRIP® will be administrated intramuscularly at 2nd dose (Day 28)."
89099595|NCT02536066|No Intervention|Control|maintain usual physical activity patterns
89099596|NCT02536066|Experimental|Intervention|Addition of daily postprandial physical activity in addition to usual activity patterns
89099597|NCT02644954|Active Comparator|Metformin|Topical coal tar and topical calcipotriol + oral metformin 850mg twice daily
89099598|NCT02644954|Placebo Comparator|Placebo|Topical coal tar and topical calcipotriol
89099599|NCT02652286|Other|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
89099600|NCT00650338|Experimental|1|<described in intervention>
89099601|NCT00650338|Experimental|2|<described in intervention>
89099602|NCT00650338|Experimental|3|<described in intervention>
89099603|NCT00650338|Placebo Comparator|4|<described in intervention>
89099604|NCT00650338|Active Comparator|5|<described intervention>
89099605|NCT02644720|Experimental|multifocal intraocular lens group|
89099606|NCT02644720|Active Comparator|monofocal intraocular lens group|
89099607|NCT03542266|Experimental|CC486 +CHOP|CC486 +CHOP
89099608|NCT02648386|Sham Comparator|Laparoscopic surgery|Patients receive no interventions after rectal cancer treatment.
89099609|NCT02648386|Experimental|NeuroRegen scaffold transplantation|Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.
89099610|NCT02648386|Experimental|NeuroRegen scaffold/BMMCs transplantation|Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
89099611|NCT02648386|Experimental|NeuroRegen scaffold/HUC-MSCs transplantation|Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
89099612|NCT02641600|Active Comparator|Elastic stockings|Class 1 elastic stockings (18-21 mmHg)
89099613|NCT02641600|Placebo Comparator|Placebo stockings|Placebo stockings (0 mmHg)
89099614|NCT02644876|Experimental|Penehyclidine group|Penehyclidine inhalation will be administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
89099615|NCT02644876|Placebo Comparator|Control group|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
89099616|NCT00652600|Experimental|A|Subjects received Par formulated product under fed conditions
89099617|NCT00652600|Active Comparator|B|Subjects received Wyeth Pharmaceuticals formulated product under fed conditions
89099618|NCT02644642|Experimental|DLT(Double Lumen Tube) group|disconnection technique will be applied
89099619|NCT02644642|Experimental|BB(Bronchial Blocker) group|disconnection technique will be applied
89099620|NCT03520504|Experimental|Proton Radiation|"Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.~The first 3 patients will be enrolled at dose level 30Gy (RBE) in 3Gy(RBE) fractions. If 1 or fewer patients develop dose-limiting toxicity (DLT), 3 additional patients will be enrolled. If 1 or fewer of the 6 patients experiences a DLT, the trial will proceed to the dose expansion cohort at 30Gy (RBE) . In contrast, if 2 or more patients experience a treatment DLT, 3 patients will be enrolled at dose level 25Gy (RBE) in 2.5Gy(RBE) fractions. If 1 or fewer patients develop a DLT, an additional three patients will be enrolled. If 2 or more patients experience a DLT at 25Gy, the study will be stopped. If 1 or fewer patients develop a DLT in these 6 patients, the trial will proceed to the dose expansion cohort at 25Gy (RBE) and the 6 patients who were treated in Phase Ib will be included in full assessment of safety and efficacy."
89099621|NCT04166578||Mydrane group|Patients were randomly selected to the group receiving intracameral 0.2 ml Mydrane (a solution of 1% lidocaine and 0.025% of adrenaline ) during phacoemulsification.
89099622|NCT04166578||Reference group|Patients were randomly selected to the group receiving intracameral a combination of intracameral solution of lignocaine 1% and adrenalin 0.025% (0.2 ml) during phacoemulsification.
89099623|NCT02647996||Conscious patients|"group: TBI patients awoken from comatose state with normal level of consciousness.~intervention: fMRI (resting state) and structural (DTI)"
89099624|NCT02647996||DOC patients|"group: TBI patients awoken from comatose state with abnormal level of consciousness~intervention: fMRI (resting state) and structural (DTI)"
89099625|NCT04166734|Other|Initial safety cohort|Patients will receive an initial dose of pembrolizumab in week 1 dosed at 200 mg. They will then receive SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
89099626|NCT04166734|Other|Expansion cohort|An additional 12 patients will be recruited for this cohort. Patients will receive an initial dose of pembrolizumab at 200 mg in week 1. This will be followed in by SBRT dosed at 30 Gy in 3 fractions (#) alternate days in week 3. Treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
89099627|NCT00651352|Experimental|2 mg nicotine prototype|2 mg nicotine prototype
89099628|NCT00651352|Active Comparator|2 mg nicotine lozenge|marketed formulation
89099629|NCT00651352|Experimental|4 mg nicotine prototype|4 mg
89099630|NCT00651352|Active Comparator|4 mg nicotine lozenge|4 mg
89099631|NCT02641444||Efavirenz|Receiving efavirenz as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
89227474|NCT00494871|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
89227475|NCT00494871|Active Comparator|Warfarin|Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period
89227476|NCT00420238|Experimental|A|
89227477|NCT00420238|Placebo Comparator|B|
89227478|NCT01016925|No Intervention|Control|
89227479|NCT01016925|Experimental|femoral tunnelized perineural catheter|
89227480|NCT01020045||HIV-seropositive, HIV seronegative|No intervention - biologic samples were collected from both HIV positive and HIV negative subjects
89227481|NCT01020045||Treatment naive subjects|HIV-seropositive subjects naive to antiretroviral therapy. HIV-seronegative subjects otherwise healthy.
89227482|NCT03994432|Experimental|Intervention group|"patients with symptomatic endometriosis in therapy with estro-progestins or progestins, who will be asked to follow a mediterranean diet and to practice an aerobic physical exercise according to the 7-minutes workout model"
89227483|NCT03994432|No Intervention|Control group|patients with symptomatic endometriosis in therapy with estro-progestins or progestins.
89227484|NCT00420004|Experimental|LY2216684|"LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 3 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 3 mg/day; it could be increased 3 mg at a time (scheduled visit) to a maximum dose of 12 mg/day; or it could be decreased 3 mg at any time (scheduled or unscheduled visits) to a minimum dose of 3 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 3 mg/day and 6 mg/day of LY2216684 also received 1 LY2216684-matching placebo tablet + 2 escitalopram-matching placebo capsules. Participants on 9 mg/day and 12 mg/day of LY2216684 also received 2 escitalopram-matching placebo capsules."
89227485|NCT00420004|Placebo Comparator|Placebo|Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks.
89099632|NCT02641444||Atazanavir|Receiving atazanavir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
89099633|NCT02641444||Raltegravir|Receiving raltegravir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
89099634|NCT02641444||Maraviroc|Receiving maraviroc as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
89099635|NCT02644564||Ultrasonography|Patients will undergo structured clinical examination and ultrasonography of both shoulders on the day of inclusion. They also fill out an injury registration form, Oxford Shoulder Score and QuickDASH. Follow-up at 3, 6 and 12 months will be identical, but without ultrasonography and injury registration form.
89099636|NCT02648074|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation.
89099637|NCT02648074|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).~Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation."
89099638|NCT02641210|Experimental|Periodontal Treatment|The experimental group underwent nonsurgical periodontal therapy, performed by a single professional who performed the scaling and root planing procedures under local anesthesia using an ultrasonic device and Gracey and mini Gracey curettes, with Robson polishing brush and prophylactic paste. This therapy was performed in two sessions at seven day intervals, with no time limit, according to the needs of each periodontal condition. In each session, subjects received oral hygiene instruction (OHI) for use of toothbrushes for the modified Bass technique, dental floss and other complementary means (interdental brush, single tuft brush, electric toothbrush, etc.) when necessary. Supportive periodontal therapy was performed in 30, 60 and 90 days. Albendazole administration.
89099639|NCT02641210|No Intervention|No Periodontal Treatment|Individuals in the control group underwent only the polishing of tooth surfaces with Robson brush and prophylactic paste fine-grained and topical fluoride application. After 90 days, they were reassessed with the same parameters of clinical examination of the baseline.
89111167|NCT02792985|Active Comparator|Control protocol|The Control group will follow the current protocol for patients in PTA at the Institut Guttmann.
89099640|NCT02641366||Tremor kinetics after DBS|This group have already undergone Deep Brain Stimulation (DBS) placement and will have measurements of tremor kinetics by using the electromagnetic tracking. The electromagnetic sensors will be placed on the arm and hand while the routine outpatient neurologic examinations are being performed. The testing will be performed with the DBS system in both the on and off settings.
89099641|NCT02641366||Tremor kinetics before and after DBS|This group will have measurements of tremor kinetics by using electromagnetic tracking prior to being scheduled to undergo Deep Brain Stimulation (DBS) placement. A total of two testing sessions will be performed: the first session will be performed during the routine preoperative visit, the second session will be performed during the routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
89099642|NCT02644330|Active Comparator|surgical group|The patients in Group A (surgical group) underwent surgical repair with cardiopulmonary bypass
89099643|NCT02644330|Experimental|closure group|The patients in Group B (closure group) underwent minimally invasive transthoracic device closure.
89099644|NCT02644408|Experimental|Megestrol and chemoradiotherapy|"Megestrol（Yining）：160mg/d，po,5 weeks in total，oen week before chemoradiotherapy and one week after chemoradiotherapy.~chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w."
89099645|NCT02644408|Active Comparator|chemoradiotherapy|chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.
89099646|NCT02644486|Experimental|A Group|
89099647|NCT02644486|Experimental|B Group|
89099648|NCT02644486|Active Comparator|C Group|
89099649|NCT00652756|Experimental|1|Patient is placed on a transport ventilator.
89099650|NCT00652756|Other|2|Patient is ventilated using the current standard at this institution.
89099651|NCT00827359|Experimental|Treatment|This is a single-arm study. All patients will receive everolimus.
89099652|NCT02641288|Experimental|Ropivacaine irrigation|Using a standard irrigation device, 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
89099653|NCT02641288|Placebo Comparator|Normal saline irrigation|Using a standard irrigation device, 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
89099654|NCT04165174|Experimental|PAS|PD-1:240mg,ivdrip,Q3W,begin with SBRT Apatinib:250mg,po,QD,begin with SBRT SBRT:6-10Gy/F,5-8F
89099655|NCT02613247|Experimental|Immediate-start group|Hylan G-F 20 6 mL intra-articular knee injection
89099656|NCT02613247|Other|Delayed-start group|Washout control group which then becomes an experimental group (Hylan G-F 20 6 mL intra-articular knee injection) at 6 weeks post-enrolment
89099657|NCT02641132|Experimental|Pterygium surgery: Head and body.|Application of Mitomycin C 0.02% after excision of the body and the head of the pterygium.
89111168|NCT02789631||chronic neck pain|experiencing neck pain for at least 3 months in the last year
89099658|NCT02641132|Active Comparator|Pterygium surgery: Body.|Application of Mitomycin C 0.02% after excision of the body only of the pterygium.
89099659|NCT02647840|Other|Voice therapy|All participants will receive voice therapy based on the Estill model. This is very similar to our usual intervention.
89099660|NCT00653614|Experimental|Arm 1|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for one day and placebo for three days in a 28 day cycle
89099661|NCT00653614|Experimental|Arm 2|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for two days and placebo for two days in a 28 day cycle
89099662|NCT00653614|Experimental|Arm 3|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, and placebo for days 25-28 in a 28 day cycle
89099663|NCT00653614|Experimental|Arm 4|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 1 (SHT04984F) for one day in a 28 day cycle
89099664|NCT00653614|Experimental|Arm 5|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891) dose 5 (80458712) for days 17-24, and placebo for 4 days in a 28 day cycle
89099665|NCT00653614|Experimental|Arm 6|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891)dose 5 (80458712) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 2 (80458690) for one day in a 28 day cycle
89099666|NCT02647762|Experimental|CF101 1mg|CF101 1mg, orally q12 hours
89099667|NCT02647762|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
89099668|NCT02647762|Active Comparator|MTX once weekly|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter.
89099669|NCT02647762|Placebo Comparator|Placebo|Placebo control , orally q12 hours
89099670|NCT02644252|Experimental|Performance status 0-1, Arm A|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.
89099671|NCT02644252|Experimental|Performance status 0-1, Arm B|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.
89099672|NCT02644252|Experimental|Performance status 2, Arm A|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression
89099673|NCT02644252|Experimental|Performance status 2, Arm B|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression
89099674|NCT00818389|Active Comparator|1|Participants randomized to lithium/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
89099675|NCT00818389|Placebo Comparator|2|Participants randomized to placebo/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
89099676|NCT02640976|Active Comparator|Poor responders|"This group will include women who underwent IVF/ICSI cycle and produced 4 oocytes or less.~intervention:~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (300 IU).~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.~Finally, when at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
89099677|NCT02640976|Active Comparator|Good responders|"This group will include women who produced (5 or more oocytes) after COH.~Intervention:~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (225 IU) for participants with AMH levels > 1.5 ng/ml and/or FSH levels ≤ 8 mIU/ml~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.~When at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
89099678|NCT04166344|Experimental|Intervention Group|Participants in the IG will be given free access to the HappyAir platform during a 6-month period. This platform combines online/offline content to help patients with chronic respiratory diseases monitor their symptoms and improve self-management. In addition to tailored information on their condition, participants will be encouraged to fill in daily data on their physical activity levels, symptomatology, use of rescue medication and mood. In children under 12 years, parents or caregivers will fill in this information. Patients will be asked to record their peak expiratory flow using an electronic peak flow meter twice daily and to fulfil the Asthma Control Questionnaire once a week. They will also have a device connected to their inhaler to record adherence to the medical treatment and will get daily reminders in their smartphones. Every patient will be assigned a respiratory coach who will monitor patient during the study and whom the patients can contact at any time.
89099679|NCT04166344|No Intervention|Control Group|Subjects in the CG will receive standard care consisting of periodic visitations at the Allergology or Paediatric Pulmonology Unit in their respective hospitals every 4 - 8 weeks according to their physician's criteria. In addition, patients and caregivers in both groups will receive one educational session regarding the correct use of their inhalers.
89099680|NCT04116463|Experimental|CDSMP|Chronic Disease Self-Management Program (CDSMP) - a 6-week, group-based behavioral intervention delivered in a 2.5 hour session each week by a trained facilitator.
89099681|NCT04116463|Active Comparator|Financial Self-Management|Financial self-management course delivered in 3 modules, with a delivery time of approximately 1 hour per module.
89099682|NCT02644018|Experimental|Ingavirin|Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
89111169|NCT02789631||without neck pain (asymptomatic)|no history of neck pain
89111170|NCT02789709||Non metastatic colon cancer patients|Consecutive patients undergoing elective surgery for non-metastatic colon or rectal cancer with curative intent.
89111171|NCT02789787||Maxillary protraction|Early adolescents (11 - 14 yrs) with cleft lip and palate and Cl III malocclusion
89099683|NCT02644018|Placebo Comparator|Placebo|Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
89099684|NCT02647684|Experimental|Self- Direced Triple P|Self-directed Triple P workbook to be completed over 10 weeks. Over the course of the workbook parents will think about the changes they would like to make to their child's behaviour. They are taught strategies to enhance their relationship with their child, and promote desirable behaviours. They learn about options for managing problem behaviours and have the opportunity to decide if they would like to use any of these approaches with their child in a clear and consistent way. Parents have practice period to use the approaches they have learnt in weeks 1-3. By the end of week 6 they will have had practice in using their chosen positive parenting approaches, learnt to set goals and monitor their own behaviour when using these strategies. The final weeks aim to help parents identify times when the strategies may not be working and provide survival tips on what to do at these times.
89099685|NCT00850135|Other|Continuous Glucose Monitor in pregnancy|The Seven Continuous Glucose Monitoring System: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
89099686|NCT02647918|Experimental|Group 1|Subjects with normal renal function
89099687|NCT02647918|Experimental|Group 2|Subjects with mild renal impairment
89099688|NCT02647918|Experimental|Group 3|Subjects with moderate renal impairment
89099689|NCT02647918|Experimental|Group 4|Subjects with severe renal impairment
89099690|NCT02647918|Experimental|Group 5|Subjects with ESRD requiring HD
89099691|NCT00651430||A|
89099692|NCT02647450||GIANT Clinic Group|Patients are required to have been refereed to the GI and Nutrition team Clinic at the Royal Marsden Hospital. In the clinic they will be assessed for their symptoms using the Gastrointestinal Symptom Rating Scale (GSRS).
89099693|NCT02640898|Active Comparator|FU-based chemoradiotherapy|patients will be treated with the INT0116 regimen.
89099694|NCT02640898|Experimental|docetaxel-based chemoradiotherapy|patients will be treated with modified DCF chemotherapy in combination with docetaxel-based chemoradiotherapy.
89099695|NCT02647606|Experimental|McGrath Group|MgGrath videolaryngoscope will be used for nasotracheal intubation with MILS
89099696|NCT02647606|Experimental|Pentax-AWS Group|Pentax-AWS videolaryngoscope will be used for nasotracheal intubation with MILS
89099697|NCT02647606|Experimental|Macintosh Laryngoscope Group|Macintosh Laryngoscope will be used for nasotracheal intubation with MILS
89099698|NCT02535910|Experimental|breakfast rich in vitamin D3|subjects are asked to consume a breakfast with (20µg) vitamin D3 fortified milk and butter
89099699|NCT02535910|Experimental|breakfast rich in 25(OH) D3|subjects are asked to consume a breakfast with (20µg) 25(OH) D3 fortified milk and butter
89099700|NCT02535910|Placebo Comparator|Control|subjects are asked to consume a normal milk and butter (no vitamin D is added) in the breakfast
89099701|NCT01154816|Experimental|Arm I (neuroblastoma- measurable)|Patients with measurable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099702|NCT01154816|Experimental|Arm II (Neuroblastoma- MIBG evaluable)|Patients MIBG evaluable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099703|NCT01154816|Experimental|Arm III (rhabdomyosarcoma)|Patients with rhabdomyosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099704|NCT01154816|Experimental|Arm IV (osteosarcoma)|Patients with osteosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099705|NCT01154816|Experimental|Arm V (Ewing sarcoma/peripheral PNET)|Patients with Ewing sarcoma/peripheral PNET receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099706|NCT01154816|Experimental|Arm VI (non-RMS soft tissue sarcoma)|Patients with non-RMS soft tissue sarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89111172|NCT02789787||Orthognathic surgery|Late adolescents to young adults (16-21 years) with cleft lip and palate and Cl III malocclusion
89099707|NCT01154816|Experimental|Arm VII (hepatoblastoma)|Patients hepatoblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099708|NCT01154816|Experimental|Arm VIII (malignant germ cell tumor)|Patients with malignant germ cell tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099709|NCT01154816|Experimental|Arm IX (Wilms tumor)|Patients with Wilms tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099710|NCT01154816|Experimental|Arm X (acute lymphoblastic leukemia)|Patients with acute lymphoblastic leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099711|NCT01154816|Experimental|Arm XI (acute myelogenous leukemia)|Patients acute myelogenous leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099712|NCT01154816|Experimental|Arm XII (rhabdoid malignancy)|Patients with rhabdoid malignancy receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89099713|NCT03057808|Experimental|Gestational weight gain intervention (GWG-only)|The GWG intervention will begin upon randomization to the GWG-only or the GWG+PPWL arm, and continue until the birth of the participant's child.
89099714|NCT03057808|Experimental|Postpartum weight loss intervention (PPWL-only)|The PPWL intervention will begin at 6-weeks postpartum (when most women will be approved for weight loss and exercise by their obstetrician) for those participants randomized to the PPWL only or the GWG+PPWL arms, and will continue until 6-months postpartum.
89099715|NCT03057808|Experimental|Combined|During the gestational phase participants will receive the same intervention as the GWG only group. During the postpartum phase participants will receive the the same intervention as the PPWL group.
89099716|NCT00849901|Placebo Comparator|Placebo|
89099717|NCT00849901|Active Comparator|Fluoxetine|
89099718|NCT00849901|Experimental|Duloxetine|
89099719|NCT04313660|Experimental|Anlotinib In Combination With PD-1/L1 Inhibitor|
89099720|NCT02641054|Experimental|CVXL-0107 then cross-over to placebo|"Study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa.~Cross-over to placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa"
89099721|NCT02641054|Placebo Comparator|Placebo then cross-over to CVXL-0107|"Placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa.~Cross-over to study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa"
89099722|NCT02643784|Experimental|Rosuvastatin|Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).
89099723|NCT02643784|No Intervention|Control|Control group(don't take rosuvastatin until 14th day), as directed by the study physician.
89099724|NCT00707317||1|HIV infected individuals
89099725|NCT00707317||2|patients with chronic renal failure
89099726|NCT00707317||3|patients after solid organ transplantation (lung, liver, kidney, kidney-pancreas)
89099727|NCT00707317||4|patients with rheumatoid arthritis
89099728|NCT00707317||5|stem cell transplant recipients
89099729|NCT00707317||6|immunocompromised patients with confirmed tuberculosis
89099730|NCT00707317||7|immunocompetent controls with no known risk of exposure or tuberculosis
89099731|NCT04166890|Experimental|NS Lower right molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
89099732|NCT04166890|Active Comparator|SD Lower Left molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
89099733|NCT04166890|Experimental|NS Lower left molar|IANB Artheek SP Articaine EPINEPHrine Cartridge 4% 1:100000
89099734|NCT04166890|Active Comparator|SD Lower right molar|IANB Septanest Articaine EPINEPHrine Cartridge 4% 1:100000
89099735|NCT02610907|Experimental|Cohort 01a|"This is a sub-study testing three patches consisting of an adhesive patch and a sleeve. The sleeve can contain one of three solutions:~Buffer Own output Simulated output (digestive enzymes)~All subjects will test the three solutions at the same time, hence the three patches with different solutions will be placed on the peristomal skin simultanously."
89099736|NCT02640820|Experimental|Sensitization Phase|Up to two doses of Sensitizing DPCP Ointment will be applied and subjects who exhibit a sensitization response will enter the Treatment Phase. Pharmacokinetics (PK) of Sensitizing DPCP Ointment will be measured in a subset of subjects. For PK, blood will be collected prior to application of the Sensitizing DPCP Ointment and again at 1, 2, and 24 hours after application.
89099737|NCT02640820|Experimental|Treatment Phase|In the Treatment Phase, subjects will receive doses of Treatment DPCP Ointment weekly for 10 weeks. Subjects who at the end of the Treatment Phase have exhibited partial clearance of warts may be given the option to continue with an additional 10 weekly treatments.
89099738|NCT02610985|Active Comparator|2-Dimensional laparoscopic hysterectomy|traditional 2-D laparoscopy
89099739|NCT02610985|Experimental|3-Dimensional laparoscopic hysterectomy|experimental 3-D laparoscopy
89099740|NCT00652912|Experimental|A|Subjects received the Kali formulated products under fasting conditions
89099741|NCT00652912|Active Comparator|B|Subjects received the Roche's product under fasting conditions
89099742|NCT01168232|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89099743|NCT02643706||CIN|CIN was defined as an absolute increase in serum creatinine concentration of at least 0.5 mg/dL (44.2umol/l) or a relative rise of at least 25% from baseline on the follow-up blood sample drawn 24 to 72 hours after the operation.
89099744|NCT02643706||Control|The enrolled patients without CIN.
89099745|NCT02647528|Experimental|Treatment|Patients in this arm receive treatment
89099746|NCT02647528|Placebo Comparator|Placebo|Patients in this arm do not receive treatment
89099747|NCT02640430|Active Comparator|standard treatment|"Control group will be made of 20 COPD patients with severe and very severe airflow obstruction, mucus hypersecretion and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.~Control group will b treated with PEP-bottle over 10 daily sessions (20 minutes twice a day). Patients are asked to breath against a positive expiratory pressure determined by a column of water in a bottle (PEP Bolltle). PEP is one of the validated treatment used in the clearance of bronchial secretions in COPD patients.~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
89099748|NCT02640430|Experimental|Free Aspire|"Experimental group will be made of 20 COPD patients with severe and very severe airflow obstruction , mucus hypersecretion , and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.~Patients are asked to use FREE ASPIRE Free Aspire is an electro-medical device which removes bronchopulmonary secretions noninvasively, without using a suction catheter and without generating airway pressure, positive or negative.~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
89099749|NCT00817531|Experimental|All subjects take open label Dasatinib|Dasatinib / Sprycel 100 mg
89099750|NCT00651586|Experimental|1|Gatifloxacin 0.3% ophthalmic solution
89099751|NCT00651586|Active Comparator|2|Ciprofloxacin 0.3% ophthalmic solution
89099752|NCT00653692||Observational|Poly drug dependent women
89099753|NCT02640508|Experimental|Combination Eribulin and lenvatinib|Eribulin will be given on days 1 and 8. Lenvatinib will be given daily in each 28 day cycle.
89099754|NCT05312606|Experimental|Trial Group|Home treatment with hyaluronic acid.
89099755|NCT05312606|Active Comparator|Control Group|Home treatment with chlorhexidine.
89099756|NCT02647372|Experimental|Endocrinological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be endocrinological evaluation including metabolic measures, calorimetric parameters.
89099757|NCT02647372|Experimental|Neurological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be neurological evaluation including UPDRS scale.
89099758|NCT02643550|Experimental|Dose escalation|Dose escalation of monalizumab in combination with cetuximab
89099759|NCT02643550|Experimental|Expansion cohort 1|monalizumab + cetuximab expansion cohort
89099760|NCT02643550|Experimental|Expansion cohort 2|monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers
89099761|NCT02643550|Experimental|Expansion cohort 3|monalizumab + cetuximab + anti-PD(L)1
89099762|NCT00817063|Experimental|Alitretinoin|Patients will receive alitretinoin 30mg capsule for up to 24 weeks
89099763|NCT00817063|Experimental|Placebo|Patients will receive placebo 30mg capsule for up to 24 weeks
89099764|NCT02640352|Active Comparator|Probi Defendum|Dietary supplement (tablet) with probiotics
89099765|NCT02640352|Placebo Comparator|Placebo|Dietary supplement (tablet) without probiotics
89111173|NCT03935607||Normal amniotic fluid index|Patients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography.
89099766|NCT04166188|Experimental|Cadavers|"20ml of 0.01% methylene blue solution (50mg of methylene blue diluted in 0.9% saline 500ml) will be injected, simulating the LESP block technique: injection between the transverse process of the fourth lumbar vertebra (L4) and the erector muscle of the underlying spine.~The injection will be performed with a Quincke 20G 100-150mm ultrasound-guided needle with a low-frequency curvilinear transducer (4-8 MHz - SonoSite) in the plane between the transverse process of L4 and the spinal erector muscle, bilaterally in each cadaver. by the same operator.~After injection of the solution the cadavers will be submitted to posterior lumbar region dissection by an anatomist and analyzed the dispersion and impregnation of the blue solution. The anatomical structures with the dye dispersion will be photographed and stored."
89099767|NCT04165876|Active Comparator|Primary motor cortex|
89099768|NCT04165876|Active Comparator|Dorsolateral prefrontal cortex|
89099769|NCT04165876|Active Comparator|Multi-modal stimulation (DLPFC+M1)|
89099770|NCT04165876|Sham Comparator|Sham-stimulation|
89099771|NCT01166750|Experimental|CD-ROM-treatment|
89099772|NCT01166750|Active Comparator|Wait-list Control Group|
89099773|NCT02640196|Placebo Comparator|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
89099774|NCT02640196|Placebo Comparator|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope laryngoscope followed with intubating the difficult airway simulator
89099775|NCT02640196|Active Comparator|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq laryngoscope followed with intubating the difficult airway simulator
89099776|NCT02640196|Active Comparator|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
89099777|NCT02640274|Experimental|Intervention group|The intervention is an individual nurse-led counselling programme in addition to usual care.
89099778|NCT02640274|Other|Control group|usual care
89099779|NCT04313270||Patients with FH starting a treatment with Evolocumab®|
89099780|NCT02640118|Active Comparator|Pancreatectomised + Lixisenatide|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously"
89099781|NCT02640118|Placebo Comparator|Pancreatectomized + lixisenatide-placebo|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously."
89099782|NCT02640118|Active Comparator|Healthy + Lixisenatide|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously"
89099783|NCT02640118|Placebo Comparator|Healthy + lixisenatide-placebo|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously"
89099784|NCT00624884||A|Patients with moderate-to-severe aortic regurgitation having normal left ventricular ejection fraction
89099785|NCT00624884||B|Age, sex and bodymass index matched healthy subjects
89099786|NCT02643316|Active Comparator|Same day 4 L preparation of PEG|Receive 1 gallon (4 L) of Polyethylene Glycol (PEG) preparation on the morning of the colonoscopy.
89099787|NCT02643316|Active Comparator|Split dose 4 L preparation of of the PEG|Receive the split-dose regimen. Will take half (2 L) of the PEG preparation the evening before colonoscopy and half (2 L) of the PEG preparation on the morning of the procedure.
89099788|NCT02647138|Experimental|White Noise|Subject will have white noise machine placed in room.
89099789|NCT02647216|Active Comparator|Mindfulness Based Cognitive Therapy (MBCT)|MBCT is a structured 8-week group intervention which integrates aspects of cognitive behavioral therapy (CBT) with components of the Mindfulness Based Stress Reduction (MBSR) program.
89099790|NCT02647216|Active Comparator|Treatment as Usual (TAU)|Subjects randomized to TAU will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study (for the TAU group) and outside of the study (for the MBCT group) will be assessed at the 3-month follow up (Visit 3).
89099791|NCT02647060||idiopathic pulmonary hypertension|"diagnose as idiopathic pulmonary arterial hypertension~clinical stable over 3 months~able to walk and can do bicycle cardiopulmonary exercise testing"
89111174|NCT03935607||Oligohydramnios|Patients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography.
89099792|NCT02647060||secondary pulmonary hypertension|"diagnose as pulmonary hypertension~clinical stable over 3 months~able to walk and can do bicycle cardiopulmonary exercise testing"
89099793|NCT00653770|Experimental|1|FP85A at day 0
89099794|NCT00653770|Experimental|2|MVA85A at day 0 and FP85A at day 28
89099795|NCT00653770|Experimental|3|FP85A at day 0 and MVA85A at day 28
89099796|NCT00910936|Experimental|Intervention|
89099797|NCT00910936|No Intervention|Control|
89099798|NCT02640040|Experimental|combined surgery|combined surgery for enrolled patients with CPT(Congenital Pseudarthrosis of Tibia): sleeve resection of the pathological soft tissues, intramedullary rod fixation, packaged lilac bone autograft,and llizarov external fixation device installation.
89099799|NCT02643160|Experimental|Functional Trunk Training Group|Functional Trunk Training which includes strengthening of trunk muscle and functional activities including trunk region.
89099800|NCT02643160|No Intervention|Control Group|No intervention, the continued their regular physical therapy
89099801|NCT00826267|Experimental|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
89099802|NCT00826267|Active Comparator|Lapatinib|Lapatinib tablets 1500 mg daily.
89099803|NCT00826267|Active Comparator|Trastuzumab|Trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly.
89099804|NCT02639962||NSTEMI|patients hospitalized with NSTEMI diagnosed according to the national Danish guidelines, and are scheduled to coronary angiography.
89099805|NCT02639962||patients with stable angina pectoris|Patients in this group have stable angina symptoms and had verified plaques by earlier CAG or Cardiac CT
89099806|NCT00653848|Experimental|Docetaxel arm|six of docetaxel every third week + hormonal treatment
89099807|NCT00653848|No Intervention|Control|hormonal treatment only
89099808|NCT00707551|Experimental|1|Ketoconazole tablet + AZD1305 Extended Release tablet
89099809|NCT00707551|Experimental|2|Verapamil Extended Release tablet + AZD1305 Extended Release tablet
89099810|NCT00707551|Experimental|3|AZD1305 Extended Release tablet
89099811|NCT02535754|Experimental|ALIVE|Email program N=170
89099812|NCT02535754|Experimental|CCS BCY|Comprehensive program N=285
89099813|NCT02535754|Experimental|ALIVE + CCS BCY|Email + comprehensive program N=225
89099814|NCT00707629||Insulin Pump Therapy|Children on insulin pumps for at least three years. Subjects must have type 1 diabetes for at least five years and diagnosed under the age of 5.
89099815|NCT02642926|Active Comparator|Monopolar endoscopic endometrial ablation|
89099816|NCT02642926|Experimental|Bipolar endoscopic endometrial ablation|
89099817|NCT00986154|Experimental|heparin/edoxaban tosylate|
89099818|NCT00986154|Active Comparator|heparin/warfarin|
89099819|NCT02611375|Experimental|tDCS + FTP group|This group of individuals with tetraplegia will receive transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1). Stimulation at 2mA will be applied for 20 minutes while subjects complete a total of 1 hour of functional task practice (FTP) per session. (Only 20 minutes of functional task practice be be performed with stimulation on). 3 sessions will be completed per week for 4 weeks.
89099820|NCT02611375|Active Comparator|PNSS + FTP group|This group of individuals with tetraplegia will receive peripheral nerve somatosensory stimulation (PNSS) to the median nerve of the primary hand being trained. Stimulation will be set to elicit a sensory - not motor - response. Stimulation will be performed concurrently with the entire functional task practice (FTP) session. 3 sessions will be completed per week for 4 weeks.
89111175|NCT02792751|Active Comparator|Group R (Ramsey)=25 patients|Propofol infusion was administered to provide Ramsey Sedation Scale 3-4 in Group R
89111176|NCT02792751|Experimental|Group B (BIS)=25 patients|Propofol infusion was given to maintain the Bispectral index monitorisation (BIS) levels between 60 and 85 in Group B.
89111177|NCT02690025|Experimental|ZP1848 High dose|s.c. administration of high dose
89099821|NCT02611375|Active Comparator|sham tDCS + FTP group|This group of individuals with tetraplegia will receive sham transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1) alongside functional task practice. Stimulation will be briefly turned on at the beginning of FTP and again after 20 minutes of practice in order to create a sham effect and maintain blinding of the participants. 3 sessions will be completed per week for 4 weeks.
89099822|NCT00653926|Active Comparator|A|Group A (Active) receives a multimodal injection intra- and postoperatively
89099823|NCT00653926|Placebo Comparator|P|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
89099824|NCT02613091|Experimental|Clemastine|This group will receive 8mg of clemastine daily.
89099825|NCT00653146|Experimental|Mindfulness-based stress reduction|The MBSR program includes meditation techniques, body scan, awareness of breathing, mindful yoga, eating meditation, and walking meditation, and meets for 2 hours, once weekly for 8 weeks.
89099826|NCT00653146|Placebo Comparator|Healthy Lifestyles Program|The Healthy Lifestyles Program includes information on nutrition and physical activity, and meets for 2 hours, once weekly for 8 weeks.
89099827|NCT02642848|Active Comparator|HTO with micro fracture|High tibial osteotomy(HTO) with micro fracture is an common treatment for the correction of malalignment of the knee treating osteoarthritis.
89099828|NCT02642848|Experimental|HTO with bone marrow stem cell|High tibial osteotomy(HTO) with transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone.
89099829|NCT02642848|Experimental|HTO with adipose derived stem cell|High tibial osteotomy(HTO) with autologous adipose-derived stromal vascular fraction transplantation using LipoSculptor collecting from abdominal fat tissue.
89099830|NCT02646904|Experimental|Beclometasone Dipropionate (BDP)|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of Nasal Beclomethasone Dipropionate for 21 days.
89099831|NCT02646904|Active Comparator|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
89099832|NCT00848965|Placebo Comparator|Placebo|
89099833|NCT00848965|Experimental|Fluticasone propionate 25ug|
89099834|NCT00848965|Experimental|Fluticason propionate 50ug|
89099835|NCT00848965|Experimental|Fluticasone propionate 100ug|
89099836|NCT00848965|Experimental|Flutciasone propionate 200ug|
89099837|NCT00654082|Active Comparator|Arm 1|
89099838|NCT00654082|Placebo Comparator|Arm 2|
89099839|NCT02639416|Active Comparator|Standard management|Standard management consists of F-100 and/or ready-to-use therapeutic food (RUTF) according to usual practice for 14 days
89099840|NCT02639416|Experimental|Polymeric formula|Exclusive polymeric formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
89099841|NCT02639416|Experimental|Elemental formula|Exclusive elemental formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
89099842|NCT02639572|Experimental|Siloss® bone graft|Based on the sequence, in the test site,Siloss® was placed.
89099843|NCT02639572|Placebo Comparator|Hydroxyapatitie Bone graf|Based on the sequence, the control site which was treated by Hydroxyapatite graft only.
89099844|NCT02639104|Experimental|Cervical postural related neck pain|Patients recruit in this group who has a neck pain without radiculopathy. If the patient examination shows neurologic deficits, this patient will exclude in this study. All patients will undergo lateral cervical spine spot radiography and serratus anterior needle electromyography. Cervical segmental angle measurements will be done in all patients.
89099845|NCT02639104|Sham Comparator|Control group|The healthy volunteers recruit in this group. All inviduals will undergo lateral cervical spot radiography and serratus anterior needle electromypography
89099846|NCT02642380|Experimental|4 cycles|Oral administration of dexamethasone 40 mg for four consecutive days every 14 days for 4 courses
89099847|NCT02642380|Active Comparator|1 cycle|Oral administration of dexamethasone 40 mg for four consecutive days
89099848|NCT02642692|Experimental|Patellar Tendon Graft|Kind of graft that will be used for acl reconstruction
89099849|NCT02642692|Experimental|Hamstring Graft|Kind of graft that will be used for acl reconstruction
89099850|NCT02642302|Experimental|HIIT With 60 sec Rest|The experimental (1) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 60 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
89099851|NCT02642302|Experimental|HIIT With 120 sec Rest|The experimental (2) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 120 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
89099852|NCT02642302|Active Comparator|Control|Continuous exercise at 50-55% of VO2max with similar total work
89099853|NCT01154036|Experimental|Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg|Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks
89099854|NCT01154036|Active Comparator|Phase I: Atorvastatin 20 mg|Atorvastatin 20 mg tablet once daily for 6 weeks
89099855|NCT01154036|Active Comparator|Phase I: Rosuvastatin 10 mg|Rosuvastatin 10 mg tablet once daily for 6 weeks
89099856|NCT01154036|Experimental|Phase II: EZ 10mg+Atorva 10mg|Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I
89099857|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [A]|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
89099858|NCT01154036|Active Comparator|Phase II: Atorva 40mg|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II
89099859|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [R]|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
89099860|NCT01154036|Active Comparator|Phase II: Rosuvastatin 20mg|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase
89099861|NCT02642458||trastuzumab plus chemotherapy|Treatment with trastuzumab plus chemotherapie as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
89099862|NCT02642458||pertuzumab plus trastuzumab plus chemotherapy|Treatment with with pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
89099863|NCT00816595|Experimental|Arm A: Pentostatin, Cyclophosphamide, Rituximab, and Avastin|Patients receive 15 mg/kg bevacizumab IV over 30-90 minutes on day 1 of courses 1-5 and on days 1, 22, and 43 of course 6; 375 mg/m^2 rituximab IV over 2-4 hours on days 2 and 3 of course 1 and on day 1 of courses 2-6; and 2 mg/m^3 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 2 of course 1 and on day 1 of courses 2-6. Patients also receive 6 mg pegfilgrastim subcutaneously (SC) on day 3 of course 1 and on day 2 of courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89099864|NCT00816595|Experimental|Arm B: Pentostatin, Cyclophosphamide, and Rituximab|Patients receive 100 mg rituximab IV over 2-4 hours on day 1 and 375 mg/m^2 on day 2 of course 1 and 375 mg/m^2 on day 1 of courses 2-6. They receive 2 mg/m^2 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1. Patients also receive 6 mg pegfilgrastim SC on day 2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89099865|NCT02886026|Active Comparator|Inpatient TUR-BT|Transurethral bladder tumor resection in operating theatre as inpatient.
89099866|NCT02886026|Experimental|laser bladder tumor destruction|Outpatient laser mediated destruction of bladder tumors (LMD-BT)
89099867|NCT00922909|Active Comparator|2|Day 1 : morning : Medication on ; Stimulation : off afternoon : Medication : on ; Stimulation : on Day 2 : morning : Medication : off ; Stimulation : off afternoon : medication : off ; stimulation : on
89099868|NCT00922909|Active Comparator|3|Day 1 : morning : Medication off ; Stimulation : on afternoon : Medication : off ; Stimulation : off Day 2 : morning : Medication : on ; Stimulation : on afternoon : medication : on ; stimulation : off
89099869|NCT00922909|Active Comparator|4|Day 1 : morning : Medication off ; Stimulation : off afternoon : Medication : off ; Stimulation : on Day 2 : morning : Medication : on ; Stimulation : off afternoon : medication : on ; stimulation : on
89099870|NCT00922909|Active Comparator|1|Day 1 : morning : Medication on ; Stimulation on afternoon : Medication on ; Stimulation off Day 2 : morning : Medication off ; Stimulation on afternoon : Medication off ; Stimulation off
89099871|NCT01166438|Experimental|Botox A|A single intradetrusor injection of 100U botulinum toxin A (Botox A®) plus daily oral placebo tablets
89111178|NCT02690025|Experimental|ZP1848 Medium dose|s.c. administration of medium dose
89111179|NCT02690025|Experimental|ZP1848 Low dose|s.c. administration of low dose
89111180|NCT02792907|Experimental|Compressive Stockings group|Patients with compressive stockings at the operated foot for 4 weeks
89111181|NCT02792907|No Intervention|No compressive stockings group|Patients with no compressive stockings at the operated foot
89099872|NCT01166438|Active Comparator|Standardized Anticholinergic Regimen|A standardized 3-step anticholinergic regimen of daily oral solifenacin 5mg, solifenacin 10mg, and/or trospium chloride XR 60mg, as well as a single intradetrusor injection of saline (placebo). All subjects will begin on solifenacin 5 mg for 2 mo. If a subject's symptoms are not adequately controlled at 2 mo, she will be escalated to solifenacin 10mg, and similarly at 4 mo to trospium XR 60mg. If a subject's symptoms are adequately controlled on solifenacin 5 mg, she may continue that study medication for the entirety of the study (6 mo). Additionally, if a subject is dose-escalated to solifenacin 10mg at study mo 2 or 4, and her symptoms are adequately controlled, she may continue the solifenacin 10mg dose for the remainder of the study.
89099873|NCT00707707|Experimental|1|paclitaxel + AZD2281
89099874|NCT02611297|Other|Transbronchial lung biopsy with cryoprobe|
89099875|NCT01153958|Experimental|Colposeptine (A)|
89099876|NCT01153958|Active Comparator|Metronidazole (B)|
89099877|NCT00707785|Experimental|1|Sepsis - vitamin A
89099878|NCT00707785|Placebo Comparator|2|Sepsis - placebo
89099879|NCT00707785|Experimental|3|NEC - vitamin A
89099880|NCT00707785|Placebo Comparator|4|NEC - Placebo
89099881|NCT00599638|Active Comparator|1|
89099882|NCT00599638|Experimental|2|
89099883|NCT00599638|Placebo Comparator|3|
89099884|NCT00654316|Experimental|1|BCG delivered intradermally into the deltoid region in volunteers who have received BCG 10 - 20 years previously.
89099885|NCT04165252||Term Birth|Delivery between 37-41 weeks of gestation
89099886|NCT04165252||Preterm birth|Delivery between 24-37 weeks of gestation
89099887|NCT02646514|Experimental|RFA with RF catheter (ELRA®) with stenting|
89099888|NCT02646514|Active Comparator|stenting|
89099889|NCT00654394|Experimental|1|
89099890|NCT00911014||Vesicovaginal fistula repair|Women undergoing repair of vesicovaginal fistula
89099891|NCT00653302|Experimental|1|Lantus once a day plus Glucophage 1000mg, twice a day per os
89099892|NCT02641990|Experimental|Group 1|ITCA 650 20/60 mcg/day, ITCA placebo
89099893|NCT02641990|Experimental|Group 2|ITCA placebo, ITCA 650 20/60 mcg/day
89099894|NCT00653380|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
89099895|NCT00653380|Active Comparator|B|Subjects received Oclassen's product (Monodox) under fasting conditions.
89099896|NCT00651898||A|This group will receive the circulating water garment
89099897|NCT00651898||B|This group will receive the circulating water mattress and be covered by a forced air warming device for both the upper body and lower body connected to two warmers.
89099898|NCT02646592|Experimental|alfentanil|"Children under general anesthesia for elective surgery. Induction with sevoflurane or propofol according to the preference of the patient.~Maintenance with sevoflurane. 5 minutes before skin incision, first assessment of the pupillary pain index. Then injection of 10 µg/kg of alfentanil. After 5 minutes second assessment of pupillary pain index. End of study period, beginning of surgery."
89099899|NCT02646670|Active Comparator|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml . This group will be five about patients about any age, with diabetic macular edema randomly chosen
89099900|NCT02646670|Active Comparator|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml. This group will be about five patients about any age, with diabetic macular edema randomly chosen
89099901|NCT02646670|Active Comparator|Ranibizumab and Aflibercept|- In this group will be held two applications of 0.1 ml Aflibercept(the first and the third doses) interspersed with one application of Ranibizumab 0.1 ml(the second dose). This group will be about five patients about any age, with diabetic macular edema randomly chosen
89099902|NCT02646670|Active Comparator|Aflibercept and Ranibizumab|- This group will be held two applications of Ranibizumab 0.1 ml(the first and the third doses) interspersed with one application of Aflibercept 0.1 ml(the second dose). This group will be five about patients about any age, with diabetic macular edema randomly chosen
89099903|NCT00654472||A|Mitral valve area above 1.5 cm2
89099904|NCT00654472||B|Mitral valve area 1.5 cm2 and below 1.5 cm2
89099905|NCT00651976|Experimental|treatment|
89099906|NCT02638792|Experimental|Internet-based exposure therapy|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
89099907|NCT02638792|Active Comparator|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
89099908|NCT02638792|No Intervention|Waitlist|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, and 4, 12 months later using the same questionnaires as the treatment group. The participants will be able to choose which treatment they receive i.e. no randomization.
89099909|NCT02638636|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
89099910|NCT02638636|No Intervention|Waitlist|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment when the first group has finished (i.e. week 10).
89111182|NCT02792673|Active Comparator|"Embryo Glue®"|Hyaluronan-enriched medium
89227486|NCT00420004|Active Comparator|Escitalopram|"Escitalopram: flexible dose of 10 or 20 milligram (mg), capsules, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 10 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 10 mg/day; it could be increased up to a maximum dose of 20 mg/day; or it could be decreased back to 10 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 10 mg/day of escitalopram also received 1 escitalopram-matching placebo capsule + 2 LY2216684-matching placebo tablets. Participants on 20 mg/day of escitalopram also received 2 LY2216684-matching placebo tablets."
89227487|NCT00494481|Placebo Comparator|1|Docetaxel + placebo vandetanib
89227488|NCT00494481|Experimental|2|Vandetanib + Docetaxel
89227489|NCT01040494|Experimental|Aliskiren, add-on|HF patients will be randomized to receive add-on aliskiren 150 mg for 6 months
89227490|NCT01040494|Placebo Comparator|placebo, add-on|patients will be randomized to receive add-on placebo for 6 months
89227491|NCT01017081|Active Comparator|Control|Non-mandatory request to maintain lateral positioning to improve air exchange, to cough in order to clear secretion, and to perform diaphragmatic and deep breathing, for five minutes, once a day, during hospital stay.
89227492|NCT01017081|Experimental|Physiotherapy|"Physiotherapy: Children younger than 5 years: Manual Thoracic vibration (TV), thoracic compression (TC), positive expiratory pressure (PEP), and forced exhalation with the glottis open (huffing). Children aged 5 years or older: same procedures in addition to the ventilatory patterns, and a forced expiratory technique (FET), consisting of one or two huffs (forced expirations) followed by a period of relaxed, controlled diaphragmatic breathing, three times per day, for 10 to 12 minutes, during hospital admission."
89227493|NCT00097591|Experimental|Prasugrel|Oral loading dose of six 10 mg prasugrel tablets and four placebo tablets matched to clopidogrel, followed by an oral maintenance dose of prasugrel one 10 mg tablet and one placebo tablet matched to clopidogrel once daily
89227494|NCT00097591|Active Comparator|Clopidogrel|Oral loading dose of four 75 mg clopidogrel tablets and six placebo tablets matched to prasugrel, followed by an oral maintenance dose of one 75 mg clopidogrel tablet and one placebo tablet matched to prasugrel once daily
89227495|NCT01082029|Experimental|Lansoprazole|
89227496|NCT01082029|Placebo Comparator|Placebo|
89227497|NCT00419926|Experimental|Intensified Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
89227498|NCT00419926|Active Comparator|Standard Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.
89227499|NCT01038622|Active Comparator|L-arginine|5-day L-arginine treatment (200 mg/kg)
89227500|NCT01038622|Placebo Comparator|placebo|5-day placebo treatment
89227501|NCT01040572||Obesity recidivism after gastric bypass|
89227502|NCT00080119|Experimental|HIVneg/INH|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
89099911|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method - presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in EKG; and acute pulmonary edema - will be treated with HD.
89099912|NCT02646436|Other|PD treatment|Patients stage 5 (creatinine clearance < 15 ml/min) requiring dialysis treatment immediately without absolute contraindication to the PD method will receive unplanned PD treatment. High volume PD (HVPD) will be used during the first 7 days of PD in order to achieve metabolic and fluid control. The procedure for acute PD has been published recently by our team . At this point, patients will be discharged from hospital and they will be treated by intermitent PD at the dialysis unit of the University Hospital.until their family be trained and home be prepared for the implementation of technique.
89099913|NCT02642068||ADHD group|Drug-naïve adult ADHD Probands
89099914|NCT02642068||Sibling group|Unaffected Siblings of Drug-naïve Adult ADHD
89099915|NCT02642068||Control group|Age-, sex-, handedness-, and IQ-matched controls without lifetime ADHD or a family history of ADHD
89099916|NCT02638714|Experimental|Stem Cells|Intervention: Transplantation of autologous purified stem cells
89099917|NCT00654550|Experimental|1|
89099918|NCT00652054|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
89099919|NCT04164862|Active Comparator|use ACCUVEIN AV400|Device to facilitate cannulation of the great saphenous vein at the ankle in infants
89099920|NCT04164862|Active Comparator|ULTRASOUND GUIDED CANNULATION|Ultrasound cannulation of the great saphenous vein in infants
89099921|NCT02646358|Experimental|Cohort 1: Normal Renal Function|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
89099922|NCT02646358|Experimental|Cohort 2: Mild Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
89099923|NCT02646358|Experimental|Cohort 3: Moderate Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
89099924|NCT02646358|Experimental|Cohort 4: Severe Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
89099925|NCT02646358|Experimental|Cohort 5: End Stage Renal Disease|Vepoloxamer Injection, 50 mg/kg for 1 hour followed by 15 mg/kg/hr for 5 hours
89099926|NCT02642224|Experimental|Social work intervention|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
89099927|NCT01166282|Placebo Comparator|Double-blind Placebo EOW|Placebo for adalimumab every other week (eow) for 12 weeks.
89099928|NCT01166282|Experimental|Double-blind Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
89099929|NCT01166282|Experimental|Open-label Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.
89099930|NCT02884700||Severe legionellosis cases|Patients admitted to Grenoble University Hospital for severe legionellosis between 2006 and 2011.
89099931|NCT01153724|Experimental|Olodaterol|
89099932|NCT01153724|Experimental|Olodaterol + Fluconazole|
89099933|NCT02884388|Experimental|experimental group|Combined nerve block will be used, involving lower lumbar plexus, sciatic nerve, and paraspinal nerve L1-2.
89099934|NCT02884388|Experimental|control group|General anesthesia will be used in this group.
89099935|NCT02885870|Experimental|Patient|"Patient with :~Spinal muscular atrophy (n=25)~X-linked spinobulbar muscular atrophy (n=25)~Amyotrophic lateral sclerosis (n=25)"
89099936|NCT02885870|Experimental|Healthy subject|Subject without any neurologic or spine affection Subject matched for sex and age with patient arm
89099937|NCT04314596|Placebo Comparator|Placebo Group|Participants will engage in a one day, whole-body, cross-training course while consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
89099938|NCT04314596|Experimental|Experimental Group|Participants will engage in a one day, whole-body, cross-training course while consuming the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days. Participants will then come in 24 and 48 hours post, cross-training course to be tested.
89099939|NCT02885948|Experimental|Naloxone|"The naloxone arm of the study will receive naloxone at a rate of 5mcg/kg/hr which equates to 0.25ml/kg/hr. Each 1 ml ampoule of solution contains 400 micrograms (0.4mg) naloxone hydrochloride present as naloxone hydrochloride dihydrate.~Excipients: each 1ml contains 3.55mg sodium. This will be diluted to a concentration of 20mcg/ml with 0.9% NaCl. Presented as solution for injection or infusion. Clear colourless sterile solution."
89099940|NCT02885948|Placebo Comparator|Saline|The placebo arm of the study will receive an infusion of normal saline at a rate of 0.25ml/kg/hr.
89099941|NCT01152788|Active Comparator|rIL-21|
89099942|NCT01152788|Active Comparator|Dacarbazine|
89099943|NCT01165424|Experimental|MFNS 50 μg device|"MFNS 50 μg spray device. The dose will be as follows:~3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
89099944|NCT01152554|Experimental|SSRI/Serotonin/SNRI + TC-5214 1-4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214 1-4 mg BID
89099945|NCT01152554|Placebo Comparator|SSRI/Serotonin/SNRI + placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + placebo BID
89099946|NCT00598702|Experimental|IV Acetaminophen|40 to 75 mg/kg/day every 4 to 6 hours
89099947|NCT01148810|Placebo Comparator|Placebo|
89099948|NCT01148810|Experimental|BAF312|
89099949|NCT00624962|Other|Correlative/Supportive Care|
89099950|NCT04313426|Experimental|Integrative Yoga Therapy|Self managed Yoga based practices were included in one to one sessions for 6-sessions.
89099951|NCT02884310|Experimental|SPI group|"Remifentanil titration before tracheal intubation and skin incision according to the SPI gradient obtained after a nociceptive test using a tetanic stimulus of 100 Hz, 60 milliamperes during 30 seconds performed at a 3 ng/ml level of the remifentanil concentration.~During surgery, the effect site remifentanil concentration was either increased or decreased by 1 ng/ml to maintain SPI below 40 or above 20, respectively."
89099952|NCT02884310|Active Comparator|Control group|"The remifentanil concentration before tracheal intubation and skin incision was fixed at 4 ng/ml.~During surgery, the remifentanil concentration was adapted according to the hemodynamic answer of the patient. It was changed by 1 ng/ml stepwise variations to maintain heart rate and mean blood pressure within 20% of the patient reference hemodynamic values."
89099953|NCT01151618|Experimental|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
89099954|NCT01164956|Experimental|M-P, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
89099955|NCT01164956|Experimental|P-M, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
89099956|NCT01164956|Experimental|P-M, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
89099957|NCT01164956|Experimental|M-P, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
89099958|NCT01164956|Experimental|M-P, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
89099959|NCT01164956|Experimental|M-P, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
89099960|NCT01164956|Experimental|P-M, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
89099961|NCT01164956|Experimental|P-M, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
89099962|NCT02884232||Workers exposed to wood dust|
89099963|NCT01164722|Experimental|Arm I: Infrared coagulator treatment|Infrared photocoagulation therapy. The infrared coagulator (IRC) contact tip is placed in direct contact with lesion under high-resolution anoscopy (HRA) guidance. Patients then undergo IRC ablation for 1.5 second pulses. IRC ablation is reapplied until the level of submucosal vessels are reached.
89099964|NCT01164722|Active Comparator|Arm II: Expectant management|Patients receive standard of care and undergo clinical observation. After 12 months, patients may receive IRC ablation to all anal intraepithelial neoplasia lesions despite of their size.
89099965|NCT04314830|Active Comparator|Gait training without perturbation|Walking on a treadmill with the same duration as a participants of the experimental arm matched for initial gait speed. Treadmill speed did not change along the training program
89099966|NCT04314830|Experimental|Gait training with perturbations|Walking on a treadmill with perturbations produced by changes in the speed of one of the belt of the split-belt treadmill during one gait cycle. Changes in treadmill speed were applied on the paretic or non-paretic side, with and increase or a decrease of the speed of the belt in various magnitude. Perturbations were either repeated with the same characteristics or with different characteristics. Outside of perturbations, treadmill speed did not change along the training program.
89099967|NCT01151540|Experimental|Rufinamide|Ralfinamide was administered orally twice daily after breakfast and dinner. Participants on placebo in Study 304 were titrated over to rufinamide within 2 weeks during the Conversion Period. As a general rule, the dose of rufinamide at the end of the Conversion Period was maintained throughout the Maintenance Period.
89099968|NCT02884466|Experimental|Intervention group|The intervention group will receive a multidisciplinary rehabilitation intervention consisting of: 1) a pre-admission day, 2) two weeks of home-based activities, 3) two-week inpatient period, 4) four weeks of home-based activities, 5) 1st two-days inpatient follow-up, 6) six weeks of home-based activities and 7) 2nd two-days inpatient follow-up.
89099969|NCT02884466|Active Comparator|Usual care group|The usual care group will receive a four-week inpatient multidisciplinary rehabilitation intervention.
89099970|NCT02883998|Active Comparator|Outpatient Physical Therapy Group|Once the patient is cleared for discharged from the hospital, the patient will be given a prescription for outpatient physical therapy to attend 3 times per week for 6 weeks.
89099971|NCT02883998|Experimental|Home Base Physical Therapy Group|Patients will be provided a packet of exercises and equipment to perform the home based physical therapy program. Patients will attend a single session of outpatient physical therapy prior to surgery no more than 4 weeks prior to the procedure to teach the patient how to perform the exercises.
89099972|NCT01163786|Experimental|Bortezomib|Patients will Receive 2 4week cycles of Bortezomib. Each cycle will consist of weekly bortezomib with a 2 week interval between cycles.
89099973|NCT00984282|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle
89099974|NCT00984282|Placebo Comparator|Placebo|Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle
89099975|NCT01147874|No Intervention|psoriatic arthritis (PsA) questionnaire|
89099976|NCT04292184|Active Comparator|UW (perfusion solution) + sodium thiosulfate (STS)|We will flush the deceased donor kidney with UW (perfusion solution) + sodium thiosulfate (STS)
89099977|NCT04292184|No Intervention|UW (perfusion solution)|Kidney will be flushed with UW (perfusion solution) which is the normal standard of care.
89099978|NCT01147640|Experimental|CXA 101/tazobactam and metronidazole|
89099979|NCT01147640|Active Comparator|meropenem with matching saline placebo|
89099980|NCT02867982|Other|Subcrestal|implants that are placed below the alveolar ridge
89099981|NCT02867982|Other|Paracrestal|implants that are placed flush to the alveolar ridge
89099982|NCT02884154|Other|Arm who will undergo EUS-FNB|
89099983|NCT01121900|Experimental|Trazodone HCl OAD|OAD: Once A Day
89099984|NCT01121900|Active Comparator|Trazodone HCl (Apotex Corp.)|
89099985|NCT00625040||A|Obese patients without diabetes with a Body Mass Index > 37 kg/m2
89099986|NCT01121666|Active Comparator|Gonal-f® (Follitropin alfa)|
89099987|NCT01121666|Experimental|AFOLIA-150 (Follitropin alfa)|
89099988|NCT00984126|Experimental|Turoctocog alfa|
89099989|NCT02867748|Experimental|1|TVT-Abbrevo
89099990|NCT02867748|Experimental|2|Serasis
89099991|NCT02867514|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
89099992|NCT02867514|Sham Comparator|sham tDCS on left DLPFC (F3)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
89099993|NCT02867514|Active Comparator|anodal tDCS on right DLPFC (F4)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
89099994|NCT02867514|Sham Comparator|sham tDCS on right DLPFC (F4)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
89099995|NCT02868060|Experimental|1 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
89099996|NCT02868060|Experimental|3 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
89099997|NCT02868996|Experimental|Low dose (Part A)|Recombinant human tissue kallikrein
89099998|NCT02868996|Experimental|Medium low dose (Part A)|Recombinant human tissue kallikrein
89099999|NCT02868996|Experimental|Medium high dose (Part A)|Recombinant human tissue kallikrein
89100000|NCT02868996|Experimental|High dose (Part A)|Recombinant human tissue kallikrein
89100001|NCT02868996|Experimental|Subcutaneous (Part B)|Recombinant human tissue kallikrein
89100002|NCT02868996|Experimental|IV (Part B)|Recombinant human tissue kallikrein
89100003|NCT04290702|Active Comparator|epidural|
89100004|NCT04290702|Active Comparator|combined|
89100005|NCT04290702|Active Comparator|dural puncture epidural|
89100006|NCT04271982||Cohort A|Cohort A includes patients (N=20 000) screened for nutritional risk at Haukeland University Hospital (HUS) during point prevalence surveys between 2008 and 2018. The point prevalence surveys included all adult patients in somatic departments, and were performed 2-4 times per year since 2008. We expect the sample in the study to include approx. 9000 patients ≥ 65 years.
89100007|NCT04271982||Cohort B|"Cohort B includes older service users (≥65 years) with information on nutrition variables from the KPR-registry in the period 2016 to 2018 (n=approx. 270 560). All Norwegian municipalities report data on nutritional risk screening and nutrition plan for individual service users in Kommunalt pasientregister (KPR). These nutritional data will be linked to registry data on health care services use and patient outcome variables from the The Norwegian Patient Registry (NPR)"
89100008|NCT00629226|Experimental|Group I|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, 11, 22, 25, 29, 32, 43, 46, 50, and 53. Beginning on day 8 or 9, patients undergo standard intensity-modulated radiotherapy (IMRT) once daily, 5 days a week, for up to 8 weeks.
89100009|NCT00629226|Experimental|Group II|Patients receive cetuximab, bortezomib (beginning at one dose level below the MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.
89100010|NCT00979602|Experimental|GSK2340274A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
89100011|NCT00979602|Experimental|GSK2340273A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
89100012|NCT02866734|Active Comparator|Free screening group|Subjects in this group receive free diabetic retinopathy screening.
89100013|NCT02866734|Active Comparator|Pay screening group ($150)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$150.
89100014|NCT02866734|Active Comparator|Pay screening group ($300)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$300.
89100015|NCT00629304|Placebo Comparator|1|standard visit at 3 and 6 months
89100016|NCT00629304|Active Comparator|2|PDA-FIT system + standard visit at 3 and 6 months
89100017|NCT00629304|Active Comparator|3|PDA-FIT system + 12 telephone visits + standard visit at 6 months
89100018|NCT00816361|Experimental|MEDI-573 0.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 0.5 milligram per kilogram (mg/kg) as a 60-minute intravenous (IV) infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89100019|NCT00816361|Experimental|MEDI-573 1.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 1.5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89100020|NCT00816361|Experimental|MEDI-573 5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89100021|NCT00816361|Experimental|MEDI-573 10 mg/Kg QWk Dose Escalation|Participants received MEDI-573 10 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89100022|NCT00816361|Experimental|MEDI-573 15 mg/Kg QWk Dose Escalation|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89100023|NCT00816361|Experimental|MEDI-573 30 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 30 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89100024|NCT00816361|Experimental|MEDI-573 45 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 45 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89111183|NCT02792673|Active Comparator|"Global Total®"|30% Protein-supplemented Culture Medium
89111184|NCT02792673|Experimental|Autologous Follicular Fluid|a novel technique
89100025|NCT00816361|Experimental|MEDI-573 5 mg/Kg QWk Dose Expansion|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89100026|NCT00816361|Experimental|MEDI-573 15 mg/Kg QWk Dose Expansion|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
89100027|NCT05297929|Experimental|Experimental: Reference formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Sanofi Winthrop Industries
89100028|NCT05297929|Experimental|Experimental: Test formulation|Irbesartan tablet (0.15g/tablet) , Manufacturer: Zhejiang Hua Hai Pharmaceutical Co. LTD
89100029|NCT00826111|Active Comparator|Eszopiclone|Lexapro for 10 weeks together with eszopiclone.
89100030|NCT00826111|Placebo Comparator|Placebo|Lexapro for 10 weeks together with placebo.
89100031|NCT00982644|Experimental|IDeg OD|
89100032|NCT00982644|Active Comparator|IGlar OD|
89100033|NCT00815659|Experimental|Rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
89100034|NCT02867904|Placebo Comparator|Group A|After arthroscopic surgery the control group (Group A) will undergo a subacromial marcaine injection (standard of care).
89100035|NCT02867904|Experimental|Group B|After arthroscopic surgery the experimental group (Group B) will undergo a subacromial corticosteroid injection+marcaine.
89100036|NCT00825175|Active Comparator|1|Treadmill Training in infants with Down syndrome only
89100037|NCT00825175|Experimental|2|Treadmill Training and supramalleolar orthoses use for infants with Down syndrome
89100038|NCT04290936|Experimental|Arm 1|NUC-naïve patients will be randomization into Tenofovir Alafenamide(TAF) treatment.
89100039|NCT04290936|Placebo Comparator|Arm 2|NUC-naïve patients will be randomization into placebo arm.
89100040|NCT04290936|Active Comparator|Arm 3|NUCs-treated patients will be switched to Tenofovir Alafenamide(TAF) treatment.
89100041|NCT00707941|Experimental|1|Oseltamivir for 5 days for patients with illness duration < 48 hours
89100042|NCT00707941|Placebo Comparator|2|Placebo for 5 days for patients with illness duration < 48 hours
89100043|NCT00707941|Experimental|3|Oseltamivir for 5 days for patients with illness duration ≥ 48 hours
89100044|NCT00707941|Placebo Comparator|4|Placebo for 5 days for patients with illness duration ≥ 48 hours
89100045|NCT02866890|Experimental|Laryngeal Tube Suction size 1|Measurement of leak pressure
89100046|NCT02866890|Experimental|Laryngeal Tube Suction size 2|Measurement of leak pressure
89100047|NCT02866890|Experimental|Laryngeal Tube Suction size 2.5|Measurement of leak pressure
89100048|NCT04290312|Other|Mastiha oil|As a control to the experimental design, timepoint 0 was considered.
89100049|NCT02867826|Experimental|Cap-assisted endoscopy|forward-viewing endoscope with a Cap attached at the tip
89100050|NCT02867358|Active Comparator|High dose of KT07 capsule|It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).
89100051|NCT02867358|Active Comparator|Low dose of KT07 capsule|It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).
89100052|NCT02867358|Placebo Comparator|Placebo|It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.
89100053|NCT00824473|Placebo Comparator|1|Placebo
89100054|NCT00824473|Active Comparator|2|0.15% azelastine hydrochloride
89100055|NCT04291092|Experimental|single-arm|single-arm
89100056|NCT02867436|Experimental|Gluten-free diet|Gluten-free diet
89100057|NCT02867436|No Intervention|Conventional diet|Conventional diet
89100058|NCT02865486|Experimental|Lipid emulsion: visit 2|One of four randomly assigned lipid emulsions
89100059|NCT02865486|Experimental|Lipid emulsion: visit 3|One of four randomly assigned lipid emulsions
89100060|NCT02865486|Experimental|Lipid emulsion: visit 4|One of four randomly assigned lipid emulsions
89100061|NCT02867280|Experimental|Sorafenib|Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.
89100062|NCT02867280|No Intervention|Control|No use of Sorafenib (Nexavar). Regular treatment.
89100063|NCT00815191|Active Comparator|Vital Heat|Vital HEAT (vH2) Temperature Management System
89100064|NCT00815191|Active Comparator|Forced air|Forced-air warming
89100065|NCT04290390|Active Comparator|Annovera (alone)|Annovera taken alone (without itraconazole or rifampin)
89100066|NCT04290390|Active Comparator|Annovera with itraconazole use|Subjects will dose with 200 mg/day of itraconazole for five days before Annovera insertion and through Days 1 to 8 of Annovera use
89100067|NCT04290390|Active Comparator|Annovera with rifampin use|Subjects will dose with 600 mg/day rifampin for 8 days, between Days 4 to 11 of Annovera use during their respective treatment cycles
89100068|NCT00708253|Active Comparator|SBE|
89100069|NCT00708253|Active Comparator|DBE|
89100070|NCT00708331|Experimental|1|
89100071|NCT02866968|Experimental|Femtosecond Laser-assisted Pterygium Surgery (FLAPS)|All patients included will undergo FLAPS in one eye.
89100072|NCT04145310|Experimental|Arm A|
89100073|NCT04145310|Placebo Comparator|Arm B|
89100074|NCT04290858|Experimental|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
89100075|NCT04290858|No Intervention|Control|The control group will receive the standard of treatment without any active, placebo or sham Comparator.
89100076|NCT02866656|Experimental|control group|patients were given Conventional conservative treatment；
89100077|NCT02866656|Experimental|therapeutic ultrasound group|patients were given Conventional conservative treatment and low intensity ultrasonic treatment ；
89100078|NCT00812929|Placebo Comparator|Placebo|
89100079|NCT00812929|Experimental|GSK2190915 10 mg|
89100080|NCT00812929|Experimental|GSK2190915 50 mg|
89100081|NCT00812929|Experimental|GSK2190915 100 mg|
89100082|NCT00812929|Experimental|GSK2190915 200 mg|
89100083|NCT05758129||The control group|the invited recently diagnosed with epilepsy (< 2 months) live in Wuxi, Jiangsu, China (low PM2.5 level based on previous official PM2.5 records)
89100084|NCT05758129||The PM2.5 exposure group|the invited recently diagnosed with epilepsy live in Xuzhou, Jiangsu, China (high PM2.5 level based on previous official PM2.5 records)
89100085|NCT02610751||Smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
89100086|NCT02610751||Non-smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
89100087|NCT00824161|Experimental|1|TAS-109
89100088|NCT02610829|Experimental|Gamma Tocopherol|Subjects will ingest 1400 mg gamma tocopherol, orally administered in 3 doses separated by 12 hours.
89100089|NCT00979134|Experimental|Part A|Ascending doses of AZD4547 administered orally to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD)
89100090|NCT00979134|Experimental|Part B|Dose expansion phase, at the RD defined in Part A
89100091|NCT00979134|Experimental|Part C|Expansion phase in patients with FGFR1 and FGFR2 amplified tumours commencing at the RD defined from Part A
89100092|NCT00824005|Placebo Comparator|Placebo Injections|Participants will receive placebo injections.
89100093|NCT00824005|Experimental|Active Stem Cell Injections|Participants will receive active stem cell injections.
89100094|NCT04289844|Experimental|Experimental group|Each session of the intervention will have a duration of 15 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength and resistance strength
89100095|NCT04289844|Active Comparator|Control group|Each session of the intervention will have a duration of 10 minutes of specific training taking place two sessions a week, during a period of 5 weeks. The exercises will be performed in the first 15 minutes of the training session. The intervention will include specific exercises of elastic-explosive strength
89100096|NCT05756647|Experimental|Interventional Arm|The Mandibular Advancement Device for this study will be the ProSomnus Sleep Device. It is a sleep device intended to reduce nighttime snoring and mild to moderate Obstructive Sleep Apnea in adults by holding the lower jaw forward during sleep
89100097|NCT05756647|Active Comparator|Conservative treatment Arm|The conservative treatment will consist of four different interventions: Mometasone nasal rinse, External nasal dilatory therapy, Mouth taping and Lateral positional therapy.
89100098|NCT05758051|Other|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
89100099|NCT04289610|Sham Comparator|Control Group|In this group a pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). The device is not going to be activated in the control group. The device will be set at 0 V. TCPRF treatment is going to be applied for one session.
89100100|NCT04289610|Active Comparator|Study Group|A pair of TCPRF electrodes will be applied to the painful shoulder at six standardized sites for 2 minutes each (approximately a total of 15 minutes). It will be activated in the study group. In the study group device will be set at 80 V, every pulse will continue for 10 milliseconds and 5 pulses per second. TCPRF treatment is going to be applied for one session in both groups.
89100101|NCT00814879|Active Comparator|a.|N(t)RTI(s) based backbone & PI/r
89100102|NCT00814879|Experimental|b.|Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
89100103|NCT04289532|Experimental|99mTc-RWY SPECT/CT|Volunteers and patients were injected intravenously with 11.1 MBq/kg of 99mTc-RWY in one dose and underwent SPECT/CT scan 30-60 min later.
89100104|NCT02866422||OCD|
89100105|NCT02866422||Healthy Controls|
89100106|NCT00708409||1|Autograft operations with the subcoronary technique
89100107|NCT00708409||2|Autograft operations with the root replacement technique
89100108|NCT03347422|Experimental|BIVV009/BIVV009|Participants with primary CAD and without a recent history of blood transfusion during the last 6 months prior to enrollment in this study, received an intravenous (IV) infusion of BIVV009 6.5 g (for participants less than [<]75 kilograms [kg]) or 7.5 g dose (for participants greater than or equal to [>=]75 kg) on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26), received placebo on Week 26 and continued to receive BIVV009 6.5 or 7.5 g in Part B, every 2 weeks starting at Week 27 for up to an additional 149 weeks (for 6.5 g) or 121 weeks (for 7.5 g). All participants who completed Part A elected to continue in Part B.
89100109|NCT03347422|Experimental|Placebo/BIVV009|Participants with primary CAD and without a recent history of blood transfusion during the last 6 months prior to enrollment in this study, received an IV infusion of placebo matched to BIVV009 on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26) received BIVV009 6.5 (if <75 kg) or 7.5 g (if >=75 kg) in Part B, on Week 26 and Week 27 and every 2 weeks thereafter for up to an additional 123 weeks (for 6.5 g) or 137 weeks (for 7.5 g). All participants who completed Part A elected to continue in Part B.
89100110|NCT00814801|Placebo Comparator|Placebo|
89100111|NCT00814801|Experimental|Galantamine 16 mg/day|
89100112|NCT00814801|Experimental|Galantamine 24 mg/day|
89100113|NCT00708487|Experimental|1|5% oxygen embryo culture condition
89100114|NCT00708487|Active Comparator|2|21% oxygen embryo culture condition
89100115|NCT02638558|Experimental|written + oral explanation|patients will undergo both written and oral explanation for preparation with split dose
89100116|NCT02638558|Experimental|written explanation|patients will receive only a written explanation for preparation with split dose
89100117|NCT04164628|Experimental|Experimental Group: quality of life assessment|Women's quality of life will be evaluated.
89100118|NCT00823615|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
89100119|NCT00823615|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
89100120|NCT00653458|Experimental|A|Subjects received Kali formulated products under fed conditions
89100121|NCT00653458|Active Comparator|B|Subjects received GlaxoSmithKline's formulated products under fed conditions
89100122|NCT02638402||Stage I, II, III, IV ovarian cancer|Stage I, II, III, IV ovarian cancer receive treatment in National Taiwan University Hospital
89100123|NCT02638402||Stage I, II, III, IV endometrial cancer|Stage I, II, III, IV endometrial cancer receive treatment in National Taiwan University Hospital
89100124|NCT02638246|Experimental|Contingent|Participants in this group received incentives contingent on meeting pre-specified daily blood-glucose testing adherence goals.
89100125|NCT02638246|Active Comparator|Noncontingent|Participants in this group received incentives independent of meeting pre-specified daily blood glucose testing adherence goals.
89100126|NCT00812461|Placebo Comparator|Placebo|
89100127|NCT00812461|Experimental|Nalmefene|
89100128|NCT00599326|Experimental|A|
89100129|NCT02646280|Experimental|Massage therapy and contact experience|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading associated with a preparation to the contact phase of the massage using the typical elements of neurocognitive rehabilitation such as motor imagery, dynamic state during which a person mentally simulates an action, and language, necessary to understand the way of perceiving and organizing sensory, cognitive and phenomenological informations by the patients and so to interpretate pain in a more articulate way.
89100130|NCT02646280|Active Comparator|Massage therapy|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading.
89100131|NCT00978432|Experimental|Arm 1a (RAD001 followed by LBH589)|"Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
89100132|NCT00978432|Experimental|Arm 1b (LBH589 followed by RAD001)|"Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
89100133|NCT00978432|Experimental|Doublet (Combination RAD001 and LBH589)|Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better may receive up to 13 cycles. LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.
89100134|NCT02646202|Active Comparator|Sclerotherapy group|thirty patients treated by sclerotherapy for OV using ethanolamine oleate 5%.
89100135|NCT02646202|Active Comparator|Endoscopic band ligation group|thirty patients treated by endoscopic banding using the Euro-Ligator system.
89100136|NCT02646202|Experimental|Sclero-ligation (SL) group|thirty patients treated by intra variceal endoscopic sclerotherapy combined with band ligation.
89100137|NCT02638480|No Intervention|Control|The control subjects will be treated with only the current SOC including NSAIDs and physical therapy.
89100138|NCT02638480|Experimental|Experimental|The experimental subjects will be treated with current SOC and will also use a kneeMD splint 3 times a day for 20 minutes per session
89100139|NCT04166812||patients with early COPD|diagnosis according to current GOLD recommendations
89100140|NCT04166812||patients at risk for COPD|no current diagnosis according to GOLD recommendations, but at risk for COPD
89100141|NCT04016155|Active Comparator|SMBG|Patients use their own glucometers as control
89100142|NCT04016155|Experimental|Flash CGMS|
89100143|NCT02641756|Experimental|Study Population|"This is a single arm study. The investigators will include 10 HIV positive patients under chronic CART (combined antiretroviral therapy).~The intervention will consist on treatment interruption after in depth sampling under CART"
89100144|NCT00975780|Experimental|enhanced oral care|
89100145|NCT00975780|Active Comparator|Usual care|The usual oral care provided at the nursing home
89100146|NCT00654862|Experimental|1|Subjects with stage 1 hypertension
89100147|NCT00654862|Experimental|2|Subjects with optimal blood pressure
89100148|NCT02865252|Active Comparator|MWM treatment|"Mobilization with movement (MWM) is a combination of sustained passive accessory joint mobilization with an active or functional movement.~MWM will be applied (three sets of 10 repetitions) during active knee flexion and extension range of motion (ROM). The therapist initially will apply the pain-free manual glide force on the tibia with the knee resting in a mid-range position. The glide force will be sustained while the patient performed 10 repetitions of self-active full range knee flexion and extension; overpressure was included at the end range."
89100149|NCT02865252|Sham Comparator|MWM sham|The patients will be handled similarly to MWM treatment group, except that they will not receive directional glide; instead, the physiotherapist's hands are just touch the knee skin without pressure; one hand on the tibia while the other hand on the femur. However, available active knee flexion and extension ROM will be performed (three sets of 10 repetitions).
89100150|NCT02646046|Experimental|Combi lone-CPR|"Intervention group~: Newly developed method"
89100151|NCT02646046|Active Comparator|Conventional lone-CPR|Conventional CPR group
89100152|NCT00814489|Experimental|GSK2254233A Group|Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89100153|NCT00814489|Experimental|GSK2254232A Group|Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89100154|NCT00814489|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89100155|NCT02610595|Experimental|experimental group|Jianpixiaozhong particles and Wuse Dietotherapy
89100156|NCT00708799|Experimental|Arm 1|Standard antibiotic therapy +Azithromycin 500 mg intravenously daily for 5 days
89100157|NCT00708799|No Intervention|Arm 2|Standard antibiotic therapy
89100158|NCT02610127||OBIZUR - Prospective Participants|Participants enrolled and treated with Obizur after the prospective study start date
89100159|NCT02610127||OBIZUR - Retrospective Participants|Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date
89100160|NCT00814333|Experimental|1|Thrombin-JMI
89100161|NCT00814333|Active Comparator|2|Merocel pack
89100162|NCT01147250|Placebo Comparator|Placebo|Placebo matched to lixisenatide once daily (QD) up to end of treatment.
89100163|NCT01147250|Experimental|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment.
89100164|NCT04205864|Active Comparator|Conventional pelvic lymphadenectomy|Conventional pelvic lymphadenectomy
89100165|NCT04205864|Experimental|Thrombin gel matrix pelvic lymphadenectomy|Thrombin gel matrix applicated after conventional pelvic lymphadenectomy
89100166|NCT00813943|Experimental|Cilengitide (2-times weekly) + Temozolomide + Radiotherapy|
89100167|NCT00813943|Experimental|Cilengitide (5-times weekly) + Temozolomide + Radiotherapy|
89100168|NCT00813943|Active Comparator|Temozolomide + Radiotherapy|
89100169|NCT05403931|Experimental|Particular joint point group|This group will receive laser irradiation on 6-7 particular points including 4-5 on tibiofemoral and 2 on patellofemoral joint.
89100170|NCT05403931|Experimental|Acupuncture points group|This group will receive laser irradiation on 6-7 particular acupuncture points which have been previously used in another study and or identified in literature.
89100171|NCT00821509|Active Comparator|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent hand washing in office and at home
89100172|NCT00821509|Active Comparator|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
89100173|NCT00821509|No Intervention|Control|No change in hygiene behaviour
89100174|NCT00821431|Experimental|Compression device|The electrical compression device is operated from battery or a main adaptor. It is based upon the use of inflatable pneumatic cuffs that apply controlled compression to the foot, ankle and calf.
89100175|NCT00821431|Active Comparator|Profore, 4-layer bandage|A high compression 4-layer bandage (Profore, Trademark of Smith and Nephew). This is a four-layer system that can be purchased either separately or as a package: a wound contact layer (Knitted viscose), a sub-compression wadding bandage, two layers of elastane bandage plus a top cohesive layer.
89111185|NCT02792595|Sham Comparator|Negative Control|Untreated area will be irradiated using a sun simulator with UV irradiation increment of 1.25 to detect MED of the unprotected skin.
89100176|NCT05389345|Experimental|Actual tDCs + ET|All interventions will involve 4 weeks of group intervention consisting of two 1-hour group sessions per week and additional practice between sessions. Half of study participants will be randomized to receive 30 minutes of transcranial direct current stimulation (tDCS) prior to beginning each ET session. ET session will begin immediately after tDCS.
89100177|NCT05389345|Sham Comparator|Sham tDCs + ET|All interventions will involve 4 weeks of group intervention consisting of two 1-hour group sessions per week and additional practice between sessions. Half of study participants will be randomized to receive 30 minutes of sham transcranial direct current stimulation (tDCS) prior to beginning each ET session. ET session will begin immediately after tDCS. During the sham tDCS, the procedures will be exactly the same as the real tDCS (e.g., application of electrodes), however, no stimulation will be provided when the device turned on.
89100178|NCT04032145||Observational|All participants who go to the Montreal Museum of Fine Arts will fill out an online questionnaire called: CESAM ( Self Administered Questionnaire). This questionnaire will asse participant's health condition. Moreover, the goal of the questionnaire is to evaluate if art activities may change the participants' health conditions in time.
89100179|NCT00813865|Experimental|Afegostat Tartrate Treatment Regimen 1|Afegostat tartrate was administered orally at a dose of 225 mg QD for 3 or 7 consecutive days followed by no study medication for 4 or 7 consecutive days (consecutive 3-days-on/4-days-off or 7-days-on/7-days-off, respectively). Amendment 2 added a MWF 3-days-on/4-days-off regimen. After Amendment 2 was implemented, all participants were assigned to one of the two 3-days-on/4-days-off regimens. Amendment 4 removed the consecutive 3-days-on/4-days-off regimen, and all participants were assigned to the MWF 3-days-on/4-days-off regimen. Participants were to receive afegostat tartrate for 30 months and be followed for 6 months after EOT.
89100180|NCT05756335|Experimental|Behavioral intervention|Subjects are presented with a simultaneous sequence of faces and spoken words. Face stimuli include a representative sample of realistic faces across a range of ages. Spoken word stimuli are simple nouns spoken by a single female speaker.
89100181|NCT04311164||Steno Tech Survey Respondents|A cohort of individuals with type 1 diabetes treated with CSII at either SDCC or NOH participating in the Steno Tech Survey.
89100182|NCT04311164||General Type 1 Diabetes Population|A cohort consisting of the entire population of people with type 1 diabetes in Denmark not included in the Steno Tech Survey cohort (ca. 25.000 individuals).
89100183|NCT02883296|Experimental|Patients with perianal fistulizing Crohn's disease|
89100184|NCT01147172|Experimental|Elevess|Gel implant (dermal filler) composed of hyaluronan produced by Streptococcus equi (bacterial fermentation) that is cross-linked and suspended in phosphate buffered saline with 0.3% lidocaine HCl and 0.1% sodium metabisulfite
89100185|NCT02610517|Other|Provider Training|Training providers to offer alcohol pharmacotherapy to at-risk drinkers interested in quitting or reducing their drinking as part of overall HIV care could be an important strategy to reduce hazardous alcohol use in this medically-ill population.
89100186|NCT02610517|Other|Patient Intervention|Determine the effectiveness of a computer-delivered brief intervention (CBI) for reducing hazardous drinking in the HIV clinical care setting at two intervention clinics: University of Alabama at Birmingham (UAB) and the University of Washington (UW).
89100187|NCT05154032|Experimental|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
89100188|NCT00913861|Active Comparator|standard sedation|propofol and fentanyl
89100189|NCT00913861|Active Comparator|structured attention-standard sedation|structured attention
89100190|NCT00913861|Experimental|hypnosis-standard sedation|hypnosis
89100191|NCT04036669||RA patients|RA patients ( N=80; BMI= 26.4± 3.96 ) Eighty patients diagnosed with Rheumatoid arthritis according to American Rheumatology Association criteria and radiographic analysis for at least 10 years previously were randomly involved in this study
89100192|NCT04036669||Healthy control|A healthy control group ( N=80; BMI=22.3± 1.85) eighty age and sex-matched healthy controls were included in the study following the assignment of informed consent.
89100193|NCT04030273||Open (laparotomic) myomectomy|Women undergoing uterine myomectomy by open surgery (laparotomy).
89100194|NCT04030273||Laparoscopic myomectomy|Women undergoing uterine myomectomy by laparoscopy.
89100195|NCT04030273||Robotic myomectomy|Women undergoing uterine myomectomy by robotic surgery.
89227503|NCT00080119|Placebo Comparator|HIVneg/PL|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
89100196|NCT01120964|Experimental|Intravenous L-Citrulline|IV bolus of 150 mg/kg L-citrulline at the initiation of bypass, followed by L-citrulline (200 μmol/L) addition to the filtration or hemoconcentration replacement fluid used during bypass. Plus L-citrulline (20 mg/kg) bolus 30 minutes after decannulation from bypass, immediately followed by 9 mg/kg/h continuous L-citrulline infusion for 48 hours.
89100197|NCT01120964|Placebo Comparator|Placebo of Intravenous L-Citrulline|Placebo administered according to the same schedule as L-citrulline
89100198|NCT05757661|Experimental|Focal Vibration Group|
89100199|NCT05757661|Sham Comparator|Sham Group|
89100200|NCT02611219|Experimental|Arm 1: Pediatric patients|"Patients will wear a Fitbit Flex during hospitalization~Completion of Demographic Data Form at baseline, discharge from hospital, and at the six week clinic visit~Assist in recording time out of bed using the SCT Daily Activity Log~Fill out (some with help of parents) applicable questionnaires: Child Health Ratings Inventories-General Health Module (5-12 years), General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years) at baseline, discharge from hospital, and at six week clinic visit~Patients will be assessed using standard physical therapy assessment tools to determine functioning, muscle strength, endurance, and mobility: The Functional Independence Measure for Children and Manual Muscle Testing is done weekly, discharge from hospital, and at six week clinic visit. The 3-Minute Step Test is done at admission, discharge from hospital, and at six week clinic visit."
89100201|NCT02611219|Experimental|Arm 2: Parents of pediatric patients|"Parents will be considered participants as they will be completing study questionnaires.~Completion of Demographic Data Form at baseline~Assist in recording time out of bed using the SCT Daily Activity Log~Fill out applicable questionnaires: General Health Module-Baseline Parent Report -Adolescent (13-18 Years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), and General Health Module Follow Up Parent Report-School Age (5-12 years), HSCT Module-Follow UP Parent Report School Age (5-12 years), HSCT Module-Follow Up Parent Report Adolescent (13-18 years), HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years) at baseline, discharge from hospital, and at six week clinic visit.~Assist child with Child Health Ratings Inventories-General Health Module (5-12 years) at baseline, discharge at hospital, and at six week clinic visit"
89100202|NCT02611141|Other|Patient with Retromolar Gap|20 patients with a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
89100203|NCT02611141|Other|Patient without a Retromolar Gap|20 patients without a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
89100204|NCT01146860|Experimental|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
89100205|NCT01146860|Placebo Comparator|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration: 15 days
89100206|NCT00591565|Experimental|1|acamprosate tablets
89100207|NCT01146782|Experimental|Treatment|Treatment with the Attune Sleep Apnea System
89100208|NCT00978120|Experimental|H1N1 vaccine high dose|Participants will be stratified according to asthma severity and will receive the high dosage of the H1N1 vaccine.
89100209|NCT00978120|Experimental|H1N1 vaccine low dose|Participants will be stratified according to asthma severity and will receive the low dosage of the H1N1 vaccine.
89100210|NCT04288986|Experimental|Keep Achieving (KA) group|Participants in the experimental group will take part in a 8-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 8-weeks. The activity sessions will include semi-structured free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
89100211|NCT04289064||Fundus image quality assessment|Device: an artificial intelligence system for quality assessment of fundus images. These patients are enrolled in primary healthcare units or the AI clinic at Zhongshan Ophthalmic Center.
89100212|NCT03971760|Active Comparator|Group 1: 30cc/24h|This group represents the currently used value of drain output used to determine the timing of drain removal
89100213|NCT03971760|Experimental|Group 2: 50cc/24h|This group represents the experimental value of drain output used to determine the timing of drain removal
89100214|NCT00978042|Experimental|VOLUMA® XC Treatment Arm|Participants treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs) at study start. Participants were eligible for re-treatment if applicable.
89100215|NCT00978042|Other|Control Arm_No Treatment then VOLUMA® XC|No treatment for 6 months, then participants were treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs). Participants were eligible for re-treatment if applicable.
89100216|NCT01133678|Experimental|Everolimus|Everolimus 5 mg PO Daily for 2 21-day cycles
89100217|NCT01133678|Experimental|Placebo|Placebo 5 mg PO Daily for 2 21-day cycles
89100218|NCT03693040|Experimental|DHFS with IS-Truvada|Digital Health Feedback System (DHFS) with IS-Truvada 1 capsule daily for 12 weeks
89227504|NCT00080119|Experimental|HIVpos/INH|HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
89100219|NCT02638324|Active Comparator|Renal nervous denervation.|Renal nervous denervation is performed to the patients who do not response properly to conventional therapy. The patients are randomised according to the waiting list principle.
89100220|NCT02638324|Active Comparator|Renal nervous denervation (delayed)|Renal nervous denervation is performed after six months on the waiting list
89227505|NCT00080119|Placebo Comparator|HIVpos/PL|HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
89227506|NCT00419380|Active Comparator|dornase alfa (Pulmozyme®)|dornase alfa - Pulmozyme®: 5 drops twice daily for 7 days to the affected ear.
89227507|NCT00419380|Active Comparator|Ofloxin|Ofloxin : 5 drops twice daily for 7 days to the affected ear.
89227508|NCT03961633|Experimental|AWARE intervention|"This arm is the treatment group, which receives the intervention, and is the only arm in the study. See the intervention column for more descriptions."
89227509|NCT01040650||Normal Controls|Normal Controls
89227510|NCT01040650||Statin associated myopathy|subjects with statin associated myopathy
89227511|NCT01082107|Other|Solar disinfection of drinking water|
89227512|NCT01085929|Active Comparator|Incision and Drainage|Abscess underwent incision and drainage
89227513|NCT01085929|Active Comparator|Ultrasound guided needle aspiration|Ultrasound was used to identify the abscess location. A needle was introduced into the abscess cavity and aspiration of the contents were attempted.
89227514|NCT00413062|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
89227515|NCT00413062|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
89227516|NCT01086007||Pain patients|Patients with pain related sexual dysfunction after laparoscopic inguinal hernia repair
89227517|NCT01086007||Non-pain patients|Patients with no pain related sexual dysfunction after laparoscopic inguinal hernia repair
89227518|NCT01082185|Other|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
89227519|NCT01034878|Experimental|Sunitinib|50 mg once daily 6 weeks cycle 4 weeks on and 2 weeks off
89227520|NCT01088113||Tai Chi|Healthy subjects with Tai Chi practice
89227521|NCT01088113||Qigong|Healthy subjects with Qigong practice
89227522|NCT01082263|Other|Midazolam/Lurasidone|Schizophrenia patient
89227523|NCT02208544|Experimental|FDG-PET/CT-driven|"Following treatment based on FDG-PET/CT:~negative: watchful waiting including confirmatory ultrasound~positive: diagnostic thyroid surgery as planned"
89227524|NCT02208544|Other|Current Practice|diagnostic thyroid surgery despite results of FDG-PET/CT
89227525|NCT00494091|Experimental|A.|
89227526|NCT00494091|Experimental|B.|
89227527|NCT01017159|Active Comparator|Subcutaneous immunoglobulin|
89227528|NCT01017159|Placebo Comparator|Saline|
89227529|NCT00494013|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
89227530|NCT00494013|Active Comparator|Detemir|Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
89230285|NCT03952975|Other|follicular phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14). In light of this formula patients were classified into the follicular phase group (defined as <15 adjusted days, group A).
89100221|NCT00652132|Active Comparator|Arm I (cisplatin)|Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
89100222|NCT00652132|Experimental|Arm II (cisplatin + STS)|Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
89100223|NCT02645890|Active Comparator|CKD-397|Tadalafil/ Tamsulosin Fixed dose combination
89100224|NCT02645890|Experimental|TD+TM|Tadalafil/ Tamsulosin Coadministration
89100225|NCT04164784|Experimental|therapeutic monitoring|"Based on the dietary habits from guidelines, the patients will be instructed to adjust the diet according to the ambulatory glucose profile (AGP) and the recorded log monitored by the continuous glucose monitoring system, thereby implementingtherapeutic monitoring."
89100226|NCT04164784|No Intervention|The control group|Patients will be given the basic diet, lifestyle instructions according guidelines.
89100227|NCT00655174|Placebo Comparator|1|
89100228|NCT00655174|Experimental|2|
89100229|NCT00655174|Experimental|3|
89100230|NCT04166422|Active Comparator|Conventional group|Conventional rehabilitation treatment
89100231|NCT04166422|Experimental|Experimental group|Virtual reality plus conventional rehabilitation treatment
89100232|NCT00655018|Experimental|Vitamin group|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
89100233|NCT00655018|Placebo Comparator|2|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
89100234|NCT02635750|Experimental|BI 409306|
89100235|NCT02635750|Experimental|Donepezil low dose|
89100236|NCT02635750|Experimental|Donepezil high dose|
89100237|NCT04164706|Experimental|HumiGard (plus standard care)|HumiGard device will be used to provide warmed humidified CO2 for insufflation during laparoscopic surgery. The device will be used alongside standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.
89100238|NCT04164706|Sham Comparator|Standard Care (with sham HumiGard device).|"Patients will receive standard methods of keeping the patient warm in theatre. The theatre team will monitor the patient's temperature at regular time points before, during and after surgery. Warmed fluids, forced air warming devices or warmed blankets will be used as required to maintain normothermia.~A sham HumiGard device will be used in the standard care arm. This will be the same HumiGard device as is in the intervention arm. However, the sham device will be turned off so that the gas delivered to the peritoneal cavity for insufflation is not heated or humidified. The sham device will deliver CO2 (as is the case for current standard practice in the hospital) through the HumiGard tubing. The sham device will look and sound the same as the active intervention arm where the HumiGard device is switched on and is delivering warm, humidified CO2 to the peritoneal cavity."
89100239|NCT04164238|Experimental|Arm A|Toripalimab 240mg IV, every 3 weeks;
89100240|NCT04164238|Experimental|Arm B|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m^2, IV, Q3W; Carboplatin AUC 5, IV, Q3W
89100241|NCT04164238|Experimental|Arm C|Toripalimab 240mg IV, Q3W; Paclitaxel 175mg/m^2, IV, Q3W; Cisplatin 25mg/m^2 IV,d1-d3, Q3W; 5-FU 3000mg/m^2 CIV 72h, Q3W
89100242|NCT04164160|Experimental|integrated-care-model benefiting group|Chronic patients whose clinical and social data will be added in the integrated care model application software.
89100243|NCT02645734|Active Comparator|Injection intravitreous bevacizumab|Injection intravitreous bevacizumab at a dose 1.25mg
89100244|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 1.25 mg|Injection ziv-aflibercept at dose of 1.25 mg
89100245|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 2.5 mg|Injection ziv-aflibercept at dose of 2.5 mg
89100246|NCT02635594|Experimental|Carnipure® tartrate|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
89100247|NCT02635594|Placebo Comparator|Placebo|1000mg cellulose + 475mg L-tartaric acid
89100248|NCT02635906|Experimental|2 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for two hours
89100249|NCT02635906|Active Comparator|4 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for four hours
89100250|NCT00652210|Experimental|MPM|Subject tissue was reviewed using multiphoton microscopy
89100251|NCT01133522|Experimental|Evolocumab|Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.
89100252|NCT01133522|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
89100253|NCT04164394|Placebo Comparator|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
89100254|NCT04164394|Experimental|Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
89100255|NCT02635516|Experimental|Treatment|Only one arm was used and this arm received Near-Infrared Phototherapy.
89100256|NCT02645578|Experimental|RMNS group|Focus intervention: right median nerve stimulation plus standard management
89100257|NCT02645578|No Intervention|Control group|Standard management
89100258|NCT00883090|Experimental|FXIII|All subjects treated with Factor XIII Concentrate (Human) (FXIII)
89100259|NCT04162288|Experimental|Online training on SDM in prenatal screening|
89100260|NCT04162288|Placebo Comparator|Online training on prenatal screening|
89100261|NCT02645656|Experimental|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals.
89100262|NCT04163848||Desflurane|desflurane administration based on a BIS index kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator and its econometer for an optimized fresh gas flow as low as the O2 consumption allows
89100263|NCT04163848||Sevoflurane|sevoflurane administration based on a BIS kept between 40-60 and with use of the semi-closed circuit of the Draeger A500 ventilator with a fixed fresh gas flow of 2L/min as requested in the gas monography
89100264|NCT01132820|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89100265|NCT04163770|Experimental|performance of pacemaker at time of implantation|
89100266|NCT04163770|Experimental|performance of pacemaker 6 months after implantation|
89100267|NCT04162444||Cohort 1|We will study safety, clinical and hemodynamic efficacy of the method of the aortic valve reconstruction with autopericardium in children with aortic valve disease.
89100268|NCT00655330|Active Comparator|1|Valsartan (160mg/day)is given in combination with Placebo
89100269|NCT00655330|Experimental|2|Valsartan (160mg/day) + Probucol (750mg/day)
89100270|NCT00353470|Experimental|1|Participants will receive panic focused psychodynamic psychotherapy for 12 weeks
89100271|NCT00353470|Active Comparator|2|Participants will receive cognitive behavioral therapy-panic control treatment for 12 weeks
89100272|NCT00353470|Active Comparator|3|Participants will receive applied relaxation training for 12 weeks
89100273|NCT00655408|Active Comparator|A|"For infants with ages between six and 24 months, iron supplementation is the main treatment for iron deficiency.This study was carried out using two intervention groups. All children received 12 weekly doses of 25 mg of elemental iron.~Group 1 administered in the government healthcare clinic. Group 2 administered children's home.~The study showed treatment compliance in both groups."
89100274|NCT04163536|Active Comparator|cortisteroids arm|
89100275|NCT04163536|Placebo Comparator|placebo arm|
89100276|NCT02637544|Active Comparator|Verum|"Acupuncture therapy.~For this study arm following acupuncture points suitable for facial pain, according to traditional chinese medicine, were chosen:~F2, F3, F34, IT3, IT19, S7, T21 and temporomandibular joint ear acupuncture points. Only intervention is the acupuncture therapy."
89100277|NCT02637544|Placebo Comparator|Placebo|Placebo acupuncture therapy. For this study arm points outside of the meridians according to traditional chinese medicine, were chosen. Only intervention is the acupuncture therapy.
89100278|NCT02645500|Experimental|Physical activity message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to physical activity.~The training workshop include one core session and one booster session at one month.~Daily messages in relation to physical activity will be sent to the participants."
89100279|NCT02645500|Active Comparator|Healthy diet message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to healthy diet .~The training workshop include one core session and one booster session at one month.~Daily messages in relation to healthy diet will be sent to the participants."
89100280|NCT00652288|Active Comparator|Catheter day 4|Adolescents with type 1 diabetes with catheters day #4
89100281|NCT00652288|Active Comparator|Catheter day 1|Adolescents with type 1 diabetes with catheter day #1
89100282|NCT00652288|Active Comparator|Aspart and Detemir|Adolescents with type 1 diabetes
89100283|NCT00652288|Active Comparator|Lispro and Glargine|Adolescents with type 1 diabetes
89100284|NCT04162132||DynamiCare group|Patients at Morgan Street location of BrightView who were given the DynamiCare smartphone app.
89100285|NCT04162132||Non-DynamiCare group|Patients at Colerain location of BrightView who were not given the DynamiCare smartphone app.
89100286|NCT02637622||Best-Worst Scaling (Case 2)|Preference elicitation survey using a best-worst scaling method.
89100287|NCT02637622||Discrete Choice Experiment|Preference elicitation survey using a discrete choice experiment method.
89100288|NCT00655720|Active Comparator|1|
89100289|NCT00655720|Experimental|2|
89100290|NCT00655720|Experimental|3|
89100291|NCT02635360|Experimental|Following chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.
89100292|NCT02635360|Experimental|Concurrent to chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab.
89100293|NCT02635282|Active Comparator|IN fentanyl and midazolam|group of patients who are randomized to receive intranasal fentanyl and midazolam
89100294|NCT02635282|Experimental|IN ketamine|group of patients who are randomized to receive intranasal ketamine
89100295|NCT02635438|Experimental|Arm A|Test Product: Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) 10mg troche 5 times a day for 14 consecutive days
89100296|NCT02635438|Active Comparator|Arm B|Reference Product: Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) troche 5 times a day for 14 consecutive days
89100297|NCT00655798|Placebo Comparator|1|
89100298|NCT00655798|Active Comparator|2|
89100299|NCT00655798|Active Comparator|3|
89100300|NCT00655798|Active Comparator|4|
89100301|NCT02635048|Other|Group 1|Patients in Group 1 undergo mini percutaneous nephrolithotomy
89100302|NCT02635048|Other|Group 2|Patients in Group 2 undergo percutaneous nephrolithotomy
89100303|NCT00652522|Active Comparator|A|Best Medical Treatment, ICD/CRT implant
89100304|NCT00652522|Experimental|B|AF Ablation, ICD/CRT implant
89100305|NCT02645344|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Low frequency rTMS at 1 Hz was applied over P5 of the contralesional hemisphere in addition to conventional rehabilitation
89100306|NCT02645344|Experimental|rTMS combined with sensory cueing (SC)|Vibration cueing was emitted using a wristwatch device on the hemiplegic arm combined with low frequency rTMS in addition to conventional rehabilitation
89100307|NCT02645344|Active Comparator|Conventional rehabilitation|Physical therapy and occupational therapy
89100308|NCT02637700|Experimental|Intravenous Immunoglobulin|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive intravenous immunoglobulin.
89100309|NCT02637700|Placebo Comparator|Placebo (Saline 0.9%)|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive placebo (saline 0.9%).
89100310|NCT02637466|Experimental|Vortioxetine|In cycle I of the study, participants will be randomized on to flexible-dose VTX (10-20 mg) versus. Vortioxetine starting dose will be 10 mg daily. Vortioxetine starting dose will be 10 mg daily with a dose escalation up to 20 mg daily at week #4. Study cycle II is an 8-week, open label treatment design for non-responders completing the Cycle I RCT. One treatment arm will continue VTX non-responders to 8 week VTX (10-20 mg/day) augmentation with cognitive behavioral therapy (10 sessions). The 2nd treatment arm will continue placebo non-responders who complete the RCT to VTX (10 to 20 mg/day). The third treatment arm will continue VTX responders/remitters who complete the RCT to open-label VTX for another 8-weeks to assess maintenance efficacy for up to 16 weeks.
89100311|NCT02637466|Placebo Comparator|Placebo|"In cycle I of the study, 80 eligible depressed women with breast cancer will be randomized into an 8-week, double-blind, placebo-controlled, flexible-dose vortioxetine (10-20 mg) treatment arm versus placebo arm.~Responders to placebo treatment will complete their study participation at the end of Cycle I, and will not proceed to Cycle II."
89100312|NCT02637388|Placebo Comparator|Placebo Comparator: Control Breakfast|Breakfast cereal and yoghurt only (placebo, negative control)
89100313|NCT02637388|Experimental|Experimental: beta-Glucan Breakfast|Breakfast cereal and yoghurt with the addition of 4g beta-glucan (14.7g Oatwell28 powder)
89100314|NCT02634892|No Intervention|Standard of Care (SOC)|Patients receive usual or standard of care regarding management of early stage pressure ulcers
89100315|NCT02634892|Experimental|SOC plus PRO-TECT|Patients receive usual or standard of care plus the addition of PRO-TECT.
89100316|NCT02634970|Experimental|Ranibizumab at 0.5 mg|Single arm, intravitreal injection
89100317|NCT00885352|Experimental|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
89100318|NCT00885352|Placebo Comparator|Placebo|Placebo to sitagliptin orally once daily for 26 weeks.
89100319|NCT02637310|Experimental|N02RS1 1200mg|Combination of Broussonetia spp and Lonicera spp
89100320|NCT02637310|Placebo Comparator|Placebo|sugar pill
89100321|NCT00655954||Healthy volunteers non smoker|18 volunteers
89100322|NCT00655954||Healthy volunteers smoker|15 volunteers
89100323|NCT00655954||Chronic Obstructive Pulmonary Disease COPD|39 volunteers
89100324|NCT00656032|Active Comparator|1|SOC medication for treatment of renal osteodystrophy
89100325|NCT00656032|Active Comparator|2|alternate SOC medication for treatment of renal osteodystrophy
89100326|NCT02637154|Active Comparator|Motivational Interviewing|With 30 patients Motivational Interviewing method will be used during each visit
89100327|NCT02637154|Active Comparator|Standard Education|With 30 patients Standard Education material will be used during each visit
89100328|NCT00656734|Experimental|MDX 1411|Dose Escalation Cohorts
89100329|NCT00885118|Experimental|BI 10773 low dose quaque die (QD)|patient to receive a BI 10773 low dose tablet and a placebo tablet once daily
89100330|NCT00885118|Experimental|BI 10773 mid-low dose QD|patient to receive a BI 10773 middle dose tablet and a placebo tablet once daily
89100331|NCT00885118|Experimental|BI 10773 mid-high dose QD|patient to receive two tablets of BI 10773 middle dose once daily
89100332|NCT00885118|Experimental|BI 10773 high dose QD|patient to receive a BI 10773 high dose tablet and a placebo tablet once daily
89100333|NCT00885118|Placebo Comparator|Placebo|patient to receive two tablets of placebo once daily
89100334|NCT00656812|Experimental|Treatment Arm|Combination therapy Rituximab plus 2CdA
89100335|NCT00656110|Experimental|1-T|Treatment Group
89100336|NCT00656110|Placebo Comparator|2-P|Placebo comparator
89100337|NCT04163692|Experimental|Exercise Group|Progressive relaxation exercises (PRE) as 1 day supervised and 3 days home based program in a week, for 6 weeks
89100338|NCT04163692|No Intervention|Control Group|Information was provided about pain and its treatment and the importance of relaxing exercises without any intervention, up to 6 weeks.
89100339|NCT00656188|Placebo Comparator|Arm 2|
89100340|NCT00656188|Active Comparator|Arm 1|
89100341|NCT00880906|Active Comparator|A|Group A receives steroids and PPI, (SOC) and esophageal dilation.
89100342|NCT00880906|Sham Comparator|B|Receives steroids and PPI only- Does not have esophageal dilation.
89100343|NCT04160182|Experimental|Energy Conservation Work Simplification Education|The intervention will be delivered online by an occupational therapist. The intervention consists of 6 weekly sessions; each session will be 45 minutes long. The focus of the intervention is to teach breast cancer survivors strategies to manage their fatigue.
89100344|NCT04160026|Active Comparator|IPTp-SP|Arm 1. Standard single-day stat course of quality-assured SP (Fansidar ®) of 3 tablets (500 mg of sulphadoxine and 25 mg of pyrimethamine). SP given monthly
89100345|NCT04160026|Experimental|IPTp-DP|Arm 2. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy). DP given monthly
89100346|NCT04160026|Experimental|IPTp-DP Plus|Arm 3. Standard 3-day course of 3 to 5 tablets (40/320mg) of DP per day based on bodyweight (Eurartesim®, AlfaSigma, Italy) plus targeted information for health providers.
89100347|NCT02636920|Other|TEP-CASES|"25 Case Patients will follow the Therapeutic Education to the Patient (TEP).~In addition the following procedures will be performed:~Pediatric Asthma Quality of Life Questionnaire (PAQLQ);~Children Asthma Control Test (C-ACT);~Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
89100348|NCT02636920|No Intervention|TEP-CONTROLS|"25 Control Patients will follow the usual care program:~The Pediatric Asthma Quality of Life Questionnaire (PAQLQ);~The Children Asthma Control Test (C-ACT);~the Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
89100349|NCT02634736|Experimental|Exergame plus usual treatment|Exergame programme plus usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
89100350|NCT02634736|No Intervention|Usual treatment|No exergame programme, just usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
89100351|NCT04159870|Experimental|Intervention Group|Rifaximin 1200 mg/day in 3 doses
89100352|NCT04159870|Active Comparator|Control Group|Norfloxacin 400 mg/day in one dose
89100353|NCT02634658|Experimental|Medical ICU Subjects|All Medical ICU subjects that meet eligibility criteria and are enrolled in the study will receive muscle Ultrasounds, Nerve Conduction Studies and Electromyography (EMG).
89100354|NCT02634658|Experimental|Neuro ICU Subjects|All Neuro ICU subjects that meet eligibility criteria and are enrolled in the study will receive Nerve Conduction Studies and Electromyography (EMG).
89100355|NCT00657514|Active Comparator|A|Drug arm - 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
89100356|NCT00657514|Placebo Comparator|P|Placebo arm - 1 tablet po bid up to 2 tablets po bid if tolerated
89100357|NCT04159792||stroke|Those with standard treatment as usual.
89100358|NCT04159948|Placebo Comparator|Water|Patients will be allowed to drink water up to 2 hours before their caesarean section.
89100359|NCT04159948|Active Comparator|Carbohydrate drink|Patients will be allowed to drink a designated carbohydrate drink up to 2 hours before their caesarean section.
89100360|NCT04159948|Active Comparator|Apple juice|Patients will be allowed to drink apple juice up to 2 hours before their caesarean section.
89100361|NCT04160104||Training cohort|This cohort was used to establish the bowel preparation score (BPS).
89100362|NCT04160104||Validation cohort|This cohort was used to verify the bowel preparation score (BPS).
89100363|NCT04163146|Experimental|Healthy children and adolescents|Healthy children and adolescents aged 6 to 18 years (N=100) for the assessment of normal PEF and FEV1 variability.
89100364|NCT04163146|Experimental|Asthmatic children and adolescents|Children and adolescents aged 6 to 18 years with diagnosed asthma (N=100) for the assessment of PEF and FEV1 variability in asthmatics.
89100365|NCT00656266|Placebo Comparator|tacrolimus & corticosteroids|Standard post-transplant immunosuppression medications: tacrolimus and corticosteroids
89100366|NCT00656266|Experimental|low-dose tacrolimus + steroids + MMF|Comparison arm: low-dose tacrolimus + steroids + MMF
89100367|NCT00882310|Experimental|Gemcitabine, Docetaxel, Capecitabine GTX|GTX - A two week regimen of Gemcitabine at 600 mg/m2 on days 4 and 1, infused over 60 minutes, Docetaxel at 30 mg/m2 on days 4 and 11, infused over 60 minutes and Capecitabine at 1000 mg/m2 (capped at 1000 mg BID days 1-14) followed by one week off for a total of a 21 day cycle. This is repeated for a total of 6 months.
89100368|NCT00884650|Active Comparator|Oral Analgesic Only|Group 1 will receive oral analgesic only
89100369|NCT00884650|Active Comparator|anesthetic continuous-infusion + oral analgesia|Group 2: anesthetic continuous-infusion device, e.g. intravenous analgesic per pump, with supplemental oral analgesia
89100370|NCT02636842|Other|Location|Deltoid or Gluteal Muscle
89100371|NCT04163380|Experimental|Early Follicular Phase (EFP)|
89100372|NCT04163380|Experimental|Late Follicular Phase (LFP)|
89100373|NCT04163380|Experimental|Early Luteal Phase (ELP)|
89100374|NCT04163380|Experimental|Late Luteal Phase (LLP)|
89100375|NCT04163302|Experimental|CD19+ Lymphoma|This study is to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with Relapsed/Refractory B Cell Lymphoma.
89100376|NCT02535598|Active Comparator|Normal presentation|Standard internet based CBT presentation.
89100377|NCT02535598|Experimental|Enhanced presentation|Enhanced internet CBT presentation.
89100378|NCT02535598|Active Comparator|Normal support|Standard internet based CBT support.
89100379|NCT02535598|Experimental|Enhanced support|Enhanced internet CBT support.
89100380|NCT04159636|No Intervention|Fasting group|Participants will be remained fasted until surgery
89100381|NCT04159636|Experimental|Carbohydrate group|Participants will be allowed to drink carbohydrate beverage before 2 hours of surgery
89227531|NCT00079339|Experimental|Treatment (radiation therapy and tipifarnib)|"PHASE I: Patients undergo radiotherapy 5 days a week for 6 weeks. Beginning 0-2 days before radiotherapy, patients receive oral tipifarnib twice daily until the completion of radiotherapy. Beginning 2 weeks after the completion of radiotherapy, patients receive oral tipifarnib twice daily in weeks 1-3. Treatment repeats every 4 weeks for up to 24 additional courses (total of 26 courses) in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients undergo radiotherapy and receive tipifarnib at the MTD as in phase I (closed to accrual as of 1/19/06). Treatment continues for up to 24 months (26 courses) in the absence of disease progression or unacceptable toxicity."
89227532|NCT01020201||PONV group|patients with postoperative nausea and vomiting
89227533|NCT01020201||Control group|patients without postoperative nausea and vomiting
89227534|NCT00493779|No Intervention|1|Effect of Clopidogrel withdrawal on biomarkers will be assessed via blood draws
89227535|NCT01088191|Active Comparator|Hyaluronan Alone|Hyaluronan Alone
89100382|NCT02634502|Experimental|Treatment|Patients will receive radiofrequency ablation for liver metastatic lesions, as well as two weeks of oral S-1 treatment every three weeks, until progression of disease or adverse effects leading to termination of treatment. Each 3-week period is one cycle of treatment.
89100383|NCT04161820|Experimental|Education and telephone follow ups based on the CCM|"After the pre-tests (self-management, quality of life and patient satisfaction were assessed by scales at the first interview), the patients were given discharge training with a booklet prepared based on the Chronic Care Model (CCM) and containing information and recommendations on self-management strategies during their stay in the hospital (0 months). Trainings were performed in a single session and in the patient room at the clinic, not to exceed 45-50 minutes. The patients who were included in the intervention group were followed up by phone on the 7th day, 15th day, 1st month and 2nd month after discharge. Patients were referred to the hospital in unexpected / unpredictable situations during the three-month period.~Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later."
89100384|NCT04161976|Experimental|LY900027|LY900027 administered to participants with type 1 diabetes mellitus (T1DM) using continuous subcutaneous insulin infusion (CSII) in one of two dosing periods.
89100385|NCT04161976|Active Comparator|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII in one of two dosing periods.
89100386|NCT04159558|Experimental|experimental hypertension|The subjects with Hypertension will be trained in the use of the personalized help tool and will use it during a period of 3 months.
89100387|NCT04159558|Experimental|experimental diabetes|The subjects with Diabetes will be trained in the use of the personalized help tool and will use it during a period of 3 months.
89100388|NCT04159558|Experimental|experimental heart failure|The subjects with Heart failure will be trained in the use of the personalized help tool and will use it during a period of 3 months.
89100389|NCT04159558|Experimental|experimental copd|The subjects with COPD will be trained in the use of the personalized help tool and will use it during a period of 3 months.
89100390|NCT04159558|Experimental|experimental asthma|The subjects with Asthma will be trained in the use of the personalized help tool and will use it during a period of 3 months.
89100391|NCT04159558|Experimental|experimental obesity|The subjects with Obesity will be trained in the use of the personalized help tool and will use it during a period of 3 months.
89100392|NCT04163068||Interview with researcher|All participants will participate in an interview with a researcher
89100393|NCT02634424|Experimental|MyPKFiT|Personalized prophylaxis : Treatment is adjustment according to PK modeling
89100394|NCT00656422|Experimental|insulin Levemir|
89100395|NCT00656422|Experimental|insulin Lantus|
89100396|NCT00881608|Placebo Comparator|Placebo|Initiation-Placebo Cycle-Five (5) placebo capsules will be dispensed to subjects to self-administer for five days starting on cycle day 18.
89100397|NCT00881608|Experimental|3 mg Proellex|First Cycle (3 mg)- Five (5) 3 mg capsules of Proellex will be dispensed to subjects to self-administer for five days starting on cycle day 18.
89100398|NCT00881608|Experimental|6 mg Proellex|Second Cycle (6 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed ten (10) 3 mg capsules of Proellex to self-administer 2, 3 mg capsules each day for five days starting on cycle day 18.
89100399|NCT00881608|Experimental|12 mg Proellex|Third Cycle (12 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed twenty (20) 3 mg capsules of Proellex to self-administer 4, 3 mg capsules for five days starting on cycle day 18.
89100400|NCT00881608|Experimental|25 mg Proellex|Fourth Cycle (25 mg)-Subjects, who have not experienced menses, will be dispensed five (5) 25 mg capsules of Proellex to self-administer for five days starting on cycle day 18.
89100401|NCT04162912|Experimental|Experimental group|Participants in the experimental group will receive a MotivationaI Interviewing tailored ACP programme.
89100402|NCT04162912|No Intervention|Control group|The participants in the control group will receive usual care offered by the palliative care team under study and its affiliated day care centres, home care team and outpatient clinics.
89100403|NCT02636764|Active Comparator|exercise group|An exercise protocol drawn up with the objective will be held to strengthen the musculature: flexor and extensor of the knee; extension, abduction, hip side rotator, using the weight and the elastic band.
89100404|NCT02636764|Placebo Comparator|exercise group + Ultrasound therapy|Apart from intervening in the exercise group, an ultrasound device is used .
89100405|NCT02636764|Experimental|exercise group + interferential current|Besides the intervention of the exercise group after the exercises will be applied to interferential current through the device. Will be positioned 4 electrodes (8x5 cm), two upper and two lower (forming a square) around the center of the knee.
89100406|NCT02636764|Experimental|exercise group + short-wave diathermy|Besides the intervention of the exercise group after the exercises will be applied diathermies short wave in continuous mode. For that will be used apparatus, 27.12 megahertz, by means of vulcanized rubber electrodes (12x17 cm) with gentle warming for 30 minutes.
89100407|NCT02636764|Experimental|exercise group + Low level laser therapy|Apart from intervening in the exercise group, will be applied to Low level laser therapy, through the laser unit, Class 3b, gallium-aluminum-arsenide, continuous mode, wavelength: 830 nanometer, power: 30 watts.
89100408|NCT00657670|Experimental|1|Ready-made spectacles
89100409|NCT00657670|Active Comparator|2|Spectacles
89100410|NCT02632630|Active Comparator|Amino Acids w/Electrolytes in Dextrose|Peripheral parenteral nutrition (PPN)
89100411|NCT02632630|Active Comparator|Ensure product|Calorie and protein dense oral nutritional supplement for patients with elevated nutritional needs.
89100412|NCT02632630|Active Comparator|Crystalloid solutions|Standard care intravenous maintenance fluids.
89100413|NCT02632630|Active Comparator|Oral nutritional supplementation|Nutrient-enhanced drink products that provide macronutrients and micronutrients with the aim of increasing oral nutritional intake.
89100414|NCT02634034|Experimental|NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)|
89100415|NCT02634034|Experimental|Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)|
89100416|NCT02634034|Experimental|Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)|
89100417|NCT00657748|Experimental|1|
89100418|NCT02636218|Active Comparator|0.9% NaCl control|Normal saline
89100419|NCT02636218|Experimental|Ketamine|Anesthetic
89100420|NCT01088399||Somatropin replacement treatment|Adult participants with growth hormone deficiency receiving somatropin replacement treatment.
89100421|NCT01088399||No treatment|Adult participants with growth hormone deficiency receiving no somatropin replacement treatment.
89100422|NCT04161508|Experimental|Sugammadex|sugammadex 2 mg/ Kg for the reversal of neuromuscular blockade at the end of surgery
89100423|NCT04161508|Active Comparator|Neostigmine|neostigmine 50 mcg/Kg + glycopyrrolate 10 mcg/kg for the reversal of neuromuscular blockade at the end of surgery
89100424|NCT00598078|Experimental|1|
89100425|NCT00598078|Experimental|2|
89100426|NCT00598078|Placebo Comparator|3|
89100427|NCT02636296|Experimental|Pilates|Group received 12 week of inspired-Pilates intervention (2 days/week, 60 minutes duration).
89100428|NCT02636296|Other|Control|Control group was oriented to maintain the habitual activities during 12 weeks
89100429|NCT00656500|Active Comparator|1|Brief assistance with smoking abstinence
89100430|NCT00656500|Experimental|2|Brief intervention to promote quitline utilization
89100431|NCT01079195||Single Patient group with Hypertension|Single Patient group with Hypertension
89100432|NCT00883558|Experimental|INSULIN-PH20 NP / Insulin Lispro|"All enrolled participants underwent a 1-month dose titration period and received 100 units per milliliter (U/mL) insulin lispro, injected subcutaneously (SC) pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~INSULIN-PH20 NP (Treatment A): 100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine or maintained their usual regimen through an insulin pump."
89100433|NCT04162834|Experimental|Papaverine group|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
89100434|NCT04162834|Active Comparator|Normal saline group|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
89100435|NCT00656578|Experimental|1|4975
89100436|NCT00656578|Placebo Comparator|2|Drug, Single dose, solution
89100437|NCT00657904|Experimental|1|
89100438|NCT00657904|Placebo Comparator|2|
89100439|NCT04161196|Active Comparator|patients with post - tonsillectomy suturing tonsil pillars|
89100440|NCT04161196|Placebo Comparator|patients without post - tonsillectomy suturing tonsil pillars|
89100441|NCT00880750|Experimental|Lanthanum carbonate granules|Lanthanum carbonate granulated formulation crossover to chewable tablet formulation
89100442|NCT00880750|Experimental|Lanthanum carbonate chewable tablets (Fosrenol)|Lanthanum carbonate chewable table formulation crossover to granulated formulation
89100443|NCT02636374|Experimental|Guided Imagery|Participants listened to a pregnancy-specific guided imagery recording on four separate occasions during their pregnancies. Perceived stress was measured immediately pre and post each listening session using the Perceived Stress Measure-9 (PSM-9).
89100444|NCT02535676|Active Comparator|Active tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 20 minutes.
89227536|NCT01088191|Experimental|MSB-CAR001|Single Dose of MSB-CAR001 Combined With Hyaluronan
89100445|NCT02535676|Sham Comparator|Sham tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 19 minutes.
89100446|NCT02633878|Experimental|CHM+MP|CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
89100447|NCT02633878|Placebo Comparator|CHM Placebo+MP Placebo|CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
89100448|NCT02633878|Experimental|CHM+MP Placebo|CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
89100449|NCT02633878|Experimental|CHM Placebo+MP|CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
89100450|NCT02877797|No Intervention|standard Esophagogastroduodenoscopy|standard Esophagogastroduodenoscopy
89100451|NCT02877797|Experimental|cap assisted Esophagogastroduodenoscopy|cap assisted Esophagogastroduodenoscopy
89100452|NCT00597766|Active Comparator|Low Dose|"Drug: Lidocaine (Neer's Test)~Drug: 20 mg Triamcinolone + Lidocaine"
89100453|NCT00597766|Active Comparator|Standard Dose|"Drug: Lidocaine (Neer's Test)~Drug: 40 mg Triamcinolone + Lidocaine"
89100454|NCT00597766|Experimental|High Dose|"Drug: Lidocaine (Neer's Test)~Drug: 60 mg Triamcinolone + Lidocaine"
89100455|NCT02877563||Patients with PAD|Patients with PAD who are to undergo surgical or percutaneous revascularization.
89227537|NCT01082341|Experimental|Fy(+)|14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites
89227538|NCT01082341|Active Comparator|Fy(+) control|Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.
89227539|NCT01082341|Active Comparator|Fy(-)|Six Fy(-) volunteers will be exposed to infective mosquito bites.
89227540|NCT01017315|Experimental|No application of baby talcum|control
89227541|NCT00541866|Experimental|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A:~Schedule B:~Expansion Phase~Schedule A:~Schedule B:"
89100456|NCT04159090|Experimental|Prostate cancer patients|
89100457|NCT04161274|Active Comparator|Traditional method: Electrosurgery|"Local anaesthesia and excision with a scalpel connected to the electric current, according to the voltage. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
89100458|NCT04161274|Active Comparator|Traditional method: Cryotherapy|"Application of liquid nitrogen to cause freezing. Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
89100459|NCT04161274|Active Comparator|Traditional method: Silver nitrate|"Excision is made with the scissors and a rod is applied containing silver nitrate with caustic power on the wound.~Traditional cure with alcohol/Betadine. Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
89100460|NCT04161274|Experimental|Moist healing environment|"Excision is made with the scissors, afterwards pressure, clorhexidine and a hydrocolloid dressing when the skin is dry.~Photograph to the lesion before and after the intervention and in each follow-up visit.~Follow-up visits every 3 days until the lesions cicatrization."
89227542|NCT01082419|Other|Group A|healthy volunteers
89100461|NCT00657982|Experimental|1|RAD001 10 BID 6 weeks before definite treatment for localized prostate cancer
89100462|NCT04159246||Sovaldi group|patients with a documented diagnosis of chronic hepatitis C , normal renal functions And Rheumatoid factor tests (to exclude Purtscher like retinopathy as a rare presentation of cryoglobuinemia which considered one of extra hepatic manifestations of HCV)
89100463|NCT02636140|Experimental|Light|Randomized amount and color of light
89100464|NCT02633722|Experimental|TRF-b|Participants are instructed to eat between 8am-5pm
89100465|NCT02633722|Experimental|TRF-d|Participants are instructed to eat only between 12-9pm
89100466|NCT02633722|No Intervention|Baseline|No lifestyle instruction given
89100467|NCT00658060||1|"1.Fulfilling the Tel Hashomer criteria for the diagnosis of FMF [5].~2.Suffering from episodes of exertional leg pain and or exertional ankle edema~3.18-45 years old~4.On a stable (≥ 2 weeks) dose of oral colchicine therapy~5.Non-smokers"
89100468|NCT00658060||2|"Control group~1.Healthy subjects~2.18-45 years old~3.Non-smokers"
89100469|NCT02633566|Active Comparator|Functional plantar orthoses|Functional plantar orthoses in polypropylene with Medial Heel Skive technique
89100470|NCT02633566|Placebo Comparator|Placebo plantar orthoses|Plantar orthoses made in Ethil Vinyl Acetate (22º Shore) without correction of the pronation
89100471|NCT02633410|Active Comparator|Transtibial|Transtibial technique used to create femoral tunnel
89100472|NCT02633410|Active Comparator|Anteromedial|Anteromedial technique used to create femoral tunnel
89100473|NCT02633254|Experimental|Single arm|Treatment group Magentic Resonance guided High Intensity Focused Ultrasound will be employed on uterine fibroids
89100474|NCT04160962||lappg|
89100475|NCT04160962||ladgbi|
89100476|NCT00658216||Longitudinal|Prospective study : cohort of consecutive patients recruited over 2 years
89100477|NCT03960996|Experimental|Dacryocystorinostomy with bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy with bicanalicular intubation.
89100478|NCT03960996|Experimental|Dacryocystorinostomy without bicanalicular intubation|Patients with lacrimal duct obstruction enrolled into this study arm will undergo dacryocystorinostomy without bicanalicular intubation.
89100479|NCT02636062||Follow-up CAC > 0|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients that develop incident CAC.
89100480|NCT02636062||Follow-up CAC zero|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients who continue to have a CAC of zero.
89100481|NCT04290156|Experimental|Joint visits|Subjects in the intervention arm attend a total of four joint transition visits performed with the participation of both the adult and the pediatric gastroenterologist.
89100482|NCT04290156|No Intervention|Usual care|Adolescents meet only the pediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologists with respect the patient's treatment plan.
89100483|NCT00657124|Experimental|1|receive a preoperative supplementation with carbohydrate and branched-chain amino acids-enriched nutrient
89100484|NCT00657124|Placebo Comparator|2|receive a preoperative supplementation without carbohydrate and branched-chain amino acids-enriched nutrient
89100485|NCT02866500|Experimental|oral cancer|
89100486|NCT04080024|Experimental|Single dose (i.v.) SN132D|
89100487|NCT00979992|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89100488|NCT01079741|Experimental|Dose-escalation component|Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen and Montanide will be held constant.
89100489|NCT01079741|Active Comparator|Phase II is the randomized component.|The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
89100490|NCT04289220|Experimental|Anti-CD19 CAR-T Cells Injection|Anti-CD19 CAR-T Cells Injection, Dosage form：injection Dosage:1-2.5x10^6/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
89100491|NCT02877641|Active Comparator|Control arm (multivitamin, placebo)|Patients receive a placebo and multivitamin orally each day for 52 weeks.
89100492|NCT02877641|Experimental|Supplementation arm (multivitamin, cholecalciferol)|Patients receive a multivitamin and cholecalciferol supplement orally each day for 52 weeks.
89100493|NCT01079663|Experimental|Chlorhexidine chip (Periochip®)|PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
89100494|NCT01079663|Placebo Comparator|Placebo chip|Placebo Chip Placebo Chips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
89100495|NCT02867046|Experimental|medial approach group|
89100496|NCT02867046|Active Comparator|lateral approach group|
89100497|NCT02865174|Active Comparator|Topical tranexamic acid|Intraarticular application of tranexamic acid Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
89227543|NCT01082419|Other|Group B|patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)
89100498|NCT02865174|Active Comparator|Floseal®|"Floseal® was applied on potential bleeding sites before prosthesis implantation.~Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay"
89100499|NCT02865174|Placebo Comparator|Control group|No intervention before closure of joint capsule. Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
89100500|NCT00879814|Experimental|1|rLP2086 vaccine 60 mcg
89100501|NCT00879814|Experimental|2|rLP2086 vaccine 120 mcg
89100502|NCT00879814|Experimental|3|rLP2086 vaccine 200 mcg
89100503|NCT00879814|Active Comparator|4|Tdap vaccine - normal saline - normal saline
89100504|NCT02633176|Active Comparator|cisplatin and docetaxel|"Induction chemotherapy: Patients receive cisplatin and docetaxel intravenously on day 1 repeated every 3 weeks for 6 cycles.~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cisplatin 30mg/m^2 intravenously every week.~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
89100505|NCT02633176|Experimental|cetuximab, cisplatin, and docetaxel|"Induction chemotherapy: Patients receive cetuximab 400mg/m^2 intravenously over at least 120 minutes on day 1 followed by 250 mg/m^2 intravenously over at least 60 minutes every week. Cisplatin and docetaxel will be administered intravenously on day 2 repeated every 3 weeks for 6 cycles.~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cetuximab 250mg/m^2 intravenously followed by cisplatin 30mg/m^2 intravenously every week.~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
89100506|NCT04156984|Other|Study arm|Subjects treated with optimized dose of golimumab, irrespective of weight: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4 weeks. In case of disease flare: discontinuation of drug.
89100507|NCT04156984|Other|Control arm|"Subjects treated according to current European Label (2019) based on body weight:~<80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 50 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): dose optimization to 100 mg sc q4wk starting at week 6 or at any time during first year.~≥80kg: golimumab 200 mg sc, followed by 100 mg sc at week 2 and then 100 mg sc q4wk. In case of disease flare (defined as PRO-2 ≥1): discontinuation of drug."
89100508|NCT04157140|Experimental|Anlotinib+ TACE+ RFA|Anlotinib+ TACE+ RFA
89100509|NCT04158778|Experimental|MDMA assisted Psychotherapy|All participants receive 2 sessions of MDMA-assisted psychotherapy
89100510|NCT01132664|Experimental|HER2+ metastatic breast cancer|Patients with HER2-overexpressing metastatic breast cancer, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
89100511|NCT01132664|Experimental|HER2+ metastatic breast cancer with BM|Patients with HER2-overexpressing metastatic breast cancer and brain metastases, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
89100512|NCT00591409|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
89100513|NCT00591409|Experimental|Rocuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
89227544|NCT01082419|Other|Group D|patients with cirrhosis
89227545|NCT01082419|Other|Group E|patients with liver tumour and surgery indication
89227546|NCT01082419|Other|Group F|patients with reversible liver diseases and with acute left cardiac insufficiency
89227547|NCT01082419|Other|Group C|patients with non cirrhotic hepatopathy
89227548|NCT01082419|Other|Group G|patients with reversible liver diseases and with biliary cholestasis
89227549|NCT00493467|Experimental|Zevalin|Ibritumomab Tiuxetan (Zevalin) + Rituximab
89227550|NCT01088269||AF|Hypertensive patients in AF
89227551|NCT01088269||Non-AF|Hypertensive Patients
89227552|NCT00090493|Experimental|MAGE-A3 and NY-ESO-1 Immunotherapy|Treatment will consist of receiving peptide vaccinations as a shot just under the skin (subcutaneous). Peptides are small pieces of proteins. We have chosen to vaccinate with peptides derived from cancer proteins found in myeloma and other cancers. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
89227553|NCT01088347|Experimental|Advanced cervical cancer patients|
89100514|NCT00591409|Experimental|Rocuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
89100515|NCT00591409|Experimental|Rocuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
89100516|NCT00591409|Experimental|Rocuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
89100517|NCT00591409|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
89100518|NCT00591409|Experimental|Vecuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
89100519|NCT00591409|Experimental|Vecuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
89100520|NCT00591409|Experimental|Vecuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
89100521|NCT00591409|Experimental|Vecuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
89100522|NCT02610361|Experimental|BGB-283|
89100523|NCT05756101|Experimental|Control group|Sponge restraint belt, restraint method: adjust the fixed wrist strap according to the diameter of the patient's hand (foot) wrist, and then circle the fixed strap around the wrist strap, one end is pierced through the strap hole without knots, and the two ends of the fixed strap are fixed on both sides of the bed as needed.
89100524|NCT05756101|Experimental|Experimental group|A new type of restraint device, which is an adjustable protective restraint device (patent number ZL202020155913.1), including upper fixation bracket I, upper fixation bracket II, lower fixation bracket I, lower fixation bracket II and gloves; The plurality of fixed brackets are provided with breathable holes and breathable cotton is placed to increase air permeability and comfort. Place the patient's elbow joint on top of the lower fixation bracket I and II, and then install and connect the upper fixation bracket I and the upper fixation bracket 2 through the upper and lower tightening belts, and adjust their tightness; The upper and lower fixed bracket connections are adjustment module 1 and adjustment module 2, forming a detachable and rotating connection within a certain angle range to adjust the angle of elbow joint movement of the patient; The patient's hand is made by wearing gloves with a grip ball on the palm surface.
89100525|NCT00709345|Experimental|Group Home|Participants will receive cognitive behavioral sessions.
89100526|NCT00709345|Active Comparator|Control|Participants will receive time-matched attention control sessions.
89100527|NCT01078805||FORTEO (teriparatide)-treated|FORTEO-treated
89100528|NCT00626249|Experimental|T Inhalation powder in diabetic subjs w/ normal renal func|T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units
89227554|NCT04329702|Experimental|coping skills training plus therapist input|Participants will receive a CST therapist call within 48 hours of randomization to discuss the study rationale, to conduct a relaxation exercise, and to review app and study logistics. Participants will use the Blueprint mobile app for 1 month.
89227555|NCT04329702|Experimental|coping skills training without therapist input|Participants will receive a call from a research coordinator to get them started with the trial. Participants will use the Blueprint mobile app for 1 month. No therapist calls will be provided. Chat room access in the app will be provided.
89227556|NCT04329702|No Intervention|usual care control|Control participants will receive the same safety oversight as intervention participants and will be provided with phone and email contacts for study staff.
89100529|NCT00626249|Experimental|T Inhalation powder diabetic subj w/mild or moderate nephrop|T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units
89100530|NCT02876939|Experimental|HSAN III|
89100531|NCT02876939|Active Comparator|Control Subjects|
89100532|NCT00820027|Experimental|Etoricoxib 90 mg|Participants received etoricoxib 90 mg once daily, matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
89100533|NCT00820027|Experimental|Etoricoxib 120 mg|Participants received etoricoxib 120 mg once daily, matching placebo to etoricoxib 90 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
89100534|NCT00820027|Active Comparator|Ibuprofen 1800 mg|Participants received ibuprofen 600 mg every 8 hours, matching placebo to etoricoxib 120 mg once daily, and matching placebo to etoricoxib 90 mg once daily for 7 days.
89100535|NCT00820027|Placebo Comparator|Placebo|Participants received matching placebo to etoricoxib 90 mg and matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen every 8 hours for 7 days.
89100536|NCT02877407|Other|laparoscopic/robotic-assisted hysteropexy|patient who undergo laparoscopic/robotic-assisted hysteropexy
89100537|NCT02877407|Other|vaginal hysterectomy|patient who undergo vaginal hysterectomy
89100538|NCT02876549|Experimental|G6PD Normal|
89100539|NCT02876549|Experimental|G6PD Deficient|
89100540|NCT02876627|Experimental|breast cancer|Effect of exercise training on breast cancer patient
89100541|NCT00913549|Experimental|1|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
89100542|NCT00913549|Experimental|2|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
89100543|NCT01076153||Patients with respiratory tract infection|Thai patients with upper or lower respiratory tract infections on Klacid MR.
89100544|NCT01076075|Active Comparator|placebo/pioglitazone|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg
89100545|NCT01076075|Experimental|Sitagliptin|Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone
89100546|NCT02876393||Cases|Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.
89100547|NCT02876393||Control definition|Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.
89100548|NCT01075763|Experimental|Treatment arm - Rebif®|Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw)
89100549|NCT01075763|Placebo Comparator|Placebo arm|Subjects in this arm received placebo
89100550|NCT00881530|Active Comparator|Sitagliptin|100 mg
89100551|NCT00881530|Active Comparator|Metformin|2000 mg
89100552|NCT00881530|Experimental|BI 10773 X mg|lower dose
89230286|NCT03952975|Other|luteal phase group|The menstrual dates of patients were normalized to a 28-day cycle with the following formula: adjusted day of the menstrual cycle = (14 X day of the cycle at the time of surgery) / (cycle length of the patient - 14) [14]. In light of this formula, patients were classified into the luteal phase group (defined as ≥15 adjusted days, group B).
89100553|NCT00881530|Experimental|BI 10773 Y mg|higher dose
89100554|NCT01075685|Experimental|Web-based alcohol programme|"Participants could log on to their account and access the programme whenever they wanted to.~They received automated email reminders inviting them to use follow-up tools, especially the diary in order to register their alcohol intake on the previous week:~4 weeks after starting the programme, so that they would take advantage of the monitoring stage in case they had not spontaneously done so.~2 weeks later for 6-week follow-up."
89100555|NCT01075685|Placebo Comparator|Minimum information|Participants could log on to their account and access the programme whenever they wanted to. At 6 week follow-up they received an automated email reminder inviting them to use the diary in order to register their alcohol intake on the previous week.
89100556|NCT01075217|Experimental|Isovue 250 (iopamidol)|
89100557|NCT01075217|Active Comparator|Visipaque 270 (iodixanol)|
89100558|NCT02632474|Experimental|Low-dose|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
89100559|NCT04156750|Experimental|LY3556050 (Part A)|LY3556050 administered orally.
89100560|NCT04156750|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
89100561|NCT04156750|Other|Iohexol (Part B)|Iohexol given intravenously (IV). (Part B is optional.)
89100562|NCT04156750|Other|Metformin (Part B)|Metformin given orally. (Part B is optional.)
89100563|NCT04156750|Experimental|LY3556050+ Iohexol (Part B)|Iohexol given intravenously (IV) coadministered with oral doses of LY3556050. (Part B is optional.)
89100564|NCT04156750|Experimental|LY3556050 + Metformin (Part B)|Metformin given orally coadministered with oral doses of LY3556050. (Part B is optional.)
89100565|NCT02877173|Experimental|Alprostadil Liposomes for Injection|Alprostadil Liposomes for Injection at low dose:20ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at medium dose:40ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at high dose:60ug,once a day,continuous administration for 3 weeks;
89100566|NCT02877173|Active Comparator|Alprostadil Injection|Alprostadil Injection:10ug,once a day,continuous administration for 3 weeks;
89100567|NCT00658450|Experimental|Cognitive rehabilitation training|Children in this arm will the receive the intervention comprising of 16 cognitive rehabilitation training (CRT) exercises for 8 weeks. These exercises will train different cognitive skills including attention, visual spatial processing, logical skills and memory.
89100568|NCT00658450|No Intervention|Treatment as usual|Children in this group will not receive any intervention, they will undergo the usual post discharge treatment for brain injured children at Mulago Hospital (the study site). This is the treatment as usual (TAU) group.
89100569|NCT04305743|Experimental|5 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 5 injections of 2 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
89100570|NCT04305743|Active Comparator|20 Injections|Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 20 injections of 0.5 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
89100571|NCT00661180|Experimental|Arm 1|
89100572|NCT02632942|Experimental|HAQ Criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~60% or greater diameter of the main AVF~50% diameter of AVF with at least one more av>40% in diameter.~50% in diameter and divides into branches of same size.~av likely to interfere with cannulation on physical examination.~>30% in diameter and associated with stenosis at site of origin."
89100573|NCT02632942|Active Comparator|Current Recommendation|Obliteration of accessory vein which satisfy the current recommendations only defined as accessory vein with a diameter greater than 25% of the AVF diameter.
89100574|NCT04032574|Experimental|Herbal medicinal product|three times daily two film coated tablets containing: extracts of restharrow root (Ononidis radix) 80mg,Java tea (Orthosiphonis folium) 90mg, goldenrod herb (Solidaginis herba) 180mg
89100575|NCT04032574|Placebo Comparator|Placebo|three times daily two film coated tablets
89100576|NCT04032496|Experimental|Mindfulness Intervention|Participants in this arm will participate in the Contemplative-Based Intervention for People Living with SLE intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
89100577|NCT04032496|Active Comparator|HEP Intervention|Participants in this arm will participate in the Health Enhancement Program (HEP) intervention in addition to one baseline fMRI and blood analysis and one post-treatment fMRI and blood analysis.
89100578|NCT02876471|No Intervention|OSA group|100 severe OSA patients without hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS),demographic and anthropometric data The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated
89100579|NCT02876471|Other|OSA with hypertension|100 severe OSA patients with hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS), antihypertensive medicine demographic and anthropometric data. The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated.Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood pressure control, the investigators would give one-night CPAP.
89100580|NCT04032340||Elderly with a companion dog|elderly living at home with a dog consulting his family doctor
89100581|NCT04032340||Elderly without a companion dog|elderly living at home without a dog consulting his family doctor
89100582|NCT04032262|Other|Parkinson's Disease Relationship to the GI track|Patients with Parkinson's.
89100583|NCT01078571||RA patients in treatment with adalimumab (Humira)|RA patients in treatment with adalimumab (Humira) at 40mg alternate weeks
89100584|NCT04017364|Active Comparator|PTCA of coronary de novo lesion PCB|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
89100585|NCT04017364|Experimental|PTCA of coronary de novo lesion SCB|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
89100586|NCT02877329|Experimental|Internet-delivered ACT|Guided Internet-delivered Acceptance and commitment therapy for 8 weeks
89100587|NCT02877329|No Intervention|Wait list control|No treatment during 8 weeks
89100588|NCT04160416|Experimental|mXELOXIRI|"Induction therapy is followed by the maintenance therapy. Induction treatment: XELOXIRI+CET/BEV Administered for 6 cycles (a maximum of 8 cycles).Bevacizumab (BEV): 5mg/kg (d.i.v.); Cetuximab 500mg/sq.m (d.i.v.)；Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) Irinotecan (IRI):135 mg/sq.m (d.i.v.) CAP 1,600 mg/sq.m /day (p.o. day1-10) Administered every 2 weeks.~Maintenance treatment: CAP+CET/BEV. The following CAP+BEV/CET therapy will be repeated in 2-week cycles."
89100589|NCT02876237|Experimental|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later.~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
89100590|NCT04158700|Experimental|LY3200882 and Pembrolizumab (Dose Level 1)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered intravenously (IV).
89100591|NCT04158700|Experimental|LY3200882 and Pembrolizumab (Dose Level 2)|Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered IV.
89100592|NCT04158700|Experimental|LY3200882 and Pembrolizumab Expansion|Participants with urothelial carcinoma, non-small cell lung cancer, or hepatocellular carcinoma: LY3200882 administered orally twice in combination with pembrolizumab administered IV.
89100593|NCT02876003|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
89100594|NCT04158544||Checkpoint Inhibitors|Patients with metastatic melanoma receiving systemic therapy with checkpoint inhibitors
89100595|NCT04158544||Kinase Inhibitors|Patients with metastatic melanoma receiving systemic therapy with kinase inhibitors
89100596|NCT04306289|Active Comparator|Real tDCS|The participant will receive anodal tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
89100597|NCT04306289|Sham Comparator|Sham tDCS|Identical to the real tDCS, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
89100598|NCT00657202|Experimental|Ranibizumab|
89230287|NCT00802451|Active Comparator|Test Drug|
89100599|NCT00626483|Experimental|CMV pp65-LAMP mRNA-loaded DC vaccination|Basiliximab will be safe in combination with CMV pp65-LAMP mRNA-loaded DC vaccination and GM-CSF
89100600|NCT02632864|Experimental|Proton arm|Proton beam therapy
89100601|NCT00626717|Experimental|1|
89100602|NCT00626717|Sham Comparator|2|
89100603|NCT04160572|Experimental|Morning-evening sleep schedule|
89100604|NCT04160572|Active Comparator|Evening-morning sleep schedule|
89100605|NCT04156204|Experimental|Adolescent and Young Adult (AYA) Kidney Transplant Recipients|AYA kidney transplant recipients will receive a Medication Event Monitoring System (MEMS) in the form of a medication bottle and cap system and once daily tacrolimus XR 1-10mg
89100606|NCT02631694|Experimental|Fear reactivation with propranolol|
89100607|NCT02631694|Placebo Comparator|Fear reactivation with placebo|
89100608|NCT02631694|Placebo Comparator|No fear reactivation with propranolol|
89100609|NCT04306133|Experimental|PENG BLOCK AND WOUND INFILTRATION|Participants receiving PENG block combined to wound infiltration
89100610|NCT04306133|Active Comparator|WOUND INFILTRATION|Participants receiving wound infiltration alone
89100611|NCT00658840|Experimental|1|"Primary objectives :~To evaluate the tumor response rate, local control rate and compliance (acute and late toxicity, esp. gastrointestinal tract toxicity) of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma~Secondary objectives :~To evaluate the impact of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma by analyzing the progression-free survival rate and overall survival rate."
89100612|NCT04305353|Experimental|ICU Diary Group|Patients randomized to this group receive the ICU diary, along with PTSD education
89100613|NCT04305353|Other|PTSD Education-only Group|Control Group: patients randomized to this group only receive PTSD education
89100614|NCT00658918|Active Comparator|1|Ciclesonide 200µg
89100615|NCT00658918|Active Comparator|2|Ciclesonide 100µg
89100616|NCT00658918|Active Comparator|3|Ciclesonide 25µg
89100617|NCT00658918|Placebo Comparator|4|Placebo
89100618|NCT02631616|Experimental|Treatment arm|Monthly injections of Somatostatin (Sandoatatin LAR - 30mg)
89100619|NCT00661648|No Intervention|1|glucose levels were controlled using sliding scale
89100620|NCT00661648|Experimental|2|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
89100621|NCT04306055|Experimental|Questionnaire with precaution information|Questionnaire in this group includes information about precaution of blood donation during epidemic of COVID-19.
89100622|NCT04306055|Experimental|Questionnaire without precaution information|Questionnaire in this group dose not include information about precaution of blood donation during epidemic of COVID-19.
89230288|NCT00802451|Active Comparator|Reference Drug|
89100623|NCT04306055|No Intervention|No questionnaire group|Ever donors in this group would not receive the questionnaire.
89100624|NCT04156282|Active Comparator|classical closure.|In this group, the rectus sheath closure will be done by simple running continuous sutures with the knots beneath the subcutaneous layer.
89100625|NCT04156282|Active Comparator|knot burial technique|The surgeon holds the left angle of the rectus sheath incision with an Allis. Using (Polyglactin 910) suture,The needle is taken from the inside outward on the upper edge.The needle is then taken lateral to the Allis and brought back into the wound by taking it through the inferior edge from outside to inside . A square knot is tied with three or four throws. The needle is then taken out of the wound through the upper edge and continuous running stitches . As the right angle is approached, the angle is held with an Allis. the suture, will be taken through the lower edge, is brought outside the wound and passed between the blades of a closed Allis before taking it inside out on the upper edge. One more bite is taken but this time just lateral to the Allis holding the angle, and the needle is brought back into the wound and to the outside between the edges of the rectus sheath. Using the loop of polyglactin held with the Allis , an Aberdeen knot is tied after removing the Allis.
89100626|NCT00977106|Experimental|1|
89100627|NCT00977106|Placebo Comparator|2|
89100628|NCT00977106|Experimental|3|
89100629|NCT00661804||Thalassemia cohort|"Thalassemia as documented by clinical diagnosis, including:~thalassemia (intermedia or major); HbH disease; HbH with non-deletional mutations, e.g., HbH Constant Spring E beta-thalassemia; Homozygous alpha-thalassemia (i.e., 4-gene alpha deletion or equivalent null alpha mutation); Other thalassemic conditions not explicitly excluded; Thalassemia intermedia due to heterozygous beta mutation with alpha-gene excess."
89100630|NCT00661804||Successful SCT cohort|Individuals who have received a successful hematopoietic SCT, defined as engraftment of all three cell lines and transfusion independence by 100 days post-transplant, for any of the disorders listed above;Monitored for end-organ injury related to thalassemia prior to their successful SCT;Participants who were enrolled in TCRN Registry or had a successful SCT after 01 Jan 2002.
89100631|NCT00665860|Placebo Comparator|1|Placebo
89100632|NCT00665860|Active Comparator|2|
89100633|NCT00665860|Active Comparator|3|
89100634|NCT00659074|Experimental|A|Ondansetron ODT
89100635|NCT00659074|Active Comparator|B|Zofran ODT
89100636|NCT02632318|Experimental|Light|Dawn simulation for 30 minutes prior to habitual wake time
89100637|NCT02632318|No Intervention|No light|Darkness for 30 minutes prior to habitual wake time
89100638|NCT00665938|Active Comparator|1|
89100639|NCT00665938|Experimental|2|
89100640|NCT00665938|Experimental|3|
89100641|NCT01077713|Experimental|1|
89100642|NCT01077713|Experimental|2|
89100643|NCT04290234||Non-medicated healthy adults with childhood maltreatment|The 25-item retrospective Childhood Trauma Questionnaire (CTQ) will be administered to assess history of abuse and neglect. The CTQ measures five types of maltreatment: emotional, physical, and sexual abuse and emotional and physical neglect.
89100644|NCT00666016|Experimental|1|TRO19622 500 mg
89100645|NCT00813709|Active Comparator|RNF 44 mcg thrice weekly|
89100646|NCT00813709|Active Comparator|RNF 44 mcg once weekly and placebo|
89100647|NCT00813709|Active Comparator|Placebo/RNF 44 mcg thrice weekly|
89100648|NCT04160884|Active Comparator|A|0.6mg/kg of ICG, iv
89100649|NCT04160884|Experimental|B|0.2mg/kg of ICG, iv
89100650|NCT02866266||All commercially insured patients in the HIRD|
89100651|NCT02866266||All Medicaid patients in a participating state Medicaid plan|
89100652|NCT00659152||1: ALI/ARDS|
89230289|NCT03956953|Experimental|Group 1: BMS-986165 Dose 1|Participants will receive Dose 1 on Day 1, and from Day 5 - 19.
89230290|NCT03956953|Experimental|Group 2: BMS-986165 Dose 2|Participants will receive Dose 2 on Day 1, and from Day 5 - 19.
89230291|NCT03956953|Placebo Comparator|Group 1: Placebo Dose 1|Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.
89100653|NCT02865876|Experimental|Accelerated Corneal Cross-linking|Cross-linking in the management of microbial keratitis is an adjunctive therapy.This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. The corneal epithelium on the edge of the ulcer is cautiously removed using a microsponge. As photosensitizer, riboflavin 0.1% (Vibex, Avedro Inc, Waltham, USA) is used for 10 minutes. After impregnation, the participant´s cornea is irradiaded with UVA-light (370 nm) using 30 mW/cm2 for 3 minutes (which corresponds to a total dose of 5.4J/cm2) with accelerated cross-linking (Avedro Inc., Waltham, USA). After procedure, conventional treatment for keratitis remains unchanged.
89100654|NCT02865876|Sham Comparator|Sham Accelerated Corneal Cross-linking|"Placebo surgery. This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. Investigators do not perform removal of the corneal epithelium in edge of the ulcer. The researchers conducted the impregnation phase applying drops of saline solution for 10 minutes. After impregnation fase, a device is placed in Avedro equipment off (Avedro Inc, Waltham, USA) this device emits white light for 3 minutes. After procedure, conventional treatment for keratitis remains unchanged."
89100655|NCT04158622|Experimental|Pneumatic Retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy + laser/cryotherapy
89100656|NCT04158622|Experimental|Pars Plana Vitrectomy|Patients with retinal detachment allocated to pars plana vitrectomy + laser/cryotherapy
89100657|NCT02866110|Experimental|Treatment group|25 patients with BPD. In a diagnostic session, diagnostics of psychiatric disorders are conducted. For BPD diagnosis, the International Personality Disorder Examination (IPDE) is used and symptom severity is assessed with the Borderline Symptom List. The Treatment group will receive fMRI amygdala neurofeedback training (3 sessions within 2 weeks). Patients in regular psychotherapeutic treatment (treatment-as-usual) will not be excluded.
89100658|NCT01077323||Exenatide Initiators|
89100659|NCT01077323||Other Antidiabetic Drug Initiators|
89100660|NCT01077323||Non-Diabetes Cohort|
89100661|NCT00662116|Experimental|1|
89100662|NCT00662116|Placebo Comparator|2|
89100663|NCT03870438|Experimental|Intervention|"Children infected with HIV-1 will be referred to the National Programme for confirmed HIV diagnosis and immediate ART.~For children that are not HIV-1 infected, the results on the mother's viral load will guide the next steps:~Mothers with a detectable plasma viral load (≥ 1000 copies/mL): their children will be initiated on lamivudine oral solution.~Mothers with an undetectable viral loads (<1000 copies/mL): their children will not be initiated on lamivudine oral solution at 6-8 weeks of age. However, additional monitoring on the viral load of the mother and the diagnosis of the child will take place at 6 months: If the maternal plasmatic viral load is ≥ 1000 copies/mL, the child will be initiated on lamivudine oral solution."
89100664|NCT03870438|No Intervention|Control|Routine Option B+ national guidelines including HIV-1 plasmatic viral load testing will be adhered to. Visits will take place at 6-8 weeks, 6 and 12 months post-partum to collect samples from the mother for the analysis of viral load results at 12 months. In addition, at 6-8 weeks, 6 and 12 months post-partum, POC tests will be done for the diagnosis of HIV-1 in their infants (by HIV-1 DNA PCR) and results will be shared within 2 hours. Children infected with HIV-1 will be referred to the National Programme for confirmed diagnosis and immediate ART.
89100665|NCT04287894|Experimental|Cohort 1A (firste cohort)|1 course Durvalumab (1500mg) + Tremelimumab (75mg) + 1 course of Durvalumab (1500mg) followed by CRT
89100666|NCT04287894|Experimental|Cohort 2A|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
89100667|NCT04287894|Active Comparator|Cohort 2B|2 course Durvalumab (1500mg) + Tremelimumab (75mg) followed by CRT
89100668|NCT04287582||Level 1 DMD|According to Brooke Lower Extremity Functional Classification Level 1
89100669|NCT04287582||Level 2-3 DMD|According to Brooke Lower Extremity Functional Classification Level 2 or 3
89100670|NCT04287582||Healthy Group|healthy children with similar demographic characteristics with children with DMD
89100671|NCT02863848|Placebo Comparator|Placebo|Maltodextrin 2g, twice per day, 6 weeks
89100672|NCT02863848|Active Comparator|Inulin-type fructans|Orafti inulin-type fructans 2g, twice per day, 6 weeks
89100673|NCT04287426|Active Comparator|Group receiving rocuronium at induction|Rocuronium 0,6 mg/kg at induction
89100674|NCT04287426|Active Comparator|Group receiving remifentanil at induction|Remifentanil 2 μg/kg at induction
89100675|NCT05757505|Experimental|experimental group|Intracranial Stent (Tonbridge)
89100676|NCT05757505|Active Comparator|control group|Wingspan Stent System (Stryker Neurovascular)
89100677|NCT04287504||Yeast, control|Women negative for vulvovaginal candidosis on Gram stain smear.
89100678|NCT04287504||Yeast, study group|Women positive for vulvovaginal candidosis on Gram stain smear.
89100679|NCT04287504||Bacterial vaginosis, control|Women negative for bacterial vaginosis on Gram stain smear.
89100680|NCT04287504||Bacterial vaginosis, study group|Women positive for bacterial vaginosis on Gram stain smear.
89100681|NCT04047576|Experimental|sirolimus group|"Sirolimus: 2 mg/day for the first 3 days and 1 mg/day thereafter. The plasma drug concentration was monitored at 14 days, 12 weeks, and 48 weeks of medication to maintain a plasma drug concentration of 4-15 ug/L.~Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until discontinuation."
89100682|NCT04047576|Active Comparator|corticosteroid group|Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until 5-7.5 mg/d.
89100683|NCT00976950||Patients with HIV-1 infection|
89230292|NCT03956953|Placebo Comparator|Group 2: Placebo Dose 2|Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.
89230293|NCT00798473|Experimental|1|Zoledronic acid, 0.06 mg/kg IV in a single infusion, maximum of 4 mg
89230294|NCT00798473|Placebo Comparator|2|IV saline infusion
89100684|NCT04290078|Experimental|Kaia Back Pain Study Intervention|"The study intervention consists of training sessions conducted daily by the participant via Kaia back pain program. This content combines several approaches that may be effective when used together such as physical exercises, relaxation practices and learning modules. Additionally, there is availability of an electronic motion coach on a set of exercises.~Users also receive behavioural health coaching provided by Kaia's coaching staff based on a coaching curriculum."
89100685|NCT04290078|Active Comparator|Control Group|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth.
89100686|NCT00629382|Experimental|1|
89100687|NCT00629382|Other|2|
89100688|NCT02865954|Experimental|iball intervention|Use of iball pelvic floor training mhealth application for 16 weeks.
89100689|NCT02865954|No Intervention|Standard Care|Standard Care - control group
89100690|NCT06200272|Experimental|Test group with standard whole wheat breads (Germ and Carob Molasses Pulp added)|Bread will be produced by adding germ (obtained after processing the wheat grain), which has a high antioxidant capacity and is rich in vitamins and dietary fiber, and carob pulp (Carob Molasses Pulp, CMP), which is not considered waste after the production of carob molasses, to the formulation of wheat bread, which has been widely consumed in recent years.
89100691|NCT06200272|No Intervention|Control group with standard whole wheat breads|control bread (whole wheat bread) made based on a standard recipe
89100692|NCT06200259|Experimental|"Spot Delete"|"A unique technique called Spot Delete will be utilized to control the placement of spots during treatment planning, to prohibit proton spots from being placed in the rectum, sigmoid, and small bowel. A specialized computer model will be used to study how the energy of the proton beam (linear energy transfer) is related to rectal and bladder side effects."
89100693|NCT06200259|Active Comparator|Control Arm|The proton spots that are placed by the treatment planning system are not modified
89100694|NCT06200181|Experimental|Arm 1|Participants will take a lower dose of olanzapine every day for Days 1-7 and then a higher dose every day for the next 3 weeks
89100695|NCT06200181|Experimental|Arm 2|Participants will take the lower dose of olanzapine every day for 4 weeks.
89100696|NCT06200181|Placebo Comparator|Arm 3|Participants will take a placebo every day for 4 weeks.
89100697|NCT06200168|Experimental|True acupuncture + standard quadruple antiemetic therapy|"Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment."
89100698|NCT06200168|Placebo Comparator|Sham acupuncture + standard quadruple antiemetic therapy|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive olanzapine-contained four-drug antiemetic therapy. All the antiemetic drugs used are the same as those in the true acupuncture group."
89100699|NCT06200142|Experimental|The unsolved|(In)capacitated patients (all ages/both genders) with a clinical (and/or family) history and abnormal additional examination (physical (neurological)/ biochemical/ radiological/ genetic) suspicious for an IEM, without diagnosis.
89100700|NCT06200129|Experimental|sws grade 1|The group that defined as scattered white spots on the normal duodenal mucosa that could not be wiped away by washing, appearing as white spots
89100701|NCT06200129|Experimental|sws grade 2|The group that defined as a diffuse or patchy white appearance on villi that could not be wiped away by washing on the mucosa.
89100702|NCT06200129|Experimental|control|The group with a normal appearance of the duodenal mucosa, where scattered white spots were not detected.
89230295|NCT01583881|Experimental|Renal denervation|Renal denervation
89230296|NCT01583881|No Intervention|control|No intervention
89230297|NCT00794105||Normal ears|
89230298|NCT00794105||Otitis media ears.|
89100705|NCT06200077|Sham Comparator|Conventional Ridge-Splitting Group|Six dental implant sites were prepared in three patients initially through ridge splitting technique associated with bone grafting followed by implants insertion after 4 months later.
89100706|NCT06200077|Active Comparator|Modified 3-Staged Ridge-Splitting Group|Six dental implant sites were prepared in four patients through mucogingival and bony incision initially then after 3-4 weeks ridge splitting with bone grafting were done, followed by implants insertion after 4 months later.
89100707|NCT06200077|Experimental|Modified 2-Staged Ridge-Splitting Group|Six dental implant sites were prepared in three patients initially through mucogingival, and bony incision followed by ridge splitting technique, bone grafting and implants insertion at the same time after 4 weeks from the bony incision.
89100708|NCT06200051||High-risk group|
89100709|NCT06200051||Moderate-risk group|
89100710|NCT06200051||Low-risk group|
89100711|NCT06200038|Experimental|Mulligan group (MG)|Individuals underwent 11 sessions (every day for the first week, every other day for the next two weeks).Hot pack was applied to the neck and upper trapezius area for 20 minutes.2 channels and 4 electrodes in the neck area; Conventional transcutaneous electrical nerve stimulation (TENS) was applied to the patient for 20 minutes with current transition time: 50-100 microseconds, frequency: 60-120 Hz and mild tingling without causing discomfort.US application was performed at a frequency of 1.5 W/cm2 and 1 Mhz for 8 minutes.Stretching exercises were applied to the trapezius upper part and levator scapula muscles for 15-30 seconds with 10 repetitions under the supervision of a physiotherapist.In addition to physiotherapy applications in MG, Mulligan natural apophyseal reversal technique was applied to the upper thoracic segments. Mulligan mobilization was performed with 3 sets of 10 repetitions and 15-20 seconds of rest between sets.
89100712|NCT06200038|Sham Comparator|Sham (different in the direction and amplitude of mobilization) group|Individuals underwent 11 sessions (every day for the first week, every other day for the next two weeks).Hot pack was applied to the neck and upper trapezius area for 20 minutes.2 channels and 4 electrodes in the neck area; Conventional TENS was applied to the patient for 20 minutes with current transition time: 50-100 microseconds, frequency: 60-120 Hz and mild tingling without causing discomfort.US application was performed at a frequency of 1.5 W/cm2 and 1 Mhz for 8 minutes.Stretching exercises were applied to the trapezius upper part and levator scapula muscles for 15-30 seconds with 10 repetitions under the supervision of a physiotherapist.Sham mobilization was applied to the segments where Mulligan mobilization was carried out in Sham group, in which the direction of thrust and thrust were different.
89100713|NCT06200038|Other|Physiotherapy group|Individuals underwent 11 sessions (every day for the first week, every other day for the next two weeks).Hot pack was applied to the neck and upper trapezius area for 20 minutes.2 channels and 4 electrodes in the neck area; Conventional TENS was applied to the patient for 20 minutes with current transition time: 50-100 microseconds, frequency: 60-120 Hz and mild tingling without causing discomfort.US application was performed at a frequency of 1.5 W/cm2 and 1 Mhz for 8 minutes.Stretching exercises were applied to the trapezius upper part and levator scapula muscles for 15-30 seconds with 10 repetitions under the supervision of a physiotherapist.
89100714|NCT06200025|Experimental|Virtual Reality Group|visual and auditory cue-based aphasia rehabilitation program in full immersive virtual reality
89100715|NCT06200025|Active Comparator|Conventional Group|visual and auditory cue-based aphasia rehabilitation program
89100716|NCT06200012|Active Comparator|Control arm: educational training only|This arm received only an educational training for mental health professionals about substance use-related stigma
89100717|NCT06200012|Experimental|Experimental arm: educational training plus a policy change for controlled substance agreements|"This arm received both 1) an educational training for mental health professionals about substance use-related stigma; and 2) a policy change that replaced the standard LifeStance Health system's controlled substance agreement (CSA) with a new agreement integrating principles of shared decision-making and offering prescribers a communication tool with suggestions for how to implement principles of shared decision-making and patient centered care in their use of the new CSA"
89227557|NCT05220930|Experimental|Foot bath for heel warming group|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap. Before piercing the heel, the heel will be wiped with a blanket and dried. After the intervention, blood collection from the heel will be performed by following the standard procedure steps that are routinely applied in the service.
89100718|NCT06199960|Experimental|Double GnRH-antagonist protocol (Duostim protocol)|In Duostim group, both follicular and luteal phases stimulation will perform with 150-225 IU of recombinant FSH (Gonal-F®, Merck-sereno, Germany) and HMG (Humegnan, Darou Pakhsh Co., Iran) in GnRH antagonist treatment. The follicular stimulation will be started on day 2-3 of the menstrual. Daily administration of 0.25 mg of GnRH antagonist (Cetrotide®, Merck-Serono; Germany) will be started when the leading follicle are 13-14mm and continue until the day of the oocyte trigger. When one follicle reached 17-18 mm ovulation will be triggered with 0.5 cc of Buserelin acetate (CinnaFact®; CinnaGen pharmaceutical Co., Iran) and oocyte retrieval will be performed after 34-36 hours. Five days after the ﬁrst oocyte retrieval, a GnRH antagonist protocol identical to the ﬁrst one will start. When at least two follicles reached 17-18 mm, the ovulation will be triggered with a subcutaneous bolus GnRH-agonist and the second oocyte retrieval will be performed.
89100719|NCT06199960|No Intervention|Double mild stimulation protocol|In double mild stimulation protocol, Clomiphene citrate 25 mg/day (Ovumid®; Iran Hormone pharmaceutical Co., Iran) and co-treatment with letrozole 2.5 mg/day (Femati®, Atipharmed Co., Iran) will be given from cycle day 3. Letrozole is given for 4 days and clomiphene citrate is used daily before the trigger day. Patients take 150 IU of Human menopausal gonadotropin (HMG) (Humegnan®, Darou Pakhsh Co., Iran) every other day beginning on cycle day 6. When one dominant follicle will reach 18 mm, the ﬁnal triggering will induce 34-36 h after 0.5 cc of Buserelin acetate (CinnaFact®; CinnaGen pharmaceutical Co., Iran) administration. In luteal phase stimulation a total of 225 IU HMG and letrozole 2.5 mg will administered daily from3 to 5 days after oocyte retrieval. Letrozole administration will be stopped when the dominant follicles reached 12 mm. When one dominant follicle will reach 18 mm, the ﬁnal triggering will be induced with 0.5 cc of Buserelin acetate.
89100720|NCT06199947|Experimental|Samples|
89100721|NCT06199921|Experimental|20mg atorvastatin with standard of care (SOC) for TB|Trial of 20mg atorvastatin with standard of care (SOC) for TB
89100722|NCT06199921|Experimental|40mg atorvastatin with standard of care (SOC) for TB|Trial of 40mg atorvastatin with standard of care (SOC) for TB
89100723|NCT06199921|Experimental|60mg atorvastatin with standard of care (SOC) for TB|Trial of 60mg atorvastatin with standard of care (SOC) for TB
89100724|NCT06199921|No Intervention|Standard of care (SOC) for TB|Standard of care (SOC) for TB
89100725|NCT06199908|Experimental|Arm 1|AMT-562 Dose Escalation
89100726|NCT06199895|Experimental|Paclitaxel Polymeric Micelles for Injection|Subjects are given paclitaxel polymeric micelles for injection, three weeks constitutes one cycle of treatment.
89100727|NCT06199882|Experimental|SBRT Sequential Surufatinib Combined With Immunotherapy|"SBRT :~Bioequivalent total dose > 75Gy, completed within 2 weeks (once daily, 5 times a week).~Drug treatment (every 3 weeks is a treatment cycle) :~1) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle."
89100728|NCT06199843|Experimental|Rifaximin|Rifaximin 550 mg BD
89100729|NCT06199843|Active Comparator|Norfloxacin|Norfloxacin 400 mg OD
89100730|NCT06199804|Experimental|Experimental Group|"A program was created to be given to the mothers in the experimental group in line with the content of the Toy Hygiene Guide Book prepared by the researchers."
89100731|NCT06199804|No Intervention|Control Group|The researcher did not apply anything other than the clinical routine to the control group during the first three days of hospitalization.
89100732|NCT06199791|Experimental|Lamotrigine 100 mg oral tablet|Test
89100733|NCT06199791|Active Comparator|Lamictal 100 mg oral tablet|Reference
89100734|NCT06199752|Active Comparator|Placebo|Placebo consisted of identical capsules of powdered glucose polymer
89100735|NCT06199752|Placebo Comparator|Synbiotics group|probiotic agent 25 Billion CFU (Nowfoods, USA), + Inulin capsules 1000mg two capsules once daily. Herbamama USA
89100736|NCT06199752|Placebo Comparator|Probiotics group|probiotic agent 25 Billion CFU (Nowfoods, USA)
89100737|NCT06199739|Experimental|Early-Weight bearing|Early Weight bearing was defined as starting Weight bearing within 48 h postoperatively, and WBAT referred to the adjustment of fracture site weight-bearing by pain tolerance.
89100738|NCT06199726||Round 1 Interviews and/or Focus Group|"Approximately12 people will be recruited complete interviews or focus groups in Round 1.~The participants will be provided with the REFLECT tool. There will be interviews and discussions via telephone or ZOOM and feedback will be obtained to enhance the REFLECT tool."
89100739|NCT06199726||Round 2 Interviews and/or Focus Group|"Approximately 13 people will be recruited to complete interviews or focus group in Round 2.~The participants will be provided with the REFLECT tool that has been modified to include feedback from Round 1 interviews/focus groups.~There will be interviews and discussions via telephone or ZOOM and feedback will be obtained on the enhanced tool."
89100740|NCT06199700|Experimental|Esketamine treatment|Esketamine, diluted with 20ml Saline at a dose of 0.25mg/kg, intravenously for 40 minutes, once a week; 5 weeks in total.
89100741|NCT06199687|Experimental|Experimental group|The patients in the experimental group were shown a virtual reality video called 'Turkey 4K - Scenic Relaxation Film With Calming Music', containing images of nature and sea with music, for 15 minutes using virtual reality glasses.
89100742|NCT06199687|No Intervention|Control Group|Patients received standard care.
89100743|NCT06199674|Experimental|PBM group|wear PBM device daily during the fixed-appliance orthodontic treatment
89100744|NCT06199674|Sham Comparator|Control group|wear sham device daily during the fixed-appliance orthodontic treatment
89100745|NCT06199661|Experimental|APEX|Physical exercise intervention based on high-intensity interval training
89100746|NCT06199648|Experimental|Arm A: web-based documentation and advice|
89100747|NCT06199648|No Intervention|Arm B: Standard of care|
89100748|NCT06199622|Experimental|experimental group|Pregnant women in the intervention group will listen to 20 minutes of music consisting of classical western music - Beethoven moonlight sonata -, classical Turkish music - Nihavend and Buselik Maqam - for three days with a MP3 player with a good sound system and headphones.
89100749|NCT06199622|No Intervention|control group|Pregnant women in the control group did not receive 20 minutes of music for three days and routine care will continue.
89100750|NCT06199609||AVF group and TCC group|AVF and TCC are two different hemodialysis pathways
89100751|NCT06199609||Before AVF establishment and After AVF establishment|Evaluate and analyze the changes in cardiac structure and function before and after the establishment of AVF;
89227558|NCT05220930|Other|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
89227559|NCT04302558|Experimental|Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while the blood flow to the leg is reduced by a blood flow restriction cuff.
89227560|NCT04302558|Sham Comparator|SHAM Blood Flow Restriction (BFR) group|Subjects previously diagnosed with a torn ACL who have yet to undergo surgical reconstruction and pre-operative rehabilitation will do a series of low-intensity strength exercises while a blood flow restriction cuff is applied but inflation pressure will be limited
89227561|NCT05692440|Other|Basivertebral Nerve Ablation|Intraosseous radiofrequency basivertebral nerve ablation
89227562|NCT04221828|Experimental|NanoPac|Direct injection of NanoPac at 15 mg/mL at a volume not to exceed the volume of the prostate cancer lesion (no more than 10% of total prostate volume). NanoPac will be administered on up to three occasions, with at least 28 days between each dose.
89227563|NCT05138328|Experimental|Treatment of basal cell carcinoma with Nd:YAG laser|All enrolled patients will be treated with the Nd:YAG laser for this study as part of the intentional intervention for this study.
89227564|NCT04221750|Experimental|Lifestyle Therapy plus Metformin|Diet-induced weight loss and Exercise Training plus Metformin 1500 mg daily
89227565|NCT04221750|Placebo Comparator|Lifestyle Therapy plus Placebo|Diet-induced weight loss and Exercise Training plus Placebo
89227566|NCT04221750|Active Comparator|Healthy lifestyle plus Metformin|Healthy lifestyle and Metformin 1500 mg daily
89227567|NCT04182126|Placebo Comparator|Regular long-lasting insecticidal nets|All participants will have LLIN coverage through routine MoH distribution of long-lasting insecticidal nets (LLINs), no other interventions will be applied. Regular LLIN: Olyset nets containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn.
89227568|NCT04182126|Experimental|Piperonyl butoxide-treated LLIN|"All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1 and Stage 2 interventions provided that PBO-LLINs are effective at Stage 1 interventions. Each household will be provided on PBO-LLIN per two people with appropriate eduction.~PBO-LLIN: Olyset Plus, containing 2% permethrin and 1% PBO."
89227569|NCT04182126|Experimental|PBO-LLIN plus larval source management|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus larval source management (LSM) at Stage 2. LSM will be implemented in selected clusters, including both physical and chemical methods by physical filling or removal of temporary larval habitats and larviciding of semi-permanent and permanent habitats, per the National Malaria Strategic Plan of Kenya. We will use the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
89227570|NCT04182126|Experimental|PBO-LLIN plus enhanced methods|All participants will received piperonyl butoxide-treated LLINs (PBO-LLINs) at Stage 1, however, Stage 1 intervention is not effective. All participants will received PBO-LLINs plus an enhanced intervention at Stage 2. The enhanced intervention is determined by machine learning method.
89227571|NCT04182126|Experimental|LLIN plus indoor residual spraying|All participants will received regular LLINs plus indoor residual spraying (IRS) (LLIN+IRS) at Stage 1 and Stage 2 interventions provided that LLIN+IRS is effective at Stage 1 interventions. For LLIN+IRS clusters, each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl (Actellic 300CS) at the recommended dosage of 1g/m² and at the recommended frequency of once a year.
89227572|NCT04182126|Experimental|LLIN+IRS+LSM|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. LSM will be added on these clusters at Stage 2 interventions. LSM at Stage 2 will be the long-lasting microbial larvicides manufactured by Central Life Sciences. Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet.
89227573|NCT04182126|Experimental|LLIN+IRS plus enhanced method|All participants will received regular LLINs plus IRS at Stage 1, provided that LLIN+IRS is not effective. Enhanced method will be added on these clusters at Stage 2 interventions.The enhanced intervention is determined by machine learning method.
89227574|NCT00481065|Experimental|Concomitant alone|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.
89227575|NCT00481065|Experimental|Concomitant +Mixed|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
89227576|NCT00481065|Experimental|Concomitant +MF59-eH5N1|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
89227577|NCT00481065|Experimental|Mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
89227578|NCT00481065|Experimental|Mixed and mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382
89227579|NCT00481065|Experimental|Mixed+MF59-eH5N1|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
89227580|NCT00481065|Experimental|MF59-eH5N1+eTIV_a|1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
89227581|NCT00481065|Experimental|eTIV_a+MF59-eH5N1|1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
89227582|NCT01017393|Experimental|ketamine|epidural ketamine added to the patient controlled epidural analgesia regimen
89227583|NCT01017393|Active Comparator|ketamine free|epidural ketamine NOT added to the patient controlled epidural analgesia regimen
89227584|NCT00493311|Experimental|IV Acetaminophen|1 g of acetaminophen in 100 mL of intravenous solution
89100752|NCT06199609||Left atrial enlargement group and Left atrial normal group|Patients in the AVF group are divided into a left atrial enlargement group and a left atrial normal group based on whether the left atrium has expanded after the establishment of AVF
89100753|NCT06199609||Atrial fibrillation group and Non atrial fibrillation group|Divide AVF group patients into atrial fibrillation group and non atrial fibrillation group based on whether new atrial fibrillation occurs after AVF establishment
89100754|NCT06199596|Experimental|ACH (Aalpha-s1 casein hydrolysate)|Each participant will take Prelactium capsules (alpha-s2 casein hydrolysate supplement; 150mg per capsule) 30 minutes before bedtime for a duration of 4 weeks: 4 capsules in the first two weeks and 2 capsules in the last two weeks.
89100755|NCT06199596|Placebo Comparator|Placebo (Maltodextrin)|Each participant will take Maltodextrin capsules (150mg per capsule) 30 minutes before bedtime for a duration of 4 weeks: 4 capsules in the first two weeks and 2 capsules in the last two weeks.
89100756|NCT06199583||Patellar tendinopathy|Contains athletes with patellar tendinopathy
89100757|NCT06199583||Non-patellar tendinopathy|Contains athletes without patellar tendinopathy
89100758|NCT06199557|Active Comparator|Hydroxyurea (HU) + Valproic Acid (VPA) part 1|"Combination treatment 1 (T1): hydroxyurea + valproic acid, combination treatment 2 (T2): 6-mercaptopurine + valproic acid.~Each patient enrolled will receive at least one cycle with T1: hydroxyurea and valproic acid. The 1st cycle in the study always constitutes of hydroxyurea (1000 mg twice a day) plus valproic acid (300 mg + 600 mg) for 14 days; then 14 days with no medication.~Each cycle duration is 28 days. Patients who do not experience clinical benefit after 1st cycle, or experience unacceptable and unmanageable toxicity after 1st cycle, will not be eligible to continue on this regimen and they will be allocated to treatment combination 2. T2 constitutes of 6-mercaptopurine ( 50 mg once a day) plus valproic acid 300 mg + 600 mg ) for 14 days; followed by 14 days with no medication. Each cycle duration is 28 days."
89100759|NCT06199557|Active Comparator|Hydroxyurea (HU) + Valproic Acid (VPA) part 2|"Part B consists of two cohort expansions where the setup is identical to part A: one for HU + VPA and one for 6-MP + VPA, 16 patients in each, in total 32 new patients.~In part B the same principles will apply for response, withdrawal and allocation from HU+ VPA to 6-MP + VPA. The treatment duration in all arms can last to up 6 cycles in total. Each cycle duration is 28 days."
89100760|NCT06199544|Experimental|Control group|metformin 500 mg twice a day
89100761|NCT06199544|Experimental|Picolin group|Picolin 500mg thrice a day
89100762|NCT06199544|Experimental|Rasoline|Rasoline 500mg thrice a day
89100763|NCT06199518|Active Comparator|GROUP(A):transperitoneal laparoscopic ureterolithotomy (T-LUL)|extraction of proximal ureteral stones by laparoscopic surgery via transperitoneal approach
89100764|NCT06199518|Active Comparator|GROUP (B):retrograde flexible ureteroscopy (R-URS)|laser lithotripsy of proximal ureteral stones via flexible ureteroscopy retrograde
89100765|NCT06199518|Active Comparator|GROUP (C):Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|laser lithotripsy of proximal ureteral stones via percutanous antegrade flexible ureteroscopy
89100766|NCT06199505|Experimental|GZR101|GZR101 injection s.c., once daily, treat-to-target dose
89100767|NCT06199505|Active Comparator|insulin degludec/insulin aspart,|insulin degludec/insulin aspart injection s.c., once or twice daily, treat-to-target dose
89227585|NCT00493311|Placebo Comparator|IV Placebo|100 mL of intravenous placebo solution
89100768|NCT06199479|Other|Arm 1|The tests and procedures done as part of your standard-of-care biopsy preparation, participants will also have advanced MRI and CT scans performed no later than 2 weeks before the biopsy. Typically, these scans are done within 1 or 2 days before surgery to provide the most accurate images to the surgeon.
89100769|NCT06199453|Experimental|Experimental|Treatment will consist of administration of 6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks.
89100770|NCT06199440|Active Comparator|Group I|Chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
89100771|NCT06199440|Experimental|Group II|Received azithromycin dosage is 250 mg/day for 5 days, after an initial dose of 500 mg one hour before NSPT
89100772|NCT06199440|Experimental|Group III|Consisted of 5 type 2 Diabetes Mellitus patients with periodontitis who were received doxycycline 20mg twice/day.
89100773|NCT06199427|Experimental|intervention/treatment|"Conditioning regimen containing treosulfan 30-42 g/m2, fludarabine 150 mg/mg, thymoglobulin 5 mg/kg and thiotepa 10 mg/kg or melphalan 140 mg/m2~GVHD prophylaxis regimen for matched unrelated (MUD) and matched related donors (MRD):~Cyclophosphamide (PTCY) 25 mg/kg/day (days +3, +4) Ruxolitinib 7 mg/m2 from day +5~GVHD prophylaxis regimen for mismatched related donor (MMRD):~Cyclophosphamide (PTCY) 50 mg/kg/day (days +3, +4) Ruxolitinib 7 mg/m2 from day +5"
89100774|NCT06199414||Subjects with Figure-of-eight (F-8) suture|This is the group of subjects for whom Figure-of-eight (F-8) suture is used for their venous closure.
89100775|NCT06199414||Subjects with LockeT Device|This is the group of subjects for whom LockeT device is used for their venous closure.
89100776|NCT06199401|Experimental|XJ-Procedure Group|"In the XJ-Procedure Group, Patients will be performed the standard Sun's procedure after general anesthesia, in which the end-to-end anastomosis between the artificial vessel and the aortic root is performed using the Vascular Grafts Eversion and Built-in Technique during the aortic root suture."
89100777|NCT06199401|No Intervention|Control Group|"In the Control Group, Patients will be performed the standard Sun's procedure which involves aortic root anastomosis using the regular technique at each cardiovascular surgery center."
89100778|NCT06199388||SEER database|The model was trained using the Surveillance, Epidemiology, and End Results (SEER) Registry database. To identify specific tumor types, the International Classification of Diseases for Oncology, 3rd Edition codes (ICD-O-3) were used, including codes 9450, 9394, 9421, 9384, 9383, 9424, 9400, 9420, 9410, 9411, 9380, 9382, 9391, 9393, 9390, 9401, 9381, 9451, 9440, 9441, 9442, 9430, and 9380, covering astrocytic tumors, oligodendroglia tumors, oligoastrocytic tumors, ependymal tumors, and other gliomas. Inclusion criteria comprised all primary brain tumors (C71.0-C71.9, C72.3, C72.8, C75.3) diagnosed between 2000 and 2018, among patients under 21 years old, and meeting the third edition of the ICD-O-3 classification. Only patients with available survival time were included, and those with unknown or missing clinical features were excluded.
89100779|NCT06199388||Chinese cohort|To assess the generalizability of the final model, an external validation cohort from China was used. This cohort consisted of 258 pediatric glioma patients diagnosed at Tangdu Hospital in Xi&#39;an, China, between January 2010 and December 2018. These patients had complete clinical data and comprehensive follow-up records.
89100780|NCT06199362||Swedish National Cohort|Children born in Sweden during the years 1987-2010, to be followed for diagnoses of neurodevelopmental disorders.
89100781|NCT06199362||Stockholm Regional Obstetrix Cohort|Children born in Region Stockholm during the years 2007-2010, to be followed for diagnoses of neurodevelopmental disorders.
89100782|NCT06199336|Experimental|Treatment Group|Single injection with JHM03 in glabellar lines
89100783|NCT06199336|Active Comparator|Active-Controlled Group|Single injection with BOTOX® in glabellar lines
89100784|NCT06199336|Placebo Comparator|Placebo-Controlled Group|Single injection with Placebo in glabellar lines.
89100785|NCT06199284|Other|Patient|Usual care and gait training with the Atalante exoskeleton
89100786|NCT06199258||Normal lung function|Normal lung function: After using a bronchodilator, FEV1/FVC ≥70%, FEV1 and FVC ≥80% of reference values.
89100787|NCT06199258||Preserved ratio impaired spirometry|After using a bronchodilator, FEV1/FVC≥70%, FEV1 and/or FVC<80% of reference values.
89100788|NCT06199258||Chronic obstructive pulmonary disease|After using a bronchodilator, FEV1/FVC <70%.
89100789|NCT06199219|Other|Intervention Group|"Sexual counseling, based on the extended (EX-PLISSIT) model was offered to women for 6-10 weeks (until a solution was achieved).~All interventions must begin with Permission. Each stage of Limited Information, Special Recommendation and Intensive Therapy is supported by Allowing. Thus, the interaction between counselors and clients is improved"
89100790|NCT06199219|No Intervention|Control Group|No intervention pretest posttest
89100791|NCT06199193|No Intervention|Control Human patient (non-Alzheimer) with routine normal diet|Control human patients (30),non suffering from Alzheimer, will continue with their normal dietary habits and samples will be collected.
89100792|NCT06199193|Sham Comparator|Alzheimer patients with routine normal diet and dietary counseling|Alzheimer patients (30) will continue with their routine normal diet and samples will be collected.
89100793|NCT06199193|Experimental|Alzheimer patients with personalized diet|Alzheimer patients (30) will be given personalized diet, with supplements based on the gut microbiota (elaborated through AI analyses). Samples will be collected.
89100794|NCT06199180|Active Comparator|Radiofrequency ablation|In this group, patients will undergo the acquisition of a 3D high-density map. If pulmonary vein (PV) reconnection is identified, radiofrequency ablation (RFA) will be employed for pulmonary vein isolation (PVI). Should PV reconnection not be detected, the operator will have the discretion to determine the necessary ablation strategies. Patients falling into this category will be included in a concurrent registry.
89100795|NCT06199180|Experimental|Pulsed field ablation|In this group, pulmonary vein (PV) reconnection is identified by the FARAWAVE system. If reconnection is observed, pulsed field ablation (PFA) will be employed for pulmonary vein isolation (PVI). Should PV reconnection not be detected, the operator will have the discretion to determine the necessary ablation strategies. Patients falling into this category will be included in a concurrent registry.
89100796|NCT06199167|Experimental|Action Observation Therapy|The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes.
89100797|NCT06199167|Experimental|Photo Observation|The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes.
89100798|NCT06199154|Active Comparator|Control - 25 mcg vaginal misoprostol|Participants will receive 25 mcg vaginal misoprostol every 4 hours.
89100799|NCT06199154|Experimental|Intervention - 50 mcg vaginal misoprostol|Participants will receive 50 mcg vaginal misoprostol every 4 hours.
89100800|NCT06199128||CONTROL GROUP|For the duration of the study, standard clinical practice will be followed wait and see strategy, without administering carboxymethyl-b-glucan treatment.
89100801|NCT06199128||TREATMENT GROUP|For a period of three months, patients will be administered once daily treatment with Carboxymethyl β-glucan and Polycarbophil
89100802|NCT06199115|No Intervention|Control|Patients will not receive any intervention during their oxaliplatin chemotherapy cycles.
89100803|NCT06199115|Experimental|Experimental|Patients will receive three photobiomodulation sessions per week during their oxaliplatin chemotherapy cycles
89100804|NCT06199102|Experimental|monitored group|Infants in the monitored group will receive an initial dose of 1000 IU of vit D (cholecalciferol/ Devikap; Polpharma, Starogard Gdański, Poland).
89100805|NCT06199102|Active Comparator|controlled group|Infants in the controlled group will receive 250 IU (cholecalciferol/ Devikap; Polpharma, Starogard Gdański, Poland) for very low birth weight infants and 500 IU (cholecalciferol/ Devikap; Polpharma, Starogard Gdański, Poland) for infants weighing above 1000 g.
89227586|NCT00571649|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
89227587|NCT00571649|Active Comparator|Enoxaparin|Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days
89227588|NCT05434793|Experimental|The meridian effect of sham testing from mechanical stimulation|The effects of sham acupuncture at Tsu San Li (St-36) were examined by analyzing noninvasive 30-sec. recordings of the radial arterial pulses for 3 groups of patients treated with different probes (blunt, sharp, and patch) on the superficial skin of the acupuncture point. The 3 groups were then treated with the sharp probe for 3 different periods (16, 30, and 50 seconds). Then we compared the harmonics of the radial arterial pulse after Fourier transformation before and after the treatment.
89227589|NCT05434715|Active Comparator|conventional technique of thyroidectomy|"A standard transverse skin incision will be done two fingers above supra-sternal notch extend from the medial head of sternomastoid muscle at one side to the other one at the opposite side, incision of platysma along the whole length of skin incision.~Dissection of the thyroid gland will begin with securing the middle thyroid vein using ligation, bipolar diathermy, or harmonic scalpel.~Dissection of the upper pole with securing the superior thyroid vessel preserving the superior parathyroid glands and the external laryngeal nerve.~Severing the Berry's ligament with ligation of its artery and vein. The contralateral lobe of the thyroid gland will then be approached in a similar fashioon."
89227590|NCT05434715|Active Comparator|Minimal invasive technique|"The procedure will start by placing a small incision 2.5-3cm at the upper border of the cricoid cartilage at one of the natural creases of the neck, followed by an incision of the platysma along the length of the skin incision.~Identification of the midline of the neck and division of the strap muscles, followed by dissection of the plane between the muscles and the anterior surface of the thyroid gland.~Dissection of the lateral surface of the thyroid lobe with identification Cutting of sternothyroid muscle at its superior portion. Individual ligaton of branches of superior thyroid artery and vein near to the gland using haemostatic techniques (Harmonic or LigaSure scalpel), guarding the superior parathyroid glands.~Appropriate dissection will then be done. Dissection of the inferior pole and vessel securing using Harmonic or LigaSure scalpel will take place, then dissection of the undersurface of the thyroid gland will be done to separate the gland from its bed."
89227591|NCT05434403|Placebo Comparator|Sham stimulation group|
89227592|NCT05434403|Experimental|stimulation group|
89227593|NCT00546572|Experimental|1|Receives 13vPnC at year 0 and 13vPnC at year 1
89227594|NCT00546572|Active Comparator|2|Receives 23vPS at year 0 and 13vPnC at year 1
89227595|NCT03917472|Experimental|Brolucizumab 6mg q4w|Brolucizumab 6 mg/0.05 mL every 4 weeks.
89227596|NCT03917472|Active Comparator|Aflibercept 2mg q4w|Aflibercept 2mg/0.05 mL every 4 weeks
89227597|NCT00681863|Active Comparator|pramipexole 0.0625 mg BID (twice daily)|all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)
89227598|NCT00681863|Active Comparator|pramipexole 0.0625 mg QD (once daily)|patients to receive one tablet of pramipexole 0.0625 mg QD
89227599|NCT00681863|Active Comparator|pramipexole 0.125 mg BID|patients to receive one tablet of pramipexole 0.125 mg BID
89227600|NCT00681863|Active Comparator|pramipexole 0.125 mg TID (three times daily)|patients to receive one tablet of pramipexole 0.125 mg TID
89227601|NCT00681863|Active Comparator|pramipexole 0.25 mg BID|patients to receive one tablet of pramipexole 0.25 mg BID
89227602|NCT02559791|Experimental|Study participants|All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV reslizumab 3mg/kg
89227603|NCT05677620||Group A - Pharyngeal Computed Tomography Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo pharyngeal CT with cephalometry and with registration in maximum comfortable protrusion (MCP)
89227604|NCT05677620||Group B - Drug-Induced Sleep Endoscopy Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo Drug-induced sleep endoscopy with registration in maximum comfortable protrusion (MCP)
89227605|NCT05677620||Group C - Pharyngeal Computed Tomography and Drug-Induced Sleep Endoscopy Group|22 randomly selected patients with mild to moderate obstructive sleep apnea will undergo a pharyngeal computed tomography + Drug-induced sleep endoscopy with registration in maximum comfortable protrusion (MCP)
89100806|NCT06199076|Experimental|Oxytocin/Placebo, Alcohol Use Disorder|"Visit 1: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures~Visit 2: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures"
89100807|NCT06199076|Experimental|Placebo/Oxytocin, Alcohol Use Disorder|"Visit 1: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures~Visit 2: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures"
89100808|NCT06199076|Experimental|Oxytocin/Placebo, Healthy Control|"Visit 1: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures~Visit 2: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures"
89100809|NCT06199076|Experimental|Placebo/Oxytocin, Healthy Control|"Visit 1: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures~Visit 2: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures"
89100810|NCT06199063|Experimental|Self-Stretching Exercises Group (SSEG)|Self-stretching (SS) is defined as stretching applied by the individual to himself/herself. For this application, firstly the painful area was determined, and stretching was applied to the muscle with pain. Firstly, the participant stood with his/her arm free on the side to be stretched and lateral flexed his/her head. With his/her other hand, he/she applied 10 seconds of stretching in the direction of lateral flexion, a 10-second rest period was given between each stretching, and this method was performed with a total of 10 repetitions.
89100811|NCT06199063|Experimental|Post-Isometric Relaxation Exercises Group (PIREG)|Post-isometric relaxation (PIR) was performed by a physiotherapist in a supine position. The physiotherapist sat on the head side of the patient. The painful side was determined, and the physiotherapist fixed the head with his/her hand and performed 50% voluntary isometric contraction of the painful muscle for 10 seconds. Then, the physiotherapist asked the patient to relax and stretch for 10 seconds to lateral flexion. This method was 10 repetitions with 10 seconds of rest between each repetition.
89100812|NCT06199063|Experimental|Reciprocal-Inhibition Exercises Group (RIEG)|Reciprocal inhibition (RI) was applied by a physiotherapist in a supine position. The physiotherapist sat on the head side of the patient. The painful side was determined, and the physiotherapist fixed the head with his/her hand and performed 50% voluntary isometric contraction of the antagonist of the painful muscle for 10 seconds. Then physiotherapist asked the patient to relax and stretch for 10 seconds in the lateral flexion direction. This method was 10 repetitions and there were 10 seconds of rest between each repetition.
89100813|NCT06199050|Experimental|360° Virtual Reality Movies|"assess the amount of fear, anxiety and stress by using specific questionnaires:~SPecifIc RadIation Treatment related questions (SPIRIT)~Hospital Anxiety and Depression Scale (HADS)~Dutch version of the Questionnaire on stress symptoms (QSC-R23)~General questions:~Education level~Marietal status~Medication use (in order to assess influence on fear)~Previous cancer diagnosis~Acquired information on treatment~Expected fear and anxiety mitigation strategies~Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~PROM at baseline~Clinical data:~Age~Gender~Cancer type~WHO status~TNM"
89100814|NCT06199050|Experimental|Group without intervention|"In a measurement over 5 months without any intervention the investigators have assessed the amount of fear, anxiety and stress by using a specific subjective questionnaire on the items below: assess the amount of fear, anxiety and stress by using specific questionnaires:~SPecifIc RadIation Treatment related questions (SPIRIT)~Hospital Anxiety and Depression Scale (HADS)~Dutch version of the Questionnaire on stress symptoms (QSC-R23)~General questions:~Education level~Marietal status~Medication use (in order to assess influence on fear)~Previous cancer diagnosis~Acquired information on treatment~Expected fear and anxiety mitigation strategies~Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~PROM at baseline~Clinical data:~Age~Gender~Cancer type~WHO status~TNM"
89100815|NCT06199037|Experimental|SHR-1707|
89100816|NCT06199037|Placebo Comparator|SHR-1707 placebo|
89100817|NCT06199024|Experimental|Cinnamon supplementation|In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
89100818|NCT06199024|Placebo Comparator|Control group|Patients take 3 placebo pills daily (containing white wheat flour, which is similar to cinnamon pills in terms of size, shape, color and smell, Sagepad Darou Pharmaceutical Company, Iran) 4 weeks before starting the ovarian stimulation/in vitro fertilization (COS/IVF) cycle and 2 weeks during the ovarian stimulation procedure, the ovary will be stimulated
89100819|NCT06199011|Active Comparator|Control Group: Standardized general anesthesia|The control group is standard of opioid anesthesia including reminfentanil and sufentanil. In addition to dexmedetomidine and transverse abdominal plane block, general anesthesia induction will be induced performed with sufentanil (0.5 μg kg-1), propofol (1.5 mg kg-1), and rocuronium (1 mg kg-1). General anesthesia was maintained with a continuous infusion of remifentanil (5-15 μg kg-1 h-1), cisatracurium (0.1-0.2 mg kg-1 h-1), dexmedetomidine (0.4 μg kg-1 h-1), and sevoflurane exposure guided by bispectral index. Dexmedetomidine administration and sevoflurane inhalation will be completed at 20 minutes before surgery finish. Propofol and remifentanil will be continuously infused till the end of surgery.
89227606|NCT00681629|Experimental|Quetiapine XR Alone|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
89227607|NCT00681629|Experimental|Quetiapine XR With Integrated Care Program (ICP)|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
89100820|NCT06199011|Experimental|Intervention Group: A standardized non-opioid anesthesia|Dexmedetomidine (0.5μg kg-1) and esketamine (0.25mg kg-1) was intravenously infused to provide sedation for the bilateral transverse abdominal plane block (0.33% ropivacaine and dexmedetomidine 1μg kg-1). General anesthesia was then induced with esketamine (0.25 mg kg-1 h-1), propofol (1.5 mg kg-1), and rocuronium (1 mg kg-1). Following endotracheal intubation, GA was maintained with a continuous infusion of esketamine (0.25 mg kg-1 h-1), cisatracurium (0.1-0.2 mg kg-1 h-1), dexmedetomidine (0.4 μg kg-1 h-1), and sevoflurane guided by bispectral index. The infusions of esketamine and dexmedetomidine, as well as sevoflurane inhalation will be finished at 20 minutes before surgery completion. Propofol will be continuously infused to maintain appropriate bispectral index.
89100821|NCT06198998|Experimental|CorVad Percutaneous Ventricular Assist System|Subjects with coronary artery disease receiving high-risk PCI will be supported by the CorVad Percutaneous Ventricular Assist System during the procedure.
89100822|NCT06198985|Experimental|Dynamic balance exercise with tecnobody prokin 252 balance device added to current medical treatment|Dynamic balance exercises: The treatment will be performed in 3 days a week for 6 weeks. Each exercise will last 30 minutes. It will take 18 sessions in total. These exercises include 14 balance exercise movements performed on tecnobody prokin 252 balance device.
89100823|NCT06198985|No Intervention|Group receiving current medical treatment|Participants in this group will receive only current medical treatment.
89100824|NCT06198946|Other|control group|Provide participants with routine rehabilitation treatment
89100825|NCT06198946|Other|observation group|Participants received EDP treatment on the basis of conventional rehabilitation treatment
89100826|NCT06198933||Pulsed-field ablation group|Patient with atrial fibrillation will undergo catheter ablation using pulsed-field energy
89100827|NCT06198907|Experimental|Part A Dose escalation|Dose escalation part Golidocitinib in combination with sintilimab
89100828|NCT06198907|Experimental|Part B Dose expansion cohort 1 (PD-L1 TPS ≥ 50%)|Dose expansion cohort 1, Golidositinib plus Sintilimab following Sintilimab
89100829|NCT06198907|Experimental|Part B Dose expansion cohort 2 (PD-L1 TPS 1-49%)|Dose expansion cohort 2, Golidositinib plus Sintilimab following Sintilimab + chemotherapy
89100830|NCT06198881||induction of labor|Patient having been induced by cervical ripening (prostin gel (2mg/24h), intravaginal prostaglandin (10mg/24h), balloon (<12h exposure time) or oral misoprostole (50µg/4h until induction of labor) or induction of contractions by oxytocin (gradual increase in dose) for suspected ultrasound macrosomia (according to the criteria of the DAME study)
89100831|NCT06198881||natural labor|Patient presenting with spontaneous labor after 37 weeks of gestation.
89100832|NCT06198855||Hypertension Diagnosis|Subject need 24-h BP monitor for hypertension diagnosis
89100833|NCT06198855||hypertension control evaluation|Patients need 24-h BP monitor for assessment hypertension control
89100834|NCT06198842|Experimental|intervention/treatment|Fludarabine 150mg/m2 (days -6, -5, -4, -3, -2) Treosulfan 21g/m2 (days -6, -5, -4) Thymoglobulin (Genzyme) 5mg/kg (days -5, -4) Rituximab 100mg/m2 (day -1) Cyclophosphamide 50mg/kg (days +3, +4)
89100835|NCT06198803|Experimental|l carnitine group|All aged from 1 month till 16 years old with DRE on KD.
89100836|NCT06198803|No Intervention|non l carnitine gruop|patient with drug resistant epilepsy on ketogenic diet
89100837|NCT06198777||Healthy adults|
89100838|NCT06198764|Experimental|Colistimethate sodium for Injection + Meropenem|Intravenous infusion of colistimethate sodium for injection for 7-14 days. Meropenem intravenous infusion once every 8 hours or 12 hours.
89100839|NCT06198764|Active Comparator|Coly-Mycin® M Parenteral + Meropenem|Intravenous infusion of Coly-Mycin® M Parenteral for 7-14 days. Meropenem intravenous infusion once every 8 hours or 12 hours.
89100840|NCT06198751|Experimental|6 mg/kg of TQB2102 for injection|6 mg/kg TQB2102, Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, for 6 or 8 cycles.
89100841|NCT06198751|Experimental|7.5 mg/kg of TQB2102 for injection|7.5 mg/kg TQB2102, Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, for 6 or 8 cycles.
89100842|NCT06198647|Experimental|tui-na|Application of tui-na techniques for the women while being in prone lying position.
89100843|NCT06198647|Active Comparator|positional release techniques|Application of positional release techniques for the women while being in prone lying position.
89100844|NCT06198595||Normobaric oxygen therapy group|"Patients Receiving Oxygen from Hospital Circuits at Normal Atmospheric Pressure"
89100845|NCT06198595||Hyperbaric oxygen therapy group|"Patients Receiving High-Pressure Oxygen at Pressures Above Atmospheric Pressure"
89100846|NCT06198595||Noninvasive mechanical ventilation group|"Patients Receiving High PEEP Oxygenation Without Advanced Airway via Mechanical Ventilation"
89100847|NCT06198595||High-flow oxygen therapy group|"Patients Reaching High FiO2 Levels Noninvasively Through High-Flow Oxygen Therapy"
89100848|NCT06198582|Experimental|Virtual Reality Intervention Group|Consisted of patients who received a virtual reality-based task-specific exercise programme in addition to the early passive mobilisation programme
89100849|NCT06198582|No Intervention|Control Group|Consisted of patients who received the early passive mobilisation programme
89100850|NCT06198569|Active Comparator|Control Group|STRENGTH EXERCISE TRAINING
89100851|NCT06198569|Experimental|Study Group|PNF EXERCISE TRAINING
89100852|NCT06198543||experimental group|proliferative diabetic retinopathy
89100853|NCT06198543||control group|patients with macular epiretinal membranes and macular holes without diabetes.
89100854|NCT06198530|Active Comparator|cognitive training in NLCs|computerized cognitive training (CCT) was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time. All the patients were capable of performing the training under the guidance of advanced practicing nurses (APNs). At the same time, according to the caregivers' feedback, APNs will give them the desired care guidance.
89100855|NCT06198530|Active Comparator|cognitive training in home|CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system. The data results of each training will be automatically stored in the personal information database in the cloud. And, a training report will be generated, including training difficulty, training results and training time. Nurses can examine patients' training through the cloud.
89100856|NCT06198530|Placebo Comparator|cognitive training in tradition|the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed. And, the patients and their families were given detailed health education on the definition, clinical manifestations, drug and non-drug treatment, home nursing, the significance of cognitive training and the methods of cognitive training. Meanwhile, we established connection with patients for later follow-up
89100857|NCT06198504|Experimental|Protocol using end-tidal oxygen monitoring during preoxygenation before intubation|In 72 consecutive eligible patients tracheal intubation procedure will be performed in accordance with current guidelines except for the duration of the preoxygenation to be individualized by EtO2 monitoring.
89100858|NCT06198491|Experimental|Training for HPV misbeliefs 1|Participants will receive misbeliefs about HPV; training where misbeliefs are mentioned before the current information.
89100859|NCT06198491|Experimental|Training for HPV misbeliefs 2|Participants will receive misbeliefs about HPV; training where misbeliefs are mentioned after the current information.
89100860|NCT06198465|Experimental|adebrelimab combined with chemotherapy|
89100861|NCT06198452|Experimental|Vision Improvement|
89100862|NCT06198439|Experimental|Transcranial magnetic stimulation|All study subjects undergo five sessions of rTMS. The 40-minute sessions target the supplemental motor area (inhibitory stimulation) and prefrontal cortex (excitatory stimulation)
89100863|NCT06198413|Experimental|LX102 Dose 1|Low dose of LX102
89100864|NCT06198413|Experimental|LX102 Dose 2|Mid dose of LX102
89100865|NCT06198413|Experimental|LX102 Dose 3|High dose of LX102
89100866|NCT06198400|Experimental|All patients undergoing the pancreaticoduodenectomy|All consecutive patients undergoing the pancreaticoduodenectomy at our institution in the 1.5.2024-31.12.2026 period will be enrolled in this study.
89100867|NCT06198387|Experimental|hormone and RT|Patients with de novo oligo-metastatic prostate cancer will receive a two-year course of androgen deprivation therapy (ADT) in combination with abiraterone, along with synchronous metastasis-directed radiation and prostate radiotherapy.
89100868|NCT06198348|Other|Aerobic Exercise (Control Group)|Group A will receive Aerobic exercise plan. The treatment will be given with the frequency of 3 times per week for 8 weeks. Treatment sessions will be of 30 minutes with short resting intervals
89100869|NCT06198348|Experimental|Aerobic exercise with resistance training (Experimental Group)|Group B will receive aerobic and resistance exercise plan. The frequency of treatment will be as same as that of aerobic exercise program i.e. 3 times a week for 8 weeks. Treatment sessions will be of 45 minutes with short resting intervals
89100870|NCT06198309||Frequent exacerbation of COPD|
89100871|NCT06198309||Non-frequent exacerbation of COPD|
89100872|NCT06198296|Experimental|21.15.GPC3-CAR T cells|GPC3-CAR and the IL15 plus IL21 will be administered to patients with GPC3-positive solid tumors.
89100873|NCT06197997|Experimental|Title 1 schools receive the Chicago Parent Program intervention|The experimental group from Title 1 schools across two Maryland school districts (Baltimore City Public Schools and Cecil County Public Schools) will receive the Chicago Parent Program intervention.
89100874|NCT06197997|No Intervention|Title 1 schools receive the usual school practice|The control group from Title 1 schools across two Maryland school districts (Baltimore City Public Schools and Cecil County Public Schools) will receive the usual school practice.
89100875|NCT06197217|Experimental|WPV01|
89100876|NCT06197217|Placebo Comparator|Placebo|
89100877|NCT06196710|Experimental|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
89100878|NCT06196710|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clips or pulse
89100879|NCT06196125||Intubated mechanically ventilated patients with thoracic trauma.|Intubated and mechanically ventilated patients with thoracic trauma (with at least 2 rib fractures with or without chest tube), who are in spontaneous/ partially assisted breathing phase.
89100880|NCT06196099|Active Comparator|rest-Blood Flow Restriction plus Neuromuscular Electrical Stimulation|
89100881|NCT06196099|Active Comparator|rest-Blood Flow Restriction|
89100882|NCT06196099|Active Comparator|Squat Exercise|
89100883|NCT06195891|Experimental|Treatment (TMLI, fludarabine, melphalan, Orca-T)|"PREPARATIVE REGIMEN: Patients undergo TMLI BID on days -8 to -5, followed by fludarabine IV on days -4 to -2 and melphalan IV on day -2. Patients receiving the lowest dose of TMLI also receive thiotepa IV on days -4 and -3.~HCT: Patients receive Orca-T CD34+HSPC and Treg products IV on day 0, followed by the Orca-T tcon product IV on day 2.~GVHD PROPHYLAXIS: Patients undergoing haplo-HCT receive tacrolimus starting on day 14 and continuing until day 90 with a taper per treating physician's discretion.~Patients also undergo ECHO or MUGA scans, DECT/MRI scans, bone marrow biopsies/aspirates, and blood sample collection throughout the study."
89227608|NCT00969176|No Intervention|paracetamol|not applicable, since all included cases will receive intravenous paracetamol
89227609|NCT00969254|Experimental|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
89100884|NCT06195709|Sham Comparator|Arm A: Endocrine therapy|"Patients in whom all tumor sites display a FES SUVmax ≥2 AND who have low levels of circulating tumor biomarkers will be treated with endocrine therapy.~Patients in whom 18F-FES PET shows an heterogenous uptake, with one or maximum two tumor sites with low FES uptake (SUVmax <2) that represent less than 20% of all tumor sites and are deemed accessible to local treatment (e.g. stereotactic radiation therapy or another equivalent local therapy) will be treated, if they have low levels of circulating tumor biomarkers, by 2nd line endocrine therapy in Arm A, combined with the local treatment of FES-negative lesions."
89100885|NCT06195709|Active Comparator|Arm B: Chemotherapy|All other patients, i.e. (i) patients in whom most or ≥3 lesions display a FES SUVmax <2 that are not amenable to local treatment, (ii) patients with high levels of circulating tumor biomarkers, will be randomized between chemotherapy in Arm B and endocrine therapy in Arm C.
89100886|NCT06195709|Active Comparator|Arm C: Endocrine therapy|All other patients, i.e. (i) patients in whom most or ≥3 lesions display a FES SUVmax <2 that are not amenable to local treatment, (ii) patients with high levels of circulating tumor biomarkers, will be randomized between chemotherapy in Arm B and endocrine therapy in Arm C.
89100887|NCT06195410|Active Comparator|Comparator: Intervention Group|
89100888|NCT06195410|Sham Comparator|Comparator|
89100889|NCT06194669||Controls|Healthy volunteers; patients referring to San Raffaele Hospital for renal/urological conditions other than VHL
89100890|NCT06194669||VHL-disease patients|Individuals with genetic diagnosis of Von Hippel Lindau disease
89100891|NCT06194487|Placebo Comparator|Placebo drink|consume 1 bottle (50mL) per day
89100892|NCT06194487|Experimental|MAXI Collagen drink|consume 1 bottle (50mL) per day
89100893|NCT06194487|Active Comparator|Normal fish collagen drink|consume 1 bottle (50mL) per day
89100894|NCT06194344|Experimental|Individualized imagery|
89100895|NCT06194344|Active Comparator|Control|
89100896|NCT06193278|Active Comparator|muti-site stimulation group1|The intervention period: 2 weeks muti-site: individual target (iTBS OR cTBS) / M1 (iTBS)
89100897|NCT06193278|Active Comparator|single-site stimulation group2|The intervention period: 2 weeks muti-site: individual target (sham) / M1 (iTBS)
89100898|NCT06193278|Sham Comparator|sham stimulation group3|The intervention period: 2 weeks muti-site: individual target (sham) / M1 (sham)
89100899|NCT06193135|Experimental|Elonva|Patients will undergo controlled ovarian stimulation with Corifolitropin α (Elonva), 100-150 micrograms (100 in< 60kg and 150 ≥ 60 kg) + Progevera 10 mg.
89100900|NCT06193135|Active Comparator|Puregon|Patients will undergo controlled ovarian stimulation with Folitropin β (Puregon) + Progevera 10 mg.
89100901|NCT06192212||Jejunostomy group|Intraoperative jejunostomy tube placement received
89100902|NCT06192212||Non-jejunostomy group|Intraoperative jejunostomy tube placement not received
89100903|NCT06190964|Experimental|Integrative medicine|The employees are treated by a team from the system for integrative medicine, including practitioners of acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) or mind-body medicine (for example, relaxation and breathing exercises) and may include one or more of the above 3 treatment areas.
89100904|NCT06189937|Experimental|Culturally Adapted Cognitive Behavioral Therapy (CA-CBT)|Participants in the experimental group will receive an 8-session group CA-CBT.
89100905|NCT06189937|No Intervention|Enhanced Care as Usual (E-CAU)|Participants in the control group will receive pamphlets containing information on mental health issues following earthquakes, coping strategies, and free psychological support centers. After completing all assessments, CA-CBT will be offered to these participants.
89100906|NCT06182215||Prospective observational cohorts|patients undergoing elective major surgery (estimated operation time over 2 hours)
89100907|NCT06180616|No Intervention|Insulin Treatment|Participants will remain on their typical insulin therapy regime for 32 weeks
89100908|NCT06180616|Experimental|Tirzepatide Treatment|Participants will remain on their typical insulin therapy regime and will also receive tirzepatide (dose incremented to 15mg QW) for 32 weeks.
89100909|NCT06172582|Experimental|Intervention|Participants will be randomized to intervention and will receive the 12-week program.
89100910|NCT06172582|Active Comparator|Delayed Intervention Control|Participants will be randomized to delayed intervention control and will receive the same 12-week program.
89100911|NCT06163222|Experimental|Getting to your appointment|Additional 14-day text message reminder that includes link to new transport index web page
89100912|NCT06163222|Experimental|Help with travel costs|Additional 14-day text message reminder that includes link to new 'help with travel costs' web page
89100913|NCT06163222|Experimental|What to expect|Additional 14-day text message reminder that includes link to 'what to expect' web page
89100914|NCT06163222|Active Comparator|Usual communications|Existing communication strategy used for each of the five clinical specialties e.g. reminder messages 3 and 7 days prior to outpatient appointment
89100915|NCT06162143||Gelsectan®|Patients in the Gelsectan® cohort will receive one capsule of Gelsectan® twice a day (after lunch and dinner) for 28 days.
89100916|NCT06158880|Experimental|Alcoholic beverage|Participants will receive a dose of alcohol mixed in fruit juice designed to achieve a peak breath alcohol concentration of .08%.
89100917|NCT06158880|Active Comparator|Non-alcoholic beverage|Participants will receive a beverage that does not contain alcohol (fruit juice only).
89100918|NCT06158880|Experimental|Partner Negative Mood Manipulation|Participants receive an experimental manipulation describing negative emotions in a hypothetical sexual partner.
89100919|NCT06158880|Active Comparator|Partner Positive Mood Manipulation|Participants receive an experimental manipulation describing positive emotions in a hypothetical sexual partner.
89100920|NCT06156202|Active Comparator|Augmented Usual Care|"Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects"
89100921|NCT06156202|Experimental|Comprehensive Rehabilitation|Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
89100922|NCT06155838|Experimental|EASE Intervention|"The intervention consists of four fundamental themes that have empirical support, structured across seven group sessions for adolescents and three group sessions for their parents or guardians. The sessions for teenagers will be conducted in person, spanning seven weeks with one session per week, each lasting 90 minutes. Similarly, three sessions are scheduled for parents.~In accordance with WHO guidelines (2016), the intervention will be administered by non-specialist co-facilitators(class teachers) who possess at least 16 years of education (undergraduate degree). These co-facilitators will undergo a ten-day training program, demonstrating mock sessions as part of this training. During the intervention delivery, they will also benefit from weekly supervision provided by a specialist, who will be a graduate psychologist or trained nurse in mental health."
89100923|NCT06155838|No Intervention|control/ wait list|Throughout the study, participants in the control group will continue to receive standard treatment. Nevertheless, following the conclusion of the trial, all control group participants will undergo the EASE intervention over a seven-week period, which will also involve three sessions for their parents and guardians. This approach ensures that the control group is not placed at a disadvantage, in alignment with ethical principles.
89100924|NCT06153251|Experimental|Administration of BMS-986453|
89100925|NCT06144645|Active Comparator|tVNS, Intermittent Stimulation|28 seconds on, 32 seconds off
89100926|NCT06144645|Active Comparator|tVNS, Continuous Stimulation|continuous stimulation
89100927|NCT06141642|Experimental|Self-adaptive serious game|"Participants in this arm will follow, during three consecutive days, a serious game (REAsmashVR) intervention whose difficulty is automatically and progressively adapted to their motor and cognitive performance.~REAsmashVR involves finding a target as fast as possible. The virtual target (a mole wearing a red miner's helmet) is presented with distractors (moles wearing different helmets). Participants use a controller to hit the target mole with a virtual hammer.~In this arm, the REAsmashVR version uses a regulator to continuously moderate the location and timing of appearance of the target mole, the number and type of distractors and the working area. This regulator enables users to score 75% successful performance (driving motivation to play / learn)."
89100928|NCT06141642|Sham Comparator|Non-adaptive serious game|"Participants in this arm will follow, during three consecutive days, a serious game (REAsmashVR) intervention whose difficulty is not automatically adapted to their motor and cognitive performance.~In this arm, the REAsmashVR version does not use a regulator to continuously adapt exercise difficulty according to user performance. Instead, the game randomly moderates the location of the target mole, the working area and the type of distractors. The appearance timing remains constant at 7 seconds, while the number of distractors gradually increases over time to simulate an adaptive game environment, ensuring participants are kept unaware of the intervention."
89100929|NCT06123897||Individuals with schizophrenia|
89100930|NCT06123897||Healthy volunteers|"Inclusion Criteria:~Ages 13-60 years old.~Clinical diagnosis not meeting ICD-10 criteria for schizophrenia.~Diagnosis not meeting schizophrenia criteria confirmed using SCID-5-RV (DSM-5 Structured Clinical Interview for DSM-5 Disorders - Research Version).~Exclusion criteria are the same as for the schizophrenia patient group."
89100931|NCT06122844|Experimental|Social, Emotional, and Ethical Development (SEED) curriculum|The kindergartens, teachers, and children will receive the training and SEED curriculum. Upon informed consent from the school principals and parents, parents, teachers, and children will complete pre-, post-, and 4-week follow-up assessments. Focus group interviews will be conducted with teachers to understand their acceptability, demand, practicality, integration, and efficacy of the teacher training at post-teacher training and delivery of the SEED curriculum for children at post-intervention. Another focus group interviews will be conducted with SEED trainers to get information about teachers' participation rate in the training session.
89100932|NCT06122844|No Intervention|Waitlist control group|One kindergarten will be assigned to the waitlist control condition. Teachers in the waitlist control schools will wait for at least 12 weeks before they receive the training, and children in the waitlist control group will receive SEED curriculum after the teachers' training. Upon informed consent from the school principals and parents, parents, teachers, and children will also complete pre-, post-, and 4-week follow-up assessments.
89100933|NCT06118853|No Intervention|Group A (control)|Standard treatment for HSCT
89100934|NCT06118853|Experimental|Group B (intervention)|Yoga or gentle massage plus standard treatment for HSCT
89227610|NCT00969254|Active Comparator|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
89100935|NCT06115642|Experimental|HLX43 group|Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
89100936|NCT06115369|Experimental|Medically Tailored Meals|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice daily prepared medically tailored meals (MTM). Study participants will be able to select choices for these from a large selection of health options. The study team will work with Season Health to create customizations to allow for the incorporation of patient dietary preferences. Study team members will assist patients in setting up their Season Health accounts.
89100937|NCT06115369|Experimental|Fresh Produce|We will work with Season Health, our food intervention partner to provide participants with weekly deliveries of a large box full of fresh produce and pantry staples. The study participants will be able to select choices for these from a large selection of health options. The study team will work with Season Health to create customizations to allow for the incorporation of patient dietary preferences. Study team members will assist patients in setting up their Season Health accounts.
89100938|NCT06115369|No Intervention|Control arm|This control arm will receive dietary education only.
89100939|NCT06110975|Experimental|Intervention group|"The primary care clinics in the intervention group will contact and evaluate all patients receiving one or more of the following drugs:~G04BD04 Oxybutynin G04BD07 Tolterodine G04BD08 Solifenacin G04BD09 Trospium G04BD10 Darifenacine G04BD11 Fesoterodine G04BD12 Mirabegron The patients will be asked to discontinue the treatment and eventually be deprescribed"
89100940|NCT06110975|No Intervention|Control group|The primary care clinics in the control group will not contact and evaluate patients and are not informed about the study. Data will be extracted from registries
89100941|NCT06109558||cohort A|Patients with MET amplication（IHC: MET++ or +++ ）and without EGFR T790 mutaion.
89100942|NCT06109558||cohort B|Patients with RET fusion and without EGFR T790 mutaion.
89100943|NCT06091540|Experimental|Beyond Quake: A Human-Centered SH+ Randomized Controlled Trial for Earthquake Survivors|The first phase of the study involves the execution of a randomized controlled trial (RCT). This phase will introduce an earthquake-adapted iteration of the SH+ intervention. Notable variations will be present compared to the original manual. While the conventional SH+ manual incorporates audio elements and paired discussions centered around specific topics, the version utilized in this study will diverge from this format. Specifically, audio components will be omitted, and the intervention will be directly delivered by the psychologist in person. Furthermore, the practice of paired discussions will encompass the entire group, fostering a collective environment for interaction. This inclusion of a personal, group-based approach within the SH+ intervention is intended to infuse a more humane dimension, thus facilitating the healing process.
89100944|NCT06091540|No Intervention|Treatment as Usual|Participants will undergo random assignment to either the treatment as usual (TAU) group or the intervention group. Upon completion of all measurements, the control group will be given the opportunity to receive the intervention.
89100945|NCT06083675|Experimental|Semaglutide 25 mg|Participants will receive 25 mg oral semaglutide once daily in maintenance period after dose escalation period.
89100946|NCT06083675|Experimental|Semaglutide 50 mg|Participants will receive 50 mg oral semaglutide once daily in maintenance period after dose escalation period.
89100947|NCT06083675|Experimental|Empagliflozin 25 mg|Participants will 25 mg empagliflozin oral once daily in maintenance period after dose escalation period.
89100948|NCT06083675|Experimental|Metformin 2000 mg|Participants will receive metformin 1000 mg orally twice daily (total 2000 mg) in maintenance period after dose escalation period.
89100949|NCT06078566|Experimental|AUR-201|AUR-201
89100950|NCT06075771|Experimental|Carbidopa Levodopa Group|"Patients randomized to the Carbidopa Levodopa Group will receive one tablet per day of L-DOPA (150 mg levodopa administered with 37.5 mg carbidopa) for 4 weeks.~Patients that respond after the initial 4 weeks will continue on the same dose for an additional 4 weeks to determine whether clinical response at the 150 mg dose is sustained over time compared to placebo.~Patients that do not exhibit a clinical response (50% reduction in HAM-D scores from baseline) after 4-weeks on the 150 mg dose will escalate to 450 mg L-DOPA (three tablets per day of 150 mg levodopa administered with 37.5 mg carbidopa) and studied over an additional 4 weeks (8 weeks total in the study)."
89100951|NCT06075771|Placebo Comparator|Placebo Group|Participants will receive placebo tablet. Placebo-treated non-responders at 4 weeks will remain on placebo but with the same instructions to increase daily pill intake.
89100952|NCT06072040|Experimental|AUR-201|AUR-201
89100953|NCT06067763|Experimental|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
89100954|NCT06067763|Experimental|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
89100955|NCT06067763|Active Comparator|Educational Video control|"Participants in this arm will be assigned to watch a four-part documentary The Weight of the Nation from their home."
89100956|NCT06064266|Experimental|8-days plant-based preconditioning mild ketogenic controlled diet followed by a high-fat shake.|
89100957|NCT06054776|Experimental|Treatment (acalabrutinib, obinutuzumab, glofitamab)|Patients recieve acalabrutinib PO BID of each cycle, obinutuzumab IV on days 1 and 7 of cycle 1 only, and glofitamab IV over 2-4 hours on days 8 and 15 of cycle 1 and day 1 of each subsequent cycle. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD positive CR, PR, or SD after 12 cycles of protocol therapy may continue receiving single agent acalabrutinib per standard of care during the follow-up phase of the study. Patients also undergo a ECHO or MUGA during screening, as well as PET/CT or CT, and blood specimen collection throughout the trial. Patients may also undergo bone marrow biopsies throughout the trial.
89100958|NCT06042322||TKA with nerve block no intervention|Patients who received a single shot adductor canal nerve block prior to total knee arthroplasty surgery January 2017-June 2018
89100959|NCT06042322||TKA with nerve block with intervention|Patients who received a single shot adductor canal nerve block prior to total knee arthroplasty surgery during March 2019-March 2020, and received an educational intervention
89100960|NCT06040840|Active Comparator|BAX group|Axillary brachial plexus block + Tourniquet
89100961|NCT06040840|Experimental|WALANT group|Wide Awake Local Anesthesia No Tourniquet
89100962|NCT06033703|Experimental|Primary retinal detachment, Phakic group|"Phakic patients with primary rhegmatogenous retinal detachment repair within 7 days of symptom onset, undergoing vitrectomy or vitrectomy with scleral buckle will be included.~Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively."
89100963|NCT06033703|Experimental|Primary retinal detachment, Pseudophakic group|"Pseudophakic patients with primary rhegmatogenous retinal detachment repair within 7 days of symptom onset, undergoing vitrectomy or vitrectomy with scleral buckle will be included.~Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively."
89100964|NCT06033703|Experimental|Secondary retinal detachment, Phakic group|"Phakic patients with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma, undergoing vitrectomy or vitrectomy with scleral buckle will be included.~Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively."
89100965|NCT06033703|Experimental|Secondary retinal detachment, Pseudophakic group|"Pseudophakic patients with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma, undergoing vitrectomy or vitrectomy with scleral buckle will be included.~Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively."
89100966|NCT06022562||With gender-affirming hormone therapy|With gender-affirming hormone therapy
89100967|NCT06022562||Without gender-affirming hormone therapy|Without gender-affirming hormone therapy
89100968|NCT06015022|Experimental|Epigallocatechin gallate 600 - 800mg|Epigallocatechin gallate (EGCG) 600mg will be administered daily via oral route for the initial 12 consecutive weeks on an outpatient basis. The dose of 600 mg will be continued for the second 12 weeks if an interim HCC biomarker test at the end of week 8 improves. If the interim test does not improve without dose-limiting adverse events, the dose will be increased to 800mg for the second 12 weeks, All participants will receive 24 weeks of treatment in total.
89100969|NCT06015022|Placebo Comparator|Placebo|Oral administration of placebo for 24 weeks
89100970|NCT06011772|Experimental|Cohort A|"LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 chemotherapy consisting of leucovorin IV, oxaliplatin IV over 2 hours, and fluorouracil IV and bevacizumab IV over 10 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial."
89100971|NCT06011772|Experimental|Cohort B1|"LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive FOLFIRI consisting of irinotecan IV, leucovorin IV over 90 minutes, and fluorouracil IV and cetuximab IV over 120 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial."
89100972|NCT06011772|Experimental|Cohort B2|"LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 chemotherapy and cetuximab IV over 120 minutes on days 1 and 15. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples throughout the trial"
89227611|NCT00921791|Experimental|Home Blood Pressure Monitoring|Automatic oscillometric device for blood pressure measurement at home plus usual care.
89227612|NCT00921791|Experimental|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists plus usual care.
89100973|NCT06011772|Experimental|Cohort C|"Description LOADING PHASE: Patients receive CIMAvax-EGF IM on days 1 and 15. Treatment repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive CIMAvax-EGF IM on day 15. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive mFOLFOX6 and cetuximab, FOLFOX6 and bevacizumab, or mFOLFOX6 per investigators preference. Treatment repeats every 2 weeks for 10 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo metastasectomy 4-8 weeks after first maintenance phase dose. Patients undergo collection of blood samples throughout the trial."
89100974|NCT06010706|Experimental|Supervised Manual Physical Therapy Program|Participants will receive a supervised physical therapy program including: mobilizing exercises, stretching exercises, and strengthening exercises. 3 sessions a week for eight consecutive weeks.
89100975|NCT06010706|Active Comparator|Home based exercise program:|Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance. The home-based program will include stretching, ROM and strengthening exercises
89100976|NCT06001697|Experimental|Intervention|The treatment group will receive information regarding wellness factors by the doctor (health advice) and they will be asked to follow those recommendations for the duration of the study. In addition they will also receive a park prescription specifying a target amount of time to spend in nature, along with frequency of visits and recommended locations (e.g., specific parks), and information about parks and programming in the study area.
89100977|NCT06001697|Other|Control|The control group will receive regular health advice and information regarding wellness factors by the doctor and they will be asked to follow those recommendations for the duration of the study.
89100978|NCT05998252|Experimental|Alveo balloon dilatation catheter|Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and undergo a planned percutaneous coronary intervention with Alveo balloon dilatation catheter.
89227613|NCT00921791|Active Comparator|Pharmaceutical care|Consultations with the pharmacists plus usual care.
89100979|NCT05975970|Experimental|MyoTrain AR System|Participants will undergo functional task training using the MyoTrain AR system, which includes the HoloLens 2 augmented reality head-mounted display, four HTC VIVE SteamVR kinematic trackers, eight surface EMG electrodes based on the Element hardware platform, and a desktop computer. Participants will be prompted to use a pattern recognition-based myoelectric controller to operate a virtual prosthesis and complete a simulation of the GaMA Cup Transfer Task.
89100980|NCT05975970|Active Comparator|Conventional Motor Imagery|Participants will be provided motor imagery exercises that involve brief attempts to move the missing limb in a similar manner to how they would control their pattern recognition system to strengthen their muscles. These exercises do not involve any real-time control feedback or functional assessment.
89100981|NCT05973487|Experimental|Monotherapy Cohort A|TSC-204-A0201
89100982|NCT05973487|Experimental|Monotherapy Cohort B|TSC-204-C0702
89100983|NCT05973487|Experimental|Monotherapy Cohort C|TSC-200-A0201
89100984|NCT05973487|Experimental|T-Plex Combination Cohort A + B|TSC-204-A0201 and TSC-204-C0702
89100985|NCT05973487|Experimental|T-Plex Combination Cohort B + C|TSC-204-C0702 and TSC-200-A0201
89100986|NCT05973487|Experimental|T-Plex Combination Cohort A + C|TSC-204-A0201 and TSC-200-A0201
89100987|NCT05973487|Experimental|Monotherapy Cohort D|TSC-203-A0201
89100988|NCT05973487|Experimental|T-Plex Combination Cohort A + D|TSC-204-A0201 + TSC-203-A0201
89100989|NCT05973487|Experimental|T-Plex Combination Cohort B + D|TSC-204-C0702 + TSC-203-A0201
89100990|NCT05973487|Experimental|T-Plex Combination Cohort C + D|TSC-200-A0201 + TSC-203-A0201
89100991|NCT05972954|Experimental|Treatment with OMT-28|24mg OMT-28, oral capsule, for 12 weeks
89100992|NCT05966532||Major Depressive Disorder (MDD) Participants:|"Male and female subjects~Age between 21-80 years old~Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnosis of major depressive disorder (MDD) based on Mini Neuropsychiatric Interview~Inventory of Depressive Symptomatology; Clinician Rated version (IDS-C) total score > 14~Able to read, write, and comprehend English~Provide informed consent; willing to comply with study protocol.~Note: For individuals with MDD diagnosis: As part of the screening procedures, the Mini International Neuropsychiatric Interview (MINI-7.0 for DSM-5) will be conducted to determine eligibility. This is related to Inclusion Criteria #3."
89100993|NCT05966532||Healthy Volunteer Participants:|"Male and female subjects~Age between 21-80 years old~Able to read, write, and comprehend English~Provide informed consent; willing to comply with study protocol"
89100994|NCT05960851|Experimental|LY3871801 (Part A)|LY3871801 administered orally in Japanese and Non-Asian Participants.
89100995|NCT05960851|Placebo Comparator|Placebo (Part A)|Placebo administered orally in Japanese and Non-Asian Participants.
89100996|NCT05960851|Experimental|LY3871801 (Part B)|LY3871801 administered orally in Chinese Participants.
89100997|NCT05960851|Placebo Comparator|Placebo (Part B)|Placebo administered orally in Chinese Participants.
89100998|NCT05958316|Experimental|Computerized Symptom Assessment Tool C-SCAT|Participants will be asked to complete the C-SCAT at three of their clinic visits for cancer treatment in addition to usual care for assessing symptoms. This intervention period will last up to about 12 weeks, depending on cancer treatment schedule (for example, every 2, 3 or 4 weeks).
89100999|NCT05958316|Active Comparator|Usual Care Control Group|Participants will follow usual care for cancer symptoms for up to 12 weeks, depending on how cancer treatment schedule (for example, every 2, 3 or 4 weeks).
89101000|NCT05955157|Experimental|Treatment Group|Receiving DC-CIK plus S1 maintenance treatment
89101001|NCT05955157|Active Comparator|Control Group|Receiving S-1 maintenance treatment alone
89101002|NCT05945875|Experimental|Diagnostic (panitumumab-IRDye800, 111In-panitumumab, SPECT/CT)|Patients receive panitumumab-IRDye800 IV over 15 minutes followed by 111In-panitumumab IV on day 0. Patients then undergo SPECT/CT between days 1 and 5, prior to standard of care surgical resection with fluorescence imaging.
89101003|NCT05944237|Experimental|Phase 1 Part A HTL0039732 (Dose Escalation Monotherapy)|Groups of participants will receive increasing doses of HTL0039732 Capsules as a single agent to find a safe dose and a dose that best targets cancer cells.
89101004|NCT05944237|Experimental|Phase 1 Part B HTL0039732 and Atezolizumab (Dose Escalation Combination)|Groups of participants will receive increasing doses of HTL0039732 Capsules in combination with a fixed 1200 mg dose of atezolizumab to find a recommended Phase 2 dose (RP2D) for HTL0039732.
89101005|NCT05944237|Experimental|Phase 2a HTL0039732 and Atezolizumab (Dose Expansion Combination)|An expansion cohort will receive the RP2D of HTL0039732 Capsules in combination with a fixed 1200 mg dose of atezolizumab.
89101006|NCT05923736|Other|Case group : digital osteoarthritis|
89101007|NCT05923736|Other|Control group : lumbago, osteoporosis|
89101008|NCT05918887|Experimental|E-cigarette arm|Participants will receive the commercially available NJOY ACE e-cigarette, nicotine pods (2 of each available flavor, for a total of 4 pods), and tailored instructions to switch. Participants will use the ACE ad libitum for 14 days, reporting their cigarette use, e-cigarette use, mood, and nicotine crazing every day via text message surveys.
89101009|NCT05911997|Experimental|High Dose MTC 01|High dose MTC 01 is 10 x 11 CFU slurry to be administered via colonoscopy
89101010|NCT05911997|Experimental|Low Dose MTC 01|Low Dose MTC 01 is 10 x 10 CFU slurry to be administered via colonoscopy
89101011|NCT05911997|Active Comparator|Low dose Fecal Microbiota Transplantation (FMT)|High dose FMT is 10 x 11 CFU slurry to be administered via colonoscopy
89101012|NCT05911997|Experimental|High Dose Fecal Microbiota Transplantation (FMT)|Low dose FMT is 10 x 10 CFU slurry to be administered via colonoscopy
89101013|NCT05903118|Experimental|Participants aged 18 to 59 years.|Escalating dose levels
89101014|NCT05903118|Experimental|Participants aged 60 years and older.|Escalating dose levels
89101015|NCT05903118|Placebo Comparator|Placebo|
89101016|NCT05900609|Experimental|Fiber arm|"Subjects receive dietary guidelines, to increase their fiber intake. Additionally, during the last 6 weeks of the intervention period subjects receive a study product containing 8,5 grams fiber per day.~Additionally, subjects receive general guidelines about the effect of nutrition on the gut microbiome."
89101017|NCT05900609|Experimental|Fermented food arm|"Subjects receive dietary guidelines, to increase their intake of fermented foods.~Additionally, during the last 6 weeks of the intervention period subjects receive a study product of 17 millilitres concentrated kombucha per day.~Additionally, subjects receive general guidelines about the effect of nutrition on the gut microbiome."
89101018|NCT05900609|Placebo Comparator|Control|"Subjects receive general guidelines about the effect of nutrition on the gut microbiome.~Additionally, during the last 6 weeks of the intervention period subjects receive a placebo product of 10 grams maltodextrin per day."
89101019|NCT05897788|No Intervention|Augmented Usual Care (AUC)|"AUC: Standard Way to Health Care text line. Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.~Participants across all arms will receive an intake survey, and follow-up surveys at day 15, day 30, month 3, and month 6."
89101020|NCT05897788|Active Comparator|Augmented usual care + text-message check-ins|"AUC: Standard Way to Health Care text line. Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.~Text check-in: Patients will also receive incentives for engagement with treatment and~Participants across all arms will receive an intake survey, and follow-up surveys at day 15, day 30, month 3, and month 6."
89227614|NCT00921791|Active Comparator|Control|Usual care: participants are instructed to keep on their current antihypertensive medication and receive non-pharmacological recommendations for hypertension treatment.
89101021|NCT05897788|Active Comparator|Augmented Usual care + Contingency Management (CM)|"AUC: Standard Way to Health Care text line. Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.~Participants across all arms will receive an intake survey, and follow-up surveys at day 15, day 30, month 3, and month 6.~CM: Patients will also receive incentives for engagement with treatment."
89101022|NCT05897788|Active Comparator|Augmented usual care + text-message check-ins + contingency management|"AUC: Standard Way to Health Care text line. Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.~Text check-in: Patients will also receive incentives for engagement with treatment and~Participants across all arms will receive an intake survey, and follow-up surveys at day 15, day 30, month 3, and month 6.~CM: Patients will also receive incentives for engagement with treatment."
89101023|NCT05892159|Experimental|HRV biofeedback|An HRV biofeedback tool will be employed in which individuals will breathe at their resonance frequency to optimize HRV and autonomic nervous system signatures.
89101024|NCT05889572|Experimental|MaaT033|"Route of administration: oral (capsule)~Between D-5 to D-1: Bowel preparation with Macrogol and Rifamixin~Between D1 to D28: MaaT033 treatment period 1~Between D28 to D56: MaaT033 treatment period 2"
89101025|NCT05888428|Experimental|Experimental|Participants will be provided with the take-home MyoTrain system, which includes the MyoTrain armband, iPad, and MyoTrain software. Participants will progress through the training modules of the MyoTrain software, starting with eliciting paired single DoF antagonistic movements and ending with the proportional control of complex, 2-DoF hand and wrist movements.
89101026|NCT05888428|Active Comparator|Control|Participants will be provided motor imagery exercises that involve brief attempts to move the missing limb in a similar manner to how they would control their pattern recognition system to strengthen their muscles. These exercises do not involve any real-time control feedback.
89101027|NCT05886634|Experimental|Participants With Dedifferentiated Liposarcoma/DDLPS|Participants will have a diagnosis of recurrent or metastatic Dedifferentiated Liposarcoma/DDLPS
89101028|NCT05869487|Other|X-ray|Whole body x-ray absorptiometry for measurement of appendicular muscle mass in kilograms. Only one measurement per participant.
89101029|NCT05868265|Experimental|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 g/kg on days 1 and 8 of 21 days cycle, for a total of three cycles, followed by radical nephroureterectomy, ureterectomy, or nephrectomy, depending on the site of the tumor and per the clinical decision of the treating urologist.
89101030|NCT05867849|Experimental|Cannabidiol|Cannabidiol 200 - 600 mg / day added to current treatment for 6 weeks.
89101031|NCT05867849|Placebo Comparator|Placebo|Placebo added to current treatment for 6 weeks.
89101032|NCT05864677|No Intervention|Group S - standard treatment|Patients will be treated in accordance with the current recommendations. Patients with every postoperative complication (severe postoperative bleeding, wound infection, hemodynamically unstable) and those undergoing reoperation will be excluded from this study.
89101033|NCT05864677|Active Comparator|Group CER - treatment with Cerebrolysin|Patients will be treated in accordance with the current recommendations and receiving additional treatment with Cerebrolysin.
89101034|NCT05856227|Experimental|Treatment Arm: Ceftobiprole|Ceftobiprole medocaril: 7.5 mg/kg to 15 mg/kg
89101035|NCT05850689|Experimental|Lumateperone 42 mg|
89101036|NCT05850689|Placebo Comparator|Placebo|
89101037|NCT05843461||Controls|10 patients without pulmonary hypertension (mean PA pressure less than 20 mmHg on RHC)
89101038|NCT05843461||PAH|10 patients with PAH
89101039|NCT05843461||CTEPH|10 patients with CTEPH
89101040|NCT05842161|Experimental|QUIT-AD|An six-session adapted cognitive-behavioral intervention for smoking cessation and treatment adherence. Intervention content will include psychoeducation related to cognitive-behavioral therapy, smoking, TB, and HIV; behavioral activation; distress tolerance; and relapse prevention.
89101041|NCT05842161|Active Comparator|Enhanced Treatment as Usual (ETAU)|After randomization, participants in the ETAU condition will receive one session of psychoeducation on the HIV- and TB-related health benefits of smoking cessation.
89101042|NCT05832229|Experimental|Active|Open-label lead-in period of 4 weeks on 20 mg (10 mg for participants of East ancestry) rosuvastatin by mouth once daily, followed by a period of 96 weeks rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry).
89101043|NCT05832229|Placebo Comparator|Placebo|Open-label lead-in period of 4 weeks on 20 mg (10 mg for participants of East ancestry) rosuvastatin by mouth once daily, followed by a period of 96 weeks placebo.
89101044|NCT05832190|Active Comparator|Arm 1: patient with usual follow-up (standard of care)|receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
89101045|NCT05832190|Experimental|Arm 2: Same usual general dietary recommendations PLUS Biotin|Patients will receive the same usual general dietary recommendations PLUS 1 capsule per day of Biotin 450 µg per day during 3 months before the surgery.
89101046|NCT05832190|Experimental|Arm 3: Same usual general dietary recommendations PLUS Fiber|Patients will receive the same usual general dietary recommendations PLUS 3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
89101047|NCT05832190|Experimental|Arm 4: Same usual general dietary recommendations PLUS Fiber PLUS Biotin|Patients will receive the same usual general dietary recommendations PLUS 3 servings per day of PureLean® Fiber and Biotin 450 µg per day (1 capsule per day), during 3 months before the surgery.
89101048|NCT05831995|Experimental|Experimental Monotherapy Dose Escalation|"A classic 3+3 design will be used to explore the maximum tolerated dose (MTD) and to determine the recommended phase II dose (RP2D). Three to four patients will be enrolled to ensure at least 3 evaluable patients for DLT (Dose Limiting Toxicity). ABM-168 monotherapy will be conducted in seven provisional dose levels starting at 0.5mg oral administration per day and up to and including 12mg oral administration. Each treatment cycle is 28-days. DLT will be evaluated in the first 28-day cycle. Patients will receive daily doses of ABM-168 until disease progression; intolerable toxicity; withdrawal consent; or other clinical observation is met."
89101049|NCT05831995|Experimental|Experimental Monotherapy Dose Expansion-1|Expansion will be conducted in the adult patients with advanced solid tumors that carry either RAS, RAF or NF-1 mutations. Cohort EX1 will enroll the patients with preferred indications (i.e., melanoma, colon cancer, lung cancer, and pancreatic carcinoma) who had confirmed RAS, RAF or NF-1 mutations and measurable target lesion(s) at baseline. Patients with measurable brain metastases lesion(s) at baseline are highly preferred. Up to 15 evaluable patients will be enrolled for each into each preferred indication. Other indication(s) that show confirmed response, complete response (CR) or partial response (PR) in at least one subject in the dose escalation study will facilitate the preferred indication(s) for Cohort EX1 enrollment as well.
89101050|NCT05831995|Experimental|Experimental Monotherapy Dose Expansion-2|Expansion will be conducted in the adult patients with advanced solid tumors that carry either RAS, RAF or NF-1 mutations. Cohort EX2 will enroll the patients who had primary CNS tumors with confirmed RAS, RAF or NF-1 mutations at baseline. Up to 30 evaluable patients will be enrolled.
89101051|NCT05818553|Experimental|Part A: Randomized, Double-Blind 0.5mg/kg/day PRAX-562 or PRAX-562/Placebo|Eligible participants from each cohort will be randomized in a 1:1 ratio to either 0.5 milligrams/kilograms/day (mg/kg/day) PRAX-562 for 16 weeks (PRAX-562 arm) or 0.5 mg/kg/day PRAX-562 for 12 weeks and matching placebo for 4 weeks (PRAX-562/placebo arm) administered orally or via gastrostomy tube (G-tube).
89101052|NCT05818553|Experimental|Part B: Open-Label Extension Treatment 0.5mg/kg/day PRAX-562|Eligible participants will receive 0.5mg/kg/day administered orally or via G-tube for 48 weeks.
89101053|NCT05816317|Experimental|Single-Session Mechanism Focused Intervention (SSMFI)|
89101054|NCT05816317|Active Comparator|Treatment as Usual|
89101055|NCT05807178|Experimental|LSA-1|Light Scheduling Algorithm-1 (LSA-1): High circadian effective irradiances
89101056|NCT05807178|Active Comparator|LSA-2|Light Scheduling Algorithm-2 (LSA-2): Irradiance levels comparable to conventional hospital lighting (control group).
89101057|NCT05804032|Active Comparator|Arm A - Intravenous isatuximab|Patients in arm A are treated with 3 cycles RVd + i.v. isatuximab, followed by a standard intensification and autologous stem cell transplantation.
89101058|NCT05804032|Experimental|Arm B - Subcutaneous isatuximab|Patients in arm B are treated with 3 cycles RVd + s.c. isatuximab, followed by a standard intensification and autologous stem cell transplantation.
89101059|NCT05802940|Active Comparator|Best practice alert (BPA) intervention group|An electronic health record best practice alert (BPA) will alert healthcare providers to recommend low dose aspirin for pregnant patients at high-risk for preeclampsia. This alert also allows the healthcare provider to order an over-the-counter-prescription for low dose aspirin and automatically documents LDA in the patient's medication list.
89101060|NCT05802940|No Intervention|Standard care group|Healthcare provider's recommendation for aspirin in patients at high-risk for preeclampsia will be based on current practice (no alerts) and the healthcare provider's knowledge.
89101061|NCT05800873|Experimental|EVER001|EVER001 for 36 weeks.
89101062|NCT05787561|Experimental|Avutometinib (VS-6766) and Defactinib|All enrolled patients will be treated with Avutometinib (VS-6766) 3.2 mg PO, twice weekly (e.g. M/Th,Tu/F, or W/Sa) + defactinib 200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
89101063|NCT05775523||Patients on SKYTROFA (Lonapegsomatropin)Treatment|SKYTROFA (Lonapegsomatropin) administered once-weekly by subcutaneous injection
89101064|NCT05766579|Experimental|K1, 18-21 mmHg|Use of elastic stockings at 18-21 mmHg after endovenous thermal ablation
89101065|NCT05766579|Experimental|K2, 23-32 mmHg|Use of elastic stockings at 23-32 mmHg after endovenous thermal ablation
89101066|NCT05764590|Experimental|AP-306|
89101067|NCT05764590|Active Comparator|Sevelamer Carbonate|
89101068|NCT05754944||Cancer patients having surgery|This is a prospective cohort study where patients who are 65 years or older with either a history of diabetes (requiring medication or insulin) or smoking history (current smoker, smoker within the last 15 years, or ≥ 20 year pack history), facing major head and neck, thoracic, abdominal, or pelvic surgery will be screened for PAD with an ABI/TBI to establish prevalence and to compare prevalence among races to meet
89101069|NCT05751434|Experimental|Participants Assigned to Exercise Therapy|Participants with histologically confirmed localized prostate cancer undergoing active surveillance
89101070|NCT05751434|No Intervention|Participants Assigned to Usual Care|Participants with histologically confirmed localized prostate cancer undergoing active surveillance
89101071|NCT05741450|Experimental|Lens 1|All participants wore Lens 1 for 15 minutes (Period 1)
89101072|NCT05741450|Experimental|Lens 2|All participants wore Lens 2 for 15 minutes (Period 2)
89101073|NCT05741294|Experimental|Tirbanibulin 2.5 milligrams (mg) ointment|Participants will apply tirbanibulin ointment- topically at a dose of 2.5 mg once daily for 5 consecutive days- on the face or scalp.
89101074|NCT05737784|Experimental|Preliminary Safety|Open-label PRAX-222
89101075|NCT05737784|Experimental|Dose Escalation - PRAX-222|Initial dose escalation consisting of double-blind ascending doses of PRAX-222
89101076|NCT05737784|Placebo Comparator|Dose Escalation - Placebo|Double-blind placebo procedure
89101077|NCT05737784|Experimental|Optional Dose Escalation - PRAX-222|Optional dose escalation consisting of double-blind ascending doses of PRAX-222
89101078|NCT05737784|Placebo Comparator|Optional Dose Escalation - Placebo|Double-blind placebo procedure
89101079|NCT05737784|Experimental|Confirmatory Dosing - PRAX-222|Double-blind fixed-dose PRAX-222
89101080|NCT05737784|Experimental|Confirmatory Dosing - Placebo|Double-blind placebo procedure
89101081|NCT05737784|Experimental|Open-label PRAX-222|Open-label PRAX-222
89227615|NCT00973466||HIV-infection|All HIV-infected patients attending the Clinic for Infectious Diseases at Berne university hospital, having been sexually active during the past 12 months and having given written informed consent
89101082|NCT05736367|Experimental|Metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer|"Administration of U-13C-glucose to participants with early-stage HR+/Her2- breast cancer fitting criteria, will be done intraoperatively at the time of resection, as well as blood sample collection.~This will allow for in depth evaluation of glycolysis as well as TCA cycle, lipid and amino acid metabolism and comprehensive genomic analyses to complement the metabolic assays that will be done by the Ludwig Institute of Cancer Research. HR+/Her2- breast cancer subtype is chosen for this feasibility pilot study given that metabolic studies have not been done in this subtype of breast cancer and it makes up the majority of breast cancer cases."
89101083|NCT05734846|Experimental|Control Lenses, then Test Lenses|Participants wore the Control Lenses for 1 week, then crossed over to the Test Lenses for 1 week.
89101084|NCT05734846|Experimental|Test Lenses, then Control Lens|Participants wore the Test Lenses for 1 week, then crossed over to the Control Lenses for 1 week.
89101085|NCT05718505|Active Comparator|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
89101086|NCT05718505|Experimental|Atmo Motility Gas Capsule System|"The Atmo Motility Gas Capsule System (Atmo Biosciences) offers a novel method for measuring GET, SBTT, SLBTT, CTT and WGTT. This device measures temperature, relative humidity, hydrogen concentration and carbon dioxide concentration, along with indicators of fermentation activity, capsule tumble and antenna reflectance as it transit through the GI tract.~It has the added benefit of recording information on the fermentation and gas profiles within the GI tract."
89101087|NCT05714488|Experimental|Blue Halo Coil Catheter for Urinary Retention|The indication for use of the Blue Halo Coil Catheter is to facilitate bladder drainage in adult male patients with urinary retention due to benign prostatic hyperplasia. The device is inserted for temporary use up to 28 days.
89101088|NCT05712876|Experimental|Single ascending dose (SAD) CK-0045 Dose level 1 to 5|At each dose level 6 healthy participants will receive a single dose of CK-0045 by s.c. administration
89101089|NCT05712876|Placebo Comparator|SAD placebo|At each dose level 2 healthy participants will receive a single dose of matching placebo by s.c. administration
89101090|NCT05712876|Experimental|Multiple ascending dose (MAD) CK-0045 Dose level 1 to 3|At each dose level 9 otherwise healthy participants with obesity will receive a loading dose of CK-0045 on Day 1 followed by a dose on Day 8, Day 15, Day 22, Day 29 and Day 36 of CK-0045 by s.c. administration
89101091|NCT05712876|Placebo Comparator|MAD placebo|At each dose level 3 otherwise healthy participants with obesity will receive matching placebo on Day 1, Day 8 , Day 15, Day 22, Day 29 and Day 36 by s.c. administration
89101092|NCT05712564||MFS_cohort|Adult patients with Marfan syndrome
89101093|NCT05712564||EDS_cohort|Adult patients with Ehlers-Danlos syndrome
89101094|NCT05709821|Experimental|Phase 1 IMM60 dose escalation safety arm|3 dose levels of IMM60 will be assessed (1, 3, 9 and 36 mg/m^2 administered IV every 3 weeks for up to 6 cycles)
89101095|NCT05709821|Experimental|Phase 1 IMM60 + pembrolizumab combination safety arm|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the IMM60 dose escalation safety cohort.
89101096|NCT05709821|Experimental|Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, IMM60 + pembrolizumab)|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles will be administered in combination with IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation safety cohorts.
89101097|NCT05709821|Active Comparator|Phase 2 PD-L1 ≥50% NSCLC Cohort 1 (Randomized, pembrolizumab monotherapy)|Pembrolizumab 200 mg IV every 3 weeks for up to 35 cycles.
89101098|NCT05709821|Experimental|Phase 2 PD-L1 <1% NSCLC Cohort 2|Participants will be treated with one cycle of IMM60 with a tumor biopsy before and after, to determine any changes in PD-L1 expression. After this one cycle, the participants will receive the combination of IMM60 IV for up to 6 total cycles + pembrolizumab 200 mg every 3 weeks administered IV. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.
89101099|NCT05709821|Experimental|Melanoma Cohort|IMM60 IV every 3 weeks for up to 6 cycles. The IMM60 dose will be determined based on the results of the Phase 1 dose escalation cohorts.
89101100|NCT05704595|Other|Initial outpatient management strategy, including outpatient IV diuretics in clinic|
89101101|NCT05704595|Other|Initial hospitalization-based management strategy|
89101102|NCT05700474|Experimental|Intervention Arm|There is one arm of the study and this involves participating in holistic behavioral health treatment for people living with HIV and the LGBTQ+ community for a 6 month period. Specific services include individual and group therapy, case management, peer support, and behavioral health education and awareness
89101103|NCT05684068|Experimental|Gum Graft Placed on Denuded Bone|Subjects in this arm will have a free epithelialized gingival/mucosal graft (gum graft) placed on full thickness periosteal bed preparation where all of the tissue was removed (test group).
89101104|NCT05684068|Active Comparator|Gum Graft Placed on Split Thickness Periosteal Bed Preparation|Group B will have a free epithelialized gingival/mucosal graft (gum graft) on split thickness periosteal bed preparation where only a portion of the tissue was removed (control group).
89101105|NCT05678348|Experimental|Pyrimethamine|Pyrimethamine will be taken by mouth at a dose of 50 mg once daily for 14 days (+/-2 days) with the last dose the day prior to surgery.
89101106|NCT05678322|Experimental|Patients with PSA > 0.2 ng/ml following Radical Prostatectomy|Men will be eligible for the study when their post-prostatectomy PSA level is initially observed to be PSA >0.2ng/ml. All participants will receive a baseline rhPSMA-7.3 (18F) MRI scan within a month of enrollment, and the second rhPSMA-7.3 (18F) scan will be performed within a year of the initial scan. Only those participants with rhPSMA-7.3 (18F) identifiable disease during the initial scan will be offered salvage intervention per standard of care. All participants with a negative initial rhPSMA-7.3 (18F) scan will undergo a second scan when the PSA> 0.5 ng/ml or one year after the initial PET scan. The salvage intervention will be at the discretion of the investigator.
89101107|NCT05670301|Experimental|Intervention|Cytokine assessment
89101108|NCT05664386|Active Comparator|propofol group|According to grouping，patients were premeditated with injection of Propofol 2-2.5mg / kg IV . If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is >60, propofol 1mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil.Then propofol was maintained in group P at 4-12 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min .BIS was kept at 40 ~ 60 during the surgery, and infusion drugs were stopped at the end of the operation. The patients were Transfered to Postanesthesia care unit(PACU) after the operation.
89101109|NCT05664386|Experimental|ciprofol group|Group C was given ciprofol 0.4 ~ 0.5mg/kg, if bispectral index(BIS) value ≤60 during anesthesia induction, cisatracurium 0.2mg/kg and sufentanil 0.5μg/kg were injected intravenously, endotracheal intubation was performed after the improvement of muscle relaxation. If the BIS value was greater than 60, ciprofol 0.2mg/kg each time, and the interval of administration was greater than 1min, until BIS≤60. Cisatracurium and sufentanil were injected intravenously, followed by endotrachealintubation.Ciprofol was maintained in Group C at 0.8-2.5 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min . Intermittent addition of cisatracurium,Sufentanil was added as required, and total dosage of Sufentanil was 0.7ug ~ 1ug/kg. BIS was kept at 40 ~ 60 during the surgery, and infusion drugs were stopped at the end of the operation. The patients were Transfered to Postanesthesia care unit(PACU) after the operation.
89101110|NCT05662397|Experimental|HST-1011 Monotherapy Dose Escalation (Part A1)|Multiple dose levels of HST-1011 to be evaluated.
89101111|NCT05662397|Experimental|HST-1011 Monotherapy Dose Optimization (Part A2)|Evaluation of HST-1011 monotherapy dose/dose regimen.
89101112|NCT05662397|Experimental|HST-1011 Dose Escalation in Combination with cemiplimab (Part B)|Multiple dose levels of HST-1011 to be evaluated in combination with cemiplimab.
89101113|NCT05662319|Experimental|All participants|"In standard of care (SOC) period, participants will receive on-demand or prophylactic treatment with clotting factor concentrates (CFCs) or bypassing agents (BPAs) for 6 months (from Day -168 to Day -1). In fitusiran treatment period, participants will receive subcutaneous fitusiran prophylaxis once every other month (Q2M) or once monthly (QM) for 36 months (from Day 1 to Day 1009). In case of bleeding events participants will receive IV CFCs or BPAs. Participants may receive Antithrombin concentrate (ATIIIC) as rescue medicine.~."
89101114|NCT05662098|Experimental|Treatment|All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
89101115|NCT05639465|Experimental|JoH-C19|After initial randomization, some participants will be assigned to receive JoH-C19
89101116|NCT05639465|Active Comparator|Switch off Get Active|After initial randomization, some participants will be assigned to receive Switch Off Get Active
89101117|NCT05634070|Experimental|Insertion of a custom-made 3D printed medical-grade polycaprolactone scaffold|Insertion of a custom-made 3D printed medical-grade polycaprolactone scaffold in the thorax region with autologous fat graft to camouflage pectus excavatum defect.
89101118|NCT05632627|Active Comparator|Full Spectrum Cannabidiol|Full Spectrum Cannabidiol (<0.3% THC) Oral softgel capsule, 210mg/day
89101119|NCT05632627|Active Comparator|Broad Spectrum Cannabidiol|Broad Spectrum Cannabidiol (0.0% THC) Oral softgel capsule, 210mg/day
89101120|NCT05632627|Placebo Comparator|Hemp Seed Oil|Placebo Oral softgel capsule, 210mg/day
89101121|NCT05629364|Experimental|0.15% KIO-101|.15% KIO-101 eyedrops
89101122|NCT05629364|Experimental|0.3% KIO-101|0.3% KIO-101 eyedrops
89101123|NCT05629364|Placebo Comparator|Vehicle|Vehicle eyedrops
89101124|NCT05629065|Experimental|Both patient and clinician receive a nudge|"Patient nudge consists of a letter and SHARE questionnaire~Clinician nudge email encouraging discussion to initiate discussion on SIC"
89101125|NCT05629065|No Intervention|Neither the patient nor clinician receive a nudge|Standard Care
89101126|NCT05629065|Experimental|Patient receives a nudge but not the clinician|-Patient nudge consists of a letter and SHARE questionnaire
89101127|NCT05629065|Experimental|Clinician receives a nudge but not the patient|"-Clinician nudge email encouraging discussion to initiate discussion on SIC"
89101128|NCT05611008|Experimental|Intervention condition|
89101129|NCT05611008|No Intervention|Control condition|
89101130|NCT05603520||healthy volunteers|
89101131|NCT05603520||patients with aortic stenosis|
89101132|NCT05603520||patients with aortic aneurysms|
89227616|NCT04503252||Study population: patients with CSAI caused by MSSA|Inpatients with CSAI caused by MSSA treated or intended to receive cefazolin within the next 24-48 hours (at least 10 (maximum of 20) critically-ill patients, at least 10 (maximum of 20) patients with an estimated glomerular filtration rate of <60ml/min, at least 10 patients with BSI).
89227617|NCT04503252||Sub-study: Torque Teno virus (TTV) viremia|TTV viral load may indicate the immunological status of the host. The TTV sub-study is to to describe the viral kinetics of TTV in CSAI patients.
89227618|NCT04503252||Sub-study: cefazolin concentrations in sweat|Out of the study population (patients with CSAI) a total of 15 CSAI patients will be included for the substudy investigating cefazolin concentrations in sweat as a non-invasive therapeutic drug monitoring.
89227619|NCT00969410|Experimental|AV-299 administered IV (monotherapy)|Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if <= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If >= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
89227620|NCT00969488|Experimental|high protein diet group|"Women in high protein diet will be stimulate to consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group. The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats). The experimental groups will also receive six cans of sardine to increase the women's commitment to the study.~Both women group will receive a nutritional plan based on an 1800 kcal diet."
89227621|NCT00969488|Active Comparator|normal protein diet group|The control group will receive a diet to lose weight with norma protein intake and will receive 2kg of pasta to increase the women's commitment to the study. The nutritional plan based on an 1800 kcal diet.
89227622|NCT03485430|Active Comparator|Intervention|Receives tapering of opioid dose at baseline
89227623|NCT03485430|No Intervention|Control|Waiting-list. Receives tapering after 4 months.
89227624|NCT00679367|Experimental|Melphalan Revlimid and Dexamethasone|Melphalan Lenalidomide Dexamethasone
89227625|NCT00969566|Experimental|Metformin+Sitagliptin|Initial combination of metformin and sitagliptin
89227626|NCT00973544||control|drains would be removed when daily discharge will be below 20 cc for 2 consecutive days
89227627|NCT00973544||study|drains will be removed on post operative day (POD) 10
89227628|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin 3 mg QD|
89227629|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin Placebo QD|
89227630|NCT00755495|Active Comparator|Ramelteon Placebo QD and Doxepin 3 mg QD|
89227631|NCT00755495|Placebo Comparator|Placebo|
89227632|NCT00964184|Experimental|Drug|1 gm metformin per day
89227633|NCT00964184|Other|control|lifestyle intervention
89227634|NCT04005300|Experimental|low calorie feeding group|Enteral nutrition was fed at 10-20kcal/kg/d for the first three days before identifying the refeeding syndrome
89227635|NCT04005300|Active Comparator|standard calorie feeding group|Enteral nutrition was fed at 500-750kcal/d for the first three days before identifying the refeeding syndrome
89230299|NCT03955003|Experimental|Group Drumming|6 week one hour/week drumming sessions. The detailed intervention protocol was created in collaboration with board-certified music therapists. The music used in the intervention will include both recorded percussion music and the use of percussion instruments.
89101133|NCT05593016|Experimental|Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)|Four, 60-minute sessions will provide training on behavioral symptom management skills, delivered over 6-8 weeks to patients in their homes using videoconferencing.
89101134|NCT05593016|Experimental|Education Control Arm|"The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer and otherwise continue their usual care."
89101135|NCT05589649|Experimental|Erector spinae plane block|Ultrasound-guided erector spinae plane block
89101136|NCT05589649|Experimental|Paravertebral|Ultrasound-guided thoracic paravertebral block
89101137|NCT05584787|Experimental|TPLA in patients with prostate cancer|Patients diagnosed with low- and intermediate risk unifocal prostate cancer undergo to focal laser ablation therapy.
89101138|NCT05584267|Active Comparator|cohort A|Chemotherapy + immunotherapy; Every three weeks, up to four cycles of chemotherapy
89101139|NCT05584267|Experimental|cohort B|Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; WBRT, 3 Gy/ time, 10 times in total
89101140|NCT05584267|Experimental|cohort C|Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; HFRT, 10 Gy/ time, 3 times in total
89101141|NCT05577468|Experimental|tegoprazan|Participants will receive Tegoprazan tablets Esomeprazole magnesium enteric-coated tablets placebo Bismuth potassium citrate capsules Amoxicillin capsules Clarithromycin tablets
89101142|NCT05577468|Active Comparator|Esomeprazole|Participants will receive Tegoprazan tablets placebo Esomeprazole magnesium enteric-coated tablets Bismuth potassium citrate capsules Amoxicillin capsules Clarithromycin tablets
89101143|NCT05574153||Patient Participant|Participants with known Metabolic Syndrome (MetS)
89101144|NCT05574153||Healthy Volunteers|NonS-moking participants with no known pre-existing conditions and who do not take any medications
89101145|NCT05574140||Patient Population|Participants diagnosed with Generalized Anxiety Disorder
89101146|NCT05574140||Healthy Volunteers|Participants with no pre-existing conditions and who are on no medications.
89101147|NCT05570500|Placebo Comparator|Control group, conventional oral health education group|
89101148|NCT05570500|Active Comparator|Comparison group, online oral health education group|
89101149|NCT05567692||T2D group|subjects with type 2 diabetes
89101150|NCT05567692||Non-T2D group|healthy subjects
89101151|NCT05558644|Experimental|single arm for all patients|"single arm for all patients tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
89101152|NCT05557864|Experimental|Parkinson's disease with DBS|Participants will have a diagnosis of idiopathic PD and have undergone/will undergo neurosurgery to implant deep brain stimulators in the globus pallidus (GP DBS) or subthalamic nucleus (STN)
89101153|NCT05557448|Active Comparator|Test drug|200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
89101154|NCT05557448|Placebo Comparator|Placebo|200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
89101155|NCT05556811|Active Comparator|LSA-1|Light Scheduling Algorithm-1 (LSA-1): High circadian effective irradiances + Blue Enriched Light episodes
89101156|NCT05556811|Active Comparator|LSA-2|Light Scheduling Algorithm-2 (LSA-2): High circadian effective irradiances without Blue Enriched Light episodes.
89101157|NCT05556811|Active Comparator|LSA-3|Light Scheduling Algorithm-3 (LSA-3): Irradiance levels comparable to conventional hospital lighting (control group).
89101158|NCT05549544|Experimental|LBBAP group|Device: Left bundle branch area pacing(LBBAP) LBBAP is a novel physiological pacing form for ventricular pacing. In patients who received LBBAP, the pacing lead will be placed at the left bundle branch area to achieve a narrow-paced QRS duration.
89101159|NCT05549544|Active Comparator|BiVP group|Device: Biventricular pacing (BiVP) Biventricular pacing is the traditional pacing modality for patients with heart failure. For BiVP, one pacing lead was placed in the coronary sinus, named LV lead, and another lead was placed in the right ventricule.
89101160|NCT05516615||Healthy volunteers|"Aged more than 35~No known current or pre-existing problems that would affect the cardiovascular or respiratory system"
89101161|NCT05516615||Patient population|"Aged more than 35~Referral of subjects with known or suspected CAD for adenosine stress first-pass perfusion MRI based on the clinical judgement of their referring physician"
89101162|NCT05514938|Experimental|Polypill|Patients will be randomized to receiving a fixed-dose polypill in addition to other guideline-directed medical therapies prescribed by their physician. Polypill formulations will include rosuvastatin 40 mg, aspirin 81 mg, and prasugrel 10 mg daily or rosuvastatin 40 mg, aspirin 81 mg, and clopidogrel 75 mg.
89101163|NCT05514938|Active Comparator|Usual Care (individual medications prescribed by primary cardiologist)|Patients will receive usual post-ACS care and medications prescribed by their provider. All of the individual components will be available at low- or no-cost to participants as individual pill formulations.
89101164|NCT05513391|Experimental|RIV4 cohort|RIV4 single injection at Day 1
89101165|NCT05513391|Active Comparator|IIV4 cohort|IIV4, single injection at Day 1
89101166|NCT05508334|Experimental|Experimental: RC88|Subjects will receive intravenous infusion of RC88 once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs
89101167|NCT05493423|Experimental|Standard of Care vs. V Needle Performance Assessment|Subjects will undergo three dialysis sessions using standard of care needles (control) and results will be compare to 6 dialysis sessions using the V Needle (experimental).
89101168|NCT05487274|Active Comparator|Total Shoulder Arthroplasty (anatomic) + augmented glenoid component|"TSA procedure involves replacing the worn-out ball and socket joint with prosthetic components. An additional surgical technique, augmented glenoid component implantation is performed when there is missing bone in the shoulder and is currently being done as standard of care. This technique is used particularly when a large amount of instability within the shoulder joint is present. This technique attempts to realign and restore balance to the shoulder joint using artificial components."
89101169|NCT05487274|Active Comparator|Reverse Shoulder Arthroplasty|RSA procedure is similar to a TSA, however the orientation of the ball and socket joint is placed in the reverse position
89101170|NCT05485805|Experimental|Naproxen sodium/caffeine - Dose 1|Participants will receive a single dose of one tablet of naproxen sodium/caffeine plus one tablet of placebo after extraction of third molars.
89101171|NCT05485805|Experimental|Naproxen sodium/caffeine - Dose 2|Participants will receive a single dose of two tablets of naproxen sodium/caffeine after extraction of third molars.
89101172|NCT05485805|Experimental|Naproxen sodium|Participants will receive a single dose of one tablet of naproxen sodium plus one tablet of placebo after extraction of third molars.
89101173|NCT05485805|Experimental|Caffeine|Participants will receive a single dose of two tablets of caffeine after extraction of third molars.
89101174|NCT05485805|Placebo Comparator|Placebo|Participants will receive a single dose of two tablets of matching placebo after extraction of third molars.
89101175|NCT05473598|Active Comparator|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
89101176|NCT05473598|Experimental|UC + Stand Down app (app only)|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
89101177|NCT05473598|Experimental|UC + Peer-Supported Stand Down (PS-Stand Down)|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approximately 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
89101178|NCT05468437|Experimental|Immediate treatment|Three months of treatment followed by a 3 month durability phase
89101179|NCT05468437|Experimental|Delayed Treatment|A 3 month waitlist period followed by 3 months of treatment
89101180|NCT05466890|Experimental|PL8177|PL8177 will be given orally and daily from baseline until end of study.
89101181|NCT05466890|Placebo Comparator|Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
89101182|NCT05466682|Experimental|RELAX|"Patients will receive Progressive Muscle Relaxation Therapy (PMR) via the RELAXaHEAD smart-phone app.~Patients will be asked to do the following:~Week 1: 5 min deep breathing at least 5/7 days of the week~Week 2: 5 min PMR session at least 5/7 days of the week~Week 3: 15 min PMR session at least 5/7 days of the week~Week 4: PMR at least 4 days a week~Week 5: PMR at least 3 days a week~Weeks 6-8: Use PMR when it is most helpful~Patients will be asked to track headache frequency, intensity, sleep, and acute medication use on the app. They will also receive written educational material about migraine."
89101183|NCT05466682|Active Comparator|Monitored Usual Care (MUC)|"Patients will be given a general education session consisting of basic migraine information. They will receive the RELAXaHEAD app but the Progressive Muscle Relaxation Therapy (PMR) function will be blocked.~Patients will be asked to track headache frequency, intensity, sleep, and acute medication use on the RELAXaHEAD app. They will also receive written educational material about migraine."
89101184|NCT05460052||Immediate treatment (IT)|Patients randomized to the IT group will begin the training sessions 14 days after the inclusion.
89101185|NCT05460052||Waiting list (WL)|"Patients randomized to the WL group will receive a weekly phone call for 6 weeks.~Then, they will benefit the same training program as IT group (56 days after the inclusion)."
89101186|NCT05452954|Other|Brief behavioral parent training|A newly developed, easily applicable, individually tailored first-line behavioral training for parents of children (4-12 years) with behavioral problems and (symptoms of) ADHD, that will be provided in an early stage, before other treatments have been applied.
89101187|NCT05451108|Experimental|Insertion of PCL Pectus scaffold|Insertion of a custom-made 3D printed medical-grade polycaprolactone (PCL) Pectus scaffold with autologous fat graft for pectus excavatum defect correction.
89101188|NCT05450354||Patients|Alive patients between the ages of 9 and 15 included at the time of their hospitalization at the Necker Enfants Malades Hospital following a serious suicide attempt that took place after January 1, 2016 and at least one of the two parents of the patient, to answer to the study questionnaires.
89101189|NCT05450354||Control patients|Patients aged 9 to 15 years hospitalized at the Necker-Enfants Malades hospital at time of the study for a non-serious suicide attempt and at least one of the two parents of the patient.
89101190|NCT05446571|Experimental|Letermovir|Maternal daily administration of letermovir + placebo of valaciclovir
89101191|NCT05446571|Active Comparator|Valaciclovir|Maternal daily administration of valaciclovir + placebo of letermovir
89101192|NCT05446298|Experimental|1 mg/kg ONC-392 and 200 mg pembrolizumab|Arm A: Pembrolizumab 200 mg will be administered by IV infusion over 30 minutes, followed by ONC-392 at 1.0 mg/kg will be administered by IV infusion over 60 minutes, q3w.
89101193|NCT05446298|Experimental|2 mg/kg ONC-392 and 200 mg pembrolizumab|Arm B: Pembrolizumab 200 mg will be administered by IV infusion over 30 minutes, followed by ONC-392 at 2.0 mg/kg will be administered by IV infusion over 60 minutes, q3w.
89101194|NCT05435495||Participants undergoing 177Lu-PSMA-617 treatment|Participants undergoing PSMA targeted radioligand therapy with at least four cycles of treatment planned will undergo the following: SPECT/CTs will be performed 24 hours after the first treatment and after the fourth treatment, a tumor biopsy will be performed prior to the first 177Lu-PSMA radioligand therapy, a blood will be drawn prior to treatment for future research, and an optional tumor biopsy and blood draw for future research, may also be obtained at time of progression.
89101195|NCT05431777||Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma who were treated with avelumab as first-line maintenance therapy
89101196|NCT05409495|Experimental|The control group treated with open flap debridement (OFD)|The control group periodontal intrabony defects were treated with open flap debridement (OFD) only.
89101197|NCT05409495|Experimental|The test group treated with OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF)|The test group periodontal intrabony defects were treated with open flap debridement (OFD) with autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF) combined.
89101198|NCT05395221|Experimental|Virtual Reality Assisted Meditation+ no intervention Group|The first cohort will undergo weekly virtual reality guided meditations across a three-month rotation using the Guided Mediation Virtual Reality App available on the Oculus Quest 2 Virtual Reality system (Oculus, Menlo Park, CA). After completion of the three-month time span, residents will receive no intervention during the second three-month study period. . A post-study survey will be completed to assess for various parameters including residents desire for continuation of virtual reality guided meditation following completion of the survey, subjective value of virtual reality as a tool for burnout, and likeliness to recommend virtual reality guided meditation to a colleague.
89101199|NCT05395221|Experimental|No intervention + Virtual Reality Assisted Meditation group|The second cohort will receive no intervention during the three-month block. After completion of the three-month time span, residents will take a follow-up MBI and then will cross over to the opposite group. After completion of the second three-month study period, an additional MBI will be completed by the residents.. A post-study survey will be completed to assess for various parameters including residents desire for continuation of virtual reality guided meditation following completion of the survey, subjective value of virtual reality as a tool for burnout, and likeliness to recommend virtual reality guided meditation to a colleague.
89101200|NCT05391737||patients with SIPE|"Adult patients (age ≥18 years) with SIPE-diagnosis during Vansbrosimningen and peripheral oxygen saturation ≤95%. SIPE-diagnosis based on pulmonary edema on lung ultrasound."
89101201|NCT05391737||control group|"Swimmers completing Vansbrosimningen without respiratory symptoms or signs of pulmonary edema on lung ultrasound. Matched to patients with SIPE for age and gender."
89101202|NCT05379166|Experimental|Treatment (venetoclax, azacitidine)|Patients receive venetoclax PO QD on days 1-14 and azacitidine IV over 10-40 minutes on days 1-7 or days 1-5 of week 1 and days 1 and 2 of week 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89101203|NCT05378373|Active Comparator|SHEETS Arm 1|Participants will receive sleep education-related content on factors that impact sleep, like getting enough exercise.
89101204|NCT05378373|Experimental|SHEETS Arm 2|Participants will receive sleep education-related content to support good sleep, like setting schedules.
89101205|NCT05365958|Experimental|African American Heterosexuals|
89101206|NCT05353556|Experimental|Study Group|Patients who perform inspiratory muscle training (IMT) with %50 loading
89101207|NCT05353556|Sham Comparator|Sham Group|Patients who perform Sham IMT
89101208|NCT05317728|Experimental|BAL-FAIOL|BAL-FAIOL IOL implanted in both eyes during cataract surgery (bilateral implantation)
89101209|NCT05317728|Active Comparator|Monofocal|Monofocal IOL implanted in both eyes during cataract surgery (bilateral implantation)
89101210|NCT05308953|Experimental|NVG-291 SAD|Doses will begin at the lowest dose level in Cohort 1, increasing in dose with each subsequent cohort to the highest dose level in Cohort 6 or until a maximum tolerated dose (MTD) is reached.
89101211|NCT05308953|Experimental|NVG-291 MAD|Participants will receive 1 dose daily for for 14 consecutive days. The maximum starting dose for MAD will be 2 dose levels lower than the maximum dose achieved during SAD. There will be a maximum of 3 dosing cohorts in Part 2. The maximum daily dose in Part 2 will not exceed the maximum daily dose tolerated in Part 1.
89101212|NCT05308953|Experimental|NVG-291 MAD - Males and Premenopausal Females|Participants will receive 1 dose daily for for 14 consecutive days. The dose maximum daily dose in Part 3 will not exceed the maximum daily dose tolerated in either Part 1 or 2.
89101213|NCT05296603|Experimental|Cohort A|Duration of response time less than 3 months
89101214|NCT05296603|Experimental|Cohort B|Duration of response time between 3 and 6 months
89101215|NCT05296603|Experimental|Cohort C|Duration of response time more than 6 months
89101216|NCT05296278|Experimental|Cohort A|patients with only 3'ALK confirmed by NGS
89101217|NCT05296278|Experimental|Cohort B|patients with 3'ALK with retention of 5'ALK
89101218|NCT05293717|Experimental|All Participants|You are being asked to apply topical medication called Ruxolitinib cream to your skin at home twice daily.
89101219|NCT05292248|Experimental|CONFIDENCE Education Intervention|Participants will attend the 5-week CONFIDENCEProgram. This program will include attending 5 group-based sessions delivered by videoconference. Each session will last approximately 1.5 hours each and will cover topics such as how to budget, accessing community resources to displace the out-of-pocket costs of caregiving, asking for help, balancing employment and caregiving, and more.
89101220|NCT05287646|Active Comparator|Suction Suspension First|The residual limb will be imaged during dynamic activities while participants use suction suspension first, then while participants use elevated vacuum suspension. Dynamic stereo x-ray will take place 4-weeks after socket fitting.
89101221|NCT05287646|Active Comparator|Elevated Vacuum Suspension First|The residual limb will be imaged during dynamic activities while participants use elevated vacuum suspension first, then while participants use suction suspension. Dynamic stereo x-ray will take place 4-weeks after socket fitting.
89101222|NCT05287568|Experimental|Cohort 1 CC-486 200 mg|CC-486 200 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
89101223|NCT05287568|Experimental|Cohort 2 CC-486 300 mg|CC-486 300 mg will be administered orally on days 1-14 of a 28-day cycle. Venetoclax will be administered days 1-3, with the following schema: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3, and it will be continued at 400mg thereafter until day 28, the completion of cycle 1.
89101224|NCT05287568|Experimental|Dose Expansion Cohort|CC-486 MTD will be determine following the completion of Cohort 1 and Cohort 2 with venetoclax at 400 mg/day PI regimen for 28 days.
89101225|NCT05285228|Active Comparator|Control group: allocation to specific taste of fluoride varnish|allocation to specific taste of fluoride varnish
89101226|NCT05285228|Experimental|Test group: child chooses taste of fluoride varnish|child chooses taste of fluoride varnish before dental treatment
89101227|NCT05279664|Experimental|Intervention (RIC + standard of care for NEC)|Neonates randomized to the intervention arm will receive RIC and will continue to receive the standard of care for NEC.
89230300|NCT03955003|Other|Attention Control Entertaining Educational Series|6 week one hour/week educational series. The educational group is largely intended to create an attention group control so group effect and time of the drumming intervention can be controlled.
89101228|NCT05279664|Sham Comparator|Control (Standard of care for NEC)|Neonates randomized to the control arm will receive the standard of care for NEC. The research fellow or nurse responsible for performing RIC will be performing sham inflation/deflation of the blood pressure cuff connected to a dummy arm to mimic the noise of the cuff for neonates in the control arm.
89101229|NCT05273320|Experimental|Open Label|"Titration: Nabilone p.o., increased in 0.25 mg increments every 2 days to a maximum of 1 mg b.i.d.~Open label: Nabilone p.o. at maximum dose tolerated for 28 days Tapering: Nabilone p.o. decreased in 0.25 decrements per day"
89101230|NCT05264779|No Intervention|Usual Care (control)|Participants assigned to this group will proceed with usual medical care and treatment, consisting of counseling by the teams of obstetricians and/or neonatologists at the respective study sites.
89101231|NCT05264779|Experimental|Periviable GOALS DST Group|Participants randomized to the intervention will be presented with the Periviable GOALS DST and instructed to review the DST in its entirety. The participant will complete the education and values clarification components of the DST with the Recruitment RA present to confirm completion. Following completion of the GOALS DST, the Recruitment RA will repeat knowledge and decisional conflict instruments and assess acceptability.
89101232|NCT05256225|Active Comparator|Arm I (paclitaxel, carboplatin)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.~Patients undergo ECHO or MUGA scan at end of treatment and every 6 months for 2 years."
89101233|NCT05256225|Experimental|Arm II (paclitaxel, carboplatin, Herceptin Hylecta)|"Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.~MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment.~Patients undergo ECHO or MUGA scan at end of treatment and every 6 months for 2 years."
89101234|NCT05256225|Experimental|Arm III (paclitaxel, carboplatin, Phesgo)|"Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.~MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment.~Patients undergo ECHO or MUGA scan at end of treatment and every 6 months for 2 years."
89101235|NCT05248880|Experimental|AGN-151586|Participants will receive 5 intramuscular injections of AGN-151586 in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
89101236|NCT05248880|Experimental|Placebo|Participants will receive 5 intramuscular injections of Placebo in the glabellar complex on Day 1. Based on meeting the retreatment criteria, the participant may also receive 1 open-label treatment of AGN-151586.
89101237|NCT05246098||Adults|Adult survivors of COVID-19 or acute respiratory infection admitted to participating ICUs. Adults are defined as greater than or equal to, 18 years old. We will include adults with a confirmed diagnosis of COVID-19 or those with suspected or proven acute respiratory infection with onset within 14 days of ICU admission and requiring invasive mechanical ventilation, non-invasive ventilation, or high-flow oxygen therapy.
89101238|NCT05246098||Pediatrics|Pediatric survivors of COVID-19, MIS-C, or acute respiratory infection admitted to participating pediatric intensive care units (PICUs). The investigators define children as less than 18 years old. We will include pediatric patients with COVID-19, those with multi-system inflammatory syndrome in children (MIS-C), and those with suspected or proven acute respiratory infection with onset within 14 days of ICU admission and requiring invasive mechanical ventilation, non-invasive ventilation, or high-flow oxygen therapy.
89101239|NCT05245474|Experimental|CRT+concurrent PD-1 inhibition (Experiment Arm 1)|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 8 of radiation therapy. TME surgery is scheduled in 8~12 weeks after completion of radiation.
89101240|NCT05245474|Experimental|CRT+sequential PD-1 inhibition (Experiment Arm 2)|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 15 after completion of radiation therapy. TME surgery is scheduled in 8~12 weeks after completion of radiation.
89101241|NCT05245474|Active Comparator|CRT without PD-1 inhibition (Control Arm)|Long-course chemoradiation plus PD-1 inhibition with no PD-1 inhibition. TME surgery is scheduled in 6~12 weeks after completion of radiation.
89101242|NCT05233605||Exposed to Dexmedetomidine during ICU stay|Dexmedetomidine has been administered in accordance with its MA (at least 24 hours continuously with a starting dose of 0.7 µg/kg/h and then adjusted to sedation scores between 0.4 and 1.1 µg/kg/h), as part of care, prior to inclusion in the protocol
89101243|NCT05233605||Non exposed to Dexmedetomidine during ICU stay|This group is unexposed to Dexmedetomidine during ICU stay.
89101244|NCT05227222|Experimental|PEP-device|Positive expiratory pressure device: continuous treatment with PEP-device breathing air for 20 minutes followed by 10 minutes rest and assessment. Inspiration through nose/mouth, expiration through device.
89101245|NCT05227222|No Intervention|spontaneous recovery|Control group: Resting and breathing air for 20 + 10 minutes.
89101246|NCT05216146|Experimental|Experimental|Specially designed program for physical fitness enhancement
89101247|NCT05216146|Active Comparator|Control|A regular program of physical exercise
89101248|NCT05204888|Active Comparator|Usual COPD care|The intervention : A pulse oximeter to record heart rate and pulse oximetry on a daily basis will be provided. A smart phone and charger will also be provided to answer a short questionnaire that queries daily respiratory symptoms plus enter heart rate and pulse oximetry data
89101249|NCT05204888|Active Comparator|Usual COPD care with use of the myAirvo 3 integrated humidifier and flow generator.|The intervention is the myAirvo 3 humidifier with integrated flow generator delivered through the Optiflow™ + Duet nasal cannula.
89101250|NCT05204381|Experimental|Theta Stimulation followed by Alpha Stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to frontal and parietal cortex during performance of a cognitive control task while electroencephalography (EEG) is recorded. In the fourth session, stimulation is delivered in near-zero phase lag theta-frequency, anti-synchrony theta-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. In the fifth session, stimulation is delivered in near-zero phase lag alpha-frequency, anti-synchrony alpha-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. The near-zero phase lag arrhythmic-in-synchrony stimulation and arrhythmic-independent stimulation is delivered in both the fourth and fifth session to serve as an active control. Each session is separated by at least one day as a washout period.
89101251|NCT05204381|Experimental|Alpha Stimulation followed by Theta Stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to frontal and parietal cortex during performance of a cognitive control task while electroencephalography (EEG) is recorded. In the fourth session, stimulation is delivered in near-zero phase lag alpha-frequency, anti-synchrony alpha-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. In the fifth session, stimulation is delivered in near-zero phase lag theta-frequency, anti-synchrony theta-frequency, near-zero phase lag arrhythmic-in-synchrony stimulation, and arrhythmic-independent stimulation. The near-zero phase lag arrhythmic-in-synchrony stimulation and arrhythmic-independent stimulation is delivered in both the fourth and fifth session to serve as an active control. Each session is separated by at least one day as a washout period.
89101252|NCT05200208|Experimental|Citicoline Supplement|Participants with AD will receive a dietary citicoline supplement
89101253|NCT05200208|Placebo Comparator|Placebo|Participants with AD will receive a placebo supplement
89101254|NCT05194917|Experimental|Older Smoker Motivational Intervention|Message package focused on the link between smoking and dementia
89101255|NCT05194917|Active Comparator|Control Motivational Message 1|CDC TIPS from former smokers campaign
89101256|NCT05194917|No Intervention|Control Treatment as Usual|No intervention
89101257|NCT05194917|Active Comparator|Control Motivational Message 2|American Lung Association campaign
89101258|NCT05188248|Experimental|Female participants with Depression|Female participants with mild to moderate depression to determine if a single-session of tDCS can alter negative attention bias. The primary objective is to study if single-session tDCS will affect attention bias in depression and is not meant to treat depression.
89101259|NCT05176977|Experimental|Peer Specialist - Whole Health Coaching (PS-WHC)|Participants will meet with a Peer Specialist for 18 sessions over 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist, and 2) a structured Whole Health Coaching curriculum.
89101260|NCT05176977|No Intervention|Enhanced Usual Care (EUC)|Usual PACT care plus Hot Spotter Analytics (consists of access to field-based dashboard that allows PACTS to identify homeless Veterans on their panels who were super-utilizers, and the hot spotter manual).
89101261|NCT05171166|Experimental|HAIC-TACE-Dona Group|200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with hepatic arterial infusion chemotherapy that consists of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. After 2-4 cycles of HAIC treatment, the sequential TACE therapy would be performed.
89101262|NCT05171166|Active Comparator|TACE-Dona Group|200 mg of donafenib (consisting of two 100-mg tablets) twice daily combine with cTACE or DEB-TACE that mixed with EPI.
89101263|NCT05169346|Active Comparator|Active Neurofeedback|"R61 Phase: Four training sessions. Each training session contains 32 minutes of active neurofeedback runs.~R33 Phase: Number of training sessions are contingent on R61 findings."
89101264|NCT05169346|Sham Comparator|Sham Neurofeedback|"R61 Phase: Four training sessions. Each training session contains 32 minutes of sham (placebo) neurofeedback runs.~R33 Phase: Number of training sessions are contingent on R61 findings."
89101265|NCT05166187|Experimental|Intervention|Patients randomized to the intervention arm will have a Best Practice Advisory (BPA) displayed as part of the discharge order workflow. This BPA requires clinicians to choose an option before completing the discharge documentation. Options include ordering one of the appropriate statins or documenting that the medication is contraindicated, the patient declined, or the patient does not meet criteria for a high-intensity statin.
89101266|NCT05166187|No Intervention|Usual Care|Patients randomized to the usual care arm will have the identical set of windows displayed in the discharge workflow minus the BPA window.
89101269|NCT05132400||Pre-Training Arm (Control)|To receive physical therapy treatment as usual, before PiPT occurs
89101270|NCT05132400||Post-Training Arm (Intervention)|
89101271|NCT05131022|Experimental|Phase 1a Dose Escalation|Multiple dose levels of NX-5948 to be evaluated; determination of Maximum Tolerated Dose/Phase 1b recommended dose
89101272|NCT05131022|Experimental|Phase 1b in CLL or SLL|CLL or SLL with prior exposure to both a Bruton's tyrosine kinase inhibitor (BTKi) and BCL-2 inhibitor, unless previously deemed ineligible for those therapies
89101273|NCT05131022|Experimental|Phase 1b in MCL|MCL with prior exposure to a BTKi and an anti-CD20 monoclonal antibody (mAb)-based chemo-immunotherapy regimen
89101274|NCT05131022|Experimental|Phase 1b in MZL|MZL (EMZL, MALT, NMZL, SMZL) with prior exposure to an anti-CD20 mAb-based chemo-immunotherapy regimen and an additional line of therapy
89101275|NCT05131022|Experimental|Phase 1b in PCNSL/SCNSL|PCNSL patients who have progressed or had no response to at least 2 prior lines of therapy, or SCNSL patients meeting criteria for non-CLL/SLL arms above with secondary CNS involvement of lymphoma
89101276|NCT05131022|Experimental|Phase 1b in WM|WM with prior exposure to a BTKi and an additional line of therapy
89101277|NCT05131022|Experimental|Phase 1b in DLBCL|DLBCL with prior exposure to an anthracycline (unless previously deemed ineligible to receive), an anti-CD20 mAb-based chemoimmunotherapy regimen, and an additional line of therapy
89101278|NCT05131022|Experimental|Phase 1b in FL|FL (grade 1-3a) with prior exposure to an anti-CD20 mAb-based chemoimmunotherapy regimen and an additional line of therapy
89101279|NCT05130138|Experimental|Pharmaceutical conciliation|Patients with Chronic Myeloid Leukemia taking TKI with a molecular response < 4,5 Log will participate to pharmaceutical conciliation.
89101280|NCT05121428||Survey 1|Survey investigating patients' experiences with buprenorphine treatment for Opioid Use Disorder before and during the COVID-19 pandemic
89101281|NCT05121428||Survey 2|Survey investigating the factors that motivate patients to abstain from opioid drug use during buprenorphine treatment for Opioid Use Disorder
89101282|NCT05121428||Survey 3|Survey investigating patients' attitudes towards and experiences with cannabis use during buprenorphine treatment for Opioid Use Disorder.
89101283|NCT05121428||Survey 4|Survey investigating patients' attitudes towards and experiences with cigarettes and e-cigarettes use during buprenorphine treatment for Opioid Use Disorder.
89101284|NCT05121428||Survey 5|Survey investigating patients' attitudes towards and experiences with benzodiazepine use during buprenorphine treatment for Opioid Use Disorder.
89101285|NCT05114798|Experimental|Time Restricted Eating (TRE)|During the active weight loss period, the TRE group will be instructed to eat ad libitum from 12:00pm - 8:00pm daily and fast from 8:00pm - 12:00pm. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, participants will be encouraged to drink plenty of water and may consume energy-free beverages, such as black tea or coffee. TRE subjects will meet with the TRE dietitian for 30 minutes at the start of the intervention to review instructions and goals, and then every week throughout the active weight loss period to review intervention adherence. At the beginning of the maintenance phase, total energy needs will be reassessed. Subjects will be instructed to main their body weight by consuming meals in an extended 10-h eating window every day and water fast between 8pm and 10 am, respectively.
88821343|NCT04429321|Experimental|Ipilimumab +Nivolumab with Embolization|"Patients initiate ICI therapy with Nivolumab 3 mg/kg + ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, followed by nivolumab 480mg flat dose IV every four weeks for a total of 6 months of therapy unless stopped for confirmed progression or intolerable toxicities.~Patients will receive 2 cycles of systemic therapy followed by embolization of their primary tumor or metastatic lesion(s) and continue systemic therapy subsequently."
89101286|NCT05114798|Active Comparator|Calorie Restriction (Cal-R)|Cal-R subjects will be instructed to restrict energy intake by 25% of their baseline total energy expenditure (TEE) daily. Subjects will meet with a study dietitian for a 60-min one-on-one session to develop individualized weight loss meal plans to help them adhere to their calorie restriction goal. Meal plans will include portion sizes and food lists that are consistent with their food preferences and prescribed calorie levels for weight loss. Food scales will be provided to help with food portioning. Cal-R subjects will meet with the dietitian every week throughout the weight loss period to review intervention adherence and modify the meal plans as needed. Subjects will be asked to maintain their baseline level of physical activity. At the beginning of the weight maintenance phase, total energy needs will be reassessed.
89101287|NCT05114798|No Intervention|Control|Controls will be instructed to maintain their weight throughout the 12 m trial and to not change eating or physical activity habits. Controls will not receive dietary counseling. Controls will visit the research center monthly for outcome measurements.
89101288|NCT05104073|Experimental|Intervention|The intervention arm is characterized by calibrated formula feeding recommendations. The intervention group parents will be given written instructions on infant hunger and satiety cues as well as copies of videos with guidance on bottle feeding and how to soothe fussy infants without feeding. N=30 meeting inclusion/exclusion criteria
89101289|NCT05104073|No Intervention|Control|The control arm will have ad lib feeds as per usual care. N=30 meeting inclusion/exclusion criteria
89101290|NCT05099679|Other|Psychosocial intervention + Cardiac Rehab Services|Cognitive Behavioral Therapy + Cardiac Rehab
89101291|NCT05099640|Experimental|Part 1: PTC923|Participants will receive PTC923 7.5 milligrams (mg)/kilogram (kg) (participants 0 to <6 months of age), 15 mg/kg (participants 6 to <12 months of age), 30 mg/kg (participants 12 months to <2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for 14 days.
89101292|NCT05099640|Experimental|Part 2: PTC923|Participants will receive PTC923 20 mg/kg daily for Weeks 1 and 2, then PTC923 40 mg/kg daily for Weeks 3 and 4, then PTC923 60 mg/kg daily for Weeks 5 and 6.
89101293|NCT05099640|Placebo Comparator|Part 2: Placebo|Participants will receive equivalent quantities of placebo to match the 20 to 40 to 60 mg/kg dose escalation of the PTC923 treatment arm.
89101294|NCT05096949|No Intervention|Clinic visit arm|Patient will receive Cabenuva injection at the clinic
89101295|NCT05096949|Experimental|Home visit arm|Patient will receive Cabenuva injection at home
89101296|NCT05093556|Experimental|iCHART - Interactive CBT for Headache And Relaxation Training|10 week interactive-voice response technology (IVR) based cognitive behavioral therapy for headache
89101297|NCT05090566|Experimental|Sub-Study A|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
89101298|NCT05090566|Experimental|Sub-Study B|BCMA-CD3 bispecific antibody + immunomodulatory drug
89101299|NCT05088395|Other|"Cohort 1: SENOLOC"|"Detecting residual disease after surgery is absolutely crucial in oncology, as this detection could allow the personalisation of post-operative treatments based on the presence of residual disease.~The laboratory wishes to develop a new technique for the detection of circulating tumour DNA, based on the recognition of translocation fragments in circulating DNA by shallow whole genome sequencing. This is an original approach, which to our knowledge has not been tested so far with the envisaged bioinformatics approach and could potentially be more sensitive than the techniques currently used to detect residual disease after surgical removal of localised (non-metastatic) breast cancer.~The analysis will therefore focus on the search for tumour chromosomal translocations, which will need to be differentiated from possible germline chromosomal translocations. The collection of constitutional DNA is therefore planned in this cohort."
89101300|NCT05088395|Other|"Cohort 2: Immuno-TNBC "|"The aim for this cohort is to study the role that variations in circulating tumour DNA might have as a marker associated with response during chemoimmunotherapy.~A fresh biopsy (subsequently stored frozen) is required for mutational profiling analysis (which will be used to track circulating tumour DNA in the blood). In addition, it will be used to analyse currently recognised biological tissue factors of response to chemoimmunotherapy (PD-L1 labelling, mutational load, ...) and to identify possible associations with circulating tumour DNA variations.~Constitutional DNA analysis is necessary for the determination of point mutations present in the tumour (to be differentiated from polymorphisms present at the constitutional level), as the determination of these mutations is essential to monitor circulating tumour DNA and will therefore be collected."
89101301|NCT05088395|Other|"Cohort 3: Trans-TNBC"|"The objective of this cohort is the development of new plasma tests, for example based on the detection of chromosomal translocations of circulating tumor DNA.~The hypothesis is that these tests would allow the detection of relapse, the prediction of treatment efficacy and the monitoring of treatment efficacy at different stages of cancer in patients with triple-negative breast cancer, either in the non-metastatic phase with planned neo-adjuvant treatment, or in the metastatic phase. The number of inclusions between these 2 populations (neo-adjuvant and metastatic) will be monitored at the operational level to avoid an excessive imbalance towards one group."
89230301|NCT03955237|Active Comparator|non glucose infusion group|Drug: LR infusion LR solution without glucose; the patients with preoperative blood glucose level higher than 90 mg/dL.
89101302|NCT05088395|Other|"Cohort 4: Treg"|"The purpose of this cohort, based on the previous results, is to:~quantify the expression level of target genes on tumor Regulatory T (Tregs) at the protein level,~perform multiparametric FACS analysis on blood and tumor samples from patients treated at the Institut Curie, with breast or ovary cancer and to understand the potential of these targets as biomarkers of disease.~In the context of this ALCINA-4 cohort n°4, for breast and ovary patients, 40 ml of blood will be collected and tumor fragments obtained from surgery (50 breast patients) or therapeutically required biopsy (30 ovary patients). No additional biopsy than the ones belonging to the therapeutic process will be performed in this protocol. Biopsies performed as part of standard of care will be used if sufficient material is available."
89101303|NCT05088395|Other|"Cohort 5: Pembro Neo"|"The purpose of this cohort is to determine the detection rate of circulating tumour DNA (ctDNA) before and after surgery in the blood of patients who received neoadjuvant treatment with chemoimmunotherapy for early triple-negative breast cancer (TNBC).~There will be two subgroups : patients who have not yet started neoadjuvant treatment (subcohort 1) and patients who have already started neoadjuvant treatment (subcohort 2).~Biopsy of a tumour lesion will be performed before the start of neoadjuvant treatment (only for subcohort 1). The collection of constitutional DNA, plasma and circulating tumour DNA are planned in this cohort at different time points."
89101304|NCT05088395|Other|"Cohort 6: THL"|"The main objective of this exploratory cohort is to characterize the detection rate of ctDNA before and during therapy with T-DXd (Trastuzumab deruxtecan) for patients with HER2-low metastatic breast cancer, requiring treatment with T-DXd.~Tumor biopsy will be performed after inclusion and before the start of treatment on cycle 1 day 1 for at least 30 patients. The collection of constitutional DNA, is planned in this cohort at different time points : T1 and T2 (before treatment start) are critical to evaluate the intra-patient reproducibility of liquid biomarkers. T3 will investigate the response to therapy while T4 will focus on resistance mechanisms."
89101305|NCT05088395|Other|"Cohort 7:CDK4/6 adjuvant"|"The purpose of this cohort is to determine the prognostic impact of circulating tumor DNA detection and monitoring in patients receiving a CDK4/6 inhibitor in adjuvant breast cancer.~50 ml of blood will be collected in EDTA tubes for constitutional DNA and plasma for research of circulating biomarkers at different time points (4 time points)."
89101306|NCT05081843|Active Comparator|Usual Health Education Curriculum|Students will receive the school's usual health education curriculum.
89101307|NCT05081843|Experimental|Usual Health Education Curriculum plus Intervention|Students will receive the school's usual health education curriculum. Students will also receive the intervention. Delivery of the intervention (i.e., timing, frequency) will be determined by discussing the results of the Aim 1 focus groups with teachers and administrators.
89101310|NCT05063032|Experimental|High-density mapping guided ablation|High-density map and return-cycles map in order to localize the protected isthmus with precision for focal/minimal ablation.
89101311|NCT05063032|Active Comparator|Empirical linear ablation|Empirical predefined set of linear ablation.
89101312|NCT05059392|Experimental|Training for Awareness, Resilience and Action (TARA)|12 weekly sessions, each 90 minutes, up to 14 participants/group. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
89101313|NCT05047198|Active Comparator|Control|Catheter Ablation using invasive mapping
89101314|NCT05047198|Experimental|Treatment|Radio-ablation using non-invasive mapping
89101315|NCT05034497|Experimental|Dose Escalation|"Each participant will receive a single 5cc administration of 186RNL.~At each dose level, a minimum of three to a maximum of six participants will be enrolled.~If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.~The dose escalation scheme will follow a modified Fibonacci dose escalation scheme."
89101316|NCT05029271|Other|InPen with Guardian 4 System Arm|"All subjects will move from phase 1 to phase 4 of the study.~Phase 1:~Blinded Continuous Glucose Monitoring (CGM) will be utilized while subjects are on their current MDI therapy.~Phase 2:~All subjects will utilize a smart bolus insulin pen injector (InPen™) and app with dose calculator (InPen™ Diabetes Management App).~Phase 3:~Subjects will continue on the InPen and InPen App utilizing the HCP insights gained during the titration follow-up visit.~Phase 4:~All subjects will utilize the InPen™ with the Guardian™ 4 system."
89101317|NCT05024773|Experimental|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|
89101318|NCT05024513|Experimental|BD-HAIC (Biliary drainage & HAIC)|The patients enrolled in this arm would receive external percutaneous biliary drainage plus 3Cir-OFF hepatic arterial infusion chemotherapy （HAIC）with oxaliplatin and 5-fluorouracil.
89101319|NCT05024513|Active Comparator|BD-BSC (Biliary Drainage & Best supportive care)|The patients enrolled in this arm would receive biliary drainage, biliary stents,or biliary stents with Iodine-125 seed strands, plus best supportive care.
89101320|NCT05021250|Experimental|Lipiodol marking|HCC patients treated with TACE and lipiodol marking, followed by SBRT with DIBH.
89101321|NCT05020665|Experimental|Intensive Chemotherapy + Entospletinib (ENTO)|Participants received intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with entospletinib (ENTO).
89101322|NCT05020665|Placebo Comparator|Intensive Chemotherapy + Placebo|Participants received intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with the matching placebo.
89101323|NCT05014893|No Intervention|Control|Control group, without specific treatments
89101324|NCT05014893|Experimental|Cognitive training|This group receives treatments to improve cognitive function.
89230302|NCT03955237|Active Comparator|Drug:1% Dextrose infusion group|Drug:LR+ 1% Dextrose infusion LR solution with % 1 glucose: the patients with preoperative blood glucose level between 60-90 mg/dL,
89230303|NCT03955237|Active Comparator|2% Dextrose infusion group|Drug:LR+ 2 % Dextrose infusion Lactate ringer (LR) solution with % 2 glucose; the patients with preoperative blood glucose level lower than 60 mg/dL,
89230304|NCT04045769|Experimental|Study Treatment 1|Saroglitazar magnesium 4 mg
89230305|NCT04045769|Experimental|Study treatment 2|Saroglitazar magnesium 20 mg
89230306|NCT04045769|Placebo Comparator|Placebo|Placebo
89101325|NCT04998318|Active Comparator|Standard of Care|"Visual Inspection with Acetic Acid (VIA): First, the cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied to the cervix using a spray bottle or fox swab. After approximately 1-minute, any changes to the cervix using the naked eye will be noted. Acetic acid may be reapplied if acetowhitening diminishes during visual inspection.~Visual Inspection with Lugol's Iodine (VILI): After imaging with Acetic acid, Lugol's iodine will be applied using a fox swab noting any yellow or non-staining areas. Lesion location(s) will be noted on a clock-face diagram and used to direct biopsy if a lesion is present or random biopsies will be obtained from two quadrants in the absence of a visible lesion."
89101326|NCT04998318|Experimental|Pocket Colposcope|"Pocket-Assisted Visual Inspection with Acetic Acid (PA-VIA): The cervix should be wiped with a cotton swab to remove any preexisting mucous and/or blood. A 3-5% acetic acid solution will be applied using a spray bottle or fox swab. After approximately 1-minute, using the Pocket Colposcope any changes to the cervix will be noted. Using the Calla Health image acquisition software, both white and green images of the cervix will be captured at low-resolution. High-resolution green light images will be obtained at the provider's discretion. Acetic acid may be reapplied between white and green imaging at the provider's discretion if acetowhitening diminishes.~Pocket-Assisted Visual Inspection with Lugol's Iodine (PA-VILI): After imaging with AA, Lugol's iodine will be applied using a fox swab noting any yellow or non-staining areas. Images will be acquired. A biopsy will be obtained using the pocket. Random biopsies will be obtained from 2 quadrants in the absence of a visible lesion."
89101327|NCT04994197||Diagnosis group of patients with urothelial cancer|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as urothelial carcinoma in this study will be assigned to this group
89101328|NCT04994197||Diagnosis group of patients with benign urinary diseases|Patients with painless intermittent gross hematuria during outpatient/emergency/hospitalization diagnose as benign urinary diseases in this study will be assigned to this group
89101329|NCT04994197||Recurrence diagnosis group with urothelial cancer|Patients who were diagnosed with non-muscle invasive urothelial carcinoma and diagnosed as recurrent urothelial carcinoma in this study will be assigned to this group
89101330|NCT04994197||Recurrence diagnosis group with benign urinary diseases|Patients who were diagnosed with non-muscle invasive urothelial carcinoma and diagnosed as benign urinary diseases in this study will be assigned to this group
89101331|NCT04934046|Experimental|DaTSCAN brain scan images from the new CZT SPECT system|All patients will undergo additional SPECT acquisition (30min added time approximately), with no added radiation, with both new multipurpose CZT camera (StarGuide system, GE Healthcare, Haïfa, Israel) and conventional SPECT camera (Discovery 670, GE Healthcare, Haïfa, Israel)
89101332|NCT04924933|Experimental|Patients (Epilepsy group)|Patients with drug-resistant focal epilepsy in whom an accelerated long-term forgetting is suspected (presence of a subjective memory complaint and absence of objective deficit in memory tests conducted in the frame of a routine comprehensive neuropsychological assessment)
89101333|NCT04924933|Active Comparator|Healthy volunteers (control group)|Age-matched healthy volunteers
89101334|NCT04918355||Provider Group 1: no alert|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
89101335|NCT04918355||Provider Group 2: Mandated alert|Control group where providers will see a generic pop-up alert within the Electronic Health Record (EHR) whenever they initiate an opioid or benzodiazepine prescription without recording use of the PDMP. Patient risk factors are not assessed or presented in the alert. Providers in ambulatory clinics will not be assigned to this group. Alerts do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders.
89101336|NCT04918355||Provider Group 3: PDMP alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on past/current prescriptions received. Patient risk factors are assessed and presented in the alert. Risk factors included are numbers of active or recent opioid and benzodiazepine prescriptions, overlapping prescriptions, co-prescribing of benzodiazepines and opioids, and use of long-acting opioids in opioid naïve patients.~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
89101337|NCT04918355||Provider Group 4: PDMP + EHR alert|"Providers will see a pop-up alert within the EHR when they initiate an opioid or benzodiazepine prescription without recording use of the PDMP and patients have one or more positive risk factors based on both prescriptions and other factors recorded in the patient's Electronic Health Record. Patient risk factors are assessed and presented in the alert. Risk factors included the risks described as in Group 3, along with a history of accidental opioid overdose, diagnosis of Opioid Use Disorder, multiple recent acute care incidents with opioid use, or high risk psychiatric diagnoses.~Alerts are seen only once regardless of the number of positive risk factors and do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
89101338|NCT04911153||Aim 1: Physical Activity|250 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of physical activity on cardiometabolic health among veterans with and without PTSD.
89230307|NCT04045769|Active Comparator|Active Control|Moxifloxacin 400 mg
89101339|NCT04911153||Aim 2: Diet Quality|200 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of diet quality on cardiometabolic health among veterans with and without PTSD.
89101340|NCT04911153||Supplemental Aim: Instrument Validation|100 participants will be recruited to examine the validity of a self-report clinical measure of physical activity against objectively measured physical activity obtained via accelerometry.
89101341|NCT04903470|Experimental|Effect of atropine on the defecation|Atropine is an anticholinergic drug and expected to inhibit rectal contractions and inhibit evacuation of the rectal balloon. Each subject will be studied twice once with and once without atropine.
89101342|NCT04903470|Experimental|Effect of bisacodyl on the defecation|Bisacodyl is a stimulant of rectal contraction and expected to facilitate evacuation of rectal balloon (fecobionics device). Each subject will be studied twice, once with and once without bisacodyl.
89101343|NCT04884945|Active Comparator|Robotic Surgery|Robotic-Assisted Laparoscopic Pyeloplasty (RALP), standard of care treatment option for UPJ obstruction
89101344|NCT04884945|Active Comparator|Open Surgery|Open Pyeloplasty (OP), standard of care treatment option for UPJ obstruction
89101345|NCT04884620||Cross-sectional cohort|Healthy children and adolescents from twenty-five selected schools in the metropolitan area
89101346|NCT04884620||Longitudinal cohort|Cases with first-time diagnoses of extremely early puberty within the period 1995-2019 in the National Patient Registry and five randomly selected references drawn from the general background population in the Danish Civil registry (CPR) matched on age and sex for each case
89101347|NCT04884152|Active Comparator|Home Exercise Group|"The home Exercise program includes an educational training program about parafunctional activities of patients having bruxism with myofascial temporomandibular disorders. The program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
89101348|NCT04884152|Experimental|Telerehabilitation Group|"The program includes the same stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises using telerehabilitation once a week by video call, and reminder messages will be sent to the patients 3 times a week.~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
89101349|NCT04878952|No Intervention|Arm I: Usual Care|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.
89101350|NCT04878952|Experimental|Arm II: Usual Care + Continuous physical activity monitoring via a wearable device|Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.
89101351|NCT04878328|Experimental|onsite Point-of-care (o-POC)|CHWs will reach out to participants to schedule O-PoC visits. At O-PoC visits, CHWs will provide: 1. COVID-19 education; 2. PoC Cepheid XpertXpressSARS-CoV-2PCR tests; 3. Needs assessments and facilitated access to masks and hygiene supplies; 4. Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5. Supportive counseling. Due to SCT's emphasis on social influence, external and internal social reinforcement, we propose our O-PoC intervention delivered by CHWs onsite at Fortune locations over a 12-month period will lead to increased uptake of mitigation behaviors.
89101352|NCT04878328|No Intervention|Standard of Care (SOC)|The current standard of care (SoC) for SARS-CoV-2 testing for Fortune clients is referral to offsite community testing sites and informal, unstructured education. In the SoC arm, Fortune staff will provide clients with a list of offsite SARS-CoV-2 testing locations, which are published online and available to all NYC residents. Those without insurance are not subject to a copay. Participants in SoC will continue to receive Fortune's suite of services as they are delivered (remote and/or in-person) at the time of study participation.
89101353|NCT04871919||Filgotinib|Individuals will receive treatment for moderate to severe active rheumatoid arthritis with at least one dose of filgotinib in accordance with the product label
89101354|NCT04869787|Other|SCD Treatment|Pediatric patients receiving SCD + CRRT for up to 10 days
89230308|NCT01095601|Other|Treatment A|2x100 mg Formulation II avanafil tablet, fasted
89227636|NCT04005300|No Intervention|RFS group|The definition of RFS is that serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded. And it is divided into three sub-group that is Group 1 that a drop of >0.16 mmol/L from any previous measurement, to below 0.65 mmol/L within 72 h after starting nutritional support, Group 2 that their serum phosphate concentration decreased to below 0.87 mmol/L within 72 h after starting nutritional support and the biological variation needed to be greater than 30% decrease from any concentration previously recorded, and Group 3 that their serum phosphate concentration decreased to below 0•32 mmol/L within 72 h after starting nutritional support.
89227637|NCT04005300|No Intervention|nRFS group|It is not up to the RFS definition
89227638|NCT00969644|Active Comparator|GH|
89227639|NCT00969644|Active Comparator|Pegvisomant|
89227641|NCT00969800|Experimental|Active Cleverin Gel|Active Cleverin Gel, which generates chlorine dioxide gas, is placed in a room of subject.
89227642|NCT00969800|Sham Comparator|Inactive Cleverin Gel|Inactive Cleverin Gel is placed in a room of subject. It does not generate chlorine dioxide gas.
89227643|NCT04008914||readmission at 30 days|
89227644|NCT04008914||readmission at 90 days|
89227645|NCT04073394|Active Comparator|Standard Lifestyle Intervention|Participants in this group will be instructed to follow a standard low calorie diet, recommended to have 30 minutes of physical activity 3-5 days per week, and will be followed by a wellness couch weekly.
89227646|NCT04073394|Experimental|Modified Lifestyle Intervention|Participants in this group will have a tailored diet, exercise, and behavioral plan according to their obesity phenotype.
89227647|NCT00964262|Experimental|SR Exenatide (PT302)|Intervention: Drug: SR Exenatide (PT302)
89227648|NCT05623410|Experimental|Botulinum toxin type A(ATGC-110)|ATGC-110 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
89227649|NCT05623410|Active Comparator|Incobotulinumtoxin A (Xeomin®)|Xeomin® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
89227650|NCT00964340|Placebo Comparator|Placebo|The Placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
89227651|NCT00964340|Active Comparator|0.5g SRT2104|The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
89227652|NCT00964340|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
89227653|NCT04004598|Experimental|golf training|12-week golf training program
89227654|NCT00973934|Experimental|Magnetic Seizure therapy (MST)|Eligible patients will be randomized to receive either a course of thrice weekly MST using either a focal or non focal stimulating coil.
89227655|NCT00973934|Active Comparator|Right Unilateral Electroconvulsive Therapy|
89227656|NCT00970034||AF|Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.
89227657|NCT00970034||SR|Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.
89227658|NCT00970112|Placebo Comparator|Placebo|Placebo 1 hour before surgery
89227659|NCT00970112|Experimental|Etoricoxib|Etoricoxib 1 hour before surgery
89227660|NCT00970112|Experimental|Dexamethaone|Dexamethasone 1 hour before surgery
89227661|NCT00964418|Experimental|IDeg|
89101355|NCT04854057|Experimental|Intermittent Hypoxia (AIH) + Transcutaneous Electrical Spinal Cord Stimulation (TESS) First|"Round 1 1st Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice alone for 45 mins.~Round 1 2nd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after AIH (15x 1.5 mins bouts of 10% oxygen with 1 min intervals of room air).~Round 1 3rd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after SHAM (15x 1.5 mins bouts of 21% oxygen with 1 min intervals of room air).~Washout (1 month)~Round 2 1st Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice alone for 45 mins.~Round 2 2nd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after SHAM.~Round 2 3rd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after AIH."
89101356|NCT04854057|Experimental|Intermittent Room Air (SHAM) + Transcutaneous Electrical Spinal Cord Stimulation (TESS) First|"Round 1 1st Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice alone for 45 mins.~Round 1 2nd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after SHAM.~Round 1 3rd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after AIH.~Washout (1 month)~Round 2 1st Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice alone for 45 mins.~Round 2 2nd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after AIH (15x 1.5 mins bouts of 10% oxygen with 1 min intervals of room air).~Round 2 3rd Intervention (4 days): Participants receive 4 consecutive days of TESS during functional task practice for 45 mins after SHAM (15x 1.5 mins bouts of 21% oxygen with 1 min intervals of room air)."
89101357|NCT04847232|Experimental|Sodium Zirconium Cyclosilicate|
89101358|NCT04847232|Placebo Comparator|Placebo|
89101359|NCT04836936|Placebo Comparator|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy will be performed in the pre-operative setting by PI or trained designee using an empty cryopuncture device without nitrogen gas. The patient will otherwise receive standard of care treatment for surgery and post-operative pain management.
89101360|NCT04836936|Active Comparator|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy will be performed in the pre-operative setting by PI or trained designee using a cryopuncture device with nitrogen gas. The patient will otherwise receive standard of care treatment for surgery and post-operative pain management.
89101361|NCT04809363|Experimental|CDPATH™|Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.
89101362|NCT04798924|Experimental|Training in the blind field|Training in the blind field using specialized software
89101363|NCT04798924|Experimental|Training in the intact field|Training in the intact field using specialized software
89101364|NCT04791826|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of HF in diabetes and the lack of an active order for SGLT2i therapy.
89101365|NCT04791826|No Intervention|No Alert|The CDS will not issue an on-screen alert.
89101366|NCT04791176|Experimental|Lenvatinib and IMRT|Concurrent Lenvatinib and IMRT, followed Lenvatinib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
89101367|NCT04790682|Experimental|NSCLC patient in a metastatic stage eligible for 1st-line TT with immune checkpoint inhibitor.|
89101368|NCT04787926||Duralock-C 4%|DuraLock-C 4.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 40 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
89101369|NCT04787926||Duralock-C 30%|DuraLock-C 30.0%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 300 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
89101370|NCT04787926||Duralock-C 46.7%|DuraLock-C 46.7%: Pouch Contains: (2) 3 mL Syringes w/ 2.5 mL Trisodium Citrate Dihydrate 467 mg/mL Solution Contains: Trisodium Citrate Dihydrate, Citric Acid Anhydrous, Water
89101371|NCT04783077|Active Comparator|FRD Control|
89101372|NCT04783077|Active Comparator|VNRBD Control|
89101373|NCT04783077|Experimental|FRD WhatsApp|
89101374|NCT04783077|Experimental|VNRBD WhatsApp|
89101375|NCT04783077|Experimental|Docudrama|
89101376|NCT04782297||Titan HD Catheter|The Titan HD Catheter is a double lumen catheter that provides 2 dedicated (arterial/venous) access lumens. Each lumen is connected through an extension line with female luer connectors. The arterial and venous catheter lumens connect to a hub to facilitate connection of extension tubes with clamps intended to prevent air/fluid communication and control fluid flow through the catheter. At the proximal end of the extension tubes are female Luer fittings to provide a needleless connection. The clamps and the sleeves are color-coded red for the arterial lumen and blue for the venous lumen. Each catheter has a cuff which is intended to be positioned underneath the skin at the skin exit to aid in securing the catheter and to provide a barrier to minimize the risk of infection. Each lumen is connected through an extension line with female Luer connectors. The transition between lumen and extension is housed within a molded hub.
89101377|NCT04782297||Hemo-Flow Catheter|The Hemo-Flow® Catheter has two lumens (one arterial lumen, one venous lumen) comprised of a biocompatible polymeric material that contains radiopaque filler to allow radiographic imaging of the distal tips to ensure proper placement into the superior vena cava. The arterial lumen is utilized to withdraw blood from the patient and the venous lumen returns the blood to the patient after treatment
89101378|NCT04760275|Active Comparator|Medication - Fluoxetine|"Approved medication by the U.S. Food and Drug Administration (FDA) for treating anxiety disorders in children.~The study's starting dose, and minimum permitted, will be 10 mg/day; should that not be tolerated, the patient will be withdrawn from active treatment (but not from study follow-up). After 1 week at 10 mg/day, the dose will increase to 20 mg/day. After completion of week 4, 10 mg/day dose increases will be permitted every other week as tolerated, up to a maximum daily dose of 80 mg/day. If patients are on doses >20mg/day, the total daily dose can be prescribed either once daily or split into twice daily administrations."
89101379|NCT04760275|Active Comparator|Cognitive Behavioral Therapy (CBT)|"Type of talk therapy that aims to identify and replace negative thoughts, using positive behavioral skills to create and maintain positive moods and healthy relationships.~The Coping Cat (CC) program will be used as the behavioral intervention for this study.CC is an established evidence-based CBT treatment for pediatric anxiety. It is delivered in individual therapy sessions with anxious children."
89101380|NCT04758507|Experimental|Donor FMT|Patients enrolled in this arm will receive donor FMT
89101381|NCT04758507|Placebo Comparator|Placebo FMT|Patients enrolled in this arm will receive placebo FMT (that will be made of saline solution)
89101382|NCT04757714|Other|COPD Patients|"Patients agreeing to participate in the study and meeting the inclusion and non-inclusion criteria will have:~The high-resolution peripheral scanner (HRpQCT) of the tibia and radius~a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)~to complete:~a physical activity questionnaire (PHAS instrument)~a COPD quality of life questionnaire (St George Hospital)~A search for sarcopenia by studying the strength of the grip (dynamometer)"
89101383|NCT04728113|Experimental|Early together group|Oncological standard of care at M0, M3, M6, M9 and M12 with early introduction of supportive care every 6 weeks.
89101384|NCT04728113|Active Comparator|Control group|Oncological standard of care at M0, M3, M6, M9 and M12.
89101385|NCT04722315|Experimental|MAD diet group|15 adult participants with confirmed KMT2D pathogenic mutations. Baseline labs and education about Modified Atkins Diet. Then 12 weeks on a Modified Atkins Diet. Weekly urine dips for ketones and diet logs. Blood draw every 3 weeks.
89101386|NCT04718441|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
89101387|NCT04714372|Experimental|Dose Level 1: FT538 at 1 x10^8 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
89101388|NCT04714372|Experimental|Dose Level 2: FT538 at 3 x10^8 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
89101389|NCT04714372|Experimental|Dose Level 3: FT538 at 1 x10^9 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
89101390|NCT04714372|Experimental|Dose Level 4: FT538 at 1.5 x10^9 cells/dose|FT538 administered at assigned dose as an IV infusion via gravity on Day 1, Day 8, and Day 15
89101391|NCT04710030|Active Comparator|Valacyclovir|Oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day (total dose: 4 grams per day) for 52 weeks.
89101392|NCT04710030|Placebo Comparator|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day for 52 weeks.
89101393|NCT04700176|Experimental|Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Len + Dex (Cohort A) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
89101394|NCT04700176|Experimental|Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Pom + Dex (Cohort B) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
89101395|NCT04677413|Experimental|Phase I Dose Cohorts|"DOSE LEVEL 1 : 30 Gy (tumor)/ 25 Gy (pelvis)~DOSE LEVEL 2 : 35 Gy (tumor)/ 25 Gy (pelvis)~DOSE LEVEL 3 : 40 Gy (tumor)/ 25 Gy (pelvis)"
89101398|NCT04639258|Experimental|Medtronic Evolut™ PRO+ System|All study subjects will be treated with the Medtronic Evolut™ PRO+ TAVR System.
89101399|NCT04628585||Subjects with sickle-cell disease|Subjects treated with ex vivo gene therapy drug product for sickle cell disease in a bluebird bio-sponsored study who agree to participate in this long-term follow-up study
89101400|NCT04622670|Experimental|Group I (yoga group)|Patients attend at least 2 yoga classes per week over 5-6 weeks lasting approximately 60 minutes each for up to 15 classes during the CRT. Patients also complete surveys pre-treatment, once a week, and post-treatment over and receive a yoga manual and DVD during and after CRT.
89101401|NCT04622670|Active Comparator|Group II (wait list control)|Patients refrain from participating in any new stress management activities and receive a DVD. Patients are also offered 4 group yoga classes after 3 months of CRT. Patients also complete surveys as in Group I.
89101402|NCT04592913|Placebo Comparator|Arm B|placebo product and FLOT chemotherapy
89101403|NCT04592913|Experimental|Arm A|Durvalumab and FLOT chemotherapy
89101404|NCT04587934|Experimental|iRes Warmer with ResusView|iRes Warmer with ResusView program with experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
89101405|NCT04587934|Active Comparator|iRes Warmer without ResusView|An external non-experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
89227662|NCT00964418|Active Comparator|IGlar|
89227663|NCT00974012|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
89227664|NCT00974012|Active Comparator|Depakote®|500 mg Extended Release Tablet
89227665|NCT04009226||Participants with GNE|
89101406|NCT04585490|Experimental|Cohort 1 minimal residual disease positive (MRD+)|Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy [carboplatin/pemetrexed] and durvalumab (1500 mg IV every 21 days, for 1 year), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks.Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.
89101407|NCT04585490|Experimental|Cohort 2 minimal residual disease negative (MRD )|Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab(10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.
89101408|NCT04575896|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive glecaprevir/pibrentasvir 300 mg/120 mg once daily by mouth for 2 weeks
89101409|NCT04575181|Experimental|NNC0286-0965|NNC0286-0965 administered together with insulin glargine placebo. If previously treated with oral anti-diabetic drugs (OADs), participants will remain on these in the trial
89101410|NCT04575181|Active Comparator|Insulin glargine|Insulin glargine administered together with NNC0286-0965 placebo. If previously treated with OADs, participants will remain on these in the trial
89101411|NCT04568122|Experimental|Saliva test|Participants perform each test assay, noting the results for comparison by technician, and completing survey questionnaires.
89101412|NCT04537637||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
89101413|NCT04533880|Placebo Comparator|Control|The control group will receive autologous bone obtained from the BTBPB graft harvest
89101414|NCT04533880|Active Comparator|Autologous Bone + DBM|Autologous bone plus demineralized bone matrix
89101415|NCT04533880|Active Comparator|Autologous Bone + Calcium Phosphate Cement|Autologous bone plus calcium phosphate cement
89101416|NCT04533815|Experimental|LOCK sleep intervention|Nursing home staff receive the LOCK sleep intervention training and thus provide to nursing home residents with dementia the LOCK sleep intervention
89101417|NCT04512378|Experimental|IU Group Treatment|Clinical intervention arm
89101418|NCT04508725|Experimental|Tyrosine kinase (TKI) inhibitor plus immune checkpoint inhibitor (ICI)|Patients are planned to be treated with vascular endothelial growth factor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
89101419|NCT04508725|Experimental|Non-ICI therapy|Patients are planned to be treated with non-ICI therapy
89101420|NCT04508309|Experimental|Cecolin® at 0 and 6 months|Two doses of Cecolin® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
89101421|NCT04508309|Experimental|Cecolin® at 0 and 12 months|Two doses of Cecolin® given at 0 and 12 months with blood draw at baseline, prior to second dose and one-month post second dose
89101422|NCT04508309|Experimental|Cecolin® at 0 and 24 months|Two doses of Cecolin® given at 0 and 24 months with blood draw at baseline, prior to second dose and one-month post second dose
89101423|NCT04508309|Active Comparator|Gardasil® at 0 and 6 months|Two doses of Gardasil® given at 0 and 6 months with blood draw at baseline, prior to second dose, one-month post second dose and 24 months after first dose
89101424|NCT04508309|Other|Gardasil® at 0 and Cecolin® at 24 months|One dose of Gardasil® at 0 months and one dose of Cecolin® at 24 months with blood draw at baseline, prior to second dose and one-month post second dose.
89101425|NCT04500756|Active Comparator|Metformin group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
89101426|NCT04500756|Placebo Comparator|Placebo Group|Participants will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day. Over the first four weeks of the study, you will increase your dosage every week by one pill, so at the end of the first month you will be taking up to four pills per day. If you develop any symptoms or side effects from pill ingestion during this process, your dose will be decreased to the last number of pills you were able to take without developing side effects.
89101427|NCT04474158|Experimental|Creating Peace|Creating Peace uses a group discussion format with activities that explore race, gender, sexual identity, and social class. Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
89101428|NCT04474158|Active Comparator|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth. Participants receive a 12 session job readiness training with linkages to businesses and employment opportunities. Discussions include a wide range of topics related to career exploration and job readiness.
89230309|NCT01095601|Other|Treatment B|2x100 mg Formulation II avanafil tablet, fed
89227666|NCT00964574|Experimental|APIDRA + LANTUS basal|The 2 first weeks, patients will receive subcutaneous injection of Insulin Glulisine and Insulin Glargine once daily in hospital. The rest of the treatement is to be take at home until week 12
89227667|NCT04008680|Other|Low response burden|Participants will be assigned to complete only the EQ-5D-5L questionnaire.
89227668|NCT04008680|Other|Low to medium response burden|Participants will be assigned to complete the General Anxiety Disorder-7 (GAD-7) questionnaire first, followed by the EQ-5D-5L questionnaire.
89227669|NCT04008680|Other|Medium to high response burden|Participants will be assigned to complete the Pain Catastrophizing Scale (PCS) questionnaire first, followed by the GAD-7, and lastly the EQ-5D-5L questionnaire.
89227670|NCT04008680|Other|High response burden|Participants will be assigned to complete the Brief Pain Inventory (BPI) questionnaire first, followed by the PCS secondly, the GAD-7 third, and lastly the EQ-5D-5L questionnaire.
89101429|NCT04469842|Experimental|Immunosuppression with Extended-Release Tacrolimus|"LCP-tacrolimus administered daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone).~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
89101430|NCT04469842|Active Comparator|Immunosuppression with Intermediate Release Tacrolimus|"IR-tacrolimus administered twice daily to target a goal trough level of 10-14 ng/mL x 7 months (with Mycophenolate mofetil and prednisone). This is currently the standard of care at Vanderbilt University Medical Center and most other lung transplant centers (ISHLT Registry 2019).~Additional standard immunosuppression with either mycophenolate mofetil (500-1500mg twice daily) OR Azathioprine (up to 2mg/kg daily) AND Prednisone (5-10mg daily) will be administered."
89101431|NCT04464655||Healthy Volunteers|Age: >18 y, No known current or pre-existing medical conditions that would affect the cardiovascular or respiratory system.
89101432|NCT04464655||Patients|Age: > 18y, Clinically indicated CMR exam
89101433|NCT04447755|Experimental|Ewing Sarcoma|Participants with Ewing sarcoma will receive lenvatinib 14 mg/m^2 once daily (QD) orally until progressive disease or unacceptable toxicity.
89101434|NCT04447755|Experimental|Rhabdomyosarcoma|Participants with rhabdomyosarcoma will receive lenvatinib 14 mg/m^2 QD orally until progressive disease or unacceptable toxicity.
89101435|NCT04447755|Experimental|High Grade Glioma|Participants with high grade glioma will receive lenvatinib 14 mg/m^2 QD orally until progressive disease or unacceptable toxicity.
89101436|NCT04447755|Experimental|Diffuse Midline Glioma|Participants with diffuse midline glioma will receive lenvatinib 14 mg/m^2 QD orally until progressive disease or unacceptable toxicity.
89101437|NCT04447755|Experimental|Medulloblastoma|Participants with medulloblastoma will receive lenvatinib 14 mg/m^2 QD orally until progressive disease or unacceptable toxicity.
89101438|NCT04447755|Experimental|Ependymoma|Participants with ependymoma will receive lenvatinib 14 mg/m^2 QD orally until progressive disease or unacceptable toxicity.
89101439|NCT04447755|Experimental|Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma|Participants with other solid tumors will receive lenvatinib 14 mg/m^2 QD orally until progressive disease or unacceptable toxicity.
89101440|NCT04396535|Experimental|Arm I (docetaxel, bintrafusp alfa)|Patients receive docetaxel IV over 1 hour and bintrafusp alfa IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bintrafusp alfa IV over 60 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89101441|NCT04396535|Active Comparator|Arm II (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may crossover to Arm I and receive bintrafusp alfa alone.
89101442|NCT04390906||All participants|Participants will receive standard of care partial brain radiation therapy at discretion of their radiation oncologist
89101443|NCT04341571|Experimental|Probiotics|15 patients to receive homologated intervention capsule (probiotics lactobacillus acidophilus y bifidobacterium lactis 400 mg) 1 time at day before breakfast along 13 weeks and receive 1 homologated placebo capsule (calcinated magnesia 500 mg) 1 time at day before dinner along 13 weeks.
89101444|NCT04341571|Experimental|Metformin|15 patients to receive homologated intervention capsule (metformin 750 mg) twice at day before breakfast and dinner for 13 weeks.
89101445|NCT04317053|No Intervention|Site-Directed Care (SDC)|Site-specific existing interventions delivered to patients with OUD as part of ED care. At a minimum SDC arm patients will receive from the study research team OD education and naloxone distribution (OEND), a list of opioid treatment programs, and an informational flyer about Relay.
89101446|NCT04317053|Experimental|Relay program (peer navigation)|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
89101447|NCT04307615|Experimental|Oxygen + CPAP-treatment|
89101448|NCT04307615|Active Comparator|Oxygen-treatment|
89101449|NCT04305925|Experimental|Focal Laser Ablation|The Orion system will be used to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy.
89101450|NCT04283045|Active Comparator|JASPER (6 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 6 weeks. If child is an early responder, he/she will continue to do JASPER daily, 5 times a week, for the remaining 18 weeks of the study.~If child is a slow responder, he/she can get randomized to receive 30 minutes of JASPER Plus+ and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 18 weeks of the study.~Or~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 18 weeks of the study."
89101451|NCT04283045|Active Comparator|JASPER (12 weeks)|"Child will be randomized to spend an hour daily, 5 days a week with teaching assistant (TA) doing JASPER for the following 12 weeks. If child is an early responder, he/she will do JASPER for 60 minutes with TA, 5 times a week, for the remaining 12 weeks of the study.~If child is a slow responder, he/she can get randomized to receive 30 minutes of JASPER Plus+ and 30 minutes of JASPER with a TA daily, 5 days a week for the remaining 12 weeks of the study.~Or~Child can get randomized to continue his/her daily sessions of JASPER with the TA for an hour each day, 5 days a week for the following 12 weeks of the study."
89101452|NCT04276116|No Intervention|Usual Care|
89101453|NCT04276116|Experimental|Usual care + communication of pulmonary age|
89101454|NCT04272606|Active Comparator|Treatment|1:1 randomization, given tranexamic acid during surgery, visual acuity exam
89101455|NCT04272606|Placebo Comparator|Placebo|1:1 randomization, given standard of care treatment during surgery, visual acuity exam
89101456|NCT04269993|Placebo Comparator|Vaporized cannabis: placebo|Vaporized cannabis: placebo dose
89101457|NCT04269993|Experimental|Vaporized cannabis: medium THC/medium CBD|Vaporized cannabis: medium THC/medium CBD dose
89101458|NCT04242992|Experimental|CETA (Common Elements Treatment Approach)|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based cognitive behavioral therapy (CBT) elements so the provider can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include Short Message Service (SMS) text reminders of their HIV care appointments, similar to the active control group. As of October 12, 2022 participants can elect to have CETA delivered by telephone.
89101459|NCT04242992|Active Comparator|Active control|Our comparison arm will be an active control receiving usual care for intimate partner violence. Short Message Service (SMS) text messages will be sent monthly to our control group participants to remind them of HIV care appointments.
89101460|NCT04228419|Active Comparator|Total Shoulder Arthroplasty (anatomic)|TSA procedure involves replacing the worn-out ball and socket joint with prosthetic components.
89101461|NCT04228419|Active Comparator|Reverse Shoulder Arthroplasty|RSA procedure is similar to a TSA, however the orientation of the ball and socket joint is placed in the reverse position
89101462|NCT04209660|Experimental|recurrent/metastatic adenoid cystic carcinoma (R/M ACC)|"All eligible patients will undergo informed consent and screening for trial enrollment.~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
89101463|NCT04209660|Experimental|recurrent/metastatic non-ACC salivary gland cancers (R/M SGC).|"All eligible patients will undergo informed consent and screening for trial enrollment.~Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)"
89101464|NCT04190550|Experimental|Treatment (navtemadlin, cytarabine, idarubicin)|Patients receive navtemadlin PO QD on days 1-7, cytarabine IV BID over 3 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease may receive cytarabine IV BID over 3 hours for 5 days and idarubicin IV over 10-15 minutes for 2 days starting between days 14-21 of cycle 1 or the second cycle of navtemadlin, cytarabine, and idarubicin. Patients who achieve a CR or a CRi in either cycle 1 or 2 may receive cytarabine IV BID over 3 hours on days 1, 3, and 5 for 3-4 additional 28 to 35-day cycles in the absence of disease progression or unacceptable toxicity.
89101465|NCT04180306|Other|Inpatient pediatric oncology patients|All patients admitted to the pediatric oncology ward will be in the cohort
89101466|NCT04171856|Experimental|Motor Skill Learning (CIRCUIT)|Intervention: training on the REAplan robot with a serious game based on motor skill learning (MSkL) serious game, the CIRCUIT.
89101467|NCT04171856|Active Comparator|Motor control recovery (EASY)|Training on the REAplan robot with a serious game that requires similar type and amount of movements but does not rely on motor skill learning (EASY), a brick buster game.
89101468|NCT04171856|Active Comparator|Conventional|Training sessions with classical exercices focused on the upper limb administered by occupation therapist.
89227671|NCT00970346|Experimental|Inhaled OligoG CF-5/20|
89230310|NCT01095601|Other|Treatment C|2x100 mg Formulation I avanafil tablet, fasted
89101469|NCT04170062|Experimental|Baseline followed by intervention 1a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
89101470|NCT04170062|Experimental|Baseline followed by intervention 1b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
89101471|NCT04170062|Experimental|Baseline followed by intervention 1c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
89101472|NCT04170062|Experimental|Baseline followed by intervention 1d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
89101473|NCT04170062|Experimental|Baseline followed by intervention 1e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
89101474|NCT04170062|Experimental|Baseline followed by intervention 1f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
89101475|NCT04170062|Experimental|Baseline followed by intervention 2a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
89227672|NCT03937778|Experimental|Tourniquet block to left upper arm|Participants underwent ~10 minutes of baseline testing followed by a tourniquet placement to left upper arm and inflated to 80-100 mmHG above systolic blood pressure. Participants repeatedly rated a variety of sensory stimuli after tourniquet was placed. Participants rated intensity and pleasantness of slow brushing and deep pressure on both hands/forearms at baseline and after loss of A-beta sensation.
89227673|NCT03935126||All patients|
89101476|NCT04170062|Experimental|Baseline followed by intervention 2b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
89101477|NCT04170062|Experimental|Baseline followed by intervention 2c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
89101478|NCT04170062|Experimental|Baseline followed by intervention 2d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
89101479|NCT04170062|Experimental|Baseline followed by intervention 2e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
89101480|NCT04170062|Experimental|Baseline followed by intervention 2f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
89101481|NCT04162613||Patients with ACL reconstruction in Lund and Umeå|Persons who have suffered a unilateral anterior cruciate ligament injury treated with reconstruction
89101482|NCT04153747|Active Comparator|Conventional ablation|"Point-by-point catheter-based pulmonary veins isolation using convencional radiofrequency parameters.~Anterior aspect of pulmonary veins: 40 W, temperature limit 45 ºC, irrigation 17-30 ml/min; objective LSI>=6 or Ablation index >=500.~Posterior aspect of pulmonary veins: 20-40 W, temperature limit 45 ºC, irrigation 17-3 ml/min; objective LSI>=5 or Ablation index >=350."
89101483|NCT04153747|Experimental|High-power and short-duration ablation|Point-by-point catheter-based pulmonary veins isolation using high-power and short duration radiofrequency: 70 W, duration per application 9-10 s (initial ramp 2-3 s according to the technical characterictics of radiofrequency sources), temperature limit 45 ºC, irrigation 17 ml/min, contac-force > 5 g.
89101484|NCT04144959||Patients with lower extremity acute limb ischemia|
89101485|NCT04126148||Age matched Healthy participants (150)|Healthy Participants Age: > 40y No known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system
89101486|NCT04126148||Coronary Artery Disease (CAD) Patients (200)|Coronary Artery Disease (CAD) Patients Age > 18 y Patients with an Indication for invasive coronary angiography based on symptoms and a test positive for inducible coronary ischemia, or previous coronary angiography.
89101487|NCT04122456|Experimental|Day Shift Work Schedule|Day shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
89101488|NCT04122456|Experimental|Night Shift Work Schedule|Night shift worker skin biopsies will be exposed to artificial sunlight (ultraviolet B radiation; UVB) at the laboratory.
89101489|NCT04119063|Experimental|Gait Training with Exoskeleton Assistance|Gait training with ankle exoskeleton assistance. All participants received high frequency gait training followed by a washout period then low frequency gait training.
89101490|NCT04114084||A. patients with MGUS and sleep apnea|
89101491|NCT04114084||B. patients with MGUS and no sleep apnea|
89101492|NCT04114084||C. patients with MM and sleep apnea|
89101493|NCT04114084||D. patients with MM and no sleep apnea|
89101494|NCT04112160|Placebo Comparator|control|normal saline 0.9%
89101495|NCT04112160|Active Comparator|Ketorolac|30 mg of Ketorolac
89101496|NCT04109456|Experimental|Part 1, Monotherapy Arm|The safety and tolerability of IN10018 monotherapy will be assessed. Other dose levels may be explored if necessary.
89101497|NCT04109456|Experimental|Part 2, Combination Arm|"The safety and tolerability of IN10018 in combination with Cobimetinib will be assessed. Other dose levels may be explored if necessary.~A modified 3+3 design will be used."
89101498|NCT04109456|Experimental|Part 3, Combination Arm|The safety and tolerability of IN10018 in combination with Cobimetinib and Atezolizumab will be assessed.
89101499|NCT04108468|Experimental|Golimumab & Methotrexate|
89101500|NCT04108468|Active Comparator|Methotrexate|
89101501|NCT04107181|Experimental|Patient surveillance|The introducer will be used during annual Pap smears for cervical cancer screening.
89227674|NCT00964652|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
89227675|NCT00970580|Experimental|BIIB022 in Combination with Paclitaxel and Carboplatin|BIIB022 in Combination with Paclitaxel and Carboplatin
89227676|NCT00974168|Active Comparator|A|Radiation Cumulative BED ≤ 100 Gy2
89227677|NCT00974168|Active Comparator|B|Cumulative BED ≤ 130 Gy2
89101502|NCT04107181|Experimental|Healthy Volunteers|There will be 2 types of healthy volunteers recruited to participate in this arm. The home study is to determine ease of use/feasibility of the introducer. The other group of healthy volunteers will be interviewed only. The goal of this study is to better understand how to improve women's health through learning about women's perceptions of their reproductive anatomy, specifically the cervix, comfort in discussing reproductive health topics with providers, and thoughts on two tools used to see the cervix.
89101503|NCT04100161|Experimental|Protein supplementation|20g protein supplementation twice daily for 3 months
89101504|NCT04100161|Active Comparator|Carbohydrate supplementation|20g maltodextrin supplementation twice daily for 3 months
89101505|NCT04087798|Active Comparator|Control|Eligible patients enrolled from the control group clinics will be given a Control-EDI which has information about kidney disease in general (not tailored to the patient) during their clinic visit.
89101506|NCT04087798|Experimental|Intervention|Eligible patients enrolled from the intervention group clinics will be given an Intervention-EDI which has personalized information about kidney disease. There will be space on this for the provider to type in any goals or key points they want the patient to remember. Additionally, patients in this group will also receive health coaching.
89101507|NCT04082754|Experimental|CSL311 Cohort A1 (SAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a Single Ascending Dose (SAD)
89101508|NCT04082754|Experimental|CSL311 Cohort A2 (SAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
89101509|NCT04082754|Experimental|CSL311 Cohort A3 (SAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
89101510|NCT04082754|Experimental|CSL311 Cohort A4 (SAD Dose 4)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
89101511|NCT04082754|Experimental|CSL311 Cohort A5 (SAD Dose 5)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
89101512|NCT04082754|Experimental|CSL311 Cohort A6 (SAD Dose 6)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
89101513|NCT04082754|Experimental|CSL311 Cohort A7 (SAD Dose 7)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
89101514|NCT04082754|Experimental|CSL311 Cohort A8 (SAD Dose 8)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a SAD
89101515|NCT04082754|Experimental|CSL311 Cohort B1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered intravenously at a MAD
89101516|NCT04082754|Placebo Comparator|Placebo|0.9% sodium chloride solution administered intravenously
89101517|NCT04082754|Placebo Comparator|Placebo (2)|0.9% sodium chloride solution administered subcutaneously
89101518|NCT04082754|Experimental|CSL311 Cohort C1 (MAD Dose 1)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously (SC)
89101519|NCT04082754|Experimental|CSL311 Cohort C2 (MAD Dose 2)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
89101520|NCT04082754|Experimental|CSL311 Cohort C3 (MAD Dose 3)|Human beta common receptor antagonist monoclonal antibody administered subcutaneously
89101521|NCT04063397||Preeclampsia|40 patients diagnosed with preeclampsia with or without severe features
89101522|NCT04063397||Control|20 Control group of patients without hypertensive disorders of pregnancy
89101523|NCT04060680|Experimental|Implant Attempt|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
89101524|NCT04054050|Experimental|Light therapy|Participants receive one hour of morning (within 9:00am-11:00am) and afternoon/evening (within 5:00pm-7:00pm).
89101525|NCT04048616|Active Comparator|whey protein isolate + KHCO3|1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3
89230311|NCT01095601|Other|Treatment D|1x50 mg Formulation II avanafil tablet, fasted
89101526|NCT04048616|Active Comparator|whey protein isolate + microcrystalline cellulose|1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules
89101527|NCT04048616|Active Comparator|maltodextrin powder + KHCO3|isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3
89101528|NCT04048616|Placebo Comparator|maltodextrin powder + microcrystalline cellulose|isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules
89101529|NCT04036396|Active Comparator|Standard of Care|A client-centered assessment of priorities and needs and customized prevention and testing referrals.
89101530|NCT04036396|Experimental|Mobile Enhanced Prevention Support|Standard of Care in addition to a client-centered assessment of priorities and needs and customized prevention and testing referrals, and the Mobile Enhanced Prevention Support Program
89101531|NCT04026620|Other|Pamphlet-only|Pamphlet-only women will be provided with two (2) informational pamphlet(s) (both in Afrikaans).
89101532|NCT04026620|Other|MET Group|MET women will be provided with a one (1) hour and 30 minute session of Motivational Enhancement Therapy (MET) and informational pamphlet(s) (both in Afrikaans).
89101533|NCT04024059|Experimental|Buprenorphine Adherence and Opiate Abstinence|Participants will receive financial incentives for buprenorphine use and opiate abstinence.
89101534|NCT04024059|Experimental|Buprenorphine Adherence Only|Participants will receive financial incentives for buprenorphine use.
89101535|NCT04024059|No Intervention|Control|Participants will not receive any intervention.
89101536|NCT03989414|Experimental|Cohort A: CC-92480 with bortezomib and dexamethasone|
89101537|NCT03989414|Experimental|Cohort C: CC-92480 with carfilzomib and dexamethasone|
89101538|NCT03989414|Experimental|Cohort H: CC-92480 with elotuzumab and dexamethasone|
89101539|NCT03989414|Experimental|Cohort I: CC-92480 with isatuximab and dexamethasone|
89101540|NCT03989414|Experimental|Cohort D: CC-92480 with bortezomib and dexamethasone|
89101541|NCT03989414|Experimental|Cohort F: CC-92480 with carfilzomib and dexamethasone|
89101542|NCT03989414|Experimental|Cohort J: CC-92480 with elotuzumab and dexamethasone|
89101543|NCT03989414|Experimental|Cohort K: CC-92480 with isatuximab and dexamethasone|
89101544|NCT03989414|Experimental|Cohort G: CC-92480 with bortezomib and dexamethasone|
89101545|NCT03989414|Experimental|Subcohort B1: CC-92480 with daratumumab and dexamethasone|
89101546|NCT03989414|Experimental|Subcohort B2: CC-92480 with daratumumab and dexamethasone|
89101547|NCT03989414|Experimental|Subcohort B3: CC-92480 with daratumumab and dexamethasone|
89101548|NCT03989414|Experimental|Subcohort E1: CC-92480 with daratumumab and dexamethasone|
89101549|NCT03989414|Experimental|Subcohort E2: CC-92480 with daratumumab and dexamethasone|
89101550|NCT03989414|Experimental|Subcohort E3: CC-92480 with daratumumab and dexamethasone|
89101551|NCT03981614|Experimental|Arm A (binimetinib, palbociclib)|Patients receive binimetinib PO BID on days 1-28 and palbociclib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89101552|NCT03981614|Experimental|Arm B (trifluridine and tipiracil hydrochloride)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may optionally crossover to Arm A.
89101553|NCT03981471|Other|Elderly without fall history|Elderly people in the community who have no fall history
89101554|NCT03981471|Other|Elderly with fall history|Elderly people in the community who have fall history
89101555|NCT03979235||Heahlthy people|perform motor function assessment by using scales, sEMG, and inertia sensors
89101556|NCT03979235||People with motor deficits|perform motor function assessment by using scales, sEMG, and inertia sensors
89101557|NCT03979235||Patients with dysphagia|perform motor function assessment by using scales, sEMG, and inertia sensors
89101558|NCT03965689|Experimental|Treatment (paclitaxel, carboplatin, pevonedistat)|Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30-60 minutes on day 1, and pevonedistat IV over 1 hour on days 1, 3, and 5. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.
89101559|NCT03958877|Experimental|BIIB017 (peginterferon beta-1a)|Participants will receive subcutaneous (SC) injection of BIIB017 (peginterferon beta-1a) 63 microgram (μg) on Day 1, followed by 94 μg at Week 2, followed by 125 μg at Week 4, and then 125 μg SC injection every 2 weeks up to Week 96 in Part 1 of the study. Eligible participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
89101560|NCT03958877|Active Comparator|Avonex|Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1, followed by an increase of 7.5 μg each week for 3 weeks, followed by 30 μg intramuscular (IM) injections every week up to Week 96 in Part 1 of the study. Eligible participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.
89101561|NCT03952377|Placebo Comparator|0.9% Sodium Chloride for Injection|
89101562|NCT03952377|Experimental|12.5 mg SX600|Low Dose
89101563|NCT03952377|Experimental|25.0 mg SX600|High Dose
89101564|NCT03945292|Experimental|Fazirsiran (also referred to as TAK-999 or ARO-AAT)|"Participants with no fibrosis: Administered on Day 1 and Week 4~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses."
89101565|NCT03945292|Placebo Comparator|Placebo|"Participants with no fibrosis: Administered on Day 1 and Week 4~Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses."
89101566|NCT03945292|Experimental|Open-Label Fazisiran (also referred to as TAK-999 or ARO-AAT)|After all enrolled participants completed the Week 16 visit, an interim analysis was performed to select a single dose level (25, 100 or 200 mg) for the open-label phase of the study. Fazirsiran 200 mg was the selected dose and all participants with fibrosis at Screening who completed the post-dose liver biopsy at Week 48 (or Week 72 or 96) receive this dose every 12 weeks for the duration of the study (open-label phase).
89101567|NCT03937375||High PEEP|Use of high levels of PEEP with recruitment maneuvers
89101568|NCT03937375||Low PEEP|Use of low levels of PEEP without recruitment maneuvers
89101569|NCT03932162|Placebo Comparator|Young Adult|One small area of skin will undergo treatment with a small amount of UVB.
89101570|NCT03932162|Active Comparator|Geriatric Adult|Four small areas will undergo injection of a small amount of IGF-1 drug and two will undergo injections with saline. Then the injected areas will be treated with a small amount of UVB.
89101571|NCT03918629|Experimental|Clostridium difficile vaccine - 3 dose|All 3 doses are the Clostridium difficile vaccine
89101572|NCT03918629|Experimental|Clostridium difficile vaccine - 2 dose|2 of the 3 doses are the Clostridium difficile vaccine with the other being placebo
89101573|NCT03896217|Active Comparator|Simvastatin|Simvastatin is part of the pharmacotherapeutic group of HMG-CoA reductase inhibitors (ATC-Code: C10A A01). Simvastatin is licensed within the EU for hypercholesterolemia and cardiovascular prevention but for this trial its use will be outside its licensed indication. Oral Simvastatin will be taken 40mg daily (one tablet in the evening) for 4 weeks and then at week 4 up titrated to 80mg daily (two tablets in the evening.
89101574|NCT03896217|Placebo Comparator|Placebo|Matched Placebo (one tablet in the evening) for 4 weeks and then at week 4 up titrated to two tablets daily in the evening.
89101575|NCT03870750|Experimental|Arm I (SPC)|Patients undergo SPC on days -15 before to +56 after transplant. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
89101576|NCT03870750|Experimental|Arm II (CMC)|Patients undergo a CMC program on days -15 to 56. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
89101577|NCT03870750|Experimental|Arm III (SPC and CMC)|Patients undergo interventions as outlined in Arm I and Arm II. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
89101578|NCT03870750|Active Comparator|Arm IV (standard of care)|Patients receive standard of care. Patients undergo HCT on day 0 and complete questionnaires and surveys at enrollment, 30, 90, 180, and 365 days post HCT. Patients complete a 4-meter walk test, 6-minute walk test, up and go test, measured strength test and cognitive assessment at enrollment, 90, 180, and 365 days post HCT. Patients may also complete surveys on medical and non-medical (transportation, lodging) costs related to transplant after HCT.
89101579|NCT03862157|Experimental|Treatment (venetoclax, azacitidine, pevonedistat)|Patients receive venetoclax PO QD on days 1-28, azacitidine IV or SC on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89101580|NCT03858322|Experimental|Carboplatin + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle~Carboplatin will be administered intravenously 3 times per cycle"
89101581|NCT03858322|Experimental|Cyclophosphamide + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle~Cyclophosphamide will be administered once per cycle"
89101582|NCT03765229|Experimental|Single Arm: Entinostat + Pembrolizumab|Subjects in this trial will be administered entinostat, 5mg PO, once weekly (D1, D8, D15 of a 21-day cycle) starting on day 1 of study treatment. Pembrolizumab, 200 mg will be administered intravenously (IV) every 3 weeks and initiated at cycle 2 after the mandatory research tumor biopsy in the end of cycle 1, beginning of cycle 2 (day 21±2 days),. Combination therapy with both agents will continue if subject is receiving clinical benefit from therapy for up to 27 weeks (8 cycles of combination therapy or approximately 6 months). Study therapy will be discontinued for intolerable toxicity, disease progression or for other reasons at the discretion of the investigator.
89101583|NCT03727971|Active Comparator|omalizumab arm|The treatment is initiated with one injection with weight and serum-Immunoglobulin E balanced omalizumab one time per cyclus
89101584|NCT03727971|Placebo Comparator|placebo arm|Participants will be administered placebo (NaCl), one time per cyclus
89101585|NCT03713593|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
89101586|NCT03713593|Active Comparator|lenvatinib plus placebo|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally QD plus saline placebo by IV infusion on Day 1 Q3W. Saline placebo will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
89101587|NCT03711760|Experimental|intervention|telepsychology treatment
89101588|NCT03711760|No Intervention|usual care|standard of care
89101589|NCT03707431|Experimental|Web-based CBT (WebMAP)|Receives access to WebMAP
89101590|NCT03707431|Active Comparator|Pain Education (WebED)|Receives access to WebED
89101591|NCT03694483||Patient population|Male individuals with elevated PSA and a positive MRI-driven biopsy AND male individuals with diagnosed prostate cancer (but prior to any treatment)
89101592|NCT03694483||Control Population|Male individuals with elevated PSA and a negative MRI-driven biopsy
89101593|NCT03685188|Experimental|Oxycodone group|PCIA is formulated at 0.4 mg/ml of oxycodone.
89101594|NCT03685188|Active Comparator|Sufentanil group|PCIA is formulated at 2 μg/ml of sufentanil.
89101595|NCT03668041|Active Comparator|Trazodone|Participants who are assigned to take trazodone, an active study medication.
89101596|NCT03668041|Active Comparator|Eszopiclone|Participants who are assigned to take eszopiclone, an active study medication.
89101597|NCT03668041|Placebo Comparator|Placebo|Participants who are assigned to take a placebo, a non-active study medication.
89101598|NCT03643744|Active Comparator|PDT + Celecoxib|Patient receiving PDT taking 200mg celecoxib.
89101599|NCT03643744|Placebo Comparator|PDT + Placebo|Patient receiving PDT taking placebo.
89101600|NCT03643744|Active Comparator|Control + Celecoxib|Control subject not receiving PDT taking 200mg celecoxib.
89101601|NCT03643744|Placebo Comparator|Control + Placebo|Control subject not receiving PDT taking placebo.
89101602|NCT03640325|Experimental|PRISM (Promoting Resilience in Stress Management)|Resilience Skills Training
89101603|NCT03640325|No Intervention|Usual Care|Usual psychosocial care (control arm, no intervention)
89101604|NCT03631017|Experimental|Phase I: [18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (< 10 0 ug) of [18 F]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
89101605|NCT03631017|Experimental|Phase II: [18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (< 10 0 ug) of [18 F]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
89227678|NCT04009304|Experimental|In-person|OSNAP intervention delivered to afterschool sites using an in-person train-the-trainer model implementation strategy
89227679|NCT04009304|Experimental|Online|OSNAP intervention delivered to afterschool sites using an online training model implementation strategy
89101606|NCT03620786||HIFU Study Participants|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the HIFU procedure as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study. The HIFU device currently used in this standard-of-care procedure at UCLA is the Sonablate 450 HIFU System.
89101607|NCT03610490|Experimental|Treatment (autologous tumor infiltrating lymphocytes MDA-TIL)|"LYMPHODEPLETION REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, and fludarabine IV over 15-30 minutes on days -5 to -1 in the absence of disease progression or unacceptable toxicity.~T-CELL INFUSION: Patients receive autologous tumor infiltrating lymphocytes MDA-TIL IV over 45 minutes on day 0. Patients then receive IL-2 IV over 30 minutes on days 1-4 for up to 6 doses in the absence of disease progression or unacceptable toxicity."
89101608|NCT03590652|Experimental|ixazomib, daratumumab, pomalidomide and dexamethasone|Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.
89101609|NCT03587662|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|"INDUCTION: Patients receive ixazomib PO, gemcitabine IV over 90 minutes, and doxorubicin IV over 15-30 minutes on day 1. Treatment repeats every 14 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ixazomib PO and gemcitabine IV over 90 minutes. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
89101610|NCT03585270|Experimental|Clazosentan|Participants will receive clazosentan for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
89101611|NCT03585270|Placebo Comparator|Placebo|Participants will receive clazosentan matching-placebo for up to 14 days, followed by a safety follow-up period of 24 hours, and an extended follow-up period to the end-of-study visit at Week 24 post aneurysmal subarachnoid hemorrhage (aSAH).
89101612|NCT03535259|Experimental|Sorafenib and IMRT|Concurrent sorafenib and IMRT, followed sorafenib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
89101613|NCT03535077||Suspicious Nevi undergoing biopsy|Subject with suspicious Nevi undergoing biopsy per SOC
89101614|NCT03480594||Fatty Liver Patients|Hyperpolarized [13C] Pyruvate Injection in Fatty Liver patients
89101615|NCT03480594||Healthy Control Subjects|Hyperpolarized [13C] Pyruvate Injection in Healthy Control Subjects
89101616|NCT03475342|Active Comparator|Tranexamic acid|One intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
89101617|NCT03475342|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
89101618|NCT03447938|Active Comparator|CABG with sternotomy|Patients in this group will undergo coronary artery bypass grafting (CABG) in the usual way, through an incision in the middle of the chest, through the breastbone or sternum (conventional CABG).
89101619|NCT03447938|Experimental|Minimally-invasive CABG|Patients in this group will undergo coronary artery bypass grafting (CABG) using a minimally-invasive approach (MICS CABG), through smaller incisions between the ribs.
89101620|NCT03423017|Other|Pierre Robin sequence|"Infants with PRS : retrognathism, glossoptosis, cleft palate~Group 1a : isolated PRS Group 1b : PRS with bone disease or collagen disease (Stickler) Group 1c : syndromic PRS or associated PRS without bone disease or collagen disease"
89101621|NCT03423017|Other|Superior airway obstruction, AWO|Infants with AWO : laryngomalacia, tracheal stenosis, laryngeal stenosis, others etiology
89101622|NCT03423017|Other|Healthy infants|Healthy infants : siblings of sudden unexpected death of the infant
89101623|NCT03412773|Experimental|Arm A: Tislelizumab & Safety Run-In Substudy [Japan Only]|
89101624|NCT03412773|Active Comparator|Arm B: Sorafenib|
89101625|NCT03410043|Experimental|Group I (LCT)|Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89101626|NCT03410043|Experimental|Group II (no LCT)|Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89101627|NCT03392246|Experimental|Osimertinib + Selumetinib|"Selumetinib are to be administered orally intermittently (4 days on, 3 days off)~Osimertinib are to be administered orally on a daily basis"
89101628|NCT03383861||SSRI long-term user|Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
89101629|NCT03383861||Non-user|Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data.
89101630|NCT03301909|Experimental|PillCam™ Endoscopy System|"PillCam™ Endoscopy System consists of the following subunits:~PillCam™ Capsule products' family:~PillCam™ COLON 2~PillCam™ UGI (upper gastrointestinal)~PillCam™ SB3 (small bowel 3)~PillCam™ Crohn's capsule~Patency capsule: PillCam™ Patency capsule~All the bellow system subunits are part of the Pillcam™ systems:~PillCam™ Recorder~PillCam™ Sensor Arrays & Sensor Belt~PillCam™ Software v. 9~Workstation unit"
89101631|NCT03293147|Experimental|Arm A|Intervention group: Non-adherent hypertensive patients randomised in Arm A will receive standard clinical care plus HPLC-MS/MS-guided intervention.
89101632|NCT03293147|Active Comparator|Arm B|Control group: Non-adherent hypertensive patients randomised in Arm B will receive clinical standard care.
89101633|NCT03293147|Active Comparator|Arm C|Control group: Adherent hypertensive patients randomised in Arm C will receive clinical standard care.
89227680|NCT04009304|No Intervention|Control|
89227681|NCT00974324|Experimental|treatment|endostar combined with CHOP regimen
89230312|NCT03953365|No Intervention|without mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without prophylactic mesh
89230313|NCT03953365|Other|with mesh|Patients undergo to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with prophylactic mesh
89230314|NCT00798629|Experimental|Vaccine Dose Escalation|Dose Escalation: Intradermal DC Injection. Level 1: Cell Dose: 2 x 10^6 Level 2: Cell Dose: 1 x 10^7 Level 3: Cell Dose: 2 x 10^7
89227682|NCT00545714|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter [mg/m^2] as intravenous [IV] infusion on Day 0 of Cycle 1 and 500 mg/m^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m^2 on Days 1-3) and cyclophosphamide (250 mg/m^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
89227683|NCT00970658|Experimental|Salonsip|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
89227684|NCT00970658|Active Comparator|Sabiá|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
89227685|NCT00964730|Experimental|Talampanel|
89227686|NCT00964730|Placebo Comparator|Placebo|
89101634|NCT03292497|Experimental|Treatment algorithm|"Mitral valve will be replaced if posterior leaflet tethering angle >=25 degrees.~Mitral valve will be repaired if posterior leaflet tethering angle <25 degrees"
89101635|NCT03292497|Active Comparator|No treatment algorithm|Mitral valve will be repaired or replaced at surgeon's discretion.
89101636|NCT03265964|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 2000 mg daily by mouth for 4 weeks
89101637|NCT03265964|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 2000 mg daily by mouth for 4 weeks.
89101638|NCT03175432|Experimental|Arm I (atezolizumab, bevacizumab)|Participants receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89101639|NCT03175432|Experimental|Arm II (atezolizumab, bevacizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles with atezolizumab and bevacizumab repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive cobimetinib PO TID on days 1-21. Cycles with cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89101640|NCT03158129|Experimental|Arm A (nivolumab)|Participants receive nivolumab IV over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
89101641|NCT03158129|Experimental|Arm B (nivolumab, ipilimumab)|Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.
89101642|NCT03158129|Experimental|Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)|Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
89101643|NCT03158129|Experimental|Arm D (ipilimumab, nivolumab, chemotherapy)|Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
89101644|NCT03140150|Experimental|Active Group|A single visit 1 to 3 months after implantation then followed by the attending cardiologist.
89101645|NCT03140150|Other|Control Group|A first visit 1 to 3 months after implantation and then every 6 months or every year according to the recommendations of pacemaker follow-up (ie 2 or 4 systematic visits during the follow-up of 2 years).
89101646|NCT03138499|Experimental|Module A|Nivolumab combined with Brentuximab
89101647|NCT03138499|Experimental|Module B|Brentuximab alone
89101648|NCT03136185|Experimental|Ph 1/2a PMF: Bomedemstat 0.25 mg/kg/d|In the Phase 1/2a portion of the study, PMF participants received 0.25 mg/kg/d bomedemstat orally every day (qd) for 85 days during the Initial Treatment Period (ITP). Qualifying participants could continue to receive treatment for an additional 85 days during an Additional Treatment Period (ATP) as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89101649|NCT03136185|Experimental|Ph 1/2a PPV-MF: Bomedemstat 0.25 mg/kg/d|In the Phase 1/2a portion of the study, PPV-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 85 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89101650|NCT03136185|Experimental|Ph 1/2a PET-MF: Bomedemstat 0.25 mg/kg/d|In the Phase 1/2a portion of the study, PET-MF participants received 0.25 mg/kg/d bomedemstat orally qd for 85 days during the ITP. Qualifying participants could continue to receive treatment for an additional 85 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89101651|NCT03136185|Experimental|Ph 2b PMF: Bomedemstat 0.5 mg/kg/d|In the Phase 2b portion of the study, PMF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89101652|NCT03136185|Experimental|Ph 2b PPV-MF: Bomedemstat 0.5 mg/kg/d|In the Phase 2b portion of the study, PPV-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89101653|NCT03136185|Experimental|Ph 2b PET-MF: Bomedemstat 0.5 mg/kg/d|In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89101654|NCT03136185|Experimental|Ph 2b PMF: Bomedemstat 0.6 mg/kg/d|In the Phase 2b portion of the study, PMF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89227687|NCT00964730|Other|Moxifloxacin|
89227688|NCT00974402|Experimental|Patients with PTSD Symptoms|Patients with Post-Traumatic Stress Disorder (PTSD) symptoms willing to undergo Cognitive Behavioral Therapy in a primary care setting.
89101655|NCT03136185|Experimental|Ph 2b PPV-MF: Bomedemstat 0.6 mg/kg/d|In the Phase 2b portion of the study, PPV-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89101656|NCT03136185|Experimental|Ph 2b PET-MF: Bomedemstat 0.6 mg/kg/d|In the Phase 2b portion of the study, PET-MF participants received 0.6 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
89101657|NCT03085719|Experimental|High Dose Radiation + Pembrolizumab|"High dose radiation will be given in 3 fractions~Pembrolizumab administered intravenously on day one of each cycle."
89101658|NCT03085719|Experimental|High Dose + Low Dose Radiation + Pembrolizumab|"High Dose radiation will be given in 3 fractions~Low Dose Radiation will be given in 2 fractions~Pembrolizumab administered intravenously on day one of each cycle."
89101659|NCT03083353|Experimental|isradipine|Participants will receive 15mg of immediate release isradipine.
89101660|NCT03083353|Placebo Comparator|placebo|Participants will receive a placebo pill identical in appearance to isradipine.
89101661|NCT03049306|Placebo Comparator|Placebo Oral Tablet|"Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.~This visit is part of both the PROSAT 1.0 and PROSAT 2.0 study."
89101662|NCT03049306|Active Comparator|Propranolol Oral Tablet|"Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.~This visit is part of both the PROSAT 1.0 and PROSAT 2.0 study."
89101663|NCT03049306|Active Comparator|CPAP|"Subjects will be admitted to the clinical research unit. They will sleep wearing CPAP according to their usual home settings. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides.~This visit part of the PROSAT 1.0 study."
89101664|NCT02985957|Experimental|Cohort A (Arm A)|
89101665|NCT02985957|Experimental|Cohort B (Arm B)|
89101666|NCT02985957|Experimental|Cohort C (Arm C)|
89101667|NCT02985957|Experimental|Cohort D (Arm D1)|
89101668|NCT02985957|Experimental|Cohort D (Arm D2)|
89101669|NCT02985957|Experimental|Cohort D (Arm D3)|
89101670|NCT02985957|Experimental|Cohort D (Arm D4)|
89101671|NCT02966886|Active Comparator|Participants with 10-15 degrees of glenoid retroversion|
89101672|NCT02966886|Active Comparator|Participants with >15 degrees of glenoid retroversion|
89101673|NCT02955758|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
89101674|NCT02954874|Experimental|Arm I (observation)|Patients receive no treatment but are monitored at standard clinical intervals during first year after randomization. Patients are examined every 12 weeks for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment. Patients may also undergo collection of blood samples throughout the trial.
89101675|NCT02954874|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on days 1 and 22. Cycles repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment. Patients may also undergo collection of blood samples throughout the trial.
89101676|NCT02915523|Active Comparator|Entinostat plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on Day 1 and Day 8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
89101677|NCT02915523|Placebo Comparator|Placebo plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on Day 1 and Day 8 of each cycle.
89101678|NCT02903940||CRT+NAVH|Surface ECG recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings.
89101679|NCT02890355|Experimental|Arm I (veliparib and mFOLFIRI)|Patients receive veliparib PO BID every 12 hours on days 1-7, irinotecan hydrochloride IV over 90-120 minutes on day 3, leucovorin calcium IV over 90-120 minutes on day 3, and fluorouracil IV over 46 hours on days 3-5.
89101680|NCT02890355|Active Comparator|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 90-120 minutes on day 1, leucovorin calcium IV over 90-120 minutes on day 1, and fluorouracil IV bolus over 15 minutes on days 1 and then over 46 hours on days 1-3.
89101681|NCT02888743|Experimental|Arm A (tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.
89230315|NCT04046705|Experimental|HLA matched haematopoietic stem cell transplantation|Peripheral blood stem cell from matched HLA related donor.
89227689|NCT00539838|Experimental|Ocrelizumab 1000 mg|Ocrelizumab was administered i.v. at a dose on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks
89101682|NCT02888743|Experimental|Arm B (tremelimumab, Durvalumab, RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.
89101683|NCT02888743|Experimental|Arm C (tremelimumab, durvalumab, and RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.
89101684|NCT02844816|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles (51 weeks) in the absence of disease progression or unacceptable toxicity.
89101685|NCT02782598||CRT+NAVH|Surface ECG and pressure-volume loop recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings at the device implant procedure
89101686|NCT02745002|Experimental|navigated bronchoscopy|
89101687|NCT02664545|Experimental|Bridge-Enhanced ACL Repair (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into.
89101688|NCT02664545|Active Comparator|Tendon Graft|ACL reconstruction is when a tendon graft (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee) is taken and used to replace the torn ACL.
89101689|NCT02645851|Experimental|"PLR-induced SV changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Stroke Volume (SV) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if SV changes ≥10%, or no administration otherwise. Measurement of beat-to-beat stroke volume by intraarterial pulse contour analysis using the PiCCO system (Pulsion, Germany) will be used to assess stroke volume changes. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
89101690|NCT02645851|Experimental|"PLR-induced PP changes based strategy"|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the final decision to administer or not the fluid bolus will be determined by the percentage changes in Pulse Pressure (PP) observed during a 1-min Passive Leg Raising test: Administration of the fluid bolus if PP changes ≥10%, or no administration otherwise. We will perform measurement of intraarterial blood pressure using vascular pressure transducers (Edwards Life Science, USA). Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
89101691|NCT02645851|Other|Usual Care|During the intervention period (i.e., within 120 hrs following inclusion), every time a fluid bolus is deemed necessary to improve the patient's cardiac output, the fluid bolus will be administered without measurement of any predictive index of fluid responsiveness. Per protocol inclusion criteria, patients will be carrying central venous and artery catheters.
89101692|NCT02595424|Experimental|Arm A (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89101693|NCT02595424|Active Comparator|Arm B (cisplatin, carboplatin, etoposide)|Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89101694|NCT02581930|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89101695|NCT02568553|Experimental|Treatment (blinatumomab, lenalidomide)|"INDUCTION: Patients receive blinatumomab IV continuously on days 1-56 and lenalidomide PO on days 29-49 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving response including stable disease receive blinatumomab IV continuously on days 1-7 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receiving response including stable disease after completion of Consolidation receive lenalidomide PO on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
89101696|NCT02567409|Experimental|Arm A (berzosertib, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 60 minutes on day 1. Patients also receive berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
89101697|NCT02567409|Experimental|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride and cisplatin as in Arm A.
89101698|NCT02527044|Experimental|Functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered functional for score of 3."
89101699|NCT02527044|Active Comparator|Non functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered non functional for scores of 0 to 2."
89101700|NCT02521103|Other|Triathlon Tritanium Cone Augments|Cases who receive the Triathlon TS Total Knee System with at least one Triathlon Tritanium Cone Augment
89101701|NCT02513563|Experimental|Carboplatin/Paclitaxel/AZD1775|Treatment: Combination of AZD1775 plus carboplatin and paclitaxel. Participants will be treated with this combination of drugs twice daily on days 1 and 2 and once on day 3 for a total of 5 doses during each 21 day cycle of treatment.
89101702|NCT02496585|Experimental|Nintedanib + Prednisone|The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
89101703|NCT02496585|Experimental|Placebo + Prednisone|Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).
89101704|NCT02479841|Experimental|self management program|Participation in an 11 week self-management program
89101705|NCT02479841|No Intervention|Control group|
89101706|NCT02473536|Experimental|Stereotactic ablative radiation therapy|SABR
89101707|NCT02466971|Active Comparator|Arm I (cisplatin, IMRT or RT, brachytherapy)|Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, 30, (and day 36 or 37 at the treating physician's discretion). Patients then undergo EBRT (either conventional RT or IMRT) QD 5 days a week for 25 fractions followed by LDR or HDR brachytherapy according to institution's standards. Treatment continues in the absence of disease progression or unacceptable toxicity.
89101708|NCT02466971|Experimental|Arm II (cisplatin, IMRT or RT, brachytherapy, triapine)|Patients receive cisplatin and undergo EBRT followed by brachytherapy as in Arm I. Patients also receive triapine IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Treatment continues in the absence of disease progression or unacceptable toxicity.
89101709|NCT02443545|Experimental|Group 1: Deferiprone 3 years|Patients in this group are those who were randomized to the deferiprone arm in study LA38-0411, and hence will receive deferiprone for a total of 3 years (1 year in the initial study plus 2 years in the extension study).
89101710|NCT02443545|Experimental|Group 2: Deferiprone 2 years|Patients in this group are those who were randomized to the deferoxamine arm in study LA38-0411, and hence will receive deferiprone for 2 years (both of them in the extension study).
89101711|NCT02432183||Football players|Football players of the first grade of high school are recruited from the topsportschool in Leuven.
89101712|NCT02432183||Basketball players|Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
89101713|NCT02432183||Swimmers|Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
89101714|NCT02432183||Control group|Age-matched controls are recruited (exercising at a recreational level, >4 hours).
89101715|NCT02388906|Experimental|Ipilimumab and Placebo matching Nivolumab|
89101716|NCT02388906|Experimental|Nivolumab and Placebo matching Ipilimumab|
89101717|NCT02375555|Experimental|Elotuzumab, lenalidomide, bortezomib, and dexamethasone|"Participants will receive therapy with the combination of lenalidomide, bortezomib, and dexamethasone and elotuzumab (E-RVD). Induction cycles (1 to 8) are 21-day cycles.~Elotuzumab will be administered by intravenous (IV) infusion~Bortezomib as a subcutaneous injection~Lenalidomide single daily oral dose~Dexamethasone as oral tablets and IV infusion~Stem cell mobilization will be performed for all subjects at the end of Cycle 4.~Subjects may elect to stop E-RVD at the end of Induction Cycle 4 and proceed to autologous SCT. Subjects who do not proceed to SCT may receive a full 8 cycles of induction therapy.~The maintenance schedule (28 days) will start after 8 cycles of induction regimen for subjects not proceeding with SCT, or after recovery from SCT for subjects proceeding with it.~Maintenance therapy with E-RVD will be administered to all patients, with the specific maintenance regimen determined by risk category."
89101718|NCT02330952|Experimental|Prednisone|
89101719|NCT02330952|Placebo Comparator|Placebo|
89101720|NCT02308852|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the brain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform motor bimanual tasks"
89101721|NCT02308852|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
89101722|NCT02299999|Experimental|Substudy 1: targeted agent|Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
89101723|NCT02299999|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
89101724|NCT02299999|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
89101725|NCT02299999|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
89101726|NCT02271243||Subject with suspected MBI|
89101727|NCT02271243||Subjects without suspected MBI|
89101728|NCT02251548|Experimental|Ibrutinib|"- Ibrutinib-~Oral, daily during each cycle~fludarabine-administered at standard dosing for up to 6 cycles~cyclophosphamide-administered at standard dosing for up to 6 cycles~rituximab-administered at standard dosing for up to 6 cycles"
89101729|NCT02193282|Experimental|Arm A (blinded erlotinib hydrochloride)|Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
89101730|NCT02193282|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)
89101731|NCT02193282|Experimental|Arm C (unblinded erlotinib hydrochloride)|Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89101732|NCT02193282|Active Comparator|Arm D (observation)|Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.
89101733|NCT02152982|Experimental|Arm I (temozolomide, veliparib)|Patients receive temozolomide PO QD on days 1-5 and veliparib PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity.
89101734|NCT02152982|Placebo Comparator|Arm II (temozolomide, placebo)|Patients receive temozolomide as in Arm I and placebo PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity.
89101735|NCT02143245|Other|Revision Population|"The study population is both men and women who have had previous shoulder surgery with symptoms suggestive of deep infection. These include the presence of pain, stiffness, and radiologic signs of infection including implant lucencies or migration.~Patients in this population will undergo a synovial biopsy, in addition to undergoing an open tissue biopsy at the time of their procedure. Diagnostic accuracy will be compared, and all participants will be tracked over time."
89101736|NCT02129348|Active Comparator|Lithium Treatment Group|"The patient will be started on lithium 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on lithium blood level. Blood will be drawn at each study visit. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
89101737|NCT02129348|Placebo Comparator|Placebo Group|"The patient will be started on placebo 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on sham lithium blood level. Blood will be drawn for sham lithium levels at weeks 2, 4, 6, 8, and 12. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
89101738|NCT02117167|Experimental|Substudy 1: targeted agent|Arm A1/ targeted arm: targeted maintenance from a list of targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, olaparib tablet per os 300 mg bd continuous dosing savolitinib tablet per os 600 mg od continuous dosing
89101739|NCT02117167|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
89101740|NCT02117167|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with durvalumab for patient without actionable genomic alterations or non eligible to Targeted substudy 1, durvalumab Intra-venous 10 mg/kg, Q2W
89101741|NCT02117167|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
89101742|NCT02112526|Experimental|Acalabrutinib|
89101743|NCT02106988|Experimental|Chemotherapy + Radiation Therapy|"Radiation therapy delivered for a total dose of 50.4 to 54 Gy over 28 to 30 treatments. Within seven days of starting radiotherapy, the first cycle of chemotherapy started and repeated every 3 weeks for a total of 3 cycles.~DeVIC on day 1 of every cycle. Dexamethasone 40 mg by vein Days 1-3, Etoposide 67 mg/m2 by vein on Days 1-3, Ifosfamide 1 g/m2 by vein on Days 1-3, Mesna 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, Mesna 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump, Carboplatin 200 mg/m2 by vein on Day 1. Cycles repeated every 21 days."
89101744|NCT02101788|Active Comparator|Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)|Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.
89101745|NCT02101788|Experimental|Arm B (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89101746|NCT02100280|Experimental|deep block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block.
89101747|NCT02100280|No Intervention|moderate block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
89101748|NCT02060227|Active Comparator|Arthroscopic Bankart repair|After the diagnostic arthroscopy is completed, any other pathology is documented. At least 3 anchors will be used for the bankart repair for repair of the labrum with an inferior to superior capsular shift. The suture anchors used will be at the discretion of the surgeon but will be of the screw-in variety. The sutures are passed through the labrum, and the labrum is tied to the glenoid rim after the bone is prepared in the standard fashion. The surgical times will be recorded on standardized forms.
89101749|NCT02060227|Active Comparator|Open Latarjet procedure|A deltopectoral approach is used. The coracoacromial ligament (CAL) is exposed and incised 1 cm from its coracoid attachment. Harvesting of a 2.5- to 3-cm coracoid graft allows use of 2 screws for fixation to the glenoid neck through a subscapularis-splitting approach. The stump of the CAL is repaired to the capsule with the arm positioned in neutral. The graft is placed in a extra-articular fashion with capsular closure to the native glenoid rim.
89101750|NCT02016872|Experimental|18F-FMISO PET/CT|All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.
89101751|NCT01950390|Active Comparator|Arm A (ipilimumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning cycle 8, patients receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
89101752|NCT01950390|Experimental|Arm B (ipilimumab and bevacizumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive bevacizumab as in Induction Therapy. Beginning cycle 8, patients also receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
89101753|NCT01935934|Experimental|Treatment (cabozantinib s-malate)|Patients receive 60 mg cabozantinib s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89101754|NCT01928394|Experimental|Arm N - Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89101755|NCT01928394|Experimental|Arm N-I, Level 1: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 1 mg/kg solution every 3 weeks for 4 doses followed by Nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89101756|NCT01928394|Experimental|Arm N-I, Level 2: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89101757|NCT01928394|Experimental|Arm N-I, Level 2b: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously plus Ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89101758|NCT01928394|Experimental|Arm N-I, Level 2c: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89101759|NCT01928394|Experimental|Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks and cobimetinib 60mg once daily 21days on/7 days off until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89101760|NCT01864018|Experimental|Treatment (ixazomib citrate, cyclophosphamide, dexamethasone)|"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89101761|NCT01850108|Experimental|Non-Myeloablative Conditioning and Bone Marrow Transplantation|
89101762|NCT01844505|Experimental|Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89101763|NCT01844505|Experimental|Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab|Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89101764|NCT01844505|Experimental|Arm C: Ipilimumab+Placebo for Nivolumab|Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends (Placebo matching with Nivolumab is no longer required)
89101765|NCT01796171|Experimental|Part A, Arm 1: 10 MBq/kg Betalutin with lower dose lilotomab pre-dosing|10 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
89101766|NCT01796171|Experimental|Part A, Arm 1: 15 MBq/kg Betalutin with lower dose lilotomab pre-dosing|15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
89101767|NCT01796171|Experimental|Part A, Arm 1: 20 MBq/kg Betalutin with lower dose lilotomab pre-dosing|20 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
89101768|NCT01796171|Experimental|Part A, Arm 2: 10 MBq/kg Betalutin with no pre-dosing|10 MBq/kg (based on body weight) Betalutin without pre-dosing
89101769|NCT01796171|Experimental|Part A, Arm 2: 15 MBq/kg Betalutin with no pre-dosing|15 MBq/kg (based on body weight) Betalutin without pre-dosing
89101770|NCT01796171|Experimental|Part A, Arm 3: 15 MBq/kg Betalutin with rituximab pre-dosing|15 MBq/kg (based on body weight) Betalutin with rituximab pre-dosing
89101771|NCT01796171|Experimental|Part A, Arm 4: 15 MBq/kg Betalutin with higher dose lilotomab pre-dosing|15 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
89101772|NCT01796171|Experimental|Part A, Arm 4: 20 MBq/kg Betalutin with higher dose lilotomab pre-dosing|20 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
89101773|NCT01796171|Experimental|Part A, Arm 5: 20 MBq/kg Betalutin with intermediate dose lilotomab pre-dosing|20 MBq/kg (based on body weight) Betalutin with 60 mg/m2 (based on body surface area) lilotomab pre-dosing
89101774|NCT01796171|Experimental|Part B, Arm 1: 15 MBq/kg Betalutin with lower dose lilotomab pre-dosing|15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
89101775|NCT01796171|Experimental|Part B, Arm 2: 20 MBq/kg Betalutin with higher dose lilotomab pre-dosing|20 MBq/kg (based on body weight) Betalutin with 100 mg/m2 (based on body surface area) lilotomab pre-dosing
89101776|NCT01796171|Experimental|Part B, Arm 3: 12.5 MBq/kg Betalutin with lower dose lilotomab pre-dosing|12.5 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
89101777|NCT01796171|Experimental|Part C: 15 MBq/kg Betalutin with lower dose lilotomab pre-dosing|15 MBq/kg (based on body weight) Betalutin with 40 mg lilotomab pre-dosing
89101778|NCT01736592|Other|Long Term Follow up|Long term follow up in all patients who received SAR422459 in previous study TDU13583
89101779|NCT01690156||Parallel Probe Position|Performing the simulated interscalene block with the ultrasound probe parallel to the shoulders of the person performing the block
89101780|NCT01690156||Perpendicular Probe Position|Performing the simulated interscalene block with the ultrasound probe perpendicular to the shoulders of the person performing the block
89101781|NCT01620944|Experimental|Arm1: ATV/RTVHS+3TC|
89101782|NCT01620944|Active Comparator|Arm2: ATV/RTVHS+TDF/FTC|
89101783|NCT01544699|Active Comparator|Real stimulation|real tDCS (well, that's the way it is I am not gonna change it)
89101784|NCT01544699|Sham Comparator|Sham|sham tDCS
89101785|NCT01522976|Experimental|Arm I (azacitidine and lenalidomide)|Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
89101786|NCT01522976|Experimental|Arm II (azacitidine)|Patients receive azacitidine as in Arm I. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
89101787|NCT01522976|Experimental|Arm III (azacitidine and vorinostat)|Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
89101788|NCT01444469|Experimental|Azithromycin (Zithromax)|500 mg of azithromycin (2×250mg capsules)
89101789|NCT01444469|Placebo Comparator|Placebo|Placebo
89101790|NCT01371981|Experimental|Arm A|See Detailed Description
89101791|NCT01371981|Experimental|Arm B|See Detailed Description
89101792|NCT01371981|Experimental|Arm C (Cohort 1)|See Detailed Description
89101793|NCT01371981|Experimental|Arm C (Cohort 2)|See Detailed Description.
89101794|NCT01371981|Experimental|Arm C (Cohort 3)|See Detailed Description. Different dose.
89101795|NCT01371981|Experimental|Arm D|See Detailed Description. May reassigned to Arm C.
89101796|NCT01345851|Experimental|Treatment (dose-escalation of RT)|Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks followed by 5 fractions of hypofractionated RT boost. Patients also receive standard carboplatin and paclitaxel for 3 weeks.
89101797|NCT01274338|Experimental|Arm A (age >= 18, high-dose ipilimumab)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity. (closed accrual as of 4/4/14) (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
89227690|NCT00539838|Experimental|Ocrelizumab 400 mg|Ocrelizumab was administered at a dose 400 mg i.v. on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks
89101798|NCT01274338|Experimental|Arm B (age >= 18, recombinant interferon alfa-2b)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
89101799|NCT01274338|Experimental|Arm C (age >= 18, low-dose ipilimumab)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cyclees in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
89101800|NCT01274338|Experimental|Arm D (age 12-17, high-dose ipilimumab)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity.
89101801|NCT01274338|Experimental|Arm E (ages 12-17, recombinant interferon alfa-2b)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
89101802|NCT01274338|Experimental|Arm F (ages 12-17, low-dose ipilimumab)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 cycles in the absence of disease progression or unacceptable toxicity. (ages 12-17)
89101803|NCT01272037|Experimental|Arm I (chemotherapy and endocrine therapy)|Patients receive a protocol-approved chemotherapy regimen based on the patient and/or physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
89101804|NCT01272037|Experimental|Arm II (endocrine therapy)|Patients receive a protocol-approved endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
89101805|NCT01199575|Experimental|Revlimid + Rituximab|"A: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.~Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity."
89101806|NCT01194570|Experimental|Placebo|Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
89101807|NCT01194570|Placebo Comparator|Ocrelizumab 600 mg|Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.
89101808|NCT01169922|Experimental|SEXUAL PLUS ALCOHOL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction as well as alcohol risk reduction.
89101809|NCT01169922|Active Comparator|INFORMATION-ONLY SEXUAL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction only.
89101810|NCT01169337|Experimental|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89101811|NCT01169337|Active Comparator|Arm B (observation)|Patients undergo observation until progression to symptomatic myeloma.
89227691|NCT00539838|Placebo Comparator|Placebo|Placebo infusions were administered on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks
89101812|NCT01064648|Experimental|Arm I (pemetrexed disodium, cisplatin, cediranib maleate))|Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
89101813|NCT01064648|Active Comparator|Arm II (pemetrexed disodium, cisplatin, placebo)|Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.
89101814|NCT00980460|Experimental|High-risk group (regimen H)|Patients receive up front VIT chemotherapy comprising vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8. Treatment with VIT repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with disease response then receive 6 courses of C5VD with 4 courses of VIT in between each 2-course block. Patients with no disease response receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection or liver transplant after course 4 of C5VD followed by 2 courses of adjuvant C5VD. Patients may also receive dexrazoxane IV over 5-15 minutes on days 1-2 of courses 5 and 6.
89101815|NCT00980460|Experimental|High-risk group (regimen W)|(regimen W replaced by regimen H as of Amendment 3B) Patients receive up front VI chemotherapy comprising vincristine sulfate IV on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5. Treatment with VI repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with disease response then receive 6 courses of C5VD with 1 courses of VI in between each 2-course block. Patients with no disease response receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity.
89101816|NCT00980460|Experimental|Intermediate-risk group (regimen F)|Patients receive C5VD chemotherapy comprising cisplatin IV over 6 hours on day 1, fluorouracil IV over 2-4 minutes on day 2, vincristine sulfate IV over 1 minute on days 2, 9, and 16, and doxorubicin hydrochloride IV over 15 minutes on days 1-2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo surgical resection after course 2 OR surgical resection or liver transplantation after course 4 of C5VD. Patients may also receive dexrazoxane IV over 5-15 minutes on days 1-2 of courses 5 and 6. (Closed to accrual as of 3/12/2012)
89101817|NCT00980460|Experimental|Low-risk group (regimen T)|Patients undergo surgery and then receive adjuvant cisplatin IV over 6 hours on day 1, fluorouracil IV over 2-4 minutes on day 2, and vincristine sulfate IV over 1 minute on days 2, 9, and 16. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
89101818|NCT00980460|Experimental|Very low-risk group|Patients undergo surgery and then receive no further treatment.
89101819|NCT00977574|Experimental|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89101820|NCT00977574|Experimental|Arm II (paclitaxel, carboplatin, temsirolimus)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89101821|NCT00977574|Experimental|Arm III (ixabepilone, carboplatin, bevacizumab)|Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89101822|NCT00972478|Experimental|Treatment (combination chemotherapy)|Patients receive vorinostat PO once daily on days 1-5 or 1-9 (according to dose level), rituximab IV, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
89101823|NCT00900575|Experimental|Colposcope|Patients referred for GYN procedures. Specifically, patients will be referred for Pap smear, colposcope or LEEP. The intervention for this arm is the use of the bench-top, miniature optical spectrometer or trans-vaginal colposcope
89101824|NCT00858884|No Intervention|No intevention|No intervention
89101825|NCT00843882|Active Comparator|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Patients undergo bone marrow biopsy at screening and during follow-up. Patients undergo blood specimen collection on study.
89101826|NCT00843882|Experimental|Arm B (lenalidomide, epoetin alfa)|Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly. Patients undergo bone marrow biopsy at screening and during follow-up. Patients undergo blood specimen collection on study.
89101827|NCT00769379|Experimental|Arm I (standard WBI)|Patients undergo standard WBI over 5-6 weeks.
89101828|NCT00769379|Experimental|Arm II (WBI, trastuzumab)|Patients receive trastuzumab IV over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I.
89101829|NCT00750841|Experimental|1|Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
89101830|NCT00658814|Experimental|Treatment (azacitidine, gemtuzumab)|See Detailed Description
89101831|NCT00644228|Active Comparator|Arm I (dexamethasone and lenalidomide)|Patients receive dexamethasone PO QD on days 1, 8, 15, and 22 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89101832|NCT00644228|Experimental|Arm II (dexamethasone, lenalidomide, bortezomib)|Patients receive dexamethasone PO QD on days 1, 2, 4, 5, 8, 9, 11, and 12; lenalidomide PO QD on days 1-14; and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
89101833|NCT00618553|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation - Rehabilitation treatment given over about 3-4 weeks. Questionnaire regarding quality-of-life that lasts about 30 minutes.
89101834|NCT00470223|Experimental|Chemotherapy + zoledronic acid|
89101835|NCT00470223|Active Comparator|chemotherapy|
89101836|NCT00324805|Active Comparator|Arm I (chemotherapy)|"Patients receive one of the following. For all, treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~REGIMEN 1: Vinorelbine ditartrate 30 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV over 60 minutes on day 1 REGIMEN 2: Docetaxel 75 mg/m2 IV and cisplastin 75 mg/m2 IV on day 1 REGIMEN 3: Gemcitabine hydrochloride 1200 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV on day 1 REGIMEN 4 (non-squamous histology only): Pemetrexed disodium 500mg/m2 IV and cisplatin 75 mg/m2 IV on day 1"
89101837|NCT00324805|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive chemotherapy as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 1 year.
89101838|NCT00248040|Experimental|reparixin group - continuous infusion|"Continuous iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.~A dose of 2.772 mg/kg/h was administered for12 hours."
89101839|NCT00248040|Experimental|reparixin group - intermittent infusion|"Intermittent iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.~A dose of 2.244 mg/kg was administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were administered over a total period of 22.5 hours."
89101840|NCT00248040|Placebo Comparator|placebo infusion|Continuous/intermittent iv infusion of a volume/schedule matched saline into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.
89101841|NCT04288440|Active Comparator|Silicone filled eyes|Eyes filled with silicone oil
89101842|NCT04288440|Active Comparator|Idiopathic ERM|Eyes not filled with silicone oil
89101843|NCT02866032|Experimental|MOB015B|
89101844|NCT02866032|Active Comparator|Ciclopirox 80 mg/g|
89101845|NCT00629460||1|there is only one group/cohort. This is a non-therapeutic study.
89101846|NCT00976716|Experimental|Celecoxib|
89101847|NCT03842982|Experimental|Arm A (PDS or IDS + HIPEC)|"Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy)~Patients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).~Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care."
89101848|NCT03842982|No Intervention|Arm B (PDS or IDS)|"Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy ONLY (standard care, without HIPEC)~Patients in the control group will ONLY receive the standard care, which consists of surgery (PDS or IDS) with Neo and/or Adjuvant chemotherapy (CT). Patients undergoing PDS will be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).~Patient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care."
89101849|NCT05757349|Experimental|Face-down position time 1-day group|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
89101850|NCT05757349|Active Comparator|Face-down position time 3-day group|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
89101851|NCT00973674|Experimental|Premarin IV|Patients randomized to receive a single dose of 0.5 mg/kg Premarin® IV
89101852|NCT00973674|Placebo Comparator|Placebo|Patients randomized to receive a single dose of placebo IV. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with traumatic brain injury.
89101853|NCT00819091|Active Comparator|BI 1356|5 mg orally (po) once daily
89101854|NCT00819091|Placebo Comparator|Placebo|one tablet once daily
89101855|NCT04288596||Eligible for Registry|All consecutive patients who undergo any of the five ACHDi interventions (complex catheterization, ASD closure, PFO closure, CoA stenting, and PPVI) at the time of Registry launch, who have also consented to participate.
89101856|NCT04287270|Other|Assesment of MSA patients and healthy controls|Demographic information (sex, age, occupation, height, bodyweight ...), clinical and medical status, diagnosis date and Mini-Mental Status Scale data of all participants will be recorded at the first visit. Inspiratory muscle strength will be evaluated with sniff nasal inspiratory pressure and maximal inspiratory mouth pressure, expiratory muscle strength will be evaluated with expiratory mouth pressure. Also, the pulmonary function test will be applied.
89101857|NCT04287114|Experimental|Healthy young men and women|Single group consisting of 10 men and 10 women
89101858|NCT04286724|Experimental|Intervention|
89101859|NCT00973362|Other|Adjunct (i.e. Normal Pap)|The Adjunct study will evaluate APTIMA HPV Assay clinical performance for detecting high-risk HPV types in female subjects 30+ years of age with negative (NILM) cytology results from routine Pap testing. This will be accomplished by evaluating the assay performance compared to known cervical disease status at baseline and after a 3-year follow-up period. A comparator FDA-Approved HPV DNA test is reported.
89101860|NCT00973362|Other|ASC-US|The ASC-US study will evaluate the APTIMA HPV Assay clinical performance for detecting high-risk HPV types in subjects with ASC-US Pap test results from routine Pap testing and known cervical disease status (based on colposcopic biopsy results). A comparator FDA-Approved HPV DNA test is reported. There is no follow-up period.
89101861|NCT00629694|Active Comparator|A-T|
89101862|NCT00629694|Experimental|A-M|
89101863|NCT04289766|Active Comparator|Conventional Treatment|Conventional Treatment includes exercises limbs
89101864|NCT04289766|Experimental|Focal Muscle Vibration (120Hz)|"Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 120 Hz.~Conventional Treatment"
89101865|NCT04289766|Experimental|Focal Muscle Vibration (60Hz)|"Each session will span 40 minutes plus 10 of Focal Muscle vibration for each muscle at a frequency of 60 Hz.~Conventional Treatment"
89101866|NCT00819013|Experimental|Study Group 1|ACAM-FLU-A low dose + Adjuvant 1
89101867|NCT00819013|Experimental|Study Group 2|ACAM-FLU-A low dose + Adjuvant 2
89101868|NCT00819013|Experimental|Study Group 3|ACAM-FLU-A low dose
89101869|NCT00819013|Placebo Comparator|Study Group 4|Saline placebo
89101870|NCT00976560|Experimental|GW856553|GW856553 7.5 mg BID
89101871|NCT00976560|Placebo Comparator|Placebo|Matching Placebo BID
89101872|NCT02610049|Active Comparator|Control|Subjects will receive 8 sessions of Cognitive Processing Therapy.
89101873|NCT02610049|Experimental|Experimental|Subjects will receive 8 sessions of CPT + Art Therapy 8 sessions of individual therapy.
89101874|NCT02610049|Experimental|Experimental 2|Subject to receive 8 sessions of individual therapy for Art + CPT Cognitive Processing Therapy intervention pre-specified to be administered separately.
89101875|NCT05755867||PNH Patients|Individuals of any age with a confirmed diagnosis of PNH or diagnosis consistent with PNH are eligible for inclusion.
89101876|NCT00976482||Pacemaker|Patients currently implanted with permanent Pacemaker according to guidelines
89101877|NCT04868461|Active Comparator|Unheated whey protein (UWP)|"Participants are given a preload of 200 mL of unheated whey protein (UWP) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
89101878|NCT04868461|Active Comparator|Heated whey protein (HWP)|"Participants are given a preload of 200 mL of heated whey protein (HWP) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
89101879|NCT04868461|Active Comparator|Casein (Cas)|"Participants are given a preload of 200 mL of Casein (Cas) in the morning, on a fasting state. After 30 minutes after the preload, participants are given ad libitum breakfast. They are asked to eat as much or as little as they want, until they feel comfortably full."
89101880|NCT04868461|Placebo Comparator|Water|The water has the same banana flavor and sweetness to match the protein beverages. Participants receive the same amount of water like protein beverages - 200mL.
89101881|NCT02865642|Experimental|Serotonin Uptake Inhibitors|"Treatment 1: Starting with Escitalopram 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage increase of 5mg/day till target dose of Escitalopram 20mg/day.~Subjects will remain on Escitalopram 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by dosage reduction of Escitalopram 10mg/day for one week."
89101882|NCT02865642|Placebo Comparator|Placebo|"Treatment 2: Starting with Placebo 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage of 5mg/day till target dose of Placebo 20mg/day.~Subjects will remain on Placebo 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by Placebo 10mg/day for one week."
89101883|NCT03774888|Experimental|connective tissue graft|Connective tissue grafting (CTG) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
89101884|NCT03774888|Experimental|Acellular Dermal Matrix|Acellular Dermal matrix (ADM) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
89101885|NCT03774888|Active Comparator|No soft tissue graft|Control group where no soft tissue graft is added to the lateral ridge augmentation.Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
89101886|NCT04204590|Other|Participants|The aim of this study is to test the feasibility of this algorithm as an intervention to carry out deprescribing a targeted medication group, proton pump inhibitors (PPI's) and statins, among nursing home residents.
89101887|NCT02863224||Healthy control|
89101888|NCT02863224||Ocular hypertension|
89101889|NCT02863224||Primary open angle glaucoma|
89101890|NCT02863224||Normal tension glaucoma|
89101891|NCT04030975||interview|emergency physicians
89227692|NCT00964808|Experimental|Buprenorphine|Double dummy; Group A: Active Buprenorphine and placebo oxycodone
89101892|NCT03762564|Experimental|Arm A (Paclitaxel + Ramucirumab)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 plus Ramucirumab 8 mg/kg as 1 hour intravenous infusion on day 1 and 15 qd 28
89101893|NCT03762564|Active Comparator|Arm B (control arm)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 qd 28
89101894|NCT00975156|Experimental|Lokomat Intervention|Lokomat gait training (five days a week for eight weeks for a total of 40 sessions).
89101895|NCT00975156|Active Comparator|Standard of Care|Conventional physical therapy focusing on gait training for five days a week for eight weeks for a total of 40 sessions.
89101896|NCT02610205||Caring touch interventions|The study was conducted as a mixed-methods design. A recruitment of potential study participants was made up from a list of incoming patients arriving at the emergency department following an MVA, and who upon medical examinations were given an injury severity score between 0-3 and subsequently discharged straight home. ISS is a 0-8 point scale rating injury severity, where a rating of 0 indicates no physical injury; 1-3 represents minor physical injuries. The patients were informed about the study by mail during the week after the MVA, and those interested in participating in the caring touch intervention were asked to contact the investigator and subsequently completed a written informed consent form during the first encounter with the therapist.
89101897|NCT04204746||3 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
89101898|NCT04204746||6 lt/min|Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
89101899|NCT00629616|Experimental|Arm A|Anastrozole
89101900|NCT00629616|Experimental|Arm B|Fulvestrant
89101901|NCT02609971|Experimental|Vibration group|The vibration group (Vibration at 50 Hz) will hold an exercise protocol on the vibration platform (model Power Plate® pro5 ™), which is to stay on on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
89101902|NCT02609971|No Intervention|Control group|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
89101903|NCT04832737|Experimental|Intervention|SDT theory-based psychotherapeutic treatment model
89101904|NCT04832737|No Intervention|Control|Wait List
89101905|NCT02864628|Experimental|Group 1|≥55 year old healthy subjects, receiving either 5x10E7 TCID50 MVA-BN-RSV or Placebo intranasal application
89101906|NCT02864628|Experimental|Group 2|≥55 year old healthy subjects, receiving either 1x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
89101907|NCT02864628|Experimental|Group 3|≥55 year old healthy subjects, receiving either 5x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
89101908|NCT02864628|Experimental|Group 4|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intranasal and intramuscular application
89101909|NCT02864628|Experimental|Group 5|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intramuscular application
89101910|NCT00810043|Active Comparator|Curette-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, curettage was performed prior to use of inflatable bone tamps.
89101911|NCT00810043|Active Comparator|IBT-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, inflatable bone tamps were used prior to curettage, then followed by a second inflation of the bone tamps.
89101912|NCT04807933|Experimental|Experimental group (BFB training)|The participants assigned to the experimental group will do the biofeedback training using the Emwave software during the intervention period (T2-T3). The biofeedback software (Emwave Pro®) includes a photoplethysmography sensor that can be positioned on the earlobe. The installation of the program and the explanations needed for using it, will be done during the second session (T2). According to the guidelines, a fractional training is proposed 5 minutes, 3 times a day for 24 days (T2-T3).
89101913|NCT04807933|No Intervention|Control group (no BFB training)|The participants assigned to the experimental group will not do a specific exercise during the intervention period (T2-T3).
89101914|NCT01120028|Experimental|Alemtuzumab/Sirolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
89101915|NCT01120028|Experimental|Alemtuzumab/Tacrolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
89101916|NCT01120028|Active Comparator|Basiliximab/Tacrolimus|"Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
89101917|NCT01120028|Active Comparator|Basiliximab/Sirolimus|"Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
89101918|NCT00878800|Experimental|Experimental: PXD101 and doxorubicin (BelDox)|5-day PXD101 IV schedule with dose escalation combined with 1 day doxorubicin dose escalation IV
89101919|NCT02884076||Symptomatic Hemorrhoid|Consecutive patients with symptomatic hemorrhoids presenting to our clinic
89101920|NCT00662194||1|HIV-HBV co-infected and receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
89101921|NCT00662194||2|HIV-HBV co-infected and receiving ART and CD4 count 200-500 cells/mm3
89101922|NCT00662194||3|HIV-HBV co-infected and receiving ART and CD4 count <200cells/mm3
89101923|NCT00662194||4|HIV-HBV co-infected and not receiving ART
89101924|NCT00662194||5|HIV-HCV co-infected & receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
89101925|NCT00662194||6|HIV-HCV co-infected and receiving ART and CD4 count 200-500 cells/mm3
89101926|NCT00662194||7|HIV-HCV co-infected and receiving ART and CD4 count <200cells/mm3
89101927|NCT00662194||8|HIV-HCV co-infected and not receiving ART
89101928|NCT00662272|Experimental|1|Arm includes treatment with Fluzone® vaccine mixed with study product JVRS-100 adjuvant
89101929|NCT00662272|Active Comparator|2|Arm includes treatment with half adult dose of Fluzone® vaccine
89101930|NCT00662272|Active Comparator|3|Arm includes treatment with full adult dose Fluzone® vaccine
89101931|NCT00662350||Symptomatic Benign Protate Hypertrophy|Symptom Score (IPSS) greater than 15, requiring invasive treatment, Prostate size greater than 25 g, Prostatic urethra length between 2.0 cm and 5.5 cm
89101932|NCT00662428|Experimental|Intervention|
89101933|NCT00662428|Active Comparator|Control|
89101934|NCT04158856|Experimental|Experimental Arm|adjuvant Pyrotinib plus Trastuzumab
89101935|NCT01119950|Experimental|NVA237 12.5 µg q.d.|NVA237 12.5 µg once daily
89101936|NCT01119950|Experimental|NVA237 25.0 µg q.d.|NVA237 25.0 µg once daily
89101937|NCT01119950|Experimental|NVA237 12.5 µg b.i.d.|NVA237 12.5 µg twice daily
89101938|NCT01119950|Experimental|NVA237 50.0 µg q.d.|NVA237 50.0 µg once daily
89101939|NCT01119950|Experimental|NVA237 25.0 µg b.i.d.|NVA237 25.0 µg twice daily
89101940|NCT01119950|Experimental|NVA237 100.0 µg q.d.|NVA237 100.0 µg once daily
89101941|NCT01119950|Experimental|NVA237 50.0 µg b.i.d.|NVA237 50.0 µg twice daily
89101942|NCT01119950|Placebo Comparator|Placebo|Placebo to NVA237 once daily
89101943|NCT02882828|Experimental|DBS (dried blood spots) collection|In this study, we make a switch from Prograf® to Envarsus®. Patients will be trained to collect their blood from a finger prick on filter paper. DBS will be done at home, collected on filter paper and mailed by the patients to a centralized laboratory (Department of Pharmacology, Toxicology and Pharmacovigilance at Limoges University Hospital), where tacrolimus concentration will be determined by HPLC-MS/MS
89101944|NCT02882204||First Episode Patients|First episode patients new to the PEPP program.
89101945|NCT02882204||Chronic Patients|Existing patients who have been enrolled in the PEPP program for >3 years
89101946|NCT02882204||Healthy Controls|Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
89101947|NCT02882204||Cliniucal High Risk patients|Patients who are accessing PEPP services during the prodromal phase of psychotic illness.
89101948|NCT02882126|Experimental|Subcutaneous Treprostinil|Open-label access; The initial dose of Remodulin for this study will be the same as each subject's final dose in study CVT-CV-003. Dose modification will be based according to clinical response and tolerability.
89101949|NCT01145222|Experimental|A. Remimazolam (CNS 7056)|"Initial 8 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
89101950|NCT01145222|Experimental|B. Remimazolam (CNS 7056)|"Initial 7 mg iv for sedation induction, and 2 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
89101951|NCT01145222|Experimental|C. Remimazolam (CNS 7056)|"Initial 5 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
89101952|NCT01145222|Active Comparator|D. Midazolam|"Initial 2.5 mg iv for sedation induction, and 1 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses"
89101953|NCT01145066|Experimental|borage and echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA
89101954|NCT01145066|Active Comparator|fish oil|Croda 18:12 fish oil
89101955|NCT01145066|Placebo Comparator|corn oil|
89101956|NCT02883920||workers of Champagne vineyard|
89101957|NCT01132118|Other|Placebo then HCQ|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
89101958|NCT01132118|Other|HCQ then Placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
89101959|NCT00637442|Experimental|CASL-MRI|Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl
89101960|NCT00972816|Experimental|3.75_(50)MF59|3.75 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
89101961|NCT00972816|Experimental|7.5_(0) MF59|7.5 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
89101962|NCT00972816|Experimental|7.5_(50) MF59|7.5 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
89101963|NCT00972816|Experimental|7.5_(100) MF59|7.5 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
89101964|NCT00972816|Experimental|15_(0) MF59|15 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
89101965|NCT00972816|Experimental|15_(50)MF59|15 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
89101966|NCT00972816|Experimental|15_(100) MF59|15 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
89101967|NCT00972816|Experimental|30_(0) MF59|30 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
89101968|NCT02882048|Experimental|Medication management & NADA Protocol|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens, and NADA protocol administered biweekly
89227693|NCT00964808|Experimental|Oxycodone|"Double Dummy:~Group B: Placebo Buprenorphine and Active Oxycodone"
89101969|NCT02882048|Active Comparator|Medication management|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens.
89101970|NCT05207306|Experimental|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA) group|Patients receiving right M-TAPA.
89101971|NCT05207306|Experimental|Subcostal transversus abdominis plane block (subcostal TAPB) group|Patients receiving right subcostal TAPB.
89101972|NCT00969618|Experimental|Atomoxetine|
89101973|NCT02864472|Other|combination Tx|combination Tx(vPDT +ranibizumab) (M0) + ranibizumab PRN (M3-6)
89101974|NCT02864472|Other|mono Tx|Ranibizumab (at 4 weeks interval) *3 (M0-2) + ranibizumab PRN (M3-6)
89101975|NCT00969540|Active Comparator|Active Mattress Cover|Subjects in this arm will be given the placebo mattress cover followed active mattress cover .
89101976|NCT00969540|Placebo Comparator|Placebo Mattress Cover|Subjects in this arm will be given the active mattress cover followed by the placebo mattress cover.
89101977|NCT00975000|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
89101978|NCT00975000|Placebo Comparator|Placebo|Participants received placebo orally once daily for 52 weeks.
89101979|NCT04286802|Experimental|Salt-meter|Patients received salt-meter in conjunction with dietary education by trained dietician to help monitoring the salt content in food, as well as usual care by their primary physicians.
89101980|NCT04286802|Active Comparator|Control|Patients received dietary education by trained dietician and usual care by their primary physicians.
89101981|NCT02863614|Experimental|Ibuprofen+Lorazepam|Oral ibuprofen (600 mg) + lorazepam (1 mg); one hour before endometrial scratching.
89101982|NCT02863614|Active Comparator|Ibuprofen|Oral ibuprofen (600 mg) + Placebo; one hour before endometrial scratching.
89101983|NCT02863614|Placebo Comparator|Placebo|Placebo + Placebo; one hour before endometrial scratching.
89101984|NCT04288908|Experimental|Social exclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives fewer passes than the other two participants (i.e., 10 out of 60).
89101985|NCT04288908|Active Comparator|Social inclusion|Cyberball is a ball-passing task in which the participant plays with two virtual players. In this condition, the user receives a comparable number of passes than the other two participants (i.e., 20 out of 60).
89101986|NCT00974922|Active Comparator|Phase I: Aliskiren|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Aliskiren 150 mg to 300 mg once daily for 6 weeks
89101987|NCT00974922|Active Comparator|Phase I: Cholecalciferol|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Cholecalciferol (3000 I.U.) once daily for 6 weeks
89101988|NCT00974922|Active Comparator|Phase II: Aliskiren and Vitamin D3|Aliskiren 150-300 mg orally once daily and Cholecalciferol 3000 I.U. in combination once daily for 6 weeks
89101989|NCT04288518|Experimental|Primary Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 megabecquerels (MBq).~At least five (5) evaluable subjects with primary brain tumor. The tested injected dose 500 MBq."
89101990|NCT04288518|Experimental|Recurrence of Brain Tumor|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.~At least five (5) evaluable subjects with recurrence of brain tumor. The tested injected dose 500 MBq"
89101991|NCT04288518|Experimental|Benign intracranial lesions|"The tested injected doses of 99mTc-1-thio-D-glucose 500 MBq.~At least five (5) evaluable subjects with benign intracranial lesions. The tested injected dose 500 MBq"
89101992|NCT04287972|Experimental|LSG-DPC|Laparoscopic Sleeve Gastrectomy and Diaphragmatic Pillar Closure.
89101993|NCT04287972|Active Comparator|LSG|Laparoscopic Sleeve Gastrectomy
89101994|NCT00972504|Active Comparator|GSK835726 (10mg)|10mg oral dose
89101995|NCT00972504|Active Comparator|GSK1004723 (1000mcg)|1000mcg nasal spray solution
89101996|NCT00972504|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
89101997|NCT00972504|Placebo Comparator|placebo|placebo
89101998|NCT00969228|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 or 2-month schedule.
89101999|NCT00969228|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 or 2-month schedule.
89102000|NCT00969150|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
89102001|NCT00969150|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
89102002|NCT00974220|Placebo Comparator|placebo|nebulized 0.9% saline placebo
89102003|NCT00974220|Experimental|fentanyl|nebulized fentanyl citrate (50 mcg)
89102004|NCT03904758|Experimental|Monitoring of pH with Restech|The patients with EER randomized into this arm will undergo pH monitoring using Restech system
89227694|NCT00970970||Von Hippel Lindau|Adult patients with Von Hippel-Lindau disease
89102005|NCT03904758|Experimental|Monitoring of oesophageal impedance|The patients with EER randomized into this arm will undergo monitoring of oesophageal impedance
89102006|NCT02863536|Other|Polybactum®|"Polybactum® ovules are administered intravaginally on 3 cycles, 1 cycle per month.~Polybactum is a medical device Class IIa used and marketed for the recurrence of Bacterial Vaginosis."
89102007|NCT00971178|Active Comparator|Local Dexmedetomidine|
89102008|NCT00971178|Placebo Comparator|Normal Saline|
89102009|NCT00971178|Active Comparator|IV dexmedetomidine|
89102010|NCT04288284||Emergency group|Patients presented to emergency by complicated colorectal cancer ( Obstruction, bleeding or perforation)
89102011|NCT04288284||Elective group|Patients presented with uncomplicated colorectal cancer for resection treatment
89102012|NCT03670602|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future cues that will be accessed via an electronic app to engage in EFT.
89102013|NCT03670602|Placebo Comparator|Daily Check in (DCI)|Participants will be asked to access an electronic app daily, but will receive no cues.
89102014|NCT00968526|Experimental|GSK2340272A 2D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (>60y), who received two doses (2D) of GSK2340272A vaccine, one administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and the other one, administered intramuscularly in the deltoid region of the dominant arm at Day 21.
89102015|NCT00968526|Experimental|GSK2340272A 1D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (>60y), who received a single dose (1D) of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
89102016|NCT03664674|Experimental|OTO-104|
89102017|NCT03664674|Placebo Comparator|placebo|
89102018|NCT00967668|Experimental|ASPIRE-Phone Lifestyle Coaching|Phone-based coaching using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
89102019|NCT00967668|Experimental|ASPIRE-Group Lifestyle Coaching|On-site weekly group visits using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
89102020|NCT00967668|Active Comparator|MOVE! Usual Care|Usual care MOVE!, which consists of weekly on-site group visits that follow MOVE! protocols with unstructured follow-up phone support
89102021|NCT00970944|Experimental|Amantadine HCL|100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.
89102022|NCT00970944|Placebo Comparator|Placebo|
89102023|NCT05780723|Experimental|The TCM group is treated with QHQYP by rectal instillation.|QHQYP is decocted in water, with a dose of 100ml each time, and rectal instillation before going to bed, once a night, for 8 weeks.
89102024|NCT05780723|Active Comparator|The control group is treated with mesalazine enema.|Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, for 8 weeks.
89102025|NCT05780697|Experimental|Children presented with septic hip arthritis in Assiut University Hospitals|Surgery of Drainage of pus in septic hip arthritis
89102026|NCT05780580||patients with a prescription for triptan reimbursed by health insurance|
89102027|NCT05780580||patients without a prescription for triptan reimbursed by health insurance|
89102028|NCT05780528|Experimental|mulligan mobilization|the patients will receive mulligan mobilization three times a week for four weeks
89102029|NCT05780528|Experimental|instrumented assisted soft tissue mobilization|the patients will receive instrumented assisted soft tissue mobilization three times a week for four weeks
89102030|NCT05780528|Active Comparator|conventional treatment|the patients will receive conventional treatment three times a week for four weeks
89102031|NCT05780515|Experimental|ANX009|Participants will receive repeat doses of ANX009 administered by subcutaneous (SC) infusion 3 times weekly during the approximate 3-week intervention period.
89102032|NCT05780476|Active Comparator|Control group|Psychoeducational program.
89102033|NCT05780476|Experimental|Experimental group|Psychoeducational program combined with virtual reality.
89102034|NCT05780411||Myloid group|Patients diagnosed as Multiple Myeloma, treated, and not in relapse
89102035|NCT05780411||Lymphoid group|Patients diagnosed as having lymphoma, treated, and not in relapse
89102036|NCT05780385|Experimental|nasotracheal intubation|
89102037|NCT05780385|Active Comparator|orotracheal intubation|
89102038|NCT05780359|Experimental|Drug eluting stent|Device: Drug-eluting peripheral arterial（G-stream） stent system Manufacturer：Alain Medical (Beijing) Co., Ltd.
89102039|NCT05780359|Active Comparator|Drug coating balloon|Device: AcoArt-Orchid® Drug Eluting Balloon Catheter Manufacturer: Acotec Scientific Co., Ltd
89102040|NCT05780320||Pharmaco-Surgical Arm|
89102041|NCT05780320||Standard of Care Arm|
89102042|NCT05780294|Placebo Comparator|Control group|"Chemotherapy:~5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Lobaplatin: 30mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 6 cycles, a total of 12 months.~Drug: Placebo After diagnosis of stage IV, recurrent or metastatic nasopharyngeal carcinoma (within 3 weeks before treatment), placebo tablets were started,) 2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy. In case of grade III-IV myelosuppression during treatment, recombinant human granulocyte-stimulating factor injection (manufactured by Qilu Pharmaceutical Co., Ltd.) was given again at 2~5ug/kg, subcutaneously once daily, and the clinical trial was terminated."
89102043|NCT05780294|Active Comparator|Experimental group|"Chemotherapy:~5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle; Lobaplatin: 30mg/m2, used on the 1st and 28th day of each cycle; Q60d; Every 2 months for a treatment cycle, use 6 cycles, a total of 12 months.~Drug: Leucogen After the diagnosis of stage IV, recurrent or metastatic nasopharyngeal carcinoma (within 3 weeks before treatment), oral leucogen tablets (manufactured by JIANGSU JIBEIER PHARMACEUTICAL CO.,LTD, 20 mg/tablet) were started and 40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy. In case of grade III-IV myelosuppression during treatment, recombinant human granulocyte-stimulating factor injection (manufactured by Qilu Pharmaceutical Co., Ltd.) was given again at 2~5ug/kg, subcutaneously once daily, and the clinical trial was terminated."
89102044|NCT05780255||COVID-19 positive patients|Patients with a PCR-confirmed COVID-19 infection, with ARDS and supported by VV-ECMO
89102045|NCT05780229||Massive Rotator Cuff Tears: Mixed Methodology|"Phase 1: A theoretical sampling of maximum variation was carried out using a segmentation criterion, being the evaluation before or after the treatment in those patients who attended the visit in 5 Spanish hospitals.~Phase 2: A consecutive sample of patients with massive rotator cuff tears, treated with conservative treatment, arthroscopy decompression surgery, or reverse prosthesis in 5 Spanish hospitals."
89102046|NCT05780190|Experimental|CABA group|new artificial liver CABA system (BS330+CA280) combined with plasma exchange
89102047|NCT05780190|Experimental|control group|BS330 combined with plasma exchange
89102048|NCT05780164|Experimental|Intervention|Nurse participants will be provided with a research readiness tool to facilitate their discussions with lung cancer patients about clinical trial opportunities. The tool will be used by nurses over a six month period, alongside usual care.
89102049|NCT05780164|No Intervention|Control|No intervention. Nurse participants will provide usual care to lung cancer patients.
89227695|NCT03765450||Single Group Study|Patients with Acute Severe Ulcerative Colitis who are either a) biologic-naïve or b) biologic-experienced without a known history of anti-infliximab antibodies requiring infliximab infusion therapy as a part of standard of care.
89227696|NCT00974558|Experimental|fan directed to cheeks|Blow draft of air generated by fan across cheeks
89102050|NCT05780112|Experimental|Experimental group|"The pregnant women did the breathing exercise in accordance with the 'Practical Guideline on Breathing Exercise for Reducing Nausea and Vomiting in the Pregnant Women'. The breathing exercise training took on average 15-20 minutes for each pregnant woman. After the training, the pregnant women were asked to do the breathing exercise properly and effectively in accordance with the guideline for a minimum of five minutes at least twice a day for four weeks.~Refresher training was given to the pregnant women through phone calls at the end of the first and third weeks and home visits at the end of the second week, and in each of these interviews, the pregnant women's breathing exercise practices were followed and the NVPI was applied to the pregnant women.~At the end of the research, in other words, at the end of the fourth week, the NVPI and SF-36 were applied once again to the pregnant women in the maternity polyclinic, and hence, the follow-up process came to an end."
89102051|NCT05780112|No Intervention|control group|"At the beginning of the research (pretest phase), without giving information about the breathing exercise practice to the pregnant women and making them practice the exercise, the researcher only asked pregnant women in the control group to fill in the Personal Information Form and applied the NVPI and SF-36 to the pregnant women.~The pregnant women were called by phone at the end of the first and third weeks and their homes were visited at the end of the second week, and in each interview, information about their health status was received from them and the NVPI was applied to them.~At the end of the research (post-test phase), in other words, at the end of the fourth week, the NVPI and SF-36 were applied once again to the pregnant women in the maternity polyclinic."
89102053|NCT05780086|Experimental|30% icodextrin and 10% dextrose|Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
89102054|NCT05779982||Multicenter retrospective cohort|This study included patients diagnosed with breast cancer who received neoadjuvant systemic therapy (NAST) followed by curative surgery between January 2013 and December 2018. All patients were cN1-3 breast cancer at initial presentation confirmed by any imaging studies (either ultrasonography or MRI) or pathological examination using ultrasonography-guided needle biopsy of suspicious axillary lymph nodes. The clinical nodal stage was determined based on findings from physical examination, with imaging studies such as ultrasonography or MRI taken into account, according to the American Join Committee on Cancer guidelines (7th edition). In addition, all patients underwent sentinely lymph node biopsy (SLNB) followed by axillary lymph node dissection. SLNB was performed using a radioactive marker, blue dye, or both (dual tracers).
89102055|NCT05779904||Stunted (Case)|In the case group, stunted children (<-2SD) (n=150) will be recruited.
89102056|NCT05779904||Non-stunted (Control)|In the control group, non-stunted children (>-1SD) (n=150) will be recruited.
89102057|NCT05779891|Experimental|Interventional Group A|
89102058|NCT05779891|Active Comparator|Interventional Group B|
89102059|NCT05779878|Experimental|Interventional Group A|This group will be given Post isometric relaxation technique. Total intervention protocol will be given for four weeks of duration 3 sessions per week with total 12 sessions.
89102060|NCT05779878|Experimental|Interventional Group B|This Group will be given myofascial arm pull technique . Total intervention protocol will be given for four weeks of duration 3 sessions per week with total 12 sessions.
89102061|NCT05779800|Experimental|Flowable resin composite stent group|Flowable resin composite is a bio compatible material used in dental field many years ago.
89102062|NCT05779800|Active Comparator|Periodontal pack group|"Non eugenol containing periodontal pack used in periodontal surgeries to protect the wound.~Other name :COE_PAK"
89102063|NCT05779748|Experimental|Isometric exercise-one repetition|"Isometric exercise consisting of 1 session only. The session will last for around 5 minutes which will include asking the patient to do 1 repetition of wall squat for 3 min or to volitional fatigue at 100° knee angle.~Intervention: Other: Single bout of exercise"
89102064|NCT05779748|Experimental|Isometric exercise-three repetitions|"isometric exercise consisting of 1 session only. The session will last for around 10 minutes which will include asking the patient to perform 3 repetitions of wall squats (each time the exercise will be performed for 3 min or to volitional fatigue at 100°degree knee angle); the patient will be given 30-sec rest between repetitions.~Intervention: Other: Single bout of exercise"
89102065|NCT05779748|No Intervention|Control|Will not receive any intervention
89102066|NCT05779722|Experimental|Intervention|wrapping the participants in a vapor barrier as the inner layer (intervention),
89102067|NCT05779722|No Intervention|No intervention|without the vapor barrier to serve as a negative control
89102068|NCT05779683||Caretaker device in CVICU patient|device placed on the subject after arrival to the cardiac intensive care unit postoperatively
89102069|NCT05779592||Cohort 1|Muscle-invasive Urothelial Carcinoma Participants who received nivolumab as adjuvant treatment at least once from March 28, 2022 to December 31, 2023
89102070|NCT05779566||OST|Patients with osteoporosis or severe osteopenia defined as having a significantly reduced BMD (T-score equal or lower than -1.5)
89102071|NCT05779566||Mild OST|Patients with mild-to-no reduction of BMD at the same post-treatment time point (T-score higher than -1.5)
89102072|NCT05779553||Group (1)(patient group):|"who are 50 newly diagnosed patient with colorectal cancer, who will be admitted at South Egypt Cancer Inistitute and Assiut University Hospital during 2023.~Patients group will be furtherly subclassified according to the American Joint Committee on Cancer Staging,TNM staging classification"
89102073|NCT05779553||Group (2) (control group)|40 apparently healthy individuals with matched age and sex are included in this study as a control group for comparison.
89102074|NCT05779540|Active Comparator|Intervention|Active Device
89102075|NCT05779540|Sham Comparator|Control|Sham Device
89102076|NCT05779527|Experimental|Online Mindful Parenting Programme|Parents or carers will be invited to complete a six week online mindful parenting programme comprising online video, audio and written content plus four group support sessions via videoconferencing.
89102077|NCT05779514|Experimental|The growth of brown adipose tissue|
89102078|NCT05779488|Experimental|maca group|
89102079|NCT05779488|Placebo Comparator|Placebo group|
89102080|NCT05779462||patients with pelvic endometriosis|Patients referred for suspected pelvic endometriosis, with pelvic endometriosis on initial MRI
89102081|NCT05779462||patients without pelvic endometriosis|Patients referred for suspected pelvic endometriosis but without endometriosis found on diagnostic MRI.
89102082|NCT05779410|Experimental|Vitamin D group|
89102083|NCT05779410|Placebo Comparator|Placebo group|
89102084|NCT05779371|Active Comparator|Experimental group|Experiment group A accepted the Integrated-based Laughing Qigong Program (IB-LQP) During the intervention, the participants formed a standing circle and could make eye contact. The time was divided into 10 minutes of warm-up (deep breathing, stretching of muscles, expressing various emotions on the face, stretching of limbs) and 30-40 minutes of main exercise (Breathing and Laughing Qigong practice). The main exercise included using the natural breath of laughter to activate the body, turning a fake smile into a real smile and laughter, using different body movements at the same time, producing a variety of types of laughter, and conducting self-emotional awareness and emotional transformation drills to reduce the backlog.
89102085|NCT05779371|No Intervention|control group|The control group received no intervention and was asked to maintain their current lifestyle for 6 weeks following the baseline test.
89102086|NCT05779358|Active Comparator|E+ G+|Participants with the expectation of receiving gluten-containing bread and actually receiving gluten-containing oat bread during the test day.
89102087|NCT05779358|Active Comparator|E+ G-|Participants with the expectation of receiving gluten-containing bread, but actually receiving gluten-free oat bread during the test day.
89102088|NCT05779358|Active Comparator|E- G+|Participants with the expectation of receiving gluten-free bread but actually receiving gluten-containing oat bread during the test day.
89102089|NCT05779358|Placebo Comparator|E- G-|Participants with the expectation of receiving gluten-free bread and actually receiving gluten-free oat bread during the test day.
89102090|NCT05779254||Oral Antibiotic Prophylaxis +|At the Uzsoki Hospital and the Department of Surgery at the University of Debrecen, patients receive preoperative neomycin- metronidazole oral antibiotic prophylaxis in addition to mechanical bowel preparation.
89102091|NCT05779254||Oral Antibiotic Prophylaxis -|Patients admitted to the Csolnoky Ferenc Hospital in Veszprém will receive preoperative mechanical bowel preparation and no oral antibiotic prophylaxis.
89102092|NCT05779215||acute ischemic stroke with large- or medium-vessel occlusion|acute ischemic stroke patients with large- or medium-vessel occlusion including all treatments.
89102093|NCT05779189|Experimental|Intervention|Participants will receive conventional health education and game-based virtual reality (game) in person.
89102094|NCT05779189|Active Comparator|Control|Participants will receive conventional health education and 4 video of balance exercise.
89102095|NCT05779176|No Intervention|Normothermia arm|Patients randomized to normothermia will be maintained at 36-37°C during the entire study period.
89102096|NCT05779176|Experimental|Therapeutic hypothermia arm|Patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C
89102097|NCT05779150|Experimental|Case group|Routine treatment together with once applicating CeraVe® Moisturising Cream after daily bath.
88812641|NCT03145688|Experimental|Family physical activity Planning|Behavoural: Family Physical Activity Planning. The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercises for parents & children where they list physical activities that they have found fun in the past, as well as some new activities they would like to try & skill training content to help with goal setting & tracking of physical activity.
89102098|NCT05779150|Placebo Comparator|Control Group|Routine treatment together with once applicating Standard Cream after daily bath.
89102099|NCT05779111||Scores greater than or equal to 3 in patients with locally advanced cervical cancer|Scores greater than or equal to 3 in patients with locally advanced cervical cancer
89102100|NCT05779111||Patients with locally advanced cervical cancer scored less than 3 points|Patients receiving radiotherapy for locally advanced cervical cancer were scored according to five factors, with a score of less than 3
89102101|NCT05779098||Extensive hepatectomy|
89102102|NCT05779059|Experimental|Initial ticagrelor|All patients will receive standard 180 mg loading dose of ticagrelor, followed by a standard maintenance dose of 90 mg bid for 30 days, after which de-escalation to 60 mg bid will take place and this dosing will be maintained for 15 days. At day 45 all patients will be loaded with standard 60 mg dose of prasugrel followed by reduced maintenance dose of 5 mg qd for 15 days. At day 60 all patients will be switched back to guideline recommended antiplatelet therapy.
89227697|NCT00974636|Experimental|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day for two weeks
89227698|NCT00974636|Placebo Comparator|Ususal Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
89227699|NCT00974714|Experimental|1|Oral L-arginine 2 g twice a day, for 14 weeks
89227700|NCT00974714|Placebo Comparator|2|oral placebo twice a day for 14 weeks
89227701|NCT00971126|Experimental|Single Group Assignment|
89227702|NCT00971360||Conversion disorder|
89227703|NCT00971360||Healthy control|
89227704|NCT00964964|Experimental|SIBA 3W|
89227705|NCT00964964|Experimental|SIBA OD|
89102103|NCT05779059|Experimental|Initial prasugrel|All patients will receive standard 60 mg loading dose of prasugrel, followed by a standard maintenance dose 10 mg qd for 30 days, after which de-escalation to 5 mg qd will take place and this dosing will be maintained for 15 days. At day 45 patients will be loaded with standard 180 mg dose of ticagrelor followed by reduced maintenance dose of 60 mg bid for 15 days. At day 60 all patients will be switched back to guideline recommended antiplatelet therapy.
89102104|NCT05779046|Experimental|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute ).
89102105|NCT05779046|Experimental|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
89102106|NCT05778929||patients diagnosed as recurrent acute pancreatitis in 12 month|Recurrent acute pancreatitis: relapse occurs more than three months after the previous episode ended, with the exclusion of re-hospitalization due to local or systemic complications of the initial episode and chronic pancreatitis.
89227706|NCT04183998|Experimental|tsES|trans-spinal Electrical Stimulation (tsES)
89227707|NCT00965042|Experimental|Ceftobiprole|Ceftobiprole 500 mg by 2 hour intravenous infusion every 8 hours for 7 days
89102107|NCT05778929||patients not diagnosed as recurrent acute pancreatitis in 12 months|No relapse occurs more than three months after the previous episode ended, with the exclusion of re-hospitalization due to local or systemic complications of the initial episode and chronic pancreatitis.
89102108|NCT05778643|Experimental|TaKeTiNa|Participants receive TaKeTiNa Music therapy
89102109|NCT05778643|No Intervention|Waiting|Participants receive no additional therapy
89102110|NCT05778422|Active Comparator|Pulsed Radiofrequency|The investigators performed pulsed radiofrequency in the suprascapular nerve
89102111|NCT05778422|Active Comparator|Bupivacaine|The investigators performed a blocade with bupivacaine in the suprascapular nerve.
89102112|NCT05777161|Experimental|Parent Coached Exposure Therapy-Individual (PCET-I) Group|Subjects will receive six to 14 weekly sessions of individual Parent Coached Exposure Therapy
89102113|NCT05777161|Active Comparator|Traditional Cognitive Behavior Therapy (CBT) Group|Subjects will receive 6 to 14 weekly sessions of individual Cognitive Behavioral Therapy
89102114|NCT05777161|Experimental|Parent Coached Exposure Therapy-5day Intensive (PCET-5day) Group (removed from study)|Subjects will receive 5 day (nine sessions) of group-based Parent Coached Exposure Therapy delivered within a span of five days (Monday through Friday), followed by 5 weeks of self-care
89102115|NCT05777070|Experimental|Remote Ischemic Conditioning (RIC)|RIC is achieved via blood pressure cuff inflation to at least 20 mmHg above systolic blood pressure to 250 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 1-7.
89102116|NCT05777070|Sham Comparator|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 25 mmHg on the more involved arm. RIC involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation and requires 45 minutes. RIC is performed on visits 1-7.
89102117|NCT05776355|Experimental|Ovarian cancer|
89102118|NCT05774860||All healthy participants|All healthy participants will undergo behavioral assessment and fMRI or EEG
89102119|NCT05774847||All healthy participants|Healthy participants will be recruited and assigned to different behavioral studies assessing the effect of the experimental manipulations of interest on decision-making metrics.
89102120|NCT05774834||All healthy participants|All healthy participants will undergo behavioral assessment and fMRI
89102121|NCT05774743|No Intervention|Standard Consent|Participants will receive the standard anesthesia consent procedure without the use of the visual aid that is being used in this study.
89102122|NCT05774743|Experimental|Consent with Visual Aid|Participants will receive standard anesthesia consent procedure with the use of the visual aid that is being used in this study.
89102123|NCT05774080||Disease Cohort|Observational
89102124|NCT05774080||Engaged Cohort|Observational
89102125|NCT05767190|Experimental|MotivAir group|Subjects in the MotivAir group will follow an intervention - lasting approximately 45 minutes - based on motivational interviewing principles and techniques delivered by a trained nurse.
89102126|NCT05767190|No Intervention|Treatment as usual|Participants assigned to the control group will receive a usual pulmonary rehabilitation program for patients with OSAS receiving CPAP therapy, which is a standard technical training comprising information regarding the use, maintenance and safety measures of the device, plus a home inspection delivered by a technician who has the only task of doing maintenance to the machinery.
89102127|NCT05760664|Experimental|Experimental Group|The fascial fitness® method (12 sessions, twice a week, for six weeks, 15 minutes a day, for 2 sets of 40 seconds each side). Assessments and reassessments will be carried out in the first, fourth and sixth week.
89102128|NCT05760664|Active Comparator|Sham Group|Static stretching exercises (12 sessions, twice a week, for six weeks, 15 minutes a day, for 2 sets of 40 seconds each side). Assessments and reassessments will be carried out in the first, fourth and sixth week.
89102129|NCT05760664|Placebo Comparator|Control Group|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Ultrasound was chosen because it is easy-to-use equipment and because this form of placebo used, equipment turned off, does not have any treatment effect and has already been established in another study (CHAIBI; BENTH; RUSSELL, 2015). Assessments and reassessments will be carried out in the first, fourth and sixth week.
89102130|NCT05759689|Experimental|Diagnose Dumping after supplement consumption|Carbohydrate ingestion to provoke dumping syndrome related symptoms
89102131|NCT05759689|Active Comparator|Fat supplementation|A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
89102132|NCT05755841||1|Outpatient management of preterm prelabor rupture of membranes
89102133|NCT05755841||2|Inpatient management of preterm prelabor rupture of membranes
89102134|NCT05739929|Active Comparator|Colchicine|0.5 mg colchicine tablets twice daily 72 to 48 hours before planned PCI
89102135|NCT05739929|Placebo Comparator|Placebo|Matching placebo
89102136|NCT05734547|Experimental|Stepping Together for Children after Trauma (ST-CT)|Parent-led, therapist assisted CBT treatment
89102137|NCT05734547|Active Comparator|Usual care|The types of interventions normally provided in the first-line municipal services
89102138|NCT05732675|Other|Immediate Intervention|Participants immediately enter the intervention upon enrollment
89102139|NCT05732675|Other|Waitlist|Participants enter a waitlist for 4-weeks prior to participating in the intervention
89102140|NCT05732610|Experimental|Individuals - ages 14 and older|This test is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
89102141|NCT05732610|Experimental|Individuals - ages 2 to 13|"This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples.~If the subject is under the age of 14, an adult lay-user will collect the sample."
89102142|NCT05726994||cystic fibrosis and Kaftrio®|20 children with cystic fibrosis aged 6 to 12 who initiate Kaftrio®
89102143|NCT05721196|Experimental|Culturally adapted Psychoeducation (CaPE)|
89102144|NCT05721196|Active Comparator|Treatment as Usual (TaU)|
89102145|NCT05715684|Other|Standard treatment Plan|This is the main arm of the study in which all 25 anticipated participants will be enrolled into.
89102146|NCT05712265|Experimental|Miricorilant - Fluvoxamine/Miricorilant|Participants will receive a single oral dose of miricorilant 600 mg on Days 1 and 10 and a single oral dose of fluvoxamine 50 mg on Days 4 to 12.
89102147|NCT05709808|Experimental|Mixed group|"This taping technique is designed to guard against lateral ankle sprains. Kinesio-tape will be applied to the unstable ankle for a lateral ankle sprain. 4 strips of the tape with different stretching percentages will be applied while the ankle joint in a relaxed position.~ankle exercises will be conducted for 8 weeks, 3 times/ week, each session will last for 60 minutes.~A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed."
89102148|NCT05709808|Active Comparator|Exercise group|received exercises and proprioceptive training similar as described in the experimental group
89102149|NCT05709808|Experimental|Kinesio-tape group|will receive Kinesio-tape only as described in the mixed group This taping technique is designed to guard against lateral ankle sprains. Kinesio-tape will be applied to the unstable ankle for a lateral ankle sprain. 4 strips of tape with different stretching percentages will be applied while the ankle joint in a relaxed position.
89102150|NCT05683860|Experimental|Experimental: WVE-004 (Dose A)|
89102151|NCT05677386|Active Comparator|Intervention group|Primary preventive treatment guided by CTCA
89102152|NCT05677386|Sham Comparator|Control group|Primary preventive treatment guided by Systematic COronary Risk Evaluation (SCORE) 2 model risk assessment according to Danish clinical guidelines.
89102153|NCT05661825||Patients diagnosed with acute myocardial infarction in the emergent department|The cases being admitted to the Emergent Department and than transferred to the general ward due to the diagnosis of acute myocardial infarction were included in the study (from Jan 1, 2012 to Jun 30, 2022). The age of these cases must be older than or equal to 20 years old.
89102154|NCT05659654|Experimental|Take ursodeoxycholic acid capsules daily for 4 weeks from the date of enrollment|Healthy volunteers took ursodeoxycholic acid capsules daily for 4 weeks from the date of enrollment
89102155|NCT05654376|Experimental|Group art therapy|Cycle of 6 2-hours bimonthly group art therapy sessions.
89102156|NCT05649683|Other|Analysis of blood cytokine|"Patients will receive anti-PD1 therapy (Nivolumab/Nivo) with anti-CTLA4 therapy (Ipilimumab/Ipi) as part of routine care, as per the MA scheme followed in case of efficacy and good tolerance of Nivolumab maintenance treatment alone. The functional test for cytokines (1ml total blood on lihtium heparinate) will be performed at the initiation of ICI (J0), at week 6 (S6, after the 2nd cure), at week 11 (S11= 1st radiological evaluation, after the 4 cures of Nivo+Ipi), and, if applicable, the progression of the disease and/or the occurrence of an ESi grade 3-4. Stimulated lymphocytes from non-therapy responders will be tested in vitro by various immunomodulatory drugs.~During each sampling we will also collect 5 ml of serum on dry tube for serological constitution, 3ml on EDTA tube for performing an immunophenotyping (T, B, NK) and 3ml on EDTA tube for freezing total PBMC and setting up a biobank."
89102157|NCT05641454|Experimental|ElevATP supplement|
89102158|NCT05641454|Placebo Comparator|Maltodextrin placebo|
89102159|NCT05638113|Active Comparator|Blood pleurodesis|
89102160|NCT05638113|No Intervention|Simple chest drainage (chest tube)|
89102161|NCT05637060|Experimental|Test Group|Subjects will take their assigned study medication (Vaptor 20mg), after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time. Those subjects who received Test Drug in first period will receive Reference drug in 2nd period of the study.
89102162|NCT05637060|Active Comparator|Reference Group|Subjects will take their assigned study medication (Crestor 20mg), after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time. Those subjects who received Reference Drug in first period will receive Test drug in 2nd period of the study.
89102163|NCT05619419|Experimental|Mindfulness-enhanced positive affect induction (MPAI)|The MPAI is a method of bringing mindful (nonjudgmental) awareness to positive emotions, thoughts, and memories and is not expected to result in adverse experiences. It includes beginning with mindful awareness of the breath (i.e., meditation focusing on the breath) to draw attention away from negative aspects of pain. With continued awareness of the breath, smiling and gentle laughter are begun in order to initiate positive affect. With continued smiling and laughter, participants then imagine the smiles and laughter of those they are fond of, to allow a positive affect state to build upon itself and trigger state dependent positive memories, thoughts, emotions (e.g., gratitude) and self-efficacy of pain management.
89102164|NCT05619419|Active Comparator|Breathing meditation (BM)|Breathing meditation is a method of bringing mindful (nonjudgmental) awareness to various aspects of the breath and is aimed toward attaining a neutral state of affect and is not expected to result in adverse experiences. It involves bringing present-moment focused, nonjudgmental awareness to aspects breathing, such as sensations of airflow with each inhalation and exhalation, as well noticing the rise and expansion of the chest and belly with each inhalation. The use of breathing mediation will serve as a comparison task for the MPAI.
89102165|NCT05619419|No Intervention|Natural Response (NR)|Participants instructed to respond naturally to the cold pressor test will be instructed to not attempt to modify or control their experience (e.g., via distraction or use of meditation). Natural response will serve as a control comparator for the MPAI and is not expected to result in adverse experiences.
89102166|NCT05616494|Experimental|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) will be administrated once every 3 weeks.
89102167|NCT05614609|Active Comparator|Lidocaine spray on the glottis|Lidocaine 20 mgl/ml- 4,4 ml will be sprayed on the glottis. Ventilation for 90 sek, intubation
89102168|NCT05614609|Active Comparator|Muscle relaxing medication|Rocuronium 0,6 mg/kg administered intravenous. Ventilation for 2.5 minutes (150seconds), intubation
89102169|NCT05601050||PSD (Psychosis spectrum disorder) group|Current DSM-V-defined diagnosis of schizophrenia, schizophreniform, schizoaffective disorder, unspecified psychotic disorder, or brief psychotic disorder, or bipolar 1 disorder with psychotic features or major depressive disorder with psychotic features using the Structured Clinical Interview for Axis I DSM-V Disorders (SCID-I/P).
89102170|NCT05599217||Case group (CSDH group)|CSDH patients recruited from neurosurgical department at 4 medical centres in China, which have apparent clinical symptoms and are confirmed by computed tomography or magnetic resonance imaging.
89102171|NCT05599217||Control group (Healthy group)|non-CSDH, age- and gender-matched patients recruited from ophthalmology, otolaryngology, and physical examination department at 4 medical centres in China.
89102172|NCT05598957||uninfected Sars-CoV-2 group (Group 1)|The study group was divided into three groups according to COVID-19 WHO clinical progression Scale: no viral RNA detected, uninfected Sars-CoV-2 patients (Group 1)
89102173|NCT05598957||mild Sars-CoV-2 group (Group 2)|The study group was divided into three groups according to COVID-19 WHO clinical progression Scale: viral RNA detected but asymptomatic disease, ambulatory mild disease (Group 2)
89102174|NCT05598957||moderate to severe Sars-CoV-2 group (Group 3)|The study group was divided into three groups according to COVID-19 WHO clinical progression Scale: hospitalized moderate disease, moderate to severe Sars-CoV-2 patients (group 3)
89102175|NCT05583162|Experimental|Intervention|All pupils attending a Elite Sport Jr High School receive intervention
89102176|NCT05580575|Experimental|First lens wear experience|Subject will wear contact lenses for 30 days during the day only.
89102177|NCT05580575|Experimental|Second lens wear experience|Subject will wear contact lenses for 30 days during the day only.
89102178|NCT05576753|Experimental|Patient|Patients scheduled for robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia
89102179|NCT05576649|Active Comparator|Control Group 1|In this group, the number of flashes per row and column during the P300 speller training will be adapted based on the participants' previous performance according to the approach used by Arvaneh et al. (2019).
89102180|NCT05576649|Sham Comparator|Control Group 2|In this group, the number of flashes per row and column during the P300 speller training will be chosen randomly. It is independent of the participants' performance.
89102181|NCT05576649|Experimental|Experimental Group|In this group, the number of flashes per row and column during the P300 speller training will be adapted according to an iterative learning control law that was developed by the principal investigator of this study. The control law uses the previous number of flashes, as well as the participants' previous performance.
89102182|NCT05571813|Experimental|Sequence 1|Period1: D958 Period2: CKD-341 Formulation I Period3: CKD-341 Formulation II
89102183|NCT05571813|Experimental|Sequence 2|Period1: CKD-341 Formulation II Period2: D958 Period3: CKD-341 Formulation I
89102184|NCT05571813|Experimental|Sequence 3|Period1: CKD-341 Formulation I Period2: CKD-341 Formulation II Period3: D958
89102185|NCT05571813|Experimental|Sequence 4|Period1: CKD-341 Formulation II Period2: CKD-341 Formulation I Period3: D958
89102186|NCT05571813|Experimental|Sequence 5|Period1: CKD-341 Formulation I Period2: D958 Period3: CKD-341 Formulation II
89102187|NCT05571813|Experimental|Sequence 6|Period1: D958 Period2: CKD-341 Formulation II Period3: CKD-341 Formulation I
89102188|NCT05567068|Other|Control Group|This group will take mesalamine 1 g three times daily
89102189|NCT05567068|Active Comparator|Atorvastatin group|This group will take mesalamine 1 g three times daily plus atorvastatin 80 mg once daily.
89102190|NCT05566782||CRES-participants|"The participants in this cohort will start rehabilitation during their inhospital stay and continue the rehabilitation course during discharge to municipality.~The rehabilitation will consist of physical exercise and measurements in relation to accelerometry, physical function and qualitative interviews regarding goal for rehabilitation."
89102191|NCT05565001|Active Comparator|Levcromakalim|Intravenous infusion of 1 mg levcromakalim followed by intravenous sumatriptan infusion.
89102192|NCT05565001|Placebo Comparator|placebo (isotonic saline)|Intravenous infusion of placebo (isotonic saline) followed by intravenous sumatriptan infusion.
89102193|NCT05561062|No Intervention|Control Group|This group will take 1 g mesalamine three times daily
89102194|NCT05561062|Active Comparator|Atorvastatin group|This group will take 1 g mesalamine three times daily and atorvastatin 80 mg once daily
89102195|NCT05551819|Experimental|Feeding Order 1|MDF then RUTF/RUSF
89102196|NCT05551819|Experimental|Feeding Order 2|RUTF/RUSF then MDF
89102197|NCT05544214|Experimental|Sequence 1|"Period 1 - A single dose of 2 tablets(D745, D759) under fasting condition.~Period 2 - A single dose of 1 tablets(CKD-371) under fasting condition."
89102198|NCT05544214|Experimental|Sequence 2|"Period 1 - A single dose of 1 tablets(CKD-371) under fasting condition.~Period 2 - A single dose of 2 tablets(D745, D759) under fasting condition."
89102199|NCT05543512|Experimental|Individualized Diet Elimination Therapy|Subjects in this arm will be assigned an allergen-specific immune signature-directed diet to follow for 8 weeks
89102200|NCT05543512|Placebo Comparator|Sham Diet Elimination Therapy|Subjects in this arm will be assigned a sham diet to follow for 8 weeks
89102201|NCT05541094||Fortified Arm|Individuals from families who are consume fortified milk + oil
89102202|NCT05541094||Unfortified Arm|families habitually consuming unfortified milk and oil
89102203|NCT05538689|Experimental|Study drug Myfembree|Participants will be asked to take a once-daily tablet of Myfembree ( relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for 24 months.
89102204|NCT05538689|No Intervention|Standard of Care|The standard of care will depend on the participant's type of surgery, health history, and clinical symptoms. It often includes pain management, bleeding management, physical exams, pelvic ultrasound, birth control, and Surgical reintervention.
89102205|NCT05535374|Experimental|Connected soles|Number of steps recorded by the soles (activation per smartphone)
89102206|NCT05535374|Active Comparator|Gold Standard|Number of steps counted by two observers viewing the film
89102207|NCT05532631|Experimental|Angioplasty|percutaneous coronary angioplasty with drug eluting stent implantation.
89102208|NCT05532631|Active Comparator|Coronary artery bypass grafting|Coronary artery bypass grafting has been chosen as the comparator because it is currently the reference strategy for revascularization in patients with multi-vessel disease and heart failure (ESC guidelines). Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines.
89102209|NCT05524064|Experimental|FLASH radiotherapy for painful bone metastasis(-es)|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
89102210|NCT05519293|Experimental|20 mg QD, oral|H002 20mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89102211|NCT05519293|Experimental|40 mg QD, oral|H002 40mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89102212|NCT05519293|Experimental|80 mg QD, oral|H002 80mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89102213|NCT05519293|Experimental|150 mg QD, oral|H002 150mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89102214|NCT05519293|Experimental|250 mg QD, oral|H002 250mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89102215|NCT05519293|Experimental|350 mg QD, oral|H002 350mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89102216|NCT05475990|Experimental|Hydroxyethyl starch coload group|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia
89102217|NCT05475990|Experimental|Crystalloid coload group|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine simultaneous with spinal anesthesia.
89102218|NCT05473871|Experimental|Standard EBI Condition|Faith in Action as originally implemented
89102219|NCT05473871|Experimental|Enhanced Condition|Standard condition + organizational-level implementation strategies
89102220|NCT05473871|Experimental|Enhanced + Sustainment condition|Enhanced implementation condition + maintenance strategies
89102221|NCT05456373|Experimental|SoC+ClearEdge device - Standard of Care + study device|Standard assessment of the surgical margins of the excised breast specimen during lumpectomy surgery plus the use of the study device to assess for breast cancer cells at the the margins
89102222|NCT05456373|No Intervention|SoC - Standard of Care|Standard assessment of the surgical margins of the excised breast specimen during lumpectomy surgery
89102223|NCT05423548||Children with congenital deafness|Children with congenital deafness followed in the ENT department of the Necker hospital and having benefited before their 10 months, from a pilot consultation, filmed, jointly carried out by a child psychiatrist from the Therapeutic Childhood and Deafness Unit of St Maurice Hospitals (UTES) and a psychologist from the ENT department of Necker for the neurodevelopmental risk assessment, between May 2018 to April 2020.
89102224|NCT05409157|Experimental|Treatment Group 1: BMS-986166|
89102225|NCT05407519|Experimental|Tislelizumab 200mg IV q3w + Sitravatinib 100mg PO qd|Tislelizumab 200mg IV q3w + Sitravatinib 100mg PO qd Tislelizumab and Sitravatinib will be administered until the disease recurrence, intolerable toxicity, death, withdrawal of consent or completion of 17 cycles of Tislelizumab.
89102226|NCT05404841|Experimental|CoffeeBerry Supplement|Caffeine and polyphenol supplement
89102227|NCT05404841|Placebo Comparator|Placebo|Placebo
89102228|NCT05399056|No Intervention|Enhanced usual care|Enhanced usual care describes a process in which automated surveillance is used to identify individuals experiencing a COPD exacerbation. This is followed by direct outreach - either through in-person visits while a patient is hospitalized, or by mail and telephone in the outpatient setting, to facilitate referral to PR. Subjects randomized to this arm will be given a pamphlet describing the benefits of PR.
89102229|NCT05399056|Active Comparator|Enhanced usual care + Storytelling|Subjects randomized to the eUC + Storytelling intervention will view the video narrative(s) of one or more individuals with COPD who has overcome similar barriers and has attended a program of PR. Subjects will be shown the first chapter of the story immediately after randomization and will receive email and/or text messages to prompt viewing of subsequent chapters at 2 weeks, 1 month, 2 months, 3 months and 5 months. Emails and text messages will include a link to a REDCap document that contains a set of embedded video clips representing the next chapter in each storyteller's narrative.
89102230|NCT05399056|Active Comparator|Enhanced usual care + Peer support|Subjects randomized to the eUC + Peer support intervention will be matched with a peer coach of the same gender, race, and approximate age. For those enrolled during a hospitalization, coaches will be instructed to attempt the initial phone contact prior to the patient's discharge; for patients enrolled after an ED visit or outpatient exacerbation, coaches will be instructed to contact the patients within 72 hours of randomization. Peer coaches will be asked to complete at least one call each week during months 1-2, biweekly calls during months 3-4, and monthly calls during months 5-6. Coaches will be asked to follow a conversation guide, provided during the initial training, to structure phone conversations with their paired patient.
89227708|NCT03659214||Treated group|Patients with proven CF (sweat-test > 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)
89227709|NCT03659214||Control group|Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco
89102231|NCT05398107|Experimental|Experimental: The BEAM program|The BEAM Program is delivered through a mobile application, weekly group telehealth sessions, and an online community forum. BEAM includes ~ 20 minutes of weekly video modules on parenting and mental health. Mental health videos provide content and emotion-regulation strategies drawn from the Unified Protocol, an evidence-based treatment for depression and anxiety disorders. Self-compassion and effective communication are also central focuses of the mental health content. Supportive parenting videos will provide mothers with emotion-focused parenting strategies and help mothers understand and respond to their children's challenging emotions and behaviours. The weekly group telehealth sessions will allow mothers to discuss content and ask questions, with the purpose of developing a sense of community and social support. The online community forum will provide a space for mothers to reflect on their learned skills and connect with other mothers taking part in the program.
89102232|NCT05398107|Active Comparator|Standard of Care: MoodMission|MoodMission is an evidence-based app which was developed based on cognitive behavioural therapy (CBT). The MoodMission app will provide mothers with missions. Missions are mental health strategies based on scientific evidence which are easily achievable (e.g., relaxation tips, exercise and fitness activities, yoga, mindfulness meditations, affirmations and coping statements). MoodMission will tailor missions based on the mothers current mood.
89227710|NCT00971438|Experimental|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of acute appendicitis are randomised to either diagnostic imaging (US or CT) or a repeat examination after 4-8 hours in-hospital observation.
89227711|NCT00971438|Active Comparator|Repeat examination after observation|Patients with a clinical scoring suggesting an equivocal diagnosis of appendicitis are randomised to either 4-8 hours of in-hospital observation or diagnostic imaging (US or CT)
89227712|NCT03657888|Experimental|Family Club Denmark (FCD)|Participation in FCD
89227713|NCT03657888|Other|Wait-list|Wait-list control
89227714|NCT00965120|Placebo Comparator|1|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of placebo (saline).
89227715|NCT00965120|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of bradykinin receptor antagonist (HOE-140).
89227716|NCT00971516|Active Comparator|Diabetes|compare cytokines between diabetes and non diabetes patients
89227717|NCT00971516|Active Comparator|Implants|Compare implant healing phases
89227718|NCT00971594|Experimental|WL+AEX|Weight loss plus aerobic exercise
89227719|NCT00971672||Toddlers from Jewish origin|Toddlers from Jewish origin aged 18 to 36 months
89227720|NCT00971672||Toddlers from non Jewish origin|Toddlers aged 18 to 36 months belonging to non Jewish (Arab) population
89227721|NCT00679289|Experimental|Cohort 1|"KW2871: 5 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
89227722|NCT00679289|Experimental|Cohort 2|"KW2871: 10 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
89227723|NCT00679289|Experimental|Cohort 3|"KW2871: 20 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
89227724|NCT00679211|Experimental|Trastuzumab emtansine|Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.
89227725|NCT00545948|Other|Arm A-Vinorelbine|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of vinorelbine sensitivity were given cisplatin + vinorelbine.
89102233|NCT05386355|Experimental|Vaccine Uptake App|24-week (8 weeks with weekly push notifications; 2 monthly push notifications for 2 months [1 notification per month]; 8 weeks without) exposure to a mobile phone application (app) designed to improve parental knowledge, attitudes, and self-efficacy regarding pediatric COVID-19 vaccination. The app will address logistical and motivational barriers to pediatric COVID-19 vaccination. Participants will also receive eight weekly nudges and 1 monthly nudge for 2 months (cues to action) regarding vaccinating their child that will be sent to participants via push notifications to their mobile devices. Through branching logic, users will access content tailored to their COVID-19 vaccine knowledge and confidence gaps, locality, degree of rural-urban primary residence, primary language (English/Spanish), race/ethnicity, and child's age.
89102234|NCT05386355|Active Comparator|General Health App|24-week (8 with weekly push notifications; 2 monthly push notifications for 2 months [1 notification per month]; 8 weeks without) exposure to a mobile phone app designed to provide information on general pediatric health and infection prevention and mitigation strategies based on recommendations from the American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC). Eight weekly nudges and 1 monthly nudge for 2 months regarding these topics will be sent to participants via push notifications to their mobile devices.
89102235|NCT05369065|Experimental|Ablation Treatment|The participants randomized to this arm will receive Neurotronic ablation treatment.
89102236|NCT05369065|Sham Comparator|Sham Treatment|The participants randomized to this arm will have a sham procedure (angiography only)
89102237|NCT05369065|Experimental|Single Arm non-Randomized Treatment|The participants treated in this arm will receive the Neurotronic ablation treatment
89102238|NCT05355311|Experimental|Acetyl-L-Carnitine|Acetyl-L-carnitine is a nutritional supplement and emerging research shows it has neuroprotective properties and may help treat alcohol use disorder and depression, 3 g daily for 6 weeks
89102239|NCT05355311|Placebo Comparator|Placebo|Daily for 6 weeks
89102240|NCT05354219||MPS patients|Any patient aged 0-100 with MPS type I, type III, type IV and type VI. Type VII MPS patients may also be eligible.
89102241|NCT05354219||Control|"For the control group -~Participants of any age currently being followed at MREH that have an eye condition unrelated to the cornea as established by clinical examination."
89102242|NCT05349539||Healthy Subjects|Cohort of healthy subjects as control.
89102243|NCT05349539||Patients with Parkinson's disease|Cohort of patients with Parkinson's disease
89102244|NCT05323266|Experimental|Nasal Continuous Positive Airway Pressure (nCPAP)|Nasal Continuous Positive Airway Pressure is the main mode of oxygen supply observed in this study, and this group of patients only use this oxygen supply mode to receive oxygen therapy after stroke.
89227726|NCT00545948|Other|Arm B-Pemetrexed|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of pemetrexed sensitivity were given cisplatin + pemetrexed.
89227727|NCT00755573|Active Comparator|Pregabalin|Pregabalin 300 mg - 600 mg BID
89227728|NCT00755573|Placebo Comparator|Placebo|Placebo arm
89227729|NCT00971906|Experimental|low dose of antigen + low dose of adjuvant|
89227730|NCT00971906|Experimental|high dose of antigen + high dose of adjuvant|
89227731|NCT00971906|Experimental|high dose of antigen|
89227732|NCT00755651|Experimental|H Pipelle|Endometrial sample obtained using the H Pipelle
89227733|NCT00755651|Active Comparator|Pipelle|Endometrial sample obtained with standard Pipelle
89102245|NCT05323266|Experimental|High-Flow Nasal Cannula (HFNC)|NasalContinuousPositiveAirwayPressure is another oxygen supply mode mainly observed in this study, and this group of patients only use this oxygen supply mode to receive oxygen therapy after stroke.
89102246|NCT05318703|Experimental|cognitively enhanced tai ji quan|Participants receive a cognitively enhanced tai ji quan exercise intervention for 16 weeks.
89102247|NCT05318703|Active Comparator|stretching exercise|Participants receive a stretching exercise intervention for 16 weeks.
89102248|NCT05311033|Experimental|Samples Without DNA|Healthy males aged 20-40 years with at risk of post-inflammatory hyperpigmentation: phototype IV or V according to the Fitzpatrick scale (1) and having a colorimetric individual typology angle (ITA°) between -20° and 28° and/or having already had post-inflammatory pigmentation or hyperpigmentation (e.g. acne scars, melasma)
89102249|NCT05310708|Experimental|Validation Study of a patch-based PSG system|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
89227734|NCT00974948|Active Comparator|Neurolysis|Patients will undergo EUS followed by EUS-guided, bilateral neurolysis with bupivicaine and absolute alcohol.
89227735|NCT00974948|No Intervention|Conventional therapy|EUS will be performed with no celiac plexus neurolysis.
89227736|NCT02559869||Amyotrophic Lateral Sclerosis (ALS)|Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.
89227737|NCT02559869||Healthy Controls|Subjects with no known neurological disorder.
89227738|NCT00975026|Active Comparator|Massages|Chair massage for 30 minutes once a week.
89102250|NCT05292703|Experimental|face-to-face group|In the face-to-face group, the intervention is a participatory activity based on art and olfactory stimulation which consists of practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, adapted to health circumstances and respecting social distancing measures. Due to the health crisis, the workshops will be offered in several groups ranging from 8 to 10 participants, these groups will be equal. A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities
89102251|NCT05292703|Experimental|remote group|For the remote group, immediately after randomization, they will receive the connection link to the internet application and an individual connection code. The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop. The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks.
89102252|NCT05281562|No Intervention|Standard of Care Group|Patients will receive standard of care wound treatment as determined by a treating physician.
89102253|NCT05281562|Experimental|Immunonutrition Supplementation Group|Patients will receive a 6 week daily oral supply of 1.68 grams Omega-3 fatty acids, 4.5 grams L-Arginine, and 500 mg Vitamin C.
89102254|NCT05276596|Active Comparator|Control group|The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
89102255|NCT05276596|Experimental|Test group|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
89102256|NCT05274971|Experimental|Active management group|Active dietary management and aerobic exercise training. Subjects will receive assessment and education of DASH diet (0, 4, and 8 weeks), with active aerobic exercise training (1 hour everyday exercise, at least 5 times per week for 12 weeks) (aerobic exercise education at baseline, 4, and 8 weeks after randomization). Each set of aerobic exercise consists of 10 minutes warm-up, 40 minutes moderate-intensity treadmill trotting, and 10 minutes cooldown. Telephone counseling at 2, 6, and 10 weeks after randomization.
89102257|NCT05274971|No Intervention|Control group|Subjects will not receive education and recommendation of dietary management and aerobic exercise training.
89102258|NCT05272644|Active Comparator|urethral hypermobility-surface electromyographic biofeedback only|Participant will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
89102259|NCT05272644|Experimental|urethral hypermobility-surface electromyographic biofeedback and electrical stimulation|Participant will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
89102260|NCT05272644|Active Comparator|intrinsic sphincter deficiency-surface electromyographic biofeedback only|Participant will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
89102261|NCT05272644|Experimental|intrinsic sphincter deficiency-surface electromyographic biofeedback and electrical stimulation|Participant will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
89102262|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 1|Participants will receive single oral dose of modified release evobrutinib tablet-1 (MR-T1) on Day 1 in treatment period 1, followed by single oral dose of modified release tablet-2 (MR-T2) on Day 1 in treatment period 2, followed by two single oral doses of immediate release (IR) oral tablet [Ref (TF2)] on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or multiparticulate system capsules (MUPS-C) formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102263|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MR-T1 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102264|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 3|Participants will receive two single oral doses of Ref (TF2) on Day 1 in treatment period 1, followed by single oral dose of MR-T1 on Day 1 in treatment period 2, followed by single oral dose of MR-T2 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89227739|NCT00975026|Active Comparator|Massages + Stretches|Chair massage for 30 minutes once a week in addition to stretching exercises, to be done twice daily for 20 minutes.
89227740|NCT00975026|No Intervention|No Intervention|
89102265|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 4|Participants will receive single oral dose of modified release evobrutinib tablet-3 (MR-T3) on Day 1 in treatment period 1, followed by single oral dose of modified release tablet-4 (MR-T4) on Day 1 in treatment period 2, followed by two single oral doses of immediate release (IR) oral tablet [Ref (TF2)] on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or multiparticulate system capsules (MUPS-C) formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102266|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 5|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MR-T3 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102267|NCT05245396|Experimental|Part A: Evobrutinib: Treatment Sequence 6|Participants will receive two single oral doses of Ref (TF2) on Day 1 in treatment period 1, followed by single oral dose of MR-T3 on Day 1 in treatment period 2, followed by single oral dose of MR-T4 on Day 1 in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102268|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 1|Participants will receive single oral dose of MUPS-C1 evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C2 on Day 1 in treatment period 2, followed by two single oral doses of Ref (TF2) on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102269|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 2|Participants will receive single oral dose of MUPS-C2 evobrutinib on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MUPS-C2 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102270|NCT05245396|Experimental|Part B: Evobrutinib: Treatment Sequence 3|Participants will receive two single oral doses of Ref (TF2) evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C1 on Day 1 in treatment period 2, followed by single oral dose of MUPS-C2 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102271|NCT05245396|Experimental|Part C: Evobrutinib: Treatment Sequence 4|Participants will receive single oral dose of MUPS-C3 evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C4 on Day 1 in treatment period 2, followed by two single oral doses of Ref (TF2) on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89227741|NCT00971984||Alpha thalassemia patients|Patients diagnosed with alpha thalassemia mutations and anemia
89102272|NCT05245396|Experimental|Part C: Evobrutinib: Treatment Sequence 5|Participants will receive single oral dose of MUPS-C4 evobrutinib on Day 1 in treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by single oral dose of MUPS-C3 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102273|NCT05245396|Experimental|Part C: Evobrutinib: Treatment Sequence 6|Participants will receive two single oral doses of Ref (TF2) evobrutinib on Day 1 in treatment period 1, followed by single oral dose of MUPS-C3 on Day 1 in treatment period 2, followed by single oral dose of MUPS-C4 on Day 1 of in treatment period 3, followed by 2 sequential periods 4 and 5. The best MR-T and /or MUPS-C formulation from period 1, 2, and 3 will be tested with additional optimization to choose the best overall formulation in treatment period 4. The best overall formulation from Period 4 may be further tested in treatment period 5 under fed or fasted conditions. There will be 72 hours washout period between Periods 1 to 3 and 28 days between Period 3 and 4 and Period 4 and 5.
89102274|NCT05245396|Experimental|Part D: Evobrutinib: Treatment Sequence 1|Participants will receive single oral dose of MR-T adapted on Day 1 of treatment period 1, followed by two single oral doses of Ref (TF2) on Day 1 in treatment period 2, followed by 1 sequential period 3. There will be 72 hours washout period between Periods 1 and 2 and 28 days between Period 2 and 3.
89102275|NCT05245396|Experimental|Part D: Evobrutinib: Treatment Sequence 2|Participants will receive two single oral doses of Ref (TF2) on Day 1 of treatment period 1, followed by single oral dose of MR-T adapted on Day 1 in treatment period 2, followed by 1 sequential period 3. There will be 72 hours washout period between Periods 1 and 2 and 28 days between Period 2 and 3.
89102276|NCT05241262|Experimental|Active drug (NAC)|Participants will receive NAC for 3 months.
89102277|NCT05224011|Experimental|Experimental|The Boppli device will be applied to the patients' arm or foot on either side of the body and is intended for single use of up to 72 hours and is discarded following use. The device will only be used in patients requiring continuous blood pressure monitoring, through the use of an invasive arterial line (IAL), to compare the data obtained by the Boppli to that obtained by the IAL.
89102278|NCT05218785||Botulinum toxin A injection|Patients will receive a total of 3 -three - injections of 75 IU Botulinum Toxin A in the proximal medial gastrocnemius muscle. Treatments will be performed by a specialist in neurology as a Ultra-Sound guided injection into the proximal medial gastrocnemius muscle Injections will be administered at baseline, 3 months and 6 months.
89102279|NCT05189860|Experimental|C-MIC Device|Device plus Standard of Care
89102280|NCT05189314||Thyroidectomy|Patients with benign thyroid nodules who undergo surgical resection
89102281|NCT05189314||RFA|Patients with benign thyroid nodules who undergo radiofrequency ablation
89102282|NCT05185427||Participants with pulse oximetry readings|The research team will take a reflectance measurement on the same location that the most recent pulse oximetry measurement was taken. In addition, a reflectance measurement will be taken bilaterally for the nailbed, dorsal and ventral side of the digits, dorsal and ventral side of the hand, dorsal and ventral side of the forearm, lower leg, foot, and either side for the ear. The most recent pulse oximetry and arterial oxygen saturation readings will be accessed through the electronic medical records, those readings are generally conducted simultaneously and will provide comparison. The duration anticipated for an individual participant's participation is 1 day.
89102283|NCT05161936|Experimental|Lumasiran Dose 1|Participants will be administered lumasiran by subcutaneous (SC) injection.
89102284|NCT05161936|Experimental|Lumasiran Dose 2|Participants will be administered lumasiran by SC injection.
89102285|NCT05161936|Placebo Comparator|Placebo|Participants will be administered placebo by SC injection.
89102286|NCT05158023|Placebo Comparator|Placebo every two weeks (q2w)|Placebo q2w - placebo loading dose equivalents at Baseline and Week 1, then placebo dose equivalents every 2 weeks (q2w) from Week 2 to Week 14.
89102287|NCT05158023|Experimental|ASLAN004 300 mg q2w|ASLAN004 300 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 300mg q2w from Week 2 to Week 14.
89102288|NCT05158023|Experimental|ASLAN004 400 mg q2w|ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14.
89102289|NCT05158023|Experimental|ASLAN004 400 mg every four weeks (q4w)|ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14.
89102290|NCT05158023|Experimental|ASLAN004 600 mg q4w|ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg ASLAN004, alternating with placebo dose equivalents, q2W from Week 4 to Week 14.
89102293|NCT05127837|No Intervention|Treatment as Usual (TAU)|CBT for psychosis distance learning course.
89102294|NCT05127837|Experimental|CBTpro|In addition to TAU, clinicians and clients receive the CBTpro training.
89102295|NCT05123313|No Intervention|Control group|The control group will not receive a series of consultations with their general practitioner. Controls will receive baseline measurements and follow-up measurements 3 months and 6 months following baseline measurements.
89102296|NCT05123313|Experimental|Intervention group|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences. Interventions will receive baseline measurements and follow-up measurements 3 months and 6 months following baseline measurements.
89102297|NCT05118828|Experimental|Guided internet-based treatment (AS-iCBT)|
89102298|NCT05118828|Active Comparator|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|
89102299|NCT05116852||Both grieving a loved one to opioid-related death and have an actively using loved one|These individuals will complete the study survey for their designated experience both supporting a loved one in treatment for Opioid Use Disorder, and having lost a loved one to opioid-related death.
89102300|NCT05116852||Individuals supporting a loved one in treatment for Opioid Use Disorder|These individuals will complete the study survey for their designated experience supporting a loved one in treatment for Opioid Use Disorder.
89102301|NCT05116852||Individuals grieving a loved one to opioid-related death|These individuals will complete the study survey for their designated experience losing a loved one to opioid-related death.
89102302|NCT05112705|Active Comparator|Ultrasound Group|Patients will be receiving twice weekly proximal lower limb ultrasound
89102303|NCT05112705|No Intervention|Control Group|Proximal lower limb ultrasound will be performed as per the treating team discretion
89102304|NCT05108649|Experimental|Nicotine Corrective Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session.
89102305|NCT05108649|Experimental|Delayed Control Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will not view nicotine messaging until the final study session (Delayed Control Messaging).
89102306|NCT05108649|Experimental|Normal Nicotine Content (NNC) cigarettes|After completing a 7-day baseline period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive normal nicotine content cigarettes.
89102307|NCT05108649|Experimental|Reduced Nicotine Content (RNC) cigarettes|After completing a 7-day baseline period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content cigarettes.
89227742|NCT00965198||Clearlink Arm, EUH|Standard catheter access device at Emory University Hospital
89102308|NCT05104515|Experimental|OVM-200|"2 mg/mL OVM-200 solution. Proposed dose levels for Phase 1a: 250, 500, and 1000 μg. The planned doses may be adjusted based on SRC recommendations. Following review of the data, 1 additional dose level may be added up to a maximum of 2000 μg.~The dose level for Phase 1b will be selected following review of the data from Phase 1a and will not exceed the dose safely administered in Phase 1a."
89102309|NCT05100888|Experimental|Theta-burst rTMS|Theta-burst repetitive transcranial magnetic stimulation
89102310|NCT05100888|Sham Comparator|Sham stimulation|Sham stimulation of the same location
89102311|NCT05097391|Experimental|Experimental group|i - Warm-up (5 minutes) ii- Conventional physiotherapy exercise (15 minutes) iii - Over-ground training with lower limb loading (15-25 minutes)
89102312|NCT05097391|Active Comparator|Control group|i - Warm-up (5 minutes) ii- Conventional physiotherapy exercise (15 minutes) iii - Over-ground training WITHOUT lower limb loading (15-25 minutes)
89102313|NCT05081401||Individualized 9-12 month all-oral regimen|Treatment regimen is individually designed in this trial by responsible physicians at study sites based on radiological, clinical, bacteriological as well as drug sensitivity test results. RIF resistance was confirmed with phenotypic or molecular drug sensitivity test. Drug resistance to FQs, SLIDs, INH and Eto was evaluated by GeneXpert MTB/XDR. PZA resistance was confirmed by whole genome sequencing. Candidate anti-TB drugs are BDQ, LZD, FQs, Cs, Cfz, Z, Dlm and INH.
89102314|NCT05075252||R1|patients affected by acute appendicitis undergoing totally laparoscopic appendectomy
89102315|NCT05070780||Healthy Subjects|
89102316|NCT05070780||Patients with rigidity|
89102317|NCT05070780||Patients with spasticity|
89102318|NCT05063461|Experimental|Sevoflurane with different site effect concentrations of remifentanil|The tetanic stimulus is conducted between laryngeal mask intubation and surgical stimulation, while no other noxious stimuli are presented. The effect site concentration of remifentanil is increased step-by-step via a Target Controlled infusion device to a concentration of 2, 4, 6 ng/ml. At least 5min of the steady-state period is maintained before tetanic stimulus.
89102319|NCT05057507||Atrial fibrillation patients undergoing radiofrequency catheter ablation|Up to 115 patients undergoing radiofrequency catheter ablation will be enrolled.
89102320|NCT05046444||Unclear diagnosis via conventional methods|The study population consists of carefully chosen patients with potential hematological malignancy, for which current diagnostic methods were not sufficient to provide clear-cut diagnosis and definitive clinical guidance. SIRIUS will be conducted for a total number of 110 patients with inconclusive diagnosis by gold standard techniques for a total of up to nine months after the first enrollment.
89102321|NCT05032131|Experimental|Experimental|"Group 1:~Patients treated by sirolimus since at least 6 months (but still disabled)~Group 2:~Patients currently (for at least 3 months) without specific treatment for inclusion myositis"
89102322|NCT05026619|Placebo Comparator|Control|Receives a fact sheet on diabetes in Singapore
89102323|NCT05026619|Experimental|Fertility-related information|Receives accurate information on age-related fertility
89102324|NCT05026619|Experimental|Policy-related information|Receives accurate information on local policy initiatives related to age at marriage and childbearing
89102325|NCT05023070|Experimental|Test condition 1|Cannabidiol 200 mg with standard meal
89102326|NCT05023070|Experimental|Test condition 2|Cannabidiol 400 mg with standard meal
89102327|NCT05023070|Experimental|Test condition 3|Epidiolex 400 mg with standard meal
89102328|NCT05023070|Experimental|Test condition 4|Cannabidiol 400 mg with high fat meal
89227743|NCT00965198||VLINK Arm, EUHM|Novel, silver-coated catheter access device at Emory University Hospital Midtown
89227744|NCT00965198||Clearlink, EUM|Standard catheter access device at at Emory University Hospital Midtown
89227745|NCT00965198||VLINK Arm, EUH|Novel, silver-coated catheter access device at Emory University Hospital
89227746|NCT00975104|Experimental|AMG 745 0.3 mg/kg|0.3 mg/kg AMG 745
89227747|NCT00975104|Experimental|AMG 745 1.0 mg/kg|1.0 mg/kg, AMG 745
89227748|NCT00975104|Placebo Comparator|Placebo|Placebo
89102329|NCT05003713|Experimental|Part 1: SAD Cohorts A through F CORT125236|Cohorts will receive a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 20-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose level and dose regimen (whether to split the dose) will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT125236 dose from the previous cohort in a fasted or fed state; the dose level, dose regimen, and prandial state will be determined after evaluation of safety and PK data from previous cohorts.
89102330|NCT05003713|Placebo Comparator|Part 1: SAD Cohorts A through F Placebo|Cohorts will receive a single dose of placebo matching CORT125236 lipid capsule formulation by mouth on Day 1. The dose regimen and prandial state will be the same as those for the cohort members receiving CORT125236.
89227749|NCT00975104|Experimental|AMG 745 3.0 mg/kg|3.0 mg/kg, AMG 745
89227750|NCT00679055|Experimental|MK-0736|Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
89102331|NCT05003713|Experimental|Part 2: MAD Cohorts A through D CORT125236|Cohorts will receive once- or twice-daily doses of CORT125236 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose level, dose schedule, and prandial state for each cohort will be determined after evaluation of safety and PK data from Part 1 and preceding Part 2 cohorts.
89227751|NCT00679055|Placebo Comparator|Placebo|Participants will be orally administered placebo once daily for 12 weeks.
89102332|NCT05003713|Placebo Comparator|Part 2: MAD Cohorts A through D Placebo|Cohorts will receive once- or twice-daily doses of placebo matching CORT125236 lipid capsule formulation by mouth for 14 days. The dose regimen and prandial state will be the same as those for the cohort members receiving CORT125236.
89102333|NCT05003713|Experimental|Part 3: Single Dose Pharmacodynamic Effect|In Period 1, participants will receive a single dose of prednisone 25 mg (20 mg + 5 mg) tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT125236 and the prandial state will be determined after evaluation of safety and PK data from Part 1. Part 3 of the study is optional.
89102334|NCT04980794|Experimental|Parent-Child Intervention|This is a four-dose intervention that includes psychoeducational modules and communication coaching administered through community organizations over the course of four weeks. Both participating adults and the participating child receive materials to review each week, paired with weekly contact from a family coach.
89102335|NCT04980794|Active Comparator|Self-study intervention|This is a four-dose intervention that include written self-study materials to review, paired with weekly contact with a family coach. Both participating adults receive self-study materials; the participating child does not receive separate materials.
89102336|NCT04980781|Experimental|Participants receiving PED-t|"Participants, i.e. females with bulimia nervosa or binge eating disorder, are recruited for therapy in the trained ERC. The treatment program consists of 20 behavioral therapy sessions covering 16 weeks, and with single follow-up sessions at 2-, and 4- months post-therapy.~Participants are interviewed on the expectations to- and experiences from having therapy in the ECR, and monitored and evaluated on therapy effectiveness (i.e. diagnostic outcomes)."
89102337|NCT04980781|Experimental|Therapists and management in ERC offering PED-t|"Employees in the ECR and the management will be trained in giving PED-t in their facility, and will then perform therapy with a single group of participants recruited.~Therapists/employees trained in PED-t will be interviewed about their expectations to- and experiences from giving the PED-t, and also being monitored according to therapy manual fidelity.~The management at the facility offering PED-t will be interviewed about their experiences on administration and implementation of the PED-t in their facility."
89102338|NCT04961645|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants will have two study visits. During the first visit, participants will have an fMRI scan to identify the OPA location in each individual participant. During the second visit, participants will receive rTMS. Each visit lasts approximately 90 minutes.
89102339|NCT04955002||Healthy UK adults|Healthy UK adults
89102340|NCT04951284||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89102341|NCT04951284||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89102342|NCT04951284||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89102343|NCT04951284||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89102344|NCT04943484||Gastric cancer|Male and female subjects, over 18 years of age, with histological diagnosis of locally advanced gastric carcinoma (AGC), surgically resectable, without evidence of distant metastases (cT2-T4a; N0-3; M0) for which a surgical intervention with curative purposes is indicated both as a first treatment and following preoperative neoadjuvant chemotherapy
89102345|NCT04939818||Group 1: Cognitive Disorders|"Alzheimer's Disease (AD) Meet National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Dementia with Lewy bodies (DLB) Diagnosis of possible or probable DLB based on the criteria defined by The Dementia with Lewy Bodies Consortium (2015)~Non-AD non-DLB MCI Diagnosis of 'probable' and 'possible' behavioral variant frontotemporal dementia (bvFTD) according to the International Behavioral Variant FTD Criteria Consortium OR semantic variant or nonfluent-agrammatic variant primary progressive aphasia (PPA) FTD according to Mesulam's criteria OR Vascular Dementia according to NINDS-AIREN International Workshop~AND~Date of diagnosis not more than five years prior to consent Subjects must have MMSE scores of 23-30 (inclusive); or TICS40 score of 20-40 (inclusive) based on a test not older than 1 month at the time of consent.~Age of 50-85 years (inclusive)"
89102346|NCT04939818||Group 2: Motor disorders|"Parkinson's Disease (PD)~Diagnosis of idiopathic Parkinson's Disease based on the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria~Date of diagnosis not more than five years prior to consent~Hoehn and Yahr stage 2 or less~Age of 30-85 years (inclusive)~Motor neuron Disease (MND)~Diagnosis of Amyotrophic Lateral Sclerosis based on gold-standard clinical criteria~Stage 3 or less on the King's ALS Staging system~Age of 18-85 years (inclusive)"
89227752|NCT04008290|Experimental|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl containing 0.6 mg liraglutide.
89227753|NCT04008290|Placebo Comparator|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 100 µl saline (0.9%) solution.
89227754|NCT02559167|Active Comparator|Cannabidiol|Participants will receive CBD 800 mg for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
89102347|NCT04939818||Group 3: Affective disorders|"Major Depressive Disorder (MDD)~Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a current major depressive episode (MDE) as assessed by the MINI~Current episode of at least moderate severity as assessed by the Clinical Global Impression (CGI) scale.~Date of diagnosis (using MINI assessment) and severity (CGI) maximum of two months prior to consent.~Age of 18-85 years (inclusive).~Bipolar Disorder (BD)~Meet DSM-5 criteria for BD as assessed by the MINI (type 1 or type 2)~Current depressive episode as assessed by the MINI~Current episode of at least moderate severity as assessed by the Clinical Global Impression (CGI) scale.~Date of diagnosis (using MINI assessment) and severity (CGI) maximum of two months prior to consent.~Age of 18-85 years (inclusive)."
89102348|NCT04939818||Group 4: Unaffected Controls|"Group 4 specific recruitment criteria matched for the 'Group 1: Cognitive Disorders' cohort:~Age of 50-85 years (inclusive)~Approximately age, gender and education matched to AD subjects on a group level.~In otherwise good health condition.~Group 4 specific recruitment criteria matched for the 'Group 2: Motor Disorders' cohort:~Age of 30-85 years (inclusive)~Approximately age, gender and education matched to PD subjects on a group level.~In otherwise good health condition.~Group 4 specific recruitment criteria matched for the 'Group 3: Affective Disorders' cohort:~Age of 30-85 years (inclusive).~Approximately age, gender and education matched to MDD/BD subjects on a group level.~In otherwise good health condition."
89102349|NCT04903054|Experimental|Lulizumab + SOC|"N=27 participants will receive a loading dose of lulizumab on Day 0, the day of surgery. This will be followed by a maintenance dose administered on a weekly basis (weeks 1 through 26 post-transplant), followed by administration every two weeks (weeks 28 through 52 post-transplant). Method of administration: subcutaneously. Dose unit of measure: milligrams (mgs).~Plus (+) Standard of Care (SOC) Regimen, per protocol-~Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center:~Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs.~Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs.~Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs.~Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs."
89102350|NCT04903054|Active Comparator|Tacrolimus + SOC|"N=27 participants will receive tacrolimus initiated according to local standard of care and adjusted over time (maintenance) to target optimal trough levels measured in ng/mL: 0 to 6 months, 7 to 12 months and, thereafter, until completion of study participation. Dose unit of measure: mg/kg.~Plus (+) Standard of Care (SOC) Regimen, per protocol-~Renal transplant recipients will receive FDA-approved, immunosuppressive medications according to standard of care at Emory Transplant Center:~Induction Thymoglobulin: Administered intravenously, dose unit of measure: mgs.~Induction Methylprednisolone: Administered intravenously, dose unit of measure: mgs.~Maintenance: Mycophenolate mofetil (MMF) administered by mouth twice daily, dose unit of measure: mgs.~Maintenance: Beginning the day after methylprednisolone is completed, prednisone will be administered by mouth daily, dose unit of measure: mgs."
89102351|NCT04894747|Experimental|Mycoprotein|Bolus ingestion of mycoprotein providing 25g of protein.
89102352|NCT04894747|Experimental|Pea protein|Bolus ingestion of pea protein providing 25g of protein.
89102353|NCT04894747|Experimental|Mycoprotein/pea protein dry blend|Bolus ingestion of mycoprotein/pea protein dry blend providing 25g of protein.
89102354|NCT04892147|Experimental|Experimental group|Randomly selected to participate first in MOBA group
89102355|NCT04892147|Other|Wait-list-control group|Randomly selected for study assessments parallel with experimental group. Participates in MOBA after completion of the experimental group
89102356|NCT04890249|Experimental|Investigational Lens Device #1|Investigational IOL Model C1V000
89102357|NCT04890249|Experimental|Investigational Lens Device #2|Investigational IOL Model C2V000
89102358|NCT04890249|Active Comparator|Control Lens|Control IOL Model ICB00
89102359|NCT04875234||Legally Blind Dry AMD Patients|Legally Blind Dry AMD Patients with either unilateral or bilateral blindness
89102360|NCT04874051|Experimental|Experimental Group (EG)|In the EG the subjects will perform balance exercises using the OAK system under the supervision of a trained physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
89102361|NCT04874051|Active Comparator|Control Group (CG)|In the CG the subjects will be asked to perform conventional balance exercises under the supervision of a physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
89102362|NCT04873245|Active Comparator|Intensive Behavioral Program Arm|"Participants randomized to this arm of the study will receive intensive behavioral therapy.~Participants will receive 52 weekly sessions (50% in person and 50% virtual)."
89102363|NCT04873245|Active Comparator|Medication Arm|Participants randomized to this arm of the study will receive semaglutide and will receive behavioral therapy. Behavioral therapy will consist of 12 monthly sessions (50% in person and 50% virtual).
89102364|NCT04863014|Experimental|evinacumab|Randomized 1:1
89102365|NCT04863014|Placebo Comparator|Placebo|Randomized 1:1
89102366|NCT04846426||Arm 1: MCI amyloid positive|"Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~Positive amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89102367|NCT04846426||Arm 2: MCI amyloid negative|"Non-AD Mild Cognitive Impairment (MCI)~Negative amyloid PET or amyloid CSF status.~MMSE 23-30 (inclusive)"
89102368|NCT04846426||Arm 3: CN amyloid positive|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Positive amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89102369|NCT04846426||Arm 4: CN amyloid negative|"Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~Negative amyloid PET or amyloid CSF status.~MMSE 26-30 (inclusive)"
89102370|NCT04846413||Patients|Patients affected by neurologic disorders showing a prominent voice impairment.
89102371|NCT04839289|Experimental|A-B-A|"Participants will be fit with hearing instruments A and B in the following order:~Hearing instrument A Hearing instrument B Hearing instrument A"
89102372|NCT04839289|Experimental|B-A-B|"Participants will be fit with hearing instruments A and B in the following order:~Hearing instrument B Hearing instrument A Hearing instrument B"
89102373|NCT04834557|Placebo Comparator|Control|Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 24 weeks.
89102374|NCT04834557|Experimental|Digoxin|Participants in this arm will receive digoxin 0.25 mg every other day + DMARDs for 24 weeks.
89102375|NCT04834557|Experimental|Ursodeoxycholic acid (UDCA)|Participants in this arm will receive ursodeoxycholic acid (UDCA) 500 mg/day + DMARDs for 24 weeks.
89102376|NCT04825093|Experimental|Intervention group|Women allocated to this group will be supplemented with 1,000 UI of vitamin D3.
89102377|NCT04825093|Active Comparator|Control group|The control group will consist of pregnant women supplemented with 400 UI of vitamin D3.
89102378|NCT04820478|Experimental|Beta Hydroxybutyrate Ester|3 x 10 g beta hydroxybutyrate ester per day, in addition to normal food intake and standard therapy (2 x 50 mg riluzole per day)
89102379|NCT04820478|Placebo Comparator|Placebo|matching placebo, in addition to normal food intake and standard therapy (2 x 50 mg riluzole per day)
89102380|NCT04797039||MR guided cryoablation|Focal MR guided cryoablation for low- to intermediate-grade prostate cancer
89111189|NCT02792595|Experimental|Test Product C|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
89102381|NCT04793152|Experimental|Vancomycin targeting trough of 10 to 15mg/L|"If the patient has not received intravenous vancomycin yet, a loading dose of 25mg/kg (maximum 2g) will be given if the patient is severely ill at the discretion of the physician and pharmacist. The initial dose is 15mg/kg with a maximum dose of 2g. The frequency would be based on creatinine clearance (CrCl) as per the Cockcroft-Gault equation: Q8H if CrCl is >100mL/min, Q12H if CrCl is 50-100mL/min, Q24H if CrCl is 30- 49mL/min, and Q48H if CrCl is <30mL/min. Pharmacists can change the initial dose at their own discretion.~Trough level will be done 30 minutes before the 4th dose. For Q48H dosing, a trough level will be done before the second dose. Vancomycin dosing will be adjusted to target trough level of 10 to 15mg/L. If not at target, the pharmacist will adjust the dose based on an assumption of linear pharmacokinetics. Trough will be remeasured before the fourth dose of the new regimen."
89102382|NCT04793152|Active Comparator|Vancomycin targeting AUC of 400 to 600|"The initial intravenous vancomycin dosing is the same as described above for the trough group.~The AUC target will be 400 to 600, which assumes a MIC of 1ug/mL by broth microdilution.~After the first non-loading dose of vancomycin, patients will have vancomycin level 30 minutes before the next dose. As per the pharmacist's discretion, patient may have an additional vancomycin level one hour after infusion of vancomycin for more accurate estimates. A pharmacist will use a Bayesian software to estimate the AUC and the optimal dose."
89102383|NCT04787978|Experimental|AAMWI-OSU Intervention|In this single-arm pilot program, 100 African American male participants will be enrolled who have poor or average cardiovascular health (< 4 life's simple 7 metrics in the ideal range) to a physical activity, education and patient activation intervention.
89102384|NCT04773483|Active Comparator|Quorn Food products|
89102385|NCT04773483|Active Comparator|Meat/fish products|
89102386|NCT04770493|Experimental|Lamotrigine|Lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks
89102387|NCT04770493|Placebo Comparator|Placebo|Identical matching placebo capsules
89102388|NCT04763993|Active Comparator|RYGBP|RYGBP: Roun-en-Y Gastric Bypass
89102389|NCT04763993|Experimental|SG|SG: Sleeve Gastrectomy
89102390|NCT04761432|Experimental|Intervention arm|Thirty (30) adult patients will be enrolled in this study. Each patient will be monitored simultaneously with the neoGuard device and a conventional patient monitor. Paired readings for temperature, respiratory rate, pulse rate and oxygen saturation will be captured every second for a maximum observation period of 1 hour.
89102391|NCT04745117||Women with suspected breast cancer|"All women referred under the diagnosis suspected breast cancer will be asked to fill out the questionnaire READHY."
89102392|NCT04727047|Active Comparator|Neuromuscular Electrical Stimulation|"Neuromuscular electrical stimulation will be applied to the calf muscles. The level of stimulation will be increased weekly from 10 to 30 mA during the first 6 weeks after surgery.~In addition, patients will follow standard therapy for Achilles tendon repair."
89102393|NCT04727047|No Intervention|Control|Patients will follow standard therapy for Achilles tendon repair.
89102394|NCT04698564|Experimental|Single-arm study in patients who are suspected or known to have prostate cancer|Perform metabolic magnetic resonance imaging on men suspected to have a prostate cancer to understand if metabolic MRI can be safely performed on this population
89102395|NCT04685265|Active Comparator|anle138b|150 mg and higher dosage
89102396|NCT04685265|Placebo Comparator|Placebo|Matching placebo dosage
89102397|NCT04663555|Experimental|DEX 20 mg|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10.
89102398|NCT04663555|Active Comparator|DEX 6 mg|Patients in the control group after randomization will receive dexamethasone 6 mg day 1-10.
89102399|NCT04662320|Experimental|Brief Electrical Stimulation|Single, 10 minute dose of electrical stimulation delivered to the ulnar nerve during surgical intervention for cubital tunnel decompression.
89102400|NCT04662320|No Intervention|Standard of Care|Surgical intervention for cubital tunnel decompression.
89102401|NCT04630262|Active Comparator|ATTUNE Cementless CR Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Cruciate Retaining Configuration.
89102402|NCT04630262|Active Comparator|ATTUNE Cementless PS Fixed Bearing|Subjects enrolled who undergo TKA with the ATTUNE Cementless Fixed Bearing Posterior Stabilizing Configuration.
89102403|NCT04616417|Experimental|Investigational Oocyte Cryopreservation|All subjects will undergo controlled ovarian hyperstimulation. They will be treated with variable dosages of injectable gonadotrophins over a period of 8 to 12 days. Response will be monitored using vaginal ultrasound and serum estradiol levels. When appropriate follicle maturation has been achieved, a single dose of human chorionic gonadotropin (hCG) will be administered to induce final oocyte maturation. Thirty-six hours after hCG administration, the subject will undergo standard transvaginal oocyte retrieval under ultrasound guidance. The procedure takes approximately 20 minutes and is carried out under conscious sedation with Fentanyl and Versed. The oocytes are immediately handed off to the embryology technicians in the IVF laboratory.
89102404|NCT04581369|Active Comparator|Direct Intervention|"Initial Evaluation: Prior to discharge, the care coordinator will review the hospital discharge plan, obtain the approval of the patient's physicians to co-manage the patient's care, and schedule a visit with the patient at their place of discharge.~Participants in this arm will receive direct interaction with a care coordinator to develop an individualized care plan. Frequent assessments, at least once every two weeks, will occur to continue to follow or to modify the care plan based on the needs of the patient.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians and their participation in this study will be ended."
89102405|NCT04581369|Sham Comparator|Standard of Care|Prior to hospital discharge, the care coordinator will identify the primary care and/or hepatology provider of patients in the usual care group and will ensure follow up appointments at the time of hospital discharge. The coordinator will compose and send a letter to the primary care and/or hepatology provider summarizing the patient's diagnosis, hospital course, discharge medications, and the plan of follow-up care. If the patient does not already have a primary care or hepatology provider, the coordinator will work with the patient to identify a new provider. Subjects in this group will receive no further intervention.
89102406|NCT04581369|Placebo Comparator|Caregiver|The caregivers of people with cirrhosis will be enrolled in the study. They will complete the assessments at baseline, 3 months and 6 months.
89102407|NCT04569136|Experimental|Intervention group|"Educating the patient about mastitis and self-management strategies~Treating with therapeutic ultrasound~Administering and teaching breast massage"
89102408|NCT04569136|Sham Comparator|Sham group|"Educating the patient about mastitis and self-management strategies~Receiving sham ultrasound~Administering and teaching breast massage"
89102409|NCT04569136|Other|Usual care group|Receiving usual obstetric care, which may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff
89102410|NCT04565288|Experimental|Atomoxetine|Atomoxetine (40 mg/day for 3 days then 80 mg/day thereafter) during a 6-week medication trial
89102411|NCT04565288|Placebo Comparator|Placebo|Identical matching placebo capsules
89102412|NCT04560361|Experimental|Electroacupuncture group|Choose the appropriate position according to the patient's herpes site, and routinely disinfect the skin. Paste the fixed insulating pad on the acupoint, and use a 0.30×40mm acupuncture needle to penetrate the skin 10mm obliquely through the fixed insulating gasket at Ashi point; According to the above operation, the SJ6 and GB34 point of the affected side are directly penetrated into the skin 15-20mm. The local Ashi point connects the two poles of the electroacupuncture device according to the first and last points of the long axis of the painful part, and the SJ6 and GB34 point on the affected side are connected to the poles of the electroacupuncture device. Electroacupuncture waveform is continuous wave, frequency is 2Hz, and current intensity is 1-5mA (causing slight tremor of the skin around the acupuncture point without pain). Continue the electroacupuncture treatment for 30 minutes.
89102413|NCT04560361|Sham Comparator|Sham electroacupuncture group|Participants randomly assigned to the sham electroacupuncture (SA) group received sham electroacupuncture by using placebo blunt needles at the same acupoints. After disinfecting the skin and placing the sterile insulating adhesive pads on unilateral Zhigou, Yanglingquan and Ashi points, placebo blunt needles are inserted through the pads and reach the insulating adhesive layer, causing the participants to feel the needle resistance (a sensation of needle insertion). Other procedures, electrode placements, parameter of electroacupuncture apparatus and treatment settings are the same as in the EA group, but with no skin penetration or electricity output.
89102414|NCT04544865|Experimental|Gastric and thoracic staple line reinforcement|ECHELON ENDOPATH Staple Line Reinforcement is used during a gastric or thoracic procedure.
89102415|NCT04511130|Experimental|MT-401 following HSCT|Treatment with MT-401 at 90 days following HSCT
89102416|NCT04511130|No Intervention|Standard of Care following HSCT|Standard of Care
89102417|NCT04511130|Experimental|MT-401 following relapse|Treatment with MT-401 following relapse after first HSCT
89102418|NCT04501393|No Intervention|0 ml/kg|The participants will not be asked to drink anything at 2 hours prior to planned procedure.
89102419|NCT04501393|Active Comparator|3 ml/kg|The participants will be asked to drink 3ml/kg of clear liquid at 2 hours prior to planned procedure.
89102420|NCT04501393|Active Comparator|7 ml/kg|The participants will be asked to drink 7 ml/kg of clear liquid at 2 hours prior to planned procedure.
89102421|NCT04501393|Active Comparator|10 ml/kg|The participants will be asked to drink 10 ml/kg of clear liquid at 2 hours prior to planned procedure.
89102422|NCT04482114|Other|ultra-low dose CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
89102423|NCT04442399|Experimental|Intervention|The intervention was based on the WHO-endorsed manual entitled Positive Connections: Leading Information and Support Groups for Adolescents Living with HIV. For Family Connections, a caregiver companion guide was developed. In brief, adolescent/caregiver pairs attended 10 intervention sessions held every other Saturday at their HIV clinic over a six-month period.
89102424|NCT04442399|No Intervention|Comparison|The comparison arm consisted of standard of care for adolescents as offered at the HIV clinics.
89102425|NCT04440813|Active Comparator|Clinician Training|Traditional healers randomized to the control arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by trained medical personnel.
89102426|NCT04440813|Experimental|Healer + Clinician Training|Traditional healers randomized to the intervention arm will receive PPE education and training, general HIV prevention education and skill building (including condom use, positive prevention, and pre-/post-exposure prophylaxis services), and three educational outreach and coaching visits at the healer's place of practice to provide on-the-ground advice and support for PPE use. All training will be provided by both healers who already use PPE regularly and trained medical personnel.
89102427|NCT04425473|Experimental|Esketamine|
89102428|NCT04425473|Placebo Comparator|Placebo|
89102429|NCT04394468|Other|patient group|Data is collected from women (18-45y) with endometriosis (superficial and / or deep infiltrating endometriosis) where the preferred treatment is a laparoscopic intervention at UZ Gent.
89102430|NCT04387071|Experimental|Treatment (CMP-001, INCAGN01949)|Patients receive CMP-001 SC on day 1 of weeks 1 and 2 and IT on day 1 of weeks 3-6 in the absence of disease progression or unacceptable toxicity. Patients also receive INCAGN01949 IT on day 1 of weeks 3-6 in the absence of disease progression or unacceptable toxicity.
89102431|NCT04385017|Other|DNA from monocytes|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
89102432|NCT04374708||trans men|fMRI: body morph test and neurocognitive testing
89102433|NCT04374708||trans women|fMRI: body morph test and neurocognitive testing
89102434|NCT04374708||homosexual cisgender men|fMRI: body morph test and neurocognitive testing
89102435|NCT04374708||homosexual cisgender women|fMRI: body morph test and neurocognitive testing
89102436|NCT04374708||cisgender women|fMRI: body morph test and neurocognitive testing
89102437|NCT04374708||cisgender men|fMRI: body morph test and neurocognitive testing
89102439|NCT04300920|Experimental|N-acetylcysteine|600 mg oral N-acetylcysteine (NAC) three times daily for 24 months.
89102440|NCT04300920|Placebo Comparator|Placebo|Placebo tablet three times daily for 24 months.
89102441|NCT04295252||cardiogenic shock patients|All-comers cardiogenic shock patients Admitted to the Intensive Coronary Care Units
89102442|NCT04286568|Experimental|WOW Intervention|"Participants will receive blood pressure monitor and health passport to record blood pressure readings for 3 months.~Participants will receive daily text message reminders to take and record blood pressure readings.~Participants will receive health education and health care navigation. Participants will be assessed for social determinants of health. Participants will take surveys 3 times over 3 months. Participants will receive home visits or phone calls to collect data and receive health coaching."
89102443|NCT04285515|Experimental|Lumateperone 42mg|Lumateperone 42mg administered once daily in the evening
89102444|NCT04285515|Placebo Comparator|Placebo|Matching placebo administered once daily in the evening
89102445|NCT04270734|Active Comparator|normal 25-36 gestational week preterm infant|
89102446|NCT04270734|Experimental|25-36 gestational week preterm infant with IVH|25-36 gestational week preterm infant with Intraventricular haemorrhages (IVH)
89102447|NCT04262232|Experimental|Ca-HELP|This intervention arm will consist of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
89102448|NCT04252768|Experimental|Eftilagimod alpha + Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15 and 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
89102449|NCT04221763|Experimental|Heart failure and abnormal cardiac conduction|Subjects will have an attempt at His-bundle pacing, left bundle pacing and biventricular pacing. Pacing at the His bundle and the left bundle will be attempted using a Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Biventricular pacing will utilise a left ventricular lead placed in the coronary sinus using any of the 5 manufactures of CS leads Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical or in participants receiving permanent conduction system pacing left ventricular pacing will be achieved using a Cordis ATW™ wire placed in the coronary sinus.
89102450|NCT04186585|Experimental|First design level|All the 8 patients receives a daily oral dose of BP-C2 in ml equals the body weight divided by 5 for 4 weeks. This represents 15 ml for a patient of 75 kg
89102451|NCT04186585|Experimental|Second design level|Based on the results from the first design level, the daily BP-C2 dose will individually be increased by a factor of 1.4 or 1.2 in case of none or mild toxicity increase. If moderate or severe increase in toxicity is observed, the individual dose will be reduced by 0.8 or 0.6, respectively. Duration of the treatment is 4 weeks
89102452|NCT04186585|Experimental|Third design level|Based on the results from the second design level, the daily BP-C2 dose will individually be increased in case of none or mild toxicity increase and reduced if moderate or severe increase in toxicity is observed. Duration of the treatment is 4 weeks
89102453|NCT04183803|Experimental|rosa robot assistance|Patients with ACL rupture requiring surgical treatment will be included. The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
89102454|NCT04169646|Other|Intervention|Multi-component intervention
89102455|NCT04169646|Other|Control|Control
89102456|NCT04159571|Experimental|Real TBS to the vmPFC|Ten sessions of real Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
89102457|NCT04159571|Sham Comparator|Sham TBS to the vmPFC|Ten sessions of sham Theta Burst Stimulation (TBS) will be delivered to the left medial prefrontal cortex (mPFC)
89102458|NCT04159571|Experimental|Real TBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (TBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
89102459|NCT04159571|Sham Comparator|Sham TBS to the dlPFC|Ten sessions of sham Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC)
89102460|NCT04156386|Active Comparator|Animal Protein|
89102461|NCT04156386|Active Comparator|Vegan Protein|
89102462|NCT04156386|Placebo Comparator|Placebo|
89102463|NCT04133701|Experimental|Time-Restricted Feeding|"Control (Baseline): Blood pressure and neurovascular control will be measured.~Post-Intervention: Blood pressure and neurovascular control will be measured."
89102464|NCT04120116|Experimental|FX-322 Single Dose, Placebo Three Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Single Dose, Placebo Three Doses.
89102465|NCT04120116|Experimental|FX-322 Two Doses, Placebo Two Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Two Doses, Placebo Two Doses.
89102466|NCT04120116|Experimental|FX-322 Four Doses|Four intratympanic injections of a hydrogel formulation, FX-322 Four Doses.
89102467|NCT04120116|Placebo Comparator|Placebo Four Doses|Four intratympanic injections of a hydrogel formulation, Placebo Four Doses.
89102468|NCT04116736||TEST Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with the ACUVUE® OASYS with Transitions™ will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
89102469|NCT04116736||CONTROL Lens|Eligible subjects that are at least 18 years old, who have been recently fitted (within the last 2 months) with spherical non-photochromic reusable marketed silicone hydrogel contact lenses (of any brand) will be asked to complete follow-up assessments performed online at approximately 2-weeks, 4-months, and 12-months following Visit 1.
89102470|NCT04115553|Experimental|idiopathic intracranial hypertension|patients with idiopathic intracranial hypertension
89102471|NCT04115553|Sham Comparator|healthy subjects|Healthy subjects
89102472|NCT04103762|Experimental|indocyanine green|During the surgery, intraoperative cholangiography using indocyanine green will be performed
89102473|NCT04103762|Active Comparator|standard cpo|"During the surgery, intraoperative cholangiography using a contrast product gold standard will be performed"
89102474|NCT04099706|Experimental|Intervention - Fat grafting|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the intervention group, the fat will be purified using decanting and injected into the painful areas of skin.
89102475|NCT04099706|Sham Comparator|Control - Saline|The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the control group, the fat will be discarded and saline will be injected into the painful areas of skin.
89102476|NCT04084171|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia.
89102477|NCT04080414|Experimental|Home-based high-intensity interval training|
89102478|NCT04080414|Active Comparator|Home-based moderate-intensity continuous exercise|
89102479|NCT04075318|Experimental|UB-312 40 mcg|UB-312 40 mcg by intramuscular injection at Weeks 1, 5 and 13
89102480|NCT04075318|Experimental|UB-312 100 mcg|UB-312 100 mcg by intramuscular injection at Weeks 1, 5 and 13
89102481|NCT04075318|Experimental|UB-312 40/300 mcg|UB-312 40 mcg at Week 1 and 300 mcg at Weeks 5 and 13 by intramuscular injection
89102482|NCT04075318|Experimental|UB-312 300 mcg|UB-312 300 mcg by intramuscular injection at Weeks 1, 5 and 13
89102483|NCT04075318|Experimental|UB-312 40/1000 mcg|UB-312 40 mcg at Week 1 and 1000 mcg at Weeks 5 and 13 by intramuscular injection
89102484|NCT04075318|Experimental|UB-312 1000 mcg|UB-312 1000 mcg by intramuscular injection at Weeks 1, 5 and 13
89102485|NCT04075318|Experimental|UB-312 2000 mcg|UB-312 2000 mcg by intramuscular injection at Weeks 1, 5 and 13
89102486|NCT04075318|Placebo Comparator|Placebo|Placebo by intramuscular injection at Weeks 1, 5 and 13
89102487|NCT04075318|Experimental|UB-312 300/100 mcg|UB-312 300 mcg at Week 1 and 100 mcg at Weeks 5 and 13 by intramuscular injection
89102488|NCT04060589||Cohort Observation|This is a cohort study where participating men will be asked to donate blood, urine, tissue in addition to access to standard of care tissue and medical data (including imaging files). Men will also consent to longer term healthcare data linkage.
89102489|NCT04050644|Experimental|Preservative-free dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preservative-free dexamethasone 0.1% and diclofenac 0.1% eye drops.
89102490|NCT04050644|Active Comparator|Preserved dexamethasone 0.1%/diclofenac 0.1%|One week before surgery, patients will be randomized to either receive the preserved dexamethasone 0.1% and diclofenac 0.1% eye drops.
89102491|NCT04047706|Experimental|Cohort I (radiation, temozolomide, BMS-986205, nivolumab)|"RADIATION THERAPY: Patients with MGMT methylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive temozolomide PO QD, IDO1 inhibitor BMS-986205 PO QD, and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins.~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Within 4 weeks of radiation therapy completion, patients also receive temozolomide PO QD on days 1-5 of cycles 2-6. Cycles repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
89102492|NCT04047706|Experimental|Cohort II (radiation, BMS-986205, nivolumab)|"RADIATION THERAPY: Patients with MGMT unmethylated promoter undergo radiation therapy 5 days per week (Monday-Friday) for up to 6 weeks. Patients also receive IDO1 inhibitor BMS-986205 PO QD and nivolumab IV over 30 minutes every 2 weeks for up to 6 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-5 and on day 1 of subsequent cycles. Cycles repeats every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity, withdrawal of consent, the study ends, or until Q4W dosing begins."
89102493|NCT04042493|Experimental|Connect for Health Program|
89102494|NCT04041089|Experimental|Recognition of objects|Patients will do the therapy in the following order: object location, object manipulation and object recognition
89102495|NCT04041089|Experimental|Location of objects|Patients will do the therapy in the following order: object recognition, object location, and object manipulation
89102496|NCT04041089|Experimental|Manipulation of objects|Patients will do the therapy in the following order: object manipulation, object recognition and object location
89102497|NCT04029623|Experimental|Partnered Rhythmic Rehabilitation (PRR)|Participants in this study are will receive the PRR intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
89102498|NCT04029623|Active Comparator|Group walking (WALK)|Participants in this study are will receive the WALK intervention. Participants will have two phases of intervention. In the three-month Training phase, participants will be assigned to 20, biweekly (90-minute) lessons over 12 weeks. In the nine-month Maintenance phase, participants will attend weekly lessons at least 3 times per month.
89102499|NCT04024150||Newborns exposed|Newborns exposed in-utero to raltegravir
89102500|NCT04024150||Newborns controls|Newborns exposed to antiretroviral therapy without anti-integrase
89102501|NCT04020432||pregnant women|"Pregnant women are coming to their monthly consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Pregnant women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
89102502|NCT04020432||childbearing age women|"Women of childbearing age, who are coming for a gynecological consultation. A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Childbearing age women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
89102503|NCT04020159||Participants with COL6-related dystrophy|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
89102504|NCT03999359|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
89102505|NCT03999359|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
89102506|NCT03998397|Experimental|patients with alcohol use disorders|
89102507|NCT03998397|Experimental|patients without alcohol use disorders|
89102508|NCT03976505|Active Comparator|textual prescription healthy volunteers|
89102509|NCT03976505|Active Comparator|table prescription healthy volunteers|
89102510|NCT03976505|Experimental|textual prescription Parkinson's disease patients|
89102511|NCT03976505|Experimental|table prescription Parkinson's disease patient|
89102512|NCT03967249|Experimental|IONIS GHR-LRx + Somatostatin Receptor Ligand (SRL)|IONIS GHR-LRx (as per dose in previous study) will be administered subcutaneously once every 28 days for 53 weeks.
89102513|NCT03937050|Experimental|Intervention|A package of three interconnected educational/behavioural film-based interventions will developed for delivery at the cluster (clinic) level. The aim of the three components will be as follows: a) improving knowledge of GDM guidelines and skills among health providers involved in GDM management, b) raising awareness of GDM and the importance of screening among pregnant women and their family members, and c) improving confidence and skills in self-management of GDM among women diagnosed.
89102514|NCT03937050|No Intervention|Control|Usual care practices.
89102515|NCT03934632|Active Comparator|Postabsorptive|Saline infusion to mimic postabsorptive circulating amino acid concentrations
89102516|NCT03934632|Active Comparator|Postprandial|Amino acid infusion to mimic postprandial circulating amino acid concentrations
89102517|NCT03926403|Experimental|Hypnosis|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
89102518|NCT03926403|Active Comparator|conventional management|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
89102519|NCT03919188|Active Comparator|air temperature control (ATC)|Incubator control using air temperature control (ATC) method
89102520|NCT03919188|Active Comparator|skin servocontrol (SSC)|Incubator control using skin servocontrol method
89102521|NCT03907657|Experimental|Perflutren Lipid Microsphere or Lumason|Patients with Von-Hippel Lindau disease will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
89102522|NCT03897777|Experimental|Hypertension (Exercise Intervention)|Participants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.
89102523|NCT03877458|Experimental|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
89102524|NCT03877458|Experimental|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
89102525|NCT03877458|Placebo Comparator|Placebo group|Taking 1 Placebo capsule at bed time everyday for three months.
89102526|NCT03871621|Active Comparator|Dapagliflozin add-on group|T2D subjects aged 20-80 years, presenting with HbA1C 7.1-9.0%, preserved kidney function (defined as estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m2), preserved LV function (defined as EF ≥ 50% by echocardiographic screening in the initial 2-week run-in period), and those treated with oral anti-diabetic drugs (except SGLT2i) and/or insulin therapy at least 3 months prior to the study were randomised to Dapagliflozin (10 mg/qd) add-on group.
89102527|NCT03871621|Active Comparator|Standard of care (SOC) group|T2D subjects aged 20-80 years, presenting with HbA1C 7.1-9.0%, preserved kidney function (defined as estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m2), preserved LV function (defined as EF ≥ 50% by echocardiographic screening in the initial 2-week run-in period), and those treated with oral anti-diabetic drugs (except SGLT2i) and/or insulin therapy at least 3 months prior to the study were randomised to SOC treatment group.
89102528|NCT03867188|Experimental|Liiposomal Bupivacaine Group|Qualified participants with a soft tissue sarcoma of the thigh will be given the alternative protocol utilizing liposomal bupivacaine (Exparel®). The alternative protocol will utilize general or spinal anesthesia, but will also include the use of intraoperative liposomal bupivacaine instead of a regional nerve block.
89102529|NCT03867188|No Intervention|Control Group|A retrospective control group will be assembled from electronic medical records of 3 patients who underwent resection of a soft tissue sarcoma of the thigh and will be accessed and analyzed for the variable of interest.
89102530|NCT03811743|Experimental|Adolescents Participants|Adolescents will participate in the Dyad Plus program along with their caregivers. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
89102531|NCT03811743|Experimental|Caregivers of adolescents participants|Adult caregivers will participate in the Dyad Plus program along with their youth participants. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
89102532|NCT03805451|Experimental|Life Steps for PrEP for Youth|Life Steps for PrEP for Youth was derived from our prior PrEP work supported by the National Institute of Mental Health and will be tailored for YMSM/TWSM based on the findings from 20 qualitative interviews with YMSM and TWSM and 10 qualitative interviews with key informants. It will likely consist of four weekly sessions at the time of PrEP initiation and two booster sessions, which occur two and three months after PrEP initiation. Overall, the core components of the intervention will focus on medication adherence, sexual behavior, and problem solving barriers to adherence, using motivational interviewing when needed.
89102533|NCT03805451|No Intervention|Standard of Care|After being prescribed PrEP, participants will receive standard-of-care adherence support for PrEP. They will have blood collected for medication adherence measures and will complete computer assisted behavioral surveys during study visits. Participants in this arm will also be followed for 6 months.
89102534|NCT03791086||Patients with bronchiectasis|Adult patients with bronchiectasis meeting the inclusion criteria.
89102535|NCT03773146|No Intervention|Control|No airtime incentive was given for completing the survey
89102536|NCT03773146|Experimental|1X Incentive|1X Airtime Incentive
89102537|NCT03773146|Experimental|Lottery|Lottery Airtime Incentive
89102538|NCT03758508|Active Comparator|HFO|Continuous high flow oxygen through nasal cannula for 45 hours; longer if the clinical need persists
89102539|NCT03758508|Active Comparator|NIV/HFO|Alternating noninvasive ventilation (3 hours) and high flow oxygen through nasal cannula (3 hours) for 45 hours; longer if the clinical need persists
89102540|NCT03745040|Experimental|Group A: Exparel|"Standard of Care plus Liposomal bupivacaine (Exparel®). Dosage: Exparel® 20 mL single use vial, 1.3% (13.3 mg/mL), Maximum dose of 266 mg (20 mL).~Frequency: Single intraoperative administration"
89102541|NCT03745040|No Intervention|Group B: No Exparel|Standard of Care
89102542|NCT03696082|Experimental|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
89102543|NCT03696082|Experimental|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
89102544|NCT03696082|Experimental|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
89102545|NCT03696082|Experimental|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
89102546|NCT03675711|Active Comparator|Midline Catheter|Pt. will receive midline catheters.
89102547|NCT03675711|Active Comparator|Standard Peripheral venous Catheter|Pt. will receive a standard Peripheral venous catheter
89102548|NCT03673371||Women Veterans with Lower Limb Amputations|Questionnaire
89102549|NCT03657810|Experimental|CL-108 5 mg|Hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg (CL-108 5 mg) bi-layered tablet
89102550|NCT03657810|Active Comparator|Norco|hydrocodone 5 mg/APAP 325 mg
89102551|NCT03657810|Placebo Comparator|Placebo|Placebo 0 mg matching CL-108
89102552|NCT03640026|Experimental|Tacrolimus treatment|
89102553|NCT03618849|Experimental|Sham tDCS|Post initial screening and baseline data collection, all study participants (a single cohort of patients) will receive a single dose of sham tDCS for 20 minutes over the left dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex in conjunction with Mozart piano sonata. For sham tDCS, the current will be ramped up and immediately ramped down for 30 seconds. The sham tDCS session will be preceded and followed by behavioral assessments.
89102554|NCT03618849|Experimental|1-mA tDCS|Post sham-tDCS, we will determine the eligibility of the participant to receive 1 mA of real tDCS based on the occurrence of adverse events and seizures occurring within 5 days of the sham session. After a minimum of 5 days post-sham stimulation (and typically around 7 days later), the participant will receive a single dose of 1-mA current (for head circumference >52 cm; children with head circumference 43-52cm will receive 0.5-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 1-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 1-mA tDCS session will be preceded and followed by behavioral assessments.
89102555|NCT03618849|Experimental|2-mA tDCS|Post 1-mA tDCS, we will again determine the eligibility of the participant to receive 2 mA current. After a minimum of 5 days post-1 mA stimulation (typically 7 days), the participant will receive a single dose of 2-mA current (if head circumference >52cm; children with head circumference 43-52cm will receive 1-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 2-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 2-mA tDCS session will be preceded and followed by behavioral assessments.
89102556|NCT03616834|Experimental|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert.
89102557|NCT03601949|Experimental|SInergy Cooled Radiofrequency|Halyard Health SInergy Cooled Radiofrequency in addition to standard medical management
89102558|NCT03601949|Active Comparator|Medical Management|Standard Medical Management
89102559|NCT03601702||EmboTrap ® II Device|The study group consists of the patients with acute ischemic stroke from large vessel occlusion treated with EmboTrap ® II Device (Neuravi)
89102560|NCT03594344|Experimental|Hyperbaric oxygen therapy|30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.
89102561|NCT03594344|No Intervention|Control group|Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.
89102562|NCT03565029|Experimental|Medium/low locally advanced rectal cancer|Patients with Stage II (cT3-4 N0) or Stage III (cT1-4, N1-3) locally advanced rectal cancer amenable to Total Mesorectal Excision (TME)/Abdominal-Perineal Amputation
89102563|NCT03555396|Experimental|Intervention|Subjects will receive an intervention is based off of current evidence-based practices and will consist of activities designed to strengthen support within the couple to improve adherence to antiretroviral therapy.
89102564|NCT03555396|Active Comparator|Standard of Care|Standard of Care is the comparison arm that consists of care currently provided at the AIDS Center. Subjects will receive a consultation with a healthcare provider every three months, prescription refills, and blood draws for viral load and CD4 testing.
89102565|NCT03544736|Experimental|Cohort A|"Subjects having palliative radiotherapy towards esophageal tumor will receive concomitant therapy With Nivolumab i.v. 240mg Q2W: first 6 patients, 360mg Q3W: Next 6 patients or 480mg Q4W: Last 6 patients, treatment to progression or up to 2 years of treatment.~Radiotherapy: 2 Gy / day, (5 fx/week) to a total of 20 - 50 Gy in 25fx (2-4Gy/fx) at the decision of the responsible physician."
89102566|NCT03544736|Experimental|Cohort B|"Subjects receiving definitive chemoradiotherapy for esophageal cancer will receive concomitant therapy with Nivolumab 240mg Q2W, during RT, and continued with 480mg Q4W, treatment to progression or up to 1 year after completion of radiotherapy. 6 patients in total.~Chemotherapy: Paclitaxel i.v. 175mg/m2 and Carboplatin AUC5, then after 21 days Radiotherapy 1,8 Gy / day (5 fx/week) up to 50,4 Gy in 28fx and concomitantly Paclitaxel 50mg/m2 and Carboplatin AUC2 Q1W and Nivolumab as described above."
89102567|NCT03544736|Experimental|Cohort C|"Subjects with operable esophageal cancer eligible for neoadjuvant chemoradiotherapy will receive Nivolumab 240mg Q2W, concomitantly with RT Then surgery 4-12 weeks after RT. Within 6-12 months after surgery: Adjuvant Nivolumab 480mg Q4W, for 12 months. 6 patients in total.~Neoadjuvant chemotherapy: Concomitantly Paclitaxel 50mg/m2 and Carboplatin AUC2 Q1W and Radiotherapy: 41,4 Gy in 23 fractions."
89102568|NCT03533010|Active Comparator|Ca500mg + VitD800IU|Daily Supplementation with 500mg Calcium plus 800IU Vitamin D3
89102569|NCT03533010|Placebo Comparator|Placebo|Dietary Supplement: Placebo
89102570|NCT03529383|Experimental|Connected device|"Women randomized to the connected device arm will follow a 6-month exercise program using a connected device that includes an activity tracker and subscription to an exercise and physical activity management program through a smartphone application and a website. They will also receive international recommendations on physical activity."
89102571|NCT03529383|Experimental|Therapeutic education|"Women randomized to the therapeutic education arm will follow a 6-month program of therapeutic patient education. They will also receive international recommendations on physical activity."
89102572|NCT03529383|Experimental|Combined|"Women will benefit from both the connected device intervention and the therapeutic education intervention and receive international recommendations on physical activity."
89227755|NCT02559167|Placebo Comparator|Placebo|Participants will receive placebo for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
89227756|NCT00975182|Experimental|A|
89102573|NCT03529383|No Intervention|Control|Women will receive standard care, i.e., international recommendations on physical activity, without further intervention.
89102574|NCT03528031|Experimental|Intervention Daily Avocado|Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
89102575|NCT03528031|No Intervention|Control Usual Diet and Lifestyle|Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.
89102576|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 1|3.70 GBq (100 mCi) x 3 times
89102577|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 2|7.40 GBq (200 mCi) up to 4 times
89102578|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 3|11.1 GBq (300 mCi) up to 4 times
89102579|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 4|14.8 GBq (400 mCi) up to 4 times
89102580|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 5|18.5 GBq (500 mCi) up to 4 times
89102581|NCT03490838|Experimental|Phase I: Dose Escalation Cohort 6|18.5 GBq (500 mCi) up to 3 times
89102582|NCT03385980||Post-mortem patients|Post-mortem oncological patients (within 2-6 hrs from death, maximum time for tissue preservation).
89102583|NCT03374631|Experimental|Active anodal tDCS, Then Sham tDCS|Active anodal tDCS followed by behavioral testing; one week later, sham tDCS followed by behavioral testing
89102584|NCT03374631|Sham Comparator|Sham tDCS, then Active anodal tDCS|Sham tDCS followed by behavioral testing; one week later, active anodal tDCS followed by behavioral testing.
89102585|NCT03371485|Experimental|Participants with advanced NSCLC, to receive AST-VAC2|Participants will receive up to a maximum of six vaccinations over six weeks. Each weekly AST-VAC2 vaccination will be administered as a split dose via two intradermal injections at a target dose defined as 1 x 10^7 viable cells. There is no dose escalation planned during the study; only one dose level will be explored.
89102586|NCT03370341|Experimental|Active anodal tDCS first, then Sham tDCS|Active anodal tDCS (20 minutes) followed by behavioral testing; Washout (1 week); sham stimulation (20 minutes) followed by behavioral testing Intervention: Device: active anodal tDCS and sham tDCS
89102587|NCT03370341|Sham Comparator|Sham tDCS first, then Active anodal tDCS|Sham tDCS (20 minutes) followed by behavioral testing; Washout (1 week); Active anodal tDCS (20 minutes) followed by behavioral testing Intervention: Device: sham tDCS and sham tDCS
89102588|NCT03329170|Experimental|CHD intervention|educational intervention using motivational interviewing
89102589|NCT03329170|No Intervention|CHD control|At 24 and 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
89102590|NCT03329170|No Intervention|Healthy control|At 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
89102591|NCT03299335|Other|Early-stage sIMB patients|
89102592|NCT03299335|Other|Late-stage sIMB patients|
89102593|NCT03299335|Other|Control subjects|
89102594|NCT03294148|Experimental|Placebo|The open-label placebo treatment the investigators will use is based on past open-label placebo trials (Kam-Hansen et al., 2014; Kaptchuk et al., 2010; Kelley et al., 2012). Prior to treatment administration, patients will view a brief (~3 min) video summarizing scientific findings regarding the therapeutic power of placebo treatments. The video will describe established findings regarding placebo and suggest that placebos may still work even when patients know the treatment is a placebo. The video will state that believing in the placebo is not necessary, and the investigators ask only that patients keep an open mind. Patients will then receive a subcutaneous injection of 1ml medical grade saline into the lower back. The injection will be administered near the location of the pain, as specified by the participant. The investigators will use a standard needle used in subcutaneous injections of 27 gauge with a length from 1in to 1.5in.
89102595|NCT03294148|Experimental|Psychotherapy|Psychotherapy will consist of one initial medical history session with Co-I Schubiner, followed by twice weekly 50 minute psychotherapy sessions for 4 weeks with a therapist, for a total of 9 sessions maximum. The purpose of the initial medical history session is to help evaluate the likelihood that the patient's back pain is caused by structural conditions in the back. Dr. Schubiner will then speak with patients for a 1 hour session in which he collects their medical history and discusses different possible causes of their back pain with them. This session will be conducted by phone, by HIPAA-compliant Zoom, or by another HIPAA-compliant videoconferencing technology in consultation with the OIT team at Dr. Schubiner's hospital.
89102596|NCT03294148|No Intervention|Waitlist|Wait-listed patients will be asked not to change their treatment regime for the 4 weeks in between their two fMRI sessions. Wait-listed patients in the placebo injection arm will be offered the opportunity to receive the placebo treatment (optional). Waitlisted participants in the psychotherapy arm will be given a copy of Dr. Schubiner's book and free access to his online self-help program (optional to accept these).
89102597|NCT03269032|Experimental|Phase 1 Healthy Volunteers|Healthy volunteers will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks.
89102598|NCT03269032|Experimental|Phase 2 IBS Patients|Participants with IBS will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks
89102599|NCT03236987|Active Comparator|Clarithromycin 1000 MG|"The patient will received a combination of 3 antibiotics :~Rifampicin (10mg/kg once daily)~Ethambutol (15 to 20 mg/kg once daily)~Clarithromycin (500 mg twice daily)"
89102600|NCT03236987|Experimental|Azithromycin 250 MG|"The patient will received a combination of 3 antibiotics :~Rifampicin (10mg/kg once daily)~Ethambutol (15 to 20 mg/kg once daily)~Azithromycin (250 mg once daily)"
89102601|NCT03187366|No Intervention|Status quo|Status quo pesticide use
89102602|NCT03187366|Active Comparator|Low risk|Villages shifted to low risk pesticides that don't kill prawns
89102603|NCT03187366|Experimental|No agrochemicals|Villages that eliminate agrochemicals
89102604|NCT03181282|Experimental|Physical Therapy|Participants assigned to Physical Therapy (PT) will attend a 1-hour visit with a physical therapist twice weekly for 8 weeks. The PT intervention, which will mirror traditional PT for those with PD, will include exercises designed to improve balance and gait.
89102605|NCT03181282|No Intervention|Control|Participants in the control group will receive the current standard of care following STN-DBS. As such, STN-DBS settings and anti-PD medications will be optimized according to the determination of their neurologist in the same fashion as they will be in the experimental group. Those in the control group will not receive prescribed exercise from a physical therapist.
89102606|NCT03149380|Experimental|Intervention|Subjects will be given access to educational content on AD using interactive learning strategies
89102607|NCT03149380|Sham Comparator|Time-neutral control|Subjects will be given access to time-neutral general educational content on AD
89102608|NCT03129282|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
89102609|NCT03129282|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
89102610|NCT03114644|Other|Babies born prematurely between 27 and 37 SA|
89102611|NCT03094637|Experimental|Treatment (azacitidine, pembrolizumab)|Patients receive azacitidine Intravenous (IV) over 10-40 minutes or Subcutaneous (SC) on days 1-7, and pembrolizumab IV over 30 minutes every 3 weeks. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89102612|NCT03057834|Active Comparator|Functionally impaired|Women with urinary incontinence and short physical performance battery score of <9
89102613|NCT03057834|Placebo Comparator|Functionally normal|Women with urinary incontinence and short physical performance battery score of > 10
89102614|NCT03055507|Active Comparator|Control|Standard pain regimen of acetaminophen 650 mg q6hrs while awake until cessation of need for scheduled pain medication with the addition of oxycodone 5 mg q3 hrs PRN (as needed) pain.
89102615|NCT03055507|Experimental|Ibuprofen|Alternating every 3 hours acetaminophen 650 mg and ibuprofen 400 mg while awake until cessation of need for schedule pain medication with the addition of oxycodone 5 mg q3hr PRN pain.
89102616|NCT03038256|Experimental|4 Cycles XELOX pre- TME|experimental group (arm B): concurrent capecitabine-based long-term radiotherapy, 4 cycles of XELOX as neoadjuvant chemotherapy and TME surgery
89102617|NCT03038256|Active Comparator|6 Cycles XELOX post- TME|control group (arm A): concurrent capecitabine-based long-term radiotherapy, TME surgery and 6 cycles of XELOX as adjuvant chemotherapy.
89102618|NCT02811653|Experimental|Alzheimer disease|Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
89102619|NCT02811653|Active Comparator|control|"Healthy age- and gender-matched volunteers will be recruited into the study from the general population.~Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation"
89102620|NCT02789982|Experimental|Reconsolidation blockade|β-adrenergic blocker propranolol 1 mg / kg to each of the 6 treatment sessions
89102621|NCT02789982|Active Comparator|Treatment as usual|Treatment as usual like SSRIs, psychotherapy, ...
89102622|NCT02746718|Other|Restrictive Respiratory Failure|A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology
89102623|NCT02714465|Experimental|Hyperbaric oxygen therapy|All patients underwent radiosurgery with clinical and instrumental signs of cerebral radionecrosis
89102624|NCT02673281|Experimental|Walnut shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
89102625|NCT02673281|Placebo Comparator|Placebo shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
89102626|NCT02667886|Experimental|Part A|X4P-001 + axitinib dose escalation
89102627|NCT02667886|Experimental|Part B|"Randomized assignment to one of two regimens:~X4P-001 at the Part A maximum tolerated dose (MTD), in combination with axitinib~X4P-001 at 0.5x Part A MTD, in combination with axitinib"
89102628|NCT02667886|Experimental|Part C|X4P-001 monotherapy
89102629|NCT02637245||Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema. There will be no intervention in this cohort, only observation of standard of care.
89102630|NCT02587195|Experimental|Teriflunomide|Teriflunomide 14 mg Once Daily
89102631|NCT02582008|Experimental|Arm A (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO for 3 days and then BID for up to 1 year post RT/CRT.
89102632|NCT02582008|Active Comparator|Arm B (varenicline, NRT)|Patients receive smoking cessation treatment tailored to individual smokers based on preference, smoking history and contra-indications. Patients are given the choice of one of the NCCN-recommended first-line pharmacotherapy options for smoking cessation comprised of varenicline PO daily for 1 week and then BID for 12 weeks or combination of nicotine patch and acute NRT for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Treatment with varenicline or NRT can be extended up to 6 months to 1 year as needed.
89102633|NCT02502799|Active Comparator|Continued Monitoring and Assessment|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. Participants randomized to the continued monitoring and assessment arm will receive no additional intervention. Primary and secondary outcomes will be monitored.
89102634|NCT02502799|Active Comparator|PT with ACBT|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (CBT).
89102635|NCT02502799|Active Comparator|PT with ACBT and Methylphenidate|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT and Methylphenidate arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (ACBT). Adolescents will also receive methylphenidate.
89102636|NCT02456246|Experimental|FLT-PET|"Cohort 1: Patients in this cohort would be treatment naïve and will be planned for SBRT treatment according to established institutional practices. FLT-PET in this subgroup will be performed before radiation therapy.~Cohort 2: Patients who have had SBRT and demonstrate typical or stable lung fibrosis on follow up CT~Cohort 3: Patients who have had SBRT and demonstrate findings suspicious for recurrence on follow up CT or who have biopsy demonstrating disease recurrence."
89102637|NCT02427269||Barrett's Esophagus (BE) Surveillance|Patients who have never received ablative therapy for Barrett's Esophagus and are receiving routine care surveillance upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
89102638|NCT02427269||Barrett's Esophagus (BE) Pre-Ablation|Patients who are receiving routine care upper endoscopy with ablative therapy for their Barrett's Esophagus for the first time. Subjects will have esophageal biopsies, blood, and data collected for this study.
89102639|NCT02427269||Barrett's Esophagus (BE) Post-Ablation|Patients with a history of Barrett's Esophagus who are status post ablation and are receiving routine care follow-up EGD for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
89102640|NCT02427269||Esophageal Cancer(ECA/IMC)|Patients with esophageal cancer who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
89102641|NCT02427269||Squamous Cell Carcinoma (SCC)|Patients with squamous cell cancer of the esophagus who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
89102642|NCT02420431|Experimental|metacognitive therapy plus CR|Group psychological treatment focused on reducing worry and rumination and modifying beliefs about thinking in addition to treatment as usual (standard cardiac rehabilitation)
89102643|NCT02420431|Active Comparator|CR alone (control)|Usual group-based cardiac rehabilitation (treatment as usual) involving stress management, exercise, education
89102644|NCT02400359|Placebo Comparator|Placebo|Subjects will be randomized to either placebo or Lorcaserin HCl.
89102645|NCT02400359|Active Comparator|Active|Subjects will be randomized to either placebo or Lorcaserin HCl.
89102646|NCT02290769|Experimental|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
89102647|NCT02290769|Active Comparator|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
89102648|NCT02196818||Mpact Acetabular Shell|Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.
89102649|NCT02175186|Experimental|ALBIS|Albis Tab 2 tab twice a day 12weeks
89102650|NCT02175186|Placebo Comparator|Placebo|placebo Tab 2 tab twice a day 12weeks
89102651|NCT02086448|No Intervention|Obese, SDB negative|No intervention, observational comparison group
89102652|NCT02086448|Active Comparator|Obese, SDB postive, CPAP|Therapeutic CPAP
89102653|NCT02086448|Sham Comparator|Obese, SDB postive, sham-CPAP|Sham (non-therapeutic) CPAP
89102654|NCT02086448|Other|Obese, SDB postive, sleep hygiene|Sleep hygiene information and local sleep resources
89102655|NCT02052583|Experimental|34°C|therapeutic hypothermia at 34 ° C
89102656|NCT02052583|Experimental|32°C|therapeutic hypothermia at 32 ° C
89102657|NCT01993836|Active Comparator|Total Intravenous Anesthesia with Propofol|Patients in this arm will receive general anesthesia with propofol as the primary amnestic agent.
89102658|NCT01993836|Active Comparator|General anesthesia with Isoflurane|Patients in this arm will undergo general anesthesia with isoflurane as the primary amnestic agent.
89102659|NCT01988285||Dysphagia and GERD controls|"The cross-sectional arm will consist of patients who are having a clinically indicated endoscopy for reflux and/or dysphagia.~Cross-sectional participants will have specimens collected and complete a questionnaire."
89102660|NCT01988285||Prospective Longitudinal EoE Cases|"The prospective longitudinal group will be subjects who have a positive EoE diagnosis during initial endoscopy. This prospective group will be followed up at their clinically indicated endoscopy after their standard of care clinical therapy of swallowed steroids.~Prospective longitudinal participants will have specimens collected and complete questionnaires s prior to their standard of care clinical therapy of swallowed steroids and at their clinically indicated follow up upper endoscopy."
89102661|NCT01962818|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
89102662|NCT01962818|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
89102663|NCT01828190|Experimental|Hyperbaric oxygen|hyperbaric oxygen therapy will be given for 2 months. TNF alpha blocker therapy will remain the treatment received before recruitment.
89102664|NCT01818739|Experimental|sentinel lymph node detection|Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.
89102665|NCT01793623||nonemergent heart surgery, atrial tissue|patients undergoing non-emergent heart surgery
89102666|NCT01717586|Active Comparator|Pravastatin Group|Pregnant women at high-risk for preeclampsia who are taking pravastatin during their pregnancy.
89102667|NCT01717586|Placebo Comparator|Control Group|Pregnant women who are at high-risk for developing preeclampsia who are taking a placebo during their pregnancy.
89102668|NCT01714349|Experimental|Nerve Transfer|Surgical - Nerve transfers for patients with stable cervical spinal cord injuries
89102669|NCT01639586|Active Comparator|D|Impact of the day care on health profit of patient
89102670|NCT01639586|Active Comparator|C|No access to a respite structure
89102671|NCT01639586|Active Comparator|B|Respite platform
89102672|NCT01620541||Preference, Ankle Arthrodesis|
89102673|NCT01620541||Preference, Ankle Arthroplasty|
89102674|NCT01428700||Non-Immune/Non-Viral (NINV)|Patients enrolled in ITN030ST transplanted for liver failure resulting from non-viral, non-immune causes
89102675|NCT01428700||Hepatitis C Virus (HCV) positive|Patients enrolled in ITN030ST transplanted for liver failure resulting from HCV genotype 1 infection
89102676|NCT01316146|Experimental|CAR.CD30 T cells|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection (IV) according to the dosing schedules: starting with the lowest cell dose (2×10^7 cells/m2) and then escalate the cell dose to the highest cell dose (2×10^8/m2) as per study design.
89102677|NCT01233661|Experimental|short AVD pacing|short AVD pacing
89102678|NCT01233661|No Intervention|prior (stable) programming|prior (stable) programming
89102679|NCT01136343|Experimental|lifestyle modified project|education, counseling
89102680|NCT01136343|No Intervention|control|waiting list control
89102681|NCT00635362|Experimental|postplacental insertion after cesarean|"Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
89102682|NCT00635362|Active Comparator|delayed insertion group|"Insertion of the LNG-IUS 4-8 weeks after cesarean delivery~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
89102683|NCT00408447|Other|SCD group|Sickle Cell Disease patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
89102684|NCT00408447|Other|BT group|Beta Thalassemia patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
89102685|NCT02864238||Pre intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2013 prior to the institution of the electronic milestone pathway
89102686|NCT02864238||post intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2014 after the electronic milestone pathway had been instituted
89102687|NCT04285320|Active Comparator|Intravesical antibiotic instillation|
89102688|NCT04285320|Active Comparator|Oral antibiotic suppressive therapy|
89102689|NCT00970632|Placebo Comparator|Placebo|Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks
89102690|NCT00970632|Experimental|Tadalafil 5 milligram (mg)|Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks
89102691|NCT00970632|Active Comparator|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks
89102692|NCT02863302|Experimental|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment until the end of hospitalization.
89102693|NCT04285710|Other|Control|Subjects enrolled in the subject group will receive standard care treatment for infected diabetic wounds, including debridement surgery and wound dressings. However, in order to maintain consistency with the phototherapy arm, subjects within the control group will visit the clinic twice a week, with the first visit being for the debridement surgery, and the second visit being for clinical wound dressing redressing.
89102694|NCT04285710|Experimental|Phototherapy|For this intervention therapy, subjects enrolled in the experimental group will still receive standard care treatment for infected diabetic wounds. However, experiment group subjects will receive phototherapy treatments alongside standard care. A mobile pulsed laser device will be utilized to apply nanosecond pulsed 410 nm light onto both the cellulitis afflicted regions and open wound portions of a patient's infected diabetic ulcer wound twice a week over the course of the 3 month study. The device will be designed and produced by the Ji Xin Cheng Lab located at the Boston University Charles River Campus. Phototherapy sessions will occur twice a week, with the first session occurring after debridement surgery, and the second session occurring later in the week during clinical wound dressing redressing.
89102695|NCT02862756|Experimental|patient with endovascular treatment|
89102696|NCT04285008|No Intervention|standard Colonoscopy|"Control arm~Colonoscopy procedure using standard flushing and suctioning - standard of care"
89102697|NCT04285008|Other|Pure-Vu System|Intervention - Colonoscopy procedure using Pure-Vu System
89102698|NCT04286880|Experimental|TEST GROUP|Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle.
89102699|NCT04286880|Active Comparator|CONTROL GROUP|In control group, dry needling will be performed.
89102700|NCT01144364|Experimental|1|
89102701|NCT04286490|Experimental|Prone position|
89102702|NCT01119248||Children undergoing MRI|120 children ages of 6 months and 8 years for MRI and axillary temperature before MRI and after the MRI with MRI compatible device
89102703|NCT01131494|Experimental|Swallowing exercises|
89102704|NCT01131260|Experimental|Open Group|• Fetal STAN monitor electrode inserted and data available to caregivers
89102705|NCT01131260|Other|Masked Group|•Fetal STAN monitor electrode inserted, but data masked to the caregivers
89102706|NCT00965094|Experimental|Everolimus|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients were switched to the CNI-free regimen. Everolimus was added to the patients immunosuppressive regimen and tacrolimus was removed successively.
89102707|NCT00965094|Active Comparator|Reference Therapy|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients continued on the prior immunosuppressive regimen consisting of MPA + tacrolimus with corticosteroids.
89102708|NCT04286256|Experimental|Treatment Group|The treatment group received motivational interviewing.
89102709|NCT04286256|No Intervention|Control Group|The control group received standard information only.
89102710|NCT03634098|Experimental|Volunteers|"Exams performed on volunteers with other purpose than liver disease or diabetes in two centers:~MRI~Ultrasound AixPlorer These examinations are carried out in 2 differents centers at 1month intervals"
89102711|NCT03634098|Experimental|T2D liver test abnormalities's participants|"Exams performed on type 2 diabetic patients with liver test abnormalities :~sample for analysis and biocollection~MRI +/-Primovist~Ultrasound AixPlorer +Sonovue"
89102712|NCT03634098|No Intervention|T2D participants without liver test abnormality|type 2 diabetic participants without liver test abnormality and not undergoing liver biopsy
89102713|NCT04285944|Active Comparator|Study|
89102714|NCT04285944|No Intervention|Control|
89102715|NCT01131182|Experimental|Sitagliptin|Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
89102716|NCT01131182|Active Comparator|Sulfonylurea|Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
89102717|NCT02862444||intervention group|Culturally Appropriate Intervention
89102718|NCT04312100||Mild cases with conventional oxygen therapy|COVID-19 patients who were considered mild cases will receive conventional oxygen therapy in addition to standard treatment
89102719|NCT04312100||Moderate/Severe cases with nasal high flow oxygen inhalation|COVID-19 patients who were considered Moderate/Severe cases will receive nasal high flow oxygen inhalation in addition to standard treatment
89102720|NCT04312100||Moderate/Severe cases with non-invasive ventilation|COVID-19 patients who were considered Moderate/Severe cases will receive non-invasive positive pressure ventilation in addition to standard treatment
89102721|NCT00964860|No Intervention|Brushing Only|Brushing Only with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice
89102722|NCT00964860|Experimental|Brushing + Flossing|Brushing with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice, plus flossing with Glide floss
89102723|NCT01131104||Cohort 1|Participants with NAION who have used PDE5 inhibitors
89102724|NCT02861430||Patients|
89102725|NCT00625118||1|Children in receipt of a Hib containing vaccine at pre-school booster (3.5-6 years old).
89102726|NCT04284696|Active Comparator|Verum|"patients with emesis gravidarum who take a chewing gum with vitamin C (verum) ad libitum several times daily for 2 weeks"
89102727|NCT04284696|Placebo Comparator|Placebo|"patients with emesis gravidarum who take chewing gum without vitamin C (placebo) ad libitum several times daily for 2 weeks"
89102728|NCT04284696|No Intervention|Nihil|patients with emesis gravidarum who do not use chewing gum during the study phase
89102729|NCT02861742|Other|Study procedure|Delivery of questionnaires, Questionnaire T1 to fill, Questionnaire T2 to fill, Questionnaire T3 to fill, Questionnaire T4 to fill, Questionnaire T5 to fill
89102730|NCT01118780|Experimental|Duloxetine 30 milligrams (mg) -120 mg|
89102731|NCT01118780|Placebo Comparator|Placebo|
89102732|NCT04285632|Experimental|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of each training session.~Prior to training, the Counter Movement Jump and Drop Jump exercises will be performed"
89102733|NCT04285632|No Intervention|Control group|Athletes included in the control group will continue with their usual warm-up routine.
89102734|NCT00629928|Experimental|1|20mg capsule once daily
89102735|NCT00629928|Experimental|2|40mg capsule daily
89102736|NCT00629928|Placebo Comparator|3|
89102737|NCT00964782|Active Comparator|Sildenafil crossover to placebo|Sildenafil dosage (0.5mg/kg (max 20mg)) administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2, placebo drug administered before the exercises.
89102738|NCT00964782|Placebo Comparator|Placebo crossover to sidenafil|Patient will receive a look-alike placebo administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2 Sildenafil dosage will be 0.5mg/kg (max 20mg) administered before the exercises.
89102739|NCT02882984|Active Comparator|WBRT along with TKI|"Drug: EGFR-TKI~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid~Other Name: Gefitinib/Tarceva/Icotinib~Radiation: whole brain radiotherapy~3750Gy/15F~Other Name: WBRT"
89102740|NCT02882984|Experimental|HFSRS with EGFR TKI|"Drug: EGFR-TKI~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid~Other Name: Gefitinib/Tarceva/Icotinib~Radiation: whole brain radiotherapy~25 to 40 Gy/5F~Other Name: HFSRS"
89102741|NCT00966654|Placebo Comparator|Saline|Saline
89102742|NCT00966654|Active Comparator|GLP-1|GLP-1 (7-36) amide
89102743|NCT02862990||Pre menopausal women with breast cancer|Pre menopausal women with breast cancer prior treatment in face of infertility evoked by chemotherapy
89102744|NCT00625196|Experimental|Subjects receiving fluticasone foroate/ vilanterol|Eligible subjects will receive single dose of fluticasone foroate/ vilanterol combination treatment 800 micrograms/ 50 micrograms administered using a novel powder inhaler. There will be a washout period of 7 to 10 days between treatments.
89102745|NCT00625196|Active Comparator|Subjects receiving fluticasone foroate|Eligible subjects will receive single dose of fluticasone foroate 800 micrograms administered using a novel powder inhaler.
89102746|NCT00625196|Active Comparator|Subjects receiving vilanterol|Eligible subjects will receive single dose of vilanterol 50 micrograms administered using a novel powder inhaler.
89102747|NCT00625196|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of placebo administered using a novel powder inhaler.
89102748|NCT03262116|Experimental|Bionic Pancreas - Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
89102749|NCT03262116|Experimental|Bionic Pancreas - Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
89102750|NCT03262116|Experimental|Bionic Pancreas - BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
89102751|NCT01130168|Experimental|Placebo/ISMN ER/Amlodipine (Sequence 1)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
89102752|NCT01130168|Experimental|ISMN ER/Amlodipine/Placebo (Sequence 2)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
89102753|NCT01130168|Experimental|Amlodipine/Placebo/ISMN ER (Sequence 3)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
89102754|NCT01130168|Experimental|ISMN ER/Placebo/Amlodipine (Sequence 4)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
89102755|NCT01130168|Experimental|Placebo/Amlodipine/ISMN ER (Sequence 5)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
89102756|NCT01130168|Experimental|Amlodipine/ISMN ER/Placebo (Sequence 6)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.
89102757|NCT02862834||patients with poikiloderma|
89102758|NCT04283292|Experimental|Capsaicin|capsaicin 0.075% cream applied once topically
89102759|NCT04283292|Active Comparator|Placebo|placebo cream applied once topically
89102760|NCT01144052|Active Comparator|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
89102761|NCT01144052|Experimental|Interferon-beta-1b|250 mcg (8 MIU) subcutaneous injections every other day
89102762|NCT02862288|Experimental|Renal tumor|Microwave ablation of renal tumor
89102763|NCT02862288|Experimental|Lung tumor|Microwave ablation of lung tumor
89102764|NCT02862288|Experimental|Bone tumor|Microwave ablation of bone tumor
89102765|NCT04283526|Experimental|NIS793 + MBG453|treatment with NIS793 + MBG453
89102766|NCT04283526|Experimental|NIS793 + MBG453 + Spartalizumab|Treatment with NIS793 + MBG453 + Spartalizumab
89102767|NCT04283526|Experimental|NIS793 + MBG453 + Decitabine|treatment with NIS793 + MBG453 + Decitabine
89102768|NCT04283526|Experimental|NIS793|treatment with NIS793
89102769|NCT04283526|Experimental|MBG453|treatment with MBG453
89102770|NCT01143896|Experimental|Arm 1: Depression Collaborative Care|Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
89102771|NCT01143896|No Intervention|Arm 2: Usual Care|Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.
89102772|NCT04283214|Active Comparator|Traditional manikin|CPR performed on a traditional manikin
89102773|NCT04283214|Experimental|Traditional manikin with athletic equipment|CPR performed on a traditional manikin wearing athletic equipment
89102774|NCT04283214|Experimental|Bariatric manikin|CPR performed on a bariatric manikin
89102775|NCT04283214|Experimental|Bariatric manikin with athletic equipment|CPR performed on a bariatric manikin wearing athletic equipment
89102776|NCT01118312|Active Comparator|Nasal Steroid|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
89102777|NCT01118312|Placebo Comparator|Placebo|Intranasal placebo, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
89102778|NCT05085236|Experimental|Fu's subcutaneous needling (FSN) in combination with rehabilitation|In this arm, the subjects will receive the intervention of FSN combined with regular rehabilitation program on Day1, Day2, and Day4, in total 3 treatments. The subjects will receive assessments before and after each interventions. After total treatments finishing, the subjects will receive assessments on Day8 and Day15.
89102779|NCT05085236|Active Comparator|Rehabilitation|In this arm, the subjects will receive the intervention of regular rehabilitation program prescribed by physician of rehabilitation. On Day1, Day2, and Day4, the subjects will receive assessments before and after each interventions. After total treatments finishing, the subjects will receive assessments on Day8 and Day15.
89102780|NCT02882750||Surgical Patients|Early stage NSCLC patients submitted to Surgical Resection
89102781|NCT02882750||SABR Patients|Early stage NSCLC patients submitted to SABR
89102782|NCT01117766|Active Comparator|Active drug|
89102783|NCT01117766|Placebo Comparator|Placebo|
89102784|NCT02883686|Experimental|Alma Mentoring plus usual care|Alma peer-mentoring
89102785|NCT02883686|No Intervention|Enhanced Usual Care|Usual care for depression within the Kaiser Permanente of Colorado healthcare system plus study monitoring of depression symptoms and feedback.
89102786|NCT04312880|No Intervention|Control|Patient will receive no transexemic acid of any kind
89102787|NCT04312880|Experimental|IV-transexemic acid|weight adjusted standard dose of TXA will be administered to these subset of patients prior to incision in IV-form
89102788|NCT04312880|Experimental|Topical-transexemic acid|the wound site after the surgery is completed will be bathed in TXA for a standardized period of time prior to skin closure
89102789|NCT01117454|Other|Flecainide then placebo|In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy with beta-blockers first, then crossover to placebo plus standard therapy with beta-blockers.
89102790|NCT01117454|Other|Placebo then flecainide|In this crossover study, half of the subjects will be randomized to placebo plus standard therapy with beta-blockers first, then crossover to flecainide plus standard therapy with beta-blockers.
89102791|NCT01116440|Experimental|BGS649 co-administered with Levora 28™|
89102792|NCT01116440|Placebo Comparator|Placebo co-administered with Levora 28™|
89102793|NCT04311944|Experimental|Early Fast-Track Care|Participants will be eligible for fast-track care after 8 to 12 weeks, if viral load is suppressed (<200 copies/mL)
89102794|NCT04311944|Active Comparator|Standard (Deferred Fast-track) Care|Participants will be eligible for fast-track care after 24 weeks, if viral load is suppressed (<200 weeks)
89102795|NCT01129622|Experimental|Letrozole, Breast enhancement, Safety|Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .
89102796|NCT04311398||Respiratory infection group|Patients went to fever clinic with respiratory infectious symptoms in Huashan Hospital affiliated to Fudan University
89102797|NCT02882672|Experimental|Experimental|experimental group did 8 weeks exercise training
89102798|NCT02882672|Experimental|Control|Control group did not do any exercise training.
89102799|NCT01128842|Experimental|Neratinib + Capecitabine|Neratinib + Capecitabine
89102800|NCT00625274|Experimental|1|Oral
89102801|NCT00625274|Experimental|2|Oral
89102802|NCT00625274|Experimental|3|Oral
89102803|NCT01143038|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
89102804|NCT00966264|Active Comparator|LNG-IUS|Levonorgestrel releasing intrauterine system
89102805|NCT00966264|Other|Hysterectomy|Hysterectomy
89102806|NCT00915525|Experimental|botulinum toxin Type A 100U|Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
89102807|NCT00915525|Experimental|botulinum toxin Type A 150U|Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
89102808|NCT00631683||MICU-1|Mechanically ventilated patients who are about to start a weaning trial at the medical intensive care unit of Memorial Hermann Hospital.
89102809|NCT04673565|No Intervention|Control|Control groups that undergo standard audiological care
89102810|NCT04673565|Experimental|Treatment|Treatment groups that undergo motivational interviewing with audiological care
89102811|NCT04669041|Experimental|Single pill combination (SPC)|Once daily rosuvastatin 10 mg for 4 weeks, then once daily SPC ezetimibe 10 mg /rosuvastatin 10 mg (E10/R10) for 8 weeks
89102812|NCT04669041|Active Comparator|Rosuvastatin|Once daily rosuvastatin 10 mg for 4 weeks, then once daily rosuvastatin 10 mg (R10) for 8 weeks
89102813|NCT04253847|Experimental|RAMPS group|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
89102814|NCT04253847|Active Comparator|SRPS group|"Standard retrograde pancreatosplenectomy(SRPS) includes several key points. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
89102815|NCT05227443|No Intervention|Control|The control group did not receive exercise training and the participants were informed to complete their medications provided by the treating physician.
89102816|NCT05227443|Active Comparator|Lower limb (LL) exercise training|All the participants in this modality of training were subjected to only lower limbs aerobic exercise training.
89102817|NCT05227443|Active Comparator|Upper, lower and breathing (ULB) exercise training|All the participants in this modality of training were subjected to upper and lower limb aerobic exercise training as well as breathing training.
89102818|NCT05132595|Placebo Comparator|Normal saline in patients|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.
89102819|NCT05132595|Active Comparator|Esketamine in patients|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
89102820|NCT05132595|Active Comparator|Ketorolac in patients|After the induction of anesthesia, ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h ketorolac until starting skin suture.
89102821|NCT05132595|Active Comparator|Esketamine and Ketorolac in patients|After the induction of anesthesia, 0.2mg/kg esketamine and 0.2mg/kg ketorolac are intravenously injected, and then a continuous infusion of 0.2mg/kg/h esketamine and 0.2mg/kg/h ketorolac until starting skin suture.
89102822|NCT01074047|Experimental|Azacitidine|Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
89102823|NCT01074047|Active Comparator|Conventional Care Regimen|Conventional Care Regimen
89102824|NCT05210907|Experimental|CD19 CAR-T therapy|SNUH-CD19-CAR-T is administered as an intravenous infusion.
89102825|NCT05185401||non-Brugada population|Adult patients who underwent general anaesthesia (with propofol as induction agent) at the catheterisation laboratory of the UZ Brussel
89102826|NCT05226117|Experimental|Treatment arm|Patients with muscle-invasive urothelial carcinoma of the bladder, who are suited for and accept radical cystectomy (RC)
89102827|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate, 2.5 mg|Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
89102828|NCT01142726|Active Comparator|Methotrexate, 2.5 mg, plus abatacept placebo|Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
89102829|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate placebo|Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period
89102830|NCT04526223|Experimental|treatment group|MF patients exposure to ruxolitinib during transplantation
89102831|NCT04472637|Experimental|Atorvastatin|They will receive atorvastatin 10 mg, as one tablet /day for 24 weeks.
89102832|NCT04472637|Placebo Comparator|placebo|They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 24 weeks.
89102833|NCT04305509||LDH patients|Patients with lumbar disc herniation which was treated with manual therapy
89102834|NCT05123937|Experimental|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
89102835|NCT05123937|Experimental|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
89102836|NCT04310618||Adults with bronchiectasis|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase
89102837|NCT05110053|Active Comparator|Active|All patients will receive surgery with implantation of a SCS device. Patients randomized to the active arm, will receive active stimulation. However, for the purposes of this study, the stimulation paradigm and intensity is designed to be below perceptional thresholds so as to assure appropriate blinding. Blinding will continue for 6 months, followed by a 6 month voluntary open-phase, active extension.
89102838|NCT05110053|Placebo Comparator|Placebo|All patients will receive surgery with implantation of a SCS device. Patients randomized to the placebo-arm of the trial will have the device switched of or set to a stimulation intensity of zero. Blinding will continue for 6 months, followed by a 6 month voluntary open-phase, active extension.
89102839|NCT01073267|Experimental|TSEBT|Total Skin Electron Beam Therapy (TSEBT) to dose of 12 Gy
89102840|NCT04457349|Experimental|Therapeutic Plasma Exchange (TPE)|Each patient will undergo two sessions. TPE will be done through filtration technique using a plasma filter at a dose of (1-1.5) plasma volume/session. Fresh frozen plasma or albumin 5% will be used to replace plasma.
89102841|NCT02876705|Experimental|Pain Patterns|In this vein, we tend to study and delineate individualized pain and discomfort patterns in exercise.
89102842|NCT01142336|Experimental|Simvastatin|Simvastatin 40mg qHS for 1 year
89102843|NCT01142336|Placebo Comparator|Placebo|Placebo 1 tablet qHS for 1 year
89102844|NCT02875691|Active Comparator|green tea extract|Patients were given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules (500 mg) for three months.
89102845|NCT02875691|Placebo Comparator|Placebo|Patients in placebo group received daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
89102846|NCT00915681|Experimental|Legalon SIL|Silibinin: loading dose of one hour infusion of 5 mg/kg, followed by 20 mg/kg/day infused continuously via pump
89102847|NCT01128296|Experimental|Hydroxychloroquine + Gemcitabine (HcGc)|Hydroxychloroquine orally twice daily in combination with gemcitabine for 31 days prior to surgical resection
89102848|NCT05072379|Experimental|Mobile health app group|routine care and mobile health app
89102849|NCT05072379|No Intervention|control group|routine care
89102850|NCT04242849||IDH1/2 mutated patients|Patients harboring mutations in IDH1 or IDH2 genes
89102851|NCT04242849||Patients without IDH1/2 mutations|Patients that don´t present any mutation in IDH1/2 genes
89102852|NCT05082909|Active Comparator|Penicillin alone|Penicillin orally at dose of either 250mg, 500mg, 750mg QDS for 36 hours.
89102853|NCT05082909|Experimental|Penicillin plus probenecid|"Penicillin orally at dose of either 250mg, 500mg, 750mg QDS for 36 hours.~PLUS~Probenecid 500mg QDS for 36 hours."
89102854|NCT04586283|Experimental|Maternal Prone Position|Participants will initially be assessed in left-lateral position for 20 minutes. Participants will then be asked to lie in a prone position for 30 minutes supported by a specially designed pillow. Participants will then return to a left-lateral position for 20 minutes.
89102855|NCT04826055|Active Comparator|loop bypass with fixed biliary limb length|in all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
89102856|NCT04826055|Experimental|loop bypass with a biliary limb is a percentage of the small intestine|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
89102857|NCT01115738|Placebo Comparator|Placebo and 60 milligram (mg) Prasugrel|Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
89102858|NCT01115738|Experimental|600 mg Clopidogrel and 60 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
89102859|NCT01115738|Experimental|600 mg Clopidogrel and 30 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 30-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
89102860|NCT00632073|Experimental|VCV + Failing HAART|Vicriviroc plus failing highly-active antiretroviral therapy
89102861|NCT04651413||Covid-19 Ct Value|All patients enrolled onto the ISARIC COVID-19 trial at The University Hospitals of North Midlands NHS Trust between the period 1st February 2020 to 1st July 2020 will be included in this study, provided that a laboratory cycle threshold (Ct) value is available.
89102862|NCT01141478|Active Comparator|Proton Beam Radiotherapy plus Sorafenib|A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.
89102863|NCT01141478|Active Comparator|Sorafenib|Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.
89102864|NCT01114880|Placebo Comparator|Placebo|Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
89102865|NCT01114880|Experimental|Adalimumab|Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
89102866|NCT05188586|Other|Pancreatic Cancer Signal Detection = Detected|"Subjects with test results detected will undergo MRI/Imaging"
89102867|NCT05188586|No Intervention|Pancreatic Cancer Signal Detection = Not Detected|
89102868|NCT01114724|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|
89102869|NCT00964392|Experimental|More-Experienced Physicians (MEP)|Physicians who perform greater than or equal to 50 atrial fibrillation ablation procedures per year.
89102870|NCT00964392|Experimental|Less-Experienced Physicians (LEP)|Physicians who perform less than 50 atrial fibrillation ablation procedures per year.
89102871|NCT00914589|Experimental|FXIII17.5IU/Kg|Recombinant factor XIII at a single dose of 17.5 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
89102872|NCT00914589|Experimental|FXIII35IU/Kg|Recombinant factor XIII at a single dose of 35 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
89102873|NCT00914589|Placebo Comparator|Placebo|Recombinant factor XIII placebo was administered as a single dose via slow i.v. push at a rate not exceeding two mL per minute.
89102874|NCT03566082||Post Approval Study|"The PAS cohort consisted of 137 subjects who were implanted with the R3 delta Ceramic Acetabular System (DoD) in the pivotal study. These patients will continue to be followed to 10 years post-operatively.~The primary endpoint for the PAS study is implant survivorship at 10 years post study procedure."
89102875|NCT03561714||CMC-TI|Cardiometabolic Care Team Intervention
89102876|NCT03561714||Non-Intervention Comparator site|Non intervention comparator site with usual care
89102877|NCT04539873|Active Comparator|COLHICINE PLUS STANDARD TREATMENT|Patients treated in the exposed group will consist of a decreasing dose of colchicine: a dose of 1.5 mg orally on the first day (initial 1 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
89102878|NCT04539873|Placebo Comparator|STANDARD TREATMENT|In this case, the centers where the patients will be included adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases), and to standard treatment
89102879|NCT02861040|Experimental|Treatment (volasertib, vincristine sulfate liposome)|Patients receive volasertib IV over 1 hour on day 1 and vincristine sulfate liposome IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression, development of an inter-current illness that prevents further administration of treatment, unacceptable toxicity, patient decides to withdraw or treating investigator determines that the patient should be taken off treatment for any reason.
89102880|NCT02862366||Primary Myelofibrosis (PMF)|Blood sampling during routine visit
89102881|NCT02862366||Essential thrombocytosis (ET)|Blood sampling during routine visit
89102882|NCT02862366||Polycythemia vera (PV)|Blood sampling during routine visit
89102883|NCT04282902|Experimental|Pirfenidone group|This study was designed to randomize approximately 147 adult subjects.The patients were stratified according to whether the onset time was less than 14 days, and randomly divided into groups at a ratio of 1:1. The group received pirfenidone orally three times a day, with two tablets each time, for a course of 4 weeks or longer.
89102884|NCT04282902|No Intervention|Standard treatment group|This study planned to randomize approximately 147 adult subjects. They will be stratified according to whether the onset time is ≤ 14 days and randomly divided into groups of 1: 1. This group only receives standard treatment
89102885|NCT00912405|Experimental|Sinexus Intranasal Splint|Patient receives a drug-coated intranasal splint
89102886|NCT04203459||Pancreatic cancer patient|(1) patients with pancreatic cancer confirmed by imaging, pathology and body fluid biopsy, or patients who recovered well one month after operation but still had residual lesions, recurrence or metastasis. ② age ≥ 30 and ≤ 75. ③ no chemotherapy, radiotherapy or targeted drugs were used before admission. ④ patients who had used immunosuppressive drugs, hormones, antibiotics and probiotics one month before admission were excluded. ⑤ patients with HIV positive and active hepatitis B or C infection were excluded. ⑥ exclude the previous history of other malignant tumors or the current combination of other malignant tumors. The patients with serious cardiopulmonary disease and liver and kidney dysfunction were excluded. ⑧ patients with obstructive jaundice were excluded.
89102887|NCT04203459||Healthy person|(1) no history of digestive tract diseases, infectious diseases or immune diseases.(2) no history of smoking or drinking.(3) did not take antibiotics and other drugs and probiotics for 1 month before enrollment.
89102888|NCT04284618||assessment of radiographic angles on standardized films|On Standing standardized radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
89102889|NCT04284618||assessment of radiographic angles on off axis view films|On off axis view radiographs of the foot the most common angles for describing a hallux valgus interphalangeus deformity are measured. The measured angles are the following: The hallux interphalangeal angle (HIA), the proximal to distal phalangeal articular angle (PDPAA), the proximal phalangeal articular angle (PPAA) or distal articular set angle (DASA), and the distal phalangeal articular angle (DPAA).
89102890|NCT04950777|No Intervention|standard of care|
89102891|NCT04950777|Experimental|patient education|The intervention group will receive the patient education document with their questionnaire, randomization will occur by the study team prior to subject visits. The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
89102892|NCT02862054|Experimental|Splenectomy|Splenectomy as a treatment for patient with relapsed haemophagocytic lymphohistiocytosis of unknown etiology
89102893|NCT02860962|Active Comparator|Dextromethorphan|2 doses of Dextromethorphan 75mg oral (PO), separated by 4 hours
89102894|NCT02860962|Placebo Comparator|Placebo|2 doses of placebo (oral/PO), separated by 4 hours
89102895|NCT02862522||Women With CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
89102896|NCT02862522||Women Without CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
89102897|NCT03548532|Active Comparator|36.6°C|Embryos of these patients will be cultured at 36.6°C from day 0 after ICSI, untill day 6.
89102898|NCT03548532|Experimental|37.1°C|Embryos of these patients will be cultured at 37.1°C from day 0 after ICSI, untill day 6.
89102899|NCT00630240||1|only one arm for study
89102900|NCT04842513|Experimental|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
89102901|NCT00878722|Experimental|Arm A|"PXD101 administered as a 30-minute intravenous (IV) infusion of 1000 mg/m²/d for five consecutive days every 3 weeks.~Idarubicin administered on day 5 (first steps) or days 4 and 5 (later steps). Patients will be treated in a 21-day cycle for a minimum of 2 cycles and a maximum of 6 cycles (depending on cumulated idarubicin dose)."
89102902|NCT00878722|Experimental|Arm B|PXD101 administered by continuous intravenous infusion over 24-48 hours and idarubicin (in the later steps) added after the first 24 hours. The second cycle will start on day 15 but under observation of possible toxicity. Further cycles will be administered q 14 d for up to 6 cycles. The first dose steps will be carried out with PXD101 alone for safety reasons.
89102903|NCT03432897|Experimental|Treatment|"Olaparib 300 mg BID q 4 weeks for up to 3 cycles. The 3rd cycle will not be given if patient is found to progress post cycle 2.~Between 22-42 days post Olaparib, patients will undergo a prostatectomy."
89102904|NCT02630836|Experimental|XCEL-MT-OSTEO-BETA|Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing
89102905|NCT02630836|Other|Standard treatment|Standard surgical treatment with isolated endomedullary nailing
89102906|NCT04266015|No Intervention|Control group|Patients assigned to control group will not receive feeding via the nasogastric tube during operation
89102907|NCT04266015|Experimental|Intraoperative feeding group|Patients assigned to intraoperative feeding group will receive enteral nutrition formula via the nasogastric tube during operation
89102908|NCT02630758|Experimental|Mindfulness-based Yoga|"Participants in the 12-week mindfulness-based yoga condition were guided by a gentle yoga DVD that included postures (asanas), pranayama (breathing exercises), and relaxation (meditation). Participants were asked to complete 60-75 minutes of the DVD twice per week and were encouraged to do more if they were interested.~Following the initial baseline assessment and randomization telephone interview, participants in the yoga group completed weekly 15-minute telephone sessions for the first month and bi-weekly telephone sessions for the second and third for a total of eight sessions over the 12 weeks. The mindfulness telephone sessions were modified from the Mindfulness-Based Stress Reduction."
89102909|NCT02630758|Active Comparator|Walking Control Group|"The 12-week walking control condition included twice-weekly home practice with a 65-minute walking DVD (Sansone, 2008) and eight telephone sessions with the telephone counselor.~Participants were asked to complete 60 minutes of the DVD (or other walking) twice weekly and encouraged to do more if they were interested.~Participants received telephone sessions on the same schedule as the yoga condition. The education sessions covered a variety of health and wellness related topics."
89102910|NCT00964158|Experimental|Group A|
89102911|NCT00659386|Experimental|A|Patients with chronic idiopathic cardiomyopathy and EMB proven high PVB19 virus load.
89102912|NCT00662584|Experimental|1|This was an open-label study - all subjects received the intervention (rTMS treatment)
89102913|NCT03986541||Retrospective cohort|Patients with advanced colorectal cancer previously treated with an anti-EGFR agent (panitumumab or cetuximab).
89102914|NCT03986541||Prospective cohort|Patients with advanced colorectal cancer newly starting treatment with an anti-EGFR agent (panitumumab or cetuximab).
89230316|NCT04046705|Other|Control arm|Best standard care : Patients will receive the best standard care according to their situation and their previous treatment: initiation of Hydroxyurea, continuation or optimization of the dose of Hydroxyurea, initiation or continuation of TP, initiation of a new drug proved to improve SCD and having authorization to use in France.
89230317|NCT01097473|Active Comparator|Exercise training|Subjects participate in a once weekly supervised exercise training group, duration of 60 min.
89230318|NCT01097473|No Intervention|Control|Control group receives no intervention
89230319|NCT00802763||vaginitis|
89102915|NCT04155814|Experimental|Iron Sucrose Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
89102916|NCT04155814|Active Comparator|Venofer Injection|IV injection (5 mL), delivered over 5 minutes to subjects that have been fasted for a minimum of 10 hours.
89102917|NCT02860884||simple fatty liver|patients with fatty liver disease
89102918|NCT02860884||NASH|patients with nonalcoholic steatohepatitis
89102919|NCT00662662||Oropharyngeal Cancer|
89102920|NCT00662662||Non-Oropharyngeal Cancer|
89102921|NCT02630524|Experimental|Low Carbohydrate Diet|
89102922|NCT02630524|Active Comparator|Standard Diet|
89102923|NCT04598997||600 patients involved in the prospective study|These patients will be contacted by telephone follow-up, offered participation in the study and sent the information and non-opposition letter. In case of refusal, data will not be used.
89102924|NCT04598997||1000 patients involved in a non-human study|To train the algorithm to recognize images in the context of STEMI revascularization, 1000 normal coronary angiograms performed in a stable disease context will also be identified.
89102925|NCT00666094|Active Comparator|endurance training|supervised endurance training
89102926|NCT00666094|Experimental|strength training|Supervised strength training
89102927|NCT04529031|Active Comparator|RFPP group intervention|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices.
89230320|NCT01095679|Experimental|Baclofen|
89230321|NCT01095679|Placebo Comparator|Placebo|Placebo
89230322|NCT00794183|Active Comparator|1|AVD set by taking the larger of 0.50ms or A-V interval 0.30
89102928|NCT04529031|Sham Comparator|attentional control condition (group process)|Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy. Parents will receive 4 sessions of relaxation techniques.
89102929|NCT04598139||Study group|
89102930|NCT04158076|Experimental|Co-administered of AD-2071 and AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2073(Telmisartan/Amlodipine) for 8 weeks."
89102931|NCT04158076|Active Comparator|Co-administered of AD-2071 and AD-2072|"48 subjects will be assigned and the subjects will be administered AD-2071(Ezetimibe/Rosuvastatin) and AD-2072(Telmisartan) for 8 weeks."
89102932|NCT04158076|Active Comparator|AD-2073|"48 subjects will be assigned and the subjects will be administered AD-2073(Telmisartan/Amlodipine) for 8 weeks."
89102933|NCT00659464||1|Children who present to the heart center exercise stress lab for investigation of syncope
89102934|NCT00911404|Experimental|Low CHO|Diet with 40% total calories from carbohydrates.
89102935|NCT00911404|Active Comparator|High CHO|Diet with 55% total calories from carbohydrates.
89102936|NCT00961350|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
89102937|NCT00961350|Active Comparator|EC Aspirin|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
89102938|NCT00666250|No Intervention|Baseline|Baseline values off chocolate supplement
89102939|NCT00666250|Experimental|Low Dose|Low dose of dietary supplement 30 ml tid (Activ Xocai Drink)
89102940|NCT00666250|Experimental|High-dose|High dose of dietary supplement 90 ml tid (Xocai Activ drink)
89102941|NCT04155970|Experimental|Manual Therapy Arm|The group will receive manual therapy, as well as an evidence-informed home management booklet.
89102942|NCT04155970|Experimental|Non-Manual Therapy Arm|The group will receive an evidence-informed home management booklet only.
89102943|NCT02630680||Colorectal diseases patients|
89102944|NCT03947541|Active Comparator|No Brace|Patients randomized to the no-brace group will not be required to wear a brace, postoperatively.
89102945|NCT03947541|Experimental|Brace|Patients randomized to the brace group will wear the brace when out of bed and will be allowed to remove the brace when in bed. This intervention will continue through their 6-week postoperative visit, after which point, patients will be allowed to wear the brace for comfort.
89102946|NCT04032184|Active Comparator|Fluoride toothpaste|
89102947|NCT04032184|Experimental|fluoride toothpaste and chlorhexidine mouthwash|
89102948|NCT04032184|Experimental|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|
89102949|NCT00662896|Experimental|naproxcinod 375 mg bid|
89102950|NCT00662896|Active Comparator|naproxen 250 mg bid|
89102951|NCT00662896|Active Comparator|ibuprofen 600 mg tid|
89102952|NCT00662896|Experimental|naproxcinod 750 mg bid|
89102953|NCT00662896|Active Comparator|naproxen 500 mg bid|
89102954|NCT00963924|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
89102955|NCT00963924|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
89102956|NCT00659542|No Intervention|1|mesh fixation by absorbable sutures
89102957|NCT00659542|Experimental|2|mesh fixation by cyanoacrylate glue
89102958|NCT02862678|Experimental|Patients with head and neck squamous cell carcinoma|
89102959|NCT00659620|Experimental|1|transplantation of mesenchymal stem cell
89230323|NCT00794183|Active Comparator|2|AVD set by taking the larger of 0.50ms or A-V interval 0.50
89230324|NCT00794183|Active Comparator|3|AVD set by taking the larger of 0.50ms or A-V interval 0.70
89230325|NCT01092793|Active Comparator|Krill|
89102960|NCT03265665|Experimental|ACTION Intervention|Women in the ACTION intervention will attend 1 asthma education/physical activity session and 5 group sessions in community location convenient to participants during the adoptive phase (24-weeks) and 1 group session during the maintenance phase (12-weeks). Each session will last approximately 2 hours. Participants will be given Fitbit Charge HR to monitor their daily steps and will be sent motivational, educational and reminder text messages up to 3 times per week.
89102961|NCT03265665|Other|Enhanced usual care|Women in the Enhanced usual care arm will attend 1 asthma education/physical activity session and be given a Fitbit Charge HR to monitor their daily steps. They will be given a static step goal to achieve. Only reminder text messages for data collection visits will be sent.
89102962|NCT02861196|Experimental|Therapy Arm|Patients who have response to neoadjuvant chemotherapy will be separated into two groups (GI cT0-1 and G2 ≥cT2). G1receive concurrent radiochemotherapy, and G2 receive partial resection of the bladder+lymphadenectomy+adjuvant radiotherapy.Patients who have no response to neoadjuvant chemotherapy or disagree to receive the sequential treatment will receive the radical resection of bladder.
89102963|NCT04155658|Experimental|Experimental SMFP Toothpaste|Toothpaste containing 1450ppm SMFP with additional calcium and phosphate
89102964|NCT04155658|Active Comparator|SMFP Toothpaste|Toothpaste containing 1450ppm SMFP
89102965|NCT04155658|Placebo Comparator|Negative control toothpaste|Toothpaste with no fluoride
89102966|NCT00631839||1|There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.
89102967|NCT00666484|Experimental|Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2|"OEPA (28day cycle):~Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15"
89102968|NCT00666484|Experimental|Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
89102969|NCT00666484|Experimental|Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
89102970|NCT00662974|Experimental|A|parturients during the second stage of labor massaged by Wheat Germ Oil
89102971|NCT00662974|Experimental|B|parturients during the second stage of labor massaged by almond oil
89102972|NCT04507893||SARS-COV-2 PNEUMONIA CONFIRMED BY PCR ON NASOPHARYNGEAL SWAB|Hospitalized patients affected by COVID-19 interstitial pneumonia (with positive PCR on naso-pharyngeal swab)
89102973|NCT04507893||NEGATIVE SARS-COV-2 PNEUMONIA|Hospitalized patients affected by negative COVID-19 interstitial pneumonia (with negative PCR on naso-pharyngeal swab)
89102974|NCT00666640||1|50 subjects who have suffered a hip fracture
89102975|NCT00666640||2|50 age matched controls
89102976|NCT00663130|Experimental|Arm 1|
89102977|NCT00663130|Active Comparator|Arm 2|
89102978|NCT01114646|Other|Cemented Hip Hemiarthroplasty|This arm received a hemiarthroplasty with a cemented femoral prosthesis (VerSys LD/Fx, Zimmer, Warsaw, IN).
89102979|NCT01114646|Experimental|Press-Fit Hip Hemiarthroplasty|This arm received a press-fit hemiarthroplasty (VerSys Beaded FullCoat, Zimmer, Warsaw, IN),
89102980|NCT00965562|Active Comparator|I|Fluoxetine
89102981|NCT00965562|Active Comparator|II|Calcium
89102982|NCT00965562|Placebo Comparator|III|
89102983|NCT02631382|Experimental|wet cupping : double cupping|wet cupping: (traditional cupping technique): cupping (suction) - Scarification - cupping (suction)
89102984|NCT02631382|Experimental|wet cupping: single cupping|wet cupping:(Asian cupping): Puncture by needles then cupping (suction):
89102985|NCT00659698|Experimental|1|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
89102986|NCT00659698|No Intervention|2|glucose levels were controlled using a manual injection of insulin according to the commonly used sliding scale
89102987|NCT00666796|Placebo Comparator|A|
89102988|NCT00666796|Experimental|B|
89102989|NCT00666796|Experimental|C|
89102990|NCT00666796|Experimental|D|
89102991|NCT00912093|Placebo Comparator|Placebo|Single subcutaneous injection of matching placebo
89102992|NCT00912093|Experimental|Icatibant|Single subcutaneous injection of icatibant, 30 mg
89102993|NCT03500484|Experimental|obese subjects|Subjects will self-administer Liraglutide once daily for 12 weeks.
89102994|NCT03500484|No Intervention|lean subjects|no intervention
89102995|NCT00659854|Placebo Comparator|Non milk or soy based formula|25 infants , non milk or soy based formula .
89102996|NCT00659854|Active Comparator|2|Intervention with milk based formula will be given to 25 infants.
89102997|NCT03372954|Experimental|Bone marrow autologous cells concentrate (BMAC)|retrograde administration on non-selected BMAC via coronary sinus
89102998|NCT03372954|Placebo Comparator|Control|standard treatment o heart failure
89230326|NCT01092793|Active Comparator|Fish oil|
89230327|NCT01092793|No Intervention|Control|
89230328|NCT00794261|Experimental|Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
89230329|NCT00794261|Active Comparator|Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
89102999|NCT02630446|Experimental|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
89103000|NCT02630446|No Intervention|standard dementia care|Control group receiving all types of standard dementia care except in-home respite care of the Baluchon type.
89103001|NCT00659932|Experimental|1|
89103002|NCT00659932|Active Comparator|2|
89103003|NCT02631460|Experimental|S1 and Carboplatin|S1 80-120 mg/d+Carboplatin AUC=5 Patients without progression received maintenance until disease progression with S1
89103004|NCT02631460|Active Comparator|pemetrexed and Carboplatin|pemetrexed 500 mg/m2+ Carboplatin AUC=5 Patients without progression received maintenance until disease progression with pemetrexed
89103005|NCT00965484|Experimental|Genotropin pen|All subjects will receive genotropin pen to use for 2 months.
89103006|NCT02630602|Active Comparator|Functional goat cheese|The functional cheese is rich in conjugated linoleic acid (CLA) and omega-3. It was used for obese and overweight people, who need a special diet advice to control of lipid profile. 9,3% of polyunsaturated fatty acids 60 g per day during 12 weeks
89103007|NCT02630602|Placebo Comparator|Control cheese|Control cheese, not enriched with conjugated linoleic acid (CLA) and omega-3 4.1% of polyunsaturated fatty acids. 60 g per day during 12 weeks
89103008|NCT00666874|Experimental|1|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
89103009|NCT00666874|Active Comparator|2|General information about healthy food choices and exercise
89103010|NCT00666952|Experimental|1|
89103011|NCT00666952|Active Comparator|2|
89103012|NCT04282824|Experimental|Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive MSG PO over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
89103013|NCT04282824|Experimental|Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)|8 patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
89103014|NCT02631304||Patients undergoing cardiac surgery|Elderly patients scheduled to undergo elective cardiac surgery (coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery) with the use of cardiopulmonary bypass.
89103015|NCT04236297|Other|Modified Bite Block|Patients undergoing transesophageal echocardiogram under sedation or general anesthesia during which a modified bite block is used
89103016|NCT00663286|Experimental|1|
89103017|NCT00663286|Active Comparator|2|
89103018|NCT00663286|Active Comparator|3|
89103019|NCT00663286|Placebo Comparator|4|
89103020|NCT04284462|Placebo Comparator|Control beverage for Habitual full-calorie CSD cohort, n=28|Full sweetness (sugar) for 6 months
89103021|NCT04284462|Placebo Comparator|Control beverage for Habitual low-calorie CSD cohort, n=28|Full sweetness low calorie sweetener (LCS) with sweetness level matched to the full sweetness sugar control for 6 months
89103022|NCT04284462|Active Comparator|Test beverage 1 for Habitual full-calorie CSD cohort, n=28|Reduced sweetness (moderate sugar level) for 6 months
89103023|NCT04284462|Active Comparator|Test beverage 1 for Habitual low-calorie CSD cohort, n=28|Reduced sweetness low calorie sweetener (LCS) with sweetness level matched to the moderate sugar sweetness level for 6 months
89103024|NCT04284462|Active Comparator|Test beverage 2 for Habitual full-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the full sweetness sugar control, followed by monthly sweetness reduction. Remains at the reduced sweetness level (moderate sugar level) from months 4-6.
89103025|NCT04284462|Active Comparator|Test beverage 2 for Habitual low-calorie CSD cohort, n=28|Step-wise sweetness reduction over 6 months. Month 1 is the low calorie sweetener (LCS) sweetness equivalent of the full sweetness sugar control, followed by monthly LCS sweetness reduction (reductions equivalent to the corresponding sugar reduction arm sweetness levels). Remains at the reduced sweetness level (LCS equivalent of moderate sugar sweetness level) from months 4-6.
89103026|NCT00660088||1|10 gram x 7 days, then 20 gram x 7 days active ingredient of original formulation
89103027|NCT00660088||2|20 grams x 14 days active ingredient of original formulation
89103028|NCT00660088||3|10 grams x 7 days; then 20 grams x 7 days of low protein formulation
89103029|NCT00660088||4|20 grams x 14 days of low protein formulation
89103030|NCT00660088||5|10 grams x 7 days; then 20 grams x 7 days of high protein formulation
89103031|NCT00660088||6|20 grams x 14 days of high protein formulation
89103032|NCT03237702|Experimental|MCS arm|The participants who will have Multi-Carotenoids for 8 weeks The intervention is Multi-Carotenoids 30 mg for 8 weeks.
89103033|NCT00667108|Experimental|Gabapentin 250 mg|
89103034|NCT00667108|Experimental|Gabapentin 500 mg|
89103035|NCT00667108|Placebo Comparator|Placebo|
89103036|NCT00961116|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered after an overnight fast of at least 10 hours
89103037|NCT00961116|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
89103038|NCT04158232|Active Comparator|Blood clotting protocol for pulp regeneration|pulp regeneration for mature teeth using blood clotting protocol
89103039|NCT04158232|Experimental|platelet rich fibrin for pulp regeneration|pulp regeneration for mature teeth using platelet rich fibrin (PRF)
89103040|NCT04492449||Obese pregnants group|Obese pregnants exposure of coronavirus infection.
89103041|NCT04492449||Normal pregnants group|Normal pregnants exposure of coronavirus infection.
89103042|NCT04492449||children with congenital malformations|Child with congenital malformations
89103043|NCT04492449||children without congenital malformations|Child without congenital malformations
89103044|NCT04158388|Experimental|EXPERIMENTAL DIET GROUP|
89103045|NCT04158388|Other|CONTROL GROUP|
89103046|NCT04158388|Experimental|EXPERIMENTAL MASSAGE GROUP|That group received moderate pressure digital manual therapy.
89103047|NCT04158388|Experimental|EXPERIMENTAL PLACEBO GROUP|That group was treated with a US (in off mode) without conductive gel. Placebo group.
89103048|NCT04283136|Active Comparator|Type 1 tablet - part 1|Subjects will receive a single dose of padsevonil Type 1 tablet in the period defined by the pre-specified sequence they were randomized on to.
89103049|NCT04283136|Experimental|Type 2 tablet - part 1|Subjects will receive a single dose of padsevonil Type 2 tablet in the period defined by the pre-specified sequence they were randomized on to.
89103050|NCT04283136|Experimental|Type 3 tablet - part 1|Subjects will receive a single dose of padsevonil Type 3 tablet in the period defined by the pre-specified sequence they were randomized on to.
89103051|NCT04283136|Experimental|Type 4 tablet - part 1|Subjects will receive a single dose of padsevonil Type 4 tablet in the period defined by the pre-specified sequence they were randomized on to.
89103052|NCT04283136|Experimental|Type 5 tablet - part 1|Subjects will receive a single dose of padsevonil Type 5 tablet in the period defined by the pre-specified sequence they were randomized on to.
89103053|NCT04283136|Active Comparator|Type 1 tablet - part 2 (2 x 200 mg fasted)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
89103054|NCT04283136|Active Comparator|Type 1 tablet - part 2 (2 x 200 mg fed)|Subjects will receive a single 2 x 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
89103055|NCT04283136|Active Comparator|Type 1 tablet - part 2 (200 mg fasted)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fasting conditions in the period defined by the pre-specified sequence they were randomized on to.
89103056|NCT04283136|Active Comparator|Type 1 tablet - part 2 (200 mg fed)|Subjects will receive a single 200 mg dose of padsevonil Type 1 tablet under fed conditions in the period defined by the pre-specified sequence they were randomized on to.
89103057|NCT03727893|Active Comparator|Roller-based intervention Group (IG)|A group participating in a high-intensity exercise on a roller-based system.
89103058|NCT03727893|Placebo Comparator|Control Group (CG)|A group participating in an independent workout program at an accessible community-based fitness facility.
89103059|NCT00663364|Active Comparator|I|Physiogel AI Lotion
89103060|NCT00663364|Active Comparator|II|Physiogel Lotion twice daily
89103061|NCT04154254|Experimental|Dementia Patients|
89103062|NCT00631995|Experimental|Group 1|
89103063|NCT00631995|Experimental|Group 2|
89103064|NCT00631995|Experimental|Group 3|
89103065|NCT00631995|Experimental|Group 4|
89103066|NCT00631995|Experimental|Group 5|
89103067|NCT00631995|Active Comparator|Group 6|
89103068|NCT00663442|Experimental|1|OROS methylphenidate 18, 36, 54m placebo in randomized order (except never starting with highest dose)
89103069|NCT00912015|Experimental|Tramadol OAD 200mg|
89103070|NCT00912015|Experimental|Tramadol OAD 300mg|
89103071|NCT00912015|Experimental|Tramadol OAD 400mg|
89103072|NCT00912015|Other|Tramadol OAD 100mg|Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.
89103073|NCT00960804|Experimental|Tanezumab 5 mg|
89103074|NCT00960804|Experimental|Tanezumab 10 mg|
89103075|NCT00960804|Placebo Comparator|Placebo|
89103076|NCT04236375||Normal|Subjects over 45 years old without cognitive dysfunction
89103077|NCT04236375||Mild cognitive decline|Subjects who are diagnosed as mild cognitive decline(MCI) according to neurologists.
89103078|NCT04236375||Alzheimer's disease|Subjects who are diagnosed as Alzheimer's disease(AD) according to neurologists.
89103079|NCT04236375||Vascular dementia|Subjects who are diagnosed as vascular dementia(VD) according to neurologists.
89103080|NCT04236375||Lewy body dementia|Subjects who are diagnosed as Lewy body demenita (DLB) according to neurologists.
89103081|NCT04236375||Frontotemporal dementia|Subjects who are diagnosed as Frontotemporal demenita (FD) according to neurologists.
89103082|NCT04236375||Other dementia|Subjects who are diagnosed as dementia but are not as AD, VD, DLB OR FD.
89103083|NCT04469439||Surgical group|Individuals with cystic fibrosis and chronic rhinosinusitis who undergo endoscopic sinus surgery
89103084|NCT04469439||Medical group|Individuals with cystic fibrosis and chronic rhinosinusitis who do not undergo endoscopic sinus surgery
89103085|NCT02859948|Experimental|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
89103086|NCT01126580|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
89103087|NCT01126580|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
89103088|NCT01126580|Active Comparator|Metformin|"Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52~Placebo: subcutaneously (SC), once weekly for 52 weeks"
89103089|NCT04204356|Experimental|tDCS group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment with active tDCS.
89103090|NCT04204356|Sham Comparator|Sham group|Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment without active tDCS (sham)
89103091|NCT00911157|Experimental|Fondaparinux|
89103092|NCT00911157|Other|unfractionated heparin|
89103093|NCT00960570|Active Comparator|Efavirenz Alone|Baseline Efavirenz pharmacokinetics.
89103094|NCT00960570|Experimental|Efavirenz with Steady State Fenofibric Acid|Efavirenz pharmacokinetics in the presence of steady state Fenofibric Acid.
89103095|NCT04463511|Experimental|PB BCC: Polyethylene Bag Before Cord Clamping|Immediately after delivery, while still attached to placental circulation, infants will be placed in a PB. After the cord has been clamped and cut, the infant will be transferred to the resuscitaire for ongoing care. In the case of caesarean section a sterile bag will be used and prepared observing sterile techniques. A member of the neonatal team donned in sterile gown and gloves will assist the obstetrician in placing the infant in the PB.
89103096|NCT04463511|No Intervention|PB ACC: Polyethylene Bag After Cord Clamping|Infants will not be placed in a PB immediately after birth. After the cord has been clamped and cut, the infant will be transferred to the resuscitaire where they will be placed in a PB.
89103097|NCT04204278|Other|Monovisc|
89103098|NCT00625430|Experimental|1|Six Cohorts with escalating vector dose
89103099|NCT04282746|Experimental|JNJ-54135419|Participants will receive a single oral dose of JNJ-54135419-AAA oral solution for sublingual administration in 1 of 3 serial dose escalating cohorts in fasted conditions.
89103100|NCT03786549|No Intervention|Control|Patients included in this arm wil have usual follow-up.
89103101|NCT03786549|Experimental|Care transitional program|"Patients included in this arm will get a care transitional program. Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~Educative, family (patient and parent), at home~Psychological, with the patient individually~Medico-social orientation, group of patients"
89103102|NCT02882360|Experimental|Elective LSCS--Kerlix AMD|Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
89103103|NCT02882360|Placebo Comparator|Elective LSCS--Placebo|Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
89103104|NCT02882360|Experimental|Labouring LSCS--Kerlix AMD|Kerlix-AMD applied to wound post-operatively for 2 weeks
89103105|NCT02882360|Placebo Comparator|Labouring LSCS--Placebo|Normal gauze applied to wound post-operatively for 2 weeks
89103106|NCT00630084|Active Comparator|A|40 naïve CHC patients concomitant with malignancy other than hepatocellular carcinoma
89103107|NCT00630084|Active Comparator|B|80 naïve CHC patients without malignancy
89103108|NCT03699501||Patients|
89103109|NCT03699501||Voluntary patients|
89103110|NCT01126424|Experimental|Solifenacin|Participants received 21 days of treatment with 5 mg solifenacin, in tablet form once a day.
89103111|NCT01126424|Active Comparator|Oxybutynin|Participants received 21 days of treatment with 10 mg oxybutynin (1 x 5 mg twice daily) in capsule form.
89103112|NCT01126424|Placebo Comparator|Placebo|Participants received 21 days of treatment with placebo.
89103113|NCT04281069||"patients visiting the centre de santé"|Women visiting to the selected health centres in the Oujda province will be invited to participate
89103114|NCT02860806|Experimental|Part 1: Period 1 (JNJ-63623872 100 mg or Placebo)|Participants will receive a single intravenous (IV) infusion of JNJ-63623872 100 milligram (mg) [3 milligram per milliliters (mg/mL) solution] (Treatment A) or matching placebo (Treatment D) over 120 minutes.
89103115|NCT02860806|Experimental|Part 1: Period 2 (JNJ-63623872 200 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 200 mg (3 mg/mL solution) (Treatment B) or matching placebo (Treatment D) over 120 minutes.
89103116|NCT02860806|Experimental|Part 1: Period 3 (JNJ-63623872 300 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 300 mg (3 mg/mL solution) (Treatment C) or matching placebo (Treatment D) over 120 minutes.
89103117|NCT02860806|Experimental|Part 2: Group 1 (EFG)|Participants will receive a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over x minutes (Treatment E) followed by a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over y minutes (Treatment F), then a single oral 600-mg dose (2* 300 mg tablets) of JNJ-63623872 under fasted conditions (Treatment G). Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
89103118|NCT02860806|Experimental|Part 2: Group 2 (FGE)|Participants will receive Treatment F, then Treatment G followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
89103119|NCT02860806|Experimental|Part 2: Group 3 (GEF)|Participants will receive Treatment G, then Treatment E followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
89103120|NCT02860806|Experimental|Part 2: Group 4 (GFE)|Participants will receive Treatment G, then Treatment F, followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
89103121|NCT02860806|Experimental|Part 2: Group 5 (FEG)|Participants will receive Treatment F, then Treatment E followed by Treatment G. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
89103122|NCT02860806|Experimental|Part 2: Group 6 (EGF)|Participants will receive Treatment E, then Treatment G followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
89103123|NCT02860806|Experimental|Part 3: JNJ-63623872 300 mg|Participants will receive multiple IV infusions of JNJ-63623872 300 mg (3 mg/mL) solution every 12 hours on Days 1 to 10, with only a morning dose on Day 10. Duration of infusion and dose will be selected after Part 2 of this study is completed.
89103124|NCT01126268|Experimental|Retapamulin ointment 1%|
89103125|NCT04372251|Active Comparator|Sinus tarsi approach (STA)|Patients randomized to this arm are operated with plate osteosynthesis via the sinus tarsi approach
89103126|NCT04372251|Active Comparator|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Patients randomized to this arm are operated with percutaneous reduction of the fracture and osteosynthesis with screws, assisted by subtalar arthroscopy
89103127|NCT04284150|Experimental|dexmedetomidine or Midazola treat supraventricular tachycardia|Comparison of efficacy of dexmedetomidine and Midazolam in the treatment of SVT
89103128|NCT02883842|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week.
89103129|NCT02883842|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
89103130|NCT04282512|Experimental|Group A : sodium bicarbonate-rich mineral water and tap water|"First 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.~15-days washout period Last 15-days period with daily intake of 1.5l of tap water."
89103131|NCT04282512|Experimental|Group B : tap water and sodium bicarbonate-rich mineral water|First 15-days period with daily intake of 1.5l of tap water. 15-days washout period Last 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.
89103132|NCT02883608|Experimental|Initial cap assisted endoscopy|undergo initial cap assisted forward-viewing endoscope then side-viewing duodenoscope
89103133|NCT02883608|Active Comparator|Initial standard endoscopy|undergo initial side-viewing duodenoscope then cap assisted forward-viewing endoscope
89103134|NCT02860026|Active Comparator|Control|Marketed cow's milk-based infant formula
89103135|NCT02860026|Experimental|Investigational|Cow's milk-based infant formula with added nutrients
89523158|NCT03380585|Experimental|Reciproc|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc single-file system. The intervention is foraminal enlargement with the Reciproc single-file system.
89103137|NCT03311334|Experimental|DSP-7888 Dosing Emulsion in combination with Nivolumab|
89103138|NCT03311334|Experimental|DSP-7888 Dosing Emulsion in combination with Pembrolizumab|
89103139|NCT04313036|Experimental|Defibrotide|5 day course of defibrotide at standard dosing 25 mg/kg/day in 4 divided doses of 6.25 mg/kg. If not in CR by day 5, will be given for >/= 21 days or per discretion of enrolling physician.
89103140|NCT02882438|Active Comparator|Infected group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Ginkgo Biloba in different dosage forms.
89103141|NCT02882438|Placebo Comparator|Control group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo without Ginkgo Biloba.
89103142|NCT00637520||1|Subjects with NAFLD
89103143|NCT00637520||2|Subjects without liver disease
89103144|NCT00637520||3|Subjects with non-steatotic hepatitis
89103145|NCT04310696|Experimental|Buteyko group|Buteyko breathing exercises
89103146|NCT04310696|Active Comparator|Pursed lip breathing|Pursed lip breathing exercises
89103147|NCT00879658|Experimental|BAF312 10mg (period 1)|
89103148|NCT00879658|Experimental|BAF312 2 mg (period 1)|
89103149|NCT00879658|Experimental|BAF312 0.5 mg (period 1)|
89103150|NCT00879658|Experimental|BAF312 dose between 0.1 to 8 mg period 2|
89103151|NCT00879658|Experimental|BAF312 dose between 0.1 - 8 mg period 2|
89103152|NCT00879658|Placebo Comparator|Placebo (period 1, 2)|
89103153|NCT00660166|Experimental|1|
89103154|NCT00959946|Experimental|1|In part 1 (phase 1), ascending and descending multiple oral doses of bosutinib + capecitabine. Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14 + bosutinib 200 mg QD; capecitabine 625 mg/m2 BID on days 1-14 + bosutinib 300 mg QD. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID and bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
89103155|NCT00667264|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
89103156|NCT00667264|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
89103157|NCT00660244||1|
89103158|NCT04282200|No Intervention|Standard of Care|Patients receiving standard of care pain management including opioids.
89103159|NCT04282200|Active Comparator|Ketorolac|Patients will receive standard of care pain management plus intravenous ketorolac.
89103160|NCT04157764|Experimental|APD|
89103161|NCT04281966|Experimental|Experiment|For young people from schools randomly assigned to the experimental ASEP condition will participate in the ASEP intervention. The ASEP intervention is a Third-Party Policing partnership that involves a partnership between police and school, an ASEP conference and follow up which is organized and led by a conference facilitator with the young person, their parent (or guardian), a school representative (e.g., teacher), and a uniformed school-based police officer. The police and school representatives will be trained by the facilitator to utilize procedurally just dialogue during the entirety of the conference. The ASEP conference script will utilize a procedurally just dialogue to increase both the young person and their parents' perceptions and knowledge of the legitimacy of the truancy laws, police, and schools in order to gain willing compliance to follow the rules.
89103162|NCT04281966|No Intervention|Control|"Participants allocated to the control condition will be given the business-as-usual' approach to handling school non-attendance. The control participants will be sanctioned in the usual manner for engaging in truancy through the requirements denoted in the Queensland Education (General Provisions) Act (2006)."
89103163|NCT00667498|Experimental|1|
89103164|NCT00667498|Placebo Comparator|2|
89103165|NCT02860650|Experimental|Group 1: AD26.Filo/MVA-BN-Filo or Placebo|Participants will receive Ad26.Filo or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
89103166|NCT02860650|Experimental|Group 2: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 57.
89103167|NCT02860650|Experimental|Group 3: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 15.
89103168|NCT02860650|Experimental|Subset of Group 3: AD26.Filo or Placebo|The first 8 participants in Group 3 who are willing to enroll in the subset for third vaccination, will receive a third vaccination at Day 92. Participants who previously received placebo will receive placebo a third time and participants who previously received MVA-BN-Filo/Ad26.Filo vaccination will receive Ad26.Filo as third vaccination. After enrollment of the 8 participants, the unblinded monitor and unblinded pharmacist will assess whether 7 participants who previously received MVA-BN-Filo/Ad26.Filo vaccination have been enrolled. If less than 7 participants of the active vaccine regimen have been enrolled, 2 additional participants will be enrolled. If at least 7 participants of the active vaccine regimen have been enrolled, no further will be enrolled. The aim is to enroll 7 or 8 participants who will receive Ad26.Filo as third vaccination.
89103169|NCT02860650|Experimental|Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
89103170|NCT00660322|No Intervention|Control|Families assigned to the control arm will receive usual asthma care from the child's primary care provider.
89103171|NCT00660322|Experimental|Intervention|The Telephone Asthma Program and usual care.
89103172|NCT00663520||1|"Women with chest pain and Clean heart vessels"
89103173|NCT00663520||2|Healthy volunteers
89103174|NCT04283760||Healthy Group|"Demographic Information~Mental Chronometry Test~Movement Imagination Questionnaire- Revised Second~Beck Depression Inventory"
89103175|NCT04283760||Acute Stroke Patients|"Demographic Information~Mental Chronometry Test~Movement Imagination Questionnaire- Revised Second~Beck Depression Inventory~Trail Making Test~Barthel Index~Motor Assessment Scale~Trunk Impairment Scale~Mini Mental Test~Glaskow Coma Scale"
89103176|NCT00667966|Experimental|Vardenafil + Placebo|Subjects received single dose of 10 mg vardenafil followed by 20 mg vardenafil and then crossed over to 10 mg placebo followed by 20 mg placebo.
89103177|NCT00667966|Experimental|Placebo + Vardenafil|Subjects received single dose of 10 mg placebo followed by 20 mg placebo and then crossed over to 10 mg vardenafil followed by 20 mg vardenafil.
89103178|NCT00911937|Experimental|Fesoterodine|
89103179|NCT00911937|Placebo Comparator|Placebo|
89103180|NCT02631226||Pregnant women colonized by resistant enterobacteria|
89103181|NCT00663598|Experimental|Arm 1|
89103182|NCT04155736|Experimental|Renew with coaching|Users will be assigned a study staff member as a support person who is notified when the user engages with the app or if they have not engaged for 7 days. Support persons are provided with psychoeducation material including information about how to be an effective support person for the user and direct messaging capacity to respond to app notifications about user engagement (e.g., user earned X points, user achieved a new level).
89227757|NCT05271071|Active Comparator|Gluteus Maximus Group|30 patients in the gluteus maximus group will be evaluated with detailed physical examination and special clinical tests. Sensitivity with sonopalpation, piriformis and gluteus maximus thicknesses, echo intensities will be evaluated with ultrasonography. Primarily diagnostic injection test for gluteus maximus muscle is planned for the first group with lidocaine with USG guide. At the first hour after injection full examination will be repeated for all patient and will be evaluated again with Numeric Rating Scale(NRS) at rest, with movement and with deep palpation. If the NRS score persists after the first injection patients will receive a diagnostic lidocaine injection into the piriformis muscle. At the first hour after the second injection, the physical examination and clinical tests of the patients will be repeated, and their pain at rest, with movement and with deep palpation will be evaluated with NRS.
89523159|NCT03380585|Active Comparator|ProTaper Next|The active comparator is foraminal enlargement with the ProTaper Next multi-file system. Endodontic treatment is identical to experimental group except file systems used. In this group, ProTaper Next multi-file system will be used in enlarging apical foramina.
89523160|NCT04715321||Training cohort|HCC patients enrolled in our study underwent a perfusion CT examination before surgery . We used CT perfusion parameters to predict the vascular pattern of tumors.
89103183|NCT04155736|Active Comparator|Renew without coaching|"Same as Renew with coaching except that the users will not be assigned a study staff member as a support person."
89103184|NCT04155736|No Intervention|Wait list|No intervention is provided
89103185|NCT04281264|No Intervention|NorCON|Normoxia Control Group
89103186|NCT04281264|Active Comparator|HypCON|Hypoxia Control Group
89103187|NCT04281264|Placebo Comparator|NorCIR|Normoxia Circuit Training with Elastic Bands Group
89103188|NCT04281264|Experimental|HypCIR|Hypoxia Circuit Training with Elastic Bands Group
89103189|NCT04281264|Placebo Comparator|NorVIB|Normoxia Whole-body Vibration Training Group
89103190|NCT04281264|Experimental|HypVIB|Hypoxia Whole-body Vibration Training Group
89103191|NCT00663754|Active Comparator|1|Participants will receive a mailed brochure about body image only.
89103192|NCT00663754|Active Comparator|2|Participants will receive the 4-hour dissonance-based eating disorder prevention program.
89103193|NCT00663754|Experimental|3|Participants will receive the 8-hour dissonance-based eating disorder prevention program.
89103194|NCT00660478|Active Comparator|1|Zotarolimus eluting stent
89103195|NCT00660478|Active Comparator|2|Sirolimus stent
89103196|NCT02859714||colorectal adenoma|
89103197|NCT04168437|Experimental|Health-Related Quality of Life Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report.
89103198|NCT04168437|No Intervention|Wait List to Receive the Report|Participants randomized to this arm will receive the 2- page Health-Related Quality of Life Report following completion of the study.
89103199|NCT02860572|Experimental|follow-up without intervention|No intervention to increase the urine output within 2 hours will be done.
89103200|NCT02860572|Active Comparator|Standard group - fluid bolus|Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes.
89103201|NCT04161417|Other|Biopsy Material Required for Registration|The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer
89103202|NCT04283838|Experimental|Humanistic care|Psychological and physical rehabilitation based humanistic care regimen was used to prevent depression and PTSD in healthcare workers who participated in the treatment of COVID-19.
89103203|NCT00880048|Experimental|orvepitant 30 mg|orvepitant 30 mg (low dose)
89103204|NCT00880048|Experimental|orvepitant 60 mg|orvepitant 60 mg (high dose)
89103205|NCT00880048|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 mg and 60 mg dosage forms
89103206|NCT02859480|Experimental|Rosuvastatin 5mg|Patients are treated with Rosuvastatin 5mg/day for 30 months after percutaneous coronary intervention
89103207|NCT02859480|Active Comparator|Rosuvastatin 20mg|Patients are treated with Rosuvastatin 20mg/day for 30 months after percutaneous coronary intervention
89103208|NCT00962208|Experimental|orthokeratology lenses|Children wearing orthokeratology at night for correcting of refractive error will be study group
89103209|NCT00962208|Other|single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
89103210|NCT02861508|Active Comparator|Usual care|Usual care as determined by treating team. Ultrasound may still be part of the workup per the treating team's discretion.
89103211|NCT02861508|Experimental|Early POCUS|Point-of-care ultrasound protocol will involve cardiac views (for pericardial effusion, left ventricular function, left and right ventricular equality, aortic root dilation, and inferior vena cava status), lung views (for pneumothorax, signs of alveolar interstitial syndrome), abdominal views for free fluid, and a view of the abdominal aorta for aneurysm.
89103212|NCT01076543|Experimental|Treatment (lenalidomide, temsirolimus)|Patients receive lenalidomide PO on days 1-21 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 2 courses may continue therapy for up to 52 weeks.
89103213|NCT00922558|No Intervention|normal children|Normal children ages 5-12 years.
89103214|NCT00922558|Experimental|postural control|
89103215|NCT02861274|Active Comparator|electrophysiological testing|Patients will receive a pacemaker.
89103216|NCT02861274|No Intervention|control group|These subjects will receive cardicor® (beta blockers).
89103217|NCT04154176||POD CAM Nu-DESC|Patients undergoing surgery under general anesthesia assessed for POD with CAM and Nu-DESC
89103218|NCT00668044|Experimental|Arm 1|
89103219|NCT00668044|Experimental|Arm 2|
89103220|NCT02860494|Experimental|Topical everolimus 0.1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
89103221|NCT02860494|Experimental|Topical everolimus 0.5%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
89103222|NCT02860494|Experimental|Topical everolimus 1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
89103223|NCT02860494|Placebo Comparator|Topical placebo|Topical placebo will be identical to the everolimus topical formulation. Topical placebo will be applied to the affected areas, once daily, in the evening, for 6 months by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
89103224|NCT04801823|Active Comparator|Home Introduction of Individual tree nuts|Current standard of care which is to advise families of infants diagnosed with peanut allergy to introduce tree nuts individually via a standardized, graded and cautious home introduction protocol. Day 1: smear of nut paste to the inside of lip; Day 2: 1/8 teaspoon; Day 3: 1/4 teaspoon; Day 4: 1/2 teaspoon; Day 5: 1 teaspoon. Repeat process with each individual tree nut.
89103225|NCT04801823|Experimental|In hospital multi-tree nut (almond, cashew hazelnut and walnut) oral food challenge (OFC)|Infant will be booked for a 4-nut butter (Almond, Hazelnut, Walnut, and Cashew) graded and supervised OFC in the allergy clinical trials unit at the Murdoch Children's Research Institute. The nut butter contains a 1g dose of each nut protein in a total weight of 20g. Doses will be administered every 15minutes (1. Smear to inside of lip, 2.1/8 teaspoon, 3.1/4 teaspoon, 4.1/2 teaspoon, 5.1 teaspoon, 6.remainder of 20g nut butter paste) If challenge negative, infants continue home introduction of tree nuts as per written instructions provided. If challenge positive, infants will have additional SPT (for full tree nut panel) and single tree nut OFC as per protocol to determine tolerance/allergic status (and +/- home introduction recommendation) for each tree nut.
89103226|NCT04281810|Experimental|TEDS|Subjects received transcutaneous electrical diaphragm stimulation (TEDS) for 30min/ day till the end of the weaning trial
89103227|NCT04281810|No Intervention|Control|Subjects received similar medical treatment except for the TEDS program.
89103228|NCT00663832|Experimental|LBH589|
89103229|NCT04281576|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with XELOX. For HER-2 positive patients, Trastuzumab is given together with XELOX.
89103230|NCT04795271|Experimental|Orthopedic treatment|"Participants who are referred for orthopedic treatment as indicated by the treating traumatologist or rehabilitating doctor will be evaluated and treated by one of the three orthopedists participating in this study.~After the orthopedic evaluation, the professional will determine the most suitable insole according to the plantar discharge needs required by the patient. The intervention in the insole can include modifications or corrections at the forefoot, midfoot, or hindfoot. The material used in each insole will also be specified. When the insole requires many modifications and raises the height of the subject's foot, the use of orthopedic footwear will also be added to prevent pressure on the dorsum of the foot that could be caused by normal footwear."
89103231|NCT00668122|Experimental|Arm 1|
89103232|NCT00668122|Experimental|Arm 2|
89103233|NCT04304807|Experimental|Group I|Forty five preterm infants with signs of feeding intolerance who received 20 mg of melatonin treatment in addition to traditional antibiotic treatment.
89103234|NCT04304807|Sham Comparator|Group II|Forty five preterm infants with signs of feeding intolerance who received traditional antibiotic treatment only.
89103235|NCT04280874|Active Comparator|GROUP A|106 randomly selected pregnant women
89103236|NCT04280874|Active Comparator|GROUP B|106 randomly selected pregnant women
89103237|NCT02875769|Experimental|Test: Mouthwash CPC+Zn+F|To rinse with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
89103238|NCT02875769|Active Comparator|Positive control: Mouthwash CHX|To rinse with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
89103239|NCT02875769|Placebo Comparator|Negative control A: No rinsing|No rinsing with pre-procedural mouthwash + full mouth dental prophylaxis using ultrasonic scaler.
89103240|NCT02875769|Placebo Comparator|Negative control B: Water|To rinse with pre-procedural mouthwash containing water from a three-way syringe (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
89103241|NCT00663988|Experimental|III|The effect of human partial facial allotransplantation
89103242|NCT04304885||Sonication method|The treatment strategies of all patients will be based on the cultural results to be made by the sonication method.
89103243|NCT04157998|Placebo Comparator|control|patient receive 10 ml normal saline intravenous
89103244|NCT04157998|Active Comparator|metoclopramide group|"patient receive 10 mg metoclopramide intravenously diluted in 10 mL saline 0.9%.~intravenous"
89103245|NCT02861352|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 10 mg/d and 25 mg supplemental zinc/d
89103246|NCT00668278|Active Comparator|A|Laryngeal Mask Airway insertion
89103247|NCT00668278|Active Comparator|B|I-gel insertion
89103248|NCT04157842|Experimental|total hip replacement with subtrochanteral osteotomy|subtrochanteral osteotomy is applied during total hip replacement
89103249|NCT04157842|Sham Comparator|total hip replacement with no osteotomy|no osteotomy is applied during total hip replacement.
89103250|NCT02860260|Experimental|Patients with fibrinolysis|
89103251|NCT02860260|Placebo Comparator|Patients without fibrinolysis|
89103252|NCT04155268|Experimental|Floatation-REST|Participants will float in a shallow pool of water with about 1000 pounds of epsom salt, in a light and sound attenuated device, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
89103253|NCT04155268|Active Comparator|Dark Room|Participants will lay on an air mattress in a dark and quiet room, with reduced environmental stimulation, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
89103254|NCT02860338||GROUP 1- CNS Protocol|"Patients in a specialized dementia practice. Evaluated and treated for hypoxia, elevated BNP, hyperhomocysteinemia, B 12 deficiency as measured by elevated methymalonic acid, Vitamin D 25-OH deficiency, elevated CRP, and decreased IGF-1, and other metabolic abnormalities.~Treated with maximal doses of acetylcholinesterase inhibitors, memantine, methylfolate/methylB12/N-acetylcysteine, dextromethorphan/quinidine, and SSRI's; dose and duration based on protocol."
89103255|NCT02860338||GROUP 2- Community Care|Patients referred to a neuropsychology practice for cognitive evaluation and treated for MCI or dementia by their primary care clinician or non-dementia specialist according to specific provider's usual practice pattern.
89103256|NCT01072877|Experimental|Polidocanol injectable foam 0.125%|Polidocanol injectable foam 0.125%
89103257|NCT01072877|Experimental|Polidocanol injectable foam 0.5%|Polidocanol injectable foam 0.5%
89103258|NCT01072877|Experimental|Polidocanol injectable foam 1.0%|Polidocanol injectable foam 1.0%
89103259|NCT01072877|Experimental|Polidocanol injectable foam 2.0%|Polidocanol injectable foam 2.0%
89103260|NCT01072877|Placebo Comparator|Vehicle|Injection of vehicle comparator
89103261|NCT02875847|Active Comparator|HMO1|Daily bolus of HMO1
89103262|NCT02875847|Active Comparator|HMO2|Daily bolus of HMO2
89103263|NCT02875847|Placebo Comparator|Dextropur|Daily bolus of dextropur
89103264|NCT00961896|Active Comparator|LDE225 (applied in parallel with vehicle) [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
89103265|NCT00961896|Placebo Comparator|Vehicle cream (applied in parallel with LDE225 [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
89103266|NCT00961896|Active Comparator|LDE225 0.25% [Part II]|Participants were exposed to topically applied 0.25% LDE225 cream twice daily for 6 weeks.
89103267|NCT00961896|Active Comparator|LDE225 0.75% [Part II]|Participants were exposed to topically applied 0.75% LDE225 cream twice daily where some basal cell carcinomas (BCCs) were teated for 6 weeks and some BCCs were treated for 9 weeks.
89103268|NCT02858388|Active Comparator|SN45|Sinuclean Nebules 45
89103269|NCT02858388|Placebo Comparator|Sal|Saline solution
89103270|NCT02859090|Experimental|patient|
89103271|NCT02706288|Experimental|Weight loss with diet with exercise|Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after ~7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until ~7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
89103272|NCT00630474|Active Comparator|1|nasal application of xylometazoline
89103273|NCT00630474|Placebo Comparator|2|nasal application of placebo
89103274|NCT02860182||experimental|patients with acute type A dissection
89103275|NCT02860182||control|patients without any pathology of the ascending aorta, but having the same characteristics as the sick patients, in terms of age and vascular risk factors including high blood pressure
89103276|NCT02860104|Other|microwave ablation|microwave ablation
89103277|NCT00957528|Placebo Comparator|Placebo|Weekly placebo treatment for a duration of 5 months.
89103278|NCT00957528|Experimental|Monthly Cycled Testosterone|A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.
89103279|NCT00957528|Experimental|Continuous Testosterone|Weekly testosterone treatment for a duration of 5 months
89103280|NCT02857062|Experimental|E45 Eczema Repair Emollient|Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children
89103281|NCT00958776|Experimental|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
89103282|NCT00958776|Placebo Comparator|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
89103283|NCT02858856|Experimental|A group|Take Sipjeondaebo-tang on 0~2 week, 3~5 week of clinical trial period, total of 4 weeks
89103284|NCT02858856|Experimental|B group|Take Sipjeondaebo-tang on 6~8 week, 9~11 week of clinical trial period, total of 4 weeks
89103285|NCT02858622|Active Comparator|dual TAB group|22 patients will receive unilateral dual transversus abdominis plane (TAB) block USING bupivacaine 0.25% at a dose of 2 mg/kg
89103286|NCT02858622|Sham Comparator|control group|22 patients who will not receive dual TAB block
89103287|NCT04278456||general anesthesia|c-section with general anesthesia
89103288|NCT04278456||spinal anesthesia|c-section with spinal anesthesia
89103289|NCT04278456||epidural anesthesia|c-section with epidural anesthesia
89103290|NCT02191566|Experimental|S-1/Oxaliplatin|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months; Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
89103291|NCT00596830|Experimental|A|Patients in Arm A will receive CP-751, 871 in combination with paclitaxel and carboplatin intravenously every 21 days for up to six cycles.'
89103292|NCT00596830|Active Comparator|B|Patient in Arm B will receive paclitaxel and carboplatin intravenously every 21 days for up to six cycles.
89103293|NCT00957372|Experimental|ESL 800 mg daily (Part I)|ESL 800mg daily
89103294|NCT00957372|Experimental|ESL 1200 mg daily (Part I)|ESL 1200mg daily
89103295|NCT00957372|Placebo Comparator|placebo (Part I)|placebo
89103296|NCT00957372|Experimental|ESL - Open-label Extension (Part II)|All patients were treated with only ESL during Part II.
89103297|NCT02858778|Experimental|Interventional group (Ig)|The interventional group (Ig) will have an early palliative care consultation ordered during their stay in the emergency department.
89103298|NCT02858778|No Intervention|Control group (Cg)|The control group will be treated as standard of care. Palliative care consultations may or may not be ordered at the attending physician's discretion.
89103299|NCT02610582|Other|Treatment arm|single subretinal injection of 1x10e11 vector genome particles of rAAV.hCNGA3 in each eye at different time-points
89103300|NCT02610582|Other|Waiting group Arm|Waiting group will serve as comparator group first and will receive the treatment at a later timepoint.
89103301|NCT04270968|Experimental|ESWT Group|received ESWT once a week for 4 weeks (0.25 ml/mm2, 1000 shocks) plus topical none steroidal anti-inflammatory drug (NSAID; 3 times /day for 4 weeks).
89103302|NCT04270968|Experimental|control group|received only topical NSAID.
89103303|NCT02857998|Experimental|HMPL-523|Oral administration, at dose of 200, 400, 600 and 800 mg once daily;at dose of 200,300, 400mg twice daily at Dose-escalation stage; At Dose-expansion stage, if patients dosing at 600mgQD.
89103304|NCT05143164|Experimental|Hydrocolloid dressing|The intervention group will use the weekly hydrocolloid dressing (Duoderm Extra Thin CGF dressing,10 x 10 cm) for peritoneal dialysis exit-site care
89103305|NCT05143164|Active Comparator|Gentamicin cream|The control group will apply topical gentamicin cream to catheter exit site daily and cover with normal dressing
89103306|NCT02630212||Control|Chinese Han people undergoing coronary angiography in Qilu Hospital in corresponding period whose coronary arteries narrowing less than 50 percent.
89103307|NCT02630212||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Qilu Hospital
89103308|NCT04278222|Experimental|Anlotinib Plus Toripalimab|the combination of Anlotinib Plus Toripalimab as first-line treatment
89103309|NCT04280484|Experimental|Acute Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts
89103310|NCT04280484|Sham Comparator|Sham Acute Intermittent Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 bouts.
89103311|NCT00660634|No Intervention|B|
89103312|NCT00660634|Experimental|A|Endovascular angioplasty/stenting
89103313|NCT02858700|Experimental|umbilical cord blood procalcitonin|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP
89103314|NCT04157452||proximal ureteral stone patient|
89103315|NCT02819856|Placebo Comparator|SPI-1000 Capsule 0mg Ebselen Placebo|0mg Ebselen SPI-1000 bid po x 21d
89103316|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x1|200mg SPI-1005 bid po x 21d Low Dose Arm
89103317|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x2|400mg SPI-1005 bid po x 21d Mid Dose Arm
89103318|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x3|600mg SPI-1005 bid po x 21d High Dose Arm
89103319|NCT02630290|Placebo Comparator|Ropivacaine|After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle tip repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under continuous ultrasound monitoring.
89103320|NCT02630290|Experimental|Ropivacaine + Dexmedetomidine|After skin infiltration with 1-2 mL of lidocaine 2%, a 21-gauge 90-mm spinal needle will be inserted into the brachial plexus sheath using in-plane technique. After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine plus 30 microg dexmedetomidine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under realtime ultrasound monitoring.
89103321|NCT04157530|Sham Comparator|sham group|15 subjects with seeds of wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
89103322|NCT04157530|Experimental|acupuncture group|15 subjects with acupuncture applied to Qingming and Qiuhou with Der-qi
89103323|NCT04157530|Experimental|Electroacupuncture group|15 subjects wth acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi
89103324|NCT00668356|Experimental|1|
89103325|NCT00668356|Active Comparator|2|
89103326|NCT00952848|Experimental|MC5-A Scramble instrument|Treatment of chronic neuropathic pain with the MC5-A device
89103327|NCT04157374|Experimental|EXPERIMENTAL GROUP|AOT and Active exercises
89103328|NCT04157374|Active Comparator|Control group|Active exercises
89103329|NCT00668512|Experimental|Antimelanoma injection-GSL alpha-Gal|Intervention consists of injection of a single melanoma metastasis with two injections of GSL alpha-Gal separated by four weeks. Both injections done with the same dose of GSL alpha-GAL each time. Phase 1 dose escalating scheme: 0.1mg, 1 mg, 10mg
89103330|NCT00664300||2|One group with Gilles de la Tourette's Syndrome One group with healthy paired volunteers
89103331|NCT00668590|Experimental|1|
89103332|NCT00668590|Active Comparator|2|
89103333|NCT02856516|Experimental|Boost Glucose Control (A)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
89103334|NCT02856516|Experimental|Boost Glucose Control (B)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
89103335|NCT02856516|Active Comparator|Boost Original|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption.
89103336|NCT04280250|Active Comparator|Group 1|Active control arm: Volitional help-sheet with instruction: We want you to plan to increase your level of physical activity. Research shows that if people can identify situations in which they are likely to be tempted not to be physically active and ways to overcome temptation they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page are a series of common situations in which people feel tempted not to be physically active; please tick all those that apply to you personally. On the right hand side of the page are a series of possible solutions; please tick all those that apply to you personally. Tick as many or as few situations and solutions as you like.
89103337|NCT04280250|Experimental|Group 2|"Experimental arm: Volitional help-sheet with instruction:~We want you to plan to increase your level of physical activity. Research shows that if people link being tempted not to be physically active with a way to overcome that temptation, they are much more likely to be successful in their intention to increase their level of physical activity. On the left hand side of the page below is the temptation not to be physically active; on the right hand side of the page are a series of possible solutions. Please draw lines linking being tempted not to be physically active (left hand side) to solutions (right hand side) that you think might work for you personally. Please make as many situation-solution links as you like."
89103338|NCT00660712||1|Patients with bipolar disorder
89103339|NCT02858544||Group1 - Validation Group|n=890 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
89103340|NCT02858544||Group 2 - Cross Validation Group|n=900 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
89103341|NCT02630134|Experimental|Baeta|These patients receive the Baeta device and take it home.
89103342|NCT00952614|Experimental|Retisert for Retinal Vein Occlusion|0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
89103343|NCT00911859|Experimental|Part 1: VMP+Siltuximab 11 mg/kg|Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP (Velcade+Melphalan+Prednisone). Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally (by mouth).
89103344|NCT00911859|Experimental|Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg|Siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
89103345|NCT00911859|Active Comparator|Part 2, Arm B: VMP|Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
89103346|NCT00664612|Experimental|1|Air Traq then Macintosh
89103347|NCT00664612|Experimental|2|Macintosh then AirTraq
89103348|NCT00956592|Active Comparator|CMAC Video laryngoscope|Subjects will have their intubation attempted first with the CMAC video laryngoscope
89103349|NCT00956592|Active Comparator|Macintosh blade|Patients will have their first intubation attempted utilizing the conventional Macintosh design laryngoscope blade
89103350|NCT02632162||cardiac surgery|active Group screening
89103351|NCT02632162||orthopedic surgery|control Group screening
89523161|NCT04715321||Validation cohort|HCC patients who would undergo a perfusion CT examination before surgery will be enrolled in our study from January 15, 2021. We use CT perfusion parameters to predict the vascular pattern of tumors.
89523162|NCT00999401|Experimental|sapacitabine and seliciclib|Sequential or concomitant administration of sapacitabine and seliciclib
89103352|NCT02739555|Active Comparator|1: Percutaneous treatment|Percutaneous treatment of OO is a thermal tumor destruction by radiofrequency or laser photocoagulation performed under CT control with strict aseptic approach and most often under general anesthesia. The introductive needle is inserted toward the nidus. Then the optic fiber or the radiofrequency probe is inserted in the nidus center and thermal destruction of the tumor is obtained.When the distance between the nidus and a nerve or the skin is less than 10 mm, infusion of normal saline or CO2 is introduced as spacing agent. When the nidus is in the subchondral bone, cold normal saline is introduced in the joint to protect the cartilage. In addition, a thermocouple is placed in the epidural or foraminal space to continuously monitor the temperature. A procedure typically required between 1 and 2 h from the time the patient entered the CT unit.
89103353|NCT02739555|Experimental|2: Bisphosphonate treatment|"The treatment consists of 3 infusions of zoledronic acid administered at a monthly interval. Bisphosphonate treatment is considered finished 1 month after the third bisphosphonate infusion (V4 visit). In few cases, the analgesic efficacy provided by 3 bisphosphonate infusions cannot be sufficient: 1 to 3 additional infusions could be proposed to the patient.~Zoledronic acid is supplied as a 4 mg/100 ml solution for infusion. It will be administered as infusion over 30 minutes under the supervision of a nurse. Adults will receive intravenous infusion of 4 mg of zoledronic acid. Children will receive infusion of 0.025 mg/kg of zoledronic acid.~The investigators propose abacus corresponding to zoledronic acid volume to infuse during 30 minutes for children."
89103354|NCT03659955|Experimental|Autologous blood|"Patients with severe dry eye and ocular surface disease who attend the corneal service within NHS Lanarkshire and who are unresponsive to conservative treatment measures will be considered for treatment of their condition with autologous blood.~Intervention is application of autologous blood."
89103355|NCT02725593|Experimental|Dapagliflozin|
89103356|NCT02725593|Placebo Comparator|Dapagliflozin placebo|
89103357|NCT00911625|Active Comparator|0.5 units/kg|Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
89103358|NCT00911625|Experimental|0.25 units/kg|Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
89103359|NCT00596752|Experimental|Alprostadil|Prostavasin® 40 μg will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
89103360|NCT00596752|Placebo Comparator|Placebo|Placebo will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
89103361|NCT04202523|Experimental|RT&RFA|
89103362|NCT04202523|Active Comparator|RFA|
89103363|NCT04151277|Experimental|FOLFOX-A|"nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first)~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1~Folinic acid: 350 mg flat dose, IV over 2 hours, day 1~5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours (or 48 hours as per standard practice))"
89103364|NCT04151277|Active Comparator|Abraxane and Gemcitabine|"nab-paclitaxel: 125 mg/m2 IV over 30 minutes, day 1, 8, and 15 (administered first)~Gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 (immediately following nab-paclitaxel)"
89103365|NCT00958074|Experimental|Cohort I (>=65 years old)|200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
89103366|NCT00958074|Experimental|Cohort II (<65 years old)|400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
89103367|NCT00660868||1|Patients with posttraumatic, idiopathic, and postinflammatory cause of smell loss; patients age between 18 and 50 years. Odor threshold better than 1.
89103368|NCT02632240|Active Comparator|Control group|Surgery:The tunnel technique for covering gingival recession. Graft: connective tissue.
89103369|NCT02632240|Active Comparator|Study group|Surgery:The tunnel technique for covering gingival recession.Graft: xenogenic collagen matrix (Mucoderm).
89103370|NCT04343157|Experimental|Image-guided cognitive sparing brain SRS|This is a single arm phase II study where enrolled subjects will receive intracranial SRS will performed identically to standard of care, except for implementing additional imaging techniques and software for additional regional avoidance for cognitive sparing (specifically sparing white matter and the bilateral hippocampus)
89103371|NCT00664690|Experimental|1|celebrex
89103372|NCT00664690|Placebo Comparator|2|placebo
89103373|NCT00664768|Experimental|New Neocate|new Neocate
89103374|NCT00664768|Active Comparator|Neocate Infant|Neocate Infant formula
89103375|NCT04202913|Experimental|Health Coaching|1:1 Health coaching with student
89103376|NCT00809965|Experimental|Rivaroxaban 2.5 mg bid|One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
89103377|NCT00809965|Experimental|Rivaroxaban 5 mg bid|One 5 mg rivaroxaban tablet twice daily for up to 6 months
89103378|NCT00809965|Placebo Comparator|Placebo|One placebo tablet twice daily for up to 6 months
89103379|NCT02630914|Experimental|Intervention|All patients will have the hybrid procedure of ablation of atrial fibrillation.
89103380|NCT04338165|Experimental|Evolocumab, 420 milligrams|Single injection of 420 milligrams of evolocumab (REPATHA®) one month before coronary angiography and coronary microcirculation (IMR) measurement.
89103381|NCT04338165|No Intervention|Control arm|Measurement of coronary microcirculation (IMR) during coronary angiography, without prior evolocumab injection.
89103382|NCT00668980||Study group|20 infants with Down syndrome
89103383|NCT00668980||Control Group|15 typically developing children
89103384|NCT04117269|Experimental|External shoe lift|Those patients allocated in the experimental group will be supplemented with a external shoe lift in the contralateral limb in their conventional shoes to compensate the differences with the affected foot (using a offloading device to active ulcer).
89103385|NCT04117269|No Intervention|Standard of care|Those patients allocated in the control group will not be supplemented, they will be treated with a standard of care treatment.
89103386|NCT00664846|Experimental|1|
89103387|NCT00664846|Active Comparator|2|
89103388|NCT00597376|Experimental|1|On Cerefolin NAC and open-label multivitamin supplement
89103389|NCT00597376|Placebo Comparator|2|On placebo and open label multivitamin supplement
89103390|NCT00669136|Other|1|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
89103391|NCT00661024|Placebo Comparator|1|RLN visualization alone
89103392|NCT00661024|Experimental|2|IONM of the RLN
89103393|NCT00913783|Experimental|1|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
89103394|NCT00913783|Active Comparator|2|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
89103395|NCT00661102|Experimental|1|
89103396|NCT00661102|Active Comparator|2|
89103397|NCT00661102|Placebo Comparator|3|
89103398|NCT05297383|Active Comparator|n-3 PUFA and flexibility- Control|Participants will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for 6 weeks. Alongside supplementation, participants will be instructed to maintain their normal level of physical activity but will participate in a time-matched control consisting of flexibility training (low-intensity exercise) for 6 weeks.
89103399|NCT05297383|Placebo Comparator|Placebo and flexibility- Control|Participants will take Placebo (safflower oil, AlaskOmega®, from Organic Technologies Inc.) will be taken by participants in placebo groups for 6 weeks. Alongside supplementation, participants will be instructed to maintain their normal level of physical activity but will participate in a time-matched control consisting of flexibility training (low-intensity exercise) for 6 weeks.
89103400|NCT05297383|Active Comparator|n-3 PUFA and HIIT- Test|Participants will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for 6 weeks. Alongside supplementation, participants will engage in a 4 x 4 HIIT exercise (4 intervals for 4 min at 85-95% HRmax with 3min active recovery at 50-70% HRmax) program, 3 days/week, for 6 weeks.
89103401|NCT05297383|Placebo Comparator|Placebo and HIIT- Test|Participants will take Placebo (safflower oil, AlaskOmega®, from Organic Technologies Inc.) will be taken by participants in placebo groups for 6 weeks. Alongside supplementation, participants will engage in a 4 x 4 HIIT exercise (4 intervals for 4 min at 85-95% HRmax with 3min active recovery at 50-70% HRmax) program, 3 days/week, for 6 weeks.
89103402|NCT00665158|Active Comparator|UC|Usual Care Group
89103403|NCT00665158|Active Comparator|BI|Behavioural Intervention Group
89103404|NCT02609347|Experimental|Manual Therapy Group|Participants in the manual therapy group will receive 3 treatment sessions of joint mobilization based on the physical therapist's clinical decision making.
89103405|NCT02609347|Sham Comparator|Control Group|Participants in the control group will receive a sham manual therapy treatment consisting of soft tissue mobilization and Grade I mobilizations at the proximal tib/fib joint.
89103406|NCT00911638|Experimental|1: Patient decision aid|Patient decision aid focused on treatment options for osteoarthritis of the hip or knee and preference report for surgeons. The patient decision aid used is from the Informed Medical Decisions Foundation
89103407|NCT00911638|Active Comparator|2: Usual care|Usual patient educational resources for patients undergoing hip or knee replacement surgery.
89103408|NCT02609191|Experimental|The study population: first 30 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Discovery A~Intervention: First whole body exam using the Stratos DR~Intervention: Second whole body exam using the Stratos DR"
89103409|NCT02609191|Experimental|The study population: last 20 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Discovery A~Intervention: First whole body exam using the Stratos DR"
89103410|NCT04157218|Active Comparator|Treatment with HIFU and immediately after insertion of threads|
89103411|NCT04157218|Active Comparator|Treatment with HIFU and 6 months later insertion of theads|
89103412|NCT04157218|Active Comparator|Treatment with lifting threads alone|
89103413|NCT02609893|Active Comparator|Modified Directly Observed Therapy|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) observed daily dosing (modified for non-observed Saturday and Sunday dosing) for 8 weeks
89103414|NCT02609893|Active Comparator|Unobserved Dosing|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) provided weekly (7 tablets) for unobserved daily dosing for 8 weeks
89103415|NCT04797871|Experimental|Exercise|Resistance training
89103416|NCT04797871|Active Comparator|Standard care|Non-supervised ACSM exercise guidelines
89103417|NCT02632006|Experimental|PIK-PD-1 cells|PIK-PD-1 cells treatment will be performed every 3 weeks with a total of three periods.
89103418|NCT02632006|Active Comparator|DC-PMAT|DC-PMAT cells treatment will be performed every 3 weeks with a total of three periods.
89103419|NCT00665236|Experimental|1|Craniosacral therapy administered once a week for an hour by a trained craniosacral therapist.
89103420|NCT00665236|Active Comparator|2|Low-strength static magnets placed around the body for periods of up to an hour once a week.
89103421|NCT00911482||Diabetes/weight loss|12 individuals with type 2 diabetes and hypertriglyceridemia
89103422|NCT00911482||Nondiabetic/hypertriglyceridemic|10 insulin resistant nondiabetic individuals with dyslipidemia
89103423|NCT00911482||Normotensive/nondiabetic|10 insulin resistant, normotensive, nondiabetic individuals
89103424|NCT00911482||Insulin resistant/dyslipidemic|14 insulin resistant nondiabetic individuals with dyslipidemia
89103425|NCT04790617|Experimental|Intervention|Community health navigator program for six months.
89103426|NCT04790617|No Intervention|Control|Usual health care.
89103427|NCT00669526|Active Comparator|SMHC referral|Referral to local Specialty Mental Health Care Services
89103428|NCT00669526|Experimental|BCBT|Brief Cognitive Behavioral Therapy
89103429|NCT02416011|No Intervention|Assessment Only (ASSESS)|Participants in this condition will not receive any intervention materials. They will participate solely in the repeated assessments. Including this comparison condition controls for the effect of repeated assessments and allows for the most meaningful evaluation of the efficacy effect size as well as the cost-effectiveness of the eTARGET intervention. This condition will also be the primary source of data for the secondary surveillance aim regarding naturalistic changes in smoking and e-cigarette use over time.
89103430|NCT02416011|Active Comparator|Generic Self-Help (GENERIC)|This will allow us to evaluate our novel self-help intervention for e-cigarette users (our If you Vape booklets) against a matched non-targeted intervention that has demonstrated efficacy for cigarette smokers in general. Such a comparison controls for the possibility that e-cigarette users are sufficiently primed to quit smoking and that even a generic, non-targeted intervention would be effective. This possibility will be directly tested by comparing this condition against both the ASSESS and eTARGET conditions in terms of clinical outcomes and cost-effectiveness.
89103431|NCT02416011|Experimental|Targeted Self-Help (eTARGET)|Participants in this condition will receive the intervention created as the product of Study I.
89103432|NCT05075395|Experimental|Intervention|The PT/OT provider will assess whether the patient meets eligibility criteria. If the patient is eligible to participate, they will then introduce the study to the patient and their parent or guardian. If the patient is interested in participating, the PI or PIs research assistant (RA) will seek written informed consent. After informed consent is obtained, the PI or RA will begin pretest data collection. Then, the PT/OT provider will begin the therapy session with Paro. The PI or RA will remain in the room during therapy session to record field notes. When the therapy session is complete, the PI or RA will begin posttest data collection. The patient will remain in the study for up to 7 PT/OT sessions or until they are discharged from the PICU. The PT/OT providers will coordinate all subsequent therapy sessions with the PI/RA while the patient remains on the study protocol.
89103433|NCT00665314|Experimental|AMD3100 added to a G-CSF Mobilisation regimen|AMD3100 added to a G-CSF Mobilisation regimen
89103434|NCT00665314|Active Comparator|G-CSF plus placebo|G-CSF plus placebo
89103435|NCT04154722|Experimental|meropenum and azithromycin group|inj meropenum 20mg/kg/dose I/v in 3 divided doses and syp azithromycin 20mg/kg/day in 2 divided doses.
89103436|NCT04154722|Active Comparator|meropenum group|inj meropenum 20mg/kg/dose I/v in 3 divided doses
89103437|NCT02631928|Experimental|Julphar Insulin 30/70|human biphasic insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
89103438|NCT02631928|Active Comparator|Huminsulin® Profil III|human biphasic insulin, reference, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
89103439|NCT02609035|Experimental|Intervention|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive a telephonic prompt to get a vaccination.
89103440|NCT02609035|No Intervention|Control|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive usual pharmacy care.
89103441|NCT00632385|Experimental|A|
89103442|NCT05579613|Experimental|Interactive virtual reality device group|"Group A will receive the same as group B and will receiveVR training by Xbox Kinect 360 (15 min per session 3 times per week) for 4 weeks. C"
89103443|NCT05579613|Experimental|chin tuck exercise for posture correction (traditional treatment ) group|Group B will receive traditional treatment (chin tuck exercise for posture correction); 3 min each day for 4 weeks, three sets of 10 repetitions (each repetition was held for 5 sec) will be performed.
89103444|NCT00910689|Placebo Comparator|1|Optimal Acute Therapy plus Beta Blocker Placebo
89103445|NCT00910689|Active Comparator|2|Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)
89103446|NCT00910689|Active Comparator|3|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo
89103447|NCT00910689|Active Comparator|4|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)
89103448|NCT00807001|Experimental|Cohort A|Subjects randomized 8:2 (active:placebo) to receive one 25 milligrams (mg) capsule of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
89103449|NCT00807001|Experimental|Cohort B|Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
89103450|NCT00807001|Experimental|Cohort C|Subjects randomized 8:2 (active:placebo) to receive three 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
89103451|NCT00807001|Experimental|Cohort D|Subjects randomized 8:2 (active:placebo) to receive four 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
89103452|NCT04222335|Other|Blood sampling|Blood sampling
89103453|NCT02608801||Patients from NoFRACT|Patients from NoFRACT who consent to participate in this sub-study, will be offered examination and treatment with anti-osteoporotic drugs cf. treatment algorithm in the main-study. I.e. if osteoporosis is present clinically or at DXA scan, treatment is started.
89103454|NCT02608957|Experimental|Latella Knee Implant System|
89103455|NCT04669717|Active Comparator|Amoxicilline and Metronidazole for 7 days|"Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 7 days~Systemic antibiotics after sub gingival mechanical debridement"
89103456|NCT04669717|Active Comparator|Amoxicilline and Metronidazole for 3 days|"Drug: AMOXICILLINE Sandoz cpr pell 500mg, Sandoz Pharmaceuticals AG + FLAGYL cpr pell 500mg, Sanofi-Aventis ( Suisse) SA, 3/d for 3 days~Systemic antibiotics after sub gingival mechanical debridement"
89103457|NCT04669717|Active Comparator|Azithromycine for 3 days|"Drug: AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH~1/d 500mg for 3 days~Systemic antibiotics after sub gingival mechanical debridement"
89103458|NCT05755009|Experimental|High- and Low-dose radiotherapy combined with immunotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain total two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
89103459|NCT00809341|Active Comparator|PET Negative|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a negative PET scan will complete their chemotherapy regimen as prescribed by their oncologist.
89103460|NCT00809341|Active Comparator|PET Positive|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a positive PET scan will receive two cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide) followed by HiCy (high-dose cyclophosphamide).
89103461|NCT01125800|Experimental|LDE225 233mg/m2 daily dose|Pediatric dose.
89103462|NCT01125800|Experimental|LDE225 372mg/m2 daily dose|Pediatric dose.
89103463|NCT01125800|Experimental|LDE225 425 mg/m2 daily dose|Pediatric dose.
89103464|NCT01125800|Experimental|LDE225 680 mg/m2 daily dose|Pediatric dose.
89103465|NCT01125800|Experimental|LDE225 800 mg/m2 daily dose|Adult dose
89103466|NCT04645381||Participants with RA|
89103467|NCT05046145|Experimental|tDCS + speech therapy+ sham|Participants will receive real tDCS and tDCS sham for 5 sessions during each treatment period. The interstice period of the total intervention will be 25 days, with 15 days of wash out between the two interventions. The probabilistic, simple randomized sample will consist of participants with food cravings randomized into two groups, according to the presence or absence of changes in eating behavior and within each group there will be subdivision to receive or not neuromodulation, according to the flowchart
89103468|NCT05046145|Experimental|sham + tDCS + speech therapy|Participants will receive real tDCS and tDCS sham for 5 sessions during each treatment period. The interstice period of the total intervention will be 25 days, with 15 days of wash out between the two interventions. The probabilistic, simple randomized sample will consist of participants with food cravings randomized into two groups, according to the presence or absence of changes in eating behavior and within each group there will be subdivision to receive or not neuromodulation, according to the flowchart
89103469|NCT01125722|Active Comparator|Investigator Placement Group|
89103470|NCT01125722|Active Comparator|Subject Placement Group|
89103471|NCT04030351|Experimental|dried fruit|100 g per day of dried fruit
89103472|NCT04030351|No Intervention|no dried fruit|no intervention to be given
89103473|NCT00811135|Experimental|1|
89103474|NCT00811057|Active Comparator|1 Magnesium Sulfate|
89103475|NCT00811057|Active Comparator|2 Nifedipine|Participants randomized to this group will receive the medication nifedipine orally.
89103476|NCT00811057|Active Comparator|3 Indomethacin|Participants randomized to this arm will receive the medication indomethacin per rectum and orally.
89103477|NCT00879970|Active Comparator|pioglitazone|PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
89103478|NCT00879970|Active Comparator|rosiglitazone|RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.
89103479|NCT00879970|Placebo Comparator|TZD placebo|Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years
89103480|NCT00879970|Active Comparator|Vitamin D|Active comparator
89103481|NCT00879970|Placebo Comparator|Vitamin D placebo|Placebo Comparator
89103482|NCT00808639|Experimental|Dose Dense MVAC|Chemo therapy with methotrexate, vinblastine, Adriamycin, Cisplatin
89103483|NCT05005195|Other|Abdominal CT Scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer.
89103484|NCT00810901|Experimental|Organ Donor|Intervention used a DVD, text messaging, emails, a website, US Mail, and telephone calls to educate teens about their choice to become a designated organ donor on their first driver's license application.
89103485|NCT00810901|Active Comparator|Alcohol Prevention|Intervention used a DVD and text messages, to educate teens about the laws that prohibit underage minors purchasing and consuming alcohol
89103486|NCT00910299|Experimental|Prasugrel|
89103487|NCT00910299|Active Comparator|Clopidogrel|
89103488|NCT00669760||Observation|CF-patients with persistent culture of Staphylococcus aureus in their respiratory specimens
89103489|NCT00671086|Experimental|Ramelteon 8 mg QD|
89103490|NCT00671086|Experimental|Ramelteon 16 mg QD|
89103491|NCT02608723|Active Comparator|Standard shock waves device|3 sessions were applied: one per week.
89103492|NCT02608723|Active Comparator|Austere shock waves device|3 sessions were applied: one per week.
89103493|NCT02608723|Active Comparator|Sophisticated shock waves device|3 sessions were applied: one per week.
89103494|NCT04094181||VPRIV Participants|Participants who has been transitioned from ERTs/SRTs to VPRIV, the data will be collected retrospectively from time of transition until the point at which participant begins in this study and then will be followed up prospectively for 12 months.
89103495|NCT04154566|Experimental|the study group|Group (A) the study group received aerobic exercise in addition to selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment.
89103496|NCT04154566|No Intervention|the control group|group (B) the control group received the same selected physical therapy program which contain strengthening exercises for upper limb and lower limb muscles, stretching exercises for elbow extensors, hand supinator, wrist extensors, knee extensors and ankle dorsiflexors, balancing exercises, coordination exercises and gait training exercises in open environment only.
89103497|NCT00665548||Normal Subjects|Female subjects scoring Kellgren & Lawrence grade 0.
89103498|NCT00665548||OA Subjects|Female subjects with Kellgren & Lawrence score of 2 or 3.
89103499|NCT03007329|Active Comparator|Dapagliflozin & Exenatide|Dapagliflozin 10mg orally once daily & Exenatide 2mg subcutaneous once weekly
89103500|NCT03007329|Placebo Comparator|Dapagliflozin & Placebo|Dapagliflozin 10mg orally once daily & Exenatide matching Placebo 2mg subcutaneous once weekly
89103501|NCT00669838||PL|Patients who receive local anesthesia with 2% lidocaine without epinephrine
89103502|NCT00669838||LE|Patients who receive local anesthesia with 2% lidocaine with 1:100.000 epinephrine
89103503|NCT04072341|Experimental|Propolis Period|Hemodialysis patients will be under regular treatment of their comorbidities and using Propolis.
89103504|NCT04072341|Experimental|Control Period|Hemodialysis patients will be under regular treatment of their comorbidities, but without using Propolis.
89103505|NCT00595504|Experimental|1|Ramelteon 8mg/day
89103506|NCT00595504|Placebo Comparator|2|sugar pill
89103507|NCT00808483|Experimental|Walking skill training group|Participation in the supervised walking skill training program.
89103508|NCT00808483|No Intervention|Control group|No participation in the supervised walking skill training program
89103509|NCT03952533|Experimental|ALA|"ALA Group will be composed of women allocated to the Treatment Group. These women will receive 2 tablets of Alpha lipoic Acid (ALA) as Dav® food supplement 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy) daily until delivery."
89103510|NCT03952533|No Intervention|Control|"Control Group will be composed by women allocated in the Control Group and will not receive any supplementation but the standard care."
89103511|NCT02629978|Experimental|radiofrequency ablation|In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation，the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
89103514|NCT00671242||I|L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer
89103515|NCT00671242||Nuclear|
89103516|NCT03753711|Experimental|LDH (lumbar disc hernia)|
89103517|NCT00676000|Active Comparator|1|Interrupted vaginal closure
89103518|NCT00676000|Active Comparator|2|Continuous vaginal closure
89103519|NCT04030039||chronic hepatitis B patients during the immune control period|Patients with chronic HBV infection during the immune control period do not have any clinical treatment intervention cohort
89103520|NCT04030039||Therapy group A|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with interferon
89103521|NCT04030039||Therapy group B|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they stopped to be treated with interferon
89103522|NCT04030039||Therapy group C|After chronic hepatitis B patients were treated with interferon, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with sequential nucleoside analogues
89103523|NCT04030039||Therapy group D|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with sequential interferon
89103524|NCT04030039||Therapy group E|After chronic hepatitis B patients were treated with nucleoside analogues, HBsAg level of these patients < 100 IU / ml, and they continued to be treated with the nucleoside analogues
89103525|NCT04154098|Experimental|NO-OA-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
89103526|NCT04154098|Experimental|NO-MA-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
89103527|NCT04154098|Experimental|OA-NO-MA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
89103528|NCT04154098|Experimental|OA-MA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
89103529|NCT04154098|Experimental|MA-NO-OA-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
89103530|NCT04154098|Experimental|MA-OA-NO-FT|Participants elevate their arm without assistance (NO) - with orthosis assistance (OA) - with manual assistance (MA) in the given order, followed by the functional task (FT)
89103531|NCT00810511|Experimental|Lotrafilcon A|Investigational, spherical, silicone hydrogel contact lenses
89103532|NCT00810511|Active Comparator|Comfilcon A|Commercially marketed, spherical, silicone hydrogel contact lenses
89103533|NCT02628574|Experimental|TRX518 monotherapy (Parts A and B)|Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
89103534|NCT02628574|Experimental|TRX518 with gemcitabine (Part C)|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
89103535|NCT02628574|Experimental|TRX518 with pembrolizumab (Part D|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
89103536|NCT02628574|Experimental|TRX518 with nivolumab (Part E)|Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
89103537|NCT00596362|Experimental|1|AVASTIN
89103538|NCT00907803|Experimental|ST-246 400 mg|ST-246 400mg (2 x 200 mg Capsules) Orally Once Daily for 14 days
89103539|NCT00907803|Experimental|ST-246 600 mg|ST-246 600 mg (3 x 200 mg Capsules) Orally Once Daily for 14 days
89103540|NCT00907803|Placebo Comparator|Placebo|Matching Placebo capsules, Orally Once Daily for 14 days
89103541|NCT00669994|Experimental|Arm 1|
89103542|NCT00808249|Experimental|A-AZD7325 2mg|AZD7325 2mg BID
89103543|NCT00808249|Experimental|B-AZD7325 5mg|AZD7325 5mg BID
89103544|NCT00808249|Experimental|C-AZD7325 10mg|AZD7325 10mg QD
89103545|NCT00808249|Experimental|D-Placebo|Placebo
89103546|NCT02790723|Experimental|Low Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{11} viral genomes.
89103547|NCT02790723|Experimental|Medium Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{12} viral genomes.
89103548|NCT02790723|Experimental|High Dose Group|Subjects will receive a single intra-articular 2mL injection consisting of 10{13} viral genomes.
89103549|NCT00676156|Active Comparator|A|This arm involves a 1-day pharmacokinetics study of three different formulations of oral lipoic acid.
89103550|NCT00676156|Active Comparator|B|This arm will examine the pharmacokinetics of LA with and without fish oil supplement in a cross over design.
89103551|NCT00676156|Active Comparator|C|This arm will include the study of a single dose of R enantiomer lipoic acid.
89103552|NCT05753527|Experimental|Progressive relaxation exercise group|The students in the intervention group will be given progressive relaxation exercises before the simulation application. Before and after the simulation, vital signs will be taken and scales will be applied.
89103553|NCT05753527|No Intervention|The group not applied progressive relaxation exercise|The students in the control group will be taken into the simulation application without applying relaxation exercises. Before and after the simulation application, vital signs will be taken and scales will be applied.
89103554|NCT03970629|Active Comparator|Robotic Assisted TKA|Robotic Assisted TKA via ROSA Robot
89103555|NCT03970629|Active Comparator|Conventional TKA|Conventional TKA
89103556|NCT00914017|Experimental|Atorvastatin|40 mg of Lipitor (atorvastatin) daily for 1 year
89103557|NCT00914017|Placebo Comparator|Sugar Pill|Sugar pill daily for 1 year
89103558|NCT00676234|No Intervention|1|
89103559|NCT00676234|Experimental|2|Administration of intravenous rhu Epo on Day 0
89103560|NCT04036851|No Intervention|Local standard of care|Women receive integrated antenatal and HIV services during pregnancy and are referred to general adult HIV services after delivery; no standardized peer support groups exist for this patient population.
89103561|NCT04036851|Experimental|Peer support intervention|Women will be invited to attend monthly peer support groups during pregnancy and postpartum, separate from any routine health services.
89103562|NCT00671320|Active Comparator|Arm 1|
89103563|NCT00671320|Active Comparator|Arm 2|
89103564|NCT05753449|Active Comparator|Standard of care programming|Standard of care DBS electrical stimulation
89103565|NCT05753449|Experimental|Experimental/Burst-type programming|Burst-type DBS electrical stimulation
89103566|NCT00670384|Active Comparator|Dose Group A|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
89103567|NCT00670384|Active Comparator|Dose Group B|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
89103568|NCT00670384|Placebo Comparator|Placebo|
89103569|NCT00671398|Experimental|Ramelteon 8 mg QD|
89103570|NCT00671398|Experimental|Ramelteon 16 mg QD|
89103571|NCT00671398|Placebo Comparator|Placebo|
89103572|NCT03926247|Other|Immigrant Well-being Project Intervention|Intervention
89103573|NCT00676312|Experimental|1|Cross-over treatment with increasing doses of PTH134, placebo and active comparator.
89103574|NCT00908895|Experimental|Radio-radial fixator|Patients are operated on using a radio-radial fixator (Distal radius fixator, Synthes)
89103575|NCT00908895|Active Comparator|Percutaneous pinning|Two K-wires inserted on a percutaneous way (dorsally and from the styloid), with a cast for 6 weeks
89103576|NCT00676390|Other|1|Congestive Heart failure patients
89103577|NCT00676468|Other|1|Active Montelukast + Fish Oil Placebo
89103578|NCT00676468|Other|2|Active Fish Oil + Montelukast Placebo
89103579|NCT00676468|Other|3|Active Montelukast + Active Fish Oil
89103580|NCT00591253|Experimental|Azilsartan Medoxomil 40 mg QD|
89103581|NCT00591253|Experimental|Azilsartan Medoxomil 80 mg QD|
89103582|NCT00591253|Placebo Comparator|Placebo QD|
89103583|NCT02629900|Experimental|Intermittent fasting group|Participants will restrict their daily food intake (time restricted feeding) to an 8-hour time period between 1200 to 2000 hours. During the remaining 16-hour intermittent fasting period (2000 to 1200 hours) participants will be allowed to drink zero calorie beverages (diet soda pop, black coffee, tea, water, etc) in order to maintain normal hydration. There will be no attempt to restrict food intake. Rather simply to restrict the time period each day when food is consumed.
89103584|NCT00676624||Uveitis|Patients suffering from uveitis, who have vitrectomy performed for diagnostic purpose
89103585|NCT00676624||Control group|"Patients suffering from either Epiretinal fibrosis og Macula hole who have vitrectomy performed for curative reasons"
89103586|NCT00676702|Experimental|001|Pancrelipase in combination with Ensure Plus 3 pancrelipase MT 21 capsules containing a total of 63 000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
89103587|NCT00676702|Active Comparator|002|Ensure Plus A high-fat liquid meal of 500 ml of Ensure Plus
89103588|NCT04152070||Community-dwelling older adults|Community-dwelling older adults living in the Valencia region (Spain).
89103589|NCT05754619||patients with HA|20 parents with hemophilic children. The sample will consist of 10 mothers and 10 fathers.
89103590|NCT05753371|Experimental|Glufor® 500 mg film-coated tablet|
89103591|NCT05753371|Active Comparator|Glucophage® 500 mg film-coated tablet|
89103592|NCT04151836|Experimental|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity 30 minutes of exercise in week 1-4,40 minutes of exercise in 5-8 weeks,50 minutes in the 9-12 week,three times weekly in three month.We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 65%-70% of the target Maximal heart rate(HRmax).
89103593|NCT04151836|No Intervention|control group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
89103594|NCT00908583|Experimental|Phase 1, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day 32. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
89103595|NCT00908583|Experimental|Phase 2, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
89103596|NCT00908583|Experimental|Phase 3, two stages|Patients will receive 1 dose of rituximab and 4 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 23, 26, 30 and 33. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
89103597|NCT00908583|Experimental|Phase 4, single stage|Patients will receive 1 dose of rituximab and 6 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered during the pre-transplant period on days 1, 4, 8, and 11, 14, and 17. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
89103598|NCT00908583|Experimental|Phase 5, single stage|Phase 5 evaluated even greater bortezomib dosing density by eliminating the inter-cycle dosing interval. Phase 5 evaluated eight consecutive doses of bortezomib with one dose of rituximab. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patient will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, 11, 14, 17, 20, and 23. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
89103599|NCT04030117|Experimental|ACTIVA Test arm|Treatment of decay in Class II second primary molars using ACTIVA restorative material.
89103600|NCT04030117|Active Comparator|Compomer Comparator arm|Treatment of decay in Class II second primary molars using compomer restorative material.
89103601|NCT04153162|Experimental|Stereotactic body radiation therapy|In patients with HCM and refractory symptoms from LVOTO, stereotactic body radiation therapy will be delivered locally to relieve symptoms
89103602|NCT05753293|Experimental|Bhastrika pranayama|"done in sitting posture and the following instructions: The back must be kept straight and shoulder muscles should be kept relaxed, patient was asked to close the right nostril with right thumb and to bring right elbow to the level of right shoulder.~To close the eyes, inhale and exhale through left nostril-first slowly, then a little faster, The subject was asked to do the above steps about 20-25 times, (Then the subject was asked to take a long breath in and retain it for as long as possible, This is one cycle of Bhastrika pranayama. The subject has to repeat this cycle by closing left nostril and breathing through right nostril."
89103603|NCT05753293|Experimental|Buteyko breathing exercise|"Step 1 beginning control pause (CP) the patient inhales and then exhales through the nose and then holds their breath until the point they feel either the first clear and distinct desire to breath or involuntary movement or jerk coming from diaphragm.Step 2 three to five minutes of relaxed reduced-volume breathing or slow breathing the patient gradually reduced their breathing until they feel a light lack of air. they sustain these while staying relaxed.~Step 3 maximum pause (MP) the maximum pause begins with gentel inhalation and exhalation. Then the breath is held as long as possible but not to the point of severe discomfort.~Step 2 and step 3 are then repeated up to 5 times. Final control pause: same as step 1."
89103604|NCT00671632|Experimental|Ramelteon, triazolam, and placebo (56 poss. combinations)|Ramelteon, triazolam, and placebo (56 possible combinations total)
89103605|NCT05754463|Experimental|athletes|Plyometric training was applied to the athletes (Group 1) (n=27) participating in our study, 2 days a week for 6 weeks, after 20 minutes of warming up and stretching movements before each training. Sociodemographic characteristics of the athletes were recorded. Dynamic balance test was applied with Y balance test and static balance was applied with strok balance test before and after plyometric training. Proprioception assessment was applied with kinematic angle reproduction test before and after plyometric training.
89103606|NCT05754463|Active Comparator|karate|Plyometric training was applied to the karate practitioners (Group 2) (n=27) participating in our study, 2 days a week for 6 weeks, after 20 minutes of warming up and stretching movements before each training. Sociodemographic characteristics of the athletes were recorded. Dynamic balance test was applied with Y balance test and static balance was applied with strok balance test before and after plyometric training. Proprioception assessment was applied with kinematic angle reproduction test before and after plyometric training.
89103607|NCT03989505||Cohort|214 consecutive patients undergoing contrast-enhanced diagnostic and/ or therapeutical intervention in the cath lab of the University Heart Center Hamburg
89103608|NCT04153708|Experimental|Retrieval by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
89103609|NCT04153708|Active Comparator|Retrieval by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
89103610|NCT00909363|Experimental|WAS patients receiving Promacta|Promacta® is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets. For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used. PfOS is only available for investigational use at 20mg. Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
89103611|NCT00909363|Experimental|WAS patients for blood drawing only|WAS patients not receiving treatment to serve as subjects for platelet parameter studies blood drawing once only
89103612|NCT00909363|Placebo Comparator|healthy children for blood drawing only|healthy children having blood obtained once as controls for platelet parameters study
89103613|NCT00676936|Experimental|Methylprednisolone|Methylprednisolone 16 mg twice daily
89103614|NCT00676936|Placebo Comparator|Placebo|Placebo capsules twice daily
89103615|NCT00810355|Active Comparator|Arm 1|Support group
89103616|NCT00810355|Experimental|Arm 2|Cognitive Behavior Therapy
89103617|NCT00810355|Experimental|Arm 3|Cognitive Behavior Therapy and Cognitive Remediation
89103618|NCT02629744|Experimental|Etrolizumab|Participants will self-administer single SC dose of etrolizumab using prefilled auto-injector, into the abdomen or the anterior thigh.
89523163|NCT04446065|Experimental|Previfenon®|Participants will receive coded non-transparent bottles of Previfenon®, each containing 90 EGCG capsules (250 mg per capsule plus excipients) The total EGCG dose per patient will be 750 mg/day (3 capsules) for 40 consecutive days as minimum or a maximum variable time between 60 to 70 days. It will be divided into three daily intakes of one capsule of Previfenon® every 8 hours.
89103619|NCT05326321|Experimental|Virtual Reality Glasses Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure. After the AVF cannulation procedure was completed and 10 minutes later, the VAS and Hemodynamic Variables Follow-up Form were reapplied, and the 2nd and 3rd measurements were obtained. Patients' satisfaction was measured with VAS 10 minutes after the procedure. During the application of virtual reality glasses, a screen was pulled between the patients in the intervention and control groups so that there would be no interaction.
89103620|NCT05326321|No Intervention|Control group|Without any application to the patients in the control group, the AVF cannulation procedure before HD was performed with the constant site-area puncture technique used by the clinic (after the patient was placed in the fowler position, the arterial needle was 3 cm away from the anastomosis at an angle of 20°-45° towards the distal, and the venous needle was from the arterial needle. 3-5 cm more proximal, again at an angle of 20°-45°) was performed by the HD nurse. The 1st, 2nd and 3rd measurements were obtained as in the intervention group.
89103621|NCT00677170|Experimental|1|MLN4924
89103622|NCT03917433|Experimental|Exposure with Tactile Feedback|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
89103623|NCT03917433|Experimental|Exposure with Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. The participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
89523164|NCT04446065|Placebo Comparator|Placebo|Participants will receive coded non-transparent bottles of placebo, each containing 90 starch capsules (250 mg plus excipients) under the same dosage, frequency and duration that Previfenon@ arm.
89523165|NCT03385031||group 1|whole breast irradiation, CBCT imaging at first and last fraction of radiotherapy treatment
89523166|NCT03385031||group 2|simultaneous integrated boost, CBCT imaging at first and last fraction of radiotherapy treatment
89103624|NCT03917433|Experimental|Exposure with Tactile Feedback and Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world. Also, the participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
89523167|NCT03385031||group 3|patients with seroma at start radiation treatment (whole breast irradiation or simultaneous integrated boost), CBCT imaging at first and last fraction of radiotherapy treatment
89523168|NCT00225095|Active Comparator|Chondrogen - dose 1|Chondrogen - 50 million cells
89523169|NCT00225095|Active Comparator|Chondrogen - dose 2|Chondrogen - 150 million cells
89523170|NCT00225095|Other|Vehicle Control|Vehicle Control
89103625|NCT03917433|Other|Virtual Reality Exposure Therapy Alone|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
89103626|NCT02629510|Experimental|Tachosil|The group composed of patients whose surgical margin of cervix will be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
89103627|NCT02629510|No Intervention|No Tachosil|The group composed of patients whose surgical margin of cervix will NOT be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
89523171|NCT05174429|Experimental|Risk-Targeted Behavioral Activation|The treatment program consisted of a 10-week standardized behavioral activation intervention supplemented by techniques to target two psychosocial risk-factors for delayed recovery, namely, catastrophic thinking and perceptions of injustice.
89103628|NCT02629588||Persons in coma or vegetative state|People who survived TBI have a period of complete unconsciousness or coma with no awareness of themselves or their surroundings received multimodal or unimodal sensory stimulation.People in a coma are unaware and unresponsive, but not asleep as there is no sleep-wake cycle. While in a coma, people are unable to speak, follow commands or open their eyes. The person in coma may have a simple reflex in response to touch or pain, but essentially there is no meaningful response to external stimuli. There is an absence of awareness of self and the environment, even under conditions of vigorous external stimulation. Coma can last from hours to days, depending on the severity of the brain damage, and sometimes a person can remain in a comatose state for months and even years.
89103629|NCT00908349|Other|Oxcarbazepine XR|Open Label Study
89103630|NCT01125566|Active Comparator|Arm B: trastuzumab with vinorelbine|patients receive weekly intravenous infusion of trastuzumab and vinorelbine
89103631|NCT01125566|Experimental|Arm A: BIBW 2992 with vinorelbine|patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine
89103632|NCT04031872|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer with LY3200882 and capecitabine
89103633|NCT03414255|Experimental|Micronized DHACM|1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)
89103634|NCT03414255|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
89103635|NCT00810277|Experimental|1|
89103636|NCT04151758|Experimental|Docosahexaenoic Acid Supplementation, lifestyle intervention|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day. Physical activity and healthy eating habits will be encouraged.
89103637|NCT00670696|Experimental|A|Rapydan medicated plaster administered 30 minutes prior to cannulation on Visit 1 and tetracaine gel administered 45 minutes prior to cannulation on Visit 2.
89103638|NCT00670696|Active Comparator|B|Tetracaine gel administered 45 prior to cannulation on Visit 1 and then Rapydan administered 30 minutes prior to cannulation on Visit 1
89103639|NCT04153630|Experimental|Haploidentical MSCs derived from bone marrow|Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
89103640|NCT00677248|Placebo Comparator|1|Ezetimibe and placebo
89103641|NCT00677248|Experimental|2|Eprotirome dose 1 and ezetimibe
89103642|NCT00677248|Experimental|3|Eprotirome dose 2 and ezetimibe
89103643|NCT00677248|Experimental|4|Eprotirome dose 3 and ezetimibe
89103644|NCT05754307|Other|Group A|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
89103645|NCT05754307|Experimental|Group B|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentional excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
89103646|NCT00637598|Experimental|Tomosynthesis scans|This is a case-only study with only one group/cohort. All women receive both mammography and tomosynthesis imaging.
89103647|NCT04311476|Placebo Comparator|Placebo|0.9% sodium chloride infusion within 24 hours after birth
89103648|NCT04311476|Experimental|ACBMNC|Autologous Umbilical Cord Blood Mononuclear Cells intravenously within 24 hours after birth,dose is 5×107cells/kg ,
89103649|NCT00911716|Experimental|cyclophosphamide, Docetaxel, bevacizumab|
89103650|NCT00912184|Experimental|1|CVVH with high cut-off polyamide membrane (P2SH) using standard continuous veno-venous hemofiltration (CVVH) settings
89103651|NCT00912184|Active Comparator|2|CVVH using standard high flux membrane with standard CVVH settings
89103652|NCT00677326|Experimental|A|Peptide administered
89103653|NCT00595582|Other|single arm|Curcumin + Bioperine
89523172|NCT04682873|Experimental|Enisamium iodide|Hospitalized patients who were randomized in to this treatment group will receive enisamium iodide containing capsules (Amizon® Max).
89523173|NCT04682873|Placebo Comparator|Placebo|Hospitalized patients who were randomized in to this treatment group will receive placebo containing capsules.
89523174|NCT02732119|Experimental|Cohort A|Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
89103654|NCT00677404|Experimental|stem cell recipient|the patients with peripheral vascular disease who receive bone marrow derived mono nuclear cells
89103655|NCT04031482||Ongoing or incipient targeted therapies|Ongoing or incipient targeted therapies with biologics and/or other targeted therapies (e.g. Janus kinase inhibitors)
89103656|NCT04153474|Active Comparator|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
89103657|NCT04153474|Active Comparator|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
89103658|NCT00671866||1|Agricultural Workers
89103659|NCT00671866||2|Non - Agricultural Workers
89103660|NCT00671866||3|Kibbitz Residents working else where
89103661|NCT00671944|Experimental|1|Low protein diet
89103662|NCT00680446|Experimental|1|
89103663|NCT04150666|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 2.0 to 2.5 L of water per day (depending on sex), in addition to usual consumed beverages, for 3 months
89103664|NCT04150666|No Intervention|Control|
89103665|NCT00677638|Experimental|1|Embracer implantation
89103666|NCT00680602|Experimental|1|Group Cognitive Behavior Therapy
89103667|NCT00680602|Active Comparator|2|Selective Serotonin Reuptake Inhibitor
89103668|NCT00677716|Experimental|131I-chTNT-1/B MAb (Cotara)|
89103669|NCT00677794|Active Comparator|1|Clear fluids only after lunch.
89103670|NCT00677794|Active Comparator|2|Two sachets of picosalax the evening prior to Video Capsule Endoscopy (VCE).
89103671|NCT00677794|Active Comparator|3|Polyethylene glycol, 2 liters the evening prior to Video Capsule Endoscopy (VCE).
89103672|NCT02628496|Experimental|Arm 1: CLM|"On the day of surgery, participants will have placement of laser-safe endotracheal tube and a rigid laryngoscope will be introduced into the oral cavity to gain access to the laryngeal introitus and then placed into suspension (standard of care)~Fluorescein dye will be administered intravenously~Confocal laser probe will be introduced through the rigid laryngoscope and touched first on the lesion of concern and put into scanning mode in order to obtain photos and video footage of the lesions. The probe will then be placed on normal appearing vocal fold tissue to obtain a control sample.~The remainder of the procedure is standard excisional biopsy and KTP laser photoablation"
89103673|NCT04150588||Good reaction to Efrin test|
89103674|NCT04150588||Unsatisfied reaction to Efrin test|
89103675|NCT04150744|Experimental|RFA plus carrizumab|
89103676|NCT04150744|Placebo Comparator|carrizumab|
89103677|NCT04150432|Experimental|propofol|propofol general anesthesia, exhaled measurement of propofol
89103678|NCT00808015||Patients in routine practice|Patients prescribed Champix by treating physician and then entered into trial
89103679|NCT00680758|Experimental|Therapeutic Intervention|
89103680|NCT04150198|Experimental|Patients with Alzheimer (<65 years) (AD-Y)|15 patients with a diagnostic of MA-J
89103681|NCT04150198|Experimental|Patients with posterior Cortical Atrophy (PCA)|15 patients with a diagnostic of PCA
89103682|NCT04150198|Active Comparator|Control|15 controls
89103683|NCT00677872|Experimental|1|
89103684|NCT00677950|Experimental|1|OP-1 Putty
89103685|NCT00677950|Active Comparator|2|Autograft
89103686|NCT00678106|Experimental|1|
89103687|NCT00810199|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
89103688|NCT00810199|Placebo Comparator|Tocilizumab + Placebo|Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
89103689|NCT00877006|Experimental|Bendamustine and Rituximab (BR)|Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m^2 IV on Day 1
89103690|NCT00877006|Active Comparator|R-CHOP/R-CVP|"Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles.~R-CHOP: rituximab 375 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m^2 IV Day 1; cyclophosphamide 750 mg/m^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5~R-CVP: rituximab 375 mg/m^2 IV on Day 1; cyclophosphamide 750 mg/m^2 IV on Day 1 or cyclophosphamide 1000 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5"
89103691|NCT02608567||Preserved LV GLS|"Patients will be compared according to the level of LV global longitudinal strain (GLS) as derived from transthoracic echocardiography and speckle tracking analysis.~Two groups will be compared regarding outcome: preserved LV GLS vs. reduced LV GLS. The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data."
89103692|NCT02608567||Reduced LV GLS|The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data.
89103693|NCT02608255|Experimental|acute coronary syndromes|
89103694|NCT00876928|Placebo Comparator|Placebo|Subjects with low vitamin D levels and pre-diabetes
89103695|NCT00876928|Experimental|vitamin D|Subjects with low vitamin D levels and pre-diabetes
89103696|NCT02627950|Active Comparator|Isotonic sodium chloride + Ticagrelor|46 patients with NaCl i.v. and 180 mg ticagrelor orally pre revascularization plus medical standard therapy
89103697|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor|46 patients with 5 mg morphine i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
89103698|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor + Metoclopramide|46 patients with 5 mg morphine i.v. and 10 mg MCP i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
89103699|NCT00807937|Experimental|A|AZD7325 5mg twice daily
89103700|NCT00807937|Experimental|B|AZD7325 15mg twice daily
89103701|NCT00807937|Active Comparator|C|Lorazepam 2mg twice daily
89103702|NCT00807937|Placebo Comparator|D|Placebo
89103703|NCT00678340|Active Comparator|1|WACA and PVI
89103704|NCT00678340|Active Comparator|2|PVAC
89103705|NCT00681070|Active Comparator|Arm1: Non-absorbable sutures|use of non-absorbable sutures in facial laceration in this arm
89103706|NCT00681070|Active Comparator|Arm 2: Absorbable sutures|use of absorbable sutures in this arm
89103707|NCT00681148|Experimental|A|Botox injection
89103708|NCT00681148|Placebo Comparator|B|Saline injection
89103709|NCT02627716|Experimental|SOS Intervention Group|Subjects benefit from the SOS Plan in addition to the usual follow-ups
89103710|NCT02627716|No Intervention|Control Group|Subjects receive no additional intervention (tracking the continuation of psychiatric care according to the standard care terms)
89523175|NCT02732119|Experimental|Cohort B|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
89103711|NCT02608333|Experimental|ESDM-12|ESDM -12 : 60 children will receive 12 hours a week of ESDM ( Early Start Denver Model)intervention delivered by trained therapists during 2 years.ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
89103712|NCT02608333|Active Comparator|Control group|control group: 120 children will receive heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period
89103713|NCT04149652|Other|Patients with COPD or fibrosis|Subjects, enrolled on either an inpatient or outpatient basis, with stable COPD or fibrosis documented by anamnestic, imaging and functional tests. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
89103714|NCT04149652|Other|Smokers with no signs of COPD|Subjects with an active smoking habit or a personal history of hard smoking dating back to maximum 5 years before, without clinical and functional signs of COPD. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
89103715|NCT04149652|Other|Healthy non-smoking volunteers|Healthy volunteers who have never smoked and who have no clinical or functional sign of COPD or other respiratory diseases. They will undergo lung function tests and bedside lung ultrasound integrated with lung elastosonography.
89103716|NCT00681304||1|Only one group of participants will be studies. There are no controls.
89103717|NCT04148950|Experimental|Kinesio Taping|Kinesio Taping group consisted of 29 patients with CVD. Kinesio Taping was applied once a week for a period of 4 weeks. Closed Fan and Closed Basketweave techniques were applied according to the clinical manifestations, intensity of symptoms, and the needs for the areas to be taped. Basketweave technique was used generally for the thigh, and the areas rich in lymph nodes while closed fan technique was used for cruris, and regions of less severe venous reflux or obstruction. Kinesio Taping was slowly removed by the patient 4 days after the application to prevent any allergic reactions. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
89103718|NCT04148950|Active Comparator|Compression Stockings|Compression stockings group consisted of 29 patients with CVD. Patients were recommended medium pressure (23-32 mmHg) compression stockings by the physician. Knee high or thigh high compression stockings were given according to the level of symptoms and signs. In addition, patients were given calf muscle pump exercises, flexibility exercises, diaphragmatic breathing exercises, and lower extremity elevation.
89103719|NCT02627014|Experimental|INTERVENTION|Manual Therapy in temporomandibular joint and cervical region. Home physical therapy in temporomandibular joint and cervical region.
89103720|NCT02627014|Active Comparator|CONTROL|Manual therapy in cervical region Home physical therapy in cervical region
89103721|NCT00678964|Experimental|A|
89103722|NCT00678964|Active Comparator|B|
89103723|NCT05299138|Experimental|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and begin Marriage and Relationship Enhancement Skills (MRES) class weekly and meet with their Case Manager as needed.
89103724|NCT05299138|No Intervention|Wait list control|The Control group will be placed on a wait-list and offered services as soon as they complete the study's final 22-week follow-up measures. Control participants will not be assigned a Case Manager and will not receive any comparable services from our agency until they complete their 22-week measures.
89103725|NCT04912453|Experimental|Primary anastomosis group|
89103726|NCT04912453|Experimental|Enterostomy group|
89103727|NCT04031638||Radioactive Iodine treatment for thyroid cancer|
89103728|NCT02627170||Healthy adults group|Age 20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
89103729|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide (TEC)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
89103730|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
89103731|NCT02627248|Experimental|Epirubicin and Docetaxel (ET)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
89103732|NCT02627248|Experimental|Epirubicin and Docetaxel+Huaier (ET+HE)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
89103733|NCT02626936|Active Comparator|Dual-hormone CL with overestimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 95g of carbohydrates.
89103734|NCT02626936|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
89103735|NCT00679198|Experimental|1|We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers
89103736|NCT00679198|No Intervention|2|Standard care
89103737|NCT02627326|Active Comparator|Group 1|Interventions done in 30 patients and included conventional endodontic treatment (ET) and periodontal surgery . After 3 months of completion of endodontic therapy without using 2%chlorhexidine gluconate gel intracanal medicament , periodontal surgery in the form of open flap debridement (OFD) was performed.
89103738|NCT02627326|Active Comparator|Group 2 Chlorhexidine|Interventions done in 30 patients and included intracanal medicament . After biomechanical preparation of root canal, 2%Chlorhexidine gluconate gel as an intracanal medicament was placed in root canal from pulp chamber to apex for 3 months (replacing every month). After 3 months,periodontal surgery in the form of open flap debridement (OFD) was performed in the respective tooth and medicament was changed and placed further for 3 months (replacing every month). Obturation was done after 3 months of OFD.
89103739|NCT00912262|Active Comparator|Low and High Concentration Capsaicin Topical Liquids|
89103740|NCT04151212|Experimental|BAT5906 injection|Single dose escalation starting from 0.3mg. Route of administration: intravitreal injection.
89103741|NCT00679276||1|Patients having surgical repair of a vaginal prolapse .
89103742|NCT02627638|Other|Osteopathic treatment|
89103743|NCT00906945|Experimental|Dose Level 1|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 240 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
89103744|NCT00906945|Experimental|Dose Level 2|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 320 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
89103745|NCT00906945|Experimental|Dose Level 3|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 420 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
89103746|NCT00906945|Experimental|Dose Level 4|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 560 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
89103747|NCT00906945|Experimental|Dose Level 5|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 750 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
89103748|NCT00906945|Experimental|MTD - Phase II|"G-CSF MTD determined in Phase 1 SQ on Days 1-8~Plerixafor MTD determined in Phase 1 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
89103749|NCT00807235|Experimental|Regimen 1|
89103750|NCT00807235|Experimental|Regimen 2|
89103751|NCT02627560|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
89103752|NCT02627560|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
89103753|NCT00681382||1|Asthma patients using inhaled steroids as maintenance treatment
89103754|NCT03784027|Experimental|Automated closed loop insulin delivery (intervention arm)|"Unsupervised home use of day and night automated hybrid closed loop insulin delivery system over 16 weeks.~Intervention: Device: CamAPS FX"
89103755|NCT03784027|Active Comparator|Sensor augmented pump therapy (control arm)|Sensor augmented pump therapy over 16 weeks.
89103756|NCT00681460|Active Comparator|1|gestational diabetes, insulin therapy
89103757|NCT00681460|Experimental|2|gestational diabetes, metformin therapy
89103758|NCT05332119|Experimental|Virtual reality|The intervention will consist of the use of VR glasses during the removal of chest drains. The VR content has been developed by VR Pharma Immersive Technologies (LtD). Its main objective is to improve patient experience and have better management of pain and anxiety. Chest drains are removed following the usual protocol.
89103759|NCT05332119|Sham Comparator|Control group|Patients in the control group will be cared for with the usual care protocol.
89103760|NCT05749939|Experimental|Treatment|Receives access to the online ACT course immediately after enrollment
89103761|NCT05749939|No Intervention|Waitlist|Receives access to the online ACT course 30 days after enrollment
89103762|NCT05332041|Experimental|Predicta Bioactive bulk fil composite restoration|Bioactive bulk fil resin composite dental restoration material
89103763|NCT05332041|Active Comparator|High viscosity glass ionomer (Equia Fil)|High viscosity dental restoration material
89103764|NCT03653325|Experimental|interventional arm|"In the interventional arm of the study clinicians will be encouraged to titrate oxygen FiO2 according to the following table:~Interventional arm (FiO2 adaptation every 2-3 min) :~ORI >0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.2 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.1 ORI >0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.1 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.05 ORI=0 et SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1~In the absence of a ORI measurement reading FiO2 will be adapted as in the observational arm according to SatO2 only."
89103765|NCT03653325|Active Comparator|Observational arm|"Observational arm (adaptation every 2-3 min):~oxygen saturation measurement SatO2>98% and FiO2>0.5 reduction of FiO2 by 0.1 SatO2>98% and FiO2≤0.5 reduction of FiO2 by 0.05 SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1"
89103766|NCT00876694|Experimental|Indacaterol 300 µg|Indacaterol 300 μg once a day (o.d.) delivered via single dose dry powder inhaler (SDDPI). Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
89103767|NCT00876694|Active Comparator|Salmeterol 50 µg|Salmeterol 50 μg twice a day (b.i.d.) delivered via Diskus®. Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
89103768|NCT05333055||Group 1|Eyes with treatment naive DR with or without DME
89103769|NCT05333055||Group 2|Eyes with DME that are incompletely responsive to anti-VEGF therapy
89103770|NCT05333055||Group 3|Eyes with various retinal conditions including eyes with DR and DME that is anti-VEGF responsive as well as non-exudative retinal pathologies such as epiretinal membrane and macular hole
89103771|NCT05749159|Experimental|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
89103772|NCT05749159|Placebo Comparator|alternative therapy|Alternative therapy: including routine physical therapy such as suffocation and drinking cold water, as well as drug therapy such as metoclopramide and Mianna.
89103773|NCT03778489|Experimental|Hypertensive|Men and women in age-group 35-65 years Resting blood pressure of >140/90 mmHg non or only anti-hypertensive medication
89103774|NCT03778489|Active Comparator|Control|Men and women in age-group 35-65 years Resting blood pressure of <140/90 mmHg no medication
89103775|NCT02607007|Experimental|2% M.F. Milk|Breakfast meal: 250 mL 2% M.F. milk, 75 g white toast, 23.2 g strawberry jam, 100 mL water
89103776|NCT02607007|Experimental|2% M.F. Plain Greek Yogurt|Breakfast meal: 175 g 2% plain Greek yogurt, 75 g white toast, 23.2 g strawberry jam, 100 mL + 75 mL water
89103777|NCT02607007|Experimental|31% M.F. Cheddar Cheese|Breakfast meal: 30 g 31% M.F. cheddar cheese, 75 g white toast, 27.0 g strawberry jam, 100 mL + 220 mL water
89103778|NCT02607007|Experimental|Soy Beverage|Breakfast meal: 250 mL soy beverage, 75 g white toast, 19.3 g strawberry jam, 100 mL water
89103779|NCT02607007|Experimental|Water (control)|Breakfast meal: 250 mL + 100 mL water
89103780|NCT00805441|Placebo Comparator|Placebo|
89103781|NCT00805441|Experimental|LY686017|
89103782|NCT00590317|Active Comparator|Prochlorperazine|Patients receiving Prochlorperazine 10mg IV
89103783|NCT00590317|Active Comparator|Ondansetron|Patient receiving Ondansetron 4mg IV
89103784|NCT01139762|Experimental|Tadalafil|
89103785|NCT01139762|Placebo Comparator|Placebo|
89103786|NCT00805285|Experimental|Combination Oral Budesonide and Rectal Hydrocortisone|See intervention
89103787|NCT02606773|Experimental|600 mg Novo C plus|Single dose of oral 600 mg Novo C plus dietary supplement (contains 600 mg ascorbic acid in liposomal formulation)
89103788|NCT02606773|Experimental|900 mg Novo C Plus|Single dose of 900 mg oral Novo C plus dietary supplement (contains 900 mg ascorbic acid in liposomal formulation)
89103789|NCT02606773|Active Comparator|500 mg intravenous vitamin C|Single dose of 500 mg intravenous ascorbic acid (Vitamin C 100 mg/ml injection; EGIS)
89103790|NCT02606773|Active Comparator|500 mg oral vitamin C|Single dose of 500 mg oral ascorbic acid (Cetebe 500 mg retard capsules; GlaxoSmithKline Consumer Healthcare - GSK Export)
89103791|NCT05715307|Experimental|Intensive experiential training group|Endocrinologists will receive 1-week intensive training in T2DM health care, including 1-week hospitalization experience in leading center (Ruijin Hospital), health examination and results interpretation, and integrated training courses for T2DM diagnosis and treatment management.
89103792|NCT05715307|Active Comparator|Regular training group|Endocrinologists will receive regular training from MMC under the guidance of T2DM diagnosis and treatment as a control group.
89103793|NCT04310774|Experimental|Consolidation therapy|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
89103794|NCT01139450|Experimental|Test|Test product that contains the active pharmaceutical ingredient
89103795|NCT01139450|Active Comparator|Reference|Reference product that contains the active pharmaceutical ingredient
89103796|NCT01139450|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
89103797|NCT05748067|Active Comparator|Group 1: SDF, HVGIC & SSC|Silver diamine fluoride (SDF) will be clinically applied in the first visit. After 1 week of caries arrest, the tooth will be restored with a high viscosity glass ionomer (HVGIC) and stainless steel crown (SSC).
89103798|NCT05748067|Active Comparator|Group 2: SDF & SSC|Silver diamine fluoride (SDF) will be clinically applied in the first visit. After 1 week of caries arrest, the tooth will be restored with a SSC only.
89103799|NCT05748067|Active Comparator|Group 3: HVGIC & SSC|The tooth will be restored in a similar fashion to atraumatic restorative treatment (ART technique) and restored with a high viscosity glass ionomer (HVGIC) and stainless steel crown (SSC).
89103800|NCT00805207|Experimental|Progesterone - PCOS|Women with obesity and polycystic ovary syndrome
89103801|NCT00805207|Experimental|Testosterone - premenopausal women|Healthy premenopausal women.
89103802|NCT00805207|Experimental|Continuous positive airway pressure|Women and men with obesity and obstructive sleep apnea
89103803|NCT00805207|Experimental|Glucocorticoid|Lean and obese healthy women, and obese men
89103804|NCT00805207|Experimental|Estrogen|Postmenopausal women
89103805|NCT00805207|Other|control|Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits
89103806|NCT00805207|No Intervention|control - baseline testing only|Healthy men and women
89103807|NCT00805207|Experimental|Progesterone - Postmenopausal women|Postmenopausal women
89103808|NCT00805207|Experimental|Testosterone - Postmenopausal women|Postmenopausal women
89103809|NCT05747755|No Intervention|Pre-intervention (usual care)|Patients admitted to study hospitals in the 12 months prior to the start of the intervention
89103810|NCT05747755|Experimental|Intervention|Patients admitted to study hospitals during the 36 months of the intervention
89103811|NCT03016351|Experimental|Aerobic Training|Participants will undergo a supervised endurance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week. During each session, participants will complete a 5 min warm-up followed by 30-45 min of endurance exercise using cycle ergometry. Intensity will be monitored using heart rate monitors during each exercise session, and each participant will receive an exercise prescription with a heart range equivalent to 65-85% of their heart rate max. Participants will be asked to complete 30 min of exercise during each session in week 1, 35 min in week 2 and 40-45 min weeks 3-8 with a 5 min cool down period.
89103812|NCT03016351|Experimental|Resistance Training|Participants will undergo a supervised resistance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week, 45 min per session. Muscle strength will be determined once before and once after resistance training by measuring ten repetition maximum (10 RM) for each exercise. Eight exercises (three sets; 8-12 repetitions) will be used on each of the large muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). In addition, workloads will be progressively increased if the patients can lift the weight more than 12 repetitions.
89103813|NCT00805675|Experimental|Telbivudine 600 mg monotherapy|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
89103814|NCT00805675|Active Comparator|Tenofovir disproxil fumarate 300 mg monotherapy|All patients in this arm were randomized to receive Tenofovir disoproxil fumarate 300 mg(equivalent to tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
89103815|NCT00805675|Active Comparator|Telbivudine 600 mg and Tenofovir 300 mg|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD and Tenofovir (TDF) 300 mg (equivalent to Tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
89103816|NCT03958201|Other|Protocol|Patients will have perioperative neuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed objectively at adductor pollicis with quantitative neuromuscular monitoring.
89103817|NCT00589303|Active Comparator|Drug Therapy|FDA approved rate and rhythm control drugs
89103818|NCT00589303|Active Comparator|Atrioventricular Node (AVN) Ablation / Pacing|AV Node ablation and device implant
89103819|NCT02607943|Experimental|Insulin Glargine|subcutaneous long acting basal insulin (insulin glargine) with added short acting regular insulin to correct hyperglycemic events
89103820|NCT02607943|Active Comparator|Regular Insulin|short acting regular insulin pre-meal with added NPH at bed time if start eating
89103821|NCT02970877|Experimental|Allogenic treatment group|Fecal filtrate from 150 g stool from healthy lean donors
89103822|NCT02970877|Placebo Comparator|Autologous control group|Fecal filtrate from 150 g of the recipient's own stool
89103823|NCT03932305|Placebo Comparator|Control|Patients taking inactive placebo tablets
89103824|NCT03932305|Experimental|Lutein|Patients taking lutein supplement
89103825|NCT02606617|Active Comparator|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
89103826|NCT02606617|Placebo Comparator|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
89103827|NCT02608021||Amnestic mild cognitive impairment|
89103828|NCT02608021||Cognitively normal|
89103829|NCT00914095|Active Comparator|methylphenidate|methylphenidate 10 mg tablets (1 mg /kg /day) 3 time a day
89103830|NCT00914095|Placebo Comparator|placebo|tablets of placebo 3 time a day
89103831|NCT05745337|No Intervention|Control|Patients randomized to the control arm will continue taking their daily beta-blocker for rate control of atrial fibrillation
89103832|NCT05745337|Experimental|As needed rate control|Patients randomized to the experimental arm will stop their daily beta-blocker and take as needed rate control guided by their implantable cardiac monitor
89103833|NCT05744791|Experimental|Active Play Intervention|Preschool teachers will be asked to implement two active play activities each preschool day, one indoors and one outdoors. This is in addition to the current outdoor free play of 30 minutes each day. Each activity is 10-15 minutes for a total of 20-30 minutes per day.
89103834|NCT05744791|No Intervention|Control|Preschool teachers will continue to implement their regular curriculum. This consists of one outdoor play opportunity for 30 minutes each day.
89103835|NCT00952380|Other|Single Arm|Single arm open-label
89103836|NCT03866161||CPAP group|Obstructive sleep apnea patients treated with continuous positive airway pressure
89103837|NCT02856750|Experimental|gabapentin|gabapentin 300 mg three times daily x 30 d
89103838|NCT02856750|No Intervention|placebo|no gabapentin administered to this arm.
89103839|NCT04277832||single arm|Group of psoriasis patients will select randomly. All selected psoriasis patients will be consulted to a physician experienced in rheumatology and all of patients will fill TUPAST and TOPAS 2 forms.
89103840|NCT05751967|Placebo Comparator|Placebo|1 tablet/ day
89103841|NCT05751967|Experimental|Fenofibrate|200 mg/day
89103842|NCT02857920|Experimental|Bevacizumab and NK immunotherapy|In this group, the patients will receive regular Bevacizumab treatment in combination with multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89103843|NCT02857920|Active Comparator|Bevacizumab|In this group, the patients will receive regular Bevacizumab treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89103844|NCT03847831|Experimental|PPASF Group|"Schools enrolled in the postprimary active school flag program. All 17 elements are included. Feasibility is measured of the 17 elements.~Student representatives are selected to have accelerometer, physical health measures and perceived health collected for feasibility purposes."
89103845|NCT02858466|Experimental|peripheric nervous lesion|MRI scan
89103846|NCT02858466|Experimental|medullar or encephalic lesion|MRI scan
89103847|NCT02858466|Other|control group|MRI scan
89103848|NCT05750953|Experimental|eHealth@H-2-H|"The intervention group will participate in a 42-day nurse-assisted intervention eHealth@ Hospital-2-Home. The intervention includes monitoring of vital signs, self-reports of symptoms, health and well-being, access to information about illness and health resources , and communication between the patients and a hospital-based Nurse Navigator."
89103849|NCT05750953|No Intervention|Care as usual|The control group will receive care as usual
89103850|NCT02857764||Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users|Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
89103851|NCT02857764||Canagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.
89103852|NCT02857764||Dapagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
89103853|NCT02857764||Empagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
89103854|NCT02857764||First-time Non-SGLT2i AHA New Users|Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
89103855|NCT02607631|Experimental|Single arm|Pembrolizumab 200mg IV every 3 weeks until tumor progression or unacceptable toxicity
89103856|NCT02858232|Experimental|solid tumor|Multiple Target Antigen Stimulating Cell Therapy (MASCT-I)
89103857|NCT02857842|Experimental|Blood eosinophil guided prednisolone treatment|Intravenous Solu-Medrol 80 mg, followed by prednisolone tablet 37.5 mg daily (maximum of 5 days in all) if the eosinophil count in the blood ≥ 0.3 x 10E9/L. Eosinophil count in the blood <0.3 x 10E9/L results in no treatment with prednisolone. If the patient is discharged during the treatment period, given treatment from the last measured eosinophil count the remaining days.
89103858|NCT02857842|Active Comparator|Standard of care|Intravenous Solu-Medrol 80 mg on the first day followed by 37.5 mg of prednisolone tablets (1 x 25 mg plus 1 x 12.5 mg) daily for 5 days
89103859|NCT00914407|Experimental|Healthy subjects|
89103860|NCT03635437|Experimental|Low dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 200 mg daily for 6 months
89103861|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 600 mg daily for 6 months
89103862|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA) + Alprazolam|Oral Alprazolam treatment 0.5 mg daily combined with oral GABA treatment 600 mg daily for 3 months. Alprazolam treatment thereafter ended, and study subjects will continue with oral GABA treatment 600 mg daily only for another 3 months.
89103863|NCT03796663|Active Comparator|Mindful Parenting Only|"Participants in this arm will receive only the Mindful Parenting Program at the start of the study. Bögels and Restifo's (2014) Mindful Parenting Program is an adaptation for parents of MBCT, and MBSR; the program will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.~Following the completion of the Mindful Parenting Sessions, participants in this arm will be asked continue to participate in data collection for the post-intervention assessment time point (i.e. 8 weeks after the completion of the Mindful Parenting group sessions) and for the 2-month follow up assessment time point (i.e. 16 weeks after the completion of the Mindful Parenting group sessions). After they have completed both assessments, they will be offered the opportunity to participate in the MATCH BPT program if they so choose (no data will be collected)."
89103864|NCT03796663|Experimental|Mindful Parenting and BPT Combined|"Participants in this arm will receive the Mindful Parenting Program at the start of the study, which will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.~Following the completion of the Mindful Parenting Sessions, participants in this arm will receive receive individually-implemented MATCH BPT sessions, which will consist of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 1 hour sessions. The MATCH manual is comprised of 33 modules (i.e. coping, giving effective instructions, learning to relax, etc.). For the purpose of this study we will be utilizing the section on BPT, which consists of 12 modules with corresponding handouts and worksheets."
89103865|NCT05701267||MDD|Major depressive disorder patients (unipolar)
89103866|NCT05701267||CON|(Control) non-depressed
89103867|NCT00803179|Experimental|Growth Hormone Therapy|"Nutropin Aqueous (AQ):~Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d"
89103868|NCT03600259||Acute Myocardial Infarction|
89103869|NCT00914173|Experimental|Pain/No Pain Stimuli|One Arm is used in this trial. The comparator is within the arm. The different types of stimuli levels and types are compared.
89103870|NCT00804193|Experimental|Test Product|Ciclopirox Olamine Topical Suspension
89103871|NCT00804193|Active Comparator|Reference Product|Loprox® Topical Suspension 0.77%
89103872|NCT00804193|Placebo Comparator|Vehicle Product|placebo of test product
89103873|NCT05697211|Experimental|Feraccru® 30 mg hard capsules|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily p.o., morning and evening, on an empty stomach
89103874|NCT02607787|Experimental|Exercise Group|As well as usual care, this group receive a behavioural change session and intervention information regarding the exercise programme. The home-based walking and strengthening intervention is individually tailored for each participant. They receive a booklet, diary and pedometer to guide them as well as weekly phone calls for 12 weeks to monitor their progress.
89103875|NCT02607787|Other|Control Group|This group attends and participates in the same assessment outcomes as the intervention group and receives usual care for the duration of the study. However they are not given any exercise instructions and do not receive the intervention information until their final assessment at week 24. They are aware of their group allocation throughout the duration of the study.
89103876|NCT04115215|Experimental|Arm 1|Physical exercise (PE)
89103877|NCT04115215|Experimental|Arm 2|Transcranial current stimulation (tCS)
89103878|NCT04115215|Active Comparator|Control|Educational sessions on healthy aging
89103879|NCT00957996|Experimental|Peramivir 300 mg|Peramivir 300 mg twice daily
89103880|NCT00957996|Experimental|Peramivir 600 mg|Peramivir 600 mg once daily
89103881|NCT02607553|Experimental|Experimental: G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
89103882|NCT04115137||Women with pelvic congestion syndrome|Women older than 18 years At least 1 birth Present symptoms
89103883|NCT02606539|Active Comparator|surgery and methotrxate|The patient will be treated by total abdominal hystrectomy(after written consent laparatomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg alternating with calcium folinate 0.1 mg/kg until normalization of B-HCG
89523176|NCT02732119|Experimental|Cohort C|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
89103884|NCT02606539|Active Comparator|methotrxate|The patient will be treated by multiple courses of methotrexate( antifolate) 1mg/kg every 14 days each one alternating in every otherday with calcium folinate 0.1 mg/kg till normalization of B-HCG
89103885|NCT00589693|Experimental|Doripenem|Doripenem from Days 1 to 7 and imipenem-cilastatin placebo from Days 1 to 10
89103886|NCT00589693|Active Comparator|Imipenem-Cilastatin|Imipenem-Cilastatin Days 1 to 10 and doripenem placebo from Days 1 to 7
89103887|NCT05735509|Active Comparator|Before rubber dam|Impression taken before rubber dam placement is used for crown manufacturing
89103888|NCT05735509|Experimental|After rubber dam|Impression taken after rubber dam placement is used for crown manufacturing
89103889|NCT02606383|Experimental|Dapaconazole|Dapaconazole 2% Cream Topical
89103890|NCT02606383|Active Comparator|Ketoconazole|Ketoconazole 2% Cream Topical
89103891|NCT02606695||NuvaMap and NuvaMap OR in Thoracolumbar Spinal Fusion|
89103892|NCT05663359|Active Comparator|1940 nm|Endovenous laser at 1940 nm
89103893|NCT05663359|Active Comparator|1470 nm|Endovenous laser at 1470 nm
89103894|NCT02607475|Experimental|Robotic telesonography compared to conventional sonography|All participants will receive two imaging studies: (1) Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix), and (2) conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare).
89103895|NCT02605681||septic patients|We recruited the patients admitted to the Department of Critical Care Medicine, Zhongda Hospital, a tertiary hospital, from November 2017 to March 2018. The inclusive criteria were adult patients (age > 18 years-old and < 80 years-old) diagnosed with sepsis, according the definition of the Surviving Sepsis Campaign (2016). Exclusive criteria included: 1. age < 18 years-old or > 80 years-old; 2. pregnancy or breastfeeding; 3. malignancy; 4. patients with potentially elevated plasma midkine apart from sepsis including acute myocardial infarction, stroke, limb thrombosis, chronic renal dysfunction (baseline plasma creatine ≥2 mg/dL), autoimmune diseases and Alzheimer syndrome; 5. patients deceased or discharge from ICU within 24 hours; or, 6. written consents could not be obtained.
89103896|NCT02606227|Experimental|Experimental group:financial incentives|Vouchers for show up + Vouchers at increasing amount to reward tobacco abstinence
89103897|NCT02606227|Other|Control group:no financial intervention|Vouchers for show up only, no financial incentive for rewarding tobacco abstinence
89103898|NCT05660473|Experimental|Pediatric-inspired Regimen Combined With Venetoclax|Induction therapy is administered as follows：Vincristine (VCR) 1.4 mg/m2 (maximum dose 2 mg) IV on D1,8,1,5,22; Daunorubicin (DNR) 30 mg/m2/day IV on D1-3; Cyclophosphamide (CTX) 1200 mg/m2 IV on D1,15; Pegaspargase 2500u/m2 IM on D5; Prednisone 1 mg/kg/d PO on D1-14, 0.5 mg/kg/d PO on D15-28; Venetoclax 100 mg PO on D6，200 mg on D7, 400mg on D8-14, All patients underwent bone marrow aspiration on day 14 during induction. Patients with bone marrow blasts ≥10% on day 14 of induction received 7 additional days of Venetoclax on day 15-22. Consolidation therapy is a combination of multi-drug pediatric-inspired regimen chemotherapy and Venetoclax. Maintenance therapy consisted of a monthly VMMP regimen (vincristine, mercaptopurine, methotrexate, prednisone) continuing until 3 years for male and 2.5 years for female patients.
89103899|NCT00803101|Experimental|Beriplex® P/N|
89103900|NCT00803101|Active Comparator|Fresh frozen plasma|
89103901|NCT03518827||Athletes|For Asymmetry measurement, the group will consist of 200 athletes of different sports (the proportion not strictly predefined) - track and field, racket sports, ball sports, other team sports, swimming, running, cycling, dancing, ice skating, etc.
89103902|NCT02607241|Active Comparator|BRS|"OCT-guided BRS implantation: implantation of a bioresorbable scaffold (BRS) under OCT guidance.~Note: Absorb™ from Abbott Vascular has been used as BRS until this product became unavailable in April 2017. Currently the recruitment is stopped due to this issue, until the use of another BRS gets final approval."
89103903|NCT02607241|Experimental|DCB-only|FFR-guided DCB-only PCI: PCI using DCB (SeQuent Please™, B Braun Melsungen GmBH) without stent implantation und FFR guidance
89103904|NCT00801229|Active Comparator|Vyvanse|Patients may be randomized to the active comparator arm. Participants randomized to this arm will receive 30, 50, or 70mg Vyvanse daily.
89103905|NCT00801229|Placebo Comparator|Placebo|Patients may be randomized to the placebo comparator arm. Those randomized to this arm will receive 30, 50, or 70mg placebo daily.
89103906|NCT04114825|Experimental|RV001V|Total of 12 SC vaccinations with RV001V. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
89103907|NCT04114825|Placebo Comparator|Placebo|Total of 12 SC vaccinations with placebo. The first 6 vaccinations (priming period) will be given every 2 weeks, and then the following 5 vaccinations (7 through 11) will be administered with 4 weeks between each vaccination (Maintenance period), and the last vaccination (12th) will be administered 6 months following the 11th vaccination (boosting injection).
89103908|NCT03444259||Atrial fibrillation|Patients with atrial fibrillation
89103909|NCT03444259||Coronary bypass|Patients undergoing coronary bypass
89103910|NCT03444259||Aortic valve replacement|Patients undergoing aortic valve replacement
89103911|NCT03444259||Mitral valve repair|Patients undergoing mitral valve repair
89103912|NCT03444259||Other|Patients undergoing cardiac surgery for indication other than above
89103913|NCT02606149|Active Comparator|Standard of information|Information on chemotherapy as done in routine practice following national and international guidelines
89103914|NCT02606149|Experimental|Truthful information on chemotherapy risks|Information on the potential role of anticancer chemotherapy in worsening life-threatening conditions
89103915|NCT04269954|Experimental|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin.
89103916|NCT04269954|Other|Low-molecular-weight heparin therapy|Low-molecular-weight heparin combined with routine drug therapy.
89103917|NCT02856672|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
89103918|NCT02856672|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
89103919|NCT00630630|Experimental|1|
89103920|NCT00630630|Placebo Comparator|2|
89103921|NCT02857608|Experimental|Lymphoseek - 0.5 mCi, 50 ug|A single dose of 50 µg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99m Tc
89103922|NCT04269564|No Intervention|group A|Group A patients received the standard ventilation protocol as follows: volume-controlled ventilation mode, with VT 6 ml/kg of ideal body weight, inspiratory : expiratory ratio 1 : 2, a PEEP of 4 cmH2O, and respiratory rate 10-12 breaths/min that will be adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mmHg and inspired oxygen fraction of 0.5.
89103923|NCT04269564|Active Comparator|group B|Patients in group B received the standard ventilation protocol with stepwise peep until end of surgery and extubation.
89103924|NCT02854722|Experimental|Deferasirox and calcium-vitamin D3|"Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy."
89103925|NCT02854722|Placebo Comparator|Calcium-vitamin D3|Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.
89103926|NCT00948246||Easyband|Subjects who had the Easyband device implanted laparoscopically.
89103927|NCT00800683|Experimental|BI 1356|patient to receive a tablet containing BI 1356 once daily
89103928|NCT00800683|Placebo Comparator|placebo|patient to receive a tablet identical to BI 1356 once daily
89103929|NCT01124864|Experimental|EGFR mutant patients|Patients with EGFR activating mutation tumors (Note: These patients must have progressed on one prior EGFR TKI containing regimen unless they have documented T790M activating mutation). Patients received AUY922 at 70 mg/m^2 weekly infusions.
89103930|NCT01124864|Experimental|Kras mutant patients|Patients with KRAS mutant tumors. Patients received AUY922 at 70 mg/m^2 weekly infusions.
89103931|NCT01124864|Experimental|EGFR and Kras wild type patients|Patients exhibiting both mutations were stratified to the KRAS mutation stratum. Patients received AUY922 at 70 mg/m^2 weekly infusions.
89103932|NCT01124864|Experimental|Patients with EML4-ALK translocation|Patients with NSCLC who have tumors with an inversion in the short arm of chromosome 2 that results in the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene leading to the production of an EML4-ALK fusion tyrosine kinase. ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung. EML4 mediate ligand-independent dimerization, and therefore constitutive activity of the ALK tyrosine kinase domain. Patients received AUY922 at 70 mg/m^2 weekly infusions.
89103933|NCT01124864|Experimental|Modified EGFR mutant patients|The modified EGFR stratum was defined as patients less heavily pretreated who had received one or two lines of prior therapy, with a documented response to a EGFR tyrosine kinase inhibitor (TKI) (complete response (CR), partial response (PR) or stable disease (SD) for ≥ 6 months), unless the patient had de novo resistance to EGFR TKI. Patients received AUY922 at 70 mg/m^2 weekly infusions.
89103934|NCT01113710||Neupro®|Routine treatment in accordance with the local marketing authorization for Neupro® in RLS
89103935|NCT05726773|Experimental|Robot Assisted Therapy Group|In the RAT group, it was planned to perform robotic rehabilitation with a hand-finger robot [Amadeo (Tyromotion, Graz, Austria)] for 30 minutes for both upper extremities, accompanied by a physiotherapist who is trained in robotic rehabilitation and has at least 5 years of experience. In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
89103936|NCT05726773|Active Comparator|Conventional Therapy Group|In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
89103937|NCT04114591||LARS symptoms|Patient suffering from LARS as identified through LARS questionnaire
89103938|NCT04114591||No LARS symptoms|Absence of LARS symptoms
89103939|NCT01124162|Experimental|Generic Test Product|Losartan 100mg Tablets
89103940|NCT01124162|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
89103941|NCT00923533|Active Comparator|Part A|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
89103942|NCT00923533|Active Comparator|Part B|Hydrochlorothiazide (7day) Hydrochlorothiazide + Fimasartan (7day)
89103943|NCT05104112|No Intervention|control group|Pregnant women followed by the center in the period before the intervention is implemented (the start of which is determined by randomization)
89103944|NCT05104112|Experimental|experimental group|Pregnant women followed by the center during the period after the intervention is implemented (the start of which is determined by randomization)
89103945|NCT04312568|Experimental|Fadanafil|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
89103946|NCT04312568|Placebo Comparator|Placebo|8 group: 12.5mg one dose; 25mg one dose; 50mg one dose; 100mg one dose; 200mg one dose; 300mg one dose; 400mg one dose; 500mg one dose
89103947|NCT04310306||Rescue stenting group|
89103948|NCT00906399|Placebo Comparator|Placebo|Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
89103949|NCT00906399|Experimental|Peginterferon Beta-1a Q2W|125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
89103950|NCT00906399|Experimental|Peginterferon Beta-1a Q4W|125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).
89103951|NCT01111838|Experimental|STA-9090|This is an open-label Phase 2 clinical study in patients with advanced colorectal cancer (CRC). Patients will be treated with 200mg/m2 of STA-9090 during a 1-hour intravenous infusion 1 time per week for three consecutive weeks followed by a 1 week dose-free interval. Patients tolerating STA-9090 will be permitted to continue treatment until disease progression.
89103952|NCT02562469|Experimental|ACTIVATE|ACTIVATE is a computerized neurocognitive training program (ACTIVATE; see: www.c8sciences.com) that simultaneously targets eight core neurocognitive factors (i.e., sustained attention, working memory (WM), response inhibition, speed of information processing, cognitive flexibility and control, multiple simultaneous attention, category formation, and pattern recognition and inductive thinking). ACTIVATE Is completed at home via computer with parent support. ACTIVATE intervention is conducted 3-5 times per week for between 20-30 minutes over the course or 3-4 months.
89103953|NCT00947856|Experimental|BV Retreatment|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
89103954|NCT00947856|Experimental|BV Extension|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
89103955|NCT02605525|Experimental|SM101 12 mg/kg|Human soluble recombinant Fcγ Receptor IIB
89103956|NCT02605525|Experimental|SM101 24 mg/kg|Human soluble recombinant Fcγ Receptor IIB
89103957|NCT02605525|Placebo Comparator|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 2
89103958|NCT05332977|Experimental|CAD-CAM fabricated provisional prothesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
89103959|NCT05332977|Active Comparator|Insertion of denture conversion (DC)|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
89103960|NCT00947544|Experimental|HPN-100 and NaPBA|1 week of NaPBA treatment followed by 1 week of HPN-100 treatment.
89103961|NCT00907335|Experimental|Retin-A Micro|Retin-A Micro 0.04% facial acne treatment used once daily
89103962|NCT00907335|Placebo Comparator|Vehicle Control|Color matched facial gel vehicle control used once daily
89103963|NCT00947154|Experimental|Open-label aripiprazol|Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
89103964|NCT05490303|Other|Patients|Patient with an echocardiography examination
89103965|NCT02856360|Experimental|Moderate Stiffness|Shoe condition that has moderate stiffness
89103966|NCT02856360|Active Comparator|High Stiffness|Shoe condition that has high stiffness
89103967|NCT01124006|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
89103968|NCT01124006|Placebo Comparator|Water for injection|Sterile water for injection
89103969|NCT03593889|Experimental|Intervention group|The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from elderly or mental health service units (NGOs) according to level of risks, symptom severity, and intervention response. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.
89523177|NCT02732119|Experimental|Group 1|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
89103970|NCT03593889|Other|Control group|The control group will receive treatment as usual, which will be determined by the responsible worker from NGO units.
89103971|NCT04270110||Case|Patients with subclinical hypothyroidism
89103972|NCT04270110||Control|Patients with Normal thyroid function
89103973|NCT03589989|Experimental|Intervention group|
89103974|NCT03589989|Active Comparator|Control group|
89103975|NCT01862952|Active Comparator|antiepileptic treatment as used in daily clinical practice|Antiepileptic treatment as used in daily clinical practice.
89103976|NCT01862952|No Intervention|No medication|
89103977|NCT02882516|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89103978|NCT02882516|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89103979|NCT02882516|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89103980|NCT02882516|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89103981|NCT02882516|No Intervention|darkness|The participants will not be exposed to any light but stay in darkness for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
89103982|NCT00952068|Experimental|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
89103983|NCT01123850|Active Comparator|Single ARM - Copios Bone Filler|All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.
89103984|NCT05572047|Experimental|Coherent Sine-Burst Electroporation for AF|"Patients with paroxysmal AF will receive treatment using the Arga Medtech Coherent Sine-Burst Electroporation ablation system to achieve pulmonary vein isolation (plus cavo-tricuspid isthmus ablation as necessary)~Patients with persistent AF will receive treatment using the Arga Medtech Coherent Sine-Burst Electroporation ablation system to achieve pulmonary vein isolation and posterior wall ablation (and cavo-tricuspid isthmus ablation as necessary)"
89103985|NCT01123382|Experimental|IM Electrical Stimulation (IM ES)|The IM ES Group will receive electrical stimulation treatment for three weeks (6 hrs daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
89103986|NCT01123382|Active Comparator|Usual Care (UC)|The Usual Care Group will receive outpatient therapy for four weeks, coupled with prescribed daily home exercises.
89103987|NCT00951912|Placebo Comparator|Placebo|10g soy protein isolated powder patch by mouth everyday for 6months
89103988|NCT00951912|Experimental|Daidzein|10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months
89103989|NCT00951912|Experimental|Genistein|10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months
89103990|NCT05332665||Angle opening distance (AOD)|The AOD measured as perpendicular distance between anterior iris surface and point at trabecular meshwork at 500 μm anterior to the scleral spur
89103991|NCT05332665||Trabecular iris space area (TISA) 500|TISA 500 was measured as an area bounded anteriorly by the AOD 500, posteriorly by a line drawn from the scleral spur perpendicular to the plane of the inner scleral wall to the opposing iris, superiorly by the inner corneoscleral wall, and inferiorly by the iris surface
89103992|NCT05332665||Anterior chamber depth (ACD)|The ACD was measured as the perpendicular distance from the corneal endothelium at the corneal apex to the anterior lens surface
89103993|NCT03575169||Patients with TBI|Admitted to Aberdeen ICU with diagnosis of TBI and expected to require greater than 24 hours sedation.
89103994|NCT02882594||CIBA Study Cohort|Patients aged 1 to 13 years undergoing inhalation inductions for general anesthesia
89103995|NCT01123148|Other|Tilt testing|
89103996|NCT02856204||Diagnostic (collection of blood samples)|Patients undergo collection of blood samples before and during the episode of febrile neutropenia for up to 6 weeks.
89103997|NCT02856048|Experimental|Triptorelin (GnRHa) + Chemotherapy|Triptorelin LP 3 mg (DECAPEPTYL LP 3 mg, IPSEN) 3 mg every 28±3 days, intramuscular during chemotherapy
89103998|NCT02856048|No Intervention|Chemotherapy alone|Patient having a chemotherapy without drug injection for fertility preservation
89103999|NCT02854410|Experimental|Sodium nitrate supplementation|Patients will receive Sodium nitrate supplementation from 7 days before radiotherapy to one month after the end of radiotherapy
89104000|NCT02854410|Placebo Comparator|Placebo Comparator(sodium chloride)|Patients will receive placebo from 7 days before radiotherapy to one month after the end of radiotherapy
89104001|NCT01123070|Experimental|TL011|TL011 infusions
89104002|NCT01123070|Active Comparator|MabThera|MabThera infusions
89104003|NCT02857686|Active Comparator|arm intravenous regional anesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
89104004|NCT02857686|Experimental|forearm intravenous regional anesthesia|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
89104005|NCT03841929|Experimental|Study Arm|ELGANs recruited to the study group in addition to standard of care will have continuous cerebral NIRS monitoring for the initial 72 hours and TNE studies at definitive time frames and a hemodynamic report will be provided to the clinical team using the results of the multimodal monitoring and clinical data. The report will be a description of the hemodynamic status without any suggestions for management.
89523178|NCT02732119|Experimental|Group 2|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
89523179|NCT03384797||Healthy Volunteers|
89523180|NCT03384797||Parkinson's Disease|
89523181|NCT04529915||Lung cancer|
89104006|NCT03841929|No Intervention|Standard Arm|ELGANs recruited into Standard arm will have the standard monitoring including cardiorespiratory monitoring. The invasive blood pressure monitoring, NIRS and TNE monitoring as per the clinical team's discretion - consistent with the current standard of care. No hemodynamic report will be provided routinely.
89104007|NCT04275648|Experimental|Asthmatuner field tests vs laboratory tests|Each participant will perform two standardized field tests either before or after Eucapnic Voluntary Hyperpnea or Methacholine bronchial provocation test. In addition, unstandardized field tests will be performed in case of exercise induced respiratory symptoms.
89104008|NCT05330403|Experimental|the lung meridian intervention group|moxibustion intervention was performed over Site 1 (LU5) of the lung meridian
89104009|NCT05330403|Experimental|the heart meridian intervention group|moxibustion intervention was applied over Site 4 (HT3) of the heart meridian
89104010|NCT02854254|Experimental|PICC|peripherally inserted central catheter
89104011|NCT02854254|Other|Control|peripherally venous access
89104012|NCT03198741|Active Comparator|Aspirin+clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),continue aspirin + clopidogrel (12-month DAPT group).The treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
89523182|NCT04529915||Healthy|
89104013|NCT03198741|Experimental|Aspirin|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive aspirin + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
89104014|NCT03198741|Experimental|Clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive clopidogrel + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
89104015|NCT01122680|Experimental|Treatment A|patients inhale 2 puffs (dose of 1.25 mcg) once daily in the evening via Respimat inhaler
89104016|NCT01122680|Experimental|Treatment C|patients inhale 2 puffs (dose of 5 mcg) once daily in the evening via Respimat inhaler
89104017|NCT01122680|Placebo Comparator|Placebo|patients inhale 2 puffs of placebo matching tiotropium once daily in the evening via Respimat inhaler
89104018|NCT01122680|Experimental|Treatment B|patients inhale 2 puffs (dose of 2.5 mcg) once daily in the evening via Respimat inhaler
89104019|NCT03186339||TAVI patients|patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis
89104020|NCT03186339||SAVR patients|patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis
89104021|NCT03186339||MM patients|patients in whom the aortic stenosis is medically managed
89104022|NCT00946998|Active Comparator|Sertraline|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
89104023|NCT00946998|Placebo Comparator|Placebo|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
89104024|NCT03147261|Experimental|lifestyle intervention|Intensive follow up in lifestyle factors with a reduced calorie DM , physical activity and behavioural therapy.
89104025|NCT03147261|No Intervention|No intervention|Healthy diet recommendations following the usual pediatric advice
89104026|NCT01138826|Active Comparator|treatment A - reference w/ water|
89104027|NCT01138826|Experimental|Treatment B - ODT (test) w/ water|
89104028|NCT01138826|Experimental|Treatment C - ODT (test) w/o water|
89104029|NCT00906087|Other|Cosopt|Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.
89104030|NCT02854332|Active Comparator|MRI by rTMS|Patients which received an MRI study of cortical plasticity by rTMS.
89104031|NCT02854332|Active Comparator|MRI by tDCS|Patients which received an MRI study of cortical plasticity by tDCS.
89104032|NCT03525795|Experimental|CPI-1205 Combination with ipilimumab|
89104033|NCT02883374|Experimental|Chidamide|Patients of advanced cephalic and cervical adenocystic carcinoma are given Chidamide 30mg,biw, then the efficacy and safety will be accessed.
89104034|NCT02855736|Experimental|Intervention group|Positive Psychology (gratitude journal)
89104035|NCT02855736|Placebo Comparator|Control group|Alimentary list
89104036|NCT02855970|Experimental|patient|
89104037|NCT05318001||Group: Pregnant women (first-timed pregnant)|This group will consist of women in first trimester of pregnancy
89104038|NCT02420574|Active Comparator|ALB-BENDEX|albendazole, 400 mg, single oral dose, (BENDEX)
89104039|NCT02420574|Active Comparator|ALB-OVIS|albendazole, 400 mg, single-oral dose, (OVIS)
89104040|NCT02855502|Active Comparator|Prednisolone|dose: 15 mg per day(divided 5 mg TDS) dosage form: tablet duration administration: 30 days
89104041|NCT02855502|Placebo Comparator|Placebo|placebo given to patient: 3 tablet (divided TDS) dosage form: tablet duration administration: 30 days
89104042|NCT05332431||Patients with Migraine|Patients diagnosed with migraine based on prespecified criteria according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) established by established by the International Headache Society, for migraine with aura and migraine without aura, attending the neurology outpatient clinic, Assiut University.
89104043|NCT05332431||Control|Age and sex matched healthy control group (with the absence of any pathological headache and eye problems), will be recruited from the outpatient clinic for comparison.
89104044|NCT02853864|Placebo Comparator|Propofol and 0.0 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
89104045|NCT02853864|Experimental|Propofol and 0.4 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
89104046|NCT02853864|Experimental|Propofol and 0.6 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
89523183|NCT03384719|Experimental|35 g protein (30% milk + 70% rapeseed)|35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening
89104047|NCT02853864|Experimental|Propofol and 0.8 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
89104048|NCT02854098||with functional constipation|n = 200 patients with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
89104049|NCT02854098||without functional constipation|n = 200 patient with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
89104050|NCT04269642|Placebo Comparator|PT320 2.0mg Placebo|will be injected subcutaneously once a week for 48 weeks
89104051|NCT04269642|Experimental|PT320 2.0mg treatment 1|will be injected subcutaneously once a week for 48 weeks
89104052|NCT04269642|Experimental|PT320 2.5mg treatment2|will be injected subcutaneously every two weeks for 48 weeks. (Actually, patients will be injected PT320 2.5 mg and placebo alternately once a week.)
89104053|NCT00907257|Experimental|Same time of day|5% benzoyl peroxide wash and 0.04% tretinoin gel used at same time of day
89104054|NCT00907257|Active Comparator|Different times of day|5% benzoyl peroxide wash used in the morning and 0.04% tretinoin gel used in the evening
89104055|NCT01138046|Experimental|Lap+weekly Pacli|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
89104056|NCT02854176|Experimental|Somatosensory electrical stimulation|
89104057|NCT02854176|Sham Comparator|Control|
89104058|NCT02853942|Experimental|Stem cell therapy group|Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.
89104059|NCT02853942|Experimental|Neurotrophic drugs treatment group|Patients were treated with routine drug therapy，do not inject stem cell to the facial nerve of patient
89104060|NCT03484533|Active Comparator|HIV Self-test kit|
89104061|NCT03484533|Active Comparator|Invitation letter-standard of care|
89104062|NCT02854020||An asian airline|
89104063|NCT00876460|Experimental|BIBF 1120 + docetaxel|Low, medium and high dose of BIBF 1120 and 60 mg/m2, 75 mg/m2 docetaxel every 3 weeks
89104064|NCT00908115||Infanrix Group|Subjects received one dose of Infanrix™ at 2, 4 and 6 months of age (primary vaccination), one dose at 15-18 months of age (booster vaccination) and one dose at 4-6 years of age (booster vaccination).
89104065|NCT05551611|Active Comparator|Playgroup|The participants were informed about the research and the mean score was calculated by applying the Vaginal Breech Delivery Management Knowledge Test to the participants before the vaginal delivery management training of the breech-presented fetus was given within the scope of the Risky Delivery and Postpartum Period Course. After playing the mobile game, Vaginal Breech Birth Management Post-Knowledge Test and General Satisfaction Level Test were applied to the participants again. In addition, the Mobile Game Evaluation Form was applied to the participants in the game group and their opinions on the mobile educational game were determined. Test-retest reliability was calculated by applying the Vaginal Breech Delivery Management Knowledge Retention Test 14 days later.
89104066|NCT05551611|Active Comparator|Control group|The participants were informed about the research and the mean score was calculated by applying the Vaginal Breech Delivery Management Knowledge Test to the participants before the vaginal delivery management training of the breech-presented fetus was given within the scope of the Risky Delivery and Postpartum Period Course. On the same date as the playgroup, but at a different time and in a class, the researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method. After the lesson, the Vaginal Breech Birth Management Post-Knowledge Test and the General Satisfaction Level Test were administered to the participants again. Test-retest reliability was calculated by applying the Vaginal Breech Delivery Management Knowledge Retention Test 14 days later.
89104067|NCT01137812|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
89104068|NCT01137812|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
89104069|NCT00679510|Active Comparator|rosuvastatin|Rosuvastatin Patients were randomly allocated rosuvastatin (crestor) 10 mgs. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
89104070|NCT00679510|Placebo Comparator|Placebo|Placebo. Patients were randomly allocated placebo. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
89104071|NCT02626858|Other|extra treatment planning CT-scan|Extra pre-operative CT-scan for treatment planning in RT
89104072|NCT04146220|Experimental|Low dose group|Prednisolone 0.5 mg/kg/day
89104073|NCT04146220|Active Comparator|High dose group|Prednisolone 1 mg/kg/day
89104074|NCT04151056||Patients without social determinant of health|"Patients without any of the five selected social determinants of health / Patients without any of the five selected social diagnosis. Patient with a registered diagnostic  Health check (Z00.00)"
89104075|NCT04151056||"Patients with the social determinantstressful work hours"|"Patients with the selected social determinant of health. Patients with a registered diagnostic stressful work hours  (Z56.3)"
89104076|NCT04151056||"Patients with the social determinant of health living alone"|"Patients with the select social determinant of health . Patients with the selected social determinant of health . Patients with a registered diagnostic  living alone problems (Z60.2)"
89104077|NCT04151056||"Patients with the social determinant of health acculturation"|"Patients with the selected social determinant of health. Patients with a registered diagnostic difficulty acculturation  (Z60.3)"
89104078|NCT04151056||"Patients with the social determinant near surrounding"|"Patients with the selected social determinant of health. Patients with a registered diagnostic other specific problems related to the nearest surroundings (Z63.8)"
89104079|NCT04151056||"Patients with the social determinant unemployment"|"Patients with the selected social determinant of health. Patients with a registered diagnostic unemployment not specified (Z56.0)"
89104080|NCT00681616|Placebo Comparator|1|Compartment Monitoring System with Active Fluid Removal
89104081|NCT00681616|Active Comparator|2|Compartment Monitoring System (CMS) without fluid removal
89104082|NCT00681694||MRBT|MRI-assisted brachytherapy, the experimental arm
89104083|NCT00681694||USBT1|Standard ultrasound-guided brachytherapy performed by group 1 (control arm 1)
89104084|NCT00681694||USBT2|Standard ultrasound-guided brachytherapy performed by group 2 (control group 2)
89104085|NCT04145596|Active Comparator|Compensated Chronic Liver Disease (Child-Pugh A)|
89104086|NCT04145596|Active Comparator|Decompensated Chronic Liver Disease (Child-Pugh B)|
89104087|NCT04145596|Active Comparator|healthy volunteers（Normal liver functions）|
89104088|NCT04051060||Patients with Bronchial Asthma|
89104089|NCT04051060||Healthy individuals|
89523184|NCT03384719|Experimental|35 g protein (54% milk + 46% rapeseed)|35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening
89104090|NCT01137578|Other|Cohort A: US, MRI with contrast, MRI without contrast|Subjects with a central venous catheter (CVC) in place and asymptomatic for a CVC-related DVT to have an Ultrasound (US), Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
89104091|NCT01137578|Other|Cohort B: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place either symptomatic for a CVC-related DVT or having an incidental diagnosis of CVC-related DVT by radiographic imaging performed for other clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
89523185|NCT03384719|Active Comparator|35 g protein (100% milk)|35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening
89104092|NCT01137578|Other|Cohort C: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place having an MRI for clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
89104093|NCT00679666|Sham Comparator|Sham treatment|Subjects are randomized to control (sham) group or a treatment group with the control group crossed over to the treatment group at the 3 month visit.
89104094|NCT00679666|Active Comparator|Treatment Arm|After randomization, the active arm will have the collagen crosslinking intervention.
89104095|NCT00679744|Active Comparator|4 dose levels|Pyrimethamine at 6.25, 12.5, 25 and 37.5 mg/day will be evaluated sequentially, starting from 6.25 mg/day. Escalation from 6.25 mg/day to 12.5 mg/day, and from 12.5 mg/day to 25 mg/day, will not perform until all patients in the previous dose cohort have been treated for 4 weeks and until results obtained 4 weeks after treatment initiation do not reveal toxicity. Additionally, escalation from 25 mg/day to 37.5 mg/day will not perform until all patients in the 25-mg/day cohort have been treated for 8 weeks, and until results obtained 4 weeks after the 8-week treatment do not reveal toxicity. Dose escalation is considered complete, if 2 patients experience a Grade 3 Adverse Event (AE) or if 1 patient experiences a Grade 4 AE at a particular cohort.
89104096|NCT00681772|Experimental|Arm 1|
89104097|NCT00946920|Experimental|Degarelix 240 mg/480 mg|
89104098|NCT00946920|Active Comparator|Goserelin acetate|
89104099|NCT04145830|Experimental|Ultrasound Cyclo Plasty (UCP)|Ultrasound Cyclo Plasty (UCP) using focused ultrasound
89104100|NCT00679822||Heart Failure|Heart Failure Out Patients at OSU
89104101|NCT00681850||1|Control group
89104102|NCT00681850||2|Benchmarking group
89104103|NCT00946530|Experimental|Bright Light|received bright light
89104104|NCT00946530|Placebo Comparator|Control|received regular light
89104105|NCT00946296|Active Comparator|Potassium Iodide|8 drops of Potassium Iodide in a glass of water, by mouth, daily for 7 days prior to operation.
89104106|NCT00946296|No Intervention|No Treatment|The experimental group receives no treatment.
89104107|NCT02853786|Experimental|LENA and advices|With the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
89104108|NCT02853786|Active Comparator|LENA without advices|Regular speech therapy follow blindly the results of LENA
89104109|NCT00679900|Experimental|1|
89104110|NCT00679900|Active Comparator|2|
89104111|NCT00679978||A|A: etidronate
89104112|NCT00945906|Experimental|FXIII|Subjects were administered FXIII Concentrate (Human) by intravenous (IV) infusion approximately every 28 days to maintain a trough FXIII level of approximately 5 to 20%.
89104113|NCT00681928||Breast Cancer patients receiving aromatase treatment|
89104114|NCT00681928||Healthy female controls age 60 and older|
89104115|NCT04269252|Placebo Comparator|CHI-804 at 6 mL|Standard 6 mL dose of placebo oil.
89104116|NCT04269252|Active Comparator|CHI-907 at 1.5 mL|Subjects are assigned to receive one dose of CHI-907.
89104117|NCT04269252|Active Comparator|CHI-907 at 3 mL|Subjects are assigned to receive one dose of CHI-907.
89104118|NCT04269252|Active Comparator|CHI-907 at 6 mL|Subjects are assigned to receive one dose of CHI-907.
89104119|NCT00594646|Other|Group 1|TRUVADA
89104120|NCT02855580||PGX Testing Based Treatment|Treatment will be administered based on the results that are obtained from the pharmacogenomics testing. Results from testing will be provided two weeks after specimen collection.
89104121|NCT02855580||Standard of Care Treatment|Treatment will be based off of the standard of care. Results from pharmacogenomics testing will be provided at the end of the study.
89104122|NCT00680134|Experimental|Group/Cohort 1|AN2690 1% Solution (30 subjects)
89104123|NCT00680134|Experimental|Group/Cohort 2|AN2690 5% Solution (30 subjects)
89104124|NCT02855658|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
89104125|NCT02855658|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
89104126|NCT00680212|Other|1|dietary carotenoids
89104127|NCT02855424|No Intervention|control|traditional rehabilitation merely, no ergocycling training
89104128|NCT02855424|Experimental|the low-intensity exercise group|traditional rehabilitation plus the low-intensity ergocycling exercise training
89104129|NCT02855424|Experimental|the moderate-intensity exercise group|traditional rehabilitation plus the moderate-intensity ergocycling exercise training
89104130|NCT00682006|Experimental|A|In this arm we recruited 2,400 subjects who received Intervention.
89104131|NCT00682006|Experimental|B|In this Arm, we recruited 2,400 subjects who received intervention.
89104132|NCT00682006|Experimental|C|In this Arm, we recruited 2,400 subjects who received intervention.
89104133|NCT00682006|No Intervention|D|In this Arm, we recruited 2,400 subjects for Observation and comparison. This was the prime control group.
89104134|NCT02855346|Experimental|200 mg of DPV|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
89104135|NCT02855346|Experimental|200 mg of DPV + 320 mg LNG|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
89104136|NCT00682084||1|Patients recently diagnosed with Cushing's syndrome
89104137|NCT02855190|Experimental|68Ga-citrate and 18F-FDG PET scans|The recruited subject with surgery/pathology proved periprosthetic joint infection will undergo total four PET scans at two different stages. At first stage, subsequent FDG PET/CT and Ga68 citrate PET/CT scans on different two days will be arranged before infective prosthesis is removed. Eight to twelve weeks after the 1st stage operation, patient will receive two subsequent PET/MR scans using Ga-68 Citrate and FDG on different two days, respectively. For the subject without surgery/pathology proved infection, PET/MR scans will NOT be applied.
89104138|NCT00680290|Experimental|1|Exercise group
89104139|NCT00682162|Sham Comparator|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
89104140|NCT00682162|Active Comparator|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
89104141|NCT02627404|Other|Main module|Blood sample
89104142|NCT04150978|Active Comparator|5% Dextrose|the parenteral formulation as prescribed by the intensive care specialist
89104143|NCT04150978|Experimental|High Protein Polymeric Formula|"Procedure :~The daily calorie and protein prescriptions were calculated from standard recommendations (calories 25-30 kcal/kg/d, proteins 1.2-2 g/kg/d)~Administered as boluses via a nasogastric tube. A total of 5 aliquots were administered at 4-hourly intervals in a daily feeding period of 24 hours, with the participant positioned 30° head-up."
89104144|NCT04150978|Experimental|Oligomeric Formula|Similar to the High Protein Polymeric Formula Procedure
89104145|NCT00682240|Active Comparator|group 3|"Group 3: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation.~Intervention: All patients will receive a multi-session panretinal laser treatment according to the conventional protocol, using a conventional laser system."
89104146|NCT00682240|Active Comparator|group 2|"Group 2: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group 2.~Intervention: This group will receive multi-session panretinal laser treatment. The treatment will be performed using Pascal laser system."
89104147|NCT00682240|Active Comparator|group 1|"Group 1: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group1.~Intervention: One group will receive a single-session panretinal laser treatment, performed using Pascal laser system."
89104148|NCT00682240|Active Comparator|group 4|"Group 4: 20 patients with persistent central or para-central diabetic macular edema receiving focal or grid laser treatment. As the treatment will be performed according to the conventional protocol (single spot), only the Pascal laser system will be used.~Intervention: focal or grid laser treatment"
89104149|NCT00684502|Experimental|1|Oral solution.
89104150|NCT00684502|Placebo Comparator|2|Oral solution
89104151|NCT01111604|Active Comparator|mFOLFOX-6|mFOLFOX-6
89104152|NCT01111604|Experimental|mFOLFOX-6 + Ramucirumab|mFOLFOX-6 + Ramucirumab
89104153|NCT01111604|Experimental|mFOLFOX-6 + Icrucumab|mFOLFOX-6 + Icrucumab
89104154|NCT00950742|Experimental|BIBW 2992 + Trastuzumab|Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally with fixed weekly infusion doses of 2mg/kg Herceptin. Escalating doses of BIBW 2992 starting at 20mg daily.
89104155|NCT04310228|Experimental|Favipiravir Combined With Tocilizumab group|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
89104156|NCT04310228|Active Comparator|Favipiravir group|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
89104157|NCT04310228|Active Comparator|Tocilizumab group|The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
89104158|NCT02881502||healthy control group|Mainly from students, family members of patients without chronic lung disease, healthy population, age 18-75 years old, the gender is not limited.
89104159|NCT02881502||mild and moderate asthma group|Patients diagnosed with asthma in the outpatient clinic, in accordance with the inclusion criteria and exclusion criteria.
89104160|NCT02881502||severe asthma group|Outpatient patients with severe asthma diagnosis, in accordance with the inclusion criteria and exclusion criteria.
89104161|NCT00955110|Experimental|Oxymorphone ER 15 mg|15mg
89104162|NCT00955110|Active Comparator|Oxycodone CR 30 mg|30mg
89104163|NCT00955110|Placebo Comparator|Placebo|
89104164|NCT00955110|Experimental|Oxymorphone ER 30mg|30mg
89104165|NCT00955110|Active Comparator|Oxycodone CR 60mg|60mg
89104166|NCT05056142|Active Comparator|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL
89104167|NCT05056142|Active Comparator|Spinal Anesthesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
89104168|NCT00950664|Experimental|Dysport® to Botox®|Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
89104169|NCT00950664|Experimental|Botox® to Dysport®|Botox® injection in first intervention period and Dysport® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
89104170|NCT02855112|No Intervention|Control|A group of 10 patients only will be subjected to electro-myogram test every 3 month and then follow up for their survival time without any cell therapy intervention.
89104171|NCT02855112|Experimental|Adipose derived Mesenchymal Stem cell|A group of 10 patients will be take stem cells intra-thecally Dose: 1 million cells/kg for three times Intervals: Every 3 weeks.
89104172|NCT01111526|Experimental|LBH589, in Addition to Glucocorticoids|Phase I Dose Escalation, Followed by Phase II Treatment at Maximum Tolerated Dose (MTD) of LBH589, in Addition to Glucocorticoids.
89104173|NCT02881346||Enstilar®|Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.
89104174|NCT00630708|Active Comparator|1|Benazepril group
89104175|NCT00630708|Active Comparator|2|Losartan group
89104176|NCT00630708|Active Comparator|3|Benazepril+Losartan group
89104177|NCT01111292|Experimental|Arm I (inositol)|Beginning within 14 days after colonoscopy, patients receive inositol PO QD on days 1-14 and BID on days 15-90.
89104178|NCT01111292|Placebo Comparator|Arm II (placebo)|Beginning within 14 days after colonoscopy, patients receive placebo PO QD on days 1-14 and BID on days 15-90.
89104179|NCT04269330|Sham Comparator|1-Normal size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
89104180|NCT04269330|Active Comparator|2- small size mesh in open inguinal herni|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
89104181|NCT02881736|Experimental|Pateint with chronic stroke|
89104182|NCT02881736|Active Comparator|Healthy volunteer|
89104183|NCT02853630|Active Comparator|Metformin|Tablet Metformin 1000 - 2500 mg/day for 96 weeks
89104184|NCT02853630|Experimental|Vildagliptin|Tablet Vildagliptin 100mg/day for 96 weeks
89104185|NCT04310384|Active Comparator|Endotracheal Intubation, gold standart|Standart of Care with Macintosh laryngoscope
89104186|NCT04310384|Active Comparator|Alternative|Endotracheal Intubation with novel device
89104187|NCT05367206|Experimental|NAC plus RCT|two circles of NAC with albumin-bound paclitaxel and carboplatin followed by standard chemoradiation with weekly cisplatin plus pelvic radiation
89104188|NCT05367206|No Intervention|RCT|standard chemoradiation with weekly cispatin plus pelvic radiation
89104189|NCT00944658|Placebo Comparator|Placebo|placebo twice a day for 12 weeks, 4 weeks follow up
89104190|NCT00944658|Active Comparator|Apremilast|30 mg twice a day for 12 weeks, 4 weeks follow up
89104191|NCT04269798|Active Comparator|Traditional Treatment Arm|Will receive conventional rehabilitation program for the lower limbs, balance and gait training. Two hours of conventional physical therapy program /session - 3 sessions/week/ three successive months.
89104192|NCT04269798|Experimental|Functional Electrical Stimulation Group|Will receive 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
89104193|NCT01110200|Active Comparator|ADVAIR DISKUS 250/50 mcg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
89104194|NCT01110200|Active Comparator|Serevent 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
89104195|NCT04309994||Experimental|bypass surgery with blood cardioplegia by means of MPS
89104196|NCT04309994||Active Comparator|bypass surgery with blood cardioplegia by means of Cardioplexol ®
89104197|NCT01108796||Patients at cardiovascular risk|
89104198|NCT02881424||alcohol-dependent patients|a group of 34 alcohol-dependent patients, currently abstinent
89104199|NCT02881424||healthy controls|a group of control subjects, without neurologic or psychiatric disease, matched for age and sex with the alcohol-dependent participants
89104200|NCT01108718|Experimental|Participants: Tempur Pedic first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder who receive the Tempur-Pedic mattress first, then the Control Mattress.
89104201|NCT01108718|Placebo Comparator|Participants: Control Mattress first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic mattress.
89104202|NCT04312646||patients with thyroid nodules|
89104203|NCT01137110|Other|Brief LEV|Administration of three days of levetiracetam twice daily after SAH
89104204|NCT01137110|Other|Extended LEV|Administration of levetiracetam twice daily after SAH
89104205|NCT05367050|Active Comparator|Treatment|"Patients participate in the Lucid Lane therapy program including working with a mental health pain coach for up to 4 weeks before surgery and 4 weeks after surgery.~All patients receive therapy provided by Lucid Lane, for 4 weeks after surgery"
89104206|NCT05367050|Active Comparator|Control|"Patients will participate in a a surgery preparedness course provided by the VA before surgery (Standard of Care) and Lucid Lane therapy after surgery~All patients receive therapy provided by Lucid Lane, for 4 weeks after surgery"
89104207|NCT01136954|Experimental|1|
89104208|NCT01136876|Active Comparator|Iopamidol|Non-ionic low-osmolar iodinated contrast media
89104209|NCT01136876|Active Comparator|Iodixanol|Non-ionic iso-osmolar iodinated contrast media comparator
89104210|NCT02880332|Active Comparator|Usual care + Extra care|This group will receive usual care and one additional session; extra care.
89104211|NCT02880332|Experimental|Usual care + PNE|Next to usual care, this group will also receive pain neuroscience education.
89104212|NCT01105130|Placebo Comparator|Arm I - Placebo|Patients receive oral placebo twice daily (total of 6 capsules per day).
89104213|NCT01105130|Experimental|Arm II - low dose|Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
89104214|NCT01105130|Experimental|Arm III - high dose|Oral L-arginine twice daily = 6 capsules per day.
89104215|NCT01108094|Experimental|Cohort A - Itraconazole 400 mg|Oral itraconazole 400 mg as 200 mg twice daily, for 1 month, stratified by prior vismodegib history
89104216|NCT01108094|Experimental|Cohort B - Itraconazole 200 mg|Oral itraconazole 200 mg as 100 mg twice daily, for up to 3 months
89104217|NCT01108094|No Intervention|Untreated Control|Patients otherwise eligible but unwilling to take itraconazole were enrolled onto the control arm of the study and received no treatment
89104218|NCT04310072|Experimental|neuromuscular electrical stimulation group|"For patients who underwent NMES therapy, four electrodes (two 50/100 mm and two 50/50 mm, Compex Performance) were placed on the skin above the quadriceps muscle approximately 5 cm below the inguinal fold and 3 cm above the upper patella border.~The electrical stimulation protocol consisted of electrical current at frequency of 10 Hz, 20 seconds stimulation time (time on) and 20 seconds resting time (time off) with variable intensity (until visible muscular contraction) for one hour per day until discharge (Compex).The NMES therapy was on top of conventional rehabilitation described below."
89104219|NCT04310072|No Intervention|Control group|"The control group consisted of patients who performed daily active upper and lower limbs exercise in bed and in a stand position (3x10 repetitions, somewhat hard on the Borg scale)."
89104220|NCT00954174|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1.
89104221|NCT00954174|Experimental|Arm II (paclitaxel, ifosfamide)|Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I.
89104222|NCT02854878|Experimental|treatment|
89104223|NCT04312724|Active Comparator|Clinical need|Participants enrolled that require a new socket.
89104224|NCT04312724|Experimental|No clincal need|Participants enrolled that do not require a new socket
89104225|NCT04312334|Experimental|Treatment 1|Treatment 1: Hand cleaning with the Supertowel for 15 seconds. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recorded by means of weighing the towel before and after soaking. The volunteers will use the soaked Supertowel for 15 seconds to clean their pre-contaminated hands.
89104226|NCT04312334|Experimental|Treatment 2|Treatment 2: Hand cleaning with a Supertowel that is damp for 60 seconds The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The water on the Supertowel will then be squeezed out so that it is not dripping. The Supertowel will be weighed before soaking and after squeezing. Volunteers will clean their pre-contaminated hands with the damp Supertowel for 60 seconds.
89104227|NCT04312334|Experimental|Treatment 3|"Treatment 3: Hand cleaning for 60 seconds with a Supertowel that has been soaked in contaminated water.~A Supertowel will be soaked in water which has artificially contaminated with non-pathogenic E.coli. The water will be designed to mimic highly contaminated grey water so it will be contaminated at 2,000 cfu/100 ml which is double the acceptable level of contamination for handwashing. Volunteers will clean their pre-contaminated hands with the contaminated Supertowel for 60 seconds."
89104228|NCT04312334|Experimental|Treatment 4|"Treatment 4: Hand cleaning for 60 seconds with a Supertowel that is visibly dirty and oily.~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water .The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 60 seconds."
89104229|NCT04312334|Experimental|Treatment 5|"Treatment 5: Hand cleaning for 30 seconds with a Supertowel that is visibly dirty and oily and it is soaked in whater which has artificially contaminated with non-pathogenic E.coli.~The Supertowel will be made visibly dirty and oily for example, by immersing it in a mix of 10 grams of sterile soil (previously autoclaved), 1 ml of clean cooking oil and 100 ml of water (which will be contaminated with E.coli).The Supertowel will be rubbed against itself to ensure the soil and oil are spread out across the surface of the Supertowel. Volunteers will clean their pre-contaminated hands with the dirty Supertowel for 30 seconds."
89104230|NCT04312334|Experimental|Treatment 6|Treatment 6: Hand cleaning with the Supertowel which is fully dry for 60 seconds.
89104231|NCT04312334|Other|Control 1|Control 1: Hand washing with bar soap and water for 15 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 15 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
89104232|NCT04312334|Other|Control 2|"Control 2: Handwashing with bar soap and water for 60 seconds The control group will wash their pre-contaminated hands with normal bar soap and water for 60 seconds by following the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps was given to them, appendix). After handwashing, hands will be allowed to dry for 3 minutes"
89104233|NCT04312334|Other|Control 3|"Control 3: Handwashing with bar soap and contaminated water for 60 seconds. Water which is contaminated with non-pathogenic E.coli. at 2,000 cfu/100ml will be stored in a bucket which has a tap at the base. The control group volunteers will wash their hands with the contaminated water and bar soap for 60 seconds. They will follow the WHO guidelines for handwashing when hands are visibly soiled (a diagram of the steps will be given to them). After handwashing, hands will be allowed to dry for 3 minutes."
89104234|NCT04312334|Other|Control 4|Control 4: Hand cleaning for 60 seconds with a clean Supertowel. The Supertowel will be soaked in water by submersing it completely in a bucket filled with tap water. The amount of water absorbed by the ST will be recordedby means of weighing the Supertowel before and after soaking. The control group will clean their pre-contaminated hands of with thesoaked Supertowel for 60 seconds.
89104235|NCT04312334|Other|Control 5|Hand washing with bar soap and water for 30 seconds. The control group will wash their pre-contaminated hands with normal bar soap and water for 30 seconds. Hands from volunteers washed with soap will be allowed to dry for 3 minutes.
89104236|NCT04309058|Experimental|Vitamin D drops|This group of patients are going to supplemented with Vitamin D drops 400IU / d orally.
89104237|NCT04309058|No Intervention|Control|The other group do not interfere.
89104238|NCT01136408|Experimental|Dabigatran etexilate 220 mg daily|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
89104239|NCT01136408|Experimental|Dabigatran etexilate 300 mg daily|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
89104240|NCT01136408|Active Comparator|Warfarin|Dose-adjusted warfarin based on target INR values
89104241|NCT01136174|Experimental|BIBF 1120 50 mg|Low dose for cohort 1
89104242|NCT01136174|Experimental|BIBF 1120 100 mg|Middle dose for cohort 2
89104243|NCT01136174|Experimental|BIBF 1120 150 mg|High dose for cohort 3
89104244|NCT01136174|Placebo Comparator|Placebo|Placebo for cohort 1,2,3
89104245|NCT02883218||Comunity-acquired severe sepsis patients|Patients with new-onset community-acquired severe sepsis within 24h without confounding factors in immune status
89104246|NCT02883218||Non-severe sepsis patients|Patients between 18 and 90 years of age and be admitted to the ICU without a diagnosis of severe sepsis.
89104247|NCT02883218||Healthy controls|Heathy vonlunteers between 18 and 90 years of age.
89104248|NCT04309760|Active Comparator|gender dysphoria subjects|Patients with MtF gender dysphoria (biological men who are transitioning to the female gender) attending the forensic psychiatric consultation for a request for hormone-surgical reassignment. Subjects will receive initial clinical assessment and MRI before and 6 months after initiation of hormone therapy
89104249|NCT04309760|Other|control subjects|Control group inclusions, of open-label patients without gender dysphoria.
89104250|NCT02881190|Experimental|RC48-ADC|The phase I component has several dose levels of RC48-ADC (0.1mg/kg，0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/kg) and is designed as a traditional dose-escalation study.Dosing interval is once two weeks.
89104251|NCT02881034||Hepatitis C patients|Hepatitis C virus (HCV) infected patients with a previous non-response to pegylated-interferon/ribavirin therapy and re-treated with pegylated-interferon/ribavirin and telaprevir
89104252|NCT00949884|Experimental|Olmesartan|Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
89104253|NCT00949884|Placebo Comparator|Placebo followed by Olmesartan|Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks
89104254|NCT00949884|Active Comparator|Losartan|Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks
89104255|NCT00949650|Experimental|BIBW 2992|BIBW 2992 tablet once daily until progression
89104256|NCT00949650|Active Comparator|Cisplatin/Pemetrexed|Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles
89104257|NCT00908037|Experimental|eltrombopag plus standard of care|eltrombopag
89104258|NCT00908037|Placebo Comparator|placebo plus standard of care|placebo
88812642|NCT03145688|Experimental|Family Physical Activity Habit Formation|Behavioural: Family Physical Activity Habit formation. The Habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
88812643|NCT00889226|Experimental|Pitavastatin Group|
89104259|NCT00631098|Experimental|1|Cannulation of external jugular vein and cannulation of cubital vein
89104260|NCT03082755|Experimental|Gabapentin Enacarbil (GEn)|1 to 2 GEn tablets (300 mg) will be administered by mouth (PO) once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The study drug will be adjusted up to a maximum dosage of 600 mg as tolerated.
89104261|NCT03082755|Placebo Comparator|Placebo|1 to 2 Placebo Oral Tablet(s) will be administered once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The placebo drug will be adjusted up to a maximum dosage of 2 tablets as tolerated.
89104262|NCT05332353||BCG responders|Non-muscle invasive bladder cancer patients who do not have T1/Ta HG recurrence within 6 months of adequate BCG therapy.
89104263|NCT05332353||BCG non-responders|Non-muscle invasive bladder cancer patients who have T1/Ta HG recurrence within 6 months of adequate BCG therapy or CIS within 12 months of BCG therapy
89104264|NCT05351853|Other|Control Group|20 healthy individual will be in the control group. Participants of control group will not change their diet and will continue omnivore diet.
89104265|NCT05351853|Other|Vegetarian|20 healthy individual will be in the control group. Participants of this group will change their diet from omnivore to vegetarian (no meat /meat products) after the beginning of the study.
89104266|NCT05351853|Other|Vegan|20 healthy individual will be in the control group. Participants of this group will change their diet from omnivore to vegan (%100 plant based) after the beginning of the study.
89523186|NCT04476329|Active Comparator|A|"Arm A: Regorafenib Cycle 1:~80 mg daily Week 1~120 mg daily Week 2~160 mg daily week 3 then 1 week off followed by Cycle 2+ (160 mg for 21 days/1 week off) Subsequent Treatment Cycles~160 mg daily for 21 days, then 1 week off."
89523187|NCT04476329|Active Comparator|B|"Arm B: Regorafenib Cycle 1:~160 mg daily for 21 days/then 1 week off Subsequent Treatment Cycles~160 mg daily for 21 days, then 1 week off"
89104267|NCT05332197|Experimental|17D Yellow fever vaccine|"All children will receive a single shot of the 17D Yellow fever vaccine. This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. This vaccine is presented as a 10 dose vial with freeze-dried content which is reconstituted with a diluent, provided with the vaccine by the manufacturer. Reconstituted vaccines have to be kept in a vaccine carrier at 2-8°C as per WHO and manufacturer requirements. Any remaining reconstituted vaccine not used has to be discarded after 6 h. The standard dose is 0·5 ml and is administered subcutaneously in the deltoid region using standard vaccination syringes (needle size 25G × 3/4) with a 45° injection angle"
89104268|NCT05234073|Experimental|Experimental: A (first group to receive the intervention)|The class will be instructed in the social emotional and ethical learning (SEELearning) for 4 weeks.
89104269|NCT05234073|Experimental|Experimental: B (second group to receive the intervention)|This arm will not receive intervention in the first month and will receive SEE Learning after this period.
89104270|NCT05317689|Active Comparator|Oral & Sublingual Psilocin, & Oral Psilocybin|Every participant will be administered Oral Psilocin, Sublingual Psilocin, and oral psilocybin in a randomized order.
89104271|NCT05317689|Active Comparator|Sublingual Psilocin|Depending on a number of factors, participants may complete a fourth session where they receive sublingual psilocin for the second time.
89104272|NCT03026127|Experimental|CRISP|Cognitive Reappraisal Intervention for Suicide Prevention (CRISP) is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
89104273|NCT03026127|Active Comparator|Supportive Therapy (ST)|Supportive Therapy focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
89104274|NCT03015753|Experimental|Tai Chi training|The participants in this arm will receive 12-week Tai Chi training (1 hour per day, 5 days per week).
89104275|NCT03015753|Other|Waiting list control group|Participants in this arm will be asked to maintain their usual lifestyles and exercises for 12 weeks. At the end of the trial , the participants will be offered Tai Chi training similar as Tai Chi group.
89104276|NCT05166915|Experimental|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2.
88812644|NCT00889226|Active Comparator|Atorvastatin Group|
89104277|NCT05166915|Sham Comparator|Sham Control Device|Sham Control Device
89104278|NCT02664207|Experimental|Fetal Surgery in Women with ex|"Fetal myelomeningocele repair surgery will be offered to pregnant women meeting the criteria for surgery (as set by the MOMS trial) with the exception of the following:~a BMI greater than 35 (but less than or equal to 40 kg/m2)~(minor) Fetal structural abnormality~(well-controlled) Diabetes~Previous preterm delivery (followed by a full term delivery)~Maternal red cell alloimmunization (must NOT be associated with fetal disease, OR fetus must have negative red cell antigen status as determined by amniocentesis).~Intervention: Open Fetal Repair of Myelomeningocele"
89104279|NCT05273541|Experimental|Prime-boost vaccination|Patients in the experimental group need to accept the prime-boost vaccination regimen
89104280|NCT05293665|Experimental|double-blind UB-612 boost of ChAdOx1-S|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with ChAdOx1-S.
89227758|NCT05271071|Active Comparator|Piriformis Muscle group|30 patients in the piriformis muscle group will be evaluated with detailed physical examination and special clinical tests. Sensitivity with sonopalpation, piriformis and gluteus maximus thicknesses, echo intensities will be evaluated with ultrasonography. Primarily diagnostic injection test for piriformis muscle (piriformis syndrome) is planned for the first group with lidocaine with USG guide. At the first hour after injection full examination will be repeated for all patient and will be evaluated again with Numeric Rating Scale(NRS) at rest, with movement and with deep palpation. If the NRS score persists after the first injection patients will receive a diagnostic lidocaine injection into the gluteus Maximus muscle. At the first hour after the second injection, the physical examination and clinical tests of the patients will be repeated, and their pain at rest, with movement and with deep palpation will be evaluated with NRS.
89227759|NCT00972062|Placebo Comparator|Placebo cream|Cream base used in compounding medications into cream media
89227760|NCT00972062|Experimental|Herbal Cream|Herbal cream (Bach's Rescue Remedy Cream) applied to skin site reactions from MS medications
89227761|NCT00972140|Experimental|Formoterol-HFA|Formoterol-HFA pMDI 12µg twice daily
89227762|NCT00972140|Active Comparator|Formoterol-DPI|Formoterol-DPI 12µg twice daily
89227763|NCT05261945|Experimental|Routine Physical Therapy|"Electrotherapy~Exercises.~Electrotherapy Hot pack Patients will be in prone position and for relaxation pillow will place beneath the abdomen. Then to reduce muscle spasm and to induce vasodilation hot pack will use for 15 minutes. Treatment with hot pack helps in improving and relaxing the muscle spasm and soft tissue elasticity.~TENS TENS will be of 50 Hz, duration of pulse will be<150 microseconds, for 15 minutes to reduce pain.~TENS and Hot Pack will use at the same time for 15 minutes.~Ultrasound Ultrasound's gel will be applied on outer surface of skin with 2-3 mm thickness. Then ultrasound which frequency will be 1MHz applied for 5 min.~• Exercises Passive Range of Motion exercises for 10 minutes~Neck Flexion~Neck Side bending~Neck Rotation~Isometric neck flexion~Isometric neck extension~Isometric neck side bending~These exercises will repeat 3 times within the treatment program."
89523188|NCT03388099||patients with FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
89104281|NCT05293665|Active Comparator|double-blind ChAdOx1-S boost|A single injection of ChAdOx1-S on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with ChAdOx1-S.
89104282|NCT05293665|Experimental|double-blind UB-612 boost of BNT162b2|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with BNT162b2
89104283|NCT05293665|Active Comparator|double-blind BNT162b2 boost|A single injection of BNT162b2 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with BNT162b2.
89104284|NCT05293665|Experimental|double-blind UB-612 boost of Sinopharm BIBP|A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with Sinopharm BIBP.
89104285|NCT05293665|Active Comparator|double-blind Sinopharm BIBP|A single injection of Sinopharm BIBP on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with Sinopharm BIBP.
89104286|NCT05293665|Experimental|open-label UB-612 boost of BNT162b2|A single injection of UB-612 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with BNT162b2.
89104287|NCT05293665|Active Comparator|open-label BNT162b2 boost|A single injection of BNT162b2 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with BNT162b2.
89104288|NCT03013257|Experimental|High Intensity Focused Ultrasound|Try to use the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the relapsed Graves' disease
89104289|NCT03013257|No Intervention|Fixed-dose radioiodine-131|Using the traditional treatment, fixed-dose radioiodine-131, to treat the relapsed Graves' disease
89104290|NCT00905307|Experimental|1|OPC-34712 0.25 mg arm
89104291|NCT00905307|Experimental|2|OPC-34712 low-dose arm
89104292|NCT00905307|Experimental|3|OPC-34712 mid-dose arm
89104293|NCT00905307|Experimental|4|OPC-34712 high-dose arm
89104294|NCT00905307|Placebo Comparator|5|
89104295|NCT00905307|Active Comparator|6|Aripiprazole arm
89104296|NCT02988453|Experimental|MBT-CD|Mentalization-based treatment program
89104297|NCT04227171||FSH only|GnRH agonist protocol & GnRH antagonist protocol
89104298|NCT00907881||All participants|Participants with type 2 diabetes mellitus (T2DM) who had sulfonylurea treatment added to an on-going regime of oral hypoglycemic agent(s).
89104299|NCT00904917|Experimental|Adapted PIP|"Participants (both mother and children) participated in an adapted cognitive family prevention program for the families of children with a depressed African American mother.~The intervention was the Prevention Intervention Project."
89104300|NCT00904917|Active Comparator|Lecture|"Mothers received psychoeducation about depression.~The intervention was psychoeducation."
89104301|NCT00904839|Experimental|BIBF 1120 + mFolfox6|BIBF1120 medium dose twice daily
89104302|NCT00904839|Active Comparator|Bevacizumab + mFolfox6|Bevacizumab 5mg/kg once daily every other week
89104303|NCT02505711|Experimental|Homestead Food Production|Enrolled in Homestead Food Production program from 2015 to 2019, 48 clusters, approx. 1350 women and 750 children
89104304|NCT02505711|No Intervention|Control|(Health system strengthening in the study area), 48 clusters, approx. 1350 women and 750 children
89104305|NCT04724265|Experimental|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation
89104306|NCT04985955|Experimental|Candin + Tofacitinib|Participants will receive a single dose of Candin injection on forearm of 1 arm along with a saline solution injection of 0.9 percent (%) sodium chloride (NaCl) on the opposite forearm on Day 3 and oral dose of tofacitinib for 5 days.
89104307|NCT04985955|No Intervention|Candin Challenge|All participants will receive a single dose of Candin injection on forearm of 1 arm along with a saline solution injection of 0.9% NaCl on the opposite forearm on Day 3.
89104308|NCT02821923|No Intervention|Control|no treatment
89104309|NCT02821923|Active Comparator|E967-Xylitol|24g xylitol/d
89104310|NCT02821923|Active Comparator|E968-Erythritol|36g erythritol/d
89104311|NCT04713813|Active Comparator|Exercise group 1(Exercise via mechanical horse-riding simulator)|Exercise via mechanical horse-riding simulator; Subjects remained in sitting position for 30 minutes on the simulator during these sessions, with extension of the trunk and stabilization of the pelvis. Feet were placed on the footplates as the simulator produced a rhythmic and repetitive movement similar to a walking horse. The simulator can produce several modes of rhythmic and repetitive motions.
89104312|NCT04713813|Active Comparator|Exercise group 2 (Home exercises)|Home exercises will be consist of a warm-up, stretching, balance, back walking, fingertip walking exercises, the first of which is shown by the physiatrist or physiotherapist to the patients. These patients will be called twice a month to ask whether they have done the exercises, and the patients whose participation rate is below 80% will be excluded from the study by following the exercise schedule when they come to the physician's control monthly.
89104313|NCT02850549|Other|physical therapy|Physical Therapy intervention provided by therapists in phase one without training in following a neck classification system and in phase two after being trained to follow a neck pain classification system.
89104314|NCT00903357|Experimental|Montelukast first, then placebo|The group received active medication (montelukast 4 mg or 5mg once daily) for 8 weeks followed by a crossover to 8 weeks of placebo after 2-weeks washout period.
89104315|NCT00903357|Experimental|Placebo first, then Montelukast|The group received placebo medication (ascorbic acid) for 8 weeks followed by a crossover to 8 weeks of active medication (montelukast 4 mg or 5mg once daily) after 2-weeks washout period.
89104316|NCT02446665|Experimental|PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
89104317|NCT02446665|Active Comparator|Non-PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
89104318|NCT02796573|Experimental|B-CBT|6 face-to-face consultations plus 6 online modules.
89104319|NCT02796573|Active Comparator|Face-to-Face CBT|12 face-to-face consultations.
89104320|NCT04651725|Active Comparator|Exercise group 1: Exercise via mechanical horse-riding simulator|All patients in both groups were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
89104321|NCT04651725|Active Comparator|Exercise group 2: Home exercises|Home exercises will be consist of a warm-up, stretching, balance, back walking, fingertip walking exercises, the first of which is shown by the physiatrist or physiotherapist to the patients. These patients will be called twice a month to ask whether they have done the exercises, and the patients whose participation rate is below 80% will be excluded from the study by following the exercise schedule when they come to the physician's control monthly.
89104322|NCT04632771||Pilot survey: non-pregnant, non-lactating women|Survey of non-pregnant, non-lactating women 15-49 years of age (n=250)
89104323|NCT04632771||Pilot survey: lactating women|Survey of lactating women 15-49 years of age who are currently breastfeeding a child 4-18 months of age (n=250)
89104324|NCT04632771||Pilot survey: children|Survey of children 2-5 years of age (n=250)
89104325|NCT04632771||RID Pilot 1|Two-week study to assess total body vitamin A stores in a sample of non-pregnant, non-lactating women 15-49 years of age (n=30)
89104326|NCT04632771||RID Pilot 2|"Kinetic study with Super-woman design to develop a prediction equation to assess total body vitamin A stores among non-pregnant, non-lactating women 15-49 years of age (n=123)"
89104327|NCT04632771||Focus group discussions|Focus group discussions conducted among women of reproductive age, older women, and men (n=120 total)
89104328|NCT04632771||Market assessment|Survey of retail outlets selling fortified staple foods and/or bouillon (n=50 shop owners or operators)
89104329|NCT04632771||Recipe observations|Observations of cooking of local dishes by selected participants (n=50) enrolled in the pilot survey.
89104330|NCT02754063|Active Comparator|ICP Management|
89104331|NCT02754063|Experimental|PbtO2 + ICP Management|
89104332|NCT02749305|Other|Preop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures preoperatively and annually postoperatively will occur with all metabolic and bariatric surgery patients scheduled for surgery at a participating center.
89104333|NCT02749305|Other|Postop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures annually postoperatively will occur with all metabolic and bariatric surgery patients who had surgery at a participating center within the preceding 12 months.
89104334|NCT00904371||Patients with arterial hypertention|
89104335|NCT02208765|Other|Study cohort|Any patient referred to the Nuclear Cardiology Laboratory of the University Hospital of Grenoble for myocardial perfusion imaging for diagnosis or prognosis evaluation of suspected or know coronary artery disease
89104336|NCT02847351|Placebo Comparator|Control Diet (CD)|Period 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.
89104337|NCT02847351|Experimental|Arabinoxylan Diet (AXD)|Period 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour
89104338|NCT04202289|Active Comparator|Silver Sulfadiazine Cream 1%|In the control group, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of Silver Sulfadiazine Cream 1% was applied and covered with gauze and bandage. The dressing changes occurred every 48 hours. The patients were evaluated every 48 hours for the study parameters.
89104339|NCT04202289|Experimental|Nile Tilapia Fish Skin|In the test group, the treatment was Nile Tilapia Fish Skin, which have a patent registered at the National Institute of Industrial Property (INPI) under number BR 10 2015 021435 9. Nile Tilapia Fish Skin was subjected to a rigorous process of chemical sterilization, glycerolization and irradiation, followed by microbiological tests for bacteria and fungi, before storage in sterile refrigerated packaging. Prior to its use in the patient, the skin was washed thrice in sterile 0.9% saline for 5 minutes, in order to remove glycerol. Regarding application in the study patients, after cleaning the lesion with tap water and 2% chlorhexidine gluconate, Nile Tilapia Fish Skin was applied and covered with gauze and bandage. Throughout the treatment, dressings with Nile Tilapia Fish Skin were only changed if the biomaterial was not properly adhered to the wound bed. The patients were evaluated every 48 hours for the study parameters.
89104340|NCT02850003|Experimental|IDP-120 Gel|Gel
89104341|NCT01730313|Experimental|Pyridoxine (B6)|Oral pyridoxine, 30- 50 mg/kg/day in one daily dose (powder form)for a period of four weeks followed by cross-over to Phenytoin arm for another four weeks
89104342|NCT01730313|Experimental|Phenytoin|Phenytoin Oral, 5 mg/kg/day in two equally divided doses(powder form)for a period of four weeks and then cross-over to Pyridoxine arm for another four weeks
89104343|NCT01730313|Experimental|Sodium Valproate|Sodium valproate oral, 10 - 15 mg/kg/day once daily powder form)for a period of four weeks and then cross-over to placebo arm for another four weeks
89104344|NCT01730313|Placebo Comparator|Placebo|Placebo will consist of an inert substance (e.g., gelatin) with an appearance similar to medication in similar dosage as the study arms for a period of 4 weeks and subsequent cross-over to Sodium Valproate arm
89104345|NCT02849925|Experimental|Glass Ionomer Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of Glass ionomer sealant, EQUIA (GC) in first permanent molars.
89104346|NCT02849925|Active Comparator|Resin Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of resin sealant, Clinpro (3M-ESPE) in first permanent molars
89104347|NCT02849769||Patients implanted with an MR-conditional Tachy device system|Patients implanted with an MR-conditional Tachy device system in the routine care
89104348|NCT02849691||Quartile 1|Quartile 1 of plasma DPP4 activity
89104349|NCT02849691||Quartile 2|Quartile 2 of plasma DPP4 activity
89104350|NCT02849691||Quartile 3|Quartile 3 of plasma DPP4 activity
89104351|NCT02849691||Quartile 4|Quartile 4 of plasma DPP4 activity
89104352|NCT02849379|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89104353|NCT02849379|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89104354|NCT02847663|Experimental|Whole-body cryotherapy|The effects of whole-body cryotherapy (-135°C for 2 minutes) are investigated after a muscle damage protocol.
89104355|NCT02847663|Other|Cold-water immersion|The effects of cold-water immersion (10°C for 15 minutes) are investigated after a muscle damage protocol.
89104356|NCT01104662|Experimental|Daptomycin, Bacteremia, Severe Renal Impairment|Cohort 1. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with Creatinine Clearance (CLcr) below 30 milliliters per minute (mL/min) and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 14 to 42 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 14 to 42 days based on disease resolution or Investigator discretion.
89227764|NCT05261945|Experimental|Manual Therapy And Routine Physical Therapy|"The routine physical therapy will be applied first, in which electrotherapy will applied for 20 mins, TENS and hot pack for 15 mins, ultrasound for 5 mins.~Manual therapy~Natural Apophyseal Glides The natural apophyseal glides, which will be applied between C2 and C7, will be the Manual Muscle Testings first action. Patients may request to sit and lean on a chair. The oscillatory motions will reapply the mobilization.~Sustained Natural Apophyseal Glides Sustained Natural Apophyseal Glides will be a mixture of mobilization and active gestures/movements.~5 repetitions for 10 minutes of each."
89227765|NCT05261945|Experimental|Stretching Exercises And Routine Physical Therapy|"The routine physical therapy will be applied first, in which electrotherapy will applied for 20 minutes, TENS and hot pack is applied for 15 minutes at the same time, then ultrasound will applied for 5 minutes.~Stretching exercises will be done in the following order;~For trapezius: Stretching into lateral flexion for the upper part, For scalene: rotation and ipsilateral flexion For the extensor muscles: flexion will be performed.~Performing each action for 30 seconds with 5 repetitions for 10 minutes Finally, by retruding the jaw, a neck straightening exercise can be performed."
89227766|NCT00972218|Experimental|Enteropathic spondyloarthritis|Patients have concomitant inflammatory spinal symptoms and inflammatory bowel disease.
89227767|NCT05230901|Other|Control group|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care
89227768|NCT05230901|Experimental|Spironolactone|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care + Spironolactone (25 mg/d, p.o.)
89227769|NCT05230901|Experimental|Spironolactone + Dihydralazine|Patients with CMR-derived ECV% levels ≥25.9% will receive Standard of care + Spironolactone (25 mg/d, p.o.) + Dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg / d p.o. in fast acethylators, confirmed by genetic testing)
89227770|NCT00965354||Influenza diagnosis|Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission
89227771|NCT02559557|Experimental|Supportive care (Spanish-adapted skills training)|"PHASE I (FOCUS GROUPS): Parents undergo a semi-structured interview with bilingual research assistants over 120 minutes. The content and purpose of the intervention is explained, and the focus group discussions elicit feedback on the intervention components and content of the sessions, and whether the material is culturally and linguistically appropriate. Following the focus group discussion, parents receive a copy of the educational handouts that they may choose to use with their child if they like.~PHASE II (PILOT TESTING): Parents of children age 5 to 17 years, 11 months old undergo adapted skills training in Spanish over 60 minutes (8 training sessions total) or 80 minutes (6 training sessions total). The adapted skills training sessions focus on parenting strategies and learning techniques. Sessions include homework assignments and techniques for parents to apply with their child for at least 30 minutes, 3 times a week at home."
89227772|NCT00972296||Persons with hemophilia with ankle pain|
89227773|NCT03908099|Experimental|Fit-For-Fertility program|The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
89227774|NCT03908099|Active Comparator|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months.
89227775|NCT03927950|Experimental|Escitalopram bupropion open-label|No comparator
89227776|NCT00678899|Experimental|Surgery|Implantation with the Nucleus Hybrid L24 Cochlear Implant
89227777|NCT00965432|Placebo Comparator|Placebo|
89227778|NCT00965432|Active Comparator|STX107|
89523189|NCT03388099||patients without FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
89104357|NCT01104662|Active Comparator|Vancomycin or SSP, Bacteremia, Severe Renal Impairment|Cohort 1. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by Methicillin-Susceptible Staphylococcus Aureus (MSSA) could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered intravenously (IV) until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
89104358|NCT01104662|Experimental|Daptomycin, Bacteremia, Moderate Renal Impairment|Cohort 2. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 14 to 42 days based on disease resolution or Investigator discretion.
89104359|NCT01104662|Active Comparator|Vancomycin or SSP , Bacteremia, Moderate Renal Impairment|Cohort 2. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
89104360|NCT01104662|Experimental|Daptomycin, cSSSI, Severe Renal Impairment|Cohort 3. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr below 30 mL/min and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 7 to 14 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 7 to 14 days based on disease resolution or Investigator discretion.
89104361|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Severe Renal Impairment|Cohort 3. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
89104362|NCT01104662|Experimental|Daptomycin, cSSSI, Moderate Renal Impairment|Cohort 4. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 7 to 14 days based on disease resolution or Investigator discretion.
89104363|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Moderate Renal Impairment|Cohort 4. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
89104364|NCT02849301|Experimental|Cervical pessary|Arabin cervical pessary
89104365|NCT02849301|No Intervention|Standard care|No treatment
89104366|NCT02849613|Experimental|Adipose derived Stem Cells ADSC|ADSC, single IV, 1.106 cells/kg
89104367|NCT02849613|Sham Comparator|Vehicle media|IV infusion of cell excipients, 1ml/kg
89104368|NCT01461291|Experimental|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
89104369|NCT01461291|Active Comparator|Cataract surgery|Cataract surgery alone
89104370|NCT02847195|Experimental|pediatric intensive care|"When aspiration is planned, pain assessment will be performed thrice :~3-5 minutes before aspiration, during aspiration, and 3-5 minutes after aspiration.~Pain assessment will be performed with both methods:~COMFORT B scale (routinely performed by nurses, and lasts less than one minute)~Simultaneously pupillometry is assessed using the device (Neurolight) (one measurement per eye, this also lasts less than one minute) These measurements can occur at any time during stay in ICU, and can be repeated."
89104371|NCT01104584|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced magnetic resonance mammography (MRM), followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg body weight (bw) [0.1 ml/kg bw] as an intravenous injection (i.v.) at a rate of 2 ml/sec. Unenhanced MRM (UMRM) and combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM) image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective X-ray mammography (XRM) was added and evaluated together with the UMRM images.
89104372|NCT05062785|Experimental|Intranasal insulin|A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin.
89104373|NCT01407627|Experimental|Fructose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure~Subjects will ingest fructose 200g daily x 14d~Study Day 2 - measurement of renal hemodynamics~Minimum 1 week washout period~Subjects will ingest dextrose 200g daily x 14d~Study Day 3 - measurement of renal hemodynamics and blood pressure"
89104374|NCT01407627|Active Comparator|Dextrose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure~Subjects will ingest dextrose 200g daily x 14d~Study Day 2 - measurement of renal hemodynamics~Minimum 1 week washout period~Subjects will ingest fructose 200g daily x 14d~Study Day 3 - measurement of renal hemodynamics and blood pressure"
89523190|NCT04448717||Children and adolescents|Children and adolescents in primary and secondary schools (aimed sample size: 2500)
89104375|NCT02849535|Experimental|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
89104376|NCT02849535|No Intervention|Standard of care|In the group with standard of care, patients will have interviews with a hospital pharmacist only dedicated to the record of data for outcomes assessment. These sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion , and at the end at month 6 after the final physical session.
89104377|NCT01103960|Experimental|Telmisartan80mg+Amlodipine5mg|combination therapy
89104378|NCT01103960|Active Comparator|amlodipine 5 mg|Monotherapy
89104379|NCT04413279|Active Comparator|Lipiflow Only Group|Patients with dry eye disease Lipiflow only
89104380|NCT04413279|Experimental|Lipiflow + Dextenza Group|Patients with dry eye disease Lipiflow + Dextenza
89104381|NCT02847039||Early repolarization syndrome|Patients with an aspect of early repolarization syndrome or belonging to a family in which the diagnosis of early repolarization was identified.
89104382|NCT05006144|Other|control group|control group
89104383|NCT05006144|Experimental|Experimental group|selective dorsal rhizotomy
89104384|NCT02846961||Crohn's disease|Patients with moderate to severe Crohn's disease who need to get a biosimilar CT-P13
89104385|NCT02846961||Ulcerative colitis|Patients with moderate to severe ulcerative colitis who need to get a biosimilar CT-P13
89104386|NCT04309448|Experimental|Perturbation-based balance training with FES|
89104387|NCT04886505|Experimental|Treatment|Single arm study - treatment with Electrolytic eCLIPs Bifurcation System
89104388|NCT04975256|Experimental|Dose escalation|Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination
89104389|NCT04975256|Experimental|Dose expansion|Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963
89104390|NCT00951951|Active Comparator|Anterior Surgical Approach|(AMIS)
89104391|NCT00951951|Active Comparator|Posterior Approach Group|Posterior surgical approach for total hip replacement.
89104392|NCT02880800|Experimental|Analgesia, patient controlled|Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of either morphine or hydromorphone.
89104393|NCT02880800|Active Comparator|Analgesia, as per needed|Patients will receive intravenous (IV) opioids as per needed.
89104394|NCT04383873|Experimental|Intervention|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
89104395|NCT04383873|Active Comparator|Control|17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy
89104396|NCT02847117|Other|Mastiha|
89104397|NCT01107392|Experimental|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
89104398|NCT01107392|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
89104399|NCT05037279|Experimental|Verity-BCG|"Bacillus Calmette-Guérin (BCG): Strain Russian BCG-I~Freeze-dried powder for bladder instillation"
89104400|NCT05037279|Active Comparator|OncoTICE|"Standard of Care~Bacillus Calmette-Guérin (BCG): Strain TICE~Freeze-dried powder for bladder instillation"
89104401|NCT01106846|Placebo Comparator|Group A: Saline group|Group A: Saline group , infusion of saline intravenously
89104402|NCT01106846|Active Comparator|Group B: 1% Ketamine group|Group B: Infusion of ketamine 1% intravenously
89104403|NCT05034783|Experimental|[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/ CT scan|Patients of Insulinoma PET/CT imaging: In two consecutive days each patient underwent a 60-min dynamic PET/CT scan after intravenous administration of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4, respectively.
89104404|NCT04309526|Experimental|NCO-48 Fumarate|NCO-48 Fumarate
89104405|NCT04309526|Placebo Comparator|Placebo|Placebo Comparator
89104406|NCT00902577|Experimental|Diagnostic (MRI and PET using FMISO)|Two weeks before initiation of chemoradiotherapy with temozolomide, patients undergo MRI (DSC, DCE,DWI and MRS) and PET scan using FMISO. A subset of 15 patients undergo FMISO PET scans approximately 1 week before chemoradiotherapy.
89523191|NCT04448717||Parents|Parents of participating children (aimed sample size: 3000)
89523192|NCT04448717||School personnel|School personnel (teaching, administrative, maintenance, etc.) (aimed sample size: 2500)
89104407|NCT04568889|Experimental|Government/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
89104408|NCT04568889|Experimental|Government/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
89104409|NCT04568889|Experimental|Government/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
89104410|NCT04568889|Experimental|Government/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
89104411|NCT04568889|Experimental|Researchers/High Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
89104412|NCT04568889|Experimental|Researchers/High Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
89104413|NCT04568889|Experimental|Researchers/High Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
89104414|NCT04568889|Experimental|Researchers/High Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to the arm that provides no messaging.
89104415|NCT04568889|Experimental|Government/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
89104416|NCT04568889|Experimental|Government/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
89104417|NCT04568889|Experimental|Government/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
89104418|NCT04568889|Experimental|Government/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing government involvement and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
89104419|NCT04568889|Experimental|Researchers/Low Incentive/Cost-Benefit Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the public health benefits of answering the survey questions (i.e. cost-benefit frame).
89104420|NCT04568889|Experimental|Researchers/Low Incentive/Duty Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes an individual's responsibility to their community (i.e. duty frame).
89104421|NCT04568889|Experimental|Researchers/Low Incentive/Racial/Ethnic Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
89104422|NCT04568889|Experimental|Researchers/Low Incentive/No Message Frame|The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $10 incentive. Then the participant is assigned to the arm that provides no messaging.
89104423|NCT04202601|Experimental|Neoadjuvant therapy group|
89104424|NCT04202601|Experimental|first-line therapy group|
89104425|NCT04202601|Experimental|≥second-line therapy group|
89104426|NCT04202367|Active Comparator|TAP block with 1 mg.kg-1 bupivacaine 0.25%|Patients had 1 mg.kg-1 bupivacaine 0.25% with US-guided TAP block
89104427|NCT04202367|Active Comparator|TAP block with 1 mg.kg-1 bupivacaine 0.125%|Patients had 1 mg.kg-1 bupivacaine 0.125% with US-guided TAP block
89104428|NCT02846805|No Intervention|complete dentures|complete dentures will be provided for all subjects according to the standardized treatment protocol
89104429|NCT02846805|Experimental|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible ,and continue wearing their complete denture in the maxilla
89104430|NCT00119847|Experimental|PCI+MED|Percutaneous Coronary Intervention (PCI) with angioplasty and stenting of the infarct-related artery and optimal medical therapy
89104431|NCT00119847|Experimental|MED|Optimal medical therapy alone
89104432|NCT02846493|Active Comparator|bromocriptine group|Rectal bromocriptine (2.5 mg, qd) for 7 days
89104433|NCT02846493|Experimental|dexamethasone group|Oral take dexamethasone(3mg,qd)for 7 days
89104434|NCT03636789|Experimental|Neurological consultation group|
89104435|NCT01106690|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.
89104436|NCT01106690|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
89104437|NCT01106690|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
89104438|NCT02690805||Breast cancer patients receiving neoadjuvant chemotherapy|One arm: Combined MRI-SMM Imaging
89104439|NCT02850393|Experimental|patients with obsessive compulsive disorder|Functional magnetic resonance imaging behavioral measures physiological measurements
89104440|NCT02850393|Experimental|healthy participants|Functional magnetic resonance imaging behavioral measures physiological measurements
89104441|NCT02880566|Experimental|Treatment|Full scalp block performed with a total of 30 ml of levobupivacaine 0.33 %.
89104442|NCT02880566|Placebo Comparator|Control|Full scalp block performed with a total of 30 ml of normal saline.
89104443|NCT04286529|Active Comparator|Men-Calcitriol|Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.
89104444|NCT04286529|Active Comparator|Premenopausal Women-Calcitriol|Calcitriol (1,25(OH)2D3) 0.25mcg capsule daily for eight weeks.
89104445|NCT04286529|Placebo Comparator|Men-Placebo|0.25mcg capsule daily for eight weeks
89104446|NCT04286529|Placebo Comparator|Premenopausal Women-Placebo|0.25mcg capsule daily for eight weeks
89104447|NCT01103180|Experimental|Escitalopram|10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
89104448|NCT01103180|Placebo Comparator|Placebo|Inert placebo (sugar pill) taken daily for eight weeks
89104449|NCT02848911|Experimental|AFM11|IV (intravenous) infusion, dose escalation
89104450|NCT00625898|Active Comparator|1A: TCH-H|Docetaxel (T), Carboplatin (C), and Trastuzumab (H) followed by Trastuzumab (H)
89104451|NCT00625898|Experimental|1B: TCHB-HB|Docetaxel (T), Carboplatin (C), Trastuzumab (H), Bevacizumab (B) followed by Trastuzumab (T) and Bevacizumab (B)
89104452|NCT00625898|Active Comparator|2A: TH-FEC-H|Docetaxel (T) and Trastuzumab (H) followed by 5-fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H)
89104453|NCT00625898|Experimental|2B: THB-FEC-HB|Docetaxel (T), Trastuzumab (H), and Bevacizumab (B) followed by 5-Fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H) and Bevacizumab (B)
89104454|NCT00944034|Experimental|B+R246_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
89104455|NCT00944034|Experimental|B+R246_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
89104456|NCT00944034|Experimental|B+R246_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
89104457|NCT00944034|Experimental|B246_12|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
89104458|NCT00944034|Experimental|B246_18|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.
89104459|NCT00944034|Experimental|B246_24|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.
89104460|NCT00944034|Experimental|B+R234_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.
89104461|NCT00944034|Experimental|B+R234_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
89104462|NCT00944034|Experimental|B+R234_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
89104463|NCT00944034|Experimental|B12 14|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.
89104464|NCT00944034|Experimental|B18 20|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.
89104465|NCT00944034|Experimental|B24 26|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.
89104466|NCT02853240|Experimental|Children with spastic CP receiving toxin injections|Children with spastic cerebral palsy receiving toxin injections
89104467|NCT02850471|Experimental|TEAS group|Before anesthesia, patients in this group treated with Transcutaneous Electric Acupoint Stimulation (TEAS) which is an electroacupuncture on Feishu, Hegu, Chize half an hour before the surgery, using the device Hua Tuo SDZ-II Acupoint Stimulator. The stimulus parameters set as 2/100Hz, 2V, 30min.
89104468|NCT02850471|No Intervention|controlled group|Patients in controlled group treated without TEAS or other placebo.
89104469|NCT04202055||Neuromyelitis optica with anti-MOG|
89104470|NCT04202055||Patients with Neuromyelitis optica with anti-AQP4|
89104471|NCT04202055||Seronegative patients with Neuromyelitis optica|
89104472|NCT04202055||Patients with recurrent-remitting multiple sclerosis|Patients with recurrent-remitting multiple sclerosis with medullary or optic involvement
89104473|NCT04202055||Progressive multiple sclerosis patients|
89104474|NCT04202055||Symptomatic controls|
89104475|NCT02853396|Experimental|Cognitive behavioural therapy|Cognitive behaviour therapy
89104476|NCT02853396|Active Comparator|Psychoeducation|psychoeducation
89104477|NCT02846727||Sepsis Group|This group will consist of surgical intensive care patients with diagnosis of sepsis, severe sepsis, or septic shock.
89104478|NCT02846727||Control Group|This group will consist of patients that serve as controls who do not have diagnosis of sepsis, severe sepsis, or septic shock.
89104479|NCT02846649|Experimental|PIER Intervention|The program will help participants learn to recognize the presence of craving and how it can be reduced through environmental, self-regulatory and mood management. Each day, the PIER1 program sends (1) a morning reflection focused on positive thinking, (2) two random prompts assessing severity of craving, (3) feedback specific to managing withdrawal symptoms, mood management, and environmental triggers that are affecting craving, (4) evening assessments of drug use with feedback, (5) goal commitment prompt with feedback, and (6) user-triggered craving assessments with feedback
89104480|NCT02854956|Other|X-linked Mental retardation|This is an observational study which will allow to precisely describe the phenotype associated to each X-linked mental retardation gene.
89104481|NCT02854956|Other|Control Group|This group will be compared to X-linked mental retardation group in order to obtain a baseline on some cognitive tests.
89104482|NCT04258917|Experimental|Total Knee Arthroplasty|
89104483|NCT04258917|Experimental|Anterior Cruciate Ligament Reconstruction|
89104484|NCT02857452||Lupus|
89104485|NCT04268472|Experimental|TR Sequence|In first Intervention period subjects was administered test medecine (GP30101) and in seconde Intervention period subjects was administered reference medecine (Prezista)
89104486|NCT04268472|Experimental|RT Sequence|In first Intervention period subjects was administered reference medecine (Prezista) and in seconde Intervention period subjects was administered test medecine (GP30101)
89104487|NCT02846337|Experimental|ULTRAFILTRATION|The ultrafiltration sodium-overload extraction will be chosen by the patient nephrologist and the patient himself (according to his comorbidities) among the following one: peritoneal dialysis (at least a daily contact), hemodialysis (>1 session per week) or isolated ultrafiltration (>1 session per week). Ultrafiltration technique could change throughout the care
89104488|NCT02846337|Other|ENHANCED MEDICAL TREATMENT|"The control group called enhanced medical treatment will not benefit of ultrafiltration (except refractory pulmonary edema, or terminal kidney failure requiring extra renal depuration). These situations will not be considered as protocol violation, because they are scientifically indicated for extra renal depuration."
89104489|NCT04269018|Experimental|Cancer specific Mobile text message|This arm will receive daily mobile text message related with cancer risks and prevention
89104490|NCT04269018|Active Comparator|general health messages|This arm will receive general health message once a week
89104491|NCT01260051||Epidural Recipients|
89104492|NCT01260051||Non-Epidural Recipients|
89104493|NCT04308980|Experimental|Active treatment|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use specialized medical nutrition product together with diet based on the measured individual requirements in energy and protein intake.
89104494|NCT04308980|Placebo Comparator|Control group|Patients with verified non-alcoholic fatty liver disease, who signed informed consent to participate in the study and are randomly selected to use masked placebo together with diet based on the measured individual requirements in energy and protein intake.
89104495|NCT02844621|Experimental|Healthy subjects|
89104496|NCT02853162|Experimental|ARREST-study|SBRT renal cell carcinoma 5 times 7Gy
89104497|NCT02844699|Experimental|Mobilan (M-VM3) on both Day 1 and on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Investigational Drug Product (Mobilan (M-VM3)) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
89104498|NCT02844699|Experimental|Placebo on Day 1 and Mobilan (M-VM3) on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) first on Day 1 and Investigational Drug Product (Mobilan (M-VM3)) in two weeks on Day 15. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
89104499|NCT02844699|Placebo Comparator|Placebo on both Day 1 and Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
89104500|NCT02848677|Active Comparator|intervention group|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
89104501|NCT02848677|Sham Comparator|control group|usual care of hypertensive patients.
89104502|NCT00941304|Active Comparator|Standard Opioid|Oxycodone 5-mg oral capsule and 2 buccal placebo films
89104503|NCT00941304|Experimental|High Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 1, buccal placebo film, and oral placebo capsule
89104504|NCT00941304|Experimental|Mid Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 2, buccal placebo film, and oral placebo capsule
89104505|NCT00941304|Experimental|Low Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.25-mg modified formulation 2, buccal placebo film, and oral placebo capsule
89104506|NCT00941304|Placebo Comparator|Placebo|Oral placebo capsule and 2 buccal placebo films
89104507|NCT02845869|Experimental|Light Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Light Therapy treatment with the THOR laser LX2 system.
89104508|NCT02845869|Sham Comparator|Sham Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Sham Therapy.
89104509|NCT02852460|Experimental|Experimental group|rapid recovery
89104510|NCT02852460|No Intervention|Controlled group|non-rapid recovery
89104511|NCT04308824|Active Comparator|Clipping|Prophylactic endoscopic clip will be placed after polypectomy
89104512|NCT04308824|Experimental|Cyanoacrilate|A solution of Cyanoacrilate will be nebulized after the placement of prophylactic clip
89104513|NCT02846025|Other|Folate|diet rich in folate
89104514|NCT02846025|Other|placebo|placebo
89104515|NCT02846025|Other|diet antioxidant|diet antioxidant
89104516|NCT02846025|Other|Hazelnut Oil|hazelnut oil capsule
89104517|NCT02880410|Experimental|LITT Treatment w/radiation therapy and temozolomide|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System in combination with radiation therapy and temozolomide
89104518|NCT02879006|Active Comparator|Chinese Herbal Medication|
89104519|NCT02879006|Placebo Comparator|Placebo|
89104520|NCT02846181|Experimental|Healthy|
89104521|NCT00941070|Experimental|Treatment (cisplatin, triapine, radiation therapy)|"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.~Patients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression."
89104522|NCT02857218|Experimental|Diagnostic (ferumoxytol, MRI)|Patients receive ferumoxytol IV over 15 minutes and then undergo ferumoxytol-enhanced MRI (Magnetic Resonance Imaging) after 24-36 hours and before surgery at week 12.
89104523|NCT01098812|Active Comparator|Control IOL|Approved Intraocular control lens
89104524|NCT01098812|Experimental|Toric IOL|Investigational Toric IOL
89104525|NCT01098812|Experimental|Higher Cylinder Toric IOL|Investigational Toric IOLs with higher cylinder powers.
89104526|NCT02879786|Experimental|Phonological dyslexia|Children with phonological dyslexia
89104527|NCT02879786|Experimental|Visuo-attentional dyslexia|Children with visuo-attentional dyslexia
89104528|NCT02879786|Other|Control|Control children, age-matched
89104529|NCT02857530|Experimental|rhTPO|rhTPO injection
89104530|NCT02857530|Placebo Comparator|control|without rhTPO injection
89104531|NCT02878928|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|Medical providers for IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
89104532|NCT02878928|No Intervention|Control Group|Medical providers for the Control Group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
89104533|NCT00903201|Experimental|Treatment A|20 mg of SB656933
89104534|NCT00903201|Experimental|Treatment B|50 mg of SB656933
89104535|NCT00903201|Experimental|Placebo|Placebo
89104536|NCT04309214|Experimental|MCT fats|MCT fats to be consumed, one portion per day to ensure tolerance and compliance to the product whilst support the dietary management for a range if disease states namely, the ketogenic diet, fatty acid oxidation disorders and malabsorption.
89104537|NCT04309136|Experimental|Neoadjuvant Anlotinib|
89104538|NCT04956302|Experimental|Treatment (panobinostat, daratumumab, bortezomib, dexa)|Patients receive panobinostat PO QD on days 1, 3, 5, 15, 17, 19, daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, bortezomib SC on days 1, 8, 15, 22 and dexamethasone PO (IV on days of daratumumab and hyaluronidase-fihj administration) QD on days 1, 8, 15, 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89104539|NCT04202133|Experimental|WW (formerly Weight Watchers)|16-weeks of the group-based WW program
89104540|NCT04202133|Other|Waitlist Control|16-weeks on waitlist then participants will be provided with 16-weeks of the group-based WW program
89104541|NCT02848443|Experimental|S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)|
89104542|NCT04954586|Experimental|Pain Informed Movement|This will be an 8-week in-person group exercise program held twice weekly, in which participants will receive pain Informed movement (60 minutes), with instructions provided for a third home session. Home sessions will be facilitated by exercise handout sheets. Pain education will be delivered through weekly access to videos. The pain informed movement component has been developed by a team member and will be delivered by an experienced yoga teacher.
89104543|NCT00632697|Active Comparator|1|
89104544|NCT00632697|Placebo Comparator|2|
89104545|NCT02848209|No Intervention|Control|No peeling applied on the skin flap
89104546|NCT02848209|Experimental|Drug: TCA 20% Peeling|Trichloroacetic acid 20% applied on the skin flap until even frosting for 2-4 minutes.
89104547|NCT02848209|Experimental|Drug: TCA 40% Peeling|Trichloroacetic acid 40% applied on the skin flap until even frosting for 2-4 minutes.
89104548|NCT02848209|Experimental|Drug: Phenol/croton oil Peeling|Phenol/croton oil applied on the skin flap occluded with silicone tape for 24 hours and not neutralized.
89104549|NCT05337969|Experimental|Metformin and Vildagliptin 850/50 mg Tablet|1 tablet of Metformin and Vildagliptin 850/50 mg as single-dose administration
89104550|NCT05337969|Active Comparator|EUCREAS® 50/850mg Tablet|1 tablet of EUCREAS® 50/850mg (each film-coated tablet contains Vildagliptin 50mg and Metformin hydrochloride 850mg) as single-dose administration
89104551|NCT02844153||6 groups, for each CKD stage (1, 2, 3a, 3b, 4, 5)|All patients with type 2 diabetes seen for the first time by a nephrologist.
89104552|NCT02844387|Experimental|Arginine|In the Arginine arm patients will receive 10 mg of L-arginine hydrochloride solution oral supplementation (in 200 ml of flavoured drinking water solution) administered twice a day prior to the radiation therapy fraction
89104553|NCT02844387|Placebo Comparator|Placebo|In the Placebo arm patients will receive 200 ml of flavoured drinking water oral solution administered twice a day prior to the radiation therapy fraction
89104554|NCT02844231|Other|Sleepwalker, SW episode|Sleepwalker patients undergo single-photon emission computed tomography during a sleepwalking episode.
89104555|NCT02844231|Other|Sleepwalkers, slow wave sleep|Sleepwalker patients undergo single-photon emission computed tomography during slow-wave sleep.
89104556|NCT02844231|Other|Control group|Control subjects undergo single-photon emission computed tomography during slow-wave sleep.
89104557|NCT04209465|Experimental|Phase 1 - Dose escalation|In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations will receive increasing doses of BDTX-189. It is expected that up to approximately 70 patients will be enrolled in this dose escalation arm. If an alternative schedule is explored, up to 24 additional patients may be enrolled.
89104558|NCT04209465|Experimental|Phase 2 - Dose expansion|In Part B, patients with a solid tumor harboring specific allosteric HER2 mutations or an HER2 or EGFR exon 20 insertion mutation will receive the recommended Phase 2 dose of BDTX-189. It is expected that approximately 100 participants will be enrolled in this phase 2 portion.
89104560|NCT02844309|Experimental|Thalidomide|thalidomide 50-150mg per night
89104561|NCT02845713|Active Comparator|Single IDA dose W. bancrofti positive|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
89104562|NCT02845713|Active Comparator|Single IDA dose W. bancrofti negative|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.
89104563|NCT05337813|Experimental|A. Overactive bladder|Overactive bladder (LiESWT therapy once a week, duration 8 weeks)
89104564|NCT05337813|Experimental|B. Stress incontinence|Stress incontinence (LiESWT therapy once a week, duration 8 weeks + PRP therapy once a month, duration 3 months)
89104565|NCT05337813|Experimental|C. Interstitial cystitis|Interstitial cystitis (LiESWT therapy once a week, duration 8 weeks + PRP therapy once a month, duration 3 months)
89104566|NCT05337813|Experimental|D. Female sexual dysfunction|Female sexual dysfunction (LiESWT therapy once a week, duration 8 weeks)
89104567|NCT02845557||Control subjects without diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
89104568|NCT02845557||Subjects with type 2 diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
89104569|NCT05243121||Clinically symptomatic patients|Clinically symptomatic patients (defined as palpable masses, nipple discharge, asymmetric thickening or nodules, and abnormal skin changes according to the guidelines) should be examined by BMRI at the judgment of the clinician.
89104570|NCT02845245|Active Comparator|Standard of Care|Standard of care imaging techniques (3D CT scan and plain film radiographs) will be obtained for the surgeon to pre-operatively plan the surgery.
89104571|NCT02845245|Experimental|Intervention|A 3D printed plastic model prototype will be developed for the surgeon to use, in addition to the standard of care imaging techniques (3D CT scan and plain film radiographs), to pre-operatively plan the surgery.
89104572|NCT00902265||desmopressin|"Participants with benign prostate syndrome suffering from nocturia associated with nocturnal polyuria.~Drug given by prescription."
89104573|NCT04510779|Experimental|Heart Failure Patients|This will be a single arm study of heart failure patients with acute decompensation
89104574|NCT02848365|Active Comparator|Glidescope|
89104575|NCT02848365|Active Comparator|Macintosh laryngoscope|
89104576|NCT02848365|Active Comparator|Bonfill's rigid scope|
89104577|NCT02848365|Active Comparator|Air traq|
89104578|NCT02848365|Active Comparator|C -Mac scope|
89104579|NCT02848365|Active Comparator|flexible fiberoptic scope|
89104580|NCT04490109|Experimental|B244 Suspension O.D. 5.0|One arm of 192 Subjects will be receiving a dose of B244 O.D. 5.0 suspension
89104581|NCT04490109|Experimental|B244 Suspension O.D. 20.0|Second arm of 192 subjects will receive a dose of B244 O.D. 20.0 suspension
89104582|NCT04490109|Placebo Comparator|Placebo|Third arm of 192 subjects will receive a vehicle dosing.
89104583|NCT02848287|Placebo Comparator|Normal Saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
89104584|NCT02848287|Experimental|Ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
89104585|NCT02847897|Experimental|CO2 AcuPulse Laser treatment|Subjects with vulvovaginal atrophy intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
89104586|NCT05337657|Experimental|GB491+Letrozole|
89523193|NCT03850951|Experimental|"Lingual appliances AO®"|Patients with moderate crowding will be treated without extraction using lingual fixed appliances from American Orthodontics company.
89523194|NCT03850951|Experimental|"Labial appliances AO®"|Patients with moderate crowding will be treated without extraction using labial fixed appliances from American Orthodontics company.
89104587|NCT05242575|No Intervention|Book condition|Participants in the control condition will be receive a pre-recorded audio-visual book presentation. The purpose of pre-reading is to provide consistency in the examiner's affect and presentation, thereby controlling for potential examiner effects on study outcomes. Participants in the control group will receive three interventions each lasting 15-minutes. The number of sessions and intervention time is equal for both the control and experimental groups. The information provided in the control book and experimental iVFT parallel one another.
89104588|NCT05242575|Experimental|Immersive virtual field trip (iVFT)|The study intervention is a multisensory immersive virtual reality trip to the moon. Participants will use 3D cardboard goggles and a smart phone. No additional interventions will occur. Participants in the iVFT experimental group will receive three interventions each lasting 15-minutes. The number of sessions and intervention time is equal for both the control and experimental groups. Participants will explore the moon through a virtual reality scene by moving their body and head, which creates a 360º view. When hovering over items, participants are presented with several key elements related to word learning (e.g., written and spoken words/narrative). Multiple items are given extra emphasis through hotspots that provide audiovisual content in the form of brief videos and spoken scripts. The information provided in the iVFT and control book parallel one another.
89104589|NCT02690961|Experimental|Kukoamine B Mesilate 0.06mg/kg|Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
89104590|NCT02690961|Experimental|Kukoamine B Mesilate 0.12mg/kg|Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
89104591|NCT02690961|Experimental|Kukoamine B Mesilate 0.24mg/kg|Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
89104592|NCT02690961|Experimental|Placebo 0.06mg/kg|Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
89104593|NCT02690961|Experimental|Placebo 0.12mg/kg|Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
89104594|NCT02690961|Experimental|Placebo 0.24mg/kg|Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
89104595|NCT05242107|Experimental|Omega-3 supplement group|This group included 35 full term Intrauterine Growth Restriction( IUGR) neonates, who received omega-3 supplement (Docosa-hexa-enoic acid (DHA) 40 mg/kg/ day) after establishment of full feeding.
89104596|NCT05242107|Experimental|Full feeding without receiving any supplementation group|This group included 35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
89104597|NCT02845167|No Intervention|Usual-care only|Patients will receive usual-care only during the preoperative period.
89104598|NCT02845167|Experimental|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods.
89104599|NCT05241951|Experimental|Clinical Pharmacist in Transition of Care|A clinical pharmacist will be provided as a patient discharges from one of four University of Washington (UW) medical centers to a skilled nursing facility randomized to the intervention arm. Pharmacist will perform additional clinical review and communication tasks with hospital and SNF clinical staff.
89104600|NCT05241951|No Intervention|Patient transitions from hospital to post-acute care|Patient will transition from one of four University of Washington (UW) medical centers to a skilled nursing facility randomized to the control arm. Patients will receive the standard discharge process.
89104601|NCT05337579|Active Comparator|Supplemental Rest Breaks|
89104602|NCT05337579|Active Comparator|Exercise Breaks|
89104603|NCT05337579|Experimental|Supplemental Rest and Exercise Breaks|
89523195|NCT05174195|Active Comparator|ESI (Implanon NXT® subdermal implant)|In this group, the implant was inserted immediately after thorough explanations of the potential side effects and possible adverse events
89523196|NCT05174195|Experimental|DSG + ESI(Desogestrel +Implanon NXT® subdermal implant)|In this group, patients were given a 3 months' supply of 75µg of DSG to be started immediately after which insertion of an ESI was proposed. Similarly, explanations of the potential side effects and possible adverse events were presented to the patient before treatment initiation.
89523197|NCT05238727|Active Comparator|1.8 ml mepivacaine IANB|
89104604|NCT04061577|Experimental|Stimulation arm|"Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers:~Tier 1 - 1 mA, and Tier 2- 2 mA: Consist of a single stimulation cycle (20min) after the endovascular procedure (EVT) in patients with TICI<2c,3 and negative immediate post-EVT CT scan for definitive evidence of ICH.~Tier 3 - 1 mA and Tier 4- 2mA consist of 2 treatment cycles after the EVT in patients with TICI<2c and 3, and negative immediate post-EVT CT scan for definitive evidence of ICH.~Tier 5 - 1 mA and tier 6- 2 mA consist of 3 treatment cycles. The first cycle will be up to 20 min cycle, after initial imaging and prior to arterial puncture, the second and third cycles after EVT in patients with TICI<2c and 3 and negative immediate post-EVT CT scan for definitive evidence of ICH."
89104605|NCT04061577|Sham Comparator|Sham arm|Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without delivery of electrical stimulation.
89104606|NCT04041921||Chronic coronary occlusion patients|≥3 months chronic total occlusion on coronary angiography
89104607|NCT04432077|Experimental|Treatment|All participants receive the DINOSAUR intervention
89104608|NCT02690883|Active Comparator|Lispro|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
89104609|NCT02690883|Experimental|Exenatide|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
89104610|NCT02942823|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). Additionally, the intervention group will take the game home on a tablet computer to play it with their parents in between session 1 and 2. The game equips the children and their parents with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
89104611|NCT02942823|No Intervention|Control|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors. The parents are not involved.
89104612|NCT02845089||Advanced/Metastatic NSCLC patients from UAE and KSA|A random sample of patients diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) from select oncology centers in Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE)
89104613|NCT05241639||group 1|of RA in the remission state
89104614|NCT05241639||group 2|of RA in the active state
89104615|NCT05241639||Group 3|120 eyes of healthy controls.
89104616|NCT02848053||Tianqi group|used Tianqi Capsule in the REDUCES study
89104617|NCT02848053||Placebo group|used placebo in the REDUCES study
89104618|NCT02847975|Experimental|Sodium nitrate|Sodium nitrate will be administered orally and functional sympatholysis assessed before and after treatment
89104619|NCT02754375|Experimental|Patient|Patient with resistant depression treated with rTMS
89104620|NCT02845011|Experimental|Audiovisual compression feedback|Cardiopulmonary resuscitation according to international guidelines with chest compressions performed with real-time audiovisual feedback using the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) device.
89104621|NCT02845011|Active Comparator|Standard chest compression|Cardiopulmonary resuscitation according to international guidelines with standard manual chest compression
89523198|NCT05238727|Experimental|3.6 ml mepivacaine IANB|
89523199|NCT05238727|Experimental|1.8 ml mepivacaine IANB plus 1.8 ml articaine BI|
89104622|NCT02384265|Experimental|IM/SMS + Incentive Condition|"Participants in the intervention condition will consist of the PWD and their two STMs. The PWD and STM will receive the same protocols that the Usual Care participants receive, including an introductory educational session, written materials on diabetes, a blood glucose log, and a physical activity monitoring log. The PWDs in this condition will also receive training in action planning with their STMs. They will also receive SMS messages supporting diabetes self-care from the study team. The study team will also encourage the STMs to interaction in person and via text messages with the PWD."
89104623|NCT02384265|No Intervention|Control|Control group participants will consist of the person with diabetes (PWD) and their two support team members (STM). The PWD will receive regular medical care from their usual providers. They will also receive an introductory educational session and written materials on diabetes, the importance of its control, and diabetes self-care strategies, and a blood glucose and physical activity monitoring log. They will be invited for study visits at 3, 6, and 12 months to measure cholesterol, A1c (for those with diabetes), blood pressure, height, and weight measurement. PWDs and STMs in the control condition will receive generic health promotion information during in-person visits or by mail. They will receive follow-up messages by text to remind them about study related events.
89104624|NCT02847819||Vocal cords movement assessment by airway USG.|Preoperatively patients undergoing thyroid surgery will be scanned by airway ultrasound and graded for vocal cord movement, the same group of patients will be again scanned and graded by airway ultrasound at 4th post operative hours.
89104625|NCT02844855|Active Comparator|patients with Alzheimer disease|Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
89104626|NCT02844855|Active Comparator|patients with Parkinson disease|Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
89104627|NCT02844855|Sham Comparator|healthy controls|Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
89104628|NCT05337111||Chinese men|Chinese men based on self-identity for three generations (parents and grandparents), age 25 - <45 years, who are physically inactive (< 150 minutes moderate or < 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (>23-<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
89104629|NCT05337111||Indian men|Indian men based on self-identity for three generations (parents and grandparents), age 25 - <45 years, who are physically inactive (< 150 minutes moderate or < 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (>23-<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
89104630|NCT05337111||Malay men|Malay men based on self-identity for three generations (parents and grandparents), age 25 - <45 years, who are physically inactive (< 150 minutes moderate or < 75 minutes vigorous leisure-time physical activity per week), with elevated body mass index (>23-<30 kg/m2) for Asians. Single measure of CRF, resting fat oxidation and fat oxidation during graded exercise.
89104631|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
89104632|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 2)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
89104633|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 3)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
89104634|NCT00943722|Experimental|9- to 15-Year-Old Males (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
89104635|NCT00943722|Experimental|16- to 26-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
89104636|NCT05190237|Experimental|TMD21-16 group|"Effective Microorganisms high content soybean paste powder group~- 2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day)"
89104637|NCT05190237|Experimental|TCD21-55 group|"Effective Microorganisms low content soybean paste powder group~- 2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day)"
89104638|NCT05190237|Placebo Comparator|TFD21-1 group|"Commercial soybean paste powder group~- 2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day)"
89104639|NCT05164731|Experimental|3 months after two doses|the third does was given 3 months after two doses
89104640|NCT05164731|Experimental|4 months after two doses|the third does was given 4 months after two doses
89104641|NCT05164731|Experimental|5 months after two doses|the third does was given 5 months after two doses
89104642|NCT05164731|Experimental|6 months after two doses|the third does was given 6 months after two doses
89104643|NCT00632775|Active Comparator|1|Subjects in this arm will receive hypotonic (0.45% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
89104644|NCT00632775|Active Comparator|2|Subjects in this arm will receive isotonic (0.9% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
89104645|NCT02847741|Other|Major depressive episode|Depressive patients will be assessed by interview (psychiatrists), questionnaires and blood sampling, as the inpatients's routine care
89104646|NCT04272918|Experimental|CSM condition|Social Worker 1 of CSM conditions will work with caregivers according to the guidelines and template of the Care Support Model, including the formulation of the intervention plan based on CNA scores of different need domains, the use of the caregiver intervention plan template, service matching drawing reference from caregiver resource database, service formulation based on CNA scores of different strength domains, the use of the case monitoring template and guideline.
89104647|NCT04272918|No Intervention|Non-CSM condition|Social Worker 2 of the Control Group will not be notified of the CNA scores of his/her caregivers. The intervention plan, services assignment and case management of participants of the control group will be based on Social Worker 2's own judgement using the information shared by the caregivers, and the social worker's own observation.
89104648|NCT04272918|Experimental|PP-E condition|Experimental Group will be led a consultant who is an expert, with the help of a degree-holder social worker to facilitate capacity building, empowerment and long-term well-being. Measurement of outcome variables will be conducted before the start of the program, at the end of the program, and 3 months after the program ended.
89104649|NCT04272918|No Intervention|Non PP-E condition|Measurement of outcome variables will be conducted at the same point of time as PP-E condition. There will be no treatment or intervention for the control group.
89104650|NCT02847585|Experimental|Open label|water-soluble ubiquinol
89104651|NCT04420689|Experimental|Dose Escalation/De-Escalation Cohorts|This arm of the study will include Dose Escalation/De-Escalation cohorts of ALM-488.
89104652|NCT04420689|Experimental|Dose Timing Cohorts|This arm of the study will include Dose Timing cohorts of ALM-488.
89104653|NCT04385589|Active Comparator|Dapagliflozin group|50 patients will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures.
89104654|NCT04385589|Placebo Comparator|Placebo group|50 patients will receive insulin for control of blood sugar plus diuretics and anti-failure measures.
89523200|NCT05174117|Experimental|single irradiation group|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
89523201|NCT05174117|Active Comparator|Double irradiation group|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
89523202|NCT05173571|Experimental|Nutritional and physical activity program|Homecare IPF patient educational, nutritional and physical activity training based on patient's needs
89104655|NCT04201977|Active Comparator|Exercise session followed passive recovery|Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). The interval between each exercise session will be one week. Volunteers will not perform any form of recovery for 20 min after resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
89104656|NCT04201977|Active Comparator|Exercise session followed active recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Active recovery for 20 minutes (MIKA et al., 2016; CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010);
89104657|NCT04201977|Active Comparator|Exercise session followed immersion in cold water recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will be immersed in cold water immediately after exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009).
89104658|NCT04201977|Active Comparator|Exercise session followed foam roller recovery|The interval between each exercise session will be one week. Prior each to the exercises sessions (4), volunteers will undergo specific warm-up in each exercise adopted (a series of 15 repetitions with 40% of the maximum load obtained in the 10RM test). The exercise sessions will consist of four sets for 10RM, with an interval of one minute between sets and two minutes between exercises. The exercise sequence (extension chair, squat and leg press) will be randomized through a closed brown envelope draw. Prior to the 10RM test and data collection, standardized instructions regarding the experimental procedure and exercise technique will be provided. Verbal stimuli to the volunteer will be performed during the evaluations and exercises (TEIXEIRA et al., 2014a, 2014b). Volunteers will undergo an FR session immediately after resistance exercise session (PEARCEY et al., 2015).
89104659|NCT05336331||laparoscopic sleeve gastrectomy (SG)|Patients operated on with a SG
89104660|NCT05336331||laparoscopic Roux-en-Y gastric bypass (RYGB)|patients operated on with aRYGB
89104661|NCT04951401||Normal & abnormal lipid parameters value|parameters value among normal and abnormal lipid profile
89104662|NCT04948359||Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size internal diameter (ID) endotracheal cuff tube.
89104663|NCT04948359||Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size internal diameter (ID) endotracheal cuff tube.
89104664|NCT04948359||Group III (The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. In this group we aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size internal diameter (ID) endotracheal cuff tube.
89104665|NCT02847429|Experimental|Crenolanib Arm|Investigational product (crenolanib)
89104666|NCT02847429|Placebo Comparator|Placebo Arm|Matching placebo
89104667|NCT03959007|Active Comparator|Control|Usual therapy and complete 3 questionnaire at 3 times during hospitalization : Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status
89104668|NCT03959007|Experimental|Experimental|9 consultations (3 x 3 sessions during hospitalization) of aesthetic care will be provided to patient include in experimental arm and 3 times questionnaires (Spielberger State-trait Anxiety Inventory + FACT-Leu quality of life and well-being OMS status)
89104669|NCT04827381|No Intervention|Usual care|Patients visiting their clinician will receive the normal, written after-visit-summary (available on paper or via the patient portal).
89104670|NCT04827381|Experimental|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
89104671|NCT04827381|Experimental|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
89104672|NCT04750005|Active Comparator|Brush only Group|Participants assigned to this group will brush their teeth using soft bristled toothbrush and colgate cavity protection toothpaste as directed under virtual supervision once daily during the week. Participants will brush second time unsupervised daily in the evening and twice daily over the weekend/holidays at home.
89104673|NCT04750005|Experimental|Brush/Rinse Group|Participants assigned to this group will perform their regimen (brushing [soft bristled toothbrush and colgate cavity protection toothpaste] and rinsing [listerine cool mint antiseptic mouthwash]) as directed under virtual supervision once daily during the week. Participants will brush and rinse a second time unsupervised daily in the evening at home. At home, participants will brush and rinse a second time unsupervised daily in the evening and twice daily over the weekend/holidays. First product use will occur at the site under supervision.
89104674|NCT04750005|Experimental|Brush/Floss Group|Participants assigned to this group will perform their regimen (brushing and flossing) as directed under virtual supervision once daily during the week. At home, participants will brush a second time unsupervised daily in the evening. Over the weekend and holidays, participants will brush and floss once daily. Only brushing will be performed a second time in the evening. First product use will occur at the site under supervision.
89104675|NCT04750005|Experimental|Brush/Floss/Rinse Group|Participants assigned to this group will perform their regimen (brushing [soft bristled toothbrush and colgate cavity protection toothpaste], flossing [reach unflavored waxed dental floss] and rinsing [listerine cool mint antiseptic mouthwash]) as directed under virtual supervision once daily during the week. Participants will brush and rinse a second time unsupervised daily in the evening. Over the weekend and holidays, participants will brush, floss and rinse once daily. Only brushing and rinsing will be performed a second time in the evening at home.
89104676|NCT02845791|No Intervention|Control|The control participants will not receive the educational intervention but will be provided with a detailed advice leaflet for themselves and their parents/guardians.
89104677|NCT02845791|Other|Intervention|The educational intervention participants will receive the eight 90 minute sessions of an interactive family based lifestyle programme.
89104678|NCT05336721|Experimental|Experimental: Chiauranib + capecitabine|Patients receive the combined treatment of Chiauranib plus capecitabine, 21 days as a cycle until objective disease progression.
89104679|NCT04691115|Experimental|Part A, Group 1: AM1476 1 mg|Part A, Group 1: AM1476 1 mg capsule, orally once on Day 1 in fasted state
89104680|NCT04691115|Experimental|Part A, Group 2: AM1476 5 mg|Part A, Group 2: AM1476 5 mg capsule, orally once on Days 1 in fasted state
89104681|NCT04691115|Experimental|Part A, Group 3: AM1476 25 mg|Part A, Group 3: AM1476 25 mg capsule, orally once on Days 1 in fasted state
89104682|NCT04691115|Experimental|Part A, Group 4: AM1476 125 mg|Part A, Group 4: AM1476 125 mg capsule, orally once on Days 1 in fasted state
89104683|NCT04691115|Experimental|Part A, Group 5: AM1476 375 mg|Part A, Group 5: AM1476 375 mg capsule, orally once on Days 1 in fasted state
89104684|NCT04691115|Experimental|Part A, Group 6: AM1476 650 mg|Part A, Group 6: AM1476 650 mg capsule, orally once on Days 1 in fasted state
89104685|NCT04691115|Experimental|Part A, Group 7: AM1476 950 mg|Part A, Group 7: AM1476 950 mg capsule, orally once on Days 1 in fasted state
89104686|NCT04691115|Experimental|Part A, Group 8: AM1476 1500 mg|Part A, Group 8: AM1476 1500 mg capsule, orally once on Days 1 in fasted state
89104687|NCT04691115|Experimental|Part A, Group 9: AM1476 2400 mg|Part A, Group 9: AM1476 2400 mg capsule, orally once on Days 1 in fasted state
89104688|NCT04691115|Placebo Comparator|Part A, Groups 1 to 9: Placebo|Part A, Groups 1 to 9: AM1476 placebo-matching capsule, orally once on Days 1 in fasted state
89104689|NCT04691115|Experimental|Part B, Group 1: AM1476 100 mg QD|Part B, Group 1: AM1476 100 mg capsule, orally once on Days 1-10 in fasted state
89104690|NCT04691115|Experimental|Part B, Group 2: AM1476 375 mg BID|Part B, Group 2: AM1476 375 mg capsule, orally twice on Days 1-9 and once on Days 10 in fasted state
89104691|NCT04691115|Experimental|Part B, Group 3: AM1476 500 mg BID|Part B, Group 3: AM1476 500 mg capsule, orally twice on Days 1-9 and once on Days 10 in fasted state
89104692|NCT04691115|Placebo Comparator|Part B, Groups 1 to 3: Placebo|Part B, Groups 1 to 3: AM1476 placebo-matching capsule, orally once or twice on Days 1-10 in fasted state
89104693|NCT04080999|Experimental|r-TMS Group|"r-TMS Parameters International 10/20 system for the location of the target area (non-lesioned left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
89104694|NCT04080999|Sham Comparator|Sham Group|Sham stimulation and Visual scanning training
89104695|NCT04573413|Experimental|r-TMS group|The interventions have a total administration time of 75 minutes per day. For rTMS stimulation, the coil will be positioned tangentially on the target area. Each rTMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The CCT (i.e. visual scanning treatment) involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities.Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the rTMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
89104696|NCT04573413|Sham Comparator|SHAM group|SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the experimental group.
89104697|NCT05336643|Experimental|Radioisotope and fluorescence guidance|Patients undergoing curative resection for rectal cancer will receive a peritumoural, submucosal administration of indocyanine green and technetium-99m nanocolloid. Intraoperatively the SENSEI gamma probe and Da Vinci Firefly will be used to identify pelvic side wall lymph nodes.
89104698|NCT00723723||Patients with coronary heart disease|Patients being treated with a statin for secondary prevention of coronary heart disease
89104699|NCT05335395|Experimental|SUNRISE clusters|SUNRISE campaign broadcast through local radio stations plus broadcasting as usual
89104700|NCT05335395|No Intervention|Control clusters|Local radio stations broadcast as usual
89104701|NCT00653913|Active Comparator|Group A|SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)
89104702|NCT00653913|Active Comparator|Group B|SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)
89104703|NCT00653913|Active Comparator|Group C|Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)
89104704|NCT00653913|Active Comparator|Group D|Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)
89104705|NCT00653913|Active Comparator|Group E|Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)
89104706|NCT00653913|Active Comparator|Group F|Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)
89104707|NCT00652431|Experimental|Vytorin + Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 + VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
89104708|NCT00652431|Active Comparator|Vytorin|VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
89104709|NCT00652431|Active Comparator|Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 for a total of 7 days of treatment
89104710|NCT03372525|Experimental|HFOV|Ventilated infants were randomized to HFOV.
89104711|NCT03372525|Active Comparator|CMV|Ventilated infants were randomized to CMV.
89104712|NCT04068363||Matched group|Same sex of both donor and recipient
89104713|NCT04068363||Mismatched group|Sex mismatch between donor and recipient, subgroups might be added
89104714|NCT00901485|Experimental|autotitrating NIV|approximately 6 weeks using domiciliary nocturnal autotitrating non-invasive ventilation
89104715|NCT00901485|Active Comparator|Standard non-invasive ventilation|approximately 6 weeks using domiciliary nocturnal standard non-invasive ventilation
89104716|NCT04067739||Readmission group|Readmission is defined as ICU readmission within ≤ 3 months of initial ICU discharge
89104717|NCT04067739||Non readmitted group|Non readmission is defined as no need for ICU readmission within ≤ 3 months of initial ICU discharge
89104718|NCT04060641||RDN Patients|Patients who have received renal denervation with the Medtronic SymplicitySpyral device will have DNA collected in using a buccal swab.
89104719|NCT02842593|Experimental|Resistance exercise training|Whole-body resistance exercise training 4x/week for 12 weeks. Either 'lower-repetition, heavier-load' or 'higher-repetition, lighter-load' intervention.
89104720|NCT02842593|No Intervention|Non-exercising control|Continue habitual physical activity for 12 weeks.
89104721|NCT02842515||Patients requiring dental avulsion|Patients requiring dental avulsion
89104722|NCT00896337|Experimental|ORION|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with iliac artery stenting with the Epic™ Nitinol Stent System.
89104723|NCT04201743|Active Comparator|1 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 1 mL NyDYN injection.
89104724|NCT04201743|Active Comparator|2 mL NyDYN injection|30 patients (out of 60) will be doubled blinded randomized to this arm and get 2 mL NyDYN injection.
89104725|NCT03832413||Stroke|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104726|NCT03832413||TBI|Diagnostic Test: DELPhI (TMS-EEG analysis)
89227779|NCT03827993|No Intervention|Routine surveillance|"Routine surveillance consists of attending gynecologic oncology office visits and being provided with an educational pamphlet discussing common sexual health concerns in gynecologic cancer patients, describing vaginal dilators, moisturizers, and lubrication. Resources for psychosocial counseling, physical therapy, and the sexual health clinic will be provided as well.~Participants will have follow up at baseline, 3, 6, 9, and 12 months. Baseline visit consists of the initial visit where the Female Sexual Function Index (FSFI) screen was performed. Subsequent follow up visits will consist of FSFI, Female Sexual Distress Scale (FSDS), Kessler 10 surveys, and clinical assessment with Vaginal Assessment Scale and Vulvar Assessment Scale (VAS and VuAS)."
89227780|NCT03827993|Experimental|Dedicated sexual health clinic appointment|"Dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This will consist of the provider performing a focused history and physical, who will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.~The participants will follow up at 3, 6, 9, and 12 months after initial visit, either with the sexual health focused provider or their primary gynecologic oncologist, as determined by the needs of the participant per the provider."
89227781|NCT00972452|Experimental|Exercise|5-10d exercise training
89227782|NCT00965510|Experimental|Care Coordination|Patients receive care coordination to improve their diabetes.
89227783|NCT00965510|No Intervention|control|patients with type II diabetes receive usual health care
89227784|NCT02559089||anti-NMDA receptor encephalitis|
89227785|NCT02559089||other autoimmune encephlitis|
89227786|NCT02559089||other encephalopathy|
89227787|NCT00972686|Experimental|GSK2126458|GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
89227788|NCT00921869|Experimental|1|
89227789|NCT00965588|Experimental|Vaccine (UB 311)|
89227790|NCT00972764||Control|
89227791|NCT00972764||Laryngomalacia Cases|
89227792|NCT04008992|Experimental|Part A SAD - A1 Cohort|Single Ascending Dose
89227793|NCT04008992|Experimental|Part A SAD - A2 Cohort|Single Ascending dose
89227794|NCT04008992|Experimental|Part A SAD- A3 Cohort|Single Ascending dose
89227795|NCT04008992|Experimental|Part A SAD- A4 Cohort|Single Ascending dose
89227796|NCT04008992|Experimental|Part A SAD - A5 Cohort|Single Ascending dose
89227797|NCT04008992|Experimental|Part A SAD- A6 Cohort|Single Ascending dose
89227798|NCT04008992|Experimental|Part B MAD- B1 Cohort|Multiple Ascending Dose
89227799|NCT04008992|Experimental|Part B MAD - B2 Cohort|Multiple Ascending Dose
89227800|NCT04008992|Experimental|Part B MAD - B3 Cohort|Multiple Ascending Dose
89227801|NCT04008992|Experimental|Part B MAD - B4 Cohort|Multiple Ascending Dose
89227802|NCT04008992|Experimental|Part C JMAD - C1 Cohort|Japanese Multiple Ascending Dose
89227803|NCT04008992|Experimental|Part C JMAD - C2 Cohort|Japanese Multiple Ascending Dose
89227804|NCT04008992|Experimental|Part C JMAD - C3 Cohort|Japanese Multiple Ascending Dose
89227805|NCT05248490|Experimental|Patients with pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization.
89227806|NCT05248490|No Intervention|Patients without pharmaceutical interview|Control group without interview
89227807|NCT00972920|Active Comparator|Blind TAP block|"TAP block technique as first described by McDonnell. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Identification of triangle of Petit just above iliac crest and between external oblique and latissimus dorsi muscles. Insertion of regional anaesthesia needle perpendicular to skin, and its advancement until sensation of two 'pops' indicating advancement of needle through both external oblique and internal oblique muscle layers.~After confirmation of negative aspiration the local anaesthetic is injected slowly, (1mg/kg of levobupivacaine), concentration 2.5 mg/mL. Repeat procedure bilaterally (to a maximum dose of 2mg/kg of levobupivacaine)."
89104727|NCT03832413||ABD|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104728|NCT03832413||Fibromyalgia|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104729|NCT03832413||PDD|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104730|NCT03832413||ADHD|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104731|NCT03832413||MCI|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104732|NCT03832413||Dementia|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104733|NCT03832413||Healthy|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104734|NCT03832413||Cognitive impairment|Diagnostic Test: DELPhI (TMS-EEG analysis)
89104735|NCT02842281|Active Comparator|Fructan|Fructans will be provided for 72 hours.
89104736|NCT02842281|Placebo Comparator|Maltodextrin|Maltodextrin will be provided for 72 hours.
89104737|NCT03789513|Other|Triage with different options|"All women will have an HPV test, partial genotyping (16/18/45 versus other high-risk HPV [hr-HPV]) and VIA. The different options for triage that will be compared are:~Participants hr-HVP+ and VIA+ participants selected for treatment;~Participants HPV 16/18/45+ selected for treatment;~Participant HPV 16/18/45+ and/or VIA+ selected for treatment;"
89104738|NCT02091843|Experimental|DBS of the Amygdala-30 days|Deep brain stimulation of the amygdala BLn starting at 30 days post-operatively.
89104739|NCT02091843|Experimental|DBS of the Amygdala-90 days|Deep brain stimulation of the amygdala BLn starting at 90 days post-operatively.
89104740|NCT02842437|Experimental|Dexmedetomidine|25 patients receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
89104741|NCT02842437|Placebo Comparator|Placebo|25 patients receive matching placebo （normal saline）
89104742|NCT05336175|Experimental|Ang-(1-7)|30 participants will take 100 micrograms of Ang-(1-7) a day via subcutaneous injection for 90 days
89104743|NCT05336175|Placebo Comparator|Saline Placebo|10 participants will take 100 micrograms of saline placebo a day via subcutaneous injection for 90 days
89104744|NCT02842125|Experimental|Ad-p53 with Xeloda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
89104745|NCT02842125|Experimental|Ad-p53 with Keytruda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
89104746|NCT02842125|Experimental|Ad-p53 with Opdivo 33.3% of patients|Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
89104747|NCT03708549|Experimental|Berberine group|"Berberine 300mg（three times a day） plus Metformin simulant 250mg（three times a day）agent plus any atypical antipsychotic drug~Metformin simulant were matched to metformin in shape, smell and colour were sealed in identical bottles"
89104748|NCT03708549|Active Comparator|Metformin group|"Metformin 250mg（three times a day） plus Berberine simulant 250mg（three times a day）agent plus any atypical antipsychotic drug~Berberine simulant were matched to Berberine in shape, smell and colour were sealed in identical bottles"
89104749|NCT00156117|Experimental|1|asenapine 5 mg BID and 10 mg BID
89104750|NCT00156117|Placebo Comparator|2|Placebo against olanzapine and asenapine
89104751|NCT00156117|Active Comparator|3|olanzapine 15 mgQD
89104752|NCT03255057|Experimental|Hemolung plus SOC IMV|Low-flow ECCO2R with the Hemolung Respiratory Assist System as an alternative or adjunct to standard-of-care (SOC) invasive mechanical ventilation (IMV)
89104753|NCT03255057|Active Comparator|SOC IMV|Standard-of-care (SOC) invasive mechanical ventilation (IMV) alone
89104754|NCT02739867||Unprovoked VTE|Patients aged 40 years or older with a first episode of objectively confirmed, symptomatic, unprovoked deep vein thrombosis of the leg (distal or proximal) or pulmonary embolism
89104755|NCT00140907|Placebo Comparator|1|Placebo
89104756|NCT00140907|Active Comparator|2|Losartan
89104757|NCT02842047|Experimental|End of Life Care with Meditation|The intervention has two content components: end of life planning education (using end of life planning videos) and strategies and kindness based meditation (using the Stop, Breathe & Think™ app). The activities comprising these components work together to improve both analytic neural processing (e.g. improving knowledge about goal setting and EOL planning, learning self-monitoring of EOL values and goals of care, and self-regulation skills of monitoring symptoms of distress and anxiety) and emotional neural processing (e.g. teaching participants to experience the moment non-judgmentally and directing thoughts to think positive thoughts and feel positive feelings like kindness and compassion.
89104758|NCT02842047|Active Comparator|Meditation Only|This arm has the single content component of kindness based meditation delivered by using the Stop, Breathe & Think™ application. This group will also be instructed to view 3 caregiver wellness videos.
89104759|NCT02841813||The normal mothers group|No intervention
89104760|NCT02841813||The normal full-term infants group|No intervention
89104761|NCT02841813||The preterm mothers group|No intervention
89104762|NCT02841813||The preterms group|No intervention
89104763|NCT00953706|Placebo Comparator|Placebo|Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
89104764|NCT00953706|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
89104765|NCT02853084|Experimental|HL2351|
89104766|NCT02853006|Other|Group 1 lung cancer in stage 1-2|Group 1 : patient with lung cancer in stage 1-2, lung cancer of all histology kind eligible for surgery
89104767|NCT02853006|Other|Group 2 lung cancer in stage 3-4|Group 2 : patient with lung cancer in stage 3-4 (no adenocarcinoma or squamous) receiving classical or targeted chemotherapy on genetic anomalies.
89104768|NCT02853006|Other|Group 3 : control patients|Group 3 control patients : carriers of non-cancerous radiological anomalies : benign nodules, cicatricial lesions, infectious or inflammatory, paired with the two other groups by age, sex or tobacco.
89104769|NCT02852382|Active Comparator|scalp block|In this arm, after general anesthesia, before surgery and head pin placement, scalp block will be applied. Scalp block will be performed with bupivacaine (Marcaine 5 mg/mL, 0,5% bupivacaine); nervus supraorbitalis, nervus supratrochlearis, n. auriculotemporalis, nervus zygomaticotemporalis, nervus occipitalis majoris and minoris will be bilaterally blocked with 2-3 ml bupivacaine.
89104770|NCT02852382|Active Comparator|local infiltration|In this arm, after general anesthesia, before surgery, 20 ml 0,5% bupivacaine (Marcaine 5 mg/ml, 0,5% bupivacaine) will be infiltrated to head pin points and skin incision area.
89104771|NCT02852382|Placebo Comparator|control|In this arm, neither scalp block, nor local infiltration will be performed.
89104772|NCT00630942|Experimental|Single Arm, active treatment|
89104773|NCT02852148|Experimental|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
89104774|NCT02856984||ZIKV infected women|The study will prospectively enroll pregnant women up to 17 weeks and 6 days gestation and follow them through their pregnancy for clinical evidence of acute ZIKV infection while controlling for potential confounders. All pregnant women will be followed throughout the pregnancy, delivery, and 6 weeks postpartum. Outcomes in women, the developing fetus, and infants will be assessed.
89104775|NCT02856984||Control (uninfected women)|The women who remain uninfected will serve as the internal comparison group. The infants who remain uninfected at delivery and throughout the follow-up period will serve as the internal comparison group.
89104776|NCT00604266||1|10-15 patients with potentially resectable hiilar cholangiocarcinoma
89104777|NCT02852226|Experimental|Study Intervention|Assess PrEP among women in the study. Assess the characteristics of women who enroll in the PrEP study. Assess the referral sources of women who enroll in the PrEP study
89104778|NCT00940992|Experimental|DER 45 EV Gel, 1%|DER 45 EV Gel, 1% topically applied once daily to face for 12 weeks
89104779|NCT00940992|Placebo Comparator|Vehicle|Placebo Gel applied topically once a day for 12 weeks
89104780|NCT00940992|Experimental|DER 45 EV Gel, 5%|DER 45 EV Gel, 5% applied topically once a day for 12 weeks
89104781|NCT02851914|Active Comparator|Arm 1 - TCA|"The Tricyclic Antidepressant (TCA) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
89104782|NCT02851914|Active Comparator|Arm 2 - SSRI|"The Selective Serotonin Reuptake Inhibitor (SSRI) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
89104783|NCT00938964|Experimental|Lidocaine|Lidocaine infusion for 48 hours
89104784|NCT00938964|Placebo Comparator|Placebo|Normal saline infusion for 48 hours
89104785|NCT04268160||Patients with severe aortic stenosis undergoing TAVR|GPx activity levels will be measured on the day of TAVR procedure, the day of discharge, 1 month, and 6 months after the procedure
89104786|NCT04268160||Patients without aortic stenosis|GPx activity levels will be measured on day of recruitment
89104787|NCT00938886|Experimental|Naltrexone|50 mg daily naltrexone for 10 weeks
89104788|NCT00938886|Placebo Comparator|Placebo|Daily matched placebo pill
89104789|NCT04268082|Experimental|Experimental Group|The Experimental Group followed the training wearing sensorized insoles that provided plantar pressures and shift of foot center of pressure images reported on monitors.
89104790|NCT04268082|Active Comparator|Control Group|The Control Group followed verbal instructions of physiotherapist during training.
89104791|NCT05381688||ET VIM DBS patients|Essential tremor patients scheduled for VIM DBS
89104792|NCT05381688||DT VIM DBS patients|Dystonic tremor patients scheduled for VIM DBS
89104793|NCT02852070|Active Comparator|control group|Bronchoscopy examination with 120ml sterile saline solution for bronchoalveolar lavage
89104794|NCT02852070|Experimental|observation group|Bronchoscopy examination with 60ml sterile saline solution for bronchoalveolar lavage
89104795|NCT00602784|Experimental|IC41-B-01/02|peptide dose 0.00 mg, polyarginine dose 2.00 mg
89104796|NCT00602784|Experimental|IC41-C-01/02|peptide dose: 5.00 mg, polyarginine dose: 0.00 mg
89104797|NCT00602784|Experimental|IC41-G-01/02|peptide dose: 2.50 mg, polyarginine dose: 1.25 mg
89104798|NCT00602784|Experimental|IC41-H-01/02|peptide dose: 2.50 mg, polyarginine dose: 2.00 mg
89104799|NCT00602784|Experimental|IC41-K-01/02|peptide dose: 5.00 mg, polyarginine dose: 2.00 mg
89104800|NCT02851680|Experimental|Fongitell test|
89104801|NCT02851680|Active Comparator|serum galactomannan|
89104802|NCT00604422||A|Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
89104803|NCT00602862|Experimental|1|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
89104804|NCT00602862|Experimental|2|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/10mg 111In-cG250. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
89104805|NCT00602862|Active Comparator|3|5 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Whole-body scintigraphic images are recorded 1 week after the injection to calculate tumor uptake. Hereafter, patients will undergo surgery.
89104806|NCT04268238|Experimental|Control group|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate). Afterwards, this group will receive no treatment. Instead of the sealant, water will be used and the laser will remain with power 0W, that is, there will be no light emission, giving the group the characteristic of the control group, no treatment.
89104807|NCT04268238|Experimental|Sealant group|In this group, besides the instructions described in the control group, the teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal (sealant) for 5 seconds to the tooth surface and light curing for 20 seconds.
89104808|NCT04268238|Experimental|Low Level Laser Group|In this group, besides the instructions described in the control group, volunteers will receive irradiation with AsGaAl laser, wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, energy density of 35 J/cm2 (considering a spot size of 0.028 cm2 of this equipment), the dose will be 1 J per point. The irradiation will be performed at a cervical, an apical point and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
89104809|NCT04268238|Experimental|Low Level Laser + Sealant Group|In this group, patients will receive the treatments described in Control group, Sealant group and Low Level Laser Group.
89104810|NCT00631176|No Intervention|1|
89104811|NCT00631176|Experimental|2|
89104812|NCT02851602|Experimental|Obese|
89104813|NCT02851602|Placebo Comparator|control|
89104814|NCT00602940|Experimental|1|Active acupuncture treatment
89104815|NCT00602940|Sham Comparator|2|Sham acupuncture treatment
89104816|NCT00942708|Other|Fluoxetine|Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.
89104817|NCT02852850||Molecular Imaging With IFX-FITC|Endoscopic examination with the fluorescent antibody (IFX-FITC) was performed in patients with active ulcerative colitis before infliximab therapy was initiated. Labeled infliximab was applied topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF+ cells after topical application of labeled adalimumab. These specific fluorescence signals were recorded.
89104818|NCT05381298|Experimental|Deep Margin Elevation|
89104819|NCT05381298|Experimental|Surgical Crown Lengthtening|
89104820|NCT00937950|Other|HPV-052 study subjects Group|The study group consisted of a subset of HPV-008 (NCT00122681) study subjects (15-25 years old at first study vaccination), who at their last study visit (Visit 10, Month 48) in HPV-008 (NCT00122681) study displayed normal cervical cytology, but were tested positive for oncogenic HPV infection, or were pregnant and hence no cervical sample could be collected at their HPV-008 (NCT00122681) concluding visit.
89104821|NCT00942162|Experimental|GSK2132231A GS+ Group|Patients with the pre-specified gene signature (GS), who received intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
89104822|NCT00942162|Experimental|GSK2132231A GS- Group|Patients without the pre-specified gene signature (GS), planned to receive intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
89104823|NCT00942162|Experimental|GSK2132231A GS-unknown Group|Patients with unknown gene signature (GS), planned to receive intramuscularly up to 24 doses of MAGE_A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
89104824|NCT02852772||PLHIV with microalbuminuria|Patient infected with HIV and well controlled by treatments, with microalbuminuria for at least 5 years
89104825|NCT02852772||PLHIV without microalbuminuria (control)|Patient infected with HIV and well controlled by treatments, without microalbuminuria, matched for age +/- 5 years
89104826|NCT00942084|Active Comparator|Protocol V2&up-Grp1-Acyclo10 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age < 14 days Dosage 10 mg/kg IV q12 Number of Infants 8
89104827|NCT00942084|Active Comparator|Protocol V2&up-Grp2_Acyclo20 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age 14-44 days Dosage 20 mg/kg IV q12 Number of Infants 8
89104828|NCT00942084|Active Comparator|Protocol V2&up-Grp3-Acyclo20 mg/kg IVq8|Gestational Age 30-34 weeks Postnatal Age <45 days Dosage 20 mg/kg IV q8 Number of Infants 4
89104829|NCT00942084|Other|Protocol V1-Grps1-4-Acyclo 500 mg/m2 IVq8h|All patients in protocol V1 were to be dosed with 500 mg/m2 IV q8h. Protocol V1 Group 1: Gestational Age: 23-29 Weeks; PNA: <14 days; Protocol V1 Group 2: Gestational Age: 30-42 Weeks; PNA: <14 days; Protocol V1 Group 3: Gestational Age: 23-29 Weeks; PNA: 14-60 days; Protocol V1 Group 4: Gestational Age: 30-42 Weeks; PNA: 14-60 days
89104830|NCT00941928|Experimental|Haploidentical NK cells + Epratuzumab|Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
89104831|NCT02851524|Experimental|posturography|
89104832|NCT05381064|Experimental|novices with AI-assisted system, Then experts without AI-assisted system|The patient is first scanned by a novice endoscopist with the assistance of a deep learning-based bile duct scanning system during the examination, and then rescanned by a specialist without the assistance of AI.
89104833|NCT05381064|Experimental|experts without AI-assisted system, Then novices with AI-assisted system|The patient is first scanned by a specialist without the assistance of AI and then rescanned by a novice endoscopist with the assistance of a deep learning-based bile duct scanning system during the examination.
89104834|NCT04203966||Common mental disorders/ versus no common mental disorders|No intervention This is a prevalence study- presence of common mental disorders (CMDs) will be assessed using the 12-item general Health Questionnaire, with responses above validated cut-points taken to indicate presence of CMDs
89104835|NCT04203966||Alcohol use disorders/ versus no alcohol use disorders|No intervention This is a prevalence study- presence of alcohol use disorders will be assessed using the World Health Organization (WHO) AUDIT, with responses above validated cutpoints taken to indicate presence of alcohol use disorders
89104836|NCT04257864||Erlotinib followed by docetaxel|Erlotinib given for twelve consecutive days before docetaxel
89104837|NCT04257864||Docetaxel followed by erlotinib|Erlotinib given for twelve consecutive days after docetaxel
89104838|NCT04257864||Bevacizumab treated|Bevacizumab treated patients
89104839|NCT00603096|Experimental|1|patients will benefit from a complete polysomnography under NIV
89104840|NCT00603096|Active Comparator|2|settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas
89104841|NCT00603174|Experimental|A|Intubated and mechanically ventilated infants with respiratory failure (age < 1 year old). see inclusion-exclusion criteria.
89104842|NCT02852616|Active Comparator|Narrative Exposure Therapy|Participants with a PTSD diagnosis
89104843|NCT02852616|No Intervention|no / standard treatment|Participants with a PTSD diagnosis / other mental health problems / no mental health problems
89104844|NCT02852694|Active Comparator|High Risk Group|subcutaneous methotrexate versus subcutaneous adalimumab
89104845|NCT02852694|Active Comparator|Low risk group|subcutaneous methotrexate versus oral dose of azathioprine / 6 mercaptopurine
89104846|NCT02852694|Other|Ancillary|the ancillary study is planned to analyse of Adalimumab treated patients from inclusion (TOP-Down) versus patients switched to Adalimumab due to failure of immunomodulator therapy (STEP-Up).
89104847|NCT00937560|Experimental|Bevacizumab + paclitaxel + carboplatin|Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = [glomerular filtration rate + 25] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.
89104848|NCT04268394|Experimental|Part 1: CC-99677 with Methotrexate and Sulfasalazine|Fixed-sequence involving CC-99677 + Methotrexate 7.5 mg and sulfasalazine 1000 mg
89104849|NCT04268394|Experimental|Part 2: CC-99677 with Itraconazole and Rifampin|Fixed-sequence involving CC-99677 + Rifampin 600 mg and Itraconazole 200 mg
89104850|NCT04268394|Experimental|Part 3: CC-99677, Midazolam, Digoxin, Metformin, Rosuvastatin|Fixed-sequence involving CC-99677 + Midazolam 2 mg, Digoxin 0.25 mg, Metformin 500 mg, and Rosuvastatin 10 mg.
89104851|NCT02851368|Other|Near Infrared Fluorescence Imaging with Indocyanine Green|Patients will receive an injection of indocyanine green (ICG) 1 day prior to surgery. Near infrared fluorescence imaging (NIFI) will be used to identify pulmonary nodules during the surgical biopsy and/or resection procedure.
89104852|NCT02851212|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with two Extended Release (XR) tablets of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 Extended Release (XR) fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin XR two tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89104853|NCT02851212|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89104854|NCT02851212|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89104855|NCT02851212|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89104856|NCT02851134||Crohn disease subject|Crohn disease affected subject
89104857|NCT02851134||family control subject|family control unaffected subject
89104858|NCT02851446||DS|
89104859|NCT02851446||no DS|
89104860|NCT00594568|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.
89104861|NCT00594568|Experimental|100 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.
89104862|NCT00594568|Experimental|140 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
89104863|NCT00684658|Experimental|1|TeenCope: Internet-based Coping Skills Training
89104864|NCT00684658|Active Comparator|2|Managing Diabetes: Internet-based Diabetes Education
89104865|NCT04144504|Active Comparator|Plastic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given balloon dilatation and plastic stenting for treatment.
89104866|NCT04144504|Active Comparator|Retrievable metallic stenting|Patients with post-liver transplantation and suffer from biliary anastomotic stricture would be given retrievable metallic stenting for treatment.
89104867|NCT02626468||Normal|Participants with no diagnosis of respiratory disease between the ages of 0 and 80
89104868|NCT02626468||COPD|Patients from different diagnostic groups between the ages of 0 and 80
89104869|NCT00684892|Experimental|1|
89104870|NCT04143802|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
89104871|NCT04143802|Active Comparator|Dulaglutide|Dulaglutide administered SC
89104872|NCT04143802|Placebo Comparator|Placebo|Placebo administered SC
89104873|NCT00684970|Other|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118 (single arm)
89104874|NCT00685048|Experimental|1|psychoeducation
89104875|NCT00685048|Experimental|2|brief advice
89104876|NCT00685048|Experimental|3|Motivational Enhancement Therapy (MET)/Cognitive-Behavioral Therapy (CBT)
89104877|NCT02626546||Major surgical procedures|All patients selected to follow up
89104878|NCT00682474|Experimental|CI|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
89104879|NCT00682474|Active Comparator|II|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
89104880|NCT00682552|Experimental|1|"A cervico-vaginal cervical smear will be realized before every colposcopique examination.~A new cervical taking for the search(research) and the detection of the HPV 16 and 18 will be realized."
89104881|NCT00685204|Experimental|A|This is a non-random, multicenter, open label, single agent study. Patients with mailgnanat mesothelioma that has reccured or progressed following chemotherapy, and who qualify for this study, will receive oral milataxel.
89104882|NCT00682630|Experimental|Clinical Trial Reference Tablets first, then To-Be-Marketed Tablets|Participants first received clinical trial reference 720:240 mg tablets on Day 0. After a washout period of 43 days, they then received to-be-marketed 720:240 mg tablets on Day 43, with a follow-up period of 42 days.
89104883|NCT00682630|Experimental|To-Be-Marketed Tablets first, then Clinical Trial Reference Tablets|Participants first received to-be-marketed 720:240 mg tablets on Day 0. After a washout period of 43 days, they then received clinical trial reference 720:240 mg tablets on Day 43, with a follow-up period of 42 days.
89104884|NCT00685282|Other|COGNITIVE BEHAVIORAL INTERVENTIONS|PSYCHOLOGICAL INTERVENTIONS TO INCLUDE, RELAXATION, STRESS REDUCTION, GUIDED IMAGERY, BREATHING EXERCISES
89104885|NCT00875056|Experimental|Follicular Lymphoma (FL)|Participants with relapsed/refractory FL received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
89104886|NCT00875056|Experimental|Indolent non-FL B-NHL or MCL|Participants with indolent non-follicular lymphoma (FL) B-cell non-Hodgkin's lymphoma (B-NHL), or with mantle cell Lymphoma (MCL) received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
89104887|NCT00875056|Experimental|Other Disease|Participants with disease other than relapsed/refractory follicular lymphoma (FL), non-FL B-cell non-Hodgkin's lymphoma (B-NHL), or mantle cell Lymphoma (MCL), as assessed by the Independent Central Pathological Committee, received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol. This group was created to include participants who enrolled, but whose later diagnoses by the Independent Central Pathological Committee excluded them from analysis in the FL and non-FL B-NHL/MCL groups because they had different disease than those prespecified in the protocol.
89104888|NCT00685594|Experimental|1|Cholecalciferol 20.000 IU per week for 5 years
89104889|NCT00685594|Placebo Comparator|2|
89104890|NCT00683098||1|patients, who had a endoscopic total extraperitoneal repair of recurrent inguinal hernia between 1995 and 2008
89104891|NCT04139746|Active Comparator|Scleral Buckling|Scleral Buckling represents the gold standard for retinal detachment in young phakic patients.
89104892|NCT04139746|Experimental|Drainage-Injection-Pneumoretinopexy|Drainage-Injection-Pneumoretinopexy is a modified pneumatic retinopexy technique, in which, before injecting the gas, the drainage of the subretinal fluid is performed with a simultaneous injection of balanced salt solution (BSS) in the vitreous chamber.
89104893|NCT00685672|Experimental|1|adrenalin
89104894|NCT00685672|Placebo Comparator|2|placebo
89104895|NCT04143178|Experimental|Expressive Writing Group|Writing group participants has been asked to write for 3 consecutive days, 20 minutes each days, all the deepest emotions and feelings related to the disease, the transplant, and their best expectations after the operation.
89104896|NCT04143178|Other|Control Group|The control group participant has been asked to describe an objects in their room, in a neutral way, without mentioning emotions or feelings,for 3 consecutive days, 20 minutes each day.
89104897|NCT00683176|Active Comparator|1|
89104898|NCT00683176|Placebo Comparator|2|
89104899|NCT02626234|Experimental|INC280|
89104900|NCT00685828|Active Comparator|Arm I|Patients receive low-dose oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
89104901|NCT00685828|Experimental|Arm II|Patients receive high-dose oral imatinib mesylate twice daily in the absence of disease progression or unacceptable toxicity.
89104902|NCT05298982||Intervention arm: TEAM protocol|Based on TEAM (III) protocol patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
89227808|NCT00972920|Active Comparator|Ultrasound-guided TAP block|"Technique as described by Hebbard. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Ultrasound probe covered with sterile sheath.~Identification of triangle of Petit with USS probe perpendicular to skin. Insertion of regional anaesthesia needle transversely to the probe, using in-plane (IP) technique, moving posteriorly. Advancement of the needle under ultrasound control until its tip is located between internal oblique and transversus abdominis muscle layers."
89104903|NCT05298982||Standard of Care arm: TEAM protocol|Based on TEAM (III) protocol the control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
89104904|NCT00685906|Experimental|1|
89104905|NCT00685906|Active Comparator|2|
89104906|NCT00683488|Experimental|1|Focus groups with adolescents with SA (Substance Abuse) will be conducted at each site (one group with 5 to 6 adolescents per site) to provide information on the areas of the intervention in need of adaptation in order to reflect the context of HIV infection.
89104907|NCT00683488|Experimental|2|The first intervention trial will enroll 9 participants (3 participants per site). Exit interviews of participants will assess acceptability, feasibility, and relevance of the intervention. Quantitative assessments pre and post intervention using audio computer-assisted self-interviewing (ACASI) will document immediate changes in substance use, sexual risk, and adherence to medical care. Additional qualitative feedback from interviews with mental health providers and study coordinators will address feasibility, acceptability, and relevance of the intervention and its methods.
89104908|NCT00683488|Experimental|3|The revised intervention will be implemented with 20 participants (6 to 8 at each site). Exit interviews with subjects and feedback from mental health providers and study coordinators will provide the same qualitative information as in the first intervention trial. Quantitative data on participant outcomes such as substance use, sexual risk, and adherence to medical care will be collected pre, post and 3 month post intervention through ACASI.
89104909|NCT00685984||1|
89104910|NCT00685984||2|
89104911|NCT00685984||3|
89104912|NCT00686062|Experimental|1|Women in this arm view the interactive, computerized, prenatal testing decision tool (PT Tool) we created.
89104913|NCT00686062|Active Comparator|2|Women in this arm view the age-appropriate computerized version of the educational pamphlet on prenatal testing developed and distributed by the State of California
89104914|NCT04139824|Experimental|Cohort|Period 1: LC350189 200mg (QD) Day 1~ Day 4, Period 2: Naproxen 500 mg (BID) Day 8 ~ Day 12 , Period 3 : LC350189 200mg (QD) + Naproxen 500 mg (BID) Day 13~19
89104915|NCT00940602|Experimental|Deferasirox|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
89104916|NCT00940602|Placebo Comparator|Placebo|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
89104917|NCT02626390|Experimental|Implicit Learning|Physiotherapy delivered based on implicit treatment guidance - achieved primarily by reducing the frequency of verbal coaching statements and promoting an external focus of attention.
89104918|NCT02626390|Active Comparator|Explicit Learning|Physiotherapy delivered based on explicit treatment guidance - achieved primarily by giving frequent verbal coaching statements and promoting an internal focus of attention.
89104919|NCT00686140|Experimental|Celecoxib, immune adjustor|Celecoxib
89104920|NCT00686140|Placebo Comparator|Placebo|Placebo looks like the active drug celecoxib, with the same dose
89104921|NCT00686218|Experimental|Treatment (panobinostat, imatinib mesylate)|Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89104922|NCT00683566|Experimental|1|A session in condition ON DOPAMINE and the other one in condition OFF DOPAMINE.
89104923|NCT00686296|Active Comparator|Group II|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing. Gauze dressing changes will continue per standard of care until the scheduled follow-up visits (first or second visit). At the scheduled follow-up visits, the subject will have a Taliderm™ dressing applied and left in place until the next scheduled dressing change (up to eight hours), then will continue standard of care wet to dry gauze dressing changes until next scheduled follow-up visit.
89104924|NCT00686296|Other|III|standard wet to dry dressing with gauze
89104925|NCT00686296|Active Comparator|group I|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing
89104926|NCT02850744|Other|Single-arm|Open label, single arm including patients with progressive glioblastoma during or after temozolomide chemotherapy obtaining PQR309 80mg capsules.
89104927|NCT04266834|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
89104928|NCT04266834|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
89104929|NCT04139668|Experimental|Vivitrol + MET/CBT|All participants will receive three 4ml doses of extended-release naltrexone 380mg (Vivitrol), administered by intramuscular injection. Three injections will be administered to each participant; one injection every 4 weeks for 12 weeks of treatment. In addition, all participants will receive weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy for 12 weeks.
89104930|NCT04266678|Experimental|Elastic band resistance training|Resistance training with elastic resistance bands two days per week for 6-weeks.
89104931|NCT04266678|Active Comparator|Dumbbell resistance training|Resistance training with dumbbell weights two days per week for 6-weeks.
89104932|NCT04266678|No Intervention|Non-exercise Control|Education and guidance for exercise recommendations in older adults but no active training sessions.
89104933|NCT00686452||1|Swimmers without AHR
89104934|NCT00686452||2|Swimmers with asymptomatic AHR
89104935|NCT00686452||3|Swimmers with symptomatic AHR and use only of beta-2 adrenargic
89104936|NCT00686452||4|Swimmers with asthma and inhaled corticosteroids
89104937|NCT00686452||5|Healthy Subjects
89104938|NCT00686452||6|Healthy subjects with AHR
89104939|NCT00686452||7|Healthy subjects with symptomatic AHR (asthma) but without treatment
89104940|NCT04266756|Experimental|Cohort 1: Selexipag Matrix Tablets|Participants will receive oral doses of selexipag matrix tablets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
89104941|NCT04266756|Experimental|Cohort 2: Selexipag Encapsulated Pellets|Participants will receive oral doses of selexipag encapsulated) pellets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
89104942|NCT00606060|Experimental|Arm 1|
89104943|NCT05379192||Group 1|Sociodemographic and clinical data of the patients who will be operated between 01:01-07:00 AM will be recorded. The total amount of antiemetic, the time of first antiemetic use, and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
89104944|NCT05379192||Group 2|Patients who were operated between 07:01-13:00. Sociodemographic and clinical data of the patients who will be operated between 07:00 AM- 01:00 PM will be recorded. The total amount of antiemetic, the time of first antiemetic use, and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
89104945|NCT05379192||Group 3|Sociodemographic and clinical data of the patients who will be operated between 01:00 - 08:00 PM will be recorded. The total amount of antiemetic, the time of first antiemetic use and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
89104946|NCT05379192||Group 4|Sociodemographic and clinical data of the patients who will be operated between 08:00 PM -01:00 AM will be recorded. The total amount of antiemetic,the time of first antiemetic use, and the VAS scores at the postoperative 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours will also be recorded.
89104947|NCT04266444|Active Comparator|Level 4|10Cubes game in virtual reality using very small bouncing blocks
89104948|NCT04266444|Active Comparator|Level 3|10Cubes game in virtual reality using very small non-bouncing blocks
89104949|NCT04266444|Active Comparator|Level 2|10Cubes game in virtual reality using large bouncing blocks
89104950|NCT04266444|Active Comparator|Level 1|10Cubes game in virtual reality using large non-bouncing blocks
89104951|NCT00875524|Experimental|CYD Dengue Vaccine Group|Participants who received CYD dengue vaccine as first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections. Participants were followed for 4 years after the third injection.
89104952|NCT00875524|Sham Comparator|Control Vaccine Group|Participants who received the Meningococcal Polysaccharide Vaccine A + C, placebo, and Typhoid Vi polysaccharide vaccine as the first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections, respectively. Participants were followed for 4 years after the third injection.
89104953|NCT04266600|Experimental|Prospective arm (extended mesenteric resection)|"Surgery can be performed either laparoscopically or open depending on surgeon preference and the circumstances of the surgery. Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis. The entire mesentery related to the specimen will be removed.~Outcomes in the prospective arm will be compared to historical controls."
89104954|NCT04266600|No Intervention|Retrospective arm|Retrospective patient data will be obtained by querying the Opera operating room database of both study institutions. Electronic records will be analyzed for all patients undergoing a first-time ileocolic resection for Crohn's Disease between January 1, 2009 - December 31, 2018.
89104955|NCT01094288|Experimental|Alisertib + Docetaxel|"Alisertib in escalating dose (10-40 mg), enteric-coated tablets (ECT), orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 along with docetaxel 60-75 mg/m^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable adverse events (AEs) or withdrawal of consent.~The starting alisertib dose is 10 mg, orally, twice daily (total 20 mg/day)."
89104956|NCT00686530||1|
89104957|NCT02850822||Therapy pre-transplantation|Chemotherapy regimen and/or demethylation drugs(such as decitabine) were given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
89104958|NCT02850822||No Therapy pre-transplantation|No therapy (chemotherapy or demethylation drugs) was given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
89104959|NCT00684034|Other|1|Volunteer healthy
89104960|NCT00684034|Other|2|Patient dialysis patient
89104961|NCT00684034|Other|3|Not dialysed chronic renal insufficient patient
89104962|NCT05380986|Experimental|Camrelizumab combined with apatinib mesylate|Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
89104963|NCT00684112|Experimental|Gabapentin|Single dose preoperative gabapentin
89104964|NCT00684112|Placebo Comparator|Placebo Control|Single dose preoperative placebo control
89104965|NCT04306796|Experimental|intervention group|Patients receiving 3D-printed made to measure splints for postoperative or post-traumatic treatment in hand surgical patients
89104966|NCT04306796|Active Comparator|control group|Patients receiving thermoplastic splints individually adjusted by occupational therapists
89104967|NCT00684190|Experimental|1|AZD3355 150 mg
89104968|NCT00684190|Experimental|2|Esomeprazole 40mg
89104969|NCT00684190|Experimental|3|AZD3355 150mg/Esomeprazole 40mg
89104970|NCT02877992|Active Comparator|Donors|Oocyte donors without infertility problems
89104971|NCT02877992|Experimental|PCOS|Patients with Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria
89104972|NCT02877992|Experimental|Endometriosis|Patients with endometriosis (I-IV)
89104973|NCT02877992|Experimental|Age|Patients with advanced maternal age (38 years or more)
89104974|NCT02877992|Experimental|Low ovarian response|Patients with low ovarian response according to Bologna criteria
89104975|NCT05380908||Patients with untreated non-small cell lung cancer|
89104976|NCT05380908||Patients with non-small cell lung cancer after chemotherapy|
89104977|NCT05380908||Normal controls|
89104978|NCT02626078||observation and interview of residents|residents will be observed over lunch and an interview will be held with each resident after lunch
89104979|NCT04307888||Study group|Patients undergoing Percutaneous Endovascular Aneurysm Repair (PEVAR), Percutaneous Endovascular Thoracic Aneurysm Repair (PTEVAR) or Transcatheter Aortic Valve Implantation (TAVI) in who percutaneous access closure device is used for implanting devices at aorta level.
89104980|NCT05379036|Experimental|Group A|a group of patients who, after the examination, were prescribed therapy with trimebutine 600 mg per day for 2 months
89104981|NCT05379036|Experimental|Group B|a group of patients who, after the examination, were prescribed therapy with rebamipide 300 mg per day for 2 months
89104982|NCT05379036|Experimental|Group C|a group of patients who, after the examination, were prescribed therapy with trimebutine 600 mg per day + rebamipide 300 mg per day for 2 months
89104983|NCT05379036|No Intervention|Control|healthy volunteers
89104984|NCT00686608|Experimental|Glucose|IV glucose
89104985|NCT00686608|Active Comparator|Fructose|
89104986|NCT00686608|Placebo Comparator|Saline|
89104987|NCT02879474||Patient with melanoma|
89104988|NCT02850666|Experimental|Interdisciplinary Process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
89104989|NCT00684268|Experimental|on treatment nonresponders|naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
89104990|NCT00684268|Experimental|Nonresponders to previous antiviral combination therapy|Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy
89104991|NCT00686764||Group 1|Trans-femoral amputees that meet the eligibility criteria.
89104992|NCT00684346|Experimental|1|
89104993|NCT00874120|Experimental|Phenylephrine HCl Extended-Release tablets 30 mg|Phenylephrine HCl Extended Release tablets 30 mg
89104994|NCT00874120|Placebo Comparator|Placebo|Placebo
89104995|NCT00939822|Experimental|Simvastatin|40 mg. Simvastatin/day
89104996|NCT00939822|Placebo Comparator|Placebo|Matching Placebo
89104997|NCT04139512|Other|guided surgery|test group, using a full digital workflow procedure
89104998|NCT04139512|Other|conventional technic|free- hand technic to place implant
89104999|NCT00687154|Active Comparator|1 Sitting|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 1 sitting
89105000|NCT00687154|Active Comparator|4 Sittings|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 4 sittings.
89105001|NCT00685126|Experimental|A|"Low dose levalbuterol (0.15 mg, 0.31 mg or 0.63 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
89105002|NCT00685126|Experimental|B|"High dose levalbuterol (0.31 mg, 0.63 mg or 1.25 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
89105003|NCT00685126|Active Comparator|C|"Racemic albuterol (0.63, 1.25 mg or 2.5 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
89105004|NCT00606216||A|TBI and Chemotherapy Conditioning Regimen. Twenty (20) patients will undergo conditioning treatment with TBI and chemotherapy prior to receiving a myeloablative allogeneic or an autologous HSCT.
89227809|NCT00975494|Active Comparator|sildenafil|sildenafil 50 mg three times/day
89227810|NCT00975494|Placebo Comparator|Placebo|Placebo
89227811|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|
89227812|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|
89227813|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 30 μg|
89227814|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|
89227815|NCT00975572|Placebo Comparator|Placebo control|
89227816|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|
89227817|NCT00678587|Placebo Comparator|Placebo|placebo, once daily, oral
89227818|NCT00678587|Active Comparator|Active|75 mg, once daily, oral
89227819|NCT00972998|Experimental|Healthy individuals|
89227820|NCT00965666|Experimental|Open Label|
89227821|NCT00965744|Experimental|Vessel sealing system LigaSure (VS group)|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
89227822|NCT00965744|No Intervention|Conventional hand-tied method (CH group)|Patients in CH group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the conventional hand-tied method.
89227823|NCT00973076|Experimental|AZD8055|AZD8055 will be administered orally
89227824|NCT02559479|Active Comparator|18%-Protein diet|Energy-restricted diet wit the following composition: 18% protein, 30% fat and 52% carbohydrates
89227825|NCT02559479|Active Comparator|35%-Protein diet|Energy-restricted diet wit the following composition: 35% protein, 30% fat and 35% carbohydrates
89227826|NCT00975728|Experimental|Group 1 Product 825 (2-servings day)|30 subjects drinking 2 servings day of Product 825 for 8 weeks
89227827|NCT00975728|Experimental|Group 1 Product 824 (2 servings-day)|30 subjects drinking 2 servings-day of Product 824 for 8 weeks
89227828|NCT00975728|Experimental|Group 2 Product 825 (1 serving-day)|30 subjects drinking 1 serving-day of Product 825 for 8 weeks
89227829|NCT00975728|Experimental|Gruop 2 Product 824 (1 serving-day)|30 subjects drinking 1 serving-day of Product 824 for 8 weeks
89227830|NCT02559011||All study participants|Patients who need a TAVI with symptomatic severe aortic valve stenosis
89227831|NCT04049747|Experimental|CHRONOS A - Arm 1 (Control)|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]). In patients undergoing radiotherapy a maximum of 6-months neo-adjuvant hormonal therapy will be allowed. In patients undergoing radical prostatectomy, cytoreduction of maximum 6 months with medication will be permissible, provided this is part of local practice.
89227832|NCT04049747|Experimental|CHRONOS A - Arm 2 (Intervention)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second focal therapy session in-field, or a first focal therapy session to an out-of-field progressive or de novo lesion will be allowed as part of the focal therapy intervention.
89227833|NCT04049747|Experimental|CHRONOS B - Arm 3 (Control)|Focal therapy alone (high intensity focused ultrasound [HIFU] or cryotherapy as per physician and centre choice). A second treatment in-field, or a first focal ablation to an out-of-field progressive or de novo lesion will be allowed but will be regarded as failure events for the purpose of CHRONOS-B.
89227834|NCT04049747|Experimental|CHRONOS B - Arm 4 (Intervention):|Neoadjuvant finasteride 5mg once daily for a minimum of 12 weeks followed by focal therapy (as per CHRONOS B control arm).
89227835|NCT04049747|Experimental|CHRONOS B - Arm 5 (Intervention)|Neoadjuvant bicalutamide 50mg once daily therapy for a minimum of 12 weeks followed by focal therapy (as per control arm).
89227836|NCT00973154|Active Comparator|Prednisone|Drug
89227837|NCT00973154|Placebo Comparator|Placebo|
89227838|NCT00965822|Active Comparator|1|
89227839|NCT00965822|Placebo Comparator|2|
89227840|NCT04822025|Experimental|High Dose|High-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89227841|NCT04822025|Experimental|Mid Dose|Mid-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89227842|NCT00965900|Active Comparator|Endoscopic band ligation|Endoscopic band ligation until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment
89227843|NCT00965900|Active Comparator|Propranolol|start with 20 mg b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
89227844|NCT00965900|Active Comparator|EBL+Propranolol|"EBL until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment~start with 20 mg of propranolol b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
89227845|NCT00973232|Experimental|Part A, Arm A|
89227846|NCT00973232|Experimental|Part A, Arm B|
89227847|NCT00973232|Active Comparator|Part A, Arm C|
89227848|NCT00973232|Active Comparator|Part A, Arm D|
89227849|NCT00973232|Experimental|Part B, Arm E|
89227850|NCT00973232|Active Comparator|Part B, Arm F|
89227851|NCT00973232|Active Comparator|Part B, Arm G|
89105005|NCT00606216||B|Chemotherapy Alone Conditioning Regimen Twenty (20) patients will undergo conditioning treatment with an all chemotherapy regimen prior to receiving an allogeneic or an autologous HSCT.
89105006|NCT00606216||C|A cohort of twenty (20) healthy controls, frequency matched on age, gender, and education, will be recruited at WCMC to participate in the study.
89105007|NCT00687232|Experimental|1|AZD4818
89105008|NCT00687232|Placebo Comparator|2|
89105009|NCT05382780|Experimental|The breather respiratory muscle trainer group|40 patients (20 males and 20 females) will receive The breather respiratory muscle trainer for 30 minutes and mild interval aerobic training and respiratory training on treadmill 3 times / week for 12 weeks.
89105010|NCT05382780|Experimental|Diaphragmatic and localized breathing exercises group|40 patients (20 males and 20 females) will receive diaphragmatic and localized breathing exercises ( especially Middle & Lower segments) and mild intensity interval aerobic training and respiratory training on treadmill 3 times / week for 12 weeks,
89105011|NCT04138654|Experimental|Normal nitrite levels|Processed meat products enriched with natural compounds will contain normal nitrite levels.
89105012|NCT04138654|Experimental|Reduced nitrite levels|Processed meat products enriched with natural compounds will contain reduced nitrite levels
89105013|NCT00604734|Other|ReCap|ReCap Total Hip Resurfacing System
89105014|NCT05380674||quality of life|The short questionnaire of healthy habits for adults of the PASOS (Physical Activity, Sedentarism and Obesity in Spanish Youth) study was used, which collects sociodemographic data, weight, height, and physical activity, self-reported.
89105015|NCT00687310|Other|1|Educational Intervention At the initial visit (Visit 1), patients in the educational intervention group will complete a short Needs Assessment Questionnaire to help the investigator/nurse determine which section(s) of the tailored patient education booklet to give to, educate, and provide instruction on to the patient. This may, at the discretion of the investigator, include providing their patient with a peak flow meter and instructions on its use.Visit 2 will be scheduled for 1-month after the Visit 1 for the education intervention group. All educational materials provided at Visit 1 will be reviewed with the patient at Visit 2. The investigator/nurse will reassess the patient's use of the Turbuhaler® and asthma treatment plan. Patients will also be asked about any adverse events that may have occurred since Visit 1 and/or are observed at Visit 2. Once Visit 2 is completed with the patient, the investigator/nurse will complete the Educator Satisfaction Questionnaire.
89105016|NCT05382624||Patients undergoing cesarean with spinal anesthesia|The AC-to-hip ratio was calculated by dividing the values of the abdominal (cm) and hip circumference (cm). Spinal anesthesia in the sitting position was performed in all patients using 2.4 ml 0.5% hyperbaric bupivacaine (12 mg). Intravenous ephedrine (5 mg) was given in case of persistent hypotension. The number of patients requiring ephedrine and the total amount of ephedrine used during surgery were recorded.
89105017|NCT04139590|Placebo Comparator|Visual Analogue Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Visual Analogue Scale."
89105018|NCT04139590|Active Comparator|Visual Analogue Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Visual Analogue Scale."
89105019|NCT04139590|Placebo Comparator|Numeric Rating Scale - Original|"Participants indicated the intensity of their pain by marking a X along the original paper version of the Numeric Rating Scale."
89105020|NCT04139590|Active Comparator|Numeric Rating Scale - Panda|"Participants indicated the intensity of their pain by marking a X on the smartphone screen using the Panda of the Numeric Rating Scale."
89105021|NCT05382468|Experimental|Intradialytic exercise|In this study intradialytic exercise comprised of a set warm up, aerobic, active, passive & cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month & supervised by principle investigator.
89105022|NCT00603876|Experimental|2|Step 1 dietary counseling plus 100-110 grams of almonds daily
89105023|NCT00603876|No Intervention|1|Step 1 dietary counseling
89105024|NCT00687388|Active Comparator|Alpha-blocker|Alpha-blocker only
89105025|NCT00687388|Active Comparator|NSAID|NSAID only
89105026|NCT00687388|Experimental|alpha-blocker and NSAID|Combination treatment of alpha-blocker and NSAID
89105027|NCT02625688|Placebo Comparator|Early cord clamping|Cord clamping will be applied after 30 seconds post delivery.
89105028|NCT02625688|Active Comparator|Delayed cord clamping|Cord clamping will be applied after 3 minutes post delivery.
89105029|NCT02625688|Active Comparator|Cord milking|The baby will be placed below the level of the placenta, between the mother's thighs (during a vaginal delivery) or at the side of the mother swaddled in sterile towels (during a caesarian delivery).
89105030|NCT00939510|Experimental|Lenalidomide (RevlimidTM ) and GM-CSF|
89105031|NCT00687466|Experimental|1|Insulin yes
89105032|NCT00687466|No Intervention|2|Insulin no
89105033|NCT00606372||1|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated with use of the cardio-pulmonary bypass
89105034|NCT00606372||2|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated without use of the cardio-pulmonary bypass
89105035|NCT00690664||B|Caucasian women
89105036|NCT00690664||A|African American women
89227852|NCT03440099|Other|Training|All participants will participate in the 16-week resistance exercise training program.
89227853|NCT04049435||horizontal deficiency anterior maxilla|Using the titanium sheet in augmentation of horizontally deficient anterior maxilla will be efficient, time saving, accurate reconstruction
89227854|NCT00973310|Experimental|Combined Treatment arm|All the patients received oral erlotinib and concurrent radiation therapy
89227855|NCT04762823|Experimental|PD-ctDCS|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
89227856|NCT04762823|Sham Comparator|PD-sham|People with Parkinson's disease will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the less PD-affected side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
89227857|NCT04762823|Active Comparator|NH-ctDCS|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is ramped up to 4 mA over the first 30 seconds and stays at 4 mA for the remainder of the stimulation time.
89227858|NCT04762823|Sham Comparator|NH-sham|Neurologically healthy older adults will have both electrodes placed 1-2 cm below and 3 cm to either side of the inion, with the anode assigned to the most PD-affected side and the cathode assigned to the non-dominant side. Stimulation is turned on (4 mA) for 30 seconds at the beginning and the end of the trial, but it turned to 0 mA in the intervening time.
89227859|NCT00965978|Experimental|Low dose group|Receives low dose of ONO-5920/YM529 with and without food
89227860|NCT00965978|Experimental|High dose group|Receives high dose of ONO-5920/YM529 with and without food
89227861|NCT00975962|Experimental|Thrombolysis + Remote perconditioning|"Remote perconditioning (rIPerC) undertaken in ambulance on rute to hospital in case of suspected stroke.~The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC."
89227862|NCT00975962|Active Comparator|Thrombolysis|Thrombolysis without pretreatment with remote perconditioning
89227863|NCT00966056|Active Comparator|Mitomycin C|Cases recruited into this arm receive topical application of mitomycin c (1mg/ml)following surgical synechiolysis
89227864|NCT00966056|Active Comparator|Teflon septal splint|Cases recruited into this arm receive insertion of teflon internal nasal septal splint following surgical synechiolysis
89227865|NCT00976040|Experimental|Early antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy within 7 days of enrollment.
89227866|NCT00976040|No Intervention|Standard antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy approximately 4 weeks after enrollment.
89227867|NCT04008212||EVAR aneurysm|
89227868|NCT04008212||Stenosis|
89227869|NCT03523728|Placebo Comparator|Stage 1- Placebo|Participants from Stage 1 were randomized to receive 2 capsules of placebo matched to venglustat once daily for treatment period of 24 months.
89227870|NCT03523728|Experimental|Stage 1- Venglustat 8 mg|Participants from Stage 1 were randomized to receive venglustat 8 milligrams (mg) (i.e., 2 capsules of 4 mg) once daily for treatment period of 24 months.
89227871|NCT03523728|Experimental|Stage 1- Venglustat 15 mg|Participants from Stage 1 were randomized to receive 1 capsule of venglustat 15 mg and 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months.
89227872|NCT03523728|Placebo Comparator|Stage 2- Placebo|Participants from Stage 2 were randomized to receive 1 capsule of placebo matched to venglustat once daily for treatment period of 24 months.
89227873|NCT03523728|Experimental|Stage 2- Venglustat 15 mg|Participants from Stage 2 were randomized to receive 1 capsule of venglustat 15 mg once daily for treatment period of 24 months.
89227874|NCT00979706|Active Comparator|HAART|Patients assigned to this arm will receive standard HAART
89227875|NCT00979706|Experimental|HAART + Immunotherapy|Patients assigned to this arm will receive HAART plus cyclosporin A during the first two months and after that will receive IFN, GM-CSF and IL-2.
89227876|NCT00979784|Active Comparator|1|
89227877|NCT00979784|Experimental|2|
89105037|NCT04266288|Experimental|Ketamine|Ketamine 0.5 mg/kg in 0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose.
89105038|NCT04266288|Placebo Comparator|Placebo|0.9% sodium chloride, total volume 50 mL via intravenous infusion over 40 minutes for one dose
89105039|NCT02625532|Active Comparator|Follicular phase|Controlled ovarian stimulation starts during follicular phase on day 2-3 of the menstrual cycle
89105040|NCT02625532|Experimental|Luteal phase|Controlled ovarian stimulation starts during luteal phase on day 3 to 5 after first LH positive urine test
89105041|NCT00687622|Experimental|GSK1120212|Part 1 will identify the maximum tolerated dose using a dose-escalation procedure. Part 2 will explore further the safety, tolerability, and clinical activity of GSK1120212 in subjects with pancreatic, melanoma, non-small cell lung, and KRAS or BRAF mutation-positive colorectal cancer. Part 3 will characterize the range of biologically effective doses by assessing pharmacodynamic markers in tumor tissue
89105042|NCT01098266|Experimental|A: NGR-hTNF + BIC|NGR-hTNF plus Best Investigator's Choice
89105043|NCT01098266|Placebo Comparator|B: Placebo+BIC|Placebo plus Best Investigator's Choice
89105044|NCT00687700|Experimental|All subjects|Eligible subjects will receive GSK961081 (400 micrograms or 1200 micrograms), GSK961081 matching placebo, propranolol (80 milligrams) and propranolol matching placebo in five treatment sessions through ten different crossover treatment sequences. There will be a washout period between treatment sessions of 7 to 14 days.
89105045|NCT00935532|Experimental|exenatide once weekly|
89105046|NCT00935532|Active Comparator|insulin glargine|
89105047|NCT04139356|Experimental|Patients with rest O2 desaturation|Patient will undergo an experimental protocol consisting of 10 deep inspirations to measure and characterize changes on pulse-oxymetry values
89105048|NCT04138420||Patients receiving Bevacizumab|Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05 mL.
89105049|NCT05378646|Experimental|Experimental|Patients received Ingaron 500,000 IU subcutaneously once a day, every other day. The course of treatment is 7 injections. The first injection was given on the first day of active therapy. Subsequent injections were given every other day. The period of active therapy was 14 days.
89105050|NCT05378646|No Intervention|Control|Patients received standard treatment for chronic prostatitis. The period of active therapy was 14 days.
89105051|NCT01093586|Experimental|Arm I|PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
89105052|NCT00687778||1|100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer, well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and lobular breast carcinoma.
89105053|NCT04266132|Active Comparator|Retrolamianar block (RLB)|General anaesthesia will be induced.Ultrasound-guided RLB will be performed under strict aseptic precautions with patient in the lateral position.The anesthetic solution will be injected.
89105054|NCT04266132|Active Comparator|Ilioinguinal nerve block (INB)|General anaesthesia will be induced. Ultrasound-guided INB will be performed under strict aseptic precautions with patient in the supine position.The anesthetic solution will be injected.
89105055|NCT02625454|Experimental|Intravenous Acetaminophen|Subjects will receive 1000 mg of intravenous Acetaminophen q 6 hours, up to two doses and an oral placebo resembling oral acetaminophen
89105056|NCT02625454|Active Comparator|Oral Acetaminophen|Subjects will receive 1000 mg of oral Acetaminophen q 6 hours, up to two doses and an intravenous placebo resembling intravenous acetaminophen
89105057|NCT00606450|Experimental|20 mg Apremilast daily|20 mg of CC-10004 daily
89105058|NCT00606450|Experimental|20mg Apremilast twice daily|CC-10004 twice daily
89105059|NCT00606450|Placebo Comparator|Placebo|Placebo arm
89105060|NCT00687934|Experimental|Ganetespib|Ganetespib once weekly infusion, dose escalation study, with treatment until progression
89105061|NCT02879552||Traditional upper blepharoplasty|Patients with an odd total number of letters in their first name received traditional upper blepharoplasty.
89105062|NCT02879552||Brassiere suture with blepharoplasty|The rest of the patients received orbicularis oculi muscle fixation to periosteum (brassiere sutures)
89105063|NCT04138888|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in Period 1 and a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89105064|NCT04138888|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 x 40 mg/ 25 mg tablet), marked as B in the sequence, in Period 1 and a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89105065|NCT04266210|Experimental|Fuji Bulk|Glass ionomer (Fuji Bulk, GC, Tokyo Japan)
89105066|NCT04266210|Experimental|G-ænial Posterior|Posterior composite resin(G-ænial Posterior, GC, Tokyo Japan)
89105067|NCT04139044|Experimental|Stable Ankle Training Group (SG)|Balance Exercise Training for Only The Stable Ankle
89105068|NCT04139044|Experimental|Unstable Ankle Training Group (UG)|Balance Exercise Training for Only The Unstable Ankle
89105069|NCT04139044|No Intervention|Control Group (CG)|No balance exercise training
89105070|NCT00937404|Experimental|IPV Group|Healthy male or female subjects between, and including, 60 and 90 days of age at the time of the first vaccination, receive 3 doses of Poliorix at 2 (Study Day 0, Visit 1), 3 (Study Month 1, Visit 2) and 4 (Study Month 2, Visit 3) months of age, administered intramuscularly into the upper right side of the thigh.
89105071|NCT00688090|Experimental|Low-Dose Peptide Cohort|
89105072|NCT00688090|Experimental|High-Dose Peptide Cohort|
89105073|NCT00688168||Symptom Assessments|Patients diagnosed with multiple myeloma (MM) complete questionnaires with Neurocognitive Testing and Neurosensory Testing
89105074|NCT00690976|Experimental|1.Group Intervention|A group-based intervention consisting of 4 sessions lasting approximately 90 minutes each. Using a variety of pedagogical and interactive approaches, facilitators will introduce new concepts and skills.
89105075|NCT00690976|Active Comparator|2. HCT|Offer of HIV counseling and testing
89105076|NCT02625142|Experimental|Family-centered rounds checklist|"During the post-intervention period, health care team members on two pediatric inpatient services received the Family-centered Rounds Checklist tool, as well as training in how to use the checklist in the delivery of effective family-centered rounds"
89105077|NCT02625142|No Intervention|Usual care|Two pediatric inpatient services were not provided the Family-centered rounds checklist tool, and delivered morning rounds in their usual manner. These services served as a control.
89105078|NCT01098110|Experimental|Asenapine 5 mg BID|Participants received a 5 mg asenapine fast dissolving tablet twice daily (BID) for 6 weeks.
89105079|NCT01098110|Experimental|Asenapine 10 mg BID|Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.
89105080|NCT01098110|Placebo Comparator|Placebo BID|Participants received matching placebo BID for 6 weeks.
89105081|NCT04138966||Patients undergoing general anesthesia|Patients are monitored with Nol-Index, skin conductance, and antinociception-index
89105082|NCT00912496|Experimental|Group 9: 2 dose prime|Received two doses of A/Vietnam/1203/04 90mcg vaccine as prime (on Days 0, 28 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
89105083|NCT00912496|Experimental|Group 8: 1 dose prime|Received A/Vietnam/1203/04 90mcg vaccine as prime (Day 0 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
89105084|NCT00912496|Experimental|Group 10: unprimed control/dose response group|Unprimed control and dose response group of H5 vaccine naive volunteers will be added in DMID 08-0013 to receive two doses of A/Anhui/05 vaccine (A) with or without MF59 adjuvant or placebo on Day 0 and Day 28.
89105085|NCT02879396|Experimental|Study Participants|A maximum of 50 participants will be enrolled in the study per the inclusion and exclusion criteria. The participants will be residents of SLH who are 55 years old or older. They will have had one or more EMS calls made, ED visit or hospital admission in the past year, as determined by the incidence report at SLH. The study participants will receive PA4LE program.
89105086|NCT04048408||Obstructive lung diseases group|
89105087|NCT04048408||Healthy group|
89105088|NCT04138342|Active Comparator|Quantum dots nanoparticles group|A group of female volunteers infected with breast cancer will receive topical Quantum dots in different dosage forms.
89105089|NCT04138342|Placebo Comparator|Topical approved placebo cream|A group of female volunteers infected with breast cancer will receive placebo cream as a negative control.
89105090|NCT00688402|Experimental|1|IR Formulation 65 mg
89105091|NCT00688402|Experimental|2|IR Formulation 150 mg
89105092|NCT00688402|Experimental|3|MR formulation, 1h 65 mg
89105093|NCT00688402|Experimental|4|MR Formulation, 1h 150 mg
89105094|NCT00688402|Experimental|5|MR Formulation, 2h 150 mg
89105095|NCT04138264|Active Comparator|Peroperative counseling|
89105096|NCT04138264|No Intervention|No preoperative counseling|
89105097|NCT00688480|Placebo Comparator|I|CKD Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2), Echo LVH
89105098|NCT00688480|Active Comparator|2|
89105099|NCT01092728|Active Comparator|Group 1: Completely Resectable|Dasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).
89105100|NCT01092728|Active Comparator|Group 2: Unresectable|100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment).
89105101|NCT00688558|Experimental|1|JTT-705 600 mg and simvastatin 40 mg
89105102|NCT00688558|Placebo Comparator|2|Placebo and simvastatin 40 mg
89105103|NCT04031326|Experimental|LENA Home|Home visitors assigned to the intervention group will be trained to use and administer LENA Home in addition to the standard ECS curriculum during designated home visits beginning when the child is between 6- and 9-months old.
89105104|NCT04031326|No Intervention|Standard Practice|Home visitors assigned to the control group will administer the standard ECS curriculum only
89105105|NCT01096550|Experimental|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
89105106|NCT01096550|Active Comparator|Outpatient|Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
89105107|NCT02625376|Experimental|Trans-Resveratrol|capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
89105108|NCT02625376|Active Comparator|Resvega|"capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.~two capsules daily : one in the morning and evening for 24 months"
89105109|NCT02625376|Placebo Comparator|Placebo|capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
89105110|NCT00688714|Experimental|1|
89105111|NCT00688714|Placebo Comparator|2|
89105112|NCT01101542||Cervarix Group|Subjects received 3 doses of the Cervarix vaccine. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0,1, 6 month vaccination schedule. According to the prescribing information, if flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose.
89105113|NCT04153084||High volume electrolytes Polyethylene Glycol (PEG 4000) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using high volume electrolytes PEG (Bohm solution®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
89105114|NCT04153084||Low volume electrolytes PEG (PEG 3350) cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using low volume electrolytes PEG (Movicol®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
89105115|NCT04153084||Sodium picosulfate cohort|Pediatric patients who have prepared for a colonoscopy during the years 2018-2019 using sodium picosulfate (Picoprep®) endoscopic preparation, as part of a diagnostic procedure not related to this study.
89105116|NCT00691288|Experimental|1|
89105117|NCT00691288|Experimental|2|
89105118|NCT00672334|Placebo Comparator|2|sodium chloride at 0.5 mmol/kg loading pre-induction and then at 0.2 mmol/kg/hr over 24 hours after induction until the next day
89227878|NCT00979862|Experimental|Treatment cediranib maleate, cilengitide)|"Part A (dose finding): Patients receive cediranib maleate PO once daily on days 1-28 and cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Part B (dose expansion): Patients are assigned to 1 of 2 groups according to prior anti-VEGF therapy (yes vs no). Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A."
89227879|NCT00966134||probands|
89227880|NCT00976118|Placebo Comparator|placebo|
89227881|NCT00976118|Experimental|oral masitinib (AB1010)|masitinib (AB1010) 3 or 6 mg/kg/day
89227882|NCT00966212|No Intervention|health promotion materials|
89227883|NCT00966212|Active Comparator|print parent education|
89227884|NCT00980252|Experimental|CBT|UK-based intervention
89227885|NCT00966290|Experimental|ACC group|Anticoagulant clinic-based shared-care group
89227886|NCT00966290|Active Comparator|UC group|Usual care group
89227887|NCT04004052|Active Comparator|Group 1|Blockade of the LFCN is performed for therapeutic management of MP in group 1.
89227888|NCT04004052|Active Comparator|Group 2|Ten sessions of conventional TENS were applied to the group 2 daily 20 minutes per session, 5 days per week, for 2 weeks.
89227889|NCT04004052|Sham Comparator|Group 3|Sham TENS was applied to the group 3 with the same protocol.
89227890|NCT00966368|Experimental|IDeg E|
89227891|NCT00966368|Experimental|IDeg M|
89227892|NCT00980408|Placebo Comparator|Sugar pill, behavioral glutamic acid|Placebo condition for D-Cycloserine
89227893|NCT00980408|Placebo Comparator|Sugar pill, fMRI, glutamic acid|Placebo condition for D-Cycloserine, fMRI
89227894|NCT00980408|Placebo Comparator|Sugar pill, memantine, behavioral|Placebo condition Memantine, behavioral
89227895|NCT00980408|Placebo Comparator|Sugar pill, memantine, fMRI|Placebo condition Memantine, fMRI
89227896|NCT00980408|Active Comparator|D-Cycloserine behavioral|
89227897|NCT00980408|Active Comparator|D-Cycloserine, fMRI|
89227898|NCT00980408|Active Comparator|Memantine, behavioral|
89227899|NCT00980408|Active Comparator|Memantine, fMRI|
89227900|NCT01563822|Experimental|follicular fluid group|Follicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.
89227901|NCT01563822|No Intervention|control group|Control group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.
89227902|NCT00980486||BMI <30|BMI <30
89227903|NCT00980486||BMI 30-39|BMI 30-39
89227904|NCT00980486||BMI >40|BMI >40
89227905|NCT04007822||Physiotherapists|Physiotherapists will be recruited using the following inclusion criteria: (1) two years of experience in treating patients with chronic pain, (2) currently working in an MSK outpatient clinic and (3) able to read and speak English to a level allowing satisfactory completion of the study procedures. There are no exclusion criterium. Potential participants will be recruited through the relevant gatekeeper. The gatekeeper will be responsible of forwarding the participant information sheet and consent form to the physiotherapists. Physiotherapists will be asked to demonstrate their interest by replying to the email. Any questions will be answered by the research team via email or phone.
89227906|NCT04007978|Experimental|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
89227907|NCT00980876|Active Comparator|Cipro HC|Reference product
89227908|NCT00980876|Experimental|Ciprofloxacin HCl and Hydrocortisone|Test product
89227909|NCT00981032|Experimental|Pre-visit Summary|Patients in this arm will receive a pre-visit summary prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
89227910|NCT00981032|Experimental|Clinical Decision Sharing Tool|Patients in this arm will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
89227911|NCT00981110|Active Comparator|Mepore Self-adhesive absorbent dressing|Mepore Self-adhesive absorbent dressing
89227912|NCT00981110|Experimental|AQUAGEL Ag Hydrofiber Wound Dressing|AQUAGEL Ag Hydrofiber Wound Dressing
89227913|NCT00981266|Other|Augmentation|"The study population will consist of women aged 22 or over who are undergoing primary breast augmentation.~The Augmentation cohort will include candidates for general breast enlargement, post-lactational involution and/or asymmetry."
89227914|NCT00981266|Other|Augmentation Revision|"The study population will consist of women aged 22 or over who are undergoing augmentation revision.~The Augmentation Revision cohort will include candidates with previous augmentation with silicone-filled or saline-filled implants."
89227915|NCT00976430|Experimental|Therapy for Parkinson's disease|Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.
89227916|NCT00976586||Patients wiht Incontinentia Pigmenti|Patients wiht Incontinentia Pigmenti
89227917|NCT00976742|Experimental|Endurance Exercise Training|
89105119|NCT00672334|Experimental|1|The active intervention is loading (05. mmol/kg) pre-surgery and continuous infusion of bicarbonate at 0.2 mmol/kg/hr for 24 hours after induction
89105120|NCT00937326|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight placebo capsules per day.~Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
89105121|NCT00937326|Active Comparator|Arm1 - 0.25g|"The 0.25g SRT2104 treatment group will be administered one SRT2104 capsules with 7 placebo capsules, for a total of 8 capsules per day.~0.25g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
89105122|NCT00937326|Active Comparator|Arm2 - 0.5g|"The 0.5g SRT2104 treatment group will be administered two SRT2104 capsules with 6 placebo capsules, for a total of 8 capsules per day.~0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
89105123|NCT00937326|Active Comparator|Arm3 - 1g|"The 1g SRT2104 treatment group will be administered four SRT2104 capsules with four placebo capsules, for a total of 8 capsules per day.~1g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
89105124|NCT00937326|Active Comparator|Arm4 - 2g|"The 2g SRT2104 treatment group will be administered eight SRT2104 capsules per day.~2g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
89105125|NCT04152694|Other|Ceftaroline in CRRT|Ceftaroline levels measured in patients receiving continuous renal replacement therapy
89105126|NCT00689182|Experimental|A|All patients will receive phlebotomy
89105127|NCT04138186|Experimental|2.0g G-PUR® capsules|
89105128|NCT04138186|Placebo Comparator|Placebo capsules|
89105129|NCT02629666|Active Comparator|Exercise Referral Scheme (ERS)|In the Exercise Referral Scheme (ERS) intervention participants will undergo a physical activity program of 16 weeks, with two sessions per week (60 minutes each session). Participants will be asked to perform the activity in a moderate to vigorous intensity (according to each individual's progression) during the central part of each session. Intensity will be estimated using the modified Borg Scale of Perceived Exertion (e.g. moderate intensity activity will be considered as a 4 to 6 and vigorous-intensity activity as a 7 to 9) or with training loads (i.e. ankle weights and dumbbells) corresponding to 70-80% of maximum, adjusted progressively during the training period. ERS programs will be based on a combination of aerobic, strength-based, balance and flexibility activities, with a specially trained PA specialist. These sessions will be always performed under the supervision of the same trainer. The PA intervention is adapted to the participants' functional status.
89105130|NCT02629666|Experimental|ERS + Self-management Strategies|"Participants will undergo the aforementioned Physical Activity program plus 11 sessions of Self-Management Strategies (SMS).~SMS start with a face-to-face session in an indoor primary-care facility. The next 6 sessions are further implemented in a group format. SMS are aimed at increasing self-efficacy in reducing sedentary behaviour and at adopting/maintaining an active behaviour as complement to a standard physical activity program (ERS). SMS group sessions will be conducted during week 3 to 11 of the ERS, after the PA sessions (6 sessions: 3 once a week, 3 once every second week). There will be 4 telephone contacts during the adherence phase, at week 15, 20, 25 and 30."
89105131|NCT02629666|No Intervention|Control group|Researchers will give to all participants during the first informative meeting (prior assessment) a written general booklet standardized across sites with WHO recommendation regarding PA regular practice for health. During the intervention, a health advice meeting with standardized topics about healthy lifestyle and feedback on some outcomes regarding their results will be held twice in the Primary Health Centre (at week 5, and at week 11). Researchers will send a letter or phone call prior to each follow up reminding the next assessment.
89105132|NCT00873730|Experimental|1|
89105133|NCT00873730|Active Comparator|2|
89105134|NCT00689416|Experimental|1|
89105135|NCT00689416|Placebo Comparator|2|
89105136|NCT00672568|Experimental|1|4975
89105137|NCT00672568|Experimental|2|4975
89105138|NCT00672568|Experimental|3|4975
89105139|NCT00672568|Placebo Comparator|4|Placebo
89105140|NCT02629432||Cosyconet COPD Cohort|MRI and CT of the lung will be performed in a multi-centre cohort of 625 COPD-patients from the main COSYCONET cohort.
89105141|NCT00922714|Experimental|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
89105142|NCT00922714|Placebo Comparator|Control|saline
89105143|NCT00691834|Experimental|1|Intracoronary delivery of unfractionated bone marrow mononuclear cells
89105144|NCT00691834|Placebo Comparator|2|Intracoronary delivery of placebo
89105145|NCT00672724|Experimental|Ramelteon 8 mg QD|
89105146|NCT00672724|Placebo Comparator|Placebo|
89105147|NCT05380596|No Intervention|Control|Patients in the control group will remain out of contact with the research group and will receive usual care, which consists of receiving medications without additional information. After completion of the project, the control group will receive educational materials related to the care of people with diabetes and, if the effectiveness of the Pharmaceutical Telecare service is proven, this possibility of care will be offered to users.
89105148|NCT05380596|Active Comparator|Intervention|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3), via cell phone. Each consultation will address an aspect of health education for DM2.
89105149|NCT00689650|Experimental|A|
89105150|NCT00689650|No Intervention|B|
89105151|NCT05382156||Osilodrostat|Osilodrostat - tablets of 1mg, 5mg, 10mg - based on patients needs - up to 3 years
89105152|NCT00604032|Placebo Comparator|1|
89105153|NCT00874432|Active Comparator|Chronic Kidney Disease-ACE-I|ace inhibitor
89105154|NCT00874432|Placebo Comparator|Chronic Kidney Disease|
89105155|NCT00874432|Active Comparator|Age matched control-ACE-I|ace-inhibitor
89105156|NCT00874432|Placebo Comparator|Age matched control|Placebo
89105157|NCT00606528||Group A|patients with chronic Hepatitis C Virus infection who have not previously received antiviral therapy
89105158|NCT00606528||Group B|Healthy volunteers willing to donate blood on 2 separate occasions
89105159|NCT04138108|Experimental|Experimental Group|Two sessions of psychoeducation were given to the parents in the experimental group.
89105160|NCT04138108|No Intervention|Control Group|The parents in the control group did not undergo any intervention and the children of the parents in this group continued their current treatment plans.
89105161|NCT00935220|Experimental|linagliptin|Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation
89105162|NCT00691912|Experimental|Myocet/Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
89105163|NCT00874276|Experimental|No EGT Allele, slow metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
89105164|NCT00874276|Experimental|1+ EGT Allele, fast metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
89105165|NCT05382390|Experimental|lderly Patients With Acute Myeloid Leukemia DCTAG|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count > 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
89105166|NCT05382390|Other|lderly Patients With Acute Myeloid Leukemia|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
89105167|NCT04265820|Experimental|Group 1|The unilateral cataract patients in the Group 1 will undergo phacoemulsification and unilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
89105168|NCT04265820|Active Comparator|Group 2|The bilateral cataract patients in the Group 2 will undergo phacoemulsification and bilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.
89105169|NCT05378412|Experimental|3Cs|
89105170|NCT05378412|No Intervention|Control|
89105171|NCT00689806|Placebo Comparator|Placebo|
89105172|NCT00689806|Active Comparator|Lovastin|
89105173|NCT00606606|Experimental|I - Intervention units|nursing home units, provided HIT CDS intervention
89105174|NCT00606606|No Intervention|C - control units|nursing home units, not provided the HIT CDS intervention
89105175|NCT05380362|Experimental|Venous Angioplasty|20 patients will have venous angio plasty
89105176|NCT05380362|Sham Comparator|Angio with no plasty|Patients will be brought to the angio suite and given and angio but no plasty although patient will not be aware of which treatment they are having.
89105177|NCT04204044|Experimental|GROUP A ( metformin 500 mg TDS)|Life style modifications, Weight reduction and folic acid will be prescribed with metformin 500 mg three times a day
89105178|NCT04204044|Experimental|GROUP B( myoinositol 2000mg x BD )|Life style modifications, Weight reduction and folic acid will be prescribed with myoinositol 2000 mg two times a day
89105179|NCT04204044|Experimental|GROUP C.(both metformin,& myoinositol)|Life style modifications, Weight reduction and folic acid will be prescribed with both metformin,& myoinositol three and two times a day respectively
89105180|NCT02625064||1: patient at High risk for ARDSp|Severe pneumonia and（PaO2/FIO2）>300mmHg
89105181|NCT02625064||2: patient at High risk for ARDSexp|Severe sepsis and without ARDS
89105182|NCT02625064||3: mild ARDS|PaO2/FiO2=201～300 mmHg，and PEEP or CPAP≤5 cm
89105183|NCT02625064||4: moderate ARDS|PaO2/FIO2=101～200 mmHg，且PEEP≥5 cm H2O
89105184|NCT02625064||5: severe ARDS|PaO2/FIO2≤100 mmHg，且PEEP≥10 cm H2O
89105185|NCT05378256|Other|Clinical scales of CIPN|Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).
89105186|NCT00672802|Experimental|Ramelteon 16 mg QD and Placebo QD|
89105187|NCT00691990|Active Comparator|A|Classic thyroidectomy with drains
89105188|NCT00691990|Active Comparator|B|Classic thyroidectomy without drains
89105189|NCT00689962|Experimental|1|Patients with unstable Lisfranc foot fracture-dislocations that receive bioabsorbable screw fixation through surgery.
89105190|NCT00689962|Active Comparator|2|Patients with unstable Lisfranc fracture-dislocations of the foot that receive steel screw fixation through surgery.
89105191|NCT00692068||A|with residual renal function
89105192|NCT00692068||B|without residual renal function
89227918|NCT00989898|Active Comparator|Closed-loops at Dinner|Automated closed-loop control starts at 18:00
89227919|NCT00989898|Active Comparator|Closed-loop at Bedtime|Automated closed-loop control starts at 21:00
89227920|NCT05400954||Reconstruction with silicone breast implant|The cohort will be composed of women who underwent surgery for first invasive breast cancer or ductal carcinoma in situ (DCIS) in the years 2000 to 2015 in the collaborating centres. Eligible for inclusion in the exposed group are all women who underwent (i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant
89227921|NCT05400954||Breast cancer surgery without silicone breast implant|. Eligible for inclusion in the comparison group are women who underwent (i) simple mastectomy without reconstruction, (ii) autologous reconstruction and (iii) breast conserving surgery. From the latter group a frequency-matched sample will be selected based on age at breast cancer diagnosis and calendar year of diagnosis.
89227922|NCT05400954||cosmetic breast augmentation|. Women who underwent cosmetic augmentation in the years 2000 to 2015 constitute a second comparison group. From this group a frequency-matched sample will be selected based on age and year of surgery.
89227923|NCT00989976|Other|8.5 h sleep|Subjects will have normal sleep times
89227924|NCT00989976|Other|restricted bedtimes|4.5 h bedtimes
89227925|NCT00990054|Experimental|plerixafor|
89227926|NCT00990132|Active Comparator|Long term oxygen therapy|LTOT will be established as per current national guidelines
89227927|NCT00990132|Experimental|Home mechanical ventilation|Patients will be set up on LTOT as per national guidelines and nocturnal non-invasive ventilation in accordance with study protocol.
89227928|NCT05361564|Experimental|Brigatinib|
89227929|NCT05399472||Participant|"The participants must be teenage basketball players (12-17 years old).~The exclusion criteria are:~have suffered in the last 3 months of lower limb musculoskeletal disorders such as pain for more than 7 days (ankle distortion outcomes, leg/foot fractures, plantar fasciopathy, metatarsalgias, etc);~athletes who have undergone surgery on their lower limb."
89227930|NCT05360004|Experimental|CHM+Vc|Participants in CHM+VC group are required to consume vitamin C 1000mg/day and 1 sachet (9 g) of granules daily (1 hour after meal by dissolving 1 sachet of 9g granules in 150 ml of hot water and drink it orally) .
89227931|NCT05360004|Placebo Comparator|Vc|Participants will receive vitamin C 1000mg/day for 14 days
89227932|NCT05359926|Experimental|Early Urethral Catheter Removal|Removal of the urethral catheter in the operating room at the conclusion of surgery
89227933|NCT05359926|Active Comparator|Delayed Urethral Catheter Removal|Removal of the urethral catheter in next morning after surgery
89227934|NCT05361408|Active Comparator|Denosumab short-term user|Denosumab injection less than 5 times
89227935|NCT05361408|Active Comparator|Denosumab long-term user|Denosumab injection more than 5 times
89227936|NCT03227406|No Intervention|Daytime Wake|Subjects are trained and retested during a single period of daytime wake
89227937|NCT03227406|No Intervention|Overnight sleep|Subjects are trained on one day and tested the next day, after a night of normal sleep
89227938|NCT03227406|Experimental|Sleep deprivation|Subjects are trained on one day and tested the next day, after a night of sleep deprivation
89227939|NCT03227406|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
89227940|NCT03069690|Experimental|HABITpreg; TAUpost|Participants will receive study intervention during pregnant and treatment as usual postpartum.
89227941|NCT03069690|Experimental|HABITpreg, HABITpost|Participants will receive study intervention during pregnancy and study intervention during the postpartum period.
89227942|NCT03069690|Experimental|TAUpreg; HABITpost|Participants will receive treatment as usual during pregnancy and study intervention during the postpartum period.
89227943|NCT03069690|No Intervention|TAUpreg; TAUpost|Participates will receive treatment as usual during pregnancy and treatment as usual during the postpartum period.
89227944|NCT00990366|Active Comparator|biliary stent without an antireflux valve|patients with biliary obstruction who need a biliary stent, selected for the stent without an antireflux valve arm
89227945|NCT00990366|Active Comparator|biliary stent with an antireflux valve|patients with biliary obstruction, who need a biliary stent, selected for the stent with an antireflux valve arm
89227946|NCT05590572|Active Comparator|Etoposide plus Ifosfamide group|Children and adolescents with relapsed or refractory drug resistant osteosarcoma
89227947|NCT05590572|Experimental|Etoposide plus Ifosfamide Combined With Sulfatinib|Children and adolescents with relapsed or refractory drug resistant osteosarcoma
89227948|NCT05359614|Experimental|GROUP A=CoolSculpting Elite and CoolTone|Group A: Study subjects will have a total of 1 or 2 bilateral CoolSculpting Elite sessions to the banana roll area 6 weeks prior to four EMMS treatment sessions during the study.
89227949|NCT05359614|Active Comparator|GROUP B CoolSculpting Elite alone|Group B: Study subjects will have a total of 1 or 2 bilateral CoolSculpting Elite sessions to the banana roll area.
89227950|NCT03050502|Active Comparator|Chest tube drain|A chest tube placed with the intent of draining all intra-pleural blood.
89227951|NCT03050502|Sham Comparator|Expectant management|No chest tube, but will undergo standard observation/conservative management by the trauma service.
89227952|NCT00990444|Placebo Comparator|Placebo|Treatment with vehicle capsule containing excipients only, taken in conjunction with standard meal.
89227953|NCT00990444|Active Comparator|Oral Insulin in Dextran|Treatment with fixed insulin dose taken in conjunction with standard meal.
89227954|NCT00990522|Experimental|debridement|monthly vs weekly debridement
89227955|NCT00990600|Experimental|Simplified one pill regimen|Fixed dose combination of tenofovir + emtricitabine + efavirenz
89227956|NCT02897076|Active Comparator|12mg betamethasone+12mg betamethasone|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
89227957|NCT02897076|Placebo Comparator|12 mg betamethasone+ placebo|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
89227958|NCT05590182|Active Comparator|CO2 first/ iodine CM second|CO2-enhanced angiography
89227959|NCT05590182|Active Comparator|iodine CM first/ CO2 second|iodine contrast media-enhanced angiography
89227960|NCT00990678|Experimental|"Strong vitamin D"|Calcium 400 Mg + Vitamin D3 10 microg, 3 times daily Rocaltrol 1.25 mg to 2.5 mg daily
89227961|NCT00990678|Active Comparator|Vitamin D|calcium 400 mg + 10 microgram Vitamin D3, 3 times daily
89227962|NCT00990678|Placebo Comparator|Calcium|Tablet Calcium 400 mg x 3 daily
89227963|NCT05265468|Experimental|Jones Group (Strain Counterstrain)|Jones Group consist in 90 seconds in a ralease positioning of no pain in muscle acortation
89227964|NCT05265468|Active Comparator|Lewit Group|Lewit Group consist in a maximum of four minutes of muscular contraction acompaind by stretching techniques
89227965|NCT05265468|Active Comparator|Chaitow Group|Chaitow Group consist in a maximum of four minutes of muscular contraction acompaind by stretching techniques and deep diaphragmatic respiration
89227966|NCT05265468|Placebo Comparator|Placebo Group|Placebo Group only have to mantain no pain positioning for 3 minutes
89227967|NCT05359458|Experimental|Emotional Freedom Liberation Technique Applied to Laparoscopic Cholecystectomy Patients|The intervention group is the group in which the investigators applied Emotional Freedom Liberation Technique Intervention: Behavioral: Emotional Freedom Liberation Technique
89227968|NCT05359458|No Intervention|Standard Clinical Care Applied to Laparoscopic Cholecystectomy Patients|The control group is the group that receives standard clinical care
89227969|NCT05590104|Experimental|Hysteroscopic CS scar defect repair|"Patient who is randomized to the hysteroscopic repair of CS scar defect will be prepared to have the surgery postmenstrual.~The surgery will be under general anasthesia. The participants will be placed in the lithotomy position. The cervix will be visualized using a Sims speculum and grasped using a single-toothed tenaculum, and the cervix, fornix, and vagina will be cleaned.~Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis. After that the patient will be prepared for another euoploid embryo transfer."
89227970|NCT05590104|No Intervention|Expectant management|Patient who is randomized to the expectant management will be prepared for another embryo transfer for euoploid embryo.
89227971|NCT00990756|Experimental|PF-03526299 1.396 mg|
89227972|NCT00990756|Experimental|PF-03526299 4mg|
89227973|NCT00538590|Active Comparator|MITOMYCIN-C|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
89227974|NCT00538590|Experimental|ologen (Oculusgen)|20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
89227975|NCT00990834|Experimental|Statin exposure|Subjects' endpoints will be measured before and after one to eight months of statin exposure.
89227976|NCT05589636|Experimental|Bergamot juice|Consumption of 400 cc/die of Bergamot juice (35% in water sweetened with stevia) for 12 weeks
89227977|NCT05589636|No Intervention|Free diet|Free diet
89227978|NCT00990990|Experimental|Cohort 1|
89227979|NCT00990990|Experimental|Cohort 2|
89227980|NCT00990990|Experimental|Cohort 3|
89227981|NCT00990990|Experimental|Cohort 4|
89227982|NCT00990990|Experimental|Cohort 5|
89227983|NCT00990990|Experimental|Cohort 6 (optional)|
89227984|NCT00990990|Experimental|Linezolid Cohort|
89227985|NCT05361096|Experimental|Educational approach (Flipped learning) group|The teaching of the patient safety subject was performed with the flipped learning to the intervention group (n=45).
89227986|NCT05361096|No Intervention|Traditional education group|The teaching of the patient safety subject was performed with the traditional educational to the control group (n=44).
89227987|NCT05589558|Experimental|Patients with suspected prostate cancer underwent 4 biopsy methods|Patients with suspected prostate cancer consequently underwent TRUS-guided, cognitive, fusion and transperineal template mapping biopsy
89227988|NCT04003662||inpatients|Vital signs measurement - standard of care and prototype
89227989|NCT04003662||outpatients|Vital signs measurement - standard of care and prototype
89227990|NCT04003662||Healthy controls|Vital signs measurement - standard of care and prototype
89227991|NCT00991146|Experimental|canakinumab|
89227992|NCT05589324||3D-printed writing aids group|Thirty subjects were recruited from outpatient rehabilitation of neurologically injured patients with limited hand function. Their basic information was recorded, including basic abilities and pen-holding posture, etc. Using three different angles of 3D printing writing aids, the writing efficiency and the satisfaction of the aids are evaluated by the writing task and the Satisfaction with Assistive Technology.
89105193|NCT00692146|Experimental|1|36 subjects receiving a specified volume of the active component AZD1386 in a single dose.
89105194|NCT00692146|Placebo Comparator|2|36 subjects receiving a specified volume of placebo in a single dose.
89105195|NCT04152928|Experimental|Neuroendocrine Tumors Patients|Patients with confirmed NET
89105196|NCT00594880|Active Comparator|Pegasys 180 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
89105197|NCT00594880|Active Comparator|Pegasys 90 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
89105198|NCT00690118|Active Comparator|1|
89105199|NCT00690118|Placebo Comparator|2|
89105200|NCT00694252|Experimental|1|Lapatinib
89105201|NCT00871858|Active Comparator|Arm A (ANA)|Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.
89105202|NCT00871858|Experimental|Arm B (FULV)|Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.
89105203|NCT00692224|Active Comparator|1|study group received zinc gluconate in a dose of 10 mg/day
89105204|NCT00692224|Placebo Comparator|2|placebo group received placebo which was identical in color, taste and appearance and packaged in similar looking bottles.
89105205|NCT00694330|Experimental|GM-K562 Vaccination|
89105206|NCT04136938||Intervention group (social marketing campaign)|People aged 60 and over will be included. They will receive a social marketing campaign.
89105207|NCT04136938||Control group|People aged 60 and over will be included.
89105208|NCT00673036||1|Adults (female and male) with a acute coronary syndrome
89105209|NCT00692302|Experimental|SAFETY I|Phase I participants who will receive SAFETY
89105210|NCT00692302|Experimental|SAFETY II|Phase II participants who will receive SAFETY
89105211|NCT00692302|Active Comparator|Control|Phase II participants who will receive enhanced usual care
89105212|NCT00692380|Experimental|A|Fractionated Radiation Therapy followed by Carboplatin and Taxol
89105213|NCT00673270|Experimental|1|Fludrocortisone and Hydrocortisone
89105214|NCT00673270|Experimental|2|Fludrocortisone and placebo of Hydrocortisone
89105215|NCT00673270|Experimental|3|Placebo of Fludrocortisone and Hydrocortisone
89105216|NCT00673270|Placebo Comparator|4|Placebo of Fludrocortisone and placebo of Hydrocortisone
89105217|NCT04152850|Experimental|Lifestyle Medicine Group|
89105218|NCT04152850|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment
89105219|NCT00871780|Experimental|Natalizumab|natalizumab 300 mg IV every 4 weeks for 48 weeks
89105220|NCT00694408|Active Comparator|Steroid immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid containing immunosuppression regimen post transplant. This group of patients will receive steroids in conjunction with other prescribed immunosuppressive agents. Intervention is use of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management
89105221|NCT00694408|Active Comparator|Steroid free immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid free immunosuppression regimen post transplant. The patients in this arm will receive immunosuppression but not steroids to compare with those treated with steroids to measure differences in rejection and safety of a steroid free immunosuppressive regimen. Intervention is omission of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management. No steroids will be used routinely in this arm
89105222|NCT04136782|Experimental|Trial group|55 cases of triple-negative breast cancer will be assigned into a trial group.
89105223|NCT04136782|Active Comparator|Control group|55 cases of triple-negative breast cancer will be assigned into a control group.
89105224|NCT04137874|Experimental|eSTROKE|
89105225|NCT04137874|Active Comparator|Control|Conventional prehospital care
89105226|NCT04137640|Other|endocrine group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into endocrine group.
89105227|NCT04137640|Other|chemotherapy group|76 postmenopausal estrogen receptor-positive LABC patients with low Ki67 expression will beassigned into chemotherapy group
89105228|NCT00694486||1|Healthy adult volunteers
89105229|NCT04137718||Rare driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation positive.
89105230|NCT04137718||Rare driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction(PCR)panel kit in the hospital requires the use of tissue samples and the results show a rare driver gene mutation negative.
89105231|NCT00692458|Experimental|1|odanacatib
89105232|NCT00692458|Placebo Comparator|2|placebo
89105233|NCT00911794|Experimental|Written Disclosure Therapy|
89105234|NCT00911794|Sham Comparator|Controls|
89105235|NCT00692536|Active Comparator|1|NNR
89105236|NCT00692536|Active Comparator|2|MPD
89105237|NCT00911872|Experimental|aging|
89105238|NCT00694642|Active Comparator|selected CD133+cells|Transendocardial injection of selected CD133+cells
89105239|NCT00694642|No Intervention|no injection|Boths groups were treated with G-CSF, underwent an apheresis and NOGA mapping
89227993|NCT00991224|Experimental|Arm 1|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
89227994|NCT00991224|Experimental|Arm 2|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
89227995|NCT00991224|Experimental|Arm 3|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir >200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI.
89227996|NCT00991224|Experimental|Arm 4|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of >200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI.
89227997|NCT00466947|Experimental|Synflorix Group|Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).
89227998|NCT00466947|Active Comparator|Control Group|Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.
89227999|NCT00991380|Experimental|Lifestyle counselling|
89228000|NCT00991380|Active Comparator|Usual Care|
89228001|NCT00537810|Experimental|Sibutramine|Sibutramine 15 mg daily
89228002|NCT00537810|Placebo Comparator|Placebo|Placebo Daily
89228003|NCT00537810|Experimental|Placebo/CBTsh|Placebo and Self-help CBT Placebo daily, Cognitive behavioral self-help manual for binge eating
89228004|NCT00537810|Experimental|Sibutramine/CBTsh|Sibutramine and Self-help CBT 15 mg daily Cognitive behavioral treatment manual for binge eating
89228005|NCT05589246|No Intervention|control|intraoperative cryoanalgesia of intercostal nerves with multimodal analgesia
89228006|NCT05589246|Experimental|intervention|regional analgesia (ESP block) with intraoperative cryoanalgesia of intercostal nerves and multimodal analgesia
89228007|NCT05589168|Experimental|Triage Nurse|Triage nurse
89228008|NCT05589168|Active Comparator|No Triage Nurse|No triage nurse
89228009|NCT01017471|Experimental|control|carpal tunnel release using standard incision
89228010|NCT00991536||Chronic respiratory failure|Patients with restrictive pulmonary disorders leading to progressive hypercapnic respiratory failure and requiring nocturnal non-invasive ventilation
89228011|NCT05589012||Human placentas and trophoblasts (biological waste) from uncomplicated pregnancies.|"The placentas will be collected following a birth by caesarean section after oral and written information by delivery of the information note for women who have had a normal singleton pregnancy at term.~Similarly, trophoblasts are collected following endo-uterine aspiration in the context of voluntary termination of pregnancy.~Cell line and virus~Infection of human placental culture explants~Determination of viral load in tissues by qRT-PCR"
89228012|NCT01355094|Active Comparator|"Stampede VAC"|"Calgary-home-made Stampede VAC system with only closed drain bulb suction"
89105240|NCT02624830|Experimental|Drug, Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to intravenous glucagon have been tested.
89105241|NCT00912652|Experimental|High Intensity Lifestyle Intervention|High intensity group will receive 48 sessions of lifestyle intervention over a two-year period
89105242|NCT00912652|Experimental|Mod. Intensity Lifestyle Intervention|Moderate intensity group will receive 32 sessions of lifestyle intervention over a two-year period.
89105243|NCT00912652|Experimental|Low Intensity Lifestyle Intervention|Low intensity group will receive 16 sessions of lifestyle intervention over a two-year period.
89105244|NCT00912652|Active Comparator|Health Education Control|Health education control group will receive 16 sessions of health education related to diet and exercise over a two-year period.
89105245|NCT02624752|No Intervention|Standard of Care|"Standard of care could include liberalized diet consisting of 3 meals and snacks served daily or the standard oral nutrition supplementation (ONS) routinely used in the hospital, as prescribed by the medical team.These routine meals and snacks are the standard of care."
89105246|NCT02624752|Experimental|Ensure|Patients randomized to Enhanced Oral Nutritional Supplementation (ONS) will receive the standard of care hospital menu (3 meals and snacks per day) plus 2 cans of Ensure (or similar product) per day while in hospital and will continue 2 cans per day of Ensure when discharged home until they have been receiving the enhanced ONS for a total of 90 days.
89105247|NCT02629042|Active Comparator|Control|
89105248|NCT02629042|Experimental|Experimental|
89105249|NCT02624674|Experimental|Multi-spectral Imaging Group|All subjects in this group will undergo baseline Near Infrared Spectroscopy (NIRS) measurement points with the Multi-spectral imaging device, baseline vascular studies (including ankle-brachial index (ABI), vascular doppler (arterial and venous), and toe pressures. At the one month mark (from baseline), NIR measurement point and vascular studies will again be performed. All measurements are incorporated into the routine wound care and will not require extra trips in hospital for wound care.
89105250|NCT00692614|Experimental|1|100 mcg triamcinolone acetonide
89105251|NCT00692614|Experimental|2|500 mcg triamcinolone acetonide
89105252|NCT00692614|Experimental|3|925 mcg triamcinolone acetonide
89105253|NCT00692614|No Intervention|4|sham control - not implanted, no medication
89105254|NCT00673348||1|Patients suspected of invasive fungal infection (proven or probable cases) with immunocompromised state (for example, during neutropenia, receiving HSCT) in Catholic Hematopoietic Stem Cell Transplantation [HSCT] Center in Seoul, Korea.
89105255|NCT00694720|Experimental|Dose Level 1|
89105256|NCT00694720|Experimental|Dose Level 2|
89105257|NCT00694720|Experimental|Dose Level 3|
89105258|NCT00694720|Experimental|Dose Level 4|
89105259|NCT00694720|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
89105260|NCT04136470||NSCLC|This cohort will consist of 100 patients with non-small cell lung cancer (NSCLC).
89105261|NCT04136470||MEL|This cohort will consist of 30 patients with melanoma (MEL).
89105262|NCT04136392||Eligible Patients|The population to be enrolled in this study includes patients whose intended treatment is to receive mechanical circulatory support with the ABIOMED, Inc. hemodynamic support devices per the treating physician's discretion and best practices.
89105263|NCT04137250|Active Comparator|Hamstring|It is the group in which the hamstrings are surgically removed to be used as an autograft for the reconstruction of the anterior cruciate ligament. The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament.
89105264|NCT04137250|Experimental|Quadriceps tendon|It is the group in which a portion of the quadriceps tendon will be surgically removed for later use as an autograft for the reconstruction of the anterior cruciate ligament. The intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
89105265|NCT04136236||esophageal mucosal lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
89105266|NCT00694798|Experimental|Mw|All enrolled patients to receive Mycobacterium w
89105267|NCT00694876||1|Adequate Health Literacy (as determined by TOFHLA)
89105268|NCT00694876||2|Inadequate Health Literacy (as determined by TOFHLA)
89105269|NCT00594178|Experimental|A|Exercise group
89105270|NCT05298826||Junior staff has started the management and called for the senior staff.|
89105271|NCT05298826||senior staff. managed the case from the start|
89105272|NCT00673426|Experimental|A|
89105273|NCT00673504|Experimental|A|Gemcitabine + Sunitinib
89105274|NCT00673504|Other|B|Gemcitabine
89105275|NCT00673582|Experimental|1|10 mg/day rosuvastatin for 96 weeks
89105276|NCT00673582|Placebo Comparator|2|Placebo
89105277|NCT00694954|Experimental|1|Wireless capsule endoscopy
89105278|NCT00694954|Active Comparator|2|Standard Care
89228013|NCT01355094|Experimental|KCI AbThera|commercial AbThera vacuum assisted abdominal closure at 125 mmHg suction
89105279|NCT04137094|Experimental|PHCI with HIV/HCV counselor|A persuasive health communication intervention will be performed by a community HIV/HCV test counselor
89105280|NCT04137094|Experimental|PHCI with ED Medical Staff|A persuasive health communication intervention will be performed by ED medical staff
89105281|NCT04137406||T1 tumor with lymph node metastasis|patients with T1 tumor and lymphnode positive
89105282|NCT04137406||T2 or T3 tumor with lymph node negative|patients with T2 or T3,lymph node negative
89105283|NCT00912574|Active Comparator|Saline|first of 4 arms: injection: 1 ml saline
89105284|NCT00912574|Active Comparator|GM-CSF|Second of 4 arms: injection: specified dose of GM-CSF in 1 ml saline
89105285|NCT00912574|Active Comparator|0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline|Third of 4 arms: injection: 0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline
89105286|NCT00912574|Active Comparator|GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant|Fourth of 4 arms: injection: specified dose of GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant
89105287|NCT00692848|Experimental|PCT+|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm procalcitonin result is revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him
89105288|NCT00692848|No Intervention|PCT-|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm, procalcitonin is not revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him.
89105289|NCT04137172|Experimental|group1|underwent laparoscopic IPOM hernioplasty without repair
89105290|NCT04137172|Experimental|group2|underwent laparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS
89105291|NCT04137172|Experimental|group3|underwent laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0
89105292|NCT02629198||normal weight|Healthy men and women ages 25-40 and 55-75. BMI 18.5 to 25.0
89105293|NCT02629198||overweight|Healthy men and women ages 25-40 and 55-75. BMI 25.0 to 30.0
89105294|NCT02629198||obese|Healthy men and women ages 25-40 and 55-75. BMI over 30
89105295|NCT04137328|Experimental|liraglutide group|Mecobalamin tablets (0.5mg/day, oral) and liraglutide (0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection) were used for 3 months.
89105296|NCT04137328|Active Comparator|control group|Take Mecobalamin (0.5mg/day, oral), add or adjust insulin (when basic insulin is preferred for those who do not use insulin, if insulin has been used, adjust the dose or program according to the condition, inject subcutaneously) for 3 months.
89105297|NCT00692926|Other|20% primed UCB|20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft
89105298|NCT00692926|Other|20% un-primed|20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft
89105299|NCT00692926|Other|Double- 1 unit primed|patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed
89105300|NCT00692926|Other|Double- 1 unit unprimed|Patient receives 1 UCB unit and a second UCB unit that has been freshly ALDHbr sorted
89105301|NCT00693004|Placebo Comparator|Placebo|
89105302|NCT00693004|Experimental|PRX-03140|
89105303|NCT00693004|Active Comparator|donepezil|
89105304|NCT04152538||healthy subjects|Healthy subjects matched with TKA patients
89105305|NCT04152538||TKA patients|age greater than 18 years old and a recent TKA.
89105306|NCT00695266||1|
89105307|NCT00695344|Experimental|1|Everolimus 2 times per day + cyclosporin low dose +/- steroids
89105308|NCT00695344|Active Comparator|2|Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).
89105309|NCT00693082|Experimental|1|
89105310|NCT00693316|Experimental|ORM-12741|
89105311|NCT00693316|Placebo Comparator|Placebo|
89105312|NCT00933270|Experimental|SUPERA® Nitinol Stent System|Implantation of SUPERA nitinol stent using the SUPERA® Nitinol Stent System
89105313|NCT00695422||Specimen Collection|Blood collection, anal cytology and biopsy of observed lesions. Additional cervical cytology and biopsy for females.
89105314|NCT04137016|Experimental|HIV-subjects with APP|HIV-infected patients using the App + standard clinical management (SCM)
89105315|NCT04137016|No Intervention|Control group|HIV-infected patients, who only receive Standard Clinical Management (without the App)
89105316|NCT02624362|Experimental|Odor+ Positive belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor improves asthma symptoms (therapeutic suggestion)
89105317|NCT02624362|Experimental|Odor + Negative belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor worsens asthma symptoms (asthmogenic suggestion)
89105318|NCT00695656||1|
89105319|NCT00607542|Active Comparator|1|starting dose of baclofen 2.5 mg PO TID with dose escalation as tolerated
89105320|NCT00605046|Experimental|Asses [123I] AV151 and SPECT imaging|
89105321|NCT04265898||Test Group|Reported mild cognitive deficits
89105322|NCT04265898||Control Group|No cognitive deficits
89105323|NCT00936858|Experimental|Arm A|RAD001 will be administered orally as once daily dose of 10 mg (one 10mg tablet or two 5mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity.
89105324|NCT00606762|Active Comparator|LPLC, HPLC|LPLC: Low pressure pneumoperitoneum is defined as intraabdominal pressure kept at8 mm Hg after initial trocar insertion at 12 mm Hg HPLC: High pressure pneumoperitoneum is defined as intra abdominal pressure kept at 12 mm Hg throughout the procedure
89105325|NCT00605124|Experimental|exercise|progressive exercise, home-based exercise program, tree exercise sessions weekly, chec-up visits every third month
89105326|NCT00605124|Active Comparator|Conventional treatment|Normal treatment, single guidance to home exercise
89105327|NCT00695734||Hemodialysis|Patients under chronic hemodialysis for chronic end stage renal failure
89105328|NCT02624440|Experimental|Clarithromycin|p.o. clarithromycin 250 mg twice daily for 180 days
89105329|NCT02624440|Experimental|Sulfamethoxazole/trimethoprim|p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days
89105330|NCT02624440|Experimental|Observation|Observation without prophylactic antibiotic treatment
89105331|NCT04254276||Symptomatic group|Office workers with neck and shoulder area musculoskeletal pain
89105332|NCT04254276||Asymptomatic group|Office workers without neck and shoulder area musculoskeletal pain
89105333|NCT04136704||Sleeve Gastrectomy in Pediatric Patients|Laparoscopic Sleeve Gastrectomy will be offered as an adjuvant to a multidisciplinary family-based program that focuses on nutrition, physical activity, and behavioral counseling.
89105334|NCT04136704||Sleeve Gastrectomy in Adult Patients|This comparison group will be composed of adult patients who undergo sleeve gastrectomy
89105335|NCT00695812||1|Siblings of children with Autism
89105336|NCT00695812||2|Siblings of children with typical development
89105337|NCT00606840|Experimental|1|One arm is a large changes group in which participants will be asked to make periodic large changes in their eating and activity, aimed at producing initial weight loss, in order to prevent weight gain over time.
89105338|NCT00606840|Experimental|2|The second arm is a small changes group in which participants will be asked to make small changes to their eating and activity and maintain these changes forever in order to prevent weight gain.
89105339|NCT00673972|Active Comparator|EPS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
89105340|NCT00673972|Active Comparator|PDS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
89105341|NCT04152616|Experimental|Optitrack®|Instrumental evaluation of posture
89105342|NCT04265352||Prenetal cardiac echogenic focus|Newborn infants who had prenatal cardiac echogenic focus
89105343|NCT04136080|Other|chronic hypertension group|septic patients with chronic hypertension
89105344|NCT04136080|Other|denying chronic hypertension group|septic patients without chronic hypertension
89105345|NCT05380128||MG group|Unrelated patients with MG were included in the study. They were enrolled in the Neurology Department of Beijing Tongren Hospital, Capital Medical University and fulfilled the clinical and electromyography diagnostic criteria for acquired MG. Simply, all MG patients met the following diagnostic criteria: typical symptoms of fluctuating muscle weakness, positive result of neostigmine test, and decremental response to low-frequency repetitive nerve stimulation. Information on age at onset, AChR / MuSK Abs status (partly), thymus status, involved muscles at onset and Osserman type at the maximum worsening during 2 years follow-up were obtained and used as the grouping basis of sub-classifications. They were genotyped for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms
89105346|NCT05380128||Healthy control|The geography and ethnically matched control group consisted of 146 unrelated healthy subjects. They were genotyped for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms.
89105347|NCT00693862|Experimental|Stalevo|
89105348|NCT00693862|Active Comparator|levodopa/carbidopa|
89105349|NCT05377788||Prospective cohort|"Inclusion criteria~adults over the age of 19~Easter Cooperative Oncology Group performance 0-4~Patients who are eligible for or are being treated for test medication as per permit: patients with NSCLC with local progressive or metastatic EGFR T790M mutation who have previously been treated with Generation 1 or Generation 2 EGFR TKI~EGFR T790M mutation allows for all results identified in tumor tissue or plasma~Patients with brain MR within 3 months of study participation~After obtaining a consent form for research participation, follow-up and monitoring survival information and safety information. Survival follow-up of prospective cohorts will be followed up to the point of first occurrence during disease progression, withdrawal of consent, failure of follow-up investigation, and death."
89105350|NCT05377788||Restrospective cohort|"Inclusion criteria~adults over the age of 19~Patients who are already using the lazertinib according to the domestic authorization of lazertinib(This includes when participants receive interventions as part of routine medical care)~Survival information is monitored after the time when the consent form for participation in the study is obtained. Survival follow-up of retrospective cohorts will be followed up to the point of first occurrence during disease progression, withdrawal of consent, failure of follow-up investigation, and death"
89105351|NCT00695890||1|Healthy volunteers
89105352|NCT00631254|Active Comparator|1|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
89105353|NCT00631254|Active Comparator|2|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
89105354|NCT02624206|Active Comparator|Juice A|Half of the group to receive Juice A, a novel juice flavor.
89105355|NCT02624206|Active Comparator|Juice B|Half of the group to receive Juice B, a novel juice flavor different from Juice A.
89105356|NCT00606918||1|Individuals with ALS
89105357|NCT00606918||2|Healthy Adults
89105358|NCT04135924|Active Comparator|walking nordic and respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will be submitted to respiratory muscle training (TMR) associated with the Nordic walking(NC) training .
89105359|NCT04135924|Active Comparator|walking nordic group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to Nordic walking training.
89105360|NCT04135924|Active Comparator|respiratory training group|It will be composed of patients with clinical diagnosis of Parkinson's disease, who will only be submitted to respiratory muscle training protocol.
89105361|NCT05379894||group (1 ) Modified Supine|Modified Supine position PNL
89105362|NCT05379894||group (2) prone|Prone position PNL
89105363|NCT00607776|Active Comparator|1|Systane
89105364|NCT00607776|Experimental|2|Blink tears
89105365|NCT00674050|Experimental|1|
89105366|NCT04267458|Other|HCV infected patients with non-elevated sCr than basal levels|a group of egyption patients with HCV infection with non-elevated sCr than basal levels and treated with sofuspovir as an direct acting antiviral drug
89105367|NCT02628652|Experimental|Gluco-Galacto-Oligosaccharide (GOS)|Subjects randomized to this treatment arm will ingest GOS once per day for a total of 14 days. One level of GOS will be taken during Phase I and 2 levels of GOS will be taken during Phase II.
89228014|NCT05588232|Experimental|Patient with virtual reality|The virtual reality sedation-analgesia solution developed by Deepsen combines 3D environment content with medical hypnosis techniques. The technology includes a wearable visual headset that contains head movement sensors, enabling patient interaction in the virtual environment, as well as isolating headphones.
89228015|NCT05588232|Active Comparator|Patient with pharmacological sedation|
89228016|NCT00991614||EVOLUTION® Duodenal Stent|
89228017|NCT05358054|Experimental|GROUP A|GROUP A
89228018|NCT05358054|Experimental|GROUP B|GROUP B
89228019|NCT01287936|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
89228020|NCT01287936|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
89228021|NCT01287936|Experimental|SB623 Implant (10.0M)|10 million SB623 cells
89228022|NCT05586984||Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension for apical prolapse. Concomitant anterior and posterior colporrhaphy may be performed.
89228023|NCT05586984||Transvaginal sacrospinous fixation|Uterus-preserving transvaginal sacrospinous fixation for apical prolapse. Concomitant anterior and posterior colporrhaphy may be performed.
89228024|NCT00991692|Experimental|Treatment dosage levels examined|
89228025|NCT00991770|Experimental|Massage Therapy|Massage therapy provided by a certified Massage Therapist
89228026|NCT00991770|Active Comparator|Control|Empathic support conversation
89228027|NCT05566626|Experimental|Camera test group|The Principal Investigator will take a hyperspectral image of all subjects, both healthy volunteers and patients.
89228028|NCT00989430|Experimental|Prism Adaptation Treatment|Two weeks of prism adaptation treatment followed by 4 weekly assessments and long-term follow-ups at the 3rd and 6th months.
89228029|NCT00989430|No Intervention|Control: Standard Rehabilitation Care|Participants will continue with their standard inpatient rehabilitation care. They will be assessed with cognitive and functional scales for tracking their recovery.
89228030|NCT00989508|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
89228031|NCT00989508|Placebo Comparator|Placebo marked PEXSIG|Pre-operative administration of placebo tablets according to dosing schedule
89228032|NCT05408442||Prone|ARDS patients during mechanical ventilation in prone position
89228033|NCT05408364|Placebo Comparator|Natural yoghurt|SRP+nature yogurt (Danone® yogurt, Luleburgaz, Türkiye)
89228034|NCT05408364|Experimental|Probiotic yoghurt|SRP+probiotic containing yogurt (Danone Activia® Plain, Luleburgaz, Türkiye)
89228035|NCT05408286||inclusion criteria|All patients aged ≥18 years admitted for COVID-19 pneumonia treated with NIV/CPAP, discharged to their home with a negative molecular swab and signed informed consent were included in the study.
89228036|NCT05360394|Active Comparator|PCB Only|Cephalic arch stenosis is first treated with conventional plain balloon angioplasty. Once treated adequately (<30% residual stenosis), CAS will be treated with PCB angioplasty.
89228037|NCT05360394|Experimental|Stent Graft and PCB angioplasty of stent edges|CAS is first treated with conventional plain balloon angioplasty. Once treated adequately (<30% residual stenosis), CAS will be treated with PCB first to avoid geographical miss. After which, stent graft will be deployed. Length of PCB shall be long enough to cover stent edges.
89228038|NCT00090259|Experimental|Losartan 50 mg|50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)
89228039|NCT00090259|Experimental|Losartan 150 mg|Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan
89228040|NCT01082497|Experimental|Mindfulness|
89228041|NCT01082497|Active Comparator|Education|8 - weekly workshops on affect consciousness for all staff
89228042|NCT03961711|Experimental|Telemedicine encounter|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
89228043|NCT03961711|Active Comparator|In-person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
89228044|NCT00079183|Experimental|Sirolimus|Study participants receive sirolimus added once daily to their baseline combination therapy of prednisone plus either cyclosporine or tacrolimus at the discretion of the managing physician. Treatment other than cyclosporine (or tacrolimus) and prednisone must be discontinued when administration of sirolimus is started. Topical therapy, including psoralen and UVA irradiation (PUVA), glucocorticoid creams, topical tacrolimus, oral beclomethasone, topical azathioprine and ophthalmic glucocorticoids may be given at the discretion of the managing physician in consultation with the transplant center.
89105368|NCT02628652|Experimental|Gluco-Oligosaccharide (GLOS)|Subjects randomized to this treatment arm will ingest GLOS once per day for a total of 14 days. One level of GLOS will be taken during Phase I and 2 levels of GLOS will be taken during Phase II.
89105369|NCT02628652|Active Comparator|FructoOligosaccharide (FOS)|Subjects randomized to this treatment arm will ingest FOS once per day for a total of 14 days. One level of FOS will be taken during Phase I and 2 levels of FOS will be taken during Phase II.
89105370|NCT04152460|Active Comparator|Thermo-Viscous preheated bulk fill resin composite|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
89105371|NCT04152460|Placebo Comparator|Conventional Bulk Fill resin Composite|GrandioSo X-tra (Voco,Cuxhaven
89105372|NCT00872170|Active Comparator|Intervention|Participants with thalassemia who have pulmonary hypertension will receive sildenafil for 12 weeks.
89105373|NCT00872170|No Intervention|Control|Participants with thalassemia who do not have pulmonary hypertension will be part of a control group and will only be undergoing screening/baseline assessments.
89105374|NCT00936702|Experimental|Treatment (carboplatin, paclitaxel, and everolimus)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive everolimus PO QD on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89105375|NCT00693940|Experimental|1|Participants will receive treatment with group mediated cognitive behavioral sessions.
89105376|NCT00693940|Active Comparator|2|Participants will receive treatment with health education sessions.
89105377|NCT04136860||Conservative management|Patients refused to accept any interventional treatment or patients were not suitable for any interventional treatment.
89105378|NCT04136860||Microsurgical resection|All microsurgical procedures were performed with intraoperative neuronavigation, ultrasonography, indocyanine fluorescence angiography (ICG), continuous monitoring of electroencephalogram and somatosensory evoked potential.
89105379|NCT04136860||Embolization|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Multi-stage embolization and target embolization were widely used within the embolization. Onyx was the main embolization material.
89105380|NCT04136860||Embolization+Radiosurgery|Embolization or radiosurgery was recommended as a priority for lesions located in deep functional locations such as brainstem and basal ganglia. Radiosurgery management was recommended for the residual lesions about 3 months after the embolization if necessary.
89105381|NCT04136860||Single-stage hybrid surgery|Hybrid surgery is a new surgical strategy defined as single-stage combined microsurgical resection and embolization in which embolization is performed firstly on the deep feeding artery, aneurysm, AVF, and meningeal arteries involved in blood supply of the nidus, and then, the microsurgical resection was performed immediately. Intraoperative angiography was performed repeatedly before the skull was closed, confirming complete occlusion of the malformation.
89105382|NCT00674518|Experimental|Counseling|One-on-one sessions conducted by a professional motivational counselor to explore ways to help motivate participants to exercise, eat healthier, and lose weight.
89105383|NCT00674518|Experimental|Group|A nutrition and exercise specialist will lead and teach a group of 4 to 5 subjects in healthy nutrition, exercise and weight loss habits
89105384|NCT00674518|Active Comparator|MD Advice|A physician will provide exercise and nutrition advice to participants immediately following testing
89105385|NCT00607854|Experimental|Zevalin|Zevalin associated with a Fludarabine-based reduced-intensity conditioning regimen,all patients will receive Zevalin in the conditioning regimen
89105386|NCT00694174|Active Comparator|1|2 ml sucrose 25% oral solution one time only dose by mouth
89105387|NCT00694174|Placebo Comparator|2|sterile water 2 ml one time only dose given by mouth prior to heel lance
89105388|NCT00607932|Experimental|Brassica Vegetables Diet Intervention|
89105389|NCT00607932|Experimental|Pill|
89105390|NCT00606996|Experimental|IPT-G|Group Interpersonal Psychotherapy
89105391|NCT00606996|Active Comparator|PSYCHOED|Psychoeducation
89105392|NCT02628730|Active Comparator|Ablation Index Group|PVI using radiofrequency ablation (RFA) guided by Ablation Index.
89105393|NCT02628730|Other|Reference Group (Contact Force Group)|That group will be formed by the 40 patients who underwent mandatory repeat EPS 8-10 weeks following contact force guided PVI in the PRESSURE study (ClinicalTrials.gov Identifier: NCT01942408). RFA ablation data from reference group (Contact Force Group) will be compared with those obtained from the Ablation Index Group.
89105394|NCT00605436|Experimental|A|Restorative yoga therapy group: one orientation workshop for 3 hours, then twice-weekly group yoga therapy classes for first 5 weeks followed by once-weekly group yoga classes for another 5 weeks. The group will also be asked to practice their yoga postures at home for 30 minutes three times per week.
89105395|NCT00605436|No Intervention|B|The control group is a wait-list control group with no active intervention.
89105396|NCT02628886|Experimental|maternal group|13-valent pneumococcal conjugate vaccine [Prevenar13®] (PCV13) vaccine, 0.5ml, once, stat, plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
89105397|NCT02628886|Placebo Comparator|control group|placebo sterile 0.9% sodium chloride, 0.5ml, once, stat plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
89105398|NCT02628886|Experimental|neonatal group|tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV 13 0.5ml at birth, 8 weeks and 16 weeks
89105399|NCT04265508||Low MELD score|MELD score of 6 - 11
89105400|NCT04265508||High MELD score|MELD score of ≥ 17
89105401|NCT02623738|Placebo Comparator|Placebo ophthalmic solution|Eyedrop
89105402|NCT02623738|Experimental|DE-117 ophthalmic solution low|Eyedrop
89105403|NCT02623738|Experimental|DE-117 ophthalmic solution high|Eyedrop
89105404|NCT02623738|Active Comparator|Latanoprost ophthalmic solution 0.005%|Eyedrop
89105405|NCT00607074|Experimental|1|
89105406|NCT02623582|Experimental|Cohort 1|The first 3 subjects to receive RNA CART123 cells will receive up to 3 doses of RNA CART123 cells, with no lymphodepleting chemotherapy prior to infusion.
89105407|NCT02623582|Experimental|Cohort 2|"The remaining 12 subjects of the study will receive up to six IV doses of RNA CART123 cells.~Subjects in Cohort 2 may be given lymphodepleting chemotherapy 4 days (+/- 1 day) prior to the first CART123 cell infusion (if ALC> 500/uL).~Lymphodepleting chemotherapy may be repeated before the fourth dose of RNA CART123 cells (if ALC> 500/uL).~Lymphodepleting chemotherapy includes a single dose of cyclophosphamide (1g/m2) Weight used for dosing will be the weight obtained prior to the apheresis procedure Cell numbers are based on CAR+ cells with CAR expression determined by flow cytometry Based on the product release criteria, at least 20% of the total cells will be RNA CART123 cells.~Dosing will not be changed for changes in subject weight The indicated doses are +/- 20% to account for manufacturing variability."
89105408|NCT04264416|Experimental|Whole-Body Electromyostimulation|16 weeks of dynamic WB-EMS: one supervised session per week, 20 min session; impulse-frequency: 85 Hz; impulse breadth 350 µs; intermittent 4-6 s; of impulse - 4 s of impulse break; impulse intensity RPE 7 (hard+ to very hard) on Borg CR 10 Scale.
89105409|NCT04264416|No Intervention|Non exercising control|...maintained physical activity and exercise habits during the study period.
89105410|NCT02623660|Experimental|Experimental|This group will receive treatment from the ODIN1 device in conjunction with standard care and diagnostic device testing.
89105411|NCT02623660|Active Comparator|Control|This group will receive the standard care and the diagnostic device testing.
89105412|NCT04264494|Experimental|PRP group|Fifty RA patients were injected intra-articularly with 3 doses of PRP in their joints
89105413|NCT04264494|Placebo Comparator|placebo group|Fifty RA patients were injected intra-articularly with 3 doses of saline in their joints.
89105414|NCT00696124|Experimental|Cohort 1|2mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
89105415|NCT00696124|Experimental|Cohort 2|4mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
89105416|NCT00696124|Experimental|Cohort 3|8mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
89105417|NCT00696124|Experimental|Cohort 4|16mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
89105418|NCT04264650|No Intervention|Control group|Standard care
89105419|NCT04264650|Experimental|One active intervention group|provided with COOL Passport, a mobile healthcare application
89105420|NCT04264650|Experimental|The other active intervention group|provided with access to the Health Promotion Cloud system and use of game-based interactive platforms along with COOL Passport
89105421|NCT05379660|Experimental|T1 treatment group|TEAS initiates at 30 minutes before induction and lasts for 30 minutes
89105422|NCT05379660|Experimental|T2 treatment group|TEAS initiates immediately after skin incision and lasts for 30 minutes
89105423|NCT05379660|Experimental|T3 treatment group|TEAS initiates immediately after extubating and lasts for 30 minutes
89105424|NCT05379660|No Intervention|control group|Electrodes are placed on the same acupoints, but no current is given
89105425|NCT04135534|Active Comparator|group A|mutonpain 0.05 mg/kg
89105426|NCT04135534|Active Comparator|Group B|mutonpain 0.1 mg/kg
89105427|NCT04135534|Active Comparator|Group C|mutonpain 0.2 mg/kg
89105428|NCT00696202|Experimental|Arm 1|
89105429|NCT00608010|Experimental|1|Vitrification
89105430|NCT00608010|Active Comparator|2|Slow freezing
89105431|NCT02628808||Autism Spectrum Disorder|For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
89105432|NCT02628808||controls|Age 6 to 40 Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
89105433|NCT00608088|Active Comparator|1|Usual Care
89105434|NCT00608088|Active Comparator|2|Health Nurse/Peer Councelor Intervention
89105435|NCT00674752|Experimental|A|
89105436|NCT00674752|Experimental|B|
89105437|NCT00674752|Placebo Comparator|C|
89105438|NCT05370456|Experimental|Xenogenic collagen matrix (XCM) + Hyaluronic acid (HA)|Multiple coronally advanced flap technique (mCAF) with the use of a XCM in combination with local application of a HA gel
89105439|NCT05370456|Active Comparator|Xenogenic collagen matrix (XCM)|Multiple coronally advanced flap technique (mCAF) with the use of a XCM
89105440|NCT05366244||Patient with COVID-19|Mild to moderate COVID-19 patient with at least one risk factor for serve COVID-19 illness or death.
89105441|NCT00674830|Experimental|1|professionally administered cognitive-behavioral therapy
89105442|NCT00674830|Experimental|2|self-administered form of cognitive behavioral therapy
89105443|NCT00674830|Placebo Comparator|3|usual care
89105444|NCT05379582|No Intervention|control group|Implement nutrition therapy according to existing feeding procedures
89105445|NCT05379582|Experimental|intervention group|Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound
89105446|NCT02623270|Experimental|Noninvasive Ventilation|After induction of anesthesia, checking of ability to bag mask ventilating the patient, the manual bag ventilation will be replaced by a Noninvasive Ventilator, V60 (Philips)
89105447|NCT00605592|Experimental|1|Islet cell transplant
89105448|NCT00594100|Experimental|GFRS Pivotal Subjects|All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).
89105449|NCT00607152|Experimental|1|IV infusion at a dose level of 0.20mg/kg per day
89105450|NCT00607152|Active Comparator|2|100mg tablets, administered orally, according to standard medical practice
89105451|NCT00696748|Active Comparator|1|Men receiving Nebido
89105452|NCT00696748|Placebo Comparator|2|Men receiving Placebo
89105453|NCT00605670||1|Postoperative Breast Surgery Patients
89105454|NCT00605670||2|Preoperative Breast Surgery Patients
89105455|NCT00696280||Group 1|"All patients will be given the Functional Living Index - Emesis (FLIE) standardized questionnaire during their scheduled clinic visit prior to receiving chemotherapy.~This is a self-administered questionnaire. Patients will complete the questionnaire during the 5 days following carboplatin administration (at 24 hours, 48 hours, 72 hours, and 96 hours) of their first and third cycles of chemotherapy.~Patients will also be interviewed by a trained CRA or research nurse over the telephone 24-48 hours following carboplatin administration in order to assess the severity of the delayed nausea and vomiting."
89105456|NCT05363124|Experimental|PEWS calculation|PEWS calculation by parents using AI-based smartphone app PEWS calculation by nurse using conventional procedure
89105457|NCT00674908|Experimental|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
89105458|NCT00674908|Active Comparator|Easy 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
89105459|NCT00607230|Experimental|E|BCG vaccination
89105460|NCT00607230|Placebo Comparator|P|Saline vaccination
89105461|NCT02621710||Minimally invasive hysterectomy|Patients undergoing scheduled minimally invasive hysterectomy (vaginal, laparoscopic, robotic) for benign condition
89105462|NCT02621710||Abdominal hysterectomy|Patients undergoing scheduled abdominal hysterectomy for benign condition
89105463|NCT04265118|Experimental|Sideward Tilt of Bed|During sleep, while lying in supine position, the participant will be tilted sidewards by the bed. In practice, the experimenter activates the bed at timepoints during the night where the participant is lying in supine position. Activating the bed results in one half of the bed lifting 10 to 40 Degrees sidewards.
89105464|NCT02621632|Other|Healthy subjects and patients|To done a novel compression system. 20 healthy subjects and 20 patients done a novel compression system termed Socknleg and a compression class III stocking as a comparator.The Socknleg compression system was developed by the investigator and produced by Sigvaris AG, St. Gallen, Switzerland.
89105465|NCT04264104|Experimental|Low dose neural mobilization|Four series of 10 repetitions of neural mobilization targeting the tibial nerve.
89105466|NCT04264104|Active Comparator|High dose neural mobilization|Eight series of 10 repetitions of neural mobilization targeting the tibial nerve.
89105467|NCT00696358|Active Comparator|A|308 nm excimer lamp
89105468|NCT00696358|Active Comparator|B|308 nm excimer laser
89105469|NCT05269212|Active Comparator|Usual care|
89105470|NCT05269212|Active Comparator|Personalized biopsychosocial rehabilitation program|
89105471|NCT02621554|Experimental|resveratrol supplementation|Dietary Supplement: Resveratrol
89228045|NCT03961243|Experimental|YUVA-GT-F901|Gene transfer to treat Hemophilia B
89228046|NCT01589341||Correlative studies|Archived DNA samples are analyzed (laboratory biomarker analysis) for segmental chromosome aberrations by MLPA, a PCR-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
89228047|NCT01086085|Experimental|A|
89228048|NCT01086085|Experimental|B|
89228049|NCT01086085|Experimental|C|
89228050|NCT01086085|Experimental|D|
89228051|NCT01088425||Spontaneous|Mothers with children conceived after spontaneous cycle
89228052|NCT01088425||Vitrificatíon|Mothers with children conceived after vitrification cycle
89228053|NCT01088425||slow- rate freezing|Mothers with children conceived after slow- rate freezing cycle
89228054|NCT01086163||Omacor dose titration|"Stable documented coronary artery disease proven by angiography treated with statin and aspirin. In order to achieve homogeneity within this population, the following additional inclusion criteria will apply:~survived first-time AMI more than 12 months ago~stable medical treatment during the last 3 months (except removal of Plavix)~Ethnicity: Caucasians~Males, 50 - 60 yrs~non-diabetics~excluded are those who eat more than one meal of fish / week~excluded are those who take omega-3 supplements of any sorts"
89228055|NCT01589419|Experimental|veliparib and capecitabine and radiation|Veliparib on days 1-7, capecitabine and radiation on days 1-5
89228056|NCT00676403|Placebo Comparator|1|Placebo
89228057|NCT00676403|Experimental|2|investigational treatment
89228058|NCT00676403|Experimental|3|investigational treatment
89228059|NCT00676403|Experimental|4|investigational treatment
89228060|NCT00676403|Experimental|5|investigational treatment
89228061|NCT00676403|Experimental|6|investigational treatment
89228062|NCT01086241|Active Comparator|A: routine 2D mammogram|Subject receives regular 2D mammogram.
89228063|NCT01086241|Active Comparator|B: Routine Mammogram + tomosynthesis|Routine Mammogram and tomosynthesis
89228064|NCT00078325|Experimental|1|Armodafinil 250 mg/day
89228065|NCT00078325|Experimental|2|Armodafinil 150 mg/day
89228066|NCT00078325|Placebo Comparator|3|Placebo
89228067|NCT01086319||Patients exposed to saxagliptin|
89228068|NCT01086319||Patients exposed to oral antidiabetic drugs (not saxagliptin)|
89228069|NCT03963271||Patients with unexplained polymorphic VT and/or VF|"Unexplained polymorphic VT and/or VF patients.~Patients with VF and the DPP6 risk haplotype, reported by the AUMC team.~The Worm population of patients with a SCN5A founder mutation and other conspiring genetic variants at MUMC+"
89228070|NCT03963271||Family members|Family members of index patients of group(s) mentioned above
89228071|NCT03963271||Control group|Control subjects with structurally normal hearts with an indication for a cardiac CT,
89228072|NCT03963193|Experimental|Etoposide plus Cisplatin|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
89228073|NCT03963193|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.
89228074|NCT01088581|No Intervention|Observation group|No adjuvant chemotherapy after resection
89228075|NCT01088581|Active Comparator|Adjuvant group|Adjuvant chemotherapy after resection
89228076|NCT01082653|Experimental|Safety|infusion of autologous bone marrow-derived stem cells
89228077|NCT03961867|Experimental|DS|D2 resection -- S1 * 1 cycle + DS * 6 cycles + S1 * 9 cycles
89228078|NCT03961867|Active Comparator|SOX|D2 resection -- SOX * 8 cycles + S1 * 8 cycles
89228079|NCT03962179|Experimental|VACStent Group|Patient s who received a VACStent
89228080|NCT00077857|Experimental|1250 mg/m^2 capecitabine + docetaxel|1250 mg/m^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
89228081|NCT00077857|Experimental|825 mg/m^2 capecitabine + docetaxel|825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
89228082|NCT01086397||1|
89228083|NCT00545402|Experimental|MMF, Adjusted Dose; Tacrolimus; Corticosteroids|Participants received mycophenolate mofetil (MMF) 3 grams per day (g/d), orally (PO), twice per day (BID) with meals from Day 0 to Day 4; the dose was adjusted based on total exposure (AUC) using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12. Participants also received tacrolimus adjusted to a target trough level of 8 to (-) 12 nanograms per milliliter (ng/mL) from Day 0 to Month 1; the dose was adjusted to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 milligrams per kilogram (mg/kg), intravenously (IV), pre-operation on Day 0.
89105472|NCT02621554|Placebo Comparator|placebo supplementation|Dietary Supplement: Placebo
89105473|NCT02623036|Active Comparator|Enalapril arm|Patients randomized to this group will receive equivalent dose enalapril to their current ACEI therapy and change the administration time to bedtime.
89105474|NCT02623036|Active Comparator|Lisinopril arm|Patients randomized to this group will receive equivalent dose lisinopril to their current ACEI therapy and change the administration time to bedtime.
89105475|NCT01092182|Experimental|Group A - Burkitt lymphoma Low Risk Arm|Burkitt lymphoma Low Risk Arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
89105476|NCT01092182|Experimental|Group B - Burkitt lymphoma High Risk Arm|Burkitt lymphoma High Risk Arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
89105477|NCT01092182|Experimental|Group C - DLBCL high risk arm|Diffuse large B-cell lymphoma (DLBCL) high risk arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
89105478|NCT02623192||ARDS|
89105479|NCT04135378|Experimental|student- ascorbic acid|Student that have presentation given ascorbic acid ( 500 mg per day) for one week before presentation .
89105480|NCT04135378|Placebo Comparator|Control- ascorbic acid like|ascorbic acid like placebo for one week before presentation
89105481|NCT02878772|Active Comparator|vinpocetine group|Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
89105482|NCT02878772|Placebo Comparator|Control group|Patients will receive aspirin only.
89105483|NCT02623114|Experimental|Methylphenidate|ADHD patients with methylphenidate administration Generic names include concerta, metadata and penid. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
89105484|NCT02623114|Experimental|Atomoxetine|ADHD patients with atomoxetine administration Generic names include strattera. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
89105485|NCT00932646|Experimental|BI1744 (Olodaterol)|Medium Dose once Daily
89105486|NCT00932646|Experimental|BI 1744 (Olodaterol)|Low Dose once Daily
89105487|NCT00932646|Placebo Comparator|Placebo|Placebo once Daily
89105488|NCT00932646|Active Comparator|Foradil|12 mcg twice daily
89105489|NCT02878460|Experimental|monitoring with ORI + SpO2|"Patients receive the regular monitoring with SpO2, but in this group, the ORI parameters is shown on the scope.~Lower and upper SpO2 limits are prescribed for each patient."
89105490|NCT02878460|Other|monitoring with SpO2|"Patients receive the regular monitoring; the ORI parameters is not shown (but it is recorded each time a blood gas is drown).~Lower and upper SpO2 limits are prescribed for each patient."
89105491|NCT04135612|Experimental|Smartphone group|"application installed to their smartphones. This application will be in Hebrew language, simple to use, and specifically designed to the needs of the current study.~Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles. In addition, patients will be encouraged to use the platform to ask questions and receive immediate answers regarding any aspect lactation. As per the study protocol, medical treatment will only be initiated in a formal clinic appointment and not via the application."
89105492|NCT04135612|No Intervention|Control group|The routine prenatal care provided by our institute includes lactation consulting during the 48-72 hour postpartum hospitalization.
89105493|NCT00675064|Experimental|Anti-malarial experimental drug|After randomization subjects will receive either 5, 25, 100, 250, 500, 1000, 2000 and 3000 mg of GSK3697969 orally . GSK3697969 will be available as 5, 25 and 250 mg capsules.
89105494|NCT00675064|Active Comparator|Matching placebo|After randomization subjects will receive matching placebo of GSK3697969.
89105495|NCT02879240|Other|Group animated cartoon-black screen (AB)|In this group, children will be exposed to a animated cartoon during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to a black screen in the same conditions for one other week.
89105496|NCT02879240|Other|Group black screen - animated cartoon (BA)|In this group, children will be exposed to a black screen during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to an animated cartoon in the same conditions for one other week.
89105497|NCT04267224||Early group|Patients receiving the loading dose of Ticagrelol 90 mg more than 60 minutes before PCI.
89105498|NCT04267224||Late group|Patients receiving the loading dose of Ticagrelol 90 mg less than 60 minutes before PCI.
89105499|NCT00675142|Experimental|1|IUI 36 hours after ovulation induction
89105500|NCT00675142|Experimental|2|IUI 42 hours after ovulation induction
89105501|NCT00675142|Experimental|3|IUI 48 hours after ovulation induction
89105502|NCT04267068|Experimental|Intervention|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
89105503|NCT04267068|Active Comparator|Control|Online daily activity scheduling interactive article (control)
89105504|NCT00675220||A|
89105505|NCT00608400|Experimental|1|CLA 1.5 g/d
89105506|NCT00608400|Experimental|2|CLA 3.0 g/d
89105507|NCT00608400|Placebo Comparator|3|
89105508|NCT00675298||1|Men with chronic prostatitis/chronic pelvic pain syndrome
89105509|NCT00675298||2|Women with painful bladder syndrome/interstitial cystitis
89105510|NCT00675298||3|Children with overactive bladder
89105511|NCT00675298||4|Bulgarian cohort with chronic prostatitis/chronic pelvic pain syndrome, painful bladder syndrome/interstitial cystitis and children with overactive bladder
89105512|NCT00675298||5|Asymptomatic healthy controls
89105513|NCT04152304|Experimental|Feasibility of the SINEX for treatment of shoulder instability|Feasibility of the SINEX program for treatment and evaluation of of traumatic anterior shoulder instability eligible for surgery
89105514|NCT04152226|Active Comparator|Cohort 1|Cohort 1 low dose of J. lividum
89105515|NCT04152226|Active Comparator|Cohort 2|Cohort 2 medium dose of J. lividum
89105516|NCT04152226|Active Comparator|Cohort 3|Cohort 3 - high dose of J. Lividum
89105517|NCT00607308|Experimental|0.1 mg/kg|
89105518|NCT00607308|Experimental|0.5 mg/kg|
89105519|NCT00607308|Experimental|1 mg/kg|
89105520|NCT00607308|Experimental|5 mg/kg|
89105521|NCT00607308|Placebo Comparator|Placebo|
89105522|NCT00607308|Experimental|10 mg/kg|
89105523|NCT04135144|Active Comparator|Group 1 (printed materials),|Group 1 was given home exercise method with printed materials
89105524|NCT04135144|Active Comparator|Group 2 (video phone reminder)|Group 2 was given exercise with home exercise method with video phone reminder
89105525|NCT00605748|Active Comparator|1|Segmental PV-Isolation of the arrhythmogenic vein(s)
89105526|NCT00605748|Active Comparator|2|Segmental PV-Isolation of all veins
89105527|NCT01091246|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
89105528|NCT01091246|Experimental|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])
89105529|NCT01091246|Experimental|FluMist/B/Victoria|FluMist/B/Victoria (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza stains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004]).
89105530|NCT02622958|Experimental|PH94B Nasal Spray|Water based solution of 16 ppm PH94B. Each nasal spray delivers .8 micrograms PH94B in 50 microliters
89105531|NCT02622958|Placebo Comparator|Placebo Nasal Spray|Water based solution, each nasal spray delivers 50 microliters of droplets.
89105532|NCT05260086|Experimental|Personalized aiTBS active - sham|counterbalanced crossover with sham neuronavigated stimulation
89105533|NCT05260086|Active Comparator|Conventional (F3) aiTBS active - sham|counterbalanced crossover with sham neuronavigated stimulation
89105534|NCT02622880|Active Comparator|: IMPACT|along 10 days before surgery
89105535|NCT02622880|Experimental|immunomodulatory supplement|along 10 days before surgery
89105536|NCT04267146|Experimental|newly diagnosed high-grade glioma|"Phase I : Open label, non-randomized, safety run study in nine patients. In case of safety issue a -1 dose level will be tested.~Phase II : Open label, non randomized, efficacy study of nivolumab in addition to radiotherapy and temozolomide. This phase will start when the RP2D has been defined after the last patients evaluable for DLT achieved the first 6 weeks of treatment (the radio-chemotherapy period) with a DLT rate below 30% during the the phase I study."
89105537|NCT00912106||HA injection|Patients with osteoarthritis of knee. They are going to received HA injection 1 vial per week for 5 weeks.
89105538|NCT04263324|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
89105539|NCT04263324|No Intervention|Control group|No intervention
89105540|NCT05258214|Experimental|Mulligan Bent Leg Raise With Conventional Therapy|"This group will receive mulligan's bent leg raise with conventional therapy. In a mulligan bent leg lift, the practitioner stands on the side of the supine subject on the couch with minimal hamstring stability. The subject's flexed knee is placed over the therapist's shoulder, and the subject is instructed to force the therapist with his leg before relaxing.~At this moment, the therapist pushes subject's bent knee as high as possible on the same side as his (therapist's) shoulder. Mulligan's Bent Leg is performed three times.~The raises took 7 seconds to keep and 5 seconds to relax. And conventional therapy includes ultrasound, lumber strengthening, stretching exercises, stabilizing exercises for 30 minutes."
89105541|NCT05258214|Experimental|Mulligan Traction Straight Leg Raise With Conventional Therapy|"This group will receive mulligan's traction Straight Leg Raise with conventional therapy. Patients were placed in a supine position on a low couch or the floor and provided the Mulligan traction leg raise with knees bent..~Mulligan's Traction is repeated three times. Straight Leg Raise was kept for 7 seconds and then relaxed for 5 seconds. Three repetitions of the pain-free Straight Leg Raise traction is performed. And conventional therapy include ultrasound, lumber strengthening, stretching exercises, stabilizing exercises for 30 minutes."
89523203|NCT03754153|Experimental|Balanced Binocular Viewing (BBV)|The experimental intervention will be BBV treatment, i.e. viewing movies for one hour or 2x30min/day on a Nintendo 3DSXL console. With this technology, the Investigators will show blurred images to the better-seeing eye and normal images to the amblyopic eye, encouraging the use of the amblyopic eye and improving acuity.
89228084|NCT00545402|Active Comparator|MMF, Standard Dose; Tacrolimus; Corticosteroids|Participants received MMF 2 g/d, PO, BID with meals from Day 0 to Month 12. Participants also received tacrolimus adjusted to a target trough level of 8-12 ng/mL from Day 0 to Month 1; the dose was reduced to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 mg/kg, IV, pre-operation on Day 0; followed by 20 mg/d, PO, 4 times per day (QDS) from Day 0 through Month 1; 15 mg/d, PO, 3 times per day (TID) from the end of Month 1 through Month 2; 10 mg/d, PO, BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
89228085|NCT03963115|Active Comparator|Coated syringe with epinephrine|Epinephrine was coated syinge before drawing the allergen to filled in.
89228086|NCT03963115|Placebo Comparator|placebo|Normal saline was coated syinge before drawing the allergen to filled in.
89228087|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Sham rTMS|
89228088|NCT01583023|Experimental|Placebo + Lithium a/o Epival + Active rTMS|
89228089|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Active rTMS|
89228090|NCT00976976|Experimental|DXP|
89228091|NCT00977054|Experimental|DFPP and Peg-IFN + RBV|Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight < 75 kg, 1,000 mg/day and body weight >= 75 kg, 1,200 mg/day)
89228092|NCT00977054|Active Comparator|Peg-IFN + RBV|Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight < 75 kg, 1,000 mg/day and body weight >=75 kg, 1,200 mg/day)
89228093|NCT00966524|Experimental|Video|Teaching tracheal intubation to medical students using video-guided feedback during the procedure.
89228094|NCT00966524|Active Comparator|Standard|Teaching tracheal intubation to medical students using direct visualization feedback during the procedure.
89228095|NCT00977132|Experimental|Lenalidomide|Lenalidomid in combination valproic acid
89228096|NCT00977210|Experimental|OXi4503|
89228097|NCT00545792|Experimental|Avastin|Avastin
89228098|NCT00977288|Experimental|1|MK0859 10 mg + placebo
89228099|NCT00977288|Experimental|2|MK0859 40 mg + placebo
89228100|NCT00977288|Experimental|3|MK0859 100 mg + placebo
89228101|NCT00977288|Experimental|4|MK0859 300 mg + placebo
89228102|NCT00977288|Experimental|5|MK0859 10 mg + atorvastatin 10mg
89228103|NCT00977288|Experimental|6|MK0859 40 mg + atorvastatin 10mg
89228104|NCT00977288|Experimental|7|MK0859 100 mg + atorvastatin 10mg
89228105|NCT00977288|Experimental|8|MK0859 300 mg + atorvastatin 10mg
89228106|NCT00977288|Placebo Comparator|9|Placebo + atorvastatin 10mg
89228107|NCT00977288|Placebo Comparator|10|Placebo
89228108|NCT00966602|Experimental|Treatment Period 1|
89228109|NCT00966602|Experimental|Treatment Period 2|
89228110|NCT00966602|Experimental|Treatment Period 3|
89228111|NCT00977366|Active Comparator|Hydrochloric acid infusion|
89228112|NCT00977366|Placebo Comparator|Saline|
89228113|NCT00966680||1|Observational study comparing the speed of general versus spinal anesthesia during emergency cesarean
89228114|NCT00977444|Experimental|kondrium|intraarticular injections once month
89228115|NCT00977444|Experimental|kondrium f|
89228116|NCT00977444|Active Comparator|corticosteroid|intraarticular injections once month
89228117|NCT04093934|Experimental|Intervention|Children in the intervention arm will receive sessions of psychosocial stimulation every two weeks at the community clinics for one year. The intervention includes songs, games, book and toy activities for undernourished children and nutritional and developmental messages for their mothers.
89228118|NCT04093934|No Intervention|Wait-listed control|The wait-listed controls will be only tested at baseline and after a year. Following completion of the 2nd test, they will be included in the study and receive the same intervention provided to children in the experimental arm.
89228119|NCT00966758|Other|1|
89228120|NCT00977600|Experimental|GT4P-F|GT4P-F (80% GT4P) was supplied as an odorless, colorless, tasteless liquid oil in 125 ml bottles. This formulation was designed to be mixed in water and create a self-emulsifying suspension, thus administered in water for the trial. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-F was mixed in 50 ml of water, taken orally, and then the cup rinsed with 50 ml of water and taken orally. GT4P-F was stored at ambient temperature away from light.
89228121|NCT00977600|Experimental|GT4P-API|GT4P-API was supplied as an odorless, colorless, tasteless oil in 125 ml bottles. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-API was taken orally and washed down with 100 ml of water. GT4P-API was stored at ambient temperature, away from light.
89228122|NCT00977600|Active Comparator|Ammonul|Ammonul® was supplied as single-use glass vials of 10% sodium phenylacetate and 10% sodium benzoate for intravenous injection. Ammonul® was diluted before use with sterile dextrose injection 10% to a concentration of 9 mg/ml. Once diluted it was kept at room temperature and used within 24 hours. The dose was 2.75 g/m2 and was administered as an intravenous infusion over a 120-minute period. Ammonul® was stored at 25°C, within a range of 15-30°C.
89228123|NCT00977600|Active Comparator|Buphenyl|Sodium phenylbutyrate or Buphenyl® was supplied as a white powder in 250 g bottles. The required amount of powder (equivalent to 3 g/m2 of PBA) was weighed out, mixed in 100 ml of water, and administered orally. Doses were calculated on a weight/volume basis and corrected for sodium content and purity. Buphenyl® was stored at ambient temperature.
89228124|NCT00966836|Experimental|Pre-emptive everolimus|
89228125|NCT00966836|Experimental|Prophylaxis mycophenolate|
89228126|NCT00966836|Experimental|Prophylaxis Everolimus|
89228127|NCT00966836|Active Comparator|Pre-emptive mycophenolate|
89228128|NCT00967070|Experimental|Both Treatments Applied on Lower Back|Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
89228129|NCT00977678||Open access gastroscopy|Patients referred to open access gastroscopy
89228130|NCT00977678||Conventional outpatient gastroscopy|Gastroscopy after preceding appointment
89228131|NCT00977756||Group G|Participants will receive a medication regimen including RAL + ATV + RTV.
89228132|NCT00977756||Group H|Participants will receive a medication regimen including RAL + TDF.
89228133|NCT00977756||Group I|Participants will receive a medication regimen including ETV + DRV + RTV.
89228134|NCT00977756||Group J|Participants will receive a medication regimen including MVC + ATV + RTV.
89228135|NCT00977756||Group K|Participants will receive a medication regimen including MVC + LPV + RTV.
89228136|NCT00977756||Group L|Participants will receive a medication regimen including MVC + RAL + ETV.
89228137|NCT00977756||Arm M|Participants will receive a medication regimen of DRV
89228138|NCT00977756||Arm N|Participants will receive a medication regimen of DRV
89228139|NCT00977756||Arm O|Participants will receive a medication regimen of unboosted ATV
89228140|NCT00977756||Arm P|Participants will receive a medication regimen of RPV
89228141|NCT00977756||Arm Q|Participants will receive a medication regimen of RPV
89228142|NCT00977834||Group 1|Patients with lymphoma or lung cancer
89228143|NCT00977834||Group 2|Caregivers
89228144|NCT04938206|Experimental|management reduction strategy|Patients classified as low risk by the DRC who will have a reduction in the management of their post-chemotherapy NF.
89228145|NCT04938206|Active Comparator|standard management|Patients classified as low risk by the DRC who will have standard management of post-chemotherapy NF.
89228146|NCT00981422||Glaucoma patients|POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
89228147|NCT00981422||Healthy|healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation
89228148|NCT00981500||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
89228149|NCT00981500||gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
89228150|NCT00981500||sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy
89228151|NCT00967148|Experimental|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
89228152|NCT00967148|Active Comparator|Standard of care|The control arm will receive a subcutaneous injection of 4,500 U of tinzaparin daily beginning with the first postoperative dose and continued for the duration of hospitalization.
89228153|NCT04007588|Experimental|Nivolumab+BMS-986205|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.~BMS-986205 will be administered orally on a daily basis"
89228154|NCT04007588|Experimental|Nivolumab|-Nivolumab will be administered intravenously Day 1 of each 28 day cycle.
89228155|NCT04007588|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously Day 1 of each 28 day cycle.~Ipilimumab will be administered intravenously every 6 weeks"
89228156|NCT00977912|Experimental|"Milk containing B. Lactis"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
89228157|NCT00977912|Placebo Comparator|"Milk containing placebo"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
89228158|NCT00967304|Experimental|1 Discontinue OAT or AAA|"Patients classified as being at low risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at low recurrence risk (<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding."
88812645|NCT00837200|Experimental|Oncaspar, Doxil, Decadron Regimen|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
89105542|NCT05258214|Experimental|Neural Mobilization With Conventional Therapy|"This group will receive neural mobilization with conventional therapy. Straight leg raise movements will be used to trigger sciatic nerve pain during neural mobilization exercises.~Based on the participant's responses and tolerance, several repetitions may be done.~The range of motion will be expanded as the symptom increases before the full Straight Leg Raise range is reached.~The position will be kept for a total of 5 minutes and 30 seconds. Repetition will be carried out. And conventional therapy include ultrasound, lumber strengthening, stretching exercises, stabilizing exercises for 30 minutes."
89105543|NCT00626132|Experimental|Eucommia|Eucommia capsules two orally three times a day for 2 weeks
89105544|NCT00626132|Placebo Comparator|1|
89105545|NCT02622646||Well controlled patients|Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
89105546|NCT02622646||Poor controlled patients|Patients with poor disease control, based on the international guidelines: AJBR>2, ABR>2 for severe BE or ABR >5 for non-severe BE
89105547|NCT02621320|Experimental|Vitamin D|alcohol-based (Ethanol 65%) Vitamin D3 (Vi-De 3®. WILD) solution 6000IU per day.
89105548|NCT02621320|Placebo Comparator|Placebo|Same alcohol-based solution (Ethanol 65%) as intervention product but without cholecalciferol
89105549|NCT01097330|Active Comparator|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia
89105550|NCT01097330|Active Comparator|Amiodarone|amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.
89105551|NCT02622490|Active Comparator|Low carb. one meal|Intervention: One meal of 750 kcal with 20 % of energy content from carbohydrates
89105552|NCT02622490|Active Comparator|Low Carb. 5 small meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 20 % of energy content from carbohydrates.
89105553|NCT02622490|Active Comparator|High carb. one meal|Intervention: One meal of 750 kcal with 50 % of energy content from carbohydrates
89105554|NCT02622490|Experimental|High carb. 5 meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 50 % of energy content from carbohydrates.
89105555|NCT02878616|Experimental|LFG316 + IVIG|
89105556|NCT02878616|Experimental|LFG316 alone|
89105557|NCT00934440|Experimental|Dose Escalation: 5-azacitidine|A traditional 3+3 dose escalation trial was implemented. Successive cohorts of patients (3 participants/cohort) received bevacizumab at the standard dose of 10mg/kg in combination with escalating doses of 5-azacitidine. If no dose limiting toxicity (DLT) is seen, subsequent patients will be treated at the next dose level. If one DLT is seen, an additional three patients will be accrued at that dose level. If two or more DLTs are seen at one dose level, then the previous dose level will be chosen for phase IIA. If two DLT's are seen at dose level 1, the trial will end. The standard 5-azacitidine dose is 75mg/m2/day for 7 days. If no DLT is seen at dose level 3, then we will proceed with the phase IIA portion of the study.
89105558|NCT02622802|Experimental|ex-vivo placenta perfusion|ex vivo placenta perfusion study with exposure to paracetamol, erythromycin and azithromycin
89105559|NCT04134988|Experimental|Medimoov|Bi-weekly 35-minute sessions of an adaptated physical activity administered by a psychomotor therapist for 8 weeks.
89105560|NCT04134988|Active Comparator|Standard rehabilitation|Bi-weekly 35-minute sessions of the standard psychomotor therapy for 8 weeks.
89105561|NCT05158374|No Intervention|Control|No medication, 6 weeks
89105562|NCT05158374|Active Comparator|Aspirin 24 Hours|24 Hours Aspirin
89105563|NCT05158374|Active Comparator|Aspirin 7 Days|7 Days Aspirin
89105564|NCT05158374|Active Comparator|Aspirin 28 Days|28 Days Aspirin
89105565|NCT05158374|Active Comparator|Aspirin 6 Weeks|6 Weeks Aspirin
89105566|NCT05158374|Active Comparator|Metformin 24 Hours|24 Hours Metformin
89105567|NCT05158374|Active Comparator|Metformin 7 Days|7 Days Metformin
89105568|NCT05158374|Active Comparator|Metformin 28 Days|28 Days Metformin
89105569|NCT05158374|Active Comparator|Metformin 6 Weeks|6 Weeks Metformin
89105570|NCT05158374|Active Comparator|Aspirin & Metformin 24 Hours|24 Hours Aspirin & Metformin
89105571|NCT05158374|Active Comparator|Aspirin & Metformin 7 Days|7 Days Aspirin & Metformin
89105572|NCT05158374|Active Comparator|Aspirin & Metformin 28 Days|28 Days Aspirin & Metformin
89105573|NCT05158374|Active Comparator|Aspirin & Metformin 6 Weeks|6 Weeks Aspirin & Metformin
89105574|NCT00675532|Experimental|1|Primary Care Counseling
89105575|NCT00675532|Experimental|2|Cognitive-behavioral psychotherapy (CBT)
89105576|NCT02621086|Experimental|Level 1|10g of Cellodextrin
89105577|NCT02621086|Experimental|Level 2|20g of Cellodextrin
89105578|NCT02621086|Experimental|Level 3|30g of Cellodextrin
89105579|NCT02621086|Experimental|Level 4|50g of Cellodextrin
89105580|NCT00934362|Other|Lucinactant first, then placebo|Active treatment first, then washout period, then placebo treatment
89105581|NCT00934362|Other|Placebo treatment first, then lucinactant treatment|0.9% NaCl vehicle treatment first, then washout period, then lucinactant treatment
89105582|NCT00675610|No Intervention|usual care|providers are not trained and patients are not coached
89105583|NCT00675610|Experimental|intervention arm|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
89105584|NCT00675688|Experimental|A|
89105585|NCT00675688|Active Comparator|B|
89105586|NCT00675688|Placebo Comparator|C|
88812646|NCT00837512|Experimental|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
89105587|NCT00934128|Experimental|Group 1: BiPAP then Vapotherm|Bilevel positive airway pressure device (BiPAP) then Vapotherm air delivery.
89105588|NCT00934128|Experimental|Group 2: Vapotherm then BiPAP|Vapotherm air delivery then BiPAP.
89105589|NCT02622334|Experimental|Part A|Participants will receive up to 3 multiple ascending dose levels with the starting dose of 0.1% RO5093151 (topical ocular instillation) and sequentially 0.5% and 1% RO5093151 doses or placebo (3:1, active:placebo) twice a day (BID) on Day 1 and once a day (QD) for 6 days.
89105590|NCT02622334|Experimental|Part B|Participants will receive highest feasible dose (HFD) or maximum tolerated dose (MTD) of RO5093151 from Part A or 0.005% latanoprost (topical ocular instillation) once daily for 7 days.
89105591|NCT00696514|Placebo Comparator|2|placebo capsule, once per day
89105592|NCT00696514|Experimental|1|Vitamin B12 and folic acid capsule, once a day
89105593|NCT02621164|Experimental|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
89105594|NCT02621164|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
89105595|NCT04263870|Experimental|Sintilimab plus capecitabine and oxaliplatin|Subjects enrolled are treated with oral capecitabine 1000mg per m2 bid for two weeks（every 3 weeks）and intravenous oxaliplatin 130mg per m2（every 3 weeks）in combination with sintilimab 200mg (every 3 weeks)
89105596|NCT05247606|Experimental|Intervention group|Mobile application
89105597|NCT05247606|No Intervention|Control group|Usual care
89105598|NCT02622412|Experimental|Intervention Group|Patients randomised to the intervention group will get immediate access to the Multi-professional breathlessness service (MBS).
89105599|NCT02622412|Other|Control Group|Patients randomised to the control group will get delayed MBS intervention. They will receive standard care and get access to the service after a waiting time of eight weeks.
89105600|NCT04262700|Experimental|Intervention 01|Subjects use new LifeScan provided BGMS for 12 weeks.
89105601|NCT05317182|Active Comparator|Analogic-Analogic|Occlusal splints made by conventional impression and conventional fabrication.
89105602|NCT05317182|Active Comparator|Analogic-Digital|Occlusal splints made by conventional impression and digital design and fabrication.
89105603|NCT05317182|Active Comparator|Digital-Digital|Occlusal splints performed by intra-oral scanner and digital design and fabrication.
89105604|NCT00871000|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Boostrix Polio™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Boostrix Polio™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
89105605|NCT00871000|Active Comparator|TETRAVAC GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Tetravac™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Tetravac™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
89105606|NCT01096784|Active Comparator|rhIGF-I/rhIGFBP-3|Continuous IV Infusion
89105607|NCT01096784|No Intervention|Control|The comparator group will receive no treatment with rhIGF-1/rhIGFBP-3
89105608|NCT02621008|Experimental|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
89105609|NCT02622256|Experimental|Health System: HTN Intervention|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys.
89105610|NCT02622256|No Intervention|Health System: HTN Control, survey only|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys. Participants in this arm will be exposed to daily messages about heart health and asked to tweet about health.
89105611|NCT04016038||QualiPas Observational|Prospective qualitative study through a participant observation procedure with 8 care teams practicing within Palliative Care Units, Palliative Care Mobile Team or Territorial Palliative Care Team.
88812647|NCT00837512|Active Comparator|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
89105612|NCT04016038||QualiPas clinical interview|Qualitative study retrospective research interviews with the doctor and another carer involved in the care of the patient, and close relatives of patients who had sedated before their death. The interviews will be based on 50 cases of patients who have been sedated.
89105613|NCT04016038||QualiPas Focus|Qualitative study by group focus group interviews with clinical teams participating in the project.
89105614|NCT02617108|Experimental|Foley balloon|Foley balloon following TCRS: a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
89105615|NCT02617108|No Intervention|control groups|control groups: women will not receive any therapy of the treatment (comparison group).
89105616|NCT02617108|Experimental|postoperative estrogen therapy groups|Subjects received postoperative hormone therapy as per the protocol in use in our center for Asherman Syndrome. Immediately after the operation, the subjects were started on a 3- month course of cyclical hormonal therapy, consisting of orally administrated oestradiol valerate 2-4mg/day for 21 days, orally administrated medroxyprogesterone acetate 8mg /day from day 12 to 21 of the oestradiol valerate therapy. The second treatment cycle started one week after the completion of the first cycle, and the third treatment cycle started one week after the second cycle.
89105617|NCT02617264|Experimental|Axillary lymph node FNA Biopsy|A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer
89105618|NCT02617420||Intervention|All patients will be enrolled in one arm. These patients will have monitoring devices placed on their asthma controller and rescue medication, with data transmitted both to their smartphones and a dashboard accessed by their primary pediatric pulmonary provider.
89105619|NCT02620696|Experimental|Treatment 1|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide placebo daily from Days 1-42"
88812648|NCT03077672||NYP-WCM|The NYP-WCM cohort will consist of patients presenting to the NewYork-Presbyterian/Weill Cornell Medicine Emergency Department with suspected sepsis.
89105620|NCT02620696|Experimental|Treatment 2|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 25 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14, and from Days 29-42"
89105621|NCT02620696|Experimental|Treatment 3|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 25 mg daily for 14 days (Days 29-42)~netazepide placebo daily from Days 1-28"
89105622|NCT02620696|Experimental|Treatment 4|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide placebo daily from Days 1-28"
89105623|NCT02620696|Experimental|Treatment 5|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 1 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14"
89105624|NCT02620696|Experimental|Treatment 6|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 5 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14"
89105625|NCT02622022|Active Comparator|Morphine|18 patients treated with oral morphine hydrochloride linctus 5 mg 4 four times daily and as needed up to 4 times daily
89105626|NCT02622022|Placebo Comparator|Placebo|18 patients treated with oral linctus corresponding to 5 mg morphine hydrochloride, four times daily and as needed up to 4 times daily
89105627|NCT02621866|Experimental|Active|UVA irradiation.
89105628|NCT02621866|Sham Comparator|Sham UVA irradiation|
89105629|NCT00934050|Experimental|ELND005|
89105630|NCT02620618|Experimental|Intravitreal Infliximab|Patients with refractory behcets uveitis.
89105631|NCT00607464|Experimental|1|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
89105632|NCT00607464|No Intervention|2|Standard care
89105633|NCT01091168|Experimental|arm A: Vinflunine|Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.
89105634|NCT01091168|Active Comparator|arm B: Alkylating agent of physician choice|Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.
89105635|NCT04135768|Experimental|Treatment|Participants who will undergo both volar locking plate fixation of the distal radius and the study procedure (wrist joint haematoma washout)
89105636|NCT04135768|Placebo Comparator|Placebo|Participants who will undergo volar locking plate fixation of the distal radius only
89105637|NCT02621788|Experimental|First Year Residents|Stress Management and Resiliency Training for Residents (SMART-R) delivered to first year residents in the departments of medicine and psychiatry at Massachusetts General Hospital
89105638|NCT05321576|Active Comparator|erector spinae plane block group|Before this process, it will be produced from the bupivacaine plan, which will be made by entering unilaterally 3 cm lateral in the ultrasound to be made from a work section that will be made before the shipment and by lidocaine.
89105639|NCT05321576|Active Comparator|control group|give opiod in this group of patients
89105640|NCT00864916|Experimental|1|Participants will receive pentoxifylline and combination antiretroviral therapy (cART).
89105641|NCT00864916|Active Comparator|2|Participants will receive placebo and cART.
89105642|NCT04130386|Experimental|Motivational Interviewing|Participants assigned to this arm will complete three MI sessions over 10 weeks.
89105643|NCT04130386|Active Comparator|E-education|The e-education group receives three educational modules lasting approximately 10 minutes each over a period of 10 weeks.
89105644|NCT00864682|Placebo Comparator|Placebo|Saline pretreatment, saline admixture
89105645|NCT00864682|Active Comparator|Lidocaine pretreatment|Lidocaine pretreatment / saline-propofol admixture
89105646|NCT00864682|Active Comparator|Lidocaine-Propofol admixture|saline pretreatment / Lidocaine-propofol admixture
89105647|NCT04130308|Experimental|ACL-R|
89105648|NCT04130308|No Intervention|Control|
89105649|NCT00931944|Experimental|KNS-760704 300 mg/day|Open-label KNS-760704 (150 mg Q12H)
89105650|NCT02614378|Active Comparator|Subject receiving treatment|participant receiving air insufflation
89105651|NCT02614378|Placebo Comparator|Subject receiving placebo|participant not receiving air insufflation
89105652|NCT02614456|Experimental|Interferon-gamma and nivolumab|"Interferon-gamma (IFN-γ): starting dose 50 mcg/m2 subcutaneously Nivolumab: 3 mg/kg intravenously~Induction phase: IFN-γ every other day alone for 1 week Combination phase: IFN-γ every other day & Nivolumab every 2 weeks for 3 months Single agent phase: Nivolumab every 3 weeks up to 1 year"
89105653|NCT04130230|Experimental|Neostigmine group|This arm will receive -in addition to standard therapy for sepsis and septic shock-Neostigmine methylsulfate ampoule diluted in normal saline, and administered as continuous infusion for five days. The rate of infusion is 0.2 mg/hr.
89105654|NCT04130230|Placebo Comparator|Standard group|This arm will receive the standard therapy for sepsis and septic shock only and followed for five days.
88812649|NCT03077672||NYP-BMH|The NYP-BMH cohort will consist of patients presenting to the NewYork-Presbyterian Brooklyn Methodist Hospital Emergency Department with suspected sepsis.
89105655|NCT00929994||Exercise|Following a 3 month non intervention period, participants will participate in Cardiac Rehabilitation, carrying out an exercise program which will last 6 months and combine both resistance and aerobic training.
88812650|NCT00837590|Experimental|Acute Salsalate|Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.
89105656|NCT02614300|Active Comparator|Pulmonary Rehabilitation|These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.
89105657|NCT02614300|Active Comparator|Chest Physiotherapy|"The ELTGOL technique (total slow expiration with glottis open in lateral decubitus) for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary."
89105658|NCT02614300|Active Comparator|Pulmonary Rehabilitation and Chest Physiotherapy|"This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.~Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs."
89105659|NCT02614300|No Intervention|Control Group|"For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.~The physiotherapist will also do monthly telephone calls for patient's monitoring."
89105660|NCT00697528||Group control with healthy subjects|Healthy subjects without thyroid disease, ocular disease and previous surgery in the orbit or eye used in the study.
89105661|NCT00697528||Graves' Ophthalmopathy - fibrotic phase|Patients that are clinically inactive (CAS equal or lower than 2). This group will be subdivided in the miogenic and lipogenic groups.
89105662|NCT00697528||Graves' Ophthalmopathy - active phase|Patients that are clinically active, presenting a CAS of 4 or more points, with or without disthyroid optic neuropathy.
89105663|NCT05148702|Active Comparator|Standard care|Clinician decided antibiotic treatment duration
89105664|NCT05148702|Experimental|Fixed-extended-duration antibiotics|28 day antibiotic treatment duration
89105665|NCT05058768||control group|Healthy people served as the control group
89105666|NCT05058768||experimental group|Patients with acute lung injury were treated as the experimental group.
89105667|NCT02616874|Experimental|MVA.HIVconsv plus romidepsin|MVA.HIVconsv plus romidepsin
89105668|NCT04263636||Study group|Patients that underwent uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs (PanOptix or PanOptix toric, Alcon Laboratories, Inc., Fort Worth, TX, USA)
89105669|NCT04263636||Control group|Patients of similar age without cataract that their crystalline lens has not been replaced.
89105670|NCT02616718|Experimental|Ventral incisional hernia|Repeated computed tomography scan of abdomen
89105671|NCT01090310|Experimental|AIN457 300mg every 2 weeks|AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks
89105672|NCT01090310|Experimental|AIN457 300 mg every 4 weeks|AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
89105673|NCT01090310|Experimental|AIN457 150 mg every 4 weeks|AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
89105674|NCT01090310|Placebo Comparator|Placebo|Placebo s.c. every 2 weeks
89105675|NCT02616952|Experimental|Chinese herbal therapy group|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks.
89105676|NCT02616952|Other|Pelvic floor muscle training group|Pelvic floor muscle training includes intensive exercises and home exercises. Intensive exercises are conducted in hospital once a week while home exercises are performed three times daily for 12 weeks.
89105677|NCT04133428||Sacubitril-Valsartan cohort|Patients with severe systolic disfunction (left ventricle ejection fraction<40%) heart failure that remain functional class II, III or IV after at least 3 months of optimal treatment and after being evaluated by the cardiologist by doing an echocardiography, blood test and clinical evaluation, start Sacubitril-Valsartan treatment.
89105678|NCT02878070|Experimental|Peer Health Coaching|Calls from a Peer Health Coach for 6 months
89105679|NCT02878070|No Intervention|Usual Care|
89105680|NCT04133350|Experimental|Active Patient Engagement|All patients are enrolled into the Active Patient Engagement (APE) arm. This arm will receive the APE intervention.
89105681|NCT01090076|Experimental|Abound|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
89105682|NCT01090076|Placebo Comparator|Placebo|Placebo comparator that contains none of the active ingredients
89105683|NCT00869050|Experimental|Capecitabine and Temozolomide|Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg and Temozolomide 150-200 mg/m2/day (PO divided BID).
89105684|NCT02878148|Experimental|Patients with suspected acute uncomplicated renal colic|Diagnostic imaging
89105685|NCT04133506||acute eczema|acute eczema patients with eczema <72 hours no drugs
89105686|NCT04133506||chronic eczema|chronic eczema with eczema > 72 hours no drugs
89105687|NCT04133506||allergic contact dermatitis|allergic contact dermatitis with a clear allergen identified no drugs
89105688|NCT04133506||psoriasis patients|patients with plaque psoriasis no drugs
89105689|NCT04133506||healthy volunteers|dithranol or DNCB (used to induce irritant or allergic eczema used safely in similar research studies for decades) aspirin to half the group to assess the effects on downstream mediators
89105690|NCT04872218|Experimental|Abatacept|
89105691|NCT04872218|Placebo Comparator|Placebo|
89105692|NCT04308746|Experimental|Individualistic|Participants write 3 statements to 3 questions relating to his/her differences from his/her immediate community
89105693|NCT04308746|Experimental|Collectivistic|Participants write 3 statements to 3 questions relating to his/her similarities with his/her immediate community
89105694|NCT00698464|Experimental|Pasireotide|
89105695|NCT00696904|Other|1|Healthy volunteers, receiving 10-1200 mg ABT-333 or placebo, single dose
89105696|NCT00696904|Other|2|HCV+ treatment-naive subjects receiving 100-300 mg ABT-333 or placebo, multi-dose, QD or BID
89105697|NCT00696904|Other|3|Healthy volunteers, receiving 100 mg ABT-333, multi-dose, food effect
89105698|NCT04933682|Experimental|Part 1: ALXN2050 plus Fluconazole|"Period 1: Participants will receive a single dose of ALXN2050 alone and in the presence of multiple doses of fluconazole.~Period 2: Participants will receive multiple doses of ALXN2050 alone and in the presence of multiple doses of fluconazole.~Scheduled pharmacokinetics (PK) blood samples for both ALXN2050 and fluconazole will be collected, with a washout period of at least 14 days between the last dose of fluconazole in Period 1 and the first dose of ALXN2050 in Period 2."
89105699|NCT04933682|Experimental|Part 2: ALXN2050 plus Rifampin|"Participants will receive a single dose of ALXN2050 alone and in the presence of both single and multiple doses of rifampin.~Scheduled PK blood samples for both ALXN2050 and rifampin will be collected."
89105700|NCT04306718|Experimental|studyarm|Hyalocytes from ERM and ILM are cultured in alphaMEM to examine their proliferation habits
89523204|NCT03754153|Active Comparator|Standard Therapy - Occlusion (patching) or blurring (atropine)|The control intervention will be either atropine eyedrops twice a week or daily occlusion (patching) therapy of the better-seeing eye (which are the current standards). As per clinical standard, parents will be offered the choice of occlusion or eyedrop treatment.
89105701|NCT04307966||Intervention|537 pre-adolescent grade 6 learners and their parent (n=537) were invited to participate. Trained educators delivered lessons about HIV and obesity to all Grade 6 students at 5 government-run schools. The classroom curriculum for students required delivery of a five-hour face-to-face intervention delivered weekly through 10 30-minute lessons. Students were asked to communicate their learnings to their parents at home. Parents were requested to read through the lesson in a workbook and to sign acknowledgement that they had read the content. The workbook contained shared student-parent homework activities that took approximately 30 minutes per week. Data was only collected from Learners (n=425) and parents (n= 427)who had consented to the study. A pretest was conducted. The intervention was then implemented. A posttest was conducted afterwards. Both parents and learners answered self-reported questionnaires.
89105702|NCT00625976|Experimental|1|
89105703|NCT00625976|Experimental|2|
89105704|NCT04308200|Other|CO-OP+NDT group|The CO-OP+NDT group received twelve sessions of CO-OP approach, with the baseline and end of treatment assessments, each lasting approximately one hour. Parents and / or caregivers were advised to observe sessions as often as possible to encourage adaptation and transfer to life. Furthermore, CO-OP+NDT group received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist.
89105705|NCT04308200|Other|NDT group|NDT group received just NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity and postural reactions.
89105706|NCT00927186|Experimental|Teriparatide|
89105707|NCT00927186|Active Comparator|Zoledronic Acid|
89105708|NCT02877602||Experience of liver disease|This is defined as either those who have had direct experience of liver disease as sufferers, or the carers of those who have had liver disease. Each individual receives an MRI (LiverMultiScan), with many also receiving a FibroScan.
89105709|NCT00593554|Active Comparator|1|Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;
89105710|NCT00593554|Experimental|2|Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG
89105711|NCT04129918|Experimental|experimental group|ear plugs and eye mask for 3 successive nights
89105712|NCT04129918|No Intervention|control group|without ear plugs and eye mask
89105713|NCT01101308|Experimental|Reformulated OXY 10 mg (Totowa)|Reformulated OXY 10 mg (Totowa) x 1 dose
89105714|NCT01101308|Active Comparator|Reformulated OXY 10 mg (Wilson)|Reformulated OXY 10 mg (Wilson) x 1 dose
89105715|NCT02616328||Participants with confirmed rheumatoid arthritis|
89105716|NCT02620462|Experimental|Wearable sensor-based exercise training|The intervention group in addition to standard of care, will receive 6 weeks of sensor-based balance training that provides real-time visual feedback of lower extremities during exercise. The visual feedback is provided on computer screen.
89105717|NCT02620462|No Intervention|Control Group|The control group only receives standard of care.
89105718|NCT02877524|Experimental|Adaptive support ventilation|Adaptive support ventilation during NIV for acute exacerbation of COPD
89105719|NCT02877524|Active Comparator|Pressure support ventilation|Pressure support ventilation during NIV for acute exacerbation of COPD
89105720|NCT00697606|Experimental|A|Seprafilm®
89105721|NCT00697606|Sham Comparator|B|Control
89105722|NCT04306640|Experimental|intervention group|the intervention group will receive the denneroll cervical traction orthotic in an attempt to improve the altered sagittal cervical spine alignment (AHT and ARA C2-C7).
89105723|NCT04306640|Active Comparator|Control group|Both the intervention group and the control group will complete a multimodal program of 10 weeks consisting of myofascial release, thoracic spine mobilization and manipulations, and physical pain relief methods.
89105724|NCT04128358|Experimental|Group on high dose dexamethasone, cyclosporin and rituximab|Egyptian patients with idiopathic thrombocytopenic purpura on high dose dexamethasone together with cyclosporine and rituximab.
89105725|NCT04128358|Active Comparator|Group on steroids only|Egyptian patients with idiopathic thrombocytopenic purpura on parenteral or oral steroids.
89105726|NCT04128358|Placebo Comparator|Placebo group|Egyptian normal healthy volunteers who share on the President Initiative (100 Million Health).
89105727|NCT00698542||1|Patients in the NCU at VUH
89105728|NCT00626054|Active Comparator|1|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
89105729|NCT00626054|Active Comparator|2|Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test.
89105730|NCT04262622|Active Comparator|Group TEA|
89105731|NCT04262622|Active Comparator|Group RSB|
89105732|NCT04134676|Experimental|Conditioned Medium Group|"In this group, the subjects will use Conditioned Medium topical therapy for 2 weeks The Conditioned Medium gel will be applied to the wound and closed by transparent dressing.~The evaluation and dressing replacement will be done every week for 2 weeks."
89105733|NCT02878694|Experimental|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections
89105734|NCT05009316|Experimental|Questionnaires|Patients will answer online surveys containing different questionnaires that will evaluate psychosocial variables as well as pain variables.
89105735|NCT00926796|Experimental|Regimen B: gemifloxacin plus azithromycin|Gemifloxacin 320 mg by mouth one time plus azithromycin 2 gm by mouth one time.
89105736|NCT00926796|Experimental|Regimen A: gentamicin plus azithromycin|Gentamicin 240 mg intramuscular (IM) one time for patients greater than 45 kg or 5 mg/kg IM one time for patients less than or equal to 45 kg plus azithromycin 2 gm by mouth one time.
89105737|NCT00696982|Experimental|A|diabetic patients who are treated with metformin wiyh HBA1C>7% will get sitagliptin
89105738|NCT00696982|Experimental|B|diabetic patients who are treated with metformin with HBA1C>7% will get glibenclamide
89105739|NCT01087736|Experimental|Topiramate|Participants will be randomly assigned to either the topiramate arm or placebo arm. Neither the participant nor the researchers will know which arm the participant is in. Participants in the topiramate arm will be ingesting daily doses of topiramate that will gradually increase to a maximum, and then taper off.
89105740|NCT01087736|Placebo Comparator|Placebo|The Drug Product Services Laboratory at UCSF will purchase and supply our lab with USP or NF grade topiramate study capsules and matching placebo capsules. Randomization will be done by a consulting biostatistician, who will be the only one to know which participants are assigned to placebo. Dosing will follow the same procedures as with topiramate in that arm of the study. If adverse events occur, there will be a procedure in place for unblinding only that participant.
89105741|NCT04262388|Experimental|Window|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with locally advanced disease (window) and treated with durvalumab 1500 mg given by IV x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to definitive therapy (e.g. surgery)."
89105742|NCT04262388|Experimental|Metastatic|"Within each cancer type, 40 patients will be enrolled (for a total of 120 patients on study): 20 patients will be enrolled with recurrent/metastatic (metastatic) disease and treated with durvalumab 1500 mg given by IV every 4 weeks and oleclumab 3000 mg given by IV every 2 weeks x 4 doses then IV every 4 weeks till disease progression, toxicity, withdrawal of subject consent, or another discontinuation reason."
89105743|NCT04262076|Experimental|Combination of pulpine with Polyamidoamine Dendrimer|Removal of Caries infected dentin from the walls and floor of the cavity and then apply polyamidoamine Denrimer for 30 secs ,then washed out of the cavity followed by placement of Pulpine over affected Dentin.
89105744|NCT04262076|Active Comparator|Pulpine|Removal of Caries infected dentin from the walls and the floor of the cavity followed by application of Pulpine over affected Dentin.
89105745|NCT04262310||Study Aims|To obtain normative data (median, 10th and 90th percentile) as well as inter-individual coefficient of variation (COV, assessed by [SD/mean]) with approximately 15 participants in each age group: 18-30, 31-45, 46-60, and 60-70 years old. To assess intra-individual COV [assessed by [SD/mean]. To assess effect of standard diets containing 16.25 or 32.5 g fiber/day during the two 24 hour periods before and during the measurement of permeability
89105746|NCT01079936|Experimental|Lenalidomide + High-Dose Melphalan|Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.
89105747|NCT00931710|Experimental|Valsartan/amlodipine/HCTZ|Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.
89105748|NCT00931710|Active Comparator|Losartan/HCTZ|Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.
89105749|NCT01100528|Experimental|Arm I|Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3 times a week for 24 weeks in the absence of disease progression or unacceptable toxicity.
89105750|NCT04306406|Other|Raspberry Smoothies|Single serving smoothies drink made with red raspberries to be consumed daily for two weeks
89105751|NCT04306328|Experimental|Neurostimulation|
89105752|NCT01079234|Experimental|Flex + insulin aspart|
89105753|NCT01079234|Experimental|Fixed + insulin aspart|
89105754|NCT01079234|Active Comparator|IGlar + insulin aspart|
89105755|NCT00931632|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
89105756|NCT00931632|Placebo Comparator|Placebo|Nitrogen Placebo
89105757|NCT02877758|Experimental|Experimental|Tomorrowlabs cosmeceutical formulation is applied to the face of the subjects twice daily for 3 consecutive months.
89105758|NCT02877758|Sham Comparator|Control|Tomorrowlabs cosmeceutical formulation without the active ingredient is applied to the face of the subjects twice daily for 3 consecutive months.
89105759|NCT04306484||patients with tumoral brain lesion|The 48 tumor patients included 8 low grade (grade II glioma, n=7; grade II ependymoma, n=1), and 40 high grade (grade III glioma, n=12; grade IV glioma, n=25, primary cerebral lymphoma, n=1; medulloblastoma, n=1, and metastatic cerebral breast cancer, n=1) tumors. Histology was available for all tumor patients.
89105760|NCT04306484||patients with non-tumoral brain lesion|The non-tumor group included patients with an inflammatory lesion (n=11), lobar primary intracerebral haemorrhage (n=3), cortical dysplasia (n=3), infectious lesion (n=2, both toxoplasmosis), cerebral cavernomatous malformation (n=1), seronegative autoimmune limbic encephalitis (n=1), deep venous sinus thrombosis-related oedema (n=1), brain infarction (n=1), chronic posttraumatic brain lesion (n=1), radionecrosis after radiation therapy for arteriovenous malformation (n=1), and mixed inflammatory/infectious lesion (n=1, multiple sclerosis lesion complicated by biopsy-related infection).
89105761|NCT04261998|Experimental|Service-learning group|Intervention group will perform a service-learning program with real patients with heart transplantation and coronary syndrome, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
89105762|NCT04261998|No Intervention|Control group|Control group will perform a physical therapy program for heart transplantation and coronary syndrome, but without meeting real patients. One meeting will be performed in order to establish groups and search information based on evidence in scientific databases.
89105763|NCT00608790|Experimental|1|
89105764|NCT01078922|Experimental|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
89105765|NCT00609570|Experimental|Fruit and vegetables|Fruits and vegetables
89105766|NCT00609570|Active Comparator|Whey protein|Whey protein
89105767|NCT00609570|Active Comparator|Ca|Calcium pills
89105768|NCT00863746|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
89105769|NCT00863746|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
89105770|NCT04259814|Experimental|Speech-Language Treatment plus mCIMT|"4 participants~Baseline phase: Speech-language treatment (SLT), 1 hour a day, 3 days a week. The length of the baseline phase will be staggered across subjects.~Treatment phase: SLT combined with modified constraint-induced movement therapy(mCIMT) 1 hour a day, 3 days a week.~Total of baseline and treatment sessions will be 20 to 30 sessions."
89105771|NCT05330910|Active Comparator|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
89105772|NCT05330910|Experimental|Laparoscopic sleeve gastrectomy with hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
89105773|NCT04992156||Patients cohort|Patients with MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FES PET/CT before the initiation of Palbociclib was included.
89105774|NCT04259268||Web based questionnaire|Information registered by patient in the web based questionnaire
89105775|NCT04259268||Outpatient assessment|"Information registered by the anesthesiologist and based on the web based questionnaire, the electronic records of patient and the face to face interview"
89105776|NCT04259268||Virtual assessment|Information registered by the anesthesiologist and based on the web based questionnaire and the electronic records of patient
89105777|NCT00608946|Experimental|1|efficacy of the intake of 8 mg of copper daily per os for one year under observation of cognitive status unless unacceptable side effects appear
89105778|NCT00608946|Placebo Comparator|2|placebo
89105779|NCT02613832|Experimental|EPAP Group|The EPAP devices increase the alveolar pressure. This effect is obtained through valves that generate a resistance to airflow during expiration.
89105780|NCT02613832|Experimental|Breath Stacking Group|The Breath Stacking consists on the implementation of subsequent inspiratory efforts through a one way valve, which allows stacked volume of gas during each inspiration, until it reaches a maximum lung volume.
89105781|NCT00609648|Experimental|CARL|CARL computer program
89105782|NCT00609648|Active Comparator|Pamphlet|Reassuring pamphlet about dental injections
89105783|NCT02616016|Other|MRI guided High Intensity Focused Ultrasound Treatment|"Intervention Group The interventional radiologist will locate the target tissue and mark the volume to be treated using MRI images.~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan.~An individual treatment sonication will last approximately 30 seconds."
89105784|NCT00609102|Placebo Comparator|Placebo|
89105785|NCT00609102|Active Comparator|antioxidant drug|n-acetylcysteine
89105786|NCT02620228|Experimental|BIP Biopsy System|Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
89105787|NCT04259502|Experimental|RIB Group|A single injection Rhomboid intercostal block will be performed under ultrasound guidance
89105788|NCT04259502|Active Comparator|ESP Group|A single injection Erector spinae plane block will be performed under ultrasound guidance
89105789|NCT02615938|Experimental|Start HCQ block Verum|During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
89105790|NCT02615938|Placebo Comparator|Start HCQ block Placebo|At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
89105791|NCT02615938|Experimental|Stop HCQ block Verum|Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.
89105792|NCT02615938|Placebo Comparator|Stop HCQ block Placebo|Patients will receive Placebo for 3 months and will be followed up for additional 3 months.
89105793|NCT00926328|Active Comparator|A -Experimental toothpaste|triclosan/copolymer/fluoride toothpaste
89105794|NCT00926328|Placebo Comparator|B - control toothpaste|sodium fluoride only toothpaste (placebo)
89105795|NCT04203732||Total Joint Arthroplasty|The cohort includes patients undergoing outpatient primary total joint replacement surgeries from 2017 to 2019. Primary total joint surgery is defined as patients who undergo unilateral total knee replacement or total hip replacement for the first time during the study years
89105796|NCT00863512|Experimental|Arm I|Patients receive cisplatin IV on day 1 and vinorelbine ditartrate IV on days 1 and 8 OR docetaxel IV and cytarabine IV on day 1 OR gemcitabine hydrochloride IV on days 1 and 8 and cytarabine IV on day 1 OR pemetrexed disodium IV and cisplatin IV on day 1.. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89105797|NCT00863512|Experimental|Arm II|Patients receive standard care (observation).
89105798|NCT04261920|Experimental|Single decoction group: Huangqi Guizhi Wuwu decoction|The dosage of granules: Sheng huangqi granule 5.5g/bag, Guizhi granule 0.9g/bag, Baishao granule 1.6g/bag, Ganjiang granule 1.7g/bag, Dazao granule 7g/bag. Take twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
89105799|NCT04261920|Placebo Comparator|Simulator group: Huangqi Guizhi Wuwu decoction Placebo|The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)
89105800|NCT05330832||Patients with confirmed SARS-Cov-2 infection|Hospitalized patients with modern or critical condition with confirmed COVID-19 infection. Patients received standard therapy for COVID-19 infection and anticoagulant prophylaxis if needed according to current temporary clinical recommendations.
89105801|NCT02619994|Active Comparator|Control Arm|"Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.~Intensive phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.~Treatment duration: for at least 20 months"
89105802|NCT02619994|Experimental|Experimental Arm|"Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.~Delamanid (100 mg bid for the entire treatment period)~Linezolid (600mg/day for 2 months and 300mg/day afterwards until the end of treatment)~Levofloxacin (750 ~1000 mg/day)~Pyrazinamide (1000~ 2000 mg/day)"
89105803|NCT04263402|Experimental|Methylprednisolone(<40mg/d)|
89105804|NCT04263402|Experimental|Methylprednisolone(40~80mg/d)|
89105805|NCT04261374||Measurement of sublingual microcirculation|
89105806|NCT04124458|Active Comparator|Pulsed Radiofrequency Ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
89105807|NCT04124458|Active Comparator|Bilateral Occipital Nerve Block|In this arm all steps are the same as other arm, except the generator will not be on and patient will have pain relief by injecting numbing medications beside the sensory nerves.
89105808|NCT04123834|Experimental|implantless Arthroscopic ACL reconstruction|implantless Arthroscopic ACL reconstruction using press-fit femoral technique
89105809|NCT04123834|Experimental|Arthroscopic ACL reconstruction with implant|ACL reconstruction with implant (hamstring autograft fixed with bioscrew and endo-button)
89105810|NCT05298280|Active Comparator|Pendulum Group (PG)|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires.
89105811|NCT05298280|Active Comparator|Clear Aligner Group (CAG)|The treatment of sequential upper arch distalization was performed by the same board-certified orthodontists as proposed by Align Technology and described by Ravera et al.
89105812|NCT02615704||Active APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP with MEMS
89105813|NCT02615704||Active APP without MEMs|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP without MEMS
89105814|NCT02615704||Control APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP with MEMS
89105815|NCT02615704||Control APP without MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP without MEMS
89105816|NCT02619916|Experimental|MBCT|Mindfulness-Based Cognitive Therapy
89105817|NCT02619916|Experimental|CBT|Cognitive Behavioral Therapy
89105818|NCT02619916|No Intervention|TAU|Treatment as usual
89105819|NCT00868192|Experimental|Pemetrexed and bevacizumab|"Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle~Bevacizumab 15 mg/kg IV on Day 1 of each 21 day cycle"
89105820|NCT02615782|Experimental|A group|"Period 1: CKD-397 1T single oral administration under fasting condition~Period 2: CKD-397 1T single oral administration under fed condition (high fat meals)"
89105821|NCT02615782|Experimental|B group|"Period 1: CKD-397 1T single oral administration under fed condition (high fat meals)~Period 2: CKD-397 1T single oral administration under fasting condition"
89105822|NCT02615626||Group 1|Periodontal healthy
89105823|NCT02615626||Group 2|Gingivitis, Non-surgical Periodontal Treatment
89105824|NCT02615626||Group 3|Chronic Periodontitis, Non-surgical Periodontal Treatment
89105825|NCT04122352|Experimental|Exercises + ischemic compression group|volunteer patients with temporomandibular joint dysfunction with trigger points
89105826|NCT04122352|Other|Exercises group|volunteer patients with temporomandibular joint dysfunction with trigger points
89105827|NCT00698698||Non diabetic|Normal age and sex matched population
89105828|NCT00698698||Grade 1|Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy
89105829|NCT00698698||Grade 2|Moderate non proliferative diabetic retinopathy
89105830|NCT00698698||Grade 3|Severe non proliferative diabetic retinopathy
89105831|NCT00698698||Grade 4|Proliferative diabetic retinopathy and advanced diabetic eye disease
89105832|NCT00930930|Experimental|Cisplatin and Paclitaxel + RAD001|Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks
89105833|NCT00930930|Active Comparator|Cisplatin and Paclitaxel + Placebo|Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks
89105834|NCT00698776|Experimental|Active|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
89105835|NCT04259112|Experimental|high pressure + deep block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards post-tetanic count (PTC) 1-2.
89105836|NCT04259112|Experimental|high pressure + moderate block|Intra-abdominal pressure will be set to 12-15 mmHg during the surgery. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards train-of-four (TOF) twitch 1-2.
89105837|NCT04259112|Experimental|low pressure + deep block|Intra-abdominal pressure will be set to 7-10 mmHg during the surgery. Deep neuromuscular block will be induced by rocuronium bolus 1 mg/kg, maintained by a continuous infusion of rocuronium (0.6mg/kg/h), and titrated towards PTC 1-2.
89105838|NCT04259112|Experimental|low pressure + moderate block|Intra-abdominal pressure will be set to 7-10 mmHg. Moderate neuromuscular block will be induced by rocuronium bolus 0.6 mg/kg, maintained by a continuous infusion of rocuronium (0.3mg/kg/h), and titrated towards TOF twitch 1-2.
89105839|NCT04122040|Active Comparator|roxithromycin|roxithromycin 300 mg oral per day
89105840|NCT04122040|Placebo Comparator|placebo|placebo one tablet per day
89105841|NCT04134364|No Intervention|control|no medication after gastric biopsy
89105842|NCT04134364|Experimental|treatment|oral administration of sodium alginate (LaminaG) after gastric biopsy
89105843|NCT04259034||systemically healthy individuals with oral lichen planus|systemically healthy individuals diagnosed with oral lichen planus on clinical and histopathological basis.
89105844|NCT04259034||systemically healthy individuals without oral lichen planus|systemically healthy individuals without any clinical feature of oral lichen planus.
89105845|NCT04120948|Experimental|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
89105846|NCT04120948|Active Comparator|Tongue scraper|tongue scraping
89105847|NCT00609882|Active Comparator|HHFNC|Infants randomized to the Humidified High Flow Nasal Cannula (HHFNC) treatment group post extubation
89105848|NCT00609882|Active Comparator|nCPAP|Infants randomized to the nasal Continuous Positive Airway Pressure (nCPAP) treatment group
89105849|NCT04259190|Experimental|Values rationale|Interoceptive exposure exercises will be introduced as a way to help participants engage in more that they value.
89105850|NCT04259190|Active Comparator|Standard rationale|Interoceptive exposure exercises will be introduced as a way to help participants experience less discomfort.
89105851|NCT00862654|Experimental|C propionate 4/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
89105852|NCT00862654|Experimental|C propionate 2/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
89105853|NCT00862654|Experimental|C propionate 2/week|Clobetasol propionate shampoo 0.05% (2/week)
89105854|NCT00862654|Active Comparator|Ketoconazole 2/week|Ketoconazole shampoo 2% (2/week)
88812651|NCT00837590|Experimental|Chronic Salsalate - Obese|Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
89105855|NCT00609180|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
89105856|NCT00609180|Experimental|2|Participants will receive initial full-calorie enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
89105857|NCT00609180|Experimental|3|Participants will receive initial minimal (trophic) enteral feeding and the placebo supplement
89105858|NCT00609180|Placebo Comparator|4|Participants will receive initial full-calorie enteral feeding and the placebo supplement
89105859|NCT00867490|Experimental|Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine|
89105860|NCT04263012||Patients with an implanted LVAD|Patients which received an implantation of a left ventricular assist device (LVAD) at the University Hospital Basel since 2014
89105861|NCT00697060|Experimental|Stage 1/2|Imexon plus docetaxel
89105862|NCT00930774|Experimental|FM System|Provision of FM assistive device
89105863|NCT00930774|Experimental|Auditory Training|Provision of auditory training
89105864|NCT00930774|Experimental|FM System and Auditory Training|Provision of FM assistive device and auditory training
89105865|NCT00930774|No Intervention|Standard-of-Care|Standard-of-care informational counseling
89105866|NCT04261530|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
89105867|NCT04261530|Experimental|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
89105868|NCT04261530|Experimental|Self-care|It is a 7-months 2 hours-session (1 session per month) of self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
89105869|NCT04261530|Experimental|Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
89105870|NCT00867334|Experimental|Imatinib mesylate and panitumumab|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 1. Each participant assigned to Arm 1 will receive imatinib mesylate for 28 days, followed by a combination of imatinib mesylate and panitumumab.
89105871|NCT00867334|Active Comparator|Panitumumab (standard-of-care)|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 2. Participants in Arm 2 will receive standard-of-care treatment with panitumumab.
89105872|NCT04120324||Eligible & Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty and is discharged home on the day of surgery.
89105873|NCT04120324||Eligible but NOT Discharged Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and Anesthesia confirms patient is Same Day Discharge eligible. Patient undergoes Primary Single Joint Total Hip Arthroplasty but is NOT discharged home on the same day as the surgery, and remains in hospital for a minimum of one night following surgery. Reasons for not being discharged same day include potential problems related to Surgery (eg. complication), Anesthesia (eg. prolonged effect), or patient factors (egs. pain, nausea, mobility difficulties, etc.).
89105874|NCT04120324||Not Eligible for Discharge Same Day|Surgeon earmarks patient as potentially eligible for Same Day Discharge. Preoperative Assessment by Physiotherapy and/or Anesthesia deems the patient to NOT be eligible for Same Day Discharge. The patient undergoes Primary Single Joint Total Hip Arthroplasty and remains for a minimum of one overnight in hospital following hip replacement surgery.
89105875|NCT00925704|Active Comparator|Calcitriol|
89105876|NCT00925704|Experimental|Lanthanum carbonate + calcitriol|
89105877|NCT00925704|Experimental|Sevelamer carbonate + calcitriol|
89105878|NCT00697138|Experimental|A|
89105879|NCT02615548|Experimental|Community exercise class|Regular community exercise class is the intervention. It is an exercise class that incorporate PWR moves( UP,ROCK,STEP,TWIST) and cardiovascular training.
89105880|NCT02615548|Active Comparator|self-directed exercise activity|Self-directed exercise.
89105881|NCT04263168|Experimental|Bariatric Surgery Candidates|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
89105882|NCT04263168|Sham Comparator|Laparoscopy Cholecystectomy|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
89105883|NCT02619604|Other|Clinician education|
89105884|NCT00609960|No Intervention|1|no medication or clowns present during the preopertaive phase
89105885|NCT00609960|Active Comparator|2|midazolam a anxiolytic drug was given in the preoperative phase
89105886|NCT00609960|Active Comparator|3|clowns where present during the preoperative phase
89105887|NCT00697840|Experimental|Group A|
89105888|NCT00697840|Active Comparator|Group B|
89105889|NCT00697840|Experimental|Group C|
89105890|NCT04879134|Experimental|Apomorphine Injections|
89105891|NCT04879134|Placebo Comparator|Placebo Injections|
89105892|NCT00697216|Experimental|Group A|
89105893|NCT00697216|Active Comparator|Group B|
89105894|NCT04879056||intra-system|reviewing selected features on images from three iterations of the same scanner.
89105895|NCT04879056||inter-system|reviewing selected features on images from three different scanners.
89105896|NCT00699088||Balance® Microplasty™ Hip System|
89105897|NCT01076192||Moderate-to-severe chronic plaque psoriasis|Participants with moderate-to-severe chronic plaque psoriasis treated with adalimumab in routine clinical practice
89105898|NCT04134130|Other|GnRH antagonist + FSH + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany) + recombinant FSH (Gonal-f, Merck Serrono S.A. Aubonne, Schweiz), 300 IU every second day for 5 weeks.~After 3 weeks: 1000 mg testosterone once."
89105899|NCT04134130|Other|GnRH antagonist + testosterone|"At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany).~After 3 weeks: 1000 mg testosterone (Nebido, Bayer AB, Solna, Sweden) once."
89105900|NCT04258644|Experimental|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1~21, 250 mg, po qd Paclitaxel-albumin：D1&D8, 100～120 mg/m2 S-1：D1~14, 60mg bid
89105901|NCT00610038|Experimental|1|Glibenclamide
89105902|NCT02876588|Active Comparator|Unrestricted|"Users have unrestricted access to open up to a maximum of 4 patient records at a time in the EHR"
89105903|NCT02876588|Active Comparator|Restricted|"Users have restricted access to open a maximum of 1 patient record at a time in the EHR"
89105904|NCT04970472||patients with Urothelial bladder carcinoma|collection of blood, urines, stool and tumor samples
89105905|NCT04031248|Experimental|WBV group (experimental)|"Participants in the experimental group will follow a program that will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work.~The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience."
89105906|NCT04031248|Active Comparator|Exercise group (control)|Control subjects will perform the same exercise program without whole-body vibration.
89105907|NCT01076036|Experimental|CorPath 200 System|Robotic-assisted PCI with the CorPath 200
89105908|NCT04119856|Other|Intervention group|"Affiliation with outgoing lung team~Instructions and teaching by the outgoing lung team.~Needs-based consultation at Dept. of Respiratory Diseases and Allergy.~Contact to the outgoing lung team in case of exacerbation of COPD."
89105909|NCT04119856|No Intervention|Control group|"The usual practice~Scheduled consultations at Dept. of Respiratory Diseases and Allergy.~Contact to GP/doctor on call in case of exacerbation of COPD."
89105910|NCT04258800|Experimental|With music|Colonoscopy performed with music
89105911|NCT04258800|No Intervention|Without music|Colonoscopy performed without music
89105912|NCT02619526|Experimental|Nebivolol|Nebivolol 10mg, once a day
89105913|NCT02619526|Active Comparator|Carvedilol|Carvedilol 25mg, twice a day
89105914|NCT04261140|Experimental|High-viscosity glass ionomer|
89105915|NCT04261140|Experimental|flowable composite|
89105916|NCT04261140|Experimental|bulkfill composite|
89105917|NCT04261140|Experimental|nanohybrid composite|
89105918|NCT04119622|Experimental|XELOX combined with Toripalimab|
89105919|NCT04261452|Other|COPD|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
89105920|NCT04261452|Other|Overlap|Body composition was assessed using a body composition. The same medical doctor performed all echocardiograms and all patients underwent comprehensive M-mode echocardiography. Spirometry, gas transfer and static lung volumes were measured in all patients. Resting blood gases were obtained by samples from the radial artery. The six-minute walk test and the four-minute step test were performed. All CPET tests were performed on an electronically braked cycle ergometer and standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system. Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. All patients performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.
89105921|NCT00912886||1: Case|Patients with early and moderate AD
89105922|NCT00912886||2: Controls|AD free volunteer-controls matched for gender and age
89105923|NCT01096316|Experimental|Intervention|"The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:~enhanced education of patients and providers~engagement of patients~depression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation."
89105924|NCT01096316|No Intervention|Usual Care|Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.
89105925|NCT00699166|Experimental|1|
89105926|NCT00699166|Experimental|2|
89105927|NCT00699166|Placebo Comparator|3|
89105928|NCT04119700|Active Comparator|Muco-muscular endorectal advancement flap|After fistulectomy a muco-muscular endorectal advancement flap is mobilised and fixed to anoderma
89105929|NCT04119700|Experimental|Primary sphincter reconstruction|After fistulectomy the defect in anal sphincters is closed
89105930|NCT04132726|Experimental|Test|Experimental group which employed with massage treatment
89105931|NCT04132726|Placebo Comparator|Placebo|Placebo group which employed with non-effective treatment
89105932|NCT04132726|No Intervention|Control|no treatment
89105933|NCT02615392|Experimental|Park prescription|The participants in this group will receive a brief counseling on physical activity together with a park prescription that highlights the importance of engaging in at least 150 minutes of physical activity per week and the possibility of engaging in physical activity in the park. In addition, they are invited to join in a structured and supervised physical activity program in the park. The structured physical activity program will take place in public parks located in the participants' neighbourhood. Participants will receive text messages for reminder and registration purposes approximately once a week. Also, participants will receive a sheet to monitor their weekly physical activity, information about parks in their neighborhood, and a counseling phone call half-way through the study.
89105934|NCT02615392|No Intervention|Control|The participants in this group will not be given any park prescription or be invited to participate in the weekly program in the park. However, they will receive all the information materials provided to the experimental group after the study has ended.
89105935|NCT00925548|Experimental|Investigational Arm|"Investigational Arm:~Pretreatment (Single Dose): 300 milligrams per square meter (mg/m^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide~tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose)"
89105936|NCT00925548|Active Comparator|Control Arm|"Control Arm:~Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/L) infusion~Placebo plus Hormonal Therapy (Standard Dose)"
89105937|NCT00866788|Experimental|Omalizumab 75 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.).
89105938|NCT00866788|Experimental|Omalizumab 300 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
89105939|NCT00866788|Experimental|Omalizumab 600 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
89105940|NCT00866788|Placebo Comparator|Placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
89105941|NCT04132570|Experimental|Budesonide 256 mcg per Day (Treatment A)|Participants will self-administer 2 nasal sprays of Budesonide (64 microgram [mcg]/spray) in each nostril once daily (every morning) up to 10 +\- 3 Days.
89105942|NCT04132570|Placebo Comparator|Placebo (Treatment B)|Participants will self-administer 2 nasal sprays of matching placebo in each nostril once daily (in the morning) up to 10 +\- 3 Days.
89105943|NCT02619370|Experimental|Intervention|Play 'My Gift of Grace,' a conversation card game for 4-6 players (the game consists of 20 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues); all game sessions will be audio recorded and transcribed.
89105944|NCT02619370|Active Comparator|Control|"Review and discuss a brochure on ACP called Advance Care Planning: Tips from the National Institute of Aging. Discussion will be prompted by the researcher asking participants to discuss the information they've just read with the group. However, there will not be a formal structure to this discussion."
89105945|NCT00697294|Experimental|Supplement|Subjects will serve as their own control in this single-arm protocol. All subjects will receive 400 IU/day of vitamin D as the intervention. Comparisons will be made between Caucasian and Hispanic infants.
89105946|NCT02619292|Experimental|Mindful Movement Program|"Mindfulness is moment-to-moment, present-centered, purposive non-judgmental awareness; Dance/movement therapy is a multidimensional approach that integrates body awareness, expression and acceptance to facilitate physical, emotional, cognitive, social and spiritual integration of individuals"
89105947|NCT00699244|Experimental|Peripheral placement of local anesthesia|to receive ultrasound guided peripheral placement of local anesthetic
89105948|NCT00699244|Active Comparator|Central placement of local anesthesia|to receive central placement of local anesthetic
89105949|NCT02619214|Experimental|Oxygen 30%|Patient receives 1 hour of general anesthesia with a 30% oxygen concentration.
89105950|NCT02619214|Experimental|Oxygen 60%|Patient receives 1 hour of general anesthesia with a 60% oxygen concentration.
89105951|NCT00699322|Experimental|1|Sitagliptin
89105952|NCT00699322|Active Comparator|2|Glimepiride
89105953|NCT04119466|Experimental|Protrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
89105954|NCT04119466|Experimental|Extrusion Group|20 session of stabilizing training based on the principles developed by Richardson over four weeks.
89105955|NCT00860470|Active Comparator|1|Iron (27 mg) and folic acid (600 ug)
89105956|NCT00860470|Experimental|2|Multiple micronutrient
89105957|NCT00923364|Experimental|Recipients and Healthy Related Donors|Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
89105958|NCT02613676|Experimental|TcB screening before discharge|Participants in this group will be screened for jaundice using the JM 105 transcutaneous device. The TcB value will be plotted on the Bhutani nomogram to assess the risk category. Infants who are categorised as high risk according to the nomogram will require blood sampling for TsB and assessment for need for phototherapy.
89105959|NCT02613676|Other|Standard care (visual inspection)|Participants in this group will be managed routinely according to the current standard of care where babies are assessed for jaundice by visual inspection. Babies in this group will require blood draw for TsB if there are visibly jaundiced
89105960|NCT01096160|Experimental|Panel A: MK-8266 BID, 1 mg/Placebo|MK-8266 1 mg (0.7 mg in the morning [AM] + 0.3 mg in the evening [PM]), or as matching placebo BID.
89105961|NCT01096160|Experimental|Panel B: MK-8266 BID, 1.8 mg/Placebo|MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
89105962|NCT01096160|Experimental|Panel C: MK-8266 TID, 1.8 mg/Placebo|MK-8266 TID, 1.8 mg (0.6 mg every 6 hours [q6hr]), or as matching placebo TID.
89105963|NCT01096160|Experimental|Panel D: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
89105964|NCT01096160|Experimental|Panel E: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.
89105965|NCT00860158|Experimental|Single Arm Assignment|Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
89105966|NCT02615314||BPPV without migraine|Two hundred and sixty-three patients with BPPV (2009-2014), confirmed by videonystagmography (VNG), were enrolled in the study. Patients' charts were reviewed. They were grouped as those with or without migraine. Distribution of gender, age, duration of symptoms and affected side were reviewed. Two hundred and thirty-one patients with no migraine were identified.
89105967|NCT02615314||BPPV with migraine|Thirty-two patients (11.4%) with migraine were identified. Diagnosis and classification of migraine and its differentiation from other type of headaches was based on third edition of International classification of headache disorders (ICHD-III beta) by international headache society (IHS). All patients with migraine had migrainous headache with or without aura and they all were diagnosed in our institution and followed by our neurology staff.
89105968|NCT02615236|Experimental|PERINEAL ULTRASOUND|Perineal ultrasound with a bedside scanner by inserting a the probe into the perineum and reviewed in real-time
89105969|NCT02615236|Active Comparator|Clinical diagnosis|Diagnosis of OASIS will be clinically
89105970|NCT02878538|Active Comparator|deferiprone|Deferiprone will be administered three times a day (25mg/kg). Total dose per day will depend on participants' body weight for one, three month block.
89105971|NCT02878538|Placebo Comparator|Placebo Phase|Placebo tablets with inactive substance will be used. Total number of placebo tablets will be equivalent to the active tablets administered depending on participants' body weight for two, three month blocks.
89105972|NCT04134598|Experimental|Breast Irradiation (RT)|Breast Irradiation (RT)
89105973|NCT04134598|Active Comparator|Endocrine Therapy (ET)|Endocrine Therapy (ET)
89105974|NCT04300634||Children whose parents are physiotherapists|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
89105975|NCT04300634||Children whose parents are athletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
89105976|NCT04300634||Parents of children who are atletes|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
89105977|NCT04300634||Parents of children who are physiotherapist|The demographic data of the child and the parent whom he/she played a role in will be recorded. The physical activity habits of the child and the parent, the sports areas he/she is interested in and the level of activity will be questioned. Physical Activity Questionnaire for Older Children (PAQ-C) and the Physical Activity Diary will be used to assess children's physical activity level. Parameters such as physical activity status, participation in a regular sports activity, daily average time spent with activity at school and during breaks, daily time allocated to the activity will be evaluated. The International Physical Activity Questionnaire (IPAQ) and Physical Activity Diary will be used to evaluate the level of physical activity of the parents.
89105978|NCT00929526|Experimental|Cervarix Group|subjects received 3 doses of Cervarix™ vaccine in primary vaccination study NCT00316693.
89105979|NCT00929526|Placebo Comparator|Aimmugen Group|subjects received 3 doses of Aimmugen ™ vaccine in primary vaccination study NCT00316693.
89105980|NCT04307342||Posterior MIPO|Patients treated with posterior MIPO for Humerus Diaphyseal Fractures With Extra-articular Distal Humeral Anatomical Plate
89105981|NCT02618902|Experimental|tolerogenic dendritic cells (tolDC)|Each vaccine (5x106, 10x106 , or 15x106cells in 500 µL NaCl 0.9% solution supplemented with 5% human albumin) will be administered through intradermal injection at 5 sites (100 µL/site) in the subclavicular region (5-10 cm from the cervical lymph nodes). Injection sites will alternate between left and right sides.
89105982|NCT04134052|Experimental|ketamine sedation|Sedation will be performed with ketamine dose 5-20mcg / kg / min in infusion with 100 ml Na Cl solution 0.9% during surgery
89105983|NCT04134052|Active Comparator|midazolam sedation|Sedation will be performed with midazolam dose 5 - 35mcg / kg / hr in infusion with 100 ml Na Cl solution 0.9% during surgery
89105984|NCT04258176||Intervention group|Patients seen in the multidisciplinary pathway
89105985|NCT04258176||Comparison group|Multimorbid patients seen several outpatient clinics who did not undergo the trajectory
89105986|NCT04307420|Experimental|Sonic Fill Restoration|Using sonic activation system turns the highly filled sonic fill composite into a flowable which enables the material to rapidly fill the cavity effortlessly- greatly reducing procedure time.
89105987|NCT04307420|Active Comparator|Composite Resin Restoration|Direct composite restorations are the most requested and performed dental procedures. The incremental placement technique is the gold standard for posterior universal composite placement.
89105988|NCT02615080|Active Comparator|CRD007|CRD007 (containing pemirolast sodium) tablets given twice daily for 14 weeks
89105989|NCT02615080|Placebo Comparator|Placebo|Matching placebo tablets given given twice daily for 14 weeks
89105990|NCT04903730|Experimental|AER-901 Solution for Nebulization|"The inhalation formulation AER-901 for Part A and Part B (Cohort B1 only) is a sterile, yellow solution composed of imatinib mesylate and sterile water for injection. AER-901 will be supplied in 2 solution strengths (5 mg/mL and 40 mg/mL) for nebulisation.~The AER-901 inhalation formulation for Part D is a sterile yellow solution composed of imatinib mesylate, sterile water for injection and propylene glycol. AER-901 will be supplied in 2 solution strengths (5 mg/mL and 40 mg/mL) and the Pharmacy Manual will provide guidance on preparation for nebulization. Following review of the Part D safety and PK data by the SRC, the SRC will recommend which formulation and dose of AER-901 (sterile water vs propylene glycol) will be used in Parts B (Cohorts B2 and B3) and Part C.~The solution will be filled into a suitable container-closure system and delivered via a nebuliser known as the FOX® MOBILE. The water acts as the medium for nebulisation."
89105991|NCT04903730|Placebo Comparator|Placebo|A volume-matching placebo (0.45% sterile saline for injection) is to be delivered via the FOX® MOBILE device.
89105992|NCT04203654|Other|Cognitive-behavior group therapy group|
89105993|NCT04260906|Active Comparator|Vagus nerve stimulation|Patients were admitted to the treatment as day visitors. Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears . The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
89105994|NCT04260906|Active Comparator|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
89105995|NCT00859456|Experimental|Sunitinib|Patients with unresectable or metastatic angiosarcoma, epithelioid sarcoma-like hemangioendothelioma and Kaposi's sarcoma, either receiving Sunitinib as first-line therapy or failure after no more than 2 prior chemotherapy regimens.
89105996|NCT01075646|Experimental|Ropivacaine|After a bolus administration of Ropivacaine a perfusion ot the same anesthetic is initiated through an elastomeric wound during 48 hours
89105997|NCT01075646|Placebo Comparator|saline solution|After a bolus administration of saline solution a perfusion ot saline solution is initiated through an elastomeric wound during 48 hours
89228159|NCT00967304|No Intervention|2 Observation arm|"Men and patients classified as being at high risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding."
89228160|NCT00978146|Experimental|Desmoid tumor|Patients with desmoid tumors
89228161|NCT00981968|Experimental|Japanese Cohort|Single and multiple oral doses of sitaxentan sodium or placebo in 12 healthy subjects.
89228162|NCT00981968|Experimental|Western Cohort|Single oral dose of sitaxentan sodium in 10 healthy subjects.
89228163|NCT00982046|Active Comparator|ACUVUE OASYS|Acuvue Oasys contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
89228164|NCT00982046|Active Comparator|AIR OPTIX AQUA|Air Optix Aqua contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
89228165|NCT00982046|Active Comparator|Biofinity|Biofinity contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
89228166|NCT00967382|No Intervention|Control|"Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
89228167|NCT00967382|Active Comparator|dalteparin sodium|"Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
89228168|NCT00982124|Experimental|Treatment Arm (only)|Zoledronic acid infusion
89228169|NCT04007354|No Intervention|Intubated|The patient was intubated with a left-sided double-lumen endobronchial tube. The protective ventilation was performed as follows: a tidal volume of 6 mL/kg predicted body weight, I:E ratio of 1:2, a respiratory rate to maintain PaCO2 within 35 to 45 mmHg, and positive end-expiratory pressure at 5 cmH2O. If the airway pressure exceeded 25 cmH2O, tidal volume was adjusted.
89228170|NCT04007354|Experimental|Non-intubated|The patients were oxygenated via facial mask with O2 5~10 L/min during the whole procedure. The end-tidal carbon dioxide (EtCO2) was measured by insertion of a detector inside one of the nostrils. Respiration rate was maintained between 12 and 20 breaths/min with adjustment of anesthetics.
89228171|NCT00982202|Experimental|PGZ|
89228172|NCT00982202|Placebo Comparator|Placebo|
89228173|NCT00967460|No Intervention|Control group: No intervention|No intervention, regular childcare program
89228174|NCT00967460|Experimental|Intervention group|Promoting unstructured spontaneous PA through an adaptation of the built environment and the provision of a supportive social environment
89228175|NCT00978224|Experimental|A|Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
89228176|NCT00978224|Placebo Comparator|B|Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
89228177|NCT00967538|Experimental|Etanercept|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
89228178|NCT00978302|Placebo Comparator|Placebo (vehicle)|
89228179|NCT00978302|Experimental|Avotermin|
89228180|NCT00978536|Other|group 1|MS with cortical cognitive troubles
89228181|NCT00978536|Other|group 2|MS with subcortical cognitive troubles
89228182|NCT00978536|Other|group 3|MS in the early stage of the disease when cognitive troubles are absent or inconspicuous
89228183|NCT00978614|Experimental|Neramexane, Placebo, Moxifloxacin|
89228184|NCT00982358|Placebo Comparator|Placebo|
89228185|NCT00982358|Active Comparator|Valsartan|
89228186|NCT00982436|Experimental|Neoadjuvant/Concomitant Chemoradiation|Three cycles of docetaxel/carboplatin neoadjuvant chemotherapy followed by chemoradiotherapy for 7 weeks with weekly carboplatin
89228187|NCT00982514||Standard dose asparaginase|Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase
89228188|NCT00982514||Reduced dose asparaginase|Children who receive reduced dose asparaginase according to NOPHO ALL 2008
89228189|NCT00982670||Systemic lupus erythematosus|Patients should fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus
89228190|NCT00982670||Normal control|Age- and sex-matched health volunteers will serve as controls.
89228191|NCT00982748|Active Comparator|Group B|Study participants in this arm attend yoga breathing classes once per week over the span of one chemotherapy cycle.
89228192|NCT00982748|Experimental|Group A|Participants in this study arm attend weekly yoga breathing classes during two consecutive cycles of chemotherapy
89228193|NCT00982826|Experimental|1|ABT-072 tablet single ascending dose
89228194|NCT00982826|Experimental|2|Placebo tablet
89228195|NCT00982826|Experimental|3|ABT-072 tablet administered under non-fasting conditions.
89228196|NCT00982826|Experimental|4|ABT-072 tablet administered under fasting conditions
89228197|NCT00982826|Experimental|5|ABT-072 tablet multiple ascending dose
89228198|NCT00978692|Experimental|Toric orthokeratology lenses|Children wearing toric ortho-k lenses at night for correcting astigmatism and myopia will be the study group
89228199|NCT00978692|Other|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive error will be serve as control group
89228200|NCT00984854|Experimental|Intradermal Juvidex|
89228201|NCT00984854|Placebo Comparator|Placebo (vehicle)|
89228202|NCT00545168|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
89228203|NCT00545168|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
89228204|NCT00545168|Active Comparator|C - NIX|Nix Creme Rinse (permethrin 1%) applied according to OTC Instructions for Use
89228205|NCT00982904|Experimental|Fexinidazole|
89228206|NCT00982904|Placebo Comparator|Placebo|
89228207|NCT04869020|Other|Otoband efficacy versus Sham A|Participants in Arm 1 will receive, in random order, an OtoBand or Sham Device A to use for two weeks each. Sham Device A is an OtoBand in which the transducer is modified so that the vibrations do not target the vestibular system. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham or effective).
89228208|NCT04869020|Other|Otoband efficacy versus Sham B|Participants in Arm 2 will receive, in random order, a OtoBand or Sham Device B. Sham Device B is an OtoBand that operates at settings found to be non-therapeutic in motion sickness studies. There will be a two-day washout period between the devices. For the second two weeks, the participants will receive the alternate device (i.e., sham, or effective).
89228209|NCT00984932|Experimental|Rosuvastatin|
89228210|NCT00983138|Experimental|recombinant asparaginase|
89228211|NCT00978848||Women seeking emergency contraception|Women seeking emergency contraception
89228212|NCT00978848||Women seeking urine pregnancy testing|Women seeking urine pregnancy testing
89228213|NCT00544544|Experimental|Riluzole|Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.
89228214|NCT05015270||Less disease group|"Patients with coronary artery diameter stenosis <70% confirmed by coronary angiography;~Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion"
89228215|NCT05015270||Severe disease group|"Patients with coronary artery stenosis ≥70% confirmed by coronary angiography;~Patients will be treated using guideline recommended medications or percutaneous coronary intervention at physician's discretion"
89105998|NCT01075412|Experimental|Group 2|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.
89105999|NCT01075412|Experimental|Group 1|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.
89106000|NCT00799903|Experimental|Darapladib|Single daily oral tablet
89106001|NCT00799903|Placebo Comparator|Placebo|Single daily oral tablet
89106002|NCT01075256|Active Comparator|5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste.
89106003|NCT01075256|Active Comparator|7.5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste.
89106004|NCT01075256|Placebo Comparator|Placebo toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with placebo toothpaste.
89106005|NCT02876432|Experimental|Device: Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
89106006|NCT02876432|Sham Comparator|Device: Sham Electroacupuncture|In sham electroacupuncture (Sham) the investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
89106007|NCT02876432|Active Comparator|Drug: Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
89106008|NCT02876276|Active Comparator|HA filler group|6 weeks after the initial therapy, patients were scheduled for the procedure.16 Local Anesthetic solution (2% Lignocaine HCl with adrenaline 1:80000) was administered.17 About 0.2 ml of a commercially available hyaluronic acid based gel was injected 2-3 mm coronal to the apical tip of the receded interdental papilla . Injections were performed using 23 gauge X 25mm intraoral injection needles . The concentration of HA gel used was 20 mg/ml.6 The area was gently massaged to ensure that the filler was uniformly distributed. Care was taken to fill each papilla to full correction (100% of defect). After the treatment the individual patient syringes were capped and stored in a refrigerator with patient names and details. The needle was discarded. Patients were seen three weeks after the initial treatment and if augmentation was still deemed necessary, another injection of 0.2ml was injected up to three times
89106009|NCT02876276|Placebo Comparator|saline filler group|with saline same protocol was performed as mentioned in test group
89106010|NCT00923130|Experimental|Bevacizumab with Ixabepilone|Bevacizumab 15mg/kg every 3 weeks Ixabepilone given on days 1,2,3,4 and 5 of each three week cycle at a dose of 6mg/m(2)/day
89106011|NCT04258098||OA+MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
89106012|NCT04258098||MBP group|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. No oral antibiotics was administered to the patients.
89106013|NCT04260750|Experimental|Expert-chosen content, regular guidance|Content chosen by the therapist, weekly guidance by a therapist.
89106014|NCT04260750|Experimental|Expert-chosen content, on-demand guidance|Content chosen by the therapist, guidance upon request from the health care team.
89106015|NCT04260750|Experimental|Participant-chosen content, regular guidance|Content chosen by participants themselves, weekly guidance by a therapist.
89106016|NCT04260750|Experimental|Participant-chosen content, on-demand guidance|Content chosen by participants themselves, guidance upon request from the health care team.
89106017|NCT04261062||Subject|Patients in surgical intensive unit
89106018|NCT05085678|No Intervention|Control group|"Standard of care:~a short overview of the physician on adjuvant endocrine therapy~a brochure on adjuvant endocrine therapy~a voluntary group session on adjuvant endocrine therapy~and a monthly questionnaire on the patient reported outcomes"
89106019|NCT05085678|Experimental|Intervention group|"Standard care with the access of to the online tool Co'moon and a monthly questionnaire on patient reported outcomes.~The outcome of the questionnaires are summarized for the physician to discuss during the follow-up consultation."
89106020|NCT05330208|Experimental|Group A|
89106021|NCT05330208|Placebo Comparator|Group B|
89106022|NCT00610194|Experimental|Arm 1|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
89106023|NCT02473003|Experimental|High intensity|high intensity exercise 80-90%
89106024|NCT02473003|Experimental|Low/Medium intensity|low/medium intensity exercise 40-50%
89106025|NCT02473003|Experimental|High Intensity with BM|high intensity exercise with Behavioral medicine strategies¨ 80-90%
89106026|NCT02473003|Experimental|Low/Medium intensity with BM|low/medium intensity exercise with Behavioral medicine strategies 40-50%
89106027|NCT02605915|Experimental|Cohort 1A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks.
89106028|NCT02605915|Experimental|Cohort 1B: Atezolizumab/Trastuzumab emtansine 3.6 mg|Participants will receive atezolizumab in combination with trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
89106029|NCT02605915|Experimental|Cohort 1C: Atezolizumab/Trastuzumab emtansine 3.0 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (3.0 mg/kg) every 3 weeks.
89106030|NCT02605915|Experimental|Cohort 1D: Atezolizumab/Trastuzumab emtansine 2.4 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (2.4 mg/kg) every 3 weeks.
89106031|NCT02605915|Experimental|Cohort 1E: Atezolizumab/ doxorubicin/ cyclophosphamide|Participants with HER2-negative breast cancer will receive atezolizumab (every 2 weeks) in combination with doxorubicin (every 2 weeks) and cyclophosphamide for four cycles. After the completion of four cycles of combination atezolizumab /doxorubicin / cyclophosphamide, atezolizumab will be continued as a single-agent at a dose of 1200 mg every 3 weeks.
89106032|NCT02605915|Experimental|Cohort 1F: Atezolizumab/Trastuzumab/Pertuzumab/ Docetaxel|Participants will receive atezolizumab in combination with trastuzumab, pertuzumab, and docetaxel every 3 weeks.
89106033|NCT02605915|Experimental|Cohort 2A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
89106034|NCT02605915|Experimental|Cohort 2B: Atezolizumab/Trastuzumab emtansine|Participants will receive atezolizumab in combination with trastuzumab emtansine every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
89106035|NCT02605915|Experimental|Cohort 2C: Safety Expansion|Participants with HER2-positive metastatic breast cancer/unresectable locally advanced breast cancer who received prior treatment with trastuzumab and a taxane chemotherapy will receive atezolizumab in combination with trastuzumab emtansine at the dose determined from stage 1, every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
89106036|NCT02605915|Experimental|Cohort 2D: Safety Expansion|Participants with HER2-positive metastatic breast cancer recently progressed on an HP containing regimen will receive atezolimumab in combination with trastuzumab and pertuzumab every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
89106037|NCT04028323|Experimental|Experimental group|Drug: Terlipressin. Terlipressin should be administrated with an initial dose of 1-2 mg intravenously and slowly injected (over 1 minute) while monitoring the heart rate and blood pressure. The maintenance dose should be administrated every 4-6 hours. Each dose of terlipressin is 1mg. The usual duration of therapy is 3-5 days.
89106038|NCT04028323|Active Comparator|Control group|Drug: Octreotide. Octreotide should be continuously and intravenously dripped at the speed of 0.025-0.05 mg/h and could be diluted with saline with the maximum duration of 5 days. The usual duration of therapy is 3-5 days.
89106039|NCT04114201|Experimental|PSI|Patients received TKA using patient-specific Instrumentation.
89106040|NCT04114201|Active Comparator|Conventional|Patients received TKA conventional Instrumentation.
89106041|NCT03253627|Experimental|MBSR|Mindfulness-Based Stress Reduction
89106042|NCT03253627|Active Comparator|Health Enhancement Program|Health Enhancement Program
89106046|NCT02607163|Experimental|dexmedetomidine|dexmedetomidine, 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
89106047|NCT02607163|Placebo Comparator|control|saline, same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
89106048|NCT01075178||Palivizumab-treated subjects (CASES)|HSCHD infants, <2 yrs old at first dose of palivizumab
89106049|NCT01075178||Non-palivizumab-treated subjects (CONTROLS)|HSCHD infants, <2 yrs old that did not receive palivizumab
89106050|NCT00799825|Experimental|Cervarix group|Female subjects who previously received the active control i.e. Hepatitis A vaccine in the primary study (NCT00122681) and who received the Cervarix vaccine in the current study. The Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1 and 6 months schedule.
89106051|NCT00799591||1|Intensive Care
89106052|NCT01075100|Experimental|Weekly Ixabepilone +carboplatin|Subjects will receive ixabepilone and carboplatin on Days 1 and 8 of each 21-day cycle.
89106053|NCT02876354|Experimental|Menaquinone 360|All patients in the study will be assigned to receive menaquinone 360 μg /d for 4 weeks.
89106054|NCT00626678|Experimental|1|Oral administration of prednisone and azathioprine throughout study
89106055|NCT00626678|Placebo Comparator|2|Oral administration of prednisone and placebo throughout study
89106056|NCT00803023|Experimental|1|Sodium Oxybate Oral Solution (4.5 grams)
89106057|NCT00803023|Experimental|2|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (4.5 grams)
89106058|NCT00803023|Experimental|3|Sodium Oxybate Oral Solution (6 grams)
89106059|NCT00803023|Experimental|4|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (6 grams)
89106060|NCT02877290|Experimental|cycling test first with NIV, then without NIV|patients in this arm will perform their first constant work rate test while using NIV and the second constant work rate test without NIV
89106061|NCT02877290|Experimental|cycling test first without NIV, then with NIV|patients in this arm will perform their first constant work rate test without NIV and the second constant work rate test with NIV
89106062|NCT04306172||Readmitted inpatients/Cases|"Outcome 1: Patients who were readmitted within 18 days of index hospitalization discharge date to the same hospital, with a diagnosis leading to the same Major Diagnostic Group as the index stay (definition according to Swiss Diagnosis Related Groups system, case merger)~Outcome 2: Patients with an unplanned readmission within 30 days of index hospitalization discharge date to the same hospital. An unplanned readmission was defined as a readmission through the emergency department."
89106063|NCT04306172||Non-Readmitted inpatients/Controls|Outcome 1 & 2: Patients who were not readmitted within 30 days of index hospitalization discharge date.
89106064|NCT04305860|Active Comparator|Modified starch without flavoring|Patients thicken water with modified starch during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
89106065|NCT04305860|Active Comparator|Modified starch with flavoring|"Patients thicken water with modified starch adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
89106066|NCT04305860|Active Comparator|Xanthan gum without flavoring|Patients thicken water with xanthan gum during 3 days of hospitalization. They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake.
89106067|NCT04305860|Active Comparator|Xanthan gum with flavoring|"Patients thicken water with xanthan gum adding any of 5 kinds of flavorings Bi1 aromas during 3 days of hospitalization.They evaluate the organoleptic characteristics of the thickened liquid and register the volume of water intake."
89106068|NCT04114279|Experimental|Laparoscopic Duodenal Atresia Repair|All participants will attempt a laparoscopic duodenal atresia repair on the synthetic high fidelity simulator.
89106069|NCT00859222|Experimental|Phase I Cohort 1: Bevacizumab +LBH589 20 mg every week|Phase I Cohort 1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting LBH589 dose of 20 mg/day orally, 3x per week, every week (days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26). Participants were treated until disease progression or unacceptable toxicity.
89106070|NCT00859222|Experimental|Phase I Cohort 2: Bevacizumab + LBH589 20 mg every other week|Phase I Cohort 2 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the amended starting LBH589 dose of 20 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
89106071|NCT00859222|Experimental|Phase I Cohort 3: Bevacizumab + LBH589 30 mg every other week|Phase I Cohort 3 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
89106072|NCT00859222|Experimental|All Phase I Participants|All phase I participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
89106073|NCT00859222|Experimental|Phase II GBM: Bevacizumab + LBH589 30 mg every other week|Phase II glioblastoma (GBM) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
89106074|NCT00859222|Experimental|Phase II AG: Bevacizumab + LBH589 30 mg every other week|Phase II Anaplastic Glioma (AG) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
89106075|NCT00859222|Experimental|All Phase II Participants|All phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
89106076|NCT01072448|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89106077|NCT01072448|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89106078|NCT00922974|Experimental|Radiosurgery/SBRT|
89106079|NCT00922974|Active Comparator|External Beam Radiation Therapy|
89106080|NCT00858988|Experimental|Rifaximin|
89106081|NCT00858988|Placebo Comparator|Placebo|
89106082|NCT04300088||Patients with advanced solid cancer treated with anti-PD(L)1|Adult patients with advanced solid cancer treated with anti-PD(L)1 immunotherapy with or without anti-CTLA4 immunotherapy.
89106083|NCT00858832|Experimental|Methergine|Methergine group received Methergine 0.2mg po every 6 hours for two days, plus routine postpartum care.
89106084|NCT00858832|No Intervention|No treatment|No treatment group received only routine postpartum care.
89106085|NCT01071512|Experimental|Tysabri|Natalizumab 300 mg IV every 4 weeks
89106086|NCT00858442|Experimental|With PRP|Each patient received a single dose of 5cc PRP before the graft.
89106087|NCT00858442|No Intervention|Without PRP|Control patients did not receive any intervention before the graft.
89106088|NCT04256148|Experimental|ALXN1830 Dosing Regimen 1|
89106089|NCT04256148|Experimental|ALXN1830 Dosing Regimen 2|
89106090|NCT04256148|Experimental|ALXN1830 Dosing Regimen 3|
89106091|NCT04256148|Active Comparator|Placebo|
89106092|NCT00626834|Experimental|Vigabatrin Dose 1|
89106093|NCT00626834|Experimental|Vigabatrin Dose 2|
89106094|NCT00626834|Experimental|Vigabatrin Dose 3|
89106095|NCT00626834|Placebo Comparator|Matching placebo|
89106096|NCT04861116|Experimental|Intervention program for test anxiety|12 weekly ICT-delivered individual sessions.
89106097|NCT04861116|No Intervention|Control|Waiting list that will have access to the intervention program after the 6-month follow-up assessment.
89106098|NCT04119076|Experimental|Intervention Group|Teacher delivered a 10 minute classroom-based physical activity on school days for eight weeks.
89106099|NCT04119076|Other|Control Group|Children in the control schools continued with their usual school routine
89106100|NCT04255992|Active Comparator|Calcium arm|1000 mg Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
89106101|NCT04255992|Active Comparator|Vitamin D/Calcium|1000 mg/800UI of VitaminD/Calcium tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
89106102|NCT02618824|Active Comparator|HTK Solution|Hearts will be arrested with HTK solution during cardiac operation
89106103|NCT02618824|Active Comparator|HTK Solution + TWBC|Hearts will be arrested with HTK solution during cardiac operation and received terminal warm blood cardioplegia before aortic cross clamp removal.
89106104|NCT01071278||Patients treated within a disease management program|Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
89106105|NCT01071278||Patients treated outside a disease management program|Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
89106106|NCT00610272|Experimental|Single Site Radiation 4Gy Fraction|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
89106107|NCT00610272|Active Comparator|Single Site Radiation 8Gy Fraction|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
89106108|NCT00610272|Active Comparator|Multiple Sites Radiation 8Gy Fraction|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
89106109|NCT00610272|Experimental|Multiple Sites Radiation 12Gy Fraction|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
89106110|NCT00858208||Patients with neovascular Age-Related Macula Degeneration|
89106111|NCT00610350|Experimental|L|
89106112|NCT00610350|Experimental|P|
89106113|NCT01071200|Experimental|A|Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)
89106114|NCT01071200|Active Comparator|B|Subjects treated with r-hFSH alone
89106115|NCT04255836|Experimental|Durvalumab therapy|Chemo+Durvalumab (PD-L1 monoclonal antibody)1500 mg every 3 weeks [q3w] intravenously [iv] for 4 cycles, then SBRT 50-60 Gy/≤10f + Durvalumab 1500 mg q4w, then Durvalumab 1500 mg q4w for up to 24 months or until progression or other discontinuation criteria are met.
89106116|NCT04257786|Active Comparator|Group 1|1ry surgery
89106117|NCT04257786|Active Comparator|Group 2|Neoadjuvant Chemotherapy followed by surgery
89106118|NCT00699478|Experimental|1|post total gastrectomized patients due to gastric cancer who has vitamin B12 deficiency - given oral vitamin B 12 supplementation
89106119|NCT04919148|No Intervention|Participants receive control message|Participants only receive standard heat risk warning
89106120|NCT04919148|Experimental|Participants receive intervention message|Participants receive standard heat risk warning plus figures incorporating the health impacts of heat and pro-environment behaviors.
89106121|NCT04119232|No Intervention|Control|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment.
89106122|NCT04119232|Experimental|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
89106123|NCT02615002|Experimental|piromelatine 5 mg|5 mg tablets once daily
89106124|NCT02615002|Experimental|piromelatine 20 mg|20 mg tablets once daily
89106125|NCT02615002|Experimental|piromelatine 50 mg|50 mg tablets once daily
89106126|NCT02615002|Placebo Comparator|Placebo|Placebo tablet once daily
89106127|NCT02207569|Experimental|CoreValve Evolut R TAVR system|"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:~Evolut R Transcatheter Aortic Valve (TAV)~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~EnVeo R Loading System (LS)"
89106128|NCT01070966||VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)
89106129|NCT01070966||VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)
89106130|NCT01070966||VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)
89106131|NCT01070966||VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)
89106132|NCT02619058|Experimental|Arm 1（NKT cells single low dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 1×10^9 on d1, 2×10^9 on d3, 4×10^9 on d29, 8×10^9 on d31.
89106133|NCT02619058|Experimental|Arm 2（NKT cells single high dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3, 5×10^9 on d29, 5×10^9 on d31.
89106134|NCT02619058|Experimental|Arm 3（NKT cells multiple dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3 of each 28 days-cycle, the dosing will be ended after 8 cycles.
89106135|NCT01070888|Experimental|Budesonide/Formoterol first|This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide and dummy inhaler.
89106136|NCT01070888|Active Comparator|Budesonide first|This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide/formoterol and dummy inhaler.
89106137|NCT04114513|Placebo Comparator|Maltodextrin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
89106138|NCT04114513|Experimental|Inulin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
89106139|NCT04114513|Experimental|Pectin|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
89106140|NCT04114513|Experimental|Beta-glucan|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
89106141|NCT04114513|Experimental|Galactooligosaccharides|Within first 6 days, there will be an increase in the fiber dose: 1st and 2nd days - 2g, 3rd and 4th - 4g per day, 5th and 6th - 6g per day. Starting from the 7th and till the 35th day - 8g per day. Placebo will be given in a powder form to be added to 250 ml of water.
89106142|NCT02875496||Healthy aging|Subjects meeting criteria for healthy aging No intervention administered
89106143|NCT02875496||Early Alzheimer Disease|Subjects meeting criteria for Early Alzheimer Disease No intervention administered
89106144|NCT02875496||Depression|Subjects meeting criteria for Depression No intervention administered
89106145|NCT02875496||MCI-Mild Cognitive Impairment|Subjects meeting criteria for MCI-Mild Cognitive Impairment No intervention administered
89106146|NCT02875496||General Arm|Subjects not meeting criteria for any of the other arms (Healthy, Early Alzheimer's, Depression, or MCI)
89106147|NCT05683249|Experimental|NRCT-101SR|Two-tiered fixed dose of 1,500 or 2,000 mg/day. Two NRCT-101SR tablets (375 mg or 500 mg based on lean body mass) by mouth twice daily
89106148|NCT05683249|Placebo Comparator|Matching Placebo|
89106149|NCT00914329|Experimental|Gelsemium 5CH|Globules of Gelsemium sempervirens 5CH
89106150|NCT00914329|Experimental|Gelsemium 15CH|Globules of Gelsemium Sempervirens 15CH
89106151|NCT00914329|Placebo Comparator|Placebo|Globules of placebo
89106152|NCT00857896|Experimental|Fesoterodine once daily|
89106153|NCT04112485|Other|Open discectomy|This group of patients are treated by open discectomy
89106154|NCT04112485|Other|Microdiscectomy|This group of patients are treated by Microdiscectomy
89106155|NCT00857818|Experimental|Aripiprazole|
89106156|NCT00857818|Active Comparator|Control group (Oanzapine, risperidone, or quetiapine)|
89106157|NCT02618668|Experimental|Ketamine / Propofol Admixture|Ketamine / Propofol Admixture: I.V propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+ 4 ml saline in a 20-ml syringe which resulted in 0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol.
89106158|NCT02618668|Active Comparator|Propofol|I.V propofol 2 mg/kg
89106159|NCT01074944|Experimental|Twice Daily (BID) Dose Regimen|Patients will receive either 50 mg BID or 100 mg BID
89106160|NCT01074944|Experimental|Once Daily (QD) Dose Regimen|Patients will receive either 100 mg QD or 200 mg QD
89106161|NCT02613520|Experimental|Group 1a (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 9 x 10^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
89106162|NCT02613520|Placebo Comparator|Group 1a (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
89106163|NCT02613520|Other|Group 1a (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).
89106164|NCT02613520|Experimental|Group 1b (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
89106165|NCT02613520|Placebo Comparator|Group 1b (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
89106166|NCT02613520|Other|Group 1b (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).
89106167|NCT02613520|Experimental|Group 2a (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
89106168|NCT02613520|Placebo Comparator|Group 2a (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
89106169|NCT02613520|Experimental|Group 2b (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
89106170|NCT02613520|Placebo Comparator|Group 2b (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
89106171|NCT02613520|Experimental|Group 3a (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
89106172|NCT02613520|Placebo Comparator|Group 3a (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
89106173|NCT02613520|Experimental|Group 3b (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
89106174|NCT02613520|Placebo Comparator|Group 3b (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
89106175|NCT02613520|Experimental|Group 4a (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
89106176|NCT02613520|Placebo Comparator|Group 4a (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
89106177|NCT02613520|Experimental|Group 4b (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
89106178|NCT02613520|Placebo Comparator|Group 4b (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
89106179|NCT02613520|Experimental|Group 5a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 2.7 x 10^5 PfSPZ Vaccine.
89106180|NCT02613520|Experimental|Group 5b (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
89106181|NCT02613520|Placebo Comparator|Group 5b (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
89106182|NCT02613520|Experimental|Group 5c (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
89106183|NCT02613520|Placebo Comparator|Group 5c (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
89106184|NCT00802945|Experimental|NKTR-102 q14d|NKTR-102
89106185|NCT00802945|Experimental|NKTR-102 q21d|NKTR-102
89106186|NCT02618746|Experimental|Group A, Telerehabilitation|The 12-month home care/rehabilitative program will include the following components: a) individualized action plan; b) educational session on self management; c) physical exercise sessions to remote monitoring; d) access to the call centre; e) professional weekly calls by physiotherapists, dietician and physician with remote connection as a response to possible incidents; f) remote monitoring selectively and temporarily.
89106187|NCT02618746|Active Comparator|Group B, Hospital based Rehabilitation|Patients assigned to the hospital based program will visit the hospital twice weekly for 12 months in order to participate in a multidisciplinary rehabilitation program including exercise, physiotherapy dietary and psychological advice by the staff of the rehabilitation centre based at the University clinic.
89106188|NCT02618746|No Intervention|Group C, Usual care Group|The control group will follow the usual care not involving the initial 8-week rehabilitation program neither maintenance hospital rehabilitation sessions or home telemonitoring of vital signs.
89106189|NCT04119310|Experimental|Lumbar thrust-mobilization|The investigator will perform a lumbar thrust-mobilization with the subject in right and then left sidelying position
89106190|NCT04119310|Sham Comparator|Sham-mobilization|No lumbar-thrust mobilization will be performed. Subject will receive simple passive inter-vertebral range of motion.
89106191|NCT01074554|Experimental|Antibiotic Regimen|"The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.~All four drugs are given concomitantly."
89106192|NCT01074554|Placebo Comparator|Placebo Regimen|The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills
89106193|NCT00857584|Experimental|Quetiapine Extended Release|Lithium or valproate at stable doses within seric therapeutic levels
89106194|NCT00857584|Active Comparator|Sertraline|Lithium or valproate at stable doses within seric therapeutic levels
89106195|NCT02876120|Other|Pre- and post-implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.~Post-implementation phase: during the post-implementation phase the GPs and PTs will treat persons with hip or knee osteoarthritis according to the START treatment model including providing information/patient education program, supervised exercise and advice/support to loose weight and other non-surgical evidence based treatments modalities prior to being referred to an orthopaedic surgeon"
89106196|NCT04132024|Experimental|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. We will deliver 5 CBT-I sessions over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
89106197|NCT00798967|Experimental|Teduglutide|0.05 mg/kg/day sc dose of teduglutide
89106198|NCT00798967|Placebo Comparator|Placebo|Matching subcutaneous dose of placebo to teduglutide
89106199|NCT02876198||Patients treated with anti-VEGF|
89106200|NCT04132102|Experimental|Afatinib treatment group|This is an open-label, sing-arm phase IV clinical study
89106201|NCT01074242||Rotateq|Korean Infants vaccinated with Rotateq in usual practice. The Rotateq vaccination series consists of 3 ready-to-use liquid (oral) doses with the first dose to be administered at age 6-12 weeks and subsequent doses to be administered at 4 to 10-week intervals.
89106202|NCT02618356|Experimental|combined use Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA(body surface area) S-1 dosage <1.25 m2 80 mg/d~1.25m2 - <1.5 m2 100 mg/d~1.5 m2 120 mg/d"
89106203|NCT04112251|Placebo Comparator|Placebo|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg oral placebo capsule (Cornstarch) every 12 hours for 12 weeks.
89106204|NCT04112251|Experimental|Supplement|This group will receive the usual therapy of the endocrinology service, dietary recommendations, physical activity recommendations and the administration of a 500 mg capsule every 12 hours (100 mg / day of epicatechin) for 12 weeks.
89106205|NCT04118842|Experimental|Savolitinib and/or Rifampicin|Treatment Period 1 consists of 16 days starting with admission on Study Day -1, followed by a single dose administration of savolitinib on Day 1, followed by a washout period of at least 14 days. Subjects will be discharged from the Study Centre on Study Day 3, after the last PK sample is collected Treatment Period 2 consists of 6 days, starting with admission on Study Day 14, followed by QD dose administrations of rifampicin for 5 consecutive days (Study Day 15 to Study Day 19) Treatment Period 3 consists of 4 days, starting immediately after Treatment Period 2, comprising of a single dose administration of savolitinib on Study Day 20 and QD dose administration of rifampicin on Study Day 20 and Study Day 21. Subjects will be discharged from the Study Centre on Study Day 22, after the last PK sample is collected
89106206|NCT02618278|Experimental|Intervention|Patients randomised to the intervention arm will receive a individual, goal -orientated physiotherapy management package within 2 weeks G.P referral for physiotherapy.
89106207|NCT02618278|Active Comparator|Usual care|Patients randomised to usual care will receive the same individual, goal-orientated physiotherapy management as the intervention arm but at 6 weeks post G.P referral, as is usual care.
89106208|NCT00698074|Experimental|1|Cardiac Resynchronisation Therapy
89106209|NCT02618200|Experimental|3D prostate ultrasound|3D prostate ultrasound will be performed in patients the day before radical prostatectomy
89106210|NCT04131868|Experimental|Extended sleep opportunity|
89106211|NCT04131868|Active Comparator|Typical sleep opportunity|
89106212|NCT04131790|Experimental|Tele-Behavioral Activation|Manualized Behavioral Activation (BA) protocol delivered via videoconferencing by a trained BA interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist guides participants in learning BA skills, focusing on strategies to decrease barriers to social connectedness (e.g., limited mobility, inadequate caregiving resources).
89106213|NCT04131790|Active Comparator|Tele-Friendly Visiting|Friendly Visitor (FV) calls delivered via videoconferencing by a trained FV interventionist; 5 sessions over 5 weeks, up to 1-hour in length. The interventionist provides social support to participants through good listening and provision of genuine regard.
89106214|NCT04131634|Experimental|SAbR 6 measurable lesions|PD-L1 assessment on biopsy of metastatic site (biopsy will be performed if no prior metastasis sample available)
89106215|NCT00798889|Experimental|Sunitinib|
89106216|NCT04113889|Active Comparator|Combination therapy group|Arm 1: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)
89106217|NCT04113889|Placebo Comparator|Standard therapy group|Arm 2: Metformin (1000 mg daily), Pioglitazone (30 mg daily), Placebo
89106218|NCT00796861|Experimental|Single Arm|Sunitinib (50mg PO daily x 4 wks + 2 wks rest x 3 cycles if able to tolerate tx
89106219|NCT04112017|Experimental|YVOIRE Y-Solution 360|Maximum 5 ml including touch-up
89106220|NCT04112017|No Intervention|No-treatment|No-treatment. At 12 weeks after the assessment, treatment maximum 5 ml including touch-up
89106221|NCT02605057|Experimental|LEO 80185 gel|LEO 80185 gel will be allocated to 7 different test sites on each subject
89106222|NCT02605057|Experimental|Dovobet Ointment|Dovobet Ointment will be allocated to 7 different test sites on each subject
89106223|NCT05638945|No Intervention|Control Period|"Delirium screening on initial assessment of all older adults presenting to the ED is considered standard of care, but not mandated. All health system EDs have access to a validated EHR integrated delirium screening tool (brief confusion assessment method, or bCAM) and all ED nurses have received training on bCAM use. The bCAM tool is an open parameter in the EHR. For positive bCAM screens, a message is displayed, This patient has delirium, alert medical team, identify/ treat the underlying cause, ensure patient safety, nonpharmacologic interventions as first line, and avoid physical and chemical restraints. The control period will include chart reviews of patient visits occurring before implementation of the ED-DDP program."
89106224|NCT05638945|Experimental|Intervention Period|ED leadership at each site have identified 5-10 delirium champions (nurse educators and managers, bedside nurses) based on their interest in delirium and commitment to program participation, including training of nurses by champions. The intervention period will include chart reviews of patient visits occurring after implementation of the ED-DDP program.
89106225|NCT04005703||Pediatric Hodgkin's lymphoma|Children with newly diagnosed Hodgkin's lymphoma
89106226|NCT00914563|Experimental|LIDCO|The extensively burnt patients (age range 18-75 years) with second and the third degree burns, with TBSA above 15%, with or without inhalation injury will be included to the study. We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. We will use in the LIDCO group the continuous real-time hemodynamic monitoring through transpulmonal lithium dilution additionally. The monitor Lithium Dilution Cardiac Output (LIDCO) Plus permits, through analysis of the arterial blood pressure trace, to acquire items about CO, SVR and DO2. In fluid resuscitation, we will use a combination of the balanced crystalloids and synthetic colloids (of the middle molecular weight) in the ratio 2 ml/kg/% TBSA: 1 ml/kg/% TBSA.
89106227|NCT00914563|No Intervention|Standard care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
89106228|NCT00802867|Experimental|1|Subjects in Study 494-01 and Study 494-03 who had received 4 doses of Pentacel™ vaccine.
89106229|NCT04113967|Experimental|Biodanza Group|The biodanza program will consist of 12 sessions, one per week, during three months. Each session will last approximately 60 minutes and an introductory phase (10-15 minutes) and an experience phase (45 minutes) will be divided. It involves moving / dancing according to the suggestions of the monitor and the rhythm of the music.
89106230|NCT04113967|No Intervention|Treatment as usual Group|The control group will continue with its usual treatment and activities, without suffering any alteration. A measurement of the groups (control group and biodanza group) will be carried out before the start and after the end of the sessions.
89106231|NCT00914797|Active Comparator|asthmatics|10 male asthmatic subjects
89106232|NCT00914797|Active Comparator|healthy|10 male healthy volunteers
89106233|NCT00914797|Active Comparator|elite athletes with asthma|10 elite athletes with asthma.
89106234|NCT02604901|Experimental|Screening and Brief Intervention (BI)|Screening and Brief Intervention (BI) at initial prescription fill and at each additional refill.
89106235|NCT02604901|Experimental|Pill Box (PB)|Pill Box (PB) and information about their medications at the initial fill and at each additional refill.
89106236|NCT02604901|Experimental|Brief Intervention + Pill Box (BI+PB)|Screening and Brief Intervention (BI) and Pill Box (PB) at initial prescription fill and at each additional refill.
89106237|NCT02604901|No Intervention|Standard Care (SC)|The Standard Care (SC) arm administered traditional dispensing and counseling by Rite Aid® pharmacists.
89106238|NCT04114045|Experimental|Whey protein|Whey protein isolate
89106239|NCT04114045|Active Comparator|Isoenergetic control - Carbohydrate|Carbohydrate or maltodextrin
89106240|NCT04114045|Placebo Comparator|Placebo control - Water|Water - chocolate flavoured
89106241|NCT00798655|Experimental|Panitumumab, Cisplatin plus radiation|Standard radiation 60-66 Gy with 200 cGy daily fractions in 6-7 weeks Cisplatin* 30 mg/m2 IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements) Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements)
89106242|NCT04111783|Experimental|POU ultrasound intervention test group|The experimental group used POU protocol ultrasound to perform a heart scan and a standard scan, a large vascular scan under the xiphoid, a body cavity scan, a standard section, and a lung scan in 10 minutes. Comprehensive preoperative circulation and assessment of systemic conditions, and guided intraoperative anesthesia management with assessment results.
89106243|NCT04111783|No Intervention|Control group|the anesthesiologist performed according to the existing preoperative evaluation program and existing experience, and guided the anesthesia management with the evaluation results.
89106244|NCT00593983|Experimental|1|
89106245|NCT00593983|Placebo Comparator|2|Control
89106246|NCT04113655||acellular pertussis vaccine|Antibody persistence at 2 years after a single dose vaccination of Pertagen (aP BioNet), Boostagen (TdaP BioNet) and Adacel (comparator vaccine) administered in parent protocol TDA202
89106247|NCT00914641|Other|Apixaban Cross-over|
89106248|NCT05632393|Experimental|Daridorexant 50 mg|Daridorexant 50 mg will be administered once in the morning of Day 1.
89106249|NCT00796549|Experimental|BIBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
89106250|NCT00856492|Experimental|Arm 1|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 and bevacizumab IV over 30- to 90-minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
89106251|NCT00856492|Active Comparator|Arm 2|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 1-12, and then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
89106252|NCT00856492|Active Comparator|Arm 3|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 1, 3, 5, 7, 9, and 11, and then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 14-25.
88812652|NCT00837590|Experimental|Chronic Salsalate - Lean|Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.
88812653|NCT00837824|Experimental|Fabrazyme 1mg/kg every 2 weeks|Fabrazyme 1.0 mg/kg every 2 weeks
89106253|NCT04113265|Experimental|SUNEKOS ® Body|The 1st treatment was performed during T0 visit, after the basal evaluations planned by the study procedure and repeated 3 more times with an interval of 1 week (T2i, T3i and T4i).
89106254|NCT04113577||geriatric inpatients with neurocognitive disorder|usability assessment after 30 minutes to test the app
89106255|NCT04113577||unformal cargivers|usability assessment after 30 minutes to test the app with their relatives
89106256|NCT04113577||health professionals|usablity assessment after the enrollement of all patients and unformal caregivers
89106257|NCT04113343|Active Comparator|Treatment A: remimazolam|Oral administration of 360 mg remimazolam
89106258|NCT04113343|Experimental|Treatment B: remimazolam + 5% v/v alcohol|Oral administration of 360 mg remimazolam and 5% v/v alcohol
89106259|NCT04113343|Experimental|Treatment C: remimazolam + 15% v/v alcohol|Oral administration of 360 mg remimazolam + 15% v/v alcohol
89106260|NCT04113343|Experimental|Treatment D: remimazolam + 40% v/v alcohol|Oral administration of 360 mg remimazolam + 40% v/v alcohol
89106261|NCT04113343|Placebo Comparator|Treatment E: placebo + 40% v/v alcohol|Oral administration of Placebo + 40% v/v alcohol
89106262|NCT04111471|Placebo Comparator|Placebo Arm|20 patients will receive 5.6 g of placebo product (maltodextrin) daily for a total of 21 days (7 days before and until 2 weeks after transplant)
89106263|NCT04111471|Experimental|Prebiotic (Inulin) Arm|20 patients will receive 10 g of inulin product daily for a total of 21 days (7 days before and until 2 weeks after transplant)
89106264|NCT04113031|Experimental|Flywheel group|The players allocated to the flywheel group will perform six weeks of squat resistance exercise using a flywheel device.
89106265|NCT04113031|Experimental|Barbell free weight group|The players allocated to the barbell free weight group will perform six weeks of squat resistance exercise using a an olympic barbell and free weight of high loads.
89106266|NCT04113031|Active Comparator|Control|All players in all three groups (including control group) will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (~one weekly match).
89106267|NCT00914875||group tramadol plus ketorolac|
89106268|NCT00914875||group tramadol plus dypirone|
89106269|NCT04111159|Experimental|HSK3486|Subjects < 65 years old:0.4mg/kg/0.15mg/kg;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
89106270|NCT04111159|Active Comparator|Propofol|Subjects < 65 years old:2mg/kg/0.75mg/kg;Subjects≥ 65 years old:75% of the dose for subjects < 65 years old.
89106271|NCT04111081|Experimental|Auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
89106272|NCT04111081|Sham Comparator|Sham auricular pressure|Use wangbuliuxing seed to stimulate auricular acupuncture point.
89106273|NCT02605291|Experimental|Experimental arm 1|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
89106274|NCT02605291|Experimental|Experimental arm 2|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
89106275|NCT02605291|Experimental|Experimental arm 3|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
89106276|NCT00697372|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
89106277|NCT00697372|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
89106278|NCT04118686|Experimental|Experimental group|The group receives CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)
89106279|NCT04118686|Sham Comparator|Control group|The group receives CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)
89106280|NCT04111003|Experimental|SFRC direct filling|Restoration of endodontically treated tooth Endodontically treated molars are restored with direct composite restorations, using a short-FRC base filling.
89106281|NCT04111003|Active Comparator|CEREC endocrown|Restoration of endodontically treated tooth Endodontically treated molars are restored with indirect ceramic CAD/CAM restorations.
89106282|NCT04110847|Active Comparator|TCM OA1|"JING CEIH SHERN YUAN EXTRACT PILL CHUANG SONG ZONG 3 TABLET For 2 Times per day"
89106283|NCT04110847|Placebo Comparator|Placebo|Placebo 3 TABLET For 2 Times per day
89106284|NCT00699712|Experimental|A|Open-label regimen of doses 1 and 2 of CDNP
89106285|NCT00699712|Experimental|B|Open-label regimen of doses 2 and 3 of CDNP
89106286|NCT00699712|Experimental|C|Open-label regimen of doses 3 and 4 of CDNP
89106287|NCT02605135||Continued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab and 10 mL of vaginal lavage at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months
89106288|NCT02605135||Discontinued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab (AIM 1) and 10 mL of vaginal lavage (Aim 2) at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months. Should the participant discontinue pessary use, we will additionally culture the microbes that are present on the pessary and compare those to the vaginal microbiota.
89106289|NCT00856180|Experimental|Bevacizumab then Cyclophosphamide with Bevacizumab|Patients were given a regimen of sequential antiangiogenic blockade and disease assessed serologically and radiologically every 2 cycles/6 weeks. Patients started with bevacizumab 15 mg/kg IV every 3 weeks until they experienced progressive disease (PD) [RECIST 1.0 or Rustin criteria] or significant toxicity. If clinically stable as assessed by their treating physician, patients then received cyclophosphamide 50 mg orally (PO) daily continuously with bevacizumab treatment. If second PD occurred, patients discontinued the combination treatment.
89106290|NCT02605213|Experimental|Vancomycin|Vancomyicn 250 mg every 6 hours for 12 weeks
89106291|NCT02605213|Placebo Comparator|Placebo|placebo every 6 hours for 12 weeks
89106292|NCT04112563|Active Comparator|WLI-LCI group|a first exploration of the right colon will be done in white light (WLI) then a second exploration will be done in LCI
89106293|NCT04112563|Active Comparator|LCI-WLI group|a first exploration of the right colon will be done in LCI and a second exploration will be done in white light (WLI)
89106294|NCT04131478||Cases|Cachectic lung, pancreas, or colon cancer patients.
89106295|NCT04131478||Control|Non- cachectic lung, pancreas, or colon cancer patients.
89106296|NCT00900627|Experimental|1|AZD8931 plus Paclitaxel
89106297|NCT00900627|Placebo Comparator|2|Placebo plus Paclitaxel
89106298|NCT00866320|Experimental|Sorafenib|Chemotherapy single agent systemic. Sorafenib given up to 600mg orally every 12 hours for up to 10 months (40 weeks).
89106299|NCT04115449|Experimental|Dexa group|"Spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Than manintance dose of dexmedetomidine will be titrated from (0.2- 0.6 mcg /kg/ min) according to the patient discomfort.~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale. Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
89106300|NCT04115449|Placebo Comparator|Control group|"Normal Saline as a placebo will be infused over a period of ten minutes then spinal anaesthesia will be performed through the L3-4 interspace in the sitting position. After dural puncture with a 25 G Quincke needle, 3.5 ml of hyperbaric bupivacaine 0.5% solution with fentanyl 20 μg will be injected intrathecally. Then the placebo will be titrated according to patient discomfort.~After turning the patient supine, level of sensory block will be assessed by the pinprick test using a 24-gauge hypodermic needle, while the motor block level will be assessed by the modified Bromage scale.Insufflation of gas will be done at the rate of 1.5 liters/min and the maximum abdominal pressure will be kept at 12 mmHg. Supplementary oxygen at 4 liters/min will be given with face mask."
89106301|NCT04133974|No Intervention|Methadone|The subjects take methadone as usual.
89106302|NCT04133974|Experimental|Methadone-10min-Extinction|The subjects were given extinction training 10 min following methadone administration.
89106303|NCT04133974|Sham Comparator|Methadone-6h-Extinction|The subjects were given extinction training 6h following methadone administration.
89106304|NCT04110925|Other|MDS patients|All Canadian MDS patients on the MDS-database to be included.
89106305|NCT02841735||Smartphone breathalyzer device & app|This is a small device that attaches to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in a simulated laboratory.
89106306|NCT02841735||BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in a simulated laboratory.
89106307|NCT02841735||Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in a simulated laboratory.
89106308|NCT04133896||Group 1 Male|group 1 (22 lean men),
89106309|NCT04133896||Group 2 Male|group 2 (22 class I obese men),
89106310|NCT04133896||Group 3 Male|group 3 (22class II obese men),
89106311|NCT04133896||Group 4 Male|group 4 (22 class III obese men).
89106312|NCT04133896||Group 1 Female|group 1 (22 lean women),
89106313|NCT04133896||Group 2 Female|group 2 (22 class I obese women),
89106314|NCT04133896||Group 3 Female|group 3 (22 class II obese women),
89106315|NCT04133896||Group 4 Female|group 4 (22 class III obese women).
89106316|NCT04112875|Active Comparator|L-arginine|L-arginine supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
89106317|NCT04112875|Placebo Comparator|Maltodextrin|Maltodextrin supplementation: 5g/sachet with water 30 minutes before breakfast for 14 days.
89106318|NCT03679611|Experimental|Interventional Arm|Interventional Arm will receive sugammadex sodium 2 mg/kg actual body weight, At the end of surgery Sugammadex will be administered when the TOF reveals at least 2 responses
89106319|NCT03679611|Active Comparator|Standard drug Arm|standard drug Arm will receive neostigmine 2.5 mg and glycopyrrolate 0.4 mg, At the end of surgery neostigmine and glycopyrrolate will be administered when the TOF reveals at least 2 responses
89106320|NCT00915109||vascular|People with a unilateral below-knee amputations due to a vascular reason
89106321|NCT00915109||nonvascular|People with a below-knee amputation due to nonvascular reasons
89106322|NCT00915109||Control|People with no gait impairments.
89106323|NCT02618044||Obese patients without preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass without preoperative GER at 24h-impedance pH monitoring (Group G-)
89106324|NCT02618044||Obese patients with preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass with preoperative GER at 24h-impedance pH monitoring (Group G+)
89106325|NCT04112719||Control arm/pregnant patients at term|Control arm where the term pregnant patient will be lying on the bed at 45 degrees.
89106326|NCT04112719||Experimental/Supine|Term pregnant patient will be positioned in supine. Changes in hemodynamics will be measured.
89106327|NCT04112719||Experimental/15 degrees lateral tilt|Term pregnant patient will be positioned at 15 degrees in lateral tilt. Changes in hemodynamics will be measured.
89106328|NCT04112719||Experimental/30 degrees lateral tilt|Term pregnant patient will be positioned at 30 degrees in lateral tilt. Changes in hemodynamics will be measured.
89106329|NCT02841891|Experimental|Test|Test group will receive Sylys® Surgical Sealant as an adjunct to standard closure of stapled anastomosis in colectomy procedure.
89106330|NCT02841891|Active Comparator|Control|Control group will receive standard of care closure of stapled anastomosis in colectomy procedure without Sylys® Surgical Sealant.
89106331|NCT00699868|Experimental|1|Infection to CMV
89106332|NCT00699868|Other|2|"Group control CMV"
89106333|NCT02604667||Group 1: Cancer and Stroke|Patients with active solid tumor cancer and acute ischemic stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
89106334|NCT02604667||Group 2: Stroke and No Cancer|Patients with acute ischemic stroke and no cancer. Will undergo blood tests and transcranial Doppler microemboli detection study.
89106335|NCT02604667||Group 3: Cancer and No Stroke|Patients with active solid tumor cancer and no stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
89106336|NCT00914953|Experimental|oxytocin|
89106337|NCT00869518|Active Comparator|Rifabutin|Subjects will be assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
89106338|NCT00869518|Placebo Comparator|Placebo|Subjects will be assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
89106339|NCT00698152||ArComXL® polyethylene|ArComXL® polyethylene
89106340|NCT00794781|Experimental|1|
89106341|NCT04112329|Experimental|Exergaming|Will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks
89106342|NCT04112329|No Intervention|Control|Asked to continue with their normal daily routine
89106343|NCT00797563|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system (BGMS) Apollo Blood Glucose Monitoring System with capillary blood; healthcare professionals use the new BGMS with subject capillary and venous blood.
89106344|NCT00869440|Experimental|1: Remimazolam (CNS 7056) 0.10 mg/kg|Remimazolam (CNS 7056) 0.10 mg/kg iv
89106345|NCT00869440|Experimental|2: Remimazolam (CNS 7056) 0.15 mg/kg|Remimazolam (CNS 7056) 0.15 mg/kg iv
89106346|NCT00869440|Experimental|3: Remimazolam (CNS 7056) 0.20 mg/kg|Remimazolam (CNS 7056) 0.20 mg/kg iv
89106347|NCT00869440|Experimental|4: Midazolam 0.075 mg/kg|Midazolam 0.075 mg/kg iv
89106348|NCT00895947|Experimental|Interferon-alpha|150 international units of interferon-alpha
89106349|NCT00895947|Placebo Comparator|placebo|placebo lozenges
89106350|NCT02604823|Experimental|Group A (Naïve Participants)|Participants who never received any HBV treatment, will receive peginterferon alfa-2a (180 micrograms [mcg]) subcutaneously once weekly for 48 weeks.
89106351|NCT02604823|Experimental|Group B (Conventional Interferon Pretreated Participants)|Participants who received conventional interferon treatment and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
89106352|NCT02604823|Experimental|Group C (Lamivudine Pretreated Participants)|Participants who received lamivudine and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
89106353|NCT00869362|Experimental|Diabetes Management Team|Evaluation and management by diabetes management team
89106354|NCT00869362|No Intervention|Control|Patients receive usual care for diabetes
89106355|NCT00915187|Active Comparator|Control|
89106356|NCT00915187|Experimental|CCS/C (Adjuvant Formulation)|
89106357|NCT04131400||Patients with Inherited Retinal Dystrophy|known patients with a diagnosis of inherited retinal dystrophy (IRD) will be recruited to identify the type of IRD diagnosis. The comprehensive ophthalmic examinations and retinal imaging will be performed. Additionally, blood sample of all participants and their family members will be kept in our bio- bank for genetic testing.
89106358|NCT02841579|Experimental|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.
89106359|NCT00588445|Experimental|Treatment|
89106360|NCT04118296|Experimental|Intervention|Intervention will be given in the form of the use of anti-acne combination creams that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
89106361|NCT00699946|Active Comparator|1|
89106362|NCT00699946|Placebo Comparator|2|
89106363|NCT00796315|Experimental|Doxylamine Succinate (USP)|Doxylamine Succinate United States Pharmacopeia (USP)
89106364|NCT00855166|Experimental|A|Dapagliflozin 10 mg plus Metformin
89106365|NCT00855166|Placebo Comparator|B|Placebo plus Metformin
89106366|NCT00587587|Experimental|A|Apligraf (bilayered living cell therapy)
89106367|NCT00587587|Active Comparator|B|Dressing regimen comprised of a primary nonadherent dressing, dry gauze dressing and bolster gauze dressing, if necessary
89106368|NCT02843841|Other|ATG group|"Renal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of polyclonal antilymphocyte globulin (ATG-Fresenius®) as recommended.~Intervention = blood and fecal sample"
89106369|NCT02843841|Other|Anti-CD25 group|"PRenal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of anti-CD25 monoclonal antibodies (basiliximab SIMULECT®) as recommended.~Intervention = blood and fecal sample"
89106370|NCT04117828|Active Comparator|Control|50 g of glucose will be given to the individuals
89106371|NCT04117828|Experimental|1st Intervention group|50 g of Aseel dates will be given to the individuals
89106372|NCT04117828|Experimental|2nd Intervention group|50 g of Ajwa dates will be given to the individuals
89106373|NCT04117828|Experimental|3rd Intervention group|50 g of Karbala dates will be given to the individuals
89106374|NCT04107259||Patient with diabetes|60 newly diagnosed type 2 diabetes
89106375|NCT04107259||Control|60 non-diabetic control subjects
89106376|NCT02841501||Candidemia patients|These patients are included in the study after the reception of a positive blood culture for Candida sp.
89106377|NCT02841501||Control patients|"These patients are matched on case patients on the following criteria:~Age+/-5 years~length of hospitalisation~type of ward~type of surgery for surgical patients~IGS2 for intensive care patients"
89106378|NCT00854620|Experimental|Sorafenib|"Cycle 1: 400 mg BID sorafenib~Cycle 2: 600 mg BID sorafenib~Cycle 3+: 800 mg BID sorafenib"
89106379|NCT00793585|Experimental|Allopurinol|Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr < 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
89106380|NCT00793585|Other|Control group|Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
89106381|NCT02013141|Experimental|Telavancin|Telavancin 10 mg/kg IV administered over one hour one time.
89106382|NCT04107103|Experimental|Single Arm|A single-arm combining nivolumab with pemetrexed
89106383|NCT04133818||Multidisciplinary program.|Patients with subacute or chronic LBP for whom first-line treatments had failed but for whom an intensive multidisciplinary rehabilitation program was not indicated.
89106384|NCT02841423|Experimental|INTRAVENOUS ANESTHESIA|neuropsychological test battery
89106385|NCT02841423|Experimental|CLOSED LOOP ANESTHESIA|neuropsychological test battery
89106386|NCT02617576||Flavored contrast|This group of patients will have the choice to flavor their contrast.
89106387|NCT02617576||Unflavored contrast|This group of patients will drink the contrast without flavoring.
89106388|NCT02841345|Other|Bipolar|bipolar patients type I or II (DSM-IV TR), euthymic phase
89106389|NCT02841345|Other|Schizophrenic|schizophrenic loss or paranoid or undifferentiated patients
89106390|NCT02841345|Other|Control|control group (paired in age and sex for patients)
89106391|NCT02617810|Experimental|JNJ-42847922 Plus Midazolam Plus Warfarin|Participants will receive Treatment A (midazolam 4 milligram [mg] syrup once on Day 1 and warfarin 25 mg tablet once on Day 3) followed by Treatment B (JNJ-42847922 20 mg once daily from Day 1 to Day 9, midazolam 4 mg syrup once on Day 7 and warfarin 25 mg tablet once on Day 9). A washout period of 14 to 21 days will be maintained between each treatment period.
89106392|NCT04111237|Active Comparator|Two Finger|two finger method for performing chest compressions
89106393|NCT04111237|Experimental|Two Thumb Technique|Two Thumb Technique
89106394|NCT00898443|Other|Spinal Anesthetic Group|This group will receive spinal anesthetic for the surgical procedure and will serve as the control group for this study.
89106395|NCT00898443|Experimental|Epidural Anesthetic Group|This is the experimental group for this study.
89106396|NCT02614612|Experimental|Itacitinib (200 mg)|Itacitinib (200 mg) + prednisone or methylprednisolone (corticosteroids)
89106397|NCT02614612|Experimental|Itacitinib (300 mg)|Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)
89106398|NCT00900159|Experimental|eszopiclone|Treatment with eszopiclone
89106399|NCT00900159|Placebo Comparator|matching placebo|Treatment with matching placebo
89106400|NCT02843997|Other|Healthy volunteers|Members of a family
89106401|NCT05334693|Experimental|Expanded haploidentical NK cell immunotherapy|After a lymphodepleting chemotherapy a patient receive two intravenous infusions of expanded haploidentical NK cells.
89106402|NCT02840955|Active Comparator|Staphefekt SA.100|Staphefekt SA.100 cream, twice daily on (lesional) skin during 12 weeks
89106403|NCT02840955|Placebo Comparator|Placebo|Placebo (Gladskin cream without the Staphefekt protein), twice daily on (lesional) skin during 12 weeks
89106404|NCT01689909|Active Comparator|Zolpidem-CR|Zolpidem 6.25 or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
89106405|NCT01689909|Placebo Comparator|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
89106406|NCT00854308|Experimental|MetMAb + Erlotinib|MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.
89106407|NCT00854308|Placebo Comparator|Placebo + Erlotinib|Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.
89106408|NCT02617498|Active Comparator|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
89106409|NCT02617498|Active Comparator|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
89106410|NCT04201587|Experimental|Henna application group|
89106411|NCT04201587|No Intervention|Control group|
89106412|NCT05334537|Experimental|the aromatherapy group|"After the birth of the baby, two drops of 100% pure medical lavender oil (Lavandula angustifolia) was inhaled for 5 min through an oxygen mask by groups A and C, respectively. After 5 min, 2 mg intravenous midazolam for sedation was administred to the patients who gained 1 point from the Ramsey Sedation Scale (RSS). Complications, such as nausea, vomiting, hypotension (mean arterial pressure<60 mmHg), and allergies that developed after aromatherapy, were recorded. At the end of the operation, the dose added to the initial midazolam dose for all patients and the total surgical time were recorded. VAS pain and STAI-I scores were re-evaluated at the third postoperative hour, and the satisfaction levels of each patient after aromatherapy were recorded according to the Likert scale as very satisfied, satisfied, moderate, and not at all satisfied."
89106413|NCT05334537|Placebo Comparator|the control group|"Then, after the birth of the baby two drops of odorless baby oil (jojoba and almond oil) was inhaled for 5 min through an oxygen mask by groups A and C, respectively. After 5 min, 2 mg intravenous midazolam for sedation was administred to the patients who gained 1 point from the Ramsey Sedation Scale (RSS). Complications, such as nausea, vomiting, hypotension (mean arterial pressure<60 mmHg), and allergies that developed after aromatherapy, were recorded. At the end of the operation, the dose added to the initial midazolam dose for all patients and the total surgical time were recorded. VAS pain and STAI-I scores were re-evaluated at the third postoperative hour, and the satisfaction levels of each patient after aromatherapy were recorded according to the Likert scale as very satisfied, satisfied, moderate, and not at all satisfied."
89106414|NCT00592852|Experimental|Fluoxetine|
89106415|NCT04117906|Experimental|STAGE course|
89106416|NCT04117906|No Intervention|Wait-list control|The wait-list control group will receive access to the STAGE course after the trial is complete.
89106417|NCT00895245|Experimental|Arm I|"Patients receive cisplatin IV on day 1. Treatment repeats every 21 days for up to 3 courses. Patients also undergo radiotherapy once daily 5 days a week for up to 7 weeks.~Patients receive fosaprepitant dimeglumine IV, palonosetron hydrochloride IV, and dexamethasone IV on day 1.Patients then receive oral dexamethasone on days 2-4. Patients with no emesis or requirement for rescue anti-emetics in the first 120 hours after cisplatin infusion continue to receive the anti-emetic regimen as above with the second and third courses of cisplatin.~Patients complete an emesis diary daily for 5 days after each cisplatin infusion. Patients also complete a Functional Living Index-Emesis Questionnaire on day 8 after each cisplatin infusion."
89106418|NCT02617732|Experimental|Tianqi capsule|a Chinese patent medicine extracted form more than10 kinds of herbs, which was approved to treat type 2 diabetes by CDFA in 2002.
89106419|NCT02617732|Placebo Comparator|placebo|a capsule looks the same as Tianqi capsule, containing starch and other edible compositions.
89106420|NCT03172377|Experimental|Intervention group|Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.
89106421|NCT03172377|No Intervention|Control group|Standard care: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks. Treatment decisions are made at the discretion of the treating physician.
89106422|NCT00865306|Experimental|Active CBT|"Seven parent-only and 8-13 child-only sessions focusing on CBT for anxiety disorders using the Being Brave protocol."
89106423|NCT00865306|No Intervention|No intervention (wait-list controls)|Control children received no intervention.
89106424|NCT02843919|Other|Healthy volunteers|Adults healthy volunteers
89106425|NCT02617654|Active Comparator|Liraglutide treatment|Liraglutide treatment in the dose of 1.8 mg daily for 52 weeks
89106426|NCT02617654|Placebo Comparator|Placebo treatment|Treatment with placebo once daily for 52 weeks
89106427|NCT00700024|Active Comparator|1|testim
89106428|NCT00700024|Experimental|2|placebo
89106429|NCT00700024|Experimental|3|training
89106430|NCT00697450||All participants|
88812654|NCT00837824|Experimental|Fabrazyme 3mg/kg every 2 weeks|Fabrazyme 3.0 mg/kg every 2 weeks
89106431|NCT00896649|Experimental|positron emission mammography|questionnaire administration digital mammography positron emission mammography
89106432|NCT00796003|Experimental|Phase I: JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
89106433|NCT00796003|Experimental|Phase I: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
89106434|NCT00796003|Experimental|Phase II: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles
89106435|NCT04110535|Experimental|Remimazolam 5 mg|IV administration of remimazolam 5 mg
89106436|NCT04110535|Experimental|Remimazolam 10 mg|IV administration of remimazolam 10 mg
89106437|NCT04110535|Active Comparator|Midazolam 2.5 mg|IV administration of midazolam 2.5 mg
89106438|NCT04110535|Active Comparator|Midazolam 5 mg|IV administration of midazolam 5 mg
89106439|NCT04110535|Placebo Comparator|Placebo|Saline injection
89106440|NCT05562895||Subjects with biopsy of pulmonary nodule using Ion Endoluminal System and Cios Spin|Subjects in which a pulmonary nodule biopsy was attempted or performed with the integrated Ion Endoluminal System and Cios Spin
89106441|NCT05335785|Active Comparator|5 session lazer therapy|30 patients will be included to 5 session lazer therapy group. They will take totally 5 sessions of high-intensity laser every other day.
89106442|NCT05335785|Active Comparator|10 session lazer therapy|30 patients will be included to 10 session lazer therapy group. They will take totally 10 sessions of high-intensity laser every other day.
89106443|NCT05335785|Other|control group|30 patients will be included to control group. They will take only exercise program three times in a week.
89106444|NCT04025203|Experimental|Median nerve neural mobilization|Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.
89106445|NCT04025203|Active Comparator|Ibuprofen arginine|Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.
89106446|NCT04025203|Active Comparator|Gabapentin|Oral capsule pharmaceutical treatment. Participants will be treated with a maximum of 1800 mg per day, subdivided in 3 intakes of 600 mg each 8 hours during a time lapse of 4 weeks.
89106447|NCT04025203|No Intervention|Control group|Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.
89106448|NCT02843607|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
89106449|NCT02843607|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
89106450|NCT04106947||Patients with Hirschsprung and anorectal malformation|Patients with Hirschsprung and anorectal malformation living in Norway
89106451|NCT00915577|Experimental|1st Injection|Manual injection with pre-filled syringe.
89106452|NCT00915577|Experimental|Single-use autoinjector|Single-use autoinjector with Avonex pre-filled syringe
89106453|NCT00895011|Placebo Comparator|Placebo|
89106454|NCT00895011|Experimental|Avanafil 100 mg|
89106455|NCT00895011|Experimental|Avanafil 200 mg|
89106456|NCT02604355|Experimental|Healthy Participants (Multiple-Ascending Dosing)|
89106457|NCT02604355|Experimental|Healthy Participants (Single-Ascending Dosing)|
89106458|NCT02604355|Experimental|Healthy Participants (Study of Food Effect)|
89106459|NCT02604355|Experimental|Participants with Chronic Hepatitis B (Proof of mechanism)|
89106460|NCT02604745||Degenerative Mitral Regurgitation|This cohort includes patients that have had mitral valve surgery for Degenerative Mitral Regurgitation (Type II)
89106461|NCT00899847|Experimental|Autologous-Allogeneic Peripheral Blood Stem Cell Transplant|Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.
89106462|NCT05558605|Experimental|Screening/Management Plan|AI-guided echo acquisition performed using a desktop echo machine (uSmart 3300, Terason, Burlington, MA) with AI software (Caption Health, Brisbane, CA) obtained by a non-expert (eg. clinic nurse, registrar general practitioner or physician) at the remote clinic, usually on the day of clinic review. Images will then be uploaded onto a secure cloud and downloaded at the core lab for measurement, interpretation and reporting.
89106463|NCT05558605|Active Comparator|Usual care|Standard echo acquisition by a sonographer either at a referral hospital, or by a visiting team - usually necessitating a delay. Measurement, interpretation and reporting will happen as usual.
89106464|NCT04208295||Patients|Type 2 diabetics
89106465|NCT04208295||Healthy controls|Matched healthy controls
89106466|NCT04106791|Experimental|Closed-loop|Pilot study: one single group of 10 ICU patients.
89106467|NCT00853762|Experimental|Atacicept 25 mg (With Loading)|
89106468|NCT00853762|Experimental|Atacicept 75 mg (With Loading)|
89106469|NCT00853762|Experimental|Atacicept 150 mg (With Loading)|
89106470|NCT00853762|Experimental|Atacicept 150 mg (Without Loading)|
89106471|NCT00789529|Active Comparator|1|Opti-Free® RepleniSH® MPDS
89106472|NCT00789529|Active Comparator|2|Renu MultiPlus®
89106473|NCT02840565|Experimental|BIA 5-453 25 mg or placebo|Multiple oral doses of BIA 5-453 25 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
89106474|NCT02840565|Experimental|BIA 5-453 50 mg or placebo|Multiple oral doses of BIA 5-453 50 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
89106475|NCT02840565|Experimental|BIA 5-453 100 mg or placebo|Multiple oral doses of BIA 5-453 100 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
89106476|NCT02840565|Experimental|BIA 5-453 200 mg or placebo|Multiple oral doses of BIA 5-453 200 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
89106477|NCT02840565|Experimental|BIA 5-453 400 mg or placebo|Multiple oral doses of BIA 5-453 400 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
89106478|NCT02840565|Experimental|BIA 5-453 600 mg or placebo|Multiple oral doses of BIA 5-453 600 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
89106479|NCT04117750|Active Comparator|intervention group|55 female patients with PCO
89106480|NCT04117750|Placebo Comparator|non -intervention group|40 female patients with PCO and 50 healthy women matched to PCOS women as regard age and ethnic origin.
89106481|NCT02603653|Experimental|Patients|Virtual radial task in 3D
89106482|NCT02603653|Experimental|Controls|Virtual radial task in 3D
89106483|NCT00894933|Experimental|Continuum|Verify the consistency of performance of the AMS CONTINUUM device in facilitating a sustainable anastomosis following a radical prostatectomy using updated Device design elements and Physician training materials on Device implant technique.
88812655|NCT03048188|Experimental|Burn with or without split-skin graft|Second degree burns and third degree burns with split-skin graft that need wound dressings
89106484|NCT02614846|Experimental|Hetrombopag Olamine|All the subjects receive 6 weeks Hetrombopag Olamine dosing, 5mg for the first 2 weeks, 2.5mg or 7.5mg for the last 4 weeks according to the PLT counting.
89106485|NCT04131322|Experimental|switch-cohort|Adalimumab biosimilar
89106486|NCT04131322|Active Comparator|non-switchcohort|Adalimumab original
89106487|NCT02843373||rTMS|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered to the left DLPFC as assessed by either the 5cm rule or F3 site. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
89106488|NCT04581759|Experimental|RIPC|Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after endovascular treatment while in-hospital.
89106489|NCT04581759|Sham Comparator|foundational treatment group (FT)|Patients in the FT group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs, during the study period without remote ischemic postconditioning after endovascular treatment.
89106490|NCT04133740|Active Comparator|Standard regime|Supplementary oxygen is given according to the standard regime with a fraction of inspired oxygen (FiO2) of at least 0.60 during mechanical ventilation and 3 liter/minute or more after weaning from the ventilator in the intensive care unit (ICU).
89106491|NCT04133740|Active Comparator|Oxygenation targeting|Supplementary oxygen is given to achieve a partial pressure of arterial oxygen (PaO2) within the normal range defined as 10-12 kPa (75-120 mmHg) during surgery and in the ICU.
89106492|NCT00792805|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89106493|NCT00792805|Experimental|Indacaterol 300 μg|Patients inhaled indacaterol 300 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89106494|NCT00792805|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89106495|NCT02840175|Experimental|Experimental|"Day 0 at Weeks 24 : Increase the interval between 2 doses of the biological agent (etanercept, adalimumab, tocilizumab, abatacept)~Weeks 24 at Weeks 72: Stop the biological agent if inactive disease is maintained."
89106496|NCT02840175|Active Comparator|Control|"Day 0 at Weeks 24: Maintain the biological agent (etanercept, adalimumab, tocilizumab, abatacept) at the same dose.~Weeks 24 at Weeks 48 : Increase the interval between 2 doses of the biological agent.~Weeks 48 at Weeks 72: Stop the biological agent if inactive disease is maintained."
89106497|NCT04133662|Experimental|Group 1|Restricted sleep condition first, longer sleep condition second
89106498|NCT04133662|Experimental|Group 2|Longer sleep condition first, restricted sleep condition second
89106499|NCT04031092|Experimental|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for patients with chronic pain.
89106500|NCT04031092|Active Comparator|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
89106501|NCT05334225||Health Workers|Doctors, nurses, paramedics, midwifes
89106502|NCT04106635|Experimental|PP group|During the induction of anesthesia, left paratracheal pressure is applied by 30N force with thumb after confirmation of the location of the esophagus using ultrasound.
89106503|NCT04106635|Active Comparator|CP group|During the induction of anesthesia, cricoid pressure is applied by 30N force with three finger.
89106504|NCT02603497|Experimental|Control (Subjects with normal renal function)|Oral
89106505|NCT02603497|Experimental|Mild renal impairment|Oral
89106506|NCT02603497|Experimental|Moderate renal impairment|Oral
89106507|NCT02603497|Experimental|Severe renal impairment|Oral
89106508|NCT04250961|Experimental|Shower Group|Patients who had a shower in 48-72 hours after Median Sternotomy
89106509|NCT04250961|Active Comparator|Control Group|Patients whose sternal incision site was not connected water until remove sutures
89106510|NCT02843139||Children group|Children recruiters were categorized into three groups: obesity, overweight and normal control based on World Health Organization child growth standards.
89106511|NCT02843139||Adults group|Adults with type 2 diabetes were defined if the individual had a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L.
89228216|NCT04810364||All HIV-positive patients with chronic coronary syndrome|The Group includes all HIV-positive patients with stable chest pain. The progression of atherosclerosis will be quantitatively characterized by the parameters of the lesions (e.g. plaque burden, cap thickness, arterial remodeling, presence of erosions or rupture, malaposition of the stent, a vessel injury score, etc.). The imaging data will be handled with expert-level post-processing software.
89228217|NCT00979160|Experimental|Dasatinib|Patient will be treat at a starting dose of 20mg once daily, that can be escalated up to 100mg once daily.
89228218|NCT00979316|Experimental|BMS-708163 (800 mg)|
89228219|NCT00979316|Experimental|BMS-708163 (200 mg)|
89228220|NCT00979316|Placebo Comparator|Placebo|
89106512|NCT04518891|Experimental|Cognitive Functional Therapy (CFT) Group|"There will be 3 main components in the intervention:~Making sense of pain: the cognitive component will focus on identifying the factors that contribute to pain during examination. This will include discussion on the multidimensional nature of persistent pain, individual beliefs, and how emotions and behaviours regarding movement and lifestyle can reinforce a vicious cycle of pain and disability.~Controlled exposure: specific functional training is designed to normalise maladaptive or provocative movement and posture. functional integration is directed at activities of daily life that are avoided by the patient. This will vary among individuals but should include basic activities such as rolling in bed, sitting, sitting to standing, walking, bending and lifting.~Lifestyle change: Physical activity and lifestyle. Patients will be advised to gradually increase physical activity based on their preference, while also focusing on sleep hygiene, stress and management strategies."
89106513|NCT04518891|Sham Comparator|Sham intervention|Placebo group will be treated with detuned photobiomodulation device (904Nm Ibramed Infrared - no-visible beam), without any emission of therapeutic dose. Nine sites will be applicate on the patient's lumbar region: three central sites on top of the spinous processes (between T11 and T12, L2 and L3, L5 and S1); in the same direction, but laterally, three sites on the left and three on the right. Three minutes of fake stimulation will be administered, summing up 27 minutes. In addition, a neutral talking control therapy of at least 15 minutes will be provided to patients in each session. Maladaptive beliefs will not be challenged; however, the therapists will be trained to show interest and warmth, empathy and encouraging participants to discuss neutral topics such as hobbies, sports, and current affairs. No advice or problem solving will be given, and any attempt to talk about emotional issues will be kindly discouraged and the talking will be redirect to neutral tropics.
89106514|NCT02840487|Experimental|Group 1|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 8.
89106515|NCT02840487|Experimental|Group 2|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 12.
89106516|NCT02840487|Experimental|Group 3|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0, Week 4 and Week 8.
89106517|NCT02840487|Experimental|Group 4|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0,Week 4 and Week 20.
89106518|NCT02843217|Experimental|Text Messaging|
89106519|NCT05334147||Anlotinib in combination with chemotherapy|anlotinib12mg qd p.o. d1-14/21day/cycle；eribulin 1.4 mg/m2，d1&d8/21day/cycle；capecitabine 1000 mg/m2，bid，d1-14/21day/cycle.
89106520|NCT05334147||chemotherapy|eribulin 1.4 mg/m2，d1&d8/21day/cycle；capecitabine 1000 mg/m2，bid，d1-14/21day/cycle.
89106521|NCT02840331|Experimental|St. John's Wort & PDD, PDT|St. John's Wort 900 milligram once oral preoperative & intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
89106522|NCT02839941|Experimental|experiment|
89106523|NCT02839941|Sham Comparator|Control|
89106524|NCT02842983|Experimental|Esmolol|After, at least six hours of hemodynamic optimization, patients with a hyperdynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 10% reduction in heart rate. This infusion is maintained for 72 hours.
89106525|NCT02842983|No Intervention|Control|Patients received conventional management of septic shock
89106526|NCT02839785|Experimental|Ibuprofen|Active ibuprofen
89106527|NCT02839785|Placebo Comparator|Placebo|Placebo of ibuprofen
89106528|NCT02843295|Experimental|Population of the study|3 stratification groups: Group 1: High immunologic risk Patients receiving a ≥ 2nd graft and/or Panel Reactive Antibody ≥ 30% and/or Human Leukocyte Antigen (HLA) mismatches ≥ 4 Group 2: High non-immunologic risk Donors over 60 years of age and/or Donor between 50 to 59 years of age who have died of stroke, or had a history of high blood pressure, or at the time of death had a creatininemia ≥ 135 µmol/L Group 3: Low risk Patients not included in Groups 1 or 2
88812656|NCT01540409|Experimental|AVI-4658 (Eteplirsen)|Multiple-Dose Extension Study
89228221|NCT00979316|Active Comparator|Moxifloxacin|
89228222|NCT00983450|Experimental|study group|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
89228223|NCT00983450|Experimental|CONTROL|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
89228224|NCT00983606||1|32 to 35 WGA Infants less than six months of age by RSV season peak.
89228225|NCT00983684|Experimental|Intra-operative radiotherapy|A single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.
89228226|NCT00983684|Active Comparator|Post-operative radiotherapy|Standard post-operative radiotherapy.
89228227|NCT00983762||MIS knee arthroplasty|Persons scheduled for Minimally Invasive Surgery Mini-Incision (MIS) Total Knee Arthroplasty (TKA)
89228228|NCT00983762||Unicompartmental knee arthroplasty|Persons scheduled for Unicompartmental knee arthroplasty
89228229|NCT00983762||Standard knee arthroplasty|Persons scheduled for Standard Para-patellar surgery TKA
89228230|NCT00983762||Heathly knee subjects|Persons with healthy knees
89228231|NCT00983840|Experimental|Family Eats|8-session program on health eating
89228232|NCT00983840|Active Comparator|Family eats- plain|Family eats without role model stories and goal setting
89228233|NCT00983996|Experimental|1|Alendronate Sodium Tablets, 10 mg
89228234|NCT00983996|Active Comparator|2|Fosamax Tablets, 10 mg
89228235|NCT00979394||Patients with type 2 diabetes|
89228236|NCT00985244|Active Comparator|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
89228237|NCT00985244|Placebo Comparator|Placebo|Subjects in this group will receive 3 times a week placebo
89228238|NCT00979472|Experimental|with urgency|
89228239|NCT00979472|Experimental|without urgency|
89228240|NCT04007120|Experimental|RVT-1601 Low Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
89228241|NCT04007120|Experimental|RVT-1601 Mid Dose|Inhaled RVT-1601 administered once daily over two days via eFlow nebulizer
89228242|NCT00984152|Active Comparator|1|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
89228243|NCT00984152|Active Comparator|2|TDF/FTC + Efavirenz (Atripla) Once-Daily
89228244|NCT00985322|Experimental|ACE inhibitor Ramipril|
89228245|NCT00985322|Active Comparator|non-RAS inhibitor antihypertensive therapy|
89228246|NCT00984230|No Intervention|Breastfeeding (Reference)|
89228247|NCT00984230|Active Comparator|Basic starter formula: BSF|
89228248|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics + OS|
89228249|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics|
89228250|NCT00984386|Experimental|Intradermal Zesteem|
89228251|NCT00984386|Placebo Comparator|Placebo|
89228252|NCT00985478|Experimental|A|SLV342 suspension or capsule
89228253|NCT00985478|Placebo Comparator|B|matching placebo
89228254|NCT00988286|Experimental|CEP|
89228255|NCT05593250|Experimental|Cohort A|dose 1
89228256|NCT05593250|Experimental|Cohort B|dose 2
89228257|NCT05593250|Experimental|Cohort C|dose 3
89228258|NCT05593250|Placebo Comparator|Placebo|
89228259|NCT00985556|Experimental|Arm I|Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
89228260|NCT00985556|Experimental|Arm II|Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.
89106529|NCT02843061|Experimental|Rituximab and NK immunotherapy|In this group, the patients will receive regular Rituximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89106530|NCT02843061|Active Comparator|Rituximab|In this group, the patients will receive regular Rituximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89106531|NCT02838147|Experimental|Normal OGTT (Oral Glucose Tolerance Test)|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
89106532|NCT02838147|Experimental|Pathological OGTT - 1 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
89106533|NCT02838147|Experimental|Pathological OGTT - 2 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
89106534|NCT02613741|Experimental|Intervention|12 weeks of lifestyle-based physical activity intervention
89106535|NCT02613741|No Intervention|Control|12 weeks of no intervention
89106536|NCT02608203|Experimental|patients with gastroenteropancreatic neuroendocrine tumors|
89106537|NCT02839239|Experimental|Drops with lactobacilli and vitamin D3|Exclusive breast feeding plus L. rhamnosus 19070-2 and L. reuteri DSM 12246 in a dose of 125 x 106 CFU (both strains) with 1,667 mg fructooligosaccharides and 2,5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
89106538|NCT02839239|Placebo Comparator|Drops with vitamin D3|Exclusive breast feeding plus 2.5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
89106539|NCT02837835|Experimental|continuous administration of ceftazidime|
89106540|NCT02837835|Experimental|intermittent administration of ceftazidime|
89106541|NCT02839161|Experimental|Low-dose (0,2,4 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
89106542|NCT02839161|Experimental|Low-dose (0,2,6 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
89106543|NCT02839161|Experimental|Medium-dose (0,2,4 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
89106544|NCT02839161|Experimental|Medium-dose (0,2,6 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
89106545|NCT02839161|Experimental|High-dose (0,2,4 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
89106546|NCT02839161|Experimental|High-dose (0,2,6 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
89106547|NCT02839161|Active Comparator|Comparator (0,2,4 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.
89106548|NCT02839161|Active Comparator|Comparator (0,2,6 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 6 months.
89106549|NCT02837991|Experimental|CDX-014|"During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~The planned dose of CDX-014 depends on the cohort assigned at enrollment."
89106550|NCT00925002|Active Comparator|Open-Label|
89106551|NCT02842905|Active Comparator|Control Group|Fitting Audiologist completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
89106552|NCT02842905|Experimental|Test Group|Participant's physician completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
89106553|NCT02839395|Active Comparator|base line|First night is the base line- no exposure to computer screen illumination.
89106554|NCT02839395|Experimental|Acute|Second night is the acute exposure to computer screen illumination.
89106555|NCT02839395|Experimental|Chronic|Chronic is the effect after five nights of exposure to computer screen light illumination.
89106556|NCT02842671|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the the procedure will serve as our intervention group. The participants will be assigned an Ambassador throughout the procedure and will complete a patient satisfaction survey afterwards. The investigators hope to enroll 25 controls.
89106557|NCT02842671|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the patient's procedure will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the procedure. No ambassador will be assigned for the procedure day. The investigators hope to enroll 25 controls.
89106558|NCT04249713|Experimental|Brodalumab|Brodalumab 210mg subcutaneously every week for 24 weeks
89106559|NCT04249869|Experimental|Group A|Group A will receive VGH-AD1 two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the placebo for another 8 weeks. Post-follow up will be 4 weeks later.
89106560|NCT04249869|Placebo Comparator|Group B|Group B will receive placebo two times per day for 8 weeks, then entry 2 weeks wash-out period. Then switch to receive the VGH-AD1 for another 8 weeks. Post-follow up will be 4 weeks later.
89106561|NCT00610506|Experimental|A|Lexapro
89106562|NCT04250649|Active Comparator|Intervention|Betadine solution disinfection of the subcutaneous tissue during primary shoulder surgery
89106563|NCT04250649|No Intervention|Controle|Control group with surgery without disinfection of the subcutaneous tissue but dissection with an electric cautery during primary shoulder surgery
89106564|NCT04914078||Mepolizumab treated patients|Severe eosinophil severe asthmatic patients treated with anti IL-5 monoclonal antibody Mepolizumab
89106565|NCT02837601|Other|LOW AIS Pressure AirSeal®|AIS with an insufflation pressure target of 9mmHg ±1mmHg
89106566|NCT02837601|Other|HIGH AIS Pressure AirSeal®|AIS with an insufflation pressure target of 15mmHg ±1mm
89106567|NCT04257708||normal uterine cavity|
89106568|NCT04257708||abnormal uterine cavity|
89106569|NCT02837679|Experimental|Intervention|Geriatric follow up
89106570|NCT02837679|No Intervention|Control|Usual care
89106571|NCT05329974|Experimental|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
89106572|NCT02837055|Experimental|VivaSight intubation|Patients are intubated with the VivaSight-SL endotracheal tube
89106573|NCT02837055|Active Comparator|conventional intubation|Patients are intubated with a conventional endotracheal tube
89106574|NCT04255758|Experimental|Vigorous-intensity Aerobic Exercise|Vigorous-intensity aerobic exercise, single intervention
89106575|NCT02837133|Experimental|other techniques group|theory and practice of pair massage with tapping, stretching of the ankle and neck, and autogenic training
89106576|NCT02837289|Other|Treatment|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
89106577|NCT02837289|Other|Placebo|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
89106578|NCT04260828|Active Comparator|Aspirin|
89106579|NCT04260828|Placebo Comparator|Placebo (sugar pill)|
89106580|NCT00928746|Other|ATROVENT 42mcg|
89106581|NCT02834871|Other|patients with cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients with cervical dystonia
89106582|NCT02834871|Other|patients without cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients without cervical dystonia
89106583|NCT00922428||Observational group|Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.
89106584|NCT02834715|Experimental|Stevia|Once-daily oral intake of 240 mg of Stevia liquid extract for 30 days as food supplement.
89106585|NCT02834715|No Intervention|Control|No intervention, similar follow up as experimental arm to control for trial effect
89106586|NCT04468815|Experimental|Treatment A: BMS-986278 suspension, fasted|
89106587|NCT04468815|Experimental|Treatment B: BMS-986278 tablet, fasted|
89106588|NCT04468815|Experimental|Treatment C: BMS-986278 tablet, fed|
89106589|NCT04468815|Experimental|Treatment D: BMS-986278 tablet + esomeprazole capsule, fasted|
89106590|NCT00610584|Experimental|1|verum acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
89106591|NCT00610584|Placebo Comparator|2|minimal (sham) acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
89106592|NCT00610584|Active Comparator|3|rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))alone
89106593|NCT00894543|Active Comparator|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI)
89106594|NCT00894543|Placebo Comparator|Placebo|Inactive pill
89106595|NCT02838849|Sham Comparator|Fiber|Participants were treated with 2 sachets of fiber orally a day for 14 days, after baseline characterization of bowel habit and stool features.
89106596|NCT02838849|Active Comparator|Fiber and Water|Participants were treated with 2 sachets of fiber orally a day and ingested 2 liters of water a day for 14 days, after baseline characterization of bowel habit and stool features.
89106597|NCT02834325||exit|HFNC with no need for mechanical ventilation
89106598|NCT02834325||failure|HFNC with need for mechanical ventilation
89106599|NCT04249791|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from live donor.
89106600|NCT04249635||Reference Group|Healthy term (> 37 weeks of gestation) newborns of women with pregestational body mass index (BMI) ≥18,5 and <24,9 in the first prenatal visit.
89106601|NCT04249635||Maternal obesity (MO) Group|Newborns of women with pregestational BMI ≥30 that received 200 mg/dayDHA supplementation.
89106602|NCT04249635||MO+DHA Group|Newborns from women with pregestational BMI ≥30 that received 800 mg/day DHA supplementation.
89106603|NCT02838771|Experimental|Research group participants|"Research group consisted of 171 elderly nursing home residents and 82 outpatients of the Hospital of Lithuanian University of Health Sciences.~The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening)."
89106604|NCT02838771|Other|Control group participants|Community-dwelling elderly healthy individuals. The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening).
89106605|NCT02837211|Experimental|Tapered Diet|
89106606|NCT02837211|Active Comparator|Traditional Low Calorie Diet|
89106607|NCT02837367|Experimental|Adult intervention|"The intervention will consist Administration of supplements containing methyl-donors (as capsules) containing: 2 g betaine, 800 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 1000 ug (micrograms) Vitamin B12, 500 mg choline bitartrate, 1 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 280 mg DHA (docosahexaenoic acid).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
89106608|NCT02837367|Placebo Comparator|Adult placebo|"The intervention will consist of the Administration of supplements containing methyl-donors (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
89106609|NCT02837367|Experimental|Children intervention|"The intervention will consist of the Administration of supplements containing methyl-donors (as syrup) containing: 1 g betaine, 400 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 500 ug (micrograms) Vitamin B12, 250 mg choline bitartrate, 0.5 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 140 mg DHA (docosahexaenoic acid).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
89106610|NCT02837367|Placebo Comparator|Children Placebo|"The intervention will consist of Administration of supplements containing methyl-donors (as syrup) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
89106611|NCT02837367|No Intervention|Adults genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in adult people with obesity.
89106612|NCT02837367|No Intervention|Children genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in children with obesity.
89106613|NCT00922272|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
89106614|NCT00922272|Placebo Comparator|Placebo|Placebo
89106615|NCT00853372|Experimental|Trebananib 10 mg/kg + Sunitinib|Trebananib 10 mg/kg intravenously (IV) once weekly (QW) plus sunitinib 50 mg orally (PO) once daily (QD) 4 weeks on/2 weeks off
89106616|NCT00853372|Experimental|Trebananib 15 mg/kg + Sunitinib|Trebananib 15 mg/kg IV QW plus sunitinib 50 mg PO QD 4 weeks on/2 weeks off
89106617|NCT02836977|Experimental|maintenance therapy|Patients will receive oral tegafur-uracil 400mg/day (100mg/Cap., 2 capsules each time, twice a day), combined with oral folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day), and continue for one year.
89106618|NCT02836977|Active Comparator|observation arm|Patients will be observed following adjuvant oxaliplatin-based regimen.
89106619|NCT00913042||1|febrile neutropenia patient
89106620|NCT00848536|Experimental|TRAVATAN APS|One drop once daily in the evening for 3 months
89106621|NCT00848536|Active Comparator|TRAVATAN|One drop once daily in the evening for 3 months
89106622|NCT00922116|Experimental|1|
89106623|NCT04117282|Active Comparator|control group|15 children received the regular exercise program including classical gait training for diplegic children (30 minutes exercises + 30 minutes gait training)
89106624|NCT04117282|Experimental|study group|15 diplegic child received the same exercise program including the use of the antigravity shoes for gait training (30 minutes exercises + 30 minutes gait training)
89106625|NCT04255524|Experimental|Group 1/Control|Spherical equivalent: -2.00～+2.00 D
89106626|NCT04255524|Experimental|Group 1/Myopia|Spherical equivalent: -3.00～-6.00 D
89106627|NCT04255524|Experimental|Group 3/High|Spherical equivalent: -6.00～-10.00 D
89106628|NCT04255524|Experimental|Group 4/Super High|Spherical equivalent: <-10.00
89106629|NCT04260516|Active Comparator|N-acetylcysteine group|Patients received oral n-acetylcysteine syrup on dose of 10 mg/kg/day as single dose for 3 months
89106630|NCT04260516|No Intervention|Non n-acetylcysteine group|Thalassemia major patients on regular chelation therapy who didn't receive n-acetylcysteine and served as controls
89106631|NCT00921024|Experimental|1|CXA-101
89106632|NCT00921024|Active Comparator|2|Ceftazidime
89106633|NCT04260594|Experimental|Arbidol tablets + basic treatment|
89106634|NCT04260594|Sham Comparator|basic treatment|
89106635|NCT04203888|Other|Massage|A licensed massage therapist will deliver 60-minute Swedish Massage in the participant's home, 2 times per week with at least 48-hours between massage sessions. Each massage arm will be 2 weeks in length, and consist of 4 total Swedish massages.
89106636|NCT04203888|Other|Yoga|"A certified yoga instructor will deliver 60-minute yoga instruction in the participant's home, 2 times per week with at least 48-hours between yoga session. Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005). Each yoga arm will be 2 weeks in length, and consist of 4 total yoga sessions."
89106637|NCT04203888|No Intervention|Usual Care|Participants will be instructed to abstain from any massage or yoga activity, and instructed to treat their chronic lower back pain as they normally would. Each usual care arm will be 2 weeks in length.
89106638|NCT04260438|Experimental|Group 1|"Period 1: Treatment A~Period 2: Treatment B~Period 3: Treatment C"
89106639|NCT04260438|Experimental|Group 2|"Period 1: Treatment A~Period 2: Treatment C~Period 3: Treatment B"
89106640|NCT04260438|Experimental|Group 3|"Period 1: Treatment B~Period 2: Treatment A~Period 3: Treatment C"
89106641|NCT04260438|Experimental|Group 4|"Period 1: Treatment B~Period 2: Treatment C~Period 3: Treatment A"
89106642|NCT04260438|Experimental|Group 5|"Period 1: Treatment C~Period 2: Treatment A~Period 3: Treatment B"
89106643|NCT04260438|Experimental|Group 6|"Period 1: Treatment C~Period 2: Treatment B~Period 3: Treatment A"
89106644|NCT00928668|Experimental|Olodaterol (BI1744) Low|Single dosing of low dose Olodaterol inhaled orally from Respimat Device
89106645|NCT00928668|Experimental|Olodaterol (BI1744) Medium Low|Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device
89106646|NCT00928668|Experimental|Olodaterol (BI1744) Medium High|Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device
89106647|NCT00928668|Experimental|Olodaterol (BI 1744) High|Single dosing of high dose Olodaterol inhaled orally from Respimat Device
89106648|NCT00928668|Placebo Comparator|Placebo|Single dosing of Olodaterol placebo inhaled orally from Respimat Device
89106649|NCT05056428|Experimental|Intervention group|8-week mindfulness program
89106650|NCT05056428|No Intervention|Wait-list control|Participants in wait-list control group will receive the same intervention, two months after experimental group completed the intervention.
89106651|NCT05329818|Experimental|Prefrontal stimulation.|Participants receive anodal tDCS on the ipsilesional dlPFC for 5days/week for 2 weeks.
89106652|NCT05329818|Experimental|Cerebellar stimulation.|Participants receive anodal tDCS on the contralesional cerebellum for 5days/week for 2 weeks. min of HD-tDCS with 2.0mA.
89106653|NCT05329818|Experimental|Fronto-cerebellar stimulation.|Participants receive simultaneous anodal tDCS on the ipsilesional dlPFC and in contralesional cerebellum for 5days/week for 2 weeks.
89106654|NCT05329818|Sham Comparator|Sham stimulation.|Participants receive sham tDCS for 5days/week for 2 weeks.
89106655|NCT00592774|Placebo Comparator|Placebo Cohort 1|
89106656|NCT00592774|Experimental|Perampanel Cohort 1, 3-week Titration|
89106657|NCT00592774|Experimental|Placebo Cohort 2|
89106658|NCT00592774|Experimental|Perampanel Cohort 2, 1-week Titration|
89106659|NCT00592774|Experimental|Perampanel Cohort 2, 2- Week Titration|
89106660|NCT04131010|Experimental|SpyGlass Pancreatoscopy|ERP with direct pancreatoscopy
89106661|NCT00700960||A|
89106662|NCT00700492|No Intervention|control|
89106663|NCT00700492|Experimental|utrogestan|daily use of vaginal progesterone capsules
89106664|NCT04116190|Experimental|Telerehabilitation (TR)|Shortened inpatient rehabilitation mixed with home-based telerehabilitation.
89106665|NCT04116190|Experimental|Conventional rehabilitation (CR)|Traditional inpatient rehabilitation
89106666|NCT00700648||A|
89106667|NCT00837694||1|Non-obese/0 kcal
89106668|NCT00837694||2|Non-obese/100 kcal
89106669|NCT00837694||3|Non-obese/300 kcal
89106670|NCT00837694||4|Obese/0 kcal
89106671|NCT00837694||5|Obese/100 kcal
89106672|NCT00837694||6|Obese/300 kcal
89106673|NCT00703300|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10 and bortezomib IV on days 5 and 8 or days 5, 8, 12, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose is determined, an additional 6 patients are treated at the recommended phase II dose.
89106674|NCT04116034|Experimental|DSR|Up to 10 subjects will be treated with alfapump DSR system for a total treatment period of 59 days post-implantation
89106675|NCT00703378|Experimental|Group 1|Group 1: normal liver function
89106676|NCT00703378|Experimental|Group 2|Group 2: AST and/or ALT up to 1-5 x upper limit of normal; SAP 1- 5x upper limit of normal, total bilirubin within normal limits
89106677|NCT00703378|Experimental|Group 3|Group 3: Any SAP and AST/ALT >5-10 x upper limit of normal and/or total bilirubin 1-1.5 x upper limit of normal
89106678|NCT00703456|Experimental|1|Balance Training, 3 times a week for 4 weeks
89106679|NCT00703456|No Intervention|2|Education/No intervention
89106680|NCT00852202|Experimental|1|0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.
89106681|NCT00852202|Experimental|2|1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.
89106682|NCT00852202|Placebo Comparator|3|Matching placebo capsules, oral administration, once daily dosing.
89106683|NCT01074008|Experimental|ABT-450/r (50/100 mg) once daily (QD) + pegIFN/RBV|Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106684|NCT01074008|Experimental|ABT-450/r (100/100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106685|NCT01074008|Experimental|ABT-450/r (200/100 mg) once daily (QD) + pegIFN/RBV|Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106686|NCT01074008|Experimental|ABT-072 (100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106687|NCT01074008|Experimental|ABT-072 (300 mg) once daily (QD) + pegIFN/RBV|Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106688|NCT01074008|Experimental|ABT-072 (600 mg) once daily (QD) + pegIFN/RBV|Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106689|NCT01074008|Experimental|ABT-333 (400 mg) twice a day (BID) + pegIFN/RBV|Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106690|NCT01074008|Experimental|ABT-333 (800 mg) twice daily (BID) + pegIFN/RBV|Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106691|NCT01074008|Placebo Comparator|Placebo + pegIFN/RBV|Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106692|NCT04117048|Experimental|At home INR measurement with LabPad®|All at home INR measurements will be performed with the LabPad® point-of-care
89106693|NCT04117204|Experimental|Fruits and Vegetables|This group will receive a prescribed amount of free fruits and vegetables (F&V) for 6 weeks of pick-up at a farm stand or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 6 weeks with minimal contact.
89106694|NCT04117204|No Intervention|Wait List Control|This group will not receive a prescribed amount of free fruits and vegetables (F&V) for 12 weeks. They will serve as the control group. After 12 weeks of control and data comparisons, they will be given 12 weeks of vouchers with minimal contact.
89106695|NCT00700726||A.|participants with atopic and non-atopic asthma
89106696|NCT02613052|Placebo Comparator|Agitated Normal Saline|Agitated saline is the current standard of care contrast agent used for bubble studies. 10 mL of agitated normal saline will be used for the bubble study.
89106697|NCT02613052|Active Comparator|Albumin only|10 mL of agitated 5% albumin will be used for the bubbly study.
89106698|NCT02613052|Experimental|Albumin and Propofol|7 mL of 5% albumin and 3 mL of propofol (10 mg/mL) will be agitated together and used for the bubble study.
89106699|NCT01073930|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy."
89106700|NCT01073930|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
89106701|NCT01073618||A.|Patients who are indicated for VFEND according to drug package insert.
89106702|NCT01073462||Paricalcitol IV|Participants with chronic kidney disease stage 5 with secondary hyperparathyroidism and cardiac morbidity received intravenous (IV) paricalcitol (Zemplar) prescribed according to current practice with regards to dose, population and indication for up to 2 years.
89106703|NCT02875964|Experimental|registration of intracerebral activity|epileptic patient receiving implantation of intracranial electrodes
89106704|NCT00789373|Experimental|pemetrexed + cisplatin followed by pemetrexed|pemetrexed plus cisplatin followed by pemetrexed plus best supportive care
89106705|NCT00789373|Placebo Comparator|pemetrexed + cisplatin followed by placebo|pemetrexed plus cisplatin followed by placebo plus best supportive care
89106706|NCT00851890|Experimental|ABT-333 (300 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 300 mg ABT-333 BID for 2 days followed by 300 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106707|NCT00851890|Experimental|ABT-333 (600 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 600 mg ABT-333 BID for 2 days followed by 600 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106708|NCT00851890|Experimental|ABT-333 (1200 mg) once daily (QD) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 1200 mg ABT-333 QD for 2 days followed by 1200 mg ABT-333 QD with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106709|NCT00851890|Placebo Comparator|Placebo + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naïve participants received matching placebo once daily (QD) or twice daily (BID) for 2 days followed by placebo QD or BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
89106710|NCT00626756|Experimental|LI|arm controled by LIDCO technology
89106711|NCT00626756|No Intervention|CA|standard approach
89106712|NCT02877368||gastrointestinal stromal tumours|Patients with advanced or high-risk resected gastrointestinal stromal tumours (GIST) .
89106713|NCT02877212|Experimental|Study subjects|Steroid refractory ITP patients will be given Eltrombopag to investigate the association of treatment outcome with Fc Receptor polymorphism and THPO expression in responders and non responders following comparison correlation with ITP patients treated with standard IST as control group
89106714|NCT04106713|Experimental|Individual Therapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
89106715|NCT04106713|Experimental|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven [behaviours] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing [behavioural] and emotional awareness, and situational and interoceptive exposure to emotion cues."
89106716|NCT04106713|Experimental|Group CBT|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
89228261|NCT04780490|Active Comparator|liberal fluid therapy|"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine (No medication from the epidural catheter will be administered during surgery).~Standard anesthesia induction will be applied (fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ), and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.~Fluid resuscitation will be started with 10 ml / kg / hr Ringer's lactate solution.~In patients with MAP <65 mmHg, 250 ml of Ringer's lactate solution will be given as a bolus.~If the hypotension persists, the bolus 250 ml Ringer's lactate solution will be repeated up to 10 times."
89228262|NCT04780490|Active Comparator|restrictive fluid therapy|"Patients will be applied 2 mg midazolam for premedication. Before anesthesia induction, epidural catheter will be inserted to all patients and test dose will be made with 3 cc % 2 lidocaine ( No medication from the epidural catheter will be administered during surgery. ) Standard anesthesia induction will be applied ( fentanyl 2 mcg/kg; propofol 2 mg/kg; rocuronium 0.6 mg/kg ) and after intubation maintenance of anesthesia will be achieved with sevoflurane with a minimum alveolar concentration (MAC) of 0.8-1.~Fluid resuscitation will be started with 2 ml / kg / hr Ringer's lactate solution and norepinephrine infusion at a dose of 2 mcg / kg / hr.~In patients with MAP<65 mmHg, norepinephrine dose will be increased up to 8 mcg / kg / hr.~If the hypotension persists although the norepinephrine dose is 8 mcg / kg / hr, 250 ml bolus Ringer's lactate solution will be given."
89228263|NCT04445246|Experimental|Inhaled Iloprost therapy|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization
89228264|NCT00541346|Experimental|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
89228265|NCT00988520|Experimental|0.6 mg/kg intubation dose under sevoflurane|
89228266|NCT00988520|Experimental|0.9 mg/kg intubation dose under sevoflurane|
89228267|NCT00988520|Experimental|continuous dose following 0.6 mg/kg intubation dose + propofol|
89228268|NCT00988520|Experimental|continuous dose following 0.9 mg/kg intubation dose + propofol|
89228269|NCT00985634|Experimental|LeGoo|Subjects in this arm, which is assigned at random, will receive the study device.
89228270|NCT00985634|Active Comparator|Control|Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
89228271|NCT00988676||colonoscopy|
89228272|NCT05498090|No Intervention|Arm 1 (Cross-sectional, Cases v. Controls)|Cases (those with Klinefelter) vs. controls (those without Klinefelter)
89228273|NCT05498090|Experimental|Arm 2 (Interventional with cases)|Cases (those with Klinefelter); Comparison of outcomes pre and post fenofibrate intervention, 145mg PO daily for 4 weeks
89228274|NCT00077623|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the week preceding the switch to the study drug.
89228275|NCT00077623|Experimental|RO0503821 (1x/4 Weeks)|Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of<8000, 8000-16000, or >16000 IU/week administered during the week preceding the switch to the study drug.
89228276|NCT00077623|Active Comparator|Epoetin Reference|Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .
89228277|NCT00541034|Experimental|cyclophosphamide, pentostatin & rituximab|Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course 1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89228278|NCT00986024|Experimental|aerobic exercise|
89228279|NCT00986024|Experimental|strength training|
89228280|NCT00986024|No Intervention|control group|
89228281|NCT01090375|Experimental|Exercise|
89228282|NCT01090375|Placebo Comparator|Non Exercise|
89228283|NCT00540644|Experimental|Revlimid, Cyclophosphamide, Prednisone|"Lenalidomide orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Cyclophosphamide twice daily, orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Prednisone every other day orally."
89228284|NCT05450900|Active Comparator|Cohort 1|hCG plus biotin supplement
89228285|NCT05450900|Placebo Comparator|Cohort 2|hCG plus placebo supplement
89228286|NCT04004858|Active Comparator|Standard margin|Patient cohort planned with the current standard PTV margin
89228287|NCT04004858|Experimental|Reduced margin|Patient cohort planned with the reduced margin validated from the retrospective study
89228288|NCT00988754|Active Comparator|A|Medical examination once per year, school and family-based lifestyle intervention including a weekly health lesson, school-affiliation to sports clubs and regularly trainings for teachers and parents
89228289|NCT00988754|No Intervention|B|Medical examination and information on a healthy lifestyle.
89228290|NCT00988910||Group 1|
89228291|NCT00988910||Group 2|
89228292|NCT00986336|Experimental|001|
89228293|NCT00986336|Experimental|002|
89228294|NCT00986336|Experimental|003|
89228295|NCT00986336|Experimental|004|
89228296|NCT00989222|Other|Volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
89228297|NCT00989222|Other|External fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
89228298|NCT00989300|Experimental|Treatment group|patients received clopidogrel 75 mg with rabeprazole 20 mg, omeprazole 20 mg, or placebo in a crossover manner
89228299|NCT00989300|Placebo Comparator|Placebo group|
89228300|NCT04005014|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SE and presence of high myopia in the subsequent 10 years.
89106717|NCT04106713|No Intervention|Delayed Waitlist|Participants in the Waitlist group will be recruited from those referred for psychotherapy and who are not assigned to either group or iCBT and not planned for psychotherapy at IMH for 8 weeks or more from the point of consent.
89106718|NCT04106713|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group are individuals who are not assigned to psychotherapy at IMH. They will be recruited from outpatient services and emergency services at IMH.
89106719|NCT00788827|Experimental|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
89106720|NCT02875808||patients|patients with an external ventricular drainage
89106721|NCT02875574||All participants|
89106722|NCT02612974|Experimental|Group A|Hirudinaria granulosa and Qurse mafasil are given
89106723|NCT02612974|Active Comparator|Group B|Qurse mafasil only given
89228301|NCT04005014|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
89106724|NCT04304924|Experimental|Personalised telephone-based health education|"The personalized telephone based intervention:~Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
89106725|NCT04304924|No Intervention|Standard health educational program|
89106726|NCT00592072|Experimental|Medium chain fatty acid (Octanoic and Decanoic acid)|
89106727|NCT00592072|Placebo Comparator|Splenda (Placebo Control)|
89106728|NCT02875418|Experimental|EUM and tocodynamometry|Pregnant women with gestational age 24+0/7 to 33+6/7 weeks of gestation and contractions, cramping, pelvic pressure or backache.
89106729|NCT04742972|Experimental|SABR|
89106730|NCT04742972|Placebo Comparator|SOC|
89106731|NCT00626288|Experimental|A|Mesalazine cpr 800 mg t.i.d. for 12 weeks
89106732|NCT00626288|Placebo Comparator|B|Placebo cpr t.i.d. for 12 weeks
89106733|NCT00792571|Experimental|B.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, b.i.d (twice a day dosing)
89106734|NCT00792571|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, q.i.d (four times a day dosing)
89106735|NCT04108975|Active Comparator|Rectus muscle reapproximation group|Rectus muscle reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures
89106736|NCT04108975|Active Comparator|Rectus muscle non reapproximation group|No rectus muscle reapproximation will be done based on the fact that rectus muscle can regain its position
89106737|NCT01069484|Experimental|Postpartum pelvic floor muscle training|Beyond a customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the participants are given supervised pelvic floor muscle group training led by physiotherapists once a week. In addition, the participants train every day at home, with at least 3 sets of 8-12 contractions. Training period is 4 months.
89106738|NCT01069484|No Intervention|Control|Beyond the customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the control group participants received no further intervention. They were not discouraged from doing PFMT on their own.
89106739|NCT04110223||non-smell cell lung cancer (NSCLC)|Advanced NSCLC patients receiving radiotherapy or chemo-radiotherapy
89106740|NCT04110223||Rectal cancer|Rectal cancer patients receiving neoadjuvant radiotherapy or chemo-radiotherapy
89106741|NCT04110223||Smell cell lung cancer (SCLC)|SCLC patients receiving radiotherapy or chemo-radiotherapy
89106742|NCT04110223||Esophageal cancer|Esophageal cancer patients receiving radiotherapy or chemo-radiotherapy
89106743|NCT04110223||Cervical cancer|Cervical cancer patients receiving radiotherapy or chemo-radiotherapy
89106744|NCT04110223||Liver cancer|Liver cancer atients receiving radiotherapy or chemo-radiotherapy
89106745|NCT04109989|Experimental|HominisTM Surgical System|Gynecological surgical procedure will be performed with the HominisTM Surgical System
89106746|NCT00794365||Open-label|
89106747|NCT01067144|Placebo Comparator|Control|Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively
89106748|NCT01067144|Experimental|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
89106749|NCT04749758|Experimental|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is approved by Andorra's Government authorities.
89106750|NCT02603185|Experimental|Hemay007|"Part 1: Single ascending dose Group Hemay007 tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.~Part 2: Food effect group Hemay007 tablets will be taken orally in single dose with a high-fat, high-calorie meal or at overnight fasting.~Part 3: Multiple doses group Hemay007 tablets will be taken orally once daily in low, medium, high doses"
89106751|NCT02603185|Placebo Comparator|Placebo|"Part 1: Single ascending dose Group Placebo tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.~Part 3: Multiple doses group Placebo tablets will be taken orally once daily in low, medium, high doses"
89106752|NCT05610943|Active Comparator|quadratus lumborum nerve block|In Group Q; The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
89106753|NCT05610943|Active Comparator|Ilioinguinal Iliohypogastric Nerve Block|In Group I; The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
89106754|NCT01078298|Experimental|varenicline|
89106755|NCT01078298|Placebo Comparator|placebo|placebo
89106756|NCT00788593|Placebo Comparator|Placebo|
89106757|NCT00788593|Experimental|EUR-1008 (APT-1008) High Dose|
89106758|NCT00788593|Experimental|EUR-1008 (APT-1008) Low Dose|
89106759|NCT04305080|Experimental|Anodic Oxidation of implant abutment|
89106760|NCT04305080|Sham Comparator|Untreated implant abutment|
89106761|NCT04106011||Patients with Neuropathic Pain|
89106762|NCT02877056||Colorectal Cancer|Participants undergo standard endoscopy before therapy. Tissue samples taken from the tumor and normal colorectal tissue.
89106763|NCT02603029|Placebo Comparator|Placebo cream|Cream with 0% Silver fir wood extract (Belinal)
89106764|NCT02603029|Active Comparator|Belinal cream|Cream with 2% Silver fir wood extract (Belinal)
89106765|NCT02875886|Active Comparator|Diuretic treatment|Patients receive amiloride and hydrochlorothiazide
89106766|NCT02875886|Active Comparator|Low-sodium diet|Patients are put on a low-sodium diet (60 mmol/day)
89106767|NCT04304300||Study group|Glioma, IDH mutated, grade 2 and 3
89106768|NCT00793819|Experimental|1 Silodosin|
89106769|NCT00793819|Placebo Comparator|2 Placebo|
89106770|NCT04109833||no antibiotic therapy (ABT) in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation without antibiotic treatment in the first week of life
89106771|NCT04109833||ABT in the first week of life|VLBWI with gestational age between 24+0 and 28+6 weeks of gestation with antibiotic treatment in the first week of life
89106772|NCT00792259||1|Patients with Retinal Disease
89106773|NCT00792259||2|Patients without Retinal Disease
89106774|NCT00792259||3|Normal Subjects
89106775|NCT00894387|Experimental|Aliskiren|Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once daliy.
89106776|NCT00894387|Placebo Comparator|Placebo|Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.
89106777|NCT02839005|Active Comparator|suture with polyglecaprone 25|
89106778|NCT02839005|Active Comparator|suture with polyamide (nylon)|
89106779|NCT02836665|No Intervention|A: Control group|Patients of group A wait routinely until the dermatological investigator in charge arrives at the emergency room. Once the dermatological investigator is on site, he gives a diagnosis and proposes a therapy.
89106780|NCT02836665|Experimental|B: Telemedicine for dermatological emergency patients|"For Patients of group B study-related photographs of the skin lesion and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal."
89106781|NCT04249479|Experimental|CM temperature 20° C|CM is administered to the patient at a temperature of 20° C.
89106782|NCT04249479|Active Comparator|CM temperature 37° C|CM is administered to the patient at a temperature of 37° C.
89106783|NCT02836821|Experimental|Apatinib|subjects receiving a single 750 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then rifampicin capsules 600 mg/day orally for 10 days with a single 750 mg oral dose of apatinib mesylate tablets co-administered on day 8 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
89106784|NCT02836587|Experimental|interventional|Experimental group will undergo balance training for 8 weeks.
89106785|NCT02836587|No Intervention|control|Control group will have no assigned intervention.
89106786|NCT02834169||pseudomyxoma peritonei|Data from pseudomyxoma peritonei cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
89106787|NCT02834169||peritoneal mesothelioma|Data from peritoneal mesothelioma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
89106788|NCT02834169||desmoplastic small round cell tumor|Data from desmoplastic small round cell tumor cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
89106789|NCT02834169||psammocarcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
89106790|NCT02834169||primary peritoneal serous carcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
89106791|NCT02834169||diffuse peritoneal leiomyomatosis|Data from diffuse peritoneal leiomyomatosis cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
89106792|NCT02834169||appendiceal mucinous neoplasms|Data from appendiceal mucinous neoplasms cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
89228302|NCT03437720|Experimental|SAR425899 (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
89228303|NCT03437720|Experimental|SAR425899 (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
89106793|NCT00633321|Experimental|1|TA-NIC 100 μg
89106794|NCT00633321|Experimental|2|TA-NIC 250 μg
89106795|NCT00633321|Placebo Comparator|3|
89106796|NCT02839083|Placebo Comparator|Thoracic Paravertebral group|Ultrasound guided thoracic paravertebral block
89106797|NCT02839083|Active Comparator|Pecs II group|Ultrasound guided Pecs II block
89106798|NCT02836743|Experimental|Circadin 2mg|low-dose (2mg) slow-release melatonin for 1 month.
89106799|NCT02836743|Experimental|Circadin 6mg|high-dose (6mg) slow-release melatonin for 1 month.
89106800|NCT02836743|Placebo Comparator|Placebo|Administer placebo pills with identical morphology
89106801|NCT00928512|Experimental|Secukinumab 25mg|Secukinumab 25mg s.c. q4wk
89106802|NCT00928512|Experimental|Secukinumab 75mg|Secukinumab 75mg s.c. q4wk
89106803|NCT00928512|Experimental|Secukinumab 150mg|Secukinumab 150mg s. c. q4wk
89106804|NCT00928512|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c. q4wk
89106805|NCT00928512|Placebo Comparator|Secukinumab Placebo|Secukinumab Placebo s.c. q4wk
89106806|NCT04249089|Active Comparator|Relaxation Group|
89106807|NCT04249089|No Intervention|Control group|
89106808|NCT04204317||Autofluorescence|"The surgeon will perform the preplanned operation with FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~Surgery date~Duration of surgery~Operation performed~Procedure related comments~Number and location of the visualized glands~Intra-operative autofluorescence score (either 0 (no visualization or 1 visualization) for each gland"
89106809|NCT04204317||Control|"The surgeon will perform the preplanned operation without FLUOBEAM XS. The following intraoperative variables will be recorded for all patients:~Surgery date~Duration of surgery~Operation performed~Procedure related comments"
89106810|NCT04255368|Experimental|Water-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as choline bitartrate; served with a bagel with margarine-butter spread and one cup of water.
89106811|NCT04255368|Experimental|Fat-soluble choline|A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as phosphatidylcholine; served with a bagel with margarine-butter spread and one cup of water.
89106812|NCT04255368|Active Comparator|No choline|A breakfast meal consisting of 1 cup of tomato soup containing no choline; served with a bagel with margarine-butter spread and one cup of water.
89106813|NCT04257240||study group|patients subjected to major hepatectomy with vascular control of blood inflow and outflow of the whole liver
89106814|NCT04257240||control group|patients subjected to major hepatectomy by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
89106815|NCT00610818||A|Patients receiving palifermin to prevent mucositis from bone marrow transplant.
89106816|NCT04255290|Experimental|Experimental group|Leg Squat Lounge: The player will be placed in squat position and her partner will be placed behind, suspending the most posterior leg in the air. With the leg that is supported, you will perform a monopodal jump with controlled fall, supporting the foot from tip to heel. It will be done with both lower limbs performing 1 series of 5 repetitions with 30 seconds of rest between sets. 180 jump: The footballer will start in bipodal support, with the trunk erect and hands on the hips. Perform a bipodal jump with a 180º turn during this, keeping the fall for 2 seconds. Each repetition, the turn will be done in a different sense. It will carry out 2 series of 20 sec of execution with 20 sec of rest between series. Brad jump stick landing: The player will stand in hands-free standing. Perform a bipodal jump as far as possible. The knees will not exceed the tip of the foot and the fall will be with a trunk position as straight as possible. He will make 5 jumps the first two weeks.
89106817|NCT04255290|Active Comparator|Control group|"Nordic Funds: One player will stand on her knees, while the other, behind, fixes her legs. The kneeling footballer must drop forward in a controlled manner until she touches the ground and returns to the starting position. The Diver: Player in monopodal support on the lower limb to work, performing hip flexion with the arms forward and the opposite lower limb back, looking for a horizontality in the pelvis (with 10º-20º knee flexion) It will be done with both lower limbs.~The Glider: With the footballer standing in front of her partner, holding both of them by the shoulders, she lets one leg slide back while the other stays fixed. To return to the starting position, it will be helped by the other player, while the knee will not exceed 10 degrees of flexion. The distribution of all the exercises will be: 2 sets of 5 repetitions with 20 sec rest between sets"
89106818|NCT04255446||Dysfunctional Breathing|Patients with Dysfunctional breathing age between 16 to 75 will be included.
89106819|NCT04255446||Healthy Volunteers|Healthy Volunteers without any respiratory problems age between 16 to 75 will be included.
89106820|NCT04255680||FRDA Subjects|Male and female subjects with FRDA confirmed by genetic testing (aim for a 50:50 distribution of males to females)
89106821|NCT04255680||Controlled Subjects|Male and female control subjects (matched by age [+/- 2 years] and sex)
89106822|NCT00787891|Experimental|Rabeprazole 0.5 mg/kg|rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
89106823|NCT00787891|Experimental|Rabeprazole 1.0 mg/kg|rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
89106824|NCT00892437|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo +ATV+FTC/TDF for 48 weeks
89106825|NCT00892437|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo +ATV+FTC/TDF for 48 weeks
89106826|NCT04108585||HFO group|HFO therapy
89106827|NCT04108585||CPAP group|CPAP therapy
89106828|NCT02838537||Triptan Arm|"Users of triptan defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
89106829|NCT02838537||Ergot Arm|"Users of ergot derivative defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
89106830|NCT04108507|Experimental|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP)operation
89106831|NCT04108507|No Intervention|without posterior branch block of spinal nerve|without posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
89106832|NCT02836509|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
89106833|NCT02836509|Experimental|Ibuprofen group|Second Group: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
89106834|NCT00792103|Experimental|NP101|sumatriptan iontophoretic transdermal patch
89106835|NCT02836197|Experimental|Experimental group|This group of 30 physicians will immediately attend the intervention communication skills training program (experimental group).For this experimental group, the first assessment will take place before the first training session and the second recording after the last session. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
89106836|NCT02836197|No Intervention|Waiting-list group|This group of 30 physicians will attend the intervention communication skills training in a delayed manner (control group). For this control group, the first and the second recording will take place with a four-month interval. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
89106837|NCT04108663|Sham Comparator|Sham|Sham tDCS (ramp up and ramp down of electrical current before as well as after task performance to elicit physical sensations similar to verum tDCS)
89106838|NCT04108663|Active Comparator|L1A|"Active tDCS~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 1 mA~polarity: anodal"
89106839|NCT04108663|Active Comparator|R1A|"Active tDCS~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 1 mA~polarity: anodal"
89106840|NCT04108663|Active Comparator|L2A|"Active tDCS~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 2 mA~polarity: anodal"
89106841|NCT04108663|Active Comparator|R2A|"Active tDCS~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 2 mA~polarity: anodal"
89106842|NCT04108663|Active Comparator|L1C|"Active tDCS~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 1 mA~polarity: cathodal"
89106843|NCT04108663|Active Comparator|R1C|"Active tDCS~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 1 mA~polarity: cathodal"
89106844|NCT04108663|Active Comparator|L2C|"Active tDCS~laterality: left PFC (F3; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 2 mA~polarity: cathodal"
89106845|NCT04108663|Active Comparator|R2C|"Active tDCS~laterality: right PFC (F4; second electrode placed on deltoid muscle of the opposing arm)~intensity: of 2 mA~polarity: cathodal"
89228304|NCT03437720|Placebo Comparator|Placebo (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
89106846|NCT05306379|Experimental|Voclosporin/Simvastatin|"Subjects will receive a single oral dose of 40 mg simvastatin (given as two 20 mg tablets) in the morning of Day 1 and Day 8.~Subjects will receive voclosporin administered as an oral 23.7 mg dose (three 7.9 mg capsules) twice-daily for 7 days from the morning of Day 2 until the evening of Day 8."
89106847|NCT05304663|Experimental|ARM 1: Fractionating Lomustine|"Patients will be treated in escalating cohorts of 6 patients with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and lomustine at different doses on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Cohort 1: 10 µg/kg L19TNF and 60 mg/m2 lomustine~Cohort 2: 10 µg/kg L19TNF and 75 mg/m2 lomustine"
89106848|NCT05304663|Experimental|ARM 2: Priming with L19TNF|"Patients will be treated in escalating cohorts of 6 patients with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and lomustine at different doses on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles.~Cohort 1: 10 µg/kg L19TNF and 90 mg/m2 lomustine~Cohort 2: 10 µg/kg L19TNF and 110 mg/m2 lomustine In each arm, patients will be enrolled sequentially and no more than 2 patients will be treated in Cycle 1 in the same arm in parallel.~Recruitment to an arm will be stopped should ≥ 2 DLTs occur in a cohort."
89106849|NCT04109755|Experimental|Experimental|Short Course Radiation Therapy (5 x 5 Gy in 1 week, SCRT) with 4 injections of Pembrolizumab starting on the first day of radiotherapy and surgery
89106850|NCT04248387|Experimental|Toripalimab group|The subjects in this group receive intravenous drip infusion of Toripalimab at a dose of 3 mg / kg once every 2 weeks for a total of two cycles
89106851|NCT02838693||APT-2D (Normoglycemic)|800 Normoglycemic
89106852|NCT02838693||APT-2D (Pre-Diabetic)|1,500 Pre-Diabetic
89106853|NCT04248309|Experimental|A1|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone <7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
89106854|NCT04248309|No Intervention|A2|The included patient should test serum progesterone level on D3 no matter which day perform the embryo transfer. According to the progesterone level, there are two groups, Group A: serum progesterone <7.24ug/L, followed by randomized A2：without additional treatment
89106855|NCT04248309|No Intervention|B|Group B：serum progesterone ≥7.24ug/L， without additional treatment
89106856|NCT00892281|Other|Oracea® as monotherapy|Oracea as monotherapy
89106857|NCT00892281|Other|Oracea® as add-on therapy|Oracea® as add-on Therapy (Oracea® + Metronidazoles and/or Azelaic Acids and/or Sodium Sulfacetamides
89106858|NCT02836275|Experimental|Perfusion and diffusion-weighted MRI|
89106859|NCT02836353|No Intervention|Observational only|Oral glucose tolerance test, neurocognitive questionnaire tasks only.
89106860|NCT02836353|Experimental|Somatostatin|Oral glucose tolerance test after 100mcg Somatostatin
89106861|NCT02836353|Experimental|Antibiotics|Oral glucose tolerance test after treatment of small intestinal bacterial overgrowth
89106862|NCT05333757||Quality of life|"Adult patients treated conservatively for idiopathic scoliosis or undergoing clinical monitoring who have completed both questionnaires at least once and simultaneously and who meet the following inclusion criteria:~Age ≥ 18 years~Diagnosis of idiopathic or degenerative scoliosis with curve ≥30 ° Cobb"
89106863|NCT02836431|Experimental|DEX 1 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
89106864|NCT02836431|Experimental|DEX 2 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
89106865|NCT02836431|Experimental|DEX 1 mcg/kg Intravenous|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
89106866|NCT02833779|Active Comparator|Group Therapy Exercises|Patients will be taught exercises in groups of six persons, on a daily basis for twelve sessions.
89106867|NCT02833779|Active Comparator|Individual Manual Therapy Exercises|Patients will be taught the same exercises as in a Group 1, individually, and will receive manual therapy consisting of muscular and joint re-centering
89106868|NCT02833545|Experimental|OZONE|injection of ozone gas
89106869|NCT02833545|Active Comparator|control|injeciton of steroids intra articularly
89106870|NCT04250181||Standard RF|ablation with RF power of 30 Watts (30W) and with 25 Watts (25W) on posterior wall
89106871|NCT04250181||High RF 40W (40 Watts)|ablation with RF power of 40 watts (40W)
89106872|NCT04250181||High RF 50W (50 Watts)|ablation with RF power of 50 watts (50W)
89106873|NCT05326425|Experimental|lazertinib(YH25448)|lazertinib 240mg, once a day, oral, before disease progression
89106874|NCT02836041||Pediatrics cancer patients|Eligible patients will be approached for enrollment after their first night in the hospital (i.e.: not on day of admission). Patient/parent will be asked to complete a brief questionnaire describing the child's general sleep habits prior to admission. The parent and/or child will then be asked to complete a questionnaire describing sleep while in the hospital; this in-hospital sleep questionnaire will be obtained for 3 consecutive nights after enrollment, or until discharge, whichever is soonest. A subgroup of patients (between the ages of 5 and 18) will be invited to participate in an additional aspect of the study, where they wear an actigraph (a small device that looks like a watch) for up to 72 hours. This device reliably measures sleep by monitoring the child's motion. This will be used to relate sleep perception to more objective measures of sleep as provided by actigraphy.
89106875|NCT00784693|Experimental|Tanezumab|
89106876|NCT00784693|Placebo Comparator|Placebo|
89106877|NCT02835885|Experimental|Active tVNS Stimulation|Stimulating electrode will be placed on left tragus of subject. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied.The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
89106878|NCT02835885|Sham Comparator|Sham tVNS Stimulation|Stimulating electrode will be placed on left ear lobe of subject for sham tVNS stimulation condition. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied. The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
89106879|NCT00893763|Experimental|Pre-intubation CHX|Chlorhexidine applied to oral cavity prior to intubation
89106880|NCT00893763|Active Comparator|Control|No chlorhexidine applied to oral cavity prior to intubation
89106881|NCT04105933|Experimental|CS-CBT|Culturally sensitive-CBT intervention was comprised of 16 sessions of cognitive behavioral therapy focused on culturally-specific beliefs and attitude.
89106882|NCT04105933|Active Comparator|CBT|CBT intervention was comprised of 16 sessions of cognitive behavioral therapy.
89106883|NCT00915811|Experimental|FBATG|Haematopoietic stem cell transplantation utilising conditioning with Fludarabine, Busulphan and Thymoglobuline
89106884|NCT00892047|Experimental|1: venlafaxine plus aripiprazole|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
89106885|NCT00892047|Experimental|2: Placebo Comparator|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
89106886|NCT05549011||PENG block|This cohort will include participants to whom a PENG block is performed before positioning for spinal anesthesia
89106887|NCT05549011||SIFI block|This cohort will include participants to whom a SIFI compartment block is performed before positioning for spinal anesthesia
89106888|NCT02602561|Active Comparator|HMB|3 g HMB/day
89106889|NCT02602561|Placebo Comparator|Placebo|Placebo administered similar to the active comparator
89228305|NCT03437720|Placebo Comparator|Placebo (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
89228306|NCT03393182|Experimental|TLDG arm|"TLDG arm(Totally laparoscopic distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy."
89106890|NCT02835729|Experimental|Phase 1a|"Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (freebase formulation). These patients will additionally receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.~All current subjects will transition from indoximod freebase capsules over to indoximod HCL F2 tablets. All new subjects enrolled will also receive indoximod HCL F2 tablets."
89106891|NCT02835729|Experimental|Phase 1b (CLOSED TO ACCRUAL)|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (HCL F1 formulation). These patients will receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
89106892|NCT02835651|Experimental|Palmitic acid|Diet rich in palmitic acid
89106893|NCT02835651|Experimental|Stearic acid|Diet rich in stearic acid
89106894|NCT02833623|Experimental|Short-message-based Re-education group|"Patients receive oral and written education before H. pylori eradication therapy at first, then they receive short message re-education twice per day during therapy.~Both the content of the oral and written education and the short message re-education are same."
89106895|NCT02833623|Active Comparator|conventional education group|Patients only receive oral and written education before H. pylori eradication therapy.
89106896|NCT00787267|Experimental|Dasatinib|"After a biopsy is done to obtain fresh frozen tumor tissue (Stage I), dasatinib is to be administered as an oral dose of 70 mg twice daily on a continuous basis for 6 weeks. Every 6 weeks radiologic exam will be done to assess response. Treatment will continue until progression of disease, intolerable toxicity or patient withdrawal.~For Stage II, a biopsy to obtain fresh frozen tumor tissue will also be done. Depending on results from Stage I and results of biopsy, treatment with dasatinib will be determined."
89106897|NCT02835573||Sepsis-induced myocardial injury group|Patients admitted to the hospital with the diagnosis of Sepsis-induced myocardial injury
89106898|NCT02835573||Blank control group|Patients admitted to the hospital without the diagnosis of Sepsis-induced myocardial injury
89106899|NCT02838615|Active Comparator|epidural steroid injection|TF epidural steroid (dexamethasone) injection
89106900|NCT02838615|Active Comparator|IL epidural steroid injection|PS interlaminar epidural steroid(dexamethasone) injection
89106901|NCT05324319|Active Comparator|homologous 3rd vaccination (mRNA vaccine)|Participants will receive a third SARS-CoV-2 vaccination with the same mRNA vaccine they received for the initial prime-boost vaccination (BNT162b2 or mRNA-1273 )
89106902|NCT05324319|Experimental|heterologous 3rd vaccination (vector vaccine)|participants will receive a third SARS-CoV-2 vaccination with a vector vaccine (Ad26COVS1 or ChAdOx1-S)
89106903|NCT02603263||Workplace Restaurant Customers|"1 Group (Workplace Restaurant Customers) across 3 sites (data to be combined at end of study)~Study consists of three phases:~Pre Intervention~Intervention~Post Intervention~All phases lasted two weeks and included monitoring till receipts for meals (these were automatically generated and held on the tills electronically). The intervention phase consisted of posters being displayed in the restaurants, featuring a Social Norms Poster."
89106904|NCT04104295|Experimental|Ultrasound following X-ray|An ultrasound scan of the abdomen within 2 hours of the routine X-ray will be performed by a physician blinded to the X-ray results.
89106905|NCT02838225|Experimental|DA|docetaxel 75 mg/m², iv, day 1, doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1, every 3 weeks for 6 cycles
89106906|NCT02838225|Active Comparator|DAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
89228307|NCT03393182|Experimental|LADG arm|"LADG arm(Laparoscopy-assisted distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy"
89228308|NCT04005950||medical doctors|
89228309|NCT04005950||paramedics|
89228310|NCT00986414|Experimental|AFQ056-10mg|
89106907|NCT00928434|Experimental|DI (Degarelix Intermittent)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.~During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered."
89106908|NCT00928434|Experimental|DC (Degarelix Continuous)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall"
89106909|NCT00928434|Active Comparator|LC (Leuprolide Continuous)|"Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0, administered intramuscular (i.m.) into a large muscle, as per manufacturer's labeling directions.~One injection of 22.5 mg leuprolide 3-month depot was administered i.m. as per manufacturer's labeling directions at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).~On Investigator's discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels."
89106910|NCT02604121|Experimental|transepithelial brushing|transepithelial brushing in liquid-based technology + biopsy
89106911|NCT02831595||Patients undergoing unilateral TKA|
89106912|NCT04248699|Experimental|Lumenato Supplement|tomato oleoresin
89106913|NCT00787189|Active Comparator|The Hearing Laser|Active low level laser light therapy of 635 nanometers (nm)
89106914|NCT00787189|Placebo Comparator|Placebo Laser|inactive low level laser light therapy with no therapeutic output
89106915|NCT04248621|Experimental|Intermittent Androgen Deprivation|ADT including luteinizing hormone-releasing hormone (LHRH) agonist and antagonist, antiandrogen, or maximum androgen blockade (MAB) should be withdrawn after 6 months of ADT, if the prostate-specific antigen (PSA) reaches its nadir (< 4 ng/dL) and serum testosterone reaches castration level (< 50 ng/dL).
89228311|NCT00986414|Experimental|AFQ056-25mg|
89228312|NCT00986414|Experimental|AFQ056-50mg|
89228313|NCT00986414|Experimental|AFQ056-75mg|
89228314|NCT00986414|Experimental|AFQ056-100mg|
89228315|NCT00986414|Placebo Comparator|Placebo|
89228316|NCT01563614|Experimental|Treatment|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
89228317|NCT00543296|Experimental|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
89228318|NCT00543140|Other|REALIZE™ Swedish Adjustable Gastric Band|All subjects have the REALIZE™ Swedish Adjustable Gastric Band. Single arm - no comparator.
89228319|NCT00543062|Other|Treatment Sequence ABCD|Treatment Sequence ABCD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
89228320|NCT00543062|Other|Treatment Sequence BDAC|Treatment Sequence BDAC where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
89228321|NCT00543062|Other|Treatment Sequence CABD|Treatment Sequence CABD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
89228322|NCT00543062|Other|Treatment Sequence DCBA|Treatment Sequence DCBA where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
89228323|NCT05235074|Experimental|Dose escalation and dose expansion|The dose-escalating phase of the phase I trial of OH2 injection is divided into two dose groups (10^6 CCID50/mL and 10^7 CCID50/mL).It will be administered by Ommaya reservoir injection, and the total amount of each dose in each dose group should not exceed 2ml according to the size of the tumor cavity.
89228324|NCT03911960|Experimental|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of Acceptance and Commitment Therapy for tobacco cessation plus up to 8 weeks of nicotine patch.
89228325|NCT03911960|Active Comparator|Enhanced Usual Care|2 in-person sessions of tobacco cessation counseling, electronic referral to state quitline, up to 8 weeks of nicotine patch
89228326|NCT04005092|Active Comparator|Helmet Continuous Positive Airway Pressure(hCPAP)|Helmet CPAP produce a better physiological outcomes after 1-hour intervention
89228327|NCT04005092|Active Comparator|High Flow Nasal Cannula(HFNC)|HFNC produce a better physiological outcomes after 1-hour intervention
89228328|NCT04004624|Active Comparator|Study Arm|The left ventricle is mapped during atrial and right or left ventricular pacing (site close to the infarct) at a similar cycle length of 600ms. Radio-frequency ablation is performed selectively in areas of activation slowing (defined as ≤40ms per 5mm while voltage abnormalities and late potentials were not specifically targeted.
89228329|NCT04004624|No Intervention|Control|Patient who underwent ablation using similar technology and irrigated catheters guided by standard substrate mapping techniques.
89228330|NCT04006574|Experimental|core stabilization training|Patient with hip dysplasia aged between 20-60, non-operated
89228331|NCT04006574|Active Comparator|traditional physiotherapy and core stabilization|Patient with hip dysplasia aged between 20-60, non-operated
89228332|NCT05192720|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 100 ml/day orally for 1 month. The intervention solution is given in a neutral plastic container
89228333|NCT05192720|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 100 ml/day orally for 1 month. The placebo solution is given in a neutral plastic container (same as for intervention/experimental solution).
89228334|NCT04006184||Endovenous Thermal Ablation|Limbs treated with either radiofrequency ablation or endovenous laser ablation
89228335|NCT04006184||Cyanoacrylate Closure|Limbs treated with cyanoacrylate closure system
89228336|NCT00986804|Experimental|Level 1|Decitabine 5.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
89228337|NCT00986804|Experimental|Level 2|Decitabine 7.5 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
89228338|NCT00986804|Experimental|Level 3|Decitabine 10.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
89228339|NCT00986804|Experimental|Level 4|Decitabine 15.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
89228340|NCT05712122|Experimental|stellat gagnliyon blockadge|Ultrasound-guided stellate ganglion blockade and for blockage, the solution was prepared by adding 8 mg dexamethasone, 40 mg lidocaine, and 10 mg bupivacaine to 10 mL with physiological saline.
89228341|NCT00676091|Experimental|13vPnC|13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
89106916|NCT04248621|Active Comparator|Continuous Androgen Deprivation|ADT including LHRH agonist and antagonist, antiandrogen, or MAB without any discontinuation during study period.
89106917|NCT00784459|Experimental|Treatment with Abatacept|Administration of Abatacept intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
89106918|NCT00784459|Placebo Comparator|Placebo|Administration of placebo (normal saline) intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
89106919|NCT04257006|Experimental|patients undergoing CRRT with oXiris membrane|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.~Indications for CRRT (SCUF) with oXiris after ICU admission:~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.~Or high risk of pulmonary edema after cardiac surgery:~Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)~CVP (central venous pressure) ˃ 12 mm H2O.~PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.~In this arm the treatment of fluid overload will be provided via SCUF with oxiris membrane"
89106920|NCT04257006|No Intervention|standard protocol|"Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.~Indications for CRRT (SCUF) with oXiris after ICU admission:~1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.~Or high risk of pulmonary edema after cardiac surgery:~Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)~CVP (central venous pressure) ˃ 12 mm H2O.~PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.~In this arm the management of fluid overload will be provided via diuretics or IHD (in condition diuretics treatment resistance)"
89106921|NCT02831517|Experimental|Part 1|48 participants: Cohorts 1,2 and 3 (Single Ascending Dose of BIIB074 or placebo) in a 6:2 ratio
89106922|NCT02831517|Experimental|Part 2|16 participants: Multiple Ascending Dosing of BIIB074 or placebo in a 6:2 ratio; 3 times daily [TID] in cohort 4 for 6 days and one time (QD) for 1 day and 2 times daily [BID] in cohort 5 for 6 days and QD for 1 day
89106923|NCT04256928|Experimental|Intervention group|"This group of participants will have any body hair in the operative field clipped with an electrical clipper by hospital personnel, during preparation for planned surgery.~4 microbiological samples will be taken from all participants in this group."
89106924|NCT04256928|No Intervention|Control group|"This group of participants serve as the control group. Any body hair in the operative field is left intact.~4 microbiological samples will be taken from all participants in this group."
89106925|NCT00786799|Active Comparator|Omega-3 Fatty Acids|
89106926|NCT00786799|Placebo Comparator|Placebo|
89106927|NCT00610896||Observation|30 Patients with dualchamber pacemakers or implantable cardioverter-defibrillators (ICDs)
89106928|NCT04248777|Other|left main PCI guided by OCT|The LM PCI strategy is guided by 3 OCT runs, according to a pre-defined standardized protocol.
89106929|NCT02834949|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS will be described to participants as the College Adjustment Session and the session will be conducted using an MI plus personalized feedback approach."
89106930|NCT02834949|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
89106931|NCT02834949|No Intervention|Assessment|Participants will fill out a battery of measures and receive no intervention.
89106932|NCT00786565|Experimental|Advanced Akreos Adapt|Advanced Akreos Adapt Aspheric Intraocular Lens (IOL).
89106933|NCT00786565|Experimental|Akreos Adapt|Akreos Adapt Spherical Intraocular Lens (IOL).
89106934|NCT00610974|Active Comparator|1|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
89106935|NCT00610974|Experimental|2|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
89106936|NCT02835105|Experimental|Surotomycin 0.5 g|A single oral dose of 0.5 g surotomycin in hard gelatin capsules
89106937|NCT02835105|Experimental|Surotomycin 1 g|A single oral dose of 1 g surotomycin in hard gelatin capsules
89106938|NCT02835105|Experimental|Surotomycin 2 g|A single oral dose of 2 g surotomycin in hard gelatin capsules
89106939|NCT02835105|Experimental|Surotomycin 4 g|A single oral dose of 4 g surotomycin in hard gelatin capsules
89106940|NCT02835105|Placebo Comparator|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
89106941|NCT05285514||Brain-damaged patients under anesthesia and requiring the administration of a vasoactive agent|Patients with severe brain injuries over 18 years of age are eligible to participate in this protocol: head trauma, subarachnoid hemorrhage, ischemic or hemorrhagic stroke and requiring the administration of a vasoactive agent as part of routine medical care to restore Cerebral Perfusion pressure (CPP).
89106942|NCT04257084|Active Comparator|CE-NBI|High definition chromoendoscopy with target biopsy, at 1st surveillance colonoscopy during the trial High definition NBI with target biopsy, at 2nd surveillance colonoscopy during the trial
89106943|NCT04257084|Active Comparator|NBI-CE|High definition NBI with target biopsy, at 1st surveillance colonoscopy during the trial High definition chromoendoscopy with target biopsy, at 2nd surveillance colonoscopy during the trial
89106944|NCT02835183|Experimental|Insulin pump followed by iDECIDE|Participants will be randomly assigned to 4 weeks of using their insulin pump to decide insulin boluses and then 4 weeks of using iDECIDE to receive recommendations for insulin dosing.
89106945|NCT02835183|Experimental|iDECIDE followed by insulin pump|Participants will be randomly assigned to 4 weeks of using iDECIDE to receive recommendations for insulin dosing and then 4 weeks of using their insulin pump to decide insulin boluses.
89106946|NCT02602483|Experimental|Triple combination|Powder for oral administration
89106947|NCT02602483|Active Comparator|Ibuprofen|Powder for oral administration
89106948|NCT02602483|Active Comparator|Magnesium + ascorbic acid|Powder for oral administration
89106949|NCT02602483|Placebo Comparator|Placebo|Powder for oral administration
89106950|NCT04245813|Experimental|Intervention|"Consists of 3 interdisciplinary educational sessions and Face-to-face with a fortnightly telephone follow-up and text messages. Each session will be directed by medical staff (cardiologist and / or physiatrist) and supported by other health professionals (physical therapist, occupational therapist, nutritionist and psychologist). The educational sessions, include the topics knowledge of the disease, recognition of alarm signs, pharmacological treatment, healthy lifestyle habits, mental health and regular aerobic exercise; The entire educational component will be based on the Colombian clinical practice guide for the prevention, diagnosis, treatment and rehabilitation of heart failure."
89106951|NCT04245813|No Intervention|Control|Once the patient ends phase II of the cardiac rehabilitation program, he/she will receive the usual care, which consists of a 5-minute educational intervention by a physiatrist at the end of the functional test, where recommendations are given on healthy lifestyle habits, adherence to pharmacological treatment and regular aerobic exercise. This educational intervention will be performed after each of the functional tests (at the end of phase II of the program and during the follow-up of patients at months 1, 3, 6 and 12 during Phase III of the program) performing 5 educational interventions in total .
89106952|NCT04256694||Healthy Adult Subjects|
89106953|NCT02828943|Active Comparator|IMT with Low Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. For the comparator group, EMT will be set to 5 cm H2O, the lowest setting on the device. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with low resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training.
89228342|NCT00676091|Active Comparator|7vPnC|7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
89106954|NCT02828943|Experimental|IMT with High Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. EMT training loads in the experimental group will be set to 30% of maximal expiratory pressure. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with high resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training. At two weeks, participants will have a follow-up office visit to monitor progress and those that have completed 80% of their training sessions will increase their training to 40% of maximum inspiratory and expiratory pressures as tolerated.
89106955|NCT04256382|Experimental|experimental group|The experimental group took two-hour online course about dementia pain care in two weeks.
89106956|NCT04256382|Active Comparator|comparison group|The comparison group took two-hour online course about dementia care in two weeks.
89106957|NCT05043168||Patients with COVID-19|Polymerase Chain Reaction-positive SARS-CoV-2 infection
89106958|NCT05043168||Patients post-SARS-CoV-2 vaccination|Onset of kidney disease potentially relatable to SARS-CoV-2 vaccination based on clinical grounds
89106959|NCT02833389|Experimental|Cohort A - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 1|Participants with 0.8-6.0 centimeters square (cm^2) index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 1 for 12 weeks (a total of 4 doses).
89106960|NCT02833389|Experimental|Cohort B - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
89106961|NCT02833389|Experimental|Cohort C - UTTR1147A, 0.8-6.0 cm^2, Mild Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
89106962|NCT02833389|Experimental|Cohort D - UTTR1147A, 1.5-6.0 cm^2, Mild Infection - Dose 2|Participants with 1.5-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
89106963|NCT02833389|Experimental|Cohort E - UTTR1147A, 0.8-6.0 cm^2, No infection - Dose 3|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 3 for 12 weeks (a total of 4 doses).
89106964|NCT02833389|Placebo Comparator|Placebo|Participants will receive UTTR1147A matching placebo SC in each cohort for 12 weeks (a total of 4 doses).
89106965|NCT00784147|Active Comparator|Ibalizumab 800 mg|every 2 weeks, combined with an Optimized Background Regimen
89106966|NCT00784147|Active Comparator|Ibalizumab 2000 mg|every 4 weeks, combined with an Optimized Background Regimen
89106967|NCT04260360|Experimental|NanoDoce|Intratumoral injection of NanoDoce (2.0 to 6.0 mg/mL) at a volume not to exceed 5.0 mL. NanoDoce will be administered on up to two occasions with at least 4 weeks between doses.
89106968|NCT04256616||Bladder cancer patients|80 patients with carcinoma of the bladder; divided in 20 patients Ta (low grade), 20 patients Ta/T1 (high grade) and 20 patients T2. Only for liquid samples collection we will include 20 CIS (carcinoma in situ) patients
89106969|NCT04256616||Controls- Healthy subjects|30 age and sex-matched subjects not suffering from carcinoma of the bladder, already hospitalized in ICH; we expect to enroll 24 males and 6 females of which 10 of 40- 60 years old, 10 of 60-70 years old, 10 of >70 years old.
89106970|NCT04254822|Experimental|HVPG-guided therapy|HVPG will be determined before randomization. In this arm, patients with an adequate reduction in HVPG (responders) receive carvedilol whereas nonresponders receive TIPS.
89106971|NCT04254822|Active Comparator|Standard therapy|In this group, both responders and nonresponders will receive combination therapy of carvedilol and endoscopic variceal ligation as first-line therapy. If first-line therapy fails, TIPS will considered.
89106972|NCT00891813|Experimental|Zemplar (paracalcitol)|
89106973|NCT05528575|Experimental|Polyphenol|Consume polyphenol combination for two weeks
89106974|NCT05528575|Experimental|Prebiotic|Consume prebiotic combination for two weeks
89106975|NCT05528575|Experimental|prebiotic and polyphenol|Combination of prebiotics and polyphenols for two weeks
89106976|NCT05528575|Placebo Comparator|Placebo|maltodextrin placebo for two weeks
89106977|NCT04254900||Male wheelchair athletes|Other
89106978|NCT04254900||Female wheelchair athletes|Other
89106979|NCT02833311|Active Comparator|Computer Tablet Group|Participants will first meet once with a trained health education specialist. During this meeting the health education specialist will work with the participant in setting constructive and manageable goals and how to achieve them safely. Participants will then receive weekly follow-up phone calls to discuss progression and/or possible trouble-shooting strategies. Participants will be asked to set goals related to increasing self managing health behaviors. Participants will be encouraged to self-monitor goals, behaviors and symptoms using a computer tablet.
89106980|NCT02833311|Active Comparator|Paper and Pencil Group|Participants will first meet once with a trained health education specialist. During this meeting the health education specialist will work with the participant in setting constructive and manageable goals and how to achieve them safely. Participants will then receive weekly follow-up phone calls to discuss progression and/or possible trouble-shooting strategies. Participants will be asked to set goals related to increasing self managing health behaviors. Participants will be encouraged to self-monitor goals, behaviors and symptoms using a paper-pencil diary.
89106981|NCT02833311|Active Comparator|Contact Control Group|Participants will first meet once with a health education specialist. During this meeting the health education specialist will provide general information about engaging in healthy behaviors. Information will primarily focus on the benefits of engaging in healthy behaviors and safety precautions. Participants will then receive weekly follow-up phone calls to discuss various health topics.
89106982|NCT04255056|Experimental|Pyrotinib|"Eligible patients will receive four cycles of epirubicin and cyclophosphamide combined with pyrotinib.~Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
89106983|NCT00783835|Experimental|Methylphenidate|
89106984|NCT04248075||Control|Patients who do not want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.
89106985|NCT04248075||Dexmedetomidine|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, dexmedetomidine is administered for sedation during surgery."
89106986|NCT04248075||Propofol|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, propofol is administered for sedation during surgery."
89106987|NCT04248075||Midazolam|"Patients who want to be sedated during spinal anesthesia are included. Electroencephalogram is performed before, during, and 1 day after surgery.~After the induction of spinal anestheisa, midazolam is administered for sedation during surgery."
89106988|NCT04254744||Acyanotic children|Acyanotic children undergoing cardiac surgery due to congenital heart disease
89106989|NCT04254744||Cyanotic children|Cyanotic children undergoing cardiac surgery due to congenital heart disease
89106990|NCT05274711|Active Comparator|Conventional treatment|will receive conventional physical therapy prograM
89106991|NCT05274711|Experimental|Experimental treatment|will receive conventional physical therapy program and whole body vibration training
89106992|NCT04103827||old patients|"During the first 24 hours of the hospitalisation in the equiped room and before the presentation of the device, A first series of questions will be asked a priori to the patients. Patient will freely use Le Qoos during all his hospitalisation. After this use, a survey concerning the usability of Le Qoos will be administered to the patient, during the 48 hours before his discharge from hospital."
89106993|NCT04103827||relatives / unformal caregivers|"Before the presentation of the device, a first series of questions will be asked a priori to the unformal caregiver. Unformal caregiver will freely use Le Qoos during the hospitalization of his relative. After this use, a survey concerning the usability of Le Qoos will be administered to the unformal caregivers, 48 hours before the discharge of his hospitalized relative from hospital."
89106994|NCT04103827||profesional caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Le Qoos will be administered to professional caregivers."
89106995|NCT02831361|Experimental|Gemigliptin 50mg|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
89106996|NCT02831361|Placebo Comparator|Gemigliptin 50mg placebo|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
89106997|NCT00611052|Experimental|1|Group cognitive intervention (the Adolescent Coping with Stress)
89106998|NCT00611052|Active Comparator|2|Treatment as usual
89106999|NCT00611052|Active Comparator|3|Healthy controls, receive usual health education in school health care
89107000|NCT04103905|Experimental|MIL62|
89107001|NCT02828631|Active Comparator|Macintosh laryngoscope|Nasotracheal intubation by Macintosh laryngoscope
89107002|NCT02828631|Experimental|McGrath videolaryngoscope|Nasotracheal intubation by McGrath videolaryngoscope
89107003|NCT02828631|Experimental|Pentax videolaryngoscope|Nasotracheal intubation by Pentax videolaryngoscope
89107004|NCT02828709|Experimental|Irreversible electroporation (IRE)|"IRE is based on high current electric pulses, transferred between two or more placed needle electrodes. Charging the cell membrane causes holes in the cell membrane called nanopores, resulting in increased permeability of the cell and subsequent cell death."
89107005|NCT05036148||Patients indicated for MH screening|Patients referred to MH center for MH diagnostic
89107006|NCT05240937|Experimental|mindfulness-based self-compassion will be applied|The group in which mindfulness-based self-compassion program will be implemented.
89107007|NCT05240937|No Intervention|Control Group|The group in which mindfulness-based self-compassion program will not be implemented
89107008|NCT02831205|Experimental|ABSORB BVS|
89107009|NCT02831205|Active Comparator|XIENCE EES|
89107010|NCT04253340|Experimental|Bone mineral analyser|"Diagnostic Test: Bone mineral analyser~high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12"
89107011|NCT04260204|Active Comparator|Retrograde priming|retrograde autologous Blood Priming of Cardiopulmonary Bypass (RAP) in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
89107012|NCT04260204|Active Comparator|conventional priming|conventional cardiopulmonary priming in young children subjected to cardiac surgery for congenital heart defects with left to right shunt associated with volume or pressure overload.
89107013|NCT02831439|Experimental|Intervention|Participating health systems in Wisconsin. Interventions include: Basic public reporting and the enhanced intervention (app)
89107014|NCT02831439|Other|Control|Health systems in comparison states. Control includes: Cost savings comparison
89107015|NCT04254432|Experimental|remote ischemic conditioning arm|Device: remote ischemic conditioningRIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 30+/-2days. Other Names:• RICDevice: ambulatory blood pressure monitoring diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment
89107016|NCT02828553||Control Group - Usual Care|At the start of the study, subjects will be enrolled in usual care when admitted to the heart failure unit following standard protocols.
89107017|NCT02828553||Intervention Group - Aggressive Ambulation|After a washout period and transition to a new aggressive ambulation protocol, subjects will be enrolled to usual care + aggressive planned ambulation with a trained mobility aide.
89107018|NCT05331534|Experimental|patients with a PTSD receiving ACTo and prolonged exposure therapy.|
89107019|NCT05331534|Sham Comparator|patients with PTSD receiving ACT and prolonged exposure therapy.|
89107020|NCT00783289|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
89107021|NCT00783289|Experimental|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
89107022|NCT00783289|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
89107023|NCT00783289|Experimental|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
89107024|NCT02828787|Experimental|Urticaria|15 patients with urticaria
89107025|NCT02828787|Experimental|Psoriasis|15 patients with psoriasis
89107026|NCT02828787|Other|healthy|15 healthy control subjects
89107027|NCT04358445|No Intervention|Historical control group|The patients were treated by aneurysm clipping in our hospital in the previous nine months, and normal saline (0.9% Sodium Chloride Injection) had applied as intraoperative perfusion solution in operation of the historical control group. All of the 35 patients selected should meet the inclusion and exclusion criteria of this study.
89107028|NCT04358445|Experimental|MACSF group|Use Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) in the operation, and the remaining treatments should strictly follow the guidelines as same as the historical control group.
89107029|NCT04245579|Experimental|Experimental Group|"The experimental group carried out a 30-session multi-factorial group memory training program (UMAM method), with a frequency of three weekly sessions of 90 minutes each. The training program consists of four modules: 1- Stimulation of cognitive processes; learning and practicing internal memory strategies and solving everyday forgetfulness; 2- Instruction in basic concepts about memory; 3- Intervention on daily living and forgetting experiences, using internal and external strategies to solve everyday memory failures; 4- Metacognition or metamemory: the subjects were to reflect about their cognitive failures by analyzing the causes and variables of those failures.~In addition, the experimental group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.)."
89107030|NCT04245579|No Intervention|Control Group|The Control Group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.).
89107031|NCT02828319|Experimental|Z-213|
89107032|NCT04025281|Active Comparator|Extra virgin olive oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
89107033|NCT04025281|Active Comparator|Refined olive oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
89107034|NCT02828163|Experimental|Autologous Platelet rich plasma|Autologous platelet-rich plasma (PRP) is autologous plasma that has platelet concentration above the baseline. 1 millilitre of autologous platelet-rich plasma will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
89107035|NCT02828163|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide is an effective treatment for oral erosions of pemphigus vulgaris patients. 10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
89107036|NCT02828475||CALYPSO-augmented|Patients' postoperative care will be augmented with the CALYPSO platform.
89107037|NCT02828475||Historical Control|Patients' postoperative care was performed using standard practice, before adopting the CALYPSO platform
89107038|NCT02833155|Experimental|Entinostat and Exemestane|"Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity.~Exemestane wil be orally administered once daily for up to six months."
89107039|NCT04105387|No Intervention|Control Group|Tracheostomy change at day 7
89107040|NCT04105387|Experimental|Treatment Group|Tracheostomy change at day 4
89107041|NCT04247841|No Intervention|Phase I: Current Practice|This represents the first phase of the study in which a prospective cohort of patients will complete the survey to define baseline rates of recall of perioperative risk and level of patient satisfaction with risk discussion
89107042|NCT04247841|Experimental|Phase II Visual Aid & Scripted Risk Discussion|This will involve a group of patients randomized to receive their perioperative risk discussion supplemented with the use of a visual aid in addition to a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
89107043|NCT04247841|Active Comparator|Phase II Scripted Risk Discussion|This will involve a group of patients randomized to receive a scripted discussion of their personalized perioperative risk of myocardial injury (MINS) during their consultation with an anesthesiologist in the PSS clinic.
89107044|NCT02875730|Experimental|CMRI Pulse Sequence|Patients will have late gadolinium cardiac magnetic resonance images of the individual pulmonary veins acquired with the standard and the cylindrical navigator preparatory pulse sequences for comparison.
89107045|NCT02876666|Experimental|Coach Intervention|
89107046|NCT02876666|No Intervention|Usual Care|
89107047|NCT04672460|Experimental|Sequence 1|Participants receive Treatment B for 28 days, followed by Treatment A for 21 days, followed by Treatment C for 21 days.
89107048|NCT04672460|Experimental|Sequence 2|Participants receive Treatment A for 28 days, followed by Treatment B for 21 days, followed by Treatment C for 21 days.
89107049|NCT02874950|Experimental|Office exercise training|A package of exercise raining was defined by the researcher and one of the intervention group did it for 6 months.
89107050|NCT02874950|Experimental|Ergonomic modification|The ergonomic group, followed 6 months ergonomic modification.
89107051|NCT02874950|Experimental|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months ergonomic modification.
89107052|NCT02874950|Experimental|Control|Control group did not do any exercise and did not follow any ergonomic modification.
89107053|NCT00847912|Experimental|Arm 1: 5-fluorouracil|Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
89107054|NCT00847912|Placebo Comparator|Arm 2: Placebo|Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
89107055|NCT04116892|Active Comparator|the peeling group|the internal limiting membrane was discarded
89107056|NCT04116892|Experimental|the Cover group|the internal limiting membrane was peeled centripetally all the way up to the MH rim and the hinged ILM flap folded upside-down on top of the MH in order to bridge the entire retinal defect with a single layer.
89107057|NCT04116892|Experimental|the Fill group|"the internal limiting membrane was folded in multiple layers and deliberately stuffed or packed within the MH defect using a forceps."
89107058|NCT00701194|Experimental|1|EIFC/MTFC-P
89107059|NCT00701194|No Intervention|2|Services as usual
89107060|NCT00701194|No Intervention|Community Comparison|Non-maltreated community pre-schoolers from low-income biological families.
89107061|NCT04116424|Experimental|nurse training of the patient|
89107062|NCT04116424|Active Comparator|simple information of the patient by neurologist|
89107063|NCT00701272||1|Patients undergoing liver transplant for end-stage liver disease due to Hepatitis C
89107064|NCT00701272||2|"Control population:~Patients undergoing liver transplantation for end-stage liver disease due to alcoholic cirrhosis"
89107065|NCT00850564|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg by subcutaneous injection once daily
89107066|NCT04030858|Experimental|Treatment group|The treatment group will eat a nutrient-dense plant-based diet and attend weekly nutrition education sessions.
89107067|NCT04030858|No Intervention|Control group|
89107068|NCT04030780|Active Comparator|Cohort 1FD (on-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks on-PPI+ sporebiotics (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
89107069|NCT04030780|Placebo Comparator|Cohort 1FD (on-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks on-PPI+ placebo (2) followed by 8 weeks on-PPI+ sporebiotics (open label)
89107070|NCT04030780|Active Comparator|Cohort 2FD (off-PPI+sporebiotics)|study procedures at inclusion (1) and after 8 weeks of sporebiotics (2) followed by 8 weeks of sporebiotics (open label)
89107071|NCT04030780|Placebo Comparator|Cohort 2FD (off-PPI+placebo)|study procedures at inclusion (1) and after 8 weeks of placebo (2) followed by 8 weeks of sporebiotics (open label)
89107072|NCT00703612|Experimental|Treatment Group|This is the only arm and that is the treatment group.
89107073|NCT00837148|Experimental|Sorafenib and Dacarbazine|This study is an open label, single arm, Simon two stage, phase 2 trial of continuous, daily oral sorafenib, with intravenous dacarbazine administered every three weeks for patients with synovial sarcoma, leiomyosarcoma and malignant peripheral nerve sheath tumor.
89107074|NCT00703690|Experimental|1|MK0767; 2.5 mg/day
89107075|NCT00703690|Experimental|2|MK0767; 5mg/day
89107076|NCT00703690|Experimental|3|MK0767; 10 mg/day
89107077|NCT00703690|Active Comparator|4|fenofibrate 200 mg
89107078|NCT00703690|Placebo Comparator|5|Matching Placebo
89107079|NCT05297968|Active Comparator|Oseltamivir Phosphate For Oral Suspension/Tamiflu|Tamiflu ,6mg/ml,batch no.3235821,manufactured by F.Hoffmann-La Roche Ltd.
89107080|NCT05297968|Experimental|Oseltamivir Phosphate For Oral Suspension|6mg/ml,batch no.GH1A0003,manufactured by Qilu Pharmaceutical(Hainan) Co., Ltd.
89107081|NCT00703768||A|Patients who have been identified as having a doubling in PSA from nadir of greater than one year
89107082|NCT00703768||B|Patients who have been identified as having a doubling in PSA from nadir of less than one year.
89107083|NCT00849940|Experimental|CAS NIRS FORE-SIGHT oximeter|Pediatric patients presenting for cardiac catheterization.
89107084|NCT02613130|Experimental|Two-Step stannous fluoride toothpaste|Two-Step stannous fluoride toothpaste
89107085|NCT02613130|Active Comparator|Potassium nitrate toothpaste|Potassium nitrate toothpaste
89107086|NCT00849472|Experimental|Treatment Arm|"Preoperative~Cycles 1-4 Doxorubicin 60 mg/m2 IV over 15 minutes + Cyclophosphamide 600 mg/m2 IV over 30 minutes of Day 1 every 21 days~followed by:~Cycles 5-8 Paclitaxel 80 mg/m2 IV over 60 minutes (Days 1, 8, and 15) every 28 days in combination with pazopanib (800 mg) PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning on Day 1 of the first paclitaxel cycle Until 7 days before surgery~Followed by Surgery~Postoperative Pazopanib 800 mg PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning 4-6 weeks after surgery 6 months from first postoperative dose"
89107087|NCT04116580||Allergic patients to raw apple and birch|Single-group studies about 28 patients allergic to birch and no longer eating raw rosaceae for at least 6 months. Patients brought back into contact with this family of fruits via the raw golden apple according to an Ultra-Rush protocol.
89107088|NCT00701350||1|Women presenting with preterm gestation and ruptured membranes
89107089|NCT00782509|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
89107090|NCT00782509|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
89107091|NCT00782509|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
89107092|NCT04116346|No Intervention|Fasting group|Fasting for both solids and fluids for up to 6 hours pre-procedure
89107093|NCT04116346|Experimental|Non Fasting group|Usual meal on the day of the procedure and allowed to drink as usual
89107094|NCT05598112|Experimental|FMT capsules|FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 36, week 48, week 60, week 72, week 84.
89107095|NCT05598112|Placebo Comparator|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 36, week 48, week 60, week 72, week 84.
89107096|NCT00701428|Active Comparator|1|Hypertensive Men and Women Without OSA on Losartan (n=30)
89107097|NCT00701428|Active Comparator|2|Hypertensive Men and Women With OSA on Losartan (n=30)
89107098|NCT00701428|Experimental|3|Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)
89107099|NCT00927810|Experimental|canakinumab|
89107100|NCT00848926|Experimental|Brentuximab vedotin|
89107101|NCT02602951|Experimental|Control|Pilot subjects
89107102|NCT02602951|Experimental|Patients|Patients with an intracranial disorder or needing a supraaortic trunk MRA
89107103|NCT00847132|Experimental|Collaborative Care|Collaborative Care Treatment: A study care manager provides depression education, consults with study psychiatrist to develop individualized treatment recommendations, and collaborates with patient and medical team to implement those recommendations
89107104|NCT00847132|Active Comparator|Usual Care|Usual Care Treatment: Primary medical providers are informed that the patient has depression and that treatment is recommended.
89107105|NCT04254510|Experimental|Study Group|Myofascial relaxation technique
89107106|NCT04254510|No Intervention|Control group|
89107107|NCT00706888|Active Comparator|1|Female with active product
89107108|NCT00706888|Active Comparator|2|Male with active product
89107109|NCT00706888|Placebo Comparator|3|Female with placebo
89107110|NCT00706888|Placebo Comparator|4|Male with placebo
89107111|NCT05019534|Experimental|Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)|Cetuximab and Camrelizumab in the fixed dose Vemurafenib have two dose groups: 960mg qd or 960mg bid
89107112|NCT00707044|Experimental|A|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
89107113|NCT00707044|Active Comparator|B|control group, care as usual, 24 hours intensive care stay
89107114|NCT04254120|Active Comparator|Cognitive-behavioral therapy (CBT)|
89107115|NCT04254120|Experimental|Integrated motivational interviewing and CBT|
89107116|NCT00707122|Other|1, Albumin and Crystalloids|Treatment
89107117|NCT00707122|Other|2, Crystalloids|Control
89107118|NCT04254042|Active Comparator|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
89107119|NCT04254042|Active Comparator|Zofenopril Arm|30 mg Zofenopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
89107120|NCT04247178||Patients undergoing elective orthopaedic surgery|
89107121|NCT04247178||Healthy Volunteers|
89107122|NCT00918138|Experimental|Saxagliptin + Metformin XR + matching Metformin XR placebo|(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
89107123|NCT00918138|Active Comparator|Metformin XR + Metformin XR + matching Saxagliptin placebo|(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
89107124|NCT04253574||Patients with malignant melanoma|258 patients (w: 112, m: 146 age: 61±16 years) met the primary inclusion criteria. They were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)).
89107125|NCT00782275|Experimental|bevacizumab and temsirolimus|"bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)~temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22~1 cycle=28-days~There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression."
89107126|NCT04107571||Cohort|
89107127|NCT02602873||good efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can reach effective outcome.
89107128|NCT02602873||poor efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can not reach effective outcome.
89107129|NCT00791557|Experimental|Infliximab|Single arm open label IV Infliximab given at weeks 1,2,14,22
89107130|NCT04107337|Experimental|Experimental group|Experimental group (N=10): this group will conduct a vocal work session based on semi-occluded vocal-tract exercises with a straw.
89107131|NCT04107337|Other|Control group|Control group (N=10): the second group acting as control group will perform a vocal work session based on open mouth exercices (vocalizations).
89107132|NCT00920790|Experimental|KW-0761|
89107133|NCT04253886|Active Comparator|Group A|The Ovassapian Fibreoptic Intubating Airway has a flat lingual surface that widens distally. This provides better retraction of the tongue to prevent it and the soft tissues of the anterior pharyngeal wall from herniating around the side of the airway. The airway has a pair of vertical sidewalls and two pairs of curved guide walls at its proximal section. These walls are separated by a gap which allows removal of the airway after intubation has been completed
89107134|NCT04253886|Active Comparator|Group B|"Fekry airway:~● It has two parts are: Airway body& Special connector~Airway body consists of:~Flange → it is the buccal end it is 7 cm wide to prevent it from~moving deeper into mouth & may also serve to fix airway in place.~Bite Portion → it is straight & fits between teeth &oral cavity.~Oral straight part → open anterior lingual part; it varies in length according to size~Pharyngeal curved part → extends backwards to correspond the shape oropharynx and ends below laryngeal inlet.~The connector: it is a special type (two sizes: adult and pediatric) can attach to all ventilating machines& it has a teeth rest act as a bite block."
89107135|NCT00781963|Experimental|CBT-I|Manual-based cognitive behavioral therapy for insomnia (CBT-I) provided in 5 individual or group sessions by a non-clinician sleep coach.
89107136|NCT00781963|Active Comparator|Control|Non-directive sleep education provided in 5 group sessions by a health educator.
89107137|NCT05176314|Experimental|Rosuvastatin + Pirtobrutinib|Rosuvastatin administered orally on day 1 followed by rosuvastatin administered with pirtobrutinib on day 6 orally. Pirtobrutinib alone administered orally from days 7 to 12 followed by rosuvastatin administered with a single dose of pirtobrutinib on day 13. Pirtobrutinib alone administered from days 14 to17.
89107138|NCT04017325||TOOKAD VTP TREATMENT|Subjects randomized in the treatment arm (TOOKAD VTP treatment) in the initial period of the study.
89107139|NCT04017325||Active surveillance|Subjects randomized in the control group (active surveillance) in the initial period of the study.
89107140|NCT00920556|Experimental|Treatment|"5.0 g SRT501 will be administered for 20 consecutive days in a 21 day cycle for a maximum of 12 cycles. SRT501 will be administered at the same time each morning (approximately 15-30 minutes after breakfast) on all dosing days. No SRT501 administration will occur on Day 21 of each cycle.~After the first two cycles of SRT501, any subject who exhibits stable disease or better with SRT501 monotherapy (5.0 g/day) will continue for an additional two cycles. If, after the first two cycles, a subject exhibits PD, that subject will receive bortezomib (1.3 mg/m2 on Day 1, Day 4, Day 8, and Day 11 in a 21 day cycle) in conjunction with SRT501. Bortezomib will be administered prior to breakfast and SRT501 administration.~If after two additional cycles of SRT501 monotherapy (4 cycles total), the subject exhibits a MR or better, they they will remain on SRT501 therapy. If PD or SD are exibited, they are to undergo bortezomib regiment listed above."
89107141|NCT04901676|Experimental|Leronlimab|Leronlimab subcutaneously once a week (up to 4 doses) until hospital discharge. The first dose will be of 700 mg, followed by weekly doses of 350 mg.
89107142|NCT04901676|Placebo Comparator|Placebo|Placebo subcutaneously once a week (up to 4 doses) until hospital discharge
89107143|NCT04843176|Active Comparator|Prototype AI algorithm|In-house prototype deep learning artificial intelligence algorithm
89107144|NCT04843176|Placebo Comparator|LI_RADS interpretation|LI-RADS criteria will be assessed independently by two specified abdominal radiologists with at least 10 years of experience in cross-sectional abdominal imaging
89107145|NCT04831086|Experimental|Intervention|"In the intervention arm, the management will be optimized according to the risk of the predictive model. The predictive model of intra-amniotic infection includes maternal C-reactive protein (CRP) (in mg/L) and amniotic fluid glucose (in mg/dL), and the predictive model of spontaneous preterm delivery within 7 days includes gestational age (in weeks), cervical length (in mm), amniotic fluid glucose (in mg/dL) and Interleukin (IL)-6 (in a log10 scale). High risk will be defined when the risk is > 10% in the predictive model of spontaneous delivery in 7 days and > 20% in the predictive model of intra-amniotic infection:~If low-risk: we will optimize the standard management reducing the dose of steroids (e.g not administering second doses), tocolysis duration and facilitating discharge home.~If high-risk: we will follow the standard management of each center and we will treat with antibiotics"
89107146|NCT04831086|No Intervention|Control|In the control arm the standard management of each center will be followed regarding doses of steroids, duration of tocolysis or maternal stay length duration.
89107147|NCT02603965|Experimental|Diagnostic (Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT at 30 minutes and 2 hours post-injection. Patients then undergo radical prostatectomy within 1 to 3 weeks after scans.
89107148|NCT02602795|Experimental|Distress Tolerance (DT)|Acceptance and Commitment Therapy based Distress Tolerance (DT) intervention to facilitate opioid detoxification delivered in six 50-minute individual telehealth sessions.
89107149|NCT02602795|Active Comparator|HIV/STI Intervention|Information Motivation Behavioral model based HIV/STI risk reduction intervention delivered in six 50-minute individual telehealth sessions.
89107150|NCT02602795|No Intervention|Treatment As Usual (TAU)|Traditional treatment given to patients who elect to transition to XR-NTX at the treatment sites.
89107151|NCT04103047||SAD group|Adult surgical patients who are due to undergo general anaesthesia and requiring SAD insertion will be identified on the day of surgery.
89107152|NCT00918684|Experimental|Escitalopram|12-week open label with 2 week placebo period (14 weeks total)
89107153|NCT05543707|Experimental|PBI-0451 (Pomotrelvir)|PBI-0451(Pomotrelvir): 2 x 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
89107154|NCT05543707|Placebo Comparator|Placebo|PBI-0451(Pomotrelvir): 2 x placebo to match PBI-0451(Pomotrelvir) tablets administered orally twice daily (BID) with food for 5 days (10 total doses)
89107155|NCT04105465|No Intervention|Surgery without trial (PJ) device|All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein.
89107156|NCT04105465|Active Comparator|Surgery with trial (PJ) device|Use of the PJ was limited to the randomised side only. All steps of surgery are conducted as per standard practice in accordance with the current practice at the time. In all cases a bilateral inguino-femoral groin node dissection was performed, with en-bloc removal of the superficial and deep inguinal nodes with conservation of the long saphenous vein. Haemostasis was ensured with diathermy and ties and just prior to wound closure, the surgeon used the PlasmaJet on the indicated groin to seal the lymph vessels and channels at a setting of 40% by spraying the argon plasma over the entire exposed surgical field at a distance of 10 mm from the surface to the tip of the instrument.
89107157|NCT04105309|Experimental|Implementation Intention (IMP)|"Following review of a psychoeducational packet regarding making changes for weight loss, all participants were assigned five dietary goals (e.g. avoiding high-fat foods, eating five servings of fruits and vegetables a day) and a goal to weight daily. Participants in the IMP condition formed an implementation intention for each of the goals at the baseline session. Two examples of implementation intentions were provided for each goal as a model. Participants thought about how they would best be able to achieve the outlined goals in their life on a daily basis (goal-aligned behavior), as well as when, where, and how they would initiate these new behaviors (retrieval cue). Participants then created and wrote down a unique implementation intention for each of the goals using the sentence structure If/When I _______, then I will ______. No repetitions or combinations of implementation intentions were allowed for standardization across participants."
89107158|NCT04105309|Experimental|Enhanced Implementation Intention (IMP+)|Participants completed all tasks of the IMP group and additionally, individuals in the IMP+ condition received fluency training and text message reminders. Fluency training occurred weekly using an online survey tool. On fluency training days, participants received a survey link via email, which consisted of six multiple-choice questions for participant's unique implementation intentions. Participants had to correctly identify their matching goal-aligned behavior among three distractor behaviors as quickly as possible and were given corrective feedback if they chose incorrectly. Text messages containing all six implementation intentions as well as goal reminders that were obtained by asking participants to write down their reasons for wanting to lose weight were sent on four days each week of the intervention (16 days total). At baseline, participants chose how text messages were bundled and when they were sent. Text schedules stayed constant across the study.
89107159|NCT04105309|Active Comparator|Goal Intentions (GOL)|Participants in the GOL condition were assigned the five dietary goals and the daily weighing goal. No additional intervention was given.
89228343|NCT02558933|Experimental|Epigallocatechin gallate (EGCG) treated|Intervention: Epigallocatechin gallate (EGCG) administered FAS children: An oral dose of 9 mg/Kg/day of EGCG will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment
89228344|NCT02558855|Active Comparator|Thrust Joint Manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying.
89228345|NCT02558855|Sham Comparator|Non-thrust Joint Manipulation|Patients will receive non-thrust joint manipulation, oscillations into slight rotation, without cavitation, to their lumbar spine in side lying.
89228346|NCT00812201||1|
89107160|NCT04883424|Experimental|Diabetes Education Program Based on Health Belief Model|Experimental group After the diabetic patients were determined according to the research criteria, they were randomly divided into intervention and control groups. First, pre-tests were applied to diabetics and family members in the experimental group. Diabetes Education Program Based on Health Belief Model It will be administered in two sessions to people with diabetes and their family members. This program; definition of diabetes, the importance of healthy nutrition in diabetes, the importance of exercise, the importance of regular medication, fingertip blood glucose measurement, acute and chronic problems that may develop in diabetic patients, diabetic foot care, personal self-care and family support. A reminder text message will be sent twice a week to diabetics and family members in the intervention group to manage their diabetes well. Once a month, both the diabetic patient and their family member will be called by phone for counseling.
89107161|NCT04883424|No Intervention|Control Group|First of all, pre-tests will be applied to diabetic patients in the control group. Diabetics in this group will not be intervened and their final tests will be made 3 months after the pre-test.
89107162|NCT00786409|Other|Gardasil|30 patients will receive 0.5 ml Gardasil vaccine at months 0,2, and 6.
89107163|NCT05150886||Patients at low risk of intubation|Patients with a ROX index of 4.88 and above measured at the 12th hour of hospitalization in the intensive care unit.
89107164|NCT05150886||Patients at hihg risk of intubation|Patients with a ROX index of less than 4.88, measured at the 12th hour of admission to the intensive care unit.
89107165|NCT04583982||Prospective Study Arm SARS-CoV-2 negative and positive samples|
89107166|NCT04881396||All haemodialysed patients with a medical prescription of BTN162b2 mRNA Cov-19 vaccine|Serological response is defined by a 4 fold increase of IgG anti-spike protein of SARS-Cov2 between Day 0 (before vaccination) and after complete vaccination (evaluated at Day 7 - 14 post-boost).
89107167|NCT00919854|Experimental|Darunavir (DRV)+Ritonavir (rtv)|Before dose adjustment, oral darunavir suspension (100 mg/mL): 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg. After dose adjustment, 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg twice daily if weight more than or equal to 15 kg. Before dose adjustment, oral ritonavir solution (80 mg/mL): 3 mg per kg body weight twice daily and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
89107168|NCT04698720|Experimental|Muscle Relaxation with Guided Imagery|Participants in the Experimental Group 1 will receive four individual 45-minute sessions, every two weeks, of progressive muscle relaxation intervention with guided imagery focused on ulcer healing, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
89107169|NCT04698720|Experimental|Hypnosis with Guided imagery|Participants in the Experimental Group 2 will receive a four individual 45-minute sessions, every two weeks, of hypnosis intervention with guided imagery focused on ulcer healing, carried out by the qualified Hypnotherapists external to the research study, on the day of the Diabetic Foot appointments.
89107170|NCT04698720|Placebo Comparator|Active Control Group|Participants in the ACG will receive four individual 45-minute sessions of neutral guided imagery placebo focused on the patient's life before the foot ulcer, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
89107171|NCT04698720|No Intervention|Passive Control Group|Participants in the PCG will not receive any intervention or placebo session.
89107172|NCT04678518|Active Comparator|SIRS|Patients will be grouped according to the presence or absence of SIRS criteria into group I (SIRS)
89107173|NCT04678518|Placebo Comparator|NON-SIRS|Patients will be grouped according to the presence or absence of SIRS criteria into group II (Non-SIRS)
89107174|NCT04669782|Experimental|Patients with osteoporosis treated with teriparatide + Vitamin K|Patients will have to take teriparatide (standard of care) + Vitamin K (MK7) at the dosage of 375 microg / day
89107175|NCT04669782|Active Comparator|Patients with osteoporosis treated with teriparatide|Patients will have to take teriparatide (standard of care)
89107176|NCT04669782|No Intervention|Controls|Subject without osteoporosis, no treatment will be administered.
89107177|NCT04667754|Experimental|10 week ICBT|CBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend ~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
89107178|NCT04253028|Experimental|Subjects with NERv's Inline Device Attached|This arm contains subjects which will have NERv's Inline Device attached to their peritoneal drain after bariatric surgery (this includes: Roux-en-Y Gastric Bypass (RYGBP), Sleeve Gastrectomy (SG), Gastric Plication and Duodenal Switch).
89107179|NCT04252872|Experimental|Sequence A|"Period 1 : HCP0605+HGP1405~Period 2 : HCP1401"
89107180|NCT04252872|Experimental|Sequence B|"Period 1 : HCP1401~Period 2 : HCP0605+HGP1405"
89107181|NCT04252482|Experimental|cpap|usage cpap 3month
89107182|NCT04252482|No Intervention|Usual care|Usual care 3month
89107183|NCT00891735|Experimental|Ranibizumab 0.5 mg monthly|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.
89107184|NCT00891735|Experimental|Ranibizumab 2.0 mg monthly|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.
89107185|NCT00891735|Experimental|Ranibizumab 0.5 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.
89107186|NCT00891735|Experimental|Ranibizumab 2.0 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.
89107187|NCT04252248|Experimental|Stratum 1|Patients having received standard, definitive chemoradiotherapy according to current, national guidelines with curative intent and being at high risk for disease recurrence (patients are considered at high risk if they display a positive nodal status of their cancer (anogenital HPV-induced tumor) or if the tumor is locally advanced and/or if they display a positive nodal status with extracapsular extension (head and neck HPV-induced tumor). Study therapy (as additional therapy to standard chemoradiation) will start after a time interval of 6-8 weeks after finishing chemoradiotherapy
89107188|NCT04252248|Experimental|Stratum 2|"Patients with non-curative and progressive disease having received all standard, national approved systemic therapies (according to current, national guidelines with regard to the specific tumor entity), and/or presently not eligible for a respective therapy, and/or refused respective therapy. Study treatment thereby represents a potential palliative, last-line systemic therapy option (late salvage)."
89107189|NCT04252326|Active Comparator|Doctor|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
89107190|NCT04252326|Active Comparator|Nurse|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
89107191|NCT04252326|Active Comparator|Dentist|Knowledge, Attitudes and Practices on Drug Hypersensitivity Reactions in Children
89107192|NCT04833192||experimental group|patients diagnosed with subclinical hypercortisolism as assessed by an endocrinologist.
89107193|NCT04833192||control grpup|patients diagnosed with nonfunctional adrenal adenoma as assessed by an endocrinologist.
89107194|NCT04251858|Experimental|Athletes with oral problems|Athletes with periodontal diseases or gingivitis
89107195|NCT04251858|No Intervention|Athletes without oral problems|Athletes diagnosed without oral problems
89107196|NCT00891657|Experimental|SprayShield™|SprayShield™
89107197|NCT00891657|No Intervention|Control|No adhesion barrier administered.
89107198|NCT04814082|Active Comparator|Medial-Pivot Knee System|Total Knee Arthroplasty will be done by implanting the MicroPort Medial Pivot Knee System into subjects.
89107199|NCT04814082|Active Comparator|Single Radius Design Total Knee System|Total Knee Arthroplasty will be done by implanting the Stryker Triathlon Tritanium Knee System into subjects.
89107200|NCT04252170|Experimental|Feasibility study, Stroke Survivors|BAC feasibility study at PowerBack, Piscataway NJ, with stroke patients.
89107201|NCT02831127|Experimental|short message service group|Patients in this arm received conventional instructions plus short message reminder.
89107202|NCT02831127|Active Comparator|conventional group|Patients in this arm just received conventional instructions.
89107203|NCT02828397|Experimental|Reference Drug|REGN2222 Reference Formulation
89107204|NCT02828397|Experimental|Test Drug|REGN2222 Test Formulation
89107205|NCT05137353|Experimental|Music Training (RitMoZ Training)|12 sessions spread in the course of 1.5 months: each session has a duration of 90 minutes; each week will have 2 sessions
89107206|NCT05137353|Active Comparator|Spelling Training|12 sessions spread in the course of 1.5 months: each session has a duration of 90 minutes; each week will have 2 sessions
89107207|NCT04251468|Other|GEPII|All patients who completed the study.
89107208|NCT04247373|Experimental|laparoscopic gastrectomy with pneumoperitoneum|
89107209|NCT02828007|Experimental|Treatment/Intervention|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
89107210|NCT04251234|Experimental|Healthy controls|"No co-morbid medical or psychiatry diagnoses~No family history of mental illness~No current medication use~Non-smoking"
89107211|NCT04251234|Experimental|Bipolar I disorder|"Clinical diagnosis of Bipolar I disorder~Can be (not required, not exclusionary) taking lithium and/or sodium valproate and/or antidepressants~Can be (not required, not exclusionary) light smokers"
89107212|NCT04795596|Experimental|surgery + chemotherapy|surgical resection for recurrent platinum resistant ovarian cancer followed by second line chemotherapy as per the investigator's choice
89107213|NCT04795596|Active Comparator|chemotherapy alone|second line chemotherapy according to investigator's choice
89107214|NCT04245267|No Intervention|Control|Patients in the wait-list being attended with the standard model of care for diabetes in primary care units.
89107215|NCT04245267|Experimental|DIABEMPIC program|Intervention comprised by an interdisciplinary team care, patient-centered care approach, structured diabetes education program, promotion of self-management, audit, and guaranteed supply of anti-diabetic medication.
89107216|NCT04250766|Other|Single arm echo-guided uterine biopsy|
89107217|NCT02832921|Experimental|VR cognitive tasks + treadmill|This is the primary group of interest, in which the investigators hypothesize the greatest cognitive gains since motor activity will augment cognitive activity.
89228347|NCT00678041|Experimental|Arm 1: Nitrofurantoin Group|extended release nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
89228348|NCT00678041|Placebo Comparator|Arm 2: Placebo Group|identical appearing placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
89228349|NCT04331561|Experimental|Sensory Re-weighting|Adults with self-reported visually-induced dizziness will be recruited to help establish the feasibility and tolerability of the testing and training methods, as well as observe for any effects of the sensory re-weighting intervention. Tests involve assessing motion sickness, vision, somatosensation, balance, and perception of verticality. The treatment provided is designed to facilitate re-weighting of sensory feedback for orientation and balance. Participants will serve as their own controls.
89228350|NCT03903822|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
89228351|NCT03903822|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
89228352|NCT03903822|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
89228353|NCT03903822|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
89228354|NCT03903822|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
89228355|NCT03903822|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
89228356|NCT03903822|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
89228357|NCT03903822|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
89228358|NCT00677807|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89228359|NCT00677807|Experimental|Indacaterol 300 µg|"Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89228360|NCT00677807|Placebo Comparator|Placebo|"Placebo once-daily (o.d.) via SDDPI.~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
89228361|NCT04003350|Active Comparator|Opioid Regimen|"Weeks 1-4~Oxycodone 5 mg PRN q4h (30 tablets)~Tramadol 50 mg PRN q6h (30 tablets)"
89228362|NCT04003350|Experimental|Multimodal pain regimen with PRN opioids|"Weeks 1-4~Tylenol 1000 mg q8h (standing)~Meloxicam 15 mg qD (standing).~Gabapentin 200 mg BID (with morning and evening Tylenol dose)~Metaxalone 800mg PO TID (Tizanidine 2mg q8h if insurance coverage is not possible for metaxalone)~Esomeprazole 20mg daily if not already on another H2 blocker or PPI~Oxycodone 5 mg PRN q4h (30 tablets)~Tramadol 50 mg PRN q6h (30 tablets)"
89228363|NCT00748007|Experimental|A|
89228364|NCT00748007|Placebo Comparator|Placebo|Placebo
89228365|NCT00748163|Experimental|Stage IV Non-Small Cell Lung Cancer Patients|Patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.
89228366|NCT00748319|Other|1|Detection of KIR receptor
89228367|NCT00748397|Experimental|A|
89228368|NCT00687401|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6, and 14.
89228369|NCT00485693|Active Comparator|Bupivacaine HCl|Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
89228370|NCT00485693|Other|SKY0402|SKY0402 at various dosage levels. Single administration.
89228371|NCT00748475|Experimental|Neurofeedback|
89228372|NCT00758537||Patients with chronic kidney disease stage 3|
89228373|NCT00758537||patients with chronic kidney disease stage 4|
89228374|NCT00758537||patients with chronic kidney disease stage 5 (ESRD)|
89228375|NCT00758537||Controls (no kidney disease)|
89228376|NCT00538902|Placebo Comparator|Placebo|Placebo administered subcutaneously every other week
89228377|NCT00538902|Experimental|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously every other week
89228378|NCT00538902|Experimental|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week
89228379|NCT00541970|Experimental|Cervarix 1/Placebo Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
89228380|NCT00541970|Experimental|Cervarix 1/Placebo/Cervarix 1 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
89228381|NCT00541970|Experimental|Cervarix 2/Placebo/Cervarix 2 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
89228382|NCT00541970|Experimental|Cervarix 2 Group|Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
89228383|NCT00687323|Experimental|Temozolomide|Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), then 200 mg/m^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m^2/day for 21 days of each 28-day cycle (12 cycle maximum).
89228384|NCT00989742|Active Comparator|Doxycycline|
89228385|NCT00989742|Placebo Comparator|Placebo|
89228386|NCT05408208|Active Comparator|Methotrexate|Intralesional injection of methotrexate
89228387|NCT05408208|Active Comparator|Triamcinolone Acetonid|Intralesional injection of trimethinolone acetonide
89228388|NCT02559245|Experimental|Ficus carica|45 grams Ficus carica before breakfast and lunch with 1 glass of water every day respectively (total consumption: Ficus carica 90g/d)
89228389|NCT02559245|Experimental|Descurainia Sophia|30 grams Descurainia Sophia before breakfast and lunch with 1 glass of water every day respectively (total consumption: Descurainia Sophia 60g/d)
89107218|NCT02832921|Active Comparator|VR cognitive tasks - treadmill|This group will be an active control, receiving the VR cognitive training without treadmill walking, to examine whether the motor component augments the effect of the VR in the experimental group.
89107219|NCT02832921|Sham Comparator|scientific TV documentary + treadmill|This group will watch a scientific TV documentary while walking on the treadmill. This control group will permit examination of whether the VR cognitive training, which requires an especially active cognitive effort while walking on the treadmill, is more advantageous than passively watching a scientific TV documentary while performing the same motor task as the experimental group.
89107220|NCT02832921|No Intervention|Passive control|This group of participants will not receive any intervention but will be assessed with the same battery of assessments as the other three groups, permitting comparisons of the cognitive and neurobiological outcomes of the intervention groups to that of the natural course of decline/deterioration of these at-risk individuals.
89107221|NCT00917124|Active Comparator|INVOS|INVOS : Cerebral oxygenation (rSO2) monitoring with INVOS. If rSO2 decreased for more than 20% from patient's baseline value, simple interventions were performed to prevent brain injury. These interventions included: repositioning of head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion.
89107222|NCT00917124|No Intervention|CONTROL|The CONTROL arm did not have INVOS or any other cerebral oxygenation monitoring, so interventions to control cerebral oxygenation were not performed.
89107223|NCT02832765|Experimental|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions
89107224|NCT02832765|Experimental|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis
89107225|NCT02832765|Experimental|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions
89107226|NCT02832765|Experimental|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis
89107227|NCT02832999|Experimental|sub cutaneous liraglutide|once daily add-on subcutaneous injection of Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week
89107228|NCT02832999|Active Comparator|Oral Vildagliptin|Once daily oral 100mg of Vildagliptine for two weeks
89107229|NCT04245033|Experimental|IPTsc arm|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment in school children (IPTsc) will be given in all wards in the IPTsc arm at an interval of four months, three times a year.
89107230|NCT04245033|No Intervention|Control|No intervention will be given to wards randomised in this arm
89107231|NCT02832843||NTM lung disease|Patients with NTM lung disease satisfying American Thoracic Society guidelines
89107232|NCT02832843||Healthy control|The age-, sex-matched control subjects without pulmonary diseases
89107233|NCT02830971|Other|Clinical specific education|Providing clinical skills conditions
89107234|NCT04244799|Experimental|Behavioral nudges|Schools randomized to this arm will receive the behavioral nudges intervention and the Philippines Department of Education national WASH in Schools (WinS) policy.
89107235|NCT04244799|Active Comparator|Control group|Schools in the control group will not receive handwashing nudges but will receive DepEd's national WASH in Schools (WinS) policy.
89107236|NCT02830737|Active Comparator|Traditional RFA|Using Traditional RFA for the treatment of small hepatocellular carcinoma
89107237|NCT02830737|Experimental|No-touch RFA|Using No-touch RFA for the treatment of small hepatocellular carcinoma
89107238|NCT04244643||Patients with soft contact lenses|
89107239|NCT00889863|Experimental|Canakinumab|In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
89107240|NCT00889863|Placebo Comparator|Placebo|Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
89107241|NCT02832453|Other|Lifestyle counseling|This group will receive lifestyle counselling but not supervised exercise training sessions
89107242|NCT02832453|Experimental|Aerobic interval training|This group will receive lifestyle counselling plus supervised high intensity (80%VO2max) interval exercise training sessions
89107243|NCT02832453|Active Comparator|Traditional continous training|This group will receive lifestyle counselling plus supervised moderate intensity (60%VO2max) continous exercise training sessions
89107244|NCT00915018|Experimental|neratinib plus paclitaxel|
89107245|NCT00915018|Active Comparator|trastuzumab plus paclitaxel|
89107246|NCT04247295|Experimental|Wood cast|Participants will be trialling the woodcast plaster method
89107247|NCT04247295|Placebo Comparator|Traditional Cast|Traditional cast used to be compared to.
89107248|NCT04246905|Active Comparator|sulforaphane|sulforaphane treatment arm
89107249|NCT04246905|Placebo Comparator|placebo|placebo arm
89107250|NCT02830503|Experimental|Intervention|Feeding tube daily replacement
89107251|NCT02830503|No Intervention|Control|Feeding tubes replaced as normal practice in the department (normally once a week).
89107252|NCT05251740|Experimental|Standing program|The child completes a 60-minute home standing program five days per week over eight weeks.
89107253|NCT02832219|Experimental|Molecular hydrogen|Molecular hydrogen, tablet, 2 g/day, 4 weeks
89107254|NCT02832219|Placebo Comparator|Placebo|Cellulose, tablet, 2 g/day, 4 weeks
89107255|NCT02827695|Experimental|SMASK|Subjects will receive electronic pill tray with reminder functions activated and Bluetooth blood pressure monitor and phone app.
89107256|NCT02827695|Other|EnhancedSC|Subjects will receive daily attention control texts with healthy lifestyle information and continue to use the pill tray without reminder functions.
89107257|NCT04528446||BoneGN participants|Participants who have already been recruited into the CureGN study, or meet its criteria.
89107258|NCT04528446||Healthy subjects|A reference population of healthy subjects who are age- sex- BMI-matched to the CureGN study participants.
89107259|NCT02830347||Amoxicillin|No randomization is performed. Patients who are prescribed antibiotics by the clinician performing the tooth extraction ( based on case complexity and intra operative judgement) are recruited into this group.The principal investigator is not involved in the decision to prescribe antibiotics or not.
89107260|NCT02830347||No Amoxicillin|Patients who do not receive antibiotics after extractions are recruited into this group.
89107261|NCT04200495||Healthy Controls|No sleep-wake disorder present
89107262|NCT04200495||Active Sleep-Wake Disorder|Presence of Sleep-Wake Disorder
89107263|NCT05253456|Experimental|intervention group|patients underwent our newly modified technique for hypospadias repair
89107264|NCT04246749|Experimental|Part A: [14C]-CRN00808 Oral Solution|Single oral dose of CRN00808 containing [14C]-CRN00808
89107265|NCT04246749|Experimental|Part B: CRN00808 Oral Capsule w/ [14C]-CRN00808 IV microtracer|Single oral dose of CRN00808 followed by [14C]-CRN00808 IV microtracer injection
89107266|NCT05253300|Experimental|Semi Recumbent|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group."
89107267|NCT05253300|No Intervention|Control|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient has pain, the time when the patients' pain started was recorded, and only analgesic medication was administered to the control group."
89107268|NCT05253222|Experimental|retrograde imaging by colonic TET|Contrast fluid will be injected through colonic TET in participants with bowel obstruction. Image parameters detected by CT and X-ray fluoroscopy will be evaluated.
89107269|NCT02832609|No Intervention|sitting position|measurement in the sitting position
89107270|NCT02832609|Active Comparator|supine position|measurement in the sitting position
89107271|NCT00916578|Experimental|Radiation Therapy + Capecitabine|"Capecitabine 825 mg/m2 twice a day. One of the two daily doses of capecitabine should be taken approximately 2 hours before receiving radiotherapy. The first day of Capecitabine is same day that radiotherapy is started, and last day that Capecitabine is given is last day of radiotherapy. Capecitabine administered only on days patient receives radiation therapy.~Radiation therapy dose 50-57 Gy to initial clinical target volume (CTV, gross disease + tissue at risk for micrometastatic disease including margin around gross disease and draining regional lymphatics)."
89107272|NCT02832297|Other|Vectra DA (Arm A)|Treatment intensification with non-biologic DMARDS guided by Vectra DA
89107273|NCT02832297|Other|Usual care (Arm B)|Treatment intensification by usual care without using Vectra DA
89107274|NCT05253144|Experimental|Arm A: Prioritise Radiotherapy|Radical radiotherapy to macroscopic tumour and/or to the tumour bed if already excised, plus a wide margin.
89107275|NCT05253144|Experimental|Arm B: Prioritise Surgery|Wide Local Excision (WLE), aiming for complete excision of all MCC, plus a wide margin
89107276|NCT04801056|Experimental|TB006|"During the SAD study, subjects will receive a single dose of TB006 (at the dosage level of 10 ~ 50 mg/kg) administered via i.v. infusion for 60 mins.~In addition, a sentinel cohort of 5 mg/kg will be open for enrollment and double-blinded randomization first, with 2 patients randomized to active/TB006 arm, to assess preliminary safety and tolerability of study drug, and to determine cohort expansion and dose escalation. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start."
89107277|NCT04801056|Placebo Comparator|Placebo|"During the SAD study, subjects will receive a single dose of the placebo administered via i.v. infusion for 60 mins.~In addition, the corresponding sentinel placebo group will include 1 patient to placebo arm. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start."
89228390|NCT02559245|No Intervention|controled|participants will follow their usual diet
89107278|NCT02830113|Experimental|non-surgical periodontal treatment|One session of non-surgical periodontal treatment consisting of a complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution.
89107279|NCT02830035|Active Comparator|Anatomical Landmark Technique|Traditional anatomical landmark technique based paramedian spinal anesthesia
89107280|NCT02830035|Active Comparator|Real-time Ultrasound-guided Technique|Ultrasound-guided paramedian spinal anesthesia Intervention: Ultrasound-guided Technique
89107281|NCT04247529|Placebo Comparator|No exposure to conflict|
89107282|NCT04247529|Experimental|Exposure to conflict|
89107283|NCT02827539|Other|Research|If the patient is randomized to the Research Arm, the physician will begin the procedure utilizing LessRay enhanced fluoroscopic images.
89107284|NCT02827539|Other|Control|For patients in the control arm standard fluoroscopy will be used with the C-arm set to the conventional full dose setting
89107285|NCT04675866|Experimental|camrelizumab+albumin-bound paclitaxel+S-1|camrelizumab+albumin-bound paclitaxel+S-1
89107286|NCT04635930|Experimental|Taping plus Traditional exercises|"kinesio tape for improving the alignment of the scapula by inhibiting the hyperactive upper trapezius and facilitating the weak serratus anterior muscleStretching of the tight muscles of upper limb.~Reaching forward sidewise and backward.~Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).~Prone lying weight bearing on elbows (four point kneeling)~side sitting with weight bearing on the effected side, for 5 minutes.~Wall pushups.~Catching and throwing of ball"
89107287|NCT04635930|Active Comparator|Traditional exercises|"Stretching of the tight muscles of upper limb.~Reaching forward sidewise and backward.~Strengthening of the weak muscles by resisted exercise. 2-3 sets of 8-12 repetition, 4 times per week (ACSM guidelines).~Prone lying weight bearing on elbows (four point kneeling)~side sitting with weight bearing on the effected side, for 5 minutes.~Wall pushups.~Catching and throwing of ball"
89107288|NCT00889707|Experimental|Active Drug|PRX302
89107289|NCT00889707|Placebo Comparator|Placebo|Placebo
89107290|NCT02829801|Experimental|AAT arm|AAT and cognitive stimulation and rehabilitation of social tie.
89107291|NCT02829801|Other|control group|Cognitive stimulation and rehabilitation of social tie.
89107292|NCT02827383|Experimental|Stair Climbing 4x/day|Participants use the stair climber 4 times per day, for 4 minutes at a time. Total dose = 16 minutes.
89107293|NCT02827383|Experimental|Stair Climbing 8x/day|Participants use the stair climber 8 times per day, for 2 minutes at a time. Total dose = 16 minutes.
89107294|NCT02829879|Experimental|arginine|25 volunteers with dentin sensitivity
89107295|NCT02829879|Active Comparator|potassium nitrate|25 volunteers with dentin sensitivity
89107298|NCT05249283|Experimental|Patients|Patients with acute or chronic otoneurological disorders, presenting or having experienced dizziness and / or balance disorders
89107299|NCT05249283|Other|Control subjects|
89107300|NCT04201509||ADHD group|Participants in the clinical group were recruited to the project when they were assessed for and diagnosed with ADHD at the Neuropsychiatric Unit of the CAP Clinic in Lund in 2011-2012. The ADHD group was treated as usual in the clinic and re-assessed during 2014-2015.
89107301|NCT04201509||Non-clinical group|Participants in the non-clinical group were recruited recruited 2012 from schools in the same district and among children of the same average age as the ADHD-group 2012. The non-clinical group did not have any intervention during the follow-up time. Th non-clinical group was re-assessed during 2015.
89107302|NCT05246007|Experimental|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
89107303|NCT05246007|Placebo Comparator|Placebo group|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
89107304|NCT00914940|Experimental|Arm 1|"CONDITIONING: Patients undergo total-body irradiation twice daily on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine IV over 30 minutes on days -6 to -2. TRANSPLANTATION: Patients undergo infusion of CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Cohort A: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 50 followed by standard taper in the absence of grade II-IV acute GVHD. Cohort B: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 30 followed by rapid taper in the absence of grade II-IV acute GVHD."
89228391|NCT05358756|Experimental|Treatment A :Fasted|A single adminstration of SACT-1 (150 mg rilpivirine oral suspension) after a supervised overnight fast of at least 10 hours.
89228392|NCT05358756|Experimental|Treatment B: Fed|A single adminstration of SACT-1 (150 mg rilpivirine oral suspension) after a supervised overnight fast of at least 10 hours followed by a high-fat, high calorie meal (fed).Subjects started the standardized high-fat, high-calorie breakfast 30 minutes prior to dosing and consumed this meal within the 30 minutes before dosing.
89228393|NCT05358756|Active Comparator|Treatment C: Fed|Adminstartion of Edurant, 150 mg (6 × 25 mg rilpivirine, oral tablets), after a supervised overnight fast of at least 10 hours followed by a high-fat, high calorie meal (fed).Subjects started the standardized high-fat, high-calorie breakfast 30 minutes prior to dosing and consumed this meal within the 30 minutes before dosing.
89228394|NCT00758615|Experimental|I|Walking School Bus Intervention
89228395|NCT00758615|No Intervention|C|Usual school procedures for student transportation to school
89228396|NCT00758693|Experimental|1|Bendamustine + Rituximab
89228397|NCT01564212|Active Comparator|standard airflow and forced air warming|Subjects will lie on operating room bed with standard airflow and forced air warming.
89228398|NCT01564212|Active Comparator|laminar airflow with surgical drapes|Subjects will lie on operating room bed with laminar airflow device on and surgical drapes surrounding bed.
89228399|NCT01564212|Active Comparator|laminar aiflow with forced air warming|Subjects will lie on operating room bed with laminar airflow on and warming forced air.
89228400|NCT01564212|Active Comparator|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow and surgical drapes surrounding bed.
89228401|NCT05407896|No Intervention|Comparison arm|Patients and caregivers in this arm will receive existing counselling by trained counsellors.
89228402|NCT05407896|Experimental|Intervention arm|Patients and caregivers in this arm will receive counselling with the newly developed web-based decision aid (myKIDNEY) by trained counsellors.
89228403|NCT00989820|No Intervention|Surgery|This is the standard arm. Surgery without hyperbaric oxygen treatment
89228404|NCT00989820|Experimental|Hyperbaric oxygen therapy with surgery|Intervention arm. Hyperbaric oxygen therapy with surgery.
89228405|NCT00748631|Experimental|1|balloon Kyphoplasty
89228406|NCT04742114|Sham Comparator|the face mask without EPAP|Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The face mask without the application of EPAP will be used.
89228407|NCT04742114|Experimental|the face mask with EPAP|Will be collected clinical and anthropometric data of the participant. Will have the pulmonary function test every two months. Will be collected CT scan data. Patients will conduct 6MWT every two months. Borg scale data will be collected.The application of EPAP (15cmH2O) via face mask will be used.
89228408|NCT00758849|Placebo Comparator|1|
89228409|NCT00758849|Active Comparator|2|
89107305|NCT02829567|Experimental|Oral hygiene counseling and motivational interviewing|This group will receive a session of oral hygiene counseling and a single session of motivational interviewing to increase the readiness of change.
89107306|NCT02829567|No Intervention|Oral hygiene counseling|
89107307|NCT04244721|Sham Comparator|a group of children receiving the usual therapy (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
89107308|NCT04244721|Experimental|a group of children receiving TAU plus the PACT intervention.|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
89107309|NCT00631800|Placebo Comparator|Placebo|Placebo
89107310|NCT00631800|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 7, 14
89107311|NCT00631800|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 7, 14
89107312|NCT02827461||MZ|Monozygotic twins
89107313|NCT02827461||DZ|Dizygotic twins
89107314|NCT00835978|Other|A|Randomized arm
89107315|NCT00835978|Other|B|Randomized arm
89107316|NCT00835978|Other|C|Non-randomized arm
89107317|NCT02831907||Cardiac surgery patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
89107318|NCT02832141||Group A|Group A: immediate effects: T0, Grade 3 central thoracic mobilization from posterior-to-anterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3 central thoracic mobilization from anterior-to-posterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
89107319|NCT02832141||Group B|Group B: immediate effects: T0, 3 central thoracic mobilization from anterior-to-posterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3-4 central thoracic mobilization from posterior-to-anterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
89107320|NCT04247685|Experimental|12-Lead ECG|The study group patients will have MRI with 12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical
89107321|NCT04247685|Active Comparator|3-lead ECG gating system|the control group will have MRI with 3-lead ECG gating which is standard of care.
89107322|NCT02829645|Other|Eating disorders|
89107323|NCT00701506|Experimental|1|"15 Patients (may be expanded) will receive stimulation with the following parameters:~20-minute session, to each affected knee, 3 times per week for 12 weeks.~PENS for 20 minutes:~Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~Minimal twitch for 5 minutes.~Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~Electrodes placed on quadriceps and hamstrings."
89107324|NCT00701506|Placebo Comparator|2|"5 Patients (may be expanded) will receive stimulation with the following parameters:~20-minute session, to each affected knee, 3 times per week for 12 weeks.~Placebo PENS for 20 minutes:~Electrodes placed on quadriceps and hamstrings."
89107325|NCT04246827|Experimental|Enhanced Lifestyle Weight Management Condition|The Enhanced Lifestyle Weight Management condition participants participated in a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors was integrated into a lifestyle behavioral weight loss intervention.
89107326|NCT04246827|No Intervention|Standard Care Control|Participants received standard care of rheumatoid arthritis.
89107327|NCT00704002|Experimental|A|antegrade intramedullary splinting
89107328|NCT00704002|Active Comparator|B|conservative treatment
89107329|NCT02831829|Active Comparator|Water-based exercise training group|"Intervention: Patients randomized to the water-based exercise training group will undergo water-based exercise training. The immersed exercise will include two session of aerobic (water-based) and calisthenic exercise per day, six days of a week, each lasting 30 minutes."
89107330|NCT02831829|Active Comparator|Land-based exercise training group|"Patients randomized to the land-based exercise training group will undergo exercise training which will include two aerobic and calisthenic exercise session per day, six days of a week, lasting 30 minutes"
89107331|NCT02831829|No Intervention|Control group (usual care)|Control group: patients randomized in control group will have usual care with no exercise
89107332|NCT04042636||1|Patients with Bacteremia after trauma
89107333|NCT04042636||2|Patients with non-bacteremia after trauma
89107334|NCT02829411|Active Comparator|Employment Services only|'Workforce Readiness Program'. job readiness workshop, organized into ten daily sessions over two weeks. The main content of these sessions will be a program-developed workforce readiness training, developed with funding from a DOL Career Pathways Bridge grant.
89107335|NCT02829411|Experimental|Employment Services with HMRE content|'Workforce Readiness Program supplemented with Relationship Education': job readiness workshop, organized into ten daily sessions over two weeks. Program will add approximately 17 hours of content from the Within My Reach relationship education curriculum to the two-week job readiness workshop - and add up to eight additional one-hour relationship skills education sessions that customers can attend in the five weeks after completing the initial two-week job readiness workshop
89107336|NCT00914628|Experimental|A|HSV-TK engineering donor Lymphocytes
89107337|NCT00914628|Active Comparator|B|T-cell depleted or T-cell replete strategies
89107338|NCT00922792|Experimental|A|
89107339|NCT00922792|Experimental|B|
89107340|NCT05493904|Active Comparator|OCT-guided PCI arm|Use of OCT will be strongly recommended at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT evaluation after stent implantation will be mandatory. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
89107341|NCT05493904|Active Comparator|Angiography-guided PCI arm|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. In case of staged procedure during the same hospitalization, following the initially allocated strategy would be strongly recommended.
89107342|NCT01077518|Experimental|Ofatumumab and Bendamustine (Arm A)|Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
89107343|NCT01077518|Active Comparator|Bendamustine (Arm B)|Up to 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days
89107344|NCT04203186|Active Comparator|Group 1 - PfSPZ, (NF54) strain|Group 1 (N=9) will receive PfSPZ Challenge (NF54) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum (Pf) NF54 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
89107345|NCT04203186|Active Comparator|Group 2 - PfSPZ, (7G8) strain|Group 2 (N=9) will receive PfSPZ Challenge (7G8) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum 7G8 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe
89107346|NCT00835120|Experimental|Pioglitazone|Pioglitazone has been approved by the U.S. Food and Drug Administration (FDA) to help people who are diagnosed with diabetes
89107347|NCT00914316|Active Comparator|Phase 1-Ranolazine, Phase 2-Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
89107348|NCT00914316|Active Comparator|Phase 1 -Ranolazine, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
89107349|NCT00914316|Active Comparator|Phase 1 -Placebo, Phase 2 -Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
89107350|NCT00914316|Placebo Comparator|Phase 1 -Placebo, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
89107351|NCT00701740|Active Comparator|A|A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
89107352|NCT00701740|Active Comparator|B|11 subjects received only the same moisturizer/sunscreen
89107353|NCT04938882|Placebo Comparator|Normal saline in transversus abdominis plane block|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
89107354|NCT04938882|Active Comparator|Ropivacaine in transversus abdominis plane block|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
89107355|NCT04938882|Active Comparator|Compound lidocaine at low-concentration in transversus abdominis plane block|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
89107356|NCT04938882|Active Comparator|Compound lidocaine at high-concentration in transversus abdominis plane block|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
89107357|NCT00704080|Experimental|1|
89107358|NCT05253066|Experimental|Chidamide group|Chidamide combined with exemestane (+/- goserelin)
89107359|NCT05253066|Active Comparator|chemotherapy group|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
89107360|NCT04797858|Experimental|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to others in their social networks.
89107361|NCT04797858|Active Comparator|Test referral distribution|Participants in the test referral arm receive multiple COVID-19 test referral cards and text messages to distribute to others in their social networks.
89107362|NCT04303442||Patients undergoing TEP|Patients diagnosed with unilateral or bilateral primary and/or recurrence inguinal hernia undergoing Total Extraperitoneal laparoscopic hernia repair.
89107363|NCT00827632|Active Comparator|Normal Weight group|Participants with a BMI of 19-24.9 kg/m^2
89107364|NCT00827632|Active Comparator|Obese group|Participants with a BMI of 30-39.9 kg/m^2
89107365|NCT02874638|Experimental|BASE egg protein|0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.
89107366|NCT02874638|Experimental|BCAA-enriched egg protein|branched-chain amino acid-enriched egg protein
89107367|NCT02874638|Experimental|small amount of essential amino acids|small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE
89107368|NCT02874638|Experimental|large amount of essential amino acids|large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA
89107369|NCT04303598|Experimental|FNC Treatment Group|FNC 3mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;3TC placebo 1 tablet;daily oral before bedtime
89107370|NCT04303598|Active Comparator|3TC control group|3TC 300mg, 1 tablet;TDF 300mg, 1 tablet;EFV 200mg, 2 tablets;FNC placebo 1 tablet;daily oral before bedtime
89107371|NCT00707200||1|Cases: Severe inpatient malaria, survivors or decedents. Severe malaria consists of any one or combination of severe malarial anemia (SMA), cerebral malaria (CM), lactic acidosis (LA), or a respiratory distress syndrome with hypoxia.
89107372|NCT00707200||2|Controls: Controls consist of mildly-affected children with P falciparum malaria who are either managed as inpatients or outpatients.
89107373|NCT02874716|Experimental|Tuberculosis Program (PPIA)|In Patna, 171 of the 321 participants were randomly selected to be sensitized and engaged into the program in Phase 1, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if engaged into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free or subsidized diagnostic testing and free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests and anti-TB treatment; financial incentives to providers based on certain indicators; training opportunities, and access to a referral network.
89107374|NCT02874716|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining part of the sample in Patna selected randomly will be phased into the program at least a year after the PPIA arm in Phase 2. However, during the year of the study, they will not be engaged into the program.
89107375|NCT00704236|Experimental|A|
89107376|NCT00704236|Placebo Comparator|B|
89107377|NCT04748718|Experimental|Injury Prevention Arm|
89107378|NCT04745520|Experimental|Rib fixation (medical devices)|Surgery and pain medication. The pain of patients will be treated with rib fixation and pain medication.
89107379|NCT04745520|Active Comparator|Pain medication (comparator treatment)|Pain medication only.
89107380|NCT04636086|Experimental|Test treatment|Test Treatment: Ampoule for enteral use containing 25,000 IU/mL of cholecalciferol taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
89107381|NCT04636086|Placebo Comparator|Placebo treatment|Placebo Treatment: Ampoule of placebo for enteral use containing excipient only taken according to the following scheme: one ampoule on Day 1, Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 and Day 36.
89107382|NCT04336410|Experimental|Group 1: INO-4800|Participants will receive one ID injection of 1.0 milligram (mg) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
89107383|NCT04336410|Experimental|Group 2: INO-4800|Participants will receive two ID injections of 1.0 mg (total 2.0 mg per dosing visit) of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
89107384|NCT04336410|Experimental|Group 3: INO-4800|Participants will receive one ID injection of 0.5 mg of INO-4800 followed by EP using the CELLECTRA® 2000 device per dosing visit.
89107385|NCT00827242|Experimental|Tadalafil|
89107386|NCT00827242|Placebo Comparator|Placebo|
89107387|NCT01077362|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 40. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
89107388|NCT01077362|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 40. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
89107389|NCT01077362|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
89107390|NCT00846586|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89228410|NCT05334186|Experimental|Telehealth Reasoning Training|Telehealth-delivered inductive reasoning training will focus on improving the ability to solve problems that require linear thinking and that follow a serial pattern or sequence. Participants will be taught strategies to identify patterns to solve problems. These problems involve identifying the pattern in series of numbers and letters, or recognizing patterns in everyday activities, like dosing for medications. Training will consist of ten training sessions, over 5 weeks, and will be conducted over Zoom. Each training session is 60-75 minutes long and typically consists of (a) 10 minutes of introductory training exercises for basic mental abilities, such as finding patterns in schedules, (b) training exercises for everyday tasks, such as filling out medication charts, recycling charts, and understanding medicine bottle labels, and (c) a 20-question practice assessment.
89228411|NCT05070884||non respondants of neo treatment|those patients with no response or partial response when administered with Chemotherapy prior to sugery
89228412|NCT05357820|Experimental|Itraconazole cohort|
89228413|NCT05357820|Experimental|Rifampicin cohort|
89228414|NCT00748787|Experimental|1|
89228415|NCT00748787|Placebo Comparator|2|
89228416|NCT05712044|No Intervention|Basal|Samples will be taken to participants.
89228417|NCT05712044|Experimental|15 days folate suplementation|5mg tablets of folic acid will be given to participants every 8 hours for a period of 15 days, then samples are to be taken in duplicate for each individual.
89228418|NCT05712044|Experimental|30 days folate suplementatio|5mg tablets of folic acid will be given to participants every 8 hours fora a period of 30 days, then samples are to be taken in duplicate for each individual.
89228419|NCT05360316|Placebo Comparator|ESWT|Patients assigned to the ESWT group received ESWT over the plantar fascia, three days/week, for six weeks. In addition patients participated additional in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.
89228420|NCT05360316|No Intervention|Placebo|Routine therapy Patients participated in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.
89228421|NCT04059731|Experimental|Surmimed®OPD Drink|Normocaloric oligomeric-hyperprotein supplement
89228422|NCT04059731|Active Comparator|Atempero® or Impact®|Inmunonutrition
89228423|NCT00986960|Active Comparator|Adrenocorticotropin hormone|Patients receive the hormone
89228424|NCT00986960|Placebo Comparator|Placebo|Patients receive placebo only
89228425|NCT00758927|Placebo Comparator|2|Placebo administration for 10 weeks with exercise and diet therapy
89228426|NCT00758927|Experimental|1|Omacor 4 gram per day with exercise and diet therapy for 10 weeks
89228427|NCT05711966|Experimental|IN-REC-SUR-E|INRECSURE infants will receive preintubation medications and HFOV starting at MAP 8 cmH2O; frequency 15 Hz, with volume-guarantee (1.5-1.7 mL/kg). The I:E will be 1:1. An oxygenation guid-ed lung recruitment procedure will be performed using stepwise increments then decrements in MAP. The starting MAP will be increased stepwise as long as SpO2 improves reducing the FiO2 keeping SpO2 within the target range (90-94 %) until the oxygenation no longer improves or the FiO2 is equal to or less than 0.25 (opening MAP). Next, the MAP will be reduced stepwise until the SpO2 deterio-rates (closing MAP). After a second recruitment maneuver at the opening pressure, the optimal MAP will be set 2 cmH2O above the closing MAP. Then 200 mg/kg of poractant alfa (Chiesi Farmaceutici S.p.A., Parma, Italy) via a closed administration system will administrate. Infants with sufficient res-piratory drive will be extubated within 30 minutes after surfactant administration starting nCPAP (7-9 cm H2O) or NIPPV.
89107391|NCT00846586|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89107392|NCT00785785|Experimental|Nilotinib|nilotinib 400 mg twice a day
89107393|NCT00785785|Active Comparator|Imatinib|imatinib 400 mg once daily
89107394|NCT00707278|Experimental|All patients|All participants enrolled.
89107395|NCT01077284|Experimental|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
89107396|NCT01077284|Active Comparator|Allopurinol|Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
89107397|NCT01077284|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 6 months.
89107398|NCT00704314|Active Comparator|1|Simvastatin therapy, 80 mg/d for 8 weeks
89107399|NCT00704314|Placebo Comparator|2|Placebo, one pill daily for 8 weeks
89107400|NCT04103437||recreational runners|Recreational runners (minimum of 2 running session and 20km of total mileage per week), with seasonal best on half-marathon comprised between 1h20' and 2h00'. Age > 18 and < 60 years. Free from musculoskeletal injuries from at least three months.
89107401|NCT00704392|Experimental|1|
89107402|NCT00704470|Active Comparator|1|Classic one-day simulator training for intensivists.
89107403|NCT00704470|Experimental|2|Crew resource management training
89107404|NCT04103125|Other|Janesse|Janesse® 20 (Cross-linked Hyaluronic Acid) Injection: follow the instruction for use
89107405|NCT04103203|No Intervention|New diagnostic results NOT available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. However, results will not be communicated. Only the results of routine blood cultures will be availabtle to the treating physician. No intervention will take place, care is provided according to normal routine practices.
89107406|NCT04103203|Experimental|New diagnostic results available|Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician. Results of routine blood cultures will also be available for all patients. Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.
89107407|NCT00826618|Experimental|Ranibizumab|
89107408|NCT01077128||Patients with psoriasis|All eligible patients with psoriasis treated with Adalimumab
89107409|NCT02876822|Experimental|Vitamin D|Enrolled subjects will receive one observed oral vitamin D dose (based on current vitamin D status and rounded to the nearest 5000IU) within 2 weeks prior to their HSCT.
89107410|NCT04304222|Other|Sequence A|To receive the conventionally made denture framework then the 3D printed denture framework.
89107411|NCT04304222|Other|Sequence B|To receive the 3D printed denture framework then the conventionally made denture framework.
89228428|NCT05711966|Active Comparator|Less Invasive Surfactant Administration|By contrast, infants allocated to the LISA group will receive 200 mg/kg of poractant alfa (Chiesi Farmaceutici S.p.A., Parma, Italy) according to the following protocol: during nasal CPAP with a pressure of 7-8 cm H2O, surfactant will be administered over 0.5-3 min using the SurfCath™ tracheal instillation catheter (VYGON S.A. - Ecouen, France), or a 4- 6 F end-hole catheter, according to local protocols. After the same pre-procedural medications, the catheters will be positioned during laryngoscopy with or without Magill forceps. The catheter will be connected to a syringe pre-filled with the surfactant, and the surfactant is instilled slowly. The infant's mouth will be closed. In cases of apnoea or bradycardia, positive pressure ventilation will be performed until recovery. After surfactant administration, CPAP (7-9 cm H2O) therapy (16) or NIPPV will be continued.
89228429|NCT05407506|Experimental|THYROID AI|
89228430|NCT00759005|Experimental|A, 4|
89228431|NCT04360070|Experimental|Ketamine Arm|Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment
89228432|NCT04360070|No Intervention|Control Arm|Patients randomized to the control arm will not receive ketamine as part of their sedation medications during their cardiac arrest treatment.
89228433|NCT04354688|Experimental|T3 Certain Tapered implant with DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
89228434|NCT04354688|Active Comparator|T3 Certain Tapered implant without DCD|Implant will be placed in the maxilla or mandible in a single stage manner and loaded with prosthesis after 6 weeks of healing. Final restorations will take place no later than 4 months following implant placement surgery. The implants will be evaluated yearly for 2 years.
89228435|NCT00749021|Active Comparator|Regimen 1|Intravitreal injection of Ranibizumab monthly for 12 months.
89228436|NCT00749021|Active Comparator|Regimen 2|Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
89228437|NCT00749021|Active Comparator|Regimen 3|Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
89228438|NCT00749021|Active Comparator|Regimen 4|Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
89107412|NCT04030624|Experimental|Remote Electronic Patient Monitoring|"The Remote Electronic Patient Monitoring intervention will entail monitoring of vital sign data and patient reported assessments to address and manage any concerning issues identified.~The Remote Patient Monitoring system uses algorithms that can indicate when patient vitals and patient-reported outcomes have changed.~Automatic patient surveys are sent to the patient with results displayed on the clinician user interface (i.e., dashboard) on a computer located in the clinical area.~Qualitative interviews with patient participants and their oncology clinicians using a semi-structured interview guide will be conducted."
89107413|NCT00627146|Placebo Comparator|B|
89107414|NCT00627146|Active Comparator|A|ChAgly CD3
89107415|NCT02874872|Experimental|OASIS Collaborative|The nursing homes in this arm will receive facilitated implementation of two tools aimed at minimizing unnecessary antibiotic use. Facilitated implementation includes coaching of the nursing home staff on use of the tools. In addition, nursing home management will be coached on how to monitor implementation fidelity, antibiotic utilization, and consequences to over- and under-utilization of antibiotics as feedback on the effectiveness of the intervention. Finally, nursing home management will receive coaching on how to develop and implement a sustain plan for the OASIS intervention.
89107416|NCT02874872|No Intervention|Control|The nursing homes in this arm will continue care as usual, with no tools or facilitated implementation.
89107417|NCT00826540|Experimental|Treatment (sorafenib tosylate and bevacizumab)|Patients receive sorafenib tosylate orally twice daily on days 1-5 and 8-12 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and then periodically during study treatment for laboratory biomarker and pharmacogenetic studies
89107418|NCT01077050|Other|SciBase III|Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.
89107419|NCT04303052|Active Comparator|over-the-wire technique with 145 cm guidewire|Catheter tip placement using Seldinger over-the-wire technique with 145 cm guidewire
89107420|NCT04303052|Active Comparator|modified technique with 70 cm guidewire|Catheter tip placement using Seldinger modified technique with 70 cm guidewire
89107421|NCT04303130|Experimental|Camrelizumab (SHR-1210) Combined With Endostar|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
89107422|NCT00707356|Experimental|WST11(TOOKAD® Soluble)|Treatment with WST11-mediated VTP
89107423|NCT04304456||HA-BSI|Patients with HA-BSI treated in an ICU
89107424|NCT02612740|Experimental|Test Group|The bone defect was filled with granules of deproteinized bovine bone (Bio-Oss, Geistlich Pharm, AG Wolhausen, Switzerland)
89107425|NCT02612740|No Intervention|Control Group|No filling material was used in the bone healing
89107426|NCT02874560||Schizophrenia|350 patients will be included in the study. The centers selection is planned with 100 hospital-based psychiatrists, in centers for preventive medicine (CMP) or in private settings. Each investigator should consecutively enroll patients fulfilling the selection criteria to participate in the study (mean expected number of participants per center is around 10).
89107427|NCT04799990||Risankizumab|Participants will receive risankizumab as prescribed by their physician.
89228439|NCT04733846||corneal trauma sutured with Vicryl 10-0 monofilament|corneal trauma sutured with Vicryl 10-0 monofilament will be included. They will have data collection of medical records.
89228440|NCT05407350||Crohns disease patients|Adult patients with moderately to severely active CD
89107428|NCT04799990||Comparator Group 1|Participants will receive biologics other than interleukin (IL)-23 antagonists as prescribed by their physician.
89107429|NCT04799990||Comparator Group 2|Participants will receive non-biologic systemic small molecules as prescribed by their physician.
89107430|NCT02611726|Active Comparator|Acupuncture treatment|Individualized acupuncture needle insertion according to traditional Chinese and Japanese medicine on top of standard medical care during In-Vitro-Fertilization. Acupuncture needles will be inserted to body surface points following traditional diagnosis (anamnesis, tongue, pulse and abdomen inspection) according to practitioner discretion.
89107431|NCT02611726|No Intervention|Control|Standard medical care during In-Vitro-Fertilization.
89107432|NCT00704548|Active Comparator|1|Simvastatin 40 mg
89107433|NCT00704548|Placebo Comparator|2|
89107434|NCT00592384|Placebo Comparator|placebo|identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks
89107435|NCT00592384|Experimental|venlafaxine XR|venlafaxine XR 37.5 - 300 mg/day for 12 weeks
89228441|NCT04048889|Experimental|Popliteal plexus block and continuous femoral nerve block|
89228442|NCT04048889|Active Comparator|continuous femoral nerve block|
89228443|NCT04005560|Other|patient|Score of PedSQL who is the Pediatric Quality of Life Questionnaire
89107436|NCT00707590|Experimental|Part A|"A: BMS-767778, Oral Solution, Oral, 1 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~B: BMS-767778, Oral Solution, Oral, 3 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~C: BMS-767778, Capsules, Oral, 10 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~D: BMS-767778, Capsules, Oral, 30 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~E: BMS-767778, Capsules, Oral, 100 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~F: BMS-767778, Capsules, Oral, 300 mg, once daily, 2 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 2 days~G: BMS-767778, Capsules, Oral, 600 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day"
89107437|NCT00707590|Experimental|Part B|"A: BMS-767778, Capsules, Oral, 10 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~B: BMS-767778, Capsules, Oral, 30 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~C: BMS-767778, Capsules, Oral, 100 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~D: BMS-767778, Capsules, Oral, 300 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~E: BMS-767778, Capsules, Oral, 600 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days"
89107438|NCT00707590|Experimental|Part C|"A: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days~B: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days"
89107439|NCT05473468|Experimental|Treatment group|
89107440|NCT00846040|Experimental|Obese RF then RC|Obese adult volunteers (BMI above 30 kg/m2) randomized to receive an 85% reduction of baseline dietary fat (RF) for 2 weeks. After a washout period of 2 weeks, they then received a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks
89107441|NCT00846040|Experimental|Obese RC then RF|Obese adult volunteers (BMI above 30 kg/m2) randomized to receive a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks. After a washout period of 2 weeks, they then received an 85% reduction of baseline dietary fat (RF) for 2 weeks.
89107442|NCT00846040|Active Comparator|Lean Control|Lean adult volunteers (BMI below 30kg/m2) placed on a weight-maintenance diet using a standard diet composition of 50% carbohydrate, 35% fat, and 15% protein on an out-patient basis
89107443|NCT00707668||Control|Chung-ju cohort populations aged over 30 year-old
89107444|NCT02611336|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
89107445|NCT04115722||Agroup of IBD patients in activity|
89107446|NCT04115722||Normal controlled group|
89107447|NCT00707824|Placebo Comparator|1|1= placebo
89107448|NCT00707824|Active Comparator|2|2=nalbuphine 5 mg
89107449|NCT00707824|Active Comparator|3|3=nalbuphine 10 mg
89107450|NCT00826228|Experimental|PTH/Weight-Bearing|
89107451|NCT00825994|Experimental|Omega-3|omega-3 fatty acids, 2grams qd [every day] (2 x 1 gram tablets), PO [by mouth]
89107452|NCT00825916|Experimental|High Dose|
89107453|NCT00825916|Placebo Comparator|Placebo|
89107454|NCT00825916|Experimental|Low Dose|
89107455|NCT00791479|Experimental|0.1 milligram (mg) LY2189265|LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)
89107456|NCT00791479|Experimental|0.5 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)
89107457|NCT00791479|Experimental|1.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)
89107458|NCT00791479|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
89107459|NCT00791479|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) once weekly (QW)
89107460|NCT00890097|Experimental|AL-8309B 1.0%|AL-8309B 1.0% Ophthalmic Solution, 1 drop in each eye twice daily for 30 months, up to a maximum of 36 months
89107461|NCT00890097|Experimental|AL-8309B 1.75%|AL-8309B 1.75% Ophthalmic Solution, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
89107462|NCT00890097|Placebo Comparator|Vehicle|AL-8309B Vehicle, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
89107463|NCT02831751|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
89107464|NCT02831751|Experimental|60 µg/strain of Quadrivalent VLP Vaccine|
89107465|NCT02831751|Active Comparator|FluLaval® Tetra (15 µg/strain)|
89107466|NCT02831751|Active Comparator|Fluzone® High-Dose (60 µg/strain)|
89107467|NCT00913458|Experimental|1|etanercept + methotrexate; etanercept + methotrexate
89107468|NCT05208333|Other|Albendazole treatment|"Treatment drugs: Albendazole (Zentel) tablets 200mg, Glaxo Wellcome Production France manufacturer .~Dose: 15 mg/kg divided into 2 times/day x 5 days, orally after meals. Procedure: Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection Advice on preventing re-infection according to Vietnam Ministry of Health disease prevention guidelines"
89107469|NCT04201041|Active Comparator|trans-gluteal approach|received pudendal nerve pulsed radiofrequency through trans-gluteal approach
89107470|NCT04201041|Active Comparator|trans-vaginal approach|received pudendal nerve pulsed radiofrequency through trans-vaginal approach
89107471|NCT04309773|Experimental|Bezafibrate in addition to standard UDCA therapy|"Bezafibrate (400mg) in addition to standard 15-20 mg/kg/day UDCA therapy (experimental arm)"
89107472|NCT04309773|Placebo Comparator|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate in addition to standard 15-20 mg/kg/day UDCA therapy
89107473|NCT00785707||cochlear implant|children less than 24 months at time of cochlear implantation
89107474|NCT02827305|Experimental|group 1|scaling and Gotukola mouthwash intervention- 1.Scaling 2.Gotukola mouthwash , 10ml twice daily to be rinsed for 60 seconds
89107475|NCT02827305|Active Comparator|group 2|Scaling
89107476|NCT02827305|Active Comparator|group 3|Intervention- Gotukola mouthwash only is advised to be used two times a day, each time 10ml rinsed for 60 seconds (morning and evening ) after the food.
89107477|NCT02827227||Primary HIV- Infected patients|Primary HIV- Infected patients with a minimum of 2 years of effective cART.
89107478|NCT02827929|Experimental|educated group|Subjects who is diagnosed as COPD or asthma by their physicians were recruited from 43 primary clinic and had been visiting each primary clinic over one year or more will be provided education of 3 times for one months about disease, inhaler use technics and action plans about exacerbation
89107479|NCT02827851|Experimental|SVF injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.
89107480|NCT02829333|Other|Group GA|22 patients receive general anesthesia and patient controlled intravenous analgesia
89107481|NCT02829333|Other|Group SA|22 patients receive spinal anesthesia and continuous postoperative epidural analgesia
89107482|NCT05251662|Experimental|experimental group1|Sintilimab Combined With GEMOX + IBI305
89107483|NCT05251662|Experimental|experimental group2|Sintilimab Combined With GEMOX
89107484|NCT05251662|Active Comparator|Comparator|GEMOX
89107485|NCT02829177|Active Comparator|Allopurinol|400 mg once daily, tablet treatment
89107486|NCT02829177|Placebo Comparator|Placebo|Identical tablet treatment
89107487|NCT00631878|Placebo Comparator|Placebo|
89107488|NCT00631878|Experimental|10 mg/kg|10 mg/kg was given on Days 0, 14
89107489|NCT00631878|Experimental|30 mg/kg|30 mg/kg was given on Days 0, 14
89107490|NCT00631878|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 14
89107491|NCT00631878|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 14
89107492|NCT05112081|Experimental|Botox injections|Patients randomised to the intervention arm will be treated with injection of 100 units of botox in 10 ml sterile saline close to superficial inguinal ring.
89107493|NCT05112081|Placebo Comparator|Sterile saline injections|Patients randomised to the control arm will be treated with injection of 10 ml sterile saline close to superficial inguinal ring.
89107494|NCT00913380|Experimental|Low-dose CT|
89107495|NCT00913380|Active Comparator|Standard-dose CT|
89107496|NCT04244097|Experimental|B group|-Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.
89107497|NCT04244097|Active Comparator|BN group|Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.
89107498|NCT02827773|Experimental|Received Talking Pill Bottles|Patients received anti-hypertensives over 90 day period in Talking Pill Bottle which contained summary of pharmacy counselling session.
89107499|NCT02827773|No Intervention|Usual Care|Patients received oral summary of pharmacy counselling session.
89107500|NCT04681872|Experimental|Marshall Plan arm|Patients will undergo (1) the destruction of Marshall bundles by ethanol infusion followed by ablation of the distal coronary sinus bundles, the ridge and the saddle; (2) the standard pulmonary veins sleeves isolation; (3) and finally the ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
89107501|NCT04681872|Active Comparator|Pulmonary vein isolation arm|
89107502|NCT02826993|Experimental|CCE in incomplete Colonoscopies|Patients in which colonoscopy is not possible are invited for CT colonography and those patients are examined by Camera Capsule Endoscopy the day before the CT colonography and the two different examinations are compared.
89107503|NCT02829255|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
89107504|NCT04612686||Frail|"At screening participants will be classed as frail if their Electronic Frailty Index score is >0.24 and if their Clinical Frailty Scale score is 6. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 3 or more frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as frail.~All participants will receive the same assessment procedures."
89107505|NCT04612686||Pre-frail|"At the point of screening, participants will be classed as pre-frail if their Electronic Frailty Index score is 0.13-0.24 and if their Clinical Frailty Scale score is 4-5. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting 1 or 2 frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as pre-frail.~All participants will receive the same assessment procedures."
89107506|NCT04612686||Non-frail|"At the point of screening, participants will be classed as non-frail if their Electronic Frailty Index score is 0-0.12 and if their Clinical Frailty Scale score is 1-2. This will be confirmed following the Fried frailty phenotype assessment made during the first visit to the University laboratory. Participants exhibiting no frailty components (slowness, weakness, weight loss, exhaustion, low physical activity) will be classed as non-frail.~All participants will receive the same assessment procedures."
89107507|NCT02829021|Other|Thermography and mammography|"All participants will be examined with~Dynamic infrared thermography (FLIR ThermaCAM P-65)~Mammography, clinical examination and if necessary breast tissue biopsy to diagnose breast cancer."
89107508|NCT00785629|Active Comparator|Calcium Acetate|667 mg with meals
89107509|NCT00785629|Active Comparator|Lanthanum Carbonate|500 mg with meals
89107510|NCT00785629|Active Comparator|Sevelamer Carbonate|800 mg with meals
89107511|NCT00785629|Placebo Comparator|Placebo|with meals
89107512|NCT05097183||Control|Transcatheter aortic valve replacement (TAVR) with standard procedure
89107513|NCT05097183||ACA|Transcatheter aortic valve replacement (TAVR) with Accurate Commissural Alignment (ACA) technique
89107514|NCT00916344|Experimental|Pacemaker therapy|
89107515|NCT00915733|Active Comparator|triple group|"Additive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) in patients with acute myocardial infarction (AMI).~Received cilostazol 100 mg twice daily in addition to aspirin 100 mg and clopidogrel 75 mg once daily."
89107516|NCT00915733|Active Comparator|high maintenance dose group|"High maintenance dose dual antiplatelet therapy in patients with acute myocardial infarction (AMI).~Received clopidogrel 150 mg/day with aspirin 100 mg once daily."
89107517|NCT04245969|Experimental|INTERVENTION|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the shoulder
89107518|NCT04245969|Experimental|Placebo Monopolar Radiofrequency stimulus|To simulate the application of Monopolar Radiofrequency stimulus on the affected shoulder
89107519|NCT04245969|Experimental|No intervention group|To evaluate at the same time than the others groups but without being treated with 448 kilohertz Capacitive Resistive Monopolar Radiofrequency.
89107520|NCT02828865|Experimental|irreversible electroporation (IRE)|irreversible electroporation (IRE) (AngioDynamics, NY) To use 2 to 6 unipolar electrodes of IRE in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
89107521|NCT02604043|Experimental|supraglottic impendence/pH probe|
89107522|NCT00913770|No Intervention|SC|Standard Care
89107523|NCT00913770|Experimental|SBIRT|Screening, Brief Intervention and Facilitated Referral to Treatment
89107524|NCT00913770|Experimental|SBI+Bup|Screening, Brief Intervention and Buprenorphine initiation
89107525|NCT02602639|Experimental|Functional electrical stimulation rowing|Using an Odstock 4 channel neuromuscular stimulator with Concept 2 Rower
89107526|NCT04617366|Experimental|Individualized rTMS strategy|The individualized strategy will adjust the rTMS parameters promptly based on the results of fNIRS. This arm selects either the high-frequency rTMS to the contralesional dorsal premotor cortex (PMd) or the low-frequency rTMS to the contralesional primary motor cortex (M1) based on the lateralization index of the PMd measured by fNIRS.
89107527|NCT04617366|Active Comparator|Traditional rTMS strategy|The control group will always be given low-frequency rTMS to contralesional M1.
89107528|NCT00780559|Other|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
89107529|NCT00780559|Other|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
89107530|NCT02826291||RD-100i, OSNA|SLNM and OSNA assessment of sentinel lymph nodes compared to ultrastaging
89107531|NCT02826057|Active Comparator|24 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 24 hours of targeted temperature management (33 degree Celsius)
89107532|NCT02826057|Experimental|48 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 48 hours of targeted temperature management (33 degree Celsius)
89107533|NCT02602249|No Intervention|Experimental Group A(control group)|saline infusion and follow up
89107534|NCT02602249|Experimental|Experimental Group B|MUC1-gene-DC-CTL will be used against tumor cells.
89107535|NCT02602249|Experimental|Experimental Group C|MUC1-peptide-DC-CTL will be used against tumor cells.
89107536|NCT00912912|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
89107537|NCT00889005|Experimental|Cognitive Behavioral Therapy|Five sessions of trauma-focused, telephone based cognitive behavioral therapy, followed by assessment and referral to clinical treatment if needed.
89107538|NCT00889005|No Intervention|Waitlist control group|Five weeks without active intervention, followed by assessment and referral to clinical treatment if needed.
89107539|NCT04104997|Experimental|The A group in 5% GLH8NDE|Three times administration both eyes, each 1 drop in Korean
89107540|NCT04104997|Placebo Comparator|The A group in placebo|Three times administration both eyes, each 1 drop in Korean
89107541|NCT04104997|Experimental|The B group in 5% GLH8NDE|Six administration both eyes, each 1 drop in Korean
89107542|NCT04104997|Placebo Comparator|The B group in placebo|Six administration both eyes, each 1 drop in Korean
89107543|NCT04104997|Experimental|The C group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Korean
89107544|NCT04104997|Placebo Comparator|The C group in placebo|Six administration both eyes, each 2 drop in Korean
89107545|NCT04104997|Experimental|The D group in 5% GLH8NDE|Six administration both eyes, each 2 drop in Caucasian
89107546|NCT04104997|Placebo Comparator|The D group in placebo|Six administration both eyes, each 2 drop in Caucasian
89107547|NCT02824653|Experimental|Mesenchymal Stem Cells|The experimental arm is comprised of GVHD patients receiving allogenic bone marrow mesenchymal stem cells
89107548|NCT00779857|Experimental|AtriCure LAA Exclusion System|AtriCure LAA Exclusion System
89107549|NCT04104919|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the brivoligide treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
89107550|NCT04104919|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal administration of placebo while in the lateral decubitus position at lumbar interspace L3/4 or higher. After injection subjects will be placed supine in a 15-degree head down tilt (Trendelenburg position) for 5 minutes and then returned to supine horizontal for surgery.
89107551|NCT04102891|Experimental|Study arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the Flemish food-based dietary guidelines. Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
89107552|NCT04102891|No Intervention|Control arm|During the three months intervention period, participants within this arm will do their groceries through the online Collect&Go platform of Colruyt Group. Dietitians will adjust their shopping carts by changing food products by healthier alternative ones taking into account the guidelines from the newly developed microbiota modulation diet (MMD). Based on participants' dietary pattern and level of food literacy, personalized dietary advice will be provided and a dietitian helpline will be available for further nutrition-related questions.
89107553|NCT04241913|Experimental|Treatment|The treatment group receives the 10-week, group-based Mom Power intervention; intervention is provided to both mothers and children by trained providers. Treatment delivery will be consistent with the Mom Power manual.
89107554|NCT04241913|No Intervention|Waitlist control|Participants randomized to waitlist control will not receive treatment during the experimental period; they will be offered treatment following completion of post- assessments.
89107555|NCT04201275|Experimental|Cohort 1|up to HEC74647PA capsule 50 mg once daily for 3 days
89107556|NCT04201275|Experimental|Cohort 2|up to HEC74647PA capsule 100 mg once daily for 3 days
89107557|NCT04201275|Experimental|Cohort 3|up to HEC74647PA capsule 200 mg once daily for 3 days
89107558|NCT04201275|Placebo Comparator|Cohort 4|up to placebo once daily for 3 days
89107559|NCT04710108|No Intervention|No treatment control|No treatment; no intervention (survey only)
89107560|NCT04710108|Experimental|Video|A Taste of Home video, Poet: Monica Mendoza (spoken word poem from The Bigger Picture; images of Hispanic female poet interspersed with images of environment)
89107561|NCT04710108|Experimental|Print|A Taste of Home comic book, Poet: Monica Mendoza (spoken word poem from The Bigger Picture; images of Hispanic female poet interspersed with images of environment)
89107562|NCT04242303|Experimental|EM Technique|use of extramedullary technique by means of inertial sensors for the execution of femoral cuts
89107563|NCT04242303|Active Comparator|IM Technique|Use of conventional intramedullary technique for the execution of femoral cuts
89107564|NCT04810026|Active Comparator|Group 1: Education only|Push notifications for online diabetes self-management education for 12 weeks, passive access to lifestyle education for 16 weeks
89107565|NCT04810026|Experimental|Group 2: Education and Meals|Meal delivery (3 meals per day, 5 days per week) for 12 weeks, push notifications for online diabetes self-management education for 12 weeks, passive access to lifestyle education for 16 weeks
89107566|NCT04810026|Experimental|Group 3: Education, Meals, Coaching|Meal delivery (3 meals per day, 5 days per week) for 12 weeks, coaching program (e.g., diabetes-specific coaching and education, push notifications for lifestyle education modules, community support) for 12 weeks, and passive access to lifestyle education for final 4 weeks
89107567|NCT04787328|Experimental|HA121-28 tablets|Patients will receive HA121-28 tablets at 450 mg once daily (QD) for 21 days on a 28-day treatment cycle.
89107568|NCT00784927|Experimental|Treatment|"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:~375 mg/m^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22."
89107569|NCT00915421||Prehospital hypothermia group|All patients included to the study
89107570|NCT04785378|Experimental|Study Group|
89107571|NCT00779779||Rotarix Group|Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.
89107572|NCT04203342|Experimental|Ketoconazole 2% cream (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Test product is Ketoconazole 2% cream manufactured by Douglas Pharmaceuticals America Ltd.
89107573|NCT04203342|Active Comparator|Ketoconazole 2% cream (Teva Pharmaceuticals USA)|Subject will be randomized to either test product/active comparator/placebo comparator. Active comparator is Ketaconazole 2% cream manufactured by Teva Pharmaceuticals USA.
89107574|NCT04203342|Placebo Comparator|Placebo (Douglas Pharmaceuticals America Ltd.)|Subject will be randomized to either test product/active comparator/placebo comparator. Placebo comparator is manufactured by Douglas Pharmaceuticals America Ltd.
89107575|NCT00915889|Active Comparator|Group I|Patients receive a survivorship booklet in the mail that contains information about cervical cancer. Patients then receive a follow-up telephone call at 3 months to clarify any issues relevant to the survivorship booklet.
89107576|NCT00915889|Experimental|Group II|Patients are randomly assigned to receive either 6 or 8 weekly telephone sessions that address managing medical issues, health education, and cancer resources; balancing emotions and managing stress; coping skills and problem solving; family and social concerns; relational, intimacy, and sexual concerns; and financial and employment concerns. Patients also receive a survivorship booklet as in group I.
89228444|NCT04901442|Active Comparator|Running with an Orthotic|Group A will receive an L700 Speed Orthotic (https://www.aetrex.com/running-orthotic/?lang=en_US) according to participants shoe size and will run with this Orthotic in the participants normal running shoes. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to run as normal over the 8-week trial period
89107577|NCT04102969|Experimental|Intervention group|"Intervention group will be instructed by an interventionist who is qualified in stress management and relaxation will perform the Benson relaxation technique to the intervention group to perform the Benson relaxation technique two times a day for 10 minutes during the study period ( two months).~Training session of the technique will be repeated if necessary over one or two sessions until the interventionist confirm that the participants acquired sufficient skills. A total of two hours will be scheduled for each session and will be coordinated with the nursing manager of the hemodialysis department."
89107578|NCT04102969|Other|Control Group|A qualified nutritionist will run out a nutrition package session for hemodialysis patients in the control group. This nutrition package session will be for one session for one hour.
89107579|NCT04203108|Experimental|ATG group|ATG group refers to treatment with a protocol including low-dose ATG, CsA, short-term MTX and MMF as GVHD prophylaxis.
89107580|NCT04203108|Active Comparator|non-ATG group|Non-ATG group refers to treatment with a protocol including CsA, short-term MTX and MMF as GVHD prophylaxis.
89107581|NCT04102657|Experimental|Intermittent Fasting with Left Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
89107582|NCT04102657|Experimental|Intermittent Fasting with Right Arm Exercise|Healthy volunteers willing to fast for a 16-hour period daily for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
89107583|NCT04102657|Experimental|Free-living Diet with Left Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
89107584|NCT04102657|Experimental|Free-living Diet with Right Arm Exercise|Healthy volunteers maintaining their current diet for 12-14 days. Volunteers will also complete a 20-minute unilateral arm exercise daily.
89107585|NCT04834206|Other|DNF-N|"Induction chemotherapy:~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~Concurrent chemoradiotherapy:~three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~Radiotherapy: radical intense modulated radiation therapy"
89107586|NCT02602717|Experimental|thyroid cancer|
89107587|NCT04107415|Experimental|Yoga group|group doing yoga
89107588|NCT04107415|No Intervention|No yoga group|group not doing yoga
89107589|NCT05227248|Experimental|Main study arm|Patients received intervention 1 and then intervention 2 after 7 weeks
89107590|NCT00631722|Experimental|A|
89107591|NCT00631722|Active Comparator|B|
89107592|NCT00845728|Experimental|Indacaterol|Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
89107593|NCT00845728|Active Comparator|Tiotropium|Tiotropium 18 µg o.d. delivered via the handihaler®
89107594|NCT00779467|Experimental|Bupivacaine with Neostimgine 8 mcg/ml|STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
89107595|NCT00779467|Experimental|Bupivacaine and Neostigmine 4 mcg/ml|STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
89107596|NCT00779467|Experimental|Bupivacaine with Neostigmine 2 mcg/ml|STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
89107597|NCT00779467|Active Comparator|BUPIVACAINE WITH FENTANYL 2 MCG/ML|Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
89107598|NCT04203030|Experimental|Physical Activity|16 week physical activity intervention
89107599|NCT04559100||Severe and critical COVID-19 survivors|"Radiological alterations assessed by chest radiography and/or thoracic computed tomography Lung function alterations assessed by spirometry, diffusing capacity for carbon monoxide, 6 minute walk.~Quality of life alterations: saint george respiratory questionnaire"
89107600|NCT00778921|Experimental|Amlodipine 10 mg|Amlodipine 10 mg
89107601|NCT00778921|Experimental|Aliskiren/Amlodipine 150/10 mg|Aliskiren/Amlodipine 150/10 mg
89107602|NCT00778921|Experimental|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg
89107603|NCT04173312|Active Comparator|Infused analgesic|Patients will be assigned to receive local anesthetic through continuous infusion by pump.
89107604|NCT04173312|Placebo Comparator|Infused saline|Patients will be assigned to receive saline through continuous infusion by pump.
89107605|NCT00915876|Active Comparator|Paricalcitol|
89107606|NCT00915876|Placebo Comparator|Placebo|
89107607|NCT04079244|Active Comparator|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children"
89107608|NCT04079244|Active Comparator|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
89107609|NCT04550988||Adult patients with severe haemophilia A or B|"Adult patients (≥ 18 years of age) suffering from severe haemophilia A or B~No professional medical background~Submitted written consent to participate in the study and to use their study related pseudonymised data"
89107610|NCT00776659||Observational|
89107611|NCT00825682|Experimental|1|20 breast cancer patients scheduled for adjunctive radiation treatment will be recruited for this study to receive reflexology treatment initiated at the beginning of radiation therapy, once a week, for 10 weeks.
89107612|NCT00825682|No Intervention|2|20 breast cancer patients, scheduled for adjunctive radiation treatment, matched by age to the intervention group will receive treatment as usual, and will be evaluated by the same measures as the intervention group.
89107613|NCT00632268|Experimental|A|Drug:RAD001 Drug:Cisplatin Drug:5-FU
89107614|NCT05469568|Experimental|Circuit training and telerehabilitation|The experimental group will participate in a 12-week rehabilitation program, including training once a week. After the end of this outpatient program, participants will gain access to a mobile application in which participants will record all their physical activities.The mobile application will also include a library of exercises taught during the outpatient program so patients can practice them at home.
89107615|NCT05469568|Sham Comparator|Usual Care|Patients have usual care and usual information about importance of regular movement activities and recommendation of proper exercises. Patients don't visit ambulatory rehabilitation program and they don't have access to an application
89107616|NCT04145076|Experimental|Placebo, Citalopram, Tianeptine|Dose order: Placebo, Citalopram, Tianeptine
89107617|NCT04145076|Experimental|Placebo, Tianeptine, Citalopram|Dose order: Placebo, Tianeptine, Citalopram
89107618|NCT04145076|Experimental|Citalopram, Placebo, Tianeptine|Dose order: Citalopram, Placebo, Tianeptine
89107619|NCT04145076|Experimental|Citalopram, Tianeptine, Placebo|Dose order: Citalopram, Tianeptine, Placebo
89107620|NCT04145076|Experimental|Tianeptine, Placebo, Citalopram|Dose order: Tianeptine, Placebo, Citalopram
89107621|NCT04145076|Experimental|Tianeptine, Citalopram, Placebo|Dose order: Tianeptine, Citalopram, Placebo
89107622|NCT00707902|Active Comparator|2|"Drug: Echinacea/sage~patients received additionally a placebo-spray for the synthetical comparator (chlorhexidine/lidocaine) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.~Arms: 1"
89107623|NCT00707902|Active Comparator|1|"Drug: Chlorhexidine/lidocaine~patients received additionally a placebo-spray for the synthetical comparator (echinacea/sage) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days."
89107624|NCT04107025|Experimental|Intervention|As part of the intervention, along with legal opinions, advise and support, participants were provided counselling support during their time to help survivors with trauma of legal proceedings.
89107625|NCT04107025|No Intervention|Usual Care|Participants were scheduled for legal consultancy only.
89107626|NCT00704860|Experimental|TR|TR- Subjects defined as having treatment resistant depression, who have failed at least 2 adequate trials of an antidepressant. Subjects will be treated in an open label trial for their depression, with the goal of sustained remission.
89107627|NCT03999931||schizophrenia with positive symptoms|schizophrenia with positive symptoms
89107628|NCT03999931||schizophrenia with negative symptoms|schizophrenia with negative symptoms
89107629|NCT03999931||bipolar disorder|bipolar disorder
89107630|NCT03999931||depression|depression
89107631|NCT03999931||panic disorder|panic disorder
89107632|NCT03999931||obsessive-compulsive disorder|obsessive-compulsive disorder
89107633|NCT03999931||control|
89107634|NCT03360942||DBS Long Term Follow Up|5 participants who were in a prior study to receive DBS are enrolled to have their progress and DBS devices monitored for a period of 12 years.
89107635|NCT00833794|Experimental|1 Tramadol Once A Day|
89107636|NCT00833794|Placebo Comparator|2 Placebo|
89107637|NCT00912288|Experimental|Dimebon|
89107638|NCT00912288|Placebo Comparator|Placebo|
89107639|NCT00778375|Experimental|Clofarabine + Cytarabine + Decitabine|Clofarabine 20 mg/m^2 by vein (IV) as a 1- to 2-hour intravenous infusion daily for 5 days. Cytarabine 20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions. Decitabine 20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
89107640|NCT04102267|Experimental|Liposomal bupivacaine injection (Group 1)|Liposomal bupivacaine 266 mg via injection
89107641|NCT04102267|Experimental|Bupivacaine HCl continuous infusion (Group 2)|Bupivacaine HCl 300 mg via continuous infusion
89107642|NCT02602171|Experimental|dereverberation condition|Oldenburger Sentence test, localization test
89107643|NCT02602171|Experimental|reverberation condition|Oldenburger Sentence test, localization test
89228445|NCT04901442|No Intervention|Running without an Orthotic|Group B will not be provided with the Orthotic and will run in the participants normal running shoes during the course of the study. The group will be asked to run as normal over the 8-week trial period. At the end of the study and following collection of data participants in Group B will also be provided with an L700 Speed Orthotic.
89228446|NCT00987038|Other|PF-04171327 and Midazolam|
89228447|NCT00761033|Experimental|music|children will listen to music during procedure
89228448|NCT00761033|Other|Standard care|Standard care
89228449|NCT05711810|Experimental|Experiment Participant|"COVID-19 recombined vaccinated, 3 dose, no intervention. Nifedipine, oral, 30 mg per day for 2 days, active comparative. Angiotensin-converting enzyme inhibitor, oral, gradually increase to 20 mg per day at night.~Beta blocker, oral, 23.75 - 95 mg per day in the morning. Proton-pump inhibitor, oral, 30 mg per day. Duloxetine hydrochloride, oral, placebo, 20 mg per day before sleep. Acetaminophen (sham comparator), oral, 250 mg four times per day for 8 days. Cefuroxime (sham comparator), oral, 100 mg twice per day for 6 days. Papaverine, oral, low-dosage in coughing pills for 4 days. Superoxide Dismutase (active comparator), oral, to be introduced. Bafilomycin A1 (active comparator), oral, 100 ug per kilogram per day, unlikely to be introduced for lack of funding."
89228450|NCT00759083|Experimental|1|Patients with HIT/HITTS who require anticoagulation for PCI
89228451|NCT04864236|Experimental|Intervention group|This group will undergo airway management in the operating room as part of the anesthesia for surgery in the presence of the novel isolation device.
89228452|NCT04864236|No Intervention|Control group|
89228453|NCT00759239|Experimental|1|One drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 am and 1 drop of Timolol vehicle as placebo in each eye at 9 pm for 12 weeks.
89228454|NCT00759239|Experimental|2|One drop of Timolol vehicle as placebo in each eye at 9 am and one drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 pm for 12 weeks.
89228455|NCT03899064|Experimental|Induction:MC2-01 Cream, irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
89228456|NCT03899064|Experimental|Induction: MC2-01 Cream, no irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
89228457|NCT03899064|Experimental|Induction: MC2-01 vehicle, irradiation|Applications with MC2-01 vehicle, followed by irradiation
89228458|NCT03899064|Experimental|Induction: MC2-01 vehicle, no irradiation|Applications with MC2-01 vehicle, no irradiation
89228459|NCT03899064|Experimental|Challenge: MC2-01 Cream, irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
89228460|NCT03899064|Experimental|Challenge: MC2-01 Cream, No irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
89107644|NCT04202718|Other|Single group|Where a wearable biosensor is being considered for use in the health management of individuals at high-risk for poor health outcomes, and in the detection or prevention of adverse events within settings where traditional monitoring devices are not currently in use, the ECG interpretation will provide Arrhythmia detection which will help ensure that irregular rhythms will be reported quickly.
89107645|NCT04498104||Borderline Personality Disorder|Borderline personality disorder diagnosed participants
89107646|NCT04498104||Control|Healthy participants
89107647|NCT00777829|Experimental|zolpidem first, then placebo|Participants received one dose of zolpidem for one nap, then had a one week washout period, followed by once dose of placebo for one nap.
89107648|NCT00777829|Placebo Comparator|Placebo first, then zolpidem|Participants received one dose of placebo for one nap, then had a one week washout period, followed by once dose of zolpidem for one nap.
89107649|NCT00916045|Other|Myeloblative conditioning regimen|
89107650|NCT00916045|Other|Reduced intensity conditioning regimen - FluCyTBI|
89107651|NCT00916045|Other|Reduced intensity conditioning regimen - FluMel|
89107652|NCT00916123|Experimental|Dose Level 1|177Lu-J591 at 20 mCi/dose
89107653|NCT00916123|Experimental|Dose Level 2|177Lu-J591 at 25 mCi/dose
89107654|NCT00916123|Experimental|Dose Level 3|177Lu-J591 at 30 mCi/dose
89107655|NCT00916123|Experimental|Dose Level 4|177Lu-J591 at 35 mCi/dose
89107656|NCT00916123|Experimental|Dose Level 5|177Lu-J591 at 40 mCi/dose
89107657|NCT00775021|Active Comparator|etafilcon A/nelfilcon A|etafilcon A contact lens worn first and nelfilcon A contact lens worn second
89107658|NCT00775021|Active Comparator|nelfilcon A/etafilcon A|nelfilcon A contact lens worn first and etafilcon A contact lens second.
89107659|NCT00916201|Experimental|Intranasal Insulin|Intranasal administered insulin
89107660|NCT00916201|Experimental|Cannabidiol CR|Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.
89107661|NCT00916201|Experimental|URB597|URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.
89107662|NCT02601781|Experimental|Primary PCI (PPCI) with BVS|Primary percutaneous coronary intervention (PPCI) with bioresorbable vascular scaffold (BVS) implantation in STEMI patients. Following the arterial route, PPCI (performed according to the international guidelines) aims to recanalize an occluded coronary artery that is then maintained patent inserting an endovascular permanent prosthesis (stent). In this study we aim to assess the results following the use of a fully bioresorbable prosthesis (BVS) during PPCI using a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation). BVS has the theoretical advantage, as compared with a permanent stent, to disappear within 24-36 months from implantation restoring the native pristine vessel state.
89107663|NCT00777205|Active Comparator|Enhanced Usual Care|Patients in the enhanced usual care arm received their usual mental health care, a copy of the Depression Helpbook, and bi-weekly study mailings with depression management tips.
89107664|NCT00777205|Experimental|Telephone-based peer support|Participants in the intervention arm received usual mental health care and biweekly study mailings. In addition, they had access to a telephone platform over which they could make free calls to their peer partner for mutual peer support over a 6-month period of time.
89107665|NCT00833638|Experimental|Tadalafil 2.5 mg|No drug during baseline period, 2.5 mg for 14 days, then will continue at 5 mg for 14 days.
89107666|NCT00833638|Experimental|Tadalafil 5 mg|No drug during baseline period, 5 mg for 14 days, then will continue at 5 mg for 14 days.
89107667|NCT00833638|Placebo Comparator|Placebo|No drug during baseline period, placebo for 14 days, then will continue tadalafil at 5 mg for 14 days.
89107668|NCT01041404|Experimental|Trastuzumab, Fluoropyrimidine, Cisplatin|Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
89107669|NCT01041404|Active Comparator|Fluoropyrimidine, Cisplatin|Participants received 800 milligrams per square meter (mg/m2) fluorouracil intravenous (i.v.) on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine orally (p.o.) twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
89107670|NCT00777049|Experimental|ER+ and/or PgR+ (Arm I)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
89107671|NCT00777049|Experimental|ER- and PgR- (Arm II)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
89107672|NCT00774787|Experimental|Imiquimod, treatment, topical cream|Imiquimod 5% cream, 1 packet (250 mg cream), applied to left or right treatment area on the face and/or balding scalp
89107673|NCT00774787|No Intervention|Control, Untreated|No treatment of treatment area on the other half of the face and/or balding scalp
89107674|NCT00888927|Experimental|Phase 1 Cohort 1|First course: 0.1 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 0.1 mg/kg over 1 hour every other week
89107675|NCT00888927|Experimental|Phase 1 Cohort 2|First course: 0.3 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 0.3 mg/kg over 1 hour every other week
89107676|NCT00888927|Experimental|Phase 1 Cohort 3|First course: 1.0 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 1.0 mg/kg over 1 hour every other week
89107677|NCT00888927|Experimental|Phase 2|First course: Maximum tolerated dose once a week over 1 hour for 4 weeks Subsequent courses: Maximum tolerated dose over 1 hour every other week
89107678|NCT01040780|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
89107679|NCT01040780|Active Comparator|Gefitinib|250 mg every 24 hours by mouth
89107680|NCT00888849|Experimental|Stapling|
89107681|NCT00888849|Active Comparator|Suturing|4 layered hand-sutured anastomosis
89107682|NCT02874482||Patients with schizophrenia|30 patients with schizophrenia (diagnosis based on the standard DSM criteria)
89107683|NCT02874482||Controls|30 healthy controls without any psychiatric or neurological diagnosis
89107684|NCT04303832|Experimental|eye exercise group|This group made different types of eye exercises beside the traditional treatment of strabismus which is eye glasses
89107685|NCT04303832|Sham Comparator|control group|This group had traditional treatment of strabismus which is eye glasses
89107686|NCT04241991|Experimental|Active laser|Each participant will receive the application of the active laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
89107687|NCT04241991|Placebo Comparator|Placebo laser|Each participant will receive the application of the placebo laser on the rectus femoris muscle during the trials 1 (acute) and 2 (chronic).
89107688|NCT04243317|Active Comparator|Control|The control group will adhere to a 1200 kcal restriction daily for 12 weeks.
89107689|NCT04243317|Experimental|Experimental|The experimental group will adhere to a 1200 kcal restriction daily for 12 weeks and will maintain sleep improvement
89107690|NCT04303988|Experimental|Cohort HR+/HER2+|Hormone receptor negative, HER2 positive participants will receive Pyrotinib in combination with Temozolomide until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89228461|NCT03899064|Experimental|Challenge: MC2-01 vehicle, irradiation|Application with MC2-01 vehicle, followed by irradiation
89228462|NCT03899064|Experimental|Challenge: MC2-01 vehicle, no irradiation|Application with MC2-01 vehicle, no irradiation
89107691|NCT04303988|Experimental|Cohort HR-/HER2-|Hormone receptor negative, HER2 negative participants will receive SHR1316 in combination with bevacizumab plus cisplatin or carboplatin until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89107692|NCT04682600|Experimental|Open-label|Volunteers who have agreed to participate in the study will have their liver scanned using the FibroScan, VE (Liver Incytes System) and MRE techniques.
88820929|NCT05422014|Experimental|LCS Intervention|With Opioid Risk Education, patients will receive opioid education after completing the validated Opioid Risk Tool (ORT), a detailed substance abuse survey and mental health screening, and Naloxone education. Therapeutic Intervention will include the Community Resiliency Model CRM), progressive muscle relaxation, sound therapy. Clinical Pain Coordination will include directed referrals for complex needs, including mental health and substance use disorders, as needed. In addition to above mentioned 3 intervention components, all patients in the LCS intervention arm will also receive the current standard-of-care.
89107693|NCT01059812|Experimental|IDegAsp BID|
89107694|NCT01059812|Active Comparator|BIAsp 30 BID|
89107695|NCT00888615|Experimental|Treatment (paclitaxel, elesclomol sodium)|Patients receive paclitaxel IV over 1 hour and elesclomol sodium IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients who are currently on treatment must not be dosed with elesclomol sodium after 12/31/2015. All other study procedures, with the exception of elesclomol sodium administration and paclitaxel administration, should continue in accordance with protocol requirements. Any treatment given after 12/31/2015, including continuation of paclitaxel, will be considered off study.
89107696|NCT05086809|Active Comparator|AAB|Starts with Device A in first and second trial period and change to Device B in third trial period.
89107697|NCT05086809|Active Comparator|ABA|Starts with Device A in first trial period, wears Device B in second trial period and change to Device A in third trial period.
89107698|NCT00888381|Experimental|Adults|Healthy volunteers aged 18 to 59 years
89107699|NCT00888381|Experimental|Older Adults|Healthy volunteers aged 60 years or older
89107700|NCT02827071||Retina abnormalities|Subjects with various retina vascular disorders
89107701|NCT02826135|Experimental|Pediatric patients with hypovolemic state|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output or decreased central venous pressure. Changes of blood pressure during abdominal compression is continuously recorded.
89107702|NCT02825823|Experimental|Ketone Salts|Acute dose of beta-hydroxybutyrate potassium/sodium salt (0.2g beta-hydroxybutyrate/kg, 0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
89107703|NCT02825823|Placebo Comparator|Placebo|Acute dose of taste-matched placebo (0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
89107704|NCT04949295||the hemodialysis group|investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.
89228463|NCT03899064|Experimental|Challenge: Control, irradiation|No application, but irradiation
89228464|NCT03742908|No Intervention|saline control|Implant immersion with 100 ml sterile saline (0.9%) for 10 minutes; Breast pocket irrigation (IRRI) with 100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards. No antibiotics is used.
89107705|NCT04949295||the normal group|investigated with the OSDI scale, and then bilateral ocular surface examinations were performed with Keratograph5M eye surface comprehensive analyzer. Non-invasive tear meniscus height (NITMH), first tear film break-up time (FTBUT), average tear film break-up time (ATBUT), dry eye severity grade, tear film lipid layer analysis (distribution and color), tear film lipid layer thickness grade, meibomian gland opening blocking site, meibomian gland opening blocking analysis, meibomian gland opening secretion oil character score, eye redness index analysis (conjunctiva, ciliary shape), and meibomian gland absence area score were recorded.
89107706|NCT00833560|Experimental|Cyclophosphamide + Bortezomib + Dexamethasone|Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.
89107707|NCT04242927|Experimental|Nicotinic acid + Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
89107708|NCT04242927|Active Comparator|Routine care|Routinely apply urea ointment and provide best supportive care.
89107709|NCT04948047||Malignant pulmonary nodules|Patients with pulmonary nodule diagnosed as malignant cancer by pathological examinations after surgical resection.
89107710|NCT04948047||Benign pulmonary nodules|Patients with pulmonary nodule diagnosed as benign disease by pathological examinations after surgical resection.
89107711|NCT02824419|Experimental|C11-methionine|To compare FDG and C11-methionine in the detection of sarcoidotic lesions.
89107712|NCT02824419|Experimental|68Ga-Dotanoc|To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.
89107713|NCT05660343|Experimental|Ozonated olive oil|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, Ozonated olive oil, 100 ml bottle, Olive Farm, GÜLLERDAĞI TURİZM TARIM İNŞ), Ozonated Olive Oil is used 3 times a day, every day for four weeks. Patients were instructed to spray three times on each side. To ensure commitment, Oil canisters were marked in the middle, which the patient was required to use until the label in the first two weeks, and the remaining amount in the second two weeks.
89107714|NCT05660343|Experimental|Ozonated olive oil with low level laser therapy|(810 nm diode laser, 3.4 j/cm2 energy density, 0.5w power, CHEESE DEN7A/DEN4A 810, 2 min for each side) was applied non-contact at a distance of 1 cm, the most painful points in the muscles diagnosed during the first examination were irradiated with circular movements and patients were called for 3 sessions per week over four weeks.
89107715|NCT02825667|Experimental|Experimental group|"Patients included in this group will receive treatment over a period of three weeks, receiving 3 physiotherapy sessions lasting approximately 30 minutes each.~The treatment program includes 8 maneuvers that must be administered bilaterally: maneuver longitudinal sliding on the fascial surface plant, maneuver induction of the plantar fascia, maneuver longitudinal surface sliding on the anterolateral compartment of the leg, induction maneuver ankle anterior compartment, maneuver pressure and sliding on the posterior region of the leg, technical release of the popliteal fascia, maneuver induction sural triceps, and lower extremity telescopic technique."
89107716|NCT02825667|No Intervention|Control group|Patients included in this group will not receive any physiotherapy treatment. However, will be evaluated under the same conditions that patients in the experimental group (pretreatment evaluation, post-treatment and follow-up).
89107717|NCT00887679|Experimental|Escitalopram|Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Open label, rater-blinded, prospective, 6-week trial of escitalopram.Subjects received escitalopram 10-20mg. Escitalopram was started at 10mg per day and augmented weekly in 10mg per day increments, the maximum dose being 20mg per day.
89107718|NCT04241523|Experimental|Treatment|The patients will receive lenvatinib treatment and will be evaluated for the feasibility of liver resection every 8 weeks. For those who underwent liver resection, they will receive lenvatinib treatment for another 48 weeks. In case of tumor recurrence, intolerance, death, or need for other antitumor treatment, the treatment shall be stopped.
89107719|NCT04242459|No Intervention|Feasibility Study|This is a radiotherapy planning study to evaluate the feasibility to acquire longitudinal MRI scans during radiotherapy (prior to the main study) thus, participants will receive standard-of-care chemoradiation therapy (CRT) as per departmental protocol without any treatment adaptation.
89107720|NCT04242459|Experimental|HPV associated OPC Participants|"Participants will be treated initially with the standard radiotherapy dose of:~65 grays (Gy) in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~In the 2nd week and 4th week of treatment, the participants will undergo Adaptive Radiotherapy to account for anatomical changes."
89107721|NCT04242459|Experimental|HPV negative OPC Participants - Radiotherapy dose escalation|"Participants will be treated initially with the standard radiotherapy dose of:~65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~After 10 fractions the participants will be stratified into either responders or non-responders categories based on Apparent Diffusion Coefficients (ADC) response at week 2 of CRT.~Participants classified as responders will complete treatment without any radiotherapy dose changes. Their radiotherapy treatment target volumes will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour.~The non-responders will undergo an increase in dose per fraction to Clinical Target Volume-1 (CTV-1) primary for fractions 11 to 30."
89107722|NCT04242459|Experimental|Base of Skull HNC Participants|"Participants will be treated initially with the standard radiotherapy dose of:~65Gy in 30 fractions (2.17Gy per fraction) over 6 weeks to the primary and nodal tumour.~54Gy in 30 fractions (1.8Gy per fraction) over 6 weeks to the nodal areas at risk of harbouring microscopic disease~Participants will undergo standard treatment with 3 cycles of induction chemotherapy followed by chemo-radiotherapy dose. Their radiotherapy treatment will be adapted at weeks 2 and 4 of CRT to account for volume changes to the tumour."
89107723|NCT02825589|Experimental|BIA-guided|Assessment of target dry weight guided by using bioelectrical impedance analysis (BIA).
89107724|NCT02825589|No Intervention|Standard clinical guided|Assessment of target dry weight guided by clinical evaluation eg. jugular venous pressure, blood pressure, edema etc.
89107725|NCT00833482|Active Comparator|Voriconazole, 200 mg BID (EM)|
89107726|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100 QD (EM & PM)|
89107727|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)|
89107728|NCT00833482|Active Comparator|Voriconazole, 50 mg BID (PM)|
89107729|NCT00833482|Active Comparator|Atazanavir/ritonavir, 300/100mgQD+voriconazole, 50mgBID (PM)|
89107730|NCT02824107|Experimental|patients with myocardial infarction|
89107731|NCT02824107|Experimental|patients with stroke|
89107732|NCT04906239|Active Comparator|Group ESP|While the patient is in a sitting position, A ultrasound probe covered with a sterile sheath will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After the T 4-5 transverse process and the erector spinae muscle above it are shown, a quincke-type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal with the entrance made using the in-plane technique. When the transverse process is touched, the needle will be pulled out and a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.The same procedure will be repeated on the contralateral side of the T5 spinous process and half of the remaining bupivacaine dose will be injected. The total volume of bupivacaine injected on both sides will be 20 mL.
89107733|NCT04906239|No Intervention|Group Control|"No block will be made to the control group.~After extubation, 1mg / kg tramadol will be applied routinely to both groups, and PCA (Patient Control Analgesia) and morphine consumption and VAS (visual analog scale) pain scores of both groups will be evaluated and recorded at the 1st, 4th, 12th and 24th hour. When VAS is 3, patients will be advised to press the PCA device."
89107734|NCT00845182|Active Comparator|Pioglitazone|Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm
89107735|NCT00845182|Experimental|Exenatide|Exenatide: 15 subjects will be randomized to receive Exenatide
89107736|NCT00845182|Experimental|Drug Pioglitazone and Drug Exentatide|Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide
89107737|NCT04934553|Experimental|Amplification of Positivity for Alcohol Use Disorders (AMP-A; 12 sessions)|
89107738|NCT04934553|Active Comparator|Cognitive-behavioral Therapy (CBT; 12 sessions)|
89107739|NCT02825511||A cohort of basal cell carcinoma|A cohort of surgically treated BCC, primitive clinically suspected or previously biopsied on a 4-month period, an expected number of 3 200 cases. The management of the BCC will be consistent with current recommendations. BCC recurrence and those who received prior medical treatment will be excluded.
89107740|NCT00833248|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
89107741|NCT00833248|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively."
89107742|NCT02612506|Experimental|Hepalatide|Hepalatide 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
89107743|NCT02612506|Placebo Comparator|Placebo|Placebo 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
89107744|NCT02612584|Experimental|Pinhole soft contact lens|
89107745|NCT00833092|Placebo Comparator|Sugar pill|Sugar Pill
89107746|NCT00833092|Active Comparator|magnesium|300 milligrams of magnesium daily
89107747|NCT00708370|Active Comparator|COACH|
89107748|NCT00708370|Placebo Comparator|Standard Care|
89107749|NCT00702130|Experimental|A|this arm will receive Pravastatin 40 mg per os daily
89107750|NCT00702130|No Intervention|1|
89107751|NCT02611414|Experimental|anodal tDCS|TDCS will be delivered with two saline-soaked sponge electrodes. The main electrode to anodal stimulation will be placed over the motor cortex, M1. The second electrode is neutral and will be placed on the skin overlying the supraorbital region The current will be delivered at the intensity of 2mA for 20 minutes. The procedure will be repeated at five consecutive days.
89107752|NCT02611414|Sham Comparator|Sham tDCS|Two electrodes are positioned at M1 and supra-orbital área. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes. The procedure will be repeated at five consecutive days.
89107753|NCT00823264|Experimental|Multiple Doses of Activated Charcoal|Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc
89107754|NCT00823264|No Intervention|Control|Will not receive activated charcoal. Serum levels will be followed.
89107755|NCT00708604|Experimental|1|Islet transplantation
89107756|NCT00832780|Experimental|Stereotactic Body Radiation (SBRT)|60 Gy using 12 Gy per fraction over 5 fractions, to be given within 10 calendar days
89107757|NCT02824341|Other|Parkinson's disease patients with RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
89107758|NCT02824341|Other|Parkinson's disease without RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
89107759|NCT02824341|Other|Healthy volunteers|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
89107760|NCT04241055|Active Comparator|Control|"The control condition of a standard values affirmation intervention"
89107761|NCT04241055|Experimental|Values affirmation|"The treatment condition of a standard values affirmation intervention"
89107762|NCT04241211|Active Comparator|Control group|
89107763|NCT04241211|Experimental|TP group|
89107764|NCT00591838|Experimental|Phase I Dose Level A: SBRT 9Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
89107765|NCT00591838|Experimental|Phase I Dose Level B: SBRT 10Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
89107766|NCT00591838|Experimental|Phase I Dose Level C: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
89107767|NCT00591838|Experimental|Phase I Dose Level D: SBRT 12Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
89107768|NCT00591838|Experimental|Phase II: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
89107769|NCT00702286||1|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
89107770|NCT00702286||2|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
89107771|NCT02611648|No Intervention|standard HLD|Standard high-level disinfectant (metricide ortho-phthalaldehyde) currently performed at BIDMC (standard HLD)
89107772|NCT02611648|Experimental|double HLD|Double the exposure time of the standard high level disinfectant (metricide ortho-phthalaldehyde)
89107773|NCT02611648|Experimental|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
89107774|NCT00705094||1|Testicular cancer patients who have received surgery and are scheduled for surveillance
89107775|NCT00705094||2|Testicular cancer patients who have received surgery and are scheduled for chemotherapy
89107776|NCT00702442|Placebo Comparator|A|Placebo Administrated 30min prior to operation
89107777|NCT00702442|Experimental|B|0.625 mg Droperidol administrated i.v 30 min prior surgery
89107778|NCT02612272|Active Comparator|Corticosteroid|"This arm will receive intra-articular betamethasone.~4cc of 1% lidocaine, 1cc of 0.9% normal saline and 1cc (6 mg) of betamethasone.~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site~Please see detailed description of study for further information."
89107779|NCT02612272|Experimental|Ketorolac|"This arm will receive intra articular ketorolac.~2cc (60 mg) of ketorolac and 4cc of 1% lidocaine~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site~Please see detailed description of study for further information."
89107780|NCT00832624|Experimental|1|sitagliptin
89107781|NCT00832078|Other|Group A|SCCM (SpeediCath Compact Male catheter) then SC (SpeediCath cathter) on test day 1. SC then SCCM on test day 2
89107782|NCT00832078|Other|Group B|SC (SpeediCath cathter)then SCCM (SpeediCath Compact Male catheter) on test day 1. SCCM then SC on test day 2
89107783|NCT00913120|Experimental|YM150 group-1|YM150 low dose group
89107784|NCT00913120|Experimental|YM150 group-2|YM150 high dose group
89107785|NCT00913120|Placebo Comparator|Placebo group|
89107786|NCT00913120|Active Comparator|Enoxaparin group|
89107787|NCT00913198|Experimental|IV CP-4126|
89107788|NCT00708838||1|
89107789|NCT00708838||2|
89107790|NCT00708838||3|
89107791|NCT00708838||4|
89107792|NCT00708838||5|
89107793|NCT00822172|Active Comparator|Cilostazol + L-Carnitine|1 tablet cilostazol 100 mg PO BID and 3 capsules L-carnitine 334 mg PO BID
89107794|NCT00822172|Placebo Comparator|Cilostazol + Placebo|1 tablet cilostazol 100 mg PO BID and 3 capsules placebo PO BID
89107795|NCT00702598|Experimental|1|Telephone-based Cognitive Behaviour Therapy
89107796|NCT00702598|Placebo Comparator|2|Telephone reminder calls
89107797|NCT00832000|Experimental|1|Participants will receive mexiletine for 4 weeks, then no intervention for 1 week, and finally placebo for 4 weeks.
89107798|NCT00832000|Experimental|2|Participants will receive placebo for 4 weeks, then no intervention for 1 week, and finally mexiletine for 4 weeks.
89107799|NCT00911508|Active Comparator|Left Atrial Ablation|Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.
89107800|NCT00911508|Active Comparator|Rate or Rhythm Control Therapy|Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.
89107801|NCT04202952|Experimental|600 mg multiple doses|Subjects receiving 600 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
89107802|NCT04202952|Experimental|800 mg multiple doses|Subjects receiving 800 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
89107803|NCT04202952|Experimental|1200 mg multiple doses|Subjects receiving 1200 mg HEC110114 tablet (N=6) or sofosbuvir tablets(N=2) once daily (q.d.) for 3 days
89107804|NCT04276740|Active Comparator|MitoQ|Participants will take oral MitoQ 40 mg daily
89107805|NCT04276740|Placebo Comparator|Placebo|Participants will take an oral matched placebo daily
89107806|NCT04394286|Experimental|Cohort 1|Cohort 1 participants will receive a single intravenous (IV) infusion of SHP648 on the day of dosing (Day 0).
89107807|NCT04394286|Experimental|Cohort 2|Cohort 2 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 1 on the day of dosing (Day 0).
89107808|NCT04394286|Experimental|Cohort 3|Cohort 3 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 2 on the day of dosing (Day 0).
89107809|NCT04378296|Experimental|Teledermatology|The 221 patients who are included in this group will be monitored from the Primary Care centers.
89107810|NCT04378296|No Intervention|Conventional monitoring|The 221 patients included in this group will have to visit the dermatologist at the hospital.
89107811|NCT04054674|Experimental|flat occlusal scheme restored by lithium disilicate crown|flat occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
89107812|NCT04054674|No Intervention|planar occlusal scheme restored by lithium disilcate crown|planar occlusal preparation of endodontically treated teeth is performed clinically and then the final restorations will be lithium disilicate (e.max) crowns.
89107813|NCT00774397|Experimental|240 mg QD TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
89107814|NCT00774397|Experimental|240 mg QD / LI-TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
89107815|NCT00774397|Placebo Comparator|Placebo|Placebo once daily combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
89107816|NCT00774397|Experimental|120 mg QD / LI-TN|120 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in (LI) phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), followed by an additional 24 weeks of PegIFN/RBV in treatment naive (TN) patients
89107817|NCT00774397|Experimental|240 mg QD TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment experienced (TE) patients
89107818|NCT00774397|Experimental|240 mg QD / LI-TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-experienced (TE) patients
89107819|NCT00774397|Experimental|240 mg BID / LI-TE|240mg BI 201335 NA (Faldaprevir) twice daily combined with PegIFN/RBV for 24 or 48 weeks, with 3-day lead-in phase of PegIFN/RBV, in treatment-experienced patients
89107820|NCT03576144|Experimental|BI 1265162|
89107821|NCT03576144|Placebo Comparator|Placebo|
89107822|NCT04454736|Experimental|SBGmentdis|Children and adolescents with mental disorders at the Department of Child and Adolescents Psychiatry in Salzburg, Austria
89107823|NCT04454736|Experimental|SBGhealthy|Healthy children and adolescents from schools in Salzburg, Austria
89107824|NCT04454736|Experimental|VIEhealthy|Members from the Vienna Boys Choir, Austria
89107825|NCT00632034|Experimental|1|
89107826|NCT04446858||With TIPS|Prospective cohort that received TIPS
89107827|NCT04446858||Without TIPS|Prospective cohort that did not receive TIPS
89107828|NCT04166292|Experimental|Treated face|The device will be injected on V1 (D0) in the cheekbones (upper part of the cheek) for all subjects and in the chin for 20 subjects minimum and if needed (optional areas) in the temple, and facial oval (mandibular angle and border). A touch-up is possible in one or several of these areas on V2 (M1). Optional treated areas will be at the discretion of subjects and injectors.
89107829|NCT04099771|Experimental|Ketamine|A total of 20 patients identified as having suicidal ideation will receive ketamine at 0.5mg/kg infused intravenously over 40 minutes.
89107830|NCT04273620|Experimental|Intervention-Control (IC)|In the Intervention-Control (IC) arm, patients will first receive the intervention (OKS-READ) containing 15 individual therapy sessions within a maximum time period of 28 days. Afterwards they will receive the control therapy (again 15 sessions within max. 28 days).
89107831|NCT04273620|Active Comparator|Control-Intervention (CI)|In the Control-Intervention (CI) arm, patients will first receive the control therapy (15 sessions within max. 28 days), followed by the intervention phase (15 therapy sessions OKS-READ within a maximum time period of 28 days).
89107832|NCT03378570|Active Comparator|5.5cm Rule Group|rTMS will be targeted at a left prefrontal target 5.5cm anterior to the primary motor strip identified on the scalp during motor threshold testing.
89107833|NCT03378570|Active Comparator|F3 Group|rTMS will be targeted at the left prefrontal scalp target identified as F3 according to the 10-20 EEG system.
89107834|NCT00909870|Experimental|1|Weekly applications of Dermagraft and compression dressings, in combination with systematic surgical wound debridement.
89107835|NCT00909870|Active Comparator|2|Weekly application of compression dressings only, in combination with systematic surgical wound debridement.
89107836|NCT00768469|Experimental|Nera 160 + Pac|Neratinib 160 mg + Paclitaxel 80 mg/m^2
89107837|NCT00768469|Experimental|Nera 240 + Pac|Neratinib 240 mg + Paclitaxel 80 mg/m^2
89107838|NCT00886821|Experimental|1|
89107839|NCT02825433||Patients receiving procedural sedation|The investigators collected ventilation data for each breath (respiratory rate, tidal volume, and end-tidal CO2) for all patients receiving procedural sedation for endoscopy.
89107840|NCT02823795|Experimental|sPATH|Motivational Interviewing in five sessions post hospital discharge
89107841|NCT02823795|No Intervention|Control|Care as usual
89107842|NCT04242693|Experimental|Experimental Group|The experimental group were asked to count the number of times they ate any red/orange vegetables and set a goal to eat one more time the next day over three days.
89107843|NCT04242693|No Intervention|Control Group|The control group uploaded photos and/or descriptions of their meals only. They did not self-monitor their vegetable intake nor set a goal to eat more.
89107844|NCT04242381|Experimental|Group 1: Cold application, Kinesiotaping treatment|"Cold application: At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.~Kinesiotaping application: KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)."
89107845|NCT04242381|Experimental|Group 2: Cold application, EX treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
89107846|NCT04242381|Sham Comparator|Group 3: Cold application, sham-KT treatment|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
89107847|NCT04242615||Prognostic score cohort|323 patients included between January 1, 2001 to December 31, 2004
89107848|NCT04242615||Prognostic score validation cohort|534 patients included between January 1, 2010 to December 31, 2013
89107849|NCT02825121|Experimental|Monitoring Neuromuscular Blockade|Monitoring Neuromuscular Blockade the Flexor Hallucis and adductor of the thumb.
89228465|NCT03742908|Experimental|Cefazolin/clindamycin immersion|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI) with100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards
89228466|NCT03742908|Experimental|Cefazolin/clindamycin immersion+ IRRI|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI): breast pocket is irrigated with100ml type III Anerdian plus 200mg cefazolin in 100 ml sterile saline (0.9%) for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead of cefazolin
89228467|NCT05357274||Respiratory|Patients attending primary care, non-specialist respiratory clinics and advanced nurse practitioner clinics with undiagnosed persisting respiratory symptoms that have been attributed to asthma by a physician.
89228468|NCT05407116|Experimental|Experimental|Patients receiving standard or hypofractionated radiotherapy for curative intent to a pelvic malignancy with an intended total dose of 25-60 Gy.
89228469|NCT04003194|Experimental|Pinto beans|1/2 cup pinto beans eaten daily by free-living individuals for 12 consecutive weeks.
89228470|NCT04003194|Active Comparator|Green beans|1/2 cup green beans eaten daily by free-living individuals for 12 consecutive weeks.
89228471|NCT05406960|Experimental|Tea infusion|The aerial parts of each plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. the powder of the mixture was added to 100 ml of boiling water and the tea infusion was taken three times a day for three consecutive days and it was repeated for three consecutive months
89228472|NCT05406882|Experimental|combination therapy group|From the first day of chemoradiotherapy, live combined Bifidobacterium and Lactobacillus tablets(2000mg each time, 3 times/day) combined with compound glutamine enteric-coated capsules (3 capsules each time, 3 times/day) until 1 month after the end of chemoradiotherapy.
89228473|NCT05406882|No Intervention|control group|After the start of chemoradiotherapy, the control group don't take the experimental drug orally . When patients have radiation proctitis of grade ≥2, they would be crossed over to the combined treatment group：live combined Bifidobacterium and Lactobacillus tablets(2000mg each time, 3 times/day) combined with compound glutamine enteric-coated capsules (3 capsules each time, 3 times/day) until 1 month after the end of chemoradiotherapy.
89228474|NCT01564134|Experimental|HepB 5ug|receive the vaccine with 5ug HBsAg
89228475|NCT01564134|Experimental|HepB 10ug|receive the vaccine with 10ug HBsAg
89228476|NCT01564134|Experimental|HepB 20ug|receive the vaccine with 20ug HBsAg
89228477|NCT01564134|Experimental|HepB 60ug|receive the vaccine with 60ug HBsAg
89228478|NCT05357196|Other|PT-112 in Combination with Gemcitabine Injection|PT-112 in combination with Gemcitabine injection for the treatment of patients with advanced solid tumors
89228479|NCT03902574|Experimental|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
89228480|NCT03902574|Experimental|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
89228481|NCT03902574|Experimental|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
89228482|NCT01564290|Placebo Comparator|probiotic|Probiotic product with Sacharomices Boulardii
89228483|NCT01564290|Active Comparator|probiotic yogurt|Yogurt with Lactobacilus Rhamnonsus strain spp
89228484|NCT01004874|Experimental|Bevacizumab, XRT, Temozolomide, Topotecan|Patients are treated with standard radiation therapy and daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation. Following completion of radiation therapy, patients have a MRI and, if there is no evidence of disease progression, patients receive 12 cycles of Avastin, temozolomide, and topotecan. Beginning a minimum of 14 days after the last radiation treatment, the Avastin is dosed at 10 mg/kg every other week; temozolomide is given at 150 mg/m2 daily the first 5 days in combination with topotecan on days 2 through 6 at 1.5 mg/ m2 for patient not taking EIAEDs and 2.0 mg/ m2 for patients taking EIAEDs on days 2-6 of each 28-day.
89228485|NCT05356026|Experimental|Online follow up group|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
89228486|NCT05356026|No Intervention|Routine follow up group|The women in the control group received the routine follow-up and care provided by the hospital.
89228487|NCT04002804|Experimental|Immunotherapy|Autologous DC loaded with a autologous tumor lysate, in order to stimulate the immune response of the patient.
89228488|NCT05355948|Experimental|MEMO Patch PLUS ECG monitoring for One-day|
89228489|NCT05355948|Experimental|MEMO Patch PLUS ECG monitoring for More than 8-days|
89228490|NCT04302818|Experimental|Social skills group training SKOLKONTAKT|Manualised social skills group training.
89228491|NCT04302818|Active Comparator|Active control comparison group|Social activities in a group setting.
89228492|NCT00987116|Active Comparator|Starting dose Prednisone Azathioprine|Classical Strategy
89228493|NCT00987116|Active Comparator|Starting dose Prednisone - Azathioprine|Rapid strategy
89228494|NCT04006340|Placebo Comparator|Empirical group|Patients receive conventional triple therapy containing esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days
89228495|NCT04006340|Active Comparator|Genotypic resistance-guided tailored group|"Patients receive triple or quadruple therapy by resistance-associated mutations in 23S ribosomal RNA which are identified by polymerase chain reaction (PCR).~Triple therapy contains esomeprazole 40 mg, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days and quadruple therapy contains esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days."
89107850|NCT02825199|Experimental|Caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received caffeine capsule (300mg). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
89107851|NCT02825199|Placebo Comparator|Non caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received placebo capsule (maize starch). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
89107852|NCT02824965|Experimental|Pembrolizumab+1x10^9 TCID50 CVA21|CVA21 will be administered IV on days: 1, 3, 5, 8 29, 50, 71, 92, 113 134, and 155. 200mg Pembrolizumab will be administered as per normal dosing frequency at Q3W IV, and will continue for up to 24 months. Should dose limiting toxicities be observed participants may be transferred a lower dosage of CVA21.
89107853|NCT04919343|Experimental|BBC Tiny Happy People intervention|Parents will be sent links each month directing them to BBC Tiny Happy People content via SMS text message using the secure service FireText. This content will be aimed at supporting language development. Parents will be asked to watch the video content and incorporate it into their parenting practices. The intervention will start when infants are aged 4-9 months and conclude when they are 18 months with a follow up to 24 months where time permits.
89107854|NCT04919343|Active Comparator|Physical health control|Similar to the experimental condition, parents will be sent links each month via SMS text message using FireText. These links will direct them to publicly available web content with tips to promote the healthy development of their baby, focusing on things such as healthy eating, physical activities, and dental care. The intervention will start when infants are aged 4-9 months and conclude when they are 18 months with a follow up to 24 months where time permits
89107855|NCT04242537|Experimental|High flow oxygen delivery|Oxygen delivery with high flow nasal cannula with head side elevation to 30 degrees
89107856|NCT04242537|Experimental|Low Flow oxygen delivery|Low flow oxygen delivery through nasal cannula with head side elevation to 30 degrees
89107857|NCT04242537|No Intervention|Standard practice of care|No oxygen delivery either high flow or low flow through nasal cannula
89107858|NCT00886743|Other|Oprelvekin as subcutaneous injection (50 mg/kg once daily)|Open label treatment with oprelvekin
89107859|NCT00886587|Experimental|11054-010|F# 11054-010 Investigational Device
89107860|NCT00886587|Active Comparator|10495-053|F# 10495-053 Atopiclair
89107861|NCT00886119|Other|Lotrafilcon B / Omafilcon A|Lotrafilcon B, followed by Omafilcon A
89107862|NCT00886119|Other|Omafilcon A / Lotrafilcon B|Omafilcon A, followed by Lotrafilcon B
89107863|NCT02823873||Normotensive|Normotensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
89107864|NCT02823873||Hypertensive|Hypertensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
89107865|NCT02826759||serum sphingolipid metabolites in healthy subjects|Healthy subjects are classified according to BMI into three subgroups: healthy normal weight subjects, healthy overweight subjects and healthy subjects with obesity. Age and sex are matched among three subgroups. serum sphingolipid metabolites including sphingosine-1-phosphate will be compared.
89107866|NCT02826759||serum sphingolipid metabolites in diabetic subjects|Diagnosed diabetic patients are divided into three subgroups: diabetic patients with normal weight, overweight and obesity. age and sex are matched.
89107867|NCT02826759||serum sphingolipid metabolites in the progression of diabetes|serum sphingolipid metabolites are compared among three age-, sex- and body mass index-matched subgroups: healthy subjects, subjects with pre-diabetes, subjects with diabetes
88820930|NCT05422014|No Intervention|No LCS Intervention|Patients will receive the current standard-of-care for pain management in the aftermath of trauma, which includes: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
89107868|NCT02826759||serum sphingolipid metabolites and HbA1c|diabetic subjects are divided by HbA1c level. the cut-offs are 7% and 9%. serum sphingolipid metabolites will be tested among diabetic patients with HbA1c <7%, 7%-9% and >9%
89107869|NCT02826759||serum sphingolipid metabolites in insulin-resistant subjects|comparison of serum sphingolipid metabolites in newly diagnosed insulin-resistant subjects and age-, sex- and BMI-matched healthy controls.
89107870|NCT02824887||Exposed group|Long term curative effect of electroacupuncture treatment of lumbar intervertebral disc herniation in exposure group
89107871|NCT02824887||control group|Long term efficacy of conventional treatment of lumbar disc herniation in the control group
89107872|NCT02823951||Rebif - 1 year MRI cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline and at 12 months
89107873|NCT02823951||Rebif - 1 year clinical cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline
89107874|NCT02823951||Rebif - early discontinuation cohort - tolerability|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
89107875|NCT02823951||Rebif - early discontinuation cohort - adverse events|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
89107876|NCT02823951||Rebif - early discontinuation cohort - disease activity|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
89107877|NCT02823951||Tecfidera - 1 year MRI cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline and at 12 months
89107878|NCT02823951||Tecfidera - 1 year clinical cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline
89107879|NCT02823951||Tecfidera - early discontinuation cohort - tolerability|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
89228496|NCT05711654|Experimental|Health coaching group|"The patients in the health coaching group will first be given data collection tools, and then the COPD patient information training created by the researcher will be given.~For the first eight weeks after the training, face-to-face meetings will be held with patients once a week.~Data collection tools will be applied to the patients again in the fourth week and 12 weeks after the interviews are over."
89228497|NCT05711654|No Intervention|Control group|"Data collection tools will be applied to the patients in the control group first, and then the COPD patient information training created by the researcher will be given.~After the training, there will be no interviews with the patients, and data collection tools will be applied again in the 12th and 20th weeks."
89228498|NCT04005326|Experimental|QLB Group|this group will receive ultrasound-guided transmuscular quadratus lumborum block; (Anterior QLB or QLB III)
89228499|NCT04005326|Experimental|FIB Group|this group will receive suprainguinal fascia iliaca block
89228500|NCT04004702|Experimental|Levetiracetam|All patients with epileptiform activity on initial screening EEG will receive levetiracetam for 1 year
89228501|NCT00542828|Experimental|Thymoglobulin|
89228502|NCT04533074|Experimental|Single-visit regeneration protocol|
89228503|NCT04533074|Active Comparator|Multiple-visits regeneration protocol|
89228504|NCT04722692|Experimental|Delayed SLND (SPIO-first arm)|"All study participants have been injected interstitially with SPIO, 2ml, at the primary operation. Magnetic axillary signal is registered at the end of the procedure but the SLN is not removed. If invasive cancer is found in the specimen, reoperation for SLND with the addition of Tc +/- BD is performed.~At reoperation, SPIO is the primary detection tracer."
89228505|NCT04722692|Active Comparator|Late SLND (RI-first arm)|"All study participants have been injected interstitially with SPIO, 2ml, at the primary operation. Magnetic axillary signal is registered at the end of the procedure but the SLN is not removed. If invasive cancer is found in the specimen, reoperation for SLND with the addition of Tc +/- BD is performed.~At reoperation, Tc is the primary detection tracer."
89228506|NCT05711342|Active Comparator|Treatment as usual (TAU)|In this control condition, participants receive in-person aggression treatment as usual (TAU). No changes to the way treatment is provided as usual are made. In general, this refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient in a one-on-one setting. The main focus of treatment as usual should lie on aggression regulation. Additionally, patients should receive individual, one-on-one treatment and should not participate in group treatment of aggression during data collection.
89228507|NCT05711342|Experimental|Treatment as usual (TAU) +Internet-based intervention Aggression|In the experimental condition, participants receive TAU, and additionally work on the 10-week internet-based intervention 'Aggression', on which they can work in their own time, i.e. outside of treatment sessions. Consequenlty, the intervention is used in a blended way. The intervention is focused on three main objectives: (1) increasing the motivation to change, (2) acquiring skills for dealing with conflict, and (3) breaking the cycle of aggression by providing knowledge on situational, emotional, cognitive and physical triggers. The module consists of 10 lessons:
88820931|NCT05420493|Experimental|Intravenous of CAR-T|Infusion of CAR-T cells by dose of 3-10 x105 cells/kg
88820932|NCT05418868|Experimental|Part A: Participants receiving CAB 200 mg/mL with rHuPH20|Part A of the study (CAB 200 mg/mL with rHuPh20) has been closed to further enrolment based on preliminary results.
89228508|NCT05710796||All population|The total population reported to Cardiology department during enrollment period
89228509|NCT05710796||COVID recovered|Patient having history of COVID 19 disease
89228510|NCT05710796||No history of COVID|Population those who never exposed to COVID 19 disease and never suffers
89228511|NCT04266470|Experimental|Lara Device Scan|This imaging study will be obtained strictly for the research purposes of mid-treatment assessment of blood flow and uptake kinetics analysis
89228512|NCT00987350|Active Comparator|Trivalent influenza vaccine by needle and syringe|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the standard needle and syringe method
89228513|NCT00987350|Experimental|Trivalent influenza vaccine by jet injection|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the experimental method of jet injection
89228514|NCT00987428|Experimental|groupe 1|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
89228515|NCT00987428|Active Comparator|Groupe 2|usual procedure
89228516|NCT01563692||Paediatric health care workers|NHS members of staff who regularly care for children admitted with RSV infections, and who therefore have a higher rate of exposure.
89107880|NCT02823951||Tecfidera - early discontinuation cohort - adverse events|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
89107881|NCT02823951||Tecfidera - early discontinuation cohort - disease activity|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
89107882|NCT02826837|Experimental|LEAC-102 and FOLFOX+Bevacizumab/Cetuximab|"The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
89107883|NCT02826525|Experimental|Treatment|Subjects in this arm will receive AZD4076
89107884|NCT02826525|Placebo Comparator|Control|Subjects in this arm will receive placebo
89107885|NCT04243083|Experimental|Single Ascending Dose (SAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
89107886|NCT04243083|Experimental|Multiple Ascending Dose (MAD)|There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.
89107887|NCT04243083|Experimental|Food Effect Panel|Twelve subjects will receive a single dose of TLL018 in 2 treatment periods, one after a high fat, high calorie breakfast (fed) and the second treatment period under fasted conditions to determine the effect of food on the PK of TLL018.
89107888|NCT04877847|Experimental|Low-Frequency Therapeutic Ultrasound|LOTUS system will be operated per operated per normal instructions
89107889|NCT04877847|Sham Comparator|Sham Control|LOTUS system will be set to Control setting
89107890|NCT02825277|Other|pathological group|pregnant women with preeclampsia and/or IUGR pregnancy with a planned or semi-urgent caesarean section or vaginal delivery will be recruited into this study.
89107891|NCT02825277|Other|physiological group|pregnant women with normal pregnancy with a planned caesarean section or vaginal delivery will be recruited into this study
89107892|NCT02823639|Active Comparator|Transcranial direct current stimulation|tDCS with varying intensity, location and polarity
89107893|NCT02823639|Placebo Comparator|Sham stimulation|Double blind sham stimulation with sham mode of neuroConn device
89107894|NCT04240977|Experimental|Treatment Group|
89107895|NCT04875507|Active Comparator|Positive psychology|The experimental group(n=60), who will receive a 1.5-hour workshop covering positive psychology techniques delivered by a qualified research assistant, in groups of less than 5 people.
89107896|NCT04875507|No Intervention|Control|The control group will receive no intervention.
89107897|NCT04243161|Experimental|Group 1|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.
89107898|NCT04243161|Active Comparator|Group 2|Common clinical practice (pulmonary expansion exercises, drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.
89107899|NCT02822547|Experimental|Peginterferon alfa-2a|
89107900|NCT05040009|Active Comparator|moderate and high risk patient with integrated foot care program|"Integrated foot care program will be applied to moderate and high-risk patients for diabetic foot with follow up after 6-12 months~Regular foot care and examination by an adequately trained professional: -~Structured education~Adequate footwear~Foot-related exercises and weight-bearing activity.~Foot examination and screening every 4 months in moderate risk and 2 months in high-risk patient for diabetic foot.~Instructions about foot self-management"
89107901|NCT05040009|No Intervention|moderate and high risk patient with conventional treatment|conventional treatment will be applied to moderate and high-risk patients for diabetic foot with follow up after 6-12 months.
89107902|NCT05660889||Study group|Five patients with strong clinical suspicion of adrenocortical carcinoma
89107903|NCT05660889||Control group|Twenty patients without suspicion of adrenal malignancy. These patients should undergo an adrenal vein sampling as part of their routine diagnostics.
89107904|NCT02823483|Experimental|Arm 1|All subjects are patched.
89107905|NCT04848597|Experimental|Single Arm|Recombinant humanized anti-PD-1 monoclonal antibody injection:200mg once every 3 weeks
89107906|NCT04240041||Pregnant women at 32-36 weeks gestational age|Pregnant women at 32-36 weeks gestational age with sure dates and crown-rump length dating ultrasound
89228517|NCT01563692||Non-paediatric health care workers|This is a comparator group made up of healthy adults who do not work in an occupation or have other risk factors for higher exposure to RSV.
89107907|NCT02822313|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89107908|NCT04803669|Active Comparator|Conventional Treatment Group|Includes Hotpack, TENS, Ultrasound and Exercise programs.
89107909|NCT04803669|Experimental|IASTM Group|Inludes Hotpack, TENS, Ultrasound, Exercise program and Instrument-assisted Soft Tissue Mobilization Technique
89107910|NCT02826447||Patients|500 patients who are going to be hospitalized for at least 24 hours at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
89107911|NCT02826447||Healthcare workers|50 healthcare workers working at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
89228518|NCT00987506||XIENCE V®|Participants receiving XIENCE V® EESS
89228519|NCT04567082||Cancer group|
89228520|NCT04567082||Control group|
89228521|NCT00987662|Active Comparator|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add HCZ 12.5 mg.
89107912|NCT04239729|Experimental|ACT Website and Coaching Condition|Participants will be asked to complete 16 brief self-help website sessions, each taking around 15-20 minutes to finish, twice a week for eight weeks. Website exercises and examples primarily focus on hoarding, although some examples also discuss related mental health concerns such as anxiety, low mood, health behaviors, etc. The sessions use multimedia and are interactive. Participants assigned to the website condition will also receive coaching. The purpose of coaching will be to help participants engage with the website and adhere to the intervention. Coaching will consist of an initial phone call of 10-15 minutes followed by weekly email contact during the 8-week treatment period. Coaches will be graduate students trained in clinical psychology.
89107913|NCT04239729|No Intervention|Waitlist Condition|Participants assigned to the waitlist will be asked to wait 12 weeks without intervention (access to the website or coaching). They will receive access to the website after 12 weeks, but supportive coaching will not be provided to waitlist participants.
89107914|NCT02826369|Experimental|3.0 Tesla in Magnetic Resonance Imaging|
89107915|NCT05660811|Other|30 days DAPT and long-term treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
89107916|NCT05660811|Other|6 months DAPT and long-term treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and long-term treatment with a single antiplatelet agent
89107917|NCT05660811|Other|30 days DAPT and 6 months treatment with a single antiplatelet agent|short postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
89107918|NCT05660811|Other|6 months DAPT and 6 months treatment with a single antiplatelet agent|extended postimplantation dual antiplatelet therapy and 6 months treatment with a single antiplatelet agent
89107919|NCT02823561|Active Comparator|Garcinia mangostana (treatment group)|Balanced low-calorie diet and regular exercise in combination with integration
89107920|NCT02823561|Other|Control group|balanced low-calorie diet and regular exercise
89107921|NCT02823405|Experimental|X4P-001 + Pembrolizumab|X4P-001 alone, then adding pembrolizumab
89107922|NCT02823249|Active Comparator|1.56 g L-Tryptophan|"1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
89107923|NCT02823249|Active Comparator|1.56 g L-Leucine|"1.56 g L-Leucine in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
89107924|NCT02823249|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water given via nasogastric tube
89107925|NCT02823249|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water given via nasogastric tube
89107926|NCT02823249|Placebo Comparator|75 g Glucose and mixed liquid meal|"75 g Glucose in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
88820933|NCT05418868|Experimental|Part C: Participants receiving CAB 400 mg/mL|
88820934|NCT05418868|Experimental|Part D: Participants receiving CAB 400 mg/mL with rHuPH20|
89107927|NCT02823249|Placebo Comparator|Tap water and mixed liquid meal|"300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
89107928|NCT04240743|Active Comparator|cephalomedullary nail|Cephalomedullary nails was inserted and fixed to the femoral head. In this study, all patients were treated with short nails (Profin®, TST).
89107929|NCT04240743|Active Comparator|sliding hip screw|Sliding hip screws was inserted and fixed to the femoral head. In this study, all patients were treated with a side plate with three holes (DHS plate, TST).
89107930|NCT02821845||Control|Individuals with no spinal cord injury or other neurological deficits.
89107931|NCT02821845||Untrained and Trained SCI Hip and Knee|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Untrained individuals will complete 3 baseline measures and then complete eccentric training which will focus on rehabilitation of the hip joint or knee joint.
89107932|NCT04240431||Epiphora|Adult patients suffering from watering of the eye included in the study to detect level of obstruction
89107933|NCT00633711|Active Comparator|fixed CPAP|
89107934|NCT00633711|Experimental|Auto-CPAP|"Auto-CPAP Weinmann Somnosmart2"
89107935|NCT00768079|Placebo Comparator|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
89107936|NCT00768079|Experimental|Benralizumab 0.3 mg/kg|A single dose of benralizumab (MEDI-563) 0.3 milligram per kilogram (mg/kg) of body weight intravenous infusion over at least 30 minutes on Day 0.
89107937|NCT00768079|Experimental|Benralizumab 1.0 mg/kg|A single dose of benralizumab (MEDI-563) 1.0 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
89107938|NCT02820675|Other|intervention|all hospitals participating in the icosmos trial will be supported in implenatation of the two main interventions.
89107939|NCT04753047||Children practicing football|Children in late childhood (age 10-12 years) practicing sport, which is high dynamic (> 75%), and low static (<10&) and in the same time it is open skill exercise sport (football)
89107940|NCT04753047||Children practicing gymnastics|Children in late childhood (age 10-12 years) practicing sport, which is low dynamic (<50%), high static (>30%) and in the same time it is closed skill exercise sport (sport gymnastics)
89107941|NCT04753047||Comparative group|A comparative group of children that do not attend sport classes or sports clubs, but carrying out sports activity and / or in other areas
89107942|NCT02603575|Experimental|Caspofungin and corticosteroids|patients treat with caspofungin and corticosteroids on the base of sulfanilamide
89107943|NCT02603575|Active Comparator|Caspofungin and no corticosteroids|patients treat with caspofungin on the base of sulfanilamide
89107944|NCT02603575|Active Comparator|corticosteroids and no caspofungin|patients treat with corticosteroids on the base of sulfanilamide
89107945|NCT02603575|Active Comparator|no corticosteroids and no caspofungin|patients treat with sulfanilamide only
89107946|NCT02823015||Study population|The study population consists of adult surgery patients, scheduled for breast cancer surgery at St-Luc University Hospital.
89107947|NCT02601859|Experimental|Phase 3|Administration of Lithium to 11 individuals with MCI (non-randomised) for 9 weeks. Lithium dose escalates from 100mg to 200mg to 400mg, then a 3 week wash out period, total study duration 12 weeks. Blood samples taken at regular intervals throughout trial and analysed for GSK-3 enzyme activity in blood.
89107948|NCT04097587|Other|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
89107949|NCT02822703|Experimental|Active 20Hz|The rTMS device used in this study is the Mastim Super Rapid2 Stimulator with a 70mm Double Air Film Coil. Guidelines indicate that the maximum safe duration of a single train of 20Hz at 110% of the Motor Threshold (MT) is 1.6 seconds. In this study, the stimulator and the coils will be used to stimulate neurons in the left dorsolateral prefrontal cortex (DLPFC), the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment in depression, in order to examine the feasibility of testing this intervention for efficacy in the treatment of tobacco dependence.
89107950|NCT02822703|Sham Comparator|Sham|The rTMS sham coil used in this study is manufactured by Magstim and currently classified as an investigational device. There is no intention to treat or prevent a disease and/or alter a function in the body with the sham stimulation provided by the sham coil. In this project, the sham coil will be placed in the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment for depression.
89107951|NCT02601079|Active Comparator|Conventional biopsy|"4 out of 8 biopsies taken with a conventional biopsy forceps from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
89107952|NCT02601079|Active Comparator|Endodrill biopsy|"4 out of 8 biopsies taken with the Endodrill instrument from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
89107953|NCT04240275||Children with Cerebral Palsy|Children diagnosed with Spastic Cerebral Palsy (Unilateral or Bilateral) among the age range of 5-15 who can walk independently
89107954|NCT02822157|Experimental|Olaparib|olaparib 300mg oral tablets twice daily for 28 days in 28-day cycles
89107955|NCT02822157|Active Comparator|Chemotherapy|physician's choice chemotherapy
89107956|NCT00767455|Sham Comparator|Positive, Negative Controls|
89107957|NCT02822937|Experimental|Placebo, Methylphenidate, Triazolam|The participants will receive placebo on the first day, 40mg Methylphenidate on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
89107958|NCT02822937|Experimental|Placebo, Triazolam, Methylphenidate|The participants will receive placebo on the first day, 0.375mg Triazolam on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
89107959|NCT02822937|Experimental|Methylphenidate, Placebo, Triazolam|The participants will receive 40mg Methylphenidate on the first day, placebo on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
89107960|NCT02822937|Experimental|Methylphenidate, Triazolam, Placebo|The participants will receive 40mg Methylphenidate on the first day, 0.375mg Triazolam on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
89107961|NCT02822937|Experimental|Triazolam, Placebo, Methylphenidate|The participants will receive 0.375mg Triazolam on the first day, placebo on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
89107962|NCT02822937|Experimental|Triazolam, Methylphenidate, Placebo|The participants will receive 0.375mg Triazolam on the first day, 40mg Methylphenidate on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
89107963|NCT04200885|Active Comparator|Postoperative NSAID Prescription|Patients in this arm received common postoperative prescriptions following removal of their impacted third molars for seven days; twice a day 500 mg amoxicillin+125 mg clavulanic acid, twice a day 25 mg dexketoprofen trometamol and three times a day 1.5 mg/ml clorhexidine gluconate+1.2 mg/ml benzydamine hydrochloride containing 200 ml mouthwash.
89107964|NCT04200885|Active Comparator|Preoperative Submucosal Corticosteroid Injection|Patients in this arm were administered 8mg/2ml dexamethasone 21-phosphate preoperatively after local anesthesia were obtained. Injection site was the depth of buccal sulcus near operation site. For the patients in this arm 25 mg dexketoprofen trometamol was excluded from postoperative prescription in order not to affect the anti-inflammatory effects of corticosteroid. Instead of NSAID, three times a day 500 mg paracetamol was prescribed. The patients were advised not to exceed maximal dosage of 3000 mg (6 tablets) in a day.
89228522|NCT00987662|Active Comparator|Amplodipine|Treatment with amlodipine 10 mg for 4 weeks. If BP>135/85 mmHg add hydrochlorothiazide 12.5 mg
89228523|NCT05698784||"Group a inappropriate"|"In the inappropriate , we placed prescriptions with no indication, 123I-FP-CIT SPECT"
89107965|NCT04200885|Active Comparator|Postoperative Therapeutic Elastic Bandage Application|In this arm the therapeutic elastic bandage applications were immediately performed after removal of mandibular third molars. The distance between tragus-lateral commissura line and supraclavicular lymph nodes was measured and the tapes were then cut into 5 tails. The base of the tape was placed on supraclavicular lymph nodes and tails were placed on the site to cover parotid, submandibular, submental and superficial cervical lymph nodes. The tapes were removed on postoperative second day.
89107966|NCT00766831|Experimental|Hydromorphone OROS|Participants will receive hydromorphone OROS (8 milligram [mg] up to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
89107967|NCT02821689|Experimental|pirfenidone|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on. Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. Investigators were allowed to adjust the dose according to the participants' tolerance.
89107968|NCT02821689|No Intervention|Blank|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on.
89107969|NCT02822859|Active Comparator|Wright|Methacholine challenge performed using the Wright nebulizer
89107970|NCT02822859|Active Comparator|Bennett-Twin|Methacholine challenge performed using the Bennett-Twin nebulizer
89107971|NCT02822859|Active Comparator|Aeroneb Solo|Methacholine challenge performed using the Aeroneb Solo nebulizer
89107972|NCT02821533|Other|TACE using a high dose of cisplatin|Two consecutive treatments at two months apart will be given. A delay in the second treatment is allowed if patients do not recover to an acceptable state for subsequent cycle of treatment. Two treatment sessions at one month apart may be required for each complete treatment to cover all lesions when the lesions are diffusely distributed and involving both lobes.
89107973|NCT05659407||BAFF-var carrier|
89107974|NCT05659407||No BAFF-var carrier|
89107975|NCT04240353||COPD group|Patients with high-risk COPD with recent exacerbation requiring hospitalisation (within last 12 months) or hypercapnia respiratory failure and/or sleep disordered breathing meeting criteria for provision of home NIV.
89107976|NCT00766675|Experimental|Tramadol hydrochloride/acetaminophen|Tramadol hydrochloride/acetaminophen oral tablet will be administered as 37.5 /325 milligram respectively once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
89107977|NCT04101799|Experimental|Intervention|Participating in the For our children's sake intervention, 10 group sessions, 2 hours each
89107978|NCT04101799|Active Comparator|Control|Participating in everyday activities that may include parenting activities in the control prisons
89107979|NCT02821611|Experimental|Meditation Group|Participants in the experimental group are practicing a mantra-based meditation twice daily for 20 minutes over the 8 week intervention period to reduce stress and blood pressure and enhance quality of sleep.
89107980|NCT02821611|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
89107981|NCT00766597|Experimental|Vicriviroc in tablet form (20/30 mg) or liquid form (1 mg/ml)|HIV-1 Infected Antiretroviral Therapy Experienced Participants with CCR5-tropic Virus
89107982|NCT02820441|Experimental|ZOPICLONE|Zopiclone 3.5 mg capsule by mouth daily for 2 weeks
89107983|NCT02820441|Placebo Comparator|PLACEBO|Placebo 3.5 mg capsule by mouth daily for 2 weeks
89107984|NCT00910962|Experimental|Treatment A|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
89107985|NCT00910962|Experimental|Treatment B|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
89107986|NCT00910962|Placebo Comparator|Treatment C|Placebo twice daily for 12 weeks
89107987|NCT02822391||Stroke-group|Screened and recruited from the Division of Neurorehabilitation, Department of Clinical Neurosciences, University Hospital and University of Geneva, Geneva, Switzerland by a senior consultant neurologist (BL). Patients were included if they were hospitalized for stroke rehabilitation, were able to undergo psychophysical testing and presented with a facial impairment according to the House-Brackmann criteria ≥2 15. They were excluded if they presented with acute pain in the oro-facial sphere (nominal question) or an additional neuro-muscular disease.
89107988|NCT02822391||Control-group|Similar to stroke group in regard to age, gender and dental state. no stroke
89107989|NCT02690571|Sham Comparator|Filtered air exposure|One hour exposure to filtered air during intermittent exercise in controlled chamber, 6 hours after exposure bronchoscopy is performed.
89107990|NCT02690571|Experimental|Biodiesel exhaust exposure|One hour exposure to biodiesel exhaust (generated at same running conditions as earlier studies with diesel exhaust at approximate particle matter concentration 300 mcg/m3) during intermittent exercise in controlled chamber. Six hours after exposure bronchoscopy is performed.
89107991|NCT04200807||Healthy preterm neonate|Neonate 26 weeks to 36 weeks + 6 days of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
89107992|NCT04200807||Healthy term neonate|Neonate from 37 weeks of gestation, without congenital heart defects and/or hemodynamically significant fetal circulation, any respiratory therapy, nor need of supplemental oxygen. Subjects had no clinically and laboratory-identified infections.
89107993|NCT04200807||Sick neonate|Neonate of any gestation, without congenital heart defects, with clinically and laboratory-identified infection.
89107994|NCT05659095|Experimental|Experiment groups|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point.
89107995|NCT05659095|No Intervention|Control groups|The control group was injected with the same volume of normal saline.
89107996|NCT02821065|Experimental|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse receives and reviews the data electronically and will follow-up with the patient.
89107997|NCT02820285|Other|Morbid obese patients|
89107998|NCT02820285|Other|Control patients|
89107999|NCT02820285|Other|Patients with overweight, steatosis and steatohepatitis|
89108000|NCT04239807|Experimental|Group 1 WBV - training with wbv|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training~Month 1:~Day 1: From this day subjects are supposed to start their training accoridng to protocol~Day 2: Telephone Visit~Day 5: Telephone Visit~Day 7: Telephone Visit~Day 10: Telephone Visit~Day 13: Telephone Visit~Day 20: Telephone Visit~Day 27: Telephone Visit~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training~Month 2:~Week 5, Day 34:~Week 6, Day 41:~Week 7, Day 48:~Week 8, Day 55:~Month 3:~Week 9, Day 62:~Week 10, Day 69:~Week 11, Day 76:~Week 12, Day 83: Final Visit"
89108001|NCT04239807|Other|Group 2 Control - training without WBV|"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training~Month 1:~Day 1: From this day subjects are supposed to start their training accoridng to protocol~Day 2: Telephone Visit~Day 5: Telephone Visit~Day 7: Telephone Visit~Day 10: Telephone Visit~Day 13: Telephone Visit~Day 20: Telephone Visit~Day 27: Telephone Visit~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training~Month 2:~Week 5, Day 34:~Week 6, Day 41:~Week 7, Day 48:~Week 8, Day 55:~Month 3:~Week 9, Day 62:~Week 10, Day 69:~Week 11, Day 76:~Week 12, Day 83: Final Visit"
89108002|NCT00773461|Experimental|1|
89108003|NCT00773461|Placebo Comparator|2|
89108004|NCT02821377|Experimental|intravenous furosemide|intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge Intervention: drug: furosemide ; other name: lasix
89108005|NCT02821377|Experimental|intravenous hypertonic saline solutions|small volumes of hypertonic saline solutions (HSS) (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge Intervention: Hypertonic saline solutions (1.4-4.6%NaCl) Intervention other name: not specified
89108006|NCT02821377|Active Comparator|seriated paracentesis|no intervention Intervention: no drug only seriated paracentesis repeated paracentesis from the first day after admission until 3 days before discharge
89108007|NCT02820987|Active Comparator|MEROPENEM|After enrollment, patients of MEROPENEM arm will receive an initial 2g bolus of MEROPENEM and 2g infusion over 3 hours every eight hours, during 48 hours, without modification of rhythm and dose according to renal function.
89108008|NCT02820987|Active Comparator|PIPERACILLIN-TAZOBACTAM|After enrollment, patients of PIPERACILLIN - TAZOBACTAM arm will receive an initial 4g bolus of PIPERACILLIN - TAZOBACTAM and a 16g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
89228524|NCT05698784||"Group b uncertain"|"In the uncertain, we did not have sufficient data to determine with certainty whether this was an inappropriate or relevant indication."
89228525|NCT05698784||"Group c relevant"|"In the relevant , the prescriptions concerned the differential diagnosis between neurodegenerative parkinsonism and secondary parkinsonian syndromes"
89228526|NCT00987740|Experimental|Hemolung Respiratory Assist System|
89228527|NCT04482374||Transgender females|Transgender females who plan to start a gonadotropin releasing hormone agonist clinically in the next 2 months
89228528|NCT04482374||Cisgender males|Cisgender male controls
89228529|NCT00987818|Experimental|PCT guided antibiotic therapy|
89228530|NCT00987818|Placebo Comparator|Standard antibiotic therapy|
89228531|NCT05690126|Active Comparator|Saffron extract|"Daily, two dietary supplements (Saffron extract) will be taken orally with water, the first one at breakfast and the second one at dinner.~Dietary supplements in capsule form"
89228532|NCT05690126|Placebo Comparator|Placebo|"Daily, two dietary supplements (Maltodextrin) will be taken orally with water, the first one at breakfast and the second at dinner.~Dietary supplements in capsule form"
89228533|NCT00987896|Experimental|Megachannel Application|Colonoscopy with loaded Megachannel is performed
89228534|NCT00090103|Active Comparator|dutasteride|dutasteride 0.5mg once daily
89228535|NCT00090103|Experimental|Combo|Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily
89228536|NCT00090103|Active Comparator|tamsulosin|tamsulosin 0.4mg once daily
89228537|NCT01088659|Experimental|1|
89228538|NCT01088659|Experimental|2|
89228539|NCT03962257|No Intervention|Conventional|This group will have standard of care infertility counseling and consent processes.
89228540|NCT03962257|Experimental|Engaged MD|This group will have standard of care infertility counseling and access to online teaching modules and the ability to sign consents online.
89228541|NCT00087607|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants received Peginterferon alfa-2a (40 kD) [Pegasys] at a dosage of 180 microgram (μg), subcutaneously (SC), once a week plus Ribavirin [Copegus] 1000 or 1200 milligram (mg)/day), orally, [according to body weight, lesser than or greater than/equal to (< or >/=) 75 kilogram (kg), respectively] twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
89228542|NCT00087607|Active Comparator|Peginterferon Alfa-2b + Ribavirin|Participants received Peginterferon alfa-2b (12 kD) [PEG-Intron] at a dosage of 1.5 μg/kg SC once weekly plus Ribavirin [Rebetol] 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
89228543|NCT00069823|Experimental|Esomeprazole|Proton pump inhibitor of gastric acid
89228544|NCT00069823|Placebo Comparator|Placebo for esomeprazoe|Placebo
89228545|NCT01088815|Experimental|Gemcitabine, nab-paclitaxel, GDC-0449|Gemcitabine and nab-Paclitaxel in combination with GDC-0449 (Vismodegib)
89228546|NCT00086515|Experimental|Sitagliptin 100 mg|The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.
89228547|NCT00086515|Placebo Comparator|Placebo / Glipizide 5 mg|The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated, in a blinded fashion, to a maximum dose of 15 mg/day.
89228548|NCT01090609|Experimental|Stent implantation|Cronus Stent implantation
89228549|NCT00541658|Active Comparator|5 mg Before Breakfast|5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
89228550|NCT00541658|Experimental|35 mg After Breakfast|35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
89228551|NCT00541658|Experimental|35 mg Before Breakfast|35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)
89228552|NCT04384952|Experimental|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeated reading with feedback from the parent and time control.
89228553|NCT04384952|Active Comparator|Dyslexic's Holliday Workbook.|Use of a special Dys holiday book, no parent-guided training.
89228554|NCT04334174|Experimental|Single Arm|Brentuximab vedotin (SGN-35), intravenous infusion, 1.8 milligrams (mg) per kilogram (kg), day one of each twenty- one day cycle with a total of ten cycles planned.
89228555|NCT00987974|Experimental|rosuvastatin 3days|8 Subjects will use rosuvastatin 20 mg/day for 3 days
89228556|NCT00987974|Active Comparator|atorvastatin 3 days|8 Subjects will use atorvastatin 80 mg/day for 3 days.pj
89228557|NCT00987974|Placebo Comparator|placebo 3days|8 Subjects will use placebo for 3 days.
89228558|NCT00987974|Experimental|rosuvastatin 7 days|8 Subjects will use rosuvastatin 20 mg/day for 7 days.
89228559|NCT00987974|Active Comparator|atorvastatin 7 days|8 Subjects will use atorvastatin 80 mg/day for 7 days.
89228560|NCT00987974|Placebo Comparator|placebo 7 days|8 Subjects will use placebo for 7 days.
89108009|NCT02820987|Active Comparator|CEFEPIME|After enrollment, patients of CEFEPIME arm will receive an initial 2g bolus of CEFEPIME and a 6g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
89108010|NCT04052490|Experimental|flat occlusal reduction with feather edge finish|
89108011|NCT04052490|Experimental|flat occlusal reduction with shoulder finish line|
89108012|NCT04052490|No Intervention|planar occlusal reduction with shoulder finish line|
89108013|NCT04041258|Experimental|evaluation of clinical and radiographic findings after surgical treatment|Evaluation of clinical and radiographic findings at least 1 year after surgical treatment for pseudoarthrosis of clavicle
89108014|NCT02820363|Experimental|Test|"Tibial fracture fixation with IM Nail. Apply CERAMENT™|G applied to bony void(s)."
89108015|NCT02820363|Active Comparator|Control|Tibial fracture fixation with IM nail.
89108016|NCT03652272|Experimental|EMC2|"Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications:~Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~Patients will receive a Medication Guide + Summary with their After Visit Summary~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
89108017|NCT03652272|No Intervention|Usual Care|Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits.
89108018|NCT02820909|Experimental|Ultrasound guidance|46 patients in the experimental ultrasound group
89108019|NCT02820909|Active Comparator|Anatomical guidance|46 patients in the anatomical group
89108020|NCT04148118|Experimental|NE+50µg rPA - sprayer|
89108021|NCT04148118|Experimental|NE+50µg rPA - pipette|
89108022|NCT04148118|Experimental|NE+100µg rPA - sprayer|
89108023|NCT04148118|Experimental|NE+100µg rPA - pipette|
89108024|NCT04148118|Placebo Comparator|Saline - sprayer|
89108025|NCT04148118|Placebo Comparator|Saline - pipette|
89108026|NCT04148118|Active Comparator|BioThrax - SC|
89108027|NCT04595721|No Intervention|Standard of care|Participants will receive standard injection procedures
89108028|NCT04595721|Active Comparator|Visual distraction|Participants engage in visual distraction during the injection procedures
89108029|NCT04595721|Active Comparator|Physical distraction|Participants engage in physical distraction during the injection procedures
89108030|NCT02820207||Vulnerable plague|The patients suffering from carotid artery stenosis were identified as the vulnerable plague group by Contrast Enhanced Ultrasound whose plagues were found intraplaque neovascularization
89108031|NCT04146636|Other|Diagnostic Test: e-LIFT|only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
89108032|NCT02820129|Experimental|Wallet Card Group|"The intervention arm is comprised of:~Patients from the TAPER study who receive a medication wallet card with their medications and medical conditions listed."
89108033|NCT02820129|Placebo Comparator|Control Group|"Standard of care as well as wait list control. These participants will receive a reminder wallet card which states, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
89108034|NCT00773383|Experimental|1|
89108035|NCT04239417|Experimental|The Study group A|graduated abdominal strengthening exercises group
89108036|NCT04239417|Experimental|The Study group B|Russian stimulation group
89108037|NCT04239417|Experimental|The Study group C|combination group
89108038|NCT04239417|No Intervention|The Control group D|presume in normal activities of daily living.
89108039|NCT04101409|Experimental|DAs group|Shared decision making using decision aids
89108040|NCT04101409|No Intervention|Control group|Standard oral explanation guided with booklets
89108041|NCT02818881|Experimental|High-speed then low-speed yoga|Subjects received a single session of High-speed yoga and within one week a single session of Low-speed yoga
89108042|NCT02818881|Experimental|Low-speed then high-speed yoga|Subjects received a single session of Low-speed yoga and within one week a single session of High-speed yoga
89108043|NCT04231188||Primary Caregiver and infant pair|Primary Caregiver and infant who is less than or equal to 12 months old
89108044|NCT04097665||patients with expanded flaps|Patients will undergo tissue expansion. When the expanded flaps are harvested and transplanted, ICGA will be conducted intraoperatively. Meanwhile, the possible area of necrosis will be marked according to clinical experience. And then this area will be further divided into perfusion units (1*1 square centimeter for each). The center of each perfusion unit will be marked as observation point, of which the fluorescence value will be recorded. After 1 week's follow-up postoperatively, the flap tissue will be determined by superimposing digital photography over ICGA imaging results, and the outcome of each observation point will be recorded. By analyzing the fluorescence value and outcome of each observation point, a cut-off point can be further identified to achieve both higher positive and negative predictive value, improving the utility and accuracy of ICGA in predicting the postoperative skin viability of expanded flaps.
89108045|NCT04097509|Experimental|autologous fibrin glue (AFG) group|In the test groups, polymerized AFG was applied to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
89108046|NCT04097509|Experimental|injectable platelet rich fibrin (i-PRF) group|In the test groups, polymerized i-PRF was applied to the donor area. Donor palate was closed with sterile aluminum foil and periodontal pack.
89108047|NCT04097509|Placebo Comparator|Control Group|In the control group, only moist sterile tamponade was applied following graft removal to the palatinal donor area. Donor palate was closed with sterile aluminum foil and periodontal pack
89108048|NCT02818803|Experimental|Propolis|Standardized-propolis extract (EPP-AF®) oral gel formulation, 3 times a day, for 14 days
89108049|NCT02818803|Active Comparator|Miconazole|Miconazole 20mg/g oral gel,3 times a day, for 14 days
89108050|NCT04238403|Experimental|Behavioral Parent Training|Parent training intervention based on social learning and operant conditioning theory, generally referred to as Behavioral Parent Training.
89108051|NCT04350060|Experimental|Intervention Group|Subjects with dementia will be living in a retro-fitted room with technological enhancements for a 12 month period.
89108052|NCT04350060|No Intervention|Standard of Care Group|
89108053|NCT00757003|Experimental|Treatment Arm - Placement of TAG device|A TAG device will be used to repair the pathology in the thoracic aorta
89108054|NCT02817009|No Intervention|Nutrition Group|This group will go through standard of care and visit the nutritionist on a monthly basis for the three months that they are a part of the study.
89108055|NCT02817009|Experimental|Healthy Families Group|Participants and their families will attend a weekly nutrition session, social support session and physical activity session for 12 weeks.
89108056|NCT00916513||1|Patients ³ 40 years old, with T2DM diagnosed and followed up in the participating site at least 1 year prior to entry in the study, treated with diet, OADs and/or insulin for at least the past three months
89108057|NCT02818647|Active Comparator|COLD-DISSECTION|Cold Dissection Technique
89108058|NCT02818647|Active Comparator|HOT-DISSECTION|Needle Electrocautery Dissection Technique
89108059|NCT04203420||patients with PA|patients who finally been diagnosed with primary aldosteronism
89108060|NCT04203420||patients without PA|patients who finally been diagnosed without primary aldosteronism
89108061|NCT04116372|Experimental|Empty Nest Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
89108062|NCT04116372|Experimental|Retirement Intervention Group|Participants will complete a baseline questionnaire, and receive access to the our online platform for 10 weeks. Completing the online platform is designed to encourage participants to engage in physical activity. At 2 and 5 weeks, a check-in session will occur over the phone. At 10 weeks the participant will be contacted to return to the lab to complete the final questionnaire, and do a wrap up interview. The end-of-trial qualitative interview will evaluate participant satisfaction and feasibility of the intervention. For this reason a lab employee unaffiliated with this study will complete these in person interviews.
89108063|NCT04116372|No Intervention|Empty Nest Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
89108064|NCT04116372|No Intervention|Retirement Control Group|This group will complete baseline and final questionnaires (online or paper). At the end of the study this group will have the option to receive access to the other group's materials (online platform) if they wish, for the 10 week period following the study.
89108065|NCT02818725|Active Comparator|Chemotherapy|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin
89108066|NCT02818725|Experimental|Arm B: chemotherapy + panitumumab|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin +/- panitumumab
89108067|NCT02817165|Experimental|Probiotic (BioK+)|Children will receive 10-40 billion CFUs/day of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2), with dose based on their weight. The product will be administered as a strawberry flavored tub of milk.
89108068|NCT02817165|Placebo Comparator|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
89108069|NCT02820051|Active Comparator|Midazolam|"In the group of midazolam, the initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor"
89108070|NCT02820051|Experimental|Propofol|"In the group of propofol, the starting dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor"
89108071|NCT02819817|Experimental|Aloe Vera Gel|Experimental gel placed in identical opaque tube as placebo gel.
89108072|NCT02819817|Placebo Comparator|Ultrasound Gel|Placebo placed in identical opaque tube as experimental gel.
89108073|NCT02819817|No Intervention|Standard care|Standard care
89108074|NCT04238871||children or adults with Idiopathic Lung Disease|
89108075|NCT02817243|Other|SP2086 and Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
89108076|NCT00766363|Experimental|EVP-6124 (0.1 mg/day)|
89108077|NCT00766363|Experimental|EVP-6124 (0.3 mg/day)|
89108078|NCT00766363|Experimental|EVP-6124 (1.0 mg/day)|
89108079|NCT00766363|Placebo Comparator|Placebo|
89108080|NCT02636946|Active Comparator|SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)|"Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.~Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later."
89108081|NCT02636946|Experimental|Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)|"Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.~Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later."
89108082|NCT05654727||Type 2 Diabetes Mellitus|
89108083|NCT05654727||Prediabetes|
89108084|NCT05654727||Healthy Control|
89108085|NCT02819895|Experimental|Intervention|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive their usual care (an immunization card). In addition they will received automated text, calls and emails (if applicable) reminders through a customized windows® software application when their child's immunization visit is due.
89108086|NCT02819895|No Intervention|Control|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive usual care (an immunization card)
89108087|NCT00766051|Experimental|Intervention Group|The infants in the intervention group were problem eaters with various diagnosis
89108088|NCT00766051|No Intervention|Matched Historical Comparison Group|The matched historical comparison group were also problem eaters and these infants did not receive the neurophysiologically based occupational therapy Intervention.
89108089|NCT00909792|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
89108090|NCT00909792|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
89108091|NCT02819739|Experimental|normoxia|During cardiopulmonary bypass inspired fraction of oxygen is adapted to maintained a oxygen arterial pressure below 150 mmHg.
89108092|NCT02819739|Active Comparator|hyperoxia|During cardiopulmonary bypass inspired fraction of oxygen is set to 100 %.
89108093|NCT03104868|No Intervention|Usual Care|Patients in this group will receive the usual standard of care.
89108094|NCT03104868|Experimental|Intervention|Patients in this group will receive the TAKE IT strategy components.
89108095|NCT02819661|Active Comparator|women BMI<30 POD 1|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
89108096|NCT02819661|Active Comparator|women BMI≥30 POD 1|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
89108097|NCT02819661|Active Comparator|women BMI<30 POD4|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
89108098|NCT02819661|Active Comparator|women BMI≥30 POD 4|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
89108099|NCT02816541|Experimental|Pelvis Retroverted|Pilates-based therapeutic exercises performed with a posterior pelvic tilt
89108100|NCT02816541|Experimental|Pelvis in Neutral Position|Pilates-based therapeutic exercises performed with a neutral position of the pelvis
89108101|NCT02816541|Active Comparator|Control Group|Aerobic exercise performed on a treadmill
89108102|NCT00765817|Placebo Comparator|1|
89108103|NCT00765817|Experimental|2|
89108104|NCT02818491|Placebo Comparator|Control group|Patients will receive ropivacaine 0.5% 20 mls with normal saline 0.9% 2 mls
89108105|NCT02818491|Active Comparator|Dex 1|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 1 mg in 2 mls
89108106|NCT02818491|Active Comparator|Dex 2|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 2 mg in 2 mls
89108107|NCT02818491|Active Comparator|Dex 3|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 3 mg in 2 mls
89108108|NCT02818491|Active Comparator|Dex 4|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 4 mg in 2 mls
89108109|NCT02818179|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every week during the brachytherapy treatment for 5 procedures
89108110|NCT02816853|Experimental|Sequence 1|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
89108111|NCT02816853|Experimental|Sequence 2|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
89108112|NCT02816853|Experimental|Sequence 3|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
89108113|NCT02816853|Experimental|Sequence 4|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
89108114|NCT04101097||training group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
89108115|NCT04101097||validation group|All patients received oral and written instructions on the appointment day. All patients were instructed to have low-residue food for lunch and dinner on the day before colonoscopy. Patients were instructed to begin drinking the first 1.5L-2L PEG at 7:00-9:00 PM on the day before colonoscopy. On the day of the procedure, they took another 1.5L-2L 4-6 hours before colonoscopy. Patients were encouraged more to drink more clear liquids after purgatives for adequate hydration.
89108116|NCT02818257|Experimental|Strip A (wet)|Six strips of Strip A are applied on skin wetted with two different buffers (3 strips each)
89108117|NCT02818257|Experimental|Strip A (dry)|Six strips of Strip A are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
89108118|NCT02818257|Experimental|Strip B (wet)|Six strips of Strip B are applied on skin wetted with two different buffers (3 strips each)
89108119|NCT02818257|Experimental|Strip B (dry)|Six strips of Strip B are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
89108120|NCT02818257|Experimental|Strip C (wet)|Six strips of Strip C are applied on skin wetted with two different buffers (3 strips each)
89108121|NCT02818257|Experimental|Strip C (dry)|Six strips of Strip C are applied on skin that is either dry (3 strips) or wetted with buffer (3 strips)
89108122|NCT02818335|Experimental|LY3023414 Reference Fasted|Single oral dose of LY3023414 (Reference) on day one fasting.
89108123|NCT02818335|Experimental|LY3023414 Test Fasted|Single oral dose of LY3023414 (Test) on day one fasting.
89108124|NCT02818335|Experimental|LY3023414 Test Fed|Single oral dose of LY3023414 (Test) on day one after a meal.
89108125|NCT02818413||U.S. Olympic Team and elite athletes|Biospecimens will be collected from and questionnaires will be administered to U.S. Olympic team members and other elite athletes
89108126|NCT02819583|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
89108127|NCT02819349|Experimental|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. The intervention will include an online interface for clinicians and an automated text messaging program for patients. Firstly, patients and providers will meet in an intake session, to identify the patient's personal early warning signs from a pre-identified list. Using the online interface, providers will enter additional warning signs or personalize the wording of the messages as requested by the patient. The patient also will determine the threshold at which the provider will be alerted about a possible relapse and whether additional contact people should be alerted.
89108128|NCT02819349|No Intervention|Treatment-As-Usual Control|The control group will be a treatment as usual comparison group. For the majority of individuals with schizophrenia/SAD in care at JHCPP, this involves meeting with their therapist every 2 to 4 weeks and meeting with their psychiatrist at least once every 90 days or more frequently as clinically indicated. All routine appointments are scheduled, but individuals can walk in or call if they do not feel well between sessions.
89108129|NCT00772603|Placebo Comparator|Placebo|Placebo - four identical tablets taken orally once daily
89108130|NCT00772603|Active Comparator|2400 mg SPN-804|2400mg OXC XR taken orally once daily as four identical tablets
89108131|NCT00772603|Active Comparator|1200mg SPN-804|1200mg OXC XR taken orally once daily as four identical tablets
89108132|NCT02819427||epilepsy|children with absence epilepsy presenting either typical or atypical seizures
89108133|NCT02819505|Experimental|Beta-alanine supplementation|Participants will be supplemented with 6.4g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets four times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
89108134|NCT02819505|Placebo Comparator|Placebo supplementation|Participants will be supplemented with 6.4g·d-1 placebo (maltodextrin; NAI, USA).
89108135|NCT04237779|Experimental|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in microTESE material.
89108136|NCT04239105||Breast cancer Group|The biopsy result is breast cancer.
89108137|NCT02819271|Experimental|CXL-1427 (BMS-986231)|Experimental
89108138|NCT02819271|Placebo Comparator|Placebo|Placebo
89108139|NCT02816463|Experimental|Ambu AuraGain (Group A)|Laryngeal mask Ambu AuraGain will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
89108140|NCT02816463|Active Comparator|LMA Supreme (Group S)|Laryngeal mask Supreme will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
89108141|NCT02818101|No Intervention|Control group|No hypnosis session before the coronary angiography
89108142|NCT02818101|Experimental|Hypnotised group|Hypnosis session before the coronary angiography
89108143|NCT02816619|Experimental|APA+|APA + : patients will beneficiate of Personalized Physical Activity coaching program during 3 months (1 hour, twice by week, during 3 months)
89108144|NCT02816619|Other|APA-|APA- : patients will do free practice of physical activity during 3 months.
89108145|NCT00772447|Experimental|AZ drug|Daptomycin
89108146|NCT00772447|Active Comparator|Comparator|Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin
89108147|NCT00765037||Encore RSP|Subjects who need treatment for rotator cuff deficiency or glenohumeral arthritis, received the Encore Reverse Shoulder Prosthesis and are willing to participate in the study.
89108148|NCT02817867|Active Comparator|tDCS|Patients who will be treated with Transcranial direct-current stimulation (tDCS) in the ipsilesional motor cortex.
89108149|NCT02817867|Active Comparator|rTMS|Patients who will be treated with Magnetic brain stimulation (rTMS) in the contralesional motor cortex.
89108150|NCT02817867|Experimental|tDCS + rTMS|Patients who will be treated with the association between Transcranial direct-current stimulation (tDCS) and magnetic brain stimulation (rTMS), in the ipsilesional and contralesional motor cortex, respectively.
89108151|NCT04687371|Experimental|Grup I|Proprioceptive vestibular rehabilitation exercises, Cawthorne Cooksey Exercises and Gaze Stabilization exercises,
89108152|NCT04687371|Experimental|Grup II|Cawthorne Cooksey Exercises and Gaze Stabilization exercises
89108153|NCT04687371|Other|Grup III|No intervention will be made, patients will be asked to continue their daily life
89108154|NCT06279182|Experimental|Barre Stretching Intervention|15 minute Barre stretching video two times a week for 6 weeks.
89108155|NCT06279182|No Intervention|Control Group: No Intervention|Participants do not participate in the Barre stretching intervention.
89108156|NCT06279169|Experimental|Heart sound group|"In the heart sound group, the heart sound with an average heart rate of 70 beats is transmitted to the loudspeaker via an Mp3 player. Two small 200 W loudspeakers (SONY®)/JBL brand loudspeakers are used, placed on either side of the newborn's head, 30 cm from the newborn's ears."
89108157|NCT06279169|Experimental|White noise group|"In the white noise group, the mother of the baby is told that the white noise to be used in the study will be used for pain relief. For the white noise, the musician Osman Orhan's colic album, which was released by the production and often used in the literature. The song Bebeğiniz Ağlamasın Pt-3 from the album Kolik will be used (permission to use it in this work has been granted by ON Music Production). The volume is set to 45 db. The JBL loudspeaker is placed on the newborn's toe 5 minutes before the procedure, about 30 cm from the newborn's ear, and white noise is played 5 minutes before, during (at the 1st minute) and 5 minutes after the administration of the Hep B vaccine."
89108158|NCT06279169|No Intervention|Control|Newborns in the control group will not receive any intervention other than Hepatitis B vaccination.
89108159|NCT06279130|Experimental|pMMR Safety run-in 1|5 Patients will be included and will be treated with 2 cycles of neoadjuvant immunotherapy consisting of 450mg balstilimab and 25mg botensilimab in Cycle 1 and 450mg balstilimab in Cycle 2 followed by surgery
89108160|NCT06279130|Experimental|pMMR Safety run-in 2|5 Patients will be included and will be treated with 2 cycles of neoadjuvant immunotherapy consisting of 450mg balstilimab and 50mg botensilimab in Cycle 1 and 450mg balstilimab in Cycle 2 followed by surgery
89108161|NCT06279130|Experimental|dMMR Safety run-in 1|5 Patients will be included and will be treated with 2 cycles of neoadjuvant immunotherapy consisting of 450mg balstilimab and 25mg botensilimab in Cycle 1 and 450mg balstilimab in Cycle 2 followed by surgery
89108162|NCT06279130|Experimental|dMMR Safety run-in 2|5 Patients will be included and will be treated with 2 cycles of neoadjuvant immunotherapy consisting of 450mg balstilimab and 50mg botensilimab in Cycle 1 and 450mg balstilimab in Cycle 2 followed by surgery
89108163|NCT06279130|Experimental|dMMR Colorectal basket|Patients with resectable colon and rectal cancer will be treated with the regimen assesses as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If >2 major pathological responses are observed accrual will continue to a total of 18 patients.
89108164|NCT06279130|Experimental|dMMR Gynaecological oncology basket|Patients with resectable endometrial, cervical and ovarian cancer will be treated with the regimen assessed as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If >2 major pathological responses are observed accrual will continue to a total of 18 patients.
89108165|NCT06279130|Experimental|dMMR Upper gastro-intestinal cancer basket|Patients with resectable oesophageal (adenocarcinoma), gastro-oesophageal junction, gastric and small bowel cancer will be treated with the regimen assessed as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If >2 major pathological responses are observed accrual will continue to a total of 18 patients.
89108166|NCT06279130|Experimental|"dMMR other cancers baskets"|Patients with resectable solid tumors of various origins such as but not limited to breast-, prostate-, bladder cancer, Head&Neck SCC, oesophageal SCC and sarcoma will be treated with the regimen assessed as safe and feasible in the dMMR safety run-in. Treatment will be administered at day 1 and day 22 followed by surgery 8 weeks after registration. Accrual will be temporarily halted after accrual of the first 8 patients. If >2 major pathological responses are observed accrual will continue to a total of 18 patients.
89108167|NCT06279117|Experimental|Therapeutic touch group|Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
89108168|NCT06279117|No Intervention|control group|No treatment will be performed on individuals in the control group.
89108169|NCT06279104||real-world study (RWS)-Chemotherapy|
89108170|NCT06279104||RWS-ICI|
89108171|NCT06279091|Experimental|tell show do technique|apply normal treatment with basic behavioral technique as a control group.
89108172|NCT06279091|Experimental|Diaphragmatic breathing technique|apply normal treatment with breathing exercises as relaxation and distruction technique to reduce the dental anxiety.
89108173|NCT06279091|Experimental|Bubble Blower breathing technique|apply normal treatment with breathing exercises by bubbleblower which is a play therapy as relaxation and distruction technique to reduce the dental anxiety.
89108174|NCT06279065||GCA Patients|Primary Diagnosis of Giant Cell Arteriitis
89108175|NCT06279065||Control|Control group without rheumatologic disease
89108176|NCT06279039|Experimental|self half face control method|One side of the face was treated with exosome liquid dressing twice a day, and the other side was treated without exosome matrix for 2 weeks. The patients were followed up before treatment and 1, 3，7, 14, 28, and 56 days after treatment
89108177|NCT06279026|Experimental|UTAA17 Injection|After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.
89108178|NCT06278974||Control Group1|This group includes children and adolescents who are correcting myopia using peripheral defocus spectacles. These spectacles are a novel corrective measure, designed to control myopia progression by creating a defocus zone around the periphery of the lenses.
89108179|NCT06278974||Control Group2|This group consists of children and adolescents using orthokeratology lenses for myopia correction. Orthokeratology lenses are specially designed rigid contact lenses worn overnight to temporarily reshape the cornea, aiming to reduce dependency on glasses or contact lenses during the day.
89108180|NCT06278974||Control Group3|This group includes children and adolescents who are using standard single-vision frame glasses for myopia correction.
89108181|NCT06278961||Conrols - health term infants|Infants, less than 10 weeks of age at enrolment who were born full-term with typical development, birthweight >2500g
89108182|NCT06278961||Bronchopulmonary dysplaspia|A history of bronchopulmonary dysplasia, defined as having a preterm birth (<33 weeks' gestational age) and requiring supplemental oxygen beyond 36 weeks' gestational age
89108183|NCT06278961||Neonatal encephalopathy|term born infants who required hypothermic cooling treatment or had a diagnosis of hypoxic ischemic encephalopathy
89108184|NCT06278961||Congenital anomalies|Congenital anomalies of any kind eg cardiac, musculoskeletal, gastrointestinal
89108185|NCT06278961||Preterm birth|Preterm birth <36 weeks gestational age
89108186|NCT06278961||Multiple gestation|One of a multiple gestation pregnancy
89108187|NCT06278948|Experimental|Group TP: Test Product|Subjects (aged 20-50 years) with mild to severe facial epidermal melasma for more than 1 year
89108188|NCT06278948|Active Comparator|Group CYS: Cysteamine 5%|Subjects (aged 20-50 years) with mild to severe facial epidermal melasma for more than 1 year
89108189|NCT06278935|Experimental|Lifestyle-based intervention by a occupational therapist|DFU patients will be offered lifestyle-based treatment sessions over telemedicine for up to 8 weeks with a licensed occupational therapist.
89108190|NCT06278922|Experimental|Seeking Safety + Signs of Safety toolkit|Experimental participants will be offered 12 one-hour, weekly individual therapy sessions of Seeking Safety delivered with the Signs of Safety toolkit. Sessions will occur virtually via National Deaf Therapy's (NDT) secure HIPAA-compliant video chat platform. Length of treatment is limited to six months; number of completed sessions will be tracked as a measure of participant adherence.
89228561|NCT04324580|Active Comparator|Delayed mobilization/Formal physical therapy group|Participants will be placed into a volar-based plaster splint post-operatively. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. After that, participants will be placed into a custom thermoplastic splint by a therapist. This will be worn for 5 weeks. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks. The splint will be removed only for formal and home physical therapy and hygiene.
89228562|NCT04324580|Active Comparator|Immediate mobilization/self guided physical therapy group|Participants will be placed into a soft dressing after surgery. Participants will be asked to keep non-weight bearing (on the operated wrist) but no restrictions for range of motion, keeping the dressing in place until first post-operative visit at 2 weeks. This group will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
89228563|NCT04229888|Experimental|Subject Treatment|All subjects will receive light based (sham) treatment, then all subjects will receive LipiFlow treatment.
89228564|NCT04004546|Experimental|Intervention group|At baseline: video and education booklet. 2-weeks after enrollment: telephone call by nurse.
89228565|NCT04004546|No Intervention|Control group|Usual care
89228566|NCT04236284|Experimental|Home-based tDCS + Prolonged Exposure Therapy|Participants will come in person to the clinic office to complete the baseline visit and the in-person training for the use of both home-based self-administered tDCS and the home-based telehealth device (iPad) for the PE sessions. They understand that they will start the sessions of tDCS once they start the in vivo and imaginal exposures assignments at home. They will self-administer (under televideo supervision) the tDCS session before doing in vivo and/or imaginal exposures assignments. The participants will be remotely supervised by trained research staff at each stimulation to ensure the technique is correct and to monitor any adverse events. We will provide secure videoconferencing software (e.g., WebEx) and ensure the participants are comfortable using the telehealth software.
89228567|NCT04005248|Other|Testing for HCV|HCV IgG test and questionnaire; both at visit to the sexual health clinic
89228568|NCT03519074|Experimental|TS-1 combined with cisplatin|Eligible patients will be stratified by degree of liver dysfunction into 4 cohorts, in accordance to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria
88820935|NCT05417932|Experimental|SCG101|"This is a single arm study.~Patients will receive infusion and will be observed for dose limiting toxicity (DLT) over a 28-day period, and thereafter enter the progression free survival observation period and continuous long term survival follow up at time of disease progression."
89228569|NCT02661542|Experimental|Phase 1: Lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89108191|NCT06278922|Active Comparator|Treatment as usual|Participants assigned to the active comparison condition will receive therapy as usual - i.e., general, open-ended, non-manualized supportive counseling provided by an NDT therapist. In the absence of any evidence-based therapies available for Deaf clients, this unstructured therapy approach is the current standard of care in the field of Deaf mental health. All NDT therapists are Deaf, fluent in ASL, and specialize in issues common to Deaf individuals seeking mental health care. Like the experimental condition, participants will receive 12 one-hour, weekly individual therapy sessions via NDT's secure virtual therapy platform. Length of treatment is limited to six months; number of completed sessions will be tracked as a measure of participant adherence.
89108192|NCT06278922|No Intervention|No treatment|Participants in states with no NDT therapists and who prefer to be placed on NDT's waitlist instead of being referred outside of NDT for therapy will be automatically assigned to the no-treatment control condition. At the time of this submission, there are approximately 200 individuals on the NDT waitlist; individuals remain on the waitlist until a licensed therapist from their state joins the NDT team. Participants in the control condition will be prompted to complete assessments at baseline, week 6, week 12 (to approximate immediate post-treatment), week 25 (to approximate three-month follow-up), and week 38 (to approximate six-month follow-up). Such repeated assessment in the control arm will allow us to quantify and control for participants' natural change over time and any potential assessment reactivity.
89108193|NCT06278896|Experimental|Intervention Arm|Participants will stop empiric antibiotic therapy after their episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
89108194|NCT06278896|No Intervention|Control Arm|Participants will continue antibiotic therapy until count recovery and/or standard of care as deemed by inpatient providers, which is the current guidelines recommended by the IDSA.
89108195|NCT06278870|Experimental|disitamab vedotin in combination with pyrotinib|disitamab vedotin 2mg/kg IV every 14 days + Pyrotinib 400mg PO daily, with each 28-day cycle. After 6-8 cycles, adding Trastuzumab initially at 8mg/kg IV followed by 6mg/kg IV every 21 days + Pyrotinib 400mg PO daily for maintenance.
89108196|NCT06278870|Active Comparator|taxane drug in combination with trastuzumab and pertuzumab|taxane drug (Docetaxel/Paclitaxel/Albumin Paclitaxel/Liposomal Paclitaxel, dosing and administration per latest National Comprehensive Cancer Network(NCCN) and Chinese Society of Clinical Oncology(CSCO) breast cancer guidelines) + Trastuzumab initially at 8mg/kg IV followed by 6mg/kg IV every 21 days + Pertuzumab initially at 840mg IV followed by 420mg IV every 21 days, with each 21-day cycle. After 6-8 cycles, continuing with Trastuzumab at 6mg/kg IV every 21 days + Pertuzumab at 420mg IV every 21 days for maintenance.
89108197|NCT06278857|Experimental|Single Arm|Participation involves seven dostarlimab sessions over 12 months, with a treatment protocol of four cycles every three weeks, followed by a three-week break, and then three cycles every six weeks.
89108198|NCT06278844|Experimental|Conduction system pacing|In the conduction system pacing group, the right ventricular lead will be placed in a septal position to achieve conduction system pacing, either His bundle pacing (HBP) or left bundle branch area (LBBA) pacing.
89108199|NCT06278844|Active Comparator|Right ventricular apical pacing|Control group, in this group patients will receive a pacemaker with the ventricular lead in the right ventricle apex.
89108200|NCT06278818|Experimental|Network-based Cognitive Training (NBCT)|The training will be delivered through a virtual platform for TR.
89108201|NCT06278818|Experimental|Home-based Cognitive Rehabilitation (HomeCoRe)|The training will be delivered through a touch-screen laptop in a home-based setting.
89108202|NCT06278818|Experimental|Semantic Memory Rehabilitation Training (SMRT)|The training will be delivered through TR with the assistance of an online therapist.
89108203|NCT06278818|Sham Comparator|Unstructured Home-based Cognitive Stimulation (Control)|The Control stimulation will be delivered through TR with therapist assistance.
89108204|NCT06278805||Stroke patients|Participants with chronic stroke who have more than 1 year after stroke onset and who fulfill the inclusion/exclusion criteria will be included in this single-arm study.
89108205|NCT06278792|Active Comparator|Standard of Care|48 hour diuretic management at the treating physician's discretion
89108206|NCT06278792|Experimental|Intervention|48-hour nurse-led natriuresis-guided protocol
89108207|NCT06278753||Standard cystoscopy|Standard cystoscopy arm
89108208|NCT06278753||carbon dioxide cystoscopy|carbon dioxide cystoscopy arm
89108209|NCT06278740||SCI with Manual Wheelchair Usage|Patients with spinal cord injuries who use manual wheelchairs
89108210|NCT06278740||SCI without Manual Wheelchair Usage|Patients with spinal cord injuries who do not use manual wheelchairs
89108211|NCT06278727||Regression group|Regression group contains the patients whose FMR regresses after taking GDMT for at least 3 months.
89108212|NCT06278727||No-reaction group|No-reaction group contains the patients whose FMR has no regression by every clinical visit.
89108213|NCT06278714|Experimental|Intervention group|The EG (experimental group) will perform the diaphragmatic fatigue protocol using a specific inspiratory endurance test, in which volunteers, one-on-one, and in a single session, will breathe against submaximal inspiratory loads equivalent to 60% of their MIP (Maximum Inspiratory Pressure) through a threshold valve device. The participants will follow a free pattern of breathing until they are unable to establish flow during at least 3 maximum inspiratory efforts.
89108214|NCT06278714|No Intervention|Control group|they will not receive any intervention. Just sit and wait the same amount of time that the intervention and the activation group needs to finish their protocol (around 10 minutes)
89108215|NCT06278714|Active Comparator|Activation group|The activation group will perform the protocol of 2 sets of 30 repetitions at 40% of their MIP, one-on-one, and in a single session, breathing against submaximal inspiratory loads using a threshold valve device. The participants will follow a free pattern of breathing until complete the protocol.
89228570|NCT02661542|Experimental|Phase 1: 1.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228571|NCT02661542|Experimental|Phase 1: 2.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228572|NCT02661542|Experimental|Phase 1: 3.375x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228573|NCT02661542|Experimental|Phase 1: 5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228574|NCT02661542|Experimental|Phase 1: 7.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228575|NCT02661542|Experimental|Phase 1: 11.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228576|NCT02661542|Experimental|Phase 1: 16.875x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228577|NCT02661542|Experimental|Phase 1: 25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228578|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228579|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Solid Tumors|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
89228580|NCT05659316||Healthy volunteers|Healthy volunteers without any patellar injury
89228581|NCT03907280|Experimental|T1-T2-R-T3|
89228582|NCT03907280|Experimental|R-T1-T2-T3|
89228583|NCT03907280|Experimental|T2-R-T1-T3|
89228584|NCT04004468|Active Comparator|Standard Periodization Training|Utilization of traditional periodization strength training model
89228585|NCT04004468|Active Comparator|Conjugate Training|Utilization of conjugate strength model
89228586|NCT03730454|Experimental|Group A. Transanastomotic Tube|Group A. Transanastomotic Tube: Standard repair of EA/TEF will be performed. TT will be used during the esophageal anastomosis creation.
89108216|NCT06278701|No Intervention|the control group|Patients who voluntarily accept a regular diet and do not eat again 1h before bedtime
89108217|NCT06278701|Experimental|the test group|Patients who voluntarily accepted to have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
89108218|NCT06278688|Experimental|Precision probiotics|The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/)
89108219|NCT06278688|Placebo Comparator|Placebo (wait-list group)|Placebo packets or capsules will be composed of maize starch only and be identical in appearance, weight, and smell. After completing trials, the Placebo group will be provided with a 6- month precision probiotic supplement.
89108220|NCT06278662|Experimental|Intervention arm|The cohort multiple Randomised Controlled Trial (also known as TwiCs 'trials within cohorts') is a prospective study design in which (eHealth) intervention arms will be established over time. The interventions will be evaluated on the primary outcome measures of the cohort.
89108221|NCT06278662|No Intervention|Cohort control group|
89108222|NCT06278649|Experimental|Relaxation and Guided Imagery Intervention|During the RGI sessions, the participant will be told to lie down on an exercise mat while a 15 minute relaxation and guided imagery audio recording is played. During the relaxation portion of the script, the participant will be instructed to let go of tension they might feel in individual parts of their body (starting with their feet and working their way up). The second portion is the guided imagery portion, which includes asking each participant to imagine themselves in a peaceful place. The participant will then be guided to imagine healing in the specific bronchial tubes and lungs, asking them to imagine themselves doing a favorite activity in which they have no trouble with their asthma, and asking them to visualize breathing in a colored air that would clear the airways and lungs.
89108223|NCT06278584|Active Comparator|iLUX Treatment System|The eyelid tissue is warmed by light energy produced by LEDs in the Instrument and transmitted through the precise Outer Pad. The Inner Pad and Eye Shield block light transmission directly into the eye during a treatment temperature sensor and measure the inner and outer eyelid temperatures to maintain a meibum melt temperature of 38-42°C.
89108224|NCT06278584|Active Comparator|Mechanical Meibomian Gland Expression|"Local heat using an electrical warming mask for 5 minutes.~Using a standardized device (Arita Meibomian Gland Compressor, Katena) to apply a standard force to individual glands"
89108225|NCT06278571|Experimental|Intervention with mobile application and website|Group with educational site and mobile App
89108226|NCT06278571|Active Comparator|Group with educational site|Group with educational site
89108227|NCT06278571|No Intervention|Control Group|Group with the usual care
89108228|NCT06278558|Experimental|Interviews with a psychologist/psychiatrist|Implementation of an interview with a psychologist or psychiatrist following a telephone conversation with patients with no psychological follow-up and a high HADS score (≥11), at all stages of the study (start of chemotherapy T1, end of chemotherapy T2, 6 months after the end of chemotherapy).
89108229|NCT06278545|Experimental|Modified FOLFIRINOX regimen D1=D15 (1 course every 14 days)|
89108230|NCT06278545|Active Comparator|Modified FOLFOX regimen D1=D15 (1 course every 14 days)|
89108231|NCT06278506|Experimental|Ablation|Ablative treatment of small kidney cancer lesion, could be given with radiofrequency, microwawe or cryoablation
89108232|NCT06278506|Active Comparator|Partial nephrectomy|Surgical resection with open or laparoscopic technique
89108233|NCT06278493|Experimental|AL2846 capsules + Gemzar injection|AL2846 capsules combined with Gemzar injection,28 days as a treatment cycle
89108234|NCT06278480||MegaCarti®|Experimental: MegaCarti® application after microfracture The experimental group is applied with MegaCarti® and underwent high tibial osteotomy(HTO) after microfracture.
89108235|NCT06278480||Microfracture only|The control group underwent microfracture and high tibial osteotomy(HTO)
89108236|NCT06278467||Patients with chronic low back pain|Consecutive patients over the age of 60, diagnosed with CBP, who have been suffering from low back pain for at least 6 months (n=57 )
89108237|NCT06278467||Healtyh control|Healthy control with compatible sociodemographic characteristics (n=50)
89108238|NCT06278454|Experimental|NRT6008 Injection|In this study, participants shall receive NRT6008 injection in combination with chemotherapy.
89108239|NCT06278441|Experimental|White noise group|After the newborns in the WNG group were taken to the blood collection department, white noise (55 dB) was played through a speaker standing 1 meter away from the newborn. The sound level was adjusted to 55 dB with a decibel meter. A heel lancing was performed after the newborn started listening to white noise and calmed down.
89108240|NCT06278441|Experimental|Kangaroo care group|Kangaroo care was started 15 minutes before heel lancing for newborns included in KCG, and heel lancing was performed.
89108241|NCT06278441|No Intervention|Control group|Control group newborns underwent routine heel lancing, and no intervention was performed.
89108242|NCT06278402|Experimental|Tofacitinib|tofacitinib 5mg twice daily for 6 months
89108245|NCT06278350|Experimental|D-2570 group 1|D-2570 group 1
89108246|NCT06278350|Experimental|D-2570 group 2|D-2570 group 2
89108247|NCT06278350|Experimental|D-2570 group 3|D-2570 group 3
89108248|NCT06278350|Placebo Comparator|Placebo group|Placebo group
89108249|NCT06278324|Experimental|Nasal spray Humer Stop Virus (HSV)|Patients treated with the nasal spray Humer Stop Virus (HSV) . Analgesics and antipyretics are authorized. Any other nasal spray, nasal cleansing (saline, water or other), and inhalation are prohibited
89108250|NCT06278324|No Intervention|Control|Analgesics and antipyretics are authorized. Any nasal spray, nasal cleansing (saline, water or other), and inhalation are prohibited
89108251|NCT06278298|Experimental|Group A|Shockwave
89108252|NCT06278298|Experimental|Group B|Shockwave
89108253|NCT06278298|Placebo Comparator|Group C|CDT
89108254|NCT06278246||Patients with Schizophrenia|Antipsychotic-free patients with schizophrenia or schizophreniform disorder
89108255|NCT06278246||Healthy Controls|Healthy controls matched for age, sex, cannabis, and nicotine consumption to the 29 patients
89108256|NCT06278233|Experimental|Transcranial direct current stimulation study arm|For bi-hemispheric stimulation, the anode will be placed at the intersection of F7 and FC5 and the cathode will be placed at the intersection of F8 and FC6. For all stimulations, the stimulation will be increased for 15 seconds at a dosage of 1 mA (milliampere) for the entire 20 minute session duration and decreased for 15 seconds at the end of the stimulation.
89108257|NCT06278233|No Intervention|Sham stimulation study arm|In the sham condition, the same electrode placement will be used, during which the current will be increased for 15 seconds, kept at 1 mA for 15 seconds, decreased for 15 seconds and terminated, and the 20 minute session duration will be performed with 45 seconds of real stimulation accompanied by speech with a metronome.
89108258|NCT06278207||Adult patients with CKD and T2D who initiate finerenone|The data sources used include a network of commercial electronic health records (EHRs) and national claims data in Japan.
89108259|NCT06278194|Other|Patients treated with gasserian ganglion RFT for trigeminal neuralgia|In patients who have undergone radiofrequency thermocoagulation (RFT) of the gasserian ganglion for the treatment of trigeminal neuralgia, the thickness of the masseter muscle will be measured bilaterally, free and contracted, by ultrasound on the day of the procedure (just before the procedure) and at 1 and 3 months after the procedure.
89108260|NCT06278168|Experimental|Experimental awareness group|Twenty children in the experimental group will undergo individual training in which they will watch relaxation videos with the Oculus device. The group sessions will be the same for both groups.
89108261|NCT06278168|Other|Traditional awareness group|Twenty children in the control group will undergo individual training without using Oculus device. The group sessions will be the same for both groups.
89108262|NCT06278155|Experimental|Experimental social relations group|In the experimental group, a social robot is expected to mediate the relationship among peers. Its task is to prompt, reinforce and support the participants' responses. In this case, it is the therapist who mediates the relationship by prompting, reinforcing and supporting the participants' responses.
89108263|NCT06278155|Other|Control social relations group|In the control group, the therapist is expected to act as a mediator of the relationship, prompting, reinforcing and supporting the participants' responses.
89108264|NCT06278142|Experimental|Guided Web-Based Intervention|Participants in this group will use the web-based intervention with guidance support.
89108265|NCT06278142|Experimental|Without Guidance Web-Based Intervention|Participants in this group will use the web-based intervention without guidance support.
89108266|NCT06278142|No Intervention|Waitlist|Participants will have no contact with the study team during the waiting period.
89108267|NCT06278077|Experimental|Neurexan|Two tablets taken sublingually 3 times daily for a period of 14 consecutive days, at approximately midday, evening and bedtime and not to be taken with meals.
88820936|NCT05415475|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x107 copy/kg
89108268|NCT06278077|Placebo Comparator|Placebo|Two tablets taken sublingually 3 times daily for a period of 14 consecutive days as for Neurexan
89108269|NCT06278064||Gastric cancer group|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
89108270|NCT06278064||esophagus cancer group|Patients diagnosed with esophagus cancer, including early esophagus cancer and advanced esophagus cancer
89108271|NCT06278064||Non-cancer group|Patients diagnosed with benign upper gastrointestinal diseases or healthy controls
89108272|NCT06278051||Xarelto (Rivaroxaban, BAY59-7939)|
89108273|NCT06278051||Warfarin|
89108274|NCT06277999||Monitoring Cohort|Monitoring cohort will enroll a targeted minimum of 20 and a maximum of 100 participants ≥ 18 years of age who have been recently diagnosed with CDI by a licensed HCP and are receiving SOC antibiotic treatment, with treatment starting ≤ 5 days before study enrollment. Participants will be recruited from hospitals which perform C difficile laboratory diagnostic testing. Recruitment will occur over a 6-month period. Participants will be followed through Day 42, with a screening period from Day -5 to Day 1
89108275|NCT06277999||Discard Stool Cohort|The Discard Stool cohort will include stool specimens from up to 200 participants, ≥ 18 years of age, who have been recently diagnosed with CDI by a licensed HCP within the past 7 days. Participants in this cohort will be screened at the study site to confirm eligibility. Following the screening period, there will be no additional study activities for the participant to complete.
89108276|NCT06277986||Gastric cancer patients with non-cachexia|
89108277|NCT06277986||Gastric cancer patients with cachexia|
89523205|NCT04371887|Experimental|Local Tailoring|The intervention arm will consist of six KPSC service areas randomly assigned to the intervention arm. Immediately after primary HPV screening opens at KPSC, the intervention arm will receive the local tailoring interventions. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
89108279|NCT06277960|Experimental|percutaneous intramyocardial septal radiofrequency ablation system|
89108280|NCT06277947|Experimental|C-HIPEC arm|Infuse paclitaxel (75mg/m^2) and cisplatin (75mg/m^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC with paclitaxel should be performed within 24 hours after cytoreductive surgery. The second HIPEC with cisplatin should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as diazoxide, or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
89108281|NCT06277921||Patients with morbidity and mortality|Patients who suffered from any type of morbidity after surgery
89108282|NCT06277921||Patients without morbidity and mortality|Patients who did not suffer from any type of morbidity after surgery
89108283|NCT06277908||Patients with morbidity|Patients who suffered from any type of morbidity after surgery
89108284|NCT06277908||Patients without morbidity|Patients who did not suffer from any type of morbidity after surgery
89108285|NCT06277895|Experimental|cardiogenic chest pain group|cardiogenic chest pain group/acute coronary syndrome
89108286|NCT06277895|Other|normal group|Healthy population
89108287|NCT06277856|Experimental|peer interaction|The rooms will be arranged for two people and experienced and inexperienced mothers will be accommodated together. At a time when the mothers are available, the researcher will visit the mothers in their rooms, explain the purpose of the study and start the peer interaction session. In providing peer interaction, firstly, introductions will be made and the general condition of mothers and babies will be evaluated. The researcher will assess the breastfeeding status of the mothers and provide training on breastfeeding and breastfeeding.
89108288|NCT06277856|No Intervention|control group|Women in this group benefit from all routine postnatal care services of the hospital. Each mother is guided to breastfeeding by the breastfeeding counsellor and receives training. This group will also be given a brochure by the researcher, their breastfeeding status will be evaluated and if they have any questions, they will be answered.
89108289|NCT06277843|Experimental|Thermal Jacket|
89228587|NCT03730454|Experimental|Group B. No Transanastomotic Tube|Group B. No Transanastomotic tube group: Standard repair of EA/TEF will be performed. TT will NOT be used during the esophageal anastomosis creation.
89108290|NCT06277817|Experimental|expiratory rib cage compression group|Expiratory rib cage compression procedure phase; Three hours after the first aspiration data were obtained, before the second aspiration, expiratory rib cage compression was applied for 5 minutes in the right lateral and left lateral positions, applying to both lungs, with the most affected lung area first. Before and after the procedure, vital signs, blood gas parameters were measured and the amount of secretion collected during the aspiration process was weighed.
89108291|NCT06277817|Experimental|percussion vibration group|Percussion, vibration process stage; Three hours after the first aspiration data were obtained, before the second aspiration, percussion and vibration were applied 3-5 times to each area, starting from the right and left lower lobes, in the right lateral and left lateral positions, with the most affected lung area being applied to both lungs first. Vital signs, blood gas parameters were measured before and after the procedure, and the amount of secretion collected during the aspiration process was weighed.
89108292|NCT06277817|No Intervention|control group|Control group phase; In this group, vital signs, blood gases, and secretion amount were recorded at the same time as the experimental groups, without any intervention.
89108293|NCT06277804|Experimental|Dose-escalation phase|"LTC004 combined with fludarabine, cyclophosphamide, 3+3design； LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) combined with fludarabine (25 mg/m2) on days 3 and 4 of each cycle.Q3W."
89108294|NCT06277804|Experimental|Dose-expansion phase|Further evaluation of the safety and efficacy of this dosing regimen in patients with sarcoma who have failed standard treatment according to the RP2D identified in Dose-escalation phase.
89108295|NCT06277791|Experimental|Treatment group|"TP: docetaxel 75 mg/m2, cisplatin 75 mg/m2 Adebrelimab: 20mg/kg, intravenous infusion, D1 Every three weeks, a total of two cycles. Surgery will be performed 1-3 weeks after the completion of neoadjuvant therapy.~After surgery, radiotherapy and chemotherapy combined with immunotherapy were chosen based on the patient&#39;s condition, and a total of two years of follow-up were conducted."
89108296|NCT06277778|Experimental|Taekwondo training with music therapy|the participating children will attend 20 sessions of Taekwondo training with the presence of music.
89108297|NCT06277778|Sham Comparator|Taekwondo training alone|the participating children will attend 20 sessions of Taekwondo training alone.
89108298|NCT06277765|Experimental|CM310 group|
89108299|NCT06277765|Placebo Comparator|Placebo|
89108300|NCT06277726|Experimental|Emotional freedom technique group|Pre-test data will be collected after women are informed about the emotional freedom technique. After the pre-test data is collected, the emotional liberation technique will be applied to the women. After the emotional liberation technique session is completed, the intrauterine device (IUD) will be applied. Post-test data will be collected within 10 minutes after IUD application is completed.
89108301|NCT06277726|Experimental|Music group|Women in the music group will be informed about the procedure steps before intrauterine device (IUD) application and pre-test data will be collected. After the pre-test data is collected, the music list prepared by the women and researchers will be shown and the women will be asked to choose a piece. Women who do not want to listen to any music on this list will be allowed to listen to the music they prefer. The music concert will be performed with headphones, and women will be asked to listen to the music until the IUD application process is completed. Post-test data will be collected within 10 minutes after IUD application.
89108302|NCT06277726|Other|Control group|No intervention will be applied to women in the control group.
89108303|NCT06277700|Experimental|Chiropractic Manipulation (CM) Group|In the side lying position, lumbar chiropractic manipulation will be performed over the transverse process of the vertebra thought to have vertebral subluxation. A total of 8 sessions of chiropractic manipulation will be performed 2 times a week.
89228588|NCT04120376|Experimental|Counseling Intervention|All participants will receive contraception counseling by study Advanced Practice Providers (APPs)
89228589|NCT04108130|No Intervention|Usual Care|Participants in this arm will receive usual anesthetic and postoperative care as provided in each site.
89228590|NCT04108130|Experimental|Intervention|This arm will receive the bundle of interventions.
89228591|NCT03905642|Experimental|560 mg Arikayce™|Subjects in this cohort will receive 560 mg of Arikayce™
89228592|NCT04499300||Covid positive|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection.
89228593|NCT04499300||Sub-group: deceased patients|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, with death as outcome.
89108304|NCT06277700|Experimental|Dynamic Neuromuscular Stabilization (DNS) Group|Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. Firstly, the participants will be taught the skill of posterior diaphragm activation in the supine position and the ability to direct the intra-abdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Our aim in this alignment is that with the correct diaphragm movement pattern, the deep stabilizers will be activated as a reflex response to intra-abdominal pressure change. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern. Exercises will be done 2 times a week for 50 minutes for 4 weeks.
89108305|NCT06277700|Experimental|CM + DNS Group|This group receives a treatment as a combination of the treatments described above.
89108306|NCT06277700|No Intervention|Control Group|No treatment will be applied to the control group.
89108307|NCT06277661|Experimental|Intervention|MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
89108308|NCT06277661|Active Comparator|Enhanced Usual Care (EUC)|Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
89108309|NCT06277635|Active Comparator|Silymarin group|Silymarin 140 mg oral tid pc + methotrexate weekly + folic acid 5 mg oral OD pc for 12 weeks
89108310|NCT06277635|Placebo Comparator|Placebo group|Placebo + methotrexate weekly + folic acid 5 mg oral OD pc for 12 weeks
89108311|NCT06277622|Experimental|Proximal Femoral Universal Nail (PFUN)|
89108312|NCT06277622|Active Comparator|Proximal Femoral Nail Antirotation (PFNA)|
89108313|NCT06277583|Experimental|Urban Care farming Intervention|This intervention group of participants will receive the experimental urban care farming treatment.
89108314|NCT06277583|Other|Waitlist control|Waitlist control group consists of participants who do not receive the experimental treatment, but who are put on a waiting list to receive the intervention after the active treatment group does.
89108315|NCT06277570|Active Comparator|conventional physiotherapy|"Demographic and medical information of the patients (age, gender, height and body weight, occupation, educational status, CV, family history and surgical history, medical history related to knee osteoarthritis) and pain level will be questioned. Conventional physiotherapy modalities will be applied in the group; exercise training, hotpack, ultrasound and transcutaneous electrical nerve stimulation (TENS). Patients will be treated for one hour, three days a week, for eight weeks.~The physical functions, muscle structure and knee joint cartilage thickness, quality of life and functional status of the patients will be evaluated before and after treatment."
89108316|NCT06277570|Active Comparator|NMES|"Demographic and medical information of the patients (age, gender, height and body weight, occupation, educational status, CV, family history and surgical history, medical history related to knee osteoarthritis) and pain level will be questioned. In addition to conventional physiotherapy methods, passive NMES treatment will be applied in the group.Patients will be treated for one hour, three days a week, for eight weeks.~The physical functions, muscle structure and knee joint cartilage thickness, quality of life and functional status of the patients will be evaluated before and after treatment."
89108317|NCT06277570|Active Comparator|superimposed NMES|"Demographic and medical information of the patients (age, gender, height and body weight, occupation, educational status, CV, family history and surgical history, medical history related to knee osteoarthritis) and pain level will be questioned. In addition to conventional physiotherapy methods, superimposed NMES treatment will be applied in the group. Patients will be treated for one hour, three days a week, for eight weeks.~The physical functions, muscle structure and knee joint cartilage thickness, quality of life and functional status of the patients will be evaluated before and after treatment."
89108318|NCT06277557|Other|High fidelity Simulation|conventional teaching method
89108319|NCT06277544||rupture group|rupture of lateral ankle ligament
89108320|NCT06277544||fracture group|avulsion fracture of lateral ankle ligament
89108321|NCT06277518||observation group,|the risk factors of patients with malignant tumors of digestive system meeting the inclusion criteria were observed without special intervention
89108322|NCT06277505|Experimental|intervention group|Take 3.5g prebiotic +2g probiotic twice a day before meals; At the same time, lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
89108323|NCT06277505|Other|control group|lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
89108324|NCT06277492|Experimental|Single dose SUL-238|PART 1: Single ascending oral doses of SUL-238 (50 mg, 100 mg, 250 mg, 500 mg, 1000 mg and 2000 mg)
89108325|NCT06277492|Placebo Comparator|Single dose placebo|PART 1: Single oral dose of placebo
89108326|NCT06277492|Experimental|Single dose pharmacokinetics of SUL-238|PART 2: Single oral dose of SUL-238 (at maximum tolerated dose)
89108327|NCT06277492|Experimental|Multiple doses SUL-238|PART 3: Multiple ascending oral doses of SUL-238 (at maximum tolerated dose and 1 dose level lower than MTD)
89108328|NCT06277492|Placebo Comparator|Multiple doses placebo|PART 3: Multiple oral doses of placebo
89108329|NCT06277453||AC ≥5|Patients with lymph node-negative gastric cancer who received neoadjuvant chemotherapy and underwent at least five cycles of adjuvant chemotherapy (AC ≥5) after surgery
89108330|NCT06277453||AC <5|Patients with lymph node-negative gastric cancer who received neoadjuvant chemotherapy and underwent at less five cycles of adjuvant chemotherapy (AC <5) after surgery
89108331|NCT06277440|Experimental|Intervention group|Traditional rehabilitation program with additional cognitive training
89108332|NCT06277440|Other|Active Control|Traditional rehabilitation programs without additional cognitive training
89108333|NCT06277427|Experimental|CAR-T treatment|"Lymphocyte clearance before PRG-1801 cells' infusion; Plan to design two dose levels (2.5x10^6 CAR-T/kg and 5.0x10^6 CAR-T/kg), with 3-6 AAV and LN subjects included in each dose group, totaling 12-24 subjects. Within each dose group, the next subject can be administered after the previous subject has completed at least 14 days of safety observation.~Dose group 1: with a dosage of 2.5x10^6 (cells/kg) per dose Dose group 2: with a dosage of 5.0x10^6 (cells/kg) per dose"
89108334|NCT06277414||ERCP|The postoperative laboratory test results, imaging results and symptoms were collected
88820937|NCT05415475|Experimental|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x107 copy/kg
89108335|NCT06277401|Experimental|Intervention|Progressive high-load resistance training program performed twice weekly for 12 weeks
89108336|NCT06277401|Active Comparator|Standard care|The standard care group will receive instructions on a neuromuscular training program with focus on knee stability and function performed at low intensities to be conducted twice weekly for 12 weeks
89108337|NCT06277375|Experimental|Slow stroke back massage|The application to the experimental group will be done 3 days a week for 10 minutes for a total of 30 minutes.
89108338|NCT06277375|No Intervention|Control Group|No intervation. Routine care.
89108339|NCT06277336|Experimental|Healthy Volunteers Intervention Order: Placebo, Apelin Low Dose, Apelin High Dose|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
89108340|NCT06277336|Experimental|Healthy Volunteers Healthy Patients Intervention Order: Apelin Low Dose, Apelin High Dose, Placebo|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
89108341|NCT06277336|Experimental|Healthy Volunteers Intervention Order: Apelin High Dose, Placebo, Apelin Low Dose|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
89108342|NCT06277336|Experimental|Healthy Volunteers Intervention Order: Placebo, Apelin High Dose, Apelin Low Dose|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
89108343|NCT06277336|Experimental|Healthy Volunteers Intervention Order: Apelin Low Dose, Placebo, Apelin High Dose|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
89228594|NCT04499300||Sub-group: patients who survived|Patients over 90 years old hospitalized within the CHU Brugmann between 03/01/2020 and 05/10/2020 with SARS Cov2 infection, who survived the infection.
89228595|NCT03518294|No Intervention|Standard of Care|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional. They will be informed to maintain their current physical activity level. Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
89228596|NCT03518294|Experimental|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
89228597|NCT05613374|Active Comparator|Control Group|"Participants in the control group will receive conventional functional training (conventional physical therapy program) for one hour as the following.~Part (1) Postural reactions exercises. (for 30 minutes)~Rest for 15 minutes between the first part and the second part.~Part (2) Indoor open environment gait training exercises (over-ground gait training exercises.). (for 30 minutes)"
89228598|NCT05613374|Experimental|Experimental Group|"Participants in the experimental group will receive a treatment program that is comprised of two parts.~The first part included training, for (30 minutes), on The C-Mill virtual reality treadmill. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications. The C-Mill applies an augmented virtual reality environment, obstacle avoidance games, and a variety of balance challenges in a safe and controlled environment to increase walking adaptability and performance in everyday life.~There will be 15 minutes rest between parts one and two of the training program~The second part (conventional training program) (30 minutes) will include:~Postural reactions exercises. ( 20 minutes)~Indoor open environment gait training exercises (over-ground gait training exercises.). (10 minutes)"
89228599|NCT03743012|Experimental|Integrated cardiac rehabilitation|Participants enrolled in integrated cardiac rehabilitation plus usual care
89228600|NCT03743012|Active Comparator|Usual Care|Participants receiving usual care only
89228601|NCT04004156|Experimental|Nucleus Replacement|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
89228602|NCT03504020|Experimental|ECG Belt|The ECG Belt arm will utilize the ECG Belt Research System at implant and all follow up visits.
89228603|NCT03504020|No Intervention|Control Arm|Standard CRT through 6 months follow-up.
89228604|NCT04126538|Experimental|Patient group|Patients with chronic kidney disease take pirfenidone capsule 400mg once orally
89228605|NCT04126538|Experimental|Control group|Healthy subjects take pirfenidone capsule 400mg once orally
89228606|NCT04004234|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
89228607|NCT00989924||Diabetes mellitus|The Diabetic patient who receives follow-up at NTUH diabetics caring network
89228608|NCT00990002||Control|A children's milk-based beverage
89108344|NCT06277336|Experimental|Healthy Volunteers Intervention Order: Apelin High Dose, Apelin Low Dose, Placebo|"The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.~Artificial SIAD induction (water loading and desmopressin administration) is performed."
89108345|NCT06277336|Experimental|Chronic SIAD Patients Intervention Order: Placebo, Selected Apelin Dose|The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.
89108346|NCT06277336|Experimental|Chronic SIAD Patients Intervention Order: Selected Apelin Dose, Placebo|The intervention sequence is assigned in random order. Each intervention corresponds to a visit of 11h. A wash-out period of 2 to 8 weeks is planned between interventions.
89108347|NCT06277323|No Intervention|Arm 1: Quarterly performance email (current state, control condition)|Eligible, randomly assigned physicians will receive status quo quarterly emails with their performance report card.
89108348|NCT06277323|Experimental|Arm 2: Monthly report card only|Eligible, randomly assigned physicians will receive behaviorally-informed monthly emails (monthly performance report card) intended to elevate their intentions to improve their performance (i.e., getting more of their patients to close care gaps).
89108349|NCT06277323|Experimental|Arm 3: Storyboard only|Eligible, randomly assigned physicians will receive status quo quarterly emails and get a more visible care gap banner in the electronic health record (EHR), intended to promptly remind them of each patient's care gaps at the start of a patient-physician encounter.
89108350|NCT06277323|Experimental|Arm 4: Monthly report card AND Storyboard|Eligible, randomly assigned physicians will receive behaviorally-informed monthly emails and get a more visible care gap banner in the electronic health record (EHR) upon patient encounter.
89108351|NCT06277310|Experimental|3WP intervention|families of patients whose loved ones died in the ICU where the 3 Wishes Program has been implemented
89108352|NCT06277284|Experimental|MG-K10 humanized monoclonal antibody injection (prefilled syringe)|single injection
89108353|NCT06277284|Active Comparator|MG-K10 humanized monoclonal antibody injection|single injection
89108354|NCT06277271|Experimental|E-cigarette|Participants will be supplied with an e-cigarette along with a 4-week supply of e-liquid. Participants will receive training on how to use the device and practice puffing with the e-cigarette during the research visit. They will be instructed to self-regulate administration according to their craving and withdrawal symptoms and to refrain from using other nicotine and tobacco products.
89108355|NCT06277258|Experimental|Patient Empowerment Model|Patients will be empowered to manage gestational diabetes mellitus themselves by acquiring knowledge and skill to monitor blood sugar levels, adjusting meals and daily activities.
89108356|NCT06277258|No Intervention|Standard of care|Patients will get the conventional way of management where patients get advice about a diet chart with a fixed menu and injection of insulin to control blood sugar levels.
89108357|NCT06277245|Experimental|LNK01001 12 mg|o Period 1: Participants receive LNK01001 12 mg twice daily for 16 weeks. Period 2: Participants will continue on LNK01001 12 mg twice daily from Week 16 to Week 52.
89228609|NCT00990002||experimental probiotic 1|children's milk-based beverage containing a bioactive ingredient
89228610|NCT00990002||experimental probiotic 2|children's milk-based beverage containing a different bioactive ingredient
89108358|NCT06277245|Experimental|LNK01001 24 mg|o Period 1: Participants receive LNK01001 24 mg twice daily for 16 weeks. Period 2: Participants will continue on LNK01001 24 mg twice daily from Week 16 to Week 52.
89108359|NCT06277245|Placebo Comparator|Placebo / LNK01001 12 mg|o Period 1: Participants receive a placebo twice daily for 16 weeks. Period 2: Participants will switch to receive LNK01001 12 mg twice daily from Week 16 to Week 52.
89108360|NCT06277245|Placebo Comparator|Placebo / LNK01001 24mg|o Period 1: Participants receive a placebo twice daily for 16 weeks. Period 2: Participants will switch to receive LNK01001 24 mg twice daily from Week 16 to Week 52.
89108361|NCT06277219|Experimental|Phase 1 LAT010 Dose Escalation|LAT010 monotherapy with ascending doses in patients with locally advanced or metastatic solid tumors. LAT010 will be administered in planned 7 dose cohorts to determine safety and RP2D. PD profile of LAT010 will also be characterized.
89108362|NCT06277219|Experimental|Phase 2 LAT010 Dose Expansion|LAT010 monotherapy at the RP2D and in combination with a PD-1 inhibitor in patients with selected tumor types. LAT010 will be administered at multiple dose levels based on the results of Phase 1. Antitumor activity and safety will be further evaluated.
89108363|NCT06277193||Non-sarcopenia group|The diagnosis of sarcopenia was determined using EWGSOP2(The European Working Group on Sarcopenia in Older People) criteria. To evaluate walking speed, muscle strength and muscle mass, hand grip test, bioimpedance and 4-meter walking test were performed on each patient, respectively. Those who had results above the critical values determined in muscle strength measurement according to criteria were defined as the group without sarcopenia.
89108364|NCT06277193||Probable sarcopenia group|Individuals with results below the critical values determined in muscle strength measurement were defined as the probable sarcopenia group if their muscle mass and physical performance values were normal.
89108365|NCT06277193||Sarcopenia group|If low muscle mass is present in addition to the decrease in muscle strength, this condition is classified as sarcopenia.
89108366|NCT06277193||Severe sarcopenia group|If there is a decrease in muscle mass and physical performance along with muscle strength, this condition can be classified as severe sarcopenia.
89108367|NCT06277180|Experimental|Newly diagnosed MTC that resect all 68Ga-TCR-FAPI-avid lesions|Newly diagnosed MTC (did not receive previous surgery, radiotherapy or target therapy) and all pre-surgically identified 68Ga-TCR-FAPI-avid lesions are/can be successfully resected.
89108368|NCT06277180|Experimental|Recurrent/persistent MTC that resect all 68Ga-TCR-FAPI-avid lesions|Recurrent/persistent MTC (underwent previous surgery with currently biochemical recurrent/residual disease) and all pre-surgically identified 68Ga-TCR-FAPI-avid lesions are/can be successfully resected.
89108369|NCT06277180|Experimental|Not all 68Ga-TCR-FAPI-avid lesions can be resected|Not all pre-surgically identified 68Ga-TCR-FAPI-avid lesions are/can be resected.
89108370|NCT06277167|Experimental|Human interferon alfa 1b inhalation solution (SAD)|Human interferon alfa 1b inhalation solution：200,000 IU, 600,000 IU, 1,200,000 IU, and 1,80,000 IU dose groups
89108371|NCT06277167|Placebo Comparator|Human interferon alfa 1b inhalation solution placebo (SAD)|Human interferon alfa 1b inhalation solution placebo ：200,000 IU, 600,000 IU, 1,200,000 IU, and 1,80,000 IU dose groups
89108372|NCT06277167|Experimental|Human interferon alfa 1b inhalation solution (MAD)|Human interferon alfa 1b inhalation solution drug product：1,200,000 IU, and 1,80,000 IU dose groups
89108373|NCT06277167|Placebo Comparator|Human interferon alfa 1b inhalation solution placebo (MAD)|Human interferon alfa 1b inhalation solution placebo ：1,200,000 IU, and 1,80,000 IU dose groups
89108374|NCT06277154|Experimental|MASCT-I+ Doxorubicin+ Ifosfamide|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells. DC cells injection will be given via subcutaneous injection, and T cells injection will be given via Intravenous (IV) infusion. Doxorubicin and Ifosfamide will be given per protocol.
89108375|NCT06277154|Active Comparator|Doxorubicin+ Ifosfamide|Doxorubicin and Ifosfamide will be given per protocol.
89108376|NCT06277128|Experimental|WS016 3g|
89108377|NCT06277128|Experimental|WS016 6g|
89108378|NCT06277128|Experimental|WS016 12g|
89108379|NCT06277128|Placebo Comparator|Matching Placebo|
89108380|NCT06277102|Experimental|Music|Music listening at postoperative day 1 and 2, 1 session per day, 20 minutes per session.
89108381|NCT06277102|No Intervention|Control|Standard of care
89108382|NCT06277089|Other|Correction of EOS by serial cast|
89108383|NCT06277024|Experimental|Treatment with combination of candenizumab, lenvatinib, and SOX regimen|
89108384|NCT06277011|Experimental|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
89108385|NCT06276985|Experimental|Experimental: Lipus side: closure of premolar extraction space|application of LIPUS with translation of closure of premolar extraction space that will be performed on intervention sides according to a standardized protocol
89108386|NCT06276985|No Intervention|No Intervention: LIPUS side control side|LIPUS side:closure of premolar extraction space control side
89108387|NCT06276985|Experimental|Experimental:iPRF side closure of premolar extraction space|closure ofpremolar extraction space that will be performed with iPRFapplication according to a standardized protocol
89108388|NCT06276985|No Intervention|iPRF side closure of premolar extraction spacecontrol side|iPRF side canine retraction control side wihout intervention
89108389|NCT06276985|Experimental|Experimental: LIPUS groupMolar distalization group inrervention side|distalization assisted with LIPUS according to a standardized protocol
89108390|NCT06276985|No Intervention|No Intervention: LIPUS groupMolar distalization group control side|distalization without LIPUS intervention
89108391|NCT06276985|Experimental|Experimental: iPRFgroup: distalization intervntion side|distalization will be commenced with application of iPRF according to a standardized protocol
89108392|NCT06276985|No Intervention|No Intervention: iPRF group: distalization control side|distalization will be commenced without application of LLLT according to a standardized protocol
89108393|NCT06276985|Experimental|Experimental: LIPUS group: leveling and alignment|leveling and alignment assisted with LIPUS according to a standardized protocol
89108394|NCT06276985|Experimental|Experimental: iPRF group: leveling and alignment|leveling and alignment be commenced with application of iPRF according to a standardized protocol
89108395|NCT06276985|No Intervention|No Intervention: leveling and alignment without intervention|leveling and alignment without intervention
89108396|NCT06276985|Experimental|Experimental: LIPUS group: Intrusion|intrusion assisted with LIPUS according to a standardized protocol
89108397|NCT06276985|Experimental|Experimental: iPRF group: Intrusion|intrusion assisted with application of iPRF according to a standardized protocol
89108398|NCT06276985|No Intervention|No Intervention: intrusion control group|intrusion without intervention
89108399|NCT06276972||Scoliosis|scoliotic adolescents ranged in age from 10- 18 years will be enrolled
89108400|NCT06276959||The population with a potential risk of proximal caries.|
89108401|NCT06276933|Experimental|Camrelizumab+Chemotherapy+Thalidomide|
89108402|NCT06276933|Active Comparator|Camrelizumab + chemotherapy+placebo|
89108403|NCT06276907|Experimental|Plasma Exchange|On day 1 Response assessment will be done to assess the need for a second session from day 3-7 and subsequently every week till day 28. A minimum of 3 sessions would be considered in the first seven days. The duration of each session would be 3-4 hours. Patients with partial response (not meeting criteria for a complete response after 3 sessions) would be considered for additional sessions as decided by the treating physician until desired complete response, adverse effects, liver transplant, death, or clinical futility. The complete response will be defined as a sustained reduction in bilirubin and international normalized ratio without any clinical worsening requiring discontinuation of therapy. Failure of therapy would be defined as the development of adverse effects, new onset sepsis, or organ failure. In such patients, further sessions would be deferred. Blood access was established with a double-lumen catheter inserted into the patient's femoral or jugular vein.
89108404|NCT06276907|Active Comparator|Standard Medical Treatment|Patients randomized to SMT Group will be given standard medical therapy (SMT) only included as per requirement.
89108405|NCT06276894|Other|Stepping on a Virtual Reality Treadmill with a Functional Near-infrared Spectroscopy (fNIRS) Device|This is a single-arm safety and feasibility study that will enroll up to 15 participants. Those meeting inclusion/exclusion criteria will be invited to enroll in the study. Following a thorough informed consent process, each participant will participate in one session of data acquisition. fNIRS data will be acquired with the NIRSport2, which is a fully-portable system as the device (weighs less than 2 pounds) is secured to the participant's back with backpack-like straps. Following signal optimization and signal quality checks, baseline fNIRS data will be obtained during 60-second periods of quiet, static standing. Then, each participant will complete up to 24 minutes of stepping on a treadmill with and without VR wearing the fNIRS cap. This training will be carried out in two 12-minute sessions with individuals being offered a sitting rest break in between. Training will be completed using the Motek C-Mill™ treadmill, which provides optional body weight support and VR feedback.
89108406|NCT06276881|Experimental|Healthy Controls|
89108407|NCT06276868|Experimental|Dalcilib+letrozole+HP|"All subjects received Dalcilib 150mg qd, stopped for 1 week after 3 weeks，and letrozole (2.5mg qd) (premenopausal combined with OFS). The subjects received 2 cycles of preoperative treatment with darcilib combined with letrozole, trastuzumab, and patstuzumab.~Then, MRI efficacy evaluation was conducted, and patients who achieved PR continued to receive the original treatment regimen for 6 cycles, while those who did not achieve PR switched to the TCHP chemotherapy regimen for 6 cycles."
89108408|NCT06276855|No Intervention|Control group|The DIF, PSQI, VAS, and BDI were also administered to individuals in the control group during the first interview, but no education was provided to them. The participants were given an appointment to meet at the hospital one month later. At the final polyclinic appointment one month later, the VAS, PSQI, and BDI were administered for the second time and took an average of 15-20 minutes to complete. In line with ethical principles, they were provided with individual education on sleep hygiene and sleep hygiene education booklets at the final polyclinic appointment. The same researcher collected the data and provided the education to avoid bias.
89228611|NCT04095416|Experimental|Intervention|Bilateral lower extremity ACE compression wraps in addition to standard medical care
89228612|NCT04095416|No Intervention|Control|Standard medical care
89108409|NCT06276855|Experimental|Experimental group|During the first interview, the DIF, PSQI, VAS, and BDI were administered to individuals in the experimental group. Each education session lasted an average of 30 minutes and was conducted face-to-face. Sleep hygiene education booklets were provided to individuals at the end of the education session. Studies suggest that at least one month should pass for behavioral change to occur after the education session. Therefore, the participants were given an appointment to meet at the hospital one month later. At the final interview one month after the education, the VAS, PSQI, and BDI were administered for the second and final time and took an average of 15-20 minutes to complete.
89108410|NCT06276842|Experimental|Patient of Group A given Inferior Alveolar Nerve Block|The intervention involved approaching the nerve from the contralateral side of the oral cavity over the contralateral premolars. The needle was inserted into the mandibular tissue along the average boundary of the mandibular ramus within the pterygomandibular space and lateral to the pterygomandibular fold. If bony contact was not achieved within 27-29 mm of needle insertion, the needle was slightly withdrawn and repositioned more distally toward the premolars. After achieving bony contact, the needle was withdrawn by 1-2 mm, aspiration was performed, and then 1.8 ml of anesthetic solution was deposited.
89108411|NCT06276842|Experimental|Group B-buccal infiltration-supplementary injection technique to Inferior Alveolar Nerve block|The intervention began by penetrating the needle into the buccal mucosa adjacent to the mandibular first molar. After aspiration, 1.8 ml of anesthetic solution (2% lignocaine with 1:100,000 epinephrine) was administered over approximately 2 minutes. Following a 15-minute period post-injection, each patient was asked about the level of numbness in their lip. Patients who did not experience significant lip numbness within this 15-minute timeframe were excluded from the study. For patients who reported positive lip numbness, the affected tooth was isolated using a rubber dam, and a traditional access opening procedure was initiated.
89108412|NCT06276829||Behçet's Disease|
89108413|NCT06276829||healthy individuals|
89108414|NCT06276790||low-risk group|
89108415|NCT06276790||high-risk group|
89108416|NCT06276777|Experimental|Varnish contains S-PRG (PRG Barrier Coat from Shofu)|Treatment of dentin hypersensitivity by application of tooth varnish containing S-PRG.
89108417|NCT06276777|Active Comparator|Varnish contains sodium fluoride and functionalized tri-calcium phosphate(Clinpro white varnish 3M)|Treatment of dentin hypersensitivity by application of tooth varnish containing sodium fluoride with functionalized tri-calcium phosphate.
89108418|NCT06276764||Patients with a documented history of IPMN|Patients with a documented history of IPMN by any imaging method will undergo the LINFU® procedure.
89108419|NCT06276712|Experimental|Ks dental implant|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants using KS implant with 3.5 mm of diameter
89108420|NCT06276712|Active Comparator|TS dental implant|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants using TS implant with 3.5 mm of diameter
89108421|NCT06276699|Placebo Comparator|1.Isometric exercise|
89108422|NCT06276699|Experimental|2. Combined conservative treatment|
89108423|NCT06276673|Experimental|single chamber blood flow restriction cuff|Single Chamber BFR (Delfi, Vancouver, Canada) training devices will be used for exercise and testing sessions (see attachment). Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) in accordance with manufacturer specifications. The cuffs will maintain pressure during training and rest periods. The LOP will be decreased to 0% immediately after the set is completed.
89108424|NCT06276673|Experimental|Multiple chamber blood flow restriction cuff|Multiple chamber BFR (B-Strong, Park City, UT) training devices will be used for exercise and testing sessions (see attachment). Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) in accordance with manufacturer specifications. The cuffs will maintain pressure during training and rest periods. The LOP will be decreased to 0% immediately after the set is completed.
89108425|NCT06276673|Placebo Comparator|No BFR cuff|No cuff will be worn during the training session.
89228613|NCT00990080|Active Comparator|Group 1|Pediacel® at 2 and 4 months of age followed by Infanrix™-IPV/Hib at 6 months.
89108426|NCT06276634|Experimental|AIH First|Participants in the AIH First arm will undergo 5 days of Acute Intermittent Hypoxia Interventions. Following the 5 Days of AIH, after a 2-week washout period, this group will then undergo 5 days of Sham AIH Interventions. The procedures are identical to AIH but with 21% oxygen for both breath cycles
89108427|NCT06276634|Experimental|Sham First|Participants in the Sham First arm will undergo 5 days of Sham-Acute Intermittent Hypoxia Interventions. Following the 5 Days of Sham-AIH, after a 2-week washout period, this group will then undergo 5 days of AIH Interventions. The procedures are identical to Sham-AIH but with 9-10% oxygen for the first breath cycle
89108428|NCT06276621|Experimental|Family Bridge Program|
89108429|NCT06276621|Active Comparator|Care as Usual- Resources Only|
89108430|NCT06276595|Experimental|TODOS Intervention|"Participants in the TODOS Intervention Group will receive the intervention Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story. They will receive 11 intervention sessions of 60-90 minutes over 11 weeks."
89108431|NCT06276595|Other|Control condition - 3 Monthly Group Activities in the Community|Children and their female caregivers randomized to the control group will receive 3 group sessions delivered monthly for three months. The first group session will occur at a community center and will consist of a meal and ice breaker activities. The second group session will consist of going to a movie at the local movie theatre. The third group session will consist of going bowling at the local bowling alley.
89108432|NCT06276582|Experimental|Screening for neonatal jaundice with a mobile health device|Neonatal jaundice will be screened using the app Picterus JP and the results will be compared to the total serum bilirubin level from a blood test.
89108433|NCT06276556|Experimental|ABP-671|
89108434|NCT06276556|Active Comparator|Allopurinol|
89108435|NCT06276543||antibiotic-impregnated catheter group|Hydrocephalus patients implanted with antibiotic-impregnated catheter.
89108436|NCT06276530|Active Comparator|Thoracotomy|The patients in this group will have a major lung resection through a conventional postero-lateral thoracotomy.
89108437|NCT06276530|Active Comparator|RATS (robotic-assisted thoracoscopic surgery)|The patients in this group will have a major lung resection through a minimally invasive approach by RATS.
89108438|NCT06276517||patients with subarachnoid hemorrhage|Patients hospitalized in Lariboisière intensive care unit for subarachnoid hemorrhage
89108439|NCT06276504|Experimental|Pembrolizumab|Pembrolizumab (commercial name: KEYTRUDA; MSD), 25 mg/ml solution for intravenous (IV) injection
89108440|NCT06276491|Experimental|Dose escalation and Dose Expansion of XmAb541|Intravenous or Subcutaneous administration
89108441|NCT06276465|Active Comparator|ADT + darolutamide|Up to 5 years of treatment
89108442|NCT06276465|Experimental|ADT + darolutamide + SBRT|Up to 5 years of treatment
89108443|NCT06276439||Positive lymph node detection with bioinspired sensor|"We will assess the effectiveness of our bioinspired sensor in identifying affected lymph nodes in ex vivo samples. This innovative sensor integrates spectral filters and vertically aligned photodiodes, mirroring the visual capabilities of the mantis shrimp, to simultaneously capture intrinsic UV fluorescence and externally introduced NIR fluorescence from ICG.~To minimize the potential harm from UV radiation, we employ a phased imaging approach. Initially, ICG is injected near the tumor area in the patient, utilizing its NIR fluorescence to accurately locate the lymph node and facilitate the removal of nearby fatty tissue as necessary. Following this, UV light is momentarily used to detect autofluorescence from amino acids frequently found in tumors, providing insights into the lymph node's condition. All resected samples will be analyzed by pathologist and provide ground truth."
89108444|NCT06276439||Positive lymph node detection with highly sensitive imaging sensor|"We will evaluate the performance of our sensor, characterized by low noise and high quantum efficiency, in detecting compromised lymph nodes in ex vivo samples. This advanced sensor combine spectral filters and low noise photodiodes, enabling the simultaneous detection of natural UV fluorescence and induced NIR fluorescence from ICG.~To minimize the potential harm from UV radiation, we employ a phased imaging approach. Initially, ICG is injected near the tumor area in the patient, utilizing its NIR fluorescence to accurately locate the lymph node and facilitate the removal of nearby fatty tissue as necessary. Following this, UV light is momentarily used to detect autofluorescence from amino acids frequently found in tumors, providing insights into the lymph node's condition. All resected samples will be analyzed by pathologist and provide ground truth."
89108445|NCT06276387|Experimental|Mindfulness Program|Individuals in the mindfulness group will complete an 8-week mindfulness course that has been adapted for individuals with rheumatic diseases (MBSR-RD).
89108446|NCT06276387|No Intervention|Treatment as Usual (TAU)|Individuals in the TAU group will continue engaging in routine care and be asked to refrain from participating in mindfulness programs during the trial.
89108447|NCT06276374|Experimental|Single antiplatelet therapy (SAPT) group with aspirin or clopidogrel|1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)
89108448|NCT06276374|Active Comparator|Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel|1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)
89108449|NCT06276010|Experimental|nafamostat mesilate group|The initial dosing of the nafamostat mesilate group is 0.5mg/kg/h. We maintain ACT at 180~220s by adjusting the dosage of nafamostat mesilate.
89108450|NCT06276010|Other|unfractionated heparin group|The initial dosing of the unfractionated heparin group is 8~12U/kg/h. We maintain ACT at 180~220s by adjusting the dosage of unfractionated heparin .
89108451|NCT06275555|Experimental|bivalirudin group|If the creatinine clearance rate > 30ml/min, the initial dose of bivalirudin is 0.04mg/kg/h. If the creatinine clearance rate<30ml/min or the patients who have received renal replacement therapy (CRRT), the initial dose of bivalirudin is 0.02mg/kg/h, and the dose is adjusted according to APPT to maintain APTT at 50-70s. After bivalirudin started, APTT was checked every 4 hours. If APTT was in the target range twice in a row, it was re-examined every 12 hours.
88820938|NCT05413785|Experimental|Participants with Hepatitis C|Participants will be clients at the Lexington Probation and Parole office who are Hepatitic C positive.
88820939|NCT05413018|Experimental|CC-486/Oral Azacitidine Administration|
88820940|NCT05413018|Placebo Comparator|Placebo Administration|
89108452|NCT06275555|Other|unfractionated heparin group|The initial dose of heparin was 8-12U/kg/h, and the dosage of heparin was adjusted according to the value of APTT. APTT was maintained at 50-70s, and APTT was reexamined every 4 hours.
89108453|NCT06275152|Experimental|RIC group|RIC interventions will be applied to the upper extremity for a total of 20 cumulative minutes of limb ischemia, at a pressure of 200 mmHg.
89108454|NCT06275152|Sham Comparator|Sham Remote Ischemic Conditioning|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
89108455|NCT06274983|Other|IVR platform trial|8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform.
89108456|NCT06274827|Experimental|Superficial electromyography|Electrode placement was performed on the participants' dominant side UT, MT, LT, and SA muscles. Following this, superficial electromyography measurements were performed during maximal voluntary isometric contraction tests and six different upper extremity closed kinetic chain exercises.
89108457|NCT06274164||Patient group|"Subject enrollment: patients with RAI1-related disorders will be enrolled and will complete the following assessments:~Clinical studies: vitals, history and physical examinations.~Neurophysiological studies: sleep/EEG study (for a selected patient population).~Molecular (biomarkers) studies: blood (required) and skin biopsy (optional)."
89108458|NCT06274164||Control group|"Subject enrollment: healthy family members of the patients with RAI1-related disorders who are willing to give a blood sample.~Molecular (biomarkers) studies: blood samples will be used as healthy control for biomarker studies."
89108475|NCT06273085|Active Comparator|Intervention|Intervention arm will receive initial face to face education during hospital admission and also an educational flier about GDMT. They will get 3 more sessions of education over phone at 1, 3 and 5 months after discharge, each session includes an overview of benefits and side effects of GDMT, inquiries about reasons of not using optimal doses of GDMT medications, and encouraging adherence to visits with providers.
89108476|NCT06273085|No Intervention|Control|Control arm will receive initial face to face education during hospital admission and also an educational flier about GDMT.
89108477|NCT06272461|Experimental|IV-Lido|Intravenous Lidocaine dose loading than continuous infusion
89108478|NCT06272461|Active Comparator|IV-Keta|Intravenous Ketamine dose loading than continuous infusion
89108479|NCT06271421|Active Comparator|NanoTherm arm (group A)|Recurrent glioblastoma multiforme patients treated with NanoTherm therapy.
89108480|NCT06271421|Placebo Comparator|Stupp protocol (group B)|Glioblastoma multiforme patients treated according to Stupp protocol including surgery, chemotherapy and radiotherapy.
89108481|NCT06270901|Experimental|High Protein Planetary Health Diet|High Protein Planetary Health Diet Meal: This meal contains 62 g of protein primarily from plant origin (particularly legumes)
89108482|NCT06270901|Experimental|Low Protein Planetary Health Diet|Low Protein Planetary Health Diet Meal: This meal contains 36 g of protein from primarily plant origin (particularly legumes)
89108483|NCT06270901|Experimental|High Protein Western Diet|High Protein Western Diet Meal: This meal contains 62 g of protein primarily form animal origin
89108484|NCT06270901|Experimental|Low Protein Western Diet|Low Protein Western Diet Meal: This meal contains 36 g of protein primarily from animal origin
89108485|NCT06270043||Focal Therapy|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received focal therapy as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study.
89108486|NCT06269549|Other|The effect of dietary supplements added to physical exercise intervention|This study arm will include two groups of participants, one receiving 12 weeks physical exercise intervention together with real dietary supplements (Active Joint, and Collagen Powder Blend), while the other group receiving exercise intervention with placebo dietary supplements (placebo Active Joint and placebo Collagen Powder Blend).
89108487|NCT06269549|Other|The effect of physical exercise added to dietary supplement intervention|This study arm will include two groups of participants, one receiving 12 weeks real dietary supplements alone (Active Joint, and Collagen Powder Blend), while the other group receiving real dietary supplements (Active Joint and Collagen Powder Blend) with physical exercise.
89108488|NCT06269367|Experimental|NewGait|Participants will put on the NewGait device and walk on the treadmill and overground. Participants may receive biofeedback of their gait patterns to engage them in the training.
89108489|NCT06269367|Other|Control|Participants will put on the Control device and walk on the treadmill and over ground. Participants may receive biofeedback of their gait patterns to engage them in the training.
89108490|NCT06268353|Experimental|pregnancy|Non-pregnant and pregnant women are compared
89108491|NCT06265441|Experimental|Group A : Adductor canal block only|Patients will receive Adductor canal block under ultrasound guide of 20 ml bupivacaine 0.25%
89108492|NCT06265441|Active Comparator|Group B : Adductor canal + IPACK block|Patients will receive Adductor canal block and IPACK block under ultrasound guidance with 20ml bupivacaine 0.25% for each block
89108493|NCT06263621|Experimental|"Intervention Standard"|"The smaller entree is labeled Standard and the larger entree is labeled Large."
89108494|NCT06263621|No Intervention|"Control Small"|"The smaller entree is labeled Small and the larger entree is labeled Large."
89108495|NCT06263504|Active Comparator|receive standard treatment group|
89108496|NCT06263504|Experimental|comprehensive treatment group|
89108497|NCT06262724|Other|Surgery|Surgical intervention for breast reshaping utilizing chest wall perforators for auto-augmentation.
89108498|NCT06262412|Experimental|Internet-delivered cognitive-behaviour therapy (ICBT)|"A therapist-guided, Internet-delivered cognitive-behaviour therapy (ICBT) programme for children and adolescents with BDD.~Cognitive-behaviour therapy, Exposure and response prevention (ERP)"
89108499|NCT06262412|Active Comparator|Internet-delivered relaxation treatment (IRT)|"A therapist-guided, Internet-delivered relaxation treatment (IRT) programme for children and adolescents with BDD.~Relaxation training (deep breathing, progressive muscle relaxation, imagery)"
89108500|NCT06261190||Active surveillance|Group with active surveillance of their Papillary Thyroid Cancer
89108501|NCT06261190||Immediate surgery|Group who underwent surgery after diagnosis Papillary Thyroid Cancer
89108502|NCT06260839|Experimental|MRN guided minimally invasive surgery group|The intervention measures of the experimental group were to analyze the relationship between the shape of the contracture band, the distance between the sciatic nerve and the contracture band, and the external rotation angle according to the preoperative MRN manifestations of the patients, and to design the individualized surgical approach according to the imaging manifestations and perform MRN-assisted minimally invasive release.
89108503|NCT06260839|Active Comparator|Minimally invasive surgery group|In the control group, preoperative magnetic resonance imaging was only used to assist in the diagnosis and evaluation of gluteal muscle contracture, and the results of magnetic resonance imaging were not used to assist in the design of surgical approach. In the control group, non-MRN-assisted minimally invasive release was performed
89108504|NCT06260683|Experimental|Arm I (PEC)|Participants receive PEC for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.
89108505|NCT06260683|Experimental|Arm II (TEC)|Participants receive TEC for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.
89108506|NCT06260683|Active Comparator|Arm III (NRT)|Participants receive NRT (nicotine patches and lozenges) for 14 weeks, including a 2-week pre-switch period to become familiar with usage. Participants in all arms participate in discussions throughout the trial.
89108507|NCT06260397|Experimental|serratus anterior plane block|while the patients in lateral position, serratus anterior plane block will be done using high frequency linear ultrasound probe at the level of fourth rib.30 ml of 0.25% bupivacaine will be injected.
89108508|NCT06260397|Experimental|costotransverse plane block|while the patients in lateral position, costotransverse block will be done using 22-gauge echogenic needle. the needle is advanced in-plane lateral to the spinous process of the 4th thoracic vertebra from caudally cephalad.30 ml of 0.25% bupivacaine will be injected
89108509|NCT06260397|Experimental|patient controlled analgesia|After successful extubation, patients will be transferred to PACU. Patients will receive a bolus dose of 5 mg nalbuphine then PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr with self-administration bolus of 0.5ml with 15 min lock-out time.
89228614|NCT00990080|Active Comparator|Group 2|Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.
88820941|NCT05409235|Experimental|OTT166 Cohort 1|Participants will receive OTT166 low dose for 24 weeks
89108510|NCT06260384||All patients attending outpatient cardiology clinics or referred for EP study|Participants will be recruited from outpatient cardiology clinics and inpatient cardiology wards at twenty cardiac centers in 17 countries spread across all African regions. They all belong to the Africa Heart Rhythm Association (AFHRA) network, and participants are included if they have a preexcitation (WPW) pattern on an ECG. A written consent will be obtained, and an ethical clearance from each center will be obtained from their institution. The exclusion criteria were a lack of consent.
89108511|NCT06259474|Experimental|Group A|Group (A): 20 subjects combined HE with traditional treatments for low back pain (heat therapy, medication, and progressive strength training).
89108512|NCT06259474|Active Comparator|Group B|Group (B) :20 subjects received the same conventional treatment for low back pain as group (A), including heat therapy, medication, and progressive strength training.
89108513|NCT06255951|Experimental|Itraconazole|Itraconazole
89108514|NCT06255951|Experimental|Rifampicin|Rifampicin
89108515|NCT06253104||Study Cohort|All enrolled participants with no randomization group allocations
89108516|NCT06252714|Experimental|Defecation Posture Modification Device|Patients will be given a Squatty Potty Device
89108517|NCT06252597|Experimental|education and training|After implementation of the pre-interview and determination/performance of necessity, education and training at a regularly scheduled occupational therapy clinic visit will be performed with handouts, verbal education, hands-on training, and video training.
89108518|NCT06251115|Experimental|QY-1-T|"Each patient will undergo a core study of approximately 1 year after enrollment: including screening period, apheresis, first treatment cycle (induction phase), observation period, second treatment cycle (maintenance phase), and routine follow-up period.~The first treatment cycle (induction period): It is planned to use 4 induction doses of 1×10^4 cells/Kg, 1×10^5 cells/Kg, 1×10^6 cells/Kg, 5×10^6 cells/Kg or 10×10^6 cells/Kg respectively on day 1 ( C1D1), day 8 (C1D8), day 15 (C1D15) and day 22 (C1D22) received stepped dosing of QY-1-T. A 30-day medical observation will be conducted after the first treatment cycle, followed by the second treatment cycle.~Second treatment cycle: The dose is 5×10^6 cells/Kg or 10×10^6 cells/Kg. TCR-T was infused once a week, that is, QY-1-T administration was performed on day 1 (C2D1), day 8 (C2D8), day 15 (C2D15), and day 22 (C2D22)."
89108519|NCT06250374|Experimental|Patients with thromboendarterectomy surgery|"Anesthesia was induced with sufentanil 0.3 g/kg, etomidate 0.3-0.4 mg/kg, rocuronium 0.4 mg/kg and maintained with continuous infusion Propofol and sufentanil. A pulmonary arterial catheter was inserted in all patients. Patients were cooled by means of the oxygenator heat exchanger at a rate of one degree Celsius every three minutes. Rewarming was achieved at a rate of one degree Celsius every five to ten minutes.~The following measures were performed:~Measure 1: In normo-thermia after induction of general anesthesia Measure 2: On CPB, before circulatory arrest and in hypothermia at 18-20°C Measure 3: On bypass, after circulatory arrest and in hypothermia at 18-20°C Measure 4: At the end of the procedure, after weaning from the bypass and in normothermia.~For each measure mean arterial pressure, cardiac output, PaCO2, pH, bilateral NIRS value were also recorded."
89108520|NCT06246201||Patients with Coronary Artery Disease|Having been diagnosed with coronary artery disease
89108521|NCT06245070|Experimental|Active high definition transcranial direct current stimulation (HD-tDCS)|High-definition anodal transcranial direct current stimulation (2 milliamps [mA]) for 5 consecutive days (one session per day for 20 minutes each). The electrical current will be administered over the left Supplementary motor area. The stimulation will be delivered at an intensity of 2 milliamps (mA) for a maximum of 20 minutes.
89108522|NCT06245070|Experimental|Sham high definition transcranial direct current stimulation (HD-tDCS)|High-definition sham transcranial direct current stimulation (2 milliamps [mA]) for 5 consecutive days (one session per day for 20 minutes each). The electrical current will be administered over the left Supplementary motor area. The current will be ramped up for the first 30 seconds following which the intensity will drop to 0 milliamps (mA).
89108523|NCT06245031|Experimental|Active|All subjects will receive a device with Active settings for use daily at home for 60-minutes for 12 months.
89108524|NCT06234956|Experimental|BIMERVAX|
89108525|NCT06233695||The Female Group|Patients with an apparent gender of female.
89108526|NCT06233695||The Male Group|Patients with an apparent gender of male.
89108527|NCT06230445|Experimental|UHealth digital therapeutic group|The patients in this group will use UHealth application to monitor their symptoms and give medical advisement through digital methods.
89108528|NCT06230445|No Intervention|Regular follow-up group|The patients in this group will use paper-based follow-up to monitor their symptoms and give medical advisement in outpatient clinic.
89108529|NCT06228196||BPPV patients|Confirmed diagnosis of BPPV
89108530|NCT06228196||Healthy controls|Healthy subjects who have not had BPPV
89108531|NCT06220162|Experimental|VAC regimen|
89108532|NCT06217029||Effective Group of Cervical Spondylotic Pain|"VAS reduction rate is used to evaluate clinical efficacy. The reduction rate = (baseline value - end value)/baseline value. The clinical efficacy is divided into four levels: cured, significant effect, slight effect, ineffective or recurrent. cured: reduction rate ≥ 75%; significant effect: 50% ≤ reduction rate < 75%; slight effect: 25% ≤ reduction rate < 50%; ineffective: reduction rate < 25%. The cured + significant effect group was classified as the treatment effective group,"
89108533|NCT06217029||Ineffective Group of Cervical Spondylotic Pain|"The slight effect + ineffective group and the recurrent group were classified as the treatment ineffective group"
89108534|NCT06215963|Experimental|App for Independence-O (A4i-O)|Participants will be provided with A4i-O for one month.
89108535|NCT06214910|Other|Investigational: Community-based TB preventive therapy (TPT)|Participants in the community arm will receive a multi-month dispensing packet at enrollment with the complete 3 month supply of TPT (3HP: 3 months of weekly isoniazid and rifapentine).
89108536|NCT06214910|Active Comparator|Standard-of-Care Tuberculosis Preventative Therapy (TPT)|Participants in the standard of care arm will receive a referral letter to their local Department of Health (DoH) clinic to continue TPT. They will be instructed to present to the DoH clinic within 2 weeks to receive their continuation doses of TPT per current South African DoH standard of care (refills administered monthly).
89108537|NCT06210100|Active Comparator|Active stimulation|Active Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 10 days.
89108538|NCT06210100|Sham Comparator|Sham stimulation|Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 10 days.
89108539|NCT06209307|Experimental|Arm 1: Preoperative and postoperative pelvic floor physical therapy|Pelvic floor physical therapy (PFPT) will be initiated 1 month before surgery in patients randomized to Arm 1.
89108540|NCT06209307|No Intervention|Arm 2: Postoperative pelvic floor physical therapy only.|At 1-3 days follow-up after surgery pelvic floor physical therapy (PFPT) will be initiated in the post-operative PFPT-only group as part of standard of care.
89108541|NCT06206343|Experimental|TENS application treatment program|"Conventional TENS will be performed for 3 weeks and 15 sessions. In this application, two electrodes will be placed on each side of the spinous processes of the patient's cervical region.~Two of them will be placed right and left, just below the skull, where the scalp ends, and the other two will follow them, about 5 cm away.~Care will be taken not to place the electrodes directly on your spine."
89108542|NCT06206343|Experimental|Tele-rehabilitation application treatment program:|"Patients who accept the treatment will be evaluated before treatment. The treatment program will be done online for 3 weeks, 3 times a week. In the first session, neck anatomy and things to be considered in neck pain will be explained to the patient. In the following sessions, neck exercises will be performed with the participation of the patients.~Neck exercises: 1.Head rotation movements 2.Chin tuck 3.Neck isometric exercises 4.Shoulder shrug 5.Scapula approach 6.Isometric strengthening 7.Exercises against gravity 8.Stretching exercises etc. will be done."
89108543|NCT06206343|No Intervention|Control group|"Control group patients will not receive any treatment. The first evaluation was done.~After 3 weeks, the second evaluation will be done again."
89108544|NCT06199934||Vaccinated|BNT162b2 recipients
89108545|NCT06199934||Unvaccinated|BNT162b2 eligible but did not receive
89108547|NCT06193590|Experimental|Carevix|suction cervical stabilizer utilized for intrauterine procedures
89108548|NCT06193590|Active Comparator|Tenaculum|standard of care cervical stabilization device
89108549|NCT06192264|Experimental|ASC40 dose 1|ASC40 dose 1 84 days of treatment
89108550|NCT06192264|Placebo Comparator|ASC40 Placebo|ASC40 Placebo 84 days of treatment
89108551|NCT06186102|Active Comparator|Spermidine|Spermidine will be given orally as capsules of cellulose with spermidine (24 mg/day) and rice flour.
89108552|NCT06186102|Placebo Comparator|Placebo|Placebo will be given orally as capsules of cellulose and rice flour (same size and visual appearance as spermidine capsules)
89108553|NCT06183671|Experimental|Ascending Single Doses|48 participants, 6 single ascending dose (SAD) cohorts (Cohorts 1 to 6). Within each cohort, 8 participants will be randomized in a 6:2 ratio, 6 participants receiving JX09 and 2 receiving placebo
89108554|NCT06183671|Experimental|Ascending Multiple Doses|32 participants, 4 multiple ascending dose (MAD) cohorts (Cohorts 7 to 10). Within each cohort, 8 participants will be randomized in a 6:2 ratio, 6 participants receiving JX09 and 2 receiving placebo
89108555|NCT06183671|Experimental|Food Effect|12 participants,1 single-dose food effect (FE) cohort (Cohort 11), open-label, two-sequence, two-period, crossover design, participants will be randomly assigned to 1 of the 2 crossover sequences
89108556|NCT06183307|Experimental|Nattokinase group|Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units.
89108557|NCT06183307|Placebo Comparator|Placebo Group|The placebo group will receive the same amount of 100mg placebo, at the same time, containing corn starch.
89108558|NCT06183164|Experimental|Mindfulness|The program lasts eight weeks, with face-to-face group meetings for 2-2.5 hours per week and applications requested from the patient. It is a program in which various mindfulness practices are used consecutively for eight weeks and completed with a six-hour silence (retreat) day at the end of the eight weeks.
89108559|NCT06183164|No Intervention|Control group|Routine main tenance will be applied.
89108560|NCT06181305|Experimental|Group A (HRT plus letrozole incorporation)|"Exogenous oestradiol in the form of 2 mg oral oestradiol valerate , three times daily will be started on the 2nd or 3rd day of the cycle. Tri-laminar endometrium of ≥ 9 mm will be the targeted cut-off. If the endometrium does not yet reach the target, oestradiol supplementation will be continued with serial US assessment until the targeted cut-off will be reached. Upon reaching the target endometrium, oral letrozole tablets 2.5 mg will be started twice daily for 5 days only with continuation of 6 mg daily oestradiol supplementation. Then, daily intramuscular progesterone in oil (100 mg intramuscular progesterone) will be started once per day with continuation of 6 mg oestradiol~interventions:~Drug:estradiol valertae~Drug :letrozole 2.5 mg tablet"
89228615|NCT00990158|Active Comparator|Low dose vitamin K + usual warfarin|Low dose oral vitamin K (0.150 mg orally once daily) + warfarin continuation with usual warfarin monitoring
89108561|NCT06181305|Active Comparator|Group B (Letrozole mild ovarian stimulation)|"Oral letrozole 2.5-5 mg daily on cycle day(3-7) will be added . TVS will be performed from cycle day 8-10 to make sure that a dominant follicle has been recruited with the endometrium thickness ≥ 7 mm . Upon reaching the dominant follicle (18-20mm) , endometrial thickness will be measured on the day of ovulation trigger and blood sample will be withdrawn from each patient for assessment of E2 , P4 and LH levels. Patients with low LH level , high E2 level , low P4 level (<1 ng/ml) will continue in the RCT; 10,000unit HCG will be injected as ovulation trigger~intervention :~Drug :letrozole 2.5mg tablet~procedure: on the day of ovulation trigger blood sample will be withdrawn from each patient for assessment of E2 , P4 and LH levels."
89108562|NCT06178198|Experimental|Ablative radioembolization for large HCC|Yttrium-90 resin microspheres (SIR-Sphere, SIRTEX) will be administered to cover the main tumor, satellite nodules, and margin.
89108563|NCT06177353||EBDR patients|
89108564|NCT06177353||Healthy control|
89108565|NCT06173310|Experimental|borderline-resectable pancreatic cancer (BRPC)|
89108566|NCT06172959|Experimental|Vocal Therapy Group|Participants in this group will receive Vocal Intonation Therapy (VIT) and Therapeutic Singing (TS) for up to three weeks
89108567|NCT06171724|Experimental|240 mg Shoden|Shoden, administered as two 120 mg capsules per dose (240 mg total)
89108568|NCT06171724|Active Comparator|480 mg Shoden|Shoden, administered as two 240 mg capsules per dose (480 mg total)
89108569|NCT06171113|Experimental|6 mg single ascending dose (SAD) Group|Participants receive a 6 mg single dose of GSK4024484 or matching placebo, in a fasted state.
89108570|NCT06171113|Experimental|12 mg SAD Group|Participants receive a 12 mg single dose of GSK4024484 or matching placebo, in a fasted state.
89108571|NCT06171113|Experimental|24 mg SAD Group|Participants receive a 24 mg single dose of GSK4024484 or matching placebo, in a fasted state.
89108572|NCT06171113|Experimental|40 mg SAD Group|Participants receive a 40 mg single dose of GSK4024484 or matching placebo, in a fasted state.
89108573|NCT06171113|Experimental|60 mg SAD Group|Participants receive a 60 mg single dose of GSK4024484 or matching placebo, in a fasted state.
89108574|NCT06171113|Experimental|80 mg SAD Group|Participants receive a 80 mg single dose of GSK4024484 or matching placebo, in a fasted state.
89108575|NCT06171113|Experimental|Food Effect Group|Participants receive a single study dose of either GSK4024484 or matching placebo in a fed state.
89108576|NCT06171113|Experimental|100 mg SAD Group|Participants receive a 100 mg single dose of GSK4024484 or matching placebo.
89108577|NCT06171113|Experimental|Optional Group|Participants may be included in this group, to allow flexibility if the dose escalation needs modification or a dose level needs to be added or repeated.
89108578|NCT06171113|Experimental|10 mg multiple ascending doses (MAD) Group|Participants receive a single dose of 10 mg per day of GSK4024484 or matching placebo during 3 subsequent days (30 mg total).
89108579|NCT06171113|Experimental|20 mg MAD Group|Participants receive a single dose of 20 mg per day of GSK4024484 or matching placebo during 3 subsequent days (60 mg total).
89108580|NCT06171113|Experimental|30 mg MAD Group|Participants receive a single dose of 30 mg per day of GSK4024484 or matching placebo during 3 subsequent days (90 mg total).
89108581|NCT06170229|Active Comparator|Education and High Intensity Interval Training (eHIIT)|1 educational session lasting 1 hour. 12 weeks of supervised High Intensity Interval Training (HIIT) 3 times/week.
89108582|NCT06170229|Active Comparator|Neuromuscular exercise and education program (NEMEX-e)|2 educational sessions lasting 1 hour each. 8 weeks of supervised Neuromuscular Exercise 2 times/week.
89108583|NCT06168760||Healthy|Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
89108584|NCT06159192|Experimental|Monitoring Effect Of Shock Wave On Microcirculation Changes In Type2 Diabetes Mellitus|Energy intensity of (0.09 mJ/mm2) for 12 treatment sessions, two per week, for six weeks
89108585|NCT06159192|Experimental|Effect Of Shock Wave On Microcirculation Changes In Type2 Diabetes Mellitus|low intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of (0.09 mJ/mm2).
89108586|NCT06150521||The hysteroscopic myomectomy group|Patients underwent cold knife hysteroscopic myomectomy
89108587|NCT06138899|Experimental|Club 25|Club 25 donation programs will be set up in schools randomized to this arm. Three blood donation events per school year will take place at study schools. Each donation event will be preceded by a motivational talk intended to inform students of the importance of blood donation and encourage students to donate blood. Donation events and motivational talks will be planned and conducted by the Malawi Blood Transfusion Services (MBTS).
89108588|NCT06138899|No Intervention|Standard procedures|Schools in this arm will not take part in a Club 25 donation program. Three blood donation events per school year will take place at study schools. Each donation event will be preceded by a motivational talk intended to inform students of the importance of blood donation and encourage students to donate blood. Donation events and motivational talks will be planned and conducted by the Malawi Blood Transfusion Services (MBTS).
89108589|NCT06138067|Experimental|High Intensity Approach|Patients will receive printed educational material (PEM) which will include information and resources regarding clinical trials/clinical trial participation, cancer center support services; and community resources and services available to cancer patients. The PEM will be reviewed by the clinical trial patient navigator with the patient prior to the clinic visit with the medical oncologist. If the patient is offered participation in a therapeutic clinical trial, the high intensity patient navigation begins. The patient navigator will arrange to meet with the patient to complete a needs assessment to identify and address barriers to trial participation within one week of the visit with the medical oncologist (and clinical trial offer).
89108590|NCT06138067|Active Comparator|Low Intensity Approach|Patients will receive printed educational material (PEM) which will include information and resources regarding clinical trials/clinical trial participation and community resources and services available to cancer patients. The PEM will be reviewed by the patient navigator with the patient prior to the clinic visit with the medical oncologist.
89228616|NCT00990158|Placebo Comparator|Usual warfarin therapy + placebo|Patients continue usual warfarin and take one placebo per day
89108591|NCT06137963|Other|Transform10 Waitlist|"The control group will receive access to the Transform10 website at 6 months.~Patients in this group will report their active minutes and weight via the Transform10 website throughout the 6 month-long programs. In addition, participants will take an Hba1c blood test at pre surgical screening, 6 months after their day of surgery and 1 year after their day of surgery as part of routine procedures."
89108592|NCT06137963|Experimental|Transform10|"Patients in this group will get access to the Transform10 website on their day of surgery.~Patients in this group will report their active minutes and weight via the Transform10 website throughout the 6 month-long program. In addition, participants will have a repeat Hba1c test ordered at 6 months after their day of surgery and 1 year after their day of surgery as part of routine procedures."
89108593|NCT06135493|No Intervention|Control arm|These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting
89108594|NCT06135493|Experimental|Intervention arm|These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting plus losartan 100mg
89108595|NCT06133348|Experimental|PRISM Intervention|This single-arm pilot study will (1) test feasibility, acceptability, and appropriateness of the PRISM intervention in individuals with breast cancer, (2) elicit patient perspectives on elements for future adaptation or expansion to meet the unique needs of women with breast cancer, (3) assess trajectory of patient-reported outcomes and biological measures of stress for patients with breast cancer receiving the PRISM intervention.
89108596|NCT06133322|Experimental|Community health worker-led implementation strategy|CHW-led church-based multifaceted implementation strategy: CHWs will conduct individualized health coaching and healthcare navigation, organize church-based health promotion programs (e.g., nutrition education and exercise sessions), and train and assist the study participants in self-monitoring of BP. Nurse practitioners will see study participants at church settings, and community pharmacies will deliver antihypertensive medications to patients' homes.
89108597|NCT06133322|Experimental|Group-based Education Strategy|The investigator team will work with church leadership and wellness coordinators to organize group-based education sessions. Health education will be delivered by local primary care providers, dieticians, and health educators. Contact information for primary care providers and information on self-monitoring of BP will also be given at group sessions.
89108598|NCT06132867|Experimental|Treatment A followed by Treatment B|Participants will receive 90 mg oral solution of brigatinib in a fasted state on Day 1 of Period 1 (Treatment A) followed by a washout period of at least 14 days and will receive 90 mg tablet of brigatinib in a fasted state on Day 1 of Period 2 (Treatment B).
89108599|NCT06132867|Experimental|Treatment B followed by Treatment A|Participants will receive 90 mg tablet of brigatinib in a fasted state on Day 1 of Period 1 (Treatment B) followed by a washout period of at least 14 days and will receive 90 mg oral solution of brigatinib in a fasted state on Day 1 of Period 2 (Treatment A).
89108600|NCT06132672|Experimental|Navigators (peer navigator) training|Training is designed to increase knowledge and skills. Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4
89108601|NCT06132672|Experimental|delayed-intervention group|Training is designed to increase knowledge and skills. The delayed-intervention group will be trained in year 5
89108602|NCT06123299|Active Comparator|pHyph treatment|Initial treatment with pHyph vaginal tablet once daily during 6 consecutive days
89108603|NCT06123299|No Intervention|No treatment|No initial treament during the first 7 days of the study
89108604|NCT06121999|Active Comparator|Acceptance-based behavioral weight loss program (ABWL)|Participants meet individually for 30 - 60 minutes with an occupational therapist for 13 consecutive weeks at a gastroenterology office. Outcome data is collected at baseline (visit 1) and at the end of the study (visit 13), Participants work on two modules per week in-between visits. During visits the participants' weight is recorded, module contents and worksheet information is reviewed and recorded, and suggestions are made as indicated in the clinician guide.
89108605|NCT06121999|Experimental|Occupational Therapy behavioral lifestyle intervention|Participants meet individually for 60-90 minutes with an occupational therapist for 13 consecutive weeks at a gastroenterology office. Outcome data is collected at baseline (visit 1) and at the end of the study (visit 13). The Model of Human Occupation Screening Tool (MOHOST) and Role Checklist version 3 (RCv3) assessment are also used for intervention in the areas of motivation for occupation, pattern of occupation, communication & interaction skills, motor skills, process skills, and environment. Participants are also educated about practice guidelines for MASLD/MASH such as a Mediterranean (MED) diet and a personalized exercise plan. In-between visits, participants work on two modules of the control intervention and implement dietary and lifestyle modifications discussed during the visit.
89108606|NCT06115499|Experimental|Arm I (nab-paclitaxel, gemcitabine, cisplatin)|Patients receive nab-paclitaxel IV over 30-40 minutes, gemcitabine IV over 30-40 minutes, and cisplatin IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.
89108607|NCT06115499|Active Comparator|Arm II (nab-paclitaxel, gemcitabine)|Patients receive nab-paclitaxel IV over 30-40 minutes and gemcitabine IV over 30-40 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT throughout the trial. Patients may optionally undergo blood sample collection at baseline and on study.
89108608|NCT06109779|Experimental|Arm A|Rilvegostomig IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)
89108609|NCT06109779|Placebo Comparator|Arm B|Placebo IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)
88820942|NCT05409235|Experimental|OTT166 Cohort 2|Participants will receive OTT166 high dose for 24 weeks
89108618|NCT06106529|Experimental|Venlafaxine|"In this open-label randomized controlled intrapatient cross-over study patients are randomly assigned to one of the two treatment groups.~After a one week baseline period, group 1 starts with venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks followed by a two-week wash-out period (no medication), hereafter the group starts with oxybutynin 5 mg twice per day for 6 weeks total."
89108619|NCT06106529|Experimental|Oxybutynin|After a one week baseline period, group 2 starts with oxybutynin 5 mg twice per day for 6 weeks total followed by a two-week wash-out period (no medication), hereafter the group starts with venlafaxine 37.5 mg once daily for 7 days followed by 75mg once daily for 5 weeks.
89108620|NCT06106035|Experimental|Intervention Group: low-fat vegan diet|This arm of participants will be asked to attend weekly online classes in nutrition and health and to follow a low-fat, vegan diet for 16 weeks.
89108621|NCT06104956|Experimental|Experimental group : Imposed weaning protocol|The flow of the HFNO will remain high (50-60 L/min) guaranteeing the effectiveness of the HFNO on the wash-out of the anatomical space. At the same time, weaning will begin with a gradual reduction in FiO2 of 0.1 every 4 hours. To achieve this reduction, the patient will have to meet the safety targets of a stable respiratory rate at rest (no increase) and pulsed oxygen saturation (SpO2). The SpO2 target will be 92-95%. Once the FiO2 has stabilised at 0.4 for 4 hours, the nurse will initiate a 10 L/min reduction in the flow of HFNO every 4 hours. The oxygen therapy support may be changed for standard oxygen when the HFNO flow rate is 40L/min with an FIO2 of 0.4 for 4 consecutive hours.
89108622|NCT06104956|Active Comparator|Control group|Weaning methods will be left to the free choice of the practitioner. Any change in the HFNO setting must be made on medical prescription. A minimum SpO2 objective is required (SpO2 ≥92%).
89108623|NCT06103877|Active Comparator|Part 1 Cohort 1 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
89108624|NCT06103877|Active Comparator|Part 1 Cohort 2 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
89108625|NCT06103877|Active Comparator|Part 1 Cohort 3 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
89108626|NCT06103877|Active Comparator|Part 1 Cohort 4 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
89108627|NCT06103877|Active Comparator|Part 1 Cohort 5a SAD|Participants will receive IV infusion of AZD1163 on Day 1.
89108628|NCT06103877|Active Comparator|Part 1 Cohort 5b SAD|Participants will receive SC injection of AZD1163 on Day 1.
89108629|NCT06103877|Active Comparator|Part 1 Cohort 6 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
89108630|NCT06103877|Active Comparator|Part 1 Cohort 7 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
89108631|NCT06103877|Active Comparator|Part 1 Cohort 8 SAD|Participants will receive IV infusion of AZD1163 on Day 1.
89108632|NCT06103877|Placebo Comparator|Part 1 pooled Placebo SAD IV|Participants will receive matching IV infusion of placebo on Day 1.
89108633|NCT06103877|Placebo Comparator|Part 1 pooled Placebo SAD SC|Participants will receive matching SC injection of placebo on Day 1.
89108634|NCT06103877|Active Comparator|Part 2 Cohort 1 MAD (Japanese participants)|Participants will receive SC injection of AZD1163 on Days 1 and 15.
89108635|NCT06103877|Active Comparator|Part 2 Cohort 2 MAD (Japanese participants)|Participants will receive SC injection of AZD1163 on Days 1 and 15.
89108636|NCT06103877|Active Comparator|Part 2 Cohort 1 MAD (Chinese participants)|Participants will receive SC injection of AZD1163 on Days 1 and 15.
89108637|NCT06103877|Active Comparator|Part 2 Cohort 2 MAD (Chinese participants)|Participants will receive SC injection of AZD1163 on Days 1 and 15.
89108638|NCT06103877|Placebo Comparator|Part 2 Placebo MAD (Japanese participants)|Participants will receive matching SC injection of placebo on Days 1 and 15.
89108639|NCT06103877|Placebo Comparator|Part 2 Placebo MAD (Chinese participants)|Participants will receive matching SC injection of placebo on Days 1 and 15.
88820943|NCT05409235|Placebo Comparator|Vehicle control Cohort 1|Participants will receive vehicle control for 24 weeks
89108640|NCT06101810|Experimental|COMET (Korrelboom)|Korrelbooms' Competitive Memory Training (2011) (abbreviated COMET) is a cognitive behavioral therapy based on counter-conditioning. It uses positive self-verbalizations, imagination, posture and facial expression and music in a protocolized intervention consisting of 8 weekly group sessions of 90 minutes. For this study the protocol is extended with 1 session, to 9 sessions, in concertation with the author.
89108641|NCT06101810|Experimental|CBT (De Neef)|"The cognitive behavioural protocol by De Neef (2010; 2018) has not been specifically named but is commonly referred to as 'the whitebook method' or 'cognitive behavioral therapy' (CBT). For convenience, this intervention will be addressed to as CBT in the current study.~This intervention relies heavily on positive data logging to specifically focus on evidence that is contradictory to the negative core belief. Patients keep a positive data log (the 'whitebook') to write down positive events and positive qualities of themselves to achieve cognitive bias modification. They also receive psycho-education and practice on alternative behavior such as receiving compliments (which is also regarded as exposure), lowering perfectionist behavior and receiving criticism. In this protocolized intervention patients receive 9 to 11 weekly group sessions of 90 minutes. for this study a version of the protocol with 9 sessions is used."
89108642|NCT06101784|Active Comparator|Avenanthramide tablet single oral dose|adaptive dose levels
89108643|NCT06101784|Placebo Comparator|Placebo to match Avenanthramide tablet single oral dose|adaptive dose levels
89108644|NCT06101784|Active Comparator|Avenanthramide tablet multiple oral dose|adaptive dose levels
89108645|NCT06101784|Placebo Comparator|Placebo to match Avenanthramide tablet multiple oral dose|adaptive dose levels
89108646|NCT06097299|Experimental|Cohort 1 (2 to <5 Years of Age)|Participants 2 to <5 years of age will receive either a single intramuscular (IM) injection of mRNA-1345 or placebo on Day 1.
89108647|NCT06097299|Experimental|Cohort 2 (5 to <18 Years of Age)|Participants 5 to <18 years of age will receive either a single IM injection of mRNA-1345 or placebo on Day 1.
89108648|NCT06092554|Experimental|Interventional: Probiotics|Patients will receive a four probiotic preparation (LactoLevure, UniPharma, Athens, Greece).) in capsules containing: Lactobacillus acidophilus LA-5 [1.75 × 109 colony-forming units (cfu)], Lactobacillus plantarum (0.5 × 109 cfu), Bifidobacterium lactis BB12 (1.75 × 109 cfu) and Saccharomyces boulardii (1.5 × 109 cfu).
89108649|NCT06092554|Placebo Comparator|Control: Placebo|Patients will receive a placebo in capsules containing powdered glucose polymer.
89108650|NCT06089291||Persona IQ Cohort|"The study device is intended to relieve pain and restore function in patients with adequate quality and quantity of bone stock to support the prosthesis.~The device is indicated for use in patients undergoing a cemented TKA procedure that are normally indicated for at least a 58mm sized tibial stem extension.~To qualify to receive the CTE with CHIRP System, the Patient must meet the following requirements in addition to any requirements for TKA surgery as determined by the patient's Health Care Professionals (HCPs):~The Patient's anatomy must be capable of accepting the Zimmer Biomet Persona Tibia Baseplate with canturio™te construct sizing. This assessment will be conducted pre-operatively by the HCP using a CTE Template supplied by Canary Medical.~The patient must have access to a computer with a USB connection to set up their Home Base Station.~The Patient must have wireless internet in their domicile."
89108651|NCT06087328|Active Comparator|Arm A|21mg patch, qd + 4mg lozenge prn [minimum of 5 & up to 20 per day]
89108652|NCT06087328|Active Comparator|Arm B|21mg patch + 14mg patch qd + 4mg lozenge prn minimum of 5 & [up to 30 per day]
89108653|NCT06087328|Active Comparator|Arm C|2 x 21mg patches qd + 4mg lozenges prn [minimum of 5 & up to 40 per day]
89108654|NCT06078189||Control|Trapezectomy group
89108655|NCT06078189||Experimental|Arthroplasty group
89108656|NCT06074185|No Intervention|Continue current care|In this arm, participants will be treated using the existing EMS protocol, and evaluate patient outcomes.
89108657|NCT06074185|Experimental|Treatment bundle and checklist|In this arm, we will implement a new treatment protocol with the study bundle, and evaluate patient outcomes.
89108658|NCT06072157|Experimental|Part A - Single Ascending Dose (SAD) Intravenous Cohorts|Part A: Healthy adult participants will receive a single intravenous infusion of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 5 cohorts evaluated.
89108659|NCT06072157|Experimental|Part B - Multiple Ascending Dose (MAD) Intravenous Cohorts|Part B: Healthy adult participants will receive multiple intravenous infusions of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 3 cohorts evaluated.
89108660|NCT06072157|Experimental|Cohort C - Multiple Dose Intravenous Cohort|Part C: Adults with Chronic Spontaneous Urticaria will receive multiple intravenous infusions of AK006 or matching placebo.
89108661|NCT06072157|Experimental|Cohort D - Single Ascending Dose (SAD) Subcutaneous Cohorts|Part D: Healthy adult participants will receive a single subcutaneous injection of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 2 cohorts evaluated.
89108662|NCT06049797||Neurokinin 3 Receptor (NK3-R) Antagonist|Participants prescribed NK3-R Antagonist for the treatment of VMS.
89108663|NCT06049797||Selective serotonin reuptake inhibitor (SSRI)/Serotonin and norepinephrine reuptake inhibitor (SNRI)|Participants prescribed SSRI/SNRI for the treatment of VMS.
89108664|NCT06049797||Other|Participants prescribed something other than NK3-R Antagonist or SSRI/SNRI for the treatment of VMS.
89108665|NCT06046950|Experimental|DAS28CRP-LDA|Arm that is allocated to strive for DAS28CRP low disease activity (LDA)
88820944|NCT05409235|Placebo Comparator|Vehicle control Cohort 2|Participants will receive vehicle control for 24 weeks
88820945|NCT05408260|Experimental|Screening (automated breast ultrasound, handheld ultrasound)|Participants undergo HHUS and ABUS in no required order over 1 hour.
89108666|NCT06046950|Experimental|SDAI-remission|Arm that is allocated to strive for SDAI-remission
89108667|NCT06043154|Experimental|Anorexia nervosa|
89108668|NCT06040593||HR+/HER2-low Breast Cancer|Participants with HR+/HER2-low breast cancer who were treated with neoadjuvant chemotherapy or endocrine therapy identified from the ConcertAI databases.
89108669|NCT06040593||HR+/HER2-negative Breast Cancer|Participants with HR+/HER2-negative breast cancer who were treated with neoadjuvant chemotherapy or endocrine therapy identified from the ConcertAI databases.
89108670|NCT06037005|Experimental|Cognitive Behavioral Therapy|Expert support was received from the Cognitive Behavioral Psychotherapy Practitioner and Trainer of the Turkish Psychiatric Association in the creation of the sessions. The researcher applying the therapy has a CBT practitioner certificate. Group intervention program based on cognitive behavioral approach of ten sessions; It was completed in approximately one and a half months (May-June 2022) in the Faculty of Nursing, by dividing the experimental group into two separate groups, two days a week for each group. Each session was held for approximately one hour. The last measurement was made three months after the last therapy session (September 2022).
89108671|NCT06037005|No Intervention|Control|While group therapy was applied to the experimental group, no intervention was made to the control group.
89108672|NCT06028529|Other|Feasibility and Safety|This is a feasibility study to assess the safety and potential utility of a lightweight ground exoskeleton (Keeogo, B-Temia, Inc.) to enhance mobility in people with Parkinson's disease (PD).
89108673|NCT06026384|Experimental|Non-Narrative Text|A short text (480 words) that deals with the preventability of cancer cases. It shows that lifestyle factors such as smoking, unhealthy diet, obesity and physical inactivity are responsible for about 40% of cancer cases. It also suggests ways to reduce the risk of cancer through behavioural changes in these areas. A special focus is on nutrition and physical activity. The text was developed on the basis of the Protection Motivation Theory.
89108674|NCT06026384|Experimental|Narrative Text|The narrative text contains the same information as the non-narrative text, except that it is built into a story. This makes the text slightly longer at 725 words. The text is about a main character and two work colleagues who share their personal experiences about nutrition and exercise.
89108675|NCT06026384|Experimental|Non-Narrative Animation|The animation with a total duration of 3:12 min is based on the text in non-narrative form and aims to be as fully comparable as possible.
89108676|NCT06026384|Experimental|Narrative Animation|The animaion (3:45 min) is based on the text in narrative form and aims to be as fully comparable as possible.
89108677|NCT06019377|Experimental|Intervention|The Intervention group receives the SYNC intervention in addition to typical child welfare services (i.e., services as usual). The SYNC intervention includes 10 weekly remote (videoconference) 90-minute sessions delivered by a facilitator and a near-peer young adult aged 20-26, both with lived experience in child welfare.
89108678|NCT06019377|No Intervention|Services-as-usual|The Services-as-usual (SAU) group receives typical child welfare services, which include ILP, or federally funded transition planning (e.g., identifying and supporting youth education and employment goals) and life skills (e.g., budgeting, renting an apartment, insurance) services typically delivered through a mix of classes, group activities, and/or individual skill-building with a paraprofessional service provider.
89108679|NCT06013449|Active Comparator|6-week Pulsed Electromagnetic Field treatment with intravesical bupivacaine/heparin instillations|Participants will be instructed to self-administer pulsed electromagnetic field therapy (PEMF) devices immediately following each intravesical bupivacaine/heparin instillation, while they are holding the instillation solution in their bladder. PEMF therapy will be self-administered using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat dry surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control B. Box) has been pre-programmed to deliver the same energy level every time. Participants will be instructed to administer this home treatment in conjunction with their self-administered bladder instillations of bupivacaine/heparin for 8-minute sessions, three times a week over a 6 week period. At the mid way point (3 weeks) and after completion (6 weeks) participants will complete the online questionnaires. At 6 weeks the PEMF device is returned.
89108680|NCT06013449|Sham Comparator|6-week Sham Treatment with intravesical bupivacaine/heparin instillations|Participants will be provided with a sham B. Body and B. Pad that appears identical to the active pulsed electromagnetic field (PEMF) device. The participant will lie the sham B- Body mat on any flat dry surface and lay on the mat with with the smaller sham B. Pad placed directly over the pelvic area. The participant will be instructed to administer this sham treatment immediately following each intravesical bupivacaine/heparin instillation, while they are holding the instillation solution in their bladder. Participants will be instructed to administer this sham treatment in conjunction with their self-administered bladder instillations of bupivacaine/heparin for 8-minute sessions, three times a week over a 6 week period. At the mid way point (3 weeks) and after completion (6 weeks) participants will complete the online questionnaires. At 6 weeks the sham PEMF device is returned.
89108681|NCT05999396|Experimental|Administration of CC-3, a bispecific CD276xCD3 antibody|"The DL in the accelerated titration phase is fixed in each patient and is applied once per week. The start dose for the first patient is 20µg. Dose increase in the next patient is determined by SRC, comprised of investigators and Sponsor, and can be up to 100% based on safety, PK and PD data. Accelerated titration is terminated and switched to a standard 3 + 3 design in case of any AE Grade ≥ 2 (except AEs unequivocally due to underlying disease or an extraneous cause), occurrence of DLT or decision of SRC based on PK, PD, and safety data.~In the dose expansion part, additional patients are treated to have 20 evaluabale patients at the MTD level defined in the dose escalation part."
89108682|NCT05998603|Experimental|High protein intake supplementation|A 60g daily dose of whey protein supplementation
88820946|NCT05407168|Experimental|Group I (decision aid)|Patients review decision aid.
88820947|NCT05407168|Active Comparator|Group II (standard of care)|Patients receive standard of care.
89108683|NCT05998603|Experimental|Moderate protein intake supplementation|A 20g dose of whey protein supplementation
89108684|NCT05998603|Placebo Comparator|Carbohydrate placebo|An isocaloic maltodextrin carbohydrate placebo
89108685|NCT05998603|Other|Control group, no supplementation|Control group, not taking any supplementation, only completing basic training activities
89108688|NCT05990998|Experimental|Patients will undergo a 68Ga-FAPI PET/CT and 68Ga-DOTATATE PET/CT|NPC patients receive a single intravenous injection of 68Ga-FAPI PET/CT and 68Ga-DOTATATE PET/CT (2-4mCi) PET/CT,and undergo PET/CT scan at 40-60 min post-injection.
89108689|NCT05981846|Experimental|BIMERVAX + SIIV|
89108690|NCT05981846|Active Comparator|BIMERVAX + PLACEBO|
89108691|NCT05981846|Active Comparator|SIIV + PLACEBO|
89108692|NCT05980858|Active Comparator|KetoneAid KE4, then Placebo drink|For five days each subject will receive beta-hydroxybutyrate (KE4), then crossed over to receive placebo drink for 5 days.
89108693|NCT05980858|Active Comparator|Placebo drink, then KetoneAid KE4|For five days each subject will receive a placebo drink three times daily, then subjects are crossed over to receive beta-hydroxybutyrate (KE4).
89108694|NCT05972343||Cryoablation|Following pre-procedural imaging evaluation, patients will receive ultrasound-guided percutaneous cryoablation as part of their routine treatment of their breast cancer. Follow up imaging (if tolerated) will be performed at 6 months and 12 months and annually thereafter for until 3 years post-procedure. Data will be collected on patient demographics, disease characteristics, treatment, treatment complications, follow-up imaging, response (for 3 years post-procedure), and quality of life.
89108695|NCT05959746|Experimental|Patients with suspected acute stroke|
89108696|NCT05954728|Experimental|CBT-AR|
89108697|NCT05954728|Experimental|Nutrition Counseling|
89108701|NCT05945823|Experimental|Cohort A|Patients with Esophageal cancer (Adenocarcinoma or Squamous cell cancer) will receive Futibatinib administered once daily on a continuous dosing regimen in combination with pembrolizumab plus investigator choice of SoC chemotherapy (FP or mFOLFOX6) for 6 cycles (induction phase) following by Futibatinib combination with pembrolizumab (consolidation phase).
89108702|NCT05945823|Experimental|Cohort B|Patients with PDAC will receive Futibatinib administered once daily on a continuous dosing regimen in combination with pembrolizumab plus mFOLFIRINOX for 6 cycles (induction phase) following by Futibatinib combination with pembrolizumab (consolidation phase) .
89108703|NCT05942495|Experimental|SFGT|Whitin subject design with one arm; SFGT groep intervention
89108704|NCT05936021|Other|Standard of care|All patients placed on dialysis receive standard of care
89108705|NCT05936021|Experimental|Model-based Aranesp doses|On entering the study cohort, patients will begin receiving doses calculated by the algorithm instead of by the standard of care procedures. Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined. The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been.
89108706|NCT05935332|Experimental|RPT193 400 mg|
89108707|NCT05935332|Placebo Comparator|Placebo|
89108708|NCT05931484|Active Comparator|Active|Active
89108709|NCT05931484|Placebo Comparator|Placebo|Placebo
89108710|NCT05918328|Experimental|Nab-PH+pyrrolitinib regimen group|Drug dose of Nab PH+pyrrolitinib scheme: albumin paclitaxel 260mg/m 2+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+pyrrolitinib (320mg, QD), one cycle every 21 days.
89108711|NCT05918328|Placebo Comparator|TCbHP regimen group|The drug dose of TCbHP protocol: docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial load dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial load dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days.
89108712|NCT05914064|Experimental|Gravitas FT System|
89108713|NCT05914064|Active Comparator|Control|
89108714|NCT05913323||COPD sub-group: GOLD 1 COPD|"A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD.~Thus, there will be a 'mild' (GOLD 1) COPD sub-group."
89108715|NCT05913323||COPD sub-group: GOLD 4 COPD|"A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD.~Thus, there will be a 'very severe' (GOLD 4) COPD sub-group."
89108716|NCT05906914|Experimental|Experimental Group|Intervention: CHA
89108717|NCT05903794|Experimental|EXG102-031|Each participant will receive a single subretinal injection of EXG102-031 in the study eye. Participants will be enrolled into one of two dosage groups sequentially, and the dose administered will be determined based on which study group the participant is enrolled into.
89108718|NCT05903131|Experimental|Arm 1: Levonorgestrel-releasing IUD (LNG-IUD) + Behavioral Weight Loss Intervention|"The levonorgestrel-releasing IUD is used in this study as per standard care.~The behavioral weight loss intervention consists of a telemedicine cognitive behavioral coaching program. At each session, patients will self-report weight, number of days they kept a food journal during the past week, average daily caloric intake for the week, number of days exercised for the week, total number of minutes of moderate physical activity, and average number of steps per day for the week."
89108719|NCT05903131|Active Comparator|Arm 2: Levonorgestrel-releasing IUD (LNG-IUD) + Enhanced Usual Care|"The levonorgestrel-releasing IUD is used in this study as per standard care.~Participants will be provided with 1- to 3-page handouts on topics including healthy eating, exercise, and behavioral eating strategies from materials provided on the American Cancer Society, Society of Gynecologic Oncology, and WebMD Nourish websites. These materials encourage weight loss through calorie counting, recording dietary intake, engaging in exercise programs, and using portion control strategies.~If participants in the enhanced usual care group do not achieve atypia-free uterine preservation (i.e., have not resolved their hyperplasia or grade 1 endometrial cancer) by one year of enrollment and continue to desire uterine preservation with progestin treatment, they will cross over to receive the telemedicine behavioral intervention for the second year."
89108720|NCT05893927|Experimental|Intervention arm|Participants enrolled in the intervention arm will be given a 6-month access period to the diabetes education application designed by the study team. The web site will offer videos related to a specific areas of education concerning diabetes self-management. To encourage compliance, participant users will receive weekly notifications from the application that will guide them through viewing all videos in the series. Participants will continue routine follow-up appointments with their primary care physicians during the study period. There will be no restrictions on starting or stopping medications during the study period.
89108721|NCT05893927|No Intervention|Control arm|Participants in the control arm will not have access to the Diabetes Application. They will continue follow-up appointments according to the standard of care with their primary care physician, diabetic educators, etc. There are no restrictions on starting or stopping medications for patients within the control arm.
89108722|NCT05891834|Experimental|Low dose|INV-202, 10 mg
89108723|NCT05891834|Experimental|High dose|INV-202, 50 mg
89108724|NCT05891834|Placebo Comparator|Placebo|Placebo Matching size and number of tablets
89108725|NCT05891834|Experimental|Middle Dose|INV-202, 20 mg
89108726|NCT05889962|Experimental|Pudendal block group|Receiving bilateral pudendal nerve block with 0.5% ropivacaine (10 ml each side)
89108727|NCT05889962|Placebo Comparator|Placebo group|Receiving bilateral pudendal nerve block with normal saline (10 ml each side)
89108728|NCT05889273|Experimental|ML-004 (IR)/(ER) tablet|ML-004 is a bilayer immediate-release (IR)/extended-release (ER, gastroretentive) oral tablet formulation. ML-004 is taken orally once daily and provided as a tablet in two dose strengths of 12 mg (3 mg IR/9 mg ER) and 24 mg tablet (6 mg IR/18 mg ER). Dose levels for this study are 12 mg (provided as one 12 mg tablet), 24 mg (one 24 mg tablet), 48 mg (two 24 mg tablets), and 72 mg (three 24 mg tablets).
89108729|NCT05884216|Experimental|Entarik|Entarik FT System guided placement
89108730|NCT05884216|Active Comparator|Control|Entarik Ft placement placement not guided with monitor
89108731|NCT05881278|Experimental|Subjects requiring a Heart Transplant|Device: Preservation of hearts for transplant.
89108732|NCT05877261||Prior Cementless Knee Replacement Cohort|Patients who received a cementless knee replacement in 2017-2018 and participated in a prior study measuring the first year of implant migration.
89108733|NCT05874843|Other|Pediatric Participants|Pediatric surgery patients undergoing elective pediatric surgical cases under anesthesia will be invited to participate in this prospective laboratory test validation study. The results of the interventional test will not be used in clinical decision making for the participant.
88820948|NCT05406687|Other|People experiencing homelessness|All homeless adults, aged 18 years and over, who visit the CANCERLESS pilot sites will be asked to participate (convenience sampling). We define individuals as being homeless if they fall under one of the categories listed in the European typology of homelessness and housing exclusion.
89108734|NCT05874284|Experimental|Experimental group|The nasopharyngeal suction with positive pressure method was employed in the sample group. In this method, the infant's head is turned to the side, 1-2 ml of PS is injected into the nostril with a syringe, and then positive pressure is exerted with the help of the end of the oxygen hose from the same nostril, with oxygen or air supply at 5-8 lt/min (if the baby requires oxygen, using an oxygen source) and the nasopharyngeal secretions are removed from the nostril into which PS has been not injected. The oxygen hose is held one centimetre away from the infant's nostril. The researchers prepared a guideline for nasopharyngeal suction with positive pressure based on the literature.
89108735|NCT05874284|No Intervention|conroul group|The nasopharyngeal suction with negative pressure method was employed in the control group in this study. In this method, the nasal secretions were softened with 1-2 ml of physiological saline (PS), and then negative pressure suction was performed using a pine-tipped suction set. In the literature, neonatal aspiration pressure is defined as 60-100 mmHg. In this study, the suction pressure was kept between 60 and 80 mmHg, and no suction lasted for more than 15 seconds.
89108736|NCT05874206|Experimental|TEVAR|Thoracic Endovascular Repair (TEVAR) provides a minimally invasive treatment option for descending thoracic aorta (DTA) pathologies.
89108737|NCT05873751||Trumenba +MenACWY Vaccinated|Exposure Cohort that received at least one dose of Trumenba and MenACWY vaccine
89108738|NCT05873751||MenACWY Only Vaccinated|Non-exposure (reference cohort) that received at least one dose of MenACWY vaccine and no Trumenba vaccine.
89108739|NCT05871424|Experimental|buprenorphine patch group|
89108740|NCT05871424|Sham Comparator|placebo group|
89108741|NCT05862766|Experimental|Peri-transplant desensitization group|Listed and will receive a lung transplant or multi-organ transplant involving a lung at NYU Langone Health that is deemed to require peri-transplant desensitization. Participants will be treated with standard-of-care consisting of plasmaspheresis, IVIG, rituximab and the experimental agent, isatuximab. Patients will be followed with standard-of-care immunologic assessment consisting of weekly DSA assessment and flow cytometry crossmatch (only in the desensitization arm). Additionally, participants will have a bone marrow biopsy with pathologic examination and cell counts performed at the time of transplant and repeated at the 30-day bronchoscopy to assess for plasma cell elimination
89108742|NCT05862766|Experimental|Treatment of antibody-mediated rejection|Received a lung transplant or multi-organ transplant involving a lung at NYU Langone Health. Participants will be treated with standard-of-care consisting of plasmaspheresis, IVIG, rituximab and the experimental agent, isatuximab.
89108743|NCT05858320|Experimental|SmartHF application|The web application-based study intervention provides adaptive medication recommendations that can be shared with their HF provider.
89108744|NCT05858320|Active Comparator|Control - Patients Standard Medication(s)|No change to current medication(s)
89108745|NCT05858008|Experimental|Time-restricted eating|Participants will have baseline and post-study data collected, including activity/sleep data, metabolic parameters (fasting labs and anthropometric measurements), and cognitive testing. In addition, food timing will be collected throughout the study. Subjects will be educated about the potential health benefits of time-restricted eating and will self-select a 10-hr window, during which all daily calories will be consumed for 8 weeks.
89108746|NCT05857020|Experimental|Auricular Acupressure (AA) Group|Participants will receive the AA intervention over a 5 day period in addition to their Standard of Care treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), and complete daily study questionnaires
89108747|NCT05852600|Experimental|Intervention|"Participants assigned to the intervention arm are immediately given the opportunity to view Lead with Love, and then to complete the PATHS toolkit. One month after completing PATHS, they complete a refresher module that is designed to boost the initial effects of PATHS."
89228617|NCT02736344||BioNIR Ridaforolimus (drug eluting stent (DES)|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
89228618|NCT02682992|Experimental|Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
89228619|NCT05279066||Patients scheduled to undergo an elective cardiac ultrasound|All cardiac patients undergoing an elective cardiac ultrasound as an outpatient at UCLA may be asked to participate in the study. The investigators will identify eligible patients from their medical record. If interested, patients will be consented prior to their scheduled ultrasound.
89228620|NCT05279066||Patients with a pulmonary arterial catheterization scheduled or completed|All patients hospitalized in the cardiac ICU at UCLA with a pulmonary arterial catheterization scheduled or completed may be asked to participate in the study. The investigators will identify eligible patients from their medical record. If interested, patients will be consented during their hospital stay.
89228621|NCT01563770|Experimental|Salvia miltiorrhiza extract (Danshen)|p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks
89228622|NCT01563770|Placebo Comparator|placebo|p.o. placebo, twice daily
89228623|NCT00412984|Active Comparator|1|
89228624|NCT00412984|Experimental|2|
89228625|NCT00539864|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~135μg total"
89228626|NCT00539864|Active Comparator|TIV (Fluzone)|"Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~45μg total~(Fluzone, sanofi pasteur)"
89228627|NCT04003376|Active Comparator|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata
89228628|NCT04003376|Experimental|fractional carbon dioxide laser and triamcinolone acetonide|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide (10mg/ml)
89228629|NCT04003376|Experimental|fractional carbon dioxide laser and platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
89228630|NCT04003376|Experimental|fractional carbon dioxide laser and vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
89228631|NCT01563848|Active Comparator|Group 1 (RFA CTI+Reveal)|assessing the incidence of atrial fibrillation in patients with atrial flutter
89228632|NCT01563848|Active Comparator|Group 2 (RFA CTI+Cryo PVI+Reveal)|efficacy of cryoablation in patients with atrial flutter
89228633|NCT04086212|Experimental|IXC Peritoneal dialysis solution|IXC (Icodextrin, Xylitol and L-Carnitine) Peritoneal dialysis solution
89228634|NCT04086212|Active Comparator|Icodextrin|Extraneal® (7.5% Icodextrin) Peritoneal dialysis solution
89228635|NCT05404490|Experimental|Bupivacaine|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
89228636|NCT05404490|Placebo Comparator|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
89228637|NCT05359874|Experimental|treatment arm|
89228638|NCT05359796||long-term T1D|Subjects who has the T1D duration ≥10 years, with or without diabetic complications.
89228639|NCT00990392|Experimental|Polysporin Triple Therapy|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
89108748|NCT05852600|Active Comparator|Waitlist Control|"Participants assigned to the waitlist control arm are immediately given the opportunity to view Lead with Love. One month after viewing the film, they complete a refresher module that reviews the most important lessons from the film. Six months after being randomized, participants are then given access to the PATHS toolkit. One month after completing the PATHS toolkit, they complete a refresher module that is designed to boost the initial effects of PATHS."
89108749|NCT05844046|Experimental|Arm A|Durvalumab (1500 mg q4w) plus tremelimumab (300 mg x 1) followed by addition of bevacizumab (15mg/kg) upon detection of radiological progression or in the absence of objective response after the second staging.
89108750|NCT05844046|Experimental|Arm B|Durvalumab plus tremelimumab followed by maintenance treatment with durvalumab and bevacizumab.
89228640|NCT00990392|Placebo Comparator|Placebo|Petroleum jelly
89108751|NCT05843786|Experimental|Interferon gamma treatment|Interferon gamma treatment (100 micrograms /day during 5 days)
89108752|NCT05843786|Placebo Comparator|Placebo|The comparator drug (placebo) is an injectable solution of sodium chloride 0.9%
89108753|NCT05833724|Experimental|Chidamide|Chidamide tablets orally, twice a week.
89108754|NCT05814146|Experimental|Lower dialysate bicarbonate|A lower dialysate bicarbonate will be used in the experimental arm (30 mEq/L).
89108755|NCT05814146|Active Comparator|Higher dialysate bicarbonate|A higher dialysate bicarbonate will be used in the active comparator arm (35 mEq/L).
89108756|NCT05798663|Experimental|Arm A: Atezolizumab|79 participants will be randomized 1:1 to Arm A. Participants in Arm A will receive induction immunotherapy with atezolizumab on Day 1 of each cycle, concurrent atezolizumab with chemoradiotherapy, and adjuvant atezolizumab Day 1 of each cycle.
89108757|NCT05798663|Experimental|Arm B: Atezolizumab and Tiragolumab|79 participants will be randomized 1:1 to Arm B. Participants in Arm B will receive induction immunotherapy with atezolizumab plus tiragolumab on Day 1 of each cycle, concurrent atezolizumab with chemoradiotherapy, and adjuvant atezolizumab plus tiragolumab on Day 1 of each cycle.
89108758|NCT05798663|Experimental|Arm C: Atezolizumab and Tiragolumab|"An additional pilot cohort of 20 patients will be accrued at selected sites towards the end of the overall accrual period and after initial safety evaluations of the addition of tiragolumab to atezolizumab before and after chemoradiotherapy.~Participants enrolled to Arm C will receive induction immunotherapy with atezolizumab plus tiragolumab on Day 1 of each cycle, concurrent atezolizumab plus tiragolumab with chemoradiotherapy, and adjuvant atezolizumab plus tiragolumab on Day 1 of each 21 cycle."
89108759|NCT05797987||FES negative in MBC|Patients who did not present with any ER-positive lesions were characterized as with negative ER expression in the metastatic stage
89108760|NCT05795348|Other|Knee Osteoarthritic Patients|Patients candidate for knee arthroplasty; Age: 65-80 years; Body Mass Index: 18.5-30 kg/m²; ASA Classification: 1 or 2; Diagnosis of primary osteoarthritis at the knee; Suspect sarcopenia.
89108761|NCT05793008|Experimental|Takotsubo Syndrome|"Patients diagnosed with either primary or secondary Takotsubo Syndrome.~TTS diagnosed based on modified Mayo Clinic Diagnostic Criteria as:~Transient wall motion abnormality in the left ventricle beyond a single epicardial coronary artery distribution;~Absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture, which can explain the wall motion abnormality;~New electrocardiographic abnormalities or elevation in cardiac troponin values;~Absence of pheochromocytoma or myocarditis."
89108762|NCT05793008|Experimental|Septic patients|"Patients with diagnosis of sepsis and septic shock with or without concurrent LVSD or/and LVDD.~Diagnosis of sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, which can be represented by an increase in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more.~Septic shock, defined as vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia.~Sepsis-induced cardiomyopathy, defined as left ventricular systolic dysfunction (LVSD) and/or LV diastolic dysfunction (LVDD) following sepsis in patients without known structural or functional cardiac disease."
89108763|NCT05787548|No Intervention|Standard practice|Patients in this arm will receive the current standard practice AVS.
89108764|NCT05787548|Experimental|Contact us first|Patients in this arm will receive the standard AVS, plus information on how to contact Geisinger if they need medical attention.
89108765|NCT05787548|Experimental|Contact us first + urgent care map|Patients in this arm will receive the standard AVS, plus information on how to contact Geisinger if they need medical attention, plus a map to their nearest Geisinger urgent care location and additional information about urgent care.
89108766|NCT05787548|Experimental|Contact us first + urgent care map + self-triage|Patients in this arm will receive the standard AVS, plus information on how to contact Geisinger if they need medical attention, plus a map to their nearest Geisinger urgent care location and additional information about urgent care. This arm will also receive a self-triage chart, with common reasons patients go to the ED and situations where seeking alternative care might be appropriate.
89108767|NCT05783843|Experimental|Pictorial Warnings|Waterpipe tobacco packages shown with pictorial warnings about health harms of waterpipe smoking
89108768|NCT05783843|Experimental|Text Warnings|Waterpipe tobacco packages shown with text-only warning about health harms of waterpipe smoking
89108769|NCT05783843|Experimental|No Warnings (Control)|Waterpipe tobacco package shown without a warning
89108770|NCT05776654||COPD cohort|Patients with COPD currently experiencing and receiving treatment for an exacerbation.
89108771|NCT05772169|Experimental|Mifepristone 300 mg|Patients who meet the entry criteria for the Study C-1073-310 will be randomized to receive 600 mg mifepristone for 24 weeks.
89108772|NCT05772169|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study C-1073-310 will be randomized to receive placebo for 24 weeks.
89108773|NCT05769426||PCOS-PRE|20 pre-menopausal women who have been diagnosed with polycystic ovarian syndrome (PCOS) will be recruited for this cohort. Participants in this group will complete a semi-structured virtual interview about barriers to healthy behaviors, self-efficacy and health literacy. The will also complete a battery of surveys related to following domains: sleep, anxiety, depression, satisfaction, physical activity, and dietary habits.
89108774|NCT05769426||PCOS-POST|20 post-menopausal women who have been diagnosed with polycystic ovarian syndrome (PCOS) will be recruited to this cohort. Participants in this group will complete a semi-structured virtual interview and a battery of surveys related to following domains: sleep, anxiety, depression, satisfaction, physical activity, and dietary habits. They will also complete a single in-person visit to the University of Texas Medical Branch where they will undergo a DEXA scan, anthropometric measurements and blood draw.
89108775|NCT05769426||CON-POST|20 post-menopausal women who have not been diagnosed with polycystic ovarian syndrome (PCOS) will be recruited for this cohort. Participants in this group will complete a battery of surveys related to following domains: sleep, anxiety, depression, satisfaction, physical activity, and dietary habits. They will also complete a single in-person visit to the University of Texas Medical Branch where they will undergo a DEXA scan, anthropometric measurements and blood draw.
89108776|NCT05763901|Experimental|Paramorphisms/dysmorphisms of spine and/or lower limbs|Only one arm of patients assessed for motor competence and balance without controls
89108779|NCT05758922|Placebo Comparator|Placebo|Participant will receive placebo once daily during the course of the study (12 weeks).
89108780|NCT05758922|Experimental|AZ-3102 (Dose 1)|Participant will receive AZ-3102 (Dose 1) once daily during the course of the study (12 weeks) and the study extension (if applicable).
89108781|NCT05758922|Experimental|AZ-3102 (Dose 2)|Participant will receive AZ-3102 (Dose 2) once daily during the course of the study (12 weeks) and the study extension (if applicable).
88812880|NCT04381442|Experimental|Buccal &palatal low level laser therapy|In group I,low level laser therapy was delivered at 10 points; 5 from buccal and 5 from palatal aspects with a total dose of 8 Joule (J) per session that distributed as follows; 2 cervical, 1 middle, 2 apical. Maxillary canines were irradiated with a gallium aluminum-arsenide diode laser in continuous mode with 635 nm, 100 mW, 25 J/cm2, 8 seconds/ point, 0.8 J/point.Maxillary canines were distalized by a standard protocol with uniform 150 gm retraction force via a nickel-titanium closed coil spring.Laser regimen was applied on days 0, 3, 7, and 14 in the 1st month, and thereafter on every 15th day until 6-month observation period of canine retraction phase.
89108782|NCT05753748|No Intervention|Endoscopic Surveillance|Subjects in the randomized control trial and observational cohort study, undergoing surveillance endoscopy will undergo surveillance biopsies in a 4-quadrant fashion every 1 cm throughout the extent of the Barrett's esophagus using the Seattle biopsy protocol, along with targeted biopsies from any visible lesions. For incident low grade dysplasia (newly diagnosed low grade dysplasia - within 12 months of enrollment), surveillance endoscopies will be performed every 6 months for the first year and then annually until the end of the study period. For prevalent low grade dysplasia (diagnosed >1 year prior to enrollment), surveillance endoscopies will be performed annually until the end of the study period. The number of evaluations will depend on a subject's enrollment time.
89108783|NCT05753748|Experimental|Endoscopic Eradication Therapy|Subjects undergoing endoscopic eradication therapy will undergo radiofrequency ablation every 2-3 months until complete eradication of intestinal metaplasia (CE-IM) is achieved or 5 treatments have been delivered, whichever is first. After achieving CE-IM, surveillance endoscopy will performed every 6 months for the first year and annually thereafter until the end of the study period. Surveillance biopsies will be obtained using a standardized protocol.
89108784|NCT05751226|Experimental|BI 1820237 treatment group|
89108785|NCT05751226|Placebo Comparator|Placebo group|
89108786|NCT05751226|Experimental|BI 1820237 + semaglutide treatment group|
89108787|NCT05751226|Active Comparator|placebo + semaglutide group|
89108788|NCT05751226|Experimental|BI 1820237 + BI 456906 treatment group|
89108789|NCT05751226|Active Comparator|placebo + BI 456906 group|
89108790|NCT05747053||AlloSure Assay prediction of Anti-body Mediated Rejection|Determine whether AlloSure predicts the incidence of active, chronic Anti-body Mediated Rejection and cellular rejection in high risk patients
89108791|NCT05745220|Other|Daily contact lens wear|Participant wear silicone hydrogel contact lenses daily for 6 weeks ±2 days for a minimum wearing time of 5 days per week and 8 hours per day - corneal sensitivity will be measured and compared at baseline versus after 7±2 days and 5 weeks ±2 days daily contact lens wear.
89108792|NCT05736458|Experimental|High regional controllability TMS target in non-symptomatic participants|We will administer TMS to an individualized target of high regional controllability while non-symptomatic participant completes a working memory task inside the MRI scanner.
89108793|NCT05736458|Active Comparator|Low controllability TMS target in non-symptomatic participants|We will administer TMS to an individualized target of low regional controllability while non-symptomatic participant completes a working memory task inside the MRI scanner.
89108794|NCT05736458|Experimental|High regional controllability TMS target in ADHD participants|We will administer TMS to an individualized target of high regional controllability while patient completes a working memory task inside the MRI scanner.
89108795|NCT05731830||Takotsubo Syndrome|Patients admitted to the Department of Cardiovascular Sciences of Fondazione Policlinico Universitario A. Gemelli IRCCS with a diagnosis of TTS. TTS will be diagnosed based on the most recent InterTAK Diagnostic Criteria. Myocarditis will be excluded based on clinical presentation (e.g.: previous flu-like symptoms, increased inflammatory biomarkers) and confirmed by cardiac magnetic resonance. We will further include all patients with a confirmed TTS diagnosis made between January 2016 and end of October 2022 (hypothetical beginning of prospective phase).
89108796|NCT05722860|Experimental|L-Citrulline|L-Citrulline 50 g/day per os for 1 week
89108797|NCT05718856|Active Comparator|efficacy of TPO-RAs|"After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag administration was an oral 37.5 mg (6-11 years old) or 50 mg (12-17 years old) once daily. The initial dose of hetrombopag administration was an oral 3.75 mg (6-11 years old) or 5mg (12-17 years old) once daily in all participants. The initial dose of avatrombopag administration was an oral 10 mg (<30kg) or 20mg (≥30kg) once daily in all participants. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the TPO-RAs will stop until the platelet count <100×10^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24."
89108798|NCT05718856|Experimental|efficacy of TPO-RAs combining anti-CD 20 monoclonal antibody|After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as patients in TPO-RAs monotherapy group. The dose of TPO-RAs was adjusted according to the subject platelet count. Two kinds of anti-CD 20 monoclonal antibody could be used in this study. All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment. Subjects weighing less than 30kg will be given rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Ps. Participants in the eltrombopag monotherapy group who have platelet count < 20×10^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of rituximab 375mg/m2. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Efficacy and safety will be evaluated at Week 4, Week 8, Week 12 and Week 24.
89108799|NCT05714319||MINOCA|"Patients undergoing clinically indicated CAG for suspected myocardial ischemia with angiographic evidence of non-obstructive CAD (angiographically normal coronary arteries or diffuse atherosclerosis with stenosis <50% and/or fractional flow reserve [FFR] >0.80 if coronary stenosis ranging from 40 to 49%) that underwent an intracoronary provocative test with ACh according to clinical practice and medical choice will be enrolled.~Patients with MINOCA will be diagnosed based on clinical evidence of acute myocardial ischemia, detection of raise and fall of serum troponin T levels with at least one value exceeding the 99th percentile of a normal reference population and at least one of the following: myocardial ischemia (1 or + episodes of chest pain at rest typical enough to suggest a cardiac ischemic origin in the previous 24 hours); new ischemic ECG changes; pathological Q waves; new loss of viable myocardium or regional wall motion abnormality consistent with an ischemic aetiology."
89108800|NCT05714319||INOCA|"All consecutive patients undergoing clinically indicated CAG for suspected myocardial ischemia with angiographic evidence of non-obstructive CAD (angiographically normal coronary arteries or diffuse atherosclerosis with stenosis <50% and/or fractional flow reserve [FFR] >0.80 if coronary stenosis ranging from 40 to 49%) that underwent an intracoronary provocative test with ACh as suggested in current guidelines and consensus and according to clinical practice and medical choice will be consecutively included in this study.~Patients with INOCA will be defined as those with a stable pattern of typical chest pain on exertion, at rest or both, without any sign of acute myocardial infarction (MI), and/or evidence of inducible myocardial ischemia undergoing a scheduled hospital admission for CAG."
89108801|NCT05714293|Experimental|Surgical Aortic Valve Replacement|Patients undergoing surgical aortic valve replacement with a bioprosthesis will be asked to perform a thorax CT scan before surgery and one more at least 90 days after surgery.
89108802|NCT05714241||Ischemia with non-obstructive coronary artery disease|Patients with INOCA will be defined as those presenting with either stable, chronic symptoms (stable angina or angina equivalent) and/or signs of ischemia on noninvasive testing (i.e.: exercise stress test, stress echocardiography or nuclear imaging) undergoing elective diagnostic CAG and without obstructive coronary artery disease (defined as <50% diameter stenosis and/or fractional flow reserve [FFR]>0.80 in any major epicardial vessel).
89108803|NCT05710172|Experimental|Auditory Mirror Therapy Device|Modified 3M Peltor Tactical 300 Electronic Hearing Protector. The modification consists of connecting the left microphone to the right microphone tab on the circuit board, and vice versa.
89108804|NCT05710172|Sham Comparator|Sham Headphone Device|Non-Modified 3M Peltor Tactical 300 Electronic Hearing Protector
89108805|NCT05706077|Experimental|active tDCS + real Physical Therapy|"Active Transcranial Direct Current Stimulation will be applied associated with real physiotherapy. The electrode position will be performed according to the 10-20 international system of marking and the different montages will be realized by distinct application sites.~To stimulate the primary motor cortex the active electrode will be positioned on the C3 point and the reference electrode on the contralateral supraorbital region."
89108806|NCT05706077|Placebo Comparator|active tDCS + placebo Physical Therapy|"Active Transcranial Direct Current Stimulation will be applied associated with placebo physiotherapy. The electrode position will be performed according to the 10-20 international system of marking and the different montages will be realized by distinct application sites.~To stimulate the primary motor cortex the active electrode will be positioned on the C3 point and the reference electrode on the contralateral supraorbital region."
89108807|NCT05706077|Sham Comparator|sham tDCS + real Physical Therapy|Sham Transcranial Direct Current Stimulation will be applied associated with real physiotherapy. The electrode position will be performed according to the 10-20 international system of marking and the different montages will be realized by distinct application sites. The anode electrode will be positioned on the C3 point (primary motor cortex) and the reference electrode on the contralateral supraorbital region.
89108808|NCT05706077|Other|sham tDCS + placebo Physical Therapy|Sham Transcranial Direct Current Stimulation will be applied associated with placebo physiotherapy. The electrode position will be performed according to the 10-20 international system of marking and the different montages will be realized by distinct application sites. The anode electrode will be positioned on the C3 point (primary motor cortex) and the reference electrode on the contralateral supraorbital region.
89108810|NCT05700630|Experimental|Determine the safety and feasibility of administering FT538 monotherapy|Administering FT538 monotherapy as an intravenous infusion once every 14 days for 4 consecutive doses and in combination with twice weekly vorinostat for the reduction of the HIV reservoir.
89108811|NCT05700630|Experimental|Characterize the toxicities and impact of FT538 and vorinostat|To characterize the toxicities associated with FT538 monotherapy and with vorinostat in this patient population. To determine the impact of FT538 on the persistence of low-level HIV viremia, defined as detectable HIV-1 RNA of ≤200 copies/mL despite good ART adherence.
89108812|NCT05700526|Sham Comparator|Standard Group|The main measures of the designed graft are extrapolated from VSP. The dimensioned drawings of the graft are delivered to the bone bank that prepares the graft according to standard procedures.
89108813|NCT05700526|Active Comparator|GSI Group|The main measures of the designed graft are extrapolated from VSP. The bone bank provides a series of CTs of bone segments from those available for processing. These bone segments are reconstructed and compared with the planning to find the best match. Once defined which bone segment will be used, if necessary, the planning is adapted to it.
89108814|NCT05692791||ITW|
89108815|NCT05692791||Control Group|
89228641|NCT05590988|Experimental|Tablet|The intervention group trained bimanual coordination once a day for about 31 minutes on a total of ten days using a tablet game. A ball is to be moved on a circular line.
89108818|NCT05679947|Experimental|Mobilization Protocol|The study group patients were mobilized according to the developed mobilization protocol.The protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the discharged day. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 h after surgery. Implement mobilization protocol 3 times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every 2 h. Level 2: ROM should occur at least 3 times a day. Level 3: The head of bed (HOB) >30 degrees. Duration goal: 5-15 min. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 min. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 min. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 min. Progress to level 6. Level 6: Patient is able to ambulate at least 3 times a day.
89108819|NCT05679947|No Intervention|Control|No intervention was made to the control group, only data were collected at the same time as the study group.The patients in the control group was mobilized by the researchers according to the routine clinical mobilization practice.
89108820|NCT05675930|Active Comparator|Adult and pediatric patients who received an allogeneic stem cell transplant (allo-HCT)|Participants are Allo-HCT recipients
89108821|NCT05675930|Placebo Comparator|Adult and pediatric patients who received a placebo treatment|Participants are Allo-HCT recipients
89108822|NCT05675046|Experimental|CTR-US|Ultrasound Guided Carpal Tunnel Release (CTR-US)
89108823|NCT05674838|Experimental|Experimental Intervention - Leg Elevation Arm|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
89108824|NCT05674838|No Intervention|Control - No Leg Elevation Arm|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge. She will remain in this position for approximately 40 minutes.
89108825|NCT05671848|Experimental|experimental arm|Patient with ET and Receiving deep brain stimulation treatment with implantation of the PERCEPT™ device
89108826|NCT05671835|Experimental|TTI-101 400 mg/day|Participants will receive 400 mg/day of TTI-101 twice daily (BID) for 12 weeks.
89108827|NCT05671835|Experimental|TTI-101 800 mg/day|Participants will receive 800 mg/day of TTI-101 BID for 12 weeks.
89108828|NCT05671835|Experimental|TTI-101 1200 mg/day|Participants will receive 1200 mg/day of TTI-101 BID for 12 weeks.
89108829|NCT05671835|Placebo Comparator|Placebo|Participants will receive a matching placebo BID for 12 weeks.
89108830|NCT05654753|Experimental|Experimental|active FMT
89108831|NCT05654753|Placebo Comparator|Placebo|placebo
89108832|NCT05654207|Experimental|WeCare|WeCare system of care - universal screening, ED-based intervention, text message follow-up.
89108833|NCT05654207|No Intervention|Usual Services|Usual care for youth presenting to the ED will be the control condition.
89108834|NCT05653518|Experimental|Closed-loop artificial pancreas (AP)|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
89108835|NCT05653518|Experimental|Sensor Augmented Pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's current insulin therapy (i.e., either insulin pump or multiple daily injections)
89108836|NCT05649696|Experimental|r-SAK group|intravenous injection of single bolus 5 mg r-SAK in 3min
89108837|NCT05649696|Placebo Comparator|normal saline group|intravenous injection of 10ml saline in 3min, r-SAK and saline are the same in appearance
89108838|NCT05649696|No Intervention|patients with coronary artery disease|20 ml arterial blood samples and 5 ml venous blood samples were collected from patients before coronary angiography
89108839|NCT05628181|No Intervention|No educational tool|This arm will collect data on total standardized daily dosage of the medication classes contributing to CNS polyRx from the Electronic Medical Record (EMR).
89108840|NCT05628181|Experimental|Educational nudge intervention|Participants will be mailed the educational tool in the form of a brochure.
89108841|NCT05619003|Experimental|Single-arm|The clinical investigation is an open-labelled, non-comparative, single-arm, prospective, multi-center investigation
89108842|NCT05598749|Placebo Comparator|Placebo|
89108843|NCT05598749|Experimental|Verum|
89108844|NCT05591066|No Intervention|Usual care|Unstructured communication during rounds and unstandardized interpretation at provider discretion.
89108845|NCT05591066|Experimental|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
89108846|NCT05591066|Experimental|PFC I-PASS+ Intervention|PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters on and after rounds and training doctors about communication and cultural humility.
89108847|NCT05584670|Experimental|SAR445877 Escalation Phase (Part 1)|SAR445877 monotherapy will be administered intravenously in patients with solid tumors over a 14-day cycle.
89108848|NCT05584670|Experimental|SAR445877 Expansion Phase: Cohort A (Part 2)|SAR445877 monotherapy will be administered intravenously (IV) in patients with non-small cell lung cancer (NSCLC).
89108849|NCT05584670|Experimental|SAR445877 Expansion Phase: Cohort B (Part 2)|SAR445877 monotherapy will be administered intravenously in patients with hepatocellular carcinoma (HCC).
89108850|NCT05584670|Experimental|SAR445877 Expansion Phase: Cohort C (Part 2)|Participants will receive SAR445877 monotherapy will be administered IV in patients with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).
89108851|NCT05584670|Experimental|SAR445877 Expansion Phase: Cohort D (Part 2)|Participants will receive SAR445877 monotherapy will be administered IV in patients with immune infiltrated tumor type.
89108852|NCT05582395|Experimental|Mavacamten|
89108853|NCT05582395|Placebo Comparator|Placebo|
89108854|NCT05575804|Experimental|experimental group|Patients will receive the recommended phase 2 dose of GQ1001 determined in phase I. GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity.
89108855|NCT05575804|Active Comparator|control group|Patients will receive pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
89108856|NCT05575492|Experimental|mRNA-1647 Dose A|CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at Dose Level A by intramuscular (IM) injection given as a 3-injection series on Day 1, Month 2, and Month 6.
89108857|NCT05575492|Experimental|mRNA-1647 Dose B|CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at Dose Level B by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.
89108858|NCT05575492|Experimental|mRNA-1647 Dose C|CMV-seronegative or CMV-seropositive participants 9 to 15 years of age and 16 to 25 years of age will receive mRNA-1647 at Dose Level C by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.
89108859|NCT05575492|Experimental|Dose Expansion: mRNA-1647|CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at selected dose level by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.
89108860|NCT05575492|Placebo Comparator|Dose Expansion: Placebo|Participants will receive placebo by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.
89108861|NCT05574881|Experimental|Arm1|Dalpiciclib 150 mg qd; Fulvestrant 500mg d1, 15, 29, and then q4w; Pertuzumab 840mg q3w, and then 420 mg q3w; Trastuzumab 8 mg/kg q3w, and then 6 mg/kg q3w
89108862|NCT05572645||PyroH|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
89108863|NCT05572645||PertH|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
89108864|NCT05571618||Group1|
89108865|NCT05558332|Experimental|YST-CHR Group|This group will recieve the new adapted YST treatment (YST-CHR). Clinicians will administer this treatment. Neither group will be blind.
89108866|NCT05558332|No Intervention|Treatment as usual|This group will receive their usual therapy/treatment as usual.
89108867|NCT05555576|Experimental|Vitamin C|1 000 mg vitamin C taken orally twice a day
89108868|NCT05555576|Placebo Comparator|Placebo|Matching placebo
89108869|NCT05554133|Experimental|The Active Biopsy Guidance System|This imaging scanning device is made up of 2 parts: the optical mapping scope and the high-resolution microendoscope (HRME):
89108870|NCT05549258|Experimental|Inebilizumab|Infusion of Inebilizumab
89108871|NCT05544513|Experimental|Group I|participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
89108872|NCT05544513|Active Comparator|Group II|participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
89108873|NCT05544513|Active Comparator|Group III|participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
89108874|NCT05539352|Experimental|Active treatment plus EUC|All caregivers are assigned to this condition and receive the treatment plus EUC.
89108875|NCT05539209|Active Comparator|The Standard Helpline Care (SC) group|The SC group will receive standard Oklahoma Smoking Cessation Helpline care AND complete daily check-ins and weekly surveys for 27 weeks.
89108876|NCT05539209|Active Comparator|OKquit group|The OKquit group will receive SC plus daily check-ins and weekly surveys for 27 weeks. In addition, the OKquit group will receive tailored smoking cessation messages in the smartphone application following completion of each survey. Further, the OKquit group will have access to on-demand smoking cessation content through the app.
89108877|NCT05537948|Active Comparator|pitavastatin|Pitavastatin 2 mg/d - 4 mg/d
89108878|NCT05537948|Active Comparator|PCSK9 Inhibitors|Evolocumab 140 mg once per 2 weeks or Alirokumab 150 mg once per 2 weeks
89108879|NCT05533632|Experimental|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.) injection once weekly in a dose escalation manner for 24 weeks: 0.25 milligrams (mg) (weeks 1 to 4), 0.5 mg (weeks 5 to 12) and 0.5 mg or 1.0 mg (weeks 13 to 24).
89228642|NCT05590988|Active Comparator|Aximo|"The patients in the control group receive an ergotherapeutic therapy unit once a day for the same length of time (approx. 31 minutes) for a total of ten days, in which they train unilaterally. In this therapy unit, the control group uses the Aximo. This is a comb stand and so-called rolls with which plugging tasks can be practiced. The patients should push the rolls into the stand fields with the affected hand. With the plug-in game, the patients can complete different tasks that challenge and train their hand-eye coordination, their fine motor skills and their ability to grasp things (e.g. following a specific pattern based on a template or putting colors in a specific order)."
89228643|NCT05590910|Experimental|Music Intervention Group|The music intervention group will receive a 15-minute music intervention and variables such as heart rate, blood pressure, anxiety, and academic performance will be measured.
89228644|NCT05590910|No Intervention|Non-Music Control Group|Variables such as heart rate, blood pressure, anxiety, and academic performance will be measured.
89228645|NCT01563926|Experimental|Somatropin|
89228646|NCT05590520|Experimental|Botulinum group|The internal anal sphincter to be palpated and injected with a 27-gauge needle while the patient lying on his or her left side. Each patient will receive 0.4 ml of solution containing botulinum toxin (for a total of 20 U), administered as two injections of equal volume (0.2 ml), one on each side of the anterior midline of the internal anal sphincter. No sedation or local anesthesia to be used during the procedure)
89228647|NCT05590520|Active Comparator|GTN group|0.2 percent nitroglycerin ointment applied twice daily for six weeks.
89228650|NCT01034956||Facial Soft Tissue Filler Patients|Patients previously treated by Principal Investigator with facial soft tissue fillers within the past 2 years
89228651|NCT01040884|Experimental|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
89228652|NCT05590052|Active Comparator|Bipolar Electrosurgery group (n=60)|Group A
89228653|NCT05590052|Active Comparator|Thermocautery group (n=60)|Group B
89228654|NCT01580878|Experimental|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
89228655|NCT01580878|Active Comparator|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
89228656|NCT01580878|Placebo Comparator|Butenafine Vehicle|Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
89228657|NCT01040962||Falls Risk Assessment, Diabetic Peripheral Neuropathy Patients|
89228658|NCT00990548||Cardiovascular Service Line patients|Patients admitted to the Cardiovascular Service Line at a major teaching hospital during a consecutive 11-month period.
89228659|NCT00990626||1|Schizophrenic outpatients
89228660|NCT00673049|Experimental|Arm A|"The CP 751,871 treatment in combination with erlotinib will be given in three week cycles.~CP 751,871 (20 mg/kg) + erlotinib (150 mg/day) CP 751,871 will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter."
89228661|NCT00673049|Active Comparator|Arm B|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food)
89228662|NCT04003844|Experimental|Experimental|Investigational product (IP)
89228663|NCT05589584|Experimental|intervention|NAC and weight reduction program
89228664|NCT05589584|No Intervention|control|weight reduction program only
89228665|NCT05359484|Experimental|detrusor underactivity|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post void residual urine (PVR), and value of Qmax minus Qave (DeltaQ) were obtained.
89228666|NCT05359484|Experimental|bladder out flow obstruction|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post void residual urine (PVR), and value of Qmax minus Qave (DeltaQ) were obtained.
89108880|NCT05525507|Experimental|Immune tolerance in HLA-identical kidney transplant recipient|We seek to establish immunological tolerance in patients with a pre-existing, well- functioning kidney transplant from an HLA-identical donor. Patients will undergo conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same donor . We will evaluate whether recipients can be withdrawn from immunosuppressive drugs without compromising allograft function. At serial time points, graft function will be monitored, and chimerism will be measured. Weaning of tacrolimus will begin at 6 months, with a goal of drug discontinuation within 12 months if the following conditions are met: (1) chimerism (defined as ≥1% donor type cells among the T cells, B cells, NK cells, and granulocytes) is detectable for at least 180 days, (2) stable graft function (defined as eGFR >30 mL/min and no greater than sustained 30% change over 3 months from baseline) without clinical rejection episodes is maintained, and (3) no evidence of graft vs. host disease (GVHD).
89108888|NCT05516472|Experimental|Hyperoxaluric group|Treatment group based on 24 hour urine analysis showing oxalate >40 mg/day.
89108889|NCT05516472|Experimental|Hypercalciuric Group|Treatment group based on 24 hour urine analysis showing urinary calcium >225 mg/day.
89108890|NCT05516472|Placebo Comparator|Control group Hyperoxaluria|Control group enrolling patients with hyperoxaluria
89108891|NCT05516472|Placebo Comparator|Control group Hypercalciuria|Control group enrolling patients with hypercalciuria
89108892|NCT05515562|Experimental|Intravenous (IV) Omadacycline|All participants will receive 5 days of IV omadacycline followed by 5 days of oral omadacycline
89108893|NCT05511415|Active Comparator|Dexmedetomidine|The myometrial samples are bathed in increasing concentrations of dexmedetomidine (from 10 -9M to 10 -4M).
89108894|NCT05511415|Active Comparator|Oxytocin|The myometrial samples are bathed in oxytocin 20nM.
89108895|NCT05511415|Active Comparator|Dexmedetomidine + Oxytocin|The myometrial samples are bathed in oxytocin at 20nM along with dexmedetomidine (10-9M to 10-4M).
89108896|NCT05511415|Active Comparator|Oxytocin pre-treatment followed by Dexmedetomidine|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then in increasing concentrations of dexmedetomidine (from 10 -9M to 10 -4M).
89108897|NCT05511415|Active Comparator|Oxytocin pre-treatment followed by Oxytocin|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then bathed in oxytocin at 20nM.
89108898|NCT05511415|Active Comparator|Oxytocin pre-treatment followed by Dexmedetomidine + Oxytocin|The myometrial samples are pre-treated with oxytocin (10-5M) for 2 hours, and then bathed in oxytocin at 20nM along with dexmedetomidine (10-9M to 10-4M)
89108900|NCT05505734|Experimental|PT027|Participants will receive Budesonide and Albuterol Sulfate Pressurised Inhalation Suspension 160/180 μg up to a maximum of 12 inhalations to max dose.
89108901|NCT05505734|Experimental|PT007|Participants will receive Albuterol Sulfate Pressurised Inhalation Suspension 180 μg up to a maximum of 12 inhalations to max dose.
89108902|NCT05503849|Experimental|Proactive management during pregnancy|A combination of dietary, physical activity and lifestyle modification.
89108903|NCT05503849|No Intervention|Standard Care|No additional intervention beyond standard care procedure.
89108904|NCT05495048|Experimental|NOSES VIIIA|totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction
89228667|NCT00412750|Experimental|LdT+ PEG-INF|Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.
89108905|NCT05495048|Active Comparator|laparoscopic surgery with mini-laparotomy|laparoscopic right hemicolectomy with trans-abdominal extraction from a mini-laparotomy
89108906|NCT05482841||ENT cancer surgery patients|all patients undergoing ENT cancer surgery with tracheotomy or tracheostomy at the Centre Léon Bérard.
89108907|NCT05480072|Active Comparator|PEA 600 mg|PEA capsules (600 mg twice a day) will be administered for 21 days
89108908|NCT05480072|Placebo Comparator|Placebo|Placebo capsules (600 mg twice a day) will be administered for 21 days
89108909|NCT05478265||Axial Spine only, Age 65+|
89108910|NCT05478265||Axial Spine only, Age 18-64|
89108911|NCT05478265||Peripheral Joint only, Age 65+|
89108912|NCT05478265||Peripheral Joint only, Age 18-64|
89108913|NCT05478265||Axial + Peripheral Joint, Age 65+|
89108914|NCT05478265||Axial + Peripheral Joint, Age 18-64|
89108915|NCT05474690|Active Comparator|TCbHP chemotherapy regimen|Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
89108916|NCT05474690|Experimental|ECHP-THP chemotherapy regimen|(Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
89108917|NCT05474391||MammaPrint group|Pre-menopausal breast cancer patients received MammaPrint test.
89228668|NCT00412750|Experimental|LdT Monotherapy|Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.
89228669|NCT00412750|Active Comparator|PEG-INF Monotherapy|Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.
89228670|NCT05361278|Experimental|Chlorhexidine irrigation solution|CHx 2% solution will be used.
89228671|NCT05361278|Experimental|Activated chlorhexidine irrigation solution|CHx 2% solution will be used with ultrasonic activation.
89108918|NCT05467657|Experimental|repetitive transcranial magnetic stimulation|Participants in the experimental group will receive one hour of rehabilitation therapy daily with 30 minutes of Task Oriented Training (TOT) and 30 minutes of Robotic-Assisted Therapy (RAT), 5 days per week, and repetitive Transcranial Magnetic Stimulation (rTMS) will be applied. This process will comprise 5 weekly sessions of excitatory stimulation over the primary somatosensory area of the participant's affected side. For this purpose, the motor area will be localised and a coil will be placed 2 cm posterior to it. An isolated pulse will be applied to the motor area to ensure that the coil is not placed over the motor area using 110% of the motor resting threshold. After this, 24 trains of 5 Hz at an intensity of 90% of the motor resting threshold will be applied for 10 seconds, with a rest between series of 5 seconds (a total of 1200 pulses).
89108919|NCT05467657|Sham Comparator|Sham repetitive transcranial magnetic stimulation|The control group treatment will consist of a daily one-hour session of 30 minutes of task-oriented training (TOT) and 30 minutes of robotic-assisted therapy (RAT), for 5 days per week, to which the repetitive Transcranial Magnetic Stimulation (rTMS) placebo treatment will be added. To achieve the placebo, the localisation of the area to be stimulated will be carried out but the coil will be placed in a vertical position so the current wil not go through the skull and the patient will just feel the vibration, communicating to the participant that it is likely that during the stimulation process he/she will not feel anything.
89108920|NCT05452538||cancer surgery|all adult patients operated at the Léon Bérard Centre for cancer surgery (excluding endoscopy, interventional radiology, brachytherapy, vascular access)
89108921|NCT05444348|Experimental|ACT intervention|Participants will receive the ACT intervention
89108922|NCT05444348|No Intervention|control|Participants will receive no intervention only usual care.
89108923|NCT05427240|Experimental|ARM A|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor."
89108924|NCT05427240|Experimental|ARM B|"Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor.~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
89108925|NCT05427240|Experimental|ARM C|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor."
89108926|NCT05427240|Experimental|ARM D|"Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.~Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention."
89108927|NCT05419037||off-spring of above|Off-spring of the women who took metreleptin during her pregnancy.
89108928|NCT05419037||Women with past pregnancy on metreleptin|Women who took metreleptin during pregnancy.
89108929|NCT05415696|Other|Prostatic artery embolization (PAE)|Study participants will be treated with a single PAE procedure performed with Embosphere microspheres.
89108930|NCT05413265|Experimental|Incentives intervention condition|Subjects will receive generic, existing resources and referral information on evidence-based tobacco/nicotine cessation treatment services including the Alaska quitline, regional Tribal cessation programs, and smokefree.gov services and Alaska Native Tribal Health Consortium (ANTHC) family wellness resources on general health topics (e.g., injury prevention, household air quality) that include regional links to programs for domestic violence. Subjects will additionally receive individual cash card rewards for achieving biochemically verified smoking abstinence at each time point.
89108931|NCT05413265|Active Comparator|No incentives control condition|Subjects will receive generic, existing resources and referral information on evidence-based tobacco/nicotine cessation treatment services including the Alaska quitline, regional Tribal cessation programs, and smokefree.gov services and ANTHC family wellness resources on general health topics (e.g., injury prevention, household air quality) that include regional links to programs for domestic violence.
89108932|NCT05412433|Active Comparator|Standard of Care|Participants in this arm will receive standard of care
89108933|NCT05412433|Experimental|Patient Level + Multilevel|Participants in the arm will receive the patient level and multi-level intervention
89108934|NCT05412433|Experimental|Multilevel|Participants in this arm will receive the multi-level intervention
89108935|NCT05411848|Experimental|Intervention|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
89108936|NCT05411315|Experimental|Restricted-use of arterial catheters|
89108937|NCT05411315|Active Comparator|Standard-use of arterial catheters|
89108938|NCT05405595|Experimental|ADG126 in combination with Pembrolizumab (Trade name KEYTRUDA®)|An IV infusion of ADG126 over 60-90 minutes will be administered 30-60 minutes after administration of pembrolizumab (KEYTRUDA®) infusion. A treatment cycle will consist of 21 days.
89108939|NCT05399368|Experimental|RPT193 400 mg|RPT193 400 mg oral tablet administered daily for 16 weeks
89108940|NCT05399368|Experimental|RPT193 200 mg|RPT193 200 mg oral tablet administered daily for 16 weeks
89108941|NCT05399368|Experimental|RPT193 50 mg|RPT193 50 mg oral tablet administered daily for 16 weeks
89108942|NCT05399368|Placebo Comparator|Placebo|Matching placebo oral tablet administered daily for 16 weeks
89228672|NCT05361278|Experimental|Chlorhexidine irrigation gel|CHx 2% gel will be used.
89228673|NCT05361278|Experimental|Activated chlorhexidine irrigation gel|CHx 2% gel will be used with ultrasonic activation.
89228674|NCT05361278|Other|Sodium hypochlorite irrigation solution|NaOCl 5,25% solution will be used.
89228675|NCT00764855||1|Patients undergoing a surgery with general anesthesia
89228676|NCT05589506|Experimental|Removable partial denture PEEK|Removable partial denture using PEEK-acrylic resin
89228677|NCT00759317|Active Comparator|1|venlafaxine
89228678|NCT00759317|Placebo Comparator|2|
89228679|NCT00764933|Experimental|1|Structured information
89228680|NCT00764933|Sham Comparator|2|Unspecific conversation
89228681|NCT00076999|Experimental|TPV/r 290/115 mg/m^2|TPV and RTV oral solution low dose
89228682|NCT00076999|Experimental|TPV/r 375/150 mg/m^2|TPV and RTV oral solution high dose
89228683|NCT00765011|Experimental|Group A|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
89228684|NCT00765011|Other|Grupo B|Surgery
89228685|NCT01035034|Experimental|One-stop hybrid coronary revasularization|Percutaneous Coronary Intervention; Coronary Artery Bypass
89228686|NCT01035034|Active Comparator|PCI with stenting|Percutaneous Coronary Intervention
89228687|NCT00765089|Experimental|Pulmonary Vein isolation|Patients in this arm will receive pulmonary vein isolation during surgery
89228688|NCT00765089|No Intervention|Standard of care|Subjects in this arm will receive standard of care and no pulmonary vein isolation
89228689|NCT00765167|Placebo Comparator|A|
89228690|NCT00765167|Active Comparator|B|
89228691|NCT00765167|Active Comparator|C|
89228692|NCT00759551|Experimental|Azilsartan 2.5 mg QD|
89228693|NCT00759551|Experimental|Azilsartan 5 mg QD|
89228694|NCT00759551|Experimental|Azilsartan 10 mg QD|
89228695|NCT00759551|Experimental|Azilsartan 20 mg QD|
89228696|NCT00759551|Experimental|Azilsartan 40 mg QD|
89228697|NCT00759551|Placebo Comparator|Placebo QD|
89228698|NCT00759551|Active Comparator|Olmesartan 20 mg QD|
89228699|NCT03905096|Experimental|Part 1|
89228700|NCT03905096|Experimental|Part 2|
89228701|NCT02557919|Experimental|Motivational Interviewing Training|Staff at the intervention sites were trained in basic tobacco control and motivational interviewing. Two booster trainings were held over 6 months.
89228702|NCT02557919|Other|Usual Best Practice|Staff at the usual best practice sites received basic tobacco control training.
89228703|NCT00412360|Experimental|Single Cord Blood Transplant|Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
89228704|NCT00412360|Experimental|Double Cord Blood Transplant|Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
89228705|NCT00761423|Experimental|1|Combination of eccentric exercises and injection of PRP
89228706|NCT00761423|Placebo Comparator|2|Combination of eccentric exercises and physiological saline injection
89228707|NCT03957967||acute pain|Patient with acute pain
89228708|NCT00761501|Experimental|1|
89228709|NCT00761501|Active Comparator|2|
89228710|NCT00761501|Active Comparator|3|
89228711|NCT01564160|Experimental|Arm 1: PCSO-524|PCSO-524
89228712|NCT01564160|Active Comparator|Arm 2: Fish Oil|Fish Oil
89228713|NCT01088893|No Intervention|observation|
89228714|NCT01088893|Experimental|Everolimus|
89228715|NCT03026036||MDD|Patients with current Major Depressive Disorder
89228716|NCT03026036||rMDD|Patients with a history of Major Depressive Disorder
89228717|NCT03026036||HC|Healthy control participants
89228718|NCT00759629|Experimental|A|Interventional treatment group - Patients assigned to PCI will receive the loading dose of clopidogrel, aspirin plus a bolus of heparin and be transferred immediately for interventional treatment. They will receive abciximab as a bolus followed by a continuous infusion of for 12 hours.
89228719|NCT00759629|Active Comparator|B|Conservative treatment group - Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards.
89228720|NCT01088971|Active Comparator|Duolac 7S|
89228721|NCT01088971|Placebo Comparator|starch capsule|
89228722|NCT00990860|Experimental|Sorafenib|
89228723|NCT02558543|Active Comparator|Stromal Vascular Fraction|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo (ringer lactate) ( placebo group)
89228724|NCT02558543|Placebo Comparator|Placebo|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo ( placebo group)
89228725|NCT01035190|Experimental|inhaled Budesonide|
89228726|NCT01090687||Group I Microcalcifications|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary findings based on microcalcifications will be recruited to have a breast CT scan.
89228727|NCT01090687||Group II Soft tissue findings|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary soft tissue findings, with or without associated microcalcifications, will be recruited to have a breast CT scan.
89228728|NCT00765401||Group A|The subject with positive breath Test for H.pylori and/or positive stool antigen test
89228729|NCT00765401||Group B|The subject with negative breath Test for H.pylori and negative stool antigen test
89228730|NCT02557841|Experimental|anodal ctDCS|Volunteers will be submitted to anodal ctDCS + motor learning assessments (SRTT and Handwriting test).
89228731|NCT02557841|Experimental|cathodal ctDCS|Volunteers will be submitted to cathodal ctDCS + motor learning assessments (SRTT and Handwriting test).
89228732|NCT02557841|Sham Comparator|sham ctDCS|Volunteers will be submitted to sham ctDCS + motor learning assessments (SRTT and Handwriting test)
89228733|NCT01041196||perforated ulcer after gastric bypass|
89228734|NCT00765479|Experimental|Arm I|Patients receive an oral soy protein isolate beverage once daily.
89228735|NCT00765479|Placebo Comparator|Arm II|Patients receive an oral casein placebo beverage once daily.
89228736|NCT01035268|Experimental|surgery by fatty tissue transfer|
89228737|NCT01035268|No Intervention|simple supervision|
89228738|NCT00571103|Experimental|1 Open Label|Open Label. At visit 2, all participants were started on Acamprosate, 1,998 mg divided into 3 equal doses.
89228739|NCT03742934|Experimental|Formula group|short peptide formula prior to capsule endoscopy
89228740|NCT03742934|Other|Control group|regular liquid diet
89228741|NCT00991016|Experimental|PF-04805712|
89228742|NCT03993652|Experimental|Screen-time and Snacking|Aim: to reduce both screen-time and unhealthy snacking
89228743|NCT03993652|Experimental|Screen-time only|Aim: to reduce screen-time only
89228744|NCT03993652|Experimental|Snacking only|Aim: to reduce unhealthy snacking only
89228745|NCT03993652|No Intervention|Control|Control
89228746|NCT02558777|Experimental|Intervention Group|Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
89228747|NCT02558777|No Intervention|Control Group|Usual care
89228748|NCT01089049|Experimental|Pre-Menopausal|
89228749|NCT01089049|Experimental|Post-Menopausal|
89228750|NCT01038934|Experimental|buccal cytobrhsh|healthy young
89228751|NCT00765557|Active Comparator|MiraLAX|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to MiraLAX versus placebo.
89228752|NCT00765557|Placebo Comparator|Placebos|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to placebo versus MiraLAX.
89228753|NCT02828618|Active Comparator|Arm I PDS and chemotherapy|PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
89228754|NCT02828618|Experimental|Arm II Timing of surgery after 3 cycles of SOC CTX|3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
89228755|NCT01086553|Experimental|A|9mg budesonide OD
89228756|NCT01086553|Active Comparator|B|3mg budesonide TID
89228757|NCT01041352|Active Comparator|Endotracheal group|airway management: endotracheal tube
89228758|NCT01041352|Active Comparator|laryngeal mask group|airway management: laryngeal mask
89228759|NCT00765635|Experimental|2|Taponoto ® (potassium carbonate 20 mg/1 ml, ethyl alcohol, glycerol 480, thymol 0.4; Teofarma Iberica S.A., Barcelona, Spain),
89228760|NCT00765635|Placebo Comparator|3|sterile saline solution (NaCl 0.9%, Braun Medical SA, Barcelona, Spain).
89228761|NCT00765635|Experimental|1: Chlorobutanol|ceruminolytic product, Otocerum® (Chlorobutanol 50 mg/1 ml, phenol 10 mg/1 ml, turpentine essence 0.15 ml/1 ml, ethyl alcohol; Reig Jofre laboratories, Barcelona, Spain),
89228762|NCT02810990|Experimental|Bosutinib treatment|
89228763|NCT01041430|Active Comparator|Day Surgery Group|discharge planned on day of surgery, inguinal hernia repair
89228764|NCT01041430|Active Comparator|Inpatient Group|overnight admission at the hospital, inguinal hernia repair
89228765|NCT00765713|Experimental|CPAP|Continuous positive airway pressure
89228766|NCT00765713|No Intervention|Conventional|Hygienic-dietetic recommendations
89228767|NCT00765869|Experimental|1|Bowel cancer screening decision aid, DVD and Question Prompt List (QPL)
89228768|NCT00765869|Experimental|2|Bowel cancer screening decision with DVD only
89228769|NCT00765869|Active Comparator|3|Australian Government Bowel Cancer Screening consumer information booklet
89228770|NCT00766025|Experimental|Rosuvastatin Calcium|
89228771|NCT01039012|Other|Tai Chi plus Standard Care|
89228772|NCT01039012|Other|Standard Care|
89523206|NCT04371887|No Intervention|Hybrid Usual Care|The hybrid-usual care arm will consist of six KPSC service areas randomly assigned to this arm. The hybrid usual care arm will receive regional educational activities for the transition (as will the intervention arm) before the roll out of primary HPV testing. However, they will not receive any research-led intervention or adaptation guidance after primary HPV screening opens at KPSC. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
89523207|NCT05173181|Other|Adult with fracture distal ulna|
89108943|NCT05393934|Placebo Comparator|PNC (Pediatric Nutrition Care)|This first group will be given pediatric nutrition care (PNC) in visit 0. In this group parents will receive nutritional advice about how many calories are needed, the type and form of food that can be given so that the baby can gain weight accordingly.
89108944|NCT05393934|Active Comparator|FSMP (Food for Special Medical Purposes) & PNC (Pediatric Nutrition Care)|In this second group, subject will receive PNC in visit 0 and food for special medically purposes/FSMP that will be given according to daily calorie needs which are determined based on ideal body weight (BB) according to body length. In general, FSMP will be given 3 times a day, according to the needs of each subject. Parents will be taught about preparation of FSMP e.g. dissolving and the correct amount of product (image will be attached in the appendix). FSMP will be given during the research period and will be discontinued when not needed anymore.
89108945|NCT05392985||FES+-|MBC patients with both FES positive(+) and negative(-) lesions.
89108946|NCT05392088||Miocardial injury|Patients hospitalized at Policlinico Universitario A. Gemelli IRCSS since March 1, 2021, with a diagnosis of SARS-CoV-2 infection (≥1 positive nasopharyngeal swab) and at least one value of high-sensitivity cardiac troponin I (hs-cTnI) >99th percentile upper reference limit measured during the index hospitalization.
89108947|NCT05392088||No Miocardial injury|Patients hospitalized at Policlinico Universitario A. Gemelli IRCSS since March 1, 2021, with a diagnosis of SARS-CoV-2 infection (≥1 positive nasopharyngeal swab) and value of high-sensitivity cardiac troponin I (hs-cTnI) <99th percentile upper reference limit.
89108948|NCT05386511||UTD1|UTD1 monotherapy or UTD1 based therapy
89108949|NCT05372809|Experimental|SkinTE|SkinTE plus standard care
89108950|NCT05372809|Other|Control|Standard care alone
89108951|NCT05372003|Experimental|Subjects on Dupilumab|"individuals with atopic dermatitis placed on dupilumab for more than 6 months will be eligible to this study. Their metabolic profile will be compared to the group of Subjects on Phototherapy"
89108952|NCT05372003|Active Comparator|Subjects on Phototherapy|"individuals with atopic dermatitis placed on phototherapy for more than 6 months will be eligible to this study to serve as an active comparator to the Subjects with Dupilumab"
89108953|NCT05371223|Experimental|Interventional|"Eligible patients affected by pancreatic cancer PM will be enrolled according to in-/exclusion criteria.~Each patient will be scheduled for three treatment combined courses for a total of six cycles of endovenous Nabpaclitaxel-Gemcitabine chemotherapy and three of Nabpaclitaxel-PIPAC."
89108954|NCT05368103|Experimental|Daxdilimab|Nine sets of Daxdilimab injections over a total of 32 weeks.
89108955|NCT05345197|Experimental|Experimental-treatment|Treatment with emicizumab
89108956|NCT05330598|Experimental|Connected Catheter Users|Device: Connected Urinary Catheter Patients will use the Connected Catheter to empty the bladder during the course of treatment.
89108957|NCT05327608|Experimental|Treatment (Intermittent Fasting)|Patients undergo intermittent fasting involving 14 hours of fasting and 10 hours of eating for approximately 4 months while undergoing standard of care neoadjuvant chemotherapy. Acceptable neoadjuvant chemotherapy regimen includes doxorubicin and cytoxan followed by paclitaxel (AC-T). The schedule will be determined by treating physician. Carboplatin and pembrolizumab can also be added to the neoadjuvant chemotherapy regimen if determined to be appropriate by treating physician.
89108958|NCT05312229|Experimental|Replicating Effective Programs (REP)|A stakeholder-informed training and technical assistance implementation strategy
89108959|NCT05312229|Active Comparator|REP + External Facilitation (Enhanced REP)|REP plus site specific weekly facilitation to support CTI implementation.
89108960|NCT05312229|No Intervention|Control Group|No CTI implementation
89108961|NCT05310591|Experimental|Patients with MRD negative disease status: Time to Event Continual Reassessment Method (TITE-CRM)|
89108962|NCT05310591|Experimental|For relapsed patients|
89108963|NCT05303402|Experimental|Experimental: COVID-19 Vaccine HIPRA 40 mcg/dose|Intramuscular injection of HIPRA's COVID-19 vaccine, consisting of 40 mcg/dose.
89108964|NCT05303194|Other|Patient Priorities Care (PPC) Adaptation|5 Hispanic patients with multiple chronic conditions (MCC) and no dementia. In order to adapt PPC for Hispanics with MCC, five Hispanics with MCC will go through the 2 parts of the PPC approach: 1) Priority setting; and 2) Care alignment.
89108965|NCT05303194|Other|PPC Feasibility Testing|20 Hispanic patients with multiple chronic conditions (MCC), including dementia. In order to adapt PPC for Hispanics with MCC and dementia, twenty Hispanics with MCC and dementia will go through the 2 parts of the PPC approach: 1) Priority setting; and 2) Care alignment.
89108966|NCT05296837|Experimental|40mg of oral doxycycline|Arm A will receive submicrobial dose doxycycline (40mg) administered as 20mg twice a day for 8 weeks
89108967|NCT05296837|Active Comparator|100mg of oral doxycycline|Arm B will receive 200mg of oral doxycycline administered as 100mg twice a day for 8 weeks
89108968|NCT05296837|Placebo Comparator|Placebo|Arm C will receive a placebo twice a day for 8 weeks
89108969|NCT05293912|Experimental|SG2501|SG2501 monotherapy intravenous (IV) infusion - Weekly doses
89108970|NCT05284487|Active Comparator|Group 1: Jalosome® Soothing gel|"Jalosome® soothing gel ((L-Acetyl Carnitine chloridrate, Allantoin, Hydrogenated phosphatidylcholine, Sodium Hyaluronate) will be applied to the irradiated area two times daily (morning after RT and evening). The first application will start in the morning after the first RT session and will continue up to two weeks after completion of RT.~Visit 1: Screening (days -7 to 0) Visit 2: Randomization and start of RT (day 1) Visit 3 -Visit 9/10: RT treatment Last visit: 2 weeks after last RT"
89108971|NCT05284487|Placebo Comparator|Group 2: Placebo|"Placebo will be applied to the irradiated area two times daily (morning after RT and evening). The first application will start in the morning after the first RT session and will continue up to two weeks after completion of RT.~Visit 1: Screening (days -7 to 0) Visit 2: Randomization and start of RT (day 1) Visit 3 -Visit 9/10: RT treatment Last visit: 2 weeks after last RT"
89108972|NCT05278650|Other|Communities Adopting Senior PharmAssist Implementation Toolkit|"Three communities will commit to learning how to implement the evidence-based, multi-component intervention, Senior PharmAssistTM (SPA), designed to improve function and quality of life of older adults with limited incomes using the SPA toolkit.~The toolkit, co-developed with community leaders, will help to create a community model for implementation that addresses equitable access to medications, medication management, and community supports that promote physical function and healthy aging in place."
89108973|NCT05277402|Experimental|Dose escalation|ADG116 combination treatment with pembrolizumab (KEYTRUDA®), both drugs will be administered in each cohort.
89108974|NCT05275868|Experimental|Dose escalation|Patients with advanced NSCLC harboring NFE2L2/KEAP1/CUL3 mutations enrolled based on locally available test results of mutation status
89108975|NCT05275868|Experimental|Dose expansion group 1|Patients with advanced NSCLC harboring NFE2L2/KEAP1/CUL3 mutations enrolled based on locally available test results of mutation status
89108976|NCT05275868|Experimental|Dose expansion group 2|Patients with advanced NSCLC irrespective of prior knowledge of NFE2L2/KEAP1/CUL3 mutational status.
89108977|NCT05273034|Experimental|1-h sepsis bundle|
89108978|NCT05273034|No Intervention|Current practice|
89108979|NCT05271773||Mayo 0|Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 0 endoscopic activity.
89108980|NCT05271773||Mayo 1|Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 1 endoscopic activity.
89108981|NCT05259800|Experimental|Peppermint Oil|Subjects will be exposed to vapor of peppermint oil
89108982|NCT05259800|Placebo Comparator|Placebo|Subjects will be exposed to vapor of placebo (mineral oil)
89108983|NCT05257980|Experimental|Dietary supplement (ONS)|All patients will receive standardised dietary advice in addition to the ONS prescribed daily for 28 days. The ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The ONS prescribed will be the same throughout the 28 days and will be taken orally.
89108984|NCT05252416|Experimental|BLU-222 Monotherapy|Dose Escalation: Multiple doses for BLU-222 for oral administration Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation
89108985|NCT05252416|Experimental|BLU-222 + Carboplatin|"Dose Escalation: Multiple doses for BLU-222 for oral administration at doses deemed appropriate based on BLU-222 Monotherapy arm and multiple doses of Carboplatin at the approved dose.~Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation and Carboplatin IV infusion at approved dose"
89108986|NCT05252416|Experimental|BLU-222 + Ribociclib + Fulvestrant|"Dose Escalation: Multiple doses for BLU-222 for oral administration at doses deemed appropriate based on BLU-222 Monotherapy arm along with Ribociclib and Fulvestrant at the approved doses.~Dose Expansion: Oral dose of BLU-222 as determined during dose escalation and approved doses of Ribociclib and Fulvestrant"
89523208|NCT03785275||Subjects with stable near-normal T1D|"Mixed-meal tolerance test~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
89108987|NCT05252416|Experimental|BLU-222 + Fulvestrant|Dose Expansion: Oral dose of BLU-222 as determined during Dose Escalation + fulvestrant at the approved dose
89108988|NCT05251454|Experimental|Electrical stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase). They will always be tested beforehand to ensure that they do not cause participants any discomfort or distress.
89108989|NCT05250960|Experimental|Intervention - SCD arm|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
89108990|NCT05250960|No Intervention|Control - no SCD arm|Patient will receive 1L of LR during and after epidural placement with no use of SCDs
89108991|NCT05247125|Experimental|Blue light exposure + Melatonin treatment|The participants will receive the combination of blue light exposure according to the protocol described by Killgore et al. (2020) and 3 mg of melatonin 1 hour before going to sleep (approximately at 20:00) (Ramos et al 2020) for 14 days
89108992|NCT05247125|Experimental|Melatonin treatment|The participants will receive 3 mg of melatonin 1 hour before going to sleep (approximately at 20:00) (Ramos et al 2020) and the morning placebo-light exposure according to the protocol described by Killgore et al. (2020) for 14 days
89108993|NCT05247125|Experimental|Blue light exposure|The participants will receive the morning blue light exposure according to the protocol described by Killgore et al. (2020) for 14 days and placebo pill 1 hour before going to sleep (approximately at 20:00)
89108994|NCT05247125|Placebo Comparator|Placebo group|The participants will receive placebo light exposure in the morning (lamp turned off) and placebo pill treatment in the evening for 14 days
89108995|NCT05242874|Experimental|Standard antiemetic therapy without dexamethasone|Olanzapine in combination with fosaprepitant and tropisetron
89108996|NCT05242874|Active Comparator|Standard antiemetic therapy|Olanzapine in combination with fosaprepitant, tropisetron and dexamethasone
89108997|NCT05230498|Active Comparator|Cochlear Implant (CI) with default fitting then anatomy-based fitting|Cochlear Implant with default fitting first during 6 weeks then with anatomy-based fitting during 6 weeks
89108998|NCT05230498|Active Comparator|Cochlear Implant (CI) with anatomy-based fitting then default fitting|Cochlear Implant with anatomy-based fitting during 6 weeks then with default fitting during 6 weeks
89523209|NCT03785275||Subjects with unstable T1D|"Mixed-meal tolerance test~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
89109000|NCT05184101|Experimental|Nebulised heparin|Participants assigned to 'nebulised heparin' will receive nebulised heparin in addition to the standard care required as determined by the treating team.
89109001|NCT05184101|No Intervention|Standard care|Participants assigned to 'standard care' will receive the standard care required as determined by the treating team and will not be treated with nebulised heparin.
89109002|NCT05183529|Experimental|Patients undergoing polysomnography|
89109003|NCT05177523||MS patient group|Recruitment of 200 MS patients at the MS Clinic of the Department of Neurology (Neurologische Klinik und Poliklinik), University Hospital Basel (Universitätsspital Basel)
89109004|NCT05177523||control group (HC)|Recruitment of 100 healthy controls (HC) by public announcements (i.e. advertisement/flyer) on the University Hospital's and the University's notice board.
89109005|NCT05173896|Experimental|Tadalafil|Oral tadalafil (20 mg) capsules once daily for three months.
89109006|NCT05173896|Placebo Comparator|Placebo|Oral placebo capsules once daily for three months.
89109007|NCT05167409|Experimental|Evorpacept (ALX148) + cetuximab + pembrolizumab|Evorpacept (ALX148) + cetuximab + pembrolizumab. Evorpacept (ALX148) 15 mg/kg IV weekly, cetuximab 400 mg/m2 once then 250 mg/m2 weekly, and pembrolizumab 200 mg every 3 weeks
89109008|NCT05166343|No Intervention|Standard of Care|All POHCA events will be handled per standard of care of epinephrine administration via intravenous or intraosseous (IV/IO) based on patient estimated weight.
89109009|NCT05166343|Other|Intramuscular Epinephrine Dose|"POHCA events will be handled per standard of care, however, first dose epinephrine administration will be via intramuscular (IM) autoinjector and/or pre-filled syringes. Dosing will be dependent on weight as follows:~3-<5kg=0.3mg IM epinephrine~5-<10kg=0.5mg IM epinephrine~10-<20kg=1.0mg IM epinephrine~20-<30kg=2.0mg IM epinephrine~30kg=3.0mg IM epinephrine"
89109010|NCT05166161|Experimental|PTC923|Participants will receive PTC923 7.5 mg/kg (participants 0 to <6 months of age), 15 mg/kg (participants 6 to <12 months of age), 30 mg/kg (participants 12 months to <2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for a minimum of 12 months or until participant experiences lack of efficacy, adverse events (AEs) that lead to discontinuation, withdraws from treatment, or PTC923 is authorized and commercially available in the specific country.
89109011|NCT05163080|Active Comparator|Arm A|Peptide Vaccine (SurVaxM) in emulsion with Montanide given together with locally administered Sargramostim plus adjuvant oral Temozolomide
89109012|NCT05163080|Placebo Comparator|Arm B|Saline-Montanide emulsion with locally administered saline (instead of sargramostim) plus adjuvant oral temozolomide
89109013|NCT05157386||Participants in Braining, years 2017-2020|"Braining was primarily open for patients with a main or secondary diagnosis within affective disorder or anxiety syndromes, sleep disturbance or stress.~Participants in Braining (n≈600), who have participated in three or more training sessions 2017-2020 (n≈250), and who agree to contribute to this study, will be included."
89109014|NCT05156372|Experimental|Exercise Intervention|Participants will engage in 2-3 supervised high intensity aerobic and resistance exercise sessions per week.
89109015|NCT05156372|No Intervention|Control|Participants will continue daily routine as usual and given an informational flyer on physical activity and cancer.
89523210|NCT03380117|Experimental|eBridge Online Counseling|In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students have the opportunity to engage with eBridge counselors via online dialogues, in which students and counselors exchange messages using a secure website.
89109016|NCT05149768|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous
89109017|NCT05142735|Experimental|Experimental|N-Acetylcysteine 2000 mg (4 x 500-mg tablets) orally every morning for 8 weeks
89109018|NCT05142735|Placebo Comparator|Placebo Comparator|N-Acetylcysteine Placebo tablet matching N-Acetylcysteine orally every morning for 8 weeks
89109019|NCT05142553|Experimental|COVID-19 Vaccine HIPRA|40 ug/0.5 ml
89109020|NCT05142553|Active Comparator|Cominarty (Pfizer-BioNtech)|30 micrograms/dose concentrate for dispersion for injection
89109021|NCT05142514|Experimental|COVID-19 Vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.
89109022|NCT05142514|Active Comparator|Commercial COVID-19 Vaccine|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
89109023|NCT05126433|Experimental|Urothelial Cancer Cohort|Participants with advanced (metastatic and/or unresectable) urothelial carcinoma who have progressed on platinum-containing regimen (prior therapies may include but are not limited to immune checkpoint inhibitor, enformumab vendotin, or sacituzumab govitecan) will receive Lurbinectedin 3.2 mg/m^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
89109024|NCT05126433|Experimental|Poorly Differentiated Neuroendocrine Carcinomas Cohort|Participants with advanced (metastatic and/or unresectable) poorly differentiated neuroendocrine carcinomas who received at least 1 prior line of therapy will receive Lurbinectedin 3.2 mg/m^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
89109025|NCT05126433|Experimental|Homologous Recombination Deficient-Positive Malignancies Agnostic Cohort|Participants with advanced (metastatic and/or unresectable) endometrial, biliary tract, urothelial, breast (TNBC or HR+HER2- breast cancer), pancreas, gastric, or esophageal solid tumors with preidentified germline and/or somatic pathogenic mutation and received at least 1 prior line of therapy will receive Lurbinectedin 3.2 mg/m^2 intravenous (IV) on Day 1 of every 3 weeks (Q3W) cycle until confirmed disease progression, withdrawal of participant consent, participant lost to follow-up, unacceptable toxicity, or the study or individual cohort may be terminated by the sponsor for lack of efficacy signal or any other reason.
89109026|NCT05122091|Experimental|Fruquintinib group|"Two-four preoperative cycles of Fruquintinib plus SOX. One cycle consists of Day 1-14 Fruquintinib 5mg oral (daily), Day 1 Oxaliplatin 130mg/M2 intravenous, Day 1-14 Tegafur gimeracil oteracil potassium capsule 40-60mg bid（dosage according to body surface area）.~Repeated every 21st day"
89109027|NCT05112458|Experimental|Cope 360 application|Participants are given access to the application and will use it to care for their child with cancer for a period of 6 months.
89109028|NCT05112458|Active Comparator|Usual Care|Participants are given usual care and not given access to the application. They will be surveyed along with the experimental group for a period of 6 months.
89109029|NCT05103345|Other|Cohort|"SGN1 will be injected into the target lesion intratumorally. According to the dose levels, the administered dose will be 0.5×108 CFU, 1×108 CFU, 2×108 CFU, 4×108 CFU, 6×108 CFU (optional). The patient will be administered once every week for 3 consecutive weeks followed by 1-week rest in 28-day treatment cycles. The duration of administration is until disease progression.~The standard 3+3 dose escalation algorithm will be applied to explore dose limiting toxicity (DLTs) in up to 5 sequential cohorts with 3- 6 patients and identify the maximally tolerated dose (MTD).~When the cohort is completed in Part 1, the Part 2 study could be started according to the SMC evaluation. Enrollment of several expansion cohorts will be opened to determine the safety and efficacy of SGN1 in specific tumor types with potential efficacy signal observed in the previous dose escalation study."
89109030|NCT05093517|Experimental|Glucagon Receptor Agonist (GRA) REMD-477 group|Participants are assigned to a 12 week treatment of REMD-477
89109031|NCT05093517|Placebo Comparator|Placebo group|Participants are assigned to a 12 week course of placebo for REMD-477
89109032|NCT05092165|Active Comparator|Methylene Blue|Methylene blue will be infused during renal replacement therapy
89109033|NCT05092165|Other|Control|usual care
89109034|NCT05090878||1. Patients with and without carotid IPH|Among patients with carotid artery atherosclerosis (stenosis 30-99%), patients with and without IPH, as assessed by MR-Plaque Imaging, are compared in terms of apoB, Lp(a) levels and other cardiovascular risk factors.
89109035|NCT05090878||2. Patients with and without first-ever ischemic stroke at baseline|Among patients with carotid artery atherosclerosis (stenosis 30-99%), the risk of first-ever ischemic stroke in relation to apoB, Lp(a) levels, and presence of IPH is assessed, after adjusting for the cardiovascular factors.
89109036|NCT05090878||3. Patients with and without recurrent ischemic stroke|Among patients with carotid artery atherosclerosis (stenosis 30-99%) with an ipsilateral ischemic stroke at baseline, the risk of recurrent ipsilateral ischemic stroke in relation to apoB, Lp(a) levels, and presence of IPH is assessed, after adjusting for the cardiovascular factors.
89109037|NCT05087628|Experimental|PRV-3279|Sterile solution for intravenous administration, every 4 weeks
89109038|NCT05087628|Experimental|Placebo|Sterile solution for intravenous administration, every 4 weeks
89109039|NCT05074940|Experimental|Amivantamab|Amivantamab weekly for the first cycle and biweekly thereafter.
89109040|NCT05072483||Healthy controls|Healthy controls for exploratory analyses, where the measurements were not commonly performed previously in other populations, for qualitative comparison with CADASIL population
89109041|NCT05072483||Subjects with CADASIL|Adult genetically-confirmed patients with a wider range of CADASIL disease duration and debility
89109042|NCT05066217|Placebo Comparator|Placebo|Placebo Comparator: Matching Placebo - Cohort 2 Matching placebo will be administered twice a day (BID) in equally divided doses with food.
89109043|NCT05066217|Experimental|Active|"Drug: EPX-100 drug product is an oral aqueous solution of clemizole hydrochloride and provided in a concentration of 5 mg/mL.~Other Name: Cohort 1"
89109044|NCT05063136|Experimental|Capecitabine+endocrine therapy|capecitabine (500mg, tid) (for 1 year)+standard endocrine therapy (at least 5 years)
89109045|NCT05063136|Placebo Comparator|Placebo+endocrine therapy|oral placebo (tid) (for 1 year) + standard endocrine therapy (at least 5 years)
89109046|NCT05049525|Active Comparator|Itraconazole and Terbinafine|During the first 4 weeks itraconazole will be administered alone at 200 mg twice daily, followed by itraconazole 200 mg twice daily and terbinafine 250 mg twice daily for the remaining 16 weeks. Both drugs will be administered orally.
89109047|NCT05049525|Placebo Comparator|Placebo|During the first 4 weeks a placebo will be administered alone at 200 mg twice daily, followed by placebo 200 mg twice daily and another placebo 250 mg twice daily for the remaining 16 weeks. Both placebos will be administered orally.
89109050|NCT05046782|Experimental|MRI technique|restriction spectrum imaging (RSI) can detect prostate cancer better than a standard-of-care MRI.
89109051|NCT05044845||Hemophilia B patients|Patients ≥12 years of age with a diagnosis of moderate (FIX ≥1% and ≤2%) or severe (<1%) hemophilia B
89109052|NCT05044845||Parents or Caregivers|Parents or caregivers to patients with hemophilia 12-17 years of age
89109053|NCT05044845||Healthcare Workers|Doctors, nurses, social workers, pharmacists and educators who participate in the care of hemophilia B patients
89109054|NCT05027594|Experimental|Dose Escalation Part|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
89109055|NCT05027594|Experimental|Dose Expansion Part - NMS-03597812 single agent|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
89109056|NCT05027594|Experimental|Dose Expansion Part - NMS-03597812 in combination with dexamethasone|Patients with a confirmed diagnosis of relapsed or relapsed and refractory multiple myeloma (as per IMWG criteria) who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable
89109057|NCT05022212|Active Comparator|LACTIN-V|"LACTIN-V contains a naturally occurring human vaginal strain of Lactobacillus (L.) crispatus CTV- 05. At a potency of 2 x 109 cfu/dose, it is preserved in powder formulation, and applied by a vaginal applicator.~Women will receive the study product for five consecutive days, followed by twice weekly for three additional weeks. Women will be followed during the dosing (4 weeks) and post-dosing phase (4 weeks) for a total of 64 days."
89109058|NCT05022212|Placebo Comparator|Placebo|"A matching placebo formulation without L. crispatus CTV-05 is supplied in an identical applicator containing just the powder formulation.~Women will receive the placebo for five consecutive days, followed by twice weekly for three additional weeks. Women will be followed during the dosing (4 weeks) and post-dosing phase (4 weeks) for a total of 64 days."
89228773|NCT04049357|Experimental|The intervention group|"If the FIT test is returned and positive the individual can choose either Camera Capsule Endoscopy (CCE) or Optical colonoscopy (OC) as the primary bowel investigation. If OC is chosen, it is performed as standard and the participant outcomes remains analyzed in the intervention group as intention to treat.~If CCE is chosen an out-clinic CCE will be done at one of four regional sites. Overall and segmental bowel preparation grade (Leighton-Rex 1-4) and all pathological findings are reported. If the anal verge is identified without video blackout in the colon the transit is considered complete. Any incomplete CCE investigation will be followed by standard optical endoscopy to the extent needed to investigate the proportion of the colon not visualized by the capsule and remove any detected polyps. If the CCE is complete with complete transit and adequate preparation, individuals with more than two polyps or one polyp over 9 mm will be referred for colonoscopy."
89109059|NCT05017766||A) Urinary tract infection|Processing of residual urine for proteomic, metabolomic and transcriptomic analysis, immunocytochemical or fluorescence in-situ hybridisation (FISH) analysis, flow cytometry analysis (FACS), immunophenotyping. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties (Highly sensitive mass spectrometry, whole genome sequencing), expression of virulence factors, genomic alterations of bacterial species, metabolism, surface molecule expression, gene expression levels, cytokine levels, immune cell biology, antibiotic concentration (chromatography/mass spectrometry). Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included. First, a pilot study from randomly selected patients within each bacterial species group (n=50, each) is done.
89109060|NCT05017766||B) Pneumonia|Processing of residual samples (tracheal secretion, bronchioalveolar lavage (BAL)) for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. If previous antibiotic treatment: plasma sample storage. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.
89109061|NCT05017766||C) Deep-seated infections|Processing of intraoperative material residual samples for proteomic, metabolomic, transcriptomic and cytological analysis. If positive for target bacteria: sample stored at biobank. Exploration of bacterial properties. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analysed. 500 samples per target bacteria (S. aureus, P. aeruginosa, E. coli, Klebsiella species) included.
89109062|NCT05017766||D) Controls for A), B) and C)|Control samples result from patients with a suspected infection (infection sites A), B) or C), in which no microbiological confirmed infection has been diagnosed. Storage at biobank
89109063|NCT05017766||E) Clinical controls for A), B) and C) without obtained samples|For clinical controls, clinical characteristics of patients with detection of target pathogens in their routine samples (but which could not be included for sample analysis in this study) will be assessed.
89109064|NCT05017766||F) Cohort with analysis whether the application of Article (Art) 34 HFV can avoid a bias|Since part of the data and samples in this study are collected with the representative consent of the ethics committees, it is investigated whether the application of Art. 34 HFV prevents selection bias with respect to the study population. For this purpose, differences between the actual study population using Art. 34 HFV and the study population with provided research consent will be descriptively investigated in terms of the prevalence of multi-resistant germs and other available population characteristics.
89109065|NCT05014698|Experimental|WGS|"at inclusion visit :~- Blood collection for whole Genome sequencing will be performed~At final visit :~the results of the WGS will be delivered to patients"
89109066|NCT05010772|Experimental|Arm A (decitabine and cedazuridine)|Patients receive decitabine and cedazuridine PO QD on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
89109067|NCT05010772|Experimental|Arm B (decitabine and cedazuridine, venetoclax)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89109068|NCT05010772|Experimental|Arm C (decitabine and cedazuridine, gilteritinib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89109069|NCT05010772|Experimental|Arm D (decitabine and cedazuridine, enasidenib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89109070|NCT05010772|Experimental|Arm E (decitabine and cedazuridine, ivosidenib)|Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89109071|NCT05010031|Experimental|radiation|Subjects will receive reduced dose radiation to radiographically progressive lesions identified on imaging (including asymptomatic bone metastases).
89109072|NCT05007990||Active|Participants include individuals who are caregivers of an individual with a chronic medical condition, OR individuals who support caregivers of an individual with a chronic medical condition.
89109073|NCT05007990||Bereaved|Participants include individuals who were caregivers of an individual with a chronic medical condition who has died, OR individuals who support the caregiver.
89109074|NCT04986605|Experimental|Administration of Extracorporeal Photopheresis Treatment|"Duration of treatment: 48 weeks. Treatments occur on 2 consecutive days every 4 weeks.~Dose of UVADEX: Treatment Volume x 0.017 = mL of UVADEX for each treatment Treatment Volume (TV) is defined as: The total volume of Buffy Coat plus prime solution that will undergo photoactivation.~Route of administration: Extracorporeal"
89109075|NCT04980001|Experimental|FOCUS TIC-COM arm|"Health care providers will be trained in FOCUS TIC-COM through professional development and from this group the investigators plan to recruit participants for the surveys about the training, intervention feasibility and acceptability. Health care providers will be encouraged to implement FOCUS TIC-COM will all of their pediatric patients who are overweight/obese.~Parents / Caregivers of children who are overweight or obese will be recruited into the study after exposure to the intervention. Only those exposed to the intervention will be recruited to participate in the study which includes one survey and focus groups."
89109076|NCT04976959|Experimental|Parkinson's patients|Parkinson's patients who will receive a high fiber supplement
89109077|NCT04976959|No Intervention|Control subjects|no supplement will be given
89109078|NCT04975217|Experimental|Treatment (FMT, FMT capsules)|Patients undergo FMT during colonoscopy. Patients also receive FMT capsules PO QW for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care resection of tumor(s).
89228774|NCT04049357|No Intervention|The control group|The control group will be invited to screening as usual. The intervention group will be informed that if the fecal test is returned and positive they can either choose to have an initial colon capsule endoscopy, and only colonoscopy if significant findings are made or an initial colonoscopy as usual.
89228775|NCT00766103|Other|crossover: hypo- and hypercarbia|
89228776|NCT05577572|Experimental|Probiotics packets|Probiotics contains 450 billion colony-forming units per packet. The compositions are maltose, lactic acid bacteria and bifidobacteria blend, cornstarch, silicon dioxide.
89228777|NCT05577572|Placebo Comparator|Placebo packets|The compositions are maltodextrin, silicon dioxide, sucralose
89228778|NCT00760097|Experimental|AtCDS|Transcranial direct stimulation
89228779|NCT00766181||1: Lifestyle|Observatonal
89228780|NCT00766181||2: Lifestyle|Observational
89228781|NCT05358002|Active Comparator|Frontalis sling|Connecting the frontalis muscle action with the tarsus of the upper eyelid with synthetic material PTFE ( gore-tex )
89228782|NCT05358002|Experimental|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
89228783|NCT04048577|Experimental|Dose Interruption|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days) except during the pre-planned dose interruption of 2 consecutive skipped doses.
89228784|NCT04048577|No Intervention|Standard Treatment|All subjects will continue to receive their prescribed Tysabri® 300 mg IV infusions at their approved infusion sites. The patients will receive Tysabri at standard intervals (28-days).
89228785|NCT00991250|Experimental|SentoClone®|SentoClone®: Specific tumour-reactive lymphocytes located in lymph nodes directly draining primary tumours or metastases are identified and expanded. These lymphocytes are infused to the patient to treat metastatic disease.
89228786|NCT00991250|Active Comparator|Temodal® or Dacarbazine Medac®|"To be decided by each centre as one of the following:~Temodal® (temozolomide)~Dacarbazine Medac® (dacarbazine) The reference treatment regimen should follow the general guiding principles for each of the two reference treatments."
89228787|NCT00762047|Experimental|Durasphere|
89228788|NCT00762047|Sham Comparator|Sham|
89109079|NCT04971694||Inclusion Group|Infants born at <30 weeks and/or <1500g that were admitted to BUMCP between January 1, 2019 and December 31, 2020
89109080|NCT04969549|Other|Theta-burst stimulation (TBS)|Receive active iTBS, 1800 pulses, 100% MT over dlPFC.
89109081|NCT04968951|Active Comparator|FMT with Antibiotics|Participants will receive antibiotics before receiving Fecal Microbiota Transplantation
89109082|NCT04968951|Placebo Comparator|FMT with placebo|Participants will receive placebo before receiving Fecal Microbiota Transplantation
89109083|NCT04968184|Placebo Comparator|Placebo|All eligible participants will receive KBP-5074 matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period, then up to 24 weeks during the Double-blind treatment Period and during the Open-label treatment period, and thereafter for 4 weeks, during the randomized Double-blind withdrawal period.
89109084|NCT04968184|Experimental|KBP-5074|All eligible participants will receive KBP-5074, for up to 24 weeks during the Double-blind treatment Period and during the Open-label treatment period. Thereafter, eligible participants will continue current dose of KBP-5074 at the end of the Open-label treatment period.
89109085|NCT04960904||In-Kone® UNIVERSAL|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges In-Kone® UNIVERSAL, including the former 3.0 range now named In-Kone® Universal NR (narrow), and including the In-Kone® Universal WD (wide).
89109086|NCT04960904||In-Kone® PRIMO|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges In-Kone® PRIMO
89109087|NCT04960904||twinKon®|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges twinKon®
89109088|NCT04960904||EVL® S|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® S
89109089|NCT04960904||EVL® K|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® K
89109090|NCT04960904||EVL® C|Implant-prosthetic systems made with dental implants and prosthetic components of the ranges EVL® C
89109091|NCT04955808||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.
89109092|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
89109093|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
89109094|NCT04912063|Experimental|Lemzoparlimab + Azacitidine in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
89109095|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
89109096|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
89109097|NCT04912063|Experimental|Lemzoparlimab Monotherapy in AML (Japan Only Escalation)|Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
89109098|NCT04912063|Experimental|Lemzoparlimab Monotherapy in MDS (Japan Only Escalation)|Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
89109099|NCT04900532|Experimental|Effects of supplementation with tocotrienol on chronic kidney disease patients|Administration of tocotrienol-rich-fraction (TRF) capsules, containing 360mg of tocotrienol and 80mg of tocopherol twice a day for six months.
89109100|NCT04900532|Placebo Comparator|Effects of supplementation with tocotrienol on lipid profile of chronic kidney disease patients|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
89109101|NCT04895488|Experimental|Arm A: Vortioxetine+Usual antipsychotic treatment (TAU)|"Drug:~First treatment phase: Vortioxetine 10 mg 1 tablet/d for 2 weeks added to Usual antipsychotic treatment, followed by Vortioxetine 20mg 1tablet/d for 22 weeks added to Usual antipsychotic treatment.~Wash-out period 2 weeks"
89109102|NCT04895488|Active Comparator|Arm B: Usual antipsychotic treatment (TAU)|Second treatment phase: Usual antipsychotic treatment: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
89109103|NCT04877691|Experimental|Anifrolumab|Solution for injection in aPFS
89109104|NCT04877691|Placebo Comparator|Placebo|Solution for injection in aPFS
89109105|NCT04860947||MS patients|
89228789|NCT00418522|Active Comparator|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
89228790|NCT00418522|Experimental|Exubera|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
89228791|NCT00991328|Active Comparator|Cerebral Desaturation, i.e; SctO2 < 60 % for 5 minutes|Once the cerebral desaturation is established, the study personnel will attempt to optimize the level of oxygen within the brain of the study patients.
89228792|NCT00991328|No Intervention|Patients with SctO2 less than 60 %.|The study patients will not get any intervention in this arm if the Sct02 falls below 60%
89228793|NCT00762125|Experimental|Cognitive restructuring and coping skills training (CR+ST)|
89228794|NCT00762125|Experimental|Exposure therapy (ET)|
89228795|NCT00762125|Experimental|Combination (COMB) treatment|
89228796|NCT00762125|Active Comparator|Attention control (AC) treatment|
89228797|NCT00762281|Other|Treatment of Hyperopic LASIK|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
89228798|NCT00760175|Active Comparator|intradermal|
89228799|NCT00760175|Active Comparator|intramuscular|
89228800|NCT02703662|Active Comparator|Strattice biologic mesh|Strattice mesh is made of noncross-linked porcine dermis, which is used to support abdominal wall reconstruction.
89228801|NCT02703662|Experimental|Permacol biologic mesh|Permacol mesh is made of cross-linked porcine dermis, which is used to support abdominal wall reconstruction.
89228802|NCT00762437|Experimental|1|
89228803|NCT02557763|Experimental|Severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
89228804|NCT02557763|Experimental|non severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
89228805|NCT00991484||control group|
89228806|NCT00991484||individuals from hernia-family|
89228807|NCT00766259||1|Hemodialysis
89228808|NCT00766259||2|Intensive care
89228809|NCT00766259||3|vascular patients with open wounds
89228810|NCT00766259||4|nursing home
89228811|NCT00766259||5|skin infections
89228812|NCT00766259||6|control- ambulatory care clinic patients with no infections
89228813|NCT00766337|Experimental|Dose Group 1|
89228814|NCT00766337|Experimental|Dose Group 2|
89228815|NCT00766337|Placebo Comparator|Dose Group 3|
89228816|NCT00760253||1|pure propofol by TCI pump with titration.
89228817|NCT00760253||2|10ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
89228818|NCT00760253||3|20ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
89228819|NCT01564004|Experimental|Clinical hypnosis|20 minutes tape recorded clinical hypnosis intervention
89228820|NCT01564004|Active Comparator|Neuro-linguistic programming|20 minutes tape recording of nouro-linguistic programming intervention
89228821|NCT00762593|Experimental|1|transvaginal electrical stimulation with a home use programmable device used 30 minutes every day during 8 weeks
89228822|NCT00762593|Placebo Comparator|2|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
89228823|NCT00762671|Placebo Comparator|2|Placebo
89228824|NCT00762671|Active Comparator|1|Ebselen
89228825|NCT05306483|Active Comparator|Ventricular septal defect closure surgery|Surgical closure would be done under general anesthesia, hypothermic cardiopulmonary bypass and cardioplegic arrest. Chest would be opened through standard median sternotomy Surgical techniques would be determined according to the nature of every defect and includes direct closure, patch closure which involves the use of autologous pericardium; however, polyethylene terephthalate (Dacron; C.R Bard, Haverhill, MA) and expanded polytetrafluoroethylene (Gore-Tex; W.L. Gore & Associates, Inc.,AZ) may be occasionally used. These patches are held with continuous or interrupted sutures. Direct closure (without a patch may be done for the very small defects.Most VSDs would be repaired through right atriotomy to avoid the the undesirable effects of the trans ventricular approach.
89523211|NCT03380117|No Intervention|Control|In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
89109106|NCT04854785||DNP-mild|Participants that have recovered from mild COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
89109107|NCT04854785||DNP-moderate|Participants that have recovered from moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).
89109108|NCT04854785||Healthy Control Participants|Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.
89109109|NCT04852120||Compound Sodium Picosulfate Granules|
89109110|NCT04852042|Experimental|mHealth Group|12 month text messaging program about diet and physical activity behavioral goals
89109111|NCT04852042|Experimental|mHealth+Community Health Worker (CHW) support|same as mHealth group + monthly behavioral phone counseling by a CHW
89109112|NCT04852042|No Intervention|Control group|Assessments only
89109113|NCT04782947|Experimental|EAW+ES+RT|The exoskeletal assisted walking with epidural simulation and resistance training (EAW+ES+RT) group will undergo 6 months of supervised EAW +ES (3X per week) followed by additional 6 months of EAW+ES (3X per week) and progressive RT twice weekly (2X per week). In the EAW+ES+RT group, RT will be administered for 12 weeks using an open kinematic chain approach of applying surface NMES and ankle weights followed by 12 weeks twice weekly of gradually using the implanted ES to perform sit-to-stand approach (i.e. using their body weights to load the exercising muscles in a closed kinematic fashion).
89109114|NCT04782947|Experimental|EAW+ delayed-ES +no-RT|The control exoskeletal assisted walking with delayed epidural simulation and without resistance training (EAW+ delayed-ES +no-RT) group will enroll in 6 months of EAW without ES (3X per week) and then this will be followed by additional 6 months (3x per week) of EAW+ES (i.e., delayed entry approach) without conducting RT and will perform either passive movement of passive stretching (2X per week).
89109115|NCT04782869|Experimental|tDCS (transcranial direct current stimulation)|Patient will be treated for 3 cycles. A cycle is composed of 5 bi-sessions (one per day) of 20 minutes each.
89109116|NCT04765735|Experimental|Open-loop (OL) testing, then Closed-loop (CL) testing|Subjects receive Open-loop testing, then Closed-loop testing (Spinal Cord Stimulation - SCS Therapy)
89109117|NCT04765735|Experimental|Closed-loop testing, then Open-loop testing|Subjects receive Closed-loop testing, then Open-loop testing (Spinal Cord Stimulation - SCS Therapy)
89109118|NCT04764695|Experimental|Patients diagnosed with HM|As it is a pre-test / post-test design, the child himself will be the control at the end of the study. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed.
89109119|NCT04744935|Active Comparator|Standard|1064 Long-pulse Nd:YAG laser Fluence: 120 J/cm2 Number of passes: Single Spot size: 2 cm Pulse width: 8-10 msec
89109120|NCT04744935|Active Comparator|Slow|1064 Long-pulse Nd:YAG laser Fluence: 20-30 J/cm2 Number of passes: Multiple Spot size: 2 cm Pulse width: 8-10 msec
89109121|NCT04742894|Experimental|Aphasia Group|
89109122|NCT04742894|Experimental|Control Group|
89109123|NCT04740736|Experimental|Saline Infusion|
89109124|NCT04740736|Sham Comparator|Sham Infusion|
89109125|NCT04740008|Experimental|Control message on low nicotine cigarettes|
89109126|NCT04740008|Experimental|Test message on low nicotine cigarettes|
89109127|NCT04738643|No Intervention|Usual Care|TUT Service Only
89109128|NCT04738643|Experimental|Tobacco Use Treatment Service + Varenicline Management|TUTS + Varenicline Management
89109129|NCT04729985|No Intervention|Standard Care|A blinded CGM will be placed to review glucoses after discharge in the Standard Care arm.
89109130|NCT04729985|Active Comparator|Diabetic education and CGM monitoring|Treatment arm will get diabetic education, active CGM use with patient feedback for 14 days, active access to the PI for concerns relating to hospitalization. They will also receive a brief, 15 minute phone call from the PI on day 3-4, 6-7, 9-10 and day 14-15.
89109131|NCT04706013|Experimental|Single Arm Active|Pyridoxal 5'-Phosphate
89109132|NCT04702139|Active Comparator|patient with game-ready splint|Installation of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
89109133|NCT04702139|Placebo Comparator|patient with standard splint|Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
89109134|NCT04699188|Experimental|Arm A|JDQ443
89109135|NCT04699188|Experimental|Arm B|JDQ443 in combination with TNO155
89109136|NCT04699188|Experimental|Arm C|JDQ443 in combination with tislelizumab
89109137|NCT04699188|Experimental|Arm D|JDQ443 in combination with TNO155 and tislelizumab
89109138|NCT04693351|Experimental|Troriluzole|Troriluzole- 2 100mg capsules once daily for the first two weeks. Troriluzole- 2 140mg capsules once daily from week two through week ten.
89109139|NCT04693351|Placebo Comparator|Placebo|Placebo- 2 100mg capsules once daily for the first two weeks. Placebo- 2 140mg capsules once daily from week two through week ten.
89109140|NCT04691544|Active Comparator|Fecal microbiota transplant from donor A|One FMT delivered by enema
89109141|NCT04691544|Active Comparator|Fecal microbiota transplant from donor B|One FMT delivered by enema
89109142|NCT04691544|Active Comparator|Fecal microbiota transplant from donor C|One FMT delivered by enema
89109143|NCT04691544|Placebo Comparator|Fecal microbiota transplant from autologous feces|One FMT delivered by enema
89109144|NCT04686786|Experimental|CVL-865 25 mg|Participants will receive CVL-865 tablets orally twice daily (BID) up to the maximum dose of 25 milligrams (mg) until Week 57 during the treatment period.
89109145|NCT04685226|Experimental|ICP-723|ICP-723
89109146|NCT04682353|Experimental|Group 1 - 120 mg/0.4 mL|
89109147|NCT04682353|Experimental|Group 2 - 180 mg/0.6 mL|
89109148|NCT04682353|Experimental|Group 3 - 240 mg/0.8 mL|
89109149|NCT04682353|Active Comparator|Group 4 - 104 mg/0.65 mL|
89228826|NCT05306483|Active Comparator|catheter closure of ventricular septal defect|"Under general anesthesia, patients will be fully heparinized (100IU/Kg) with follow up by activated clotting time. IntraoperativeTEE will be done for more detailed assessment of the defect size, relation to the surrounding structures especially the distance from the tricuspid and the aortic valve to guide the procedure and for proper assessment after device positioning yet before its release.~Left ventricular angiogram will be done in LAO 60, cranial 30 projection to define location and size of the defect. Accordingly, proper selection of the device siz."
89228827|NCT02558309||Intracranial Pressure Reduction|"Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.~The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant.~A slit lamp examination and indirect ophthalmoscopy will be performed.~Experimental:~The subject's eye will be held open with an eye speculum during the exam.~Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed.~Intraocular Pressure will be measured.~An Optic Coherence Tomography (OCT) will be performed.~At each step along the process of ICP reduction, the eye exam, IOP & OCT will be performed.~Optional:~The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained.~OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure."
89228828|NCT02558387|Experimental|Nintedanib arm|Nintedanib has never been applied to salivary gland cancer. Nintedanib was given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
89228829|NCT00766805|Active Comparator|EVL + Drugs|Patients randomized to the EVL plus drugs therapy received EVL plus beta-blocker (propranolol) and nitrate (ISMN).
89228830|NCT00766805|Placebo Comparator|EVL alone|Patients assigned to the EVL group underwent variceal band ligation alone till variceal obliteration.
89228831|NCT00766961|Active Comparator|TAE group|Trans-catheter arterial embolization
89228832|NCT00766961|Active Comparator|Surgery group|Surgery
89228833|NCT00762749|Experimental|diphenhydramine HCl|diphenhydramine HCl / Children's Benadryl Allergy Liquid
89228834|NCT00403546|Experimental|High-Dose Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the study drug will be increased to a total ziprasidone dose of 320 mg/d for 7 weeks.
89228835|NCT00403546|Placebo Comparator|Placebo, Standard Treatment Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take matching placebo oral capsule twice daily added to their regular open-label ziprasidone dose of 160 mg/d. After the first week, the matching placebo will be increased to two capsules twice daily and their regular open-label ziprasidone will remain the same (160 mg/d) for 7 weeks.
89228836|NCT00760409||Radiation Injury|Radiation Injury Recurrent symptoms after radiation therapy of a brain tumor are not always the result of tumor recurrence but may represent radiation necrosis of the brain.
89228837|NCT00760409||Tumor Recurrence|Symptoms are the result of actual tumor recurrence
89228838|NCT02558621|Experimental|Device: AQrate Robotic Assistance System|Precise positioning of surgical instruments and spinal implants during general spinal surgery.
89228839|NCT00760565|Experimental|1|
89228840|NCT00760565|Placebo Comparator|10|
89228841|NCT00760565|Experimental|11|
89228842|NCT00760565|Placebo Comparator|12|
89228843|NCT00760565|Placebo Comparator|2|
89228844|NCT00760565|Experimental|3|
89228845|NCT00760565|Placebo Comparator|4|
89228846|NCT00760565|Experimental|5|
89228847|NCT00760565|Placebo Comparator|6|
89228848|NCT00760565|Experimental|7|
89228849|NCT00760565|Placebo Comparator|8|
89228850|NCT00760565|Experimental|9|
89228851|NCT00403390|Experimental|Brand name levothyroxine (Synthroid)|Dose previously demonstrated to normalize thyroid function given daily for 2 months
89228852|NCT00403390|Active Comparator|Generic formulation of Levothyroxine|Dosage previously determined to normalize thyroid function given daily for 2 months
89228853|NCT00767195||1. Control group|Patients in the intensive care unit who have no pulmonary edema
89228854|NCT00767195||2. Study group 1|Patients with cardiogenic pulmonary edema in the intensive care unit
89228855|NCT00767195||3. Study group 2|Patients with non-cardiogenic pulmonary edema in the intensive care unit
89228856|NCT00762905|Active Comparator|1|LiquiBand Laparoscopic
89228857|NCT00762905|Active Comparator|2|Dermabond
89228858|NCT00762983||Group 1|Pediatric patients who are treated with Claritin for any of the following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema, dermatitis, or pruritus cutaneous)
89228859|NCT00403234|Experimental|BTDS 10|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
89228860|NCT00403234|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
89228861|NCT00403234|Experimental|BTDS 30|Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
89228862|NCT00403234|Placebo Comparator|Placebo TDS|Placebo patches were similar to BTDS 10 and 20.
89228863|NCT00767429|Experimental|1|subjects with fall risk
89228864|NCT00760721|Experimental|1|Educational small group session with HBV screening resources provided
89228865|NCT00760721|Sham Comparator|2|Educational small group discussion, diet/physical activity resources provided
89228866|NCT04049201|Experimental|Group tablet|group T will receive interactive Tablet containing many cartoon's videos 20 minutes before parental separation until the anesthesia induction
89228867|NCT04049201|Active Comparator|Group Midazolam|group Midazolam will receive oral midazolam 0.5 mg/kg (max 20 mg) 20 minutes before the parental separation
89228868|NCT00767585||A:|70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
89109150|NCT04678414||Observational (focus group, survey)|"FOCUS GROUP: Patients attend an audiotaped focus group over 90 minutes to provide feedback for survey development.~SURVEY VALIDATION: Patients complete an online survey over 15-30 minutes at baseline and 2 days later.~TELEPHONE SURVEY: Patients complete a telephone survey."
89109151|NCT04667013|Experimental|Cohort 1|2 x 300 mg TBN tablets for a total dose of 600 mg or 2 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
89109152|NCT04667013|Experimental|Cohort 2|4 x 300 mg TBN tablets for a total dose of 1200 mg or 4 matching placebo tablets (given approximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.
89109153|NCT04650854|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized/assigned to dosage regimen 1 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
89109154|NCT04650854|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized/assigned to dosage regimen 2 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
89109155|NCT04645277||Patients with MRI using two dimensional reconstruction|
89109156|NCT04645277||Patients with MRI using three dimensional reconstruction|
89109157|NCT04641143|Active Comparator|Troriluzole|Troriluzole - 2 100mg capsules once daily for the first two weeks. Troriluzole - 2 140mg capsules once daily from week two through week ten.
89109158|NCT04641143|Placebo Comparator|Placebo|Placebo - 2 100mg capsules once daily for the first two weeks. Placebo - 2 140mg capsules once daily from week two through week ten.
89109159|NCT04635241|Experimental|Inhaled heparin|Inhaled nebulised unfractionated heparin in addition to standard care Dose 25,000 IU every 6 hours for up to 21 days
89109160|NCT04635241|No Intervention|Standard care|Standard care
89109161|NCT04630808|Experimental|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
89109162|NCT04630808|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
89109163|NCT04617938|Experimental|TACUNA|Randomized participants will attend 3 virtual TACUNA workshops, focused on behavioral, physical, and spiritual domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use. They will also attend a Wellness Circle, focused on healthy social networks and engaging in traditional practices.
89109164|NCT04617938|Active Comparator|Opioid education|Randomized participants will attend 1 virtual opioid education workshop, focused on behavioral and physical domains, and designed to guide AI/AN youth to make healthy choices surrounding opioid and AOD use.
89109165|NCT04608903|Experimental|Sulforaphane Group|Administration of 4g L-sulforaphane per day, for 2 months and after the washout period (2 months) the groups will be crossed and will receive the same amount of placebo as the other group for 2 months.
89109166|NCT04608903|Placebo Comparator|Placebo Group|Administration of 4g of corn starch colored with chlorophyll, per day, for 2 months and then after the washout period (2 months) the groups will be crossed and will receive the same amount of sulfarophane as the treatment group.
89109167|NCT04604522||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of blood samples and 6 brushings of the airway during SOC bronchoscopy. Patients' medical records are also reviewed for data collection.
89109168|NCT04590664|Experimental|Treatment (verteporfin)|Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89109169|NCT04585477|Experimental|Cohort 1 minimal residue disease positive(MRD+)|"Subjects with detectable ctDNA (MRD+) will receive up to 12 cycles of durvalumab (1500mg dose by intravenous (by vein) injection every 28 days). ctDNA will be re checked following 2 cycles (8 weeks) of durvalumab and compared to baseline levels. In the absence of progression or toxicity after 2 cycles, subject will continue with durvalumab to complete 1 year of treatment about 10 additional cycles).~Subjects will be monitored for secondary endpoints of progression free survival (PFS) and overall survival (OS)."
89109170|NCT04585477|Active Comparator|Cohort 2 minimal residue disease negative (MRD-)|Subjects with undetectable ctDNA (MRD) will receive Standard of care and no treatment
89109171|NCT04568044||Group A: Mild to moderate COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with mild to moderate illness.~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
89109172|NCT04568044||Group B: Severe to critical COVID-19 (non-pregnant)|"Current male or female COVID-19 infected (age 18-60 years old) with severe to critical illness.~Blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
89109173|NCT04568044||Group C: Controls (non-pregnant)|"Male of female uninfected (age 18-60 years old) who have no history of COVID-19 symptoms or illness.~A blood sample will be taken on 1 day and at 1 time point."
89109174|NCT04568044||Group D: Pregnant or postnatal with COVID-19|"Current pregnant or postnatal COVID-19 infected (age 18-50 years old) Pregnant or postnatal who were diagnosed with COVID-19 less than 8 months previously (age 18-50 years old). Singleton pregnancies only.~For most participants in this group, blood samples will be taken between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months).~However, for pregnant women admitted to hospital with severe COVID-19, we will aim to collect earlier timepoints (day 1-3, day 5-7 and then day 7-14). Thereafter, we will follow the above mentioned the long-term schedule (i.e. 1, 4, 8, 12 months)."
89109175|NCT04568044||Group E: Pregnant or postnatal with influenza|"Current pregnant or postnatal influenza infected (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months)."
89228869|NCT00767585||B|70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
89109176|NCT04568044||Group F: Pregnant and have received the influenza vaccine|"Current pregnant and due to receive the influenza vaccine (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
89109177|NCT04568044||Group G: SARS-CoV-2 vaccinated pregnant/postnatal women|"Current pregnant or postnatal (within 6 weeks of birth) and due to receive the SARS-CoV-2 vaccine (age 18-50 years old). Singleton pregnancies only.~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
89109178|NCT04568044||Group H: SARS-CoV-2 vaccinated non-pregnant women|"Non-pregnant and due to receive the SARS-CoV-2 vaccine (age 18-50 years old).~Blood samples over 12 months and 6 time points (i.e. Before the vaccine, 7-14 days after the vaccine, then at 1, 4, 8, 12 months post vaccine)."
89109179|NCT04566445|Experimental|GT005 Medium Dose|Approximately 83 subjects are planned, with subjects randomised to GT005 Medium Dose.
89109180|NCT04566445|Experimental|GT005 High Dose|Approximately 83 subjects are planned, with subjects randomised to GT005 High Dose.
89109181|NCT04566445|No Intervention|Untreated control|Approximately 83 subjects are planned, with subjects randomised to untreated control.
89109182|NCT04563026|Experimental|DUR-928 (larsucosterol, 30 mg)|
89109183|NCT04563026|Experimental|DUR-928 (larsucosterol, 90 mg)|
89109184|NCT04563026|Placebo Comparator|(Placebo) Sterile Water for Injection|
89109185|NCT04550104|Active Comparator|Radiotherapy only|
89109186|NCT04550104|Experimental|Olaparib + radiotherapy|
89109187|NCT04550104|Experimental|AZD1390 + radiotherapy|
89109188|NCT04550104|Experimental|Ceralasertib (AZD6738) + radiotherapy + Consolidation durvalumab|This study arm will include up to 12 months of consolidation durvalumab for eligible participants following the completion of radiotherapy +/- DDRi.
89109189|NCT04550104|Experimental|AZD5305 + radiotherapy + Consolidation durvalumab|This study arm will include up to 12 months of consolidation durvalumab for eligible participants following the completion of radiotherapy +/- DDRi.
89109190|NCT04550104|Active Comparator|RT + consolidation durvalumab|
89109191|NCT04550104|Experimental|Arm D - did not proceed|Arm D - did not proceed
89109192|NCT04549571|Experimental|Arm I: (iCanDecide - ESE)|Patients utilize the iCanDecide - ESE website, then undergo surgery within 5 weeks of registration. Patients may also participate in an audio-recorded phone interview over 20 minutes at 9-12 months post registration.
89109193|NCT04549571|Active Comparator|Arm II: (iCanDecide - S)|Patients utilize the iCanDecide - S website, then undergo surgery within 5 weeks of registration. Patients may also participate in an audio-recorded phone interview over 20 minutes at 9-12 months post registration.
89109194|NCT04549571|Experimental|Clinics 1-5: (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 1-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
89109195|NCT04549571|Experimental|Clinics 6-8 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 10-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
89109196|NCT04549571|Experimental|Clinics 9-11 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 20-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
89109197|NCT04549571|Experimental|Clinics 12-14 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 30-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
89109198|NCT04549571|Experimental|Clinics 15-17 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 40-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
89109199|NCT04549571|Experimental|Clinics 18-20 (CDB)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and utilize the CDB over weeks 50-60. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
89109200|NCT04549571|Active Comparator|Clinics 21-25 (usual care)|Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and continue to provide breast cancer surgical care per their usual care. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
89109201|NCT04546542||pSS patients under Hydroxychloroquine (HCQ) 2016-AAO dose|Patients under Hydroxychloroquine (HCQ) 2016-American Academy of ophtalmology (AAO) dose will have HCQ blood levels, disease activity and adherence evaltuated at study entry and before 3 and 6-months.
89109202|NCT04541212||Cohort A|Prospective
89109203|NCT04541212||Cohort B|Retrospective/Prospective
89109204|NCT04541173|Active Comparator|Arm A|TARE alone
89109205|NCT04541173|Experimental|Arm B|TARE then Bevacizumab and Atezolizumab
89109206|NCT04537286|Experimental|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
89109207|NCT04520139|Experimental|Phase 1 Dose Escalation|Patients will receive NAC beginning at Cohort 1. If, at a given dose, none of the 3 patients shows a dose-limiting toxicity during the first cycle of PBT, then the dose is escalated 1 step for subsequent subjects. If, at a given dose, only 1 of 3 shows a dose-limiting toxicity, then up to 3 additional participants will be enrolled at that dose.If, at a given dose, the first 2, or any 2 of 3 subjects show a dose-limiting toxicity, then the dose will be de-escalated 1 step for future participants. At a dose where enrollment is expanded to between 4 and 6, if only 1 of 6 subjects shows a dose-limiting toxicity, then the dose will be escalated 1 step for future participants. However, if 2 or more of 4, 5, or 6participants show a dose-limiting toxicity, then the dose will be reduced one step for future participants. The maximum tolerated dose is defined as the highest dose not requiring deescalation. This is the dose to be used for the NAC arm of Phase II study.
89109208|NCT04520139|Experimental|Phase 2 Dose Expansion|Patients will be randomized to receive NAC at the maximum tolerated dose or placebo.
89109209|NCT04518449||SMA group|the medial border along the left side of superior mesenteric artery (SMA)
89109210|NCT04518449||SMV group|the medial border along the left side of superior mesenteric vein (SMV)
89109211|NCT04514029|Experimental|Simvastatin and Dexamethasone|Simvastatin 40 mg/day will be started at least 5 days prior to apheresis and will be continued until day +30 after infusion. Intrathecal dexamethasone 8 mg will be administered on days (related to CAR-T infusion) -1, +6, +13, (+/- 2 days).
89109212|NCT04492293|Experimental|ICP-192|ICP-192
89109213|NCT04479683|Other|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
89109214|NCT04479683|Experimental|FTH (full-time hospitalisation) then day hospitalization)|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
89109215|NCT04471844|Experimental|Optune® + RT + TMZ for 6 weeks|Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression or 24 months.
89109216|NCT04471844|Active Comparator|RT +TMZ for 6 weeks|RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression or 24 months.
89109217|NCT04458116|Experimental|Tumeric Group|participants will receive capsules containing 1.5 grams of turmeric 95% curcumin
89109218|NCT04458116|Placebo Comparator|Placebo Group.|will receive capsules containing corn starch.
89109219|NCT04441580|Experimental|Artificial intelligence arm|Patients undergoing colonoscopy with artificial intelligence.
89109220|NCT04441580|Active Comparator|standard colonoscopy arm|Patients undergoing colonoscopy with standard colonscopy
89109221|NCT04437368|Experimental|Part 1 - GT005 Low Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 Low Dose.
89109222|NCT04437368|Experimental|Part 1 - GT005 High Dose|Approximately 25 subjects are planned, with subjects randomised to GT005 High Dose.
89109223|NCT04437368|No Intervention|Part 1 - Untreated control|Approximately 25 subjects are planned, with subjects randomised to untreated control.
89109224|NCT04437368|Experimental|Part 2 - GT005 Low Dose|Approximately 116 subjects are planned, with subjects randomised to Part 2 - GT005 Low Dose.
89109225|NCT04437368|No Intervention|Part 2 - Untreated control|Approximately 54 subjects are planned, with subjects randomised to untreated control.
89109226|NCT04421261||Air-Q Self Pressurized Airway Device with Blocker|
89109227|NCT04421261||Proseal Laryngeal Mask Airway|
89109228|NCT04411758|Placebo Comparator|Placebo Group|Patients will receive 4 capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months
89109229|NCT04411758|Experimental|Propolis Group|Patients will receive 4 capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months
89109230|NCT04378647|Active Comparator|Induction ESHAP|3 Cycles ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4]
89109231|NCT04378647|Experimental|Induction BV-ESHAP|3 Cycles of Brentuximab VEedotin + ESHAP ( 21 days) : Etoposide [40 mg/m2/ day IV, D1-4], Solumedrol [250 mg/day IV, D1-4], High dose Ara-C [2 g/m2 IV, D5] Cisplatinum [25 mg/m2/day IV, D1-4] Brentuximab Vedotin [1.8 mg/kg IV, D1]
89109232|NCT04378439|Active Comparator|intervention group|7 community health leaders; 56 social network members
89109233|NCT04378439|Active Comparator|delayed-intervention|7 community health leaders; 56 social network members
89228870|NCT00767585||C|70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
89228871|NCT00767585||D|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
89109234|NCT04364165|Experimental|Standard of care messaging|On mobile clinic days randomized to standard of care messaging, participants will receive standard invitation cards distributed at the Tutu Tester containing basic information encouraging HIV testing. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the standard invitation card and share a brief script including the standard Tutu Tester message that free HIV testing is available at the Tutu Tester, with no further information or motivation to test.
89109235|NCT04364165|Experimental|U=U messaging|On mobile clinic days randomized to U=U messaging, participants will receive the U=U invitation cards distributed at the Tutu Tester that will seek to assuage the fears of testing HIV positive by conveying the message that HIV treatment makes it possible for HIV positive people to be untransmittable and to live normal lives. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the U=U invitation card and share a brief script asking people if they knew they could control HIV and that pills exist that can keep them healthy and ensure they don't transmit the virus to their sex partners, and that free HIV testing is available at the Tutu Tester.
89109236|NCT04336644|Experimental|Continuous patch monitoring system|-Participants will receive standard of care treatment with either arsenic trioxide, ribociclib, or capecitabine. They will have continuous patch monitor system (BodyGuardian Mini Plus) applied on or prior to the first day of therapy and will receive at least 5 ECGs for comparison during the first 30 days of treatment.
89109237|NCT04326504||Patients starting DTG-based regimens|ART-naïve patients, starting cART regimens based on DTG
89109238|NCT04326504||Switch cohort|Patients on stable ART regimens switching to DTG (any reason)
89109239|NCT04326504||Therapy failure|ART-experienced patients switching to DTG-containing regimens due to virological failure
89109240|NCT04326504||Non-DTG group|Patients who started a non-DTG containing regimen
89109241|NCT04325282|Experimental|Children with BECTS|Children will receive sham and active rTMS on 2 separate study visits separated by at least 1 week.
89109242|NCT04317664|No Intervention|Control Group|The Control Group will have the in-vehicle device installed in the teen's car, but all feedback features will be disabled.
89109243|NCT04317664|Experimental|Feedback Only Group|The Feedback Only Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens can review their driving data. Teens will also receive biweekly cumulative driving reports.
89109244|NCT04317664|Experimental|Feedback and Parent Communication Group|The Feedback and Parent Communication Group will have the in-vehicle devices in the teen's car and download the smartphone app on the teen's smartphone. Researchers will provide instructions on how teens and parents can review their driving data. The parent will also receive communication training on how to motivate their teen to adopt safe driving habits via online modules and a video call with a motivational interviewing professional. A second booster session will also occur two months after the initial training. Both teens and parents will receive a biweekly cumulative driving report.
89109245|NCT04314544|Experimental|Arm A|
89109246|NCT04314544|Placebo Comparator|Arm B|
89228872|NCT00767585||E|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
89109247|NCT04306315|Experimental|Brodalumab 210 mg + brodalumab 70 mg add-on* (adjusted brodalumab dosing regimen)|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. *Participants not fulfilling a predefined response at any visit with efficacy assessments after Week 16 will receive a dose adjustment to 280 mg brodalumab every 2 weeks.
89109248|NCT04306315|Placebo Comparator|Brodalumab 210 mg + placebo add-on* (standard brodalumab treatment)|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. *Participants not fulfilling a predefined response at any time visit with efficacy assessments Week 16 will receive a dose adjustment to 210 mg brodalumab + placebo every 2 weeks.
89109249|NCT04280458|Experimental|Intervention group|patients will receive intensive care of rehabilitation of psychomotor
89109250|NCT04280458|Active Comparator|Control group|patients will receive standard care
89109251|NCT04267887|Experimental|Treatment (apalutamide, abiraterone acetate, prednisone, ADT)|Patients receive apalutamide PO QD, abiraterone acetate PO QD, and prednisone PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive androgen deprivation therapy per standard of care. Patients undergo CT scan, bone scan and blood sample collection throughout the study.
89109252|NCT04267198|Active Comparator|Massed Intention Treatment (massed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 3 weeks.
89109253|NCT04267198|Active Comparator|Distributed Intention Treatment (distributed-INT)|Participants will receive 30 hours of Intention Treatment (INT) over 12 weeks.
89109254|NCT04227405|No Intervention|Control group|Control group of couples will receive no intervention
89109255|NCT04227405|Experimental|Intervention|Intervention group of couples received the intervention: case management (connection to community services), 20 hour pscycho-educational workshop on communication, conflict resolution, problem-solving, stress management, and financial management, booster session, and employment support services if needed
89109256|NCT04175327||CardioCel group|Patients who require repair of cardiac and vascular defects including intracardiac defects; septal defects, valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing
89109257|NCT04174105|Experimental|Initial Dose Cohort|3x10^13 vg/kg of AT845 administered via intravenous infusion
89109258|NCT04174105|Experimental|Second Dose Cohort|6x10^13 vg/kg of AT845 administered via intravenous infusion
89109259|NCT04174105|Experimental|Third Dose Cohort|1x10^14 vg/kg of AT845 administered via intravenous infusion
89109260|NCT04171219|Experimental|Treatment (talabostat, pembrolizumab)|Patients receive talabostat PO BID on days 1-14 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89109261|NCT04159415|Experimental|Treatment A|
89109262|NCT04159415|Experimental|Treatment B|
89109263|NCT04151199|No Intervention|No Intervention Control|The control group is randomized but does not participate in the intervention but does complete the acute test and biospecimen collection following the intervention period.
89109264|NCT04151199|Active Comparator|Endurance Exercise|Participants randomized to EE participate in the intervention and complete the acute test and biospecimen collection following the intervention period.
89109265|NCT04151199|No Intervention|Cross Sectional HA|Do not participate in intervention after single acute exercise test of Endurance Exercise.
89109266|NCT04151199|No Intervention|Cross Sectional LA|Do not participate in intervention after single acute exercise test of Endurance Exercise.
89109267|NCT04148430|Experimental|Arm 1 (CART Cell Group)|"Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days.~Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days"
89109268|NCT04137159|Experimental|FES rowing|Exercise training sessions will be performed 3 times per week for 12 weeks. The initial training sessions will include 6 sets of FES-rowing for 5 min at 60% of VO2 peak with a work-to-rest ratio of 2:1. Participants unable to row continuously for 5 min will row for 2-4 min with 30-second breaks incorporated until they achieve sets totaling 30 min. The goal is for each volunteer to achieve an exercise intensity of 70-85% maintained for a continuous 30-40 min performed 3 times each week.
89109269|NCT04137159|No Intervention|Wait list|During the 12-week treatment as usual program, subjects will not participate in FES-rowing.
89109270|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)|
89109271|NCT04126200|Experimental|Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)|
89109272|NCT04126200|Experimental|Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)|
89109273|NCT04126200|Experimental|Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)|
89109274|NCT04126200|Experimental|Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)|
89109275|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)|
89109276|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)|
89109277|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 8)|This cohort will enroll Northeast Asian participants.
89109278|NCT04126200|Active Comparator|Belantamab mafodotin monotherapy cohort expansion|
89109279|NCT04126200|Experimental|Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)|
89109280|NCT04126200|Experimental|Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)|
89109281|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat cohort expansion (Sub-study 3)|
89109282|NCT04126200|Experimental|Belantamab mafodotin+ dostarlimab cohort expansion (Sub-study 4)|
89109283|NCT04126200|Experimental|Belantamab mafodotin+ isatuximab cohort expansion (Sub-study 5)|
89109284|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)|
89109285|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)|
89109286|NCT04126200|Experimental|Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 8)|This cohort will enroll Northeast Asian participants.
89109287|NCT04104022|No Intervention|OAT as usual|Those randomized to OAT as usual will continue to receive standard buprenorphine or methadone treatment and complete assessments of PTSD symptom severity, psychosocial functioning and drug use at intake and Study Weeks 4, 8, and 12.
89109288|NCT04104022|Active Comparator|OAT+PET|In addition to receiving OAT and completing monthly assessments, OAT+PET participants will receive 12 weekly PET sessions with a trained therapist.
89109289|NCT04104022|Experimental|OAT+PET+|OAT+PET+ participants will receive the procedures for the OAT+PET group plus monetary incentives contingent upon completion of PET sessions
89109290|NCT04100135|Experimental|Test Arm|Device PFO closure with the GORE® CARDIOFORM Septal Occluder
89109291|NCT04100135|Sham Comparator|Control Arm|Sham device PFO closure (PFO not closed)
89228873|NCT00767585||F|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
89109292|NCT04094688|Experimental|Arm I (bevacizumab, chemotherapy, high-dose vitamin D3)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV on days 1-3 or irinotecan hydrochloride IV on day 1, leucovorin calcium IV over 90 minutes on day 1, and fluorouracil IV on days 1-3. Patients also receive high-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
89109293|NCT04094688|Active Comparator|Arm II (bevacizumab, chemotherapy, standard-dose vitamin D3)|Patients receive bevacizumab and chemotherapy as in Arm I. Patients also receive standard-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
89109294|NCT04088630|Experimental|Fingolimod Group|In addition to Standard of care treatment, those participants randomized to the fingolimod group will receive a single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset.
89109295|NCT04088630|Placebo Comparator|Control Group|In addition to Standard of care treatment, those participants randomized to the control group will receive a single dose placebo pill within 24 hours of symptom onset
89228874|NCT00767585||G|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
89228875|NCT00767585||H|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
89228876|NCT00767663|Experimental|1|dipyridamole
89228877|NCT00767663|Placebo Comparator|2|placebo
89228878|NCT00767741|Experimental|with treatment|
89228879|NCT00763217||stroke patient cohort|Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
89228880|NCT00763295||HIV infection|
89228881|NCT00402688|Active Comparator|001|levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
89228882|NCT00402688|Active Comparator|002|levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
89228883|NCT00402688|Active Comparator|003|levofloxacin 500mg tablet once daily for 4 weeks.
89228884|NCT04049045|Active Comparator|Verum arm|25 mg tablet of empagliflozin once daily for five days
89228885|NCT04049045|Placebo Comparator|Placebo arm|one tablet of the matching Placebo once daily for five days
89228886|NCT00763373||1|Observation group
89228887|NCT00763373||2|Intervention group
89228888|NCT00760799|Active Comparator|1|Standard discectomy without anular repair
89228889|NCT00760799|Experimental|2|Standard Discectomy with anular repair
89228890|NCT01035580|Experimental|curcurim|This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.
89228891|NCT03993730|Other|Device Implantation|A prospective, blocked, randomised, controlled trial of primary prophylaxis ICD therapy or ILR insertion in patients with LVEF <45% and LGE on CMR.
89228892|NCT03993730|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF <45% and no LGE on CMR.
89109296|NCT04077736|Experimental|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
89109297|NCT04053842|Experimental|Multi-modality prostate cancer imaging|The study requires eligible patients to complete one imaging session at St. Joseph's Health Care to begin within 6 weeks of the scheduled Radical Prostatectomy. Imaging will consist of simultaneous multiparametric MRI (mpMRI), sodium MRI and positron emission tomography (PET) with a radio-labeled probe for prostate-specific membrane antigen (PSMA).
89228893|NCT01041586|Experimental|BTVA|
89228894|NCT00671879|Experimental|Carisprodol SR 700 mg|Carisoprodol 700 mg twice daily
89109298|NCT04053361|Active Comparator|Group A: Clinical ablation|"Cinical arrhythmia is fairly documented AF, pulmonary vein isolation will be performed. If AF persists after this step, electrical cardioversion will be performed.~If clinical arrhythmia is fairly documented type 1 AFL, cavo-tricuspid isthmus ablation will be performed.~If clinical arrhythmia is AT, it will be induced (if not persistent), identified by means of activation and/or entrainment mapping, and ablated.~If clinical arrhythmia is AT that is non-inducible during EP study, no ablation will be done.~If other incidental (or induced) AT is observed that can be qualified as non-clinical it will not be targeted unless considered important to ablate at discretion of operator.~No induction protocols for other, on top of already ablated, arrhythmias will be attempted."
89228895|NCT00671879|Experimental|Carisoprodol SR 500mg|Carisoprodol SR 500 mg twice daily
89228896|NCT00671879|Placebo Comparator|Placebo|Placebo
89228897|NCT01039168|Active Comparator|Workplace dialogue|Clinical examination and dialogue with supervisor to find solutions to reduce job-person mismatch and facilitate return to work
89228898|NCT01039168|Sham Comparator|Care as usual|No intervention besides of the care as usual being available for the patient
89523212|NCT03712267|Experimental|Electronic Media Enhanced|Research assistants will collect information on participants' electronic messaging behavior and content and provide that for use to participants' clinicians.
89523213|NCT03712267|Placebo Comparator|Treatment As Usual|Participants will not have their electronic messaging reviewed prior to their typically scheduled clinical appointments.
89109299|NCT04053361|Experimental|Group B: Clinical plus substrate-based ablation|"- The initial ablation steps will be identical to those in patients from Group A.~Supplemental ablation will consist of:~Empirical lesion set within right atrium: superior vena cava isolation, posteroseptal bicaval line, and cavo-tricuspid isthmus ablation (if not already ablated)~AND~Homogenization of low-voltage zones (if any) in left / right atrium defined by bipolar voltage <0.5 mV in sinus rhythm or <0.2 mV in AF / AT. The threshold can be adapted in severely diseased atria to delineate reasonably smaller zones (<20% of atrial surface) achievable to ablate.~Arrhythmia induction protocol by10-second burst atrial pacing with cycle length of 300 ms decremented by 10 ms up to atrial refractoriness or cycle length of 200 ms.~Inducible ATs will be mapped and ablated if feasible. In case of inducible persistent (>5 min) AF, pulmonary vein isolation will be performed if not previously done as per protocol."
89109300|NCT04040673||Normal benign|participants with normal benign nodules (no cancer)
89109301|NCT04040673||Follicular thyroid cancer|participants with follicular thyroid cancer
89109302|NCT04040673||Papillary thyroid cancer|participants with papillary thyroid cancer
89109303|NCT04040673||Anaplastic thyroid cancer|participants with anaplastic thyroid cancer
89109304|NCT04040673||Medullary thyroid cancer|participants with medullary thyroid cancer
89109305|NCT04010344|Experimental|Enhanced Usual Care Group|All participants in the enhanced usual care arm must own a cell phone with at least short message service (SMS) and voicemail. To control for attention exposure, they will receive SMS messages daily dealing with healthy lifestyle behaviors (smoking, diet, physical activity) but not with medication adherence or hypertension-specific issues. Every three days (comparable to intervention group monitoring) they will receive an automated SMS directing them to a different 2-3 min video/YouTube™ clips on healthy lifestyles. Patients in this arm of the study will also receive usual care as determined by their providers. Usual care is described in the next section.
89109306|NCT04010344|Active Comparator|Usual Care|Patients in this arm of the study will receive usual care as determined by their providers. Usual care in the region typically involves at least one visit every 2-3 months for review of adherence to treatment, blood pressure control, and prescriptions for medication refills. Similar to the intervention group, participants will have a total of three follow-up visits which will be separate from their regular appointments during which study outcomes will be assessed.
89109307|NCT04003805|Experimental|Switching from Smoking Cigarettes to SREC|
89109308|NCT04003805|Experimental|Switching from Smoking Cigarettes to Nicotine Mini-Lozenge|
89109309|NCT04003805|No Intervention|Usual Brand Cigarettes|
89109310|NCT04001634||Dual anti-HER2 group|Dual anti-HER2 therapy (lapatinib and trastuzumab) plus chemotherapy
89109311|NCT03998735|Experimental|Group 1 (N=15)|160 µg/g herbal snuff, median level found in commercial moist snuff
89109312|NCT03998735|Experimental|Group 2 (N=15)|70 µg/g herbal snuff, lowest level found in commercial moist snuff (rounded)
89109313|NCT03998735|Experimental|Group 3 (N=15)|3.5 µg/g herbal snuff, 5% of the lowest level found in commercial moist snuff
89109314|NCT03998735|Active Comparator|Group 4(N=10)|0 µg/g herbal snuff, control group will use unmodified herbal snuff
89109315|NCT03983850|No Intervention|Donor Arm|Collection of bone marrow and/or PBSC (Up to 40 donors)
89109316|NCT03983850|Experimental|Phase I Dose De-escalation|PTCy at de-escalating doses (25 mg/kg/day on days +3 and +4, and PTCy 25 mg/kg on day +4) to assess for safety and determine Phase II dose (up to 12 evaluable patients)
89109317|NCT03983850|Experimental|Phase I duration de-escalation of MMF|MMF at de-escalating duration (days +5 to +18 only, no MMF))
89109318|NCT03983850|Experimental|Phase I Pilot for Comparative Data|Standard PTCy 50 mg/kg/day on days +3 and +4, in a small pilot (up to 5 evaluable patients) for comparative data
89523214|NCT03384485|Other|antiphospholipid syndrome|blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease
89109319|NCT03983850|Experimental|Phase II Efficacy|PTCy at shortest duration, safe dose (from Phase I) to assess efficacy at providing adequate protection from grade 3-4 acute GVHD (up to 14 additional patients)
89109320|NCT03983850|Experimental|Phase II efficacy of reduced duration MMF|MMF at duration identified from de-escalation evaluation.
89109321|NCT03960827|No Intervention|Sedentary control|The control group does not engage in any acute exercise testing protocol, but biospecimens are collected prior to and following a period of rest.
89109322|NCT03960827|Active Comparator|Sedentary EE|Participants randomized to EE first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
89109323|NCT03960827|Active Comparator|Sedentary RE|Participants randomized to RE first engage in a single acute exercise test of Resistance Exerciser, consistent with their random assignment.
89109324|NCT03960827|No Intervention|Highly Active EE|A comparison group of highly active EE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Endurance Exerciser (HAEE) participants are tested on a cycle ergometer.
89109325|NCT03960827|No Intervention|Highly Active RE|A comparison group of highly active RE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Resistance Exerciser (HARE) participants are tested via a bout of resistance exercise.
89109326|NCT03946423|Experimental|Sleeve Gastrectomy & Lifestyle Intervention|
89109327|NCT03946423|Active Comparator|Lifestyle Intervention|
89109328|NCT03899987|Experimental|Arm I (aspirin, interferon alpha, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7. Patients also receive recombinant interferon alfa-2b IV over 20 minutes and rintatolimod IV over 2 hours on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24..
89109329|NCT03899987|Experimental|Arm II (aspirin, rintatolimod, surgery)|Patients receive aspirin PO BID on days -7 to 7 and rintatolimod IV over 2 hours on days 1-3,and 8-10 in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy on or between day 17-24.
89109330|NCT03899987|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy about 4 weeks after enrollment.
89109331|NCT03894410||Continuing Lapatinib|Patients continued using treatment containing Lapatinib after progression on Lapatinib.
89109332|NCT03894410||Change HER-2 treatment|Patients changed to another HER-2 targeted treatment after progression on Lapatinib (ado-trastuzumab emtansine, trastuzumab, etc.).
89109333|NCT03894410||Lapatinib plus capetabine|Patients used lapatinib plus capetabine.
89109334|NCT03894410||Lapatinib plus Trastuzumab and one chemotherapy|Patients used lapatinib plus trastuzumab and one chemo regimen.
89109335|NCT03889912|Experimental|Cemiplimab|Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion. After completion of the above, three additional cohorts (A, B and C) of patients will be evaluated. Cohorts D, E, F, G may open after completion of Cohort B.
89109336|NCT03875235|Experimental|Treatment Arm|Durvalumab + Gemcitabine + Cisplatin
89109337|NCT03875235|Placebo Comparator|Placebo Arm|Placebo + Gemcitabine + Cisplatin
89109338|NCT03863197|Experimental|Intervention group|During a 12-week period children receive 3-4 sessions of progressive strength training per week on top of the usual care. All children will be provided with an individualized training program and supporting equipment. One or 2 session per week will be performed under supervision of the physical therapist, whilst the remaining sessions will be performed at home. Progression is closely monitored by the principal investigator and training programs are adjusted if necessary.
89109339|NCT03863197|No Intervention|Waitlist-control group|The waitlist-control group will continue their usual care without additional treatment for 12-weeks, followed by a 12-week period of progressive supervised home-based strength training.
89109340|NCT03862859|Active Comparator|Treatment with Warfarin|Warfarin with dosing targeting an international normalized ratio of 2-3.
89109341|NCT03862859|No Intervention|No treatment|No treatment
89109342|NCT03858231|Active Comparator|Opioid|
89109343|NCT03858231|Active Comparator|Non-opioid|
89109344|NCT03841058|Active Comparator|Abaloparatide|Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
89109345|NCT03841058|Placebo Comparator|Placebo|Placebo administered subcutaneously with a pen once daily for 6 months
89109346|NCT03836287|Experimental|Active|Sofpironium bromide, 15% gel, once per day
89109347|NCT03836287|Placebo Comparator|Vehicle|Vehicle gel, once per day
89109348|NCT03829072|Experimental|cooking Education and adapted physical activity|
89109349|NCT03828994|Experimental|TECH-PN|Participants receive community health nurse visits, text-messaging support, additional testing and field based visits with a nurse practitioner.
89109350|NCT03828994|No Intervention|TECH-N|Participants receive enhanced standard of care with community health nurse visits and text-messaging support.
89109351|NCT03824522||All Study Participants|Participants who are newly prescribed with Adynovate and participants previously treated with Adynovate will be treated with ADYNOVATE for hemophilia A at the time of enrollment according to a regimen determined by the study site treating physician.
89109352|NCT03801213|Active Comparator|Urinary catheterization|
89109353|NCT03801213|Experimental|manual bladder stimulation Technique|
89109354|NCT03784755|Active Comparator|Arm 1 (standard of care)|"Standard systemic therapy~+ Ablative therapy to untreated prostate primary for patients with low volume metastatic disease burden"
89228899|NCT00770393|Experimental|1|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging.
89228900|NCT00770393|Active Comparator|2|Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
89228901|NCT03994276|Placebo Comparator|Phase 1: Control|oral glucose tolerance test (OGTT): 58g Dextrose in 330ml water
89228902|NCT03994276|Active Comparator|Phase1: Chickpea Control|"sub-cellular Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring"
89228903|NCT03994276|Experimental|Phase1: Chickpea Powder|Chickpea powder: 58g total available carbohydrate, provided as 50g from chickpea powder + 8g from chocolate flavouring
89228904|NCT03994276|Active Comparator|Phase 2: Control|Wheat bread: breakfast consisting of a 100% wheat bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
89228905|NCT03994276|Experimental|Phase 2: 30%Chickpea Powder|Wheat bread: breakfast consisting of a 70% wheat / 30% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
89228906|NCT03994276|Experimental|Phase 2: 60%Chickpea Powder|Wheat bread: breakfast consisting of a 40% wheat / 60% Chickpea powder bread roll containing 54g available carbohydrate + 20g diabetic strawberry jam containing 2g sugar + 360ml water
89228907|NCT01036048||cabg disease|pts with saphenous vein graft disease
89228912|NCT00767975|No Intervention|2|For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm.
89228913|NCT00767975|Experimental|1|Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness
89228914|NCT00768131|Experimental|A1 FISH (+)|
89228915|NCT00768131|Active Comparator|B1 FISH (+)|
89228916|NCT00768131|Experimental|A2 FISH (-)|
89228917|NCT00768131|Active Comparator|B2 FISH (-)|
89228918|NCT00401830|Placebo Comparator|Placebo|
89228919|NCT00401830|Experimental|Lacosamide|Lacosamide Tablet 400mg daily
89228920|NCT00768209|Experimental|Treatment A|
89228921|NCT02557685|No Intervention|Fecal Microbiota Translantation|After completing at least 10 days course of antibiotic treatment for C. difficile infection, subjects will receive Fecal Microbiota transplantation with a 300 mL fecal suspension delivered via sigmoidoscopy.
89228922|NCT00768365||group 1|patients with adrenal incidentaloma
89228923|NCT00768365||group 2|Thirty-five subjects comparable for sex, age, and BMI were enrolled as a control group (group 2).
89228924|NCT00768365||group 3|The other control group (group 3) of 35 healthy individuals matched for sex, age, BMI, metabolic syndrome criteria, cardiovascular risk parameters, menopausal status, smoking status, consumption of alcohol, usage of antihypertensive drugs, insulin or oral hypoglycaemic agents to perform a 1:1 case-control analysis.
89228925|NCT04048967|Experimental|Intervention|Preschool staffs will participate in 50 hours of professional development over 7 months focused on promotion of physical activity in the preschool setting. Staffs and investigators will work together to develop models to ensure children receive 60 minutes per day of moderate-to-vigorous physical activity, 90 minutes per week of motor challenging physical activity, 90 minutes per week of cognitively engaging games/play, and 90 minutes per week of physically active learning.
89228926|NCT04048967|No Intervention|Control|Staffs receive no professional development and children will receive standard care.
89228927|NCT00770471|Experimental|Dose Escalation|
89228928|NCT01039324|Experimental|Intermediate Intervention (arm #1)|Care transition reports sent to primary care clinics, care transition letters sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
89228929|NCT01039324|Experimental|Full Intervention (arm #2)|E-mail notices sent to care managers about care transitions plus care transition reports sent to primary care clinics, care transition reports sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
89228930|NCT01039324|Experimental|Control (arm #3)|"Subjects assigned to the control group will receive usual care which is the standard of care coordination currently existent between patients, providers and care managers."
89228931|NCT00539240|Placebo Comparator|Rabeprazole morning/evening placebo bedtime|AciPhex 20 mg BID and once daily placebo
89228932|NCT00539240|Placebo Comparator|Rabeprazole breakfast, placebo dinner and bedtime|AcipHex 20 mg once daily and BID placebo
89228933|NCT00539240|Active Comparator|Rabeprazole breakfast, placebo dinner, nortriptyline bedtime|AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
89228934|NCT00770627|Placebo Comparator|Placebo caps|
89228935|NCT00770627|Active Comparator|Omega 3 caps|
89228936|NCT00417976|Experimental|Bevacizumab|
89228937|NCT00770705|Experimental|1|Group receiving phenoxybenzamine
89228938|NCT00770705|Other|2|Historical control
89109355|NCT03784755|Experimental|Arm 2 (standard systemic therapy + ablative therapy))|"Local Ablative therapy to all sites of disease (including untreated prostate primary)~+ Standard systemic therapy"
89109356|NCT03769441|Active Comparator|Ferric(III) carboxymaltose|The intervention group will be treated with four dosages of 500 mg iron in the form of 10 mL ferric(III) carboxymaltose dissolved in 240 mL of NaCl 0.9%, with interval periods of six weeks.
89109357|NCT03769441|Placebo Comparator|Placebo|The placebo-controlled group will receive four dosages of 250 mL of NaCl 0.9% solution with interval periods of six weeks.
89109358|NCT03769155|Experimental|A (VX15/2503, nivolumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes and nivolumab IV over 30 minutes on days 1 and 21 and undergo surgery between days 35-49.
89109359|NCT03769155|Experimental|B (VX15/2503, ipilimumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes and ipilimumab IV over 30 minutes on days 1 and 21 and undergo surgery between days 35-49.
89109360|NCT03769155|Experimental|C (VX15/2503, nivolumab, ipilimumab, surgery)|Participants receive VX15/2503 (pepinemab) IV over 60 minutes, nivolumab IV over 30 minutes, and ipilimumab IV over 30 minutes on days 1 and 21 and undergo between days 35-49.
89109361|NCT03769155|Experimental|D (nivolumab, surgery)|Participants receive nivolumab IV over 30 minutes on days 1 and 21 and undergo between days 35-49.
89109362|NCT03769155|Active Comparator|E (surgery)|Participants undergo surgery.
89109363|NCT03768414|Experimental|Arm I (nab-paclitaxel, cisplatin, gemcitabine hydrochloride)|Patients receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89109364|NCT03768414|Experimental|Arm II (cisplatin, gemcitabine hydrochloride)|Patients receive cisplatin IV over 60 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89109365|NCT03748420|No Intervention|Usual Care|Patients in the usual care arm receive the basic cardiovascular related clinical decision support which is considered standard of care at the organization.
89109366|NCT03748420|Experimental|Adherence Intervention|Patients in the medication adherence enhanced clinical decision support received the enhanced decision support intervention over a 6 month period. Patients were accrued over 6 months and followed for 12 months at which point they were assessed for improved medication adherence and clinical outcomes.
89109367|NCT03708432||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
89109368|NCT03707262|Experimental|Donor CD34+ and CD3+ cell infusion|"The investigational products are (1) an intravenous infusion of granulocyte colony-stimulating factor (GCSF)-mobilized, Miltenyi-enriched CD34+ cells (≥ 5 million cells per kilogram) followed by (2) an infusion of CD3+ cells (5 million cells per kilogram) from an HLA-identical sibling living donor.~The cells are infused around Day 11 post-transplant after the following pre-conditioning regimen:~5 doses of rATG (1.5 mg/kg IV per day for 5 days, starting on the day of transplant)~10 doses of TLI (120 centigray [cGY] x 10 fractions, starting the day after transplant)"
89109369|NCT03703830|Experimental|Experimental I|Cerebellar transcranial current stimulation associated with locomotor training
89109370|NCT03703830|Sham Comparator|Sham comparator I|Cerebellar transcranial current stimulation sham associated with locomotor training
89109371|NCT03703830|Experimental|Experimental II|Cerebello-spinal direct current stimulation associated with locomotor training
89109372|NCT03703830|Sham Comparator|Sham comparator II|Cerebello-spinal direct current stimulation sham associated with locomotor training
89109373|NCT03660332|Active Comparator|IL-6 infusion|Healthy young men will receive IL-6 infusion
89109374|NCT03660332|Placebo Comparator|Placebo infusion|Healthy young men will receive saline infusion
89109375|NCT03631706|Experimental|M7824|
89109376|NCT03631706|Active Comparator|Pembrolizumab|
89109377|NCT03630328|Experimental|Cogni.Q|800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
89109378|NCT03630328|Placebo Comparator|Placebo|Two capsules in the morning and two capsules in the evening for 21 days
89109379|NCT03600883|Experimental|Phase 1 Dose Exploration Part 1 monotherapy|"Cohorts with food effect and alternative dosing regimens~Enrollment into the dose exploration cohorts may be from any eligible solid tumor type. Dose escalation will begin with 2-4 subjects treated at the lowest planned dose level of 180 mg. If no DLT is observed, dose escalation will continue to the next planned dose cohort"
89109380|NCT03600883|Experimental|Phase 1 Dose Expansion Part 2 monotherapy|Upon completing the dose exploration part of the study, dose expansion may proceed with 3 groups consisting of subjects with KRAS p.G12C mutant advanced solid tumors. Dose expansion in these 3 groups may be done concurrently
89109381|NCT03600883|Experimental|Phase 1 combination arm with sotorasib and anti PD-1/L1|Additional subjects will be enrolled into the combination arm with sotorasib in combination with an anti (PD-1/L1)
89109382|NCT03600883|Experimental|Phase 1 monotherapy treatment naive advanced NSCLC|Separate cohort of part 1 dose expansion subjects to evaluate the safety and clinical activity of sotorasib administered orally once daily in subjects with previously untreated advanced non-small cell lung cancer (NSCLC). Drug-drug interaction will be evaluated in 6 of the subjects enrolled in the treatment naive cohort by adding Midazolam alone on Day -1 and in combination with sotorasib on Day 15 of Cycle 1, where each cycle is 21 days.
89109383|NCT03600883|Experimental|Phase 2 monotherapy dose comparison|Subjects with NSCLC will be enrolled in a dose comparison study evaluating safety and efficacy
89109384|NCT03600883|Experimental|Phase 1 Does escalation and Expansion monotherapy BID|BID 2L+solid tumors (fed state)
89109385|NCT03579316|Active Comparator|Arm I (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89109386|NCT03579316|Experimental|Arm II (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-21 and adavosertib PO QD on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89109387|NCT03579316|Experimental|Arm III (ceralasertib, olaparib)|Patient receive ceralasertib tablets by PO BID each day on Days 1-14. You will also take olaparib tablets by PO BID each day on Days 1-28.
89228939|NCT00991718|Experimental|A|On Day 1, subjects received a single oral dose of non-labeled GDC-0449 and a single IV tracer dose of 14C-GDC-0449.
89228940|NCT00991718|Experimental|B|On Day 1, subjects received a single oral dose of 14C-GDC-0449.
89109388|NCT03576378|Experimental|Experimental: Brentuximab vedotin plus EPEM|Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)
89109389|NCT03575832|Experimental|Supportive care (exercise, nutrition counseling)|Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.
89109390|NCT03550885|Experimental|High taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 125 mg taurine, 40% of calories from fat, 15% of calories from saturated fat, 25% of calories from protein (4:1 animal to plant grams of protein), and 11.5 grams fiber/1000 calories.
89109391|NCT03550885|Experimental|Low in taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 7 mg taurine, 36% of calories from fat, 8% of calories from saturated fat, 13% of calories from protein (3:1 plant to animal grams of protein), and 13.5 grams fiber/1000 calories.
89109392|NCT03547128||Parents with newborns recruited from 1992-5|Parents of newborns recruited from 8 Iowa hospitals in 1992-5
89109393|NCT03537534|Experimental|Experiment|Lidocaine jelly (2%) 5mL x 1 dose only
89109394|NCT03537534|Placebo Comparator|Placebo|Surgilube 5mL x 1 dose only
89109395|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the Recommended Phase 2 Dose ([RP2D], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
89109396|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
89109397|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
89109398|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
89109399|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
89109400|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
89109401|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
89109402|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
89109403|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
89109404|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
89109405|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
89109406|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
89109407|NCT03488693|Active Comparator|No Regional Radiotherapy|A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
89109408|NCT03488693|Active Comparator|Regional Radiotherapy|A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
89109409|NCT03488420||Atrial Fibrillation and/or Atrial Flutter|Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.
89109410|NCT03487926||Group 1 (IBD primary diagnosis)|Participants have active IBD
89109411|NCT03487926||Group 2( IBD + comorbid MDE)|1 [18F]FEPPA PET scan in those with IBD symptoms in the past 2 years as well present with MDE
89109412|NCT03487926||Group 3-Controls|"Matched for Level of Depressive Symptoms and Otherwise Healthy~-Subjects in an otherwise healthy state with major depressive episodes, obsessive compulsive disorder, or generalized anxiety disorder will provide psychiatric diagnosis matched controls to those with IBD. Data for group three will be largely obtained from previous recent studies (it is anticipated that 95% of this data is already available)."
89109413|NCT03462030|Experimental|Baked Milk Immunotherapy|Subjects will receive baked milk oral immunotherapy with baked non-fat cow's milk powder as the intervention. Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
89109414|NCT03462030|Placebo Comparator|Placebo|Subjects will receive oral immunotherapy with the placebo control (tapioca powder). Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
89109415|NCT03459729|Experimental|Antitumor B|ATB will be administered on an outpatient basis.
89109416|NCT03441100|Experimental|Experimental: IMA202 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.~Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2"
89109417|NCT03395392|Experimental|NRX-101|Following study enrollment and randomization, subjects will receive twice daily NRX-101
89109418|NCT03395392|Active Comparator|Lurasidone|Following study enrollment, subjects will receive twice daily lurasidone
89109419|NCT03370393|Experimental|Pathways for African-Americans' Success|Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
89109420|NCT03370393|No Intervention|Wait-list|Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
89109421|NCT03354416||1/ Cohort 1|Subjects with an increased risk of prostate cancer or a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
89109422|NCT03343197|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
89109423|NCT03343197|Experimental|AG-881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
89109424|NCT03343197|No Intervention|No Treatment Pre-Surgery|Subjects will not receive treatment prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 or AG-881.
89109425|NCT03340753|Active Comparator|KBP-5074 Capsule|KBP-5074 capsule, 0.5 mg or 1.0 mg, QD, single dose
89109426|NCT03340753|Experimental|KBP-5074 Tablet|KBP-5074 tablet, 0.5 mg or 1.0 mg, QD, single dose
89109427|NCT03331133||Identical Twins|Twins develop from one zygote with no intervention
89109428|NCT03331133||Dizygotic Twins|Twins develop from two different zygote with no intervention
89109429|NCT03318549|Other|Glaucoma group|Patients with diagnosed glaucoma will be in the group for up to 5 years.
89109430|NCT03318549|Other|Suspicious of having glaucoma group|Patients with suspicious of having glaucoma will be in the group for up to 5 years.
89109431|NCT03318549|Other|Non-glaucomatous optic neuropathies group|Patients with optic neuropathies that do not look glaucomatous-like will be in the group for up to 5 years.
89109432|NCT03318549|Other|Age-related macular degeneration (AMD) group|Patients with diagnosed age-related macular degeneration will be in the group for up to 5 years.
89109433|NCT03318549|Other|Retinal degenerations group|Patients with other retinal degenerations excluding AMD will be in the group for up to 5 years.
89109434|NCT03318549|Other|Other diseases of visual pathways group|Other diseases of the visual pathway not included in the previous groups will be in the group for up to 5 years.
89109435|NCT03318549|Other|Healthy control group|Patients labeled as healthy controls for not having any other eye diseases that would be included on the other groups will be in the group for up to 5 years.
89109436|NCT03317990|Experimental|NeuroSAFE procedure|These patients will undergo robotic radical prostatectomy with bilateral nerve spare.The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade.The tissue sample will be snap frozen and embedded in OCT.Using a cryostat, 10 micron thick slices will be placed on slides.The entire length of the area of interest will be sampled in this way generating ≈10 frozen sections per side.The slides will be stained with H&E and will be examined by a consultant pathologist.As soon as examination is complete the pathologist will telephone the operating surgeon to give the result.Presence of cancer cells at the margin of resection constitutes a positive margin and the neurovascular bundle on that side will be resected
89109437|NCT03317990|Active Comparator|Control|These patients will undergo robotic radical prostatectomy with a nerve sparing procedure based on surgical planning performed by a consultant radiologist. The mp-MRI will be reviewed by a consultant radiologist along with the details of the prostate biopsy and DRE a decision to perform unilateral, bilateral or non-nerve sparing will be established and recorded in the clinical record form (CRF) for each patient.
89109438|NCT03310632|Experimental|Antroquinonol with SOC|"Antroquinonol will first be conducted by dose escalation(200mg TID and 300mgTID) to characterize the safety of antroquinonol in combination with the standard of care (SOC) (nab-paclitaxel + gemcitabine) and to identify the MTD of antroquinonol in patients with metastatic pancreatic cancer.~At the cohort expansion part of the study, up to an additional 40 patients will be enrolled at the MTD or MFD/RD."
89109439|NCT03291847|Experimental|Buprenorphine-naloxone treated|Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
89109440|NCT03267277|Experimental|Treatment|Participants received intravenous sodium thiosulfate 16 g/m^2 three times weekly for 10 weeks
89109441|NCT03221751|Experimental|Prazosin|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
89109442|NCT03221751|Placebo Comparator|Placebo|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
89109443|NCT03194646|Experimental|A1(3/1 regimen)|2.0 mg treatment of 12 weeks, each separated by 1 bleeding break
89109444|NCT03194646|Experimental|A2(6/2 regimen)|2.0 mg treatment period of 24 weeks, each separated by 2 bleeding break
89109445|NCT03194646|Experimental|A3(3/2 regimen)|2.0 mg treatment period of 12 weeks, each separated by 2 bleeding break
89109446|NCT03194646|Other|B(Standard of care)|Standard of care as determined by the investigators, this could be watch & wait or non-hormonal medical treatment
89109447|NCT03169894|Experimental|MDGN-002|MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
89109448|NCT03149445|Experimental|Tesofensine/Metoprolol|Tesofensine + metoprolol administered once a day, in the morning with a meal
89109449|NCT03149445|Placebo Comparator|Tesofensine/Metoprolol placebo|Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal
89109450|NCT03137303|Placebo Comparator|Patient Subject Usual Care|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit. The following will be performed.~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Subjects will be advised to go to their clinics and be managed by their PCP thereafter.~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry and undergo the same spirometry protocol as the intervention group."
89109451|NCT03137303|Experimental|Patient-Subject Intervention|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit in the same building as the clinic site. The following information will be collected and procedures will be performed:~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Pre and post-bronchodilator using Albuterol (BD) spirometry"
89109452|NCT03105336|Experimental|axicabtagene ciloleucel|Participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide, followed by a single infusion of CAR transduced autologous T cells.
89109453|NCT03096093|Experimental|Immunotherapy - pancreatic cancer|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer. Treatment will run concurrently with standard chemotherapy.
89109454|NCT03096093|Experimental|Immunotherapy - other late stage cancers|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with other late stage cancers, not receiving any other standard treatment.
89109457|NCT03066531|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
89109458|NCT03066531|Active Comparator|CBT-based intervention included in Usual Care|"These programs are based on current guidelines for the long- term multi-disciplinary rehabilitation and prevention of obese patients, including Cognitive Behavioral Therapy (CBT), in a group setting, as Gold Standard.~Assigned Interventions: Behavioral: usual care (CBT)"
89109459|NCT03040999|Experimental|Pembrolizumab + Cisplatin + CRT|Participants receive a priming dose of pembrolizumab before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of pembrolizumab and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of pembrolizumab alone as maintenance therapy for a total of 17 cycles of pembrolizumab. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with pembrolizumab.
89109460|NCT03040999|Placebo Comparator|Placebo + Cisplatin + CRT|Participants receive placebo before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of placebo and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of placebo alone for a total of 17 cycles of placebo. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with placebo.
89109461|NCT03010176|Experimental|Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions)|Participants with cutaneous (cut) or subcutaneous (subcut) lesions will receive escalating doses of ulevostinag monotherapy via IT injection on Days 1, 8, and 15 of each 21-day cycle for Cycles 1, 2, and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond for up to 35 cycles (up to approximately 2 years).
89228941|NCT00991718|Experimental|C|On Days 1-7, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects also received a single IV tracer dose of 14C-GDC-0449.
89109462|NCT03010176|Experimental|Part 1 Arm 2: Ulevostinag +Pembro (Cut/Subcut Lesions)|Participants with cut or subcut lesions will receive escalating doses of ulevostinag via IT injection on Days 1, 8, and 15 of each 21-day cycle for Cycles 1, 2, and 3 and then on Day 1 of each 21-day cycle for Cycles 4 and beyond PLUS pembrolizumab (pembro) via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
89109463|NCT03010176|Experimental|Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions)|Participants with visceral lesions will receive escalating dose frequencies of ulevostinag via IT injection at escalating dose frequencies (Day 1 of each 21-day cycle for up to 35 cycles, then Days 1 and 8 of each 21-day cycle for two cycles, then Day 1 of each 21 day cycle up to 35 cycles, then Days 1, 8, and 15 of each 21-day cycle for two cycles followed by Day 1 of each 21-day cycle up to 35 cycles, PLUS pembrolizumab IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (approximately 2 years).
89109464|NCT03010176|Experimental|Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory|Participants with HNSCC who are anti-programmed cell death-1 or anti-programmed cell death-ligand 1 refractory will receive ulevostinag at the preliminary Recommended Phase 2 Dose (RP2D) determined by dose escalation in Part 1 Arm 1 and 2 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
89109465|NCT03010176|Experimental|Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC|Participants with TNBC who are anti-PD-1/PD-L1 treatment-naïve or who have refractory unresectable locally advanced or metastatic TNBC will receive ulevostinag at the preliminary RP2D determined by dose escalation in Part 1 via IT injection on Days 1, 8, and 15 of Cycles 1 and 2 and on Day 1 of each 21-day cycle from Cycle 3 onward (up to a total of 35 cycles) PLUS pembrolizumab via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
89109466|NCT03010176|Experimental|Part 2 Cohort C: Anti-PD-1/PD-L1 TrT-Naïve Solid Tumors-Liver|Participants with solid tumors with liver metastases/lesions who are anti-PD-1/PD-L1 treatment-naïve will receive ulevostinag at the preliminary RP2D based on Part 1: ulevostinag + pembro (visceral lesions) treatment arm via IT injection in a to-be-determined dose and frequency, based on data from Arm 3, PLUS pembrolizumab via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years).
89109467|NCT02988297|Experimental|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
89109468|NCT02988297|Placebo Comparator|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
89109469|NCT02963818|Experimental|Smartphone breathalyzer device & app|This is a small device that connects to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in an actual bar and during a two-week field period.
89109470|NCT02963818|Experimental|BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in an actual bar and during a two-week field period.
89109471|NCT02963818|Experimental|Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in an actual bar and during a two-week field period.
89109472|NCT02954055|Active Comparator|Arm A|Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
89109473|NCT02954055|Experimental|Arm B|"Metronomic VEX:~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability."
89109474|NCT02945566|Active Comparator|Standard TME surgery|Radical total mesorectal excision
89109475|NCT02945566|Experimental|Long course concurrent chemoradiation|Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
89109476|NCT02945566|Experimental|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
89109477|NCT02932150|Experimental|TAF (Cohort 1)|Participants (12 to < 18 years) weighing ≥ 35 kg will receive TAF 25 mg tablet for 24 weeks
89109478|NCT02932150|Placebo Comparator|Placebo (Cohort 1)|Participants (12 to < 18 years) weighing ≥ 35 kg will receive placebo tablet for 24 weeks
89109479|NCT02932150|Experimental|TAF (Cohort 2 Group 1)|Participants (6 to < 12 years) weighing ≥ 25 kg will receive TAF 25 mg tablet for 24 weeks
89109480|NCT02932150|Experimental|TAF (Cohort 2 Group 2)|Participants (6 to < 12 years) weighing ≥ 14 kg to < 25 kg will receive TAF 15 mg oral granules for 24 weeks
89109481|NCT02932150|Experimental|TAF (Cohort 2 Group 3)|"Participants (2 to < 6 years) will receive TAF for 24 weeks as follows:~weight ≥ 10 kg to < 14 kg (7.5 mg oral granules)~weight ≥ 14 kg to < 25 kg (15 mg oral granules)"
89109482|NCT02932150|Placebo Comparator|Cohort 2 Placebo|Participants will receive matching placebo of TAF (tablet or oral granules) for 24 weeks.
89109483|NCT02932150|Experimental|Open-Label TAF|Following 24 weeks of blinded randomized treatment, participants will be eligible to participate in an open-label extension phase to receive TAF for an additional 216 weeks.
89109484|NCT02901496|Experimental|Endurance exercise + infusion of Tocilizumab|Endurance exercise training + monthly infusion of Tocilizumab
89109485|NCT02901496|Experimental|Endurance exercise + infusion of placebo|Endurance exercise training + monthly infusion of placebo
89109486|NCT02901496|Experimental|No exercise + infusion of Tocilizumab|No exercise + monthly infusion of Tocilizumab
89109487|NCT02901496|Placebo Comparator|No exercise + infusion of placebo|No exercise training + monthly infusion of placebo
89109488|NCT02901496|Experimental|Resistance exercise + infusion of placebo|Resistance exercise training + monthly infusion of placebo
89109489|NCT02881554|Experimental|Diagnostic (SC SPECT/CT)|"There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol.~In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT.~In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans."
89109490|NCT02876510|Experimental|IMA101 product only (Cohort 1)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~Infusion of the IMA101 T-cell product(s)~Post-infusion administration of low-dose recombinant human interleukin-2"
89109491|NCT02876510|Experimental|IMA101 product + atezolizumab (Cohort 2)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~Infusion of the IMA101 T-cell product(s)~Post-infusion administration of low-dose recombinant human interleukin-2~Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year"
89109492|NCT02788227|Experimental|Boosted Group|Group randomized at Month 18 to receive booster vaccination
89109493|NCT02788227|Experimental|Non-boosted Group|Group randomized to 'no booster' at Month 18
89109494|NCT02769962|Experimental|1/Phase I|EP0057 + olaparib
89109495|NCT02769962|Experimental|2/Phase II|EP0057 + olaparib at MTD/RP2D
89109496|NCT02766582|Experimental|Chemotherapy combined with pembrolizumab|"Single arm study:~Pembrolizumab IV every 21 days (200 mg) Carboplatin IV every 21 days Paclitaxel IV infusion (80 mg/m2) every 7 days for 6 cycles Followed by 12 months pembrolizumab IV every 21 days"
89109497|NCT02746328|Experimental|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
89228942|NCT00991718|Experimental|D|On Days 1-6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.
89109499|NCT02682641|Experimental|IBRUTINIB + RITUXIMAB|"Subjects will receive the ibrutinib in combination with rituximab according to the following schedule:~Ibrutinib 560 mg daily po until disease progression or unacceptable toxicity. In case of sustained negative MRD (at least for 6 months) after 2 years of continuous therapy, ibrutinib will be discontinued.~Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1). Rituximab 375 mg/m2 iv, day one of every cycle 3, 5, 7 and 9."
89109500|NCT02589392|Experimental|Moisturizer + Body wash|Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)
89109501|NCT02589392|Active Comparator|Body wash|Cetaphil® Restoraderm® body wash (1/day)
89109502|NCT02553161|Experimental|MED - Escitalopram with psychotherapy|Youth will also be assigned a board certified child psychiatrist (Drs. Singh or Chang at Stanford; Drs. DelBello or Patino at UC), who will be blind to treatment condition and see youth weekly for the first 4 weeks, then biweekly until 16 weeks. Youth in the MED condition will be given the USFDA (US Food & Drug Administration) approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks.
89109503|NCT02553161|Placebo Comparator|No MED -Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
89109504|NCT02553161|No Intervention|Healthy Control|60 (30 at Stanford, 30 at University of Cincinnati) 12- to 17-year old male and female typically developing healthy controls. Healthy controls will receive behavioral, neural, and physiological assessments at baseline only. healthy controls will be scanned at baseline only and serve as a reference group to determine whether MRI changes observed in the high-risk group from baseline to week 4 are toward or away from normal.
89109505|NCT02536742|Experimental|Experimental|Palbociclib plus Fulvestrant
89109506|NCT02526901||No treatment|
89109507|NCT02448667|Experimental|FAXE Kondi - a sugary soft-drink|100 ml FAXE Kondi (10 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
89109508|NCT02448667|Placebo Comparator|FAXE Kondi Free - a sugarfree soft-drink|100 ml FAXE Kondi Free (0 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
89228943|NCT01036282|Experimental|Computerized Cognitive Remediation|Two arms: 1. Computerized Cognitive Remediation treatment using COGPACK. and 2. PositScience. Each arm is further randomized to either MindReader or no Mindreader.(Social Cognition Training).
89228944|NCT01036282|Experimental|CRT + Social Cognition Training|Two 45-minute sessions of Computerized Cognitive Remediation using COGPACK, one 45-minute discussion session, plus one 45 minute Mind Reader Interactive Guide to Emotions per week for 12 weeks. compared to two 45-minute sessions of PositScience, plus one 45-min Discussion session plus one minute of Mind Reader, Interactive Guide to Emotions
89228945|NCT04048733|Experimental|Patchy type-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.~Second and third 12 lead ECG will be taken using patchy-type 12-lead ECG device as a doctor's order. This device will be automatically record 12-lead ECG 3 times in 1 minutes at a time by its algorithm."
89228946|NCT04048733|No Intervention|Standard 12-lead ECG|"ED physicians will prescribe to perform second and third 12-lead ECG in every 15 minutes.~Second and third 12 lead ECG will be taken using standard 12-lead ECG device as a doctor's order. Interns and ECG technicians will perform 12-lead ECG as they perform as usual."
89228947|NCT01036360||physical activity|
89228948|NCT00991796|Experimental|CS-1008|CS-1008 with carboplatin and paclitaxel
89228949|NCT00991796|Placebo Comparator|Placebo|Placebo with carboplatin and paclitaxel
89228950|NCT00673673|Experimental|1|FOLFOX in combination with bevacizumab
89228951|NCT00770783|Experimental|Magnetic Seizure Therapy (MST)|
89228952|NCT00770783|Active Comparator|Electroconvulsive Therapy (ECT)|
89228953|NCT00763685|Active Comparator|etoricoxib 120 mg|active control
89228954|NCT00763685|Placebo Comparator|2|Placebo
89228955|NCT00763685|Active Comparator|3|Paracetamol 1 g and etoricoxib 120 mg
89228956|NCT01039402||1|Adults ≥ 50 years old
89228957|NCT04048655|Other|Study group|Single arm and everyone gets the same treatment according the protocol
89228958|NCT02557997||ART-naive (primary infection)|ART-naive (primary infection) HIV infected adults
89228959|NCT02557997||ART-naïve (chronic infection)|ART-naïve (chronic infection) HIV infected adults
89228960|NCT02557997||ART-controlled|ART-controlled HIV infected adults
89228961|NCT02557997||ART-failing|ART-failing HIV infected adults
89228962|NCT02557451|Experimental|surgery + antiangiogenic|surgery (vitrectomy - air - TPA) with injections of an antiangiogenic
89228963|NCT02557451|Experimental|intravitreal injection of gas/TPA + antiangiogenic|intravitreal injection of gas - TPA with injections of an antiangiogenic
89228964|NCT02558153|Experimental|DEB - drug eluting balloon (APERTO)|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon
89228965|NCT02558153|Active Comparator|standard PTA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).
89228966|NCT01039480||dual therapy (ASS/CLO)|patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel
89228967|NCT01039480||clopidogrel users (CLO)|patients with a prescription for clopidogrel
89228968|NCT01039480||aspirin users (ASP)|patients with a prescription for aspirin
89228969|NCT04048187|Experimental|Phone Application|
89228970|NCT05408858|Experimental|LGBTQ-affirmative cognitive behavioral group therapy|LGBTQ-affirmative cognitive behavioral group therapy consists of 10 weekly, 90-minute group therapy sessions, delivered remotely via Zoom. Intervention sessions and associated home practice will cover the following topics: Building and keeping motivation; Introduction to LGBTQ-related stress; Getting to know your emotions; Introduction to emotional behaviors and behavioral experiments; Awareness of physical sensations and introduction to flexible thinking; Being flexible in your thinking; Awareness of emotional experiences; Assertiveness; Situational exposures; Reviewing accomplishments and looking ahead. Participants will be taught intervention content through a range of teaching modalities including use of the Zoom whiteboard feature, videos, interactive activities, worksheets, and group discussion.
89228971|NCT01041742|Experimental|OPCAB|
89228972|NCT00763763|Experimental|1|imatinib in combination with chemotherapy by vincristin and dexamethasone
89228973|NCT04003298|Experimental|Electric toothbrush and power interdental device|Electric toothbrush and power interdental device
89228974|NCT04003298|Active Comparator|Electric toothbrush|Electric toothbrush
89228975|NCT01041820|Experimental|Exercise group|Children will participate in a 10-week moderate to vigorous exercise program
89228976|NCT01041820|No Intervention|non-exercising|Participants will receive no intervention
89228977|NCT00763841|Experimental|1|Stimulation will be given daily at a particular site for three days a week
89228978|NCT00763841|Sham Comparator|2|
89228979|NCT05408702||Autoimmune Myasthenia Gravis|
89228980|NCT05408702||Congenital Myasthenic Syndrome|
89228981|NCT05408702||Lambert Eaton Syndrome|
89228982|NCT01037140|Active Comparator|cholecalciferol|
89228983|NCT01037140|Placebo Comparator|placebo|
89228984|NCT05357456||autonomous cortisol secretion|Patients admitted to the hospital with adrenal incidentalomas are evaluated for adrenal function, and then ACS patients are diagnosed based on the serum cortisol ≥ 50 nmol/L following the 1 mg dexamethasone suppression test and without any other signs or symptoms of cortisol excess.Patients with ACS will undergo a physical exam, cognitive function test as well as structural and functional brain MRI at baseline and 12 months after their surgery or conservative treatment.
89228985|NCT05357456||non-functioning adrenal adenomas|Patients admitted to the hospital with adrenal incidentalomas are evaluated for adrenal function, and then non-functioning adrenal adenomas patients are diagnosed based on the serum cortisol < 50 nmol/L following the 1 mg dexamethasone suppression test .Patients with non-functioning adrenal adenomas will undergo a physical exam, cognitive function test as well as structural and functional brain MRI at baseline.
89228986|NCT00069121|Active Comparator|5-Fluorouracil/Leucovorin (5-FU/LV)|Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks).
89228987|NCT00069121|Experimental|Capecitabine in Combination with Oxaliplatin (XELOX)|Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).
89228988|NCT00768911|Experimental|1|
89228989|NCT01860404|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 21 days
89228990|NCT01860404|Experimental|Branched Chain Amino Acids (27g BID)|27 grams of BCAA's will be administered twice-daily for 21 days
89228991|NCT01860404|Experimental|Branched Chain Amino Acids (22.5g BID)|22.5 grams of BCAA's will be administered twice-daily for 21 days
89228992|NCT01860404|Experimental|Branched Chain Amino Acids (15g BID)|15 grams of BCAA's will be administered twice-daily for 21 days
89228993|NCT01860404|Experimental|Branched Chain Amino Acids (7.5g BID)|7.5 grams of BCAA's will be administered twice-daily for 21 days
89228994|NCT00769145|Experimental|Ranibizumab|Patients to receive two injections of 0.5 mg ranibizumab subconjunctivally
89228995|NCT00399802|Active Comparator|Single IV infusion of ZA 4 mg|Participants will receive a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.
89228996|NCT00399802|Experimental|Odanacatib 5 mg|Participants will receive a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.
89228997|NCT00763997|Experimental|1|Dipyrone
89228998|NCT00763997|Active Comparator|2|Ibuprofen
89228999|NCT00763997|Active Comparator|3|Acetaminophen
89229000|NCT00763997|Placebo Comparator|4|Parecoxib/Valdecoxib
89229001|NCT00771095|Active Comparator|Control (available) podcast|
89229002|NCT00771095|Experimental|Enhanced podcast|
89229003|NCT00771251|Experimental|CNTO 148 50 mg|
89229004|NCT00771251|Experimental|CNTO 148 100 mg|
89229005|NCT00771251|Experimental|Placebo|
89229006|NCT00399568|Experimental|IV acetaminophen 1 g/100 mL solution|
89229007|NCT00399568|Placebo Comparator|IV Placebo 100 mL solution|
89229008|NCT03960853|Experimental|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
89229009|NCT03960853|Placebo Comparator|volume controlled ventilation|patients will be allocated to volume controlled ventilation in operation
89229010|NCT01326949|Active Comparator|ET+NSBB|"Endoscopic treatment(ET)- Endoscopic variceal ligation (EVL)~Non-selective beta blocker(NSBB)-Propranolol.~Anticoagulation(AT)- Heparin followed by warfarin."
89229011|NCT01326949|Active Comparator|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS.
89229012|NCT00764075|Experimental|1|guided implantation of the left ventricular lead
89229013|NCT00764075|Placebo Comparator|2|standard implantation of the left ventricular lead
89229014|NCT00764075|Experimental|Pilot Group|feasibility of guided placement of CRT-leads in 20 Patients
89229015|NCT01039558|Active Comparator|lansoprazole + ecabet sodium|
89229016|NCT01039558|Placebo Comparator|lansoprazole + placebo|
89229017|NCT03900728|Active Comparator|Auriculotherapy with needles (acupuncture) + usual care|A designated trained therapist will perform auriculotherapy with 1mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place until removal at the 1-week follow-up visit
89229018|NCT03900728|Active Comparator|Auriculotherapy with gold beads (acupressure) + usual care|A designated trained therapist will perform auriculotherapy with beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place until removal at the 1-week follow-up visit.
89229019|NCT03900728|Sham Comparator|Placebo group + usual care|A designated trained therapist will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place until removal at the 1-week follow-up visit.
89229020|NCT04994912|Experimental|EI-001|IV infusion
89229021|NCT04994912|Placebo Comparator|Placebo|IV infusion
89229022|NCT00769301||1|Not hospitalized cancer patients under active treatment
89229023|NCT00769301||2|Caregivers of these cancer patients
89229024|NCT01324258|Experimental|GSK1120212|Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
89109509|NCT02420860|Experimental|Treatment (elotuzumab, lenalidomide)|Patients receive elotuzumab IV over 2-4 hours on days 1, 8, 15, and 21 of courses 1-2 and on day 1 of each subsequent course. Patients also receive lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89109510|NCT02396979|Experimental|Methadone Maintenance|Methadone induction and management provided
89109511|NCT02396979|Experimental|Holistic Health Recovery Program|Administration of the Holistic Health Recovery Program (HHRP-M), which is an eight-session substance abuse relapse prevention and harm reduction program administered by a trained substance abuse counselor.
89109512|NCT02396979|Experimental|Methadone Maintenance and Holistic Health Recovery Prorgram|Methadone induction and management provided in combination with the Holistic Health Recovery Program (HHRP-M).
89109513|NCT02396979|No Intervention|Standard of Care|Standard of care provided for substance abuse treatment. No methadone maintenance or holistic health recovery program intervention provided.
89109514|NCT02395003||High VAT/SAT high Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming high Palmatite oil diet for 12 weeks
89109515|NCT02395003||Low VAT/SAT|Subjects with a low ratio of visceral to subcutaneous fat
89109516|NCT02395003||Lean Controls|Lean control
89109517|NCT02395003||High VAT/SAT- low Palmitate Diet|Subjects with a high ratio of visceral to subcutaneous fat consuming low Palmatite oil diet for 12 weeks
89109518|NCT02386670|Experimental|tDCS + CR|"Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions promotes transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
89109519|NCT02386670|Sham Comparator|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
89109520|NCT02369770|Experimental|Study group|Subjects in the Study group will receive stretching and active movement training with robotic guidance and intelligent control
89109521|NCT02369770|Experimental|Control group|Subjects in the Control group will receive stretching and active movement training without robotic guidance.
89109522|NCT02298504|Experimental|Indirect pulp cap|IDP will be performed for this group
89109523|NCT02298504|Experimental|MTA pulpotomy|MTA pulpotomy will be performed for this group
89109524|NCT02298504|Experimental|Biodentin pulpotomy|Biodentin pulpotomy will be performed for this group
89109525|NCT02285816|Experimental|Arm A (MG1MA3 virus alone)|The starting dose of MG1MA3 will be 1 x 10^10 pfu administered by IV on day 1 and day 4.MG1MA3 dose will be escalated as per protocol.
89109526|NCT02285816|Experimental|Arm B- AdMA3 (vaccine prime) alone|Six patients will receive prime AdMA3 vaccine at a dose of 1x10^10 pfu administered IM on day (-14). No dose escalation is planned.
89109527|NCT02285816|Experimental|Arm C- AdMA3 plus MG1MA3 (prime + boost)|Prime AdMA3 vaccine will be administered as a single dose of 1x10^10 pfu IM at day (-14) followed by dose escalation of MG1MA3 boost, IV administered on days 1 & 4 at a starting dose of 1 log below the recommended phase II dose (RP2D), as determined in Arm A of this study. MG1MA3 dose will be escalated as defined in protocol.
89109528|NCT02276495|Experimental|ACB Control + Local Infiltration|ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
89109529|NCT02276495|Experimental|ACB Study + Local infiltration|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
89109530|NCT02276495|Experimental|ACB Study Only|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
89109531|NCT02262832|Other|Leptin study drug|Administration of study drug SQ BID
89109532|NCT02262806|Other|Leptin therapy|leptin administered via SC injections BID
89109533|NCT02257866||Healthy Volunteers|Patients without known auto immune diseases
89109534|NCT02257866||Vasculitis|Patients with known or suspected vasculitis age 5 or older
89109535|NCT02157324|Experimental|acalabrutinib|Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
89109536|NCT02157324|Experimental|ACP-319|Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
89229025|NCT01324258|Experimental|GSK1120212+Gemcitabine|Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
89229026|NCT00769457|Experimental|1|Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data
89229027|NCT00769457|No Intervention|2|Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink
89229028|NCT01037296|Other|manual ablation|
89229029|NCT01037296|Experimental|robotic ablation|
89229030|NCT05120999||Dominant hand|Application of either TetraGraph or TOFScan device on dominant hand
89229031|NCT05120999||Non-Dominant hand|Application of either TetraGraph or TOFScan device on non-dominant hand
89229032|NCT00068419|Experimental|Treatment (enzyme inhibitor therapy, anti-estrogen therapy)|Patients receive oral sulindac and oral tamoxifen citrate twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.
89229033|NCT01039636|Experimental|FBS0701 - 5 escalating doses|5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
89229034|NCT00769535|Experimental|HSP70 and TNF polymorphisms|
89229035|NCT01039714||Total Thyroidectomy|
89229036|NCT01037374|Experimental|Difficult Airway Assessment Form|
89229037|NCT00764153|Other|Internal fixation|Closed reduction and internal fixation with two parallel screws (Olmed)
89229038|NCT00764153|Other|Bipolar hemiarthroplasty|Hemiarthroplasty with Charnley/ Hastings prosthesis
89229039|NCT01042054|Active Comparator|Epidural|Patients will follow a standard optimised recovery protocol, including epidural analgesia for the first 48 hours postoperatively.
89229040|NCT01042054|Experimental|Wound catheter|Patients will follow a standard optimised recovery protocol, but analgesia in the first 48 hours will be delivered through local anaesthetic wound catheters and additional patient-controlled analgesia, instead of epidural analgesia.
89229041|NCT02557373|Placebo Comparator|Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial.
89229042|NCT02557373|Experimental|Rice Bran + Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial plus consume a measured dose of rice bran daily.
89523215|NCT03380039|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
89109537|NCT02108041||Physicians that interact with the black/High SES avatar patien|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income and Black/African American.
89109538|NCT02108041||Physicians that interact with the black/Low SES avatar patient|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low-Middle Income and Black/African American.
89109539|NCT02108041||Physicians that interact with the white race/high SES avatar|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income White andCaucasian.
89109540|NCT02108041||Physicians that interact with the white race/low SES avatar p|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low Income White and Caucasian.
89109541|NCT02091960|Experimental|Enzalutamide + Trastuzumab|Participants received 160 mg enzalutamide orally once daily and 6 mg/kg trastuzumab administered by intravenous infusion or subcutaneous injection every 21 days. Participants continued on treatment until disease progression, unacceptable toxicity or any other discontinuation criteria were met.
89109542|NCT02043678|Experimental|Radium-223 dichloride + Abi/Pred|Participants received 6 intravenous (IV) administrations of radium-223 dichloride 50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) body weight at intervals of 4 weeks, along with oral abiraterone acetate tablets 1000 milligrams (mg) every day plus prednisone/prednisolone 5 mg twice daily (abi/pred) for 6 cycles, followed by abi/pred until an on-study symptomatic skeletal event (SSE) occurred (or other withdrawal criteria were met)
89109543|NCT02043678|Placebo Comparator|Placebo + Abi/Pred|Participants received 6 IV administrations of placebo matched to radium-223 dichloride at intervals of 4 weeks, along with abi/pred for 6 cycles, followed by abi/pred until an on-study SSE occurred (or other withdrawal criteria were met)
89109544|NCT02029443|Experimental|Relapsed/Refractory Cohort|Phase 1 (dose-escalation) and Phase 2 (dose-expansion) will be conducted for participants with relapsed/refractory CLL or SLL. In Phase 1, participants will receive oral once daily (QD) acalabrutinib at Dose 1 (Cohort 1), Dose 2 (Cohort 2a), Dose 3 (Cohort 3), and Dose 4 (Cohort 4a), and twice daily (BID) acalabrutinib at Dose 1 (Cohort 2b) and Dose 5 (Cohort 4b) for 28 days (1 cycle). In Phase 2, participants will receive oral acalabrutinib at Dose 1 BID (Cohort 2b) or Dose 5 QD (Cohort 2c, later will be switched to Dose 1 BID per protocol amendment 6) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest. Participants from Phase 1 will be continued to receive Dose 1 BID until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
89109545|NCT02029443|Experimental|Treatment-naive Cohort|Treatment-naïve participants with confirmed CLL or SLL, will receive oral acalabrutinib Dose 5 QD (Cohort 7, later will be switched to Dose 1 BID per protocol amendment 6) or Dose 1 BID (Cohort 11) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
89229043|NCT01757626|Experimental|Hu3F8 with GM-CSF|The phase I single arm trial assesses escalating doses of iv hu3F8 (days 1, 3, 5) in the presence of sc GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. The expansion phase II single arm trial assesses the anti-NB activity of hu3F8+GM-CSF.in 3 groups of patients: Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123I-MIBG scan. Group 2 patients are in ≥2nd CR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123I-MIBG scan. Ph II: Groups 1 & 3 pts can continue to get cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved.
89229044|NCT01757626|Experimental|expansion phase II single arm trial|Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123^I-MIBG scan. Group 2 patients are in >2nd CR/VGPR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123^I-MIBG scan. GM-CSF can be omitted if patients have a history of an allergy to GM-CSF or develop an allergic reaction to GM-CSF after initiating therapy while on the protocol.
89229045|NCT00764231|Experimental|Exercise|This group will undergo a 12-week home-based exercise intervention with follow-up fitness assessments.
89229046|NCT00764231|Other|Wait list control|This group will go on a 12-week wait list, during which time they will be asked not to change their exercise habits. After 12 weeks, this group will participate in the exercise intervention.
89229047|NCT05408234|Experimental|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
89229048|NCT01042132|Active Comparator|1) IMN and EF/IMN|"Two parts of the study are randomized;~1)initial intramedullary reaming and primary external fixation with secondary intramedullary nailing"
89109546|NCT02029443|Experimental|Ibrutinib-intolerant Cohort|Participants with confirmed CLL or SLL and were not tolerating ibrutinib treatment, will receive oral acalabrutinib Dose 5 QD (Cohort 8a, later switched to Dose 1 BID per protocol amendment 4) or Dose 1 BID (Cohort 8b) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
89109547|NCT02029443|Experimental|Richters Syndrome/Prolymphocytic Leukemia Transformation Cohort|Participants with diffuse large B-cell lymphoma (DLBCL) Richter's transformation (RS) or prolymphocytic leukemia (PLL) transformation, will receive oral acalabrutinib Dose 5 BID (Cohort 9) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
89109548|NCT02029443|Experimental|Ibrutinib Relapsed/Refractory Cohort|Participants with confirmed CLL/SLL and had relapsed/refractory to ibrutinib treatment, will receive oral acalabrutinib Dose 5 QD (Cohort 10) until disease progression or until the investigator will consider the study treatment to be intolerable or no longer in the participant's best interest.
89109549|NCT02015013|Experimental|Filgrastim|ICL and healthy volunteers will be given 10 microgram/kg daily for 5 days administered according to a vial-based algorithm to reduce wastage and increase the G-CSF dose given to lighter-weight donors to improve CD34+ yields
89109550|NCT02015013|Experimental|Plerixafor|ICL and healthy volunteers will be given 0.24 mg/kg as a single dose (maximum dose: 40 mg) 11 hours prior to apheresis
89109551|NCT02012088|Experimental|RCOMP|"R-COMP Regimen:~Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
89109552|NCT02012088|Active Comparator|RCHOP|"R-CHOP Regimen:~Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
89109553|NCT01901094|Other|Arm 1: ALND + nodal radiation therapy|"Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment.~Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks."
89109554|NCT01901094|Other|Arm 2: Axillary radiation and nodal radiation therapy|Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
89109555|NCT01829724||Healthy volunteer|The control groups for each participant cohort will consist of up to 50 individuals spanning Objectives 1 and 2, for a total recruitment of up to 100 healthy volunteers within the same age range.
89109556|NCT01829724||Individuals with childhood-onset brain or peripheral injury|The childhood-onset brain injury group 120 individuals spanning the three objectives.
89109557|NCT01812694|Active Comparator|Enhanced Standard Care|Standard prenatal care plus education
89109558|NCT01812694|Experimental|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
89109559|NCT01660607|Experimental|Dose escalation|For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.
89109561|NCT01526603|Other|Patients Treated for Neuroblastoma|According to patient weight and renal function, consolidation chemotherapy using various doses of Melphalan, Etoposide, and Carboplatin followed by autologous stem cell infusion and serial post-transplant Granulocyte Colony Stimulating Factor, radiation therapy and Isotretinoin maintenance therapy.
89229049|NCT01042132|Active Comparator|2) TR and RIA|Two parts of the study are randomized; 2)traditional reaming (TR)is compared to a new reaming device, RIA, which is a reamer connected to suction and flushing for prevention of increased intramedullary pressure
89229050|NCT00068107|Experimental|Relagal|All participants received Relagal administered weekly
89229051|NCT04048811|Experimental|HSK3486|HSK3486 induction + maintenance group
89229052|NCT04048811|Active Comparator|Propofol|Propofol induction + maintenance group
89229053|NCT04048811|Other|Propofol HSK3486|Propofol induction + HSK3486 maintenance group
89229054|NCT01564082|Experimental|ETT first|Patients will have the endotracheal tube (ETT) introduced into the pharynx prior to GlideScope insertion, and then advanced under GlideScope guidance into the trachea.
89229055|NCT01564082|No Intervention|Control Group|Patients will have the GlideScope introduced into the pharynx. The endotracheal tube (ETT) will then be advanced under direct vision into the mouth/pharynx. The ETT will then be advanced into the trachea under GlideScope guidance.
89229056|NCT00764387|Experimental|Arm 1|
89229057|NCT00764387|Active Comparator|Arm 2|
89109562|NCT01505569|Other|Arm A: Patients with High Risk or Relapsed Solid Tumor|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, busulfan (1.1 mg/kg IV every 6 hours on days -8 through -6), melphalan (50 mg/mg^2 on days -5 and -4), thiotepa conditioning (250 mg/m^2 IV over 2 hours on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0) and, if appropriate, disease specific radiation therapy at day +60.
89109563|NCT01505569|Other|Arm B: Certain CNS Tumors|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, carboplatin (dose based on GFR and age 17 mg/kg/day IV or 510 mg/m^2/day IV) , thiotepa conditioning (10 mg/kg/day or 300 mg/m^2 IV on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0). This will be repeated up to 2 additional 30 day cycles.
89109564|NCT01505569|Other|Arm C: Germ Cell Tumors|"High-Dose Chemotherapy (3 cycles)~Carboplatin AUC=8 & Etoposide 400 mg/m^2 daily, days -4, -3, and -2 every 21 days~Autologous Stem Cell Infusion ≥ 3 x 106 CD34+ cells/kg Day 0 Cycles 1, 2 and 3~TI Chemotherapy & PBSC Collection.~Paclitaxel 200mg/m^2 IV over 3 hours on Day 1 every 14 days for 2 cycles~Ifosfamide 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles~Mesna 2000 mg/m^2 on Days 1-3 every 14 days for 2 cycles~G-CSF 10 μg/kg sub q daily on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first~Leukapheresis starting on approx. day 11 and continued daily until reaching the collection goal of ≥ 8 x 106 CD34+ cells/kg) or day 15, whichever occurs first"
89109565|NCT01505569|Other|Arm D: Certain CNS Tumors|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~Pre-Transplant Conditioning Chemotherapy (3 cycles)~Day -8, -7, -6: Carboplatin as calculated from AUC of 7 approx.~Day -5, -4, -3: Thiotepa 10 mg/kg, Etoposide 8.3 mg/kg~Day 0: Autologous Hematopoietic Cell Reinfusion~Day +1: Begin G-CSF(filgrastim) 5 mcg/kg"
89109566|NCT01505569|Other|Arm E: Neuroblastoma|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~Pre-Transplant Conditioning Chemotherapy (day -7 to day -0)~Day -7: anti-seizure prophylaxis with lorazepam or levetiracetam~Day -6 - -3: Busulfan IV q24 hours x 4 doses~Day -1: Melphalan 140 mg/m2 IV~Day 0: Autologous Hematopoietic Cell Reinfusion"
89109567|NCT01492231||Chart Review|Chart review of patients who had a procedure done at H. H. Chao Comprehensive Digestive Disease Center
89109568|NCT01396408|Active Comparator|Sunitinib|
89109569|NCT01396408|Active Comparator|Temsirolimus|
89109570|NCT01327781|Experimental|Treatment (Z-endoxifen hydrochloride)|Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89229058|NCT03957889||Student|
89523216|NCT05238259|Other|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
89109575|NCT01224691||Asmathics|Asmathics
89109576|NCT01224691||Non-Asmathics|Non-Asmathics
89109577|NCT01212029|Experimental|1/All Subjects|Imaging studies related to functional brain activation
89109578|NCT01139970|Experimental|Treatment (temozolomide and veliparib)|"Patients receive veliparib PO QD on day 1 and twice daily on days 4-12 and temozolomide PO QD on days 3-9 of course 1.~Beginning at least 30 days after the start of treatment, patients receive veliparib PO BID on days 1-8 and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients achieving complete remission receive 5 more courses in the absence of disease progression or unacceptable toxicity."
89109579|NCT01139242|Other|Body & Soul nutritional intervention|This is a standardized intervention to increase fruit and vegetable consumption among church members through pastoral and peer counseling and church activities/menus.
89109580|NCT01139242|Experimental|Newsletters/peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening among church members out-of-date according to screening guidelines. For those up-to-date, promotion is of increased physical activity.
89109581|NCT00937924|Placebo Comparator|Meperidine and midazolam group|Control. Normal Saline Injections.
89109582|NCT00937924|Experimental|Meperidine and midazolam, plus Diphenhydramine group|Diphenhydramine injections given as adjunct sedative.
89109583|NCT00937924|Experimental|Meperidine and midazolam, plus Promethazne group|Promethazine given as an adjunct sedative.
89109584|NCT00792948|Experimental|Treatment (chemotherapy, transplant, maintenance)|See Detailed Description
89109585|NCT00740805|Experimental|Treatment (veliparib, cyclophosphamide, doxorubicin)|"GROUP I: Patients receive veliparib PO every 12 hours on days 1-4 and cyclophosphamide IV over 60 minutes on day 3.~GROUP II: Patients receive veliparib PO every 12 hours on days 1-4, cyclophosphamide IV over 60 minutes on day 3, and doxorubicin hydrochloride IV over 15 minutes on day 3.~GROUP III: Patients receive veliparib PO every 12 hours on days 1-7, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1.~GROUP IV: Patients receive veliparib PO every 12 hours on days 1-14, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride over 15 minutes on day 1.~In all groups, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89109586|NCT00720785|Experimental|1|NK Cell Infusion (cell /kg pt wt)
89109587|NCT00720785|Experimental|2|1.3 mg/m2/dose administered as a 3 to 5 second bolusintravenous injection
89109588|NCT00655096||Affected participants|Adults and children with either diagnosed or un-diagnosed ocular conditions.
89109589|NCT00655096||Disease free control|Adults and children without any ocular disorders.
89109590|NCT00655096||Unaffected relative|Unaffected first degree relative of a genetic ocular disease participant.
89109592|NCT00342264||1|The study cohort will be comprised of underground, and surface workers (excluding administrative workers) who have been employed in the candidate non-metal mines for at least one year during the period between the date of dieselization of each mine and December 31, 1996.
89109593|NCT00341523||1|Chinese adults at high risk for esophageal cancer
89109594|NCT00319579||Observation|Living Kidney Donors with controls who have not donated a kidney and meet certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
89109595|NCT00268385|Experimental|Treatment (vorinostat, temozolomide)|"PART I: Patients receive vorinostat PO QD or BID on days 1-7 and 15-21 OR QD or BID on days 1-7. Patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Treatment may continue beyond 13 courses at the discretion of the investigator.~PART II: Patients receive vorinostat and temozolomide as in part I*.~[Note: Beginning in course 2, some patients may receive a higher dose of temozolomide.]"
89109596|NCT00245219|No Intervention|Health Tracking (control)|Participants assigned to the health-tracking condition received usual care and did not attend any meetings.
89109597|NCT00245219|Experimental|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
89109598|NCT00245219|Experimental|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
89109602|NCT00027326||1/Patients|Candidate for or currently receiving radiotherapy
89109603|NCT00006319||ADA deficient SCID|Patients with ADA deficient SCID
89109604|NCT00006319||Wiskott-Aldrich syndrome|Male patients with Wiskott-Aldrich syndrome
89109605|NCT04200573|Experimental|Normal Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with normal hepatic function
89229059|NCT03957889||Trainers|
89109606|NCT04200573|Experimental|Mild Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with mild hepatic impairment
89109607|NCT04200573|Experimental|Moderate Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with moderate hepatic impairment
89109608|NCT04200573|Experimental|Severe Hepatic Function|Ampreloxetine Dose A single dose administration to subjects with severe hepatic impairment
89109609|NCT00831844|Experimental|Group 1 - Recurrent or Refractory Hepatoblastoma|Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109610|NCT00831844|Experimental|Group 2 - Recurrent or Refractory Synovial Sarcoma|Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109611|NCT00831844|Experimental|Group 3 - Recurrent or Refractory Rhabdomyosarcoma|Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109612|NCT00831844|Experimental|Grp 4-Recurrent or Refractory Adrenocortical Carcinoma|Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109613|NCT00831844|Experimental|Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109614|NCT00831844|Experimental|Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease|Group 6 - Recurrent or Refractory Neuroblastoma -meta-iodobenzylguanidine (MIBG) Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109615|NCT00831844|Experimental|Grp 7-Neuroblastoma with measurable disease|Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89229060|NCT00769691||Group A|Adult patients undergoing cardiac surgery
89229061|NCT04909502|Experimental|EHP-101 Once a day (OD)|
89229062|NCT04909502|Experimental|EHP-101 Twice a day (BID)|
89109616|NCT00831844|Experimental|Group 8 - Recurrent Osteosarcoma|Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109617|NCT00831844|Experimental|Group 9 - Recurrent or Refractory Wilms Tumor|Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109618|NCT00831844|Experimental|Group 10 - Recurrent or Refractory Retinoblastoma|Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89109619|NCT04191915||Frail|Participants with 3 or more components of Fried frailty scale
89109620|NCT04191915||Moderately Frail|Participants with 1-2 components of Fried frailty scale
89109621|NCT04191915||Not Frail|Participants without any components of Fried frailty scale
89109622|NCT02816073|Active Comparator|1,700|Patients receive 1,700 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
89109623|NCT02816073|Active Comparator|2,500|Patients receive 2,500 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
89109624|NCT02816229|Experimental|Insertion of endobronchial valve|Patients in this group will have one or more EBV inserted into the relevant lung regions to manage the haemoptysis via flexible bronchoscopy.
89109625|NCT02816229|No Intervention|Best care|Patients will receive best medical care.
89109626|NCT00764881|Experimental|EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles.
89109627|NCT00764881|Active Comparator|EE/LNG (Microgynon) + Placebo|Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placebo for 7 days (28 days total per cycle) for 6 treatment cycles.
89109628|NCT02816385|Active Comparator|Antegrade Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
89109629|NCT02816385|Experimental|Retrograde Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
89109630|NCT02819193||exposed group : early raw mother's own milk|"The use of raw MOM is considered as early when it begins before day 7."
89109631|NCT02819193||unexposed group : no use of raw mother's own milk|Neonates who receive, or not, raw MOM before day 7.
89109632|NCT00705328|Experimental|1|
89109633|NCT00705328|Experimental|2|
89109634|NCT00705328|Experimental|3|
89109635|NCT00922870|Active Comparator|Standard treatment|
89109636|NCT00922870|Experimental|Cascade|
89109637|NCT00702676|Experimental|1|Quetiapine Fumarate Immediate Release
89109638|NCT00702676|Experimental|2|Quetiapine Fumarate Extended Release
89229063|NCT00769769|Experimental|Telephone-based psychotherapy|
89229064|NCT00769769|Active Comparator|Face-to-face psychotherapy|
89229065|NCT00769847||Sagittal synostosis|Male and female infants from 1-6 months of age with isolated, single suture sagittal craniosynostosis.
89109639|NCT04609215|Experimental|ALECSAT|"This is an exploratory single arm study. 20 patients will be included with the objective to investigate the safety, tolerability and trends of efficacy of ALECSAT for the treatment of recurrent TNBC.~ALECSAT is a form of adoptive cell therapy medicinal product. ALECSAT is an abbreviation for Autologous Lymphoid Effector Cells Specific Against Tumor. ALECSAT is an autologous product that induces an immune response against a broad repertoire of CTAs expressed on cancer cells (including TNBC) leading to killing of these cells.~Patients will receive standard treatment with carboplatin and gemcitabine along with ALECSAT."
89109640|NCT05384548|Experimental|Problematic smart phone use course|
89109641|NCT02817477|Experimental|IN Ketamine|A single administration of 1 mg/kg ketamine hydrochloride delivered in an intranasal route using an atomizer
89109642|NCT02817477|Active Comparator|IM Morphine|A single administration of 0.15 mg/kg intramuscular morphine
89109643|NCT02817477|Active Comparator|IV Morphine|A single administration of 0.1 mg/kg slow intravascular bolus of morphine.
89109644|NCT00844558|Experimental|Gait Training|Gait Training Intervention Group Participants
89109645|NCT00844558|Placebo Comparator|Control|Gait Training Control Group Participants
89109646|NCT02819115||Healthy adults group|Healthy adults aged 18 to 59 years
89109647|NCT02819115||Elderly group|Elderly over 60 years old.
89109648|NCT02818959|Experimental|Transcatheter Aortic Valve Replacement|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.
89109649|NCT04101175||Request for abortion|Patient in first trimester of pregnancy in request for abortion
89109650|NCT02815839|Experimental|Cohort 1|2.5-mg SHR4640 or placebo
89109651|NCT02815839|Experimental|Cohort 2|5-mg SHR4640 or placebo
89109652|NCT02815839|Experimental|Cohort 3|7.5-mg SHR4640 or placebo
89109653|NCT02815839|Experimental|Cohort 4|10-mg SHR4640 or placebo
89109654|NCT02815839|Experimental|Cohort 5|20-mg SHR4640 or placebo
89109655|NCT04099069|Placebo Comparator|trachial intubation|patient was insert trachial intubation with normal frequency jet ventilation
89109656|NCT04099069|Experimental|rigid bronchoscopy|patient was insert trachial intubation with high frequency jet ventilation
89109657|NCT00709072|Experimental|1|SMS reminders
89109658|NCT00709072|No Intervention|2|control group
89109659|NCT04097197|Experimental|Patients receiving information|Patients in the experimental arm will receive a brief educational intervention if they initially refuse flu vaccination. The intervention was designed towards the most common barriers to flu vaccination that were found after a brief review of the literature. After the intervention, patients will be asked again whether or not they wish to receive the flu vaccine.
89109660|NCT00821236|Active Comparator|Wavelight|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
89109661|NCT00821236|Active Comparator|AMO/VISX CustomVue|AMO/VISX CustomVue™
89109662|NCT00821236|Active Comparator|LADARVision 4000 excimer laser|LADARVision 4000 excimer laser
89109663|NCT02816151|Experimental|Group 1|
89109664|NCT02816151|Experimental|Group 2|
89109665|NCT00756457|Active Comparator|Active Treatment Group|Participants in Group A will undergo bracing and perform stretching exercises.
89109666|NCT00756457|Experimental|Passive Treatment Group|Participants in Group B will undergo bracing and perform stretching and strengthening exercises.
89109667|NCT02814123|Active Comparator|Rapid Insulin-alone closed-loop delivery|Rapid Insulin will be delivered by subcutaneous infusion. Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine)
89109668|NCT02814123|Experimental|Rapid Insulin-plus-pramlintide closed-loop delivery|"Rapid insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).~Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine) Drug: Pramlintide"
89109669|NCT02814123|Experimental|Regular Insulin-plus-pramlintide closed-loop delivery|"Regular insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).~Interventions: 24-hour inpatient intervention Drug: Regular Insulin (humulin R) Drug: Pramlintide"
89109670|NCT04101019|Placebo Comparator|Control|The patient will undergo the SPGB block with saline.
89109671|NCT04101019|Active Comparator|Active drug|The patient will undergo the SPGB block with the active drug which will include 10% lidocaine diluted to 5%.
89109672|NCT02817321|Experimental|Single-injection TPVB +continuous TPVB|Single-injection of TPVB is given preoperatively followed with continuous infusion+ postoperative IPCA.
89109673|NCT02817321|Active Comparator|IPCA|postoperative IPCA is given alone
89109674|NCT00844480|Experimental|zoledronic acid|
89109675|NCT00844480|Placebo Comparator|placebo|
89109676|NCT00771901|Placebo Comparator|Placebo|Subjects will be given a placebo rather than tauroursodeoxycholic acid.
89109677|NCT00771901|Experimental|tauroursodeoxycholic acid|Subjects will receive tauroursodeoxycholic acid for four weeks.
89109678|NCT00771901|Experimental|PBA|Subjects will receive sodium phenylbutyrate for four weeks.
89109679|NCT04099147||ETHON|Subjects from the general population identified in the ETHON
89109680|NCT04099147||HEPAmet|Subjects belonging to the Spanish registry of NAFLD (HEPAmet)
89109681|NCT00705562|Experimental|1|Experimental milk protein based infant formula with varying carbohydrate and protein source
89109682|NCT00705562|Experimental|2|Experimental milk protein based infant formula with varying carbohydrate and protein source
89109683|NCT00705562|Experimental|3|Experimental milk protein based infant formula with varying carbohydrate and protein source
89109684|NCT00705562|Experimental|4|Experimental milk protein based infant formula with varying carbohydrate and protein source
89109685|NCT00705562|Experimental|5|Experimental milk protein based infant formula with varying carbohydrate and protein source
89109686|NCT02814201||Parkinson best-On|two hours after taking two tablets of 125 mg dispersible Modopar®
89109687|NCT02814201||Parkinson worst-off|after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)
89109688|NCT02814201||Huntington|
89109689|NCT02814201||Control|Data collected from the existing database
89109690|NCT04098991||Participants with primary hypothyroidism|All participants will receive the same treatment (levothyroxine, a synthetic T4 hormone replacement) at a dose that will be titrated using serum thyrotropin (TSH) levels as a goal, according to the American Thyroid Association Task Force recommendations
89109691|NCT00843856|Active Comparator|tacrolimus|Intervention type -drug tacrolimus therapy 2mg bd adjust to obtain levels of 5-12ng/L
89109692|NCT00843856|Active Comparator|tacrolimus and mycophenolate mofetil|tacrolimus 2mgs bd (adjusted to obtain levels 5-12mg/L and mycophenolate mofetil 500mg bd adjusted to obtain levels 1.5-3mg/L
89523217|NCT05238259|Other|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the patient to easily roll wrist back and forth focusing on the wrist and arm
89523218|NCT03125213|Active Comparator|Peg-IFN plus AL-3778|
89109693|NCT04480125|Experimental|Aza+Chida|Azacitidine ivgtt D1-7 Chindamide 30mg,PO,twice a week Every 21 days for total 6 courses
89109694|NCT00764491|Experimental|Optimesh 1500S|OptiMesh 1500S, filled with a mixture of demineralized bone matrix (DBM) and cortico-cancellous bone, placed into the interbody space from the posterior approach and supplemental pedicle screws.
89109695|NCT00764491|Active Comparator|Structural Allograft Spacer|Structural Allograft Spacer with pedicle screws.
89109696|NCT00705640|Experimental|Arm 1A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
89523219|NCT03125213|Placebo Comparator|Peg-IFN plus matching placebo|
89229066|NCT00394654|Experimental|MEDI528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
89109697|NCT00705640|Experimental|Arm 1B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
89109698|NCT00705640|Experimental|Arm 1C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
89109699|NCT00705640|Experimental|Arm 1D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
89109700|NCT00705640|Experimental|Arm 1E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
89109701|NCT00705640|Experimental|Arm 2A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
89109702|NCT00705640|Experimental|Arm 2B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
89229067|NCT00394654|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
89229068|NCT01086787||Non heart failure patients|Patients without heart failure undergoing open chest surgery
89109703|NCT00705640|Experimental|Arm 2C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
89109704|NCT00705640|Experimental|Arm 2D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
89109705|NCT00705640|Experimental|Arm 2E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
89109706|NCT02814045||Alzheimer with OSA|Alzheimer with OSA after PSG
89109707|NCT02814045||Alzheimer without OSA|Alzheimer without OSA after PSG
89109708|NCT02813733||Thyroid surgery|All patients who underwent a thyroid procedure in 5 high volume referral centers in France were eligible for inclusion.
89109709|NCT00705796|Experimental|Group 1|Group 1 will be treated with MPP10, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
89109710|NCT00705796|Active Comparator|Group 2|Group 2 will be treated with AndroGel® 50 mg, once daily in the morning after washing/showering.
89109711|NCT02811081|Experimental|Control|Passive deflation of residual carbon dioxide
89109712|NCT02811081|Experimental|Normal Saline Instillation|Instillation of isotonic normal saline in the sub-diaphragmatic region
89109713|NCT02811081|Experimental|Combined Intervention|Normal Saline Instillation + Pulmonary Recruitment
89109714|NCT04021693|Experimental|Handheld Ultrasound Devices|
89109715|NCT04021693|No Intervention|No Handheld Ultrasound Devices|
89109716|NCT02813967|Experimental|chemoradiotherapy|Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42
89109717|NCT02813967|Active Comparator|Radiotherapy 60 Gy|Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.
89109718|NCT00913432|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day
89109719|NCT00913432|Experimental|masitinib 6 mg|masitinib 6 mg/kg/day
89109720|NCT02600689|Experimental|Physical exercise training|Combined aerobic and resistance exercise for 30 or more minutes at least 3 times per week for 12 weeks using the Wii Fit Plus
89109721|NCT02600689|Active Comparator|Cognitive exercise training|Cognitive, brain-training, video gaming ~30 minutes per session, 3 times per week for 12 weeks
89109722|NCT00702832|Experimental|Vestibular rehabilitation|early supported vestibular rehabilitation
89109723|NCT00702832|Active Comparator|standard|standard treatment
89109724|NCT02811237|Other|HESTIA group|
89109725|NCT02811237|Other|sPESI group|
89229069|NCT01086787||Orthopedic patients|Patients without heart failure undergoing orthopedic surgery
89109726|NCT04257123|Experimental|Controlled-Feeding|For two weeks (separated by a wash-out week), participants will consume all meals in the Nutrition Science facility.
89109727|NCT04257123|Experimental|Free-Feeding|For two weeks (separated by a wash-out week), participants will receive no dietary guidance and will be allowed to consume whatever they desire.
89109728|NCT02810847|Experimental|I-BiT Plus|6 weeks of I-Bit treatment plus (at least 30 mins/day, 6 days/week)
89109729|NCT02810847|No Intervention|Control|Refractive adaption or observation
89109730|NCT00843778|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg every two weeks at the hospital by a nurse. Certolizumab Pegol 200 mg every two weeks at the patient's home done by patient (self-injection).
89109731|NCT04251507|Experimental|Virtual Reality Goggles|Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.
89109732|NCT04251507|No Intervention|Control|Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.
89109733|NCT02813343|Experimental|Immediate Treatment Group|The Immediate Treatment group will receive access to the study intervention - BlueStar app, immediately after consenting for a total duration of 6 months.
89109734|NCT02813343|Other|Delayed Treatment Group|The Delayed Treatment group will receive access to the study intervention - BlueStar app, 3 months after consenting for a total duration of 3 months.
89109735|NCT02815371|Experimental|Needle Acupuncture|Sterile, disposable needles were inserted into specific acupoints until Deqi sensation was elicited. The needles were retained for 25 minutes before and after embryo transfer.
89109736|NCT02815371|Experimental|Laser Acupuncture|Each point was stimulated with a laser (Luminex Laser Therapy System: Medical Laser Systems, Branford, CT) set at 5 joules/cm2 (J/cm2) in continuous mode for 0.10 seconds. Based on various studies, a minimum of 4 J/cm2 produces an improved circulatory effect.
89109737|NCT02815371|Sham Comparator|Sham Laser Acupuncture|However, support staff uninvolved in the design of the trial or analysis of the data disarmed the machine, such that no laser irradiation was emitted. This system created an illusion for both the patient and the acupuncturist, and allowed for a truly double blinded control group.
89109738|NCT02815371|No Intervention|No Treatment|This control group was not exposed to any additional physical contact or acupuncture related protocol. They were only exposed to dim light and calming music before and after embryo transfer, mimicking the natural waiting room and procedure room setting for all patients undergoing embryo transfer.
89109739|NCT02810769|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
89109740|NCT02810769|Experimental|Juiced berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
89109741|NCT02810769|Experimental|Powdered berry drink|Berry drink made up from a powdered concentrate. each drink will be standardised to contain 500mg of polyphenols
89109742|NCT02810691|Active Comparator|Soluble fiber, dose #1|Soluble fiber supplementation with dose #1 (smaller dose) of psyllium fiber.
89109743|NCT02810691|Active Comparator|Soluble fiber, dose #2|Soluble fiber supplementation with dose #2 (bigger dose) of psyllium fiber.
89109744|NCT02810691|Placebo Comparator|Placebo|A 250 ml placebo solution of orange-flavored water will be drink at breakfast.
89109745|NCT00910728|Experimental|1|AZD1480
89109746|NCT04235517||Axial deviations in children|Children with axial deviations in the lower extremity treated with guided growth
89109747|NCT04235517||Limb length discrepancy in children|Children with limb length discrepancy treated with temporary epiphysiodesis
89109748|NCT02813499||CARE Rule|Evaluation of the clinical suspicion of myocardial infarction and calculation of CARE rule.
89109749|NCT02332200||Early referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is less than or equal to 10 weeks.
89109750|NCT02332200||Later referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is >10 weeks.
89109751|NCT05631249|Experimental|Sotorasib treatment|Sotorasib : 120 mg, once a day, per os, until progression, unacceptable toxicity, death or lost to follow-up
89229070|NCT01086787||Heart failure patients|Patients with heart failure undergoing open chest surgery.
89109752|NCT02810925|Experimental|PENS T6 and 1200 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
89109753|NCT02810925|Active Comparator|PENST6 + Normocaloric 2000 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a normocaloric 2000 Kcal/day diet.
89109754|NCT02810925|Placebo Comparator|TENS T11/ T12 + 1200 Kcal/day diet|Patients undergo 12 sessions of transcutaneous electrical stimulation of dermatomes T11-T12 , weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
89109755|NCT02810925|Active Comparator|1200 Kcal/day diet|Patients follow only a hypocaloric 1200 Kcal/day diet.
89109756|NCT00634335||sk|professional Israeli bicyclists
89109757|NCT04248894|Experimental|High-intensity interval training (HIIT)|High-intensity interval training (HIIT) = the exercise of high intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the HIIT session was established based on the HR and workload levels corresponding to 5% above the respiratory compensation point.
89109758|NCT04248894|Experimental|Moderate-intensity continuous training (MICT)|Moderate-intensity continuous training (MICT) = the exercise of moderate intensity perform on a cycle ergometer, three times per week for 12 weeks, and training sessions were matched for energy expenditure (i.e., an isocaloric energy expenditure of 200 Kcal/session). The intensity of the MICT session was established based on the HR and workload levels corresponding to anaerobic threshold and respiratory compensation point
89109759|NCT04248894|Sham Comparator|No training|The patients are instructed to avoid any regular exercise program or any non-supervised exercise protocol during the study.
89109760|NCT04419207||Patients with Surbery|Patients who with pulmonary nodules in computed tomography and planned to receive thoracic surgery will be included. And those who have other types of cancer, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
89523220|NCT05173025|Experimental|Fimasartan|- Fimasartan group: Fimasartan, 60 mg once a day, oral administration
89229071|NCT04048265|Experimental|Pain in PD Arm one|This arm will receive a total 5 sessions of TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
89229072|NCT04048265|Sham Comparator|Pain in PD Arm two|This arm will receive a total 5 sessions of sham-TMS stimulation in a week. Pre and post intervention scales will be performed on week one, week 2 and week 4.
89229073|NCT03900416|Experimental|Mindfulness App|Guided mindfulness exercises will be delivered via mobile app for three weeks.
89229074|NCT03900416|No Intervention|Control condition|Participants will use app for assessment for three weeks, but no mindfulness exercises will be delivered.
89229075|NCT02557607|Other|Monitoring a subarachnoid hemorrhage|Any patient hospitalized at the University Hospital of Angers in neurosurgical intensive care unit for supervision by ASL and DTC a subarachnoid hemorrhage from all etiologies (excluding traumatic). An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
89109761|NCT04419207||Healthy Controls|Adult participants (>18 yr) who plan to receive annual physical examination and low-dose computed tomography will be included. And those who have history cancers, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
89109762|NCT02815527||Fresubin Intensive|Adult critically ill non-septic ventilated patients admitted to the intensive care unit with an expected intensive care stay of four days or more.
89109763|NCT02810379|Placebo Comparator|written informed consent|participants read the written informed consent documents befor ERCP
89109764|NCT02810379|Experimental|video+written informed consent|participants watch a video about the ERCP and read the written informed consent documents before ERCP
89229076|NCT00769925|Experimental|Therapist Assisted Bibliotherapy-Primary Care (TAB-PC)|
89229077|NCT00769925|Experimental|Cognitive Behavior Therapy-Primary Care (CBT-PC)|
89229078|NCT00770003|Experimental|1|
89229079|NCT00770003|Placebo Comparator|2|
89229080|NCT00771329|Experimental|1|BIIB023
89229081|NCT00771329|Placebo Comparator|2|
89109765|NCT05629923||Kidney and Liver Transplant|All Kidney and Liver Transplant recipients who are at follow-up in our institution will be enrolled. anti-COVID-19 title was obtained by ECLIA Test(Elyx, Roche). In the case of antibody level <100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca). At three months, a follow-up was performed to assess any COVID-19 infection.
89109766|NCT02810535|Active Comparator|Allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and positive prick test for house dust mite
89109767|NCT02810535|Experimental|Non-allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and negative prick test for house dust mite
89109768|NCT02810535|Other|Healthy Control|Clinical observation of 20 subjects without nasal symptoms and with negative prick test
89109769|NCT02810223|Experimental|Single dose of CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
89109770|NCT02810145||TBI with GCS <or= 8|Adult patients admitted to the surgical intensive care unit with traumatic brain injury and a Glasgow coma score less than or equal to 8.
89229082|NCT00771485|Experimental|1|
89229083|NCT00771485|Other|2|
89109771|NCT02810301|Experimental|Treatment (Probiotic ES1)|Capsules containing 1 billion CFU of B. longum ES1 per capsule. One capsule taken before and after consuming 2 slices of bread for 7 days.
89109772|NCT02810301|Placebo Comparator|Placebo|Capsules not containing the active ingredient B. longum ES1. One capsule taken before and after consuming 2 slices of bread for 7 days.
89109773|NCT00820222|Experimental|Lapatinib plus capecitabine|Lapatinib 1250 mg once daily and capecitabine 2000mg/m2/day, days 1-14, every 21 days
89523221|NCT05173025|Active Comparator|Amlodipine|- Comparator group: Amlodipine, 5 mg once a day, oral administration
89109774|NCT00820222|Active Comparator|Trastuzumab plus capecitabine|trastuzumab loading dose of 8mg/kg followed by 6mg/kg q3weekly infusions, and capecitabine 2500mg/m2/day, days 1-14, every 21 days
89109775|NCT04181151||Stroke patients|
89109776|NCT04181151||Healthy Subjects|
89109777|NCT02810067|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
89109778|NCT02810067|Experimental|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
89109779|NCT02815449|Experimental|Low stabilizer level|Meals prepared with iron fortified cube with low stabilizer level
89109780|NCT02815449|Experimental|Medium stabilizer level|Meals prepared with iron fortified cube with medium stabilizer level
89109781|NCT02815449|Experimental|High stabilizer level|Meals prepared with iron fortified cube with high stabilizer level
89109782|NCT02815215|Experimental|Intervention group|Minimally Invasive Carroll's Technique
89109783|NCT02815215|Active Comparator|Control group|Ponseti method
89109784|NCT02814825||ViviGen|Patients undergoing a two or three level ACDF using ViviGen Cellular Bone Matrix in conjunction with cervical allograft spacers and DePuy Synthes anterior cervical plate systems.
89109785|NCT01039688|Experimental|5 mg BID CP-690,550|
89109786|NCT01039688|Experimental|10 mg BID CP-690,550|
89109787|NCT01039688|Active Comparator|methotrexate|
89109788|NCT02815137|Other|XPO1 E571K mutation detection|Determination of mutation of XPO1571K in patient with classical hodgkin Lymphoma by digital PCR on blood samples and biopsy
89109789|NCT02237508|Experimental|A-B1-B2-C-D|"Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 days followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89229084|NCT04002752|Experimental|Panel A: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 1) or matching placebo as single subcutaneous injection.
89229085|NCT04002752|Experimental|Panel B: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 2) or matching placebo as single subcutaneous injection.
89229086|NCT04002752|Experimental|Panel C: JNJ-73763989 or Placebo|Participants will receive JNJ-73763989 (Dose Level 3) or matching placebo as single subcutaneous injection.
89229087|NCT00770159|Experimental|1|MK0822
89229088|NCT00770159|Placebo Comparator|2|Placebo to MK0822
89229089|NCT00399490|Experimental|1|
89229090|NCT00770237|Experimental|Cues|Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).
89229091|NCT02557529|Experimental|Progressive Resistance Training|12 weeks progressive resistance training (PRT) during and after concomitant chemoradiotherapy. Also optional/voluntary physical activity performed on their own is registered, as well as diet diary.
89229092|NCT02557529|Active Comparator|Control|Control arm. Optional/voluntary physical activity performed on their own is registered, as well as diet diary.
89229093|NCT00398866|Active Comparator|1|Bupivicaine (local anesthetic)
89229094|NCT00398866|Active Comparator|2|Corticosteroid (trimcinolone (Kenalog) 40 mg)
89229095|NCT00398866|Experimental|3|Synvisc
89229096|NCT00771563|Active Comparator|Arm A|Chemotherapy without LMWH
89229097|NCT00771563|Experimental|Arm B|Chemotherapy with LMWH
89229098|NCT04780802|Other|Ballloon catheter|Balloon-assisted transarterial therapy will be performed in the first treatment session only
89229099|NCT00775073|Experimental|Treatment|Bevacizumab (Avastin) & Everolimus (RAD001)
89229100|NCT00398632|Experimental|Duloxetine|Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)
89109790|NCT02237508|Experimental|B1-C-A-D-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89109791|NCT02237508|Experimental|C-D-B1-B2-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89229101|NCT00922025||1|Male patients with non-small cell lung cancer (NSCLC) of adeno histology
89229102|NCT03993418|Experimental|Stevia arm|stevia drops
89229103|NCT03993418|No Intervention|Control arm|No change in diet
89109792|NCT02237508|Experimental|D-B2-C-A-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89109793|NCT02237508|Experimental|B2-A-D-B1-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89109794|NCT02237508|Experimental|D-C-B2-B1-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89523222|NCT03395119|Sham Comparator|No Supplements|The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
89523223|NCT03395119|Experimental|Fish oil|Twenty healthy young adults will receive fish oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
89109795|NCT02237508|Experimental|B2-D-A-C-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89109796|NCT02237508|Experimental|A-B2-B1-D-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89109797|NCT02237508|Experimental|B1-A-C-B2-D|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89523224|NCT03395119|Experimental|Olive oil|Twenty healthy young adults will receive olive oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
89523225|NCT03384407|Experimental|Open label|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
89109798|NCT02237508|Experimental|C-B1-D-A-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal~A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89109799|NCT02813031|Experimental|Functional meat products with healthy lipids from olive oil|Healthy people consuming 300g/week of functional meat products with high diglyceride lipid from olive oil
89109800|NCT02813031|Placebo Comparator|Traditional meat products|Healthy people consuming the same amount of traditional meat products
89109801|NCT02812875|Experimental|CA-170|Taken orally in a once or twice daily schedule.
89109802|NCT00909090|Active Comparator|Intervention|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
89109803|NCT00909090|Placebo Comparator|Placebo|visually identical placebo
89109804|NCT04187079||IPF|Patients diagnosed with idiopathic pulmonary fibrosis after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
89109805|NCT04187079||Other ILDs|Patients diagnosed with other interstitial diseases other than IPF after multidisciplinary team discussion using medical history, HRCT pattern, laboratory findings, pulmonary function tests and cryobiopsy specimens.
89109806|NCT04243746|Experimental|Time Restricted Feeding +Standard Malaysian Healthy Plate(QQH)|Subjects practise time restricted feeding (TRF) in addition to the Standard Malaysian Healthy Plate (QQH).
89109807|NCT04243746|Active Comparator|Standard Malaysian Healthy Plate (QQH)|Subjects practise the QQH dietary plan.
89109808|NCT04220034||Patients receiving inhibitor checkpoint treatment|adult patients that will receive for the first time checkpoint inhibitor for a neoplasic disease in a center participating to the study
89109809|NCT03955302|Experimental|Exercise|Patients in this group will perform the water exercise protocol, 3 times a week, for 12 weeks.
89109810|NCT03955302|No Intervention|Control|Patients in this group will not perform any type of exercise during the 12 weeks of the treatment.
89109811|NCT02814903||Planned cardiac surgery. POAF occurence or not|The ALDO-POAF study is an observational, 1-center and prospective pilot study that will enroll patients undergoing CABG ± aortic valve replacement. Patients who had emergency CABG, need for concomitant mitral surgery, left ventricular ejection fraction (LVEF) < 50%, a history of AF or other atrial arrhythmia, unstable angina or heart failure, cardiogenic shock, atrioventricular block, hypothyroidism/hyperthyroidism, previous heart surgery, and off-pump or on-pump beating CABG will be excluded.
89109812|NCT02809755|Experimental|4% lidocaine|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
89109813|NCT02809755|Placebo Comparator|Placebo Saline|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
89109814|NCT02812719|Active Comparator|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
89109815|NCT02812719|Experimental|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
89523226|NCT02520817||Antioxidant supplementation and zinc plus Lactulose(Group A)|Patients With MHE were assigned to receive zinc and antioxidant plus lactulose (group A)
89109816|NCT04236765|Experimental|TB infection-screening benefiting group|children VFRs under 15 years of age (which are children of immigrants and born or not in Spain) who travel to countries with an elevated incidence of TB will be screened for LTBI after their return.
89109817|NCT02876978|Experimental|CAR-GPC3 T cells|"Intravenous infusion with escalating dose is adopted in this study.~Total dosage: 1 x 10^5 - 2 x 10^9 CAR-GPC3 T cells/kg~The next dose and interval depends on the response of the subject to previous dose.~Lymphodepletion:~Fludarabine: 30 mg/m^2/day x 4 days; Cyclophosphamide: 500 mg/m^2/day x 2 days. Adjustment is in discretion of the investigator based on individual response."
89109818|NCT04782596|Experimental|One-centimeter resection|In the study subjects enrolled into this study arm, one-centimetre resection will be used for the transnasal endoscopic pituitary surgery procedure.
89109819|NCT04782596|Experimental|Two-centimeter resection|In the study subjects enrolled into this study arm, two-centimetre resection will be used for the transnasal endoscopic pituitary surgery procedure.
89109820|NCT00909480|Experimental|IDet|Individually adjusted insulin detemir once daily + metformin at least 1500 mg/day
89109821|NCT00909480|Active Comparator|IGlar|Individually adjusted insulin glargine once daily + metformin at least 1500 mg/day
89109822|NCT05642715|Experimental|EX+/HR|The harm reduction arm (described in detail elsewhere)
89109823|NCT05642715|Active Comparator|EX+/TAU|The treatment as usual arm
89109824|NCT02874170|Experimental|drepanocytose affected patient|
89109825|NCT02874170|Other|Healthy volunteers|
89109826|NCT04291274||inhalation anesthesia group|Unilateral and Bilateral cochlear implantation,which used inhalation anesthesia
89109827|NCT04291274||intravenous anesthesia group|Unilateral and Bilateral cochlear implantation, which used intravenous anesthesia
89109828|NCT04302506||Patients with drug-induced liver injury|Patients who underwent liver biopsy and were diagnosed with drug-induced liver injury were diagnosed as DILI.
89109829|NCT04368039|Experimental|Normobaric Oxygen Therapy (40% FiO2)|4 weeks of nightly normobaric oxygen therapy (40% FiO2)
89109830|NCT04368039|Placebo Comparator|Placebo Condition|4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)
89109831|NCT02874326|Experimental|Active comparator: Octreotide LAR|Sandostatin LAR Sandostatin LAR 20 mg will be administered once every 4 weeks as a intramuscular injection
89109832|NCT00627302|Active Comparator|2|Systane
89109833|NCT00627302|Active Comparator|1|PEG-400
89109834|NCT02812641|Experimental|BPF-CCRT (Run-in Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil~Chemotherapy:~Bevacizumab(B): 10 mg/kg on day 1~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
89109835|NCT02812641|Experimental|BPF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil~Chemotherapy:~Bevacizumab(B): 10 mg/kg on day 1~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
89109836|NCT02812641|Active Comparator|PF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Cisplatin and 5-fluorouracil~Chemotherapy:~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
89109837|NCT02809365|Other|Libre|FreeStyle Libre users: FreeStyle Libre Flash Glucose Monitoring System is an interstitial glucose monitoring system intended to be replacement for the capillary blood glucose measurement. The system contains several features that distinguish it from exiting sensor technology including no user calibration during 14 days of wear. The sensor is applied to the upper arm of the patient and the hand-held reader is used to scan the sensor to receive glucose result along with historic results with a 15 min frequency for up to 8 hours.
89109838|NCT02809365|Other|SMBG|Self monitoring blood glucose: patients in this arm will measure blood glucose with personal glucometer
89109839|NCT01058096|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
89109840|NCT01058096|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
89109841|NCT05581134|Experimental|Virtual Reality Group|Patients will attend the in-person 5-day rehabilitation program (2 h/day) to re-establish normal movement patterns in a dynamic and challenging VR environment. During each session, the patients will be supervised by the physiotherapist. The immersive VR system will simultaneously deliver visual and auditory distractors during the exercises.
89109842|NCT05581134|Active Comparator|Control Group Treatment|Patients will attend the in-person 5-day rehabilitation program (2 h/day) to re-establish normal movement patterns within a multidisciplinary etiological framework according to a validated rehabilitation protocol for FMDs.The conventional group will undergo the same dose, frequency, and intensity of rehabilitation treatment as the VR group consisting of rehabilitation without VR exercises.
89109843|NCT02809287||study group|patients with left lateral position plus jackknife posture when perform laparoscopic hepatectomy
89523227|NCT02520817||Lactulose only (Group B)|Patients with MHE were assigned to receive lactulose oly (group B)
89523228|NCT02520193|No Intervention|Standard mobilization strategy|
89523229|NCT02520193|Experimental|protocolized early mobilization strategy|
89109844|NCT04219839|No Intervention|SOC only patient education post- kidney transplant|Participants in this group will receive only SOC patient education following kidney transplant
89109845|NCT04219839|Experimental|SOC + Videos for patient education post-kidney transplant|Participants in this group receive SOC patient education following kidney transplant and access to educational videos designed specifically for post-kidney transplant patients.
89109846|NCT02814747|Experimental|quantitive study: 500 patients likely to be candidates for HTS|quantitive study: 500 patients likely to be candidates for HTS at CR in Dijon and Lyon, that is to say patients with development anomalies and/or intellectual deficiency with no etiological diagnosis.
89109847|NCT02814747|Experimental|qualitative study: 30 patients who have benefited from HTS and|qualitative study: 30 patients who have benefited from HTS and the medical geneticists who accompanied them in this approach.
89109848|NCT02812017|Experimental|1 - Intervention|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the Thirty Million Words-Well Baby intervention, which consists of educational, multimedia modules at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
89109849|NCT02812017|Placebo Comparator|2 - Neutral|The Neutral Video group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the neutral videos about car safety at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
89109850|NCT02812017|No Intervention|3 - Usual care|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will receive care as usual at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
89109851|NCT01057862|Experimental|Naltrexone|
89109852|NCT01057862|Placebo Comparator|Placebo|
89109853|NCT04117113||Elderly, 60+ hospitalized with Invasive ExPEC Disease|Patients 60 years or older hospitalized with Invasive Extraintestinal Pathogenic Escherichia coli Disease.
89109854|NCT02812251|Experimental|Part 1: Cohort 1|Participants will receive 1 milligram (mg) JNJ-61393215 or placebo.
89109855|NCT02812251|Experimental|Part 1: Cohort 2|Participants will receive 5 mg JNJ-61393215 or placebo.
89109856|NCT02812251|Experimental|Part 1: Cohort 3|Participants will receive 15 mg JNJ-61393215 or placebo.
89109857|NCT02812251|Experimental|Part 1: Cohort 4|Participants will receive 30 mg JNJ-61393215 or placebo.
89109858|NCT02812251|Experimental|Part 1: Cohort 5|Participants will receive 45 mg JNJ-61393215 or placebo.
89109859|NCT02812251|Experimental|Part 1: Cohort 6|Participants will receive 60 mg JNJ-61393215 or placebo.
89109860|NCT02812251|Experimental|Part 1: Cohort 7|Participants will receive 90 mg JNJ-61393215 or placebo.
89109861|NCT02812251|Experimental|Part 1: Cohort 8|Participants will receive 120 mg JNJ-61393215 or placebo.
89109862|NCT02812251|Experimental|Part 2|Participants will receive JNJ-61393215 (dose to be determined).
89109863|NCT02812251|Experimental|Part 3|Participants will receive JNJ-61393125 (dose to be determined) or placebo under fed conditions.
89109864|NCT01038128|Experimental|Memantine|Memantine, 10-40 mg daily
89109865|NCT02812329|Experimental|HIV prevention videogame|Participants will play PlayForward on a tablet computer for 1 hour, two times per week for 3 weeks.
89109866|NCT04303520|Experimental|anti-CD19/CD22 CAR-T cells|Administration with anti-CD19/CD22 CAR-T cells in the CD19-positive ALL patients
89109867|NCT02812095|Experimental|The refeeding group|Refeeding is initiated when 120mL/kg/day of enteral feed reaches or stoma loss exceeds more than 40ml/kg/day after operation.
89523230|NCT03379883|Placebo Comparator|Pulsed radiofrequency (P-RF)|Patients will receive both intra articular RF and genicular nerve RF ablation
89109868|NCT02812095|No Intervention|The control group|
89109869|NCT02812407|Experimental|Mucosal Impedance|"Patient's having a clinically indicated endoscopy, a high resolution impedance manometry and a 24 hour pH impedance study.~During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. This device has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it."
89229104|NCT04048031|Active Comparator|Nutrafol Supplement Capsules|"NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal."
89229105|NCT04048031|Placebo Comparator|Placebo Capsules|The placebo capsules contain no active ingredients. Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
89229106|NCT04048031|Other|Open Label 6 month Extension|"During the 6 month open label extension all 70 subjects will receive NUTRAFOL's Synergen Complex Plus® which is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested.~Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for the six month extension with a substantial meal."
89229107|NCT04734548|Active Comparator|Phase Ib ApTOLL|ApTOLL is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include six patients.
89229108|NCT04734548|Placebo Comparator|Phase Ib Placebo|Placebo is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include two patients.
89229109|NCT04734548|Active Comparator|Phase IIa ApTOLL|ApTOLL is administered intravenously (two doses selected in Phase Ib). The two dose levels include 35 patients each one.
89109870|NCT02809599|No Intervention|Pre-intervention|Patients in hospitals that have not received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess BPPV processes at the ED Index visit. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
89109871|NCT02809599|Experimental|Post-intervention|Patients in hospitals that have received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess the main study outcome, behavior change in medical providers. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
89109872|NCT02562378|Experimental|Experimental arm|Trastuzumab emtansine (T-DM1) will be administered at a fixed dose of 3.6 mg/kg IV on Day 1 every 3 weeks and three cohorts of patients with three different dose levels of conventional non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
89109873|NCT04141137|Experimental|TricValve® System Single-Arm|Two self-expanding biological valves for implantation into the inferior and superior vena cava.
89109874|NCT00842530|Experimental|CYD Dengue Vaccine Group|Participants (both Cohort 1 and 2) received 3 injections of the CYD Dengue vaccine, 1 injection each at 0, 6, and 12 months.
89109875|NCT00842530|Placebo Comparator|Control Group|Participants (Cohort 1) received rabies vaccine at Month 0 and placebo at 6 and 12 months. Participants (Cohort 2) received placebo at 0, 6, and 12 months.
89109876|NCT04190238|Experimental|Spasticity after stroke 1|Physical therapy with super inductive system on the agonist and antagonist muscles
89109877|NCT04190238|Active Comparator|Spasticity after stroke 2|Physical therapy with super inductive system on the antagonist muscles
89109878|NCT04236921|Experimental|Treatment A|1 x DopaSnap® tablet, administered under fasting conditions.
89109879|NCT04236921|Active Comparator|Treatment B|1 x RLD of CD-LD tablet administered under fasting conditions.
89109880|NCT04236921|Experimental|Treatment C|Test - fed 1 x DopaSnap® tablet , administered under fed conditions.
89109881|NCT04236921|Experimental|Treatment D|DopaSnap® tablet administered at 0 and 4 hours post-first dose, for a total daily dose of CD/LD 50/200 mg.
89109882|NCT04236921|Experimental|Treatment E|½ x DopaSnap® tablet administered at 0, 2, 4, and 6 hours post-first dose
89229110|NCT04734548|Placebo Comparator|Phase IIa Placebo|Placebo is administered intravenously in one arm which includes 49 patients.
89229111|NCT01589146|No Intervention|short heparin|
89229112|NCT01589146|Experimental|extended heparin|
89229113|NCT00775151|Experimental|1|amlodipine 10 mg tablet of Ranbaxy
89229114|NCT00775151|Active Comparator|2|Norvasc® 10 mg tablets
89229115|NCT04694300|Experimental|Naproxen sodium|Naproxen sodium 440 mg followed by naproxen sodium 220 mg q 8h (max 660 mg/day)
89229116|NCT04694300|Active Comparator|Acetaminophen|Acetaminophen 1000 mg followed by acetaminophen 1000 mg q 6h (max 3000 mg/day according to Tylenol package insert)
89109883|NCT05580510|Active Comparator|Conventional treatment of Heart failure and Sacubitril/Valsartan|"Patients will receive conventional treatment consisting of spironolactone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours) or eplerenone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours); beta-blockers: bisoprolol 1.5 mg orally every 24 hours (maximum dose 10 mg every 24 hours) or metoprolol succinate 12.5 mg every 24 hours orally (maximum dose 200 mg every 24 hours) or carvedilol 3125 mg every 24 hours (maximum dose 25 mg every 24 hours) or ivabradine 5 mg every 12 hours (maximum dose 7.5 mg every 12 hours); diuretics: furosemide 20 to 400 mg orally every 24 hours or bumetanide 1 to 15 mg orally every 24 hours and/or chlorthalidone 25 mg orally every 24 hours.~Additionally, patients will receive Sacubitril/Valsartan, with the intention to titrate up to 49 mg/51 mg orally every 12 hours."
89109884|NCT05580510|Experimental|Conventional treatment plus Empagliflozin and Sacubitril/valsartan|"Patients will receive conventional treatment consisting of spironolactone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours) or eplerenone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours); beta-blockers: bisoprolol 1.5 mg orally every 24 hours (maximum dose 10 mg every 24 hours) or metoprolol succinate 12.5 mg every 24 hours orally (maximum dose 200 mg every 24 hours) or carvedilol 3125 mg every 24 hours (maximum dose 25 mg every 24 hours) or ivabradine 5 mg every 12 hours (maximum dose 7.5 mg every 12 hours); diuretics: furosemide 20 to 400 mg orally every 24 hours or bumetanide 1 to 15 mg orally every 24 hours and/or chlorthalidone 25 mg orally every 24 hours.~Additionally, patients will use Sacubitril/Valsartan, with the intention to titrate up to 49 mg/51 mg orally every 12 hours and Empagliflozin 10 mg orally every 24 hours."
89109885|NCT05580510|Experimental|Conventional treatment plus Empagliflozin|"Patients will receive conventional treatment consisting of spironolactone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours) or eplerenone 25 mg orally every 24 hours (maximum dose 50 mg every 24 hours); beta-blockers: bisoprolol 1.5 mg orally every 24 hours (maximum dose 10 mg every 24 hours) or metoprolol succinate 12.5 mg every 24 hours orally (maximum dose 200 mg every 24 hours) or carvedilol 3125 mg every 24 hours (maximum dose 25 mg every 24 hours) or ivabradine 5 mg every 12 hours (maximum dose 7.5 mg every 12 hours); diuretics: furosemide 20 to 400 mg orally every 24 hours or bumetanide 1 to 15 mg orally every 24 hours and/or chlorthalidone 25 mg orally every 24 hours.~Additionally, patients will use Empagliflozin 10 mg orally every 24 hours."
89109886|NCT02811627|Experimental|Memantine and Magnetic Resonance Imaging|"Subjects will be started on memantine post the imaging session.~Memantine is available commercially as Namenda, Namenda XR and in the liquid form (for subjects who do not wish to take pills). Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks."
89109887|NCT00634413|Experimental|1|
89109888|NCT00634413|Placebo Comparator|2|
89109889|NCT02815059|Experimental|Ibrutinib, Dasatinib and prednisone, all patients|
89109890|NCT05638269||disease group|no intervention
89109891|NCT05638269||control group|no intervention
89109892|NCT03735732||weight status|
89109893|NCT03735732||mindset|
89109894|NCT03918720|Experimental|Trekkers|
89109895|NCT03918720|No Intervention|Controls|
89109896|NCT02811393||Bariatric surgery|Women who have been submitted to a Roux-en-Y Gastric Bypass Surgery for at least 2 years
89109897|NCT02811393||Unoperated|Women with similar characteristics to control group (age, body mass index, physical activity level), but they have not been submitted to bariatric surgery
89109898|NCT00819910|Active Comparator|Rosiglitazone + Placebo|Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
89109899|NCT00819910|Active Comparator|Fenofibrate + Placebo|Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks
89109900|NCT00819910|Experimental|Rosiglitazone +Fenofibrate|Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks
89109901|NCT00819910|Placebo Comparator|Placebo Therapy Daily|Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
89109902|NCT04197843|Experimental|NaviCam (ANKON)|NaviCam (ANKON)
89109903|NCT02808117||Targeted initially|Children who were in the Haiti villages and targeted by the MFI program with MNP delivery initially.
89109904|NCT02808117||Targeted later|Children who were in the Haiti villages and not targeted by the MFI program with MNP delivery until later.
89109905|NCT02808039||DAPT patients|Patients planned for cessation of DAPT regimen containing Ticagrelor after 12 months of treatment following coronary stent implantation . the platelet reactivity will be assessed 1 week prior to cessation of DAPT and than at 1,3,and 12 weeks post DAPT cessation.
89109906|NCT04321395|Experimental|Vigabatrin|
89109907|NCT02807961|Placebo Comparator|Placebo|Placebo comparator arm
89109908|NCT02807961|Active Comparator|Active treatment|ELX-02, active comparator
89109909|NCT02814669|Experimental|Cohort 1: ATZ + R-223-D (Concurrent)|Participants will receive concurrent radium-223 dichloride and atezolizumab for a single-cycle, 28-day dose limiting toxicity (DLT) assessment. If the combination is initially found to be safe and tolerable, additional participants will be randomized to Arms A, B, and C.
89109910|NCT02814669|Experimental|RT Arm A: ATZ + R-223-D (Concurrent)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm (randomized treatment [RT]) to receive concurrent radium-223 dichloride and atezolizumab.
89109911|NCT02814669|Experimental|RT Arm B: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
89109912|NCT02814669|Experimental|RT Arm C: ATZ + R-223-D (Staggered, 28-Day ATZ Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive atezolizumab in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
89109913|NCT02814669|Experimental|Cohort 2: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is not tolerable, Arms A, B, and C will not be introduced and additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab in Cycle 2. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward). If, at Cycle 2, Cohort 2 regiment is not tolerable, additional participants will be enrolled in Cohort 3.
89229117|NCT02556983||Suspected appendicitis|Patients who are suspected as having acute appendicitis
89229118|NCT01589224||Healthy people|
89229119|NCT04002596|Experimental|ExAblate MRgFUS treatment|Ablation of Thalamus Vim nucleus with ExAblate 4000 Neuro MRgFUS for TDPD
89229120|NCT00764621|Experimental|Arm 1|
89109914|NCT02814669|Experimental|Cohort 3: ATZ + R-223-D (Staggered, 56-Day R-223-D Run-In)|If Cohort 2 regimen is not tolerable, additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab in Cycle 3. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab from Cycle 3 onward). If, at Cycle 3, Cohort 3 regiment is not tolerable, no additional participants will be enrolled in this study.
89109915|NCT04237389|Active Comparator|Ablation Index guided catheter radiofrequency ablation|30 patients, who undergo Ablation Index (AI) guided catheter RF ablation
89109916|NCT04237389|Active Comparator|Thoracoscopic surgical epicardial ablation|"30 patients, who undergo thoracoscopic ablation using Box-lesion set"
89109917|NCT02808741|Experimental|F901318 SDD|Liquid formulation
89109918|NCT02808741|Experimental|F901318 IR|Solid formulation
89109919|NCT02808741|Experimental|F901318 IR Fasting|Fasting solid formulation
89109920|NCT02808741|Experimental|F901318 IR Fed|Fed solid formulation
89109921|NCT02808663|Experimental|Severe Alcoholic Hepatitis|
89109922|NCT02807727|Active Comparator|Intralipid 20%|Intravenous single bolus of 1.5 ml/kg of Intralipid 20% over 3 minutes.
89109923|NCT02807727|Placebo Comparator|Modified Ringers Lactate|Intravenous single bolus of 1.5 ml/kg of MRL over 3 minutes.
89109924|NCT05561907|Active Comparator|Surgical gastrojejunostomy (SGJ)|An anastomosis will be created between the stomach and the proximal loop of the jejunum during a laparoscopic surgical procedure.
89109925|NCT05561907|Experimental|Endoscopic gastrojejunostomy (EGJ)|A stent is placed between the stomach and adjacent small intestine under endoscopic ultrasound guidance during an upper endoscopic procedure.
89109926|NCT02807649|Placebo Comparator|Placebo|Placebo: Methyl cellulose and dextrose
89109927|NCT02807649|Active Comparator|Low dose|This blend contains Ginko at 120 mg/day and Cistanche at 300 mg/day
89109928|NCT02807649|Active Comparator|High dose|This blend contains Ginko at 180 mg/day and Cistanche at 450 mg/day
89109929|NCT02814435||Patients|Patients with inherited retinal degeneration will answer two questionnaires and undergo a computerised contrast sensitivity function test.
89109930|NCT02814435||Normal controls|Normal controls recruited by advertising will answer two questionnaires and undergo a computerised test that assess contrast sensitivity function.
89109931|NCT02814513|Experimental|ANDAGO|ANDAGO
89109932|NCT02814357|Placebo Comparator|Control (market standard)|100 g wheat flour (atta)
89109933|NCT02814357|Active Comparator|High fibre 1|81% wheat flour (atta) + 15% chickpea + 4% guar gum
89109934|NCT02814357|Active Comparator|High fibre 2|80% wheat flour (atta) + 15% chickpea + 2% guar gum + 3% barley
89109935|NCT02814357|Active Comparator|High fibre 3|77% wheat flour (atta) + 15% chickpea + 3% guar gum + 5% barley
89109936|NCT02807337|Experimental|Caphosol rinse group|Caphosol consists of two solutions (A and B) which are mixed immediately before use. Caphosol mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
89109937|NCT02807337|Active Comparator|0,9% NaCl group.|0,9% NaCl consists of two solutions (A and B). Two vials of 0.9% NaCl will be mixed to maintain blinding. The study mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
89109938|NCT02804841|Experimental|Intervention|Healthy, Community Dwelling; Aged 60-80 years; Cholecalciferol -Vitamin D3, 4000 international units (IU) on alternating days.
89109939|NCT02804841|Placebo Comparator|Placebo|Healthy, Community Dwelling; Aged 60-80 years; Placebo -gel capsule containing no vitamin D on alternating days.
89109940|NCT02807025||Idiopathic Pulmonary Fibrosis(IPF)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
89109941|NCT02807025||Sarcoidosis|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
89229121|NCT00764621|Active Comparator|Arm 2|
89229122|NCT00764621|Active Comparator|Arm 3|
89229123|NCT01043770|Experimental|Group lifestyle education|Multi-component behaviour change intervention
89109942|NCT02807025||Tuberculosis(TB)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
89109943|NCT02807025||Chronic Obstructive Pulmonary Disease|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
89109944|NCT02807025||Asthma|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
89109945|NCT02807025||Healthy|Nasal, tracheal and bronchial sampling of MLF in patients from healthy controls for comparative data.
89109946|NCT05529537|Active Comparator|control|
89109947|NCT05529537|Experimental|MLD|
89109948|NCT02808273||Retrospective control|Patients who had received enoxaparine as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
89109949|NCT02808273||Prospective Cohort|Patients who will receive bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
89109950|NCT00634491|Active Comparator|1|150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
89109951|NCT00634491|Active Comparator|2|Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
89109952|NCT00634491|Active Comparator|3|normal salin 1cc/kg/hr before and after angiography
89109953|NCT02807103|Experimental|Rituximab with FFS=0|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.~Patients with FFS=0 will receive 1 gram of rituximab at day 1 and day 15 as induction treatment"
89109954|NCT02807103|Placebo Comparator|Conventional therapy with FFS=0|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.~Patients with FFS=0 will receive placebo-rituximab at day 1 and day 15."
89109955|NCT02807103|Experimental|Rituximab with FFS≥1|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.~Patients with FFS≥1 will receive a total of 9 pulses :~1 gram of rituximab at day 1 and day 15 as induction treatment~placebo-cyclophosphamide at days 1, 15, 29, 50, 71, 92, 113, 134 and 155.~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
89229124|NCT01043770|No Intervention|Routine care|Routine care
89523231|NCT03379883|Experimental|Platelet rich plasma (PRP)|Patients will receive intra-articular platelet rich plasma (PRP)
89229125|NCT01042210||Mothers, preeclampsia|Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h).
89229126|NCT01042210||Newborns, physiological pregnancy-delivery|The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery.
89229127|NCT01042210||Newborns, pregnancy with preeclampsia|Newborns from the pregnancies complicated by preeclampsia.
89229128|NCT01042210||Mothers, Physiological pregnancy-labour|The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery.
89229129|NCT00771641|Active Comparator|Standard Fractionation|Standard Fractionation: 2 Gy/Fx, Q.D. 5 Days/wk, Total Dose: 70 Gy/35 Fx x 7 wks
89229130|NCT00771641|Experimental|Hyperfractionation|Hyperfractionation: 1.2 Gy/Fx, b.i.d. (> 6 hours apart, 5 days/wk) Total Dose: 81.6 Gy/68 Fx/7 weeks
89229131|NCT00771641|Experimental|Accelerated Hyperfractionation with split|Accelerated Hyperfractionation with split: 1.6 Gy/Fx b.i.d. (> 6 hours apart), 5 days/wk, Total Dose: 67.2 Gy/42 Fx/6 wks with a 2 week rest after 38.4 Gy
89229132|NCT00771641|Experimental|Accelerated fractionation with concomitant boost|Accelerated fractionation with concomitant boost
89229133|NCT05408078|Experimental|Intervention group - Treatment as Usual (TAU) + SLEEPexpert|"SLEEPexpert is a behavioral programme for insomnia.~The TAU + SLEEPexpert group will receive a specific treatment for insomnia. This treatment will consist of the following three phases:~a face-to-face treatment initiation (kick-off) guided by a medical doctor/ psychologist in a group format~self-managed implementation of behavioral changes supported by the nursing team (individual brief contact during the week)~self-management by the patients, potentially assisted by the Webapplication after discharge from the hospital."
89229134|NCT05408078|Other|Control group - TAU + sleep monitoring|"In addition to TAU, patients in the control group (TAU + sleep monitoring) receive a smartphone app (sleep monitoring). No further interventions will be provided through this app.~TAU comprises standard clinical care, including intensive daily contacts with health care providers on the wards, medical treatment, pharmacotherapy, psychotherapy in individual and group setting, nurse support, additional therapies such as music or ergotherapy and social support, informed by current guidelines for the respective disorder and adapted to individual needs. Of note, no change to any aspects of TAU will be made. Sleep monitoring will consist of daily sleep diary entries with the help of a smartphone app."
89229135|NCT05408000|Active Comparator|ketofol|patient given titrated dose of ketofol
89229136|NCT05408000|Active Comparator|propofol|patient given titrated dose of propofol
89229137|NCT00771719|Experimental|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
89229138|NCT05407922||Laparoscopy Group|The laparoscopy group included every pregnant woman having laparoscopic intervention because of acute abdominal pain during any trimester of her pregnancy.
89229139|NCT05407922||Non-laparoscopy Group|Non-laparoscopy Group included every pregnant woman having treatment approach other than the laparoscopic approach because of acute abdominal pain.
89229140|NCT00771797|Experimental|1|Treatement with low dose flavanoids over 60 days
89229141|NCT00771797|Experimental|2|Treatment with high dose flavanoids over 60 days
89229142|NCT00673361|Experimental|"Chemo-Switch Regimen"|
89229143|NCT00393718|Experimental|Liraglutide|Liraglutide 0.9 mg + glibenclamide placebo
89229144|NCT00393718|Active Comparator|Glibenclamide|Glibenclamide 1.25-2.5 mg + liraglutide placebo
89229145|NCT00669071|Active Comparator|IPL / Tri-Luma® Cream|
89229146|NCT00669071|Active Comparator|IPL/Cetaphil® Moisturizing Cream as Inactive Control|
89229147|NCT00398320|Experimental|Bevacizumab (Avastin), Oxaliplatin (Eloxatin)|
89229148|NCT00670007|Experimental|Zemaira®|
89229149|NCT00775307|Placebo Comparator|B|Placebo 400 mg/day (24 weeks)
89229150|NCT00775307|Experimental|A|Pazopanib 400 mg/day (24 weeks)
89229151|NCT05407298||CBD users|
89229152|NCT05407298||CBD non-users|
89229153|NCT00775385|Active Comparator|A|Standard chemotherapy
89229154|NCT00775385|Experimental|B|Customized treatment
89229155|NCT05407220|Experimental|group1|Period1: HCP1904-1
89229156|NCT05407220|Experimental|group2|Period1: HCP1904-3
89229157|NCT04003688|Placebo Comparator|Placebo group|Patient will be administered saline solution followed by venous general anesthesia.
89229158|NCT04003688|Experimental|Magnesium sulfate through real weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's actual weight followed by venous general anesthesia.
89229159|NCT04003688|Experimental|Magnesium sulfate through ideal corrected weight group|Patient will be administered magnesium sulfate 40 mg/kg of the patient's ideal corrected weight followed by venous general anesthesia.
89229160|NCT00775541|Experimental|Vitamin C|2 gms vitamin C
89229161|NCT05406986|Experimental|the group to which the care bundle will be applied|"Patients with a score of 13 or higher on the Braden QD medical instrument risk assessment scale.~Patients with attached nasogastric tube, intubation tube and saturation probe."
89229162|NCT05406986|No Intervention|group not to be interfered with|Patients with attached nasogastric tube, intubation tube and saturation probe.
89229163|NCT00764777|Experimental|Stenting|
89229164|NCT00779129|Experimental|Single Arm|Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2
89229165|NCT00779207|Experimental|1|weight loss
89229166|NCT00779207|Experimental|2|Weight loss and exercise
89229167|NCT00779363|Experimental|Implanted Device|
89229168|NCT00535496|Experimental|1|sugammadex 1.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
89229169|NCT00535496|Experimental|2|sugammadex 1.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
89229170|NCT00535496|Experimental|3|sugammadex 4.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
89109956|NCT02807103|Active Comparator|Conventional therapy with FFS≥1|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.~Patients with FFS≥1 will receive intravenous pulses of cyclophosphamide for a total of 9 pulses: 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
89109957|NCT00830518|Experimental|Alisertib|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
89109958|NCT02804685|No Intervention|Control|It consists on only a regular training performance
89109959|NCT02804685|Experimental|Experimental|It consists on performing the protocol which includes 6 strength, agility and balance exercises together with the regular training. The exercise program has to be performed twice a week during 6 weeks
89109960|NCT00908544|Experimental|PHI-patients|"Patients with primary HIV infection (PHI) (see also Eligibility) are immediately treated with 2 NRTI + 1 PI/r + Maraviroc + Raltegravir"
89109961|NCT00908544|Experimental|CHI-patients|"Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also Eligibility) intensified by Maraviroc + Raltegravir"
89109962|NCT02804607||skin lesion|severe skin traumatism occurring during childhood and which had required an initial graft.
89109963|NCT00830440|Experimental|EndoBarrier Device|EndoBarrier Device and Diet & Lifestyle Counseling
89109964|NCT00830440|Active Comparator|Control|Diet & Lifestyle Counseling
89109965|NCT00913354|Experimental|1|30 minutes of acupuncture just before and just after embryo replacement
89109966|NCT00913354|Placebo Comparator|2|Sham acupuncture for 30 minutes just before and just after embryo transfer
89109967|NCT05523687|Experimental|Single, oral dose of [14C]-PC14586|Healthy, male participants will receive a single, oral dose of [14C]-PC14586
89109968|NCT00702910|Experimental|GW642444M/lactose|GW642444M/lactose 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
89229171|NCT00535496|Experimental|4|sugammadex 4.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
89229172|NCT00772187|Experimental|1|General anesthesia + I.V pca
89229173|NCT00772187|Experimental|2|General anesthesia + spinal analgesia + I.V pca
89229174|NCT00772265|Experimental|Wosulin N|Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL
89229175|NCT00772265|Active Comparator|Novolin N|Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.
89229176|NCT04002128|Placebo Comparator|Group air|"Group air was mechanically ventilated using 35% oxygen in 65% air during the whole surgical procedure.~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
89109969|NCT00702910|Experimental|GW642444M/MgSt|GW642444M/MgSt 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
89109970|NCT00702910|Placebo Comparator|Placebo|Placebo containing lactose, single inhaled dose for two days treatment in each treatment sequence (crossover design)
89109971|NCT02806635|No Intervention|Waitlist|Participants are assessed start, during, and end wait list; however, no active intervention is given.
89229177|NCT04002128|Active Comparator|Group nitrous oxyde (N2O)|"Group N2O was mechanically ventilated using 35 % oxygen and 65 % of nitrous oxyde during the surgical procedure.~Nitrous oxyde may increase cuff pressure during the general endotracheal anesthesia and result in the respiratory symptoms like sore throat, hoarseness and postoperative cough.~Thiopental sodium was used for induction of anesthesia, muscle relaxation was maintained with vecuronium. General anesthesia with sevoflurane was maintained during the surgical procedure. Intraoperative analgesia was achieved with fentanyl boluses."
89109972|NCT02806635|Experimental|OurRelationship|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s).
89109973|NCT02806635|Experimental|PREP Online|The PREP Online program is based on the in-person Prevention and Relationship Enhancement Program. The PREP Online program consists of seven sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour.
89109974|NCT00908310|Other|Omniscan|
89109975|NCT02804529|Experimental|Meng's Point entry|Meng's entry involved a 0.2 cm horizontal or vertical incision using the Veress needle in the cross of lateral border of the left rectus abdominis and rib arch.
89109976|NCT02804529|Experimental|Palmer's Point entry|Palmer's entry involved a 0.2 cm horizontal or vertical incision with the Veress needle in the left midclavicular line approximately 3 cm caudal to the 10th rib
89109977|NCT02804529|Experimental|Periumbilllicus entry|Periumbilllicus entry involved a 0.2 cm horizontal or vertical midline incision using the Veress needle in the lower or uper border of the umbilicus.
89109978|NCT03896334|Experimental|Isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training will train three times per week, during 24 weeks. They will perform a bout of isometric handgrip exercise: four sets of 2-min of isometric contractions (using alternate hands) at 30% of maximal voluntary contraction.
89109979|NCT03896334|Sham Comparator|Control group|All participants randomized to control group will realize stretching and relaxation exercises, three times per week, during 24 weeks.
89109980|NCT00830128|Experimental|pregabalin (Lyrica)|
89109981|NCT04034550|Experimental|hospitalized patients diagnosed with leptospirosis|hospitalized patients diagnosed with leptospirosis: 12 months of follow up with biological samples and data collection
89109982|NCT05580120|Experimental|Online-supervised exercise group|After the pre-tests (The Brief Resilience Scale, Quality of Life) , the patients were given online-supervised exercise education for 6 weeks.
89109983|NCT05580120|Experimental|The unsupervised-exercise training group|After the pre-tests (The Brief Resilience Scale, Quality of Life) , the patients were given unsupervised exercise education for 6 weeks.
89109984|NCT00841906|Other|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
89109985|NCT00841906|Other|Alice PDx with written and verbal instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
89109986|NCT05557227|Experimental|Galactose|30 g in 200 ml liquid
89109987|NCT05557227|Experimental|Lactose|30 g in 200 ml liquid
89109988|NCT05557227|Experimental|Dextrose|30 g in 200 ml liquid
89109989|NCT05557227|Experimental|Water|200 ml liquid sweetened
89109990|NCT00632346||1 group|200 patients presenting to the Adolescent Medicine Clinic at Brooke Army Medical Center between the ages of 18 and 23 years-old.
89109991|NCT00771667|Placebo Comparator|Placebo (IP)|
89109992|NCT00771667|Experimental|Ustekinumab 1mg/kg (IP)|
89109993|NCT00771667|Experimental|Ustekinumab 3 mg/kg (IP)|
89109994|NCT00771667|Experimental|Ustekinumab 6 mg/kg (IP)|
89109995|NCT00771667|Placebo Comparator|Placebo IV - Responder - Placebo SC (MP)|
89109996|NCT00771667|Placebo Comparator|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC|
89109997|NCT00771667|Placebo Comparator|Ustekinumab IV - Responder - Placebo SC (MP)|
89109998|NCT00771667|Experimental|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|
89109999|NCT00771667|Placebo Comparator|Ustekinumab IV - Nonresponder - Placebo SC (MP)|
89110000|NCT00771667|Experimental|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|
89110001|NCT02801175||RF|Patients with paroxysmal atrial fibrillation slated for radiofrequency pulmonary vein isolation
89110002|NCT02801175||Cryoballoon|Patients with paroxysmal atrial fibrillation slated for cryoballoon pulmonary vein isolation
89110003|NCT02800395|Other|Nutritional evaluation|
89110004|NCT04236063||Haematological malignancy|Patients with haematological malignancy
89110005|NCT02804451|Experimental|Intubation without chest compression|normal airway, without chest compression during intubation.
89110006|NCT02804451|Experimental|Intubation with uninterrupted chest compression|normal airway, with continuous chest compressions
89229178|NCT00779441|Experimental|1|Zolpidem 10mg tablets of ranbaxy
89229179|NCT00779441|Active Comparator|2|AmbienÂ® 10mg tablets
89229180|NCT00989378||control|normal healthy men and women
89229181|NCT02556437|Experimental|Group A|24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia
89229182|NCT02556437|Experimental|Group B|24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia)
89229183|NCT04946006|Experimental|Oxytocin infusion rate 2 IU/h|The maintenance infusion rate of oxytocin will be 2 IU/h.
89229184|NCT04946006|Experimental|Oxytocin infusion rate 4 IU/h|The maintenance infusion rate of oxytocin will be 4 IU/h.
89229185|NCT04946006|Experimental|Oxytocin infusion rate 6 IU/h|The maintenance infusion rate of oxytocin will be 6 IU/h.
89110007|NCT04008537|Experimental|Halcyon kV CBCT imaging|-Each patient will undergo five Halcyon kV CBCT imaging sessions that will then be utilized to simulate the CBCT-guided online ART workflow. Halcyon imaging will be scheduled as per the patient's schedule and availability, with intent but not mandate for imaging on the same days as clinical treatments, preceding clinical treatment. Multiple images may be acquired in one session but no more than 6 Halcyon kV CBCT images will be acquired per day. No more than 6 additional Halcyon kV CBCT images will be acquired in one imaging session and no more than 10 total additional Halcyon kV CBCT images for the duration of the study
89110008|NCT05579808||Epidural Analgesia|
89110009|NCT05579808||No analgesia|
89110010|NCT05520879|Experimental|To provide Sharnali-1 to severe acute malnourished children|We will provide Sharnali-1 among 225 severe acute malnourished children to assess the proportion of children graduating from SAM to non-acute malnutrition status (MUAC ≥ 125 mm or WLZ/WHZ ≥ -2 for two consecutive weeks) by 90 days of intervention.
89110011|NCT05520879|Experimental|To provide Sharnali-2 to severe acute malnourished children|We will provide Sharnali-2 among 225 severely acute malnourished children to assess the proportion of children graduating from SAM to non-acute malnutrition status (MUAC ≥ 125 mm or WLZ/WHZ ≥ -2 for two consecutive weeks) by 90 days of intervention.
89110012|NCT03893175|Experimental|Ibuprofen|"During the double-blind stage, subjects will receive blinded ibuprofen (400 mg by mouth) when pain is at least 4/10 following third molar extraction.~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
89110013|NCT03893175|Placebo Comparator|Placebo|"During the double-blind stage, subjects will receive blinded placebo when pain is at least 4/10 following third molar extraction.~During the open-label stage, all subjects will receive ibuprofen (400 mg by mouth) and acetaminophen (500 mg by mouth) to be taken every 4 hours around the clock for the first 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction.~Rescue medication (oxycodone 5 mg by mouth) will be available if additional analgesic is requested."
89110014|NCT02235792|Experimental|Deep Brain Stimulation 37604 Activa PC+S|All subjects will undergo DBS using the 37604 Activa PC+S device (single arm study).
89110015|NCT04236453|Experimental|Treatment A|Participants will receive Treatment A (a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide [D/C/F/TAF] as one fixed dose combination [FDC] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A wash out period of at least 7 days will be maintained between each treatment period.
89110016|NCT04236453|Active Comparator|Treatment B|Participants will receive Treatment B (a single dose of Darunavir [DRV], Emtricitabine/Tenofovir Alafenamide [F/TAF] and Cobicistat [COB] tablet under fed condition on Day 1) as per assigned treatment sequence (Treatment sequence ABBA or BAAB). A washout period of at least 7 days will be maintained between each treatment period.
89110017|NCT00984672||Bone morphogenetic protein within an interbody cage|Transforaminal Lumbar Interbody Fusion with the use of BMP
89110018|NCT00984672||Other bone grafting techniques within cage (non-BMP)|Use of iliac crest autograft, allograft, or local autogenous bone grafting within the cage during Transforaminal Lumbar Interbody Fusion.
89229186|NCT04946006|Experimental|Oxytocin infusion rate 8 IU/h|The maintenance infusion rate of oxytocin will be 8 IU/h.
89110019|NCT02801019|Experimental|E-XLPE|E-poly
89110020|NCT02801019|Active Comparator|C-XLPE|ArComXL
89229187|NCT04946006|Experimental|Oxytocin infusion rate 10 IU/h|The maintenance infusion rate of oxytocin will be 10 IU/h.
89110021|NCT02800473|Other|Experimental|"Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care.~Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices.~24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects"
89110022|NCT00770965|Experimental|AIN457 0.3 mg/kg|Participants received AIN457 0.3 mg/kg IV on Day 1.
89110023|NCT00770965|Experimental|AIN457 1.0 mg/kg|Participants received AIN457 1.0 mg/kg IV on Day 1.
89110024|NCT00770965|Experimental|AIN457 3.0 mg/kg|Participants received AIN457 3.0 mg/kg IV on Day 1.
89110025|NCT00770965|Placebo Comparator|Placebo|Participants received placebo to AIN457A IV on day 1.
89110026|NCT05518773||Nusinersen treated|Children and adults who are currently treated with nusinersen for at least 6 months prior to enrollment.
89110027|NCT05518773||Risdiplam treated|Children and adults who are currently treated with risdiplam for at least 6 months prior to enrollment.
89110028|NCT04096651|Other|PSP Classic|"15 patients with a classical form of PSP are recruited to realize all the tests of the multimodal approach."
89110029|NCT04096651|Other|Caribbean PSP|"15 patients with a Caribbean PSP are recruited to realize all the tests of the multimodal approach."
89110030|NCT04096651|Other|Healthy controls|15 persons with no PSP are recruited to realize all the tests of the multimodal approach.
89110031|NCT02806557||High risk group|"Defined as risk of severe neutropenia >20% or risk of neutropenic infective complications >10%, with severe neutropenia defined as absolute neutrophil count <1.0 x10^9/L.~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
89110032|NCT02806557||Frequently given regimens|"Defined as high number of cases of neutropenia, but risk of severe neutropenia <5%.~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
89110033|NCT02806557||Prophylactic GCSF|"Patients on primary prophylactic granulocyte colony stimulating factor (GCSF).~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
89110034|NCT05461339|Experimental|TAB014|intravitreal injection at 1.25mg once every 4 week
89110035|NCT05461339|Active Comparator|Ranibizumb|intravitreal injection at 0.5mg once every 4 week
89110036|NCT02806479||Case: Hypertrophic cardiomyopathy|HCM patients at high risk for ventricular arrhythmia
89110037|NCT02806479||Control I: Healthy|Healthy Controls
89110038|NCT02806479||Control II: Post-MI with arrhythmogenic substrate|Ischemic cardiomyopathy patients with documented history of ventricular tachyarrhythmia and left ventricular hypertrophy
89110039|NCT02806479||Control III: VT/VF-free ischemic cardiomyopathy|Ischemic cardiomyopathy patients without ventricular arrhythmia, as proven by non-inducibility and history of freedom from ventricular tachyarrhythmia during at least one ICD generator life
89110040|NCT02800629|Active Comparator|Intervention|Patients will be given Modified Citrus Pectin twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
89110041|NCT02800629|Placebo Comparator|Control|Patients will be given placebo twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
89110042|NCT03854682|Experimental|Surgical|Radiofrequency microtenotomy (RF): A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
89229188|NCT04946006|Experimental|Oxytocin infusion rate 12 IU/h|The maintenance infusion rate of oxytocin will be 12 IU/h.
89229189|NCT04946006|Experimental|Oxytocin infusion rate 14 IU/h|The maintenance infusion rate of oxytocin will be 14 IU/h.
89229190|NCT04946006|Experimental|Oxytocin infusion rate 16 IU/h|The maintenance infusion rate of oxytocin will be 16 IU/h.
89110043|NCT03854682|Active Comparator|Non-surgical|Strength training: Consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
89110044|NCT02806245|Experimental|Biventricular pacing|Patients will be randomized pre-operatively to either the pacing group or to the control group. Patients randomized to receive pacing will 1st undergo an acute pacing phase where the order of the pacing mode will be randomized and then will continue to an extended pacing phase of biventricular pacing.
89110045|NCT02806245|No Intervention|Control|Controls will receive standard of care treatment consisting of placement of 2 pacing leads (right atrial and right ventricular), monitoring of the study outcomes, monitoring of oxygen consumption and echocardiography, but no pacing.
89110046|NCT05562414|Experimental|High-intensity Interval Training (HIIT)|Participants will complete one heart-rate-controlled HIIT bout within their 3-week inpatient stay.
89110047|NCT05562414|Active Comparator|Moderate Continuous Training (MCT)|MCT represents the standard treatment at Valens rehabilitation clinic. Participants will complete one heart-rate-controlled MCT bout within their 3-week inpatient stay.
89110048|NCT02800707|Active Comparator|Sucralose|Participants will be asked to consume 180 mg/day of sucralose (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 340 mg/day of sucralose (or 5.5 12-oz cans of sucralose-sweetened diet soda).
89110049|NCT02800707|Active Comparator|Stevia|Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda).
89110050|NCT02800239|Experimental|Active, adolescent females|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
89229191|NCT00779597|No Intervention|Care as usual|Care as usual, i.e. standard pain treatment and standard care
89110051|NCT03409848|Experimental|A: Chemo-free immunotherapy|Week 1-12 Trastuzumab 6mg/kg d1 every 3 weeks (loading dose 8mg/kg) Nivolumab 1mg/kg i.v. d1 every 3 weeks Ipilimumab 3mg/kg i.v. d1 every 3 weeks Week 13 till EOT (max treatment period 12 months) Trastuzumab 4mg/kg d1 every 2 weeks Nivolumab 240mg i.v. d1 every 2 weeks
89110052|NCT03409848|Experimental|B: Chemo- / immunotherapy|"Trastuzumab 4mg/kg d1 every 2 weeks (loading dose 6mg/kg) Nivolumab 240mg i.v. d1 every 2 weeks mFOLFOX6 every 2 weeks Oxaliplatin at a dose of 85 mg/m2 IV over two hours (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv over two hours (day 1) 5-FU at a dose of 2400 mg/m2 IV over 46 hours (day 1-3)~Max Treatment period 12 months"
89110053|NCT02806323|Experimental|Yoga Practice|12 week yoga intervention; 45 minutes/weekly practice Participants will be encouraged to practice their prescribed program of yoga at home, daily, for 20 minutes each day.
89110054|NCT02804295|Other|Collaborative Care Intervention|All enrolled participants received the collaborative care intervention over 6 months.
89110055|NCT00763555|Experimental|Calcitriol 3 mcg/g Spray|
89110056|NCT00763555|Placebo Comparator|Calcitriol Vehicle|
89110057|NCT02804373|Placebo Comparator|placebo daily|daily administration of placebo during 28 days : placebo continuous
89110058|NCT02804373|Active Comparator|24 IU of oxytocin daily|24 IU of daily oxytocin administration during 28 days : oxytocin continuous
89110059|NCT02804373|Active Comparator|24 IU of oxytocin every 3 days|24 IU of daily oxytocin every 3 days and placebo the following 2 days after each oxytocin administration during 28 days
89229192|NCT00779597|Experimental|SCION-PAIN program|SCION-PAIN program - Additionally to standard pain treatment, patients from the intervention wards received, the SCION-PAIN program consisting of 3 modules: pharmacologic pain management, non-pharmacologic pain management and discharge management.
89229193|NCT00775619|Active Comparator|2|Coreg® 12.5 mg tablets
89229194|NCT00775619|Experimental|1|Carvedilol 12.5 mg tablets
89229195|NCT00775697|Experimental|Montelukast|the single arm will receive montelukast
89229196|NCT05357066|Active Comparator|Treatment; Nitrous Oxide 50%|A single 60-minute session of inhaled 50% nitrous oxide.
89229197|NCT05357066|Placebo Comparator|Control; Oxygen-air mixture|A single 60-minute session of inhaled Oxygen-air mixture
89229198|NCT02556905||Korean patients|All Korean patients intended to be treated with REVLIMID® according to the approved package insert
89229199|NCT00775775||TBI|Patients with moderate to severe TBI
89229200|NCT00772421||Responder|A subject having at least a 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase
89229201|NCT00772421||Non-responder|A subject with a less than 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase.
89229202|NCT00539006|Active Comparator|FFNS, FPNS|active compound
89229203|NCT00539006|Active Comparator|FPNS, FFNS|active compound
89229204|NCT00539006|Placebo Comparator|placebo FFNS, placebo FPNS|placebo arm
89229205|NCT00539006|Placebo Comparator|placebo FPNS, placebo FFNS|placebo arm
89229206|NCT00776087|Experimental|1 = Home Monitoring|Remote monitoring of ICD and CRT-D function and patient status
89229207|NCT00776087|Active Comparator|2 = No Home Monitoring|Home Monitoring option is switched off
89229208|NCT00776165|Experimental|1|Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha) Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
89110060|NCT05514678|Experimental|Cognitive Stimulation Therapy|In the 2nd, 3rd, 4th, 6th, 7th and 8th weeks, IPT implementation twice a week, as two themes, for 7 weeks, with each session of 45 minutes.
89110061|NCT05514678|Experimental|CST nonpharmacological intervention|Individuals in the control group will be given two sessions in the 2nd week, and they will continue their daily lives in the following weeks.
89110062|NCT02806401|Experimental|landmark|landmark method_subclavian venous cannulation
89110063|NCT02806401|Active Comparator|US_Ax|ultrasound guided axillary venous cannulation
89110064|NCT02800083|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
89110065|NCT02800083|Placebo Comparator|Placebo|placebo
89110066|NCT02806167|Experimental|Clinical algorithm|This is a single arm study. All eligible patients will be subject to our clinical algorithm.
89110067|NCT00763321|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
89110068|NCT00763321|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
89110069|NCT00763321|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
89229209|NCT00776165|Active Comparator|2|Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
89229210|NCT00989456|Experimental|exercise and education|Supervised physical exercise in groups, plus a self management education programme (patient education).
89229211|NCT00989456|Active Comparator|exercise only|Supervised physical exercise in groups.
89229212|NCT04521374|Experimental|Standard Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 7) will consist of meat, potatoes and peas: 333kcal, 16g protein.
89229213|NCT04521374|Experimental|Standard Protein Fortified Meal|A regular meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 7) will consist of meat, potatoes and peas: 333kcal, 25g protein.
89229214|NCT04521374|Experimental|Texture Modified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 4) will consist of meat, potatoes and peas: 340kcal, 16g protein.
89229215|NCT04521374|Experimental|Texture Modified Protein Fortified Meal|A pureed meal (equivalent to International Dysphagia Diet Standardisation Initiative [IDSSI] Level 4) will consist of meat, potatoes and peas: 350kcal, 25g protein.
89229216|NCT04047329||Without post-operative myocardial infarction|Patients without post-operative myocardial infarction after first admission for transurethral resection of the prostate
89229217|NCT04047329||With post-operative myocardial infarction|Patients with post-operative myocardial infarction after first admission for transurethral resection of the prostate
89229218|NCT00779753|Experimental|Neonates|Sixteen neonates admitted to the Neonatal Intensive Care Unit (NICU) at the Hospital for Sick Children (SickKids) will be required for this study. The diagnoses will include, but are not limited to, the following: Trachea-esophageal fistula and/or esophageal atresia, Congenital diaphragmatic hernia, imperforate anus, Hirschsprung's disease, Malrotation with or without volvulus, Intestinal atresias, Gastroschisis, Omphalocele, Necrotizing enterocolitis, Respiratory distress syndrome.
89229219|NCT00537056|Experimental|F-18 FDG PET/CT and DCE MRI|FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po
89229220|NCT00779831|Experimental|1|120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy
89229221|NCT00779831|Active Comparator|2|(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets
89229222|NCT00776243||wDM|Early diabetes
89229223|NCT00776243||pDM|Poorly controlled diabetic patients
89229224|NCT00776321|Placebo Comparator|1|
89229225|NCT00776321|Experimental|Eprotirome dose 1|
89229226|NCT00776321|Experimental|Eprotirome dose 2|
89229227|NCT00535262|Experimental|EmSam|EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.
89229228|NCT00776399|Experimental|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
89229229|NCT00989534|Experimental|Sleep loss and circadian alignment|Sleep restriction without circadian misalignment
89229230|NCT00989534|Experimental|Sleep loss and circadian misalignment|
89229231|NCT00772499|Experimental|1|olmesartan medoxomil tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
89229232|NCT00772499|Active Comparator|2|Atenolol tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
89229233|NCT00779987|Other|Autologous serum -Systane|Crossover arm starting with autologous serum for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)
89229234|NCT00779987|Other|Systane- Autologous serum|Crossover arm starting with artificial tears (Systane) for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.
89229235|NCT04819022||Musculoskeletal disorder|
89229236|NCT00074581|Experimental|1|Participants will begin ART in addition to receiving HIV primary care
89229237|NCT00074581|Experimental|2|"Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.~Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible."
89229238|NCT00776477|Experimental|1|
89229239|NCT00776477|Active Comparator|2|
89229240|NCT04692116|Experimental|ExAblate Arm|ExAblate Model 4000 System for the treatment of Parkinson's disease
89229241|NCT00772655|Experimental|Study Therapy|Induction therapy with a single course of 90Yttrium-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111Indium-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 up to a maximal dose of 12.000 MBq [if platelets are below 150000/µl only 11 MBq/kg are administered). Observation for patients achieving complete clinical and molecular response or partial clinical response. Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2 (t14;18)-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
89229242|NCT04299542|Active Comparator|conventional Multi-detector CT (MDCT)|Percutaneous lung biopsy using MDCT
89229243|NCT04299542|Active Comparator|cone-beam CT (CBCT)|Percutaneous lung biopsy using CBCT
89229244|NCT00780221||control|patients without coronary artery disease
89229245|NCT00780221||case|patients with coronary artery disease
89229246|NCT01086865|Active Comparator|Petivit BC|
89229247|NCT01086865|Experimental|Apetiviton BC|
89229248|NCT00780299|Active Comparator|2|control
89110070|NCT02799927|Experimental|Biodentine|"Biodentine (Septodont, Saint-Maur-des-Fosses, France) has been recently introduced and marketed as a bioactive dentin substitute. The Biodentine powder contains tricalcium silicate, dicalcium silicate and calcium oxide, while its liquid consists of calcium chloride and a carboxylate-based hydrosoluble polymer (water-reducing agent).~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the preparation of Biodentine liner (a mix of powder and liquid), following the manufacturers' instructions, and its placement over the remanent carious dentin layer."
89110071|NCT02799927|Active Comparator|Ultra-Blend plus (Calcium hydroxide)|"Ultra-Blend plus® (Ultradent Products Inc., South Jordan, UT, USA). This material is a light-activated calcium hydroxide based-liner. Calcium hydroxide has demonstrated to reduce and promote immediate deactivation of the residual microorganisms after IPT.~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the placement of Ultra-Blend plus liner over the remanent carious dentin layer, using a dycal metallic applicator. Finally, the liner is cured through light exposure during 20 seconds ."
89229249|NCT00780299|Experimental|1|HDHP
89110072|NCT02800005|Other|BMI group (Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese. Investigators declare that there exists no conflicts of interest.
89229250|NCT03895034|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
89229251|NCT03960931|Experimental|Aquatic rehabilitation|
89229252|NCT03960931|Experimental|Land based physical activities|
89229253|NCT03960931|Other|Conventional rehabilitation|
89229254|NCT00776633|Experimental|Short triple|6 weeks triple therapy
89229255|NCT00776633|Active Comparator|Long triple|6 months triple therapy
89229256|NCT01093963|Active Comparator|Lisdexamfetamine|Drug
89229257|NCT01093963|Placebo Comparator|Placebo|Drug
89110073|NCT02800005|Experimental|AFA group(Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit. No contrast agent is needed. Patients in the AFA group will be also measured by BMI. Investigators declare that there exists no conflicts of interest.
89110074|NCT02804139|Active Comparator|Standard care|Standard Care after C-section with no additional physical therapy.
89110075|NCT02804139|Experimental|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization
89110076|NCT02806089|Experimental|Muscle strength|"single evaluation (the day of inclusion) of muscle strength (by handheld dynamometer), muscle mass (by creatinine index estimation), lean body mass (by electrical bioimpedance analysis), physical activity (by Voorrips score questionnaire), inflammatory and nutritional status."
89110077|NCT04099017|Experimental|Mulligan mobilization group|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~Mulligan joint mobilization in Non-weight bearing (NWB):~Knee strengthening~Kinesiotaping"
89110078|NCT04099017|Experimental|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Trunk stabilization i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~Iv. lateral step up:~Knee strengthening i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~Kinesiotaping:"
89110079|NCT04099017|Other|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Knee strengthening i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~Kinesio-taping:"
89110080|NCT02799849|Other|Narcoleptic patients|
89110081|NCT02799849|Other|hypersomnic patients|
89110082|NCT00770653|Experimental|Pioglitazone 15 mg and Metformin 850 mg BID|
89110083|NCT00770653|Active Comparator|Glimepiride 2 mg and Metformin 850 mg BID|
89110084|NCT02806011||no Intervention|Long-term follow up of no intervention group
89110085|NCT02806011||1-time injection group|Long-term follow up of 1-time injection group
89110086|NCT02806011||2-time injection group|Long-term follow up of 2-time injection group
89110087|NCT04079907|Experimental|Ketone|This arm will receive a supplement with 25g ketone ester. It is a commercially available supplement and will be provided as a standard dose.
89110088|NCT04079907|Placebo Comparator|Placebo|This arm will receive an isocaloric supplement.
89110089|NCT04036773|Experimental|Intervention Group|
89110090|NCT04036773|No Intervention|Control Group|
89110091|NCT00819052|Active Comparator|NVP IR|200 mg orally twice a day (po BID)
89110092|NCT00819052|Experimental|NVP XR|400 mg orally once a day (po QD)
89110093|NCT02799537|Experimental|Intervention|Participants in the intervention arm complete the Stanford letter advance directive
89110094|NCT02799537|Active Comparator|Control|Participants in the control arm complete the California state traditional advance directive
89110095|NCT00763009|Other|All subjects receive dipyridamole|Compare to baseline
89110096|NCT04098757||Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
89110097|NCT04098757||acupuncture|2 sessions a week, for a total of 10 (5 weeks), performed by the same operator, repeatable if necessary, after a therapeutic interval of at least one month. Each session lasts about 20-30 minutes per patient. Tewa J Type sterile disposable needles, coated, with a Chinese-style copper wire handle, with a guide tube, of 22x13 mm (CJ 2213) and 30x25 mm (CJ 3025) will be used. Acupuncture will be carried out by same trained operator.
89110098|NCT02799459||General anaesthesia|this group will allow us to compare the results like it is the treatment used in current practice ie general anesthesia.
89110099|NCT02799459||Hypnosis in conization|This group is the treatment being tested , where hypnosis is used in the conization
89110100|NCT02803983||Pediatric hip plate|The children were treated with pediatric hip plate.
89110101|NCT02803983||Cannulated screw|The children were treated with cannulated screw.
89229258|NCT01564316||neurodegeneration patients|•neurodegeneration patients and control group include dementia patients visited the part of neurology
89110102|NCT02612350||Increased Risk for Cancer Development|The group is to include at least 1000 individuals who are at high risk for the development of cancer. Risk is assessed through the completion of a clinical history questionnaire. Examples of such subjects include those with known hereditary cancer syndrome pathogenic variants without a diagnosis of cancer, with significant family history of breast, ovarian, colon, or lung cancer or melanoma, or another strong history of cancer but no prior molecular diagnosis, heavy smokers or those exposed to carcinogens and mutagens. The individuals who meet criteria for inclusion will undergo cell-free DNA isolation and circulating-tumor DNA (ctDNA) analysis for the detection of genetic mutations associated with the possible development of a malignancy.
89110103|NCT02805777|Experimental|Washing procedure 1|this group will apply washing technique 1
89110104|NCT02805777|Experimental|Washing procedure 2|this group will apply washing technique 2
89110105|NCT05477589|Active Comparator|BuCyMel|a combination of busulfan, cyclophosphamide and melphalan, conditioning regimen
89110106|NCT05477589|Experimental|CloFluBu|a combination of clofarabine, fludarabine and busulfan conditioning regimen
89110107|NCT05758636|Experimental|Emotional Freedom Technique Group|Nurses (40) enrolled in the emotional freedom technique group will receive a total of 4 rounds of EFT, 50 minutes, 3 days a week.
89110108|NCT05758636|No Intervention|Control|Participants in the control group (n= 40) will not receive intervention throughout the study.
89110109|NCT00841672|Experimental|Aliskiren/amlodipine 300/10 mg tablet|Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
89110110|NCT00841672|Active Comparator|Amlodipine 10 mg capsule|Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
89110111|NCT05549115|Experimental|clarithromycin-sensitive(first-line)|If H. pylori is sensitive to clarithromycin, we will administer clarithromycin triple therapy-esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily)-for 14 days
89229259|NCT03956563|Active Comparator|Active treatment arm|Youlaser MT: sequential 10600+1540 nm with vaginal (2 passes) and intritus (1 pass) treatment
89229260|NCT03956563|Sham Comparator|Control arm|Youlaser MT: no laser emission with vaginal (2 passes) and intritus (1 pass) treatment
89110112|NCT05549115|Experimental|clarithromycin-resistant(first-line)|If H. pylori is clarithromycin resistance, we selected the High-dose dual therapy (HDDT) regimen as first-line treatment. HDDT-esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily)-will be used for 14 days.
89110113|NCT05549115|Active Comparator|empirical therapy group first-line|The empirical therapy group will receive Bismuth-containing quadruple therapy(BQT) as first-line treatment, The BQT regime is comprising of esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days.
89110114|NCT05549115|Experimental|levofloxacin-sensitive(rescue treatment)|If H. pylori was levofloxacin-sensitive, we will use the levofloxacin quadruple regimen as rescue treatment-esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily)-for 14 days.
89110115|NCT05549115|Experimental|levofloxacin-resistant(rescue treatment)|If H. pylori was levofloxacin-resistant, we will use furazolidone quadruple regimen as rescue treatment-esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily)-for 14 days.
89110116|NCT05549115|Active Comparator|empirical therapy group rescue treatment|If BQT fails, HDDT-esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily)-will be used as a rescue treatment for 14 days.
89110117|NCT02805699|Experimental|Baofeikang Granule|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,cough,give BaoFeikang Granules(by Beijing KangRentang Pharmaceutical Co., Ltd.), 1 bag, twice each day.
89110118|NCT02805699|Placebo Comparator|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,coughand give Chinese medicine placebo (by Beijing Kang Rentang Pharmaceutical Co., Ltd., requirements and Chinese medicine BaoFeikang Granules in appearance and taste similar),1bag，twice each day.
89110119|NCT04236219|Experimental|ALLN-346|ALLN-346
89110120|NCT04236219|Placebo Comparator|Placebo|Placebo
89110121|NCT00908232|Experimental|Stable Disease: VD|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
89110122|NCT00908232|Experimental|Stable Disease: VDC|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8
89110123|NCT00908232|Experimental|Stable Disease: VDL|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8
89110124|NCT00908232|Experimental|Complete to Partial Response: VD|Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
89110125|NCT05545761|Experimental|intervention group|music will be played to the intervention group. They will be asked to listen to the Hüseyni makam for at least 15 minutes at 11.00 in the morning, 5 times a week for 5 weeks, and to listen to the Zirgüle makam for at least 15 minutes at 20.00 on the same day.
89110126|NCT05545761|No Intervention|control group|group that does not listen to music and is not interfered with
89110127|NCT00770341|Experimental|MK-3009 (daptomycin) 4 mg/kg|
89110128|NCT00770341|Active Comparator|Vancomycin|
89110129|NCT00770341|Experimental|MK-3009 (daptomycin) 6 mg/kg|
89110130|NCT02805621||Subject|Patients with know or suspected coronary artery disease, who underwent both CT angiography and invasive coronary angiography including invasive FFR measurements.
89229261|NCT03743090||CABG with ECC|Group of patients for whom CABG was performed under ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
89229262|NCT03743090||CABG without ECC|Group of patients for whom CABG was performed without ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
89229263|NCT00772811|No Intervention|Flu-Mel|Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.
89229264|NCT03961087|Active Comparator|case group|patients with liver cirrhosis and frequent hepatic encephalopathy received coenzyme Q10 and Meclofenoxate in addition to usual hepatic support
89229265|NCT03961087|No Intervention|control group|patients with liver cirrhosis and frequent hepatic encephalopathy received usual hepatic support only
89229266|NCT03960775|Experimental|Group A (dexmedetomidine)|dexmedetomidine infusion group
89229267|NCT03960775|Placebo Comparator|Group B (saline)|normal saline infusion group
89229268|NCT00536978|Experimental|NK Cell/T-Cell Infusion|Possible Cell Adback - infusion NK cells or T-cells from donor given after blood stem cell transplantation for either Reduced intensity chemotherapy of campath, modified BEAM regimen of Campath-IH 15 mg intravenous (IV) Daily for 3 Days + BEAM Daily for 4 days (BCNU 300 mg/m^2 IV, Etoposide 100 mg/m^2 IV, Ara-C 100 mg/m^2 IV Daily for 4 days and Melphalan 100 mg/m^2 IV Over 30 Minutes for 1 Day) + Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks]; or Non-myeloablative Preparative Regimen [Fludarabine 30 mg/m^2 IV Daily Over 1 Hour for 3 Days; Cyclophosphamide 1000 mg/m^2 IV Daily Over 1 Hour for 3 Days; Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks; Campath-IH 15 mg IV Daily Over 30 Minutes for 3 Days; plus Total Body radiation (TBI)].
89229269|NCT05356832||continent|able to hold urine during sports
89229270|NCT05356832||incontinent|leaking urine during sports
89229271|NCT03809611|Experimental|UNR844-Cl Ophthalmic Solution|1.5% UNR844-Cl ophthalmic solution for twice-daily dosing
89229272|NCT03809611|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution for twice-daily dosing
89229273|NCT05360342|Experimental|Vitamin K supplement|Administration of a single dose vitamin K
89229274|NCT00989846||lung disease|patients with various chronic or acute lung diseases
89229275|NCT05356754|Experimental|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals. The VLDBPM captures PPG signals using the existing camera systems on iPhones. These PPG signals are normalized and processed to determine markers of blood pressure change. These markers, when transformed using a predetermined model, are capable of determining blood pressure changes from a known (calibration) set-point.
89229276|NCT03807739|Experimental|Part I: GDC-0134 F16 vs F09 Capsule Formulation|In Part 1 participants will receive single doses of either GDC-0134 F16 capsules (prototype) or GDC-0134 F09 capsules (reference) after having consumed a standard meal.
89229277|NCT03807739|Experimental|Part II: GDC-0134 F15 vs F09 Capsule Formulation|In Part 2, participants will receive a single dose of either GDC-0134 F15 capsules (prototype) or GDC-0134 F09 capsules (reference) after an overnight fast.
89229278|NCT05290220|Experimental|Arm A: As first-line therapy|HLX07 1500 mg + HLX10 300 mg + HLX04 15mg/kg iv q3w
89229279|NCT05290220|Experimental|Arm B: As second-line therapy|HLX07 1500 mg iv Q3w + Lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW <60 kg) po qd
89229280|NCT05290220|Experimental|Arm C:As third-line or above therapy|HLX07 1500 mg iv Q3w
89110131|NCT03813420|Other|Physiotherapy students|"Pittsburgh Sleep Quality Index-PSQI:The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month~International Physical Activity Questionnaire-IPAQ: The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as the intensity of physical activity in the last seven days.~Short Form-36-SF-36: The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts."
89110132|NCT02601547|Experimental|intervention|"PET-FDG brain imaging and NPT should be performed at T0 (within the 15 days before chemotherapy), at Tf (within 1 month after chemotherapy termination), T+12 (Tf+12 months: within the first month after one year of achievement of chemotherapy). Several PET parameters should be calculated: minimal Standard Uptake Value (SUV), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.~NPT scores (3 values) should be correlated with the five better values on PET-FDG.~Each patient will be monitored along a time period of 18 months.~Duration of the study: one year to include the 15 patients with all the exams; 18 months follow-up for each; total of 30 months."
89110133|NCT02691000|Experimental|Bright White Light (BWL) Litebook|Participants will be instructed to use the BWL Litebook for an hour every day for 8 weeks.
89110134|NCT02691000|Placebo Comparator|Dim Red Light (DRL) Litebook|Participants will be instructed to use the DRL (comparison condition) Litebook for an hour every day for 8 weeks.
89110135|NCT04097041|Active Comparator|Surgical Arm|Surgery arm - patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).Patient has routine follow up - H&P, 2 weeks after surgery and then H&P, Audiometry and Tympanometry over 12 months post surgery (3rd month, 6th month and 12th month).
89229281|NCT01583257|Experimental|Active Video Gaming|An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.
89110136|NCT04097041|Active Comparator|Non-Surgery|"Non surgery arm - patient has audiological consult and fitting of masking device.~The Patient has a routine follow up - H&P, 2 weeks after masking fitting and then H&P, Audiometry, Tympanometry over 12 months (3rd month, 6th month and 12th month). Patient cross over to change arms, at 6 months, if they have no resolution of symptoms."
89110137|NCT04236687|Experimental|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
89110138|NCT04236687|Active Comparator|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate. The injected microspheres will slow the blood flow to the prostate.
89110139|NCT02803827|Experimental|Rapid diagnostics and probiotic|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
89110140|NCT02803827|Other|Rapid diagnostics and placebo|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given placebo x 60 days.
89110141|NCT02803827|Other|No rapid diagnostics and probiotic|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
89110142|NCT02803827|Placebo Comparator|No rapid diagnostics and placebo|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given placebo x 60 days.
89110143|NCT02799303|Experimental|Multi-parametric MRI|Patients from the general population without history of previous prostate biopsy will be allocated to receive mpMRI in order to evaluate for risk of prostate cancer.
89229282|NCT03956329|No Intervention|Usual care, control arm|Usual care in which participants will not see a video intervention. This group will attend their influenza vaccination appointment as usual, without intervention. Participants will receive Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
89229283|NCT03956329|Experimental|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
89229284|NCT03956329|Experimental|Individualised Digital Intervention|Similar to the standardised digital intervention, however participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. Following intervention, participants will receive the Northern Hemisphere Influenza Vaccine 2019/20 (Delivered as part of Standard Care).
89229285|NCT01583413|Experimental|Opt Out Protocol|
89229286|NCT00536744|Active Comparator|Active PACE application - 4 applications|Application of acoustical pulse energy (extracorporeal shockwaves) to target ulcer + standard of care
89229287|NCT00536744|Sham Comparator|Inactive, non-energy application|Non-energized (inactive - Sham)) application + standard of care
89229288|NCT01094041|Experimental|Gluten free diet|
89229289|NCT01094041|Experimental|Gluten rich diet|
89229290|NCT04076072|Active Comparator|Alcon Advanced Ultravit High-Speed Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
89523232|NCT03388021|Experimental|routine use of completion angiography after thromboembolectomy|"this group will undergo surgical revascularization followed by routine completion angiography assisted with one of these adjuvant techniques as:~Thromboembolectomy under fluoroscopic guidance using Fogarty over the wire~Balloon angioplasty and/or stenting~Intraarterial thrombolysis~Aiming to correct any residual angiographic lesion as:~Residual thrombus~Retained embolus~Atheromatous plaque"
89110144|NCT02799303|Active Comparator|PSA Only|"Patients from the general population without history of previous prostate biopsy will be allocated to receive serum PSA testing in order to evaluate for risk of prostate cancer.~Patients with a serum PSA level less than 4.0 ng/mL will be managed expectantly with results provided to their primary care physician."
89110145|NCT03793608|Experimental|Dupilumab|Open label weight base subcutaneous (SC) injection every two (Q2) weeks.
89110146|NCT02798991|Experimental|10 mg of GSK3179106 QD-Cohort 1|Eligible six subjects will receive 10 mg oral dose once daily for 14 days
89110147|NCT02798991|Experimental|50 mg of GSK3179106 QD-Cohort 2|Eligible six subjects will receive 50 mg oral dose once daily for 14 days
89110148|NCT02798991|Experimental|200 mg of GSK3179106 QD-Cohort 3|Eligible six subjects will receive 200 mg oral dose once daily for 14 days
89110149|NCT02798991|Experimental|400 mg of GSK3179106 QD-Cohort 4|Eligible six subjects will receive 400 mg oral dose once daily for 14 days
89110150|NCT02798991|Experimental|25 mg of GSK3179106 BID-Cohort 5|Eligible six subjects will receive 25 mg oral dose twice daily for 14 days
89110151|NCT02798991|Experimental|200 mg of GSK3179106 BID-Cohort 6|Eligible six subjects will receive 200 mg oral dose twice daily for 14 days
89110152|NCT02798991|Placebo Comparator|Matching placebo QD-Cohort 1, 2, 3, 4|Eligible two subjects, per cohort, will receive oral dose of matched placebo once daily for 14 days
89110153|NCT02798991|Placebo Comparator|Matching placebo BID-Cohort 5, 6|Eligible two subjects, per cohort, will receive oral dose of matched placebo twice daily for 14 days
89110154|NCT03787836|No Intervention|Controls|The primary purpose of the control participants are to provide a measure of variability. They will be used in our calculations of typical error to classify participants as responders or non-responders, and to quantify inter-individual variability.
89110155|NCT03787836|Experimental|Exercisers (Maintained)|The maintained exercise group will complete the original 16-week exercise intervention at an intensity of 4.5 metabolic equivalents (METs), and repeat the intervention for another 12-weeks following its completion.
89110156|NCT03787836|Experimental|Exercisers (Increased Intensity)|The increased intensity exercise group will complete the original 16-week exercise intervention, followed by an additional 12 week intervention completed at an intensity of 6.0 METs.
89110157|NCT05472753|Experimental|Group 1 (25 patients)|A product of the company DCOOP, with hydroxytyrosol extract
89110158|NCT05472753|Experimental|Group 2 (25 patients)|A product of the company Indukern, with extract of curcumin and selenium
89229291|NCT04076072|Active Comparator|Alcon Non-Beveled Tip Vitrectomy Probe|On the day of surgery, patients will be randomized to the Ultravit High-Speed Beveled Probe or the current non-beveled Alcon Probe. All patients will undergo routine vitrectomy surgery as scheduled; patients will be unaware of the vitrector probe used. Time to completion of vitrectomy and time to completion of vitreous base shave will be recorded by study staff unaware of the vitrector probe used. All examination will be repeated as regularly scheduled postoperative visits by a reader unaware of which probe was used. Safety will be assessed at each visit by evaluation for any adverse events.
89229292|NCT04026230|Experimental|Atorvastatin|Capsules of atorvastatin. Daily dose of 80 mg for max. 10 years or until development of castration resistance.
89110159|NCT05472753|Placebo Comparator|Group 3 (25 patients)|Placebo
89110160|NCT02799147|Experimental|280 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 140 mg/m2/day iv.
89110161|NCT02799147|Experimental|200 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 100 mg/m2/day iv
89110162|NCT02799147|Experimental|140 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3, +4: Bendamustine 70 mg/m2/day iv.
89110163|NCT03396042||Group 1|5 Patient target, ages 3 to 5 yr, with visual acuity Light Perception (LP) to <=20/200
89110164|NCT03396042||Group 2|5 Patient target, ages 3 to 5 yr, with visual acuity >20/200 to <=20/50
89110165|NCT03396042||Group 3|5 Patient target, ages 6 to 11 yr, with visual acuity LP to <=20/200
89110166|NCT03396042||Group 4|5 Patient target, ages 6 to 11 yr, with visual acuity >20/200 to <=20/50
89110167|NCT03396042||Group 5|5 Patient target, ages 12 to 17 yr, with visual acuity LP to <=20/200
89110168|NCT03396042||Group 6|5 Patient target, ages 12 to 17 yr, with visual acuity >20/200 to <=20/50
89110169|NCT03396042||Group 7|5 Patient target, ages 18yr and older, with visual acuity LP to <=20/200
89110170|NCT03396042||Group 8|5 Patient target, ages 18yr and older, with visual acuity >20/200 to <=20/50
89110171|NCT02799225||Enterobacteria|
89110172|NCT03394326|Experimental|LOW-ED|In the LOW-ED condition each participant will consume at least 10 low-ED foods/day (ED ≤1.0 kcal/g) and no more than 2 high ED foods/day (ED ≥3.0 kcal/g). Foods with an ED >1.0 kcal/g and <3.0 kcal/g will be unlimited; however, lowering the overall ED of the diet will be encouraged.
89110173|NCT03394326|Active Comparator|STANDARD|In the STANDARD condition participants will consume the recommendations for calories, fruits, vegetables and whole grains based on age and sex corresponding with MyPlate. The daily caloric recommendations from MyPlate are for weight maintenance.
89110174|NCT02798913|Experimental|Short DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
89110175|NCT02798913|Experimental|Long DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
89110176|NCT03388476||Suspicion of pulmonary hypertension|At Patients with suspicion of pulmonary hypertension, which get a right heart catheterization, in the context of the study the exhaled air, precious the endtidal carbon dioxide (CO2), before or after the right heart catheterization will be measured through capnography.
89110177|NCT02805543||diabetes group|34 T2DM patients without vascular complications as diabetes group
89110178|NCT02805543||control group|32 healthy people were recruited as control group
89110179|NCT04016025|Active Comparator|cream|Treatment with topical Methylprednisolone aceponate 0,1% cream (Advantan®) plus Basic care (Bepanthen® Sensiderm)
89110180|NCT04016025|Active Comparator|fatty ointment|Treatment with topical Methylprednisolone aceponate 0,1% fatty ointment (Advantan®) plus Basic care (Bepanthen® Sensiderm)
89110181|NCT03327636|Experimental|High Intensity Focused Ultrasound|Apply the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the papillary thyroid microcarcinoma.
89110182|NCT03327636|No Intervention|Active surveillance|The participants will be monitored by the doctors actively, like more frequent in follow-up to observe their current situation.
89110183|NCT05331924|Active Comparator|IPL therapy|Fifteen patients with severe to moderate evaporative dry eye disease were treated with 3 sessions of IPL therapy.
89110184|NCT05331924|Active Comparator|Punctal plugs|Fifteen patients with severe to moderate evaporative dry eye disease were treated with silicone punctal plug insertion.
89110185|NCT02805387|No Intervention|no treatment|Dystocic women where no bicarbonate was given
89110186|NCT02805387|Experimental|Treatment|Dystocic women where bicarbonate was ingested
89110187|NCT05333094|Active Comparator|American orthodontics brackets|"Roth prescription, 0.022 slot size"
89110188|NCT05333094|Active Comparator|FANTA brackets|"Roth prescription, 0.022 slot size"
89110189|NCT05333094|Active Comparator|MATT brackets|"Roth prescription, 0.022 slot size"
89110190|NCT00762463|Experimental|Celecoxib 200 mg QD|
89110191|NCT00762463|Active Comparator|Diclofenac SR 75 mg QD|
89110192|NCT02805465|Experimental|HBP Group|CRT Device and His-bundle Pacing. Patients will get His-bundle pacing through a CRT device first for 9 months then switch to Bi-ventricular pacing by the same CRT device for another 9 months.
89110193|NCT02805465|Active Comparator|BiVP Group|CRT Device and Bi-ventricular Pacing. Patients will get BiV pacing for 9 months through a CRT device then switch to His-bundle pacing by the same CRT device for another 9 months.
89110194|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ angled tip|Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
89110195|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ angled tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
89110196|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ straight tip|Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
89110197|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ straight tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
89110198|NCT00762385|Active Comparator|galyfilcon A/comfilcon A|galyfilcon A first, comfilcon A second
89110199|NCT00762385|Active Comparator|comfilcon A/galyfilcon A|comfilcon A first, galyfilcon A second
89110200|NCT00906282|Experimental|Pemetrexed/Carboplatin|"4 cycles of preoperative treatment (1 Cycle = 21 days):~Pemetrexed: 500 mg/m2 intravenously (IV) for 10 minutes on Day 1 each cycle; Carboplatin: AUC 6.0 by IV on Day 1 each cycle."
89110201|NCT02798445|Experimental|tapirs|this group will have surgery with endovascular laser treatment (EVLT) in the axial vein and foam sclerotherapy echo-guided in perforator veins and veins in relation with the ulcer, after the surgery the patients will have conventional wound care plus juxta cure system that give a continuous compression in the leg.
89110202|NCT02798445|Active Comparator|multilayer bandage|multilayer bandage and conventional wound care (grade 1A) recommendation in management of vein ulcers. gold standard
89110203|NCT02798757|Experimental|Dapagliflozin|All patients will take dapagliflozin, the intervention does not refer to a drug or device but to the specific 1HNMR test spectroscopy
89110204|NCT04100863||Individuals with Autism|Individuals who have been diagnosed with autism
89110205|NCT05200806|Other|Intervention|Pre-Op Enhanced Recovery After Surgery (ERAS): Gabapentin (900mg capsule), Acetaminophen (1,000mg tablet), Dexamethasone (8mg IV), Granisetron (1mg IV), Morphine (0.15mg Intrathecal) Intraoperatively: Appropriate medications administered at discretion of the treating anesthesiologist during colectomy, with Ketamine use encouraged if not contraindicated. Post-Op (PACU, Onward during inpatient stay): Acetaminophen (Oral) (650mg, q4hrs), Gabapentin (300mg, q6hours), Methocarbamol (750mg, QID), 5% Lidocaine Patch (q12hrs PRN) One time rescue dose (Hydromorphone, Morphine, Oxycodone) available for breakthrough pain during hospital stay (differs from traditional ERAS protocol where medications can be administered as needed). If one-time rescue dose is needed, the covering physician will be notified and can choose to order an appropriate narcotic regimen for remainder of patient's hospitalization. All patients are discharged with a narcotics prescription that they can choose to fill.
89110206|NCT02798367|Experimental|CBT-I plus Melatonin 3 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 3mg. Melatonin 3mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
89110207|NCT02798367|Experimental|CBT-I plus Melatonin 5 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 5mg. Melatonin 5mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
89229293|NCT04026230|Placebo Comparator|Placebo|Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 10 years or until development of castration resistance
89229294|NCT00536510|Experimental|1|laropiprant/niacin (MK0524A)
89229295|NCT00536510|Placebo Comparator|2|placebo
89229296|NCT04526600|No Intervention|No fidget|
89110208|NCT02798367|Other|CBT-I plus placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo. The participants shall administer the placebo tablets to enable the double-blind study. Placebo will be dispensed to 65 (first stage) and 56 (second stage) participants of this group and shall administer 01 tablet orally every 24 hours one hour before bedtime for 21(±2) days.~Sleep hygiene is a psychoeducational intervention that teaches patients to prevent external or environmental factors generate adverse effects and harmful to sleep. The stimulus control technique is based on five instructions that encourages the patient to establish a proper sleep-wake rhythm and strengthens the links between the way for a quick and well consolidated sleep. The CBT-I guidelines are standardized in clinical protocol."
89110209|NCT00762229|Active Comparator|Ezetimibe 10 mg|A whole ezetimibe 10 mg tablet
89110210|NCT00762229|Experimental|Ezetimibe 5 mg|"Ezetimibe 5 mg, formulated by splitting a 10 mg ezetimibe tablet in half"
89110211|NCT00907374|Active Comparator|Low dose inhibition of RAS|Standard low dose inhibition of the RAS with 10 mg of benazepril orally daily to treat microalbuminuria
89110212|NCT00907374|Experimental|Agressive inhibition of the RAS|40-80 mg benazepril plus 25-100 mg losartan both orally once or twice daily
89110213|NCT02805153|Experimental|Experimental/PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
89110214|NCT02805153|Active Comparator|Active Comparator/rhG-CSF|patients received daily subcutaneous injections of rhG-CSF(filgrastim) 5 ug/ kg/day. Injections on day 3 after chemotherapy and continued daily until an ANC of at least 10.0 X 10^9/L was documented after the expected nadir, or for a maximum of 14 days
89110215|NCT04096339|Active Comparator|EGD followed by Colonoscopy|Randomized to group Esophagogastroduodenoscopy followed by Colonoscopy
89110216|NCT04096339|Active Comparator|Colonoscopy followed by EGD|Randomized to group Colonoscopy followed by Esophagogastroduodenoscopy
89110217|NCT04100707|Experimental|Operated|Genicular block will aply to the patients with knee pain who was operated before
89110218|NCT04100707|Sham Comparator|Nonoperated|Genicular block will aply to the patients with knee pain who wasn't operated before
89110219|NCT02805231||primary open-angle glaucoma patients|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
89110220|NCT02805231||randomly age-matched people|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
89110221|NCT02803671|Experimental|patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
89110222|NCT02803671|Experimental|without patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
89110223|NCT02803671|Experimental|patent ductus arteriosus + cardiac or respiratory therapy|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
89110224|NCT02805075|Experimental|Supportive care (Fructooligosaccharide)|Patients receive FOS PO BID for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.
89110225|NCT02803515|Experimental|Patient with HIPEC|
89110226|NCT02803515|Sham Comparator|Patient without HIPEC|
89110227|NCT03240978|Experimental|High intensity intervention|Exercise intervention at 70 to 80% of estimated heart rate maximum for 12 weeks.
89110228|NCT03240978|Experimental|Moderate intensity intervention|Exercise intervention at 50 to 70% of estimated heart rate maximum for 12 weeks.
89110229|NCT03240978|No Intervention|non-exercise group|Participants will not receive any type of exercise training.
89110230|NCT05461209|Experimental|Arm A: Talquetamab|Participants will receive talquetamab subcutaneously (SC).
89110231|NCT05461209|Active Comparator|Arm B: Belantamab Mafodotin|Participants will receive belantamab intravenously (IV).
89229297|NCT04526600|Experimental|With fidget|The participant is given a specially designed fidget ball
89110232|NCT03230604|Active Comparator|Bulk-Fill composite Class I, II and V cavities|Restorative with Filtek Bulkfill composite in class I, II and V Restorative with Tetric N Ceram composite in class I, II and V
89110233|NCT03230604|Active Comparator|Z 350 xt Composite|Restorative with Z 350 xt composite in class I, II and V
89110234|NCT03223194|Experimental|Cohort 1|1.5 x 10^12 vg/kg of AT342 delivered intravenously one time
89110235|NCT03223194|Experimental|Cohort 2|6.0 x 10^12 vg/kg of AT342 delivered intravenously one time
89110236|NCT03223194|Experimental|Cohort 3|1.5 x 10^13 vg/kg of AT342 delivered intravenously one time
89110237|NCT03223194|No Intervention|Delayed-Treatment Control|Control subjects will generally have the same assessments as treated subjects. Once the optimal dose is selected, control subjects will undergo pre-treatment baseline procedures to confirm that they are eligible to receive treatment with AT342. Once eligible control subjects are dosed with AT342, they will initiate the same post-dose procedures as subjects who received AT342.
89110238|NCT02804919|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
89110239|NCT05331768|Experimental|24-h group|The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
89110240|NCT05331768|Active Comparator|72-h group|The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe
89110241|NCT04235595|Experimental|Connective Tissue Manipulation|The participants were administered CTM by a physiotherapist with 11 years of experience in the application from the point at which their menstrual cycles had ended to the beginning of the next cycle. Another assessment was made immediately after the treatment and this was repeated at the second, third and fourth menstrual cycles. The CTM took an average of 20-30 minutes to complete.
89110242|NCT04235595|Experimental|Transcutaneous Electrical Nerve Stimulation|Following the assessment made in the participants' first menstrual cycle, on the most painful day of their second cycle (1st or 2nd day of the cycle), high-frequency TENS was applied at a frequency of 120 Hertz, at intervals of 100 µsn for 20 minutes. The intensity of the current was increased until the participant felt it.
89110243|NCT03609762|Experimental|Intervention group|EQ-5D-5L HRQOL results be available to the attending doctor
89110244|NCT03609762|No Intervention|Control group|usual care. All subjects attending the control clinics will not need to complete the electronic EQ-5D-5L before seeing the doctor during their follow-up visits. The doctor will manage the patient as usual, based on the usual clinical information. The doctor will complete the clinician-reported follow-up clinical data form (CRF) for each subject at the end of the consultation.
89110245|NCT04235439|Experimental|Gan & Lee Insulin Lispro Injection|Insulin lispro, 3 mL cartridge in prefilled pen, 100 units/mL (U-100)
89110246|NCT04235439|Active Comparator|EU - approved Humalog ®|Insulin lispro (product approved and marketed in the EU), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
89110247|NCT04235439|Active Comparator|US - licensed Humalog ®|Insulin lispro (product approved and marketed in the US), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
89110248|NCT05119686|Experimental|Group 1|AR882 Dose 1 x 12 weeks
89110249|NCT05119686|Experimental|Group 2|AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks
89110250|NCT05119686|Placebo Comparator|Group 3|AR882 matching placebo x 12 weeks
89110251|NCT02798133|Experimental|OLA|recruitment maneuver + individualized PEEP
89110252|NCT02798133|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
89229298|NCT04496258|Experimental|Positive VR Scene|Participants will explore a virtual reality (VR) environment of a beach scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
89229299|NCT04496258|Experimental|Neutral VR Scene|Participants will explore a virtual reality (VR) environment of a neutral office scene. Participants will be randomly assigned (between subjects) to beach or office scene. VR will be presented on an Occulus Rift device.
89229300|NCT04424264|Experimental|Tenofovir Alafenamide|TAF 25 mg once-daily administered with RIF/INH 600*/300mg
89229301|NCT05355662||OLDs|Older liver donors (OLDs) and recipients were defined as individuals whose donor age was equal to or greater than 60 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
89229302|NCT05355662||ILDs|Ideal or young liver donors (ILDs) and recipients were defined as donors aged 18-40 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
89110253|NCT02797743||Whole blood from all ages and gender|- Ages from 0 to Adults (18 yrs of age or older)
89110254|NCT02640222||AC-naive treated with VKA|AC-naive treated with VKA
89110255|NCT02640222||AC-naive treated with apixaban|AC-naive treated with apixaban
89110256|NCT02640222||AC-naive treated with dabigatran|AC-naive treated with dabigatran
89110257|NCT02640222||AC-naive treated with rivaroxaban|AC-naive treated with rivaroxaban
89110258|NCT02640222||AC-experienced treated with VKA|AC-experienced treated with VKA
89110259|NCT02640222||AC-experienced treated with apixaban|AC-experienced treated with apixaban
89110260|NCT02640222||AC-experienced treated with dabigatran|AC-experienced treated with dabigatran
89110261|NCT02640222||AC-experienced treated with rivaroxaban|AC-experienced treated with rivaroxaban
89110262|NCT03868605|Experimental|EMR/ESD|Standard EMR or ESD technique
89110263|NCT03868605|Experimental|Over- the- scope full- thickness resection device|Endoscopic full thickness resection
89110264|NCT02795871|Experimental|Group D+ 1|Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.
89110265|NCT02795871|Experimental|Group D+ 2|Girls and boys affected by CAH and treated in utero by Dexamethasone.
89110266|NCT02795871|Active Comparator|: Group D - 1|Girls and boys not affected by CAH and not treated in utero by Dexamethasone.
89110267|NCT02795871|Active Comparator|Group D - 2|Girls and boys affected by CAH and not treated in utero by Dexamethasone.
89110268|NCT02795871|Other|Group D - 3|Girls and boys enrolled in school closed to Lyon
89110269|NCT02795715|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
89110270|NCT02795715|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
89110271|NCT00818662|Experimental|IGIV, 10% 400mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
89110272|NCT00818662|Experimental|IGIV, 10% 200mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
89229303|NCT05355662||ALDs|Average liver donors (ALDs) and recipients were defined as donor age 40-59 years. Subjects matching the characteristics of this group were screened from the database according to inclusion and exclusion criteria, and preoperative and postoperative characteristics of the corresponding recipients and donors were collected and recorded for subsequent analysis.
89229304|NCT00398086|Experimental|100 mg/m^2|Participants received albumin-bound paclitaxel 100 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
89110273|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 4 mL/kg|0.25% human albumin solution infused at 4 mL/kg/2weeks
89110274|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 2 mL/kg|0.25% human albumin solution infused at 2 mL/kg/2weeks
89229305|NCT00398086|Experimental|125 mg/m^2|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.
89229306|NCT00398086|Experimental|150 mg/m^2|Participants received albumin-bound paclitaxel 150 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.
89110275|NCT00903786|Experimental|Perampanel|"Participants were treated with the perampanel dose that was administered in maintenance period of Study E2007-J081-231 (Study 231) [NCT00849212]. In some instances, a 1-step down-titration from the viewpoint of safety and up-titration to the maintenance dose of Study 231 was allowed. In general, 1 to 6 tablets of perampanel was administered orally as a 2-milligram (mg) tablet (2 mg to 12 mg) once daily before bedtime (under fed conditions as much as possible).~The investigator, or subinvestigator, was allowed to complete the treatment by tapering the study drug after end of treatment or discontinuation (Follow-up Period), as appropriate. The taper period was 4 weeks at the longest."
89110276|NCT02795637|Experimental|dasotraline|dasotraline 8mg capsule/day
89110277|NCT00703066|Experimental|1|three doses of 30µg GMZ2,
89110278|NCT00703066|Experimental|2|3 doses of 100 µg of GMZ2
89110279|NCT00703066|Active Comparator|3|Rabies vaccine
89110280|NCT02803359|Experimental|Planned Procedure|Endoscope will be connected to a camera and monitor. Needle electrodes will then be positioned into the false vocal fold mucosa bilaterally, under direct visualization of the needle tip on the monitor, but the needles will be passed trans-orally in the operating room. For those participating during an open-neck surgery, the surgery will commence as planned and once exposure of the superior laryngeal nerve is obtained, the surgeon will insert the electrodes directly into the nerve trunk for the purposes of recording. In Surgery or cervical lymphadenectomy, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold.
89110281|NCT02803359|Experimental|Routine Laryngoscopy|Nasolaryngoscopy will be performed in the office in the standard fashion with the use of oxymetazoline for topical decongestion of the nasal mucosa, In both settings, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold
89110282|NCT00762073|Placebo Comparator|1|
89110283|NCT00762073|Experimental|2|Low Dose Group
89110284|NCT00762073|Experimental|3|Medium Dose Group
89110285|NCT00762073|Experimental|4|High Dose Group
89110286|NCT04030468|Experimental|General practitioners|Educational intervention
89110287|NCT04030468|Experimental|Patients|Informative intervention
89110288|NCT04030468|Experimental|General practitioners and patients|Combined strategy
89110289|NCT04030468|No Intervention|Control|No intervention
89110290|NCT02795793|Experimental|Non-operative management group (NOM)|Children in the NOM group will receive intravenous Piperacillin with Tazobactam (Tazocin) 100mg/kg/dose every 8 hours for at least 24 hours, and they will be observed and reassessed within 24 hours after randomisation. A further 24 hours of intravenous Piperacillin with Tazobactam therapy will be offered to children in invariable condition. A clinical decision will be made by the attending surgeon to offer OM if a patient's condition deteriorates at any time, or if a patient has failed to improve after 48 hours of intravenous antibiotic therapy. Once the patient is clinically improving and tolerating oral intake, the antibiotic regimen will be changed to oral Amoxicillin plus Clavulanic acid (Augmentin) 22.5mg/kg/dose twice per day to complete a total seven day course of antibiotics. Oral Ciprofloxacin 15mg/kg/dose twice daily and oral Metronidazole 10mg/kg/dose twice daily will be offered to children who are known to have an intolerance or allergy to Amoxicillin or Clavulanic acid.
89229307|NCT05280860|Experimental|Group R: bilateral RSB under ultrasound guidance after general anesthesia|Group R was subjected to a bilateral RSB under ultrasound guidance after general anesthesia.
89229308|NCT05280860|No Intervention|Group G: simple general anesthesia|Group G received simple general anesthesia.
89110291|NCT02795793|Active Comparator|Appendectomy group (Operative management, OM)|Children allocated to OM may receive preoperative antibiotic prophylaxis as clinically indicated. Appendicectomy will be performed laparoscopically, or via open surgery according to the surgeon's standard practice. Postoperative antibiotic treatment will be determined on the basis of intraoperative findings in accordance with the institutional practice. The appendix specimen will be examined by a paediatric pathologist, and the formal histopathology report will be recorded.
89110292|NCT00913588|Experimental|1|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
89110293|NCT00913588|Experimental|2|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
89110294|NCT00913588|Active Comparator|3|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
89110295|NCT02803281||Lung Cancer - Frialty Assessment|Patients who will undergo surgery for lung cancer
89110296|NCT02803281||Esophageal Cancer - Frailty Assessment|Patients who will undergo esophagectomy for esophageal cancer
89110297|NCT02610946|Placebo Comparator|Paper-based|Use of paper-based calenders, reminders, medication list, and blood pressure, fluid intake tracking methods in adolescent renal transplant care
89110298|NCT02610946|Experimental|Electronic application|Use of electronic apps (iphone or i-Pad mini) to determine whether it can improve compliance with transplant care and readiness to transition to adult care.
89110299|NCT04100785|Experimental|Internet-delivered Cognitive Behavioural Therapy (iCBT)|The iCBT programme comprised of 6 online modules, delivered over 4 weeks, with 3 face-to-face sessions provided by a clinician.The face-to-face sessions were conducted at week 1, 3 and 4. The objectives of the face-to-face sessions was for participants to discuss with the clinician about the application of the content of the modules and the active therapeutic interventions were all found in the online modules.
89110300|NCT04100785|No Intervention|Delayed Wait-list control|The delayed wait-list control did not receive any therapy interventions for 4 weeks from the pre-treatment assessment and from the fifth week onwards, they received the same intervention as the iCBT experimental group.
89110301|NCT02797665|Active Comparator|Steroids group|The patients will be treated with oral corticosteroids (prednisone 0.6mg/kg/d) alone.
89110302|NCT02797665|Active Comparator|Stent group|The patients will be treated with oral corticosteroids and biliary stent.
89110303|NCT05297149|Experimental|hippotherapy group|Participants that are performed hippotherapy
89110304|NCT05297149|Active Comparator|Control group|Participants that are performed home exercise program
89110305|NCT02795091|Other|Manual clean|clean the rag and floor towel manually
89110306|NCT02795091|Other|machine clean|clean the rag and floor towel by machine
89110307|NCT02797587|Active Comparator|Varenicline + Nicotine Replacement Therapy placebo|Study participants will receive active varenicline and be instructed to take the medication for 12 weeks; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
89110308|NCT02797587|Placebo Comparator|Varenicline placebo + Nicotine Replacement Therapy|Study participants will receive placebo varenicline and be instructed to take the placebo medication for 12 weeks; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
89110309|NCT02797587|Active Comparator|Cytisine + Nicotine Replacement Therapy placebo|Study participants will receive active cytisine and be instructed to take the medication for 25 days; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
89110310|NCT02797587|Placebo Comparator|Cytisine placebo + Nicotine Replacement Therapy|Study participants will receive placebo cytisine and be instructed to take the medication for 25 days; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
89229309|NCT04364360|Experimental|Sulforaphane supplementation|Daily (2 capsules) consumption of BroccoMax (Jarrow Formulas Los Angeles, CA) for 3-weeks.
89229310|NCT00536198|Experimental|Sertraline|Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
89229311|NCT00536198|Placebo Comparator|Placebo|Participants will take similar looking placebo during the symptomatic period.
89229312|NCT00393484|Experimental|Arm A|"Entecavir + Lamivudine placebo (0-96 weeks)~Entecavir (96-240 weeks)"
89229313|NCT00393484|Active Comparator|Arm B|"Lamivudine + Entecavir placebo (0-96 weeks)~Lamivudine (96-240 weeks)"
89229314|NCT00667823|Experimental|ACT-064992|ACT-064992
89229315|NCT00397930|Experimental|Yoga Intervention (YOCAS)|Standardized Yoga for Cancer Survivors (YOCAS)
89110311|NCT04098601|Experimental|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
89110312|NCT04098601|No Intervention|Standard of Care Control|Patients in the control condition receive the current standard of care, which entails a treatment referral with a list of addiction recovery facilities, groups, and resources. It is the patient's responsibility to call a treatment facility or group on the list and thus relies on self-referral. The medical team is not permitted to call a facility or group on behalf of the patient. The physician may counsel the patient on the dangers of substance abuse and addiction, but the extent of counseling is variable and dependent on the individual physician.
89110313|NCT02797509|Experimental|Psychosocial Skills-Based Intervention|Based on information from Phase I (semi-structured interviews), the investigators will develop a detailed psychosocial intervention manual. The intervention will be tailored consistent with American Heart Association (AHA) recommendations for stroke skills based interventions and will include 2 general and 4 specific modules (selected from 7 available). Generally, in the intervention, stroke patients and stroke caregivers will learn skills to cope and manage stroke-related stressors. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered within the NICU face to face and 4 tailored specific sessions to be delivered via live video using Vidyo. Participants in the intervention group will also receive treatment as usual.
89110314|NCT02797509|No Intervention|Minimally Enhanced Usual Care (MEUC)|Those in the MEUC will continue with their current care. This may include meeting with nurses, physical therapist, medical doctors, and other members of the stroke patient's medical team. Treatment as usual may also involve administration of Selective Serotonin Reuptake Inhibitors (SSRIs) to those patients with motor problems. They will also received a pamphlet with educational information on stroke and recovery
89110315|NCT04100941|Experimental|standard suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the standard suction technique with 10ml negative pressure
89110316|NCT04100941|Experimental|slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
89110317|NCT04100941|Experimental|wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
89110318|NCT02795325|Experimental|PH Patients|
89110319|NCT02795325|Experimental|Healthy Volunteers|
89110320|NCT00761761|Experimental|1- Sensoril (Ashwagandha)|Sensoril (Ashwagandha) will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
89110321|NCT00761761|Placebo Comparator|2 - Placebo|Placebo will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
89110322|NCT02803047|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89110323|NCT02795403|Experimental|Viraemic|
89110324|NCT02795403|Experimental|responder group|
89110325|NCT04235361||EVD patients|"The samples of all subjects (male, female, adults and children) meeting the WHO case definition of suspected and probable EVD case eligible for real time RT-PCR assay, according to the currently used case definition in DRC, will be tested by differential RPA."
89110326|NCT04235283|Experimental|Group I|Primary total knee replacement by pinless navigation and minimally invasive technique
89110327|NCT04235283|Active Comparator|Group II|Primary total knee replacement by traditional jig and minimally invasive technique
89110328|NCT00761605|Experimental|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
89110329|NCT02797431|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
89110330|NCT02797431|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
89110331|NCT02797431|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
89110332|NCT00761527||Participants with allergic rhinitis or idiopathic urticaria|Outpatient pediatric participants (ages 6 months-11 years) in the Philippines with a diagnosis of allergic rhinitis or chronic idiopathic urticaria.
89110333|NCT00770029|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
89229316|NCT00397930|Experimental|Standard Care Control Condition|Standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses.
89229317|NCT05356676|Experimental|Isometrics|They will be treated with progressive isometric exercises added to 60 min of combined therapy (excluding scapular stabilizing exercises) treatment session at alternative 3 days/week for 8weeks
89229318|NCT05356676|Experimental|Combination Therapy|They will be treated with both isometric and scapular stabilizing exercises.and will get 60minutes of treatment sessions at alternative 3 days/week for 8weeks
89229319|NCT00397540|Active Comparator|percutaneous ethanol injection therapy|Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)
89229320|NCT00397540|Active Comparator|radiofrequency thermal ablation|Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)
89229321|NCT03993496||EVAR Patients|Patients with infrarenal abdominal aortic aneurysm scheduled for elective endovascular aneurysm repair (EVAR) surgery will undergo intraoperative assessments of aneurysm wall pulsatility using ultrasound M-Mode.
89229322|NCT00536120|Experimental|Tysabri Plus Vaccinations|Participants receive 9 monthly doses of Tysabri 300 mg intravenous (IV), and receive vaccinations with neoantigen and recall antigen (keyhole limpet hemocyanin [KLH] and tetanus diphtheria toxoid [Td], according to manufacturer's prescribing information) at Month 6 (following the 7th dose of Tysabri) for both KLH and Td, and 14 and 28 days later for KLH.
89229323|NCT00536120|Other|Vaccinations Only|Participants receive only vaccinations with neoantigen and recall antigen (KLH and Td, according to manufacturer's prescribing information) at Month 0 for both KLH and Td, and 14 and 28 days later for KLH. They do not receive any treatment for their MS and remain in the study through Month 2.
89229324|NCT00057811|Experimental|Group B (chemotherapy, protective therapy, monoclonal antib.)|Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.
89229325|NCT00057811|Experimental|Group C (Chemotherapy, monoclonal antibody therapy)|Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.
89229326|NCT03502148|Experimental|Open-Label, Single Arm Study of PRV111|Subjects received 3 treatment applications of PRV111 (Cisplatin Transmucosal System) at each of the 4 planned visits within 3 weeks prior to their tumor surgery.
89229327|NCT01094197||Transfused microchimeric subject|Former trauma patient who underwent blood transfusion and has recent evidence of long-term transfusion-associated microchimerism
89229328|NCT03957811|No Intervention|Controls|Subjects under treatment for diabetes will receive the standard treatment for their condition.
89229329|NCT03957811|Experimental|Intervention|Subjects under treatment for diabetes not diagnosed for diabetic foot will receive the standard treatment plus exercise on a vibrator platform for a period of 12 weeks.
89229330|NCT01090999|No Intervention|1|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The No Intervention group will undergo a standard, minimal monitoring program."
89229331|NCT01090999|Active Comparator|2|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The active comparator group will undergo an intensive maintenance program after the initial in-hospital rehabilitation program."
89229332|NCT02530801|Other|Avastin and 5 fluorouracil|Subconjunctival injection of bevacizumab combined with 5 fluorouracil
89229333|NCT01091077|Placebo Comparator|Naringenin|Single dose of naringenin, compared to placebo in the same individual.
89229334|NCT01094275||wild / normal type allele of CYP2C gene|clopidogrel 75 mg alone.
89229335|NCT01094275||wild / normal type allele of CYP2C|clopidogrel 75 mg + omeprazole 20 mg.
89229336|NCT01094275||Loss of Haplotype CYP2C19|clopidogrel 75mg alone
89229337|NCT01094275||Loss of function haplotype of CYP2C|clopidogrel 75mg + omerprazole 20mg.
89229338|NCT05355506||The Development and Effectiveness of Heart Failure Self-Health Management Application|"Heart Failure can cause physical disability and death. According to the Ministry of Health and Welfare, there were 20,644 deaths from heart disease, ranking second among the top 10 causes of death [1]. The World Health Organization (WHO) has advocated nursing guidance with the concept of empowerment, where patients can play an active and aggressive role in managing their health [2]. This paperless nursing health education guidance information can be designed through the application, which features non-professional expressions and visualization methods. The users can participate in feedback-based interactions and complete the questionnaires after receiving nursing guidance. This study used the Technology Acceptance Model (TAM) to evaluate patients' acceptance of the nursing guidance application and the effectiveness of such nursing guidance."
89229339|NCT01094353|Active Comparator|Mini-sling|The minisling Ophira™ is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
89229340|NCT01094353|Active Comparator|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
89229341|NCT01089205|Experimental|Torrent's Metformin tablets 750 mg|
89229342|NCT01089205|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA|
89229343|NCT02866682|Other|Brand Tacrolimus Only : Prograf|Arm 1 will receive brand tacrolimus for the entire study
89229344|NCT02866682|Other|Generic A Only|Arm 2 will receive specific generic tacrolimus for the entire study
89229345|NCT01089283||LRRK2 mutation|Parkinson patients that carry mutation on LRRK2 gene
89229346|NCT01089283||GBA mutation|Parkinson patients that carry mutation on GBA gene
89229347|NCT01089283||no mutation|Parkinson patients that don't carry mutation on LRRK2 or GBA genes
89229348|NCT01089283||healthy|Healthy volunteers
89229349|NCT02822924|Other|Prostate artery embolization treatment|Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
89229350|NCT01089439|Active Comparator|1: INOMAX|"Nitric oxide by inhalation INOMAX:~active arm treated with nitric oxide"
89229351|NCT01089439|Placebo Comparator|2: Placebo|placebo arm treated with placebo at the same conditions
89229352|NCT02774642|Experimental|CBTI-PE|Integrates the core components of CBT-I and PE in 14 90-minute weekly sessions.
89229353|NCT02774642|Active Comparator|Hygiene-PE|Uses non-active sleep hygiene to account for the dose response of experimental condition before starting PE. Uses 14 90-minute weekly sessions.
89229354|NCT00992030|Experimental|ARM A|Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
89229355|NCT00992030|Active Comparator|ARM B|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation
89229356|NCT00992342|Experimental|PF-03893787 5 mg|
89229357|NCT00992342|Experimental|PF-03893787 15 mg|
89229358|NCT00992342|Experimental|PF-03893787 50 mg|
89229359|NCT01976390|Active Comparator|Zortress (Everolimus)|Zortress will be started on day of transplant and initially dosed at 0.75 mg twice a day (12 hours apart) dosed simultaneously with Neoral.
89229360|NCT01976390|Active Comparator|Rapamune (Sirolimus)|Rapamune will be dosed on day of transplant at 5 mg/d, decreasing to 3 mg/d.
89229361|NCT00570713|Experimental|MORAb-009|MORAb-009 plus gemcitabine ('MORAb-009'): MORAb-009 was administered at 5 mg/kg on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
89229362|NCT00570713|Active Comparator|Placebo|Placebo plus gemcitabine ('Placebo') Placebo was administered on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
89229363|NCT04002440|Active Comparator|AMIA with SHARESOURCE|For this arm, dialysis nurses will review those patients using the AMIA with SHARESOURCE connectivity platform twice a week and will contact patients who meet certain triggers. They will then offer patients interventions, ie. a change in the preset AMIA ultrafiltration program, in order to achieve prescribed dry weight.
89110334|NCT00770029|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
89110335|NCT02797353|Experimental|Intervention Arm|Antenatal Care, Post natal care, Skilled birth attendance, recognition and referrals of complicated cases, immunization
89110336|NCT02797353|No Intervention|Control|This arm will receive the standard MNCH services as outlined in the MNCH policy of Government of Pakistan
89110337|NCT02794935|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
89229364|NCT04002440|Placebo Comparator|HomeChoice PRO|For this arm, routine standard of care for peritoneal dialysis patients will continue using the HomeChoice PRO device. Data regarding treatments will be captured on a chip to be analyzed at the end of 6 months to evaluate compliance with treatments.
89110338|NCT02794935|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
89110339|NCT04095949|Experimental|Artichokes|1 day of artichokes intake
89110340|NCT02795013||Participants with Hodgkin Lymphoma|Those with a confirmed diagnosis of Hodgkin Lymphoma (HL) and family members who consent and enroll in this study.
89110341|NCT02795013||Family Members without Hodgkin Lymphoma|Those unaffected by HL will serve as a control group to compare with those with HL.
89110342|NCT04096183|Other|Ventilation of healthy volunteers|
89110343|NCT04235985|Other|All time points|
89110344|NCT00817414|Experimental|Cohort A: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.
89110345|NCT00817414|Experimental|Cohort A: LCI699 1.0 mg QD|Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
89110346|NCT00817414|Experimental|Cohort B1: LCI699 1.0 mg BID|Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.
89110347|NCT00817414|Experimental|Cohort B1: LCI699 2.0 mg QD|Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
89110348|NCT00817414|Placebo Comparator|Placebo|Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.
89110349|NCT00769561|Experimental|BFB-CBT|"Biofeedback-based cognitive-behavioral treatment:~The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits."
89110350|NCT00769561|Active Comparator|Occlusal Splint (OS)|"Dental treatment with occlusal splints:~Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment."
89110351|NCT02794779|Experimental|Rule of three|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
89110352|NCT02794779|Active Comparator|Continuous infusion|Continuous infusion of variable rate if 0,4 UI of oxytocin until obstetrician determines that uterine tone is adequate.
89110353|NCT00817336|Experimental|D-serine|60 mg/kg/day
89110354|NCT00817336|Placebo Comparator|Placebo|
89110355|NCT02802657|Experimental|Conbercept 0.5mg Treat-and-Extend regimen|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and Treat-and-Extend Regimen of the same dose guided by BCVA stabilization and optical coherence tomography (OCT) in the extension treatment period.~Intervention: Drug: Conbercept"
89110356|NCT02802657|Active Comparator|Conbercept 0.5mg Pro Re Nata|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization in the extension treatment period.~Intervention: Drug: Conbercept"
89110357|NCT00761215|Experimental|TR-701 200 mg|
89110358|NCT00761215|Experimental|TR-701 300 mg|
89110359|NCT00761215|Experimental|TR-701 400 mg|
89110360|NCT04235751|Experimental|Immediate Coaching Intervention|Subjects will receive 6 professional coaching sessions
89110361|NCT04235751|Experimental|Delayed Coaching Intervention|Subjects will receive no coaching for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
89110362|NCT02794857|Experimental|NP001|NP001 2 mg/kg by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
89110363|NCT02794857|Placebo Comparator|Placebo|Normal saline by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
89110364|NCT04100629|Placebo Comparator|Control Group|The control group will receive medical facts and are not meant to support newly licensed nurses and are not known to affect stress, resilience, perceived social support, or Intention To Leave one's job.
89110365|NCT04100629|Experimental|Experimental Group|Texts sent to the experimental group will be based on nurturant support messages and are intended to decrease stress, Intention To Leave, increase resilience, and perceived sense of support.
89110366|NCT05805293|Experimental|High-Velocity Nasal Insufflation|
89110367|NCT05805293|Experimental|Non-Invasive ventilation|
89229365|NCT05294939|Experimental|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
89110368|NCT05805228|Experimental|Experimental Group|"The sexual counseling program was applied to the couples in the experimental group in 2 sessions. The Sexual Counseling I session which includes information about sexual life specific to the pregnancy period, was conducted at least one week later the pre-test, with face-to-face interview method in a private room in the pregnancy outpatient clinic. The Sexual Counseling II session, which contains information on sexual life specific to the postpartum period, was conducted online in the third trimester of pregnancy with the video interview method. Counseling sessions consisted of power point presentations (including figures and drawings) and counseling booklet. The counseling booklet prepared by the researcher in accordance with literature consisted of two parts; sexual life during pregnancy and postpartum sexual life. Each session lasted 45 minutes and additional time was allocated for answering the questions."
89110369|NCT05805228|No Intervention|Control Group|Only routine antenatal and postnatal care was given to the couples in the control group
89110370|NCT05805163|Active Comparator|Control|Participants will be mailed a standard COVID-19 home-based test kit.
89110371|NCT05805163|Experimental|Intervention|Participants will be mailed a standard COVID-19 home-based test plus the FABI culturally sensitive COVID-19 educational pamphlet.
89110372|NCT05805098|Experimental|Venetoclax Combined With Homoharringtonine and Cytarabine|All recipients in this arm received Venetoclax, Homoharringtonine and Cytarabine. Venetoclax was uesd as 100 mg on day 1, 200 mg on day 2, 400mg from day-3 to day-28. Homoharringtonine was uesd as 1 mg/m2 qd from day-1 to day-5. Cytarabine was uesd as 100 mg/m2 qd from day-1 to day-5.
89110373|NCT05804994|Experimental|Medical device group|Group applying the tested medical device
89110374|NCT05804994|No Intervention|Control group|Group not applying the tested medical device
89110375|NCT05804981|Other|new screener group|this is the group that has annual wellness visits after the new screener is adopted by the UPMC health system
89110376|NCT05804981|No Intervention|pre screener group|this is the group that has annual wellness visits before the new screener is adopted by the UPMC health system
89110377|NCT05804968|Experimental|Digital HIV self disclosure intervention|"This study will develop a digital HIV onward disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. Participants will be asked to be involved in this study for 11 weeks, consisting of three weeks baseline, four weeks intervention and four weeks follow up.~A single case experimental design will be used to explore HIV disclosure intention, HIV disclosure behaviour, HIV disclosure motivation, general wellbeing and mood via daily and weekly measures throughout baseline, intervention and follow up phases. All these measures will be completed online via a secure qualtrics network.~Participants will further be asked to complete a participant experiences questionnaire to explore how they found this digital intervention. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K."
89110378|NCT02795559|Other|Lean|Subjects within the range of desirable body weight (BMI<25)
89110379|NCT02795559|Other|OWO|Subjects who are overweight or obese (BMI between 25 and 40)
89110380|NCT05804942|Experimental|High glycemic index|The participants will be fed a fixed calorie meal, which is high glycemic index with constant fat and protein.
89110381|NCT05804942|Experimental|Medium glycemic index|The participants will be fed a fixed calorie meal, which is medium glycemic index with constant fat and protein.
89110382|NCT05804942|Experimental|Low glycemic index|The participants will be fed a fixed calorie meal, which is low glycemic index with constant fat and protein.
89110383|NCT05804929||Control|21.5≤BMI<25, age between 25-40 years old, 200subjects.
89110384|NCT05804929||Superlean|BMI≤18.5, age between 25-40 years old, 200 subjects.
89110385|NCT05804916|Experimental|SGRT+DIBH group|Patients with left breast cancer treated with SGRT combined with DIBH technique
89110386|NCT05804916|No Intervention|common+Free breath group|Patients with left breast cancer treated with traditional laser alignment with free breathing treatment
89110387|NCT05804890||ZORFLEX|Activated Carbon Cloth Dressing
89110388|NCT05804890||AQUACEL|Silver-Based Dressing
89110389|NCT05804877|Experimental|online mindfulness-based cognitive therapy program|The online mindfulness-based cognitive program was delivered on the platform of LINE to the experimental group 3 times a week for 8 weeks
89110390|NCT05804877|Placebo Comparator|mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
89110391|NCT05804864|Experimental|KM501-1001|
89110392|NCT05804799||Liver CT study group|"Patients with a suspicion of focal liver lesions had the plan to perform a contrast-enhanced liver CT scan.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
89110393|NCT05804760||General population (i)|All participants of the study, including any periodontal condition.
89110394|NCT05804760||Periodontally healthy patients with history of periodontitis (ii)|Patients whose current periodontal condition is healthy but who have developed periodontitis in the past.
89110395|NCT05804760||Periodontally healthy patients without history of periodontitis (iii)|Patients whose current periodontal condition is healthy, who have also not had periodontitis in the past.
89110396|NCT05804734||Cases|Patients with hemophilia receiving an anticoagulant treatment in the period 2012-2021
89110397|NCT05804734||Controls|Patients with hemophilia cross-matched with cases on the age, the hemophilia's severity, the hemophilia's type, and the HAS-BLED score.
89110398|NCT05804721|Experimental|T test|1 orally disintegrating tablet contains 10 mg Aripiprazole administrated according to a randomization scheme with 240 ml of water
89110399|NCT05804721|Active Comparator|R Reference|1 orodispersible tablet contains 10 mg Aripiprazole administrated according to a randomization scheme with 240 ml of water
89110400|NCT05804695|Experimental|Arthroscopic Temporo-mandibular joint disc repositioning under General anathesia|
89110401|NCT05804682||Patients that underwent fascial dissection for N1b papillary thyroid cancer|
89110402|NCT05804682||Patients that underwent ftandard dissection for N1b papillary thyroid cancer|
89110403|NCT05804656|Experimental|CKDB-501A|
89110404|NCT05804656|Active Comparator|Botox®|
89110405|NCT05804630|Active Comparator|Experiment 1, arm 1: Articaine infiltration anesthesia|This arm aims to compare efficacy and safety of infiltration anesthesia of Articaine (Orabloc®) to block anesthesia of Lidocaine (Octocaine®). It would be a split-mouth study design. The patient in this arm would be randomly assigned to one anesthetic agent and technique at one side (left or right) of the wisdom tooth surgery first, and the other side (left or right) of wisdom tooth surgery would use the other anesthetic agent and technique accordingly.
89110406|NCT05804630|Active Comparator|Experiment 1, arm 2: Lidocaine block anesthesia|This arm aims to compare efficacy and safety of infiltration anesthesia of Articaine (Orabloc®) to block anesthesia of Lidocaine (Octocaine®). It would be a split-mouth study design. The patient in this arm would be randomly assigned to one anesthetic agent and technique at one side (left or right) of the wisdom tooth surgery first, and the other side (left or right) of wisdom tooth surgery would use the other anesthetic agent and technique accordingly.
89110407|NCT05804630|Active Comparator|Experiment 2, arm 1: Lidocaine+1:100000 adrenaline block anesthesia|This arm aims to compare efficacy and safety of block anesthesia of Lidocaine containing different concentration of epinephrine (adrenaline), i.e. Octocaine® (Lidocaine+1:100000 adrenaline) vs. Xylestesin-A® (Lidocaine+1:80000 adrenaline). It would be a split-mouth study design. The patients in this arm would be randomly assigned to one anesthetic agent at one side (left or right) of the wisdom tooth surgery first, and the other side (left or right) of wisdom tooth surgery would use the other anesthetic agent accordingly.
89110408|NCT05804630|Active Comparator|Experiment 2, arm 2: Lidocaine+1:80000 adrenaline block anesthesia|This arm aims to compare efficacy and safety of block anesthesia of Lidocaine containing different concentration of epinephrine (adrenaline), i.e. Octocaine® (Lidocaine+1:100000 adrenaline) vs. Xylestesin-A® (Lidocaine+1:80000 adrenaline). It would be a split-mouth study design. The patients in this arm would be randomly assigned to one anesthetic agent at one side (left or right) of the wisdom tooth surgery first, and the other side (left or right) of wisdom tooth surgery would use the other anesthetic agent accordingly.
89110409|NCT05804617|Placebo Comparator|Surgeon group|Dome-type morcellation performed by one skillful surgeon
89110410|NCT05804617|Active Comparator|Trainee group|Dome-type morcellation performed by trainees (residents) under supervision
89110411|NCT05804591|Placebo Comparator|Multimodal analgesia group|Patients receiving placebo per os 1 hour preoperatively and anesthesia with standard, multimodal analgesia afterwards.
89110412|NCT05804591|Experimental|Multimodal analgesia with preemptive pregabalin group|Patients receiving pregabalin 150mg per os 1 hour preoperatively and anesthesia with standard, multimodal analgesia afterwards.
89110413|NCT05804565|Active Comparator|Bone Saw|"In the intervention arm, the metatarsal bone will be transected using an oscillating microsaw. This is an accepted surgical method."
89110414|NCT05804565|Other|Bone Cutter|"In the control arm, the metatarsal bone will be transected using a manual bone cutters. This is also an accepted surgical method"
89110415|NCT05804539|Experimental|Manual therapy|Each lesson has a duration of 40 minutes, including the first five minutes of warm-up, 30 minutes of manual therapy and the last five minutes of cool-down.
89110416|NCT05804539|Experimental|Tai Chi|Each lesson has a duration of 40 minutes, including the first five minutes of warm-up, 30 minutes of Tai Chi and the last five minutes of cool-down.
89110417|NCT05804539|Experimental|Tai Chi and Manual therapy|Each lesson has a duration of 40 minutes, including the first five minutes of warm-up, 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy, and the last five minutes of cool-down.
89110418|NCT05804474||Intracranial Aneurysms|
89110419|NCT05804474||Normal Vessels|
89110420|NCT05804422|Active Comparator|Probiotic lysate (postbiotic and metabiotc) group|oral, 2 capsules per day (BID) for 3 month treatment
89110421|NCT05804422|Placebo Comparator|Placebo group|placebo, oral, 2 capsules per day (BID) for 3 month treatment
89110422|NCT05804357|Active Comparator|Exercise Group|In our study, stabilization exercises were applied to the patients in the exercise group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Stabilization exercises: It is an approach that is combined with diaphragmatic breathing and activates the passive. The stabilization exercise program was applied in three phases and was progressed in line with the developments in the patients
89110423|NCT05804357|Experimental|Manual Therapy Group|In our study, stabilization exercises and spinal mobilization practices were performed to the patients in the manual therapy group. The treatment was applied two days a week for five weeks, for a total of ten sessions. After the end of the treatment, stabilization exercises were recommended as a home exercise program until the follow-up evaluation at the third month. A telephone connection was established with the patients once a week and the home program was followed up.Mobilization applications were applied at Maitland IV degree as standard.Three mobilization methods were applied Anterior-Posterior Lumbal Spinal Mobilization Lumbal Spinal Rotational Mobilization Joint Mobilization in Lumbal Flexion Position
89110424|NCT05804331||Patient with Gastrointestinal neoplasm|Pt referred for resection of gastrointestinal neoplasm. Observational data collected from endoscopic submucosal dissection (ESD), submucosal-tunnelling endoscopic resection (STER) or endoscopic full-thickness resection (EFTR) of gastrointestinal neoplasm
89110425|NCT05804305|Active Comparator|Misoprostol|600 mcg of Misoprostol per day in three divided doses was given to the patients in the treatment group for a period of two months
89110426|NCT05804305|Placebo Comparator|Placebo|Placebo was given to the patients three times daily for a duration of two months
89110427|NCT05804292||Community sample|Questionnaires administration
89110428|NCT05804292||Subjects with obesity and comorbid eating disorder|Questionnaires administration
89110429|NCT05804292||Subjects with obesity without comorbid eating disorder|Questionnaires administration
89110430|NCT05804279|Experimental|BPDO-1603|1 tablet contains memantine 20mg/donepezil 10mg
89110431|NCT05804279|Active Comparator|BPDO-16031,BPDO-16033|1 tablet memantine 20mg and 1 tablet donepezil 10mg
89110432|NCT05804253|Active Comparator|bovine bone|Patients received maxillary sinus augmentation grafting with bovine bone mineral
89110433|NCT05804253|Active Comparator|Porcine bone mineral|patients received maxillary sinus augmentation grafting with porcine bone mineral
89110434|NCT05804149|Experimental|study group|"Each patient in the study group will be instructed about the beneficial effect of the acupuncture.~Each woman in the study group will assume side lying position with uncovered treatment area,~thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine.~low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months.~Fine sterile needles will be used with a size 0.25x25mm. They will be inserted to various depths (2-5 cm) at acupoints points on the body according to site and fat deposition. 16 needles will be used in the treatment"
89110435|NCT05804149|Other|control group|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
89110436|NCT05804097|No Intervention|Control|Control group
89110437|NCT05804097|Experimental|HBOT 20|Patients receiving 20 sessions of concurrent Hyperbaric oxygen treatment
89110438|NCT05804097|Experimental|HBOT 30|Patients receiving 30 sessions of concurrent Hyperbaric oxygen treatment
89110439|NCT05804097|Experimental|HBOT 40|Patients receiving at least 40 sessions of concurrent Hyperbaric oxygen treatment
89110440|NCT05804071|Active Comparator|150mg QD|Each subject took vitamin C 1 tablet and 150mg polysaccharide iron complex at 20:00 ± 1 hour every day.
89110441|NCT05804071|Active Comparator|150mg QOD|Each subject took vitamin C 1 tablet and 150mg polysaccharide iron complex at 20:00 ± 1 hour every other day.
89110442|NCT05804071|Active Comparator|300mg QD|Each subject took vitamin C 1 tablet and 300mg polysaccharide iron complex at 20:00 ± 1 hour every day.
89110443|NCT05804071|Active Comparator|300mg QOD|Each subject took vitamin C 1 tablet and 300mg polysaccharide iron complex at 20:00 ± 1 hour every other day.
89110444|NCT05804071|Active Comparator|Intravenous iron supplement|Each subject was given intravenous iron supplements according to the instructions
89110445|NCT05804058||Orthopaedic Patients|Patients due to undergo prosthetic hip revision surgery
89229366|NCT05294939|Placebo Comparator|Control product|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
89229367|NCT00773045||pain training program|ICU Patients treated with or without pain management protocol
89229368|NCT00556946|Other|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains
89229369|NCT00776867|Experimental|perifosine|This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.
89229370|NCT02556515|Active Comparator|Trapeziektomi and ligament interposition|Interpositional arthroplasty Interpositional arthroplasty (Burton-Pellegrini procedure)
89229371|NCT02556515|Experimental|Total joint replacement|Elektra CMC1 uncemented prosthesis Elektra prosthesis
89229372|NCT05356286|Experimental|Electrical Stimulation group|Epidural Electrical Stimulation of the Cervical Spinal Cord
89229373|NCT00780377|Experimental|Bradykinin|Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.
89229374|NCT05219942|Placebo Comparator|low dose insulin infusion +Subcutaneous saline|low dose insulin infusion +Subcutaneous saline
89229375|NCT05219942|Active Comparator|low dose insulin infusion +subcutaneous Glargine insulin|low dose insulin infusion +subcutaneous Glargine insulin
89229376|NCT04002206|Experimental|Muscle Energy Technique|Post isometric relaxation technique was used in experimental group
89229377|NCT04002206|Active Comparator|Static Stretch|Static stretching was given in control group
89229378|NCT04002284|Experimental|anlotinib|anlotinib 12mg qd p.o. d1-14/21day/cycle
89229379|NCT00669617|Experimental|Ind 150μg, Salm/flut, Ind 300μg, Placebo, Salbut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Placebo, Salbutamol 200 μg (Salbut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89523233|NCT03388021|Active Comparator|if the results were not satisfactory intraoperatively as fail|this group will undergo surgical thromboembolectomy. if the results were not satisfactory intraoperatively as failure to advance the Fogarty catheter or to get satisfactory inflow or backflow or Extraction of intimal fragments.patient will undergo diagnostic angiography and endovascular or surgical intervention according to result of diagnostic angiography.
89110446|NCT05804019|No Intervention|Usual Care Group (Control)|Approximately 100 participants will be included and cluster randomized by nursing home (n= 3) to either 6 months of nutritional and physical intervention or 6 months of usual care (control). Usual Care Group will receive the usual care at the control nursing homes (n=3)
89110447|NCT05804019|Experimental|Nutritional and Physical Intervention Group (Intervention Group)|Approximately 100 participants will be included and cluster randomized by nursing home (n= 3) to either 6 months of nutritional and physical intervention or 6 months of usual care (control). The Nutritional and Physical Intervention Group will receive nutritional and physical interventions collaborative defined by residents, relatives, care staff, and nursing home management during the PDSA workshops.
89110448|NCT05804006|Experimental|HIIT-REC|High-intensity interval training program on a recumbent cycle SOLE R92 (HIIT-REC)
89110449|NCT05803993|Experimental|FMT from healthy donor|Subjects receiving a single infusion FMT via colonoscopy from healthy donor
89110450|NCT05803993|Placebo Comparator|Autologous FMT|Subjects receiving a single infusion autologous FMT via colonoscopy
89110451|NCT05803980|Experimental|FMT from healthy donor|Subjects receiving a single infusion FMT via colonoscopy from healthy donor
89110452|NCT05803980|Placebo Comparator|Autologous FMT|Subjects receiving a single infusion autologous FMT via colonoscopy
89110453|NCT05803967|Experimental|group number 1|Females with sub-clinical hypothyroidism exhibit cognitive problems (mild cognitive impairement), they will be elderly, will receive baduanjin training that will be applied 5 times per the week, under supervision for 12 weeks, number of patients will be 20), also women of this group will receive their prescribed daily one-dose medication tablet (levothyroxine).
89110454|NCT05803967|No Intervention|group number 2|Females with sub-clinical hypothyroidism exhibit cognitive problems (mild cognitive impairement), they will be elderly, will receive will receive their prescribed daily one-dose medication tablet (levothyroxine).
89110455|NCT05803915|Experimental|Neoadjuvant Toripalimab plus Nimotuzumab|The participants will receive 2 doses of neoadjuvant Toripalimab plus Nimotuzumab, then the participants will take a radical surgery or radiotherapy according to the efficacy assessed by investigator per RECIST1.1
89110456|NCT05803902|Experimental|9MW1911 Dose 1|9MW1911 injection ( Dose 1) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
89110457|NCT05803902|Experimental|9MW1911 Dose 2|9MW1911 injection (Dose 2) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
89110458|NCT05803902|Experimental|9MW1911 Dose 3|9MW1911 injection (Dose 3) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
89110459|NCT05803902|Experimental|9MW1911 Dose 4|9MW1911 injection (Dose 4) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
88821049|NCT05247866|Experimental|Study Group|"30 patients will be given dupilumab (dose based on current approved doses or used in current EoE clinical trial, q weekly dosing) and monitored for clinical response after 12 weeks of therapy)~Dosing:~>12 years of age > 40 kg 300 SQ weekly 30- 40 kg 300 mg SQ Q2 weeks 15-29.9 kg 200 mg SQ Q2 weeks~6-11 years of age 5-15 kg 100 mg SQ Q2W 15-30 kg 200 mg SQ Q2W >30-60 kg 300 mg SQ Q2W"
88821050|NCT05237349|Experimental|envafolimab plus chemotherapy|Envafolimab:300mg,sc,d1,Q3W; Chemotherapy:SOX(Oxaliplatin，130mg/m2, iv,d1,Q3W + S-1，40mg/m2, op,bid,d1-14,Q3W).
89110460|NCT05803902|Experimental|9MW1911 Dose 5|9MW1911 injection (Dose 5) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
89110461|NCT05803902|Experimental|9MW1911 Dose 6|9MW1911 injection (Dose 6) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
89110462|NCT05803902|Experimental|9MW1911 Dose 7|9MW1911 injection (Dose 7) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
89110463|NCT05803902|Experimental|9MW1911 Dose 8|9MW1911 injection (Dose 8) by intravenous injection once on the first day of treatment. 8 subjects will be enrolled, including 2 subjects for placebo administration.
89110464|NCT05803863|Experimental|Myatro|Prescribing one 0,01% Myatro (Atropine) drop/eye/night , in 12 months Then wash-out in next 12 months
89110465|NCT05803863|Experimental|Myatro XL|Prescribing one 0,05% Myatro XL (Atropine) drop/eye/night , in 12 months Then wash-out in next 12 months
89110466|NCT05803863|No Intervention|Conventional spectacles|Prescribing conventional spectacles and follow-up in 24 months.
89110467|NCT05803837||intervention group|one group
89110468|NCT05803746|Experimental|Imaging cohort|All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-Mirc415 PET/CT scan.
89110469|NCT05803720|Experimental|Provider Intervention|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain the knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
89110470|NCT05803720|No Intervention|Control|No intervention control
89110471|NCT05803707|Experimental|Home-based Adapted Physical Activity|Home-based Adapted Physical Activity sessions by videoconference
89110472|NCT05803681|Experimental|CCEF group|"In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.~Clinical study protocol: (1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption."
89110473|NCT05803681|Other|Control Group|(1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
89110474|NCT05803642|Experimental|Olanzapine|
89110475|NCT05803642|Active Comparator|Haloperidol|
89110476|NCT05803590|Active Comparator|Green Tea Mouthwash ( intervention )|"Green tea (GT), obtained from the extracts of a small plant, Camelia sinesis, is common worldwide. It is rich in flavonoids such as catechins and various other polyphenols, contributing to its antioxidant and anti-inflammatory properties. Green tea consumption is also associated with lower incidences of diabetes, cardiovascular disease, and obesity. Moreover, its antibacterial property aids in the reduction of bacterial colonization and thereby prevents oral diseases such as gingivitis, periodontal diseases, dental caries, and malodor .~When used as a mouthwash, green tea preparations can obliterate bad breath by suppressing anaerobic bacteria and eradicating the production of volatile sulfur compounds. There is a lack of critically appraised summaries on the efficacy of green tea mouthwash for promoting dental hygiene ."
89110477|NCT05803590|Experimental|Chlorhexidine Mouthwash ( control )|Chlorhexidine was developed in 1950 and is the most used anti-plaque agent. However, the long-term usage of chlorhexidine (CHX) is limited by altered taste perception and tooth staining with prolonged usage. Though CHX has been the gold standard mouthwash in controlling plaque formation, its undesirable side effects, such as the enhanced ability of calculus formation, bitter taste, and interference with taste, have inspired a search for alternatives
89110478|NCT05803538|Experimental|SMS|
89110479|NCT05803538|Experimental|Telephone interview|
89110480|NCT05803538|Experimental|Diary card|
89110481|NCT05803538|Active Comparator|Usual Care|
89110482|NCT05803525|Active Comparator|• Group I: BC scaffold and 0.5% concentration of NaOCl irrigant solution.|BC will be made & use 0.5 NaOCl conc
89110483|NCT05803525|Active Comparator|• Group II: BC scaffold and 2.5% concentration of NaOCl irrigant solution. •|BC will be made & use 2.5 NaOCl conc
89110484|NCT05803525|Active Comparator|• Group III: PRF scaffold and 0.5% concentration of NaOCl irrigant solution. •|PRF will be made & use 0.5 NaOCl conc
89110485|NCT05803525|Active Comparator|Group IV: PRF scaffold and 2.5% concentration of NaOCl irrigant solution. •|PRF will be made & use 2.5 NaOCl conc
89110486|NCT05803525|Active Comparator|• Group V: Collagen scaffold and 0.5% concentration of NaOCl irrigant solution.|Collagen will be made & use 0.5 NaOCl conc
89110487|NCT05803525|Active Comparator|• Group VI: Collagen scaffold and 2.5% concentration of NaOCl irrigant solution.|Collagen will be made & use 2.5 NaOCl conc
89110488|NCT05803460|Experimental|Stage 1 Experimental A group: Actual experience of nature environment|actual natural environment
89110489|NCT05803460|Experimental|Stage 1 Experimental B group: virtual reality experience of nature environment|virtual reality experience of nature environment
89110490|NCT05803460|Active Comparator|Stage 1 Control group: actual experience of city|actual experience of city
89110491|NCT05803460|Other|Stage 2 group|tree element virtual natural environment and tree and water element virtual natural environment experiences
89110492|NCT05803460|Experimental|Stage 3 Experimental group|virtual reality experience of nature environment
89110493|NCT05803460|Active Comparator|Stage 3 Control group|routine care
89110494|NCT05803447||G1K-women|The G1K group consisted of women experiencing suicidal thoughts without a tendency of implementation, in whom the result of M.I.N.I. 7.0.2 test was 1 to 8 points (n=14)
89110495|NCT05803447||G1M-men|The G1M group consisted of men experiencing suicidal thoughts without a tendency of implementation, in whom the result of M.I.N.I. 7.0.2 test was 1 to 8 points (n=16)
89110496|NCT05803447||G2K-women|The G2K group consisted of women experiencing suicidal thoughts with a tendency of implementation, in whom the result of M.I.N.I. 7.0.2 test was 9 to 16 points (n=19)
89110497|NCT05803447||G2M-men|The G2M group consisted of men experiencing suicidal thoughts with a tendency of implementation, in whom the result of M.I.N.I. 7.0.2 test was 9 to 16 points (n=9)
89110498|NCT05803447||G3K-women|The G3K group consisted of women after a suicide attempt, in whom the result of M.I.N.I. 7.0.2 test was equal to or greater than 17 points (n=15)
89110499|NCT05803447||G3M-men|The G3M group consisted of men after a suicide attempt, in whom the result of M.I.N.I. 7.0.2 test was equal to or greater than 17 points (n=17)
89110500|NCT05803447||G0K-women|The G0K group consisted of women displaying no suicidal behaviour, in whom the result of M.I.N.I. 7.0.2 test was zero points (n=10)
89110501|NCT05803447||G0M-men|The G0M group consisted of men displaying no suicidal behaviour, in whom the result of M.I.N.I. 7.0.2 test was zero points (n=20)
89110502|NCT05803369|Experimental|Regulating Together (RT)|Participants will receive Regulating Together -the emotion dysregulation intervention
89110503|NCT05803369|Active Comparator|Achieving Independence and Mastery in School (AIMS)|Participants will receive AIMS, the academic functioning/organizational skill intervention.
89110504|NCT05803330|No Intervention|PXB combined with venous dilation group|Use of PXB combined with intravenous volume expansion during preoperative preparation in patients with pheochromocytoma
89110505|NCT05803330|Experimental|PXB group|PXB alone during preoperative preparation in patients with pheochromocytoma
89110506|NCT05803278|Experimental|Children positive to screening test|"Children positive to the online test InTempo, which includes standardized and scientifically validated tests in the following areas: Metaphonology, Reading and Writing"
89110507|NCT05803252|Experimental|FACT Group|4-6 FACT consultation sessions, one weekly session, 45-60 mins per session. These sessions will be using online video conferencing platforms.
89110508|NCT05803252|Other|Waitlist Control Group|The waitlist control group participants will commence their intervention trial immediately after they complete their follow-up assessment.
89523234|NCT03379805||Fontan-Kreutzer operated patients|Patients with a Fontan-Kreutzer circulation. No interventions are done. (The intervention is the operation done 15-20 years ago)
89523235|NCT03379805||Healthy Control subjects|Age, gender and weight matched control subjects
89523236|NCT05172635||Patients, who received a VEGF antibody|We distinguished between patients who received a VEGF antibody therapy and patients who received a EGFR antibody therapy.
89229380|NCT00669617|Experimental|Ind 300μg, Ind 150μg, Salbut, Salm/flut, Placebo|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo. At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89229381|NCT00669617|Experimental|Salm/flut, Placebo, Ind 150μg, Salbut, Ind 300μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo, Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89229382|NCT00669617|Experimental|Salbut, Ind 300μg, Placebo, Ind 150μg, Salm/flut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg), Placebo, Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89229383|NCT00669617|Experimental|Placebo, Salbut, Salm/flut , Ind 300μg, Ind 150μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Placebo, Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89229384|NCT00773123||1|Primary open angle glaucoma
89229385|NCT00773123||2|Normal controls
88821051|NCT05229146|Experimental|Episodic Future Thinking|"Mothers will receive episodic future thinking (EFT). Mothers will meet with a peer mother who will administer the EFT intervention, including generation of several specific future events reflecting positive interactions with their child. We will also teach each parent a behavioral parent training element called Special Play Time. Following this session, mothers will receive daily text messages over the course of two weeks including a reminder cue generated as part of the EFT and a prompt to remember these episodes in vivid detail."
89523237|NCT05172635||Patients, who received a EGFR antibody|We distinguished between patients who received a VEGF antibody therapy and patients who received a EGFR antibody therapy.
89110509|NCT05803226|Experimental|Intervention|The first 10-minute of Slow Art Plus involves a brief psychoeducation on slow looking, mindfulness, and self-compassion practices. This is followed by a 10-minute participants self-introduction and sharing of one act of self-kindness; a 10-minute facilitator led mindfulness meditation on affectionate breathing to foster greater somatic and emotional clarity for slow-looking. This is followed by a set of 30-minute slow looking activity with 1 selected art-piece, including: (a) creating an Artwork Title with one sentence description, (b) imaging music that resonates with the viewers' emotional response to artwork, and (c) sketching a Response Art that facilitates a dialogue between the viewer and the art piece for perspective widening. A 10-minute dyadic sharing follows with a 5-minute large group sharing of joint collective experience. Artwork reveal and sharing of its self-care implications is offered. Finally, a closure self-compassion activity of Supportive Healing Touch.
89110510|NCT05803226|No Intervention|Control|Wait-list Control Arm who will receive the Slow Art Plus after the Experimental Arm completes the Intervention.
89110511|NCT05803213|Experimental|Virtual Reality|The medical students use the virtual reality headset to watch an interactive 360 video about the clinical situation on the learning platform
89110512|NCT05803213|Active Comparator|Traditional|The mini-lecture is provided by the instructor to medical students about the clinical situation
89110513|NCT05803174||Emmetropic subjects|Spherical equivalent (Diopter, D) to be between -0.5 and +0.5 D
89110514|NCT05803174||Low and moderate myopic subjects|Spherical equivalent (Diopter, D) to be less than -0.5 but over -6.0D
89110515|NCT05803174||High myopic subjects|Spherical equivalent (Diopter, D) to be over or equal to -6.0D
89229386|NCT03979352|Active Comparator|Empagliflozin arm|"Participant will be treated by empagliflozin for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the placebo arm.~Participant and research staff is blinded to arm assignment."
89523238|NCT03387943|Experimental|PLD plus Cisplatin|liposomal doxorubicin(PLD) 35 mg/m2,iv,d1, plus cisplatin 75 mg/m2,drip,d1-3, once every 21days, for 6 cycles, to progression or intolerance.
89523239|NCT03384251|Experimental|Intervention group|This group shall be given a comprehensive sex education in approximately six sessions.
89523240|NCT03384251|No Intervention|Control group|This group will not be given any form of education.
89229387|NCT03979352|Placebo Comparator|Placebo arm|"Participant will take placebo for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.~After finishing the entire arm intervention participant will undergo 7 day of washout and enters the empagliflozin arm.~Participant and research staff is blinded to arm assignment."
89229388|NCT00780767|Experimental|Thrombectomy arm|
89229389|NCT00773201|Experimental|1|Healthy subjects
89229390|NCT05355194|Experimental|Group A: Kinesiotaping with pelvic tilts|Kinesiotape will be applied to patients. In addition, patients will be instructed to perform pelvic tilts.
89229391|NCT05355194|Active Comparator|Group B: Kinesiotaping without pelvic tilts|Kinesiotape will be applied to patients.
89229392|NCT03905174|Active Comparator|Standard treatment|A porous collar for either distal or proximal femoral replacements
89229393|NCT03905174|Active Comparator|standard treatment + HA|A porous collar with hydroxyapatite (HA) for either distal or proximal femoral replacements
89229394|NCT03905174|Active Comparator|standard treatment + HA + autogenic cells|A porous collar with hydroxyapatite (HA) and stem cells for either distal or proximal femoral replacements
89110516|NCT05803161|Experimental|Congrong Runtong oral liquid high-dose group|Congrong Runtong oral liquid, 2 bottles (1g herb content per bottle) per dose, three times a day
89110517|NCT05803161|Experimental|Congrong Runtong oral liquid low-dose group|Congrong Runtong oral liquid, 2 bottles (0.5g herb content per bottle) per dose, three times a day
89110518|NCT05803161|Placebo Comparator|Placebo group|Congrong Runtong oral liquid, 2 bottles (0g herb content per bottle) per dose, three times a day
89110519|NCT05803135|Active Comparator|Double-Blind Iguratimod|Iguratimod (25mg twice daily) combined with Tofacitinib (5mg twice daily) for 24 weeks (6 months)
89110520|NCT05803135|Placebo Comparator|Double-Blind Placebo|Placebo (25mg twice daily) combined with Tofacitinib (5mg twice daily) for 24 weeks (6 months)
89110521|NCT05803122||Patients with Mild Cognitive Impairment (MCI)|Patients with diagnosis of MCI based on diagnostic research criteria , after a protocol of clinical, neuropsychological, structural brain imaging evaluation and biomarkers positivity assessment (amyloid-Positron Emission Tomography (PET) and/or Cerebral Spinal Fluid -CSF).
89110522|NCT05803122||Patients with Alzheimer's Disease (AD)|Patients with diagnosis of AD based on diagnostic research criteria , after a protocol of clinical, neuropsychological, structural brain imaging evaluation and biomarkers positivity assessment (amyloid-PET and/or CSF).
88821052|NCT05224661||Adult patients with AML in complete remission undergoing alloHCT|Adult patients with AML in complete remission undergoing alloHCT
89110523|NCT05803070||A|patients with alopecia areata who will be treated with topical cetirizine 1%
89110524|NCT05803070||B|patients with alopecia areata who will be treated with topical betamethasone valerate 0.1%
89110525|NCT05803031|Experimental|Group I (Test group)|Eleven patients with localized periodontitis, receiving full mouth non-surgical periodontal debridement followed by local delivery of tea tree oil gel as an adjunctive treatment.
89110526|NCT05803031|Placebo Comparator|Group II (Control group)|Eleven patients with localized periodontitis, receiving full mouth non-surgical periodontal debridement only.
89110527|NCT05803005||children with autism spectrum disorder|: 50 patients aged 3_18 years, equally sex distributed, who visit pediatric neurology outpatients clinic with autistic disorder at assiut university hospital will enrolled in this study and 50 controls . (According to DSM IV and ADT-R)
89110528|NCT05802992|Experimental|Experimental group|Patients will be treated with colchicine, lenalidomide and dexamethasone, every 28 days as a cycle.
89110529|NCT05802992|Active Comparator|Control group|Patients will receive lenalidomide and dexamethasone as background treatment, every 28 days as a cycle.
89110530|NCT05802979|Active Comparator|group 1|consists of patients receiving Serratus anterior plane block using Bupivacaine + Ketamine.
89110531|NCT05802979|Active Comparator|group 2|consists of patients receiving Serratus anterior plane block using Bupivacaine + neostigmine.
89110532|NCT05802979|Placebo Comparator|group 3|consists of patients receiving Serratus anterior plane block using Bupivacaine + normal saline.
89110533|NCT05802888|Experimental|Tid group|Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
89110534|NCT05802888|Active Comparator|Qid group|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid
89110535|NCT05802875|Experimental|RASMUS Resilience Training|RASMUS is a systematic, behavior-oriented group training in which the following methods are used: mindfulness exercises, exercises in self-compassion/guided meditations, knowledge transfer by means of a teaching talk/lecture, working out the topics in individual and small group work, group exercises, group discussion and exchange, train coping strategies: somatic, cognitive, and emotional levels, independent reflection on what has been learned, homework, weekly protocols, transfer to everyday life, questionnaires on resilience factors, mindfulness, and self-compassion for self-control, linking the course topics with one another.
89110536|NCT05802875|Active Comparator|Progressive Muscle Relaxation|As a relaxation method with scientifically proven effects, progressive muscle relaxation aims at the conscious, voluntary tension and relaxation of certain muscle groups, which can bring the body into a state of deep relaxation. The application is not only effective in patients with various diseases, but also in healthy people.
89110537|NCT05802862|Experimental|22011|
89110538|NCT05802862|Active Comparator|Ryzodeg|
89110539|NCT05802823|Experimental|Experimental Group|Resources will be distributed to the students 1 week before the application, a scenario will be given 5 minutes before the application, and informed consent will be obtained from the students. Just before the application, information about the simulation process and analysis will be given. Students will be divided into 6 groups with the random numbers table and the application will be made on different days and times. The application time is 10-15 minutes and the camera will be recorded during the interview. At the end of the application, standard patient feedback will be given for each student. At the end of the application, analysis sessions will be held with the students as a group and feedback will be given by peers and trainers about their own performances. Analysis sessions will take between 30-45 minutes.
89110540|NCT05802823|No Intervention|Control Group|No application will be made.
89110541|NCT05802810|Experimental|[14C]JT001|
89110542|NCT05802771||enrolled patients|Non small cell lung cancer patients underwent surgical resection. We will use part of this cohort to built the predictive models and a second part to validate the creted models.
89110543|NCT05802745||Extubation failure|Patients who will require to be re-intubated within 72 hours after extubation.
89110544|NCT05802745||Extubation success|Patients who will not require reintubation within 72 hours of extubation.
89110545|NCT05802563||Heart Failure|Study participants with systolic heart failure (Left ventricular ejection fraction < 35%) without documented atrial fibrillation
89110546|NCT05802563||Atrial Fibrillation|Study participants with documented atrial fibrillation without heart failure
89110547|NCT05802563||Reference|Individuals without cardiovascular disease
89110548|NCT05800574|Experimental|Cohort A (>N1 or single node > 3cm )|More extensive neck involvement or proximity to the midline can qualify a patient in cohort A. Cohort A will have patients with either more than one lymph node adenopathy or 1 lymph node that is large (>3cm).
89110549|NCT05800574|Experimental|Cohort B (N0 or N1 <3cm)|For Cohort B patients need to have either no lymph nodes or only one lymph node adenopathy, provided it is smaller than 3cm.
89110550|NCT05796063|Experimental|Intervention|On postoperative day one, patients will be asked if they are having any GI symptoms. These are defined as presence of nausea, emesis, belching, and/or hiccups. In the intervention arm, clinicians will use the results of G-POCUS and presence/absence of GI symptoms to inform decision making according to one of two standardized algorithms.
89110551|NCT05796063|No Intervention|Control|On postoperative day one, patients will be asked if they are having any GI symptoms. These are defined as presence of nausea, emesis, belching, and/or hiccups. In the control arm, presence of GI symptoms will be assessed, and once of two standardized algorithms which are representative of the current standard of care for postoperative diet management.
89110552|NCT05795205|Experimental|Normal dinner consumption|Participants will have their dinner between 1800-1830pm
89110553|NCT05795205|Experimental|Delayed dinner consumption|Participants will have their dinner between 2200-2230pm
89110554|NCT05795205|Experimental|Exercise with delayed dinner consumption|Participants will exercise on a treadmill for 45 min followed by delayed dinner between 2200-2230pm
89110555|NCT05791812|Experimental|active treatment|2mA of tDCS for 20 min every weekday for six weeks
89110556|NCT05791448|Experimental|Treatment (AU409)|Patients receive AU409 PO on study. Patients also undergo CT or MRI and collection of blood samples throughout the trial.
89110557|NCT05787288|Experimental|Test Group|Nebulized Mesenchymal Stem Cell Exosomes-derived extracellular vesicles twice a day (BID) for 5 days
89110558|NCT05787288|Sham Comparator|Control Group|Nebulized saline solution twice a day (BID) for 5 days
89110559|NCT05783999|Experimental|standard care + vibra plus|patients will undergo treatment with the vibra plus device on top of traditional rehabilitation
89110560|NCT05783999|No Intervention|Standard care|patients undergo a traditional rehabilitation program
89110561|NCT05783583||Enrolled participants|Adult human subjects showing either healthy eyes or specific ocular pathologies.
89110562|NCT05781412|Active Comparator|ASD_anodalstimulation|ASD participant, anodal stimulation on the first session, sham stimulation on the second sesion
89110563|NCT05781412|Sham Comparator|ASD_shamstimulation|ASD participant, sham stimulation on the first session, anodal stimulation on the second sesion
89110564|NCT05781412|Active Comparator|NT_anodalstimulation|Neurotypical participant, anodal stimulation on the first session, sham stimulation on the second sesion
89110565|NCT05781412|Sham Comparator|NT_shamstimulation|Neurotypical participant, sham stimulation on the first session, anodal stimulation on the second sesion
89110566|NCT05781412|Active Comparator|H-AQ_anodalstimulation|non diagnosed autistic participant,anodal stimulation on the first session, sham stimulation on the second sesion
89110567|NCT05781412|Sham Comparator|H-AQ_shamstimulation|non diagnosed autistic participant, sham stimulation on the first session, anodal stimulation on the second sesion
89110568|NCT05776290|Experimental|Hyaluronic acid injection|The hyaluronic acid will be injected into the implant socket before implantation.
89110569|NCT05776290|No Intervention|Traditional treatment|The socket will be prepared in the normal manner without being injected with any material.
89110570|NCT05776264|Experimental|Music Condition|3 self-selected music choices to be played during the study
89110571|NCT05776264|Placebo Comparator|Podcast Condition|One self-selected podcast choice to be played during the study
89110572|NCT05776069|Placebo Comparator|Part 1|Cohorts 1-8 IV or SC VGA039 or Placebo dose to be determined
89110573|NCT05776069|Experimental|Part 2|Cohorts A-H IV or SC VGA039 dose to be determined
89110574|NCT05774782|Experimental|Cerebral flow diverter|The cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms
89110575|NCT05772390|Experimental|Partial breast re-irradiation|partial breast re-irradiation in patients with local recurrence of breast cancer, previously treated with breast conservative surgery and whole breast radiotherapy. A total dose of 35 Gy in 10 daily fractions, 5 fractions per week, will be prescribed.
89110576|NCT05770726|Active Comparator|probiotics-spray (PS) group|In the PS group, the colonoscopic prescription of 10 grams of probiotics powder is performed once on one of the first three days (D0-D3).
89110577|NCT05770726|Active Comparator|probiotics-oral (PO) group|In the PO group, we will prescribe oral probiotics 2 capsules once per day for 5 days (a total of 10 grams) as adjunctive treatment during the first five days (D0-D4).
89110578|NCT05765227|Other|LID#224381, then AOHG MF|Lehfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second in pre-determined order. Each study lens type will be worn bilaterally (in both eyes) for approximately 2 days. CLEAR CARE will be used for nightly cleaning and disinfection.
89110579|NCT05765227|Other|AOHG MF, then LID#224381|Lotrafilcon B multifocal contact lenses worn first, with lehfilcon A multifocal contact lenses worn second in pre-determined order. Each study lens type will be worn bilaterally (in both eyes) for approximately 2 days. CLEAR CARE will be used for nightly cleaning and disinfection.
89110580|NCT05758948||Patients diagnosed with de novo metastatic breast cancer|Blood and tissue sample from patients diagnosed with DN-MBC will be analyzed using next generation sequencing (NGS)
89110581|NCT05730101|No Intervention|No treatment waitlist group|Participants receive neither cognitive-behavioral nor imaginary pill treatment and are told that they are in the no treatment waitlist group. They are told that they can receive one of the treatments at the end of the study. The treatment they receive will be chosen based on study results.
89110582|NCT05730101|Active Comparator|Cognitive-behavioral treatment group (CBT)|"Participants receive two individual and six group sessions with a therapist following the treatment manual Prokrastination."
89110583|NCT05730101|Active Comparator|Imaginary pill treatment group (IP)|In accordance with the imaginary pill technique, participants are instructed to take an imaginary pill. This instruction consists of a procedure including five steps (i.e., 1) identifying the IP sensitive problem, 2) building trust/belief/reality of the IP, 3) constructing a personally meaningful IP, 4) taking the IP, 5) suggestions for self-administering the IP in real life and building adherence. The session is repeated with small modifications seven weeks later.
89110584|NCT05728775|Experimental|Remimazolam TIVA|Remimazolam is administered at 6-12 mg/kg/h intravenously for anesthesia induction and at 1.0-2.0 mg/kg/h for maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
89110585|NCT05728775|Active Comparator|Propofol TIVA|Propofol 1.5-2.5mg/kg is administered intravenously for anesthesia induction and propofol at 4-12mg/kg/h is used for maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
89110586|NCT05721209|Experimental|VRTT With Feedback - Adults|"Adults aged 18-65 with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill with augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill with AR/VR feedback."
89110587|NCT05721209|Experimental|VRTT With Feedback - Older Adults|"Adults aged 65 and older with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill with augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill with AR/VR feedback."
89110588|NCT05721209|Active Comparator|VRTT Without Feedback - Adults|"Adults aged 18-65 with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill without augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill without AR/VR feedback."
89110589|NCT05721209|Active Comparator|VRTT Without Feedback - Older Adults|"Adults aged 65 and older with TBI. At Week 1 after baseline, participants will begin study intervention on the C-Mill without augmented/virtual reality (AR/VR) guidance. Starting at Week 2, the study intervention on C-Mill will be repeated 3 sessions/week for 8 weeks.~Each one hour session will include about 15 minutes of standing balance training, about 5 minutes of stepping balance training and about 30 minutes of walking training on the C-Mill without AR/VR feedback."
89110590|NCT05717023|Experimental|Online guided self-help intervention for sexual distress following sexual assault|The intervention only has one arm. All participants will be provided 4 sessions of guided self-help intervention to be completed once weekly.
89110591|NCT05714605|Experimental|THRIVE Intervention|1 month intensive post discharge case management and care coordination.
89110592|NCT05714605|No Intervention|Usual Care|Discharge to home without intensive post acute case management or care coordination.
89110593|NCT05707897|Experimental|Fed condition|Period in which subjects receive a single oral dose of TS-142 tablet in fed condition.
89110594|NCT05707897|Experimental|Fasted condition|Period in which subjects receive a single oral dose of TS-142 tablet in fasted condition.
89110595|NCT05705453|Experimental|Volitional EMG power|Assessing the change in volitional EMG power during the Brain Motor Control Assement (BMCA) between nonstimulation baseline and stimulation.
89110596|NCT05705089|Experimental|Rivaroxaban-based antithrombotic regimen|All patients assigned to the rivaroxaban-based antithrombotic regimen will receive rivaroxaban (15 mg once daily, orally) plus clopidogrel (75 mg daily, orally) plus aspirin (80 mg once daily, orally). Aspirin will be discontinued within 7 days of its initiation. The antithrombotic regimen (i.e., dual therapy) will be continued until three months after randomization.
89110597|NCT05705089|Active Comparator|warfarin-based antithrombotic regimen|All patients assigned to the warfarin-based antithrombotic regimen will receive warfarin (overlapping with enoxaparin until reaching an INR goal of 2-2.5) plus clopidogrel (75 mg once daily, orally) plus aspirin (80 mg once daily, orally). Aspirin will be discontinued within 7 days of its initiation. The antithrombotic regimen (i.e., dual therapy) will be continued until three months after randomization.
89110598|NCT05682495|Experimental|ARM A：SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2|
89110599|NCT05682495|Experimental|ARM B：HR20031 FDC 10/100/1000 mg|
89110600|NCT05682495|Experimental|ARM C：SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR*2|
89110601|NCT05682495|Experimental|ARM D：SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3|
89110602|NCT05682495|Experimental|ARM E：HR20031 FDC 5/50/750 mg*2|
89110603|NCT05682495|Experimental|ARM F：SHR3824 5 mg*2+ SP2086 50 mg*2+ Metformin 500 mg XR*3|
89110604|NCT05672901|Experimental|StrataMGT|Participants will apply StrataMGT (silicone gel) 2-5 times daily (no limit in application times) to treat GSM for 3 months.
89110605|NCT05672901|Active Comparator|Estrace|Participants will receive Estrace vaginal cream (estrogen) to treat GSM for 3 months. Application will be 1 g daily for the first two weeks. Afterwards, a maintenance dosage of 1 g three times a week is applied.
89110606|NCT05671822|Experimental|Arm 1A: SHR-A1811 and SHR-1701|
89110607|NCT05671822|Experimental|Arm 1B: SHR-A1811 and capecitabine|
89110608|NCT05671822|Experimental|Arm 1C: SHR-A181,SHR-1701,and capecitabine|
89110609|NCT05671822|Experimental|Arm 1D: SHR-A1811,capecitabine,and oxaliplatin|
89110610|NCT05671822|Experimental|Arm 2A: SHR-A1811 and SHR-1701|
88821053|NCT05221502|Experimental|Arm 1|Delamanid + Bedaquiline + OPC-167832 10 mg
88821054|NCT05221502|Experimental|Arm 2|Delamanid + Bedaquiline + OPC-167832 30 mg
88821055|NCT05221502|Experimental|Arm 3|Delamanid + Bedaquiline + OPC-167832 90 mg
88821056|NCT05221502|Active Comparator|Arm 4|RHEZ
88821057|NCT05213078|Experimental|Supportive Care (teaching intervention, questionnaire)|Participants attend 2 teaching sessions with a research nurse. Participants also complete questionnaires at baseline, 3, and 7 weeks.
89110611|NCT05671822|Experimental|Arm 2B: SHR-A181,SHR-1701,and capecitabine|
89110612|NCT05671822|Experimental|Arm 2C: SHR-A1811,capecitabine,and oxaliplatin|
89110613|NCT05650515||Experts|A panel of experts in the geriatric field consisting of older adults (65+ years) as well as experts (geriatric rehabilitation/medicine/research)
89110614|NCT05649540|Active Comparator|high dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days
89110615|NCT05649540|Experimental|standard dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 1000mg bid for 14 days
89110616|NCT05649540|Experimental|low dose amoxicillin with vonoprazan group|vonoprazan 20mg bid and amoxicillin 500mg tid for 14 days
89110617|NCT05646693|Experimental|Drusen Mega® + Sertraline|It will consist of 29 patients with Chronic Subjetive Endotic Tinnitus. Patients will eat one capsule of antioxidant therapy (Drusen Mega®) and one capsule of sertraline per day in the night for 3 months.
89110618|NCT05646693|Placebo Comparator|Placebo + Sertraline|It will consist of 29 patients with Chronic Subjetive Endotic Tinnitus. Patients will eat one capsule of placebo (Magnesium Oxide 100mg) per day in the morning and one capsule of sertraline per day in the night for 3 months.
89110619|NCT05624463|Experimental|Modified intubation protocol+early resumption of oral intake|Participants receive modified intubation protocol and early resumption of oral intake.
89110620|NCT05624463|Other|Modified intubation protocol+delayed resumption of oral intake|Participants receive modified intubation protocol and delayed resumption of oral intake.
89110621|NCT05624463|Other|Conventional intubation protocol+early resumption of oral intake|Participants receive conventional intubation protocol and early resumption of oral intake.
89110622|NCT05624463|Other|Conventional intubation protocol+delayed resumption of oral intake|Participants receive conventional intubation protocol and delayed resumption of oral intake.
89229395|NCT05064527||Patients|"OCD (ICD-10 F42) as the primary or secondary diagnosis, verified with a semi-structured psychopathological interview using Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-PL).~CY-BOCS > 7: mild (8-15), moderate (16-23), severe (24-31), extreme (32-40)~A psychiatrist determined that the child is eligible for care within psychiatry for their primary diagnosis.~Patient is age 8 through 17 years (both inclusive)."
89229396|NCT05064527||Controls|"Ages 8 through 17 years (both inclusive).~Sex and age (+/- 3months) matched to an included patient."
89110623|NCT05616624|Experimental|Phase I: ADI-PEG + gemcitabine + docetaxel|"ADI-PEG 20 is given as an intramuscular injection on a weekly basis (Day 1, 8 and 15) at a dose of 36 mg/m^2. ADI-PEG 20 dosing will start one week prior to the initiation of gemcitabine + docetaxel on Day -7 prior to the initiation of Cycle 1.~Gemcitabine is given intravenously at the assigned dose level on Day 2 of each cycle.~Docetaxel is given intravenously at the assigned dose level on Day 1 of each cycle.~A cycle is defined as 21 days.~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) per physician discretion or patient request.~Treatment may continue for up to 34 cycles."
89110624|NCT05616624|Experimental|Phase II Non-small cell lung cancer: ADI-PEG + gemcitabine + docetaxel|"ADI-PEG 20 is given as an intramuscular injection on a weekly basis (Day 1, 8 and 15) at a dose of 36 mg/m^2. ADI-PEG 20 dosing will start one week prior to the initiation of gemcitabine + docetaxel on Day -7 prior to the initiation of Cycle 1.~Gemcitabine is given intravenously at the assigned dose level on Day 2 of each cycle.~Docetaxel is given intravenously at the assigned dose level on Day 1 of each cycle.~A cycle is defined as 21 days.~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) per physician discretion or patient request.~Treatment may continue for up to 34 cycles."
89110625|NCT05616624|Experimental|Phase II Small cell lung cancer: ADI-PEG + gemcitabine + docetaxel|"ADI-PEG 20 is given as an intramuscular injection on a weekly basis (Day 1, 8 and 15) at a dose of 36 mg/m^2. ADI-PEG 20 dosing will start one week prior to the initiation of gemcitabine + docetaxel on Day -7 prior to the initiation of Cycle 1.~Gemcitabine is given intravenously at the assigned dose level on Day 2 of each cycle.~Docetaxel is given intravenously at the assigned dose level on Day 1 of each cycle.~A cycle is defined as 21 days.~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) per physician discretion or patient request.~Treatment may continue for up to 34 cycles."
89110626|NCT05606367|Experimental|Non-slip Balloon Catheter|Subjects in experimental arm will be treated with the Non-slip Balloon Catheter manufactured by Shanghai Microport Rhythm Co. Ltd.
89110627|NCT05606367|Active Comparator|NSE Coronary Dilatation Catheter|Subjects in control arm will be treated with Lacrosse® NSE manufactured by Goodman Medical Co. Ltd.
88821058|NCT05212818|Experimental|Low Dose of Active Drug|80 patients will be randomly assigned to low dose, take active drug BID.
88821059|NCT05212818|Experimental|Low Dose Placebo Control|80 patients will be randomly assigned to Low dose placebo, take the placebo BID.
88812657|NCT00891176|Experimental|Synflorix-Meningitec Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age. 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
89110628|NCT05601817|Experimental|Vita (virtual reality-based cognitive restoration intervention)|Participants randomized to Vita will receive a virtual reality head-mount device (e.g., Oculus Quest) to view nature pictures for 10 minutes (1 set of 10 pictures)/day, 2-3 days/week for 8 weeks (a total of 20 sets for 200 minutes, approximately 3.3 hours) based on the provided activity schedule. Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
89229397|NCT05064527||Caregivers of Patients|Parent or guardian of patient with OCD
89110629|NCT05601817|Experimental|Com (computerized cognitive training intervention )|Participants randomized to Com will receive a tablet computer (e.g., iPad) to complete BrainHQ training for 1 hour (6 exercises)/day, 2-3 days/week for 8 weeks (total of 20 hours) based on the provided activity schedule. Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
89110630|NCT05601817|Experimental|Vita+Com (Both Vita and Com intervention)|Participants randomized to Vita+Com will receive both Vita and Com simultaneously. They will spend 10 minutes on Vita and then 1 hour on Com per day, 2-3 days/week for 8 weeks (a total of 23.3 hours). Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
89110631|NCT05601817|No Intervention|Usual care|Participants randomized to this control condition will continue to receive their usual care, but no interventions from the study team. We will monitor changes in their activities that may affect changes in cognitive function (e.g., starting book clubs) by weekly check-in calls during the 8 weeks of intervention phase.
89110632|NCT05597397|Experimental|Repeated Low-Level Red-Light Therapy (RLRL)|Single vision spectacles (SVS) & RLRL.
89110633|NCT05590065|Experimental|Arm 1 - Treatment|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device two times a week for five weeks for a total of 10 sessions.
89110634|NCT05585372|No Intervention|control group|The control group will receive general stability exercises and neurodynamic mobilization only
89229398|NCT05064527||Caregivers of Controls|Parent or guardian of control participant
89229399|NCT05355038|Experimental|lifesyle modification|intervention group will take lifestyle modification protocol which composed of health teaching about low glycemic index diet, physical activity and self glucose monitoring
89229400|NCT05355038|No Intervention|control group|routine care of the hospital
89229401|NCT00777413|Experimental|1|Minocycline 100 mg tablets of Ranbaxy
89229402|NCT00777413|Active Comparator|2|Minocin 100mg tablets
89229403|NCT05199974|Active Comparator|Group A: Linea alba was closed with conventional continuous technique .|Group A: 25 patients included . Linea alba will be closed with conventional continuous technique .
89229404|NCT05199974|Active Comparator|Group B: Linea alba was closed with Modified Smead Jones technique with Far-near near-far technique.|Group B:25 patients included. Linea alba will be closed with Modified Smead jones technique with Far-near near-far technique.
89229405|NCT02556671||Moderate CKD Patients Undergoing PCI|
89229406|NCT02556671||Normal renal function Patients Undergoing PCI|
89229407|NCT05189912|Experimental|Specimen retrieving bag group|Resected polyps were retrieved by specimen retrieving bag. This group was set as a experimental group.
89229408|NCT05189912|Active Comparator|Suction group|"Resected polyps were retrieved by removing the colonoscope suction valve and connecting a polyp trap to suction onto the instrument channel port.~This group was set as a control group."
88821060|NCT05212818|Experimental|High Dose of Active Drug|160 patients will be randomly assigned to high dose, take the active drug BID.
89110635|NCT05585372|Experimental|CT guided opening mobilization of cervical intervertebral foreman|"Grade four manual therapy mobilization of cervical intervertebral foreman guided by 3 dimensions computed tomography (CT) as following :~Determining the poper direction of cervical IVF by 3D CT.~the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
89110636|NCT05561335|Experimental|Hearing Aid use for listening to speech in a common difficult situation|The hearing aids will be worn in two different programs, each with a different microphone configuration. The participants will listen to speech while wearing the hearing aids and alternate programs to form their opinions about these programs; they will only know that they are rating different settings, not what the settings are. They will then rate their listening experiences via rating scales to determine their preferences.
89110637|NCT05554926|Experimental|[4-14C] AEF0117|Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the dose administration. Up to 8 subjects will be enrolled to ensure that 6 subjects complete the study. Subjects will be admitted into the study site on Day -1. On the morning of Day 1, all subjects will receive a single oral dose of 2 mg containing approximately 100 μCi of [4-14C]AEF0117 approximately 1 hour after completion of a low-fat breakfast
89110638|NCT05550857|Active Comparator|Myofascial release|"Group A:~This group will receive routine physiotherapy with myofascial release. This protocol will be given for 3 alternative days per week. Each session will be of 45 minutes. Data will be collected at baseline, at 2nd week and at 4th week."
89110639|NCT05550857|Experimental|eccentric resistance exercise|"Group B:~This group will receive routine physiotherapy and myofascial release with eccentric resistance exercise . This protocol will be given for 3 alternative days per week. Each session will be of 60 minutes. Data will be collected at baseline, at 2nd week and at 4th week."
89110640|NCT05526066|Experimental|ARCT-810|Participants receive an initial intravenous (IV) infusion ARCT-810. If considered safe and well tolerated, participants will receive up to 5 additional IV infusions of ARCT-810 administered at 14-day intervals.
89110641|NCT05526066|Placebo Comparator|Placebo, Normal Saline|Participants receive an initial IV infusion of placebo. If considered safe and well tolerated, participants receive up to 5 additional IV infusions of placebo administered at 14-day intervals.
89110642|NCT05513469|Other|Peptide receptor radionuclide therapy|PRRT 4x7.4GBq
89110643|NCT05484349|Experimental|group A|Tizanidine Hydrochloride 1 mg Tid
89110644|NCT05484349|Experimental|group B|Tizanidine Hydrochloride 2 mg Tid
89110645|NCT05484349|Placebo Comparator|group C|placebo 1 tablet Tid
89110646|NCT05470244|Active Comparator|Therapeutic Exercise Group|This group will receive Routine Physical therapy protocol along with prescribed intra-venous regimen.
89110647|NCT05470244|Experimental|TENS Plus Therapeutic Exercise Group|This group will receive high frequency Transcutaneous Electrical Nerve Stimulation with routine physical therapy and prescribed intra-venous regimen.
89110648|NCT05449548|Experimental|Intervention with lenalidomide|All subjects will be treated with lenalidomide 10mg/day.
89110649|NCT05438264|Experimental|Experimental|Donepezil 5 mg, QD
89110650|NCT05438264|Placebo Comparator|Control|Placebo, QD
89110651|NCT05425797|Active Comparator|In-Person|Standard Prevention Practitioner visit that will take place in-person
89110652|NCT05425797|Experimental|Video|Prevention Practitioner visit that will take place through video call
89110653|NCT05425797|Experimental|Phone|Prevention Practitioner visit that will take place through phone call
89110654|NCT05424341|Experimental|Group A|This group will receive muscle energy technique along with routine physical therapy. This protocol will be given for 3 alternative days for 2 weeks . Each session will be of 50 mins. Data will be collected at baseline , at 1st week and at 2nd week.
89110655|NCT05424341|Active Comparator|Group B|This group will receive counterstrain technique along with routine physical therapy. This protocol will be given for 3 alternative days for 2 weeks . Each session will be of 50 mins. Data will be collected at baseline , at 1st week and at 2nd week.
89110656|NCT05418413|Active Comparator|Conventional Twin-block appliance|The patients in this control group will be treated using the conventional Twin-block appliance (CTB).
89110657|NCT05418413|Experimental|Esthetic Twin-block appliance|the patients in this experimental group will be treated using the esthetic Twin-block appliance (ETB).
89110658|NCT05415813|Active Comparator|Ischemic Compression|Ischemic Compression will be applied to the upper trapezius trigger points in patients recruited in group 1.
89110659|NCT05415813|Experimental|Ischemic compression and Muscle Energy Technique|ischemic compression along with muscle energy technique will be applied to the upper trapezius trigger points in patients allocated to group 2.
89110660|NCT05409651|Experimental|Time restricted eating|Everyone in this arm will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
89110661|NCT05396768||Novices|Junior residents from the departments of surgery, pneumology or emergency medicine. These participants are in their first or second year of residency, and have observed or placed less than 5 CTIs in their career.
89110662|NCT05396768||Experienced|Faculty members from Ghent University Hospital from the departments of surgery, pneumology or emergency medicine. These participants must have finished their residency training, and must be involved in resident education.
89110663|NCT05393440|Experimental|Dose-escalation cohort|Three subjects will be enrolled in this cohort. First subject will receive first injection in dose level of 1 million CCID50/mL. If tolerated, second injection for this subject will be accelerated to 10 millions CCID50/mL. If tolerated, the third injection will be further accelerated to 100 million CCID50/mL. The maximum volume for per injection time point is 8 mL. Injection will repeat every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. If dose limiting toxicity (DLT) happens in any dose level, the injection dose will be decrease to the last tolerable level.
89110664|NCT05393440|Experimental|Dose-expansion cohort|Fifteen subjects will be enrolled in this cohort. The maximal tolerable dose (MTD) confirmed in the first stage will be utilized in 15 patients. This stage should not be initiated before the completion of dose escalation of all three subjects in the first stage. Treatment will be repeated every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. Dose interruption, not reduction, is permitted. Treatment will be terminated if toxicity-related treatment interrupt is longer than 28 days. Radiology assessment will be conducted every six weeks.
89110665|NCT05361356|Experimental|Experimental group, all volunteer will be scanned.|All participation accept Spectral CT scanning; No group;
89110666|NCT05355857|Other|18F-FDG injection|Health volunteers with 18-F-FDG injection
89110667|NCT05350280|Experimental|Low-intensity electrical current (LIEC)|A removable device containing a small electrical circuit will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
89110668|NCT05350280|Active Comparator|Traditional fixed orthodontic appliance|The maxillary arch will be levelled and aligned. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction.
89110669|NCT05350085|Experimental|Remimazolam Group|Use remimazolam as sedation.Sufficient sedation is defined as Ramsay Sedation score grade III.
89110670|NCT05350085|Active Comparator|Midazolam Group|Use midazolam as sedation.Sufficient sedation is defined as Ramsay Sedation score grade III.
89110671|NCT05322629|Experimental|Intervention (enhanced PrEP HIV biofeedback)|"Women in the intervention arm (n=325) will receive enhanced PrEP bio-feedback adherence counseling:~Real-time novel immunoassay using urine that measures tenofovir and enhanced bio-feedback counseling. The novel urine assay shows tenofovir concentrations if PrEP is taken in the past 48 hours thereby enabling counselors to provide feedback on adherence levels, immediately.~Enhanced counseling on recent adherence levels~Rapid PrEP collection~In second randomization at 6m, women on PrEP with poor adherence or continuation, will be offered differentiated PrEP delivery in the community or in the clinic. The study will follow these participants for 15m to assess longer term PrEP continuation and adherence."
89110672|NCT05322629|Active Comparator|Standard of care|Women in the standard of care arm (n=325) will receive facility-based PrEP and monthly HIV testing in pregnancy and quarterly in postpartum. PrEP prescriptions and HIV testing will be provided according to the national PrEP guidelines. The women will be followed through 6m postpartum for the first randomization and through 15m with the standard of care for the second randomization.
89110673|NCT05320939|Experimental|Mepolizumab 100mg|The Investigators will recruit a total of 30 subjects for this study (all subjects for the mepolizumab treatment).
89110674|NCT05313308||Midazolam|Participants will receive a single age-specific dose midazolam oromucosal solution through buccal mucosa upon onset of seizures. Dose will be dependent by age of participants as follows: >= 52 weeks and < 1 year; 2.5 mg/dose of midazolam, for >= 1 year and < 5 years; 5 mg/dose of midazolam, for >= 5 years and < 10 years; 7.5 mg/dose of midazolam, for >= 10 years and < 18 years; 10 mg/dose of midazolam. Participants received interventions as part of routine medical care.
89110675|NCT05276180|Experimental|Arm A) Multifactorial intervention strategy|Experimental: Multifactorial intervention strategy for safe patient handling and movement (PHM) - Arm A The multifactorial intervention strategy for care units randomized to Arm A includes: 1) Swedish guideline for PHM and digital introduction for using the guideline (two workshops for manager and implementation team) 2) Training modules (theoretical and practical - one session) 3) Risk assessment with TilThermometer (four times) and 4) Fall risk assessment using Downton Fall Risk Index (DFRI) or existing fall risk assessment instrument at the care unit (all patients) and 5) Work environment mapping with Structured Multidisciplinary Work Environment Survey (SMET) including active/personal feedback
89110676|NCT05276180|Active Comparator|Arm B) Single intervention strategy|No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
89110677|NCT05275127||Q-SRP|Evaluation of changes of gingival crevicular fluid miRNA
89110678|NCT05275127||FM-SRP|Evaluation of changes of gingival crevicular fluid miRNA
88821061|NCT05212818|Experimental|High Dose Placebo Control|80 will be randomly assigned to high dose placebo, take the placebo BID.
89110679|NCT05273359|Active Comparator|Benralizumab Intervention|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
89110680|NCT05273359|Placebo Comparator|Benralizumab Placebo|15 subjects (>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
89110681|NCT05273359|Other|Comparison (control) group; no intervention|15 subjects (<150 eosinophils/microliter) will not receive any intervention.
89110682|NCT05272059|Experimental|Part A: Cohort 1 - MHS552 low dose|Participants will receive MHS552 low dose once weekly subcutaneously for 4 weeks
89110683|NCT05272059|Placebo Comparator|Part A: Cohort 1, 2, 3 - Placebo|Participants will receive placebo once weekly subcutaneously for 4 weeks
89110684|NCT05272059|Experimental|Part A: Cohort 2 - MHS552 medium dose|Participants will receive MHS552 medium dose once weekly subcutaneously for 4 weeks
89110685|NCT05272059|Experimental|Part A: Cohort 3 - MHS552 high dose|Participants will receive MHS552 high dose once weekly subcutaneously for 4 weeks
89110686|NCT05272059|Experimental|Part B: MHS552|Participants will MHS552 (dose to be determined) once weekly subcutaneously for 12 weeks
89110687|NCT05272059|Placebo Comparator|Part B: Placebo|Participants will receive placebo once weekly subcutaneously for 12 weeks
89110688|NCT05266144||atrial fibrillation|Atrial fibrillation patients who underwent radiofrequency ablation in Peking Union Medical College Hospital.
89110689|NCT05264129|Experimental|Atogepant + Ubrogepant|Participants will receive atogepant for 12 weeks followed by atogepant + ubrogepant for 12 weeks.
89110690|NCT05259345|Active Comparator|Group SE-TAP block|Bilateral subcostal exterior semilunaris transverses abdominis plane (SE-TAP) block will be performed with 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline)
89110691|NCT05259345|Active Comparator|Group M-TAPA block|Bilateral modified thoracoabdominal nerves block through perichondrial approach (M-TAPA) will be performed with 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline)
89110692|NCT05259345|Active Comparator|Group RS block|Bilateral rectus sheath block will be performed with 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline)
89110693|NCT05248178|Experimental|CO-OP and tDCS group|Each session will consist of 20 minutes of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. This will be followed by 45 minutes of the assigned CO-OP.
89110694|NCT05248178|Active Comparator|CO-OP and sham tDCS group|Each session will consist 20 minutes of sham tDCS followed by 45 minutes of the assigned CO-OP.
89110695|NCT05248178|Active Comparator|Computer cognitive training and tDCS group|Each session will consist of 20 minutes of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. This will be followed by 45 minutes of the assigned computer cognitive training.
89110696|NCT05248178|Active Comparator|Computer cognitive training and sham tDCS group|Each session will consist 20 minutes of sham tDCS followed by 45 minutes of the assigned computer cognitive training.
89110697|NCT05214170|Experimental|Electroanatomic mapping with NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
89110698|NCT05192148|Experimental|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
89110699|NCT05188612||Male|Non-interventional patient registry
89110700|NCT05188612||Female|Non-interventional patient registry
89110701|NCT05188612||Elderly|Non-interventional patient registry
89110702|NCT05188612||Hypertension|Non-interventional patient registry
89110703|NCT05188612||Diabetes|Non-interventional patient registry
89110704|NCT05188612||Dyslipidemias|Non-interventional patient registry
89110705|NCT05188612||Smoking|Non-interventional patient registry
89110706|NCT05188612||Kidney Disease|Non-interventional patient registry
89110707|NCT05188612||Heart Diseases|Non-interventional patient registry
89110708|NCT05188612||Vascular diseases|Non-interventional patient registry
89110709|NCT05181995|Experimental|50 mg NYX-783 QD|50 mg NYX-783 QD
89110710|NCT05181995|Placebo Comparator|Placebo|Placebo QD
89110711|NCT05175170|Experimental|Decision-aid|Participants will spend up to one hour freely navigating the web-based decision aid. They will complete pre- and post-test measures to determine if using the decision-aid website increased knowledge and impacted decision self-efficacy regarding fertility and fertility preservation.
89110712|NCT05171790|Experimental|QL1706 injection|This clinical trail is a single arm study, all the patients that meet the entry criteria will receive treatment until disease progression occurs or meet other criteria for the discontinuation of treatment. QL1706 will be administered by intravenous infusion, 5 mg/kg, Q3W.
89110713|NCT05169905|Experimental|RSV_dTpa-P Group|Healthy non-pregnant girls 9-17 years of age received a single dose of RSV MAT vaccine at Day 1 and were scheduled to receive a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). Participants who were enrolled and were due to receive the dTpa vaccine at Day 31, did no longer receive the dTpa as part of this study, but they were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.
89110714|NCT05169905|Experimental|dTpa_RSV-P Group|Healthy non-pregnant girls 9-17 years of age were scheduled to receive a single dose of dTpa vaccine at Day 1 and a single dose of RSV MAT vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration), but there were no participants assigned to this study group, and hence, there was no vaccine administered in this study group.
89229409|NCT02556827||H, Rosacea patients|"Rosacea patients who were between the ages of 18-70, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
88821062|NCT05209152|Experimental|Part 1A - AMG 176 Monotherapy (Dose Exploration)|Two dose levels of AMG 176 will be tested in Part 1A to find the optimal biological dose/minimum safe biologically effective dose (OBD/MSBED).
88821063|NCT05209152|Experimental|Part 1B - AMG 176 and Azacitidine Combination Therapy (Dose Exploration)|After the OBD is found in Part 1A, two dose levels of AMG 176 in combination with azacitidine will be tested in Part 1B to find the OBD/MSBED.
89110715|NCT05169905|Experimental|RSV_dTpa-A Group|Healthy non-pregnant adult women 18-49 years of age received a single dose of RSV MAT vaccine at Day 1 and were scheduled to receive a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). Participants who were enrolled and were due to receive the dTpa vaccine at Day 31, did no longer receive the dTpa as part of this study, but they were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.
89110716|NCT05169905|Experimental|dTpa_RSV-A Group|Healthy non-pregnant adult women 18-49 years of age received a single dose of dTpa vaccine at Day 1 and were scheduled to receive a single dose of RSV MAT vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). RSV MAT vaccine was no longer administered to participants at Day 31.
89110717|NCT05167955|Experimental|Experimental Randomized controlled waitlist|n=34 (will receive Mindfulness-based cognitive intervention)
89110718|NCT05167955|Other|Waitlist Randomized controlled waitlist|waitlist Randomized controlled waitlist n=34 (will not receive Mindfulness-based cognitive intervention for 1 month)
88821064|NCT05209152|Experimental|Part 2 - AMG 176 and Azacitidine Combination Therapy (Dose Expansion)|"After the completion of Part 1, the Part 2 dose expansion phase will begin at the OBD/MSBED identified in Part 1.~Venetoclax-naïve and venetoclax-exposed R/R HR-MDS participants after HMA failure will be enrolled along with participants with newly diagnosed HR-MDS/CMML."
89110719|NCT05163223|Experimental|AST-301(pNGVL3-hICD)+Chemotherapy|"AST-301/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy*~A booster (AST-301/rhuGM-CSF) at 24 weeks post the third vaccination~Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)"
89110720|NCT05163223|Active Comparator|Placebo + Chemotherapy|"Placebo/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy*~A booster (Placebo/rhuGM CSF) at 24 weeks post the third vaccination~Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)"
89110721|NCT05156736||Young Pakistanis|Young pakistani population with no history of cardiovascular disease and stroke
89110722|NCT05130944|Experimental|Entre Nosotras (group psychosocial intervention) + stress management intervention|Experimental condition: Women residing in the study community (displaced and host population) will receive both group psychosocial intervention and stress management intervention. Participants will be given the Spanish version of the Doing What Matters in Times of Stress illustrated guide, that is published and made publicly available by the World Health Organization.
89110723|NCT05130944|Active Comparator|Entre Nosostras (group psychosocial intervention)|Comparison condition: Women residing in the study community (displaced and host population) will receive group psychosocial intervention only.
89110724|NCT05123963|Active Comparator|Morning exercise|Participant to perform high-intensity interval training in the morning (~9 am)
89110725|NCT05123963|Experimental|Afternoon exercise|Participant to perform high-intensity interval training in the morning (~4 pm)
89110726|NCT05101122|Active Comparator|Dosing Period 1: Atomoxetine|3 days of atomoxetine 40 mg followed by 4 days of atomoxetine 80 mg.
89110727|NCT05101122|Experimental|Dosing Period 2-4: AD313|Week 2: atomoxetine 40 mg/dronabinol 2.5 mg Week 3: atomoxetine 80 mg/dronabinol 5 mg Week 4: atomoxetine 80 mg/dronabinol 10 mg
89110728|NCT05090774|Experimental|Supervised Exercise Therapy (SET) Plus Balance Exercises|Intervention meetings surrounding supervised exercise therapy (SET) with the addition of the adapted Otago Exercise Program (OEP) will occur individually with participants in a 1:1 format once per week for 30 minutes over 8 weeks. Additionally, participants will be encouraged to practice exercises at home at least 2 additional days between intervention meetings using visual handouts (up to 7 times/week total, approximately 140 minutes/week).
89110729|NCT05090774|No Intervention|Supervised Exercise Therapy (SET) Only|Intervention meetings surrounding supervised exercise therapy (SET) will occur individually with participants in a 1:1 format once per week for 30 minutes over 8 weeks. Additionally, participants will be encouraged to practice exercises at home at least 2 additional days between intervention meetings using visual handouts (up to 7 times/week total, approximately 140 minutes/week).
89110730|NCT05087771|Active Comparator|Oral naltrexone|patients will receive a 30 day supply of oral naltrexone 50 mg daily at hospital discharge. This medication was FDA approved in 1984 for the treatment of alcohol use disorder
89110731|NCT05087771|Experimental|injectable naltrexone|patient will receive 360 mg injection of naltrexone prior to hospital discharge
89110732|NCT05084235|Active Comparator|Empaglifloxin|
89110733|NCT05084235|Placebo Comparator|Placebo|
89110734|NCT05062252|Experimental|Mirror group|Mirror Medacta Shoulder System
89110735|NCT05062252|Active Comparator|Historical Control group|Total shoulder arthroplasty system
89110736|NCT05049694|Experimental|zirconia crowns|esthetic crowns for capping permanent molars with caries
89110737|NCT05049694|Experimental|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
89110738|NCT05048901|Experimental|Cabozantinib and Lanreotide|Oral cabozantinib 40-60 mg/day and lanreotide 120mg deep subcutaneous injection (SC) in day 1 every 4 weeks.
89110739|NCT05042973|Active Comparator|Active drug (Empagliflozin)|Empagliflozin 10 mg, 1 capsule per day
89110740|NCT05042973|Placebo Comparator|Inactive drug (placebo)|Placebo, 1 capsule per day
89110741|NCT05038163|No Intervention|Control Arm|In Part II of the experiment, subjects are not presented with nutrition or warning labels when choosing between beverages.
89110742|NCT05038163|Experimental|Nutrition Labels Arm|In Part II of the experiment, subjects are shown enlarged nutrition labels when choosing between beverages.
89110743|NCT05038163|Experimental|Text Warning Labels Arm|In Part II of the experiment, subjects are shown a warning message about the health risks of sugary beverages when choosing between beverages.
89110744|NCT05038163|Experimental|Graphic Warning Labels Arm|In Part II of the experiment, subjects are shown a graphic warning message about the health risks of sugary beverages when choosing between beverages. The message, for example, could include photos of tooth decay and other negative health outcomes.
89110745|NCT05034003|Experimental|zirconia crowns|Zirconia crowns placed on primary incisor teeth
89110746|NCT05034003|Experimental|composite strip crowns|composite strip crowns placed on primary incisor teeth
89110747|NCT05034003|No Intervention|Control tooth|Caries-free primary incisor tooth
89110748|NCT05020496|No Intervention|Group 1 (Negative Control, 20 participants)|"At the first visit, various doses of diphenylcyclopropenone (DPCP) are applied in acetone to give the required dose range, increasing by 60% increments. Elicitation patch is applied on the upper inner arm skin and removed by patients themselves exactly 6 hours after the application.~The second visit will be 48 hours after the DPCP treatment. At this visit, the bi-fold skin thickness will be measured using a Medical Skinfold Caliper.~The group1 will have only one treatment with DPCP and serve as negative controls for DPCP induced cutaneous immune responses in comparison to Group 2 and 3, which require two treatments with DPCP (sensitization and challenge) as described in the following group 2 and 3. The first reading of skin thickness prior to DPCP application serves as the baseline and the second reading after DPCP indicates an increase in skin thickness, which represents a quantitative parameter of DPCP induced immune responses."
89110749|NCT05020496|Other|Group 2 (Positive Control, 20 participants)|"This group of the study will take approximately 5 weeks and requires 3 visits. At the first visit, skin sites on the right upper buttock will be topically treated with a patch of the contact sensitizer (DPCP) for sensitization on the upper buttock for 48 hours. The skin patches will be removed by patients themselves after the application.~The second visit will be four weeks after the DPCP sensitization, participants will have a DPCP treatment again on the right upper inner arm with the same agent. At the visit, the bi-fold skin thickness will be measured prior to the application of DPCP skin patch by using a Medical Skinfold Caliper. Various DPCP doses are applied increasing by 60% increments. The patches are applied on the upper inner arm skin and removed by patients themselves exactly 6 hours after application.~The third and final visit will be 48 hours after the second DPCP treatment. At this visit, bi-fold skin thickness will be measured using a Caliper."
89229410|NCT02556827||K, Healthy volunteers|"Healthy volunteers who were compatible in terms of age, sex and skin phenotype, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
89229411|NCT05162690|Active Comparator|The Drug Arm|"Dapagliflozin 10 milligram Once a day~1 year"
89229412|NCT05162690|Placebo Comparator|The Placebo Arm|Metformin 1gram Per Oral Twice a day Glimepiride 2 milligram oral twice a day Dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors)
89229413|NCT00773435|Active Comparator|1. Echinacea purpurea|
88821065|NCT05205512|Experimental|Group I (telehealth exercise)|Patients participate in telehealth exercise intervention for 30 minutes per day, 3 days a week for 8 weeks.
88821066|NCT05205512|Active Comparator|Group II (delayed control)|Patients maintain current levels of physical activity for 8 weeks. Patients may then participate in telehealth exercise intervention for 8 weeks.
89229414|NCT00773435|Placebo Comparator|2. placebo|
88821067|NCT05203250||Brain tumors, skull base tumors, spinal cord tumors|NEUROPARTICLE
88821068|NCT05203250||Ocular melanomas|
89229415|NCT00777569|Experimental|Extra-low nicotine cigarettes|
89229416|NCT00777569|Experimental|Nicotine-free cigarettes|
89229417|NCT00777569|Active Comparator|Medicinal Nicotine|
89229418|NCT00777647|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
88821069|NCT05203250||Head and Neck tumors|
88821070|NCT05203250||Tumors of thorax and/or abdomen|GI-Particle
89229419|NCT00777647|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
89229420|NCT00777647|Active Comparator|Semi-skimmed milk|202kJ/100mL
89229421|NCT00777647|Placebo Comparator|Water|0kJ/100mL
89229422|NCT00777725||1|Chronic stable left sided HF patients
89229423|NCT00777725||2|Predominant right sided HF patients secondary to valvular heart disease, pulmonary artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic disease and etc
89229424|NCT00777725||3|Acute decompensated left sided heart failure patients who have volume overload and have been admitted for diuresis
89229425|NCT00777725||4|Control subjects with no evidence of heart disease.
88821071|NCT05203250||Pelvic tumors|GYN-Particle
89229426|NCT02556593|Experimental|IMRT & erlotinib|Patients in experimental group receive IMRT and erlotinib: Daily IMRT(45Gy in 15 fractions) to the brain metastases with daily erlotinib(150mg.po) for three weeks
89229427|NCT02556593|Active Comparator|whole-brain radiotherapy|Patients in this group receive WBRT at 30Gy in 10 fractions
89229428|NCT00780845||AKI (-)|Patients without acute kidney injury after on-pump CABG
89229429|NCT00780845||AKI (+)|Patients with acute kidney injury after on-pump CABG
89229430|NCT00535730|Placebo Comparator|1|Placebo Comparator
89229431|NCT00535730|Experimental|2|vaccine
89229432|NCT00780923|Experimental|CPAP|
89110750|NCT05020496|Experimental|Group 3 (UVB & Biopsy 30 participants)|"This group of the study will take approximately 10 weeks and requires 10 visits.~At the first visit, blood will be collected and MED will be determined. The second visit will be 24h after UV when MED will be measured. Blood will be collected from patients at this time. The third visit will be on the 8th day. The two marked skin sites will be UV exposed at 2MED on 4 consecutive days.~Days 9-11 make up the fourth, fifth, and sixth visits. Following the last UV exposure blood will be collected. A single dose of DPCP will be placed on the upper buttock for 48 hours. The seventh visit will be on the 12th day when two skin biopsies will be taken. The ninth visit will be four weeks after the sensitization with DPCP, when the upper inner arm will be treated with DPCP. Bi-fold skin thickness will be measured prior to the application of DPCP. Various DPCP doses are applied. The tenth visit will be 48 hours after the DPCP treatment. At this visit, bi-fold skin thickness will be measured."
89110751|NCT05017233|Experimental|Experimental group, all volunteer will be scanned.|All participation accept Spectral CT scanning; No group;
89110752|NCT05013333|Other|AED 3 with Uni-padz|
89110753|NCT05002803|Experimental|Otago Exercise Program|Older adults will receive the Arabic Otago Exercise Program for 8 weeks plus health awareness videos.
89110754|NCT05002803|No Intervention|Control group|Older adults will receive only health awareness videos every 2 weeks.
89110755|NCT04998149|No Intervention|standard care|The control group subjects will receive standard of care during labor using pillows and wedges as positional devices.
89110756|NCT04998149|Experimental|Peanut ball intervention|The experimental group will receive peanut ball as positioning device during labor
88821072|NCT05203250||Sarcomas and tumors of limbs|SarTAP-Particle
88821073|NCT05203250||Pediatric tumors|
88821074|NCT05203250||Mobile spine and sacral tumors|
89110757|NCT04976257|Experimental|Ga-PSMA-11, PET/CT, Angiogram, and Prostatic Arterial Catheterization|Patients receive 68Ga-PSMA-11 IV over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after on day 1. One to 14 days later, patients undergo pelvic angiogram and prostatic arterial catheterization. Patients then receive 68Ga-PSMA-11 IA over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after.
89110758|NCT04954365||Cohort 1|Patients that received rescue treatment according to the standard of care (SOC).
89110759|NCT04954365||Cohort 2|Patients that received rescue treatment with IV amisulpride.
89110760|NCT04936009|Active Comparator|Transcranial Magnetic Stimulation - real|Participants will receive active TMS during their study visit
89110761|NCT04936009|Placebo Comparator|Transcranial Magnetic Stimulation - sham|Participants will receive sham stimulation during their study visit simulating TMS
89110762|NCT04923685||MDD with elevated CM and suicidality scores|Major Depressive Disorder with elevator childhood maltreatment and suicidality scores.
89110763|NCT04923685||MDD with CM history but lower suicidality|Major Depressive disorder with childhood maltreatment history but lower suicidality scores.
89110764|NCT04923685||MDD without CM but with elevated suicidality|Major Depressive Disorder without childhood maltreatment, but with elevated suicidality scores.
89110765|NCT04923685||MDD without CM but with lower suicidality|Major Depressive Disorder without childhood maltreatment but with lower suicidality scores.
89110766|NCT04923685||Healthy controls with CM history|Healthy controls with childhood maltreatment history,
89110767|NCT04923685||Healthy controls without CM history|Healthy controls without childhood maltreatment history.
89110768|NCT04920617|Experimental|Arm 1: DPX-Survivac, pembrolizumab, CPA|Subjects will receive two 0.5 mL doses of DPX-Survivac three weeks apart followed by up to twelve 0.1 mL doses eight weeks apart. Pembrolizumab will be administered on the first day of every three week cycle at a flat dose of 200 mg. CPA will be self-administered 50 mg BID for 7 days on and 7 days off starting on D0.
89110769|NCT04920617|Experimental|Arm 2: DPX-Survivac, pembrolizumab|Subjects will receive two 0.5 mL doses of DPX-Survivac three weeks apart followed by up to twelve 0.1 mL doses eight weeks apart. Pembrolizumab will be administered on the first day of every three week cycle at a flat dose of 200 mg. Subjects randomized to Arm 2 will not receive CPA.
89110770|NCT04913766|Active Comparator|Services as usual|Persons screening positive for depression will be referred from community-based organizations. The referrals will be made to mental health specialists who will provide care based on their standard of care.
89229433|NCT02556125||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
89110771|NCT04913766|Experimental|Problem Management Plus|Persons screening positive for depression will be offered Problem Management Plus delivered by community based organization staff.
89110772|NCT04860804|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
89110773|NCT04860804|Active Comparator|OK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine
89110774|NCT04817345|Experimental|Plerixafor|Participants will receive a subcutaneous dose of 0.24 mg/kg of plerixafor once daily (Q24hr) x 2 days.
89110775|NCT04812080|Experimental|EXPLORER PET/CT Imaging|Study participants will be injected with 10 +/- 2 mCi of 18F-FDG using and IV line and a 60 minute PET scan will begin on EXPLORER. Prior to the PET scan, an ultra-low-dose CT scan (less than 1 minute ) will be acquired for attenuation correction purposes only. Ninety (90) minutes after being injected with FDG, participants will have another ultra-low dose CT scan (less than 1 minute) which will be acquired for attenuation correction purposes only. This will be followed by a 20 minute PET scan on EXPLORER. One-hundred and twenty (120) minutes after being injected with FDG, participants will be positioned supine on the scanner table for the last time. At this time, a low dose CT scan (less than 1 minute) will be acquired once again for attenuation correction purposes. This will be followed by one last 20 minute PET scan on EXPLORER. The IV line will be removed after completion of the study.
89110776|NCT04764396|Experimental|Heparin priming biopsies|
89110777|NCT04764396|Active Comparator|Standard of care (saline)|
89110778|NCT04763317||AFFECTED|"Affected with PrCa < 70 years~Affected with metastatic castration resistant PrCa (mCRPC) at any age~Affected with PrCa and a family history defined as~two or more cases in family with one case < 70~three or more cases any age (FDR or SDR)"
89229434|NCT05354960||Validation of LIMB-Q questionnaire|We plan to validate the questionnaires for quality of life and functional impairment in a mixed study population. In addition, CROMs, specifically the active range of motion, the 2 PD, compara-tive circumference measurements, AOFAS and MFS will be collected. In addition, photo documen-tation of the operated lower extremity will be performed. The results obtained will be correlated with each other.
89229435|NCT00781001|Placebo Comparator|1|Placebo cannabis
89229436|NCT00781001|Experimental|2|Active cannabis - 1% THC by weight
89229437|NCT00781001|Experimental|3|Active cannabis - 4% THC by weight
89229438|NCT00781001|Experimental|4|Active cannabis - 7% THC by weight
89229439|NCT02556047|Other|Injections|"Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.2mm needle length~Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.5mm needle length~Two injections of 0.1 ml saline per subject using Mantoux technique by N&S"
89229440|NCT05252234||Group 1|Patients undergoing elective surgeries with past history of COVID-19 infection during the past six months
89229441|NCT00773591|Active Comparator|Botulinum Toxin Typ A|
89229442|NCT00773591|Placebo Comparator|Placebo|
89229443|NCT00992810|Experimental|Lateral-to-Medial Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
89229444|NCT00992810|Experimental|Medial-to-Lateral Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
89229445|NCT00995306|Active Comparator|1|Civamide Cream 0.075%
89229446|NCT00995306|Active Comparator|2|Civamide Cream 0.01%
89229447|NCT00992888|Experimental|albumin liver dialysis|
89229448|NCT00992888|No Intervention|Standard medial care without dialysis|
89229449|NCT05351372|Experimental|ULD protocol|ultra-low dose protocol in cone-beam computed tomography with a field of view including the cleft area
89229450|NCT05351372|Active Comparator|Standard dose protocol|Standard dose protocol in cone-beam computed tomography with a field of view including the cleft area
89229451|NCT00666965|Placebo Comparator|1|inactive placebo
89229452|NCT00666965|Experimental|2|2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets
89229453|NCT00666965|Experimental|3|4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet
89110779|NCT04763317||UNAFFECTED|"- Aged >30 and with a family history defined as::~FDR diagnosed < 70~2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed < 70 years~3 or more cases at any age (on same side of family)"
89110780|NCT04731051|Experimental|First Arm (Hydroxychloroquine sulfate, 5 days)|Participants will receive continued standard of care therapy (SOC) for COVID-19 together with 2 ml HCQ01 (12.5 mg/ml) twice a day for 5 consecutive days.
89110781|NCT04731051|Active Comparator|Second Arm (Continued Standard of Care (SOC) Therapy)|Participants will receive continued standard of care therapy for COVID-19
89110782|NCT04706923|Experimental|BCV 0.2mg/kg BIW|BCV: 0.2 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
89110783|NCT04706923|Experimental|BCV 0.3mg/kg BIW|BCV: 0.3 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
89110784|NCT04706923|Experimental|BCV 0.4 mg/kg BIW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 and Day4 for a minimum of 4 weeks.
89110785|NCT04706923|Experimental|BCV 0.4 mg/kg QW|BCV: 0.4 mg/kg administered as a continuous IV infusion over 2 hours on Day1 for a minimum of 4 weeks.
89110786|NCT04684589|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: screening visit, baseline visit, an interim visit (10 weeks post-baseline), and a 12-week visit.
89229454|NCT00666965|Experimental|4|6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets
89229455|NCT05350358||Patients who have undergone surgical treatment with LeMaitre Cardial Dialine II|Subject who has undergone surgical treatment for the replacement or bypass in aneurysmal and/or occlusive diseases and for arterial reconstruction in patients requiring systemic heparinization with LeMaitre Cardial Dialine II.
89229456|NCT00781157|Experimental|1|
89229457|NCT00995462|No Intervention|Control|
89229458|NCT00995462|Experimental|Small-group seminar for 2 years|
89229459|NCT00995462|Experimental|Small-group seminars for 1 year followed by email intervention|
89229460|NCT00777959|Experimental|Open Label|ridaforolimus (MK8669)+ bicalutamide
89229461|NCT00777959|Experimental|Ridaforolimus|ridaforolimus (MK8669)+ bicalutamide
89229462|NCT00777959|Placebo Comparator|Placebo|Placebo + bicalutamide
89229463|NCT00995540|Placebo Comparator|Placebo|Placebo subcutaneous injection tid for 12 weeks
89229464|NCT00995540|Active Comparator|100 mg INGAP Peptide tid|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
89229465|NCT00995540|Active Comparator|200 mg INGAP Peptide tid|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
89229466|NCT00778037|Experimental|1|Cyclobenzaprine hydrochloride 10 mg tablet of ranbaxy
89229467|NCT00778037|Active Comparator|2|Flexeril® 10 mg tablets
89229468|NCT00778115|Experimental|1|Loperamide HCl 2 mg and simethicone 125 mg tablets of ranbaxy
89229469|NCT00778115|Active Comparator|2|Imodium® Advanced caplets
89229470|NCT02557217|Experimental|NP202|1000mg oral NP202 daily for 90 days
89229471|NCT02557217|Placebo Comparator|Placebo|Oral placebo daily for 90 days
89229472|NCT03474224||FloTrac patients|patients belong to this group will be managed with a stroke volume target hemodynamic protocol
89229473|NCT00773825||1|Pregnancy after ICSI or IVF
89229474|NCT00773825||2|Pregnancy after ovarian stimulation
89229475|NCT00773825||3|natural pregnancy
89229476|NCT00993122|Active Comparator|ribavirin pre-treatment|patient will receive ribavirin in monotherapy for 8 weeks before the combined 48 weeks antiviral therapy
89229477|NCT00993122|Active Comparator|combined stardard therapy|patients will receive the standard combined therapy with ribavirin and pegylated interferon for 48 weeks
89229478|NCT00778193|Placebo Comparator|Placebo|
89229479|NCT00778193|Active Comparator|Naproxen|
89229480|NCT00778193|Experimental|Aspirin|
89229481|NCT00778193|Experimental|Clopidogrel|
89229482|NCT00778193|Experimental|Celecoxib|
89229483|NCT00778271|Experimental|1|Gabapentin 400mg capsules
89229484|NCT00778271|Active Comparator|2|Neurontin® 400 mg capsules
89229485|NCT00778349|Experimental|1|Metformin solution 100 mg/mL under fasting condition
89229486|NCT00778349|Experimental|2|Metformin solution 100 mg/mL, after low fat meal
89229487|NCT00778349|Experimental|3|Metformin solution 100 mg/mL, after high fat meal
89229488|NCT00995618|Experimental|Tranilast|Tranilast tablets
89110787|NCT04684589|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 50 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: screening visit, baseline, an interim visit (10 weeks post-baseline), and a 12-week visit.
89110788|NCT05443438|No Intervention|3D-3D|All items presented in 3D form
89110789|NCT05443438|Experimental|3D-2D|Initial items in 3D, generalization in 2D
89110790|NCT05443438|Experimental|2D-3D|Initial items in 2D, generalization in 3D
89110791|NCT05443438|Experimental|2D-2D|Initial items in 2D, generalization in 2D
89110792|NCT04632654|Experimental|PAfitME|For 6 weeks, the experimental (PAfitME) group will receive the PAfitME intervention.
89110793|NCT04632654|No Intervention|Attention Control|For 6 weeks, the attention control group will receive National Cancer Institute-based survivorship education and exergame equipment (Nintendo Switch).
89110794|NCT04607668|Experimental|trilaciclib + FOLFOXIRI/bevacizumab|"During Induction the following study drugs are administered on Day 1:~Irinotecan- IV Oxaliplatin - IV Leucovorin- IV Fluorouracil - continuous infusion (CI) over 48 hours beginning on Day 1; Bevacizumab - IV~Following completion of Induction, patients will continue in Maintenance, where they will continue to receive trilaciclib per randomization allocation. Trilaciclib will be administered prior to infusional-5FU/leucovorin/bevacizumab at the same dose and schedule used during Induction."
89229489|NCT00995618|Active Comparator|Febuxostat|Febuxostat tablets
89229490|NCT00995618|Experimental|Combination|Tranilast plus febuxostat
89229491|NCT00778427|Experimental|1|metformin hydrochloride 1000 mg tablets of Ranbaxy
89229492|NCT00778427|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
89229493|NCT00773981|Active Comparator|1|Endoluminal vacuum therapy.
89229494|NCT00773981|No Intervention|2|Patients not receiving vacuum therapy should be treated with a catheter with daily rinsing for a minimum of 7 days.
89229495|NCT03889886|Placebo Comparator|Vehicle|Vehicle
89229496|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (0.1%)|Low concentration of SDP-4
89110795|NCT04607668|Placebo Comparator|placebo + FOLFOXIRI/bevacizumab|The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib
89110801|NCT04597086|Experimental|Group I (BWLT, best practice)|Patients receive BWLT over 30 minutes in addition to standard of care daily during hospital stay.
89110802|NCT04597086|Active Comparator|Group II (standard of care)|Patients receive standard of care during hospital stay.
89110803|NCT04582617|Active Comparator|Cocoa extract + multivitamin|
89110804|NCT04582617|Active Comparator|Cocoa extract + multivitamin placebo|
89110805|NCT04582617|Active Comparator|Cocoa extract placebo + multivitamin|
89110806|NCT04582617|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
89110807|NCT04527289|Experimental|Amantadine Group|Group, I are patients who will receive amantadine (100mg) as add on therapy to the standard regimen.
89110808|NCT04527289|Placebo Comparator|Placebo Group|Group II are patients who will be managed with the standard regimen.
89110809|NCT04505735||Normal Control|Adults with no history of memory complaints, diagnosis of MCI, or dementia from a physician
89110810|NCT04505735||Adults with Mild Cognitive Impairment|Adults with cognitive decline verified by a study partner or cognitive impairment verified by the study physician. The cognitive decline has had limited impact on functional activities; general cognition and functional performance are sufficiently preserved such that a diagnosis of dementia cannot be made by the enrolling physician
89110811|NCT04502524|Experimental|Arm I (New website program, handout, text message)|Participants complete the new website smoking cessation program which provides values driven, mindfulness based coping skills and utilizes non-judgmental acceptance of uncomfortable internal states like cravings. Participants will also receive text messages consisting of motivational messages and reminders to use the program. At the end of the program, participants receive an email with all session handouts and available resources provided by the VA for continued support for smoking cessation.
89110812|NCT04502524|Active Comparator|Arm II (Standard care VA website, handout, text message)|Participants use the standard of care website, which provides educational materials about cessation treatments, tools to cope with urges and relapse, how to stay motivated, and brief tips on coping with physical and mental health problems. Participants also receive text messages consisting of motivational messages and reminders to use the program. At the end of the program, participants receive an email with a handout of available resources provided by the VA for continued support for smoking cessation.
89110813|NCT04492215|Experimental|Physicians trained in motivational interviewing|Patients followed by general practitioners trained in motivational interviewing
89110814|NCT04492215|No Intervention|Physicians did not trainned in motivational interviewing|Patients followed by general practitioners who did not receive motivational interviewing.
89110815|NCT04487886|Experimental|Duvelisib|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive duvelisib for 14 days.
89110816|NCT04487886|Placebo Comparator|Placebo|Participants with severe COVID-19 who do not require mechanical ventilation randomized to receive a placebo to match duvelisib for 14 days.
89110817|NCT04460872|Experimental|testosterone enanthate|Testosterone enanthate via i.m. injection (100 mg/week)
89110818|NCT04460872|Experimental|locomotor training, testosterone enanthate|Treadmill and overground walking training and testosterone enanthate via i.m. injection (100 mg/week)
89110819|NCT04460872|No Intervention|non-interventional control|Non-interventional control group
89229497|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Mid concentration of SDP-4
89229498|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (3.0%)|High concentration of SDP-4
89110820|NCT04437602|Experimental|CEM|Patients in experimental arm will go through additional preoperative staging with contrast enhanced mammography
89110821|NCT04437602|No Intervention|No CEM|Patients in No intervention arm will go through no additional preoperative imaging
89110822|NCT04422795|Experimental|External thermomechanical device delivering stimuli|The thermomechanical device is placed on the digit proximally to the injection site with the ice wings frozen and the vibration mechanism switched on.
89110823|NCT04422795|Placebo Comparator|External thermomechanical device without delivering stimuli|The thermomechanical device is placed on the digit proximally to the injection site with the ice wings at room temperature (unfrozen) and the vibration mechanism switched off.
89110824|NCT04422795|Active Comparator|Nail injection with ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection immediately before needle insertion
89110825|NCT04413617|Experimental|PF-06650833 + tofacitinib|
89110826|NCT04413617|Experimental|PF-06650833 + PF-06651600|
89110827|NCT04413617|Experimental|PF-06650833|
89110828|NCT04413617|Experimental|PF-06651600|
89110829|NCT04413617|Experimental|Tofacitinib|
89110830|NCT04405115|No Intervention|No intervention arm|routine care only; will not be scheduled for comprehensive geriatric assessment
89110831|NCT04405115|Active Comparator|Active comparator arm|those that will be scheduled for comprehensive geriatric assessment with a geriatric nurse practitioner or physician
89110832|NCT04244123||growth hormone deficiency|growth hormone deficiency, requiring growth hormone treatment
89110833|NCT04244123||small for gestational age|small for gestational age and failure of post natal catch up height gain, requiring growth hormone treatment
89110834|NCT04244123||Turner syndrome|short stature due to Turner syndrome, on growth hormone treatment
89110835|NCT04244123||chronic renal failure|short stature due to chronic renal failure, treated with growth hormone treatment
89110836|NCT04244123||Prader Willi syndrome|short stature due to Prader Willi syndrome, treated with growth hormone treatment
89110837|NCT04233086||Patients referred through the BNP pathway|Patients throughout 2016 referred through the BNP pathway at Queen Alexandra Hospital will retrospectively be assessed for Reddy et al (2018) H2FPEF score.
89110838|NCT04218565|Experimental|Golimumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
89110839|NCT04193449||Adult patients undergoing colonoscopy|All patients' ≥18 years of age who underwent endoscopy at Portsmouth Hospitals NHS Trust, including repeat colonoscopies performed for surveillance purposes aged ≥18 in either males or females.
89110840|NCT04145635|Experimental|Aortix Device|Aortix Pump, Aortix Delivery System, Introducer Set, Aortix Control System, Aortix Retrieval System
89110841|NCT04129502|Experimental|TAK-788 Group (Arm A)|TAK-788 160 milligram (mg) with or without food, capsules, orally, once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
89110842|NCT04129502|Active Comparator|Platinum-based Chemotherapy Group (Arm B)|Pemetrexed 500 milligram per meter square (mg/m^2) plus cisplatin 75 mg/m^2, infusion, IV, once on Day 1 of 21-day cycle pemetrexed 500 mg/m^2 plus carboplatin, infusion, IV, once at a dose calculated to produce area under curve (AUC) of 5 milligram*minute per milliliter (mg*min/mL) on Day 1 of 21-day cycle until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria. Pemetrexed/cisplatin or pemetrexed/carboplatin will be repeated every 3 weeks for 4 cycles, followed by maintenance treatment with pemetrexed 500 mg/m^2, on Day 1 of a 21-day cycle thereafter.
89110843|NCT04112940||Adults with oropharyngeal cancer|Adult participants who have completed radiation therapy for oropharyngeal cancer within the past 3 months will undergo a swallowing x-ray study in which they will swallow up to 15 liquid stimuli prepared to different consistencies using starch and gum based thickeners.
89229499|NCT00781469||Naive patients|12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
89229500|NCT00781469||Patients in remission|6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
89229501|NCT00781469||Patients still have active disease|12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2
89229502|NCT03888482|Other|DDT2, then Clariti|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
89229503|NCT03888482|Other|Clariti, then DDT2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
89229504|NCT00995696|Experimental|PhaST|Group receiving PhaST IVR phone calls.
89229505|NCT00995696|No Intervention|Usual Care|Group NOT receiving IVR phone calls.
89229506|NCT00993278|Active Comparator|Low-Carbohydrate (Modified Atkins) Diet|
89229507|NCT00993278|Active Comparator|Low-Fat (Heart Healthy) Diet|
89229508|NCT00667355|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
89229509|NCT00778505|Experimental|1|closed-loop administration of propofol and remifentanil using bispectral index as the controller
89229510|NCT00778505|Active Comparator|2|manual administration of propofol and remifentanil according to bispectral index values
89229511|NCT00532844|Experimental|Sapropterin dihydrochloride|Sapropterin dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
89229512|NCT00532844|Experimental|Sapropterin dihydrochloride+Vitamin C|Sapropterin dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
89229513|NCT00778583|Experimental|1|Nitrofurantoin 100 mg capsules of Ranbaxy
89229514|NCT00778583|Active Comparator|2|Macrobid 100 mg capsules
89229515|NCT00778661|Experimental|1|amoxicillin 400mg + clovalunic acid 57.5mg tablets of Ranbaxy
89229516|NCT00778661|Active Comparator|2|Augmentin® tablets of glaxosmithkline
89229517|NCT00993356|Other|Group 2|After a baseline evaluation, patients underwent transsphenoidal surgery (direct surgery group).
89229518|NCT00993356|Experimental|Group 1|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
89229519|NCT00781547|Experimental|Recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
89229520|NCT00781547|Placebo Comparator|Placebo|
89229521|NCT00995852|Active Comparator|bilateral|"Treatment arm B - incomplete bilateral treatment of in total two lobes (contralateral).~The study will only use Intrabronchial Valves™"
89229522|NCT00995852|Active Comparator|unilateral|Treatment arm A - unilateral treatment with complete closure of the worst lobe of the lungs
89229523|NCT00774293|Experimental|1|Arnica 5CH and Bryonia 9CH (homeopathic drugs)
89229524|NCT00774293|Placebo Comparator|2|placebo Arnica 5CH and Bryonia 9CH
89229525|NCT04000958|Experimental|PIFR group|
89229526|NCT04000958|Active Comparator|control group|
89229527|NCT00778739|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
89229528|NCT00778739|Active Comparator|2|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
89229529|NCT00781625|Active Comparator|Probiotic vaginal capsules|Probiotic vaginal capsule, placebo oral capsule
89229530|NCT00781625|Placebo Comparator|placebo|placebo oral capsule, placebo vaginal capsule
89229531|NCT00781625|Active Comparator|Probiotic oral capsules|Probiotic oral capsules, placebo vaginal capsules
89229532|NCT03190460|Experimental|Intervention|
89229533|NCT03190460|Other|Education|
89229534|NCT00993434|Active Comparator|Kid STRIDE Booklet|
89229535|NCT00993434|Placebo Comparator|Safety Booklet|
89229536|NCT00781703|Other|DIAMOND Care Model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.
89229537|NCT00774449||1|individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at Hannover Medical School 6 months prior to inclusion
89229538|NCT02557061|Experimental|Patient with colorectal cancer|Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer
89229539|NCT00781781|Experimental|1|"High risk patients (at least one GVHD high risk criterion):~Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive)."
89229540|NCT00781781|Experimental|2|"Low Risk patients (no GVHD high risk criterion):~Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive)."
89229541|NCT00666263|Experimental|IGIV, 10% Then Placebo|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle)."
89229542|NCT00666263|Experimental|Placebo Then IGIV, 10%|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)"
89229543|NCT00667277|Experimental|bevacizumab (Avastin)|Use of bevacizumab (Avastin) in the treatment of myelofibrosis.
89229544|NCT00774527|No Intervention|ArmI(CyATG)|•Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter
89229545|NCT00778973|Experimental|1|sertraline 100 mg tablets of Ranbaxy
89229546|NCT00778973|Active Comparator|2|Zoloft® 100 mg tablets
89229547|NCT00774605|Experimental|Varenicline free base solution|
89229548|NCT00774605|Experimental|Varenicline transdermal delivery system|
89229549|NCT00779051|Experimental|1|Zolipidem 10mg tablets of Ranbaxy
88821134|NCT05081102|Active Comparator|Group 2: Tylex® (codeine 30 mg/paracetamol 500 mg)|Participants randomized to this group will receive one (01) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (01) tablet of FCD placebo when post-surgical pain intensity reaches moderate to intense intensity (≥ 40 mm on a 0-100 mm VAS). Participants will be instructed to, from then on, use this same treatment whenever needed for pain relief, observing a minimum interval of six (06) hours between two intakes, for up to 3 days (72 hours after the initial dose).
89229550|NCT00779051|Active Comparator|2|Ambien® 10mg tablets
89229551|NCT00774683||Sub-study Group A|Six HIV-positive African American women from the main study, CID 0706
89229552|NCT02556281|Experimental|Patient with colorectal cancer|Blood sampling is done for patient with colorectal cancer
89229553|NCT00782015|Active Comparator|almonds|3 oz/d almonds
89229554|NCT00782015|Placebo Comparator|Placebo|NCEP Step 2 diet
89229555|NCT00774839||Newly diagnosed stage II-III colon cancer 65 years or older|Medicare-eligible (≥ or = to 65 years) patients diagnosed with stage II - III colon cancer, are at least 4 months into chemotherapy and up to 7 months post-chemotherapy.
89229556|NCT00784433|Experimental|alcohol 1|
89229557|NCT00784433|Experimental|alcohol 2|
89229558|NCT00784433|Placebo Comparator|control|
89229559|NCT00774917|Experimental|Numen|
89229560|NCT00784511|Experimental|1 vitamin D3|vitamin D3, 4000 IU/d
89229561|NCT00784511|Placebo Comparator|2|placebo
89229562|NCT00784589|Experimental|Rituximab|
89229563|NCT00784589|Active Comparator|Corticotherapy|General Corticotherapy
89229564|NCT00789893||Women with cervical, endometrial, rectal or anal cancer|Women seen in the radiation oncology clinic with cervical, endometrial, rectal or anal cancer who will receive external beam pelvic radiation or brachytherapy
89229565|NCT00784745|Experimental|Dexamethasone|
89229566|NCT00534638|Experimental|Cervarix/Engerix-B A Group|The A group includes subjects from communities where 70% of male and female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate study participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated subjects were randomized to Cervarix). Finally, subjects from A group were either vaccinated with Cervarix, Engerix-B (control vaccine), or not vaccinated (enrolled control without vaccination). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
89229567|NCT00534638|Experimental|Cervarix/Engerix-B B Group|The B group includes subjects from communities where 70% of female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate female participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated females were randomized to Cervarix). In this group, all male adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from B group were either vaccinated with Cervarix (females) or Engerix-B/not vaccinated (males and females). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
89229568|NCT00534638|Active Comparator|Engerix-B Group|In this control group, all adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from this group were either vaccinated with Engerix-B or not vaccinated. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
89229569|NCT00996008|Placebo Comparator|Placebo only|Subjects will apply placebo cream to all 4 target lesions
89229570|NCT00996008|Active Comparator|Active plus placebo|Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.
89229571|NCT00993512|Experimental|TPCS2a|No comparative treatment is given in this open-label phase I, dose escalating safety study
88821135|NCT05060380|Experimental|Exercise training|The exercise training group will receive progressive muscle resistive exercise, 10 sets of exercises for 2 times per week for a total of 6 months.
89229572|NCT00996086||CRT device-recipients|
89110844|NCT04112576||HFrEF|Participants that are diagnosed with NYHA class II or III heart failure with reduced ejection fraction.
89110845|NCT04112576||HFpEF|Participants that are diagnosed with NYHA class II or III heart failure with preserved ejection fraction.
89110846|NCT04055116|Experimental|Unbuffered Lidocaine, then Buffered Lidocaine|Subjects will receive an injection of non-buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.
89110847|NCT04055116|Experimental|Buffered Lidocaine, then Unbuffered Lidocaine|"Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion.Subjects will receive an injection of this buffered 2% lidocaine with 1:100,000 epinephrine on one occasion; they will be randomized to this group. After a minimum of one week, subjects will receive the alternate solution.~We will use 8.4% Sodium Bicarbonate manufactured by Hospira, Inc. Lake Forest, IL"
88821136|NCT05060380|No Intervention|Control|The control group will be asked to maintain their normal lifestyle and will be advised to continue their standard care of treatment.
88821137|NCT05057806|Experimental|Empagliflozin Group|Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months
89229573|NCT00993590|Experimental|M CHESS group|The intervention group will receive access for 12 months to M-CHESS via a smartphone to: (1) contact their case managers and primary provider; (2) communicate with the managed care organization case managers; (3) communicate with peers; (4) share information about changes in health status; (5) receive reminders to take medications and complete medical follow-up; (6) receive feedback on use of their asthma action plan; (7) receive tailored inquiries and insights regarding attendance or use of asthma resources; and (8) access audio and video versions of asthma educational materials and lower reading level versions of text materials; (9) provide monthly study outcome data monthly for 12 months.
89229574|NCT00993590|Active Comparator|Control group|The control group will receive standard care plus a smartphone for 12 months; they will provide study outcome data monthly for the next 12 months.
89229575|NCT00662129|Experimental|paclitaxel + gemcitabine + bevacizumab|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after every other course, and then after completion of treatment.~After completion of study treatment, patients are followed periodically for 5 years."
89229576|NCT00996242|Experimental|L-lysine|
89229577|NCT00996320|Experimental|Intervention Schedule|Interns on the intervention schedule work the a modified ICU schedule averaging about 60 hours per week over 4 weeks, with maximum scheduled shift length 16 hours.
89229578|NCT00996320|No Intervention|Traditional Schedule|Interns on the traditional schedule work the usual ICU schedule averaging about 80 hours per week over 4 weeks, with maximum shift length 30 hours.
89229579|NCT00993746|Active Comparator|Bupivacaine plus lidocaine|Group 1: bupivacaine 20 ml plus lidocaine 10 ml
89229580|NCT00993746|Experimental|Bupivacaine alone|Group 2: bupivacaine 30 ml
89229581|NCT00785057||1|Hypertension patients with history of stroke
89229582|NCT00785057||2|Hypertension patients without history of stroke
89229583|NCT00996398|Experimental|Cold water immersion|14°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
89229584|NCT00782405|Experimental|1|quetiapine
88821138|NCT05057806|Placebo Comparator|Placebo group|Subjects will be randomized to receive the empagliflozin placebo for 3 months
89229585|NCT00782405|Active Comparator|2|mirtazapine
89229586|NCT04000646|Other|standard care|Standard care non-pharmacologic interventions during anesthesia induction
89229587|NCT04000646|Experimental|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
89229588|NCT05250362|Experimental|Treatment|
89229589|NCT00790283|Experimental|Numen|
89229590|NCT00790283|Active Comparator|Vision/MiniVision|
89229591|NCT00996554|Experimental|Double-Layer-Suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
89229592|NCT00996554|Active Comparator|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread).
89229593|NCT00782561|Experimental|FG-3019|FG-3019 5 mg/kg
89229594|NCT02996396||1|Patients diagnosed with AAA who are considered candidates for Endovascular Repair and meet the study eligibility criteria and sign the Informed consent may be subsequently enrolled in the study.
89229595|NCT00785135|Active Comparator|Standard (Treatment)|
89229596|NCT00785135|Sham Comparator|Placebo (control)|
89229597|NCT00993902|Sham Comparator|Single IUI|Single IUI will be carried on after 36-38 hours of HCG administration
89229598|NCT00993902|Active Comparator|Double IUI|
89229599|NCT02555735||Solid Tumor Cancer|Participants with solid tumor cancer treated with physician-choice standard of care chemotherapy.
89229600|NCT05343260|Active Comparator|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
89229601|NCT05343260|Experimental|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol, and rocuronium.~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
89229602|NCT01564472||PSG Scoring|Retrospective, de-identified PSG studies will be collected and scored by registered polysomnogrpahy technicians. The manually scored studies will be compared to the automatic scoring performed by the new Sleepware Software G3 Autoscoring Algorithm.
89229603|NCT04001660|Experimental|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
89229604|NCT00664859|Experimental|Single|Open-label LCP-AtorFen
89229605|NCT00996788|Experimental|Rebamipide|Rebamipide 100 mg tid for 28 days
89229606|NCT00785369|Other|1|Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo
89229607|NCT01564550||type 2 diabetes|
89229608|NCT01564550||healthy subjects|
89229609|NCT00790361||Control|"Controls (healthy volunteers) will have two scans (fMRI, MRS and DTI) six months apart to determine reproducibility.~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
89229610|NCT00790361||CCS Participants|"CCS participants will have three scans (fMRI, MRS and DTI), one acutely (up to 48 hours after injury), one subacutely (15 days after injury), and one late (6 months after injury).~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
89229611|NCT00785447|Other|1|Twenty healthy subjects between 18 to 59 years of age meeting ASA I-II criteria, undergoing elective surgery, requiring general anesthesia and being able to breathe through both their nose and mouth.
89229612|NCT00790439|Experimental|LMW-SD|18 participants randomized to immunosuppression with Low Molecular Weight Sulfated Dextran (LMW-SD)
89229613|NCT00790439|Active Comparator|Control Group, Standard of Care|18 participants randomized to immunosuppression without Low Molecular Weight Sulfated Dextran (LMW-SD)
89229614|NCT00570401|Experimental|Dasatinib|"Beginning 1 week after completion of erlotinib hydrochloride or gefitinib therapy, patients receive oral dasatinib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.~Response is assessed by CT scan at 4 weeks, 8 weeks, and then every 8 weeks thereafter."
89229615|NCT00785681|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
89229616|NCT00785837|No Intervention|Before Hidrotherapy|
89229617|NCT00785837|Experimental|Hidrotherapy|
89229618|NCT00785915|Experimental|1|
89229619|NCT00785915|Placebo Comparator|2|given (2 subjects in each ethnic/dose group)
89229620|NCT00785993|Active Comparator|Control Group|Fresh donor oocytes
89229621|NCT00785993|Experimental|Group I|vitrified donor oocytes
89229622|NCT00532298|Experimental|GSK576389A- 2006/2007 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.
89229623|NCT00532298|Experimental|GSK576389A - 2006/2007 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.
89229624|NCT00532298|Active Comparator|Fluarix 2006/2007 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
89229625|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.
89229626|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.
89229627|NCT00532298|Active Comparator|Fluarix 2007/2008 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
89229628|NCT00786071||Rett syndrome girls|The study population consists of a well-defined group of Dutch RTT thirteen girls with complete clinical, molecular and neurophysiological work-up.
89229629|NCT04047017|Experimental|Test group|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd
89229630|NCT00997022|Experimental|Sorafenib|Daily sorafenib taken orally
89229631|NCT00786149|Experimental|1|Participants will receive NRT and Motivational Interviewing counseling
89229632|NCT00786149|Active Comparator|2|Varenicline plus brief advice
89229633|NCT00997100|Other|ABR-215757|
89229634|NCT02555501|Experimental|PDT + Low level laser|"PDT (photosensitizer and low level laser) and low level laser~Photosensitizer: aqueous solution of 0.005% methylene blue; Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)"
89229635|NCT02555501|Active Comparator|Low level laser|Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)
89229636|NCT04001738|Active Comparator|Direct Transfer to Angio Suite|After a fast neurological evaluation, patient will be direct transferred to angiography suite where endovascular treatment (EVT) team will be waiting for it. It will be done a cone beam-CT and if the image don't contraindicate endovascular treatment it will be performed and the large vessel occlusion will be confirmed by arteriography. If intravenous treatment have not been previously administered, it will be able to start in parallel.
89229637|NCT04001738|No Intervention|Direct Transfer to CT Scan|After a fast neurological evaluation, patient will be transferred to CT suite where usual image protocol will be performed (CT and CT-angio). Within 6 hours from onset CT perfusion could be required to take detections. Once interpreted image results, it will be decided intravenous and/or endovascular treatment.
89229638|NCT00993980|Experimental|1|qigong
89229639|NCT00993980|Active Comparator|2|exercise therapy
89229640|NCT00786227||Legacy HAQ-DI first, PROMIS 20-item short form first|To eliminate effects due to order of administration, patients with RA will be randomized to complete either the Legacy measure HAQ-DI first in the assessment battery or the PROMIS 20-item short forms first.
89110848|NCT04045028|Experimental|Arm A: Tiragolumab R/R MM|Participants with relapsed or refractory (R/R) Multiple Myeloma (MM) will receive a single dose of 600 mg tiragolumab by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W).
89110849|NCT04045028|Experimental|Arm B: Tiragolumab R/R NHL|Participants with relapsed or refractory (R/R) non-Hodgkin Lymphoma (NHL) will receive a single dose of 600 mg tiragolumab by IV infusion Q3W.
89110850|NCT04045028|Experimental|Arm C: Tiragolumab + Daratumumab R/R MM|Participants with R/R MM will receive 600 mg tiragolumab Q3W + daratumumab by subcutaneous (SC) injection.
89110851|NCT04045028|Experimental|Arm D: Tiragolumab + Rituximab R/R NHL|Participants with R/R NHL will receive 600 mg tiragolumab Q3W + rituximab by IV infusion and SC injection (optional).
89110852|NCT04045028|Experimental|Arm E: Tiragolumab + Atezolizumab + Daratumumab R/R MM|Participants with R/R MM will receive 600 mg tiragolumab Q3W + atezolizumab by IV infusion Q3W + daratumumab by SC injection.
89110853|NCT04010747|Experimental|Motivational Interviewing for Loved Ones (MILO)|"MILO consists of four sessions of coaching in communication skills called motivational interviewing. Participants meet with a trainer/therapist for each session. At the first session, participants learn about the ideas behind motivational interviewing. In the second session, participants practice motivational interviewing skills. In the third and fourth sessions, the participant and therapist discuss the participant's efforts to communicate with their loved one using MI skills. Participants will also be offered direct assistance with a referral to mental health treatment for their loved one."
89110854|NCT04010747|Active Comparator|Mental Health Services Consultation and Waitlist|This consultation will consist of a 30 minute appointment in which participants can speak with a clinician knowledgeable about psychosis treatment resources. He/she can recommend specific programs, educational websites, and/or support groups that might be relevant for the participant's family. Participants will then be placed on a 6-week waitlist, after which they will have the opportunity to participate in the active intervention (four sessions of MILO).
89110855|NCT04007900|Experimental|Positive Affect Treatment|Individuals randomized to the intervention will participate in 20 therapy visits. Before each therapy visit, the participant will meet briefly with a member of the research staff, who will measure weight (blind to the participant) and administer the CHEDS, PANAS, and a pre-session feedback form that will assess how helpful the skills learned in the prior session had been over the past week. After the session, the participant will complete the post-session feedback form, which will assess how helpful the skills he or she perceived the skills from this session to be. These procedures will take approximately 10 minutes. Each intervention session will take approximately 50 minutes to complete. Therefore, each intervention visit will be approximately 1 hour long. Therapy sessions will take place either in the private office of a study therapist or in a consultation room of the Ambulatory Research Center.
89110856|NCT04007900|No Intervention|Waitlist|For participants randomized to the waitlist control, the opportunity will be offered to participate in the intervention following the second assessment (20 weeks following their Baseline assessment).
89110857|NCT04000256||Spinal Cord Injury|The data during the first visit involves questionnaires, performance and observational measures for baseline evaluation. The 2nd to 8th visit involves feedback survey and interview data collection based on experiences of participants undergoing activity-based training using upper extremity rehabilitation equipment.
89110858|NCT03990623|Experimental|Diagnostic (CT perfusion scans, liver biopsy)|Prior to PVE, patients undergo CT perfusion scan of the liver and liver biopsy over 15 minutes. Patients undergo a second CT perfusion scan immediately after PVE and a third CT perfusion scan 3-6 weeks post PVE.
89110859|NCT03950973|Experimental|CareAvenue|Participants receive access to CareAvenue, an e-health tool, and receive one weekly automated telephone call and 4-5 text messages per week for 52 weeks.
89110860|NCT03950973|Active Comparator|Guest Assistance Program|Participants receive information about the Guest Assistance Program (GAP) and receive 3-4 text messages per week related to diabetes management and resources for 52 weeks.
89110861|NCT03929315||Non-spaced learning|Learning/testing sessions will take place within 30 minutes of one another
89110862|NCT03929315||Spaced learning|Learning/testing sessions will take place 1 week after one another
89110863|NCT03929120|Experimental|Interstitial Lung Disease with Connective Tissue Disorder|Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
89110864|NCT03925454||In-Centre Haemodiafiltration (ICHDF) Group|Participants undergoing ICHDF treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
89110865|NCT03925454||Home HaemoDialysis (HHD) Group|Participants undergoing HHD treatment will be recruited into this group, their treatment will follow the standard care pathway in this observational study.
89110866|NCT03924102|Experimental|patients with acute decompensated systolic and diastolic heart|
89110867|NCT03916328|Active Comparator|DMPA+ and TDF+|HIV-infected women on DMPA, and TDF containing ART.
89110868|NCT03916328|Experimental|DMPA+ and B/F/TAF+|HIV-infected women on DMPA, and B/F/TAF.
89110869|NCT03916328|Experimental|DMPA- and B/F/TAF+|HIV-infected women on non hormonal contraception, and B/F/TAF.
89110870|NCT03916146|Experimental|Behavioral Parent Training|
89110871|NCT03916146|No Intervention|Control|
89110872|NCT03901638|Experimental|Tllsh2910 to placebo|Tllsh2910 160mg per day for 12 weeks with wash-out period 12 weeks and subsequent placebos for 12 weeks.
89110873|NCT03901638|Experimental|Placebo to Tllsh2910|Placebos for 12 weeks with wash-out period 12 weeks and subsequent Tllsh2910 160mg per day for 12 weeks
89229641|NCT02725814|Experimental|Sucrose|
89229642|NCT00782873||obese subjects|BMI > 35
89229643|NCT00410410|Experimental|Abatacept (ABA)|"Induction Period; 3 arms for Cohort 1: ABA 30/~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at ~10 mg/kg), ABA ~10 mg/kg, ABA 3 mg/kg~Induction Period; 2 arms for Cohort 2: ABA 30/~10 mg/kg and Second Cohort ABA ~10 mg/kg~1 arm for maintenance period (ABA ~10 mg/kg)"
89229644|NCT00410410|Placebo Comparator|Placebo|"1 arm for induction period~1 arm for maintenance period"
89229645|NCT00410410|Other|abatacept|1 arm for open-label extension phase (ABA ~10 mg/kg)
89229646|NCT00997178|Experimental|Non-surgical periodontal therapy|Non-surgical periodontal therapy consisted of scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
89229647|NCT00997178|Other|Delayed non-surgical periodontal therapy|No periodontal treatment for 6 months
89229648|NCT00782951|Experimental|Org 28611|
89229649|NCT00782951|Active Comparator|morphine sulfate|
89229650|NCT00782951|Placebo Comparator|Placebo|
88821139|NCT05054257|Experimental|Autologous CAR19 T lymphocytes|Human Autologous T Lymphocytes Expressing the Chimeric Antigen Receptor Specific to CD19
89229651|NCT00997256|Experimental|Verum|Neurapas balance, film-coated tablets
89229652|NCT00997256|Placebo Comparator|Placebo|Film-coated sugar-pill
89229653|NCT02555813||Abraxane + Gemcitabine|Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression
89229654|NCT00994058|Experimental|Intevention with Inhibitor|
89229655|NCT00997412|Experimental|MA|MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
89229656|NCT00997412|Active Comparator|AZA|AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
89229657|NCT00783029||Healthy Subjects|Healthy participants between the ages of 21 and 65 years old.
89229658|NCT04047407||Fibromyalgia|
89229659|NCT04047407||Healthy volunteers|
89229660|NCT00997490|Experimental|Verum|Neurapas balance, film-coated tablet
89229661|NCT00997490|Placebo Comparator|Placebo|
89229662|NCT00783107|Experimental|Cyclosporine|
89229663|NCT00783107|Placebo Comparator|Placebo|Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.
89229664|NCT00997568||TEE Procedure|Patients who have been scheduled for a TEE procedure by their physician
89229665|NCT00783185|Experimental|ACT|Anti-Cannabis-Consumption-Training
88821140|NCT05053334|Experimental|BP11 (Proposed biosimilar)|Subcutaneous injection of Omalizumab developed by CuraTeQ.
88821141|NCT05053334|Active Comparator|US-Xolair|Subcutaneous injection of Omalizumab licensed for use in USA
89110874|NCT03896438|Experimental|right active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA right (AF4 anode - AF3 cathode) for 20 min, and then ramp-down for 30 seconds.
89110875|NCT03896438|Experimental|left active-tDCS|2-3 times/week for 12 weeks: ramp-up for 30 seconds, 2mA left (AF3 anode - AF4 cathode) for 20 min, and then ramp-down for 30 seconds.
89110876|NCT03896438|Sham Comparator|sham tDCS|Current will be turned off immediately after the initial 30-second ramp-up period.
89110877|NCT03870217||Cochlear implant users with Nucleus and AB devices|Speech recognition will be evaluated after poor electrodes are turned off.
89110878|NCT03867500|Experimental|Niacin|Intravenous niacin infusion
89110879|NCT03867500|Placebo Comparator|Saline|Intravenous saline infusion
89229666|NCT00783185|Active Comparator|CG|Control group
89229667|NCT00997646||Patients in hospitalist-run ward|Patients was admitted from ER to a hospitalist-run ward.
89229668|NCT00997646||Patients in conventional ward|Patients was admitted from ER to a non hospitalist-run ward.
89229669|NCT00783341|Experimental|GAP-134|
89110880|NCT03867136|Experimental|PZA sensitivity guided ultra-short all Oral Regimen|The PZA sensitivity guided ultra-short regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of levofloxacin, linezolid, cycloserine, pyrazinamide, and clofazimine. Then based on molecular PZA drug sensitivity results, patients will be in divided into two sub-groups: pyrazinamide-susceptible (PZA-S) patients and pyrazinamide-resistant (PZA-R) patients. The Regimen for PZA-S patients, consisting of levofloxacin, linezolid, cycloserine, and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week). PZA-R sub-group regimen, consisting of levofloxacin, linezolid, cycloserine, and clofazimine given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week)
89229670|NCT00783341|Placebo Comparator|placebo|
88821142|NCT05053334|Active Comparator|EU-Xolair|Subcutaneous injection of Omalizumab approved for use in Europe.
89110881|NCT03867136|Active Comparator|Standardized Shorter Regimen|WHO standardized shorter regimen group consists of 36-44 weeks with two phases of treatment. The first is an intensive phase of 16 weeks (extended up a maximum of 20 or 24 weeks in case of lack of smear conversion at the end of 16 or 20 weeks), and included moxifloxacin, amikacin, prothionamide, pyrazinamide, high-dose isoniazid, ethambutol and clofazimine. This is followed by a continuation phase of 20 weeks with the following agents: moxifloxacin, pyrazinamide, ethambutol and clofazimine.
89110882|NCT03867058||Cochlear implant users with Nucleus and AB devices|"Temporal processing acuity will be compared using electrodes or electrode configurations that create broad versus sharp spatial excitation.~Speech recognition will be compared in the same group of subjects using electrode-dependent focused versus monopolar stimulation."
89110883|NCT03867032|Experimental|Cochlear implant users|The group will receive auditory training (psychophysical), and will be evaluated for speech recognition to determine the effect of training.
89110884|NCT03866850||Cochlear implant users with late-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration).~Examine neural spatial excitation patterns with long and short phase duration. Measure speech recognition using long and short phase duration stimulation patterns."
89110885|NCT03866850||Cochlear implant users with early-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration) and compare that with the late-onset group.~Examine neural spatial excitation patterns with long and short phase duration within the non-leaky phase duration range.~Measure speech recognition using long and short phase duration stimulation patterns."
89110886|NCT03862014|Experimental|SDF only|SDF will be applied on molars with MIH
89110887|NCT03862014|Active Comparator|SDF+ARR|SDF+ARR will be applied on molars with MIH
89110888|NCT03857048|Active Comparator|Control|Persons with obesity who do not undergo weight loss will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
89110889|NCT03857048|Experimental|Reduced obese + diet + exercise|Persons with obesity randomized to a weight loss program consisting of caloric restriction, behavioral support, and supervised endurance exercise training. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
89110890|NCT03857048|Active Comparator|Reduced obese + diet group|Persons with obesity randomized to a weight loss program consisting of caloric restriction and behavioral support. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
89110891|NCT03840434|Other|CCS group|Measurements by intramuscular punction and non invasive tool
89110892|NCT03824496||Suspected acute stroke|"Any patient with suspected acute stroke triggering a stroke code and had a brain imaging angiogram"
89229671|NCT00534404|Experimental|NRT Patch, Phone Counseling, Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches, contingent upon participation in proactive telephone counseling. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
89229672|NCT00534404|Active Comparator|Nicotine Patches and Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
89229673|NCT00534404|Placebo Comparator|Internet|Research participants in this arm will have free access to internet-assisted tobacco treatment (iQuit Smoking website).
89229674|NCT00783497||1|Caucasian Americans
89229675|NCT00783497||2|African Americans
89229676|NCT00783575||Inflammatory Bowel Disease|Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD) are chronic, life-long, destructive inflammatory conditions of the gastrointestinal tract.
89229677|NCT00393094|Experimental|Bevacizumab & Irinotecan Patients|Bevacizumab - 10 mg/kg intravenous injection Irinotecan - 125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
89229678|NCT04047485||Elderly Female (A)|Female subjects between 65 and 85 years old
89229679|NCT04047485||Great Elderly Female (B)|Female subjects with more than 85 years old
89229680|NCT04047485||Elderly Male (C)|Male subjects between 65 and 81 years old
89229681|NCT04047485||Great Elderly Male (D)|Men subjects with more than 81 years old
89229682|NCT01043848|Experimental|Early pudendal stimulation|Subjects in this arm will start with the intervention within 2 weeks after SCI
89229683|NCT01043848|Experimental|Late pudendal stimulation|Subjects in this arm will start with the intervention 12 weeks after SCI
89229684|NCT01043848|No Intervention|Control|Subjects in this arm will be treated according to standard therapy but will receive no pudendal stimulation
89229685|NCT00786305|Experimental|1: nebulized ceftazidime and amikacin|
89229686|NCT00786305|Active Comparator|2: intravenous ceftazidime and amikacin|
89229687|NCT00790517|Experimental|1|Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
89229688|NCT00790517|No Intervention|2|Usual care
89229689|NCT01044004|Experimental|Post treatment remission armodafinil|Armodafinil 150 mg/day for 13 weeks
89229690|NCT01044004|Placebo Comparator|Post treatment remission placebo|Placebo 150mg/day for 13 weeks
89229691|NCT01044004|Experimental|Chemotherapy armodafinil|Armodafinil 150 mg/day for 13 weeks
89229692|NCT01044004|Placebo Comparator|Chemotherapy placebo|Placebo 150mg/day for 13 weeks
89229693|NCT00786383|Experimental|IMC-1121B|IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.
89229694|NCT01042444|Experimental|Embolic Protection Device|The study will involve up to 20 patients to be enrolled using the GARDEX system during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 3 investigative sites. The study is a prospective multi center registry with sequential enrollment of qualified patients who consent to participate and meet the eligibility criteria.
89229695|NCT00790595|Experimental|Group A|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
88821143|NCT05045443|Active Comparator|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea
88821144|NCT05045443|Placebo Comparator|Standard of nutritional care|Standard of nutritional support care
89229696|NCT00790595|Experimental|Group B|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
89229697|NCT00790595|Experimental|Group C|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
89229698|NCT00790595|Experimental|Group D|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
89229699|NCT00790595|Experimental|Group E|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
89229700|NCT00783731|Experimental|Low dose midazolam|
89229701|NCT00409708|Active Comparator|1|
89229702|NCT00409708|Other|2|
89229703|NCT00790985|Experimental|flavocoxid 500 mg|flavonoid mixture
88821145|NCT05042908|Experimental|A phase I clinical study evaluating LBL-003 in the treatment of subjects with advanced solid tumors|Drug: LBL-003Injection The test drugLBL-003will be preset with 6 escalation dose levels: dose A, dose B, dose C, dose D and dose E, dose F , administered twice a week.
89229704|NCT00790985|Active Comparator|naproxen|nonsteroidal anti-inflammatory drug
89229705|NCT01044082|Experimental|controlled cord traction|Controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs.
89229706|NCT01044082|Active Comparator|clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
89229707|NCT01324336||4-17 years, receiving 6-MP|
89229708|NCT00783887||1|Patients with suspected or confirmed primary ciliary dyskinesia after ciliary investigations who accepted to participate to the genetic studies
89229709|NCT01039870|Experimental|PVB|Paravertebral block initiated at the later part of thoracotomy is used for postoperative pain control
89229710|NCT01039870|Active Comparator|TEA|Thoracic epidural block initiated before the surgical incision is used for postoperative pain control.
89110893|NCT03743402|Experimental|Pain self-management|"This intervention will have 4 components:~telephone-delivered evidence-based pain self-management training,~web-based video of successfully tapered patients with motivational interviewing debriefing,~a voluntary, self-paced opioid taper~opioid and non-opioid prescribing guidance for the patient's primary care provider."
89110894|NCT03743402|Active Comparator|usual care|Patients randomized to usual care will continue to receive care as usual from their Kaiser primary care provider.
89110895|NCT03734861|Experimental|BreatheSmart System|"BreatheSmart mobile application that tracks medication usage and sends real time reminders~HeroTracker sensor that counts dosage and monitors real-time medication adherence~CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)"
89229711|NCT00784121|Experimental|1|Lactic Acid (Dermacyd Breeze)
89229712|NCT04047173|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
89229713|NCT04047173|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
89229714|NCT01324492|Experimental|RAD001|
89229715|NCT01042834||Air pollution|The subjects will have to live in districts where important atmospheric pollution is established
89229716|NCT01039948|Experimental|Phase 2: AV-299 + gefitinib|Phase 2: AV-299 (formerly SCH 900105) administered IV at RP2D (as determined by Phase 1b portion) in combination with gefitinib 250 mg/day orally.
89229717|NCT01039948|Active Comparator|Phase 2: Gefitinib|Phase 2: Gefitinib 250 mg/day, orally.
89229718|NCT00391846|Other|Guided by NT-proBNP|Treatment guided by clinical symptoms and signs + NTproBNP
89229719|NCT00391846|Other|Not Guided by NT-proBNP|Treatment guided by clinical symptoms and signs
89229720|NCT00448630||Atypical Antispychotics (or second generation antipsychotics)|Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.
89229721|NCT01042990|Active Comparator|Home Exercise Only|Participants receive education and instruction on a home exercise program which they do on their own, with intermittent encouragement from study personnel.
89229722|NCT01042990|Experimental|APA|Participants exercise in a gym setting 3x/week for six months, performing gait and balance exercises along with a progressive walking program.
89229723|NCT01042990|Experimental|APA+TM|Participants exercise in a gym setting 3x/week for six months, performing a combined program of adaptive physical activity (gait and balance training) and progressive treadmill walking.
89110896|NCT03734861|Active Comparator|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
89110897|NCT03727438|Experimental|Tele-Self CBTI|The tele-self intervention is comprised of two treatment components: 1) self-management via a workbook with weekly readings, and 2) weekly telephone-based nurse support over 6 weeks
89110898|NCT03727438|Active Comparator|Health Education Control|6 weekly phone calls from a study nurse on a range of health topics (non-sleep), similar call duration to intervention phone calls. At the end of the study, participants will be offered assistance through the Durham Behavioral Sleep Medicine clinic.
89110899|NCT03714334|Experimental|DNX-2440 injection|all the patients included will be treated with the experimental agent
89110900|NCT03712527|Experimental|Platelet-Rich Plasma|
89110901|NCT03712527|Placebo Comparator|Placebo|
89110902|NCT03703765|Experimental|Lower limb volume estimation|"Patients referred for a preoperative venous assessment as part of an indication for interventional management, whether by conventional or endovascular surgery, of a chronic venous pathology.~Intervention is measurement of lower limb volume with scanner 3D system before and after surgery or vascular intervention."
89110903|NCT03646487|Experimental|Probiotic LP299v|Women will receive 1 LP299v (10x10 colony forming units) in capsule form and 1 standard prenatal supplement in tablet form daily beginning at 15 weeks gestation through delivery.
89110904|NCT03646487|Placebo Comparator|Placebo|Women will receive 1 placebo in capsule form and 1 standard prenatal supplement in table form daily beginning at 15 weeks gestation through delivery.
89110905|NCT03634397|Experimental|Less-Impaired Arm Training|Intervention condition includes therapy of the less-impaired (ipsilesional) arm.
89110906|NCT03634397|Sham Comparator|Contralesional Arm Comparison|Comparison control condition includes therapy of the paretic (contralesional) arm.
89110907|NCT03606421||Arm A|Patients in Arm A will be treated with stereotactic radiosurgery (SRS) which is a modern method of treating brain lesions that delivers a high amount of radiation to a small volume of the brain affected by a tumour; and is the standard of care for patients with a limited number of brain metastases.
89110908|NCT03606421||Arm B.|Patients in Arm B will be treated with whole brain radiotherapy, due to the number of lesions in their brain.
89110909|NCT03582189||Pancreatic Cancer|Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
89110910|NCT03582189||Liver Metastases|Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
89110911|NCT03582189||Hepatocellular carcinoma|Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
89110912|NCT03562416|Experimental|Nintedanib|Nintedanib 150 mg tablet by mouth twice daily for 24 months.
89110913|NCT03562416|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 24 months
89110914|NCT03518736|No Intervention|Usual Care|Infants randomly assigned to this arm will not receive any study intervention but will continue with any intervention in the community recommended by their health care team.
89110915|NCT03518736|Experimental|SPEEDI_Early|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting in the hospital and lasting for 4 months. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.~In addition they will continue with any intervention in the community recommended by their health care team."
89110916|NCT03518736|Experimental|SPEEDI_Late|"Infants randomly assigned to this arm will participate in the SPEEDI intervention starting at 4 months post baseline or approximately 3 months after discharge from the hospital. This intervention includes 10 visits with a physical therapist and parent working together to advance an intervention program and 12 weeks of parent daily intervention.~In addition they will continue with any intervention in the community recommended by their health care team."
89110917|NCT03512262|Experimental|Abaloparatide|Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.
89110918|NCT03512262|Placebo Comparator|Placebo|Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen that delivers 30 doses. Participants received a new injection pen every 30 days.
89110919|NCT03499600|Experimental|Clinical Assessment and CFI|CA and CFI families will receive the Cultural Formulation Interview prior to their standard Clinical Assessment during their intake.
89110920|NCT03499600|Active Comparator|Clinical Assessment Only|CA families will receive a standard Clinical Assessment during intake.
89229724|NCT00534248|Experimental|Zostavax™|Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
89229725|NCT00534248|Placebo Comparator|Placebo|Participants randomized to receive Placebo.
89229726|NCT00994136|Experimental|Normal saline|In the intervention group the use of heparin as locking solution in the catheter lumen (or lumina) when the catheter is not longer in use is omitted. Catheters are locked under positive pressure with normal saline in stead injecting an extra volume of heparinised saline (100IU/ml).
89229727|NCT00994136|No Intervention|Heparin lock|
89229728|NCT00997724|Experimental|a-VATS|Patients with NSCLC underwent assisted-VATS sleeve lobectomy with bronchoplasty.
89229729|NCT00997802|Other|CT colonography and optical colonoscopy|
89229730|NCT00391768|Experimental|oseltamivir (Tamiflu®)|
89229731|NCT00391222|Experimental|001|Risperidone Long Acting Injectable (LAI) Intramuscular injections of risperidone LAI (25 37.5 or 50 mg) every 2 weeks and oral placebo daily
89229732|NCT00391222|Placebo Comparator|002|Placebo Intramuscular injections of placebo every 2 weeks and oral placebo daily
88821146|NCT05036408|Experimental|Supportive care (cancer pain rehabilitation program)|Patients participate in the cancer pain rehabilitation program for 6 weeks, including educational sessions over 2 hours once weekly, group psychological interventions, group physical therapy, and 1:1 physical and occupational therapy treatment per the patient's treatment plan. Patients may also undergo osteopathic manual treatments per physical and occupational therapy assessments.
89229733|NCT00391222|Active Comparator|003|Olanzapine Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
89229734|NCT01043068|Experimental|Pain control|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
89110921|NCT03481777|Active Comparator|Remote Ischemic Conditioning|"Remote ischemic conditioning (RIC) is applied in the hyperacute prehospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg; but if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~Initial remote ischemic conditioning: prehospital phase, all included patients~Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy"
89110922|NCT03481777|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham remote ischemic conditioning (Sham-RIC) is applied in the hyperacute prehospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be always be 20 mmHg.~Initial Sham remote ischemic conditioning: prehospital phase, all included patients~Sham Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~Sham Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy."
89110923|NCT04353648||Duke ICU/Trauma Center Patients|Any patient admitted to the Duke Trauma Center or Duke ICU will be approached to participate in this study.
89110924|NCT03396211|Experimental|Apatinib with Nivolumab|Participants will receive an oral dose of apatinib once per day with a fixed dose of nivolumab given intravenously every 2 weeks.
89110925|NCT03326167||Patients with or suspected coronary heart disease|
89110926|NCT03301896|Experimental|LHC165 single agent|LHC165 intratumoral injection given alone
89110927|NCT03301896|Experimental|LHC165 in combination with PDR001|LHC165 intratumoral injection given with PDR001 infusion
89110928|NCT03269084||Children at HLA-conferred risk for T1D|
89110929|NCT03268993|Other|Avmacol|You will be given a higher dose of Avmacol® each month, taking 2 Avmacol® tablets per day the first month (Cycle 1), 4 Avmacol® tablets per day the second month (Cycle 2), and 8 Avmacol® tablets per day the third month (Cycle 3). Investigators will study how Avmacol® affects your body by collecting three different tissues: 1) your cheek cells (buccal cells); 2) your urine; and 3) your blood. After you have finished three months of Avmacol®, you will return one month later for an end-of-study visit.
89110930|NCT03260322|Experimental|ASP8374 0.5 mg - Monotherapy Dose Escalation|Participants received ASP8374 0.5 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89110931|NCT03260322|Experimental|ASP8374 2 mg - Monotherapy Dose Escalation|Participants received ASP8374 2 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89110932|NCT03260322|Experimental|ASP8374 7 mg - Monotherapy Dose Escalation|Participants received ASP8374 7 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89110933|NCT03260322|Experimental|ASP8374 20 mg - Monotherapy Dose Escalation|Participants received ASP8374 20 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89110934|NCT03260322|Experimental|ASP8374 70 mg - Monotherapy Dose Escalation|Participants received ASP8374 70 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89110935|NCT03260322|Experimental|ASP8374 200 mg - Monotherapy Dose Escalation|Participants received ASP8374 200 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89110936|NCT03260322|Experimental|ASP8374 700 mg - Monotherapy Dose Escalation|Participants received ASP8374 700 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89110937|NCT03260322|Experimental|ASP8374 1400 mg - Monotherapy Dose Escalation|Participants received ASP8374 1400 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89110938|NCT03260322|Experimental|ASP8374 1400 mg - Monotherapy Dose Expansion|Participant received ASP8374 1400 mg intravenously, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met during treatment period. Qualifying participants entered re-treatment period and received treatment for an additional 16 cycles or until a discontinuation criteria was met.
89229735|NCT00409006|Experimental|Pemetrexed/Cisplatin/Gefitinib|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
89229736|NCT00409006|Experimental|Pemetrexed/Cisplatin|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.
89229737|NCT00997880|Experimental|Rosuvastatin calcium 40mg|high-dose (40mg rosuvastatin)
89229738|NCT00997880|Active Comparator|Rosuvastatin calcium10mg|low-dose statin (10mg rosuvastatin)
89110939|NCT03260322|Experimental|ASP8374 20 mg - Combination Dose Escalation|Participants received ASP8374 20 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
89110940|NCT03260322|Experimental|ASP8374 70 mg - Combination Dose Escalation|Participants received ASP8374 70 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
89229739|NCT00408928|Experimental|Bortezomib for Treatment of GHVD|To determine if bortezomib (VELCADE®) will successfully inhibit T-cell responses in clinically acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
89229740|NCT00997958|Experimental|CellCept|Administered in tablet form twice daily one hour after eating.
89110941|NCT03260322|Experimental|ASP8374 200 mg - Combination Dose Escalation|Participants received ASP8374 200 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
89229741|NCT00998036|Experimental|Temsirolimus, cisplatin, erlotinib|Cisplatin and temsirolimus will be administered weekly on days one and eight of a three week cycle. Erlotinib will be taken by mouth daily.
89229742|NCT05309876|Experimental|Usage of tool|Participants get access to the tool and use it regularly
89229743|NCT05309876|No Intervention|Controls on usual care|Participants who get randomized to control cannot access the tool. Development of cardiovascular disease is followed via clinical registries.
89523241|NCT03390049|Active Comparator|Fractional CO2 Laser Treatment|Fractional CO2 laser will be applied to the entire vestibule, anteriorly to the fourchette, and laterally to the labia majora. This takes approximately 5 minutes to complete. A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. EMLA cream will be applied to the introitus for 20 minutes and wiped clean and dried prior to each laser session. Subjects will be advised to avoid intercourse for at least 3 days after each laser session because a mild inflammatory reaction may last up to 48 hours after a laser session. Topical lidocaine 5% ointment may be used for any vulvar discomfort post-procedure.
89523242|NCT03390049|Sham Comparator|Sham Laser Treatment|A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. Subjects assigned to sham laser will undergo the same pre-treatment with EMLA cream and will receive the same post-treatment instructions as the fractional CO2 laser subjects.
89229744|NCT05254808|Active Comparator|Fosfomycin in a single dose of 3000mg on day 1|Fosfomycin-trometamol Single dose scheme: 3000mg taken orally once (arm A)
89229745|NCT05254808|Experimental|Extended dosing of 3000mg fosfomycin on day 1 and 3|Fosfomycin-trometamol Extended dosing scheme: 3000mg taken orally on day 1 and day 3 (arm B)
89523243|NCT03379493|Experimental|ET190L1 ARTEMIS™ T cells|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
89523244|NCT03384095|Experimental|Hyaluronic Acid|Subjects in this arm will be given 100 mg of hyaluronic acid in capsule form. Subject in this arm will be asked to 1 capsule take twice daily for 26 weeks.
89523245|NCT03384095|Placebo Comparator|Placebo|Subjects in this arm will be given a placebo comparator capsule that is identical to the hyaluronic capsule containing microcrystalline cellulose as the sole ingredient. Subjects in this arm will be asked to take 1 capsule twice daily for 26 weeks.
89229746|NCT05254808|Active Comparator|Nitrofurantoin 100mg bid (slow release) for 5 days|Nitrofurantoin 100mg b.i.d. in slow release form (Furabid) taken orally for 5 days (arm C)
89523246|NCT03379415|Experimental|Meniscus Injured|These meniscus patients will be recruited to participate in a single session to wear 4 different pairs of shoes
89110942|NCT03260322|Experimental|ASP8374 700 mg - Combination Dose Escalation|Participants received ASP8374 700 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
89110943|NCT03260322|Experimental|ASP8374 1400 mg - Combination Dose Escalation|Participants received ASP8374 1400 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
89110944|NCT03260322|Experimental|ASP8374 200 mg - Combination Dose Expansion|Participants received ASP8374 200 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
89110945|NCT03260322|Experimental|ASP8374 700 mg - Combination Dose Expansion|Participants received ASP8374 700 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
89110946|NCT03260322|Experimental|ASP8374 1400 mg - Combination Dose Expansion|Participants received ASP8374 1400 mg intravenously in combination with pembrolizumab 200 mg adminstered as a 30 minutes intravenous infusion, on day 1 of every 3 week cycle for a period of up to 16 cycles or until a discontinuation criterion was met. Qualifying participants received combination treatment for an additional 16 cycles or until a discontinuation criteria was met. Participants who completed 16 cycles of combination treatment who entered the follow-up period with PR or SD were allowed to continue on pembrolizumab alone for a period of up to an additional 19 cycles. If the participant was eligible for the re-treatment period during follow up, administration of pembrolizumab alone was discontinued and combination therapy with ASP8374 was resumed per the protocol.
89110947|NCT03233256|Experimental|Healthy adults (18-45 yrs.)|Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
89110948|NCT03229551|Experimental|Xylitol|This arm will evaluate the effect of topical xylitol therapy on biofilm production with the use of PCR bacterial sequencing before and after medical intervention.
89110949|NCT03229551|Active Comparator|Control|This arm is the standard of care saline irrigation solution.
89110950|NCT03222245||Exposed group|This group consists of participants identified as needing to start injectable therapy within 1 month from the recruitment date (50% insulin and 50% GLP-1 analogues)
89110951|NCT03222245||Non-exposed group|This group consists of participants treated with oral anti- hyperglycaemic agents (OAHAs) and their combinations
89110952|NCT03197077|Experimental|Elonva|A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
89110953|NCT03197077|Active Comparator|Puregon|Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
89110954|NCT03165487||Luminal A Breast Cancer|Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
89110955|NCT03165487||Triple Negative Breast Cancer|Triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
89110956|NCT03158922||Stage 1|Caucasian men aged 55-69 to undergo genetic profiling.
89110957|NCT03158922||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer.
89110958|NCT03136562||Kidney transplanted patients|Kidney transplanted patients in prednisolone treatment. Adrenal function is assessed by a synacthen test.
89110959|NCT03136562||Control group|Patients in dialysis not in prednisolone treatment. Adrenal function is assessed by a synacthen test.
89110960|NCT03112369|Experimental|Narrative Exposure Therapy (NET)|Counseling program
89110961|NCT03112369|Experimental|Motivational Interviewing w/Skills Training (MIST)|Counseling program
89110962|NCT03078855|Experimental|Vitamin D plus rituximab|
89110963|NCT03078855|Placebo Comparator|Placebo plus rituximab|
89110964|NCT03066349||Patients with PCOS undergoing conventional ovarian stimulation|
89110965|NCT03066349||Patients with PCOS undergoing IVM|
89110966|NCT03055923||Asthma Patients|30 people who suffer from a confirmed diagnosis of asthma
89110967|NCT03055923||Chronic Obstructive Pulmonary Disease Patients|30 people who suffer from a confirmed diagnosis of COPD
89110968|NCT03055923||Healthy Controls|30 healthy volunteers who have no known diagnosis of Lung disease
89523247|NCT03379415|Experimental|Footwear|4 Different types of trainers will be used to see the difference in gait in meniscectomy patients
89523248|NCT03660865|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's primary eye will receive the light adjustable lens.
89229747|NCT00994370||liver cancer|Patients referred for SIRT will be considered for this investigation. These patients will predominantly have stage IV colorectal metastases with liver dominant metastases or hepatocellular carcinoma. A team of oncologists, interventional radiologists, radiation oncologists and oncologic surgeons will determine that the patients are not candidates for surgical resection or ablative therapy. The patients will then be screened to confirm the patient's eligibility to receive standard of care SIRT treatment. SIRT treatment and imaging studies included in this investigation are standard of care for the patients' liver dominant disease.
89229748|NCT02275286|Experimental|Trabectedin+Radiotherapy|Trabectedin 1.3 or 1.5mg/m2 and radiotherapy 30Gy or 45Gy.
89229749|NCT04000412||CASE GROUP|patients with chronic infarction undergoing catheter ablation of ventricular arrhythmias
89229750|NCT00998114|Experimental|Exercise and diastolic dysfunction|Aerobic exercise for 30-45 minutes five times a week for six months
89229751|NCT00998270|Active Comparator|Autologous arm|
89229752|NCT00998270|Experimental|Allogeneic arm|
89229753|NCT00998348|No Intervention|Comparison Group|The comparison group will receive children's picture books (1 per month for the duration of the 8-month program).
89229754|NCT00998348|Experimental|Parenting Program|The parenting program is an 8-month obesity prevention intervention for parents with preschool-age children.
89229755|NCT00994526|Placebo Comparator|Ham|
89229756|NCT00994526|Experimental|Ham + calcium|
89229757|NCT00994526|Experimental|Ham + vitamin E|
89229758|NCT00998504|Placebo Comparator|placebo|starch pill
89229759|NCT00998504|Active Comparator|resVida|synthetic pill containing 75 mg of resveratrol
89229760|NCT00788684|Experimental|ABT-263 + rituximab|
89229761|NCT00454220|Placebo Comparator|Placebo|
89229762|NCT00454220|Experimental|0.01 mg MRrhTSH + 131-I arm|
89229763|NCT00454220|Experimental|0.03 mg MRrhTSH + 131-I arm|
89229764|NCT00998894||decision-support alerts|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will be generated for clinicians.
88820698|NCT05766267|Experimental|2BMZRb/2 BMRb|"Eight weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), plus rifabutin (Rb), followed by nine weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb)~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily.~Study drug doses: Bedaquiline (B): 200 mg once daily x 56 days, then 100 mg daily; Moxifloxacin (M): 400 mg once daily; Pyrazinamide (Z) 1500 mg (weight <75kg) or 2000mg(> 75kg) once daily x 56 days; Rifabutin (Rb): 300 mg once daily"
89229765|NCT00998894||routine practice|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will not be generated for clinicians.
89229766|NCT00998972|No Intervention|control|control arm without any specific intervention
89229767|NCT00998972|Experimental|N-acetylcysteine|administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death
89229768|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group I|Very preterm infants born after a gestation period of 27-30 weeks (189-216 days)
89229769|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group II|Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)
89229770|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group III|Infants born after a gestation period of more than 36 weeks (more than 258 days)
89229771|NCT00998816|Placebo Comparator|Placebo capsules|one placebo capsule will be administered 1 hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12h BID for 10 days following lateral thoracotomy.
89229772|NCT00998816|Active Comparator|pregabalin capsules|Pregabalin capsules (150mg) will be administered one hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12 hours (BID) for 10 days following lateral thoracotomy.
89229773|NCT05219084|Placebo Comparator|placebo group|5ml of normal; saline-injected subcutaneously
88820740|NCT05703672|Placebo Comparator|Placebo and electronic cigarette|At the end of the 6-week open label phase, dual users of cigarettes and e-cigarettes will receive placebo pills to take twice daily for 12 weeks. They will also receive an additional 12 weeks of the nicotine salt-based pod system e-cigarette.
88820741|NCT05703672|Other|Open label electronic cigarette|All participants will receive an initial 6-week supply of the study electronic cigarette.
89229774|NCT05219084|Active Comparator|Hip denervatiopn|Hip denervation with lidocaine 2% to each genicular branch, 2ml at each point
89229775|NCT05219084|Active Comparator|Inra-articular hydration|10 ml of normal saline injected inside the hip under ultrasound guidance
89229776|NCT05219084|Active Comparator|compined group|hip denervation and intra-articular hydration were conducted together in this group
89229777|NCT05133908|Active Comparator|Digital Sleep Hygiene and Self-Monitoring Control|Participants assigned to this condition will receive an app to track sleep and offers sleep hygiene recommendations
89229778|NCT05133908|Experimental|dCBTi-ADHD|Participants assigned to this condition will receive a 7-module digital cognitive behavioral therapy for insomnia (dCBTi) tailored for adults with ADHD
89229779|NCT00999050|Experimental|diabetic pts <35BMI|All patients will be in a single arm receiving bypass surgery to assist with diabetes management
89229780|NCT00533702|Experimental|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab)
89229781|NCT00533702|Active Comparator|IMC-1121B (ramucirumab) + dacarbazine|IMC-1121B (ramucirumab) + dacarbazine
88820742|NCT05699473|Experimental|5-MTHF glucosamine|1 single dose (400µg)
89523249|NCT03660865|Active Comparator|Control IOL|A pre-determined randomization scheme will be utilized to designate each of the patient's eyes as the primary eye (LAL) or the fellow eye (Control). Patient's fellow eye will receive the control IOL.
88820743|NCT05699473|Experimental|5-MTHF calcium salt 1|1 single dose (400µg)
88820744|NCT05699473|Experimental|5-MTHF calcium salt 2|1 single dose (400µg)
88820745|NCT05698875|Other|Test meal 1|High glycaemic load breakfast meal
88820746|NCT05698875|Other|Test meal 2|High glycaemic lead with additional 10g protein breakfast meal
88820747|NCT05698875|Other|Test meal 3|Medium glycaemic load breakfast meal
89110969|NCT03007979|Experimental|Palbociclib + letrozole or + fulvestrant|"Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).~Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.~Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.~Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.~Optional research biopsy at baseline and progression~Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression"
89110970|NCT02960893|Experimental|Troriluzole|"Troriluzole - Randomization Phase: Participants received Troriluzole 140 mg capsules orally once daily (QD) for 8 weeks.~Troriluzole/Troriluzole - Extension Phase: Participants received Troriluzole 140 mg capsules orally QD for 48 weeks."
89110971|NCT02960893|Placebo Comparator|Placebo|"Placebo - Randomization Phase: Participants received matching placebo capsules orally QD for 8 weeks.~Placebo/Troriluzole - Extension Phase: Participants who received placebo during randomization phase, received Troriluzole 140 mg capsules orally QD for 48 weeks."
89110972|NCT02912572|Experimental|Pole Mutated Endometrial Cancer|Participants with Pole mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
89523250|NCT03379337|Experimental|Dental imaging|4 incisors and 4 canine teeth of subjects were imaged with the experimental and the commercial device.
89523251|NCT03384017|Experimental|TSCS and gait training|
89523252|NCT03379181|Experimental|Propranolol 80 mg|Patients receive a single dose of 80 mg propranolol p.o.
89110973|NCT02912572|Experimental|MSS Endometrial Cancer|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
89110974|NCT02912572|Experimental|MSS Avelumab/Talazoparib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Talazoparib will be administered one time per day by mouth
89110975|NCT02912572|Experimental|MSS Avelumab/Axitinib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Axitinib will be administered twice per day by mouth
89110976|NCT02867813|Experimental|evolocumab (AMG 145)|All subjects are randomized to a single arm and will receive evolocumab 140mg every two weeks (Q2W) or 420mg monthly (QM) according to subject's preference.
89110977|NCT02840747||Patients with CTCL|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria).
89110978|NCT02840747||Patients with benign dermatoses|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis.
89110979|NCT02840747||Healthy Controls|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers.
89110980|NCT02829606|Active Comparator|small scotoma using Head Mounted Display No re-mapping|patients with scotoma smaller than 5 degrees NO re-mapping PLUS re-mapping
89110981|NCT02829606|Active Comparator|Large scotoma using Head Mounted Display PLUS re-mapping|patients with scotoma larger than 5 degrees NO re-mapping PLUS re-mapping
89110982|NCT02813083||Rheumatoid Arthritis|Rheumatoid arthritis patients
89230330|NCT03953287|Experimental|Pharmacokinetic Study of Paracetamol.|"Detailed Description:~Twelve healthy young volunteers are recruited, and the experiments begin at 07:45 after an overnight fast. BMI and blod pressure are recorded and a catheter is inserted in an antecubital vein for blood samples.~At 08.00 participants take 500 mg paracetamol as a tablet with 200 ml tap water or a Paracetamol1523 capsule in random order. Subsequently, blood samples are taken every minute for 3 minutes the first hour, then every 10 minutes the following two hours. In addition, blood pressure and puls rate are measured every 20 minute the first hour, and then every 30 minutes.Side effects and time to the participants registrate any effect of the drugs are assessed in a prefabricated scheme.~The disadvantages associated with the experiment are sought monitored by adverse event registration which ends at the end of the trial. The trial day lasts 2 hours in which blood samples are taken as described above, and blood pressure and records are stored ."
89230331|NCT02554565|Other|Tumor biopsies and blood sampling|
89230332|NCT03952819||Diabetic group,|The study was designed with 28 chronic hemodialysis patients (17 men, 11 women) receiving treatment at our hospital. Of the 28 hemodialysis patients, 14 had Type 2 diabetes mellitus. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
89230333|NCT03952819||Non-Diabetic group,|Of the 28 hemodialysis patients, the other 14 were not diabetic. On the day of hemodialysis, blood samples were obtained within 30 minutes of before and after dialysis. Intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
89230334|NCT03952819||Control group,|The study was designed with 56 individuals; 28 healthy volunteers as a control group. Venous blood samples of the control group were obtained at the blood sampling unit by the healthcare personnel during morning hours following overnight fasting while they were sitting after being rested. The intervention is to take blood samples and determine serum sclerostin level in blood samples. Any drugs or substances will not be given.
89230335|NCT02530333|No Intervention|Basketball Control|Control group of basketball players
89230336|NCT02530333|Experimental|Basketball intervention|Intervention group of basketball players
89230337|NCT02530333|No Intervention|Soccer Control|Control group of soccer players
89230338|NCT02530333|Experimental|Soccer Intervention|intervention group of soccer players
89230339|NCT00803231||Retrospective cohort|Patient treated with Xigris between January 2006 and November 2008.
89230340|NCT00803231||Prospective cohort|Patient treated with Xigris between November 2008 and November 2009.
89230341|NCT01097551||Patients with type 1 diabetes|Diabetes duration >= 5 years, age >= 18 and <= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension
89230342|NCT01097551||Healthy subjects|Sex and age-matched control healthy subjects
89230343|NCT00803309|Active Comparator|A|PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up
89230344|NCT00803309|Active Comparator|B|PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up
89230345|NCT03953209|Experimental|spironolactone 50 mg|Oral administration of spironolactone 50 mg once daily for 12 weeks
89230346|NCT03953209|Experimental|spironolactone 100 mg|Oral administration of spironolactone 100 mg once daily for 12 weeks
89230347|NCT03953209|Experimental|spironolactone 200 mg|Oral administration of spironolactone 200 mg once daily for 12 weeks
89230348|NCT00794651||OA|moderate to severe osteoarthritis of the knee
89230349|NCT01583959|Active Comparator|Folic acid 30 mg per week|Patients will be administered 5 mg folic acid for 6 days a week, no tablet on the day they take methotrexate (5 mg x 6 days = 30 mg per week)
89230350|NCT01583959|Active Comparator|Folic acid 10 mg|Patients will be given folic acid 5 mg for two days per week and placebo tablets for four days a week, no tablet on the day they take methotrexate (Folic acid 5mg x 2 days = 10mg per week)
89230351|NCT00803387||Patients taking Xalatan with ocular dryness or irritation|"patient must already be using xalatan for at least 1 month prior to study enrollment in both eyes and have complaints of dry eye and/or irritation.~any race and of either sex, diagnosed with open angle glaucoma (OAG) (with or without pseudoexfoliation or pigment dispersion components) or ocular hypertension (OHT)"
89230352|NCT03952897||Group 1|Subjects treated with balneotherapy for 10 days, previously diagnosed with knee and/or hip osteoarthritis, and subjects previously diagnosed with rheumatoid arthritis.
89230353|NCT02553551|Experimental|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
89230354|NCT02553551|Placebo Comparator|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
89290554|NCT01226862||Hub Hospital|Hub Hospital Cohort: Joint Commission-certified Primary Stroke Centers where patients are treated using hospital-based stroke teams and pathways; these hospital personnel also provide telemedicine consultation to satellite hospitals.
89230355|NCT01584037||Observational|This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. The intent of the Adenovirus Vaccine Pregnancy Registry, Protocol DR-501-401, is to collect observational data on pregnancy outcomes, including birth defects, in women who were exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.
88805807|NCT03011801|Placebo Comparator|Enhanced Usual Care|Maternity support services (MSS) is the usual standard of care for pregnant women. A multi-disciplinary team of obstetric care providers routinely screen women for possible depression diagnosis. If a woman screens positive, she is seen by a behavioral health specialist (BHS) for further assessment and to initiate treatment, if necessary. The goals of MSS include offering services to promote healthy pregnancies and positive birth and parenting outcomes, including integrating mental health and prenatal care. Women with elevated depressive symptoms are seen by BHS throughout the pregnancy and postpartum period and then bridged to mental health treatment. BHS provides eclectic-based care but does not provide IPT.
88805808|NCT03010241|Experimental|Tangbi Prescription|Based on the standard medical care, experimental group were treated with Tangbi Prescription 4.87g granules, 2 times/d, which The prescripton was composed by five Chinese herbal medicines.
88805809|NCT03010241|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 4.87g granules, 2 times/d
88805810|NCT01164137|Experimental|Medication Reconciliation Intervention|Participants receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
88805811|NCT01164137|No Intervention|Medication Reconciliation Non-Interven.|Participants not receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
88805812|NCT01165541|Active Comparator|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine XR 50-400mg
88805813|NCT01165541|Experimental|Quetiapine XR and Mirtazapine|Quetiapine XR 50-400mg + Mirtazapine 7.5-45mg
88805814|NCT00284180|Experimental|HER2 Negative Intervention|Vinflunine 320 mg/m2 intravenously day 1 over 20 minutes, repeated every 21 days
88805815|NCT00284180|Experimental|HER2 Positive Intervention|Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/kg, followed by 6 mg/kg IV on day 1 of each subsequent cycle, repeated every 21 days. If no grade 3/4 adverse events were encountered after the first cycle of vinflunine/trastuzumab, the dose of vinflunine could be escalated to 320 mg/m2.
89230356|NCT00803465||Cohort Group 1|Subjects number 1 to 24
89230357|NCT00803465||Cohort Group 2|Subjects number 25 to 44
89230358|NCT00803465||Cohort Group 3|Subjects number 45 to 68
88805816|NCT01165775||Threatened pre term labor patients|Patients receiving betamethasone to minimize the complications of prematurity will monitor blood glucose levels using the Dexcom Seven Plus Continuous Glucose Monitoring System.
88805817|NCT03011957||Group 1|HIV positive viral load < 200 copies/ml 50-65 years old CD4 > 350 cells/ml Male or Female
88805818|NCT03011957||Group 2|HIV negative 50-65 years old CD4 > 350 cells/ml Male or Female
89230359|NCT00803465||Cohort Group 4|Subjects number 69 to 91
89230360|NCT00803465||Cohort Group 5|Subjects Number 92 to 115
89230361|NCT03954847||Lung cancer patients|Lung cancer patients with PET/CT or CT examination before any cancer-specific treatment
89230362|NCT01095913|Experimental|IC-Green Injections|ICG Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
89230363|NCT00803699|Placebo Comparator|Placebo|Capsule contains no selenium
89230364|NCT00803699|Active Comparator|Selenium as L-selenomethionine|50, 100, or 200 micrograms of selenium
89290555|NCT01226862||Spoke Hospital|Spoke Hospital Cohort: non-stroke center certified sites, where patients are treated at an in-network telestroke community hospital using telemedicine technology with consultation provided by physicians from a hub hospital.
89290556|NCT01226862||Control Hospital|Control Hospital Cohort: non-stroke center certified sites with no telemedicine services.
88805819|NCT01899872|Experimental|Patients with type 1 diabetes|Patients with type 1 diabetes
88805820|NCT04087460|Experimental|Low-dose Group A|Subjects received three doses of PBPV with 20μg each antigen
89290557|NCT01129596||1|
89290558|NCT04799158|Experimental|Run-In Period|Participants will receive vonoprazan 20 mg once daily for up to 4 weeks.
89111191|NCT02792595|Experimental|Test Product E|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
89111192|NCT02792595|Experimental|Test Product F|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
89111193|NCT02792595|Experimental|Test Product G|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
89230365|NCT03952741|Experimental|Cognitive Functional Therapy|The intervention is a targeted cognitive functional therapy and will be based on examination findings. It is behaviorally directed with a focus on normalizing mal-adaptive pain, cognitive and movement behaviors in a graduated manner. In the evaluation process it is considered whether the patient has adjusted to the back complaints in a positive way (confrontation, active coping, minimal avoidance behavior) or in a negative way (passive coping, fear and avoidance behavior). Work related issues will be a particular focus, with the aim of achieving close co-operation between the worker, the workplace and the worker's responsible health care provider.
88805821|NCT04087460|Placebo Comparator|Low-dose Group B|Subjects received three doses of placebo
88805822|NCT04087460|Experimental|Middle-dose Group A|Subjects received three doses of PBPV with 50μg each antigen
89111194|NCT02792595|Experimental|Test Product H|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
89111195|NCT00906204|Experimental|Single-dose Thymoglobulin|Biological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion
89111196|NCT00906204|Active Comparator|Divided-dose Thymoglobulin|Biological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4
89111197|NCT02792361|No Intervention|Control Group|Subjects who did not have a suction drain placed post-operatively following a Pterional Craniotomy.
89111198|NCT02792361|Experimental|Treatment Group|Subjects who did have a suction drain placed post-operatively following a Pterional Craniotomy at the location of surgical incision.
89111199|NCT03554148||SSI|This group receives an additional swab of the surgical site infection. Follow up is terminated at the occurence of SSI.
89111200|NCT03554148||No SSI|This group is systematically followed up until 30 days after surgery (one year if a implant is implanted, e.g. mesh) by a third party (www.swissnoso.ch).
89111201|NCT02792127|Experimental|Experimental|These participants will be given access to a six-month online program for social anxiety.
89111202|NCT02792127|No Intervention|Wait List Control|These participants will not be given an intervention until after they have completed the study.
89111203|NCT02794077|Experimental|Cyclophosphamide|Patients receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progression or unacceptable toxicity.
89111204|NCT02792283|Experimental|patients undergoing hemodialysis|
89111205|NCT02791971|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
88805823|NCT04087460|Placebo Comparator|Middle-dose Group B|Subjects received three doses of placebo
88805824|NCT04087460|Experimental|High-dose Group A|Subjects received three doses of PBPV with 100μg each antigen
89290559|NCT04799158|Experimental|Vonoprazan 10 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 10 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
89111206|NCT02791971|Active Comparator|Alcohol Control Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
89230366|NCT03952741|Active Comparator|Cognitive Patient Education and PT|The intervention in the second group will receive much training in cognitive coping techniques after the COPE LBP trial principles (Werner et al. 2010). The educational part of the COPE for new instructors with a PT background takes 2 days supervised by Werner and his group, with regular follow-up meeting with the project leaders, together with a psychologist trained in cognitive therapy
89230367|NCT00798785|Experimental|group I ATG-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=30"
89230368|NCT00798785|Experimental|group II ATG-Rituximab-MMF-TAC|"Two clinical implants in the liver:~First Implant: ATG fresenium + Rituximab Maintained immunosuppression: MMF-TAC n=5"
88805825|NCT04087460|Placebo Comparator|High-dose Group B|Subjects received three doses of placebo
89230369|NCT00798785|Experimental|group III ATG-Basilixumab-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Second implant: basilixumab Maintained immunosuppression: MMF-TAC n=5"
89230370|NCT00798785|Experimental|group IV omentum|"Two clinical implants: first in the omentum followed by a clinical implant in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=10"
89230371|NCT01095991|Experimental|1|AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.
89230372|NCT01095991|Experimental|2|Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.
88805826|NCT02044172|Active Comparator|Radical prostatectomy|Radical prostatectomy
88805827|NCT02044172|Active Comparator|Conformal radiation therapy|Conformal radiation therapy External beam radiation therapy
89230373|NCT01096069||Rituximab|Rheumatoid arthritis patients undergoing treatment with rituximab.
89230374|NCT00798863|Experimental|operative group|The patients of the group will have the operation of two step video assisted submandibular sialadenectomy.
89230375|NCT00798941|Experimental|pain intervention|music and massage for 30 minutes
89230376|NCT00798941|Experimental|thirst intervention|sterile water mouth spray, lip moisturizer,mouth swab
89230377|NCT00798941|No Intervention|control|
89230378|NCT00803855|Experimental|AZD1446 Oral or placebo|Single oral administration of AZD1446 or placebo
89230379|NCT00803855|Experimental|AZD1446 Oral, with or without food|Single oral administration of AZD1446 with or without food
89230380|NCT00794807|Experimental|Alefacept|
89230381|NCT00794885|Experimental|Enalapril/folic acid|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
89230382|NCT00794885|Active Comparator|Enalapril|Enalapril maleate 10 mg per day is given
89230383|NCT00795041||1|10 women with indication for ART with ICSI or IVF
89230384|NCT00803933|Experimental|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
89230385|NCT00803933|Active Comparator|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
89111207|NCT02791737|Experimental|Supportive care (otago exercise programme)|Patients attend 8 physical therapy visits twice monthly for 4 months or until transplant. Patients also undergo an individualized exercise program at home for 6 months. The program comprises 3 main components: walking over 30 minutes twice a week, strengthening and balance retraining exercise over 30 minutes three times a week.
89111208|NCT02535936|Other|3Tesla MRI with DTI-MRI and rsfcMRI|Patients will receive 2 post-operative MRI's with DTI and rsfcMRI at 2 months and 12 months.
89111209|NCT02788539|No Intervention|Science Cafe|One time event, Group discussion for 30 participants who are chronic pain stakeholders on pain in their community.
89111210|NCT02788539|Experimental|Cohort 1- Pilot OWL Study|Participants will pilot test a website- Our Whole Lives website for nine weeks in order to determine if it will help with their chronic pain management.
89111211|NCT02789319|Other|FreeStyle Lite|Blood Glucose Meter type
89111212|NCT02789319|Other|Contour Next|Blood Glucose Meter type
89111213|NCT02789319|Other|OneTouch Ultra2|Blood Glucose Meter type
89111214|NCT02789319|Other|ACCU-CHEK AVIVA Plus|Blood Glucose Meter type
89111215|NCT02789319|Other|Prodigy Auto Code|Blood Glucose Meter type
89111216|NCT02789319|Other|Walmart ReliOn Prime|Blood Glucose Meter type
89111217|NCT02789319|Other|Embrace|Blood Glucose Meter type
89111218|NCT02789319|Other|True Result|Blood Glucose Meter type
89111219|NCT02789319|Other|True Track|Blood Glucose Meter type
89111220|NCT02789319|Other|Walmart ReliOn Confirm|Blood Glucose Meter type
89111221|NCT02789319|Other|Advocate Redi-Code +|Blood Glucose Meter type
89111222|NCT02789319|Other|CVS Advanced|Blood Glucose Meter type
89111223|NCT02789319|Other|OneTouch Verio|Blood Glucose Meter type
89111224|NCT02789319|Other|Contour|Blood Glucose Meter type
89111225|NCT02789319|Other|Accu-Chek Nano|Blood Glucose Meter type
89111226|NCT02789319|Other|Walmart ReliOn Ultima|Blood Glucose Meter type
89111227|NCT02789319|Other|Gmate Smart|Blood Glucose Meter type
89111228|NCT02789319|Other|SolusV2|Blood Glucose Meter type
89111229|NCT02791815|Experimental|Sequence AB|Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.
89111230|NCT02791815|Experimental|Sequence BA|Subjects participate in two study periods: During the first period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. During the second period, they receive a single oral dose of midazolam on Day 1. There is a washout period of 14 to 21 days between the two periods.
89111231|NCT02789475|Experimental|amplodipine group|Amlodipine for 8 days and Amlodipine+Rosuvastatin for 5 days
89111232|NCT02789475|Experimental|rosuvastatin group|Rosuvastatin for 5 days and Amlodipine+Rosuvastatin for 8 days
89111233|NCT05379777|Experimental|Remimazolam|A maintenance dose of remimazolam is administered for sedation
89111234|NCT03649347|Experimental|AR Therapy Intervention for Spider Phobia|AR Therapy Intervention participants first complete a behavioral approach test (BAT). They approach a live spider to get as close as they comfortably can. This BAT provides a baseline measure of the degree of fear of spiders; the BAT is not a form of exposure therapy. Participants then complete exposure therapy using an augmented reality (AR) headset. A therapist controls the AR paradigm, placing virtual spiders in a participant's real environment as a method of exposure therapy. Once a participant's anxiety is reduced to low, stable levels (as measured by the participant's subjective units of distress assessed at intervals during session), the participant then completes a second BAT to measure their degree of fear immediately following AR therapy. The difference between the first and second BAT are used to assess the efficacy of the AR exposure therapy treatment. One month later, the AR Therapy Intervention participants complete a third BAT to assess for treatment efficacy over time.
89111235|NCT03649347|No Intervention|No Treatment Control Group for Spider Phobia|The No Treatment Control group participants do not receive any AR exposure therapy for the duration of the study. These participants complete a behavioral approach test (BAT) at their first study visit, during which they approach a live spider as close as they comfortably can. This BAT provides a baseline measure of the degree of fear of spiders; the BAT is not a form of exposure therapy. One month later, the No Treatment Control group participants return for a second BAT to assess the degree to which their fear has changed as a function of time, in the context of NOT receiving any exposure therapy. After completion of the second BAT at this one-month follow-up visit, these participants are offered the opportunity for some form of exposure therapy following the conclusion of the study.
89111236|NCT03649347|Experimental|AR Therapy Intervention for Snake Phobia|Augmented reality (AR) exposure therapy involves placing virtual objects in the participant's real environment as a method of exposure therapy. The AR therapy intervention group will complete an exposure therapy session using an augmented reality headset. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The exposure therapy session will be as long as needed to reduce anxiety to low and stable levels, as measured by the participant's subjective units of distress.
89230386|NCT02553707|Experimental|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
89111237|NCT03649347|No Intervention|No Treatment Control Group for Snake Phobia|This will be a waitlist control group that will receive no treatment for the duration of the study, however they will be offered the opportunity for some form of exposure therapy following the conclusion of the study (1 month).
89111238|NCT03761823||Healthy subjects|Healthy subjects
88805828|NCT02044172|Active Comparator|Active monitoring|Active monitoring of prostate specific antigen levels and disease surveillance
89111239|NCT03761823||Patients|Patients extubated after > 5 days of mechanical ventilation.
89111240|NCT02791347|No Intervention|Control|"Upon discharge from the medical center, patients would be advised on a qualitative, neutropenic diet. Participants' quality of life, physical activity level, functional and nutritional status would be assessed at days +30, +60 and +100 post transplantation.~These participants will not receive nutritional counseling by the dietitian as outpatients except if referred by the medical team."
89230387|NCT00804011|Experimental|1|Automatic tube compensation plus pressure support
89230388|NCT00804011|Active Comparator|2|Pressure support alone
89230389|NCT00799097||Endoscopic Sinus Surgery|Subjects who have failed maximum medical management and have elected for endoscopic sinus surgery
89230390|NCT00799175|Active Comparator|1 Group A(Active)|Group A (Active) receives a multimodal injection intra- and postoperatively
89230391|NCT00799175|Placebo Comparator|2 Group P (Placebo)|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
89230392|NCT00799331|Experimental|A|AZD5985
89230393|NCT00799331|Experimental|B|placebo
89230394|NCT00804089|Experimental|1|Traditional needle acupuncture
89230395|NCT00804089|Active Comparator|2|Myofascial trigger point dry needling
89230396|NCT00804089|Active Comparator|3|Myofascial trigger point acupressure
89230397|NCT00656513|Active Comparator|Pilocarpine: Phase III|
89230398|NCT00656513|Experimental|ALTENS: Phase III|
89230399|NCT00656513|Experimental|ALTENS: Phase II|
89230400|NCT04017221||Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current use of a SGLT2 inhibitor alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
89230401|NCT04017221||Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current use of a DPP-4 inhibitor alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
89230402|NCT04017221||Other treatment combinations|Current use of other antidiabetic drugs, current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
89230403|NCT00804245|Experimental|radiolabeled choline tracer scans|PET-CT scans supplemented with Choline 11 tracer
89230404|NCT00805883|Experimental|1|
89230405|NCT00804323|Experimental|Group 1|Patients with open-angle glaucoma
89230406|NCT04045847|Experimental|CD147-CART|CD147-CAR modified T cells, intracavity injection, 3+3 design with de-escalation in half step, every 7 days for 3 weeks
89230407|NCT00804401|Active Comparator|Test Product|
89230408|NCT00804401|Active Comparator|Reference Product|
89230409|NCT00804479||no treatment|Available 301 subjects enrolled in CALM-PD Available 82 subjects enrolled in CALM-PD imaging substudy
89230410|NCT00655889|Experimental|Active|
89290560|NCT04799158|Experimental|Vonoprazan 20 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 20 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
89230411|NCT00804557||Uro-Ease Spirus Catheter|10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
89230412|NCT00804557||Standard Urinary Catheter|10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.
89230413|NCT00806039|Other|1|Early renal involvement
89230414|NCT00806039|No Intervention|2|control
89230415|NCT00804791|Active Comparator|Systane|One drop dispensed into each eye
89230416|NCT00804791|Active Comparator|Unisol|One drop dispensed into each eye
89230417|NCT02553239|Experimental|Cryoablation|Cryoablation with the CoolLoop® catheter
89230418|NCT00806117|Active Comparator|Radiotherapy (RT)|Radiotherapy
89230419|NCT00806117|Experimental|Concurrent chemoirradiation (CCRT)|"Concurrent chemoirradiation:~External beam radiation with concurrent weekly platinum chemotherapy"
89230420|NCT00806117|Experimental|Sequence chemo and radiation (SCRT)|"Sequence chemotherapy and radiotherapy:~2 cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation"
89230421|NCT00804869||1|PalmScan biometric group
89230422|NCT00804869||2|A-mode ultrasonography biometric group
89230423|NCT02553083|Active Comparator|Group 1|Nexium 40 mg and amoxicillin 1.5 gr twice daily for 14 days
89230424|NCT02553083|Active Comparator|Group 2|Nexium 40 mg and doxycycline 200 mg twice daily for 14 days
89230425|NCT02553083|Active Comparator|Group 3|Nexium 20 mg, clarythromicin 500 mg, and amoxicillin 1 gr twice daily for 14 days
89230426|NCT00804947|Experimental|Intravenous busulfan and melphalan|
89230427|NCT02553005|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
89230428|NCT02553005|Experimental|verum acupuncture|Real acupuncture treatment
89230429|NCT02553005|No Intervention|Control|
89230430|NCT00806273|Active Comparator|Group 2|For Group II, the ultrasonic irrigation system involves using an initial irrigation with a conventional syringe followed by ultrasonic irrigation.
89230431|NCT00806273|Active Comparator|Group 1|For Group I, needle irrigation will be delivered into the pulp chamber using a syringe tip placed above the access opening and removed with high volume suction.
89230432|NCT00805103|Experimental|(HFA-SRT) in Large-Volume Brain Metastases|
89230433|NCT00805181||Acute uncomplicated pyelonephritis|
89230434|NCT00655733|Experimental|HMPL-004|Subjects who fulfilled all entry criteria and randomized HMPL-004 arm will receive HMPL-004 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
89230435|NCT00655733|Placebo Comparator|Placebo|Subjects who fulfilled all entry criteria and randomized Placebo arm will receive matching placebo 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
89230436|NCT00806429|Experimental|1|transvaginal appendectomy
89230437|NCT00806429|No Intervention|2|
89230438|NCT00657371|Experimental|Third Eye Retroscope|Colonoscopy exam using the Third Eye Retroscope device
89230439|NCT00805259|Active Comparator|1. Atomistic|payment for own work
89230440|NCT00805259|Active Comparator|2. Altruistic|payment for partner's work
89230441|NCT00805259|Active Comparator|3. Team-based|payment for relative performance of combined effort of each team
89230442|NCT00805259|No Intervention|4. Control|access to software but no financial incentives
89230443|NCT00806507||Echocardiogram + Blood Test|Additional Echocardiogram views performed in 5-10 minutes of regularly scheduled echocardiograms plus blood tests measuring of hormones and metabolic proteins (such as sugars and acids).
89230444|NCT04017065||Patients treated with the MAXFRAMETM system|Any patient undergoing surgical treatment (primary or revision) for deformity correction using the MAXFRAME™ system
89230445|NCT00806663|Experimental|Sunitinib Arm|Sutent sunitinib 37 mg once daily (4 weeks on/2 weeks off)
89230446|NCT00805415|Experimental|Arm 1|
89230447|NCT00805415|Experimental|Arm 2|
89230448|NCT02553863|Experimental|Intervention group|Acupuncture for 30min [twice weekly for 8 weeks]
89230449|NCT02553863|Other|Control group|Standard care
89230450|NCT00799565|Experimental|1|Subject with a Mitral Valvular Prolapse
89230451|NCT00799565|Experimental|2|Healthy Volunteers
89230452|NCT00806741|Active Comparator|1|NG-monomethyl-L-arginine (L-NMMA)
89230453|NCT00806741|Active Comparator|2|Phenylephrine
89230454|NCT00806741|Placebo Comparator|3|Physiological saline solution
89230455|NCT00799721||1|VLBW infants with erythropoietin therapy
89230456|NCT00799721||2|VLBW infants without erythropoietin therapy.
89230457|NCT00805571||Adult|Adult patients with end-stage kidney disease awaiting kidney transplantation.
89230458|NCT00805571||Pediatric|Children with end-stage kidney disease awaiting kidney transplantation.
89230459|NCT00806897||A|
89230460|NCT00805649|Experimental|1|eyes with predominately classic lesions
89230461|NCT00805649|Experimental|2|eyes with occult lesions
89230462|NCT00799799|Experimental|NK|patient treated as per protocol
89230463|NCT00806975|Other|usability and preference|
89111241|NCT02791347|Experimental|Nutrition Intervention Group|"Upon discharge from the medical center, NIG patients will receive tailored nutrition counseling with the provision of patient education material and oral nutritional supplements if needed. Patients will be advised on a diet high in energy and proteins and tailored to their medical condition in the hospital before discharge.~Patients will be followed up at days +30, +60 and +100 post transplantation. Compliance will be measured at each visit by comparing patients caloric and protein needs to their actual protein and energy intake. Compliance will be reinforced to meet patients' goals using nutritional tips, oral supplementation, and artificial nutrition use."
89111242|NCT04202484|Experimental|Toripalimab combine CT|
89111243|NCT02791425|Experimental|Brain Computer Interface (BCI) device|The patient uses the Brain Computer Interface (BCI) device in the ICU for communication for 2 hours a day for 3 consecutive days. The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
89111244|NCT02380404||Edentulous maxilla|Ibuprofen (600 mg - Film-coated Tablets) 3x/day before the surgery. Duration : 5 days Amoxicilline Teva (500 mg - dispersible tablets) 3x/day before the surgery. Duration : 16 days
89111245|NCT05375565|Experimental|weight bearing exercises|weight bearing exercises
89111246|NCT05375565|Experimental|non weight bearing exercises|non weight bearing exercises
89111247|NCT02790957|Experimental|Plerixafor|Single subcutaneous injection of Plerixafor (0.24 mg/kg)
89111248|NCT02790957|Placebo Comparator|Placebo|Single injection of an equal volume of NaCl solution
89111249|NCT05408013||ward patients in psychiatric hospitals|Patients in psychiatric hospitals will be assessed so that the prevalence of insomnia in psychiatric inpatients can be estimated.
89111250|NCT00905424|Experimental|Active|Antidepressant + SPD489
89111251|NCT00905424|Placebo Comparator|Placebo|Antidepressant + placebo
89111252|NCT04234269||Assessment Group|Individuals with spinal cord injury. There is one group.
89111253|NCT02791035|Experimental|Ipragliflozin|Ipragliflozin 50 mg/tablet, orally, 1 tablet once daily for 12 weeks
89111254|NCT03753243|Experimental|Intervention|Treatment will be planned for a total of 14 to 16 weeks. Pembrolizumab will be administered every 3 weeks via IV infusion with a dose of 200 mg per infusion. Enzalutamide will be given orally and dispensed to the patient on the date of their first infusion. The dosage of Enzalutamide will be 160 mg, administered once daily for approx. 16 weeks. GNRH agonist therapy will be administered as a standard of care therapy and will follow a standard dosage to maintain castrate levels.
89230464|NCT00809315|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
89111255|NCT02788617||Non treatment group|This is a non-interventional study in which embryo selection is performed according to standard of care. The Diafert output, the granulocyte colony-stimulating factor (G-CSF) concentration in follicular fluid (FF), will be recorded but will not be used in patient management, ie, values will not be used for embryo selection in the assisted reproduction procedure.
89111256|NCT02790879||Transition|Patients who switched from pediatric cystic fibrosis care center to an adult cystic fibrosis care center during 2013 or 2014, regardless of their clinical status.
89111257|NCT02790801||1 group|observation of patients with chronic heart failure and atrial fibrillation
89111258|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
89111259|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
89111260|NCT02790645|Other|Group 1b. Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
89230465|NCT00809315|Experimental|Fostering Healthy Futures (FHF) Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Weekly therapeutic skill groups and mentoring over a 9-month period.
89111261|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months).
89111262|NCT00632580|Active Comparator|1|intraarticular injection with local anesthetic
89111263|NCT00632580|Experimental|2|intracapsular injection with local anesthetic
89230466|NCT00807053|Active Comparator|1|Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily
89230467|NCT00807053|Active Comparator|2|Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily
89230468|NCT00807053|Active Comparator|3|Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily
89230469|NCT00807053|Placebo Comparator|4|Placebo
89230470|NCT00809393|Active Comparator|low dose|low dose tranexamic acid
89230471|NCT00809393|Experimental|high dose|
89230472|NCT00799955|Placebo Comparator|1|Subjects will receive 100 micrograms of spinal morphine, at the time of spinal needle insertion (standard care at BCW). At the end of the case, one of two investigators, using ultrasound, will visualize the transversus abdominis plane. A capped needle will be pushed against the skin to mimic the pressure sensation of the TAP block. The needle will not break the skin and nothing will be injected in this control group. The procedure will then be repeated on the other side. A dressing will be applied on each side to blind the subject and researcher to which group she is in.
89230473|NCT00799955|Active Comparator|2|No additional spinal medications will be given. At the end of the case, one of the two investigators, under sterile conditions, and using ultrasound, will visualize the tip of a blunt regional anaesthesia needle entering the transversus abdominis plane. After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected, under vision, into the transversus abdominis plane, on each side. The subjects will still have spinal anesthesia of the abdomen and therefore will not feel needle insertion as sharp although most will have a sensation of pressure. A dressing will be applied over the needle's entry points.
89230474|NCT00807131|Experimental|1|Patient follow-up
89230475|NCT00807131|Experimental|2|Counseling
89230476|NCT00807131|Experimental|3|Drug dispensing
89230477|NCT00807131|Active Comparator|4|pharmacy usual care
89230478|NCT00658775|Experimental|1|
89230479|NCT00658775|Active Comparator|2|
89230480|NCT00807287|Experimental|1|Placement of jejunal feeding tube using the unguided frictional method
89230481|NCT00807287|Active Comparator|2|Jejunal tube placement using the endoscopic method
89230482|NCT00800033|Experimental|Aerobic exercise training|
89230483|NCT00800033|Placebo Comparator|Resistance exercise training|
89230484|NCT00800033|Experimental|pulse diet|Pulse based diet containing peas, lentils, and beans
89230485|NCT00800033|No Intervention|Regular diet|
89230486|NCT00800111|Other|Treatment|Endothelial keratoplasty procedure is performed.
89290561|NCT04799158|Experimental|Vonoprazan 40 mg: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take vonoprazan 40 mg when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
89230487|NCT00488631|Placebo Comparator|Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
89230488|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 50 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.
89230489|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 100 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.
89230490|NCT00488631|Placebo Comparator|Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance|Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
89230491|NCT00488631|Experimental|PBO-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
89230492|NCT00488631|Experimental|GLM-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
89230493|NCT00809549|Placebo Comparator|Normal Saline|
89230494|NCT00809549|Experimental|Filgrastim|
89230495|NCT00809627|Experimental|1|IV caffeine with saline and opiate
89230496|NCT00809627|Placebo Comparator|2|IV saline with opiate
89230497|NCT00809705|Experimental|1|
89230498|NCT00809705|Experimental|2|
89230499|NCT00809705|Placebo Comparator|3|
89111264|NCT02787993|Active Comparator|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
89111265|NCT02787993|No Intervention|Treatment as usual|Treatment as usual
89111266|NCT02789397|Active Comparator|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12. Azathioprine: Starting dose of azathioprine will be 50 mg and increased in 25 mg increments to a maximum dose of 150 mg or 2 mg/k/day (whichever is lowest) as tolerated. Azathioprine will be administered by mouth daily for 18 months.
89111267|NCT02789397|Placebo Comparator|Placebo|IV placebo will be administered on the same schedule as Rituximab. Oral placebo will be administered by mouth daily for 18 months.
89111268|NCT03286725|No Intervention|Control Group|The Control Group will be asked to continue with their normal PE lessons.
89111269|NCT03286725|Experimental|Intervention Group|'Physical Education (PE) Programme'
89111270|NCT05134428|Experimental|ADAM System|All subjects who consent and meet inclusion and none of the exclusion will be enrolled and receive the ADAM System, which is a hydrogel device implanted into the vas deferens.
89111271|NCT02789241|Experimental|Endotoxin (LPS)|The safety and tolerability will be assessed at different doses that will consist of 4 groups; each consisting of 4 subjects receiving endotoxin (LPS). Group 1 will test the low dose of LPS (0.6 ng/kg); Group 2 will test the 1.0 ng/kg dose; Group 3 will test the 2.0 ng/kg dose and Group 4 will test the 4.0 ng/kg dose.
89111272|NCT02789241|Placebo Comparator|Placebo|The trial will consist of 4 groups each group will have 2 subjects receiving Placebo (normal saline)].
89111273|NCT04233411|Active Comparator|Milk|Acute ingestion of 20 g milk protein
89111274|NCT04233411|Experimental|20g|Acute ingestion of 20 g mycoprotein
89111275|NCT04233411|Experimental|40g|Acute ingestion of 40 g mycoprotein
89111276|NCT04233411|Experimental|60g|Acute ingestion of 60 g mycoprotein
89111277|NCT04233411|Experimental|80g|Acute ingestion of 60 g mycoprotein
89111278|NCT00816166|Experimental|Stent Group|"Medical therapy + PHAROS Vitesse neurovascular stent (Stent Group)"
89111279|NCT00816166|Active Comparator|Medical Therapy Group|"Medical therapy alone (Medical Therapy Group)"
89230500|NCT00655499|Experimental|Panitumumab + CPT11 (irinotecan hydrochloride)|1 cycle every 14 days (J1= J15)
89230501|NCT00809861|Active Comparator|1|volar locking plating of distal radius fractures
89230502|NCT00809861|Active Comparator|2|
89230503|NCT00654875|Experimental|Aliskiren 300 mg (Once a Day)|Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks.
89230504|NCT00654875|Experimental|Aliskiren 150 mg (Twice a Day)|Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.
89230505|NCT00800267|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
89230506|NCT00800267|Active Comparator|latanoprost 0.005%|
89230507|NCT00800267|Active Comparator|Timolol - 0.5%|
89230508|NCT00809939|Active Comparator|1|previous preterm delivery, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
89230509|NCT00809939|Active Comparator|2|previous preterm delivery, treatment with daily vaginal natural progesterone
89230510|NCT00809939|Active Comparator|3|short cervical length, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
89230511|NCT00809939|Active Comparator|4|short cervical length, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
89230512|NCT00807443|Experimental|Raltegravir|
89230513|NCT00807521|Active Comparator|1|High dose bolus of dexamethasone before surgery
89230514|NCT00807521|Placebo Comparator|2|Placebo control
89230515|NCT00810173|Experimental|1|This group received call phone support to incentive the increase of the number of steps during 6 weeks
89230516|NCT00810173|No Intervention|2|This group just received a pedometer to register the number of steps for 6 weeks but this group don´t received a phone call.
89230517|NCT00922259|Experimental|H7N7 Vaccine|Participants will be administered two doses of the candidate live influenza A H7N7 vaccine
89230518|NCT00800423|Experimental|brimonidine|"50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.~they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
89230519|NCT00800423|Active Comparator|2 tmolol|"50 patients receiving timolol maleate 0.5% drops in the operated eye~1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
89230520|NCT00800423|No Intervention|3|50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)
89230521|NCT00800501|Experimental|sNN0029|
89230522|NCT00800501|Placebo Comparator|Placebo|
89230523|NCT00807677|Experimental|1|TAK-901
89290562|NCT04799158|Placebo Comparator|Placebo: On-Demand Treatment Period|Participants who have stable disease (no heartburn on the last 7 days of the Run-In Period) will take a placebo when heartburn occurs during the 6 week On-Demand Treatment Period. Participants can take no more than one dose in a 24 hour period.
89111280|NCT02788851|Active Comparator|Medication only|Stimulant or non-stimulant medication only - Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine. Investigators will be using a product approved for clinical use in Canada), with dose optimized for each participant based on report of efficacy and side effects. Once on an optimal dose of stimulant or non-stimulant medication they will attend 8 weekly education sessions about ADHD.
89111281|NCT02788851|Experimental|Aerobic Exercise only|Participants attend a structured aerobic exercise class, twice a week for 8 weeks.
89111282|NCT02788851|Active Comparator|Combination Group|Participants assigned to this group will be optimally medicated (either stimulant or non-stimulant medication - approved for clinical use in Canada) and will attend a structured aerobic exercise class, twice a week for 8 weeks.
89111283|NCT05758324|Experimental|Trace elements|Nutri PNEA in a single dose (4 sequences of 10 tablets). Nutri PNEA is a complex of trace elements with the status of a food supplement.
89111284|NCT05758324|Placebo Comparator|Placebo|4 sequences of 10 tablets containing only excipients
89111285|NCT02787915|Experimental|dendritic cell vaccine|DC1-CTL cellular therapy
89111286|NCT04200027||Robotic total mesorectal Excision|robotic assissted total mesorectal excision
89111287|NCT04200027||Transanal total mesorectal excision|Transanally assissted total mesorectal excision
89111288|NCT02786823|Experimental|Folic acid|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks
89111289|NCT02786823|Experimental|Vitamin B12|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks
89111290|NCT02786823|Experimental|"Folic acid and Vitamin B12"|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks
89111291|NCT02786823|Active Comparator|Control|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and receive no additional supplementation
89111292|NCT05332314|Experimental|NSAIDs|This arm is given NSAIDs perioperatively and after discharge
89111293|NCT05332314|No Intervention|Opioids|This arm will be given the standard opioids treatment to control pain perioperatively and at discharge.
89111294|NCT00815308|Experimental|cetuximab, concurrent chemo-radiotherapy|Cetuximab, injection, loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8) Paclitaxel, injection,45 mg/m^2 (Day 1, every week for Weeks 2-8) Cisplatin, injection,20 mg/m^2 (Day 1, every week for Weeks 2-8) radiation therapy, 59.4 Gy, 1.8 Gy/33 fractions,1 fraction daily, Days 1-5 every week for Weeks 2-7, and Days 1-3 for Week 8
89111295|NCT05261958|Experimental|Interventional Group|"Warm up and cool down (10 minutes before physical activity)~Players will be given the SAQ training which includes~High Knees with Mini Hurdles.~30 Yard Sprint.~Agility Ring Hops.~Ladder 2 in 2 out.~Depth Jumps.~Overhead Ball Drop Reaction Drill"
89111296|NCT05261958|No Intervention|Control Group|"Players in this group did not undergo any interventional Programme rather than their daily routine work which includes:~Dumbbell squat~Dumbbell bicep arm curl~Burpee pull up~Medicine ball pushups~Sprints~HIIT on treadmill"
89111297|NCT03251313|Experimental|JS001 120mg+GP|Level 1: JS001 120mg +GP q3w,*6 cycles, then JS001 120mg q3w for maintenance therapy for up to approximately 2 years.
89111298|NCT03251313|Experimental|JS001 240mg+GP|Level 2: JS001 240mg +GP q3w,*6 cycles, then JS001 240mg q3w for maintenance therapy for up to approximately 2 years.
89111299|NCT03251313|Experimental|JS001 480mg +GP|Level 3: JS001 480mg+GP q3w,*6 cycles, then JS001 480mg q3w for maintenance therapy for up to approximately 2 years.
89111300|NCT03251313|Experimental|GP followed by JS001|sequential treatment: Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
89111301|NCT01039376|Experimental|ARM A: Ofatumumab|300 mg IV Week 1 followed by 1000 mg IV Week 2 1000 mg IV (a dose every 8 weeks for up to 2 years following the first 1000 mg dose)
89111302|NCT01039376|Other|ARM B: Observation and assessments as per Arm A|Disease status assessments to determine subject response or progression performed approximately every 8 weeks for up to 2 years for both arms according to IWCLL criteria
89111303|NCT04729686|Active Comparator|Pericapsular Nerve Block Group|Pericapsular Nerve Block targets the anterior hip capsule by blocking the articular branches of the femoral nerve and accessory obturator nerve.
89111304|NCT04729686|Active Comparator|Fascia Iliaca Nerve Block Group|Fascia Iliaca Nerve Block targets the space between the iliacus muscle and the fascia that overlies it (fascia iliaca), within which the femoral nerve and lateral femoral cutaneous nerve (LFCN) course.
89111305|NCT04200183|Experimental|iACTwithPain|
88805829|NCT05031806|Experimental|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
89111306|NCT04200183|Experimental|ACT-only intervention|
89111307|NCT04200183|No Intervention|Wait list (inactive control)|
89111308|NCT02610712|Experimental|TRD patients|Treatment-Resistant (TRD) patients to receive intravenous ketamine at 0.5 mg/kg dose.
89111309|NCT02789085|No Intervention|Control|without tens stimulation
89111310|NCT02789085|Experimental|Test|with tens stimulation
89111311|NCT00705952|Experimental|1|
89111312|NCT00905034|Experimental|MOAD|Chemotherapy regimen of methotrexate, rituximab, vincristine, pegylated L-asparaginase and dexamethasone (MOAD).
89111313|NCT02611804|Experimental|Diclofenac Sodium Gel, 3%|Diclofenac Sodium Gel, 3%, applied twice daily for 60 days
89111314|NCT02611804|Active Comparator|Solaraze®|Solaraze® (diclofenac sodium) Gel, 3%, applied twice daily for 60 days
89111315|NCT02611804|Placebo Comparator|Vehicle of Test Product|Vehicle of Test Product, Gel, applied twice daily for 60 days
89111316|NCT04233333|Active Comparator|mustache fixation|
89111317|NCT04233333|Experimental|W.K fixation|
89111318|NCT02157636|Experimental|CPI-0610|
89111319|NCT02787837||Abiraterone Acetate|Abiraterone Acetate 1000 mg/24h plus Prednisone 5mg/12h
89111320|NCT00706108||1|Simulation of anesthesia induction with critical incidents: Analysis of technical and non-technical performance (15 Teams)
89111321|NCT00706108||2|Analysis of technical and non-technical performance in live anesthesia inductions (40 teams)
89111322|NCT00706108||3|Simulation of anesthesia inductions with advanced simulated critical incidents or events and analysis of technical and non-technical performance (max. 50 teams)
89111323|NCT04232865|Experimental|Bןםפ Sטדאקצ|Biop Colposcopy procedure
89111324|NCT02611492|Active Comparator|Intensive Arm (A)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)~+ Post-SCT Maintenance"
89111325|NCT02611492|Experimental|Light Arm (B)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)~+ Post-SCT Maintenance"
89111326|NCT00706576|Experimental|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
89111327|NCT02788071|Experimental|FMT capsules|FMT capsules
89111328|NCT02788071|Placebo Comparator|FMT placebo|Placebo capsules
89111329|NCT04232787||Case|Thai patients with diagnosed Brugada syndrome by confirmed Brugada type 1 ECG.
89111330|NCT04232787||Control|Healthy volunteers without Brugada marker from ECG.
89111331|NCT00828568|Experimental|Imiquimod 5% Taro|Imiquimod 5% manufactured by Taro applied for 16 weeks
89111332|NCT00828568|Active Comparator|Aldara - Imiquimod 5%|Aldara, Imiquimod 5% applied for 16 weeks
89111333|NCT00828568|Placebo Comparator|Vehicle|Imiquimod vehicle applied for 16 weeks
89111334|NCT01038752|Experimental|Suramin|This group will receive the combination of non-cytotoxic suramin with docetaxel and carboplatin.
89230524|NCT00651755|Experimental|Aprepitant + CHOP/R-CHOP|Aprepitant 125 mg oral (PO) Day 1 of Cycle 1 followed by 80 mg PO Daily Days 2-3 with CHOP (steroid in CHOP) or R-CHOP plus Rituximab 375 mg/m^2 intravenous Day 1. CHOP or R-CHOP chemotherapy: (1) bolus or 48-hour infusion CHOP [cyclophosphamide 750 mg/m^2 IV Day 1, doxorubicin 25 mg/m^2/day IV given bolus or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg * 5 days]; or (2) Bolus or 48-hour infusion R-CHOP [Rituximab 375 mg/m^2 on Day 1 + CHOP as above]. [For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician]
89230525|NCT00651755|Experimental|Standard of Care (Control) + CHOP/R-CHOP|Anti-emetics, Ondansetron 8 mg daily for 2 days, plus steroids in CHOP or R-CHOP regimen.
89230526|NCT02552381||Group I|"Patients without LMWH treatment.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays~Other markers activity : sFVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
89230527|NCT02552381||Group II|"Patients with LMWH treatment at prophylactic dose at enrollment only.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays,~Anti-FXa activity measured at baseline and every month,~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
89230528|NCT02552381||Group III|"Patients with LMWH treatment at therapeutic dose.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays,~Anti-FXa activity measured at baseline and every month,~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
89230529|NCT02552771|Active Comparator|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
89230530|NCT02552771|Active Comparator|Mitral repair with leaflet resection|Removal of one or both of the mitral leaflets that flop or bulge back.
89230531|NCT00810251||MatrixRIB|
89230532|NCT00807755|Experimental|Phase I Dose-Escalation|This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.
89230533|NCT00813527|Experimental|Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD|
89230534|NCT00813527|Active Comparator|Fenofibrate 145 mg QD|
89230535|NCT00654641|Experimental|Negative pressure wound closure|Negative Pressure wound closure
89230536|NCT00654641|Active Comparator|Standard wound closure|Standard Wound Closure
89230537|NCT00810329||1|This group consists of patients with Chronic fatigue syndrome, Fibromyalgia and other conditions like Multiple chemical sensitivity, Irritable bowel syndrome, Interstitial Cystitis, Gulf War Illness.
89230538|NCT00810329||2|The healthy control group
89230539|NCT00810485|Experimental|ADX10059 50 mg|twice-daily
89111335|NCT01038752|Placebo Comparator|Standard of care|This group will receive placebo with docetaxel and carboplatin.
89111336|NCT00627380|Placebo Comparator|STOC|Standard of care arm continues to receive standard of care treatment for HIV, but does not receive any new treatment/intervention or change in anti-HIV medications. Runs parallel to experimental group. At the end of this 16-wk control period, participants are invited to crossover into the experimental group
89111337|NCT00627380|Experimental|YOGA|Yoga lifestyle intervention administered by certified yoga instructor.
89111338|NCT00903630|Experimental|Phase 1 - Dose Level 1|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 10 mg daily on Days 1-28 every 28 days
89111339|NCT00903630|Experimental|Phase I - Dose Level 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 15 mg daily on Days 1-28 every 28 days
88805830|NCT05031806|Experimental|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
89111340|NCT00903630|Experimental|Phase 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: maximum tolerated dose from Phase I portion of the study (10mg) daily on Days 1-28 every 28 days
89111341|NCT04302584|Active Comparator|NE|patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)
89111342|NCT04302584|Active Comparator|NE/VP|patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)
89111343|NCT00706732|Active Comparator|T1|
89111344|NCT00706732|Active Comparator|T2|
89111345|NCT00706732|Placebo Comparator|C1|
89111346|NCT00706732|Placebo Comparator|C2|
89111347|NCT02875106||Atrial Fibrillation Patients|Adult female and male patients with diagnosed atrial fibrillation
89111348|NCT02875106||Sinus Rhythm Patients|Adult female and male patients with diagnosed sinus rhythm
89230540|NCT00810485|Experimental|ADX10059 100 mg|twice-daily
89230541|NCT00810485|Experimental|ADX10059 150 mg|twice-daily
89230542|NCT00810485|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
89111349|NCT00703144|Experimental|Pharmacokinetic|
88805831|NCT05031806|Experimental|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
89230543|NCT00810563|Placebo Comparator|1|Saline solution 0.9% 5mL in each portal
89230544|NCT00810563|Active Comparator|2|Bupivacaine 0.5% 5mL in each portal
89230545|NCT00807833||CBF measurement|"It is a proof of concept study, aimed to evaluate whether the optimal CPP, defined by the best PRx, corresponds to the acceptable CBF values.~Patients admitted with the diagnosis of TBI and SAH in for whom ICP and CPP needs to be monitored on clinical ground will be also monitored with a TD probe and routinely tested for cerebral autoregulation, thus obtaining the CBF corresponding at a given the best CPP and autoregulation status."
89230546|NCT00807911|Active Comparator|Adjuvant FL|FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
89230547|NCT00807911|Experimental|Adjuvant FOLFOX|FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)
89230548|NCT00808145|Experimental|Gemcitabine/Cisiplatin/Sorafenib|All eligible patients will receive intravenous gemcitabine/cisplatin + daily oral sorafenib until disease progression occurs
89230549|NCT00922337||MGuard|eligible patients implanted with minimum one MGuard stent
89230550|NCT00810875||hepatitis C|pregnant women with hepatitis C virus infection and their infants
89230551|NCT00810875||controls|pregnant women without hepatitis C infection and their infants
89230552|NCT02552459|Active Comparator|sufentanil|sufentanil 150μg，intravenous administration during the following 72 hours after operation.
89111350|NCT02788929|Active Comparator|Fitbit Charge HR|"Use of the Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.~All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback."
89111351|NCT02788929|No Intervention|No Device|No Fitbit used and no feedback on exercise goal adherence. All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback.
89111352|NCT01037114|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the first long-term follow-up NCT00289718 and this long-term follow-up.~A challenge dose of the Havrix or Engerix-B vaccines can be administered in this study based on serology results at each time point."
89111353|NCT02979366|Experimental|S64315 (also referred as MIK665) administered once a week|
89111354|NCT02979366|Experimental|S64315 (also referred as MIK665) administered twice a week|
89111355|NCT03114033|Experimental|Targeted therapeutic mild hypercapnia|Target arterial carbon dioxide range of 50-55 mmHg for 24 hours following randomisation
89111356|NCT03114033|Active Comparator|Targeted normocapnia (Standard care)|Target arterial carbon dioxide range of 35-45 mmHg for 24 hours following randomisation
89230553|NCT02552459|Experimental|sufentanil&dexmedetomidine 1|sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.
89230554|NCT02552459|Experimental|sufentani&dexmedetomidine 2|sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.
89230555|NCT02552459|Experimental|sufentanil&dexmedetomidine 3|sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.
89230556|NCT00810953|Experimental|single arm|Use of pentamidine in locally advanced or metastatic pancreatic cancer
89230557|NCT00811031|Experimental|Taxotere + Prednisone|
89230558|NCT02552537|Active Comparator|Omeprazole|patients will take Omeprazole 40mg, in capsules, once a day, during five days before walnut challenge
89230559|NCT02552537|Sham Comparator|Placebo|patients will take Mannitol, in capsules, once a day, during five days before walnut challenge
89230560|NCT00811109|No Intervention|Standard|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity
89230561|NCT00811109|Active Comparator|2|With Blood Volume on-line monitoring only
89230562|NCT00811109|Active Comparator|3|With Blood volume and Blood temperature on-line monitoring
89111357|NCT02850198|Experimental|Scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
89230563|NCT00811265|Experimental|Simulated ExAblate MRgFUS|Patients undergoing simulated ExAblate MRgFUS device use
89230564|NCT00808223|Experimental|1. alefacept|
89230565|NCT00811343|Experimental|1|
89230566|NCT04045535|Experimental|Intervention group|Intervention with nurse and patients
89230567|NCT04045535|Active Comparator|Usual care|Usual clinical care based on current clinical practice guidelines.
89230568|NCT00811421|Active Comparator|Trial 1: IPTp-SP+LLITNs|HIV-negative pregnant women receiving 2 doses of IPTp (500mg of sulfadoxine and 25 mg of pyrimethamine) in the context of long lasting Insecticide Treated Nets (LLITNs)
89111358|NCT02850198|Sham Comparator|Sham scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. with shame electroacupuncture. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
89111359|NCT00840970|Active Comparator|Efficacy Unilateral Control|Non-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator following FESS (control arm)
89111360|NCT00840970|Experimental|Efficacy Unilateral Treatment|Drug-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the intervention following FESS (treatment arm)
89111361|NCT00840970|Experimental|Safety/PK Bilateral Treatment|Drug-coated splints placed bilaterally in both ethmoid sinus openings following FESS
89111362|NCT04232475|No Intervention|Control|Seated control
89111363|NCT04232475|Experimental|1 minute SCD|1 minute of stair climbing and descending
89111364|NCT04232475|Experimental|3 minute SCD|3 minute of stair climbing and descending
89111365|NCT04232475|Experimental|10 minute SCD|10 minute of stair climbing and descending
89111366|NCT01054820|Experimental|FLECTORA Patch (diclofenac epolamine topical patch) 1.3%|One patch applied every 12 hours
89111367|NCT02062164||bariatric surgery group|subjects who participate in the overall project and undergo bariatric surgery
89111368|NCT02062164||conservative care group|subjects who participate in the overall project and do not undergo bariatric surgery
89111369|NCT05343819|Experimental|AON-D21|Multiple ascending doses by iv infusion
89111370|NCT05343819|Placebo Comparator|Placebo|Placebo medication identical in appearance to active
89111371|NCT00840658|Placebo Comparator|Group A|Didactic safer injection & sexual activity education: In each city, 75 women will participate in a 60 minute lecture-format presentation and printed materials on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). In this component, there will be no theory-driven active skill building elements oriented towards safer sex or safer injection.
89111372|NCT00840658|Active Comparator|Group B|"Interactive injection risk intervention and didactic safer sex education: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] counseling session. This one-on-one intervention incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared. In addition, participants will be provided a lecture-format presentation on safer sex. However, in this component, there will be no theory-driven active skill building elements oriented towards safer sex."
89111373|NCT00840658|Active Comparator|Group C|"Interactive sexual risk intervention and didactic safer injection education: In each city, 75 women will participate in the 60 minute Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one on one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe sex and condom use with clients. In addition, participants will be provided a lecture format presentation on safer injection sharing. However, in this component, there will be no theory-driven active skill building elements oriented towards safer injection behavior."
89111374|NCT00840658|Experimental|Group D|"Interactive injection and sexual risk intervention: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] and Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one-on-one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy)."
89111375|NCT02874248|Active Comparator|Group 1: 15 mg E4/3 mg DRSP (n=10)|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
89111376|NCT02874248|Placebo Comparator|Group1: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
89111377|NCT02874248|Active Comparator|Group 2: 30 mg E4/6 mg DRSP (n=10)|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
89111378|NCT02874248|Experimental|Group 2: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
89111379|NCT02874248|Active Comparator|Group 3: 60 mg E4/12 mg DRSP (n=10)|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
89111380|NCT02874248|Placebo Comparator|Group 3: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
89111381|NCT02874248|Active Comparator|Group 4: 75 mg E4/15 mg DRSP (n=9)|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
89111382|NCT02874248|Placebo Comparator|Group 4: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
89111383|NCT02787603|Experimental|group A|Interruption of antibiotic treatment due to PCT measurement
89111384|NCT02787603|No Intervention|group B|Antibiotic therapy period will be determined by the physician without the knowledge of PCT levels.
89111385|NCT02788305||non obese|BMI<30. Misoprostol is given for induction of labour according to Bishop score
89111386|NCT02788305||obese|BMI>30. Misoprostol is given for induction of labour according to Bishop score
89111387|NCT01036724||Carto 3|Those subjects whose cases use the CARTO 3 EP Navigation System.
89111388|NCT01036724||NAVX|Those subjects whose cases use the NAVX(TM) EP Navigational System.
89111389|NCT05758012||oxytocin group|Oxytocin 5 IU will be administered by a trained anaesthetist as a one-minute IV injection.
89111390|NCT05758012||Carbetocin group|Carbetocin 100 μg will be administered by a trained anaesthetist as a one-minute IV injection.
89111391|NCT05013528|Experimental|Bal-A-Vis-X training Group|Bal-A-Vis-X training Group
89111392|NCT05013528|Active Comparator|Aerobic Training Group|Aerobic Training Group
89111393|NCT02786667|Experimental|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
89111394|NCT02786667|Placebo Comparator|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
89230569|NCT00811421|Experimental|Trial 1: IPTp-MQ (full dose) + LLITNs|HIV-negative pregnant women receiving 2 full doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
89230570|NCT00811421|Experimental|Trial 1: IPTp-MQ (split dose)+LLITNs|HIV-negative pregnant women receiving 2 doses of MQ as IPTp split dose over 2 days (15mg/kg) in the context of long lasting Insecticide Treated Nets (LLITNs
89230571|NCT00811421|Experimental|Trial 2: CTX+IPTp-Placebo+LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (placebo) in the context of long lasting Insecticide Treated Nets (LLITNs)
89230572|NCT00811421|Experimental|Trial 2: CTX + IPTp-MQ+ LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
89230573|NCT00808301|Other|A/B|This is a cross-over design, i.e. each patient is treated with either oat or control products in different times.
89111395|NCT00913276|Other|Sevoflurane anesthesia|
89111396|NCT00913276|Other|Propofol anesthesia|
89230574|NCT00808379|Other|Arm 2 (Radiation + boost )|"Radiation dose to pelvis will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Boost Field - Will be given to all the patients in the radiotherapy alone followed by surgery arm.~The boost will be given with by 3dimensional conformal radiotherapy to a dose of 15-20 Gy. After 45Gy the boost will be planned on the original tumor volume."
89230575|NCT00808379|Active Comparator|Arm 1 (standard) Chemoradiation|"The Radiation dose will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles."
89230576|NCT00808457||patients with suspected pneumonia|
89230577|NCT00569777|Experimental|K-lens|etafilcon A contact lens with ketotifen.
89230578|NCT00569777|Placebo Comparator|Placebo|etafilcon A contact lens without ketotifen
89230579|NCT00808535||diabetics|
89230580|NCT00808535||healthy controls|
89230581|NCT03868163||Glecaprevir plus Pibrentasvir|"Participants in this observational study will receive treatment with glecaprevir and pibrentasvir for up to 16 weeks for treatment of chronic hepatis C (CHC) genotypes 1, 2, 3, 4, 5, or 6.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice, international guidelines and/or label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
89230582|NCT00811811|Experimental|1|Behavioral neurocardiac training
89230583|NCT00811811|Active Comparator|2|Autogenic relaxation training
89230584|NCT00569231|Experimental|Candida Antigen|
89230585|NCT00654095|Experimental|Ezetimibe + Atorvastatin|Ezetimibe 10 mg + Atorvastatin 20 mg
89230586|NCT04016831|Other|Mapping Enhanced Counseling (MEC) only|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
89230587|NCT04016831|Experimental|Mapping Approaches to Prepare for Implementation Transfer|an implementation intervention to explore and address agency preparation needs in order to promote implementation success (includes MEC training)
89230588|NCT00808691||1|Patients with sepsis
89230589|NCT00808691||2|Patient admitted for postoperative care
89230590|NCT00808691||3|Patients with ARDS
89230591|NCT00808691||4|Patients with ARF
89230592|NCT00808691||5|Patients who receive liver support treatment
89230593|NCT00808691||6|Patients wiht brain death
89230594|NCT00811967|Experimental|Treatment Arm|
89230595|NCT00811967|No Intervention|Control Arm|
89230596|NCT02552615|Experimental|body awareness therapy (BAT)|Each session started with short warm-up, continued with specific exercises. Following each session, verbal reflexions was taken for 10 minutes. Exercises fulfilled in lying, sitting, standing and walking positions. Additionally program included vocal-breathing exercises and massage. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
89230597|NCT02552615|Active Comparator|Traditional exercises|Program included traditional exercises intended for strengthening back, abdominal, pelvis and shoulder girdle muscles and muscles in convex side of the curve, stretching exercises especially for the concave side of the curve, flexibility exercises for spine, postural training and breathing exercises. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
89111397|NCT00632658||Patients with cGVHD|Pediatric Patients with cGVHD will be asked to participate in an interview with their Physician. The interview will ask the pediatric patients questions about their cGVHD. The interview will be audio-recorded.
89230598|NCT02552615|Experimental|core stabilization exercises|Exercises started to progress from static to dynamic positions in which muscle activation incorporate into functional tasks including trunk and extremity movements. Local, global muscle stability training, global muscle mobility training and strengthening training of these core structure was carried out progressively advancing more difficult. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
89230599|NCT00812045|Experimental|1|
89230600|NCT00812045|Placebo Comparator|2|
89230601|NCT04046159|Active Comparator|Radiotherapy arm|Radiotherapy for ipsilateral whole breast with 50 Gy/25 fractions or 40.05 Gy/15 fractions
89230602|NCT04046159|Experimental|Tamoxifen arm|Tamoxifen 5 mg QD for 10 years
89230603|NCT00650585|No Intervention|Control group|Did not receive Project ALERT
89230604|NCT00650585|Experimental|Treatment group|Received Project ALERT
89230605|NCT02552069||Tritanium® cup|
89230606|NCT00653939|Active Comparator|Arm 1: Chemotherapy+Bevacizumab|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg)administered intravenously on Day 1 of a 21-day cycle for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) alone on Day 1 every 3 weeks until progression or until 12 months from randomization.
89230607|NCT00653939|Experimental|Arm 2: Active Comparator+Fosbretabulin|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg), administered intravenously Day 1 of a 21-day cycle and fosbretabulin (60 mg/m2) on Days 7, 14, and 21 for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) on Day 1 and fosbretabulin on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
89230608|NCT00812123|Experimental|Calcineurin free|Immunosuppression with Sirolimus, Mycophenolate and Steroids
89230609|NCT00812123|Active Comparator|Calcineurin|Immunosuppressive therapy with Cyclosporin A, Mycophenolate and Steroids
89230610|NCT00808925|Experimental|research arm|
89230611|NCT00809003||Sjogren's group|
89230612|NCT00809003||Dry eye|
89230613|NCT00809003||Normals|
89230614|NCT00809081|Other|1|1. Enteral Feeding
89230615|NCT00809081|No Intervention|2|Total Parental support
89230616|NCT00646451|Active Comparator|Pregabalin (Lyrica)|Pregabalin (Lyrica) 75 mg bid to a maximum dose of 300 mg bid
89230617|NCT00646451|Placebo Comparator|Placebo|Placebo to 4 capsules bid
89230618|NCT02552849||Overall study|Specific treatment, dose, and treatment duration will be decided by the investigator independently of the participation of a patient in the study.
89230619|NCT02552927|Experimental|CALF|Chest shield with aluminum foil
89230620|NCT02552927|Sham Comparator|SHIELD|Chest shield without aluminum foil
89230621|NCT00813683|Experimental|1|"Stimulation of 67 Bladder point"
89111398|NCT04302116|Experimental|Combination therapy with vigabatrin and prednisolone|"Vigabatrin (tablet of 500 mg) dose based on weight divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment. Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks.~Prednisolone (tablet of 5 mg), 40 mg of prednisolone (10 mg oral 4 times a day) for 14 days. Prednisolone will be increased to 60 mg/day (20 mg oral 3 times a day) if seizures still occur at Day 7 or recur within Day 8 - 14. Then, prednisolone will be reduced every 5 day until completely off within 1 month. Total prednisolone duration is 1 month."
89111399|NCT04302116|Active Comparator|Vigabatrin alone|"Vigabatrin (500 mg/tab) dose will be calculated on weight basis divided in two times. The protocol for vigabatrin dose is 50 mg/kg/day at Day 1, 100 mg/kg/day at Day 2, and increase to 150 mg/kg/day if seizures still occur after 72 hours after treatment.~Vigabatrin will be continued for 3 months, then reduced and completely off within 4 weeks."
89111400|NCT02786511||Subjects with multiple myeloma|Subjects treated with ex vivo gene therapy in a bluebird bio sponsored trial who agree to participate in this study.
89111401|NCT05756998|Active Comparator|classic technique|
89111402|NCT05756998|Experimental|new technique|
89111403|NCT04202562|Experimental|Combined surgery|Participants intervened of combined ab interno trabeculectomy and cataract surgery at the same time
89230622|NCT00813683|Sham Comparator|2|"Stimulation of 45 Stomach point (sham)"
89230623|NCT00809237|Experimental|Gefitinib, Hydroxychloroquine|"For the lead in phase I study, recruited patients will receive one week of 250 mg of Gefitinib, before HCQ at the assigned dose is introduced in addition to Gefitinib 250 mg om.~After the MTD of HCQ is determined, the phase II study will proceed with the combination of 250 mg of Gefitinib and the MTD dose of HCQ."
89230624|NCT00813839|Experimental|1 SmartCare|automated ventilator controlled adjustment of pressure support
89230625|NCT00813839|Active Comparator|2 spontaneous breathing Trial|daily SBT on minimum pressure support
89230626|NCT02552693|Experimental|Experimental Facility|"Enhanced training, supervision and support for MOHCC Standard Operating Procedure (SOP) implementation of identifying, tracing and returning to care (tracking and tracing) defaulting mother/infant pairs.~Facilities in the experimental group will receive additional training, supervision and support in identifying, tracing and returning to care defaulting mother/infant pairs."
89230627|NCT02552693|No Intervention|Control Facility|Facilities in the control group will be operating as described in the MOHCC SOP. (Standard practice in tracking and tracing of defaulting mother/infant pairs)
89230628|NCT02551913|Active Comparator|control|The adolescents will not receive any specific information
89230629|NCT02551913|Experimental|Intervention|The adolescents will receive relevant information on the importance of adequate sleep, the consequences of sleep deprivation, Provide information about others' approval,Provide normative information about others' behaviour,Goal setting ,action planning, coping planning, Set graded tasks,Prompt self-monitoring of sleep behaviour
89230630|NCT00817505|Active Comparator|1|AZD1656 tablet + food
89230631|NCT00817505|Active Comparator|2|AZD1656 susp. without food
89230632|NCT00817505|Active Comparator|3|AZD1656 tablet
89230633|NCT02551835||Tromso Impaired Glucose Tolerance (IGT) study|RCT on 20000 IU vitamin D3/week versus placebo for 1 year among persons with impaired glucose tolerance and/or impaired fasting glucose.
89230634|NCT02551835||Tromso OBESITY study|RCT on 20000 or 40000 IU vitamin D3/week plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 1 year among persons with a high body mass index.
89230635|NCT02551835||Tromso Bone Mineral Density (BMD) study|RCT on 40000 IU vitamin D3/week plus 800 IU/day and 1000 mg calcium/day versus placebo plus 800 IU/day and 1000 mg calcium/day for 1 year among women with a low bone mineral density.
89111404|NCT04202562|Active Comparator|Cataract surgery|Participants intervened of cataract surgery alone
89111405|NCT02788695||Group 1 - aged 20-90 years|25 participants from each decade from 20-90. Those from 50+ will be recruited from the NICOLA study and retinal/lens images assessed to confirm normality.
89111406|NCT02788695||Group 2: aged 60 years|Group 2: 250 participants NICOLA participants aged 60 will be invited to participate; only those whose ocular images confirm normality will be included.
89111407|NCT04302194||Patients with Phenylketonuria|
89111408|NCT04302194||normal healthy children|
89230636|NCT02551835||Tromso CLAMP study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <42 nmol/L.
89230637|NCT02551835||Tromso DEPRESSION study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <55 nmol/L.
89230638|NCT02551835||Styrian Vitamin D Hypertension Trial|RCT on 2800 IU vitamin D3/day versus placebo for 8 weeks among persons a history of arterial hypertension and 25(OH)D values <75 nmol/L.
89230639|NCT02551835||Paravit study|RCT on 7000 IU vitamin D3/day versus placebo for 6 months among persons with a high body mass index and 25(OH)D values <50 nmol/L.
89230640|NCT02551835||Oosterwerff study|RCT on 1200 IU vitamin D3/day plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 16 weeks among non-western immigrants with pre-diabetes and 25(OH)D values <50 nmol/L.
89230641|NCT02551835||Chel study|RCT on 600 IU vitamin D3/day (or daily equivalent) versus placebo for 4 months among nursing home residents >70 years of age.
89230642|NCT02551835||Wicherts study|RCT on 800 IU vitamin D3/day versus 100,000 IU/3 months versus sunlight advice for 6 months among non-western immigrants with 25(OH)D values <25 nmol/L.
89230643|NCT02551835||University College Cork (UCC) 1 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons > 63 years of age.
89230644|NCT02551835||UCC 2 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons 20-40 years of age.
89111409|NCT04198077|Experimental|CONSERVATIVE|Participants in the conservative group will receive the lowest FiO2 to maintain SpO2 between 94 and 98 percentage, or when available a PaO2 between 70 mmHg and 100 mmHg. A SpO2 alarm limit of 99 percent will apply whenever supplemental oxygen is being administered. The FiO2 will be reduced or oxygen supplementation discontinued whenever the SpO2 or PaO2 exceeded 98 percent or 100 mm Hg. An oxygen supplementation will be given only if SpO2 falls below 94 percent. Pre-oxygenation with FiO2 1.0 will not be performed during in-hospital transports or in anticipation of diagnostic and therapeutic manoeuvres.
89111410|NCT04198077|Active Comparator|CONVENTIONAL|In the conventional group, participants will receive a FiO2 aiming to maintain a SpO2 equal or major than 98 percentage, accepting an upper limit of PaO2 of 150 mmHg and a lower limit of 70 mmHg. The use of a FiO2 of less than 0.3 whilst ventilated is discouraged. According to standard Intensive Care Unit practice, control patients will receive a FiO2 of 1.0 during endotracheal intubation manoeuvre, airway suction or in-hospital transfers.
89111411|NCT04038268||Patients|Adults and children, males and females, with IgE mediated pollen, house dust mites, animal dander and moulds respiratory allergy who will initiate aeroallergen AIT, either SCIT, SLIT-drops or SLIT-tablets according to real life clinical standards of practice
89111412|NCT04038268||Prescribers|Doctors who are currently prescribing AIT as part of their regular clinical practice
89230645|NCT00817583|Experimental|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous intravenous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2.
89230646|NCT00817661|Experimental|1|Vitamin A group
89230647|NCT00817661|Placebo Comparator|2|Placebo group
89230648|NCT00642707|Active Comparator|Arm 1|PRO 140 for three single SC doses: Days 1, 8, and 15
89230649|NCT00642707|Active Comparator|Arm 2|PRO 140 for three single SC doses: Days 1, 8 and 15
89230650|NCT00642707|Active Comparator|Arm 3|PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
89230651|NCT00642707|Placebo Comparator|Arm 4|PBO for three single SC doses: Days 1, 8 and 15
89230652|NCT02551523|Experimental|Dolutegravir monotherapy|92 patients will be simplified to once daily dolutegravir monotherapy.
89230653|NCT02551523|Active Comparator|Standard of care combination antiretroviral therapy|46 patients will go on with standard of care combination antiretroviral therapy consisting of either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or a integrase inhibitor in combination with two nucleoside reverse transcriptase inhibitors.
89230654|NCT00814151||MicroPhage|Blood Culture positive specimens available within 24 hours of alarm.
89230655|NCT00814151||Standard of Care|Blood Culture positive specimens.
89230656|NCT00817739|Active Comparator|Continuous Therapy|Continuous complete androgen suppression therapy with leuprorelin 3.75 mg sustained release (SR), injection, subcutaneously once every 28 days and flutamide, 250 mg, tablet, orally thrice daily until there are signs of disease progression.
89111413|NCT04301960|Experimental|Single task group|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
89111414|NCT04301960|Experimental|Dual-task|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
89111415|NCT02890212|Experimental|selenium|subjects resistant to treatment of major depression with sertraline who were randomized and ingest selenium pills (400 microgram) during six weeks
89111416|NCT02890212|Placebo Comparator|placebo|subjects resistant to treatment of major depression with sertraline who were randomized and ingest placebo pills
89111417|NCT02850432|Active Comparator|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
89111418|NCT02850432|Active Comparator|Conservative treatment|rehabilitation with medical therapy
89111419|NCT05387577|Active Comparator|Sublingual Estradiol|Sublingual estradiol administered for 8 weeks
89111420|NCT05387577|Active Comparator|Oral Estradiol|Oral estradiol administered for 8 weeks
89111421|NCT05387577|Active Comparator|Transdermal Estradiol|Transdermal estradiol administered for 8 weeks
89111422|NCT02850354|Experimental|anti-g maneuvers|"Before the first parabola, pulmonary function will be evaluated. Then during each weightlessness period the subject will be instructed either to stay at rest (control condition) or to perform anti-g maneuvers (4 times each): intermittent exhalation on exertion, lower limbs and abdomen muscular contraction, combined maneuver ('intermittent exhalation on exertion' + 'muscle contraction'). Before, the exhalation on exertion, the subject will close the airway after the mouthpiece by pushing on a button actuating a pneumatic valve.~Each subject will be tested during 15 parabola where the anti-g maneuvers will be performed in randomized order. After the 15th parabola, pulmonary function will be again evaluated."
89111423|NCT02787759|Active Comparator|Hands-Free Walking|Body-weight supported treadmill training
89230657|NCT00817739|Experimental|Intermittent therapy|Intermittent complete androgen suppression therapy starting at randomization with interruption of treatment given in the induction period until PSA levels reach >=10 ng/mL or other signs of progression appear. Upon treatment resumption, leuproreline 3.75 mg SR, injection, subcutaneously once every 28 days and flutamide 250 mg, tablet, orally thrice daily, until PSA levels are <normal (that is, <4 ng/mL) and no signs of disease progression appear. The intermittent therapy will be continued similarly until the study end or the appearance of signs of disease progression under treatment.
89230658|NCT00817895|Experimental|5-FU+Cisplatin|50 HCC patients will be implanted 600mg sustained released 5-FU and 60mg sustained released cisplatin into liver incisal margin after tumor is resected.
89230659|NCT00817895|Active Comparator|5-FU|50 HCC patients will be implanted 600mg sustained released 5-FU into liver incisal margin after tumor is resected.
89230660|NCT00817895|Experimental|control|
89230661|NCT00814229|Active Comparator|Vaccine 1|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
89230662|NCT00814229|Active Comparator|vaccine 2|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
89230663|NCT00814229|Active Comparator|Vaccine 3|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
89111424|NCT02787759|Experimental|Challenge Based plus Hands-Free|9 different balance and locomotor challenges applied during walking while not holding onto anything
89111425|NCT01052714|No Intervention|Usual Care|Control group with time-matched study visits
89111426|NCT01052714|Active Comparator|Lifestyle Balance|Weight management group education and individual counseling
89111427|NCT01052714|Other|Usual Care then Lifestyle Balance|Participants originally randomized to Usual Care, allowed to change over to Lifestyle Balance at month 6 per their request.
89111428|NCT02837406||Doctors|specialists and general practitioners by ich territory
89111429|NCT02837406||Health professionals|"pharmacists~nurses~physiotherapists~Medical and social professionals: social workers, psychologists, educators ..."
89111430|NCT02837406||Medical-social institutes|"Hospital,~Healthcare structure,~Local Centre of Information and Gerontological Coordination ..."
89111431|NCT02786433|Active Comparator|GROUP CONTROL|"Participants in the control group only underwent conventional physiotherapy. Conventional therapy includes stretching and strengthening exercises with cane aid, leggings , elastic band and overball for upper and lower limbs , in addition to gait and balance training.~The intervention for the control group was applied for five weeks with sessions of 60 minutes twice a week"
89111432|NCT02786433|Experimental|EXPERIMENTAL GROUP|The subjects in the experimental group underwent conventional physiotherapy (The same applied in the control group) associated with virtual reality , performed with the console X -Box Kinect® of Microsoft. Durante the achievement of the virtual reality practice, Kinect and Kinect games Adventures® Dance® demanded the anterior movements players -posterior and lateral , as well as jumps and squats to get rid of the game obstacles. They Kinect Dance® game were all required movements of the previous game more dance . The intervention lasted five weeks , with two weekly sessions lasting 30 minutes to conventional therapy and 30 minutes to virtual reality.
89111433|NCT03573609|No Intervention|Control|Usual respiratory care
89111434|NCT03573609|Active Comparator|Supranav|"Respiratory care with supranav which is a continuous supraglottic suction device"
89111435|NCT04702620||healthy children without symptoms|healthy children without symptoms
89111436|NCT04702620||sick children without wheezing|sick children without respiratory wheezing
89111437|NCT04702620||sick children with respiratory wheezing|
89111438|NCT05385393|Experimental|Arthroscopic posterior capsulotomy of the knee|
89111439|NCT02850120||Unconfounded|"All hospital admissions including Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with:~no concomitant procedures,~any concomitant procedures which were considered unlikely to have an effect on outcomes from their mesh insertion, or~only other concomitant procedures which were considered likely to be rescue procedures treating complications caused by the mesh insertion procedure itself."
89111440|NCT02850120||Confounded|All hospital admissions for insertion of Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with concomitant procedures likely to affect outcomes.
89111441|NCT05383677|Active Comparator|Anifrolumab|20 patients will receive anifrolumab treatment
89111442|NCT05383677|Placebo Comparator|Placebo|10 patients will receive placebo treatment
89111443|NCT02849964||First time renal replacement therapy|Patients beginning renal replacement therapy by renal dialysis or preemptive kidney transplant.
89111444|NCT02850042|Experimental|Occupation-based practice|Occupation-based intervention (OBP) is a form of activity-based therapy consisting of client-directed occupations that match client-identified goals. OBP group will participate in activities such as wood working, scrap booking, higher level dressing (don/doffing a bra, zipping coat), hair care, opening doors, using bathroom stalls, typing, cooking, tying shoes, washing dishes, carrying dirty dish carts, clearing dirty dishes and raking. Repetition of the tasks are not the focus in the OBP group. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
89111445|NCT02850042|Active Comparator|Modified-constraint induced therapy|Modified-constraint induced therapy (m-CIT) group will target functional goals (eg, activities of daily living) or goal subcomponents (eg, pinching, grasp/release, or functional reach patterns). Tasks were repeated at rate of approximately 10 to 50 repetitions each session according to the demands of the task. No physical constraint of the less-affected UE will be applied, but training compelled highly repetitive use of the more-affected upper extremity. Subjects will attempt tasks with progressive difficulty. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
89111446|NCT03742635|Experimental|GMA Assessment|"Conduct General Movements Assessment (GMA) in-person/via-telemedicne (real-time) and recorded (standard of care)"
89111447|NCT02785575|Active Comparator|HeProCalc|This arm receives heparin and protamine doses according to the novel HeProCalc calculation model.
89111448|NCT02785575|No Intervention|Traditional calculations|This arm receives heparin and protamine doses according to the standard protocol (using calculations with body weight and ACT)
89111449|NCT05058144|Experimental|novel alpha glucan|50g novel alpha glucan dissolved in 300ml water
89111450|NCT05058144|Active Comparator|glucose syrup|50g dissolved in 300ml water
89111451|NCT05058144|Active Comparator|Inulin|15g Inulin dissolved in 300ml water
89230664|NCT00814229|Active Comparator|Vaccine 4|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
89230665|NCT00814229|Active Comparator|Vaccine 5|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
89230666|NCT00814229|Active Comparator|Vaccine 6|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
89230667|NCT00814229|Active Comparator|Vaccine 7|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
89230668|NCT00814229|Active Comparator|Vaccine 8|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
89230669|NCT00814229|Active Comparator|Vaccine 9|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
89230670|NCT00814229|Active Comparator|Vaccine 10|influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection
89230671|NCT00814229|Active Comparator|Vaccine 11|influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection
89230672|NCT00814229|Active Comparator|Vaccine 12|influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection
89230673|NCT00814229|Active Comparator|Vaccine 13|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
89230674|NCT00814229|Active Comparator|Vaccine 14|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
89230675|NCT00568685|Active Comparator|Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day)|
89230676|NCT00568685|Active Comparator|Atomoxetine 0.5 mg/kg/day|
89230677|NCT00568685|Active Comparator|Atomoxetine 1.2 mg/kg/day|
89230678|NCT00814385|Active Comparator|Vaccine arm 1|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
89230679|NCT00814385|Active Comparator|Vaccine arm 2|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
89230680|NCT00814385|Active Comparator|Vaccine arm 3|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
89230681|NCT00814385|Active Comparator|Vaccine arm 4|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
89230682|NCT00814385|Active Comparator|Vaccine arm 5|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
89111452|NCT04232709|No Intervention|After-hours care|Patients in the after-hours care (AH) group will receive the usual (telemedicine) care. That is, they will have the option to call the after-hours centre and receive help from the oncology nurses using the COSTaRS practice guides to manage their after-hours symptoms.
89111453|NCT04232709|Experimental|After-hours care w/personal health info|Patients in the after-hours care with personal health information (AH-PHI) group will also receive the usual (telemedicine) care. However, if they call the telemedicine service, the oncology nurses will have access to some of their personal health information from the cancer centre (i.e., a shared electronic patient record) via the MedChart platform.
89111454|NCT04232241|Active Comparator|Treatment A|Allogeneic stem cell transplantation from 10/10 HLA matched unrelated donor
89111455|NCT04232241|Experimental|Treatment B|Allogeneic stem cell transplantation from haploidentical donor
89111456|NCT01372254|Active Comparator|Standard smoking cessation|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
89111457|NCT01372254|Experimental|BA for substance abusing smokers|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
89111458|NCT04217616||Headache Resistant Participants|Male participants who have never had a headache.
89111459|NCT04217616||Non-Resistant Participants|Male participants who have experienced headache. Age matched.
89111460|NCT02785653|Experimental|sevoflurane and rocuronium|After induction of general anaesthesia, patients in the sevoflurane group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen with 2% inspired concentration of sevoflurane. After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
89111461|NCT02785653|Active Comparator|rocuronium|After induction of general anaesthesia, patients in the control group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen . After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
89111462|NCT01052480|Experimental|Plasma and Standard Care|Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies (Anti-Influenza Immune Plasma) in addition to standard care.
89111463|NCT01052480|Active Comparator|Standard Care|Participants will receive standard care.
89111464|NCT02787447|Experimental|1|After 3 mos TKI, patients showed stable disease take TKI, radiotherapy and thymosin alpha 1 till tumor progression.
89111465|NCT00904722|Experimental|CT-011 in combination with Rituximab|Combination of the immunotherapy drugs, CT-011 and rituximab.
89111466|NCT02909361||Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
89111467|NCT02873858|Active Comparator|1.independent patients|
89111468|NCT02873858|Experimental|2. less mobile patients|
89111469|NCT02873858|Experimental|patient in a residence|
89111470|NCT02873858|Experimental|patients in a home for the elderly (EHPAD)|
89111471|NCT00627068||1|High cardiovascular risk age over 61 years.
89111472|NCT00627068||2|Low Cardiovascular risk age over 61.
89111473|NCT00627068||3|High cardiovascular risk age over 25 but under 61.
89111474|NCT00627068||4|Low cardiovascular risk age over 25 under 61.
89111475|NCT02787525||A: patients on anticoagulation|Questionnaire to patients with non-valvular atrial fibrillation on OAC or NOAC
89111476|NCT02787525||B: patients treated by LAA-Closure|Questionnaire to patient with non-valvular atrial fibrillation who underwent LAAC between 2009 and 2014 at the University hospitals Bern or Zurich
89111477|NCT04301024||nitrous oxide misusers|nitrous oxide misusers among the teenagers consulting in an addictology center dedicated to young drug users in Montpellier
89111478|NCT02849886|Experimental|LT icasp9 ΔCD19 (cohort1)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 Gene Modified Cells (GMC)/kg).
89111479|NCT02849886|Experimental|LT iCASP9 ΔCD19 & GvHD (cohort2)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 GMC/kg). Patients who develop GVHD after administration of Gene Modified Cells (GMC) will be treated with dimerizer drug (AP1903)
89111480|NCT02785497|Experimental|Treatment group|"Chronic ulcer patients will be treated with 50 minutes of the high-voltage current or 10 minutes of the diadynamic current. To burn patients 50 minutes high voltage current in the donor area. For both group the metal electrodes will be sterilized and the negative polarity in the active electrode.~50 min, 100Hz, intensity according to the sensitivity patient - High Voltage; 10 min, intensity according to the sensitivity patient - Diadynamic"
89111481|NCT02785497|Sham Comparator|Control group|"For the control group the unit is turned on, the time will pass but will not be given intensity~50min, 100Hz, Intensity according to the sensitivity patient"
89111482|NCT01340430|Experimental|FEC-paclitaxel-trastuzumab|fluorouracil 600 mg/m2; epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2 for 4 cycles followed by paclitaxel 80 mg/m2/week in combination with trastuzumab for 12 weeks
89111483|NCT01029782|Active Comparator|IV cefazolin plus oral probenecid and placebo cephalexin|
89111484|NCT01029782|Active Comparator|Oral cephalexin and saline IV plus probenecid placebo|
89111485|NCT04232319|Experimental|Sleep Hygiene Training|The intervention will be delivered online by an occupational therapist. The intervention consists of 3 weekly sessions; each session will be 30-45 minutes long. The focus of the intervention is to teach breast cancer survivors sleep hygiene strategies to improve their sleep.
89230683|NCT00814385|Active Comparator|vaccine arm 6|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
89111486|NCT01146990||Infants Born to Mothers in the 17P-ES-003 Study|Infants Born to Mothers Who Participated in the 17P-ES-003 Study and whose mothers consented for them to be followed for this study.
89111487|NCT04232007|Experimental|Closed-loop|Closed-loop system to titrate vasopressor during surgery
89111488|NCT02785419|Experimental|Arm Training with Action Selection|Task-oriented, functional arm training with the addition of action selection cues to practice. All participants receive the same arm training intervention.
89111489|NCT04583748|Experimental|Sahaj Samadhi Meditation|Participants randomized to the Sahaj Samadhi Meditation (SSM) arm will undergo SSM training in groups of 10. SSM will be delivered virtually using the Cisco WebEx platform by trained, certified non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
89111490|NCT04583748|Active Comparator|Health Enhancement Program|Participants randomized to the Health Enhancement Program (HEP) arm will undergo HEP training in groups of 10. HEP will be delivered virtually using the Cisco WebEx platform by trained non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
89111491|NCT04583748|No Intervention|Treatment as Usual|Participants randomized to the Treatment as Usual (TAU) arm will continue to receive their treatment as usual. The usual standard of care for irreversible age-related vision patients includes no active treatment since eye surgeons have done all that could possibly be done to restore vision.
89111492|NCT02785341|Other|Immediate adaptated physical activity (Group A)|"Group A began a physical activity program for 12 consecutive weeks from inclusion in the protocol, then underwent the usual care for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
89111493|NCT02785341|Other|Without immediate adaptated physical activity (Group B)|"Group B followed the usual care for 12 weeks then started the physical activity program for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
89111494|NCT02849808||Keratoplasty patients|All patients who underwent one or more keratoplasties since january 1983.
89111495|NCT02901717|Active Comparator|Standard of Care|Antibiotic lock + standard of care antibiotics. The standard of care antibiotic will be chosen by the investigator at the time of the infection.
89111496|NCT02901717|Experimental|Mino-Lok Therapy (MLT)|Standard of care plus MLT. MLT contains minocycline with EDTA and ethanol.
89111497|NCT02849730||Young adults|Patients aged 20 to 39 who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
89111498|NCT02849730||Elderly patients|Patients aged 70 and over who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
89111499|NCT02786043|Experimental|Single arm|
89111500|NCT03530163|Experimental|Respiratory Muscle Training|
89111501|NCT03530163|Sham Comparator|Sham Breathing Training|
89111502|NCT02785965|Experimental|acupuncture & lifestyle modification|Electro-acupuncture is given three times a week with diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks.
89111503|NCT02785965|Active Comparator|lifestyle modification|diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks
89111504|NCT04682028|Other|experiment group|Nurses provide web-based continuous care to patients.
89111505|NCT04682028|Other|contral group|Nurses provide the routine care to patients.
89111506|NCT04232397|Experimental|therapy|therapy with 1 arm. Anlotinib 8mg qd po。
89111507|NCT02786199||Hepatocellular carcinoma|patients HCC who are going to receive surgical resection
89111508|NCT02785887|Experimental|Oncological and geriatrician review|Routine oncological care plus geriatric intervention
89111509|NCT02785887|No Intervention|Oncological care|Routine oncological care only
89111510|NCT02849340|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89111511|NCT02849340|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89111512|NCT02785731||Women with a pelvic mass|Women diagnosed with a pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass) who are scheduled for a laparotomy or laparoscopy for removal of the pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 60 days prior to surgery.
89111513|NCT02787213||Women with preterm delivery|
89111514|NCT02787213||Women without preterm delivery|
89111515|NCT03936192|Experimental|glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)|glucosamine sulfate 1500mg plus meloxicam 15mg combination, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
89111516|NCT03936192|Active Comparator|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg plus Chondroitin Sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.
89111517|NCT03936192|Placebo Comparator|Placebo|Placebo administered once daily for 12 weeks
89230684|NCT00814385|Active Comparator|Vaccine arm 7|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
89230685|NCT00814385|Active Comparator|Vaccine arm 8|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
89111518|NCT02845635||Relapsing Remitting Multiple Sclerosis|Those who document during the study on-boarding process that they suffer from relapsing-remitting multiple sclerosis.
89111519|NCT02845635||Primary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from primary progressive multiple sclerosis.
89111520|NCT02845635||Secondary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from secondary progressive multiple sclerosis.
89111521|NCT02845635||Control|This who document during the on-boarding process that they do not suffer from multiple sclerosis.
89111522|NCT02847390||Pre-implementation group|"The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes education intervention to our staff over a 6-month time frame from August 2016-January 2017. The investigators will use a before and after study design to assess the impact of the educational intervention on hospital-wide hypoglycemia and hyperglycemia.~Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/16 to 6/30/16)."
89111523|NCT02847390||Post-implementation group|Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/17 to 6/30/17).
89111524|NCT02787135|Active Comparator|CBTd-E|Experimental: emotion-oriented Cognitive Behavior Therapy focused on delusions for patients with schizophrenia-spectrum disorders and delusions. The therapeutical intervention follows a treatment-manual consisting of two modules. Patients work on two modules every week for 25 weeks in a row. Module I comprises psychoeducation on emotions, training radical acceptance of emotions and mindfulness, cognitive and behavioral strategies in order to change negative emotions and in order to foster positive emotions and suggestions for life-style changes (positive activities, sports, stress reduction). In the second module, the focus is on self-acceptance. Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
89111525|NCT02787135|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait-list receive treatment as usual (regular visits to a physicist every third month and antipsychotic medication). After six month the waiting list patients receive the treatment specified above.
89111526|NCT01029704|Experimental|EGT0001442|
89111527|NCT01029704|Placebo Comparator|Placebo|
89111528|NCT02786979|Experimental|Beraprost sodium tablet and Aspirin combination group|Oral
89111529|NCT02786979|Experimental|Aspirin Group|Oral
89111530|NCT02689869|Experimental|Ibrutinib and GA 101|"Initial therapy 6 cycles of Ibrutinib:~Ibrutinib 560 mg once daily every day until start of maintenance for a total of 24 weeks.~1000 mg of GA101 I.V. on days d 1, 8, 15 of cycle 1 and on day 1 of cycles 2-6 (21 day cycles).~Maintenance with another 24 months of ibrutinib plus GA101 in patients with clinical remission after the last induction cycle:~Ibrutinib 560 mg once daily every day. GA101 at a dose of 1000 mg I.V. every 2 months for a total of 24 months. The total duration of ibrutinib plus obinutuzumab therapy will therefore be 30 months.~In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months."
89111531|NCT04457700||Triple-negative and HER2 Positive breast cancer|Patients with triple-negative or HER2 Positive breast cancer, axillary lymph node metastasis who underwent NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis. CT-based radiomics will be uesd in evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast cancer patients.
89111532|NCT02847312|Active Comparator|High avenanthramide, phenolic acid|66.8g Pepsico Oatmeal + 60g Oat cake
89111533|NCT02847312|Active Comparator|Low avenanthramide, medium phenolic acid|17g Oatwell + 63.6g Cream of Rice + 60g Melba Toast
89111534|NCT02847312|Placebo Comparator|Control|69.8g Cream of Rice + 8.1g Cellulose + 4.8g Pectin + 60g Melba Toast
89111535|NCT02847156|Other|cystic fibrosis infants|1 year follow-up in CF infants
89111536|NCT04200105|Active Comparator|EBUS TBNA|Patients will undergo a standard EBUS examination, with sampling using a standard 22G EBUS needle.
89111537|NCT04200105|Experimental|Acquire TBNB|Patients will undergo a standard EBUS examination, with sampling using an Acquire TBNB needle.
89111538|NCT02849262|Experimental|Omiganan (CLS001)|CLS001 Topical Gel, 2.5%
89111539|NCT02849262|Placebo Comparator|Vehicle|Vehicle Topical Gel
89230686|NCT00814385|Active Comparator|Vaccine arm 9|No priming dose and single dose MF59 adjuvanted H5N1 vaccine at 52 weeks
89230687|NCT04044911|Active Comparator|Tea making followed by stepping|Five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (CogWatch) is followed after a 3-week break by a control condition in which participants receive five 1-hour weekly stepping training sessions.
89230688|NCT04044911|Active Comparator|Stepping followed by tea making|A control condition comprising five 1-hour weekly stepping training sessions is followed after a 3-week break by five 1-hour weekly tea making training sessions in which progress is monitored and feedback given using a computer-based system that implements a Markov Decision Process (MDP) task model (COgWatch)
89230689|NCT04045457|Other|SIngle arm|Single arm, intervention All recipients were treated with dry needling technique into active myofascial trigger points They received 1 treatment weekly for three weeks.
89230690|NCT02551601||Healthy volunteers|to measure the subfoveal choroidal thickness in healthy volunteers
89230691|NCT00061945|Experimental|Treatment (alemtuzumab and combination chemotherapy)|See detailed description.
89230692|NCT00817973|Active Comparator|Casein|
89230693|NCT00817973|Active Comparator|Whey|
89230694|NCT00817973|Active Comparator|Cod|
89230695|NCT00817973|Active Comparator|Gluten|
88805832|NCT05031806|Placebo Comparator|Vehicle (eye drop formulation without aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
88805833|NCT01899404|Experimental|18-FDG PET/CT, DWI, DCE-MRI|
89111540|NCT02341911|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
89111541|NCT02341911|Active Comparator|Gemcitabine,carboplatin|GC (gemcitabine and carboplatin combination)
89111542|NCT02849028||TBI Patients with sleep disorder|All the patients should be diagnosed by polysomnographic (PSG)
89111543|NCT02849028||health people|The people have a normal sleep
89111544|NCT04200261|Experimental|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
89111545|NCT04200261|Placebo Comparator|placebo|sodium chloride injection Once daily for 7 days
89111546|NCT02847000|Experimental|Decitabine + Tetrahydrouridine|Tetrahydrouridine (THU) is supplied as 250 mg/capsule, Decitabine (Dec) as 5 mg/capsule.
89111547|NCT02784327|Experimental|PRF110- oily solution|Post-operative application of new extended release PRF110- oily solution (Ropivacaine)
89111548|NCT03362541|Experimental|MS INFoRm group|Participants in the MS INFoRm group will be given a login and password that will take them to the MS INFoRm webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
89111549|NCT03362541|Active Comparator|Usual care control group|Participants in the usual care group will be given a login and password that will take them to a usual care webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
89111550|NCT02849106|Experimental|biopsy to obtain a chemogram|
89111551|NCT04231149|Experimental|Test product 2|Test catheter 2
89111552|NCT04231149|Experimental|Test product 3|Test catheter 3
89111553|NCT04231149|Active Comparator|Comparator|SpeediCath Flex
89111554|NCT04202250|Active Comparator|CEMP (closed-ended multiport catheter) group|closed-ended multiport femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
89111555|NCT04202250|Active Comparator|OESP (open-ended single port catheter) group|open-ended single port femoral nerve catheter will be included in the patients undergoing total knee arthroplasty surgery for postoperative analgesia
89111556|NCT02784249|Experimental|Goniotomy|Procedure: Goniotomy and trabecular excision in combination with planned cataract extraction via Phaco and PCIOL implant.
89111557|NCT02784249|Active Comparator|Trabecular Micro-Bypass Stent|Procedure: Device implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
89111558|NCT04908462|Experimental|Part A Healthy volunteers: Single ascending doses|
89111559|NCT04908462|Experimental|Part B Healthy Volunteers Multiple ascending doses|
89111560|NCT02850510|Experimental|Brief Incredible Years parent training|Parent training
89111561|NCT02850510|No Intervention|No parent training|No parent training
89111562|NCT02845050|Experimental|Vinflunine+Cisplatin+radical cystectomy|neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
89111563|NCT02690922|Experimental|ph+ ALL with dasatinib|patients in the arm are newly diagnosed ph+ ALL,the patient first receive dexamethasone as pretreatment,then dasatinib and prednisone are used as inductive treatment,and methotrexate to consolidate the therapy.
89111564|NCT02846844||Group A|"Whole body vibration training~manuelle therapy~exercises for power and coordination~performance training as needed"
89111565|NCT02846844||Group B|"manuelle therapy~Exercises for power and coordination~Performance training as needed"
89111566|NCT03890718|Experimental|Photorefractive keratectomy in mile keratoconus|Photorefractive keratectomy in mile keratoconus type of corneal surface ablation in for correct refractive error
89111567|NCT00840034|Experimental|LY2216684|
89111568|NCT00840034|Placebo Comparator|Placebo|
89111569|NCT02848950|Active Comparator|treatment|drug: metformin
89111570|NCT02848950|No Intervention|control|without metformin
89111571|NCT00580710||conventionally treated|conventionally treated, relatively poorly controlled patients with type 1 diabetes
89111572|NCT00580710||intensively treated|intensively treated, well controlled patients with type 1 diabetes
89111573|NCT00580710||lean healthy|age- and sex- matched non-diabetic, normal weight (BMI > or = 18.5 but < or = 25 kg/m2) control subjects
89111574|NCT00580710||obese subjects|obese individuals defined as BMI > or = 30kg/m2
89111575|NCT00580710||type 2 diabetics|Type 2 diabetics on diet only or diet and Metformin
89111576|NCT00580710||type 1 diabetes unaware|Type 1 diabetics unaware of hypoglycemic symptoms
89111577|NCT00580710||type 1 diabetes aware|Type 1 diabetics aware of hypoglycemic symptoms
89111578|NCT02846610||regional anesthesia|surgical patients (age: 0-100 years) having regional anesthesia along with the procedure and postoperative course
89111579|NCT02846610||systemic analgesia|surgical patients (age: 0-100 years) having systemic analgesia along with the procedure and post procedure course
89111580|NCT00813904|Experimental|rThrombin, 1000 IU/mL|
89111581|NCT04202406|Experimental|Acetaminophen, codeine,and caffeine|Oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine.
89111582|NCT04202406|Experimental|Acetaminophen|Oral single dose of 1000mg acetaminophen.
89111583|NCT04202406|Placebo Comparator|Placebo|Maize starch.
89111584|NCT02846766|Experimental|Lenvatinib|The starting dose of lenvatinib will be 24 mg orally per day. The duration of one cycle is defined as 28 days (4 weeks). Subjects will be treated for 2 cycles (8 weeks) and then restaged. Subjects will continue study drug until progression or unacceptable toxicity occurs.
89111585|NCT00839956|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89111586|NCT04905732|Experimental|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
89111587|NCT04905732|Active Comparator|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
89230696|NCT00818051|Active Comparator|Arm I (control)|Patients undergo sequential boost dose intensity-modulated radiotherapy (IMRT) 5 days a week for 4.6 weeks (23 fractions; 56 Gy).
89230697|NCT00818051|Experimental|Arm II|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 48 Gy).
89230698|NCT00818051|Experimental|Arm III|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 53 Gy).
89230699|NCT01097941|Active Comparator|LAIV/LAIV|
89230700|NCT01097941|Active Comparator|IIV/IIV|
89230701|NCT01097941|Active Comparator|IIV/LAIV|
89230702|NCT00642473|Experimental|Prevention (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated at the same day as the start of erlotinib. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
89230703|NCT00642473|Experimental|Treatment (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated when participants develop rash. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
89230704|NCT00818129|Experimental|1|
89230705|NCT00818129|Placebo Comparator|2|
89230706|NCT00645671|Experimental|Loteprednol Etabonate|Loteprednol etabonate 0.5% ophthalmic ointment
89230707|NCT00645671|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ointment
89230708|NCT00366340|Experimental|1|13-valent pneumococcal conjugate vaccine
89230709|NCT00366340|Active Comparator|2|7-valent pneumococcal conjugate vaccine
89230710|NCT03992326|Experimental|TIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Low Dose Irradiation (LDI), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
89230711|NCT01049386|Active Comparator|Sugar absorption test|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine.
89230712|NCT01049386|Experimental|Sugar absorption test and high-fat breakfast|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine. Subjects will eat a high-fat breakfast together with the sugar drink, to investigate the disturbance caused by fat in intestinal absorption.
89230713|NCT01046032|Active Comparator|Metformin|Drug (including placebo)
88805834|NCT01898546|Experimental|Primary angioplasty and postconditioning|Primary angioplasty followed by postconditioning
89111588|NCT04545528||Test group|100 Patients that were referred to our stone clinic for follow up with risk factors for stone recurrence like metabolic syndrome and diabetes, uric acid stones etc. In addition to seeing our urologist and nephrologist these patients will also be referred to a nutritionist in order to balance risk factors and will be followed for one year with our usual blood tests and imaging
89111589|NCT04545528||Control group|100 Patients that were referred to our stone clinic for follow up without risk factors for stone recurrence will see our urologist and nephrologist and will be followed for one year with our usual blood tests and imaging
89111590|NCT02844738|Experimental|StroMed + platelet rich plasma (PRP)|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
89111591|NCT02844426|Placebo Comparator|Placebo|patients allowed to take maltodextrin by the experienced doctor.
89111592|NCT02844426|Experimental|synbiotic|patients are allowed to take synbiotic (BIFICOPEC) contained 0.63g bifid triple viable capsule (BIFICO) and 8g soluble dietary fiber (Pectin) .
89111593|NCT04212312||Single course of Betamethasone|Women with twin pregnancy who received 1 course of betamethasone between 24 - 34 weeks' gestation.
89111594|NCT04212312||Repeat course of Betamethasone|Women with twin pregnancy who received 2 courses (Repeat course) of betamethasone between 24 - 34 weeks' gestation.
89111595|NCT00839800|Experimental|1|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
89111596|NCT00839800|Active Comparator|2|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
89111597|NCT00867321|Experimental|Arm I (Phase II)|Patients receive oral sorafenib tosylate on days 1-28 twice daily and bevacizumab IV on days 1 and 15.
89111598|NCT00867321|Experimental|Arm II (Phase II)|Patients receive oral sorafenib tosylate twice daily on days 1-28.
89111599|NCT00753415|Experimental|Part A: V935 LD|Two intramuscular (IM) injections of V935 low dose (LD), 1 given every other week over a 3-week period.
89111600|NCT00753415|Experimental|Part A: V934 LD(3)+V935 LD|Three electroporation (EP) injections of V934 (LD) , 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (LD) will be administered, 1 given every other week over a 3-week period.
89111601|NCT00753415|Experimental|Part A: V935 HD|Two IM injections of V935 high dose (HD), 1 given very other week over a 3-week period.
89111602|NCT00753415|Experimental|Part A: V934 HD(3)+V935 HD|Three EP injections of V934 (HD), 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
89111603|NCT00753415|Experimental|Part A: V934 HD(5)+V935 HD|Five EP injections of V934 (HD), 1 given every other week over a 9-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
88805835|NCT01898546|Active Comparator|Primary angioplasty|Primary angioplasty alone
88805836|NCT04389008||Postoperative death|
89111604|NCT00753415|Experimental|Part B: V935 LD/V934 Booster|Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.
89111605|NCT00753415|Experimental|Part B: V934 LD(3)+V935 LD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
89111606|NCT00753415|Experimental|Part B: V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
89111607|NCT00753415|Experimental|Part B: V934 HD(3)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
88805837|NCT04389008||Postoperative non-death|
88805838|NCT00216320|Experimental|WalkAide|Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
88805839|NCT00216320|Active Comparator|Ankle Foot Orthosis|Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
89111608|NCT00753415|Experimental|Part B: V934 HD(5)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
89111609|NCT00913666|No Intervention|Group 1|Healthy Volunteers
89111610|NCT00913666|Experimental|Group 2|MS patients previously naïve to interferon therapy
89111611|NCT00913666|Experimental|Group 3|MS patients on Interferon beta-1a treatment with no history of breakthrough disease (clinically stable)
89111612|NCT00913666|Experimental|Group 4|MS patients on interferon beta-1a treatment with a history of breakthrough disease.
89111613|NCT05194137|Active Comparator|a proprioception protocol associated with vaginal palpation and feedback (CG)|"The participants of CG will be placed in the supine position with flexion of the hip and knee and feet supported on the stretcher. Vaginal palpation will be used as a proprioceptive resource to facilitate PFM voluntary contraction. The physiotherapist responsible for conducting the treatment, wearing gloves, will perform a one or two-finger vaginal palpation, depending on participant's vaginal canal.~Positive reinforcements will be verbalized after each PFM contraction. The training protocol will be tailored, and the evolution will be the same for CG and BPFMT."
89230714|NCT01046032|Placebo Comparator|Sugar pill|Drug (including placebo)
89111614|NCT05194137|Experimental|a proprioception protocol associated with biofeedback (BG)|The participants of BG will receive the same protocol of CG but associated with biofeedback with an electromyographic sensor through the Miotol equipment (Miotec, Brazil). The participants of the BG will also be positioned in the same position described to CG. The electromyographic sensor will be covered with neutral gel and inserted into the participant's vaginal canal. Participants will see the visual response of the contraction on the computer screen. The software has five different interfaces for visualize PFM contraction and each participant will be able to choose the one that she prefers at each session. The training protocol will be tailored, and the evolution will be the same for CG and BG. During the first session, it will be explained what is biofeedback and what means everything that appears on the software interface.
89111615|NCT02782611|Experimental|Treatment|ENHANCE (Enduring Happiness and Continued Self-Enhancement) is a 12-week program that includes an introductory session, 10 weekly sessions focusing on different happiness principles, and a final session focusing on integrating aspects of the program and continuing to practice these principles moving forward. Through completing this program, participants will gain an education on a wide-range of happiness principles and an arsenal of strategies for developing happiness boosting habits and skills.
89111616|NCT02782611|No Intervention|Waiting Group Control|The waiting group control will complete the same assessments as the experimental group but without receiving the intervention.
89111617|NCT00754741|No Intervention|Usual care|All Physicians are given limited training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software when they see patients assigned to this arm
89111618|NCT00754741|Active Comparator|Adherence|
89111619|NCT00754741|Active Comparator|Adherence Plus|
89111620|NCT05342649|Experimental|Main treatment group|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
89111621|NCT05342649|Active Comparator|Control group|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
89111622|NCT05308095|Experimental|Intervention group|
88805840|NCT00216320|Other|No Crossover|Subjects wear AFO for entire 12 weeks with no crossover
88805841|NCT00217490|Experimental|Computer Only|Dietary Counseling delivered by interactive computer program, without the addition of individual counseling provided by a health counselor. This arm tested a completely automated counseling program that did not include personalized behavioral counseling provided by a study staff member.
89230715|NCT01046188|Experimental|Web-based Teaching Group|Patients randomized to the intervention group will receive a unique login and password to a link on the Ottawa Fertility Centre website. This will allow them access to a secure site containing required teaching modules. They will then complete an interactive teaching tool that contains the same educational content as the traditional presentation. Patients will be able to access a module that is specific to their stimulation protocol. The teaching tool does not need to be completed all at one time. Once completed, the information can still be accessed as many times as required.
88805842|NCT00217490|Experimental|Counseling only|In this arm, dietary counseling was delivered by nutritionist, and this counseling did not include use of an automated, computer program.
89111623|NCT02601391|Other|STEPPS within forensic services.|"Forensic inpatients attend the STEPPS-HI group. Consent will be obtained. Pre and post group psychometric questionnaires will be completed as well as each service user attending a short semi-structured interview following the conclusion of the group .~Primary nurse will fill in pre and post group questionnaires. Facilitators will complete short feedback forms each session and attend a focus group upon completion.~Psychology Assistants/Interns will collect records of self harm and violence/aggressive incidents for each service user as well as records of nursing observation level and leave status taken."
89111624|NCT02538861||ARM-A|Arm-A patients will receive the standard of care diagnostic test at Baptist Hospital, which includes SPECT imaging
89111625|NCT02538861||ARM-B (Group-1)|Group-1 will receive CT Angiography and CT myocardial perfusion with new Revolution CT scanner.
89111626|NCT02538861||ARM-B (Group-2)|The Group-2 of arm B will receive SPECT imaging test.
89111627|NCT02601157|Experimental|Orsiro SES or CX-ISAR/3-months DAPT|Patients allocated to this group will be implanted with Orisro sirolimus-eluting stents or Corflex ISAR stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
89111628|NCT02601157|Active Comparator|Orsiro SES or CX-ISAR/1-year DAPT|Patients allocated to this group will be implanted with Orisro sirolimus-eluting stents or Coroflex ISAR stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
89111629|NCT02785107|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
89111630|NCT02785107|No Intervention|Control|Participants exercised on their own without receiving any instructions.
89111631|NCT02784873|No Intervention|Usual care|"Usual care cardiac rehabilitation with exercise training as per current guidelines~Warm up: 15 mins, < 40% heart rate reserve (HRR) Cardiovascular component: progress towards 20 - 40 mins continuous cardiovascular exercise at 40-70% HRR.~Muscular strength and endurance programme. Cool down: 10 mins, < 40% HRR. Initial duration based on participant's previous and current physical activity (PA) levels and cardiopulmonary exercise test (CPEX) performance.~Duration and workload of cardiovascular component adjusted, as tolerated, within the above parameters, in response to exercising heart rate (HR), participant reported rating of perceived exertion (RPE) and symptoms."
89111632|NCT02784873|Experimental|High intensity interval training|"High intensity interval training within a standard cardiac rehabilitation programme.~Warm up: 15 mins total, 10 mins <40-70% HRR, 5 mins <70% HRR. Cardiovascular component: exercise bike interval training: 10 x high @ 85-90% peak power output (PPO) from CPEX, 10 x low @ 20-25% PPO (exercise intensity will not to be prescribed from gas exchange data i.e. %VO2 peak). Change in intensity from low to high achieved by altering cadence (rpm).~Muscular strength and endurance programme. Cool down: 10 mins, <40% HRR. Duration of intervals and total programme duration increased in a standardised fashion.~Workload increased bi-weekly in response to participant reported RPE (only after the full 10 x 1 protocol has been achieved). If RPE < 17 then workload will be increased."
89111633|NCT04230993|Experimental|Ocean Bio Actif-Fluid+|Moderate hypertonic seawater solution (15 g / L NaCl) with polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
89111634|NCT04230993|Experimental|Ocean Bio Active-Stuffy nose|Moderate hypertonic seawater solution (15 g / L NaCl) without polysorbate 80. The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
89111635|NCT04230993|Active Comparator|Ocean Bio Active-Hygiene of the nose|Isotonic seawater solution (9 g / L NaCl). The use is 1 to 2 sprays per nostril 4 times a day until symptoms of cold disappear, according to the instructions for use of the products.
89111636|NCT04230915|Active Comparator|Low Dose Rocuronium|This group patients will determine as those who were administered 0.3 mg/kg rocuronium
89111637|NCT04230915|No Intervention|Strandart Dose Rocuronium|This group patients will determine as those who were administered 0.6 mg/kg rocuronium
89111638|NCT00752791|Experimental|Peginesatide|
89111639|NCT04230603|Experimental|Hyperspectral imaging|diagnostic hyperspectral imaging of the human tissue an correlation with local blood parameters and local pathological examination
89111640|NCT05261529|No Intervention|Control Group|Control Group with 30 patients diagnosed with SLE following their normal lifestyle in terms of dietary intake and physical exercise.
89111641|NCT05261529|Experimental|Oil Group|Group with 30 patients diagnosed with SLE that add to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, without changing their lifestyle in terms of physical exercise.
89111642|NCT05261529|Experimental|Oil + Exercise Group|Group with 30 patients diagnosed with SLE that besides adding to their normal dietary intake a supplementation with 40ml of EVOO daily during 24 weeks, will follow a physical exercise multimodal program the 12 last weeks.
89111643|NCT02782299|No Intervention|Control|This group will not be exposed to the decision aid. Patients will complete the same surveys, and will be followed for the same length of time.
89111644|NCT02782299|Experimental|Decision Aid|This group will be exposed to the decision aid before the patients appointment with the surgeon. Patients will also complete the same outcome surveys, and will be followed for the same length of time.
89111645|NCT02784093|Experimental|Exposure Group|Participants were allocated to receive 100 mL of Gastrograﬁn orally once daily for 6 consecutive days.
89111646|NCT02784093|Placebo Comparator|Control Group|Participants were allocated to receive enemas twice daily for 6 consecutive days.
89111647|NCT04229589||Study population|Consecutive patients undergoing pacemaker implantation for bradyarrhythmic syncope
89111648|NCT02163681|Experimental|Hyperpolarized Helium 3 MRI of the chest|Using hyperpolarized helium-3 as an inhaled contrast agent for MRI, we will assess the lung ventilation.
89230716|NCT01046188|Active Comparator|Control group|Participants randomized to the control arm of the study will participate in a traditional didactic teaching session. This session will be carried out by the nurse educator. This session will be attended by up to 10 other couples that may or may not be participating in the study. The nurse educator administering the session will not know which couples are participating in the study. Slides shown and information conveyed will be the same as that provided to the web-based group, however all three stimulation protocols will be presented to the participants regardless of their actual treatment protocol.
89230717|NCT00061633|Experimental|Telavancin|
89230718|NCT00061633|Active Comparator|Standard of care for cSSSI|cSSSI - complicated skin and skin structure infections
89230719|NCT01044940||Birth asphyxia|Babies suffering from birth asphyxia
89230720|NCT01044940||Blood transfusion|Babies who receives blood transfusion
89230721|NCT01044940||Heart Surgery|Babies who need heart surgery
89230722|NCT00645593|Active Comparator|Arm 1, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin, as described in the intervention
89230723|NCT00645593|Experimental|Arm 2, Cetuximab, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin with Cetuximab, as described in the intervention
89230724|NCT01093261|Experimental|Hydrocortisone and fludrocortisone|Patients with glucocorticoid insufficiency
89230725|NCT01093261|Placebo Comparator|Placebo|Patients with glucocorticoid insufficiency
88805843|NCT00217490|Experimental|Combined|In this arm, participants received dietary counseling delivered using both the automated computer program and additional counseling by a study nutritionist. That is, this arm combined the intervention programs delivered in the other two active intervention arms.
89230726|NCT01093261|No Intervention|Controlled|Adapted glucocorticoid function
89230727|NCT03957031||Cases|Patients with a pathological confirmation of GC diagnosis
89230728|NCT03957031||Control|Patients with confirmed absent of GC
89230729|NCT02550977|Experimental|Gestodene/EE Patch|
89230730|NCT01093339||No treatment|Subjects w/ condition and subjects w/o condition of GERD (gastroesophageal reflux disease)
89230731|NCT03832738|Experimental|JTE-451 Dose 1|JTE-451 Tablets Dose 1 daily for 16 weeks.
89230732|NCT03832738|Experimental|JTE-451 Dose 2|JTE-451 Tablets Dose 2 daily for 16 weeks.
89230733|NCT03832738|Placebo Comparator|Placebo|Placebo Tablets daily for 16 weeks.
89230734|NCT01045018|Active Comparator|mesalamine 400 mg tablet|
89230735|NCT01045018|Active Comparator|Asacol 400 mg Delayed Release Tablet|
89230736|NCT01045018|Placebo Comparator|Placebo delayed release tablet|
89230737|NCT00267904|Experimental|Healthy Volunteer for Banana|Ingestion of a single banana
89230738|NCT00267904|Experimental|Healthy Volunteer for Coffee|Ingestion of caffeinated coffee on one day and decaffeinated coffee on another day
89230739|NCT00267904|Experimental|Healthy Volunteer for Olive|Ingestion of olives
89230740|NCT00267904|No Intervention|Healthy Volunteer for Quality Control Plasma|Arm venous blood is drawn via an indwelling i.v. catheter from HVs to obtain quality control plasma
89230741|NCT00267904|Experimental|Healthy Volunteer for Temp. Manip.|Manipulation of temperature at skin of the back
89230742|NCT01045252||congenital heart disease|Neonates that are enrolled in the NICU and are confirmed of congenital heart diseases.
89230743|NCT01045252||sepsis|Neonates that are enrolled in the NICU and are diagnosed as sepsis.
89230744|NCT01045252||Health|Neonates that are enrolled in the NICU and have no congenital heart diseases and sepsis.
89230745|NCT01049464|Placebo Comparator|5%D/W|The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.
89230746|NCT01049464|Experimental|Magnesium sulphate|The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours
89230747|NCT01046266|Experimental|A|
89230748|NCT01046266|Active Comparator|B|
89230749|NCT00046891|Experimental|Ginkgo Biloba|120 mg per day (60 mg BID)
89230750|NCT00046891|Placebo Comparator|Placebo|1 tablet BID
89230751|NCT01045330|No Intervention|Usual Care Group|Usual care consists of standard hospital services provided by physicians, nurses, and support staff (e.g., physical therapist, dietitian) in the general surgery units.
89230752|NCT01045330|Experimental|Experimental Group|The intervention consisted of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
89230753|NCT00365794|Experimental|Single arm|Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.
89230754|NCT03954457|Experimental|A-CWS Intervention|Participants received A-CWS Intervention.
89230755|NCT03954457|Active Comparator|Standard Care Control|Participants received standard care.
89230756|NCT00383500|Experimental|Flexitouch device|Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)
89230757|NCT00383500|Experimental|Manual Lymphatic Drainage (MLD)|Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment
89230758|NCT00383500|No Intervention|Observational Control (no intervention)|Control group, no intervention. No Flexitouch or manual massage therapy
89230759|NCT01098019|Experimental|Xeomin|Each bottle of Xeomin will be reconstituted with 2 mL of NaCl 0.9 which will give a final concentration of 5 U of botulinum toxin A per 0.1 mL. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum total dose of 200 units (4mL).
89230760|NCT01098019|Placebo Comparator|Placebo|Patients will receive 0.9% mL NaCl alone. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum volume of 4 mL.
89230761|NCT03956641|Experimental|experimental: observational cohort|Evaluation of the physical condition and the quality of life
89230762|NCT01098175||Control group|open surgery with exposure of the surgical wound to the air.
89230763|NCT01098175||Full peritoneal conditioning|Full peritoneum cavity conditioning will be performed as follows. A continuous flow of less than 0.5 l/min of gas will be instilled in the lowest part of the operating wound. As gas premixed bottles with CO2+ 4% of oxygen and 10% of N2O will be used. This gas will be humidified and at 31-32 °C to be achieved by a commercial humidifier (Fisher and Paykel) programmed in order to maintain 100% relative humidity at 31-32°C upon entrance of the peritoneal cavity.
89230764|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
89111649|NCT05342571|Experimental|Supportive care (ABC session, surveys, biospecimen collection)|Phase 1 of the intervention (10 weeks) will follow the following agenda: 1) Overview and progressive muscle relaxation, 2) Seeking and asking for disease-related and treatment-related information, 3) Problem solving skills, 4) Breathing techniques and sleep hygiene, 5) Assertive communication skills, 6) Identifying social network, 7) Asking for support, 8) Further information on social support, 9) Physical activity, and 10) Review of major topics, transition. Phase 2 of the intervention (4 weeks) which will be completed only by patients who do not experience remission in depressive symptoms by the end of phase 1, will follow the following agenda: 1) Identifying negative thoughts and problematic thinking patterns, 2) Generating alternative thoughts, 3) Behavioral activation, and 4) Review and wrap-up, transition to optional maintenance. Each session in Phase 1 and Phase 2 occurs once per week, for 60 minutes each. Maintenance sessions occur monthly, 60 minutes each.
89111650|NCT02784717||Rivaroxaban (Xarelto, BAY 59-7939)|Female and male patients, who are at least 18 years of age with a diagnosis of non-valvular atrial fibrillation will be enrolled after the decision for a pharmacologic prophylaxis with rivaroxaban to prevent stroke or non-CNS systemic embolism has been made.
89111651|NCT00902304|Active Comparator|Usual care|Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
89111652|NCT00902304|Experimental|Monotherapy (initial monotherapy arm)|Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
89111653|NCT00902304|Experimental|Combination (initial combination therapy arm)|Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
89111654|NCT02784795|Experimental|LY3039478 + Taladegib|LY3039478 given orally 3 times per week (TIW) in combination with taladegib given orally daily on a 28 day cycle. A single dose of taladegib will also be given on day 1 during a 3-day lead-in period.
89111655|NCT02784795|Experimental|LY3039478 + LY3023414|LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.
89111656|NCT02784795|Experimental|LY3039478 + Abemaciclib|LY3039478 given orally TIW in combination with abemaciclib given orally every 12 hours on a 28-day cycle. A single dose of abemaciclib will also be given on day 1 during a 3-day lead-in period.
89111657|NCT02784795|Experimental|LY3039478 + Cisplatin/Gemcitabine|LY3039478 given orally TIW in combination with cisplatin and gemcitabine given as intravenous (IV) infusions on days 1 and 8 of a 21 day cycle.
89111658|NCT02784795|Experimental|LY3039478 + Gemcitabine/Carboplatin|LY3039478 given orally TIW in combination with gemcitabine and carboplatin given as IV infusions on days 1 and 8 of a 21 day cycle.
89111659|NCT04230837|Experimental|A: Abutments of 1 mm|Definitive abutments of 1 mm height were located.
89111660|NCT04230837|Experimental|B: Abutments of 3 mm|Definitive abutments of 3 mm height were located.
89111661|NCT04214964||Gynecological cancer|patients who has been pathological diagnosed with Gynecological cancers between 2002 and 2022 in China
89111662|NCT00759109|Experimental|Arm A - PegIntron|Participants randomized to Arm A received peginterferon α-2b (PegIntron), 50 μg, weekly, subcutaneously (SC), for a period of 3 years.
89111663|NCT00759109|Other|Arm B - Control|Participants randomized to Arm B were under observation and received no treatment.
89111664|NCT02848794|Experimental|Apatinib+Irinotecan|Apatinib and irinotecan in treating patients with recurrent high-grade glioma,who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .
89111665|NCT04096027|Experimental|Early administration|Cabergoline administered the day before egg collection.
89111666|NCT04096027|Experimental|Late administration|Cabergoline administered after egg collection.
89111667|NCT04095481||Obalon NTS|Patients who commercially purchased the NTS Compatible Obalon Balloon System
89111668|NCT02846454|Experimental|inulin|Investigating the satiating effects of consuming 4g/d inulin (Fruitafit IQ by CHIMAB)
89111669|NCT02846454|No Intervention|non inulin and arabinoxylan|investigating the satiating effects of a control drink (2.6g/d maltodextrin)
89111670|NCT02846454|Experimental|arabinoxylan|Investigating the satiating effects of consuming 4g/d arabinoxylan (Medium Chain Naxus, BioActor b.v)
89111671|NCT04216134|Experimental|Diagnostic (68GA-PSMA-11 PET)|Patients receive gallium Ga 68-labeled PSMA-11 IV over less than 1 minute, and then undergo PET over 60 minutes.
89111672|NCT00916825|Experimental|3-week family oriented rehabprogramme|waiting control group
89111673|NCT00638079|Experimental|A|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal
89111674|NCT00638079|Active Comparator|B|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast
89111675|NCT00759031|Placebo Comparator|A - Marketed fluoride toothpaste|
89111676|NCT00759031|Active Comparator|B -Triclosan/NaF/CoPolymer toothpaste|
89111677|NCT02844504|Experimental|Low Intensity Exercise Training 1|Cancer survivors will receive low intensity handgrip exercise training.
89111678|NCT02844504|Experimental|Low Intensity Exercise Training 2|Cancer survivors will receive low intensity handgrip exercise training different than other arm.
89111679|NCT02844504|No Intervention|Control|This group will receive no training.
89111680|NCT04197219|Experimental|Pembrolizumab & axitinib|All participants enrolled will receive pembrolizumab as standard of care (SOC) combined with axitinib. Axitinib will be self-administered orally twice daily at 5 mg. On days when both drugs are administered, axitinib will be administered first, followed by pembrolizumab. Treatment will continue until disease progression or unacceptable grade 3/4 toxicities. For patients with a complete response to therapy, maintenance therapy with both drugs will be continued for 12 months.
89111681|NCT04093687|Experimental|Intervention Arm|"The intervention will consist of one training session, focusing on technical and non-technical aspects identified in the study Phase I (according to the evaluation questionnaire). The training will be conducted by a team consisting of (i) supervisors (researchers) and (ii) teachers experienced in the previous trial (Train-Colonoscopy-Leaders course - TCL; this methodology has already been evaluated (citation)). There will be 7 trainees per session: 1 under-, 4 average and 2 overperformers.~The training session will be divided into two parts: theoretical and practical. During the first, theoretical part of the training, the body of research on the phenomenon of colonoscopy pain will be presented. The second, practical part of the training, will consist of a one-day session of 7 colonoscopies.~Each average and underperforming endoscopist who underwent training in the randomized phase will receive a written, customized feedback on his/her performance during the training session."
89111682|NCT04093687|No Intervention|Control Arm|The endoscopists in the control arm will not be informed about participation in the study and will receive only tailored feedback on adjusted painful colonoscopy rate (practice as usual). They will receive a reminder, that dedicated report on painful colonoscopy rate is provided in the Polish Colonoscopy Screening Program database and they will be monitored for endpoints through Polish Colonoscopy Screening Program database.
89111683|NCT04834908|Experimental|Equine COVID-19 Antiserum [F(ab')2] (BSVEQAb) Along with Standard of care|"Dose of BSVEQAb - 5 mg/kg or 10 mg/kg body weight. It is administered as a single dose intravenously after diluting in 100 -150 ml saline. The infusion will be done over 1 to 2 hours.~Standard of care for treatment of COVID-19 positive patients"
89111684|NCT04834908|Active Comparator|Standard of care.|Treatment as per current treatment guidelines and institutional practice for COVID-19 positive patients will be administered
89111685|NCT02512497|Experimental|Romidepsin + Busulfan + Fludarabine + Stem Cell Transplant|"Part 1:~Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the optimal dose. Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1. Stem cell infusion on Day 0.~Romidepsin Maintenance Therapy - Part 2:~Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
89111686|NCT00916669|Active Comparator|Group A|Cisplatin and Etoposide
89111687|NCT00916669|Experimental|Group B|Cisplatin and etoposide, plus low-dose enoxaparin sodium
89111688|NCT00916669|Experimental|Group C|Cisplatin and etoposide, plus high-dose enoxaparin sodium
89111689|NCT02689557|Other|measures of the volumes|Measures of the volumes of the lower limbs. A measure to rest, a measure of effort (walk) and a measure recovery. Intervention.
89230765|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
89230766|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
89230767|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 225|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
89230768|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 450|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
89230769|NCT01049542|Experimental|Astressin 2B|Healthy volunteers will receive incremental doses of intra arterial Astressin 2B (a selective and potent Urocortin 2 & 3 antagonist). This serves as a dose finding Protocol for Astressin 2B, which will be used in subsequent protocols.
89230770|NCT01049620|Experimental|Xelox+RAD001|
89111690|NCT02844348|No Intervention|Standard pain control|Classical pain assessment and drug treatment at each dialysis session.
89111691|NCT02844348|Experimental|Hypnosis|Besides the classical pain assessment and drug treatment, hypnosis sessions during 2 periods of one week of dialysis sessions.
89111692|NCT04093453|Placebo Comparator|Placebo + Fasting|Sodium Chloride tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
89111693|NCT04093453|Placebo Comparator|Placebo + Exercise|Sodium Chloride tested in an exercise state. Participants will have the placebo then exercise will be performed at 40% of maximal aerobic capacity for one hour.
89111694|NCT04093453|Placebo Comparator|Placebo + Post-prandial|Sodium Chloride tested in a post-prandial state. Participants will have the placebo then a mixed liquid meal test is given.
89111695|NCT04093453|Experimental|Propionate and Fasting|Sodium Propionate tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
89230771|NCT00059839|Experimental|Standard APO with Vincristine (Arm I )|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV over 15 minutes, vincristine sulfate (1.5 mg/m2 (maximum dose 2 mg)) IV, and methotrexate intrathecally (age-adjusted dosing) (IT) on day 1 and oral prednisone (40 mg/m2/day) three times daily and oral mercaptopurine (225 mg/m2) once daily on days 1-5. In courses 4 and 5, patients receive doxorubicin (30 mg/m2), vincristine sulfate (1.5 mg/m2 (Maximum dose 2 mg)), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3. In courses 6-15, patients receive vincristine sulfate (1.5 mg/m2), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3 and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
89230772|NCT00059839|Experimental|Consolidation with Vinblastine|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV, methotrexate (age adjusted dosing) IT, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) IV over 1 minute on days 1, 8, and 15. In courses 4 and 5, patients receive doxorubicin hydrochloride (30 mg/m2) IV, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) as in arm II (courses 1-3). In courses 6-15, patients receive prednisone (120 mg/m2/day) and mercaptopurine (225 mg/m2) as in arm I, vinblastine sulfate (4 mg/m2) IV as in arm II (courses 1-3), and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
89230773|NCT00059215|Experimental|Prasugrel (CS-747) 40 mg LD/7.5 mg MD|Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days
89230774|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/10 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days
89230775|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/15 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days
89230776|NCT00059215|Active Comparator|Clopidogrel|Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.
89230777|NCT01096147|Active Comparator|SCS|patients receiving SCS for chronic leg and/or back pain.
89230778|NCT00058825|Experimental|Stem Cell Transplant|Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
89230779|NCT00364858|Other|Q2 Cerezyme|Patients receiving Cerezyme one infusion every 2 weeks (Q2).
89230780|NCT00364858|Other|Q4 Cerezyme|Patients receiving Cerezyme one infusion every 4 weeks (Q4).
89230781|NCT01098409|Experimental|sodium nitrite 24 hours before|
89230782|NCT01098409|Experimental|sodium nitrite during surgery|
89230783|NCT01098409|Placebo Comparator|0.9% sodium chloride|
88805844|NCT00217490|Active Comparator|Physical Activity-computer|Participants assigned to this arm did not receive nutrition counseling, but they were provided physical activity counseling delivered by computer only.
88805845|NCT00217724|Experimental|Glutamine Arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral glutamine three times daily for 4 days.
88805846|NCT00217724|Placebo Comparator|Placebo arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral placebo three times daily for 4 days.
89230784|NCT03956719|Experimental|Autologous adipose-derived mesenchymal stem cells|Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells
89230785|NCT02535208|Experimental|Restrictive transfusion group|
89230786|NCT02535208|Active Comparator|Liberal transfusion group|
89230787|NCT01093495|Experimental|CPAP group|Subjects in this group will continue receiving CPAP until no oxygen requirement for 24 hours, then will be weaned off CPAP completely as long as they tolerate. CPAP will be re-instituted if subjects meet failing criteria. Another trial off CPAP will start 24 hours after failure and/or after being on 21% for 24 hours. CPAP will be weaned off directly to room air at all times.
89230788|NCT01093495|Experimental|Nasal Cannula Group|Subjects will be weaned from CPAP (when FiO2 <0.30) to Nasal cannula (2 L/min) with whatever FiO2 they need until they are off oxygen and NC completely. However, if these infants fail on NC they will be put back to nCPAP. Infants will then be maintained on CPAP until stable on CPAP-30% for 24 hours. Infants will be tried for another weaning using NC. So, infants assigned to NC will be weaned only through NC. CPAP will be used only for stabilization in between trials if needed.
89230789|NCT02535052||Chronic Kidney Disease (CKD) patients|Any gender, aged 65 years and over. Chronic kidney disease with eGFR between 15 and 60 ml/min. No immunological cause of kidney disease. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
89230790|NCT02535052||Healthy Control subjects|Any gender, aged 65 years and over. No known renal disease and eGFR 60ml/min or greater. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
89230791|NCT03741205|Experimental|Treatment Group|SPEAC System
89230792|NCT03741205|No Intervention|Standard of Care|Standard of Care
89290013|NCT03132220|Experimental|MBCT Intervention|The subject will participate in 16 in-person hours that are broken into sessions for the Mindfulness-Based Cognitive Therapy intervention. The intervention will be facilitated by 1-2 instructors who are trained in clinical psychology/ social work and are also trained in MBCT. This intervention will include mindfulness activities, didactic learning, homework assignments and group dialogue. This adapted MBCT intervention will follow the empirically-based MBCT intervention for depression structure with fidelity.
89290014|NCT02529228|Experimental|CON-2|Consuming 2 Low Protein, High Carbohydrate Meals i.e. changing Meal Frequency and Protein Composition.
89230793|NCT03953989|Experimental|Patients with hypertrophic cardiomyopathy|"Thestudy is articulated into Screening visit plus other 3 visits. One visit (V2 ) for dose titration. V0 screening eligibility, consent, Medical History, physical examination, BP, ECG, Echocardiography, Biochemistry (haematology, electrolytes, glycaemia, ALS and bilirubin, creatinine and urine-analysis) V1 Baseline PET scan, physical examination, vital signs, and drug supply (500 mg bid).~V2 physical examination, safety check, biochemistry, drug compliance and up-titration (750 mg bid), drug supply.~V3 (2 months)safety check ,drug supply, drug compliance V4 (4 months, end of treatment) repeat PET scan, physical examination, BP, ECG, drug compliance, safety.~Drug of the study Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die"
89230794|NCT01096225||vaccinated group|
89230795|NCT01049698|Active Comparator|1. Resistance Training|3 d/wk resistance training
89230796|NCT01049698|Experimental|2. Resistance Training + Diet|Resistance training plus caloric restriction
89230797|NCT02535130|Experimental|Nebulization combined to positive expiratory pressure|Experimental arm
89230798|NCT02535130|Active Comparator|Nebulization|Control arm
89230799|NCT03803059|Experimental|Wrinkles of the Neck|Microneedle treatment neck areas.
89230800|NCT01046500|Active Comparator|metformin|
89230801|NCT01046500|Active Comparator|myo-inositol|
89230802|NCT01046578|Experimental|Single Dose 12mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
89230803|NCT01046578|Experimental|Single Dose 18mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
89230804|NCT01046578|Experimental|Single Dose Post Ovulation|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 post ovulation
89230805|NCT01046578|Experimental|Multi Dose 12mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
89230806|NCT01046578|Experimental|Multi Dose 18mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
89230807|NCT01046578|Experimental|Multi Dose Post Ovulation|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 hours post ovulation
89230808|NCT01046578|No Intervention|Control|No intervention given, followed for course of study on a natural cycle
89230809|NCT01098565|Experimental|Study device arm|
89230810|NCT01096303||COPD tobacco and/or marihuana users|COPD patients with history of tobacco and/or marihuana smoking.
89230811|NCT03956875|Active Comparator|yoga|Yoga treatment
88805847|NCT00287222|Experimental|1 - Bevacizumab/Erlotinib|Subjects will be treated with bevacizumab and erlotinib
89230812|NCT03956875|Placebo Comparator|massage|massage
89230813|NCT01096381||Will receive bevacizumab|
89230814|NCT01096381||Will not receive bevacizumab|
89230815|NCT00372424|Experimental|1|Combination of SU011248 (37.5 mg once daily [Schedule 2/1]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)
89230816|NCT01098721|Placebo Comparator|Group 1|A placebo cream applied topically twice daily (BID)by each of 20 patients, once in the morning and once in the evening for 12 weeks.
89230817|NCT01098721|Active Comparator|Group 2|A 1.0% WBI-1001 cream applied topically twice daily (BID) by each of 40 patients, once in the morning and once in the evening for 12 weeks.
88805848|NCT04751240|Experimental|SIT and Resistance|Participants will complete 10 weeks of a SIT and resistance training paradigm.
89290015|NCT02529228|Experimental|CON-6|Dividing meal intake into 6 smaller Low Protein, High Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
88805849|NCT00218426|Active Comparator|ONP + DNI|Oral naltrexone placebo (ONP) + Depot Naltrexone Implant (DNI) 1000 mg
88805850|NCT00218426|Active Comparator|ON + DNIP|Oral naltrexone (ON) 50 mg + Depot Naltrexone placebo Implant (DNIP)
88805851|NCT00218426|Placebo Comparator|ONP + DNIP|Oral placebo naltrexone + placebo naltrexone implant
89111696|NCT04093453|Experimental|Propionate and Exercise|Sodium Propionate tested in an exercise state. Participants will have the sodium propionate then exercise will be performed at 40% of maximal aerobic capacity for one hour.
89111697|NCT04093453|Experimental|Propionate and Post-prandial|Sodium Propionate tested in a post-prandial state. Participants will have the sodium propionate then a mixed liquid meal test is given.
89111698|NCT02784015|Experimental|Unresectable localized soft tissue sarcoma|"Six cycles of chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen.~Surgery, if possible~Concurrent chemoradiotherapy according to the treatment response (necrosis rate, tumor volume reduction, and residual FDG uptake in PET scan)~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation, if there are still residual tumors after 9 cycle of chemotherapy, surgery, and radiotherapy.~1st HDCT: carboplatin, thiotepa, etoposide~2nd HDCT: cyclophosphamide, melphalan"
89111699|NCT02601235|Experimental|Naridrin|Naridrin: 2 drops in each nostril once daily as prescription
89111700|NCT02601235|Active Comparator|0.05 % Oxymetazoline Hydrochloride|2 pumps in each nostril every 12 hours
89111701|NCT02783937|Active Comparator|Filgrastim arm|Intervention: Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days
89111702|NCT02783937|Placebo Comparator|Placebo arm|Intervention: Injection of saline SC injection twice daily for five consecutive days.
89111703|NCT00758485|Experimental|sugammadex|Participants receiving 4.0 mg.kg-1 Sugammadex at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
88805852|NCT01790672|Placebo Comparator|Water|Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
89111704|NCT00758485|Placebo Comparator|Placebo|Participants receiving Placebo (0.9% NaCl) at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
89111705|NCT02782455|Experimental|CDobi|Calcium dobesylate is given in this group
89111706|NCT02782455|Active Comparator|Flavono|Flavonoids are given in this group
89111707|NCT02846220|Experimental|Health coaching|"Two-hour in-person group counseling session led by health coach, involving development of personalized immunity maps that lay out adherence goal, behaviors that distract from goal, hidden motives that compete with achieving goal, and underlying assumptions~Eight 50-minute individual telephone counseling sessions every three weeks with a health coach, focusing on uncovering hidden motives and challenging assumptions with the goal of overturning nonadherence mindsets"
89111708|NCT02846220|No Intervention|Usual care|
89111709|NCT02599909||1/ Cohort 1|Subjects with hepatocellular carcinoma
89111710|NCT02783781||Cardiac surgery|All patients (planned and urgent) needed cardiac surgery, and agreed to participate
89111711|NCT02848872||NSCLC patients|Resected patients
89111712|NCT03505554|Experimental|Lorlatinib|100 mg QD
89111713|NCT04810416|Experimental|Texting- 10 minutes|Assigned participants will do texting for 10 minutes.
89111714|NCT04810416|Experimental|Writing- 10 minutes|Assigned participants will do writing for 10 minutes.
89111715|NCT04810416|Experimental|Texting- 15 minutes|Assigned participants will do texting for 15 minutes.
89111716|NCT04810416|Experimental|Writing-15 minutes|Assigned participants will do writing for 15 minutes.
89111717|NCT04810416|No Intervention|Control group|No hand activities.
89111718|NCT05342415|Active Comparator|Internally Focused|Focusing on the muscles that reveal the movement.
89111719|NCT05342415|Experimental|Externally Focused|Focusing on the result of the movement.
89111720|NCT02846142|Active Comparator|SAD PTI-428|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
89111721|NCT02846142|Placebo Comparator|SAD placebo|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
89111722|NCT02846142|Active Comparator|MAD PTI-428|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
89111723|NCT02846142|Placebo Comparator|MAD placebo|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
89111724|NCT02846142|Experimental|OC (ethinyl estradiol and levonorgestrel) DDI Period A|Treatment period A will consist of once daily oral contraceptive (OC) for 28-days (21-day hormonal active + 7 days off).
89111725|NCT02846142|Active Comparator|OC (ethinyl estradiol and levonorgestrel) DDI Period B|Treatment period B will randomize subjects to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
89111726|NCT02846142|Placebo Comparator|OC (ethinyl estradiol and levonorgestrel) DDI|Treatment period B will randomize subjects 4:1 to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
89111727|NCT02783703|Experimental|MCT|Medium chain triglyceride (MCT) oil ingested daily for 6 weeks
89111728|NCT05243160|No Intervention|control|Treatment as usual
89111729|NCT05243160|Experimental|Intervention|Intervention group will be exposed to a medication review by a clinical pharmacologist
89111730|NCT02848482|Active Comparator|Control group|Plastic curette will be used to perform the mechanical debridement. Then, irrigation (2% chlorhexidine) will be performed at contaminated sites.
89111731|NCT02848482|Experimental|Test group|Plastic curette will be used to perform the mechanical debridement. Then, the addition photodynamic therapy (PDT) will be performed. This will be performed with a set-up for PDT (HELBO Photodynamic Systems, German).
89111732|NCT02782533|Experimental|DBS V3|Deep Brain Stimulation V3
89111733|NCT00757783|Experimental|darunavir|darunavir 800 mg tablet once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg tablet once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
89111734|NCT00757783|Experimental|atazanavir|atazanavir 300 mg capsule once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
89111735|NCT01770249|Other|POEM procedure|An endoscopic surgical procedure for achalasia; Per-oral Endoscopic Esophagomyotomy (POEM)will be performed. The POEM procedure will be performed in the operating room under general anesthesia and a scope will then be inserted into your mouth and down your throat and measurements will be taken. With the use of this lighted flexible scope the surgeon will make a small incision in the inner lining of your esophagus (throat), create a tunnel and then cut the muscle between the esophagus (throat) and the stomach. The initial little opening will be closed with a small clip. This procedure will allow easier passage of food into the stomach.
89111736|NCT05242926|Experimental|ModraDoc006/r|Six evaluable patients will be included for collection of plasma, faeces and urine samples during 168 hours after one day of bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir.
89111737|NCT02782221|Active Comparator|Growth hormone|Subjects are receiving growth hormone
89111738|NCT02782221|Placebo Comparator|Placebo|Subjects are receiving pegvisomant to block the action of growth hormone
89111739|NCT02781987||CP group|Those patients with chronic pancreatitis underwent ERCP for pancreatic stone clearance, pancreatic stent placement, etc..
89111740|NCT02781987||BD group|Those patients with biliary ductal disease, such as choledocholithiasis, underwent ERCP to relieve outflow obstruction of the common bile duct.
89111741|NCT02846064|Other|Ovarian tissue cryopreservation|
89111742|NCT04231617|Active Comparator|CGRP and glibenclamide|Participants will recieve CGRP infusion after glibenclamide/placebo administration
89111743|NCT04231617|Active Comparator|CGRP and placebo|Participants will recieve CGRP infusion after glibenclamide/placebo administration
89111744|NCT04810104|Experimental|Active drug: AZD0328|Participants will receive AZD0328 capsules for oral administration.AZD0328 is a selective α7 nicotinic receptor agonist, The total daily dosage of AZD0328 is 1mg per day; administered as 0.5mg twice daily / BID. The study treatment period is 12-weeks.
89111745|NCT04810104|Placebo Comparator|Placebo|Participants will receive identical-appearing placebo capsules for oral administration.Participants will be instructed to take 2 capsules in the morning and 2 capsules in the evening for a 12-week period.
89111746|NCT00757705|Experimental|Paliperidone Extended-Release (ER)|
89290016|NCT02529228|Experimental|PRO-2|Consuming 2 High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
89111747|NCT02845908|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
89111748|NCT02845908|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
89111749|NCT02845908|Active Comparator|FOLFOX|The FOLFOX regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
89111750|NCT04197531|Experimental|EndoActivator|
89111751|NCT04197531|Experimental|Conventional Endodontic Syringe|
89290017|NCT02529228|Experimental|PRO-6|Dividing meal intake into 6 smaller High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
89111752|NCT05242614|Experimental|A hybrid Mindfulness-based Dementia Caregiving Program (MBDCP)|Participants from the experimental group will receive a hybrid Mindfulness-based Dementia Caregiving Program (MBDCP). It is a 6-week program. In the 1st, 2nd and 6th session, it is delivered through face to face, while in the 3rd, 4th and 5th sessions, it will be delivered via online approach.
89111753|NCT05242614|Active Comparator|Control group|The family caregivers in the control group will receive 6 week education programme on dementia. It is a control for the social effects of the MBDCP. In the 1st, 2nd and 6th session, it is delivered through face to face, while in the 3rd, 4th and 5th sessions, it will be delivered via online approach.
89111754|NCT02784483|Experimental|Atezolizumab (1200mg via IV infusion)|
89111755|NCT05242536|Experimental|Nurse- led program|A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
89111756|NCT05242536|No Intervention|Routine follow-up group|The control group will be applied usual care. Patients in the control group will be discharged by receiving standard care and performing discharge trainings used in the routine care.
89111757|NCT02784561|Experimental|Busulfan/FLAG conditioning regimen|"All recipients in this arm received the conditioning regimen consisting of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor).~The conditioning regimen for peripheral blood stem cell transplantation consisted of busulfan (3.2 mg/kg/ day intravenously [i.v.], days -10 to -8), fludarabine (30 mg/m2, day -7 to -3), cytarabine (1.6 g/m2/day, days~-7 to -3), granulocyte colony-stimulating factor (5 ug/ kg, day -8 to -3). ATG (Thymoglobuline, rabbit) for haploidentical and matched unrelated donors transplantation recipients was used on 2.5 mg/kg/d from days -5 to -2)."
89111758|NCT00757627|Experimental|1|Etoricoxib
89111759|NCT02848248|Experimental|SGN-CD123A|SGN-CD123A every 3 weeks
89111760|NCT02600455||Patients who are treated with ORENCIA|Patients who are treated with ORENCIA according to the approved indications, and dosage and administration
89111761|NCT02599987|Experimental|Inspiratory Muscle Training Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The training group will carry with IMT load of 50% of MIP. Weekly, patients attend the Cardiopulmonary Physical Therapy Laboratory for evaluation of MIP and load adjustment, performing a training session in the presence of the therapist, while other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
89290018|NCT01217034|Experimental|TACE with sorafenib|TACE(on demand) with sorafenib till untreatable progression
89290019|NCT01217034|Active Comparator|TACE alone|TACE(on demand) till unreatable progression
88805853|NCT01790672|Active Comparator|Alcoholized wine|"Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study.~Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol."
88805854|NCT01790672|Placebo Comparator|De-alcoholized wine|Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
89111762|NCT02599987|Sham Comparator|Sham Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The sham group will carry without load, but will be subjected to the same procedures in the experimental group (simulation of load adjustment in the Cardiopulmonary Physical Therapy Laboratory) to ensure blinding of the study, other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
89111763|NCT03982147||Stroke patients|Patients with recent ischaemic stroke
89111764|NCT05342181|Experimental|Static exercises|static exercises i.e traditional exercises along with base line treatment of TENS and hot pack
89111765|NCT05342181|Experimental|Dynamic exercises|dynamic (Swiss ball) exercises along with base line treatment of TENS and hot pack
89111766|NCT01023308|Experimental|Panobinostat + Bortezomib + Dexamethasone|
89111767|NCT01023308|Placebo Comparator|Placebo + Bortezomib + Dexamethasone|
89290020|NCT01373554|Placebo Comparator|Placebo|
89290021|NCT01373554|Experimental|Oltipraz|
89111768|NCT04230525||Bioimpedence|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia.
89111769|NCT02784639|Other|determination of KRAS mutation|circulating cell free DNA (ccfDNA) plasma analysis
89111770|NCT02783391|Experimental|BRAINSPEAK|Electrocorticographical (ECoG) and intracortical electrodes
89111771|NCT02781909|Active Comparator|Control: Standard of Care TB treatment|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines; n=12
89111772|NCT02781909|Experimental|Ibuprofen-treated|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines plus ibuprofen (400mg/day/2 months); n=12
89111773|NCT02781831|Active Comparator|Standard Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation program
89111774|NCT02781831|Experimental|Robot-assisted Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation as well as robot-assisted gait rehabilitation program
89290022|NCT02529150|Experimental|exercise|
89111775|NCT04302038|Experimental|Potato protein|Participants will be provided with 25 g of potato protein twice per day in addition to a diet set at the recommended daily allowance. Total protein intake for this group will be 1.6 g/kg/day
89290023|NCT01319344|Experimental|Eplerenone|
89111776|NCT04302038|Placebo Comparator|Control group|This group will consume protein from food sources set at 0.8 /kg/day including 2 pudding placebo cups per day.
89111777|NCT02783313|Experimental|PR-plasma-PCs|Pooled buffy coat-derived pathogen reduced plasma-stored platelet concentrates (PR-plasma-PCs)
89111778|NCT02783313|Active Comparator|Plasma-PCs|Pooled buffy coat-derived plasma-stored platelet concentrates (plasma-PCs)
89111779|NCT04229823||Ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of 3 points or more.
89111780|NCT04229823||Pre-ataxic carriers|Subjects with a CAG repeat expansion on ATXN3 and Scale for Assessment and Rating of Ataxia (SARA) of less than 3 points.
89111781|NCT04229823||Related controls|Subjects without a CAG repeat expansion on ATXN3, but with a first degree relative affected by the disease.
89111782|NCT02783079|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT)
89111783|NCT02783079|Active Comparator|Arm 2|Mindfulness Based Stress Reduction (MBSR)
89111784|NCT04229511||Infection caused by CRKp|Group 1 cases are constituted by one BSI episode or non-bactereamic invasive infection episode (eg. pneumonia, intra-abdominal infection or urinary tract infection) with CRKp and a positive rectal swab screening or invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other invasive infection with CRKp
89111785|NCT04229511||Infection caused by any other bacteria|Group 2 cases who are colonized with CRKp or had invasive infection (e.g. pneumonia, urinary tract infection and BSI) with CRKp within 90 days before identification of index BSI or other types of invasive infection with any bacteria other than CRKp and develop subsequent BSI or non-bactereamic invasive infection with these bacteria
89111786|NCT04229511||No infection|Group 3 cases involve the colonized patients with CRKp who do not develop subsequent BSI or other invasive infections with CRKp or any other bacteria
89111787|NCT03411915|Experimental|XmAb18087|XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles
89111788|NCT01521039||Allogeneic SCT recipients|Patients who are receiving allogeneic stem cell transplantation at the Ohio State University are eligible and will be consented for the study.
89111789|NCT01022996|Experimental|RAD001|"Patients with a history of classical Hodgkin lymphoma (ie, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) whose disease had progressed after receiving high-dose chemotherapy with AHSCT (if eligible) and/or after therapy with a gemcitabine- or vinorelbine- or vinblastine-containing regimen, were enrolled into this study. All patients were assigned to a daily dose of everolimus 10 mg (two 5-mg tablets), selfadministered orally and continuously from Cycle 1 Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death, or discontinuation from the study for any other reason.~A treatment cycle consisted of 28 days."
89111790|NCT02781597|Active Comparator|Tranexamic acid|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients in group T will receive Inj Tranexamic acid in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h.
89111791|NCT02781597|Placebo Comparator|Placebo|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.
89111792|NCT02783235|Other|cervical cancer|cervical cancer screening and training for ANMs/ASHAs/PHWs To develop video-based tutorials to train ANMs/ASHAs/PHWs in conducting cervical cancer related health education, screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
89111793|NCT00757237|Experimental|AZLI 75 mg 3 times a day (TID)|
89111794|NCT00757237|Active Comparator|TIS 300 mg 2 times a day (BID)|
89111795|NCT01029392|Experimental|Required Vitamin D|Those children whose Vitamin D level was low (<30 ng/mL) are given Vitamin D supplementation
89111796|NCT01029392|No Intervention|Normal Vitamin D|Those children whose Vitamin D level was normal (50-80 ng/mL) did not receive Vitamin D supplementation
89111797|NCT02781753|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C.
89111798|NCT02781753|Active Comparator|Pegasys|Peginterferon 180 μg single dose S.C.
89111799|NCT00903006|Active Comparator|Group 1: Fulvestrant|Group 1 will receive Fulvestrant only.
89111800|NCT00903006|Active Comparator|Group 2: Fulvestrant + Dasatinib|Group 2 will receive Fulvestrant and Dasatinib.
89111801|NCT00903006|Active Comparator|Group 3: Fulvestrant + MK-0646|Group 3 will receive Fulvestrant and MK-0646.
89111802|NCT00903006|Active Comparator|Group 4: Fulvestrant, MK-0646 + Dasatinib|Group 4 will receive Fulvestrant, MK-0646, and Dasatinib.
89111803|NCT02873312|Experimental|StimRouter Treatment|The Treatment group will receive therapeutic level StimRouter electrical stimulation. At the end of the Month 3 visit the Treatment group will continue to receive therapeutic level StimRouter electrical stimulation for an additional 3 months.
89111804|NCT02873312|Sham Comparator|StimRouter Control|The Control group will receive sham (sub-therapeutic level only) StimRouter stimulation. At the end of the Month 3 visit the Control group will be allowed to receive therapeutic level StimRouter electrical stimulation for 3 months.
89111805|NCT02781675|Experimental|Western Diet|Dietary Intervention: 3 wks of a typical Western Diet
89111806|NCT02781675|Experimental|Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet
89230818|NCT03952507|Experimental|Group 1: JNJ-64417184|Participants will receive JNJ-64417184 600 milligram (mg) oral tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg oral tablet in fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted condition on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89290024|NCT03936816||GBS screened positive|150 patients that were screened positive by culture at 35-37 weeks gestational age.
89290025|NCT03936816||GBS unknown with risk factors|150 patients that were not screened for GBS and have risk factors for GBS prophylaxis.
89230819|NCT03952507|Experimental|Group 2: JNJ-64417184|Participants will receive JNJ-64417184 600 mg oral tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89230820|NCT03952507|Experimental|Group 3: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89230821|NCT03952507|Experimental|Group 4: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89230822|NCT03952507|Experimental|Group 5: JNJ-64417184|Participants will receive JNJ-64417184 600 mg tablet under fed conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89230823|NCT03952507|Experimental|Group 6: JNJ-64417184|Participants will receive JNJ-64417184 600 mg as oral suspension in fasted conditions on Day 1 in Treatment Period 1; followed by JNJ-64417184 600 mg tablet under fed conditions on Day 8 in Treatment Period 2; followed by JNJ-64417184 600 mg tablet under fasted conditions on Day 15 in Treatment Period 3. A washout period of at least 7 days will be maintained between each treatment period.
89230824|NCT02872792|Experimental|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer in addition of Standard physiotherapy during sepsis for patient with sepsis in ICU
89230825|NCT02872792|Active Comparator|Standard physiotherapy|Standard physiotherapy during sepsis for patient with sepsis in ICU
89230826|NCT02530411|Experimental|Experimental|Fulvestrant 500mg Intra Muscular (IM) Day 1 (D1), D15, then D1 of every 28 day cycle Vandetanib 300 mg Per os (po) daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. Computerised Axial Tomography (CT) at week 8, 16, 24 then 12 weekly.
89230827|NCT02530411|Placebo Comparator|Control|Fulvestrant 500mg IM D1, D15, then D1 of every 28 day cycle Placebo po daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. CT at week 8, 16, 24 then 12 weekly.
89230828|NCT00372190|Experimental|Mesh surgery|Trocar guided tension free vaginal mesh insertion by Prolift mesh kit
89230829|NCT00372190|Active Comparator|Conventional vaginal surgery|Classical vaginal prolapse surgery (fascia plication)
89230830|NCT01093729|Experimental|Cohort1|HM11260C 0.5mcg/kg or Placebo
89230831|NCT01093729|Experimental|Cohort2|HM11260C 2mcg/kg or Placebo
89230832|NCT01093729|Experimental|Cohort3|HM11260C 4mcg/kg or Placebo
89230833|NCT01093729|Experimental|Cohort4|HM11260C 8mcg/kg or Placebo
89230834|NCT01093729|Experimental|Cohort5|HM11260C 14mcg/kg or Placebo
89230835|NCT03992794||Total patients|Consecutive patients presenting to the ED with either a suspected or documented infection in which blood samples were taken during routine. An extra blood sample was taken to measure PCT & MR-proADM using the Samsung IB10 point of care assay.
89230836|NCT01327027|Experimental|Vasopressin, Arginine, ADH|We will test how vasopressin affects emotional responses to facial stimuli in healthy men and women.
89230837|NCT01327027|Placebo Comparator|Sterile Salilne|Sterile saline will be administered intranasally and emotional responses to facial stimuli measured.
89230838|NCT01093807|Placebo Comparator|Placebo|
89230839|NCT01093807|Experimental|Lercanidipine 10 mg|
89230840|NCT01093807|Experimental|Lercanidipine 20 mg|
89230841|NCT01093807|Experimental|Enalapril 10 mg|
89230842|NCT01093807|Experimental|Enalapril 20 mg|
89230843|NCT01093807|Experimental|Lercanidipine 10 mg/Enalapril 10 mg|
89230844|NCT01093807|Experimental|Lercanidipine 10mg/Enalapril 20 mg|
89230845|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril 10 mg|
89111807|NCT02781675|Experimental|Modified Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet including full fat dairy products
89111808|NCT04229121||Driver gene mutation-positive|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation positive.
89111809|NCT04229121||Driver gene mutation-negative|Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation negative.
89111810|NCT05242224|Experimental|Experimental Group|Receives evolutionary nutrition package [high quality diet plus nutrition messaging + standard of care (iron-folic acid and calcium supplements)]
89111811|NCT05242224|No Intervention|Control Group|Receives standard-of-care, iron-folic acid and calcium supplements.
89111812|NCT04229277|Other|in tumours|consecutive enrollment of newly referred skin tumour patients
89111813|NCT05242068|Other|Standard care of group|Patients in standard care of group received traditional peripheral intravenous catheterization
89111814|NCT05242068|Experimental|Veinlite group|Patients in veinlite group received peripheral intravenous catheterization with Veinlite
89111815|NCT04097899||Group A in preimplementation phase|Patient and antibiotic related data were collected to calculate and define; ventilator associated pneumonia incidence, mean ventilation days and mean length of stay, antibiotic selection, antibiotic cost, antibiotic susceptibility pattern, antibiotic consumption.
89111816|NCT04097899||Group B in postimplementation phase|The appropriateness of antibiotic use (selection, initiation, duration & time of discontinuation) before and after implementing the educational program was compared, calculation of the change in the ventilator associated pneumonia incidence & length of ICU stay, calculation of the change in the rate of antibiotic resistance and calculation of the cost change of antibiotics used after implementing the educational program.
89111817|NCT04201938|Active Comparator|Symbiter-Omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
89111818|NCT04201938|Placebo Comparator|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
89230846|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril20mg|
88805855|NCT01790672|Active Comparator|Ethanol|"Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study.~Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.~Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water."
89230847|NCT01046734||Adult Community|
89230848|NCT01046734||Adult Hospital|
89230849|NCT01046734||Children Hospital|
89230850|NCT01046734||Children Community|
89111819|NCT02599831|Experimental|Electrical pudendal nerve stimulation|"Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum).~Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45~55 mA). EPNS was given for 60 min a time, 3 times per week for 8 weeks."
89230851|NCT01096537||Young workers|"Exposed young workers graduated in sectors at risk of occupational asthma (bakery, pastry-making or hairdressing)~Non-exposed young workers graduated in sectors without specific occupational exposure as the sale or the food sectors."
89230852|NCT01098799||Control|Healthy controls
89230853|NCT01098799||Chronic kidney disease-1|Chronic kidney disease not taking dialysis treatment
89230854|NCT01098799||Kidney Transplant|Kidney transplants
89111820|NCT02599831|Active Comparator|PFM training with Transanal ES|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co. Ltd, China) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB4, Electronic Concept Lignon Innovation, France)) at a current intensity of < 60 mA (as high as possible within the patient's tolerance) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients were also required to conduct 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks.
89111821|NCT02845986|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed laparoscopic spleen-preserving No.10 lymph node dissections.After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
89111822|NCT02598739|Experimental|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
89111823|NCT02598739|Other|Control group|Waiting list for the exercises.
89111824|NCT05340933|Experimental|Arm 1|intervention correspond to the voice registration
89111825|NCT04095325|Active Comparator|transversus abdominis plane block|Group 1 (n: 50): those who underwent TAP block after induction of propofol atropine and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
89111826|NCT04095325|Active Comparator|erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
89111827|NCT00839332|Experimental|LY2603618 + Gemcitabine|"Participants participated in Phase 1 or 2.~LY2603618 (Phase 1): 70 to 250 milligrams/meter squared (mg/m^2) LY2603618 as a 1-hour continuous intravenous (IV) infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression (DP). Participants received LY2603618 as part of the dose escalation cohort (dose of 70, 105, 150, 200, or 250 mg/m^2) or the expansion cohort (flat dose of 200 mg or 230 mg).~LY2603618 (Phase 2): 230 mg LY2603618 as a 1-hour continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP.~Gemcitabine (Phase 1 and 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP. Participants received gemcitabine 24 hours prior to LY2603618 administration."
89111828|NCT00839332|Active Comparator|Gemcitabine|"Participants participated in Phase 2 only.~Gemcitabine (Phase 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression."
89111829|NCT03325452|Experimental|cardio-respiratory arrest|
89111830|NCT05341947|Experimental|Activated T cells|
89111831|NCT02845830||Participants in early stage of dementia|Subjects with any type of dementia at an early phase diagnosed in the last 12 months with MMSE score 20-25 points
89111832|NCT02845830||Participants without dementia|Subjects without dementia with MMSE score 26-30 points
89230855|NCT01046890|Experimental|darunavir/ritonavir + root of Echinacea purpurea|darunavir/ritonavir + root of Echinacea purpurea
89230856|NCT01096615|Active Comparator|Tested product: Lactobacillus paracasei LP-33|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table
89290026|NCT01373632|Experimental|Firebird 2 stent group|the patients who receive Firebird 2 stent
89230857|NCT01096615|Placebo Comparator|Comparative product : placebo|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table .
89230858|NCT01046968|Experimental|Lepticore|
89230859|NCT01047046||SNM device placement|Patients who have undergone a placement of a SNM device to treat refractory OAB. A retrospective chart review will be performed on all patients who underwent a one or two-stage placement of an SNM device, which includes an implantable pulse generator (IPG), for refractory urge incontinence and urgency frequency symptoms. The patients will be those of Dr. Karen Noblett, having their device placed after 2001.
89230860|NCT01098877|Placebo Comparator|Placebo|
89230861|NCT01098877|Experimental|Cohort 1, 1mg|
89230862|NCT01098877|Experimental|Cohort 1, 3mg|
89230863|NCT01098877|Experimental|Cohort 1, 10mg|
89230864|NCT01098877|Experimental|Cohort 2, 30mg|
89230865|NCT01098877|Experimental|Cohort 2, 100mg|
89230866|NCT01098877|Experimental|Cohort 2, 300mg|
89230867|NCT01098877|Experimental|Cohort 3, 600mg|
89230868|NCT01098877|Experimental|Cohort 3, 900mg|
89230869|NCT01098877|Experimental|Cohort 3, up to 900mg (fed)|
89230870|NCT01098877|Placebo Comparator|Cohort 3, placebo (fed)|
89230871|NCT00044083|Placebo Comparator|Placebo Arm|Placebo one week
89230872|NCT00044083|Active Comparator|Tolcapone Arm|Tolcapone one week
89230873|NCT00058123|Experimental|Poly-ICLC Recurrent gliomas|"Poly-ICLC 20ug/kg 3 times a week 4 week cycles (Monday-Wednesday-Friday)~Intramuscular injection~Drug Poly-ICLC"
89111833|NCT04095169||axSpA|Patients with low back pain ≥three months who a) fulfilled the ASAS definition for a positive MRI scan of sacroiliac joints (definite inflammation) or b) were HLA-B27 positive with at least one concomitant clinical spondyloarthritis feature.
89111834|NCT04095169||non-axSpA|Patients with a) positive MRI according to the ASAS definition, but no additional clinical spondyloarthritis features, or b) positive HLA-B27 and one clinical spondyloarthritis feature.
89111835|NCT04095169||Controls|Patients with non-specific low back pain without spondyloarthritis-related features and negative MRI SIJ.
89111836|NCT04230057||Healthy volunteer|"In good general health and feeling well (no diagnosed disorders/illnesses)~At least 18 years old~BMI in the range of 18-29.9 kg/m²~No known history of substance abuse~No known allergies to food/drug"
89111837|NCT00917215|Experimental|Active acupuncture|
89111838|NCT00917215|Sham Comparator|Sham acupuncture|
89111839|NCT00917215|No Intervention|Waiting list control|
89111840|NCT04494594|Sham Comparator|Control|
89111841|NCT04494594|Active Comparator|Intervention|
89111842|NCT03203460|Experimental|Exercise Group|Supervised high-intensity aerobic interval training (HIIT) during active surveillance
89111843|NCT03203460|No Intervention|Usual Care Group|The usual care group will be provided with standard active surveillance medical care.
89111844|NCT00922948|Experimental|Cryoablation|
89111845|NCT00922948|Active Comparator|Radiofrequency ablation|Radiofrequency ablation
89111846|NCT03167892|Experimental|Intervention|Oral screen
89111847|NCT03167892|No Intervention|Control|No intervention
89111848|NCT02845284|No Intervention|Routine Care|Group education/counseling from Antenatal clinic midwives, routine PMTCT, HIV C&T and family planning C&T services on request.
89111849|NCT02845284|Experimental|Routine Care plus group support|Routine Care plus enhanced group support
89111850|NCT02845284|Experimental|Routine Care plus individual support|Routine Care plus enhanced individual support
89111851|NCT04229433|Experimental|SHR2285|Participants received one of 3 dose levels of SHR2285 administered as multiple oral doses.
89111852|NCT04229433|Experimental|Placebo|Participants received one of 3 dose levels of placebo administered as multiple oral doses.
89111853|NCT02845206|Experimental|Patient Specific Cutting Blocks|For the bespoke individualised cutting blocks to be manufactured, the patients will undergo a preoperative CT scan under a set protocol. The CT radiation dose will be considerably less than a conventional diagnostic CT scan.
89111854|NCT02845206|Active Comparator|Conventional Cutting Blocks|The patients in this arm will be operated on using conventional instruments.
89111855|NCT02783157|Experimental|Transcutaneous low-level vagal nerve stimulation (LLVNS)|n=100 patients will be randomized to transcutaneous low-level vagal nerve stimulation (LLVNS), via a clip applied to the ear. Stimulation will be delivered throughout the procedure.
89111856|NCT02783157|Sham Comparator|Sham LLVNS|n=100 patients will be randomized to sham LLVNS, with the clip applied but no stimulation delivered.
89111857|NCT02845362|Experimental|Dysphagia assessment|
89111858|NCT02782689|Experimental|Kit Biflex|The Kit Biflex® will be applied according to manufacturer recommendations for 16 weeks or until full healing.
89111859|NCT02782689|Active Comparator|Profore|The compression system Profore will be applied according to manufacturer recommendations for 16 weeks or until full healing.
89111860|NCT02845128||HFNC failure|requiring intubation and invasive mechanical ventilation
89111861|NCT02845128||HFNC success|not requiring intubation nor invasive mechanical ventilation
89111862|NCT05241912|No Intervention|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
89111863|NCT05241912|Experimental|Goal-directed fluid group|"Intervention: administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia.~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
89111864|NCT04212156||TMH test|Patient will be asked to lay supine while the head and neck maintained in a neutral position using a pillow under the head. By using digital depth gauge, the TMH will be measured from the anterior border of the thyroid cartilage directly on the thyroid notch till the anterior border of the mentum
89111865|NCT05212545|Placebo Comparator|Placebo|10 g maltodextrin per day
89111866|NCT05212545|Experimental|Prebiotic Supplement|10 g Prebiotic supplement + maltodextrin per day
89111867|NCT05212545|Experimental|Prebiotic combination|10 g prebiotic supplement+ prebiotic oligosaccharide per day
89111868|NCT05212545|Experimental|prebiotic oligosaccharide|10 g maltodextrin + prebiotic oligosaccharide per day
89111869|NCT05241756||FLACS using FEMTO LDV-Z8|
89111870|NCT05121129|Experimental|iTBS|Subjects suffering of MDD assigned to start the trial by 25 sessions of iTBS applied in left DLPFC
89111871|NCT05340543||Patient with basal cell carcinoma|"- CBC: Presence of lobule of basal cells with palisading on the edges, stromal reaction and dilated horizontal vessels."
89111872|NCT05340543||Patient with squamous cell carcinoma|- CSC: Proliferation of keratinocytes presenting cellular atypia, crossing the JDE (invasive CSC versus in situ), glomerular vessels
89111873|NCT05340543||Patient with melanoma|Melanoma: Destructured dermal-epidermal junction (DEJ), presence of pagetoid cells, clusters of atypical melanocytes, dendritic cells
89111874|NCT05341635||COVID-19 Symptomatic inpatients|Patients admitted to the Unit of Infectious Diseases of the ASST Monza for COVID-19 will run the collection of a nasopharyngeal swab, performed as part of the normal diagnostic routine; will take up to two samples collected in parallel to the development and optimization of the new method/process preanalitico and for the clinical validation of the performance of the pre-analytic method. The subjects will be adequately informed, both verbally and by means of a summary document of the study before signing a consent for participation in the study.
89111875|NCT05341635||COVID-19 Suspected subjects|To the subjects who present at the Emergency department of the ASST Monza for symptomatology referable to the COVID-19 and to patients on discharge from the Unit of Infectious Diseases of the ASST Monza for complete healing from COVID-19 will run the collection of a nasopharyngeal swab, performed as part of the normal diagnostic routine; will take up to two samples collected in parallel to the development and optimization of the new method/process preanalitico and for the clinical validation of the performance of the pre-analytic method. The subjects will be adequately informed, both verbally and by means of a summary document of the study before signing a consent for participation in the study.
89111876|NCT05234034||chronic low back pain (LBP)|persons with chronic low back pain (LBP) will be included in this arm.
89111877|NCT05234034||chronic neck pain (CNP)|persons with chronic neck pain (CNP) will be included in this arm.
89111878|NCT05234034||chronic shoulder pain (CSP)|persons with chronic shoulder pain (CSP) will be included in this arm.
89111879|NCT05234034||osteoarthritis (OA)|persons with osteoarthritis (OA) will be included in this arm.
89111880|NCT05234034||fibromyalgia (FM)|persons with fibromyalgia (FM) will be included in this arm.
89111881|NCT05234034||chronic Temporomandibular Disorder (CTMD)|persons with chronic temporomandibular disorder (CTMD) will be included in this arm.
89111882|NCT02781441|Active Comparator|Control group|Patients will receive only the education brochure of GFM
89111883|NCT02781441|Experimental|General QPL group|Patients will receive the brochure and the newly developed QPL (general version)
89111884|NCT02781441|Experimental|Targeted QPL group|Patients will receive the brochure and the newly developed QPL (general version)
89111885|NCT04229043|Active Comparator|Early labor, no analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
89111886|NCT04229043|Placebo Comparator|Early Labor, no analgesia: Water|Subject will ingest 100 ml of water
89111887|NCT04229043|Active Comparator|Early labor, analgesia: Sports drink|Subject will ingest 100 ml of a carbohydrate sports drink
89111888|NCT04229043|Placebo Comparator|Early labor, analgesia: Water|Subject will ingest 100 ml of water
89111889|NCT04230291|Other|Verbal Consultation, then Written Action Plan|"CONTROL GROUP~Survey A~Routine clinic visit~Verbal consultation only~Survey B~Verbal consultation AND Written Action Plan~Survey C"
89111890|NCT04230291|Experimental|Written Action Plan|"INTERVENTION GROUP~Survey A~Routine clinic visit~Verbal consultation AND Written Action Plan~Survey C"
89230874|NCT00022633|Experimental|gemcitabine, paclitaxel|
89111891|NCT05217654|Active Comparator|Dapagliflozin|14 day orally treatment with dapagliflozin
89111892|NCT05217654|Placebo Comparator|Dapagliflozin-placebo|14 day orally treatment with dapagliflozin - placebo
89111893|NCT05340231|Experimental|Study group|sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy
89111894|NCT05340231|Active Comparator|Control group|neoadjuvant chemotherapy alone
89111895|NCT04202016|Experimental|Piezocision on high facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
89290027|NCT01373632|Active Comparator|Excel stent group|the patients who receive Excel stent
89230875|NCT00021541|Experimental|Tipifarnib (R11577)-Arm I|Patients receive oral R115777 (Tipifarnib) first followed by placebo. 200 mg/m^2/dose BSA every 12 hours by mouth (po)on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89230876|NCT00021541|Placebo Comparator|Placebo-Arm II|Patients receive oral placebo first followed by R115777 (Tipifarnib). 200 mg/m^2/dose BSA every 12 hours by mouth (po)every 12 hours on days 1-21. Courses repeat as in arm I.
89230877|NCT01100827||EGFR mutation status in patients|
89230878|NCT00021229|Experimental|Imatinib mesylate|
89230879|NCT00372112|Active Comparator|100 mcg GW642444H|Twice daily in the morning.
89230880|NCT00372112|Active Comparator|400 mcg GW642444H|Twice daily in the morning.
89230881|NCT00372112|Active Comparator|50 mcg salmeterol|Twice daily.
89230882|NCT00372112|Placebo Comparator|placebo|Twice daily
89230883|NCT02731144|Experimental|Study group|Individualization of caloric administration with indirect calorimetry and 2.0 to 2.2 g/kg/day of protein. Early initiation of nutritional support (24 hours of admission)
89230884|NCT02731144|Active Comparator|Control group|Nutritional support initiated in the first 24 hours of admission. Protein and caloric goals calculated as 25 Kcal/kg/day and 1.4 to 1.5 g/kg/day of protein.
89230885|NCT02688790|Experimental|Cohort 1|One dose of intravenous dalbavancin infusion 22.5 mg/kg in young infants aged greater than 28 days to 3 months
89230886|NCT02688790|Experimental|Cohort 2|One dose of intravenous dalbavancin infusion 22.5 mg/kg in term neonates (defined as gestational age at or greater than 37 weeks) aged up to 28 days
89230887|NCT02688790|Experimental|Cohort 3|One dose of intravenous dalbavancin infusion 22.5 mg/kg in preterm neonates (defined as gestational age of 32 weeks, up to 37 weeks) aged no more than 28 days
89230888|NCT01047124|Experimental|Intervention|Specialist mood disorders team: treatment plan according to need
89230889|NCT01047124|No Intervention|Treatment as usual|
89230890|NCT00488475||Patients with Rheumatoid Arthritis|
89230891|NCT01020279|Other|Parallel Group A|Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
89230892|NCT01020279|Other|Parallel Group B|oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
89230893|NCT01020357|Active Comparator|caffeine|
89230894|NCT01020357|Placebo Comparator|placebo|
89230895|NCT01017627|Other|Early anemia management|Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions
89230896|NCT01017627|Other|case control|"Each case will be data-matched to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm."
89290028|NCT01219374||egg donors|anonymous egg donors
89290029|NCT01214460||All MET calls|We make an Utstein type analyze to all MET calls
89290030|NCT01214460||All EMS calls|We make an Utstein type analyze to all EMS calls during June 2015
89230897|NCT00042991|Experimental|Treatment (gefitinib and radiation therapy)|"Phase I portion: Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity.~Phase II portion: Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed BSG are treated at the MTD or the recommended Phase-II dose."
89230898|NCT01022385|No Intervention|12-hour fast|
89230899|NCT01022385|Active Comparator|24-hour low-residual diet and 12-hour fast|
89230900|NCT01017783|Other|Healthy Choices|
89230901|NCT01017783|Experimental|Diet Substitution A|
89230902|NCT01017783|Experimental|Diet Substitution B|
89230903|NCT00466167|Other|Pramipexole ER|
89230904|NCT00466167|Other|Pramipexole IR|
89230905|NCT00466167|Placebo Comparator|Placebo|
89230906|NCT01017861||Pregnant, 12th week|Pregnant women in the 12th week of pregnancy.
89230907|NCT01017861||Pregnant, 28th week|Pregnant women in the 28th week of pregnancy.
89230908|NCT01017861||Pregnant, full term|Pregnant women at full term, in hospital for an elective cesarean section.
89230909|NCT01017861||Non pregnant women|Non pregnant women
89230910|NCT01017939|Experimental|Group A: abiraterone + prednisone + dextromethorphan|Group A will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP2D6 using 2 single doses of dextromethorphan hydrobromide as a probe drug.
89230911|NCT01017939|Experimental|Group B: abiraterone + prednisone + theophylline|Group B will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP1A2 using 2 single doses of theophylline as a probe drug.
89230912|NCT00480441|Active Comparator|1|Dronabinol+ BRENDA therapy
89230913|NCT00480441|Placebo Comparator|2|Placebo+BRENDA therapy
89230914|NCT01022463|Active Comparator|Ivabradine|Crossover study to compare ivabradine and atenolol
89230915|NCT01022463|Placebo Comparator|Atenolol|
89230916|NCT00488319|Experimental|001|Paliperidone ER1.5 to 12 mg tablet once daily for 6 months
89230917|NCT01018017|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
89230918|NCT01018017|Placebo Comparator|Placebo|The placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
89230919|NCT01018251|Experimental|Arm I|Patients undergoing definitive surgery after cancer diagnosis undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT)-PET prior to definitive surgery. Patients undergoing neoadjuvant chemotherapy prior to definitive surgery undergo FLT-PET prior to and after completion of neoadjuvant chemotherapy
89230920|NCT01018329|Experimental|I|Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.
89230921|NCT00463047|Experimental|Fentanyl Buccal Tablets (FBT)|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
89230922|NCT00463047|Active Comparator|Oxycodone|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
89230923|NCT00487695|Active Comparator|CLE followed by standard EGD|Participants are randomized to have either confocal laser endomicroscopy (CLE) or standard endoscopy (EGD) first. Then 6 weeks later, they have the other procedure. This arm is for patients randomized to CLE followed by standard EGD
89230924|NCT00487695|Active Comparator|standard EGD followed by CLE|Patients are randomized to either have standard endoscopy (EGD)or confocal laser endomicroscopy (CLE) first. The second procedure is then completed 6 weeks later. This arm is for patients who had standard endoscopy first.
89230925|NCT00487539|Placebo Comparator|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
89230926|NCT00487539|Experimental|Golimumab 100 mg -> 50 mg|Golimumab 100 milligram (mg) subcutaneous injection administered at Week 0 and dose is decreased to 50 mg at Week 2.
89230927|NCT00487539|Experimental|Golimumab 200 mg -> 100 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 and dose is decreased to 100 mg at Week 2.
89111896|NCT04202016|No Intervention|High facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
89111897|NCT04202016|Experimental|Piezocision on average facial divergence|Piezocision Surgery prior to space closure with closing coil spring four months after extraction. Six weeks later, three follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
89111898|NCT04202016|No Intervention|Average facial divergence|Space closure with coil spring four months after extraction. Six weeks later, three other follow up appointments, six weeks apart, taking impressions to measure the rate of space closure.
89111899|NCT05199558||eclamptic patients|
89111900|NCT05199558||preeclamptic patients|
89111901|NCT05199558||healthy pregnant women of same gestation and parity|
89111902|NCT04229355|Experimental|DEB-TACE plus Sorafenib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive sorafenib (400 mg/d, po, bid) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
89111903|NCT04229355|Experimental|DEB-TACE plus Lenvatinib|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive lenvatinib (8 mg/d, po, qd) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. Lenvatinib will be taken orally for six months, untill tumor progression, or intolerable adverse reactions.
89111904|NCT04229355|Active Comparator|DEB-TACE plus PD-1 inhibitor|Patients with unresectable hepatocellular carcinoma (HCC) in this group will receive drug-eluting bead transarterial chemoembolization (DEB-TACE).And then, they will receive PD-1 inhibitor (200 mg, iv, 3 weeks) one week after DEB-TACE therapy. The second DEB-TACE will be performed after one month later the first DEB-TACE. PD-1 inhibitor will be taken for six months, untill tumor progression, or intolerable adverse reactions.
89111905|NCT02848170|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 12 weeks
89111906|NCT02848170|Active Comparator|olmesartan medoxomil|olmesartan medoxomil 10 to 20 mg, orally, once daily after breakfast for 12 weeks
89111907|NCT05341479||Surgical treatment for early-stage OPC|Early-stage OPC patients treated with surgery according to proper indications (CSCO 2021 and NCCN 2021).
89111908|NCT05341479||RT treatment for early-stage OPC|Early-stage OPC patients treated with radiotherapy (RT) according to proper indications (CSCO 2021 and NCCN 2021).
89111909|NCT05341479||CRT treatment for advanced OPC|Advanced OPC patients treated with chemoradiotherapy (CRT) according to proper indications (CSCO 2021 and NCCN 2021).
89111910|NCT05341479||Surgical treatment for advanced OPC|Advanced OPC patients treated with surgery according to proper indications (CSCO 2021 and NCCN 2021).
89111911|NCT05341479||Neoadjuvant treatment for advanced OPC|Advanced OPC patients treated with neoadjuvant treatment according to proper indications (CSCO 2021 and NCCN 2021).
89111912|NCT04202172|Active Comparator|BIOFREEDOM|Implantation of Drug-eluting coronary stent without polymer in patients with myocardial infarction.
89111913|NCT04202172|Experimental|COMBO|Implantation of Bioactive coronary stent in patients with myocardial infarction.
89111914|NCT02848404|Experimental|Categorical Language Fluency Smartphone Application|Smartphone game application specifically aimed at training categorical language fluency
89111915|NCT02782767|Active Comparator|Epidural catheter infusion|epidural catheter in the thoracic vertebra level to provide local anesthetic infusion
89111916|NCT02782767|Experimental|Wound catheter infusion|A multiorificed wound infusion catheter kept within the incision site to provide continuous local anesthetic infusion
89111917|NCT02782845|Experimental|Pegfilgrastim|Participants will receive CT or ICT for 6 cycles on Days 1-6, as per standard of care. Protocol does not specify any choice of CT or ICT drugs. Participants will receive pegfilgrastim at a fixed dose of 6 mg subcutaneously, 24 hours after the last dose of CT or ICT in each treatment cycle. CT or ICT cycles of 21 days, as per standard of care.
89111918|NCT05341401|Active Comparator|Budesonide MMX|this study aims to detect the safety and side effects of budesonide MMX in the management of mild to moderate cases of ulcerative colitis in comparison to prednisolone. Budesonide MMX will be given after randomization to patients with mild to moderate cases who failed to respond to mesalazine. The dose will be 9mg as a single dose given for 8 weeks.
89290031|NCT01214460||All patient in the emergency department|We make an Utstein type analyze to all Emergency visits during June 2015
89230928|NCT00487539|Experimental|Golimumab 400 mg -> 200 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 and dose is decreased to 200 mg at Week 2.
89230929|NCT01018407|Experimental|Discrete Trial Training|Targets nonverbal imitation, match-to-sample, verbal imitation, imitation of play activities, receptive language, and expressive language. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
89290032|NCT01214538||Control group - culture negative|50 children with pneumococcal culture-negative Acute Otitis Media
89290033|NCT01214538||study group- culture positive|50 children with pneumococcal culture-positive Acute Otitis Media
89230930|NCT01018407|Experimental|Interpersonal Developmental Approach|Targets Joint Attention and Symbolic Play. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
89230931|NCT00486837|Experimental|Group 1|Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
89230932|NCT00486837|Experimental|Group 2|Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
89230933|NCT04199247|Experimental|Exercise|Within 1 week of injury, participants will be randomized to either a sub symptom threshold exercise program (intervention group) or usual care (recommendation from their doctor). Those in the intervention group will participate in an exercise program 5x/week, 20-30 minutes/session, for 2 months.
89230934|NCT04199247|No Intervention|Usual Care|Participants will continue with their return to play progression based upon the advice given to them at their initial post-injury evaluation.
89230935|NCT00486759|Experimental|Bevacizumab + rituximab + CHOP|Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
89230936|NCT00486759|Active Comparator|Placebo + rituximab + CHOP|Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
89230937|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 200 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT. Starting dose of HCQ is 200mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
89290034|NCT04562974|Experimental|One group of 30 healthy subjects|Perception and memory tasks inside a MRI-scanner for all participants
89290035|NCT03119662|Experimental|Visipaque™: Contrast-Enhanced Computed Tomography (CECT)|Participants received 1 intravenous injection of Visipaque™ 320 mg I/ml injection (100 mL iodixanol) and underwent computed tomography (CT) examination.
89290036|NCT03119662|Placebo Comparator|Saline: Non-Enhanced Computed Tomography (NECT)|Participants received 1 intravenous injection of saline placebo (matched to Visipaque™ 320 mg I/ml injection) and underwent computed tomography (CT) examination and supplemental non-contrast duplex ultrasonography imaging examination.
89290037|NCT01124760|Experimental|1|AZD9742
89111919|NCT05341401|Active Comparator|prednisolone|this study aims to detect the safety and side effects of budesonide MMX in the management of mild to moderate cases of ulcerative colitis in comparison to prednisolone. prdinisolone MMX will be given after randomization to patients with mild to moderate cases who failed to respond to mesalazine. The starting dose will be 40 mg and reduced by 5 mg each weak for 8 weeks .
89111920|NCT05340153|Active Comparator|Artemether-lumefantrine|Drug: Artemether-lumefantrine drug combination Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains a blister of 12 tablets. It will be administered each day as one, two or three tablets depending on the weight of the child.
89111921|NCT05340153|Experimental|Dihydroartemisinin-piperaquine|Drug: Dihydroartemisinin-piperaquine drug combination Dihydroartemisinin-piperaquine is formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains a blister of 6 tablets and given each day as half, one, two or three tablets depending on the weight of the child.
89111922|NCT00902850|Experimental|SofLens Daily Disposable|SofLens Daily Disposable Lenses
89111923|NCT00902850|Active Comparator|Marketed 1 Day Contact Lens|Marketed 1 Day Contact Lens
89111924|NCT05078502|Active Comparator|Intervention Vitamin D3 along with CsDMARDs|One capsule of vitamin D3 (40000IU) weekly for 8 weeks
89111925|NCT05078502|Placebo Comparator|Placebo of Vitamin D3 along with CsDMARDs|One capsule of placebo of vitamin D3(40000IU) weekly for 8 weeks
89111926|NCT02780739|Experimental|Cognitive Training - 48 sessions|56 hours of video game training with Mind Frontiers adaptive cognitive training software (48 70-min sessions distributed over 16 weeks)
89111927|NCT02780739|Experimental|Fitness, Cognitive Training, sham tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers adaptive cognitive training software with simultaneous sham tDCS (20 70-min sessions distributed over weeks 5-16)
89230938|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 400 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 400 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
89230939|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 600 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 600 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
89290038|NCT01217268|Experimental|Training and supervision of staff|Staff members get training in person centered care by supervision using video-conference kit
89230940|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 800 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 800 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
89230941|NCT00486603|Experimental|Phase 2: RT + TMZ + HCQ MTD|"Phse 2: daily hydroxychloroquine (HCQ) (MTD 600mg) on 1st day of RT and concomitant temozolomide for 6wks during RT. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~Other: pharmacological study (PK)~Pts will continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 2~Radiation (RT)"
89230942|NCT00486291|Experimental|1|Phentermine 15mg/topiramate 100mg
89230943|NCT00486291|Placebo Comparator|2|Matched placebo
89230944|NCT00474045|Experimental|Insulin detemir|Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
89230945|NCT00474045|Active Comparator|Neutral Protamine Hagedorn (NPH) insulin|Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
89230946|NCT01020825||ASCs|Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
89230947|NCT01020825||Fibrin glue|Patients randomized to the control treatment (application of fibrin glue) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
89230948|NCT01020825||ASCs + Fibrin Glue|Patients randomized to the control treatment (application of fibrin glue) + intralesional injection of ASCs in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
89111928|NCT02780739|Experimental|Fitness, Cognitive Training, active tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers 1.0 adaptive cognitive training software with simultaneous active tDCS for a total of 10 hrs (20 70-min sessions distributed over weeks 5-16)
89111929|NCT02780739|Active Comparator|Active Control|56 hours of video game training with visual search and change detection tasks using open sesame software (48 70-min sessions distributed over 16 weeks)
89111930|NCT02780739|No Intervention|No Contact Control|Completed no study activities for 16 weeks after pre-assessment, then returned for post-assessment
89111931|NCT05026164|Active Comparator|Active|CHI-202. Participants will drink one 7.0g CHI-202 powder sachet mixed into 16oz of water twice daily.
89230949|NCT01018485|Experimental|Botulinum Toxin First Dose|Blinded and Randomized injection of 20 upper limbs with Botulinum Toxin Type A
89230950|NCT01018485|Experimental|Botulinum Toxin Second Dose|20 patients will receive Placebo as first dose and Botulinum Toxin as second dose injection 3 months after initiation of the study
89230951|NCT00462501|Experimental|Chemotherapy and Bevacizumab With or Without Radiation|FOLFOX/Bevacizumab will be given for 4 cycles over 8 weeks; FOLFOLX6 without Bevacizumab will be given for an additional 2 cycles over 4 weeks. Oxaliplatin will be given on Day 1 of each cycle over 2 hours at 85 mg/m2 IV. Leucovorin will be given Day 1 of each cycle over 2 hours at 400 mg/m2 IV. Fluorouracil will be given on Day 1 of each cycle at 400 mg/m2 IVP, then Fluorouracil will be given at 1200 mg/m2 IVCI over Day 1 and 2. Bevacizumab will be given at 5mg/kg over 10 minutes on day 1. Patients will undergo re-staging within 3 weeks of completing their 6th cycle of FOLFOX. If the reassessment reveals that there has been no disease progression as compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection. If the surgical oncologist's reassessment is that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous infusional 5-fluorouracil.
89230952|NCT03996603|Experimental|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
89230953|NCT03996603|No Intervention|Control Cohort|No intervention will be given.
89230954|NCT01018641|Experimental|1|SA3Ag in both stage 1 and stage 2
89230955|NCT01018641|Experimental|2|SA3Ag in stage 1 followed by placebo in stage 2.
89230956|NCT01018641|Placebo Comparator|3|Placebo in both stage 1 and stage 2
89230957|NCT01018641|Experimental|4|SA3Ag in stage 1 and no vaccine in stage 2.
89230958|NCT01018641|Placebo Comparator|5|Placebo in stage 1 and no vaccine in stage 2.
89230959|NCT01018719||Left side breast cancer|
89230960|NCT01018719||Right side breast cancer|
89230961|NCT00383188|Placebo Comparator|1|
89230962|NCT00383188|Experimental|2|
89230963|NCT00383188|Experimental|3|
89230964|NCT00383188|Experimental|4|
89230965|NCT00383188|Experimental|5|
89230966|NCT01021059|Experimental|1|rh IL-15 daily for 12 days of 42 days cycle.
89290039|NCT03936582|Experimental|Treatment|All owners/managers of small businesses in 10 treatment neighborhoods will receive a request to support youth physical activity. The owners/managers will be able to direct support to specific programs, get recognized for their support, receive added information on the benefits of supporting such programs, have the oversight of an advisory board and interface with a local program representative
89290040|NCT03936582|Active Comparator|control|All owners/managers of small businesses in 10 control neighborhoods will will receive a request to support youth physical activity. None of the other components of the treatment arm (e.g., direct support to specific programs, advisory board) will be provided.
89111932|NCT05026164|Placebo Comparator|Placebo|CHI-101. Participants will drink one 7.0g CHI-101 powder sachet mixed into 16oz of water twice daily.
89111933|NCT05340075||Staged percutaneous nephrolithotomy group 1|Those who underwent percutaneous nephrolithotomy 2-4 weeks after percutaneous nephrolithotomy for stones in the other kidney
89111934|NCT05340075||Staged percutaneous nephrolithotomy group 2|Those who underwent percutaneous nephrolithotomy 4-6 weeks after percutaneous nephrolithotomy for stones in the other kidney
89111935|NCT02844894|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine in 20 ml normal saline will be infused in 5 minutes before intubation
89111936|NCT02844894|Experimental|Esmolol|0.5 mg/kg esmolol in 20 ml normal saline will be infused in 5 minutes before intubation
89111937|NCT02844894|Placebo Comparator|Placebo|20 ml normal saline infused in 5 minutes before intubation
89111938|NCT04196439|Active Comparator|continuous epidural analgesia|continuous lumbar epidural catheter inserted preoperatively before induction of general anaesthesia
89111939|NCT04196439|Active Comparator|continuous supra-inguinal fascia iliaca compartment block|ultrasound guided supra-inguinal FICB with insertion of catheter for continuous infusion before induction of general anaesthesia.
89111940|NCT02847780|Active Comparator|C-Mac video laryngoscope.|Active Comparator: C-Mac Videolaryngoscope for vocal cord movement assessment.
89111941|NCT02847780|Experimental|Airway Ultrasound|Experimental: Airway Ultrasound for vocal cord movement assessment.
89111942|NCT05025540||Experimental group|Experimental group1：DKD patients with Type 2 diabetes patients with DKD Experimental group2：High level DKD patients with diabetic kidney disease Stage III and IV.
89111943|NCT05025540||Control group|Control1：T2DM patients with Type 2 diabetes Control2：Low level DKD patients with diabetic kidney disease Stage I and II.
89111944|NCT05338203|Experimental|experimental group (tandem breastfeeding)|mother mılk wıll collected from these mother and they wıll be analyzed
89111945|NCT05338203|No Intervention|control group ( non-tandem breastfeeding)|mother mılk wıll collected from these mother and they wıll be analyzed
89111946|NCT05341245|Experimental|Graphene oxide group|The surgical defect will be managed by open flap debridement and application of Graphene oxide
89111947|NCT05341245|Other|Open flap group|The surgical defect will be managed by open flap debridement
89111948|NCT04778904|Experimental|Group 1 (MVA-HBV)|Day 0: MVA-HBV 1 x 10^8 pfu IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection
89111949|NCT04778904|Experimental|Group 2 (ChAdOx1-HBV, MVA-HBV)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection
89111950|NCT04778904|Experimental|Group 3 (ChAdOx1-HBV, MVA-HBV and nivolumab)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 28: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
89111951|NCT04778904|Experimental|Group 4 (ChAdOx1-HBV and nivolumab, MVA-HBV and nivolumab)|Day 0: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection + nivolumab 0.3 mg/kg IV infusion Day 28: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
89111952|NCT04228887|Active Comparator|Control Group|The control group will be receive 45 minutes training sessions 3 times a week for 8 weeks; 2 days a week for home based balance training and 1 day for supervisory training with Bio-Dex Balance-System ®.
89111953|NCT04228887|Active Comparator|Training Group|The training group will receive inspiratory muscle training; 15 minutes sessions 5 times a week for 8 weeks in addion to balance training same as control.
89111954|NCT03986502|Experimental|Arm I (financial navigation program)|Patients and caregivers watch a web-based financial literacy video and receive information about financial counseling, direct medical cost and healthcare coverage assistance, and indirect and non-medical cost assistance.
89111955|NCT03986502|Active Comparator|Arm II (usual care)|Patients and caregivers participate in usual clinic procedures and utilize any available clinic or community-based financial resources. Patients and caregivers will also be provided the financial navigation videos and worksheets from the intervention.
89111956|NCT02780895|Experimental|Single Arm Study|stereotactic brain surgery of human stem cells (OK99)
89111957|NCT02780817|Experimental|Error enhancement|Arm reaching rehabilitation training with error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
89111958|NCT02780817|Other|Control group|Arm reaching rehabilitation training without error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
89111959|NCT04229199|Experimental|intervention group (IG)|Dyads of children and parents allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
89111960|NCT04229199|No Intervention|control group (CG)|Dyads assigned to the CG were provided only the standard practice on their day admission to the hospital.
89111961|NCT05098197|Experimental|Tumor Infiltrating Lymphocytes|1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced hepatobiliary-pancreatic cancers after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
89111962|NCT02847936|Active Comparator|VICRYL PLUS|triclosan-coated sutures
89111963|NCT02847936|Active Comparator|VICRYL|non antibacterial coated sutures
89111964|NCT05329233||minimal flow|For minimal-flow anesthesia, oxygen 0.3 L/min and medical air 0.2 L/min (FGF 0.5 L/min, FiO2 68%) were administered to patients in group M.
89111965|NCT05329233||low flow|For low-flow anesthesia, oxygen 0.37 L/min and medical air 0.63 L/min (FGF 1 L/min, FiO2 50%) were administered to patients in group L.
89111966|NCT05329233||high flow|For high-flow anesthesia, oxygen 1 L/min and medical air 3 L/min (FGF 4 L/min, FiO2 40%) were administered to patients in group H.
89111967|NCT00634725|Active Comparator|Arm 1 (A1) - Gemcitabine|Gemcitabine 2 months, then stop until progression
89111968|NCT00634725|Experimental|Arm 2 (B1) Gemcitabine + Erlotinib|B1 Gemcitabine + Erlotinib (100mg/d) 2 months, then erlotinib maintenance (150 mg/d)until progression
89111969|NCT00634725|Experimental|Arm 3 (A2) CRT|A2 CRT then stop until progression
89111970|NCT00634725|Experimental|Arm 4 (B2) CRT then erlotinib|B2 CRT then erlotinib maintenance (150mg/d) until progression
89111971|NCT04228809|Experimental|anodal tDCS|anodal tDCS stimulation
89111972|NCT04228809|Active Comparator|cathodal tDCS|cathodal tDCS stimulation
89111973|NCT04228809|Placebo Comparator|sham tDCS|sham tDCS stimulation (stopped after 30 seconds)
89111974|NCT05327673||patients who accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)|
89111975|NCT05327673||patients who did not accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)|
89111976|NCT05325489|Experimental|Nebulized Budesonide|Drug: budesonide 0.5mg/2ml Pulmicort Respules budesonide inhalation suspension(BIS) once a day (QD) oral montelukast sodium chewable tablets 4mg QD
89111977|NCT05325489|Active Comparator|Intranasal Budesonide Spray|Drug: budesonide nasal spray 100μg QD oral montelukast sodium chewable tablets 4mg QD
89111978|NCT00902538|Experimental|Olmesartan (OLM) 40mg-Amlodipine (AML) 10mg|The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2.
89111979|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3.
89111980|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Participants could start receiving this combination in randomized, double-blind, 8- week Period 2.
89111981|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Responders)|Participants who meet their blood pressure goals in Period 3 and continued into the 8-week, double-blind Period 4 continued to receive this combination.
89111982|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
89111983|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
89111984|NCT02779335|Other|Enteral formula tube feeding|Enteral fed children, ages 1-13, with establish enteral feeding access
89111985|NCT04228185|Experimental|Laparoscopic banded sleeve gastrectomy|Group undergoing banded sleeve
89111986|NCT04228185|Active Comparator|Laparoscopic sleeve gastrectomy|Group undergoing standard sleeve
89111987|NCT05339763|Active Comparator|radiation group|Those are patient with rectal cancer who underwent preoperative neoadjuvant chemo radiotherapy before surgery.
89111988|NCT05339763|Active Comparator|non radiation group|Those are patient with rectal cancer who did not receive preoperative neoadjuvant chemo radiotherapy before surgery.
89111989|NCT04228653|Experimental|No Arm|As this is the follow up study, there are no arms
89111990|NCT02780037|Experimental|Prevention|Regulatory frame: prevention
89111991|NCT02780037|Experimental|Promotion|Regulatory frame: promotion
89111992|NCT02780037|Sham Comparator|Neutral|Regulatory frame: not implied
89111993|NCT02780505|Active Comparator|vitamin c|vitamin C supplement orally up to 250 mg per day for 6 weeks was prescribed. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study.
89111994|NCT02780505|Placebo Comparator|placebo|ُPlacebo prescribed to Group B. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study
89111995|NCT02690844|Active Comparator|Clonazepam|Clonazepam (Klonopin®) treatment arm - 1 mg clonazepam (Klonopin® tablet) TID, dissolved in mouth for 3 minutes then expectorated
89111996|NCT02690844|Placebo Comparator|Mucolox® alone|Mucolox® only - 5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated
89111997|NCT02690844|Experimental|Mucolox® and clonazepam|Mucolox® and clonazepam - 1mg Clonazepam/5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated.
89111998|NCT04201860||Blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue handled explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
89111999|NCT04201860||Not blasters group|The volunteers of the blasters group of Italian Mountain and Cave Rescue did not handle explosive with nitrogen compounds and nitroglycerin of micro-charges, before the accidental uncontrolled detonation.
89112000|NCT05075889|Experimental|Benign Bone patients|Patients with Benign Bone tumors requiring intralesional operative management will be administered immunofluorescent indocyanine green 24 hours prior to surgery, imaging of perfused tissues will be performed at the time of tumor removal.
89112001|NCT02848014|Experimental|Expectation|Participants are asked to think and write about ways how they can positively influence/control the stress during stress induction. They also can think of strategies they used in their past. The purpose of this arm is to improve participants' personal control expectations.
89112002|NCT02848014|Experimental|Emotion|Participants in this group are asked to write a gratitude-letter to a person they want to thank. The purpose of this arm is to foster positive emotions.
89112003|NCT02848014|Active Comparator|Control|Participants in this group are asked to do a neutral writing task. The task is to write a protocol of yesterday's to-dos.
89112004|NCT04972929|Experimental|Spinal Manipulation|The spinal manipulation (SM) group will receive manually delivered SM limited to the thoracic spine.
89112005|NCT04972929|Sham Comparator|Sham Spinal Manipulation|Sham-spinal manipulation will be delivered by setting the expansion control knob on an Activator II (Activator Methods®) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician. At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted.
89112006|NCT02847702|Experimental|VM902A 200 mg|VM902A 200-mg Capsules
89112007|NCT02847702|Experimental|VM902A 400 mg|VM902A 400-mg Capsules (2 x 200-mg capsules)
89112008|NCT02847702|Active Comparator|Naproxen|Naproxen 500-mg Capsules
89112009|NCT02847702|Placebo Comparator|Placebo|Placebo
89112010|NCT05236881|Experimental|ANíMATE mobile application|Standard care protocol (3 face-to-face visits: basal, 2 and 4 months) + ANíMATE mobile application
89112011|NCT05236881|No Intervention|Standard care|Standard care protocol (3 face-to-face visits: basal, 2 and 4 months)
89112012|NCT02779413||Insulin degludec|
89112013|NCT04887402||clomiphene citrate sensitive|"Based on the ovulation pattern, these patients will be divided into two groups, one who ovulated with CC maximum 150 mg and others who did not ovulate considered as CC resistant. The patients who ovulated will be further classified into three subgroups based on whether they ovulated with 50 mg or 100 mg or 150 mg of CC.~The various parameters will be compared between the CC-resistant and CC-sensitive groups."
89112014|NCT04887402||clomiphene citrate resistent|"Based on the ovulation pattern, these patients will be divided into two groups, one who ovulated with CC maximum 150 mg and others who did not ovulate considered as CC resistant. The patients who ovulated will be further classified into three subgroups based on whether they ovulated with 50 mg or 100 mg or 150 mg of CC.~The various parameters will be compared between the CC-resistant and CC-sensitive groups."
89112015|NCT05336916|Experimental|Blended MBCT|"The blended MBCT consists of four 2,5 hour group sessions through videoconference (session 1, 3, 5 and 8), taught by experienced mindfulness trainers. The other sessions (2, 4, 6 and 7) are delivered online and are individual. Mindfulness trainers will provide online feedback to participants for these sessions. The sessions include meditation exercises, psycho-education, and group discussion. In addition to the sessions, participants are instructed to do daily home practice 45 minutes a day. The regular MBCT program was adapted to fit the needs of the target group and, for instance includes psycho-education about grief and cancer-related fatigue.~Online sessions were built around a specific theme. Participants are provided with information, audio files of meditations, and recording assignments around the theme of the session through a personal, secure webpage. The sessions look appealing and persuasive technologies such as reminders and videos are used."
89112016|NCT05336916|Experimental|Unguided online MBCT|"Participants in the unguided online arm receive access to the 8 online mindfulness sessions (same intervention as blended MBCT arm), but no mindfulness trainer will be involved.~Each online session was built around a specific theme, for instance automatic pilot, communication or self-care. Participants are provided with information, audio files of meditations, and recording assignments around the theme of the session through a personal, secure webpage. Participants are encouraged to read the information and do the assigned meditations and recording assignments within one week. The sessions will look appealing and persuasive technologies such as reminders and video's will be used."
89112017|NCT05336916|No Intervention|Treatment As Usual|Not offered the mindfulness program, treatment as usual
89112018|NCT04793568|Experimental|Recombinant Interferon gamma 1b (IMUKIN®)|
89112019|NCT04793568|Placebo Comparator|Recombinant Interferon gamma 1b placebo|
89112020|NCT05339217|Experimental|Telitacicept and low dose IL2|"160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.~Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL2 was injected once a week for 12 weeks subcutaneously."
89112021|NCT05339217|Active Comparator|Telitacicept|160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
89112022|NCT05339217|Active Comparator|low dose IL2|Interleukine-2 was first added to the original treatment for systemic lupus erythematosus with 1 million IU qod for 12 weeks, injected subcutaneously at the outer side of upper arm, abdomen and thigh, then the same dose of IL2 was injected once a week for 12 weeks subcutaneously.
89112023|NCT04793490|Other|Group A (Control group)|Patients will receive paracetamol 1 g thrice daily intravenously
89112024|NCT04793490|Active Comparator|Group B (Sphenopalatine ganglion block group)|patients will receive sphenopalatine ganglion block via transnasal approache by a cotton tipped applicator soaked in 2%lignocaine with 4 mg dexamethasone
89112025|NCT00779532|Active Comparator|Group A|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.~Once daily intake (orally) of one moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of one moxifloxacin capsule of 400 mg at Day 14."
89112026|NCT00779532|Experimental|Group B|"Once daily intake (orally) of 4 NOMAC-E2 placebo tablets and 1 NOMAC-E2 (2.5/1.5 mg) tablet from Day 1 to Day 14.~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14."
89112027|NCT00779532|Experimental|Group C|"Once daily intake (orally) of 5 NOMAC-E2 (2.5/1.5 mg) tablets from Day 1 to Day 14.~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14"
89112028|NCT00779532|Placebo Comparator|Group D|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Days -1 and 14."
89112029|NCT01036022|Experimental|Group 2|ASACOL 800mg t.i.d.
89112030|NCT01036022|Experimental|Group 1|GSK1399686 at 3-4 dose levels
89112031|NCT01036022|Experimental|Group 3|Placebo
89112032|NCT04172766|No Intervention|Basic|"Participants in the first (Basic) group will have the iOS version 13.2 or later shipping user interface (UI) that provides ability to review exposure level data for headphone audio levels and environmental sound levels in the Health app."
89290041|NCT02728804||Health Services Research (questionnaire administration)|Patients complete questionnaires (including the Baseline, Financial/Employment Impact, Insurance Impact, Quality of Life, and Treatment Perceptions questionnaires) over 30-60 minutes at baseline and at 3, 6, 9, and 12 months. Caregivers complete questionnaires over 30-60 minutes at baseline and at 6 and 12 months.
89290042|NCT01217346||cardiac syndrome X|subjects fulfilling the clinical triad of cardiac syndrome X
89290043|NCT01214694|Experimental|Active Comparator: Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
89290044|NCT01214694|Experimental|I-InTERACT|Participants will receive a 24 week, 27 session internet-based parenting skills program
89112033|NCT04172766|Active Comparator|Advanced|"Participants in the second (Advanced) group will have a UI that includes notifications prompting personal data pattern review in the Health app and then prompting to do an abbreviated Pure Tone Audiometry module completed 0-24 hours after loud headphone audio level exposure (equivalent continuous average noise level, or LEQ, to >97 A-weighted decibels, or dBA for >30 minutes) to evaluate for a temporary threshold shift from baseline."
89112034|NCT04227795|Experimental|Artificial intelligence-Assisted real time colonoscopy|AI assisted real-time detection of colonic lesions
89290045|NCT01214694|Experimental|I-InTERACT Express|Participants will receive an abbreviated 7 week, 14 session version of the I-InTERACT parenting skills program.
89290046|NCT01120080|Placebo Comparator|Practical Counseling|
89290047|NCT01120080|Active Comparator|Alcohol Intervention Counseling|
89290048|NCT01217502|Experimental|Self management|
89290049|NCT01214772|Experimental|heparin,pregnancy,IVF failure|Women in the heparin arm are administered 5000 IU twice a day on the day of embryo transfer
89290050|NCT01120548|Experimental|Rehabilitation + Ventilation Group|Patient Heart Failure with sleep disordered breathing who follows ventilation therapy and physical training.
89112035|NCT05321901|Active Comparator|Experimental Group: Telerehabilitation assisted exercise program|"The telerehabilitation-assisted exercise program included a Biopsychosocial Exercise Therapy approach (BETY).~The approaches that make up the BETY innovation are grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.~Tele-rehabilitation group participated in the sessions that lasted for one and a half hours, 3 days a week for 8 weeks, over the Whatsapp group.~The investigators, who provided supervision during the sessions, also participated in the exercises simultaneously."
89112036|NCT05321901|Other|Control Group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
89112037|NCT04156230|Experimental|Deep vein thrombosis|Subjects with Deep vein thrombosis will receive a single IV injection of [18F] GP1
89112038|NCT02779023|Experimental|ICHP + CBT-I|Participants in this arm will receive the usual care (ICHP program) plus 6 Cognitive-Behavior Therapy for Insomnia (CBT-I) treatment sessions. Four of the treatment sessions will be in person and two will be over the phone.
89112039|NCT02779023|No Intervention|ICHP Only|Participants in this arm will receive the usual care (ICHP program).
89290051|NCT01120548|No Intervention|Rehabilitation Only Group|
89230967|NCT00462345|Experimental|Rituximab, Methotrexate|Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.
89230968|NCT01025115|Experimental|A|Diamel
89230969|NCT01025115|Placebo Comparator|B|Placebo
89230970|NCT01022541|Other|This is a single arm study|This is a single arm study
89230971|NCT01045408|Placebo Comparator|Berry|
89230972|NCT01045408|Placebo Comparator|Placebo|
89230973|NCT01047202|Experimental|Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart
89230974|NCT01047202|Experimental|Group 2 : 15 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart
89230975|NCT01047202|Sham Comparator|Group 3 : 7.5 μg seasonal trivalent vaccine|60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart
89112040|NCT05319093||Early Ozanimod treatment|"In this group the effect of Ozanimod will be assessed in patients who initiated on Ozanimod treatment at study baseline (n=10).~Treatment schedule and dosage of Ozanimod and the other disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital."
89112041|NCT05319093||Medium-term Ozanimod treatment|"In this group, the effect of Ozanimod will be assessed in patients treated with Ozanimod for ≥6 months at study baseline (n=10).~Treatment schedule and dosage of Ozanimod and the other disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital."
89112042|NCT05319093||Non-Ozanimod treatment|"In this group, investigators will involve patients initiated on any disease-modifying drug (other than Ozanimod) at study initiation (n=10).~Treatment schedule and dosage of the disease-modifying treatments (DMTs) will be solely based on clinical indication and will be instituted by the patient's treating neurologist at Brigham and Women's Hospital or Massachusetts General Hospital. The proposed study is purely observational and will not influence the selection, schedule or dosage of patient treatments."
89112043|NCT05319093||Untreated|In this group, MS patient will be involved who did not receive any disease-modifying drug for at least 3 months before study initiation (i.e., untreated patients, n=10)
89112044|NCT03817086|Experimental|Hand coordination and mental practice|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to mentally imagine doing the task with an action observation of perfect performance.
89112045|NCT03817086|Active Comparator|Hand coordination and action observation|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to observe a visual feedback of performance.
89112046|NCT04693182|No Intervention|With quick returns|The control condition in this trial implies that employees maintain the same number of quick returns as in previous years for the six-month intervention period. Hospital units in the control group are not expected to experience any increase in the number of quick returns.
89112047|NCT04693182|Experimental|Without quick returns|The intervention entails implementing a shift schedule which abolishes quick returns for a six-month intervention period. The number of quick returns in the various hospital units in this trial varies from 329-2356 per year. The intervention means that this number is abolished or reduced as much as possible. For practical reasons it is reasonable to expect that for many of the units it may be a matter of reducing rather than completely abolishing quick returns, as ensuring adequate staffing (e.g., due to sickness absence), often on short-notice make it impossible to comply with the rule of avoiding quick returns. The human resources department at the hospital assisted shift planners in scheduling shift schedules without quick returns.
89112048|NCT00752557|Experimental|1|rhBMP-2/CPM , 1.0 mg/mL
89112049|NCT00752557|Experimental|2|rhBMP-2/CPM , 2.0 mg/mL
89112050|NCT00752557|Active Comparator|3|Oral bisphosphonate therapy (standard of care)
89112051|NCT04228029|Active Comparator|Carboxytherapy|
89112052|NCT04228029|Active Comparator|Intralesional steroids|
89112053|NCT04228029|Active Comparator|Combination of carboxytherapy and intralesional steroids|
89112054|NCT04570176|Experimental|Urologic tumor group|patients with adrenal adenoma, muscle-invasive bladder cancer or renal cell carcinoma are included in the experiment.
89230976|NCT01047280|Placebo Comparator|Safflower oil|This arm of the study constitutes the control phase
89112055|NCT00751218|Active Comparator|Arm 1|desloratadine
89112056|NCT00751218|Placebo Comparator|Arm 2|Placebo
89112057|NCT00751218|Active Comparator|Arm 3|cetirizine
89112058|NCT05318079|Experimental|Group virtual reality gaming|The intervention will include home-based exercise using the Oculus Quest 2. Participants will be prescribed two gaming goals to achieve across the 8-week intervention. The first goal will be to play with the Quest for at least ≥60 minutes, 5 days per week (Monday - Friday) across the 8-week intervention: a total of 300 minutes. Participants can achieve these goals through either single- or multiplayer gaming but will be prescribed to engage in online multiplayer or peer-to-peer gaming at least 2 days per week.
89230977|NCT01047280|Experimental|Clarinol G-80®|
89112059|NCT05318079|No Intervention|Wait-list Control|People who are randomized to the waitlist group will undergo 4-weeks of wait (habitual daily activities), followed by 8-weeks of VR intervention. People in the wait-group will be in the study for a total of 12 weeks.
89112060|NCT02600533|No Intervention|Standard care/control group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the standard of care group will be provided standard educational resources (booklet and DVD), with no additional instructions. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
89112061|NCT02600533|Experimental|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
89112062|NCT05336604||General population, aged 15 years or more, living in France|Population-based ohort of general population, aged 15 years or more, living in France in May 2020, selected at random from national administrative sample frame
89112063|NCT02779569|Experimental|Ultra-low-dose group|decitabine was subcutaneously administered at 5 to 7 mg/m2 once daily for successive 3 days at the first week, and once daily at weeks 2 to 4, with a total dose of 60 mg in a 4-week cycle.
89112064|NCT02779569|Active Comparator|Low-dose group|decitabine was subcutaneously given at 20 mg/m2 once daily for successive 3 days, with a total dose of 60 mg/m2 in a 4-week cycle.
89112065|NCT04095013|Experimental|Group BF|hyperbaric Bupivacaine 10mg with fentanyl 10micrograms
89112066|NCT04095013|Experimental|Group BD|hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
89112067|NCT05336526|Experimental|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Participants who meet the requirements for bilateral breast augmentation in primary intention and have been implanted with ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants
89230978|NCT01047280|Experimental|G-c9, t11|
89230979|NCT02672956|Experimental|Supraumbilical entry group|Umbilical port will be insert to supra umbilical area.
89230980|NCT02672956|Experimental|Intraumbilical entry group|Umbilical port will be insert to intra umbilical area.
89112068|NCT02600299|Experimental|Intervention Arm|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship. This program is designed to take place on three individual days on a weekend. For each session, three major topics will be covered, with lectures and interactive workshop integrated. Sessions will be conducted by healthcare professionals who are experts/well-versed in their respective domains.
89112069|NCT02600299|Placebo Comparator|Usual Care|No active intervention provided.
89112070|NCT04107246||Newly transplanted corneal patients|
89112071|NCT05316441|Experimental|Intervention Group|A total of 5 sessions of 1.5 hours of group therapy will be applied to the Intervention Group. Group therapies will be carried out over the internet once a week, after appropriate days and times are determined.
89112072|NCT05316441|No Intervention|Control Group|The control group will not be interfered with.
89112073|NCT04287998||1|PE group
89112074|NCT04287998||2|Control group
89112075|NCT02779881||Healthy controls|Healthy controls
89112076|NCT02779881||Children at diagnosis of cow's milk allergy|Children at diagnosis of cow's milk allergy
89112077|NCT02779881||Subjects outgrown cow's milk allergy with formula+probiotic|Tolerant with extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG
89112078|NCT02779881||Subjects outgrown cow's milk allergy assuming other formulas|Subjects tolerant with other formulas
89112079|NCT00651378|Experimental|Rosuvastatin|
89112080|NCT00651378|Active Comparator|Ezetimibe + Atorvastatin|
89112081|NCT00651378|Active Comparator|Double Atorvastatin|
89112082|NCT00747643|Active Comparator|Varenicline|For participants in the varenicline group, the medication doses followed the recommended dose schedule for the first 15 days of treatment: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day on days 8-15.
89112083|NCT00747643|Placebo Comparator|Placebo|Participants in this group received a placebo instead of medication. The placebo was taken once a day on days 1-3, twice a day on days 4-15.
89112084|NCT02780271|Experimental|Arm A|Subjects will receive in-person education plus e-communication AND subjects will receive control intervention
89112085|NCT02780271|Experimental|Arm B|Subjects will receive e-communication alone AND subjects will receive control intervention
89112086|NCT02780271|Experimental|Arm C|Subjects will receive in-person education alone AND subjects will receive control intervention
89112087|NCT02780271|Active Comparator|Arm D|Subjects will receive control intervention
89112088|NCT05336292|Active Comparator|Meaningful life intervention|We will work with psychological skills, meaningful life model, mindfulness skills ,personal values, the Wellbeing Model (Ryff, 1989) . The strengths of character (Park et al., 2004) and sources meaningful life. We will identify ways to use strengths and enhance meaningful life and develop an action plan to improve strengths. ). To identify the Meaning at the work. Link our strengths and values to our goals and purposes. Apply the SMART Method to achieve meaningful goals. Visualizing Our Best Future Self (Burton & King, 2004).
89112089|NCT05336292|Active Comparator|Meaningful life and emotional regulation|Program Based on meaningful life and Emotional Regulation (MLI+ER) Session 1 Emotional regulation as a path towards the meaningful life Mindfulness training (emotional mindfulness) Generate knowledge of emotions and their functioning Session 2 Emotional Psychoeducation Emotional care To Know the well-being model Carol Ryff and Vital Sense To Understand the process of emotional regulation Session 3 Strengths and Personal Values Cultivate introspection and self-knowledge (Mindfulness, Carlson, 2013; Klussman, 2020) To Know the strengths of character (Park et al., 2004) and sources of vital meaning Identify ways to use strengths and enhance the sense of life Making Core Values Real (My 80th Birthday Speech; Harris, 2009) Note: Sessions 4, 5 and 6 are the same as the intervention based on meaningful life
89112090|NCT05336292|Active Comparator|Control group|The waiting list will be the control group. Participants will not be part of the program. They will participate in a day of positive psychology
89112091|NCT00627692|Active Comparator|1|Prucalopride
89112092|NCT00627692|Active Comparator|2|Prucalopride
89112093|NCT00627692|Active Comparator|3|Prucalopride
89112094|NCT00627692|Placebo Comparator|5|Placebo
89112095|NCT00627692|Active Comparator|4|Prucalopride
89112096|NCT00634881|Experimental|Cohort A: Alemtuzumab i.v.|Intravenous administration of alemtuzumab according to the 3 + 3 dose escalation design.
89112097|NCT00634881|Experimental|Cohort B: Alemtuzumab s.c.|After i.v. MTD (maximum tolerable dosage) has been determined, subcutaneous dose escalation is performed according to the same escalation rules as for cohort A, starting with the recommended dose level of i.v. application.
89112098|NCT04301882||interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
89112099|NCT04301882||direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
89112100|NCT04300322|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
89112101|NCT04300322|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
89112102|NCT05457673|Experimental|AtaCor EV Temporary Pacing Lead System|Subjects implanted with the AtaCor StealthTrac Lead Model AC-1013
89112103|NCT04228341|Other|Glucose Reference 1|Glucose solution 1
89112104|NCT04228341|Other|Glucose Reference 2|Glucose solution 2
89112105|NCT04228341|Other|Glucose Reference 3|Glucose solution 3
89112106|NCT04228341|Experimental|Brown Rice|Cooked brown rice
89112107|NCT04228341|Experimental|3 % polished rice|Cooked 3 % polished rice
89112108|NCT04228341|Experimental|6 % polished rice|Cooked 6 % polished rice
89112109|NCT04228341|Experimental|9 % polished rice|9 % polished rice
89112110|NCT04228341|Experimental|20 % Polished rice|Cooked 20 % Polished rice (White Rice)
89112111|NCT04496310|Experimental|Telemedicine|"Baseline: in office clinical assessment of all patients (collection of seizure diary).~Followup: scheduled 6-month consultations through a telemedicine device providing remote outcome assessment, counselling and follow-up. If required, on call video consultations available by contacting a provider through telemedicine, 3-hr/week."
89112112|NCT04496310|No Intervention|Usual care|"Baseline: in office clinical assessment of all patients (collection of seizure diary).~Followup: scheduled 6-month in-office consultations with outcome assessment, counselling and follow-up. On-call consultations are possible if needed by the patient, by contacting a clinician through an in-office phone call, 3-hr/week."
89112113|NCT02842788||ARDS patients receiving invasive mechanical ventilation in ICU|"ARDS criteria (Berlin definition) fulfilled the day of the study, whatever the ARDS stage. The onset of ARDS could have been established at any time between ICU admission and study day but ARDS criteria must be still present the day of the study. The ARDS criteria are listed below~Within 1 week of a known clinical insult or new or worsening respiratory symptoms~Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules~Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present~PaO2/FIO2 ≤ 300 with Positive end-expiratory pressure (PEEP) ≥ 5 cmH2O~Age ≥ 18 years~Intubated or tracheotomized and mechanically ventilated"
89112114|NCT01022762|Active Comparator|repaglinide|1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily
89112115|NCT01022762|Active Comparator|gliclazide|80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily
89112116|NCT04093141|Experimental|Intervention|
89112117|NCT05338515|Experimental|Selpercatinib Cohort 1|Selpercatinib administered orally.
89112118|NCT05338515|Experimental|Selpercatinib Cohort 2|Selpercatinib administered orally.
89112119|NCT05338515|Experimental|Selpercatinib Cohort 3|Selpercatinib administered orally.
89112120|NCT01028378|Experimental|Topography-guided LASIK|Topography-guided LASIK for Myopia or Hyperopia
89112121|NCT00747565|Experimental|Tecnis Multifocal IOL group|Subjects implanted bilaterally with the Tecnis Multifocal IOL. Participants were enrolled in this arm in the original study and also in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
89112122|NCT00747565|Active Comparator|CeeOn 911A monofocal control IOL group|Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
89112123|NCT04227561|Active Comparator|Pudendal nerve block|Neurostimulation-guided pudendal nerve block
89112124|NCT04227561|Active Comparator|Penile nerve block|Ultrasound-guided penile nerve block
89112125|NCT02599675|Experimental|Vitamin D3|Vitamin D3 capsules for 12 weeks (2000 IU daily, equivalent to 50 ug)
89112126|NCT02599675|Placebo Comparator|Placebo|Placebo capsules for 12 weeks (the number of daily capsules will match that of the vitamin D-group)
89112127|NCT01028300|Other|ProDisc L|
89230981|NCT02672956|Experimental|Infraumbilical group|Umbilical port will be insert to infra umbilical area.
89230982|NCT01047514|Experimental|Online Chronic Disease Self-management|6 week, online, small group online self-management workshop
89230983|NCT01047592|Active Comparator|sarcosine|
89230984|NCT01047592|Active Comparator|sarcosine+ BE|
89230985|NCT01047592|Placebo Comparator|Placebo|
89230986|NCT01049854|Experimental|Thiotepa/Cyclophosphamide/ATG|Full intensity with TBI
89230987|NCT01049854|Experimental|Busulfan/Melphalan/ATG|Full intensity without TBI
89230988|NCT01049854|Experimental|Busulfan/Fludarabine/Alemtuzumab|Reduced Intensity Chemotherapy
89230989|NCT01049854|Experimental|Fludarabine/Cyclophosphamide/ATG|Reduced Intensity Chemotherapy for Fanconi Anemia
89230990|NCT01045486|Active Comparator|Group A|Group A received active medication (ATP mixed probiotics) for 6 weeks followed by a crossover to 6 weeks of placebo after 4-weeks washout period.
89230991|NCT01045486|Placebo Comparator|Group B|Group B received placebo medication for 6 weeks followed by a crossover to 6 weeks of active medication (ATP mixed probiotics) after 4-weeks washout period.
89230992|NCT01045564|Experimental|A|One dose of study vaccine (GSK 1557484A) on Day 0, Day 182, and Day 364
89230993|NCT01045564|Experimental|B|One dose of study vaccine (GSK 1557484A) on Day 0, Day 91, and Day 364
89230994|NCT01045564|Experimental|C|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
89112128|NCT03741972||Treatment|Patients with diabetes and heart failure that are treated with iSGLT2
89112129|NCT02778789||Tocilizumab|Drug administration of Tocilizumab s.c. or i.v. depending on the preference of the patient and/or physician according to the label
89112130|NCT02778789||TNF-alpha Inhibitor|Drug administration s.c. or i.v. of the TNF-Alpha Inhibitor depending on the preference of the patient and/or physician according to the label
89112131|NCT04228497|Active Comparator|clear fluids fasting for one hour|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml one hour before surgery
89112132|NCT04228497|Placebo Comparator|clear fluids fasting for two hours|children fasting for 6 to 8 hours will be allowed to drink 3 mL/kg of apple juice to a maximum of 250 ml two hours before surgery
89112133|NCT00212784|Experimental|Arm 1|
89112134|NCT00212784|Active Comparator|Arm 2|
89230995|NCT01045564|Experimental|D|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
89230996|NCT01045564|Experimental|E|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
89230997|NCT00453999|Experimental|Arm 1: Peramivir 200 mg|Peramivir 200 mg administered intravenously once daily for 5 days (5 doses)
89230998|NCT00453999|Experimental|Arm 2: Peramivir 400 mg|Peramivir 400 mg administered intravenously once daily for 5 days (5 doses)
89230999|NCT00453999|Experimental|Arm 3: Oseltamivir|Oseltamivir 75 mg oral suspension administered orally twice daily for 5 days (10 doses)
89231000|NCT00453921|Placebo Comparator|1|Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
89231001|NCT00453921|Active Comparator|2|Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
89231002|NCT00453921|Active Comparator|3|Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
89231003|NCT00453921|Active Comparator|4|Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
89231004|NCT03995745|Experimental|adherence based financial incentives|Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
89231005|NCT03995745|No Intervention|control|Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.
89231006|NCT00382720|Experimental|TE (Taxotere and Eloxatin)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study."
89290052|NCT01217658|Experimental|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
89112135|NCT00752089|Experimental|Sodium fluoride/potassium nitrate/Isopentane dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice containing active ingredients: 1450 ppm F as sodium fluoride (NaF) and 5% potassium nitrate (KNO3) and isopentane as an excipient ingredient.
89112136|NCT00752089|Experimental|NaF/KNO3 Dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice, containing as active ingredients: 1450 ppm NaF and 5% KNO3 but no isopentane.
89112137|NCT00752089|Active Comparator|NaF Dentifrice|Participants to brush their teeth for one timed minute twice daily with a dentifrice containing 1450 ppm F as NaF.
89112138|NCT00752089|Placebo Comparator|Placebo Dentifrice|Participants to brush their teeth for one timed minute twice daily with a fluoride free dentifrice (0 ppm F).
89112139|NCT02779179|Experimental|Immediate Periodontal treatment group|
89112140|NCT02779179|Active Comparator|Delayed Periodontal treatment Group|
89112141|NCT02842554|Other|DPA|Drug Placebo Administration
89112142|NCT02842554|Other|C|Control
89112143|NCT02842554|Other|EPT|Evoked Pain Training
89112144|NCT05295147|Experimental|Palmar Grasp Reflex Stimulation|
89112145|NCT05295147|No Intervention|Control Group|
89112146|NCT00751933|Experimental|2|Vaccination with Vivotif and Dukoral
89112147|NCT00751933|Experimental|3|Dietary supplement with oats
89112148|NCT00751933|Placebo Comparator|4|Placebo instead of vaccines No dietary supplement
89112149|NCT00751933|Experimental|1|Vaccination with Vivotif and Dukoral + dietary supplement with oats.
89231007|NCT00382720|Experimental|TEF (Taxotere, Eloxatin and 5-FU)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study."
89231008|NCT00382720|Experimental|TEX (Taxotere, Eloxatin and Xeloda)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study."
89231009|NCT01022619||Premature labor|Women at the third trimester of pregnancy with premature contractions and cervical dilation of effacement
89231010|NCT01022619||Control|Women at the third trimester of pregnancy with uncomplicated pregnancy
89231011|NCT01022619||Pre-eclampsia|Women at the third trimester with pre-eclampsia
89231012|NCT01022619||Gestational diabets|Women at the third trimester of pregnancy with gestational diabetes requiring insulin
89231013|NCT01025349|Experimental|metastatic breast cancer|Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
89231014|NCT01022697|Active Comparator|A|Glucose drink
89231015|NCT01022697|No Intervention|B|Fasting
89231016|NCT01021371|Experimental|Patient interview and communication to GP from hospital|Intervention group: The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group about their rehabilitation needs and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus.
89231017|NCT01021371|No Intervention|Control group: Usual practice, no intervention|
89231018|NCT01022775|Experimental|1: Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
89231019|NCT01022775|Active Comparator|2: Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
89231020|NCT00453063|Experimental|MFNS 200 mcg QD|
89231021|NCT00453063|Placebo Comparator|Placebo|
89231022|NCT00371566|Experimental|Lapatinib|
89231023|NCT00371566|Placebo Comparator|Placebo|
89231024|NCT00382408|Experimental|Vaccine|Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
89231025|NCT00382408|Placebo Comparator|Placebo|Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
89231026|NCT00371254|Experimental|1|
89231027|NCT00371254|Experimental|2|
89231028|NCT00452673|Experimental|50 mg BID dasatinib + 825 mg/m^2 BID capecitabine|Twice a day (BID) for 2 weeks of a 3-week cycle
89231029|NCT00452673|Experimental|70 mg BID dasatinib + 825 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
89231030|NCT00452673|Experimental|70 mg BID dasatinib + 1000 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
89231031|NCT00452673|Experimental|100 mg QD dasatinib + 1000 mg/m^2 BID capecitabine|2 weeks of a 3-week cycle
89231032|NCT01021449||Control|Healthy subjects
89231033|NCT01021449||Schizophrenia|Schizophrenic patients
89231034|NCT00461253||1|Breast Cancer Cases
89231035|NCT00461253||2|Matched Controls for Breast Cancer Cases
89231036|NCT00469833|Experimental|Arm 1|Intervention: Insulin glargine treatment. The study is designed as a within subjects comparison of insulin secretion in type 2 diabetic patients before and after 2 months of insulin treatment to reduce blood glucose. Insulin secretion will be determined with a hyperglycemic clamp using 20% dextrose, and ingestion of an oral glucose solution (75 g).
89231037|NCT00382174|Placebo Comparator|1|0.00% thymosin beta 4 w/w administered topically once daily for up to 84 days
89231038|NCT00382174|Active Comparator|2|3 doses of thymosin beta 4: 0.01% w/w, 0.02% w/w, and 0.1% w/w, administered topically once daily for up to 84 days
89231039|NCT00641537|Placebo Comparator|Cladribine Low/Placebo (LLPP)|
89231040|NCT00641537|Placebo Comparator|Cladribine High Dose/Placebo (HLPP)|
89231041|NCT00641537|Experimental|Cladribine Low/Low Dose (LLLL)|
89231042|NCT00641537|Experimental|Cladribine High/Low Dose (HLLL)|
89231043|NCT00641537|Experimental|Placebo/Cladribine Low Dose (PPLL)|
89231044|NCT00641537|No Intervention|Placebo/No Treatment|
89290053|NCT01217658|Active Comparator|AAP Education|Those receiving the control group allocation will be counseled in the American Academy of Pediatrics guidelines regarding Infant Colic (AAP Infant Colic counseling).
89112150|NCT01701570|Active Comparator|An Active Comparator exercise training intervention|The Active Comparator Groupwill participate in an exercise training intervention to distinguish the relative roles of objective factors (lactate level) and subjective factors (self-efficacy) in mediating pre-post change in RPE during low, moderate, and vigorous exercise.
89112151|NCT01701570|Placebo Comparator|A Placebo Attention Control|The placebo attention control group will receive monthly diabetes education and phone calls phone calls to monitor their blood glucose levels. Participants will receive an accelerometer to wear for one week.
89112152|NCT04195269|Experimental|Pure Green Sublingual Tablet - Daily|Subjects will take 2 tablets daily, one in the morning and one in the evening, and are able to take up to 2 additional tablets per day as needed for pain.
89112153|NCT04093063|Experimental|Intervention Group|Subjects in the intervention group were tasked with building a micro-stellated icosahedron using a detailed instruction manual. They were each provided with a dissecting microscope and necessary materials to complete the task at home at their leisure. They were given two weeks to complete the task. They were asked to return for a second in-person meeting two weeks.
89112154|NCT04093063|No Intervention|Control Group|Subjects in the non-intervention control group were not given any task or any materials. They were asked to return for a second in-person meeting in two weeks.
89112155|NCT03258138|Experimental|More Intensive Program (MIP)|Participants will receive the more intensive program, which combines usual care with the full version of the healthy lifestyles program. Participants in this arm will meet weekly for group health and wellness learning sessions or brainstorming group sessions. In addition, they will meet monthly for individual sessions with a multidisciplinary health team, including a family physician, physical therapist and dietician to tailor their health goal development and action plans to their particular needs and situations. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
89112156|NCT03258138|Experimental|Less Intensive Program (LIP)|Participants will receive the less intensive program, which combines usual care along with health goal development. Participants in this arm will meet at baseline to set health goals with the support of a research assistant trained in theories of health behaviour and goal setting. They will also meet every three months to measure progress in achieving their goals. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
89112157|NCT05338437|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation of the quadriceps. 45 minutes, 5 days per week
89112158|NCT05338437|No Intervention|Control|No treatment control
89112159|NCT04093375|Experimental|Radical Prostatectomy|Patients with locally advanced prostate adenocarcinoma receives Radical Prostatectomy with or without enlarged lymph node dissection
89112160|NCT04093375|Active Comparator|Radical Radiotherapy|Patients with locally advanced prostate adenocarcinoma receives Radical Radiotherapy with adjuvant androgen deprivation therapy
89112161|NCT04090255|Experimental|Ultrasonographic guided renal access|The use of ultrasound to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
89112162|NCT04090255|Experimental|Fluoroscopic guided renal access|The use of fluoroscopy to make a puncture in kidney for pcn for drainage or evaluation of function or for shunt of urine
89112163|NCT04094857|Experimental|HBN-1 Plus Standard of Care|Subjects will receive an intravenous loading dose of HBN-1 followed by a 12 hour maintenance infusion plus standard of care targeted temperature management
89112164|NCT04094857|No Intervention|Standard of Care|Subjects will receive standard of care targeted temperature management only
89290054|NCT01219452|Experimental|umbilical cord mesenchymal stem cells|intramuscular injection of umbilical cord mesenchymal stem cell
89231045|NCT00641537|No Intervention|Cladribine 3.5 mg/kg/No Treatment|Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
89231046|NCT00641537|No Intervention|Cladribine 5.25 mg/kg/No Treatment|Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
89231047|NCT01025583|Active Comparator|group 1 (standard ORS)|Children with acute diarrhea receive standard hypotonic ORS.
89231048|NCT01025583|Active Comparator|Group 2 (hypotonic super-ORS)|Children with acute diarrhea receive hypotonic super-ORS containing zinc and prebiotics.
89231049|NCT03840135|Experimental|Polyoxidonium 6 mg/ml|Polyoxidonium 6 mg/ml nasal and sublingual spray - 0,15 mg/kg daily - 7 days.
89231050|NCT03840135|Placebo Comparator|Placebo|Placebo, nasal and sublingual spray - 7 days.
89112165|NCT02842398|Experimental|Balance Master Training|Children receive one weekly Balance Master training session, in addition to their weekly physical therapy sessions. During Balance Master training, children practice balance on a Balance Master device that simulates crossing a city street.
89112166|NCT02842398|Active Comparator|Customary Care|Children received their customary scheduled physical therapy sessions, without Balance Master training
89112167|NCT04988997|Active Comparator|Vurolenatide 50 mg/PBO|50 mg biweekly SC administration, PBO alternate weeks
89112168|NCT04988997|Active Comparator|Vurolenatide 100 mg/PBO|100 mg biweekly SC administration, PBO alternate weeks
89112169|NCT04988997|Active Comparator|Vurolenatide 50/50 mg|50 mg weekly SC administration
89112170|NCT04988997|Placebo Comparator|Placebo|PBO - weekly SC administration
89112171|NCT04092751|Experimental|Treatment A|Single oral 20-mg dose of PRA on Day 1 AM
89112172|NCT04092751|Experimental|Treatment B|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later.
89112173|NCT05334810|Experimental|DP303c|Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.
89112174|NCT02842008|Experimental|Exercise group|Wheelchair basketball players participating in home therapeutic exercise program that use the protocol of postural hygiene.
89112175|NCT02842008|No Intervention|Control group|Wheelchair basketball players that not participate in home therapeutic exercise program and use a protocol of postural hygiene provided.
89112176|NCT02598505|Experimental|Indacaterol|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
89112177|NCT02598505|Placebo Comparator|Placebo|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
89112178|NCT02778945|Experimental|Group D (Deep NMB group)|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
89112179|NCT02778945|Active Comparator|Group I (Intermediate NMB group)|Use NMB as conventional clinical usage Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
89112180|NCT02721342||Ramipril, Irbesartan and Atorvastin treatment|A multidrug approach, including Angiotensin II Converting Enzyme (ACE) inhibitor, Ramipril, and Angiotensin II Receptor Blocker (ARB), Irbesartan, and Atorvastin will be done. Treatment doses of drugs will be up-titrated gradually considering the tolerability.
89112181|NCT02779101|Experimental|Single arm|pembrolizumab
89112182|NCT05336058||Gastric cancer group|A total of about 500 cases are expected to be enrolled, including 150 cases in stage I and 100 cases in II-IV. Pathological diagnosis is required.
89112183|NCT05336058||Negative group|A total of about 740 cases were included, including 400 cases without abnormal gastroscopy, 100 cases with other cancers, and 240 cases with precancerous gastric cancer and other lesions.
89112184|NCT02779959|Experimental|Buccal Prochlorperazine|Experimental arm of two buccally absorbable prochlorperazine tablets (6 mg) plus 2 cc IV saline
89112185|NCT02779959|Active Comparator|Intravenous Prochlorperazine|Accepted Standard of care receiving 10 mg (2 cc) of intravenous prochlorperazine plus two saccharin absorbable placebo tablets.
89112186|NCT05335278|Experimental|Nintedanib treatment|Single arm treatment with nintedanib
89112187|NCT05173233|Experimental|K-clipTM transcatheter annuloplasty system|
89112188|NCT00751621|Experimental|IgPro20|Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).
89112189|NCT02778477|Experimental|Part A_Cohort 1_Active|Multiple ascending dose of PF-06423264
89112190|NCT02778477|Placebo Comparator|Part A_Cohort 1_Placebo|Multiple dose of placebo
89112191|NCT02778477|Experimental|Part A_Cohort 2_Active|Multiple ascending dose of PF-06423264
89112192|NCT02778477|Placebo Comparator|Part A_Cohort 2_Placebo|Multiple dose of placebo
89112193|NCT02778477|Experimental|Part A_Cohort 3_Active|Multiple ascending dose of PF-06423264
89112194|NCT02778477|Placebo Comparator|Part A_Cohort 3_Placebo|Multiple dose of placebo
89112195|NCT02778477|Experimental|Part A_Cohort 4_Active|Multiple ascending dose of PF-06423264
89112196|NCT02778477|Placebo Comparator|Part A_Cohort 4_Placebo|Multiple dose of placebo
89112197|NCT02778477|Experimental|Part A_Cohort 5_Active|Multiple ascending dose of PF-06423264
89112198|NCT02778477|Placebo Comparator|Part A_Cohort 5_Placebo|Multiple dose of placebo
89112199|NCT02778477|Experimental|Part A_Cohort 6_Active|Multiple ascending dose of PF-06423264
89112200|NCT02778477|Placebo Comparator|Part A_Cohort 6_Placebo|Multiple dose of placebo
89112201|NCT02778477|Experimental|Part A_Cohort 7_Active|Multiple ascending dose of PF-06423264
89112202|NCT02778477|Placebo Comparator|Part A_Cohort 7_Placebo|Multiple ascending dose of placebo
89112203|NCT02778477|Experimental|Part B_Cohort 1_Active|Multiple doses of PF-06423264
89112204|NCT02778477|Placebo Comparator|Part B_Cohort 1_Placebo|Multiple doses of placebo
89112205|NCT02778477|Experimental|Part B_Cohort 2_Active|Multiple doses of PF-06423264
89112206|NCT02778477|Placebo Comparator|Part B_Cohort 2_Placebo|Multiple doses of placebo
89112207|NCT04094467|Experimental|Study group|"the antagonist protocol group where they will do intra-cytoplasmic injection using classical antagonist protocol"
89112208|NCT04094467|Active Comparator|control group|"agonist stop/antagonist protocol group where they will receive mid luteal agonist in the preceding intra-cytoplasmic injection cycle before starting classical antagonist protocol"
89112209|NCT02842476||Disposable Sensor|Adhesive based Pulse Oximeter Probes, Model S0136J
89112210|NCT02842476||Reusable Sensor|Reusable Pulse Oximeter Probes, Model S0080D
89112211|NCT02842476||Control Pulse Oximetry|Reference CO-Oximeters ABL80 Flex OSM (Radiometer), # 302125, 307205 IL682 (Instrumentation Laboratories), # 012511B (ILH), #012511A (ILG)
89112212|NCT02568930||Heart Transplantation (HT)|The cohort includes advanced heart failure patients (60-80 years of age) listed for HT and their caregivers.
89112213|NCT02568930||Mechanical Circulatory Support (MCS)|The cohort includes advanced heart failure patients (60-80 years of age) scheduled for DT MCS and their caregivers.
89112214|NCT04227249||Experimental|women who do not undergo lymph node dissection
89112215|NCT02599597|Experimental|Therapist-assisted iCBT|Internet-delivered cognitive behavioral therapy (iCBT), containing physical activity and sleep management for preventing depressive relapse. Monthly depression screening with therapist feedback.
89112216|NCT02599597|Active Comparator|Monthly screening with feedback|Monthly depression screening with therapist feedback.
89112217|NCT02599597|No Intervention|Control|No intervention, follow-up along with all participants at 6 and 12-months.
89112218|NCT02842164|Other|Foley Catheter Balloon with Tension group|a 16 French transcervical Foley catheter balloon will be advanced to or past the internal os and the balloon will be filled. Then catheter will be placed on gentle traction by taping the distal tip to the medial thigh for maximum 24 hours. To maintain gentle traction, periodic repositioning of the distal tip on the thigh will be necessary.
89231051|NCT00461175||1|Mirena®
89231052|NCT00461175||2|Copper IUD
89112219|NCT02842164|Other|Foley Catheter Balloon without tension group|The Foley catheter balloon will be just supported by simple taping to the thigh.
89112220|NCT03977857||28-day nonsurvival or transplantation|patients who died or underwent liver transplantation within 28 days since admission
89112221|NCT03977857||28-day transplantation-free survival|patients who survived without liver transplantation at 28 days since admission
89112222|NCT02778711|Experimental|Cosentyx|secukinumab (anti-IL-17)
89112223|NCT02599753|Experimental|18F-DTBZ for Parkinson's Disease|The participants qualify for the study will return to the clinic at a later date and will have catheter(s) placed for i.v. administration of 18F- DTBZ for injection. The participants will receive a single i.v. bolus of 18F- DTBZ, followed by brain PET imaging of 10 minutes duration, approximately 80 minutes post-dose injection. Vital signs will be obtained prior to and immediately after the administration of 18F- DTBZ, and at the completion of the imaging session. Adverse events will be continuously monitored during the imaging session. The participants experience any adverse event will not be discharged until the event has resolved or stabilized.
89112224|NCT04094623|Experimental|NSSI-DBT|Dialectical behavior therapy, 2 hours every week for 13 weeks.
89112225|NCT04094623|Active Comparator|NSSI-SSGT|Social support group therapy, 2 hours every week for 13 weeks.
89112226|NCT04094389|Experimental|Orthotic continuous wear group|Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance.
89112227|NCT04094389|Experimental|Orthotic wear during waking hours only group|Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping.
89112228|NCT04094389|Experimental|Orthotic wear only while sleeping group|In the night-wear group, participants will be told to wear their orthosis only at night.
89112229|NCT02778633||Sepsis|Patients diagnosed with septic shock, admitted to the intensive care unit, with a good left ventricular ejection fraction without significant co-morbidity are highly eligible for this study. Patients must be equipped with a pulse-contour cardiac output (PICCO)-system with a central venous catheter which will be applied by the intensivist on admission.Patients will be subsequently connected to the hemodynamic monitoring device Navigator™. In those patients with clinical signs of inadequate tissue perfusion, passive leg raising and standardized fluid challenge will be performed.
89112230|NCT04092985||Patients suspected with Cardiac Arrhythmia|iECG + 12-lead ECG recording in patients suspected with any type of cardiac arrhythmias at the time of recruitment
89112231|NCT04195035|Experimental|Air-Q intubating laryngeal airway mask|"Where Air-Q intubating laryngeal airway will be used for ventilation & intubation through fiberoptic bronchoscope.~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Air-Q will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2were recorded 5 minutes after device insertion.~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
89112232|NCT04195035|Experimental|Ambu-Aura intubating laryngeal mask|"Ambu-Aura intubating laryngeal mask will be used for ventilation & intubation through fiberoptic bronchscope.~After complete muscle relaxation a suitable sized (according to the patient's weight and BMI) Ambu-Aura laryngeal mask will be lubricated inserted and the ventilator circuit will be connected to the device to ventilate the patient. The ventilator will be set with tidal volume 4-6 ml/kg at a respiratory rate 12-15 breath/minute to keep normocapnia (ETCO2=30-35 mmHg). Vitals (HR, ABP and O2 saturation) and ET CO2 will be recorded 5 minutes after device insertion.~Then intubation using the fiberoptic bronchoscope will be started through the supraglottic device, laryngeal view grade will be recorded, success of endotracheal intubation through the device and time of intubation (time starting from disconnection of the circuit from the device to use the fiberoptic brochoscope for intubation till tube insertion in the trachea)."
89112233|NCT02844270|Experimental|Galaxy stent|The galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System will be implanted in all subjects.
89112234|NCT05261763|Active Comparator|Group A|Group A will receive trigger point dry needling in quadricep muscles
89112235|NCT05261763|Sham Comparator|Group B|Group B will get Sham needling in quadriceps muscles
89112236|NCT02843958|Other|Healthy volunteers and patients under Vitamin K antagonist|
89112237|NCT02779647|Experimental|Study group|Consisting of 49 children who were recommended a programme of physical activity, play and nutritional advice, for both the children and their parents
89112238|NCT02779647|No Intervention|Control group|49 children, who received only nutritional advice
89112239|NCT04931823|Experimental|Part A-1: Dose Escalation|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks).
89112240|NCT04931823|Experimental|Part A-2: Dose escalation|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) with the option to administer G-CSF in cycle one. Starting dose will be 45 mg/m2.
89112241|NCT04931823|Experimental|Part B: Cohort 1|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced solid tumors of gastric, head and neck, lung, and ovarian.
89112242|NCT04931823|Experimental|Part B: Cohort 2|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced breast cancer.
89112243|NCT04931823|Experimental|Part B: Cohort 3|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced prostate cancer.
89112244|NCT04931823|Experimental|Part B: Cohort 4|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with either ovarian or/and breast cancer who have failed prior taxane treatment (ie, either progressed on a taxane regimen or within 6 months of receiving a taxane regimen).
89112245|NCT04092517|Active Comparator|Control Corn Soya Diet|Control Corn Soya Diet will be prepared to a formulation for Corn Soya Blend (SUPER CEREAL) product adopted by the WFP as complementary food for children over than 6 months.
89112246|NCT04092517|Experimental|Test Corn Moringa Diet|Test Corn Moringa Diet will be prepared to the same formulation as Corn Soya Blend, but the Soya content will be replaced with Moringa and no micronutrient premix will be added.
89112247|NCT04094233|Experimental|Beetroot Extract|Capsule containing 600mg of beetroot extract.
89112248|NCT04094233|Experimental|Placebo|Capsule containing 600mg of starch.
89112249|NCT00634959|Experimental|1|
89112250|NCT00634959|Experimental|2|
89112251|NCT00634959|Experimental|3|
89112252|NCT00634959|Experimental|4|
89112253|NCT00634959|Placebo Comparator|5|
89112254|NCT02598427|Experimental|Intrathecal Pertuzumab and Trastuzumab|"Four cohorts will enroll in a dose escalation of pertuzumab and a consistent dose of trastuzumab. The cohorts will be assigned as follows:~Cohort: Intrathecal Dose:~10mg pertuzumab, 80mg trastuzumab~20mg pertuzumab, 80mg trastuzumab~40mg pertuzumab, 80mg trastuzumab~80mg pertuzumab, 80mg trastuzumab"
89112255|NCT04226001||Patients|Patients screened for carriers infected or colonized by emerging highly resistant bacteria.
89112256|NCT04092439|Experimental|Watermelon juice|100% watermelon juice
89112257|NCT04092439|Placebo Comparator|Placebo|Fructose matched control
89112258|NCT04094077|Experimental|Aguix + Stereotactic Radiation|
89112259|NCT04092595|Experimental|PF-06651600 and Rosuvastatin|Period 1 is 4 days in length. On Day 1 of Period 1 participants will receive a single dose of Rosuvastatin 10 mg given as a tablet orally. Period 2 is 11 days in length and will immediately follow Period 1 with no washout. In Period 2, participants will be dosed with oral 200 mg PF-06651600 once-daily (QD) for 7 days. On Day 8 of Period 2, a single dose of 10 mg Rosuvastatin oral tablet will be administered following administration of the 200-mg dose of PF-06651600. Dosing with oral 200 mg PF-06651600 QD will continue until Day 10 of Period 2.
89112260|NCT04092205|Experimental|Experimental: Treatment|28 days treatment with NBMI 600 mg/day
89112261|NCT04226157|Experimental|Home Blood Pressure Self Management|The HBPS group will check their blood pressure at home daily using a smart BP cuff with telemonitoring capability (Home Qardio) and guided to use a self-titration plan between office visits for persistently elevate blood pressures.
89112262|NCT04226157|Active Comparator|Usual Care|The Usual Care group will have their blood pressure monitored and medications adjusted by their primary care provider.
89112263|NCT05117853|Experimental|Autofluorescent detection and injection of indocyanine green|"Drug: indocyanine green (ICG)~Autofluorescence detection of the parathyroid glands and injection of indocyanine green at two predefined timepoints will be performed to evaluate the vascularization of the parathyroid glands."
89112264|NCT05117853|Placebo Comparator|Control group|Gold standard of visual identification and evaluation of viability.
89112265|NCT02776371|Experimental|Modified non-clarithromycin triple therapy|H.pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
89112266|NCT02776371|Active Comparator|Sequential therapy|H.pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
89112267|NCT01028222|Experimental|Nilotinib|400 mg twice daily
89112268|NCT01028222|Active Comparator|DTIC|850 mg/m2 IV every 3 weeks
89112269|NCT00586495|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
89112270|NCT04226079||Normal control|Normal population with low prevalence of gastrointestinal bleeding who underwent EGD and CFS which revealed no abnormal finding.
89112271|NCT04226079||Patients with GI bleeding|Patients who visited emergency room and were highly suspected to have recent or active upper GI bleeding and scheduled for upper GI endoscopy.
89112272|NCT04225143|Experimental|bilateral|25 patients with an overactive bladder
89112273|NCT04225143|Active Comparator|unilateral|25 patients with an overactive bladder
89112274|NCT02776137|Experimental|Docetaxel Group|Concurrent Chemoradiotherapy With Docetaxel
89112275|NCT04093999||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction with additional sensory nerve coaptation.
89112276|NCT04093999||Noninnervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral DIEP flap breast reconstruction without sensory nerve coaptation.
89112277|NCT01027754|Experimental|Varenicline|Drug treatment in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
89112278|NCT01027754|Placebo Comparator|Placebo|Matched placebo capsules in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
89112279|NCT02773017|Experimental|Youth female group|patients in the Youth female group, aged 20~35, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
89112280|NCT02773017|Experimental|Middle-aged female group|patients in the Middle-aged female group, aged 40~60, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
89112281|NCT02773017|Experimental|Elderly female group|Patient in the elderly female group, aged 65~79, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
89290055|NCT01124994|Active Comparator|Mucosectomy|Patients in this arm are undergoing mucosctomy after previous confocal laser endomicroscopy.
89231053|NCT00814541|Experimental|1|Relapsed patients, previously treated with VAD or VAD like regimen (VAMP, C-VAMP and Z-Dex are examples of VAD like therapy) and who have had autologous transplants at least 1 year previously.Patients may proceed directly to PAD therapy or have had a maximum of one other line of therapy before PAD.
89231054|NCT00814541|Experimental|2|Relapsed patients, previously treated with VAD or VAD-like regimen who have not had autologous transplantation and achieved at least PR (Appendix A). Patients may proceed directly to PAD therapy or have had a maximum of two other lines of therapy before PAD.
89231055|NCT00814541|Experimental|3|Patients refractory (MR, NC or PD) to VAD or VAD-like therapy. Patients should proceed directly to PAD therapy. Patients with NC or PD may proceed to PAD after a minimum of two cycles of VAD or VAD-like therapy or a minimum of 4 cycles, if MR.
89231056|NCT01021527|Experimental|Treatment Sequence 1|A-B-C-C
89231057|NCT01021527|Experimental|Treatment Sequence 2|B-C-A-C
89231058|NCT01021527|Experimental|Treatment Sequence 3|C-A-B-C
89231059|NCT01021527|Experimental|Treatment Sequence 4|A-C-B-C
89231060|NCT01021527|Experimental|Treatment Sequence 5|B-A-C-C
89231061|NCT01021527|Experimental|Treatment Sequence 6|C-B-A-C
89231062|NCT00814619|Experimental|Arm I|Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.
89231063|NCT00814619|Active Comparator|Arm II|Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.
89231064|NCT01023009||eye occlusion|
89231065|NCT01025661|No Intervention|Waiting list control|The waiting list controls did not receive any intervention during the study period.
89112282|NCT02776293|Active Comparator|Relaxation Group|The relaxation group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to sit undisturbed for 20 minutes.
89112283|NCT02776293|Experimental|Music Group|The music group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to listen to pre-recorded songs specifically composed for pregnancy.
89112284|NCT03976531||Elderly cancer patients included in randomized controlled trials|
89112285|NCT04301648|Active Comparator|Common Practice|Patients included in the phase before will receive common practice.
89112286|NCT04301648|Experimental|STAR Nurse|Patients included in the phase after will receive care by a STAR Nurse.
89112287|NCT04833309|Experimental|Pharmacopuncture therapy|Pharmacopuncture will be administered to the subjects in the pharmacopuncture therapy group. The physicians will choose the specific type and volume of pharmacopuncture according to participants' conditions.
89112288|NCT04833309|Active Comparator|Physical therapy|Physical therapy will be applied to the subjects in the physical therapy group. The physicians will choose the specific type and volume of pharmacopuncture according to participants' conditions.
89112289|NCT02872766|Experimental|Corneal cross linking (CXL)|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.
89112290|NCT02772861|Experimental|Citrulline|Citrulline is a non-protein amino acid that is present in substantial amounts in watermelon (Citrullus vulgaris), with a mean content of 2.1 mg/g fresh weight, ranging from 0.5 to 3.6 mg/g according to variety. The oral dose can reach 20 g, which was administered orally in the present study in one single dose, followed by a washout period of one week Amino Acid Supplement - One dose
89112291|NCT02772861|Experimental|Glutamine|"L-glutamine is a protein amino acid found in proteins of all life forms. It is classified as a semi-essential or conditionally essential amino acid. This means that under normal circumstances the body can synthesize sufficient l-glutamine to meet physiological demands. However, there are conditions where the body cannot do so. Recently, l-glutamine has come to be regarded as one of the most important of the amino acids when the body is subjected to such metabolic stress situations as trauma (including surgical trauma), cancer, sepsis and burns. In the present study, glutamine was administered orally in one single dose of 20 g, followed by a washout period of one week.~Amino Acid Supplement - One dose"
89112292|NCT02772861|Experimental|Arginine|"Arginine was administered orally in 20 g for one single dose, followed by a washout period of 1 week.~Amino Acid Supplement - One dose"
89112293|NCT02772861|Experimental|3-Methyl-Histidine|"This amino acid is made by methylation of the actin and myosin peptide chains in the muscle. Metabolism after intravenous administration of L-3-methylhistidine involves excretion in the urine of 75% of the administered dose in 24 h and 95% in 48 h.~3-Methyl-Histidine was administered orally in 120 mg for one single dose, followed by a washout period of 1 week."
89112294|NCT02772861|Placebo Comparator|Placebo|Dextrose (glucose) was used in a dose of 20 g in this study.
89290056|NCT01219530||Gestational Carriers|
89290057|NCT01219530||Intended Parents|
89112295|NCT02772705||Hyperthyroidism|Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.
89112296|NCT02772705||Health Humans|Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.
89112297|NCT01034540|Experimental|POM3|POM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment
89112298|NCT01034540|Placebo Comparator|Placebo|Placebo for the first six weeks of treatment. POM3 for the second six weeks of treatment
89112299|NCT02775981|Experimental|Active|RX0041-002
89112300|NCT02776059|Experimental|prednisolone or pentoxifylline + pegfiltrastim|prednisolone or pentoxifylline for 28 days PO plus pegfilgrastim subcutaneous weekly shot
89112301|NCT02776059|Active Comparator|prednisolone or pentoxifylline|prednisolone or pentoxifylline for 28 days
89231066|NCT00641147|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 12 months. Laboratory Biomarker Analysis
89231067|NCT00641147|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 months. Laboratory Biomarker Analysis
89231068|NCT00460239|Experimental|Placebo|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
89231069|NCT00460239|Experimental|Morphine 15|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
89231070|NCT00460239|Experimental|Morphine 30|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
89231071|NCT00460239|Experimental|Buprenorphine 8|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
89231072|NCT00460239|Experimental|Buprenorphine 16|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
89231073|NCT00460239|Experimental|Buprenorphine 32|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
89231074|NCT00460239|Experimental|Buprenorphine 48|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
89231075|NCT00460239|Experimental|Buprenorphine 60|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
89231076|NCT06334263||Conservative managment|No intervention for splenic injury other than supportive care
89231077|NCT06334263||Splenic embolisation|Interventional radiology guided splenic artery embolisation
89231078|NCT06334263||Splenectomy|Surgical splenectomy
89231079|NCT06334250|Active Comparator|Left atrial appendage occlusion alone|Left atrial appendage occlusions with the Watchman device (Boston Scientific)
89231080|NCT06334250|Experimental|Combined left atrial appendage occlusion and pulsed field ablation of atrial fibrillation|Left atrial appendage occlusion with the Watchman device (Boston Scientific) and catheter ablation of atrial fibrillation with the FaraPulse system (Boston Scientific)
89231081|NCT06334224|Active Comparator|Low-load resistance training|Twice-daily low load resistance training for four days
89231082|NCT06334224|Experimental|Blood flow restriction training|Twice-daily low load resistance training with blood flow restriction for four days
89231087|NCT06334172|Placebo Comparator|Placebo|Infusion of placebo
89231088|NCT06334172|Experimental|Oxytocin 0.1 IU/min|Infusion of oxytocin 0.1 IU/min
89231089|NCT06334172|Experimental|Oxytocin 0.2 IU/min|Infusion of oxytocin 0.2 IU/min
89231090|NCT06334159|Experimental|Control Group|Horizontal Guided Bone Regeneration with a mixture of xenograft (Cerabone 0.5-1mm particles) and allograft (Maxgarft <2mm particles) bone substitute (50/50) with non-fixed resorbable collagen membranes (Jason Membrane 20x30mm)
89231091|NCT06334159|Experimental|Test Group|Horizontal Guided Bone Regeneration with a mixture of xenograft (Cerabone 0.5-1mm particles) and allograft (Maxgarft <2mm particles) bone substitute (50/50) with fixed resorbable collagen membranes(Jason Membrane 20x30mm) with the use of pins (Titan Pins)
89231092|NCT06334146|Experimental|Tap dance program|Participants undertake tap dance program.
89231093|NCT06334133|Experimental|52 Week Double Blind Treatment Period Arm A|"The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.~Arm A: Cadisegliatin 800 mg QD for 52 weeks"
89290058|NCT01329120||Pectus excavatum|Patients who has undergone minimally invasive repair of pectus excavatum
88816292|NCT02498769|Experimental|Epicardial Botulinum|After instituting cardiopulmonary bypass (CPB), botulinum toxin injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 50U (1mL) of botulinum toxin (OnabotulinumtoxinA, Botox®). After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
89290059|NCT01329120||Pectus carinatum|Patients who has undergone open surgical repair of pectus carinatum
89231094|NCT06334133|Experimental|52 Week Double Blind Treatment Period Arm B|"The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.~Arm B: Cadisegliatin 800 mg BID for 52 weeks"
89231095|NCT06334133|Placebo Comparator|52 Week Double Blind Treatment Period Arm C|Matching placebo
89231096|NCT06334120||Male patients with nmCRPC or mHSPC|Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator.
89231097|NCT06334107|Experimental|Aerobic Exercise Training|Participants will be asked to complete a 16-week aerobic exercise training program.
89231098|NCT06334107|No Intervention|Mitochondrial DNA Sequencing|Participants will be asked to provide a blood or saliva sample for mitochondrial DNA sequencing analysis to assess for variants unique to individuals born prematurely.
89231099|NCT06334094|Experimental|Ozanimod|Participants will receive Ozanimod and work up to .92 mg. They will then take one pill daily for a duration of 12 months.
89231100|NCT06334081|Experimental|Group A dental implant placement by undersized drilling technique.|8 dental implants placed in the healed alveolar posterior maxillary ridge using undersized drilling technique
89231101|NCT06334081|Experimental|Group B dental implant placement by single drilling technique|8 dental implants placed in the healed alveolar posterior maxillary ridge using singledrilling technique
89231102|NCT06334068|Experimental|Short-term glycemic control group|Patients will be admitted to the hospital for 2-3 days before surgery. During this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. We aim to maintain moderate glucose control (140-180 mg/dl) using the basal-bolus insulin protocol, plus correctional doses as needed.
89231103|NCT06334068|Active Comparator|Standard-of-care group|Patients will be admitted the day before surgery with the usual patient treatment.
89231104|NCT06334042||Intensive Care Patients|
89231105|NCT06334029||Epilepsy|Recording of resting state EEG and MRI
89231106|NCT06334029||Control group|EEG resting state data recording
89231107|NCT06334016|Experimental|Arm A (placebo, THC, nicotine)|"Participants complete 3 vaping sessions separated by 7-14 days on study:~VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.~VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.~VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.~All participants also undergo blood sample collection throughout the trial."
89231108|NCT06334016|Experimental|Arm B (placebo, THC, nicotine)|"Participants complete 3 vaping sessions separated by 7-14 days on study:~VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.~VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.~VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.~All participants also undergo blood sample collection throughout the trial."
89231109|NCT06334016|Experimental|Arm C (placebo, THC, nicotine)|"Participants complete 3 vaping sessions separated by 7-14 days on study:~VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.~VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.~VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.~All participants also undergo blood sample collection throughout the trial."
89231110|NCT06334003||FET-group|Children conceived by frozen embryo transfer
89231111|NCT06334003||Fresh ET-group|Children conceived by fresh embryo transfer
89231112|NCT06334003||NC group|Naturally conceived children
89231113|NCT06333990|Experimental|Quetiapine|Quetiapine will be cross-tapered up to a maximum dose of 200 mg (as tolerated) as other standard of care medications are discontinued.
89112302|NCT02772627|Experimental|Nebicapone 100 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
89231114|NCT06333990|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will have doses adjusted over the same period as indicated by usual care criteria.
89231115|NCT06333977|Experimental|LC542019|oral dose, once daily.
89231116|NCT06333977|Placebo Comparator|Placebo|matching placebo capsules.
89231117|NCT06333964|Experimental|AST-001|
89231118|NCT06333964|Placebo Comparator|Placebo of AST-001|
89231119|NCT06333951|Experimental|Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A|Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 orally (PO) and carboplatin, paclitaxel, and pembrolizumab intravenously (IV)
89231120|NCT06333951|Experimental|Subprotocol A: NSCLC Arm B|Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 PO and carboplatin, pemetrexed, and pembrolizumab IV
89231121|NCT06333951|Experimental|Subprotocol A: NSCLC Arm C|Participants with MTAP-deleted NSCLC will receive a combination of AMG 193 PO and pembrolizumab IV
89231122|NCT06333951|Experimental|Subprotocol B: NSCLC With KRasG12C Mutation|Participants with MTAP-deleted NSCLC and KRasG12C mutation will receive a combination of AM193 and sotorasib PO
89231123|NCT06333951|Experimental|Subprotocol C: NSCLC With Brain Metastases|Participants with MTAP-deleted NSCLC with brain metastases will receive AMG 193 PO
89231124|NCT06333938|Experimental|Bridge|Experimental - 30 participants will receive the Bridge device, up to 10 patients per month
89231125|NCT06333938|Active Comparator|Battlefield Acupuncture (BFA)|30 participants will receive BFA, up to 10 patients per month
89112303|NCT02772627|Experimental|Nebicapone 200 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
89112304|NCT02772627|Experimental|Nebicapone 300 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
89112305|NCT00774930|Experimental|Lanreotide Autogel (Somatuline Depot) 120 mg|"Subjects received deep s.c. lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for early roll over [ERO]) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
89112306|NCT00774930|Placebo Comparator|Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE|"Subjects received deep s.c. placebo every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for ERO) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
89112307|NCT02772471|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and invasive ICP monitoring. HS-1000 ICP monitoring intervals will last at least 30 minutes, continuously depending on the patient's clinical condition.
89112308|NCT04201626|Experimental|ERAS|
89112309|NCT04201626|No Intervention|Control|
89112310|NCT02775747|Experimental|platelet rich plasma gel|Injection of Platelet rich plasma (PRP) gel in 64 cases at time of wound closure in women undergoing cesarean section for improving wound healing after fullfit to all the inclusion and exclusion craiteria
89112311|NCT02775747|Placebo Comparator|Saline|64 Controlled Women with recurrent cesarean section and fullfit to all the inclusion and exclusion craiteria will reseve saline injection at time of wound closure
89112312|NCT05335200|Experimental|(S)-[18F]FBFP injection and PET/CT scan|Patients will be intravenously injected with(S)-[18F]FBFP and undergo PET/CT scan.
89112313|NCT02841774|Active Comparator|Moderate Intensity Group|pravastatin 40mg daily for 12 weeks
89112314|NCT02841774|Experimental|High Intensity Group|rosuvastatin 20 - 40 mg daily for 12 weeks
89112315|NCT02772315||Hypertensive patients|Diagnostic procedures in patients with hypertension applying omics results
89290060|NCT05187676|Experimental|Oxygen cutaneous saturation rate (ScO2) then transcutaneous oxygen partial pressure (TcPO2)|ScO2 values will be measured using IPAM first then TcPO2 values will be measured using Periflux6000. ALways in the same order.
89231126|NCT06333925|Experimental|Cognitive Restructuring + High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|30 eligible participants will receive training in Cognitive Restructuring (CR). These participants will use CR while being exposed to misophonic trigger sounds and also receiving high frequency rTMS over their personalized right dorsal lateral prefrontal cortex (dlPFC) target. These participants will partake in short term and long term follow-up testing.
89231127|NCT06333925|Active Comparator|Cognitive Restructuring + Shame Repetitive Transcranial Magnetic Stimulation (rTMS)|30 eligible participants will receive training in Cognitive Restructuring (CR). These participants will use CR while being exposed to misophonic trigger sounds and also receiving placebo rTMS over their personalized right dorsal lateral prefrontal cortex (dlPFC) target. These participants will partake in short term and long term follow-up testing.
89231128|NCT06333912|Experimental|study group treated with guided ridge splitting.|virtual surgical planning using planning software Blue Sky Bio (BSB) and 3D printed surgical guide are fabricated to guide the ridge splitting procedure and implant drilling and placement.
89231129|NCT06333912|Active Comparator|control group treated with conventional ridge splitting.|Freehand surgery is done including ridge splitting and implant plaement
89231130|NCT06333899|Experimental|Lorlatinib Monotherapy|Lorlatinib administered as monotherapy by PO (per os) or NG (nasogastric) for two 28-day cycles at 115 mg/m2/day (or maximum 200mg/dose), after which disease evaluation by Magnetic Resonance Imaging (MRI) imaging will be performed.
89231131|NCT06333899|Experimental|Lorlatinib Combination with BABY POG chemotherapy|Lorlatinib monotherapy x2 cycles followed by maintenance therapy with lorlatinib (115 mg/m2/day) and BABY-POG chemotherapy backbone (vincristine, cyclophosphamide, cisplatin) The BABYPOG chemotherapy backbone regimen will consist of six 12-week courses. Each course will consist of cycles A, A2 and B, which will be administered consecutively, in 28-day cycles for a total of 72 weeks
89231132|NCT06333899|Experimental|Lorlatinib Combination with HIT-SKK chemotherapy|Lorlatinib monotherapy x2 cycles followed by maintenance therapy with lorlatinib (115 mg/m2/day) and HIT-SKK chemotherapy backbone (cyclophosphamide, vincristine, methotrexate, carboplatin, etposide) The recommended HIT-SKK chemotherapy backbone regimen consists of modular chemotherapy cycles, three courses of 4 blocks each (Element IIS, Element IIIS/1, Element IIIS/2, and Element IVS). Each element will be administered consecutively at 2-3-week intervals. Elements IIS and IVS cycles will be repeated twice thereafter. The entire length of treatment for HIT-SKK will be approximately 42 weeks.
89231133|NCT06333899|Experimental|Lorlatinib Maintenance Therapy post RT|Lorlatinib monotherapy x2 cycles followed by Radiation Therapy and continue lorlatnib maintenance monotherapy (115 mg/m2/day) 28 days post completion of RT for 12 cycles
89231134|NCT06333886||SCI patients with neuro-sacral dysfunction|450 patients with traumatic and non-traumatic acute SCI admitted to a level-1 trauma hospital in Montreal, Quebec, Canada
89231135|NCT06333873|Other|Patients with early-stage AMD|30Patients with early-stage AMD
89231136|NCT06333873|Other|Patients with intermediate-stage AMD|30 with intermediate-stage AMD
89231137|NCT06333873|Other|30 healthy volunteers|Without AMD risk
89231138|NCT06333873|Other|30 healthy volunteers with central microdrusens (at risk of developing AMD)|with central microdrusens (at risk of developing AMD)
89231139|NCT06333860|Experimental|Period A: Arm 1 Risankizumab Dose A|Participants will be centrally randomized at the Baseline (Day 1) visit to receive Risankizumab as a single SC injection
89231140|NCT06333860|Experimental|Period A: Arm 2 Deucravacitinib Dose A|Participants will be centrally randomized at the Baseline (Day 1) visit to receive Deucravacitinib orally once per day until the day prior to Week 16
89231141|NCT06333860|Experimental|Period B: Arm 2a Risankizumab Dose A (Continued)|Participants initially randomized to risankizumab (Arm 1) will continue to receive risankizumab as a single SC injection at Weeks 16, 28, and 40
89231142|NCT06333860|Experimental|Period B: Arm 2b Deucravacitinib Dose A|Participants initially randomized to Deucravacitinib (Arm 2) will be re-randomized at the Week 16 visit to receive Deucravacitinib orally once per day up to Week 52
89231143|NCT06333860|Experimental|Period B: Arm 2a Risankizumab Dose A|Participants initially randomized to Deucravacitinib (Arm 2) will be re-randomized at the Week 16 visit to receive Risankizumab as a single SC injection at Weeks 16, 20, 32, and 44
89231144|NCT06333847||Group 1|Patients who responded to the first invitation to participate
89231145|NCT06333847||Group 2|Patients who responded to the second invitation to participate
89231146|NCT06333847||Group 3|Patients who responded to the third invitation to participate
89231147|NCT06333847||Group 4|Patients who did not respond to inviations to participate
89231148|NCT06333847||Group 5|Patients who responded to invitations to participate and thus an amalgamation of the people from groups 1, 2 and 3
89231149|NCT06333834|Active Comparator|Traditional scorpion antivenom regimen|Active/placebo comparator
89231150|NCT06333834|Experimental|Serial dose of scorpion antivenom regimen|
89290061|NCT01125072||entire cohort|patients presenting to the emergency department with chest pain and being admitted to rule out acute coronary syndrome
89290062|NCT02699554||Orthopaedic surgery|
89112316|NCT02841384|Other|Group taping McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
89112317|NCT02841384|Other|Group placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
89112318|NCT02772237|Active Comparator|Treatment group|Riboflavin 400mg daily
89112319|NCT02772237|Placebo Comparator|Placebo group|Placebo
89112320|NCT02841306|Active Comparator|3-5 hours|Duration between oral UDCA intake and surgery of 3-5 hours.
89112321|NCT02841306|Active Comparator|6-8 hours|Duration between oral UDCA intake and surgery of 6-8 hours.
89112322|NCT02841306|Active Comparator|9-12 hours|Duration between oral UDCA intake and surgery of 9-12 hours.
89112323|NCT02841306|Active Comparator|> 12 hours|Duration between oral UDCA intake and surgery of >12 hours.
89112324|NCT02841306|No Intervention|Control|No medication
89112325|NCT04225689|Experimental|CD-TREAT diet|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for a maximum of 21 days. Individualised diet based on energy requirements and physical activity levels."
89290063|NCT01217736|Experimental|VTP-27999|
89112326|NCT04225689|No Intervention|Unrestricted diet|Free, unrestricted diet. Daily for a maximum of 21 days.
89112327|NCT01027364|Experimental|Fixed Weekly Interval|"50 IU/kg rFIXFc via intravenous (IV) injection once every 7 days initially, then at a dose indicated by the participant's baseline pharmacokinetic (PK) assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial weekly dose of rFIXFc (50 IU/kg) were to be made based on baseline PK assessments, occurrence of spontaneous bleeding episodes, and the trough levels, which were to be monitored at Weeks 4, 16, 26, and 39.~Prior to the first dose of rFIXFc, participants in the Sequential PK subgroup were to receive a single dose of 50 IU/kg BeneFIX administered IV in the clinic, followed by PK sampling. A single dose of 50 IU/kg rFIXFc was administered following a 120-hour washout from BeneFIX, followed by PK sampling for a baseline PK profiling. At Week 26 (±1 week) subjects were to receive a single dose of 50 IU/kg rFIXFc for repeat PK profiling."
89112328|NCT01027364|Experimental|Individualized Interval|100 IU/kg rFIXFc via IV injection once every 10 days initially, then at an interval derived from the baseline PK assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial 10-day interval were to be made based on baseline PK assessments and trough levels, which were monitored at Weeks 4, 16, 26, and 39.
89112329|NCT01027364|Experimental|On Demand|20 to 100 IU/kg rFIXFc via IV injection, or the dose indicated by the participant's baseline PK to target a plasma level of 20% to 100%, as needed for the treatment of mild to severe bleeding episodes
89112330|NCT01027364|Experimental|Surgery|The surgical period and dosing are dependent on the type of surgery the participant undergoes. Participants who started the study in one of the other treatment arms prior to surgery will return to the original treatment arm. Participants who joined the study in the Surgery arm will be assigned to one of the other treatment arms following post-operative rehabilitation.
89112331|NCT02775669||intracranial ICP monitoring|invasive intracranial ICP monitoring
89112332|NCT02775669||tranfontanel ICP monitoring|Noninvasive transfontanel ICP monitoring
89112333|NCT02771925|Experimental|gabapentin|Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
89112334|NCT02771925|Placebo Comparator|Placebo|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
89112335|NCT03205956|Experimental|PD Group|A broad range of Parkinson's disease severity and disease duration. Some subjects will not be treated currently with levodopa, and thus likely will be early in the disease process.
89112336|NCT02840994|Experimental|CV301 + Pembrolizumab|CV301 + Pembrolizumab (Phase 1b portion of the trial)
89112337|NCT02840994|Experimental|CV301 + Nivolumab|CV301 + Nivolumab (Phase 1b portion of the trial)
89112338|NCT02775591|Experimental|Motilitone arm|DA-9701 (Motilitone) 30mg 1T three times per day for 4+8 weeks
89112339|NCT02775591|Placebo Comparator|Placebo arm|DA-9701 placebo 30mg 1T three times per day for 4 weeks, DA-9701 (Motilitone) 30mg 1T three times per day for 8 weeks
89112340|NCT02844036|Experimental|Patients with a pulmonary hypertension|Pulmonary hypertension group 4 of Dana point, chronic thromboses lesions, thromboembolic.
89112341|NCT02771457|Experimental|Infliximab at weeks 0,2, and 6|In this arm subjects will receive re-induction treatment of infliximab at weeks 0,2, and 6.
89112342|NCT02771457|Experimental|Infliximab at weeks 0,4, and 8|In this arm subjects will receive re-induction treatment of infliximab at weeks 0, 4, and 8
89112343|NCT02771457|Active Comparator|Infliximab at weeks 0, and 8|In this arm subjects will not be randomized. They will receive re-induction therapy weeks 0 and 8.
89112344|NCT01027286|Experimental|Vitagel|
89112345|NCT01027286|No Intervention|Control|No Vitagel used.
89112346|NCT02843802|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
89112347|NCT02843802|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
89112348|NCT02771379||Patients who are treated with Raxone®|
89231151|NCT06333821|Experimental|Nimotuzumab+chemoradiotherapy|Participants receive Nimotuzumab 400 mg intravenously (IV) on Day 1 of each week cycle (QW) for 7-8 cycles followed by Nimotuzumab 400 mg IV on Day 1 of each 2-week cycle (Q2W) for an additional 12 cycles. During the QW dosing period of Nimotuzumab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once or divides into 3 times per week (QW) for 4 or 5 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80-85 Gray Units (Gy) for volume-directed given with the total duration of radiation treatment not to exceed 8 weeks .
89112349|NCT01026870|Active Comparator|Mometasone furoate (MF) metered-dose inhaler 100 mcg BID|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks
89112350|NCT01026870|Placebo Comparator|Placebo metered-dose inhaler BID|2 inhalations from a matching placebo inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
89112351|NCT02771535|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
89112352|NCT02771535|Active Comparator|Health Training Group|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
89112353|NCT02771691|Experimental|MBT therapy plus treatment as usual|Mentalization based group treatment for adolescents plus standard care
89112354|NCT02771691|No Intervention|Treatment as usual alone|Standard care provided by local Child and Adolescent Mental Health Services
89112355|NCT02696811|Placebo Comparator|Oat biscuits|Participants will eat 3 oat biscuits per day for 6 weeks
89112356|NCT02696811|Experimental|White Carrots|Participants will eat 100g (cooked weight) of white carrots per day for 6 weeks
89112357|NCT02841228|Experimental|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction, SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
89112358|NCT02775513||Mutation|Patients with functional mutation in ion channels
89112359|NCT02775513||Control|Matched control
89112360|NCT02844114|Experimental|Ganoderma lucidum spore & Chemotherapy|Ganoderma lucidum spore 1500mg tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
89112361|NCT02844114|Placebo Comparator|Placebo & Chemotherapy|Placebo tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
89231152|NCT06333821|Experimental|placebo for Nimotuzumab+chemoradiotherapy|Participants receive placebo for Nimotuzumab 400 mg intravenously (IV) on Day 1 of each week cycle (QW) for 7-8 cycles followed by placebo 400 mg IV on Day 1 of each 2-week cycle (Q2W) for an additional 12 cycles. During the QW dosing period of placebo, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once or divides into 3 times per week (QW) for 4 or 5 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80-85 Gray Units (Gy) for volume-directed given with the total duration of radiation treatment not to exceed 8 weeks .
89112362|NCT04810143|Experimental|Aim 1|"All patients presenting for routine post-transplant care including, but not limited to: cardiac catheterization, cardiac biopsy, inpatient admission, or outpatient visits. A convenience sample of 25 inpatient samples will be collected for Aim 1. Although the assay developed by the MSCF will be validated for accuracy, the purpose of Aim 1 is to test real world application of the Mitra Microsampler tubes against the gold standard of blood collected by venipuncture in a controlled setting. To accomplish this, consecutive inpatient heart transplant patients will be enrolled. That sample will be collected at the same time (+/- 15 minutes) as a clinically-indicated, appropriately-timed venipuncture for measurement of a tacrolimus trough and prior to the subject taking tacrolimus so as to represent a trough."
89290064|NCT01217736|Active Comparator|aliskiren|
89290065|NCT01217736|Placebo Comparator|placebo|
89290066|NCT01373710|Experimental|Trastuzumab intrathecal|
89112363|NCT04810143|Experimental|Aim 2|Outpatient. A convenience sample of 25 outpatients collecting 1-2 samples will be collected for Aim 2. For those who agree to participate, the parent/patient will be taught by a member of the team on how to use the Microsampler to collect blood from a finger stick. They will be provided with a kit for collection of up to 2 samples and will also be provided with appropriate shipping materials to return samples to CCHMC. Participants will then be instructed to collect a sample in the Mitra Microsampler via fingerstick. In addition to the process of collecting the sample in Aim 2, appropriately-aged participants and/or families will be asked to fill out a brief survey regarding sample collection. This will include questions about the ease or difficulty of performing the steps and tolerability of the procedure relative to past experiences with values obtained by venipuncture.
89112364|NCT05334498|Experimental|Motor dual-task gait training|Motor dual task gait training was the protocol which performed by the patients after the measurement of the balance and gait ability
89112365|NCT05334498|Experimental|Cognitive dual-task gait training|Cognitive dual task gait training was the protocol which performed by the patients after the measurement of the balance and gait ability
89112366|NCT02775357|Experimental|Enhanced HIV counseling and testing|In addition to standard HIV testing and counseling,men randomized to this arm received Measurement and communication of HIV risk from the HIV counselors using an index developed and validated through the Rakai community cohort study. Their risk was communicated to them and subsequent HIV risk reduction counseling including male circumcision was given.
89112367|NCT02775357|Active Comparator|Standard HIV testing and counseling|Men randomized to this arm were given standard HIV testing and counseling following the current Uganda Ministry of Health guidelines. Following the counseling HIV risk reduction counseling including male circumcision was given.
89112368|NCT05335980|Experimental|Nu-V3 Device|Treatment with the Nu-V3 Device.
89112369|NCT05335902||standard cardiopulmonary bypass|patients 18 year or older undergoing heart surgery with standard cardiopulmonary bypass
89112370|NCT05335902||mini-cardiopulmonary bypass|patients 18 year or older undergoing heart surgery with standard mini-cardiopulmonary bypass
89112371|NCT02696733|Experimental|UG - ONB|Patients with the bladder tumor located on the lateral wall, with the high risk of adductor muscles contraction during TURBT under spinal anesthesia.
89112372|NCT02771613||Active experience feedback|Multi professional, in situ simulation , with scenarios based on the adverse events analyzed in MMR : After analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
89112373|NCT02771613||Passive experience feedback|Large diffusion of information about discussions and decisions of Morbidity Mortality Reviews : after the analysis of adverse effects in Morbidity Mortality reviews, a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out.
89112374|NCT02771613||No experience feedback|MMR will be performed as usual, without any feedback to the medical staff
89112375|NCT02771301|Other|dendritic cell|Patients will receive autolgous IDH1R132H dendritic cells and cytotoxic lymphocytes treatment.
89112376|NCT02775279||Acute coronary syndrome group|200 consecutive patients were recruited, who have diagnosed with acute coronary syndrom(ACS) by quantitative coronary angiography.
89112377|NCT02775279||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
89112378|NCT02771067|Experimental|Pulse pressure variation|Pulse pressure variation will be recorded via an arterial catheter after anesthetic induction, before pneumoperitoneum, after pneumoperitoneum, before infusion of 6% hydroxyethyl starch, and after infusion of 6% hydroxyethyl starch. Stroke volume will be also measured to differentiate the fluid responders.
89112379|NCT02775123|No Intervention|Control|Conventional cardio-pulmonary bypass
89112380|NCT02775123|Experimental|Cytosorb|Cytosorb added to cardio-pulmonary bypass
89112381|NCT02770989|Experimental|Vimecon Laser CAI Cardiac Ablation|Ablation of the cardiac tissue by the use of the Vimecon Laser CAI (Cardiac Ablation Instrument).
89112382|NCT02775201|Active Comparator|Plantaris release under ultrasound guidance|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris released under ultrasound guidance by a consultant radiologist
89112383|NCT02775201|Active Comparator|Plantaris excision surgically|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris excised in surgery by a consultant orthopaedic surgeon
89112384|NCT01026974|Experimental|4rMenB|Subjects received three primary doses of rMenB vaccine (at the age of 6-8 months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB vaccine at 40 months of age in the present study.
89112385|NCT01026974|Experimental|4rMenB+OMV NZ|Subjects received three primary doses of rMenB+OMV NZ vaccine (at the age of 6-8months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB+OMV NZ vaccine at 40 months of age in the present study.
89112386|NCT01026974|Experimental|Naive_4042|Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.
89112387|NCT01026974|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study.
89112388|NCT02770911|Experimental|"without Dog Ear group"|Before anastomosis, the surgeon made a laparoscopic suturing on the two dog ears by using 3-0 monofilament sutures, and pull two dogears of staple line around the trocar by a tied suture through two dog ears. By this way, the staple line was kept within the circular knife when the circular stapler was closed. Then a true end-to-end anastomosis was performed after stapler firing.
89112389|NCT02770911|Active Comparator|"with Dog Ear group"|traditional double-stapled anastomosis was used for laparoscopic anterior resection
89112390|NCT04225299|Experimental|TOOKAD®|TOOKAD® , lyophilized formulation, given at a dose of 4mg/Kg.
89112391|NCT04225299|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have intermediate risk localised prostate cancer
89112392|NCT02775045||Eosinophil esophagitis|Adult patients (>18 yr) will be recruited from the Gastroenterology clinic following a diagnostic endoscopy for esophageal dysfunction with predominant symptom(s) of solid food dysphagia and/or esophageal food impaction. Patients with esophageal biopsy showing greater than 15 eosinophil/hpf (pathology results typically available within three business days) despite greater than two months use of high dose proton pump inhibitor will be invited to participate and enroll in the study within 1 week of the endoscopy.
89112393|NCT02771223||Study group|patients scheduled for prolonged cardiac surgery (over 3 hours anticipated ECC time) with no known coagulation disorders
89112394|NCT02774967|Active Comparator|extended flap technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.~Other Names:~acellular dermal matrix extended flap technique"
89112395|NCT02774967|Experimental|tunnel technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.~Other Names:~acellular dermal matrix extended flap technique"
89112396|NCT00897390|Other|Arm A|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
89112397|NCT00897390|Other|Arm B|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
89112398|NCT00897390|Other|Arm C|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
89112399|NCT00897390|Other|Arm D|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal
89112400|NCT01034462|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
89112401|NCT01034462|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
89112402|NCT01033448|Experimental|Single arm|
89112403|NCT02843724|Active Comparator|Control (Conventional) Arm|Treatment of Type 2 Diabetes according to the Canadian Diabetes Association guidelines. Participants' other health concerns to be addressed as per usual care by practitioners at Wise-Elephant Family Health Team.
89112404|NCT02843724|Active Comparator|Integrative (Naturopathic + Conventional) Arm|In addition to conventional care, participants will receive free naturopathic care at Brampton Naturopathic Teaching Clinic (located within the Brampton Civic Hospital). Senior student clinicians will provide care under the direct supervision of licensed naturopathic doctors. A naturopathic menu of treatment options have been designed to reflect naturopathic practice and vetted by 3 licensed naturopathic doctors and experts in the field. Participants' other health concerns will be addressed as per naturopathic doctors' discretion.
89112405|NCT02774655|Experimental|PAI APP|personal activity index application
89112406|NCT02774655|Active Comparator|FitBit APP|
89112407|NCT02843880||Septic shock patients|Septic shock patients staying over 3 days mechanically ventilated in the ICU
89112408|NCT04754607|Experimental|Low-level laser therapy group|"Low Level Laser Therapy (LLLT): Low-level laser therapy will be applied to the cases in addition to LT4 hormone replacement therapy.~LLLT group will be treated using a continuous wave GaAIAs type diode laser (Intelect® Mobile Laser, Model No: 2779, Production Year: 2016; Chattanooga Group) device in the treatment area of 0.07 cm2. Continuous mode at 850 nm wavelength, 100 mW output power,1.43 W/cm2 power density and 28.57 J / cm2 energy density will be used."
89112409|NCT04754607|Sham Comparator|Sham Group|Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
89112410|NCT02873390|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
89112411|NCT02770833|Experimental|Salmon vs. veal and CHO with low or high GI|"In the first clinical study (Study 1), subjects will eat salmon or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:~Meat balls with salmon served with tomato sauce and other accompaniments with low GI~Meat balls with salmon served with tomato sauce and other accompaniments with high GI~Meat balls with veal served with tomato sauce and other accompaniments with low GI~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
89112412|NCT02770833|Experimental|Cod vs. veal and CHO with low or high GI|"In the second clinical study (Study 2), subjects will eat codfish or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:~Meat balls with codfish served with tomato sauce and other accompaniments with low GI~Meat balls with codfish served with tomato sauce and other accompaniments with high GI~Meat balls with veal served with tomato sauce and other accompaniments with low GI~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
89112413|NCT05335824|Experimental|The platelet-rich plasma (PRP) group:|The patients in this group received PRP injections immediately before the canine retraction, and after 8 weeks of the onset of retraction
89231153|NCT06333808|Experimental|Treatment Group 1: Bictegravir (BIC)/ Lenacapavir (LEN) (75/50 mg) + PTM B/F/TAF|"Blinded Phase: Participants will switch from bictegravir/emtricitabine/tenofovir (B/F/TAF) FDC tablets to BIC/LEN (75/50 mg) FDC tablets and placebo-to-match (PTM) B/F/TAF. Participants will receive a 2-day oral loading dose of LEN 600 mg on Day 1 and on Day 2, in addition to the daily doses of BIC/LEN FDC tablet starting on Day 1 up to end of blinded treatment (EBT) visit.~Open-label (OL) Phase: Following treatment in the Blinded Phase, participants from Treatment Group 1 will receive BIC/LEN FDC tablets through Week 48 in the Open-label Phase. At the OL Week 48 visit, participants from Treatment Group 1 will be given the option to continue to receive BIC/LEN FDC tablets until the conclusion of the OL Phase."
89231154|NCT06333808|Experimental|Treatment Group 2: B/F/TAF (50/200/25 mg) + PTM BIC/LEN|"Blinded Phase: Participants will continue with their B/F/TAF (50/200/25 mg) FDC tablets and start PTM BIC/LEN tablets on Day 1. Participants will receive PTM LEN tablets for 2 days (2 PTM LEN tablets on Day 1 and on Day 2. The blinded phase will continue until the EBT visit.~Open Label Phase: Participants in Treatment Group 2 who complete the EBT visit will be given the option to enter the OL phase to receive BIC/LEN FDC tablets until the conclusion of the OL Phase."
89231155|NCT06333795|Experimental|Active treatment|Active capsule FMT-treatment
89231156|NCT06333795|Placebo Comparator|Placebo|Placebo capsules are given.
89231157|NCT06333782|Experimental|Genefill Contour®|Participants will be injected with the investigational device Genefill Contour at Visit 1, and Visit 2 only if touch-up needed.
89231158|NCT06333782|Active Comparator|Comparator (Desirial®Plus)|Participants would be injected with the marketed comparator (Desirial Plus) at Visit 1, and Visit 2 only if touch-up needed.
89231159|NCT06333769|Experimental|Short-course Radiotherapy Combined with CAPOX and Tislelizumab|
89231160|NCT06333756|Experimental|Cross education training group|Cross education on elbow flexor
89112414|NCT05335824|Experimental|The injectable platelet-rich fibrin (I-PRF) group|The patients in this group received I-PRF injections immediately before the canine retraction, and after 8 weeks of the onset of retraction
89112415|NCT05335824|Active Comparator|The control group|The patients in this group did not receive any injections
89112416|NCT02873234||Traditional Chinese Medicine|Including Zishui Qinggan Yin,Xiaoyao San, Longdan Xiegan Tang, Guipi Decoction, Ningshen Dingzhi Wan, HuangLian-EJiao decoction and Jiaotai Wan.
89112417|NCT02873234||TCM plus antidepressants|This is a integrative therapy that refers to a new treating system including TCM and antidepressants.
89112418|NCT02873234||Antidepressants|Antidepressants include Selective serotonin reuptake inhibitors (SSRIs), Norepinephrine-reuptake inhibitors and other antidepressants, such as Paroxetine, Citalopram, Venlafaxine, Sertraline, Trazodone, Maprotiline and so on.
89112419|NCT02774811|Active Comparator|Selective laser trabeculoplasty|Selective laser trabeculoplasty
89112420|NCT02774811|Active Comparator|Prostaglandin analogue|Prostaglandin analogue topical medical therapy
89112421|NCT00817050|Active Comparator|Nasonex Followed by Flonase|
89112422|NCT00817050|Active Comparator|Flonase Followed by Nasonex|
89112423|NCT04224831|Active Comparator|Before application|"The chronic CSCR cases included here meet one or more of the following criteria:~Complaints of recurrent symptoms lasting longer than 3 months;~Recalcitrant or unresponsive to all known current treatment modalities including PDT and MPL;~Typical B-scan SD-OCT findings of chronicity such as elongation of photoreceptor outer segments indicating chronic nature of sub-macular fluid and/or the presence of serous flat-irregular RPED and focal areas of thickened RPE that lie below the collection of SRF;~Widespread RPE/photoreceptor damage, RPE mottling and atrophy along with chronic submacular fluid;~Widespread multifocal areas of chronic serous retinal detachment and/or flat-irregular RPEDs in those eyes that effective and reliable laser application is impossible."
89112424|NCT04224831|Active Comparator|After application|The changes in SMT, CMT, DRCD, and BCVA before and after the interventions were compared.
89112425|NCT00816972|Active Comparator|DL 2.5 mg|Desloratadine 2.5 mg twice daily (BID) + Placebo for Oxybutynin 2.5 mg BID for 7 days
89112426|NCT00816972|Active Comparator|OXY 5 mg|Placebo for Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
89112427|NCT00816972|Experimental|DL 2.5 mg + OXY 2.5 mg|Desloratadine 2.5 mg BID + Oxybutynin 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
89112428|NCT00816972|Experimental|DL 2.5 mg + OXY 5 mg|Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
89112429|NCT00816972|Placebo Comparator|Placebo|Placebo for Desloratadine 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
89112430|NCT02770677|No Intervention|Control group|Control group will be asked to continue their normal daily life without Yoga training
89112431|NCT02770677|Experimental|Yoga group|Yoga group will be exposed to Modified Dantien Salee Yoga Training Program for 12 weeks
89112432|NCT02690688||Pneumoperitoneum|Patients scheduled for laparoscopic (minimal invasive) abdominal surgery supported by pneumoperitoneum. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
89112433|NCT02690688||Open Surgery|Patients scheduled for conventional (open) abdominal surgery. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
89112434|NCT02774577|Experimental|healthy young and elderly|young adults (20 to 30 years) compare to elderly (60 to 74 years)
89112435|NCT02841150|Experimental|Treatment Sequence 1|Participants will receive treatment A, on Day 1 of Intervention Period 1 followed by treatment B , on Day 1 of Intervention Period 2 followed by treatment A, Day 1 of Intervention Period 3 and then followed by treatment B, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
89231161|NCT06333743|Experimental|laser ablation treatment|Laser vaporization is performed using a carbon dioxide laser under colposcopy. All patients received 1% mepivacaine hydrochloride paracervix block. No general anesthesia was used. Before laser vaporization began, scaly columnar nodules were visible in all patients. The evaporation depth is 8-10mm, and the edge is 5mm from the abnormal discovery or transition area.
89231162|NCT06333743|Active Comparator|LEEP or conization treatment|The cervix was stained with iodine solution and the diseased lesion was visualized. LEEP or conization was performed to a depth of approximately 1.5 cm to resect disease in the cervical canal.
89231163|NCT06333730|Experimental|Inferior Alveolar Nerve Block (IANB)|48 patients will be randomly selected in inferior alveolar nerve block group
89231164|NCT06333730|Experimental|Mental Nerve Block (MNB)|48 patients will be randomly selected in mental nerve block group
89231165|NCT06333717|Experimental|High-fibre bread|Six slices (180 g) of whole grain rye bread divided over the meals during the day for 3 weeks
89231166|NCT06333717|Placebo Comparator|Control bread|Six slices (180 g) of control bread containing refined wheat and oat flour divided over the meals during the day for 3 weeks
89231167|NCT06333704||SPIKEVAX BIVALENT or SPIKEVAX X|Participants receiving at least 1 dose of SPIKEVAX BIVALENT vaccine or SPIKEVAX X Injection are monitored for safety parameters up to 28 days post vaccination.
89231168|NCT06333691|Active Comparator|Group A:(Calcium gluconate Group)|About 60 women patients,in which took IV infusion of calcium gluconate (Calcionate 10ml of 10% calcium gluconate, Memphis) in 200ml saline within 30 minutes of ovum pickup and contained for the next 3 days in addition to diosmin 2 tablets (500mg) t.d.s for 2 weeks.
89231169|NCT06333691|Active Comparator|Group B:(Cabergoline Group)|About 60 women patients,in which took cabergoline (Dostinex 0.5 mg, Pfizer, Montreal, Canada) orally daily for 8 days after hCG triggering.
89231170|NCT06333691|Active Comparator|Group C:(Diosmin Group)|About 60 women patients,in which took diosmin , 2 tablets (500mg) t.d.s for 2 weeks in addition to cabergoline 1 tablet 0.5 mg/day orally for 8 days starting at the day of hCG injection.
89231171|NCT06333678|Active Comparator|continue standard of care (SOC) durvalumab treatment|Will continue to receive durvalumab, 10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.
89231172|NCT06333678|Experimental|switch sotorasib treatment until progression|Will receive sotorasib at 960 mg daily until progression. A dose de-escalation regimen based on toxicity will be implemented as below. If 120 mg cannot be tolerated, sotorasib will be discontinued and the patient will be removed from the trial.
89231173|NCT06333665||Coe-T2DM group|There was a definitive diagnosis of type 2 diabetes mellitus before surgery
89231174|NCT06333665||No-T2DM group|There was no clear diagnosis of type 2 diabetes mellitus before surgery
89231175|NCT06333652|Experimental|Revulizumab Treatment|Subjects will receive an single-dose infusion of Ravulizumab.
89231176|NCT06333639||orthopaedic surgery (goup 1 control)|30 individuals installed according to the usual procedures for an orthopaedic surgery
89231177|NCT06333639||orthopaedic surgery and fitted with a virtual reality headset (group 2 case)|30 individuals installed according to the usual procedures for an orthopaedic surgery and fitted with a virtual reality headset
89231178|NCT06333626|Experimental|Observation group|
89231179|NCT06333626|No Intervention|Control group|
89231180|NCT06333613|Experimental|Test Lens|Eligible subjects will be fitted bilaterally with the TEST lens for approximately 2 weeks of wear (two 1-week wear periods).
89231181|NCT06333600|Active Comparator|Group minoxidil (Treatment group)|Topical application of Minoxidil 5% solution
89231182|NCT06333600|Active Comparator|Group calcipotriol (Treatment group)|Topical application of vitamin D3 analogue (Calcipotriol ointment)
89231183|NCT06333600|Placebo Comparator|Group 3 (Negative control group)|This group will be given saline
89231184|NCT06333587||image-guided thermal ablation|image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
89231185|NCT06333574|Other|Control group|received routine outpatient management. Specific methods: The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
89112436|NCT02841150|Experimental|Treatment Sequence 2|Participants will receive treatment B, on Day 1 of Intervention Period 1 followed by treatment A, on Day 1 of Intervention Period 2 followed by treatment B, Day 1 of Intervention Period 3 and then followed by treatment A, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
89112437|NCT02774499|Experimental|Methadone|Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
89112438|NCT02774499|Placebo Comparator|Placebo|Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
89112439|NCT02770443|Experimental|Treatment|Withdrawal of beta blockers and ACE inhibitors
89112440|NCT02770443|Placebo Comparator|control|no withdrawal, standard of care
89112441|NCT02770053|Experimental|Intervention|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with #35 K-files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
89112442|NCT02770053|Active Comparator|Control|In the control group, no foraminal enlargement will be performed.
89112443|NCT02770209|Experimental|the experimental group|Patients in the experimental group will be treated with the biomimetic cartilage matrix combined with autologous chondrocytes. The entire course of treatment includes two surgeries. The first surgery will be performed to observe articular cartilage damage by arthroscopy and assess treatment potential. If the patient's condition meets the surgical requirement, we will extract cartilage from the fossa intercondylar non-weight-bearing area during the first surgery. Chondrocytes will be in vitro-amplified and inoculated into the cartilage scaffold. The fully prepared seeded scaffold will be implanted into the site of injury during the second surgery.
89112444|NCT02770209|Experimental|the control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
89112445|NCT02774109|Experimental|Experimental group|Participants in the experimental group will take fish oil (five 1000mg fish oil soft capsules per day, each capsule containing 350mg EPA and 250mg DHA) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
89112446|NCT02774109|Placebo Comparator|Control group|Participants in the control group will take placebo (five 1000mg sunflower oil soft capsules per day) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
89112447|NCT02774031|Experimental|Aisys with Et control|the ventilation modus will be pressure control ventilation with volume guarantee (PCV-VG). Settings: tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR) 12 -14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP). Target for end expired desflurane concentration (F A des) is set to 4.2%, and target for end expired oxygen (F AO2) is set to 35%.
89112448|NCT02774031|Active Comparator|Aisys conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Aisys with PCV-VG'
89112449|NCT02774031|Experimental|Flow-i with ACG|the following parameters will be preset: FIO2= 40%; end expired gas concentration (FA des) to 4.2%; speed 6; and ventilation modus = pressure regulated volume control (PRVC) with tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR)12-14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP).
89112450|NCT02774031|Active Comparator|Flow-I conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Flow-i with ACG'
89112451|NCT04224909||Patients with Sudden Sensorineural Hearing Loss|
89112452|NCT02769663||OSA|Patients with newly diagnosed obstructive sleep apnea and no medical comorbidity affecting cognition.
89112453|NCT02769663||healthy controls|Participants with no sleep disorder or other medical comorbidity affecting cognition.
89112454|NCT02769819|Experimental|Intubation with a flexible fiberscope|Following induction of general anesthesia and administration of a neuromuscular blocking agent, intubation will be performed using a flexible fiberscope.
89112455|NCT02774187|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
89112456|NCT02774187|Active Comparator|Sorafenib alone|Sorafenib alone
89112457|NCT02769897|Experimental|Intervention group|The exercise program, nutritional counseling and oral health will last for five to six months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC). The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
89112458|NCT02769897|No Intervention|Control group|The control group did not receive the intervention.
89112459|NCT02773797|Placebo Comparator|IN-DEX 1.0 mcg/kg, intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Intranasal-Dexmedetomidine (IN-DEX) intranasal 1.0 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
89112460|NCT02773797|Placebo Comparator|IN-DEX, 1.5 mcg/kg intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label IN-DEX intranasal 1.5 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
89112461|NCT02773797|Active Comparator|Placebo - Saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Placebo - Saline will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
89231186|NCT06333574|Other|Intervention group|On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
89231187|NCT06333561||HAIC+Len+PD-1 inhibitor group|HAIC combined with Lenatinib and PD-1 inhibitor group
89231188|NCT06333561||Len group|Lenvatinib alone
89112462|NCT02769741|Other|Crossover 1: Control Diet followed by Active Diet|Treatment Period 1: Controlled diet without cashew nuts; Treatment Period 2: Controlled diet with cashew nuts
89112463|NCT02769741|Other|Crossover 2: Active Diet followed by Control Diet|Treatment Period 1: Controlled diet with cashew nuts; Treatment Period 2: Controlled diet without cashew nuts
89112464|NCT02769429||ultrasound-guided CISB|Group 1 will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
89112465|NCT02769429||nerve stimulator-guided CCPVB|Group 2 will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
89112466|NCT02769507|Experimental|real tDCS|DC Stimulator PLUS (NeuroConn) The real tDCS condition comprises two daily sessions of 20 min tDCS, separated by a minimum break of 3h, for five consecutive days. Anodal and cathodal tDCS will be applied with 2mA to the left dorsolateral prefrontal cortex (a point midway between F3 and FP1) and the left peri-Sylvian region (a point midway between T3 and P3), respectively. Electrode size is 7cm x 5cm.
89112467|NCT02769507|Sham Comparator|sham tDCS|"DC Stimulator PLUS (NeuroConn) The sham condition is identical to the real tDCS condition except that after 40s of tDCS stimulation is going to be reduced to a small pulse every 550msec (110 μA over 15 msec) through the remainder of the 20 minute period."
89112468|NCT02773953|Experimental|CPAP + T4PTelemonitoring device|T4P® (Telemonitoring device) is added to CPAP at home. Sleep lab technical staff are connecting to the web portal 2 X/ week. In case of air leaks, persistant significant apnea-hypopnea index, use < 3h on three consecutive days, they have to call the patient .
89112469|NCT02773953|Active Comparator|CPAP standard care|After CPAP titration night, patients are instructed to use the device each night for the whole night. They receive written instruction and can reach the sleep unit (phone call, visit) how often they need, during week days, to resolve CPAP-related problems. A group educational session is scheduled 1 month after and a visit to the pneumologist 1.5 months after.
89112470|NCT02769585|Experimental|Self-hypnosis|Subjects underwent two group sessions one week apart with a certified hypnotherapist to teach them the process of self-hypnosis for the purpose of attaining weight loss. Subjects were asked to perform self-hypnosis once or twice a day for the duration of the one year trial.
89112471|NCT02769585|Active Comparator|CDE training|Subjects underwent two group sessions one week apart with a certified diabetes educator to teach them re: diet and nutrition specifically as regards to a diabetic striving to lose weight. Subjects were asked to remain compliant with dietary restrictions for the duration of the one year trial.
89231193|NCT06333535|Experimental|Foot massage group|"Stage 1/Pretest: After the colonoscopy procedure, after the patients regained consciousness in the recovery unit, the Patient Introduction Form, Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were filled out.~2nd Stage/Intervention: The patients were massaged on both feet in accordance with the foot massage instructions.~3rd Stage / 30th minute: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded. .~4th Stage / 2nd hour: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~5th Stage / 4th Hour Abdominal Pain NRS Scale Form, Abdominal Distension NRS Scale Form and satisfaction (NRS satisfaction) scores were directed to the patients and recorded."
89231194|NCT06333535|Experimental|Abdominal massage group|"Stage 1/Pretest: After the colonoscopy procedure, after the patients regained consciousness in the recovery unit, the Patient Introduction Form, Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were filled out.~2nd Stage/Intervention: The patients were massaged in the abdominal area in accordance with the abdominal massage instructions.~3rd Stage / 30th minute: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded. .~4th Stage / 2nd hour: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~5th Stage / 4th Hour Abdominal Pain NRS Scale Form, Abdominal Distension NRS Scale Form and satisfaction (NRS satisfaction) scores were directed to the patients and recorded."
89231195|NCT06333535|Experimental|Foot and Abdominal massage group|"Stage 1/Pretest: After the colonoscopy procedure, after the patients regained consciousness in the recovery unit, the Patient Introduction Form, Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were filled out.~2nd Stage/Intervention: The patients were massaged in the abdominal area in line with the abdominal massage instructions, and then both feet were massaged in line with the foot massage instructions.~3rd Stage / 30th minute: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~4th Stage / 2nd hour: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~5th Stage / 4th Hour Abdominal Pain NRS Scale Form, Abdominal Distension NRS Scale Form and satisfaction (NRS satisfaction) scores were directed to the patients and recorded."
89231196|NCT06333535|No Intervention|Control group|"Stage 1/Pretest: After the colonoscopy procedure, after the patients regained consciousness in the recovery unit, the Patient Introduction Form, Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were filled out.~Stage 2/Attempt: No attempt was made. 3rd Phase / 30th minute: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~4th Stage / 2nd hour: Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded.~5th Stage / 4th Hour Abdominal Pain NRS Scale Form and Abdominal Distension NRS Scale Form were administered to the patients and recorded."
89231197|NCT06333522|Experimental|Losartan cohort|Patients will initiate Losartan treatment 2 weeks pre-operatively and will continue until 4 weeks post-operatively. Range of motion will be measured as part of standard of care at the time of enrollment and at post-op office visits 2-4 weeks, 4-8 weeks and 8-20 weeks post-operatively.
89231198|NCT06333522|No Intervention|Control cohort|No additional steps in management are required for the control arm of the study. Range of motion will be measured as part of standard of care at the time of enrollment and at post-op office visits 2-4 weeks, 4-8 weeks and 8-20 weeks post-operatively.
89231199|NCT06333509|Experimental|Phase 1|Dose Escalation followed a dose expansion.
89231200|NCT06333509|Experimental|Phase 2|Single group of patients for each indication (rrMM, RRpPCL).
89231201|NCT06333496|Experimental|GLP-1 Booster|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, White kidney bean (Phaseolus vulgaris) extract, and chromium (III) an essential trace mineral. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
89231202|NCT06333483|Experimental|AUTO1|
89231203|NCT06333457||VR group|50 patients with diagnosed alcohol dependence (in-patients, patients in the outpatient department or day clinics) receiving VR Cue-Exposure Therapy (VR-CET) additional to the standard treatment.
89231204|NCT06333457||control group|50 patients with diagnosed alcohol dependence (in-patients, patients in the outpatient department or day clinics) receiving standard treatment.
89231205|NCT06333444|Experimental|Psychological intervention|four weekly psychological counselling intervention
89231206|NCT06333431|Experimental|Glass Waterfall|Except for the preparation the gastroscopy procedure takes approximately 20 minutes, patients will be asked to focus on portative glass waterfall during the procedure.
89231207|NCT06333431|Experimental|White Noise|Except for the preparation of the patient for the procedure, since the gastroscopy procedure takes approximately 20 minutes, 20-minute white noise be listened using phone
89231208|NCT06333431|No Intervention|control group|Patients of the control group, will not receive any intervention except for applied routine hospital gastroscopy procedures.
89231209|NCT06333418|Experimental|Virtual Reality Glasses|Before the colonoscopy procedure, 360-degree VR video scenes will be watched to patients 30 minutes using VR head device.
89231210|NCT06333418|Experimental|Glass waterfall|Before the colonoscopy procedure, patients will watch and listen 30 minutes a portative glass waterfall
89231211|NCT06333418|No Intervention|control group|Patients of the control group, will not receive any intervention except for applied routine hospital colonoscopy procedures
89231212|NCT06333405|Experimental|Experimental: Fecal Microbiota Transplantation|
89231213|NCT06333392|Active Comparator|Conventional colonoscopy (CO2) group|this groups receives conventional colonoscopy with CO2 withdrawal
89231214|NCT06333392|Experimental|Total underwater colonoscopy (TUC) group|This group receives total underwater colonoscopy
89231215|NCT06333379||IPA group|Investigators enrolled patients who meet diagnostic criteria for IPA according to EORTC/MSG: new exudative lung lesions unresponsive to antimicrobial therapy; positive Aspergillus on LRT and/or BALF microscopy cultures, positive BALF GM and positive BALF NGS results for Aspergillus. Investigators will test and compare the EBC-GM and BALF-GM levels in these patients.
89231216|NCT06333379||control group|Investigators enrolled patients who were mechanically ventilated patients without Aspergillus infection or colonization. BALF and EBC samples from the same patients were collected less than 4 hours apart, and BALF samples were used for NGS and microbiological cultures. Investigators will test and compare the EBC-GM and BALF-GM levels in these patients.
89231217|NCT06333366|Experimental|intraabdominal pressure (IAP) monitor|Patient who will take laparoscopic surgery will be checked for intra-abdominal pressure, intra-vesical pressure, and intra-gastrointestinal pressure ri-operative stage. PDT passage time will be checked.
89231218|NCT06333353|Experimental|Real RepetitiveTranscranial Magnetic Stimulation (rTMS) 5 sessions|The real rTMS intervention will be delivered to the primary motor cortex (M1) on the left side, over the hand representation, using high frequency (HF) rTMS applied by way of a Magstim Rapid² system. The coil position and orientation will be standardized between treatment visits through using a Brainsight neuronavigation system (Rogue Research, Canada). Each of 5 rTMS sessions will consist of a total of 1500 pulses: 15 sets of pulses delivered at 10Hz for 10s at 80% resting motor threshold (RMT), separated by 50s intervals. The real rTMS intervention will be delivered daily over 5 consecutive days.
89231219|NCT06333353|Sham Comparator|Sham RepetitiveTranscranial Magnetic Stimulation (rTMS) 5 sessions|The sham rTMS intervention will be delivered to the primary motor cortex (M1) on the left side, over the hand representation, using high frequency (HF) rTMS applied by way of a Magstim Rapid² system interfaced with a placebo coil, whose position and orientation will standardized between treatment visits using a Brainsight neuronavigation system (Rogue Research, Canada) The sham stimulation target will be individually defined at baseline as the site eliciting the highest averaged motor evoked potential (MEP) peak-to-peak amplitude in the first dorsal interosseous (FDI) muscle. Each of 5 sham rTMS sessions will consist of a total of 1500 sham pulses: 15 sets of sham pulses (0% output) delivered at 10Hz for 10s, separated by 50s intervals. The sham intervention will be delivered daily over 5 consecutive days.
89231220|NCT06333353|Experimental|Real RepetitiveTranscranial Magnetic Stimulation (rTMS) 10 sessions|The real 10-session rTMS intervention will be the same as that delivered for the real 5-session rTMS intervention, but delivered as 5 daily sessions, a two day break, and 5 more daily sessions.
89231221|NCT06333353|Sham Comparator|Sham RepetitiveTranscranial Magnetic Stimulation (rTMS) 10 sessions|The sham 10 session rTMS intervention will be delivered identically to the sham 5 session intervention, but delivered as 5 daily sessions, a two day break, and 5 more daily sessions.
89231222|NCT06333340|Active Comparator|Oxytocin 5IU|IV oxytocin 5 IU diluted in 10 mL normal saline over 1 min followed by continuous infusion of 250 mIU/min over 4 hours.
89112472|NCT02773875|No Intervention|Sensor Augmented Pump (control)|Use sensor augmented pump (SAP) for 3 weeks.
89112473|NCT02773875|Experimental|Artificial Pancreas (intervention)|Artificial pancreas system (Algorithm + CGM + pump)--use the AP system for 3 weeks which consists of: (1) Fault detection and Zone MPC algorithm housed on the DiAs platform + (2) Roche insulin pump + (3) Dexcom CGM
89112474|NCT02773719|Experimental|True biofield therapist|Subject will have a 40 minutes therapy with a real biofield therapist to treat the wart
89112475|NCT02773719|Placebo Comparator|Fake biofield therapist|Subject will have a 40 minutes therapy with a fake biofield therapist to treat the wart
89112476|NCT02768961|Experimental|Active treatment|"All HCV chronic infected patients will be treated with oral anti-HCV regimens containing sofosbuvir, ledipasvir (associated or not to ribavirin) according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
89112477|NCT02769039||Parkinson's Disease participants|People with early Parkinson's disease with mild-to-moderate severity of disease.
89112478|NCT02769039||Control participants|Volunteers who are age (+/- 3 years) and sex matched to the participants with Parkinson's disease
89112479|NCT02773641|Active Comparator|Botulinum Toxin Type A|50 Allergan units (0.5 ml) injected in m bulbocavernosus twice with 3 months in between treatments
89112480|NCT02773641|Placebo Comparator|Sterile saline solution|0.5 ml of sterile saline injected in m bulbocavernosus twice with 3 months in between treatments
89112481|NCT02773563||EUS with CO2 insufflation|Patients undergoing EUS with CO2 insufflation
89112482|NCT02773563||EUS with air insufflation|Patients undergoing EUS with air insufflation
89112483|NCT02773329|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive exercise program (game-based exercise) intervention twice a week for 6 weeks.
89112484|NCT02773329|Active Comparator|Intervention without game-based exercise|Subjects will be receiving non-technology based foot and ankle exercise twice a week for 6 weeks
89112485|NCT02768805|Experimental|15 µg/strain of Quadrivalent VLP Vaccine|
89112486|NCT02768805|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
89112487|NCT02768805|Active Comparator|15 µg/strain of the licensed quadrivalent vaccine|
89112488|NCT02773251|Experimental|hyaluronic acid-carboxymethylcellulose treatment group|the HA/CMC treatment group after laparoscopic pelvic surgery
89112489|NCT02773251|No Intervention|control group|the HA/CMC non-treatment group after laparoscopic pelvic surgery
89112490|NCT04224597||Patients with acne vulgaris|patients with acne vulgaris aged between 18-25 year
89112491|NCT04224597||Healthy controls|healthy controls aged between 18-25 year
89112492|NCT02768649|Experimental|Cohort 1|Eligible subjects received a test dose of 0.25 risperidone prior to dosing with RBP-7000. Fifteen eligible subjects then received low dose RBP-7000
89112493|NCT02768649|Experimental|Cohort 2|After safety and tolerability review of the data from Day 1 to Day 15 of the low dose arm, 3 subjects were dosed in Cohort 2 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
89112494|NCT02768649|Experimental|Cohort 3|After safety and tolerability review of the data from Day 1 to Day 15 of the medium dose arm, 3 subjects were dosed in Cohort 3 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
89112495|NCT02773173|Experimental|Individualized Pneumoperitoneum Pressure|In Individualized Pneumoperitoneum Pressure (IPP) group, measures to optimize and individualize intra-abdominal pressure (PIA) will be apply.
89112496|NCT02773173|Other|Standard Pneumoperitoneum Pressure|In Standard Pneumoperitoneum Pressure (SPP) group, a conventional operation without optimization measures and PIA preset to 12 mmHg will be conducted.
89112497|NCT02768883|Experimental|Clinic + Home + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator~Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
89112498|NCT02768883|Experimental|Clinic + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
89112499|NCT02768883|Experimental|Home + Community|"Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
89112500|NCT02768883|Active Comparator|Community only|Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook.
89112501|NCT04224675|Other|Ate|
89112502|NCT04224675|Other|Cap|
89112503|NCT02768493|Experimental|low dose group|Patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block.
89112504|NCT02768493|Active Comparator|high dose group|Patients in the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block.
89112505|NCT02768415|Experimental|lapatinib+oral vinorelbine|"apatinib 425/500mg qd, 21days/cycle~oral vinorelbine 60mg/m2 d1, 8, 15 21days/cycle*3cycles, after 3 cycles: 80mg/m2 d1, 8, 15 21days/cycle"
89112506|NCT02773095|Experimental|Intervention counties|In intervention counties, a Novartis Access portfolio of 15 medicines will be sold to local purchasers at a cost of 150 Kenyan Shillings (KES), around US$1.50, per monthly dose.
89112507|NCT02773095|No Intervention|Control counties|Control counties not exposed to the intervention.
89112508|NCT02768571|Experimental|Cerebrolysin|"Cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)~Rehabilitation~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day~5 times/week for 3 weeks~Duration of Treatment:~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
89112509|NCT02768571|Placebo Comparator|Placebo|"Saline 100 ml/day * 21 days with rehabilitation~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)~Rehabilitation~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day~5 times/week for 3 weeks~Duration of Treatment:~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
89112510|NCT02696889|Experimental|ROSE-1 Protocol|Patients with POF, POI or Low Ovarian Reserve choosing to enroll will be provided informed consent for Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1). They will undergo diagnosis and screening confirming diagnosis including History and Physical Exams, Labs and Diagnostic Procedures. Following final approval and under anesthesia, bone marrow aspiration with separation of the bone marrow derived stem cell fraction will be performed. Diagnostic laparoscopy will allow for assessment of pelvic anatomy and subsequent injection of the bone marrow derived stem cells into the right ovary.
89112511|NCT02768025|Experimental|Intervention group|NRT, counselling, traditional & complementary medicine treatment (Body acupuncture, Ear acupuncture and aromatic therapy).
89112512|NCT02768025|Active Comparator|Control group|NRT, counselling
89112513|NCT02767713|Experimental|Dexamethasone|Dexamethasone dose of 0.1 mg/kg was administered intravenously 10h before surgery
89112514|NCT02767713|Placebo Comparator|Control|Equal volume of normal saline (placebo) was administered intravenously 10h before surgery
89112515|NCT02767245|Active Comparator|Thiamine|Thiamine intravenously 100 mg/day for 3 days
89112516|NCT02767245|No Intervention|No thiamine|No thiamine was given to the patient
89112517|NCT02768181|Experimental|Arm 1: BCC+PNS+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with a lipid-based nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with a lipid-based nutrient supplement for children (CNS) aged 6m to 2 years.
89231223|NCT06333340|Active Comparator|Carbetocin 100mcg|IV carbetocin 100 mcg diluted in 10 mL normal saline over 1 min followed by placebo infusion for 4 hours after the delivery of the fetus.
89231226|NCT06333301||TIME-ZZZ|Group will complete several surveys
89231227|NCT06333288|Other|Treatment group|The intervention group will receive individual PST (60 min individual sessions for 6 weeks, in addition to engaging with APPLE Watch features including fitness tracking (such as regular walks), heart rate, and sleep management on a daily basis. Throughout the final 6 individual self-engaged sessions, participants will persist in engaging and utilizing APPLE Watch features, incorporating daily fitness tracking (such as regular walks), wellness applications, and sleep management and apply PST.
89231228|NCT06333288|Other|Control group|"Participants assigned to Education-only control will be asked to watch Quit Drinking Motivation, a 20-min video created by the MotivationHub. This video consists of a speech and conversation discussing the negative consequences resulting from their alcohol misuse and the importance of getting sober. The video will be followed by a 30-minute group discussion via zoom."
89231229|NCT06333275||CAR T-cell recipients|Patients with B-cell malignancies receiving anti-CD19 or anti-BCMA CAR T-cell therapies
89231230|NCT06333262|Experimental|Pirtobrutinib-Obinutuzumab|Eligible participants will receive initial treatment with pirtobrutinib and obinutuzumab for 12 cycles. Participants with progressive chronic lymphocytuc leukemia or small lymphocytic lymphoma during the off-treatment follow-up will receive continuous pirtobrutinib monotherapy.
89231231|NCT06333249|Experimental|Low Dose Group|Male subjects at least 8 y/o treated with a lower dose (Dose 2 in RPGR-001 Horizon Phase 1/2 study) of rAAV2tYF-GRK1-RPGR study drug.
89231232|NCT06333249|Experimental|High Dose Group|Male subjects at least 8 y/o treated with a higher dose (Dose 5 in RPGR-001 Horizon Phase 1/2 study) of rAAV2tYF-GRK1-RPGR study drug.
89231233|NCT06333236|Experimental|Group KRON|Active Treatment: Kron® (300ml) oral solution containing citicoline free acid 40 mg/ml; nicotinamide 15 mg/ml. In addition to the IOP-lowering medications, Kron will be administered at a dosage of 10 ml in the morning. To each patient will be given two bottles during the baseline visit and will be asked to return them at the end of the study (3 month) for the compliance assessment.
89231234|NCT06333236|No Intervention|Control Group|No interviention in addition to the IOP-lowering medications.
89231237|NCT06333210|Experimental|bDMARDs and/or tsDMARD experienced subjects, BCD-180 group|Subjects in this arm will receive a fixed dose of BCD-180 infusions
89231238|NCT06333210|Placebo Comparator|bDMARDs and/or tsDMARD experienced subjects, Placebo group|Subjects in this arm will receive Placebo infusions till the assessment of the primary endpoint and then will be switched to BCD-180 infusions
89231239|NCT06333210|Experimental|bDMARDs and tsDMARD-naive subjects, BCD-180 group|Subjects in this arm will receive a fixed dose of BCD-180 infusions and subcutaneous injections of placebo to maintain blindness of adalimumab therapy till the assessment of the primary endpoint, thereafter subjects will receive only BCD-180 infusions
89231240|NCT06333210|Placebo Comparator|bDMARDs and tsDMARD-naive subjects, Placebo group|Subjects in this arm will receive Placebo infusions and subcutaneous injections of placebo to maintain blindness of adalimumab therapy till the assessment of the primary endpoint, thereafter subjects will be switched to BCD-180 infusions
89231241|NCT06333210|Active Comparator|bDMARDs and tsDMARD-naive subjects, Adalimumab group|Subjects in this arm will receive subcutaneous injections of adalimumab and infusions of placebo till the assessment of the primary endpoint, thereafter subjects will be switched to BCD-180 infusions
89231244|NCT06333184|Active Comparator|Control|50 g glucose (55 g dextrose powder accounting for hydration) plus 417 mL water
89231245|NCT06333184|Experimental|Product|"417 mL of commercially available Mango & Passion fruit fruit smoothie providing 50 g carbohydrate"
89231246|NCT06333184|Experimental|Whole|Apples (51%), Mango (16%), Banana (16%), Orange (12%), Passionfruit (3%), Peach (2%), Lime (0.4%; recipe matched to PRODUCT) eaten as whole fruit with added water as needed to match volume.
89231247|NCT06333184|Experimental|Blend|Apples (51%), Mango (16%), Banana (16%), Orange (12%), Passionfruit (3%), Peach (2%), Lime (0.4%; recipe matched to PRODUCT) eaten as blended fruit with added water as needed to match volume.
89231248|NCT06333184|Experimental|Slow|"417 mL of commercially available Mango and Passionfruit fruit smoothie providing 50 g carbohydrate ingested slowly over 25-35 mins."
89231249|NCT06333184|Experimental|Fibre|"417 mL of commercially available Mango and Passionfruit fruit smoothie providing 50 g carbohydrate with 6 g of added inulin."
89231250|NCT06333184|Experimental|Dose|"250 mL of commercially available Mango and Passionfruit fruit smoothie providing 30 g carbohydrate."
89231251|NCT06333171|Active Comparator|Group A: 4-aminopyridine|dalfampridine (generic) 10 mg capsule po every 12 hours
89231252|NCT06333171|Placebo Comparator|Group B: Placebo|Placebo-1 capsule po every 12 hours
89231253|NCT06333158|Experimental|Cholesfytol NG|
89231254|NCT06333158|Placebo Comparator|Placebo|
89231255|NCT06333145|Experimental|normal group|BMI: ≥18.5 and <24
89231256|NCT06333145|Experimental|overweight group|BMI: ≥24 and <30
89231257|NCT06333145|Experimental|obese group|BMI: ≥30
89231258|NCT06333132|Experimental|Obese subjects with type 2 diabetes mellitus|Individualized weight-loss nutritional intervention
89231259|NCT06333119||individuals with stroke|
88816293|NCT02498769|Placebo Comparator|Epicardial Placebo|After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
89231260|NCT06333106|Other|Patient suspected to suffer from fecal impaction|Any patients aged 75 years or older coming to the ED and for whom the emergency physician suspects fecal impaction.
89231261|NCT06333093|Experimental|Cold snare resections|Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
89231262|NCT06333080||Study Cohort|People with dysregulated type 2 diabetes on metformin treatment, which are naïve to second line antidiabetic treatment. These participants will be started on oral semaglutide, as a second line antidiabetic treatment, in addition to their treatment with metformin. The participants will be started on 3mg and the dose increased according to the label. The oral semaglutide will be administered once daily.
89231263|NCT06333067|Experimental|lax tissue|
89231264|NCT06333054|Experimental|Silcap Shampoo|Subjects with head lice were treated with Silcap Shampoo at visit 1 (day 0) and at visit 3 (day 7).
89231265|NCT06333054|Active Comparator|Goldgeist® Forte|Subjects with head lice were treated with Goldgeist® Forte at visit 1 (day 0) and at visit 3 (day 7).
89231268|NCT06333028||enVista Aspire intraocular lens (IOL)|Subjects bilaterally implanted with enVista Aspire EA IOLs.
89231269|NCT06333015|Experimental|enVista Beyond EY IOL|Subjects implanted with enVista Beyond Extended Depth of Focus (EDF) Intraocular Lens (IOL) Model EY
89231270|NCT06333015|Active Comparator|TECNIS 1-Piece monofocal IOL|Subjects implanted with TECNIS 1-Piece monofocal IOL
89231271|NCT06333002||Derivation cohort|It will contain 800 patients randomly selected (80% of 1,000 patients with AHRF)
89231272|NCT06333002||Validation cohort|It will contain 200 patients randomly selected (20% of 1000 patients with AHRF
89231273|NCT06333002||Confirmatory cohort|It will contain the remaining 241 patients randomply selected (por external validation)
89231274|NCT06332976||Before chemotherapy start|Women candidate to adjuvant or neoadjuvant chemotherapy for breast cancer at the time of informed consent (interview before the start of CT)
89231275|NCT06332976||During chemotherapy|Women who are receiving chemotherapy at the time of informed consent (interview within 1 year from beginning of CT)
89231276|NCT06332976||After chemotherapy end|Women who already received chemotherapy at the time of informed consent (interview after more than 4 years of CT end)
89231277|NCT06332963|Experimental|Interoceptively Focused Treatment (IFT)|The IFT intervention will guide participants through a tailored application of present-moment focus toward experiencing awareness and acceptance of bodily signals and defusing thoughts related to those signals. For example, participants will engage in several exercises to increase awareness of body sensations, thoughts, and emotions. IFT consists of one introduction session with a clinician (~60 minutes) the introduction session was designed as a brief introduction to acceptance- and mindfulness-based concepts with guided practice exercises and closing time for participants to briefly process challenges to execution of exercises and the experience during the session. This is followed by three IFT sessions which combine acceptance- and mindfulness-based skills practice with floatation-REST (Reduced Environmental Stimulation Therapy via floatation).
89231278|NCT06332963|Active Comparator|Exteroceptively Focused Treatment (EFT)|In the EFT condition, exercises are tailored toward experience of the present moment via external environment mindfulness (i.e., attending to experience) and defusion of thoughts. EFT consists of one introduction session with a clinician (~60 minutes) the introduction session, similar in format to IFT, introduces acceptance- and mindfulness-based concepts. This is followed by three EFT sessions during which participants engage in brief guided skills training followed by video guided skills practice. The EFT condition is designed to increase awareness of the present moment and experience of the environment and view thoughts or emotions that may impact engagement with the current moment in a nonjudgmental way.
89231279|NCT06332950|Experimental|Adebrelimab plus Irinotecan Liposome (II)|"Adebrelimab: 1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W"
89231280|NCT06332950|Experimental|Adebrelimab plus Irinotecan Liposome (II) and Famitinib|"Adebrelimab: 1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD"
89290563|NCT03632980|Experimental|HIFU prostate treatment|"The HIFU intervention will concern Primary care patients or Secondary care patients (salvage).~Intervention with Ablatherm Foc/Dyn or Focal One HIFU treatment devices~HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - First line to Patients suffering from localized prostate cancer that has not been previously treated or Salvage HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - Post radiotherapy to subjects harboring prostate cancer recurrency after radiotherapy"
89231281|NCT06332924|Experimental|Motivational interviewing group|"The patients in the intervention group will be informed about the study, and after the purpose and method of the study are explained, their consent will be obtained and the Pregnant Information Form will be applied.~There will be 3 meetings for both groups, one week apart. Interviews will include primipara pregnant women in their 30th, 32nd and 34th weeks of pregnancy.~Preliminary tests will be conducted before the interviews.~After the interviews are completed, final tests will be carried out and the study will be terminated.~Motivational Interviewing Training for the intervention group will be prepared in detail, with the aim of answering the pregnant woman's questions, and with methods that are relevant to her needs and interests by providing body awareness."
89231282|NCT06332924|No Intervention|Control group:|Scales will be applied to the control group as pre-test and post-test with a 2-week interval.
89231283|NCT06332911||complex endovascular thoracic aortic repair|Patients submitted to complex endovascular thoracic aortic repair with hostile iliac access vessels using the Shockwave device to gain access.
89231284|NCT06332898|Placebo Comparator|Placebo|Maltodextrin + Flavoring
89231285|NCT06332898|Experimental|AG1 - Nutritional Supplement|AG1, a foundational nutritional supplement
89231287|NCT06332872|Experimental|Oral ivermectin|For the treatment of head lice infestation, participants are receiving two single doses of oral ivermectin on days 0 and 7 of the experiment. (spaced 7 days apart)
89231288|NCT06332872|Experimental|Dimeticone liquid gel|For the treatment of head lice infestation, participants are receiving one application of 4% dimenticone liquid gel on day 0 of the experiment.
89231289|NCT06332872|No Intervention|Permethrin shampoo|Participants are receiving two applications of 1% permethrin shampoo, which is the current drug of choice for Pediculosis capitis, on days 0 and 7. This group is defined as a control group.
89231290|NCT06332859|Experimental|TakoTsubo|Individuals with TakoTsubo cardiomyopathy who participate in an inpatient rehabilitation programme receive an additional psychological intervention, specifically resilience training. This is not a common practice in such rehabilitation programmes.
89231291|NCT06332859|Experimental|Acute coronary event|Individuals after an acute coronary event who participate in an inpatient rehabilitation programme receive an additional psychological intervention, specifically resilience training. This is not a common practice in such rehabilitation programmes.
89231292|NCT06332846||study group|The study group consisted of 59 individuals subjects with a first ischemic stroke, with symptoms from the anterior cerebral artery (basin of the internal carotid artery), with a significant neurological deficit (minimum 3 points according to National Institute of Health Stroke Scale
89231293|NCT06332846||control group|The control group (59 individuals) matched for age and gender was selected among patients of the Department of Interdisciplinary Dentistry at Pomeranian Medical University in Szczecin.
89231294|NCT06332807|Experimental|NGGT002|Low dose and high dose group Six to twelve patients will be enrolled into two cohorts at two dose levels. The safety of this study can be ensured by selecting the highest dose under the No Observed Adverse Effect Level (NOAEL) doses observed in preclinical toxicology studies.
89231295|NCT06332794|Experimental|KOKU user|SIngle arm study - all participants will use the KOKU app for 4 weeks.
89231298|NCT06332768|Active Comparator|NIV|Non-invasive ventilation
89231299|NCT06332768|Active Comparator|HFO|High Flow Oxygenation
89231300|NCT06332755|Experimental|Dose Escalation|
89231301|NCT06332742||Exposome group|"5g lotus seed heart, 3g coptis, 15g uncaria, 15g fried jujube kernel, 10g dried rehmannia glutinosa, 9g dogwood meat, 10g salvia miltiorrhiza, 30g floating wheat.~1 dose per day, decocted in water twice, 200ml each time, taken warmly after breakfast and dinner"
89112518|NCT02768181|Experimental|Arm 2: BCC+PNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
89112519|NCT02768181|Experimental|Arm 3: BCC+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with nutrient supplement to children (CNS) 6m to 2 years.
89112520|NCT02768181|Experimental|Arm 4: BCC only|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
89112521|NCT02768181|No Intervention|Arm 5: comparison|No intervention will be provided by the study. The existing services delivered though government health systems will be continued. Government /NGO-led routine counseling and supplementary services available at Upazila and union levels, which include prenatal counseling, exclusive breastfeeding counseling, and maternal iron-folic acid supplementation and vitamin-A supplementation for children will continue. However, assessment of outcomes will be conducted in same frequency and schedule, alike in intervention arms, described in data collection section.
89112522|NCT02767401|Active Comparator|PCI using stenting or balloon expansion|Opening single CTO lesions using drug-eluting stents (such as Xience V and Prime, Endeavor Resolute, Taxus express and Libete, Excel, Partner, BUMA, YINYI, TIVOLI,Firebird2,FireHawk, and Coroflex) or balloon expansion plus optimal medical therapy. Intravascular ultrasound (IVUS),optimal coherence tomgraphy (OCT) or fractional flow reserve (FFR) is used if they are needed. Optimal medical therapy includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-angina therapy should be used if the patients have symptoms.
89112523|NCT02767401|No Intervention|Optimal medical therapy|Optimal medical therapy. It includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
89112524|NCT02767479|Active Comparator|rabeprazole group|rabeprazole-based regimen. This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
89112525|NCT02767479|Active Comparator|esomeprazole group|'esomeprazole^based regimen. This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
89112526|NCT02767791|Active Comparator|Acupuncture|Acupuncture wrist 6
89112527|NCT02767791|Active Comparator|Auriculotherapy|Auriculotherapy
89112528|NCT02767791|Experimental|Auriculotherapy and acupuncture|Auriculotherapy and acupuncture
89112529|NCT02767791|No Intervention|No treatment|No treatment
89112530|NCT02767635|Experimental|Botox-Epic group|20 units of Botox injection into lateral epicondyle in Botox-Epic group
89112531|NCT02767635|Experimental|Botox-Tend group|20 units of Botox injected into tender point of muscles in Botox-Tend group
89112532|NCT02767635|Active Comparator|Steroid group|40mg of triamcinolone acetonide but not Botox injected into lateral epicondyle in Steroid group
89112533|NCT04224441|Experimental|Standard protocol plus chlorpromazine (CPZ)|Combination of chlorpromazine to the standard treatment with temozolomide in the sole adjuvant phase of the standard protocol.Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide (TMZ)
89112534|NCT02767089|Other|Sequence A|Period 1: Placebo Period 2: Prednisone 2.5 mg Period 3: Prednisone 10 mg
89112535|NCT02767089|Other|Sequence B|Period 1: Prednisone 2.5 mg Period 2: Prednisone 5 mg Period 3: Prednisone 20 mg
89112536|NCT02767089|Other|Sequence C|Period 1: Prednisone 5 mg Period 2: Prednisone 10 mg Period 3: Prednisone 40 mg
89112537|NCT02767089|Other|Sequence D|Period 1: Prednisone 10 mg Period 2: Prednisone 20 mg Period 3: Prednisone 60 mg
89112538|NCT02767089|Other|Sequence E|Period 1: Prednisone 20 mg Period 2: Prednisone 40 mg Period 3: Placebo
89112539|NCT02767089|Other|Sequence F|Period 1: Prednisone 40 mg Period 2: Prednisone 60 mg Period 3: Prednisone 2.5 mg
89112540|NCT02767089|Other|Sequence G|Period 1: Prednisone 60 mg Period 2: Placebo Period 3: Prednisone 5 mg
89112541|NCT02767167|Active Comparator|Milk treatment group|Semi-skimmed cow's milk + normal diet for 12 weeks
89112542|NCT02767167|No Intervention|Control group|Normal diet for 12 weeks
89112543|NCT04711317|Experimental|Preoxygenation with nasal high flow oxygen|Preoxygenation with nasal high flow oxygen
89112544|NCT04711317|No Intervention|Control group|Standard preoxygenation according to hospital protocol with tight fitting facemask
89112545|NCT02766855|Experimental|cysteamine eye drops|Patients used cysteamine eye drops every 2 hours while awake to both eyes.
89112546|NCT04705701|Experimental|Arm A group participants receive same day post-op dialysis|Arm A group participants receive same day post-op dialysis
89112547|NCT04705701|No Intervention|Arm B group participants receive dialysis per standard care|Arm B group participants receive dialysis per standard care
89112548|NCT02762643|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
89112549|NCT02762643|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
89112550|NCT02766699|Experimental|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox administered via 20 minute intravenous infusion once a week for seven weeks (1 Cycle). Subjects will receive one of two dose levels: 5 x 10^9 or 8 x 10^9. All subjects will undergo an adapted dose escalation regime in the first cycle of treatment. For subsequent cycles all doses will be administered at full strength (5x10^9 or 8x10^9 EGFR(V)-EDV-Dox). Subjects may receive further cycles of treatment if the tumor remains stable or is responding, and/or they are deriving clinical benefit from the therapy and are tolerating treatment.
89112551|NCT04224363|Experimental|Downward Staining|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
89112552|NCT04224363|Experimental|Upward Staining|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
89112553|NCT04552041|Experimental|Prospecta|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.
89112554|NCT04552041|Placebo Comparator|Placebo|Two tablets per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablets should be held in mouth until completely dissolved.
89112555|NCT04222881||End To Side|End to Side Anastomosis
89112556|NCT04222881||Side To Side|Side To Side Anastomosis
89112557|NCT02762409||patients exposed|Patients exposed will be estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015, and in 17 centers of the group control some study IPREA3 during October 2015
89112558|NCT02762409||patients non exposed|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015 and in 17 centers of the interventional group during October 2014"
89112559|NCT04224207|Active Comparator|Before application|RP patients with progressive visual acuity and visual field loss: before stem cell application.
89112560|NCT04224207|Active Comparator|After application|RP patients, after stem cell applications.
89112561|NCT04223895|Experimental|Group 1|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F1(1 tab, once)/ Period 3: CKD-386 F2(1 tab, once)
89112562|NCT04223895|Experimental|Group 2|Period 1: D012, D326, D337(3 tabs, once) / Period 2: CKD-386 F2(1 tab, once)/ Period 3: CKD-386 F1(1 tab, once)
89112563|NCT04223895|Experimental|Group 3|Period 1: CKD-386 F1(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once) Period 3: CKD-386 F2(1 tab, once)
89112564|NCT04223895|Experimental|Group 4|Period 1: CKD-386 F1(1 tab, once) / Period 2: CKD-386 F2(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
89112565|NCT04223895|Experimental|Group 5|Period 1: CKD-386 F2(1 tab, once) / Period 2: D012, D326, D337(3 tabs, once)/ Period 3: CKD-386 F1(1 tab, once)
89112566|NCT04223895|Experimental|Group 6|Period 1: CKD-386 F2(1 tab, once) / Period 2: CKD-386 F1(1 tab, once) / Period 3: D012, D326, D337(3 tabs, once)
89112567|NCT02762487|Experimental|LINX arm|Previous LSG patient will be treated with the LINX device and serve as their own control
89112568|NCT04547283|Active Comparator|Usual Care|Participants randomized to this arm will remain in their clinician's team standard practice and their natural choice of position, which is anticipated to favor a supine (rather than prone) position.
89112569|NCT04547283|Experimental|Awake-Prone Positioning Strategy|Participants randomized to this arm will receive guidance from their Inpatient treatment team to assume the prone position for as much time as is tolerable during hospitalization.
89112570|NCT04540341|Experimental|Mulligan mobilization group|Painless movement
89112571|NCT04540341|Experimental|Core stabilization group|Abdominal drawing-in maneuver
89112572|NCT04540341|Active Comparator|conventional therapy group|Ultrasound TENS Hotpack
89112573|NCT02762253|Other|Riboflavin drops - epithelium on or off|Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax
89112574|NCT02762097|Experimental|intervention|All women would undergo saline sonography with normal saline. Women with endometrial polyps who consent to the removal of polyps will be offered polypectomy
89112575|NCT02762097|Placebo Comparator|control|All women would undergo saline sonography with normal saline. Women with endometrial polyps who do not consent to the removal would serve as controls
89112576|NCT00746941|No Intervention|Local standard of care|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants in this treatment arm had the option of adding 250 mg mefloquine by mouth at Week 4 (Day 28) or Week 8 (Day 56) daily for 3 days, and then weekly through Week 24."
89112577|NCT00746941|Experimental|Local standard of care plus mefloquine 250 mg|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants received 250 mg mefloquine by mouth on Days 0, 1, and 2 and then weekly through Week 24."
89112578|NCT02761863||CD74 - VEGF arm|
89112579|NCT04532463||Amphotericin B,Flucytosine, Fluconazole|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
89112580|NCT04092361||anisometropic amblyopia|
89112581|NCT04092361||strabismic amblyopia|
89112582|NCT04092361||deprivational amblyopia|
89112583|NCT02762019|Experimental|Laser therapy|Children are allocated to receive Laser therapy
89112584|NCT02762019|Sham Comparator|Sham therapy|Children are allocated to receive Sham therapy
89112585|NCT04092049|Experimental|lollipop|
89112586|NCT04092049|No Intervention|control|
89112587|NCT02766621|Placebo Comparator|Placebo injection SC/IV|Placebo for injection SC/IV
89112588|NCT02766621|Active Comparator|PF-06823859|Study Drug being used in the study
89112589|NCT02761707||Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Parkinson's Disease. Must be Hoehn and Yahr stage 2 or less with a history of motor symptoms less than two years.
89112590|NCT02761707||Alzheimer's Disease|Non-smokers, ages 18-80, diagnosed with Alzheimer's Disease. Must meet the 2011 National Institute on Aging-Alzheimer's Association and the 1984 National Institute for Neurological and Communicative Disorders and Stroke-Alzheimer's disease and Related Disorders Association criteria for probable AD.
89112591|NCT02761707||Progressive Supranuclear Palsy|Non-smokers, ages 18-80, diagnosed with Progressive Supranuclear Palsy. Must meet the NINDS-SPSP criteria for probable PSP, which requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as a number of other clinical features.
89112592|NCT02761707||Essential Tremor|Non-smokers, ages 18-80, diagnosed with Essential Tremor.
89112593|NCT02761707||Drug-Induced Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Drug-Induced Parkinson's Disease.
89112594|NCT02761707||Myasthenia Gravis|Non-smokers, ages 18-80, diagnosed with Myasthenia Gravis.
89112595|NCT02761707||Multiple System Atrophy|Non-smokers, ages 18-80, who have been diagnosed with Multiple System Atrophy.
89112596|NCT02761707||Diffuse Lewy Body Disease|Non-smokers, ages 18-80, diagnosed with Diffuse Lewy Body Disease. Must meet the Consensus Criteria for the clinical diagnosis of DLBD.
89112597|NCT02761707||Healthy Controls|Non-smokers, ages 18-80, with no neurodegenerative disease, and no first-degree relatives with a neurodegenerative disease.
89112598|NCT02761707||Spinal Cord Injury|
89112599|NCT02761707||Asymptomatic Relatives|
89112600|NCT04019977|Experimental|Nurse Home Visiting Group|This group will be offered services from the nurse home visiting program.
89112601|NCT04019977|No Intervention|Non-intervention Group|This group will not be offered services from the nurse home visiting program.
89112602|NCT04091815|Active Comparator|I group - general anaesthesia|General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), opioids (fentanyl and morphine), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture.
89112603|NCT04091815|Experimental|II group - combined - spinal and general anaesthesia|"Spinal anesthesia: L3-4 interspace, 27G needle, bupivacaine hyperbaric, 16 mg, morphine sulfate 0.1% - 0.1ml.~General anesthesia, induction with fentanyl, propofol, roqurium. Maintenance - sevoflurane (BIS ranges 40 - 60), roqurium. Intraoperative fluid administration - 2000ml sterofundine, 500ml Gelaspan. 75mg intravenous diclofenac sodium on anesthesia induction, 1000mg intravenous acetaminophen at the start of wound closure. Surgical site infiltration, bupivacaine, 0.25%-10 ml, after the last suture."
89112604|NCT02761785||Celiacs with oat-related symptoms|Celiac patients who have self-reported gastrointestinal symptoms after ingestion of gluten-free oats
89112605|NCT02761785||Celiacs without oat-related symptoms|Celiac patients who include gluten-free oats in their diet and have no symptoms related to oats
89112606|NCT02761785||Healthy controls|Healthy controls (without celiac disease) who include oats in their diet
89112607|NCT02761785||Non-celiac gluten sensitive subjects|Subjects with manifestations precipitated by ingestion of gluten in whom celiac disease and wheat allergy are excluded.
89112608|NCT03976453||Group A|Women who underwent caesarean hysterectomy
89112609|NCT03976453||Group B|Women who underwent lower segment caesarean section
89112610|NCT03976453||Group C|Women who underwent spontaneous Vaginal delivery
89112611|NCT02761473||Patients with Urticaria Pigmentosa|This group will undergo skin biopsy, blood and buccal swab analyses
89112612|NCT02761473||Family members of affected patients|This group will undergo blood and buccal swab analyses
89231302|NCT06332742||Non-exposed group|All patients who met the inclusion criteria and did not use Qingxin Zishen Decoction.
89112613|NCT02599285||Fixation|Patients with a trimalleolar AO Weber C fracture with open reduction and fixation of the posterior malleolar fragment.
89112614|NCT02599285||No Fixation|Patients with a trimalleolar AO Weber C fracture without open reduction and fixation of the posterior malleolar fragment.
89112615|NCT02766387|Experimental|2 minutes walk test|fast walk test during 2 minutes in first and the 10 meters walk test, the 6 minutes walk test and the 2 kilometers walk test
89112616|NCT02766387|Experimental|6 minutes walk test|comfortable walk test during 6 minutes in first and the 10 meters walk test, the 2 minutes walk test and the 2 kilometers walk test
89112617|NCT00746785|Experimental|2.5 mg Olanzapine|"2.5 mg Olanzapine~1x per day for 12 weeks."
89112618|NCT00746785|Active Comparator|5mg Olanzapine|"5 mg Olanzapine~1x per day for 12 weeks."
89112619|NCT00746785|Placebo Comparator|Placebo|"Placebo~1x per day for 12 weeks."
89112620|NCT02761551|No Intervention|Usual Care|Patients in this group will not receive any reminders for influenza vaccine.
89112621|NCT02761551|Experimental|1 notice|Patients in this group will receive one reminder for influenza vaccine across the 2016 influenza season.
89112622|NCT02761551|Experimental|2 notices|Patients in this group will receive up to two reminders for influenza vaccine across the 2016 season.
89112623|NCT02761551|Experimental|3 notices|Patients in this group will receive up to three reminders for influenza vaccine across the 2016 season.
89112624|NCT04515771|Experimental|Active PARTNER-MH|The Active PARTNER-MH arm will test the intervention program starting immediately after enrollment in the study. Participants enrolled into this arm will continue to receive normal mental health services in addition to the peer-administered intervention.
89112625|NCT04515771|Other|Waitlist Control|The Waitlist Control arm will test the intervention program after a waiting period of 6-months following enrollment into the study. During the 6-month waiting period, participants in this arm will continue to receive normal mental health services.
89112626|NCT04090021|Experimental|Genotypic resistance-guided triple therapy|"In the group of genotypic resistance-guided triple therapy, a molecular assay based on DNA-strip technology was used to determine the genotypic resistance of H. Pylori to clarithromycin (23SrRNA mutations) and fluoroquinolones (gyrA mutations) from gastric biopsy specimens. According to 23SrRNA and gyrA mutational analyses, a 7-day tailored triple therapy therapy was given as follows:~Wild-type 23SrRNA: Clarithromycin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d.~23SrRNA mutated/wild-type gyrA: Levofloxacin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g b.i.d. and levofloxacin 500 mg b.i.d.~23SrRNA mutated/gyrA mutated: Rifabutin-based triple therapy comprising esomeprazole 40 mg b.i.d., amoxicillin 1 g t.i.d. and rifabutin 150 mg b.i.d."
89112627|NCT04090021|Active Comparator|Empirical concomitant therapy|In the empirical concomitant group, patients received esomeprazole 40mg, amoxicillin 1gr, clarithromycin 500mg and metronidazole 500mg, all b.i.d., for 10-14 days.
89112628|NCT04223973|Experimental|Active Group|Using the Medtrum Pump A7+ during 3 months
89112629|NCT04223973|Active Comparator|Control Group|using the usual Insulet Patch pump
89112630|NCT00750919|Experimental|Esmirtazapine|Participants receive esmirtazapine 4.5 mg tablet, orally, once daily (QD) for up to 6 months.
89112631|NCT02761161|No Intervention|Treatment as usual|TAU: medicine according to algorithm, manual-based cognitive therapy, psychoeducation
89112632|NCT02761161|Active Comparator|Mianserin|10-30 mg of mianserin af sleep enhancing
89112633|NCT02761161|Active Comparator|Imagery Rehearsal Therapy|Therapy focusing on nightmares
89112634|NCT02761161|Active Comparator|mianserin and Imagery Rehearsal Therapy|Both mianserin and IRT
89112635|NCT00917371||atomoxetine group|
89112636|NCT00917371||methylphenidate group|
89112637|NCT00917371||psychological counseling group|
89112638|NCT04094155|Experimental|Retinal fundoscopy|Retinal vascular analysis by retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
89112639|NCT02761395|Experimental|Group 1: ALhijama|20 patients under went Al-hijamah procedure for iron chelation
89112640|NCT02761395|Experimental|Group 2: AL-hijama with deferasirox|20 patients receive deferasirox and Al-hijamah.
89112641|NCT02761395|Active Comparator|Group 3:deferasirox|20 patients already receiving deferasirox
89112642|NCT04091737|Experimental|CSL200|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
89112643|NCT02599207|Experimental|Matched related umbilical cord blood|Six subjects will receive an infusion of HLA matched sibling umbilical cord blood cells.
89112644|NCT02599207|Experimental|Mismatched related umbilical cord blood|Nine subjects will receive an infusion of HLA-mismatched (≥3/6 match) or matched sibling umbilical cord blood cells.
89112645|NCT02761317|Active Comparator|GroupA：standard preparation|Subjects who are randomized into group A receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
89112646|NCT02761317|Experimental|Group B:low-volume preparation|Subjects who are randomized into group B receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure. ( 2L PEG-ELS and 10mg bisacodyl )
89112647|NCT02761317|Experimental|Group C：high-volume preparation|Subjects who are randomized into group C will receive 2L PEG-ELS at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure. (4 L PEG-ELS)
89112648|NCT04019899|Active Comparator|Control group|
89112649|NCT04019899|Experimental|Study group|
89112650|NCT02761239|Other|Cricopharyngeal muscle innervation|The recurrent laryngeal nerve (RLN), vagus nerve, external branch of the superior laryngeal nerve (EBSLN) and pharyngeal plexus were stimulated intraoperatively by the NIM 3.0 Nerve Monitoring System (Medtronic Xomed, Jacksonville, FL, USA). Responses were evaluated by visual observation of the cricopharyngeal muscle and electromyographies via needle electrodes inserted into the cricopharyngeal muscle.
89112651|NCT02761083|Experimental|Novosyn® Quick|Eye surgery using suture material
89112652|NCT02761083|Active Comparator|Vicryl® Rapid|Eye surgery using suture material
89112653|NCT00746551|Active Comparator|Ferrous fumarate, Ferri-6®, Oral tablet|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
89112654|NCT00746551|Experimental|iron sucrose, Venofer®, intravenous drug|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
89112655|NCT02766075|Experimental|Supervised TAVR Exercise Program (STEP)|Subjects in the experimental arm will participate in an individualized 4-week STEP prior to undergoing TAVR. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
89112656|NCT02766075|No Intervention|Standard of Care|Subjects in the no intervention arm will proceed with their TAVR after a minimum 4 weeks without an exercise intervention. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
89112657|NCT04223817|Experimental|7.0 Tesla MRI of both hands|Single 7.0 Tesla MRI of both hands for all the SSc and control subjects
89112658|NCT03974971||BPDCN diagnosis group|By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018
89112659|NCT02761005|Experimental|23S rRNA wt|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains without mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.
89112660|NCT02761005|Experimental|23S rRNA mutation|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains with mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week for the eradication of H. pylori,
89112661|NCT02696577|Active Comparator|Low dose aspirin|Received aspirin 81mg once daily for 6 weeks
89112662|NCT02696577|Active Comparator|Low dose aspirin plus omega 3 group|Received aspirin 81mg and omega 3 once daily for 6 weeks.
89112663|NCT00753649|Experimental|Aboriginal infants group|
89112664|NCT00753649|Active Comparator|Other Non-Aboriginal infants|
89112665|NCT04093609||cases|
89112666|NCT04093609||control|
89112667|NCT04091425|Experimental|TAK-925 Dose A|TAK-925 dose A intravenous (IV) infusion in each treatment sequence (crossover design).
89112668|NCT04091425|Experimental|TAK-925 Dose B|TAK-925 dose B IV infusion in each treatment sequence (cross over design).
89112669|NCT04091425|Placebo Comparator|Placebo|TAK-925 placebo-matching IV infusion in each treatment sequence (crossover design).
89112670|NCT04223427|Active Comparator|Single ring STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
89112671|NCT04223427|Experimental|Directional STN-DBS|The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.
89112672|NCT04222491|Experimental|active peanut OIT|active peanut oral immunotherapy
89112673|NCT02765685|Experimental|ODRA|
89112674|NCT02765685|Active Comparator|usual care|
89112675|NCT00750139|Experimental|1|Naftin 2% cream applied daily for 2 weeks
89112676|NCT00750139|Placebo Comparator|2|Placebo cream applied daily for two weeks
89112677|NCT00750139|Active Comparator|3|Active comparator applied daily for 4 weeks
89112678|NCT00750139|Placebo Comparator|4|placebo cream applied daily for 4 weeks
89231303|NCT06332729|Active Comparator|effect of universal exercis unit on genu recurvatum in diplegic cerbral palsy children|Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
89231304|NCT06332729|Active Comparator|effect of functional electrical stimulation on genu recurvatum in diplegic cerbral palsy children|Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement
89231305|NCT06332716|Experimental|Treatment group based on organoid drug sensitivity testing|Develop relevant treatment plans through organoid drug sensitivity testing and guide the experimental group in medication use.
89112679|NCT04192461|Experimental|tooth guided immediate implant placement group|
89112680|NCT02765763|Sham Comparator|Group 1 Sham|Null Formula of the Test System
89112681|NCT02765763|Active Comparator|Group 2 Treated|Full Formulas of Test System
89112682|NCT02765919|Experimental|Radiation HDR Brachytherapy 9 Gy|High dose rate (HDR) Brachytherapy of weekly 9 Gray in two fractions in two weeks after 50 Gray of EBRT in 2 Gray per fraction of 5 weeks with chemotherapy cisplatin 40 mg /m2 weekly for five weeks in locally advanced carcinoma cervix
89112683|NCT02765919|Active Comparator|Radiation HDR Brachytherapy 7 Gy|High dose rate (HDR) brachytherapy of weekly 7 Gray in three fractions in three weeks after 50 Gray EBRT of 2 Gray per fraction of 25 fractions concurrently with weekly chemotherapy cisplatin40 mg /m2 in five weeks in locally advanced carcinoma cervix
89112684|NCT02765841|Experimental|Lomitapide|
89112685|NCT02760771||with BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) with predilation of the aortic valve
89112686|NCT02760771||without BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) without predilation of the aortic valve
89112687|NCT02760693||bipolar patients|unselected admissions of bipolar patients
89112688|NCT00750061|Placebo Comparator|Placebo|Placebo tablet
89112689|NCT00750061|Experimental|Lithium carbonate|Lithium Carbonate tablet, 250mg
89112690|NCT04223739|Active Comparator|Landiolol|Landiolol infusion starting at 2.5 µg/kg/min and titrating up to 80µg/kg/min with a heart rate goal of under 90 bpm.
89112691|NCT04223739|Active Comparator|Amiodarone|Amiodarone bolus of 5-7 mg/kg in 1 hour, followed by an infusion of 1g/day until conversion to sinus rhythm.
89112692|NCT04091269|Placebo Comparator|PSV-10%|PSV mode using E5 ventilator with fixed flow trigger and Esense 10%
89112693|NCT04091269|Placebo Comparator|PVS-30%|PSV mode using E5 ventilator with fixed flow trigger and Esense 30%
89112694|NCT04091269|Placebo Comparator|PSV-50%|PSV mode using E5 ventilator with fixed flow trigger and Esense 50%
89112695|NCT04091269|Experimental|PSV-auto|PSV mode using automatic adjustmen of inspiratory triger and cycling-off based on waveform
89112696|NCT04091269|Active Comparator|PSV-neuro|NAVA mode using NAVA level of 15 cmH2O/uV and pressure limit function to simulated EAdi triggered PSV.
89112697|NCT02765997|Active Comparator|Unmanipulated UCB|Subjects will receive unmanipulated umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
89112698|NCT02765997|Experimental|StemRegenin-1 UCB|Subjects will receive StemRegenin-1 (SR-1) cultured umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
89112699|NCT02597725||Urodynamics|There is no intervention in this study.
89112700|NCT02765295|Active Comparator|hydrogen inhalation|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixture gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min). Usual care referred to mucolytics (see below for details) alone or plus chest physiotherapy.
89112701|NCT02765295|Sham Comparator|oxygen inhalation|Oxygen will be generated by an instrument provided by the sponsor, that would be capable of generating oxygen equivalent to that generated by the MUNHO (3L/min mixed gas containing 33.3% oxygen). Usual care referred to mucolytics [[ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily)/ serrapeptase (10mg thrice daily), or carbocisteine (500mg thrice daily)] alone or in combination with chest physiotherapy.
89112702|NCT02765529|Experimental|20-30 years|Blood sampling
89112703|NCT02765529|Experimental|45-55 years|Blood sampling
89112704|NCT02765529|Experimental|70-80 years|Blood sampling
89112705|NCT02765529|Experimental|Control|Blood sampling for standardization of technical procedures
89112706|NCT02760537|Experimental|Lay Health Worker Intervention|LHWs conducted phone interventions by reminding participants of a series of vaccinations at months 1, 2, and 5 among those assigned to the intervention group. Those who had health insurance were encouraged to complete vaccinations through their providers. If participants did not have health insurance, LHWs provided resources to help those in the intervention access vaccinations by referring them to free vaccine events in the community.
89112707|NCT02760537|Placebo Comparator|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
89112708|NCT02765451|Active Comparator|A : 1 year of intervention|interventions of Cancéropôle Nord-Ouest during 1 year after an observational period of 2 years.
89112709|NCT02765451|Active Comparator|B : 2 years of intervention|interventions of Cancéropôle Nord-Ouest during 2 years after an observational period of 1 year.
89112710|NCT02760303|Experimental|Cognitive Behavioral Therapy|Hains' adaptation of cognitive behavioral therapy for adolescents and young adults with type 1 diabetes
89112711|NCT02760303|Experimental|Mindfulness Based Stress Reduction|Sabinga's adaptation of Mindfulness Based Stress Reduction for adolescents and young adults with type 1 diabetes
89112712|NCT02760303|Active Comparator|Diabetes Support and Education|Investigator developed peer support group and diabetes education
89112713|NCT02765373||steroidal aromatase inhibitors(AIs)|Exemestane 25mg Qd for 5 years
89112714|NCT02765373||non-steroidal aromatase inhibitors(AIs)|Letrozole 2.5mg Qd or Anastrozole 1mg Qd for 5 years
89112715|NCT02760615|Other|Part 1: UC and CD Participants|Participants with UC or CD and not concurrently treated with vedolizumab or other biologics will receive caffeine 200 milligram (mg), tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan, 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
89112716|NCT02760615|Other|Part 1: Healthy Participants|Healthy participants will receive caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
89112717|NCT02760615|Experimental|Part 2: Vedolizumab|Participants who are on established vedolizumab intravenous (IV) maintenance treatment of 300 mg for treatment of UC or CD and in clinical remission will receive vedolizumab 300 mg IV infusion, once, caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
89112718|NCT02760459|Active Comparator|Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of Dexamethasone 10 mg IV postoperatively at 24 and 48 hrs.
89112719|NCT02760459|Placebo Comparator|Placebo|The control group will receive sterile normal saline solution, serving as placebo, IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of placebo IV postoperatively 24 and 48 hrs. Both Dexamethasone and normal saline solution will be administered as an IV push.
89112720|NCT02765217|Experimental|Study group 1|"Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (5 drops per day, same time with the first dose of antibiotics).~Study Group 1a will received L. reuteri for 10-14 days. Study Group 1b will received L. reuteri for 21 days."
89112721|NCT02765217|Placebo Comparator|Study group 2|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 5 drops per day, same time with the antibiotics) Study Group 2a will received placebo for 10-14 days. Study Group 2b will received placebo for 21 days.
89112722|NCT02765217|Experimental|Study group 3|Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (2 x 5 drops per day) Study Group 3a will received L. reuteri for 10-14 days. Study Group 3b will received L. reuteri for 21 days.
89112723|NCT02765217|Placebo Comparator|Study group 4|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 2 x 5 drops per day, same time with the antibiotics) Study Group 4a will received placebo for 10-14 days. Study Group 4b will received placebo for 21 days.
89112724|NCT02760381|Experimental|Routine colonoscopy Cohort|Patients receiving routine colonoscopy receive the intervention: NBI + Acetic Acid (AA)
89112725|NCT02760225|Experimental|89Zr-Pembrolizumab PET imaging|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
89112726|NCT02764983|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Driving safety professional, three x 1 hour sessions to discuss traffic safety, rules of the road, defensive driving, driving under influence, driver attitudes and safety. Additionally, the study will obtain real world driving data from the Department of Motor Vehicles (public records) which will include citations, violations, and recorded collisions/ crashes.
89112727|NCT02764983|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors, and driving simulator with feedback. The study will also obtain real world driving data from the Department of Motor Vehicles (public records) which includes citations, violations, and recorded collisions/crashes.
89112728|NCT02764983|Active Comparator|Caregiver Control Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
89112729|NCT02764983|Active Comparator|Caregiver Experimental Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
89112730|NCT02764983|Other|Focus Group Discussion Interview Guide|This group will comprise of a subset of the control and experimental groups. A focus group with 8 participants (4 with Traumatic Brain Injury/Post Traumatic Stress Disorder and 4 with orthopedic conditions). The focus group will meet once for a discussion which will be guided with a semi-structured interview that will explore the driving behavior prior to war, during war and post-deployment. Responses will be outlined in an intervention matrix.
89112731|NCT04685967|Experimental|Glass-ionomer|Equia Forte HT, GC, Tokyo, Japan (EHT)
89112732|NCT04685967|Experimental|Bulk-Fill|SonicFill2, Orange, CA, USA (SBF)
89112733|NCT00744757|Experimental|Decitabine|Decitabine 20 milligram per square meter (mg per m^2) will be administered intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
89112734|NCT02760147|Other|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
89112735|NCT02760147|Other|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
89112736|NCT02760147|Other|PEEP Over Level|PEEP Level upward by 50%, 2 hours
89112737|NCT02760147|Other|PEEP Under Level|PEEP Level downward by 50%, 2 hours
89112738|NCT02765139|Experimental|EMAP Treatment|Engaging Men through Accountable Practice: 30 communities are matched into 15 pairs on a set of socio-demographic characteristic and within each pair, 15 treatment sites are randomly selected. Within each treatment community, all adult men (20+ years old) are eligible to participate in the EMAP intervention. A random draw of 50 participants determines who will participate in EMAP in case more than 50 eligible men express interest.
89112739|NCT02765139|Other|Control|In the 15 control sites, the male participants will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
89112740|NCT00917527|Placebo Comparator|Control|
89112741|NCT00917527|Experimental|Atorvastatin|
89112742|NCT04222179|Other|Naso-enteric tube placement|The participants needed nutrition from naso-enteric tube feeding are enrolled into this study. Double-blind was not needed here.
89112743|NCT02597647|Experimental|Live attenuated influenza vaccine|Healthy adult volunteers given intranasal FluMist (Live Attenuated Influenza vaccine). Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after LAIV.
89112744|NCT02597647|Placebo Comparator|Saline nasal spray|Healthy adult volunteers given intranasal saline nasal spray. Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after saline administration.
89112745|NCT02764905||intensive cognitive-physical rehabilitation group|will include a 2 phase multi-disciplinary intervention. The 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies
89112746|NCT00745849|Experimental|1|esomeprazole 40mg po bid
89112747|NCT00745849|Placebo Comparator|2|
89112748|NCT02759913||Amyotrophic lateral sclerosis|Participants recently diagnosed with ALS in a neuromuscular clinic, using the ALS functional rating scale (ALSFRS-R). Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
89112749|NCT02759913||ALS mimics|Other motorneuron disorders, isolated upper and lower motoneuron disorders Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection
89112750|NCT02599051|Active Comparator|Monarc|Placement of a transobturator monarc sling for stress urinary incontinence
89112751|NCT02599051|Experimental|Mini-arc|Placement of a single incision mini-arc sling for stress urinary incontinence
89112752|NCT02764671|Experimental|10μg/0.5ml recombinant HBV vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
89112753|NCT02759991|Active Comparator|HEV vaccine|Hecolin, 0.6 ml intramuscular injection day 0, 1 month and 6 months.
89112754|NCT02759991|Placebo Comparator|HBV vaccine|Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.
89112755|NCT00749203|Experimental|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
89112756|NCT00749203|Active Comparator|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
89112757|NCT02764515|Experimental|Kunxian capsule group|"Intervention:~Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo."
89112758|NCT02764515|Active Comparator|Methotrexate group|"Intervention:~Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks."
89112759|NCT02598115|No Intervention|Before collarborative pharmaceutical care|"All clusters start in this arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
89112760|NCT02598115|Experimental|After collarborative pharmaceutical care|"All clusters start in the No Intervention arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
89112761|NCT04223271||Acutely Decompensated Heart Failure Patients|Patients who are admitted with acutely decompensated heart failure and are receiving intravenous diuretics will be recruited to undergo testing. Testing with the Indicor device will occur every day during hospitalization, and twice a day for up to 30 days after discharge.
89112762|NCT00748969|Experimental|Growth hormone treatmen|Growth hormone treatment arm. Somatropin (DNA origin)
89112763|NCT00748969|No Intervention|No growth hormone treatment in year 1|No growth hormone treatment in year 1; option for treatment in year 2 open-label period.
89112764|NCT02764749|Experimental|freeze dried powder whole cranberry dissolved in water|Dietary Supplement: freeze dried cranberry powder
89112765|NCT02764749|Placebo Comparator|freeze dried cranberry deprived powder dissolved in water|Placebo comparator: freeze dried cranberry deprived powder
89112766|NCT02759757|Experimental|Kinesio Taping|"Patients from this group will receive the kinesio Taping® Tex Gold tape according to the manufacturer's instructions. Kinesio Taping will be applied for the purpose of inhibiting the erector spinal muscle from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae with 10 to 15% tension (paper-OFF) in a I position bilaterally."
89112767|NCT02759757|Placebo Comparator|Placebo|Patient from this group will receive a 5cm-wide Micropore® tape from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae bilaterally.
89112768|NCT02759757|No Intervention|Control|Patients allocated will not receive any intervention.
89112769|NCT02764437||MRI-Bronch, PET-WLAC (Stress vs Control)|Subjects will have a functional MRI scan 24 hours before a bronchoscopy with segmental allergen challenge. 48 hours post segmental allergen challenge, the subject will have another MRI and bronchoscopy. 4-6 weeks later, subjects will have a PET scan and whole lung antigen challenge under a stress condition or control condition. 4-6 weeks later, subject will have another PET scan and whole lung antigen challenge under a stress condition or control condition (whatever they did not have the first time).
89112770|NCT02759601|Other|Tefinostat|"This is an open label, dose escalating, phase I/II study of Tefinostat administered orally, once or twice daily in 28 day cycles of treatment in patients with advanced hepatocellular carcinoma.~Up to 5 cohorts of 3-6 patients (number is dependent on DLT occurrence) will be treated for 28 days once or twice daily (360, 480mg once daily, then 240, 360, 480mg twice daily) to determine safety and tolerability of Tefinostat and to identify the recommended dose for Phase II."
89112771|NCT02764359|Experimental|IV Vancomycin loading dose- higher|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg
89112772|NCT02764359|Experimental|IV Vancomycin loading dose- lower|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg
89112773|NCT02759289||Group A|Prediabetes glycohemoglobin test A1c 5.7-6.4%
89112774|NCT02759289||Group B|"T2D glycohemoglobin test= A1c 6.5-7.9% without T2D medications~T2D glycohemoglobin test=A1c ≥ 8.0% with/without T2D medications"
89112775|NCT02759289||Group C|Control
89112776|NCT04221867|Experimental|Esophageal stricture patients|Patients suffering from benign esophageal stricture are treated with through-the scope CRE dilation balloon. Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
89112777|NCT02759367|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
89112778|NCT02759367|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake.
89112779|NCT04594707|Experimental|PRM-151|"Corhort A: Participants entering, following participation in study PRM-151-202.~Cohort B: Participants entering, following participation in study WA42293."
89112780|NCT02696655|Experimental|liver transplant patients|Patients will use a behavioural intervention to assess its usability
89112781|NCT02696421||Non diabetic, non obese|
89112782|NCT02696421||Non diabetic obese|
89112783|NCT02696421||Diabetic|
89112784|NCT04221399|Experimental|DWP16001 Single dose|Single dose
89112785|NCT04221399|Experimental|DWP16001 Multiple dose|Up to 7 days
89112786|NCT02764125|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
89112787|NCT02764125|Experimental|levodopa MR|Levodopa MR/carbidopa/ODM-104
89112788|NCT02764281|Experimental|MEDA/Auto-HSCT|Patients will be initially treated with four cycles MEDA chemotherapy, followed by autologous hematopoietic stem cell transplantation (Auto-HSCT).
89112789|NCT02764203|Experimental|Chocolate consumption|Subjects will consume 50g of dark chocolate for 2 weeks and have their blood pressure compared before chocolate and after chocolate
89112790|NCT02763969|Experimental|Part A: Single Ascending Dose|BMS-986202 or Placebo specified dose on specified days
89112791|NCT02763969|Experimental|Part B: Multiple Ascending Dose|BMS-986202 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
89112792|NCT02763969|Experimental|Part C: Multiple Ascending Dose-Japanese descent|BMS-986202 or Placebo specified dose on specified days in patients of Japanese descent
89112793|NCT02763969|Experimental|Part D: Relative Bioavailability|BMS-986202 (Liquid) or BMS-986202 (Capsule) + Famotidine specified dose on specified days
89112794|NCT02763969|Experimental|Part E: Proof of Mechanism|BMS-986202 or Placebo + Ustekinumab specified dose on specified days
89112795|NCT02696187|Experimental|KOLwebben|Patients in the experimental group will be introduced to KOL-webben during their ordinary visits to the primary care center. All patients will receive a pedometer
89112796|NCT02696187|No Intervention|Control group|Other than receiving a pedometer the patients in the control group will not receive any intervention.
89112797|NCT02758977|Experimental|ALPPS|"ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS)~Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) is performed according to local practice in the respective centers. Preconditions to participation are experience with major liver resections and documentation of having performed at least 5 ALPPS cases prior to participation due to the learning curve with this quite complex procedure.~The amount of transsection (in-situ split/liver partition) in Step 1 is left to the participating center, no minimal % of transsection is specified."
89112798|NCT02758977|Active Comparator|TWO STAGE HEPATECTOMY|"TWO STAGE HEPATECTOMY (TSH)~Two-Stage Hepatectomy is defined as:~Partial resection + portal vein ligation (RES PVL)~Partial resection + secondary portal vein embolization (RES PVE). Followed by (extended) hemihepatectomy after an interval to induce hypertrophy of the liver.~Conventional Two- Stage Hepatectomies will be standard procedures of the centers participating in the study."
89112799|NCT02759211|Active Comparator|Forwards Walking Group (FWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
89112800|NCT02759211|Experimental|Backwards Walking Group (BWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
89112801|NCT04660929|Experimental|Group 1 and Group 2|Both groups will receive the full dose manufactured per patient. Group 1 will undergo intra subject dose escalation of IV administrations of up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5. Group 2 will receive the full dose IV on Day 1 of up to 5 billion cells total.
89112802|NCT04660929|Experimental|Intraperitoneal Administration|"All cohorts will receive the full dose manufactured per patient. Cohorts 1-3 will undergo intrasubject dose escalations of IP administration as follows:~Cohort 1 up to 500 million total cells on Day 1, up to 1 billion total cells on Day 3 and up to 1.5 billion total cells on Day 5.~Cohort 2 up to 1.5 billion total cells on Day 1, up to 2 billion total cells on Day 3 and any remaining cells on Day 5.~Cohort 3 up to 2.5 billion total cells on Day 1 and up to 2.5 billion total cells on Day 3.~Cohort 4 will 1 dose on Day 1 of up to 5 billion total cells."
89112803|NCT04660929|Experimental|89[Zr]radiolabeled CT-0508|89[Zr] radiolabeled group will receive a full dose IV on Day 1 of up to 500 million total cells of 89[Zr] radiolabeled CT-0508 and non-radiolabeled CT-0508 of up to 4.5 billion total cells (Univ of Penn Abramson Cancer Center only).
89112804|NCT04660929|Experimental|CT-0508 in Combination with Pembrolizumab|"All regimen levels will receive the full dose manufactured per patient up to 5 billion total cells. Regimen Levels 1 and 2 will undergo intrasubject dose escalations of IV administration as follows:~Regimen Level 1: up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5 plus pembrolizumab 200 mg q3w starting on Day 8.~Regimen Level 2: up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5 plus pembrolizumab 200 mg q3w starting on Day 1.~Regimen Level 3 will receive the full dose IV on Day 1 of up to 5 billion total cells plus pembrolizumab 200 mg q3w starting on Day 1."
89112805|NCT04223349|Experimental|Part 1: Treatment A|Participants will receive JNJ-70033093 dose twice daily (BID) for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
89112806|NCT04223349|Experimental|Part 1: Treatment B|Participants will receive JNJ-70033093 dose BID for 8 days followed by a placebo dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
89112807|NCT04223349|Experimental|Part 1: Treatment C|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
89112808|NCT04223349|Experimental|Part 1: Treatment D|Participants will receive JNJ-70033093 dose BID for 8 days followed by a JNJ-70033093 dose on Day 9 or placebo BID for 8 days followed by a placebo dose on Day 9.
89112809|NCT04223349|Experimental|Part 2: Treatment Sequence EFG|Participants will receive Treatment E (JNJ-7003309 single dose in the morning in fasted condition) in treatment Period 1; followed by Treatment F (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 2; followed by Treatment G (JNJ-7003309 single dose administered in the evening in fasted condition) in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
89112810|NCT04223349|Experimental|Part 2: Treatment Sequence FGE|Participants will receive Treatment F in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period.
89112811|NCT04223349|Experimental|Part 2: Treatment Sequence GEF|Participants will receive Treatment G in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
89112812|NCT04223349|Experimental|Part 2: Treatment Sequence EGF|Participants will receive Treatment E in treatment Period 1; followed by Treatment G in treatment Period 2; followed by Treatment F in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
89112813|NCT04223349|Experimental|Part 2: Treatment Sequence GFE|Participants will receive Treatment G in treatment Period 1; followed by Treatment F in treatment Period 2; followed by Treatment E in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
89112814|NCT04223349|Experimental|Part 2: Treatment Sequence FEG|Participants will receive Treatment F in treatment Period 1; followed by Treatment E in treatment Period 2; followed by Treatment G in treatment Period 3, on Day 1 of each treatment period. A washout period of at least 4 days will be maintained between each treatment period
89112815|NCT02764047|Placebo Comparator|Placebo|Placebo capsule
89112816|NCT02764047|Active Comparator|Probiotic|Probiotic capsule
89112817|NCT02763657|Experimental|Brain activity during reasoning|
89112818|NCT02758821|Other|CRP-Control|The health care provider will manage the patient using standard guidelines. No CRP will be measured onsite
89112819|NCT02758821|Other|CRP-A|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
89112820|NCT02758821|Other|CRP-B|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
89112821|NCT04221711|Experimental|Repetitive pulsed magnetic stimulation|Patients randomized in this group will receive rPMS (80 milliTesla ; 2 Hertz; OMNITRON® promed; Healthfactories Holding GmbH) three times a week for a total of 12 weeks. Thereby they will be lying in a prone position or sitting for 20 minutes with the magnet coil positioned over the mid-portion of the affected Achilles tendon (manufactures instruction).
89112822|NCT04221711|Active Comparator|Eccentric Calf Muscle Training for Achilles Tendinopathy|Two types of eccentric exercises will be used. The calf muscle will be eccentrically loaded both with the knee straight and with the knee bent. Each of the two exercises will include an increasing number of repetitions (1. Week, 2-3 weeks, 4-12 weeks) done in 3 sets (e.g. 3x15, 3x20, 3x30 repetitions). The patients will be informed that muscle soreness during the first 1 to 2 weeks of training was to be expected. Patients will receive a visual exercise protocol.
89112823|NCT04221633|Experimental|Webinar only|Participants in this arm will attend a webinar training program (3 webinars over the course of 4 to 8 weeks) to receive training in evidence-based engagement strategies, trauma, evidence-based practices, and mental health screening.
89231306|NCT06332716|Other|Historical control group|Select patients who have previously received full standardized treatment at our center as the control group to evaluate the effectiveness of organoid drug sensitivity screening.
89112824|NCT04221633|Experimental|Webinar plus consultation|Participants in this arm will receive the same webinar training as subjects in arm 1, but they will also receive 10 consultation calls over the course of four months to further develop their skills in engaging families and screening for mental health services.
89112825|NCT04221633|No Intervention|Delayed training group|This group will not receive any training for the duration of the study year, in order to serve as a waitlist control group. They will be eligible to receive the training after the randomized control trial has been completed.
89112826|NCT02763735||Pulmonary Arterial Hypertension|Patients diagnosed with idiopathic or heritable pulmonary arterial hypertension according to consensus guidelines. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and [18F]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging.
89112827|NCT02763735||Subjects without cardiopulmonary disease|Subjects without known cardiopulmonary disease. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and [18F]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging
89112828|NCT02758743|Experimental|Acetium Lozenge|Acetium lozenge (L-cysteine 3mg) is used in context of each cigarette smoked.
89112829|NCT02758743|Placebo Comparator|Placebo|Identical in appearance with Acetium lozenge, placebo lozenges will be used in the same manner as in experimental arm.
89112830|NCT02758587|Experimental|Dose - escalation|"Does-escalation in an all-comers phase I population, with treatment-refractory advanced solid malignancies, unselected by tumour type. Two cohorts of up to evaluable 6 patients in each:~Cohort 1: 200mg (IV) pembrolizumab every 3 weeks; plus 200mg (oral) defactinib twice daily~Cohort 2: 200mg (IV) pembrolizumab every 3 weeks; plus 400mg (oral) defactinib twice daily~Interventions:~Drug: Defactinib~Drug: Pembrolizumab"
89112831|NCT02758587|Experimental|Pancreatic|Pancreatic expansion for response assessment (single arm). Optional paired biopsies prior to treatment and after 14 days of treatment. All would have concurrent therapy with pembrolizumab + defactinib (VS-6063) from the start (c.f. NSCLC & mesothelioma expansions below). 15 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 6
89112832|NCT02758587|Experimental|NSCLC|NSCLC paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and after around 14 days of treatment. 1:1 randomised split of patients having their mandatory on-treatment biopsy after concurrent therapy, or after a defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
89112833|NCT02758587|Experimental|Mesothelioma|Mesothelioma paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and around 14 days of treatment. 1:1 randomised split of patients having thier on-treatment biopsy after concurrent therapy, or after defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
89112834|NCT02763891|Experimental|Intervention group|Subjects submitted to a 30-minute session of suspension and tilting exercises on the Chordata equipment (PI: 0804871-1 and BR 10 2012 009901-2) twice a week for eight weeks.
89112835|NCT02763891|Sham Comparator|Control group|Subjects submitted to a 30-minute passive muscle stretching session twice a week for eight weeks.
89112836|NCT04634955|Active Comparator|S1 transforaminal injection with oboique view|S1 transforaminal injection with oblique fluoroscopic view
89112837|NCT04634955|Active Comparator|S1 transforaminal injection with AP view|S1 transforaminal injection with anteroposterior fluoroscopic view
89112838|NCT02758509||PEG/RBV|Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2011)
89112839|NCT02758509||PEG/RBV+BOC or TVR|Boceprevir 800 mg/8h or Telaprevir 750 mg/8h plus Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2014)
89112840|NCT02758509||IF-DAAs|"Interferon-free direct-acting antiviral combinations according to routine practice and European Guidelines (EASL recommendations 2015)~Fixed-dose combination of sofosbuvir (400 mg) and ledipasvir (90 mg) daily +/- ribavirin 12-24 weeks~Fixed-dose combination of ombitasvir (75 mg), paritaprevir (12.5 mg) and ritonavir (50 mg) in one single tablet (two tablets once daily) and dasabuvir (250 mg) (one tablet twice daily) with ribavirin 800-1200 mg 12 weeks (Genotype 1b) or 24 weeks (genotype 1a)~Daily sofosbuvir (400 mg) and daily simeprevir (150 mg) +/- ribavirin 12-24 weeks~Daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) +/- ribavirin 12-24 weeks"
89112841|NCT02763813|Experimental|Propulsion type appliance (Herbst)|
89112842|NCT02763813|Active Comparator|Retention type appliance (ORM)|Retention type appliance
89112843|NCT02758353|Experimental|Community distribution of SP|All the eligible pregnant women were reached with SP either at health clinic and/or at community/household level with sulphadoxine-pyrimethamine (SP). Alerts and reminders were sent to them by community-based health volunteers ahead of subsequent SP doses.
89112844|NCT00635583|Experimental|Increased Dairy Consumption|Increased Dairy Consumption - Each subject in this arm will receive three additional servings of dairy to consume each day for 18 months.
89112845|NCT00635583|No Intervention|Control|This group will not receive the intervention but will continue their normal diet; they will act as the control.
89112846|NCT02763423|Experimental|umbilical cord mesenchymal stem cell|single- or double-dose intravenous injection of umbilical cord mesenchymal stem cells for the treatment of severe type 1 diabetes patients
89112847|NCT02758275|Experimental|Teaching: Individual (5606)|People will receive an education session per month for a period of six months with an average duration of 30 minutes. These will be performed by nurses outside the collection of phase base line and follow-up measurements, previously trained for the purpose.
89112848|NCT02758275|No Intervention|Usual care|People will continue to receive usual care in the health center where they usually assist to medical controls.
89112849|NCT02758197|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
89290564|NCT03930888||Patients with nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients nutritionally supported by nutritional supplements.
89112850|NCT02758197|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
89112851|NCT02758041|Experimental|Sebacia Microparticles|
89112852|NCT02763501|Active Comparator|RCT|"patients operated with laparoscopic gastric bypass surgery within a register based RCT from May 1st 2010 until Nov 14th 2011.~1:1 randomization to closure of mesenteric defects by running, non-absorbable sutures"
89112853|NCT02763501|Active Comparator|non-RCT|"patients operated with laparoscopic gastric bypass surgery outside of the RCT from May 1st 2010 until Nov 14th 2011.~Intervention of mesenteric defects according to local tradition or choice of surgeon (non-randomized)"
89112854|NCT02763267||Pregnant Women|Pregnant women with history of GDM or at risk for diabetes mellitus will enter study during first trimester (4-14 weeks) and receive an oral glucose tolerance test (OGTT) at baseline, mid-pregnancy, and at delivery.
89112855|NCT02763267||Nonpregnant Women|Nonpregnant women with a history of GDM will undergo an OGTT at baseline.
89112856|NCT02762955|Experimental|BCD-057 group|"BCD-057 group includes patients with moderate to severe plaque psoriasis, who will receive BCD-057 subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Patients will be invited for randomization at week 24 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). From week 25 patients of this group will continue to receive BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa."
89112857|NCT02762955|Active Comparator|Humira® group|"Humira® group includes patients with moderate to severe plaque psoriasis, who will receive Humira® subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23. At week 24 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057. Patients will receive BCD-057 or Humira® at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.~Humira® is original drug of adalimumab, monoclonal antibody to tumor necrosis factor alfa."
89112858|NCT02757807|Experimental|Utilization of Serenita for Relaxation|Intervention is that Users continue to take their PDE-5 Inhibitor prior to sexual interaction and IN ADDITION Utilize the Serenita App daily and before any sexual encounters.
89112859|NCT04191681|Experimental|Sacubitril-valsartan study arm|"Start medication-naïve patients on low-dose sacubitril-valsartan (24/26 mg PO BID) without a washout period per guideline and label recommendations.~Switch patients to equivalent dose sacubitril-valsartan if on prior ACE inhibitor (after a 36 hour washout period) or ARB therapy (after discontinuing one day prior).~If therapeutic range MAP (65 to 85 mm Hg), discontinue other oral vasodilator (e.g., hydralazine, isordil) or non-rate limiting dihydropyridine calcium channel blocker (non-DHP CCB, e.g., amlodipine) therapy on the day prior to sacubitril-valsartan initiation. If MAP > 85 mm Hg, low-dose sacubitril-valsartan will be added with or without discontinuation of other oral vasodilator or non-DHP CCB per physician's discretion based on drug tolerability and maintenance of therapeutic range MAP.~Sacubitril-valsartan can be up-titrated every 2-4 weeks per standard practice guidelines per physician's discretion as above."
89112860|NCT04191681|Active Comparator|Usual care (standard-of-care) arm|"1. Continue current regimen of patients on oral vasodilator therapy (e.g., ACE inhibitor, ARB, hydralazine, isordil), allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above.~2. Start medication-naïve patients de novo on one of the oral vasodilators as below per guideline and label recommendations, allowing for up-titration of the drug every 2-4 weeks per standard practice guidelines in keeping with physician's discretion as above: i. ACE inhibitor: Enalapril 2.5 mg PO BID or Lisinopril 5 mg PO daily; ii. ARB: Valsartan 20 mg PO BID or Losartan 25 mg PO daily; iii. Other: Hydralazine 10 mg PO TID or Isordil 5 mg PO TID."
89112861|NCT02757729|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 8 weeks
89112862|NCT02757729|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 8 weeks
89112863|NCT02757729|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 8 weeks
89112864|NCT02757729|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 8 weeks
89112865|NCT02757651|Experimental|Radiotherapy + radiation sensitizer|Patients in phase I and patients randomised to the test group in phase II will receive standard radiotherapy for breast cancer + a radiation sensitizer
89112866|NCT02757651|No Intervention|Radiotherapy alone|Patients randomised to the control group in phase II will receive standard radiotherapy for breast cancer alone.
89112867|NCT02753049|Experimental|Peer led mHealth adherence intervention|Eligible participants enrolled will receive five, weekly-60 minute, 'ACCESS' sessions, delivered by a peer adherence coach via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
89112868|NCT02752503|Experimental|Nalmafene|
89112869|NCT04479579|Experimental|Apixaban|apixaban for extended prophylaxis against VTE after discharge
89112870|NCT02752659|Experimental|Women with breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
89112871|NCT02752659|Experimental|Women at risk of breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
89112872|NCT02757495|No Intervention|Traditional|This will utilize the traditional method of performance of single dose caudal epidural block
89112873|NCT02757495|Experimental|Caudal dexmedetomidine|In this arm, single dose caudal epidural injection will be done patients in this arm will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%
89112874|NCT02752581|Other|Drain Group|Suction drain was applied to these patients after arthroscopic knee surgery.
89112875|NCT02752581|Other|Control Group|No suction drain was applied to this group, therefore used as a control group.
89112876|NCT02752347|Experimental|unilateral crossbite|unilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
89112877|NCT02752347|No Intervention|control|the surface Electromyography (surface EMG device) device will be used to examine the muscle activities on normal patients
89112878|NCT02752347|Experimental|Bilateral crossbite|Bilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
89112879|NCT04220697|Experimental|patients undergo lateral thoracotomy for primary lung cancer|"Electroencephalography (EEG) will be acquired before surgery~Questionnaires assessing psychological status of the patients before and after surgery~High frequency electrical stimulation of the skin (HFS) will be delivered before surgery~Quantification of mechanical sensitivity after HFS and after surgery"
89290565|NCT03930888||Patients without nutritional support|Evaluation of changes in muscle strength, muscle mass and self-sufficiency (ADL-Activites of Daily Living) over a 5-day time period in patients without special nutritional supplements.
89290566|NCT04677244|Experimental|Portal vein blood sample|
89290567|NCT01223898|Experimental|Nilotinib|
89290568|NCT03924648||premature ovarian insufficiency|Idiopatic premature ovarian insufficiency (POI), defined as loss of ovarian function and subsequent amenorrhea before the age of 40.
89231307|NCT06332677|Experimental|the main genes and expression by comparing the transcriptomic lipidomic profile|"To identify the main genes and pathways differentially expressed and the main factors associ- ated with SUV420H1/H2 expression by comparing the transcriptomic and lipidomic profile of indi- viduals with low hepatic SUV420H1/H2 mRNA expression levels (lowest expression quartile) to that from individuals with high expression levels (top quartile).~In order to evaluate the role of SUV420H1/H2 in the regulation of gene expression in NAFLD pa- tients, we will exploit already available transcriptomic and lipidomic data by analyzing the gene ex- pression databases deriving from ongoing studies conducted at the Fondazione and by the PI of the Catanzaro collaborating centre. Data have been generated from liver and visceral adipose biopsy of obese individuals at high risk of developing NASH (SERENA Study at Fondazione, and MAFALDA Study, coordinated by prof Stefano Romeo, PI of the Università Magna Graecia Catanzaro)."
89231308|NCT06332664|Experimental|Early Nutrition Intervention|For patients meeting the inclusion criteria and randomly assigned to the intervention group, the investigators will assess their nutritional status monthly. During the home-based period between chemotherapy cycles, the investigators will conduct follow-up and provide care using a mobile application (APP). In the event of new nutritional risks emerging in patients, timely recommendations for medical consultation will be made, and nutritional plans will be formulated accordingly.
89231309|NCT06332664|No Intervention|standard care|Patients randomly assigned to the standard treatment group will receive standard care for cancer patients and will not be scheduled for interdisciplinary supportive therapy assessment unless requested by the patient, the primary oncologist, or their family.
89231310|NCT06332651|Experimental|Methionine in black beans in older men|This group of 7 participants will have 3 test days where they consume black beans with 3 different levels of methionine and they will have 4 test days where they consume the reference amino acid mixture with 4 different levels of methionine.
89231311|NCT06332651|Experimental|Methionine in black beans in younger men|This group of 7 participants will have 3 test days where they consume black beans with 3 different levels of methionine and they will have 4 test days where they consume the reference amino acid mixture with 4 different levels of methionine.
89231312|NCT06332651|Experimental|Lysine in milk or sorghum in older men|This group of 7 participants will have 3 test days where they consume milk with 3 different levels of lysine, they will have 3 test days where they consume sorghum with 3 different levels of lysine and they will have 4 test days where they consume the reference amino acid mixture with 4 different levels of lysine.
89231313|NCT06332651|Experimental|Lysine milk or sorghum in younger men|This group of 7 participants will have 3 test days where they consume milk with 3 different levels of lysine, they will have 3 test days where they consume sorghum with 3 different levels of lysine and they will have 4 test days where they consume the reference amino acid mixture with 4 different levels of lysine.
89231314|NCT06332638|Experimental|Group A|Tegoprazan 12.5mg
89231315|NCT06332638|Active Comparator|Group B|Tegoprazan 25mg
89231316|NCT06332638|Active Comparator|Group C|Famotidine 20mg
89231317|NCT06332612|Active Comparator|Standard|Group 1: Standard treatment with topical cream betamethasone and Pentoxifylline tablet.
89231318|NCT06332612|Experimental|MetforminO|Metformin 500 mg thrice daily.
89231319|NCT06332612|Experimental|MetforminT|Topical cream metformin thrice daily
89231320|NCT06332599||BQT|
89231321|NCT06332599||EBM4M4|
89231322|NCT06332599||EBM3M3|
89231323|NCT06332599||EBM2M4|
89231324|NCT06332599||EBM2M3|
89231325|NCT06332586|Experimental|The learning effect of applying diversified teaching in emergency triage and classification|
89231326|NCT06332573|Experimental|"Early intervention group"|
89231327|NCT06332573|Other|"Late intervention group"|
89231328|NCT06332560|No Intervention|Standard care (control group)|
89231329|NCT06332560|Experimental|Standard care and an anti-inflammatory diet (DI group)|
89231330|NCT06332560|Experimental|Standard care, anti-inflammatory diet and cognitive behavioral therapy (DI + CBT group)|
89290569|NCT03924648||Control|The investigators compared patients with POI to a cohort of age matched healthy controls recruited among women who visited the gynecology clinic for routine examination or from hospital workers. All volunteers for the control group had regular menstrual cycles and no concomitant health problems.
89290570|NCT01127880|Active Comparator|Ancef 1 gm or Clindamycin 300 mg|Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists
89290571|NCT01127880|Placebo Comparator|Placebo|Group B will receive .9% Normal Saline as a placebo.
89290572|NCT01228344||Artemether-lumefantrine|
89112880|NCT02757261|Experimental|Application of Low-level laser therapy.|The intervention will be twelve sessions (two per week). Laser parameters: wavelength - 786.94 nm; conventional tip; energy density - 25 J/cm²; intensity - 1.675 mW/cm²; output power - 70 mW (0.070 W); and exposure time - 20 seconds per point. The point application method will be used with direct contact with the skin (spot beam of 0.04 cm²), following the protocol suggested by Carvalho et al.50 and Venezian et al.44 A potentiometer will be used to determine the mean power of the laser equipment to ensure the safety of the operator.
89112881|NCT02757261|Experimental|Treatment with Occlusal splint.|The intervention will be a maxillary occlusal splint will be used on the maxilla with palatal and occlusal coverage. Following the protocol established by Hachmann et al., the children will only use the splint at night for two months, with weekly adjustments of a quarter turn.46
89112882|NCT02757261|Active Comparator|Placebo laser|Placebo laser will be performed using the same equipment.
89112883|NCT02757261|No Intervention|Children without bruxism|Control group
89112884|NCT02752425|Experimental|With visual feedback|Session of speech therapy conducted with the additional use of articulatory visual feedback based on ultrasound echography, which allows to visualize the patient's tongue in real time on a computer screen
89112885|NCT02752425|No Intervention|Without visual feedback|Session of speech therapy without use of ultrasound echography
89112886|NCT02757027|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
89112887|NCT02757027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
89112888|NCT02756871|Experimental|Online guided self-help intervention|CBT based online guided self-help intervention. Intervention can be found at www.overcomingperfectionism.co.uk
89112889|NCT02756871|No Intervention|Control|No intervention.
89112890|NCT04220541|Experimental|Motor learning based exercise group|
89112891|NCT04220541|Experimental|Symptomatic exercise group|
89112892|NCT02752113|Active Comparator|Empagliflozin and Linagliptin|After the 4 weeks run-in phase (stable metformin medication), patients will be consecutively randomized (1:1) to empagliflozin 10 mg and linagliptin 5 mg orally once daily. After 14 days empagliflozin will be up-titrated to 25 mg (once daily), if fasting blood glucose is ≥ 100 mg /dl and no hypoglycemic symptoms are recognized.
89112893|NCT02752113|Active Comparator|Metformin and Insulin sc|Metformin p.o. and insulin sc After the 4 weeks run-in phase (stable metformin medication), patients will maintain on their metformin dosage (850 or 1000 mg orally twice daily) and insulin glargine (Lantus™) once daily subcutaneous will be added. Initially 2 - 4 U Lantus™ daily (depending on body weight) will be given, and adjusted every third day (telephone counseling) by adding 2 U if fasting blood glucose is not ≤ 125 mg/dl (16). After a stable dosage (i.e. no change of dosage for 1 week) has been reached, adjustments regarding an increment of Lantus™ will be based on confirmed fasting blood glucose of ≥ 126 mg/dl (on at least two consecutive day).
89112894|NCT02751957|Experimental|Intervention|Receives caregiver coaching version of the Early Start Denver Model (ESDM) intervention, delivered by non-specialist workers. ESDM is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
89112895|NCT00745615|Experimental|Double-Blind: Laquinimod 0.3 mg|Participants who will be receiving laquinimod 0.3 milligram (mg) tablet once daily orally in double-blind core study, will continue to receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
89112896|NCT00745615|Experimental|Double-Blind: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally in double-blind core study, will continue to receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
89112897|NCT00745615|Experimental|Double-Blind: Placebo/Laquinimod 0.3 mg|Participants who will be receiving placebo matching to laquinimod 0.3 mg tablet once daily orally in double-blind core study, will receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
89112898|NCT00745615|Experimental|Double-Blind: Placebo/Laquinimod 0.6 mg|Participants who will be receiving placebo matching to laquinimod 0.6 mg (2 tablets of placebo) once daily orally in double-blind core study, will receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
89112899|NCT00745615|Experimental|Open-Label: Laquinimod 0.3 mg/Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.3 mg tablet once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
89112900|NCT00745615|Experimental|Open Label: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
89112901|NCT02756715|Active Comparator|propofol group|The patient who anesthetized by using propofol.
89112902|NCT02756715|Active Comparator|Desflurane group|The patient who anesthetized by using sevoflurane.
89112903|NCT02756559||sepsis, severe sepsis and septic shock|Septic patients were divided into sepsis, severe sepsis and septic shock
89112904|NCT02756481||NVAF Treatment patterns|"Treatment patterns will be collected during the follow-up period. Data will be directly extracted from medical charts of the arrhythmia unit.~Anticoagulation use will be reported as drug class: Vitamin K antagonist, antiplatelet, nonsteroidal anti-inflammatory drugs. The following data on anticoagulation use will be collected:~Type of treatment, start & stop dates, dosage, administration schedule, method of administration, reason for discontinuation if applicable~Type of therapy utilized (monotherapy/combination therapy)~Total number of therapy changes or switches through the course of treatment~Monitoring visit (visits per month) for International normalized ratio (INR) control by Time in Therapeutic Range(cTTR)~Routine care (visits per month) by anticoagulation regimen"
89112905|NCT02756325|Experimental|MRI|
89112906|NCT02756169|Experimental|Intervention|One workshop during pregnancy Support for breastfeeding at immediate postpartum Telephonic support after delivery
89112907|NCT02756169|No Intervention|Control|Standar procedures of neonatal and pregnancy health care at the clinics or hospitals.
89112908|NCT04221321|Placebo Comparator|Atorvastatin 40 mg|Oral administration of Atorvastatin 40 mg tablet once daily for 7 days
89112909|NCT04221321|Experimental|Atorvastatin 40 mg + Tegoprazan 50 mg|Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days
89112910|NCT04221321|Active Comparator|Atorvastatin 40 mg + RAPA114|Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days
89112911|NCT04221243|Experimental|Group 1: Children with 3D printed space maintainer|
89112912|NCT04221243|Active Comparator|Group 2: Children with conventional band and loop|
89112913|NCT02755701|Experimental|BCAA group|Branched-chain amino acid, 4.15g, Tid
89112914|NCT02755701|Placebo Comparator|Placebo group|Placebo, 4.15g, Tid
89112915|NCT02751801||Adults and children with hypophosphatasia|Healthcare use interview
89112916|NCT02755857|Experimental|Lozanoc|65 mg, capsules, at least 2 capsules twice a day
89112917|NCT02755545|Active Comparator|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
89112918|NCT02755545|Active Comparator|Product B (salicylic acid)|Product B applied topically to the affected area of the skin 1 to 3 times daily.
89112919|NCT02755389|Placebo Comparator|0 L/min|These participants will receive 0 L/min oxygen via conventional nasal cannulae during the apneic period.
89112920|NCT02755389|Experimental|15 L/min|These participants will receive 15 L/min oxygen via conventional nasal cannulae during the apneic period.
89112921|NCT02755389|Experimental|60 L/min|These participants will receive 60 L/min oxygen via high-flow nasal cannulae during the apneic period.
89112922|NCT02695797|Experimental|Immunotherapy|Intravenous immunoglobulin (IVIG) and oral prednisolone. IVIG and oral prednisolone are administered simultaneously: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day).
89112923|NCT02695797|No Intervention|Control|No immunotherapy.
89112924|NCT02755311|Experimental|liver resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
89112925|NCT02755311|Active Comparator|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
89112926|NCT04554771|Experimental|ADAM12 high with tocilizumab and standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
89112927|NCT04554771|Active Comparator|ADAM12 high with standard of care|Patients have serum ADAM12 higher than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
89112928|NCT04554771|Experimental|ADAM12 low with tocilizumab and standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 in addition to paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
89112929|NCT04554771|Active Comparator|ADAM12 low with standard of care|Patients have serum ADAM12 lower than 203ng/mL. Patients will receive paclitaxel 50mg/m2 and carboplatin AUC 2 intravenously on day 1, 8, 15, 22 and 29. External beam radiation of 41.4 Gy will be given in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.
89112930|NCT02755233||Pulmonary function|Patients in whom treatment with ipilimumab due to metastatic melanoma is indicated
89112931|NCT02751723||lung cancer|validated questionnaires
89112932|NCT02751723||malignant melanoma|validated questionnaires
89112933|NCT02751723||cancer of the hepatobiliary system|validated questionnaires
89112934|NCT02751723||head and neck cancer|validated questionnaires
89112935|NCT02751723||breast cancer|validated questionnaires
89112936|NCT02751723||ovarian carcinoma|validated questionnaires
89112937|NCT02751723||pancreatic cancer|validated questionnaires
89112938|NCT02751723||stomach cancer|validated questionnaires
89112939|NCT02751723||oesophageal cancer|validated questionnaires
89112940|NCT02751723||colorectal cancer|validated questionnaires
89112941|NCT02755155|Experimental|Continuous low dosage (CLD)|The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
89112942|NCT02755155|Active Comparator|Intermittent high dosage (IHD)|The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%
89112943|NCT02751645|No Intervention|Standard of Care Control|This group will consist of all the participants that receive the standard of care treatment for elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
89112944|NCT02751645|Experimental|Acute Normovolemic Hemodilution|This group will consist of all the participants that receive the acute normovolemic hemodilution prior to their elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
89112945|NCT02754843|Active Comparator|Naida Q90-SP|Phonak's commercial power Behind-The-Ear (BTE) device, type 1.
89112946|NCT02754843|Active Comparator|Naida Q90-UP|Phonak's commercial power Behind-The-Ear (BTE) device, type 2.
89112947|NCT02751411|Experimental|micro-enema with Promelaxin|2,5 g, 5 g or 2X5 g (calculated considering patient age) have to be administered daily (in the evening) for one week, once every other day for the second week and as needed for the following 6 weeks
89112948|NCT02751411|Active Comparator|Macrogol 4000|One/Two sachets of the study treatment has to be solubilized in 50mL of water and then administered daily. The administration should take place in the morning (the first sachet or in the event that only one sachet/day should be administered) and in the evening (second sachet).
89112949|NCT02754921|Experimental|Ultra-perc|
89112950|NCT02754921|Experimental|Ciaglia Blue Dolphin|
89112951|NCT02755077|Experimental|Mask ventilation in rotated head position|Patient's head will be axially rotated 45 degrees to the right
89112952|NCT02755077|No Intervention|Mask ventilation in neutral head position|
89112953|NCT00744523|Experimental|Mo.ma cerebral protection device|Mo.Ma cerebral protection device
89112954|NCT02597569||Historical Control|Patient participants will be recruited from an inpatient rehabilitation stroke unit prior to introducing CO-OP KT training to the stroke team. Patient participants will receive Usual Care from their stroke team.
89112955|NCT02597569||CO-OP KT Exposure group|Patient participants will be recruited from an inpatient rehabilitation stroke unit after the stroke team has been exposed to CO-OP KT training. Patient participants will receive Usual Care, augmented by CO-OP KT, from their stroke team.
89112956|NCT00744991|Experimental|Enzastaurin|Open Label
89112957|NCT02754999|Experimental|SANGUINATE™|As Needed Dosing of SANGUINATE
89112958|NCT02751489|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
89112959|NCT04090801|Active Comparator|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|Group A applied topical minoxidil 5% in 90% ethanol and 5% propylene glycol
89112960|NCT04090801|Active Comparator|Topical minoxidil 5% in pure ethanol alone|Group B applied topical minoxidil 5% in pure ethanol alone
89112961|NCT04090801|Placebo Comparator|Placebo|Group C applied pure ethanol (placebo)
89112962|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-10|A total of 40 participants week 0 and week 8 will have low dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 10 L3 in 200 microliter (uL) of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
89290573|NCT03924570|Experimental|Intervention|This arm will receive training in the use of the IPASS package to improve communications during hands off.
89231331|NCT06332547|Active Comparator|Restrictive transfusion strategy|"Restrictive transfusion strategy: Blood transfusion triggers of Hb valve less than 6.0g/dL or Hct value less than 18% during CPB, Hb valve less than 7.0g/dL or Hct value less than 21% in ICU or general ward.~Red blood cell transfusion will be given when Hct values fall below 18% or Hb fall below 6.0g/dL during CPB, 2 units RBC transfusion will be administered. In ICU or general ward after surgery, RBC transfusion will be given when Hct values fall below 21% or Hb fall below 7.0g/dL during CPB, 2 unit RBC transfusion will be administered. Following administration of the 2 units transfusion a repeat HCT or Hb is performed, if their values greater than threshold, no further transfusions will be administered, or will be received 2 units RBC again."
89231332|NCT06332547|Active Comparator|Liberal Transfusion Strategy|"Liberal Transfusion Strategy: Blood transfusion triggers of Hb valve less than 8.0g/dL or Hct value less than 24% during CPB, Hb valve less than 10.0g/dL or Hct value less than 30% in ICU or general ward.~Red blood cell transfusion will be given when Hct values fall below 24% or Hb fall below 8.0g/dL during CPB, 2 units RBC transfusion will be administered. In ICU or general ward after surgery, RBC transfusion will be given when Hct values fall below 30% or Hb fall below 10.0g/dL during CPB, 2 units RBC transfusion will be administered. Following administration of the 2 units transfusion a repeat HCT or Hb is performed, if their values greater than threshold, no further transfusions will be administered, or will be received 2 units RBC again."
89231333|NCT06332534|Experimental|Period 1: Open Label Induction Phase (Dose A)|All participants in the open label induction phase of Period 1 will receive upadacitinib Dose A for 12 weeks based on body weight.
89231334|NCT06332534|Experimental|Period 1: Double-Blind Maintenance Phase (Dose B)|Clinical responders per PCDAI at the end of open label induction phase of Period 1 will be randomly assigned to receive Dose B or C for 52 weeks (oral solution dose will be based on body weight)
89231335|NCT06332534|Experimental|Period 1: Double-Blind Maintenance Phase (Dose C)|Clinical responders per PCDAI at the end of open label induction phase of Period 1 will be randomly assigned to receive either upadacitinib Dose C or B for 52 weeks (oral solution dose will be based on body weight)
89231336|NCT06332534|Experimental|Period 2: Open Label Long-Term Extension Phase Cohort 1|Participants receiving double-blind maintenance therapy with upadacitinib Dose B or upadacitinib Dose C daily in Period 1 who complete the Week 64 visit will receive upadacitinib Dose B daily for up to 156 weeks.
89231337|NCT06332534|Experimental|Period 2: Open Label Long-Term Extension Phase Cohort 2|Participants who were receiving rescue therapy with open-label upadacitinib Dose C during maintenance phase in Period 1 and completed the Week 64 visit will continue to receive upadacitinib Dose C daily for up to 156 weeks.
89231338|NCT06332534|Experimental|Period 2: Open Label Long-Term Extension Phase Cohort 3|Participants who did not achieve clinical response per PCDAI at Week 12 of Period 1 will receive an extended treatment with open-label upadacitinib Dose C daily for an additional 12 weeks. If they are responders after 12 weeks extended treatment, they will continue, otherwise they may be discontinued at the discretion of the investigator
89231339|NCT06332521||birth of term babies|Study of crying in a group of newborns (birth of term babies)
89231340|NCT06332521||Premature babies|Study of crying in a group of newborns (Premature babies )
89231341|NCT06332508|Experimental|PEMFs prior to surgery|During the study period, subjects will receive local magnetic therapy (PEMFs). The study aims to enrol subjects in 4 groups - in dose level 1 and 2 (subjects who do not need chemotherapy prior to surgery), PEMF will be administered prior to surgery;
89231342|NCT06332508|Experimental|PEMFs prior to chemotherapy|In dose level 3 and 4 (subjects who require chemotherapy), PEMF will be administered prior to chemotherapy.
89231343|NCT06332495||Assessment of pain during pelvic positioning|48-hour follow-up of patients included in the study, with data collected on two pelvis fittings per 24 hours of follow-up (one fitting = one installation and one removal).
89231344|NCT06332482|Active Comparator|Group 1|Patients who will use surgical stent in recording the digital Jaw relation
89231345|NCT06332482|Active Comparator|Group 2|Patients who will use acrylic complete denture in recording the digital Jaw relation
89231346|NCT06332482|Active Comparator|Group 3|Patients who will use mandibular stent in recording the digital Jaw relation
89231347|NCT06332469|Experimental|Treatment group|This group gets immediate access to the program
89231348|NCT06332469|No Intervention|Wailtlist group|This group gets access to the same program after a 9 week waiting time
89231349|NCT06332456||Control|15 healthy volunteers
89231350|NCT06332456||CKD|15 patients with CKD and CAD risk factors with GFR between 30 and 45 mL/min/1.73m2
89231351|NCT06332443|Active Comparator|SA|SA will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected (32-34)
89231352|NCT06332443|Active Comparator|SED-EA|EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
89231353|NCT06332430|Experimental|CAN2109|CAN2109 IT injection every three weeks (Q3W)
89231354|NCT06332417|Experimental|Intervention group|Ba-Duan-Jin Exercise + FET (Forced Expiratory Technique)
89231355|NCT06332417|Active Comparator|Control Group|FET (Forced Expiratory Technique) only
89231356|NCT06332404||Obstructive sleep apnea (OSA) patients treated with hypoglossal nerve stimulation (HNS) therapy|OSA patients treated with HNS therapy will be asked to participate in the registry.
89231357|NCT06332391|Experimental|Exercise-similar cardiac pacing|Atrial pacing to replicate exercise heart rate envelope once daily, 3 days per week, over 6 weeks while symptoms and vital signs are monitored and outcome measures assessed.
89290574|NCT03924570|No Intervention|Control|Until randomization this arm will continue running hands offs per usual care.
89231358|NCT06332391|Sham Comparator|Sham cardiac pacing|Sham pacing to replicate exercise heart rate envelope once daily, 3 days per week, over 6 weeks while symptoms and vital signs are monitored and outcome measures assessed.
89231359|NCT06332378|Experimental|ball training exercise|
89231360|NCT06332378|Experimental|Frenkel training exercise|
89231361|NCT06332378|Active Comparator|control group|
89231362|NCT06332365|Experimental|Group I experimental|Group I: Received a combination of 0.1% hyaluronic acid and 0.2% triamcinolone acetonide.
89231363|NCT06332365|Active Comparator|Group II|Was treated exclusively with 0.2% triamcinolone acetonide.
89231364|NCT06332365|Active Comparator|Group III|Received only 0.1% hyaluronic acid.
89231365|NCT06332352|Experimental|Intra-Articular hip injection of PRP|Single Group Assignment Recruitment will occur at the University of Utah Orthopedic Center by physician and study staff members medical chart review before patient visits. 45 mL of blood will be collected from eligible participants and processed. A single processed neutrophil-poor PRP injection will be given once to a single hip.
89231366|NCT06332339|Experimental|Treatment 1|16055 NFL delta Gly4 trimer, 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate intramuscular (IM) injections (0.27 mL each) at months 0, 2, 4, 8, and 12.
89231367|NCT06332339|Experimental|Treatment 2|"16055 NFL delta Gly4 trimer, 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each) at months 0 and 2.~Ad4-Env145NFL, 5 x 108 viral particles (vp) to be administered intranasally (IN) (0.07 mL into 1 nostril) at month 4.~Trimer 4571, 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each) at months 8 and 12."
89231368|NCT06332339|Experimental|Treatment 3|"16055 NFL delta Gly4 trimer, 200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each) at months 0 and 2.~Trimer 4571, 100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each) at month 4.~Ad4-Env145NFL, 5 x 108 vp to be administered IN (0.07 mL into 1 nostril) at months 8 and 12."
89290575|NCT03927456|Experimental|SHR6390 + Fulvestrant|Intervention Drug: SHR6390, Fulvestrant
89231369|NCT06332326|Experimental|VR+VAGUS GROUP|VR+VAGUS GROUP (n=20): PATIENTS USED NON-INVASIVE VAGUS NERVE STIMULATION IN ADDITION TO VESTIBULAR REHABILITATION
89231370|NCT06332326|Active Comparator|VR GROUP|VR GROUP (n=20) : PATİENTS UNDERGOİNG VESTİBULAR REHABİLİTATİON
89231371|NCT06332313|No Intervention|Group control|The control group is followed with PCA without a block.
89231372|NCT06332313|Active Comparator|Group E20|Group E20 receive PCA with 20cc volume of ESP block
89231373|NCT06332313|Active Comparator|Group E30|Group E30 receive PCA with 30 volume of ESP block çevir
89231374|NCT06332300|Experimental|Adebelimumab+famitinib+chemotherapy|Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
89231375|NCT06332287|Experimental|Trilaciclib+Pemetrexed|Patients were treated with Trilaciclib (240mg/m2, administered within 4 hours before each chemotherapy,Q3W) and pemetrexed (30mg,Q3W) until disease progression as assessed by the investigator according to RECIST 1.1 criteria or withdrawal or discontinuation criteria were met.
89231376|NCT06332274|Experimental|Arm A. MRD(+) - Tislelizumab treatment|Systemic treatment with tislelizumab monotherapy at the recommended dose of 400 mg administered intravenously every 6 weeks for a maximum of 9 cycles and followed-up as per standard of care (clinical examination plus imaging every 3 months the first year and every 6 months the second year) in addition to ctDNA (circulating tumoral DNA) analysis at M6 and M12.
89231377|NCT06332274|Placebo Comparator|Arm B. MRD(+) - placebo treatment|Control arm for MRD (+) subjects who will be administered with placebo instead of tislelizumab
89231378|NCT06332274|Experimental|Arm C. MRD(-) - De-escalated follow-up|De-escalated follow-up: clinical examination plus imaging every 6 months the first year and yearly the second year) with standard of care in addition to biobanking at M12 for subsequent ctDNA analyses.
89231379|NCT06332274|Other|Arm D. MRD(-) - De-escalated follow-up|Control arm for MRD (-) subjects , followed up as per standard of care (clinical examination plus imaging every 3 months the first year and every 6 months the second year) in addition to biobanking at M12 for subsequent ctDNA analyses.
89231380|NCT06332248|Experimental|Magnesium 375 mg|375 mg dietary supplement magnesium, one pill daily for up to 3 months.
89231381|NCT06332248|Placebo Comparator|Placebo|Placebo (rice powder), one pill daily for up to 3 months. Identical appearance as the magnesium pill.
89231382|NCT06332235||Experiment group|"Subject ≥ 20 years of age~Newly diagnosed of acute brain injury with Foley insertion with 5 days"
89231383|NCT06332222|Active Comparator|Vistula Tart Cherry|Supplemented with tart cherries.
89231384|NCT06332222|Placebo Comparator|Placebo|Supplemented with a calorie matched placebo.
89231387|NCT06332196|Other|Patient with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL)|Patient with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL)
89231388|NCT06332183||Presence of polymorphisms|Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
89231389|NCT06332170|Experimental|Cohort 1a|HS-20093 and Adebrelimab
89231390|NCT06332170|Experimental|Cohort 1b|HS-20093, Adebrelimab and Cisplatin/ Carboplatin
89231391|NCT06332170|Experimental|Cohort 2a|HS-20093 and Cetuximab
89231392|NCT06332170|Experimental|Cohort 2b|HS-20093, Cetuximab and Cisplatin/ Carboplatin
89231393|NCT06332170|Experimental|Cohort 3a|HS-20093 and Enzalutamide
89231394|NCT06332157|Experimental|Remimazolam group|Anesthesia was induced by pump injection of remimazolam besylate at a rate of 6mg/min. Anesthesia was maintained with 1.0-2.0mg/min remimazolam besylate by continuous pump.
89231395|NCT06332157|Active Comparator|Propofol group|Anesthesia was induced with propofol injection 2mg/kg intravenously. Anesthesia was maintained by continuous pumping of 6-8mg/kg/h propofol injection.
89231396|NCT06332144||Children with ASD|Structural vs. Random sequences of stimuli; Intact vs. Degraded speech; Repeating 5-syllable nonwords or 2-syllable nonwords; Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data
89231397|NCT06332144||Typically Developing Children|Structural vs. Random sequences of stimuli; Intact vs. Degraded speech; Repeating 5-syllable nonwords or 2-syllable nonwords; Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data
89112963|NCT02754609|Placebo Comparator|Tabasco® Sauce|A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing. Tabasco® Sauce is an ideal placebo as the sensation to the skin is similar to a hookworm. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge.
89112964|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-20|A total of 10 participants at week 0 and week 8 will have medium dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 20 L3 in 200 uL of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
89112965|NCT04089631|Experimental|Chemotherapy|"Capecitabine mono or Capecitabine/Oxaliplatin as investigator choice:~Patients who are positive for postoperative ctDNA (ctDNApos) and not microsatellite instable are randomized (2:1) to adjuvant chemotherapy with capecitabine or to follow up.~Capecitabine 2 x 1250 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days). Patients with a GFR between 30 and 50 ml/min start with capecitabine dose of 2 x 1000 mg/m^2. Treatment duration: 8 cycles (approx. 6 months)~Capecitabine, if combined with Oxaliplatin (investigator choice):~If the investigation decides to add oxaliplatin, the following schedule should be used:~[Oxaliplatin 130 mg/m^2 i.v. (2 hours on d1)] Capecitabine 2 x 1000 mg/m^2, oral (d1-14), repeated at day 22 (- 2 ... + 6 days) Treatment duration: 4 or 8 cycles (approx. 3 or 6 months)"
89112966|NCT04089631|No Intervention|Follow-up|Patients negative for postoperative ctDNA (ctDNAneg) are randomized (1:4) to follow-up within CIRCULATE or to routine follow up outside the Trial protocol.
89112967|NCT00917059|Active Comparator|1|Participants will receive a 1-week treatment of escitalopram and then an 8-week treatment with escitalopram.
89112968|NCT00917059|Active Comparator|2|Participants will receive a 1-week treatment with escitalopram and then an 8-week treatment with bupropion XL.
89112969|NCT02751333|Active Comparator|FCSEMS with Endostitching (ES)|General anesthesia or conscious sedation will be started and an upper endoscope will be inserted into the participants mouth and advanced into the stomach. Endoscopic stenting with a fully covered self-expanding metal stents (FCSEMS) will then be performed. Once the stent is in place, the endoscope will be withdrawn from the participant to set-up the endostitch device unto the endoscope. Bites are taken separately with the first on the esophageal mucosa followed by a second on the stent itself and finishing with a last bite on esophageal mucosa. A cinch is then used to secure the deployed suture. An attempt at placing 2 sutures will be performed. Stent removal will then be performed at 8-weeks post-stent insertion.
89112970|NCT02751333|Active Comparator|FCSEMS with No Suturing (NS)|The procedure will be done in the same manner with same endoscopic technique, stent deployment, and timing of stent removal. The only difference would be the lack of suturing and naturally the need for suture cutting at stent removal.
89112971|NCT03973723||Patients with NPC after treatment|All patients with NPC without distant metastases who receiving adequate RT dose
89112972|NCT02754531|Experimental|Subjects|USG was used to measure the internal transversal subglottic diameter on the crichoid cartilago level while the head was in sniffing position. After USG measurement was recorded, Cole formula was used to measure internal diameter of uncuffed endotracheal tube.
89112973|NCT00917137||Peripheral pulmonary lesions|
89112974|NCT02598037|Other|FTO gene polymorphism|test meal after fasting for 12 hours
89112975|NCT02751567|Experimental|Arm 1|All subjects are patched with the same product
89112976|NCT00917449|Active Comparator|L-arginine|L-arginine (3.2 gr bid) plus lifestyle counselling vs placebo plus lifestyle counselling
89112977|NCT00917449|Placebo Comparator|placebo|placebo plus lifestyle counselling for 18 months
89112978|NCT02754687|Placebo Comparator|Placebo|Placebo
89112979|NCT02754687|Experimental|11βmethyl nortestosterone dodecylcarbonate|11β-MNTDC in doses of 100 mg, 200 mg, 400 mg, and 800 mg
89112980|NCT02597959||risk factors of musculoskeletal injuries|trainees for surgical assistants - determining the level of risk
89112981|NCT02597959||design wearable devices|Creating feedback mechanism to reduce surgical assistant musculoskeletal risk
89112982|NCT02597335|Experimental|IDH1/IDH2|
89112983|NCT02754453|Other|Behavioral|
89112984|NCT04254315|Experimental|Cardiac rehabilitation+cognitive therapy|"The intervention group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively.~In addition, the intervention group follows a standardized group based cognitive therapy program with participation of maximum four patients, consisting of 5 sessions (each 2 hours) performed by a trained cardiac rehabilitation nurse."
89112985|NCT04254315|No Intervention|Cardiac rehabilitation|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
89112986|NCT04254315|No Intervention|Control group without psychological distress|The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
89112987|NCT04220151||Hepatocellular carcinoma|Sixty patients with HCC
89112988|NCT04220151||Hepatic cirrhosis|Thirty patients with hepatic cirrhosis
89112989|NCT04220151||Healthy controls|Ten healthy controls.
89112990|NCT05429775|Experimental|Budesonide: Formulation 1|single dose of 2 mg oral suspension formulation 1 administered orally under fasting conditions
89112991|NCT05429775|Experimental|Budesonide: Formulation 2|single dose of 2 mg oral suspension formulation 2 administered orally under fasting conditions
89112992|NCT05429775|Experimental|Budesonide: Formulation 3|single dose of 2 mg oral suspension formulation 3 administered orally under fasting conditions
89112993|NCT05429775|Experimental|Budesonide: Formulation 4|single dose of 2 mg oral suspension formulation 4 administered orally under fasting conditions
89112994|NCT02754219|Experimental|Evogliptin|Hepatic dysfunction, Healthy control
89112995|NCT04232631||patients with diabetic foot ulcers|"Patient of the investigators~Diagnosis of diabetes mellitus~One or more moderate to severe diabetic foot ulcers/infections~18-89 years of age"
89112996|NCT05429385|Experimental|HLX70 3 mg/kg or Placebo|Random allocation to HLX70 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
89112997|NCT05429385|Experimental|HLX70 10 mg/kg or Placebo|Random allocation to HLX70 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
89112998|NCT05429385|Experimental|HLX70 30 mg/kg or Placebo|Random allocation to HLX70 30 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.
89112999|NCT02753829|Experimental|Experimental group 1|Cardiovascular rehabilitation program using Kinect of Xbox, in home care context,virtual format
89113000|NCT02753829|Experimental|Experimental group 2|Cardiovascular rehabilitation program using paper manual, in home care context, conventional format
89113001|NCT02753829|Other|Control Group|Educational component
89113002|NCT04220073|Experimental|JS005|
89113003|NCT04220073|Placebo Comparator|placebo|
89113004|NCT02753907|Experimental|Low LA (linoleic acid)|Individuals who replaced 10 mL soy oil with one apple
89113005|NCT02753907|No Intervention|Medium LA|Individuals who maintained their usual food intake
89113006|NCT02753907|Experimental|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9 g of soy oil as a supplement
89113007|NCT05429151|Active Comparator|group 1|will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions
89113008|NCT05429151|Active Comparator|group 2|will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions.
89113009|NCT04219995|Experimental|Interventional start|Patients who randomize to the interventional start arm will receive the study drug, methylprednisolone sodium succinate, in the first month of the study, followed by placebo in the cross-over phase of the study.
89113010|NCT04219995|Placebo Comparator|Placebo start|Patients who randomize to the placebo start arm will receive placebo in the first month of the study, followed by the study drug, methylprednisolone sodium succinate, in the cross-over phase of the study.
89113011|NCT02753517|Other|Extended hepatectomy|Hepatic Scintigraphy
89113012|NCT04191369|Placebo Comparator|EGD evaluation|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
89113013|NCT04191369|Experimental|EUS evaluation|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
89290576|NCT03927456|Placebo Comparator|Placebo + Fulvestrant|Intervention Drug: Placebo, Fulvestrant
89290577|NCT01127958|Active Comparator|SeQuent Please|PCI with drug-eluting balloon
89290578|NCT01127958|Active Comparator|Xience Prime|PCI with a drug-eluting stent
89231398|NCT06332118|Experimental|ice massage group|Measurement surveys will be applied to obtain pre-test data from hemodialysis patients who meet the research criteria. After the preliminary test data are obtained, ice cubes prepared by the researchers before the needle insertion into the arteriovenous fistula for the hemodialysis procedure will be wrapped in a thin sponge and an ice massage will be applied to the needle insertion area of the patient in a direction that will not disrupt the circulation. This process will take approximately 3-5 minutes or the massage will be terminated when the patient feels drowsiness. In the next stage, the patient will undergo needle intervention for hemodialysis. At the end of this stage, the patient's pain will be evaluated. Patients will be re-evaluated at 24, 48 and 72 hours for ecchymosis and hematoma and relevant measurements will be provided.
89231399|NCT06332105|Active Comparator|Sequence AB: GMP-AA -> L-AA|"Participants to continue usual diet prescription from low protein diet. Participants to keep a daily log of protein substitute intake Dietitian to keep a log of bi-weekly Phe blood spot. Spots taken on days 3 and 7 for weeks 1, 2, 3 and 4, in the morning before any food or formula is consumed.~GMP-AA-based protein substitute will be provided to match Protein Equivalent intake from usual protein substitute."
89231400|NCT06332105|Active Comparator|Sequence BA: L-AA -> GMP-AA|"Participants to continue usual diet prescription from low protein diet. Participants to keep a daily log of formula/ protein substitute intake Dietitian to keep a log of bi-weekly Phe blood spots. Spots taken on days 3 and 7 for weeks 1, 2, 3 and 4, in the morning before any food or formula is consumed.~L-AA based protein substitute will be provided to match Protein Equivalent intake from usual protein substitute (this may be their usual protein substitute if their usual protein substitute is L-AA based)"
89231401|NCT06332092|Active Comparator|Arm A|FID-007 (75 mg/m2) plus Cetuximab (500 mg/m2)
89231402|NCT06332092|Active Comparator|Arm B|FID-007 (125 mg/m2) plus Cetuximab (500 mg/m2)
89231403|NCT06332079|Experimental|COHORT A/B|"Eligible patients will receive Scout dose procedure. After 1-2 weeks, patients eligible for radioembolization will receive 166Ho-TARE and at least after 3 weeks, maintenance treatment with fluoropyrimidine plus target agents (anti-EGFR or bevacizumab) according to the respective study cohort.~Maintenance treatment:~Cohort A:~CETUXIMAB iv day1, over 1 hours, 500 mg/sqm or PANITUMUMAB iv over 1 hours, 6 mg/kg, every 14 days~LED 200 mg/sqm iv over 1 hour, day 1~5-FLUOROURACIL ic 48 h, starting on day 1 every 14 days; 2400 mg/sqm and 400 mg/sqm bolus if FOLFOX/FOLFIRI in the induction treatment~Cohort B:~BEVACIZUMAB 5 mg/kg iv biweekly day1, over 30 minutes~LED 200 mg/sqm iv over 1 hour, day 1~5-FLUOROURACIL ic 48 h, starting on day 1 every 14 days; 2400 mg/sqm and 400 mg/sqm bolus if FOLFOX/FOLFIRI in the induction treatment~CAPECITABINE, 1000 mg/sqm orally twice daily, day 1-14, plus bevacizumab 7,5 mg/kg iv every 21 days is allowed."
89231404|NCT06332066|Experimental|Oxytocin|24IU (12IU*2) of Oxytocin, Sorbitol, Benzyl, alcohol glycerol, distilled water.
89231405|NCT06332066|Placebo Comparator|Placebo|24IU (12IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water.
89231406|NCT06332053|Experimental|Group A, Treatment Sequence (SY-5007-SY-5007/Itraconazole)|SY-5007 80mg, tablets, once daily on Day 1 and Day 11 before meal; Itraconazole 200mg, once or twice daily from Day 8 to Day 18.
89231407|NCT06332053|Experimental|Group B, Treatment Sequence (SY-5007-SY-5007/Rifampin)|SY-5007 160mg, tablets, once daily on Day 1 and Day 16 before meal, Rifampicin 600mg, once daily from Day 8 to Day 21.
89231408|NCT06331988||resectable colorectal cancer patient|patients with resectable CRC candidate to radical surgery and - after approximately 4-8 weeks - adjuvant chemotherapy (if indicated), accordingly to standard of care (SOC)
89231409|NCT06331611|Experimental|TOF Monitoring|Instrumental monitoring with electromyography (TOF Group)
89231410|NCT06331611|Active Comparator|Clinical monitoring (Standard Group)|Clinical monitoring
89231413|NCT06331182|Experimental|Ketamine group|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) after induction of general anesthesia.
89231414|NCT06331182|Experimental|Dex group|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg after induction of general anesthesia.
89290579|NCT01128036||CHF, cardomyopathy|Patients with signs of poor peripheral perfusion due to cardiomyopathy or congestive heart failure
89113014|NCT02753673||Breast Cancer|The assessments are all qualitative. The assessments include an in-person, open-ended qualitative interview, during which the interviewer will use an interview guide to ensure that all relevant topics are discussed. Participants will also complete the Patient Expectations with Breast Reconstruction questionnaire using the think-aloud technique in order to identify which questions reflect the expectations of BCT patients, which questions need modification to reflect the expectations of BCT patients and which questions are not appropriate for BCT patients. The responses to the expectations questionnaire for this portion of the interview will not be recorded or analyzed; only the participants' thoughts and opinions about the questions will be recorded.
89113015|NCT04506645|Experimental|REGN5381|Single dose REGN5381 administered via IV infusion
89113016|NCT04506645|Other|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
89113017|NCT02753361|No Intervention|Traditional|This will utilize the traditional method of performance of regional block
89113018|NCT02753361|Experimental|US-guided|In this arm, regional block will be performed under the ultrasound guidance
89113019|NCT05428371||Thyroid carcinoma|Patients with indeterminate thyroid nodule and pathological diagnosis of thyroid carcinoma
89113020|NCT05428371||Follicular adenoma|Patients with indeterminate thyroid nodule and pathological diagnosis of follicular adenoma
89113021|NCT04200417|Experimental|Lung, Endobronchial, Mediastinal or Pleural Metastases|Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy
89113022|NCT04219527|Experimental|Dual-Target injection|Corticosteroid injection into the subacromial bursa and biceps tendon
89113023|NCT02753439|Experimental|3rd molar|Drug: Geistlich Bio Oss
89113024|NCT02753205|Experimental|Control|Infusion of normal saline
89113025|NCT02753205|Active Comparator|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
89113026|NCT05358561|No Intervention|Nutritional analyzes applied to four cakes|The study is two-fold. In the preliminary study, the standard and test cakes (chia added cake, flax seed added cake, and chia+flax seed added cake) were developed and the amount of cake containing 50 g carbohydrate and the amount of moisture, ash, pulp, protein, fat, and digestible carbohydrate will be determined via analyses that will be carried at Toros University Food Chemistry Laboratory. Based on the results obtained, the amount of cakes containing 50 g digestible carbohydrate will be calculated and produced.
89113027|NCT05358561|Experimental|Flaxseed cake|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed cake
89113028|NCT05358561|Experimental|Chia cake|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of chia cake
89113029|NCT05358561|Experimental|Flaxseed and chia cake|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed and chia cake
89113030|NCT05358561|Experimental|Standart|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of standart cake
89113031|NCT04219683|Experimental|Patient with resected Mandible|Patient with resected mandible who is candidate for free fibula flap
89113032|NCT04174677|Experimental|Inebilzumab Treatment|Infusion of Inebilizumab
89113033|NCT04174677|Experimental|VIB4920 Treatment|Infusion of VIB4920
89113034|NCT04174677|Experimental|Inebilzumab+VIB4920 Treatment|Infusion of Inebilizumab and VIB4920
89113035|NCT00635895|Active Comparator|1|Manual Lymph Drainage Therapy is a manual therapy method
89113036|NCT00635895|Active Comparator|2|Connective Tissue Massage
89113037|NCT05157633||Controls|Children without eating difficulties
89113038|NCT05157633||Patients|Children with eating difficulties
89113039|NCT02751021|Other|Sleep apnea diagnosis|The intervention is the use of the pacemaker diagnostic algorithm named Sleep Apnea Monitoring to detect sleep apnea and the attended cardiorespiratory sleep study to confirm the diagnostic.
89113040|NCT04488003|Experimental|Part A: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
89113041|NCT04488003|Experimental|Part B: Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
89113042|NCT04488003|Experimental|Part B: Physician's choice of treatment|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice). If a patient progresses on physician's choice of treatment, crossover to the ulixertinib arm is permitted.
89113043|NCT02751099||de novo renal transplanted patients|renal transplanted patients
89113044|NCT02751177|Experimental|OncoBEAM|KRAS, NRAS and BRAF mutations will be analyzed in circulating plasma DNA using ONCOBEAM technique.
89113045|NCT02750787|Experimental|Nutritional Study Product|A ready-to-drink peptide-based liquid formula for patients with impaired gastro-intestinal function.
89113046|NCT02750631|Experimental|Triple Therapy|Combined Wake Therapy (one night of missed sleep), early morning bright light and sleep phase advance
89290580|NCT01129752||children at risk for depression|children at familial risk for depression
89113047|NCT05125731|Experimental|Parental absence|The parent will not be present in the dental clinic during the treatment. Parents will be instructed to wait in a waiting room outside the clinic, out of sight of the child.
89113048|NCT05125731|Active Comparator|Parental visual support|The parent will watch and wait behind a transparent barrier without disrupting the interaction between the dentist and the child. This type of separation differs from the total absence of the parent because the parent is within the child's sight.
89113049|NCT05125731|Active Comparator|Parental presence|One of the parents will accompany the child during the dental treatment. The parent is allowed to sit next to the child without disturbing the interaction between the dentist and the child.
89113050|NCT04475289||Patients with an coronary artery anomaly (focus on ACAOS)|Patients eligible for study participation have a CAA and a prior, clinically indicated testing (noninvasive and/or invasive measurement) at our institution to evaluate the hemodynamic significance of this coronary anomaly. They will be approach either after start of this study (retrospective inclusion) or before their testing (prospective inclusion).
89113051|NCT02695641|Experimental|Stage 1 - Low dose administration|Ten hemodialysis patients will receive IV infusion treatment with 1.25mg bevacizumab and undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and pharmacokinetic/dynamic (PK/PD) data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcomes are met in stage 1, the study will be terminated, otherwise the study will progress to stage 2.
89113052|NCT02695641|Experimental|Stage 2 - Dose escalation|If outcomes are not met in stage 1, Ten additional hemodialysis patients will receive IV infusion treatment with 2.50mg bevacizumab treatment. They will undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and PK/PD data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcome is not met, the study will be terminated.
89113053|NCT02695407|Experimental|3 days cannulation|radial artery cannula removed after 3 days
89113054|NCT02695407|Experimental|5 days cannulation|radial artery cannula removed after 5 days
89113055|NCT02750553|Experimental|Pre-test|Three healthy male subjects were randomized in 2:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
89113056|NCT02750553|Experimental|Cohort 1|Eight healthy subjects were randomized in 3:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
89113057|NCT02750553|Experimental|Cohort 2|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 10 mg SHR0534 or matching placebo.
89113058|NCT02750553|Experimental|Cohort 3|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 25 mg SHR0534 or matching placebo.
89113059|NCT02750553|Experimental|Cohort 4|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 50 mg SHR0534 or matching placebo.
89113060|NCT02750553|Experimental|Cohort 5|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 100 mg SHR0534 or matching placebo.
89113061|NCT02750475|Experimental|Arm 1|All subjects are patched.
89113062|NCT02750241|Experimental|Active video game-based intervention|This arm will receive the active video game-based intervention, which will include attending 12 weekly group sessions at the UTMB Breast Health Clinic, participate in self-paced home session, and monitor daily, weekly, and monthly steps using Wii Fit Meter. All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
89113063|NCT02750241|Active Comparator|Pedometer|This arm will receive the pedometer intervention, which will include attending 3 monthly UTMB Breast Cancer Support Group sessions, and monitor daily, weekly, and monthly steps using a pedometer (Digit-Walker CW-700/701). All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
89113064|NCT02750085||2-point and 6-point PK sampling|
89113065|NCT02749851||Non-smokers|Pregnant women that identify as non-smokers with low risk for placental insufficiency will receive the MRI Imaging intervention.
89113066|NCT02749851||Smokers|Pregnant women that identify as smokers will receive the MRI Imaging intervention.
89113067|NCT02749851||High risk/Non-Smokers|Pregnant women that identify as non-smokers who are at a high risk for adverse outcomes based on prior clinical history will receive the MRI Imaging intervention.
89113068|NCT02749851||Confirmed IUGR|Pregnant women identified by their clinical care provided to have confirmed IUGR during their current pregnancy
89113069|NCT04217265|Experimental|study group|2 tablets of Letrozole 2.5 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
89113070|NCT04217265|Placebo Comparator|control group|2 tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum three doses
89290581|NCT01129830|Other|Dehydroepiandrosterone|infertile women with low anti mullerian hormone levels
89290582|NCT01228422||1|test interferon - blausiegel
89290583|NCT01228422||2|reference interferon - Roferon A (Roche)
89290584|NCT01319422|Experimental|Pomalidomide 2 mg/d on 28 days/28 day cycle|
89113071|NCT02749929|Experimental|Low-Level Laser therapy|"After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the laser to make skin contact. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. The light from the laser is not visible to the eye, and will not give any perceptible stimulus.~Low-Level Laser therapy (LLLT) will be given according to the recommended dosage from World Association of Laser Therapy (WALT). A LLLT dose of 3.6 Joules will be administered at two points over the fracture site."
89113072|NCT02749929|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the placebo laser to make skin contact. The placebo laser is identical in apperance to a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Since the light from the laser is invisible, neither the participant nor the therapist will know whether the laser is a placebo. The treatment time and number of treated points will be identical to group 1.
89113073|NCT02752971|Experimental|Bupivacaine|A dilution of Bupivacaine 0,25% , 15 ml was infiltrated in surgical wound after close the aponeurosis
89113074|NCT02752971|Experimental|Bupivacaine, sodium diclofenac|A dilution of Bupivacaine 0,25% and sodium diclofenac 75 mgr, was infiltrated in surgical wound after close the aponeurosis
89113075|NCT02752971|Experimental|Sodium diclofenac|A dilution of sodium diclofenac 75 mgrs (3ml) and 12 ml of solution 0,9% was infiltrated in surgical wound after close the aponeurosis
89113076|NCT02750007|Experimental|Experimental|Weekly-dose titration from 0.04mg/day HS-20004 to the maximum tolerable dose or of the ultimate 0.18mg/day
89113077|NCT04217421|Active Comparator|Allopurinol|
89113078|NCT04217421|Placebo Comparator|Placebo|
89113079|NCT02749695|Experimental|Group 1 (Melsmon)|20 women used placental extract Melsmon® (Japan), 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
89113080|NCT02749695|Placebo Comparator|Group 2 (placebo)|20 patients used placebo (normal saline solution): 2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
89113081|NCT04217187|Experimental|Electrical Stimulation Group|This arm will receive neuromuscular electrical stimulation to the antagonist muscles of the upper extremity.
89113082|NCT04217187|Sham Comparator|Sham Stimulation Group|This arm will receive sensory stimulation without muscle contraction to the antagonist muscles of the upper extremity.
89113083|NCT02749773|Active Comparator|Oocyte aspiration with 17G needle|Oocyte Aspiration with 17G needle.
89113084|NCT02749773|Active Comparator|Oocyte aspiration with (20-17G) needle|Oocyte Aspiration (20-17G) needle.
89113085|NCT02749539|Experimental|Kinesio tape|The first 3 kinesio tape application was inhibition technique for supraspinatus, deltoid and teres minor muscles. the fourth Kinesio tape was mechanical correction for the shoulder joint. in addition to active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
89113086|NCT02749539|Active Comparator|Physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
89113087|NCT00636051||1|staff Registered Nurses receiving EBP peer mentoring
89113088|NCT00636051||2|staff Registered Nurses not receiving EBP peer mentoring
89113089|NCT04219371||Healthy volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
89113090|NCT04217031||Decision variability assessment group|Patients with angiographically confirmed 3-vessel or left main disease will be enrolled. Patients data and heart team decision will be collected to analyze the variability between different heart team decisions.
89113091|NCT04583241||BJI group|"Patients with an BJI on material (prosthesis or other implant) infected by Staphylococcus aureus* Patients are follow-up during two years after surgery.~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
89113092|NCT04583241||Control Group With material|"Patients with mechanical problems on implanted equipment (control cohort), without infection* Patient of this group are follow-up until surgery.~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
89113093|NCT04583241||Group osteomyelitis|"Patients with chronic osteomyelitis* Patient of this group are follow-up until surgery.~*Diagnosis of staphylococcus aureus monoinfection realized a posteriori after surgery on bacteriological sample"
89113094|NCT04583241||Control Group with cruciate ligament surgery|Patients having cruciate ligament surgery Patient of this group are follow-up until surgery.
89113095|NCT00636129||1|Relaxation Response + Stress Management Curriculum
89113096|NCT04572789|Placebo Comparator|placebo|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
89113097|NCT04572789|Experimental|Omega-3|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
89113098|NCT02749383|Experimental|PAC-14028 cream 0.3%|Twice daily for 4 weeks
89113099|NCT02749383|Experimental|PAC-14028 cream 1.0%|Twice daily for 4 weeks
89113100|NCT02749383|Placebo Comparator|PAC-14028 cream vehicle|Twice daily for 4 weeks
89113101|NCT02748993|Experimental|PAC-14028 Cream 0.1%|PAC-14028 Cream 0.1%, Twice daily for 4 weeks
89113102|NCT02748993|Experimental|PAC-14028 Cream 0.3%|PAC-14028 Cream 0.3%, Twice daily for 4 weeks
89113103|NCT02748993|Experimental|PAC-14028 Cream 1.0%|PAC-14028 Cream 1.0%, Twice daily for 4 weeks
89113104|NCT02748993|Placebo Comparator|PAC-14028 Cream Vehicle|PAC-14028 Cream Vehicle, twice daily for 4 weeks
89113105|NCT04036929|Experimental|Estrogen-bazedoxifene|Tablet, once daily for 6 months.
89113106|NCT04036929|Placebo Comparator|Placebo|Closely matched tablet, once daily for 6 months.
89113107|NCT04219293|Other|Microneedling with NO PRP|Patient will receive Standard of Care micro needling on randomized side of the face.
89113108|NCT04219293|Active Comparator|Microneedling WITH PRP|Patient will receive Standard of care microneedling with PRP on randomized side of the face.
89113109|NCT04281147||No Ra-223 received|Patients did not receive Ra-223
89113110|NCT04281147||Early Ra-223 (2nd line)|Patients received Ra-223 in 2nd line
89113111|NCT04281147||Late Ra-223 (3rd or later lines)|Patients received Ra-223 in 3rd or later lines
89113112|NCT02749071|Sham Comparator|Control Group|This group will undergo laparoscopic implantation surgery. The device will not be activated: Sham EndoStim stimulation for first six months of study. It will be activated at the Month 6 visit and provide lower esophageal stimulation from Month 6 thru end of study.
89113113|NCT02749071|Experimental|Treatment Group|The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.
89113114|NCT02748915|Experimental|Patients using cochlear implants|All patients using cochlear implants included in the study will take electrophysiological and psychoacoustic tests to measure auditive parameters regarding the study objectives : ECAP, EABR, speech recognition and MCL.
89113115|NCT02748915|Experimental|Patients using EAS device|Patients using EAS device for more than 11 months will take electrophysiological and psychoacoustic tests with the implant functioning only with electrical pulses or in bimodal mode to measure ECAP, EABR, speech recognition and MCL ; this will allow to perform bimodal comparison.
89113116|NCT02748915|Experimental|Patients with bilateral cochlear implant|Patients with bilateral cochlear implant for more than 11 months will take electrophysiological and psychoacoustic tests to measure ECAP, EABR, speech recognition, and MCL. The binaural interaction component will also be measured ; this will allow to perform binaural comparison.
89113117|NCT02749149||Cardiac Surgery|Patients undergoing cardiac surgery: coronary artery bypass graft (CABG); valve replacement/repair; or transcatheter aortic valve implantation (TAVI) surgery
89113118|NCT04218981|Experimental|Schizophrenia group|"Schizophrenia was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~Choose one of the antipsychotics drugs treatment( olanzapine, risperidone, aminosulpiride) according to the patient's condition"
89113119|NCT04218981|Experimental|Bipolar disorder group|"Bipolar disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~Choose one of the mood stabilizer drugs treatment( lithium, valproate) according to the patient's condition"
89113120|NCT04218981|Experimental|Major depressive disorder group|"Major depressive disorder was diagnosed using the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).~MRI scan and evaluation of clinical symptoms at baseline and 8 weeks~Choose paroxetine treatment"
89113121|NCT04218981|No Intervention|Healthy controls|MRI scan at baseline and no drugs treatment
89113122|NCT04218513|Experimental|Compound Edaravone|30 mL (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg)
89113123|NCT04218513|Experimental|Edaravone|30 mL (containing edaravone 30 mg)
89113124|NCT04218513|Experimental|2-Aminoethanesulfonic Acid|30 mL (containing 2-aminoethanesulfonic acid 600 mg)
89113125|NCT02748759|Active Comparator|EXP 1: Manual mobilization / CPM|Patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist. After a pause of 5 minutes, the patient was collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension.
89113126|NCT02748759|Active Comparator|EXP 2: CPM / Manual mobilization|Patients were collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension. After a pause of 5 minutes, patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist.
89113127|NCT04218435||Observational|"Sacubitril/valsartan is a combination of a neprilysin inhibitor, sacubitril and an angiotensin II receptor blocker, valsartan.~The recommended starting dose is one 49/51 mg (sacubitril/valsartan) tablet twice-daily. Double the dose of Sacubitril/valsartan after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.~Reduce the starting dose to 24/26 mg (sacubitril/valsartan) twice-daily for:~Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.~Patients with severe renal impairment (CrCl less than 30 ml/min)~Patients with moderate hepatic impairment. (Child Pugh B) Double the dose of Sacubitril/valsartan every 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient"
89113128|NCT02748837|Experimental|Dose escalation cohort of ERY974|Dose escalation (DE) will proceed with the dose level increment and the dose cohort size being guided by a safety evaluations during and at the end of each cohort. DE initially utilizes an accelerated titration design (ATD) and once the first dose limiting toxicity (DLT) is observed, DE will continue using a modified continual reassessment method (mCRM) until MTD.
89113129|NCT02748837|Experimental|Cohort expansion in gastric cancer|Patients with GPC3 positive advanced gastric cancer or gastroesophageal junction cancer will receive ERY974 at recommended dose until disease progression.
89113130|NCT02748837|Experimental|Cohort expansion in esophageal carcinoma|Patients with GPC3 positive advanced squamous cell esophageal carcinoma will receive ERY974 at recommended dose until disease progression.
89113131|NCT02748837|Experimental|Cohort expansion in other solid tumors|Patients with other GPC3 positive advanced solid tumors will receive ERY974 at recommended dose until disease progression
89113132|NCT02695485|Other|sensate flap|the donor nerve harvested with the flap
89113133|NCT02748681|Active Comparator|Telemedicine Group|Patient group with a telemedicine monitoring system
89113134|NCT02748681|Active Comparator|Standard Group|Patient Group without a telemedicine monitoring
89113135|NCT04158765||Infertile men|Men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
89113136|NCT04218669|Active Comparator|T-tube drainage|The T-tube was placed for biliary drainage
89113137|NCT04218669|Experimental|Roux-en-Y Hepaticojejunostomy|biliary-enteric anastomosis was performed
89113138|NCT04452045|Experimental|SweetDreams|Access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
89113139|NCT04452045|No Intervention|Waitlist Control|Wait list condition with future access to a mobile and computer accessible adaptation of existing evidence based sleep interventions.
89113140|NCT04138875|Active Comparator|Low Risk|Low risk patients (those in complete response (CR) after induction) will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 of 21 day cycles, for 4 cycles.
89113141|NCT04138875|Active Comparator|High Risk|High risk patients (those who do not achieve a CR after induction), will receive rituximab (375mg/m2) and brentuximab vedotin (1.8mg/m2) on day 1 and bendamustine (90mg/m2) on day 1-2 of 21 day cycles for up to 8 cycles. Interim imaging will be performed in cycle 4 (days 14-21) and patients achieving CR will receive additional 2 cycles for a total of 6, patients achieving partial response (PR) will receive 4 additional cycles.
89113142|NCT04124445|Active Comparator|Pulsed Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine with Maximum allowable temperature 50° rotation: 90.; Pulse rate: 3 Hz; pulse duration: 50 ms; 3 minutes
89113143|NCT04124445|Active Comparator|Continuous Radiofrequency Ablation|Radiofrequency ablation of sensory nerves at minimum 3 levels of cervical spine, burn will be made at 80° for 60 seconds.
89113144|NCT02748603||Patient with non ST Elevation - Acute Coronary Syndrome|
89113145|NCT02748603||Patient with stable Coronary Artery Disease (CAD)|
89113146|NCT04218747|Experimental|VA 365 Demonstration Benefits|Children in treatment schools received: (1) three meals during the school day and food packages for weekends and school breaks; (2) $60 monthly Electronic Benefit Transfer (EBT) benefits during summer months if they were eligible for FRP meals; and (3) nutrition education for their parents.
89113147|NCT04218747|No Intervention|Control Group|"Schools in the control group operated under business as usual."
89113148|NCT02748447|Experimental|A-FiO2|24 hours in automated FiO2 adjustment to maintain SpO2 within a target range
89113149|NCT02748447|No Intervention|M-FiO2|24 hours in manual adjustment of FiO2 to maintain SpO2 within a target range
89113150|NCT02748135|Experimental|TB-403 20mg/kg|
89113151|NCT02748135|Experimental|TB-403 50mg/kg|
89113152|NCT02748135|Experimental|TB-403 100mg/kg|
89113153|NCT02748135|Experimental|TB-403 175mg/kg|
89113154|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA330)|Combination of hemodialysis and hemoperfusion (HA330) therapy All subjects in the study phase will receive hemodialysis plus hemoperfusion(HA330) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
89113155|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA130)|Combination of hemodialysis and hemoperfusion (HA130) treatment All subjects in the study phase will receive hemodialysis and hemoperfusion(HA130) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
89113156|NCT02747979|Active Comparator|hemodialysis only|hemodialysis only All subjects in the study phase will receive regular hemodialysis treatment three times per week.
89113157|NCT02695563|No Intervention|controls|The patients will be not treated with vaginal lactoferrin
89113158|NCT02695563|Active Comparator|Lactoferrin|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
89113159|NCT04218045|Active Comparator|Laparoscopic sleeve gastrectomy group|The group of morbidly obese patients undergoing laparoscopic sleeve gastrectomy
89113160|NCT04218045|Experimental|SASI bypass group|The group of morbidly obese patients undergoing laparoscopic single- anastomosis sleeve ileal bypass (the new procedure being evaluated)
89113161|NCT03838965|Experimental|biobeat sensor|
89113162|NCT02747901|Experimental|Kinesiotaping Group|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
89113163|NCT02747901|Active Comparator|Cold Therapy Group|Cold Therapy group received cold pack immediately after operation and following postoperative days.
89113164|NCT02747901|No Intervention|Control Group|Control group have no intervention.
89113165|NCT02747823|Experimental|CBT124|CBT124, single dose of 1 mg/kg, IV infusion
89113166|NCT02747823|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 1 mg/kg, IV infusion
89113167|NCT02747823|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 1 mg/kg, IV infusion
89113168|NCT02747745|No Intervention|Control Group|Group receive no intervention
89113169|NCT02747745|Experimental|Interventional Group|Four risk areas reflecting the great needs of FCGs of PWDs: depressive symptoms, burden, distress to problematic behaviors of PWDs and healthy behaviors.
89113170|NCT02747667||Eye with late IOL complication|Alle patients with IOL complication (subgroup: in-the-bag dislocation; out-of-the-bag dislocation; haptic dislocation)
89113171|NCT02747667||Eyes with no late IOl complication|
89113172|NCT04217889||Adherent patient|This group is composed of adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
89113173|NCT04217889||Not-adherent patient|This group is composed of not-adherent patients to the chest physiotherapy based on the number of chest physiotherapy session per week.
89113174|NCT02747511|Active Comparator|Haloperidol|
89113175|NCT02747511|Placebo Comparator|Placebo|
89113176|NCT04217733|Active Comparator|Mebeverine|Mebeverine 3 times daily for 3 months
89113177|NCT04217733|Experimental|Ethosuximide|Ethosuxemide 3 times daily for 3 months
89113178|NCT04217733|Experimental|Pentoxyifylline|pentoxyifylline 2 times daily for 3 months
89113179|NCT04216875||single primary care practices intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility following the best practice procedure of the diabetes score.
89113180|NCT04216875||primary care group practice intervention|Independent primary care practices with more than one medical doctor working in their responsibility following the best practice procedure of the diabetes score.
89113181|NCT04216875||single primary care practices no intervention|Independent primary care practices with one single medical doctor in the practice, usually ther owner of the practice working in his responsibility without the intervention (not using Diabetes score)
89113182|NCT04216875||primary care group practice no intervention|Independent primary care practices with more than one medical doctor working in their responsibility without the intervention (not using Diabetes score).
89113183|NCT03363087|Experimental|Mapping (Rhythmia) and ablation (IntellaNav MiFi)|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation
89113184|NCT03363087|Experimental|Mapping (Rhythmia) and ablation (StablePoint)|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation Contact force measurements
89113185|NCT03363087|Experimental|Mapping (Precision)|Automated high density left atrial mapping in AF and SR in different bipole orientations
89290585|NCT01319422|Experimental|Pomalidomide 4 mg/d on 21 days/28 day cycle|
89290586|NCT01224054||Bypass gastric|The mixed surgery which combine the gastric reduction with some degree of disabsorption
89113186|NCT03889353|Experimental|BCI sessions|up to 3 test sessions (Day-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (Day 1-Day 5 and Day 8-Day 12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
89113187|NCT03961737|Experimental|prostatic explants|A first series of biopsies will be performed during the procedure to place the gold grains prior to radiotherapy. Explants will be performed from these biopsies. Half of these explants will be irradiated with a research irradiator at a dose of 2 Gy then placed for 24 hours in an appropriate culture medium. The other half will be directly cultured for 24 hours. After 24 hours of incubation, half of the irradiated explants and half of the explants will be used to study the transcriptome. The tissues will be stored in RNAlater solution and then frozen at -80°C. The remaining half explants will be used for immunohistochemical analysis. Two years after the end of radiotherapy, a new series of biopsies will be performed for research, in order to verify histologically the effectiveness of radiotherapy.
89113188|NCT02747199|Active Comparator|Coronary artery implanted with SYNERGY stent|One of the blocked coronary artery of a patient will received SYNERGY stent
89113189|NCT02747199|Active Comparator|Coronary artery implanted with ABSORB scaffold|Another blocked coronary artery of the same patient will received ABSORB scaffold
89113190|NCT02746887||Preterm cohort|Preterm infants with a gestational age less than 32 weeks or birth weight less than 1,500 g
89113191|NCT02746887||Term control cohort|Healthy term infants
89113192|NCT02414607|Experimental|Elderberry Juice|Participants will drink 5ml of elderberry juice, diluted in 8oz of water, 3 times per day for three months.
89113193|NCT02414607|Placebo Comparator|Placebo|Participants will drink 5ml of colored water, diluted in 8oz of water, 3 times per day for three months.
89113194|NCT02746731|Experimental|Prehabilitation|'Cardiorespiratory and resistance training.
89113195|NCT02746731|Active Comparator|Reference|Usual care.
89113196|NCT04403139|Other|Cohort 1: 30-40 year of age|
89113197|NCT04403139|Other|Cohort 2: 70 years of age or older|
89113198|NCT02746653|Experimental|Use of TroClose1200(TM) for access port and closure device|TroClose in 1 port
89113199|NCT02746497|Active Comparator|Group E (early intervention)|One weekly treatment with acupuncture in five consecutive weeks. In trial week 1-5 Group E will receive treatment and Group L will act as control group.
89113200|NCT02746497|Active Comparator|Group L (late intervention)|After trial week five the Groups must cross-over. Group L will then receive treatment for five weeks (trial week 6-11) and Group E will act as follow up group.
89113201|NCT02746419|Experimental|Experimental|Subjects will receive renal denervation.
89113202|NCT02746419|Sham Comparator|Control|Subjects will receive all procedures as experimental group but renal denervation system will not be turned on.
89113203|NCT00636285|Placebo Comparator|1|Placebo
89113204|NCT00636285|Experimental|2|BSYX-A110, Dosed intravenously, 3mg/kg
89113205|NCT00636285|Experimental|3|BSYX-A110, Dosed intravenously, 10mg/kg
89113206|NCT02746185|Active Comparator|Low-molecular-weight heparin|dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months
89113207|NCT02746185|Experimental|Rivaroxaban|rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks
89113208|NCT04216485|Experimental|Lifestyle intervention|Intervention group: Intensive lifestyle intervention will be initiated from the first trimester (8-12wks) to delivery, with follow up every 2-4 weeks. Participants in the intervention group will be provided with an individualized dietary protocol with not less than 1500 calories per day in the first trimester and not less than 1800 calories per day after 13 weeks of gestation. Guidance on regular exercise is reinforced at the first and each follow up visit.
89113209|NCT04216485|Active Comparator|Standard Care|Standard care group: Participants will receive a 1.5-hour group session in which standard prenatal intervention on diet, nutrition and physical activity and recommendation for gestational weight gain are reviewed by a registered dietitian. Thereafter, participants will receive their regularly scheduled follow up visits without additional lifestyle guidance.
89113210|NCT05630391|Experimental|Intervention|In the process of teaching personnel protective equipment (PPE) use with the scenario-based high-fidelity simulation mannikin, a simulation application was made with 26 students. The simulation scenario was implemented with 13 groups consisting of 3 students each playing different roles (nurse, head nurse, patient relative). Throughout the scenario, the students who played the role of the nurse and the head nurse simulated the PPE wearing-removal practice in a way to cover all steps of the process (preparation, implementation, and evaluation). During the implementation of the scenario, the student playing the role of the patient's relative provided guiding clues to the nurse when needed. Debriefing was started right after the simulation. Frequency of administration the implementation of each group is once and the debriefing stage where the learning process was reinforced and lasted 30 minutes.
89113211|NCT05630391|Other|Control|The 26 students who constituted the control group performed the personnel protective equipment (PPE) wearing-removal practice once under the supervision of the researcher at the Fundamentals of Nursing skills laboratory. Frequency of administration the implementation of each group is once. The students applied experiential learning principles through active experience and reflective observation.
89113212|NCT05630157|Experimental|Unplugged plus gambling component|The experimental arm will receive the Unplugged curriculum plus a gambling component
89113213|NCT05630157|No Intervention|Usual curriculum|The Usual curriculum arm won't receive any specific prevention program
89113214|NCT02745951|Experimental|Heliox|Cardioplegia enriched with a 70:30 (Helium:Oxygen) Heliox mixture while the patient is on cardiopulmonary bypass
89113215|NCT02745951|Active Comparator|Standard of care|Cardioplegia enriched with a Nitrogen and Oxygen mixture while the patient is on cardiopulmonary bypass
89113216|NCT02742051|Experimental|Everolimus+Letrozole|everolimus 10mg/d,po + letrozole 2.5mg/d,po * 18 weeks
89113217|NCT02742051|Active Comparator|Fluorouracil+epirubicin+cyclophosphamide|Fluorouracil 600mg/m2,iv,d1 + epirubicin 90mg/m2,iv,d1 + cyclophosphamide 600mg/m2,iv,d1 * 6 cycles (every 21 days per cycle)
89113218|NCT02741973|Experimental|Yoga|Students have 10 weeks yoga instead of school sport.
89113219|NCT02741973|Active Comparator|School sport|Students have 10 weeks regular school sport.
89113220|NCT02741895||Postoperative patients|The target populations for the study are patients undergoing robotic cystectomy, open colectomy, abdominal hysterectomy, esophagectomy, lung lobectomy, gastric bypass, and hip replacement at Cedars-Sinai Medical Center.
89113221|NCT02741817|Experimental|Aspirin 20mg|Supplied with sachets of 100mg soluble aspirin and training, instructions and equipment will be provided to prepare 20 mg dose twice daily x14 then aspirin 75mg once daily x14
89113222|NCT02741817|Experimental|Aspirin 75mg|This is the standard dose of aspirin the participant will already be taking. The study will require the participants to switch to soluble aspirin for two weeks to enable accurate comparison with the other dose and to take their aspirin dose in the morning. Participants will be provided with a supply of soluble aspirin, along with training, instructions and equipment to help prepare it. They should not take their usual aspirin tablets whilst receiving the study medication, but should continue all other usual medications.
89113223|NCT02745873|Experimental|Arm A|Ascorbic Acid 250 mg in tablet form was used.
89113224|NCT02745873|Experimental|Arm B|Ascorbic Acid 500 mg in tablet form was used.
89113225|NCT02745639|Experimental|VMAT-SIB + XELOX|"A VMAT-SIB technique was used. Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and Organs at risks.~The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment."
89113226|NCT02741739|Experimental|Reference Drug|REGN1033 Reference Formulation
89113227|NCT02741739|Experimental|Test Drug|REGN1033 Test Formulation
89113228|NCT02745717|Experimental|cord blood and IST group|Administration of antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days, Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml, plus one unit of at least 4/6 HLA loci matched cord blood transfusion 24 hours after last dose of ATG.
89113229|NCT02745717|Active Comparator|IST group|Antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days , Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml.
89113230|NCT02745561|Experimental|Chemoradiotherapy Arm|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy. Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
89113231|NCT02745795|Experimental|MIG: Motivational Interview Group|Group submitted to three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
89113232|NCT02745795|Sham Comparator|CIG: Conventional Intervention Group|Group submitted to three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
89113233|NCT02745483|Experimental|Separable clustered electrodes|Enrolled patients in the prospective study (RFA using separable clustered electrodes (Octopus®)) for treatment-naive HCC (n=79)
89113234|NCT02745483|No Intervention|Historical control group|Patients who received RFA according to routine protocol in our center (multiple internally-cooled electrodes) for treatment-naive HCC from Jan 2011 to July 2013 in our institution (n=74) .
89113235|NCT02741583|Experimental|altitude rehabilitation program|3 weeks rehabilitation program at high altitude (3200m)
89113236|NCT02741583|Active Comparator|rehabilitation program|3 weeks rehabilitation program at low altitude (760m)
89113237|NCT02741661||Normal coronary arteries|Patients in whom coronary arteriography has demonstrated no significant tortuosity.
89113238|NCT02741661||Tortuous coronary arteries|Patients in whom coronary arteriography has demonstrated tortuous coronary arteries defined as >1 major bend of >45 degrees in a major coronary artery
89113239|NCT02695251|Experimental|Low AGE meal|Renal functional parameters are measured at baseline and after a low AGE (eggs) meal
89113240|NCT02695251|Experimental|High AGE meal|Renal functional parameters are measured at baseline and after a high (mixed nuggets) AGE (eggs) meal
89113241|NCT04347603|Experimental|General Anesthesia|- General anesthesia : After pre-anesthetic preparation (25-50 mg Hydroxizine orally), the anesthesia induction will be performed by IV perfusion of Propofol 1 to 2 mg/kg, Sufentanyl for analgesia 0,2 to 0,4 µg/kg, curarisation with Atracurium 0,15 mg/kg. The anaethesia depth will be monitored by the bispectral index (BIS). Orotracheal intubation will be performed, the patient will be ventilated to controlled volume with 6-8 mL/kg of current volume based on expected body weight (PBW). The respiratory rate will be adjusted to have an ETCO2 between 35 and 45 mmHg. The anesthesia will be maintained through the Sevorane at 0.7-1 MAC, the average blood pressure will be controlled through a pressure cuff with a target between 60 and 80 mmHg. The Fio2 will be adapted to obtain saturation > 94% with 5 cmH2O PEEP.
89113242|NCT04347603|Active Comparator|Local Anesthesia|Local anesthesia at the device introduction site will be obtained by infiltration of Naropein.
89113243|NCT02745015|Experimental|treatment|immediate non-surgical periodontal treatment
89113244|NCT02745015|Other|control|non-surgical periodontal treatment scheduled for the following 3-monthly visit
89113245|NCT02741427|Placebo Comparator|G1 (group 1) - Conventional toothpaste|G1 used a conventional toothpaste in daily oral regimen
89113246|NCT02741427|Experimental|G2 (group 2) - Whitening toothpaste|G2 used a whitening toothpaste containing blue pigment in daily oral regimen
89113247|NCT02741427|Active Comparator|G3 (group 3) - 10 % Carbamide peroxide|G3 made an at-home tooth bleaching with 10 % Carbamide peroxide
89113248|NCT02745093|Experimental|64-84 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-84 days will receive 200 µg mifepristone followed by misoprostol 24-48 hours later.
89113249|NCT02745093|No Intervention|57-63 days gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range: 200 µg mifepristone administered orally in the clinic on Day 1 then 800 μg misoprostol administered sublingually 24-48 hours later at home with a subsequent dose of 400 μg misoprostol sublingually 6 hours later if she has not expelled the pregnancy).
89113250|NCT02741505|Experimental|Sleep Deprivation followed by Normal Sleep|Subjects will be sleep deprived at the sleep laboratory.
89113251|NCT02745171|No Intervention|Control group|This group will be evaluated after three months there will be a reassessment, in this case the participating subjects do not perform any kind of therapy.
89113252|NCT02745171|Experimental|Experimental group|There will be an initial evaluation, after a month of physical therapy at the end of the protocol, and twice more after the protocol, both interval a month.
89113253|NCT02745249|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention which focus on improving dietary practices, specifically improved diversity of foods and energy intakes of pregnant women, and improved intake of calcium and iron/folic acid (IFA) supplements.
89113254|NCT02745249|No Intervention|A&T-non intensive|A&T-non intensive aim only receive MNCH services
89113255|NCT04326075|Experimental|Early CPAP treatment|Early treatment with CPAP in addition to current clinical practice
89113256|NCT04326075|No Intervention|Control|Current clinical practice, which currently does not involve the use of CPAP.
89113257|NCT03797391|Experimental|Dose Escalation-Part 1, Expansion-Part 2|"In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks)."
89113258|NCT02740881|Experimental|Training Support System|Participants receive training in Contingency Management and immediately receive the full training support system and quality assurance feedback for 15 months while they provide the treatment.
89113259|NCT02740881|Active Comparator|CM-CAT then TSS|Participants are trained in Contingency Management and use the treatment without training support and quality assurance feedback for 9 months. After 9 months they continue using Contingency Management but now receive the full training support system and quality assurance feedback for 6 months.
89113260|NCT00839254|Experimental|10Pn3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
89113261|NCT00839254|Experimental|10Pn2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
89113262|NCT00839254|Active Comparator|Ctrl3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
89113263|NCT00839254|Active Comparator|Ctrl2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
89113264|NCT00839254|Experimental|10Pn7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
89113265|NCT00839254|Active Comparator|Ctrl7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
89113266|NCT00839254|Active Comparator|10Pn12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
89113267|NCT00839254|Experimental|Ctrl12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
89113268|NCT02740959|Experimental|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
89113269|NCT02740959|Experimental|Astragalus Polysaccharides 250 mg|PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
89113270|NCT02745405|Experimental|Fat Suit Condition|Participants are randomly assigned to wear a fat suit and then walk across campus.
89113271|NCT02745405|Other|Control Condition|Participants are randomly assigned to wear the same clothing that is on the fat suit but in their own size and then walk across campus.
89113272|NCT02741115|Experimental|Drug|Udenafil. One tablet twice daily for 26 weeks
89113273|NCT02741115|Experimental|Placebo|Placebo. One tablet twice daily for 26 weeks
89113274|NCT02740803|Experimental|NaF - R|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
89113275|NCT02740803|Experimental|NaF - NR|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
89113276|NCT02740803|Experimental|NaMFP- R|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
89113277|NCT02740803|Experimental|NaMFP- NR|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
89113278|NCT02740803|Experimental|SnF + NaF - R|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
89113279|NCT02740803|Experimental|SnF + NaF - NR|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
89113280|NCT02740803|Experimental|NaF + NaMFP - R|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
89290587|NCT01224054||Biliopancreatic diversion|The mal-absorptive surgery which reduce the intestinal absorption of food
89231415|NCT06331039|Experimental|PFMT+Balance Group|PFMT+Balance group will be included in the program that includes balance exercises and pelvic floor muscle training. Balance exercises combined with pelvic floor muscle training will be performed 3 days a week (with a 1-day rest gap between 2 sessions) for 45 minutes per day. Balance exercises will include 12 different exercises (squatting, walking backwards, turning around, walking sideways, tandem stance, tandem walking, standing on one leg, walking on the heel, walking on the toes, walking backwards, sitting down, going down stairs). starting from a supported position and progressing to exercises performed without support.
89231416|NCT06331039|Experimental|PFMT Group|PFMT group will be included in a program that includes pelvic floor muscle training, 3 days a week (with 1 day of rest between 2 sessions) and 45 minutes per day.
89231417|NCT06330246|Experimental|colonization with Oxalobacter formigenes|Colonization with a live preparation of Oxalobacter formigenes, strain OxCC13.
89231418|NCT06329960|Experimental|Experimental group|Ultrasound-guided dorsal scapular nerve injection combined with needle release of major and minor rhomboideus
89231419|NCT06329830|Experimental|177Lu-PSMA-617 in Combination with Niraparib/Abiraterone Acetate plus Prednisone|177Lu-PSMA-617 will be administered per standard of care at 7.4 gigabecquerel (GBq) (200 mCi) via intravenous (IV) infusion once every cycle (6 weeks) for 6 cycles. Niraparib/Abiraterone Acetate (Nira/AA) will be taken orally by the participant daily until disease progression or unacceptable toxicity. The starting dose level is 150 mg/1000 mg Nira/AA. Other dose levels include 200 mg/1000 mg, 100 mg/1000 mg, or 50 mg/500 mg Nira/AA once daily. Prednisone (5 mg) will be taken orally by the participant twice daily each day that Nira/AA is taken.
89231420|NCT06329791|Experimental|AZR-MD-001|AZR-MD-001 sterile ophthalmic ointment 0.5% to be administered twice weekly at bedtime.
89231421|NCT06329791|Placebo Comparator|Vehicle|AZR-MD-001 Vehicle to be administered twice weekly at bedtime.
89231423|NCT06329440|Active Comparator|Costoclavicular block|Patients who will receive costoclavicular brachial plexus block for hand surgery. Costoclavicular block is performed via depositing local anesthetic in the costoclavicular space which is placed in the posterior of middle part of the clavicle. The diaphragma thickness will be evaluated after the surgery in postanesthesia care unit.
89231424|NCT06329440|Active Comparator|Supraclavicular block|Patients who will receive supraclavicular brachial plexus block for hand surgery. Supraclavicular is performed via depositing local anesthetic using corner pocket technique which is described as injecting the drugs to the inferolateral side of axillary artery above the 1st rib. The diaphragma thickness will be evaluated after the surgery in postanesthesia care unit.
89231425|NCT06329401|Experimental|AP01 High Dose BID|Pirfenidone Solution for Inhalation
89231426|NCT06329401|Experimental|AP01 Low Dose BID|Pirfenidone Solution for Inhalation
89231427|NCT06329401|Placebo Comparator|Placebo BID|Placebo solution for inhalation
89231428|NCT06327503||T2DM patients|patients with diagnosed controlled Type 2 Diabetes Mellitus with or without systemic complications
89231429|NCT06327503||non-T2DM patients|age and general health matched control group without Type 2 Diabetes Mellitus
89231430|NCT06327412|Active Comparator|Hospital Exercise Group|According to the Cardiopulmonary Exercise test (CPET), the patients should exercise on the treadmill (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) for 40 minutes (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) at an exercise intensity of 50-60% of the individually recorded VO2 max (the maximum amount of oxygen that an individual can utilize during intense or maximal exercise) level in the patients. Aerobic exercise therapy will be organized to include treadmill.
89231431|NCT06327412|Placebo Comparator|Home Exercise Group|Patients will be asked to walk 40 minutes a day, 5 days a week, for 4 weeks. Training will be given for the first session in the hospital to ensure that the patient's walking pace is between 12-13 RPE (The Borg Rating of Perceived Exertion) according to the Modified Borg scale.
89231432|NCT06327308||Patient with cirrhosis requiring liver transplantation|
89231433|NCT06327165||pregnant women|Women undergoing cesarean section under spinal anesthesia with ANI monitor applied
89231434|NCT06326684|Placebo Comparator|Placebo|Subjects will be treated with an oral placebo.
88816294|NCT04441749||nCLE Analysis|Needle based confocal laser endomicroscopy (nCLE) employs a small fiber which can be passed through a biopsy needle to enable real time microscopic imaging of cells. With resolution of 3.5 microns it is possible to identify key features consistent with malignancy and pulmonary fibrosis
88816295|NCT01650558|Active Comparator|Standard of Care Prophylaxis (TS)|Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
89113281|NCT02740803|Experimental|NaF + NaMFP - NR|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
89113282|NCT02740803|Experimental|AmF - R|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes followed by rinsing with distilled water.
89113283|NCT02740803|Experimental|AmF - NR|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes not followed by rinsing with distilled water.
89113284|NCT02740803|Experimental|0 Fluoride - R|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes followed by rinsing with distilled water.
89113285|NCT02740803|Experimental|0 Fluoride - NR|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes not followed by rinsing with distilled water.
89113286|NCT02695017|Experimental|Iso inertial|Subjects should do 12 exercise repetition with Iso inertial machine
89113287|NCT02695017|Experimental|Conventional machine|Subjects should do 12 exercise repetition with conventional machine
89113288|NCT02744859|Experimental|Calorie Label|"Labels will read [lower calorie bound] - [upper calorie bound] calories per container. 2,000 calories a day is used for general nutrition advice but calorie needs vary."
89113289|NCT02744859|Experimental|Warning Label|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay."
89113290|NCT02744859|Experimental|Warning Label with Graphics|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay. These labels will also have graphic depictions of each health condition above the corresponding text."
89113291|NCT02744859|No Intervention|No label|We will also have a condition where no labels are presented-- business as usual.
89113292|NCT02740647|Experimental|Intervention group|Intervention group will be getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery.
89113293|NCT02740647|Placebo Comparator|Control group|the Control group will be getting intra-venous Placebo (0.9% 50 ml of sodium chloride) for 5 days.
89113294|NCT02744781|Experimental|Lumbar disc degeneration; LDD|The LDD group included subjects with at least 1 abnormal disc from L1-2 to L5-S1 of grade III, IV, or V. The non-LDD group included subjects with 5 normal discs of grade I or II. For further assessment, the most damaged disc of the 5 constituted the highest grade of LDD.
89113295|NCT02740725|Active Comparator|Recommendation of Patching|Patients will receive two hours of patching in the case of one line difference of best corrected visual acuity(BCVA) between two eyes during one month.
89231435|NCT06326684|Experimental|Suvorexant Dose 1|Subjects will be treated with oral suvorexant dose 1.
89113296|NCT02740725|Active Comparator|Recommendation of Patching and interactive binocular treatment|Patients will receive interactive binocular treatment addition to patch therapy in the least of 4 to 5 days of a week within 20-30 minutes in each day during one month.
89113297|NCT05628909|Experimental|Silicone oil group|Patients randomized into this group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
89113298|NCT05628909|Active Comparator|Gas group 1|Patients randomized into this group were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
89113299|NCT05628909|Active Comparator|Gas group 2|Patients randomized into this group were received pars plana vitrectomy surgery with gas tamponade and without internal limiting membrane peeling.
89113300|NCT05629455|Experimental|individuals ages 14 years and older|This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
89113301|NCT05629455|Experimental|individuals aged 2 to 13 years|"This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples.~If the subject is under the age of 14, an adult lay-user will collect the sample."
89113302|NCT00586339|Experimental|HIV+/Cervarix Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm, according to a 0, 1, 6-month schedule.
89113303|NCT00586339|Active Comparator|HIV+/Aluminium Hydroxide Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of control Aluminium Hydroxide [Al(OH)3], administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
89113304|NCT00586339|Experimental|HIV-/Cervarix Group|Human immunodeficiency virus negative (HIV-) subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
89113305|NCT02740491||The study population|The study population consists of adult patients diagnosed with localized breast cancer who have completed adjuvant treatment (chemotherapy, radiotherapy) and who are cared for in the Medical Oncology department of the Nîmes University Hospital.
89113306|NCT02744547|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
89113307|NCT02744547|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
89113308|NCT03737253|Active Comparator|Follitropin alpha|Follitropin alpha (GONAL-f, Merck-Serono, Darmstadt, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
89113309|NCT03737253|Active Comparator|Menotropin|Menotropin (Menopur, Ferring GmbH, Kiel, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
89113310|NCT00812968|Experimental|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
89113311|NCT02744703|Active Comparator|self-etch adhesive|application of self-etch adhesive on cavities.
89113312|NCT02744703|Experimental|CAPE-S|CAPE before self-etch adhesive
89113313|NCT02744703|Active Comparator|total-etch adhesive|total-etch adhesive on cavities.
89113314|NCT02744703|Experimental|CAPE-T|CAPE before total-etch adhesive application
89113315|NCT02744937|Experimental|A|continuing LDA
89113316|NCT02744937|No Intervention|B|discontinuing LDA
89113317|NCT02744625|Active Comparator|Shock lower Mean Arterial Pressure (MAP)|Vasopressor-dependent treated to lower MAP (65 mmHg)
89113318|NCT02744625|Experimental|Shock higher MAP|Vasopressor-dependent treated to higher MAP (75 mmHg)
89113319|NCT02744625|No Intervention|Healthy participant awake|Healthy participant awake
89113320|NCT02744625|Experimental|Healthy participant sedated|Healthy participant Under light sedation
89113321|NCT00839098|No Intervention|Control Group|Control Group
89113322|NCT00839098|Experimental|Instruction Group|Instruction Group
89113323|NCT00839098|Experimental|Instruction and Virtual Coach Group|Instruction and Virtual Coach Group
89113324|NCT02598973|Active Comparator|Exercise|aerobic walking
89113325|NCT02598973|No Intervention|No exercise|normal activity
89113326|NCT02744469||New patients|''New tuberculosis patients'' are patients just diagnosed for tuberculosis, and who were never treated for tuberculosis or who are treated for less than 1 month. In total, 1192 new patients will be recruited.
89113327|NCT02744469||Retreatment patients|''Retreatment tuberculosis patients'' are patients just diagnosed for tuberculosis and who were previously treated for tuberculosis (for a duration of 1 month at least). This group includes: patients with treatment relapse, failure and patients who return after default. In total, 298 retreatment patients will be recruited.
89113328|NCT02610556|Experimental|TP plus IMRT|Concurrent chemotherapy: TP - Docetaxel 60mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
89113329|NCT02610556|Active Comparator|DDP plus IMRT|Concurrent chemotherapy: DDP - Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
89113330|NCT02744313||AP Naive|Group followed over 12 weeks to measure fat deposition, insulin resistance, and glucose tolerance.
89113331|NCT02740101|Experimental|oxytocin nasal spray|subjects administrating oxytocin were divided into experimental group
89113332|NCT02740101|Placebo Comparator|placebo nasal spray|subjects administrating placebo were divided into controlled group
89113333|NCT02612116|Active Comparator|pulverized ticagrelor sublingually|Pulverized ticagrelor 180 mg (Brilique) administered sublingually
89113334|NCT02612116|Active Comparator|pulverized ticagrelor orally|Pulverized ticagrelor 180 mg (Brilique) administered orally
89113335|NCT02612116|Active Comparator|Integral ticagrelor orally|Ticagrelor 180 mg (Brilique) administered orally in integral tablets
89113336|NCT02744235|Other|Patients undergoing Polysomnography|
89113337|NCT02744079|Active Comparator|Low carbohydrate diet|45 subjects will receive a very low carbohydrate diet between a positive breast biopsy and surgical tumor removal
89113338|NCT02744079|Active Comparator|Low fat diet|20 subjects will receive a lo fat diet between a positive breast biopsy and surgical tumor removal
89113339|NCT02610790||Connected bracelet|Patients with a colorectal surgery planned will be included. Fifteen days before surgery, patients will have a connected bracelet permitting to quantify the number of steps and distance achieved each day before surgery.
89113340|NCT02744157|Other|structured lifestyle program|The program consisted of an individual visit to a nurse for a health check-up and lifestyle counseling at baseline, six month and one year. The program also consisted of five group educations which included lectures on nicotine, alcohol, physical inactivity, eating habits, stress, sleeping habits and behavior changes
89113341|NCT02740023|Active Comparator|Phonak Audéo V90-13|The Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
89113342|NCT02740023|Experimental|Successor of Phonak Audéo V90-13|The successor of Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
89113343|NCT02739945|Other|Open cubital tunnel release|In situ decompression (MacKinnon and Novak 2005) is made through a 6-10 cm longitudinal incision along the course of the ulnar nerve midway between the medial epicondyle and the olecranon.
89113344|NCT02739945|Other|Endoscopic cubital tunnel release|Endoscopic release follows Hoffmann's technique (Hoffmann 2006) that demonstrated the safety and efficacy of this technique in a cadaveric model and in a clinical study.
89113345|NCT02743767|No Intervention|Before interventions|Only observational activity for this arm, to record the frequency and triggering factors of airway complications during general anaesthesia.
89113346|NCT02743767|Experimental|After interventions|After introducing five different treating adaptations in airway management we want to record the frequency of airway complications during general anaesthesia.
89113347|NCT05629299|Other|Monkey Pox infection|Men will give semen, saliva, skin, urine and blood specimens
89113348|NCT02610400|Experimental|RACD without RAVC|In this arm, subjects will receive RACD without the addition of RAVC.
89113349|NCT02610400|Experimental|RACD+RAVC|"In this arm, subjects will receive both:~(i) reactive case detection (RACD) and (ii) additional reactive vector control (RAVC)"
89113350|NCT02610400|Experimental|rfMDA without RAVC|In this arm, subjects will receive reactive focal mass drug administration (rfMDA) without the addition of RAVC.
89113351|NCT02610400|Experimental|rfMDA+RAVC|"In this arm, subjects will receive both:~(i) reactive focal mass drug administration (rfMDA) and (ii) RAVC."
89113352|NCT02743299|Experimental|CPR simulation|CPR simulation with and without ventilator
89113353|NCT00813592|Experimental|All participants|
89113354|NCT02743143|Experimental|Exercise therapy|High aerobic intensity training and maximal strength training 2 times per week in 1 year at the Hospital's Exercise Training Clinic. Patients receive comprehensive support from Trondheim municipal administration to facilitate adherence.
89113355|NCT02743143|Active Comparator|Follow-up care as usual|The usual care (UC) group will receive the usual physical activity offered by the primary health care system. UC includes the traditional physical activity advice from the Health Directorate. The UC group are invited to supervised exercise at the exercise training Clinic after 1 year.
89113356|NCT02739633|Experimental|Genexol-PM + Gemcitabine|Genexol-PM125 mg/m2 will be administered in combination with gemcitabine 1,000 mg/m2 weekly for 3 weeks followed by one week of rest. Each cycle is 28 days.
89113357|NCT02739477|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
89113358|NCT02739399|Other|Patient receiving phenylephrine 2ug/kg|phenylephrine 2ug/kg in case of hypotension
89113359|NCT02742831|Experimental|Intervention|"The intervention group will receive a one-on-one in-person intervention of 6 sessions, each lasting approximately 60 minutes. The intervention is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. The overview of the 6 sessions is as follows:~Behavioral chain analysis of episodes where parent felt stressed and episode where things went well. Identification of sources of interpersonal support.~Stress relief. Development of a detailed crisis plan.~Problem solving techniques.~Emotional regulation exercises.~Positive parenting, review of parenting challenges.~Reflection, repeat behavioral chain analysis. Update crisis plan."
89113360|NCT02742831|Active Comparator|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
89113361|NCT02694861||Registry Group|Patients previously enrolled in the ANGINA RELIEF Registry who are eligible for a 1-year, prospective follow-up (date of ANGINA RELIEF Registry TMR procedure performed within 12-18 month follow-up window).
89113362|NCT02694861||Prospective Group|A group of up to 100 new, prospectively enrolled patients from active centers that receive TMR with the CardioGenesis Laser System and complete a 30-day and 1-year follow-up.
89113363|NCT02743065||Device: HepaSphere Microspheres|HepaSphere Microsphere
89113364|NCT06179433|Experimental|root canal treatment|Two-visit root canal treatment will be performed.
89113365|NCT06179433|Active Comparator|REP with I-PRF|The first appointment will be performed similar to the conventional RCT group. in the second appointment, i-PRF will be prepared by collecting venous blood and centrifugate at 700rpm for 3 minutes. i-PRF will be injected into canal followed by a bioceramic material.
89231436|NCT06326684|Experimental|Suvorexant Dose 2|Subjects will be treated with oral suvorexant dose 2.
89231437|NCT06326502|Experimental|ETN101|ETN101
89231438|NCT06326411|Experimental|Part A Dose Escalation and Part B Dose Expansion|"Part A will evaluate the safety of NST-628 with advanced solid tumors and determine the recommended dose for expansion of NST-628.~Part B will evaluate the objective tumor response rate in subjects with advanced solid tumors harboring specified genetic alterations receiving NST-628 and evaluate the safety of NST-628 in subjects with advanced solid tumors in cohorts defined below:~i. Melanoma Cohorts~Activating NRAS mutations~Select BRAF alterations~ii. Non-Melanoma Cohorts:~Solid tumors with NRAS activating mutations~Solid tumors with KRAS activating mutations~Solid tumors with select BRAF alterations~Glioma with BRAF alterations"
89231439|NCT06326346|Experimental|Oral Paclitaxel (Liporaxel)|Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)
89231440|NCT06326177||Competitive Swimmer Group|Spine posture, spine movement, scapular dyskinesia, ısometric and eccentric shoulder strength and core muscle endurance will be assessed.
89231441|NCT06326177||Recreational Swimmer Group|Spine posture, spine movement, scapular dyskinesia, ısometric and eccentric shoulder strength and core muscle endurance will be assessed.
89231442|NCT06326008|Experimental|Arm-1|Participants receive donor-derived CD19 CAR therapy bridged Allo-HSCT and sequential donor-derived CD22 CAR therapy
89231443|NCT06325930|Experimental|single dose of [14C]-HU6|
89231448|NCT06324929|Other|Aim 1 Survey|We will enroll up to 300 Native women ages 18-44 to complete a 35-minute survey to characterize demographics, parity, literacy, AEP risk, drinking levels, knowledge of FASD, location, Tribal affiliation, cultural preferences for tailoring, preferred digital platforms, methods of access to mobile devices/Internet, and interest in a digital women's health study about alcohol and birth control
89231449|NCT06324851|Experimental|Drospirenone/Estetrol|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Drospirenone/Estetrol at any time of the menstrual cycle
89231450|NCT06324851|Experimental|Nomegestrol Acetate/Estradiol|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol at any time of the menstrual cycle
89231451|NCT06324851|Experimental|Ethinylestradiol/Dienogest|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
89231452|NCT06324006|Experimental|LIB-01|LIB-01 oral suspension
89231453|NCT06324006|Placebo Comparator|Placebo|Placebo oral suspension
89231454|NCT06323265||Experimental|
89231455|NCT06321185|Active Comparator|Subcostal TAP block|Subcostal TAP block will be applied bilaterally with 20 ml 0.25% bupivacaine for each side.
89231456|NCT06321185|Active Comparator|Port site local anesthetic infiltration|A total solution of 20 ml 0.25% bupivacaine will be infiltrated into the port sites before port placements.
89231457|NCT06321185|Other|Standard multimodal IV analgesia|There will not be an intervention or local anesthetic administration.
88816296|NCT01650558|Experimental|Chloroquine (CQ) prophylaxis|Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
88816297|NCT01650558|No Intervention|Discontinuation of standard of care|Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.
89113366|NCT06179433|Active Comparator|REP with blood clot|The first appointment will be performed similar to the conventional RCT group. In the second appointment, after anesthetizing with 3% mepivacine, the canals will be re-entered and irrigated well with 17% EDTA. Bleeding will be induced by inserting sterile #25 K-file into the 2-3 mm beyond the apical foramen into periapical tissues.
89113367|NCT06179342||Cardiopulmonary healthy|Patients in whom there is no evidence of cardiopulmonary dysfunction in the course of diagnostics
89113368|NCT06179342||Idiopathic pulmonary fibrosis|idiopathic pulmonary fibrosis (IPF), confirmed according to the guidelines
89113369|NCT06179342||Chronic obstructive pulmonary disease|Chronic obstructive pulmonary disease (COPD) with/without emphysema
89113370|NCT06179342||Asthma bronchiale|
89113371|NCT06179329|Other|Radial - Anterolateral / Saphenous - RCA|"Radial artery graft for the anterolateral wall, and no-touch saphenous vein graft for the right coronary artery territory"
89113372|NCT06179329|Other|Radial - RCA / Saphenous - Anterolateral|"Radial artery graft for the territory of the right coronary artery and no-touch saphenous vein for the anterolateral wall."
89113373|NCT06179316||preoperative patients|
89113374|NCT06179316||Patients in the 3rd postoperative month|
89113375|NCT06179316||Patients in the 6th month postoperatively|
89113376|NCT06179277|Experimental|Treatment/experimental group|Patients undergoing surgical crown lengthening of a single site with application of PrefGel® + Emdogain®
89113377|NCT06179277|Placebo Comparator|Control group|Patients undergoing surgical crown lengthening of a single site with application of PrefGel® only
89113378|NCT06179199|Experimental|Active tDCS stimulation|
89113379|NCT06179199|Placebo Comparator|Placebo tDCS stimulation|
89113380|NCT06179173|Experimental|HIIT-RCE|All participants will receive conventional physiotherapy for half an hour thrice weekly for six weeks. Conventional physiotherapy will be followed by a 15 min rest period, then the HIIT on a semi-recumbent cycle SOLE R92 (HIIT-RCE) will be performed.Each HIIT-RCE session will be preceded by 3-min of unloaded cycling as a warm-up and ended with 3-min of stretching. The HIIT-RCE procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload for weeks 1-2 (4 repetitions for 20 min) and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (6 repetitions). The training intensity will progress similarly by 5% peak work rate two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5. The cycle frequency will be at least 50 rpm.
89113381|NCT06179173|Active Comparator|Conventional physiotherapy|The group will receive conventional physiotherapy that will consist primarily of passive movement, stretching, balance training, strengthening, and lower intensity overground walking for 30 minutes. This will be followed by a 15-minute rest period. Then an unloaded cycling session on a semi-recumbent cycle ergometer with preferred cadence until to get equal energy expenditure per session between groups by case-matching.
89113382|NCT06179147|Experimental|cervical traction group (intervention group)|Immediately after the placenta was expelled, clamping with collum overpens and controlled traction visible through the vaginal introitus were applied to the women in the intervention group of the study. Traction was applied for 90 seconds.
89113383|NCT06179147|No Intervention|control group|No procedure was applied to the women in the control group after the placenta was expelled.
89113384|NCT06179134|Experimental|cognitive rehabilitation group|will be treated by GMT for 5 weeks (two hour sessions per week, one day of rest in between).
89113385|NCT06179134|No Intervention|wait-list control group|will be given a list cognitive compensatory strategies that they can do on their own to improve their memory.
89113386|NCT06179121||Phase 1 Cohort (Validation of HLA- DQ2/8 typing)|Children (1-18 years old) coming for consultation at the LUMC for (suspicion of) CD
89113387|NCT06179121||Phase 2 Cohort (Implementation of HLA-DQ2/8 typing on the Preventive YHCCs)|Children (12 months to 4 years old), at least with one of the 10 CD-related symptoms, not diagnosed with CD, and not on a GFD,
89113388|NCT06179095|Experimental|Virtual reality group|Virtual reality to be applied to women undergoing intrauterine device insertion.
89113389|NCT06179095|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practive on their own to reduce anxiety during intrauterine device insertion.
89113390|NCT06179056||study group|
89113391|NCT06179017|Experimental|Intervention Group:Endovascular treatment|Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
89231458|NCT06320938|Active Comparator|Neuroscience-Based Pain Education Combined with Home Exercise Program|Patients in this group will receive Neuroscience-Based Pain Education (NPE) treatment in addition to the home exercise program. Training sessions are planned once a week for an average of 35-45 minutes and 8 sessions. NPE will be performed by a physiotherapist who has an internationally recognized certificate in this regard. Training sessions will be organized as one-on-one conversation sessions focusing on the neurophysiology of pain, and patients will be reinforced through PowerPoint presentations and visual pictures, templates, and metaphors.
89231459|NCT06320938|Active Comparator|Myofascial Induction Techniques Combined with Home Exercise Program|In addition to the home exercise program, Myofascial Induction Techniques (MIT) group patients will have MIT applied to the cervical and upper thoracic regions by a physiotherapist trained and experienced in myofascial treatments. The application will be once a week for 8 weeks, with an average duration of 35-45 minutes.
89231460|NCT06320938|Active Comparator|Home Exercise Program|Patients in this group will be taught an exercise program after undergoing general training. Exercises will include stretching and strengthening exercises for neck muscles and posture exercises. Patients are asked to take 35-45 minutes once a day, five days a week, for 8 weeks. They will be asked to do the given home exercises and fill out follow-up charts. The continuity of the exercises will be ensured by sending reminder messages to this group of patients once a week by the physiotherapist about doing their exercises.
89231461|NCT06320457|Experimental|Intervention group|Brief case management intervention group
89231462|NCT06317688|No Intervention|Pre-Screening|Pre-Screening to meet qualifications and conditions of study.
89231463|NCT06317688|No Intervention|Demographic Data Stage I|Data information gathered for enrollment
89231464|NCT06317688|No Intervention|Demographic Data StageII|Data gathered after delivery
89231465|NCT06317688|Experimental|Clinical Data|50%Administration of Extra-Virgin Coconut Oil/ 50% HPA Lanolin
89231466|NCT06317038|Other|Digital Device uses for 8 hours per day|Observational responses from patients using digital devices for 8 hours per day will be given a monthly Total 30 Contact lens.
89231467|NCT06316674||Anorexia Nervosa (AN)|People affected by AN (DSM5); female, age 18-55, BMI ≤ 17.5 Kg/m2
89231468|NCT06316674||Healthy controls (HC)|female, age 18-55, BMI between 18.5 Kg/m2 and 25 Kg/m2
89231469|NCT06316635||patient group|patient group has formed as operated patients because of OME A paracentesis and ventilation tube insertion will be performed them. After paracentesis, effusion otitis media will be trapped and sampled for microplastic analysis.
89231470|NCT06316219|No Intervention|Control|Patients with endometrial polyps undergone hysteroscopic polipectomy without endometrial preparation.
89231471|NCT06316219|Experimental|Intervention|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol 2.5mg/1.5mg at any time of the menstrual cycle
89231472|NCT06316206|No Intervention|Control|Patients with endometrial polyps undergone hysteroscopic polipectomy without endometrial preparation.
89231473|NCT06316206|Experimental|Treatment|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
89231474|NCT06316180|No Intervention|Control|Patients with endometrial polyps undergone hysteroscopic polipectomy without endometrial preparation.
89231475|NCT06316180|Active Comparator|Intervention|Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
88816298|NCT02579343|Experimental|Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants in this group will be treated twice weekly during their follow-up visits with micro-currents of electricity through auricular acupuncture.
89113392|NCT06179017|Placebo Comparator|Control group: Best medical treatment|Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on.
89113393|NCT06178978||Age-related macular degeneration|Patients with age-related macular degeneration.
89113394|NCT06178965|Other|Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation|Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation in patients with incisional hernia
89113395|NCT06178939|Active Comparator|control group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
89113396|NCT06178939|Experimental|intervention group|For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
89113397|NCT06178926|Active Comparator|Propofol|Use propofol for sedation during anesthesia.
89113398|NCT06178926|Experimental|Ciprofol|Use ciprofol for sedation during anesthesia
89113399|NCT06178913|Experimental|Exercise intervention|
89113400|NCT06178874|Active Comparator|group S|The random blood sugar in the patients in group S will be managed using regular insulin based on a sliding scale together with an Insulin Glargine, 0.2 units/kg , SC, initially to be titrated as per the clinical situation to be given at 9 PM
89113401|NCT06178874|Active Comparator|Group L|The random blood sugar in the patients in group L will be managed using regular insulin based on a sliding scale together with an Insulin Degludec 0.2 units/kg, SC, initially to be titrated as per the clinical situation to be given at 9 PM
89113402|NCT06178874|Active Comparator|Group R|The random blood sugar in the patients in group R will be managed using regular insulin based on a sliding scale
89113403|NCT06178861|Experimental|Group wearing a bra|Patients wear a bra while receiving radiotherapy.
89113404|NCT06178861|No Intervention|Group not wearing a bra|Patients do not wear a bra while receiving radiotherapy.
89113405|NCT06178848|Active Comparator|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
89113406|NCT06178848|Experimental|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
89113407|NCT06178835|Experimental|Erythropoietin|500 IU/kg of EPO given intramuscularly 3 times for each patient
89113408|NCT06178835|Placebo Comparator|Control|Same amount of normal saline given intramuscularly 3 times for each patient
89113409|NCT06178822||Patients with infection|Patients with an (suspected) infection and a MEWS score 2 or higher
89113410|NCT06178770||Overall cohort|
89113411|NCT06178770||12-month BRO cohort|
89113412|NCT06178770||18-month BRO cohort|
89113413|NCT06178770||12-month ALT cohort|
89113414|NCT06178770||18-month ALT cohort|
89113415|NCT06178731|Experimental|Virtual reality + rTMS|Each treatment session involves: 12-15 min VR viewing, 15 min descriptive and imaginal recounting followed immediately by 3 min rTMS delivery with iTBS to the left DLPFC.
89113416|NCT06178731|Sham Comparator|Virtual reality sham + rTMS|Each treatment session involves: 12-15 min VR viewing, 15 min descriptive and imaginal recounting followed immediately by 3 min rTMS delivery with iTBS to the left DLPFC.
89113417|NCT06178718|Experimental|TNP-2092 capsules 100mg|
89113418|NCT06178718|Experimental|TNP-2092 capsules 200mg|
89113419|NCT06178718|Experimental|TNP-2092 capsules 400mg (Food effect study Group A)|After completed the single ascending dose study, the participant will convert to the food effect study. The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days.
89113420|NCT06178718|Experimental|TNP-2092 capsules 800mg|
89113421|NCT06178718|Experimental|TNP-2092 capsules 1200mg|
89113422|NCT06178718|Experimental|Food effect study Group B (TNP-2092 capsules 400 mg)|The drugs will be administered in the fasting state and in the fed state for two cycles, with a wash-out period of 4 days.
89113423|NCT06178718|Placebo Comparator|Placebo|
89113424|NCT06178705|Experimental|Treatment Group|"Experimental Group:~Participants in experimental group would receive 8-10 sessions of intervention based helpful parenting program"
89113425|NCT06178705|No Intervention|Control Group|"Control Group:~Participants in the control group will not receive the said intervention of helpful parenting program."
89113426|NCT06178692||Arm 1|IDH1 mutated
89113427|NCT06178692||Arm 2|IDH1 wt
89113428|NCT06178666|Experimental|Low dose of BCG being tested in dose ranging study|The lowest dose of BCG (standard Malawi BCG vaccine (BCG Bulgaria 150000-600000 cfu) given as intradermal injection) will be used to determine safety and feasibility. The investigators do not expect to be able to meet study endpoints in this arm which will recruit 10 subjects.
89231477|NCT06307457||Palbociclib in combination with AI|Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI, in Denmark.
89231478|NCT06305000|No Intervention|Peri-implant healthy group with sufficient keratinized mucosa (≥ 2mm)|
89231479|NCT06305000|Experimental|Peri-implant mucositis group with sufficient keratinized mucosa (≥ 2mm)|Only non-surgical therapy will apply
89231480|NCT06305000|Experimental|Peri-implant mucositis group with insufficient keratinized mucosa (< 2mm)|Only non-surgical therapy will apply
89231481|NCT06305000|Experimental|Peri-implant mucositis group with insufficient keratinized mucosa (< 2mm) receiving FGG|Free gingival graft will apply following non-surgical therapy
89231482|NCT06303960|Experimental|Bilateral Cerebellar deep brain stimulation|Following enrollment, participants underwent 1 month of upper-extremity rehabilitation twice per week to rule out potential for recovery with rehabilitation therapy alone. Thereafter, each participant underwent surgical implantation of the DBS system, with the lead implanted in the DN contralateral to the stroke-affected cerebral hemisphere. 1 months later, DBS was activated bilaterally.
89231483|NCT06303960|Active Comparator|Unilateral Cerebellar deep brain stimulation|Following enrollment, participants underwent 1 month of upper-extremity rehabilitation twice per week to rule out potential for recovery with rehabilitation therapy alone. Thereafter, each participant underwent surgical implantation of the DBS system, with the lead implanted in the DN contralateral to the stroke-affected cerebral hemisphere. 1 months later, DBS was activated unilaterally.
89231486|NCT06303180||1|Patients with head and neck conditions affecting hearing, balance, smell, taste, swallowing, voice and speech.
89231487|NCT06301945||Patients with TET|"Patients diagnosed with the following TET subtypes:~Thymoma Type A~Thymoma Type AB~Thymoma Type B1~Thymoma Type B2~Thymoma Type B3~Thymic Carcinoma"
89231488|NCT06301945||Recurrence|Patients with thymic epithelial tumors who have experienced recurrence.
89231489|NCT06300554|Experimental|Participants from the 10th Mountain Division|
89231490|NCT06300463|Experimental|Botensilimab and Balstilimab|Two balstilimab infusions will be given prior to surgery and two infusions will be given after surgery, for a total of four doses. Each infusion will be scheduled approximately 3 weeks apart. On the same day as the first and third balstilimab infusions, botensilimab will also be given, for a total of two doses, one before and one after surgery.
89231491|NCT06300463|Experimental|Botensilimab, Balstilimab, and AGEN1423|Two balstilimab infusions will be given prior to surgery and two infusions will be given after surgery, for a total of four doses. On the same day as each balstilimab infusion, participants will also receive AGEN1423 infusions, for a total of four doses. Each infusion will be scheduled approximately 3 weeks apart. On the same day as the first and third balstilimab + AGEN1423 infusions, botensilimab will also be given, for a total of two doses, one before and one after surgery.
89231492|NCT06300463|Experimental|Botensilimab, Balstilimab, and Radiation|Participants will receive 3 doses of radiation prior to surgery. Additionally, two balstilimab infusions will be given prior to surgery and two infusions will be given after surgery, for a total of four doses. Each infusion will be scheduled approximately 3 weeks apart. On the same day as the first and third balstilimab infusions, botensilimab will also be given, for a total of two doses, one before and one after surgery.
89231493|NCT06299592||Participants with asthma|
89231494|NCT06299592||Participants without asthma|
89231495|NCT06295809|Experimental|Pembrolizumab plus V940 with SOC|Participants will receive V940 1 mg intramuscular (IM) injection every 3 weeks (q3w) for up to 6 weeks and pembrolizumab 400 mg intravenous (IV) infusion every 6 weeks (q6w) up to 12 weeks as neoadjuvant therapy prior to surgery; followed by V940 1 mg IM injection q3w up to 21 weeks and pembrolizumab 400 mg IV infusion q6w or until discontinuation.
89231496|NCT06295809|Active Comparator|Standard of Care (SOC)|Participants will receive surgical resection as per local guidelines with/without adjuvant radiation therapy (RT) at investigator's discretion.
89231497|NCT06295809|Experimental|Pembrolizumab with SOC|Participants will receive pembrolizumab 400 mg IV infusion q6w up to 12 weeks as neoadjuvant therapy prior to surgery; followed by pembrolizumab 400 mg IV infusion q6w or until discontinuation.
89231498|NCT06295640|Experimental|Intranasal insulin spray|160 Units of human insulin as nasal spray
89231499|NCT06295640|Placebo Comparator|Placebo spray|Nasal spray containing placebo solution
89231500|NCT06294067|Placebo Comparator|DHA0 - 0mg of DHA/d|DHA0 participants are in the placebo group and will take 5 soybean oil based capsules per day and will not receive any DHA. Every group takes 5 capsules per day to maintain blinding.
89231501|NCT06294067|Active Comparator|DHA1 - 100mg of DHA/d|DHA1 participants will take 100mg/d of DHA. As the DHA supplements are 200mg of DHA per capsule the participants here will take one 200mg capsule every other day and the rest of the capsules will be placebos.
89231502|NCT06294067|Active Comparator|DHA2 - 200mg of DHA/d|DHA2 participants will take one 200mg capsule of DHA and 4 placebos per day.
89231503|NCT06294067|Active Comparator|DHA3 - 400mg of DHA/d|DHA3 participants will take two 200mg capsules of DHA and 3 placebos per day.
89231504|NCT06294067|Active Comparator|DHA4 - 800mg of DHA/d|DHA4 participants will take four 200mg capsules of DHA and 1 placebo per day.
89231505|NCT06294067|Active Comparator|DHA5 - 1000mg of DHA/d|DHA5 participants will take five 200mg capsules of DHA and no placebos per day.
89231506|NCT06292637|No Intervention|Control|
89231507|NCT06292637|Experimental|CB-FAITH treatment|
89231508|NCT06287073||New JARDIANCE® users with chronic kidney disease (CKD)|Patients with CKD starting JARDIANCE® for the first time in accordance with the approved label in Korea
89231509|NCT06286475|Experimental|Part 1: VRG50635 Sequence A, B, C|Participants will receive a single dose of VRG50635 in each of 3 treatment periods separated by 14-day washout periods.
89290588|NCT01224054||Duodenal exclusion|This surgery provides disabsortion by duodenal derivation maintaining an intact stomach
89113429|NCT06178666|Experimental|Mid-range dose BCG being tested in dose ranging study|The mid-range dose of BCG (4x standard Malawi dose (BCG Bulgaria 600000-2400000 cfu intradermal) and equal to the model tested in Oxford, UK) will be used to determine safety and feasibility. The investigators hope to to be able to meet study endpoints (measuring microbiological and immunological features of BCG skin lesion) in this arm which will recruit 10 subjects.
89113430|NCT06178666|Experimental|High dose BCG being tested in dose ranging study|The highest dose of BCG (10x standard Malawi dose (BCG Bulgaria 2400000-9600000 cfu intradermal) and equal to USA dose used in Seattle) will be used to determine safety and feasibility. The investigators expect to be able to meet study endpoints in this arm which will recruit 10 subjects. In the event that study endpoints are met in the mid-range dose, the investigators will introduce a rifampicin dosing schedule to this arm.
89231510|NCT06286475|Experimental|Part 1: VRG50635 Sequence B, A, C|Participants will receive a single dose of VRG50635 in each of 3 treatment periods separated by 14-day washout periods.
89231511|NCT06286475|Experimental|Part 2: Cohort 1 VRG50635|Participants will receive VRG50635 (Dose X) for 14 consecutive days.
89231512|NCT06286475|Placebo Comparator|Part 2: Cohort 1 Placebo|Participants will receive VRG50635-matching placebo for 14 consecutive days.
89231513|NCT06286475|Experimental|Part 2: Cohort 2 VRG50635|Participants will receive VRG50635 (Dose Y) for 14 consecutive days.
89231514|NCT06286475|Placebo Comparator|Part 2: Cohort 2 Placebo|Participants will receive VRG50635-matching placebo for 14 consecutive days.
89113431|NCT06178653|Experimental|Pulmonary Rehabilitation Group|"The program will be carried out 3 days a week, 30 minutes, for 8 weeks, one day in the clinic under the supervision of the researcher, and the other two sessions in the home environment under the supervision of the caregiver. Caregivers will also be taught respiratory rehabilitation techniques to apply at home.~Pulmonary Rehabilitation Training Program consists of diaphragmatic breathing, Pursed-lip breathing, and segmental breathing.~Inspiratory muscle training: In our research, IMT will be performed in a sitting position using a handheld threshold device (POWERbreathe Medic Plus International Ltd, Southam, UK) that offers an adjustable inspiratory resistance via a spring-loaded valve with variable pressure load adjustment from 1-78 cmH2O. Inspiratory muscle training will be applied by calculating 30% of the maximal inspiratory pressure (MIP). During weekly clinic visits, the MIP value will be recalculated and the current threshold pressure value will be determined."
89113432|NCT06178653|Experimental|Trunk Control Training Group|The program will be carried out 3 days a week, with pulmonary rehabilitation in each session, for a total of 45-60 minutes, for 8 weeks. The training of children whose evaluations are completed will begin after individually structured pulmonary rehabilitation and trunk control training programs are created. The content of pulmonary rehabilitation will consist of diaphragmatic breathing, pursed-lip breathing, and segmental breathing. Exercises and activities for trunk muscle activation, pelvic control and proximal stabilization will be used together with trunk and gluteal muscle strengthening exercises. The intensity and level of exercises will be increased gradually. Body control work will first start on hard ground and then continue on soft ground and dynamic surfaces. All trunk control training will be applied actively or actively assisted.
89113433|NCT06178627|Active Comparator|Normal dose amphotericin B (0.7 mg/kg/d)|Study regimen 1: amphotericin B 0.7 mg/kg/day i.v. plus flucytosine for 4 weeks
89113434|NCT06178627|Experimental|Low dose amphotericin B (0.5 mg/kg/d)|Amphotericin B 0.5 mg/kg/day i.v. plus flucytosine for 4 weeks
89113435|NCT06178601|Experimental|RC48-ADC plus cadonilimab（AK104）|RC48-ADC plus cadonilimab（AK104）
89113436|NCT06178575||Manual microscopic observation|Control Group: Manual analysis of urine crystal images, distinguishing crystal types, recording accuracy, and analyzing the time consumed.
89113437|NCT06178575||Machine interpretation|The urine crystal images undergo analysis for crystal types, followed by image preprocessing and category labeling for machine software learning and inference. Subsequently, the interpreted results will be subjected to statistical analysis software to assess accuracy.
89113438|NCT06178536|Experimental|Rex implant machined transcortical portion|Implants in these group will have a machined portion at the neck of the implant
89113439|NCT06178536|Active Comparator|Rex implant roughened transcortical portion|Rex implants with a rough surface until the neck of the implant
89113440|NCT06178523|Active Comparator|Sildenafil & Clomiphene Group|"Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle + Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle.~Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound."
89113441|NCT06178523|Active Comparator|IUI & Clomiphene Group|"Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle + Intrauterine insemination (IUI) 42 hours after human chorionic gonadotropin (Pregnyl®) 10,000 IU injection IM.~Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound."
89113442|NCT06178523|Placebo Comparator|Clomiphene only Group|"Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle.~Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound."
89113443|NCT06178510|Other|INTELLiVENT-ASV|The ventilator set parameters such as tidal volume, respiratory rate, and positive end-expiratory pressure to ensure adequate ventilation and oxygenation. The investigators monitor it and define clinical target.
89113444|NCT06178510|No Intervention|conventional ventilation|The investigators set and monitor parameters such as tidal volume, respiratory rate, and positive end-expiratory pressure to ensure adequate ventilation and oxygenation.
89113445|NCT06178445|Experimental|SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab|"Gemcitabine: 1000 mg/m2 on day 1 and day 8 of each 21-days cycle (Q3W)~Cisplatin: 25 mg/m2 on day 1 and day 8 of each 21-days cycle~Trastuzumab: initial dose 8 mg/kg, then 6 mg/kg on day 1 of each 21-days cycle~Pembrolizumab: 200 mg on day 1 of each 21-days cycle"
89113446|NCT06178432|Experimental|Arm of CRG003 injection|The dose of CRG003 injection will be calculated according to the participant's weight with single intravenous infusion.
89113447|NCT06178419|Experimental|RIC group|The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
89113448|NCT06178419|Sham Comparator|sham RIC group|The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.
89113449|NCT06178406||dysmenorrhea|
89113450|NCT06178406||female healthy controls|
89113451|NCT06178393||OA monotherapy|
89113452|NCT06178393||Nusinersen monotherapy|
89113453|NCT06178393||Other DMTs switched to OA|
89113454|NCT06178393||OA add-on other DMTs|
89113455|NCT06178393||Combination, other DMTs with OA|
89113456|NCT06178393||Other treatment sequence|
89113457|NCT06178354|Experimental|Treatment (cryosurgery, high intensity focused ultrasound)|Patients undergo focal cryotherapy or high intensity focused ultrasound on study.
89231516|NCT06284486|Experimental|Venetoclax + Revumenib|Participants may receive the combination of venetoclax and revumenib for up to 1 year, and then 1 more year of venetoclax alone. You will no longer be able to take the study drug(s) if the disease gets worse or if intolerable side effects occur. Participants will take venetoclax by mouth on 1 time a day at about the same time each day, on Days 1-14 of each cycle. Take each dose with about 1 cup of water within 30 minutes after a meal, preferably breakfast.
89113458|NCT06178328||Brief psychological intervention (Things You Do)|All participants will have access to the online course materials for a period of 4 weeks from the time of enrolment. The materials are self-directed and can be accessed at any time during the 4-week period.
89113459|NCT06178315|Active Comparator|Endoscopic ultrasound-guided celiac plexus block|EUS-guided celiac plexus block will be performed.
89113460|NCT06178315|Sham Comparator|Sham|Celiac plexus block will not be performed.
89113461|NCT06174272|Experimental|Transitional Care Program|Participants will receive a digital scale and monitoring log, educational material, a phone call within 72 hours of discharge and weekly for 8 weeks, and a follow up appointment with a hepatologist within 4 weeks of discharge.
89113462|NCT06174272|No Intervention|Standard of Care|Participants will be given typical discharge and follow up instructions.
89113463|NCT06174207|Placebo Comparator|Placebo Group|Start with Constant Work Rate Exercise Test with 5l/min room air applied via nasal cannula.
89113464|NCT06174207|Experimental|Experimental Group|Start with Constant Work Rate Exercise Test with 5l/min Oxygen Therapy applied via nasal cannula.
89113465|NCT06173492|Experimental|Socket ridge preservation with PRF|40 ml of blood is drawn and collected in plastic tubes of 10 ml. The tubes are placed in a centrifuge at 2700 rpm for 12 minutes to get the clot of fibrin. After extraction, the clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
89113466|NCT06173492|Active Comparator|Spontaneous healing|No treatment is applied. The socket is made to heal spontaneously.
89113467|NCT06173466|Experimental|Liposomal bupivacaine|Patients in the bupivacaine liposomal group were treated with liposome bupivacaine 133 mg under ultrasound-guided TPVB. And ultrasound-guided TPVB was performed at the right T7-8, T8-9, T9-10, and T10-11 paravertebral interval under left lateral decubitus position, with 7.5 ml of medication injected into each paravertebral interval, for a total of 30 ml.
89113468|NCT06173466|Active Comparator|Standard bupivacaine combined with dexamethasone|Patients in the standard control group were treated with 0.5% bupivacaine hydrochloride 150 mg combined with dexamethasone 4 mg. the volume were expended to 30ml in both groups with normal saline. And ultrasound-guided TPVB was performed at the right T7-8, T8-9, T9-10, and T10-11 paravertebral interval under left lateral decubitus position, with 7.5 ml of medication injected into each paravertebral interval, for a total of 30 ml.
89113469|NCT06173375|Experimental|Mailed Cologuard Outreach|Receipt of mailed Cologuard test for colorectal cancer screening to be completed and returned by participant. If test is negative, participant will be advised to undergo another test in 3 years. If test is positive, participant will be advised to schedule colonoscopy for further testing.
89113470|NCT06173375|Active Comparator|Mailed Fecal immunochemical test Outreach|Receipt of mailed FIT for colorectal cancer screening to be completed and returned by participant. If test is negative, participant will be advised to undergo another test in 1 year. If test is positive, participant will be advised to schedule colonoscopy for further testing.
89113471|NCT06172374||PCD Individuals confirmed positive for DNAI1|
89113472|NCT06172374||PCD Individuals confirmed positive for other genotypes of interest|
89113473|NCT06172374||Individuals negative for a gene causing PCD|
89113474|NCT06169267|Active Comparator|Group I (no music)|Patients undergo standard of care bone marrow biopsy and/or aspiration.
89113475|NCT06169267|Experimental|Group II (listen to music)|Patients listen to music while undergoing standard of care bone marrow biopsy and/or aspiration.
89113476|NCT06169046|Experimental|clenbuterole|45 patients will receive Clenbuterol at a final dosage of 0.04 mg/day, treated for a total of 48 weeks
89113477|NCT06169046|Placebo Comparator|placebo|45 patients will receive placebo, treated for a total of 48 weeks
89113478|NCT06168786|Experimental|Cadonilimab plus Fruquintinib and SBRT|
89113479|NCT06166498|Active Comparator|Sulphadoxine-pyrimethamine (SP)|Children in the SP group will receive a 7-day course of placebo artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed by the standard of care, 5 doses of SP.
89113480|NCT06166498|Active Comparator|Artesunate monotherapy (AS)|Children in the AS group will receive a 7-day course of 7-day course of active artesunate (at day -7, -6, -5, -4, -3, -2, and -1), followed by placebo SP.
89113481|NCT06166446|Active Comparator|a CAD/CAM-milled mandibular overdenture and a maxillary acrylic conventional complete denture|patients received lower denture fabricated by milling technique
89113482|NCT06166446|Active Comparator|3rd printed mandibular overdenture and a maxillary acrylic conventional complete denture|The denture base was fabricated by adding the material layer by layer
89113483|NCT06164496|Experimental|control group|A control group will be formed using a manual brush with a classic head.
89113484|NCT06164496|Experimental|study group|A study group will be formed using a 360-degree bristle brush.
89113485|NCT06163352|Experimental|Patients with pressure injury|The intervention is vasopressor infusion. In this am, 64 surgical and medical patients treated with vasopressor agents in the intensive care unit and developed pressure injury were included.
89113486|NCT06163352|Active Comparator|Patients without pressure injury|The intervention is vasopressor infusion. In this arm, 84 surgical and medical patients treated with vasopressor agents in the intensive care unit and did not develop pressure injury were included.
89113487|NCT06160817|Active Comparator|Weekly Sharp Debridement|"Participants in this arm will undergo sharp debridement on a weekly basis.~Purpose: Evaluate the effect of weekly sharp debridement, in combination with conventional treatment, on granulation tissue and healing time in diabetic foot ulcers. And assess if this regimen yields better outcomes for ulcers with a specific location.~Active Comparator: Yes, as it represents an active treatment modality."
89113488|NCT06160817|Active Comparator|Biweekly Sharp Debridement|"Participants in this arm will undergo sharp debridement on a biweekly basis.~Purpose: Assess the impact of biweekly sharp debridement, in combination with conventional treatment, on granulation tissue and healing time in diabetic foot ulcers. And assess if this regimen yields better outcomes for ulcers with a specific location.~Active Comparator: Yes, as it represents an active treatment modality."
89113489|NCT06154356|Experimental|Action observation and motor imagery therapy for rehabilitation|Action observation and motor imagery therapy for rehabilitation in Parkinson's Disease in addition to conventional rehabilitation programs.
89113490|NCT06154356|Sham Comparator|Sham action observation and motor imagery therapy for rehabilitation|Sham comparator for action observation and motor imagery therapy for rehabilitation in Parkinson's Disease in addition to conventional rehabilitation programs.
89113491|NCT06151314|Active Comparator|"digital milled implant supported removable partial overdenture"|patients received digital milled implant supported removable partial overdenture.
89113492|NCT06151314|Active Comparator|"implant supported fixed bridge"|patients received an implant supported fixed bridge
89113493|NCT06150014|Placebo Comparator|Placebo +Nucleoside (acid) analogs (NAs) combination therapy 24 weeks|Placebo and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.
89113494|NCT06150014|Active Comparator|50 mg of TQA3605 tablets +NAs combination therapy 24 weeks|50 mg of TQA3605 tablets and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.
89113495|NCT06150014|Active Comparator|100 mg of TQA3605 tablets +NAs combination therapy 24 weeks|100 mg of TQA3605 tablets and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.
89113496|NCT06150014|Active Comparator|200 mg of TQA3605 tablets +NAs combination therapy 24 weeks|200 mg of TQA3605 tablets and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.
89113497|NCT06150014|Active Comparator|Placebo +Nucleoside (acid) analogs (NAs) combination therapy|Placebo taken orally once daily, continue for 12 weeks. Placebo combined with Nucleoside (acid) analogues, taken orally once daily, continue for 12 weeks.
89113498|NCT06150014|Active Comparator|100 mg of TQA3605 tablets +NAs combination therapy|100 mg of TQA3605 tablets taken orally once daily, continue for 12 weeks. 100 mg of TQA3605 tablets combined with Nucleoside (acid) analogues, taken orally once daily, continue for 12 weeks.
89113499|NCT06150014|Active Comparator|200 mg of TQA3605 tablets +NAs combination therapy|200 mg of TQA3605 tablets taken orally once daily, continue for 12 weeks. 200 mg of TQA3605 tablets combined with Nucleoside (acid) analogues, taken orally once daily, continue for 12 weeks.
89113500|NCT06140810||Right ventricular End diastolic pressure|Measurement of pre and post recruitment right ventricular end diastolic pressure
89113501|NCT06140615|Experimental|Lung ultrasound|Participants undergo pre- and post-extubation lung ultrasound
89113502|NCT06135103|Experimental|talfirastide (TXA127)|TXA127 will be given daily for 12 weeks at a dose of 0.5.mg/kg via SC injection.
89113503|NCT06135103|Placebo Comparator|placebo|Placebo will be given daily for 12 weeks via SC injection.
89113504|NCT06122831|Experimental|TQ05105 Tablets + TQB3617 Capsules|TQ05105 Tablets combined with TQB3617 Capsules, orally administered. 21 days as a treatment cycle.
89113505|NCT06121258|Experimental|Video website access|Participants will gain access to the educational video website in order to watch the series.
89113506|NCT06118346|Experimental|Female-Specific Cognitive Behavioral Therapy|Participants in this arm will receive female-specific cognitive behavioral therapy and usual VA care for alcohol use disorder.
89113507|NCT06118346|Active Comparator|Usual Care|Participants in this arm will receive usual VA care for alcohol use disorder.
89113508|NCT06114407|Experimental|Baricitinib|Participants of 'Baricitinib' arm will be treated with tablet baricitinib 2 mg twice daily for 12 weeks
89113509|NCT06114407|Active Comparator|Tofacitinib|Participants of 'Tofacininib' arm getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis
89113510|NCT06111443|Experimental|Dapagliflozin|Dapagliflozin (FORXIGA) 10 mg QD for 3 months
89113511|NCT06111443|No Intervention|Usual care|guideline-direct usual care
89113512|NCT06107192|Experimental|Apple catechin|A 3-day controlled diet
89113513|NCT06107192|Placebo Comparator|Low catechin|A 3-day controlled diet
89113514|NCT06106256|Experimental|Positive GVS During VR Flight Simulation|Subjects will receive positive galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
89113515|NCT06106256|Experimental|Negative GVS During VR Flight Simulation|Subjects will receive negative galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
89113516|NCT06106256|Experimental|No GVS During VR Flight Simulation|Subjects will not receive any galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
89113517|NCT06106256|Experimental|Positive GVS During 3-DOF Bertec Portable Essential's dual-balance force plate system|Subjects will receive positive galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
89113518|NCT06106256|Experimental|Negative GVS During 3-DOF Bertec Portable Essential's dual-balance force plate system|Subjects will receive negative galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
89113519|NCT06106256|Experimental|No GVS During 3-DOF Bertec Portable Essential's dual-balance force plate system|Subjects will not receive any galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
89113520|NCT06104670|Experimental|Experimental: Synaquell Male Group|Male youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
89113521|NCT06104670|Placebo Comparator|Placebo Comparator: Placebo Male Group|Male youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
89113522|NCT06104670|Experimental|Experimental: Synaquell Female Group|Female youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
89113523|NCT06104670|Placebo Comparator|Placebo Comparator: Placebo Female Group|Female youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.
89113524|NCT06101797|Experimental|Remote supervised exercise group|The intervention will last 12 weeks and consist of muscle-strengthening exercises for the lower extremities supervised remotely by video call.
89113525|NCT06101797|Experimental|In-person supervised exercise group|The intervention will last 12 weeks and consist of muscle-strengthening exercises for the lower extremities supervised in person at a physiotherapy clinic.
89113526|NCT06090721|Experimental|DMT310 Topical Powder|DMT310 Powder mixed with Hydrogen Peroxide
89113527|NCT06090721|Experimental|Placebo Topical Powder|Placebo powder mixed with Hydrogen Peroxide
89113528|NCT06088173|Experimental|Early Passive Mobilization Group|This group will be given Modifiye Kleinert Protocol based rehabilitation
89113529|NCT06088173|Experimental|Graded Motor Imagery Training Group|This group will be given Modifiye Kleinert Protocol and Graded Motor Imagery Training
89113530|NCT06077877|Experimental|Part 1 - GSK4524101 Monotherapy|
89113531|NCT06077877|Experimental|Part 1 - GSK4524101 plus Niraparib|
89113532|NCT06077877|Experimental|Part 1 - GSK4524101 Food Effect Cohort|
89113533|NCT06077877|Experimental|Part 2 - GSK4524101 plus Niraparib|
89113534|NCT06077877|Active Comparator|Part 2 - Niraparib|
89113535|NCT06073535|Experimental|i-PRF|i-PRF will be used after the extraction of the third molar to reduce postoperative complications (swelling, pain) and wound healing.
89113536|NCT06073535|Active Comparator|Spontaneous healing|After the extraction of the lower third molar the socket will be left to heal spontaneously.
89113537|NCT06069869|Experimental|MM 30mg; then MMS 45mg; then MMS 60mg|Participants first receive MMS with 30 mg for one month, then MMS with 45 mg of iron for one month, then MMS with 60 mg of iron for one month
89113538|NCT06069869|Experimental|MM 30mg; then MMS 60mg; then MMS 45mg|Participants first receive MMS with 30mg for one month, then MMS with 60mg of iron for one month, then MMS with 45 mg of iron for one month
89113539|NCT06069869|Experimental|MM 45mg; then MMS 30mg; then MMS 60mg|Participants first receive MMS with 45 mg for one month, then MMS with 30 mg of iron for one month, then MMS with 60 mg of iron for one month
89113540|NCT06069869|Experimental|MM 45 mg; then MMS 60mg; then MMS 30mg|Participants first receive MMS with 45 mg for one month, then MMS with 60 mg of iron for one month, then MMS with 30 mg of iron for one month
89113541|NCT06069869|Experimental|MM 60mg; then MMS 30mg; then MMS 45mg|Participants first receive MMS with 60 mg for one month, then MMS with 30 mg of iron for one month, then MMS with 45 mg of iron for one month
89113542|NCT06069869|Experimental|MM 60mg; then MMS 45mg; then MMS 30mg|Participants first receive MMS with 60 mg for one month, then MMS with 45 mg of iron for one month, then MMS with 30 mg of iron for one month
89113543|NCT06069206|Active Comparator|Usual Care|Patients will receive blood cultures and will not receive direct-from-blood testing.
89113544|NCT06069206|Active Comparator|Direct-from-blood testing|In addition to usual care, patients will receive direct-from-blood testing using the T2Bacteria® Panel.
89113545|NCT06062069|Experimental|CT-868 Low Dose|Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 1.8 mg, and it will be administered once daily for a total duration of 16 weeks.
89113546|NCT06062069|Experimental|CT-868 Medium Dose|Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 4.1 mg, and it will be administered once daily for a total duration of 16 weeks.
89113547|NCT06062069|Experimental|CT-868 High Dose|Participants in this arm will receive the drug CT-868 in a subcutaneous injection form. The dosage is set at up to 6.6 mg, and it will be administered once daily for a total duration of 16 weeks.
89113548|NCT06062069|Placebo Comparator|CT-868 Placebo|Participants in this arm will receive a placebo designed to match the appearance and formulation of the drug CT-868. The intervention consists of a subcutaneous injection of this placebo. The placebo will be administered once daily for a duration of 16 weeks.
89113549|NCT06052553|No Intervention|Control Group|Subjects will receive no intervention for the duration of the hockey season.
89113550|NCT06052553|Experimental|TopSpin360 Intervention Group|Subjects will use TopSpin360, twice- weekly and use for the duration of the hockey season.
89113551|NCT06051318|Experimental|Standardized breakfast A|Consumption order: Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
89113552|NCT06051318|Experimental|Standardized breakfast B|Consumption order: Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
89113553|NCT06046794|Experimental|metastatic pancreatic adenocarcinoma patients|Analyze of GemCore status
89113554|NCT06045416||LD_Diff_Diag|LD differential diagnosis cohort: Patients presenting at the ED with differential diagnosis of LD according to the treating physician
89113555|NCT06045416||Heathy_Control|Previously healthy patients (HC) with routine blood investigations presenting at the ED or PID outpatient department
89113556|NCT06040619|Experimental|Therapy Together|Participants will complete the 8-week Therapy Together program.
89113557|NCT06040619|Active Comparator|Usual Care|Participants will complete 8 weeks of usual care in early intervention.
89113558|NCT06026046|Experimental|Patients benefiting from the adapted sport program based on fencing|
89113559|NCT06017479|Experimental|Pre-urodynamic Fosfomycin|Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
89113560|NCT06017479|Experimental|Pre-urodynamic Levofloxacin|Levofloxacin 500 miligrams single dosage 1 hour before the urodynamic examination
89113561|NCT06016920|Experimental|Phase1: Dose Escalation: 3 mg VB10.16 + Pembrolizumab|"3 mg of VB10.16 via i.m. needle-free injections in the deltoid muscles~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
89113562|NCT06016920|Experimental|Phase 1: Dose Escalation: 6 mg VB10.16 + Pembrolizumab|"6 mg of VB10.16 via i.m. needle-free injections in the deltoid muscles and quadriceps or gluteus muscles~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
89113563|NCT06016920|Experimental|Phase 1: Dose Escalation: 9 mg VB10.16 + Pembrolizumab|"9 mg of VB10.16 via i.m. needle-free injections in the deltoid muscles and quadriceps and/or gluteus muscle~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
89113564|NCT06016920|Experimental|Phase 2: Dose Expansion: High dose of VB10.16 + Pembrolizumab|"The highest dose of VB10.16 to be safety-cleared in the escalation phase will be given via i.m. needle-free injections in the deltoid muscles and quadriceps and/or gluteus muscle~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
89113565|NCT06016920|Experimental|Phase 2: Dose Expansion: 3 mg VB10.16 + Pembrolizumab|"3 mg of VB10.16 via i.m. needle-free injections in the deltoid muscles~Pembrolizumab will be given as standard of care/ background medication via i.v. infusions"
89113566|NCT06011109|Experimental|APG-157|"The participants will receive APG-157 daily by taking two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth.~The participants will continue to receive Bevacizumab as standard of care."
89113567|NCT06005350|Experimental|NR-Treatment|"NR-Chloride Preparation 1000mg/day for 10 days~(500mg - 0 - 500mg -0)"
89113568|NCT06005350|Placebo Comparator|Placebo|"Placebo for 10 days~(1 - 0 - 1 - 0)"
89113569|NCT05998460|Experimental|GGE with CGM|Participants randomized to the Glucose-Guided Intervention will be trained to align their mealtimes with a personalized glucose threshold monitored using continuous glucose monitoring (CGM) and the GGE study app.
89113570|NCT05998460|Active Comparator|CGM only|Participants randomized to the control arm will only wear a CGM.
89113571|NCT05995444|Experimental|500 mg epetraborole|500 mg epetraborole
89113572|NCT05995444|Experimental|2000 mg epetraborole|2000 mg epetraborole
89113573|NCT05995444|Placebo Comparator|Epetraborole-matching placebo|Epetraborole-matching placebo
89113574|NCT05995444|Active Comparator|400 mg moxifloxacin|400 mg moxifloxacin
89113575|NCT05995106|Experimental|App Group|Patients assigned to the app group receive assistance from the research team to install the Heart4U application and familiarize themselves with its usage.
89113576|NCT05995106|No Intervention|Usual Care Group|The app (n=290) and usual care groups (n-290) continue to receive active treatment as previously administered (guideline-based prenatal care).
89113577|NCT05992935|Experimental|mRNA-1403 Dose Level 1|Participants will receive 2 intramuscular (IM) injections of mRNA-1403 at Dose Level 1.
89113578|NCT05992935|Experimental|mRNA-1403 Dose Level 2|Participants will receive 2 IM injections of mRNA-1403 at Dose Level 2.
89113579|NCT05992935|Experimental|mRNA-1403 Dose Level 3|Participants will receive 2 IM injections of mRNA-1403 at Dose Level 3.
89113580|NCT05992935|Experimental|mRNA-1403 Dose Level 4 Regimen 1|Participants will receive 2 IM injections of mRNA-1403 at Dose Level 4.
89113581|NCT05992935|Experimental|mRNA-1403 Dose Level 4 Regimen 2|Participants will receive 1 IM injection of mRNA-1403 at Dose Level 4 and 1 IM injection of study vaccine-matched placebo.
89113582|NCT05992935|Experimental|mRNA-1405 Dose Level 1|Participants will receive 2 IM injections of mRNA-1405 at Dose Level 1.
89113583|NCT05992935|Experimental|mRNA-1405 Dose Level 2|Participants will receive 2 IM injections of mRNA-1405 at Dose Level 2.
89113584|NCT05992935|Experimental|mRNA-1405 Dose Level 3|Participants will receive 2 IM injections of mRNA-1405 at Dose Level 3.
89113585|NCT05992935|Experimental|mRNA-1405 Dose Level 4 Regimen 1|Participants will receive 2 IM injections of mRNA-1405 at Dose Level 4.
89113586|NCT05992935|Experimental|mRNA-1405 Dose Level 4 Regimen 2|Participants will receive 1 IM injections of mRNA-1405 at Dose Level 4 and 1 IM injection of study vaccine-matched placebo.
89113587|NCT05992935|Placebo Comparator|Placebo|Participants will receive 2 IM injections of study vaccine-matching placebo.
89113588|NCT05991102|Experimental|TAS-102 and Bevacizumab and radiofrequency electromagnetic field treatment|"Each treatment cycle with TAS-102 will be 28 days in duration.~One treatment cycle consists of the following:~Days 1: Bevacizumab (5 mg/m2/dose) intravenous.~Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery~Days 15: Bevacizumab (5 mg/m2/dose) intravenously.~Radiofrequency electromagnetic field treatment using the EHY-2030 device starts within the first week of systemic therapy 2 times weekly (60 min each) with an interval of at least 48h. A modulated electric field with a carrier radiofrequency 13.56 MHz will be generated."
89113589|NCT05985694|Placebo Comparator|Cohort 1 Placebo|Formulation buffer
89113590|NCT05985694|Experimental|Cohort 1 Low dose|Formulation buffer + 10 μg LTh(αK)
89113591|NCT05985694|Placebo Comparator|Cohort 2 Placebo|Formulation buffer
89113592|NCT05985694|Experimental|Cohort 2 High dose|Formulation buffer + 20 μg LTh(αK)
89113593|NCT05975593||Cervical Cancer|"Patients will have blood and tumor collected at various time points throughout participation in the study.~Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI."
89113594|NCT05975593||Pancreatic Cancer|"Patients will have blood and tumor collected at various time points throughout participation in the study.~Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI."
89113595|NCT05975268|Experimental|JS005 150mg (recombinant humanized monoclonal antibody against IL-17A)|
89113596|NCT05975268|Experimental|JS005 300mg (recombinant humanized monoclonal antibody against IL-17A)|
89113597|NCT05975268|Placebo Comparator|Placebo|
89113598|NCT05975099|Experimental|mRNA-1975: Dose 1|Participants will receive 3 intramuscular (IM) injections of the mRNA-1975 vaccine at Dose Level 1 on Days 1, 57, and 169.
89113599|NCT05975099|Experimental|mRNA-1975: Dose 2|Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 2 on Days 1, 57, and 169.
89113600|NCT05975099|Experimental|mRNA-1975: Dose 3|Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose Level 3 on Days 1, 57, and 169.
89113601|NCT05975099|Experimental|mRNA-1975: Dose 4|Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 4 on Days 1, 57, and 169.
89113602|NCT05975099|Experimental|mRNA-1982: Dose 1|Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 1 on Days 1, 57, and 169.
89113603|NCT05975099|Experimental|mRNA-1982: Dose 2|Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 2 on Days 1, 57, and 169.
89113604|NCT05975099|Experimental|mRNA-1982: Dose 3|Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose level 3 on Days 1, 57, and 169.
89113605|NCT05975099|Placebo Comparator|Placebo|Participants will receive 3 IM injections of vaccine-matching placebo on Days 1, 57, and 169.
89113606|NCT05974202|Active Comparator|Active (high-frequency) rTMS|Daily high-frequency (10 Hz) repetitive transcranial magnetic brain stimulation for 3 weeks (15 sessions).
89113607|NCT05974202|Placebo Comparator|Sham (placebo) rTMS|Sham rTMS uses the same device and mimics the auditory and scalp sensations without stimulating the brain.
89113608|NCT05964179|Experimental|time restricted feeding|total feeding time (from the first meal or snack to the last) is assigned as 8 hours/day.
89113609|NCT05964179|Experimental|time extended feeding|total feeding time (from the first meal or snack to the last) is assigned as 14 hours/day.
89113610|NCT05956860||radial access for abdominopelvic vascular intervention|abdominopelvic vascular intervention through the radial artery access
89113611|NCT05953935|Experimental|A-E group|Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments, in patients with ulcers of venous etiology.
89113612|NCT05953935|Experimental|B-E group|Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in patients with diabetic foot ulcers.
89113613|NCT05953935|Experimental|A-C grouop|Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in CDH.
89113614|NCT05953935|Experimental|B-C grouop|Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under subthermal conditions plus standard clinical treatments in CDH.
89113615|NCT05953935|Experimental|C-C group|Standard clinical treatments established on the basis of the treatment standards of the International Working Group on the Diabetic Foot (IWGDF), in the case of diabetic foot ulcers (2, 3). For ulcers of venous etiology, the treatment standards according to the guidelines of the Spanish Association of Vascular Nursing and Wounds (Asociación Española de Enfermería Vascular y Heridas) will also be applied.
89113616|NCT05932667|Experimental|Single arm: combination of Milademetan at the recommended dose and fulvestrant|"In the safety run-in, 6 patients will be included milademetan at dose D and fulvestrant 500mg IM at Day1, Day15 of cycle 1, then Day1 of every 28 day-cycle. In case of unacceptable toxicity at the D-dose, a D-1 dose will be investigated, followed by a D-2 dose in case of unacceptable toxicity at D-1 dose.~In the phase II, patients will be treated at the milademetan dose recommended in the safety run-in. Dose reductions will be allowed on subsequent cycles in case of toxicity."
89113617|NCT05925907||Handsurgery patients|patients recruited from trauma handsurgery outpatient clinic in an academic teaching hospital, level 1 trauma unit.
89113618|NCT05925907||Medicolegal patients|Medicolegal patients that are examined in order to asses their personal injury claim.
89113619|NCT05924464|Experimental|Intervention arm|Group preconception care
89113620|NCT05924464|No Intervention|Control arm|Usual care (completion of questionnaires only)
89113621|NCT05917340|Experimental|Arm- 1( Intervention arm with aspirin)|Intensified with high dose rifampicin, moxifloxacin, aspirin and steroids in the initial two months.
89113622|NCT05917340|Experimental|Arm -2 (Intervention arm without aspirin)|Intensified with high dose rifampicin, moxifloxacin and steroids in the initial two months.
89113623|NCT05917340|Active Comparator|Arm -3 (Control)|Regimen as per the current National Tuberculosis Elimination Program in India.
89113624|NCT05902819|Experimental|PTSD intervention group|30 individuals with PTSD will receive imagery with minocycline.
89113625|NCT05902819|Placebo Comparator|PTSD control group|30 individuals with PTSD will receive imagery with placebo.
89113626|NCT05902819|Experimental|CUD intervention group|30 individuals with CUD will receive imagery with minocycline.
89113627|NCT05902819|Placebo Comparator|CUD control group|30 individuals with CUD will receive imagery with placebo.
89113628|NCT05902819|No Intervention|Healthy control group|30 healthy individuals who will not receive any intervention.
89113629|NCT05902819|No Intervention|Clinical control group|30 individuals with both PTSD and CUD who will not receive any intervention
89113630|NCT05901051|Experimental|dual therapy A|Vonoprazan 20mg bid ac and amoxicillin 0.75g qid pc
89113631|NCT05901051|Experimental|dual therapy B|Vonoprazan 20mg bid ac and amoxicillin 1g tid pc
89113632|NCT05901051|Experimental|dual therapy C|Vonoprazan 20mg bid ac and amoxicillin 1g tid ac
89113633|NCT05898776|Experimental|10°C lung preservation|
89113634|NCT05898776|Active Comparator|Standard lung preservation|
89113635|NCT05890469|Experimental|Zirconia surface implant and guided bone regeneration (Test)|Zirconia surface implant (Straumann PURE®, Basel, Switzerland) and guided bone regeneration (GBR) with a porcine collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland) and a deproteinized bovine bone substitute (Bio-Oss Collagen®, Geistlich, Wolhusen, Switzerland).
89113636|NCT05890469|Other|Hydrophilic titanium surface implant and guided bone regeneration (Control)|Hydrophilic titanium surface implant (Straumann Standard Plus (SP) Tissue level, SLActive®, Basel, Switzerland) and guided bone regeneration (GBR) with a porcine collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland) and a deproteinized bovine bone substitute (Bio-Oss Collagen®, Geistlich, Wolhusen, Switzerland).
89113637|NCT05868382|Experimental|mRNA-1010 Dose C|Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
89113638|NCT05868382|Experimental|mRNA-1010.4 Dose B|Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.
89113639|NCT05868382|Experimental|mRNA-1010.4 Dose C|Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.
89113640|NCT05868382|Experimental|mRNA-1010.6 Dose A|Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
89113641|NCT05868382|Experimental|mRNA-1010.6 Dose B|Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
89113642|NCT05868382|Experimental|mRNA-1010.6 Dose C|Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.
89113643|NCT05865106|Experimental|Smartphone-based speech therapy|Smartphone-based speech therapy: Participants will be instructed to use smartphone-based speech therapy (application), including oro-motor exercises, phonation, articulation, resonance, syllable repetition, and reading exercises.
89113644|NCT05865106|Other|Traditional speech therapy|Traditional speech therapy: Traditional speech therapy methods, such as face-to-face sessions, oro-motor exercises for the tongue, lips, chin, and jaw, reading aloud slowly and clearly, and practicing proper breathing and sustained speech, will be employed.
89113645|NCT05832567|Active Comparator|Active rTMS|The participant will receive a session of low frequency rTMS to the contralesional primary motor cortex. Low frequency rTMS stimulation will be applied according to the following parameter: intensity of 80% MT (intensity could be adjusted if not comfortable to the subject), frequency of 1 Hz, 1200 pulses as a single, continuous train lasting 20 minutes.
89113646|NCT05832567|Sham Comparator|Sham rTMS|The investigators will place the coil in the same location, usually used for the active stimulation with the same stimulation parameters. However, the investigators will replace the active coil with a sham coil to ensure no stimulation is provided.
89113647|NCT05832567|Placebo Comparator|Open Placebo|"The open placebo will consist of typical prescription medicine bottle of placebo pills with a label clearly marked placebo pills take 2 pills twice daily. The placebo pills are made from Microcrystalline Cellulose."
89113648|NCT05832567|No Intervention|No Intervention|It consists of treatment-as-usual group.
89113651|NCT05829993||Cohort|patients with a clinical indication to perform an ECG
89113652|NCT05820191|Experimental|AMY-GBM|Amyvid-PET scan will be performed. According to approved protocol for Alzheimer's disease diagnostics, 370MBq (10mCi) absorbed dose 7mSv of Amyvid will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
89113653|NCT05808309||PRp|Patients with a diagnostic of rheumatoid arthritis with an age of onset before 60 years
89113654|NCT05808309||PRt|Patients with a diagnostic of rheumatoid arthritis with an age of onset from 65 years
89113655|NCT05808309||Tem|Patients with a diagnostic of osteoarthritis without RA
89113656|NCT05808309||Ap|Relatives to PRt, with RA (with any age of onset) or without RA
89113657|NCT05801809|Experimental|Active taVNS|TaVNS will be administered by an earset, with conductive eartips placed on the auricular concha of the ears, connected to a stimulator, and during active stimulation, we stimulate both the cymba conchae and external auditory canal of both left and right ears with the following parameters: 30Hz, 200-250 us, and with adjustable intensity for 60 min.
89113658|NCT05801809|Sham Comparator|Sham taVNS|Sham condition will have the same device, with an earset, and conductive eartips placed in the same location of the active stimulation; however during 60 min there will be no current and the device will be turned off.
89113659|NCT05798156|Experimental|chemolight R-Pola-Glo treatment|
89113660|NCT05783063|Active Comparator|active stimulation|Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
89113661|NCT05783063|Sham Comparator|Sham stimulation|Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
89113662|NCT05778825|Experimental|Oral Minoxidil|Patients receive oral minoxidil at a dose of 0.01 (<40kg) and 0.02 (≥40kg) mg/kg/day for 8 months
89113663|NCT05778825|Active Comparator|Placebo followed by oral Minoxidil|Patient receive placebo for 4 months followed by oral minoxidil for 4 months
89113664|NCT05774899|Experimental|Experimental: Cohort 1A - CB-103 + Abemaciclib|"A modified 3+3 dose escalation design will be used. 3-9 participants will receive:~Standard of care Abemaciclib.~Cycle 1 - End of Treatment~--Days 1- 28 of 28-day cycle: Predetermined dose of CB-103 2x daily on five consecutive days followed by two days of treatment break in each treatment week.~A safety review will be performed by primary investigation after completion of the ramp-up phase."
89113665|NCT05774899|Experimental|Experimental: Cohort 1B - CB-103 + Abemaciclib|"Participants will receive:~Cycle 1 - End of Treatment~--Days 1- 28 of 28-day cycle: Predetermined dose of CB-103 2x daily on five consecutive days followed by two days of treatment break in each treatment week and predetermined dose of Abemaciclib 1x daily.~Therapy will continue until disease progression, therapy intolerance, or participant withdrawal.~End of Treatment (EOT) visit within 30 days of last administration of study treatments."
89113666|NCT05774899|Experimental|Experimental: Cohort 2A- Lenvatinib + CB-103|"A modified 3+3 dose escalation design will be used. 3-9 participants will receive:~Standard of care VEGFR TKI.~Cycle 1 - End of Treatment~--Days 1- 28 of 28-day cycle: Predetermined dose of CB-103 2x daily on five consecutive days followed by two days of treatment break in each treatment week.~A safety review will be performed by primary investigation after completion of the ramp-up phase."
89113667|NCT05774899|Experimental|Experimental: Cohort 2B- Lenvatinib + CB-103|"Participants will receive:~Continue standard of care VEGFR TKI at prior dose and schedule.~Cycle 1 - End of Treatment~--Day 1- 28 of 28-day cycle: Predetermined dose of CB-103 2x daily on five consecutive days followed by two days of treatment break in each treatment week.~Therapy will continue until disease progression, therapy intolerance, or participant withdrawal.~End of Treatment (EOT) visit within 30 days of last administration of study treatments."
89113668|NCT05767047|Experimental|Apremilast|Participants with a weight between ≥ 12 kg to < 20 kg will receive apremilast 10 mg BID (twice a day), participants with a weight between ≥ 20 kg to < 50 kg will receive 20 mg BID, and participants with a weight ≥ 50 kg will receive apremilast 30 mg BID.
89113669|NCT05766202|Other|Pilot intervention for multiparas with fear of childbirth|A group intervention with four meetings and one telephone call.
89113672|NCT05733455|Experimental|Alpelisib treatment|Participants will ingest a single dose of alpelisib 300 mg (two overencapsulated 150-mg tablets)
89113673|NCT05733455|Placebo Comparator|Placebo treatment|Participants will ingest a single dose of placebo (two capsules filled with microcrystalline cellulose)
89113674|NCT05729399|Experimental|GT201 treatment group|Autologous tumor infiltrating lymphocyte injection
89113675|NCT05727891|Placebo Comparator|Placebo|
89113676|NCT05727891|Active Comparator|Tonabersat (80 mg)|
89113677|NCT05727787|Experimental|Single fraction SBRT 27 Gy|vGRID SBRT 3+3 dose escalation, single fraction, one day cycle length
89231527|NCT06278883|Experimental|Intervention|Risk assessment pipeline
89231528|NCT06277973|Experimental|Immediate Stabilization Procedure|"Participants in this arm will answer questionnaires and go through the intervention according to this schedule:~Day 1 - questionnaires (T1) Day 4 - intervention Day 7 - questionnaires (T2) Day 97 - follow up questionnaires (T3)"
89231529|NCT06277973|Other|Waiting list|"Participants in this arm will answer questionnaires and do the intervention according to this schedule:~Day 1 - questionnaires (T0) Day 7 - questionnaires (T1) Day 11- intervention Day 14- questionnaires (T2) Day 104- follow up questionnaires (T3) Thus, unlike in the experimental arm, the intervention will be delayed by a week and participants will fill out questionnaires one additional time, a week before they begin the same protocol as the experimental arm."
89231532|NCT06273488||Auriculotherapy intervention group|
89231533|NCT06273488||Control group|
89231534|NCT06272994|No Intervention|No MRSA Nasal Swab|Subjects will not have a nasal swab collected.
89231535|NCT06272994|Active Comparator|MRSA Nasal Swab|Subjects will have a nasal swab collected and sent to the clinical laboratory for the MRSA nasal swab PCR test to be run. For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.
89231543|NCT06267768||Stroke participants|People diagnosed with stroke and meeting all inclusion criteria will be included in this study.
89231544|NCT06267768||Healthy participants|Healthy adults meeting all inclusion criteria will be included in this study.
89231545|NCT06267521|Experimental|Group 1: Mediation Only|"Baseline measures including imaging~Meditation plus Sham Stimulation 2 nights per week for 4 weeks~Post Intervention (week 5) measures including imaging~Follow up measures (week 20)"
89231546|NCT06267521|Experimental|Group 2: Stimulation Only|"Baseline measures including imaging~Sham Meditation plus Stimulation in Lab 2 nights per week for 4 weeks~Post Intervention (week 5) measures including imaging~Follow up measures (week 20)"
89231547|NCT06267521|Experimental|Group 3: Combined, Low Frequency|"Baseline measures including imaging~Meditation plus Stimulation in Lab 1 night per week for 4 weeks~Post Intervention (week 5) measures including imaging~Follow up measures (week 20)"
89231548|NCT06267521|Experimental|Group 4: Combined, High Frequency|"Baseline measures including imaging~Meditation plus Stimulation in Lab 2 nights per week for 4 weeks~Post Intervention (week 5) measures including imaging~Follow up measures (week 20)"
89231549|NCT06263751|No Intervention|Usual Care (Control)|Patient is screened for food or financial insecurity, if positive, social worker will refer him/her to community service programs.
89231550|NCT06263751|Experimental|NutriConnect Credit|Patient is given $20 credit to their Schnucks (grocery) Reward account every other week for F&V shopping.
89231551|NCT06263751|Experimental|NutriConnect Delivery|Patient receives produce (F&V) box (with equivalent $20 value) delivered to home every other week.
89231552|NCT06263712|Experimental|ASSIP Group|Patients in the ASSIP Group will receive 3-4 sessions of the Attempted Suicide Short Intervention Program (ASSIP) which is a specific therapy for patients with a suicide attempt in their personal history. Each ASSIP session takes approximately 50 minutes.
89231553|NCT06263712|Active Comparator|STAR Group|Patients in the STAR group will receive the standard of care plus resource interview (STAR) which will be a risk assessment interview, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the sessions are focused on activation of existing resources and the patients' social environment is discussed.
89231554|NCT06260163|Experimental|Open-label Induction Phase: Guselkumab Intravenously (IV)|Participants will receive a guselkumab dose IV based on their body weight (BW) during the 12-week open-label induction phase.
89231555|NCT06260163|Experimental|Open-label Induction Phase: Guselkumab Subcutaneously (SC)|Participants will receive a guselkumab dose SC based on their BW during the 12-week open-label induction phase.
89231556|NCT06260163|Experimental|Double-blind Maintenance Phase: Guselkumab SC or Guselkumab SC and Placebo SC|At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive a guselkumab dose SC based on their BW or a guselkumab dose SC based on their BW and placebo SC up to Week 56.
89231557|NCT06260163|Experimental|Open-label Maintenance Phase: Guselkumab SC|Week 12 non-responders will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 56.
89231558|NCT06257355|Experimental|CSB-001|One drop CSB-001 four times daily for 14 days in the study eye
89231559|NCT06255665|Experimental|Part 1 (Dose Escalation): JNJ-79032421|In Part 1 (Dose escalation), participants will receive JNJ-79032421. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
89231560|NCT06255665|Experimental|Part 2 (Dose Expansion): JNJ-79032421|In Part 2 (Dose expansion), participants will receive JNJ-79032421 at the RP2D regimen(s) determined in Part 1.
89231565|NCT06251037|Experimental|Intervention|"The participants in this group will:~Participate in the initial survey; Undergo the YAM program; Participate in the final survey (follow-up)."
89231566|NCT06251037|No Intervention|No intervention|"The participants in this group will:~Participate in the initial survey; Participate in the final survey (follow-up)."
89231568|NCT06245057|Experimental|Maternity care home model (MCHM)|Office based prenatal care integrated with comprehensive social services within the maternity care home model.
89231569|NCT06245057|No Intervention|Usual care arm|Office based prenatal care with individually outsourced social service referrals.
89231570|NCT06244043|Active Comparator|Initial Interventional Coaching Call Plus Email Support|
89231571|NCT06244043|Active Comparator|Initial Interventional Coaching Call No Email Support|
89231572|NCT06244043|Active Comparator|Initial Informational Coaching Call Plus Email Support|
89113678|NCT05710718|Experimental|PureWick™ System|The PureWick™ System includes the PureWick™ Female External Catheter and the PureWick™ Urine Collection System. The PureWick™ Female External Catheter (PureWick™ FEC) is marketed in both the United States and Europe. In the U.S. PureWick™ FEC is a Class I, 510(k) exempt device. In Europe, the PureWick™ FEC is a Class I, Conformitè Europëenne (CE) marked, non-sterile device.
89113679|NCT05710718|Active Comparator|Hollister® Female Urinary Pouch External Collection Device|The urinary collection pouch with a skin barrier is suitable for non-ambulatory females with urinary incontinence.
89113680|NCT05708482|Experimental|Sling-Swing Group|"While the pregnant woman has 6 cm cervical dilatation examination, the flexible fabric will pass under the arms of the pregnant woman to form a hanger shape. The pregnant woman will be asked to hold the fabric on her feet in a squat and the hanging technique will be applied for 10 minutes. Then, a swing shape will be created in such a way that the flexible fabric will wrap around the chest area of the pregnant woman. The pregnant woman will be asked to hold the fabric in a squat above the knee and the rocking technique will be applied for 10 minutes. Subsequently, uterine contractions, fetal heart rate, fetal head level, position and presence of molding will be evaluated.~Until the completion of the first stage of labor (10 cm cervical dilatation, 100% cervical effacement), this applicant will be experienced by them as the same procedure, hourly.~A Birth Satisfaction Form will be filled at the 2nd hour after delivery.."
89113681|NCT05708482|No Intervention|Standard Care Group|"While the pregnant woman has 6 cm cervical dilatation examination, uterine contractions, fetal heartbeat, fetal head level, position and presence of molding will be evaluated.~Until the completion of the first stage of labor (10 cm cervical dilatation, 100% cervical effacement), uterine contractions, fetal heartbeat, fetal head level, position and presence of molding will be evaluated every hour.~A Birth Satisfaction Form will be filled at the 2nd hour after delivery. At the end of the study, delivery times and satisfaction of pregnant women will be analyzed."
89113682|NCT05700266|Experimental|Rivaroxaban and Aspirin|Rivaroxaban (2.5mg orally twice a day for 90 days) and Aspirin (100mg once a day for 1 year)
89113683|NCT05700266|Active Comparator|Clopidogrel and Aspirin|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days) and Aspirin (100mg once a day for 1 year)
89113684|NCT05699226|Experimental|Variable amplitude|Individualized amplitude
89113685|NCT05699226|Active Comparator|Fixed amplitude|Fixed (800 milliamperes) amplitude
89113686|NCT05694169|Experimental|Renal Autologous Cell Therapy (REACT)|Participants will receive 2 REACT injections separated by 6 months. All participants will be followed for 12 months post last supplemental REACT injection.
89231573|NCT06244043|Active Comparator|Initial Informational Coaching Call No Email Support|
89113687|NCT05690113||Clinical population|250 children aged from 7 to 17 will be recruited in 6 clinical departments (child and adolescent psychiatry, forensic medicine, psychotraumatism centers) They will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire) to assess convergent and divergent validity.
89113688|NCT05690113||Non-clinical population|250 children aged from 7 to 17 will be recruited in schools They will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire) to assess convergent and divergent validity.
89113689|NCT05685173|Experimental|Odronextamab and REGN5837|Odronextamab and REGN5837 will be administered by IV infusion using a step-up dosing schedule.
89113690|NCT05680116|Active Comparator|Home based exercise group|Patients who will start radiotherapy after breast cancer surgery will be evaluated prior to treatment. During the radiotherapy process, all of the patients will be included in the home exercise program, 5 days a week, 2 sessions a day, each exercise will be 10x2 repetitions. Exercise follow-up of the patients will be provided with weekly routine face-to-face checks. After an average of 6 weeks of radiotherapy, the initial evaluations will be repeated.
89113691|NCT05680116|Experimental|Home based exercise plus vibration therapy group.|Patients who will start radiotherapy after breast cancer surgery will be evaluated prior to treatment. During the radiotherapy process, all of the patients will be included in the home exercise program, 5 days a week, 2 sessions a day, each exercise will be 10x2 repetitions. The study group continues their home based exercise, in addition they will receive 30 minutes of Myovolt (Myovolt TM, Myovolt Limited, Christchurch, New Zealand) device which is wearable vibration therapy 2 days a week. The vibration program will continue for 6 weeks, in the form of 2 sessions per week. Intermittent and sinusoidal modes between 20-100 Hz will be used for the vibration frequency.
89113692|NCT05674617|Experimental|Written Exposure Therapy (WET)|5 individual therapy sessions of WET via video telehealth
89113693|NCT05674617|Active Comparator|PTSD Education Control|5 individual sessions of PTSD psychoeducation via video telehealth
89113694|NCT05651945|Experimental|Cardiac rehabilitation group|Traditional medically supervised center-based cardiac rehabilitation program; including 36 sessions (30-50 minutes) of a progressive exercise program and educational sessions for cardiovascular disease (CVD) risk factors.
89113695|NCT05651945|No Intervention|Standard of care|Depending on functional deficits, conventional rehabilitation therapies can include physical therapy, occupational therapy, and/or speech therapy sessions with 2-3 visits per week. Participants will receive their standard of care therapies as prescribed by their treating physicians.
88816299|NCT02579343|Sham Comparator|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
89113696|NCT05630014|Experimental|Family Caregivers of PLWD at High Risk for Delirium|Participants will complete the Aliviado DSD Caregiving Mastery Program. This involves a caregiver education/training period from Week 0 to Week 2, and an implementation period from Week 3 to Week 6.
89113697|NCT05617300|Experimental|MBDC course|8 week MBDC Course including 8 weekly 2 hour classes and a retreat (4 hours). Individual classes will be held virtually via web-based video calls.
89113698|NCT05616312|Experimental|Postoperative teach-back educational program|Patients will receive teach-back education while they fill out questionnaires.
89113699|NCT05616312|No Intervention|Control|Patients will not receive any teach-back education while filling out questionnaires.
89113700|NCT05613387|Experimental|ZP8396|"Part 1: 2 dose cohorts are planned with 10 subjects in each; 7 participants in each cohort will receive active treatment.~Part 2: 3 dose cohorts are planned with 16 subjects in each; 12 participants in each cohort will receive active treatment."
89113701|NCT05613387|Placebo Comparator|Placebo (ZP8396)|"Part 1: In each of the 2 dose cohorts, 3 subjects will receive placebo.~Part 2: In each of the 3 cohorts, 4 subjects will receive placebo."
89113702|NCT05613283||Accuracy verification group|Assessment reagent urine sample HPV-PCR test result Assessment reagent vaginal secretion sample HPV-PCR test result Comparative Methods NGS Nucleic Acid Sequencing Results
89113703|NCT05613283||Consistency verification group|Assessment reagent urine sample HPV-PCR test result Assessment reagent vaginal secretion sample HPV-PCR test result ApprovedListed Reagent Cervical Sample HPV-PCR Test Result
89113704|NCT05613283||Efficacy and safety verification group|Thin-layer liquid-based cytology (TCT) results panel Colposcopy results Tissue biopsy pathological diagnosis result
89113705|NCT05607862|Experimental|Intervention Group|The intervention group will continue with its usual medical-pharmacological treatment, and will also receive a multi-component exercise program and health education guidelines.
89113706|NCT05607862|Other|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment.
89113707|NCT05599711|Experimental|Transitioning Together|Participants in this arm will receive the Transitioning Together intervention in English or Spanish either at BMC, at BMC's Supporting Parents & Resilient Kids (SPARK) Center or on BMC Zoom.
89113708|NCT05599711|Active Comparator|Usual Care|Participants in this arm will receive a referral to usual transition-related care through the BMC Developmental and Behavioral Pediatrics (DBP) clinic/the BMC Autism Program.
89231574|NCT06242418|Experimental|FOLFOXIRI|Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
89231575|NCT06242418|Active Comparator|XELOX|Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
89231576|NCT06238921|Experimental|SG + Zimberelimab with SRS|Treatment will be initiated with SRS followed 1 week later by SG on days 1 and 8 (10mg/kg) with zimberelimab on day 1 (360 mg IV) repeated every 3 weeks follow-up imaging response assessments will be conducted at q9 week intervals.
89231577|NCT06238726|No Intervention|Passive control|Patients in this arm will not be sent any messages.
89231578|NCT06238726|Active Comparator|Active control|Patients in this arm will be sent messages encouraging them to ask about Shingrix at their upcoming appointment.
89231579|NCT06238726|Experimental|High risk|Patients in this arm will be sent messages informing them that they are at high risk for shingles because they are ages 50+, and encouraging them to ask about Shingrix at their upcoming appointment.
89231580|NCT06238726|Experimental|Multi-fact|Patients in this arm will be sent messages with facts about shingles and Shingrix, and encouraging them to ask about Shingrix at their upcoming appointment.
89231581|NCT06238726|Experimental|High risk + multi-fact|Patients in this arm will be sent messages informing them that they are at high risk for shingles because they are ages 50+, with additional facts about shingles and Shingrix, and encouraging them to ask about Shingrix at their upcoming appointment.
89231584|NCT06237062||adult migraine patients|adult migraine patients across the 4 Gulf Countries (UAE, Qatar, Oman and Kuwait)
89231585|NCT06236815|Experimental|delta-9-THC|
88816300|NCT01144286|Placebo Comparator|placebo|placebo pessary, single dose
88816301|NCT01144286|Experimental|Arasertaconazole nitrate 150 mg|Arasertaconazole nitrate 150 mg pessary, single dose
88816302|NCT01144286|Experimental|arasertaconazole nitrate 300 mg|Arasertaconazole nitrate 300 mg pessary, single dose
89231586|NCT06236815|Experimental|delta-8-THC|
89231587|NCT06236815|Placebo Comparator|Placebo|
89231588|NCT06236347|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
89231589|NCT06236347|Active Comparator|Treatment as usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
89231590|NCT06235281|Experimental|POTELIGEO & Phototherapy combination therapy|POTELIGEO (mogamulizumab-kpkc) will be given according to FDA approved dose and scheduled for 8 cycles. After 2 cycles of POTELIGEO, all subjects will start phototherapy as combination therapy.
89231591|NCT06229925|Experimental|Experimental Stimulation|Active direct current stimulation for 20 minutes.
89231592|NCT06229925|Sham Comparator|Sham Stimulation|Sham direct current stimulation for 20 minutes.
89231593|NCT06229483|Experimental|Tranexamic Acid|Participants will be randomized in a 1:1 ratio to receive tranexamic acid 20 mg/kg IV bolus or identical volume of placebo 0.9 % NaCl within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, or identical volume of placebo 0.9 % NaCl, for the duration of surgery. Treatment is blinded.
89231594|NCT06229483|Placebo Comparator|Matching Placebo|Participants will be randomized in a 1:1 ratio to receive tranexamic acid 20 mg/kg IV bolus or identical volume of placebo 0.9 % NaCl within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, or identical volume of placebo 0.9 % NaCl, for the duration of surgery. Treatment is blinded.
89231599|NCT06227832|Experimental|KP-001/Metformin|
89231600|NCT06227832|Experimental|KP-001/Midazolam|
89231601|NCT06227832|Experimental|KP-001/Clarithromycin|
89231602|NCT06227377|Experimental|Part 1a: QTX3034 monotherapy dose-escalation|QTX3034 will be administered at protocol defined dose based on cohort assignment
89231603|NCT06227377|Experimental|Part 1b: QTX3034 combination with cetuximab dose-escalation|QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment
89231604|NCT06227377|Experimental|Part 2: QTX3034 monotherapy dose-expansion|QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment
89231605|NCT06227377|Experimental|Part 3: QTX3034 combination with cetuximab dose-expansion|QTX3034 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment
89231606|NCT06226883|Experimental|Group 1|Blinded MORF-057 Dosing Regimen 1 for Induction Period and open-label MORF-057 for Maintenance Period
89231607|NCT06226883|Experimental|Group 2|Blinded MORF-057 Dosing Regimen 2 for Induction Period and open-label MORF-057 for Maintenance Period
89231608|NCT06226883|Placebo Comparator|Group 3|Blinded matching placebo for Induction Period and open-label MORF-057 for Maintenance Period
89231609|NCT06225453|Experimental|Individualized strategy|"Targeting mean arterial pressure and systolic blood pressure of ≥ -20% of their baseline values in each patient during surgery. The baseline values are defined as the average of all measurements between one day before surgery and the morning of the surgery. The target is applied until discharge from the post-anesthesia care unit. If the patient is transported to the intensive care unit after surgery, not the post-anesthesia care unit, then the strategy is applied until the end of surgery.~The target is applied until discharge from the post-anesthesia care unit. It the patient is transported to the intensive care unit after surgery, not the post-anesthesia care unit, then the strategy is applied until the end of surgery."
89113709|NCT05584241|Active Comparator|Diagnostic Disclosure|"Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.~For reporting purposes those participants randomized to this condition are analyzed by biomarker status (positive/+ or negative/-)."
89113710|NCT05584241|Experimental|Biomarker and Diagnostic Disclosure|"Participants receive information about their cognitive test results and research diagnosis. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.~For reporting purposes those participants randomized to this condition are analyzed by biomarker status (positive/+ or negative/-)."
89113711|NCT05580601|Experimental|Cytokine-Induced Memory-Like Natural Killer (CIML-NK) Cells|The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product.
89113712|NCT05572957|Active Comparator|GDMT group|"With the current guidelines of recommended therapies for HF, each patient who meets the inclusion criteria should begin being on all 4 drug classes after enrollment, including a beta-blocker (BB), a RAS inhibitor (ACEI, ARB) or ARNI (preferred), an MRA, and an SGLT2i.~The appeal drugs should be gradually uptitrated to the maximum tolerated dose within the first 3-6 months.~Ivabradine will be added to the patients whose resting heart rates remain above 70 beats per minute (bpm) after adequate medical treatment, including a BB at maximum tolerated dose."
89113713|NCT05572957|Experimental|LBBP+GDMT group|"In this arm, medications are the same as the GDMT group. The LBBP lead is introduced into the right ventricle (RV) and is placed on the right side of the interventricular septum (IVS). The lead is advanced deeply into the IVS until reaching the LV septal subendocardium and right bundle branch block (RBBB) morphology of the paced QRS complex is observed in electrocardiogram (ECG) lead V1.~If LBBP fails, his bundle pacing (HBP) should be considered when HBP could correct LBBB.~If both of LBBP and HBP fail, conventional BiVP-CRT could be the last option."
89113714|NCT05561829|Experimental|Sleep Hygiene|Administration of sleep hygiene education (single intervention)
89113715|NCT05561829|Experimental|Cognitive Therapy|Administration of cognitive therapy only (single intervention)
89113716|NCT05561829|Experimental|Relaxation Training|Administration of relaxation training only (single intervention)
89113717|NCT05561829|Experimental|Relaxation Training, Cognitive Therapy, Sleep Hygiene|Administration of relaxation training, cognitive therapy, and sleep hygiene education (3 interventions)
89113718|NCT05561829|Experimental|Stimulus Control|Administration of stimulus control therapy only (single intervention)
89113719|NCT05561829|Experimental|Stimulus Control, Cognitive Therapy, Sleep Hygiene|Administration of stimulus control therapy, cognitive therapy, and sleep hygiene education (3 interventions)
89113720|NCT05561829|Experimental|Stimulus Control, Relaxation Training, Sleep Hygiene|Administration of stimulus control therapy, relaxation training, and sleep hygiene education (3 interventions)
89113721|NCT05561829|Experimental|Stimulus Control, Relaxation Training, Cognitive Therapy|Administration of stimulus control therapy, relaxation training, and cognitive therapy (3 interventions)
89113722|NCT05561829|Experimental|Sleep Optimization|Administration of sleep optimization only (single intervention)
89113723|NCT05561829|Experimental|Sleep Optimization, Cognitive Therapy, Sleep Hygiene|Administration of sleep optimization, cognitive therapy, and sleep hygiene education (3 interventions)
89113724|NCT05561829|Experimental|Sleep Optimization, Relaxation Training, Sleep Hygiene|Administration of sleep optimization, relaxation training, and sleep hygiene education (3 interventions)
89113725|NCT05561829|Experimental|Sleep Optimization, Relaxation Training, Cognitive Therapy|Administration of sleep optimization, relaxation training, and cognitive therapy (3 interventions)
89113726|NCT05561829|Experimental|Sleep Optimization, Stimulus Control, Sleep Hygiene|Administration of sleep optimization, stimulus control therapy, and sleep hygiene education (3 interventions)
89113727|NCT05561829|Experimental|Sleep Optimization, Stimulus Control, Cognitive Therapy|Administration of sleep optimization, stimulus control therapy, and cognitive therapy (3 interventions)
89113728|NCT05561829|Experimental|Sleep Optimization, Stimulus Control, Relaxation Training|Administration of sleep optimization, stimulus control therapy, and relaxation training (3 interventions)
89113729|NCT05561829|Experimental|Sleep Optimization, Stimulus Control, Relaxation Training, Cognitive Therapy, Sleep Hygiene|Administration of sleep optimization, stimulus control therapy, relaxation training, cognitive therapy, and sleep hygiene education (5 interventions)
89113730|NCT05557734|Active Comparator|caudal epidural group|"the patient will be positioned in lateral position, sterilized from the iliac crest margin to the lower buttock by betadine and will be covered by sterile drapes exposing the sacral area. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound. Short axis (transverse) will be used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) will be used for direct puncture of sacrococcygeal membrane out of plane then the probe will be rotated to long axis (longitudinal) and the needle will be seen in plane in the epidural space. Injection of 40 ml 0.125% bupivacaine will expand the epidural space. The patient will be repositioned to lithotomy position and surgery will start after 5 min. of preparing the patient and sterilization to the surgery"
89113731|NCT05557734|Active Comparator|perianal block group|, the patient will be in the lithotomy position, paint and drape the area of the block under strict aseptic precaution, draw a circle with a radius of 2.5cm around anal opening, mark a point at 2,4,8,10 clock position, prepare 40 ml 0.125% bupivacaine, use 1.5-inch 23/24 gauge needle connected to 10 ml syringe, insert full length of the needle into the ischiorectal fat immediately peripheral to the external sphinchter. This injection scheme target the terminal nerve branches of the anus rather than blocking the trunk of major nerves. At 2 clock position, inject 2-3 ml of LA with tilting in lateral direction,withdraw needle 1cm and after every 1cm inject 2-3ml of LA, repeat procedure at 4,8,10 clock position, remaining around 10 ml of LA is used to infiltrate in subcutaneous tissue in circumference of anal opening.
89113732|NCT05554835||Mitochondrial patients|Patients with a suspected or confirmed mitochondrial disease.
89113733|NCT05546515|Active Comparator|Suvorexant|20mg Suvorexant
89113734|NCT05546515|Placebo Comparator|Placebo|Placebo oral capsules
89113735|NCT05537610|Experimental|Contingency-Discrimintation Training (CDT)|In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
89113736|NCT05537610|Active Comparator|Control|This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
89113737|NCT05522374||NBIA Patients|Patients with suspected or confirmed NBIA
89113738|NCT05501990|Experimental|Health intervention based on intelligent applet|Health interventions using electronic applet, including nutrition, psychology, and patient self-management components.
89113739|NCT05499975|Experimental|Older adults completing the CHAMP tool before treatment decision is made|Eligible participants who consent to the study will be asked to complete questionnaires about socio-demographic characteristics, literacy, and technology comfort. Subsequently, participants will be asked to complete the CHAMP tool at home or in the clinic before their medical appointment with the oncologist. Next, participants will see their oncologist for their consultation. Approximately one week after the consultation, participants will be asked to complete 3 questionnaires about their experience and satisfaction with the CHAMP tool
89113740|NCT05473442|Experimental|EQU-001 60 mg|EQU-001 60 mg (3 x 20 mg pills)
89113741|NCT05473442|Experimental|EQU-001 20 mg|EQU-001 20 mg (1 x 20 mg pill + 2 x matching placebo pills)
89113742|NCT05473442|Placebo Comparator|EQU-001 0 mg|EQU-001 0 mg (3 x matching placebo pills)
89113743|NCT05465590|Experimental|MB1707 Single Dose Phase 1|Phase 1 MB1707 given as a single intravenous (IV) dose of 0.3 mg/kg
89113744|NCT05462704|Experimental|IV Iron|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes and daily placebo tablets until delivery.
89113745|NCT05462704|Active Comparator|Oral Iron|Participants assigned to the oral iron group will receive a single 250 mL IV normal saline infusion given over 20 minutes and 325mg tablets of ferrous sulfate (65 mg of elemental iron) to be taken until delivery.
89113746|NCT05455346|Experimental|Romanian Deadlift|The training intervention groups will undergo the same program with the only difference being the interventional hamstring exercise. The program will consist of a 2-week acclimatization period followed by 4-weeks of progressive training. The RDL will be performed with a 6 second eccentric component with the athlete returning to the start position with a maximal concentric hip extension.
89113747|NCT05455346|Active Comparator|Nordic Hamstring Exercise|The training intervention groups will undergo the same program with the only difference being the interventional hamstring exercise. The program will consist of a 2-week acclimatization period followed by 4-weeks of progressive training. During the acclimatization period, the relative intensity will be lower compared to the 4-week progressive training to ensure each participant performs the exercise with proper technique. During the subsequent progressive training weeks, the participants will perform the NHE without the bands.
89113748|NCT05441982|Active Comparator|Acesulfame Potassium|Controlled feeding study. Dosage of acesulfame potassium will follow 25% of the acceptable daily intake (equivalent to 3.75 mg/kg). This amount represents 225 mg/day of acesulfame potassium for a 60 kg adult.
89113749|NCT05441982|Active Comparator|Saccharin|Controlled feeding study. Dosage of saccharin will follow 25% of the acceptable daily intake (equivalent to 3.75 mg/kg). This amount represents 225 mg/day of saccharin for a 60 kg adult.
89113750|NCT05441982|Placebo Comparator|No NNS|controlled feeding study with no non-nutritive sweeteners
89113751|NCT05438329|Experimental|DB-1305 Dose Level 1|Enrolled subjects will receive a single-dose of DB-1305 at Dose Level 1 on Day 1 of each cycle Q3W
89113752|NCT05438329|Experimental|DB-1305 Dose Level 2|Enrolled subjects will receive a single-dose of DB-1305 at Dose Level 2 on Day 1 of each cycle Q3W
89113753|NCT05438329|Experimental|DB-1305 Dose Level 3|Enrolled subjects will receive a single-dose of DB-1305 at Dose Level 3 on Day 1 of each cycle Q3W
89113754|NCT05438329|Experimental|DB-1305 Dose Level 4|Enrolled subjects will receive a single-dose of DB-1305 at Dose Level 4 on Day 1 of each cycle Q3W
89113755|NCT05438329|Experimental|DB-1305 Dose Level 5|Enrolled subjects will receive a single-dose of DB-1305 at Dose Level 5 on Day 1 of each cycle Q3W
89113756|NCT05438329|Experimental|DB-1305 Dose Expansion 1|Enrolled subjects with NSCLC with AGAs who will receive a single-dose of DB-1305 on a selected dose level once every 3 weeks
89113757|NCT05438329|Experimental|DB-1305 Dose Expansion 2|Enrolled subjects with NSCLC without AGAs who will receive a single-dose of DB-1305 on a selected dose level once every 3 weeks
89113758|NCT05438329|Experimental|DB-1305 Dose Expansion 3|Enrolled subjects with OC who will receive a single-dose of DB-1305 on a selected dose level once every 3 weeks
89113759|NCT05438329|Experimental|DB-1305 Dose Expansion 4|Enrolled subjects with BC who will receive a single-dose of DB-1305 on a selected dose level (RP2D) once every 3 weeks
89113760|NCT05438329|Experimental|DB-1305 Dose Expansion 5|Enrolled subjects with TNBC who have progressed on or after standard systemic treatments and without prior treatment of sacituzumab govitecan who will receive a single-dose of DB-1305 on a selected dose level (RP2D) once every 3 weeks
89113761|NCT05438329|Experimental|DB-1305 Dose Expansion 6|Enrolled subjects with TNBC with treatment failure on sacituzumab govitecan who will receive a single-dose of DB-1305 on a selected dose level (RP2D) once every 3 weeks
89113762|NCT05438329|Experimental|DB-1305 Dose Expansion 7|Enrolled subjects with EC with disease progression on or after treatment with at least one platinum-containing regimen for advanced or metastatic disease with or without immune checkpoint inhibitor (ICI) who will receive a single-dose of DB-1305 on a selected dose level (RP2D) once every 3 weeks
89113763|NCT05438329|Experimental|DB-1305 Dose Expansion 8|Enrolled subjects with malignant mesothelioma who have progressed on or after standard systemic treatments who will receive a single-dose of DB-1305 on a selected dose level (RP2D) once every 3 weeks
89113764|NCT05438329|Experimental|DB-1305 Dose Expansion 9|Enrolled subjects with CC who have progressed on or after standard systemic treatments who will receive a single-dose of DB-1305 on a selected dose level (RP2D) once every 3 weeks
89113765|NCT05438329|Experimental|DB-1305 Dose Expansion 10|Enrolled subjects with other advanced or metastatic solid tumors who have progressed on or after standard systemic treatments who will receive a single-dose of DB-1305 on a selected dose level (RP2D) once every 3 weeks
89113766|NCT05438329|Experimental|DB-1305 Dose Expansion 11|Enrolled subjects with NSCLC without AGAs who has not received PD-1/PD-L1, PD-L2, CTLA-4 directed immunotherapy and previously received ≤1 line of platinum-based chemotherapy for advanced or metastatic NSCLC who will receive a single-dose of DB-1305 on a selected dose level in combination with pembrolizumab 200mg once every 3 weeks
89231610|NCT06225453|Active Comparator|Conventional strategy|Targeting a mean arterial pressure of 65 mmHg or higher and a systolic blood pressure of 90 mmHg or higher during surgery. The target is applied until discharge from the post-anesthesia care unit. If the patient is transported to the intensive care unit after surgery, not the post-anesthesia care unit, then the strategy is applied until the end of surgery.
89113767|NCT05434767|Active Comparator|Standard rehabilitation program|
89113768|NCT05434767|Experimental|Mobile application|
89113769|NCT05433467|Experimental|CT-guided localization for micro hepatocellular carcinoma before surgical resection|fter preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
89113770|NCT05430854|Experimental|Daxdilimab|Daxdilimab injections over a total of 48 weeks.
89113771|NCT05430360|Experimental|GT201 treatment group|Autologous tumor infiltrating lymphocyte injection
89113772|NCT05416125|Placebo Comparator|Lifestyle therapy plus placebo|Individuals randomized to this arm will receive lifestyle therapy plus placebo for 24 weeks.
89113773|NCT05416125|Active Comparator|Lifestyle therapy plus lisdexamfetamine|Individuals randomized to this arm will receive lifestyle therapy plus lisdexamfetamine for 24 weeks.
89113774|NCT05404711|Other|CGM use for T2D risk evaluation|All participants will complete a standard 2-hour oral glucose tolerance test (OGTT), wear a CGM for 10 days, complete at-home glucose challenge, and provide qualitative feedback about their experiences with both OGTT and CGM use for risk evaluation.
89113775|NCT05401045|Experimental|observation group|"Exercise plan: Each session of the self-designed METexercises were divided into 8 components. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening.Metabolic equivalent intensity: The intensity of exercise was expressed as metabolic equivalents (METs).~Exercise training: Members of the fatigue management team in the ward taught the patients to perform MET exercises using videos.The fatigue management team members confirmed that the patient could perform the exercise independently and correctly."
89113776|NCT05401045|No Intervention|control group|Participants received routine exercise health education that included information pertaining to CRF (causes of CRF, clinical manifestations, related factors, the necessity and importance of fatigue prevention, and measures to improve CRF, etc.) and exercise (3-5 times per week, regardless of the type of exercise). The patients were also informed about the precautions for exercise.
89113777|NCT05390723|Experimental|video 1|The investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
89113778|NCT05390723|Experimental|video 2|The investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
89113779|NCT05390723|Experimental|video 3|the investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
89113780|NCT05390723|Experimental|video 4|the investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
89113781|NCT05382403|Experimental|Jada® System|Patients in this group will have the Jada® System applied when the initial medical treatment fails, and estimated blood loss reaches 1000 mL. It is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted.
89113782|NCT05382403|Active Comparator|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy
89113783|NCT05369182||Deferred Population: Patients with CMD (CFR<2.0 and IMR≥25)|Among patients who did not undergo PCI at the discretion of the operator, patients diagnosed CMD (CFR<2.0, IMR≥25) in physiologic assessment.
89113784|NCT05369182||Deferred Population: Patients with preserved microvascular function (CFR≥2.0 OR IMR<25)|Among patients who did not undergo PCI at the discretion of the operator, patients with preserved microvascular function (CFR≥2.0 OR IMR<25) in physiologic assessment.
89113785|NCT05369182||Revascularized Population: Patients treated by intravascular imaging-guided PCI optimization|Among patients who received PCI, patients whose PCI was optimized through intravascular imaging device (IVUS or OCT).
89113786|NCT05369182||Revascularized Population: Patients treated by angiography-only guided PCI|Among patients who received PCI, patients whose PCI was optimized through angiography-only.
89113787|NCT05339269|Experimental|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
89113788|NCT05338294|Experimental|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
89113789|NCT05325437|Experimental|Experimental Group|Laparoscopic splenectomy and azygoportal disconnection
89113790|NCT05325424|Other|Experimental Group|Laparoscopic splenectomy
89113791|NCT05316623|Sham Comparator|Control group|Simulated TENS and personalized exercise program in telerehabilitation (3 sessions/week over 3 weeks) n = 12
89113792|NCT05316623|Experimental|Intervention group|Real TENS and personalized exercise program in telerehabilitation (3 sessions/week over 3 weeks) n = 12
89113793|NCT05315648|Experimental|General anesthesia group|Patients in GA group will receive general anesthesia combined with FNB. All patients received routine anesthesia and surgical protocols. GA will be induced by intravenously administering propofol 2-4 mg/kg, cisatracurium 0.2mg/kg, sufentanil 0.2-0.3 μg/kg and maintained with remifentanil at 0.15-0.2 μg/kg/min and 2%-3% sevoflurane to keep bispectral index (BIS) values at 40 - 60. FNB will be performed under ultrasound-guieded and combined with nerve stimulation. Using an in-plane technique, a 10-cm long 18- gauge (G) Tuohy needle will be inserted in the lateral to medial direction towards the femoral nerve (FN). As the needle is being advanced toward the FN, the nerve stimulator is set at 1 mA, 0.1-millisecond pulse duration, and 2-Hz frequency. When the muscle contraction of the quadriceps muscle is identified, the current is reduced to 0.5 mA. After the negative aspiration, 20 mL of ropivacaine 0.375% is injected.
89113794|NCT05315648|Experimental|Non-general anesthesia group|"Patients in NGA group will receive combined spinal-epidural anesthesia（CSEA）at L3 to L4 interspace with 3.0 ml of 0.5% hyperbaric ropivacaine followed with FNB , and without sedation. The FNB will be performed under aseptic precautions using ultrasound guidance and nerve stimulation. A high frequency linear ultrasound transducer 5-12 MHz (Sonosite, Inc. Bothell WA 98021 USA) was placed on the inguinal crease to identify the femoral artery and nerve. Using an in-plane technique, a 10-cm long 18- gauge (G) Tuohy needle connected to the nerve stimulator will be inserted in the lateral to medial direction towards the femoral nerve. When the muscle contraction of the quadriceps muscle and negative aspiration are identified, 20 mL of ropivacaine 0.375% is injected.~If the CSEA analgesia is invalid (two times of epidural remedial analgesia) , change non-general anesthesia to general anesthesia, and the subjects withdrew from the trial."
89113795|NCT05304455|Experimental|Apixaban group|From postoperative day 3, Patients will receive oral Dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.
89231615|NCT06222437|Experimental|Protocol group|PCOS women in the age 18 to 45 years
89113796|NCT05300516|Experimental|vagus nerve-guided group|Procedure/Surgery: vagus nerve-guided group The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
89113797|NCT05300516|No Intervention|Conventional group|Every patient of conventional group will receive the conventional Robotic-assisted azygoportal disconnection procedure.
89113798|NCT05292391|Experimental|A|0.5 mL of 100 micrograms of Sm-p80 administered intramuscularly on Days 1, 29, and 57. N=9
89113799|NCT05292391|Experimental|B|0.5 mL of 10 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 57. N=9
89113800|NCT05292391|Experimental|C|0.5mL of 30 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 180. N=9.
89113801|NCT05292391|Experimental|D|0.5mL of 30 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29, and 57. N=9.
89113802|NCT05292391|Experimental|E|0.5mL of 100 micrograms Sm-p80 + 5 micrograms GLA-SE administered intramuscularly on Days 1, 29 and 57. N=9.
89113803|NCT05287685|Experimental|Screen media adapted School Readiness Parenting Program|Screen media adapted School Readiness Parenting Program (Once weekly session of 1.5 hours for 8 weeks)
89113804|NCT05287685|Active Comparator|Original School Readiness Parenting Program|Original School Readiness Parenting Program (Once weekly session of 1.5 hours for 8 weeks)
89113805|NCT05284227|Active Comparator|Clinical Decision Support Application guided Anaesthesiological Assessment|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application.
89113806|NCT05284227|Sham Comparator|Standard Anaesthesiological Assessment|Preoperative anaesthesiological assessment using standard procedures of the hospital and a sham clinical decision support application.
89113807|NCT05282264||Patient with hybrid closed-loop systems|
89113808|NCT05282264||Patient without hybrid closed-loop systems|
89523292|NCT03048799|Active Comparator|Radiofrequency on and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment, maintained for 2 minutes. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in lateral decubitus position. The session will be quick, with an average duration of 20 minutes.Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
89113811|NCT05281263|Experimental|Group 1, young adult cohort (age 18-59)|BLB-201 administered as a single dose of 10^7.5 PFU by intranasal route on Day 1
89113812|NCT05281263|Experimental|Group 2, older adult cohort (age 60-75)|BLB-201 administered as a single dose of 10^7.5 PFU by intranasal route on Day 1
89113813|NCT05279937|Experimental|Prolotherapy|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
89113814|NCT05279937|Active Comparator|Control|10mL of 1% Lidocaine (Control)
89113815|NCT05258422|Experimental|Radiation: 20 Gy in 1 fraction|External beam, stereotactic body radiotherapy of 20 Gy delivered in 1 fraction to the planning target volume (PTV) of the arrhythmogenic substrate
89113816|NCT05257603|Experimental|Revictimization Prevention for College Women (RPCW)|Active intervention that includes information to reduce hazardous drinking and increase sexual assault risk perception.
89113817|NCT05257603|Active Comparator|Health Education Control (HEC)|Time and attention control.
89113818|NCT05238883|Experimental|Dose Escalation - HFB200301 monotherapy|Participants will be administered HFB200301 at dose levels 1-5 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).
89113819|NCT05238883|Experimental|Dose Escalation - HFB200301 in combination with tislelizumab|Participants will be administered HFB200301 at dose levels 1-4 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Dose for Expansion (RDE).
89113820|NCT05238883|Experimental|Dose Expansion - HFB200301 monotherapy|Participants will be administered HFB200301 at monotherapy RDE as an intravenous infusion.
89113821|NCT05238883|Experimental|Dose Expansion - HFB200301 in combination with tislelizumab|Participations will be administered HFB200301 in combination with tislelizumab at combination RDE as an intravenous infusion.
89113822|NCT05238493|Experimental|"Subcutaneous (SQ) Dose A"|Single dose of VEL-101 by SQ injection
89113823|NCT05238493|Experimental|"Intravenous (IV) Dose A"|Single dose of VEL-101 by IV infusion
89113824|NCT05238493|Experimental|"SQ Dose B"|Single dose of VEL-101 by SQ injection
89113825|NCT05238493|Experimental|"SQ Dose C"|Single dose of VEL-101 by SQ injection
88816303|NCT01144286|Experimental|arasertaconazole 600 mg|Arasertaconazole nitrate 600 mg pessary, single dose
88816304|NCT01144442|Experimental|HIPC Treatment|
88816305|NCT02408484|Experimental|Octafibrin|Plasma-derived fibrinogen concentrate
88816306|NCT01144598||Turkish patients with rheumatoid arthritis|
88816307|NCT04909788||Healthy adults with regular exercise|Subjects will be asked to wear a small monitoring equipment before,during and after a long distance running (over 3 km).
89113826|NCT05238493|Experimental|"IV Dose C"|Single dose of VEL-101 by IV infusion
89113827|NCT05238493|Experimental|"SQ Dose D"|Single dose of VEL-101 by SQ injection
89113828|NCT05238493|Experimental|"SQ Dose E"|Single dose of VEL-101 by SQ injection
89113829|NCT05238493|Placebo Comparator|SQ or IV Placebo|Single dose of Placebo by SQ injection or IV infusion
89113830|NCT05228470|Experimental|Elranatamab|BCMA-CD3 bispecific antibody
89113831|NCT05210257|Other|Conventional physiotherapy|Conventional physiotherapy program consists of neck isometric exercises, neck isotonic exercises, stabilization exercises, stretching exercises and posture exercises and physiotherapy agents.
89113832|NCT05210257|Active Comparator|Neuroscience education|Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.
89113833|NCT05205005|Experimental|Dietary supplementation of glycocalyx precursors (DSGP)|Participants will daily ingest 3,712mg (i.e., six capsules) of DSGP for eight weeks. DSGP, commercially available as Endocalyx (Microvascular Health Solutions LLC, Alpine, UT), include glucosamine sulfate, fucoidan, superoxide dismutase, and high molecular weight hyaluronan.
89113834|NCT05205005|Placebo Comparator|Placebo|Participants will daily ingest 6 capsules daily of placebo
89113835|NCT05193942|Experimental|Intervention|From baseline to 4-month post-test, participants in the intervention arm will have access to the Our Plan web app program.
89113836|NCT05193942|Other|Informational control|From baseline to 4-month post-test, participants in the informational control arm will not have access to the Our Plan web app program. Participants will instead receive a webpage with information about HIV/STI prevention options and resources to represent the current equivalent of a standard of care for online HIV resources.
89113837|NCT05179499|Active Comparator|Intervention Arm|Participants will receive peripheral vasopressor infusion of norepinephrine (16 micrograms/ml) during the initial 48 hour study period. All other care will be as per local protocol.
89113838|NCT05179499|Placebo Comparator|Standard care|Participants allocated to the control arm will receive standard care as defined by the UK NICE guidelines and the Surviving Sepsis Campaign guidelines during the 48 hour study period post randomisation. All other care will be as per local protocol.
89113839|NCT05165069|Experimental|Mecobalamin group|Mecobalamin (0.5mg / time, 3 times / day) for 6 months
89113840|NCT05165069|Placebo Comparator|Placebo group|placebo (0.5mg / time, 3 times / day) for 6 months
89113841|NCT05157880|Experimental|Experimental Patient-Caregiver Dyads|There will be 6 sessions with 2 general sessions delivered in person at bedside in the NICU (or virtual depending on COVID and discharge status) and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom. Content will be primarily skills.
89113842|NCT05157880|Active Comparator|Control Patient-Caregiver Dyads|There will be 6 sessions with 2 general sessions delivered in person at bedside in the NICU (or virtual depending on COVID and discharge status) and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom. Content will be primarily educational.
89113843|NCT05157126|Experimental|Gentamicin|The intervention consists of 80mg of liquid gentamicin diluted in 5 mL normal saline (16mg/mL). The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.
89113844|NCT05157126|Placebo Comparator|Saline|The control consists of 5 mL normal saline injected immediately after wound closure at the open fracture site. The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.
89113845|NCT05154019|Experimental|Intervention|Line Managers from organisations in the intervention arm will complete a self-led online training course consisting of 5 modules, over a period of 5-6 weeks
89113846|NCT05154019|No Intervention|Waitlist Control|Line Managers from organisations in the intervention arm will receive no training. They will be given access to the online intervention at the end of a 3-month period.
89113847|NCT05153668|Experimental|Adjuvant Everolimus After Surgical Dilation|Individuals will take low dose everolimus for 6 weeks after dilation.
89113850|NCT05139368|Experimental|Treatment (hypo-fractionated radiotherapy)|Patients undergo hypo-fractionated radiotherapy over 3 weeks in the absence of disease progression or unacceptable toxicity.
89113851|NCT05122754|Experimental|B/F/TAF group|Bictegravir/emtricitabine/tenofovir alafenamide for 48 weeks.
89113852|NCT05122754|Active Comparator|TDF-based triple ART regimen switching to B/F/TAF|TDF-based triple ART regimen for 24 weeks, and all switch to bictegravir/emtricitabine/tenofovir alafenamide for the later 24 weeks.
89113853|NCT05119855|Experimental|Concomitant Group|Participants will receive the first dose of 9vHPV vaccine and first dose of mRNA-1273 vaccine on Day 1; participants will then receive the second dose of mRNA-1273 vaccine at Month 1 and the second dose of 9vHPV vaccine at Month 6.
89113854|NCT05119855|Experimental|Non-concomitant Group|Participants will receive the first and second doses of mRNA-1273 vaccine on Day 1 and at Month 1, respectively; participants will then receive the first and second doses of 9vHPV vaccine at Months 2 and 8, respectively.
89113855|NCT05078450|Experimental|Graduate Student Program|This is the graduate student version of the program. The original program has been tailored to this population to meet its specific needs and address its specific concerns.
89113856|NCT05078450|Experimental|Young Professional Program|This is the young professional version of the program. The original program has been tailored to this population to meet its specific needs and address its specific concerns.
89113857|NCT05078450|No Intervention|Waitlist|This is the waitlist. Participants may be randomly assigned here first. After the typical period fo the intervention on the waitlist (12 weeks), these participants will be invited to join the arm which they are most appropriate for (i.e., graduate student or young professional).
88816308|NCT02499081|Experimental|Ixazomib|Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.
88816309|NCT02380248|Experimental|Systane|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days
88816310|NCT01146704|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
89113859|NCT05067647|Experimental|Thoracic, Urologic, Ear, Nose and Throat (ENT) Procedures|Any thoracic, urologic, or ENT procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use. Participants will be considered enrolled when the ENSEAL X1 device has been attempted to be used for a vessel transection during thoracic, urologic, or ENT procedures.
88816311|NCT01146704|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
88816312|NCT04909320|Experimental|Intervention group|
89113860|NCT05067491|Experimental|Intervention|The experimental group will go through an exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable.
89113861|NCT05067491|No Intervention|Non-intervention|The control group will not go through an exposure therapy session using an augmented reality headset device. This will be a no-intervention control group that can have some form of exposure therapy following the conclusion of the treatment/research period.
89113862|NCT05058872|Experimental|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg - once a day for 21 days
89113863|NCT05058872|Placebo Comparator|Placebo|Placebo once a day for 21 days
89113864|NCT05048264||Diabetic patients receiving a corticosteroid injection of their shoulder, knee or hip joints.|There are no study-related interventions for this study.
89113865|NCT05042128|Experimental|Standard Care + CEND1|Participants will receive nab-paclitaxel 125mg/m2; CEND1 3.2mg/kg IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
89113866|NCT05042128|Placebo Comparator|Standard Care + Placebo|Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
89113867|NCT05040568|Experimental|Cetuximab|given to patients with high-risk colorectal cancer
89113868|NCT05033080|Experimental|VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
89231619|NCT06219278|Experimental|Matrix Pro Applicator|Source study subjects received up to three (3) full-face treatments for wrinkles with Matrix Pro Applicator (27W)
88816313|NCT04909320|Active Comparator|Control group|
89113869|NCT05033080|Active Comparator|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
89113870|NCT05023200||Population|Adults (age ≥18 years) identified by their treating clinician as having lower limb cellulitis that requires intravenous or oral antibiotic treatment either from the hospital or another service based outside of the hospital, which will conduct ongoing follow-up regardless of location.
89113871|NCT05022901|Experimental|Melphalan/HDS|Eligible patients will be treated with Melphalan/HDS 3.0 mg/kg Ideal Body Weight (IBW). Melphalan/HDS treatment will be administered every 6 weeks for a total of 6 cycles with an acceptable delay of another 2 weeks before the next planned treatment to allow for recovery of melphalan-related toxicity, if needed.
89113872|NCT04997356|Experimental|Hostile Bias Modification (HBM) Training plus Unambiguous Feedback|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They are instructed not to respond if only an aggressive word can be formed. They will receive unambiguously hostile feedback to an essay.
89113873|NCT04997356|Placebo Comparator|Other training plus Unambiguous Feedback|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words. They will receive unambiguously hostile feedback to an essay.
89113874|NCT04997356|Experimental|Hostile Bias Modification (HBM) Training plus Ambiguous Feedback|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They are instructed not to respond if only an aggressive word can be formed. They will receive ambiguously hostile feedback to an essay.
89113875|NCT04997356|Placebo Comparator|Other training plus Ambiguous Feedback|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words. They will receive ambiguously hostile feedback to an essay.
89113876|NCT04989946|Active Comparator|Arm 1: Degarelix|- Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57
89113877|NCT04989946|Experimental|Arm 2: Degarelix and pTVG-AR|"Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57~pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71"
89113878|NCT04989946|Experimental|Arm 3: Degarelix and pTVG-AR and Nivolumab|"Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57~pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71~Nivolumab 240 mg IV administered at days 29, 43, 57 and 71"
89113879|NCT04989946|Experimental|Arm 4: Degarelix and pTVG-AR and Cemiplimab|"Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57~pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71~Cemiplimab 350 mg IV administered at days 1, 22, 43 and 64"
89231620|NCT06219135||contamination|Patients with a positive blood culture due to contamination microorganism
89231621|NCT06219135||Bacteraemia|This group includes all adults and children with a positive blood culture due to pathogen microorganism
89231622|NCT06217523|No Intervention|Control Group|Doctor-only care; receiving standard care without genetic information
89231623|NCT06217523|Experimental|Intervention Group|Pharmacist-guided care; dosing of statin medication based on genetic information
89231624|NCT06214286|Experimental|Shockwave|One group received shock wave therapy with the conventional physical therapy program including kinesio taping
89231625|NCT06214286|Active Comparator|conventional|conventional physical therapy program including kinesio taping without shock wave therapy
89231626|NCT06214143|Experimental|T3011|
89231627|NCT06212453|Experimental|patients with BPH|Targeted Microwave Ablation
89231628|NCT06203691|Experimental|Supplement Group|50 of the 100 participants will be given supplements (Prepare & Recover) for pre & post operation.
89231629|NCT06203691|Placebo Comparator|Non-Supplement Group|No supplements will be given to the non-supplement group.
89231631|NCT06195761|Experimental|computer guided modified ridge splitting technique (study group)|The first treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide.
89231632|NCT06195761|Experimental|conventional modified ridge splitting technique (control group)|The second treatment plan includes manually harvesting and fixing the bone graft in posterior mandibular area without a surgical guide
89231633|NCT06193863||Rivaroxaban|Pediatric patients with CHD who had undergone the Fontan procedure were prescribed with Xarelto before enrollment.
89231634|NCT06191211|No Intervention|Control group|Standard of care - no engagement or communication skills training for first-line providers.
89231635|NCT06191211|Active Comparator|Doctors Light Communication|"In facilities randomised to this group, all front-line health workers receiving patients in outpatient consultations over the trial duration will be asked to encourage eligible patients to get vaccinated or receive a booster of the Covid-19 vaccine.~At the start of the intervention period, all facilities will receive a visit from the District office of the Ghana Health Service. The visit will (1) remind them of the importance of covid19 vaccination to all consulting staff; (2) ask all consulting staff to have discussions with patients about Covid19 vaccination during routine consultations and (3) provide a simple tracking sheet to be used by consulting staff to record these consultations."
89231636|NCT06191211|Experimental|Doctors Enhanced Communication|"In addition to facility engagement described in the Doctor light communication group, five front-line health workers from each of the facilities in the treatment group will be invited to take part in a training providing information and developing specific communication skills to encourage patients to get vaccinated. The communication skills are based on principles rooted in Motivational Interviewing (MI) and have been used in Ghana to address vaccine hesitancy."
89231639|NCT06189248|Experimental|Intervention group|"6 group activities designed with resourcefulness skills will be performed in the intervention group.~Introduction of Resourcefulness~Issue of the Interpersonal Competence: Applications of both personal and social resourcefulness strategies~Issues of the Interpersonal Competence & Relationship Adjustment: Applications of both personal and social resourcefulness strategies~Issue of the Relationship Adjustment: Applications of both personal and social resourcefulness strategies~Issue of the Negative Emotion: Applications of both personal and social resourcefulness strategies~Conclusion"
89231640|NCT06189248|No Intervention|Observation group|No intervention for the observation group.
89231641|NCT06185686||Brain tumor patients receiving proton radiation therapy|Patients between 8 and 21 years old (inclusive) with a newly diagnosed primary brain tumor that will be treated with proton radiation therapy
89231642|NCT06177977|Active Comparator|Group 1 - Progressive Inherited retinal dystrophy (IRD)|50 participants with progressive IRD; the most common IRD seen at Duke Clinics.
89231643|NCT06177977|Active Comparator|Group 2 - Non-progressive Inherited Retinal Dystrophy (IRD)|20 participants with non-progressive IRD (n=20), a subset of IRDs that are less frequently referred to Duke Clinics
89231644|NCT06177977|Active Comparator|Group 3 - Control participants|10 participants with normal retinal anatomy undergoing anesthesia for strabismus surgery as part of their clinically-indicated care.
89231645|NCT06171555|Active Comparator|Standard of Care Steroid Injection|Group 1 Control Group: standard corticosteroid injection: 1cc of celestone (6mg) diluted with 1 cc of 1% lidocaine and inject at the ECRB origin at area of maximal pain when palpated.
89231646|NCT06171555|Experimental|Test CTM Injection|Group 2 Test Group: CTM injection: 1cc of CTM Boost will be diluted with 1 cc of 1% lidocaine and injected at the ECRB origin at area of maximal pain when palpated. CTM Boost is a connective tissue matrix suspended in saline. (injection will need to be with a 23 gauge needle and 3 cc syringe)
89231647|NCT06171542|Experimental|CTM Shoulder Injection|
89231650|NCT06164704|Experimental|Verekitug (UPB-101)|Participants will be administered 0.5 milliliter (mL) of verekitug (UPB-101) formulated solution (containing 100 milligrams [mg] of verekitug [UPB-101]) subcutaneously, every 12 weeks for 24 weeks.
89231651|NCT06164704|Placebo Comparator|Matching placebo|Participants will be administered verekitug (UPB-101) matching placebo solution, subcutaneously, every 12 weeks for 24 weeks.
89231652|NCT06162728|Experimental|Briquilimab|This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled.
89231653|NCT06162728|Placebo Comparator|Placebo|Placebo Comparator
88816314|NCT02501265|Active Comparator|Varenicline Standard Protocol|Participant choses Varenicline-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Varenicline. Consistent with Varenicline Standard Treatment, 1 week prior to the TQD the participant will switch to active Varenicline and placebo Bupropion. Participant will continue active Varenicline and placebo Bupropion to 12 weeks post-TQD.
89231660|NCT06159790|Experimental|GME751 + pemetrexed + carboplatin or cisplatin|Participants will receive GME751 + pemetrexed + carboplatin or cisplatin via intravenous (IV) infusion.
89231661|NCT06159790|Active Comparator|Keytruda-EU + pemetrexed + carboplatin or cisplatin|Participants will receive Keytruda-EU + pemetrexed + carboplatin or cisplatin via intravenous (IV) infusion.
89231662|NCT06159725|Placebo Comparator|Placebo|Matching placebo, 100mL normal saline
89231663|NCT06159725|Experimental|5 mg/kg CMTX-101|5mg/kg CMTX-101 in 100mL normal saline
89231664|NCT06159725|Experimental|30 mg/kg CMTX-101|30 mg/kg CMTX-101 in 100mL normal saline
89231665|NCT06159725|Experimental|15 mg/kg CMTX-101|15 mg/kg CMTX-101 in 100mL normal saline
89231666|NCT06159686|Experimental|hemp group|They was assigned to apply the hemp-containing cream.
89231667|NCT06159686|Placebo Comparator|Control group|They was assigned to apply the placebo cream.
89231668|NCT06159621|Active Comparator|Arm A: PD1|Subjects in this arm will receive one dose of LVGN3616 (300mg).
89231669|NCT06159621|Active Comparator|Arm B: PD1 + CD40|Subjects in this arm will receive one dose of LVGN3616 (300mg) followed by one dose of CD40 LVGN7409 (1mg/kg).
89231670|NCT06159335|Experimental|PET-MRI|Participants will undergo F-Fluciclovine PET radiotracer and MRI
89231671|NCT06154850|Experimental|Immersive Virtual Reality|Individuals will wear the headset for 10 minutes while playing NatureTrek application
89231672|NCT06154850|Active Comparator|Non-immersive Virtual Reality|Individuals will watch a video including scenes from NatureTrek application for 10 minutes.
89231673|NCT06153238|Experimental|GME751|Subjects will receive GME751 via intravenous (IV) infusion.
89231674|NCT06153238|Active Comparator|Keytruda - EU|Subjects will receive Keytruda-EU via intravenous (IV) infusion.
89231675|NCT06153238|Active Comparator|Keytruda - US|Subjects will receive Keytruda-US via intravenous (IV) infusion.
89231678|NCT06139887|Experimental|BESST|Patients randomized to the BESST intervention arm will receive the BESST intervention combined with standard mental health care.
89231679|NCT06139887|Other|Control|Patients randomized to the control arm will receive standard mental health care alone.
89231680|NCT06136832|No Intervention|Control|Patients randomized into this arm DO NOT RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.
89231681|NCT06136832|Experimental|Treatment|Patients randomized into this arm RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.
89231682|NCT06136221|No Intervention|Enhanced Usual Care|Patients will undergo baseline interviews with study coordinators. All participants will be screened for malnutrition with the validated malnutrition screening tool (MST). At the baseline interview, patients will receive instructional handouts on dietary changes and recipes as per the updated 2019 European Society for Clinical Nutrition & Metabolism (ESPEN) guidelines. Information on the resource CirrhosisCare.ca will also be provided. Participants in the control arm will receive Fitbits to monitor their steps. They will be asked to try and get up to 7000 steps per day, and no follow-up on their progress in terms of step counts will be given during the 12 weeks. All participants will be allowed to keep their Fitbit once they complete the study.
89231683|NCT06136221|Experimental|LiverWatch Intervention|"Patients will undergo symptom-based monitoring with targeted nutrition support. participants in Arm 2 will also receive educational text messages related to cirrhosis and physical activity. In summary, there are four components to the~Remote Symptom Monitoring~Targeted Nutrition Assessment and Intervention~Physical Activity and Rewards Program~Motivational Messages~Subjects will be enrolled in an online portal, Way to Health (W2H), which automates many of the research and monitoring functions of the intervention. Patients will receive remote symptom monitoring on a weekly basis, enhanced nutrition assistance through weekly education videos, and motivational messages on Mondays and Fridays that include education on diet, physical activity, and cirrhosis. Participants in this arm will also be encouraged to increase their step count using a rewards system built through the W2H."
89231684|NCT06134804|Experimental|Group 1: Coadministration (CoAd) Group|Participants will receive intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) along with high-dose (HD) quadrivalent influenza vaccine, concomitantly, on Day 1 and placebo on Day 30.
89231685|NCT06134804|Experimental|Group 2: Control Group|Participants will receive IM injection of matching placebo along with HD quadrivalent influenza vaccine, concomitantly, on Day 1 and ExPEC9V on Day 30.
89113880|NCT04989946|Experimental|Arm 5: Degarelix and pTVG-AR and Cemiplimab and Fianlimab|"Degarelix 240 mg s.c. day 29, 80 mg s.c. day 57~pTVG-AR (100 µg) administered intradermally (i.d.) at days 1, 8, 15, 22, 29, 43, 57 and 71~Cemiplimab 350 mg IV administered at days 1, 22, 43 and 64~Fianlimab 1600 mg IV administered at days 1, 22, 43 and 64"
89113881|NCT04983745|Experimental|Experimental|niraparib and dostarlimab
89113882|NCT04965090|Experimental|Patients with parenchymal brain metastases|All patients in both cohorts will receive both oral lazertinib and amivantamab by intravenous injection (IV). Lazertinib dosing will start at 240 mg daily. For patients who weigh <80 kg, on C1D1 amivantamab 350 mg will be given IV via peripheral line for C1D1, D2 and D8, with 700 mg IV given on C1D2. For all other treatments, amivantamab 1050 mg IV will be given. For patients who weigh ≥ 80 kg, on C1D1 350mg IV amivantamab will be given and 1050 mg IV on C1D2, with 1400 mg IV given for all.
89113883|NCT04965090|Experimental|Patients with leptomeningeal (LM) disease with or without parenchymal brain metastases|All patients in both cohorts will receive both oral lazertinib and amivantamab by intravenous injection (IV). Lazertinib dosing will start at 240 mg daily. For patients who weigh <80 kg, on C1D1 amivantamab 350 mg will be given IV via peripheral line for C1D1, D2 and D8, with 700 mg IV given on C1D2. For all other treatments, amivantamab 1050 mg IV will be given. For patients who weigh ≥ 80 kg, on C1D1 350mg IV amivantamab will be given and 1050 mg IV on C1D2, with 1400 mg IV given for all.
89113884|NCT04956445||Population 1|Once a positive diagnosis of COVID-19 has been made in the clinical setting, the clinical team caring for the patient will ask the patient / family whether they would be willing to be contacted by the study team about the study. If so, a trained member of the study team will describe the study in person or by telephone. Community members who see the study flyer will also be able to reach out to the study team to learn more about the study and to find out if they meet eligibility criteria. If the eligible patient / legally authorized representative / legal guardian would like to participate. The verbal informed consent / verbal HIPAA, assent, and/or parental permission (as appropriate) will then be obtained in person.
89113885|NCT04956445||Population 2|Persons with a history of past (>14 days ago) diagnosis of COVID-19 infection will be invited to participate in this study. In addition, persons who have had significant exposure to a patient with COVID-19 (contact at a distance of less than 6 feet without personal protective equipment) and have remained asymptomatic for 14 days following exposure will be recruited. Candidates will be identified through initial enrollment in Population 1, or by clinicians who have been informed of the study but are not part of the study team. Then, the clinical care team will ask the patient if he/she is willing to be contacted by the study team. Community members who see the study flyer or are otherwise informed of the study will also be able to reach out to the study team. Additionally, individuals with no defined past COVID-19 infection, but the potential to have been exposed to, and mounted antibodies against, COVID-19 will also be enrolled in Population 2 for this study.
89113886|NCT04938128|Experimental|CPAP treatment|This group will receive CPAP treatment
89113887|NCT04938128|No Intervention|Control|This group will receive Diet and Lifestyle advice only
89113888|NCT04933084|No Intervention|Usual Care|During their pre-operative visit, the usual care group will undergo usual pre-surgery patient education care dependent on their provider.
89113889|NCT04933084|Experimental|Text Handout|This group will receive limited opioid analgesia in conjunction with pre-operative education in the form of a text handout.
89113890|NCT04933084|Experimental|Text handout and Pre-recorded Video|This group will receive limited opioid analgesia in conjunction with pre-operative education in the form of a text handout AND pre-recorded video.
89113891|NCT04932109||Healthy Group|
89113892|NCT04932109||Hand Injuries Group|
89113893|NCT04927065|Experimental|Part A.1: mRNA-1273.211 50 μg|Participants will receive 1 intramuscular booster dose of 50 micrograms (μg) of mRNA-1273.211 on Day 1.
89113894|NCT04927065|Experimental|Part A.1: mRNA-1273.211 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.211 on Day 1.
89113895|NCT04927065|Experimental|Part B: mRNA-1273 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273 on Day 1.
89113896|NCT04927065|Experimental|Part C: mRNA-1273.617.2 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.
89113897|NCT04927065|Experimental|Part C: mRNA-1273.617.2 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.617.2 on Day 1.
89113898|NCT04927065|Experimental|Part D: mRNA-1273.213 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213 on Day 1.
89113899|NCT04927065|Experimental|Part D: mRNA-1273.213 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
89113900|NCT04927065|Experimental|Part E: mRNA-1273.213 100 μg|Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
89113901|NCT04927065|Experimental|Part F Cohort 1: mRNA-1273.529 50 μg|Participants will receive 1 intramuscular first booster dose of 50 μg of mRNA-1273.529 on Day 1.
89113902|NCT04927065|Experimental|Part F Cohort 2: mRNA-1273.529 50 μg and mRNA-1273 50 μg|Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.529 or mRNA-1273 enrolled sequentially (after receiving a primary series of mRNA-1273 and a single booster dose of mRNA-1273 50 μg) on Day 1.
89113903|NCT04927065|Experimental|Part G: mRNA-1273.214 50 μg|Participants will receive 1 intramuscular second booster dose of mRNA-1273.214 50 μg on Day 1.
89113904|NCT04927065|Experimental|Part A.2: mRNA-1273.214 50 μg|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.214 on Day 1.
89113905|NCT04927065|Experimental|Part H: mRNA-1273.222 50 μg|Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.222 on Day 1.
89113906|NCT04927065|Experimental|Part J: mRNA-1273.815 or mRNA-1273.231|Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.815 or 50 ug of mRNA-1273.231 on Day 1.
89113907|NCT04914689|Active Comparator|Internal focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback in a mirror of their movement patterns.
89113908|NCT04914689|Experimental|Visual external focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving visual feedback of their movement patterns from a laser.
89113909|NCT04914689|Experimental|Auditory external focus of attention feedback|Participants will complete 12 sessions over 3 weeks receiving auditory feedback of their movement patterns.
89113910|NCT04906759|Experimental|Meals plus exercise|
89231686|NCT06130254|Experimental|Adagrasib+Olaparib|"Participants will take adagrasib and olaparib by mouth 2 times each day. Each dose should be taken at about 12 hours apart (1 dose in the morning, 1 dose in the evening). The study drugs should be swallowed whole with water. Do not chew, crush, dissolve, or divide the study drugs.~If forget a dose and less than 2 hours have passed since the usual time participants take the study drug, take the dose as soon as participants remember. If more than 2 hours have passed, do not take the dose. Wait and take the next dose as scheduled"
89231687|NCT06126809|Experimental|Steep-tRAS,|Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. The condition of interest, steep-tRAS, mimics a steep slope of the aperiodic signal characterized by greater low relative to high frequency power. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
89231688|NCT06126809|Active Comparator|Flat-tRAS|Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. The active control, flat-tRAS, mimics a flat slope aperiodic signal characterized by greater high relative to low frequency power. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
89231689|NCT06126809|Sham Comparator|Sham-tRAS|Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. For active sham stimulation, steep-tRAS or flat-tRAS is delivered for only 15 seconds at the beginning and end of the block. This mimics the skin sensations (e.g., itching, burning, tingling) to assist with blinding the participant. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
89231690|NCT06118099|Experimental|Amlitelimab|Subcutaneous injection (SC) as per protocol.
89231691|NCT06118099|Placebo Comparator|Placebo|Subcutaneous injection as per protocol.
89231692|NCT06109272|Experimental|Stage 1: Cohort 1|Participants will receive livmoniplimab Dose 1 in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.
89231693|NCT06109272|Experimental|Stage 1: Cohort 2|Participants will receive livmoniplimab Dose 2 in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.
89231694|NCT06109272|Active Comparator|Stage 1: Cohort 3 - Group 1 (Control)|Participants will receive atezolizumab in combination with bevacizumab every 3 weeks until disease progression or until discontinuation criteria are met.
89231695|NCT06109272|Active Comparator|Stage 1: Cohort 3 - Group 2 (Control)|Participants will receive a single dose of tremelimumab in combination with durvalumab every four weeks until disease progression or until discontinuation criteria are met.
89231696|NCT06109272|Experimental|Stage 2: Arm 1|Participants will receive livmoniplimab (optimized dose) in combination with budigalimab every 3 weeks until disease progression or until discontinuation criteria are met.
89113911|NCT04906759|Experimental|Meals only|
89113912|NCT04901767||Receiving drug coated balloon (DCB)|
89113913|NCT04901767||Receiving drug eluting stent (DES)|
89113914|NCT04894240|Experimental|Monepantel treatment arm|Monepantel tablets will be administered to participants in this arm daily for 28 days. Dose escalation will occur at the end of each 28 day period according to a modified Fibonacci sequence based upon recommendations from the safety management committee
89113915|NCT04889755|Other|SibACCESS|This is a single-arm trial of a group-based, posttraumatic stress intervention for adolescent siblings of children with cancer. The intervention includes a parent educational webinar, seven group sibling sessions, one individual parent session, and one individual sibling session.
89113916|NCT04885621||underserved patients with diabetes mellitus|patients with type 2 diabetes mellitus living in underserved, financially challenged areas of Southwest Virginia who are poorly controlled
89113917|NCT04854616|Experimental|CoSTED Intervention|"CoSTED is an opportunistic smoking cessation intervention comprising three elements:~brief smoking cessation advice~the provision of an electronic cigarette (e-cigarette) and training in its use~referral to stop-smoking services"
89113918|NCT04854616|No Intervention|Treatment as Usual|Signposting to NHS smoking cessation services through provision of written information about local services.
89113919|NCT04843371||Patient Group|All patients undergoing an echocardiogram at Tulane Medical Center may be asked to participate in the study. Doctors, including PI and co-PI, will identify eligible patients from their clinic using their clinical knowledge and expertise and the patients' medical history and records. They will provide patients with information regarding the study and if interested, patients will be consented prior to their scheduled echocardiogram.
89113920|NCT04836494|Experimental|BBP-671 for SAD|The SAD portion of the study will consist of up to 8 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
89113921|NCT04836494|Placebo Comparator|Placebo for SAD|The SAD portion of the study will consist of up to 8 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
89113922|NCT04836494|Experimental|BBP-671 for MAD|The MAD portion of the study will consist of up to 6 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).
89113923|NCT04836494|Placebo Comparator|Placebo for MAD|The MAD portion of the study will consist of up to 6 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).
89113924|NCT04836494|Experimental|BBP-671 for SAD Food Effect|Eight (8) healthy male or female adult subjects will be randomized to receive BBP-671.
89113925|NCT04836494|Experimental|BBP-671 for PA and MMA Patients|Up to sixteen (16) patients with either PA or MMA will receive BBP-671.
89113926|NCT04836026||HF20™ for Pediatric CRRT|Pediatric patients in an intensive care unit requiring CRRT for acute kidney injury (AKI)
89113927|NCT04833907|Experimental|3.7 x 10^13 v.g. rAAV-Olig001-ASPA|3.7 x 10^13 v.g. of rAAV-Olig001-ASPA administered as a single dose neurosurgically to the brain via 2 pre-defined intracerebroventricular sites
89113928|NCT04814420|Experimental|Experimental group|The group will include 15 patients with OSA 5 with mild OSA 5 with moderate OSA 5 with severe OSA
89113929|NCT04814420|Other|Control group|This group will include 5 patients with no OSA
89113931|NCT04809259|Experimental|Continuous infusion of meropenem|The meropenem solution will be administered continuously using elastomeric pumps which will be changed every 24 hours and which will be inserted in an isothermal pouch to ensure that the antibiotic solution is maintained at a temperature between 10° and 15°
89113932|NCT04803123|Experimental|Copanilisib|
89113933|NCT04795323|Experimental|Cohort 1: TARA v3.1, only non-pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
89231697|NCT06109272|Active Comparator|Stage 2: Arm 2 (Control)|Participants will receive a single dose of tremelimumab in combination with durvalumab every 4 weeks until disease progression or until discontinuation criteria are met.
89231698|NCT06104683|Experimental|Pirtobrutinib Dose 1|Participants will receive pirtobrutinib orally.
89231699|NCT06104683|Experimental|Pirtobrutinib Dose 2|Participants will receive pirtobrutinib orally.
89231700|NCT06104683|Experimental|Pirtobrutinib Dose 3|Participants will receive pirtobrutinib orally.
89231701|NCT06104683|Placebo Comparator|Placebo|Participants will receive placebo orally.
89231702|NCT06104306|Experimental|B/F/TAF|Participants will receive a fixed dose combination of B/F/TAF 50/200/25 mg once daily for 24 weeks
89231704|NCT06100887|Experimental|Cohort 1|Drug: EDG-5506 Drug: Placebo
89231705|NCT06100887|Experimental|Cohort 2|Drug: EDG-5506 Drug: Placebo
89231708|NCT06099691||Older adults with frailty|Participants will be interviewed about what matters to them. They will then give their opinions on questionnaires that aim to measure what matters to them.
89231715|NCT06096727|Experimental|Energize!|Participants randomized to Energize! will start the program immediately after baseline.
89113934|NCT04795323|Experimental|Cohort 2: TARA v3.2, both non-pharmacological and pharmacological self-management support|TARA is a digital behaviour change intervention (DBCI) intended to support patients with COPD in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA is used independently at home by patients via an internet-enabled device and is a fully online digital system that offers guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication) in TARA version 3.1 (v3.1). Additionally, in TARA v3.2, pharmacological self-management support module (including modules on inhaler techniques and correct use of inhalers, plus a module to close track inhaler use and symptoms over a 7-day period) was included. The study comprised a screening (pre-TARA) period (included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
89113935|NCT04784091|Experimental|Active|TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
89113936|NCT04784091|Placebo Comparator|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
89113937|NCT04777643|Experimental|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
89113938|NCT04777643|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
89113939|NCT04769310|Other|Patient arm|"All patients will undergo a CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
89113940|NCT04766866|No Intervention|Non-intervention or non-reveal group|Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery
89113941|NCT04766866|Experimental|Intervention group or reveal group|A ratio cutoff of >p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
89113942|NCT04766723|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limbs."
89113943|NCT04766723|Placebo Comparator|Placebo|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of the upper limbs."
89113944|NCT04732871|Experimental|RSV_annual Group|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 12 months post-Dose 1 and at 24 months post-Dose 1, respectively and are followed up until the study end (Month 60).
89113945|NCT04732871|Experimental|RSV_flexible revaccination Group|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 24 months post-Dose 1 and at 48 months post-Dose 1, respectively and are followed up until the study end (Month 60).
89113946|NCT04732871|Experimental|RSV_1dose Group|Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until Month 36. At Month 36, participants in this group will be re-randomized in 2 groups (RSV_1dose_M36 and RSV_1dose_flexible groups), which will be followed up until the study end (Month 60).
89113947|NCT04718779|Experimental|Arm A: Prospective|Participants with Gaucher's Disease 1 (GD1) transitioning from SRTs to ERT (VPRIV) or ERT to SRT and then to ERT (VPRIV) in a real-world setting among adults 18 and older will be studied by observing standard patient care and by reviewing the results of tests and assessments that would be performed as part of their routine treatment.
89113948|NCT04718779|Experimental|Arm B: Retrospective|Participants with GD1 transitioning from SRT to ERT (VPRIV) or ERT to SRT and then to ERT (VPRIV) previously (within the past 5 years at the time of enrollment) will be assessed retrospectively after switch to ERT for up to 12 months.
89113949|NCT04714190|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
89113950|NCT04714190|Active Comparator|Physician's Choice|Participants will receive physician choosed chemotherapy from the following options: Paclitaxel Injection or Irinotecan Hydrochloride Injection or Apatinib Mesylate Tablets oral.
89113951|NCT04703166||Participants with Atrial Fibrillation or have Moderate-high risk factors for Atrial Fibrillation|"Participants who have atrial fibrillation or have moderate to high-risk factors for the development of atrial fibrillation as verified by the Atherosclerotic CardioVascular Disease (ASCVD) risk calculation tool.~Participants will be provided with a Samsung Galaxy Watch Active2 to wear daily and will also be asked to wear an ECG patch for 30-days at baseline, 6, 9 and 12 months.~A Cardiac MRI (CMR) will be taken at baseline and at 12 months."
88816315|NCT02501265|Active Comparator|Nicotine Patch Standard Protocol|Participant choses Nicotine patch-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Nicotine Patch. One week prior to TQD, participant will start placebo Bupropion. Consistent with Nicotine Patch Standard Treatment, participant will start active Nicotine Patch on TQD. Participant will continue active Nicotine Patch and placebo Bupropion to 12 weeks post-TQD.
89113952|NCT04702542|Experimental|Enteral oxygen therapy for the improvement of children with chronic gastroduodenal pathology.|Enteral oxygen therapy is prescribed for children with chronic gastroduodenal pathology during the recovery period, after inpatient treatment, for 14 days, every day, in the form of an oxygen cocktail. An oxygen cocktail is prepared on the basis of a pharmaceutical product using herbal ingredients. The patient takes a 200 ml oxygen cocktail. using a small spoon, during the daytime.
89113953|NCT04682964|Experimental|Nebulizer inhalation bacteriophage therapy|To study the effects of bacteriophage therapy on acute tonsillitis in children and adolescents in an outpatient setting.
89113954|NCT04670549|Other|Pre and post implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.~Post-implementation phase: during the post-implementation phase patients with hip and knee OA will receive OA care more in line with the treatment recommendations."
89113955|NCT04667169|Experimental|Laser Haemorrhoidoplasty|A stab incision was made at the ano-cutaneous junction and the anodermis was tunneled with artery forceps to the pedicle of the haemorrhoids. The laser catheter was introduced submucosally towards the pedicle guided by a visible beam to ascertain the exact location of the laser fibre. This was then followed by about six pulsed laser energy delivered at five mm interval, while gradually withdrawing the laser catheter.
89113956|NCT04667169|Experimental|Haemorrhoidal Artery Ligation|In addition to the delivery of laser energy as per the procedure described above, each identified pedicle was ligated with a suture, without Doppler guidance.
89113957|NCT04664972|Placebo Comparator|TAC regimen group|The control group was treated with TAC (docetaxel 75mg/m2 + adriamycin 50mg /m2 + cyclophosphamide 500mg/m2) for 6 cycles, 21 days as a cycle.
89113958|NCT04664972|Experimental|TP regimen group|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
89113959|NCT04658238||Dry eye disease|Patients with dry eye disease
89113960|NCT04658238||Healthy controls|Healthy controls without dry eye disease
89113961|NCT04649957||Cohort Observation|"Study investigators will identify eligible participants within 72 hours of expected discharge from hospital. Eligibility will be determined using the criteria outlined in section 5.1 which incorporates the Post-COVID-19 Functional Status (PCFS) Scale, a tool which has been developed and endorsed by the European Respiratory Society to measure functional status over time following COVID-19 infection. Patients graded 2, 3 or 4 on the PCFS will be eligible for participation. Eligible patients will be provided with a detailed explanation of the study including the provision of written information (PIS). Patients will be given time to consider participation in the research study before being approached again by the research team.~If the patient expresses an interest in study participation the research team will invite participants to a baseline data collection session that will be held at the University of Derby (Kedleston Road campus) in the days following discharge."
89113962|NCT04647136|Active Comparator|Fertility Health Screening|Clinic-based fertility health screening and counselling
89113963|NCT04647136|Active Comparator|Fertility Awareness Tools|Online intervention to provide fertility education and behavioural nudge for optimal reproductive timing.
89113964|NCT04647136|No Intervention|Control|No intervention but exposed to usual information from the media on fertility and family benefits (no different from general population).
89113965|NCT04645654|Experimental|Hypnosis|3 sessions of script-based hypnosis (analgesic suggestions) + recordings provided for self-hypnosis
89113966|NCT04645654|No Intervention|Standard of care|Standard of care ERAS based optimized multimodal analgesia, without any complementary medicine
89113967|NCT04645550|Experimental|Apixaban with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Apixaban 2.5mg bid for six months.
89113968|NCT04645550|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for six months irrespective of the occurrence of portal vein thrombus.
89113969|NCT04645550|Experimental|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for six months.
89113970|NCT04611802|Experimental|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial vaccination)|2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in Initial Vaccination Period.
89113971|NCT04611802|Placebo Comparator|Placebo (Initial Vaccination)|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21in Initial Vaccination Period.
89113972|NCT04611802|Experimental|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination)|One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 or Day 21 in Crossover Vaccination Period.
89113973|NCT04611802|Experimental|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 Booster Vaccination Period.
89113974|NCT04611802|Experimental|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster)|One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 Second Booster Vaccination Period.
89113975|NCT04611802|Placebo Comparator|Placebo (Crossover Vaccination)|One dose of Placebo (Saline) on Day 0 or Day 21 in Crossover Vaccination Period.
89113976|NCT04601480|No Intervention|Care as Usual|Clinics assigned to this arm will continue to care for the patients as usual in regards to opioid prescribing.
89113977|NCT04601480|Experimental|Choice Architecture Nudge|Clinics in this arm will receive the choice architecture nudge intervention.
89113978|NCT04601480|Experimental|PMP Integration & Nudge|Clinics in this arm will receive the Prescription Drug Monitoring (PMP) Integration & Nudge intervention.
89113979|NCT04601480|Experimental|Choice Architecture Nudge + PMP Integration & Nudge|Clinics in this arm will receive both the choice architecture nudge and prescription drug monitoring (PMP) integration & nudge interventions.
89113980|NCT04601233|Experimental|Treatment open label arm|Open-label feasibility study to determine the effects of testosterone (Xyosted 75mg subcutaneous once per week for 3 months) on erectile function in male Multiple Sclerosis patients with low testosterone.
89113981|NCT04592744|Experimental|Intervention|Patients assigned to the study group will receive Ang 2 infusion in addition to standard vasopressor regimen. Ang 2 is currently approved at UCLA as a second line vasopressor and will be used as such for the purposes of our study. Hemodynamic goals will be established at the beginning of the case by the anesthesiology and surgical teams. Ang 2 will be started as a second vasopressor once the norepinephrine dose has reached 0.05mcg/kg/min. Ang 2 will be initiated at a starting dose of 5ng/kg/min. That dose will be up titrated one time to 10ng/kg/min as vasopressor requirements escalate. Once a patient is on the 10ng/kg/min dose of ang 2, no additional up titration will be performed. Hemodynamic management will continue throughout the case with titration of other vasopressors as needed. Ang 2 will be continued throughout the intraoperative period but will be weaned off prior to leaving the operating room.
89113982|NCT04592744|Active Comparator|Control|Patients assigned to the control group will undergo intraoperative management with a standard vasopressor regimen composed of norepinephrine, vasopressin and epinephrine based on hemodynamic goals established by the surgical and anesthesia teams prior to surgery.
89113983|NCT04588285|Experimental|Ambroxol|Oral ambroxol medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
89113984|NCT04588285|Experimental|Placebo|Oral placebo medication, from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)).
89113985|NCT04583826|Experimental|CAVA|20 participants will wear the CAVA device, and a consumer-grade sleep monitoring device, and undergo polysomnography, for one night. 40 participants will wear the CAVA device and undergo polysomnography for two nights
89113986|NCT04567160|Active Comparator|Propofol group|Induction and maintenance of general anesthesia using propofol
89113987|NCT04567160|Active Comparator|Sevoflurane group|Induction and maintenance of general anesthesia using sevoflurane
89113988|NCT04564911|Experimental|Flash Glucose Monitoring and Education|Participants randomised to the experimental arm will receive an education package and wear the flash glucose monitoring system. They will use sensor glucose data for self-management.
89113989|NCT04564911|Active Comparator|Capillary Glucose Monitoring and Education|Participants randomised to the control arm will receive an education package and self-manage their glucose levels utilising a standard capillary blood glucose device, and keeping a glucose diary for the duration of the intervention period.
89113990|NCT04535011|No Intervention|Usual Care|No prevention or educational information verbally or written coinciding with current usual care
89113991|NCT04535011|Experimental|PPKAY|One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use
89231716|NCT06096727|Other|Delayed Energize!|Participants randomized to Delayed Energize! will start the program after the 3 month assessment.
89231717|NCT06095089|Experimental|Part 1 (Dose Escalation) and Part 2 (Dose Expansion)|Participants will receive JNJ-78278343+JNJ-87189401 escalated sequentially in Part 1 to select a recommended Phase 2 regimen (RP2R). Participants will receive the combination treatment at the RP2R in Part 2 (dose expansion).
88816351|NCT02976363||Quadrantectomy Group|The Quadrantectomy Group sample performed adjuvant radiotherapy with a linear accelerator, whose the total dosage was 5000 centigray (cGy), the daily dose 200 cGy distributed into twenty-five sessions, totaling 25 days of treatment. And data from Maximal Respiratory Pressures (MIP/MEP) were collected at two phases in the sample of Quadrantectomy Group: before the first session of radiotherapy and after the twenty-fifth session corresponding to the last day of the radiotherapy treatment.
88816352|NCT02976363||Control Group|While for the control group women with no breast cancer history were invited. Data from Maximal Respiratory Pressures (MIP/MEP) were collected at one phase in the sample of control group.
88816353|NCT04430049||no visitation group|relatives cannot visit ICU patient during Covid pandemic period in France
89113992|NCT04535011|Experimental|PPKAY with Standard Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use.~Weekly standard text booster until final follow-up (e.g., Reducing your alcohol intake to less than 4 drinks per day reduces your risk of alcohol-related consequences)"
89113993|NCT04535011|Experimental|PPKAY with Personalized Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use Weekly personalized text booster until final follow-up (e.g., Remember to reduce your alcohol less than 4 drinks to achieve your goal of… [being a better husband].)"
89113994|NCT04530058|Placebo Comparator|Control|
89113995|NCT04530058|Experimental|Metformin|
89113996|NCT04526236|Placebo Comparator|Methadone 0|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered the placebo drug.
89113997|NCT04526236|Experimental|Methadone 1|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.05 mg/kg.
89113998|NCT04526236|Experimental|Methadone 2|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.1 mg/kg.
89113999|NCT04526236|Experimental|Methadone 3|Induction will be performed with a bolus of propofol, continuous infusion of remifentanil, and rocuronium. Once the patient is intubated and has hemodynamic stability will be administered an intravenous methadone dose of 0.2 mg/kg.
89114000|NCT04521348|Experimental|RAIR-DTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
89114001|NCT04521348|Experimental|MTC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
89114002|NCT04521348|Experimental|ATC arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
89114003|NCT04521348|Experimental|DTC unsuitable for RAI arm|Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
89114004|NCT04505397|Experimental|Single Ascending Dose Level 1|4 Subjects will receive one dose of 10 mg and 2 subjects will receive one dose of placebo
89114005|NCT04505397|Experimental|Single Ascending Dose Level 2|4 Subjects will receive one dose of 25 mg and 2 subjects will receive one dose of placebo
89114006|NCT04505397|Experimental|Single Ascending Dose Level 3|4 Subjects will receive one dose of 50 mg and 2 subjects will receive one dose of placebo
89114007|NCT04505397|Experimental|Single Ascending Dose Level 4|4 Subjects will receive one dose of 100 mg and 2 subjects will receive one dose of placebo
89114008|NCT04505397|Experimental|Single Ascending Dose Level 5|4 Subjects will receive one dose of 200 mg and 2 subjects will receive one dose of placebo
89114009|NCT04505397|Experimental|Single Ascending Dose Level 6|4 Subjects will receive one dose of 300 mg and 2 subjects will receive one dose of placebo
89114010|NCT04505397|Experimental|Single Ascending Dose Level 7|4 Subjects will receive one dose of 400 mg and 2 subjects will receive one dose of placebo
89114011|NCT04505397|Experimental|Single Ascending Dose Level 8|4 Subjects will receive one dose of 800 mg and 2 subjects will receive one dose of placebo
89114012|NCT04505397|Experimental|Single Ascending Dose Level 9|4 Subjects will receive one dose of 1200 mg and 2 subjects will receive one dose of placebo
89114013|NCT04505397|Experimental|Single Ascending Dose Level 10|4 Subjects will receive one dose on the outcome of preceding dose levels and 2 subjects will receive one dose of placebo
89114014|NCT04505397|Experimental|Multiple Ascending Dose Level 1|6 Subjects will receive one dose of 50 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose).
89114015|NCT04505397|Experimental|Multiple Ascending Dose Level 2|6 Subjects will receive one dose of 200 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).
89114016|NCT04505397|Experimental|Multiple Ascending Dose Level 3|6 Subjects will receive one dose of 400 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).
88816354|NCT04430049||restrictive visitation group|relatives have restriction to visit ICU patient during Covid pandemic period in France
88816355|NCT04430049||open visitation group|relatives can visit ICU patient during no Covid period in France
89114017|NCT04505397|Experimental|Multiple Ascending Dose Level 4|6 Subjects will receive one dose of 800 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).
89114018|NCT04505397|Experimental|Multiple Ascending Dose Level 5|6 Subjects will receive one dose of 1200 mg each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).
89114019|NCT04505397|Experimental|Multiple Ascending Dose Level 6|"6 Subjects will receive one dose of 1200 mg each day (using tablet formulation instead of capsule formulation*) for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).~*Tablet formulation is utilized, instead of capsule formulation, in the marked dose levels."
89114020|NCT04505397|Experimental|Food Effect Cohort|After completing the fasting Single Ascending Dose escalation, the same 6 subjects who received one dose of 50 mg under fasting conditions will return to the clinic after a washout period for a second confinement to receive a second dose (same as fasting) under fed conditions.
89114021|NCT04505397|Experimental|Gender Effect Cohort|6 female subjects of non-childbearing potential will receive one dose of 50 mg under fasting conditions.
89114022|NCT04505397|Experimental|Optional Food Effect Cohort|Up to 12 male subjects will undergo an open-label, two period, two-sequence crossover design at the maximum daily dose tested in Part A.
89114023|NCT04505397|Experimental|Optional Formulation Effect Cohort|Up to 12 male subjects will be treated with the maximum daily dose tested in Part A using open-label, two period, two-sequence crossover design.
89114024|NCT04505397|Experimental|Multiple Ascending Dose Level 7|"6 Subjects will receive one dose of 2000 mg each day (using tablet formulation instead of capsule formulation*) for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).~*Tablet formulation is utilized, instead of capsule formulation, in the marked dose levels."
89114025|NCT04505397|Experimental|Multiple Ascending Dose Level 8|"6 Subjects will receive one dose each day (using tablet formulation instead of capsule formulation*) for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined based on the outcome of Part A (Single Ascending Dose) and/or preceding dose levels of Part B (Multiple Ascending Dose).~*Tablet formulation is utilized, instead of capsule formulation, in the marked dose levels."
89114026|NCT04498377|Experimental|F-652|Patient receives standard care plus F-652
89114027|NCT04498377|Placebo Comparator|Placebo|Patient receives standard care plus placebo
89114028|NCT04497389|Experimental|Intervention|10ml intravenous hAF QD (once daily) for 5 consecutive days
89114029|NCT04497389|No Intervention|Standard of Care|10 mL normal saline QD (once daily) for 5 days
89114030|NCT04475432|Experimental|Active|TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
89114031|NCT04475432|Placebo Comparator|Control|Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
89114032|NCT04465214||1/Cohort 1|Participants with a diagnosis of cancer who are under active treatment on a protocol at NIH
89114033|NCT04425629|Experimental|casirivimab+imdevimab low dose|Low dose or body-weight equivalent for those under 18 years of age.
89114034|NCT04417959|Other|Phaco-DSAEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's stripping automated endothelial keratoplasty.
89114035|NCT04417959|Other|Phaco-DMEK|Subjects randomized to this arm will consist of patients with both Fuchs' endothelial dystrophy and cataract. These will be treated with phacoemulsification and Descemet's membrane endothelial keratoplasty.
89114036|NCT04417218|Experimental|Normal Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the normal lysine diet, participants will be asked to adhere to a specific diet for 1 week. Each study subject will receive 3 meals and 1-2 snacks per day during the study period.
89114037|NCT04417218|Experimental|High Lysine Diet|Participants will complete two one-week dietary interventions, in a randomized order. For the high lysine diet, participants will be asked to consume the same foods as in the normal lysine diet, but with the addition of lysine supplements (5g/day).
89114038|NCT04342000|Experimental|Intervention Group|Movement Education Workshop
89114039|NCT04342000|Sham Comparator|Control Group|Sham Education Workshop
89114040|NCT04317066|Experimental|Pembrolizumab in Participants with rrPMBCL|Participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months.
89114041|NCT04312932|Experimental|Long chain polyunsaturated fatty acid (LCPUFA) Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of gamma-linoleic acid (GLA) + eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) as Omega 3-6 oil to be administered twice per day by mouth for 90 days
89114042|NCT04312932|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
89114043|NCT04292743|Experimental|Eryaspase plus FOLFIRINOX|"Eryaspase will be administered on day 1 and 15 of a 4 week cycle (intravenous infusion) in dose escalating/reduction depending on the cohort the patient is assigned to~mFOLFIRINOX dosing will include 5-fluorouracil 2400 mg/m² over 46 hours, oxaliplatin 85 mg/m², Irinotecan 150 mg/m² (intravenous infusion) on Day 1 and 15 of the 4 weeks cycle for a maximum of 12 cycles."
89114044|NCT04286555|Active Comparator|DASH4D diet with lower sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 1500 mg/day
89114045|NCT04286555|Active Comparator|DASH4D diet with higher sodium|DASH-style dietary pattern, modified for people with diabetes, with sodium level of 3700 mg/day
89114046|NCT04286555|Active Comparator|Comparison diet with lower sodium|Dietary pattern that is typical of what many Americans eat, with sodium level of 1500 mg/day
89114047|NCT04286555|Other|Comparison diet with higher sodium|Dietary pattern that is typical of what many Americans eat, with sodium level of 3700 mg/day
89114048|NCT04267939|Experimental|Dose escalation of elimusertib_Part A.1|Dose escalation will initiate with Part A.1 in which niraparib is used at a lower fixed dose.
89114049|NCT04267939|Experimental|Dose escalation of elimusertib_Part A.2|If the starting dose level in Part A.1 is tolerated, dose escalation in Part A.2 may be initiated on an optional basis. In Part A.2, niraparib is used at a higher fixed dose.
89114050|NCT04267939|Experimental|Dose expansion_sub-population 1_lower dose of niraparib|"MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a lower fixed dose.~MTD: Maximum tolerated dose. RP2D: Recommended phase 2 dose."
89114051|NCT04267939|Experimental|Dose expansion_sub-population 2_lower dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a lower fixed dose.
89114052|NCT04267939|Experimental|Dose expansion_sub-population 1_higher dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a higher fixed dose.
89114053|NCT04267939|Experimental|Dose expansion_sub-population 2_higher dose of niraparib|MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a higher fixed dose.
89114054|NCT04264403|Active Comparator|Renal Denervation|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. If randomized to the Renal Denervation Group RDN procedure will be applied using the Paradise® Renal Denervation System. The Paradise® Renal Denervation System is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
89114055|NCT04264403|No Intervention|Sham Procedere|All subjects will undergo a diagnostic, renal angiogram (based on clinical grounds to rule out renal artery stenosis) which should be per Institutional practice via femoral artery access. Randomization will occur following the diagnostic renal angiogram. In these patients no RDN will be performed.
89231719|NCT06092970||RBT-1|Patients undergoing CABG, valve, or combined CABG/valve surgery
89231720|NCT06092970||Placebo|Patients undergoing CABG, valve, or combined CABG/valve surgery
89114056|NCT04263285|Experimental|rTMS (Repetitive Transcranial Magnetic Stimulation)|
89114057|NCT04251819|Placebo Comparator|Placebo|Participants randomized to this arm will receive Placebo.
89114058|NCT04251819|Experimental|Baclofen 5mg|Participants randomized to this arm will receive 5 mg of Baclofen.
89114059|NCT04251819|Experimental|Baclofen 10mg|Participants randomized to this arm will receive 10 mg of Baclofen.
89114060|NCT04241341|Experimental|axillary lymph node dissection with ILR|
89114061|NCT04241341|Active Comparator|axillary lymph node dissection (ALND) without ILR|
89114062|NCT04232969|Active Comparator|Exenatide|Exenatide extended release 2mg (Bydureon) once weekly for 96 weeks n=100
89114063|NCT04232969|Placebo Comparator|Placebo|Exenatide extended release placebo once weekly for 96 weeks n=100
89114064|NCT04232267||Patients prescribed Polysomnology (PSG - sleep study)|Patients that are at least 18 years old but not older than 75 years old, who have been referred to a sleep clinic for sleep disturbance.
89114065|NCT04228627|Active Comparator|Treatment|Intravenous Iron to correct Iron deficiency without anaemia
89114066|NCT04228627|No Intervention|Prophylaxis|Usual antenatal care
89114067|NCT04214028||Maviret Participants|Participants receiving glecaprevir plus pibrentasvir (GLE/PIB, other names: Maviret) as routine standard of care for HCV.
89114068|NCT04209842|Experimental|gastric ballon placement|will receive gastric balloon placed via endoscopy
89114069|NCT04197336|Sham Comparator|Control Arm|27 participants enrolled in the procedure arm. Participants randomized to the control arm will follow the same screening. Pre-procedure assessment will take the same pre-procedure meds. Procedure day, interventional radiologist will determine radial or groin access. After the participant and procedure area are prepped, participants will be under standard moderate sedation medications; all participants will receive lidocaine & a skin nick to their groin or their wrist as determined by the operating physician. Participant will have a blind fold placed & their hearing damped either with ear plugs or noise cancelling headphones. Participants randomized to the control arm will not receive other procedural intervention. Procedural team will follow a prescribed simulated protocol. Participants randomized to the control arm will be given under skin lidocaine and receive a skin nick on the wrist or groin.
89114070|NCT04197336|Active Comparator|Bariatric Embolization Procedure|27 subjects will be enrolled in the bariatric embolization(BM) procedure arm. BM procedure will be performed under moderate sedation. Procedure will take 1.5 hr to 3 hr subject will be placed on the X-ray fluoroscopy table. Radial or femoral vascular access will be achieved using a small gauge needle, dilated over a guidewire to accommodate a 5 French vascular sheath. Standard catheters, 3 dimensional imaging will be acquired of the stomach, the arteries supplying the fundus arising off the celiac vessel. Microcatheter into the left gastric and/or gastroepiploic arteries supplying the fundus and small calibrated spheres will be infused until stasis of anterograde arterial flow is achieved, with particular care to avoid infusion of non-target arteries. The left gastric and/or gastroepiploic arteries will be embolized. Repeat 3 dimensional imaging: assess bead distribution and fundal coverage. Subject will be monitored in the recovery room and will be observed overnight.
89114071|NCT04150718|Experimental|Subjects with Major Depressive Disorder|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine is they meet criteria for MDD.
89114072|NCT04150718|Active Comparator|Control|Subjects who get assigned to this group will undergo a Diagnostic and Statistical Manual for Mental Disorders (SCID) assessment to determine they do not meet criteria for MDD.
89114073|NCT04134767|Experimental|Health Linkage|Research staff will: 1) meet with participants in person or virtually to ask questions about drug use and related behaviors, service access, and personal goals; provide overdose education and help develop a plan for reducing risks and accessing services; conduct drug testing, offer HIV and HCV testing and counseling, naloxone, and harm reduction supplies, and connection with needed services; 2) follow up with participants monthly for three months to help overcome challenges; and 3) six months post-enrollment, contact participants to conduct drug testing. Participants will complete surveys at baseline, 3 months, and 6 months
89231722|NCT06089980||Acute kratom exposure|Participants who regularly consume kratom will orally self-administer a single serving of the participants commercial kratom product under direct observation in order to evaluate acute physiological, subjective, and cognitive effects and determine pharmacokinetics. This will occur during the first 24 hours of study participation. Participants will undergo direct observation and assessment for after ceasing all kratom product use. Physiological, subjective, and cognitive effects during this supervised withdrawal will be assessed.
89231723|NCT06087835|Experimental|Zibotentan/Dapagliflozin dose A or Zibotentan/Dapagliflozin dose B|Drug dose (dose A or B) are determined based on eGFR values. Participants will receive daily oral dose of zibotentan/dapagliflozin in fixed dose combination.
89231724|NCT06087835|Active Comparator|Dapagliflozin alone|Participants will receive daily oral dose of dapagliflozin.
89231725|NCT06084936|Experimental|Glofitamab monotherapy|Participants will receive two intravenous (IV) obinutuzumab pretreatments prior to receiving IV glofitamab for 12 cycles (cycle length = 21 days).
89231726|NCT06084936|Active Comparator|BR or R-Len|Participants will receive bendamustine + rituximab for up to 6 cycles (cycle length = 28 days), or rituximab + lenalidomide (cycle length = 28 days) until disease progression.
89231727|NCT06080698|Active Comparator|Intravenous Antibiotics|IV antibiotics from the time of randomization to the completion of antibiotic treatment. Includes antibiotics such as ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem.
89231728|NCT06080698|Active Comparator|Oral Antibiotics|Oral antibiotics from the time of randomization to the completion of antibiotic treatment, Includes antibiotics such as amoxicillin, cephalexin, ciprofloxacin, and trimethoprim-sulfamethoxazole.
89231729|NCT06080503|Experimental|Highly conformal hypofractionated radiotherapy|LT-SABR 42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly
89231730|NCT06080503|Experimental|Conventional radiotherapy|Conventional Radiotherapy 63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)
89231731|NCT06075953|Active Comparator|chemoprevention therapy per investigator choice|a. For premenopausal women: 20 mg or 5 mg tamoxifen orally b. for postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily; or reduced exemestane dosing: 25 mg 3 times per week orally i. For postmenopausal women who are not tolerating an AI, low dose (5 mg) or standard dose (20 mg) of tamoxifen There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants may continue treatment for up to 5 years.
89231732|NCT06075953|Experimental|Testosterone + Anastrazole (T+Ai)|White solid pellet for subcutaneous insertion consisting of 100mg Testosterone and 4mg Anastrazole, an aromatase inhibitor. A cylindrical pellet (4.5mm diameter, 6.35mm diameter) is inserted subcutaneously in the upper outer gluteal region or iliac fossa every 3 months, with treatment up to 36 months. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.
89231733|NCT06075953|Experimental|Elacestrant|Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years.
89231734|NCT06075953|Experimental|Endoxifen|(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen. Standard dose: 10mg PO delayed release capsule of z-endoxifen once daily for treatment up to 36 months. same time with a glass of water either 1 hour before a meal or 2 hours after a meal and should not take with alcohol. For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.
89231735|NCT06075901|Active Comparator|Blood Flow Restriction with Cuffing|The participant will use the Cuffing for Blood Flow Restriction training
89231736|NCT06075901|Experimental|Blood Flow Restriction with Tissue Flossing|The participant will use Tissue Flossing for Blood Flow Restriction training
89231737|NCT06067269|Experimental|Treatment (apalutamide, SBRT)|Patients receive apalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 6 or 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo SBRT for 5 fractions over 1-2 weeks beginning on day 1 of cycle 1. Patients also undergo multiparametric MRI and collection of blood samples throughout the trial. Patients undergo PSMA-PET/CT scans during screening and follow up.
89231738|NCT06066580|Experimental|Treatment|Drug: EDG-5506
89290589|NCT03931122|No Intervention|Group A - Weight Based Method|"Body Weight Based method: This is the conventional method for LMA size selection. The patient will be weighed and LMA size corresponding to their weight will be used as follows.~(LMA Size - 1 for up to 5 kg of body weight) (LMA Size - 1.5 for 5 to 10 kg of body weight) (LMA Size - 2 for 10 to 20 kg of body weight) (LMA Size - 2.5 for 20 to 30 kg of body weight) (LMA Size - 3 for 30 to 50 kg of body weight)"
89231740|NCT06064695|Experimental|Whole-body Electrical Muscle Stimulation (WB-EMS) Exercise|"All participants will receive the WB-EMS Exercise intervention 2 times per week for 4 weeks. Participants will only perform Level 1 exercise programs (simple movements) in the Strength Training Mode. These programs are 20-minute videos led by exercise professionals. They are full-body workouts with no one muscle group receiving more attention than another. They consist of 10-12 exercises performed for 14 repetitions. Each repetition takes 4 seconds to complete (the time that the stimulation is on) and is followed by a 4 second rest (the time that the stimulation is off). All exercises occur in a double-limb stance position. Most exercises occur with feet in wide base of support, hips width or more apart. All exercises are modifiable by the healthcare professional administering and monitoring the intervention based on participant's safe and available range of motion (i.e. arm movements, torso positions, extent of knee bend)."
89231744|NCT06056830|Experimental|64Cu-SAR-bisPSMA|200MBq 64Cu-SAR-bisPSMA.
89231748|NCT06052319||Participants with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) or Both|Participants with CAD or PAD or both will be directed to download the Care4Today® (C4T) Connect CAD-PAD mobile application on iPhone or Android device to assess engagement and usefulness of C4T in disease management for 3 months. No study drug and other treatment(s) will be provided as a part of this study. All aspects of treatment and clinical management of participants will continue to be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
89231749|NCT06049290|Experimental|LBL-034|LBL-034 for Injection; Initial dose - MTD; Q2W
89231750|NCT06048263|Experimental|Intervention Interpersonal psychotherapy plus ketamine|Five sessions of interpersonal psychotherapy (IPT) and pre-, and post-, ketamine sessions b) Two doses of subcutaneous (SC) ketamine in the first 4 post-cesarean days
89231751|NCT06047080|Experimental|Glofitamab + Pola-R-CHP|Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP).
89231752|NCT06047080|Active Comparator|Pola-R-CHP|Participants will receive Pola-R-CHP.
89231753|NCT06046989|Experimental|BEAM Program|The BEAM Program is delivered via mobile application, weekly check-ins, and peer coaching. BEAM includes videos with emotion-regulation strategies that come from the Unified Protocol (evidence-based treatment for depression and anxiety disorders) and Dialectical Behavior Therapy (DBT) to help with mental health, as well they focus on developing self-compassion and effective communication. There are also supportive parenting videos which focus on providing parents with emotion-focused parenting strategies, based on Tuning in to Kids® and Parent Management Training - The Oregon Model (PMTO), which aim to help parents better understand and respond to their child. There will be approximately 15-20 minutes of videos to watch weekly.
89231754|NCT06046989|No Intervention|Treatment-As-Usual|This is the control arm of the study. It is designed to account for the potential effects of time on symptoms of depression, anxiety, and anger.
89231755|NCT06045754|Experimental|Part A, Cohort 1: Vedolizumab + Adalimumab|Participants will receive vedolizumab IV 300 mg, at Weeks 0, 2, and 6, then every 8 weeks (Q8W) until Week 22 and adalimumab SC 160, 80, and 40 mg at Weeks 0, 2, and 4, respectively, then 40 mg every 2 weeks (Q2W) until Week 26.
89231756|NCT06045754|Experimental|Part A, Cohort 2: Vedolizumab + Ustekinumab|Participants will receive vedolizumab IV 300 mg, at Weeks 0, 2, and 6, then Q8W until Week 22 and ustekinumab IV 520, 390, or 260 mg (weight-based), then SC 90 mg 8 weeks after initial IV dose, then Q8W until Week 24.
89231757|NCT06045754|Experimental|Part B: Vedolizumab Monotherapy|Participants who achieve clinical remission in Part A will receive vedolizumab IV 300 mg monotherapy, Q8W from Week 30 until Week 46.
89231758|NCT06045507|Experimental|MK-8527 Low Dose QM|Participants receive oral MK-8527 low dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
89231759|NCT06045507|Experimental|MK-8527 Medium Dose QM|Participants receive oral MK-8527 medium dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
89231760|NCT06045507|Experimental|MK-8527 High Dose QM|Participants receive oral MK-8527 high dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
89231761|NCT06045507|Placebo Comparator|Placebo to MK-8527|Participants receive oral placebo matched to MK-8527 QM for 6 months, followed by an 8-week blinded safety follow-up period.
89231762|NCT06042725|Experimental|Arm A (Ven-Dd)|Patients receive venetoclax PO QD on days 1-28 of each cycle, daratumumab SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7+, and dexamethasone PO on days 1, 8, 15, 22 of cycles 1-12. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo chest x-ray and optional collection of blood samples during screening. In addition, patients undergo x-rays, WBLDCT, PET/CT or MRI scans during screening and on study, and bone marrow aspiration and biopsy during screening, and during follow-up.
89231763|NCT06042725|Experimental|Arm B (Ven-Rd)|Patients receive venetoclax PO QD on days 1-28 of each cycle, lenalidomide PO QD on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, 22 of cycles 1-12. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo chest x-ray and optional collection of blood samples during screening. In addition, patients undergo x-rays, WBLDCT, PET/CT or MRI scans during screening and on study, and bone marrow aspiration and biopsy during screening, and during follow-up.
89231764|NCT06042725|Experimental|Arm C (Ven-DRd)|Patients receive venetoclax PO QD on days 1-28 of each cycle, daratumumab SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7+, lenalidomide PO QD on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of cycles 1-12. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo chest x-ray and optional collection of blood samples during screening. In addition, patients undergo x-rays, WBLDCT, PET/CT or MRI scans during screening and on study, and bone marrow aspiration and biopsy during screening, on study, and during follow-up.
89231768|NCT06040762|Experimental|Arm A ([P]REHAB intervention)|Patients use the ExerciseRx app to follow the (P)REHAB exercise program, which consists of four 20-30 minute home exercise sessions per week and personalized step count goal setting and tracking, during receipt of SOC NAC prior to SOC RC and for 90 days following surgery (total ~7 months). Patients also download the FitBit app and wear a FitBit throughout the study.
89231769|NCT06040762|Active Comparator|Arm B (standard of care)|Patients receive SOC educational materials and wear a FitBit and use the FitBit app during receipt of SOC NAC prior to SOC RC and for 90 days following surgery (total ~7 months).
89231770|NCT06039189|Experimental|Group 1: Guselkumab|Participants will receive guselkumab by subcutaneous injection with placebo as needed to maintain the blind.
89231771|NCT06039189|Placebo Comparator|Group 2: Placebo|Participants will receive placebo by subcutaneous injection then receive guselkumab by subcutaneous injection.
89231772|NCT06038032|Experimental|Intervention group|"Participants will receive the intervention for 24 weeks. The first 16 weeks will involve an intensive behavioral program (digital wellness platform plus online healthcare professional support), followed by an 8-week maintenance period (digital wellness platform alone).~At baseline, participants will receive handouts with publicly available health information; they will also wear an activity monitor and receive support telephone calls for the 24 weeks."
89231773|NCT06038032|No Intervention|Control group|At baseline, participants will receive handouts with publicly available health information; they will also wear an activity monitor and receive support telephone calls for the 24 weeks.
89231774|NCT06036914|Experimental|Ultra-high dose diuretic group|Subjects with decompensated heart failure requiring hospitalization will receive IV bumetanide.
89231775|NCT06036914|Active Comparator|Standard dose diuretic group|Subjects with decompensated heart failure requiring hospitalization will receive IV furosemide.
89231776|NCT06028984|Experimental|Intervention app|Digitally-delivered self-guided intervention for depression accessed via mobile app
89231777|NCT06028984|Active Comparator|Control app|An app based control condition
89231778|NCT06028438|Active Comparator|Certolizumab + Placebo|Participants will receive placebo intravenously (IV) and certolizumab dose 1 subcutaneously at Week 0, 2, and 4 followed by placebo IV and certolizumab dose 2 subcutaneously at Weeks 6 to 22.
89231779|NCT06028438|Experimental|Certolizumab + Nipocalimab|Participants will receive nipocalimab IV and certolizumab dose 1 subcutaneously at Week 0, 2, and 4 followed by nipocalimab IV and certolizumab dose 2 subcutaneously at Weeks 6 to 22.
89231780|NCT06028113|Experimental|Treatment Group|The Teaching Healthy Responsive Parenting during Infancy to promote Vital growth and rEgulation (THRIVE 2.0) group will consist of 4 sessions delivered by the trained IBH provider, in conjunction with the 1, 2, 4, and 6 month well-child visit in primary care. The THRIVE curriculum teaches responsive parenting principles targeted to establish healthy eating, sleeping, and regulation habits for infants.
89231781|NCT06028113|No Intervention|Control Group|Control arm: Usual Pediatric Care. The control condition is usual care delivered by pediatricians at 1, 2, 4, and 6 month well child visits.
89231782|NCT06020417|Active Comparator|O-Arm neuronavigator|The O-ARM imaging system can help surgeons to view the spine in real time and verify the placement of implants such as screws or rods. Primarily, therefore, in image acquisition, during surgery, the O-ARM is activated and generates real-time images of the patient's spine, so that these images are displayed on a screen, allowing the surgeon to visualize the anatomical structures and check that implant placement is proper. Therefore, when analyzing these images, the surgeon can, for example, analyze and verify the placement of the implants and ensure that the arthrodesis is performed correctly, in such a way that, if necessary, the surgeon can make adjustments and then acquire new images for verification.
89290590|NCT03931122|Experimental|Group B - Ear Size Based Method|"Ear Size Based method: External ear size will be measured by using a paper ruler and will be recorded in cm as follows:~Vertical length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W )~Based on these ear measurements, nearest smaller LMA size will be selected."
89114074|NCT04134767|Other|Overdose Education|"The investigators will initiate the comparison group in Group 2 counties six months before the intervention begins. Research staff will conduct an overdose intervention with the comparison cohort. This will occur pre-release if individual is recruited in jail. The comparison group participants will watch a video on preventing, recognizing, and responding effectively to an opioid OD, accompanied by information about Kentucky's Good Samaritan Law and Naloxone Access Law. Research staff will answer questions after the video. Individuals will receive a Community Resource Guide at this visit.~As in the intervention group, the comparison group participants will complete surveys at the baseline (in jail if recruited in jail, in a community setting if recruited in the community), and at 3 months and 6 months after the baseline. Surveys will be identical to those delivered to the intervention cohort."
89114075|NCT04132050|Experimental|R788|Patients are administered R788 for 24 weeks (double-blind period), followed by R788 for up to 52 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
89114076|NCT04132050|Placebo Comparator|Placebo|Patients are administered Placebo for 24 weeks (double-blind period), followed by R788 for up to 28 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).
89114077|NCT04115345|Experimental|Renal Autologous Cell Therapy (REACT)|The volume of REACT to be administered will be determined by pre-procedure MRI volumetric 3D evaluation or ellipsoid formula. The participant will receive a second injection 6 months after the first injection into the same kidney.
89114078|NCT04096716|Experimental|Cohort 1: Tc-99m tilmanocept|"The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~Portable planar imaging will be obtained at 4.5 ± 2.5 hours and 24 +/- 8 hours after injection of Tc-99m tilmanocept."
89114079|NCT04096716|Experimental|Cohort 2A: Tc-99m tilmanocept frontal lobe injection site|"The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~SPECT/CT of the head and neck will be obtained when practical on the day of surgery.~If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
89114080|NCT04096716|Experimental|Cohort 2B: Tc-99m tilmanocept parietal lobe injection site|"The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~SPECT/CT of the head and neck will be obtained when practical on the day of surgery.~If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
89114081|NCT04096716|Experimental|Cohort 2C: Tc-99m tilmanocept temporal lobe injection site|"The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~SPECT/CT of the head and neck will be obtained when practical on the day of surgery.~If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
89114082|NCT04096716|Experimental|Cohort 2D: Tc-99m tilmanocept occipital lobe injection site|"The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor~SPECT/CT of the head and neck will be obtained when practical on the day of surgery.~If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
89114083|NCT04096716|Experimental|Cohort 3: Tc-99m tilmanocept stereotactic needle biopsy of tumor|"The surgeon will inject up to 0.3 mL of reconstituted Tc-99m tilmanocept after completing the stereotactic biopsy of the tumor~SPECT/CT of the head and neck will be obtained on the day of biopsy, when practical. If the patient is not sufficiently recovered from biopsy to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2"
89114084|NCT04093427|Active Comparator|softSTOPP active|
89114085|NCT04093427|No Intervention|softSTOPP inactive|
89114086|NCT04092010|Experimental|Stepped-care intervention (SCI) group|In the SCI group, mothers with low baseline depressive symptoms are offered the problem-solving education (PSE) prevention intervention, and mothers with greater depressive symptoms are offered Engagement Sessions.
89114087|NCT04092010|Active Comparator|Usual care control group|Families in the control group will receive usual Head Start services.
89114088|NCT04091022|Active Comparator|Diclofenac + DFMO|Participants in this arm will apply topical diclofenac to bilateral forearms once per day and topical DFMO to bilateral forearms once per day.
89114089|NCT04091022|Placebo Comparator|Placebo + Placebo|Participants in this arm will apply placebo for topical diclofenac to bilateral forearms once per day and placebo for topical DFMO to bilateral forearms once per day.
89114090|NCT04088799||FSGS requiring LDL-apheresis|Pediatric patients with FSGS requiring LDL-apheresis with the Liposorber
89114091|NCT04070287|Active Comparator|SMART Pack|"This involves using SMART Pack a HIV self-testing kit to promote uptake of HIV self-testing among young people at community centers."
89114092|NCT04070287|Active Comparator|Luv Box|"The intervention involves using Luv Box a box that include personal hygiene products and HIV self-testing kit as strategy to promote uptake of HIV testing among young people."
89114093|NCT04070287|Active Comparator|Bili Vibes|"The intervention involves using a program program called Bili that leverages community youth events such as football matches as a strategy to promote the uptake of HIV self-testing among young people."
89114094|NCT04070287|Active Comparator|BeterDoc|"This intervention involve using BeterDoc Safety kits that includes HIV self-testing kit, location and phone number to the health centers in the community as a strategy to promote update of HIV self-testing among young people."
89114095|NCT04070287|Active Comparator|IUNGO|This intervention involves using a program utilizes community vocational skills training centers to promote uptake of HIV self-testing among young people.
89114096|NCT04062552|Experimental|Virtual Learning Collaborative|
89114097|NCT04062552|Experimental|Technical Assistance|
89114098|NCT04028063|Experimental|doxorubicin with AGEN1884 and AGEN2034|Doxorubicin with dual checkpoint blockade with anti-CTLA-4 antibody AGEN1884 and anti-PD-1 antibody AGEN2034. Doxorubicin dosing is standard at 75 mg/m2 via Bolus with prior Dexrazoxane. AGEN2034 - 300 mg IV over 60min with infusion pump. AGEN1884 - 1 mg/kg IV over 90 min (-10 /+20 min) with infusion pump, within 30 minutes (0 / +20) of completion of AGEN2034.
89114099|NCT03978936|Experimental|MTM-EAM|Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management [MTM-EAM]
89114100|NCT03978936|Active Comparator|EAM only|Electronic Adherence Self-Management [EAM] only
89114101|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 during Part A [Single Ascending Dose (SAD)].
89114102|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 2|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
89114103|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 3|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
89114104|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 4|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
89114105|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 5|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
89114106|NCT03976349|Experimental|Part A (SAD): BIIB094 Dose 6|Participants will receive a single IT injection of BIIB094 during Part A (SAD).
89114107|NCT03976349|Experimental|Part B (MAD): BIIB094 Dose 1|Participants will receive a single IT injection of BIIB094 on multiple days during Part B [Multiple Ascending Dose (MAD)].
89114108|NCT03976349|Experimental|Part B (MAD): BIIB094 (Non LRRK2) Dose 2|Participants [Non leucine-rich repeat kinase 2 (Non LRRK2)] will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
89114109|NCT03976349|Experimental|Part B (MAD): BIIB094 (LRRK2) Dose 2|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
89114110|NCT03976349|Experimental|Part B (MAD): BIIB094 (Non LRRK2) Dose 3|Participants (Non LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
89114111|NCT03976349|Experimental|Part B (MAD): BIIB094 (LRRK2) Dose 3|Participants (LRRK2) will receive a single IT injection of BIIB094 on multiple days during Part B (MAD).
89114112|NCT03976349|Placebo Comparator|Part A (SAD): Matching Placebo|Participants will receive matching placebo during Part A [Single Ascending Dose (SAD)].
89114113|NCT03976349|Placebo Comparator|Part B (MAD): Matching Placebo|Participants will receive matching placebo on multiple days during Part B (MAD).
89114114|NCT03964532|Experimental|Phase I/Phase II|Talazoparib (1mg by mouth [PO] daily D1-28) will be provided as monotherapy for the first cycle. Starting with cycle 2 and for all subsequent cycles, treatment with avelumab (800 mg intravenously [IV] D1 every 2 weeks) will be added to talazoparib.
89114115|NCT03960580|Active Comparator|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
89114116|NCT03960580|Active Comparator|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
89114117|NCT03960580|Placebo Comparator|Placebo|Matching Placebo BID x 24 Weeks
89114118|NCT03942783|Active Comparator|Control Group|"The control group will receive a written work self-help information pack plus usual care. The pack includes published arthritis patient information booklets about work; a decision-tree flowchart; information about the UK Equality Act. The self-help information pack is mailed to the participants by the CTU following randomisation.~Usual care consists of: prescribed medication; attending Rheumatology clinics; referral to rehabilitation, as and when deemed necessary from the Rheumatology clinic, but not including work advice. Any rehabilitation required will be provided as normal, e.g. provision of exercise, self-management education, activities of daily living advice, psychosocial support."
89114119|NCT03942783|Experimental|WORKWELL Group|The same as the Control Group (i.e. self-help information pack, plus usual care) PLUS the WORKWELL intervention. This consists of, on average, 4.5 hours contact, including: a structured work assessment; identification of work-related barriers and priority problems; collaborative treatment planning with the participant; a range of self-management, work advice and job modifications appropriate to the individual participant's problems; goal setting and action planning; and a 30 minute telephone review to identify progress with goals at the end of treatment.
89114120|NCT03941379||Subjects previously participated in an Aura Biosciences bel-sar study|Subjects with Choroidal Melanoma or Indeterminate Lesions.
89114121|NCT03939169|Other|Skin-to-skin support|The newborn is dressed in one layer of clothing with a hat, he is placed in the ventral position directly on the mother's chest, covered with a warm blanket and held in place with a band during the insertion of the naso-gastric feeding tube.
89114122|NCT03939169|Other|Holding|The newborn is held in his mother's arms during insertion of the naso-gastric feeding tube.
89114123|NCT03939169|Other|Four hands care|Carried out by two professionals: one health-care professional supports the child and helps stabilize the newborn whilst the other professional inserts the naso-gastric feeding tube.
89114124|NCT03939169|Other|Containing support with equipment|Carried out by one healthcare Professional, who places the newborn in such a manner that he will be held in the optimum position (using a soft sheet) during the insertion of the naso-gastric feeding tube.
89114125|NCT03896581|Experimental|Bimekizumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen.
89114126|NCT03896581|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo.
89114127|NCT03877497|Experimental|SBIRT-T|The screening, brief intervention and referral to treatment (SBIRT-T) will be adapted and used as the intervention in the experimental arm
89114128|NCT03877497|Active Comparator|INFO-C|The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT-T format via printed and audio-visual study material
89114129|NCT03868592|Experimental|Gastric sleeve surgery|before and after weight loss from bariatric surgery
89231783|NCT06020417|Placebo Comparator|Conventional|The conventional procedure for spinal arthrodesis will involve the intervertebral disc removal step between the vertebrae that will be fused. This is done precisely to create space for the bone graft that will be placed later. Then, there is bone surface preparation, where you prepare the bone surfaces of the vertebrae that will be fused, removing any soft tissue that might interfere with bone fusion. Then, there is bone graft placement, where the surgeon places a bone graft between the vertebrae that will be fused together. This graft can be obtained from another part of the patient's body (such as the pelvis) or from a deceased donor. Then, in the spinal column fixation step, rods, screws and/or plates are used to fix the vertebrae that will be fused.
89231790|NCT06011954||PADCEV|Patients who receive PADCEV Injection 20 mg and 30 mg (enfortumab vedotin) in routine clinical practice according to the drug label approved at the time of marketing authorization.
89231791|NCT06010498|Experimental|Eye Mask Group|
89231792|NCT06010498|No Intervention|Standart Care|
89231793|NCT06009406|Experimental|Intervention Group|This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The persons treated with graston are applied at a 45° angle parallel to the muscle fibers for approximately 20 seconds. Immediately afterwards, the graston is applied to the muscles in a direction perpendicular to the same muscle fibers at a 45° angle for 20 seconds, resulting in a total treatment time of approximately 40 seconds. This results in an increase in temperature and tonus relaxation on the skin surface. In our study, the application will be performed for Gastarocnemius, Soleus muscle and Achilles tendon.
89231794|NCT06009406|Active Comparator|Control Group|The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures. The static stretching technique is a widely used method that lengthens muscle length by autogenic inhibition that stimulates the Golgi tendon organ. This technique involves passively stretching a specific antagonist muscle by placing it in a position of maximum stretch and holding it there for an extended period of time. Recommendations on the optimal length of time to hold this flexed position typically indicate that a 30-second hold, repeated 3 to 4 times, will provide the most beneficial results. 3 repetitions of passive stretching for 30 seconds will be applied to the same structures.
89231795|NCT06005220|Active Comparator|SBD121 Medical Food|Two capsules administered twice daily with food
89231796|NCT06005220|Placebo Comparator|Placebo|Two capsules administered twice daily with food
89231797|NCT06003556|Experimental|PSMA PET|"These patients will have been diagnosed with unilateral prostate cancer by standard of care diagnostic tests deemed eligible and interested in focal therapy. These patients will be randomized to undergo a single [18]F-PSMA-1007 PET/CT or PET/MRI scan prior to focal therapy. If they are diagnosed with bilateral disease, they will be ineligible for focal therapy and be referred for radical therapy. Those with unilateral disease will then proceed to focal therapy. They will then receive PSMA PET, MRI, and combined targeted and systematic biopsy 12 months after ablation~Intravenous bolus injection of 4 MBq/kg +/- 10% of [18]F-PSMA-1007, up to a maximum of 400 MBq."
89114130|NCT03855449|Experimental|eDECIDE Web-based Intervention Group|Participants randomized to the eDECIDE arm will use the online version of the program through the eDECIDE study portal. Participants in this group will receive bi-weekly calls from their health coach to mark their progress with the program.
89114131|NCT03855449|Active Comparator|DECDIE Traditional Group|Participants randomized to the DECIDE group will receive a copy of the curriculum via mail and will be a self-study group where they go through the curriculum on their own with 4 calls from their health coach.
89114132|NCT03854903|Experimental|Dose Level A1|"Palbociclib: 75mg daily for 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
89114133|NCT03854903|Experimental|Dose Level A2|"Palbociclib: 75mg daily for the first 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle"
89114134|NCT03854903|Experimental|Dose Level B1|"Palbociclib: 100mg daily for 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
89114135|NCT03854903|Experimental|Dose Level B2|"Palbociclib: 100mg daily for 21 days of each 28 day cycle~Bosutinib: 500mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
89114136|NCT03849443|Placebo Comparator|Group 1 PLACEBO|
89114137|NCT03849443|Experimental|Group 2 IV TXA|
89114138|NCT03849443|Experimental|Group 3 Pre-Oral TXA|
89114139|NCT03849443|Experimental|Group 4 Full Oral TXA|
89114140|NCT03827798|Experimental|CFZ533|s.c.
89114141|NCT03827798|Experimental|LYS006|p.o.
89114142|NCT03827798|Placebo Comparator|Placebo to CFZ533|Matching placebo (s.c.)
89114143|NCT03827798|Placebo Comparator|Placebo to LYS006|Matching placebo (p.o.)
89114144|NCT03827798|Experimental|MAS825|s.c.
89114145|NCT03827798|Placebo Comparator|Placebo to MAS825|Matching placebo (s.c.)
89114146|NCT03827798|Active Comparator|LOU064 25mg|p.o.
89114147|NCT03827798|Active Comparator|LOU064 100mg|p.o.
89114148|NCT03827798|Placebo Comparator|Placebo to LOU064|Matching placebo p.o.
89114149|NCT03827798|Experimental|VAY736|s.c.
89114150|NCT03827798|Placebo Comparator|Placebo to VAY736|Matching placebo (s.c.)
89114151|NCT03803202|Experimental|Stage 1, Group 1 Adults, ASP3772 Low dose|Healthy adults aged 18 to 64 years received a low dose [1 microgram (μg)] of ASP3772 intramuscularly on Day 1.
89114152|NCT03803202|Experimental|Stage 1, Group 1 Adults, ASP3772 Medium dose|Healthy adults aged 18 to 64 years received a medium dose (2 μg) of ASP3772 intramuscularly on Day 1.
89114153|NCT03803202|Experimental|Stage 1, Group 1 Adults, ASP3772 High dose|Healthy adults aged 18 to 64 years received a high dose (5 μg) of ASP3772 intramuscularly on Day 1.
89114154|NCT03803202|Active Comparator|Stage 1, Group 1, PCV13 Pooled Comparator|Healthy adults aged 18 to 64 years received a single dose of PCV13 0.5 milliliter (mL) intramuscularly on Day 1. Data from participants in each group given PCV13 were pooled for comparison with each ASP3772 dose group (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose).
89114155|NCT03803202|Experimental|Stage 2, Group 2 Older Adults, ASP3772 Low dose|Healthy older adults aged 65 to 85 years received a low dose (1 μg) of ASP3772 intramuscularly on Day 1.
89114156|NCT03803202|Experimental|Stage 2, Group 2 Older Adults, ASP3772 Medium dose|Healthy older adults aged 65 to 85 years received a medium dose (2 μg) of ASP3772 intramuscularly on Day 1.
89114157|NCT03803202|Experimental|Stage 2, Group 2 Older Adults, ASP3772 High dose|Healthy older adults aged 65 to 85 years received a high dose (5 μg) of ASP3772 intramuscularly on Day 1.
89114158|NCT03803202|Active Comparator|Stage 2, Group 2, PCV13 Pooled Comparator|Older adults aged 65 to 85 years received a single dose of PCV13 0.5 mL intramuscularly on Day 1. Data from participants in each group given PCV13 were pooled for comparison with each ASP3772 dose group (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose).
89114159|NCT03803202|Active Comparator|Stage 2, Group 3, PPSV23 Comparator|Older adults aged 65 to 85 years who had been previously vaccinated with PCV13, were enrolled and received a single of dose PPSV23 on Day 1.
89114160|NCT03801720|No Intervention|Control Group|Utilize standard practice for obtaining a CCU in pre-continent children; this consists of cleaning the GU area with betadine and waiting 5 minutes for micturition to occur.
89114161|NCT03801720|Experimental|Experimental Group|Consists of cleaning the GU area with betadine followed by using an ultrasound probe to apply cool ultrasound gel and subprapubic pressure to the patient to induce micturition.
89114162|NCT03786224|Experimental|Abstinent|
89114163|NCT03737812|Placebo Comparator|Placebo|Participants randomized to receive placebo by intravenous infusion.
89114164|NCT03737812|Experimental|Elezanumab 400mg Dose|Participants randomized to receive 400mg of elezanumab by intravenous infusion.
89114165|NCT03737812|Experimental|Elezanumab 1800 mg Dose|Participants randomized to receive 1800mg of elezanumab by intravenous infusion.
89114166|NCT03727360|Experimental|Exercise Training|Group exercise and treadmill walking
89114167|NCT03727360|Active Comparator|Flexibility Control|Group exercise and flexibility exercise
89114168|NCT03719859|Experimental|Physical Therapy (PT) Group|Subjects will attend formal physical therapy after surgery.
89114169|NCT03719859|Active Comparator|Home Therapy (HT) Group|Subjects will receive instruction from clinical staff regarding home therapy exercises after surgery.
89114170|NCT03692325|Experimental|Nivolumab|"Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle~Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent"
89114171|NCT03680859||Diabetic|Participants with a primary etiology of diabetic gastroparesis
89114172|NCT03680859||Idiopathic|Participants with a primary etiology of idiopathic gastroparesis
89114173|NCT03680859||Post-fundoplication|Participants with a primary etiology of post-Nissen fundoplication gastroparesis
89114174|NCT03680859||Diabetic with Normal Emptying|Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying
89114175|NCT03680859||Idiopathic with Normal Emptying|Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying
89114176|NCT03680859||Post-fundoplication with Normal Emptying|Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying
89114177|NCT03673722|Experimental|MDP only|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern through interaction with the online LEAP2 platform
89114178|NCT03673722|Experimental|MDP plus PA|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern AND to increase Physical Activity using a mixture of structured and non-structured activities through interaction with the online LEAP2 platform
89114179|NCT03673722|Placebo Comparator|Control|Participants will be given generic healthy eating advice based on the NHS 'Eatwell' plate and British Heart Foundation (BHF) guidelines
89114180|NCT03642509|Experimental|LAAO group|Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.
89114181|NCT03642509|Experimental|NOAC group|Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.
89114182|NCT03640481|Experimental|Arm A: belumosudil 200 mg QD|Eligible subjects randomized to arm A will take belumosudil 200 mg once daily
89114183|NCT03640481|Experimental|Arm B: belumosudil 200 mg BID|Eligible subjects randomized to arm B will take belumosudil 200 mg twice daily
89114184|NCT03635424|Experimental|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
89114185|NCT03632356|Experimental|Stepped Care Intervention (STEP)|In a stepped-care model, all patients start with an evidence-based intervention of low intensity as a first treatment step. Progress is monitored and patients who do not respond adequately can subsequently be 'stepped up' to a higher intensity treatment. This model is now being recommended as the best strategy for treating panic attacks and panic disorder.
89114186|NCT03632356|Active Comparator|Screening only|Screening only for panic attacks and panic disorder using a gold standard clinical interview that provides coverage of the core symptoms of panic attacks and panic disorder.
89114187|NCT03598790|Experimental|Bimekizumab dose regimen 1|"Subjects are randomized to receive either dose regimen 1 (BKZ 1) or dose regimen 2 (BKZ 2) during the 144-week Treatment Period (open-label), those on BKZ 1 will switch to BKZ 2 at Week 24 or later (at the next scheduled clinic visit after Week 48)~Eligible subjects who completed the Treatment Period (open-label), and have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks.~Intervention Name: Bimekizumab"
89114188|NCT03598790|Experimental|Bimekizumab dose regimen 2|"Subjects are randomized to receive BKZ 2 during the 144-week Treatment Period (open-label).~Eligible subjects who completed the Treatment Period (open-label), would continue OLE2 on BKZ 2.~Intervention Name: Bimekizumab"
89114189|NCT03565367|Experimental|Healthy Volunteers|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes.
89114190|NCT03565367|Experimental|Known CNS Malignancy|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes (participants may receive gadolinium at the discretion of the protocol director).
89114191|NCT03561896|Experimental|IGRT|Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity
89114192|NCT03561896|Experimental|SRS|Stereotactic Radiosurgery of the resection cavity (SRS)
89114193|NCT03553095|Active Comparator|Chronic Periodontitis and Depression Medications|Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis
89114194|NCT03553095|Active Comparator|Chronic Periodontitis without Depression Medications|Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis
89114195|NCT03553095|Active Comparator|Chronic Periodontitis|Patients without depression, not taking any antidepressants and with chronic periodontitis
89114196|NCT03529513||Depressed|Subjects currently experiencing a moderate-to-severe major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
89114197|NCT03529513||Control|Subjects not currently experiencing a major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
89114198|NCT03521596||Patient enrolled|Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
89114199|NCT03513510|Experimental|iChoose|6 biweekly family sessions, 6 biweekly telephone support calls to parents, 6 biweekly newsletters for children, and 3 supervised exercise sessions per week/3 months; delivers intervention to parents and children only
89114200|NCT03505086||cohort|All patients fulfilling the eligibility criteria who can be asked for consent. Basic register of only patient diagnosis, treatment and bleeding yes or no (without identifiable information).
89114201|NCT03505086||cases|Patient with clinically relevant bleeding, defined as major and clinically relevant non-major bleeding that leads to substantial additional medical care: WHO score 3-4 and part of the WHO score 2 bleedings (depending on the need for additional care).
89114202|NCT03505086||controls|Patient without clinically relevant bleeding matched to a case patient based on diagnosis and therapy.
89231798|NCT06003556|No Intervention|No Additional Imaging|"These patients will have been diagnosed with unilateral prostate cancer by standard of care diagnostic tests deemed eligible and interested in focal therapy. These patients will undergo no further testing and will undergo focal therapy.~They will then receive PSMA PET, MRI, and combined targeted and systematic biopsy 12 months after ablation.~Intravenous bolus injection of 4 MBq/kg +/- 10% of [18]F-PSMA-1007, up to a maximum of 400 MBq."
89231799|NCT05998616|Experimental|Exercise Training Program|Participants will receive a theory-based, remotely-delivered exercise training program that includes aerobic and resistance exercise training.
89231800|NCT05998616|Active Comparator|Flexibility Program|Participants will receive a remotely-delivered flexibility program, focusing on improving flexibility and range of motion.
89231801|NCT05987332|Experimental|Phase 2a Dose Optimization of IDE196 + crizotinib|Multiple doses of IDE196 will be tested in combination with fixed dose of crizotinib to identify the optimal combination dose.
89231802|NCT05987332|Experimental|Phase 2b / 3 Chosen Combination dose of IDE196 + crizotinib|Chosen combination dose of IDE196 + crizotinib will be tested in additional participants.
88816356|NCT02581839|Experimental|Eribulin Mesylate|The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
89114203|NCT03493711||Breast Fed|Exclusively breastfed for first 3 months of life
88816357|NCT02976207||OSA diagnosed patients|patients at the age range of 18-90, male or female, who are diagnosed as suffering from OSA and are surgery candidates for their condition.
88816358|NCT02504775|Experimental|Tylenol® Caplets, then Mejoral® 500 Tablets|Participants will first receive one tablet [500 milligram (mg) of paracetamol] of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
89114204|NCT03493711||Milk-based formula fed|Exclusively on Similac Advance Formula for at least 1 month prior to visit
89114205|NCT03480659||Breast Cancer|Early stage luminal A and triple negative breast cancer [TNBC] (estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2-negative (HER2-)
89114206|NCT03480659||Control|Age matched control females
89114207|NCT03454451|Experimental|Cohort 1a|CPI-006
89114208|NCT03454451|Experimental|Cohort1b|CPI-006 + ciforadenant
89114209|NCT03454451|Experimental|Cohort 1c|CPI-006 + pembrolizumab
89114210|NCT03454451|Experimental|Cohort 2a|CPI-006
89114211|NCT03454451|Experimental|Cohort 2b|CPI-006 + ciforadenant
89114212|NCT03454451|Experimental|Cohort 2c|CPI-006 + pembrolizumab
89114213|NCT03445481|Experimental|Femoral prosthesis|newly developed prosthesis for trans-femoral amputation
89114214|NCT03443687|Active Comparator|Pelvic Floor Physical Therapy|If randomized to this arm, women will complete demographic forms and questionnaires. They will then undergo the intervention of 4 pelvic floor physical therapy visits over 3 months. At that time they will return for a follow up visit and complete questionnaires.
89114215|NCT03443687|Experimental|Home Biofeedback|If randomized to this arm, women will complete demographic forms and questionnaires. They will then be given a pelvic floor exercise device that is bluetooth linked to a smartphone application. They will be instructed on how to use the device daily for 3 months and their intervention will be to perform daily exercises with the device in place. At 3 months they will return for a follow up visit and complete questionnaires.
89114216|NCT03384654|Experimental|Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL|Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.
89114217|NCT03384654|Experimental|Cohort 2: T-Cell ALL/LL|Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.
89114218|NCT03379168|Placebo Comparator|Placebo Injection|Patients who are randomized to the placebo group will receive an injection of 7cc of sterile saline in the affected knee.
89114219|NCT03379168|Active Comparator|Corticosteroid Injection|Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain lidocaine for a total of 7cc of fluid injected in the affected knee.
89114220|NCT03379168|Experimental|Lipogems Injection|Patients who are randomized to the Lipogems treatment group will undergo a lipoaspiration from their abdomen and autologous injection of the harvested adipocytes into their knee. It is standard to harvest three to four times more adipose tissue than is planned to be injected to account for tissue processing by the Lipogems device. The investigators plan to inject 7cc of autologous adipose tissue. Thus, the investigators will harvest between 25 and 30 cc of adipose tissue from each patient. The tissue will be processed immediately and 7cc will be injected. Any remaining adipose tissue will be disposed of immediately in biohazardous waste.
89114227|NCT03245320||TITAN™ Total Shoulder System Generation 1.0|Integra TITAN™ Total Shoulder System Generation 1.0
89114228|NCT03231306|Experimental|Open label study of Binimetinib (MEK162)|"Subjects (≥ 18 years) (Stratum A) will receive a course of binimetinib by mouth twice a day (12 hours apart) of 45 mg/dose. Duration of each course is 4 weeks. After 8 courses, subjects will receive additional courses if MRI results showed at least 15% reduction in volume of the target tumor. Subjects can continue on therapy and will be evaluated at the end of 12 courses. Subjects who have ≥ 20% reduction in volume of the target tumor according to the MRI results can continue therapy up to an additional year (maximum of 24 total courses). Subjects who have not met the tumor reduction at the specified times will be removed from the study therapy. Subjects will be carefully monitored for toxicities associated with binimetinib.~Recruitment of subjects 1 - 17 years of age (Stratum B) is currently available. The pediatric maximum tolerated dose (MTD) of binimetinib the pediatric patients (Statum B) was established by a phase 1 study (NCT022)."
89114229|NCT03219268|Experimental|Tebotelimab: 1 mg|
89114230|NCT03219268|Experimental|Tebotelimab 3 mg|
89114231|NCT03219268|Experimental|Tebotelimab: 10 mg|
89114232|NCT03219268|Experimental|Tebotelimab: 30 mg|
89114233|NCT03219268|Experimental|Tebotelimab: 120 mg|
89114234|NCT03219268|Experimental|Tebotelimab: 400 mg|
89114235|NCT03219268|Experimental|Tebotelimab: 600 mg|
89114236|NCT03219268|Experimental|Tebotelimab: 800 mg|
89114237|NCT03219268|Experimental|Tebotelimab: 1200 mg|
89114238|NCT03219268|Experimental|Combination cohort 1|Tebotelimab and margetuximab
89114239|NCT03219268|Experimental|Combination Cohort 2|Tebotelimab and margetuximab
89114240|NCT03219268|Experimental|Monotherapy Cohort Expansion|Monotherapy expansion at 600 mg
89114241|NCT03153202|Experimental|Participants with CLL|Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
89114242|NCT03153202|Experimental|Participants with MCL|Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
89114243|NCT03146754|Experimental|Stable ADHF patients|Lung ultrasound to access b lines
89114244|NCT03146754|Active Comparator|Control Patients|Patients without any cardiopulmonary disease will be control patients for the active subjects, age-matched accordingly.
89114245|NCT03108131|Experimental|Treatment (cobimetinib, atezolizumab)|Participants receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89114246|NCT03088878|Experimental|Part 1|Cirmtuzumab followed by Cirmtuzumab plus ibrutinib
89114247|NCT03088878|Experimental|Part 2|Cirmtuzumab plus ibrutinib
89114248|NCT03088878|Experimental|Part 3 - Arm A|Cirmtuzumab plus ibrutinib
89114249|NCT03088878|Active Comparator|Part 3 - Arm B|Ibrutinib only
89114250|NCT03087071|Experimental|Cohort 1 (panitumumab)|Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
89231803|NCT05987332|Active Comparator|Phase 2a / 2b / 3 Comparator Arm|Participants will receive investigator's choice of Pembrolizumab, Ipilimumab + Nivolumab, or Dacarbazine.
89231804|NCT05981534|Experimental|Intervention group|The intervention group will receive vitamin D supplement for 6 months
88816359|NCT02504775|Experimental|Mejoral® 500 Tablets, then Tylenol® Caplets|Participants will first receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
88816360|NCT02504931|Experimental|Sertraline|"Subjects will receive a fixed dose of 150 mg sertraline per day. Sertraline dose will be gradually increased by giving sertraline subjects capsules filled with 50 mg for the first three days and then capsules filled with 100 mg for 4 days before beginning the 150 mg per day in the second week. After completing the study Visit 12, subjects will be given an additional two week supply of medicine to gradually taper down so as to minimize any withdrawal discomfort.~Subjects in the Sertraline arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
88816361|NCT02504931|Placebo Comparator|Placebo|"Matching placebo capsules will be filled with corn starch only on the same schedule as the Sertraline.~Subjects in the Placebo arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
88816362|NCT02582151|Sham Comparator|Sham tibial nerve stimulation|Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve.
88816363|NCT02582151|Active Comparator|Tibial nerve stimulation|Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve.
88816364|NCT02584725|Active Comparator|5 mg/kg/dose tranexamic acid|5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
88816365|NCT02584725|Active Comparator|10 mg/kg/dose tranexamic acid|10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
88816366|NCT02584725|Active Comparator|15 mg/kg/dose tranexamic acid|15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
88816367|NCT04423029|Experimental|Monotherapy Dose Escalation|
88816368|NCT04423029|Experimental|Monotherapy Dose Expansion (Melanoma)|
88816369|NCT04423029|Experimental|Monotherapy Dose Expansion (NSCLC)|
88816370|NCT04423029|Experimental|Combination Dose Escalation|
88816371|NCT04423029|Experimental|Combination Dose Expansion (Melanoma)|
88816372|NCT04423029|Experimental|Combination Dose Expansion (NSCLC)|
88816373|NCT01186562|Active Comparator|Sitagliptin|
88816374|NCT01186562|Placebo Comparator|Placebo|
88816375|NCT01187498|Experimental|Behavioral Training|Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
88816376|NCT01187498|Active Comparator|Drug Therapy|Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg
88816377|NCT01147406|Experimental|Active|N6022
88816378|NCT01147406|Placebo Comparator|Placebo|Placebo
88816379|NCT01148420|Experimental|DMPA & MPA|150 mg intramuscularly received DMPA and two 10 mg tablets of MPA every 8 hours for 3 days
88816380|NCT01149434|Experimental|Pharmacokinetic Arm|Patients going on Pharmacokinetic arm will receive JI-101 & Everolimus (4 patients only)
89231805|NCT05981534|Placebo Comparator|Control group|The control group will receive placebo for 6 months
89290591|NCT01228500|Experimental|Experimental Arm (Internal Control)|"One-half of ulcer receives negative pressure wound therapy~One-half of ulcer receives a fetal bovine collagen bioscaffold (PriMatrix, TEI Biosciences, Boston, MA) in addition to the same negative pressure wound therapy"
89290592|NCT05633290||ICU Survivors of Sepsis|ICU survivors of sepsis who would routinely attend ICU follow-up.
89290593|NCT01129986|Experimental|Dermastream|
88816381|NCT01149434|Experimental|Pharmacodynamic arm|Patients going on the Pharmacodynamic study will receive JI-101 only.
88816382|NCT04375124|No Intervention|non-peptide group|This group will receive routine treatment and care for COVID-19.
89114251|NCT03087071|Experimental|Cohort 2 (panitumumab, trametinib)|Patients with KRAS, NRAS, or BRAF mutation receive trametinib PO QD on days 1-14 and panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89114252|NCT03087071|Experimental|Cohort 3 (panitumumab)|Patients without EGFR ectodomain, KRAS, NRAS, or BRAF mutation receive panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
89114253|NCT03085485|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
89114254|NCT03085485|Placebo Comparator|Placebo|matching placebo
89114255|NCT03071861|Experimental|Darbepoetin Alpha|IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at <24 hours of age
89114256|NCT03071861|Placebo Comparator|Placebo|IV, Normal saline (placebo dose), one dose at <24 hours of age
89114257|NCT03043872|Experimental|Arm 1|durvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)
89114258|NCT03043872|Experimental|Arm 2|durvalumab+EP (carboplatin or cisplatin + etoposide)
89114259|NCT03043872|Active Comparator|Arm 3|EP (carboplatin or cisplatin + etoposide)
89114260|NCT03020381||Cognitively Normal (Control Group)|Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD.
89114261|NCT03020381||Subjective Cognitive Impairment (SCI)|"Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
89114262|NCT03020381||Mild Cognitive Impairment (MCI)|Participants aged 60 and older that have self-experienced persistent decline in cognitive capacity and unrelated to an acute event. MCI is operationalized following Peterson's criteria as: i) presence of subjective memory complaints from the patient and family; ii) objective memory impairment in cognitive tests (below 1.5 SD on standardized cognitive tests adjusted by age, sex, and education-); iii) preserved activities of daily living (assessed using the Lawton-Brody scale); iv) absence of clinical dementia established using DSM-IV-TR (from 2007 to 2013) and DSM V (from 2014 and onwards)
89114263|NCT03015610|Placebo Comparator|Placebo|participants will receive oral blinded matched placebo once daily
89114264|NCT03015610|Experimental|Genotype-guided Lansoprazole|participants will receive oral blinded commercially available lansoprazole once daily with a dose appropriate for the participant's metabolizer phenotype
89114265|NCT03005860|Active Comparator|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anaesthesia will be induced with Thiopental 5 - 7mg/kg, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 & 1.0.
89114266|NCT03005860|Experimental|2,6 diisopropylphenol|In Propofol group, anesthesia will be will be induced with Propofol TCI [target controlled infusion pump - Injectomat® TIVA Agilia (Fresenius Kabi)] using Schneider model to achieve target site concentration of 4-6mcg/ml, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with TCI propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60.
89114267|NCT02950337|Experimental|Group 1: Peripherally Located Tumors|Peripherally Located Tumors - SBRT
89114268|NCT02950337|Experimental|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Peripherally Located Chest Wall Adjacent Tumors - SBRT
89114269|NCT02950337|Experimental|Group 3: Centrally Located Tumors|Centrally Located Tumors - SBRT
89114270|NCT02928224|Experimental|Safety Lead-in, Triplet Arm|Encorafenib + binimetinib + cetuximab.
89114271|NCT02928224|Experimental|Doublet Arm|Encorafenib + cetuximab.
89114272|NCT02928224|Active Comparator|Control Arm|Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
89114273|NCT02842086|Experimental|F/TAF|F/TAF+ F/TDF placebo for at least 96 weeks
89114274|NCT02842086|Experimental|F/TDF|F/TDF+ F/TAF placebo for at least 96 weeks
89114275|NCT02842086|Experimental|Open-label|Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment for 96 weeks.
89114276|NCT02842086|Experimental|Open-Label Extension|Participants who remain on study at Open-label Week 96 will have the option to continue on open-label F/TAF treatment in the Open-label extension phase for 408 weeks.
89114277|NCT02800070|Experimental|Treatment Arm|Patients will receive Health Canada approved transduced autologous CD34+ cell product.
89114278|NCT02788474|Placebo Comparator|placebo|
89114279|NCT02788474|Experimental|nintedanib|
89114280|NCT02720445|Experimental|Nicotine Transdermal Patch|190 participants will wear nicotine transdermal patches during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment
89114281|NCT02720445|Placebo Comparator|Placebo Patch|190 participants will wear matching placebo patches during waking hours.
89114282|NCT02678572|Experimental|Melphalan/HDS|3 mg/kg ideal body weight of melphalan for infusion administered directly to the liver via percutaneous hepatic perfusion (PHP) over 30 minutes followed by a 30 minute washout. Treatment cycles are to be repeated every 6-8 weeks until disease progression.
89114283|NCT02631746|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 46 courses in the absence of disease progression or unacceptable toxicity.
89290594|NCT04545112|Experimental|XABG|
89290595|NCT03931278|Other|persons with Multiple Sclerosis (MS)|
89290596|NCT03931278|Other|Healthy controls|
88816383|NCT04375124|Active Comparator|peptide group|This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.
89114284|NCT02598531||Test Arm|Test Arm participants will be enrolled in the standard of care bariatric surgery program and will undergo surgical weight loss through Laparoscopic Sleeve Gastrectomy or Laparoscopic Gastric Bypass. Approximately 9-13 months post surgery, each participant will be evaluated to determine if he/she is still eligible for a total knee replacement or if their need has been removed. If still eligible, participants will be enrolled in the standard of care TKA program and will undergo a TKA procedure. Participants will complete nine (9) research visits over 3.5-4 years.
89114285|NCT02598531||Control Arm|Control Arm participants will be enrolled in the standard of care TKA program and complete six (6) research visits over 2.5-3 years. This group of participants will undergo a TKA procedure without any surgical weight loss intervention.
89114286|NCT02529319|Experimental|MRI-Guided Ablation|"Surgery~Patients will undergo catheter ablation using DE-MRI as a guide for fibrosis imaging."
89114287|NCT02529319|Active Comparator|Conventional Ablation|"Surgery~Patients will undergo conventional catheter ablation as described by the HRS guidelines."
89114288|NCT02484950|Experimental|Rotator cuff repair with stem cells|Using clinically accepted methods, subjects will undergo bone marrow aspiration (from hip, proximal humerus or tibia) through a small incision prior to arthroscopy in the group undergoing MSC augmentation. They will then undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique with mesenchymal stem cell augmentation.
89114289|NCT02484950|Placebo Comparator|Rotator cuff repair without stem cells|Subjects will undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique, without augmentation of mesenchymal stem cells. To maintain patient blinding, all patients will receive a small incision around the site of expected bone marrow aspiration (hip, proximal humerus, or tibia), regardless of whether or not they receive bone marrow.
89114290|NCT02467231||Exposed|Females ages 11-35 to be exposed to alkylating agent chemotherapy
89114291|NCT02394964||Systemic Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
89114292|NCT02394964||Subacute Cutaneous Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
89114293|NCT02394964||Control|Blood, stool, and swab samples will be collected for comparison to each disease group
89114294|NCT02394964||Cutaneous T-Cell Lymphoma|Blood and swab samples will be collected for comparison to each disease group
89114295|NCT02394964||Autoimmune Disorders|Blood, stool, and swab samples will be collected for comparison to each disease group
89114296|NCT02293655|Placebo Comparator|MPH Discontinuation|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~DB 4-week MPH Discontinuation Phase. Pts in this arm will receive placebo (qAM)."
89114297|NCT02293655|Active Comparator|Sustained MPH|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~DB 4-week MPH Discontinuation Phase. Pts in this arm will continue their optimal MPH dose (qAM)."
89114298|NCT02166463|Active Comparator|Arm I (ABVE-PC)|Patients receive doxorubicin hydrochloride IV over on days 1-2, bleomycin sulfate IV or SC on days 1 and 8, vincristine sulfate IV on days 1 and 8, etoposide IV on days 1-3, prednisone orally PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
89114299|NCT02166463|Experimental|ARM II (Bv-AVEPC)|Patients receive brentuximab vedotin IV on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
89114300|NCT02118467|Active Comparator|Norepinephrine and epinephrine|"Patients will receive norepinephrine infusion per standard protocol. Dose range will be 0.03-0.3 mcg/kg/minute. Norepinephrine concentration will be 16 mg/250 mL. If a second vasopressor is required, epinephrine will be added. Dose range of epinephrine will be 0.03-0.3 mcg/kg/minute. Epinephrine concentration will be 16 mg/250 mL. The drugs norepinephrine and epinephrine will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.~If the patient's shock is not adequately treated with the highest doses of both norepinephrine and epinephrine, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
89114301|NCT02118467|Active Comparator|Phenylephrine and vasopressin|"Patients will receive phenylephrine infusion per standard protocol. Dose range will be 0.3 to 3.0 mcg/kg/minute. Phenylephrine concentration will be 160 mg/250 mL. If a second vasopressor is required, vasopressin will be added. Dose range of vasopressin will be 0.1 to 0.6 milliunits/kg/minute. Vasopressin concentration will be 40 units/250 mL. The drugs phenylephrine and vasopressin will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.~If the patient's shock is not adequately treated with the highest doses of both phenylephrine and vasopressin, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
89290597|NCT01227096||Electro-acupuncture, Control|
89290598|NCT01227096||Preconditioning, No preconditioning|
89114302|NCT02101034|Experimental|Phase I: Dose Level 1|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
89114303|NCT02101034|Experimental|Phase I: Dose Level 2|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
89114304|NCT02101034|Experimental|Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
88816384|NCT01149512||LAGB patients in Weight Wise Program|All patients seen within the Weight Wise program and selected for surgical management, who have undergone LAGB will be included in this analysis.
88816385|NCT03012698|Experimental|RMS treatment|
89114305|NCT02101034|Experimental|Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
89114306|NCT02101034|Experimental|Phase II Arm 3:|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
89114307|NCT02016599||Initial cohort|Initial cohort used to develop a series of multivariate clinical deterioration indices using monitoring modalities and biospecimen collection
89114308|NCT02016599||Validation cohort|Separate cohort of infants used to validate the clinical deterioration indices using monitoring modalities and biospecimen collection
89114309|NCT02000622|Experimental|Olaparib|Olaparib tablet 300mg bd po
89114310|NCT02000622|Active Comparator|Physician's choice chemotherapy|Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
89114311|NCT01817192|Active Comparator|Observation|Post-operative observation of Stage I or Stage IIA non squamous non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as low risk will be observation. Those patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.
89114312|NCT01817192|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy is a current standard of care for intermediate or high-risk Stage I or Stage IIA non-squamous non-small cell lung cancer. Patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Observation Arm.
89114313|NCT01244802||Group 1: 18 to 45 years of age|Between the ages of 18 and 45 at the time of yellow fever vaccination
89114314|NCT01244802||Group 2: 55 years of age and above|Aged 55 or greater at the time of yellow fever vaccination
89114315|NCT01016340|Active Comparator|MCS-5|Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
89114316|NCT01016340|Placebo Comparator|Placebo|Group 4: Placebo for 16 weeks
89114317|NCT00965991|Active Comparator|Metformin|
89114318|NCT00965991|Active Comparator|Glyburide|
89114319|NCT00959140|Experimental|CD3+ T-cell depletion|CD3+ T-cell depletion
89114320|NCT00811668|Experimental|CPAP before SOMNOVentCR|started with CPAP and continued with SOMNOvent CR
89114321|NCT00811668|Experimental|SOMNOVentCR before CPAP|began with SOMNOvent CR and ended with CPAP
89114322|NCT00798135|Experimental|itraconazole|Patients will receive oral itraconazole 200mg a day until disease progression.
89114323|NCT00782574|Experimental|1|"Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator.~Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid).~The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions."
89114324|NCT00643955||DS|Individual with Down Syndrome
89114325|NCT00579969|Experimental|Latanoprost Effects on Aqueous Humor Dynamics in Ocular Hypertensive Patients|Evaluating the Effects of Latanoprost on Aqueous Humor Dynamics in Ocular Hypertensive Patients (prostaglandin analogue)
89114326|NCT00579969|Experimental|Timolol Effects on Aqueous Humor Dynamics in Ocular Hypertensive Patients|Evaluating the Effects of Timolol on Aqueous Humor Dynamics in Ocular Hypertensive Patients (prostaglandin analogue)
89114327|NCT00579371|Experimental|Transplantation of Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000 International Units/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
89114328|NCT00135226|Active Comparator|Aspirin + Omega-3 Ethyl Esters|Participants receive 100mg of aspirin once daily and 1g of omega-3 ethyl esters once daily.
89114329|NCT00135226|Active Comparator|Aspirin + Placebo Omega-3 Ethyl Esters|Participants receive 100mg of aspirin once daily and placebo omega-3 ethyl esters once daily.
89114330|NCT00135226|Active Comparator|Placebo Aspirin + Omega-3 Ethyl Esters|Participants receive placebo aspirin once daily and 1g of omega-3 ethyl esters once daily.
89114331|NCT00135226|Active Comparator|Placebo Aspirin + Placebo Omega-3 Ethyl Esters|Participants receive placebo aspirin once daily and placebo omega-3 ethyl esters once daily.
89114332|NCT00097292||Annual Re-Testing/Annual Metabolic Monitoring|Participants will be monitored annually for risk of type 1 diabetes.
89114333|NCT00097292||Semi-Annual Metabolic Monitoring|Participants will be monitored every six months for risk of type 1 diabetes
89290599|NCT05416606|Active Comparator|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
89231806|NCT05972005|Experimental|Intervention (Stronger at Home model)|This study implements a 14-week home-based rehabilitation program for older adults after hip fractures. Participants will receive 8 home visits by a Physiotherapist (PT) and/or Physio assistant(PTA), focusing on individualized exercise programs and pain self-management. The intervention aims to improve functional recovery and includes PT-led assessments, exercise adjustments, and discharge assessments. PTAs support exercise delivery and education. The clinical team comprises PTs and PTAs, receiving training on exercise principles, pain education, and goal setting. The program emphasizes progressive strengthening, balance, and functional exercises, adhering to evidence-based principles. The intervention aims to enhance efficiency, reduce wait times, and promote adherence.
89231807|NCT05972005|Active Comparator|Control (usual care)|The control group will receive usual home care provided by the healthcare system, which could vary between cases. We'll document their received care during follow-ups as it is inconsistent and poorly recorded. Regular check-in calls by the study coordinator will remind them of assessments, reducing attrition.
89231808|NCT05966194|Experimental|RRx-001 Pre-Treatment (8mg RRx-001) + Chemoradiation Therapy (CRT)|Pretreatment consists of 8 mg RRx-001 given twice weekly during the 2 weeks prior to the start of CRT (4 doses total) followed by the CRT treatment period
89231809|NCT05966194|Experimental|RRx-001 Pre-Treatment (4mg RRx-001) + Chemoradiation Therapy (CRT)|Pretreatment consists of 4 mg RRx-001 given twice weekly during the 2 weeks prior to the start of CRT (4 doses total) followed by the CRT treatment period.
89231810|NCT05966194|Placebo Comparator|Placebo Pre-Treatment + Chemoradiation Therapy (CRT)|No doses of RRx-001 will be administered. Patients assigned to this arm will receive placebo twice weekly during the 2 weeks prior to the start of CRT followed by the CRT treatment period.
89231811|NCT05957276||Participants With Inherited Retinal Diseases (IRDs)|Adult and pediatric (greater than or equal to [>=] 3 years) participants with a documented genetic diagnosis of X-linked retinitis pigmentosa (XLRP) or Achromatopsia (ACHM) and any signs or symptoms of IRD or documented retinal changes detected by imaging or electrophysiology.
89231812|NCT05955625|Experimental|TIMELY intervention and care as usual|The intervention group will receive the TIMELY intervention including wearable monitoring devices and app in addition to care as usual for a duration of 6 months.
89231813|NCT05955625|No Intervention|Care as usual|The care as usual group will receive the standard care as they would receive without being enrolled in the current trial.
89231815|NCT05952687|Experimental|Dose Finding/Safety Phase|Patients with progressive/relapsed atypical teratoid/rhabdoid tumors (AT/RT) & malignant rhabdoid tumors (MRT) or synchronous/metachronous AT/RT &MRT
89231816|NCT05952687|Experimental|Expansion Phase: Stratum A|Patients with progressive/relapsed AT/RT
89231817|NCT05952687|Experimental|Expansion Phase: Stratum B|Patients with progressive/relapsed MRT
89231818|NCT05952687|Experimental|Expansion Phase: Stratum C|Patients with progressive/relapsed, synchronous/metachronous AT/RT & MRT
89231819|NCT05948657|Other|PSMA-PET CT|Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
88816386|NCT04352348|Other|COVID-19 negative|Patients with exclusion diagnosis for COVID-19 infection
89231820|NCT05947981|No Intervention|Control group|Patients will be fasted and not receiving any pre-operative fluids
89231821|NCT05947981|Active Comparator|Dextrose group|Patients will take 100ml/HR of clear fluids (apple juice) during the fasting hours till 2 hrs before the operation and will receive dextrose 5% infusion at a rate of 1ml/kg/h 2hrs before the operation and till the end of the operation
89231822|NCT05947981|Placebo Comparator|Normal saline group|Patients will take 100ml/HR of water during the fasting hours till 2 hrs before the operation and will receive normal saline 0.9% at a rate of 1ml/kg/h (group NS) intravenously (IV)2hrs before the operation and till the end of the operation
89231823|NCT05947500|Active Comparator|Arm 1 (tuvusertib)|Patients receive tuvusertib PO QD on days 1-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI, biopsy, and collection of blood and stool/rectal swabs at screening and on study. Patients with documented progression may cross over to Arm 2.
89231824|NCT05947500|Experimental|Arm 2 (tuvusertib, avelumab)|Patients receive tuvusertib PO QD on days 1-14 of each cycle and avelumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI, biopsy, and collection of blood and stool/rectal swabs at screening and on study.
89231825|NCT05944042||Intra-Operative Data:|Intra-Operative Data: Operative time, donor type, transfusions, intraoperative adverse events, mechanical ventilation, portal vein thrombosis, etc.
89231826|NCT05944042||Post-Operative Data and Follow-Up:|Post-Operative Data and Follow-Up: Post-operative laboratories (MELD score, ctDNA, etc.), adverse events, discharge status, hospital length of stay, readmissions, recurrence of primary disease, graft survival, renal disease, post-transplant metabolic syndrome and major cardiovascular events, etc.
89231827|NCT05942040|Experimental|Intervention Group|Intervention group will consist of all MA plan members eligible for community-based palliative care and of those who refused it (to calculate refusal rate) during the six month period following the introduction of tailored informational materials developed on CBPC
89231828|NCT05942040|No Intervention|Control Group|Control group will be a retrospective review of individuals who were eligible for community-based palliative care and of those who refused it, for the 6-month period prior to introducing the tailored informational materials. All of these individuals will have received usual care/information regarding community-based palliative care.
89231829|NCT05940402|Experimental|Mild Renal Impairment|Participants will receive a single oral dose of 10 milligrams (mg) emraclidine on Day 1.
89231830|NCT05940402|Experimental|Moderate Renal Impairment|Participants will receive a single oral dose of 10 mg emraclidine on Day 1.
89231831|NCT05940402|Experimental|Severe Renal Impairment|Participants will receive a single oral dose of 10 mg emraclidine on Day 1.
89231832|NCT05940402|Experimental|Normal Renal Function|Participants will receive a single oral dose of 10 mg emraclidine on Day 1.
89231833|NCT05926583|Experimental|Group 1: AAV5-hRKp.RPGR Low Dose|Participants will receive bilateral subretinal administration of AAV5-hRKp.RPGR low dose, with surgical delivery to the 2 eyes performed within 7 to 21 days apart.
89231834|NCT05926583|Experimental|Group 2: AAV5-hRKp.RPGR High Dose|Participants will receive bilateral subretinal administration of AAV5 hRKp.RPGR high dose, with surgical delivery to the 2 eyes performed within 7 to 21 days apart.
89231835|NCT05923970||Women with low rubella antibodies|Women with rubella antibodies <10 IU/mL
89231836|NCT05923970||Women with high rubella antibodies|Women with rubella antibodies ≥10 IU/mL
89231837|NCT05923749|Experimental|Biatain Ag|
89231838|NCT05923749|Active Comparator|Cutimed Siltec Sorbact|
89231839|NCT05923073|Experimental|Open-label induction phase: Guselkumab Intravenously (IV)|Participants will receive guselkumab dose IV based on their body weight (BW) during the 12-week open-label induction phase.
89231840|NCT05923073|Experimental|Open-label induction phase: Guselkumab Subcutaneously (SC)|Participants will receive guselkumab dose SC based on their BW during the 12-week open-label induction phase.
89290600|NCT05416606|Active Comparator|open prostatectomy|open surgical transvesical prostatectomy
88816387|NCT04352348|Other|COVID-19 positive, not severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and not requiring hospitalization
89114334|NCT02742909|Active Comparator|rhBNP|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received rhBNP.
89114335|NCT02742909|Placebo Comparator|Placebo|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received placebo.
89114336|NCT02742675|Experimental|androgen deprivation therapy|Patients will receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide acetate, goserelin acetate, buserelin, or triptorelin) subcutaneously or as an injection AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily).
89114337|NCT02742675|Experimental|androgen deprivation therapy plus definitive treatment|Patients will receive androgen-deprivation therapy as in arm I in addition to definitive treatment including surgery to remove prostate or radiation therapy to the prostate.
89114338|NCT02742753||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
89114339|NCT02742597|Active Comparator|Group A|Intervention group (n = 86) Intervention: Participates in Telemedicine Impact Plus (TIP)/ IMPACT Plus Care Coordination meeting
89114340|NCT02742597|Active Comparator|Group B|Before/After Intervention group (n = 10) Intervention: Participates in TIP / IMPACT Plus Care Coordination meeting
89114341|NCT02742597|No Intervention|Group C|Control group (n = 77)
89114342|NCT02742597|No Intervention|Group D|Health Administrative Data Group (n = 430) Number of matched data controls. Not taking part in intervention.
89114343|NCT00813358|Experimental|Endovascular repair|treatment
89114344|NCT02742207||Observational|All comers with Atrial fibrillation
89114345|NCT00812812|Experimental|paroxetine group|paroxetine 10-40mg/day
89114346|NCT00812812|Placebo Comparator|placebo group|matched placebo to paroxetine
89114347|NCT02739165|Experimental|ART-123|
89114348|NCT02739165|Placebo Comparator|Placebo|
89231841|NCT05923073|Experimental|Double-blind maintenance phase: Guselkumab SC or Guselkumab SC and Placebo SC|At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive a guselkumab dose SC based on their BW or a guselkumab dose SC based on their BW and placebo SC up to Week 48.
89231842|NCT05923073|Experimental|Open-label maintenance phase: Guselkumab SC|Week 12 non-responders will enter open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48.
89231843|NCT05911321|Experimental|Single Arm|Subjects with relapsed or refractory multiple myeloma receiving the study treatment.
89290601|NCT01224132|No Intervention|Probiotics|
89290602|NCT01224132|No Intervention|skim milk powder, dextrose|
89114349|NCT02739243|Experimental|Tailored group intervention|"Participants take part in the tailored group intervention which consists of five 90-minute group sessions over eight weeks. The sessions are in the form of structured group talk/discussions following specific themes:~Session 1 - Coping and acceptance: identification of common themes from participants' feedback, provision of information about support services, mindfulness practices~Session 2 - Distress: introduction of the distress model, identification of resources, breathing practices~Session 3 - Handling of stressful situations: individual identification in tandems, discussion of common pitfalls in the group~Session 4 - Self-care: inspection of individual daily routines, group collects positive experiences with windows for self-care~Session 5 - Feedback and outlook: stabilisation, retrospective reflection on the group experience and its benefits and, if applicable, potential adverse events"
89114350|NCT02739243|Active Comparator|Treatment as usual|Participants are provided with brief information in a leaflet, about the possibilities for individual counselling including referral to the local outpatient cancer counselling centre providing client-centred counselling and financial social work.
89114351|NCT02742285|Other|Artemether + lumefantrine|One single adult dose of artemether + lumefantrine 80 + 480 mg
89114354|NCT04190199||Type 2 diabetes mellitus (T2DM)|Subjects in this group are diagnosed with type 2 diabetes mellitus. They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
89114355|NCT04190199||Pre-diabetes (IFG or IGT)|Subjects in this group are diagnosed with pre-diabetes (impaired fasting glucose [IFG] or impaired glucose tolerance [IGT]). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
89114356|NCT04190199||Non-type 2 diabetes mellitus (healthy)|Subjects in this group are not diagnosed with type 2 diabetes mellitus or pre-diabetes (healthy). They receive no intervention. Their nutritional status, metabolite profile, dietary pattern, and lifestyle practices will be assessed.
89114357|NCT05756608||Aortic stenosis|The investigators will recruit 70 patients with aortic stenosis (25 patients with asymptomatic moderate aortic stenosis and 25 patients with symptomatic severe aortic stenosis, 10 patients with mild aortic stenosis and 10 patients with aortic sclerosis) and 10 healthy volunteers, who will undergo baseline 68Ga-FAPI or 18F-AlF-FAPI PET/MR imaging to establish fibrosis activity in healthy myocardium and in context of chronic myocardial injury. All patients will have a follow up FAPI PET/ MR scan 1 year after their baseline scan to assess whether myocardial fibrosis activity reverses following aortic valve replacement and restoration of normal afterload in patients with severe aortic stenosis and if baseline myocardial fibrosis activity can predict progression in the fibrosis burden and clinical progression in patients with mild or moderate aortic stenosis or aortic sclerosis. Healthy volunteers will not undergo any repeat imaging.
89114358|NCT05756608||Chemotherapy-induced cardiotoxicity|The investigators will recruit 60 patients who have undergone anthracycline treatment >1 year from enrollment and 10 healthy volunteers as part of this cohort. This will include 50 patients who have either clear evidence of cardiotoxicity (Ejection fraction <50% and a 10%point fall in ejection fraction) or a subclinical cardiac injury (elevated troponin, elevated T2, impaired global longitudinal strain) and 10 patients with no evidence of cardiotoxicity on their cardiac MRI scan (performed as part of the ongoing Cardiac CARE study). These patients will undergo baseline FAPI PET/MR imaging to establish the extent and pattern of myocardial fibrosis activity in context of delayed myocardial injury (chemotherapy-induced cardiotoxicity). All patients will have a follow up cardiac MRI scan 1-2 years after their baseline scan to assess whether baseline fibrosis activity is associated with a deterioration in cardiac function. Healthy volunteers will not undergo any repeat imaging.
89114359|NCT05756608||Carcinoid syndrome|In collaboration with the South East Scotland NET Service, the investigators will recruit 30 patients with carcinoid syndrome for this cohort. These patients will undergo a baseline echocardiogram and a FAPI PET/MR scan to investigate fibrosis activity within the cardiac chambers and valves. The investigators will recruit patients with established cardiac involvement as well as carcinoid syndrome patients with high circulating 5-HT concentrations who have no evidence of valve disease on echocardiography. All patients will have a follow up cardiac MRI scan and an echocardiogram, 6 months - 1 year after their baseline scan to assess whether baseline fibrosis activity is associated with subsequent deterioration in cardiac and valvular function.
89114360|NCT03673527|Experimental|topical formulation of tacrolimus|
89114361|NCT04030546|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until the last chemotherapy session
89114362|NCT04030546|No Intervention|Usual care|Patient will receive usual care
89114363|NCT05756530||Cases|Right-handed women diagnosed with restricting type or binge-eating/purging type AN, according to the Diagnostic and Statistical Manual of Mental Disorders (5th Edition)'s criteria (DSM, American Psychiatric Association, 2013), will be consecutively recruited during their rehabilitative treatment at the Istituto Auxologico Italiano, IRCCS, San Giuseppe Hospital (Italy). Concurrent neurological, neurodevelopmental (e.g., autism), motor, somatosensory and/or psychiatric disorders will be the exclusion criteria, as well as the evidence of any skin-related condition possibly affecting sensitivity on the participants' forearm (e.g., eczema, scars)
89114364|NCT05756530||Controls|Age-matched, right-handed, healthy women (i.e., with no history of eating disorders) will be recruited outside the hospital through personal contacts of the researchers and word-of-mouth.
89114365|NCT04030390|Experimental|Physical Fatigue Condition|
89114366|NCT04030390|Placebo Comparator|Control Condition|
89114367|NCT02739009|Experimental|MOR106|Single intravenous administration of MOR106
89114368|NCT02739009|Placebo Comparator|Placebo|Single intravenous administration of Placebo
89114369|NCT02739009|Experimental|MOR106 MAD|Multiple intravenous administration of MOR106
89114370|NCT02739009|Placebo Comparator|Placebo MAD|Multiple intravenous adminstration of Placebo
89114371|NCT05210296|Experimental|Trunk strengthening exercises|"After 5 minutes of warm-up exercises, 20 minutes of trunk strengthening exercises and 10 minutes of balance exercises will be applied to the participants, and the session will end with 5 minutes of cooling-off exercises.~In trunk strengthening exercises, trunk resistance exercises will be applied with an elastic exercise band."
89114372|NCT05210296|Experimental|Lower extremity strengthening exercises|"After 5 minutes of warm-up exercises, lower extremity strengthening exercises and 10 minutes of balance exercises will be applied to the participants, and the session will end with 5 minutes of cool-down exercises.~In lower extremity strengthening exercises, lower extremity resistance exercises will be applied with elastic exercise band."
89114373|NCT05210296|No Intervention|Control|Participants will not be included in any exercise program. At the end of the study, the elderly will be informed about the effects of exercises and appropriate exercise program training will be given.
89114374|NCT02738931|Experimental|Treatment Sequence ABC|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
89114375|NCT02738931|Experimental|Treatment Sequence BCA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
89114376|NCT02738931|Experimental|Treatment Sequence CAB|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
89114377|NCT02738931|Experimental|Treatment Sequence ACB|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
89114378|NCT02738931|Experimental|Treatment Sequence BAC|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
89114379|NCT02738931|Experimental|Treatment Sequence CBA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
89114380|NCT00810082|Active Comparator|Group A|Standard physical therapy for fall prevention
89114381|NCT00810082|Experimental|Group B|Physical therapy for fall prevention that includes ActiveStep
89114382|NCT02738697|Experimental|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
89114383|NCT02738697|Other|Follow-up|Routine follow-up were performed instead of adjuvant chemotherapy
89114384|NCT02736747|Active Comparator|Cryotherapy (ice pack)|A pack with 1000g of crushed ice without air will be placed for 20 consecutive minutes on a pre-delimited rectangular area with dimensions of 25 x 35 cm and will be fixed with a non-compressive elastic band. One strip of plastic paper will encompass the paretic leg of the subjects, avoiding direct contact from the skin with the ice pack.
89114385|NCT02736747|Placebo Comparator|Placebo (sand pack)|"For placebo application, the pack will be filled with 1000g of thin sand, in environmental temperature, so that the pressure exerted will be the same as the ice pack. All other experimental procedures will follow the same protocol as cryotherapy application."
89114386|NCT02738619|Active Comparator|vitamin d3|1600 UI
89114387|NCT02738619|Placebo Comparator|placebo|placebo
89114388|NCT04016116|Experimental|Pembrolizumab (Cohort 1)|Pembrolizumab IV every 3 weeks (Cohort 1: Advanced progressive MPNs)
89114389|NCT04016116|Experimental|Pembrolizumab + Ruxolitinib|Pembrolizumab IV every 3 weeks & Ruxolitinib po days 1-21 (Cohort 1: Advanced progressive MPNs)
89114390|NCT04016116|Experimental|Pembrolizumab + Ruxolitinib (Cohort 2)|Pembrolizumab IV every 3 weeks & Ruxolitinib po days 1-21 (Cohort 2, unresponsive to PD-1)
89114391|NCT02736591|Active Comparator|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI
89114392|NCT02736591|Active Comparator|Growth hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
89231846|NCT05908734|Experimental|Phase 1 (Combination Dose Selection)|Participants will receive amivantamab low dose or high dose intravenous (IV) infusion based on body weight from Cycle 1 Day 1, Day 2, and subsequently Day 8, Day 15, and Day 22 and then every 2 weeks from Cycle 2 in combination with cetrelimab IV infusion from Cycle 1 Day 2 (after the Day 2 infusion of amivantamab). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET).
89231847|NCT05908734|Experimental|Phase 2 (Dose Expansion)|Participants will receive amivantamab in combination with cetrelimab in Cohorts A and B at the RP2CD determined by the SET in Phase 1. Participants will continue study treatment until disease progression, unacceptable toxicity, or until another criterion for discontinuation of study treatment is met.
89231848|NCT05908331|Experimental|MagicTouch Sirolimus-Coated Balloon|Magic TouchTM is a Sirolimus Coated Balloon catheter intended to be used in coronary applications, treats the atherosclerosis of the coronary arteries by eluting the immunosuppressant agent Sirolimus without leaving behind a metallic scaffold.
89231849|NCT05908331|Active Comparator|POBA|plain old balloon angioplasty
89231851|NCT05904028|Experimental|Treat and Extend|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
89231852|NCT05904028|Experimental|Home optical coherence tomography-Guided Treatment|Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
89231853|NCT05903482||Diabetic, in GLP-1 RA|non-invasive, gastric ultrasound in children who are on GLP-1 RA medications and have type 2 diabetes mellitis (DM) and/or obesity and/or type 1 DM
89231854|NCT05903482||Diabetic, not on GLP-1 RA|non-invasive, gastric ultrasound in children who are not on GLP-1 RA medications and have type 2 diabetes mellitis (DM) and/or obesity and/or type 1 DM.
89231855|NCT05903482||Non-diabetic, not on GLP-1 RA|non-invasive, gastric ultrasound in non-diabetic children who are not on GLP-1 RA medications and do not have diabetes or obesity.
89231856|NCT05902052|Experimental|Open Heart Surgery Patient Care Protocol|"Specific Practices for Pain in the Protocol~Evaluation of patients' pain in the extubated period with the Visual Anolog Scale~Active participation of the patient in pain reporting~Regular questioning of the patient's pain~Questioning pain at rest and movement~Implementing nursing interventions in painful condition (VAS≤ 4)"
89231857|NCT05902052|No Intervention|Standart Care Protocol|Standard care of intensive care will be given.
89231858|NCT05901961|Active Comparator|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
89231859|NCT05901961|Active Comparator|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
89231860|NCT05901961|Active Comparator|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
89231861|NCT05901649||Apalutamide Plus Androgen Deprivation Therapy (ADT)|Participants with metastatic hormone-sensitive prostate cancer (mHSPC) will be observed who are being treated with apalutamide under clinical practice setting. Only data available per routine clinical practice will be collected within this study.
89231862|NCT05901649||Enzalutamide Plus Androgen Deprivation Therapy (ADT)|Participants with metastatic hormone-sensitive prostate cancer (mHSPC) will be observed who are being treated with enzalutamide under clinical practice setting. Only data available per routine clinical practice will be collected within this study.
89231863|NCT05901636|Experimental|INFLUENZA G1 mHA Dose Level 1|Participants will receive single intramuscular (IM) injection of INFLUENZA G1 mHA Dose level 1 on Days 1 and 57 in Cohort 1.
89231864|NCT05901636|Experimental|INFLUENZA G1 mHA Dose Level 1 along with Al(OH)3|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 1 with Aluminum Hydroxide (Al[OH])3 adjuvant on Days 1 and 57 in Cohort 1.
89231865|NCT05901636|Placebo Comparator|Placebo|Participants will receive IM injection of placebo on Days 1 and 57 in Cohorts 1 and 2.
89231866|NCT05901636|Experimental|INFLUENZA G1 mHA Dose Level 2|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 2 on Days 1 and 57 in Cohort 2.
89231867|NCT05901636|Experimental|INFLUENZA G1 mHA Dose Level 2 along with Al(OH)3|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 2 with Al(OH)3 adjuvant on Days 1 and 57 in Cohort 2.
89231868|NCT05901636|Experimental|INFLUENZA G1 mHA Dose Level 2 + Placebo|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 2 on Day 1 and placebo on Day 57 in Cohort 2.
89231869|NCT05901636|Experimental|INFLUENZA G1 mHA Dose Level 2 along with Al(OH)3 + Placebo|Participants will receive single IM injection of INFLUENZA G1 mHA Dose level 2 with Al(OH)3 adjuvant on Day 1 and placebo on Day 57 in Cohort 2.
89231872|NCT05897723|Experimental|Treatment Group|All enrolled subjects will undergo breast reduction or breast mastectomy in which scar assessment will be made after pre-surgical treatment in a split-body design, involving a single treatment of RF application to one side of the surgical area(s) within 24 hours prior to the procedure. The subject will act as their own control, where one surgical area will be treated, and the other will not be and will act as the control. Tissue samples will be biopsied from RF treated skin, as well as non-treated skin, at follow up visits. The samples will be used for histological evaluation to assess tissue structure and regeneration following surgery.
89231873|NCT05895955|Experimental|TetraFluvac TF vaccine|20 participants in phase I study and 200 participants in phase II study will receive a prefilled single dose of 0.5 ml of TetraFluvac TF vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
89114393|NCT02738463||Group 1 case|This group will include 32 pregnant females whose fetuses show intrauterine growth restriction at full term ( the 32 neonates with birth weight less than 10th percentile for corresponding gestational age will be included as small for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
89114394|NCT02738463||Group 2 control|This group will include at least 32 pregnant females whose fetuses are appropriate for gestational age at full term ( the 32 neonates with birth more than or equal to the 10th percentile for corresponding gestational age will be included as average for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
89114395|NCT02736513|Experimental|AZD9291 80 mg - naive patients|naive patients with tumors harbouring either exon 19 deletion, L858R, T790M, or uncommon sensitizing EGFR mutations, will be treated with AZD9291 80 mg/day
89114396|NCT02736513|Experimental|AZD9291 80 mg - previously treated T790M was diagnosed|Patients previously treated with first and second generation EFGR TKIs (either Gefitinib, Erlotinib or Afatinib) in whom T790Mwas diagnosed either in the tumor specimen or in the ctDNA after testing it following the most recent disease progression, will be treated with AZD9291 80 mg/day
89114397|NCT02736513|Experimental|AZD9291 80 mg - previously treated unrelated to T790M|patients advanced NSCLC previously treated with 1st/2nd generation EGFR TKIs (either gefitinib. erlotinib or afatinib) who progressed unrelated to T790M (T790M-). No restriction regarding the number of prior EGFR TKIs or cytotoxic chemotherapy lines of treatment is applied.
89114398|NCT02610322|Experimental|Whole soy group|Whole soy replacement diet: to incorporate 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods.
89114399|NCT02610322|Placebo Comparator|Control group|Usual diet: to receive a conventional lifestyle education on MetS.
89114400|NCT05756452|Experimental|Partecipants with ACS and obstructive CAD|The study is to identify a difference in the correlation between HRV and CRP parameters in ACS patients with or without obstructive CAD
89114401|NCT05756452|Experimental|Partecipants with ACS without CAD, in a 1:1 ratio|Evaluate whether cardiac autonomic dysfunction is associated with low-grade systemic inflammation, inflammasome-dependent activation of IL-18 and IL-1β, and Th1/Treg frequency, in patients with ACS with or without obstructive CAD on angiography
89114402|NCT02738385|Experimental|High Intensity Interval Training|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal until the end of training.
89114403|NCT02738385|Active Comparator|Moderate Intensity Interval Training|Walking on a treadmill at 60-80% peak heart rate until expenditure of 300 kcal until the end of training.
89114404|NCT04853290|Experimental|Intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
89114405|NCT04853290|Active Comparator|Control group|Conventional peripheral venipuncture performed by a registered nurse from a clinical inpatient unit.
89114406|NCT02736435|Experimental|Fibroid dimension < 8 cm|"Women with a maximum fibroid dimension less than 8 cm and a total uterine volume less than 900 cc.~Intervention: Treatment of fibroids with Magnetic Resonance Guided High Intensity Focused Ultrasound."
89114407|NCT02736435|Experimental|Fibroid dimension > 8 cm|"Women with a maximum fibroid dimension greater than 8 cm or a total uterine volume greater than 900 cc.~Intervention A: Pre-treated with 11.25mg leuprolide acetate for depot suspension for 3 months to reduce size of fibroids.~Intervention B: Treatment with Magnetic Resonance Guided High Intensity Focused Ultrasound if fibroids decrease to treatable size of less than 8cm and uterine volume less than 900cc."
89114408|NCT02738541|Active Comparator|Group 1|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
89114409|NCT02738541|Placebo Comparator|Group 2|PLACEBO DENTRIFICE WITHOUT PYROPHOSPATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
89114410|NCT02610244|No Intervention|Treatment As Usual|Standard treatment as usual as directed by the physician.
89114411|NCT02610244|Experimental|Modified Cogmed Training|10 weeks of computerized training (3x weekly for 35-minutes each session) that targets thinking skills that are often impaired in individuals diagnosed with ADHD.
89114412|NCT04851262|Experimental|Intervention|The intervention is a 12-week home-based resistance training programme with phased progression. The intervention will have three phases: (i) an initial phase focused on training the target muscle(s)/movements with minimal or no external weight; (ii) an intermediate phase targeting muscle strength with increased practice resistance; and (iii) an advanced phase targeting the further enhancement of muscle strength by challenging multiple muscle groups. Each phase will involve exercises targeting the trunk, back, hip, upper-limb and lower-limb muscles.
89114413|NCT04851262|Other|Waitlist control|The waitlist control participants will start the intervention 12 weeks after the baseline assessment.
89114414|NCT00748189|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
89114415|NCT00748189|Active Comparator|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
89114416|NCT02610166|Experimental|Game|Access to the game.
89114417|NCT02610166|Active Comparator|Usual Care|Control group.
89114418|NCT02736201|Experimental|IMT+ T-CaRe®on; n = 10|The instrumental manual therapy with the switched on capacitive diathermy electrode
89114419|NCT02736201|Sham Comparator|IMT+ T-CaRe® off; n = 10|The instrumental manual therapy with the switched off capacitive diathermy electrode
89114420|NCT02609230|Experimental|A|For the first arm (A), dose escalation will use the following single patient dose-escalation cohorts based on 'Design 4' proposed by Simon and colleagues: 125, 250, and 500 mg. every 3 weeks.
89114421|NCT02609230|Experimental|B|Following completion of Arm A dose escalation, subsequent cohorts will be tested in a minimum of 3 patients, the Arm B dose cohort will consist of dose levels administered every week (planned dosing of 250, 375, 500 and 625 mg).
89114422|NCT02738307|Experimental|altitude exposure|Altitude Exposure Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
89114423|NCT00913822|Experimental|1|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
89114424|NCT00913822|Active Comparator|2|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
89114425|NCT05603091||Pressure guided cryoablation|Patients undergoing cryoablation of atrial fibrillation with catheter-balloon, where the evaluation of the pulmonary veins occlusion will be assessed by the analysis of the pressure waveforms obtained from the tip of the catheter (without injecting contrast).
89114426|NCT02736123|Experimental|Arm A consists of 3 phases or steps|"Induction Phase Nivolumab 3 mg/kg IV infusion every 2 weeks for 3 doses~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)~Maintenance Phase (after recovery from surgery) Nivolumab 3 mg/kg IV infusion every 3 weeks"
89114427|NCT02736123|Experimental|Arm B consists of 3 phases or steps|"Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)~Maintenance Phase (after recovery from surgery) Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses; then, Nivolumab 3 mg/kg IV infusion every 3 weeks"
89114428|NCT02735967|Experimental|Group manual therapy + diadynamic|"Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.~Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient."
89114429|NCT02735967|Active Comparator|Group manual therapy|Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
89114430|NCT02735967|Active Comparator|Group diadynamic|An electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF),4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
89114431|NCT00744055|Experimental|Prazosin|prazosin (16mg/day)
89114432|NCT00744055|Placebo Comparator|Placebo|Placebo in identical looking capsule blister packs
89114433|NCT00748033|Experimental|LoFric POBE Hydro-Kit II, 5 seconds and then LoFric POBE Hydro-Kit II, 24 hours|"All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 5 seconds.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 24 hours."
89114434|NCT00748033|Experimental|LoFric POBE Hydro-Kit II, 24 hours and then LoFric POBE Hydro-Kit II, 5 seconds|"All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 24 hours.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 5 seconds."
89114435|NCT03545763||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
89114436|NCT03545763||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
89114437|NCT02736903|Active Comparator|Individual intervention|Behavioral: PennFit mobile individual intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their own daily steps and the minutes for vigorous, moderate, and muscle-strengthening exercises that they completed for each day. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening.
89114438|NCT02736903|Experimental|Online network intervention|Behavioral: PennFit mobile online network intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their exercises. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening. Participants were randomly assigned to 4-person online networks in the PennFit app. Participants in the online networks could see both their own information and the profiles and activity logs of the three other people assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
89114439|NCT02737995|Experimental|Iron Replacement|
89114440|NCT02738073|Placebo Comparator|Control|
89114441|NCT02738073|Active Comparator|Interventional|
89114442|NCT02737761|Experimental|Optimal Adherence|"Participants will all undergo a qualitative interview and adherence measurements at baseline and 12 weeks after hospital discharge.~In person the participants will receive a MEMSCaps device and an Actigraph accelerometer. They will be asked to begin wearing the accelerometer after their initial interview and to begin using the MEMSCaps device once they arrive at home. Participants will use the MEMSCap throughout the entire study and will wear the Actigraph for 2 weeks at baseline and again at 12 weeks."
89114443|NCT00735553|Active Comparator|25 mg Proellex|25 mg oral daily dose of Proellex
89114444|NCT00735553|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
89114445|NCT00735553|Placebo Comparator|placebo|oral daily dose of placebo
89114446|NCT02595775|Experimental|Round 1: Intervention arm|"Half of the endoscopists in Ontario will receive an individualized audit & feedback report.~Individualized A/F report."
89114447|NCT02595775|No Intervention|Round 1: Control|Half of the endoscopists in Ontario will NOT receive an individualized audit & feedback report.
89114448|NCT02595775|Other|Round 2: Month 12|"All endoscopists in Ontario will receive an individualized audit & feedback report at month 12.~Individualized A/F report"
89231874|NCT05895955|Active Comparator|Vaxigrip vaccine|20 participants in phase I study and 50 participants in phase II study will receive a prefilled single dose of 0.5 ml Vaxigrip vaccine (Commercially available seasonal quadrivalent split, manufactured by Sanofi Pasteur, Ltd. France) will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
89231875|NCT05888051||Young Adult|
89231876|NCT05888051||Adult|
89114449|NCT02595775|Other|Round 2: Poor performers|"In Round 2, selected 60 poorer performers will be randomly assigned to receive one of the following interventions at month 12:~A/F report plus a high intensity intervention~A/F report plus a low intensity intervention~A/F report alone"
89114450|NCT00740779|Experimental|Silodosin 4 mg|4 mg daily
89114451|NCT00740779|Experimental|Silodosin 8 mg|Silodosin 8 mg daily
89114452|NCT00740779|Placebo Comparator|Placebo|1 placebo capsule daily
89114453|NCT00735475|Experimental|Afluria®|
89114454|NCT00735475|Active Comparator|Fluzone®|
89114455|NCT01026818|Experimental|Tadalafil daily [5 milligrams (mg)]|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
89114456|NCT01026818|Experimental|Tadalafil on demand (20 mg)|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
89114457|NCT01026818|Placebo Comparator|Placebo|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
89114458|NCT00735397|Experimental|Perampanel|Participants previously receiving perampanel/placebo in the double blind-study, were titrated to receive perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years.
89114459|NCT02593747|Experimental|Loratadine oral solution/syrup then Claritin peach syrup|Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
89114460|NCT02593747|Experimental|Claritin peach syrup then Loratadine oral solution/syrup|Subjects received a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
89114461|NCT00735007|Experimental|1|
89114462|NCT03964987||Control group|Women with normoevolutionary gestation.
89114463|NCT03964987||Problem group|Patients with GDM.
89114464|NCT04089397|Experimental|Light therapy group|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis (at home, for patients dialyzing the afternoon, or during dialysis for patients dialyzing in the morning)
89114465|NCT04089397|No Intervention|Control group|Usual care, without light therapy
89114466|NCT00743509|Experimental|Oral Cyclophosphamide and Sirolimus (OCR)|Sarcoma patients were given oral Cyclophosphamide and Sirolimus (OCR) in 28 day cycles.
89114467|NCT04089319|Experimental|Acupuncture + mindfulness|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen to a 15-minute mindfulness recording followed by music for 30 minutes. Acupuncture needles will then be removed.
89290603|NCT01227174|Experimental|Propofol sedation|Patients will be undergo procedural sedation using propofol.
89290604|NCT03924258|Experimental|HEART FAILURE|Patients with Heart Failure diagnosis
88816388|NCT04352348|Other|COVID-19 positive, severe|Patients with confirmed diagnosis of COVID-19 infection or suspected of being and requiring hospitalization
89290605|NCT05415904||HANTA-NE|All adult patient hospitalized for hantavirus infection between 01/01/2013 and 31/12/2022 in North Eastern France
89114468|NCT04089319|Other|Acupuncture control|Participants will receive acupuncture treatment for chronic pain. After acupuncture needles have been inserted, participants will listen music for 45 minutes. Acupuncture needles will then be removed.
89114469|NCT02595697|Experimental|J-EMT for Toddlers with Autism|The J-EMT intervention:(a) teach foundational social communicative behaviors, (b) teach related skills that predict long term language outcomes, (c) teach a range of communicative functions, (d) target specific spoken language skills as well as foundational skills, (e) incorporate instructional methods, contexts, and partners that increase social use of language in natural contexts, and (f) promote generalization and maintenance of newly learned skills to everyday activities and routines. In addition, because parents are essential partners for young children with ASD who are learning to communicate, studies are needed that (g) include parents and (h) specify the method and fidelity of parent instruction and fidelity and dosage with which parents use the trained strategies
89114470|NCT02595697|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
89114471|NCT00734929|Experimental|1|Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
89114472|NCT00734929|Active Comparator|2|Ondansetron 4 mg within 30 min of the end of surgery + Dexamethasone 10 mg after induction of anesthesia
89114473|NCT00734851|Experimental|Multimodality|4 cycles of 70 mg/m2 Docetaxel + 37.5 mg daily Sunitinib for 14 days followed by a 7 day break for 3 cycles + external beam radiotherapy to 66 Gray over 6-7 weeks
89114474|NCT02593591||Biomarker group|Advanced cancer undergoing genomic profiling
89114475|NCT00918073||HIV positive smokers|50 HIV infected patients who enroll in a parent protocol to quit smoking and elect to participate in this sub-study.
89114476|NCT02597413||Before group|Women in this group are included before the implementation of a strategy of systematic catheterization (they will not be catheterized).
89114477|NCT02597413||After group|"Women in this group are included after the implementation of a department-wide strategy of systematic catheterization.~Intervention: catheterization"
89114478|NCT00734617|Experimental|Less Dependent Smokers|
89114479|NCT00734617|Experimental|More Dependent Smokers|
89114480|NCT00743431||1|Women with advanced ovarian cancer
89114481|NCT02737839|Experimental|Arm 1: STEPPING ON|"Adaptation Waves is to adapt Stepping On to the oncology setting/Pilot Waves is to determine the feasibility & acceptability of the program for older adults receiving cancer care/Gait & Balance Waves is to determine whether the participants experience changes in their gait & balance~Complete baseline questionnaires about Instrumental Activities of Daily Living, Medical Outcome Study Activities, Karnofsky Performance Status, falls in past 3 months, medications, comorbidities, vision & hearing, The Falls Behavioral Scale, The Falls Efficacy Scale-International, Patient Reported Outcome pain, PRO neuropathy~7 week STEPPING ON program is multi-component learning environment which has shown to help reduce falls~A home visit to gather any feedback on the experience of the program~Follow-up questionnaires up to 3 months after completion of the program~Participants may elect to participate in a booster session to reinforce concepts 3-6 months after completion of the program"
89114482|NCT02737605|Experimental|Sequence 1|Participants will receive Treatment A (intravenous placebo, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 1, Treatment B (intravenous placebo, 84 milligram (mg) of intranasal esketamine and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 2, Treatment C (intravenous placebo, Intranasal placebo and 400 mg oral moxifloxacin tablet) on Day 1 of period 3, Treatment D (0.8 milligram per kilogram of intravenous esketamine, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet ) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
89114483|NCT02737605|Experimental|Sequence 2|Participants will receive Treatment A on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
89114484|NCT02737605|Experimental|Sequence 3|Participants will receive Treatment B on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
89114485|NCT02737605|Experimental|Sequence 4|Participants will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
89114486|NCT02737605|Experimental|Sequence 5|Participants will receive Treatment C on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
89114487|NCT02737605|Experimental|Sequence 6|Participants will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
89114488|NCT02737371|Experimental|F901318 Dose level A oral|F901318 adverse events days 1-10
89114489|NCT02737371|Placebo Comparator|Placebo Dose level A oral|Placebo adverse events days 1-10
89114490|NCT02737371|Experimental|F901318 Dose level B oral|F901318 adverse events days 1-10
89114491|NCT02737371|Placebo Comparator|Placebo Dose level B oral|Placebo adverse events days 1-10
89114492|NCT02737371|Experimental|F901318 Dose level C oral|F901318 adverse events days 1-10
89114493|NCT02737371|Placebo Comparator|Placebo Dose level C oral|Placebo adverse events days 1-10
89231878|NCT05884398|Experimental|Arm A (Intermittent ADT Group)|Participants with PSA level <0.2 ng/mL after 6 months of treatment with Apalutamide and ADT during initial treatment phase, will enter main treatment phase and treated with apalutamide with intermittent ADT per protocol or followed up for at least 18 months from Day 1 of Cycle 7 (each cycle 28 days) or have discontinued the study, whichever occurs first.
89231879|NCT05884398|Experimental|Arm B (Continuous ADT Group)|Participants with PSA level <0.2 ng/mL after 6 months of treatment with Apalutamide and ADT during initial treatment phase, will enter main treatment phase and continue to receive apalutamide plus ADT or followed up for at least 18 months from Day 1 of Cycle 7 (each cycle 28 days) or have discontinued the study, whichever occurs first.
89231880|NCT05883319|Active Comparator|cervical mobilization|Cervical mobilization methods will be applied to 1st group for 3 days / week for 6 weeks.
89231881|NCT05883319|Active Comparator|clinical pilates exercises|clinical pilates exercises will be applied to 2nd group,for 3 days / week for 6 weeks.
89231882|NCT05883319|Active Comparator|cervical mobilization and clinical pilates exercises|cervical mobilization and clinical pilates exercises will be applied to 3rd group,for 3 days / week for 6 weeks.
89231885|NCT05875805|Experimental|Telehealth Serious Illness Care Program|The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
89231886|NCT05875805|Other|Control|"Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version"
89231887|NCT05869669|Active Comparator|Neflamapimod|Neflamapimod will be administered with food for 16 weeks in subjects with DLB. Subjects will receive 3 capsules per day (TID) with food (i.e., with the morning, mid-day and evening meals).
89231888|NCT05869669|Placebo Comparator|Placebo|Placebo will be administered with food for 16 weeks in subjects with DLB. Subjects will receive 3 capsules per day (TID) with food (i.e., with the morning, mid-day and evening meals).
89231889|NCT05864534|Experimental|Blood-brain barrier opening with concomitant BAL, BOT, DOX|Patients will undergo implantation of Sonocloud-9 after completion of radiotherapy. Within 21 days after implant, ultrasound-based BBB opening with concomitant administration of DOX (30 mg) + BAL (450 mg) every 3 weeks, and BOT (dose 1mg/kg) every 6 weeks will be initiated.
89231890|NCT05859360||Trained CP|Adolescents and young adults with CP who have continued their regular training after completing the pilot study.
89231891|NCT05859360||Untrained CP|Adolescents and young adults with CP who have not continued their regular training after completing the pilot study.
89231892|NCT05859360||Trained Peers|Healthy peers who perform high-intensity strength training on a regular basis.
89231893|NCT05859360||Untrained Peers|Healthy peers who do not perform high-intensity strength training on a regular basis.
89231894|NCT05856747|Experimental|TBP-PI-HBr 600 mg|Healthy participants meeting eligibility criteria will receive a single oral dose of TBP-PI-HBr 600 mg tablets (2 x 300 mg) on Day 1 under fasted conditions.
89231895|NCT05853861|No Intervention|MONITOR|Participants in this arm will be provided with information to track the early development of their infants, along with specific developmentally targeted activities.
89231896|NCT05853861|Experimental|COACH|Participants will be provided with a blended intervention of two evidence tested intervention, JASPER and Babble Bootcamp along with continued monitoring.
89231897|NCT05852691|Experimental|Arm A|Participants will receive tobemstomig every 3 weeks, plus nab-paclitaxel administered on a repeating schedule of 3 weeks on, 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
89231898|NCT05852691|Active Comparator|Arm B|Participants will receive pembrolizumab every 3 weeks, plus nab-paclitaxel administered on a repeating schedule of 3 weeks on, 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
89231901|NCT05849467|Experimental|Multiple Sclerosis|"MS cohort- Three study visits. (1) Baseline; (2) Day 0: MRI brain/spinal cord (with gadolinium) followed by an intravenous injection of anti-CD8 minibody (akaPET/CT tracer); (3) Day 1: PET/CT scan"
89231902|NCT05849467|Experimental|Progressive Multifocal Leukoencephalopathy|"PML cohort- Up to five study visits. (1) Baseline; (2) Day 0: MRI brain (with gadolinium) followed by an intravenous injection of anti-CD8 minibody (aka PET/CT tracer); (3) Day 1: PET/CT scan; (4) Study visit 4 (optional; time-period between study visit 3 and 4 is variable): MRI brain (with gadolinium) followed by an intravenous injection of anti-CD8 minibody (aka PET/CT tracer) following clinical, radiological and/or laboratory-defined immune reconstitution (spontaneous or facilitated); (5) Study visit 5: PET/ CT scan"
89231903|NCT05846308|Active Comparator|Synchronous condition|This arm (n=30) will include a synchronous intervention only.
89231904|NCT05846308|Active Comparator|Non-synchronous condition|This arm (n=30) will include a non-synchronous intervention only.
89231905|NCT05844982|Active Comparator|Intravitreal faricimab|Study eyes assigned to receive faricimab will receive a dose of 6.0 mg of faricimab. Faricimab is supplied in a single use vial.
89231906|NCT05844982|Active Comparator|Fluocinolone Acetonide Intravitreal Implants|Study eyes assigned to receive fluocinolone acetonide intravitreal implant will receive a dose of 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien). The implant is supplied in a sterile single use applicator with a 25-gauge needle
89231907|NCT05844982|No Intervention|Observation|
89231908|NCT05843578|Experimental|AGMB-129 High|AGMB-129 high dose
89231909|NCT05843578|Experimental|AGMB-129 Low|AGMB-129 low dose
89231910|NCT05843578|Experimental|Placebo|Matching placebo
89231911|NCT05843071|Experimental|Nasal spray treatment arm|
89114494|NCT02737527|Experimental|Ultrasound with Fluoroscope|"This group undergoes lumbar sympathetic block using ultrasound and fluoroscope.~Preparation: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Ultrasound for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
89114495|NCT02737527|Active Comparator|Fluoroscope only|"This group undergoes lumbar sympathetic block using fluoroscope only.~Device: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Fluoroscope for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
89114496|NCT00734539|Experimental|1|fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
89114497|NCT00734539|Placebo Comparator|2|Placebo IV or PO twice weekly for 6 weeks
89114498|NCT02737137|Other|Manual measurement by the anesthetist|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic : Group 1
89114499|NCT02737137|Experimental|Measurement by a pressure gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the injection pressure of the local anesthetic : Group 2
89114500|NCT02737059|Placebo Comparator|Codeine/naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Codeine tablet 30 mg q.i.d., and placebo tablet matching naloxegol q.d."
89114501|NCT02737059|Placebo Comparator|Naloxegol/ codeine placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Naloxegol tablet 25 mg q.d and placebo tablet matching codeine q.i.d."
89114502|NCT02737059|Active Comparator|Codeine/ naloxegol|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Codeine tablet 30 mg q.i.d., and naloxegol tablet 25 mg q.d."
89114503|NCT02737059|Active Comparator|codeine placebo/ naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Placebo tablet matching codeine q.i.d., and placebo tablet matching naloxegol q.d."
89114504|NCT00743275|Experimental|Study Group|Participants received one dose of Fluzone® vaccine on Day 0.
89114505|NCT02735889|Other|No carbonation (control)|No carbonation (NC, control): Potable water + sugar
89114506|NCT02735889|Active Comparator|Low carbonation|Low carbonation (LC): Potable water + sugar + little CO2
89114507|NCT02735889|Active Comparator|High carbonation|High carbonation (HC): Potable water + sugar+ high CO2
89114508|NCT02731989||study group|The surgeon will estimate the size difference between the undescended and the normally located testis. Independently the ultrasonographer will measure the true size of both testes in the study group.
89114509|NCT02731989||Control group|The same measurments will be done by the surgeon and the ultrasonographer on boys without cryptorchism.
89114510|NCT02731911||Ozurdex® (dexamethasone intravitreal implant)|Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.
89114511|NCT02731677|Experimental|Experimental|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
89114512|NCT02731677|No Intervention|Control|The control group no suffered intervention.
89114513|NCT02731599|Experimental|treadmill training|20-minutes treadmill training per day, 6 times a week, for 4 weeks
89114514|NCT05461677|Experimental|SAIRE smart walker|"The investigational device used in this clinical investigation is called the SAIRE smart walker. This first prototype version is equipped with a depth camera and two cheaper cameras. The depth camera is used to acquire high-quality data to train artificial intelligence (AI) models which then can run on the cheaper camera modules. Additionally, two ultrasonic sensors are applied to estimate the distance. A touch monitor is used to provide audiovisual feedback and display the user interface. Two LED strips are also attached to the walker to provide additional visual feedback to the patient.~The SAIRE smart walker gives feedback to the patient in terms of cadence using a metronome, and foot placement using the LED strips and the video stream presented on the monitor. Additionally, the walker will give information about step length and step width through AI-models."
89114515|NCT05461677|Active Comparator|Standard walker|The comparator device consist of a standard 4-wheeled walker
89114516|NCT05461677|Active Comparator|No walking aid|
89114517|NCT02731365|Experimental|DBS LFP Activa PC+S|The study aims at testing a slightly modified device (battery) that is similar to the approved system that has the potential of offering future patients a closed loop system with automatic adjustments of stimulation. The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming.
89114518|NCT04089163|Experimental|Sequential Dose Cohorts|Doses of Toca 511 will be evaluated in sequential cohorts. Toca 511 will be administered as a single intravesical instillation. Following Toca 511 administration, Toca FC will be administered orally at a dose of 220 mg/kg/day for 7 days every 6 weeks.
89114519|NCT02731443||ESx|Epilepsy patients undergoing elective surgical resection of brain tissue; study group: epilepsy surgery=ESx.
89114520|NCT02731443||DE|Epilepsy patients undergoing elective depth electrodes insertion in general anesthesia; control group: depth electrodes=DE.
89114521|NCT00743197|No Intervention|Usual Care Group|USUAL CARE GROUP-therapy in this group will be no dictated medical therapy, but usual care, as dictated by their referring physician.
89114522|NCT00743197|Active Comparator|Medical Treatment Group|TREATMENT GROUP-therapy in this group will be conventional treatment for CAD but targeting endothelial function, which will include aspirin, ACE-inhibitor and statin therapy, and therapeutic lifestyle changes.
89114523|NCT02731287|Experimental|Timolol|Timolol maleate 0.5% topical solution; 50% of the patients treated (randomized)
89114524|NCT02731287|Placebo Comparator|Placebo|Saline topical solution; 50% of the patients treated (randomized)
89114525|NCT02595385|Active Comparator|RAP|Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.
89231912|NCT05841030||MDD Participants With Anhedonia|Data will be collected, for major depressive disorder (MDD) participants with anhedonia who have had an inadequate response to a standard of care (SOC) antidepressant treatment, from participant's source medical records from routine clinical practice over a period of 12 months.
89114526|NCT02595385|Active Comparator|CS|Reinfusion of shed blood during the operation
89114527|NCT02595385|Active Comparator|RAP and CS|RAP and CS used in combination
89114528|NCT02595385|No Intervention|Control|No intervention
89114529|NCT02731209|Experimental|catheter insertion for 2 weeks|50 randomized patients that will do urodynamic urinary examination and will be inserted urinary catheter for 2 weeks
89114530|NCT02731209|No Intervention|follow up|50 randomized patients that will do urodynamic urinary examination and will be regularly followed by nephrologist
89114531|NCT02735499|Experimental|Treatment with Botox|Onabotulinum toxin A. 200 units of Botox installed into the bladder by catheter.
89114532|NCT02735733|Active Comparator|Room temperature arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at room temperature.
89114533|NCT02735733|Experimental|Cold arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at approximately 32 degrees F for the study group.
89114534|NCT02730975|Experimental|AA Reduced dose-normal diet (A)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a standard breakfast
89114535|NCT02730975|Experimental|AA reduced dose-fat diet (B)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a fat breakfast
89114536|NCT02730975|Active Comparator|AA normal dose-fasting conditions (C)|Abiraterone acetate at approved dose of 1000 mg po daily in cycles of 28 days administered in fasting conditions
89114537|NCT00734071|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
89114538|NCT00734071|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
89114539|NCT02735265|Experimental|Virtual reality group|45 min standard treatment plus 45 min virtual reality balance training used by Kinect for Xbox game. Game choosed based on motor learning principle. Training task such as reach or stepping in various direction, squat, stand up, upper trunk forward or lateral bench.
89114540|NCT02735265|Active Comparator|Standard treatment only group|90 min standard treatment. Depended on patient's ability, principle used by motor learning, sensory process, motor control, task oriented training, symmetry w't bearing.
89114541|NCT02730897||VATS|Patients operated by means of minimal invasive technique (VATS or roboticVATS)
89114542|NCT02730897||Open|Patients operated by means of open thoracotomy
89114543|NCT02731053|Experimental|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
89114544|NCT02731053|No Intervention|Control|Participants will receive a brochure describing the nature, causes, and consequences of depression, as well as available prevention/treatment options
89114545|NCT02730741|Experimental|Lcr restituo® sachet and placebo|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening) and the placebo at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening).
89114546|NCT02730741|Experimental|Lcr restituo® sachet|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
89114547|NCT02730741|Placebo Comparator|Placebo|The placebo at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
89114548|NCT04188951|Other|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|
89114549|NCT02730585||Acute appendicitis|all patients admitted to our hospital with a clinically suspected acute appendicitis.
89114550|NCT00739297|Placebo Comparator|1|montelukast Placebo
89114551|NCT00739297|Experimental|2|montelukast
89114552|NCT00739297|Experimental|3|montelukast
89114553|NCT00739297|Experimental|4|montelukast
89114554|NCT05430243|Experimental|Empagliflozin group|
89114555|NCT05430243|Active Comparator|standard treatment only group|
89114556|NCT02730117|Experimental|Early renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, starting within 12 hours after randomization~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
89114557|NCT02730117|Placebo Comparator|Conventional renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, after the patients reached at least one of the following criteria;~pH < 7.15 or serum HCO3 < 15 mEq/L~serum K >= 6 mEq/L~Signs of volume overload or P/F ratio < 200~BUN > 60 mg/dL~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
89114558|NCT05423223|Active Comparator|Paraffin Bath Therapy|Paraffin bath therapy is a physical therapy method that can create a temperature increase of 7.5 °C in the joint capsule and 4.5 °C in the muscle.
89114559|NCT05423223|Active Comparator|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a noninvasive treatment that involves delivery of shock waves to injured soft tissue to reduce pain and promote healing.
89114560|NCT02595619|Experimental|RRT plus ECCO2R|
89114561|NCT05557617||Memory clinic cohort|A cohort of 120 individuals that has been investigated for cognitive impairment at the Memory Clinic, Department of Geriatric Medicine, Örebro University Hospital and from which a sample of cerebrospinal fluid has been stored in biobank.
89114562|NCT02595463|Experimental|Lidocaine|Following intraoperative IV placement, a 1.5 mg/kg bolus does of lidocaine hydrochloride is given and is followed by a continuous infusion of 2 mg/kg/hr until discharge from the Phase 1 recovery period.
89231913|NCT05838495|Experimental|Enteral tube fed children|Children being fed an enteral formula with a feeding tube
89231914|NCT05837039||Healthcare Provider and Caregiver Perception of Discomfort|Participants will be providing demographic information about you (age, sex/gender, race, ethnicity, educational level, if the participant are in the same household as the patient, if participants are the primary caregiver of the patient, and whether you live in a rural, suburban, or urban environment) Your feelings about your loved one's comfort level Your feelings about symptoms you think affect comfort level Behaviors seen while at the bedside of your loved one
89231915|NCT05835986|Experimental|Part 1: SAD: RO7507062|Participants will receive RO7507062 at an assigned dose as subcutaneous (SC) injection on Day 1.
89231916|NCT05835986|Experimental|Part 2: Dose Escalation with Fractionated Dosing: RO7507062|Participants will receive RO7507062 as SC injection at the dose determined in Part 1, on Day 1 and at an escalated dose, based on emergent safety data, on Day 8.
89231918|NCT05826379|Active Comparator|Control|Participants receive the adaptive daily step goal mHealth intervention
89231919|NCT05826379|Experimental|Treatment|Participants receive the adaptive daily step goal mHealth intervention plus interim goal setting prompts each day
89231920|NCT05825755|No Intervention|Usual care (UC)|"The follow-up of the patients in the UC arm will be carried out in accordance with the usual clinical practice of each recruitment center. All recruiting centers have active and mature HF programs in place and therefore each center will decide how to follow up the patient. However, medical professionals will be required to register each patient on the platform, enter their baseline data (sociodemographics and risk factors) and enter all possible clinical events (death, non-fatal HF event, hospitalization or emergency room visit). that the patient could suffer during the entire follow-up period.~The number of pre-planned contacts will be defined according to the particular clinical practice of each recruitment center."
89231921|NCT05825755|Experimental|Telemonitoring (TM)|"Patients in the TM arm will be followed up with the HumanITcare platform and app.~Physiological parameters (measured periodically), socio-demographic data, risk factors, medication tracking, symptomatology questionnaire for patients, NYHA-class, clinical interventions, health questionnaire answers, classified alarms with their respective timestamp and annotation by the MD, and measurement ranges for each personalized alarm and their changes."
89231922|NCT05823961|Experimental|Eyedrops treatment arm|
89231923|NCT05822479|Active Comparator|Group EOIB|A bilateral EOIB (60 ml, %0.25 bupivacaine, totally) + IV morphine patient-controlled analgesia (PCA)
89231924|NCT05822479|Other|Group Control|IV morphine PCA
89231925|NCT05818683|Experimental|JNJ-78278343 + Cetrelimab: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)|Participants will receive subcutaneous (SC) administration of JNJ-78278343 in combination with intravenous (IV) infusion of cetrelimab during Part 1 (dose escalation). The dose of JNJ-78278343 will be escalated sequentially until a recommended phase 2 dose (RP2D). Participants will receive the combination treatment at the RP2D in Part 2 (dose expansion)
89231926|NCT05818475|Active Comparator|Angiography-guided PCI|Patients will receive PCI of all lesions with at least 50% diameter stenosis at visual estimation. PCI plan and assessment of PCI results will be based on angiography.
89231927|NCT05818475|Experimental|Angiography-derived FFR PCI indication and planning|Patients will receive PCI of all lesions with at least 50% diameter stenosis and positive angiography-derived FFR value (≤0.80). PCI planning will be based on the pullback curve obtained by angiography-derived FFR to obtain an optimal post-PCI physiology.
89231928|NCT05818137|Experimental|Sotatercept|Participants on background PAH therapy will receive sotatercept subcutaneous (SC) injections at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 3 weeks up to 24 weeks. Thereafter, participants may choose to continue receiving the treatment until approval of sotatercept in Japan.
89231929|NCT05811351|Experimental|Arm A: JNJ-81201887 Low Dose|Participants will receive a single low dose intravitreal injection of JNJ-81201887 in the study eye on Day 4. In addition, participants will receive a 20-day oral prednisone course starting on Day 1 and a single, long acting periocular triamcinolone (corticosteroid injection) on Day 4 for prophylaxis of intraocular inflammation.
89231930|NCT05811351|Experimental|Arm B: JNJ-81201887 High dose|Participants will receive a single high dose intravitreal injection of JNJ-81201887 in the study eye on Day 4. In addition, participants will receive a 20-day oral prednisone course starting on Day 1 and a single, long acting periocular triamcinolone (corticosteroid injection) on Day 4 for prophylaxis of intraocular inflammation.
89231931|NCT05811351|Sham Comparator|Arm C: Sham Procedure|Participants will receive sham procedure that matches the single JNJ21801887 injection on Day 4, a sham procedure that matches the long acting periocular corticosteroid injection (triamcinolone) on Day 4 and a 20-day placebo matching oral prednisone starting on Day 1.
89231932|NCT05807360|Experimental|Eyedrops treatment arm|
89231933|NCT05807035|Experimental|Radvax|This is a single arm study where all participants will get active Radvax autologous tumour vaccine weekly for 4 weeks and then monthly thereafter
89231934|NCT05786157|Experimental|alcohol administration paradigm|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
89114563|NCT02595463|Placebo Comparator|Placebo|Following intraoperative IV placement, a bolus of saline is given and is followed by a continuous infusion until discharge from the Phase 1 recovery period. The volume of the bolus and rate of infusion are equivalent to that which would have been given in the experimental arm.
89114564|NCT02730273|Experimental|Trial Nasal Mask|Participants to use nasal mask in-home for a week and one night in lab overnight polysomnography.
89114565|NCT02593669|Experimental|Neutral IOL|Phacoemulsification cataract surgery is performed with neutral IOL implantation.
89114566|NCT02593669|Experimental|Blue-blocking IOL|Phacoemulsification cataract surgery is performed with blue-blocking IOL implantation.
89114567|NCT02729961|Experimental|Treatment (brentuximab vedotin, ceritinib)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive ceritinib PO QD on days 8-21 of course 1 and on days 1-21 for all subsequent courses. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
89114568|NCT02597179||Metastatic Breast Cancer, Young Breast Cancer|Patients with feasible biopsy site.
89114569|NCT02735031|Active Comparator|EXENATIDE|"Exenatide~week 1-2: 5 µg twice daily~week 3-6: 10 µg twice daily (if tolerated)"
89114570|NCT02735031|Placebo Comparator|PLACEBO|"Placebo matched to exenatide~week 1-2: 5 µg twice daily~week 3-6: 10 µg twice daily (if tolerated)"
89114571|NCT02595541|Active Comparator|milrinone group|milrinone
89114572|NCT02595541|Active Comparator|sildenafil and milrinone group|milrinone and sildenafil
89114573|NCT03433911|Experimental|FemBloc|Investigational device and procedure
89114574|NCT03433911|Active Comparator|Control|Laparoscopic bilateral tubal sterilization
89114575|NCT00739063|Experimental|Tarceva daily|Tarceva oral 150 mg daily.
89114576|NCT01026194|Placebo Comparator|Placebo / Teneli + Pio|
89114577|NCT01026194|Experimental|Teneli / Teneli + pio|
89114578|NCT03374553|Experimental|MINIject DO Integrated System CS636 (MINI DO636)|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery. In this arm the implant is placed using Dual Operator Delivery Tool (DODT)."
89114579|NCT03374553|Experimental|MINIject SO Integrated System CS636 (MINI SO636)|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery. In this arm the implant is placed using Single Operator Delivery Tool (SODT)."
89114580|NCT02593513|Experimental|Daifert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
89114581|NCT02593513|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
89114582|NCT02734875|Experimental|Intervention|Primary care providers in the intervention arm will receive lists of their patients with AF who are identified as being at high risk of stroke but not currently on anticoagulation therapy. Along with this list, which includes information on risks and benefits of anticoagulation, primary care providers will receive an offer of assistance from a respected Anticoagulation Management Service within the hospital network to help manage anticoagulation for referred patients.
89114583|NCT02734875|No Intervention|Usual Care|Primary care providers will provide usual care.
89114584|NCT04300712|Other|Tracking of the children with difficulties|All parents and teachers will respond to the questionnaires and the beginning and end of school year which is not done in the routine for tracking the children in difficulty.
89114585|NCT05416593|Placebo Comparator|General exercise prescription (FITT)|Exercise group; control; general exercise prescription
89114586|NCT05416593|Experimental|Affective regulation (AFFECT)|Exercise group; experimental; general exercise prescription plus affective response and preferences regulation
89114587|NCT02595307|Experimental|Pamphlet|Participant group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
89114588|NCT02595307|No Intervention|No Pamphlet|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
89114589|NCT02595229|Active Comparator|PQ (Pronator quadraus) repair|Following volar plate osteosynthesis the pronator quadratus muscle is sutured with 3 to 5 U-shaped stitches using a polyfilament absorbable synthetic suture.
89114590|NCT02595229|No Intervention|No PQ repair|Following volar plate osteosynthesis the pronator quadratus muscle is placed in its anatomical position without suture repair.
89114591|NCT05411289|Experimental|acupressure|Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6)
89114592|NCT05411289|Sham Comparator|sham acupressure|
89114593|NCT04088461|Experimental|Linagliptin + Metformin and lifestyle|Patients with impaired glucose tolerance randomly assigned to linagliptin 2.5 mg + metftormin 850 mg every 12 hours during 6 months.
89114594|NCT04088461|Active Comparator|Metformin|Patients with impaired glucose tolerance randomly assigned to metftormin 850 mg every 12 hours during 6 months.
89114595|NCT01033136|Experimental|MCET-V|Multiple Channel Exposure Therapy -Veterans (MCET-V) is a 12-session cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks. It is an integrated treatment designed to target panic and PTSD symptoms simultaneously.
89114596|NCT01033136|Active Comparator|CPT|Cognitive Processing Therapy (CPT) is a 12-session cognitive-behavioral treatment for persons with PTSD. It is a gold-standard cognitive behavioral intervention designed to target PTSD symptoms.
89114597|NCT04246983|Experimental|Patients with HIV undergoing point of care ultrasound|
89114598|NCT02595151||gastric intestinal metaplasia|Those fulfilling the criteria of GIM by CLE according to the study by Yuting Guo et al were included.
89114599|NCT02595151||normal gastric|diagnosed during routine colonoscopy procedures.
89231935|NCT05779943|Experimental|Treatment (furosemide, F-18 rhPSMA-7.3, PET-CT)|Patients receive F-18 rhPSMA 7.3 tracer IV and then undergo PET-CT scans with and without furosemide IV on study.
89231937|NCT05770531|Active Comparator|Arm A (biospecimen banking)|Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for banking on study. Patients undergo CT or MRI during screening and on study.
89231938|NCT05770531|Experimental|Arm B (biospecimen evaluation, possible treatment change)|Patients receive providers choice of standard of care chemotherapy and undergo blood sample collection for ctDNA evaluation on study. Patients may receive sacituzumab govitecan IV based on ctDNA results on study. Patients undergo CT or MRI during screening and on study.
89114600|NCT02729883|Experimental|Supportive care (Take the Fight)|Patients receive patient navigation via strategists from the Take the Fight for 8 weeks. Patients also complete interviews regarding perceived physical, logistical, psychosocial, and informational challenges experienced prior to meeting with strategists/navigators and how challenges were addressed by navigator or others, perceived benefits or limitations of navigator assistance. Strategists also complete interviews regarding their perceptions on how patients benefited from participation, challenges patients experienced that were directly or indirectly related to their cancer diagnosis and treatment, how these concerns were addressed, barriers to addressing these concerns, and patient health literacy.
89114601|NCT00738673|Experimental|Degarelix|"Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0.~Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections."
89114602|NCT02734641||intravenous (IV) iron therapy|"Patients register to intravenous (IV) iron therapy due to iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects.~20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines the appetite of the patient before and after treatment. At the end of Iron administration Ghrelin will be retested."
89114603|NCT02734641||healthy volunteer|healthy volunteer, will be asked 20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines his appetite. Ghrelin will be retested after 6 weeks.
89114604|NCT02694627|Experimental|Intervention|See intervention description
89114605|NCT02694627|No Intervention|Control|Participants randomized into the control arm are surveyed at the same time points as intervention participants, but do not receive any intervention.
89114606|NCT02594995|Experimental|NBP in thrombolysis group|NBP 25mg bid for 2 weeks administered after 24 hours after receiving recombinant plasminogenactivator(rt-PA) thrombolysis
89114607|NCT02594995|Experimental|NBP group|NBP 25mg bid for 2 weeks administered for the patients who do not receive rt-PA
89114608|NCT02594995|No Intervention|Control group|Control group not receiving rt-PA thrombolysis, receiving basic therapy for acute stroke, e.g. aspirin/clopidogrel and lipid-lowering therapy
89114609|NCT02594995|No Intervention|Control in thrombolysis group|Control group receiving rt-PA thrombolysis
89114610|NCT00811954|Experimental|Arm A: ATV/RTV + FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
89114611|NCT00811954|Experimental|Arm B: RAL + FTC/TDF|FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
89114612|NCT00811954|Experimental|Arm C: DRV/RTV + FTC/TDF|FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
89114613|NCT00917839|Experimental|lamotrigine|7 weeks initial phase with increasing dose beginning with 25 mg oral 12 months treatment phase with fixed dose of 100 mg oral
89114614|NCT00917839|Placebo Comparator|Placebo|300mg Mannitol with 2% Aerosil
89114615|NCT02694705|Experimental|CPAP|3 minutes of preoxygenation with a portable ventilator providing Continuous Positive Airway Pressure (CPAP) at 5 cmH20 and an FiO2 of 100%.
89231939|NCT05769023|Experimental|Experimental|behavioral intervention
88816389|NCT04352348|Other|Follow-up after COVID-19 hospitalization|"Patients previously hospitalized for COVID-19 infection but not recruited for the study can be recruited during a follow-up visit in hospital scheduled in standard care at 3 to 6 months after the hospitalization.~For this arm, T0 = 3 to 6 months post-COVID-19 follow-up visit"
88816390|NCT01150760||Alvimopan Users|
88816391|NCT01150760||Matched controls|
88805856|NCT01134887|Experimental|Arm 1: Intervention-Veterans|"Veterans enrolled in the Intervention-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. Just prior to their next scheduled visit an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Educational Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management."
89114616|NCT02694705|Experimental|BVM|3 minutes of preoxygenation with a bag-valve-mask (BVM) device and oxygen flow rate of 15 litres / minute.
89114617|NCT02694705|Experimental|NRM|3 minutes of preoxygenation with a non-rebreather mask (NRM) device and oxygen flow rate of 15 litres / minute.
89114618|NCT01032200|Experimental|Arm I - Armodafinil|Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
89114619|NCT01032200|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
89114620|NCT05539599||Cohort|Patients will undergo a spontaneous breathing trial. Any extubation will be decided by an independent operator.
89114621|NCT02694471|Experimental|Old group|16 old participants (55-65 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
89114622|NCT02694471|Active Comparator|Young group|7 young participants (18-30 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
89114623|NCT02734563||Multiple hernia group|Males undergoing at least three repairs of abdominal wall hernias at three different anatomic locations. Collagen turnover is analysed.
89114624|NCT02734563||Control group|Males without any history or presence of hernias
89114625|NCT05756374|Experimental|OUT to IN Group|This group will participate in biweekly sessions of psychomotricity for 10 weeks. Sessions will be implemented in the outdoors of the preschool, by a psychomotor therapist and children's teacher. Sessions will involve physical play, relaxation and expressive activities.
89114626|NCT05756374|No Intervention|Control group|This will will maintain their usual routine at preschool.
89114627|NCT03345771|Active Comparator|Antimicrobial Barrier Dressing|postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7
89114628|NCT03345771|Active Comparator|Closed-incision Negative Pressure Therapy|portable NPWT device placed in the operating room from surgery to postoperative day 7
89114629|NCT00586105|Experimental|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
89114630|NCT02729571|Experimental|MTBVAC Group 1|Intervention: MTBVAC live vaccine (low dose)
89114631|NCT02729571|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose)
89114632|NCT02729571|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose)
89114633|NCT02729571|Active Comparator|BCG Control Group|Intervention: commercially available BCG live vaccine
89114634|NCT00743119|Placebo Comparator|Placebo + inactive marijuana (0% THC)|Participants received placebo capsules and smoked inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
89114635|NCT00743119|Experimental|Dronabinol 10 mg + Marijuana (0% THC)|Participants received low dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
89114636|NCT00743119|Experimental|Dronabinol 20 mg + Marijuana (0% THC)|Participants received High dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
89114637|NCT00743119|Experimental|Placebo + Marijuana (1.98% THC)|Participants received placebo + low THC marijuana (1.98% THC) on 1 of 5 outpatient sessions in randomized order.
89114638|NCT00743119|Experimental|Placebo + Marijuana (3.56% THC)|Participants received placebo + smoked high THC marijuana (3.56 % THC) on 1 of 5 outpatient sessions in randomized order.
89114639|NCT02729493|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,28days,29days Duration:total five times
89114640|NCT02734251|Placebo Comparator|Placebo|Dietary Supplement: Placebo
89114641|NCT02734251|Experimental|Relora|Dietary Supplement: Relora, 750 mg/day
89114642|NCT04089241|Experimental|all cohort|Patients will perform CTA 1 months after the EVAR procedure. Following CTA, an ultrasound examination which will include a 3D reconstruction and CEUS will be performed using SONOVIEW contrast agent. The dimensions and volume of the aorta will be compared to the measurements in CTA using the fusion method. In the case of endoleak type 1 or 3 the patient will be urgently refered to endovascular repair . In the case of endoleak type 2 or a normal exam the patient will undergo another fused exam with CEUS at 6 month . In the case of endoleak type 2 with a growth of more than 1 cm in the aneurysm diameter , the patient will be refered to endovascular repair. In the case of a normal exam or an endoleak type 2 with a shrinkage of 1 cm or more ,the patient will undergo another fused exam with CEUS at 12 months. At any case of a new endoleak type 1 or 3 the patient will undergo CTA.
89114643|NCT02610010|Experimental|IMRT alone|Intensity-modulated radiotherapy without cisplatin-based concurrent chemotherapy
89114644|NCT02610010|Active Comparator|IMRT plus concurrent chemotherapy|Intensity-modulated radiotherapy with cisplatin-based concurrent chemotherapy
89114645|NCT02734329|Experimental|Zero Ischemia group|Radiofrequency ablation(RFA) /Microwave ablation(MVA) will be performed for 1 to 4 cycles each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping in most cases.
89114646|NCT02734329|Active Comparator|Conventional group|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
89114647|NCT02597023|Experimental|MitoQ|MitoQ, 20 mg per day for six weeks
89114648|NCT02597023|Placebo Comparator|Placebo|Placebo, inert excipient, one time per day for six weeks
89114649|NCT02610088|Active Comparator|Dapagliflozin|Dapagliflozin will be started in patient with type 2 diabetes mellitus
89114650|NCT02610088|Active Comparator|Gliclazide|Gliclazide will be started in patient with type 2 diabetes mellitus
89114651|NCT02734407|Experimental|Open-Label Arm|"2mg Aflibercept, as needed, intravitreal administration.~All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
89114652|NCT02596789|Other|state dependency TMS|TMS performed at rest and during a cognitive/emotional task
89114653|NCT05757232||Breast cancers cases diagnosed with tomosynthesis and ultrasound|
89114654|NCT05757232||Brest cancers cases diagnosed with mammography and ultrasound|
89114655|NCT02734173|Active Comparator|Genotype 1a Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1a-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
89114656|NCT02734173|Active Comparator|Genotype 1b Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy without ribavirin
89114657|NCT02734173|Active Comparator|Genotype 1a/1b Compensated Cirrhotic Arm|• 8 compensated cirrhotic genotype 1a or 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
89114658|NCT05757154|Experimental|Coffee A|Coffee type A. All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
89114659|NCT05757154|Experimental|Coffee B|Coffee type B. All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
89114660|NCT05757154|Experimental|Coffee C|Coffe type C. All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
89114661|NCT02729337|Experimental|ITG (In This Together)|This will be a multi-week behavioral intervention delivered daily via text messaging. Content will be based upon the IMB model of HIV preventive behavior and informed by our formative work.
89114662|NCT02729337|No Intervention|Control Group|Given the preliminary nature of the intervention development, the control group will be inactive but blinded. They will receive two messages per week encouraging them to make healthy sexual decisions to reduce their HIV risk. Messages will be didactic and not driven by the IMB model.
89114663|NCT05297422|Active Comparator|Control|Axillary Approach to Brachial Plexus Blockade will be performed using 30ml Ropivacaine 0.5% ,without Ketamine as an adjuvant.
89114664|NCT05297422|Active Comparator|Ketamine IV|Axillary Approach to Brachial Plexus Blockade will be performed using 30ml Ropivacaine 0.5% ,with Ketamine as an adjuvant 30mg intravenously.
89114665|NCT05297422|Active Comparator|Ketamine Regional|Axillary Approach to Brachial Plexus Blockade will be performed using 30ml Ropivacaine 0.5% ,with Ketamine as an adjuvant 30mg regionally.
89114666|NCT02734095|Experimental|Intravascular Ultrasound data|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
89114667|NCT02609074|Experimental|CPC/rhBMP-2|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC/rhBMP-2 microffolds (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
89114668|NCT02609074|Active Comparator|CPC|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC paste (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
89114669|NCT00733369|Other|PFC Sigma RP-F|125 patients to be allocated to this arm according to blinding envelopes
89114670|NCT00733369|Active Comparator|PFC Sigma RP|125 patients to be allocated to this arm according to blinding envelopes
89114671|NCT02729415|Experimental|Stromal Vascular Fraction Cells (SVF Cells)|The participants will undergo a standard tumescent liposuction to harvest adipose tissue. The adipose tissue will then be processed for obtain the Stromal Vascular Fraction Cells (SVF Cells) for a single injection for the treatment of androgenetic alopecia. Before the procedure, hair measurements will be performed in the 2cm x 2cm site for density (number of hairs per square centimeter) and thickness (mm) of the hair to compare to the measurements after the procedure at pre-procedure, 6 weeks, 3 months and 6 months.
89114672|NCT00813124|Experimental|Azacytidine Maintenance after allotx|Busulfan + Fludarabine + ATG + Azacytidine after allogeneic stem cell transplantation (allotx)
89114673|NCT02733939|Experimental|Technology intervention|Patients randomized in the intervention group will receive a technical home monitoring kit for 12 months. The kits will be composed of a control unit and a set of sensors that immediately notify caregivers, through their phones, of any potential risks for the person with dementia. The kit will have home leaving sensors, bed occupancy sensors, smoke and water leak sensors, automatic lights, and other interactive functions. These devices will be connected to a single-board microcontroller that will transmit alarm messages to the caregivers in case of need.
89231940|NCT05765435|Other|Control|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program. There will be no stimulation.
89231941|NCT05765435|Experimental|NMES|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program and receive stimulation assistance during the exercise sessions.
89231942|NCT05765435|Experimental|NMES and FES|Device: Cionic Neural Sleeve NS-100. Participants will wear the device during the 12-week exercise and walking program and receive stimulation assistance during the exercise and walking sessions.
89231943|NCT05762055|Experimental|Intervention Group|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology will be implanted for participants in this group
89231944|NCT05762055|Experimental|Control Group|Participants in this arm will receive an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology.
89231945|NCT05760651||Multiple Sclerosis Patients|Patients diagnosed with multiple sclerosis.
89114674|NCT02733939|No Intervention|Usual care|"Patients receiving usual care, as provided to people with dementia in Southern Sweden can vary. In the target area, people with dementia usually receive comparable pharmaceutical treatment depending on the dementia type, as prescribed by a general practitioner or a specialist at a memory clinic. The social worker from the Municipality (Biståndshandläggaren) where the person resides, together with the district nurse, have a meaningful role in tailoring the care plan by mediating access to other care services such as respite care homes, home help and (dementia) nurse home visits. Use of such services depends on the specific needs of the person with dementia, which can also be unrelated to dementia, but rather dependent upon concomitant health and social issues."
89114675|NCT02729259|Other|Virtual Reality Snowworld|The subjects will receive Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
89114676|NCT02729259|Other|Virtual Reality slides of nature|The subjects will see several slides of the nature through virtual reality goggles during their wound care. The nurse will be doing the wound care.
89114677|NCT02729259|Other|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
89114678|NCT05133700||Qualitative interviews and focus group|Qualitative semi-structured individual interviews and focus groups to be held with people living in care homes (with and without nursing), health and social care staff supporting these people, commissioners and regulators.
89114679|NCT05133700||Qualitative medicines monitoring tools|Submission of current medicines monitoring tools by care homes and services supporting care homes including community pharmacies.
89114680|NCT00733291|Active Comparator|Nelfilcon A soak / Nelfilcon A no-soak|Nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by nelfilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
89114681|NCT00733291|Active Comparator|Nelfilcon A no soak / nelfilcon A soak|Nelfilcon A contact lenses inserted directly from the blister package, followed by nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
89114682|NCT00733291|Active Comparator|Etafilcon A soak / etafilcon A no soak|Etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by etafilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
89114683|NCT00733291|Active Comparator|Etafilcon A no soak / etafilcon A soak|Etafilcon A contact lenses inserted directly from the blister package, followed by etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
89114684|NCT03969667||healthy young adults|healthy young adults
89114685|NCT02733783|Experimental|septorhinoplasty patients|Elective septorhinoplasty patients that will undergo bilateral osteotomies. All the patients will undergo cold dry air provocation and 3 hours later capsaicin provocation, during a preoperative visit, one week before the intervention and during three post-operative visits two weeks, three months and six months.
89114686|NCT00732199|Other|Arm 1|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Young adults.
89114687|NCT00732199|Experimental|Arm 2|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Older adults.
89114688|NCT02733549||patient|Patients with sudden onset dizziness (SOD) analysed LFTs
89114689|NCT02733549||control|The control group with 98 healthy volunteer analysed LFTs
89114690|NCT02728869|Experimental|Heat Stable Rotavirus (HSRV) Vaccine|25 healthy adults who will be administered a single dose of test HSRV vaccine
89114691|NCT02728869|Placebo Comparator|Placebo for Heatstable Rotavirus vaccine|25 healthy adults who will be administered a single dose of placebo
89114692|NCT02728869|Experimental|Heat Stable Rotavirus Vaccine|25 healthy infants who will be administered 3-doses of test HSRV vaccine spaced at 4-week intervals
89114693|NCT02728869|Active Comparator|RotaTeq|25 healthy infants who will be administered 3-doses of comparator Rotateq® vaccine spaced at 4-week intervals
89114694|NCT02594761|Experimental|Treatment A|Hercules: 8 mg/kg i.v. infusion over 90 minutes
89114695|NCT02594761|Active Comparator|Treatment B|Herceptin EU: 8 mg/kg i.v. infusion over 90 minutes
89114696|NCT02594761|Active Comparator|Treatment C|Herceptin US: 8 mg/kg i.v. infusion over 90 minutes
89114697|NCT02728947|Active Comparator|2mg|1 week on 2mg/24 hr patch
89114698|NCT02728947|Active Comparator|4mg|1 week on 4mg/24hr patch
89114699|NCT02728947|Active Comparator|6mg|1 week on 6mg/24hr patch
89114700|NCT02728947|Active Comparator|8mg|1 week on 8mg/24hr patch
89114701|NCT02594605|Experimental|Platelet Rich Fibrin|Platelet Rich Fibrin was applied with conventional flap surgery for treatment of periodontal bone loss in test group.
89114702|NCT02594605|Active Comparator|Conventional Flap Surgery|Platelet Rich Fibrin was not applied to control groups. Only conventional flap surgery was applied to control groups.
89114703|NCT02594839|Experimental|MSCs|2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
89114704|NCT02594839|Placebo Comparator|placebo|2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
89231946|NCT05757869|Experimental|Milvexian|Participants will receive milvexian 100 milligrams (mg) orally, twice daily and placebo that matches apixaban beginning on Day 1 through end of treatment (EOT). Participants after the EOT visit may have an option to receive open-label apixaban at the appropriate dose (5 mg or 2.5 mg, twice daily), for which the sponsor provides a 30-day supply.
89231947|NCT05757869|Active Comparator|Apixaban|Participants will receive a placebo that matches milvexian and a capsule containing apixaban 5 mg or 2.5 mg orally, twice daily. Participants after the EOT visit may have an option to receive open-label apixaban (5 mg or 2.5 mg, twice daily) at the appropriate dose, for which the sponsor provides a 30-day supply.
88805857|NCT01134887|Active Comparator|Arm 2: Control-Veterans|"Veterans enrolled in the Control-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
89231948|NCT05754957|Experimental|Milvexian|Participants enrolled within 7 days of an acute coronary syndrome (ACS), who have undergone cardiac catheterization with percutaneous intervention (PCI) or who are being managed conservatively with or without catheterization, and who are receiving antiplatelet therapy standard-of-care (single antiplatelet therapy [SAPT] or dual antiplatelet therapy [DAPT]) as determined by the investigator will receive milvexian 25 milligrams (mg), orally, twice daily.
89231949|NCT05754957|Placebo Comparator|Placebo|Participants enrolled within 7 days of an ACS, who have undergone cardiac catheterization with PCI or who are being managed conservatively with or without catheterization, and who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) as determined by the investigator will receive placebo orally, twice daily.
89231950|NCT05747014||Novapak Subjects|Subjects that are enrolled in the Novapak Study.
89114705|NCT02729103||Treatment patterns, healthcare resource utilization and costs|Part 1 - Assessment of treatment patterns, healthcare resource utilization and costs. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no skeletal-related events (SREs) in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before and at least 6 months after the index date.
89114706|NCT02729103||Mortality|Part 2 - Assessment of mortality. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no SREs in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before the index date. Unlike in Part 1, there will be no required minimum follow-up time after the index date (in order to assess mortality).
89114707|NCT02594527|Experimental|Volunteer-led physical activity sessions|Patient will receive volunteer-led physical activity sessions twice a day during admission.
89114708|NCT02733705|Placebo Comparator|Control|normal saline IV plus propofol infusion
89114709|NCT02733705|Active Comparator|Fentanyl|0.5 mcg/kg ideal body weight IV plus propofol infusion
89114710|NCT02694939|Experimental|STAND|Receives STAND intervention delivered in community mental health setting.
89114711|NCT02694939|Active Comparator|Usual Care|Receives usual care from community therapists.
89114712|NCT02597257|Placebo Comparator|Normal Saline|"normal saline~total 250 ml~once a week~4 times"
89114713|NCT02597257|Active Comparator|Lidocaine HCl|"lidocaine 3 mg/kg mixed in normal saline~total 250 ml~once a week~4 times"
89114714|NCT02596477|Experimental|Vepoloxamer - Low dose|Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
89114715|NCT02596477|Experimental|Vepoloxamer - High dose|Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
89114716|NCT02596477|Placebo Comparator|5% dextrose in water (D5W)|D5W administered intravenously over 3 hours
89114717|NCT02690337|Experimental|DS-1123|This study will follow a modified Continual Reassessment Method (mCRM) + Escalation with Overdose Control (EWOC),design with a starting intravenous (IV) dose of 0.1 mg/kg.
89114718|NCT04089007|Experimental|SOmNI intervention group|"Participants will receive an iPhone with the SOmNI app and will be instructed to move their bedtime earlier by 5 minutes (from their average baseline week bedtime) on each school night (Sunday to Thursday). Participants will also be given sleep hygiene information related to the embedded features of the SOmNI app. A research assistant will help the participant to enter the appropriate goal bedtime in the SOmNI app and orient them to the features of the SOmNI app. Participants will also be instructed to aim for <1 hour difference between school night and weekend bedtimes and wake times (i.e. avoid staying up late and sleeping in on weekends).~The SOmNI application will allow the user to graphically track sleep behaviour across the four-week intervention period as recorded by the wearable sensor (e.g. bedtimes, wake times, amount of sleep achieved will all be displayed in the app)."
89114719|NCT04089007|Active Comparator|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
89114720|NCT02596633|No Intervention|Treatment as Usual|Participants carry on with their usual care
89114721|NCT02596633|Active Comparator|Intervention|ACT self help book with telephone support calls; Telephone-support Acceptance and Commitment therapy (ACT)
89114722|NCT04178811||Benign Prostatic Hyperplasia patients with predominant voiding lower urinary tract symptoms|Outcomes of Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia patients with predominant voiding lower urinary tract symptoms
89114723|NCT04178811||Benign Prostatic Hyperplasia patients with predominant storage lower urinary tract symptoms|Outcomes of Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia patients with predominant storage lower urinary tract symptoms
89114724|NCT02596555|Experimental|Dabigatran treatment|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
89114725|NCT03328065||Stable patients, early responders to treatment and caregivers|
89114726|NCT03328065||Stable patients and intermediate responders and c|Stable patients and intermediate responders to treatments and caregivers
89114727|NCT03328065||Doctors|
89114728|NCT03328065||Patients in therapeutic escape and their caregivers|
89114729|NCT00807040|Active Comparator|Mitral Valve Repair with Annuloplasty|Participants will undergo mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
89114730|NCT00807040|Active Comparator|Mitral Valve Replacement|Participants will undergo mitral valve replacement and complete preservation of the sub-valvular apparatus.
89114731|NCT02728713|Experimental|Cranial manipulation|"Assessment for cranial strain patterns, followed by indirect cranial manipulation to treat dysfunctions found on assessment, followed by reassessment.~Repeated for a total of eight visits no less than one week apart."
89114732|NCT02728713|Sham Comparator|Sham/placebo|Assessment for cranial strain patterns, followed a laying on of hands, followed by reassessment. Repeated for a total of eight visits no less than one week apart.
89114733|NCT02733471|Experimental|Lidocaine|Five lidocaine solution puffs (10mg lidocaine/puff) on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy.
89114734|NCT02733471|Placebo Comparator|Control|Five placebo solution puffs on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy
89114735|NCT05756218|Experimental|Experiment|Obtaining Consent, Demographic Information Form, Teaching Material Motivation Scale and Nursing Diagnosis Perception Scale face-to-face filling Playing the game with nursing diagnosis taboo cards prepared on the day of no practice for 7 weeks
89114736|NCT05756218|No Intervention|Control|Obtaining Consent, Demographic Information Form, Teaching Material Motivation Scale and Nursing Diagnosis Perception Scale face-to-face filling Continuing the application as in the curriculum for 7 weeks
89114737|NCT04189887||PD+AEX|The group of people with PD which will perform aerobic exercise after motor skill acquisition
89114738|NCT04189887||PD-AEX|The group of people with PD which will not perform aerobic exercise after motor skill acquisition
89114739|NCT04189887||CON+AEX|The group of control participants which will perform aerobic exercise after motor skill acquisition
89114740|NCT04189887||CON-AEX|The group of control participants which will not perform aerobic exercise after motor skill acquisition
89114741|NCT02733237|Experimental|male oxytocin group|male subjects with oxytocin treatment
89114742|NCT02733237|Experimental|female oxytocin group|female subjects with oxytocin treatment
89114743|NCT02733237|Placebo Comparator|male placebo group|male subjects with placebo treatment
89114744|NCT02733237|Placebo Comparator|female placebo group|female subjects with placebo treatment
89114745|NCT02728401||INSI|Infection-negative systemic inflammation (INSI). The INSI group consists of children who have undergone congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for ~24 hours thereafter; all children in this cohort are culture negative. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
89114746|NCT02728401||CSSS|Clinical severe sepsis syndrome (CSSS). Children assigned to the CSSS group had confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), exhibited 2 or more systemic inflammatory response syndrome criteria (including temperature and leukocyte criteria), and demonstrated at least cardiovascular ± pulmonary organ dysfunction. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
89114747|NCT02728401||Viral|The Viral Infection group consists of children who displayed signs and symptoms of severe viral infection, and who tested positive for respiratory viral infection(s) by a molecular virus panel test. These children were clinically evaluated to not have bacterial sepsis. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
89114748|NCT02728323|Active Comparator|Levobupivacaine 100 mg, USG TAP Block|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
89114749|NCT02728323|Placebo Comparator|Placebo|20 ml of Saline (for 100 mg Levobupivacaine) intramuscularly, at the end of surgery
89114750|NCT00811720|Placebo Comparator|Placebo|
89114751|NCT00811720|Experimental|Nalmefene|
89114752|NCT04030156||ultrasonographic tonsil volume|All measurements were done by the same radiologist with over 20 years of experience. GE LOGIQ E9 (GE Healthcare, Milwaukee, WI, USA) was used in USG examination. The patients were viewed using a 2-9 MHz linear probe from the submental region. The examination was done while the patient was in a supine position, with a neck support. Right tonsil measurement was done by turning the neck slightly to the upper left whereas left tonsil measurement was done by turning the neck slightly to the upper right. Tonsil volume was calculated with standard ultrasonography formula (height x length x thickness x 0.52) due to its ellipsoid shape.
89114753|NCT04030156||Actual tonsil volume|Excised tonsil volumes were calculated by water replacement method.
89114754|NCT04202679|Placebo Comparator|Placebo|Participants received placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 followed by placebo matched to dupilumab 300 mg once every 2 weeks (q2w) for 24 weeks added to background therapy of topical corticosteroids/topical calcineurin inhibitors (TCS/TCI) at stable dose.
89114755|NCT04202679|Experimental|Dupilumab 300 mg Q2W|Participants received dupilumab at a loading dose of 600 mg, SC on Day 1 followed by dupilumab 300 mg q2w for 24 weeks added to background therapy of TCS/TCI at stable dose.
89114756|NCT00811642|Experimental|Posaconazole|Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks
89114757|NCT05756062|Experimental|DHA group|Supplementation with a highly-concentrated docosahexaenoic acid (DHA) triglyceride (1000 g/day) for 3 months
89114758|NCT05756062|No Intervention|Control group|Routine care
89114759|NCT02609152|Experimental|Continuous perfusion of esmolol|Intervention: Drug: Continuous perfusion of esmolol
89114760|NCT02609152|Placebo Comparator|Continuous perfusion of saline|Intervention: Continuous perfusion of saline
89114761|NCT02733393|Experimental|SPG Block|
89114762|NCT02733315|Experimental|DCMP|
89114763|NCT02728011|Experimental|Intervention|Scientific Brain Training (SBT)
89114764|NCT02728011|Placebo Comparator|Controle|Tetris
89114765|NCT02728167|Experimental|Pre-coagulation by HIFU-AR|Pre-coagulation of the liver parenchyma with HIFU and standard liver resection
89114766|NCT02728167|No Intervention|Standard liver resection|Standard liver resection
89114767|NCT00809926|Experimental|Valsartan/aliskiren|
89114768|NCT00809926|Active Comparator|Valsartan|
89114769|NCT05344131|Experimental|BETY exercise group|"intervention group Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model.~Exercise dosage is 60 minute three days a week."
89114770|NCT05344131|No Intervention|Control group|Control group No intervention
89114771|NCT02728245|Placebo Comparator|Control group|"Placebo drug 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
89114772|NCT02728245|Experimental|Case group|"Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
89114773|NCT02732925|Sham Comparator|Arm 1 - Sham Procedure|"Sham Procedure & Conservative Treatment~Subjects will be blinded and randomised to Arm 1 and will undergo a general anaesthetic and undergo a sham procedure. They will also be treated under conservative management alone.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy~This is a non interventional as conservative treatment (standard of care for multiple myeloma patients) is used."
89114774|NCT02732925|Active Comparator|Arm 2 - Balloon Kyphoplasty|"Balloon Kyphoplasty & Conservative Treatment - Interventional Arm~Subjects will be blinded and randomised to Arm 2 (balloon kyphoplasty) and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy~This is a interventional arm (balloon kyphoplasty procedure) and the patient will receive conservative treatment (standard of multiple myeloma patients) is used."
89114775|NCT02732769|Active Comparator|Group treated by radiosurgery with stereotaxic frame|Subjects will receive a radiosurgery during a brief hospitalization by LeksellGammaKnifePerfexion® (LGKP)
89114776|NCT02732769|Experimental|Group treated by radiosurgery with the thermoformed mask|Subjects will receive a radiosurgery with thermoformed mask during a brief hospitalization by GammaKnifeICON® (GKI) with Efficast®
89114777|NCT02690415||Antibiotics Given|Patients who's treating physician prescribed antibiotics following incision and drainage of their abscess.
89114778|NCT02690415||Antibiotics Not Given|Patients who's treating physician did not prescribed antibiotics following incision and drainage of their abscess.
89114779|NCT00590980||Observation|Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.
89114780|NCT05753722|Experimental|PRTH-101|Mono-therapy
89114781|NCT05753722|Experimental|PRTH-101 with Pembrolizumab|Combo therapy
89114782|NCT02732613|Experimental|Actual weight Group|Patients in Actual weight Group: The selection of Laryngeal Mask Airway classic will be based on actual body weight, followed the recommendations of manufacturer (size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
89114783|NCT02732613|Experimental|Ideal weight Group|Patients in Ideal weight Group: The selection of Laryngeal Mask Airway classic will be based on ideal body weight, followed the recommendations of manufacturer ( size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
89114784|NCT02727621|Active Comparator|Dexmedetomidine group|
89114785|NCT02727621|Active Comparator|Propofol group|
89114786|NCT02608606|No Intervention|oral administration of tacrolimus|Oral administration of tacrolimus (FK506) in the usal dose and measuring plasmatic levels at hours 0, 0.5, 1, 2, 3, 4 and 6. Measuring AUC.
89114787|NCT02608606|Active Comparator|sublingual administration of tacrolimus|sublingual administration of tacrolimus (FK506) in the dose that allows similar plasmatic level at time 0 compared with the oral administration, and measuring plasmatic levels at hours 0, 0.5, 1 , 2, 3 , 4 and 6. Measuring AUC.
89114788|NCT02727465||meningitis cases|any individual with culture-confirmed IMD in England from 01 September 2015 to 31 August 2019 with written informed consent from the individual, the parent (for children aged <16 years) or next-of-kin (for non-survivors)
89114789|NCT05755828|Experimental|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was > 2*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
89114790|NCT02727543|No Intervention|Control|Participants randomized to this arm will not receive the intervention.
89114791|NCT02727543|Experimental|Intervention|Participants randomized to this arm will receive the intervention, Medisafe, a smartphone application.
89114792|NCT02608918|Experimental|BMS-955176|BMS-955176 specified dose on specified days
89114793|NCT02732223|Experimental|Functional treatment|Daily functional treatment consisted of seven fish oil softgels (1.7g EPA+DHA), two dark chocolate truffles containing plant sterol esters and two green tea sachets.
89114794|NCT02732223|Placebo Comparator|Control treatment|Control treatment consisted of seven soy bean oil softgels, two regular dark chocolate truffles and two anise tea sachets
89114795|NCT02727309|Experimental|apatinib|Patients with advanced hepatocellular carcinoma after been treated with TACE receive apatinib (750mg) daily, until disease progression or unacceptable toxicity.
89114796|NCT02732379|Experimental|Lavender Aromatherapy|Aromatherapy with lavender essential oil.
89114797|NCT02732379|Experimental|Rose Aromatherapy|Aromatherapy with rose essential oil
89114798|NCT02732379|Experimental|Ginger Aromatherapy|Aromatherapy with ginger essential oil
89114799|NCT02732379|Placebo Comparator|Placebo Aromatherapy|Aromatherapy with pure water
89114800|NCT05755750|Experimental|Intratendinous genipin injection|"Genipin was administrated intratendinously under sonographic guidance. For lesions up to 3 cm in length, two separate 0.2 ml injections of genipin solution were administered into the region of transition from degenerated to normal tendon tissue. One injection was given at the proximal end of the lesion and the other at the distal end.~For lesions longer than 3 cm, an additional 0.2 ml injection was used for every additional 3 cm of lesion length. In the illustrated example, the 6 cm lesion required a total of three injections, and therefore one additional injection was given in the middle of the lesion between the distal and proximal injections.~Genipin treatment solution contained 100 mM genipin and 20% of the solvent dimethyl sulfoxidee in phosphate buffered saline. Instead of one administration of a relatively large volume, several individual administrations of 0.2 ml were performed depending on lesion size ."
89114801|NCT05093062|Other|Tian Jiu Therapy|
89114802|NCT00636597||1|
89114803|NCT02609932|Other|SD or SS|In this study, IFN- γ-1b will be subcutaneously administered a total of 30 subjects in one of two cohorts; Single Dose (SD) or Steady State (SS) dosing. Dosing of IFN- γ-1b will be based upon the time subject became eligible and started study. In this non-randomized, open-label study, subjects will be enrolled on the SD cohort first, and once that cohort has been filled, enrollment to the SS cohort will begin. Although not required, subjects in the SD cohort may also volunteer to participate in the SS cohort if they still meet eligibility criteria. Separate consents will be used for the SD and SS cohorts. In the event not all the SD subjects choose to continue onto the SS cohort, we will plan to recruit new participants from our local campus community.
89114804|NCT02727231|Experimental|day and night closed loop control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
89114805|NCT02727231|Active Comparator|usual insulin pump therapy management|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (FreeStyle Navigator CGM)
89114806|NCT02726919|Other|Clobazam treatment|This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment
89114807|NCT02727153|Experimental|"Ultra E.R.A.S."|Discharge patients on Post Operative Day 2
89114808|NCT02727153|Active Comparator|Classic E.R.A.S.|Discharge patients on Post Operative Day 4
89114809|NCT05753566|Experimental|Rezvilutamide +ADT+ SRT|Rezvilutamide along with ADT for 6 cycles (28 days for each cycle) in combination with salvage radiation therapy (SRT) according to standard of care
89114810|NCT05753566|Experimental|Rezvilutamide +ADT|Rezvilutamide along with ADT for 12 cycles (28 days for each cycle)
89114811|NCT02726841|Experimental|Hybrid TAAD repair|The group includes patients who underwent open thoracoabdominal aortic repair + abdominal stenting.
89114812|NCT02726841|Active Comparator|Conventional TAAD repair|The group includes patients who underwent classic thoracoabdominal aortic repair with dacron prosthesis.
89114813|NCT05753488||ınflammation|
89114814|NCT05753488||non inflammation|
89114815|NCT05187741|Experimental|Daily message group|This group would be receiving text messages intended to improve treatment adherence and text reminders for appointments to improve care retention.
89114816|NCT05187741|No Intervention|Control group|This group would be just observed through the same period as the intervention group but the participants will only receive the standard care provide by the clinic.
89114817|NCT02721615|Active Comparator|Laminectomy|Comparison of bone decompression versus no decompression for reducing intra spinal pressure
89114818|NCT02721615|Active Comparator|Duraplasty|Expansion duraplasty versus no duraplasty for reducing intraspinal pressure
89114819|NCT02721615|Active Comparator|Hypothermia|Localised hypothermia for reducing intra spinal pressure and improving spinal cord metabolism
89114820|NCT03060213|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
89114821|NCT03060213|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
89114822|NCT02726529|Experimental|Brighter Bites|Children of families in the intervention group will also receive the Coordinated Approach to Child Health (CATCH) school-based curriculum in addition to families receiving fresh fruits and vegetables to take home from school once a week along with nutrition education for 8 weeks in Fall and 8 weeks in Spring semesters of the school year.
89114823|NCT02726529|Active Comparator|Comparison|
89114824|NCT02721303|Active Comparator|obese older aged, aged 65-85, BMI 30-40|Older aged patients who are obese and between the ages of 65-85 with a BMI between 30-40.
89114825|NCT02721303|Active Comparator|normal weight older aged, aged 65-85, BMI 18-25|Older aged patients who are of normal weight and between the ages of 65-85 with a BMI between 18-25.
89114826|NCT02721303|Active Comparator|obese younger aged, aged 21-45, BMI 30-40|Younger aged patients who are obese and between the ages of 21-45 with a BMI between 30-40 .
89114827|NCT02721225|Active Comparator|Fructooligosaccharide|"One kind of prebiotics agent defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
89114828|NCT02721225|Placebo Comparator|Pocari-Sweat|Commercially produced isotonic solution by Otsuka Pharmaceutical Co., Ltd., Tokyo,Japan
89114829|NCT02726607|Experimental|HITSystem 2.0|Pregnant women who are eligible for PMTCT services will be enrolled in the HIV Infant Tracking System 2.0 (HITSystem 2.0) intervention during their first PMTCT appointment and followed until 12 weeks postpartum.
89114830|NCT02726607|Active Comparator|Standard of PMTCT Care|Pregnant women who are eligible for PMTCT services will receive standard of care PMTCT services at the control hospital. The records of women enrolled during their first PMTCT appointment will be used to assess outcomes during the same follow-up period.
89114831|NCT02726685|Experimental|RT (respiratory training) group|Besides traditional rehabilitation therapy, subjects also receive 12-week respiratory training.
89114832|NCT02726685|Sham Comparator|Control group|Besides traditional rehabilitation therapy, subjects receive 12-week sham training unrelated to respiratory function.
89114833|NCT00590824|Experimental|A|Hu14.18-IL2 -->Resection-->Hu14.18-IL2
89114834|NCT00590824|Experimental|B|Resection -->Hu14.18-IL2-->Hu14.18-IL2
89114835|NCT02841969|Active Comparator|Normal care - Prontosan|Patient wounds will be irrigated using the in-use product (Prontosan)
89114836|NCT02841969|Experimental|Investigational arm - Electrolysed water|Patient wounds will be irrigated using electrolysed water
89114837|NCT02720913|Experimental|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
89114838|NCT02720913|Active Comparator|Standard Suture Tying|Standard Suture Tying
89114839|NCT05753410|Experimental|Mindful Courage|Mindful Courage is a digital intervention including mindfulness and cognitive behavioral elements for individuals with anorexia nervosa or bulimia nervosa. Mindful Courage will consist of 8-weeks of self-guided modules which will be completed over the course of 8 weeks. Elements included in the intervention include psychoeducation, self-monitoring, regular eating, body image, values clarification, and mindful awareness and acceptance. Participants learn a range mindfulness skills and practice a range of mindfulness meditations. Participants will also receive phone coaching. Homework consists of meditation practices.
89114840|NCT02726217|Experimental|CareSmarts Intervention|Participants in the program receive text messages about diabetes self-care
89114841|NCT02726217|Active Comparator|Control|Standard of Care reminders and assessments for individuals with Diabetes
89114842|NCT05753332||The control group|the invited volunteers live in Yangzhou, Jiangsu, China (low PM2.5 level based on previous official PM2.5 records)
89114843|NCT05753332||The PM2.5 exposure group|the invited volunteers live in Xuzhou, Jiangsu, China (high PM2.5 level based on previous official PM2.5 records)
89114844|NCT02720991|Experimental|Mifepristone and sublingual misoprostol|200 mg mifepristone and 400 ug sublingual misoprostol
89114845|NCT04687228|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
89114846|NCT04687228|Experimental|Body Project: More than Muscles (MTM)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
89114847|NCT02726373|Experimental|Intermittent walking training|
89114848|NCT02726373|Active Comparator|Continuous Walking Training|
89114849|NCT02726139||Emory University|Samples obtained at and shipped from Emory University
89114850|NCT02726139||University of Michigan|Samples obtained at and shipped from University of Michigan
89114851|NCT02720601|Experimental|Irinotecan & Capecitabine|"Irinotecan at 120 mg/m2 intravenously every three weeks + Capecitabine at 1500 mg/m2/day orally twice per day for a total of 14 days.~The treatment cycle is once every 21 days."
89114852|NCT02725983|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015). Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
89114853|NCT02725983|Active Comparator|No Intra Oral camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015) and considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon was not used.
89114854|NCT00590590|Placebo Comparator|3 (Placebo)|
89114855|NCT00590590|Experimental|1 (Lidocaine)|
89114856|NCT00590590|Experimental|2 (Lidocaine/Diphenhydramine)|
89114857|NCT02720367|Experimental|7-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the TURBT.
88816392|NCT01150838|Experimental|Propofol administration|"For each of the 6 groups, propofol 2 mg/kg will be administered to first subject. The propofol dose will move separately for each of the 6 groups, and be increased by 0.3 mg/kg for the next subject if intubation score is not excellent and decreased by 0.3 mg/kg if intubation score is excellent. This dosing scheme will be continued until there are 6 crossovers as described above."
89231951|NCT05742321||Patients with FECD|Patients with Fuchs Endothelial Corneal Dystrophy (FECD). They will have a collection of data and a blood sample
89231952|NCT05730036|Experimental|Linvoseltamab|Randomization 1:1
89231953|NCT05730036|Active Comparator|Elotuzumab/Pomalidomide/Dexamethasone (EPd)|Randomization 1:1
89231954|NCT05729373|Experimental|SEP-363856|dosed once daily tablet
89231955|NCT05729373|Placebo Comparator|Placebo|dosed once daily tablet
89231958|NCT05726227|Experimental|Group Kids|Participants in the age group 6 to less than (<) 12 years will receive once weekly subcutaneous (s.c.) injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.
89231959|NCT05726227|Experimental|Group Teens|Participants in the age group 12 to < 18 years will receive once weekly s.c. injection of either semaglutide or placebo matched to semaglutide in dose escalation fashion for 16 weeks (0.25 mg from weeks 0-4, 0.5 mg from weeks 5-8, 1.0 mg from weeks 9-12 and 1.7 mg from weeks 13-16) followed by 2.4 mg as maintenance dose for 88 weeks as an adjunct to a reduced-calorie diet and increased physical activity.
89231960|NCT05722925|Experimental|Fluciclovine PET/CT|Participants will undergo Fluciclovine PET/CT within 30 days of a negative or equivocal PSMA PET scan. After the Fluciclovine PET/CT, the patient will follow up with their treating physician as per standard-of-care. The research team will collect clinical and imaging data at 6 months post Fluciclovine-PET/CT.
89231961|NCT05722444|Experimental|Women with reported heavy menses|
89231964|NCT05720663||nonalcoholic steatohepatitis (NASH)|Adult patients nonalcoholic steatohepatitis (NASH)
89231967|NCT05712356|Experimental|LSTA1 arm for Advanced Head and Neck Squamous Cell Carcinoma|
89231968|NCT05712356|Experimental|LSTA1 arm for Cholangiocarcinoma|
89231969|NCT05712356|Placebo Comparator|Placebo arm for Advanced Head and Neck Squamous Cell Carcinoma|
89231970|NCT05712356|Placebo Comparator|Placebo arm for Cholangiocarcinoma|
89231971|NCT05708846||Heart Failure patients telemonitored|Patients will be monitored with the HumanITcare app and platform
89231972|NCT05704543|Active Comparator|Extended-release Buprenorphine: Abdomen|Participants will receive a single, subcutaneous injection of 300 mg extended-release buprenorphine in the abdomen on Day 1.
89231973|NCT05704543|Experimental|Extended-release Buprenorphine: Upper Arm|Participants will receive a single, subcutaneous injection of 300 mg extended-release buprenorphine in the back of the upper arm on Day 1.
89231974|NCT05704543|Experimental|Extended-release Buprenorphine: Buttocks|Participants will receive a single, subcutaneous injection of 300 mg extended-release buprenorphine in the buttocks on Day 1.
89231975|NCT05704543|Experimental|Extended-release Buprenorphine: Thigh|Participants will receive a single, subcutaneous injection of 300 mg extended-release buprenorphine in the thigh on Day 1.
89231976|NCT05703880||Finerenone (Kerendia, BAY948862)|Adults with CKD and T2D from the USA who initiate finerenone.
89231977|NCT05702034|Experimental|Milvexian|Participants after an acute ischemic stroke or high-risk transient ischemic attack (TIA) who are receiving antiplatelet therapy standard-of-care (SAPT [single antiplatelet therapy] or DAPT [dual antiplatelet therapy]) will receive milvexian 25 milligrams (mg), orally, twice daily.
89114858|NCT02720367|Experimental|21-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 21. TAR-200 releases gemcitabine gradually during the 21 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 42.
89114859|NCT02693769|Experimental|fluticasone/formoterol BAI|To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)
89114860|NCT02693769|Active Comparator|Ultibro Breezhaler|Ultibro Breezhaler 85/43 µg (1 puff o.d.)
89114861|NCT02726295|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Mutaflor® group will receive E. coli Nissle 1917 (Mutaflor®) 28mg 2T tid for initial 2 days, then E. coli Nissle 1917, Mutaflor® 4T qd for the next 26 days.
89114862|NCT02726295|Placebo Comparator|Matched placebo|Matched placebo group will receive placebo drug 28mg 2T tid for initial 2 days, then placebo 4T qd for the next 26 days. Placebo drug has same shape and size with E. coli Nissle 1917 (Mutaflor®).
89114863|NCT04044820|Active Comparator|Standardized Discharge Prescription|Based on a previous study examining mean number of opioid pills used by patients undergoing elective, unilateral hand and forearm surgery
89114864|NCT04044820|No Intervention|Usual Discharge Prescription|Routine standard of care involves prescription for opioids at the discretion of the surgical team
89114865|NCT02725749|Experimental|Laser|
89114866|NCT02725749|Experimental|Exercise|
89114867|NCT02725749|Experimental|Laser and Exercise|
89114868|NCT05071924|Experimental|PLH Teens Original|The original in-person PLH programme is delivered by community-based workers in low-resource settings. Implementation occurs in a group-based format with both joint parent and teen sessions (10 sessions) and separate parent and teen sessions (4 sessions).
89114869|NCT05071924|Experimental|PLH Teens Hybrid|The hybrid delivery of PLH Teens consists of 8 sessions delivered to parents via WhatsApp (ParentChat-Teens) and 4 sessions delivered to parents and adolescents in person.
89114870|NCT02720289|Experimental|Video-based social learning|Video-based social learning class
89114871|NCT02720289|Active Comparator|Traditional didactic|Traditional didactic class
89114872|NCT02725827|Active Comparator|HA group|One the day of frozen-thawed embryo transfer, frozen embryos will be thawed and incubated for at least 10 minutes in embryo transfer medium. For women allocated to the HA group, EmbryoGlue (Vitrolife), a hyaluronan-enriched embryo transfer medium, will be used as embryo transfer medium. EmbryoGlue contains a higher concentration of hyaluronan than the control medium.
89114873|NCT02725827|Active Comparator|Control group|For women allocated to the control group, the usual transfer medium used in the study centers will be used and will serve as control. The main difference between the two media is that EmbryoGlue contains a higher concentration of HA.
89114874|NCT05755126|Experimental|Iatrosedation|
89114875|NCT05755126|Experimental|Musical Therapy|
89114876|NCT05755126|No Intervention|Control|
89114877|NCT02720133||Patients with cardiovascular risk factors who fast Ramadan|Stable clinical and biochemical parameters before Ramadan fasting
89114878|NCT02725437|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
89114879|NCT02725437|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
89114880|NCT02725437|Placebo Comparator|Placebo (accelerated schedule)|
89114881|NCT02725437|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
89114882|NCT02725437|Experimental|High-dose C. difficile Vaccine (non-accelerated schedule)|
89114883|NCT02725437|Placebo Comparator|Placebo (non-accelerated schedule)|
89114884|NCT02720055|Experimental|Psychological Workbook|Psychological work book containing information and activities aimed at improving outcomes.
89114885|NCT02720055|Active Comparator|Basic information workbook|Basic information which represents current practice
89114886|NCT02725359|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo 1 hour before surgery and bilateral superficial cervical block with saline 10 ml each side
89114887|NCT02725359|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 6 mg tizanidine 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
89114888|NCT02725359|Active Comparator|Bupivacaine|Group Bupivacaine will receive placebo 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
89114889|NCT00809614|Experimental|AIN457 (2x 10mg/kg)|Each patient received 10 mg/kg AIN457 intravenously, on Day 1 and Day 22.
89114890|NCT00809614|Placebo Comparator|Placebo|Each patient received 10 mg/kg of matching placebo intravenously, on Day 1 and Day 22.
89114891|NCT04150419|Experimental|G1|
89114892|NCT04150419|Experimental|G2|
89114893|NCT04150419|Active Comparator|G3|
89114894|NCT02725281|No Intervention|Control group|"The patients in Group-I were not interfered by researchers before and during lithotripsy."
89114895|NCT02725281|Active Comparator|Stress ball|"The patients in Group II were given stress ball into their both palms as a before the lithotripsy and told to squeeze the ball whenever they would like."
89114896|NCT02725281|Active Comparator|Music|"The patients in Group-III were listened to the music chosen by them with a headset as a nonpharmacological method during lithotripsy."
89114897|NCT02725203|Experimental|Intervention: Activate intervention|Participants in the intervention arm will visit their primary care nurse four times in a three-month period for structured and comprehensive support in achieving an improved level of physical activity.
89114898|NCT02725203|No Intervention|Control|Patients in the control arm will receive care as usual.
89114899|NCT04674592||Tibial fracture|Patients with a traumatic tibial fracture and without acute compartment syndrome.
89114900|NCT04674592||Tibial fracture complicated by acute compartment syndrome|Patients with a tibial fracture and acute compartment syndrome of fractured leg.
89114901|NCT04674592||Acute compartment syndrome without fracture|Patients with acute compartment syndrome but without a fracture.
89114902|NCT02719821|Experimental|Intervention|Individuals treated with HSCT will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. Study investigators will conduct semi-structured interviews after each session to determine participant satisfaction with and acceptability of the behavioral strategies, timing, delivery mode, assessment strategy, and time commitment. Participants will be asked to complete a daily checklist indicating which intervention strategies they used daily. Participants will be asked to complete self-report assessments, to wear a wrist-worn actigraphy device, and to complete a sleep log at three time points: prior to HSCT and approximately 9 and 18 weeks post-HSCT.
89114903|NCT00731731|Experimental|Treatment (radiation therapy, vorinostat, temozolomide)|Patients undergo radiotherapy and receive vorinostat PO QD on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients also receive temozolomide PO QD on days 1-42. Beginning 4-6 weeks later, patients receive vorinostat PO QD on days 1-7 and 15-21 and temozolomide PO QD on days 1-5. Treatment with vorinostat and temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89114904|NCT02719665|Experimental|Phase 1a (OMEGA-SPM-DOSE)|PAD patients and healthy volunteers in study for SPM Emulsion, dose-modality.
89114905|NCT02719665|Active Comparator|SPM - Phase 1b (OMEGA-SPM-DOSE)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
89114906|NCT02719665|Placebo Comparator|Placebo - Phase 1b (OMEGA-SPM-PLACEBO)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
89114907|NCT02719587|Placebo Comparator|control group|Control group (8 males, 7 females; 42.54±5.82 years) (SRP): SRP followed by administration of a placebo. The placebo was identical except for the fish oil.
89114908|NCT02719587|Active Comparator|test group|Test group (8 males, 7 females; 40.87±9.7 years) (SRP+omega-3 PUFAs): SRP followed by omega-3 PUFAs supplementation. The test drug contained omega-3 PUFAs including 6.25 mg EPA and 19.19 mg DHA obtained from the Atlantic salmon Salmo salar.Both test and placebo drugs were taken twice a day by the patients for six months. Subjects came to the clinic every 4 weeks during the 6 month course of the experiment to replenish their medication. Remaining medications were checked for compliance. At each evaluation visit (1, 3 and 6 months), oral soft and hard tissue examinations and adverse-event evaluations were performed.
89114909|NCT02719509||Observational Cohort|All emergency department patients who had a cardiac ultrasound performed as part of their diagnostic workup
89114910|NCT02719197|Experimental|AC-083, Single Ascending Dose|AC-083 administered at different single dose levels in a sequential manner, and in a maximum of 9 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
89114911|NCT02719197|Placebo Comparator|Placebo, Single Ascending Dose|Matched placebo administered as single ascending doses in parallel to AC-083
89114912|NCT02719431|Other|Warfarin/Warfarin + K-877|
89114913|NCT00806494|Experimental|Treatment Arm|Fesoterodine 4mg, escalating to 8mg as required
89114914|NCT02725125|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0days,the first day,the second day,28 days,29 days Duration:total five times
89114915|NCT02719275||Suicidal Behaviour|
89114916|NCT02719275||Suicidal Ideation|
89114917|NCT02719275||Other Mental Health|
89114918|NCT02719275||Other Health|
89114919|NCT02725047|Experimental|TREATMENT - CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
89114920|NCT02725047|Placebo Comparator|PLACEBO - SAND|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
89114921|NCT02719119|Experimental|monthly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation monthly.
89114922|NCT02719119|Experimental|bi-weekly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation bi-weekly.
89114923|NCT02948361|Experimental|QT Ultrasound breast scan|
89114924|NCT02719041||Tissue samples|Tissue samples taken from women treated for ovarian cancer will be stained.
89114925|NCT02718885|Sham Comparator|Maltodextrin|Maltodextrin
89114926|NCT02718885|Active Comparator|Inulin|Inulin-type fructans
89114927|NCT02724813|Experimental|Intervention arm|Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
89114928|NCT02724813|Active Comparator|Wait-list arm|Participant in this arm will receive therapy 8 weeks after initial assessment. Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
89114929|NCT00806416|Experimental|Sequence 1|alendronate/vitamin D combination then alendronate
89114930|NCT00806416|Experimental|Sequence 2|alendronate then alendronate/vitamin D combination
89114931|NCT00806416|Experimental|Sequence 3|alendronate/vitamin D combination then vitamin D
89114932|NCT00806416|Experimental|Sequence 4|vitamin D then alendronate/vitamin D combination
89114933|NCT02724969|Experimental|MILK intervention group|Semi-automated text messages sent to participants' cellular phones 3-5 times per week beginning Week 25 of pregnancy, through 8 weeks postpartum, specific to breastfeeding support and prevention of perceived insufficient milk supply.
89114934|NCT02724969|Active Comparator|Text4Baby control intervention group|Text4Baby automated texts sent to participants' cellular phones 3-5 times per week from Week 25 of pregnancy through the postpartum period from the national Text4Baby system. Messages provide general prenatal and postpartum support, including breastfeeding.
89114935|NCT02724735||Longitudinal Observational Cohort|Following completion of the NS2014-1 final study visit procedures, Subjects will be offered the opportunity to enroll in this longitudinal observational cohort protocol to monitor their depression and to assess durability of effect and long-term safety of NSI-189.
89114936|NCT02724657|Experimental|Buteyko Method|Children will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
89114937|NCT02724657|No Intervention|Control|Asthma education.
89114938|NCT02724891||Arm 1 paper form first|paper questionnaires first then web/smart phone questionnaires after a 2-week washout period
89114939|NCT02724891||Arm 2 web/smartphone form first|web/smart phone questionnaires first then paper questionnaires after a 2-week washout period
89114940|NCT00811252|Placebo Comparator|Placebo|
89114941|NCT00811252|Experimental|Vortioxetine 5 mg|
89114942|NCT00811252|Other|Duloxetine 60 mg|Active reference
89114943|NCT02724345||CK18 positive|HCC patients with CK18 high expression levels in tumor tissue.
89114944|NCT02724345||CK18 negative|HCC patients with CK18 high expression levels in tumor tissue.
89114945|NCT02718729|Other|Rectal cancer patients|All patients who will fulfill the inclusions criteria. Patients will undergo formal curative radical Laparoscopic resection for rectal cancer
89114946|NCT02609854|Experimental|Sham Sustained Acoustic Medicine Device|Sham Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
89114947|NCT02609854|Experimental|3 MHz Sustained Acoustic Medicine Device|3 MHz Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
89114948|NCT02718573||Non-liver transplants with HCV|
89114949|NCT02718573||Liver transplants with HCV|
89114950|NCT05755594|Other|Robot-assisted Pancreaticoduodenectomy|By performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
89114951|NCT04114617||Healthy Adults|Participants will be asked to swallow a series of up to 54 liquid stimuli: a) liquid barium (different brands and concentrations); b) a 20% w/v concentration liquid barium thickened to different consistencies using either a starch-based or xanthan-gum based food thickener; and c) lemon-flavored water thickened to different consistencies using either a starch-based or xanthan-gum based food thickener.
89114952|NCT04029532||Non-overweight/obese & normal weight|Body mass index (BMI) < 24.0 kg/m^2
89114953|NCT04029532||Overweight and obese|Body mass index (BMI) >= 24.0 kg/m^2
89114954|NCT02608996|Active Comparator|Subcutaneous BNP|Patients will receive gradually increasing doses (10-25 µg/kg) of subcutaneously administered nesiritide (BNP) twice daily for two days, to determine the feasibility, safety and blood pressure lowering effect of BNP so as to identify the optimal dose.
89114955|NCT02608996|Placebo Comparator|Subcutaneous placebo|Patients will receive subcutaneously administered placebo twice daily for two days for determination of the effect of BNP.
89114956|NCT00736957|Experimental|Tramadol HCL plus Acetaminophen|
89114957|NCT02608294|Experimental|Experimental Group|Kinesio Taping Procedure application with 35% strain.
89114958|NCT02608294|Sham Comparator|Sham Group|Kinesio Taping Sham procedure application without strain.
89114959|NCT04189185|Active Comparator|K-wire tension band wiring|The patient is treated with 1.6 mm k-wires and 1 mm cerclage
89114960|NCT04189185|Active Comparator|Suture fixation|The fracture is reduced and fixed with 2.0 Orthocord suture.
89114961|NCT05754970|Experimental|laser/machined|on the same customized healing abutment laser-treated/machined surface treatments were repeated with the following order: Laser treated/machined/laser treated/machined. This order was performed to eliminate the bias of the different surface allocation on patients.
89114962|NCT02724267|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE only.
89114963|NCT02724267|Experimental|internal radiation group|Patients will be treated with TACE combined with internal radiation.
89114964|NCT02718495|Placebo Comparator|Part A|Part A consists of two treatment groups, SAD and MAD. Both treatment groups will consist of 3 cohorts. In SAD, subjects will receive a single dose of PTI-428 or placebo. In MAD, subjects will receive once daily dosing of PTI-428 or placebo for 7 days.
89114965|NCT02718495|Placebo Comparator|Part B|Part B will consist of 2 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
89114966|NCT02718495|Placebo Comparator|Part C|Part C will consist of 3 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
89114967|NCT04659226|Experimental|Episodic or chronic migraine|Women starting treatment with erenumab according to clinical indication
89114968|NCT02724189||Patients attending the preoperative assessment clinic|Patients in preoperative assessment clinic
89114969|NCT05294523|Active Comparator|Rocuronium priming dose 0.06mg/kg|Add the priming dose of rocuronium 0.06mg/kg after the first supramaximal stimulation data measured
89114970|NCT05294523|Active Comparator|Rocuronium priming dose 0.12mg/kg|Add the priming dose of rocuronium 0.12mg/kg after the first supramaximal stimulation data measured
89114971|NCT05294523|Active Comparator|Rocuronium priming dose 0.18mg/kg|Add the priming dose of rocuronium 0.18mg/kg after the first supramaximal stimulation data measured
89114972|NCT04640662|Experimental|Platelet-Rich plasma|2 ml PRP using commercial kit- YCell Biokit
89114973|NCT04640662|Active Comparator|Prolotherapy|2 ml 16.5% Dextrose solution
89114974|NCT02723877|Experimental|Eribulin and PQR309|PQR309 in combination with standard approved dose of eribulin mesylate 1.4 mg/m2 intravenous (iv) on days 1 and 8 in a period of 21 days per cycle will be investigated. . PQR309 will be administered maximum 15 minutes after eribulin iv dosing.
89114975|NCT00736879|Experimental|Dapagliflozin 1 mg|Dapagliflozin: 1 mg
89114976|NCT00736879|Experimental|Dapagliflozin 2.5 mg|Dapagliflozin: 2.5 mg
89114977|NCT00736879|Experimental|Dapagliflozin 5 mg|Dapagliflozin: 5 mg
89114978|NCT00736879|Placebo Comparator|Placebo|Placebo: 0 mg
89114979|NCT02608372|Experimental|Sequence A|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-UP-CTR
89114980|NCT02608372|Experimental|Sequence B|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-CTR-UP
89114981|NCT02608372|Experimental|Sequence C|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-LD-CTR
89114982|NCT02608372|Experimental|Sequence D|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-CTR-LD
89114983|NCT02608372|Experimental|Sequence E|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-LD-UP
89114984|NCT02608372|Experimental|Sequence F|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-UP-LD
89114985|NCT02718339|Experimental|Intensive counseling by a pulmonologist|Counselor visit during hospitalization, telephone follow up for 4 weeks and a follow up visits.
89114986|NCT02718339|No Intervention|Usual care|
89114987|NCT02718261|Experimental|Verum (pantoprazole)|
89114988|NCT02718261|Placebo Comparator|Placebo|0.9% saline
89114989|NCT00806260|Experimental|Treatment 1|Dosed first with alcohol, then active VI-0521, and last, VI-0521 placebo
89114990|NCT00806260|Experimental|Treatment 2|First dosed with alcohol placebo (fruit juice), then active VI-0521, and last, placebo VI-0521
89114991|NCT00806260|Experimental|Treatment 3|First dosed with alcohol, then VI-0521 placebo, and last, active VI-0521
89114992|NCT00806260|Experimental|Treatment 4|First dosed with alcohol placebo, then VI-0521 placebo, and last, active VI-0521
89114993|NCT05753020|Experimental|CKM Jumpstart Tool|Receives intervention
89114994|NCT05753020|No Intervention|Control|Does not receive intervention
89114995|NCT02718183|Experimental|PH|Hydrogen peroxide 35% to intracoronal bleaching in discoloration teeth eith endodontic treatment
89114996|NCT02718183|Experimental|PC|Carbamide peroxide 37% to intracoronal bleaching in discoloration teeth eith endodontic treatment
89114997|NCT00742885|Experimental|Influenza A (H5N1) 20-40 Years Group|Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
89114998|NCT00742885|Experimental|Influenza A (H5N1) 41-64 Years Group|Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
89114999|NCT00811174|Experimental|Octagam 10%|
89115000|NCT02723487|No Intervention|Group A|Control
89115001|NCT02723487|Active Comparator|Group B|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.125%), 0.5 ml/kg on each side.
89115002|NCT02723487|Active Comparator|Group C|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.25%), 0.5 ml/kg on each side.
89115003|NCT02717871|Experimental|Treatment (PACK-CXL)|Photoactivated chromophore for infectious keratitis-corneal cross-linking (PACK-CXL)
89115004|NCT02717871|Active Comparator|Antimicrobial therapy|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).~OR~1b. a Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)~2. Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.~3. Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium"
89115005|NCT02593435||No treatment|There will be two groups, one is breast cancer patient group, another group inlude the first-degree relatives and second degree relatives of patients with BRCA1/2 mutation. All volunteers should provid tissue(s) and blood for NGS test.
89115006|NCT02717715|Experimental|Intervention group|Stroke patients from the intervention group will be, on top of usual care, offered a holistic home based and semi-supervised stroke rehabilitation program followed by a period of tele-supervision.
89115007|NCT02717715|No Intervention|Control group|The participants in the control group will only receive usual care.
89115008|NCT04088929|Experimental|CBD for Treatment of Diabetic Neuropathic Pain|Patients are instructed to take 3 total tablets a day, under the tongue, six hours apart for three weeks. Patients are to enter their pain scale score into the smartphone app as instructed during the initial site visit. Patients are to enter into the notes section of the app any additional information such as side effects (positive or negative), medication changes.
89115009|NCT02723253|Experimental|Radiotherapy plus Tom-Ox|Patients received concomitant boost RT (55 Gy/5 weeks) with concurrent Tom-Ox chemotherapy. The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
89115010|NCT04616794|Experimental|Cognitive Engagement Group|Participants eligible to enter this group must show low cognitive engagement in cognitively stimulating activities, defined as a score < 22 on the Cognitive Activity Questionnaire (CAQ)
89115011|NCT04616794|Experimental|Physical Activity Group|Participants eligible to enter this group must have a low level of physical activity defined as less than 600 MET-min/week (~150 minutes/week) of moderate to vigorous physical activity (MVPA), measured using the International Physical Activity Questionnaire - short form (IPAQ-SF)
89231978|NCT05702034|Placebo Comparator|Placebo|Participants after an acute ischemic stroke or high-risk TIA who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) will receive placebo orally twice daily.
89231982|NCT05694013|Experimental|Cohort A - Arm 1|Participants with metastatic non-small cell lung carcinoma (mNSCLC), extensive-stage small-cell lung carcinoma (ES-SCLC), and advanced or unresectable hepatocellular carcinoma (HCC) and who are prescribed an anticancer regimen including intravenous (IV) atezolizumab will use the Roche Digital Patient Monitoring (DPM) Module along with local standard of care (SOC) support.
89231983|NCT05694013|Experimental|Cohort A - Arm 2|Participants with mNSCLC, ES-SCLC, and HCC who are prescribed an anticancer regimen including IV atezolizumab will receive local SOC support.
89231984|NCT05694013|Experimental|Cohort B|Participants with resected Stage IIB-IIIB NSCLC will use the Roche DPM Module along with subcutaneous (SC) atezolizumab in both the hospital and flexcare (home) setting.
89231985|NCT05690152|Experimental|Single Arm|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
89231986|NCT05687721|Experimental|Therapeutic arm|Copanlisib will be administered through intravenous infusion (IV) at 60 mg on Day 1, 8 and 15, and avelumab will be administered 800 mg IV on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
89231987|NCT05685953|Experimental|Active vaccine|Plasmid DNA vaccine, OC-007
89231988|NCT05685953|Placebo Comparator|Placebo|Sodium chloride solution (0.9 %)
89231989|NCT05682326|Experimental|Daprodustat|All participants will receive daprodustat for up to 52 weeks.
89231996|NCT05674890|Experimental|Single arm|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with both the Humphrey HFA-III perimeter and the SmartSystem VR headset on the same clinic visit, spaced roughly 10-15 minutes apart. The sequence in which each patient undertakes the two tests will be randomized.
89231997|NCT05671302|Experimental|Walk Together|Walk Together involves four sessions delivered in patients' primary care clinic over approximately two months. Sessions are dyadic (i.e., all sessions include the patient and a family support person), last 30-90 minutes, and are delivered by a trained family therapist. The intervention is a culturally-response, family-based intervention that is strengths-based and includes components of integrative behavioral couples therapy and motivational interviewing. The goals of the intervention are to (a) optimize family support and communication, (b) improve hypertension knowledge, (c) enhance self-management goal-setting, and (d) increase shared problem-solving to address self-management adherence barriers. Environmental barriers to adherence are also addressed consistent with standard care.
89231998|NCT05669014|Experimental|Daxdilimab|Daxdilimab will be administered by subcutaneous (SC) injection over a total of 44 weeks.
89231999|NCT05669014|Placebo Comparator|Placebo|Matching placebo will be administered by SC injection over a total of 24 weeks, then will be administered active drug by SC injection up to Week 44
89232004|NCT05663866|Experimental|Background Anti-cancer Therapy with Amivantamab Plus Lazertinib|Participant will receive following treatments in 4 different cohorts prior to administration of combination therapy of IV Amivantamab and oral Lazertinib (anti-cancer regimen): dexamethasone dose-1 in Cohort A; dexamethasone dose-2 in Cohort A2; montelukast in Cohort B; and methotrexate in Cohort C.
89115012|NCT04616794|Experimental|Diet Group|Participants eligible to enter this group must have a low adherence to the Mediterranean-type diet defined as a score of ≤ 8 on the adapted Canadian Mediterranean Diet Scale (MDS).
89115013|NCT04616794|Experimental|Multi-modal Group|Participants eligible to enter this group must be eligible for at least two of the three single-arm conditions.
89115014|NCT05752942|Experimental|Treatment: Student Intervention Matching System|In the treatment condition, the students received a performance-based interventions matched to their individual needs and characteristics based on Student Intervention Matching System (SIMS).
89115015|NCT05752942|Active Comparator|Active control: group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based EBI (group-based social skills training).
89115016|NCT02717481||Patients with known aortic aneurysm|"Patients with known abdominal aortic aneurysm diagnosed in clinical follow-up or after an invasive procedure to repair it.~US-CT Fusion examination"
89115017|NCT05264727|Experimental|Healthy Adults, Obese Adults, Adults with Type 2 diabetes: Saline and Glucose|Study visit: Subjects will receive a caffeine free, standardized evening meal and remain fasting overnight. An IV infusion of saline and glucose (50%) will be given the next morning and continue until the end of study. Blood draws will be collected frequently from the IV line to monitor blood glucose levels.
89115018|NCT05264727|Experimental|Healthy Adults, Obese Adults, Adults with Type 2 diabetes: Amino Acid and Glucose|Study visit: Subjects will receive a caffeine free, standardized evening meal and remain fasting overnight. An IV infusion of glucose (50%) will be given the next morning together with an IV infusion of Clinisol 15% (an amino acid mixture) will be given the next morning and continue until the end of study. Blood draws will be collected frequently from the IV line to monitor blood glucose levels.
89115019|NCT02723097|Experimental|Relaxation Response Resiliency Program (3RP)|
89115020|NCT02722785|No Intervention|Usual Care Observation Group|Patients allocated to usual care control will receive the standard patient care program as provided by the department of surgical gastroenterology, Rigshospitalet
89115021|NCT02722785|Experimental|Aerobic and Resistance Exercise Training|Patients allocated to this group will receive usual care plus a supervised aerobic and resistance exercise program at CFAS' facilities consisting of 2 weekly sessions of approximately 60 minutes.
89115022|NCT02722473|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5°C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5°C for 24 hours.
89115023|NCT02722473|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5°C for 48 hours
89115024|NCT02722551|Experimental|Treatment|Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve (transapical or transseptal delivery)
89115025|NCT02722629|Experimental|Aspiration in COPD patients|All COPD patient will be evaluated systematically by FEESST (Flexible Endoscopic Evaluation of Swallowing with Sensory Testing) with direct evaluation of aspiration by direct observation.
89115026|NCT00730405|Active Comparator|Albaconazole 100mg|Albaconazole for 36 weeks
89115027|NCT00730405|Active Comparator|Albaconazole 200mg|Albaconazole for 36 weeks
89115028|NCT00730405|Active Comparator|Albaconazole 400mg|Albaconazole for 36 weeks
89115029|NCT00730405|Active Comparator|Albaconazole 400mg 24 weeks, Placebo 12 weeks|Albaconazole for 24 weeks, Placebo for 12 weeks
89115030|NCT00730405|Placebo Comparator|Placebo 400 mg|Placebo for 36 weeks
89115031|NCT02722395||Single arm cohort study|
89115032|NCT04129359|Experimental|FamilieTrivsel|Enhanced care as usual in general practice plus training in the use of the online mentalisation programme
89115033|NCT04129359|Active Comparator|control|Enhanced care as usual in general practice
89115034|NCT02596399|Experimental|DSTA4637S|
89115035|NCT02596399|Placebo Comparator|Placebo|
89115036|NCT04088695|Experimental|Intervention|The arm exposed to the intervention video
89115037|NCT04088695|Active Comparator|Control|The control group exposed an informative text.
89115038|NCT02722161|Experimental|[14C]BI 1482694|
89115039|NCT02694237|Active Comparator|Verbal|This group will only receive a verbal discussion based on the same script used for all three groups. This is the control group.
89115040|NCT02694237|Active Comparator|Verbal + Model|This group will receive a verbal discussion aided with an anatomic model intervention that group participants will be able to touch throughout the discussion.
89115041|NCT02694237|Active Comparator|Verbal + Video|This group will receive a verbal discussion aided with a knee anatomy video intervention that will be played on silent an orated by an interviewer.
89115042|NCT02594449|Active Comparator|low concentration Benzalkonium Chloride|To use low concentration Benzalkonium Chloride Solution to gargle
89115043|NCT02594449|Active Comparator|high concentration Benzalkonium Chloride|To use high concentration Benzalkonium Chloride Solution to gargle
89115044|NCT02594449|Placebo Comparator|Normal Saline|To use Normal Saline to gargle
89115045|NCT02722083|Experimental|BAY X002134|Subjects will be given BAY X002134
89115046|NCT02722083|Placebo Comparator|Placebo|Subjects will be given a placebo
89115047|NCT05257135|Experimental|Biological collection|"For all patients included in the study:~Blood samples collected at different times: at inclusion and during treatment every 6 months~In parallel to this biological collection, standardized clinical data will be entered into a database"
89115048|NCT02694081|Experimental|Uncut Roux-en-Y Reconstruction|Uncut Roux-en-Y Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
89115049|NCT02694081|Active Comparator|Billroth II Reconstruction|Billroth II Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
89115050|NCT02722005|Experimental|Financial Coaching & Access to Services|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
89115051|NCT02722005|Active Comparator|Access to Services|Participants will have access to a host of referrals to social services (this is the intervention for this group)
89115052|NCT00736723||Patients non-septic shock|Postoperative/posttraumatic critically ill patients with non-septic shock
89115053|NCT00736723||Patients septic shock|Postoperative/posttraumatic critically ill patients with septic shock
89115054|NCT02721849|Experimental|adolescent yoga / parent control|The adolescent will receive an 12 week yoga course, while one parent will only answer the questionnaires.
89115055|NCT02721849|Experimental|adolescent waitlist / parent yoga|One parent will participate in an 12 week yoga course, while the adolescent will receive the intervention after the follow-up period.
89115056|NCT02721849|Experimental|adolescent yoga / parent yoga|Both adolescent and parent will participate in an 12 week yoga course at the same time.
89115057|NCT02721849|No Intervention|adolescent waitlist / parent control|The adolescent will receive the intervention after the follow-up period, while one parent will only answer the questionnaires.
89115058|NCT02721693|Experimental|Treadmill exercise test|Patients are subjected to an incremental Cardiopulmonary Exercise Test to exhaustion
89115059|NCT00736645|Experimental|Arm I|Patients receive oral selenomethionine and oral finasteride once daily for 4-5 weeks.
89115060|NCT00736645|Experimental|Arm II|Patients receive oral placebo and oral finasteride once daily for 4-5 weeks.
89115061|NCT00736645|Experimental|Arm III|Patients receive oral selenomethionine and oral placebo once daily for 4-5 weeks.
89115062|NCT00736645|Placebo Comparator|Arm IV|Patients receive two oral placebos once daily for 4-5 weeks.
89115063|NCT02716467|Experimental|intercessory prayer group|Patients in the experimental group receive prayer of intercession during radiotherapy treatment.
89115064|NCT02716467|Active Comparator|Radiotherapy Treatment|Patients in the radiotherapy group not receive prayer of intercession during radiotherapy treatment.
89115065|NCT02716701|Experimental|Exercise Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will be asked to increase their activity level, with a goal of at least doubling their average daily activity (steps)
89115066|NCT02716701|Active Comparator|Control Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will not be encouraged to increase their activity level
89115067|NCT02716389|Other|Mask on|
89115068|NCT02716389|Other|Mask off|
89115069|NCT00736489|Experimental|crossover dose 1|AZD3199 120 microgram
89115070|NCT00736489|Experimental|crossover dose 2|AZD3199 480 microgram
89115071|NCT00736489|Experimental|crossover dose 3|AZD3199 1920 microgram
89115072|NCT00736489|Placebo Comparator|crossover dose 4|Placebo
89115073|NCT00736489|Active Comparator|crossover dose 5|Formoterol 9 microgram
89115074|NCT00736489|Active Comparator|crossover dose 6|Formoterol 36 microgram
89115075|NCT02318355|No Intervention|Control|Control group that receives no intravenous fluid after blood donation
89115076|NCT02318355|Experimental|Lactated Ringers|Experimental group that receives two liters lactated ringers after blood donation.
89115077|NCT02318355|Experimental|Normal Saline|Experimental group that receives two liters normal saline after blood donation.
89115078|NCT04964973|Active Comparator|Control Group|1. Control group. Patients have performed the conventional postsurgical program without adding TENS.
89115079|NCT04964973|Experimental|Experimental Group|Experimental group. The application of TENS has been added to the physiotherapy program. It had a frequency of 100 Hz and a phase duration of 100 µsec for a period of 30 minutes (through channel 1 of the TENS equipment), receiving and feeling the patient the physical sensation of the current.
89115080|NCT04964973|Placebo Comparator|Placebo Group|Placebo group. In this group, the same program as group 2 was proposed, using, in this case, channel 2, which did not activate the electric current, and the patient did not receive any physical sensation
89115081|NCT02288637|Experimental|Conventional Olyset LLIN|High coverage (>80% access) of conventional Olyset LLIN The arm is the standard of care from the National Malaria Control Program
89115082|NCT02288637|Experimental|Olyset Plus LLIN|High coverage (>80% access) of Olyset Plus LLIN
89115083|NCT02288637|Experimental|Conventional Olyset LLIN and IRS|High coverage (>80% access) of conventional Olyset LLIN and high coverage IRS (>80% of the household sprayed) with pirimiphos methyl CS
89115084|NCT02288637|Experimental|Olyset Plus LLIN and IRS|High coverage (>80% access) of Olyset Plus LLIN and high coverage Indoor Residual Spraying (>80% of the household sprayed) with pirimiphos methyl CS
89115085|NCT02069925|Experimental|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
89115086|NCT02069925|Active Comparator|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
89115087|NCT02716233|Active Comparator|Arm 1|pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1
89115088|NCT02716233|Experimental|Arm 2|pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each
89115089|NCT02047929|Active Comparator|Facilitator-Led|This approach to dissemination allows clinics some freedom to tailor the Asthma Shared Decision Making (SDM) Toolkit and training process for their specific environment and patient population while maintaining fidelity of certain key elements that are felt to be essential for success. The expertise of the trained Practice Facilitator will help guide the process of implementation at the practice level.
89115090|NCT02047929|Active Comparator|Traditional|"The most commonly used dissemination technique is active diffusion, which includes didactic presentations, academic detailing, exposure to journal publications and subject matter experts, and educational material distribution. We have defined this type of dissemination, traditional dissemination. For the purpose of this study, practices randomized to traditional dissemination will receive a lunchtime presentation by a physician champion / subject matter expert on shared decision making. The presentation will give an overview of the Asthma Shared Decision Making (SDM) Toolkit, access to the internet link with additional information, and a copy of all printed materials associated with the Toolkit."
89115091|NCT02047929|No Intervention|Control|A third group will be randomized into an arm with no formal dissemination. This arm will receive information only through passive exposure to the concepts of shared decision making. This would include introduction to the SDM concepts through the media, conferences, or social networks. Having this control in place will allow the research team to isolate the effect of both the FLOW approach and the traditional approach to dissemination.
89115092|NCT00730327|Experimental|BIB®|Receives BioEnterics® Intragastric Balloon Intervention as well as diet and exercise counseling with the Behavioral Modification Intervention.
89115093|NCT00730327|Other|Control|Control arm receives the Behavioral modification intervention only.
89115094|NCT01999569|No Intervention|Control|Control cycle. No intervention.
89115095|NCT01999569|Experimental|Letrozole|5mg daily
89115096|NCT02716077|Experimental|Single arm|FDG PET/CT scan pre-therapy
89115097|NCT04087915||High risk coronary artery disease|Participants with high risk coronary artery disease.
89115098|NCT02715921|Experimental|Cystic fibrosis patients|Receive tele-exercise training and undergo pulmonary function testing and exercise testing
89115099|NCT02715687|Placebo Comparator|Placebo|Will receive 30 days treatment with oral placebo of 200mg
89115100|NCT02715687|Active Comparator|Interventional|Will receive 30 days treatment with oral Amiodarone of 200mg
89115101|NCT00742417|Experimental|Albutein 5%|Patients allocated to this arm underwent plasma exchange with Albutein 5%.
89115102|NCT00742417|Sham Comparator|Control|
89115103|NCT00917995|Experimental|Colostomy with a prophylactic mesh|
89115104|NCT00917995|No Intervention|Colostomy without a prophylactic mesh|
89115105|NCT04859517|Experimental|ADG20|Participants will be dosed on Day 1 with ADG20 IM
89115106|NCT04859517|Placebo Comparator|Placebo|Participants will be dosed on Day 1 with placebo IM
89115107|NCT02715999|Active Comparator|Quadratus Lumborum Block|Quadratus Lumborum block group (QL) patients will receive unilaterally Quadratus Lumborum block using Bupivacaine 0.2 %
89115108|NCT02715999|Active Comparator|Transversus abdominis plane block|Transversus abdominis plane block (TAP) patients will receive unilaterally TAP block using Bupivacaine 0.2 %
89115109|NCT01798173|Experimental|Cases: cirrhotic patients with hepatocellular carcinoma|
89115110|NCT01798173|Active Comparator|Controls: cirrhotic patients without hepatocellular carcinoma|
89115111|NCT02715531|Experimental|Arm A (Hepatocellular Carcinoma [HCC], All subtypes)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior treatment are non-randomized and will receive atezolizumab and bevacizumab, every 3 weeks (q3w), each cycle of 21 days, as long as participants are experiencing clinical benefit in the opinion of the investigator.
89115112|NCT02715531|Experimental|Arm B (Gastric Cancer)|Participants with previously untreated human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastroesophageal junction (GEJ) are non-randomized and will receive atezolizumab, bevacizumab, and FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil [FU]), every 2 weeks (q2w), each cycle of 28 days, as long as participants are experiencing clinical benefit in the opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. After 6 months, at discretion of investigator, capecitabine may be administered as maintenance therapy without oxaliplatin instead of infusional 5-FU and leucovorin, and biologic therapy may be given every 3 weeks (q3w). In the event that a patient experiences unacceptable toxicity after replacement of infusional 5-FU and leucovorin with capecitabine, the patient may be allowed to switch back to 5-FU and leucovorin following investigator discussion with the Medical Monitor.
89115113|NCT02715531|Experimental|Arm C (Metastatic Pancreatic Cancer)|Participants with previously untreated metastatic pancreatic cancer are non-randomized and will receive atezolizumab q2w starting on Day 1, Cycle 1 (each cycle of 28 days). Administration of nab-paclitaxel followed by gemcitabine will occur on Days 1, 8, and 15 of each cycle (3-weeks-on/1-week-off schedule). Treatment consisting of atezolizumab with gemcitabine and nab-paclitaxel may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator.
89115114|NCT02715531|Experimental|Arm E (Randomized Metastatic Esophageal Cancer)|Participants with squamous metastatic esophageal cancer (mEC) will be randomized (1:1) into Group E1 and Group E2. All participants with metastatic adenocarcinoma of esophageal carcinoma or GEJ Siewert Classification Type I will be enrolled into Group E3. In Groups E1 and E3, participants will receive atezolizumab and FOLFOX, q2w, each cycle of 28 days, as long as participants are experiencing clinical benefit in opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. In Group E2, participants will receive atezolizumab followed by cisplatin and 5-FU q3w. Cisplatin will be administered for up to 6 cycles. Treatment with atezolizumab in combination with 5-FU may be continued as long as participants experience clinical benefit in opinion of the investigator.
89115115|NCT02715531|Experimental|Arm F (Randomized HCC)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior systemic treatment will be randomized (1:1) into Group F1 and Group F2. Participants will receive atezolizumab alone (Group F2) or combined with bevacizumab (Group F1) on a q3w schedule, with dosing on Day 1 of each 21 day Cycle. Treatment with atezolizumab with or without bevacizumab may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator. Participants who are randomly assigned to Group F2 (atezolizumab monotherapy) and experience investigator-assessed unequivocal radiographic progression as per RECIST v1.1 will also be given the option to cross over to atezolizumab and bevacizumab combination therapy, provided they meet the criteria for crossover and Medical Monitor approval is obtained.
89115116|NCT02715453|Experimental|Intervention on frailty|Intervention on frailty in addition to the usual care by the cardiologist. A multidisciplinary team (physicians, nurses and physiotherapists and nutritionists) will carry out the intervention on frailty
89115117|NCT02715453|No Intervention|Control|Conventional strategy consisting only of the usual care by the cardiologist
89115118|NCT00811018|Experimental|Sitaxsentan|Sitaxsentan
89115119|NCT02715297|Experimental|Arm A: SRT to the resection cavity|Postoperative stereotactic fractionated radiotherapy (SRT) to the resection cavity to a Total Dose of 46 Gy, 2 Gy single dose, or 36 Gy in 3 Gy single dose 5 fractions/week, depending on the volume and location of the treatment region.
89115120|NCT02715297|No Intervention|Arm B: Observation|Observation without adjuvant radiotherapy.
89232014|NCT05652335|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-79635322. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
89232015|NCT05652335|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-79635322 at the RP2D regimen(s) determined in Part 1.
89232016|NCT05646849|No Intervention|Classic care|Home exercise book, personalized advices and development of an individualized project post-cardiac rehabilitation.
89232017|NCT05646849|Experimental|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
89232018|NCT05644262|Experimental|T2:C100|
89232019|NCT05644262|Placebo Comparator|Placebo|
89232020|NCT05642325|Experimental|Arm A|Participants will receive 4 low-dose vamikibart intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.
89232021|NCT05642325|Experimental|Arm B|Participants will receive 4 high-dose vamikibart IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.
89232022|NCT05642325|Sham Comparator|Arm C|Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.
89232027|NCT05639244|Other|First TRE, then regular diet|This group will start with 2 weeks TRE and will switch to the 2 week period of consuming their regular diet after a wash-out period.
89232028|NCT05639244|Other|First regular diet, then TRE|This group will start with the 2 week period of consuming their regular diet and will switch to 2 weeks TRE after a wash-out period.
89232032|NCT05634408|Experimental|TEST Lens|Eligible subjects will bilaterally wear the TEST Lens for the duration of the study.
89232033|NCT05634044|Experimental|eNose device use|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections, and questionnaires over the course of 4 visits during a 3 week period.
89232034|NCT05633160|Experimental|67Cu-SAR-BBN|"In the dose escalation phase:~64Cu-SAR-BBN: Patients will receive up to 2 administrations of 200MBq~67Cu-SAR-BBN: Cohorts 1 - 3: Single administration (dose will be determined based on cohort allocation).~Cohort 4: 2 administrations at the recommended dose (determined by cohorts 1-3).~In the cohort expansion phase:~Patients will receive up to 3 administrations of 200MBq of 64Cu-SAR-BBN and 2 administrations at the recommended dose level of 67Cu-SAR-BBN, determined through the dose escalation.~Additional administrations: (up to a maximum total of 4) may be offered to those participants, in either the dose escalation or cohort expansion, with radiological non-progression."
89232035|NCT05630118|Experimental|SHUTi Intervention|Adult heavy drinkers with insomnia
89232036|NCT05630118|Active Comparator|Web-Based Insomnia Education Program|Adult heavy drinkers with insomnia
89232037|NCT05626751|Experimental|HZN-825|HZN-825 will be administered by mouth (PO) twice daily (BID) for 52 weeks
89115121|NCT02715063|Experimental|High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal during adaptation (first 4 weeks) and 500 kcal after week number 4 until the end of training.
89232038|NCT05623020|Experimental|Part 1, Dose Level 1: Elranatamab + Daratumumab + Lenalidomide|
89232039|NCT05623020|Experimental|Part 1, Multiple Dose Levels, Elranatamab + Daratumumab + Lenalidomide|
89232040|NCT05623020|Experimental|Part 2 Randomized Arm A: Elranatamab + Daratumumab + Lenalidomide|
89232041|NCT05623020|Active Comparator|Part 2 Randomized Arm B: Daratumumab + Lenalidomide + Dexamethasone|
89115122|NCT02715063|Active Comparator|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 300 kcal during adaptation (first 4 weeks) at 20-30% of 1 one-rep max and 500 kcal after week number 4 until the end of training, at 40-60% of one-rep max.
89115123|NCT02715063|Active Comparator|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached. Exercise will be performed at three sessions per week.
89115124|NCT02715063|Placebo Comparator|Usual clinical care|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
89115125|NCT02714985||confirmed chikungunya cases|cases with confirmed chikungunya fever and included for follow-up as per protocol
89115126|NCT04037085|Experimental|Ketamine|Ketamine - IV after cord clamping; IV infusion for 12 hours OR in the weaning population IV Ketamine infusion for 12 hours in the Montefiore CTRC
89115127|NCT00914056|Experimental|Lactulose withdrawal|Patients who were started on lactulose as a result of a precipitated HE episode underwent analysis while they were on lactulose; after this they underwent a controlled lactulose withdrawal with 3 visits post-withdrawal at 2 days, 14 days and 30 days after lactulose withdrawal
89115128|NCT02715219|Experimental|intervention group|Subjects in intervention group will be given an appointment date to attend the an Asthma Education Programme.
89115129|NCT02715219|No Intervention|control group|Subjects in control group will routinely go for the normal follow up in Respiratory Clinic without receive any intervention.
89115130|NCT02714907|Experimental|AF assessed from Cortrium C3 data|Atrial fibrillation assessed from Cortrium C3 device data
89115131|NCT02714907|Experimental|AF assessed from Holter data|Atrial fibrillation assessed from Holter data
89115132|NCT02714673||ADELC|Cohort of patients on long term anticoagulation and undergoing a primary hip or knee replacement.
89115133|NCT02714673||CONTROL|Cohort of patients not on long term anticoagulation and undergoing a primary hip or knee replacement.
89115134|NCT00730171|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator.
89115135|NCT04787835|Experimental|Forearm Nerve Block|Patients will receive a nerve block of the radial, median, and ulnar nerves at the level of the forearm using 1% lidocaine with epinephrine. The lidocaine will be injected subcutaneously, using a total dose of less than 7mg per kilogram.
89115136|NCT04787835|Active Comparator|Local Anesthetic Infiltration|Patients will receive local anesthetic infiltration, using 1% lidocaine with epinephrine, to the fracture site and surrounding tissue. No nerve blocks will be performed. The lidocaine will be injected subcutaneously, using a total dose of less than 7mg per kilogram.
89115137|NCT02714751|No Intervention|Observational group|
89115138|NCT02714751|Other|Group after information intervention|Control group after daily information to healthcare team
89115139|NCT02714829|Experimental|Inject BMP|ExcelOS-inject containing rhBMP-2
89115140|NCT02714829|Active Comparator|ExcelOS-inject|ExcelOS-inject without rhBMP-2
89115141|NCT02593981|Active Comparator|Fruit/Honey Drink|Fruit/Honey Drink (2 canisters) will be taken orally twice a day. Subjects will consume the drink on days 1 through 28.
89115142|NCT02593981|Placebo Comparator|Placebo|Placebo (2 canisters) will be taken orally twice a day. Subjects will consume the placebo drink on days 1 through 28.
89115143|NCT00730015|Experimental|145 μg linaclotide|
89115144|NCT00730015|Experimental|290 μg linaclotide|
89115145|NCT00730015|Placebo Comparator|Matching Placebo|
89115146|NCT00806026|Experimental|PBO/PGB 300 mg|
89115147|NCT00806026|Active Comparator|PBO/PPX 0.25 mg|
89115148|NCT00806026|Active Comparator|PBO/PPX 0.5 mg|
89115149|NCT00806026|Experimental|PGB 300 mg|
89115150|NCT00806026|Active Comparator|PPX 0.25 mg|
89115151|NCT00806026|Active Comparator|PPX 0.5 mg|
89115152|NCT04026165|Experimental|Selonsertib|"Run-in Period (5 Weeks): Participants will receive placebo-to-match SEL for at least one week and then SEL 18 mg for at least 4 weeks.~Randomized Period: Participants will be randomized to receive SEL 18 mg for at least 48 weeks."
89115153|NCT04026165|Placebo Comparator|Placebo|"Run-in Period (5 Weeks): Participants will receive placebo-to-match SEL for at least one week and then SEL 18 mg for at least 4 weeks.~Randomized Period: Participants will be randomized to receive placebo-to-match SEL for at least 48 weeks."
89115154|NCT04227093|Active Comparator|Acetazolamide|Acetazolamide will be prescribed in unembellished white capsules of 250 mg. The drug will be administered twice daily in the morning and evening (approximately one hour before bedtime). The total treatment length will amount to 16 weeks. In case of side effects hampering treatment adherence, the daily dosage will be reduced to a single evening dose of 250 mg.
89115155|NCT04227093|Placebo Comparator|Placebo|The placebo regimen will be identical.
89115156|NCT02714517|Experimental|hydrotherapy|patients receive daily conventional physiotherapy and three 30- minutes sessions of in- water exercises per week, for four weeks
89115157|NCT02714517|Active Comparator|controls|patients receive daily conventional physiotherapy and three 30- minutes sessions of on- land exercises per week, for four weeks
89115158|NCT00805792|Experimental|Donepezil|Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.
89115159|NCT02714127||Cases|"Women (25-64 years old) with abnormal cytology results and/or (high risk) HPV infection refered for colposcopy, and hence possibly diagnosed with an (high risk) HPV infection and/or cervical (pre)cancerous lesions.~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
89115160|NCT02714127||Controls|"Healthy women (25-64 years old), falsely diagnosed with abnormal cytology and/or (high risk) HPV infection, but referred for colposcopy, are included as negative controls. Based on a specificity of 76.14% of the HPV type-specific PCR (polymerase chain reaction) used, an estimated 24 out of these 100 participants will be incorrectly scheduled for colposcopy and serve as the control group.~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
89115161|NCT04777929||healthy pregnant woman|pregnant woman without any disease of pregnancy
89115162|NCT04777929||pregnant woman with preeclampia|pregnant woman with preeclampia but without any other disease of pregnancy
89115163|NCT00590044|Experimental|Insulin glargine+glulisine|Daily insulin glargine + glulisine before meals
89115164|NCT00590044|Active Comparator|Split-mixed NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
89115165|NCT04227015|Experimental|Administration of CTA101|Dose escalation follows the standard 3+3 dose escalation design. A total of 2 dose levels are set for subjects.
89115166|NCT02714361|Active Comparator|Vitamin D3 supplement|Participants will be asked to take 1 capsule of vitamin D3 supplement (1500 IU) (37.5ug) daily for a total duration of 8 weeks.
89115167|NCT02714361|Placebo Comparator|Placebo|Participants will be asked to take 1 capsule of placebo (65% olive oil) daily for a total duration of 8 weeks.
89115168|NCT04741581|Other|Thicken up|Assess the effect of ThickenUp® Gel Express at increasing viscosities (slightly thick, nectar, honey, and pudding) on swallowing function compared to water using VFS (N=100), in patients affected by Oropharyngeal dysphagia (OD).
89115169|NCT02778321|Other|Uses of SpiderFlash monitor|"The intervention corresponds to the use of Spiderflash as Holter monitor. Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist."
89115170|NCT05069649|Experimental|Ergoferon|Tablet for oral use. 1 tablet twice daily. The tablets are taken outside of meals (between meals or 15-30 minutes before meals), keep the tablets in the mouth, without swallowing, until completely dissolved.
89115171|NCT05069649|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Ergoferon scheme.
89115172|NCT02778087|Experimental|TAU plus 30 minutes of BT.|Intervention: Subjects randomized to the 30 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently two times per day in addition to their treatment as usual.
89115173|NCT02778087|Experimental|TAU plus 60 minute of BT.|Intervention: Subjects randomized to the 60 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently four times per day in addition to their treatment as usual.
89115174|NCT02778087|Sham Comparator|TAU plus 30 minutes of sham BT.|Intervention: Subjects randomized to the control (sham) group will perform the above Sham Mirror Box Therapy intervention independently two times per day. The control group will be using a mirror box with an opaque surface as opposed to a reflective mirror.
89115175|NCT02778243|Experimental|Bladder cancer|▪ Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer).
89115176|NCT02778243|Other|benign prostate hyperplasia|▪ Patients with benign prostate hyperplasia who justified a prostatectomy.
89115177|NCT02713971|Experimental|Gamepad|Biofeedback rehabilitation with Gamepad system.
89115178|NCT02713971|Active Comparator|Control|Conventional physiotherapy.
89115179|NCT02778009|Experimental|Fit Physician Group|"Subjects will receive activity monitor and will be required to attend monthly wellness lectures and weekly exercise intervention.~Every subject will undergo an iDEXA scan to measure body mass composition"
89115180|NCT02778009|Active Comparator|Activity Monitor Only Group|"Subjects will receive an activity monitor without any intervention Every subject will undergo an iDEXA scan to measure body mass composition~)"
89115181|NCT02778009|Other|Control Group|Subjects will not an activity monitor nor will they receive any intervention Every subject will undergo an iDEXA scan to measure body mass composition
89115182|NCT00248703|Experimental|Docetaxel|Patients with presence of disseminated tumor cells in bone marrow after (no-taxane) epirubicin-containing adjuvant treatment receive 6 cycles of docetaxel (100 mg/m2) 3 qw.
89115183|NCT02713893|Experimental|Econazole nitrate 1% plus Benzydamine HCl 0.12%|5 grams of Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days
89115184|NCT02713893|Active Comparator|Placebo plus Econazole nitrate 1%|5 grams of Placebo plus Econazole nitrate 1% intravaginal cream, once daily for 15 consecutive days
89115185|NCT02713893|Active Comparator|Placebo plus Benzydamine HCl 0.12%|5 grams of Placebo plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days.
89115186|NCT02713893|Placebo Comparator|Placebo|5 grams of Placebo intravaginal cream, once daily for 15 consecutive days.
89115187|NCT02713737|Experimental|HFNC group|HFNC: Heated humidified high-flow nasal cannula.
89115188|NCT02713737|Active Comparator|NIV group|NIV: Noninvasive ventilation.
89115189|NCT00805480|Experimental|AIN457 3 mg/kg|Participants randomized to this arm received AIN457 3 mg/kg on day 1, and then matching placebo on days 15 and 29.
89115190|NCT00805480|Experimental|AIN457 10 mg/kg|Participants randomized to this arm received AIN457 10 mg/kg on day 1, and then matching placebo on days 15 and 29.
89115191|NCT00805480|Experimental|AIN457 10 mg/kg x3|Participants randomized to this arm received AIN457 3 mg/kg on days 1, 15 and 29.
89115192|NCT00805480|Placebo Comparator|Placebo|Participants randomized to this arm received matching placebo to AIN457 on days 1, 15 and 29
89115193|NCT02713815|Sham Comparator|control group|sham repetitive transcranial magnetic stimulation (rTMS) of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
89115194|NCT02713815|Active Comparator|rTMS group|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
89115195|NCT02777853|Experimental|Active (green) tea|Tea to be ingested 3 times per day for 7 days.
89115196|NCT02777853|Placebo Comparator|Placebo tea|Tea to be ingested 3 times per day for 7 days.
89115197|NCT02713581||Women with proximal VTE|"Patients will correspond to cases of proximal venous thromboembolism. They will be recruited during consultations conducted for the chronic management of a history of proximal venous thromboembolism or thrombophilia following a recent history of proximal venous thromboembolism. Venous thromboembolism, outside of acute phase episodes, has good symptom stability over time; no difference is to be expected between patients with a chronic history of proximal venous thromboembolism and new patients coming in for a checkup. Note that these patients may or may not have a history of placental vascular disease.~Intervention: Blood sampling"
89115198|NCT02713581||Women with >1 healthy pregnancy|"This populations is composed of healthy, female, adult volunteers (<50 years in age) that have had at least 1 healthy pregnancy.~Intervention: Blood sampling"
89115199|NCT05030103|Active Comparator|Glasses|The participants are asked to wear reading glasses during near-work. The reading glasses have a lenspower of +2.0 diopters.
89115200|NCT05030103|No Intervention|Control|Age matched children and adolescents, no intervention.
89115201|NCT00729937|Experimental|TMP/SMX vs. Placebo|Subjects with an acute uncomplicated cutaneous abscess will be randomized to receive either Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or 4 placebo pills (twice per day).
89115202|NCT00729937|Experimental|TMP/SMX vs. Clindamycin|Subjects with an acute uncomplicated wound infection will be randomized to receive Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day, with alternating 1 identical placebo pill, twice per day) or clindamycin (300 mg, four times per day, with 3 placebo pills on alternating doses).
89115203|NCT00729937|Experimental|Cephalexin and TMP/SMX vs. Cephalexin|Subjects with acute uncomplicated cellulitis will be randomized to receive cephalexin (500 mg, four times per day) and Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or cephalexin (500 mg, four times per day) and placebo (4 pills, twice per day).
89115204|NCT02713347|Experimental|ADAPT Intervention|"The intervention includes 3 components:~nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist.~The nurse and social worker visits are in-person or by phone."
89115205|NCT02713347|No Intervention|Enhanced usual care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referrals to and ongoing care from cardiology, pulmonary, palliative care, or mental health. They will also have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency. Patients' providers will be given the results of baseline depression surveys if they screen positive for depression, and patients will be given an information sheet that outlines self-care for CHF or COPD.
89115206|NCT04981366|No Intervention|Control group (CTRL)|Patients allocated to this arm will not receive any intervention.
89115207|NCT04981366|Experimental|Caloric Restriction associated to exercise training plus protein supplementation (CREX+PTN)|Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus protein supplementation.
89115208|NCT04981366|Placebo Comparator|Caloric Restriction associated to exercise training plus isocaloric placebo (CREX+PLA)|Patients allocated to this arm will be submitted to caloric restriction associated with exercise training program plus isocaloric placebo.
89115209|NCT02609620|Experimental|Treatment|In the treatment group: The LunGuard Peristaltic Feeding Tube (PFT) will be positioned in the ICU and positioning will be verified by X-ray. Nutritional formula will be fed into the stomach via the feeding lumen of the PFT
89115210|NCT02609620|Active Comparator|Control|Patients in the control group will have a Convatec Levin Duodenal Tube inserted according to standard procedure, which is considered the gold standard.
89115211|NCT02713503||Healthy Drivers|Driving Observation and VisionCoach
89115212|NCT00611091|Experimental|I|Intervention Group - (receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
89115213|NCT00611091|No Intervention|C|Control Group - (do not receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
89115214|NCT05755516|Experimental|experimental group|Self-expanding Intracranial Stent (Tonbridge)
89115215|NCT05755516|Active Comparator|control group|LVIS and LVIS Jr. (MicroVention)
89115216|NCT00913900|Active Comparator|Autologous Stem cells (CD133+)|Intramuscular injection
89115217|NCT00913900|Placebo Comparator|Control|Intramuscular Injection
89115218|NCT00729859|Experimental|Group 1|Acyline 300 µg/kg injections every two weeks (2 doses) + placebo (no active ingredients) gel daily for 28 days + oral placebo pill daily for 28 days
89115219|NCT00729859|Experimental|Group 2|Acyline 300 µg/kg injections every two weeks (2 doses) + Testosterone gel 100 mg daily for 28 days + oral placebo pill daily for 28 days
89115220|NCT00729859|Experimental|Group 3|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
89115221|NCT00810394|Experimental|Sorafenib|Dose Re-Escalation Following a Dose Reduction
89115222|NCT00736333||Pegylated Liposomal Doxorubicin|Subjects with metastatic breast cancer
89115223|NCT02608840|Experimental|MCI auditory stimulation|MCI patients receiving auditory stimulation during sleep (crossover arm 1)
89115224|NCT02608840|Sham Comparator|MCI sham stimulation|Sham intervention: MCI patients sleeping with headphones but sounds not played (crossover arm 2)
89115225|NCT02608840|Experimental|Older adult auditory stimulation|healthy older adults receiving auditory stimulation during sleep (crossover arm 1)
89115226|NCT02608840|Sham Comparator|older adult sham stimulation|Sham intervention: healthy older adults sleeping with headphones but sounds not played (crossover arm 2)
89115227|NCT03929302|No Intervention|Brain Energy Metabolism and Sleep on cognition|In the phase-1 of the study, the investigator will be investigating the basic science of the relationship of sleep abnormalities, genes, brain energy metabolites variables with cognitive performance in three cohorts: cognitively normal adults, mild cognitive impairment, and Alzheimer's disease between the age of 55-85 years.
89115228|NCT03929302|Experimental|Dental Intervention to improve sleep and cognition|To investigate if MyTAP oral airway management with mouth shield will improve sleep and cognition in three cohorts: cognitively healthy adults, mild cognitive impairment, and Alzheimer's disease between the age of 55-85 years.
89115229|NCT00736255|Experimental|Vyvanse and transdermal nicotine patch|The first group will receive LDX/SPD489 titrated up to 70 mg qd for 4 weeks after the identified quit date. Subjects will continue to receive NRT 21 mg at week 1 post quit date, then 14mg at week 2 post quit date and 7 at weeks 3 and 4 post quit date.
89115230|NCT00736255|Placebo Comparator|Placebo and transdermal nicotine patch|The second group will receive matching placebo and NRT after the quit date.
89115231|NCT03920254|Experimental|Active Treatment TD-1473 with Dose A|Oral daily dose of TD-1473 for up to 156 weeks
89115232|NCT03920254|Experimental|Active Treatment TD-1473 with Dose B|Oral daily dose of TD-1473 for up to 156 weeks
89115233|NCT03920254|Experimental|Active Treatment TD-1473 with Dose C|Oral daily dose of TD-1473 for up to 156 weeks
89115234|NCT04087993|Experimental|Polyglucoferron|once intravenously, dosing according to Hb-levels and body weight, 500 - 2000 mg
89115235|NCT04087993|Active Comparator|Ferric Carboxymaltose|Once intravenously (a second administration is allowed), dosing according to Hb-levels and body weight (500 - 2000 mg, max. single dose of 1000 mg)
89115236|NCT04087993|Active Comparator|Ferrous sulfate|capsules, orally, dosing 50 mg - 200 mg (50 mg: 1 capsule in total, 200 mg: 4 capsules in total, taken as 2 capsules twice daily), duration of treatment 28 days
89115237|NCT00917683||1|Autistic patients.
89115238|NCT00917683||2|Matched controls
89115239|NCT02593357|Experimental|COPD patients|measure of endothelial function with EndoPAT® in COPD patients
89115240|NCT05754814||Controls|Healthy participants
89115241|NCT05754814||Cases|Patients with malignant lymph nodes on the neck
89115242|NCT00729469|Experimental|Ospemifene 60 mg/day and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
89115243|NCT00729469|Placebo Comparator|Placebo and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
89115244|NCT00742183|Experimental|Mepilex® Ag|"Mepilex® Ag consists of a Safetac® soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film. Mepilex® Ag is an antimicrobial soft silicone foam dressing that absorbs exudate and maintains a moist wound environment.~Mepilex® Ag contains silver sulphate that releases silver ions to inactivate a wide range of wound related pathogens (bacteria and fungi), shown in vitro. By reducing the number of microorganisms, Mepilex® Ag may also reduce odour."
89115245|NCT00742183|Active Comparator|Silvadene® Cream 1%|Silvadene® Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second-and third-degree burns.
89115246|NCT00808444|Experimental|Synflorix Clinical Lot & Infanrix Group|Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
89115247|NCT00808444|Experimental|Synflorix Commercial Lot Infanrix Group|Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
89115248|NCT05752084||group 1|the group that develops Nis during the study
89115249|NCT05752084||group 2|the group doesn't develop NIs
89115250|NCT00914134|Experimental|Levodopa Infusion|Patients with advanced Parkinson's disease and motor fluctuations that cannot be adequately controlled with oral medication.
89115251|NCT04952896||Group of patients with pigmented villonodular synovitis|Diagnosis confirmed by arthroscopic pathological biopsy.
89115252|NCT04952896||Group of patients with rheumatoid arthritis|Diagnosis determined by clinical history, laboratory tests and arthroscopic pathology biopsy.
89115253|NCT04952896||Group of patients with gout|Diagnosis was determined by laboratory tests, energy spectrum imaging and arthroscopic pathology biopsy.
89115254|NCT05754736|Experimental|Ametinib combined with bevacizumab|Ametinib 110 mg po qd bevacizumab 15mg/kg ivdrip q3w
89115255|NCT04946812|Experimental|Intervention group|The velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%. While the speed of the treadmill will not change throughout the study, the duration of the training will increase each week. In the first week, the SBTM training will take place for 10 minutes. There will be a 5-minute rest period, and the split-belt conditions will continue for another 10 minutes of training (total training time= 20 minutes).
89115256|NCT04946812|Active Comparator|Control group|"The subject will continue to walk under tied-belt conditions adjusted to the over-ground walking speed. In the first week, the treadmill training will be for 10 minutes. They will get a 5-minute break, similar to the intervention group, and continue for another 10 minutes under tied-belt conditions.~The duration of each session will increase by 8 minutes every week. For example, in week 1, the treadmill training will be for a total of 20 minutes; in week 2, for 28 minutes; in week 3, for 36 minutes, and so forth, until it gets to 60 minutes by week 6. The rest period will remain at 5 minutes each session, and will always take place at the halfway mark. All 3 sessions in the week will have the same duration of training.~If the subject cannot tolerate the velocity or duration of the session, the protocol will be adjusted to most recently tolerated session (and will be recorded for further interpretation and analysis)."
89115257|NCT00742027|Experimental|Panobinostat|Participants received panobinostat 40 mg, capsules, orally, thrice every week (i.e. days 1, 3 and 5), in each cycle of 21 days until unacceptable toxicity, disease progression, start of new anti-cancer therapy or withdrawal of consent (up to approximately 48 months).
89115258|NCT03996369|Experimental|Etrasimod 2 mg|
89115259|NCT03996369|Placebo Comparator|Placebo|
89115260|NCT03844282||CArBON (baseline)|The RESCUE-RACER programme is formed of two studies; baseline (CArBON) and one post-injury (CARS). At baseline the larger CArBON study involves completion of a thorough single baseline neuroscientific assessment of healthy motorsport competitors including clinical, neuropsychological, neurocognitive, biomarker and vestibulo-ocular assessments, in addition to MRI of the brain.
89115261|NCT03844282||CARS (exposure to a potentially concussive event)|The RESCUE-RACER programme has a single post-injury study; after involvement in a potentially concussive event sustained during motorsport, CARS serially repeats the CArBON assessment battery in the immediate post-concussion recovery period. CARS participants will under-go post-exposure neuroscientific assessments immediately after injury and then at one, two and three weeks post-injury. If symptoms persist beyond this time, a further two assessments at monthly intervals will be offered.
89115262|NCT05750368||women undergoing epigastric hernia repair|all women who have undergone epigastric hernia repair open or laparoscopic in Denmark during af 4-year period from January 1st, 2018, to Dec 31st, 2021.
89115263|NCT03790852|Experimental|KSI-301 2.5 mg|KSI-301 2.5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
89115264|NCT03790852|Experimental|KSI-301 5 mg|KSI-301 5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
89115265|NCT02609698|Experimental|Coroflex ISAR 3 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 3 months
89115266|NCT02609698|Active Comparator|Coroflex ISAR 6 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 6 months
89115267|NCT05750134||Moderately obese patients|Moderately obese patients undergoing endoscopic sleeve gastroplasty
89115268|NCT02713113|Active Comparator|group 1|patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
89115269|NCT02713113|Active Comparator|group II|patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
89115270|NCT02713113|Active Comparator|group III|patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
89115271|NCT05749822|Placebo Comparator|Placebo-UDCA|1 tablet/ day and UDCA 13-15mg/kg/day for 12 months
89115272|NCT05749822|Experimental|Fenofibrate-UDCA|Fenofibrate 200 mg/day and UDCA 13-15mg/kg/day for 12 months
89115273|NCT04226781|Active Comparator|ICG|Fluorescence imaging for blood Perfusion of the gastrointestinal tissue
89115274|NCT04226781|Experimental|HSI|Hyperspectralimaging for blood Perfusion of the gastrointestinal tissue
89115275|NCT05749744||Home-based cardiac telerehabilitation (interventional group)|Patients followed the cardiac rehabilitation program at home.
89115276|NCT05749744||Traditional centre-based cardiac rehabilitation (control group)|Patients participates in the cardiac rehabilitation program in hospital.
89115277|NCT02713191|Experimental|Dexmedetomidine|Dexmedetomidine + fentanyl before, and dexmedetomidine infusion during, procedure
89115278|NCT02713191|Active Comparator|Midazolam|Midazolam + fentanyl before, and matching saline infusion during, procedure
89115279|NCT00611169|Experimental|1|Aspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose
89115280|NCT00611169|No Intervention|2|Aspirin, clopidogrel, unfractionated heparin
89115281|NCT02608138||1|Urinary iodine will be measured at one point in time in school children aged 6-12. A sample of salt used at home and schools will be collected to estimate iodine levels.
89115282|NCT02777697||cancer patients|
89115283|NCT05749120|Experimental|Superficial temporal recipient vessels (group A)|Participants in whom superficial temporal vessels were used as the recipient vessels.
89115284|NCT05749120|Active Comparator|Cervical recipient vessels (group B)|Participants in whom cervical vessels were used as the recipient vessels.
89115285|NCT04226703||Study group|Patients over the age of 18 who underwent surgery in the ear, nose and throat department.
89115286|NCT04897048|Experimental|Oxygen|Supplemental oxygen will be applied via a mask during CPET
89115287|NCT04897048|Sham Comparator|Air|Sham ambient air will be applied via mask during CPET
89115288|NCT02713035|No Intervention|Usual|Receive standard medical therapy for eczema
89115289|NCT02713035|Experimental|Treatment|Receive standard medical therapy for eczema plus behavioral self help intervention
89115290|NCT02712957|Experimental|NEO6860|NEO6860 is provided as a powder in individual containers to be reconstituted as a suspension. In this arm patients will receive both NEO6860 and a placebo of naproxen.
89115291|NCT02712957|Placebo Comparator|Placebo|In this arm, patients will receive both placebo: oral liquid suspension (NEO6860 placebo) and capsule (naproxen placebo).
89232043|NCT05618808|Experimental|REGN9933|REGN9933 will be administered by intravenous (IV) infusion
89232044|NCT05618808|Active Comparator|Enoxaparin|Enoxaparin will be administered by subcutaneous (SC) administration
89232045|NCT05618808|Active Comparator|Apixaban|Apixaban will be administered orally twice a day
89232046|NCT05615012|Experimental|Part 1: Rosuvastatin + BMS-986322|
89232047|NCT05615012|Experimental|Part 2: Metformin + BMS-986322 + Glucose|
89232048|NCT05615012|Experimental|Part 3: Methotrexate + BMS-986322 + Leucovorin|
89232049|NCT05612724|Other|SARS-CoV-2 testing|There is only one arm in this study- the study is a non-randomized pilot. All the subjects will be tested for SARS CoV 2 viral Antigen as described.
89232050|NCT05602623|Experimental|770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nm|Eligible subjects will be randomized to wavelength sequence 770 +/- 9nm/ 830 +/- 15nm/ 900 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
88816393|NCT02405442|Experimental|Andecaliximab 150 mg Every 2 Weeks|Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
89232051|NCT05602623|Experimental|770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nm|Eligible subjects will be randomized to wavelength sequence 770 +/- 9nm/ 900 +/- 15nm/ 830 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
89115292|NCT02712957|Active Comparator|Naproxen|Naproxen is provided as over-encapsulated tablets using a commercially approved medication. In this arm patients will receive both naproxen and a placebo of NEO6860.
89115293|NCT05023083||diseased individuals|post CABG patients will be included in the study to fill the tool
89115294|NCT05023083||healthy individuals|20 healthy individual will be included to solve questionnaire
89115295|NCT05748652|Experimental|Digital CBT|digitally-delivered CBT for anxiety accessed via mobile app
89115296|NCT05748652|Active Comparator|Psychoeducation|psychoeducation delivered via digital written materials
89115297|NCT04025086||Study group|"44 patient undergoing spinal surgery in prone position at Gaspare Rodolico Presidium, in which the new Perioperative Goal Directed Therapy protocol has been used"
89115298|NCT04025086||Control group|44 patients who underwent spinal surgery in the period January 2016 - December 2017, in which was not used a Perioperative Goal Directed Therapy approach but a classical hemodynamic monitoring, according to the recommendations of good clinical practice and the international guidelines.
89115299|NCT04226625|Active Comparator|Propofol|Patients will receive Propofol as an intravenous (IV) agent, which is administered into a vein through an IV line as a continuous infusion.
89115300|NCT04226625|Active Comparator|Desflurane|Patients will receive Desflurane as a gas that is administered through an anesthesia machine.
89115301|NCT02777541|Other|Early enteral nutrition|3 hours after PEG implantation
89115302|NCT02777541|Other|Late enteral nutrition|8 hours after PEG implantation
89115303|NCT02777619|Placebo Comparator|Propofol and 0.0ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
89115304|NCT02777619|Experimental|Propofol and 0.4ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
89115305|NCT02777619|Experimental|Propofol and 0.6ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
89115306|NCT02777619|Experimental|Propofol and 0.8ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
89115307|NCT05747560|Placebo Comparator|Placebo|Participants in the Placebo will consume buckwheat at a dose of 500 mg, twice a day (morning and evening) for 6 months.
89115308|NCT05747560|Active Comparator|Astragalus extract|Participants in the Astragalus extract will take dietary supplement with astragalus extract at a dose of 450 mg, twice a day for the same duration.
89115309|NCT05747560|Experimental|Wolfiporia extract|Participants in the Wolfiporia extract will take dietary supplement with wolfiporia extract at a dose of 15 g, twice a day for the same duration.
89115310|NCT02777307|Experimental|Hemopatch Sealing Hemostat|
89115311|NCT02777307|No Intervention|No Hemopatch Sealing Hemostat|
89115312|NCT00636831|Placebo Comparator|cont|
89115313|NCT00636831|Active Comparator|intervention|
89115314|NCT04193631|Experimental|Pure Green Tablet|A water-soluble sublingual tablet that contains 5 mg of cannabidiol (CBD).
89115315|NCT04856631|Experimental|Experimental group|Toripalimab Injection (JS001) + Cetuximab
89115316|NCT00611481|Experimental|Tai Chi|
89115317|NCT00611481|Active Comparator|B. Strength training|
89115318|NCT00611481|Other|C. Low-Impact|
89115319|NCT00808210|Experimental|Ocrelizumab 200mg|Participants received two intravenous (IV) infusions of 200 mg ocrelizumab administered on Day 1 and Day 15 and placebo IV infliximab infusions administered on Day 1, Day 15, Week 6, and Week 14. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
89115320|NCT00808210|Active Comparator|Infliximab 5mg/kg|Participants received four IV infusions of 5 mg/kg infliximab administered on Day 1, Day 15, Week 6, and Week 14 and placebo ocrelizumab infusions administered on Day 1 and Day 15. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
89115321|NCT02712411|Experimental|Sequence 1|"T → R~T : HCP1303 R : HGP1201 + HIP1402"
89115322|NCT02712411|Experimental|Sequence 2|"R → T~T : HCP1303 R : HGP1201 + HIP1402"
89115323|NCT02777229|Experimental|Dolutegravir|Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
89115324|NCT02777229|Active Comparator|Efavirenz|Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD
89115325|NCT02712489||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-003"
89115326|NCT02606812|Experimental|Traditional-food|During the 3 months, a dish containing traditional food will be provided 5 days per week. The food will contain an average of 600 Kcal, ≤ 50 mg of cholesterol, ≥ 10 g of fiber, ≥ 130 g of vegetables, and ≤ de 200 mg of sodium. Each dish will be accompanied with 3 standard-sized corn tortillas.
89115327|NCT02606812|No Intervention|Control|Is the group who will intake the cafeteria fast food. The control group will receive habitually consumed fast food provided by the cafeteria of the campus at a similar caloric proportion.
89115328|NCT02712177||Coadministration B_RV246|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).
89115329|NCT02712177||Coadministration B_RV234|Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..
89115330|NCT02712177||Coadministration B_MMRV12|Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.
89232052|NCT05602623|Experimental|830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nm|Eligible subjects will be randomized to wavelength sequence 830 +/- 15nm/ 770 +/- 9nm/ 900 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
89232053|NCT05602623|Experimental|830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nm|Eligible subjects will be randomized to wavelength sequence 830 +/- 15nm/ 900 +/- 15nm/ 770 +/- 9nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
89232054|NCT05602623|Experimental|900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nm|Eligible subjects will be randomized to wavelength sequence 900 +/- 15nm/ 830 +/- 15nm/ 770 +/- 9nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
89232055|NCT05602623|Experimental|900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nm|Eligible subjects will be randomized to wavelength sequence 900 +/- 15nm/ 770 +/- 9nm/ 830 +/- 15nm. Within each wavelength, subjects will be further randomized to a pupil size sequence (3mm, 4mm, 6mm). Study endpoints will be measured at 3 different pupil sizes.
89232057|NCT05595642|Experimental|Astegolimab SC Q2W|Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W)
89232058|NCT05595642|Experimental|Astegolimab SC Q4W|Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving SC astegolimab Q4W.
89232059|NCT05595642|Placebo Comparator|Placebo SC Q2W|Participants will receive SC placebo Q2W
89232060|NCT05585320|Experimental|IMM-1-104 monotherapy (Treatment Group A)|IMM-1-104 monotherapy for first/second line pancreatic adenocarcinoma; first/second/third line melanoma; or second/third line non small cell lung cancer
89232061|NCT05585320|Experimental|IMM-1-104 in combination with mGnP (Treatment Group B)|IMM-1-104 in combination with modified gemcitabine and nab-paclitaxel (mGnP) for first line pancreatic adenocarcinoma
89232062|NCT05585320|Experimental|IMM-1-104 in combination with mFFX (Treatment Group C)|IMM-1-104 in combination with modified FOLFIRINOX (mFFX) for first line pancreatic adenocarcinoma
89232063|NCT05577416|Experimental|Safusidenib Erbumine (AB-218)|Part A: Peri-operative treatment (Phase 0); Part B: Post operative adjuvant therapy (phase 2)
89232064|NCT05574959|Experimental|investigational Lens Device|investigational IOL Model DEN00V
89232065|NCT05574959|Active Comparator|Control Lens Device|control IOL Model ZCB00/DCB00
89232066|NCT05572515|Experimental|Teclistamab|Participants will receive teclistamab monotherapy.
89115331|NCT02712177||Separate administration B246_RV357|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.
89115332|NCT02712177||Separate administration B12_MMRV13|Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.
89115333|NCT02712177||Routine vaccines only at 2, 3 and 4 months of age (RV234)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.
89115334|NCT02712177||Routine vaccines only at 2, 4 and 6 months of age.(RV246)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.
89115335|NCT00635037|Experimental|A|"G1 (n=15)received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~G2(n=15) was submitted to classical and trigger point acupuncture twice a week."
89115336|NCT02777151|Experimental|Cohort 1|REGN3470-3471-3479 dosing level 1 or placebo
89115337|NCT02777151|Experimental|Cohort 2|REGN3470-3471-3479 dosing level 2 or placebo
89115338|NCT02777151|Experimental|Cohort 3|REGN3470-3471-3479 dosing level 3 or placebo
89115339|NCT02777151|Experimental|Cohort 4|REGN3470-3471-3479 dosing level 4 or placebo
89115340|NCT02776995|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every 5 fraction of radiation, starting prior to the first radiation treatment, periodically, until the end of radiation therapy (a period of several weeks).
89115341|NCT02711865||MK-0646|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.
89115342|NCT02711865||Control|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.
89115343|NCT02712021|Experimental|Cerebral Palsy-Study group|The intervention consisted of wearing a lycra suit, with shoulder, trunk and pelvis coverage, for more than 4 hours per day for 6 months. The motor function assessments will be performed without the Lycra suit, whereas the static balance assessments were performed with and without the suit.
89115344|NCT02712021|Active Comparator|Cerebral Palsy-Control Group|Children with clinical characteristics similar to the study group; they will be assessed using the same protocol but with no use of lycra garments
89115345|NCT02711787|Experimental|Experimental group|Robotic device Gloreha (Gloreha, Idrogenet, Italy) and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
89115346|NCT02711787|Active Comparator|Control group|Physiotherapy, occupational therapy and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
89115347|NCT02776761|Experimental|Hantaan Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
89115348|NCT02776761|Experimental|Puumala Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
89115349|NCT02776761|Experimental|Hantaan/Puumala Vaccine|The HTNV and PUUV vaccine will be combined (equal volumes) before use: 1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
89115350|NCT00736099|Experimental|linagliptin 5 mg|open label
89115351|NCT00736099|Experimental|linagliptin 5 mg and pioglitazone 30 mg|open label
89115352|NCT00611637|Experimental|1|
89115353|NCT04188795|Experimental|Intervention|"Participants who met the criteria for inclusion in the study and volunteered to participate in the study were divided into experimental and control groups by block randomization method.~After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
89115354|NCT04188795|No Intervention|Control Group|After obtaining written informed consent, the Patient Information Form, Mini Nutritional Assessment- Short Form, Confusion Assessment Method, Barthel Index and Visual Analog Scale were applied to patients. Routine nursing care was applied to hip fracture patients in the control group. Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day.
89115355|NCT02711397||Celiac patients|Celiac patients following a GFD for at least one year prior to the inclusion in the study.
89115356|NCT02711397||Positive controls|Healthy children and adults on an unrestricted gluten containing diet.
89115357|NCT02711397||Negative controls|Healthy infants who were exclusively fed with infant formula specifically labelled as gluten-free.
89115358|NCT02711631|No Intervention|Control: Standard therapy|Participants in this arm of the study will receive standard therapy.
89115359|NCT02711631|Experimental|MedBIKE|Participants in this arm will be using the new MedBIKE system as their method of rehabilitation.
89115360|NCT02711085||Acute trauma|Those within the first 3 weeks of a non-catastrophic injury affecting the musculoskeletal system, including but not limited to whiplash or other road-traffic collisions, sports injuries, work-related injuries, sprains, strains, slips and falls and non-displaced fractures that don't require surgical correction.
89115361|NCT02711319|Active Comparator|active (real) rTMS (ACTIVE GROUP)|"The patients were randomly distributed in two study groups: real or sham rTMS group.~For real rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes."
89115362|NCT02711319|Sham Comparator|sham rTMS (SHAM GROUP)|For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
89115363|NCT02693613|Experimental|Group 1|Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)
89115364|NCT02693613|Experimental|Group 2|Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)
89115365|NCT04087837|Experimental|bougie group|The bougie group: The end of the endotracheal tube was guided to the glottis using the endotracheal tube in the bougie mode under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
89115366|NCT04087837|Experimental|Nasogastric(NG) tube group|NG tube group: The end of the endotracheal tube is guided to the glottis by using the endotracheal tube in the nasogastric tube under the direct view of the electronic imaging laryngoscope. The Magill Forceps is used to assist the tip of the endotracheal tube in guiding the glottis.
89115367|NCT04087837|No Intervention|control group|Control group: The general anesthesia method of placing the endotracheal tube through the nasal cavity is used to guide the tip of the endotracheal tube to the glottis under the direct view of the electronic imaging laryngoscope.
89115368|NCT02711241|Active Comparator|Dipyrone|
89115369|NCT02711241|Active Comparator|Papaverine|
89115370|NCT02594059|Experimental|Pulmonary idiopathic fibrosis|Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
89115371|NCT02711163|Experimental|Extensively hydrolyzed formula|Feeding extensively hydrolyzed formula
89115372|NCT02711163|Placebo Comparator|Amino acid formula|Feeding amino acid formula
89115373|NCT02711007|Experimental|apatinib|apatinib 750mg tablet or 500mg tablet by mouth, Qd half an hour after dinner
89115374|NCT04226235|Experimental|1-hour vinyasa yoga session|One hour of vinyasa yoga was completed by all participants while following a DVD.
89115375|NCT02776839|Other|Mobile Sensing|This phase of the study is designed to develop the app. due to algorithms the app should lern to detect depressive symptoms
89115376|NCT04193241|Active Comparator|Conventional purse-string suture closure|A common-place conventional method of closure of chest tube or thoracostomy wound using a Prolene 1 purse-string suture (also known as U-suturing), at the time of chest tube removal.
89115377|NCT04193241|Experimental|Suture-less occlusive-absorbent dressing closure|Unconventional method of closing chest tube or thoracostomy wounds using Occlusive adhesive-absorbent dressing material (Primapore*) application i.e. Un-reapproximated wound edges, at time of chest tube removal
89115378|NCT02710773|Experimental|Backward Walking Treadmill Training|The subjects will perform a backward walking training on treadmill device
89115379|NCT02710773|Active Comparator|Treadmill training|The subjects will perform a walking training on treadmill device
89115380|NCT04226469||Subjects require canine retraction|Subjects require canine retraction during orthodontic tooth movement and their gingival crevicular fluid is collected during the tooth movement. The control is the initial timepoint.
89115381|NCT02710695|Active Comparator|Control|This group will receive a 10 minute discussion
89115382|NCT02710695|Active Comparator|Intervention|This group will receive a 10 minute standardized discussion
89115383|NCT02710929||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
89115384|NCT02710929||TD group|Typically development controls without lifetime diagnosis with ADHD
89115385|NCT02710539|Active Comparator|Free combination|Perindopril 10 mg/daily, indapamide 2,5 mg/daily, and amlodipine 10 mg/daily will be given according to a free combination strategy
89115386|NCT02710539|Active Comparator|Tripliam|fixed combination of perindopril 10 mg/daily, indapamide 2,5 mg/daily, amlodipine 10 mg/daily
89115387|NCT02710461|Experimental|Subjects with abdominal obesity|Intervention with grape pomace and pomegranate pomace
89115388|NCT00735709|Experimental|Vortioxetine 1 mg|Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks.
89115389|NCT00735709|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks.
89115390|NCT00735709|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks.
89115391|NCT00735709|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
89115392|NCT00635115|Experimental|1|
89115393|NCT00635115|Active Comparator|2|
89115394|NCT02776527|Experimental|A group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox,and taking Apatinib 500mg/qd orally, 28 days as a cycle, till disease progresses.
89115395|NCT02776527|No Intervention|B group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox
89115396|NCT02776449||Normal Tension Glaucoma|Patients with manifest normal tension glaucoma
89115397|NCT02596165|Experimental|Pulse wave analysis measurement|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
89115398|NCT04088617|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
89115399|NCT04088617|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
89115400|NCT02708589|Active Comparator|probiotic|the probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, and Lactobacillus bulgaricus) and prebiotic (fructooligosaccharide).
89115401|NCT02708589|Placebo Comparator|Placebo|Placebo capsules have identical appearance to probiotic capsules and contain Maltodextrin.
89115402|NCT02611089||Radial dysplasia patients|Recruited participants will have 2-3 small tissue biopsy samples taken during 1-2 of their planned reconstructive surgical procedures for radial dysplasia, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
89115403|NCT02611089||Control patients|Recruited participants will have 2-3 small tissue biopsy samples taken during their planned reconstructive surgery for hand trauma, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
89115404|NCT00729157|Experimental|Treatment (ziv-aflibercept and fludeoxyglucose F 18)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients experiencing clear clinical benefit with aflibercept may continue treatment beyond 12 months, at the discretion of the study sponsor. Patients undergo FDG-PET scans at baseline and after 8 weeks of study therapy to evaluate changes in FDG avidity on FDG-PET scan. Blood samples are obtained at baseline and periodically during study for laboratory correlative studies. Samples are examined for pretreatment serum VEGF concentration, thyroglobulin levels (when elevated), serum pharmacokinetics of aflibercept by ELISA, and anti-aflibercept antibodies.
89115405|NCT02710305|Active Comparator|Group A|oral hyoscine butyl bromide tablets plus lidocaine cream
89115406|NCT02710305|Placebo Comparator|Group B|oral placebo tablets plus placebo cream
89115407|NCT02708511|Experimental|Diagnostic (Cu 64 DOTA-B-Fab)|Patients receive copper Cu 64-DOTA-B-Fab IV followed by PET/CT 60 minutes post-injection and 24 hours post-injection
89115408|NCT00728689|Active Comparator|Group ST-246 Form I (followed by Form V)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
89115409|NCT00728689|Active Comparator|Group ST-246 Form V (followed by Form I)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
89115410|NCT02596243|Experimental|GX-188E|GX-188E + EP
89115411|NCT02596243|Placebo Comparator|placebo|Placebo + EP
89115412|NCT02717793|Experimental|isometric muscle strength|"isometric muscle strength was measured with a digital hand-held dynamometer. The digital hand-held dynamometer was held by the therapist against the flexor aspect of the distal forearm of the subject, on the wrist joint. Subject was asked to maintain the position and a break test was done with progressive loading of 5 seconds given by the tester. The peak isometric strength was recorded by a second tester at the end of 5 seconds. A standardised instructions and verbal encouragement was given to the subject for motivation. Subject as well as the tester was blinded to the values recorded on the digital hand-held dynamometer. An average of three measurements (with a rest period of 4 minutes in between each trial session) was recorded for the analysis. After each trial session, the rate of perceived exertion (RPE) was asked to the subject using the 1-10 Borg rating of perceived exertion scale"
89115413|NCT02717793|Experimental|1RM measurement of muscle strength|1RM measurement was done using the Brzycki 1RM prediction equation. In first testing session, subject was instructed to perform a general warm up for 5 minutes. Thereafter, the subject was asked to perform 10 repetitions of the movement using the amount of resistance that the subject felt she will be able to lift for only less than 10 times. The selection of the weight is made based on a list of weights provided (1kg to 10kg). When the subject performed the movement for 10 times or more, then the resistance was increased 1kg at a time, until the subject can perform only 9 or fewer repetitions of the movement correctly throughout the range of motion. A 3 minutes rest period was given to the subject before the new attempt was done with the increased weight. A standardized verbal encouragement was provided for motivation
89115414|NCT02710227||liver cirrhosis|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
89115415|NCT02710227||control|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
89115416|NCT02594137|Experimental|Without Watertight Duraplasty|"After standard craniectomy (12x15cm) and dural opening, the intervention, which is to not perform watertight duraplasty is carried out. The exposed brain parenchyma is covered with Surgicel. Usual closure is then performed."
89115417|NCT02594137|No Intervention|With Watertight Duraplasty|After standard craniectomy (12x15cm) and dural opening, watertight duraplasty with pericranium or an artificial graft is performed. Usual closure is then performed. This kind of duraplasty is performed by most neurosurgeons and this group will be used as a control.
89115418|NCT02710149|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD20-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
89115419|NCT02592811|Active Comparator|ESLBD|"Endoscopic Sphincterotomy plus Large Balloon Dilatation +/- lithotripsy~ERCP with deep cancellation of BDS~Endoscopic large sphincterotomy~Large Balloon Dilatation of Oddi Sphincter: with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)~Stone extraction with dormia basket or extraction balloon~Mechanical Lithotripsy if needed"
89115420|NCT02592811|Active Comparator|CONV|"Conventional treatment associating Endoscopic Sphincterotomy +/- Mechanical Lithotripsy (ES+/-LM)~ERCP with deep cancellation of BDS~Endoscopic large sphincterotomy~Stone extraction with dormia basket or extraction balloon~Mechanical Lithotripsy if needed"
89115421|NCT02717091|Experimental|FOLFIRINOX|4 course of FILFIRINOX before surgery
89115422|NCT02717091|Experimental|GEM + nab-PTX|2 course of GEM + nab-PTX before surgery
89115423|NCT02592733||Historical Cohort|Patients who have undergone infrarenal endovascular repair at each centre in the past.
89115424|NCT02592733||Prospective Cohort|Patients undergoing infrarenal endovascular repair in the study using CYDAR in addition to the local angiography equipment.
89115425|NCT02593279|Active Comparator|asthma with proximal or diffuse lung damage|
89115426|NCT02593279|Experimental|asthma with small airway prevailing damage|
89115427|NCT02592889|No Intervention|CONTROL|OPTIMIZED MEDICAL TREATMENT
89115428|NCT02592889|Active Comparator|DEVICE|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM + OPTIMIZED MEDICAL TREATMENT
89115429|NCT00727909|Experimental|Hearing Aid Treatments|"Hearing aid treatments:~TC (Traditional Custom), RITA (Receiver-in-the Aid), and RITE (Receiver-in the-Ear)"
89115430|NCT02708043|Other|F-LMA group|LMA were placed to 814 patients for adenoidectomy surgery. Researchers evaluated flexible laryngeal mask airway use during pediatric adenoidectomies in terms of patient safety, comfort, complications and surgeon satisfaction levels.
89115431|NCT00726895|Experimental|Quinine Sulfate Capsules 1 x 324 mg Dose|Quinine Sulfate 1 x 324 mg capsule dose.
89115432|NCT00726895|Experimental|Quinine Sulfate Capsules 2 x 324 mg Dose|Quinine Sulfate 2 x 324 mg capsules dose.
89115433|NCT02593201|Experimental|Treatment|One extra week of antibiotic therapy
89115434|NCT02593201|Sham Comparator|Control|No extra antibiotics
89115435|NCT02707809|No Intervention|Control|Routine anesthesia care for kidney transplant
89115436|NCT02707809|Experimental|Dexmedetomidine|Routine anesthesia care for kidney transplant and perioperative intravenous infusion of dexmedetomidine
89115437|NCT00585325|Experimental|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
89115438|NCT00585325|Placebo Comparator|Instilled Placebo (0.9% Normal Saline)|receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
89115439|NCT02717325|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application fo test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
89115440|NCT02717169|Other|Biometrical Tracker|The participants are equipped with an wrist watch. The activity tracker measures biometrical information like, steps, sleep duration and heart rate.
89115441|NCT02717247|Experimental|Active tRNS treatment|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsalateral prefrontal cortex (F4).~100 (Hertz)Hz-650Hz, 2milliampere(mA), 30min, twice daily, 5 days"
89115442|NCT02717247|Sham Comparator|Placebo tRNS treatment|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
89115443|NCT02514525|Other|CryoBalloon Ablation System|Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.
89115444|NCT04164537||Latina adolescents and parents|Latina adolescent young women experiencing depression and their parents will be recruited from community and primary care settings for one-time individual interviews.
89115445|NCT04164537||Healthcare providers|Primary care and mental health providers who commonly work with Latina adolescent patients will be recruited for focus groups from an integrated primary care clinic.
89115446|NCT02717013|Placebo Comparator|Placebo Diet Restriction|
89115447|NCT02717013|Placebo Comparator|Placebo No Diet Restriction|
89115448|NCT02717013|Active Comparator|HMB Diet Restriction|
89115449|NCT02717013|Active Comparator|HMB No Diet Restriction|
89115450|NCT02716857|Experimental|Oxycodone extended-release|Egalet ADER oxycodone tablet
89115451|NCT02716857|Placebo Comparator|Placebo of Oxycodone extended-release|Egalet ADER oxycodone placebo tablet
89115452|NCT02716935|Experimental|Fortified lipid based nutrient supplement|lipid based nutrient supplement (Nutributter) fortified with fructo-oligosaccharides and inulin
89115453|NCT02716935|Active Comparator|lipid based nutrient supplement|lipid based nutrient supplement (Nutributter)
89115454|NCT02716935|No Intervention|non intervention group|This group will not be supplemented
89115455|NCT02716623|Experimental|CR Diet and Exercise|Participants will be asked to follow specific diet intervention and exercise regimen.
89115456|NCT00636753||1|schizophrenic patients
89115457|NCT00636753||2|controls
89115458|NCT02709993|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
89115459|NCT02709915|Experimental|Breakfast Diet (Bdiet)|The Bdiet will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
89115460|NCT02709915|Active Comparator|6 small meals diet (6Mdiet)|The 6Mdiet will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% each of the three snacks.
89115461|NCT02716545|Experimental|Endoscopic Intervention Group|Endoscopic therapy
89115462|NCT02709837|Active Comparator|Poorly cooked meat-Good chewing|Meat cooked 10min at 75°C, chewing without appliance
89115463|NCT02709837|Active Comparator|Highly cooked meat-Good chewing|Meat cooked 45min at 90°C, chewing without appliance
89115464|NCT02709837|Active Comparator|Poorly cooked meat-Bad chewing|Meat cooked 10min at 75°C, chewing with appliance
89115465|NCT02709837|Active Comparator|Highly cooked meat-Bad chewing|Meat cooked 45min at 90°C, chewing with appliance
89115466|NCT02709759|Active Comparator|MI|Motivational interviewing focused on reducing alcohol use, delivered by videoconferencing.
89115467|NCT02709759|Active Comparator|BA|Brief Advice to reduce drinking delivered by videoconferencing
89115468|NCT02709759|Active Comparator|MI + ITM|Motivational intervention to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
89115469|NCT02709759|Active Comparator|BA + ITM|Brief Advice to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
89115470|NCT02709759|Active Comparator|MI + ITM + EI|Participants in this arm receive MI delivered by videoconferencing and ITM over 9 months rather than 1
89115471|NCT02709759|Active Comparator|BA + ITM + EI|Participants in this arm receive BA delivered by videoconferencing and ITM over 9 months rather than 1
89115472|NCT02709759|Active Comparator|BA + EI|Participants in this arm receive BA delivered by videoconferencing over 9 months rather than 1
89115473|NCT02709759|Active Comparator|MI + EI|Participants in this arm receive MI delivered by videoconferencing over 9 months rather than 1
89115474|NCT02709681||SCD patients|Patients followed in 32 Italian Centers.
89115475|NCT00726661||Chemotherapy Cohort|Eligible participants with HER2-negative disease who received their first cytotoxic chemotherapy and/or targeted therapy were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
89232067|NCT05572515|Experimental|Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)|Participants will receive either PVd or Kd based on principal investigator's choice.
89115476|NCT00726661||Hormonal Therapy Cohort|Eligible participants with hormone receptor positive disease who received their first hormonal therapy for advanced disease were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
89115477|NCT00917761|Experimental|Entecavir and peginterferon (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
89115478|NCT00917761|Experimental|Peginterferon (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
89115479|NCT00917761|Active Comparator|Peginterferon (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
89115480|NCT02709603|Experimental|Group A|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
89115481|NCT02709603|Placebo Comparator|Group B|oral 2 tablets (PLACEBO) 30 minutes before the procedure
89115482|NCT05162469|Experimental|SHR-1909 monotherapy|
89115483|NCT02593045|Experimental|IPH4102|
89115484|NCT05156775|No Intervention|Intravenous analgesia group|35 Patients will receive intravenous morphine (mg) analgesia only.
89115485|NCT05156775|Experimental|Serratus Plane Block (SPB) group|35 Patients will receive ipsilateral serratus plane block using 30 ml bupivacaine 0.25% at the level of the 5th rib.
89115486|NCT05156775|Experimental|Rhomboid intercostal nerve block (RIB) group|35 Patients will receive ipsilateral rhomboid intercostal nerve block using 30 ml bupivacaine 0.25%.
89115487|NCT00611793|Experimental|1|PTK787/ZK222584 and Bevacizumab
89115488|NCT02709213||Patients with CT-diagnosed acute colitis|Patients with symptomatic colitis (fever and/or pain and/or diarrhea) proven by computed tomography
89115489|NCT03821337|Experimental|rTMS|Participants will receive 18 sessions of active rTMS delivered at 120% rMT.
89115490|NCT03821337|Placebo Comparator|Sham TMS|Participants will receive 18 sessions of sham rTMS delivered through an inactive coil.
89115491|NCT00611871|Experimental|1|Propranolol following traumatic memory
89115492|NCT00611871|Active Comparator|2|Propranolol following neutral memory
89115493|NCT00611871|Placebo Comparator|3|Placebo following traumatic memory
89115494|NCT02709447|Experimental|Date SMART|Group based prevention
89115495|NCT02709447|Active Comparator|Health Promotion|Group based prevention
89115496|NCT02709291|Other|Community Health Workers|Community health workers will complete a 5-day interventionist training to deliver a behavioral parent training intervention.
89115497|NCT02709291|Other|Parent-Child Dyads|Parents and children will receive a behavioral parent training intervention delivered by community health workers.
89115498|NCT02693301|No Intervention|Control|Children who follow the recommendations of their pneumologist
89115499|NCT02693301|Experimental|Experimental|A two month intervention program 3 days/week will be carried out. The session will last ~60 minutes, and will consist of a combined training (aerobic training ~30 min, and strength ~30 min of 7 whole body exercises (3 sets x 10 repetitions).The load was gradually increased as the strength of each child improved, i.e., from 40% of five-repetition maximum (5RM) lifting ability at the start of the program to 60% of 5RM at the end of the program. All sessions were individually supervised by trained professionals.
89115500|NCT02709525|Experimental|hyaluronic acid|Immediately after the extractions, one socket was randomly filled with 1% hyaluronic acid gel.
89115501|NCT02709525|Placebo Comparator|Blood clot|Immediately after the extractions, the other side socket was naturally filled with blood clot.
89115502|NCT05087589|Experimental|tofacitinib|Tofacitinib 5mg was taken orally twice a day for 6 months
89115503|NCT00741091|Experimental|Registry|Registry to gather data on early clinical outcomes for the Carotid WALLSTENT Endoprosthesis and FilterWire EZ System in routine clinical practice.
89115504|NCT02708979|Active Comparator|University Exam Period|This visit takes place the week before an exam at the university assuming that this will induce a stress response. Measurements (see description elsewhere) are being taken within 1-2 weeks prior to an university exam.
89115505|NCT02708979|Placebo Comparator|University Non-exam Period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period. Measurements (see description elsewhere) are being taken in a control-period without exams (at least 4 weeks after and 4 weeks prior to an exam)
89115506|NCT00611949|Active Comparator|1 Geranium Oil|
89115507|NCT00611949|Active Comparator|2 Geramium Oil|
89115508|NCT05066451|Experimental|%5 dextrose prolotherapy|A total of 3 sessions of prolotherapy solution containing 5% dextrose will be applied at the beginning, 3rd week, and the 6th week.
89115509|NCT05066451|Active Comparator|%15 dextrose prolotherapy|A total of 3 sessions of prolotherapy solution containing 15% dextrose will be applied at the beginning, 3rd week, and the 6th week.
89115510|NCT02709057|Active Comparator|Life-style intervention 1|Life-style intervention in participants with low genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
89232068|NCT05567848|Experimental|repetitive Transcranial Magnetic Stimulation (rTMS)|repetitive Transcranial Magnetic Stimulation (rTMS) in a iTBS pattern to the cerebellum at 100% of resting motor threshold
89290606|NCT03927534|Experimental|Experimental|Mindful Eating program is apply face to face 7 sessions of 120 minutes/session. ME is apply in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
89115511|NCT02709057|Active Comparator|Life-style intervention 2|Life-style intervention in participants with high genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
89115512|NCT02709057|No Intervention|Control 1|No intervention in participants with low genetic risk score
89115513|NCT02709057|No Intervention|Control 2|No intervention in participants with high genetic risk score
89115514|NCT04999371|No Intervention|Control without intervention|No information or cash incentives are provided to the participants in the control group, but it is also necessary to collect the information of the participants in the control group and perform an alcohol test. Therefore, the project team will provide a certain degree of compensation for participants in the control group (participants of the intervention group also will receive this part of compensation).
89115515|NCT04999371|Active Comparator|Mobile-based information intervention|The participants in this group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.
89115516|NCT04999371|Active Comparator|Mobile-based information intervention with performance-based incentive|The participants in this group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
89115517|NCT04087447||Thyroidectomy group|patient undergoing thyroidectomy for simple nodular goiter
89115518|NCT02708901|Active Comparator|GI Vivomixx®|25 children with GI symptoms
89115519|NCT02708901|Placebo Comparator|GI Placebo|25 children with GI symptoms
89115520|NCT02708901|Active Comparator|NGI Vivomixx®|25 children without GI symptoms
89115521|NCT02708901|Placebo Comparator|NGI placebo|25 children without GI symptoms
89115522|NCT04087525|Experimental|Sequence 1|Period 1 : Fasted state + HIP1701, Period 2 : Fasted state + HGP1809
89115523|NCT04087525|Experimental|Sequence 2|Period 1 : Fasted state + HGP1809, Period 2 : Fasted state + HIP1701
89115524|NCT04260087||New Daily Persistent Headache|"This cohort will consist of participants diagnosed with New Daily Persistent Headache (NDPH). New daily persistent headache (NDPH) is a primary headache syndrome which can mimic chronic migraine and chronic tension-type headache. The headache is daily and unremitting from very soon after onset (within 3 days at most), usually in a person who does not have a history of a primary headache disorder.~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
89115525|NCT04260087||Chronic Migraine|"This cohort will consist of participants diagnosed with chronic migraine. Chronic migraine is defined as headache occurring on 15 or more days per month for more than three months, which, on at least 8 days per month, has the features of migraine headache. Chronic migraine occurs in approximately 1% of the population. Studies estimate that about 2.5% of people with episodic migraine will transition to chronic migraine each year.~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
89115526|NCT04260087||Healthy Volunteers|"This cohort will consist of healthy volunteers who have not been diagnosed with either NDPH or chronic migraine.~Protein levels of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) will be measured in this cohort."
89115527|NCT00612651|Other|enzyme-inducing anti-epileptic drugs (EIAEDs)|Patients receiving enzyme-inducing anti-epileptic drugs (EIAEDs)such as carbamazepine, phenobarbitol, phenytoin, phosphenytoin, oxcarbamazepine, primadone)
89115528|NCT00612651|Other|no enyzme-inducing anti-epileptic drugs|Patients on non CYP3A4-inducing anti-convulsants or patients not on any anti-convulsants.
89115529|NCT02592577|Experimental|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
89115530|NCT00918307|Experimental|Varenicline|Varenicline titrated to 2 x 0.5 mg twice daily for 12 weeks
89115531|NCT00918307|Placebo Comparator|Placebo|placebo titrated to 2 pills twice daily for 12 weeks
89115532|NCT00741013|Placebo Comparator|Placebo pill and placebo IV|
89115533|NCT00741013|Experimental|Lovastatin pill and placebo IV|
89115534|NCT00741013|Experimental|Placebo pill and rhAPC IV|
89115535|NCT05373745|Experimental|Active Brains 1|Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
89115536|NCT05373745|Placebo Comparator|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity."
89115537|NCT04087603|Experimental|Weekend Morning Bright Light & Early Bedtime|"Assigned a set sleep schedule for 2 weeks~Receives evening time management goals to help facilitate scheduled bedtime~Receives morning bright light from 2 light boxes (Phillips EnergyLights) on two weekend mornings."
89115538|NCT04087603|No Intervention|Healthy Control|- Sleep as usual at home for 2 weeks
89115539|NCT02592967|Experimental|Cohort 1A and 1B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
89115540|NCT02592967|Experimental|Cohort 2A and 2B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
89115541|NCT04087759|Experimental|Treatment Sequence BAE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
89115542|NCT04087759|Experimental|Treatment Sequence CAF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet II under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
89115543|NCT04087759|Experimental|Treatment Sequence DAG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 1, followed by bedaquiline oral reference tablet under fasted condition (Treatment A) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
89115544|NCT04087759|Experimental|Treatment Sequence ABE|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 1 under fasted condition (Treatment B) in period 2, thereafter will receive bedaquiline oral test tablet 1 under fed condition (Treatment E) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
89115545|NCT04087759|Experimental|Treatment Sequence ACF|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 2 under fasted condition (Treatment C) in period 2, thereafter will receive bedaquiline oral test tablet 2 under fed condition (Treatment F) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
89115546|NCT04087759|Experimental|Treatment Sequence ADG|Participants will receive a single dose of bedaquiline in 3 subsequent sessions as bedaquiline oral reference tablet under fasted condition (Treatment A) in period 1, followed by bedaquiline oral test tablet 3 under fasted condition (Treatment D) in period 2, thereafter will receive bedaquiline oral test tablet 3 under fed condition (Treatment G) in period 3. Each treatment period will be separated with a washout period of at least 28 days.
89115547|NCT00740857|Placebo Comparator|1|
89115548|NCT00740857|Active Comparator|2|
89115549|NCT00740857|Active Comparator|3|
89115550|NCT05239663|Experimental|experimental group|standard (neo)adjuvant chemotherapy plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
89115551|NCT05239663|Other|Control group|standard (neo)adjuvant chemotherapy plus 250ml normal saline (NS)
89115552|NCT00808132|Experimental|1|bazedoxifene 20 mg/conjugated estrogens 0.45 mg
89115553|NCT00808132|Experimental|2|bazedoxifene 20 mg/conjugated estrogens 0.625 mg
89115554|NCT00808132|Experimental|3|bazedoxifene 20 mg
89115555|NCT00808132|Active Comparator|4|Prempro
89115556|NCT00808132|Placebo Comparator|5|Placebo
89115557|NCT00727441|Experimental|Arm A|Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.
89115558|NCT00727441|Experimental|Arm B|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..
89115559|NCT00727441|Experimental|Arm C|Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.
89115560|NCT03954769||Inpatients|Patients admitted to Stanford Hospital and Clinics medical and surgical units
89115561|NCT02983279|Experimental|Dietary counseling, caloric restriction diet|Patients then undergo 25% caloric intake for 3-12 weeks prior to definitive cancer surgery.
89115562|NCT00717769|Experimental|SUN13834|
89115563|NCT00717769|Placebo Comparator|Placebo|
89115564|NCT04153929|Experimental|BI 456906 0.3 mg|
89115565|NCT04153929|Experimental|BI 456906 0.9 mg|
89232069|NCT05566041|Experimental|Arm 1|"RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks~Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
89232070|NCT05566041|Active Comparator|Arm 2|"Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
89232071|NCT05564117|Experimental|Oral semaglutide 25 mg|Participants will receive semaglutide tablets orally once daily. Participants will receive semaglutide in a dose escalation manner for 64 weeks: 3 mg (weeks 0 to 4), 7 mg (weeks 5 to 8), 14 mg (weeks 9 to 12), and 25 mg (weeks 13 to 64).
89232072|NCT05564117|Placebo Comparator|Oral semaglutide placebo|Participants will receive placebo tablets matched to semaglutide orally once daily for 64 weeks.
89115566|NCT04153929|Experimental|BI 456906 1.8 mg|
89115567|NCT04153929|Experimental|BI 456906 2.7 mg|
89115568|NCT04153929|Experimental|BI 456906 1.2 twice weekly (2.4) mg|
89115569|NCT04153929|Experimental|BI 456906 1.8 twice weekly (3.6) mg|
89115570|NCT04153929|Active Comparator|Semaglutide|
89115571|NCT04153929|Placebo Comparator|Placebo|
89115572|NCT00591214|Experimental|MP-424|
89115573|NCT05754268||Chinese version of Surgical risk Assessment system Group|This group of patients used the Chinese version of the surgical risk assessment system to evaluate the complications.
89115574|NCT00613431|Experimental|1|6 dose groups, 9 subjects on active, 3 subjects on placebo in each group
89115575|NCT00613431|Placebo Comparator|2|3 subjects on placebo in each group
89115576|NCT00914368|Active Comparator|1|Patients with previously experienced stent thrombosis while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
89115577|NCT00914368|Active Comparator|2|Patients with previously experienced myocardial infarction while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
89115578|NCT00914368|Active Comparator|3|Patients without previously experienced myocardial infarction or stent thrombosis 6 within months after coronary stenting for coronary artery disease(matched controls for group 1 and 2)
89115579|NCT04168983|No Intervention|Control|Usual care: local anesthesia + nitrous oxide and oxygen administration
89115580|NCT04168983|Experimental|Experimental|"Usual care: local anesthesia + nitrous oxide and oxygen administration~In this arm : sophrology is added"
89115581|NCT00725725|Experimental|4 mg Org 25935|Participants took a total of 3 doses of 4 mg Org 25935 prior to therapy sessions over a 2-week period.
89115582|NCT00725725|Experimental|12 mg Org 25935|Participants took a total of 3 doses of 12 mg Org 25935 prior to therapy sessions over a 2-week period.
89115583|NCT00725725|Placebo Comparator|Placebo|Participants took a total of 3 doses of placebo matched to Org 25935 prior to therapy sessions over a 2-week period.
89115584|NCT02607982|Experimental|Concurrent Chemoradiotherapy Arm|Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Concurrent paclitaxel (135mg/m², d1) and oxaliplatin (125mg/ m², d1) were administered on Days 1 and Day 29 of radiotherapy.
89115585|NCT04018222||Lupus Cases|This cohort of patients will involve individuals with a confirmed medical history of Systemic Lupus Erythematosus. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
89115586|NCT04018222||Healthy Controls|This cohort of patients will involve individuals whom do not have a diagnosis of Systemic Lupus Erythematosus or any other rheumatological or auto-immune diseases. Qualified individuals will satisfy all Inclusion/Exclusion criteria.
89115587|NCT05743660||POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
89115588|NCT05743660||non-POD group|According to the occurrence of postoperative delirium, the patients were divided into POD group and non-POD group
89115589|NCT00725101||Fibromyalgia (FM) Participants|FM participants starting any new pharmacologic FM agent.
89115590|NCT04882293|Experimental|Group A: Atorvastatin / Fenofibrate in fixed dose|Group A: Atorvastatin / Fenofibrate in fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg /160 mg Adminstration way: Oral
89115591|NCT04882293|Active Comparator|Group B: Atorvastatin (Lipitor ®)|Group B: Atorvastatin (Lipitor ®) Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
89115592|NCT04866693||Service users|Up to 20 people with current or recent experience of using community-based mental health services will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
89115593|NCT04866693||Carers|Up to 20 family members/ carers with experience of supporting another adult who is accessing community-based mental health services, will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
89115594|NCT04866693||Healthcare professionals|Up to 20 healthcare professionals from different disciplinary backgrounds and community-based mental health services will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
89115595|NCT04862715|Active Comparator|Treatment|"Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited"
89115596|NCT04862715|Placebo Comparator|Placebo|Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
89115597|NCT04856475|Experimental|HER2 metastatic breast cancer locally pretreated for previous CNS events and currently progressive|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
89232073|NCT05564052|Experimental|Phase 2: Treatment Arm A1 (Rituximab plus Ibrutinib)|Participants will receive rituximab 375 milligrams per meter square (mg/m^2) intravenously (IV) on Day 1 of Cycles 1 to 6 with ibrutinib 560 milligrams (mg) orally, once daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
89232074|NCT05564052|Experimental|Phase 2: Treatment Arm A2 (Rituximab plus Ibrutinib)|Participants will receive rituximab 375 mg/m^2 IV on Day 1 of Cycles 1 to 6 with ibrutinib 420 mg orally, once daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
89232075|NCT05564052|Experimental|Phase 2: Treatment Arm A3 (Rituximab plus Ibrutinib)|Participants will receive rituximab 375 mg/m^2 IV on Day 1 of Cycles 1 to 6 with ibrutinib 140 mg orally, twice daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).
89232076|NCT05564052|Experimental|Phase 2: Treatment Arm B (Rituximab plus Lenalidomide or Bortezomib)|Participants will receive rituximab 375 mg/m^2 IV on Day 1 of Cycles 1 to 6 (each cycle length is 21 or 28 days) with physician's choice of either lenalidomide 20 mg orally, once daily from Day 1 through Day 21 of 28-day cycle or bortezomib 1.3 mg/m^2 IV or subcutaneously (SC) on Days 1, 4, 8 and 11 of a 21-day cycle until disease progression or unacceptable toxicity.
89232077|NCT05563961|Active Comparator|Panadol|• Cohort 1- 6 Subjects to receive oral Panadol® 4,000 mg (2 tablets Q6H, 4 dosages, 8 tablets or 4,000 mg)
89232078|NCT05563961|Experimental|SafeTynadol®|"Cohort 2- 6 Subjects to receive oral SafeTynadol® 4,000 mg (2 tablets Q6H, 4 dosages, 8 tablets or 4,000 mg)~Cohort 3- 6 Subjects to receive oral SafeTynadol® 4,500 mg (3 tablets at first dosage and 2 tablets at second to forth dosage Q6H, 4 dosages, 9 tablets or 4,500 mg)~Cohort 4- 6 Subjects to receive oral SafeTynadol® 5,000 mg (3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H, 4 dosages, 10 tablets or 5,000 mg)~Cohort 5- 6 Subjects to receive oral SafeTynadol® 6,000 mg (3 tablets Q6H, 4 dosages, 12 tablets or 6,000 mg)~Cohort 6- 6 Subjects to receive oral SafeTynadol® 8,000 mg (4 tablets Q6H, 4 dosages, 16 tablets or 8,000 mg)~Cohort 7- 6 Subjects to receive oral SafeTynadol® 10,000 mg (5 tablets Q6H, 4 dosages, 20 tablets or 10,000 mg)~Cohort 8- 6 Subjects to receive oral SafeTynadol® 12,000 mg (6 tablets Q6H, 4 dosages, 24 tablets or 12,000 mg)"
89232079|NCT05556863|Experimental|Part 1: Single Ascending Dose|"Cohort 1 Single dose: 0.001 mg/kg IV~Cohorts 2 - 11 Single dose: dose level and route (IV or SC) to be determined~Japanese Cohort Single dose: dose level and route (IV or SC) to be determined"
89232080|NCT05556863|Experimental|Part 2: Multiple Ascending Dose|Cohort 1 - 6 Multi-dose: dose level, route (IV or SC) and frequency to be determined
89232083|NCT05552222|Experimental|Teclistamab, Daratumumab SC, and Lenalidomide (Tec-DR)|Participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab and lenalidomide.
89232084|NCT05552222|Experimental|Talquetamab, Daratumumab SC, and Lenalidomide (Tal-DR)|Participants will receive talquetamab as SC injection in combination with daratumumab and lenalidomide.
89232085|NCT05552222|Active Comparator|Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)|Participants will receive daratumumab as SC injection with lenalidomide and dexamethasone.
89232086|NCT05550532|Experimental|Aticaprant|Participants will receive Aticaprant 10 milligrams (mg) tablet orally, once daily for 42 days during double-blind (DB) treatment phase in addition to their current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy. Participants who will complete the DB treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study 67953964MDD3003.
89232087|NCT05550532|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally, once daily for 42 days during DB treatment phase in addition to their current antidepressant SSRI/SNRI therapy. Participants who will complete the DB treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study 67953964MDD3003.
89232090|NCT05548556|Placebo Comparator|Placebo|Participants will complete a 4-week pre-treatment period to collect baseline movement data with a wearable device, then receive subcutaneous (SC) placebo every 4 weeks for 52 weeks. After the treatment period, participants will have the option to receive RO7204239 for an additional 52 weeks.
89232091|NCT05548556|Experimental|RO7204239|Participants will complete a 4-week pre-treatment period to collect baseline movement data with a wearable device, then receive SC RO7204239 every 4 weeks for 52 weeks. After the treatment period, participants will have the option to receive RO7204239 for an additional 52 weeks.
89232092|NCT05544552|Experimental|Phase 1 Part A - dose escalation|TYRA-300 taken once daily by mouth in 28-day cycles starting at 10 mg daily.
89232093|NCT05544552|Experimental|Phase 1 Part B - dose expansion|TYRA-300 taken once or twice daily by mouth in 28-day cycles.
89232094|NCT05544552|Experimental|Phase 2|TYRA-300 taken once or twice daily by mouth in 28-day cycles at doses determined during Phase 1.
89232098|NCT05531292|Experimental|Study Lens|investigational IOL Model C0002
89232099|NCT05531292|Active Comparator|Control Lens|control IOL Model ZCB00/DCB00
89232100|NCT05528510|Experimental|Group 1: Guselkumab|Participants will receive guselkumab (Dose 1) subcutaneous (SC) injection followed by guselkumab (Dose 2) SC injection.
89232101|NCT05528510|Experimental|Group 2: Guselkumab|Participants will receive guselkumab (Dose 1) SC injection followed by guselkumab (Dose 3) SC injection.
89232102|NCT05528510|Placebo Comparator|Group 3: Placebo|Participants will receive matching placebo SC injection.
89232104|NCT05521087|Experimental|Arm A: <2 Years Old|Participants aged less than (<) 2 years old in dose escalation portion of the study will receive JNJ-75276617 orally on a 28-day cycle. Starting dose of JNJ-75276617 is based on the adult dose from the ongoing study NCT04811560 with additional dose reductions based on age. Further dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by study evaluation team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in dose expansion portion of the study will receive JNJ-75276617 orally at one of the RP2D(s) determined in dose escalation portion of the study, in 3 cohorts divided on the basis of disease diagnosis. Participants with acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (ALL) will receive conventional chemotherapy backbone regimen (dexamethasone, vincristine, pegaspargase, fludarabine, cytarabine and intrathecal chemotherapy) in combination with JNJ-75276617.
89232105|NCT05521087|Experimental|Arm B: >=2 Years Old|Participants aged greater than or equal to (>=) 2 years old in dose escalation portion of the study will receive JNJ-75276617 orally on a 28-day cycle. Starting dose of JNJ-75276617 is based on the adult dose from the ongoing study NCT04811560 with additional dose reductions based on age. Further dose levels will be escalated based on the DLT evaluation by SET until the RP2Ds has been identified. Participants in dose expansion portion of the study will receive JNJ-75276617 orally at one of the RP2D(s) determined in dose escalation portion, in 3 cohorts divided on the basis of disease diagnosis. Participants with AML and B-cell ALL will receive conventional chemotherapy backbone regimen (dexamethasone, vincristine, pegaspargase, fludarabine, cytarabine and intrathecal chemotherapy) in combination with JNJ-75276617.
89232106|NCT05520567|Experimental|Dose Ranging Cohort (Phase 1)|Participants will receive daily dose of gilteritinib and venetoclax for 28 days, and azacitidine for 7 days in each 28-day cycle.
89232107|NCT05520567|Experimental|Dose Expansion Cohort (Phase 2)|Participants will receive daily dose of gilteritinib, venetoclax, and azacitidine at an optimized dose established from dose ranging cohort (Phase 1)
89232108|NCT05519215||ECHELON 3000 Stapler|This prospective study will include the participants who plan to have a laparoscopic sleeve gastrectomy (LSG) or lung resection surgical procedure and collect clinical data in a post-market setting. Investigators will perform each procedure using the device in compliance with their standard surgical approach and the ECHELON 3000 Stapler and reloads instructions for use (IFU).
89232109|NCT05519072|Experimental|Antibiotic arm|Antibiotics will be administered for 2 days pre-treatment, on the treatment day, and 2 days post-treatment.
89232110|NCT05519072|No Intervention|No treatment arm|No antibiotics administered.
89232111|NCT05518149|Experimental|Aticaprant 10 mg|Participants will enter this study directly or after completing double-blind phase of studies 67953964MDD3001 or 67953964MDD3002 and will receive Aticaprant 10 milligrams (mg), once daily, orally in addition to the current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy on Day 1 up to 52 weeks.
89115598|NCT04856475|Experimental|HER2 positive metastatic breast cancer patients with newly diagnosed brain metastases|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
89115599|NCT04856475|Experimental|HER2 positive metastatic breast cancer patients with leptomeningeal carcinomatosis|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), contrast-enhanced neuraxis brain and spine MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. CSF cytological assessment should also be performed.~Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
89115600|NCT04106739|Active Comparator|Active Arm|Active arm: Auricular Percutaneous Electrical Neural Field Stimulation (PENFS) device will stimulate the outer auditory canal. It will deliver with a pulse width of 500 ms. The stimulation frequency pattern is 1.12Hz(hertz), 2.24Hz,4.56Hz, 9.12Hz, 100Hz then 9.12Hz, 4.56Hz,2.28Hz,1.12Hz. This cycle will keep on continuing. An input voltage will be 4.2V(volt).
89115601|NCT04106739|Sham Comparator|Sham Arm|Sham arm: Auricular Percutaneous Electrical Neural Field Stimulation (PENFS) device will stimulate centre of the left ear lobe to a pulse width of 500 ms at same pattern of stimulation frequency mentioned in active PENFS with an input voltage of 4.2V
89115602|NCT03755895|Experimental|experimental|patients to benefit from brachytherapy detachment under KALINOX and formal hypnosis
89115603|NCT03755895|Active Comparator|active comparator|patients to benefit from brachytherapy detachment under KALINOX
89115604|NCT04824885|Experimental|Acetate free then acetate containing dialysate|Patients in group 1 will first be treated with the acetate-free dialysate (A-D) for 6 months and then the acetate-containing dialysate (A + D) for 6 months.
89115605|NCT04824885|Experimental|Acetate containing dialysate then acetate free dialysate|Group 2 patients will continue on the usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months. Patients will be blinded from study treatment.
89115606|NCT02608060|Experimental|Epoetin Beta - 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
89115607|NCT03504579|Experimental|rt-fMRI neurofeedback aimed at STG|One session of rt-fMRI neurofeedback from the patient's STG.
89115608|NCT03504579|Sham Comparator|sham rt-fMRI|One session of rt-fMRI neurofeedback from the patient's motor cortex.
89115609|NCT02607826|Experimental|Intervention arm|
89115610|NCT02607826|No Intervention|Standard of Care|
89115611|NCT02607670|Experimental|TAT4 Gel|The participant will apply TAT4 Gel to the nasolabial fold area once daily.
89115612|NCT02607670|Placebo Comparator|Placebo|The participant will apply Placebo Gel to the nasolabial fold area once daily.
89115613|NCT05357599|Experimental|Beta Blocker at EUS|
89115614|NCT04905381|Active Comparator|Usual care|Behavioral: This arm receives usual care (control group). This group will attend their usual Alief group sessions.
89115615|NCT04905381|Experimental|LENA Star program|Behavioral:LENA Star program. Participants who are selected via the lottery to participate in the LENA Star program will complete ten weekly, 1-hour sessions.
89115616|NCT04085575|Active Comparator|tranexamic acid - The G1 group|The G1 group received 1 g of intra-articular tranexamic acid (TXA). The G1 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
89232112|NCT05513859|Experimental|Diagnostic (qOBM)|Patients undergo craniotomy with intraoperative ex vivo and in situ tumor assessment with qOBM. Patients then undergo postoperative exam with CT or MRI any of days 1-5 after surgery.
89232114|NCT05505435|Active Comparator|DMPA-SC|self-administered subcutaneous depot medroxyprogesterone acetate 104 mg
89232115|NCT05505435|Active Comparator|DMPA-IM|provider-administered intramuscular depot medroxyprogesterone acetate 150 mg
89115617|NCT04085575|Active Comparator|tranexamic acid - The G2 group|The G2 group received 2 g of intra-articular tranexamic acid (TXA). The G2 group received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.
89115618|NCT04796883|Experimental|single arm|Hanita Glaucoma shunt Ver.3.2
89115619|NCT00585169|Experimental|memantine|10 to 30 mg/day memantine. The study consisted of 10 weeks of open-label memantine. All eligible study subjects were started at 10 mg/day for 2 weeks. The dose was increased to 20 mg/day after 2 weeks and then to 30 mg/day after 4 weeks unless remission of PG symptoms was attained at a lower dose.
89115620|NCT00807742|Experimental|Contingency Management (CM)|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
89115621|NCT00807742|Active Comparator|Noncontingent Reinforcement (NR)|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
89115622|NCT04085497|Experimental|Treatment|KT was applied once a week, 6 times in total. Exercises were performed for all patients for 5 weeks 5 days a week, 3 sets 15 repetitions each day.
89115623|NCT04085497|Placebo Comparator|Group 2|The exercise program included quadriceps set exercise, straight leg lifting, mini squat, stretching to hamstring and gastrosoleus muscle groups.
89115624|NCT04741815|Experimental|Forced Air Warming Group|There is no intervention in patients before the operation. When he comes out of the operation and comes to the post-anesthesia care unit (PACU), he is warmed by forced air. When the body temperature of the patients reaches 36 ° C, they are transferred to the clinic with a cover and blanket.
89115625|NCT04741815|Experimental|Peripheral Carbon Fiber Warming Group|Gloves and socks developed by the researcher are applied half an hour before the operation. These materials, called environmental warming, have three layers. The first layer in contact with the patient is a thermal inner sheath made of 90% Polyester and 10% Polyamide and is used to maintain body temperature. The second layer consists of carbon fiber warmer and foil. The end of the carbon fiber warmer is USB connected. When the connection is plugged in, the warmer works. The third layer is again made of thermal fabric. A rubber bandage is made to separate the last layer from the external environment and to maintain the patient's body temperature. The USB connection is removed while patients are sent for surgery. After the operation, rewarming is started in the post-anesthesia care unit. When the patient's body temperature reaches 36 ° C, he is transferred to the clinic with a cover and blanket.
89115626|NCT04741815|No Intervention|Control Group|A routine hospital procedure is applied. The patient is not warmed before going to surgery. A cover and blanket are used passively after being taken to the PACU from the operation.
89115627|NCT03413163|Sham Comparator|control|"Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.~Intervention: Other: Standard Pain Followup and Monitorization"
89115628|NCT03413163|Experimental|ESP block|"In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
89115629|NCT00724945|Active Comparator|senofilcon A / balafilcon A|senofilcon A multifocal lenses worn first, balafilcon A multifocal lenses worn second
89115630|NCT00724945|Active Comparator|balafilcon A/senofilcon A|balafilcon A multifocal lenses worn first, senofilcon A multifocal lenses worn second
89115631|NCT05754112||ACPA/RFpos asyntomatic individuals|ACPA and/or RF positive individuals without active arthritis
89115632|NCT05754112||Naive Active RA|Treatment-naive active RA (disease duration<1 year)
89115633|NCT05754112||Resistant RA|Active despite treatment RA
89115634|NCT05754112||Remission RA|RA in sustained clinical and ultrasound remission
89115635|NCT05754112||Control Group|Individuals asymptomatic for joint inflammation without ACPA/RF positivity
89115636|NCT05738434|Experimental|Short-course Chemotherapy|
89115637|NCT05738434|Active Comparator|Chemotherapy|
89115638|NCT03925935|Experimental|Experimental|Up to 3 sequential dose escalation cohorts of AB-205
89115639|NCT02954224|Experimental|CPAP therapy arm|Auto-titrating Continuous Positive Airway Pressure (CPAP)) treatment will be given on postoperative days 1, 2, and 3.
89115640|NCT02954224|No Intervention|Control arm|no auto-titrating CPAP, standard care
89115641|NCT00803452|Active Comparator|Doxycycline|Oral doxycycline
89115642|NCT00803452|Active Comparator|azithromycin|Topical azithromycin daily to the conjunctival culdesac
89115643|NCT02949076|Experimental|Exercise|Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.
89115644|NCT00613197|Experimental|1 Epanova|
89115645|NCT00613197|Placebo Comparator|2 Placebo|
89115646|NCT03957759||COPD patients|
89232118|NCT05498428|Experimental|Cohort 1(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q2W) + Lazertinib|Participants with treatment-naive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) exon 19 deletion (exon19del) or exon 21 leucine 858 to arginine substitution (exon 21 L858R) mutation, will receive amivantamab SC-CF injection, 1600 milligrams (mg) or 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily.
89232119|NCT05498428|Experimental|Cohort 2(Exon20 NSCLC,1L, Previously Untreated): Amivantamab (Q3W) + Chemotherapy|Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR exon20ins mutation will receive Amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle, starting with Cycle 2 along with pemetrexed 500 milligrams per meter square (mg/m^2) as intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and IV infusion carboplatin area under the concentration-time curve 5 milligrams per milliliters (mg/mL) per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles.
89232120|NCT05498428|Experimental|Cohort 3(Exon19del/Exon21 L858R NSCLC,2L,Post Osimertinib):Amivantamab(Q3W)+Lazertinib+Chemotherapy|Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Lazertinib 240 mg orally once daily starting Cycle 5 Day 1 when carboplatin is complete or sooner if carboplatin discontinued earlier than Cycle 4.
89232121|NCT05498428|Experimental|Cohort 3b(Exon19del/Exon21 L858R NSCLC, 2L, Post Osimertinib): Amivantamab (Q3W)+Chemotherapy|Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression.
89232122|NCT05498428|Experimental|Cohort 4(Previously Treated with Amivantamab IV): Switch from Amivantamab IV to SC-CF (Q2W)|Participants who were previously on amivantamab IV once every 2 weeks (Q2W) regimen as part of standard of care, for at least 8 weeks, either as monotherapy or combination with lazertinib, will receive amivantamab SC-CF injection 1600 mg and 2240 mg if body weight is greater than or equal to 80 kg.
89232123|NCT05498428|Experimental|Cohort 5(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q4W) + Lazertinib|Participants with treatment-naïve locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation will receive amivantamab SC-CF induction with 1,600 mg (or 2,240 mg if BW >=80 kg) on Cycle 1 Days 1, 8, 15, and 22, starting with Cycle 2 on Day 1 of each next 28-day cycle, amivantamab SC-CF (160 mg/mL co-formulated with rHuPH20) by manual injection at 3,520 mg (or 4,640 mg if BW >=80 kg); along with lazertinib 240 mg by mouth once daily from Cycle 1 Day 1.
89232124|NCT05498428|Experimental|Cohort6(Exon19del/Exon21L858R,NSCLC1L,PreviouslyUntreated):Amivantamab(Q2W)+Lazertinib+Anticoagulant|Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation treated will receive will receive amivantamab SC-CF injection, 1600 milligrams (mg) and 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily from Cycle 1 Day 1. Participants will additionally take prophylactic anticoagulation with a direct oral anticoagulant (DOAC) or a low molecular weight heparin (LMWH) for the first four months of study treatment (from Day 1 through Day 120) with the combination of amivantamab and lazertinib.
89232125|NCT05498428|Experimental|Cohort 7(Exon19del/Exon21 L858R NSCLC,2L,Post Amivantamab+Lazertinib):Amivantamab(Q3W)+Chemotherapy|Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after the combination of amivantamab and lazertinib will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression.
89232126|NCT05496972||Telemedicine Visits|Participants are asked to fill out a survey about their experience.
89115647|NCT04565769||Cancer patients with melanoma|Forty two cancer patients with melanoma included prior to treatment with ICI.
89115648|NCT04565769||Healthy controls|Forty two age- and gender- matched healthy controls.
89115649|NCT04546113|Active Comparator|Paravertebral Block|If the patient is randomized to group Paravertebral Block, the anesthesiologist performs TPVB before induction of general anesthesia. The patient is positioned in lateral décubitus position. The anesthetist performs the bilateral paravertebral block with ultrasound identification of the paravertebral space at the T4-T5 level. Slow injection of 0.3 to 0.35 ml / kg of ropivacaine on each side (diluted to 3.75 mg / ml = dilution in a 20 ml syringe with 10 ml of ropivacaine 7.5 mg / ml and 10 ml of NaCl 0.9%) after aspiration test.
89115650|NCT04546113|Experimental|Erector Spinae Plane Block|"If the patient is randomized to group Erector Spinae Plane Block, the anesthesiologist performs the ESPb block before induction of general anesthesia. The patient is positioned in a right lateral decubitus position. The anesthesiologist performs the erector block of the spine ESP with ultrasound identification at the T4-T5 level (identify the 1st rib on ultrasound then the space T4 to T5). Slow injection of 20 ml of ropivacaine on each side (diluted to 3.75 mg / ml = dilution in a 20 ml syringe with 10 ml of ropivacaine 7.5 mg / ml and 10 ml of 0.9% NaCl) after aspiration test.~The patient is then turned in left lateral decubitus position and the contralateral block is performed according to the same procedure."
89115651|NCT05737342|Experimental|ANKASCIN 568-P Red yeast rice capsules|ANKASCIN 568-P is a fermented product from the red yeast rice fungus <Monascus purpureus NTU 568>. It does not contain Monacolin K, an ingredient that may harm the human body, and is rich in new active ingredients. Take 2 red yeast rice capsules (each containing 440mg ANKASCIN 568-P) every day, and the control group takes 2 placebo capsules (containing equal weight maltodextrin) every day, respectively, at the 0th, 4th , , 12, 24, Collect blood samples for biochemical analysis and record the general body position measurement, blood pressure, blood lipid, blood sugar and other related changes of the subjects, and monitor the liver, kidney, and thyroid functions.
89115652|NCT05737342|Placebo Comparator|Placebo Capsules|Maltodextrin was used as a placebo.
89115653|NCT00914212|Active Comparator|1|Sibutramine
89115654|NCT00914212|Placebo Comparator|2|Placebo
89115655|NCT05736328||Subjects admitted for percutaneous needle tenotomy of the knee flexor muscles|Postoperative lower extremity traction.
89115656|NCT04480203|Active Comparator|Cognitive based stress management (CBSM)|Cognitive based digital intervention.
89115657|NCT04480203|Active Comparator|Mindfulness based intervention (MBI)|Mindfulness based digital intervention.
89115658|NCT04480203|Placebo Comparator|Control|Control arm. No intervention.
89115659|NCT00914758||MS patients on Campath®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Campath® treatment arm of the Care-MS II trial, for which this study is a sub-study
89115660|NCT00914758||MS patients on Rebif®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Rebif® treatment arm of the Care-MS II trial, for which this study is a sub-study
89115661|NCT00914758||Control group|This group is comprised of non-MS, non-CNS compromised control participants matched in age, education level, and socioeconomic status to the participants in the 2 MS treatment groups
89115662|NCT03889665|Experimental|Suspension training group|
89115663|NCT00589108|Active Comparator|Mobile-Bearing Knee|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
89115664|NCT00589108|Active Comparator|Modular-Metal-Backed Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
89115665|NCT00589108|Active Comparator|All-Polyethylene Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray
89115666|NCT04456023|Experimental|Tisagenlecleucel|All patients eligible for treatment with tisagenlecleucel will receive a single dose of tisagenlecleucel.
89115667|NCT04188483|Experimental|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days. Thirty days after the start of the supplementation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
89115668|NCT04188483|Other|Non-Selenium Supplementation|The control group will not receive selenium supplementation. Thirty days after allocation, the subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
89115669|NCT05732194|Experimental|Cohort 1: 0.75 mg ITI-333 or placebo once daily for 14 days|
89115670|NCT05732194|Experimental|Cohort 2: 1.5 mg ITI-333 or placebo once daily for 14 days|
89115671|NCT05732194|Experimental|Cohort 3: 3 mg ITI-333 or placebo once daily for 14 days|
89115672|NCT05732194|Experimental|Cohort 4: 6 mg ITI-333 or placebo once daily for 14 days|
89115673|NCT02693145|No Intervention|standard of care (SOC) arm|Individuals found to be out of HIV medical care will receive standard of care to re-engage. This will not include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
89115674|NCT02693145|Experimental|Intervention arm|Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care. Intervention may include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
89115675|NCT00717067|Experimental|Healthy Subjects|Subjects with Normal Renal Function (Creatinine Clearance > 80mL/min) (I) Maraviroc single dose, followed by (II) Maraviroc + Saquinavir/Ritonavir
89115676|NCT00717067|Experimental|Mild Renal Impairment|Subjects with Mild Renal Impairment (Creatinine Clearance >50 and ≤80 mL/min)
89115677|NCT00717067|Experimental|Moderate Renal Impairment|Subjects with Moderate Renal Impairment (Creatinine Clearance ≥30 and ≤50 mL/min)
89115678|NCT00717067|Experimental|Severe Renal Impairment|Subjects with Severe Renal Impairment (Creatinine Clearance <30 mL/min)
89115679|NCT00717067|Experimental|ESRD on Hemodialysis|Subjects with End Stage Renal Impairment receiving Hemodialysis(Creatinine Clearance <30 mL/min) (I) Maraviroc single dose one hour following completion of hemodialysis, followed by (II) Maraviroc single dose three hours prior to start of hemodialysis
89115680|NCT04403607||COVID-19|Patients with confirmed COVID-19 meeting the eligibility criteria specified in the protocol.
89115681|NCT04403607||Control|COVID-19 negative. Age/sex matched to the COVID-19 cohort. Age range 40-80 years. At least one cardiovascular risk factor by ASSIGN criteria.
89115682|NCT04393311|Experimental|Ulinastatin|Patients will receive ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
89115683|NCT04393311|Placebo Comparator|Placebo|Patients will receive placebo to match ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
89115684|NCT02607436|Experimental|Sarpogrelate + Aspirin|Sarpogrelate as an active drug
89115685|NCT02607436|Active Comparator|Aspirin alone|Aspirin as an active comparator
89115686|NCT04362579||Subjects seen in hospital|Subjects will be recruited from Prentice Women's Hospital inpatient antepartum and labor and delivery services, and the outpatient Obstetrics and Gynecology practice, located within Galter tower with the assistance of staff.
89115687|NCT04362579||Home Study subjects|Subjects will be prescreened by an IRB approved staff and recruited from Prentice Women's Hospital's Department of Obstetrics and Gynecology.
89115688|NCT02607592|Experimental|Nedaplatin and Pemetrexed|nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
89115689|NCT02607592|Active Comparator|Cisplatin and Pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
89115690|NCT02607514|Experimental|immediate yoga arm|participants will immediately start the 8-week hyperthermic yoga intervention
89115691|NCT02607514|Other|delayed yoga arm|participants will wait 8-weeks to start the 8-week hyperthermic yoga intervention
89115692|NCT04356339||BETASERON|Participants with Multiple Sclerosis treated with BETASERON using BETACONNECT autoinjector and myBETAapp will be enrolled
89115693|NCT04334187|Experimental|Smoke Cessation Group|Mindfulness-based smoking cessation sessions will follow the mindfulness based addiction treatment (MBAT) intervention for smoking cessation. Sessions are in group format for two hours, weekly. Two groups of sessions with about 10 participants per group will be organized.
89115694|NCT04331145|No Intervention|Clopidogrel 75 mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~Normal basal platelet reactivity (PRU < 160 assessed with VerifyNow P2Y12 assay): Patients will continue with clopidogrel 75 mg/day until TAVI and during the following three months. All patients will be assessed by clinical follow up and platelet reactivity according to the protocol. Prescription of aspirin 100mg/day will be encourage as per guidelines recommendations."
89115695|NCT04331145|Active Comparator|Ticagrelor 60 mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hrs before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24 hours before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
89115696|NCT03460522|Experimental|Induction Therapy with Inotuzumab Ozogamicin|Patients will receive up to 3 cycles Inotuzumab with applications on day 1, 8 and 15 in each cycle. First dose will be 0.8 mg/m² on Day 1. All subsequent doses will be 0,5 mg/m².
89115697|NCT00613353||I|Caucasian and African American females between the ages of 18 and 65.
89115698|NCT00802438|Experimental|Mepolizumab|up to 3 monthly doses of 750mg i.v. mepolizumab
89115699|NCT04330131|Experimental|Treated families|The treated families will complete up to 3 interventions: 3Ts - Newborn, 3Ts - Well Baby, and 3Ts - Let's Talk! The ideal progression is that treated families will complete all three interventions. Before completing their first intervention, participants will complete set of baseline surveys measuring their knowledge and beliefs about child development. They will repeat these measures when their child is 6 months, 9 months, 1-, 2-, and 3-years old.
89115700|NCT04330131|No Intervention|Comparison Families|Comparison families will not receive any of the 3Ts interventions but will complete the same surveys as the treatment group at study enrollment and again when their child is 6 months, 9 months, 1-, 2-, and 3-years old.
89232127|NCT05484882||GENEFORECAST|African American men and women residing in the Washington DC area
89115701|NCT03440086|Experimental|Abdominal Jackson-Pratt drain|Patients in this arm will undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
89115702|NCT03440086|No Intervention|Controls|Patients in this arm will not undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
89115703|NCT04283253|Experimental|Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
89115704|NCT02605720|Experimental|Dihydroartemisinin-piperaquine|
89115705|NCT04188561|Active Comparator|Intraarticular injection Group|Patients included in the study had been received 2 ml hyaluronic acid with concentration of 22mg/ml . Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval
89115706|NCT04188561|Active Comparator|Radiofrequency Group|Radiofrequency Generator is a four electrode pain management for interventional pain management procedures. Patients had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
89115707|NCT00588952|Experimental|Family History Positive|Subjects with a positive family history of alcoholism
89115708|NCT00588952|Experimental|Family History Negative|Subjects with a negative family history of alcoholism
89115709|NCT02606344|Experimental|Intervention Group (IG)|Loans were provided to poor women who enrolled in the intervention group. A participatory learning and action curriculum was integrated into loan meetings, which took place every 2 weeks.
89115710|NCT02606344|No Intervention|Control Group (CG)|
89115711|NCT05327283||Sporadic POI|"Idiopathic, sporadic POI Caucasian cases. The inclusion criteria will be:~age at diagnosis <38 years;~a normal 46,XX karyotype (no FRM1 premutation);~at least one marker of ovarian reserve not age-appropriate:~baseline FSH levels > cut-off [1] and/or~age-specific AMH < cut-off [2] and/or~AFC < 5; and/or~cancellation of a PMA cycle because of poor response (<3 follicles) to high-dose gonadotrophins (250 U/die) and/or~retrieval of < 4 oocytes in response to high-dose stimulation protocols (3000 U of gonadotrophins)."
89115712|NCT05327283||Familial POI|Familial POI cases and not-affected members of pedigrees.
89115713|NCT05298267|Experimental|Monitoring phase|Participants will be monitored for 4 weeks. Halfway through the monitoring period, participants will be asked to turn on DNDWD.
89115714|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg QD|Participants receive MK-2206 45 mg oral tablets once every other day (QOD) PLUS AZD6244 75 mg oral capsules once daily (QD) starting on Day 1 of each 28-day cycle.
89115715|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg BID|Participants receive MK-2206 45 mg oral tablets QOD PLUS AZD6244 75 mg oral capsules twice daily (BID) starting on Day 1 of each 28-day cycle.
89115716|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 50 mg BID|Participants receive MK-2206 90 mg oral tablets once weekly (QW) PLUS AZD6244 50 mg oral capsules BID starting on Day 1 of each 28-day cycle.
89115717|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules QD starting on Day 1 of each 28-day cycle.
89115718|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg BID|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules BID starting on Day 1 of each 28-day cycle.
89115719|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
89115720|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 150 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 150 mg oral capsules QD starting on Day 1 of each 28-day cycle.
89115721|NCT01021748|Experimental|MK-2206 100 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 100 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
89115722|NCT01021748|Experimental|MK-2206 135 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 135 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
89115723|NCT00614133|Experimental|1|Preoperative nutrition.
89115724|NCT00614133|Active Comparator|2|Preoperative fasting.
89115725|NCT02872610|Experimental|Self-help Online|6 weeks of internet-based self-help intervention
89115726|NCT02872610|No Intervention|Wait-list|Waiting list control condition
89115727|NCT02690493|Active Comparator|Acupuncture Only|Patients will be treated with acupuncture only.
89115728|NCT02690493|Active Comparator|Functional Taping Only|Patients will be treated with taping only.
89115729|NCT02690493|Experimental|Acupuncture and Functional Taping|Patients will be treated with both acupuncture and taping at the same session.
89115730|NCT04885257|Placebo Comparator|Placebo|Patient with both PTSD and recent history of stroke. Placebo control arm. The frequency will be up to twice a day, with oral dosing.
89115731|NCT04885257|Experimental|Methylphenidate|Patient with both PTSD and recent history of stroke. Methylphenidate active arm. The oral dosing maximum will be up to 20mg twice daily.
89115732|NCT02692677|Experimental|JNJ-42756493|Each participant will receive a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed with 14C JNJ-42756493 at Pre-dose,0.5,1,2,3,4,8,12 hour post-dose(pd) on Day 1;24,36 h pd on Day 2;48 h pd on Day 3,72 h pd on Day 4; 96 h pd on Day 5;192 h pd on Day 9,216 h pd on Day 10,240 h pd on Day 11,264 h pd on Day 12,288 h pd on Day 13 and 312 h pd on Day 14
89232128|NCT05478694||Ablative Therapy Group|Enrolled subjects will undergo the ablative therapy as part of their standard of care treatment
89232131|NCT05468931|Experimental|Prostate stimulation device arm|Participants will be asked to use our prostate stimulation device.
89232132|NCT05464030|Experimental|Part 1: M9140|
89232133|NCT05464030|Experimental|Part 2A: M9140|
89232134|NCT05464030|Experimental|Part 2B: M9140|
89232135|NCT05464030|Experimental|Part 2C: M9140 + Bevacizumab + Capecitabine|
89232139|NCT05456087|Experimental|Single treatment with Xeomin® (incobotulinumtoxin A)|Individual balding scalps will be outlined and mapped to include up to 30 injection sites evenly distributed within the hair loss area. At each site, 5 Units of Xeomin® will be injected with a maximum of 150 Units total per subject. This will be a single, one-time treatment session.
89232140|NCT05455684|Experimental|Aticaprant|Participants will receive aticaprant tablets orally once daily for 42 days during double-blind treatment phase in addition to the current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy. Participants who will complete the double-blind treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study (67953964MDD3003).
89232141|NCT05455684|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 42 days during double-blind treatment phase in addition to their current antidepressant (SSRI/SNRI) therapy. Participants who will complete the double-blind treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study (67953964MDD3003).
89232142|NCT05455320|Experimental|Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP)|Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
89232143|NCT05455320|Experimental|Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd)|Participants will receive daratumumab as SC injection; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
89115733|NCT04982991|Experimental|SAR443820|Participants will receive a single sequence of 3 different doses of SAR443820 in a total of 3 treatment periods
89115734|NCT02690259|Experimental|Sentinel node procedure|Enrolling all eligible endometrial cancer patient to the Sentinel node concept using indocyanine green.
89115735|NCT00802360|Experimental|Menopur/Endometrin|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
89115736|NCT00802360|Experimental|Menopur/Progesterone in Oil|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
89115737|NCT00802360|Active Comparator|Follistim/Endometrin|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
89115738|NCT00802360|Active Comparator|Follistim/Progesterone in Oil|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
89115739|NCT04896411|Experimental|Alternative Phrase|This arm will have the code status question randomized to offer CPR vs the alternative phrase
89115740|NCT04896411|Active Comparator|Standard of care phrase|This arm will have the code status question randomized to offer CPR vs the standard of care phrase
89115741|NCT04824729||French PAD revascularized population|Patients with lower-extremity peripheral artery disease (PAD) who have undergone lower limb revascularization (PAD revascularized population) in France from 2016 to 2019.
89115742|NCT04824729||French VOYAGER PAD-like population|"VOYAGER PAD-like patients in France from 2016 to 2019.~This population will be constituted to fit the VOYAGER PAD clinical trial population. It will be created using the VOYAGER PAD exclusion criteria and resembles a subgroup of the PAD revascularized population."
89115743|NCT04820517|Experimental|Experimental Group|The Roy Adaptation Model Based Empowerment Program, which consists of 12 sessions that will create awareness of social media and its effects in students and contribute to students gaining and maintaining a healthy lifestyle by providing controlled and purposeful use of social media with behavioral change, will be held with online group sessions for 12 weeks to the students in the experimental group. .
89115744|NCT04820517|No Intervention|Control Group|No intervention will be made to the students in the control group. When the research is completed, student nurses in the control group will be informed about social media addiction and its effects.
89115745|NCT04811625|Other|PL-ASA capsule, then EC-ASA tablet|PL-ASA capsule 81 mg, then crossover to EC-ASA tablet 81 mg
89115746|NCT04811625|Active Comparator|EC-ASA tablet, then PL-ASA capsule|EC-ASA tablet 81 mg, then crossover to PL-ASA capsule 81 mg
89115747|NCT00914446|Other|morbid obese subject|
89115748|NCT00914446|Other|overweight and NASH subjects|
89115749|NCT00914446|Other|control subjects|
89115751|NCT02607358||Clopidogrel|Clopidogrel non-responders (HOTPR) Blood sampling for HOTPR-testing
89115752|NCT02607358||Acetacylicacid|Acetcylicacid non-responders (HOTPR), Blood sampling for HOTPR-testing
89115753|NCT02764593|Experimental|Arm 1 (Nivolumab + Cisplatin)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cisplatin will be given weekly. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
89115754|NCT02764593|Experimental|Arm 2 (Nivolumab + High-dose Cisplatin)|Patients will receive Nivolumab via IV administration starting 14 days prior to IMRT, then Day 1 of IMRT and then every 21 days for 6 doses. Cisplatin will be given every 21 days for 3 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
89115755|NCT02764593|Experimental|Arm 3 (Nivolumab + Cetuximab)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cetuximab will be given for 7 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
89115756|NCT02764593|Experimental|Arm 4 (Nivolumab + IMRT)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
89115757|NCT03362476|Experimental|Computer-based alcohol reduction intervention + Clinician-delivered brief MET counseling|"Brief, computer-based, alcohol reduction intervention based on motivational enhancement therapy (MET) tailored for HIV/HCV co-infected women who used alcohol.~Clinician-based MET counseling plus standard-of-care (SOC) for current substance users."
89115758|NCT03362476|Active Comparator|Clinican-delivered brief MET counseling|Clinician-based brief MET counseling plus standard-of-care (SOC) for current substance users. only
89115759|NCT02692599|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated mumps vaccine;"
89115760|NCT02692599|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated mumps vaccine;"
89115761|NCT01026038|Experimental|1|1 dose (0.5 mL), IM of 13vPnC vaccine.
89115762|NCT02606266|Experimental|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension), at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
89115763|NCT02606266|No Intervention|Control group|Control group with standard care who do not receive the investigational medicinal product
89115764|NCT04115020|Experimental|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
89115765|NCT04115020|Experimental|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
89115766|NCT02720211|Active Comparator|Gray tinted spectacle lenses|Subjects in this arm will be asked to wear a neutral gray tint that blocks all wavelengths equally
89115767|NCT02720211|Experimental|Thin-Film spectacle lenses|Subjects in this arm well be asked to wear a thin-film coating that specifically blocks 480-nm wavelength
89115768|NCT02801266|Experimental|Intervention|The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.
89115769|NCT02801266|No Intervention|No intervention|The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.
89115770|NCT02606188|Active Comparator|Modified High-flow nasal cannula therapy|Patients undergoing bronchoscopy are given Modified High-flow nasal cannula oxygen therapy all the time.
89115771|NCT02606188|Active Comparator|Nasal cnnnula therapy|Patients undergoing bronchoscopy are given nasal cannula oxygen therapy all the time.
89115772|NCT00612027||1|patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole.
89115773|NCT02707731|Experimental|Hydrokinesiotherapy in preterm|Salivary cortisol samples, pain applying the Neonatal Infant Pain Scale Scale, heart rate, respiratory rate and oxygen saturation were collected before and after hydrokinesiotherapy
89115774|NCT03292666||Extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for > 3 months
89115775|NCT03292666||No extended anticoagulation|Patients with acute VTE treated with oral anticoagulants for no longer than 3 months
89115776|NCT02707653|Other|Miso|Misoprostol 400 s/l
89115777|NCT00801892|Active Comparator|1 subjects treated with CPAP|Continuous Positive Airway Pressure treatment (CPAP)
89115778|NCT00801892|Sham Comparator|2 subjects treated with sham-CPAP|Sham Continuous Positive Airway Pressure treatment (sham-CPAP)
89115779|NCT03901131||BAY98-7040|"Female adult patients of reproductive age, who want to use a contraceptive method, will be enrolled after the investigator has made the decision for treatment with Mesigyna.~Investigators should prescribe Mesigyna for medically approved indications as per the label of the medicine locally approved."
89115780|NCT02707419|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
89115781|NCT02707419|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
89115782|NCT02773264||UltraSound Patients|All patients will undergo next to the clinical indicated conventional US-examination, US Elastography after informed consent. After completion of these three examinations, the participation in the study is completed.
89115783|NCT04371393|Experimental|Remestemcel-L Plus Standard of Care|Intravenous infusion of remestemcel-L 2x10^6 MSC/kg of body weight plus standard of care
89115784|NCT04371393|Placebo Comparator|Placebo Plus Standard of Care|Placebo (Plasma-Lyte) plus standard of care
89115785|NCT00923182|Experimental|Alemtuzumab|The starting dose of alemtuzumab was 3 mg. The dose was gradually escalated on a daily basis (3 mg, 10 mg, and then 30 mg) until the patient tolerated a dose of 30 mg IV infusion over 2 hours. All subsequent doses of alemtuzumab were 30 mg IV 3 times a week (every other day).
89115786|NCT03868839|Experimental|Telmisartan Pill|Subjects will start telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
89115787|NCT02605564|Active Comparator|study Group A|Gluten free diet
89115788|NCT02605564|Placebo Comparator|Study Group B|No intervention
89115789|NCT03844659|Experimental|Intervention Group|"The song Weightless by Marconi Union will be playing during subjects labor epidural placement."
89115790|NCT03844659|Other|Non Intervention Group|No song will be played during subjects labor epidural placement.
89115791|NCT03054376|Active Comparator|Immobilization|After baseline studies, the subjects will have one leg immobilized by full length plaster for two weeks. During the two weeks, the other leg will not be trained. After the two weeks the subjects will train both legs for four weeks.
89115792|NCT03054376|Active Comparator|Training of non-immobilized leg|After baseline studies, the subjects will have one leg immobilized by full length plaster for two weeks. During the two weeks, the other leg will be trained. After the two weeks the subjects will train both legs for four weeks.
89115793|NCT02680587|No Intervention|Observational (no SBRT)|Men with oligometastatic prostate cancer lesions randomized to observation
89115794|NCT02680587|Experimental|SBRT|Men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT).
89115795|NCT00589420|Experimental|Phase II|All patients received sorafenib 200 mg bid daily and docetaxel 75 mg/m2 every 3 weeks
89115796|NCT01025336|Other|23vPS Naive|Group 1.1 13vPnC/13vPnC Group 1.2 13vPnC/23vPS Group 2 23vPS/13vPNC
89115797|NCT01025336|Other|Prior 23vPS>/= 5 years|Group 1 13vPnC/13vPnC Group 2 23vPS/13vPnC
89115798|NCT04114630|Experimental|erenumab|Solution for s.c injection. Prefilled autoinjector
89115799|NCT00914524|Experimental|Treatment|16 weeks of treatment starting with 5 mg of olmesartan medoxomil. If tolerated, the dose was increased to the next higher dose at weeks 4, 8, and 12.
89115800|NCT02605408||Cataract surgery|Phacoemulsification and artificial IOL implantation with and without LenSx® laser system
89115801|NCT03787095|Experimental|Cohort 1: Cemiplimab|"Participants received 0.3 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.~Participants continued their current non-study provided ART regimen."
89115802|NCT03787095|Placebo Comparator|Cohort 1: Placebo|"Participants received placebo, administered at Day 0 and Week 6 for a total of two infusions.~Participants continued their current non-study provided ART regimen."
89115803|NCT04103385|Experimental|Reconnecting to Internal Sensations and Experiences|"Aims to improve interoception or connection to the body's emotions & internal sensation and reduce suicidal ideation."
89115804|NCT04103385|Active Comparator|Restoring Individual Strength and Energy|Aims to reduce life stressors and improve physical health
89115805|NCT00796978|Experimental|trastuzumab|
89115806|NCT03779295|Experimental|Pulse laser therapy|Pulse laser therapy will be randomly applied to right side or left side of face in addition to Clindamycin
89115807|NCT03779295|Experimental|Clindamycin|Clindamycin only applied to side of face that does not receive pulse laser therapy.
89115808|NCT00613665|Experimental|1|
89115809|NCT00613665|Experimental|2|
89115810|NCT00613665|Experimental|3|
89115811|NCT00613665|Experimental|4|
89115812|NCT00613665|Placebo Comparator|5|
89115813|NCT00613665|Experimental|6|
89115814|NCT00613665|Experimental|7|
89115815|NCT04112056|Experimental|Study formula|The infants recruited are provided with the study formula named NAN Comfort producted by Nestle Deutschland AG, Werk Biessenhofen containing moderately hydrolyzed protein and low lactose for free during study, and asked to drink the study formula more than half of the total diet daily.
89115816|NCT02607501|Other|eCLIPs BRS|Implant eCLIPs BRS at target aneurysm
89115817|NCT00923572||Group 1|
89115818|NCT02692833||AKI Patients|Patients who develop acute kidney injury within the first 5 days following their cardiac surgical operation.
89115819|NCT02692833||Non-AKI patients|Patients who do not develop acute kidney injury within the first 5 days following their cardiac surgical operation.
89115820|NCT00796822|Experimental|1|Participants will receive pentoxifylline.
89115821|NCT00796822|Placebo Comparator|2|Participants will receive placebo.
89115822|NCT02692911||Women with gallstones|Women aged 50-74 with gallstones
89115823|NCT03884829|Experimental|CYC140 single agent|CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle
89115824|NCT03622983||Collection of sample and data|Collection of biological samples and clinical data
89115825|NCT02873156|Experimental|E2027|"Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 up to the maximum tolerated dose (MTD). A total of 6 participants per cohort will be randomized to E2027.Proposed doses of E2027 are:~Part A Cohort 1: 50 mg (1 × 50 mg capsule)~Cohort 2: 100 mg (2 × 50 mg capsules)~Cohort 3: 200 mg (4 × 50 mg capsules)~Cohort 4: 400 mg (8 × 50 mg capsules)~Cohort 6: 25 mg (5 × 5 mg capsules) Part B~Cohort 5: 400 mg (8 × 50 mg capsule)~Part C:~• Cohort 7: 50 mg (1 × 50 mg capsules)~Part D:~Cohort 8: 5 mg (1 × 5 mg capsules)~Cohort 9: 10 mg (2 × 5 mg capsules)"
89115826|NCT02873156|Placebo Comparator|Placebo|Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 matched placebo up to the MTD. A total of 2 participants per cohort will be randomized to E2027 matched placebo.
89115827|NCT03822507|Experimental|KHK7580 1mg-12mg|
89115828|NCT03822507|Active Comparator|Cinacalcet 25mg-100mg|
89115829|NCT04300166|Active Comparator|Telemedicine & Humidification Intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse/sleep technologist is checking the downloaded data three times per week. The contacts will be due to:~CPAP usage <4h/ night for 3 consecutive night~the median leakage was above 0.4 L/sec on 3 consecutive nights The nurse/sleep technologist informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits) will be discussed. The patient is encouraged to use CPAP every night. In the case of adherence >4h/night and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail."
89115830|NCT04300166|No Intervention|Control without Telemedicine & humidification|In the control arm, no wireless telemedicine and humidifier will be used with CPAP but data stored in the CPAP machine are collected at the follow-up visit after 1 month
89115831|NCT04301570|Other|Ultrasound|The intervention measurement is the determination of bone age using the ultrasound device.
89115832|NCT04301570|Other|XR|The control measurement is the determination of the bone age by the imaging method using X-rays.
89115833|NCT02872922|Active Comparator|Endothelial function after CWUT|Endothelial function of the all patients before and after application continuous waveform of ultrasound therapy (CWUT) measured by technique flow-mediated dilation (FMD).
89115834|NCT02872922|Active Comparator|Endothelial function after PWUT|Endothelial function of the all patients before and after application pulsed waveform of ultrasound therapy (PWUT) measured by technique flow-mediated dilation (FMD).
89115835|NCT02872922|Active Comparator|Endothelial function after PLACEBO|In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off. Endothelial function of the all patients before and after application placebo waveform of ultrasound therapy measured by technique flow-mediated dilation (FMD)
89115836|NCT02692287|Other|Use of the PPH Butterfly|The PPH Butterfly will be inserted into the vagina of a healthy postnatal woman
89115837|NCT04301726|Experimental|Deutetrabenazine|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
89115838|NCT04301726|Placebo Comparator|Placebo|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg once daily; Week 2: 6 mg twice daily (BID); Week 3: 9 mg BID; Week 4: 12 BID; Week 5: 15 mg BID; Week 6: 18 mg BID; Week 7: 21 mg BID; Week 8: 24 mg BID.
89115839|NCT00614679|Experimental|1|single arm trial of experimental catheter lock solution
89115840|NCT02873000|No Intervention|Routine Care Group|Routine Care (R): Standard of care therapy based on admitting diagnosis
89115841|NCT02873000|Experimental|Experimental Group|"Intervention 1 (E1): addition of incentive spirometry every hour while awake;~There will be a computerized protocol with specific instructions documenting:~compliance~patient position while using [sitting up vs laying flat in bed]~inspiratory volume attained~effort, motivation and compliance will subjectively be documented using a visual analogue 0-5 point scale."
89115842|NCT03760965|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
89115843|NCT03760965|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
89115844|NCT03760965|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
89115845|NCT01020812|Experimental|Stereotactic body radiotherapy (SBRT)|"SBRT will be delivered on Varian's linear accelerator with On-Board Imaging (OBI) capabilities. The tumor will be tracked with the ethiodol material from the TACE procedure, and respiratory gating will be used to minimize motion due to respiration. Treatment will be given in either 3 or 5 fractions . SBRT will take place after the treatment planning and within 12 weeks of the last TACE procedure.~Doses: 45 Gy at 15 Gy/fraction , 36 Gy at 12 Gy/fraction, 45 Gy at 9 Gy/fraction, 40 Gy at 8 Gy/fraction"
89115846|NCT03703869||Insulin glargine (U300)|Insulin glargine (U300) dosage and dosing time as per local product labeling
89115847|NCT02872688|Experimental|GanedenBC30|
89115848|NCT02872376||Anemic|Anemic patients
89115849|NCT02872454|Experimental|Text Messaging|
89115850|NCT01032044|Active Comparator|Standard endoscopic evaluation|Standard high-definition white light endoscopy guided evaluation
89115851|NCT01032044|Experimental|pCLE-guided evaluation|Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)
89115852|NCT01024946|Experimental|Pts getting everolimus|This is a multicenter, open label, phase II study of everolimus as a second or third line therapy for the treatment of advanced malignant pleural mesothelioma, which will also evaluate Merlin/NF2 loss as a biomarker to predict sensitivity to everolimus. Patients who have disease progression after one or two prior chemotherapy regimens will be eligible. In the first stage of this design, 19 patients will be accrued. If 6 or less patients among the first 19 patients show clinical benefit, then the study will be terminated and declared negative. If 7 or more patients show clinical benefit, than an additional 20 patients will be accrued to the second stage. At the end of the study, if 17 or more patients show clinical benefit out of a total of 39 patients enrolled, the regimen will be considered worthy of further investigation.
89115853|NCT00627614|Experimental|breast imaging study|
89115854|NCT00724867|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV every 28 days
89115855|NCT00724867|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV every 28 days
89115856|NCT02873078|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of cognitive behavior therapy (CBT). Parents will also receive 10 weekly modules. Main components in the children's modules are exposure for abdominal symptoms, feared stimuli and situations in which the children are afraid of having symptoms. The parental receive information on how they can support their children in the treatment and how to reinforce health y behaviors and decrease attention to pain behaviors. Therapist support is provided through written messages within the secure platform.
89115857|NCT02873078|No Intervention|Waiting list|This is a wait-list control where the children and parents are allowed to carry on with any contacts within the health-care system, exempt for psychological treatments.
89115858|NCT00627536|Experimental|1|Avotermin 5ng/100μL/linear cm wound margin
89115859|NCT00627536|Placebo Comparator|2|Placebo
89115860|NCT00627536|Experimental|3|Avotermin 50ng/100μL/linear cm wound margin
89115861|NCT00627536|Placebo Comparator|4|Placebo matched to avotermin 50ng/100μL/linear cm
89115862|NCT00627536|Experimental|5|Avotermin 200ng/100μL/linear cm
89115863|NCT00627536|Placebo Comparator|6|Placebo matched to avotermin 200ng/100μL/linear cm
89115864|NCT00627536|Experimental|7|Avotermin 500ng/100μL/linear cm wound margin
89115865|NCT00627536|Placebo Comparator|8|Placebo matched to avotermin 500ng/100μL/linear cm
89115866|NCT00724711|Experimental|FTC/TDF (Truvada [TVD]) + PI/r|Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.
89115867|NCT00724711|Active Comparator|ABC/3TC + PI/r|Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.
89115868|NCT04019743|Experimental|Group 1|"Period 1: Treatment A~Period 2: Treatment B~Period 3: Treatment C"
89115869|NCT04019743|Experimental|Group 2|"Period 1: Treatment C~Period 2: Treatment A~Period 3: Treatment B"
89115870|NCT04019743|Experimental|Group 3|"Period 1: Treatment B~Period 2: Treatment C~Period 3: Treatment A"
89115871|NCT04019743|Experimental|Group 4|"Period 1: Treatment C~Period 2: Treatment B~Period 3: Treatment A"
89115872|NCT04019743|Experimental|Group 5|"Period 1: Treatment B~Period 2: Treatment A~Period 3: Treatment C"
89115873|NCT04019743|Experimental|Group 6|"Period 1: Treatment A~Period 2: Treatment C~Period 3: Treatment B"
89115874|NCT04019509|Active Comparator|Tg AB positive, TPO AB negative|Includes patients with only anti-thyroglobuline autoantibodies present and no anti-thyreoperoxydase antibodies at start of fertility treatment.
89115875|NCT04019509|Active Comparator|Tg AB negative, TPO AB negative|Includes patients without thyroid autoantibodies at start of fertility treatment
89115876|NCT04019509|Active Comparator|Tg AB positive, TPO AB positive|Includes patients with anti-thyroglobuline autoantibodies and anti-thyreoperoxydase antibodies at start of fertility treatment.
89115877|NCT02591797|Experimental|"hand-eye-mouth technique"|"hand-eye-mouth (MOB) seeks to focus the patient in performing a sequence of movements in a fun way so that your attention is diverted from the puncture dental needle, also it seeks to the patient does not see the needle. The operator prior to infiltrate local anesthetic teaches the child a game to put the sleepy little water.After explain a first time, the sequence once or twice is repeated until the patient has mastered. We call this test. When we apply the anesthetic, the entire sequence must be repeated as in trials with the same tranquility and in the same tone of the game. The operator will use this technique during the inferior alveolar and lingual nerve block procedure"
89115878|NCT02591797|Active Comparator|Conventional technique|the operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child´s field of view by hand during the inferior alveolar and lingual nerve block
89115879|NCT01024244|Placebo Comparator|0 milligrams (mg) Placebo|Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks.
89115880|NCT01024244|Experimental|100 mg LY2599506|Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks.
89115881|NCT01024244|Experimental|200 mg LY2599506|Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
89115882|NCT01024244|Experimental|400 mg LY2599506|Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
89115883|NCT01024244|Experimental|200 mg LY2599506 once daily|Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).
89115884|NCT01030952|Experimental|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
89115885|NCT01030952|Active Comparator|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
89115886|NCT02872298|Experimental|Treatment|Treatment: Targeted Lung Denervation (TLD)
89115887|NCT04299074|Other|Addiction|problematic addiction
89115888|NCT04299152|Experimental|Stem Cell Educator therapy treat patients with SARS-CoV-2|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
89115889|NCT04299152|No Intervention|Conventional treatment of patients with SARS-CoV-2|Patients will receive the regular treatments by only addressing their symptoms such as reducing fever and cough.
89115890|NCT04299932|Experimental|Electroacupuncture(EA) group|Participants in EA group will receive treatment at bilateral Bladder Meridian (BL) 33 [Zhongliao], BL35 [Huiyang] and Spleen Meridian (SP) 6 [Sanyinjiao]. The EA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
89115891|NCT04299932|Sham Comparator|Sham Electroacupuncture (SA) group|Participants in SA group will receive treatment at bilateral sham BL33 [Zhongliao], sham BL35 [Huiyang] and sham SP6 [Sanyinjiao]. The SA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
89115892|NCT04299932|No Intervention|Waiting List (WL) group|Participants in WL group will be followed up for 20 weeks. Participants only receive healthcare education and advice on lifestyle modification, which will be received by all the participants in the three groups.
89115893|NCT01030874|No Intervention|Usual Rehabilitation Care|Usual rehab care
89115894|NCT01030874|Experimental|Experimental Treatment/Medication Review|Treatment for, and prevention of, orthostatic hypotension
89115895|NCT00628082||HfpEF|Patients with Heart Failure with preserved ejection fraction
89115896|NCT00628082||Control|Healthy Volunteers
89115897|NCT03611751|Experimental|BMS-986165|BMS-986165 oral administration
89115898|NCT03611751|Placebo Comparator|Placebo|Placebo oral administration
89115899|NCT03611751|Active Comparator|Active comparator|Active comparator oral administration
89115900|NCT00613743|Placebo Comparator|1|D1-D3 receive placebo
89115901|NCT00613743|Active Comparator|2|receive D1 D3 morphine
89115902|NCT00614757|No Intervention|2|One half of the patients will take not medication for 30 days and then have labs redrawn
89115903|NCT00614757|Experimental|1|one half of the patients with insulin resistance will take 4ml of 20% N-acetylcysteine BID for 30 days
89115904|NCT02692365|Experimental|Calcium channels|Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride
89115905|NCT02692365|Experimental|Tumor perfusion|Magnetic Resonance + hemodynamic + infusion of gadolinium
89115906|NCT03558009||Participants with abdominal pain attacks|Participants experiencing recurrent abdominal pain attacks without a clear etiolgy aged between 2-60 years
89115907|NCT03492099|Experimental|Buprenorphine Arm|This is the main and only arm of the study. All patients in this arm will undergo the steps outlined in the protocol to convert to buprenorphine treatment.
89115908|NCT03481959|Experimental|Methylphenidate|Methylphenidate delay shape, 10 and 30 mg capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).
89115909|NCT03481959|Placebo Comparator|Matching Placebo|
89115910|NCT03245229|Experimental|Treatment A|In the morning of Day 1, a single dose of 10 mg rosuvastatin will be administered in the fasted state followed by an observation period of 96 h
89115911|NCT03245229|Experimental|Treatment B1|25 mg ACT-132577 will be administered o.d. from Day 5 to Day 12
89115912|NCT03245229|Experimental|Treatment B2|"In the morning of Day 13, a single dose of 10 mg rosuvastatin will be administered in the fasted state, concomitantly with 25 mg ACT-132577, followed by an observation period of 120 h.~Doses of 25 mg ACT-132577 will be administered o.d. from Day 14 to Day 17."
89115913|NCT03327597|Active Comparator|Abnormal Non-MGUS|Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease.
89115914|NCT03327597|Experimental|MGUS group arm 1|Participants diagnosed with MGUS, randomized to group 1.
89115915|NCT03327597|Experimental|MGUS group arm 2|Participants diagnosed with MGUS, randomized to group 2.
89115916|NCT03327597|Experimental|MGUS group arm 3|Participants diagnosed with MGUS, randomized to group 3.
89115917|NCT03327597|Active Comparator|Normal group|Participants without MGUS.
89115918|NCT03327597|Active Comparator|Controls|Participants without MGUS, matched to MGUS participants by age and gender.
89115919|NCT03462069|Experimental|Treatment A (Test)|Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day
89115920|NCT03462069|Active Comparator|Treatment B (Reference)|Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day
89115921|NCT04148625||atrial fibrillation, persistent|Subjects with documented symptomatic persistent or longstanding persistent AF (> than 3 months and < 3 years continuous AF duration) who has failed a previous PVI catheter ablation procedure and/or needs LAA exclusion; and catheter ablation or minimally surgical approach is planned.
89115922|NCT03414723|Experimental|SAR439954 with or without ramipril|"On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing.~On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing."
89115923|NCT02692131||Speckle strain|All adult patients undergoing on pump CABG Surgery.
89115924|NCT02692131||Tissue doppler strain|All adult patients undergoing on pump CABG Surgery
89115925|NCT03387657|Experimental|Sotagliflozin + Hydrochlorothiazide (HCTZ)|Sotagliflozin to be administered alone in Period 1. HCTZ to be given in Period 2 for 4 days followed immediately by HCTZ and sotagliflozin for 5 days.
89115926|NCT00721123|Experimental|Tocilizumab 8 mg/kg|All participants received tocilizumab 8 mg/kg to a maximum of 800 mg, administered by intravenous (IV) infusion over one hour, every 4 weeks. Concomitant therapies were limited to dosage and administration constraints detailed in the protocol.
89115927|NCT02694003|Experimental|Intervention|The intervention arm will receive access to the BNBD-NDD Intervention.
89115928|NCT02694003|No Intervention|Usual Care|The usual care arm does not receive the BNBD-NDD intervention. This arm is free to access other resources while enrolled in the study. After the 8-month follow up time point, the usual care arm will be able to access the intervention.
89232144|NCT05455320|Experimental|Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D)|Participants will receive talquetamab and daratumumab as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
89232145|NCT05453903|Experimental|Arm A: Relapsed/Refractory Setting|Participants with relapsed/refractory AML harboring either NPM1 or KMT2A alterations will receive JNJ-75276617 in combination with either venetoclax (VEN) (Cohort A1: JNJ75276617+VEN) or azacitidine (AZA) (Cohort A2: JNJ-75276617+AZA) or VEN+AZA (Cohort A3: JNJ-75276617+VEN+AZA) to select the recommended phase 2 dose (RP2D) of JNJ-75276617 in combination with VEN, AZA or VEN+AZA (dose selection). In dose expansion portion of the study, participants will receive JNJ-75276617 in combination with AML directed therapies at the RP2D(s).
89115929|NCT02590549|Experimental|MyoRing Implantation combined with corneal cross linking|Surgical technique: Implantation of a MyoRing in a corneal pocket was performed by using a PocketMaker microkeratome a guided, vibrating diamond blade to create a stromal pocket 9 mm in diameter at a 300-μm depth via a 4- to 5-mm-wide corneal tunnel followed by Corneal Collagen Crosslinking (standard surface UVA irradiation (370 nm, 3 mW/cm2) using Ufalink device)
89115930|NCT00720499|Experimental|BI 1744 CL low dose+tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
89115931|NCT00720499|Experimental|BI 1744 CL medium dose+tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
89115932|NCT02592187|Experimental|Experimental intervention|ReMemory-MCI training
89115933|NCT02592187|Active Comparator|Control intervention|Control intervention
89115934|NCT04087369|Experimental|Bundled NCD WHO PEN Intervention|Mixed-methods type 2 hybrid effectiveness-implementation study to evaluate an integrated NCD care management intervention
89115935|NCT04086979|Experimental|Parental Friendship Coaching (PFC)|
89115936|NCT04086979|Active Comparator|Coping with ADHD through Relationships and Education (CARE)|
89115937|NCT02592109|Experimental|Enhanced Counseling using CFR based on LP|"The counseling will be done by individual face-to-face communications. The intervention's arm will get a counseling with an additional of 7-day cycle with adequate n-3 and optimal n-3/6 ratio for complementary feeding menu obtained from linear programming formulation.~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet; definition, function, and source of omega-3; example of menu that contains adequate omega-3. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
89115938|NCT02592109|Active Comparator|General CFR Counseling|"The control's arm will get general counseling combining balance diet and IYCF principal, which already been used by Ministry of Health, with additional of 7-day cycle menu guidance modified from existing or available menu which can be downloaded for public on Ministry of Health official website.~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet based on Ministry of Health's Recommendation, and example of balanced diet menu. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
89115939|NCT04087135|Experimental|participant LD|
89115940|NCT04087135|Experimental|participant VL|
89115941|NCT04087135|Experimental|participant VLS|
89115942|NCT00724243||Rheumatoid Arthritis Patients in Slovakia|Rheumatoid arthritis patients in Slovakia who are starting treatment with infliximab for the first time, in accordance with normal clinical practice.
89115943|NCT02590705|Experimental|Group 1|surface anesthesia with lidocaine
89115944|NCT02590705|No Intervention|Group 2|no anesthesia
89115945|NCT04085107||243 PwMCI|
89115946|NCT00720343|Experimental|Choline|Oral choline
89115947|NCT00720343|Placebo Comparator|Placebo|Gelatin Capsule
89115948|NCT00720109|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|See Detailed Description
89115949|NCT02590627|Active Comparator|A|Artemether-lumefantrine
89115950|NCT02590627|Experimental|B|Dihydroartemisinin-piperaquine
89115951|NCT01015118|Experimental|BIBF 1120|patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
89115952|NCT01015118|Placebo Comparator|Placebo|patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
89115953|NCT00800176|Placebo Comparator|Placebo|"During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast.~During the 12-week double-blind treatment period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test."
89115954|NCT00800176|Experimental|RO4998452 10mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 10 mg of RO4998452.
89232146|NCT05453903|Experimental|Arm B: Newly Diagnosed Chemotherapy Ineligible Setting|Participants will receive JNJ-75276617 in combination with VEN+AZA as frontline chemo therapy for newly diagnosed AML participants harboring either KMT2A or NPM1 alterations who are greater than or equal to (>=)18 years of age to less than (<) 75 years of age with comorbidities that preclude the use of intensive induction chemotherapy.
89232147|NCT05453903|Experimental|Arm C: Newly Diagnosed Chemotherapy Eligible Setting|Participants will receive combination of JNJ-75276617 with cytarabine+daunorubicin or idarubicin chemotherapy as frontline treatment regimen for participants >=18 to <75 years of age with AML harboring either NPM1 or KMT2A alterations and eligible for intensive chemotherapy.
89232148|NCT05451563|Experimental|Double-S arm|Participants will be asked to use the wearable penile device during intercourse.
89232152|NCT05444530|Experimental|Dose Escalation|Participants with essential thrombocythemia (ET) and myelofibrosis (MF) will receive VAC85135 target dose intramuscular (IM) injection in the safety lead-in cohort (Cohort 0). Participants in subsequent cohorts will receive VAC85135 target dose IM injection along with ipilimumab intravenous (IV) infusion. Ipilimumab dose may be escalated based on dose limiting toxicity (DLT) observations.
89232153|NCT05444530|Experimental|Dose Expansion|Participants with polycythemia vera (PV) or post-polycythemia vera myelofibrosis, ET and MF will receive VAC85135 target dose IM injection with ipilimumab IV infusion at the dose(s) determined by study evaluation team (SET).
89232154|NCT05441501|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-80038114. The dose levels will be escalated based on the dose limiting toxicities (DLTs) evaluation by the study evaluation team (SET).
89232155|NCT05441501|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-80038114 at the recommended Phase 2 dose (RP2D) determined in Part 1.
89232156|NCT05438043|Experimental|Daratumumab|Participants will receive a single dose of daratumumab 16 milligrams per kilograms (mg/kg) intravenous (IV) or 1800 mg subcutaneous (SC) infusion on Cycle 1 Day 1 (28-day cycle), as monotherapy or in combination with standards of care treatment (that is, pomalidomide and dexamethasone, lenalidomide and dexamethasone, carfilzomib and dexamethasone) or standards of care treatment alone, depending on the treatment received in the parent study. Participants who received daratumumab IV during the parent study, will have an option to switch to daratumumab SC on Day 1 of any cycle during this long-term extension study.
89232157|NCT05431075|Experimental|Tid group|Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 20mg bid
89232158|NCT05431075|Active Comparator|Qid group|Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 20mg bid
89232159|NCT05424822|Experimental|Part A: Dose Escalation|Participants will receive JNJ-80948543 by subcutaneous (SC) administration to determine the putative recommended Phase 2 dose (RP2D) and dosing schedule(s) based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens.
89232160|NCT05424822|Experimental|Part B: Cohort Expansion|Participants will receive JNJ-80948543 by SC administration.
89232161|NCT05421091||Asciminib|Patients prescribed with Asciminib
89115955|NCT00800176|Experimental|RO4998452 2.5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 2.5 mg of RO4998452.
89115956|NCT00800176|Experimental|RO4998452 20mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 20 mg of RO4998452.
89115957|NCT00800176|Experimental|RO4998452 40mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 40 mg of RO4998452.
89115958|NCT00800176|Experimental|RO4998452 5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 5 mg of RO4998452.
89115959|NCT04086355|Experimental|Effect of electrical stimulation on dysphagia in cp|the study group that was treated by selected oromotor exercise program in addition to neuromuscular electrical stimulation, Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
89115960|NCT04086355|Experimental|effect of oromotor exercise on dysphagia in cp|the control group was treated by the same oromotor exercise program in addition to placebo effect of neuromuscular electrical stimulation. Feeding level progress was evaluated by functional oral intake scale,oro motor skills were evaluate by oromotor assessment scale, weight gain and height were measured pre and post 2 months of the treatment.
89115961|NCT04086667|Experimental|Pain group|"The segment on the lower back marked as most painful"
89115962|NCT04086667|Experimental|Stiff group|"The segment on the lower back marked as most stiff"
89115963|NCT04086901|Experimental|Dose escalation Arm|Chemo-radiotherapy with radiotherapy dose escalation based on Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG/PET) scans
89115964|NCT04086901|No Intervention|Standard|Standard chemo-radiotherapy
89115965|NCT02502903|Placebo Comparator|Part A|Single ascending dose (SAD) in NHVs, 7 cohorts, BIVV009 by IV infusion (0.3,1, 3, 10, 30, 60, or 100 mg/kg) or placebo.
89115966|NCT02502903|Placebo Comparator|Part B|Multiple ascending dose (MAD) in NHVs, 2 cohorts, 4 weekly IV doses of BIVV009 (30 or 60mg/kg) or placebo.
89115967|NCT02502903|Experimental|Part C|Multiple dose (MD) in a single cohort of patients with various complement-mediated disorders. All patients in Part C will receive a single IV test dose of BIVV009 of 10 mg/kg followed by 4 weekly doses of 60 mg/kg.
89115968|NCT02502903|Experimental|Part E|Multiple dose (MD) in a single cohort of patients with cold agglutinin disease previously treated with BIVV009. All patients in Part E will receive a single IV test dose at week 0, week 1, and every 2 weeks thereafter until EOT. Patients who weigh less than 75 kg will receive fixed doses of 6.5 grams of BIVV009; patients who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009. Dose will be increased from 6.5g to 7.5g dose level if patients current weight is >= 75 kg and there is evidence of hematologic breakthrough OR patients current weight is >= 75 kg and there has been at least a 10 percent increase from the patients last recorded weight. Dose will be decreased from 7.5g to 6.5g for patients whose last weight was >= 75 kg and current weight decreased to < 75 kg. Dose decrease will require Sponsor approval.
89115969|NCT04112446|Experimental|Study Treatment|4 mg [14C]-saroglitazar magnesium (approximately 100 μCi) oral suspension
89115970|NCT02415153|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89115971|NCT04111744|Experimental|Training Group|Preoperative Exercise Training Optimal medical therapy,
89115972|NCT04111744|Other|Control Group|Optimal medical therapy, inactive control group
89115973|NCT02337621||pectus excavatum surgical candidates|Any person who is eligible to undergo the Nuss procedure for surgical correction of pectus excavatum
89115974|NCT00628160|Experimental|Terlipressin group|Terlipressin in continuous infusion plus alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
89115975|NCT00628160|Active Comparator|Control group|Alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
89115976|NCT02590471|Active Comparator|Stenting of the femoral artery.|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted.
89115977|NCT02590471|Experimental|Stenting of the femoral artery and fasciotomy.|Under local anesthesia standard endovascular exposure is made and lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.
89115978|NCT04298996||study group (passive smoking children)|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
89115979|NCT04298996||control group|examining for caries prevalence and taking saliva samples to determine oxidative stress markers TAS and TOS
89115980|NCT02274285|Experimental|Group A (SP0204)|Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously
89115981|NCT02274285|Active Comparator|Group B (control)|Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously
89115982|NCT02274285|Experimental|Group C|Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly
89115983|NCT00614835|Experimental|1 patients with completely resected uterine leiomyosarcoma|Docetaxel plus Gemcitabine
89115984|NCT00715429|Experimental|vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks|Vitamin D arm
89115985|NCT00715429|Placebo Comparator|placebo x 10d, + placebo weekly 7 wks|placebo
89115986|NCT02606032|Active Comparator|Metronidazole+doxycylcine+terbinafine|Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days
89115987|NCT02606032|Placebo Comparator|Placebo|Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days
89115988|NCT02145507|Other|Arm 1: Room Temperature Storage/Filtration|SOLX (Investigational Product) and AS-3 (Control)
89115989|NCT02145507|Other|Arm 2 : Cold storage|SOLX (Investigational Product) and AS-3 (Control)
89115990|NCT02138175||Patients at risk for bleeding|Patients at risk for bleeding
89115991|NCT02043405|Experimental|Exercise Training and Weight Loss Intervention|Combination weight loss/exercise training, on insulin sensitivity, muscle lipid composition and localization in skeletal muscle.
89115992|NCT02043405|Active Comparator|4 Month Weight Loss Only Intervention|Use exercise training and weight loss as separate interventions in obese subjects with and without pre-diabetes.
89115993|NCT01828749||CT abdomen and pelvis|blunt trauma patients without suspected fractures of the pelvis, hip or lumbar spine in two age groups: ages 3-17 years and 18-60 years
89115994|NCT02590237|Active Comparator|Direct Laryngoscopy|The trachea will be intubated via direct laryngoscopy using a traditional straight blade (Miller) laryngoscope.
89115995|NCT02590237|Experimental|KingVision Video Laryngoscope|The trachea will be intubated using the Ambu KingVision Video Laryngoscope size 1 pediatric blade.
89115996|NCT01743651|Placebo Comparator|Placebo|Placebo
89115997|NCT01743651|Active Comparator|Baclofen|80 mg/day of Baclofen Tablets, USP
89115998|NCT01743651|Experimental|Arbaclofen|40 mg/day of Arbaclofen Tablets
89115999|NCT00715117|Placebo Comparator|Sugar pill|Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks.
89116000|NCT00715117|Experimental|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.
89116001|NCT04086277|Experimental|Women in labor with continuous intrapartum support|Continuous intrapartum support was based on three basic aspects: 1) emotional support, 2) physical support and comfort measures and 3) information and advice.
89116002|NCT04086277|No Intervention|Women in labor without continuous intrapartum support.|The no intervention group received the usual obstetric care, without continuous intrapartum support.
89116003|NCT00855855||Hib vaccine|Participants has received at least one dose of an Hib vaccine
89116004|NCT00723229|Active Comparator|1|
89116005|NCT00723229|No Intervention|2|
89116006|NCT02590081|Active Comparator|Normal saline|Normal saline will be used for wash back procedure at the end of hemodiaysis.
89116007|NCT02590081|Experimental|dextrose 5%|Dextrose 5% will be used for wash back procedure at the end of hemodiaysis.
89116008|NCT01093521|Experimental|100 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 100 mg/m2
89116009|NCT01093521|Experimental|200 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 200 mg/m2
89116010|NCT04084639|Experimental|Ingestion of 20g Mycoprotein Drink|Milkshake containing 20g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
89116011|NCT04084639|Experimental|Ingestion of 40g Mycoprotein Drink|Milkshake containing 40g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
89116012|NCT04084639|Placebo Comparator|Ingestion of Isocaloric Control Drink|Milkshake containing 250ml full-fat milk, 50g glucose, 19g dried skim milk and 9g full-fat dried milk
89116013|NCT01030718|Experimental|dasatinib (CML-CP)|CML - Chronic Phase
89116014|NCT01030718|Experimental|dasatinib (CML-AP/BP)|CML - Accelerated Phase and Blast Phase
89116015|NCT01030718|Experimental|dasatinib (Ph+ ALL)|Ph+ Acute Lymphoblastic Leukemia
89116016|NCT00722761|Active Comparator|Drosperinone and Ethinyl estradiol|Drospirenone and Ethinyl estradiol (3mg/0.02mg)(YAZ)tablet once a day
89116017|NCT00722761|Placebo Comparator|Placebo tablet|Placebo tablet once a day
89116018|NCT02692053|Experimental|Patients with septic shock|
89116019|NCT02692053|Other|Blood samples from a historical cohort of healthy volunteers|
89116020|NCT00628238|Active Comparator|A|Subjects younger than 65 years old.
89116021|NCT00628238|Active Comparator|B|Subjects aged 65 years and older
89116022|NCT03207087|Experimental|WEB Aneurysm Embolization Device|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant. Subjects will be screened for study eligibility after giving informed consent.
89116023|NCT05132179|Active Comparator|HOCl arm|Dakin´s Solution, with the active substance Hypochlorous Acid, HOCl was first invented 1915 for use on infected war wounds. The DFU will be cleaned with HOCl twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.
89116024|NCT05132179|No Intervention|PHMB arm|Prontosan, with the active substance PHMB, is recommended by 19 out of 21 regions in Sweden, for cleaning DFU. The DFU will be cleaned with PHMB twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.
89116025|NCT02871830|Experimental|Physical activity intervention group|
89116026|NCT02871830|No Intervention|Control group|
89232162|NCT05419089|Experimental|Robotic surgery only|"Complete resection to negative frozen section margins (pT1-2)~< 4 nodes, ≤ 2 mm extranodal extension (ENE), no supraclavicular nodes"
89232163|NCT05419089|Experimental|Robotic surgery with de-intensified adjuvant therapy|"The presence of any of the following: 4 positive nodes, gross ENE, final positive margins, or bilateral neck disease~High-risk PNI/LVI (defined as PNI and LVI in combination or either factor in the presence of 3 or more positive nodes)"
89232164|NCT05409300|Experimental|BBIBP-CorV|Intramuscular administration of two doses of vaccine at 28 days (+/- 2 days) interval (0.5 mL/dose)
89232165|NCT05409261|Experimental|Ad26.COV2.S|Single dose (0.5mL) of SARS-CoV-2 vaccine Ad26.COV2.S.
89232166|NCT05402345|Experimental|GlcNAc|GlcNAc powder
89232167|NCT05402345|Placebo Comparator|Placebo|Placebo glucose powder
89232168|NCT05400941|Active Comparator|Practice Led Intervention|Clinic staff will participate in learning collaborative and practice facilitation as well as receive expert consultation and audit and feedback.
89232169|NCT05400941|No Intervention|Standard of Care|No intervention.
89232170|NCT05398276|Experimental|Behavioral Exposure For Introceptive Tolerance|The BE-FIT intervention is a cognitive-behavioral intervention and is designed to target exercise anxiety. The three main components of BE-FIT include: 1) exposure to feared bodily sensations and exercise, 2) prevention of safety behavior use before/during/after exercise, and 3) use of a wrist-worn activity monitor (Fitbit) for PA feedback and activity goal setting.
89232171|NCT05398276|Active Comparator|Health Education Control|HEC is a time-matched control intervention that will be delivered on the same delivery schedule as BE-FIT. In this arm, participants will be provided educational information about health topics relevant to healthy aging delivered through PowerPoint lectures and handouts and use a Fitbit for PA monitoring.
89232172|NCT05389982|Placebo Comparator|Standard Care|
89232173|NCT05389982|Active Comparator|standard care + mHealth (GetWell)|
89232174|NCT05389982|Active Comparator|mHealth (GetWell)|
89232175|NCT05384145|Other|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
89232178|NCT05379634|Experimental|Nipocalimab|Participants will receive Nipocalimab at Week 0 (Baseline) and then every 2 weeks (Q2W) up to Week 50 during double-blind period. Participants on glucocorticoids (GC) at baseline will receive a stable dose of oral GC (prednisone or equivalent) from 4 weeks prior to the first administration of study intervention to Week 0. No changes in GC doses are allowed between Week 0 and Week 24. From Week 24 to Week 44, GC doses will be tapered. No changes to GC doses will be allowed from Week 44 to Week 52. Eligible participants will enter long-term extension (LTE) period and continue receiving Nipocalimab starting from Week 52 up to Week 98 and will be followed up to Week 106.
89232179|NCT05379634|Placebo Comparator|Placebo|Participants will receive Nipocalimab matching placebo at Week 0 (Baseline) and then Q2W up to Week 50 during double-blind period. Participants on GC at baseline will receive a stable dose of oral GC (prednisone or equivalent) from 4 weeks prior to the first administration of study intervention to Week 0. No changes in GC doses are allowed between Week 0 and Week 24. From Week 24 to Week 44, GC doses will be tapered. No changes to GC doses will be allowed from Week 44 to Week 52. Eligible participants will enter LTE period and continue receiving Nipocalimab matching placebo Q2W starting from Week 52 up to Week 98 and will be followed up to Week 106.
89232180|NCT05379595|Experimental|Cohorts A, B, and C: Amivantamab Monotherapy|Participants with left-sided colorectal cancer (CRC) in Cohort A (no prior anti-epidermal growth factor receptor [EGFR] therapy) and in Cohort B (post anti-EGFR therapy), and right-sided CRC in Cohort C (with or without anti-EGFR therapy), will be administered intravenous (IV) infusion of amivantamab 1050 milligrams (mg) if body weight (BW) is less than (<) 80 kilograms (kg) or 1400 mg if BW is greater than or equal to (>=) 80 kg, as monotherapy on Days 1 and 15 of Cycle 2 (28-days cycle).
89232181|NCT05379595|Active Comparator|Cohorts Ph1b-D and D: Amivantamab+5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6)|Participants who are anti-EGFR treatment naïve, have not received oxaliplatin-based chemotherapy in the metastatic setting, will be administered IV infusion of amivantamab 1050 or 700 mg (dose level 0 [DL0]) if BW is <80 kg, or 1400 or 1050 mg (dose de-escalation [DL-1]) if BW is >= 80 kg, on Days -1, -2, 8 and 22 of Cycle 1 and along with mFOLFOX6 SOC chemotherapy on Days 1 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 (each cycle of 28 days) in Phase 1b dose confirmation Cohort (Cohort Ph1b-D). Participant in Phase 2 Cohort (Cohort D) will receive recommended Phase 2 combination dose (RP2CD) of amivantamab along with mFOLFOX6 SOC chemotherapy determined in Cohort Ph1b-D.
89232182|NCT05379595|Active Comparator|Cohorts Ph1b-E and E: Amivantamab+5-Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)|Participants who are anti-EGFR treatment naïve, have not received irinotecan-based chemotherapy in the metastatic setting, will be administered IV infusion of amivantamab along with FOLFIRI SOC chemotherapy on Days -1, -2, and 8 of Cycle 1 and Days 1 and 15 of Cycle 2 in Ph1b-E. For Cohort E, RP2CD determined in Ph1b-E will be administered.
89232183|NCT05378958||Caregivers|Any health professional (medical or paramedical profession) practicing therapeutic education in distance mode by videoconferencing, regardless of the programs concerned
89232184|NCT05378958||Participants|"Patient's caregivers or parents who have taken part in a therapeutic education session by videoconference (individual or collective) as part of a program, regardless of their age, sex or the pathology concerned by education program~Patients: from 10 years old and only if the therapeutic education session was intended for them, regardless of gender or pathology"
89232185|NCT05376397|Experimental|iTHRIVE 365|
89232187|NCT05371886|Other|Dose-effect relationship of morphine +/- midazolam administration|
89232188|NCT05369533|Active Comparator|Telerehabilitation + Sinemet|Patients will receive 36 telerehabilitation sessions targeting arm motor function. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6-8 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently. Sinemet is taken one hour before starting TR, for the first 18 sessions.
89232189|NCT05369533|Placebo Comparator|Telerehabilitation + Placebo|Patients will receive 36 telerehabilitation sessions targeting arm motor function. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6-8 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently. Placebo is taken one hour before starting TR, for the first 18 sessions.
89232190|NCT05369533|No Intervention|Usual care|Participants in the usual care group will receive no TR or study pill, but will continue with the recommendations made by their care team. All participants will be offered TR at the end of the study.
89232191|NCT05358925|Experimental|BPD Videos and Feedback|Ten daily 4-10 minute psychoeducational videos about BPD and personalized feedback about performance on neuropsychological tasks.
89232192|NCT05358925|Experimental|BPD Videos and No Feedback|Ten daily 4-10 minute psychoeducational videos about BPD.
89232193|NCT05358925|Sham Comparator|Non-BPD Videos and No Feedback|Ten daily 4-10 minute educational videos about health-related topics other than BPD.
89232194|NCT05347095|Experimental|Group 1: Guselkumab|Participants will receive guselkumab Dose 1 intravenous (IV) infusion followed by Dose 2 subcutaneously (SC). Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) period and continue to receive guselkumab.
89232195|NCT05347095|Experimental|Group 2: Guselkumab|Participants will receive guselkumab Dose 1 IV infusion followed by Dose 3 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
89232196|NCT05347095|Experimental|Group 3: Placebo|Participants will receive placebo IV infusion followed by placebo SC. At Week 24, placebo non-responders will continue to receive guselkumab Dose 4 followed by guselkumab Dose 2 SC. Participants will receive matching placebo to maintain the blind. Participants who are eligible and willing to continue guselkumab may enter the LTE period and continue to receive guselkumab.
89232197|NCT05343013|Experimental|TAS-102|TAS-102 should be taken by mouth 2 times a day, within 1 hour after your morning and evening meals (about 12 hours apart).
89232198|NCT05340582|Experimental|Combination Therapy|Intravenous or enteral ibuprofen, as decided by clinical team, in the standard clinical dose used in participating NICUs (typically, for neonates < 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3) And study drug (intravenous acetaminophen 15 mg/kg/dose IV q6h for 3 days).
89232199|NCT05340582|Placebo Comparator|Standard Clinical Practice - Monotherapy|Intravenous or enteral ibuprofen, as decided by clinical team, in the standard clinical dose used in participating NICUs (typically, for neonates < 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates > 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3) And Placebo [(0.9% saline IV q6h for 3 days).
89232200|NCT05338775|Experimental|Part 1: Dose Escalation|Participants will receive either talquetamab (treatment regimen A) or teclistamab (treatment regimen B) with a PD-1 inhibitor biweekly.
89232201|NCT05338775|Experimental|Part 2: Dose Expansion|Participants will receive either treatment regimen A or treatment regimen B with a PD-1 inhibitor at the dose levels identified in Part 1.
89232202|NCT05332795|Active Comparator|group 1: gouty patients on metformin.|metformin users: include gouty patients, who will receive metformin tablets (1000 mg) once daily for about 3 months.
89232203|NCT05332795|Placebo Comparator|gouty patients on placebo.|placebo users: include gouty patients, who were on placebo tablets once daily for about 3 months.
89232204|NCT05332093||Local cutaneous leishmaniasis patients group (LCL)|local cutaneous leishmaniasis patients
89232205|NCT05332093||Mucocutaneous leishmaniasis patients group (MCL)|mucocutaneous leishmaniasis patients
89232206|NCT05332093||Diffuse cutaneous leishmaniasis patients group (DCL)|diffuse cutaneous leishmaniasis patients
89232207|NCT05332093||Healthy control patients group Ethiopia (HC - Ethiopia)|healthy control patients undergoing elective surgery in Northern Ethiopia
89232208|NCT05332093||Healthy control patients group Belgium (HC - Belgium)|healthy control patients undergoing plastic surgery in Belgium
89232209|NCT05328297|Experimental|JNJ-55308942|Participants will receive a JNJ-55308942 capsule once daily for 6 weeks.
89232210|NCT05328297|Placebo Comparator|Placebo|Participants will receive a matching placebo capsule once daily for 6 weeks.
89232211|NCT05327322|Experimental|Low Glycemic Load|This group will be prescribed a daily GL of <45 points/1000 kcal and 25% of daily calorie intake from carbohydrates. This group will be provided few processed foods. During the first 16 weeks, this group will eat enough calories to maintain baseline weight, and will reduce daily calorie intake by 500 kcal/day in the second 16 weeks.
89232212|NCT05327322|Active Comparator|Standard Glycemic Load|This group will be prescribed a daily GL of >75 points/1000kcal and 60% of daily calorie intake from carbohydrates. This group will be provided more processed foods than the low GL group. During the first 16 weeks, this group will eat enough calories to maintain baseline weight, and will reduce daily calorie intake by 500 kcal/day in the second 16 weeks.
89232213|NCT05327114|Experimental|Nipocalimab|Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.
89232214|NCT05327114|Placebo Comparator|Placebo|Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.
89232215|NCT05319496|Experimental|isCGM with education and feedback|Intervention subjects will receive three isCGM sensors (FreeStyle Libre 2, Abbott Laboratories) for use over weeks 1-6. They will have encounters with a diabetes educator for individualized education and coaching during weeks 1-2 and 5-6.
89232216|NCT05319496|Active Comparator|Enhanced usual care with education and feedback only|Enhanced usual care subjects will receive two encounters with a diabetes educator for individualized education and coaching, during weeks 1-2 and 5-6. They will not be provided with isCGM sensors.
89232217|NCT05316311|Experimental|CERENOVUS ENTERPRISE 2 Intracranial Stent|Participants with severe symptomatic intracranial artery stenosis will be treated with CERENOVUS ENTERPRISE 2 Intracranial Stent.
89232218|NCT05316155|Experimental|Part 1: Dose Escalation|Participants with recurrent, bacillus Calmette-Guerin (BCG)-experienced high risk papillary-only Non-Muscle-Invasive Bladder Cancer (NMIBC), refusing or ineligible for radical cystectomy or with recurrent, intermediate-risk NMIBC will receive Erdafitinib Intravesical Delivery System. The dose will be escalated to determine preliminary recommended phase 2 dose(s) (RP2D[s]) for Part 2.
89116027|NCT02591641|Experimental|Standard of Care First, then Liquicell|Subjects were secured on a standard ambulance stretcher, with a shear and pressure sensors attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken during the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated with the LiquiCell® ASMO.
89116028|NCT02591641|Experimental|Liquicell First, then Standard of Care|Subjects were secured on a standard ambulance stretcher with an anti-shear mattress overlay placed on top of the stretcher, with a shear and pressure sensor attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken throughout the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated without the LiquiCell ASMO.
89116029|NCT04084873|Experimental|Experimental PBrE|Participants are exposed to several words of emotional contents (positive, and negative). The differences between these words will allow the regulation and counter regulation of emotional processes (Schwager y Rothermund, 2013). The words are related to clinical and personal characteristics of the patients and they will promote an emotional identification that improve the emotional regulation (Kashdan, Barret y McKnight, 2015).
89116030|NCT04084873|Placebo Comparator|Control PBrE|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
89116031|NCT04084873|Other|Control|Participants do not receive the intervention.
89116032|NCT01019486|Experimental|Type 1 Diabetic Subjects|Regadenoson 400mcg slow IV bolus to identify assess myocardial blood flow (MBF). Stratified by coronary calcium score of below 100 or greater than score of 100 for low and high risk individuals respectively.
89116033|NCT01019486|Active Comparator|Nondiabetic Subjects|Regadenoson myocardial perfusion imaging (MPI) Intervention: Regadenoson (400mcg slow IV bolus) stress to assess myocardial blood flow (MBF) and MPI to identify occult coronary artery disease (CAD). These individuals serve as an active control with higher risk non-diabetic individuals with scores greater than 100.
89116034|NCT02891265|No Intervention|Group A|Group A - smoking cessation with no assistance
89116035|NCT02891265|Placebo Comparator|Group B|Group B - smoking cessation with the addition of a smoking cessation patch
89116036|NCT02803203|Experimental|osimertinib and bevacizumab|"Phase 1:~3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks~Phase 2:~Use MTD determined during phase 1"
89116037|NCT00714493|Other|001|Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
89116038|NCT03277131|Experimental|1|Antimicrobial Dressing
89116039|NCT01019252|Experimental|CBT for ADHD first, then follow-up|Participants received Cognitive Behavioral Therapy following randomization.
89116040|NCT01019252|No Intervention|Wait list first, then CBT for ADHD|Cross-over: Participants were assigned to a wait list after the initial assessment. They received Cognitive Behavioral Therapy after the 4 month assessment.
89116041|NCT04216407|Experimental|Remote Ischemic Preconditioning|Short-term tourniquet on to the lower extremity before surgery
89116042|NCT04216407|No Intervention|Control|No intervention
89116043|NCT01013870|Experimental|MTBI subjects randomized to drug|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the treatment arm of the phase II drug trial of atorvastatin. These subjects will receive a daily weight-based dose of atorvastatin 1mg/kg (up to 80 mg) for seven days and started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving a placebo.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
89116044|NCT01013870|Placebo Comparator|MTBI subjects randomized to placebo|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the placebo arm of the phase II drug trial of atorvastatin. These subjects will receive a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
89116045|NCT01013792|Experimental|Non-adherent Wound Dressing|The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.
89116046|NCT01013792|Active Comparator|Tegaderm Matrix Dressing with PHI|A commercial wound dressing to be used per manufacturer's instructions for use.
89116047|NCT01018862|Active Comparator|MP03-36 (0.15% solution)|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
89116048|NCT01018862|Active Comparator|MP03-33 (0.10% solution)|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
89116049|NCT01018862|Placebo Comparator|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
89116050|NCT01018394|Active Comparator|nicotine lozenges|40 subjects will be assigned to receive nicotine lozenges for 8 weeks. They will use the nicotine lozenges ad lib, up to 8 lozenges per day.
89116051|NCT01018394|Active Comparator|tobacco free snuff|41 subjects will receive tobacco free snuff for 8 -12 weeks. The tobacco-free snuff will be used ad lib - as needed.
89116052|NCT04299698||Carbohydrate reduction group|Participants chose to control their body fat mass by reducing their carbohydrate intake through observation study periods.
89116053|NCT04299698||Fat reduction group|Participants chose to control their body fat mass by reducing their fat intake through observation study periods.
89116054|NCT04299698||Intense exercise group|Participants chose to control their body fat mass by vigorously increasing the time and intensity of exercise through observation study periods.
89116055|NCT04299698||Moderate exercise group|Participants chose to control their body fat mass by moderately increasing the time and intensity of exercise through observation study periods.
89116056|NCT04567394|Experimental|Intervention|Participants randomized to the Intervention group will complete questionnaires at baseline, 1 month, 3 months, and 6 months and will receive 4 weeks of the PNC-txt intervention.
89116057|NCT04567394|No Intervention|Waitlist Control|Participants randomized to the waitlist control group will complete questionnaires at baseline, 1 month, 3 months, and 6 months.
89116058|NCT04301336|Experimental|Omega-3 experimental group|"50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA & 200-300mg DHA) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
89116059|NCT04301336|Experimental|Vit-D experimental group|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
89116060|NCT04301336|Experimental|Zinc supplements experimental group|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
89116061|NCT04301336|Experimental|Statin experimental group|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
89116062|NCT04301336|Active Comparator|Ordinary hospital treatment group|"50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.~in addition, Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response in addition, Morphine medication as a pain killer is administered, if Patient weight <50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.~This group received regular blood transfusion session."
89116063|NCT02873546|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 minutes for 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
89116064|NCT02873546|Sham Comparator|sham tDCS on left DLPFC (F3)|Sham tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 minutes - 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
89116065|NCT04298060|Experimental|DAS181 SD group Cohort 1, Stage 1|DAS181 SD group 4.5mg/day for 7 or 10 days
89116066|NCT04298060|Experimental|DAS181 HD group Cohort 1, Stage 1|DAS181 HD group 9mg/day for 7 or 10 days.
89116067|NCT04298060|Placebo Comparator|Placebo, Cohort 1, Stage 1|Placebo 0mg/day for 7 or 10 days
89116068|NCT04298060|Experimental|DAS181 group, Cohort 1, Stage 2|DAS181 4.5mg/day or 9mg/day. Dosage will be determined after completion of stage 1.
89116069|NCT04298060|Placebo Comparator|Placebo, Cohort 1, Stage 2|Placebo 0mg/day for 7 or 10 days
89116070|NCT04298060|Experimental|DAS181 group, Cohort 2, Stage1 and 2|DAS181 4.5mg/day or 9mg/day for 7 or 10 days
89116071|NCT04299854||Vaginal Dinoprostone|Induction of labor by 10mg of vaginal dinoprostone
89116072|NCT04299854||Single Balloon Foley Catheter|Induction of labor by single balloon Foley catheter
89116073|NCT02872220|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products compared to that of a negative control [0.9% NaCl] were tested simultaneously on each subject.
89116074|NCT01017146|Experimental|1|Tazarotene foam, 0.1%
89116075|NCT01017146|Placebo Comparator|2|Vehicle Foam
89116076|NCT02872064|Experimental|Treatment with PDT|A single intravenous injection of Verteporfin (0.4mg/kg) will be administered, at least 60minutes and up to 90 minutes before laser activation. A 690nm red laser light will be delivered with a diffuser laser fibre inserted through the skin into the breast tissue, with light dose escalation after every three patients. All patients will have fixed dose of the photosensitizer but variable light dose.
89116077|NCT02871908|Experimental|L reuteri DSM 17938|L reuteri DSM 17938 2 x 10^8 twice daily
89116078|NCT02871908|Placebo Comparator|Controls|Identically appearing placebo twice daily
89116079|NCT04525586||It's just an observational study, no interventions|children with recurrent wheezing
89116080|NCT02871596|Experimental|Placebo,Flavonoids,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
89116081|NCT02871596|Experimental|Placebo,Flavonoids+Prebiotics,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
89116082|NCT02871596|Experimental|Flavonoids,Placebo,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
89116083|NCT02871596|Experimental|Flavonoids,Flavonoids+Prebiotics,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
89116084|NCT02871596|Experimental|Flavonoids+Prebiotics,Placebo,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
89116085|NCT02871596|Experimental|Flavonoids+Prebiotics,Flavonoids,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
89116086|NCT01010750|Active Comparator|LDX + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
89116087|NCT01010750|Active Comparator|MAS-IR + LDX Placebo|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
89116088|NCT01010750|Placebo Comparator|Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
89116089|NCT01012622|Experimental|OROS Methylphenidate Hydrochloride|
89116090|NCT00722371|Experimental|Sitagliptin 100 mg|
89116091|NCT00722371|Experimental|Pioglitazone 15 mg|
89116092|NCT00722371|Experimental|Pioglitazone 30 mg|
89116093|NCT00722371|Experimental|Pioglitazone 45 mg|
89116094|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 15 mg|
89116095|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 30 mg|
89116096|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 45 mg|
89116097|NCT04298762|Placebo Comparator|Comparison Group|Physicians in the control group did not receive peer comparison emails.
89116098|NCT04298762|Experimental|Intervention Group|Physicians in the intervention group received peer comparison emails.
89116099|NCT02871986||Individuals with hypogonadism|Individuals with hypogonadism requiring pubertal induction. Participants will receive oestrogen therapy in the form of transdermal oestrogen patch, which is standard care.
89116100|NCT04298840|Experimental|Creatine Monohydrate|
89116101|NCT04298840|Placebo Comparator|Placebo|
89116102|NCT00722137|Active Comparator|R-CHOP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, Vincristine 1.4 mg/m^2, and Prednisone 100 mg/m^2
89116103|NCT00722137|Experimental|VcR-CAP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, VELCADE 1.3 mg/m^2, and Prednisone 100 mg/m^2
89232219|NCT05316155|Experimental|Part 2: Dose Expansion|Participants in each of 5 disease-specific NMIBC or MIBC cohorts may be enrolled at one or more dose levels that have been determined to be safe in Part 1.
89232220|NCT05316155|Experimental|Part 3: RP2D Dose Expansion|Participants in 2 of the disease-specific NMIBC cohorts (cohorts 1 and 3) may be enrolled at RP2D to determine the safety, evaluate PK and preliminary clinical activity.
89232221|NCT05306288||Individuals with elevated-risk lung cancer (screening population)|
89232222|NCT05299606|Experimental|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
89232223|NCT05297344|Experimental|direct pulp capping|If a pulp exposure occurred, direct pulp capping will be performed according to the parents' wishes
89232224|NCT05297344|Active Comparator|pulpotomy|If a pulp exposure occurred, pulpotomy will be performed according to the parents' wishes
89232225|NCT05295407||Men 40-69 years old|Men with moderately-elevated PSA (2.5-10 ng/mL) undergoing prostate biopsy for detecting prostate cancer at NorthShore University HealthSystem, Northwestern University, or Johns Hopkins Hospital. The trial will not alter any clinical practice for diagnostic biopsy that includes state-of-the-art procedures (transperineal fusion biopsy, multiparametric MRI, and novel biomarkers).
89232226|NCT05291091|Experimental|Adult Cohort 1|Drug: EDG-5506 Drug: Placebo
89232227|NCT05291091|Experimental|Adult Cohort 2|Drug: EDG-5506 Drug: Placebo
89232228|NCT05291091|Experimental|Adult Cohort 6|Drug: EDG-5506 Drug: Placebo
89232229|NCT05291091|Experimental|Adolescent Cohort 4|Drug: EDG-5506 Drug: Placebo
89232230|NCT05291091|Experimental|Adolescent Cohort 5|Drug: EDG-5506 Drug: Placebo
89232231|NCT05288140|No Intervention|usual ICU practice|The patient's evolution is reported verbally to the family.
89232232|NCT05288140|Experimental|ICU diary|Made a diary
89232233|NCT05282173|No Intervention|Treatment As Usual (TAU)|Monitoring of treatment as usual (i.e., routine interactions between community health workers (CHWs) and their patients).
89232234|NCT05282173|Experimental|Siyakhana CHW Training|The Siyakhana CHW Training is a multi-day group training that aims to reduce stigma around mental health and substance use among CHWs. It integrates psychoeducation around TB/HIV, stigma, depression, and substance use, including countering myths and stereotypes around mental health and substance use; skills for CHW self-care; evidence-based skills for working with patients living with depression and substance use, such as components of motivational interviewing and problem-solving therapy; and exposure to individuals with lived experience of mental health and substance use. The training is a combination of informative presentations, discussions, worksheets/activities, and role-plays aimed at increasing awareness of mental health and substance use, reducing stigma, and improving interactions when working with patients with HIV/TB and mental health and substance use concerns.
89232235|NCT05275023|Experimental|Arm 1: JNJ-73763989 + PD-1 Inhibitor + Nucleos(t)ide analog (NA)|Participants will receive JNJ-73763989 subcutaneous (SC) injections and single dose of programmed cell death protein receptor-1 (PD-1) inhibitor as intravenous (IV) infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, tenofovir alafenamide [TAF] or entecavir [ETV]).
89232236|NCT05275023|Experimental|Arm 2: JNJ-73763989 + PD-1 Inhibitor + NA|Participants will receive JNJ-73763989 SC injections and multiple doses of PD-1 inhibitor as IV infusion. Participants will also receive background treatment with NA (either tenofovir disoproxil, TAF or ETV).
89232237|NCT05272631||Retrograde Femoral Nail Advanced (RFNA) Cohort|Participants with a distal femur or femoral shaft fracture or who require revision due to a malunion or nonunion will undergo surgery with RFNA based on surgeon's decision and the site's standard of care (SOC). Participants with impending pathologic fracture are also included.
89232238|NCT05272631||Tibial Nail Advanced (TNA) Cohort|Participants with open or closed, proximal, distal or shaft fractures of the tibia, or who require revision due to a malunion or nonunion will undergo surgery with TNA based on surgeon's decision and the site's SOC.
89232239|NCT05272150|Experimental|Cohort A: Moderate-to-severe Plaque Psoriasis|Participants will receive either guselkumab subcutaneously (SC) or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
89116104|NCT02591329|Experimental|Experimental|The experimental condition (EXP) will receive the targeted intervention material developed and designed by the researchers using focus group discussions with parents. This information will include salient benefits of the consumption of calcium-rich products. In addition, self-regulatory strategies will be provided to encourage purchasing and consumption of calcium-rich products and address any potential barriers to purchase and consumption. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a grocery pad and a recipe book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
89116105|NCT02591329|Active Comparator|Standard Care|Individuals in the Control condition (CON) will receive general healthy eating materials including Canada's Food Guide, Healthier Grocery Shopping Guide and Cooking with Kids. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a note pad and an activity book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
89116106|NCT02590315|Experimental|Digital Breast Tomosynthesis - DBT|Invitation for breast screening and random allocation. Participants randomised to DBT will be screened with bilateral, two-view combo mode (DBT images are obtained with DM images). DBT participants will have an additional radiation exposure for the combined DM and DBT examinations.
89116107|NCT02590315|Active Comparator|Conventional digital mammography - DM|Invitation for breast screening and random allocation. Participants randomised to DM will be screened with bilateral, two-view DM.
89116108|NCT04086043|Experimental|Endovascular Denervation|
89116109|NCT01775722|Other|Pulsed Dye Laser|port wine stain treatment using Pulse Dye Laser
89116110|NCT01775722|Experimental|Bipolar Radiofrequency&Pulsed Dye Laser|Port wine stain using Combined Bipolar Radiofrequency&Pulsed Dye Laser
89116111|NCT02604862|Experimental|FIB ONE administration|All participants in this clinical study will be dosed on one occasion with FIB ONE. The final dosage will be less than 100 µg.
89116112|NCT02604862|Experimental|AZD1236 administration|To quantify the change in mean FIB ONE fluorescence amplification gradient in the presence of AZD1236 in the fibroproliferative lung
89116113|NCT04114396||Severe asthma|Untreated by anti-IL5 treatment for severe asthma at point of recruitment. To be prescribed anti-IL5 as part of their treatment following consent. Note: Anti-IL5 treatment is prescribed as per agreed multidisciplinary team meeting, outside of the decision to enrol the patient on the study, and is administered by the clinical team as part of the patient's clinical care outside of the research study.
89116114|NCT04114396||Healthy control|Control group without respiratory condition
89116115|NCT00796666|Experimental|Sitaxsentan and Placebo|Monotherapy arm
89116116|NCT00796666|Experimental|Sitaxsentan and Sildenafil|Combination treatment
89116117|NCT04025944||chronic hepatitis B|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
89116118|NCT04025944||chronic hepatitis C|No intervention. The clinical data of patients (including demographic information, details of antiviral therapy, imaging and laboratory testings) will be collected and analyzed.
89116119|NCT01637506||Study group|"Age > 19~Radiological evidence indicating presence of a current renal or ureteric stone"
89116120|NCT01637506||Control group|"Age > 19.~No history of kidney stone disease"
89116121|NCT00799708|Placebo Comparator|1|Placebo
89116122|NCT00799708|Active Comparator|2|Estrace 0.5 mg
89116123|NCT00799708|Active Comparator|3|Estrace 2 mg
89116124|NCT00796510|Experimental|Sitaxsentan|Monotherapy arm
89116125|NCT00796510|Experimental|Sitaxsentan and Sildenafil|Combination treatment
89116126|NCT04111432|Experimental|Group I-EV71 and EPI vaccines Concomitant administration|EV71 Vaccine (intramuscular injection,0.5ml,first dose)/measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and EV71 Vaccine (intramuscular injection, 0.5ml,second dose)/ encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
89116127|NCT04111432|Active Comparator|Group II-EPI vaccine only Single injection of EPI vaccine:|measles mumps, and rubella combined live attenuated vaccine (subcutaneous injection,0.5ml) on day 0 and encephalitis live attenuated vaccine (subcutaneous injection, 0.5ml) on day 30
89116128|NCT04111432|Active Comparator|Group III-EV71 vaccine only EV71 Vaccine only|the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 andday 30 respectively
89116129|NCT00915070|Active Comparator|BQ-123|
89116130|NCT00915070|Placebo Comparator|Physiological saline solution|
89116131|NCT00588640|Experimental|Phase I, Group|This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.
89116132|NCT00588640|Experimental|Phase II, Group I|patients receiving around the clock opioid therapy-No patients were accrued to this group
89116133|NCT00588640|Experimental|Phase II, Group II|patients not receiving around the clock opioid therapy.No patients were accrued to this group
89116134|NCT04111198||coronary artery disease in diabetic and non diabetic patients|
89116135|NCT01016912|Experimental|Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
89116136|NCT01016912|Experimental|Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
89116137|NCT01016912|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
89116138|NCT01016912|Experimental|Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)|Non-Responder
89116139|NCT01016912|Experimental|Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Non-Responder
89116140|NCT04114318|Experimental|Cognitive-Cycling|Dual-task cognitive-cycling training; cognitive and cycling training simultaneously
89116141|NCT04114318|Active Comparator|Cycling|Single-task cycling training; stationary bicycle exercise training
89116142|NCT04111120||Cirrhosis with variceal bleeding|Coagulation factor assays and heparinase treated SONOCLOT at Days 0,3, and 7
89116143|NCT04111120||Cirrhosis without Bleeding|Control group of 25 subjects
89116144|NCT04299308|Experimental|Moderate Intensity Aerobic Exercise|45-55% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.45 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.55 + Resting HR
89116145|NCT04299308|Experimental|High Intensity Aerobic Exercise|65-75% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.65 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.75 + Resting HR
89116146|NCT04110964|Experimental|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
89116147|NCT02605798|Experimental|T test|Test drug (Elbanovir)1 tablet contains 400 mg Sofosbuvir
89116148|NCT02605798|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
89116149|NCT02605798|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
89116150|NCT04114240||Xybilun: mild erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with mild ED (score IIEF-6 between 22 and 25) and begin treatment at 50 mg
89116151|NCT04114240||Xybilun: moderate erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with moderate ED (score IIEF-6 between 11 and 21) and begin treatment at 50 mg
89116152|NCT04114240||Xybilun: severe erectil dysfunction|Patient who has never been treated for his ED (erectil dysfunction), with severe ED (score between 6 and 10) and begin treatment at 50 mg
89116153|NCT04114240||Xybilun switch|Substitution dose to dose of previous treatment by Xybilun whatever the severity of ED.
89116154|NCT04113850|Experimental|Sitting|Subjects will undergo acoustic startle testing in the sitting position.
89116155|NCT04113850|Experimental|Standing|Subjects will undergo acoustic startle testing in the standing position.
89116156|NCT00802672|Experimental|Test Product|Ciclopirox Olamine Cream 0.77%
89116157|NCT00802672|Active Comparator|Reference Product|Loprox Cream 0.77%
89116158|NCT00802672|Placebo Comparator|Vehicle Product|placebo of test product
89116159|NCT04113772|Active Comparator|Orfandin .5 mgm/kg mgm bid|Two participant will receive .5 mgm/kg mgm of orfadin
89116160|NCT04113772|Experimental|Nitinosine .5 mgm/kg bid|Two participant will receive .5 mgm/kg of nitinosine
89116161|NCT04113928|Experimental|Broccoli & mustard seed soup|200ml acute feed
89116162|NCT04113928|Active Comparator|Broccoli soup|200ml acute feed
89116163|NCT00914680|Experimental|MST|
89116164|NCT04115800|Experimental|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
89116165|NCT04115800|Placebo Comparator|Liposomal|Subconjunctival liposomal injections in patients with conventional treatments and moderate and severe dry eye disease
89116166|NCT04115410||PD-1 inhibitor|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received PD-1 inhibitors as a second line treatment from cytotoxic chemotherapy or as a third line for those received tyrosine kinase inhibitors as a first line, from August 2017 (the first month PD-1 inhibitors were reimbursed in South Korea) to September 2018.
89116167|NCT04115410||Chemotherapy Drugs, Cancer|Patients over 18 years of age with a diagnosis of non-small cell lung cancer and being received cytotoxic chemotherapy or tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) from August 2017 to September 2018. Each patient switching to PD-1 inhibitor will be matched to three reference standard chemotherapy users.
89116168|NCT05668780|Experimental|Intervention - Nominal Group Technique, Training, Coaching|Each group of clinics will receive the same intervention in a step-wedge design, starting every 6-months.
89116169|NCT04115332|Experimental|Interventional|"EEG Recording The one-channel EEG sensor was recorded from Cz with linked-ear reference based on the International 10-20 system. EEG signals were recorded using BioGraph Infiniti software (Version 6.0.4, n.d.) with a band-pass between 1-30 Hz. The sample rate was 256 Hz with 60-Hz notch filters, and the electrode impedances were lower than 5 kΩ.~A lead II electrocardiogram (ECG) was collected for 5 minutes at baseline using the ProComp InfinitiTM system (Thought Technology Ltd., Montreal, Canada), which was installed on a laptop. A sampling rate of 2,048/second was set in order to acquire real-time interbeat intervals."
89116170|NCT02604706|Experimental|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
89116171|NCT02604706|Experimental|LP Acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. BC-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
89232240|NCT05272150|Experimental|Cohort B: Moderate-to-severe Scalp Psoriasis|Participants will receive either guselkumab SC or placebo SC. Placebo participants will then crossover to receive guselkumab SC.
89116172|NCT02604706|Active Comparator|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
89116173|NCT02604628|No Intervention|Control|Patients will be treated as standard of care.
89116174|NCT02604628|Experimental|Antibiotic Stewardship Intervention|Patients will be treated as standard of care. The Antibiotic Stewardship Intervention will be targeted at the physicians treating the community-acquired pneumonia patients. The purpose of the intervention is to increase prescription concordance with the national guideline for community-acquired pneumonia.
89116175|NCT02604784|Experimental|cohort A|Cohort A: For patients that have indication for systemic therapy with standard chemotherapy. This cohort has a phase II design; the Objective Response Rate (ORR) will be evaluated according to the RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC with Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m2 ) or Oxaliplatin (92 mg/m2) according to the primary cancer, in association with standard systemic chemotherapy.
89116176|NCT02604784|Experimental|cohort B|Cohort B: For patients that have not indication for systemic therapy with standard chemotherapy. This cohort has a phase I design; with a dose-escalation design the maximum tolerated doses and recommended doses of Cisplatin + Doxorubicin and Oxaliplatin (according to the pathology) administered through PIPAC in patients with peritoneal carcinomatosis will be evaluated.
89116177|NCT04110808|Active Comparator|Nitroglycerine|Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.
89116178|NCT04110808|Other|Phentolamine|Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.
89116179|NCT04110652|Active Comparator|patient|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.(20-22) in addition to pulmonary rehabilitation program.
89116180|NCT04110652|Placebo Comparator|control group|40 patients with acute stroke will receive Stroke management based on the guidelines of the American Heart Association/American Stroke Association.
89116181|NCT04110886|Experimental|HSK21542 single ascending doses|
89116182|NCT04110886|Placebo Comparator|Placebo single dose|
89116183|NCT00714415||A|Patients with Hemophilia B
89116184|NCT00714259|Other|Non Myeloablative Treatment|"Non-myeloablative Transplant Conditioning Chemotherapy :~Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight."
89116185|NCT00918541||A|asymptomatic patients with mild to moderate carotid artery stenosis
89116186|NCT02591485|Experimental|Attention Control Training|Computerized attention modification training, comprised of six sessions that delivered by internet, in purpose of modulate biases in attention for threat stimuli.
89116187|NCT02591485|No Intervention|Follow-up only|In this condition, a follow-up interviews will be conducted 3 months since the traumatic event had occurred.
89116188|NCT00918619|Experimental|Sangustop|
89116189|NCT00918619|Active Comparator|Tachosil|
89116190|NCT00796120|Experimental|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
89116191|NCT00796120|Active Comparator|Doxorubicin plus Ifosfamide|Doxorubicin (as a monotherapy) 75 mg per m^2 will be given intravenously every 3 weeks or Doxorubicin 60 mg per m^2 will be given intravenously every 3 weeks followed by ifosfamide 6 to 9 gram (g)/m^2 every 3 weeks until disease progression.
89116192|NCT05685121|Experimental|Apollo Neuro Group|The group will use the Apollo Neuro device daily for six weeks as an adjunct to their standard treatment plan.
89116193|NCT05685121|No Intervention|Standard Treatment Group|The group will follow their standard treatment plan.
89116194|NCT04005742||Healthy|Participants recruited to the healthy arm of the BORICC Study (BORICC1) at baseline.
89116195|NCT04005742||Polyp|Participants recruited to the polyp arm of the BORICC Study (BORICC2) at baseline, with a prior history of polyps.
89116196|NCT00795886|Experimental|All participants|
89116197|NCT04110418|Active Comparator|Methylene Blue group (Group MB)|"Methylene Blue is supplied in 1 ml or 10 mL single-dose ampules. Each 1 mL ampule contains 10 mg of methylene blue as a clear dark blue solution~Any unused product or waste material should be disposed of in accordance with local practice,~For administration to be diluted before use in a solution of 50 mL 5% Dextrose in Water (D5W) in order to avoid local pain, particularly in the paediatric population. Use the diluted solution immediately after preparation.~Do not mix with sodium chloride 9 mg/mL (0.9%) solution for injection, because it has been demonstrated that chloride reduces the solubility of methylene blue."
89116198|NCT04110418|Placebo Comparator|Terlipressin Group (Group TP )|"The active substance is terlipressin acetate. Each ampoule contains~1 mg of terlipressin acetate in 8.5 ml solution for injection. This is equivalent to 0.12 mg terlipressin acetate per ml.~The powder is to be dissolved in the enclosed solvent and slowly administered intravenously. Further dilution up to 10 ml with sterile isotonic sodium chloride solution is possible.~Store in a refrigerator at 2-8˚C.~Keep the ampoules in the outer carton in order to protect from light"
89116199|NCT02604472||CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy
89116200|NCT02604472||IC+CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and concurrent chemoradiotherapy
89116201|NCT00719563|Experimental|Arm I|Patients receive oral American ginseng twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
89116202|NCT00719563|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
89116203|NCT04110184||active systemic lupus erythematosus|
89116204|NCT04110184||inactive systemic lupus erythematosus|
89116205|NCT02604316|Experimental|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate
89116206|NCT02604316|No Intervention|Control- Non Arabinoxylan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
89116207|NCT02604316|Experimental|Beta-Glucan|10 days of weight loss diet calculated as 100% RMR AND 6g Beta-Glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
89116208|NCT02604316|No Intervention|Control Non Beta glucan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
89116209|NCT00795184|Other|Imaging Procedures HDWLE first NBI second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
89116210|NCT00795184|Other|Imaging Procedures NBI first HDWLE second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
89116211|NCT02589925|Sham Comparator|sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
89116212|NCT02589925|Active Comparator|NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
89116213|NCT02589769|Experimental|unsaturated fat|an intervention diet substituting unsaturated fats from oil and nuts for saturated fats from meat and dairy foods
89116214|NCT02589769|Active Comparator|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced.
89116215|NCT05292859||Rollover subjects from Alaunos Therapeutics TCR-T cell drug product interventional studies|"This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in any Alaunos Therapeutics autologous, neoantigen specific TCR-T cell drug product interventional studies.~Patients will be followed for up to 15 years after dosing of Alaunos Therapeutics autologous, neoantigen specific TCR-T cell drug product."
89116216|NCT02589457|Active Comparator|Viread® tablet|Tenofovir Disoproxil Fumarate
89116217|NCT02589457|Experimental|CKD-390|Tenofovir Disoproxil Fumarate
89116218|NCT00718861|Placebo Comparator|Placebo|Matching placebo administered intravenously.
89116219|NCT00718861|Experimental|Zoledronic acid|
89116220|NCT02589613|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
89116221|NCT02589613|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
89116222|NCT02589613|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
89116223|NCT05310643|Experimental|Treatment phase|"Induction therapy:~nivolumab 240 mg~ipilimumab 1 mg/kg~every 3 weeks for 4 dosing cycles (4 infusions of nivolumab and ipilimumab).~Maintenance therapy:~- nivolumab 480 mg~every 4 weeks (21 infusions)."
89116224|NCT02589535||septic|Group Gb: postoperative septic patients in intensive care unit (ICU)] Gb1: the group of septic patients treated with extracorporeal hemoperfusion therapy and conventional therapy according to the Surviving Sepsis Campaign guidelines Gb2 group treated with conventional therapy according to the Surviving Sepsis Campaign guidelines
89116225|NCT02589535||no septic|Ga: postoperative patients in emergency surgical ward (ES)
89116226|NCT02589535||healthy|Healthy people
89116227|NCT04086199||Anterior discectomy|The discectomy is made by an anterior muscle sparring approach (extraperitoneal).
89116228|NCT04086199||Posterior discectomy|The discectomy is made by a posterior approach (posterior midline incision).
89116229|NCT00918697|Active Comparator|Mechanical debridment|In this arm, corneal epithelium was removed during PRK using conventional mechanical method.
89116230|NCT00918697|Experimental|Alcohol-asstisted debridement|In this arm, corneal epithelium was removed using ethanol 20% during PRK.
89116231|NCT05325697|Experimental|Single - Arm|12 weeks intervention with a combined physical exercise program (vivifrail) and oral nutritional supplementation (Moltein Plus)
89116232|NCT00918853|Experimental|resection for adenocarcinoma|quality standard resection for adenocarcinoma of the head of the pancreas
89116233|NCT02589223|Active Comparator|Multisensory Stimulation Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
89116234|NCT02589223|Placebo Comparator|Control Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
89116235|NCT05253391||Patients treated for asthma exacerbation|
89116236|NCT05684731|Experimental|Experimental: KM1 + Chemotherapy|"Biological: KM1 Administer via intraperitoneal infusion for 3 or 6 doses Q3D.~Drug: Chemotherapy: Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6."
89232243|NCT05265715|Experimental|Low AGE dietary intervention|"Patients will complete a food frequency questionnaire, & if found to have a high AGE diet at baseline, will then begin the study the 24-week low AGE dietary intervention. Patients will complete a 3 day food record prior to receiving remotely delivered education on AGEs on how to adhere to a low AGE diet by the study dieticians prior to starting. This session will provide education on dietary AGE & how to prepare & choose low AGE meals~Subsequent sessions with the dieticians will be conducted remotely & will be 30-60 minutes in duration, with the exception of sessions scheduled for weeks when a study blood draw is required, when visits with the dietician may occur in person. These sessions will occur at the following schedule: weekly during the first 2 months (8 sessions), every other week during the next 2 months (4 sessions, aka step down sessions), monthly for the remaining 2 months (2 sessions)~3 day food records will be collected at 12 & 24 weeks, in addition to baseline."
89232244|NCT05251259|Experimental|Lead-in PK Cohort (Atuliflapon)|Randomised participants will receive Atuliflapon
89232245|NCT05251259|Experimental|Part 1: Atuliflapon|Randomised participants will receive Atuliflapon
89232246|NCT05251259|Placebo Comparator|Lead-in PK, Part 1 Placebo|Randomised participants will receive placebo
89232247|NCT05250973|Experimental|Cohort1 (Arm A): Immediate Daratumumab + Cyclophosphamide, Bortezomib and Dexamethasone (VCd)|Participants with newly diagnosed systemic amyloid light chain (AL) amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive daratumumab 1800 milligrams (mg) subcutaneously (SC) starting on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square [mg/m^2] either orally or intravenously [IV], bortezomib 1.3 mg/m^2 SC, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
89232248|NCT05250973|Experimental|Cohort1 (Arm B): Daratumumab + Deferred VCd|Participants with newly diagnosed systemic AL amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive SC daratumumab 1800mg on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (Cyclophosphamide 300 mg/m^2 either orally or IV, Bortezomib 1.3 mg/m^2 SC, Dexamethasone 40 mg weekly either orally or IV) starting at Cycle 4 Day 1, weekly (Days 1, 8, 15, 22) in every 28-day cycle for a maximum of 6 cycles (Cycle 9 Day 22).
89232249|NCT05250973|Experimental|Cohort 2: Daratumumab + VCd|Participants with racial and ethnic minorities, including Black or African American participants, with newly diagnosed AL amyloidosis will receive SC injection of daratumumab 1800 mg SC on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square [mg/m^2] either orally or intravenously [IV], bortezomib 1.3 mg/m^2 SC, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
89232250|NCT05249426|Experimental|Cohort A: BI 765063 + ezabenlimab + cetuximab|30 Signal Regulatory Protein Alpha (SIRPα) V1/V1 homozygous patients with 2nd line recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) who had received prior platinum-based therapy within the recurrent/metastatic setting.
89232251|NCT05249426|Experimental|Cohort B: BI 765063 + ezabenlimab + chemo (invest choice)|30 SIRPα V1/V1 homozygous patients with 2nd line recurrent/metastatic HNSCC who had received prior platinum-based therapy within the recurrent/metastatic setting.
89232252|NCT05249426|Experimental|Cohort C: BI 765063 + ezabenlimab|30 SIRPα V1/V1 homozygous patients with advanced or metastatic 1st line Hepatocellular Carcinoma (HCC).
89232253|NCT05249426|Experimental|Cohort D: BI 765063 + ezabenlimab + BI 836880|30 SIRPα V1/V1 homozygous patients with advanced or metastatic 1st line HCC.
89232254|NCT05249426|Experimental|Cohort E: BI 765063 + ezabenlimab + BI 836880|30 SIRPα V1/V1 homozygous patients with advanced or metastatic 2nd line HCC who progressed on therapy with atezolizumab in combination with bevacizumab.
89232255|NCT05242484|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232256|NCT05242484|Experimental|Group 2: Guselkumab|Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232257|NCT05242484|Experimental|Group 3: Golimumab|Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232258|NCT05242484|Experimental|Group 4: JNJ-78934804 (High-dose)|Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232259|NCT05242484|Experimental|Group 5: JNJ-78934804 (Mid-dose)|Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232260|NCT05242484|Experimental|Group 6: JNJ-78934804 (Low-dose)|Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232261|NCT05242471|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232262|NCT05242471|Experimental|Group 2: Guselkumab|Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89116237|NCT05184907|Experimental|RME Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing with 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
89116238|NCT05184907|Active Comparator|Information Only Arm|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
89116239|NCT02591407|Active Comparator|TAP Block- Exparel|Transversus abdominis plane block utilizing the medication Exparel®
89116240|NCT02591407|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia
89116241|NCT04085965|Experimental|CAMP|Children randomized to CAMP were enrolled in the Boys and Girls Club Camp in one of two low-income Rhode Island communities in summer 2017 or 2018 for 7-weeks in 2017 and 8-weeks in 2018 due to a delayed end to the 2017 school year (i.e. snow days). Camp was offered daily from 8:30 to 4:30.
89116242|NCT04085965|No Intervention|Summer As Usual|Children randomized to the SAU group were asked to experience an unstructured summer as otherwise planned by their parent / guardian. They agreed to not attend structured summer programming (i.e. camp, summer school, or day care) for more than one week over the summer so as to provide an inactive control group for comparison to those in CAMP.
89116243|NCT02589301|Experimental|Pegfilgrastim|Pegfilgrastim (Hematopoietic Growth Factor) injectable solution 6 mg / 0,6mL in a single subcutaneous application.
89116244|NCT02589301|Active Comparator|Neulastim (pegfilgrastim)|Neulastim injectable solution 6 mg / 0,6mL in a single subcutaneous application.
89116245|NCT01016600|Experimental|Cohort 1|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 25 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
89116246|NCT01016600|Experimental|Cohort 2|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 50 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
89116247|NCT01016600|Experimental|Cohort 3|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
89232263|NCT05242471|Experimental|Group 3: Golimumab|Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232264|NCT05242471|Experimental|Group 4: JNJ-78934804 (High-dose)|Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232265|NCT05242471|Experimental|Group 5: JNJ-78934804 (Mid-dose)|Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232266|NCT05242471|Experimental|Group 6: JNJ-78934804 (Low-dose)|Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.
89232267|NCT05241834|Experimental|Phase 1A: LOXO-260 Dose Escalation|LOXO-260 administered orally
89232268|NCT05241834|Experimental|Phase 1B: LOXO-260 Dose Expansion|LOXO-260 administered orally
89232269|NCT05238155||Orthotopic Liver Transplantation recipients prior to protocol implementation date|Orthotopic Liver Transplantation recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid.
89232270|NCT05238155||Orthotopic Liver Transplantation recipients after protocol implementation date|Over the last several years, there have been changes made to this protocol, and the current protocol now suggests consideration for the omission of the antimetabolite at discharge if there is a donor-recipient age discrepancy that is greater than 30 years. This change was made with the intention to reduce the risk of GVHD, given that a greater disparity in donor-recipient age may put these patients at a higher risk for GVHD.
89232273|NCT05233631||T-EUS Patients|Any patient who has undergone clinically indicated and/or standard of care T-EUS procedures from October 2014 - June 2022.
89232274|NCT05232123|Placebo Comparator|Placebo|Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.
89232275|NCT05232123|Experimental|Cannabidiol 25 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.
89232276|NCT05232123|Experimental|Cannabidiol 50 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.
89232277|NCT05232123|Experimental|Cannabidiol 200 mg|Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.
89232278|NCT05231278|Experimental|nCLE aided RANB biopsy|Single arm study
89232279|NCT05231122|Active Comparator|Arm I (pembrolizumab, bevacizumab)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
89232280|NCT05231122|Experimental|Arm II (pembrolizumab, bevacizumab, CDX-1140)|Patients receive pembrolizumab IV over 30 minutes, bevacizumab IV over 30-90 minutes, and CDX-1140 IV over 90 minutes on day 1. Cycles repeat every 3 weeks until disease progression or development of unacceptable toxicity.
89232281|NCT05224752||healthcare workers at MRMC|healthcare workers at MRMC
89232282|NCT05224739||Patients who underwent MILR from January 1, 2000 to December 31, 2020|Hospital of patients who underwent MILR from January 1, 2000 to December 31, 2020.
89232283|NCT05224635||subjects presenting to the emergency room|Chart review will include subjects presenting to the emergency room from the 1st of November 2021 through 1st of July 2024.
89232284|NCT05224557||New onset HFrEF AA patients|New onset HFrEF AA patients
89232285|NCT05224557||New onset HFrEF Caucasian patients|New onset HFrEF Caucasian patients
89232286|NCT05217914||r/r iNHL Patients: Copanlisib treatment|"The data in patients who received at least one dose of copanlisib before 01-May-2022 will be included for interim analysis. All study data collection will end in Q2 2024, or when the data collection of maximal 50 enrolled patients is completed, whenever comes first.~Subgroup analysis: r/r iNHL Patients: Copanlisib 2nd line treatment Subgroup analysis: r/r iNHL Patients: Copanlisib 3rd line treatment"
89232287|NCT05217628|Experimental|Arm A: Basimglurant|"Period 1 (Run-in: Baseline1 to Week 8): Basimglurant once daily dosing starting dose 1.5mg~Period 2 (Double blind: Weeks 9 to 20): Participants will receive double-blind treatment with Basimglurant once daily.~Open-label Extension (OLE): On completion of Period 2, participants will be offered open label treatment with Basimglurant in an open label extension for up to 52 weeks."
89232288|NCT05217628|Placebo Comparator|Arm B: Placebo|- Period 2 (Double blind: Week 9 to Week 20): Participant randomized to placebo will receive the corresponding number of matching placebo capsules.
89232289|NCT05207670|Experimental|Cohort A|Participants with high tumor burden with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. Participants that achieve complete or partial metabolic response will have the option of receiving maintenance therapy with mosunetuzumab every 8 weeks for 1 year.
89116248|NCT01016600|Experimental|Phase II|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 (dose determined in Phase I) mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
89116249|NCT04084405|Experimental|IMT group|Inspiratory muscle training + aerobic exercice
89116250|NCT04084405|Active Comparator|Control group|aerobic exercice
89116251|NCT05175235|Experimental|CURATE.AI|"Participants will undergo two treatment periods: selection period and CURATE.AI modulation period. During the selection period, baseline ctDNA measurements and CT scans will be performed. Subsequently, participants will receive Standard of Care (SOC) doses of nivolumab/pembrolizumab and have their ctDNA measured at the end of the third cycle together with other SOC monitoring.~After the first ctDNA measurement and CT scan, selected patients who responded to treatment through both ctDNA and CT scan may continue into the CURATE.AI modulation period. Non-responders will receive SOC doses of nivolumab/pembrolizumab for 2 cycles before having their ctDNA measured and CT scan at the end of the 2 cycles. Subsequent responders through both ctDNA and CT scans may then continue into the CURATE.AI modulation period.~Only the dose of nivolumab/pembrolizumab will be modulated with CURATE.AI, based on measurements of the response marker (ctDNA)."
89116252|NCT01015820|Experimental|Cancer group|Participants in this group had pathologically confirmed pancreatic adenocarcinoma. They received an EGD with EUS. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
89116253|NCT01015820|Other|Control group|Participants in this group were without pancreatic adenocarcinoma. Participants in the control group received an EGD with EUS for the indication of abdominal pain. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
89116254|NCT04297670||Unvaccinated against HPV boys|Sexually active unvaccinated against HPV 16-20 years old boys.
89116255|NCT00628004|Experimental|1|
89116256|NCT00628004|Active Comparator|2|
89116257|NCT00628004|No Intervention|No treatment|No treatment as wound was healed
89116258|NCT04298684|Experimental|Metformin|In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control.
89116259|NCT04298684|Placebo Comparator|Sitagliptin|In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months.
89116260|NCT04298294|Experimental|injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with i-PRF& bone graft
89116261|NCT04298294|No Intervention|no injectable platelet rich fibrin group|8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with bone graft
89116262|NCT02871674|Experimental|Intervention group|Participants in the intervention group will receive behavioural training by psychologists in three sessions over three weeks
89116263|NCT02871674|No Intervention|Control group - usual care|Participants in the control group will receive usual care. They will also attend their usual appointments with the psychiatrists. They will not receive any intervention.
89116264|NCT04424888|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 2 weeks
89116265|NCT04424888|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 2 weeks
89116266|NCT01010204|Experimental|Varenicline|We will be comparing Varenicline to placebo in a double-blind placebo controlled, randomized study.
89116267|NCT01010204|Placebo Comparator|Placebo|We will be using placebo in a randomized, controlled, and blinded trial to compare to varenicline in subjects with bipolar disorder.
89116268|NCT04296188|Active Comparator|serratus anterior plane block|The serratus anterior plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via patient controlled analgesia (PCA) device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
89116269|NCT04296188|Active Comparator|erector spina plane block|The erector spina plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via PCA device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
89116270|NCT00718549|Experimental|Induction: Rituximab, Cladribine, Cyclophosphamide|Participants will receive rituximab at a dose of 375 milligrams per meter squared (mg/m^2) as intravenous (IV) infusion on Day 1, cladribine at a dose of 0.12 milligrams per kilogram per day (mg/kg/day) as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 in Cycle 1. Then, rituximab at a dose of 500 mg/m^2 as IV infusion on Day 1, cladribine at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 will be administered in Cycles 2-6. Each cycle will be of 28 days in duration.
89116271|NCT00718549|Experimental|Maintenance Arm: Rituximab|Participants with PR or CR after induction phase who will be randomized to maintenance arm will receive rituximab treatment for 8 cycles. Twelve weeks after the last induction cycle, participants will receive rituximab at a dose of 375 mg/m^2 as IV infusion on Day 1 of each 12-week cycle until disease progression (up to approximately 96 weeks).
89116272|NCT00718549|No Intervention|Observation Arm: No Intervention|Participants with PR or CR after induction phase who will be randomized to observation arm will not receive any intervention. Participants will be assessed every 4-weeks for the first 12 weeks and every 12-weeks afterwards up to 96 weeks.
89116273|NCT00793624|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
89116274|NCT00793624|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
89116275|NCT00793624|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
89116276|NCT00793624|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
89116277|NCT00919243|Experimental|prednisone|
89116278|NCT00919243|Active Comparator|allopurinol|
89116279|NCT05160571||Subjects with Ion Endoluminal sampling of pulmonary nodule|Subjects in which a pulmonary lesion biopsy was attempted or performed with the Ion Endoluminal System
89116280|NCT02589379||Pancreatic Resection|All consecutive patients undergoing pancreatic resection for benign or malignant disease and meet inclusion criteria.
89116281|NCT05612386|Experimental|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
89116282|NCT05612386|Experimental|Planning message recommending same time/location as last vaccination|This condition will use a text message recommending the same time and location as the participant's last vaccination to get a COVID vaccination.
89116283|NCT00794950|Experimental|Sunitinib treatment|Intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma.
89116284|NCT02591173|Experimental|Angiotensin-(1-7)|Patients will receive an intravenous infusion of five ascending doses of Angiotensin-(1-7). The doses are: 1, 2, 4, 8 and 16 ng/kg/min. Each dose will be maintained for 10 minutes, for a total of 50 minutes.
89116285|NCT02591173|Placebo Comparator|Saline|Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.
89116286|NCT02605330||Fibrinogen plasma level in CABG|In all patients undergoing coronary artery bypass grafting (CABG) the investigators plan to measure the fibrinogen plasma level
89116287|NCT02605330||Fibrinogen plasma level in AVR|In all patients undergoing aortic valve replacement (AVR) the investigators plan to measure the fibrinogen plasma level
89116288|NCT02605330||Fibrinogen plasma level in AAR|In all patients undergoing aortic arch replacement (AAR) the investigators plan to measure the fibrinogen plasma level
89116289|NCT02590861|Experimental|Dental implant|All participants will receive the same intervention, this is a single group study.
89116290|NCT02604394|Active Comparator|Rheolytic Thrombectomy with PCI|"Rheolytic Thrombectomy (RT) will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The single-pass antrograde thrombectomy technique will be used."
89116291|NCT02604394|Sham Comparator|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
89116292|NCT00793546|Experimental|1|combination of bosutinib and exemestane
89116293|NCT00793546|Active Comparator|2|exemestane
89116294|NCT05607082|No Intervention|Holdout control condition with no message|Participants will only receive the standard pharmacy messaging.
89116295|NCT05607082|Experimental|"Control condition with waiting for you message"|This control condition will use the text message that we've found to be the best performing in our last mega-study of vaccine text messages to recommend a COVID vaccination.
89116296|NCT05607082|Experimental|"Control condition with waiting for you message with a GIF"|This control condition will use the text message that we've found to be the best performing in our last mega-study of vaccine text messages and includes a GIF to recommend a COVID vaccination.
89116297|NCT05607082|Experimental|Planning message recommending same time/location as last vaccination|This condition will use a text message recommending the same time and location as the participant's last vaccination to get a COVID vaccination.
89116298|NCT05607082|Experimental|Message from local pharmacy team|This condition will use a text message from the participant's local pharmacist recommending a COVID vaccination.
89116299|NCT05607082|Experimental|Message including link to resources combating misinformation|This condition will use a text message including a link to to resources combating misinformation and then recommend a COVID vaccination.
89116300|NCT05607082|Experimental|Message including link to resources combating misinformation with a GIF|This condition will use a text message including a link to to resources combating misinformation and then recommend a COVID vaccination and will include a GIF.
89116301|NCT05607082|Experimental|Message offering free round trip ride to the pharmacy|This condition will use a text message offering a free round trip ride to the pharmacy to get a COVID vaccination.
89116302|NCT05607082|Experimental|Message communicating latest data on COVID transmission in patient's area|This condition will use a text message informing the participant of the latest data on COVID transmission in participant's area and recommend a COVID vaccination.
89116303|NCT05607082|Experimental|Message encouraging vaccination in preparation for the holidays|This condition will use a text message to encourage a COVID vaccination in preparation for the holidays.
89116304|NCT05607082|Experimental|Message conveying the CDC recommends vaccination|This condition will use a text message to encourage a COVID vaccination by conveying the CDC recommends vaccination.
89116305|NCT04113460|Experimental|Yoga Group|The yoga group received the 8-week yoga sessions at work setting once a week by trained teacher followed by self practices.
89116306|NCT04113460|No Intervention|Control Group|Participants had one introductory session on proper physical position and stretching exercises to be practiced daily during work.
89116307|NCT02604238|Experimental|Group A|"Administered a safe dose of Alteplase. All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin in addition it is administered a safe dose of Alteplase."
89116308|NCT02604238|No Intervention|Group B|All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin. It not added any treatment.
89116309|NCT04109092|Experimental|Dose Escalation: NMIBC And BCG Unresponsive NMIBC|
89116310|NCT04109092|Experimental|Dose Expansion: CIS With/Without Ta or T1|
89116311|NCT04109092|Experimental|Dose Expansion: High-grade Ta or T1, Without CIS|
89116312|NCT00798694|Other|New to Meds|Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
89116313|NCT00798694|Other|Currently on Xalatan|Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
89116314|NCT00718315|Experimental|1|
89116315|NCT00718315|Experimental|2|
89116316|NCT00718315|Experimental|3|
89116317|NCT00798304|Experimental|1|Dose level 1 of meningococcal B rLP2086 vaccine and routine childhood vaccines
89116318|NCT00798304|Experimental|2|Dose level 2 of meningococcal B rLP2086 vaccine and routine childhood vaccines
89116319|NCT00798304|Experimental|3|Control group
89116320|NCT04109872||Mantle cell lymphoma treated with lenalidomide cohort|Patients diagnosed with mantle cell lymphoma treated with leanalidomide through the RRMCL spanish program.
89116321|NCT00718237|Experimental|1|RotaTeq™
89116322|NCT00718237|Placebo Comparator|2|Placebo
89116323|NCT04109794|Active Comparator|E-CTG|Envelope connective tissue graft
89116324|NCT04109794|Active Comparator|SCAF|Semilunar connective tissue graft
89116325|NCT00793780|Active Comparator|Naltrexone 25mg|
89116326|NCT00793780|Placebo Comparator|Placebo|
89116327|NCT04109326|Experimental|Adapted Physical Activity and Dietetique|tailored PA program associated with individual nutritional counseling whilst hospitalization and at home during the 26-week duration of adjuvant treatment
89116328|NCT04109326|No Intervention|Control|Standard of care
89232290|NCT05207670|Experimental|Cohort B|Elderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
89116329|NCT05605210|Experimental|FN-NMES - 20 Hz|This group will receive a NMES-induced fatigue protocol, which will be applied to the femoral nerve (FN) using a stimulation frequency of 20 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee in 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contraction.
89116330|NCT05605210|Experimental|FN-NMES - 100 Hz|This group will receive a NMES-induced fatigue protocol, which will be applied to the femoral nerve (FN) using a stimulation frequency of 100 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee in 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
89116331|NCT05605210|Experimental|MP-NMES - 20 Hz|This arm will receive a NMES-induced fatigue protocol, which will be applied to the motor point (MP) of the rectus femoris muscle using a stimulation frequency of 20 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee at 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
89116332|NCT05605210|Experimental|MP-NMES - 100 Hz|This arm will receive a NMES-induced fatigue protocol, which will be applied to the motor point (MP) of the rectus femoris muscle using a stimulation frequency of 100 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee at 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
89116333|NCT05605210|Experimental|FNMP-NMES - 20 Hz|This group will receive a NMES-induced fatigue protocol, which will be applied to the femoral nerve (FN) and to the motor point (MP) of the rectus femoris muscle using a stimulation frequency of 20 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee at 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
89116334|NCT05605210|Experimental|FNMP-NMES - 100 Hz|This group will receive a NMES-induced fatigue protocol, which will be applied to the femoral nerve (FN) and to the motor point (MP) of the rectus femoris muscle using a stimulation frequency of 100 Hz. For this, the participant will be positioned on the isokinetic dynamometer (Biodex Medical System, Shirley - NY, USA) with the knee at 90° of flexion (0°=total extension). The participant will be instructed to remain relaxed and to not perform active muscle contractions.
89116335|NCT04107220|Other|one arm|One arm study patients where NT-proBNP and BNP tests will be monitored.
89116336|NCT04107142|Experimental|CAR-T Cell Therapy Group|"One arm study consisting of 3 + 3 dose escalation study design ranging from 3 x 10^8 - 3 x 10^9 cells CAR-γδ T cell.~Each cycle of therapy will consist of 4 intravenous infusions, given 7 days apart."
89116337|NCT02591017|Other|morphine drops solo and placebo spray|"morphine 2% drops~daily fixed dose of morphine equivalents < 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards~daily fixed dose of morphine equivalents =/> 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards"
89116338|NCT02591017|Other|ketamine/chitosan spray nasal and placebo drops|5 mg ketamine all 5 minutes, maximal 4 times an hour
89116339|NCT02591017|Other|morphine drops and ketamine/chitosan spray nasal|see above
89116340|NCT04113148||Healthy volunteer|Physiological measurements from heel over 60 minute period
89116341|NCT04113148||At risk of Pressure Ulcer|Physiological measurements from heel over 60 minute period
89116342|NCT04113148||Confirmed Catefory I Pressure Ulcer|Physiological measurements from heel over 60 minute period
89116343|NCT04113148||Suspected Deep Tissue Injury|Physiological measurements from heel over 60 minute period
89116344|NCT02591095|Experimental|ABT-263|oral Navitoclax (ABT-263) daily
89116345|NCT02588755|Active Comparator|TACE+ Tegafur|Patients will be treated with Tegafur after resection soon, and TACE in 4 or 8 weeks after resection.
89116346|NCT02588755|Experimental|TACE|Patients will be treated with TACE alone in 4 or 8 weeks after resection.
89232291|NCT05207670|Experimental|Cohort C|Participants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
89116347|NCT00919321|Other|PPV|
89116348|NCT00919009|Experimental|Sorafeinb|Oral sorafenib (400 mg BID) will be start the 3 day after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.
89116349|NCT05684263|Experimental|Weight Science + Healthy Eating Education|In this condition participants will watch two educational videos on the topics of weight science, and healthy eating. The videos were created by a registered psychologist and are each between 20 and 30 minutes in length.
89116350|NCT05684263|Other|Weight Science + Healthy Sleep Education|"In this condition participants will watch two educational videos on the topics of weight science, and healthy sleep. The videos were created by a registered psychologist and are each between 20 and 30 minutes in length.~We are interested in the effect of weight science education alone, the healthy sleep video was added as an active control so that each condition was watching the same amount of videos."
89116351|NCT05684263|Other|Healthy Eating + Healthy Sleep Education|"In this condition participants will watch two educational videos on the topics of healthy eating, and healthy sleep. The videos were created by a registered psychologist and are each between 20 and 30 minutes in length.~We are interested in the effect of healthy eating education alone, the healthy sleep video was added as an active control so that each condition was watching the same amount of videos."
89116352|NCT05684497|Experimental|experimental group|The Training on Prevention and Coping Support Program in Pregnancy Based on Pender's Health Promotion Model, which was created by the researcher in line with the current literature, and the training booklet (Appendix-3) containing this training will be provided. Two weeks after the first interview, women will be called and reminded to follow the training booklet, and at the end of four weeks, the Low Back Pain Evaluation Form, Visual Analog Scale (VAS), Oswestry Disability Index and Checklist will be applied.
89116353|NCT05684497|No Intervention|control group|For women who only receive routine pregnant care, no attempt will be made for low back pain, and the Low Back Pain Evaluation Form, Visual Analog Scale (VAS) and Oswestry Disability Index will be re-applied four weeks after the first interview, according to routine pregnant follow-ups.
89116354|NCT02643303|Experimental|Phase 1, Cohort 1A|Subjects received durvalumab (1500 mg IV every 4 weeks [Q4W] for 12 cycles). Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3.
89116355|NCT02643303|Experimental|Phase 1, Cohort 1B|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (75 mg IV Q4W for the first 4 cycles).~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116356|NCT02643303|Experimental|Cohort 1C + Phase 2; Head + Neck Squamous Cell Carcinoma|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116357|NCT02643303|Experimental|Cohort 1C + Phase 2; Locally Recurrent or Metastatic Breast Cancer|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116358|NCT02643303|Experimental|Cohort 1C + Phase 2; Sarcoma|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116359|NCT02643303|Experimental|Cohort 1C + Phase 2; Merkel Cell Carcinoma|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116360|NCT02643303|Experimental|Cohort 1C + Phase 2; Cutaneous T-cell Lymphoma|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116361|NCT02643303|Experimental|Cohort 1C + Phase 2; Melanoma After Failure of Available Therapies|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116362|NCT02643303|Experimental|Cohort 1C + Phase 2; Genitourinary Cancers with Accessible Metastases|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116363|NCT02643303|Experimental|Cohort 1C + Phase 2; Solid Tumors with Accessible Masses|"Subjects received durvalumab (1500 mg IV Q4W for 12 cycles) and tremelimumab (10 mg) intratumorally on days 1, 8, and 15 of Cycle 1, days 1 and 15 of Cycle 2 and day 1 of Cycles 3 and 4.~Poly-ICLC (1 mg) was administered intratumorally on days 1, 3, 5, 8, 10 and 15 and intramuscularly on days 17, 22, and 24 of Cycle 1 as well as intramuscularly on days 1, 3, 8, 10, 15, 17, 22 and 24 of Cycle 2 and on days 1 and 4 of Cycle 3."
89116364|NCT02555397|Experimental|Single|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at a dose of 1 x 10e10 to 1 x 10e12 viral particles.
89116365|NCT02475759|Active Comparator|two weeks prehabilitation group|Nutritional perioperative prehabilitation program for two weeks in malnourished congenital heart disease children
89116366|NCT02475759|Active Comparator|one week prehabilitation group|Nutritional perioperative prehabilitation program for one week in malnourished congenital heart disease children
89116367|NCT04216173|Experimental|Acupuncture|
89116368|NCT02345655|Experimental|Urine Drug Testing|GPs of the intervention group will dedicate an average 5 minutes during the consult to perform OS-UDT. Patients will be asked to collect a urine sample at the GP's medical office. GP will read and communicate the results immediately to the patients. GPs will keep free of their management according to OS-UDT results.
89116369|NCT02345655|Other|No test|Patients will not have to performed the OS-UDT test
89116370|NCT04216095|Active Comparator|Electroconvulsive Therapy (ECT)|Right unilateral (RUL, N=15), or Bitemporal (BT, N=15) ECT
89116371|NCT04216095|Active Comparator|Magnetic Seizure Therapy (MST)|High-dose magnetic seizure therapy (HD-MST)
89116372|NCT02119767||Natural gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have natural gradients sampled using the LBS
89116373|NCT02119767||Induced gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have induced gradients sampled using the LBS
89116374|NCT01974531||Preterm birth/ Timely birth|
89116375|NCT01974531||Women/men|
89116376|NCT00615147||1|Patients to have a CT pulmonary angiogram for suspected pulmonary embolism will have a d-dimer drawn as is routinely done.
89116377|NCT01029717|Experimental|Standard polyurethane Central Venous Catheter|"Standard polyurethane Central Venous Catheter~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
89116378|NCT01029717|Active Comparator|Antibiotic impregnated polyurethane CVC|"Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
89116379|NCT01029717|Active Comparator|Heparin bonded polyurethane CVC|"Heparin bonded polyurethane CVC~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
89116380|NCT00790036|Experimental|Everolimus|Participants who received Everolimus 10 mg (two 5 mg tablets), daily for 12 months
89116381|NCT00790036|Placebo Comparator|Placebo|Participants who received Everolimus placebo 10 mg (two 5 mg tablets), daily for 12 months
89116382|NCT05563168|Experimental|Standard Of Care (SOC) + diltiazem|Patients will receive the standard of care at the time of their inclusion in the trial and will also receive diltiazem (60mg 3 times a day) for 7 days.
89116383|NCT05563168|Placebo Comparator|SOC + placebo|Patients will receive the standard of care at the time of their inclusion in the trial and will also receive a diltiazem placebo (3 times a day) for 7 days
89116384|NCT00789958|Experimental|Adjuvant Chemo+ Chemoradiotherapy|"Adjuvant Chemotherapy~Capecitabine, 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Gemcitabine hydrochloride, 1000 mg/m^2, IV, Days 1 & 8 of each cycle~Chemoradiotherapy~-Capecitabine, 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT~Radiation (RT):~3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.~intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions."
89116385|NCT00789880|Experimental|Vitamin D3|Subjects received a 21-day course of oral vitamin D3 (cholecalciferol, 4,000 international units [IU]
89116386|NCT00789880|Placebo Comparator|Placebo|Subjects received a 21-day course of oral vitamin D3-placebo
89116387|NCT04108780||CBD exploration with T-tube|repair of CBD after CBD exploration over T-tube
89116388|NCT04108780||CBD exploration with primary repair|primary repair of CBD after CBD exploration
89116389|NCT04109170||Dry Eye Group|This group of subjects were diagnosed with dry eye.
89116390|NCT04109170||Normal Control Group|This group of subjects had no dry eye symptoms and signs and belonged to the normal control group.
89116391|NCT00915616|No Intervention|control|9 healthy normal subjects.
89116392|NCT00915616|Active Comparator|Group II|Included 9 patients suffering from GERD; receiving melatonin alone for treatment of GERD in a dose of 3 mg once daily at the bed time.
89116393|NCT00915616|No Intervention|Group III, combined group|Included 9 patients suffering from GERD; receiving omeprazole alone for treatment of GERD in a dose of 20 mg twice daily.
89116394|NCT00915616|Active Comparator|Group IV|Included 9 patients suffering from GERD receiving omeprazole and melatonin for treatment of GERD in the same dose of each of them.
89116395|NCT00914836|Active Comparator|1 cc - Betamethasone Sodium Phosphate|1 cc - Betamethasone Sodium Phosphate
89232292|NCT05207670|Experimental|Cohort D|Participants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
89232293|NCT05207670|Experimental|Cohort E|Participants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
89232294|NCT05201794|Experimental|High-dose JNJ-64281802 regimen (HDR)|Participants will receive JNJ-64281802 400 milligrams (mg) loading dose (LD) twice daily for 48 hours (2 days), followed by JNJ-64281802 150 mg maintenance dose (MD) once daily for 26 days in fed conditions.
89232295|NCT05201794|Experimental|Low-dose JNJ-64281802 regimen (LDR)|Participants will receive JNJ-64281802 150 mg LD twice daily for 48 hours (2 days), followed by JNJ-64281802 50 mg MD once daily for 26 days in fed conditions.
89232296|NCT05201794|Placebo Comparator|Placebo|Participants will receive JNJ-64281802 matching placebo LD and MD from Day 1 to Day 28.
89232297|NCT05201781|Experimental|Cilta-cel|Participants who had previously received treatment with cilta-cel in a Company-sponsored clinical study (example, NCT04923893, NCT03758417, NCT04181827, NCT05347485, NCT04133636, and NCT03548207) in the global development program will be enrolled into this study once the individual's participation in the particular interventional study has ended or a study has been terminated. Participants will not receive any treatment in this study and will be followed-up at least once per year on delayed adverse events for up to 15 years after receiving the last dose of cilta-cel.
89232298|NCT05199948|Experimental|Soybean Oil|Consumption of study foods each day made with soybean oil
89232299|NCT05199948|Placebo Comparator|Palm Oil|Consumption of study foods each day made with palm oil
89232300|NCT05197049|Experimental|Group 1: Guselkumab|Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 2) injection subcutaneously.
89232301|NCT05197049|Experimental|Group 2: Guselkumab|Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 3) injection subcutaneously.
89232302|NCT05197049|Placebo Comparator|Group 3: Placebo|Participants will receive placebo injection subcutaneously.
89232303|NCT05182905|Experimental|Arm A: Recurrent Grade 4 Glioma Surgical Cohort Time Escalation|
89232304|NCT05182905|Experimental|Arm B: Recurrent Grade 4 Glioma Dose Escalation|
89232305|NCT05182905|Experimental|Arm C: Newly-diagnosed Grade 4 Glioma|
89232306|NCT05179876|Experimental|Macitentan|Participants who have completed a parent study, benefit from their study intervention maintenance and have no adequate alternative local treatment option will be enrolled in this study and will continue to receive study drug macitentan orally during the course of the study. For adult participants study visits will be scheduled every 6 months and for pediatric participants study visits will be scheduled every 3 months. The study includes on-site visits to collect efficacy and safety information until participant discontinuation/withdrawal, or the respective study intervention is made commercially available in the country/territory or an equivalent approved therapy becomes available, or the sponsor decides to terminate the study prematurely.
89232307|NCT05179876|Experimental|Selexipag|Participants who have completed a parent study, benefit from their study intervention maintenance and have no adequate alternative local treatment option will be enrolled in this study and will continue to receive study drug selexipag orally during the course of the study. Study visits are scheduled every 6 months to collect efficacy and safety information until participant discontinuation/withdrawal, or the respective study intervention is made commercially available in the country/territory or an equivalent approved therapy becomes available, or the sponsor decides to terminate the study prematurely.
89232308|NCT05179876|Experimental|Macitentan/Tadalafil FDC|Participants who have completed a parent study, benefit from their study intervention maintenance and have no adequate alternative local treatment option will be enrolled in this study and will continue to receive drug Macitentan and Tadalafil fixed dose combination (FDC) orally during the course of the study. Study visits are scheduled every 6 months to collect efficacy and safety information until participant discontinuation/withdrawal, or the respective study intervention is made commercially available in the country/territory or an equivalent approved therapy becomes available, or the sponsor decides to terminate the study prematurely.
89232309|NCT05171647|Experimental|M+P (Arm A)|Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.
89232310|NCT05171647|Active Comparator|R-GemOx (Arm B)|Participants will receive IV rituximab, IV gemcitabine, and IV oxaliplatin (R-GemOx) on Day 1 of each cycle for 8 cycles. Cycle length = 14 days.
89232312|NCT05167825|Experimental|Macitentan|Participants will receive oral dose of macitentan based on age and weight through Week 52.
89232313|NCT05167734|No Intervention|Control (Standard of Care) Group|Subjects will receive standard clinical care for the treatment of anemia while in the ICU.
89232314|NCT05167734|Experimental|Anemia Treatment Bundle|The intervention arm is multi-faceted with 3 primary components: 1) Optimized phlebotomy, defined by minimal volume draws and closed-loop blood sampling, all performed by a dedicated phlebotomy team independent from the treatment team; 2) Decision support aids, including visual and electronic alerts reminding the care team to minimize non-essential laboratory testing and mitigate patient-specific bleeding risk; and 3) Pharmacologic anemia treatment with a single dose of IV iron and/or subcutaneous erythropoietin (given immediately following enrollment) targeted to 2 broad groups: 1) anemias responsive to iron supplementation alone (i.e. acute blood loss, iron deficiency) and 2) anemias requiring erythropoietic stimulation (e.g. anemia of inflammation, anemia of renal disease).
89232315|NCT05160584||Participants with Relapsed/Refractory Multiple Myeloma|Participants with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The primary data source will be medical records of each participant.
89232316|NCT05157984||Retrospective cohort|Any patient of the physicians listed in this study who has undergone the ZPOEM procedure to treat ZD at Methodist Health System
89116396|NCT00914836|Active Comparator|2 cc - Betamethasone Sodium Phosphate|2 cc - Betamethasone Sodium Phosphate
89116397|NCT04106752|Active Comparator|meal followed by caffeine|A standardized meal consisting of 2 slices of toast bread, organic peanut butter and jam was given to the participant. One and a half hours later, the participant ingested a caffeinated drink (3 mg per kg body weight of caffeine powder dissolved in water). After 30 mins, resting EE was measured using FM for 15 min while seated on the comfortable seat, and then for 5 min while seated on a cycle ergometer. Participants were then asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively. During cycling, EE was being measured using the FM, HR was monitored and rating of perceived exertion (RPE) was recorded in the last minute of every load cycle.
89116398|NCT04106752|Active Comparator|Caffeine followed by meal|Caffeine was given to the participant. After 1.5 hours the standardized meal was given followed by the same protocol mentioned above.
89116399|NCT04106752|Active Comparator|caffeine only|Caffeine will be given to the participant. 2 hours later the same protocol mentioned above will be applied
89116400|NCT04106752|Active Comparator|Meal only|A standardized meal will be given to the participant. 2 hours later the same protocol mentioned above will be applied.
89116401|NCT04106752|Active Comparator|meal plus caffeine|A standardized meal + a caffeinated drink (3 mg/kg of body weight of caffeine powder dissolved in water) will be given to the participant. 2 hours later resting EE is measured using a facemask (FM) for 10 min while seated on a cycle ergometer . The participant will be asked to pedal at 60 revolutions per minute (rpm) for 5 min per load at 20 watts (W), 35W, 50W, 65W, 80 W respectively.
89116402|NCT04113070||Overweight and obesity group|"Children with BMI cutoff points greater than 25.0 or 30.0 at 18 years old were defined overweight or obesity according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.~Willingness to comply with study requirements"
89116403|NCT04113070||Non-overweight group|"Children with BMI smaller than 25.0 at 18 years old were defined non-overweight according to age- and sex-specific cutoff points standard proposed by International Obesity Task Force (IOTF) for 2- to 18-year-old children.~Willingness to comply with study requirements"
89116404|NCT02603692||Pediatric group (ages 8-17)|PROMIS pediatric domains for emotional distress (anxiety and depression), physical function (fatigue, pain interference, mobility and upper extremity), and peer relations
89116405|NCT02603692||Adult group (ages 18-35)|PROMIS adult domains. To reduce respondent burden, the multi-form design will be used which includes the short form of physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference and pain intensity.
89116406|NCT02603692||Parent/guardian proxy|Parent/guardian will complete the parental proxy PROMIS instruments based on corresponding child age (ages 5 to 17 years)
89116407|NCT04106596||Patients with antibodies against LGI1|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
89116408|NCT04106596||Patients with antibodies against CASPR2|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
89116409|NCT04106596||Patients with antibodies against GAD|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
89116410|NCT04106440|Experimental|Application Use|Participants will be asked to use applications to track food intake, carbohydrate counts, insulin delivered, and blood sugar values and share the data with the study team.
89116411|NCT04106440|No Intervention|Standard of Care|The control group will receive usual care during their hospitalizations at the time of diabetes diagnosis, and during the time between hospital discharge and first visit to the UCD Pediatric Diabetes clinic.
89116412|NCT00792298|Experimental|Suvorexant 10 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 10 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
89116413|NCT00792298|Experimental|Placebo → Suvorexant 10 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 10 mg suvorexant daily prior to bedtime during Treatment Period 2.
89116414|NCT00792298|Experimental|Suvorexant 20 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 20 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
89116415|NCT00792298|Experimental|Placebo → Suvorexant 20 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 20 mg suvorexant daily prior to bedtime during Treatment Period 2.
89116416|NCT00792298|Experimental|Suvorexant 40 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 40 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
89116417|NCT00792298|Experimental|Placebo → Suvorexant 40 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 40 mg suvorexant daily prior to bedtime during Treatment Period 2.
89116418|NCT00792298|Experimental|Suvorexant 80 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 80 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
89116419|NCT00792298|Experimental|Placebo → Suvorexant 80 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 80 mg suvorexant daily prior to bedtime during Treatment Period 2.
89116420|NCT04108390|Experimental|Intervention group|Individuals for this group will be treat with a dry needling intervention at the gluteus medius trigger point.
89116421|NCT04108390|Active Comparator|Control group|Individuals for this group will be treat with a dry needling technique at 1,5 cm from the trigger point (not in the trigger point).
89116422|NCT04001452||Level of experience in interventional cardiology|"Total cohort will be grouped according to experience in interventional cardiology, as defined by a single choice questionnaire:~Yearly personal PCI volume Less than 75 / Between 75 and 150 / Between 151 and 250 / More than 250"
89116423|NCT04001452||Level of experience with intravascular ultrasound|"Total cohort will be grouped according to experience with intravascular ultrasound, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
89116424|NCT04001452||Level of experience with optical coherence tomography|"Total cohort will be grouped according to experience with optical coherence tomography, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 15 / Between 15 and 50 / More than 50"
89116425|NCT04001452||Level of experience with fractional flow reserve|"Total cohort will be grouped according to experience with fractional flow reserve, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
89116426|NCT04001452||Level of experience with non-hyperaemic pressure ratios|"Total cohort will be grouped according to experience with non-hyperaemic pressure ratios, as defined by a single choice questionnaire:~General: No experience / Less than 1 year / Between 1 and 3 years / Between 3 and 5 years / More than 5 years~Yearly: None / Less than 50 / Between 50 and 150 / Between 151 and 250 / More than 250"
89116427|NCT02605096|Experimental|MRI group|"This arm assess the use of MRI as the first line examination of suspected scaphoid fracture (replacing conventional plain x-ray).~Patients with negative findings will receive a splint and contact card to a specialist wrist clinic if the pain persists for ten to fourteen days after initial presentation.~Patients with positive findings will receive a plaster cast and undergo a CT scan (to evaluate displacement) and will be referred to the fracture clinic. Furthermore, if the CT scan confirms a displaced fracture, that might require surgery, the patient should be seen by a Hand Specialist at fracture clinic.~All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
89116428|NCT02605096|Active Comparator|X-ray group|"This arm is the current standard of care pathway for the diagnosis of patients with suspected scaphoid fracture. This includes an initial clinical assessment on arrival to the Emergency Department of Urgent Care Centre followed by a plain x-ray (using a 4-view scaphoid protocol).~Patients with negative/positive findings for scaphoid fracture in the initial X-ray will be immobilised with a splint/plaster cast.~All patients will be referred to an initial fracture clinic and a proportion of patients are likely to require additional imaging scans (usually CT but also MRI) and follow-up appointments in the fracture clinic. All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
89116429|NCT04112836||Normal nutritional status|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of 24-30 points.
89116430|NCT04112836||Malnourished|Patients, fulfilled inclusion criteria with Mini-Nutritional Assessment score of fewer than 17 points.
89116431|NCT02603458|Placebo Comparator|Placebo|Group of enrolled subjects receiving two infusions of intravenous placebo (5% glucose solution)
89116432|NCT02603458|Experimental|NRX-1074 Dose Group|Group of enrolled subjects receiving two infusions of intravenous NRX-1074 (10 mg)
89116433|NCT02603380||Clinical staff|Clinicians in the Royal Infirmary of Edinburgh.
89116434|NCT02603380||Patients|Patients in intensive care units and general wards in the Royal Infirmary of Edinburgh.
89116435|NCT00718159|Experimental|LY573636|
89116436|NCT02603302|Experimental|Locally advanced rectal cancer|"RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV + Chemotherapy with 5-FU~Surgery 8 weeks after the neoadjvuant treatment."
89116437|NCT04112680|Experimental|Intervention group 1|Audio messages in this group are focussed on providing a Plausible Alternative to the misinformation
89116438|NCT04112680|Experimental|Intervention group 2|Audio messages in this group focus on Avoiding the Misinformation and instead only provide the correct information
89116439|NCT04112680|Placebo Comparator|Control group|Audio messages in this control group are on a different topic
89116440|NCT05136313|Experimental|MHO|metabolically healthy obese subjects undergoing TRE
89116441|NCT05136313|Experimental|MUO|metabolically unhealthy obese subjects undergoing TRE
89116442|NCT02603068|Experimental|Individual Maximum Tolerated Dose (iMTD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 12 mg TID.
89116443|NCT02603068|Experimental|Fixed Dose (FD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 1 mg TID.
89116444|NCT05684185||IM, <15 years old|Group with Intramuscular (IM) rabies post-exposure prophylaxis
89116445|NCT05684185||IM, 15 years old and older|Group with Intramuscular (IM) rabies post-exposure prophylaxis
89116446|NCT05684185||ID, <15 years old|Group with Intradermal (ID) rabies post-exposure prophylaxis
89116447|NCT05684185||ID, 15 years old and older|Group with Intradermal (ID) rabies post-exposure prophylaxis
89116448|NCT05325931|Experimental|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal Low Add Power (LA) and High Add Power (HA)
89116449|NCT05325931|Active Comparator|samfilcon A for Presbyopia|B+L ULTRA for Presbyopia Low Add Power (LA) and High Add Power (HA)
89116450|NCT00718081|Experimental|1|Oral Sufentanil
89116451|NCT00718081|Experimental|2|Oral sufentanil
89116452|NCT00718081|Placebo Comparator|3|Oral dosage of placebo
89116453|NCT00788710|Experimental|Etoricoxib 120 mg|etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
89116454|NCT00788710|Experimental|Etoricoxib 90 mg|etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
89116455|NCT00788710|Placebo Comparator|Placebo|Placebo- 3 tablets once daily
89116456|NCT04084093|Experimental|Surfactant Gel|
89116457|NCT05684107|Active Comparator|IPACK block|
89116458|NCT05684107|Active Comparator|sciatic nerve block|
89116459|NCT05684107|Active Comparator|adductor canal block|
89116460|NCT04106206|Experimental|LY3372689|LY3372689 administered orally
89116461|NCT04106206|Placebo Comparator|Placebo|Placebo administered orally
89116462|NCT04017286||depressive disorder group|At 21 weeks of pregnancy, women diagnosed with depressive disorder by the Hamilton depression scale and Beck depression rating scale and their offspring were enrolled.
89116463|NCT04017286||Nutrient-deficient group|Nutrients (Vitamin A,D,E) were tested at 21 weeks of pregnancy, and pregnant women with one or more nutrient deficiencies or insufficiency and their offspring were enrolled.
89116464|NCT04017286||depressive disorder and nutrient deficiency group|At 21 weeks of pregnancy, pregnant women with depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
89116465|NCT04017286||Neither group|At 21 weeks of pregnancy, pregnant women without depressive disorder and nutrient deficiency or insufficiency and their offspring were enrolled.
89116466|NCT04083625|Experimental|carbetocin|100microgram in 10 cm syringe carbetocin IV just before skin incision of myomectomy.
89116467|NCT04083625|Placebo Comparator|placebo|10 cm syringe normal saline IV given just before skin incision of myomectomy.
89116468|NCT00787930||Manic Subject with DWM Hyperintensities >2|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid) who had a BOYKO DWM Hyperintensity rating >2 and a YMRS <15 at week 3.
89116469|NCT00787930||Manic Subjects with DWM Hyperintensities <3|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid)who had a BOYKO DWM Hyperintensity rating <3 and a YMRS <15 at week 3.
89116470|NCT02588911|Active Comparator|Conventional Surgery|Limb with GSV insufficiency in the same patient, randomised to conventional surgery
89116471|NCT02588911|Active Comparator|Radiofrequency Ablation|Limb with GSV insufficiency in the same patient, randomised to radiofrequency ablation
89116472|NCT04083547||HIPEC group|All patients undergoing HIPEC will asked to join this prospective study.
89116473|NCT00914914|Experimental|p28 Phase I Safety|A total of 15 patients were administered p28 i.v. as a short infusion three times per week for 4 weeks followed by a 2-week rest under an accelerated titration 3þ3 dose escalation design.
89116474|NCT04083703|Experimental|Simple lumbar discectomy|
89116475|NCT04083703|Experimental|Lumbar discectomy with inter vertebral cage|
89232317|NCT05157984||Prospective cohort|Any patient of the physicians listed in this study who has undergone the ZPOEM procedure to treat ZD at Methodist Health System and has agreed to be follow-up post-procedure.
89232318|NCT05152147|Active Comparator|Arm A|Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
89232319|NCT05152147|Experimental|Arm B|Zanidatamab plus physician's choice of CAPOX or FP
89232320|NCT05152147|Experimental|Arm C|Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP
89232321|NCT05148000|Experimental|QM1114-DP|QM1114-DP
89232322|NCT05145491|Active Comparator|Immediate Vitrectomy|
89232323|NCT05145491|Other|Deferred Vitrectomy|
89232324|NCT05143424|Active Comparator|CBD (350 mg)|CBD 350 mg twice per day for 3 days
89232325|NCT05143424|Active Comparator|CBD (700 mg)|CBD 700 mg twice per day for 3 days
89232326|NCT05133596|Experimental|Study population|Adult subjects up to 55 years of age with persistent olfaction disorder after a symptomatic episode of COVID-19.
89232327|NCT05127330|Experimental|LifePlans|LifePlans is a video series using real patients telling their stories of overcoming suicidal thoughts and behaviors to help others who are struggling with these issues.
89232328|NCT05127330|Active Comparator|Treatment as Usual|Individuals will receive unrestricted routine care only.
89232329|NCT05123599|Experimental|JNJ-73763989 plus JNJ-64300535 plus Nucleos(t)ide Analogs (NAs)|Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (q4w), NA (either Entecavir monohydrate [ETV], Tenofovir disoproxil or Tenofovir alafemide [TAF]) oral tablets once daily (qd) and JNJ-64300535 intramuscular (IM) injection q4w. From day 187, participants will receive treatment with NA oral tablets qd up to Week 36.
89232330|NCT05115812||RAT|patients having undergone robotic-assisted RAT procedure
89232331|NCT05112939|Experimental|Panel A: Rilpivirine (RPV) Long-acting (LA)|Participants will receive one dose of RPV LA (formulation 1) under different conditions (Treatment A and B) on Day 1.
89232332|NCT05112939|Experimental|Panel B: RPV LA|Participants will receive one dose of RPV LA (formulation 2) under different conditions (Treatment C and D) on Day 1.
89232333|NCT05112939|Experimental|Panel C: RPV LA|Participants will receive one dose of RPV LA (formulation 1) under different conditions (Treatment E and F) on Day 1, based on interim data of Panel A.
89232334|NCT05112939|Experimental|Panel D: RPV LA|Participants will receive one dose of RPV LA (formulation 2) under different conditions (Treatment G and H) on Day 1, based on interim data of Panel B.
89232335|NCT05112939|Experimental|Panel E: RPV LA + Cabotegravir (CAB) LA|Participants will receive one dose of RPV LA (formulation 1) with CAB LA (formulation 3) (Treatment I) on Day 1.
89232336|NCT05112809|Experimental|Normal hearing subjects|Subjects with normal hearing will have a standard hearing test utilizing the cochlear stimulation system.
89232337|NCT05112809|Experimental|Bilateral hearing impaired|Subjects with bilateral hearing impairment will have a standard hearing test utilizing the cochlear stimulation system.
89232338|NCT05112809|Experimental|Asymmetrical hearing-impaired|Subjects with asymmetrical hearing-impairment will have a standard hearing test utilizing the cochlear stimulation system.
89232339|NCT05102006|Experimental|LBL-007&Toripalimab|LBL-007 Injection; dose A or dose B; Q3W
89523293|NCT03048799|Placebo Comparator|Radiofrequency off and Kinesiotherapy|"The patient will be in lateral decubitus, the anal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radio frequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given. In addition, at this point will be advised on the performance of The Knack, which is a pre-contraction of the PA during the performance of some abdominal effort such as coughing, sneezing or laughing."
89232340|NCT05092269|Experimental|Ustekinumab|Participants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004, CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study. Participants enrolling from the Exposure Optimization Substudy may be eligible to remain on the every 4 weeks (q4w) dosing regimen.
89232341|NCT05090826|Experimental|TECNIS Synergy IOL|Model ZFR00V
89232342|NCT05090813|Experimental|TECNIS Eyhance IOL|Model ICB00
89232343|NCT05083182|Experimental|Cohort 1: Ustekinumab|Participants will receive a weight-based dose of ustekinumab subcutaneously (SC) at Week 0, Week 4 and then every 12 weeks up to Week 52.
89232344|NCT05083182|Experimental|Cohort 2: Guselkumab|The dose of guselkumab will be based on the participant's weight. Participants will receive guselkumab SC at Weeks 0 and 4 followed by either every 4 weeks (Q4W) (with historical radiographic evidence of joint damage) or every 8 weeks (Q8W) (without historical evidence of joint damage) dosing with the last dose at Week 52. Participants at high risk of joint damage can also be considered for Q4W dosing per investigator.
89232345|NCT05083169|Experimental|Arm A: Teclistamab-daratumumab (Tec-Dara)|Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose.
89232346|NCT05083169|Experimental|Arm B: DPd or DVd|Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously.
89232347|NCT05075746||enVista Toric 0.9D intra ocular lens|
89232348|NCT05075746||enVista non-Toric (spherical) intra ocular lens|
89232349|NCT05071664|Experimental|Group 1: Guselkumab and Golimumab|Participants will receive subcutaneous (SC) guselkumab and golimumab.
89232350|NCT05071664|Active Comparator|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab and placebo.
89232351|NCT05058339||Observational (survey)|Patients complete survey over 20 minutes.
89232352|NCT05053750|Experimental|Paclitaxel|
89232353|NCT05053750|Experimental|Bevacizumab|
89232354|NCT05053191|Experimental|Nurses|MSKCC day-shift nurses (Clinical Nurse I to IV) assigned to the GI inpatient unit (MH16) at the time of study, all of whom provide initial and ongoing assessment of patients' physical, psychosocial, cultural and informational needs
89232355|NCT05050097|Experimental|Treatment Regimen A: Talquetamab + Carfilzomib|Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.
89232356|NCT05050097|Experimental|Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib|Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.
89232357|NCT05050097|Experimental|Treatment Regimen C: Talquetamab + Lenalidomide|Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.
89232358|NCT05050097|Experimental|Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide|Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.
89232359|NCT05050097|Experimental|Treatment Regimen E: Talquetamab + Pomalidomide|Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.
89232360|NCT05049798||Cohort 1: Guselkumab|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
89523294|NCT03125057|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
89232361|NCT05049798||Cohort 2: Interleukin-17 inhibitor (IL-17i)|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.
89232362|NCT05048524|Experimental|SLOG|
89232363|NCT05047263|Experimental|Finerenone (BAY94-8862)|Participants will receive finerenone.
89232364|NCT05047263|Placebo Comparator|Placebo|Participants will receive placebo.
89232365|NCT05043506||Palbociclib + aromatase inhibitor|Adult patients with advanced breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between September 1, 2016, and July 31, 2020.
89232366|NCT05043506||Aromatase inhibitor|Adult patients with advanced breast cancer patients who initiated an aromatase inhibitor as first line therapy between January 1, 2010,, and July 31, 2020
89232368|NCT05039021|Experimental|Pediatric; adult (HPB, lower gastrointestinal, gastric, gynecological, urological, thoracic)|Any pediatric or adult (hepato-pancreato-biliary, lower gastrointestinal, gastric, gynecological, urological, thoracic) procedures where the HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
89232369|NCT05038592|Experimental|Treatment (decitabine, tagraxofusp-erzs)|Patients receive decitabine IV over 60 minutes on days 1-5, and tagraxofusp-erzs IV over 15 minutes on days 1-3. Cycles of decitabine repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment with tagraxofusp-erzs repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
89232370|NCT05036083|Experimental|Diagnostic (CEM, DBT, medical record)|Patient receive iodinated contrast agent IV and undergo CEM. Patients who have not undergone DBT as part of their screening or diagnostic imaging within 3 month, undergo DBT. Patients medical records are reviewed.
89232371|NCT05036070|Experimental|Study Lens|Model C0001
89232372|NCT05036070|Active Comparator|Control Lens|Model ZCB00
89232373|NCT05035602||Oesophagectomy|Patients who have undergone oesophageal cancer resection.
89232374|NCT05035602||Gastrectomy|Patients who have undergone gastric cancer resection.
89232375|NCT05035602||Control group|A cohort consisting of healthy controls who have not been diagnosed with, or have undergone treatment for oesophageal or gastric cancer.
89232376|NCT05033990||Healthy Controls|Participants with no smoking history (< 100 cigarettes in lifetime); pre-bronchodilator FEV1/FVC ≥ 0.70; pre-bronchodilator FEV1 ≥ 80% predicted; and pre-bronchodilator FVC ≥ 80% predicted.
89232377|NCT05033990||Gold 0|"Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted.~GOLD stands for the Global initiative for Chronic Obstructive Lung Disease."
89232378|NCT05033990||Preserved Ratio Impaired Spirometry (PRISm)|Participants with ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 < 80% predicted.
89232379|NCT05033990||GOLD 1 - 2|Participants graded as GOLD 0 by the GOLD grading system: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 ≥ 50% predicted.
89232380|NCT05032066|Experimental|HZN-825 300 mg once daily (QD)|Two 150 mg oral tablets given in the morning with a meal and two matching placebo tablets given in the evening with a meal; total daily dose 300 mg HZN-825.
89232381|NCT05032066|Experimental|HZN-825-300 mg twice daily (BID)|Two 150 mg oral tablets given in the morning with a meal and two 150 mg oral tablets given in the evening with a meal; total daily dose 600 mg HZN-825.
89232382|NCT05032066|Placebo Comparator|Placebo BID|Matching placebo tablets (2) given in the morning with a meal and matching placebo tablets (2) given in the evening with a meal; total dose 4 placebo tablets.
89116476|NCT04106050|Experimental|Part A: BIIB095 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 1 capsules from Day 1 to Day 8.
89116477|NCT04106050|Experimental|Part A: BIIB095 Dose 2|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 2 capsules from Day 1 to Day 8.
89116478|NCT04106050|Experimental|Part A: BIIB095 Dose 3|Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 3 capsules from Day 1 to Day 8.
89116479|NCT04106050|Placebo Comparator|Part A: BIIB095 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB095 capsules from Day 1 to Day 8.
89116480|NCT04106050|Active Comparator|Part A: Lidocaine|Healthy participants and participants with DPN will receive single injection of lidocaine for partial nerve conduction block and single injection of lidocaine for skin infiltration on Day 8.
89116481|NCT04106050|Experimental|Part B: BIIB074 Dose 1|Healthy participants and participants with DPN will receive oral dose of BIIB074 Dose 1 tablets from Day 1 to Day 8.
89116482|NCT04106050|Placebo Comparator|Part B: BIIB074 Placebo|Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB074 tablets from Day 1 to Day 8.
89116483|NCT02588365|Experimental|Brain Training (Active)|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
89116484|NCT02588365|Experimental|Brain Training (Passive)|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent level."
89116485|NCT02588365|Experimental|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
89116486|NCT00588094|Experimental|Treatment|R-ICEesc will be administered with the intent of administering 2 cycles, each 21 days apart admixed with 4 doses of rituximab. G-CSF will be administered at 960 ug or 10 ug/kg if patient is > 100 kg after cycles one and two for PBPC collection for the first 10 patients enrolled. G-CSF will be administered in standard dosing for cycle one and then at 960 ug or 10 ug/kg (if patient is > 100 kg) after cycle two for PBPC collection for the remaining 22 patients. All responding patients who make at least 2 x 106 CD34+ cells/kg will receive high dose therapy and ASCT on other protocols.
89116487|NCT05684029||Near-infrared Step|1. Use near-infrared equipment to detect surgical specimens; 2. Timing near-infrared equipment detects parathyroid glands and takes photography; 3. recording the positive tissue in NIRAF; 4. analyzing the accuracy of NIR equipment to see positive points.
89116488|NCT05684029||Senior Surgeon Step|1. Senior Surgeon inspects for parathyroid glands in postoperative thyroid specimens with the naked eye; 2. Timing senior doctors with parathyroid glands; 3. PTH test strips confirm all suspicious tissues. 4. all analyzing the accuracy of the positive points of senior doctors.
89116489|NCT04107922|Active Comparator|Glicoset|Glicoset is a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
89116490|NCT04107922|Placebo Comparator|Placebo|
89116491|NCT05193175|Experimental|Prolonged sitting|Uninterrupted sitting for 6 hours.
89116492|NCT05193175|Experimental|Sitting interrupted with standing|Sitting interrupted with 5 minutes of static standing every 30 minutes for 6 hours.
89116493|NCT05193175|Experimental|Sitting interrupted with light stepping|Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.
89116494|NCT02603224|Experimental|MRG-201|
89116495|NCT02603224|Placebo Comparator|Placebo|
89116496|NCT02602990||Cerebral AVM treated with SQUID™|
89116497|NCT02588989||transposition of the great arteries|Patients with a TGA
89116498|NCT02605252|Experimental|CHB patients|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2b 80 micrograms/week for 48 weeks.
89116499|NCT05047627|Experimental|Smartphone Digital Intervention Group|The Smartphone Digital Intervention Group is the experimental group. Participants randomized to this group will download the smartphone intervention and be asked to use the intervention four times per week for four weeks ( 16 digital sessions). The smartphone digital intervention will also continuously collect passive sensing data. The smartphone digital intervention will be designed to treat anxiety and depression by providing informational videos to help participants treat these symptoms. These videos include information about physical activity, muscle relaxation, and other proven helpful interventions to help with anxiety and depression.
89116500|NCT05047627|No Intervention|Wait list Control Condition|The wait list control condition will not receive the digital intervention treatment for the duration of the study. They will still provide urine samples during the study. Participants assigned to this condition will be able to access the digital intervention after their participation in the study.
89116501|NCT04107844||Athletes without concussion|We follow the athletes in terms of injuries and make a baseline test each season.
89116502|NCT04107844||Athletes suffering a concussion|We follow the athletes in terms of injuries and make a baseline test each season and when they suffer a concussion, then we follow them with the same test as at baseline every 14th day for 3 months, after that they will get enrolled in another study.
89116503|NCT04215939|Experimental|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116504|NCT04215939|Experimental|Thermoneutral environment participants with spinal cord injury|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116505|NCT04215939|Experimental|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116506|NCT04215939|Active Comparator|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116507|NCT04215939|Active Comparator|Thermoneutral environment healthy male participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116508|NCT04215939|Active Comparator|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116509|NCT04215939|Active Comparator|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116510|NCT04215939|Active Comparator|Thermoneutral environment healthy female participants|In a thermoneutral enviroment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116511|NCT04215939|Active Comparator|Warm enviroment healthy fmale participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
89116512|NCT02706015|Experimental|Cefaliv® & Placebo|Dihydroergotamine mesylate+ dipyrone sodium + caffeine
89116513|NCT02706015|Active Comparator|Neosaldina® & Placebo|Isometheptene mucate + dipyrone sodium + anhydrous caffeine
89116514|NCT00615225||Brain dead patients|All patients meeting criteria for brain death
89116515|NCT00615225||Healthy control|Any healthy volunteers accepting to give some blood
89116516|NCT00615225||Volunteers having hip surgery|Patients undergoing hip surgery for degenerative non-inflammatory hip disease
89116517|NCT02705937|Experimental|Dairy product|The product will be taken for 14 days
89116518|NCT02705937|Active Comparator|Aequasyal mouth spray medical device|The spray will be taken for 14 days
89116519|NCT04215705|Active Comparator|Group Q|Patients in this group receive Quadratus Lumborum Block with 20 ml bupivacaine 0.5%
89116520|NCT04215705|Active Comparator|Group L|Patients in this group receive peritubal local infiltration at 6 and 12 o'clock position with 20ml bupivacaine 0.5%
89116521|NCT02705781|Experimental|General|One arm study: smARTrack Feeding Tube System.
89116522|NCT04083313|Active Comparator|Endoloop|Patients in which appendiceal stump was ligated using Endoloop
89116523|NCT04083313|Active Comparator|Endostapler|Patients in which appendiceal stump was ligated using Endostapler
89116524|NCT04083313|Active Comparator|Endoclip|Patients in which appendiceal stump was ligated using Endoclip
89116525|NCT04083469|Experimental|Peer-Led Peer-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated the peer-leader.
89116526|NCT04083469|Other|Adult-Led Intervention|The e-cigarette intervention program will be administered to students by an adult educator.
89116527|NCT04083469|Other|Peer-Led Non-Elected Intervention|The e-cigarette intervention program will be administered to students by an elected peer leader. The audience will consist of students that nominated a different peer-leader.
89116528|NCT02707575||Ranibizumab|Intravitreal Ranibizumab
89116529|NCT00784654|Experimental|Lisdexamfetamine dimesylate (LDX)|Open-label 30, 50, or 70mg
89116530|NCT00784654|Placebo Comparator|Placebo|
89116531|NCT02707185|Other|Physicians|"Physician in training:~All internal medicine (IM), emergency medicine (EM), anesthesia (A), surgery (S) residents and all hospital ICU nurses."
89116532|NCT02707185|Other|Nurses|Nurses in Training
89116533|NCT02588287|Experimental|Tenofovir PK before and after SOF/LDV|
89116534|NCT02707107|Active Comparator|3 g of zidebactam (1 g q8h) and 6 g of cefepime (2 g q8h) or 6|administered as IV infusions every q8h, over a period of 60 minutes.
89116535|NCT02707107|Placebo Comparator|Placebo|administered as IV infusions every q8h, over a period of 60 minutes.
89116536|NCT02707263|Active Comparator|Intravenous continuous infusion of heparin (IV UFH)|Heparin will be administered intravenously.
89116537|NCT02707263|Active Comparator|Subcutaneous heparin|Heparin will be subcutaneously administered.
89116538|NCT04105348||IBD with DM|
89116539|NCT04105348||IBD without DM|
89116540|NCT02705547|Experimental|Rosuvastatin (Crestor)|This is an open-label study of Rosuvastatin (Crestor) in patients with FRDA. Study subjects will receive 10 mg of Rosuvastatin daily for 3 months.
89116541|NCT05345379|Experimental|Transbond MIP|Transbond primer group will be randomly allocated using a split-mouth, cross-quadrant design and two diagonal quadrants (i.e. upper right and lower left, or vice versa) for each participant.
89116542|NCT05345379|Experimental|Assure plus|Assure Plus primer group will be randomly allocated using a split-mouth, cross-quadrant design and two diagonal quadrants (i.e. upper right and lower left, or vice versa) for each participant.
89116543|NCT02587507|Placebo Comparator|Water|The subjects will ingest the HFHC meal with 500mL of water.
89116544|NCT02587507|Experimental|Orange juice|The subjects will ingest the HFHC meal with 500mL of orange juice.
89116545|NCT02587507|Active Comparator|Water with glucose|The subjects will ingest the HFHC meal with 500mL of water with glucose (isocaloric control of the orange juice).
89116546|NCT00615303|Placebo Comparator|2|
89116547|NCT00615303|Active Comparator|1|
89116548|NCT04082845|Experimental|Experimental Group|The experimental group will be educated via a website that was created by the researchers.
89116549|NCT04082845|No Intervention|Control Group|The control group will take rutin patient care.
89116550|NCT04831281|Experimental|40mg Dose|Daily subcutaneous injection of 40mg ATH-1017
89116551|NCT04831281|Experimental|70mg Dose|Daily subcutaneous injection of 70mg ATH-1017
89116552|NCT04831281|Placebo Comparator|Placebo|Daily subcutaneous injection of Placebo
89116553|NCT00787150|Experimental|Apixaban 5mg BID|
89116554|NCT00787150|Experimental|Apixaban 2.5mg BID|
89116555|NCT00787150|Active Comparator|Warfarin|
89116556|NCT02705469|Experimental|Dose Escalation and Dose Confirmation - ZEN003694 Single Agent|ZEN003694 will be administered orally as a single agent once daily in 28-day cycles, enrolling mCRPC patients.
89232383|NCT05030415|Experimental|Ixekizumab|ixekizumab 80 mg injection, 160 mgs injected subcutaneously on week 0, 80 mgs injected subcutaneously every two weeks
89116557|NCT02705703|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
89116558|NCT03606837|Experimental|PET/CT Imaging|
89116559|NCT02587585|Experimental|Feedback against tailored target|For each two hour epoch, the watch calculate the level of activity for the same epoch the day before, and adds 5% as the new target to be achieved.
89116560|NCT02587585|Sham Comparator|No Feedback|For participants assigned to the control group, the smart watch will not provide any activity feedback against a target; it simply shows which two hour epoch a person is in.
89116561|NCT03016065|Experimental|Pea Fiber|Snacks fortified with 10 g of pea hull fiber will be administered for two weeks, followed by a two-week washout, and a two-week period with control snacks.
89116562|NCT03016065|Placebo Comparator|Control|Control snacks will provided for 2 weeks, followed by a two-week washout, and snacks with 10 g/d of pea fiber for 2 weeks.
89116563|NCT05109403||LH post-trigger < 15 UI/l|Oocyte donors that present with LH levels < 15UI/I, post trigger by agonists of GnRH
89116564|NCT05109403||LH post-trigger > 15 UI/l|Oocyte donors that present with LH levels > 15UI/I, post trigger by agonists of GnRH
89116565|NCT02587663|Active Comparator|Group 1 (standard of care)|Patients undergo standard of care diagnostic imaging comprising bilateral mammography and targeted breast ultrasound.
89116566|NCT02587663|Experimental|Group 2 (bilateral whole-breast ultrasound)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral whole-breast ultrasound.
89116567|NCT02587663|Experimental|Group 3 (bilateral breast contrast-enhanced MRI)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral breast contrast-enhanced MRI.
89116568|NCT00786838|Experimental|Trabectedin|3-hour placebo intravenous infusion on Day 1 and trabectedin 1.3 mg/m2 3-hour intravenous infusion on Day 2 (single-blind). Patients may continue treatment with trabectedin until clinical benefit or drug is commercially available (open-label).
89116569|NCT05683951|Experimental|DWKH|
89116570|NCT05683951|Active Comparator|DWKH-R|
89116571|NCT05683951|Placebo Comparator|PLACEBO|
89116572|NCT02604004|Active Comparator|Period 1|Epivir ® tablet 150-mg single dose (drug reference)
89116573|NCT02604004|Experimental|Period 2|Lamivudine 150-mg tablet single dose (drug test)
89116574|NCT02588521|Experimental|AL-794|AL-794 administered orally in a suspension
89116575|NCT02588521|Placebo Comparator|Vehicle|Suspension vehicle alone
89116576|NCT02705157||Bone metastasis of the long bone|Patients with bone metastases of the long bone(s) receiving surgical stabilisation of a pathologic or impending fracture or receiving radiotherapy for a painful metastasis.
89116577|NCT04104880|Experimental|Continuous Positive Airway Pressure (CPAP) group|Three-month CPAP use
89116578|NCT02604082|Active Comparator|Vibocompression (VB)|Grup 1 - Vibrocompression: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration
89116579|NCT02604082|Active Comparator|Hyperinflation (HMV)|Grup 2 - Hyperinflation with Mechanical ventilator: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the increase in inspiratory pressure ventilator .
89116580|NCT02604082|Experimental|HMV+VB|Grup 3 - Hyperinflation with mechanical ventilator and vibrocompression:Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration and the increase in inspiratory pressure ventilator.
89116581|NCT02602912|Experimental|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability.
89116582|NCT03354039|Experimental|Tamoxifen 20 mg once daily|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of TAM daily.
89116583|NCT03354039|Placebo Comparator|Matching placebo once daily|Patients randomised to placebo will be administered matching placebo.
89116584|NCT04105426|Active Comparator|Antioxidants|This arm of patients received one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
89116585|NCT04105426|Placebo Comparator|Placebo|This arm of patients received placebo for 3 months.
89116586|NCT02704923|Active Comparator|Atropine|
89116587|NCT02704923|Placebo Comparator|Placebo|
89116588|NCT02704845||Ankylosing Spondylitis|
89116589|NCT02704845||Chronic non-specific low back pain|
89116590|NCT03936439||Consecutive stroke patient|All consecutive stroke patients from five time points, i.e. 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018 are selected for analysis.
89116591|NCT04105504|Experimental|Glutathione Group|Subjects were randomised to receive Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
89116592|NCT04105504|Placebo Comparator|Placebo Group|Subjects were randomised to receive Placebo capsules, which were identical in appearance and packaged in identical-looking containers with the Glutathione capsules. The capsules were taken once daily for 12 weeks and evaluated every 4 weeks.
89116593|NCT02704611|Active Comparator|Group I|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week).
89116594|NCT02704611|Sham Comparator|Group II|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec.
89116595|NCT04815967|Experimental|Phase 2; Low Dose MYOBLOC|Low Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
89116596|NCT04815967|Experimental|Phase 2; High Dose MYOBLOC|High Dose MYOBLOC is a single treatment and will be compared to volume-matched placebo
89116597|NCT04815967|Placebo Comparator|Phase 2; Placebo|Volume-matched placebo is a single treatment
89116598|NCT04815967|Experimental|Phase 3; MYOBLOC|MYOBLOC is a single treatment and will be compared to volume-matched placebo
89116599|NCT04815967|Placebo Comparator|Phase 3; Placebo|Volume-matched placebo is a single treatment
89116600|NCT02704767|Placebo Comparator|TarceP|Tarceva with Placebo
89116601|NCT02704767|Experimental|TarceA|Tarceva with Apatinib
89523295|NCT03125057|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
89116602|NCT02587273|Other|Fentanyl|This is a pharmacokinetics study with a single arm. All participants will will undergo the intervention described under the intervention section
89116603|NCT02704533|Experimental|Optimization Phase - Group A|"n=6; three times 9x10^5 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group A will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 (Group B1).~If <75% efficacious, the treatment will be increased to three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group B2)"
89116604|NCT02704533|Experimental|Optimization Phase - Group B1|"n=6; two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 by DVI. Group B1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to one injection 2.7x10^6 PfSPZ Vaccine (Group C1).~If <75% efficacious, the treatment will be increased to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2)."
89116605|NCT02704533|Experimental|Optimization Phase - Group B2|"n=6; three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group B2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2).~If <75% efficacious, the treatment will be increased to three times 2.7x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group C3)."
89116606|NCT02704533|Experimental|Optimization Phase - Group C1|"n=6; one time 2.7x10^6 PfSPZ Vaccine by DVI. Group C1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~If Group C1 gets vaccinated, study will proceed to verification phase after completion."
89116607|NCT02704533|Experimental|Optimization Phase - Group C2|"n=6; two times 2.7x10^6 PfSPZ Vaccine by DVI. Group C2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~If Group C2 gets vaccinated, study will proceed to verification phase after completion."
89116608|NCT02704533|Experimental|Optimization Phase - Group C3|"n=6; three times 2.7x10^6 PfSPZ Vaccine by DVI. Group C3 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~In case C3 shows <75% efficacy, verification phase will not be done."
89116609|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D1|"n=3, one dose of 800 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
89116610|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D2|"n=3, one dose of 1,600 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
89116611|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D3|"n=3, one dose of 3,200 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
89116612|NCT02704533|Experimental|Verification Phase - Group V1|"n=12; optimal regimen from phase 1 - shortest, well tolerated safe schedule that provides >75% protection (5/6) against homologous CHMI (V1).~Optimal & maximum regimens will be compared in this phase. The maximum regimen is a 3-dose regimen (Day 0, 7, 28) with highest well-tolerated PfSPZ Vaccine dose/injection (V2).~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered in one of 2 sequences (NF54-7G8 or 7G8-NF54). Allocation to the 2 sequences will be double blind, random, at a 1:1 ratio and nested within the intervention groups (V1 and V2 PfSPZ Vaccine and placebo (P1 and P2)). CHMI will be done at a dose of 3,200 PfSPZ unless the dose escalation study of PfSPZ Challenge (7G8) indicates that a different dose would be preferable for 7G8."
89116613|NCT02704533|Experimental|Verification Phase - Group V2|"n=12; maximum regimen from the phase 1 - 3-dose regimen (Day 0, 7 and 28) with highest well-tolerated PfSPZ Vaccine dose per injection (V2).~Optimal & maximum regimens will be compared in this phase. The optimal regimen (shortest, well tolerated and safe schedule) that provides >75% protection (5/6) against homologous CHMI (V1).~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
89116614|NCT02704533|Placebo Comparator|Verification Phase - Group P1|"n=6; normal saline as placebo. This group will follow the regimen selected for Group V1.~Efficacy of the vaccination regimen will be determined by CHMI which will be done by repeat CHMI three and eight weeks after the last immunization. Inoculation of the two CHMIs will be done approximately 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
89116615|NCT02704533|Placebo Comparator|Verification Phase - Group P2|"n=6; NS as placebo. This group will follow the regimen selected for Group V2.~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.~Efficacy will be determined by repeat CHMI 3 and 8 weeks after the last immunization. Inoculation of the 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
89116616|NCT04104724|Experimental|Self-help|Immediate access to self-help materials
89116617|NCT04104724|No Intervention|Control|Wait-list control - treatment as usual (no intervention)
89232384|NCT05029921|Experimental|Ustekinumab|Participants will receive a single dose of ustekinumab intravenously (IV) (weight-based dose approximating 6 milligrams per kilogram [mg/kg]) at Week 0. Participants with body weight less than or equal to (<=) 55 kg will receive ustekinumab IV of 260 mg, greater than (>) 55 kg and <=85 kg will receive ustekinumab IV of 390 mg, and >85 kg will receive ustekinumab IV of 520 mg at Week 0 in induction phase followed by ustekinumab 90 mg subcutaneously (SC) in maintenance phase from Week 8 to Week 52. For participants who achieve clinical response with ustekinumab induction dosing at Week 8, will continue to receive 90 mg ustekinumab SC every 12 weeks with final dose at Week 44. If these participants meet the criteria for loss of response from Week 16 to Week 40, dose can be adjusted to 90 mg every 8 weeks (q8w). Participants who are non-responders to ustekinumab at Week 8, and achieve clinical response at Week 16, will continue to receive ustekinumab 90 mg SC q8w from Week 16 to Week 48.
89232387|NCT05026346||Healthy|Healthy subjects, wothout shoulder pathology
89232388|NCT05026346||Rotator cuff tears|Patients after arthroscopic reconstruction of rotator cuff
89232389|NCT05022849|Experimental|Part 1: Dose Escalation|Participants will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by JNJ-75229414 IV infusion escalated sequentially with a targeted dose consistent with the dose required by the cohort being enrolled to determine recommended Phase 2 dose (RP2D) regimen(s). Additional, intermediate dose levels may be implemented based on the review of all available data including, but not limited to, safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) by the study evaluation team (SET). Participants may receive bridging therapy (anti-androgen receptor agents [example, abiraterone, enzalutamide] and radiotherapy, or chemotherapy [example, docetaxel]) if clinically indicated to maintain disease stability.
89232390|NCT05022849|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-75229414 for each RP2D regimen determined in Part 1.
89232391|NCT05016882|Experimental|NNC0194-0499 7.5 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232392|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232393|NCT05016882|Experimental|NNC0194-0499 15 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232394|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232395|NCT05016882|Experimental|NNC0194-0499 30 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232396|NCT05016882|Experimental|NNC0194-0499 30 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232397|NCT05016882|Active Comparator|Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232398|NCT05016882|Placebo Comparator|Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232399|NCT05016882|Experimental|NNC0174-0833 2.4 mg + semaglutide 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232400|NCT05016882|Placebo Comparator|Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg|Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
89232401|NCT05011045||Observational (neurocognitive assessment, questionnaires, MRI)|Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.
89232402|NCT05009979|Experimental|1/Baseline and Post-treatment Imaging|18F-DCFPyL PET/CT imaging, CT and/or MRI and standard of care local ablative treatment
89232403|NCT04995224||Study 1A|Prospective cohort study with 150 newly diagnosed patients with inflammatory bowel disease
89232404|NCT04995224||Study 1B|Prospective cohort study with 450 newly diagnosed patients with IBD
89116618|NCT04107454|Active Comparator|Active group|The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
89116619|NCT04107454|Placebo Comparator|Placebo group|Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
89116620|NCT02704221|Active Comparator|Behavioral Parent Training (BPT)|The control group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks and 2) attend 12 weekly BPT training sessions.
89116621|NCT02704221|Experimental|BPT + Contingency Management (BPT+CM)|The experimental group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks, 2) attend 12 weekly BPT training sessions, and 3) receive monetary rewards for achieving weekly step-count goals.
89116622|NCT02602834|Experimental|HTx|Heart transplant recipients n=15
89116623|NCT02602834|Active Comparator|Control|Healthy controls n=5
89116624|NCT02587975|Experimental|Evogliptin 10 mg|Single oral administration of 2 tablets of evogliptin 5 mg with water 250 mL
89116625|NCT02704299|Experimental|Autologous T cells-Based Immunotherapy|Surgery Chemotherapy Autologous T cells-Based Immunotherapy
89116626|NCT02703831|Active Comparator|Dual attending|Two attending spine surgeons during the critical portions of the surgery
89116627|NCT02703831|Placebo Comparator|Single attending|One spine attending and an assistant during the critical portions of the surgery, The assistant can be a spine fellow, a resident or a physician's assistant.
89116628|NCT04104568|Experimental|iSupport for dementia - European-Portuguese version|Access, for 3 months, to an online self-help training and support program: iSupport for dementia - European-Portuguese version. The e-program offers information, skills training and support for informal caregivers of people with dementia. It comprises five modules, including twenty-three lessons on dementia and caregiver support. In line with good practices on digital engagement, the education plan can be personalized by the caregiver. This means that it can be adjusted to the person's availability and lessons can be selected according to particular needs. Each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques including psycho-education, behavioral activation, cognitive reframing, relaxation and antecedent-behavior-consequence (ABC) analysis.
89116629|NCT04104568|Active Comparator|Education-only e-book|The control group will receive a minimal education-only intervention, consisting on an e-book. The manual contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
89116630|NCT04082065|Active Comparator|conventional physical therapy|Myofacial release Stretching of hamstring and Piriformis
89116631|NCT04082065|Experimental|cyriax lumber manipulation group|Myofacial Release stretching of hamstrings and Piriformis Cyriax Lumbar Manipulation Techniques
89116632|NCT02704065||Recurrent AA amyloidosis|Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft
89116633|NCT02704065||Control group 1|Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft
89116634|NCT02704065||Control group 2|Renal transplant recipients whose primary diseases are other than amyloidosis
89116635|NCT05683795||Healthcare Professionals|Members of The PelvEx Collaborative who are experts in performing pelvic exenteration surgery, and managing the complications relating to the empty pelvis syndrome as a result of this surgery.
89116636|NCT05683795||Patient Representatives|Patients that have undergone pelvic exenteration surgery and likely to have been exposed to the morbidity of the empty pelvis syndrome.
89116637|NCT02703753|Experimental|Intervention group|The intervention is an integral and multidisciplinary lifestyle intervention consisting of a healthy diet, appropriate physical activity and, if applicable, smoking cessation, customised to the needs of the women.
89116638|NCT02703753|No Intervention|Control group|The control group will receive usual care, including standard lifestyle advices during consultation with the GP, midwife, obstetrician or at the child well being centre. Furthermore, the control group will receive 1 recipe for a healthy meal per week.
89116639|NCT02587741|Experimental|oral drugs|oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard，added to 500mg tid→1000mg bid.if metformin reach the biggest dosage，added gliclazide modified release tablets，from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target，add acarbose 50mg tid
89116640|NCT02587741|Experimental|lantus|basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm（at 8am if patients are night workers）,add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.
89116641|NCT02587741|Experimental|Novomix30|premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .
89116642|NCT04105192|Experimental|experimental group (Lippia citriodora + sabdariffa)|"Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days."
89116643|NCT04105192|Placebo Comparator|control group Placebo (sucrose)|Consumption for 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg or Placebo (sucrose) Two capsules per day will be consumed thirty minutes before breakfast orally for 84 days.
89116644|NCT02703519|No Intervention|1 cesarean section|control group
89116645|NCT02703519|No Intervention|2 cesarean sections|control group
89116646|NCT02703519|Experimental|resection of uterine scar tissue|2 cesarean sections with resection of uterine scar tissue from first cesarean section
89116647|NCT04024618|Active Comparator|Parenteral Nutrition|Patients who have been randomized to receive PN will be started on day 5 post AHSCT. This will be if patient intake is < 80% of usual oral intake at that time. The central venous catheter required for PN administration will be already in place for AHSCT treatment, prior to admission and pre-transplant evaluation. Nutritional support will continue until oral intake is >50% or until the patient is ready for discharge if intake remains < 50% of recommendations.
89116648|NCT04024618|Experimental|Enteral Nutrition|Patients who have been randomized to receive EN will have a Nasogastric tube (NGT) inserted on day 5 post AHSCT, prior to start of Enteral feeds. This would be a polyurethane tube, 8-10 French, which will be inserted by physician or Nurse Practitioner with position confirmed by radiological examination. This will be if patient intake is < 80% of usual oral intake at that time. Nutritional support will continue until oral intake is >50% or until the patient is ready for discharge if intake remains < 50% of recommendations.
89116649|NCT02703363|Experimental|Minocycline with TAU|
89116650|NCT02703363|Experimental|Celecoxib with TAU|
89116651|NCT02703363|Experimental|Minocycline and celecoxib with TAU|
89116652|NCT02703363|Active Comparator|Placebo with TAU|
89116653|NCT00615381|Active Comparator|Normal insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using normal intensive insulin infusion rates (0-10 U/hr).
89116654|NCT00615381|Experimental|Supraphysiologic insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using supraphysiologic insulin infusion doses (0.3 U/kg/hr) and exogenous dextrose to provide stable blood glucose levels .
89116655|NCT00785980|Active Comparator|Quinine Sulfate|Baseline quinine sulfate pharmacokinetics
89116656|NCT00785980|Experimental|Quinine Sulfate with Ciprofloxacin|Quinine sulfate pharmacokinetics in the presence of steady state ciprofloxacin
89116657|NCT04805073|Experimental|Promethazine|The treatment will consist of a blinded syringe of 1cc clear liquid 25mg/ml Promethazine
89116658|NCT04805073|Placebo Comparator|Placebo|The treatment will consist of a blinded syringe of 1cc 0.9% Sodium Chloride
89116659|NCT05683561|Active Comparator|CoronaVac|one dose of CoronaVac on D0
89116660|NCT05683561|Experimental|SCTV01E|one dose of SCTV01E on D0
89116661|NCT00915694|Experimental|Single arm|NFV-RT-Tem
89116662|NCT02703675|Experimental|adult healthy volunteer|Adult healthy volunteers will be recruited from staff in Dept. Neurology, medical students. They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.
89116663|NCT02703675|Experimental|adult normothermic patient|"Adult normothermic patients will be recruited from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.~They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours."
89116664|NCT02703675|Experimental|adult sick febrile patient|"Adult sick febrile patients will be enrolled from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.~Five of the patients will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.~Other five patients will received 2 rounds of cooling process each 2 hours long"
89116665|NCT04802629||Term neonates|≥ 37+0 weeks of gestation
89116666|NCT04802629||Preterm neonates|≤ 36+6 weeks of gestation
89116667|NCT02703441|Experimental|Intervention: Tablet computer|Patients from the local municipality, planned to be discharged to a rehabilitation stay at the municipality training centre receive a tablet computer. The patient will be introduced to the tablet and informed about the nutritional and mobilisation intervention based on his/her individual needs and preferences. The patient and the research assistant will jointly prepare an individual plan for nutrition and physical activity The patient uses the tablet for ordering meals, registering dietary intake, viewing his/her instruction videos for the activity programme and registering physical activity during hospital admission and at the training centre up to 6 weeks after discharge from hospital.
89116668|NCT02703441|No Intervention|Control group|Patients in the control group receive usual care during their hospital stay and after discharge at the municipality training centre. Data are recorded at baseline and 6 and 12 weeks after discharge.
89116669|NCT02703285|Experimental|questionnaire|task of the participants in the study to determine the chest sound based on specific sounds
89116670|NCT00791518||No group|No group
89116671|NCT02703129|Experimental|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
89116672|NCT03293901|No Intervention|Rest|
89116673|NCT03293901|Active Comparator|Exercise|Militarily relevant exercise
89116674|NCT04787419|Experimental|probiotics|"2 sachets per day for 4 weeks.~1 sachet of probiotics (1gram) contains: Viable Counts 1 x 107 CFU/g living bacteria in dual pH dependent release coated (Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus), Vitamin C 10 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Niacin 2 mg."
89116675|NCT04787419|Placebo Comparator|placebo|"2 sachets per day for 4 weeks.~1 sachet of placebo (1gram) contains: saccharum lactis"
89116676|NCT02703051|Experimental|GMI-1271|GMI-1271
89116677|NCT02703051|Active Comparator|Filgrastim|Filgrastim
89116678|NCT02703051|Experimental|GMI-1271 with Filgrastim|GMI-1271 with Filgrastim
89116679|NCT04107688|Experimental|PROP non-taster subjects|This arm will comprise of PROP non-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
89116680|NCT04107688|Experimental|PROP super-taster subjects|This arm will comprise of PROP super-taster subjects. Subjects will use a cranberry-derived oral rinse twice a day for 11 days following a 3-day control-rinse period.
89116681|NCT02691975|Experimental|SHR3680|Tablet
89116682|NCT02702973||Observe the fundus characteristics|Observe the fundus characteristics after high doses of interferonα-2b therapy in patients with melanomas of the skin.
89232405|NCT04995224||Study 2|Cross-sectional study with 10,000 patients in IBD Boost study
89116683|NCT00785512|Active Comparator|1|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
89116684|NCT00785512|Placebo Comparator|2|Matching placebo tablets, oral administration
89116685|NCT02702817|Active Comparator|naproxen|naproxen sodium tablets 220 mg twice daily for two years
89116686|NCT02702817|Placebo Comparator|placebo|tablets identical in appearance to naproxen tablets twice daily for two years
89116687|NCT04083079|Experimental|PEG-rhG-CSF cohort|"PEG-rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle for only once.~Dosage: 6mg for weight ≥45kg，3mg for weight <45kg, subcutaneous injection"
89116688|NCT04083079|Experimental|rhG-CSF cohort|"rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle until absolute neutrophil count ≥2×10^9/L.~rhG-CSF treatment will be given when there is neutropenia until absolute neutrophil count ≥2×10^9/L.~Dosage: 5μg/kg/d, subcutaneous injection"
89116689|NCT02702739|Active Comparator|Group I (<65 years)|Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
89116690|NCT02702739|Active Comparator|Group II (>65 years)|Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
89116691|NCT02602444||STEMI|ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
89116692|NCT02602444||NSTEMI|non-ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
89116693|NCT02602678|Experimental|PRONE-Supine|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
89116694|NCT02602678|Experimental|SUPINE - Prone|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
89116695|NCT02702661|Experimental|Procedure - FICB|Fascia Iliaca Block following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
89116696|NCT02702661|Active Comparator|Procedure - LAI|Local Anaesthetic Infiltration following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
89116697|NCT04107532|Other|Virtual Reality Therapy for Acrophobia|There were a total of 5 treatments in the VR treatment group, followed by cliffs, cliffs, cliffs, single-plank bridges, and high-altitude rescues. The difficulty of the scene increased in turn. The frequency of treatment twice a week, about 30 minutes each time, fills in the motion sickness questionnaire before and after each treatment to understand the safety of VR treatment. In the course of treatment, physiological data such as skin electricity, skin temperature, heart rate, and blood volume were measured, and the state of the subjects was objectively evaluated. At the same time, every two minutes, participants were asked about sud values and recorded.
89116698|NCT04107532|Other|Imagination Exposure Therapy for Acrophobia|The imaginary exposure treatment program is to convert the five scenes of VR exposure treatment through language, guide the subjects through the guidance language, guide the subjects to expose, and achieve the purpose of adaptation. Both treatment groups were required to collect scales and nuclear magnetic data before, after and after six months of follow-up.
89232406|NCT04995224||Study 3|Cross-sectional study with 15,000 patients in IBD BioResource
89232407|NCT04990167|Experimental|Tiotropium arm|"Subjects on this arm will start the study on tiotropium for 6 weeks. Received prescribed asthma controller medication for 2 weeks  washout and complete 6 week on the prescribed asthma controller medication."
89232408|NCT04990167|Active Comparator|ICS arm|"Subjects on this arm will start the study on the prescribed asthma medication for 6 weeks. Received prescribed asthma controller medication for 2 weeks  washout and complete 6 week on Tiotropium."
89232409|NCT04988295|Experimental|Arm A: LACP/ACP-L|LACP dosing (from study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression.
89232410|NCT04988295|Active Comparator|Arm B: CP (Carboplatin and Pemetrexed)|Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.
89232411|NCT04988295|Experimental|Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
89232412|NCT04988295|Experimental|Arm A2 (Extension Cohort): ACP-L|Participants will receive Amivantamab and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression.
89232413|NCT04988295|Experimental|Arm C2 (Extension Cohort): ACP|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
89232414|NCT04987476||ATRT|Children affected by an ATRT at time of surgical resection
89232415|NCT04975763|Experimental|Soybean Oil|Consumption of study foods each day made with soybean oil
89232416|NCT04975763|Placebo Comparator|Palm Oil|Consumption of study foods each day made with palm oil
89232417|NCT04975750|Experimental|Problem solving intervention|Problem solving as developed by Nexu and colleguages. First-line managers are trained in the problem solving intervention (1 1/2 day). Thereafter, they apply the problem-solving in 2 - 5 meetings (about 30 - 45 min each) with employees at risk of future sick leave due to common mental disorders.
89232418|NCT04975750|Active Comparator|Care as usual|First-line managers participate in a 3 hour lectur including a brief overview about worker health, occupational stress and the mismatch model and self-efficacy. Thereafter, they provide care-as-usual to employees at risk of future sick leave due to common mental disorders.
89232419|NCT04969250|Experimental|Group I1|Immediate, one dose. Vaccination at study entry
89232420|NCT04969250|Experimental|Group I2|Immediate, two doses. Vaccination at study entry and Week 4
89232421|NCT04969250|Experimental|Group D1|Deferred, one dose. Vaccination at Week 12 only
89232422|NCT04969250|Experimental|Group D2|Deferred, two doses. Vaccination at Week 12 and Week 16
89232423|NCT04951778|Experimental|Participants with R/R AML and R/R HR-MDS - Part A|Part A (Dose Escalation) of the study will enroll R/R AML (Relapsed or Refractory Acute Myeloid Leukemia) and R/R HR-MDS (Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes) participants and will evaluate the safety and tolerability of escalating doses of CC-91633, administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
89232424|NCT04951778|Experimental|Participants with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R AML participants.
89232425|NCT04951778|Experimental|Participants with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (HR-MDS)|Part B (expansion part) will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R HR-MDS participants.
89232426|NCT04951622|Experimental|Nipocalimab|"Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase.~Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion till study end."
89232427|NCT04951622|Placebo Comparator|Placebo|Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.
89232428|NCT04951609|Experimental|Seltorexant|Participants will receive weight based dose of Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6). Participants will continue baseline selective serotonin reuptake inhibitor (SSRI) antidepressant (Fluoxetine or escitalopram) orally once daily.
89232429|NCT04951609|Placebo Comparator|Placebo|Participants will receive matching placebo tablets to seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
89523296|NCT03387241|Experimental|Fluticasone/ Formoterol (Flutiform)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/5 µg Mid dose: 125/5 µg High dose 250/10 µg Dosing Frequency:BID Mode of Administration:Inhaled"
89116699|NCT04215549||Participants|OCD patients come from 13 hospitals located in the north, south, east and west of China
89116700|NCT02702505|Experimental|NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time. The new formulation has received the Food and Drug Administrations 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).19
89116701|NCT02702505|Other|ProRoot MTA|Control group. This group will receive the old formulation of MTA in the pulpotomy and the tooth will receive a full coverage stainless steel crown restoration.
89116702|NCT02702349|Other|1|penicillin test and challenge
89116703|NCT00785356|Experimental|25 mg Proellex|Proellex 25 mg
89116704|NCT00785356|Experimental|Proellex 50 mg|Proellex 50 mg
89116705|NCT00785356|Placebo Comparator|Placebo|Placebo
89116706|NCT02702427|Experimental|ARM 1|Patients with Adenovirus or CMV infection after HSCT and no reduction of viral disease or stable disease with 10E6 viral copies within 2 weeks of antiviral treatment will receive a single infusion of virus-specific T-Cells
89116707|NCT04104334|Active Comparator|"Monitored group M (optimized controlled anesthesia)"|"Patients in the Monitored group M, the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume."
89116708|NCT04104334|Active Comparator|"Control group C (standard of care anesthesia)"|"Patients in the Control group C will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100."
89116709|NCT02701959|Placebo Comparator|Low nitrate lettuce|50g of low nitrate lettuce (placebo) on single occasions
89116710|NCT02701959|Active Comparator|High nitrate lettuce|50g of high nitrate lettuce (intervention) on single occasions
89116711|NCT05055427|Experimental|• Experimental: Investigational arm|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng) and the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.
89116712|NCT05055427|No Intervention|• Controlled arm|Patients receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline
89116713|NCT00785044||Group|No participants received any drug administration. No intervention conducted.
89116714|NCT04215393|Experimental|Conbercept eye drop (0.1mg/ mL)|Subjects in this arm will receive 0.1mg/mL Conbercept eye drop 4 times a day, one drop at a time.
89116715|NCT04215393|Experimental|Conbercept eye drop (0.5mg/ mL)|Subjects in this arm will receive 0.5mg/mL Conbercept eye drop 4 times a day, one drop at a time.
89116716|NCT04215393|Experimental|Conbercept eye drop (1.0mg/ mL)|Subjects in this arm will receive 1.0mg/mL Conbercept eye drop 4 times a day, one drop at a time.
89116717|NCT02702037|Experimental|Intervention|"The participants will be supported to perform the sit-to-stand exercise at least four times per day during 12 weeks (7 days/week).~The participants will also be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week)."
89116718|NCT02702037|No Intervention|Control|Standard care
89116719|NCT02602600|Experimental|Liraglutide|Liraglutide up to 3.0 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks followed by 2 weeks of weight maintenance diet. Before initiating treatment participants will serve as their own controls for 4 weeks.
89116720|NCT04104958||Group 1|"Group 1 (n=50): women (age 20-40year) with PCOS who are diagnosed according to the criteria of the Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2003), which require two of the following 3 manifestations:~oligo- or anovulation,~clinical and/or biochemical signs of hyperandrogenism (> 2.08 nmol/l),~polycystic ovaries on ultrasound examination (the presence of ≥12 follicles measuring 2-9 mm in diameter and/or ovarian volume > 10 cm)"
89116721|NCT04104958||Group 2|Group 2 (n=50): women (age 20-40 year) with male factor infertility.
89116722|NCT00615615|Experimental|Levetiracetam (LEV)|LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.
89116723|NCT00615615|Placebo Comparator|Placebo|Subjects received Placebo matching to LEV treatment.
89116724|NCT02602366|Other|Month 1|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
89116725|NCT02602366|Other|Month 2|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
89116726|NCT02602366|Other|Month 3|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
89116727|NCT02602366|Other|Month 4|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
89116728|NCT00784810|Experimental|Oxycodone/Naloxone Tablets|Oxycodone/Naloxone combination
89116729|NCT00784810|Active Comparator|Codeine/Paracetamol Tablets|Codeine/Paracetamol combination
89232430|NCT04948866|Experimental|Intervention Condition: ADRD-PC Program|"Dementia-specific palliative care delivered by hospital-based specialty interdisciplinary palliative care teams.~Standardized caregiver education will be provided by the palliative care team. Clinicians will share and discuss the booklet Advanced Dementia: A Guide for Families, which addresses common concerns and treatment decisions.~Transitional care will be provided by the palliative care team, including facilitation of community-based services and two post-discharge telephone calls."
89232431|NCT04948866|Active Comparator|Control Condition|Patient-family caregiver dyads randomized to the control arm will receive educational materials from the Alzheimer's Association, specifically designed for late-stage ADRD caregivers. The patient will receive usual hospital and post-acute care.
89232432|NCT04948060|Experimental|Control 1-1|Patients and clinicians in control practices will receive usual Electronic Health Record (EHR) reminders for lung cancer screening (LCS).
89232433|NCT04948060|Experimental|Intervention 1-1|In addition to control group improvements, patients and clinicians in the intervention group will also receive an LCS Care Coordinator.
89232434|NCT04948060|Experimental|Control 1-2|Patients and Clinicians in control practices will have access to existing LCS services, smoking cessation, and lung cancer treatment services, but no additional system improvements will be introduced.
89232435|NCT04948060|Experimental|Intervention 1-2|In addition to control group improvements, patients and clinicians in the intervention group will also receive quality of care benchmarking and feedback academic detailing.
89232436|NCT04948060|Experimental|Intervention 1-3|In addition to control group improvements, patients and clinicians in the intervention group will also receive practice facilitation.
89232437|NCT04948060|Experimental|Intervention 1-4|In addition to control group improvements, patients and clinicians in the intervention group will also receive the opportunity to participate in a learning collaborative.
89232438|NCT04948060|Experimental|Intervention 1-5|In addition to control group improvements, patients and clinicians in the intervention group will also receive information technology support.
89232439|NCT04940039|Experimental|Paliperidone Palmitate|Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their routine clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.
89116730|NCT02603770|Experimental|XueZhiKang (XZK)|XueZhiKang (XZK) 1200 mg
89116731|NCT02603770|Active Comparator|Lovastatin|Lovastatin 20 mg
89116732|NCT04081909|Active Comparator|Opioid Based Anesthesia(OBA)|
89116733|NCT04081909|Experimental|Opioid Free Anesthesia(OFA)|
89116734|NCT03272217|Experimental|Arm A - Atezolizumab + Bevacizumab|Patients will receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days
89116735|NCT02586571||Exclusive Breastfeeding A|Mother/infant pairs with exclusive breastfeeding up to 6 months of age. Secondary outcome measure 2 (Metabolisable energy content of breast milk) measured in this group only.
89116736|NCT02586571||Exclusive Breastfeeding B|Mother/infant pairs with exclusive breastfeeding up to 6 months of age.
89116737|NCT02586571||Partial Breastfeeding|Mother/infant pairs with partial breastfeeding along with complementary foods at 6 months of age.
89116738|NCT00919945|Experimental|1|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
89116739|NCT00919945|Experimental|2|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.
89116740|NCT00613899|Other|Telesurveillance|"At time of discharge from hospital, 40 ALS patients willbe enrolled in a telesurveillance program (TP) for the management of cought at home.~Two hours of an in-hospital educational training will be provided to patients and caregivers on the use of:~air stacking with Ambu balloon~manual manoeuvres and~in-Exoflator device indications and use"
89116741|NCT00791128|Experimental|EndoBarrier GI Liner|22 patients were implanted with the GI Liner for a 52-week duration. Assessments were performed during the 6 months post-explant period.
89116742|NCT04081597|Experimental|STAR-101|Doses in two of three crossover periods
89116743|NCT04081597|Placebo Comparator|Placebo|Matching placebo in one of three periods
89116744|NCT04107376|Experimental|Retroviewing endoscopy (RVE)|Withdrawal in every colonic segment with SFV (standard forward view) followed by another withdrawal with the retroviewing endoscope. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
89116745|NCT04107376|Active Comparator|standard forward viewing endoscopy (SFVE)|Withdrawal in every colonic segment with SFV followed by another withdrawal with SFV. Allocation of patients to each arm (RVE or SFVE) is done by randomization using sealed envelopes.
89116746|NCT02587039|Placebo Comparator|Control: Usual care|This group will receive usual care and delirium assessments.
89116747|NCT02587039|Experimental|Treatment: Ischemic Pre-conditioning|Remote Ischemic pre-conditioning before cardiac surgery and delirium assessments.
89116748|NCT03262701|Experimental|Hydrogen Peroxide gel for 13weeks|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 13 weeks.
89116749|NCT03262701|Experimental|Hydrogen Peroxide gel for 26weeks|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis and be given 1.7% hydrogen peroxide gel, oral, 0.75g, twice-daily for 15 minutes for 26 weeks.
89116750|NCT03262701|Other|Scaling and Root Planing|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without any interventional hydrogen peroxide application in one or two visits.
89116751|NCT00915382|Active Comparator|3 weekly regimen of S-1 and cisplatin|
89116752|NCT00915382|Active Comparator|5 weekly regimen of S-1 and cisplatin|
89116753|NCT04103866|Experimental|Pressure Offloading Innersole System|Use of Juvederm Voluma in the foot for fat pad restoration
89116754|NCT02701881|Experimental|Long stenting group|
89116755|NCT02701881|Active Comparator|Short stenting group|
89116756|NCT02602522|Experimental|Experimental|The patients in this arm will be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
89116757|NCT02602522|Active Comparator|controlled|The patients in this arm will be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule prepared, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
89116758|NCT02701569|Experimental|Rebound exercise|Repeated jumping on a mini trampoline was performed with feet slightly apart
89116759|NCT02701569|No Intervention|Control|No exercise was administered but participants continued with routine medical care
89116760|NCT05344443|Experimental|Active Treatment|Participants randomized into this arm will receive Lemborexant (5-10mg).
89116761|NCT05344443|Placebo Comparator|Placebo Treatment|Participants randomized into this arm will receive a placebo medication which appears the same as the active treatment.
89116762|NCT02701335|Experimental|Experimental group|Neural mobilization and standardized exercise . 12 sessions over 4 weeks (3 sessions per week).
89116763|NCT02701335|Active Comparator|Control group|Gloreha device and standardized exercise. 12 sessions over 4 weeks (3 sessions per week).
89116764|NCT02701491|Experimental|Ginger|Ginger
89116765|NCT02701491|Placebo Comparator|Placebo|Placebo-no intervention
89116766|NCT00919555|Active Comparator|Tretionoin and Pioglitazone HCL|20 patients will be randomized blindedly to Tretinoin and Pioglitazone HCL
89116767|NCT00919555|Placebo Comparator|Sugar Pill|10 Patients will randomly receive placebo
89116768|NCT02979093|Other|Addicted|The addiction group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
89116769|NCT02979093|Other|Control|The control group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
89116770|NCT02588131|Experimental|tremelimumab plus MEDI4736|Tremelimumab in combination with MEDI4736
89116771|NCT04767139||pre-intervention group|mothers included for the pre-intervention assessment of contraceptive prevalence rate in the selected health centers
89116772|NCT04767139||post intervention group|mothers included for the post-intervention assessment of contraceptive prevalence rate in the selected health centers
89116773|NCT04766983||VAP - BAL positive|Clinically suspected VAP, microbiologically confirmed by BAL
89116774|NCT04766983||VAP - BAL negative|Clinically suspected VAP, not microbiologically confirmed by BAL
89116775|NCT04766983||NO VAP|No clinically suspected VAP during mechanical ventilation
89116776|NCT04766437|Experimental|Prasugrel or ticagrelor monotherapy|Once daily 10 mg prasugrel or twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 60 mg prasugrel or 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
89116777|NCT00776230|Active Comparator|IC51 (~12 months post filling)|6 mcg (~12 months post filling)
89116778|NCT00776230|Active Comparator|IC51 (~18 months post filling)|6 mcg (~18 months post filling)
89116779|NCT00776230|Active Comparator|IC51 (~24 months post filling)|6 mcg (~24 months post filling)
89116780|NCT02586259||Cortiment®|Treatment according to routine clinical practice.
89116781|NCT00775606|Active Comparator|ARM A/Lopinavir/ritonavir|Subjects randomized to Arm A initiated Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD
89116782|NCT00775606|Active Comparator|ARM B/Efavirenz|Subjects randomized to Arm B initiated Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD
89116783|NCT02960763|Experimental|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
89116784|NCT02960763|Experimental|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
89116785|NCT02960763|Experimental|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
89116786|NCT02960763|Experimental|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
89116787|NCT02960763|Experimental|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
89116788|NCT00775528|Experimental|A|
89116789|NCT04760665|Experimental|Fecal microbiota transplantation|
89116790|NCT04760665|Placebo Comparator|Placebo|
89116791|NCT00920179||Dry eye group|Dry eye patients with Primary Sjogren's syndrome
89116792|NCT00920179||Controls|Healthy subjects without dry eyes
89116793|NCT02700867|Experimental|Proximal tibia|Assumption of intraosseous access into the proximal tibia. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
89116794|NCT02700867|Experimental|Proximal humerus|Assumption of intraosseous access into the proximal humerus. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
89116795|NCT05343897|Experimental|2-month Ping-Shuai Gong (PSG) training|"Ping-Shuai Gong (PSG) is pioneered by Qi Gong master, Li Feng-shan. It is featured in synchronous and rhythmic arm-swinging movement, with arms straightly forward flexing to shoulder level and backward extending repeatedly, and combined with lightly squat twice while arms swing to the fifth time and continue this cycle.~They were asked to conduct and record 30 minutes of PSG in one day lasting for 2-month, and at least 3 days a week."
89116796|NCT05343897|Active Comparator|2-month Arm-Swing-Exercise (ASE) training|"Participents in Arm-Swing-Exercise (ASE) group were instructed to keep whole upper limbs pronated, and maintain their trunk straight while movement. The movement is to swing bilateral arms forward to around 30 degree and backward to around 60 degree continuously. The participants need to stabilize their trunk, pelvic, and legs while bilateral arms swinging passing through the side of the trunk. The most significant difference from PSG group is the way they pull the arm, not just swing backward and downward.~They were asked to conduct and record 30 minutes of ASE in one day lasting for 2-month, and at least 3 days a week."
89116797|NCT04081129||ICU patients with early mobilization|
89116798|NCT02701179|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
89116799|NCT02701179|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
89116800|NCT05343663|Experimental|Education|In the COVID-19 Pandemic, the Self-Management Program with Tele-Nursing Developed Based on the Roper Logan Tierney Model will increase Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients.
89232440|NCT04936308|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
89232441|NCT04936308|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
89232442|NCT04936308|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive guselkumab SC.
89232443|NCT04930783|Experimental|CDX-301 + Neovax + Nivolumab|"Participants will have vaccine made from tissue collected from metastatic tumor biopsy or surgical resection, or from previously collected archival biopsy or surgical tissue.~Participants will receive Nivolumab at a flat dose every 4 weeks up to two years.~Participants will receive CDX-301 at a predetermined dose dependent on the number of participants previously enrolled for 5 days starting 2 days before the initiation of NeoVax. CDX-301 will then be administered at a predetermined dose dependent on the number of participants previously enrolled 2 days before and for 5 days coinciding with the administration of NeoVax on days 50 and 78."
89232444|NCT04930783|Experimental|CDX-301 + Neovax + Pembrolizumab|"Participants will have vaccine made from tissue collected from tumor biopsy, or from previously collected archival biopsy or surgical tissue.~Participants will receive neoadjuvant Pembrolizumab for 3 doses every 3 weeks, then undergo standard-of-care surgical resection.~Participants will receive adjuvant NeoVax and CDX-301. CDX-301 will be administered at a predetermined dose, dependent on the number of participants previously enrolled, for 5 days starting 2 days before the initiation of NeoVax. CDX-301 will then be administered at a predetermined dose dependent on the number of participants previously enrolled 2 days before and for 5 days coinciding with the administration of NeoVax on days 50 and 78.~Participants will receive adjuvant Pembrolizumab for 15 doses every 6 weeks."
89232445|NCT04929210|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.
89232446|NCT04929210|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
89232447|NCT04929210|Experimental|Group 3: Placebo followed by Guselkumab|Participants will receive matching placebo and will cross over to receive guselkumab SC.
89232448|NCT04929041|Experimental|Arm A (immunotherapy, +/- chemotherapy)|Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
89232449|NCT04929041|Experimental|Arm B (immunotherapy, +/- chemotherapy, SBRT)|Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of SBRT every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
89232450|NCT04927416|Experimental|Differentiated thyroid cancer (DTC)|Patients with DTC but not HTC
89232451|NCT04927416|Experimental|Hurthle cell thyroid cancer (HTC)|Molecularly and histologically unique subtype of DTC - Hurthle cell thyroid cancer (HTC),
89232452|NCT04927416|Experimental|Medullary thyroid cancer (MTC)|Patients with metastatic thyroid cancer of neuroendocrine origin - medullary thyroid cancer (MTC)
89232453|NCT04925531||Antibiotic use for <3 days|a retrospective chart review to examine if either the utility of antibiotics administered for 3 days make a difference in the clinical outcomes after facial fractures
89232454|NCT04925531||Antibiotic use for 5 days|a retrospective chart review to examine if either the utility of antibiotics administered for 5 days make a difference in the clinical outcomes after facial fractures
88816394|NCT02405442|Experimental|Andecaliximab 150 mg Weekly|Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
89232455|NCT04923893|Experimental|Arm A: VRd+Rd (Standard Therapy)|Participants will receive bortezomib, lenalidomide, and dexamethasone (VRd) regimen for 6 cycles before randomization. Following randomization, participants in Arm A will receive 2 more cycles of VRd. In VRd treatment, participants will receive bortezomib 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each cycle (Cycles 1 to 8), oral lenalidomide 25 mg on Days 1 to 14 of each cycle (Cycles 1 to 8) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle (Cycles 1 to 8). Each cycle will consist of 21 days. After 8 cycles of VRd, treatment will continue with lenalidomide and dexamethasone (Rd) maintenance therapy. In Rd treatment, participants will receive oral lenalidomide 25 mg on Days 1 to 21 of each cycle and oral dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle. Each cycle will consist of 28 days. Participants will continue to receive Rd until confirmed progressive disease or unacceptable toxicity.
89232456|NCT04923893|Experimental|Arm B: VRd+Ciltacabtagene Autoleucel (Cilta-cel)|Participants will receive VRd regimen for 6 cycles before randomization. Following randomization, participants in Arm B will undergo apheresis and receive two more cycles of VRd as bridging therapy. In VRd treatment, participants will receive bortezomib 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each cycle for Cycles 1 to 8; oral lenalidomide 25 mg on days 1 to 14 of each cycle for Cycles 1 to 8 and oral dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle for Cycles 1 to 8. Each cycle will consist of 21 days. After 8 cycles of VRd, participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg).
89232457|NCT04919512|Experimental|Cohort 1: TAR-200 + Cetrelimab|Participants will receive TAR-200 in combination with cetrelimab.
89232458|NCT04919512|Experimental|Cohort 2: Cetrelimab|Participants will receive cetrelimab.
89232461|NCT04912869|Experimental|Crovalimab|Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.
89232462|NCT04912869|Placebo Comparator|Placebo|Participants will receive a single IV infusion of matching Placebo.
89232463|NCT04899336|Experimental|ExPEC9V|Participants will receive a single intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) on Day 1.
89232464|NCT04899336|Placebo Comparator|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
89232465|NCT04898634|Experimental|JNJ-78278343|Participants will receive JNJ-78278343 either subcutaneously (SC injection or SC infusion) or intravenous (IV) infusion. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 either SC or IV at recommended phase 2 dose (RP2D) as determined in Part 1.
89232469|NCT04883619|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every two weeks (q2w) from Week 0 through Week 50 along with standard-of-care treatment of mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved complete renal response (CRR) may have the option to participate in the long-term extension (LTE) until unblinding of the study.
89232470|NCT04883619|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
89232471|NCT04883619|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 IV q2w from Week 0 through Week 50 along with standard-of-care treatment of MMF or MPA and glucocorticoid. Participants who will complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
89232472|NCT04882878|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every two weeks (q2w) through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and Glucocorticoids [GCs]).
89232473|NCT04882878|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
89232474|NCT04882878|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
89232475|NCT04882098|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) and will receive guselkumab and placebo SC. After the study is unblinded to the investigative sites, participants will receive guselkumab and no longer be required to dose with placebo to maintain the blind.
89232476|NCT04882098|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
89232477|NCT04882098|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive SC guselkumab. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
89232478|NCT04876092|Experimental|JNJ-67856633 and Ibrutinib|Participants will receive JNJ-67856633 together with Ibrutinib orally on a 21-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET).
89232479|NCT04868916||Participants with X-Linked Retinitis Pigmentosa (XLRP)|Participants with confirmed diagnosis of XLRP associated with pathogenic variants in retinitis pigmentosa GTPase regulator (RPGR) in the Japanese population will be enrolled in the study and the data will be collected and observed. The primary data source for this study will be the medical records of each participant.
89232480|NCT04868604|Experimental|67Cu-SAR-bisPSMA|"In the dosimetry phase patients will receive a single 200 MBq administration of 64Cu-SAR-bisPSMA.~In the dose escalation phase patients will receive up to 2 administrations of 200 MBq of 64Cu-SAR-bisPSMA.~In the cohort expansion phase patients will receive up to 3 administrations of 200 MBq of 64Cu-SAR-bisPSMA.~In the dose escalation phase patients will receive up to 2 administrations of 67Cu-SAR-bisPSMA (dose will be determined based on cohort allocation).~In the cohort expansion phase patients will receive 2 administrations of 67Cu-SAR-bisPSMA at the recommended dose level determined through dose escalation."
89232481|NCT04844073|Experimental|Dose Escalation Phase|TAK-186 initial 60 minutes infusion and 30 minutes subsequent infusions on Day 1 of every week in Dose Escalation Phase. Participants may receive additional treatment with TAK-186. Dose escalation will be carried out in sequential cohorts of escalating doses.
89232482|NCT04844073|Experimental|Cohort Expansion Phase: NSCLC|Participants with non-small cell lung cancer (NSCLC) will be randomized to receive low dose or high dose of RDE of TAK-186 infusion on Day 1 of every week during Dose Expansion Phase of the study. Participants may receive additional treatment with TAK-186. Based on the results for this cohort additional cohorts for HNSCC and CRC, may be enrolled.
89232483|NCT04840602|Active Comparator|Arm I (ibrutinib, rituximab)|Patients receive ibrutinib PO QD on days 1-28 of cycles 1-24 and rituximab IV on days 1, 8, 15, and 22 of cycles 1 and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm I may receive rituximab and venetoclax as in Arm II for up to an additional 24 cycles. Patients undergo CT or PET/CT and bone marrow biopsy and aspiration as well as blood sample collection during screening and on the trial.
89523297|NCT03387241|Active Comparator|Fluticasone/ salmeterol (Seretide)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/25 µg Mid dose: 125/25 µg High dose 250/25 µg Dosing Frequency:BID Mode of Administration:Inhaled"
89523298|NCT03383159||Observation group 1|Patients who suffered metachronous adenoma after proximal colorectum cancer surgery.
88816395|NCT02405442|Experimental|Andecaliximab 300 mg Weekly|Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
89116801|NCT05343663|No Intervention|Control|It will not change the Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients of the Self-Management Program Conducted by Tele-Nursing, Developed Based on the Roper Logan Tierney Model in the COVID-19 Pandemic.
89116802|NCT02586961|Placebo Comparator|0.9% saline solution - oral betamethasone placebo|Control arm: 0.9% saline solution - oral betamethasone placebo
89116803|NCT02586961|Experimental|adrenaline - oral betamethasone|Experimental arm : adrenaline and betamethasone
89116804|NCT02586337|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
89116805|NCT02586337|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
89116806|NCT04781595|Active Comparator|Watermelon|Watermelon powder containing 3 g of L-citrulline.
89116807|NCT04781595|Active Comparator|Beetroot|Beetroot powder containing 8 mmol of nitrate.
89116808|NCT04781595|Active Comparator|Watermelon + beetroot|Watermelon powder containing 3 g of L-citrulline and Beetroot powder containing 8 mmol of nitrate.
89116809|NCT04781595|Placebo Comparator|Placebo|Maltodextrin
89116810|NCT02700711|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance.
89116811|NCT02700711|Experimental|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on placebo and methylphenidate during duloxetine maintenance.
89116812|NCT04215159|Experimental|Samfenet and Treatment of physician's choice|"Samfenet : 1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.~Treatment of physician's choice (Gemcitabine or Irinotecan)~Gemcitabine : 1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.~Irinotecan : 100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks."
89116813|NCT02700633||Those with pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
89116814|NCT02700633||Those without pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
89116815|NCT02586883|Experimental|Patients with multiple bronchi dilations|
89116816|NCT02586883|Active Comparator|Control patients without transport abnormality|
89116817|NCT02586883|Active Comparator|Patients with typical cystic fibrosis|
89116818|NCT02700789||Pregnant women|Women with a positive urinary pregnancy test following in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This will be conducted by a single investigator with experience in early pregnancy ultrasound using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe and following standard operating procedures.
89116819|NCT05342961|Experimental|spinous balloon dilatation catheter(Plastic-Blade)|Patients with CAD will be treated with spinous balloon dilatation catheter(Plastic-Blade).
89116820|NCT05342961|Experimental|spinous balloon dilatation catheter(lacrosse NSE)|Patients with CAD will be treated with spinous balloon dilatation catheter(lacrosse NSE)
89116821|NCT00920257|Experimental|GSK2141795|Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified.
89116822|NCT02699541|Experimental|Intervention group|Intervention group participants will receive the educational intervention based on the Information, Motivational, Behavioral change model.
89116823|NCT02699541|No Intervention|Control group|Control group participants will receive usual care treatment and referral to diabetes educational consultation if required.
89116824|NCT02700243|Experimental|Fitbit|Participants receive a Fitbit and are followed over the course of one year, completing surveys and exercise tests.
89116825|NCT02700243|No Intervention|Usual Care|Participants receive usual care over the course of one year and are offered a Fitbit in the second year. Followed to assess use of Fitbit and health outcomes.
89116826|NCT00775450|Experimental|Group 1a: Fluzone ID After Fluzone ID|
89116827|NCT00775450|Experimental|Group 1b: Fluzone IM After Fluzone ID|
89116828|NCT00775450|Active Comparator|Group 2a: Fluzone IM After Fluzone IM|
89116829|NCT00775450|Experimental|Group 2b: Fluzone ID After Fluzone IM|
89116830|NCT00775450|Active Comparator|Group 3: Fluzone HD After Fluzone HD|
89116831|NCT02700477|Active Comparator|Fenugreek seed extract|Fenugreek seeds extract 500 mg capsule twice a day for 12 weeks
89116832|NCT02700477|Placebo Comparator|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
89116833|NCT02700321|Experimental|High Flow nasal cannula oxygen (HFNC)|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/Airvo® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
89116834|NCT02700321|Active Comparator|STANDARD high flow Face Mask (HFFM)|"Patients randomized in Standard face mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
89116835|NCT04103944|Experimental|Osteonecrotic Repair Device|A biphasic osteochrondral composite method to support the regeneration of articular cartilage in vivo. With its concept that could be securely installed by press-fit without additional fixation, this approach can present an alternative to perform graft harvest and implantation in a single surgery.
89116836|NCT04103944|Active Comparator|Core Decompression|Core decompression is a common surgical procedure that aims to improve vascular inflow by decreasing intraosseous pressure in the femoral head. It is performed that involves removing a cylindrical core of bone from the proximal femur.
89116837|NCT02699385|Experimental|Oral Rehydration Therapy (ORT) + Domperidone|Each participants will initiate ORT in the physician's office and domperidone 0.25 milligram per kilogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
89116838|NCT02699385|Experimental|Oral Rehydration Therapy + Placebo|Each participants will initiate ORT in the physician's office and placebo oral suspension thrice daily for up to 7 days.
89116839|NCT02586103||MRI|Patients who undergo simulated practice MRI on the day of or prior to their scheduled MRI.
89116840|NCT02700399|Other|Erigo® First|"Erigo® 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Traditional Tilt table 0 - 60 degrees~Step frequency on Erigo® = 48"
89116841|NCT02700399|Other|Traditional first|"Traditional Tilt table 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Erigo® 0 - 60 degrees~Step frequency on Erigo® = 48"
89116842|NCT04082923|Other|Gastric bypass operated patients|Two test days in a randomized, patient-blinded, cross-over design
89116843|NCT04082923|Other|Gastric sleeve operated patients|Two test days in a randomized, patient-blinded, cross-over design
89116844|NCT04082923|Other|Control arm|Two test days in a randomized, patient-blinded, cross-over design
89116845|NCT02700087|Placebo Comparator|H2 blocker versus placebo|"The patient will then be randomly placed in the control group (placebo) or the intervention group (ranitidine 2mg/kg every 12 hours or famotidine 0.5 mg/kg daily).~Patients will stay on medication for a minimum of 6 months, or until symptoms resolve. Patients will be seen in follow up at 1, 2, 3, 4, 5, 6, 8 and 10 months. At which time I-GERQ, ASQ and weights will be taken. The primary outcome measure will be the time for the ASQ score to drop to normal on ranitidine or famotidine versus placebo."
89116846|NCT02700087|Active Comparator|Treatment arm|Patients who develop severe airway symptoms while they are in the H2 blocker versus placebo arm will then cross over to the treatment arm of the study. These patients will exit randomization and be unblinded. These patients will all be given H2 blockers, and the effects of the H2 blockers will be monitored and studied. Alternatively, patients' families may also elect to undergo surgery to treat laryngomalacia.
89116847|NCT00615771|Experimental|Day 2 embryo transfer|Embryos are transferred 2 days after fertilization.
89116848|NCT00615771|Active Comparator|Day 3 embryo transfer|Standard of care for women undergoing IVF with a limited number of embryos is to transfer all embryos on Day 3 after fertilization
89116849|NCT02586181|Placebo Comparator|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate"
89116850|NCT02586181|Experimental|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
89116851|NCT02699307|Experimental|Intervention|OT-led counseling based on home activity pattern
89116852|NCT03181035|Experimental|FAZA and pimonidazole|(18)F-Fluoroazomycin arabinoside (FAZA) will be administered via intravenous injection at a dose of 5.2 MBq/kg with a minimum dose of 200 Megabecquerel (MBq) (5.4 Millicurie (mCi)) and a maximum dose of 600 MBq (16.2 mCi) prior to positron emission tomography (PET) imaging. A single dose of oral pimonidazole capsules at a dose of 0.5 g/m2, will be taken by participants 16-20 hours prior to tumor resection surgery.
89116853|NCT05626465||Abusive Head Trauma (AHT)|
89116854|NCT05626465||Accidental traumatic brain injury|
89116855|NCT05626465||Cranioplasty|
89116856|NCT05626465||Infant malaise without AHT|
89116857|NCT02698917|Active Comparator|Group 1|Low normal PaCO2, low normal PaO2, low normal MAP
89116858|NCT02698917|Active Comparator|Group 2|High normal PaCO2, low normal PaO2, low normal MAP
89116859|NCT02698917|Active Comparator|Group 3|Low normal PaCO2, high normal PaO2, low normal MAP
89116860|NCT02698917|Active Comparator|Group 4|High normal PaCO2, high normal PaO2, low normal MAP
89116861|NCT02698917|Active Comparator|Group 5|Low normal PaCO2, low normal PaO2, high normal MAP
89116862|NCT02698917|Active Comparator|Group 6|High normal PaCO2, low normal PaO2, high normal MAP
89116863|NCT02698917|Active Comparator|Group 7|Low normal PaCO2, high normal PaO2, high normal MAP
89116864|NCT02698917|Active Comparator|Group 8|High normal PaCO2, high normal PaO2, high normal MAP
89116865|NCT02699853|Experimental|Arm I (RRC)|Patients undergo RRC at day 0.
89116866|NCT02699853|Experimental|Arm II (ORC)|Patients undergo ORC at day 0.
89116867|NCT04080973|Experimental|osteopenic patients|patients with a kidney stone and osteopenic changes.
89116868|NCT02699931|Experimental|Electric3D|3D electric toothbrush (Oral-B) with orthodontic head.
89116869|NCT02699931|Active Comparator|Manual|Manual orthodontic toothbrush (Oral-B).
89116870|NCT02699619|Active Comparator|2 Hansson pins without plate|Patients with undisplaced femoral neck fractures operated with 2 isolated Hansson pins.
89523299|NCT03383159||Control group 1|Patients who do not suffere metachronous adenoma after proximal colorectum cancer surgery.
89116871|NCT02699619|Active Comparator|3 Hansson pins interlocked in a plate|Patients with undisplaced femoral neck fractures operated with 3 Hansson pins interlocked in plate (Pinloc).
89116872|NCT00775138|Experimental|Cohort 1 - 280 mg Arikayce™|Subjects in this arm of the cohort 1 will receive 280 mg of Arikayce™
89116873|NCT00775138|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of the cohort 1 will receive matching placebo.
89116874|NCT00775138|Experimental|Cohort 2 - 560 mg Arikayce™|Subjects in this arm of the cohort 2 will receive 560 mg of Arikayce™
89116875|NCT00775138|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of the cohort 2 will receive matching placebo
89116876|NCT02699073|Experimental|Regorafenib|dose of regorafenib : 160mg once daily
89116877|NCT04748601|Placebo Comparator|Placebo|
89116878|NCT04748601|Experimental|Qudexy XR|
89116879|NCT04081519|Active Comparator|DLPFC-DLPFC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over DLPFC
89116880|NCT04081519|Experimental|DLPFC-LPC|15 sessions of active rTMS over DLPFC + 15 sessions of active rTMS over LPC
89116881|NCT04081519|Sham Comparator|DLPFC-SHAM|15 sessions of active rTMS over DLPFC + 15 sessions of sham rTMS over DLPFC or LPC
89116882|NCT02699775||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
89116883|NCT03236805|Experimental|Ketamine IV|
89116884|NCT03236805|Active Comparator|Morphine IV|
89116885|NCT02698995|Placebo Comparator|Group A|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+1 ml saline=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
89116886|NCT02698995|Active Comparator|Group B|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+2 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
89116887|NCT02698995|Active Comparator|Group C|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+4 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
89116888|NCT02699229||Malignant|Tissue sample
89116889|NCT02699229||Benign|Tissue sample
89116890|NCT02699229||Normal|Tissue Sample
89116891|NCT00920101|Active Comparator|Atorvastatin|
89116892|NCT00920101|Placebo Comparator|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
89116893|NCT02698839|Experimental|BuMA Supreme group|This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.
89116894|NCT02698839|Active Comparator|BuMA™ group|This group contains 220 subjects.
89116895|NCT02888587||Control group|no gastrointestinal symptoms
89116896|NCT02888587||Symptomatic group|Patients with Visceral hypersensitivity
89116897|NCT00616005|Other|1|Pts taking EIAEDs
89116898|NCT00616005|Other|2|Pts not taking EIAEDs
89116899|NCT02698527|Active Comparator|Non-Buffered Lidocaine|Vulvar biopsy conducted using non-buffered lidocaine as anesthesia
89116900|NCT02698527|Experimental|Buffered Lidocaine|Vulvar biopsy conducted using buffered lidocaine as anesthesia
89116901|NCT04215237|Other|Atorvastatin regulates intestinal flora|
89116902|NCT05593315|Other|Mindfulness and Buteyko techniques|A Mindfulness relaxation program and a Buteyko technique respiratory rehabilitation program will be administered individually and weekly, in 10 sessions (5 face-to-face and 5 telematic sessions afterwards).
89116903|NCT02586649|Experimental|Tiotropium Bromide group|The study participants will be randomly assigned to receive Tiotropium bromide,single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Tiotropium bromide capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
89116904|NCT02586649|Placebo Comparator|Placebo|The study participants will be randomly assigned to receive placebo , single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Placebo capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
89116905|NCT04213833|Placebo Comparator|group I (control group)|patients will receive propofol 50 mg
89116906|NCT04213833|Active Comparator|group II|patients will receive propofol 50 mg + dexmedetomidine 0.5 mcg/ kg
89116907|NCT04213833|Active Comparator|group III|patients will receive propofol 50 mg +15 g palatable lidocaine gel
89523300|NCT03383159||Observation group 2|Patients who suffered metachronous adenoma after distal colorectum cancer surgery.
89523301|NCT03383159||Control group 2|Patients who do not suffered metachronous adenoma after distal colorectum cancer surgery.
89116908|NCT04605991|Experimental|LY900014|LY900014 (100 units/milliliter (U/mL)) is a mealtime insulin administered subcutaneously (SC) 0-2 minutes prior to each meal in combination with insulin glargine (100 U/mL) SC as long-acting insulin. Mealtime (bolus) and long-acting (basal) insulin doses were titrated to achieve glucose targets during the study.
89116909|NCT00783796|Experimental|2.25mm XIENCE V®|Patients receiving the 2.25 mm XIENCE V® stent
89116910|NCT02698605|Experimental|Usability test study of the MirrorPath|This study was a one-arm study and all subjects used the device and received usability test.
89116911|NCT04951921|Experimental|Hyperpolarized 13C pyruvate DNP-MRI scan|Patients receive hyperpolarized 13C pyruvate through IV injection less than 1-2 minute then undergo MRI over 3-5 minutes at baseline and 2 weeks after CCRT treatment. Total 2 times of MRI scan.
89116912|NCT00637065|Active Comparator|1|Bosentan tablets (62.5mg bd for first 4 weeks, then 125mg bd as tolerated)
89116913|NCT00637065|Placebo Comparator|2|Placebo tablets
89116914|NCT02698683||malnourished|low zinc, low albumin, anthropometric measures lower than percentile 5 lymphocyte count
89116915|NCT02698683||well nourished|normal zinc, normal albumin, anthropometric measures higher than percentile 5 lymphocyte count
89116916|NCT02698761|No Intervention|Standard of Care|Patient will receive standard of care. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be aware of study presence but will not receive any specific instruction for the patient.
89116917|NCT02698761|Experimental|Comprehensive Care Plan|Patient will abide by the comprehensive care plan and sign an agreement stating compliance. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be notified of study and support patient's compliance with study procedures.
89116918|NCT02603536|Experimental|Vulnerable or pilot participant|"In addition to standard care, WelTel will send a weekly text message to participants in this arm for a one year period. Participants will be requested to respond to the outgoing message How are you? within 48 hours; they may respond that they are doing well or that they have a problem. A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
89116919|NCT04213443||Women of short stature|Women that are under 1.6 meters.
89116920|NCT04102306||Temporomandibular disorder group (TMD)|"Patients with temporomandibular disorder coming at the Cabinet Saint Alexandre for orofacial rehabilitation.~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a rehabilitation session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next rehabilitation session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 45 days).~Questionnaires were performed during the course of the patient rehabilitation that was instructed not to perform imagined movement during the interval."
89116921|NCT04102306||Control healthy group (CTL)|"Healthy individuals with no temporomandibular disorder (i.e., no orofacial medical consultation or rehabilitation) aged-matched and gender-matched to TMD group.~Test 1: passation of the KVIQ questionnaire, followed by the passation of the TMIQ during a session supervised by the physical therapist (PT) Test 2: passation of the TMIQ during the next session supervised by the same PT(interval between PT session 1 and 2 is a maximum of 8 days).~Questionnaires were performed with no additional rehabilitation and participants were instructed not to perform imagined movement during the interval."
89116922|NCT04936477|Experimental|Assessment of alveolar surface area by functional morphometry|Non-invasive measurements of V/Q
89116923|NCT04214847|Experimental|polypropylene plate of Ahmed Glaucoma Valve|polypropylene plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The polypropylene plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
89116924|NCT04214847|Active Comparator|silicone plate of Ahmed Glaucoma Valve|silicone plate of Ahmed Glaucoma Valve procedures were performed under local anesthesia except for children, general anesthesia was used. The silicone plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
89116925|NCT04935697|Experimental|nVNS|nVNS treatment will be applied three times daily. One treatment is defined as 2 consecutive stimulations: one, 2-minute stimulation on the side of the neck followed by a second, 2-minute stimulation on the same side of the neck. The treatment will be done 3 times per day (morning, mid-day and 1 hour before bed at night), every day, until patient is discharged from the hospital or requires mechanical ventilation. Patient will record the time they administered these treatments. If the patient is unable to do this, a research staff member who has been trained on the device can assist. Will also receive SOC for TBI.
89116926|NCT04935697|Other|SOC only|Patients will be managed according to the institutional best practices and SOC for TBI.
89116927|NCT00616083||1|Healthy breast fed infants
89116928|NCT00616161|Experimental|1|Istaroxime dose of 0.5 microgram/kg body weight/minute of iv infusion for six ours
89116929|NCT00616161|Experimental|2|Istaroxime dose of 1.0 microgram/kg body weight/minute of iv infusion for six ours
89116930|NCT00616161|Experimental|3|Istaroxime dose of 1.5 microgram/kg body weight/minute of iv infusion for six ours
89116931|NCT00616161|Placebo Comparator|4|Placebo iv infusion for six ours
89116932|NCT02584387|Experimental|3D VVRET|"Behavioral: 3D Video Virtual Reality Exposure Therapy (VVRET)~1 30 minute 3D VRET treatment session for arachnophobia."
89116933|NCT02584387|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the 3D VVRET. After the conclusion of their sessions, these participants will be offered the full 3D-VVRET treatment.
89232484|NCT04840602|Experimental|Arm II (venetoclax, rituximab)|Patients receive venetoclax PO QD on days 1-28 of each cycle and rituximab IV on days 1, 8, 15, and 22 of cycles 1 and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm II may receive ibrutinib and rituximab as in Arm I for up to an additional 24 cycles. Patients undergo CT or PET/CT and bone marrow biopsy and aspiration as well as blood sample collection during screening and on the trial.
89232485|NCT04838613|Experimental|PET/CT imaging with [18F]CTT1057 followed by [68Ga]Ga-PSMA-11 or vice versa|"All eligible participants will be assigned to one of the following two PET/CT scan sequences at random in a 1:1 ratio:~Sequence 1: [18F]CTT1057 on Day 1 (investigational imaging agent of interest) followed by [68Ga]Ga-PSMA-11 at least 14 days apart (as part of CTS if required, and for secondary endpoint)~Sequence 2: [68Ga]Ga-PSMA-11 (as part of CTS if required, and for secondary endpoint) on Day 1 followed by [18F]CTT1057 (investigational imaging agent of interest) at least 14 days apart"
89232486|NCT04834518||Negative result at the first autoantibodies screening test|Participants will be invited to repeat the screening test at the age of 2-5 years old
89232487|NCT04834518||Positive result at the first or second autoantibodies screening test|"Participants will be monitored annually for risk of type 1 diabetes. (HbA1c, repeated OGTT, monitoring of urine and blood glucose where indicated)~Families will attend diabetes-educational program emphasizing on DKA prevention~Stress assessment for the families involved and stress alleviating interventions when required."
89232488|NCT04829318|Experimental|Esketamine|Participants who were randomly assigned to the esketamine arm in Study 54135419TRD3013 (NCT04338321), had esketamine nasal spray administered through Week 30 (every 2 weeks dosing) or Week 31 (once weekly dosing), completed the maintenance phase at Week 32 will continue to receive esketamine nasal spray once weekly or every 2 weeks along with serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI) in this long-term extension (LTE) study. The duration of the study participation is 2 years or when esketamine is commercially available.
89232489|NCT04826341|Experimental|1/Phase I|Dose escalated Sacituzumab Govitecan and Berzosertib
89232490|NCT04826341|Experimental|2/Phase II|Sacituzumab Govitecan and Berzosertib treatment with identified MTD based on phase I.
89232491|NCT04822181|Experimental|Semaglutide OW (once weekly )|Semaglutide administrated subcutaneously once weekly
89232492|NCT04822181|Placebo Comparator|Placebo|Placebo administrated subcutaneously once weekly
89232493|NCT04821310|Active Comparator|Arm 1 Full Dose Pantoprazole and matching placebo|Full Healing Dose of pantoprazole
89232494|NCT04821310|Active Comparator|Arm 2 Half Dose Pantoprazole and matching placebo|Half Healing Dose of pantoprazole
89232495|NCT04817670|Experimental|Cohort 1|Participants receive VIT-2763 60 mg, twice a day during 8 weeks.
89116934|NCT00617019||Parkinson's patients|Observational study to compare rates of impulse control disorders in patients taking different medications for Parkinson's Disease
89116935|NCT03932539||Twenty-five de-novo heart transplant recipients|Twenty-five de-novo heart transplant recipients will be enrolled, male and female, aging 18-70 years, receiving TAC in combination with steroids and antiproliferative drugs, either Everolimus or Sirolimus.
89116936|NCT04079647||Patient with endocrinopathy after immunotherapy|Patient with endocrinopathy after immunotherapy
89116937|NCT02697981|Experimental|intervention group|Pregnant post bariatric surgery women will receive nutritional counseling from a specialist dietitian, to ensure a healthy balanced diet including adequate daily servings from all food groups, intake of essential nutrient during pregnancy such as iron and folic acid and limitation of high-sugar and fatty foods. Patients will also be advised concerning eating at scheduled times (e.g., 4-6 times daily), supplements, preference of water. Advice concerning healthy cooking methods will also be given, as well as advised to avoid soft drinks, drinking during meals, grazing and emotional eating, and fast foods. Subject of lifestyle in general - encouraged to incorporate suitable physical activity on most days, refraining from alcohol, and smoking. intervention: nutrition counseling
89116938|NCT02697981|No Intervention|control group|The control group is comprised of healthy pregnant women, of similar age, smoking behavior and background. No treatment will be given, just follow-up data collection.
89116939|NCT04081207|Experimental|AAC-LaRc|all participants receive the experimental treatment
89116940|NCT04213599||Anterior infarction|Patients with anterior ST-elevation myocardial infarction
89116941|NCT04213599||Inferior infarction|Patients with inferior ST-elevation myocardial infarction
89116942|NCT04213599||Lateral infarction|Patients with lateral ST-elevation myocardial infarction
89232496|NCT04817670|Experimental|Cohort 2|Participants receive VIT-2763 120 mg, twice a day during 8 weeks.
89232497|NCT04817670|Experimental|Cohort 3|Participants receive VIT-2763 120 mg, three times a day during 8 weeks.
89232498|NCT04817670|Placebo Comparator|Cohort 4a|Participants receive a placebo, twice a day during 8 weeks.
89232499|NCT04817670|Placebo Comparator|Cohort 4b|Participants receive a placebo, three times a day during 8 weeks.
89116943|NCT04213521|Experimental|Multisensory balance training group|The participants in the multisensory balance training group were provided with multiple-sensory balance exercises using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system-postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
89116944|NCT04213521|Active Comparator|Conventional balance training group|The participants in the Conventional balance training group performed conventional balance exercises, such as static and dynamic standing balance without altered sensory inputs.
89116945|NCT04214769||Head and Neck Cancer patients|
89116946|NCT04214925|Experimental|Group of Tai Chi intervention|Tai Chi exercise program will create by selecting the first-basic 10 forms from 24 short forms of Yang style. The forms' name: Beginning, Parting the Horse's Mane, Stork Spreading Its Wings, Brushing Your Knees and Stepping, Playing The Pipes, Fending Off the Monkey, Grasping the Sparrow's Tail Left, Grasping the Sparrow's Tail Right, Simple Whip, Moving Hands Like Clouds-Conclusion. All forms will be completed at 10 weeks. Each session will take 1 hour (15 min for warming up exercises, 30 min of Tai Chi forms, and 15 min for cooling down exercises). The 14 patients of SS in this group will be divided into two groups of 7.
89116947|NCT04214925|Other|Group of home exercises|The home exercise group will receive a one-hour home program, 2 days a week. The first and last 15 minutes of the exercise program will consist of warm-up and cooling- down exercises. After warm-up exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles will be performed 10 times each for 30 minutes.
89116948|NCT02698059|Experimental|Treated|iNAP® Sleep Therapy System Treatment
89116949|NCT02698059|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline
89116950|NCT02697903|Experimental|9 elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Natural Pomegranate Juice supplementation during and 48h following the first weightlifting training session."
89116951|NCT02697903|Placebo Comparator|9elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Placebo Juice supplementation during and 48h following the second weightlifting training session."
89116952|NCT00617253|Experimental|A|
89116953|NCT00617253|Experimental|B|
89116954|NCT00617253|Experimental|C|
89116955|NCT00617253|Experimental|D|
89116956|NCT02585947|Experimental|tenofovir for 24 weeks|"prophylactic (preemptive) treatment~300mg for 24 weeks~once daily"
89116957|NCT02585947|Experimental|tenofovir for 48 weeks|"prophylactic (preemptive) treatment~300mg for 48 weeks~once daily"
89116958|NCT04079569|Experimental|Tobacco|"Participants will receive education delivered by a lay health worker on Quit Smoking For a Healthy Family. Participants will receive written information on nutrition and physical activity."
89116959|NCT04079569|Active Comparator|Healthy Living|"In this comparison arm, participants will receive education delivered by the lay health worker about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
89116960|NCT02697825|Other|changes in eye|Changes in both intraocular pressure and optic nerve sheath diameter will be correlated in robotic surgeries to find out any statistical relation existing between two.
89116961|NCT04081051|Experimental|Intervention|Diagnostic algorithm( paper and electronic) utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change training for healthcare workers
89116962|NCT04081051|No Intervention|control|Standard of care practices for acute febrile illness
89116963|NCT02697513|No Intervention|Before Period|Collection of patient-related data without interventions being made
89116964|NCT02697513|Active Comparator|After Period|Implementation of a simple infection management protocol as well as a 'Sepsis First Aid' kit to assist in the management of patients with acute infection
89116965|NCT04649671|No Intervention|Standard care|Hepatocellular carcinoma (HCC) patients with insulin resistance who underwent hepatic resection or radiofrequency ablation (RFA) will be enrolled. Patients included in the control arm will receive a booklet including information about physical activity recommendations and practice (education). After 12 weeks, they will also be provided mobile application and wearable device and perform exercise for 12 weeks.
89116966|NCT04649671|Active Comparator|Mobile health|HCC patients with insulin resistance who underwent hepatic resection or RFA will be enrolled. Patients included in the intervention arm will receive both booklet and mobile health program. They will perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening) for 24 weeks.
89116967|NCT02607891|Experimental|STP + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the open-label-extension (OLE) phase or who withdraw early.~STP Arm: Last patient completion October 2018"
89116968|NCT02607891|Placebo Comparator|STP + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~STP Arm: Last patient completion February 2018"
89116969|NCT02607891|Experimental|VPA + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~VPA Arm: Last patient completion February 2018"
89116970|NCT02607891|Placebo Comparator|VPA + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~VPA Arm: Last patient completion January 2018"
89116971|NCT02585869|Experimental|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
89116972|NCT02585869|Experimental|Gemcabene 300 mg|Gemcabene 300 mg once daily (QD)
89116973|NCT02585869|Experimental|Gemcabene 600 mg|Gemcabene 600 mg once daily (QD)
89116974|NCT02585869|Experimental|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
89116975|NCT02585869|Placebo Comparator|Placebo|Placebo once daily (QD)
89116976|NCT02607813|Experimental|Dose escalation LXH254|
89116977|NCT02607813|Experimental|Dose expansion LXH254: Group 1|
89116978|NCT02607813|Experimental|Dose expansion LXH254: Group 2|
89116979|NCT02607813|Experimental|Dose expansion LXH254: Group 3|
89116980|NCT02607813|Experimental|Dose expansion: LXH254 + PDR001|
89116981|NCT02607813|Experimental|Dose escalation LXH254 + PDR001|
89116982|NCT04079725|Experimental|Experimental : Infants with primary congenital glaucoma|
89116983|NCT02697747||Ultrasound education|Training in the use of ultrasound to identify the L3-L4 interspace
89116984|NCT00783718|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
89116985|NCT00783718|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
89116986|NCT04213287|Experimental|Peri-Articular Injections and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine~At the end of surgery;~PAI: 30 ml 0,025% bupivacaine and~IPACK: 20 ml 0,025% bupivacaine"
89116987|NCT04213287|Active Comparator|Adductor Canal Block, and IPACK|"Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine~At the end of surgery;~ADD: 20 ml 0,025% bupivacaine and~IPACK: 20 ml 0,025% bupivacaine"
89116988|NCT04917601|Experimental|Evira Care treatment|"The intervention arm will receive Evira Care in combination with Standard Lifestyle Care. If the standard treatment, after the first month of treatment, contains more frequent visits than every third month, the number of standard visits shall be reduced to a maximum of one visit every third month. During the first 2-4 weeks, participants will receive information about the system and how to utilize the daily weighings and communication system. The families will be informed about possible lifestyle changes that may be effective and that they are supposed to do lifestyle changes primarily regarding energy intake that they do consider feasible in their specific living situations.~Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, and blood pressure. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction."
89116989|NCT04917601|Active Comparator|Standard Lifestyle Care|"The control group will receive the standard care of treatment for childhood obesity, which addresses lifestyles without any restriction in visits or clinical support.~Clinical investigations will be completed and includes physical and abdominal examinations, weight, height, and blood pressure. All participants will also be asked to answer questionnaires including quality of life, eating disorders, and treatment satisfaction."
89116990|NCT02585791|Experimental|vape NFEC containing 100% PG|Subjects will then be instructed how to use the NFEC (eGo-T® with light emitting diode (LED) display) for 1 week of regularly vaping NFEC containing 100% Propylene Glycol . Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
89116991|NCT02585791|Experimental|vape 100% vegetable glycerin -VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 100% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
89116992|NCT02585791|Experimental|vape PG+VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 50% PG and 50% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 milliamp hours (mAh) battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
89116993|NCT04913389|Active Comparator|Acetazolamide|Acetazolamide (oral capsules)
89116994|NCT04913389|Placebo Comparator|Placebo|Placebo (oral capsules)
89116995|NCT04080817|Experimental|Neolexon Therapy|
89116996|NCT04080817|Active Comparator|Standard logopedic therapy|
89116997|NCT02528721|Experimental|Initial Diagnosis Subjects|Patients with clinical indication for H.pylori infection
89116998|NCT02528721|Experimental|Post Therapy Subjects|Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
89116999|NCT04904965|Experimental|Propofol Group 1|Patients will receive induction of anesthesia with Propofol at a rate of 2.0 mg/kg/hr.
89117000|NCT04904965|Experimental|Propofol Group 2|Patients will receive induction of anesthesia with Propofol at a rate of 4.0 mg/kg/hr.
89117001|NCT04904965|Experimental|Propofol Group 3|Patients will receive induction of anesthesia with Propofol at a rate of 6.0 mg/kg/hr.
89117002|NCT04904965|Experimental|Propofol Group 4|Patients will receive induction of anesthesia with Propofol at a rate of 8.0 mg/kg/hr.
89117003|NCT02602132|Experimental|Clamping group|Indwelling urinary catheter is clamped before removal and unclamped when the patient expresses his desire to urinate.
89232500|NCT04816591|Experimental|Experimental: Interventional Cohort: Treatment Arm|Standard of Care Surgery + Embolization
89232501|NCT04816591|Active Comparator|Active Comparator: Interventional Cohort: Control Arm|Standard of Care Surgery Only
89232502|NCT04816591|Experimental|Experimental: Observational Cohort: Treatment Arm|Standard of Care Medical Management + Embolization
89232503|NCT04816591|Active Comparator|Active Comparator: Observational Cohort: Control Arm|Medical Management Only
89232504|NCT04811560|Experimental|JNJ-75276617|Participants in Part 1 (dose escalation) will receive JNJ-75276617 orally on a 28-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in Part 2 (dose expansion) will receive JNJ-75276617 orally at one of the RP2D(s) determined in Part 1. Food effect cohort (optional) participants will receive JNJ-75276617 orally on Cycle 2 Day 1 under fasted condition and on Cycle 2 Day 2 under fed condition.
89232505|NCT04804540|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2 and 6 during induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.
89232506|NCT04790812|Placebo Comparator|Celecoxib plus Placebo|Single oral dose of celecoxib 200 mg with placebo 30 to 60 minutes prior to the dental procedure
89232507|NCT04790812|Active Comparator|Celecoxib plus Acetaminophen|Single oral dose of celecoxib 200 mg in combination with acetaminophen 1000 mg 30 to 60 minutes prior to the dental procedure.
89232508|NCT04784988|Experimental|PROPEL-like arm|EHL-FVIII prophylaxis targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
89232509|NCT04784988|Active Comparator|Control arm|standard treatment with FVIII concentrate according to current guidelines
89232510|NCT04775082|Experimental|Liraglutide 3.0 mg|The treatment duration is 56 weeks and the follow-up period is 26 weeks.
89232511|NCT04775082|Placebo Comparator|Placebo|The treatment duration is 56 weeks and the follow-up period is 26 weeks.
89232512|NCT04773522|Experimental|Talquetamab|Participants will receive talquetamab injection subcutaneously (SC) in 3 cohorts: Cohort 1 and Cohort 2 as 2 step-up doses and Cohort 3 as 3 step-up doses followed by a treatment dose.
89232513|NCT04770220|Experimental|ALZ-801|ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one table of ALZ-801 265mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265mg tablet BID.
89232514|NCT04770220|Placebo Comparator|Placebo|Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study
89232515|NCT04762602|Experimental|Part 1 Dose Escalation Cohorts|Patients from each cohort will be administered HMPL-306 orally QD
89232516|NCT04762602|Experimental|Part 2 Dose Expansion Cohorts|Patients from each cohort will be administered HMPL-306 orally QD at the recommended phase 2 dose
89117004|NCT02602132|No Intervention|Free drainage group|The urinary catheter will be removed without prior clamping.
89117005|NCT05324865|Experimental|Experimental Group|Information about the experimental group was given. Progressive muscle relaxation (PMR) for 6 weeks to patients with schizophrenia will be heard. At the end of 6 weeks, psychiatric evaluation and mental well-being scale will be used.
89117006|NCT05324865|No Intervention|Control Group|Patient identification form, psychological evaluation form and mental health form were filled in for the control group. At the end of 6 weeks, the psychological evaluation form and the mental well-being form were filled again without any intervention.
89117007|NCT00774748|Experimental|I|All participants in the study will use the subcutaneous catheter twice for a period of one week each to inject the enoxaparin. For the remainder of the study the participants will inject subcutaneously.
89117008|NCT05324787|Experimental|Grency venous stent system|
89117009|NCT04079413|Experimental|GP40071|Subcutaneous (SC), before meals intake, up to Week 26
89117010|NCT04079413|Active Comparator|NovoRapid® Penfill®|Subcutaneous (SC), before meals intake, up to Week 26
89117011|NCT00915460|Experimental|1|Patients previously enrolled in BIogen Idec study C95-812.
89117012|NCT00915460|Experimental|2|Patients previously enrolled in Biogen Idec study C96-823.
89117013|NCT00915460|Experimental|3|Patients previously enrolled in Biogen Idec study C97-830.
89117014|NCT02434107|Experimental|Completion Lymphadenectomy|Completion Lymphadenectomy and monitoring afterwards
89117015|NCT02434107|Experimental|Clinical Monitoring (Palpation and node ultrasound)|Monitoring only
89117016|NCT02585635||Families|Families of children with haemophilia
89117017|NCT02585635||Clinicians|Haemophilia physicians
89117018|NCT00587860|Placebo Comparator|Placebo|
89117019|NCT00587860|Active Comparator|St. John's Wort|
89117020|NCT00617643|Active Comparator|2|Triomune® 30 one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
89117021|NCT00617643|Experimental|1|Triomune® 30 one tablet twice daily for two weeks
89117022|NCT04106908||Eqwilate|
89117023|NCT03147807|Experimental|betaLACTA® result given to physician|In the experimental group, betaLACTA® rapid diagnostic test guided de-escalation result will be given to physician at Day 0 and empirical carbapenems will be de-escalated to Cefepime or Ceftazidime +/- Amikacin since the second dose.
89117024|NCT03147807|No Intervention|betaLACTA® result NOT given to physician|In the control group, betaLACTA® result will not be given to physician and patients will receive empirical carbapenem during the time required to obtain final results of antibiotic susceptibility test
89117025|NCT02585557|Experimental|Cluster A|50 practices randomly assigned to start intervention at month 9. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
89117026|NCT02585557|Experimental|Cluster B|50 practices randomly assigned to start intervention at month 11. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
89117027|NCT02585557|Experimental|Cluster C|50 practices randomly assigned to start intervention at month 12. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
89117028|NCT02585557|Experimental|Cluster D|50 practices randomly assigned to start intervention at month 14. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
89117029|NCT02585557|Experimental|Cluster E|50 practices randomly assigned to start intervention at month 16. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
89117030|NCT00617721||1|patients with unexplained bleeding disorder
89117031|NCT00617721||2|healthy volunteers
89117032|NCT02791503|Experimental|IRE group|FOLFIRINOX + IRE For patients diagnosed with LAPC, a combination of chemotherapy plus local tumor destruction using irreversible electroporation (IRE), a novel tumor ablation technique, has recently shown great promise. IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
89117033|NCT02791503|Active Comparator|SABR group|FOLFIRINOX + SABR Focal therapy using external beam radiation therapy (EBRT) may further improve survival, but outcome remains poor. Stereotactic ablative radiotherapy (SABR) is a form of EBRT that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
89117034|NCT02584075|Experimental|Lifestyle intervention|
89117035|NCT02585479|Experimental|systemic chemotherapy|Pirarubicin 30mg/m2 intravenously on Day 1 and Oxaliplatin 100 mg/m2 intravenously on Day 2 every 3 weeks until disease progression or limiting toxicity.
89117036|NCT02585479|Active Comparator|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using Gelfoam every 4 weeks until disease progression or limiting toxicity.
89117037|NCT00583453|Active Comparator|A|Celecoxib 200 mg tablets
89117038|NCT00583453|Placebo Comparator|B|Placebo with same dosing schedule as the active comparator arm
89117039|NCT02584231|Experimental|Patients needing an urinary concentration test|Patients who need a urinary concentration test because of uro- or nephropathy (age: 6 months - 8 year)
89117040|NCT02584231|Experimental|Patients suffering from treatment resistant nocturnal enuresis|Patients suffering from treatment resistant nocturnal enuresis (age: 5 - 8 year)
89117041|NCT04080193|Experimental|Intervention Group|The study will be a Smartphone-based interventional trial. To assess the effectiveness of the intervention weight- and eating-related behavior and cognitive and emotional responding as well as body-weight will be assessed using questionnaires and ecological momentary assessment (EMA) for one week at a pre- (T0), post- (T1) and two follow-up-assessments after six (T2) and 12 months (T3).
89117042|NCT04080193|No Intervention|Control Group|Members of the control group will participate at each assessment. During the intervention phase they will receive treatment as usual.
89117043|NCT04630873|Active Comparator|LOW-HIGH VOLUME|Initially a low volume of the drug (100IU botulinum toxin diluted in 2 ml) after a safe washout period of 6 months the same patients will be injected with a high volume (100IU botulinum toxin in 4 ml) of the drug.
89117044|NCT04630873|Experimental|HIGH-LOW VOLUME|initially a high volume of the drug (100IU botulinum toxin diluted in 4 ml) after a safe washout period of 6 months the same patients will be injected with a low volume (100IU botulinum toxin in 2 ml) of the drug.
89117045|NCT02584153|Experimental|Myoseal|The fibrin sealant and silver microparticles are sprayed onto the surface of the sutured myofascial incision following abdominal surgery.
89117046|NCT03930979||Clearsight measurements|All patients presenting to the ED who have a painful condition for which procedural sedation is required will undergo Clearsight measurements
89117047|NCT02585401||Eylea product and application information / Cohort 1|Physicians prescribing aflibercept in Canada will be selected to reflect the distribution of retinal specialists and ophthalmologists who prescribe aflibercept.
89117048|NCT04080349|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
89117049|NCT04080349|Active Comparator|misoprostol|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
89117050|NCT04080349|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
89117051|NCT02587429|Experimental|Patienteducation|(Patients with PCS>22). An education in pain coping delivered by physiotherapists. The education consist of seven sessions over a four months period. Each session is individual and will last 30 minutes. Focus will be on pain behaviour and pain coping based on Cognitive Behavioral Therapy.
89117052|NCT02587429|No Intervention|Control group 1|(Patients with PCS>22). Patients randomly assigned to this arm will undergo usual treatment for total knee arthroplasty.
89117053|NCT02587429|No Intervention|Control group 2|(Patients with PCS<12). Patients in this arm will undergo usual treatment for total knee arthroplasty. Patients in this arm are not randomized but matched by age, gender and BMI with patients in control group 1.
89117054|NCT02585323|Active Comparator|Immediate Intervention Group|Education session, Fitbit/FitViz, PT counselling: Participants receive this intervention in Months 1-3. The session will include a presentation on physical activity, an individual goal-setting session with a registered physiotherapist, and an orientation to the Fitbit Flex and the FitViz app. In Months 1 and 2, participants will use the Fitbit/FitViz. The PT will review the progress with participants via 20-minute bi-weekly phone calls, and progressively modify their activities. In Month 3, participants will continue using the Fitbit/FitViz and have access to a PT via email as needed, but no bi-weekly phone calls. In Months 4-9, participants may continue using the Fitbit/FitViz without access to a PT.
89117055|NCT02585323|Placebo Comparator|Delayed Intervention Group|Same intervention with a 3 month delay: The full intervention will be initiated in Month 4 and with a brief education session, use of a Fitbit Flex paired with the FitViz app, and counseling by a physiotherapist. In Months 6-9, participants will continue using Fitbit/FitViz without the PT phone calls.
89117056|NCT02585167|Active Comparator|Operation|"the fistula will be excised after dividing the sphincter and primary reconstruction~."
89117057|NCT02585167|Experimental|VAAFT|the fistula tract will be visualized by scope, closing the internal opening with absorbable sutures.
89117058|NCT02585089|Active Comparator|Spanish cured-pork ham|"One group will receive dry-cured pork ham of >10 months proteolysis (intervention product).~Intervention: Dietary intake Dry-cured pork ham contains high doses of bioactive peptides produced during more than 10 months of proteolysis."
89117059|NCT02585089|Placebo Comparator|Cooked pork ham|The other group will receive cooked, uncured ham (placebo product). Intervention: Dietary intake. Cooked ham does not display bioactive peptides as they are produced during proteolysis of pork ham.
89117060|NCT02585011|Experimental|Ropivacaine|Local infiltration anesthesia, single shot during surgery. 150 ml Ropivacaine (2mg/ml), added 0.5 ml Epinephrine (1mg/ml)
89117061|NCT02585011|Placebo Comparator|Placebo|Single shot during surgery.150 ml saline
89117062|NCT00920413|Active Comparator|vitamin C|vitamin C 500mg orally once a day
89117063|NCT00920413|Placebo Comparator|placebo|
89117064|NCT02583997|Active Comparator|Routine third molar extraction|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care (i.e. with suturing of the lower alveoli).~Intervention: Suturing of lower alveoli"
89117065|NCT02583997|Experimental|Third molar extraction without suturing|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care, except that the resulting alveoli will not be sutured.~Intervention: Non suturing of lower alveoli"
89117066|NCT02584777|Experimental|Pacritinib|Oral administration
89117067|NCT02583529|Experimental|Back Tibial Nerve Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
89117068|NCT02583529|Placebo Comparator|Placebo Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
89117069|NCT00920725|Active Comparator|Subcutaneous Insulin|Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours
89117070|NCT00920725|Active Comparator|IV Regular Insulin|Intravenous Regular Insulin 0.1 units/kg/hour
89117071|NCT00920725|Active Comparator|Intravenous Novolog Insulin|Intravenous Novolog Insulin 0.1 units/kg/hour
89117072|NCT00920491||patients with non-specific complaints|patients who do not have specific presenting symptoms (e.g. dyspnea, chest pain etc.)
89117073|NCT05449249|Experimental|Long-term fasting|Long-term fasting according to the Buchinger Wilhelmi fasting program.
89117074|NCT02583451|Experimental|Treatment A|Treatment A is a placebo tablet matching lemborexant and placebo tablet matching zopiclone on nights in the clinic; placebo tablet matching lemborexant on nights at home.
89117075|NCT02583451|Experimental|Treatment B|Treatment B is zopiclone 7.5 mg tablet and placebo tablet matching lemborexant on nights in the clinic; placebo tablet matching lemborexant on nights at home.
89117076|NCT02583451|Experimental|Treatment C|Treatment C is lemborexant 2.5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 2.5 mg tablet on nights at home.
89117077|NCT02583451|Experimental|Treatment D|Treatment D is lemborexant 5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 5 mg tablet on nights at home.
89117078|NCT02583451|Experimental|Treatment E|Treatment E is lemborexant 10 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 10 mg tablet on nights at home.
89117079|NCT05435911|Experimental|Remimazolam with flumazenil|Patients allocated to remimazolam with flumazenil group receive remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
89117080|NCT05435911|Active Comparator|Propofol-based total intravenous anesthesia|Patients allocated to the propofol-based total intravenous anesthesia group receive propofol as the main anesthetics during general anesthesia until the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
89117081|NCT02583607|Experimental|Brava and fat transfer|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~Woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
89117082|NCT04479631|Experimental|Cohort 1|BRII-196 dose level 1 or placebo
89117083|NCT04479631|Experimental|Cohort 2|BRII-196 dose level 2 or placebo
89117084|NCT04479631|Experimental|Cohort 3|BRII-196 dose level 3 or placebo
89117085|NCT02584699|Experimental|SABR|SABR group includes patients receiving pre-identified fractionated Stereotactic Ablative Radiotherapy (SABR)
89117086|NCT02584621|Experimental|Check Yourself App With Feedback|Participants complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their visit with their health provider. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Health providers receive a summary report of health risk behaviors from Check Yourself prior to the visit.
89117087|NCT02584621|No Intervention|Usual Care|Participants are asked to complete health risk screening questions on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
89117088|NCT04080037|Experimental|Study Participants|All eligible and consented participants will be asked complete a multiple-choice opioid assessment based on the latest CDC opioid guidelines, then care for 6 online QualityIQ patient simulations and receive feedback on their care decisions. They will then all complete an other multiple-choice assessment at the conclusion of the study.
89117089|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.
89117090|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.
89117091|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.
89117092|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.
89117093|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.
89117094|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.
89117095|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.
89117096|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.
89117097|NCT04079959||women who are undergoing frozen embryo transfer|endometrial biopsy will be done one cycle before the frozen embryo transfer
89117098|NCT04079101|Experimental|BIIB104 0.15 mg|Participants will receive multiple oral doses of BIIB104 0.15 mg capsules twice daily (BID) for 9 days, with an additional dose occurring in the morning on Day 10.
89117099|NCT04079101|Experimental|BIIB104 0.5 mg|Participants will receive multiple oral doses of BIIB104 0.5 mg capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
89117100|NCT04079101|Experimental|Placebo|Participants will receive multiple oral doses of placebo-matched BIIB104 capsules BID for 9 days, with an additional dose occurring in the morning on Day 10.
89117101|NCT04606771|Experimental|Arm A|"Savolitinib 300 mg oral QD~Osimertinib 80 mg oral QD"
89117102|NCT04606771|Experimental|Arm B|"Savolitinib 300 mg oral QD~Placebo to Osimertinib 80mg oral QD"
89117103|NCT04079023||Obese|30 obese patients (12 M/ 18 F) with a mean BMI of 46 candidate to SG Alcohol drink mean volume: 158 Ml administered in 10 minutes
89117104|NCT04504123|Experimental|Doxycycline|Participants received doxycycline hyclate 50 mg capsule orally once a day for 6 months
89117105|NCT04504123|Placebo Comparator|Placebo|Participants received placebo (inactive) capsule orally once a day for 6 months
89117106|NCT04078633|Experimental|Normal Liquid Soap (250mL)|A normal hygiene kit will be distributed to the households. In addition, a liquid soap will be added to see the impact of having a liquid soap for hand washing on hygiene behaviors.
89117107|NCT04078633|Experimental|Bar soap (250gram)|A normal hygiene kit will be distributed to the households. In addition, a nice bar soap will be added to see the impact of having a nicer bar soap for hand washing on hygiene behaviors.
89117108|NCT04078633|Experimental|Mirror (50x30cm)|A normal hygiene kit will be distributed to the households. In addition, a mirror will be added to see the impact of having a mirror by the handwashing stand on handwashing behaviour. The mirror will have a plastic edge and be 30x 50cm in size.
89117109|NCT04078633|No Intervention|Control|A normal hygiene kit will be distributed to the households. No additional interventions will be given.
89117110|NCT04078633|Experimental|Nurture story for hygiene promotion|Hygiene promoters will share a story of being a good parent through teaching their children to do hand washing with soap at critical times. A story about a good mother who every day reminds her child to wash her/his hands before eating or preparing food and after going to the toilet will be shared with participants. The story ends with the child growing up healthy, happy and with a good education. This story if belived to increae handwashing with soap in the household/
89117111|NCT04078633|Experimental|Comfort story for hygiene promotion|Hygiene promoters will deliver hygiene promotion through an activity that provoke the feeling of comfort by having clean hands. Hygiene promoters will deliver this intervention to up to 5 neighbor households at the time, sharing a story about a family that keeps good hygiene behaviors and therefore are clean, healthy and happy. This story is believed to encourage families to increase handwashing with soap in the household.
89117112|NCT04078633|No Intervention|Education session for hygiene promotion|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
89117113|NCT04078633|Experimental|Hygiene Promotion Activity - Disgust|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will use 5 buckets of clean water and place them in front of households. They will then ask a member of one of the households to rinse their hands in the first bucket. Some dirt will come of their hands. Then the participant rinses their hands again in bucket number 2, then 3 and then 4. Before the 5th bucket the participant receives a bar of soap to use when they rinse their hand. When they do the water will have a dirty colour as the dirt comes of their hands. This activity is believed to encourage handwashing with soap.
89117114|NCT04078633|Experimental|Hygiene Promotion Activity - Comfort|The activity will be delivered to a group of maximum 5 neighbouring households at the time. Hygiene promoters will bring some food oil and ask participants to cover their hands in food oil. They will then ask the participants to cover their hands in turmeric powder. The participants will then be asked to wash their hands with water only. This will have little effect on the cleanliness of their hands. Then participants will be given a bar of soap. The participants will then be asked to wash their hands again. This will leave their hands nice comfortable and clean. They will experience the comfort of clean hands and the activity hope to increase regular handwashing.
89117115|NCT04078633|No Intervention|Education Hygiene Promotion Activity|Hygiene promoters will deliver regular hygiene promotion activities; an educational message about disease transmission and how handwashing with soap can help protect against disease. This would include teaching participants about the benefits of handwashing with soap, such as reducing diarrhea incidence and preventing cholera.
89117116|NCT04465669|Active Comparator|Orsiro|Implantation of a Orsiro® biolimus a9 eluting coronary stent (drug-eluting stent, DES)
89232523|NCT04755205||Cohort 1|Subjects with confirmed olfactory neuroblastoma.
89232524|NCT04750928|Experimental|1/ Phase I Dose Escalation|Abemaciclib orally twice daily at escalating doses to determine the MTD/RP2D
89232525|NCT04750928|Experimental|2/ Phase II Objective Response Rate|Abemaciclib orally twice daily at the RP2D
89232526|NCT04747613|Experimental|Iptacopan|Participants will be receiving open label oral iptacopan 200 mg b.i.d monotherapy
89232527|NCT04732962|Experimental|AposHealth|"Following the initial consultation and calibration of the Apos device in the clinic, the patients will receive from his therapist a home-based treatment plan. This usually includes wearing the device for about 20 minutes with about 20% of weight-bearing (patient is instructed to wear the Apos and just be with the device and go about his/her daily routine). A gradual increase in usage time is prescribed reaching up to 60 min wear time with about 40% weight-bearing.~Patients are requested to return to follow-up (FU) appointments after 1, 3, 6, 9 and 12 months. In addition, patients will have a remote FU after 1-week to confirm they use AposHealth as advised. During the follow-up appointment, re-assessment of clinical outcomes and gait patterns are performed and the calibration of the Apos device is adjusted as needed. The treatment plan is adjusted, and patients are encouraged to continue to wear the device regularly at home."
89232528|NCT04732962|Active Comparator|Total Knee Replacement (TKR)|"Patients will undergo TKR according to Geisinger's policy, guidelines and care protocol.~The study baseline visit will occur 6 weeks postoperative for TKR groups."
89232529|NCT04732962|Experimental|Post TKR traditional physical therapy (PT) and AposHealth|"Patients who have had a knee replacement and were assigned to the traditional PT+ AposHealth group will follow Geisinger post-operative rehab protocol and will also receive AposHealth and follow the rehabilitation protocol.~AposHealth will start six weeks post-op and will continue for 12 months. Patients will receive AposHealth similar to the non-invasive group, i.e., will have an initial evaluation (IE) and calibration of the Apos device, have a remote FU after one week from IE and in-clinic FUs at 1, 3 6, 9 and 12 months."
89232530|NCT04722146|Experimental|Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide|Participants will receive teclistamab plus daratumumab plus pomalidomide.
89117117|NCT04465669|Active Comparator|Resolute Integrity|Implantation of a Resolute Integrity® zotarolimus eluting coronary stent (drug-eluting stent, DES)
89117118|NCT02584543|Experimental|HEV vaccine and HBV vaccine Co-administration group|
89117119|NCT02584543|Active Comparator|HEV vaccine control group|
89117120|NCT02584543|Active Comparator|HBV vaccine control group|
89117121|NCT04078165|Experimental|Zero-Gravity|In this group, the operator uses the Zero-Gravity protection system
89117122|NCT04078165|Active Comparator|Conventional|In this group, the operator uses conventional radiation protection
89117123|NCT02583763||Fetuses/Children with IUGR|"The moving sequences of the heart movement are collected at the regular ultrasound examinations during pregnancy. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyse the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
89117124|NCT02583763||Healthy Controls|"The moving sequences of the heart movement are collected at two occasions approximately 4 weeks apart. This takes place during gestational weeks 28-36. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyze the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
89117125|NCT02581813|Experimental|RDa (Recommended dairy group)|4 servings of dairy per day + exercise (3 times per week with combination of aerobic and resistance exercise).
89117126|NCT02581813|Experimental|LDa (Low dairy group)|0-1 serving of dairy per day + exercise (the same as the RDa group)
89117127|NCT02581813|No Intervention|GCon (growth controls)|This no-intervention group will serve as the control to account for growth during the study.
89117128|NCT02583841|Active Comparator|Scaling and Root Planing( SRP)|This was an interventional study in which scaling and root planing was done in systemically healthy patients with chronic periodontitis
89117129|NCT02583841|No Intervention|Control Group|Scaling and root planing was not done , that is no intervention is carried out in the patients of this group.
89117130|NCT04077853|Experimental|study group|women will be given 17-OHPC 250 mg intra-muscular at admission and every 7 days thereafter in addition to other conservative measures of early-onset PE
89117131|NCT04077853|No Intervention|control group|No intervention will be given apart from the usual conservative measures of early-onset PE
89117132|NCT00583219|Experimental|Botox/DMSO Solution|"Subjects received Botulinum-A toxin and Dimethyl sulfoxide solution. The first 3 subjects in Phase 1 underwent bladder instillation of 50 cc of the solution utilizing 200 units of botulinum-A toxin and 50cc DMSO. The next 6 subjects in the Phase 1 trial received 300 units of botulinum-A toxin and 50cc DMSO.~All subjects in the Phase 2 trial received 300 units of botulinum-A toxin and 50cc DMSO."
89117133|NCT04490785|Experimental|patients under aortic surgery with CPB|Patients under aortic surgery with CPB will have MRI and postoperative dosage of released troponin
89117134|NCT05674669|Experimental|Group 1 N=3|Single dose, follow-up visits at one day, one week, and one month after dose.
89117135|NCT05674669|Experimental|Group 2 N=7|Single dose, follow-up visits at one day, one week, and one month after dose.
89117136|NCT05674669|Experimental|Group 3 N=3|Single dose, follow-up visits at one day, one week, and one month after dose.
89117137|NCT05674669|Experimental|Group 4 N=10|Randomized treatment with placebo followed by single dose, separated by 7 days. Follow-up visits at one day, one week, and one month after last dose.
89117138|NCT05674669|Experimental|Group 5 N=9|Randomized treatment with single dose followed by second dose, separated by 7 days. Follow-up visits at one day, one week, and one month after last dose.
89117139|NCT02583373|Active Comparator|CAL02 Low-dose|Liposomal formulation
89117140|NCT02583373|Active Comparator|CAL02 High-dose|Liposomal formulation
89117141|NCT02583373|Placebo Comparator|Placebo|Saline
89117142|NCT02583295|Active Comparator|Music group|Music sound
89117143|NCT02583295|Active Comparator|Maternal sound group|Maternal sound
89117144|NCT04307407|Experimental|Aerobic Exercise|The aim is for participants to complete three weekly sessions of supervised aerobic treadmill based exercise for five months. Session duration varies from 20-60 minutes, with exercise intensity ranging from 55-95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate), will be determined by the CPET performed by certified exercise physiologists at baseline.
89117145|NCT04307407|No Intervention|Standard care|Participants in this arm will not receive any follow-up on exercise during the intervention period.
89117146|NCT04307407|Other|Reference Group|Participants in this arm are age-matched women with no history of any malignant disease, which will undergo similar assessments at baseline and post-intervention and also follow similar exercise intervention as the breast cancer survivors randomized to the Aerobic exercise arm
89117147|NCT04449211|Experimental|Participants with massive bone defect|"Adult participants with health insurance regardless of sex having bone defect greater than 5cm due to trauma or tumour resection agree to participate the research.~The customised 3D-Printed implant is manufactured and undergoes post-processing treatment before being ready for implantation surgery."
89117148|NCT04296877|Experimental|All study participants|All subjects are fit into daily disposable contact lenses after wearing their optimized habitual contact lenses for ~ 1 week. Subjects are requested to wear the lenses for two weeks, for a minimum of at least 6 hours per day for 10 days.
89232531|NCT04722146|Experimental|Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles)|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 21-day cycles.
89232532|NCT04722146|Experimental|Treatment Regimen C: Teclistamab + Nirogacestat|Participants will receive teclistamab plus nirogacestat.
89232533|NCT04722146|Experimental|Treatment Regimen D: Teclistamab + Lenalidomide|Participants will receive teclistamab plus lenalidomide.
89117149|NCT02581501|Experimental|Gemcitabine, ABRAXANE®, and Xeloda|"Level-1~ABRAXANE® 75 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12.~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 1~ABRAXANE® 100 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 2~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 75 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 3~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 750 mg/m2 over 75 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day"
89117150|NCT05292079||Coronary Artery Disease (CAD)|
89117151|NCT01072175|Experimental|Arm Part A|Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction
89117152|NCT01072175|Experimental|Arm Part B|GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose
89117153|NCT01072175|Experimental|Arm Part C|GSK2118436 + GSK1120212 cohort expansion for safety and efficacy
89117154|NCT04078711|Experimental|losartan & qianyangyuyin|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Chinese Medicine (Qianyangyuyin granule) 20g by mouth, bid for 6 months.
89117155|NCT04078711|Placebo Comparator|Losartan & Placebo|Losartan 100mg tablet (if necessary combined with CCBs) by mouth, qd for 6 months and Qianyangyuyin placebo 20g by mouth, bid for 6 months.
89117156|NCT04078009|Experimental|Aquagen (Starts with Aquagen and finish with Grazax)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
89117157|NCT04078009|Experimental|Grazax (Starts with Grazax and finish with Aquagen)|In order to explore a possible order effect with the challenges, in this single group cross-over trial, participants will be randomised (by computer-generated randomisation) to receive either Aquagen or Grazax as the first challenge, followed by the other allergen extract at the second challenge a minimum of 4 weeks later.
89117158|NCT04076449||Cerebral Cavernous Malformation with Epilepsy|Patients with cerebral cavernous malformation and associated with epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
89117159|NCT04076449||Cerebral Cavernous Malformation without Epilepsy|Patients with cerebral cavernous malformation but without epilepsy will undergo MR imaging and be followed-up annually as our protocol defined.
89117160|NCT04304573||Patients with hypocalcemia symptoms and low serum calcium|Patients with postoperative hypocalcemia defined as serum calcium levels < 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
89117161|NCT04304573||Patients with hypocalcemia symptoms and normal serum calcium|Patients with hypocalcemia symptoms but without postoperative hypocalcemia defined as serum calcium levels > 2.00 mmol/L. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
89117162|NCT02581735||Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
89117163|NCT04426669|Experimental|CISH CRISPR TIL / Phase I Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dose aldesleukin
89117164|NCT04426669|Experimental|CISH CRISPR TIL / Phase II Arm|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of CISH inactivated TIL
89117165|NCT00627107|Experimental|A|A group of paraplegics.
89117166|NCT02874989|Experimental|Dasatinib + Quercetin|
89117167|NCT02874989|Placebo Comparator|Placebo|
89117168|NCT01071317|Experimental|Comprehensive care|Reinforcement of diagnosis, education, medications, and referral
89117169|NCT01071317|Active Comparator|Typical care|Usual care
89117170|NCT04283149|Experimental|Primary Eyes|First implanted eyes of enrolled participants
89117171|NCT04283149|Experimental|Fellow Eyes|Second implanted eyes of enrolled participants
89117172|NCT00783094|Experimental|Tadalafil 2.5 milligrams (mg)|2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.
89117173|NCT00783094|Experimental|Tadalafil 5 mg|5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.
89117174|NCT00783094|Placebo Comparator|Placebo|"Placebo tablet taken by mouth once a day for 12 weeks.~Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks."
89117175|NCT02874599|Experimental|Patients|Patients who require multiple dental restorations. Teeth will be restored with commercial restorative composites
89117176|NCT02581579|Active Comparator|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
89117177|NCT02581579|Placebo Comparator|Placebo|MANITOL CAPSULES
89117178|NCT04303637||High school student|13-18 year old students enrolled in schools within Singapore.
89117179|NCT02874833|Experimental|Exercise Group|Experimental arm type will assess whether a newly developed, supervised 8-week individualized, internet-based exercise therapy is effective in reducing depressive symptoms.
89117180|NCT02874833|No Intervention|Treatment as usual group|Treatment as usual. Other form of therapy (e.g. antidepressive medication) will not be affected.
89117181|NCT04303247|Experimental|CD19+CD22 targeted CAR-T|"The study will employ dose level cohorts of three patients that will be treated at each level described below, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy to find MTD followed by a dose-expansion phase at determined optimal dosage.~dosage: the number of anti CD19+CD22 CAR T cells~-1(if needed) 1×10^5/KG~3×10^5 /KG~6×10^5 /KG~1×10^6/KG~Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion."
89117182|NCT02875925|Experimental|MTM|Patients will receive MTM at an individualized frequency for 1 year.
89117183|NCT02875925|No Intervention|Control|Patients enrolled in the control group will not experience any change in their medical care.
89117184|NCT02874755|Experimental|Tuberculosis Program (PPIA)|Half of the 300 participants were randomly selected to be sensitized and engaged into the program, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if networked into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free and/or subsidized diagnostic testing and referrals to providers for free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests; training opportunities, and access to a referral network.
89117185|NCT02874755|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining half of the sample in Mumbai selected randomly will be phased into the program at least a year after the PPIA arm. However, during the year of the study, they will not be networked into the program.
89117186|NCT00790582|Experimental|lithium carbonate|
89117187|NCT04078087||Non obese|"Non obese (whether normal weight or overweight) = Group NO"
89117188|NCT04078087||Obese|"obese = Group O"
89117189|NCT01048541|Active Comparator|SpeediCath catheter|Standard treatment
89117190|NCT01048541|Experimental|Test product|
89117191|NCT04077931|Experimental|Aerobic exercises|She asked to start walking with the speed of the machine was adjusted at 0.8 km/hour, so her resting pulse rate increases, then we increased the speed by 0.2 km/hour gradually every 2 minute (to give a time for adjustment of heart rate) till reaching our target heart rate (not less than 60% and not more than 75% of target heart rate). So the intensity of exercises can be increase or decrease only by changing the speed of treadmill according to target heart rate [13]
89117192|NCT04077931|Experimental|Deep breathing exercises|Technique of breathing exercises: Regular aerobic exercises in a form breathing exercises included duration of 30 min. at 40-70% VO2 max. performed 2-3 per week. Each woman practiced deep breathing exercises 30 min. in the of form (diaphragmatic breathing exercises, 15 min. and lateral costal breathing exercises 15 min.) 3 times per week for 12 weeks.
89117193|NCT00916240|Experimental|1|Participants will receive Multisystemic Therapy (MST).
89117194|NCT00916240|Active Comparator|2|Participants will receive home-based, non-directive family support.
89117195|NCT02583217||Ketamine|Ketamine+propofol
89117196|NCT02583217||Remifentanyl|Remifentanyl+propofol
89117197|NCT00774046|Experimental|Induction chemotherapy followed by stem cell transplant|Ara-C Mitoxantrone Etoposide Stem cell mobilization Autologous transplant
89117198|NCT01046903||1|
89117199|NCT02581423|Experimental|Capecitabine|Participants will receive capecitabine for up to approximately 6 months.
89117200|NCT04102072|Experimental|Trendelenburg Maneuver|The Trendelenburg position is a common treatment in medicine.It is used either as a diagnostic tool to assess fluid loading response or as a therapeutic maneuver pending fluid resuscitation.With the advantage of autotransfusion readily available,the Trendelenburg position is used for expected instantaneous effect on cardiovascular performance.
89117201|NCT04102072|Experimental|dobutamine stress test|Dobutamine is a selective beta 1 receptor agonist. It [<10 ug/(kg.min)] can effectively increase myocardial contractility.
89117202|NCT02875457|Experimental|Arm A|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and apatinib 250mg/d , repeated every 21 days, a total of 6 cycles, and then continue to take apatinib 250mg/d until progressive Disease(PD).
89117203|NCT02875457|Placebo Comparator|Arm B|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and placebo, repeated every 21 days, a total of 6 cycles, and then continue to take placebo until PD.
89117204|NCT00773968|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants will receive methoxy polyethylene glycol-epoetin beta once monthly by subcutaneous (SC) injection for 28 weeks.
89117205|NCT04078867||DeVega|The DeVega repair is performed when the patient had minimal annular dilation and lower severity of pulmonary hypertension
89117206|NCT04078867||MC3 ring|MC3 ring annuloplasty is performed in patients with severe tricuspid annular dilation and severe pulmonary hypertension
89117207|NCT04077385|Experimental|Retrieval Extinction (R-E) Training Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the R-E training group will observe 5-min of high calorie pictorial food cues during retrieval which will purportedly retrieve cue-reward associative memories. This will be followed by 60-min of extinction training to high calorie food cues. The R-E training group will only differ from the extinction control group in regards to the 5-min exposure to high calorie food cues prior to the 60-min of extinction training to high calorie food cues."
89117208|NCT04077385|Active Comparator|Extinction Control Group|"On the two retrieval-extinction (R-E)/extinction training days, participants randomized to the extinction control group will observe 5-min of non-food-related cues (e.g., pictures of office supplies, tools) during retrieval, which will purportedly avoid retrieval of the food cue-reward associative memories that are targeted in the R-E training group. The 5-min of exposure to non-food-related cues will be followed by the same 60-min of extinction training to high calorie food cues that the R-E training group receives."
89117209|NCT04101994|Experimental|VCT and real rTMS|In virtual cycling training and intermittent theta burst stimulation group (VCT + iTBS group), they received VCT and iTBS (80% of active motor threshold) on affected hemisphere.
89117210|NCT04101994|Experimental|VCT and sham rTMS|In virtual cycling training and sham theta burst stimulation group (VCT + iTBS group), they received VCT and sham TBS stimulation.
89117211|NCT04101994|Experimental|real rTMS|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
89117212|NCT04101994|Sham Comparator|sham rTMS|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
89117213|NCT04101994|Experimental|VCT and real TES|In virtual cycling training and transcranial electric stimulation group (VCT + TES group), they received TES stimulation over motor cortex.
89117214|NCT04101994|Experimental|VCT and sham TES|In virtual cycling training and sham transcranial electric stimulation group (VCT + sham TES group), they received VCT and sham TES stimulation.
89117215|NCT04101994|Experimental|real TES|In transcranial electric stimulation group (TES group), they received TES stimulation over motor cortex.
89117216|NCT04101994|Sham Comparator|sham TES|In sham transcranial electric stimulation group (sham TES group), they received sham TES stimulation.
89117217|NCT04060381||Fetuses of normal weight women|Fetuses of normal pregnancies of normal weight mothers are included from gestational week 37
89117218|NCT04060381||Fetuses of severely obese women|Fetuses of normal pregnancies of severly obese mothers are included from gestational week 37
89117219|NCT04060381||New-borns in need of blood transfusion|Neonates mainly receive blood due to blood loss, often because of repeated blood sampling
89117220|NCT04060381||New-borns in need for closure of the arterial duct|Neonates mainly receive medication (Ibuprofen) because of symptoms like apnea, due to their patent arterial duct.
89117221|NCT04032379||Certain IIH or IIH-WOP|According to revised diagnostic criteria, Friedmann, 2013.
89117222|NCT04032379||Suspected IIH|IIH is suspected, does not fulfill diagnostic criteria.
89117223|NCT04032379||IIH ruled out|Patients in whom another diagnosis is made.
89117224|NCT00782626|Experimental|everolimus|Patients rcvd oral everolimus 5.0 mg/m2/day for a 28-day treatment course up to a total of 12 courses (48 weeks) if a patient had stable disease except if toxicity was unacceptable. Two dose reductions were permitted (3.0 5.0 mg/m2/day and 2.0 mg/m2/day).
89117225|NCT04076371|Experimental|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
89117226|NCT04076371|Placebo Comparator|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
89117227|NCT04076371|Experimental|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
89117228|NCT04076371|Placebo Comparator|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
89117229|NCT04076371|Experimental|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
89117230|NCT04076371|Placebo Comparator|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
89117231|NCT04076371|Experimental|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
89117232|NCT04076371|Placebo Comparator|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
89117233|NCT02583139|Experimental|Music Narrative Group|Prescribed medical/chemotherapy treatment plus standard care + Designed Music Narratives
89117234|NCT02583139|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
89117235|NCT05400733|Other|Healthy male older adults|Healthy male older adults
89117236|NCT05400733|Other|Healthy female older adults|Healthy female older adults
89117237|NCT04077697||ITBA group|ITBA group is : invasive tracheobronchitis aspergillosis form.
89117238|NCT04077697||IPA without tracheobronchial involvement|IPA group is : invasive pulmonary aspergillosis without tracheobronchial involvement
89117239|NCT01071083|Active Comparator|natalizumab|
89117240|NCT01071083|Placebo Comparator|IV placebo|
89117241|NCT01071083|Active Comparator|interferon β-1a, glatiramer acetate, or methylprednisolone|
89117242|NCT04302935||chronic pain patients|
89117243|NCT04077307|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution to be taken every other day. There are three planned dose cohorts. Patients will be given every second day dosing.
89117244|NCT02581033|Experimental|Nucleoside analogue therapy cessation|To determine if a sustained virological response can be achieved after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
89232534|NCT04722146|Experimental|Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide|Participants will receive teclistamab plus daratumumab plus lenalidomide.
89232535|NCT04722146|Experimental|Treatment Regimen F: Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles)|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib in 28-day cycles.
89232536|NCT04715958|Experimental|Diagnostic (CEUS, Definity)|Patients undergo CEUS and receive perflutren lipid microspheres IV over 10-15 minutes before NAC, after 10% of NAC, and after 30% of NAC
89232537|NCT04708470|Experimental|1/Arm 1|Dose escalation/de-escalation of entinostat and dose escalation of NHS-IL12 with fixed dose of bintrafusp alfa
89232538|NCT04708470|Experimental|2/Arm 2|RP2D of entinostat, NHS-IL12, and bintrafusp alfa
89232539|NCT04708470|Experimental|3/Arm3|Entinostat and NHS-IL12 (without bintrafusp alfa)
89232540|NCT04706221|Experimental|Blood Volume Monitoring|
89232541|NCT04701593|No Intervention|Control|No additional drug given
89232542|NCT04701593|Experimental|Experimental (Triamcinolone Acetonide)|receives a sub-tenon irrigation of 1 cc 40mg/mL triamcinolone acetonide around the base of the scleral buckle (0.25 cc in each quadrant) at time of operation
89232543|NCT04696809|Experimental|Japanese Participants with Relapsed or Refractory Multiple Myeloma (MM)|Japanese participants will receive Teclistamab subcutaneously (SC) at four dose levels. Cohort 1 will receive Teclistamab at Dose 1 and 2 (step-up doses) prior to first treatment dose on Day 1 followed by Dose 3 weekly (that is, on Days 1,8, and 15 of a 21-day cycle). Cohort 2 will receive Teclistamab at Dose 1 and 4 (step up doses) prior to first treatment dose on Day 1 followed by Dose 5 weekly. Cohort 3 will receive Teclistamab at Dose 1, 4, and 5 (step up doses) prior to first treatment dose on Day 1 followed by Dose 6 weekly. Cohort 4 will receive Teclistamab at Dose 1, 4, and 5 (step up doses) prior to first treatment dose on Day 1 followed by Dose 7 weekly for (2 cycles), then biweekly (cycle 3 to 6) on Days 1 and 15 and monthly (cycle 7) on Day 1 of 1 28-day cycle. In Phase 2 , participants will receive Teclistamab SC at Dose 1 and 4 (step up doses) up to 8 days prior to first treatment dose on Day 1 followed by Dose 5 on Days 1,8,15, and 22 of a 28-day cycle.
89232544|NCT04692675|Experimental|AS + mpMRI|Active surveillance (AS) with the following: a) Initial PSA and DRE screen; then, PSA screening every 12 months, with DRE every year mpMRI or prostate biopsy is performed; b) Initial mpMRI and then prior to all biopsies; c) Initial systemic prostate biopsy and MRI/US fusion-guided prostate biopsy of all suspicious lesions; then, every 2 years for 5 years and then every 3 years
89232545|NCT04685070|Experimental|HS-10296 (Almonertinib)|
89232546|NCT04683029|Experimental|Group A: Guselkumab|Participants will receive intravenous (IV) injection of Guselkumab Dose 1 at Week 0, 4, and 8 followed by subcutaneous (SC) injection of Dose 2 Guselkumab every 4 weeks (Q4W) from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Guselkumab Dose 2 and IV injection of placebo at long-term extension (LTE) Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
89232547|NCT04683029|Placebo Comparator|Group B: Placebo|Participants will receive IV injection of matching placebo at Week 0, 4, and 8 followed by SC injection of matching placebo Q4W from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Placebo and IV injection of Guselkumab Dose 1 at LTE Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
89232548|NCT04681040||UrBMC19 Group (International Cooperative Group)|The examination of urine for mild pre-diagnosed COVID-19 cases are conducted to evaluate the risk classification and detect the effectiveness of early intervention by COVID-19 treatment such as dexamethasone, chloroquine, remdesivir, ivermectin, actemra, and so forth within the period of 14 days after starting the intervention.
89232549|NCT04679311|Experimental|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with 2 units of fresh frozen plasma that have been preselected to contain ACE activity ≥50 U/L
89232550|NCT04679311|Placebo Comparator|Normal Saline|Subjects will be treated with normal saline 500 cc.
89232551|NCT04674462|Experimental|CpG-adjuvanted HBV Vaccine|
89232552|NCT04674462|Active Comparator|Traditional HBV Vaccine|
89232553|NCT04673383|Experimental|Healthy volunteers (active)|SPL026 to be administered by IV injection
89232554|NCT04673383|Experimental|Healthy volunteers (placebo)|SPL026-matched placebo to be administered by IV injection
89232555|NCT04673383|Experimental|Patients (active)|SPL026 to be administered by IV injection
89232556|NCT04673383|Experimental|Patients (placebo)|SPL026-matched placebo to be administered by IV injection
89232557|NCT04673357|Experimental|Open- Label Ustekinumab Intravenous (IV): Induction Period|All participants will receive a single IV administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
89232558|NCT04673357|Experimental|Ustekinumab Subcutaneous (SC) Every 8 Weeks (q8w): Maintenance Period|Participants will receive SC administration of ustekinumab q8w based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at maintenance weeks (Weeks M)-0, M-8, M-16, M-24, M 32, and M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
89232559|NCT04673357|Experimental|Ustekinumab SC Every 12 Weeks (q12w): Maintenance Period|Participants will receive SC administration of ustekinumab q12w based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
89232560|NCT04671433|Experimental|Experimental - Immediate Treatment|Intermediate dose.
89232561|NCT04671433|Other|Deferred Treatment|Deferred Treatment
89232562|NCT04671433|Experimental|Experimental Immediate Treatment|Low dose.
89232563|NCT04661358|Experimental|Fenofibrate 160-mg|
89232564|NCT04661358|Placebo Comparator|Placebo|
89232565|NCT04658862|Experimental|TAR-200 + Cetrelimab|Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with intravenous (IV) Cetrelimab.
89232566|NCT04658862|Active Comparator|Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy|Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 4 to 6 treatment weeks or gemcitabine intravenously twice weekly for 4 to 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray [Gy], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks.
89232567|NCT04657224|Experimental|Part A: Dose escalation: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 will be administered together until disease progression, intolerable toxicity, withdrawal of consent, or the investigator.
89117245|NCT03968341|Experimental|intraocular antibiotic concentrations determination|"In the event that the patient develops unfavourably, the ophthalmologist include the patient in the trial.~The patient is reviewed at 48 hours after the introduction of probabilistic antibiotic therapy for clinical reassessment and the return of microbiological test results. Following this inclusion, the new samples will be taken when the patient passes through the operating room for the treatment of his pathology as part of the care. Ophthalmologists may have to adapt the patient's management (i.e. adjustment of antibiotic therapy) as part of their usual care routine. An anterior chamber puncture and a vitrectomy are performed. Eye fluids collected as part of the treatment are sent for analysis."
89117246|NCT02875379|Experimental|HME|Passive humidification with heat and moisture exchanger, Y-piece circuit.
89117247|NCT02875379|Experimental|HH33|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
89117248|NCT02875379|Experimental|HH37|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
89117249|NCT02875379|Experimental|NoH|Passive humidification, double tube circuit
89117250|NCT05674591|Experimental|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a manual-guided therapy that incorporates cognitive processing techniques to relieve PTSD symptoms (Resick et al., 2016). Each group session will be 90 to 120 minutes long and will be occur once each week for 12 weeks.
89117251|NCT01070381|Other|nelfilcon A / ocufilcon D|Nelfilcon A contact lenses worn first, with ocufilcon D contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
89117252|NCT01070381|Other|ocufilcon D / nelfilcon A|Ocufilcon D contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
89117253|NCT04302779|Experimental|Solid Model|Whey Permeate Lemon Cupcake and Protein Fortified Lemon Cupcake
89117254|NCT04302779|Experimental|Liquid Model|Whey Protein Beverage
89117255|NCT00627185|Experimental|1|Intervention group (dental practices) that received the interactive motivational website for patient tobacco cessation
89117256|NCT00627185|Placebo Comparator|2|Control group (dental practices) that did not receive any materials or resources on tobacco cessation. This is a wait-list control.
89117257|NCT02580955|Experimental|LEGFLOW DCB|patients treated with the LEGFLOW Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter
89117258|NCT04078399|Experimental|patients with recurrence after allogeneic transplantat|One arm
89117259|NCT04077151|No Intervention|Standard of Care|PrEP prescribed with no intervention
89117260|NCT04077151|Experimental|Intervention Recipients|PrEP Demonstration Project intervention will be given
89117261|NCT04076995|Experimental|High Water intake|High water intake of 3.0 L/day in males and 2.0 L/day in females
89117262|NCT04076995|Active Comparator|Low Water Intake|Low water intake of 0.5 L/day in males and 0.4 L/day
89117263|NCT04077229|Experimental|Intervention|A total of 28 intervention text messages (1/day for 4 weeks) will be sent to participants following the baseline self-report assessment. After each message is sent, participants will receive a second text message asking them to rate the utility of the message. Following the 4-week intervention, participants will complete the same self-report assessments as in the baseline assessment (via phone) and will provide feedback about the program. Finally, 4 weeks later (at 8 weeks), participants will repeat the self-report questionnaires by phone.
89117264|NCT02582827|Experimental|ABI-011|IDN 5404 protein-bound particles for injectable suspension
89117265|NCT05189509|Experimental|TNK group|intravenous thrombolysis with 0.25 mg/kg TNK, with the biggest dose of 25 mg
89117266|NCT05189509|Placebo Comparator|control group|
89117267|NCT04076293|Experimental|HM15912|
89117268|NCT04076293|Placebo Comparator|Placebo|
89117269|NCT03897751|Experimental|ABT12 Multi-Purpose Solution|Participants will use ABT12 Multi-Purpose Solution to clean their contact lenses daily for 3 months. Participants will use Sensitive Eyes Rewetting Drops as needed during the study.
89117270|NCT03897751|Active Comparator|COMPLETE Multi-Purpose Solution|Participants will use COMPLETE Multi-Purpose Solution to clean their contact lenses daily for 3 months. Participants will use Sensitive Eyes Rewetting Drops as needed during the study.
89117271|NCT01010126|Experimental|Treatment (temsirolimus, bevacizumab)|Patients receive temsirolimus IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89117272|NCT01043705||CIED replacement with CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with a CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
89117273|NCT01043705||CIED replacement with ICD and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD and the TYRX Anti-bacterial envelope, with or without lead revision.
89117274|NCT01043705||CIED replacement with ICD or CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD or CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
89117275|NCT01043705||CIED replacement w/ CRT & no TYRX|(Retrospective Case-Control Arm) Patients who have undergone CIED replacement with a CRT and no TYRX Anti-bacterial envelope, with or without lead revision/addition.
89117276|NCT01043705||CIED replacement w/ CRT & TYRX vs. Case Match Arm|Patients who have undergone CIED replacement with a CRT and TYRX Anti-bacterial envelope, with or without lead revision/addition. Cohort is TYRX Case, Matched to Retrospective Case-Control Arm)
89117277|NCT04076839|Experimental|Goal Management Training (GMT)|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Participants assigned to this group will attend 9 weeks of GMT group sessions, each 2 hours in length, occurring once per week.
89232568|NCT04657224|Experimental|Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
89117278|NCT04076839|No Intervention|Wait-list Control|Following baseline testing, participants randomly assigned to the wait-list control group will have no intervention during the 9 weeks that the GMT group attends their group sessions. Following the completion of the GMT group intervention, the wait-list control will attend a a testing session, and subsequently, a 3 month follow-up testing session, the results of which will be compared to those of the GMT group. This group will then be offered a complimentary 9-week GMT program once the final testing session is complete. Again, during these sessions participants will be required to complete questionnaires every third session in order to monitor their progress and symptoms. Following the completion of the complimentary 9-week GMT program, individuals in the WLC will complete post-intervention testing
89117279|NCT02580487||retrospective group|Patients whose pain evaluation, analgesics used and details of surgery were collected from patient files
89117280|NCT02580487||Prospective group|Patients who were interviewed before and after surgery when they were at the hospital
89117281|NCT03892603|Experimental|Strengthening exercises program|
89117282|NCT03892603|Experimental|Motor control exercises program|
89117283|NCT03892603|Active Comparator|Education and advice|
89117284|NCT05380141||Patients|Patients, children and adolescents referred to the chronic pain consultation of Necker Hospital with identification of school absenteeism or dropping out and having been the victim of school bullying.
89117285|NCT04137835|Experimental|Showmotion|"Performing an analysis requires the positioning of sensors on the patient's skin in predetermined positions, according to the related protocols. Each sensor positioned on patient's skin provides both raw data (accelerometer, magnetometer, gyroscope) and the orientation matrix, representing the orientation of the local System of Reference (SoR) with respect to a fixed SoR. A proprietary sensor-fusion algorithm allows provides an accurate estimate of the orientation, as assessed by stereo-photogrammetric system-based testing.~Data from each sensor are sampled at 50 Hz and transferred wirelessly to a laptop with a proprietary software that processes the data according to the biomechanical model chosen for the analysis."
89117286|NCT04076137|Experimental|Targeted T-cell|This study is a pre-phase I immunotherapy trial in 10 people with malignant solid tumor consisting of 9 infusions of bispecific antibody armed anti-CD3-Actibated T cells(ATC) to determine safety, maximum tolerated dose (MTD), technical feasibility, immune responses.
89117287|NCT03879577|Experimental|Docetaxel|Investigators will give patients docetaxel through drip every 3 weeks for four doses for 12 weeks before a repeat breast ultrasound. After breast ultrasound, if the investigator feels the injection is good, surgery will be done.
89117288|NCT03879577|Other|Herceptin|Herceptin will be given to patients under the skin of the thigh every 3 weeks for 18 times if they are HER2-positive
89117289|NCT03879577|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with a poor response to docetaxal will receive FEC injection by drip every 3 weeks.
89117290|NCT03879577|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years every 3 months for contraception and fertility preservation.
89117291|NCT03879577|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
89117292|NCT03875209|Experimental|Arm 1: 10E8.4/iMab IV or SC HIV-|Arm 1; Groups A-C; 3 dosing groups: HIV-uninfected individuals
89117293|NCT03875209|Experimental|Arm 2: 10E8.4/iMab IV HIV-|Arm 2; Groups D-F; 3 dosing groups: HIV-uninfected individuals
89117294|NCT03875209|Experimental|Arm 3 and 3a: 10E8.4/iMab IV HIV+|Arm 3; Group H; 1 dosing group: HIV-infected individuals with HIV-1 RNA levels between 1,000 and 100,000 copies/mL and cluster of differentiation 4 (CD4)>350 cells/mm3; Arm 3a; Group I; 1 dosing group: HIV-infected and suppressed individuals
89117295|NCT03875209|Experimental|Arm 4: 10E8.4/iMab SC HIV-|Arm 4; Groups J and K: HIV-uninfected individuals
89117296|NCT05325541|Experimental|Arms 1|Game-Based Rehabilitation received total 24 sessions, 45-50 minutes/session, 3 times/week for total 8 weeks.
89117297|NCT05325541|Placebo Comparator|Arms 2|Conventional Rehabilitation received total 24 sessions, 45-50 minutes/session, 3 times/week for total 8 weeks.
89117298|NCT03837379|Other|Treatment As Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
89117299|NCT03837379|Experimental|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
89117300|NCT00617877|Experimental|1|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
89117301|NCT04076215|Experimental|Pariticapnts with PTSD|
89117302|NCT04076215|Experimental|Pariticapnts without PTSD (controls)|
89117303|NCT00617955||Surgical|Cardiac surgery patients that received Aprotinin or Amicar
89117304|NCT05324007|Experimental|White-White|"Infants will first view 4 familiarization trials, in which the two adults each take turns waving and saying a short sentence. Each trial will last 10.5s. Which adult speaks first and which side she appears on will be counterbalanced. These familiarization trials will ensure infants encode each person separately. Then infants will watch 6 test trials (3 affiliation and 3 disengagement). The test trials will alternate, and the order will be counterbalanced across infants. In affiliation trials, the two adults will say hello and wave, whereas in the disengagement trials, the two adults will say hmph, and turn away from each other. Both affiliation and disengagement will have the same length (3s), with actors maintaining the same distance from each other throughout the video. The procedure will be identical for all arms except in White-White arm, the two adults infants see will be two White adults."
89232569|NCT04653961|Experimental|Intervention|Subject's glucose and insulin data will be transferred to the DreaMed Advisor Pro system. Optimization of insulin treatment plan will be done using the DreaMed Advisor Pro Decision Support System-MDI algorithm. During the feasibility segment an approval of the study physician (may override the suggestions for safety reasons) will be required prior to sending the recomendations to participants. During the Proof of Concept segment, the recomendations will be sent directly to participants. Participants will be asked to follow the tretment plan for the following 2.5 weeks.
89232570|NCT04647786|Experimental|Humidified and Augmented gas flows|
89232571|NCT04647786|Experimental|Humidified but not Augmented gas flows|
89232572|NCT04647786|Experimental|Not Humidified but Augmented gas flows|
89232573|NCT04647786|No Intervention|Neither humidified nor augmented gas flows|
89232574|NCT04647786|Experimental|Use of finalised device (SEA CtV) in final phase|
89232575|NCT04647786|No Intervention|Standard care (no SEA CtV)|
89232576|NCT04646473|Experimental|App only|Sweetgoals app only
89232577|NCT04646473|Experimental|App plus Incentives|SweetGoals app + incentives=yes + coaching=no
89232578|NCT04646473|Experimental|App plus Coaching|Sweetgoals app + incentives=no + coaching=yes
89232579|NCT04646473|Experimental|App plus Coaching plus Incentives|Sweetgoals app + incentives=yes + coaching=yes
89232580|NCT04644770|Experimental|Part 1: Dose Escalation|Participants will receive intravenous (IV) injection of JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
89232581|NCT04644770|Experimental|Part 2: Dose Expansion|Participants in one or more cohorts will receive intravenous (IV) injection of JNJ-69086420 at the RP2D(s) determined in Part 1.
89232582|NCT04644237|Experimental|Trastuzumab deruxtecan 6.4 mg/kg|Participants will be randomized to receive trastuzumab deruxtecan 6.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).
89232583|NCT04644237|Experimental|Trastuzumab deruxtecan 5.4 mg/kg|Participants will be randomized to receive trastuzumab deruxtecan 5.4 mg/kg administered by intravenous infusion every 3 weeks (Q3W).
89232584|NCT04642976||Atrial fibrillation ablation|All patients undergoing ablation with undergo pre-procedural CT as well as HFS mapping and ablation of GPs.
89232585|NCT04640623|Experimental|Cohort 1: TAR-200 and Cetrelimab|TAR-200 is placed into the bladder through a urinary placement catheter in participants with carcinoma in situ (CIS), with or without papillary disease, on Day 0 and will be dosed every 3 weeks (Q3W) for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2). In addition, Cetrelimab will be dosed Q3W through Week 78 (18 months).
89232586|NCT04640623|Experimental|Cohort 2: TAR-200|TAR-200 is placed into the bladder through a urinary placement catheter in participants with CIS, with or without papillary disease, on Day 0 and will be dosed Q3W for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2).
89232587|NCT04640623|Experimental|Cohort 3: Cetrelimab|Participants with CIS, with or without papillary disease, will receive Cetrelimab which will be dosed Q3W through Week 78 (18 months).
89232588|NCT04640623|Experimental|Cohort 4: TAR-200 (Participants with Papillary Disease only)|TAR-200 is placed into the bladder through a urinary placement catheter in participants with papillary disease only, on Day 0 and will be dosed Q3W for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Year 2).
89232589|NCT04634552|Experimental|Part 3: Cohort A (Talquetamab)|Cohort A will enroll participants with multiple myeloma who have previously received greater than or equal to (>=) 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
89232590|NCT04634552|Experimental|Part 3: Cohort B (Talquetamab)|Cohort B will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
89232591|NCT04634552|Experimental|Part 3: Cohort C (Talquetamab)|Cohort C will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
89232592|NCT04634552|Experimental|Part 3: Cohort D (Talquetamab)|Cohort D will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
89232593|NCT04633447|Experimental|Guselkumab|Participants will receive guselkumab subcutaneously (SC) every 4 weeks from Week 0 through Wweek 48. This will be in combination with a protocol specified 26-week GC taper. Participants of the long-term extension (LTE) period will continue to receive subcutaneous (SC) injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a Giant cell arteritis (GCA) flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
89232594|NCT04633447|Experimental|Placebo|Participants will receive matching placebo SC every 4 weeks from Week 0 through Week 48. This will be in combination with a protocol-specified 26-week GC taper. Participants of the LTE period will continue to receive SC injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a GCA flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
88816396|NCT02405442|Placebo Comparator|Placebo|Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
89117305|NCT05324007|Experimental|Black-Black|"The procedure is identical to the White-White arm except the two adults infants see will be two Black adults."
89117306|NCT05324007|Experimental|Black-White|"The procedure is identical to the White-White arm except the two adults infants see will be one White and one Black adult."
89117307|NCT02582437|Experimental|Chronic Opioid User|"The patients (ASA class I-III) who receive elective surgery s aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.~The Patients who use opioid medication daily and regularly immediately before the day of surgery for more than four weeks. The minimum criteria for opioid dose in the intervention goup is oral morphine 20mg per day: Morphine Equivalent Daily Dose(MEDD)"
89117308|NCT02582437|No Intervention|Opioid Naive patient|"The patients (ASA class I-III) who receive elective surgery aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.~The patients who do not use opioid medications immediately before the day of surgery for four weeks."
89117309|NCT00618033|Active Comparator|1|
89117310|NCT00618033|Active Comparator|2|
89117311|NCT04213131|Other|Rehabilitation control group|Routine rehabilitation treatment for chronic spinal cord injury and Intravenous injection of 100 mL 0.9% saline solution.
89117312|NCT04213131|Experimental|hUC-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUC-MSCs
89117313|NCT04213131|Experimental|hUC-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUC-MSCs and 5 mL of cerebrospinal fluid
89117314|NCT04213131|Experimental|hUC-MSCs local administration group|hUC-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUC-MSCs/point.
89117315|NCT04213131|Experimental|hUCB-MSCs intravenous administration group|intravenous administration of 100 mL of cell suspension containing 5×107 hUCB-MSCs
89117316|NCT04213131|Experimental|hUCB-MSCs lumbar administration group|lumbar administration of a solution prepared by 5 mL of cell suspension containing 5×107 hUCB-MSCs and 5 mL of cerebrospinal fluid
89117317|NCT04213131|Experimental|hUCB-MSCs local administration group|hUCB-MSCs (100,000 cells/μL) were injected via 4 points in the edge of injured spinal cord (2 points in the upper edge and 2 points in the lower edge), 16 μL hUCB-MSCs/point.
89117318|NCT05674201||Group DP|"Propofol (Dexmedetomidine (Sedadomide 200 µg/2 ml, KOÇAK FARMA Turkey)~1mcg/kg bolus was administered to Group DP in 10 minutes, then 0.2-1.4 mcg/kg/hour infusion dose was started.-®Lipuro 1%(10 mg/ml), B. Braun Indonesia ) 1mg/kg bolus was administered."
89117319|NCT05674201||Group RP|Propofol (Propofol-®Lipuro 1%(10 mg/ml), B. Braun Indonesia ) 1mg/kg bolus was administered, After a 0.25mcg/kg bolus of Remifentanil (Ultiva®, GlaxoSmithKline, Belgium) was administered to Group RP, a 0.025-0.1mcg/kg/minute infusion dose was started.
89117320|NCT01070303|Experimental|Adalimumab 40 mg every other week or every week|
89117321|NCT01009814|Experimental|BMS-663068 600 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 600 milligram (mg) and Ritonavir (RTV) 100 mg every 12 hours (Q12H) from Day 1 to Day 8.
89117322|NCT01009814|Experimental|BMS-663068 1200 mg QHS + RTV 100 mg QHS|All participants received BMS-663068 1200 mg and RTV 100 mg every night (quaque hora somni [QHS]) from Day 1 to Day 8.
89117323|NCT01009814|Experimental|BMS-663068 1200 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 1200 mg and RTV 100 mg Q12H from Day 1 to Day 8.
89117324|NCT01009814|Experimental|BMS-663068 1200 mg Q12H + RTV 100 mg QAM|All participants received BMS-663068 1200 mg Q12H and RTV 100 mg every 24 hours in the morning (quaque ante meridiem [QAM]) from Day 1 to Day 8.
89117325|NCT01009814|Experimental|BMS-663068 1200 mg Q12H|All participants received BMS-663068 1200 mg Q12H from Day 1 to Day 8.
89117326|NCT04212819|Experimental|Before erythrocyte suspension (ES) transfusion group|50 (Female/Male: 25/25) patients were included in this study. Total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients after diagnoses of anemia.
89117327|NCT04212819|Experimental|After erythrocyte suspension transfusion group|24 hours after ES transfusion, total antioxidant status (TAS), total oxidant status (TOS) and ADMA levels were measured from the patients.
89117328|NCT04212741|Experimental|A+ HA(tm)|20 ml oral solution of hyaluronic acid mixture in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
89117329|NCT04212741|Placebo Comparator|Placebo|20 ml oral solution without active ingredients in a bottle. Administration with 250~500 ml water under fasting condition in the morning.
89117330|NCT03824587|Experimental|Tenapanor 30 mg BID|"During the Double-Blind Treatment Period, subjects will receive tenapanor starting at a dose of 30 mg bid (three 10 mg tablets each time).~Investigators may decrease or increase the dose of study medication based on s-P levels and/or gastrointestinal (GI) tolerability in 10 mg increments to a minimum of 10 mg bid or a maximum of 30 mg bid at any time during the Double-Blind Treatment Period."
89117331|NCT03824587|Placebo Comparator|Placebo|same size, weight and appearance of experimental drug
89117332|NCT00773734|Experimental|Apremilast 10mg|Apremilast 10 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 10 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
89117333|NCT00773734|Experimental|Apremilast 20mg|Apremilast 20 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 20 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
89117334|NCT00773734|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
89117335|NCT00773734|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 16 weeks during the placebo-controlled phase.
89117336|NCT00773734|Experimental|Placebo/Apremilast 20 mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 20 mg apremilast BID during the 8 week active treatment phase
89117337|NCT00773734|Experimental|Placebo/Apremilast 30mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 30 mg apremilast BID during the 8 week active treatment phase
89117338|NCT04502888|Experimental|SL-172154|Intratumoral administration
89117339|NCT02871206|Experimental|Adjuvanted Influenza Vaccine|Fluad
89117340|NCT02871206|Active Comparator|Quadrivalent Influenza Vaccine|Fluzone
89117341|NCT04297202|Experimental|Apatinib Combined With SHR-1210 Injection|"SHR-1210 Injection: 3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle; Apatinib : D1-D21 : 250 mg, orally, qd; Before surgery, the patient's surgical pathology samples still need to be collected.~D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation;~After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. The cycle of a three-week plan will be performed with a total of 8 cycles with the treatment of Apatinib combination with SHR-1210 Injection."
89117342|NCT02582281|Experimental|Non touch technique|"the intrauterine device TCu 380A will be inserted in the conventional method as follows: First, insert the speculum and view the cervix. The position of the cervix will very often confirm if the uterus is anteverted or retroverted. Second, using the Allis forceps hold the back of a cotton-ball swab and dip it into a povidine-iodine disinfectant solution, or equivalent. Swab the cervix. Then cut the threads to the appropriate length and remove the speculum.~This technique omits the sounding of the uterus which is considered a quintessential procedure before IUD insertion for which there is no one established piece of evidence.The IUD is checked afterwards by transvaginal ultrasound."
89117343|NCT02582281|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
89117344|NCT02237469||Prone and supine simulation|Women with breast cancer receiving simulation in prone and in supine position for adjuvant radiation treatment.
89117345|NCT04297982|Experimental|Intervention group (Mandala activity)|Scales were applied to the experimental group in the first encounter with the adolescent (pre-test). Then, a total of two sessions of individual mandala activities were performed at least 48 hours apart. Each adolescent freely drawn and painted the unstructured mandala on white paper, starting from the center and expanding. The same scales were reapplied last (post-test).
89117346|NCT04297982|Other|Control group|Scales were applied to the control group with an interval of 5 days and received routine nursing care (pre-test, post-test).
89117347|NCT02691897|Experimental|Melatonin|Melatonin 3mg once daily at bedtime
89117348|NCT02691897|Placebo Comparator|Placebo|Placebo 1 tablet once daily at bedtime
89117349|NCT03067155|Experimental|Treatment group|The patients for which a suitable donor product can be obtained will be included in the treatment arm of the protocol. Treatment consists of the administration of CMV-specific T-cells, administered through intravenous transfusion. Depending on response in viral load and GVHD status, a second and/or third administration is possible.
89117350|NCT03067155|Active Comparator|Control group|Patients for which the investigator can't obtain a suitable donor product, will be included in the control group consisting of standard anti-viral treatment.
89117351|NCT04214223||PANE -> PAC|First, the patient carry out her Pre-Anesthesic Numerical Evaluation and then she benefits from her Pre-Anesthesic Consultation.
89117352|NCT04214223||PAC -> PANE|First, the patient benefits from her Pre-Anesthesic Consultation and then, she carry out her Pre-Anesthesic Numerical Evaluation
89117353|NCT01009580|Experimental|IDegAsp BID|
89117354|NCT01009580|Experimental|BIAsp 30 BID|
89117355|NCT04101604||Patients with VKH, BD, DR, AMD, or PCV|Collection of blood samples and clinical information from patients with VKH, BD, DR, AMD, or PCV
89117356|NCT04101604||Healthy subjects|Collection of blood samples and clinical information
89117357|NCT04212897|Experimental|Music Therapy|This group will be asked to practice a rhythmic auditory SFT intervention task at home.
89117358|NCT04212897|No Intervention|No Music Therapy|This group will not engage in an intervention task at home and will be asked to continue their normal daily routine.
89117359|NCT01009346|Experimental|RAD001|Daily RAD001 in combination with weekly cetuximab and cisplatin/ carboplatin on Day 1, 8 of each 28 day cycle.
89117360|NCT05323305|Active Comparator|Pectointercostal Group (n=30)|They will receive ultrasound-guided pectointercostal fascial block after induction of anesthesia with equal dose before extubation in the intensive care.
89117361|NCT05323305|Active Comparator|Transversus thoracic Group (n=30)|They will receive ultrasound-guided ultrasound-guided transversus thoracic plane block after induction of anesthesia with equal dose before extubation in the intensive care.
89117362|NCT04103164|Experimental|Cutera® excel V laser arm|After the PWS is be divided into five equal portions, four of those portions treated once with a different laser fluence using the multiple-pass approach (2 J/cm² vs 4 J/cm² vs 6 J/cm² vs 8 J/cm²), and one of the portions treated with single-pass approach at 8 J/cm²
89117363|NCT04212975|Experimental|group 1|lavage by dextrose
89117364|NCT05323227||Group 1|Patients with Lp(a) <60mg/dL
89117365|NCT05323227||Group 2|Patients with Lp(a) ≥60 mg/dL
89117366|NCT04101682|Active Comparator|Single Shot|Patients will receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine
89117367|NCT04101682|Active Comparator|Continuous Block|Patients will have a catheter inserted into the adductor canal which will be attached up to a continuous infusion pump of bupivacaine that will have a set flow rate over the next couple days
89117368|NCT01001702|Experimental|Oral Aripiprazole|Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
89117369|NCT05322915|Experimental|dance group|The dance group, each patient received a goal-oriented line dancing program.
89117370|NCT05322915|No Intervention|control|The control group did not receive any treatment program during this period.
89117371|NCT02602210|Active Comparator|group A|Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)
89117372|NCT02602210|Placebo Comparator|group B|Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)
89117373|NCT04294394||rhomboid block|With a 6-13 Mhz linear USG probe, at the thoracal level of 6-7 vertebra in the sagittal position, in the cranio-caudal direction with a 22 G and 100 mm block needle in the medial of the scapula, after entering the facial plane between the rhomboid muscle and the intercostal muscle, 0.25% bupivacaine 20 ml of the local anesthetic solution will be given.
88816397|NCT01189136|Sham Comparator|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
89117374|NCT04294394||erector spinae group|After the patient is taken in the lateral position, the probe T5 is 3 cm lateral to the spinous process, 22 G and 100 mm block needle with 6-13 Mhz linear ultrasonography and the facial plane between the transverse proces and the erector spina muscle is entered, and 20 ml of a local anesthetic solution consisting of 0.25% bupivacaine will be given.
89117375|NCT04294394||control group|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
89117376|NCT02601898|Experimental|Lipoic acid|vaginal capsules of lipoic acid (10 mg, one capsule per day)
89117377|NCT02601898|Active Comparator|Progesterone|Vaginal soft gel of progesterone (200 mg, two capsules per day)
89117378|NCT01070069|Active Comparator|Standard EVAR (IntuiTrak)|EVAR using standard vascular exposure for access
89117379|NCT01070069|Experimental|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
89117380|NCT01070069|Experimental|PEVAR (ProstarXL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
89117381|NCT00618423|Placebo Comparator|Physiologic saline|
89117382|NCT00618423|Active Comparator|Ketamine|
89117383|NCT04296032|Experimental|virtual reality group|Standard treatment 30 minutes plus virtual reality game 30 minutes, twice a week for 9 weeks.
89117384|NCT04296032|Active Comparator|standard treatment group|Standard treatment 60 minutes, twice a week for 9 weeks.
89117385|NCT04101760|Experimental|Study group|Patients in study group accept prophylactic treatment of long-acting granulocyte colony stimulating factor
89117386|NCT04101760|Active Comparator|Control group|Patients in control group accept regular or prophylactic treatment of short-acting granulocyte colony stimulating factor according to current guidelines
89117387|NCT00616551|Experimental|A|
89117388|NCT00616551|Active Comparator|B|
89117389|NCT04214145|Experimental|Phenylephrine|
88816398|NCT01189136|Experimental|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
88816399|NCT01189292|Active Comparator|Dexamethasone injection|Administration of 8mg(2ml) intravenous Dexamethasone (Mephameson®)
88816400|NCT01189292|Placebo Comparator|Placebo (NaCl 0.9%)|
89117390|NCT04214145|Experimental|Norepinephrine|
89117391|NCT04214145|Experimental|Vasopressin|
89117392|NCT04103008||Group A|single coronary artery lesion
89117393|NCT04103008||Group B|multiple coronary artery lesions
89232595|NCT04630145|Experimental|Group A: Bedaquiline (BDQ) + Clarithromycin (CAM) + Ethambutol (EB)|Participants will receive BDQ 400 milligrams (mg) (4*100 mg tablets) once daily (qd) from Week 1-2 (loading phase), BDQ 200 mg (2*100mg tablets) bi-weekly (biw) from Week 3 to 48 (maintenance phase) and CAM 400 mg or 500 mg twice daily (2*200 mg tablets) along with EB 500-750 mg or 15 mg/kg once a day or maximum daily dose of 1.0 gram for up to Week 48.
89117394|NCT04295954|Experimental|Yoga Intervention|"This group will receive the Yoga Intervention for dysmenorrhea that will consist of 3 yoga sessions a week of 30 minutes each, for 12 weeks. The first 4 weeks 1 of the sessions will be face to face and the other 2 home sessions guided by a vieo and a brochure, and tutored from the virtual platform by the yoga teacher and researchers. This space will also serve for participants to share experiences.~After the first 4 weeks, participants will continue with the virtually tutored home yoga program, consisting of 3 weekly sessions of 30 minutes until completing the 12 weeks. They will be protected in all cases by the teacher and researchers.~All intervention group participants will be invited to participate in online focus groups during week 12 to explore their experiences and satisfaction with the progress of the study and to implement adaptations, if necessary.~They will be evaluated before the start of the yoga program per month, 3 months, 6 months and a year after the intervention."
89117395|NCT04295954|No Intervention|Control group without intervention|Participants in the comparison group without intervention will not receive yoga intervention, will follow their conventional treatment and their usual daily activities. They will be told not to do yoga. They will be evaluated in advance, per a month, 3 months, 6 months and a year after the intervention.
89117396|NCT04212429|Active Comparator|Levofloxacin -1 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89117397|NCT04212429|Active Comparator|Levofloxacin-2 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89117398|NCT04212429|Active Comparator|Levofloxacin-4 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89117399|NCT04212429|Active Comparator|Levofloxacin-6 hour group|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 6-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89117400|NCT04212429|Active Comparator|Moxifloxacin-1 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 1-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89117401|NCT04212429|Active Comparator|Moxifloxacin-2 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 2-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89117402|NCT04212429|Active Comparator|Moxifloxacin-4 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 4-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89117403|NCT04212429|Active Comparator|Moxifloxacin-6 hour group|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily (8am, 12pm, 4pm, 8pm) for 3 days prior to the surgery. On the day of surgery, there will be 8-hour gap between last drop of study medication and the time of aqueous and vitreous humor sample collection.
89117404|NCT01068665|Experimental|IDeg 200 U/mL OD|
89117405|NCT01068665|Active Comparator|IGlar OD|
89117406|NCT01001390|Other|Group One|Group one will take a six minute walk test with AFO device, and after a rest of fifteen minutes, they will take another six minute walk test without AFO, with similar speed to the previous test.
89117407|NCT01001390|Other|Group Two|Group two will take a six minute walk test without AFO device, and after a rest of fifteen minutes, they will take another six minute walk test with AFO, with similar speed to the previous test.
89117408|NCT05322759|Active Comparator|Aquatic exercises|this group receives sessions for consecutive 8 weeks and 3 days per week. warm up for 10 min, that will include walking in shallow water and stretchings of upper and lower extremities. After that APE for 30 min followed cool down period for 5 min. exercise frequency is 3 sets of each exercise with 15 repetitions.
89117409|NCT05322759|Experimental|Halliwick exercise programme|this group receives sessions for consecutive 8 weeks and 3 days per week. warm up for 10 min that specifically includes mental adjustments along with walking in shallow side of pool and static stretchings. After that Halliwick exercise programme for 30 min that followed by cool down period for 5 min. exercise frequency is 3 sets of each exercise with 15 repetitions.
89117410|NCT04294316|Other|Sonovue group|ICU patients with successful resuscitation after out-hospital or in-hospital cardiorespiratory arrest who are eligible for enhanced-contrast brain ultrasound, extracranial echo-color duplex, and ocular ultrasound.
89117411|NCT04212507||1|50 psoriatic patients
89117412|NCT04212507||2|30 age and sex-matched healthy volunteers as a control group
89117413|NCT02870426||Group 1A:|Donors after brainstem death (DBDs) undergoing solid organ donation
89117414|NCT02870426||Group 1B:|Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
89117415|NCT02870426||Group 2:|Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure. The OB of the concomitant severed ON would be donated.
89117416|NCT00772954|Placebo Comparator|Placebo vaccine group|Participants scheduled to receive a dose of placebo vaccine on Day 0, Day 28, and Day 56, respectively.
89117417|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 1|Participants scheduled to receive a dose of 50 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
89117418|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 2|Participants scheduled to receive a dose of 100 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
89117419|NCT05322681|Experimental|Pregabalin|Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
89117420|NCT05322681|No Intervention|Active Comparator|Active Comparator group will take no medicine
89117421|NCT04295876|No Intervention|Standard of Care|Women assigned to the control arm will receive self-directed (non-PN supported) treatment as usual at the HIV care service provider of choice following the Ryan White standard of care (i.e., referrals to physical, dental and mental health services; case management; and ancillary services. Annual assessments (e.g., updates on insurance, housing, referrals needed, behavioral assessment [e.g., depression, substance use]) are conducted by a case manager. For women who have fallen out of care and re-engage care, case management begins with an interview and assessment of current needs. Goals are set to create an individual care plan related to medical care, housing, and other resources, as needed. Referrals are made to appropriate services (e.g., primary care, housing, benefits counseling, food, support services) based on the intake assessment.
89117422|NCT04295876|Experimental|BRIDGES Arm|Women assigned to The BRIDGES Project intervention arm will be connected with and receive Ryan White HIV/AIDS Program services (see above as described under Control Arm), as well as receive Peer Navigation support via one-on-one sessions, phone/text-based check-ins, and 6 unique syndemic-responsive 120 -minute group sessions designed to build coping skills (3 sessions) and assertive communication and behavior (3 sessions).
89117423|NCT05322603|Experimental|the first group: a fixed combination of Orphenadrine and Diclofenac|dynamics of points 100 mm visual-analog scale,minute inspiratory lung volume
89117424|NCT05322603|Experimental|the second group: patient-controlled analgesia (РСА) with Morphine|dynamics of points 100 mm visual-analog scale,minute inspiratory lung volume
89117425|NCT05508256|Active Comparator|Catheter Ablation|Symptomatic HFmrEF or HFpEF patients with AF that meet I/E criteria will be randomized 1:1 to receive either CA or usual medical care without the aim of CA. Patients assigned to rhythm control group will be treated with catheter ablation as first line therapy to restore and maintain sinus rhythm, additionally to the therapeutic recommendations of the current ESC guidelines for the management of atrial fibrillation (AF) and the current ESC Heart Failure (HF) guidelines.
89117426|NCT05508256|No Intervention|Usual Medical Care|Symptomatic HFmrEF or HFpEF patients with AF that meet I/E criteria will be randomized 1:1 to receive either CA or usual medical care without the aim of CA. Subjects randomized to usual care will be treated according to current ESC guidelines for the management of AF and current ESC HF guidelines. Usual care of AF in the context of CABA-HFPEF consists of an initial treatment limited to rate control in addition to adequate antithrombotic therapy, typically oral anticoagulation.
89117427|NCT04214301|Experimental|BLI800|BLI800
89117428|NCT00618579|Experimental|LMWH arm - active LMWH|
89117429|NCT00618579|Placebo Comparator|LMWH arm - placebo|
89117430|NCT00618579|Experimental|Warfarin arm - active warfarin|
89117431|NCT00618579|Other|Warfarin arm - control|
89117432|NCT04101448||Group A|COPD patients with bronchiectasis
89117433|NCT04101448||Group B|COPD patients without bronchiectasis
89117434|NCT04214457||Myometrial tumor with suspected leiomyosarcoma|Women between 18 and 75 years of age diagnosed with a myometrial tumor (probably leiomyoma) with suspected leiomyosarcoma
89117435|NCT00781768|Placebo Comparator|Standard PO (Zofran + Dexamethasone)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion.
89117436|NCT00781768|Active Comparator|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
89117437|NCT01005680|Experimental|Pemetrexed plus Cisplatin|
89117438|NCT01005680|Active Comparator|Gemcitabine plus Cisplatin|
89117439|NCT04214379|Other|severe congenital ptosis|Patients with severe congenital ptosis with poor levator muscle function
89117440|NCT04101370|Experimental|Bosentan|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
89117441|NCT04101370|Active Comparator|Tracleer®|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
89117442|NCT04101214|Experimental|Dry needling|One session of dry needling technique will be applied by a physiotherapist specialized in the technique. Dry needling technique will be performed in the muscle of the lower limb whose MMAS score is >1 by locating a sensitive point within a taut band. After that, a thin needle (0,32x40mm) is introduced directly into those muscle that present spasticity, decide by the clinician expert.
89117443|NCT04101214|Sham Comparator|Sham Dry needling|A physiotherapist specialized in dry needling technique will use a sham needle in order to simulate the active intervention. Sham acupuncture uses non-penetrating needles.The palpation and evaluation of the spastic muscle will be exactly the same that in the active group.
89117444|NCT04188249||RA patients|"Patients (or a representative) must provide informed consent before any procedures occur.~Main Inclusion Criteria:~18 years and older~Fulfil the ACR/EULAR classification criteria for RA in 2010~Patients able to understand and complete self-evaluation questionnaires.~General Exclusion Criteria:~Contraindications for golimumab~Prior exposure to TNFi/JAKi"
89117445|NCT01005602|Experimental|Digoxin Dosing per Nomogram|Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
89117446|NCT01005602|Other|Standard Digoxin Dosing|This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.
89117447|NCT00916318|Experimental|A: experimental|"(A) internet based information and communication tool Sundabarn.se("
89117448|NCT00916318|Experimental|(B): experimental|(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A
89117449|NCT00916318|Experimental|(c): experimental|(C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A
89117450|NCT00916318|Active Comparator|(D): control group|
89117451|NCT02601742|Active Comparator|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
89117452|NCT02601742|Placebo Comparator|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
89117453|NCT01068509|Experimental|Non-randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs. The 6-8 injections contained ~ 60 × 10^6 dendritic cells. Following evaluation after the first dose, participants received additional injections as described for the randomized Cvac group below.
89117454|NCT01068509|Experimental|Randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs every 4 weeks for 24 weeks (7 doses at Weeks 8, 12, 16, 20, 24, 28, and 32), and then every 8 weeks for 24 weeks (3 doses at Weeks 40, 48, and 56). The 6-8 injections contained ~ 60 × 10^6 dendritic cells.
89117455|NCT01068509|No Intervention|Observational standard of care|Participants in this group did not receive any treatment during the study.
89117456|NCT01009034||12 male HIV-positive patients|Male HIV-positive patients who have been receiving stable antiretroviral therapy that includes maraviroc for a minimum of three months.
89117457|NCT04212663|Placebo Comparator|control|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release
89117458|NCT04212663|Experimental|experiment|receive the procure of Anterior tibial tendon transfer(TATT) + Achilles tendon lengthing + fascial release+ The tendon release of musculi tibialis posterior
89117459|NCT05490940|No Intervention|Microsurgical end-to-end neurorrhaphy alone|This group of patients receives a simple, tension-free, end-to-end microsurgical neurorrhaphy alone (without fibrin glue)
89117460|NCT05490940|Experimental|Microsurgical end-to-end neurorrhaphy in combination with an enwrapping with fibrin sealant Tisseel®|This group of patients receives a simple, tension-free, end-to-end microsurgical neurorrhaphy in combination with an enwrapping with fibrin sealant Tisseel®.
89117461|NCT04304261|Experimental|Dapagliflozin|12 weeks of Dapagliflozin(10mg/day) treatment, randomly
89117462|NCT04304261|Experimental|Metformin|12 weeks of Metformin (1500-2000mg/day) treatment, randomly
89117463|NCT04212585||children with upper gastrointestinal symptoms|
89117464|NCT04212585||children without upper gastrointestinal symptoms|
89117465|NCT05345821||primary augmentation group|Women undergoing primary breast augmentation with Silimed® smooth surface Breast Implant.
89117466|NCT05345821||secondary (revision) augmentation group|Women undergoing secundary or revision breast augmentation with Silimed® smooth surface Breast Implant.
89117467|NCT02874911|Experimental|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
89117468|NCT00618735|Experimental|1|Subjects in Schedule A will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (Beginning at midnight).
89117469|NCT00618735|Experimental|2|Subjects in Schedule B will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (beginning at midnight). The second dose will be taken, following at least a 2-hour fast, 12 hours (+/- 2 hours) after the first dose, except on Day 1 of Cycle 1 and Day 1 of Cycle 2.
89117470|NCT02580721|Active Comparator|Thick mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
89117471|NCT02580721|Experimental|Thin mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
89117472|NCT02580721|Experimental|Thickened mucosa with connective tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Soft tissue augmentation will be performed with sub epithelial connective tissue graft.
89117473|NCT02580721|Experimental|Thickened mucosa with ADM|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Acellular dermal matrix, thick 1 x 4 cm will be used for vertical soft tissue augmentation.
89117474|NCT02037945|Experimental|pts with brain mets going for surgery|"This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection. Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively. Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects. The patients who have a positive 18F-FCH PET study (in which there is visible focal hot spots (a focus of lesion/normal white matter ratio >1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery. The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue."
89117475|NCT00768430|Experimental|1|Ketamine
89117476|NCT00768430|Active Comparator|2|Midazolam
89117477|NCT04211883|Experimental|Active intervention|Participants will come to the Project Active clinic and be asked questions about their health history, assist in their health goals, medications will be adjusted, lab work and screening tests will be ordered. At end of each visit, current health recommendations and goals as well as previous health changes will be given after each visit.
89117478|NCT04211883|No Intervention|Standard Clinical Treatment|Participants will continue with their usual clinic care.
89117479|NCT04212195||Part 1|Genetic determinants (n=500)
89117480|NCT04212195||Part 2|Biomarker discovery (n=40)
89117481|NCT04101136|Active Comparator|Atorvastatin 20 mg|Study pharmacist will make code (A and B) for atorvastatin and placebo, then save the code in safe place. Pharmacist will record each subject as participant received A or B intervention.
89117482|NCT04101136|Placebo Comparator|Placebo 20 mg|The placebo tablets will be prepared by Cipto Mangunkusumo hospital pharmacist, were composed of starch and were similar to atorvastatin tablets in size, shape, and colour.
89117483|NCT00618969|Experimental|Haploidentical allogeneic PBSC transp|Non-myeloablative preparative regimen (reduced-intensity) of busulfan, melphalan and alemtuzumab followed by a haploidentical-related peripheral blood stem cell transplant.
89117484|NCT00619047||Observation|
89117485|NCT01064297||Women exposed to lamotrigine during pregnancy|
89117486|NCT00619125||A|20 patients with IBS C
89117487|NCT00619125||D|20 Subjects without IBS
89117488|NCT00619125||B|20 patients with IBS D
89117489|NCT00619125||C|20 patients with IBS M
89117490|NCT01939665|Experimental|Irreversible electroporation|Single arm study: Percutaneous irreversible electroporation of locally advanced pancreatic carcinoma
89117491|NCT00781456|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
89117492|NCT00781456|Placebo Comparator|Placebo|Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
89117493|NCT04984447|Experimental|Feasibility of TNIB catheter|The feasibility of using the TNIB catheter to obtain microscopic images of the intestine. Healthy adult volunteers, and healthy pregnant women in their 2nd trimester of pregnancy will be enrolled, and their upper gastrointestinal tract will be imaged by the TNIB device
89117494|NCT00627263|No Intervention|1|Participants will receive the usual cardiologic care for ICD patients provided by their medical team.
89117495|NCT00627263|Experimental|2|In addition to the usual cardiologic care for ICD patients provided by the participants medical team, those randomized to Intervention will receive the stress reduction treatment (SRT) program (see below).
89117496|NCT02580175|Active Comparator|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation
89117497|NCT02580175|Active Comparator|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
89117498|NCT02874521|Experimental|Intra-dialytic LF-EMS|Performed twice weekly whilst seated on a standard dialysis chair. Delivered by adhesive electrodes in a neoprene garment, applied bilaterally to the quadriceps and hamstrings. Cardiovascular stimulus via rapid, rhythmical, sub-tetanic contractions. Short bursts of four pulses repeatedly delivered by stimulator at a frequency of 4Hz. Current amplitude adjustable from 40 - 200 mA with inbuilt controller. Conducted for one hour at the maximum tolerable intensity. Five minute warm-up and cool down at a lower frequency (3 Hz).
89117499|NCT02874521|Experimental|Intra-dialytic cycle training|Semi-recumbent cycling performed twice weekly whilst seated on a standard dialysis chair. Performed for up to one hour per session, initially at a workload (Watts) equivalent to that achieved at 40-60% VO2 reserve during cardiopulmonary exercise test. Exercise intensity regulated using a combination of heart rate and rating of perceived exertion (12-14). Workload adjusted weekly and controlled with a combination of pedal resistance and cadence to provide a personalised exercise prescription. Five minute warm-up and cool down each session.
89117500|NCT02874521|No Intervention|Usual care|Continuation of dialysis treatment without the addition of an intra-dialytic exercise intervention.
89117501|NCT03798223|Experimental|180/low|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
89117502|NCT03798223|Experimental|180/high|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
89117503|NCT03798223|Experimental|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
89117504|NCT03798223|Experimental|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
89117505|NCT04205825|Experimental|New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
89117506|NCT04205825|No Intervention|Habitual Practice|Patients randomized in this arm they will receive the habitual practice.
89117507|NCT04028089|Experimental|Diet Modification Group|
89117508|NCT04028089|Other|Regular Diet Group|
89117509|NCT05674123|Experimental|Device Feasibility (Flex Robotic System)|Patients undergo resection with Flex Robotic System on study. Patients also undergo colonoscopy with or without rectal endoscopic ultrasound at screening.
89117510|NCT00626873|Experimental|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
89117511|NCT02579941|Experimental|Pregnant women at term, vaginal childbirth|
89117512|NCT02579941|Experimental|Pregnant women at term, cesarean delivery|
89117513|NCT02579941|Experimental|Female volunteers, age 18 to 40|
89117514|NCT02874209|Experimental|Patient with amyotrophic lateral sclerosis|ALS patients with, spinal and bulbar form, certain or probable diagnosis according to the revised El Escorial criteria will go through the MRI sodium
89117515|NCT02874209|Placebo Comparator|Healthy volunteer|Healthy Volonteer apparied for sexe and age with selected ALS patients will go through the MRI sodium
89232596|NCT04630145|Active Comparator|Group B: Rifampicin (RFP) or Rifabutin (RBT) + CAM + EB|Participants will receive maximum of 4 capsules of RFP 450 mg daily (or maximum daily dose of 600 mg), CAM 400 mg or 500 mg (2*200 mg tablets) twice a day along with EB 500-750 mg daily or 15 mg/kg once a day or maximum daily dose of 1.0 gram for up to Week 48, followed by 2 capsules of RBT 300 mg or 150 mg once a day.
89232597|NCT04630028|Experimental|Induction Period (I): Ustekinumab|All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
89232598|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 8 Week (q8w)|Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
89232599|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 12 Week (q12w)|Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
89232600|NCT04628767|Experimental|Arm A (durvalumab, chemotherapy)|Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.
89232601|NCT04628767|Active Comparator|Arm B (chemotherapy)|Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.
89232602|NCT04628767|Experimental|Arm C (durvalumab, gemcitabine hydrochloride)|Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial.
89232603|NCT04619420|Experimental|JNJ-63733657 Low-dose|Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks.
89232604|NCT04619420|Experimental|JNJ-63733657 High-dose|Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks.
89232605|NCT04619420|Placebo Comparator|Placebo|Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks.
89232606|NCT04619251|Experimental|SRD part: PM Subjects, BI1323495 10mg|Participants were administered on Day 1 a single oral dose of 10 milligram (mg) of BI 1323495 film-coated tablet together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
89232607|NCT04619251|Experimental|SRD part: PM Subjects, BI1323495 30mg|"Participants were administered on Day 1 a single oral dose of 30 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration.~One authorized employee of the trial site was witness of the administration of the trial medication."
89232608|NCT04619251|Experimental|SRD part: PM Subjects, BI1323495 100mg|Participants were administered on Day 1 a single oral dose of 100 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
89232609|NCT04619251|Experimental|SRD part: EM Subjects, BI1323495 30mg|Participants were administered on Day 1 a single oral dose of 30 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
89232610|NCT04619251|Experimental|SRD part: EM Subjects, BI1323495 70mg|Participants were administered on Day 1 a single oral dose of 70 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
89232611|NCT04619251|Experimental|SRD part: EM Subjects, BI1323495 150mg|Participants were administered on Day 1 a single oral dose of 150 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication.
89232612|NCT04619251|Placebo Comparator|SRD part: Placebo|"This arm comprises all placebo treated participants in trial part SRD, regardless of the dose group in which they were treated. Participants were randomized within each dose group in a 3:1 ratio (test treatment to placebo).~Participants were administered on Day 1 a single oral dose of placebo film-coated tablet(s) together with about 240 milliliter (mL) of water. A standardized meal was served 30 minutes (min) before drug administration. One authorized employee of the trial site was witness of the administration of the trial medication."
89232613|NCT04619251|Experimental|MD part: PM Subjects, BI1323495 30mg BID|Participants were administered from Day 1 to Day 10 two times per day (bid) an oral dose of 30 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water, At Day 11 participants were administered only a single dose in the morning. Participants took a normal caloric meal 30 minutes (min) before drug administration. Subjects fasted for 4 hours (h) after intake of morning dose. Morning and evening dose were taken with a 12 h time interval approximately at the same time each day during the treatment phase. One authorized employee of the trial site was witness of the administration of the trial medication.
89232614|NCT04619251|Experimental|MD part: PM Subjects, BI1323495 60mg QD|Participants were administered from Day 1 to Day 11 one time per day (qd) an oral dose of 60 milligram (mg) of BI 1323495 film-coated tablets together with about 240 milliliter (mL) of water. Participants took a normal caloric meal 30 minutes (min) before drug administration. Subjects fasted for 4 hours (h) after intake of morning dose. One authorized employee of the trial site was witness of the administration of the trial medication.
89232615|NCT04619251|Placebo Comparator|MD part: Placebo|This arm comprises all placebo treated participants in trial part MD, regardless of the dose group in which they were treated. Participants were randomized within each dose group in a 3:1 ratio (test treatment to placebo). Participants were administered from Day 1 to Day 11 one time per day (qd) an oral dose of placebo film-coated tablets or two times per day (bid) an oral dose of placebo together with about 240 milliliter (mL) of water. Participants took a normal caloric meal 30 minutes (min) before drug administration. Subjects fasted for 4 hours (h) after intake of morning dose. One authorized employee of the trial site was witness of the administration of the trial medication.
89232616|NCT04619251|Experimental|DDI part: PM Subjects, BI1323495 / BI1323495+ Itraconazole|"Period 1: Participants were administered the reference treatment (R) which consisted of a single oral dose of 10 milligram (mg) film-coated tablet of BI 1323495 together with about 240 milliliter (mL) of water on Day 1 of Period 1. One authorized employee of the trial site was witness of the administration of the trial medication.~Period 2: Participants were administered the test treatment (T) which consisted of a single oral dose of 10 milligram (mg) film-coated tablet of BI 1323495 with about 240 milliliter (mL) of water on Day 1 of Period 2, together with multiple oral doses of 200 mg itraconazole from Day -3 to Day 7, in total 10 doses, as oral solution formulation. One authorized employee of the trial site was witness of the administration of the trial medication.~Administration of BI 1323495 in treatment R and T were separated by at least 11 days."
89232617|NCT04614428|No Intervention|Standard Care Group|Participants will receive the standard care provided by their institution.
89232618|NCT04614428|Active Comparator|RESILIENCE Program group|Participants will receive the RESILIENCE Program on top of the standard care provided by their institution.
89232619|NCT04613674|Experimental|Arm A|
89232620|NCT04613674|Experimental|Arm B|
89117516|NCT04205591|Active Comparator|Autologous cortical plate|Thin autologous cortical plates that allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
89117517|NCT04205591|Experimental|Porcine cortical plate|Thin porcine cortical platesthat allow to made a rigid and resistant framework that will be filled with autogenous bone chips bone
89232621|NCT04609826|Experimental|Arm A: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until a recommended Phase 2 dose (RP2D) has been identified.
89232622|NCT04609826|Experimental|Arm B: JNJ-74856665 + Azacitidine (AZA)|Participants will receive JNJ-74856665 orally in combination with AZA administered intravenously (IV) or subcutaneously (SC) in a 28-day cycle.
89232623|NCT04609826|Experimental|Arm C: JNJ-74856665 + Venetoclax (VEN)|Participants will receive JNJ-74856665 orally in combination with VEN in a 28-day cycle.
89232624|NCT04609826|Experimental|Arm D: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. Participants with transfusion dependent relapsed/refractory Myelodysplastic Syndrome (MDS) will be included.
89232625|NCT04606381|Experimental|Part 1: Ami-LC-MD and Ami-LC|Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion.
89232626|NCT04606381|Experimental|Part 2: Ami-HC and Ami-HC-CF|Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or amivantamab co-formulated with rHuPH20 (Ami-HC-CF).
89232627|NCT04606381|Experimental|Part 3: Ami-HC-CF + Lazertinib and Ami-HC+ Lazertinib|Participants will receive SC infusion of either Ami-HC-CF or Ami-HC in combination with lazertinib tablet.
89232628|NCT04598919|Active Comparator|Saracatinab|saracatinib 125 mg once daily by mouth for 24 weeks
89232629|NCT04598919|Placebo Comparator|Placebo|matching placebo once daily by mouth for 24 weeks
89232630|NCT04598854|Experimental|Treatment group|The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.
89232631|NCT04598854|Sham Comparator|Control group|The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
89232632|NCT04592341|Experimental|Gantenerumab|Participants will receive gantenerumab by subcutaneous (SC) injection at a dose of 120 mg every 4 weeks (Q4W) for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg every 2 weeks (Q2W) for another 12 weeks, followed by the target dose 255 mg once weekly (Q1W) for up to Week 103. Participants who complete Week 104 visit will be given an option to take part in 2-year extension of the study to receive gantenerumab 255 mg Q1W for up to Week 207.
89232633|NCT04586426|Experimental|Part 1: Dose Escalation|Participants will receive tec+tal with or without daratumumab in 28-day cycles following initial step-up doses.
89232634|NCT04586426|Experimental|Part 2: Dose Expansion|Participants will receive treatment doses (combination of tal+tec and dara+tal+tec regimens) which will be determined by the recommended Phase 2 regimen (s) (RP2R[s]) of the study treatment identified in Part 1.
89232635|NCT04586426|Experimental|Part 3: Phase 2|Participants will receive teclistamab + talquetamab combination therapy, at the RP2R selected from Part 1 and Part 2.
89232636|NCT04577833|Experimental|Treatment Sequence ABD|Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
89117518|NCT04302701|Experimental|Dichoptic arm|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
89117519|NCT04302701|Active Comparator|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near. Adherence to the treatment protocol will be assessed by having the parent call / send a message to an investigator at the start and end of the occlusion sessions completed each day, thus making the most as accurate as possible assessment of the patient's adherence to the prescribed treatment
89117520|NCT00587158|Other|Immunosuppression without paricalcitol (control)|Subjects will receive the standard immunosuppressive therapies consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®).
89117521|NCT00587158|Active Comparator|Immunosuppression with paricalcitol|Subjects will receive the standard immunosuppressive therapy consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®). In addition, subjects will receive the study medication paricalcitol (Zemplar®).
89117522|NCT04303091|Experimental|Exercise group|Single-arm study. Participants enrolled engaged in a 12-week exercise program.
89117523|NCT00582907|Experimental|1|Treatment Arm A: Rilonacept (IL-1 Trap) at a dose of 2.2 mg/kg/wk (max 160 mg)given by subcutaneous injection for 3 months plus colchicine at a stable dose for those subjects already taking colchicine, or without colchicine for those intolerant or non-compliant with colchicine. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention
89117524|NCT00582907|Placebo Comparator|2|Treatment Arm B: Placebo given by subcutaneous injection weekly with or without colchicine for 3 months. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention.
89117525|NCT01062113|Experimental|Celecoxib 400mg|
89117526|NCT01062113|Experimental|Celecoxib 200mg|
89117527|NCT01062113|Placebo Comparator|Placebo|
89117528|NCT02875145||Keratoplasty with cataract surgery|Patients who underwent keratoplasty who also underwent a cataract surgery during follow up.
89117529|NCT02875145||Keratoplasty without cataract surgery|Patients who underwent keratoplasty who never underwent cataract surgery.
89117530|NCT00916396|Active Comparator|real drug|
89117531|NCT00916396|Placebo Comparator|placebo|
89117532|NCT04303871|Active Comparator|patients|pregnant female with hypertension admitted in ICUfor control of BP invasive assessment of BP by radial cannulation was compared against non-invasive assessment of BP by an automated oscillometric BP device (Mobil-O-Graph )
89117533|NCT04303871|Placebo Comparator|control|matched control females of the same age but not pregnant invasive compared to non-invasive measurement of BP by same technique
89117534|NCT00626951|Experimental|1|LMA Supreme
89117535|NCT00626951|Experimental|2|LMA ProSeal
89117536|NCT03925441||Pediatric participants with chronic severe plaque psoriasis|Participants with chronic severe plaque psoriasis receiving adalimumab in routine clinical practice
89117537|NCT04302389|Experimental|Lifestyle Modification Program|This 6-month intervention includes the use of three components: WW's mobile app, virtual workshops, and a private online community. The WW Program involves: self-monitoring of weight, dietary intake, and physical activity; making dietary changes; increasing physical activity; shifting to a more helpful mindset; and learning behavioral strategies to manage these goals. Each week, participants will set goals and weigh-in with a coach via virtual workshop. Participants will be encouraged to use the app and private online community daily and attend weekly virtual workshops. The weekly virtual workshop led by a trained WW Coach features a behavior change technique and enables the participant to practice it to support their goals. These are actionable techniques and strategies that are grounded in scientific research.
89117538|NCT00772330|Experimental|MIDI Arrow|Ab externo glaucoma drainage device with no reservoir
89117539|NCT04019587||Test of reliability and validity|
89117540|NCT04694885|No Intervention|Standard of Care|The control group will receive the standard of psycho-oncological care.
89117541|NCT04694885|Experimental|Standard of Care + Structured Hypnotherapy|The intervention group will receive the standard of psycho-oncological care plus 10 hypnotherapeutic sessions every two weeks.
89117542|NCT04075201|Experimental|Adults-Experimental group|One dose of investigational vaccine
89117543|NCT04075201|Experimental|Children-Experimental group|One dose of investigational vaccine
89117544|NCT04075201|Active Comparator|Children-Control group|One dose of control vaccine
89117545|NCT04075201|Experimental|Neonates-Experimenatal group|Three doses of investigational vaccine
89117546|NCT04075201|Active Comparator|Neonates-Control group|Three doses of control vaccine
89117547|NCT04304027|Experimental|Tailored exercise intervention|8 weeks of aerobic interval training at moderate intensity which is modified according to the levels of self-reported fatigue
89117548|NCT04304027|Active Comparator|Standard exercise intervention|8 weeks of aerobic interval training at a moderate intensity
89117549|NCT04304027|No Intervention|Usual care control|Participants in the usual care control group will continue to receive their standard care independent of this study
89117550|NCT01038869|Experimental|Azelaic acid 15% (Finacea)|Open label pilot study, Topical gel to be appiled twice daily for 16 weeks
89117551|NCT01038713|Experimental|Resectable; plastic stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a plastic biliary stent to relieve their biliary obstruction.
89117552|NCT01038713|Experimental|Resectable; uncovered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
89117553|NCT01038713|Experimental|Resectable; fully covered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
89117554|NCT01038713|Experimental|Unresectable; uncovered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
89117555|NCT01038713|Experimental|Unresectable; fully covered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
89117556|NCT00768040|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily for 12 weeks
89117557|NCT00768040|Placebo Comparator|Placebo|Matching placebo once daily for 12 weeks
89117558|NCT03771937|Experimental|Intervention|Intervention group received a telephone follow-up intervention, which consisted of a pre-discharge education program and three telephone follow-up sessions based on the RAM.
89117559|NCT03771937|No Intervention|Control group|the control group received routine care.
89117560|NCT04364191|Experimental|Intervention Arm|Meaningful activity protocol during the day and Assisted Relaxation Therapy (ART) at night; includes 1) Sleep Hygiene Education; 2) Meaningful Activity Modules a) Physical Activity b) Cognitive Activity and c) Social engagement; 3) ART, a breath-based relaxation intervention that is coupled with a physical anchoring task. Participants will complete a daily sleep diary, use the activity modules daily as pre-determined times personalized to the participant, use the ART software when they get in bed to help with insomnia symptoms, and wear an actiwatch for a four-week period. Participants will have weekly to biweekly phone consultation with the research nurse.
89117561|NCT04364191|Active Comparator|Control Arm|Study participants in the control group will also receive a tablet and watch, but the meaningful activity modules and ART software will not be accessible to them. The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education. This approach provides staff and technology interaction/attention that is comparable to the intervention arm, and thereby promotes adherence; it has been used as a placebo comparator for many insomnia treatment studies and has low attrition rates. Control subjects will also be asked to complete electronic sleep diaries and wear the actiwatch on the non-dominant wrist to monitor sleep/wake patterns. For both arms, participants will be asked to complete baseline assessments, 4-week (post-intervention) and 12-week (follow-up).
89117562|NCT05056051|Active Comparator|Post-EET Surveillance Group: WATS-3D samples followed by Forceps biopsies|Sampling will occur with WATS-3D followed by forceps biopsies. For each patient, resection samples will be identified by the endoscopy method used to locate the sample as either HD-WLE/NBI or WATS-3D. For each method of detection, the highest grade of histology for each patient will be assigned based on the identified samples. Dysplasia detected on random biopsies will be attributed HD-WLE/NBI given it is part of the standard of care.
89117563|NCT05056051|Active Comparator|Post-EET Surveillance Group: Forceps biopsies followed by WATS-3D samples|Sampling will occur with forceps biopsies followed by WATS-3D. For each patient, resection samples will be identified by the endoscopy method used to locate the sample as either HD-WLE/NBI or WATS-3D. For each method of detection, the highest grade of histology for each patient will be assigned based on the identified samples. Dysplasia detected on random biopsies will be attributed HD-WLE/NBI given it is part of the standard of care.
89117564|NCT03445663|Experimental|AMG 424|Comparison of different dosages of AMG 424
89117565|NCT02580643||APS Injection|Autologous Protein Solution
89117566|NCT02580331|Placebo Comparator|SRP and placebo|Oral prophylaxis followed by placement of placebo gel
89117567|NCT02580331|Active Comparator|SRP and 1% metformin|Oral prophylaxis followed by placement of 1% metformin gel
89117568|NCT04075357|No Intervention|Control|The patients underwent conventional CTS surgery
89117569|NCT04075357|Experimental|Experimental|The patients underwent conventional CTS surgery and transplantation of amniotic membrane
89117570|NCT05042167|Experimental|High-load resistance exercise|Subjects in high-load trial performed 3 sets per exercise, 8 repetitions with load of 70%-1RM with 90 sec of rest between sets, followed by a fourth set to voluntary failure.
89117571|NCT05042167|No Intervention|Sedentary control|Subjects in control trial stayed sedentary during the period.
89117572|NCT00767806|Experimental|Duloxetine|Participants received duloxetine 60 milligram by mouth once daily for 12 weeks of double-blind treatment
89117573|NCT00767806|Placebo Comparator|Placebo|Patients received placebo by mouth once daily for 12 weeks of double-blind treatment
89117574|NCT02580409|Other|Single-arm studies|Behavioral Intervention
89117575|NCT04074889|Active Comparator|Group A|Patients will be given Lactobacillus & Bifidobacterium containing probiotics [Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg], to be taken 1 sachet twice daily for 6 months.
89117576|NCT04074889|Placebo Comparator|Group B|Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 6 months.
89117577|NCT05674045|Experimental|EG017 3mg|
89117578|NCT05674045|Experimental|EG017 6mg|
89117579|NCT05674045|Experimental|EG017 9mg|
89117580|NCT05674045|Placebo Comparator|Placebo Comparator: matching placebo|
89117581|NCT02580253|Experimental|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
89117582|NCT02580253|Active Comparator|mFOLFOX6|Oxaliplatin (85 mg/m2 )+Fluorouracil (2800 mg/m2 ) q2w
89117583|NCT00780910|Experimental|MP-424|
89117584|NCT04099576|Experimental|Physiotherapy plus Education|The experimental group received a three-week program consisting of 15 sessions of physiotherapy and six sessions of therapeutic neuroscience education.
89117585|NCT04099576|Active Comparator|Control group|The control group received a three-week program consisting of 15 sessions of physiotherapy alone. .
89117586|NCT02582203|Active Comparator|Ceftaroline|600 mg IV (over 1 hour) every 12 hours for renal function > 50 mL/min, adjusted for renal function based on package insert for no more than 14 days.
89117587|NCT02582203|Active Comparator|Vancomycin|Dosed by institutional pharmacy protocol to reach goal trough level of 10 - 20 mg/L steady state concentration for no more than 14 days.
89117588|NCT03395275|Experimental|Intrathecal Pump Therapy Participants|Patients eligible for intrathecal pump therapy will undergo quantitative sensory tests and surveys during various stages of the treatment process.
89117589|NCT00767104|Experimental|Silk-Like Pillowcase|Silk- Like pillowcase-One-half of subjects will be assigned to sleep on the study product, which is a standard size pillowcase made of a silk-like fabric every night for 12 weeks. The study pillowcases are fabricated from a light-weight plain-weave fabric woven of 100 percent synthetic yarns. The fabric is comprised of approximately 50% polyester and 50% nylon. The yarns in the fabric are formed from continuous-filament fibers, with no fibers projecting beyond the planar surface of the fabric. The antimicrobial technology used in the fabric is incorporated into the fibers during the finishing process and does not migrate out of the fabric or cause adverse reactions with skin contact.
89117590|NCT00767104|Placebo Comparator|Cotton Pillowcase|Placebo Comparator-One-half of subjects will be assigned to sleep on the placebo pillow case every night for 12 weeks. Placebo pillowcase is made of 100% cotton
89117591|NCT04100980||Chronic UTI|Patients who have been diagnosed with chronic urinary tract infections (UTI).
89117592|NCT05035927|Experimental|Open Label Oral Psilocybin|
89117593|NCT04075045|No Intervention|"Group A. Standard Care (Control)"|Does not receive Wellth app.
89117594|NCT04075045|Experimental|"Group B. Wellth App (Treatment 1)"|Receives Wellth app without additional financial rewards tied to adherence.
89117595|NCT04075045|Experimental|"Group C. Wellth App (Treatment 2) with targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at local pharmacies for using the app to track adherence.
89117596|NCT04075045|Experimental|"Group D. Wellth App (Treatment 3) with non-targeted rewards"|Receives Wellth app with additional ability to earn up to $150 rewards usable at many stores for using the app to track adherence.
89117597|NCT03363373|Experimental|GM-CSF + Naxitamab|Each investigational cycle is started with 5 days of GM-CSF administered at 250 µg/m2/day in advance of the start of Naxitamab administration. GM-CSF is thereafter administered at 500 µg/m2/day on days 1 to 5. As standard treatment, Naxitamab is administered at 3 mg/kg/day on days 1, 3, and 5 totalling 9 mg/kg per cycle. Treatment cycles are repeated every 4 weeks until CR or PR followed by 5 additional cycles every 4 weeks (±1 week). Subsequent cycles are repeated every 8 weeks (±2 weeks) through 101 weeks from first infusion at the discretion of the investigator. After end of treatment patients will enter a long-term follow up for up to 3 years after end of treatment visit.
89117598|NCT00771472|Experimental|Vorinostat|
89117599|NCT00771316|Experimental|Group 1|MK0826 (ertapenem)
89117600|NCT00771316|Active Comparator|Group 2|meropenem
89117601|NCT02601664|Active Comparator|Combined Intervention|Combined intervention: pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
89117602|NCT02601664|Active Comparator|Conventional PCI|Conventional PCI
89117603|NCT04074577|Active Comparator|Standard Technique followed by Combination|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. The first colonoscopy will be performed without automated polyp detection software (standard technique) followed immediately by another colonoscopy with automated polyp detection software (combination technique).
89117604|NCT04074577|Active Comparator|Combination +followed by Standard Technique|Back-to-back tandem colonoscopies by the same endoscopist using an Olympus 190 colonoscope. In this arm, the first colonoscopy with be performed with automated polyp detection software (combination technique) followed immediately by another colonoscopy without automated polyp detection software (standard technique)
89117605|NCT03347227|Active Comparator|Pulmonary Vein Isolation|Wide area circumferential catheter ablation for pulmonary vein isolation
89117606|NCT03347227|Experimental|Pulmonary Vein Isolation and scar ablation|Wide area circumferential catheter ablation for pulmonary vein isolation and scar ablation
89117607|NCT02582047|Active Comparator|Influenza vaccination with PPV23|concomitant vaccination with trivalent inactivated influenza vaccine and 23-valent polysaccharide pneumococcal vaccine
89117608|NCT02582047|Active Comparator|Influenza vaccination with PCV13|concomitant vaccination with trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine
89117609|NCT06184893||General cohort|
89117610|NCT06184893||RAIDbio|Sub-cohort studying biomarkers: volatile organic compounds, induced sputum and blood biomarkers
89117611|NCT06184893||RAIDomix|Sub-cohort studying radiomic patterns (based on high resolution computed tomography of the chest)
89117612|NCT06184854|Active Comparator|2D LapPass Training Models|Participants in the 2D group practised laparoscopic skills using the 2D LapPass training models for polo manipulation and intracorporeal suturing
89117613|NCT06184854|Experimental|3D Training Models|Participants in 3D group practised laparoscopic skills using the 3D training models for polo manipulation and intracorporeal suturing
89117614|NCT06184841|Experimental|esophageal squamous cell carcinoma with liver metastasis|Patients with esophageal squamous cell carcinoma with liver metastasis have poor response to first-line treatment, especially those with advanced esophageal cancer with progression or recurrence in the liver.
89117615|NCT06184828|Experimental|Whole Blood Transfusion|Transfusion of whole blood units
89117616|NCT06184828|Active Comparator|Blood Component Transfusion|Transfusion of blood components units
89117617|NCT06184815|Experimental|Educational programme 12|The educational programme consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months. The multidisciplinary treatment consists of 4, each one every month, consultations of specialties of nutrition, endocinrology and psychology.
89117618|NCT06184815|Active Comparator|Standard|The standard educational program consists of outpatient management with diabetic education slides and material for the patient, with a duration of 4 months. Standard treatment consists of endocrinology consultation with nutrition and psychology referral if required
89117619|NCT06184802|Experimental|Experimental Group (EG)|"The group consists of 50 patients diagnosed with autism spectrum disorder, randomly assigned.~The patients underwent treatment as usual (TAU) integrated with the use of multisensory room, in a 1:1 ratio. All the exercises have been customized by the therapists according to the individual treatment needs, adapting the level of difficulty to the patient's abilities.~Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each."
89117620|NCT06184802|Active Comparator|Control Group (CG)|"The group consists of 50 patients diagnosed with autism spectrum disorder randomly assigned.~The patients underwent TAU, consisting in standard neuro-psychomotor training. The treatment was tailored according to each child's goals need and preferences.~Overall, each patient was treated over a period of 6 months, up to a total of n. 48 sessions, twice a week, lasting 45 minutes each."
89117621|NCT06184763||ELEXACAFTOR/TEZACAFTOR/ IVACAFTOR treated patients|"Patients ≥ 12 years old with cystic fibrosis followed at the Renee Sabran Hospital, heterozygous for the F508del mutation of the CFTR gene, treated with ELEXACAFTOR/ TEZACAFTOR/ IVACAFTOR.~Intervention: 6-minute walk test before and after starting treatment."
89117622|NCT06184724|Experimental|Post Implementation|"Participants will be recruited from two surgery clinics in the Post-Implementation group. They will receive care using an implementation package for CGA use before surgery.~The control group will be historic baseline data. That is, older surgical patients who were treated Pre-Implementation. These patients would have received standard, routine clinical care without the use of the implementation package."
89117623|NCT06184711|Experimental|Transcranial Magnetic Stimulation combined with the McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.
89117624|NCT06184711|Sham Comparator|Sham Transcranial Magnetic Stimulation combined with the McNeill Dysphagia Therapy programme|The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
89117625|NCT06184711|Experimental|Transcranial Magnetic Stimülation|Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
89117626|NCT06184698|Experimental|Experimental Group|liposomal irinotecan+5-FU/LV+ bevacizumab q2w
89117627|NCT06184685|Experimental|Sahasthara Microemulsion|The extract of Sahasthara remedy was obtained by maceration with 95% ethanol for 3 days. The marc was re-extracted using the same process two more times. After that, the extract was filtered, concentrated using a rotary evaporator at 40 degree C and vacuum (Rotavapor R-205, Buchi, Switzerland), to gave a yield of 10.3% w/w. Finally, SHT ethanolic extract was formulated into a microemulsion with 1% (w/w) of extract and was stored in 50 ml bottles.
89117628|NCT06184685|Experimental|Diclofenac Microemulsion|DF-ME, which consists of 2% diclofenac sodium, was compounded according to the published instructions by RS Therapeutics Inc. (Canada) and stored in the same containers as SHT-ME.
89117629|NCT06184646|No Intervention|Control (0 g prune/day)|Participants only receive 500 mg calcium and 400 IU vitamin D daily for 24 months.
89117630|NCT06184646|Experimental|30 g prune/day|Participants receive 500 mg calcium and 400 IU vitamin D daily for 24 months and 30 g of prune daily for 24 months.
89117631|NCT06184620||PACG group|All patients in the experimental group met the diagnostic criteria of primary angle-closure glaucoma in the Chinese Glaucoma Guidelines(2020).
88816401|NCT01189370|Experimental|Intra-Patient Dose Escalation: Sorafenib|All patients will receive a starting dose of sorafenib 400 mg by mouth twice daily. At four weeks, all patients who have not experienced Grade 3 or 4 toxicity will undergo dose escalation using a treatment schedule of days 1-5 days of each week. Doses will continue to be escalated every 4 weeks depending on tolerability and tumor response.
88816402|NCT04352504|Experimental|Almonds|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
88816403|NCT04352504|Active Comparator|Pretzels|Consume 2 oz. serving pretzels (216 calories) daily for 12 weeks
89117632|NCT06184620||control group|The depth of the anterior chamber is normal, and the whole corner of the chamber is open; The cup-to-plate ratio is less than 0.5; No family history of glaucoma
89117635|NCT06184555||colorectal cancer|colectomy
89117636|NCT06184516|Experimental|Reproductive organ sparing radical cystectomy|
89117637|NCT06184516|Active Comparator|Radical cystectomy|
89117638|NCT06184503||Paediatric patients with alpha-mannosidosis treated with Lamzede before 3 years of age|Paediatric patients with a confirmed diagnosis of alpha-mannosidosis with data for at least one pre- and one post-Lamzede treatment sample obtained when < 3 YOA.
89117639|NCT06184490|No Intervention|Usual prone position|Prone position with thoraco-abdominal support (cushions on the chest and hips, leaving the abdomen free)
89117640|NCT06184490|Experimental|Modified prone position|Prone position with lateral support (lateral cushions on the chest, hips and abdomen)
89117641|NCT06184464||prostate patient|use of Leupreline
89117642|NCT06184438|Experimental|Daflon group|Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day 0 to day 7.
89117643|NCT06184438|Placebo Comparator|Placebo group|Received placebo after surgery from day 0 to day 7.
89117644|NCT06184425|Active Comparator|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|
89117645|NCT06184425|Experimental|Dural Puncture Epidural technique using 27 G Whitacre needle|
89117646|NCT06184386||Prospective NIDCAPARENTALIM|A group of prospectively assigned preterm newborns that will be included in NIDCAP strengthened with a practice focalized on feeding, named PARENTALIM.
89117647|NCT06184386||Retrospective SOFS|A group of retrospectively assigned preterm newborns that had standardized orofacial stimulations named SOFS.
89117648|NCT06184360||Treatment-Experienced|
89117649|NCT06184360||Treatment-Naive|
89117650|NCT06184334|Active Comparator|Group A : patients will receive mirabegron|patients will receive mirabegron
89117651|NCT06184334|Active Comparator|Group B: patients will receive tadalafil 5mg|patients will receive tadalafil 5mg
89117652|NCT06184334|Active Comparator|Group C: patients will receive solfenacin|patients will receive solfenacin
89117653|NCT06184321||Arm I (alteplase)|Patients receive alteplase instilled into the IPC which is capped for 1-2 hours before the catheter is drained.
89117654|NCT06184321||Arm II (placebo)|Patients receive placebo instilled into the IPC which is capped for 1-2 hours before the catheter is drained. Beginning 1 week later, patients may receive alteplase as in arm I.
89117655|NCT06184308|Experimental|Piolt (Aim 1) Group: Home-Based Program of Rehabilitation and Health Coaching|5-10 subjects will be assigned to complete 20 minutes of Home-based Physical Rehabilitation and Health Coaching for approximately 12 weeks to test feasibility of the home-based rehabilitation program. This will be the initial phase of the study prior to RCT phase.
89117656|NCT06184308|Experimental|Home-Based Program of Rehabilitation and Health Coaching|Subjects will complete 20 minutes of Home-based Physical Rehabilitation and Health Coaching for approximately 12 weeks.
89117657|NCT06184308|No Intervention|Usual Care|Subjects will receive clinical standard of care.
89117658|NCT06184243|Experimental|Parent-Implemented Video Modeling|Parent intervention teaches the skills to implement video modeling intervention for their young child with a developmental delay. Video modeling intervention teaches the young child new play and conversation skills.
89117659|NCT06184230|Other|Revaccinated at 32 Years|
89117660|NCT06184191|Active Comparator|Robotic Hand Rehabilitation|"RHR group received hand rehabilitation through the robotic device. A home-based rehabilitation program was used to these patients for hand and upper extremity rehabilitation in addition to RHR.~Each rehabilitation session consisted of six parts:~A sequence of 17 cycles of digital flexion-extension joint motions, from the thumb to the fifth finger (7 min).~A sequence of 23 cycles of motion to counting from one to five (7 min).~A sequence of 70 cycles of motions including thumb-finger opposition motions from the second to the fifth finger (7 min).~A sequence of 28 cycles of motions including wave-like finger motions (7 min).~A sequence of 42 cycles of motions including fist opening/closing (7 min).~A sequence of 20 cycles of motions including flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min).~The patients underwent Robotic Hand Rehabilitation in the hospital 5 days per week for 1 month."
89117661|NCT06184191|Active Comparator|Conventional Rehabilitation|CVR group received 60 minutes of consecutive occupational therapy sessions in the hospital 5 days per week for 1 month. The rehabilitation program involved strength, balance, manual dexterity exercises, and stretching/weight-bearing by the affected arm. Treatments focused on practice of specific functional tasks when possible. These included reach and grasp of various objects, isolated hand motions (writing, playing an instruments, molding putty, cooking), and whole body activities (swinging a racquet, basketball handling skills). The rehabilitation also included training in ADLs. The patients underwent individualized programs based on assessment and patient goals. Manual therapy techniques were used to obtain isometric contractions in weak muscles. The patients received mobilization and stretching exercises to restricted joints as needed to increase range of motion.
89117662|NCT06184191|Experimental|Combined Rehabilitation|The patients underwent 60 minutes of CVR followed by 40 minutes of hand rehabilitation through the robotic device. A home-based rehabilitation was not involve in this group.
89117663|NCT06184178|Experimental|INTERVENTION GROUP|Implementation of socio-health care based on TEC-MED model
89117664|NCT06184178|No Intervention|CONTROL GROUP|No intervention
89117665|NCT06184165|Experimental|N°1: PMI in PPC|"Progressive periodic catatonia (SSD phenotype) Premotor inhibition using personalized rTMS (40 sec continuous theta-burst on each of the 5 targets corresponding to hyper-perfused regions, i.e. functional biomarker, 120%).~N = 40."
89117666|NCT06184165|Active Comparator|N°2: PFA in PPC|"Progressive periodic catatonia (SSD phenotype) Classical left-prefrontal activation using intermittent theta-burst rTMS (72 trains, 120%).~N = 40."
89117667|NCT06184165|Active Comparator|N°3: PMI in nPPC|"Other phenotype of SSD than PPC (nPPC) Premotor inhibition using personalized rTMS (40 sec continuous theta-burst on each of the 5 targets corresponding to most perfused premotor regions).~N = 40."
89117668|NCT06184165|Experimental|N°4: PFA in nPPC|"Non-progressive periodic catatonia SSD phenotype Classical left-prefrontal activation (PFA) using intermittent theta-burst rTMS (72 trains, 120%).~N = 40."
89117669|NCT06184100|Experimental|SMP Program with Standard Care|four 60-90 minute virtual educational sessions over 8 weeks with a group of 4-6 participants
89117670|NCT06184100|Active Comparator|Standard Care Only|Standard of care(no formal education program similar to SMP) and placed on 8-week waitlist for optional intervention.
89117671|NCT06184087|Experimental|Control group|"The control group (n = 34) participated in routine childbirth education. The group received the same content via a childbirth class as the intervention group of five meetings (a total of 12.5 hours) given by a nurse midwife.~Women in the control group received a routine instructional approach which was based on lectures, videos, discussions, and practice/rehearsals."
89117672|NCT06184087|Experimental|Intervention group|"The intervention group (n= 36) learned with childbirth education that included interactive and constructive cognitive engagement activities.~The intervention group received the same content as the control group (a total of 12.5 hours), however, the content regarding upright positions and mobility was instructed using the ICAP constructive-interactive engagement modes."
89117673|NCT06184074||Breast Cancer Patients Using Aromatase Inhibitors Group|Breast cancer patients using aromatase inhibitors at least 1 year
89117674|NCT06184074||Breast Cancer Patients Group|Breast cancer patients who have not used aromatase inhibitors before
89117675|NCT06184048|Other|Directly Address Two Concerns - Proper Reporting of PRP Composition and Greatly Decreasing Cost|As socioeconomic inequity directly relates to disability related to knee Osteoarthritis (OA), limiting the cost of treatment is of the utmost importance to ensure appropriate delivery of care to all patients. As PRP is currently not covered by the vast majority of public and private payors, patients are required to pay for the injections out of pocket, with an average cost of $714 per injection (as high as $2,092). Furthermore, research studies relating to PRP are often expensive due to the cost of the traditional method of extracting PRP, generally with commercial kits, and thus limited in scope. The investigators have developed and implemented a low-cost PRP (LC-PRP) preparation technique and have safely performed the injections on hundreds of patients with knee OA.
89117676|NCT06184035|Experimental|Phase I/IIa Dose escalation and dose expansion|"Participants will initially receive 1 cycle of [177Lu]Lu-SN201 via slow intravenous infusion and progress to up to 3 cycles, provided retreatment criteria are met before the start of each cycle, occurring every 6 weeks (with an allowable window to delay each cycle by +3 weeks per retreatment criteria).~Dose escalation: The study will evaluate up to 5 dose levels of [177Lu]Lu-SN201 (A1=10 MBq/kg, A2=25 MBq/kg, A=50 MBq/kg, A4= <33% of A3, A5= <33% of A4). Additional dose levels may be explored until MTD/RP2D is identified. Up to 9 participants may be enrolled at any pre-specified dose level shown to be tolerated for confirmation of MTD and/or RP2D.~Dose expansion: Once the MTD/RP2D has been defined, an expansion phase consisting of multiple tumor types, each with up to 20 participants, will be enrolled to further characterize the safety, tolerability, and assess preliminary efficacy of [177Lu]Lu-SN201 at the RP2D and/or MTD identified in Phase I."
89117677|NCT06184022|Experimental|Augmented reality serious game|"Before the test started, the experimenter gave the basic information of the experiment to the participants. The participants were requested to complete a cognitive exam on the notion of light, and were asked to perform a POE test for each question. The experimental group utilized the three game lesson modules of the AR science education app designed for this study, including Animals vision,  Light transmission, and Color-Light mixing. On their initial encounter with the game, respondents were given around 10 minutes to comprehend its mechanics. The experimental group's total learning time was limited to 20 minutes, the testing process was completed under the supervision of the instructor and the experimenter. During the experiment, the participants were not disturbed in any way; researchers only intervened when they faced difficulties or requested assistance. The participants were given a 15-minute respite at the conclusion of the trial to take another POE test."
89117678|NCT06184022|Active Comparator|non-ar serious game|"The control group completed the same three game courses for a maximum of 20 minutes using the non-AR app Light and Color after completing the pre-test.For the non-AR game we used Light and Color designed by Tinybop available in Appstore Tools for young artists and scientists. Both games have the same scientific educational content on optics (in fact, to experiment with control variables, we adopted the same scientific knowledge as in this non-AR app at the stage of designing the content), so it is possible to perform a POE test. The participants took a 15-minute break at the conclusion of the trial to complete another POE test and the IMI scale."
89117679|NCT06184009|Experimental|ALL, High risk with DI #2(Doxorubicin)|"Clinical and genetic factors consistent with High risk : Induction → Consolidation~BM MRD &lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~BM MRD ≥ 0.01% after Induction, &lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~BM MRD ≥ 0.01% after Consolidation~T cell ALL : Change to very high risk regimen~Pre-B ALL : IM #1 → Intensification~BM MRD &lt; 0.01% after IM #1 : Continue with &#39;No. 2&#39; of High risk regimen starting with DI #1~BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported."
89117680|NCT06250192|Experimental|Intervention with patient-centered virtuel educational tools|Patient randomized to intervention with patient-centered virtuel educational tools based on small videos
89117681|NCT06250192|No Intervention|Control: Women were randomized to usal care|Randomized to standard treatment without acces to virutel educational tools
89117682|NCT06250179|Experimental|Non-smoking patients|The patient will receive a free gingival graft for insufficient keratinized gingival height.
89117683|NCT06250179|Active Comparator|'Light' smokers who report smoking less than 5 cigarettes per day|The patient will receive a free gingival graft for insufficient keratinized gingival height.
89117684|NCT06250179|Active Comparator|Non-smoker for 5 years, quit smoking patients|The patient will receive a free gingival graft for insufficient keratinized gingival height.
89117685|NCT06250153|No Intervention|Treatment as Usual|This group will receive routine substance use screening questions during their in-person primary care visit as part of standard of care.
89117686|NCT06250153|Experimental|m-SBIRT (mobile-Screening, Brief Intervention, and Referral to Treatment)|This group will receive a mobile phone text message based substance use screening (questions used in standard of care) with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to substance use disorder (SUD) treatment.
89117687|NCT06250140||Internal hemorrhoid ligation group|Endoscopic internal hemorrhoid ligation
89117688|NCT06250140||Hemorrhoids injection group|Endoscopic hemorrhoid injection was performed
89117689|NCT06250140||Internal hemorrhoids combined treatment group|Lines of endoscopic hemorrhoids and internal ligation under endoscope to injection
89117690|NCT06250114||retreatment|Voluntary patients with at least one previously treated tooth needing a retreatment
89117691|NCT06250114||dental implant|Voluntary patients with at least one previously treated tooth needing an extraction and implant placement
89117692|NCT06250101|Experimental|Grammar treatment including semantic support|Children receiving grammatical treatment will also receive a simple explanation concerning the meaning of verbs used to elicit grammatical forms.
89117693|NCT06250101|Active Comparator|Grammatical treatment excluding semantic support|Children receiving grammatical treatment will not receive any explanation concerning the meaning of verbs used to elicit grammatical forms.
89117694|NCT06250075|Experimental|G1 Intervention Group|In group 1, the intervention will take place with intake from the 1st day Post-OP when releasing the diet (Orally or ENT) and up to 7 days post-operatively with probiotic capsules.
89117695|NCT06250075|No Intervention|Non-Intervention Group G2|Group G2 followed general nutritional guidelines. This group will not take probiotics, it will be the surgical comparator.
89117696|NCT06250075|Sham Comparator|G3 Negative Control Group|Group G3 (guest employees) will follow the intake of probiotic capsules for 7 days during follow-up, without surgical intervention, these will be chosen at random and standardized by social level paired with G1
89117697|NCT06250075|Active Comparator|Intervention for Clinical Outcomes -G4|The G4 and G5 groups will be recruited and randomized in the second stage of the research after the end of the collection of the G1 and G2 groups, for analysis of clinical outcomes in the 7-day postoperative period.
89117698|NCT06250075|Placebo Comparator|Non-intervention for Clinical Outcomes -G5|G5 will use placebo capsules with 0.5g calcium carbonate to test the power of the intervention in reducing postoperative surgical complications or not.
89117699|NCT06250062|Experimental|Placebo（JS005）|
89117700|NCT06250062|Experimental|Recombinant humanized IL-17A Monoclonal Antibody（JS005）150mg|
89117701|NCT06250062|Experimental|Recombinant humanized IL-17A Monoclonal Antibody（JS005）300mg|
89117702|NCT06250049|Experimental|Intervention Group|This group of patients will be attended according to a diabetic foot care protocol implemented in Primary Care in Salamanca. In addition, those patients and/or caregivers will receive group education sessions on Diabetic Foot Care at the Health Centers.
89117703|NCT06250049|No Intervention|Control Group|Usual care
89117704|NCT06250036|Experimental|Single agent zimberelimab|Single agent zimberelimab (PD-1 inhibitor) Q3W
89117705|NCT06250036|Experimental|Combination zimberelimab + domvanalimab|Combination zimberelimab + domvanalimab
89117706|NCT06250010||Cohort 1: tissue samples (healthy and tumor taken from the same patient)|Tissue samples (healthy and tumor taken from the same patient) collected at the Institute's Biobank (starting from 2017) (retro-prospective). The data relating to the neoplastic pathology will also be indicated: histotype, grading, FIGO stage. And data on oncological follow-up: any intra or post-operative complications, any adjuvant therapies, type and date of any recurrence/metastasis, type of treatment, any recurrence, date and manner of death
89117707|NCT06250010||Cohort 2: tissue samples (decidualized endometrium and trophoblast taken from it patient)|The tissue samples (decidualized endometrium and trophoblast taken from it patient) which will be collected from the Gynecology and Obstetrics Unit of the Polyclinic Federico II University of Naples (prospective) and transferred to the Regina National Cancer Institute Elena, IRE-IFO
89117708|NCT06249997|Experimental|Leniolisib|"Leniolisib - Film coated tablets~Leniolisib tablets in doses ranging from 40 to 70 mg twice daily (BID) based on body weight.~A Part 1 clinical study report will be generated once the last patient completes the Day 85 Visit for Part 1. Patients who complete the Day 85 Visit will enter the Extension Period of the study (Part 2), in which patients will be administered leniolisib doses ranging from 40 to 70 mg BID (based on body weight) for 1 year or until marketing approval in Japan, whichever is longer. A 4-week Follow-up Period will occur after the last dose of study treatment is received."
89117709|NCT06249984|Placebo Comparator|Prevention (Smokeless tobacco use: Usual Brand)|Participants use their usual brand of moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
89117710|NCT06249984|Active Comparator|Prevention (Smokeless tobacco use: Low FBN Long Cut)|Participants use low FBN long cut moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
89117711|NCT06249984|Active Comparator|Prevention (Smokeless tobacco use: Low FBN Fine Cut)|Participants use low FBN fine cut moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
89117712|NCT06249984|Active Comparator|Prevention (Smokeless tobacco use: High FBN Long Cut)|Participants use high FBN long cut moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
89117713|NCT06249984|Active Comparator|Prevention (Smokeless tobacco use: High FBN Fine Cut)|Participants use high FBN fine cut moist snuff on study. Participants also undergo blood sample collection and carbon monoxide testing on study.
89117714|NCT06249971|Active Comparator|Split thickness skin graft alone|"Intra-individual approach Patient has 2 comparable (near) full thickness skin defects or 1 (near) full thickness skin defect that can be divided into 2 comparable regions.~Randomization: the defect randomized in this arm receives only a skin graft."
89117715|NCT06249971|Experimental|Split thickness skin graft + Glyaderm|"Intra-individual approach Patient has 2 comparable (near) full thickness skin defects or 1 (near) full thickness skin defect that can be divided into 2 comparable regions.~Randomization: the defect randomized in this arm receives a skin graft combined with Glyaderm"
89117716|NCT06249945|Experimental|empagliflozin|Jardiance, 25 mg, QD, for 6 months
89117717|NCT06249945|Placebo Comparator|Placebo|QD, for 6 months
89117718|NCT06249932|Experimental|empagliflozin|Jardiance, 25 mg, QD, for 6 months
89117719|NCT06249932|Placebo Comparator|placebo|QD, for 6 months
89117720|NCT06249919|Experimental|Group A|NS101 15mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)
89117721|NCT06249919|Experimental|Group B|NS101 30mg/kg IV infusion Biweekly for 6weeks in Healthy Volunteers (active:placebo=6:3)
89117722|NCT06249919|Active Comparator|Cohort A|NS101 15mg/kg IV infusion Biweekly for 12weeks in Sudden Sensorineural Hearing Loss patients
89117723|NCT06249919|Placebo Comparator|Cohort B|Placebo 15mg/kg IV infusion Biweekly for 12weeks in Sudden Sensorineural Hearing Loss patients
89117724|NCT06249893||Included patients|
89117725|NCT06249867|Experimental|Darifenacin Treatment|Patients in the Treatment arm will receive a daily dose of 1 or 2 darifenacin extended-release tablets.
89117726|NCT06249867|Placebo Comparator|Placebo|Patients in the Placebo arm will receive a daily dose of 1 or 2 placebo tablets.
89117727|NCT06249828|Experimental|MegaCarti^® application after Microfracture Surgery|The study group is applied with MegaCarti^® after microfracture. Afterwards, they visit at 12 weeks, 24 weeks, and 48 weeks to conduct examinations and assess Questionnaires.
89117728|NCT06249828|Active Comparator|Microfracture Surgery without Medical Devices|The control group undergoes microfracture and they visit at 12 weeks, 24 weeks, and 48 weeks after surgery to conduct examinations and assess Questionnaires.
89117729|NCT06249802|Experimental|Nebivolol arm|Patients randomly assigned to receive active treatment with escalating doses of nebivolol.
89117730|NCT06249802|Placebo Comparator|Placebo arm|Patients randomly assigned to receive matching placebo tablets.
89117731|NCT06249789|Active Comparator|Spinal Anesthesia|This arm gets preoperative single-dose spinal anesthesia plus an ultrasound-guided Fascia Iliaca Compartment Block (FICB).
89117732|NCT06249789|Active Comparator|General Anesthesia|This arm gets preoperative general anesthesia plus an ultrasound-guided Fascia Iliaca Compartment Block (FICB).
89117733|NCT06249750|Experimental|Immuno-targeted therapy group|ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d; RTK inhibitor regimen: Anlotinib, 12mg (at an initial dose of 12mg, later adjusted according to the instructions), po., d1~14, q21d.
89117734|NCT06249750|Experimental|Hyperthermia-immuno-targeted therapy group|ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5~39 ℃ and then maintain 1h. ICI regimen: Tislelizumab, 200mg, ivgtt., d2, q21d; RTK inhibitor regimen: Anlotinib, 12mg (at an initial dose of 12mg, later adjusted according to the instructions), po., d2~15, q21d.
89117735|NCT06249737|Experimental|Control Group|This group will train the DoF target (shoulder flexo-extension) and DoF dorsi-ankle flexion of the contralateral lower extremity.
89117736|NCT06249737|Experimental|Proximal Interference Group|This group will train the DoF target and shoulder abduction-adduction DoF.
89117737|NCT06249737|Experimental|Distal Interference Group|This group will train the DoF Tf and the wrist flexion-extension DoF.
89117738|NCT06249698|Experimental|Active Nutrition program|Subjects in this arm will follow the Active Nutrition program for 60 days with study visits at 0 days, 30 days, and 60 days.
89117739|NCT06249698|No Intervention|Regular Diet|Subjects in this arm will follow their regular diet for 60 days with study visits at 0 days, 30 days, and 60 days.
89117740|NCT06249685|No Intervention|Baseline-Unaided|No hearing aids.
89117741|NCT06249685|Experimental|Aided|Fitted with bilateral hearing devices.
89117742|NCT06249685|No Intervention|Follow-up-Unaided|No hearing aids.
89117743|NCT06249672||Organ preservation without local excision|
89117744|NCT06249672||Organ preservation after local excision|
89117745|NCT06249659||Extubation in operative room|Patients are extubated in operative room after the end of surgery
89117746|NCT06249659||Extubation in post anesthesia care unit|Patients are extubated in post anesthesia care unit, after transfer from operative room
89117747|NCT06249633|Experimental|iNOMAX|
89117748|NCT06249620|Experimental|Active group|The product (with the active ingredients) is randomly given to 20 participants for ingestion for two months.The dosage regimen is two capsules per day in a single dose.
89117749|NCT06249620|Placebo Comparator|Placebo|The other 20 participants will receive a similar looking product but with inert substances (placebo group).The dosage regimen is two capsules per day in a single dose.
89232637|NCT04577833|Experimental|Treatment Sequence ADB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
89117750|NCT06249607|Experimental|Group A: combined sleep hygiene and storytelling|
89117751|NCT06249607|Experimental|Group B: combined sleep hygiene and mindfulness breathing exercise group|
89117752|NCT06249607|Other|Group C: sleep hygiene group|
89117753|NCT06249568||patients who will have coroner arter bypass surgeon|Patients undergoing coronary artery bypass surgery will be eliminated if there are exclusion criteria. Patients who do not have exclusion criteria will be included in the study if they agree to volunteer.
89117754|NCT06249555||Vedolizumab|"Group one will include participants who will be starting Vedolizumab as part of routine care.~Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider."
89117755|NCT06249555||Ustekinumab|"Group two will include participants who will be starting Ustekinumab as part of routine care.~Dose, frequency and duration are not mandated as part of the study and are determined by the health care provider."
89117756|NCT06249542|Experimental|Care Delivery Improvement Intervention|The care delivery improvement intervention consisted of a period of 4 months during which practice facilitators supported each clinic in implementing routine, population-based screening, assessment, treatment, and follow-up for depression and unhealthy substance use and substance use disorders.
89117757|NCT06249542|No Intervention|Usual Care|"Usual care consisted of care received in a study clinic after January 1, 2015 and prior to active implementation of the quality improvement intervention in that clinic. The usual care period included 1) a two-month pre-intervention preparatory period during which EHR tools designed to support the intervention had been activated in the EHR and were available to clinic staff but had not yet been actively promoted by practice facilitators (a condition the investigators refer to as passive access), and 2) a two-month preparation period during which practice facilitators, who were not members of the local clinic staff, engaged clinic staff in team building exercises and pretesting of the intervention."
89117758|NCT06249529|Experimental|Interventional|Patients in the interventional arm will receive implant of one or more airway bypass devices.
89117759|NCT06249477|Other|Control group|Patients receive a wrist activity monitor and a scale. They are also followed with monthly calls ensuring adequate functioning of devices and receiving case-specific nutritional guidance.
89117760|NCT06249477|Experimental|Group intervention group|In addition to receiving a wrist activity monitor, scale, and being followed with monthly calls, patients in this arm received every other month nutritional coaching group sessions on topics related to nutrition and physical activity to promote education and lifestyle changes
89117761|NCT06249451|No Intervention|Retrospective control group (n= 62)|Analysis of patients with the diagnosis of S. aureus-bacteraemia between 01.10.2022-01.10.2023
89117762|NCT06249451|Other|Prospective quality-improvement group (n= 62)|Analysis of patients with the diagnosis of S. aureus-bacteraemia between 22.01.2024-22.01.2025
89117763|NCT06249412|Experimental|MI-E with Positive expiratory pressure during pause (PEP)|With the MI-E EOVE-70 device, it is possible to enable the setting of PEP (Positive Expiratory Pressure) during the pause. When this setting is activated, PEP can be adjusted between 1 and 20 cmH2O. The MI-E session will last, depending on patient tolerance, between 8 and 15 minutes. In this study, the MI-E will be set in automatic or semi-automatic mode with settings proposed by the physiotherapists based on the effectiveness and tolerance of the patient. To titrate PEP, the practitioner will start at 8 cmH2O; the setting can be decreased or increased at the discretion of the practitioner to optimize it, based on the inspiratory volume and peak expiratory flow (PEF) measured by the device at each cycle (usual clinical practice). The practitioner can adjust PEP between a minimum of 4 and a maximum of 15 cmH2O. A wash-out period of 30 minutes is planned between each INEX session with and without the PEP function activated (Experimental arm and comparative arm)
89117764|NCT06249412|Active Comparator|MI-E without Positive expiratory pressure during pause (PEP)|The MI-E session will last, depending on patient tolerance, between 8 and 15 minutes. In this study, the MI-E will be set in automatic or semi-automatic mode with settings proposed by the physiotherapists based on the effectiveness and tolerance of the patient. The PEP function will not be used by the practitioner (ie. 0 cmH2O of PEP during the pause). A wash-out period of 30 minutes is planned between each INEX session with and without the PEP function activated (Experimental arm and comparative arm)
89117765|NCT06249386|Experimental|Behavioral Activation (BA)|Individual psychotherapy
89117766|NCT06249386|Active Comparator|Relapse Prevention (RP)|Individual psychotherapy
89117767|NCT06249373|Experimental|LIPUS intervention group|Low intensity pulse ultrasound （LIPUS） intervenes at the anastomotic site, and if the ultrasound examination indicates the presence of a narrow site in the outflow tract, it also intervenes at the narrow site. It belongs to non-invasive extracorporeal intervention, with three times a week （during dialysis） for 20 minutes each time. The sound intensity is 350mW/cm2, the pulse frequency is 1MHz, the pulse repetition frequency is 100Hz, the pulse frequency is 100 times, and the treatment period is 12 weeks.
89117768|NCT06249373|No Intervention|Simulated LIPUS control group|Using the same forearm wearable portable ultrasound as the LIPUS arteriovenous fistula intervention group, but not issuing low-intensity pulse ultrasound.
89117769|NCT06249360||Lower Limb Lymphedema|Patients with cancer-related unilateral lower limb lymphedema were enrolled.
89117770|NCT06249334|Experimental|Whole-body electrical stimulation (WB-EMS)|WB-EMS will be performed with ReCare® equipment (Visuri, Minas Gerais, Brazil). Patients will perform sessions once a day, totaling a maximum of 15 sessions. In addition to the WB-EMS protocol, the patients will receive routine physiotherapy at the hospital.
89117771|NCT06249334|Active Comparator|Routine physical therapy|"Patients in the control group (active comparator) will receive routine hospital physical therapy until the moment of hospital discharge.~No intervention with electrical stimulation will be performed in this group."
89117772|NCT06249308||Ovarian cancer|Participants with new diagnosis of ovarian cancer, from whom a peripheral blood sample will be collected.
89117773|NCT06249295|Experimental|Intervention group|The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies, and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth).
89117774|NCT06249295|No Intervention|control group|The control group received general routine care.
89117775|NCT06249269||RASTA AF Cohort|Patients who meet the inclusion criteria for RASTA-AF, and do not meet any of the exclusion criteria but decline or are not approached for participation in the RCT will be asked to participate.
89117776|NCT06249256|Experimental|Fast CAR T cells|The safety and efficacy of BZT2312 will be assessed in a standard 3+3 dose escalation approach. Three doses of CAR T cells will be evaluated in this study: 5×10^5 CAR+ T cells/kg, 1×10^6 CAR+ T cells/kg, and 5×10^6 CAR+ T cells/kg.
89117777|NCT06249217|Experimental|Experimental|At Week 0, participants will provide a comprehensive assessment of sleep environment and sleep hygiene practices and participants will be given a Fitbit watch to wear for the duration of the study. At Week 2, participants will receive information about the benefits of good sleep, feedback about their sleep environment and sleep hygiene practices based on the assessment data to implement at home, and sleep environment modification items based on participant-identified areas of need (e.g., a fan, sound machine, bedding). At Week 4, families in the intervention group will provide post-intervention assessment data and feedback on the intervention.
89117778|NCT06249217|No Intervention|Waitlist control|The waitlist control group will not receive the sleep intervention at Week 2 but families in the waitlist-control group can elect to receive the intervention if they choose to after Week 4.
89117779|NCT06249191|Experimental|Treatment (Mosunetuzumab and EPOCH)|Patients receive mosunetuzumab IV, over 2-4 hours, on day 1, 8 and 15 of cycle 1 and day 1 of subsequent cycles. Patients receive etoposide IV, doxorubicin IV, and vincristine IV on days 1-4, cyclophosphamide IV, over 2 hours, on day 5 and prednisone PO BID on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity for up to 6 cycles. Patients undergo bone marrow aspiration and biopsy, tumor biopsy and may undergo echocardiography or MUGA at screening and PET scan, CT scan or MRI and blood sample collection throughout the study.
89117780|NCT06249165|Experimental|Inclisiran|Inclisiran + Usual Care
89117781|NCT06249165|No Intervention|Usual Care|Usual Care
89117782|NCT06249139|Experimental|Compass for Care (Well-being intervention)|Participants receive 12 weekly modules containing interactive activities and static content and tailored messages delivered via text message or email. The intervention focuses on five self-care behaviors critical to ADRD caregiver well-being: 1) taking time to recharge; 2) finding information about your loved one's diagnosis and needs; 3) discovering your strengths and limits; 4) exploring outside help; and 5) seeking emotional support.
89117783|NCT06249139|Active Comparator|Compass for Care (Safety intervention)|Participants receive 12 weekly modules and tailored messages delivered via text message or email. The intervention focuses on safety behaviors (e.g., weather safety, first aid, home safety, etc.)
89117784|NCT06249100|Experimental|flexible mini percutaneous nephrolithotomy|In Group A (flexible mini-PCNL cases), puncture will be done under fluoroscopic guidance medial to the posterior axillary line using an 18-gauge puncture needle. The puncture will be directed horizontally or with slight upward inclination towards lower or middle calyx. After a successful puncture, a 0.035 Fr Super Stiff guidewire will be inserted either to the ureter or to another calyx. Tract dilatation will be done with Storz 15/16 Fr one step metal dilator followed by 16.5 Fr access sheath. Stone disintegration will be done with the flexible mini-nephroscopy (WiScope Digital Endoscope System by OTU Medical, California, USA) which has a shaft length of 38 cm, distal tip diameter is 15.3 F tapering to 10 F, working channel inner diameter is 6.6 F, and the angle of deflection of distal tip is 210 degrees.
89117785|NCT06249100|Active Comparator|retrograde intrarenal surgery|In Group B (retrograde intrarenal surgery cases), a 0.035 Fr guidewire will be inserted into the ureteric orifice under fluoroscopic guidance. Ureteric dilatation will be done with serial semi-rigid dilators 6- 16 Fr (Nidhi Meditech) followed by 14-16 Fr access sheath. Stone disintegration will be done with the LithoVue Flexible URS (Boston Scientific, Massachusetts, U.S.) which has a shaft length of 68 cm, distal tip diameter is 7.7-10 F, working channel inner diameter is 3.6 F, and the angle of deflection of distal tip is 270 degrees.
89117786|NCT06249074|Experimental|Gluten|Gluten group received gluten in gastrosoluble capsules - 2 g of gluten in 3 capsules daily for 4 weeks (week 5 to week 8).
89117787|NCT06249074|Placebo Comparator|Placebo|Placebo group received rice starch in gastrosoluble capsules - 3 capsules daily for 4 weeks (week 5 to week 8).
89117788|NCT06249061|Experimental|Oral Sodium Bicarbonate|Those in the intervention group will be encouraged to sip a solution of sodium bicarbonate (1 imperial teaspoon (~5g) of sodium bicarbonate dissolved into 250ml of water; if the entire 250mL is consumed, another 1 imperial teaspoon (~5g) of sodium bicarbonate dissolved in 250mL of water will be provided to the patient) throughout labour with other drinks as desired. All other care will remain the same.
89117789|NCT06249061|No Intervention|Usual Care|Those in the usual care group will be encouraged to sip fluids of their choice throughout labour as they would normally be encouraged to do. All other care will remain the same.
89117790|NCT06249035|Experimental|TEE as POCUS modality.|TEE will be performed during cardiac arrest.
89117791|NCT06249009|Active Comparator|CPAP-first group|After a wash out of 15 minutes with conventional oxygen therapy, CPAP with a Positive End -Expiratory Pressure of 7 cmH2O will be introduced, with an inspiratory oxygen fraction required for an oxygen saturation of 94%, during 30 minutes. The collection of EAdi min/max will be done every minutes over 30min as well as the collection of HR, Respiratory rate (RR), SpO2, while TCPCO2, distress respiratory score and pain score will be taken at M0 and M30.
89232638|NCT04577833|Experimental|Treatment Sequence CBD|Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
89232639|NCT04577833|Experimental|Treatment Sequence CDB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
89117792|NCT06249009|Active Comparator|HFNC-first group|"After a wash out of 15 minutes with conventional oxygenotherapy, increasing flow rates for up to 2 hours according to the following augmentation:~Initiation at a flow rate of 2 L/kg/min with FiO2 required to achieve SpO2≥94% (increase FiO2 if reliable SpO2 signal <94% for 1 minute) for 30min.~Increase to 3 L/kg/min after the first 30min of ventilation and repeat the previously described experimental scheme.~Further increase to 4 L/kg/min after 30min of ventilation and repetition of the experimental scheme (if weight < 16 kg).~Last increase to 5 L/kg/min after 30 min of ventilation and repetition of the experimental scheme (if weight < 13 kg).~The collection of EAdi min/max will be done every minutes over 30min as well as the collection of HR, RR, SpO2, while TCPCO2, distress respiratory score and pain score will be taken at M0 and M30."
89117793|NCT06248996|Active Comparator|Conventionally fractioned (standard) group|This groups is treated with standard radiotherapy treatment: RT 2.0 Gy daily to final radiation dose 68.0 Gy or
89117794|NCT06248996|Experimental|HFX-RT group|Treated with Hyperfractionated radiotherapy (HFX-RT): Gy twice daily (10 fractions/week) with final dose 83.0 Gy
89117795|NCT06248957||Patients with immune dysregulation|Patients sampled before and during different immunomodulatory therapies due to immune system dysregulation.
89117796|NCT06248957||Healthy subjects|Age-matched healthy individuals sampled longitudinally
89117797|NCT06248931|Active Comparator|valproate arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
89117798|NCT06248931|Active Comparator|topiramate arm|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 50-100mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
89117799|NCT06248905|Experimental|exercise plus shockwaves|"Enrolled subject will be treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician, using a device powered by an electromagnetic generator.~Focusing: (out-of-line) ultrasound-guided with the patient lying in lateral decubitus.~Dosimetry: 1500-1800 shots per session with an energy flux density equal to 0.10-0.20 mJ/mm2 (frequency=4Hz).~The experimental group will then start a physiotherapy program for the following 8 weeks. The program is made up of strengthening and stretching exercises of gluteal muscles, planned to be daily performed at home. Four supervised physiotherapy session will be planned on week 0-1-2-4, during which the exercise loading will be implemented."
89117800|NCT06248905|Active Comparator|shockwaves|"Enrolled subject will be treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician, using a device powered by an electromagnetic generator.~Focusing: (out-of-line) ultrasound-guided with the patient lying in lateral decubitus.~Dosimetry: 1500-1800 shots per session with an energy flux density equal to 0.10-0.20 mJ/mm2 (frequency=4Hz)."
89117801|NCT06248866|Experimental|Extracorporeal Shock Wave Therapy|patients will receive Extracorporeal Shock Wave Therapy and traditional treatment three times a week for six weeks
89117802|NCT06248866|Active Comparator|traditional treatment|patients will receive traditional treatment three times a week for six weeks
89117803|NCT06248853|Experimental|Garston technique|the patients will receive graston technique with exercise program three times aweek for six weeks
89117804|NCT06248853|Active Comparator|exercise program|the patients will receive an exercise program three times a week for six weeks
89117805|NCT06248827||Lumbar Spine MRI exams|"An information letter will be delivered by the investigator physician to the patients to inform them on the study, its implementation and their complete freedom to participate or not.~MRI Data from exams (DICOM format)~Sagittal T1~Sagittal T2~Sagittal DIXON~Sagittal STIR~Sagittal FLAIR~Axial T2~Clinical Data from questionnaires~biometric data (height, weight),~age~gender,~smoking status,~comorbidities,~basic clinical examination,~medical history."
89117806|NCT06248814|Experimental|Placebo, followed by BMS-986326 Dose A or Dose B|
89117807|NCT06248814|Experimental|BMS-986326 Dose A, followed by Placebo|
89117808|NCT06248814|Experimental|BMS-986326 Dose B, followed by Placebo|
89117809|NCT06248801|Experimental|Sequence 1-Vildagliptin and Metformin test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Vildagliptin and Metformin tablets 50/1000 mg test product, treatment 2= Vildagliptin and Metformin tablets 50/1000 mg reference product.
89117810|NCT06248801|Experimental|Sequence 1-Vildagliptin and Metformin reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Vildagliptin and Metformin tablets 50/1000 mg test product, treatment 2= Vildagliptin and Metformin tablets 50/1000 mg reference product.
89117811|NCT06248775|Other|Nursing prehabilitation intervention group|Patients all undergo the intervention aimed at lifestyle improvement and glucose regulation
89117812|NCT06248762|Experimental|Intervention condition|Participants will use the app for 4 weeks, daily for 10-15 minutes
89117813|NCT06248762|Other|Waitlist control condition|Participants in the control condition will start using the app 4 months after the start (baseline)
89117814|NCT06248749|Experimental|Iron Infusion Arm|Group A: Treatment study group All patients will be treated with iron infusion for Hgb lower than 100 g/L and/or TSAT < 20%.
89117815|NCT06248749|No Intervention|No Iron Infusion|Group B: No iron Infusion
89117816|NCT06248723|Experimental|Active intervention arm|"Physical exercise regime~Mediterranean diet-based nutritional plan~Cognitive training~Regular medical check-ups~Oral hygiene treatments and counseling~Counseling on sleep hygiene and treatment~Control of cardiovascular, metabolic, and infectious risk factors~Adjustment of drug therapy~Suggestions for improving social interactions~Physical exercise and cognitive training interventions will be monitored and partially administered through wearable devices and digital tools. Sleep quality will be monitored through wearable devices. Social interactions will be encouraged through a validated app."
89117817|NCT06248723|Active Comparator|Self-administered intervention arm|"Subjects in the control group will receive regular health advice in the same domains as the intervention group, via dedicated app and/or access to the dedicated portal on the Age-It website.~In addition, participants randomized to the self-guided intervention will receive an initial 30-60 minute counseling session on all domains covered by the study, in which guidelines for healthy diet, physical and cognitive activity, benefits of social activity, information on cardiovascular risk factors, as well as sleep, oral hygiene will be explained.~Subjects will therefore be treated as per normal clinical practice, albeit with the help of dedicated apps and counseling session."
89117818|NCT06248710|Experimental|Condition 1: Oxytocin + dog present|
89117819|NCT06248710|Experimental|Condition 2: Oxytocin + no dog present|
89117820|NCT06248710|Experimental|Condition 3: Placebo + dog present|
89117821|NCT06248710|Placebo Comparator|Condition 4: Placebo + no dog present|
89117822|NCT06248697|Experimental|CAR T cells|αPD1/CTLA4-MSLN-CAR T Cells
89117823|NCT06248684|Other|prevention group|patients receive standardized perioperative care using Standard Operating Procedures (SOPs) in accordance with the guidelines of the professional societies for the prevention of postoperative delirium.
89117824|NCT06248671|Active Comparator|Atorvastatin 40mg|Each participant in this arm will receive 40mg atorvastatin once daily for 84 days.
89117825|NCT06248671|Active Comparator|Atorvastatin 20mg|Each participant in this arm will receive 20mg atorvastatin once daily for 84 days.
89117826|NCT06248671|Placebo Comparator|Placebo|Each participant in this arm will receive placebo once daily for 84 days.
89117827|NCT06248658||Inpatient cohort|Patients who were admitted to hospital for any cardiac diagnosis (ICD-10 codes I00-I99), with CHF of stage 2a or higher and/or FC II and higher as the primary or secondary (concomitant or as a complication) diagnosis. Index event is the earliest hospitalization for any cardiac diagnosis during which an ICD code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding) is specified as a primary or secondary diagnosis, or the clinical diagnosis specify CHF of stage 2a or higher and/or FC II and higher, or according to the CDSS algorithm criteria, the patient's clinical presentation corresponds to CHF (a subcohort of patients included based on the diagnosis established by the CDSS is subject to an individual analysis).
89117828|NCT06248658||Outpatient cohort|Patients who had an outpatient visit for any cardiac diagnosis (ICD-10 codes I00-I99), with: 1) CHF of stage 2a or higher and/or FC II and higher as the primary or secondary (concomitant or as a complication) diagnosis at the same visit. Index event is the earliest outpatient visit to a general practitioner or cardiologist for any cardiac diagnosis for which an ICD code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding) is specified as a primary or secondary diagnosis, or the clinical diagnosis specify CHF of stage 2a or higher and/or FC II and higher, or according to the CDSS algorithm criteria, the patient's clinical presentation corresponds to CHF of stage 2a or higher and/or FC II and higher (a subcohort of patients included based on the diagnosis established by the CDSS is subject to an individual analysis).
89117829|NCT06248606|Experimental|Adagrasib + SRS (Stereotactic Radiosurgery)|All patients will receive oral adagrasib 600mg twice daily for every cycle and SRS which will be administered as standard of care. Initiation of adagrasib and treatment with SRS will occur within 3 weeks of each other, in whichever order. Patients may have received SRS prior to study enrollment. Cycle 1 Day 1 will begin on the first day of adagrasib dosing. Adagrasib should be held the day before and the day of SRS. There is no maximum duration of treatment.
89117830|NCT06248580||Family Physicians|1. 250 Family Physicians
89117831|NCT06248580||HDV Screening|2. 20,000 HBsAg positive patients
89117832|NCT06248567|Experimental|Experimental 1: participants with severe renal impairment|8 participants with severe renal impairment will be given 600mg of ZSP1273
89117833|NCT06248567|Experimental|Experimental 2: healthy participants|8 participants with normal renal function will be given 600mg of ZSP1273
89117834|NCT06248554|Experimental|PD-1 inhibitor adjuvant therapy group|Received adjuvant PD-1 inhibitor 2-4 weeks after microwave surgery for a total of 9 cycles of treatment
89117835|NCT06248554|No Intervention|Control group|Receive regular monitoring and follow-up
89117836|NCT06248541|Experimental|Group 1: treatment with low-level laser therapy|Patient gets treated with a low-level laser (wavelength of 620 - 640nm) two times a day for 3 weeks.
89117837|NCT06248541|Placebo Comparator|Group 2: treatment with conventional light diodes|Patient gets treated with conventional light diodes two times a day for 3 weeks.
89117838|NCT06248528|Experimental|Liver resection-based group|Patients in the liver resection-based group received adjuvant PD-1 inhibitors plus targeted drugs following liver resection.
89117839|NCT06248528|Active Comparator|Locoregional treatment-based group|Patients in the locoregional treatment-based group received PD-1 inhibitors plus targeted drugs following locoregional therapy.
89117840|NCT06248489||Individuals with neck pain|
89117841|NCT06248489||Individuals without neck pain|
89117842|NCT06248476|Active Comparator|iTBS + robotic rehabilitation|iTBS combined with robotic rehabilitation and conservative treatment applied to patients with chronic incomplete spinal cord injury
89117843|NCT06248476|Active Comparator|rTMS + robotic rehabilitation|rTMS combined with robotic rehabilitation and conservative treatment applied to patients with chronic incomplete spinal cord injury
89117844|NCT06248476|Sham Comparator|sham iTBS + robotic rehabilitation|Sham iTBS combined with robotic rehabilitation and conservative treatment applied to patients with chronic incomplete spinal cord injury
89117845|NCT06248450|Other|Physical setting|Medical yoga at a yoga local led by a yoga-instructor for 75 minutes once a week and individual yoga for a minimum of 10 minutes daily using a yoga-application for 12 weeks.
89117846|NCT06248450|Other|Digital setting|Medical yoga online using videoconference system led by a yoga-instructor for 75 minutes once a week and individual yoga for a minimum of 10 minutes daily using a yoga-application for 12 weeks.
89117847|NCT06248398|Experimental|Experimental arm|Patient having cochlear implantation surgery with RobOtol®.
89117848|NCT06248398|Other|Control arm|Patient having conventional manual cochlear implantation surgery.
89117849|NCT06248372|Experimental|External Focus Group (EFG)|Receive exercise program that includes strengthening and stretching exercises however this group will focus on environmental cues apart from body movement by using metaphors or analogies.
89117850|NCT06248372|Experimental|Internal Focused Group (IFG)|Receive exercise program that includes strengthening and stretching exercises however this group will follow internal cues directing attention to the body movement (i.e., joint movement) while doing exercises.
89117851|NCT06248372|Other|Control Group (CG)|Receive exercise program that includes strengthening and stretching exercises however, this group will not focus on any attentional cues while doing exercises.
89117852|NCT06248359||Arginine Use|At least one dose of L-arginie was administered in the early postoperative stage
89117853|NCT06248359||Without Arginine|No L-arginie was administered
89117854|NCT06248346||dexmedetomidine|dexmedetomidine group: abbreviated for dexmedetomidine group, refers to the group with intraoperative administration of dexmedetomidine adjunct to propofol
89117855|NCT06248346||non-dexmedetomidine|non-dexmedetomidine group: abbreviated for non-dexmedetomidine group, refers to the group without intraoperative administration of dexmedetomidine adjunct to propofol
89117856|NCT06248333|Experimental|Active Stimulation|After randomization, participants will undergo STN-DBS ON in the 3-month blinded phase (Month 2 to Month 5) with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
89117857|NCT06248333|Sham Comparator|Sham Stimulation|After randomization, participants will undergo STN-DBS OFF in the 3-month blinded phase (Month 2 to Month 5) with 0mA current, then the stimulator will be turned on with individual stimulation parameters and left on for the remainder of the study.
89117858|NCT06248307|Experimental|Barrita experimental|Two bars to be consumed before lunch and before dinner
89117859|NCT06248307|Placebo Comparator|Barrita placebo|Two bars to be consumed before lunch and before dinner
89117860|NCT06248294||TAVI patients with native BAV|Patients undergoing TAVI for severe aortic stenosis and native bicuspid aortic valve
89117861|NCT06248281||Experimental group|The experimental group will attend a structured psychoeducational program developed to build and promote psychological flexibility. In combination with this, participants of this group will have to follow a head and neck cooling protocol. Also, participants of this group will be required to increase their habitual exercise levels and follow a video exercise program specifically designed for their needs and improve their nutrition based on the instructions of a nutritionist and videos specially designed for them.
89117862|NCT06248281||Control group|As per the study plan, the Control group has been designated as the control group. They will continue with their normal lifestyle without any participation in rehabilitation activities or programs.
89117863|NCT06248242|No Intervention|The control group|The control group received basic treatment following intravenous drip of rt-PA (specification: 50 mg), including statins and drugs that improve circulation.
89117864|NCT06248242|Experimental|The edaravone dexborneol group|The edaravone dexborneol group received an injection of concentrated edaravone dexborneol solution (specifications: edaravone, 10 mg and dexborneol, 2.5 mg in a 5 mL solution) and 0.9% sodium chloride injection [(100 mL), intravenous infusion twice per day, completed within 30 minutes]. The time between the two doses was no less than 6 hours, and each cycle lasted 12 days.
89117865|NCT06248229|Active Comparator|Dyanavel XR (Active Agent)|Dyanavel 5, 10, 15 or 20 mg once daily in the morning
89117866|NCT06248229|Placebo Comparator|Placebo|Matching placebo 5, 10, 15 or 20 mg once daily in the morning
89117867|NCT06248216|Experimental|Virtual reality arm|In the virtual reality intervention, participants will complete the scheduled educational module five times in the week of the intervention. This VR is assisting users in using immersive reality to reduce pain, learning cognitive and behavior self-coping skills and retraining the pain pathways. There are several sessions, which will be delivered using an all-in-one head-mounted display. Each session varies in duration approximately from 3 to 15 minutes.
89117868|NCT06248216|Placebo Comparator|Audio Mp4 arm|In the audio intervention, participants will complete the scheduled module 5 times a week of the intervention. The content is similar to that of the VR, which will be delivered by the audio player. Each session varies in duration approximately from 3 to 15 minutes.
89117869|NCT06248190|Other|Intervention|"Treatment literacy in chronic condition waiting rooms/pick-up points (posters, health promotion talks)~1-2 longer consultations with ENHANCE guide trained clinician~Treatment literacy event - a contact between a CHW and a person with MLTC in their home (hopefully with carer), at 2 weeks and 4 weeks, using Health Diary~Referrals to additional adherence counselling if necessary"
89117870|NCT06248190|No Intervention|Control|Usual care at primary health care clinic, which includes consultation with a clinician using the PACK/APC guide. No additional support is usually provided for care of MLTCs.
89117871|NCT06248164||Children and adolescents (sons and daughters)|The study will consist of children and adolescents from six years of age.
89117872|NCT06248164||Parents (mothers and fathers)|The study will consist of children and adolescents from six years of age and at least one of their biological parents to be evaluated.
89117873|NCT06248151|Experimental|Exercise|In the exercise session, participants will perform aerobic, free active and flexibility exercises and will last approximately 45 minutes.
89117874|NCT06248151|Other|Control|In the control session, participants will remain seated for 60 minutes.
89117875|NCT06248138||Progression|There is at least one major coronary artery (left main artery, left anterior descending artery, left circumflex artery or the right coronary artery) had non-target lesions, and the coronary artery stenosis rate reached the progressive level on follow-up angiography.
89117876|NCT06248138||Non-progression|The rate of coronary stenosis of the non-target lesion did not reach progressive levels during the repeat angiography.
89117877|NCT06248125|Experimental|Singing intervention (music with enrichment)|The goal of this intervention is to improve the frequency and quality of active parent-infant interaction via infant-directed singing. Throughout the 20-week intervention period, parents will be offered a weekly, smartphone- based, music intervention program featuring video-recorded music classes specifically designed for parents with infants. The video classes, which are part of Music Together Wiggle & Sing curriculum, introduce new songs and demonstrate hands-on activities with the songs that parents can easily incorporate into their daily routines. The activities are highly interactive, emphasizing physical contact, gross-motor play, eye contact, cuddling, and rocking. Recordings of these songs will be also provided to supplement parents' learning in the instructional videos with audio-only content (e.g., for parents to use when viewing a video is not convenient). Parents will use the Music Together app and receive a weekly access code for a fresh set of intervention resources.
89117878|NCT06248125|Active Comparator|Music listening intervention (music with limited enrichment)|This intervention follows the same structure as the singing intervention but focuses on the use of passive music listening rather than live singing. On a weekly basis, parents will be provided with a carefully curated music playlist, along with tips on how to effectively incorporate recorded music into their daily lives. These weekly playlists will feature 10 music recordings suitable for everyday scenarios commonly experienced together by parents and infants (e.g., calming lullabies for naptime, exciting play songs for free play). The playlists are intended to serve as background music, thus creating a very different musical experience compared to that of the singing intervention. Each week, parents will receive a link to access a new playlist, along with an information sheet about the music and tips on how to use them. Parents will use Spotify to access the playlists on their smartphones and computers.
89117879|NCT06248125|Active Comparator|Book reading intervention (enrichment with limited music)|This intervention follows the same structure as the singing intervention, but without the musical elements, while emphasizing enriched parent-infant interaction in non-musical (or less-musical) contexts. Throughout the intervention period, parents will be provided with developmentally appropriate books, carefully selected to encourage increased parent interaction. Along with each book, a demonstration video analogous to the Wiggle and Sing videos used in the singing intervention will be offered. These videos demonstrate techniques to create a rich listening experience for young infants, such as using infant-directed speech and highlighting aspects of illustrations to engage the infant. In line with the singing intervention, the activities will be highly interactive, emphasizing the use of infant-directed speech and physical interactions with their infants.
89117880|NCT06248125|No Intervention|No intervention|No intervention will be provided.
89117881|NCT06248112|Experimental|Sequence 1-Sacubitril and Valsartan test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sacubitril 97 mg and Valsartan 103 mg test product, treatment 2= Sacubitril 97 mg and Valsartan 103 mg reference product.
89117882|NCT06248112|Experimental|Sequence 2-Sacubitril and Valsartan reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sacubitril 97 mg and Valsartan 103 mg test product, treatment 2= Sacubitril 97 mg and Valsartan 103 mg reference product.
89117883|NCT06248099|Experimental|Sequence 1-Nebivolol test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Nebivolol tablets 5 mg test product, treatment 2= Nebivolol tablets 5 mg reference product.
89117884|NCT06248099|Experimental|Sequence 2-Nebivolol reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Nebivolol tablets 5 mg test product, treatment 2= Nebivolol tablets 5 mg reference product.
89117885|NCT06248073|Experimental|on-line self-management group|The investigators plan to conduct 12 sessions of intervention, one hour per session, 2 sessions per week, for a total of 6 weeks. Participants will receive interventions in their home via online meetings with a certified occupational therapist. The training will be related to functional tasks in daily life. In addition, the investigators will guide participants to use self-management skills in their daily routines. Participants will receive booklets to conduct their self-practice and exercise for 30 minutes per session, two sessions per week, for a total of 6 weeks.
89117886|NCT06248073|Experimental|on-site task-related group|The investigators plan to conduct 12 sessions of intervention, one hour per session, 2 sessions per week, for a total of 6 weeks. Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. The training will include motor function of upper extremities, balance training and functional tasks. The level of difficulty of the tasks will be adjusted based on the participants' abilities.
89117887|NCT06248073|No Intervention|control group|To compare the two experimental groups in the context of early Parkinson's disease, the control group will not receive any additional intervention and will continue their regular daily activities without changes.
89117888|NCT06248060|Active Comparator|Before preanaesthetic teleconsultation implementation|
89117889|NCT06248060|Experimental|After preanaesthetic teleconsultation implementation|
89117890|NCT06248047||conventional repair|the patients will undergo repair with no regard to the vessels .then follow up by uroflow ,ascending urethrogram and penile doppler .
89117891|NCT06248047||the new technique|the patients will undergo repair with sparing of the vessels .then follow up by uroflow ,ascending urethrogram and penile doppler .
89117892|NCT06248034|Experimental|Participants for Smartphone Home-based Rehabilitation Program (N=15)|Study participants will be recruited from orthopaedic surgeons in Singapore General Hospital. Study participants will be recruited during their outpatient appointment session at the outpatient orthopaedic specialist clinic pre-admission clinic.
89117893|NCT06248034|Experimental|Participants for Hospital-based rehabilitation program (N=15)|Study participants will be recruited from orthopaedic surgeons in Singapore General Hospital. Study participants will be recruited during their outpatient appointment session at the outpatient orthopaedic specialist clinic pre-admission clinic.
89117894|NCT06248021|Experimental|Ecological Footprint Awareness Program Group|The program was conducted for four weeks, one day each week, for 40 minutes. Each week, a different topic was addressed such as waste evaluation, water and energy usage, food consumption, and transportation. The program was created in line with expert opinions and literature.
89117895|NCT06248021|No Intervention|Control Group|No intervention was applied to the group
89117896|NCT06247995|Experimental|Dose A: [177Lu]Lu-NeoB 150mCi q6w + capecitabine|[177Lu]Lu-NeoB 150mCi q6w + Capecitabine 1000mg/ m2 BID Day1-14 in a 21-day schedule
89117897|NCT06247995|Experimental|Dose B: [177Lu]Lu-NeoB 100mCi q3w + capecitabine|[177Lu]Lu-NeoB 100mCi q3w+ Capecitabine 1000mg/m2 BID Day1-14 in a 21-day schedule
89117898|NCT06247995|Experimental|Dose C: [177Lu]Lu-NeoB 200mCi q6w + capecitabine|[177Lu]Lu-NeoB 200mCi q6w + Capecitabine 1000mg/m2 BID Day1-14 in a 21-day schedule
89117899|NCT06247995|Experimental|Dose D: [177Lu]Lu-NeoB 100mCi q6w + capecitabine|[177Lu]Lu-NeoB 100mCi q6w + Capecitabine 1000mg/m2 BID Day1-14 in a 21-day schedule
89117900|NCT06247982||DCB de novo PCI|All patients who recieved a de novo DCB PCI
89117901|NCT06247982||BOS PCI|All patients who recieved a stent after DCB treatment of de novo coronary lesion beacuse of high grade dissection or recoil more than 30%
89117902|NCT06247956|Experimental|SHR-8068 combined with adebrelimab and platinum-containing chemotherapy|
89117903|NCT06247956|Active Comparator|Adebrelimab combined with platinum-containing chemotherapy|
89117904|NCT06247891|Other|Control Group|
89117905|NCT06247878||Sleep apnea/hypopnea detection|Ability of Skiin underwear chest band in detecting sleep apnea or hypopnea will be tested against polysomnography.
89117906|NCT06247826|Experimental|Experimental arm|Patients presenting advanced NSCLC with EGFR ins20 already treated with amivantamab as monotherapy in France under Temporary Use Authorisation or Early Access Program who will accept to provide blood samples at disease progression.
89117907|NCT06247813|Experimental|Nerve Health|
89117908|NCT06247813|Experimental|Oxidative Stress|
89117909|NCT06247813|Experimental|Inflammation|
89117910|NCT06247787|Experimental|Treatment (Imetelstat, fludarabine, cytarabine)|Patients receive imeletstat IV over 2 hours on days 1 and 8, fludarabine IV over 1 hour on days 2-6, and cytarabine IV over 1-3 hours on days 2-6 of each cycle. Patients also receive cytarabine IT or methotrexate IT, and hydrocortisone IT at the provider's discretion. Patients then receive leucovorin calcium IV or PO 24 and 30 hours after each IT triples dose. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, bone marrow biopsy and/or aspirate, blood sample collection, and lumbar puncture for CSF sample collection during screening and on the trial.
89117911|NCT06247774|Experimental|Cardiac Rehabilitation|Participants will participate in a 12-week cardiac rehabilitation program
89117912|NCT06247774|Placebo Comparator|Attention Control|Participants will not participate in a cardiac rehabilitation program and will receive phone calls in place of cardiac rehabilitation visits.
89117913|NCT06247761|Active Comparator|Vicryl rapide suture for Skin closure|Skin closure at end of hand trauma surgery
89117914|NCT06247761|Active Comparator|Nylon suture for Skin closure|Skin closure at end of hand trauma surgery
89117915|NCT06247748|Experimental|Exendin-4 Fc fusion protein (JY09) injection|D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29 to D78 received continuous subcutaneous abdominal injections of 2.4 mg of JY09 injection in the morning, once weekly (total of 8 administrations). All doses were to be administered within 3 min.
89117916|NCT06247735|Placebo Comparator|Placebo + K-877 (Group A)|Placebo for 12 Weeks followed by K-808 (Dose A) for 52 Weeks
89117917|NCT06247735|Placebo Comparator|Placebo + K-877 (Group B)|Placebo for 12 Weeks followed by K-808 (Dose B) for 52 Weeks
89117918|NCT06247735|Experimental|K-808 Group A|K-808 (Dose A) for 64 Weeks
89232640|NCT04577352|Experimental|Vatiquinone|Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if ˂12 years of age and weighing ˂25 kilograms (kg) or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 72 weeks during the placebo-controlled phase and for 24 weeks during the open-label extension phase.
89232641|NCT04577352|Placebo Comparator|Placebo|Participants will receive placebo matching to vatiquinone (per age and weight) orally TID for 72 weeks during the placebo-controlled phase and vatiquinone at a dose of either 200 mg orally TID if ˂12 years of age and weighing ˂25 kg or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 24 weeks during the open-label extension phase.
89117919|NCT06247735|Experimental|K-808 Group B|K-808 (Dose B) for 64 Weeks
89117920|NCT06247709||Cases|All patients undergone surgery for the removal of a pituitary adenoma. Tissue samples of these cases were sent to biochemical essay to measure the expression and localisation of KLHL14.
89117921|NCT06247696|Placebo Comparator|Placebo Pillow|
89117922|NCT06247696|Active Comparator|Control Pillow|
89117923|NCT06247696|Experimental|Vata Pillow|
89117924|NCT06247696|Experimental|Pitta Pillow|
89117925|NCT06247696|Experimental|Kapha Pillow|
89117926|NCT06247657|Experimental|BL0006|Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
89117927|NCT06247631||Control|Easy airway: unassisted mask ventilation, ventilation without the need for an airway, achieving oxygen saturation above 90% during mask ventilation, and unassisted intubation with less than three attempts.
89117928|NCT06247631||Difficult airway|Difficult airway: assisted mask ventilation, need for airway during ventilation, oxygen saturation falling below 90% during mask ventilation, assisted intubation, intubation attempt three and above
89117929|NCT06247618|Experimental|Virtual reality|
89117930|NCT06247605|Experimental|active group（AL8326）|Oral AL8326 (28-day cycle, once daily) until confirmation of disease progression, intolerable toxicity or death, voluntary withdrawal from the study, for a total of no more than 12 months (approximately 13 cycles).
89117931|NCT06247605|Placebo Comparator|Control group（Placebo)|Oral placebo (28-day cycle, once daily) until confirmation of disease progression, intolerable toxicity or death, voluntary withdrawal from the study, for a total of no more than 12 months (approximately 13 cycles).
89117932|NCT06247592|Experimental|Radiofrequency group|Pulse radiofrequency will be applied at 42 degrees for 240 seconds with a channel placed near the greater occipital nerve.
89117933|NCT06247592|Active Comparator|Block group|Nerve blockade will be applied to the greater occipital nerve with 5 cc 2% prilocaine.
89117934|NCT06247553|Experimental|Gait Training|The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device. A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph. After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph. Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm. Reseachers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.
89232642|NCT04577118|Other|iotaSOFT Insertion System|The iotaSOFT Insertion System is a surgical device that aids the surgeon in implanting cochlear electrode arrays by controlling the speed and distance of implant insertion. All subjects enrolled in the trial will have the iotaSOFT Insertion System used during surgery.
89232643|NCT04576832|Experimental|Group A (MT group)|Participants will receive 4 weeks of mindfulness training during the first training interval between the first (T1) and second (T2) assessment sessions.
89232644|NCT04576832|Active Comparator|Group B (Wait-list group)|Participants will not receive 4 weeks of mindfulness training during the first training interval; they will receive 4 weeks of mindfulness training during the second training interval between the second (T2) and third (T3) assessment sessions.
89117935|NCT06247553|Active Comparator|Leg Cycling Exercise|The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group. The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate. If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased. The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes. Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety. Each session including setting up will be about one hour.
89117936|NCT06247527|Experimental|PROACT group|Participants in intervention clinics with at least mild psychological distress (having depressive, anxiety or trauma symptoms) will receive a brief, modular, transdiagnostic psychological intervention (PROACT) delivered by non-specialist health providers at the HIV clinic.
89117937|NCT06247527|Active Comparator|Control group|Participants in control clinics with at least mild psychological distress (having depressive, anxiety or trauma symptoms) will be enrolled in the study, and will receive the standard of care interventions available in the HIV clinic.
89117938|NCT06247514|Experimental|The BEET Diabetes Program|The BEET Diabetes program consists of 6 sessions that follow a sequence: the first 3-sessions weekly and the last 3-sessions every other week. These sessions help participants learn strategies and health behavior change through a self-monitoring form. Supporters (in this study, the BHPs) guide individuals through the program, maintain motivation, and facilitate appropriate goal-setting. The BEET Diabetes Program emphasizes treating disorder eating behaviors (DEBs) in the context of diabetes (i.e., psychoeducation on DEBs in diabetes, optimal daily glucose management, benefits of physical activity, and fruit and vegetable intake).
89117939|NCT06247514|Active Comparator|Cognitive behavioral Therapy Guided Self-help|"The Cognitive Behavioral Therapy Guided Self-help consists of 6 sessions that follow a sequence: the first 3-sessions weekly and the last 3-sessions every other week. These sessions help participants learn strategies and health behavior change through a self-monitoring form. The CBTgsh program is delivered through the self-help book: Overcoming Binge Eating by Christopher G. Fairburn. Guided support sessions can be provided by personnel with no background training or knowledge of CBT or DEBs, as the book acts as the expert."
89117940|NCT06247488|Experimental|Placebo|- Oral dose
89117941|NCT06247488|Active Comparator|Oxycodone 20 mg|- Oral dose
89117942|NCT06247488|Experimental|GE-IR 200 mg + Oxycodone 20 mg|- Oral dose
89117943|NCT06247488|Experimental|GE-IR 450 mg + Oxycodone 20 mg|- Oral dose
89117944|NCT06247488|Experimental|GE-IR 200 mg|- Oral dose
89117945|NCT06247488|Experimental|GE-IR 450 mg|- Oral dose
89117946|NCT06247462|Experimental|Ibuprofen|600 mg of Ibuprofen was ingested 12- and 1-hour prior to exercise.
89117947|NCT06247462|Placebo Comparator|Placebo (Corn Starch)|600 mg of corn starch was ingested 12- and 1-hour prior to exercise.
89117948|NCT06247332||Retrospective Long COVID cases|The target population will be as balanced as possible between subjects who needed specialized care due to long COVID-19 complications (either specialized care consultations or any non-planned hospital admission) at 1 month, 3 months, 6 months and 1 year from the long COVID-19 diagnose and those who did not require such specialized care.
89117949|NCT06246955|Experimental|Supportive care (group therapy sessions)|Patients attend acceptance and commitment virtual group therapy sessions over 1.5 hours each, once a week for 6 weeks.
89232647|NCT04572893|Experimental|MYK-491|Primary DCM due to MYH7 or TTN Variant or due to other causalities not related to MYH7 or TTN variants
89232649|NCT04568434|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
89232650|NCT04568434|Placebo Comparator|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
89232651|NCT04567602||Participants with PAH|Participants with confirmed diagnosis of pulmonary arterial hypertension (PAH) will be enrolled in the study and the data will be collected and observed to describe the application of European ESC/ERS guidelines and related 6th WSPH proceedings on risk assessment and related treatment strategy, in clinical practice.
89232652|NCT04565457|Experimental|Participants Scanned|All participants will be scanned with a CBCT system equipped with 2D antiscatter grid technology, referred to as research CBCT. Each participant will also be scanned with a standard clinical CBCT as part of their standard clinical care, which will serve as the baseline, or control.
89232653|NCT04559685|Experimental|Arm A Energy Dose-escalation|In Arm A, the dose-escalation cohort, there will be 3 cohorts of ascending MRgFUS power/energy dose combinations with a fixed SONALA-001 dose and fixed surgical time. Arm A will determine the power/energy dose combination for Arm B.
89232654|NCT04559685|Experimental|Arm B Time-escalation|In Arm B, the time-escalation cohort, the SONALA-001 and power/energy dose combination will be fixed. Participants will be enrolled into two time cohorts (2 days and 6 days post-SDT).
89232655|NCT04559685|Experimental|Arm C ALA Dose-escalation|In Arm C, the MRgFUS power/energy dose will be fixed based on Arm A MTD/OBD, with the SONALA-001 dose escalation.
89232656|NCT04559685|Experimental|Arm D MRgFUS alone|In Arm D, MRgFUS treatment alone will be given at the optimal energy determined from previous Arms.
89232657|NCT04559685|Experimental|Arm E Optimal energy and ALA dose|In Arm E patients will receive treatment at the optimal energy and ALA dose determined form prior Arms.
89232658|NCT04557098|Experimental|Part 3: Teclistamab|Participants will receive teclistamab subcutaneously (SC) at recommended Phase 2 dose (RP2D) (Cohort A and Cohort C) and will receive alternative dosing schedule of teclistamab (Cohort D).
89232659|NCT04557059|Active Comparator|Interventional Cohort (Group 1): RT+ LHRHa|Participants will receive radiotherapy (RT) which is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy with or without optional stereotactic body radiation therapy (SBRT), along with a luteinizing hormone-releasing hormone agonist (LHRHa) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization.
89232660|NCT04557059|Experimental|Interventional Cohort (Group 2): RT+LHRHa + Apalutamide|Participants will receive prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), along with a LHRHa as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization. Participants will also receive 240 milligram (mg) of apalutamide starting within 3 days after randomization as film-coated tablets, to be swallowed whole and together once daily with or without food, for a period of 180 Days.
89232661|NCT04557059|No Intervention|Observational Cohort(Group3) PSMA-PET Negative Participants|Enrollment into this cohort will be stopped further. Participants who were PSMA-PET-negative at screening and were already enrolled in the Observational Cohort will continue in this cohort. Data collected in the course of routine clinical practice during this period will include clinical evaluations, disease progression, therapies administered as per standard-of-care at the study-sites and survival status. For Observational Cohort, information will be entered into the electronic case report form (eCRF) from the medical records at least twice a year. The use of any medicinal product(s) for the treatment and management of participants will be at discretion of the treating physician.
89232662|NCT04548752|Experimental|Arm A (olaparib, pembrolizumab)|Patients receive olaparib PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 19, patients receive olaparib PO BID on days 1-42 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI, tumor biopsy and blood sample collection throughout the study.
89232663|NCT04548752|Active Comparator|Arm B (olaparib)|Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI, tumor biopsy and blood sample collection throughout the study.
89232664|NCT04540796|Experimental|Part A: Dose Escalation|Participants will receive JNJ-75348780. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along with the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.
89232665|NCT04540796|Experimental|Part B: Cohort Expansion|Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.
89290067|NCT03935412|Active Comparator|ES Erector Spinae Plane Block|By the end of surgery parturient in the ESPB underwent bilateral ESPB at the level of T9 using a linear ultrasound (US) transducer (Phillips Saronno Italy) the transducer was placed vertically3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine 22-G short bevel needle (spinocan, B.Braun melsungen AG, Germany) was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml 0.5% bupivacaine was done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
89117950|NCT06246942|Experimental|Healthy Participants|"All participants will be scheduled for a minimum of four separate visits. The first visit will consist of MRI scanning sessions (including T1 and T2 structural MRI, diffusion MRI, and resting-state fMRI), followed by a single-pulse TMS session to determine the participant's resting motor threshold. The remaining three visits consist of a series of TMS-EEG runs using the paired associative stimulation (PAS) methodology. Each visit will be restricted to a single asynchrony condition with every participant receiving all three conditions over the course of the three visits. Participants will not be informed of which asynchrony condition they are receiving on any given visit.~Some subjects may be invited for additional sessions for the purposes of optimizing TMS, EEG, or MRI parameters, and to assess test-retest reliability."
89117951|NCT06246812|Experimental|DFFC Group|Students who participated in the 2022 DFFC
89117952|NCT06246812|Experimental|DFFC + Text Group|Students who participated in the 2022 DFFC and received text messages
89117953|NCT06246812|No Intervention|Control Group|Students who did not participate in the 2022 DFFC
89117954|NCT06246552|Experimental|JTM201|Botulinum toxin
89117955|NCT06246552|Placebo Comparator|Placebo|Placebo
89117956|NCT06246279|Experimental|Experimental group|"In addition to the routine diabetes training of the institution, the Adaptation to Adolescence and Type 1 Diabetes Management Training Program prepared in line with Meleis's Transition Theory will be administered online to adolescents via Microsoft Teams Program in groups of 10 people, for a total of 10 sessions in 2 months."
89117957|NCT06246279|No Intervention|Control group|The routinely planned diabetes education of the institution will be given by the training nurse.
89117958|NCT06245980||With SGLT2I|
89117959|NCT06245980||Without SGLT2i|
89117960|NCT06245863|Experimental|Negative pressure and Laser: Combined Therapy|Vacuum therapy combined with laser on back pain.
89117961|NCT06245863|Experimental|Positive Pressure and Laser: Combined Therapy|Rollers combined with laser on back pain.
89117962|NCT06245863|Experimental|Ultrasound and Laser: Combined Therapy|Ultrasound combined with laser on back pain.
89117963|NCT06245863|Active Comparator|Laser|Infrared Laser on back pain.
89117964|NCT06245863|Placebo Comparator|Placebo Laser|The placebo laser treatment.
89117965|NCT06245577|Experimental|Biomesh|"Biodesign (TM) Rectopexy Graft~Mesh used in the mesh sacropexy of the middle pelvic organ compartment (vagina, cervix, or uterus); the mesh fixes the middle pelvic organ compartment to the promontory"
89117966|NCT06245577|Active Comparator|Synthetic mesh|"DynaMesh (TM) VASA~Mesh used in the mesh sacropexy of the middle pelvic organ compartment (vagina, cervix, or uterus); the mesh fixes the middle pelvic organ compartment to the promontory"
89117967|NCT06245200|Experimental|Guided Internet Based Intervention|Participants in this group will use the UNIPDES intervention with guidance support.
89117968|NCT06245200|Experimental|Unguided Internet Based Intervention|Participants in this group will use the UNIPDES intervention without guidance
89117969|NCT06245200|No Intervention|Waitlist|Participants in this group will not receive any intervention. However, if they wish, they will be able to access the UNIPDES unguided version when the trial ends.
89117970|NCT06245148||Hypothermia|
89117971|NCT06245148||Normothermia|
89117972|NCT06243211|Active Comparator|DMED|Dorsal myelotomy and expansive duraplasty (DMED) only.
89117973|NCT06243211|Active Comparator|DMED + ANGI|Dorsal myelotomy and expansive duraplasty (DMED) and supplemental autologous nerve graft implantation (ANGI).
89117974|NCT06242028||Group P (Perinuerally)|Ultrasound guided PENG block with perinuerally dexamethasone administration group
89117975|NCT06242028||Group S (Systematic)|Ultrasound guided PENG block with systemic dexamethasone administration group
89117976|NCT06241664|Experimental|AEYE-DS Software Device|Eligible participants will undergo the following procedures: photographic imaging of each eye using various fundoscopy camera devices. Images obtained will be sent to the AEYE-DS software for analysis. Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second fundoscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. All study subjects will have their pupils dilated using dilation drops.
89117977|NCT06241391|Experimental|Efficiency of 68 Ga-PSMA-11 PET-CT in detection of recurrent gliomas|"Primary objective Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas Secondary objectives~Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images~Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas~Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan~Correlation between PSMA expression in histopathology specimen (using IHC) and SUVmax of recurrent lesion on 68Ga- PSMA PET-CT scan.~Any adverse events of Ga-68 PSMA-11 will be recorded according to CTCAE"
89117978|NCT06240728|Experimental|NPX887 Treatment|
89117979|NCT06240351|Experimental|Baricitinib|All patients will be treated with the active product, Baricitinib. Each patient will take 4mg of Baricitinib daily for 36 weeks.
89117980|NCT06240299|Experimental|Rheumatoid Arthritis - neurofeedback training|"Intervention: visual neurofeedback~Research Assessments~EEG: relaxed state and motor imagery~Quantitative sensory testing~Questionnaires (after each intervention session):~visual analog scale - rate pain intensity~pain description and pain intensity reporting~mental strategies, affects (emotional experience) and sensations during NF~adverse event reporting~NASA task load index~Questionnaires (week before and week after intervention weeks)~Routine Assessment of Patient Index Data 3 (RAPID3)~American College of Rheumatology Fibromyalgia Scale (ACRFS)~McGill Pain Questionnaire~Patient-Reported Outcomes Measurement Information System (PROMIS) Depression~PROMIS-Anxiety~PROMIS-Fatigue~PROMIS-Sleep related impairment~Pain Number Rating Scale~Generalised Self-Efficiency Scale questionnaire~Multidimensional Health Locus of Control Scale questionnaires~Remote follow-up: semi-structured interview over the telephone"
89117981|NCT06239207|Experimental|Exosomes|Group A patients are injected exosomes 1 session intradermally at a dose of 0.1 ml/cm2 of scalp. Exosomes used are GFC CELL(TM) EXO SCALP KIT
89117982|NCT06239207|Active Comparator|B PRP|Group B patients are injected PRP intradermally in scalp. Uunder aseptic around 10ml of blood is collected from the median cubital vein and is transferred into a sodium citrate tube. Then the tubes are rotated in a centrifuge machine at 1500 RPM for 10 minutes.It separates the blood into 2 layers: the lower RBC layer; the upper plasma layer buffy coat. The buffy coat was transferred into another test tube. This tube was again subjected to a second centrifugation at 4000 RPM for 10 minutes. Both the upper layer containing platelet poor plasma and the lower layer of the PRP was collected. The plasma is filled into insulin syringe and then injected evenly into the affected areas of the scalp. Multiple PRP injections of 0.1 mL were given at each site in a linear pattern 1 cm apart
89117983|NCT06238973|Active Comparator|Group Low|Group Low will aim to maintain an average arterial pressure in the range of 50-57 mmHg.
89117984|NCT06238973|Active Comparator|Group Middle|The target is to keep the average arterial pressure within the range of 58-65 mmHg
89117985|NCT06233656|Experimental|Acceptance and commitment therapy (ACT) group|The ACT group will receive eight weekly individual ACT sessions guided by a coach through videoconferencing with a booster session at 1-month follow-up.
89117986|NCT06233656|No Intervention|Wait-list control group|The wait-list control group will maintain his or her own care as usual during the study period and receive eight individual ACT sessions after study participation ends.
89117987|NCT06227910|Experimental|Induction Period: Vedolizumab + Upadacitinib|Participants will receive vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, 6 and 10 along with upadacitinib 45 mg, orally, once daily (QD) during the 12-week Induction Period.
89117988|NCT06227910|Placebo Comparator|Induction Period: Vedolizumab + Placebo|Participants will receive vedolizumab IV 300 mg infusion, at Weeks 0, 2, 6 and 10 along with upadacitinib matched placebo, orally, QD during the 12-week Induction Period.
89117989|NCT06227910|Experimental|Maintenance Period: Vedolizumab Monotherapy|Participants who achieve a CDAI reduction of ≥70 points from baseline at Week 12 will receive vedolizumab 300 mg IV infusion (monotherapy), every 8 weeks (Q8W) during the 40-week Maintenance Period. The Q8W vedolizumab monotherapy may be escalated to Q4W as per protocol-specified criteria.
89117990|NCT06227650||Group1|Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
89117991|NCT06221566|Experimental|Group A|Muscle energy technique (MET)
89117992|NCT06221566|Active Comparator|Group B|Stretching exercise program
89117993|NCT06220396|Experimental|Healthy Volunteers|Healthy volunteers with no history of Heart Failure (HF) will undergo a Right Heart Catheterization with Hemodynamics and Limited Echocardiogram, MRI, and DEXA scan.
89117994|NCT06216613|Experimental|Sensory Enhanced Aquatics|Sensory Enhanced Aquatics is a specialized swimming and water safety program for autistic children.
89117995|NCT06216613|Active Comparator|Standard Swim Lessons|Standard swim lessons which are provided to the general public will be used as the comparison group.
89117996|NCT06214481|Experimental|Rocatinlimab|Participants will receive a single SC dose of rocatinlimab.
89117997|NCT06210932|Experimental|Intervention group-seed video|The participants will engage in a total of four weeks of intervention. The intervention sessions are conducted three times per week, there will be a total of 12 intervention sessions. The intervention group will receive a social, emotional, and ethical development video intervention. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
89117998|NCT06210932|No Intervention|Control group-languag enhancement video|The participants will engage in a total of four weeks of intervention. The intervention sessions are conducted three times per week, there will be a total of 12 intervention sessions. The participants in control group will watch a language enhancement video.
89117999|NCT06207929||Study Population|Adult participants (ages 18+) who reside in the contiguous United States
89118000|NCT06207032||Participants with cancer|No intervention.
89118001|NCT06205654||Intervention|innovative lighting designs are implemented in the living area.
89118002|NCT06205654||Control|no significant modifications to their lighting conditions are implemented in the living area
89118003|NCT06194123|Experimental|Experimental|All subjects will be instructed to use the Crest Daily Whitening Serum for 1 week as described on the label. This product is available for purchase at any pharmacy.
89118004|NCT06193421|Experimental|Ambroxol hydrochloride|Daily administration of Ambroxol in newly diagnosed GBA1 PD.
89118005|NCT06189976|Other|Rapid atrial pacing|Diagnostic test group (single group)
89118006|NCT06188481|Other|Intervention group with WB-EMS Training|The Intervention group receives 1.5 times a week WB-EMS training, wears an activity tracker for 16 weeks and completes 6 sessions of an evidence-based lifestyle education program.
89118007|NCT06188481|Other|Control group with activity tracker and evidence-based lifestyle education program|The control group wears an activity tracker for 16 weeks and completes 6 sessions of an evidence-based lifestyle education program.
89118008|NCT06188481|Other|Control group with evidence-based lifestyle education program|The control group completes 6 sessions of an evidence-based lifestyle education program.
89118009|NCT06185062||oART|Patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART (online Adaptied Radiotherapy).
89118010|NCT06185062||IGRT|Patients with pelvic or thoracic tumors with an indication for radiotherapy treated with conventional IGRT (Image Guided Radiotherapy).
89118011|NCT06182345||Experiment gourp|Autologous skin cell suspension combined with autologous skin graft was used to treat burn wound
89118012|NCT06182345||Control group|Autologous skin graft was used to treat burn wound
89118013|NCT06174038|Other|Hearing Intervention|Participants will receive 4 sessions across 8 weeks with a later booster session and hearing aid fitting. Each session will take ~75 minutes.
89118014|NCT06174038|Other|Health Education Intervention|Participants will receive a modified health education program on healthy aging. It will match the number and length of sessions as the hearing intervention, including compliance/phone checks. Participants will be on a waitlist to obtain hearing aids without fee at the end of their 12-month participation.
89118015|NCT06163092||Observational study|Women with recurrent miscarriage would be invited to do endometrial sampling (ES) procedure. The ES will be conducted precisely 7 days after LH surge. It will be obtained using a Pipelle sampler as an outpatient procedure.
89118016|NCT06162572|Experimental|S095018 (anti-TIM3 antibody) in combination with cemiplimab|Part A: Combination-therapy safety lead-in
89118017|NCT06162572|Experimental|S095024 (anti-CD73 antibody) in combination with cemiplimab|Part A: Combination-therapy safety lead-in
89118018|NCT06162572|Experimental|S095029 (anti-NKG2A antibody) in combination with cemiplimab|Part A: Combination-therapy safety lead-in
89118019|NCT06162572|Experimental|S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab|Part B: Randomized dose expansion
89118020|NCT06162572|Experimental|S095024 (anti-CD73 antibody) RDE in combination with cemiplimab|Part B: Randomized dose expansion
89118021|NCT06162572|Experimental|S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab|Part B: Randomized dose expansion
89118022|NCT06162572|Active Comparator|Cemiplimab (control arm)|Part B: Randomized dose expansion
89118023|NCT06162130|Experimental|Other|female athletes
89118024|NCT06161493|Experimental|Niraparib|"ZEN003694: Oral capsules - Starting dose 36 mg Dose escalated to 48 mg, following the mTPI-2/Keyboard design administered orally once daily in 28-day cycles~Niraparib: Oral tablets - Starting dose 100 mg Dose escalated to 200 mg, following the mTPI-2/Keyboard design administered once daily at the same time as ZEN003694"
89118025|NCT06161194|Experimental|Intervention Group (IG)|IG will perform the home-exercise program supported by the digital real-time exercise feedback prototype for digitally guided training.
89118026|NCT06161194|Active Comparator|Control Group (CG)|The CG will perform a usual care home-exercise by means of printed hand-outs describing each exercise.
89118027|NCT06152133|Experimental|Telerehabilitation Core stability exercises group|
89118028|NCT06152133|Active Comparator|Core stability exercises group|
89118029|NCT06151834|Experimental|Patients|Patients older than 18 years-old, with a surgical indication of interphalangeal arthrodesis of finger
89118030|NCT06151145|Active Comparator|Usual care|Usual care
89118031|NCT06151145|Experimental|Text-message intervention with digital tools (SELF)|Text-message intervention
89118032|NCT06151145|Experimental|Stepped Care (STEP)|Stepped care
89118033|NCT06145919|Experimental|Episodic Future Thinking (EFT)|"Mothers will receive episodic future thinking (EFT). Mothers will meet with a peer mother who will administer the EFT intervention, including generation of several specific future events reflecting positive interactions with their child. The participant will be asked to discuss their relationship with their child and to give examples of both positive and negative parenting from their personal experience. The peer mother will then ask the participant to think about their long-term parenting goals and will discuss how to create a vivid event that will be easy to remember. We will also teach each parent a behavioral parent training element called Special Play Time. Following this session, participants are asked to engage in messaging that will prompt them to think about future events."
89118034|NCT06145919|Active Comparator|Episodic Recent Thinking (ERT)|"In the episodic recent thinking (ERT) condition, the participant will be asked to discuss their relationship with their child and to give examples of both positive and negative parenting from their personal experience. The peer mother will then ask the participant to think about the present and discuss how to focus on the present. Two positive recent events and two negative recent events will be used to create ERT scenes for the parent to envision their current relationship with their child. We will also teach each parent a behavioral parent training element called Special Play Time. Following this session, participants will receive messages over the course of two weeks helping parents to focus on recent events with their child."
89118035|NCT06141239|No Intervention|primary closure +Collagen plug +Bone graft|Placement of bone graft and collagen plug
89118036|NCT06141239|Experimental|primary closure + Collagen plug +Bone graft +Vit.D3|Placement of bone graft, collagen plug and local administration of Vit.D3
89118037|NCT06141239|Experimental|primary closure +Collagen plug+Bone graft+Autologous Tooth Root|Placement of bone graft, collagen plug and placement of autologous root slices
89118038|NCT06141239|Experimental|primary closure +Collagen plug+Bone graft+Autologous Tooth Root+Vit.D3|Placement of bone graft, collagen plug and local administration of Vit.D3, and placement of autologous root slices
89232666|NCT04538664|Experimental|Arm A: Amivantamab + Chemotherapy|Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.
89232667|NCT04538664|Experimental|Arm B: Chemotherapy Alone|Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.
89232668|NCT04537936|Experimental|Meaning Centered Psychotherapy for Latinos (MCP-L)|
89232669|NCT04537936|Active Comparator|Control|
89232670|NCT04537013|Active Comparator|Control Arm|Patients with small chondral lesions of the knee
89118039|NCT06140407|Experimental|Treatment (pembrolizumab)|Patients undergo radiation therapy and receive cisplatin or carboplatin on day 1 of each cycle and etoposide on days 1-3 for 4 cycles. Patients then receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan during screening. Patients also undergo MRI throughout the trial as well as CT. Additionally, patients undergo blood sample collection throughout the trial.
89118040|NCT06134921|Experimental|Active tDCS and conventional physical therapy program|Participants will receive Active tDCS for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
89118041|NCT06134921|Experimental|Active tACS and conventional physical therapy program|Participants will receive Active tACS for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
89118042|NCT06134921|Sham Comparator|Sham stimulation and conventional physical therapy program|Participants will receive sham stimulation for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
89118043|NCT06129903|Experimental|Early Psychiatric Referral|Participants will be randomized to the Early Psychiatric Referral group
89118044|NCT06129903|No Intervention|No Referral|Participants will be randomized to the No Referral group
89118045|NCT06129695|Experimental|Computer guided intra sinus approach for Zygomatic implant placement.|"After reflection of mucoperiosteal flap then the non-working tip of the coarse diamond bur will be inserted till the initial marking point and further preparation of osteotomy site will be performed along the lateral wall of maxillary sinus then sinus membrane will be reflected gently to get easily access for 3.5 mm drill or 4-4.5 mm diameter Zygomatic implant. The surgical stent will be inserted inside the patient's mouth; it will be adapted and held in place by the anchoring screws to Zygoma and osteotomy will progressively widened by using standard 2.9 mm diameter drill and 3.5 mm twist diameter drill.~Depth indicator will be used to determine the length of Zygomatic implant. Zygomatic implant will be placed.~The platform of Zygomatic implant will be emerged over and close to the top of the crest of the residual alveolar ridge near to first molar region. Closure will done with 3-0 silk suture."
89118046|NCT06129695|Active Comparator|Computer guided extra sinus approach for Zygomatic implant placement.|"After adequate exposure of surgical The surgical stent will inserted inside the patient's mouth; it will adapted and held in place by the anchoring screws to Zygoma and osteotomy will progressively widened by using standard 2.9 mm diameter drill and 3.5 mm twist diameter drill.~Depth indicator will be used to determine the length of Zygomatic implant. Zygomatic implant that will placed.~The platform of Zygomatic implant will be emerged over and close to the top of the crest of the residual alveolar ridge near to first molar region. Closure will done with 3-0 silk suture."
89118047|NCT06127550|Experimental|Active taVNS|Participants will receive custom current at 5 Hz to the left auricular branch of the vagus nerve while learning new letter-sound relationships.
89118048|NCT06127550|Sham Comparator|Sham taVNS|Participants will undergo current thresholding but device will be turned off without their knowledge during the training.
89118049|NCT06108544|Experimental|TAK-279|
89118050|NCT06108544|Placebo Comparator|Placebo|
89118051|NCT06108544|Active Comparator|Apremilast|
89118052|NCT06106451|Active Comparator|Standard of Care plus Enhanced Patient Education|Each participant in this arm will receive enhanced patient education. The research staff will discuss the benefits of cardiac rehabilitation and provide a pamphlet describing the benefits discussed. The research staff will also call the patient four times throughout their participation in the study to encourage physical activity. The enhanced patient education program will begin approximately 2 weeks after the TAVR procedure.
89118053|NCT06106451|Active Comparator|Motivational Interviewing Intervention|Each participant in this arm will have a motivational interviewing program created by a psychologist. The motivational interviewing program will be tailored to the individual participant. The goal of the motivational interviewing program is improved adherence to standard of care cardiac rehabilitation. The motivational interviewing program will begin approximately 2 weeks after the TAVR procedure.
89118054|NCT06106451|Active Comparator|Home-Based Activity Program plus Motivational Interviewing Intervention|Each participant in this arm will be evaluated by a physical therapist and psychologist. The physical therapist will use the evaluation to create an individually tailored home-based activity program plan. This home-based activity program will be implemented at the 1-month post-operative cardiology clinic appointment. The psychologist will use the evaluation to create an individually tailored motivational interviewing program. The motivational interviewing program will begin approximately 2 weeks after the TAVR procedure.
89118055|NCT06102330|No Intervention|Usual Care|No alteration in care. Will interview families and clinicians at 1 month, and families again at 6 and 12 months
89118056|NCT06102330|Experimental|Intervention|Will review a web-based decision-making tool with families and simultaneously interview family regarding website topics. Will interview families and clinicians at 1 month, and families again at 6 and 12 months
89118057|NCT06093919||Liver transplant patients|This cohort will consist of all liver transplant patients followed between 01/01/2023 and 06/30/2024
89118058|NCT06090500|Experimental|Submucosal Cryotherapy|preoperative submucosal infiltration injection of (2.5C-5C) cold saline
89118059|NCT06090500|Active Comparator|Submucosal NSAIDs|preoperative submucosal infiltration injection of Diclofenac sodium
89118060|NCT06090500|Active Comparator|Submucosal corticosteroids|preoperative submucosal infiltration injection of dexamethasone
89118061|NCT06090500|No Intervention|Control|no preoperative injection apart from the normal anaesthetic routine
89118062|NCT06090305|Experimental|Intervention group|"Participants allocated to the intervention group will receive access to levidex in addition to treatment as usual (TAU). levidex is a digital health application designed for individuals with Multiple Sclerosis (MS), accessible through a web browser. The application comprises 16 modules, with the majority focusing on treatment methods derived from cognitive behavioral therapy (CBT) and health behavior change. The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 365 days."
89118063|NCT06090305|Active Comparator|Control group|Participants allocated to the control group will receive an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in Multiple Sclerosis (MS) in addition to treatment as usual (TAU). After 6 months, they will be offered access to levidex.
89118065|NCT06088043|Experimental|TAK-279|
89118066|NCT06088043|Placebo Comparator|Placebo|
89118067|NCT06088043|Active Comparator|Apremilast|
89118068|NCT06074029|Experimental|Immunotherapy cohort|Patients who were administered with immunotherapy
89118069|NCT06073652|Active Comparator|Control formula group|The Control Formula group will receive 1st age infant formula exclusively for the first six months.
89232671|NCT04537013|Experimental|Investigational Group|Patients with large chondral lesions of the knee
89232672|NCT04535544|Experimental|Immediate Active Treatment arm: JNJ-73763989 + NA|Participants will receive JNJ-73763989 subcutaneous (SC) injection every 4 weeks (Q4W) along with NA (entecavir [ETV], tenofovir disoproxil, or tenofovir alafenamide [TAF]) once daily for 144 Weeks in Part 1 and 2.
89118070|NCT06073652|Experimental|Experimental formula group|The Experimental Formula group will receive 1st age infant formula identical to Control formula, but supplemented with a HMO blend and a probiotic exclusively for the first six months.
89118071|NCT06070987|Experimental|BoNT-A injection and robot therapy|Training session included 40 minutes Robotic Therapy, the group will receive 2 sessions per week, for 12 weeks.
89118072|NCT06070987|Experimental|None BoNT-A injection and robot therapy|Training session included 40 minutes Robotic Therapy, the group will receive 2 sessions per week, for 12 weeks.
89118073|NCT06069492|Active Comparator|Standard-dose group|Consumes one serving containing 38 grams wheat pasta daily for 6 days every week
89118074|NCT06069492|Active Comparator|Low-dose group|Consumes one serving containing 5 grams wheat pasta and 33 grams gluten-free pasta daily for 6 days every week
89118075|NCT06065228||UC|
89118076|NCT06065228||CD|
89118077|NCT06062992||Patients with 'recombined imaging only lesions' or ROLs|Women that recently underwent CEM, which showed a suspicious breast lesion only on the recombined (enhancement) images: a 'recombined image only lesions' or ROL. These women are indicated to undergo CESB.
89118078|NCT06052488|Experimental|Strength After Breast Cancer (SABC) Intervention|"Participants will undergo study procedures as outlined:~Complete a baseline survey regarding exercise self-efficacy, physical activity level, quality of life, and fatigue~Attend a 1-on-1 physical therapy evaluation and 4 group exercise sessions at MGH Waltham~After completing the 4 exercise sessions, complete follow-up surveys including a program satisfaction survey~At 1-month post-program, complete follow-up surveys and an individual, semi-structured interview with study staff to supply feedback about the program.~At 3-months post-program, complete follow-up surveys"
89118079|NCT06036316|Experimental|early psychotic symptoms|This group includes patients with ARMS and those with FEP. Although they are not in the same place in the continuum of psychosis, these patients benefit from the same language assessment and CAST, do not benefit from the TLC or the MINI, and the data from their neuropsychological and psychiatric assessment will be used , which is why we have chosen to bring them together in the same arm. They are between 16 and 35 years old and are cared for as part of their usual follow-up at the CPN (Nancy Psychotherapeutic Center). They must have received the diagnosis of ARMS and FEP according to the criteria of CAARMS and SPI-A.
89118080|NCT06036316|Experimental|patients with schizophrenia|The schizophrenic patients group will benefit from language assessment, TLC and CAST. They are between 18 and 55 years old and are cared for as part of their usual follow-up at the CPN. They must have been diagnosed with schizophrenia according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria.
89118081|NCT06036316|Experimental|healthy controls|The control group for this study will be made up of volunteers between the ages of 16 and 55, not suffering from any mental disorder detected on the MINI or from a developmental disorder of oral or written language. They will also benefit from an assessment of cannabis use using the CAST.
89118082|NCT06034418|Active Comparator|Pulse Radiofrequency Group|Pulse radiofrequency therapy will be applied to each nerve in 2 cycles of 120 seconds for patients in the pulse radiofrequency group. After the pulse radiofrequency procedure, 1 cc betamethasone and 1 cc 1% lidocaine will be injected for each nerve.
89118083|NCT06034418|Active Comparator|Block Group|For the patients in the block group, nerve block will be performed by applying 1 cc betamethasone and 1 cc 1% lidocaine for each nerve.
89118084|NCT06029296|Active Comparator|Diclofenac|Participants will take a single 100mg dose of diclofenac.
89118085|NCT06029296|Placebo Comparator|Placebo|Participants will take a single dose of placebo.
89118086|NCT06023407|Experimental|Heat therapy Group|40.5°C water
89118087|NCT06023407|Sham Comparator|Thermoneutral Control Group|36°C water
89118088|NCT06022822|Experimental|Arm I (urolithin A)|Patients receive urolithin A PO on study. Patients also undergo biopsy at time of surgery and collection of blood samples during screening and on study. Patients may also undergo collection of stool samples during screening and on study.
89118089|NCT06022822|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on study. Patients also undergo biopsy at time of surgery and collection of blood samples during screening and on study. Patients may also undergo collection of stool samples during screening and on study.
89118090|NCT06021600|Experimental|Cohort 1 (Pilot)|Participants will only receive 1 dose of oral cladribine, followed by 4 daily doses of cladribine by vein
89118091|NCT06021600|Experimental|Cohort 2 (PK)|Participants will only receive 1 dose of oral cladribine, followed by 4 daily doses of cladribine by vein
89118092|NCT06021600|Experimental|Cohort 3 (All-Oral HCL)|Participants will all receive the same dose of oral cladribine over the course of 5 days.
89118093|NCT06018337|Experimental|DB-1303/BNT323|Enrolled Subjects will be randomized to receive a 8 mg/kg IV dose of DB-1303/BNT323 on Day 1 of each cycle Q3W
89118094|NCT06018337|Active Comparator|investigator's choice single agent chemotherapy|Enrolled Subjects will be randomized to receive investigator's choice single agent chemotherapy (capecitabine:1000 or 1250 mg/m2, Oral, Twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles; paclitaxel：80 mg/m2， IV, Every week (QW) in 3-week cycles; or nab-paclitaxel: 100 mg/m2, IV, Every week (QW) for 3 weeks followed by a one-week rest period in 4-week cycles) until RECIST 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
89118095|NCT06014658|Experimental|Phase 1 Dose Escalation|
89118096|NCT06014658|Experimental|Phase 1b Expansion|
89118097|NCT06002386|Experimental|Vsling device|Vsling device implantation
89118098|NCT06002269|Experimental|BOOST Box Intervention|"Baseline: Questionnaires (FACT-Bl-Cys, mPG-SGA, Short 2012, FAACT, Godin, TCC), exercise prescription, compensation.~Pre-Surgery: Dietitian consultation, at least 3-weeks and up to 6-weeks of Boost Box deliveries and check-ins (nutritional intervention), up to 6 weeks of exercise intervention and logs, ASA Food Record (x2), compensation Post-Surgery: post-surgery surveys once (FACT-Bl-Cys, mPG-SGA, FAACT, Godin), 6 weeks of Boost Box deliveries and check-ins (nutritional intervention), 6 weeks of exercise intervention and logs, weekly hunger check-in, ASA Food Record (x2), Dietitian consultation, compensation.~Follow-up (estimated 6 months after baseline) : 6-month questionnaire, compensation.~Compensation total: up to $100 via electronic gift card."
89118099|NCT06002269|No Intervention|Usual Care|"Baseline: Questionnaires (FACT-Bl-Cys, mPG-SGA, Short 2012, FAACT, Godin, TCC), compensation.~Pre-Surgery: Dietitian consultation, ASA Food Record (x2), compensation. Post-Surgery: post-surgery surveys once (FACT-Bl-Cys, mPG-SGA, FAACT, Godin), Dietitian consultation, ASA Food Record (x2), compensation.~Follow-up (estimated 6 months after baseline): 6-month questionnaire, compensation.~Compensation total: up to $100 via electronic gift card."
89118100|NCT06002217|Active Comparator|TAP Block|
89118101|NCT06002217|Placebo Comparator|saline solution|
89118102|NCT05999110|Experimental|Exercise Group|The participants receive twelve weeks of a supervised personalised exercise program, based on aerobic and strength training. This group also receives a behavioral change session with a psychologist and nutritional advice session with a nutritionist.
89118103|NCT05999110|No Intervention|Control Group|This group receive no exercise intervention. The group receives equally as the exercise group, a behavioral change session with a psychologist and nutritional advice session with a nutritionist.
89118104|NCT05998161|Experimental|reviga + TAU|"Participants allocated to the intervention group will receive access to reviga in addition to treatment as usual (TAU).~reviga is a digital health application designed for individuals with stress and burnout, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by reviga are relaxation, psychoeducation and exercises regarding relevant cognitions and behavior, acceptance, relationships, problem solving strategies, and positive psychology.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
89118105|NCT05998161|No Intervention|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
89118106|NCT05995899|Experimental|Patients with IBS-C|
89118107|NCT05994534|Active Comparator|cysteamine|Single dose, tablets in current treatment dose
89118108|NCT05994534|Experimental|NPI-001|Single dose, NPI-001 (N-acetylcysteine amide) oral solution at molar equivalent of current cysteamine dose.
89118109|NCT05993949|Experimental|Dasatinib|Oral dasatinib 100mg
89118110|NCT05991687|Active Comparator|In-home|
89118111|NCT05991687|Active Comparator|Mail-in|
89118112|NCT05989620||LGMD, DM2, LOPD|
89118113|NCT05983276|Experimental|Decitabine / Selinexor/ Carboplatin / Paclitaxel|"C1:~Days 1-5: Decitabine 10 mg/m2 IV daily Day 6: carboplatin AUC 5 and paclitaxel 80 mg/ m2 Days 13, 20, and 27: paclitaxel 80 mg/m2 For a single 28 day cycle~Assess Response toxicities and immune effector cell changes~C2-C6:~Days 1-5: Decitabine 10 mg/m2 IV daily Day 6: carboplatin AUC 5 and paclitaxel 80 mg/ m2 Day 7 and weekly thereafter (day 14, 21, 28, 35…) Selinexor 60 mg PO Days 13, 20, and 27: paclitaxel 80 mg/m2 each given x five 28 day cycles~Assess responses by exam, CT scan and blood tests, assess toxicities, and immune effector cell changes as well as progression and overall survival"
89118114|NCT05971368|Active Comparator|Group A: Patients will receive ultrasound guided thoracic paravertebral block|Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.
89118115|NCT05971368|Active Comparator|Group B: Patients will receive ultrasound guided serratus anterior muscle block|Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.
89118116|NCT05968924||High risk DFU|"Type 1 or Type 2 diabetes mellitus~Prior history of a healed DFU within 12 months~Subject had at least one outpatient follow up with a provider after diagnosis with a DFU~No active ulcer at the time of enrollment~Male or female, aged <18-75 yrs>~Ambulatory~Provision of signed and dated informed consent form~Stated willingness to comply with all study procedures and availability for the duration of the study~Amputation (not TMA or BKA) allowed"
89118117|NCT05966077|Experimental|SMS|Sending an SMS 48 hours before the 3-month evaluation call planned as part of the VigilanS Lorraine system
89118118|NCT05966077|No Intervention|Without SMS|without Sending an SMS 48 hours before the 3-month evaluation call planned as part of the VigilanS Lorraine system
89118119|NCT05965518|Experimental|High-Intensity Interval Training|
89118120|NCT05965518|Active Comparator|Continuous Moderate Exercise|
89118121|NCT05949541|Experimental|Arm-A|"Everolimus + CDK4/6 inhibitor+ Endocrine therapy group:~Everolimus, 10mg po. qd; Dalpiciclib 125mg po. qd. for 3 weeks, followed by 1 week off, 4 weeks as a cycle.~Aromatase inhibitors (Letrozole/Anastrozole/Exemestane), po. qd. at specific doses (Letrozole 2.5mg/day; Anastrozole 1mg/day, Exemestane 25mg/day); Or Fluvestrant, 500mg im. q28d, (Extra 500mg given after 2 weeks of first dose); Premenopause participants: Goserelin 3.6mg, subcutaneously, once every 4 weeks."
89118122|NCT05949541|Active Comparator|Arm-B|"CDK4/6 inhibitor+ Endocrine therapy group:~Dalpiciclib 125mg po. qd. for 3 weeks, followed by 1 week off, 4 weeks as a cycle.~Aromatase inhibitors (Letrozole/Anastrozole/Exemestane), po. qd. at specific doses (Letrozole 2.5mg/day; Anastrozole 1mg/day, Exemestane 25mg/day); Or Fluvestrant, 500mg im. q28d, (Extra 500mg given after 2 weeks of first dose); Premenopause participants: Goserelin 3.6mg, subcutaneously, once every 4 weeks."
89118123|NCT05947955|Experimental|Rhu-pGSN Treatment|Subjects will receive rhu-pGSN 24 mg/kg once, followed by 5 daily doses of 12 mg/kg based on actual body weight in addition to standard care .
89118124|NCT05947955|Placebo Comparator|Normal Saline Placebo|Subjects will receive 6 doses of normal-saline placebo in volumes equivalent to subjects given rhu-pGSN in addition to standard care.
89118125|NCT05941897|Experimental|Group A|Ceralasertib plus durvalumab combination therapy Participants will be administered orally ceralasertib followed by IV durvalumab each 28 days cycle.
89118126|NCT05941299|Experimental|REGENERA breast implant implantation|
89118127|NCT05940025|Experimental|MORT-LBP|Participants randomly assigned to this arm will use the app, MORT-LBP.
89118128|NCT05940025|Active Comparator|treatment as usual (TAU)|Participants randomly assigned to this arm will receive their TAU only (no use of the app, MORT-LBP).
89118129|NCT05933499|Experimental|IV bimagrumab|
89118130|NCT05933499|Active Comparator|IV placebo plus semaglutide|
89118131|NCT05933499|Placebo Comparator|IV placebo alone|
89118132|NCT05929703|Active Comparator|Hospital Elder Life Program (HELP)|Hospital Elder Life Program (HELP) is built upon multicomponent, non-pharmacologic strategies that target delirium risk factors to optimize cognitive and clinical function during hospitalization.
89118133|NCT05929703|Active Comparator|Family-Augmented Hospital Elder Life Program (FAM-HELP)|The FAM-HELP program will incorporate a family member and/or care partner, who will play a central role with providing bedside support for delirium risk reduction. Family members and care partners will provide social and emotional support along with augmentation of HELP-based protocols.
89118134|NCT05927987|Experimental|Problem Management Plus and care-as-usual|The five sessions of PM+ will be delivered by trained master students in clinical psychology on an individual basis. Care-as-usual will not be withheld.
89118135|NCT05927987|No Intervention|Care-as-usual|Care-as-usual includes all social, health, and mental health services already available for individuals detained in Dutch prisons.
89118136|NCT05922878|Experimental|ALTO-300|Participants will receive ALTO-300 capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).
89118137|NCT05922878|Placebo Comparator|Placebo|Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.
89118138|NCT05917522|No Intervention|Observational Study - Full Cohort|"800 adults first kidney transplant recipients will be followed observationally to evaluate HLA-DR/DQ molecular mismatch (mMM) as a risk-stratifying prognostic biomarker.~Donor-recipient HLA-DR/DQ mMM score will be determined at enrollment and recipients will be followed over 24-months post-kidney transplant for primary alloimmune events (i.e., TCMR, DSA, and ABMR).~Standard of care (SOC) therapy will be used to satisfy the FDA requirement to prospectively evaluate the HLA-DR/DQ mMM score as a prognostic biomarker for post-kidney transplant outcomes."
89118139|NCT05917522|Experimental|Nested RCT - Treatment Group (Abatacept)|"Eligible subjects will be re-consented and randomized to the investigational (abatacept/Mycophenolate mofetil (MMF)/Pred) Arm.~Starting with abatacept at a fixed dose (125 mg s.c. weekly) and eliminate Calcineurin Inhibitor (CNI) over ~3 months using serial Tacrolimus (TAC) C0 level targets to taper the dose.~2200 subjects will be followed for 18 months post-randomization, monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM).~Subjects who develop Biopsy Proven Acute Rejection (BPAR) will have concurrent serum/urine/tissue samples collected and stored."
89118140|NCT05917522|Active Comparator|Nested RCT - Control Group (SOC)|"Eligible subjects will be re-consented and randomized to the control group (tacrolimus/Mycophenolate mofetil (MMF)/Pred) .~100 subjects will be and followed for 18 months post-randomization, monitoring for safety and improvement in renal function, neurocognitive function, and a life participation patient reported outcome measure (PROM).~Subjects who develop Biopsy Proven Acute Rejection (BPAR) will have concurrent serum/urine/tissue samples collected and stored."
89118141|NCT05916339|Active Comparator|Stage 1 - Stimulant|"This proposed naturalistic, pragmatic clinical trial does not involve investigational drugs. Sequential, multiple assignment randomized trial (SMART) pragmatic clinical trial.~Stage 1 - randomization to either Amphetamine (AMP) or Methylphenidate (MPH). The specific medication prescribed by the physician will be determined by discussion between physician and parent / caregiver and review of the subject's insurance coverage. Subjects will receive their medication from their pharmacy."
89118142|NCT05916339|Active Comparator|Stage 2 - Alpha-2 Agonist or Alternate Stimulant|"Stage 2 - randomization to either Alpha-2 Agonist or other stimulant not randomized to in Stage 1: Amphetamine (AMP) or Methylphenidate (MPH).~(frequency, dosage, format, and duration dependent on participant and study doctor discussion)."
89118143|NCT05914246|Experimental|CABG surgery with use of VIOLA|patients will be treated for routine CABG, using VIOLA for maintaining hemostasis during suturing of multiple aortic anastomoses
89118144|NCT05912075|Experimental|LCRT|"LCRT: Long-course pelvic radiotherapy given concomitantly with capecitabine chemotherapy and TOLINAPANT (ASTX660):~mFOLFIRINOX will be given prior to tolinapant (ASTX660) for 6 cycles over 12 weeks;~Pelvic radiotherapy to a planned volume at a 50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks;~Chemotherapy (capecitabine) at 800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy;~TOLINAPANT (ASTX660) starting from 14 days before the first dose of radiotherapy, for 10 weeks. Tolinapant (ASTX660) will be given concomitantly with RT and chemotherapy for 5 weeks."
89118145|NCT05912075|Experimental|SCRT|"SCRT: Short course pelvic radiotherapy followed by chemotherapy in combination with TOLINAPANT (ASTX660):~Pelvic radiotherapy will be given to a planned volume at a total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)~Chemotherapy (FOLFOX4): given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy. Alternative: CAPOX given every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.~Tolinapant (ASTX660) starting from 14 days before the first dose of radiotherapy, for 10 weeks. Tolinapant (ASTX660) will be given concomitantly with RT for 5 days."
89118146|NCT05912023||Vaping patients|Includes patients that actively vape that are undergoing general anesthesia
89118147|NCT05912023||Non-vaping patients|Includes patients that do not actively vape that are undergoing general anesthesia
89118148|NCT05902312|Active Comparator|repetitive Transcranial Magnetic Stimulation|rTMS on a MagPro X100 research grade stimulator (MagVenture) equipped with a B70 fluid-cooled coil. Participant will receive the MDD FDA-approved iTBS protocol (triplet 50 Hz bursts repeated at 5 Hz, 2 s ON and 8 s OFF; 600 pulses per session; total duration of 3 min 9 s, 120% hand motor threshold)
89232673|NCT04535544|Placebo Comparator|Deferred Active Treatment arm: Placebo+NA+JNJ-73763989+NA|Participants will receive matching placebo to JNJ-73763989 SC injection Q4W along with NA (ETV, tenofovir disoproxil, or TAF) once daily for 52 Weeks followed by JNJ-73763989 SC injection Q4W along with NA once daily for 96 weeks in Part 1 and 2.
89232674|NCT04535037|Experimental|Infanrix Hexa|All subjects in this group received 3 doses (2 primary doses and 1 booster dose) of DTPa-HBV-IPV/Hib vaccine co-administered with 3 doses of pneumococcal 13 valent conjugate vaccine at 2, 4, and 12 months of age.
89232675|NCT04535037|Active Comparator|Vaxelis|All subjects in this group received 3 doses (2 primary doses and 1 booster dose) of DTaP5 HBV IPV Hib vaccine co-administered with 3 doses of pneumococcal 13 valent conjugate vaccine at 2, 4, and 12 months of age.
89232676|NCT04533529|Experimental|Seltorexant|Participants will receive seltorexant tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase. Eligible participants who will enter the open label (OL) treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ early withdrawal (EW) visit (Up to 1 Year).
89232677|NCT04533529|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase.
89232678|NCT04530019||MR Group|Following standard MRI-guided Brachytherapy, patients will have images analyzed for quantification of residual tumor versus fibrosis. We will pilot-test an endovaginal coil, a deflectable MR stylet, real-time planning software, and auto-segmentation of normal and tumor tissue.
89232679|NCT04519528||Patients|Minors who required veno-venous or veno-arterial ECMO, in pediatric intensive care unit at Necker Enfants Malades hospital between 2014 and 2019.
89232680|NCT04511039|Experimental|Treatment Arm|Patients receive trifluridine/tipiracil PO BID and talazoparib tosylate PO QD on days 1-5. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89232681|NCT04497844|Experimental|Niraparib with Abiraterone Acetate plus Prednisone (AAP)|Participants will receive the following in each 28-day treatment cycle: niraparib 200 milligrams (mg), abiraterone acetate (AA) 1000 mg plus prednisone 5 mg once daily.
89232682|NCT04497844|Active Comparator|AA plus Prednisone (AAP)|Participants will receive the following in each 28-day treatment cycle: matching placebo for Niraparib along with AA 1000 mg plus prednisone 5 mg once daily.
89232683|NCT04487080|Experimental|Treatment Arm A (Open-label): Amivantamab and Lazertinib|Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.
89118149|NCT05902312|Experimental|deep Transcranial Magnetic Stimulation|dTMS on a research Brainsway system equipped with an H7-Coil. Participants will receive the MDD FDA-cleared 18 Hz stimulation protocol (2 sec ON, 20 sec OFF, 55 trains; 1980 pulses per session; 20 min 10 s duration; 120% hand motor threshold)
89118150|NCT05893810|Experimental|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares prior to treatment with radiotherapy (RT) for patients with nasopharyngeal carcinoma, can prevent radiation-induced oral mucositis(RIOM) and improve quality of life.
89118151|NCT05893810|No Intervention|Control|Patients in the control arm will be treated according to standard of care.
89118152|NCT05891093|Experimental|Fluzoparib+Endocrine Therapy|Fluzoparib 50mg bid orally for 1 year, combined with physician's choice of endocrine therapy as clinically indicated (eg, aromatase inhibitor, tamoxifen, toremifene endocrine therapy for 5 to 10 years; CDK4/6 inhibitor therapy for 2 years; ovarian function suppression with LHRH agonist).
89118153|NCT05891093|Active Comparator|Endocrine Therapy|Physician's choice of endocrine therapy as clinically indicated (eg, aromatase inhibitor, tamoxifen, toremifene endocrine therapy for 5 to 10 years; CDK4/6 inhibitor therapy for 2 years; ovarian function suppression with LHRH agonist).
89118154|NCT05877313|Active Comparator|Nitric Oxide Releasing Solution 1X|"Foot bath with nitric oxide releasing solution (NORS) at 1X dosage delivered 3 times weekly (Mon, Wed, Fri).~500mL NORS in a footbath @ 4110 ppm*min"
89118155|NCT05877313|Active Comparator|Nitric Oxide Releasing Solution 2X|"Foot bath with nitric oxide releasing solution (NORS) at 2X dosage delivered 3 times weekly (Mon, Wed, Fri).~500mL NORS in a footbath @ 12190 ppm*min"
89118156|NCT05877313|Placebo Comparator|Vehicle Control|"Foot bath with sterile water delivered 3 times weekly (Mon, Wed, Fri)~500mL sterile water in a foot bath."
89118157|NCT05875428|Experimental|Mitoxantrone Hydrochloride Liposome Injection|The eligible patients will receive mitoxantrone hydrochloride liposome injection (20 mg/m^2) once every 4 weeks for a maximum of 8 cycles.
89118158|NCT05870579|Experimental|Arm 1|Participants will receive [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant, in the dose escalation and the dose expansion parts of the study. Goserelin administration is only applicable for pre/peri-menopausal participants, in the dose expansion part.
89118159|NCT05870267||Cohort 1 (arms 1-3)|"Arm 1 will be designed as observational study providing the efficacy and safety of the load applied on osseointegrated fixation by transfemoral BAP fitted with the Power Knee for the whole cohort of 20 participants.~Arm 2 will be designed as matched case-control study comparing the efficacy and safety the load applied on osseointegrated fixation by transfemoral BAP fitted with Power Knee and usual MPKs (e.g., C-Leg, Genium) for the whole cohort of 20 participants.~Arm 3 will be designed as matched case-control study comparing the efficacy and safety the load applied on osseointegrated fixation by transfemoral BAP fitted with Power Knee and Rheo Knee XC for a subgroup of 5 participants."
89118160|NCT05870267||Cohort 2 (arm 4)|• Arm 4 will be designed as matched case-control study comparing the efficacy and safety the load applied on osseointegrated fixation by transfemoral BAP fitted with Power Knee for the whole cohort of 20 participants and non-MPKs for another cohort of 10 participants.
89118161|NCT05868941|Experimental|Broncho Muco Cleaner|It will be applied to patients with a diagnosis of chronic bronchitis-predominant COPD, who cannot achieve adequate clinical and functional improvement despite optimal medical therapy. In patients who meet the patient selection criteria, anesthesia approval will be obtained before the procedure will be performed under general anesthesia
89118162|NCT05868369|Experimental|Standard regimen +iVR Group|postoperative iVR therapy in addition to the standard multimodal pain regimen (including a preoperative local field block
89118163|NCT05868369|Active Comparator|Standard regimen|hip arthroscopy patients who receive only the standard regimen (including field block) in the acute postoperative ambulatory setting
89118164|NCT05865977||the failure group|Re-intubation within 48 h after passing the SBT was defined as failed weaning.
89118165|NCT05865977||the success group|Extubation and invasive mechanical ventilation was not needed within 48 h after extubation was defined as successful weaning.
89118166|NCT05859854||Adult patients diagnosed treated with adjunctive cenobamate in Italy.|"Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy.~A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below"
89118167|NCT05856435|Other|Chicago Parent Program for Foster Care|Caregiver parent training sessions.
89118168|NCT05854641|Experimental|Stempeucel®|Stempeucel® (Ex-vivo cultured MSCs) supplied in 15 ml cryo bags consisting of 200 million or 150 million MSCs, 85% PlasmaLyte-A, 5% HSA and 10% DMSO in a total volume of 15 ml. Following thawing, 35 ml of PlasmaLyte A will be added to the Stempeucel® to make a total volume of 50 ml (Refer section 6.6 IMP Preparation and Designation). The final concentration of components will be 1.5% HSA and 3% DMSO.
89118169|NCT05854615|Experimental|Stempeucel®|Stempeucel® (Ex-vivo cultured MSCs) supplied in 15 ml cryo bags consisting of 200 million or 150 million MSCs, 85% PlasmaLyte-A, 5% HSA and 10% DMSO in a total volume of 15 ml. Following thawing, 35 ml of PlasmaLyte A will be added to the Stempeucel® to make a total volume of 50 ml. The final concentration of components will be 1.5% HSA and 3% DMSO.
89118170|NCT05854095|Experimental|Pivot Bridge|transcatheter for short-term treat Functional Tricuspid regurgitation
89118171|NCT05847153|Experimental|Intervention|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
89118172|NCT05843838|Experimental|Hypotensive group|Patients who are hypotensive (even once) and need ephedrine under spinal anesthesia with routine doses of heavy bupivacaine (Hypotension, Mean Arterial Pressure<65 mmHg, or Systolic arterial pressure < 30% will be considered an initial value.)
89118173|NCT05843838|Placebo Comparator|Normotensive group|Patients who are not hypotensive under spinal anesthesia with routine doses of heavy bupivacaine
89118174|NCT05841121|Experimental|Dexamethasone group|The intervention is antenatal dexamethasone. Participants in the intervention group will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
89118175|NCT05841121|No Intervention|Control group|Participants in the control group will be received standard care.
89118176|NCT05839444|Active Comparator|BioPB-01|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner.
89118177|NCT05839444|Placebo Comparator|Placebo|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner.
89118178|NCT05838521|Experimental|Sacituzumab Govitecan|Sacituzumab govitecan, 10 mg/kg for the first 2 weeks of 21-day cycle until progression or adverse effects prohibit further treatment.
89232684|NCT04487080|Active Comparator|Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib|Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.
89232685|NCT04487080|Experimental|Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib|Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.
89232686|NCT04486573|Other|CMRI|"Clinical data will be collected regarding cardiac risk factors, cancer type, and cancer treatment.~CMRI will be performed:~Within 2 weeks before the first fraction of radiation therapy (RT)~Within 1 week of the final fraction of RT (before or after)~Any patient with a pre-RT and post-RT MRI scan will be considered evaluable.~Pre- and post-RT CMRI parameters will be compared.~3D reconstructed CMR images will be co-registered with RT treatment plans to assess for spatial associations."
89232687|NCT04482400|Experimental|NEAT!2|Participants randomized to this arm will use the NEAT!2 app and receive biweekly coaching calls for 8 weeks, and monthly maintenance calls between months 2-5.
89232688|NCT04482400|Active Comparator|MyKneeGuide|Participants randomized to this arm will use the MyKneeGuide app/website and receive biweekly coaching calls for 8 weeks, and monthly maintenance calls between months 2-5.
89232689|NCT04464564|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
89232690|NCT04464564|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
89232691|NCT04459507||Participants With Palmoplantar pustulosis (PPP)|Participants treated with a new systemic therapy for their PPP, having had an inadequate response to a prior PPP therapy either as their first systemic therapy or as a switch from, or addition to, a previous systemic therapy will be observed. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting. The primary data source for this study will be the medical records of each participant.
89232694|NCT04442425||1DF/NoPain_IV-VI_Female|Worst pain in past month = 0; Skin Type IV-VI, Female
89232695|NCT04442425||1DM/NoPain_IV-VI_Male|Worst pain in past month = 0; Skin Type IV-VI, Male
89232696|NCT04442425||1LF/NoPain_I-III_Female|Worst pain in past month = 0; Skin Type I-III, Female
89232697|NCT04442425||1LM/NoPain_I-III_Male|Worst pain in past month = 0; Skin Type I-III, Male
89232698|NCT04442425||2DF/MildPain_IV-VI_Female|Worst pain in past month = 1-3; Skin Type IV-VI, Female
89232699|NCT04442425||2DM/MildPain_IV-VI_Male|Worst pain in past month = 1-3; Skin Type IV-VI, Male
89232700|NCT04442425||2LF/MildPain_I-III_Female|Worst pain in past month = 1-3; Skin Type I-III, Female
89232701|NCT04442425||2LM/MildPain_I-III_Male|Worst pain in past month = 1-3; Skin Type I-III, Male
89232702|NCT04442425||3DF/ModPain_IV-VI_Female|Worst pain in past month = 4-6; Skin Type IV-VI, Female
89232703|NCT04442425||3DM/ModPain_IV-VI_Male|Worst pain in past month = 4-6; Skin Type IV-VI, Male
89232704|NCT04442425||3LF/ModPain_I-III_Female|Worst pain in past month = 4-6; Skin Type I-III, Female
89232705|NCT04442425||3LM/ModPain_I-III_Male|Worst pain in past month = 4-6; Skin Type I-III, Male
89232706|NCT04442425||4DF/SeverePain_IV-VI_Female|Worst pain in past month = 7-10; Skin Type IV-VI, Female
89232707|NCT04442425||4DM/SeverePain_IV-VI_Male|Worst pain in past month = 7-10; Skin Type IV-VI, Male
89232708|NCT04442425||4LF/SeverePain_I-III_Female|Worst pain in past month = 7-10; Skin Type I-III, Female
89232709|NCT04442425||4LM/SeverePain_I-III_Male|Worst pain in past month = 7-10; Skin Type I-III, Male
89232710|NCT04438824|Experimental|Palbociclib and INCMGA00012|"Initial design (safety lead-in and expansion): One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib on Day 1 and INCMGA00012 on day 15 (+/- 7 days) of each cycle at the following dose schedule: INCMGA00012: 500 mg IV (flat dose) q28 days Palbociclib: 125 mg PO daily for 21 days, followed by 7 days off, q28 days Palbociclib will be taken on Day 1 of each cycle for 21 consecutive days followed by 7 days off (days 22-28 of each Cycle). INCMGA00012 will be administered on Day 15 of (+/- 7 days) each cycle and repeat every 28 days.(No longer using this)~Amended design (Expansion only): One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib and INCMGA00012 on day 1 of each cycle: 500 mg IV (flat dose) of INCMGA00012 will be administered q28 days concurrently with palbociclib 125 mg PO daily for 21 days, followed by 7 days off, q28 days."
89232711|NCT04437914||Group 1 - Smartwatch - single lead (D1)|To obtain the automatic electrocardiographic diagnosis of the clock, two ECG tracings of 30 seconds will be obtained, in a calm environment, with the patient at rest, in the horizontal supine position. The device will be attached to the wrist on the left side with the use of the fingers of the right hand on the sensor button of the watch to complete the electrocardiographic DI derivation following the Einthoven triangle derivation criteria. The automatic diagnosis obtained must be the same in both plots to be validated. The specific results of the automatic diagnosis obtained by the watch will be: low beats with FC≤40 beats per minute (bpm); high beats with HR≥120bpm; sinus rhythm when interpreted as normal by the clock, atrial fibrillation, inconclusive and does not allow analysis due to poor technical quality and did not allow tracing.
89232712|NCT04437914||Group 2 - conventional ECG|The conventional ECG tracing will be obtained in the 12 leads of the frontal plane (DI, DII, DIII, aVR, AVL, AVF) and the horizontal plane (V1 to V6) and a 30-second rhythm trace in the DI lead. The diagnostic results of conventional ECG tracings will be: normal or abnormal; sinus rhythm, AF, atrial flutter or other non-sinus rhythm; intraventricular conduction disorder: left bundle branch block (BRE), right bundle branch block (BRD), right posteroinferior lower block (BDPI or left anterior superior (BDAS), isolated or associated; normal electrical axis, shifted to the right or shifted to the right) left, inconclusive and does not allow analysis due to poor technical quality.
89232713|NCT04431011||Participants|Healthy right-handed participants aged 18-50
89232716|NCT04408820||Roxadustat|Participants will receive oral dose of roxadustat.
89232717|NCT04408755|Experimental|AVP-786|Participants will be assigned to treatment with AVP-786 capsules administered twice a day over a 12-week period.
89232718|NCT04408755|Placebo Comparator|Placebo|Participants will be assigned to treatment with placebo capsules administered twice a day over a 12-week period.
89232721|NCT04401020|Experimental|Dose escalation|SAR442257 will be given intravenously with lead-in doses (LID) in the first-week, followed by once weekly until week 4 (Cycle 1) and once weekly for each subsequent cycle(s).
89232722|NCT04397276|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
89232723|NCT04397276|Experimental|Part 2: Dose Expansion|Participants with mCRPC will receive JNJ-70218902 at the RP2D determined in Part 1.
89232724|NCT04391595|Experimental|Arm 1|400 mg of LY3214996 QD for 6 doses and 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. On Day 6, participants will receive Abemaciclib + LY3214996 dose 7 to 9 hours prior to craniotomy for tumor resection.
89232725|NCT04389970|Experimental|Time Restricted Feeding|Participants will be asked to follow a time-restricted meal pattern (8:16 protocol)
89232726|NCT04384146|Experimental|Quad Shot Radiation|In this trial, patients with centrally located lung tumors will be treated with up to 3 cycles of Quad Shot Radiation. Radiation treatment will be given within 1 week of administration of chemotherapy. Quad Shot radiation will involve: 3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break. The first group of patients will be treated with 2 cycles of quad shot radiation, followed by a 3-month observation period post-RT to allow a complete evaluation of acute toxicity. The next group of patients will be treated with either 1 cycle or 3 cycles of quad shot radiation. The minimum accrual is 4 patients with an expected accrual of 16 patients. Twenty additional patients will be recruited to an expansion cohort.
89232727|NCT04381260||2016-2019 STEMI Registry|Retrospective data will be collected to develop a well-characterized registry of patients treated from 2016-2019 by any of 14 local rural EMS agencies and transported to a facility capable of performing Percutaneous Coronary Intervention. This registry will be used to determine the time to PCI performance for each of the EMS agencies. Time will be adjusted for patient distance from a PCI center using a linear mixed model with a random effect for center and a fixed effect for distance. This process will allow qualitative methods to identify organizational culture, structure, and clinical processes that impact STEMI care from the two highest and lowest performing rural EMS agencies. (n=750)
89118179|NCT05827159|Experimental|SBIRT|Participants will receive the Brief Negotiation Interview (BNI) and Referral to Treatment. The BNI has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.
89118180|NCT05827159|Experimental|SBIRT+ED-MAUD|Participants with receive BNI, Referral to Treatment, and MAUD. In the MAUD component, either XR-NTX or oral naltrexone will be provided, supplemented by ancillary treatment with gabapentin. Participants will receive their first doses of XR-NTX (injection) and gabapentin in the ED and will receive 7 days of gabapentin take-home doses. Those who prefer to initiate treatment in ED with oral naltrexone receive their first doses of naltrexone and gabapentin in the ED and receive 30-day take-home doses of naltrexone and 7 days of gabapentin.
89118181|NCT05825222|Active Comparator|E-PR-01 (Low Dose)|One capsule twice a day
89118182|NCT05825222|Active Comparator|E-PR-01 (High Dose)|One capsule twice a day
89118183|NCT05825222|Placebo Comparator|Placebo|One capsule twice a day
89118184|NCT05817669|Experimental|Efgartigimod IV arm|patients receiving infusions of Efgartigimod IV
89118185|NCT05817669|Placebo Comparator|Placebo arm|patients receiving infusions of placebo IV
89118186|NCT05813730|Other|Healthy neonates|A single arm evaluating creatinine renal excretion in healthy neonates' urine
89118187|NCT05811247|Experimental|AD109|AD109
89118188|NCT05811247|Placebo Comparator|Placebo|Placebo
89118189|NCT05809908|Active Comparator|Tricaprilin|Tricaprilin formulation twice daily for 26 weeks, liquid for oral administration
89118190|NCT05809908|Placebo Comparator|Placebo|Placebo formulation, twice daily for 26 weeks, liquid for oral administration
89118191|NCT05806060|Experimental|De novo or DFI≥12m Arm 1|If patients were De novo or their disease-free interval (DFI) were more than or equal to 12 months and were randomized to experimental arm, they would receive VEGFR BP102 with nab-palitaxel (Nab-P). And maintained by VEGFR and capecitabine if intolerable toxicity was observed with no progression.
89118192|NCT05806060|Active Comparator|De novo or DFI≥12m Arm 2|If patients were De novo or their disease-free interval (DFI) were more than or equal to 12 months and were randomized to control arm, they would receive nab-palitaxel (Nab-P). And maintained by capecitabine if intolerable toxicity was observed with no progression.
89118193|NCT05806060|Experimental|DFI<12m Arm 1|If patients' disease-free interval (DFI) were less than 12 months and were randomized to experimental arm, they would receive VEGFR BP102 with treatment of physician's choice (TPC).
89118194|NCT05806060|Active Comparator|DFI<12m Arm 2|If patients' disease-free interval (DFI) were less than 12 months and were randomized to control arm, they would receive physician's choice (TPC).
89118195|NCT05789602|Experimental|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-460372 administered, once daily (QD).
89118196|NCT05789602|Experimental|Dose Expansion|Oral tablets administered at MTD/RP2D defined dose. Each treatment cycle will be 21 days in duration with BPI-460372 administered, once daily (QD)
89118197|NCT05787587|Experimental|Module 1 Part 1: Monotherapy Dose Escalation|Participants will be assigned to a dose level.
89118198|NCT05787587|Experimental|Module 1 Part 2: Monotherapy Dose Expansion|After a dose is decided in Part 1, participants entering part 2 will be assigned to a dose level.
89118199|NCT05783817|Experimental|MDMA-assisted cognitive behavioral therapy|Administration of 80mg MDMA HCl (with a supplemental dose offered 1.5 to 2 hours later of 40 mg MDMA HCl) in combination with cognitive behavioral therapy (CBT).
89118200|NCT05783817|Active Comparator|Methamphetamine-assisted cognitive behavioral therapy|Administration of 10mg methamphetamine (with a supplemental dose offered 1.5 to 2 hours later of 5 mg methamphetamine) in combination with cognitive behavioral therapy (CBT).
89118201|NCT05773352||Tornier Perform® Humeral System - Fracture|Commercially available convertible humeral system for anatomic and reverse shoulder arthroplasty.
89118202|NCT05762432|Experimental|Study Device|This Arm of the study will receive the study device. Although the Study Device is not experimental as it is already CE marked and being used for it's intended purpose.
89118203|NCT05762432|Active Comparator|Standard of Care|This arm of the study will use the NHS' existing standard of care device as is normally used in podiatry clinics.
89118204|NCT05761405|Active Comparator|Ceftriaxone (CRO)|Ceftriaxone infusion. Ceftriaxone is a beta-lactam antibiotic that is the standard-of-care antibiotic for prophylaxis of asymptomatic bacteriuria in Switzerland. The choice of 2000 mg delivered intravenously reflects the general practice.
89118205|NCT05761405|Active Comparator|Aminoglycoside (AMK)|Amikacin infusion Amikacin is an aminoglycoside routinely used in Australia (e.g. amikacin, gentamicin) as the standard of care for antibiotic prophylaxis for endourological treatments. It is also used globally for fever in neutropenia in hematological patients. Due to their relatively limited use, aminoglycosides have low resistance rates amongst Enterobacteriaceae. A single dose of 1000mg will be used intravenously
89118206|NCT05761405|Experimental|AminoglycosideLD + Mannitol (AMK1/2 + MAN)|Amikacin + Mannitol combination The addition of Mannitol enhances bactericidal effect of amikacin in E.coli and K.pneumoniae in animal models and allows for a decrease of amikacin dosing. A single dose of 500mg (low dose or LD - decrease by 50%) systemic amikacin will be used intravenously in combination with 5 grams mannitol delivered intravenously.
89232728|NCT04381260||Key Informant Interviews|After identifying the two highest and lowest performing rural EMS agencies in the 2016-2019 STEMI Registry, key employees from each of those agencies will be recruited to participate in semi-structured key informant interviews. The interviews will assess current clinical care, organizational culture and opportunities for improvement. (n=32)
89232729|NCT04381260||Stakeholder Surveys|Employees at all local EMS agencies will be invited to participate in stakeholder surveys to quantify each agency's use of the care strategies identified during Key Information Interviews. (n=240)
89118207|NCT05760898|Experimental|Blood pressure intervention arm|The investigators will recruit 25 Black RA patients with HTN for the study. Participants will be provided with a home blood pressure monitor, teaching from nursing staff regarding the correct use of the monitor, and a guide to help interpret normal and elevated blood pressure values. Participants will be instructed to obtain and record blood pressure values at least three times per week over the course of 3 months. Every 2 weeks, these results will be sent to the study team, and participants will complete a brief survey regarding other factors that may influence blood pressure control, including RA disease activity (RAPID3 score), pain, current use of acute RA therapies, anti-hypertensive medication use, anti-hypertensive medication adherence, and current perceived barriers to HTN self-management.
89118208|NCT05757947|Active Comparator|"no-touch saphenous vein as I-graft"|Coronary bypass surgery according to the I-graft method. Proximal anastomosis to RIMA.
89118209|NCT05757947|Active Comparator|"no-touch saphenous vein as conventional free graft"|Coronary artery bypass grafting using the free conduit technique. Proximal anastomosis to aorta.
89118210|NCT05747547||mild disease|asymptomatic or paucisymptomatic patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV2-infection) who received outpatient care
89118211|NCT05747547||moderate disease|patients with laboratory-confirmed SARS-CoV2-infection and radiology-confirmed pneumonia who did not require extracorporeal membrane oxygenation
89118212|NCT05747547||severe disease|patients with laboratory-confirmed SARS-CoV2-infection and acute respiratory distress syndrome who required extracorporeal membrane oxygenation
89118213|NCT05746559|Placebo Comparator|Placebo|Participants will receive a single weight-based dose of placebo via intravenous infusion, 1 to 7 days prior to surgery.
89118214|NCT05746559|Experimental|Ravulizumab|Participants will receive a single weight-based dose of ravulizumab, via intravenous infusion, 1 to 7 days prior to surgery.
89118215|NCT05745844|Experimental|NeuroMuscular Electro Stimulation group|Patients in the NeuroMuscular Electro Stimulation group will also have neurostimulation sessions using a CE marked medical device, in its destination, according to its instructions for use, therefore without expected clinical risk
89118216|NCT05745844|Active Comparator|Control Group|The control group (without NeuroMuscular Electro Stimulation) corresponds to the standard care routinely offered to patients in the investigating centre.
89118217|NCT05737940|Experimental|AZD3427 Dose A|The participants will receive single dose of AZD3427 Dose A every 2 weeks for 24 weeks from Day 1 to Day 155.
89118218|NCT05737940|Experimental|AZD3427 Dose B|The participants will receive single dose of AZD3427 Dose B every 2 weeks for 24 weeks from Day 1 to Day 155.
89118219|NCT05737940|Experimental|AZD3427 Dose C|The participants will receive single dose of AZD3427 Dose C every 2 weeks for 24 weeks from Day 1 to Day 155.
89118220|NCT05737940|Placebo Comparator|Placebo|The participants will receive single dose placebo every 2 weeks for 24 weeks from Day 1 to Day 155.
89118221|NCT05728892|Active Comparator|Group A|patients undergoing abdominal surgery receiving melatonin
89118222|NCT05728892|Placebo Comparator|Group B|control group
89118223|NCT05726708|Experimental|E-Learning|E-Learning coaching. 11 modules on line. 5 debriefing on visio conference with a professional (1/month)
89118224|NCT05726708|Active Comparator|Paediatric Autism Communication Therapy (PACT)|Parents will have 12 coaching sessions with a therapist, following the PACT model. Between each session, the parent will be asked to practice the strategies at home and to film themselves doing an activity with their child (10-minute film).
89118225|NCT05726708|No Intervention|Control|No parental coaching
89118226|NCT05708066|Experimental|Lavender Aromatherapy Tab|If part of the experimental group, participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations. After the lavender patch has been in place for 5 minutes, participants will receive the same visual analogue scale (VAS) anxiety questionnaire.
89118227|NCT05708066|Placebo Comparator|Non-scented Tab|If part of the placebo comparator group, participants will have an unscented tab placed on the chest, according to manufacturer recommendations. Participants in this group will only receive the initial visual analogue scale (VAS) anxiety questionnaire.
89118228|NCT05707949|Experimental|Atogepant Dose A (12-17 yrs)|Participant aged 12-17 will receive oral tablets of atogepant Dose A once a day for up to 52 weeks.
89118229|NCT05707949|Experimental|Atogepant Dose B (6-11 yrs)|Participants aged 6-11 will receive the highest dose of oral tablets of atogepant tested in the lead-in study M21-201.
89118230|NCT05705791|Experimental|166Holmium SIRT arm|"166Holmium selective internal intra-arterial radiation therapy (QuiremSpheres®, experimental medical device) in combination with approved first line therapy:~Atezolizumab1200mg Q3W IV~Bevacizumab 15mg/kg Q3W IV"
89118231|NCT05704556|Experimental|Cohort 1: Severe Renal Impairment|Participants will receive a single dose of VX-548 in a fasted state.
89118232|NCT05704556|Experimental|Cohort 2: Matched Healthy Participants|Healthy participants matched to cohort 1 will receive a single doses of VX-548 in a fasted state.
89118233|NCT05704556|Experimental|Cohort 3: Moderate Renal Impairment|Participants will receive a single dose of VX-548 in a fasted state.
89232730|NCT04377672|Experimental|Anti- SARS-CoV-2 Plasma|Human Convalescent Plasma
89232731|NCT04377516|Experimental|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
89232732|NCT04377516|Active Comparator|Exercise group|pelvic floor muscle training
89232733|NCT04377516|Placebo Comparator|Control group|pelvic girdle education
89118234|NCT05704556|Experimental|Cohort 4: Matched Healthy Participants|Healthy participants matched to cohort 3 will receive a single dose of VX-548 in a fasted state.
89118235|NCT05702749|Active Comparator|Intervention: PREHAB and Surgery|PREHAB exercises will be determined during the physical therapy visit (1x/week) and completed daily with varying frequency for three weeks. Subjects will undergo microsurgical resection of VS.
89118236|NCT05702749|Placebo Comparator|Control: Surgery (No PREHAB)|Subjects will undergo microsurgical resection of VS.
89118237|NCT05702749|Active Comparator|Intervention: PREHAB and SRS|PREHAB exercises will be determined during the physical therapy visit (1x/week) and completed daily with varying frequency for three weeks. Subjects will undergo stereotactic radiosurgery.
89118238|NCT05702749|Placebo Comparator|Control: SRS (No PREHAB)|Subjects will undergo stereotactic radiosurgery.
89118239|NCT05701475|No Intervention|Control/Single prevention|Standard pre-operative cutaneous disinfection using iodine.
89118240|NCT05701475|Experimental|Double prevention|Pre-operative cutaneous and subcutaneous disinfection using iodine.
89118241|NCT05701475|Experimental|Triple prevention|Pre-operative cutaneous and subcutaneous disinfection using iodine and preparation of the skin with benzoyl peroxide in the days prior to surgery.
89118242|NCT05691660|Experimental|Single dose cohort|
89118243|NCT05691660|Experimental|Repeated dose cohort Once daily (QD)|
89118244|NCT05691660|Experimental|Repeated dose cohort Twice daily (BID)|
89118245|NCT05684094|Experimental|"Sleep extension and advance Lark Routine"|Participants go to bed 90 minutes earlier than their typical average bedtime to extend sleep duration and advance sleep timing
89118246|NCT05684094|Active Comparator|"Regular sleep duration and timing Owl Routine"|Participants go to bed at their typical average bedtime
89118249|NCT05681039|Experimental|Neoadjuvant and Adjuvant|
89118250|NCT05680987|Other|Retrograde Femoral Nail-Advanced|
89118251|NCT05680779|Experimental|PNM group|Subjects were treated once time. The technique consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, with 250 μs pulse width and the maximal torelable intensity to cause an exacerbated muscle contraction during ten seconds with a rest period of another ten seconds y total number of ten times. The subjects were lying in lateral decubitus. The common peroneal nerve was located with ultrasound (cross section) near to the peroneal head. After, an acupuncture needle (0,30mm x 30mm) was inserted in a long axis approach until the perineurium of the common peroneal nerve (in close proximity)
89118252|NCT05680779|Other|Control group|Subjects were treated once time. The subjects were lying in lateral decubitus. The common peroneal nerve was located with ultrasound (cross section) near to the peroneal head. After, an acupuncture needle (0,30mm x 30mm) was inserted in a long axis approach until the perineurium of the common peroneal nerve (in close proximity). The needle remains in this location during 200 seconds without any electrical current.
89118253|NCT05674474|Experimental|Group A: Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of 20 mg (2 × 10 mg) vorasidenib tablets on Day 1.
89118254|NCT05674474|Experimental|Group B: Moderate or Mild Hepatic Impairment|"Stage 1: Participants with moderate hepatic impairment (Child-Pugh [C-P] Class B, score of 7 to 9) will receive a single oral dose of 20 mg (2 × 10 mg) vorasidenib tablets on Day 1.~Stage 2: Participants with mild hepatic impairment (C-P Class A, score of 5 to 6) will receive a single oral dose of 20 mg (2 × 10 mg) vorasidenib tablets on Day 1. Stage 2 will be conducted if a clinically meaningful increase in exposure of vorasidenib is observed in participants with moderate hepatic impairment in Stage 1."
89118255|NCT05672095|Experimental|Treatment (selenium, niraparib)|Patients receive selenium IV and niraparib PO on study. Patients also undergo CT, MRI, biopsy, and collection of blood samples throughout the trial.
89118256|NCT05672082|Experimental|[18F]DPA-714 PET|
89118257|NCT05665699|Experimental|Cohort A|week 1: D-0120 low dose in combination with Allopurinol week 2-12: D-0120 increased dose in combination with Allopurinol
89118258|NCT05665699|Experimental|Cohort B|week 1: D-0120 low dose in combination with Allopurinol week 2: D-0120 increased dose in combination with Allopurinol week 3-12: D-0120 high dose in combination with Allopurinol
89118259|NCT05662722|Experimental|Pecutaneous electrolysis group|Subjects were treated twice (one day and one week). The technique consisted in the application of a galvanic electrical current using a needle as an electrode that will be inserted into the concha of the ear. The subjects were lying in supinus.
89118260|NCT05662722|Other|dry needling group|Subjects were treated twice (one day and one week). The technique consisted in the puncture with a needle in the concha of the ear. The subjects were lying in supinus.
89118261|NCT05662722|Sham Comparator|Sham group|Subjects were treated twice (one day and one week). The technique consisted in the puncture with a sham-needle in the concha of the ear. The subjects were lying in supinus.
89118262|NCT05652543|Experimental|Vaccine group|Participants ≥3 years old who have received the recommended dose and immunization procedure of domestically approved COVID-19 vaccine will receive vaccine (SCTV01E).
89118263|NCT05652543|Placebo Comparator|Placebo group|Participants ≥3 years old who have received the recommended dose and immunization procedure of domestically approved COVID-19 vaccine will receive placebo (normal saline)
89118264|NCT05650450||Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)|
89118265|NCT05644600|Experimental|Treatment A|The subjects will receive Nintedanib soft capsules, fasted state.
89118266|NCT05644600|Experimental|Treatment B|The subjects will receive dose B of the oral suspension of AZD5055 immediately followed by nintedanib in the fasted state.
89118267|NCT05644600|Experimental|Treatment C|The subjects will receive dose C of the oral suspension of AZD5055 immediately followed by nintedanib in the fasted state.
89118268|NCT05644600|Experimental|Treatment D|"The subjects will receive dose C of the oral suspension of AZD5055 4 hours after nintedanib in the fasted state.~Participants would remain in the fasted state until 1.5 hours after AZD5055 administration."
89118269|NCT05636878|Experimental|With EMPPer|All children (0 to 3 years old) in the areas Meurthe-et-Moselle South will benefit from the intervention of the Mobile Perinatal Psychiatry Team (EMPPer)
89118270|NCT05636878|No Intervention|without EMPPer|All children (0 to 3 years) from Strasbourg and Reims will not benefit from the Mobile Intervention Team in Perinatal Psychiatry
89118271|NCT05633602|Active Comparator|ARM A (standard of care chemotherapy)|Patients receive chemotherapy per standard of care on study.
89118272|NCT05633602|Experimental|ARM B (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV and pembrolizumab IV on study.
89118273|NCT05632315|Experimental|ESCRE/CRE BL-BLI|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI)
89118274|NCT05632315|No Intervention|ESCRE/CRE BL-BLI standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI) standard of care (SOC)
89118275|NCT05632315|Experimental|ESCRE/CRE carbapenem +/- BLI|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: carbapenem +/- BLI
89118276|NCT05632315|No Intervention|ESCRE/CRE carbapenem +/- BLI standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: carbapenem +/- BLI standard of care (SOC)
89118277|NCT05632315|Experimental|ESCRE/CRE Fluoroquinolone|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Fluoroquinolone
89232734|NCT04377516|Placebo Comparator|Health group|pelvic girdle education
89232737|NCT04358315||Observational (smell or puff e-liquids)|All panel participants smell and user panelists puff flavored e-liquids and answer questions about the products.
89232738|NCT04340596|Experimental|Arm A: N-803 only|Participants will receive N-803 6 mcg/kg 1 week after Step 2 entry and then every 3 weeks for a total of eight doses.
89232739|NCT04340596|Experimental|Arm B: N-803 in combination with 10-1074 and VRC07-523LS|"Participants will receive N-803 in combination with 10-1074 and VRC07-523LS as follows:~At Step 2 entry:~VRC07-523LS 20 mg/kg~10-1074 30 mg/kg~At Step 2, week 1: N-803 6 mcg/kg every 3 weeks for eight doses~At Step 2, week 9: 10-1074 30 mg/kg"
89232741|NCT04337749|Active Comparator|Chorhexidine scrub|Chorhexidine scrub was given to participants for 2 weeks
89232742|NCT04337749|Active Comparator|ZnO-NPs socks|ZnO-NPs socks were given to participants for 2 weeks
89232743|NCT04337749|Active Comparator|Combination of chorhexidine scrub and ZnO-NPs socks|Chorhexidine scrub and ZnO-NPs socks were given to participants for 2 weeks
89232744|NCT04337749|Placebo Comparator|Placebo|Placebo socks were given to participants for 2 weeks
89232745|NCT04325828|Experimental|Apalutamide plus GnRH Agonist|Participants will receive apalutamide 240 milligram (mg) in combination with a gonadotropin-releasing hormone (GnRH) agonist until disease progression, unacceptable toxicity, death, or the end of the study and each treatment cycle will be of 28 days. Participants who are benefitting from this study will enter long term extension phase.
89232746|NCT04313634|Experimental|Dasatinib plus Quercetin Treatment Goup|Subjects will receive Dasatinib (D; 100 mg for two days) plus Quercetin (Q; 1000 mg total daily for three consecutive days taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
89232747|NCT04313634|Experimental|Fisetin Treatment Group|Subjects will receive Fisetin (F; ~20 mg/kg/day for three consecutive days) taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
89232748|NCT04313634|No Intervention|Untreated Control Group|Subjects will not receive any intervention
89232749|NCT04312672||Follow up cohort|no intervention follow up study
89232750|NCT04298541|Experimental|Patients with Meningioma|Subjects with suspected meningioma planned for surgery who meet the inclusion and exclusion criteria.
89232751|NCT04290403|Experimental|Pull ups|Pull-up continence products
89232752|NCT04290403|Experimental|Styled briefs with tapes|Styled briefs with tapes
89232753|NCT04289480||ENTERPRISE 2 group|"The study population enrolled for this clinical study is aneurysm patients who need stent-assisted coiling treatment, using ENTERPRISE 2 device."
89232754|NCT04276493|Experimental|Cohort 1- ZW25 + Docetaxel|ZW25 intravenous (IV) infusion followed by docetaxel IV infusion first-line therapy once every three weeks (Q3W) in female participants with metastatic breast cancer
89232755|NCT04276493|Experimental|Cohort 2- ZW25 + Tiselizumab + Chemotherapy|ZW25 intravenous (IV) infusion followed by tiselizumab IV infusion and CAPOX chemotherapy (oral capecitabine + IV oxaliplatin) first-line therapy once every three weeks (Q3W) in participants with metastatic gastric / GEJ adenocarcinoma
89232756|NCT04273945|Active Comparator|Macitentan 10 milligrams (mg) + Placebo|Run-in period:Participants who are either endothelin receptor antagonist (ERA)-naïve or who are receiving daily dose of macitentan or ambrisentan less (<) 10 milligrams (mg), or daily dose of bosentan <250 mg, will enter 4-week open-label run-in period with macitentan 10 mg prior to randomization. ERA-pre-treated participants will bypass run-in period and will be randomized to either macitentan 75 mg or macitentan 10 mg directly.Double-blind Treatment (DBT) Period:Participants will receive macitentan 10 mg orally up to End of DBT.To maintain blind, participants will receive macitentan 37.5 mg-matching placebo for 4 weeks and macitentan 75 mg-matching placebo thereafter up to DBT.Treatment Extension Period:After EDBT, participants will receive macitentan 37.5 mg once a day (qd) orally for 4 weeks, prior to receiving open-label macitentan 75 mg qd orally for 2 years. To maintain blind, participants will receive macitentan 75 mg-matching placebo during 4-week uptitration.
89232757|NCT04273945|Experimental|Macitentan 75 mg + Placebo|Run-in period:Participants who are either ERA-naive or who are receiving a daily dose of macitentan or ambrisentan <10 mg, or a daily dose of bosentan <250 mg, will enter 4-week open-label run-in period with macitentan 10 mg prior to randomization. ERA-pre-treated patients will bypass the run-in period and will be randomized to either macitentan 75 mg or macitentan 10 mg directly.DBT Period: participants will receive macitentan 37.5 mg orally for 4 weeks and macitentan 75 mg thereafter up to End of DBT. To maintain the blind, participants will receive macitentan 10 mg-matching placebo up to End of DBT.Treatment Extension Period: After EDBT, participants will continue to receive macitentan 75 mg orally for 2 years. To maintain the blind, participants will receive macitentan 37.5 mg-matching placebo during the 4-week up-titration period.
89118278|NCT05632315|No Intervention|ESCRE/CRE Fluoroquinolone standard of care (SOC)|MDRO: extended-spectrum cephalosporin resistant Enterobacterales ESCRE/CRE Antibiotic Class: Fluoroquinolone standard of care (SOC)
89118279|NCT05632315|Experimental|MRSA lipo/glycopeptide|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: lipo/glycopeptide
89118280|NCT05632315|No Intervention|MRSA lipo/glycopeptide standard of care (SOC)|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: lipo/glycopeptide standard of care (SOC)
89118281|NCT05632315|Experimental|MRSA oxazolidinone|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: oxazolidinone
89118282|NCT05632315|No Intervention|MRSA oxazolidinone standard of care (SOC)|MRDO: methicillin-resistant S. aureus (MRSA) Antibiotic Class: oxazolidinone standard of care (SOC)
89118283|NCT05632315|Experimental|MDR-PA BL-BLI|MDRO: two-class resistant Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI)
89118284|NCT05632315|No Intervention|MDR-PA BL-BLI standard of care (SOC)|MDRO: two-class resistant Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: Beta Lactamase Inhibitors (BL-BLI) standard of care (SOC)
89118285|NCT05632315|Experimental|MDR-PA carbapenem +/- BLI|MDRO: two-class resistant Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: carbapenem +/- BLI
89118286|NCT05632315|No Intervention|MDR-PA carbapenem +/- BLI standard of care (SOC)|MDRO: two-class resistant Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: carbapenem +/- BLI standard of care (SOC)
89118287|NCT05632315|Experimental|MDR-PA Fluoroquinolone|MDRO: two-class resistant Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: Fluoroquinolone
89118288|NCT05632315|No Intervention|MDR-PA Fluoroquinolone standard of care (SOC)|MDRO: two-class resistant Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: Fluoroquinolone standard of care (SOC)
89118289|NCT05632315|Experimental|VRE lipopeptide|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: lipopeptide
89118290|NCT05632315|No Intervention|VRE lipopeptide standard of care (SOC)|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: lipopeptide standard of care (SOC)
89118291|NCT05632315|Experimental|VRE oxazolidinone|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: oxazolidinone
89118292|NCT05632315|No Intervention|VRE oxazolidinone standard of care (SOC)|MDRO: vancomycin resistant Enterococcus (VRE) Antibiotic Class: oxazolidinone standard of care (SOC)
89118293|NCT05632315|Experimental|ESCRE/CRE cefepime/cefidericol|MDRO: ESCRE/CRE Antibiotic Class: cefepime/cefidericol
89118294|NCT05632315|No Intervention|ESCRE/CRE cefepime/cefidericol standard of care (SOC)|MDRO: ESCRE/CRE Antibiotic Class: cefepime/cefidericol standard of care (SOC)
89118295|NCT05632315|Experimental|MDR-PA cefepime/cefidericol|MDRO: two-class resistant Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: cefepime/cefidericol
89118296|NCT05632315|No Intervention|MDR-PA cefepime/cefidericol standard of care (SOC)|MDRO: two-class resistant Pseudomonas aeruginosa (MDR-PA) Antibiotic Class: cefepime/cefidericol standard of care (SOC)
89118297|NCT05629611|Experimental|Study 1 Vi-Sealer|This group of women undergoing hysterectomy is randomized to the energy device, Vi-sealer.
89118298|NCT05629611|Active Comparator|Study 1 Ligasure|This group of women undergoing hysterectomy is randomized to the energy device, Ligasure.
89118299|NCT05629611|Experimental|Study 2 Vi-sealer|This group of women undergoing hysterectomy is randomized to the energy device, Vi-sealer.
89118300|NCT05629611|Active Comparator|Study 2 Other AHD|This group of women undergoing hysterectomy is randomized to energy devices other than Ligasure.
89118301|NCT05622669||Myeloma|Individuals experiencing fatigue related to myeloma or its treatment
89118302|NCT05622669||Long COVID|Individuals experiencing fatigue related to Long COVID
89118303|NCT05622669||Heart failure|Individuals experiencing fatigue related to heart failure or its treatment
89118304|NCT05622669||Controls|Individuals who are not experiencing problematic fatigue and who do not have myeloma, long COVID, or heart failure
89118305|NCT05619913|Experimental|Arm 1 - Single agent eribulin arm|"Eribulin until progression of disease (PD) as defined by RECIST v1.1, unacceptable toxicity or physician/patient discretion or choice to cease treatment.~Patients who progress on the single agent eribulin arm may receive combination eribulin and pembrolizumab."
89118306|NCT05619913|Experimental|Arm 2 - Combination eribulin and pembrolizumab arm|Eribulin for a maximum of 6 cycles. Pembrolizumab until PD or a maximum of 35 cycles (including the 6 cycles where it is administered in combination with eribulin) or until unacceptable toxicity or physician/patient discretion or choice to cease treatment.
89118307|NCT05618496|Experimental|Patients treated with Epipad|Epipad
89118308|NCT05611047|Experimental|Active cognitive rehabilitation|
89118309|NCT05611047|Active Comparator|Sham cognitive rehabilitation|
89118310|NCT05610514|No Intervention|Combustible Cigarette|Participants in this arm will smoke their usual brand of combustible cigarettes for two weeks.
89118311|NCT05610514|Experimental|E-Cigarette|Participants in this arm will smoke electronic cigarettes for two weeks. E-cigarettes (either JUUL or Vuse Alto) and pods (JUUL: Virginia tobacco flavor at 3% or 5% nicotine concentration; Vuse Alto: golden tobacco flavor at 1.8%, 2.4%, or 5% nicotine concentration) will be provided.
89118312|NCT05607732|Experimental|MyCog Paradigm|The MyCog paradigm establishes a protocol for implementing our self-administered assessment in the clinic whenever a patient or involved family member reports a concern. The MyCog test can be completed either in the exam room or the waiting room. The MyCog app, on an iPad, can be readily linked to the electronic health record, so once the two tests are completed, results are securely transmitted and will populate within discrete, fields that can be queried found in the patient record; specifically: 1) in a screening tab, under 'cognitive abilities', 2) a flow sheet to capture trend with future repeated tests - informing physicians of a patient's relative vs. normative cognitive decline. Both a binary, objective classification of 'impairment detected or suspected' or 'no impairment detected' will populate in the record, as well as a summary score to further guide the clinician by clarifying the extent to which a patient's performance falls outside a normal threshold.
89118313|NCT05607732|No Intervention|Usual Care Arm|At Oak Street Health, cognitive assessments included when concerns are reported by patients or family members, if a clinician suspects a concern, or during Annual Wellness Visits (AWVs) are limited to the Mini-Cog©, and are variably administered, particularly outside of AWVs. Oak Street practices vary by clinician in terms of making referrals, how results are documented, what diagnosis code, placement in problem list or visit diagnosis, and any follow-up plans. While we will not make any explicit recommendations to usual care practices regarding their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to a data field that can be queried in the EHR, and 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will be provided to each clinical leadership.
89118314|NCT05601531|Experimental|Autologous Tooth Root+Vit.D3+Bone graft|Placement of bone graft and local administration of Vit.D3, and placement of autologous root slices
89118315|NCT05601531|Experimental|Autologous Tooth Root+ Bone graft|Placement of bone graft without local administration of Vit.D3 and placement of autogenous root slices
89118316|NCT05601531|Experimental|Bone graft|Only bone graft materials were placed, no local administration of Vit.D3, and no autologous root slices were placed
89118317|NCT05601531|No Intervention|Natural healing|After the wound healed naturally, no bone graft material was filled, and Vit.D3 was not administered locally, and autologous tooth root slices were not placed.
89118318|NCT05591820|Experimental|Brief behavioral parent training with optional booster sessions|A brief, individualized, three-session parent training that exists of two (bi)weekly individually tailored training sessions of two hours and a third session of one hour in which the training will be evaluated, and maintenance training will be provided. After that, parents wishing to receive additional support can receive single booster sessions maximum once every four weeks and/or receive care as usual.
89118319|NCT05591820|Active Comparator|Care as usual (CAU)|The care that is usually provided by the clinical institutions to treat children's disruptive behaviors. There will be no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
89118320|NCT05581979||68-Ga PSMA PET scan|68-Ga PSMA PET scan
89118321|NCT05581953|Experimental|Omnivorous|Animal protein-lean pork
89118322|NCT05581953|Other|Vegetarian|Lacto-ovo-vegetarian without any meat
89118323|NCT05578560|Experimental|Prehabituation group|Patients with vestibular Schwannoma are indicated for the surgery. The patients in this group undergo chemical labyrinthectomy via intratympanically installed gentamicin before the vestibular Schwannoma resection. After the operation, vestibular training under supervision will be performed.
89118324|NCT05578560|Experimental|Virtual reality group|Patients with vestibular Schwannoma are indicated for the surgery. After the surgery, they will perform vestibular training under supervision and in addition to this, they will be exposed to 3D optokinetic stimulation in virtual reality space.
89118325|NCT05578560|Experimental|Vestibular training group|Patients with vestibular Schwannoma are indicated for the surgery. After the surgery, they will perform vestibular training under supervision.
89118326|NCT05572749|Experimental|Arm 1|Participants of Arm 1 are going to be administered Crocus Kozanis for 12 weeks (30mg twice per day), wash-out period for 12 weeks and metformin (1000mg once per day) for 12 weeks.
89118327|NCT05572749|Experimental|Arm 2|Participants of Arm 2 are going to be administered metformin (1000mg once per day) for 12 weeks, wash-out period for 12 weeks and Crocus Kozanis (30mg twice per day) for 12 weeks.
89118328|NCT05572749|Placebo Comparator|Arm 3|Participants of Arm 3 are going to be administered placebo (5ml twice per day) for 12 weeks
89118329|NCT05557487||Previous heavy smokers|Age 50 to 80 years who have at least a 20-pack-year smoking history with successful smoking cessation history (stopping smoking for more than 6 months), but less than 15 years
89118330|NCT05557487||First degree relatives of lung cancer patients|"First-degree relatives of lung cancer patients~aged more than 50 years~age less than 50 years old, but older than the age at diagnosis of the youngest lung cancer proband in the family"
89118331|NCT05557487||With other high-risk occupational or environmental factors|"Age 50 to 80 years, meet one or more of the following criteria.~air-pollution exposed occupations (such as traffic policeman, street cleaners….) for at least 10 years~cooking index ≥ 110, defined as 2/7 * days cooking by pan frying, stir frying, or deep frying in one week * years cooking.~cooking without using ventilation for more than 20 years~history of pulmonary tuberculosis and complete anti-tuberculosis treatment with interval more than 5 years before this study"
89118332|NCT05553457|Experimental|MyHand-SCI Device Testing|Subjects will attend 1-20 sessions (of approximately 90 mins) to trial a variety of the MyHand-SCI device controls and/or components. Participants will practice various grasp and release activities with the device
89118333|NCT05552547|Active Comparator|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row.
89118334|NCT05552547|Experimental|24-Hour Blood Pressure Machine|Participants will be asked to wear this machine for 24 hours.
89118335|NCT05551533|Experimental|Intervention|To use the mobile app developed by the study team for one month. The app has a few key features including a positive reflection journal, online peer support, knowledge sharing, self-assessment, and locally available resources. Participants in the intervention group will be required to complete at least two positive reflection journal entries per week, and will be encouraged to use other features of the app during the one month period.
89118336|NCT05551533|No Intervention|Wait list|Participants in this group will be put on a wait-list for one month before they can use the app.
89118337|NCT05547113||Cochlear implant patients|The group of patients will consist of 40 adult patients indicated for cochlear implantation at the Department of ENT and Head and Neck Surgery, 1st Faculty of Medicine and FN Motol. Patients who meet the indication criteria for implantation also meet the conditions for inclusion in the study, another criterias are absence of diseases of the bearing joints, absence of diseases peripheral nervous system or muscle disease and absence of disease vision that would prevent visual fixation.
89118338|NCT05540990|Experimental|Robotic assisted gait training (RAGT) + conventional physiotherapy (CPt) group|This group will receive 15 sessions of robot-assisted gait training (two or three times per week with a maximum of 45 minutes each) and conventional physiotherapy, which is individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
89118339|NCT05540990|Active Comparator|Conventional physiotherapy (CPt) group|This group will receive conventional physiotherapy, which is individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
89118340|NCT05537038|Experimental|BNT164a1|Escalating dose levels
89118341|NCT05537038|Experimental|BNT164b1|Escalating dose levels
89118342|NCT05537038|Experimental|Placebo|Isotonic NaCl solution (0.9%)
89118343|NCT05534945|Experimental|F5 ml PIEB|Female patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118344|NCT05534945|Experimental|F6 ml PIEB|Female patients in this group will receive a 6 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118345|NCT05534945|Experimental|F7 ml PIEB|Female patients in this group will receive a 7 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118346|NCT05534945|Experimental|F8 ml PIEB|Female patients in this group will receive a 8 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118347|NCT05534945|Experimental|F9 ml PIEB|Female patients in this group will receive a 9 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118348|NCT05534945|Experimental|F10 ml PIEB|Female patients in this group will receive a 10 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118349|NCT05534945|Experimental|M5 ml PIEB|Male patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118350|NCT05534945|Experimental|M6 mL PIEB|Male patients in this group will receive a 6 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118351|NCT05534945|Experimental|M7 mL PIEB|Male patients in this group will receive a 7 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118352|NCT05534945|Experimental|M8 mL PIEB|Male patients in this group will receive a 8 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118353|NCT05534945|Experimental|M9 mL PIEB|Male patients in this group will receive a 9 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118354|NCT05534945|Experimental|M10 mL PIEB|Male patients in this group will receive a 10 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.
89118355|NCT05529173|Experimental|treatment|Application of Povidone-Iodine 10% prior to surgery to Nares
89118356|NCT05529173|Placebo Comparator|placebo|Application of 0.9% Sodium Chloride (NaCl) solution prior to surgery to Nares
89118357|NCT05528341|Experimental|NKG2D-CAR-NK92 cells immunotherapy|Preparation of NKG2D-CAR-NK92 cells suspended in saline solution.
89118358|NCT05521828|Other|Follitropin delta and dydrogesterone (treatment A followed by treatment B)|"Treatment A: Ovarian stimulation is started with daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily from day 2 of the follicular phase onwards. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 until the criteria for oocyte trigger are achieved.~Treatment B: From day 20 of the menstrual cycle onwards, daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily will be administered. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 or when serum LH > 10 IU/L until day of trigger.~For both treatment (A and B) oocyte maturation trigger will be planned when transvaginal ultrasound shows at least 3 follicles >20mm in diameter with a single subcutaneous injection of GnRH agonist (Gonapeptyl 0.2 mg). Oocyte retrieval will be performed 36 hours after trigger. The retrieved cumulus oocyte complexes will be counted, denuded and the number of mature oocytes evaluated."
89118359|NCT05521828|Other|Follitropin delta and dydrogesterone (treatment B followed by treatment A)|"Treatment B: From day 20 of the menstrual cycle onwards, daily subcutaneous injections of Follitropin delta (Rekovelle) 12 mcg/daily will be administered. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 or when serum LH > 10 IU/L until day of trigger.~Treatment A: Ovarian stimulation is started with daily subcutaneous injections of Follitropin delta12 mcg/daily (Rekovelle) from day 2 of the follicular phase onwards. Dydrogesterone (Duphaston) 20mg/day will be initiated on stimulation day 7 until the criteria for oocyte trigger are achieved.~For both treatment (B and A) oocyte maturation trigger will be planned when transvaginal ultrasound shows at least 3 follicles >20mm in diameter with a single subcutaneous injection of GnRH agonist (Gonapeptyl 0.2 mg). Oocyte retrieval will be performed 36 hours after trigger. The retrieved cumulus oocyte complexes will be counted, denuded and the number of mature oocytes evaluated."
89118360|NCT05509439|Experimental|Home Transfusion|"This research study involves completing questionnaires, a brief interview, blood draws, and blood transfusions when needed.~Home Transfusion Program Components~Participants will be in the research study for up to six months"
89118361|NCT05508971|Experimental|Drug-Induced Sleep Endoscopy|DISE will be performed at the time of surgery under the same sedation. The decision on specific surgical approach will be made at that time based on DISE findings. Prior to intubation, patients will be sedated with either a propofol infusion or a combination of ketamine and dexmedetomidine. Once adequate sedation is achieved, endoscopy will be performed using a flexible endoscope advanced through the nose. The nasal airway will be evaluated on both sides, then the endoscope will be advanced into the pharynx. The degree of obstruction is scored on a 3-point rating scale. Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery. Caregivers will be consented for all possible procedures with the understanding that only those needed based on DISE will be performed. Importantly, these procedures are all established treatments with published outcomes data.
89118362|NCT05508971|Active Comparator|Adenotonsillectomy|Adenotonsillar hypertrophy is the most common risk factor for OSA in children, and adenotonsillectomy (AT) is the first line treatment. An adenotonsillectomy is an operation to remove both the adenoids and tonsils.
89118363|NCT05504434|Experimental|Adults patients treated with single use gastroscope|Patients will be treated with a single-use gastroscope instead of a reusable gastroscope. The procedure will be performed as normal, no additional actions will be performed.
89118364|NCT05494697|Experimental|Ampligen / rintatolimod|Subjects will receive rintatolimod [intravenous (IV)], up to 400 mg twice weekly until disease progression.
89118365|NCT05494697|No Intervention|Control Group / No Treatment|Subjects will be followed / no treatment until evidence of disease progression.
89118366|NCT05471609|Experimental|levodopa/carbidopa oral formulation A|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 100mg CD/100mg LD and inner sachet contains 0mg CD /300mg LD.
89118367|NCT05471609|Experimental|levodopa/carbidopa oral formulation B|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 100mg CD/0mg LD and inner sachet contains 0mg CD /400mg LD.
89118368|NCT05471609|Experimental|levodopa/carbidopa oral formulation C|LD/CD will be delivered using an assembly of nested sachets made of permeable material. The assembly is placed in the oral/buccal cavity (between cheek and gum of lower jaw) and delivers continuous release of CD and LD for both transmucosal and gastrointestinal absorption. Outer sachet contains 50mg CD/200mg LD and inner sachet contains 50mg CD /200mg LD.
89118369|NCT05463926|Experimental|Standard hospital care with follow-up + PDA mobile application|Receive standard hospital care and follow-up, and access to the Parentbot - a Digital healthcare Assistant (PDA) mobile application from pregnancy until one-month postpartum
89118370|NCT05463926|No Intervention|Standard hospital care with follow-up|Receive standard hospital care with follow-up
89118371|NCT05458479|Experimental|Fluoxetine|Subjects will receive fluoxetine 5 mg each morning at the start of the trial. The dose will be increased by 5 mg every 2 weeks depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 5 mg and the maximum total daily dose will be 30 mg.
89118372|NCT05458011|Experimental|Fremanezumab Monthly|"Double Blind (DB) Period: Participants will receive fremanezumab once a month (approximately every 4 weeks). Participants will receive a single injection of fremanezumab and two placebo injections on Day 1, and a single injection of fremanezumab on Days 29 and 57.~Open Label (OL) Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141."
89118373|NCT05458011|Experimental|Fremanezumab Quarterly|"DB Period: Participants will receive fremanezumab once a quarter (once at the beginning of the 12-week double-blind treatment period). Participants will receive 3 injections of fremanezumab on Day 1, and a single placebo injection on Days 29 and 57.~OL Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141."
89118374|NCT05458011|Placebo Comparator|Placebo|"DB Period: Participants will receive placebo once a month (approximately every 4 weeks). Participants will receive 3 placebo injections on Day 1, and a single injection of placebo on Days 29 and 57.~OL Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141."
89118375|NCT05453851|Experimental|Treatment (pancreatectomy, autologous islet cell transplant)|Patients undergo total pancreatectomy and autologous islet cell transplant IV over 15-60 minutes on day 1.
89118376|NCT05449418|Active Comparator|Enhanced Usual Care|Distribution of COVID-19 vaccine promotion materials from the Centers for Disease Control and Prevention [CDC] or other national organization with limited distribution support at long-term care centers.
89118377|NCT05449418|Experimental|Full Intervention|Development of materials co-designed with and tailored to language/cultural affinity groups and distributed with assistance from co-design participants who will serve as peer advocates.
89118378|NCT05448768|Active Comparator|Amyloid-positive MCI|The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.
89118379|NCT05448768|Active Comparator|Amyloid-negative MCI|The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.
89118382|NCT05445323|Experimental|Cohort 1/ Cohort 2/ Cohort 3|
89118383|NCT05440110|Active Comparator|active and active|The patients will be subjected to TBS for 5 daily interventions per week for four consecutive weeks.
89118384|NCT05440110|Sham Comparator|sham and active|The patients will be subjected to TBS for 5 daily interventions per week for the first two weeks, followed by an open-label trial for the next two weeks.
89118385|NCT05436106|Experimental|intervention educational content|The base intervention design will contain educational content informed by the Transgender Resilience Intervention Model (TRIM) and adapted from Seeking Safety specific to a) identifying symptoms of psychological distress, b) managing symptoms via coping (individual resilience), and c) developing a social network and using social support/community connection (group resilience).
89118386|NCT05434377|Active Comparator|Vitamin D supplementation using titration regimen|"Patients will receive ergocalciferol orally depending on serum 25(OH)D level as described~serum 25(OH)D < 5 ng/ml --> receive ergocalciferol 50,000 IU/week for 3 months followed by 50,000 IU monthly for 3 months~serum 25(OH)D 5-15 ng/ml--> receive ergocalciferol 50,000 IU/week for 1 month followed by 50,000 IU monthly for 5 months~serum 25(OH)D 16-30 ng/ml--> receive ergocalciferol 50,000 IU monthly for 6 months"
89118387|NCT05434377|Experimental|Vitamin D supplementation using fixed dose regimen|Patients will receive ergocalciferol 20,000 unit orally per week for 6 months.
89118388|NCT05429762|Experimental|Tusamitamab ravtansine|Participants will receive tusamitamab ravtansine intravenous (IV) infusion until disease progression, unacceptable toxicity, the start of a new anti-cancer therapy, or the participant's or Investigator's decision to stop the treatment, whichever comes first.
89118389|NCT05422040|Experimental|Dry needling|"Dry needling is performed with a 4cm needle (APS Dry Needles®) on the most symptomatic side of the patient on palpation. To perform the technique, the patient is positioned in prone position on the couch. The physiotherapist palpates the lateral border of the lumbar iliocostalis muscle and performs the tapping technique in a latero-medial direction parallel to the stretcher.~The technique is performed by applying 12 incisions. After the application of the technique, ischaemic compression shall be performed for 1 minute."
89118390|NCT05422040|Experimental|Diathermy treatment|Diathermy treatment will be applied using the TCaRe Power diathermy instrument (PRIM Physio©), using a capacitive system with an intensity of 50%, with slight variation depending on patient tolerance and 500khz. The therapy will be applied for 10 minutes on each side of the patient's lumbar region, who will be positioned in prone decubitus during the intervention.
89118391|NCT05419492|Experimental|Part 1|Part 1 will follow an open-label, rule-based, dose-escalation design and will initially evaluate 2 dose levels of ETX101 in approximately 4 participants.
89118392|NCT05419492|Sham Comparator|Part 2|"Part 2 is a dose-selection study, which will follow a double-blind (up through Week 52), randomized, sham delayed-treatment control design in approximately 18 participants.~There will be up to 3 cohorts in Part 2. Participants will be randomized 1:1:1 to study treatment (ie, Dose Level 1 or Dose Level 2) or sham procedure with delayed treatment. At the conclusion of Part 1, if the recommendation is made to proceed with a single dose level of ETX101 in Part 2, participants will be randomized 1:1 to study treatment or sham procedure with delayed treatment."
89118393|NCT05419453||Parkinson's|Those with Parkinson's Disease
89118394|NCT05417594|Experimental|Module 1 Part A: Dose escalation|Participants with advanced/relapsed ovarian, breast, pancreatic, or prostate cancer who are deemed suitable for a PARPi will receive AZD9574 monotherapy at escalating cohorts.
89118395|NCT05417594|Experimental|Module 1 Part B: Dose expansion|Participants with breast cancer who are PARPi naive at doses determined in dose-escalation.
89118396|NCT05417594|Experimental|Module 2 Part A: Dose escalation|Participants with IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 and TMZ at escalating cohorts.
89118397|NCT05417594|Experimental|Module 3 Panel 1: AZD9574 monotherapy (Sweden only)|Participants with advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm.
89118398|NCT05417594|Experimental|Module 3 Panel 2: AZD9574 + TMZ (Sweden only)|Participants with IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 and TMZ at escalating cohorts.
89118399|NCT05417594|Experimental|Module 3 Panel 3: AZD9574 monotherapy (Sweden only)|Participants with breast cancer (without BM).
89118400|NCT05417594|Experimental|Module 4 Part A: Dose escalation (AZD9574 + T-DXdat)|Participants with advanced, unresectable, or metastatic solid tumours that are HER2-positive will receive a combination of AZD9574 and T-DXdat at escalating cohorts.
89118401|NCT05417594|Experimental|Module 5 Part A : Dose escalation (AZD9574 + Dato-DXd)|Participants with advanced, unresectable, or metastatic solid tumours in different types of cancers will receive a combination of AZD9574 and Dato-DXd at escalating cohorts.
89118402|NCT05413525||Women undergoing USG- MVA for the treatment of early pregnancy loss|Medical notes of all women undergoing USG- MVA for the treatment of early pregnancy loss with gestation < 12 weeks at the Department of Obstetrics and Gynaecology in The Prince of Wales Hospital and Union Hospital will be reviewed.
89118403|NCT05411627|Experimental|Treatment Group|Pilot group of all 8 anticipated participants
89118404|NCT05402930|Experimental|Neoadjuvant chemotherapy|
89118405|NCT05400174|Other|Supine cognitive testing first|"The cognitive testing sessions will be alternated between supine and upright positions.~This group will perform cognitive testing sessions in the following order: 1) supine, 2) upright, 3) supine, 4) upright."
89118406|NCT05400174|Other|Upright cognitive testing first|"The cognitive testing sessions will be alternated between supine and upright positions.~This group will perform cognitive testing sessions in the following order: 1) upright, 2) supine, 3) upright, 4) supine."
89118407|NCT05389852|Active Comparator|intravenous dexmedetomidine|Patients will receive intravenous dexmedetomidine 1 mcg/kg just after the supraclavicular brachial plexus block is completed
89118408|NCT05389852|Placebo Comparator|Placebo|Patients will receive intravenous placebo (normal saline) just after the supraclavicular brachial plexus is completed
89118409|NCT05388981|Experimental|Cohort 1|Intramuscular (IM) dose level 1
89118410|NCT05388981|Experimental|Cohort 2|IM dose level 2
89118411|NCT05388981|Experimental|Cohort 3|IM dose level 3
89118412|NCT05388981|Experimental|Cohort 4|IM dose level 4
89118413|NCT05388981|Experimental|Cohort 5|Intravenous (IV) dose level 1
89118414|NCT05388409||CASE|Kidney transplanted patients with PSVD
89118415|NCT05388409||Control 1|Kidney transplanted patients without PSVD
89118416|NCT05388409||Control 2|patient with PVSD without transplantation
89118417|NCT05367362|Experimental|Intervention|Patients randomized to minocycline will receive 200mg administered once a day for 21 days. The first dose will be administered in the emergency room or the angiography suite prior to endovascular intervention or within the first two hours of endovascular stroke intervention. If the patient is considered able to swallow as per the routine swallow test, the study drug will be administered orally as intact capsules. If the patient is considered to be at any risk for aspiration or is unable to swallow based on swallowing evaluation, study drug may be started using intravenous route and later switched to oral or via feeding tube as it becomes available.
89118418|NCT05367362|No Intervention|Control|Patients randomized to control arm will receive look-alike placebo administered once a day for 21 days. The first dose will be administered in the emergency room or the angiography suite prior to endovascular intervention or within the first two hours of endovascular stroke intervention. If the patient is considered able to swallow as per the routine swallow test, the placebo will be administered orally as intact capsules. If the patient is considered to be at any risk for aspiration or is unable to swallow based on swallowing evaluation, placebo may be started using intravenous route and later switched to oral or via feeding tube as it becomes available.
89118419|NCT05360862||Prone positioning session|
89118420|NCT05357989|Experimental|10 mg buntanetap/posiphen|Buntanetap/posiphen 10 mg oral capsule with daily administration for a period of 6 months
89118421|NCT05357989|Experimental|20 mg buntanetap/posiphen|Buntanetap/posiphen 20 mg oral capsule with daily administration for a period of 6 months
89118422|NCT05357989|Placebo Comparator|Placebo|Placebo oral capsule with daily administration for a period of 6 months
89118423|NCT05353790|Experimental|Avocado mango meal plan|2 meals and snacks per day, including 1 avocado + 1 cup of mango, covering 75% of daily calories needs,
89118424|NCT05353790|Other|Control meal plan|2 meals and snacks per day, without avocado and mango, covering 75% of daily calories needs
89118425|NCT05351151|Experimental|Loco Regional anesthesia (LRA)|The LRA group is made up of patients benefiting from the V2 and V3 ultrasound-guided LRA technique without mucosal infiltration.
89118426|NCT05351151|Active Comparator|Infiltration|"The Infiltration group is made up of patients who benefit from the infiltration technique by local anesthesia of the incision sites by the surgeon without recourse to ultrasound-guided LRA."
89118427|NCT05339139|Experimental|Ci-Ca Arm|The study population will include critically ill subjects who are a minimum of 18 years old, in an acute setting, requiring CRRT. the Subjects will receive Regional Citrate Anticoagulation (RCA) which will be delivered by MultiFiltiratePRO system
89118428|NCT05335499|Experimental|TAS5315 Dose 1|
89118429|NCT05335499|Experimental|TAS5315 Dose 2|
89118430|NCT05335499|Experimental|TAS5315 Dose 3|
89118431|NCT05335499|Experimental|AS5315 Dose 4|
89118432|NCT05335499|Experimental|TAS5315 Dose 5|
89118433|NCT05335499|Placebo Comparator|Placebo|
89118434|NCT05334914|Other|Intervention Arm|Participants will complete the baseline session, a 1:1 motivation building session, and 8 weeks of ACT group therapy. They will then complete a final study visit and a follow-up study visit to occur 6 month after the end of therapy.
89118435|NCT05328752|Experimental|XXB750 Cohort 1|XXB750, single dose
89118436|NCT05328752|Placebo Comparator|Placebo Cohort 1|Placebo, single dose
89118437|NCT05328752|Experimental|XXB750 Cohort 2|XXB750, multiple doses
89118438|NCT05328752|Placebo Comparator|Placebo Cohort 2|Placebo, multiple doses
89118439|NCT05318209|Experimental|Study grou[p|Closed-chain shoulder girdle scapular depression exercise
89118440|NCT05318209|Active Comparator|control group|Shoulder girdle depression against manual resistance exercise
89118441|NCT05309668|Experimental|Selumetinib single arm|This study consists of a screening period (up to 28 days), a treatment period (25 cycles) and a long term safety follow-up for participants until they are 5 years old or commence an alternative systemic NF1-PN treatment, whichever is the earlier. Participants may continue treatment with selumetinib throughout the long term safety follow-up as long as they are considered to be receiving clinical benefit in the opinion of their Investigator. A safety follow up assessment will be performed 30 days after the last dose of study intervention for all study participants.
89118442|NCT05299762||Patients treated with the INFUSE™ Bone Graft|Patients intended to be treated with the INFUSE™ Bone Graft are eligible for enrollment. The investigator screen candidate patients against inclusion/exclusion criteria and enroll a patient only when all inclusion/exclusion criteria meet, and the patient provide written informed consent.
89118443|NCT05299658|Experimental|Open label extension|This is an unblinded open-label extension, all participants will be on active drug.
89118444|NCT05299333|Experimental|Pulmonary Rehabilitation Group|A total of 24 sessions of breathing exercises and high-repetitive muscle endurance and strengthening exercises will be applied to the pulmonary telerehabilitation group for 8 weeks, two days a week and one day a week unsupervised, via online systems. High-repetition muscle endurance and strengthening exercises will be applied to large muscle groups of the lower and upper extremities by creating resistance with body weight and theraband.
89118445|NCT05299333|Active Comparator|Physical Activity Group|Respiratory exercises and physical activity recommendations will be given to the physical activity group. Physical activity recommendations are; It will include information about the importance of physical activity and walking 3-5 days a week for at least 30 minutes of moderate intensity (4-6 on the Modified Borg scale of perceived exertion level).
89118446|NCT05296720|Other|Patients|Patients with schizophrenia
89118447|NCT05296720|Other|Controls|Controls matched with patients on age, sex and education level
89118448|NCT05292794|Experimental|PD Patients treated with CereGate Software|This singular arm contains participants diagnosed with Parkinson's Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System. Participants will use the CereGate software for 60(+/-8) days on demand.
89118449|NCT05289986|Experimental|immediate switch arm|"Experimental arm (baseline visit switch group, N=30): One DOR/TDF/3TC tablet taken orally once daily for 48 weeks.~Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period."
89118450|NCT05289986|Active Comparator|delayed switch arm|"Control arm (deferred switch group, N=30): Participants will continue their current triple cART regimen for 24 weeks, and then switched to taking one TDF/3TC/DOR tablet orally once daily (24 -48 weeks).~Virally suppressed participants on a stable combined ART regimen will be randomised (1:1) to an immediate switch to 3TC/TDF/DOR (immediate switch arm, N=30) for the duration of the 48-week study, or to maintaining their current cART followed by a switch to 3TC/TDF/DOR from week 24-48 (delayed switch arm, N=30). Participants will be monitored for the length of the study (48 weeks) plus a 30-day follow-up period."
89118451|NCT05287581|Experimental|Experimental|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
89118452|NCT05287581|No Intervention|Waitlist Control|24-week waitlist control condition
89118453|NCT05283876|Active Comparator|Active psoriasis|
89118454|NCT05283876|Active Comparator|Stable psoriasis|
89118455|NCT05264506|Experimental|Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A)|The NOMAC-E2 COC active tablets contain 2.5 mg NOMAC and 1.5 mg E2 and will be used in a 24/4 regimen, i.e., 28-day cycles with 24 days of active tablet intake followed by 4 days of placebo tablet intake.
89118456|NCT05252767|Experimental|Cohort A - Patient Engagement Tools|Participants will be enrolled from the a pain management clinic. Participants randomized into the experimental cohort will receive access to a clinic brochure, clinic website, as well as 'My Pain Passport' and 'My Treatment Plan' tools.
89118457|NCT05252767|Sham Comparator|Cohort B - Educational Guide|Participants randomized into the control cohort will receive a brief educational guide on general pain management.
89118458|NCT05248425|No Intervention|Usual Care|All participants will answer questionnaires at specified time points. This arm will receive usual care and their questionnaire responses will not be reviewed.
89118459|NCT05248425|Experimental|Monitored|All participants will answer questionnaires at specified time points. The monitored arm will have their responses reviewed for new or worsening symptoms which will be assessed and managed by a study nurse in addition to usual care.
89118460|NCT05247489|Experimental|Group A: Ruxolitinib + Narrow-Band Ultraviolet B Phototherapy (NB-UVB)|Participants will initially apply ruxolitinib 1.5%mg cream as a monotherapy. At week 12, those who have < 25% improvement in total body Vitiligo Area Scoring Index (T-VASI25) will have NB-UVB phototherapy added to their ruxolitinib 1.5% cream BID regimen. NB-UVB will be given 3 times per week starting at Week 12 through Week 48 (36 weeks). For participants who receive combination therapy, NB-UVB machines will be supplied by the sponsor for at home use during the study.
89118461|NCT05247489|Experimental|Group B: Ruxolitinib Monotherapy|Participants will apply ruxolitinib 1.5% cream BID as monotherapy. Participants who have ≥ T-VASI25 at Week 12 will continue on ruxolitinib 1.5% cream BID alone.
89118462|NCT05234229||covagrip women in immediate post partum|women in immediate post partum
89118463|NCT05234229||Caregivers|health care personnel
89118464|NCT05233007||All participants|All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
89118465|NCT05226247|Other|high-risk of weaning-induced pulmonary edema|Critically-ill patients under mechanical ventilation for more than 48h, who are at high-risk of weaning-induced pulmonary edema and in whom the attending physician decided to perform a spontaneous breathing trial.
89118466|NCT05223829|Experimental|Brexanaolone|In this single-arm study, participants will be administered brexanolone as a continuous IV infusion over 20 hours (titrated up to 90mcg/kg/hour).
89118467|NCT05223374||Assess the time to diagnosis from initial concern by EAC utilizing Canvas Dx|Time from initial concern to diagnosis when using Canvas Dx as part of the diagnostic process (Reported time to diagnosis)
89118468|NCT05217810||Atectura inhalation capsule (150/80ug)|Indacaterol acetate/Mometasone furoate; 150/80ug
89118469|NCT05217810||Atectura inhalation capsule (150/160ug)|Indacaterol acetate/Mometasone furoate; 150/160ug
89118470|NCT05217810||Atectura inhalation capsule (150/320ug)|Indacaterol acetate/Mometasone furoate; 150/320ug
89118471|NCT05206539|Experimental|SAP11-4 group (Gr CR)|The Gr CR will receive treatment with Curodont RepairTM (Credentis; Windisch, Switzerland), according to the manufacturer's instructions.
89118472|NCT05206539|Active Comparator|CPP-ACFP group (Gr V)|The Gr V will receive treatment with MI varnishTM (GC Corporation, Tokyo, Japan), according to the manufacturer's instructions.
89118473|NCT05206539|Active Comparator|Resin infiltration group (Gr I)|The Gr I receive treatment with Icon Vestibular (DMG, Germany), according to the manufacturer's instructions.
89118474|NCT05206539|Placebo Comparator|Control group (Gr NT)|The control group (Gr NT) receive no intervention except brushing twice daily with aminofluoride toothpaste and toothbrush provided by researcher.
89118475|NCT05205200|Experimental|Cohort 1A|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1316 (anti-PD-L1) and endocrine therapy.
89118476|NCT05205200|Active Comparator|Cohort 1B|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with endocrine therapy.
89118477|NCT05205200|Experimental|Cohort 2A|In this cohort, a patient would receive SHR1316 (anti-PD-L1) combined with nab-paclitaxel.
89118478|NCT05205200|Active Comparator|Cohort 2B|In this cohort, a patient would single nab-paclitaxel.
89118479|NCT05205200|Other|Cohort 2C|In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with fulvestrant.
89118480|NCT05198765|Experimental|BMI-CDS|Clinicians and their patients assigned to intervention clinics will receive shared decision support tools for weight loss management.
89118481|NCT05198765|No Intervention|Usual Care|Clinicians and their patients assigned to control clinics will engage in the usual standard of care.
89118482|NCT05192200|Experimental|Anti-Beta Interferon drug (PF-06823859)|IV infusion
89118483|NCT05181761|Experimental|Left Hand with gel polish|The participants will receive gel nail polish on their left hand. The right hand will remain natural (no gel polish)
89118484|NCT05181761|Experimental|Right Hand with gel polish|The participants will receive gel nail polish on their right hand. The left hand will remain natural (no gel polish).
89118485|NCT05175885|Experimental|Experimental group|Ex vivo normothermic perfusion (EVNP) of the graft with the Ark Kidney System
89118486|NCT05175885|Active Comparator|Historical control group|Nonrandomized historical control group formed by patients transplanted without ex vivo normothermic perfusion (EVNP) in the period Sept 2015-Sept 2020, selected by retrospective matching.
89118487|NCT05168904|Experimental|Phase I Dose escalation|Phase 1 = fadraciclib administered orally in escalating doses starting at 50mg bid MWF for 3 weeks of a 4-week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.
89118488|NCT05168904|Experimental|Phase 2|Recommended fadraciclib phase 2 dose and schedule administered orally in 28-day cycles.
89118489|NCT05168384|Experimental|Group A (ECP + SoC Group)|Extracorporeal photopheresis (ECP) plus Multiple Sclerosis (MS) standard of care
89118490|NCT05168384|Active Comparator|Group B (SoC Group)|MS standard of care alone (SoC, defined by Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN
89118491|NCT05165329|Active Comparator|Probiotic and Peanut Oral Immunotherapy (PPOIT)|Probiotic and peanut oral immunotherapy taken daily for 18 months
89118492|NCT05165329|Active Comparator|Placebo Probiotic and Peanut Oral Immunotherapy|Placebo probiotic and peanut oral immunotherapy taken daily for 18 months
89118493|NCT05165329|Placebo Comparator|Placebo Probiotic and Placebo Oral Immunotherapy|Placebo probiotic and placebo oral immunotherapy taken daily for 18 months
89118494|NCT05154214||Adenotonsillectomy|Excision of the palatine tonsils and excision or ablation of the adenoids by each individual surgeon's preferred techniques.
89118495|NCT05154214||Drug-induced sleep endoscopy directed surgery (DISE)|DISE will be performed by the surgeon performing the surgical intervention. The DISE Rating Scale assesses the degree of maximal closure or obstruction at six locations in the upper airway: the nose, nasopharynx (adenoids), velopharynx (soft palate), oropharynx (tonsils), tongue base (tongue, lingual tonsils), and larynx (epiglottis, arytenoids). The degree of obstruction is scored on a 3-point rating scale as none (0), partial (+1), or complete (+2) at each anatomic site. The rating at each anatomic level can be summed into a DISE Rating Scale total. The actual surgery performed will determine which established surgical treatments will be used based on the results of the DISE.
89118496|NCT05151172|Placebo Comparator|best medical care|All patients will receive the best standard of medical care according to modern acute stroke care guidelines All patients including the ones in control arm will receive the best standard of medical care according to modern acute stroke care guidelines. The model will be the Canadian best practices guidelines for acute stroke care. These are very similar to the guidelines of the American Stroke Association and the European Stroke Organization. All participants are expected to be admitted to hospital as part of routine standard of care.It is expected that all participants will undergo a routine work-up for the mechanism of their stroke and be treated appropriately and definitively.
89118497|NCT05151172|Experimental|endovascular thrombectomy|All participants will receive the best standard of medical care according to modern acute stroke care guidelines. In the intervention/experimental arm, participants will be treated with endovascular thrombectomy with a Solitaire device (Medtronic) as the first line approach. The trial mandates that the first attempt is performed with a Solitaire X device (3mm, 4mm or 6mm diameter devices; Medtronic). The remaining treatment technique is left to the discretion of the treating neurointerventionalist. Secondary devices may be used if success is not achieved after use of the first device.
89118498|NCT05148091|Experimental|18~59 yrs. low dosage (20 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of 18~59 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
89118499|NCT05148091|Placebo Comparator|18~59 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of study adjuvant (SCT-VA02B ,0.5mL) on Day 0 and Day 28
89118500|NCT05148091|Placebo Comparator|18~59 yrs. low dosage (20 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
89118501|NCT05148091|Experimental|≥60 yrs. low dosage (20 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
89118502|NCT05148091|Placebo Comparator|≥60 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
89118503|NCT05148091|Placebo Comparator|≥60 yrs. low dosage (20 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
89118504|NCT05148091|Experimental|18~59 yrs. high dosage (40 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of 18~59 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
89118505|NCT05148091|Placebo Comparator|18~59 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
89118506|NCT05148091|Placebo Comparator|18~59 yrs. high dosage (40 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
89118507|NCT05148091|Experimental|≥60 yrs. high dosage (40 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
89118508|NCT05148091|Placebo Comparator|≥60 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
89118509|NCT05148091|Placebo Comparator|≥60 yrs. high dosage (40 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
89118510|NCT05124925|Experimental|Treatment Arm|Ianalumab 300 mg subcutaneous monthly
89118511|NCT05116046|Experimental|Low Dose|Low Dose
89118512|NCT05116046|Experimental|Medium Dose|Medium Dose
89118513|NCT05116046|Experimental|High Dose|High Dose
89118514|NCT05108428|Experimental|MRI-guided adaptive radiation|Patients will receive capecitabine-based chemoradiotherapy (chemotherapy with capecitabine + radiation). Dosing will be modified based on tumor changes measured daily and weekly by MR-guided radiotherapy (MRgRT) utilizing MR-linac (MRL) systems. Chemoradiotherapy will be followed by standard of care consolidated chemotherapy. (FOLFOX)
89118515|NCT05093049|Active Comparator|Gynecomastia Surgery Followed by Renuvion|Patients receiving gynecomastia correction surgery followed by Renuvion treatment were randomly assigned to the left or the right side of the chest in a split-body randomized design. The gynecomastia surgery and Renuvion APR System use will be as per investigator's standard clinical practice.
89118516|NCT05093049|Active Comparator|Gynecomastia Surgery Only|Patients receiving gynecomastia correction surgery followed by Renuvion treatment were randomly assigned to the left or the right side of the chest in a split-body randomized design. The gynecomastia surgery will be as per investigator's standard clinical practice.
89118517|NCT05092646|Placebo Comparator|Control Group|Single dose, 2.0 mL of 0.9% normal saline, administered via intra-articular injection administered to the affected tibiotalar joint.
89118518|NCT05092646|Experimental|Investigational Group|"Biological/Vaccine: Axolotl Ambient~Axolotl Ambient is an allogeneic amniotic intraarticular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.~Other Names:~• CA20"
89118519|NCT05084261|Experimental|BT051 200 mg|Participants will receive oral BT051 200 mg once daily for 28 days.
89118520|NCT05084261|Experimental|BT051 800 mg|Participants will receive oral BT051 800 mg once daily for 28 days.
89118521|NCT05084261|Experimental|BT051 3200 mg|Participants will receive oral BT051 3200 mg once daily for 28 days.
89118522|NCT05084261|Placebo Comparator|Placebo|Participants will receive oral Placebo to match BT051 once daily for 28 days.
89118523|NCT05072314|Active Comparator|Lidocaine|2% Lidocaine infusion intra-operative and 10% Lidocaine infusion post-operative.
89118524|NCT05072314|Placebo Comparator|Placebo|0.9% Saline infusion intra-operative and 0.9% Saline infusion post-operative.
89118525|NCT05071053|Experimental|Tusamitamab ravtansine+Ramucirumab|"Part 1: participants to receive an intravenous (IV) dose of tusamitamab ravtansine in combination with an IV dose of ramucirumab on Day 1 of Cycle 1 followed by an additional IV dose of tusamitamab in combination with IV dose of ramucirumab at Day 1 Cycle 2 of 14-day cycle in all subsequent cycles.~Part 2: participants to receive the recommended dose of tusamitamab ravtansine established in the Part 1 in combination with IV dose of ramucirumab on Day 1 of Cycle 1 followed by IV dose of tusamitamab in combination with IV dose of ramucirumab at Day 1 Cycle 2 of 14-day cycle in all subsequent cycles."
89118526|NCT05061771|Active Comparator|nomacopan (rVA576)|"PART A:~High dose nomacopan (standard complement ablating doses on Day 1 followed by 45 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd~or~Low dose nomacopan (standard complement ablating doses on Day 1 followed by 15 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS~PART B:~Nomacopan (standard complement ablating doses on Day 1 followed by to be confirmed mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd"
89118527|NCT05061771|Placebo Comparator|Placebo|"PART A:~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 45mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd~or~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 15mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd~PART B:~Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of active dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd"
89118528|NCT05044611|Experimental|Amiloride|the experimental arm will receive 5mg of amiloride twice daily during 2 months
89118529|NCT05044611|Placebo Comparator|Placebo|the control arm will receive a placebo twice daily during 2 months
89118530|NCT05026632|Experimental|Single NPI-002 Intravitreal Implant|one NPI-002 implant inserted at the time of vitrectomy
89118531|NCT05026632|Experimental|Double NPI-002 Intravitreal Implant|two NPI-002 implants inserted at the time of vitrectomy
89118532|NCT05026632|No Intervention|Control|No implant inserted at time of vitrectomy
89118533|NCT05023395|Experimental|Investigational Medicinal Product|Patients will be assigned to receive oral MEE-HU Medicus with the empirical antibiotic. A study pharmacist will prepare visually matched packages in identical, sequentially numbered treatment packs according to a previously done computer-generated randomization list, using block randomization with variable blocks of length 4 and 6. To be dispended, in sequential order, as participants will be recruited. All participants, enrolling physicians and investigators will be blinded to the treatment allocations. Attending physicians will be responsible for enrolling the participants and ensuring that the study medications are given from the appropriate treatment pack. Selection bias is minimized by randomization, while performance bias is minimized by blinding.
89118534|NCT05023395|Placebo Comparator|Placebo|Patients will be assigned to receive oral matching placebo with the empirical antibiotic. A study pharmacist will prepare visually matched packages in identical, sequentially numbered treatment packs according to a previously done computer-generated randomization list, using block randomization with variable blocks of length 4 and 6. To be dispended, in sequential order, as participants will be recruited. All participants, enrolling physicians and investigators will be blinded to the treatment allocations. Attending physicians will be responsible for enrolling the participants and ensuring that the study medications are given from the appropriate treatment pack. Selection bias is minimized by randomization, while performance bias is minimized by blinding.
89118535|NCT05021939|No Intervention|Control Group|No treatment will be given to the control group. Evaluation will be done at the at the baseline and 8th week.
89118536|NCT05021939|Experimental|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
89118537|NCT05021939|Experimental|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
89118538|NCT05016895|Experimental|Bi-annual single dose azithromycin|Mass, community-based distribution of single dose azithromycin solution (200 mg/5ml) dosed at 20 mg/kg weight to all eligible infants ages 1 to 11 months twice yearly (approximately 6 months apart)
89118539|NCT05006781|Experimental|tDCS+Dose A|Drug: DAOIB at dose A The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
89118540|NCT05006781|Experimental|tDCS+Dose B|Drug: DAOIB at dose B The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
89118541|NCT05006781|Experimental|tDCS+Dose C|Drug: DAOIB at dose C The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
89118542|NCT05006781|Placebo Comparator|tDCS+placebo|Drug: Placebo Placebo Device: tDCS tDCS
89118543|NCT05003401|Experimental|HabitAware Keen 2|Participants will receive the wrist device device that alerts the participant when the participant is engaging in hair pulling behavior.
89118544|NCT04987463|Experimental|Vigabatrin arm|Vigabatrin in capsules co-administered with placebo in liquid.
89118545|NCT04987463|Experimental|Rapamycin arm|Rapamycin in liquid co-administered with placebo in capsules.
89118546|NCT04986358|Other|Patient cohorte|Cohort of patients who will benefit from surgical management of their Hallux Valgus with post-operative follow-up at 2 years
89118547|NCT04982510|Experimental|Thermoplastic tray definitive impression|
89118548|NCT04982510|Active Comparator|Conventional tray definitive impression|
89118549|NCT04978311|Experimental|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
89118550|NCT04978311|Active Comparator|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
89118551|NCT04978311|Active Comparator|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
89118552|NCT04971681|Experimental|Low frequency repetitive transcranial magnetic stimulation (rTMS)|Low frequency repetitive transcranial magnetic stimulation (rTMS)
89118553|NCT04971681|Sham Comparator|Sham rTMS Stimulation|Sham rTMS Stimulation
89118554|NCT04964414|Active Comparator|Smell Retraining Only|Participants will undergo smell retraining for 8 weeks. Each week, participants will choose 4 scents. They will smell each item for 15 seconds very close to the nose once a day.
89118555|NCT04964414|Experimental|Smell Retraining + Budesonide|Participants will undergo smell retraining as described above. They will also complete budesonide irrigations once a day by pouring 0.5mg/2ml of budesonide into a irrigation bottle with saline and irrigating the nose.
89118556|NCT04953104|Experimental|Treatment (nivolumab & relatlimab)|Participants found to be eligible to take part in this study, you will receive nivolumab and relatlimab by vein over about 30 minutes on Day 1 of every 28-day study cycle (about every 4 weeks).
89118557|NCT04937816||EMPA-REG - Placebo|Participants of the EMP-REG OUTCOME study (1245.25) who received placebo.
89118558|NCT04937816||EMPA-REG - Empagliflozin low dose|Participants of the EMPA-REG OUTCOME study (1245.25) who received a low dose of empagliflozin once daily (QD).
89118559|NCT04937816||EMPA-REG - Empagliflozin high dose|Participants of the EMP-REG OUTCOME study (1245.25) who received a high dose of empagliflozin once daily (QD).
89118560|NCT04937816||EMPEROR-Preserved - Empagliflozin|Participants of the EMPEROR-Preserved study (1245.110) who received empagliflozin once daily (QD).
89118561|NCT04937816||EMPEROR-Preserved - Placebo|Participants of the EMPEROR-Preserved study (1245.110) who received placebo once daily (QD).
89118562|NCT04937816||EMPEROR-Reduced - Empagliflozin|Participants of the EMPEROR-Reduced study (1245.121) who received empagliflozin once daily (QD).
89118563|NCT04937816||EMPEROR-Reduced - Placebo|Participants of the EMPEROR-Reduced study (1245.121) who received placebo once daily (QD).
89118564|NCT04934800||Cladribine|
89118565|NCT04930614||Transgender and non-binary people|Adult transgender and non-binary people in Flanders and Brussels (Belgium)
89118566|NCT04925791|Experimental|The IPC group|subjects will get a standardized pre-conditioning treatment 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of occlusion alternating with 5 minutes of reperfusion while seated.
89118567|NCT04925791|Other|The CON group|subjects will get a controlled treatment of 20% of limb occlusion pressure 24 hours prior to their hip arthroscopy. This consists of 3 rounds of 5 minutes of minimal occlusion alternating with 5 minutes of reperfusion while seated.
89118568|NCT04912596|Placebo Comparator|Placebo group|Two different Reference Placebo inhalers and two different Test Placebo inhalers
89118569|NCT04912596|Active Comparator|Reference 1 group|One Reference inhaler, one Reference Placebo inhaler, and two different Test Placebo inhalers
89118570|NCT04912596|Active Comparator|Reference 2 group|Two different Reference inhalers and two different Test Placebo inhalers
89118571|NCT04912596|Experimental|Test group|One Test inhaler, one Test Placebo inhaler, and two different Reference Placebo inhalers
89118572|NCT04908683|Experimental|Group 1: Respiratory Syncytial Virus (RSV) vaccine|All participants in the active group will receive a single dose intramuscular (IM) injection of study vaccine on Day 1.
89118573|NCT04908683|Placebo Comparator|Group 2: Placebo|All participants in the placebo group will receive a single IM injection of matching placebo on Day 1.
89118574|NCT04904575|Experimental|Block|"The Block group will be made up of patients who will benefit from an injection of levobupivacaine for the realization of the erector spinae plane block."
89118575|NCT04904575|Placebo Comparator|Placebo|"The placebo group corresponds to the reference group, that is to say that it will consist of patients who will benefit from an injection of physiological serum for the realization of the erector spinae plane block."
89118576|NCT04901975|Experimental|Spironolactone|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.~All SV children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation.~Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every ~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg.~Spironolactone administration will begin after the Fontan procedure in the hospital prior to discharge or at the first outpatient visit ~ 2 weeks after discharge."
89118577|NCT04901975|No Intervention|Observational|"Children will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers immediately prior to the Fontan operation.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
89118578|NCT04901975|No Intervention|Control|"The purpose of this study is to non-invasively characterize the fibrotic consequences of SV physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion (figure 1) along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.~Control subjects who are non-SV patients but who have normal heart function who are undergoing CMR for evaluation (eg patients undergoing CMR for vascular ring evaluation, family history of congenital heart disease but found to be normal, etc) will have study related MRI and CMR sequences performed."
89118579|NCT04901975|No Intervention|Observational - 1A|"Subjects who were enrolled in this study in Spironolactone arm and patient's family would like to continue participation.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
89118580|NCT04901975|No Intervention|Observational - 1B|"Subjects who were enrolled in other studies with intervention.~All SV children, whether they received spironolactone or not, will undergo characterization and measurement of liver and cardiac fibrosis with MRI and cardiac magnetic resonance (CMR) as well as serum biomarkers ~1 year after the Fontan operation. Demographics and medical history will be collected again along with adverse events. Children will also undergo CMR for evaluation of hemodynamics, ventricular function (including strain), computational modeling and lymphatic abnormalities. A few of these patients will be undergoing CMR for clinical reasons and study CMR related and study MRI related imaging and blood draws will be performed in coordination with their clinical care (ie these sequences will be added on to their clinical sequences)."
89118581|NCT04893811|Experimental|Single Arm|Bivalent recombinant lipoprotein 2086 vaccine
89118582|NCT04878211|Experimental|Ofatumumab - vaccine 2 weeks prior|RMS participants will receive non-live COVID-19 mRNA vaccine at least two weeks prior to start of ofatumumab (20 mg subcutaneous)
89118583|NCT04878211|Experimental|Ofatumumab -vaccine 4 weeks after|RMS participants will receive non-live COVID-19 mRNA vaccine at least four weeks after start of ofatumumab (20 mg subcutaneous)
89118584|NCT04878211|Active Comparator|Interferon or glatiramer acetate - vaccine 4 weeks after|RMS participants will receive non-live COVID-19 mRNA vaccine at least 4 weeks after start of prescribed interferon or glatiramer acetate
89118585|NCT04878211|Experimental|Ofatumumab - fully vaccinated|RMS participants fully vaccinated with a non-live COVID mRNA vaccine and on ofatumumab for at least 4 weeks (20 mg subcutaneous)
89118586|NCT04878211|Experimental|Interferon or glatiramer acetate - fully vaccinated, with or without booster|RMS participants fully vaccinated with a non-live COVID mRNA vaccine, without or without a booster, and on interferon or glatiramer acetate for at least 4 weeks
89118587|NCT04878211|Experimental|Ofatumumab - fully vaccinated, with a booster|RMS participants fully vaccinated with a non-live COVID mRNA vaccine with a booster and on ofatumumab for at least 4 weeks (20 mg subcutaneous)
89118588|NCT04872556|Experimental|Laser acupuncture group|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment, besides the control group arrange pseudo-laser acupuncture. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
89118589|NCT04872556|Sham Comparator|Pseudo-laser acupuncture group|The experiment group would arrange laser acupuncture on day1 and day 3 after Taxanes treatment, besides the control group arrange pseudo-laser acupuncture. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
89118590|NCT04866407|Experimental|Mentha x piperita|A diluted solution of Mentha x piperita in carrier oil will be applied to the subject's interventional extremity.
89118591|NCT04866407|Experimental|Eucalyptus globulus|A diluted solution of Eucalyptus globulus in carrier oil will be applied to the subject's interventional extremity.
89118592|NCT04866407|No Intervention|No intervention|Each participant will have one extremity that receives no essential oil intervention.
89118593|NCT04863898|Other|Staff (Study Participants) Working in HIV Care and Treatment Clinics|"Single arm, Pre-post with staff (study participants) working in HIV care and treatment clinics~Drug use stigma reduction training intervention for staff (study participants) working in HIV care and treatment clinics. The intervention consists of five-2.5 hour participatory training sessions. We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building."
89118594|NCT04863222|Experimental|MTA, then Biodentine|The participant will receive the standard of care procedure using MTA in on a right primary molar. A left primary molar will then be treated using Biodentine.
89118595|NCT04863222|Experimental|Biodentine, then MTA|Investigators will prepare and treat a participants right primary molar with Biodentine. The participant will then receive the standard of care procedure using MTA in on a left primary molar.
89118596|NCT04855968|Active Comparator|control (CON)|will receive the usual standard of care post-operative pain pills for the involved shoulder (Control Group)
89118597|NCT04855968|Experimental|Mindfulness/Meditation (MM)|will receive the usual standard of care post-operative pain pills for the involved shoulder with the addition of access to the Headspace application for mindfulness/meditation (Mindfulness/Meditation Group)
89118598|NCT04852822||Observational (biospecimen collection, medical record review)|"For patients who have not been vaccinated at the time of enrollment, they will undergo collection of blood samples prior to the first vaccine dose, just before the second vaccine dose, and then at 1, 6, and 12 months after the second vaccine dose. Patients' medical records are also reviewed.~For patients enrolled after vaccination, they will undergo collection of blood samples at 1-4, 6, and 12 months after completing the vaccination series. Patients who receive booster dose also undergo collection of blood samples at 1, 6, and 12 months post final booster dose."
89118599|NCT04848974|Experimental|Treatment (uproleselan, cladribine, cytarabine)|"INDUCTION THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q 12 hours on days 2-12, cladribine IV over 1-2 hours on days 1-5 and cytarabine SC BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR or CRi after cycle 1 may receive a second induction cycle.~CONSOLIDATION/MAINTENANCE THERAPY: Patients receive uproleselan IV over 20 minutes on day 1 and Q12 hours on days 2-1. Patients who have achieved at least CR/CRi or morphologic leukemia-free state after induction therapy receive uproleselan IV QD on days 1-12. Patients also receive cladribine IV over 1-2 hours on days 1-3 and cytarabine SC BID on days 1-10. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
89118600|NCT04839601|Experimental|Evaluation Group (stimulation ON)|Group of participants that have an RNS System implanted and are being treated with responsive stimulation.
89118601|NCT04830605|Experimental|Intervention|Internet-delivered treatment for parents with health anxiety on behalf of their child. Eight weeks with therapist support.
89118602|NCT04829565|Experimental|botulinum toxin|50 IU of botulinum toxin
89118603|NCT04829565|Placebo Comparator|placebo|50 IU of placebo
89118604|NCT04827810|Experimental|Dose -1|Accelerated Phase: - Standard Phase: 5 mg
89118605|NCT04827810|Experimental|Dose 1|Accelerated Phase: 10 mg Standard Phase: 10 mg
89118606|NCT04827810|Experimental|Dose 2|Accelerated Phase: 20 mg Standard Phase: 20 mg
89118607|NCT04827810|Experimental|Dose 3|Accelerated Phase: 40 mg Standard Phase: 35 mg
89118608|NCT04827810|Experimental|Dose 4|Accelerated Phase: 80 mg Standard Phase: 50 mg
89118609|NCT04827810|Experimental|Dose 5|Accelerated Phase: 160 mg Standard Phase: 65 mg
89118610|NCT04827810|Experimental|Dose 6|Accelerated Phase: 320 mg Standard Phase: 85 mg
89118611|NCT04826432|Experimental|Pasireotide|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
89118612|NCT04826432|Placebo Comparator|Placebo|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
89118613|NCT04810559|Experimental|Investigational Device|
89118614|NCT04810182||Glioblastoma Patients treated with Regorafenib|Patients with a confirmed diagnosis of Glioblastoma for whom a decision to treat with regorafenib has been made (by the treating physician).
89118615|NCT04807660||Prospective cohort|Middle ear fluid sample for each enrrolled children
89118616|NCT04800367|Experimental|Romosozumab followed by denosumab|Romosozumab 210 mg subcutaneous injection, once a month for 12 months followed by denosumab 60 mg subcutaneous injection, once every six months for 12 months.
89118617|NCT04795492|Experimental|Intervention group|Remote intervention
89118618|NCT04795492|Active Comparator|Control group|Routine outpatient follow-up
89118619|NCT04793360||LiverCare Surveillance|Participants undergoing orthotopic liver transplant (de-novo or re-transplant) will be considered for this study
89118620|NCT04790461|Experimental|1. experimental group: face to face education+PMR exercise|The education and PMR exercises prepared in line with the face-to-face Roy adaptation model will be applied. In groups of 8-10 people, the first 4 sessions in rehabilitation centers will last for the first 4 sessions, and then PMR exercises will be taught and applied (between the 2nd and the 5th weeks, they will be encouraged to do PGE twice at home). The next 4 weeks will be provided with PMR consultancy (3 times a week application / total 24 sessions of PMR application). PMR exercises will be given a follow-up schedule and the caregivers will be followed up by the caregivers themselves and the researchers.
89118621|NCT04790461|Experimental|2. experimental group: mobile health education + PMR exercise|Access to mobile applications will be provided for 8 weeks, including the Roy adaptation model-based training and PMR exercises, which include video and training presentations prepared by the consultant and researcher, as a power point presentation. PMR exercises will be uploaded to the system by uploading a follow-up schedule to the system, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers can follow the participants.
89118622|NCT04790461|Experimental|3rd experimental group: face to face and mobile health education + PMR exercise|4 sessions prepared in line with the Roy adaptation model face to face and held in rehabilitation centers, training in groups of 8-10 people, teaching PMR exercises and installing phone applications that can be accessed for 8 weeks), 8-week intervention including training (enabling them to do progressive relaxation exercises and access to training content) will be provided. . The PMR exercises will be uploaded to the system / given as a printout according to the caregiver's preference, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers watch the participant.
89118623|NCT04790461|Other|Control group|Without applying any intervention, the post-test YBYKA, ASÖ and SBÇYA scales will be applied in the 10th week of the study. After all the tests for the study are measured and finished, they will be provided with training and relaxation exercises.
89118624|NCT04784455|Experimental|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
89118625|NCT04773795|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
89118626|NCT04765241|Experimental|mHealth Physical Activity Intervention|The intervention arm will receive a 12 month mobile health (mHealth) physical activity intervention with a goal of increasing their moderate-vigorous intensity physical activity levels by 90 minutes per week above baseline
89118627|NCT04765241|No Intervention|Control|Controls will receive general health education materials
89118628|NCT04751175|Experimental|Ketamina bolus plus Dexamethasone bolus plus infusion ketamine|Ketamine bolus (0.5 mg / kg) + dexamethasone 0.1 mg / kg bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the Post-Anesthesia Resuscitation Unit (URPA)
89118629|NCT04751175|Experimental|Ketamine bolus plus ketamine infusion|Ketamine bolus (0.5 mg / kg) + physiological serum bolus + ketamine infusion (0.1 mg / kg / h) up to three hours after admission to the URPA.
89118630|NCT04751175|Active Comparator|Dexametasone arm|Saline bolus + dexamethasone bolus 0.1 mg / kg + saline infusion up to three hours after admission in URPA
89118631|NCT04751175|Placebo Comparator|Saline bolus|Saline bolus + saline bolus + saline infusion up to three hours after admission to the URPA
89118632|NCT04732286|Experimental|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89118633|NCT04725617|Active Comparator|Health Intervention Approach 1|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
89118634|NCT04725617|Active Comparator|Health Intervention Approach 2|Subjects randomized into Group 1 will be provided with approach 1, a behavioral health intervention administered by a Clinical Psychologist, in addition to administration of medication (Varenicline), and counseling, during 6 study visits.
89118635|NCT04714749|Experimental|Endovenous treatment|Endovenous treatment with cyanoacrylate glue
89118636|NCT04711824|Experimental|Study Treatment Arm|Cycle 1 of study treatment will consist of Olaparib twice daily concurrently with stereotactic radiosurgery (SRS). Olaparib will start one week prior to SRS and continue during and following SRS (1-5 fractions) for up to 28 days total. Once the subject has recovered from SRS, Cycle 2 will be initiated with physician's choice systemic therapy and durvalumab. Cycle 2+ will equal 21 days. During Cycles 2 and 3, physician's choice systemic monotherapy will be given along with durvalumab. Each cycle will last 21 days. Imaging to evaluate intracranial and extracranial disease will be performed after Cycle 3, and subjects with response will continue with the systemic therapy and durvalumab until progression (intracranial or extracranial), unacceptable toxicity or death.
89118637|NCT04699838|Experimental|Cisplatin or Carboplatin + Etoposide + Durvalumab + Ceralasertib|"Initial Phase: Cycles 1-4 Cisplatin or Carboplatin: Day 1 Etoposide: Days 1-3 Durvalumab, 1500 mg: Day 1 q 3 weeks~Maintenance Phase, Cycles 5+ Durvalumab, 1500 mg: Day 8 q 4 wks. Ceralasertib at 240mg po BID twice a day: Days 1-7"
89118638|NCT04685005|Experimental|Wake up|Drinking regular formula of Wake Up
89118639|NCT04685005|Active Comparator|Caffeine|Drinking 100mg of Caffeine
89118640|NCT04685005|Placebo Comparator|Placebo|Drinking Placebo (only water with sugar)
89118641|NCT04685005|Experimental|Wake up Double Dose|Drinking formula of Wake Up with double doses of guarana, green tea, elderberry and Fruit-up
89118642|NCT04685005|Experimental|Wake up tripple dose|Drinking formula of Wake Up with tripple doses of guarana, green tea, elderberry and Fruit-up
89118643|NCT04675996|Experimental|Phase 1/1b|"Phase 1: dose escalation phase with a 'hybrid' 3+3 design in all-comers cancer patients. Approximately 30 patients will be included.~Phase 1b: dose expansion phase in selected tumor types at the recommended phase 2 dose. Approximately 50 patients will be included."
89118644|NCT04672993|Experimental|Urine Collection Device for Men|Test of Urine Collection Device for Men for 7 (+/- 3/0 days).
89118645|NCT04661150|Experimental|Arm A: Atezolizumab plus Trastuzumab with XELOX (Capecitabine + Oxaliplatin)|Participants will receive atezolizumab + trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, patrticipants will receive 5 further cycles of this regimen.
89118646|NCT04661150|Active Comparator|Arm B: Trastuzumab with XELOX (Capecitabine + Oxaliplatin)|Participants will receive trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, participants will receive 5 further cycles of this regimen.
89118647|NCT04659603|Experimental|Cohort A metastatic breast cancer (mBC)|tusamitamab ravtansine every 2 weeks administered via intravenous infusion (IV)
89118648|NCT04659603|Experimental|Cohort B metastatic pancreatic adenocarcinoma (mPAC)|tusamitamab ravtansine every 2 weeks administered via intravenous infusion (IV)
89118649|NCT04659603|Experimental|Cohort C Metastatic pancreatic adenocarcinoma (mPAC)|tusamitamab ravtansine every 2 weeks combined with gemcitabine on Day 1, Day 8 and Day 15 every 4 weeks administered via intravenous infusion (IV)
89118650|NCT04653610||HIV-infected individuals|
89118651|NCT04653610||HIV-seronegative healthy volunteers|
89118652|NCT04653194|Experimental|Biktarvy treatment|First-line HIV treatment of Biktarvy OD for 48 weeks
89118653|NCT04653194|Active Comparator|Symtuza treatment|First-line HIV treatment of Symtuza OD for 48 weeks
89118654|NCT04639167|Experimental|Paths to everyday life (PEER)|The Paths to everyday life (PEER) intervention added to service as usual (SAU) consists of a 10-week group course and an opportunity of individual companionship to persons with mental vulnerability and mental health difficulties. The 10 week group sessions is facilitated by two volunteer peers with their own lived experiences with mental vulnerability.
89118655|NCT04639167|No Intervention|Service as usual (SAU)|Participants who will be allocated to the control group of the trial will receive service as usual (SAU) by their social security officer, or no specific service if the participant has been referred to the trial by self-referral. Participants who are referred to the trial via §82 in the municipality, can receive other §82 offers depending on the individual municipality.
89118656|NCT04634578|Experimental|Bevacizumab- 0.063 mg|Participants will receive a single intravitreal injection of 0.063 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.
89118657|NCT04634578|Experimental|Bevacizumab- 0.25 mg|Participants will receive a single intravitreal injection of 0.25 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.
89118658|NCT04626947|Other|Open label|Single arm
89118659|NCT04625205|Experimental|Part 1 dose finding phase: NEO-PTC-01 Dose 1|Monotherapy - Dose 1
89118660|NCT04625205|Experimental|Part 1 dose finding phase: NEO-PTC-01 Dose 2|Monotherapy - Dose 2
89118661|NCT04625205|Experimental|Part 1 dose finding phase: NEO-PTC-01 plus IL-2|NEO-PTC-01 in combination with a fixed dose of IL-2 (cohort will only be open in countries where IL-2 is approved)
89118662|NCT04625205|Experimental|Part 1 dose finding phase: NEO-PTC-01 plus αPD- 1 therapy|The αPD-1 therapy will be introduced, beginning 1 to 2 weeks post NEO-PTC-01, to patients who failed αPD-1/α programmed death ligand 1 (αPD-L1) therapy prior to enrollment in the NTC-001 study
89118663|NCT04625205|Experimental|Part 2 dose expansion phase: NEO-PTC-01|Patients currently receiving PD-1/PD-L1 inhibitors (as single agent or in combination with cytotoxic T-lymphocyte-associated antigen-4 [CTLA4] inhibitors) as therapy for metastatic melanoma
89118664|NCT04620681|Experimental|Phase 1 Dose Level 1|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 1: 1X10^6 CD4 T Cells/kg
89118665|NCT04620681|Experimental|Phase 1 Dose Level 2|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 2: 1X10^7 CD4 T Cells/kg
89118666|NCT04620681|Experimental|Phase 1 Dose Level 3|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 3: 5 X10^7 CD4 T Cells/kg
89118667|NCT04620681|Experimental|Phase 2 -Treatment at Maximum Tolerated Dose (MTD)|All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at MTD.
89118668|NCT04620226|No Intervention|Conventional Serum Testing|Participants will be screened by conventional HCV antibody (anti-HCV) serology and if screen positive, a second sample will be collected and tested for HCV RNA using a standard commercial assay.
89118669|NCT04620226|Experimental|Rapid Point-of-Care Testing|Participants will be screened using the OraQuick® Rapid Anti-HCV Point-of-Care Test (OraSure) and if screen positive, an additional whole blood sample will be collected and tested for HCV RNA using Xpert® HCV RNA (Cepheid) point-of-care testing and confirmed using a standard commercial assay.
89118670|NCT04607590||Group I (DY)|Patients and their partners attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy.
89118671|NCT04607590||Group II (PY)|Patients attend yoga sessions 3 days per week for up to 15 sessions, lasting 60 minutes each, in-person or via videoconferencing over the course of radiation therapy. Once data collection is completed, partners will be offered intervention materials, and encouraged to attend yoga classes at the Integrative Medicine Clinic.
89118672|NCT04607590||Group III (WLC)|Patients and their partners receive usual care. Once data collection is completed, couples may participate in the DY or PY program of their choice over 60 minutes each. Partners are also offered intervention materials along with five 60 minute optional yoga sessions.
89118673|NCT04599166|Experimental|Participant arm|Participants will be recruited to complete the WWYC intervention.
89118674|NCT04586660|Experimental|Surgically unsalvageable disease|Participants with surgically unsalvageable disease (eg, sacral, spinal Giant cell tumor of bone [GCTB], or multiple lesions including pulmonary metastases).
89118675|NCT04586660|Experimental|Surgically salvageable disease|Participants with surgically salvageable disease whose planned on-study surgery is associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy).
89118676|NCT04569240|Other|Dexcom G6 continuous glucose monitor|All patients will have a Dexcom G6 continuous glucose monitor placed pre-operatively. The glucose readings will be collected for 10 days or upon discharge from the ICU and data will be compared with arterial blood glucose readings or venous Accu-Check Inform II glucose readings
89118677|NCT04557306|Experimental|CBT101 q2w|CBT101 (2-6 x 10^9 cells), every 2 weeks
89118678|NCT04557306|Experimental|CBT101 q4w|CBT101 (2-6 x 10^9 cells), every 4 weeks
89118679|NCT04535479|Experimental|Individuals with spasticity resulting from stroke|This is an experimental intervention in which individuals will receive dry needling to relieve spasticity in the target muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
89118680|NCT04535479|Experimental|Individuals with no known neurological injury|This is an experimental intervention in which individuals will receive dry needling of an arm or leg muscle. The study team will examine the effects of this treatment on the nervous system by performing assessments just prior to, immediately after, 90 minutes after, and 72 hours after dry needling. These assessments will examine how you move your arm or leg and how your nervous system responds to non-invasive nerve stimulation.
89118681|NCT04532424|Experimental|Targeting insistence on sameness|
89118682|NCT04532424|Experimental|Targeting stereotyped motor behaviors|
89118683|NCT04530630|Experimental|Biktarvy|Participants receive a Biktarvy tablet orally once daily with or without food.
89118684|NCT04524689|Experimental|Tusamitamab ravtasine + Pembrolizumab|Pembrolizumab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
89118685|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + carboplatin or cisplatin|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Carboplatin will be infused over 15 to 60 minutes immediately after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after tusamitamab ravtansine infusion on Day 1 and Q3W for the first 4 cycles.
89118686|NCT04524689|Experimental|Tusamitamab ravtansine + Pembrolizumab + carboplatin or cisplatin + pemetrexed|Pembrolizumab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles. Cisplatin will be infused approximately 30 minutes after pemetrexed infusion after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
89118687|NCT04512105|Experimental|Dose Level -1 (DL-1)|"Patients receive Pitavastatin (PIT) 1 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~The 1 mg/day dose level will be held in reserve to allow dose reduction in those patients who cannot tolerate DL1."
89118688|NCT04512105|Experimental|Dose Level 1 (DL1)|"Patients receive Pitavastatin (PIT) 2 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~This is the starting dose level for the study."
89118689|NCT04512105|Experimental|Dose Level 2 (DL2)|"Patients receive Pitavastatin (PIT) 4 mg PO daily. For CLL patients, they will also receive stabilized Venetoclax (VEN) 400mg PO daily. For AML patients, they will VEN mg PO daily when dosing in combination with azacitidine or decitabine.~If DL1 is well tolerated, the next cohort will progress to this dose level."
89118690|NCT04510168||MRI Only|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study and the Washington Heights-Inwood Columbia Aging Project (NOMAS) participants. The investigators aim to include at least 50-60 people with dementia (as determined by the ongoing NOMAS procedures).
89118691|NCT04510168||MRI and PET|The investigators will acquire de-novo brain MRI and time-of-flight MRA in randomly selected surviving Northern Manhattan Study (NOMAS) participants. The investigators aim to include at 20 participants with dementia and 40 participants without (as determined by the ongoing NOMAS procedures). In addition to MRI, participants in this group will have three PET studies.
89118692|NCT04494425|Experimental|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
89118693|NCT04494425|Active Comparator|Standard of Care|Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm
89118694|NCT04489212|Experimental|Treatment (follow-up, observation)|Patients who have recurrence or progression during treatment or observation have medical charts are reviewed every 6 months for 5 years. Patients who complete adjuvant treatment are followed for observation 3 days after radiation therapy, 1 month after radiation therapy, every 3 months after radiation therapy for 2 years, every 6 months for 1 year, and then annually for 2 years.
89118695|NCT04478643|Placebo Comparator|PLACEBO|"Collection of microbiological samples from the two deepest sites in two different quadrants.~All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).~Study lozenges without live bacteria are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
89118696|NCT04478643|Experimental|PROBIOTIC (L. Reuteri)|"Collection of microbiological samples from the two deepest sites in two different quadrants.~All patients receive full periodontal charting, full mouth periodontal treatment and OHI (oral hygiene instruction).~Study lozenges containing Lactobacillus Reuteri are administered to consume at home. The patients are instructed to dissolve the lozenges on their tongue twice a day, preferably after brushing, for 3 weeks."
89118697|NCT04477343|Experimental|Experimental: SX-682 and Nivolumab|"SX-682 Dose: 25, 50, 100, 200, 400mg BID taken as an oral pill~Nivolumab Dose: 240mg, every 2 weeks via intravenous infusion"
89118698|NCT04470570|No Intervention|Control Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder only.
89118699|NCT04470570|Experimental|Cross-Education Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder with the addition of upper extremity strengthening exercises to the uninvolved side.
89118700|NCT04470570|Experimental|Cross-Education + Blood-Flow Restriction Group|This group will undergo a standardized rehabilitation protocol of the involved shoulder with the addition of upper extremity strengthening exercises to the uninvolved side with blood-flow restriction simultaneously.
89118701|NCT04468659|Experimental|A45 Trial: Lecanemab 5 mg/kg + 10 mg/kg (Core Study)|Participants will receive lecanemab 5 milligram per kilogram (mg/kg), administered as intravenous (IV) infusion, every two weeks from Week 0 to 6, then 10 mg/kg, administered as IV infusion, every two weeks from Week 8 to 94, and 10 mg/kg, administered as IV infusion, every four weeks from Week 96 to 216 in core study.
89118702|NCT04468659|Placebo Comparator|A45 Trial: Placebo (Core Study)|Participants will receive placebo (0.9 percent [%] sodium chloride solution), administered as IV infusion, every two weeks from Week 0 to 94, then every four weeks from Week 96 to 216.
89118703|NCT04468659|Experimental|A3 Trial: Lecanemab 5 mg/kg + 10 mg/kg (Core Study)|Participants will receive lecanemab 5 mg/kg, administered as IV infusion, every four weeks from Week 0 to 4, then 10 mg/kg, administered as IV infusion, every four weeks from Week 8 to 216 in core study.
89118704|NCT04468659|Placebo Comparator|A3 Trial: Placebo (Core Study)|Participants will receive placebo (0.9% sodium chloride solution), administered as IV infusion, every four weeks from Week 0 to 216.
89118705|NCT04468659|Experimental|A45 Trial: Lecanemab 10 mg/kg (Extension Phase)|Participants progressing to early Alzheimer's disease (EAD) during the core study (progressors) will receive lecanemab 10 mg/kg, administered as IV infusion, every two weeks after transition to the extension phase through to at least Week 216 from randomization in the core study. Participants completing the core study (completers) will enter extension phase and will receive lecanemab 10 mg/kg, administered as IV infusion, every two weeks for up to Week 312. Eligible participants receiving placebo in core study will continue to extension phase.
89118706|NCT04468659|Experimental|A3 Trial: Lecanemab 10 mg/kg (Extension Phase)|Participants progressing to EAD during the core study (progressors) will receive lecanemab 10 mg/kg, administered as IV infusion, every two weeks after transition to the extension phase through to at least Week 216 from randomization in the core study. Participants completing the core study (completers) will enter extension phase and will receive lecanemab 10 mg/kg, administered as IV infusion, every two weeks for up to Week 312. Eligible participants receiving placebo in core study will continue to extension phase.
89118707|NCT04448262||G1 Asthma|Diagnosis of bronchial asthma according to the Global Initiative for Asthma (GINA) 2018 guideline Clinical stability of asthmatic disease Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
89118708|NCT04448262||G2 Diabetes|Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
89118709|NCT04448262||G3 Asthma plus diabetes|Concomitant diagnosis of bronchial asthma according to the GINA 2018 guideline, Clinical stability of asthmatic disease and Diagnosis of Type II diabetes according to the last Italian guidelines and HbA1c < 9%, 54-75mmol/mol Age ≥18 years Not-smokers, smokers or ex-smokers with pack/year ≤10
89118710|NCT04444440|Active Comparator|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
89118711|NCT04444440|Placebo Comparator|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
89118712|NCT04439552||CXL group|Patients who are about to undergo a corneal cross-linking (CXL) surgery to treat keratoconus.
89118713|NCT04439552||Control group|Healthy volunteers age and sex matched to the CXL group.
89118714|NCT04439318|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89118715|NCT04437199|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
89118716|NCT04437199|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
89118717|NCT04435691|Experimental|Treatment (azacitidine, venetoclax, magrolimab)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 (may be reduced to days 1-21 for subsequent cycles after principal investigator approval), and magrolimab IV over 2-3 hours on days 1, 4, 8, 11, 15, and 22 of cycle 1, days 1, 8, 15, and 22 of cycle 2, and days 1 and 15 of cycle 3 and subsequent cycles. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89118718|NCT04414553|Experimental|Community-AHF|Participants in this arm will receive the Community Active and Healthy Families Intervention
89118719|NCT04400409|Active Comparator|Intervention A + site 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.~6-Minute Walk Test (6MWT) will be administered by site staff."
89118720|NCT04400409|Active Comparator|Intervention B + site 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.~6-Minute Walk Test (6MWT) will be administered by site staff."
89118721|NCT04400409|Active Comparator|Intervention A + CPC EQuIP 6MWT administration|"Intervention A subjects will receive a vascular care team approach to care including pharmacy and healthcare provider assistance with medication adherence.~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
89118722|NCT04400409|Active Comparator|Intervention B + CPC EQuIP 6MWT administration|"Intervention B will receive standard care augmented with a single consultation with a Vascular Medicine physician who will provide the treating doctor with a personalized risk assessment for the patient and a summary of the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on Management of Blood.~6-Minute Walk Test (6MWT) will be administered by CPC EQuIP staff."
89118725|NCT04389281|Experimental|X-PACT Treatment|Single arm consisting of a six-week treatment period with X-PACT (phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) administered as an intra-tumoral injection. Intra-tumoral injections will be given on D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6. After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart.
89118726|NCT04389099||Healthy placenta (control)|Pregnant women without preeclampsia and/or fetal growth restriction
89118727|NCT04389099||Pathological placenta|Pregnant women with preeclampsia and/or fetal growth restriction divided into two subgroups : preeclampsia with or without fetal growth restriction ; fetal growth restriction without preeclampsia.
89118728|NCT04360473|Active Comparator|Control group|The patients in this group will receive general balanced anesthesia
89118729|NCT04360473|Experimental|Ketamine group|The patients in this group will receive 0.3 mg / kg of ketamine in saline (total volume of 100 ml) 15 min before general balanced anesthetic induction
89118730|NCT04360473|Experimental|Magnesium sulfate group|The patients in this group will receive 40 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
89118731|NCT04360473|Experimental|Magnesium / ketamine group|The patients in this group will receive 0.15 mg / kg of ketamine + 20 mg / kg of magnesium sulfate in saline solution (total volume of 100 ml) 15 min before general balanced anesthetic induction
89118732|NCT04355689|Experimental|NPI-001|NPI-001 Tablet, 250 mg, BID
89118733|NCT04355689|Placebo Comparator|Placebo|Placebo Tablet, BID
89118734|NCT04351438||Centrifuge TPE with citrate|These participants were undergoing centrifuge TPE using citrate anticoagulant
89118735|NCT04351438||Filter TPE with heparin|These participants were undergoing filter TPE using filter-based heparin anticoagulant
89118736|NCT04351438||Filter TPE with citrate|These participants were undergoing filter TPE using filter-based citrate anticoagulant
89118737|NCT04348929|Experimental|Confinement group|Delivery during covid-19 confinement period
89118738|NCT04348929|Other|Control group|Delivery after the withdrawal of all sanitary measures (mask, social distancing, limited visits during post-partum immediate)
89118739|NCT04348929|Other|Epidemic group|Delivery after confinement period and before the withdrawal of sanitary measures implemented (mask, social distancing, limited visits during post-partum immediate)
89118740|NCT04348500|Active Comparator|Clazakizumab|25 mg in 50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
89118741|NCT04348500|Placebo Comparator|Placebo|50 mL of 0.9% saline given by IV infusion x 1 dose over 30 minutes
89118742|NCT04343807|Active Comparator|PECS block|For patients in PECS group (PG), after induction of general anesthesia, the nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
89118743|NCT04343807|Active Comparator|Control Group|For patients in control group, after induction of general anesthesia, no nerve block will be performed and only intravenous nalbuphine will be given.
89118744|NCT04335799|Experimental|Weight Loss Plus Stress Management|Diabetes Prevention Program Intensive Lifestyle Intervention augmented with stress management training
89118745|NCT04335799|Active Comparator|Weight Loss Only|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics
89118746|NCT04319237||All Participants|
89232763|NCT04251481|Experimental|Optimization of Techniques|To optimize the diffusion MRI methods for assessment of cell viability, metabolism and perfusion in head and neck cancer. There will be 24 subjects enrolled for 2 year duration. Treatment-naïve patients with cervical metastatic lymph nodes (diameter > 10 mm) of HNSCC will be recruited to have one research PET/MR scan (including dMRI) and one dMRI-only scan within three days prior to treatment. These data will be used to optimize the dMRI method and assess the repeatability.
89232764|NCT04251481|Experimental|: Longitudinal Monitoring|To assess the feasibility of using diffusion MRI metrics at early stages of treatment for prediction of treatment response in head and neck cancer patients undergoing standard-of-care chemoradiation therapy. There will be 36 subjects enrolled for 3 year duration. The study will do bi-weekly measurement to monitor tumor response longitudinally. This study will be restricted to treatment-naïve patients who present pathologically confirmed HNSCC with metastatic lymph nodes and who are scheduled to receive standard care of radiation therapy with concurrent chemotherapy. The patients enrolled in this arm of the study will have 4 dMRI scans. The imaging data for each patient will be the proposed dMRI measures at the baseline and their changes at each follow-up time period. DCE-MRI will be included in the baseline scan for tumor delination as in standard-of-care cancer imaging and to compare with the proposed dMRI method.
89232765|NCT04240080|No Intervention|Control Goup|Subjects will undergo clinically indicated facial injection procedures per standard of care without venous mapping
89232766|NCT04240080|Experimental|Intervention Group|Subjects will undergo clinically indicated facial injection procedure with pre-procedural facial venous mapping by Accuvein® Veinfinder
89232767|NCT04229979|Experimental|Galinpepimut-S + Montanide + GM-CSF|"A maximum of 15 total injections will be administered as follows:~First 6 galinpepimut-S injections: every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment. The first series of 6 injections of galinpepimut-S define the initial immunization induction phase.~Injections 7 to 12: every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment. The second series of injections of galinpepimut-S define the early immune booster phase.~Injections 13 to 15: every 6 weeks (between Weeks 40 and 52). The third series of injections of galinpepimut-S define the late immune booster phase.~Note: Galinpepimut-S is admixed with Montanide adjuvant before administered as a subcutaneous injection. GM-CSF is administered one day before and on the same day as the galinpepimut-S + Montanide injection."
89232768|NCT04229979|Active Comparator|Best Available Therapy|"Four options, as monotherapy or as combination of agents listed below, (per treating investigator's choice):~Observation (whereby palliative management with hydroxyurea is allowed), or~HMA (decitabine or azacitidine), and/or~Venetoclax, and/or~Low-dose ara-C"
89232769|NCT04225871|Experimental|0.3 mg/kg zilucoplan (RA101495)|
89232770|NCT04222413|Experimental|1/Arm 1|Escalating/de-escalation doses of metarrestin
89232771|NCT04222413|Experimental|2/Arm 2|MTD of metarrestin
89232772|NCT04210219|Experimental|JNJ-64264681: Dose Escalation and Expansion|Participants will receive oral administration of JNJ-64264681 capsule at a dose assigned by the sponsor Study Evaluation Team (SET), based on the available safety, pharmacokinetics, and pharmacodynamics data in dose escalation treatment group (Part 1); and recommended Phase 2 dose (RP2D) determined in Part 1 in cohort expansion treatment group (Part 2).
89232774|NCT04192136|Experimental|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
89232775|NCT04192136|Placebo Comparator|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
89118747|NCT04319198|Experimental|Sacituzumab Govitecan-hziy|"Participants will receive sacituzumab govitecan-hziy at the dose that they were receiving in the parent study until they experience toxicity, disease progression, loss of clinical benefit, withdrawal of consent, lost to follow-up, or Sponsor termination of the study is documented. Participants who continued to receive sacituzumab govitecan-hziy in the Gilead sponsored parent study after disease progression (PD), may continue to receive sacituzumab govitecan-hziy until there is no clinical benefit as determined by the treating physician.~No participant will receive more than 10 mg/kg dose of sacituzumab govitecan-hziy."
89118748|NCT04316676|Other|Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR|Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.
89118749|NCT04297332|Experimental|Arm I (active EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
89118750|NCT04297332|Experimental|Arm II (active EFT, control FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.
89118751|NCT04297332|Experimental|Arm III (control EFT, active FTP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.
89118752|NCT04297332|Active Comparator|Arm IV (control EFT, control TFP)|Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.
89118753|NCT04283019|Experimental|CBD without THC|oral formulation containing 100mg CBD and 0mg THC
89118754|NCT04283019|Experimental|CBD with 3.7 mg THC|oral formulation containing 100mg CBD and 3.7mg THC
89118755|NCT04283019|Experimental|CBD with 2.8 mg THC|oral formulation containing 100mg CBD and 2.8 mg THC
89118756|NCT04282044|Experimental|Monotherapy Dose-Escalation Cohorts|Prior to the current amendment, no DLTs were observed at Dose Levels 1-5. Starting with the current protocol amendment, dosing decisions in monotherapy cohorts will utilize a 3+3 design for Dose Level 6. CRX100 infusion will occur every nine weeks (+/- 7 days). Subjects will receive up to a maximum of four infusions of CRX100 unless it is determined by the treating physician and the sponsor that it is in the best interest of the subjects to receive additional doses of CRX100 beyond four doses. A minimum of three DLT-evaluable subjects will be doses at Dose Level 6 and expanded to six subjects if determined necessary based on DLT incidence using the 3+3 design, and discussion with SRC and Sponsor.
89118757|NCT04282044|Experimental|Combination Therapy Cohorts|"Subjects with relasped or refractory solid tumors, as defined in the inclusion criteria, will be enrolled to evaluate the safety and anti-tumor activity of CRX100 in combination with Pembrolizumab in patients with advanced solid malignancies. The dose of CRX100 used will be determined from the monotherapy cohorts.~CRX100 infusion will occur every nine weeks (+/- 7 days). Subjects will receive up to a maximum of four doses of CRX100 unless it is determined by the treating physician and the sponsor that it is in the best interest of the subjects to receive additional doses of CRX100 beyond four doses.~Pembrolizumab will be administered at 200mg IV every three weeks (Q3W) per the approved label."
89118758|NCT04280224|Experimental|NK Cells Treatment Group|Conventional treatment plus NK cells. Participants will receive conventional treatment plus twice a week of NK cells (0.1-2*10E7 NK cells/kg body weight).
89118759|NCT04280224|No Intervention|Conventional Control Group|Participants will only receive conventional treatment.
89118760|NCT04276363|Experimental|Thrive Professional Learning plus ParentCorps|1) Professional Development, Program Training and Coaching; 2) Program for Parents of Pre-K Students; and 3) Program for Pre-K Students. The three intervention components are expected to strengthen relationships and communication between parents and teachers and promote safe, nurturing and predictable environments, which contribute to child mental health and achievement.
89118761|NCT04276363|Experimental|Thrive Professional Learning only|Best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders.
89118762|NCT04276363|Experimental|Inspire Professional Learning|Led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
89118763|NCT04276220|Other|Tenosynovial Biopsy|
89118764|NCT04275895|Experimental|Prematurely born Children|"Evaluation of different attention or/and postural activities :~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).~Child perception of the vertical compared to the real vertical~Evaluation of the posture of the child during different visual conditions~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
89118765|NCT04275895|Active Comparator|Term born Children|"Evaluation of different attention or/and postural activities~Speed and accuracy answer to visual fish (target) appearance evaluated in two conditions of chair (mobile or classic).~Child perception of the vertical compared to the real vertical~Evaluation of the posture of the child during different visual conditions~Evaluation of the posture of the child during different attention tasks at different levels of difficulty"
89118766|NCT04268004|No Intervention|Standard of Care (Control)|Participants will receive a standard of care fertility consult.
89118767|NCT04268004|Experimental|FP Decision Tool and Discussion (Treatment)|Participants will receive a standard of care fertility consult and will participate in a family-centered psychoeducational intervention consisting of completing a FP Decision Tool and participating in a guided discussion about responses and discrepancies identified in the FP Decision Tool.
89118768|NCT04265950|Experimental|Arm 1 (3 doses of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment, and at 2 and 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.
89118769|NCT04265950|Experimental|Arm 2 (2 doses of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment and at 6 months. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 30 months.
89118770|NCT04265950|Experimental|Arm 3 (1 dose of 9vHPV vaccine)|Participants living with HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment. Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.
89118771|NCT04265950|Active Comparator|Arm 4 (1 dose of 9vHPV vaccine)|Participants without HIV receive recombinant human papillomavirus nonavalent vaccine IM at enrollment . Participants also receive recombinant human papillomavirus nonavalent vaccine booster dose IM at 24 months and recombinant human papillomavirus nonavalent vaccine completion dose IM at 30 months.
89118772|NCT04252066||Cohort 1|Cohort 1 will be pregnant and/or breastfeeding patients who have Fabry Disease, and have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
89118773|NCT04252066||Cohort 2|Cohort 2 will be pregnant and/or breastfeeding patients who have Fabry Disease, who were not exposed to migalastat during pregnancy and/or breastfeeding.
89118774|NCT04250116|Experimental|NOAC monotherapy|
89118775|NCT04250116|Active Comparator|Dual antithrombotic therapy|
89118776|NCT04236414|Experimental|Cohort A: ≥12 to <18 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
89118777|NCT04236414|Experimental|Cohort B: ≥3 to <12 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib tablets should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards.
89118778|NCT04236414|Experimental|Cohort C: ≥6 months to <6 years|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart. Patients in Cohort C will receive a predetermined number of each sprinkle capsule strength (15 and 19.5 mg,) to make up the required dose. Olaparib sprinkle capsules will be administered to the child by the parent/caregiver. Patients in Cohort C are not required to fast including PK sampling days. The dispensed granules should be swallowed whole and not chewed, crushed, dissolved or divided, and should be consumed within 30 minutes of preparation.
89118779|NCT04236414|Experimental|Signal identification|A secondary analysis of response in patients recruited into the signal identification phase will be conducted. Patients included in this analysis must have documented evidence of a deleterious or suspected deleterious germline or tumour HRR gene mutation. A minimum of 10 patients across age and dose cohorts with deleterious or suspected deleterious HRR mutations will be enrolled.
89118780|NCT04206540|Experimental|ABVN and Vagal Maneuvers|There is only one arm and subjects can choose the intervention.
89118781|NCT04205409|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89118782|NCT04193826|Experimental|Non-valvular AF adults|Left atrial appendage closure (LAAC) with the Conformal LAAC device will be performed according to the device Instructions for Use, based on ICE and angiographic guidance, femoral venous access and inter-atrial septum crossing.
89118783|NCT04191616|Experimental|Carfilzomib combined with pomalidomide and dexamethasone|Carfilzomib, pomalidomide, and dexamethasone (KPd)
89118784|NCT04175613|Experimental|Patients treated with Apremilast|Subjects with a weight between 20 kg to < 50 kg will receive apremilast 20 mg BID and subjects with weight ≥ 50 kg at Visit 1 will receive apremilast 30 mg BID. Subjects that begin the study receiving apremilast 20 mg BID and later record a body weight ≥ 50 kg, will be switched to apremilast 30 mg BID.
89118785|NCT04154956|Experimental|SAR408701 (tusamitamab ravtansine)|Administered intravenously once every 2 weeks
89118786|NCT04154956|Active Comparator|Docetaxel|Administered intravenously once every 3 weeks
89118787|NCT04139317|Experimental|Capmatinib 400mg BID + pembrolizumab 200mg Q3W|Capmatinib (INC280) 400 mg orally twice daily (BID) in combination with pembrolizumab 200 mg intravenously every 3 weeks (Q3W)
89118788|NCT04139317|Active Comparator|Pembrolizumab 200mg Q3W|Pembrolizumab 200 mg intravenously every 3 weeks (Q3W)
89118789|NCT04133077|Other|Succeed PDX|Genetic analysis will be performed in patients who got a successful PDX
89118790|NCT04120883|Experimental|HCQ treatment 1|In treatment arm 1, the dose of study drug will be 4 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
89118791|NCT04120883|Experimental|HCQ treatment 2|In treatment arm 2, the dose of the study drug will be 5 mg/kg/day. The daily dose will not exceed 400 mg. In both groups, the dose will be rounded down to 100, 200, 300, or 400 mg/day.
89118792|NCT04120714|Experimental|Active tDCS group|Active tDCS
89118793|NCT04120714|Placebo Comparator|Placebo tDCS group|Inactive tDCS
89118794|NCT04111458|Experimental|BI 1701963 monotherapy|
89118795|NCT04111458|Experimental|BI 1701963 + Trametinib|
89118796|NCT04110756|Experimental|ChangeGradients|100 adolescents will be enrolled in the CHANGEGRADIENTS intervention.
89118797|NCT04110756|No Intervention|Comparison, non-intervention condition|100 participants will not participate in the ChangeGradients intervention, and will continue to have treatment as usual at the clinic.
89118798|NCT04099342|Experimental|A: FEAST|Focally Electrically-administered Seizure Therapy (FEAST) is a form of Electroconvulsive therapy (ECT) that combines unidirectional stimulation, control of polarity, and an asymmetrical electrode configuration.
89118799|NCT04099342|Experimental|B: RP FEAST|Focally Electrically-administered Seizure Therapy (FEAST) with Reversed Polarity (RP) utilizes the same electrode placement as FEAST but a reversed directionality of current flow.
89118800|NCT04081337|Placebo Comparator|Placebo|Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
89118801|NCT04081337|Experimental|15 Milligram (mg) Tirzepatide|Participants received 15 mg of tirzepatide QW by SC injection.
89118802|NCT04076813||STEMI/NSTEMI|Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction
89118803|NCT04072393|Experimental|Home-based cardiac rehabilitation|"The intervention consists of a prescribed course of home-based cardiac rehabilitation: 36 sessions, three times a week, one hour each, over a period of 12 weeks.~Each customized exercise session includes three phases:~a 5- to 10-minute warm-up which consists of stretching, flexibility movements, and aerobic activity which gradually raises the heart rate to the desired level~a conditioning or training phase, which consists of 20 to 45 minutes of continuous or discontinuous aerobic activity~a cool down for 5 to 10 minutes consisting of low-intensity exercise that permits a gradual recovery from the conditioning phase~The patient will complete a brief questionnaire on the teleHeart application after completing each exercise session on how well they tolerated the exercise. The patient's CR team will receive daily updates from the patient's teleHeart application. Based on feedback from the application, the CR team may modify the patient's exercise program going forward."
89118804|NCT04056429|Experimental|BHA|Subjects treated with BHA + standard of care
89118805|NCT04056429|No Intervention|Control|Subjects treated as per standard of care
89118806|NCT04049799||Medically-supervised withdrawal (MSW)|
89118807|NCT04049799||Opioid agonist treatment (OAT)|
89118810|NCT04042532|Active Comparator|Active group|Active group will receive active stimulation of standard intermittent TBS (iTBS) protocol.
89118811|NCT04042532|Sham Comparator|Sham group|Sham group will receive sham stimulation of the same iTBS protocol with the coil set at 90 to the skull.
89118812|NCT04042532|No Intervention|Cognitively normal control|Cognitively normal controls will be recruited for neuroimaging comparison.
89118813|NCT04040608||experimental group|differences in responses to visual analog scales depending on screen sizes
89118814|NCT04038476|Other|Standard monitoring|"When assigned to the group Standard monitoring:~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. The examiner (doctor or physicians involved in the study) are blinded to the transcutaneous CO2 measurement. An adjustment of the sedation management therefore takes place on the basis of the monitoring measures mentioned above. Transcutaneous CO2 monitoring is recorded in the background (Excel table of all registered values) and also monitored by the sedation assisting nurse and integrated into the standard sedation protocol."
89118815|NCT04038476|Other|Standard monitoring + transcutaneous CO2 monitoring|"When assigned to the group Standard monitoring + transcutaneous CO2 monitoring:~In the area of the forehead of the patient, the adhesive electrode is attached according to manufacturer's instructions before the first dose of sedatives. The sedation monitoring is performed under standard conditions by continuous measurement of oxygen saturation, continuous circulatory monitoring (heart rate and regular non-invasive blood pressure measurements) and half-hourly venous blood gas analysis, on receipt in the left atrium an additional arterial blood gas analysis. In this group, the values of transcutaneous, continuous CO2 monitoring, including an alarm sound, are accessible to the treating physicians. Moreover, sedation management is adjusted on the basis of transcutaneous CO2 measurement. The above-mentioned measurements of the standard monitoring are carried out as described, in addition there is the the transcutaneous CO2 monitoring."
89118816|NCT04014374||Transplant Arm|Patients with CTCL or ATLL who received mogamulizumab within one year prior or up to 18 months after alloHCT
89118817|NCT04014374||Control Arm|Patients who have undergone alloHCT without exposure to mogamulizumab pre- or post-alloHCT
89118818|NCT04005534|Placebo Comparator|Standard group|Patients from this group will undergo only ultrasound examination of the brachial plexus, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.
89118819|NCT04005534|Experimental|Preemptive group|Patients from this group will undergo ultrasound-guided brachial plexus blockade, two days before the surgery. On the day of surgery they will undergo ultrasound-guided brachial plexus blockade (interscale access; 15 ml 1% ropivacaine and sedation (midazolam 3 mg, fentanyl 50 µg and 15 mg ketamine.
89118820|NCT04004247|Experimental|Experimental group|"10-12 young healthy volunteers. Placed on semi-sitting position on the bed (40 deg.elevation). Calibration of electrical impedance tomography (EIT) on defined tidal volume 500ml, done with 500ml syringe connected to closed breathing circuit using full face mask as an interface.~Insertion an esophageal and nasopharyngeal catheter for pressures measurement. In the first phase - spontaneous breathing with full face mask at 0, 5 and 10 cm H20 levels of PEEP.~In the second phase - high flow oxygenation through nasal cannula, start with flow rate 10 L/min with gradual increase up to 60 L/min.~Spirometry to determine functional residual capacity (FRC) before and after procedure is planed."
89118821|NCT03993678|Experimental|Ablation + IP-001|"Ablation + IP-001 will be administered every 4 weeks for up to 6 treatment visits.~Trial treatment will stop in case of tumor progression according to RECIST 1.1 or iRECIST or unacceptable toxicity.~In all cases, toxicity assessment will continue for at least 100 days after discontinuing the last treatment of Ablation + IP-001 or until resolution of Ablation + IP-001-associated toxicity."
89118822|NCT03991156||Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|
89118823|NCT03965494|Experimental|AXL inhibitor BGB324 then surgery|Participants receive AXL inhibitor BGB324 PO QD on days 1-5, then undergo surgery 3-6 hours after last dose. Within 45 days, participants receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89118824|NCT03965494|Experimental|Surgery then AXL inhibitor BGB324|Participants undergo surgery, then within 45 days receive AXL inhibitor BGB324 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89118825|NCT03928743|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
89118826|NCT03928743|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
89118827|NCT03909334|Active Comparator|Arm A (Osimertinib and Ramucirumab)|Osimertinib and Ramucirumab
89118828|NCT03909334|Active Comparator|Arm B (Osimertinib)|Osimertinib
89118829|NCT03880955||ReUnion RSA System|"Subject's joint has gross rotator cuff deficiency, a functional deltoid muscle and is anatomically and structurally suited to receive the implant and subject has one or more of the following:~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis or rheumatoid arthritis~Failed previous shoulder joint replacement"
89118830|NCT03871179|Other|ASD Diagnostic Device|"The ASD Diagnostic Device is a machine learning algorithm-based software as a medical device that is incorporated into a parent/caregiver-facing mobile application, the Cognoa App, used outside of a clinical setting"
89118831|NCT03856229|Active Comparator|Group A conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
89118832|NCT03856229|Experimental|Group B shortened steroid regimen|"Subjects will receive the shortened steroid regimen for the severity of pneumonia with prednisone or equivalent with methylprednisolone, depending the severity of pneumonia:~Moderate PCP. 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~Severe PCP. 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
89118833|NCT03812159|Experimental|Presurgical planning|Undergo crania-vault reconstruction following the presurgical planning (iCSPlan)
89118834|NCT03787355|Experimental|Cone Morse Connection Implants|2 neighboring Morse connection Implants
89118835|NCT03787355|Active Comparator|platform matched implants|2 neighboring platform matched implants.
89118836|NCT03779139|Active Comparator|Intrahepatic islets alone|
89118837|NCT03779139|Experimental|Intrahepatic and omental pouch islets|
89118838|NCT03779139|Sham Comparator|Normal Volunteers|
89118839|NCT03778827|Experimental|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of one weekly 60-minute individual parent training session and 12 weekly hours ( 3 hours per day for 4 days per week) with the child in center-based therapy environment for a total of 13 weekly treatment hours.
89118840|NCT03778827|No Intervention|Delayed Treatment Group (DTG)|Delayed Treatment Group will consist of treatment as usual. At the end of controlled phase, participants in the DTG will be offered PRT-C in a preschool setting in an open-label fashion with a design similar to the double-blind phase.
89118841|NCT03778658|Experimental|Outpatient Physical Activity Program|The intervention will investigate a multi modal outpatient physical activity program incorporating both strength training utilizing resistance bands, as well as an aerobic activity based on hip-hop dancing.
89118842|NCT03771469|Experimental|Questionnaires and sleep studies|Caregivers of patients meeting eligibility criteria will be invited to participate. If they agree to participate, baseline SRBD-PSQ, OSA-18, and PedsQL questionnaires along with written informed consent forms will be mailed to them along with their standard scheduling paperwork. Caregivers will be asked to review the consent form and complete the questionnaires and bring the paperwork to clinic on the day of their visit. Sleep study testing will also be ordered prior to their visit so that it can be scheduled within a month of the initial clinic visit and again three months later.
89118843|NCT03765619|Experimental|Aspirin|250 patients will be randomized to receive Aspirin postoperatively.
89118844|NCT03765619|No Intervention|Non-Aspirin|250 patients will be randomized to not receive Aspirin postoperatively.
89118845|NCT03723928|Active Comparator|Arm I (usual care)|Patients will have imaging studies (modality and frequency per treating physician, however at a minimum frequency of every 12 weeks) alone or in conjunction with STMs (frequency determined by treating physician). Patients will continue with usual care disease monitoring for up to 312 weeks in the absence of disease progression.
89118846|NCT03723928|Experimental|Arm II (serum tumor directed disease monitoring)|Patients undergo disease specific serum tumor marker evaluation (CEA and either CA 15-3 or CA 27.29, whichever were tested at Step 1 Registration and Step 2 Registration) every 4-8 weeks (starting from randomization) without imaging until an elevation of at least one disease specific STM. In the event of an elevated STM, the patient will have imaging within 4 weeks to evaluate for disease progression. Patients continue with STMDDM for up to 312 weeks in the absence of disease progression.
89232776|NCT04192136|Experimental|Exercise Intervention and NR|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.~Participants in this arm will receive both the Exercise Intervention and the NR."
89118847|NCT03701581|Experimental|Group A: Investigational Treatment|"4-Aminopyridine (FDA-approved drug)~Subjects will not take more than 2 tablets in a 24-hour period~Subjects will take the tablets whole. They will not break, crush, chew, or dissolve tablets before swallowing.~The subjects will be told that the medication is released slowly over time and if the tablet is broken, the medicine may be released too fast which can raise the chance of having a seizure.~Study drug can be taken with or without food.~If a dose is missed they should not make up the missed dose. They will be told not to take two doses at the same time but to take the next dose at the regular scheduled time.~Subjects will be reminded not to take study drug together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine or fampridine)."
89118848|NCT03701581|Placebo Comparator|Group B: Placebo|"Subjects will receive an oral dose of placebo treatment the day after surgery, continuing daily for 3 months (90 days) following the same administration instructions as the investigational treatment. The placebo tablets will be manufactured by The University of Iowa Pharmaceuticals, 115 South Grand Avenue G-20, Iowa City, IA 52242. The Investigational Drug Service at the University of Rochester will manage the placebos.~Placebo composition will include:~97% Microcrystalline Cellulose, NF (Avicel Ph 102) 2% Sodium Starch Glycolate, NF~1% Magnesium Stearate, NF~The placebo will be covered in White Opadry, formulation OY-S-9603 and tooled to look similar to the investigational treatment."
89118849|NCT03641664|Experimental|Treatment: Family Centered Treatment|Family is offered choice of FCT or Level III out-of-home placement
89118850|NCT03641664|Active Comparator|Control: Level III Out of Home Placement|Family is offered Level III out-of-home placement
89118851|NCT03627013|Experimental|Kidney Custodiol-N|
89118852|NCT03627013|Active Comparator|Kidney Custodiol|
89118853|NCT03627013|Experimental|Liver Custodiol-N|
89118854|NCT03627013|Active Comparator|Liver Custodiol|
89118855|NCT03627013|Experimental|Kidney/Pancreas Custodiol-N|
89118856|NCT03627013|Active Comparator|Kidney/Pancreas Custodiol|
89118857|NCT03625141|Experimental|Cohort 1- cobimetinib and atezolizumab|Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1-21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.
89118858|NCT03625141|Experimental|Cohort 2 - cobimetinib, atezolizumab and vemurafenib|Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.
89118859|NCT03599960|Experimental|Chemotherapy|
89118860|NCT03581487|Experimental|Arm I (intermittent selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-7 and 15-21 and durvalumab intravenously (IV) over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89118861|NCT03581487|Experimental|Arm II (continuous selumetinib, durvalumab, tremelimumab)|Participants receive selumetinib PO BID on days 1-28 and durvalumab IV over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89118862|NCT03570112||Pregnant Women with Hep C|SOF/VEL Therapy-sofosbuvir 400mg, velpatasvir 100mg, once daily for 12 weeks at 24 weeks post partum
89118863|NCT03564782|Experimental|PVSRIPO|Polio vaccine booster will be administered 1 week prior to PVSRIPO injection. On the day of PVSRIPO injection (Day 0), a pre-treatment biopsy is obtained. PVSRIPO in injected into the tumor mass at a dose of 1x10^8 TCID50. On day 14, women will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.
89118864|NCT03553186|Experimental|ivTXA + topical TXA|"TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2 mg/kg/hr maintenance dosing as per hospital protocol"
89118865|NCT03553186|Placebo Comparator|IV TXA + topical placebo|"Placebo solution (200 cc sterile normal saline + placebo TXA ampule (normal saline) (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2mg/kg/hr maintenance dosing as per hospital protocol"
89118866|NCT03506308|Other|LUTONIX 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
89118867|NCT03503669|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
89118868|NCT03503669|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 12 minute meditation
89118869|NCT03492840|Active Comparator|Cohort 1 - Dercum's Disease|Nodular size - diameter (cm) 2-2.9, 3-3.9, 4-8 Total dose of RZL-012(mg) 10 15 20 Dose per NOAEL 1/25th , 1/18.75th, 1/12.5th Number of injections: 2,3,4
89118870|NCT03492840|Active Comparator|Cohort 2 - Lipedema|Total dose of RZL-012 (mg) 60 , 80 Dose per NOAEL: 1/4.6888, 1/3.125 Number of injections: 12, 16
89118871|NCT03486457|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
89118872|NCT03486457|Placebo Comparator|Treatment Sequence B|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
89118873|NCT03486431|Experimental|Level I|5 x 7 Gy SABR
89118874|NCT03486431|Experimental|Level II|3 x 10 Gy SABR
89118875|NCT03486431|Experimental|Level III|1 x 20 Gy SABR
89118876|NCT03463954|Experimental|Novilase Laser Ablation and excision|Eligible subject will receive image-guided laser ablation of a targeted malignant breast tumor. At 4-6 weeks following the ablation, she will receive a MRI and excision. Pathology and MRI will determine rate of complete ablation. Subject is expected to proceed with radiation and/or adjuvant therapy per standard of care.
89232777|NCT04192136|Experimental|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.~Participants in this arm will receive both the Exercise Intervention and the Placebo."
89118877|NCT03441958|Experimental|ECT-001 (UM171) expanded cord blood|"Patients will receive a reduced intensity conditioning regimen containing Cyclophosphamide 50 mg/kg, Fludarabine 40 mg/m2 x 5 days and total body irradiation 200 cGy.~The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1.~Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus."
89118878|NCT03432182|Other|very premature infants|Electroencephalography allowing sleep observation
89118879|NCT03427060|Experimental|Coversin treatment|Coversin - 22.5mg followed by 45mg for 6 months.
89118880|NCT03414463|Experimental|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
89118881|NCT03414463|Experimental|Waitlist Control|After Time 1 testing in Week 1, participants randomized to WLC will not receive any treatment during Weeks 2-5. The only staff interaction during this no treatment time period will be to schedule Time 2 testing appointment for week 6. After Time 2 testing, WLC will receive TREAT (weeks 14-17), followed up with testing.
89118882|NCT03402035||Whole Blood|Subjects at enrolling centers that utilize whole blood for hemorrhagic shock
89118883|NCT03402035||Component Therapy|Subjects at enrolling centers that utilize component therapy for hemorrhagic shock
89118884|NCT03382158||Type I PPB|Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
89118885|NCT03382158||Types II and III PPB|Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
89118886|NCT03382158||Type Ir PPB|Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
89118887|NCT03382158||DICER1 Gene or Cond Assoc with DICER1|PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
89118888|NCT03374332|Experimental|Treatment 1: Gemtuzumab Ozogamicin and DLI Dose Level 1|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)~Patients < 70 years old: GO 9mg/m2 (3mg/m2 each dose)~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^7 CD3+ cells and maximum of 2x10^7 CD3+ cells/kg irrespective of the number of CD34+ cells.~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
89118889|NCT03374332|Experimental|Treatment 2: Gemtuzumab Ozogamicin and DLI Dose Level 2|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)~Patients: < 70 years old: GO 9mg/m2 (3mg/m2 each dose)~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^8 CD3+ cells and maximum of 2x10^8 CD3+ cells/kg irrespective of the number of CD34+ cells.~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
89118890|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - PILOT|"Proactive Psychiatry Consultation and Case Management is:~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
89118891|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - Randomized Trial|"Proactive Psychiatry Consultation and Case Management is:~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
89118892|NCT03360695|Active Comparator|Enhanced Usual Care (EUC) - Randomized Trial|Study staff will send a templated email to the treating oncologist at enrollment informing the oncologists of the psychiatric diagnosis and available psychosocial services. Study staff will also inform the patient and caregiver of available psychosocial services.
89118893|NCT03351296|Experimental|LV5FU2 + streptozotocin|
89118894|NCT03351296|Experimental|Capecitabine + temozolomide|
89118895|NCT03351296|Experimental|LV5FU2 + streptozotocin + Bevacizumab|
89118896|NCT03351296|Experimental|Capecitabine + temozolomide + Bevacizumab|
89118897|NCT03348540|Experimental|Attention Control Training|"6 sessions in the clinic lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
89118898|NCT03348540|Placebo Comparator|Comparison Task|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~• Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
89118899|NCT03315260||Bone metastatic CRPC patients|Japanese patients who are designated to undertake Ra-223/Xofigo therapy based on physician judgement
89118900|NCT03246529|Experimental|BL-8040 1.25 mg/kg + G-CSF|Double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
89118901|NCT03246529|Active Comparator|Placebo + G-CSF|Double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
89118902|NCT03215849|Sham Comparator|Routine Medical Therapy|Routine Medical Therapy
89118903|NCT03215849|Experimental|Routine Medical Therapy + LVP|Routine Medical Therapy + LVP
89118904|NCT03215849|Experimental|Routine Medical Therapy + BiVP|Routine Medical Therapy + BiVP
89118905|NCT03171545|Experimental|Patient Activation|This arm focuses on patients. It includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 5 multimedia-aided meetings with other patients that include motivational interviewing and role modeling.
89118906|NCT03171545|Experimental|Provider Education|This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists.
89118907|NCT03171545|No Intervention|No Intervention|Patients in clinic receive usual care.
89118908|NCT03171545|Experimental|Patient and Provider|This arm includes both Patient Activation and Provider Education interventions
89118909|NCT03127709||Participants with a histiocytic disorder diagnosis|Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
89118910|NCT03113201|Experimental|Collabri Flex|Collaborative care
89118911|NCT03113201|Experimental|Consultation-Liaison|Consultations with general practitioner
89118912|NCT03113175|Experimental|Collabri Flex|Collaborative care
89118913|NCT03113175|Experimental|Consultation-Liaison|Consultations with general practitioner
89118914|NCT03111459|Experimental|Primary Study Arm|Patients meeting primary inclusion/exclusion criteria will be enrolled in this arm and treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
89118915|NCT03111459|Experimental|Expanded Selection Arm|Patients who fail to meet the inclusion criteria of the Primary Study Arm may be enrolled under the Expanded Selection Arm and be treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
89118916|NCT03108495|Experimental|Cohort 1 LN-145 monotherapy|Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
89118917|NCT03108495|Experimental|Cohort 2 LN-145 monotherapy|Patients previously treated with an antiprogrammed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor: Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
89118918|NCT03108495|Experimental|Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only|Patients will be administered with pembrolizumab, followed by NMA lymphodepletion, then infused with their autologous TIL (LN-145) followed by pembrolizumab every 3 or 6 weeks post IL-2 administration up to 24 months.
89118919|NCT03108495|Experimental|Cohort 4 - Non-enrolling Cohort|Cohort includes patient population not meeting inclusion criteria in cohort 1 and 2. Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
89118920|NCT03108495|Experimental|Cohort 5 Retreatment Cohort|Patients who have been previously treated with LN-145 may be given a second treatment with TIL.
89118921|NCT03107416|Experimental|Bumetanide|Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.
89118922|NCT03048370|Experimental|Left body temperature VS|Left body temperature (37°C) vestibular stimulation
89118923|NCT03048370|Experimental|Right body temperature VS|Right body temperature (37°C) vestibular stimulation
89118924|NCT03048370|Experimental|Left warm CVS|Left warm (44°C) caloric vestibular stimulation
89118925|NCT03048370|Experimental|Right warm CVS|Right warm (44°C) caloric vestibular stimulation
89118926|NCT03048370|Experimental|Left cold CVS|Left cold (30°C) caloric vestibular stimulation
89118927|NCT03048370|Experimental|Right cold CVS|Right cold (30°C) caloric vestibular stimulation
89118928|NCT03037294|No Intervention|Control group|Subjects in the control group will receive no intervention.
89118929|NCT03037294|Experimental|Protein group|Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.
89118930|NCT03025698|Experimental|Cohort A (Option 1)|Regimen 1: hATG (ATGAM®), CsA and eltrombopag begin on Day 1.
89118931|NCT03025698|Experimental|Cohort A (option 2)|CsA and eltrombopag begin on Day 1.
89118932|NCT03025698|Experimental|Cohort B|previously untreated SAA), hATG (ATGAM®), CsA and eltrombopag begin on Day 1 and all patients will be treated with the same regimen
89118937|NCT02979587|Other|Harmony TPV System|Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery Systems
89118938|NCT02925949|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
89118939|NCT02925949|Active Comparator|LifeSteps|A 3-session HIV medication adherence support program for individuals.
89118940|NCT02820506|Other|High risk endometrial cancer|Patients will receive sentinel node mapping, removal of PET-positive lymph nodes and finally conventional pelvic and paraaortic lymphadenectomy.
89118941|NCT02820506|Other|Cervical cancer tumor size 2-4 cm|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
89118942|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy|Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10^8 pfu/mL.
89118943|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy|Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.
89118944|NCT02775773|Experimental|arm A (TXA)|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
89118945|NCT02775773|Active Comparator|arm B (OXY)|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
89118946|NCT02595892|Active Comparator|Arm I (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
89118947|NCT02595892|Experimental|Arm II (gemcitabine, ATR kinase inhibitor M6620)|Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor M6620 IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89118948|NCT02568423|Experimental|Mirikizumab IV|Participants received 200mg Mirikizumab by intravenously.
89118949|NCT02568423|Experimental|Mirikizumab SC|Participants received single dose of either 60mgor 200mg 0r 600mg or 1200mg or 2400mg Mirikizumab by subcutaneously.
89118950|NCT02568423|Placebo Comparator|Placebo IV|Participants received placebo by intravenously.
89118951|NCT02568423|Placebo Comparator|Placebo SC|Participants received placebo by subcutaneously.
89118952|NCT02521753|Active Comparator|Metformin|Metformin 850mg twice a day for six months
89118953|NCT02521753|Experimental|Magnesium|Magnesium chloride 250mg daily for six months
89118954|NCT02521753|Experimental|PUFA omega 3|Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months
89118955|NCT02503319|Experimental|arm A|2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
89118956|NCT02503319|Experimental|arm B|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
89118957|NCT02503319|Active Comparator|arm C|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
89118958|NCT02500316|Experimental|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
89118959|NCT02494063||Sentinel lymph node (SLN)|Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
89118960|NCT02494063||Control|Control group is composed by either those who were enrolled into the trial, but who did not fulfil intra-operative criteria (especially failure to detect SLN on both pelvic side walls) or those in whom systematic lymphadenectomy is planned upfront.
89118961|NCT02455531||Transplant-free survivors|Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)
89118962|NCT02438904|Experimental|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells. If the first infusion is not effective, an additional infusion may be given 4 - 6 weeks after the first infusion.
89118963|NCT02408276||dGEMERIC MRI technique|All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant.
89118964|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA, no NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
89118965|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA, no NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
89118966|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA, no NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.
89118967|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA + NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
89118968|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA + NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
89118969|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA + NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
89118970|NCT02407028|Experimental|Normobaric Hyperoxia (NBH)|Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.
89118971|NCT02407028|Active Comparator|Usual care|Usual care for severe TBI
89118972|NCT02378974|Other|Cohort 1|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0
89118973|NCT02378974|Other|Cohort 2|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0 and day 7
89118974|NCT02357797|Active Comparator|Vortioxetine|Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.
89118975|NCT02357797|Placebo Comparator|Placebo|Matching placebo pills will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of placebo can be lowered to 10 mg for tolerability reasons.
89118976|NCT02333825|Other|Surgical Intervention|The surgical intervention to be studied in this arm is medial patellofemoral ligament reconstruction surgery using hamstring tendon. The tendon used will generally consist of autograft semitendinosus. If the hamstrings have been previously harvested or injured (i.e. in the setting of anterior cruciate ligament reconstruction or proximal tibial surgery), or if the patient/his or her family prefers to minimize donor site morbidity, allograft may be used.
89232778|NCT04182997|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
89232779|NCT04182997|Active Comparator|Dexamethasone Group|Patients in this group will be given the study drug (dexamethasone).
89118977|NCT02333825|Other|Conservative treatment|The intervention to be studied in this arm is a rehabilitation program directed by physical therapists. If patients in this arm are found to have a small loose body, a simple arthroscopy will be performed to remove the loose body, but no stabilization of the patellofemoral joint will be performed. The rehabilitation program will be compiled into a booklet and distributed for use by the physical therapist chosen by the patient.
89118978|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 3|Azacitidine (AZA) Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
89118979|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 5|Azacitidine (AZA) 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
89118980|NCT02269280|Experimental|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
89118981|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
89118982|NCT02220985|Experimental|Arm A (MRD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
89118983|NCT02220985|Experimental|Arm B (MRD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
89118984|NCT02220985|Experimental|Arm C (MUD)|"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
89118985|NCT02220985|Experimental|Arm D (MUD)|"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.~TRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.~GVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator."
89118986|NCT02165813|Active Comparator|Nitazoxanide|oral nitazoxanide suspension twice daily for 3 days
89118987|NCT02165813|Placebo Comparator|Placebo|oral placebo suspension twice daily for 3 days
89118988|NCT02145871|Active Comparator|Standard fluid management|The non-intervention group will receive maintenance crystalloid fluid at 10cc/kg/h. Blood loss will be replaced 1:1 with albumin. Transfusion will follow transfusion criteria. Fluid management will not be dependent on the EV1000
89118989|NCT02145871|Experimental|Goal directed fluid therapy (GDT)|In the GDT arm, patient's SV will be optimized before induction with crystalloid boluses prior to induction of general anesthesia. The GDT arm will have fluid therapy guided by the Edwards EV1000-clinical platform and maintenance crystalloid fluid will be 3cc/kg/h. During the surgical procedure when SVV rises above 12 an albumin bolus will be administered at 250 ml increments until the SVV falls below 8. Transfusion will follow transfusion criteria.
89118990|NCT02100449|Other|Lung ultrasound and Doppler, pneumonia|In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed in patients with high clinical suspicion of pneumonia on Day 0. A bronchoalveolar lavage will also be performed on Day 0.
89118991|NCT02100449|Other|Lung ultrasound and Doppler, atelectasis|Patients without clinically active pulmonary disease but presenting a consolidation of suspected atelectatic nature. Fever, hypothermia, leucocytosis and leucopenia will not be present. Tracheal secretions will remain unchanged. There will be no deterioration of oxygenation. In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0.
89118992|NCT02070835|Experimental|autologous skin cell|autologous skin cell with skin graft
89118993|NCT02070835|Active Comparator|skin graft|split-thickness skin graft as control group
89118994|NCT02049658||Healthy volunteers|Healthy volunteers measured by currently used healthy screening procedures
89118995|NCT02049658||Suspected breast cancer subjects|Suspected breast cancer subjects without pathological examination yet but will have it soon
89118996|NCT02049658||Suspected lung cancer subjects|Suspected lung cancer subjects without pathological examination yet but will have it soon
89118997|NCT02049658||Suspected neurological tumor subjects|Suspected neurological tumor subjects without pathological examination yet but will have it soon
89118998|NCT02049658||Suspected patients with gynecological tumor|Suspected subjects with gynecological tumors without pathological examination yet but will have it soon
89118999|NCT02049645||faculty staff and their adult family members|faculties and their adult family members of the Third Xiang-Ya Hospital
89119000|NCT02034526|Placebo Comparator|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
89119001|NCT02034526|Experimental|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
89119002|NCT01970345|Experimental|IGF-1|"Randomized, placebo-controlled, crossover format with 12 weeks in each treatment arm (IGF-1 and placebo), separated by a four-week wash-out phase.~Dose titration will be initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Doses may be decreased according to tolerability by 0.04 mg/kg per dose. Medication will be administered twice daily with meals, and preprandial glucose monitoring will be performed by parents at treatment initiation, prior to each injection, and until a well tolerated dose is established."
89119003|NCT01970345|Placebo Comparator|Placebo|Placebo
89119004|NCT01735955|Experimental|Nilotinib|Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
89119005|NCT01674829|Experimental|Cohort 1|Biological: MA09-hRPE Cellular therapy Cohort 1 50,000 cells
89119006|NCT01674829|Experimental|Cohort 2|Biological: MA09-hRPE Cellular therapy Cohort 2 100,000 cells
89119007|NCT01674829|Experimental|Cohort 3|Biological: MA09-hRPE Cellular therapy Cohort 3 150,000 cells
89119008|NCT01674829|Experimental|Cohort 4|Biological: MA09-hRPE Cellular therapy Cohort 4 200,000 cells
89119009|NCT01653925|Experimental|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids.
89119010|NCT01653925|Experimental|Drug intervention first|Intake of 5α-Reductase Inhibitor
89119011|NCT01625559|Experimental|50,000 cells|Biological: MA09-hRPE Cellular therapy
89119012|NCT01456221|Experimental|omega 3 and an hypocaloric diet|Participants will receive a supplement containing omega 3: Docosahexaenoic acid (DHA) and EPA fatty acids together with an hypocaloric diet.
89119013|NCT01456221|Placebo Comparator|Placebo|Participants will receive a supplement containing sunflower oil with an hypocaloric diet.
89119014|NCT01344200|Active Comparator|Phase I: Study drug Group 1 (Celecoxib 7 mg/kg)|Study participants randomized to this group will receive a single 7 mg/kg dose of celecoxib approximately 121-180 minutes before their scheduled LP ± BMA. The study medication will be a liquid and the study participant will be asked to drink it.
89119015|NCT01344200|Active Comparator|Phase I: Study drug Group 2 (Celecoxib 14 mg/kg)|Study participants randomized to this group will receive a single 14 mg/kg dose of celecoxib approximately 121-180 minutes before their scheduled LP ± BMA. The study medication will be a liquid and the study participant will be asked to drink it.
88805858|NCT01134887|Experimental|Arm 3: Intervention-Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians [Monograph for Physicians]. The Four Habits provided practical evidence-based advice for improving patient-physician communication. Second, physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients [Video-Assisted Coaching], but before seeing them for follow-ups. The main goal of this meeting was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management."
89119016|NCT01344200|Placebo Comparator|Phase II: Group A: Placebo|"Study participants will receive a single dose of placebo. Placebo will be liquid. The study participant will drink it.~The timing of when the study participants in this group will take placebo will be determined in a second randomization:~Group A.1: will take placebo 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.2: will take placebo 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.3: will take the placebo 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.4: will take the study medication 1 to 2 hours prior to having their LP±BMA. The study medication will be taken at the hospital.~Group A.5: will take the study medication 0 to 60 minutes prior to having their LP±BMA. The study medication will be taken at the hospital."
89119017|NCT01344200|Active Comparator|Phase II: Group B: Study drug (Celecoxib 7 mg/kg)|"Study participants randomized to this group you will receive a single 7 mg/kg dose of celecoxib which will be in a liquid form, and the study participant will drink it.~The timing of when the study participant in this group will take this medication will be determined in a second randomization:~Group B.1: will take the study medication 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.2: will take the study medication 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.3: will take the study medication 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.4: will take the study medication 1 to 2 hours prior to having their LP±BMA. The study medication will be taken at the hospital.~Group B.5: will take the study medication 0 to 60 minutes prior to having your LP±BMA. The study medication will be taken at the hospital."
89119018|NCT01344200|Active Comparator|Phase II: Group C: Study drug (Celecoxib 14 mg/kg)|"Study participants randomized to this group you will receive a single 14 mg/kg dose of celecoxib which will be in a liquid form, and the study participant will drink it.~The timing of when the study participant in this group will take this medication will be determined in a second randomization:~Group C.1: will take the study medication 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.2: will take the study medication 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.3: will take the study medication 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.4: will take the study medication 1 to 2 hours prior to having your LP±BMA. The study medication will be taken at the hospital.~Group C.5: will take the study medication 0 to 60 minutes prior to having your LP±BMA. The study medication will be taken at the hospital."
89119019|NCT01305499|Experimental|A: 5AC days 1-10 / entinostat days 3, 10|Arm A will be given an overlapping schedule of drugs with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle and entinostat given at a flat dose of 8 mg orally on days 3 and 10.
89119020|NCT01305499|Experimental|B: 5AC days 1-10 / entinostat days 10,17|In Arm B the agents will be administered sequentially with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle followed by entinostat at a 8 mg flat dose on days 10 and 17.
89119021|NCT01297400|Experimental|Investigational Drug, MW-III|Investigational Drug, MW-III
89119022|NCT01297400|Active Comparator|Standard of care|Silvadene® Cream 1% [Silver Sulfadiazine]
88805859|NCT01134887|Active Comparator|Arm 4: Control-Physicians|"Primary care providers randomly assigned to the Control-Physicians arm of the study did not receive coaching or additional resources, and conducted their primary care practice as usual [Control]."
88805860|NCT03011879||1.STEMI patients with symptom onset within 30 days|First round enrollment of STEMI patients with symptom onset within 30 days
89119023|NCT00727103|Active Comparator|1 Varenicline|Varenicline will be dispensed in 0.5 mg (blue capsules containing a 0.5 mg varenicline tablet) and 1 mg (red capsules containing a 1 mg varenicline tablet) capsules taken orally. During the first 3 days of medication, participants will take one blue capsule (0.5 mg tablet) of varenicline daily. If the medication is well-tolerated, the dose will be increased to one blue capsule (0.5 mg) po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 red capsule (1 mg) po twice daily. At the end of the 8th week, varenicline will be discontinued.
89119024|NCT00727103|Placebo Comparator|2 Placebo|Placebo will be dispensed in blue and red color coded capsules. During the first 3 days, participants will take one blue capsule po daily. If the medication is well-tolerated, the dose will be increased to one blue capsule po twice daily for 4 days. On day 8, the patients will take 1 red capsule po twice daily. At the end of the 8th week, placebo will be discontinued.
89119025|NCT00588315||skin lesions|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
89119026|NCT00588315||normal skin|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
89119027|NCT00586391|Experimental|CD19CAR-28-zeta T cells|"Three dose levels of CTLs will be evaluated. Each patient will receive one injection according to their assigned dose over 1-10 minutes IV.~*At the discretion of the attending physician, if after a 4 to 6-week evaluation period the patient has had apparent clinical benefit (as determined by symptoms, physical exam or radiological studies); repeat infusions separated by 4 to 6 weeks (up to a maximum of 3 extra doses) of modified T cells at the same dose level or below the patient's original dose can be administered."
89119028|NCT00160732|Experimental|Transplant|
89119029|NCT00085202|Experimental|Stratum 1 (high-risk group)|"Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks. Six weeks after the completion of radiotherapy, patients receive high-dose chemotherapy followed by autologous stem cell transplantation (SCT) and filgrastim (G-CSF) with post-transplantation vincristine. High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional courses in the absence of unacceptable toxicity.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
89119030|NCT00085202|Experimental|Stratum 2 (average-risk group)|"Patients undergo craniospinal radiotherapy as in stratum 1, but at a lower dose. Patients receive high-dose chemotherapy, autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
88805861|NCT03011879||2.STEMI patients with symptom onset within 30 days|Second round enrollment of STEMI patients with symptom onset within 30 days
89232780|NCT04181827|Experimental|Arm A: PVd or DPd (Standard Therapy)|Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
89232781|NCT04181827|Experimental|Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])|Participants will receive at least one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of JNJ-68284528 (cilta-cel) along with conditioning regimen (cyclophosphamide 300 milligram [mg]/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days), and JNJ-68284528 (cilta-cel) infusion 0.75 * 10^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).
89232782|NCT04181060|Active Comparator|Arm A (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, MUGA, CT and may undergo MRI and blood sample collection on study.
89232783|NCT04181060|Experimental|Arm B (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, MUGA, CT and may undergo MRI and blood sample collection on study.
89232784|NCT04180462|Experimental|Intervention Group|Practices randomly assigned to this arm will receive the multi-component intervention.
89232785|NCT04180462|No Intervention|Wait list control group|Practices randomly assigned to this arm will be placed on a waiting list to receive the intervention in the last two years of the study.
89119031|NCT06183970|Experimental|AssistI patients|Patients will receive rehabilitation training using the AsistI software package in conjunction with standard upper limb rehabilitation interventions.
89119032|NCT06183970|Active Comparator|Habilect patients|Patients will receive rehabilitation training using the Habilect software and hardware complex, in addition to standard rehabilitation interventions for the upper limb.
89119033|NCT06183970|No Intervention|Conventional therapy patients|Patients will undergo standard upper limb rehabilitation interventions without the utilization of additional methods.
89119034|NCT06183944||Patient with acute pulmonary embolism|Patient with acute pulmonary embolism in Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, hospitalised or not since 2019
89119035|NCT06183918|Active Comparator|1. Group|Gauze soaked with 1000 mg TXA-topical
89119036|NCT06183918|Active Comparator|2. Group|Gauze soaked with 500 mg TXA + 5 cc saline -topical
89119037|NCT06183918|Active Comparator|3. Group|Gauze soaked with 10 cc of saline-topical.
89119038|NCT06183905|Experimental|Imaging (multiparametric ultrasound and multiparametric MRI)|All patients will undergo multiparametric ultrasound and multiparametric MRI. In case of suspicious multiparametric ultrasound and/or multiparametric MRI,they will undergo combined targeted biopsy and systematic biopsy. In case of nonsuspicious imaging findings, only systematic biopsy will be performed.
89119039|NCT06183892|Experimental|Prolonged-release tacrolimus|
89119040|NCT06183879|Active Comparator|Medtronic 4th gen balloon|Cryoballoon pulmonary vein isolation with Medtronic Artic Front Advance Pro 28 mm fixed size cryoballoon
89119041|NCT06183879|Active Comparator|Boston 2nd gen balloon|Cryoballoon pulmonary vein isolation with Polar X Fit, 28 to 31 mm expandable cryoballoon
89119042|NCT06183827|Active Comparator|the Oxygen Supply strategy|"During the 4-month period of control, the care teams will:~- Use Oxygen Supply by face mask (15Liters/minutes) from pre-hospital to intensive care unit admission until the 6th hour following the start of drowning care (Emergency Medical Service arrival at the scene).~Indeed, current concepts of advanced prehospital care include the use of oxygen by face mask (15Liters/minutes) and intubation-Mechanical Ventilation in case of failure. The requirement of intubation-Mechanical Ventilation by the Emergency Medical Service (pre-hospital phase) or Intensive Care Unit (hospital phase) practitioners during this first 6 hours period will be left to the discretion of the practitioners in charge of the patient;~- Continue this strategy in the Intensive Care Unit until the Acute Respiratory Failure resolution allows a reduction of Oxygen Supply. The Oxygen Supply will be reduced progressively litter by litter each 12 hours period with maintenance of capillary saturation up to 92%."
89119043|NCT06183827|Experimental|the 'Continuous Positive Airway Pressure strategy|"During the 4-month period of experimentation, the care teams will:~- Use Non-Invasive Ventilation by Continuous Positive Airway Pressure (set between 8 to 10 cm H2O) from pre-hospital setting to Intensive Care Unit admission until the 6th hour following the start of drowning care (Emergency Medical Service arrival at the scene).~The requirement of Mechanical Ventilation by the Emergency Medical Service (pre-hospital phase) or Intensive Care Unit (hospital phase) practitioners during this first 6 hours period will be left to the discretion of the practitioners in charge of the patient.~- Continue this strategy in the Intensive Care Unit until the Acute Respiratory Failure resolution allows a reduction of Non-Invasive Ventilation-Continuous Positive Airway Pressure. Non-Invasive Ventilation-Continuous Positive Airway Pressure support will be weaned progressively (left at practitioners' convenience) with maintenance of capillary O2 saturation up to 92%."
89119044|NCT06183801|Experimental|Probiotic 1|Subjects take probiotics capsule three times a day before meal.
89119045|NCT06183801|Experimental|Probiotic 2|Subjects take probiotics capsule three times a day before meal.
89119046|NCT06183801|Experimental|Probiotic 3|Subjects take probiotics capsule three times a day before meal.
89119047|NCT06183801|Experimental|Probiotic 4|Subjects take probiotics capsule three times a day before meal.
89119048|NCT06183801|Experimental|Probiotic 5|Subjects take probiotics capsule three times a day before meal.
89119049|NCT06183801|Placebo Comparator|Placebo 1|Subjects take probiotics capsule three times a day before meal.
89119050|NCT06183801|Experimental|Probiotic 6|After 1 month wash out,subjects take probiotics capsule three times a day before meal.
89119051|NCT06183801|Experimental|Probiotic 7|After 1 month wash out,subjects take probiotics capsule three times a day before meal.
89119052|NCT06183801|Placebo Comparator|Placebo 2|After 1 month wash out,subjects take probiotics capsule three times a day before meal.
89119053|NCT06183762||ICIs|Patients receiving in first-line immunotherapy with or without anti-angiogenic or chemotherapy
89119054|NCT06183762||Savolitinib|Patients receiving in first-line savolitinib treatment
89119055|NCT06183762||Glumetinib|Patients receiving in first-line glumetinib treatment
89119056|NCT06183762||Bozitinib|Patients receiving in first-line bozitinib treatment
89119057|NCT06183749||group 1general body trauma (Group 1)|Diagnosed as traumatic brain injury due to general body trauma neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and those who have been in intensive care within the past two years.
89119058|NCT06183749||isolated head trauma (Group 2).|diagnosed as traumatic brain injury due isolated head trauma neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and those who have been in intensive care within the past two years.
89119059|NCT06182592|Experimental|Arm A (liposomal cytarabine-daunorubicin for injection)|Patients are eligible to receive up to 2 inductions and up to 2 consolidations with liposomal cytarabine-daunorubicin for injection. The number of inductions and consolidations a patient received will depend on response.
89119060|NCT06182592|Experimental|Arm B (7+3)|Patients are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7+3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received will depend on response.
89119061|NCT06180174|Experimental|MC-1-50 cell preparation|Patients will be be treated with CD19 CAR- T cells
89119062|NCT06180096|Experimental|Riociguat film coated tablets|Riociguat 2.5 mg film coated tablets
89119063|NCT06180096|Active Comparator|Adempas Filmtabletten|Adempas (Riociguat) 2.5 mg Filmtabletten
89232786|NCT04177108|Experimental|Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel|TNBC participants with programmed death-ligand 1 (PD-L1) non-positive received a combination of paclitaxel, 80 milligrams per meter square (mg/m^2), intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib, 400 mg, orally (PO), once daily (QD), from Day 1 to Day 21 of each 28-day cycle and atezolizumab, 840 mg, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
89232787|NCT04177108|Experimental|Cohort 1 Arm B: Ipatasertib + Placebo + Paclitaxel|TNBC participants with PD-L1 non-positive received a combination of paclitaxel, 80 mg/m^2, IV infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib, 400 mg, PO, QD, from Day 1 to Day 21 of each 28-day cycle and atezolizumab-matching placebo, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
89232788|NCT04177108|Experimental|Cohort 1 Arm C: Placebo + Placebo + Paclitaxel|TNBC participants with PD-L1 non-positive received a combination of paclitaxel, 80 mg/m^2, IV infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib-matching placebo, PO, QD, from Day 1 to Day 21 of each 28-day cycle and atezolizumab-matching placebo, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
89232789|NCT04177108|Experimental|Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel|TNBC participants with PD-L1 positive received a combination of paclitaxel, 80 mg/m^2, IV infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib, 400 mg, PO, QD, from Day 1 to Day 21 of each 28-day cycle and atezolizumab, 840 mg, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
89232790|NCT04177108|Experimental|Cohort 2 Arm B: Placebo+ Atezolizumab + Paclitaxel|TNBC participants with PD-L1 positive received a combination of paclitaxel, 80 mg/m^2, IV infusion on Days 1, 8, and 15 of each 28-day cycle and ipatasertib-matching placebo, PO, QD, from Day 1 to Day 21 of each 28-day cycle and atezolizumab, 840 mg, IV infusion on Day 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent, whichever occurred first.
89232791|NCT04175600|Experimental|Selexipag|Participants will receive selexipag based on the body weight on Day 1 and will continue thereafter with twice daily dosing. Selexipag will be uptitrated during the first 12 weeks until the participants reaches the individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline body-weight category is achieved. Uptitration is followed by a maintenance period after Week 12 until end of treatment (EOT), at the maximum tolerated dose.
89232792|NCT04175600|Placebo Comparator|Placebo|Participants will receive matching placebo based on the body weight on Day 1 and will continue thereafter with twice daily dosing.
89232793|NCT04172675|Experimental|Cohort 1: Erdafitinib|Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ [CIS], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy will receive treatment with erdafitinib.
89119064|NCT06180083|Experimental|Azelastine Hydrochloride/ Fluticasone propionate nasal spray|Azelastine Hydrochloride/ Fluticasone propionate 137 microgram/50 microgram nasal spray
89119065|NCT06180083|Active Comparator|'DYMISTA' Nasal Spray|'DYMISTA' (Azelastine Hydrochloride/ Fluticasone Propionate) Nasal Spray 137 microgram/50 microgram
89119066|NCT06180057|Experimental|Chenodeoxycholic acid capsules|Chenodeoxycholic acid capsules (250mg chenodeoxycholic acid)
89119067|NCT06180057|Active Comparator|Chenodeoxycholic acid leadiant hard capsules|Chenodeoxycholic acid leadiant hard capsules (250mg chenodeoxycholic acid)
89119068|NCT06176820|Active Comparator|Arm 1|Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
89119069|NCT06176820|Active Comparator|Arm 2|Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
89119070|NCT06176651|Experimental|Experimental Arm|This is a single arm open label study with no randomization or control group. All participants will receive the Miebo eye drop for use while enrolled in the study.
89119071|NCT06176547||H.pylori in predibetic with lipid profile|Lipid profile HbA1c
89119072|NCT06176170|Experimental|VividWhite Glaucoma Implant (VW-51)|Surgical implantation of VW-51.
89119073|NCT06174363|Placebo Comparator|Study group|Group administered Maxigesic solution
89119074|NCT06174363|Experimental|Control group|Group administerd 0.9% saline solution
89119075|NCT06173869|Experimental|FE 999049|"The participants receive either low or high starting dose as appropriate according to Investigators Judgement.~10 or 15 µg"
89119076|NCT06173869|Active Comparator|GONAL-F|"The participants receive either low or high starting dose as appropriate according to Investigators Judgement.~150 or 225 IU."
89119077|NCT06169306|No Intervention|control|Following endotracheal intubation, no throath pack will inserted into the hypopharynx.
89119078|NCT06169306|Experimental|throath pack|Following endotracheal intubation, throath pack will inserted into the hypopharynx.
89119079|NCT06166628|Active Comparator|Genicular artery embolization|Genicular artery embolization will be performed by board certified Interventional Radiologists in the interventional radiology angiography suite at Kingston General Hospital. Patients will be blinded to which procedure they have been randomized too, careful language will be used by the clinical and research team throughout the procedure to not compromise the blinding. Patients will be positioned supine on the procedure table. The affected knee will be prepped and draped using standard sterile technique and 1-2cc of 1% lidocaine will be administered to the area for local anesthetic. A drape will be placed such that the patient is unable to see the affected knee during the procedure. Geniculate artery embolization will be performed via an intraarterial access and use of embolization microspheres injected into the hypervascular arteries feeding the knee joint.
89119080|NCT06166628|Active Comparator|Genicular nerve phenol nerve ablation|Genicular nerve phenol nerve ablation All procedures will be performed by a fellowship trained interventional pain physician in a fluoroscopy suite in Hotel Dieu Hospital using sterile precautions. Patients will be blinded to which procedure they have been randomized too, careful language will be used by the clinical and research team throughout the procedure to not compromise the blinding. IV access and saline lock obtained per our usual clinic protocol. Patients will be positioned supine on the procedure table. The affected knee will be prepped and draped using standard sterile technique and 1-2cc of 1% lidocaine will be administered to the area for local anesthetic. Phenol nerve ablation will be performed via ultrasound guidance.
89119081|NCT06166628|Sham Comparator|Sham procedure|The sham procedure will be performed by a fellowship trained interventional pain physician in a fluoroscopy suite in Hotel Dieu Hospital using sterile precautions. Patients will be blinded to which procedure they have been randomized too, careful language will be used by the clinical and research team throughout the procedure to not compromise the blinding. IV access and saline lock obtained per our usual clinic protocol. The patient will be placed supine, and the appropriate knee prepped and draped using appropriate sterile technique . A drape will be placed such that the patient is unable to see the affected knee during the procedure.
89119082|NCT06156449|No Intervention|Control Group|No intervention will be applied to the control group and the measurements will be recorded simultaneously.
89119083|NCT06156449|Experimental|experimental group|After filling out the forms, thyme oil aromatherapy will be applied to the patients assigned to the experimental group .The oregano oil to be prepared must have a high carvacrol ratio. Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and COPD symptom will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
89119084|NCT06155643|Other|Eko Device|Patients with cardiac risk factors
89119085|NCT06154447|Experimental|Part A: Single Ascending Dose (SAD)|Participants will be randomized to receive a single dose of different dose levels of VX-828.
89119086|NCT06154447|Placebo Comparator|Part A: Placebo|Participants will be randomized to receive placebo matched to VX-828.
89119087|NCT06154447|Experimental|Part B: Multiple Ascending Dose (MAD)|Participants will be randomized to receive multiple doses of different dose levels of VX-828. The dose levels will be determined based on the data from Part A.
89119088|NCT06154447|Placebo Comparator|Part B: Placebo|Participants will be randomized to receive placebo matched to VX-828.
89119089|NCT06154447|Experimental|Part C: Drug Drug Interaction|"Participants will receive a single dose of VX-828, followed by a washout period, Itraconazole administration, and concomitant administration of itraconazole and VX-828; or participants will receive Midazolam followed by VX-828 administration, and concomitant administration of VX-828 and Midazolam.~Part C will be an open-label optional cohort."
89119090|NCT06149507|Experimental|Acetaminophen|Syrup 10-15 mg/kg/dosage every 6-8 hours as needed and do not exceed more than 5 doses in 24 hours Duration 1 week
89119091|NCT06149507|Active Comparator|ibuprofen|Syrup 4-10 mg/kg/dosage every 4-6 hours as needed and do not exceed more than 5 doses in 24 hours Duration 1 week
89119092|NCT06149013|Experimental|MindAhead + TAU Group|The intervention group receives the digital health app MindAhead Active for 3 months as well as treatment-as-usual (TAU, see Control intervention).
89119093|NCT06149013|Active Comparator|TAU Group|The control group receives TAU which may include antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins depending on clinical findings.
89119094|NCT06148948|Placebo Comparator|Placebo|Placebo matching BI 1584862
89119095|NCT06148948|Experimental|BI 1584862 dose group 1|Group receiving dose 1 of BI 1584862
89119096|NCT06148948|Experimental|BI 1584862 dose group 2|Group receiving dose 2 of BI 1584862
89119097|NCT06148948|Experimental|BI 1584862 dose group 3|Group receiving dose 3 of BI 1584862
89119098|NCT06148948|Experimental|BI 1584862 dose group 4|Group receiving dose 4 of BI 1584862
89119099|NCT06141603||Lower Extremity Group|"The first test is the cardiopulmonary exercise test (CPET), which evaluates the maximal exercise capacity of the lower extremities and will be performed on a treadmill.~During the test, the muscle oxygen of the individuals will be measured with a near-infrared spectrometer, and their energy consumption will be measured with a multisensory physical activity monitor."
89119100|NCT06141603||Upper Extremity Group|"In the second test, the maximal exercise capacity for the upper limb will again be evaluated by CPET and performed on the arm ergometer.~The second test will be conducted 48 hours after the lower extremity exercise test.~During the test in the second group, as in the first test, muscle oxygen will be measured with a near-infrared spectrometer, and energy expenditure with a multisensory physical activity monitor."
89119101|NCT06124456|Placebo Comparator|Usual Care Control Group|
89119102|NCT06124456|Experimental|Moderate-intensity Exercise Intervention|
89119103|NCT06124456|Experimental|Vigorous-intensity Exercise Intervention|
89119104|NCT06117930||Observational|Participants undergo blood, tissue, saliva, urine and stool sample collection and complete questionnaires on study.
89119105|NCT06108492|Experimental|SHR-2005|Only one arm with SHR-2005
89119106|NCT06104657||Observational|Patients take part in interview on study.
89119107|NCT06088693|No Intervention|Control|Patients diagnosed with Oligozoospermia who only receive standard therapy from an Andrologist as a standard therapy.
89119108|NCT06088693|Experimental|Intervention|Patients diagnosed with Oligozoospermia receive standard therapy from an Andrologist and Electroacupuncture.
89119109|NCT06072339|Experimental|Experimental|The intervention group will benefit from the physiotherapist's use of lung ultrasound for the PEEP adjustment during the first NIV session.
89119110|NCT06072339|Active Comparator|Control|The conventional group will benefit from the NIV under the current terms.
89119111|NCT06070610|Experimental|Pirfenidone + nintedanib (R) then BI 1015550 + pirfenidone+ nintedanib (T)|Reference Treatment (R) Test Treatment (T)
89119112|NCT06068764|Experimental|Etomidate|Etomidate as the principal hypnotic agent in a single bolus dose of 0.2-0.3 mg/kg along with 250mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.
89119113|NCT06068764|Active Comparator|Propofol|Propofol as the principal hypnotic agent in a single bolus dose of 50mg of propofol along with 250 mcg of fentanyl, 50mg ketamine, 0.7 mg/kg rocuronium, and 5ml of 2% lidocaine.
89119114|NCT06067919|No Intervention|usual care|
89119115|NCT06067919|Experimental|use of a decision tree to guide antibiotic prophylaxis prescription|
89119116|NCT06061627|Experimental|LOT-CRT group|"In this arm, an right artrial (RA) lead, an implantable cardioverter defibrillator (ICD) lead and a LV pacing lead are placed are conventionally implanted.~A left bundle branch pacing(LBBP) lead is attempted to be placed."
89119117|NCT06061627|Active Comparator|BiVP group|In this arm, an RA lead , an ICD lead and a LV pacing lead are placed.
89119119|NCT06053372|Experimental|Apple Watch|Participants will wear an Apple Watch for 6 months
89119120|NCT06052566|Experimental|Efinopegdutide in Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment receive a single 7 mg dose of efinopegdutide 14 mg/ml by subcutaneous (SC) injection.
89119121|NCT06052566|Experimental|Efinopegdutide in Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment receive a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.
89119122|NCT06052566|Experimental|Efinopegdutide in Healthy-Matched Control Group|Healthy matched participants receive a single 7 mg dose of efinopegdutide 14 mg/ml by SC injection.
89119123|NCT06049095|Experimental|LTG-001|Part A: Single-Ascending dose cohorts; relative bioavailability; food effect; Part B: Multiple-ascending dose cohorts
89119124|NCT06049095|Placebo Comparator|Placebo|Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
89119125|NCT06043674|Active Comparator|Monotherapy Cohort: Obinutuzumab and Glofitamab|"Study procedures will be conducted as follows:~Baseline visit with screening procedures, including bone marrow biopsy and Positron Emission Tomography (PET) or Computed Topography (CT) scans.~PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment.~Cycle 1:~Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily.~Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation.~Cycle 2 - 12~--Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for second dose and post-dose observation~End of treatment visit.~Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months.~After completion of a 10-patient safety lead-in cohort, enrollment will open to the other two cohorts."
88805862|NCT03011879||3.STEMI patients with symptom onset within 30 days|Third round enrollment of STEMI patients with symptom onset within 30 days
89119126|NCT06043674|Experimental|Combination A Group: Obinutuzumab, Glofitamab, and Polatuzumab Vedotin|"Study procedures will be conducted as follows:~Baseline visit with screening procedures, including bone marrow biopsy and PET/CT scans.~PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment.~Cycle 1:~Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily.~Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation.~Cycle 2 - 7:~- Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Predetermined dose of Polatuzumab Vedotin 1x daily.~Cycle 8 - 12~- Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily.~End of treatment visit.~Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months."
89119127|NCT06043674|Experimental|Combination B Group: Obinutuzumab, Glofitamab,and Atezolizumab|"Study procedures will be conducted as follows:~Baseline visit with screening procedures, including bone marrow biopsy and PET/CT scans.~PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months after end-of-treatment.~Cycle 1:~Day 1, 2, and 7 of 21- day Cycle: Predetermined dose of Obinutuzumab 1x daily.~Day 8 and 15 of 21- day Cycle: Predetermined dose of Glofitamab 1x daily. Hospitalization will be required for initial dose and post-dose observation.~Cycle 2 - 12~- Day 1 of 21-day Cycle: Predetermined dose of Glofitamab 1x daily. Predetermined dose of Atezolizumab 1x daily.~End of treatment visit.~Follow up visits: for months 10 - 24, visits will be every 3 months. For months 25 - 60 visits will be every 6 months."
89119128|NCT06033066|Active Comparator|Messaging Only|16,000 participants will be randomized to Arm 1 where no monetary incentive is offered.
89119129|NCT06033066|Experimental|Small Incentive|16,000 participants will be randomized to Arm 2 where a small one-time monetary incentive is offered.
89119130|NCT06033066|Experimental|Prize Incentive|16,000 participants will be randomized to Arm 3 where an opportunity based incentive (or a drawing with a prize) with a single winner will be offered.
89119131|NCT06027463||xi'an/Tangdu hospital|
89119132|NCT06026462||Asthma with frequent acute exacerbations phenotype|Asthma with frequent acute exacerbations phenotype was defined as having at least two acute attacks in the past 12 months.
89119133|NCT06026462||Asthma with Intermittent acute exacerbations phenotype|Asthma with Intermittent acute exacerbations phenotype was defined as having less than or equal to one acute attacks in the past 12 months.
89119134|NCT06009757|Experimental|Percutaneous Coronary Intervention with Guiding Catheter GUIDEX|Patients with coronary artery disease during a percutaneous coronary intervention will be treated with one of the guiding catheter
89119135|NCT06009757|Experimental|Percutaneous Coronary Intervention with Guiding Catheter Medtronics|Patients with coronary artery disease during a percutaneous coronary intervention will be treated with one of the guiding catheter
89119136|NCT06007586|Placebo Comparator|Two antiemetic groups|Placebo 130mg iv d1 30min d1 before chemotherapy (IV time &gt; 2min);Ondansetron 8mg iv once d1 30min before chemotherapy; Dexamethasone 12mg iv once d1 before chemotherapy 30min, dexamethasone 8mg po qd d2 ~ 4.
89119137|NCT06007586|Experimental|Three antiemetic group|Aprepitant injection 130mg iv d1 30min d1 before chemotherapy (push-back time &gt; 2min);Ondansetron 8mg iv once d1 30min before chemotherapy;Dexamethasone 12mg iv once d1 30min before chemotherapy, 8mg po qd d2-4.
89119138|NCT06005740|Experimental|Monotherapy Dose Dose Finding - Part 1|TORL-4-500 iv once every 3 weeks
89119139|NCT06005740|Experimental|Expansion as Monotherapy - Part 2|TORL-4-500 iv once every 3 weeks
89119140|NCT06003283|Experimental|Tapering of rituximab based on disease activity guided dose reduction|"Treatment with rituximab every 6 months (24 weeks) with dosing based on disease activity, measured by the DAS28-CRP.~DAS28-CRP ≤ 3.2: dose reduction according to the following sequence: 1 x 1000 mg IV (maximum), 1 x 500 mg IV, 1 x 200 mg IV (minimum).~DAS28-CRP > 3.2: administration of previously effective dose."
89119141|NCT06003283|Active Comparator|Tapering of rituximab based on interval prolongation|Treatment with fixed dose of rituximab (1 x 1000 mg IV) if DAS28-CRP ≥ 3.2 AND interval of at least 6 months (24 weeks) since previous administration of rituximab.
89119142|NCT06000813|Experimental|REACH-Es|Participants in the REACH-Es arm will receive REACH-Es short message service (SMS), as follows: 1) Daily SMS (information related to diet, exercise, self-monitoring of blood glucose, their specific diabetes medication(s), and top 4 medication adherence barriers); 2) Daily two-way SMS (diabetes medication adherence question); 3) Weekly one-way SMS (participants receive weekly feedback on Sunday regarding how many of the last 7 days they took their medicine); 4) A SMS each time an HbA1c is collected with a link to a secure website that displays the result.
89119143|NCT06000813|Active Comparator|Enhanced treatment as usual (ETAU)|Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
89119144|NCT05985148|Experimental|Single-fraction stereotactic radiosurgery (SRS)|"Patients will be treated with single-fraction radiation therapy at three dose levels:~70 Gy, 80 Gy, and 90 Gy using image-guided SRS techniques."
89119145|NCT05967117|Active Comparator|Chest CT evaluation (Administrate contrast media for CECT)|Patients who are planned chest contrast enhanced CT scan ; Conventional concentration iodine contrast agents with the conventional tube voltage
89119146|NCT05967117|Experimental|Chest CT evaluation (Experimental 1)|Patients who are planned chest contrast enhanced CT scan ; Conventional concentration iodine contrast agents with the low tube voltage
89119147|NCT05967117|Experimental|Chest CT evaluation (Experimental 2)|Patients who are planned chest contrast enhanced CT scan ; Low concentration iodine contrast agents with the low tube voltage)
89119148|NCT05967117|Experimental|Chest CT evaluation (Experimental 3)|Patients who are planned chest contrast enhanced CT scan; Ultra Low concentration iodine contrast agents with the low tube voltage)
89119149|NCT05965856|Experimental|BL-B01D1 + SI-B003|Participants receive SI-B003 or BL-B01D1+SI-B003 dual therapy in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
89119150|NCT05957289|Experimental|Multidimensional rehabilitation group|The intervention is based on the behavior change wheel and includes dietary intervention, exercise intervention, psychological support, and behavior management. Through various methods such as training, education, and motivation, the patient's ability, opportunities, and motivation will be increased, thereby promoting healthy behavior.
89119151|NCT05956990|Experimental|multidimensional rehabilitation group|The intervention is based on the behavior change wheel and includes dietary intervention, exercise intervention, psychological support, and behavior management. Through various methods such as training, education, and motivation, the patient's ability, opportunities, and motivation will be increased, thereby promoting healthy behavior.
89119152|NCT05956990|No Intervention|Control group|The patients will receive the conventional clinical guidance according to The First Affiliated Hospital of Xiamen University, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
89119153|NCT05954377|Experimental|Standard multidisciplinary follow-up reinforced with telemedicine|Standard annual multidisciplinary follow-up, reinforced with telemedicine (remote quarterly motivational interviews)
89119154|NCT05954377|No Intervention|Standard multidisciplinary follow up|Standard annual multidisciplinary follow-up without telemedicine follow up
89119155|NCT05938621|No Intervention|Standard of Care|Health care providers in this arm will receive no intervention
89119156|NCT05938621|Experimental|Resilience intervention|Providers in this arm will receive training to improve their resilience and well-being
89119157|NCT05938621|Experimental|Resilience and Stigma group|Providers in this group will receive training to improve their resilience and well-being as well as receive sessions about the impact of stigmatizing their patients.
88805863|NCT00223652|Experimental|Arm 1 - Telephone CBT|Telephone cognitive behavioral therapy
89119158|NCT05938621|Experimental|Anti-stigma group|Providers in this group will receive sessions focusing on the impact that stigmatizing patients can have on themselves and their patients. Strategies to minimize negative feelings will be developed.
89119159|NCT05930171|Active Comparator|Group A: L-ESPB and PENG|receiving after end of hip surgery (PENG) block first and (LESPB) at lumber 4 vertebrae level
89119160|NCT05930171|Active Comparator|Group B: conventional analgesia|receiving postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
89232794|NCT04172675|Active Comparator|Cohort 1: Investigators Choice|Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy will receive the investigator's choice of either intravesical gemcitabine or intravesical mitomycin C (MMC) or hyperthermic MMC. Participants who are randomized to gemcitabine or MMC or hyperthermic MMC in Cohort 1 and demonstrate a recurrence via investigator disease assessment will have the opportunity to cross over to treatment with erdafitinib.
88805864|NCT00223652|No Intervention|Arm 2 - Treatment as Usual|Treatment as usual control.
89232795|NCT04172675|Experimental|Cohort 2|Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor will receive treatment with erdafitinib.
89232796|NCT04172675|Experimental|Cohort 3|Marker lesion study in intermediate-risk NMIBC presenting as papillary disease only. All enrolled participants will receive treatment with erdafitinib.
89232797|NCT04170348|Experimental|Daily oral vitamin D3|Oral vitamin D3, 3,333 IU
89232798|NCT04170348|Active Comparator|Monthly bolus oral vitamin D3|Bolus oral vitamin D3, 100,000 IU
89232799|NCT04167813|Active Comparator|Active Treatment|Participants randomised to the active treatment arm will take 8-24mg/day of ondansetron.
89232800|NCT04167813|Placebo Comparator|Matched placebo|Participants randomised to the placebo treatment arm will take matched placebo, administered as tablets.
89232801|NCT04154774|Experimental|Group 1: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive single oral dose of apalutamide on Day 1 under fasted condition.
89232802|NCT04154774|Experimental|Group 2: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive single oral dose of apalutamide on Day 1 under fasted condition.
89232803|NCT04139564|Experimental|EaseVRx group|Each subject will be asked to complete a 56-day program using the EaseVRx virtual reality headset with assigned modules each week. Each week, subjects will be asked to complete 7 modules (one per day), each approximately 5 minutes in duration, for a total of 56 modules across the program.
89232804|NCT04139564|Active Comparator|Active control group VR Sham|Each subject will be asked to complete a program accessible via VR that includes 2d visual wildlife scenes similar to some EaseVRx content
89232805|NCT04133636|Experimental|JNJ-68284528|Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A(Progressive disease post 1-3 prior lines of therapy), Cohort B(Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma [NDMM], standard risk [International Staging System Stage I/II] and post initial therapy); Cohort E(NDMM,transplant not planned,high risk disease) will first receive quadruplet induction regimen of daratumumab,bortezomib,lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Part B:Cohort G(NDMM,transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel; Cohort H(NDMM,transplant-eligible) will receive D-VRd followed by cilta-cel.
89232806|NCT04129138||Observational (survey)|Participants complete a survey over 30 minutes.
89232807|NCT04124380|Experimental|Imaginal Exposure First, then Alcohol Skills|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. After imaginal exposure, alcohol skills targeting alcohol misuse after sexual assault.
89232808|NCT04124380|Experimental|Alcohol Skills First, then Imaginal Exposure|Alcohol skills targeting alcohol misuse after sexual assault. After alcohol skills training, imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault.
89232809|NCT04124380|Active Comparator|Supportive Counseling/Telehealth|Internet-based intervention focusing on providing support.
89232810|NCT04124380|Experimental|Alcohol Skills First, no additional treatment|Alcohol skills targeting alcohol misuse after sexual assault only. No additional treatment.
89232811|NCT04124380|Experimental|Imaginal Exposure First, no additional treatment|Imaginal exposure to the sexual assault memory targeting PTSD symptoms after sexual assault. No additional treatment.
89232812|NCT04119050|Experimental|M281 administered every 4 weeks (double-blind period)|Participants will receive M281 administered every 4 weeks alternating with placebo every 4 weeks during the 24 weeks double-blind period.
89232813|NCT04119050|Experimental|M281 administered every 2 weeks (double-blind period)|Participants will receive M281 administered every 2 weeks during the 24 weeks double-blind period.
89119161|NCT05921747|Active Comparator|Core stability exercise by Physiotherapist|Postpartum women in this group will receive standard core stability exercise program (Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting) under the supervision of physiotherapist.
89119162|NCT05921747|Experimental|Core stability exercise by Virtual Reality|Postpartum patients with lumbopelvic pain will receive two sessions per week for a period of 4 weeks of a novel digital therapeutic that combines virtual embodiment with graded motor imagery to deliver functional rehabilitation exercises using an off-the-shelf virtual reality system. The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
89119163|NCT05871606|Experimental|Dose 1 Group|Dose 1- Inhaled Nitrous Oxide (iNO) 40ppm.
89119164|NCT05871606|Experimental|Dose 2 Group|Dose 2- Inhaled Nitrous Oxide (iNO) 50ppm.
89119165|NCT05871606|Experimental|Dose 3 Group|Dose 3- Inhaled Nitrous Oxide (iNO) 60ppm.
89119166|NCT05871606|Experimental|Dose 4 Group|Dose 4- Inhaled Nitrous Oxide (iNO) 70ppm.
89119167|NCT05871606|Experimental|Dose 5 Group|Dose 5- Inhaled Nitrous Oxide (iNO) 80ppm.
89119168|NCT05827926|Experimental|Cohort A2: mRNA-1083.1 Dose B|Participants will receive single intramuscular (IM) injection of mRNA-1083.1 at Dose Level B on Day 1.
89119169|NCT05827926|Experimental|Cohort A3: mRNA-1083.1 Dose C|Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.
89119170|NCT05827926|Experimental|Cohort A4: mRNA-1083.2 Dose A|Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.
89119171|NCT05827926|Experimental|Cohort A5: mRNA-1083.2 Dose B|Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.
89119172|NCT05827926|Experimental|Cohort A6: mRNA-1083.2 Dose C|Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.
89119173|NCT05827926|Experimental|Cohort A7: mRNA-1083.3|Participants will receive single IM injection of mRNA-1083.3 on Day 1.
89119174|NCT05827926|Active Comparator|Cohort A8: mRNA-1010.4|Participants will receive single IM injection of mRNA-1010.4 on Day 1.
89119175|NCT05827926|Active Comparator|Cohort A9: mRNA-1283.222|Participants will receive single IM injection of mRNA-1283.222 on Day 1.
89119176|NCT05827926|Active Comparator|Cohort A10: mRNA-1273.222|Participants will receive single IM injection of mRNA-1273.222 on Day 1.
89119177|NCT05827926|Active Comparator|Cohort A11: mRNA-1010|Participants will receive single IM injection of mRNA-1010 on Day 1.
89119178|NCT05827926|Active Comparator|Cohort A12: Fluarix|Participants will receive single IM injection of Fluarix on Day 1.
89119179|NCT05827926|Active Comparator|Cohort A13: Fluzone HD|Participants will receive single IM injection of Fluzone HD on Day 1.
89119180|NCT05827926|Experimental|Cohort B1: mRNA-1083.1 Dose A|Participants will receive single IM injection of mRNA-1083.1 at Dose Level A on Day 1.
89119181|NCT05827926|Experimental|Cohort B2: mRNA-1083.1 Dose B|Participants will receive single IM injection of mRNA-1083.1 at Dose Level B on Day 1.
89119182|NCT05827926|Experimental|Cohort B3: mRNA-1083.1 Dose C|Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.
89119183|NCT05827926|Experimental|Cohort B4: mRNA-1083.2 Dose A|Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.
89232814|NCT04119050|Experimental|Placebo administered every 2 weeks (double-blind period)|Participants will receive M281 matching placebo administered every 2 weeks during the 24 weeks double-blind period.
89232815|NCT04119050|Experimental|M281 administered every 4 weeks (open-label extension period)|Participants will receive M281 administered every 4 weeks during the 144 weeks open-label extension period.
89232816|NCT04119050|Experimental|M281 administered every 2 weeks (open-label extension period)|Participants will receive M281 administered every 2 weeks during the 144 weeks open-label extension period.
89232817|NCT04116541|Experimental|HDM201 + Ribociclib|Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.
89232818|NCT04116541|Experimental|Cabozantinib|Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB),TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation and/or ROS1 translocation, and/or MET translocation detected on tumor sample from primary tumor or metastatic lesion.
89232819|NCT04116541|Experimental|Alectinib|Activating ALK alterations: translocation, or selected mutations
89232820|NCT04116541|Experimental|Regorafenib|Patient with activating mutation and/or amplification of VEGFR1-3, TIE-2, KIT, RET, RAF1, BRAF (other than V600 mutations), CRAF, HRAS, Platelet Derived Growth Factor Receptor (PDGFR), Fibroblast Growth Factor Receptor 1-2 (FGFR1-2), FLT3 and/or Colony Stimulating Factor 1 Receptor (CSF1R), and/or amplification of the ligands, and/or biallelic inactivation of SMAD4
89232821|NCT04116541|Experimental|Trametinib|Patient with activating mutation and/or amplification of KRAS (except all KRAS G12 mutations), NRAS, HRAS and/or Mitogen-Activated Protein Kinase Kinase (MAP2K); and/or biallelic inactivation of Neurofibromin 1 (NF1); and/or activating mutation Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11); and/or amplification or translocation of BRAF ; and/or translocation RAF1
89232822|NCT04116541|Experimental|Trametinib + Dabrafenib|Patient with BRAF V600 mutation
89232823|NCT04116541|Experimental|Avapritinib|Activating mutations of KIT exon 17 or PDGFRA exon 18 associated or not to mutation on KIT exon 11 or PDGFRA exon 12/14
89232824|NCT04116203|Other|Fish Oil|Fish oil capsules 1200mg 6 tablets/day 12 weeks
89232825|NCT04116203|Other|Metformin|Metformin tablets (500 mg) 2/day 12 weeks
89232826|NCT04116203|Other|Fish Oil and Metformin|Combo of other 2 arms
89232827|NCT04114890|Experimental|Pregnant woman with second trimester and third trimester|
89232828|NCT04110054|Experimental|S-600918 50 mg|Participants will receive 50 mg S-600918 orally once a day for 28 days.
89232829|NCT04110054|Experimental|S-600918 150 mg|Participants will receive 150 mg S-600918 orally once a day for 28 days.
89232830|NCT04110054|Experimental|S-600918 300 mg|Participants will receive 300 mg S-600918 orally once a day for 28 days.
89232831|NCT04110054|Placebo Comparator|Placebo|Participants will receive placebo to S-600918 orally once a day for 28 days.
88805865|NCT03012035|Experimental|experimental group|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
89232832|NCT04108208|Experimental|Apalutamide 240 milligram (mg) plus ADT|Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.
89232833|NCT04108208|Placebo Comparator|Placebo plus ADT|Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.
89232834|NCT04108195|Experimental|Part 1: Dose Escalation|Participants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
89232835|NCT04108195|Experimental|Part 2: Dose Expansion|Participants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1.
89232836|NCT04107766||Population|Patients with at least one soft-tissue liver lesion ablated with the NEUWAVE Microwave Ablation System or NEUWAVE Microwave Ablation System with Ablation Confirmation.
89232837|NCT04106427|Experimental|cTBS plus SCRT|10 daily sessions of continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
89232838|NCT04106427|Placebo Comparator|Placebo plus SCRT|10 daily sessions of placebo continous theta burst (cTBS) on the right inferior parietal cortex for two weeks together with 16 sessions of social cognitive remediation therapy (SCRT) twice per week over an eight week period according to the manual
89232839|NCT04106427|Sham Comparator|Sham SCRT|16 sessions of sham social cognitive remediation therapy (SCRT) twice per week over an eight week period. Participants will engage in non-effective group activities
89232840|NCT04103554|Experimental|sacubitril/valsartan|
89232841|NCT04103554|Active Comparator|Standard of care|Standard of care for treating blood pressure per center protocols
89232842|NCT04097561|Experimental|Single arm, open-label|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
89232843|NCT04095234|Experimental|Acupuncture|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
89232844|NCT04095234|Active Comparator|Massage|Participants will receive up to 10 treatments in the first 10 weeks (+/- 4 days) and then receive monthly booster treatments (+/- 7 days) for up to 26 weeks.
89232845|NCT04093765|Experimental|Sustained high incidence villages|Villages classified as high incidence, low probability of elimination (P. falciparum cumulative incidence >84 cases/1000/year, in spite of >1 year of functioning malaria post) will be eligible to be included in group 1. Villages in this group will be addressed by MSAT waves of 10-15 villages. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.
89232846|NCT04093765|Experimental|Seasonal focal transmission villages/locations|"This group will follow the NMCP case/and foci investigation guidelines, but use URDT instead of standard RDT for screening. MSAT group 2 locations will be cluster of houses, villages or clusters of villages selected based on the results of case or foci/outbreak investigation. Interventions will consist of 1 Ultrasensitive Rapid Diagnostic Test (URDT) and antimalarials drugs.~Village inclusion after case investigation~Village inclusion after outbreak investigation"
89232847|NCT04090034||Treated w PRRT|Patients who received treatment of gastroenteropancreatic primary NETs with PRRT per the treating physicians discretion.
89232848|NCT04083976|Experimental|Erdafitinib|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of erdafitinib oral tablets until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
89232849|NCT04077723|Experimental|Part I|Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab seven days prior to first administration of RO7227166. RO7227166 will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).
89232850|NCT04077723|Experimental|Part II|Combination Dose-Escalation: Mixed r/r participants and participants with mixed r/r mantle cell lymphoma (MCL) and Richters transformation will receive a fixed dose of obinutuzumab seven days prior to first administration of RO7227166. RO7227166 will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
89232851|NCT04077723|Experimental|Part III|Dose-Expansion Stage: Participants with r/r follicular lymphoma (FL), r/r diffuse large B-cell lymphoma (DLBCL), and r/r MCL will receive RO7227166 administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
89232852|NCT04077463|Experimental|Phase 1 (monotherapy dose escalation): Lazertinib|Participants will receive Lazertinib monotherapy orally once daily (QD) in 21-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. The subsequent doses of Lazertinib will be assigned by the Study Evaluation Team (SET) according to the dose escalation strategy by Bayesian logistic regression model (BLRM).
89232853|NCT04077463|Experimental|Phase 1b (combination): Lazertinib and Amivantamab|Participants will receive Lazertinib and Amivantamab, after the safety of RP2D of Lazertinib is confirmed in the Phase 1, in 28-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. This phase will start enrolling participants after the safety of Amivantamab is confirmed in Japanese participants in Study 61186372EDI1001 (NCT02609776).
89119184|NCT05827926|Experimental|Cohort B5: mRNA-1083.2 Dose B|Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.
89119185|NCT05827926|Experimental|Cohort B6: mRNA-1083.2 Dose C|Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.
89119186|NCT05827926|Experimental|Cohort B7: mRNA-1083.3|Participants will receive single IM injection of mRNA-1083.3 on Day 1.
89119187|NCT05827926|Active Comparator|Cohort B8: mRNA-1010.4|Participants will receive single IM injection of mRNA-1010.4 on Day 1.
89119188|NCT05827926|Active Comparator|Cohort B9: mRNA-1283.222|Participants will receive single IM injection of mRNA-1283.222 on Day 1.
89119189|NCT05827926|Active Comparator|Cohort B10: mRNA-1273.222|Participants will receive single IM injection of mRNA-1273.222 on Day 1.
89119190|NCT05827926|Active Comparator|Cohort B11: mRNA-1010|Participants will receive single IM injection of mRNA-1010 on Day 1.
89119191|NCT05827926|Active Comparator|Cohort B12: Fluarix|Participants will receive single IM injection of Fluarix on Day 1.
89119192|NCT05795465|Experimental|Part 1 Cohort 1: GEn-1124|Subjects in cohort 1 will receive low dose GEn-1124 BID intravenous 5 days.
89119193|NCT05795465|Experimental|Part 1 Cohort 2: GEn-1124|Subjects in cohort 2 will receive high dose GEn-1124 BID intravenous for 5 days.
89119194|NCT05795465|Placebo Comparator|Placebo|Subjects randomized to placebo will receive a placebo in a matching dosing regimen (Placebo BID intravenous for 5 days).
89119195|NCT05795465|Experimental|Part 2: GEn-1124|Depending on the analysis of part 1, subjects in part 2 will receive GEn-1124 BID intravenous for 5 days.
89119196|NCT05781100|Experimental|Order of Technology Use during Feeding Conditions: TV Use, Mobile Device Use, Control|This arm will be exposed to the feeding conditions in the following order: TV Use, Mobile Device Use, Control
89119197|NCT05781100|Experimental|Order of Technology Use during Feeding Conditions: TV Use, Control, Mobile Device Use|This arm will be exposed to the feeding conditions in the following order: TV Use, Control, Mobile Device Use
89119198|NCT05781100|Experimental|Order of Technology Use during Feeding Conditions: Mobile Device Use, TV Use, Control|This arm will be exposed to the feeding conditions in the following order: Mobile Device Use, TV Use, Control
89119199|NCT05781100|Experimental|Order of Technology Use during Feeding Conditions: Mobile Device Use, Control, TV Use|This arm will be exposed to the feeding conditions in the following order: Mobile Device Use, Control, TV Use
89119200|NCT05781100|Experimental|Order of Technology Use during Feeding Conditions: Control, TV Use, Mobile Device Use|This arm will be exposed to the feeding conditions in the following order: Control, TV Use, Mobile Device Use
89119201|NCT05781100|Experimental|Order of Technology Use during Feeding Conditions: Control, Mobile Device Use, TV Use|This arm will be exposed to the feeding conditions in the following order: Control, Mobile Device Use, TV Use
89119202|NCT05772871|Experimental|Prednisone, Huaiqihuang granule, and Levamisole placebo|In this group, patients will take Prednisone, Huaiqihuang granule, and Levamisole placebo.
89119203|NCT05772871|Placebo Comparator|Prednisone, Levamisole, and Huaiqihuang granule placebo|In this group, patients will take Prednisone, Levamisole, and Huaiqihuang granule placebo.
89119204|NCT05754177|Experimental|Probiotic|Arm receiving investigation product (probiotic)
89119205|NCT05754177|Placebo Comparator|Placebo|Arm receiving placebo
89119206|NCT05739643|Experimental|Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)|N=3 patients with Infantile or Late Infantile Krabbe disease will receive a single infusion at the low dose
89119207|NCT05739643|Experimental|Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)|N=3-6 patients with Infantile or Late Infantile Krabbe disease will receive a single infusion at the high dose
89119208|NCT05718882|Experimental|Lenvatinib plus VIC-1911 combination therapy|Subjects with lenvatinib unresponsive or lenvatinib resistant hepatocellular HCC will receive Lenvatinib plus VIC-1911 combination therapy.
89119209|NCT05714839|Experimental|Part 1 - Dose Escalation Phase in Participants with RRMM|Bela will be administered in participants with RRMM until progressive disease (PD). Participants may switch to Belamaf in case of PD.
89119210|NCT05714839|Experimental|Part 2 - Combination Treatments in Participants with RRMM|Participants with RRMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment for Multiple Myeloma.
89119211|NCT05714839|Experimental|Part 3 - Combination Treatments in Participants with TI-NDMM|Participants with TI-NDMM will receive Bela-xRd and Belamaf-xRd. The combination treatment xRd includes lenalidomide (R) and dexamethasone (d). x will be either a standard of care (SoC) or an emerging treatment for Multiple Myeloma.
89119212|NCT05707351|Experimental|Adynovate 45±5 IU/kg|Participants will receive prophylactic treatment with Adynovate (45 [±5] international units per kilogram [IU/kg]), infusion, intravenously, twice-weekly, over a period of 26 weeks or at least 50 EDs, whichever occurs last.
89119213|NCT05690061|Active Comparator|Sequence 1: Grain-Fed, Grass-Fed, Impossible|"On the first visit, a grain-fed beef burger (250 grams) will be consumed.~On the second visit, a grass-fed beef burger (250 grams) will be consumed.~On the third visit, an Impossible BurgerTM (250 grams) will be consumed."
89119214|NCT05690061|Active Comparator|Sequence 2: Grass-Fed, Grain-Fed, Impossible|"On the first visit, a grass-fed beef burger (250 grams) will be consumed.~On the second visit, a grain-fed beef burger (250 grams) will be consumed.~On the third visit, an Impossible BurgerTM (250 grams) will be consumed."
89119215|NCT05690061|Active Comparator|Sequence 3: Impossible, Grass-Fed, Grain-Fed|"On the first visit, an Impossible BurgerTM (250 grams) will be consumed.~On the second visit, a grass-fed beef burger (250 grams) will be consumed.~On the third visit, a grain-fed beef burger (250 grams) will be consumed."
89119216|NCT05690061|Active Comparator|Sequence 4: Impossible, Grain-Fed, Grass-Fed|"On the first visit, an Impossible BurgerTM (250 grams) will be consumed.~On the second visit, a grain-fed beef burger (250 grams) will be consumed.~On the third visit, a grass-fed beef burger (250 grams) will be consumed."
89119217|NCT05690061|Active Comparator|Sequence 5: Grain-Fed, Impossible, Grass-Fed|"On the first visit, a grain-fed beef burger (250 grams) will be consumed.~On the second visit, an Impossible BurgerTM (250 grams) will be consumed.~On the third visit, a grass-fed beef burger (250 grams) will be consumed."
89232854|NCT04077463|Experimental|Phase 1b (combination): Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP)|Participants will receive Lazertinib starting dose administered orally once daily (QD) in combination with Amivantamab, and doses of platinum-based chemotherapy (carboplatin and pemetrexed) per standard of care according to local guidance in a 21-day cycle for 4 cycles followed by maintenance with Lazertinib, Amivantamab and pemetrexed until disease progression or unacceptable toxicities.
89232855|NCT04077463|Experimental|Phase 1b (expansion) Cohort A: Lazertinib and Amivantamab|"This cohort A will further characterize the safety, tolerability, and preliminary antitumor activity of Lazertinib and Amivantamab based combinations within specific NSCLC population who have progressed after osimertinib and subsequent platinum-based chemotherapy, and platinum-based chemotherapy regimen as the last line of therapy prior to study enrollment. Prior use of first or second generation EGFR TKI is allowed if administered prior to osimertinib. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter."
89232856|NCT04077463|Experimental|Phase 1b (expansion) Cohort B: Lazertinib and Amivantamab|This Cohort B will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants previously treated with advanced or metastatic NSCLC with documented primary EGFR Exon 20ins activating mutation. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
89232857|NCT04077463|Experimental|Phase 1b (expansion) Cohort C: Lazertinib and Amivantamab|This Cohort C will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants with uncommon EGFR mutations. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
89232858|NCT04077463|Experimental|Phase 1b (expansion) Cohort D: Lazertinib and Amivantamab|Cohort D will seek to validate one or both potential biomarker strategies (next generation sequencing [NGS] and Immunohistochemical [IHC]), previously identified in Cohort E of Study 61186372EDI1001, in participants with osimertinib-relapsed, but chemotherapy-naive, EGFR Exon19del or L858R mutated NSCLC. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
89232859|NCT04077463|Experimental|Phase 1b (expansion) Cohort E: Lazertinib and Amivantamab|Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter. Cohort E will seek to validate the immunohistochemical (IHC)-based biomarker strategy, by characterizing the activity of Amivantamab and Lazertinib combination in biomarker-positive participants with osimertinib-relapsed, but chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC. In addition, Cohort E will seek to collect prospective data to confirm that prophylactic anticoagulation safely and effectively decreases the incidence of VTE events for patients treated with the combination of Amivantamab and Lazertinib, using Cohort F as reference.
89119218|NCT05690061|Active Comparator|Sequence 6: Grass-Fed, Impossible, Grain-Fed|"On the first visit, a grass-fed beef burger (250 grams) will be consumed.~On the second visit, an Impossible BurgerTM (250 grams) will be consumed.~On the third visit, a grain-fed beef burger (250 grams) will be consumed."
89119219|NCT05682378|Experimental|Inclisiran|Inclisiran sodium 300mg (equivalent to 284mg inclisiran*) in 1.5mL solution
89119220|NCT05665972|Experimental|Mandala coloring group|Mandala painting will be applied to women suffering from premenstrual syndrome.
89119221|NCT05665972|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce premenstrual syndrome symptoms.
89119222|NCT05659914|Experimental|olaparib +durvalumab|olaparib+durvalumab
89119223|NCT05655299|Experimental|VTX958 Dose A|
89119224|NCT05655299|Experimental|VTX958 Dose B|
89119225|NCT05655299|Experimental|VTX958 Dose C|
89119226|NCT05655299|Experimental|VTX958 Dose D|
89119227|NCT05655299|Placebo Comparator|Placebo|
89119228|NCT05648279|No Intervention|Routine hemodynamic management (control)|In patients assigned to routine hemodynamic management, hemodynamic management will performed as per anesthesiologist preference. Cardiac index monitoring will be will measured using the Baxter Starling Fluid Management System (Baxter, Deerfield, IL, USA). The attending anesthesiologist will be blinded to cardiac index measurements. Cardiac index monitoring can be unblinded upon request. Mean arterial blood pressure will be maintained above 65 mmHg.
89232860|NCT04077463|Experimental|Phase 1b (expansion) Cohort F: Amivantamab Monotherapy|Participants will receive Amivantamab monotherapy once weekly (QW) for 4 weeks, then every 2 weeks thereafter. Cohort F will seek to validate the IHC-based biomarker strategy, previously identified in Cohort D, by characterizing the activity of JNJ-61186372 monotherapy (Cohort F) in biomarker-positive participants with osimertinib-relapsed, but chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC.
89232861|NCT04075591|Experimental|Wavefront-guided Lasik Monovision Treatment|Wavefront-guided LASIK monovision treatment of myopic subjects with presbyopia using the STAR S4 IR® Excimer laser System with the iDesign Refractive Studio.
89232862|NCT04070105|Experimental|CAESAR Foot, Prescribed Feet, AllPro|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is CAESAR Foot, Prescribed Feet, AllPro.
89232863|NCT04070105|Experimental|CAESAR Foot, AllPro, Prescribed Feet|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is CAESAR Foot, AllPro, Prescribed Feet
89232864|NCT04070105|Experimental|Prescribed Feet, AllPro, CAESAR Foot|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is Prescribed Feet, AllPro, CAESAR Foot
89232865|NCT04070105|Experimental|Prescribed Feet, CAESAR Foot, AllPro|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is Prescribed Feet, CAESAR Foot, AllPro
89232866|NCT04070105|Experimental|AllPro, Prescribed Feet, CAESAR Foot|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is AllPro, Prescribed Feet, CAESAR Foot
89232867|NCT04070105|Experimental|AllPro, CAESAR Foot, Prescribed Feet,|Participants will walk and run with different prostheses on different days in a laboratory. The order of testing is AllPro, CAESAR Foot, Prescribed Feet
89232868|NCT04068194|Active Comparator|Arm A (hypofractionated RT, avelumab)|Patients undergo 8 fractions of hypofractionated RT QD on days -17 to -7. Patients also receive avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, CT, and collection of blood on the trial.
89232869|NCT04068194|Experimental|Arm B (hypofractionated RT, peposertib, avelumab)|Patients undergo 8 fractions of hypofractionated RT QD on days -17 to -7. Patients also receive peposertib PO BID on days 1-28, and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, CT, and collection of blood on the trial.
89232870|NCT04063501||Advanced stage unresectable Non-Small Cell Lung Cancer|Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
89232871|NCT04059562|Experimental|Treatment|Combination of Lonsurf® and Irinotecan
89232872|NCT04053140|Experimental|Routine intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV 1200mg administered every 4 hours.
89232873|NCT04053140|Experimental|Closed-loop control of intermittent slow bolus|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
89232874|NCT04053140|Experimental|Closed-loop control of continuous infusion|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
89232875|NCT04042740|Experimental|Glecaprevir/Pibrentasvir (G/P)|"In Step 1, participants will receive G/P FDC tablets to be taken orally once daily for 4 weeks.~Any participant who experiences viral re-infection, suspected relapse, virologic failure, or undefined post-treatment HCV viremia may enter Step 2. In Step 2, participants may receive G/P FDC tablets orally once daily for 8-16 weeks. Some participants may also receive ribavirin (RBV) tablets orally twice daily. Alternate regimens are allowed in Step 2."
89232876|NCT04042376|Experimental|Ibrutinib 420 milligram (mg)|Participants will receive ibrutinib 420 mg once daily, continuously starting at Day 1 of Week 1 until disease progression or unacceptable toxicity, whichever occurs first.
89232877|NCT04034095||Cohort 1: ADT alone/ ADT + Bicalutamide|Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade [CAB]) under routine clinical practice will be observed.
89232878|NCT04034095||Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide|Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.
89232879|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 1|Participants will receive guselkumab dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
89232880|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 2|Participants will receive guselkumab dose 2 IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
89232881|NCT04033445|Placebo Comparator|Induction Study 1: Placebo IV|Participants will receive matching placebo IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
89232882|NCT04033445|Experimental|Induction Study 2: Guselkumab IV|Participants will receive guselkumab IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
89232883|NCT04033445|Placebo Comparator|Induction Study 2: Placebo IV|Participants will receive matching placebo IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
89232884|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 1|Participants will receive guselkumab maintenance dose regimen 1 subcutaneously (SC) every 4 weeks (q4w).
89232885|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 2|Participants will receive guselkumab maintenance dose regimen 2 SC every 8 weeks (q8w).
89232886|NCT04033445|Placebo Comparator|Maintenance Study: Placebo SC|Participants will receive matching placebo SC q4w.
89232888|NCT04021706|Active Comparator|anamorelin|one 100 mg tablet daily, taken one hour before breakfast
89232889|NCT04021706|Placebo Comparator|microcrystaline cellulose|one identical appearing tablet daily, taken one hour before breakfast
89232890|NCT04020913||Short Stature Boys|Prepubertal boys with short stature defined as a height ≤-2 SDS with either GH deficiency (defined as peak GH responses to pharmacologic stimuli <10ng/ml) or idiopathic short stature (i.e., no identifiable pathology) will be studied pre and post 12 months of GH therapy.
89232891|NCT04020913||Normally Statured Boys|A group of 15 healthy, normally statured (between 10th- 90th %), age-matched boys not on Growth Hormone replacement, preferably siblings (although not exclusively), will be recruited to serve as healthy controls.
89232892|NCT04008797|Experimental|Dose Escalation Part: HCC: E7386 QD Subpart + Lenvatinib|Participants with hepatocellular carcinoma (HCC) will receive E7386 tablets, orally, QD for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386 tablets, orally, QD in combination with lenvatinib 8 milligram (mg) (participants with body weight of less than [<] 60 kg) or 12 mg (participants with body weight >=60 kg), capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
89232893|NCT04008797|Experimental|Dose Escalation Part: HCC: E7386 BID Subpart + Lenvatinib|Participants with HCC will receive E7386 tablets, orally, BID for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386 tablets, orally, BID in combination with lenvatinib 8 mg (participants with body weight of < 60 kg) or 12 mg (participants with body weight >=60 kg) capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
89232894|NCT04008797|Experimental|Dose Escalation Part: Other ST: E7386 QD Subpart + Lenvatinib|Participants with solid tumor (ST) (except for HCC) will receive E7386 tablets, alone orally, QD for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386 tablets, orally, QD in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
89232895|NCT04008797|Experimental|Dose Escalation Part: Other ST: E7386 BID Subpart + Lenvatinib|Participants with ST (except for HCC) will receive E7386 tablets, alone orally, BID for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386 tablets, orally, BID in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.
89232896|NCT04008797|Experimental|Dose Expansion Part: HCC Subpart: Lenvatinib Only|Participants with HCC will receive lenvatinib 8 mg (participants with body weight of <60 kg) or 12 mg (participants with body weight >=60 kg), capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
89232897|NCT04008797|Experimental|Dose Expansion Part: HCC Subpart: E7386 + Lenvatinib|Participants with HCC will receive lenvatinib 8 mg (participants with body weight of <60 kg) or 12 mg (participants with body weight >=60 kg), capsule, orally QD in combination with E7386 tablets, orally, BID in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program. E7386 dose will be determined from recommended dose level of the HCC BID Subpart in Dose Escalation Part.
89232898|NCT04008797|Experimental|Dose Expansion Part: CRC Subpart: E7386 + Lenvatinib|Participants with colorectal cancer (CRC) will receive E7386 tablets, orally, BID in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program. E7386 dose will be determined from recommended dose level of the ST BID Subpart in Dose Escalation Part.
89232899|NCT04008797|Experimental|Dose Expansion Part: EC Subpart: E7386 + Lenvatinib|Participants with endometrial cancer (EC) will receive E7386 tablets, orally, BID in combination with lenvatinib 14 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program. E7386 dose will be determined from recommended dose level of the ST BID Subpart in Dose Escalation Part.
89232900|NCT04000997||Failure group|Patients with a failure extubation
89232901|NCT04000997||Success group|Patients with a successful extubation
89232902|NCT03991936|Placebo Comparator|Placebo|Participants receive an intralesional injection of 0.1-0.2 mL of normal saline in one psoriatic fingernail once per 6 weeks until 24 weeks.
89232903|NCT03991936|Experimental|Triamcinolone Acetonide 2.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 2.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
89232904|NCT03991936|Experimental|Triamcinolone Acetonide 5.0 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 5.0 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
89232905|NCT03991936|Experimental|Triamcinolone Acetonide 7.5 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 7.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
89232906|NCT03991936|Experimental|Triamcinolone Acetonide 10 mg/mL|Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
89232908|NCT03983668|Experimental|CMP-001 plus pembrolizumab|Intratumoral administration of CMP-001 and intravenous administration of pembrolizumab
89232909|NCT03980483|Experimental|GSK3196165 90mg + MTX|Participants received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with methotrexate (MTX).
89232910|NCT03980483|Experimental|GSK3196165 150mg + MTX|Participants received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with MTX.
89232911|NCT03980483|Active Comparator|Tofacitinib 5mg + MTX|Participants received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with MTX plus placebo injection weekly to maintain the blind for 52 weeks.
89232912|NCT03980483|Placebo Comparator|Placebo + MTX and GSK3196165 90mg + MTX|Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with MTX until Week 52.
89232913|NCT03980483|Placebo Comparator|Placebo + MTX and GSK3196165 150mg + MTX|Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with MTX until Week 52.
89232914|NCT03980483|Placebo Comparator|Placebo + MTX and Tofacitinib 5mg + MTX|Participants received Placebo capsule weekly in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with MTX plus placebo injection to maintain the blind for 52 weeks.
89232915|NCT03972709|Experimental|Galegenimab Q4W|Participants will receive galegenimab every 4 weeks (Q4W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab injections.
89232916|NCT03972709|Sham Comparator|Sham Control Q4W|Participants will receive Sham-control Q4W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab injections.
89232917|NCT03972709|Experimental|Galegenimab Q8W|Participants will receive galegenimab every 8 weeks (Q8W). After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab injections.
89232918|NCT03972709|Sham Comparator|Sham Control Q8W|Participants will receive Sham-control Q8W. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab injections.
89232919|NCT03965143||3D talar group|Patients that will undergo a 3D custom talar augment
89232920|NCT03949647||1|Healthy males and females aged 18 years and older
89232921|NCT03939637|Experimental|Eltrombopag|Patients randomized to eltrombopag will be treated for 12 weeks, with the possibility to continue therapy for up to 1 year depending on response.
89232922|NCT03939637|Active Comparator|Standard first-line therapy|"Subjects randomized to the standard therapy arm will receive one of three treatments at the discretion of the treating physician. Patients who previously failed standard management prior to study entry must be treated with a different agent than their original failed agent. e.g. Patient who failed steroids could receive either IVIg or anti-D if randomized to the standard treatment arm.~Standard therapy will be administered as commercially available drug.~Investigator may choose amongst the following:~IVIg: IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)~Steroids: Prednisone/Prednisolone 4 mg/kg/day (Max 120 mg/day) x 4 days~Rho(D) Immune Globulin: Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)"
89232925|NCT03932253|Experimental|1a：0.2 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 6 mg，8mg, 12mg, 15mg.1b(NRAS),1b(NF1)|1a dose-escalation phase: 9 dose groups during the dose-escalation phase, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 6 mg,8mg, 12mg and 15mg orally, continuous once a day for 28 days a cycle. 1b dose-extension phase: 12mg orally,continuous once a day for 28 days a cycle.
89232926|NCT03923725|Experimental|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
89232927|NCT03923725|Active Comparator|artemether-lumefantrine+placebo (AL+PBO)|ACTs
89232928|NCT03923725|Experimental|Artesunate-mefloquine+Piperaquine (AS-MQ+PPQ)|Triple ACTs
89232929|NCT03923725|Active Comparator|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs
89232932|NCT03904147|Experimental|Randomized - Device Group|Subjects will undergo TriClipTM implantation and will continue to be managed on medical therapy, per physician discretion
89232933|NCT03904147|Active Comparator|Randomized - Control Group|Subjects will continue to be managed on medical therapy, per physician discretion
89232934|NCT03904147|Experimental|Single Arm Group|Subjects will receive the TriClip TM device and will continue to be managed on medical therapy, per physician discretion.
89232935|NCT03901963|Experimental|Daratumumab + Lenalidomide|Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
89232936|NCT03901963|Active Comparator|Lenalidomide|Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
88800030|NCT03960658|Experimental|Ketamine and PE|ketamine treatment followed by a standardized prolonged exposure session for the first 3 weeks; then, weekly prolonged exposure as usual.
88800031|NCT04580290||JewelACL + Autograft (Hybrid)|JewelACL + Autograft (Hybrid)
88800032|NCT04580290||JewelACL only|JewelACL only
88800033|NCT04617574||AEON Endostapler|Stapling performed with AEON Endostapler
88800034|NCT04617574||Endo GIA Reloads with Tri-Staple Technology|Stapling performed with Endo GIA Reloads with Tri-Staple Technology
88800035|NCT01005407|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
88800036|NCT01005407|Active Comparator|Engerix-B(1)|1.0 mL Engerix-B
88800037|NCT03633448|Experimental|Mucinex® 1 x 200 mg (10 mL)|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
88800038|NCT03633448|Experimental|Mucinex® 1 x 400 mg (20 mL)|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
88800039|NCT05313958|Experimental|treatment arm|"The patients in this arm will receive SCCLG-M5 2022 regimen for newly dignosed acute monocytic leukemia (M5) ,including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period and followed by three courses(HA1M, HA2E, HA3) in consolidation therapy prescribed as the NOPHO-AML 2004 protocol.~The targeted drugs sorafenib 200mg/m2/day orally is used for FLT3 positive acute monocytic leukemia until molecular biology remission for 2 years."
88800040|NCT03019679||Study group|Patients with polycystic ovary syndrome
88800041|NCT03019679||Control group|Patients without polycyctic ovary syndrome
88800042|NCT01006655|Placebo Comparator|placebo, adenosine challenge test|Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test,
88800043|NCT01006655|Active Comparator|Qvar, adenosine challenge test|Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day
88800044|NCT01006967|Active Comparator|ActiveStep|Subjects will use the ActiveStep treadmill as part of their physical therapy program for balance
88800045|NCT01006967|Active Comparator|Standard physical therapy|Subjects will receive a standard physical therapy program for gait and balance.
88800046|NCT03633526|Experimental|VX-659/TEZ/IVA|Participants who received VX-659 120 milligram (mg)/TEZ 50 mg/ IVA 75 mg as fixed-dose combination (FDC) in the morning and IVA 75 mg as a mono tablet in the evening in the triple combination (TC) treatment period.
88800047|NCT03017027|Experimental|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
88800048|NCT03017027|Other|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
88800049|NCT03016949|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
89232937|NCT03900598|Experimental|Part 1 (Dose Escalation): JNJ-67856633|Participants will receive JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent, or the investigator or sponsor decision. Subsequent dose levels will be assigned by the sponsor using an adaptive dose escalation strategy based on all available safety, pharmacokinetic (PK), and biomarker data.
89232938|NCT03900598|Experimental|Part 2 (Cohort Expansion): JNJ-67856633|Participants will receive JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
88800050|NCT03016949|Experimental|Group B|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
88800051|NCT03016949|Experimental|Group C|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
89232942|NCT03888040|Experimental|Blood Flow Restriction Training|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training with blood flow restriction.
89232943|NCT03888040|Experimental|Resistance Training Only|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training without blood flow restriction.
89232944|NCT03887702|Experimental|Group A (TAF, TDF, entecavir)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD immediately or within 42 days after initial dose of chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
89232945|NCT03887702|Experimental|Group B (TAF, TDF, entecavir)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD after HBV reactivation during chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
89232946|NCT03887702|Experimental|Group C (TAF, TDF, entecavir, usual care)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD at the discretion of the physician during usual care. Treatment continues for up to 6 months after discontinuation of usual care or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
89232950|NCT03866382|Experimental|Treatment (cabozantinib, nivolumab, ipilimumab)|Patients receive cabozantinib PO, nivolumab IV and ipilimumab IV while on study. Patients undergo CT scan, MRI, PET and bone scans throughout the study.
89232951|NCT03861273|Experimental|PF-06838435/ fidanacogene elaparvovec|
89232952|NCT03847610|Experimental|Healthy volunteer|
89232953|NCT03842189|Experimental|M281|
89232954|NCT03836417||Idiopathic interstitial pneumonias|Patients with idiopathic interstitial pneumonias undergoing surgical lung biopsy
89232955|NCT03796988|Experimental|Intervention arm|The donor area will be anesthetized with injected local anesthesia, harvested with the ART device, and bandaged with an occlusive dressing. The skin harvested will be placed on the recipient wound area. The area will be bandaged will a non-stick silicone dressing (covered by appropriate primary and secondary dressings) and left intact for 1-7 days.
89232958|NCT03774069|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.
89232959|NCT03774069|Active Comparator|Control group- medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team
89232960|NCT03767244|Experimental|Apalutamide + ADT|Participants will receive androgen deprivation therapy (ADT) plus oral administration of apalutamide 240 milligram (mg) (4 tablets of 60 mg each) daily in each cycle (each cycle of 28 days). Participants will receive six cycles of treatment, followed by radical prostatectomy (RP) with pelvic lymph node dissection (pLND), followed by an additional six cycles of treatment.
89232961|NCT03767244|Experimental|Placebo + ADT|Participants will receive ADT with oral administration of matching placebo treatment daily in each cycle (each cycle of 28 days). Participants will receive six cycles of placebo treatment, followed by RP with pLND, followed by an additional six cycles of placebo treatment.
89232962|NCT03762733||Patient Relatives|Biological relatives (1st-3rd degree) of participants with histologically confirmed malignancy
89232963|NCT03762733||Patients|Participants with histologically confirmed malignancy
88800052|NCT03016949|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
89232964|NCT03739827||1/Cohort 1|Subjects with a diagnosis of rare tumor (fewer than 15 cases in 100,000 people per year)
89232965|NCT03739827||2/Cohort 2|Relatives of subjects with a rare tumor who have a germline genetic variant that predispose to a rare solid tumor or a subject who has a germline genetic variant that predispose to a rare solid tumor
89232966|NCT03739827||3/Cohort 3|Relatives of subjects with a diagnosis of rare tumor that do NOT have known germline genetic variants that predispose to a rare solid tumor.
89232967|NCT03739827||4/ Cohort 4|Parents/guardians of children with a diagnosis of rare tumor participating in focus groups (if not enrolled in Cohorts 1, 2 or 3)
89232968|NCT03737955|Experimental|Treatment (gemtuzumab ozogamicin)|Patients receive gemtuzumab ozogamicin IV on days 1, 4, 7. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Responders and non-responders, without significant adverse events during the first course, may receive a second course of gemtuzumab ozogamicin within 60 days after course 1.
89232969|NCT03727789|Experimental|Treatment (CBL0137)|Patients receive FACT complex-targeting curaxin CBL0137 IA over 15 minutes.
89232971|NCT03705078|Other|early TIPS|Transjugular portosytemic shunt within 72h
89232972|NCT03705078|Other|Glue obliteration|glue obliteration repeated sessions
89232973|NCT03685578||Mechanical Thrombectomy|EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
89232974|NCT03672630|Active Comparator|2-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
88800053|NCT03016949|Experimental|Group E|3 doses IPV IM at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
88800054|NCT03016949|Experimental|Group F|3 doses f-IPV ID at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
88800055|NCT04502056|Experimental|AMA RI - B- B - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color.
88800056|NCT04502056|Experimental|AMA RI - B - B - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
88800057|NCT04502056|Experimental|AMA RI - W - W - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
88800058|NCT04502056|Experimental|AMA RI - W - W - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
88800059|NCT04502056|Experimental|AMA DP - B- B - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color .
88800060|NCT04502056|Experimental|AMA DP - B- B - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
88800061|NCT04502056|Experimental|AMA DP - W- W - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
89232975|NCT03672630|Active Comparator|3-drug regimen|This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg + rifampin 600 mg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
89232976|NCT03655223||Newborn infants born in North Carolina|All newborn infants in North Carolina will have the opportunity to participate in Early Check. Those who screen positive for the conditions identified in the study will be subject to confirmatory testing.
89232977|NCT03655223||Birthing Mothers in North Carolina|All birthing mothers in North Carolina will have the opportunity to participate in Early Check.
89232978|NCT03652753|Experimental|N-acetylcysteine (NAC)|Injection of N-acetylcysteine at the time of external fixation
89232979|NCT03652753|Placebo Comparator|Saline|Injection of saline at the time of external fixation
89232980|NCT03652389|Experimental|MJS DIABETES|will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
89232981|NCT03652389|Active Comparator|Usual Care|Standard Diabetes Treatment
89232982|NCT03652064|Active Comparator|Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd|Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.
89232983|NCT03652064|Experimental|Daratumumab + VRd (D-VRd) and DRd|Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.
89232984|NCT03648268|Active Comparator|Active DLPFC rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC at 80% of active motor threshold.
88800062|NCT04502056|Experimental|AMA DP - W- W - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
88800063|NCT04502056|Placebo Comparator|Control: AMA RI - B - B|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA"
88800064|NCT04502056|Placebo Comparator|Control: AMA RI - W - W|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA"
88800065|NCT04502056|Placebo Comparator|Control: AMA DP - B - B|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
88800066|NCT04502056|Placebo Comparator|Control: AMA DP - W - W|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
88800067|NCT05502432|Active Comparator|Active Repetitive Transcranial Magnetic Stimulation(rTMS)|15 days with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) with active mood.
88800068|NCT05502432|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation(rTMS)|15 days with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) with sham mood.
88800069|NCT05314894|Experimental|initiative group|The first session will be right after the pre-test, the second session will be 15 days after the first session, and the last session will be 15 days after the second session. After the training is over, a total of 40 messages will be sent to the students in the initiative group, taking into account the factors that affect, strengthen and activate the main communication via the WhatsApp program.
88800070|NCT05314894|No Intervention|control group|No intervention will be made
88800071|NCT01007591|Active Comparator|LEO 80190 ointment|
88800072|NCT01007591|Active Comparator|Hydrocortisone 10 mg/g ointment|
88800073|NCT03019601|Experimental|Group education|Non pregnant HIV+ mothers were exposed to a structured educational intervention on family planning facilitated by Peer Champions.
88800074|NCT03019523|Placebo Comparator|Sugar Pill|Maltodextrin (~2 grams to match weight of active treatment) placebo pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
88800075|NCT03019523|Active Comparator|Caffeine Blend|75 mg caffeine, 75 mg theanine, and 2g tyrosine pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
88800076|NCT01008059|Experimental|Alfentanil|Alfentanil (0.5-1 mg IV bolus) followed 3 hours later or simultaneously by 1-4 mg oral deuterium-labeled (d3) alfentanil on each study visit.
88800077|NCT03634306|Active Comparator|ARM 1|Laparoscopic hysterectomy with use of the Ultravision System
89119229|NCT05648279|Experimental|Personalized hemodynamic management (intervention)|"In patients assigned to personalized hemodynamic management, intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index measured the day before surgery using a predefined treatment algorithm.~Preoperative baseline cardiac index will be determined at least one day before surgery with the patient being awake and resting in supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2).~Mean arterial blood pressure will be maintained above 65 mmHg. The study intervention will start at the beginning of surgery and will end at the end of surgery."
89119230|NCT05646680|Other|two step adnexectomy|Patients planned for unilateral or bilateral adnexectomy (removal of ovary and salpinx) will have their adnexectomy performed in two steps in the same surgical episode: first the salpingectomy (removal of the salpinx), then the oophorectomy (the removal of the ovary).
89232985|NCT03648268|Sham Comparator|Sham DLPFC rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the right DLPFC
89232986|NCT03648268|Active Comparator|Active cerebellum rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum at 100% of active motor threshold.
89232987|NCT03648268|Sham Comparator|Sham cerebellum rTMS|Sham repetitive Transcranial Magnetic Stimulation (rTMS) with iTBS pattern to the cerebellum
89232988|NCT03642639|Other|Coils|MICRUSFRAME and GALAXY coils
89232989|NCT03634488|Experimental|SCD - Ready-to-use therapeutic food and Hydroxyurea|50-75 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive ready-to-use therapeutic food and hydroxyurea (20mg/kg/day)
89232990|NCT03634488|Placebo Comparator|SCD - Ready-to-use therapeutic food alone|50-75 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive ready-to-use therapeutic food alone
89232991|NCT03634488|Placebo Comparator|Non-SCD siblings with severe malnutrition|To decrease the likelihood of sharing limited food resources, we will enroll up to 100 malnourished non-SCD siblings.
89232992|NCT03633058|Experimental|0.75 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
89232993|NCT03633058|Experimental|1.5 mg/kg|ketamine will be dosed orally twice daily for 5 days at 0.75 mg/kg, in addition to 5 days of placebo
88800078|NCT03634306|Placebo Comparator|ARM 2|Laparoscopic Hysterectomy per Standard of Care/no Ultravision System
88800079|NCT03634306|Active Comparator|ARM 3|Laparoscopic myomectomy with use of the Ultravision System.
88800080|NCT01008605|Experimental|Caverject Impulse|representative users
88800081|NCT00377026|Experimental|lifestyle|participants receive lifestyle intervention
88800082|NCT01009619|Experimental|Azithromycin|250 mg daily for 5 days, followed by 250 mg three times a week (Mon.-Wed.-Fri.) until the end of study
88800083|NCT01009619|Placebo Comparator|Placebo|PLacebo daily for 5 days, followed by placebo three times a week (Mon.-Wed.-Fri.) until end of study.
88800084|NCT01010009|Experimental|Resveratrol 250mg|
88800085|NCT01010009|Experimental|Resveratrol 500mg|
88800086|NCT01010009|Placebo Comparator|Placebo|
88800087|NCT04467424|Experimental|Pediatric anesthesia with ketofol|ketamine, propofol
88800088|NCT04467424|Experimental|Pediatric anesthesia with ketofol plus lidocaine|ketamine, propofol, lidocaine
88800089|NCT03016715|Experimental|Treatment|Sirolimus, 2% topical ointment will be used during randomization
89232994|NCT03610802||Biological relatives|Biological relative (mother, father, siblings, children, grandparents, aunts, uncles, or first cousins) of patient, with no clinical evidence of having a PID.
89232995|NCT03610802||Patients|Patients with PID, which may be defined by laboratory and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity.
89232996|NCT03605368|Active Comparator|Phase IIA - in-person|Participants will be assigned to either a) a virtual reality-based intervention or b) an video modeling intervention both aimed at improving police interaction skills. Assessments of police skills will occur before intervention and after intervention (three sessions of each).
89232997|NCT03605368|Active Comparator|Phase IIB - remote|Participants will be assigned to either a) three sessions of virtual reality-based intervention aimed at improving police interaction skills or b) no intervention. Assessments of police skills will occur before intervention, after intervention, and 3-4 weeks follow up in the intervention group and at comparable timepoints in the no intervention group.
88800090|NCT03016715|Placebo Comparator|Vehicle|A placebo topical ointment will be used during randomization.
88800091|NCT03637348|Other|TrueTear|Use of TrueTear device to stimulate tear production
88800092|NCT00377104|Experimental|Treatment (chemotherapy)|Patients receive alvocidib IV over 30 minutes (loading dose), followed by alvocidib IV over 4 hours on days 1, 8, and 15. Treatment repeats every 5 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
88800093|NCT03016793|Experimental|puerarin and β- tricalcium phosphate|"purabone (puerarin) is an osteoinductive bone grafts used to augment bone healing.~β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing"
88800094|NCT03016793|Active Comparator|β- tricalcium phosphate alone|β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing
88800095|NCT03016637|Experimental|EUS biopsy|EUS guided SharkCore (TM) biopsy of pancreatic lesions suspected of malignancy
88800096|NCT03928522|Active Comparator|Pre-mixed tobramycin|patients will receive pre-mixed tobramycin cement
88800097|NCT03928522|Active Comparator|hand mixed tobramycin|patients will receive hand mixed tobramycin cement
88800098|NCT03928522|Active Comparator|hand mixed vancomycin|patients will receive hand mixed vancomycin cement
88800099|NCT03928522|Experimental|hand-mixed vancomycin and tobramycin|patients will receive hand mixed vancomycin and tobramycin
88800100|NCT01010399|Experimental|Boosted Lexiva with Lovaza|
88800101|NCT03638908|Other|Fluoxetine|"Dosing will be~Week 1-4: 20 mg daily~Week 5-8: 40 mg daily~Week 9-12: 60 mg daily~Week 13-24: 80 mg daily"
88800102|NCT01041781|Experimental|Arm I|Patients receive gemcitabine hydrochloride* IV on days 1 and 8 OR pemetrexed disodium* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.
88800103|NCT01041781|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride* OR pemetrexed disodium* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.
89119232|NCT05595213|Experimental|Group 1 Wrist Cooling Devices|Participants randomized into Group 1 will be provided two wrist cooling devices that are worn like watches. Group 1 participants will be instructed to first use the skin cooling watch device with a cooling plate for 2 weeks and then stop using it and switch to using the watch device that activates the fan without the cooling plate for 2 weeks.
89119233|NCT05595213|Experimental|Group 2 Wrist Cooling Devices|Participants randomized into Group 2 will be provided two wrist cooling devices that are worn like watches. Group 2 participants will be instructed to first use the cooling watch device that activates the fan without the cooling plate for 2 weeks and then stop using it and switch to using the skin cooling watch device with the cooling plate.
89119234|NCT05594875|Experimental|SHR-1921|
89119235|NCT05591625|No Intervention|Control|Participants who exhibit symptoms of PTSD and are randomised to the control group, will receive usual care offered by their hospital.
89119236|NCT05591625|Experimental|Eye Movement Desensitisation and Reprocessing|Participants who exhibit symptoms of PTSD and are randomised to the intervention group, will receive EMDR plus usual care offered by their hospital. EMDR will be delivered by trained and accredited psychological therapists, employed by National Health Service community mental health teams.
89119237|NCT05591625|No Intervention|Observation|Participants who do not exhibit symptoms of PTSD will receive usual care offered by their hospital and repeat the psychological assessment at 12-months post-hospital discharge.
89119238|NCT05590949||Post- menopausal breast cancer patients|Participants are post- menopausal with a breast cancer diagnosis who received at least 2 doses of denosumab, and then discontinued therapy, and discontinued Aromatase Inhibitors/AI prior to or within 6 months of stopping denosumab
89119239|NCT05581667|Experimental|PIR Group|PIR Group participants will be given a one-time PIR Technique for each of the neck and upper back muscles, right after the classical Swedish massage is applied to the cervical region and upper back area.
89119240|NCT05581667|Experimental|Control Group|Control group participants will receive classical Swedish massage only to the cervical and upper thoracic region.
89119241|NCT05573646|Experimental|Dual-task training|Dual-task training group
89119242|NCT05573646|Other|Attention control|Attention control group
89119243|NCT05566301||Clopidogrel|Patients who undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel and whose aggregometry test shows correct response to the effect of clopidogrel
89119244|NCT05566301||Ticagrelor|Patients who undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel and whose aggregometry test shows incorrect response to the effect of clopidogrel, therefore therapy is switched to ASA + ticagrelor
89119245|NCT05563090||0HEA|Healthy or sub-healthy subject without clinically diagnosed chronic conditions such as diabetes, hypertension or dyslipidemia
89119246|NCT05563090||1PRE|Prediabetes with IFG of FPG 6.1-6.9 mmol/L, and/or IGT with 2hPG of 7.8-11.0 mmol/L
89119247|NCT05563090||2DIA|Diabetes with FPG of ≥ 7.0 mmol/L, 2hPG of ≥ 11.1mmol, or HbA1c of > 6.5%
89119248|NCT05563090||3PREHD|Prediabetes with hypertension and dyslipidemia
89119249|NCT05563090||4DIAHD|Diabetes with hypertension and dyslipidemia
89119250|NCT05553704|No Intervention|Control Group|this group will take mesalamine 1 gm three times daily for 6 months
89119251|NCT05553704|Active Comparator|metformin group|this group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily for 6 months
89119252|NCT05548764||Prevention Bundles|Patients in which prevention bundles for SSIs have been implemented.
89119253|NCT05548764||No Prevention Bundles|Patients in which prevention bundles for SSIs have not been implemented.
89119254|NCT05545280|Active Comparator|Neostigmine|Reversal of Neuromuscular Block by Neostigmine.
89119255|NCT05545280|Active Comparator|Sugammadex|Reversal of Neuromuscular Block by Sugammadex.
89119256|NCT05509621|Experimental|Supine position|To determine the effect of supine position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
89119257|NCT05509621|Experimental|Prone position|To determine the effect of prone position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
89119258|NCT05509621|Experimental|Left lateral position|To determine the effect of left lateral position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
89119259|NCT05509621|Experimental|Right lateral position|To determine the effect of right lateral position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
89119260|NCT05509621|Experimental|Quarter prone position|To determine the effect of quarter prone position used during daily routine care in the neonatal intensive care unit on physiological parameters (oxygen saturation, heart rate, respiratory rate).
89119261|NCT05498766||Huaier group|The participants volunteering to take Huaier granule will be assigned to the Huaier group.
89119262|NCT05498766||Control group|The participants volunteering to take SOX or XELOX will be assigned to the control group.
89233002|NCT03598257|Experimental|Group I (olaparib, radiation therapy)|Patients receive olaparib PO BID the day before standard RT commences (Day 0) and throughout the RT course until the last day of RT administration. Olaparib is also continued on weekends (routine days without RT) throughout the RT course. Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.
89233003|NCT03598257|Active Comparator|Group II (radiation therapy)|Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.
89233004|NCT03596645|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab through Week 50. Doses will be based on body surface area. Following the Week 54 evaluations (end of main pivotal study) participants who are benefiting from golimumab at the discretion of the investigator may continue to receive SC golimumab in an extension period until end of study.
88800104|NCT01010477|Experimental|Nicotine Nasal Spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. . Nasal spray will be used from the TQD through the end of Week 20.
88800105|NCT01010477|Placebo Comparator|Placebo nasal spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Nasal spray will be used from the TQD through the end of Week 20.
88800106|NCT03921190|Active Comparator|Open-mouth|Patients receiving maxillary buccal infiltration anesthesia (MBIA) with their mouth wide open
88800107|NCT03921190|Experimental|Closed-mouth|Patients receiving MBIA using a closed-mouth technique
88800108|NCT00953849|Experimental|Arm 1: Celecoxib|Celecoxib treatment prior to surgery
88800109|NCT00953849|Experimental|Arm 2: Calcitriol|Treatment with Calcitriol prior to surgery
88800110|NCT00953849|Experimental|Arm 3: Celecoxib plus Calcitriol|Treatment with Celecoxib plus Calcitriol prior to surgery.
88800111|NCT00953849|No Intervention|Arm 4: No Treatment|no treatment prior to surgery
88800112|NCT03911752||People with Acquired Brain Injury|People with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=8).
88800113|NCT03911752||Partners of people with Acquired Brain Injury|Partners of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
89233005|NCT03596645|Experimental|Group 2: Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
89233006|NCT03593070|Experimental|CGMI-V|Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
88800114|NCT03911752||Relatives of people with Acquired Brain Injury|Relatives of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
88800115|NCT01010555|Active Comparator|lotrafilcon B|Lotrafilcon B contact lens randomly assigned to one eye, with balafilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
88800116|NCT01010555|Active Comparator|balafilcon A|Balafilcon A contact lens randomly assigned to one eye, with lotrafilcon B contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
88800117|NCT01010555|Active Comparator|senofilcon A|Senofilcon A contact lens randomly assigned to one eye, with enfilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
88800118|NCT01010555|Active Comparator|enfilcon A|Enfilcon A contact lens randomly assigned to one eye, with senofilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
88800119|NCT03019211|Experimental|Hydrotherapy|Exercise performed in an aquatic environment. The participants will perform static/dynamic exercises (balance and resistance training) in an aquatic environment. Training volume and intensity we will increase systematically over 12 weeks.
88800120|NCT03019211|Active Comparator|Control|The participants will perform exercises (balance and resistance training) like hydrotherapy group but out of the aquatic environment, during a 12 weeks training period (3sessions/week). Training volume and intensity we will increase systematically over 12 weeks.
88800121|NCT04425850||IVER+|Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
88800122|NCT04425850||IVER-|Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.
88800123|NCT01011179|Experimental|Internet-based JIA Self-Management Program|
88800124|NCT01011179|Active Comparator|Attention Control Group|
88800125|NCT03639766|Experimental|Abobotulinum toxin A|Injection of 300 units of abobotulinum toxin A in 10 ml of non-bacteriostatic normal saline to chosen hand.
88800126|NCT03639766|Placebo Comparator|Saline solution|Injection of 10 ml of non-bacteriostatic normal saline to chosen hand.
88800127|NCT03016559|Other|releasing muscle|The physical therapist placed thumbs on the quadratus lumborum to release muscle.
88800128|NCT03641716|Experimental|Mealtime PREP Intervention|Parents of young children will receive 6 weekly sessions, each lasting approximately one-hour, in the home environment. An occupational therapy clinician will deliver the Mealtime PREP intervention to the family.
88800129|NCT05307445|Active Comparator|peri-implant mucositis treated with standard of care-professional mechanical debridement|patients with peri-implant mucositis are treated with standard of care, i.e. professional mechanical debridement
88800130|NCT05307445|Experimental|peri-implant mucositis treated with photobiomodulation in addition to standard treatment|patients with peri-implant mucositis are treated with photobiomodulation in addition to standard treatment
88800131|NCT01042795|Experimental|Continuous Daily Dosing of Sunitinib|
88800132|NCT03644212|Active Comparator|Vitamin D treatment|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
88800133|NCT03644212|No Intervention|Non treated|Sixteen vitamin D deficient women (6 with PCOS and 10 without PCOS) were not supplemented vitamin D3. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
88800134|NCT01043653||Maryland Assessment of Recovery in Serious Mental Illness|Individuals with serious mental illness treated in mental health outpatient programs
88800135|NCT03906448|Experimental|Astrocytoma Patients|Patients newly diagnosed with Grade II and III astrocytoma.
88800136|NCT03906448|No Intervention|Control Arm|Data collection from medical record only
88800137|NCT03012919|Other|active decision support system (GDT protocol)|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
88800138|NCT03897634|Experimental|Experiences Hearing Aid user|Single arm study, all participants in this arm. Participants will be experienced hearing aid users.
88800139|NCT01011413|Active Comparator|600 milligram (mg) Efavirenz|Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
88800140|NCT01011413|Experimental|400mg Efavirenz|Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
88800141|NCT03889444||OZURDEX®|Participants with diabetic macular edema prescribed dexamethasone intravitreal implant, 0.7 mg (OZURDEX®) as per routine clinical practice.
88800142|NCT04352647||female athletes over the age of 18|the presence or absence of urinary incontinence in female athletes is studied. In addition, the quality of life and other aspects are evaluated
88800143|NCT01104025|Experimental|Induction Therapy|ATG, rabbit: intravenous, 5 mg/kg/dose, 5 consecutive days Dexamethasone: intravenous, 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days Etoposide: intravenous, 150 mg/m2 weekly, starting 7 days after first dose of Thymoglobulin Methotrexate and hydrocortisone: intrathecal to patients with central nervous system involvement, age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg, on day 7, 14, 21 and 42
88800144|NCT03649750|Experimental|Treatment A: Mucinex® 600 mg (fast)|Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose
88800145|NCT03649750|Experimental|Treatment B: Mucinex® 600 mg (fed)|Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration
88800146|NCT01104103|Experimental|BOA(R)|Nurse or paramedic uses the BOA(R)-Constricting IV Band to attempt placement of an upper extremity IV in an adult
88800147|NCT01104103|Active Comparator|Standard care|Nurse or paramedic uses standard IV starting technique in the upper extremity of adults
88800148|NCT04343092|Experimental|Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)|Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily + azithromycin 500mg daily
88800149|NCT01105117|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
88800150|NCT01105117|Active Comparator|2|Flolan®
88800151|NCT03888274|Experimental|Active|
88800152|NCT03650842|Experimental|Laparoscopic pyloromyotomy|Infants undergoing laparoscopic pyloromyotomy.
88800153|NCT01044589|Experimental|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft
88800154|NCT01044589|Active Comparator|Overlapping Sphincter Repair|Control
88800155|NCT03885154|Active Comparator|Valproic Acid|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
88800156|NCT03885154|Active Comparator|Dihydroergotamine|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
88800157|NCT03885154|Active Comparator|Cross-Over to Dihydroergotamine|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
88800158|NCT03885154|Active Comparator|Cross-Over to Valproic Acid|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
88800159|NCT01106833|Active Comparator|calcineurin inhibitor|Sirolimus + calcineurin inhibitor + prednisone
88800160|NCT01106833|Experimental|Sirolimus and prednisone|Sirolimus + prednisone
88800161|NCT00957047|Experimental|ESL 400 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400 mg tablets for Part I
88800162|NCT00957047|Experimental|ESL 800 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 800-mg tablets for Part I
89233007|NCT03593070|No Intervention|Minimal Treatment (MT)|Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.
89233008|NCT03581318||Assessing Gadolinium deposition within the brain in healthy and patient subjects|Both healthy subjects and patient subjects who have previously undergone MRI and received gadolinium.
89233009|NCT03581318||Child Patient or Healthy Child|Healthy children will be used as controls for children with cardiac disease. Child patient will undergo MRI scans.
88800163|NCT00957047|Experimental|ESL 1200 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400-mg and 800-mg tablets for Part I
88800164|NCT00957047|Placebo Comparator|placebo|Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied
88800165|NCT00957047|Experimental|ESL - Part II|All patients in Part II (Open-label Extension ) received ESL on an open-label basis, starting at 800 mg once daily.
88800166|NCT00957359|Experimental|Psilocybin|Drug intervention
88800167|NCT00957359|Active Comparator|Niacin|Active control
88800168|NCT03013777|Experimental|Cognitive behavioral therapy (CBT)|The patient would participate in eight forty-five minute sessions of CBT with a mental health therapist. Cognitive behavioral therapy (CBT), defined as a program of interventions that utilize education to teach relaxation, healthy coping skills, stress management, assertiveness training in order to help the individual identify and correct maladaptive beliefs in combination with education to help practice symptom reduction and improve quality of life and function.
88800169|NCT03013699|Active Comparator|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
88800170|NCT03013699|Experimental|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
88800171|NCT03880474|Experimental|MVA-NP+M1|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.)
88800172|NCT03880474|Placebo Comparator|Saline Placebo|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)
88800173|NCT01045057|Experimental|Puncture Set and Flexible Protector|Provox Vega Puncture Set is used to create the primary puncture and insert the prosthesis during total laryngectomy
88800174|NCT00957593|Active Comparator|Oxytocin|Continuation of oxytocin per protocol once the patient reaches active labor
88800175|NCT00957593|Active Comparator|Oxytocin discontinuation|Oxytocin will be stopped once the patient reaches active labor
88800176|NCT00957671|Experimental|Human Growth Hormone|recombinant human growth hormone (rhGH) self administered daily for one year
88800177|NCT04322968|Experimental|Chronic pain with PTSD+IV ketamine infusion|
88800178|NCT04322968|Active Comparator|Chronic pain with PTSD+IV ketorolac infusion|
88800179|NCT04322968|Experimental|Chronic pain without PTSD+IV ketamine infusion|
88800180|NCT04322968|Active Comparator|Chronic pain without PTSD+IV ketorolac infusion|
88800181|NCT01108003|Experimental|Arm I|Patients receive oral broccoli sprout extract once daily on days 1-14 in the absence of disease progression or unacceptable toxicity.
88800182|NCT01108003|Placebo Comparator|Arm 2|Patients receive mango juice alone.
88800183|NCT03018899|Experimental|paravertebral block|patients received ultrasound guided two-segment paravertebral block for percutaneous nephrolithotomy
88800184|NCT03018899|Active Comparator|Epidural|patients received thoracic epidural anesthesia for percutaneous nephrolithotomy
88800185|NCT01108081|Experimental|Arm 1|Physical activity
88800186|NCT01108081|Experimental|Arm 2|Diet
88800187|NCT01108081|Active Comparator|Arm 3|Health education
88800188|NCT01108081|Experimental|Arm 4|Combined physical activity and diet
88800189|NCT00958919|Experimental|naloxone|
88800190|NCT00958919|Placebo Comparator|normal saline|
88800191|NCT01045135||first time delivery|Women giving birth to their first child
89233010|NCT03581318||Healthy Volunteers|Subjects will be used as controls for adults with cardiac disease.
88800192|NCT04323592||Exposed to Methylprednisolone|Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.
88800193|NCT04323592||Non-exposed to Methylprednisolone|Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.
88800194|NCT04353245||Arm treatment (HCQ + Azithro)|Participants that used HCQ + Azithro in their treatment for COVID19
88800195|NCT04353245||Arm control (without HCQ + Azithro)|Participants that did not used HCQ + Azithro in their treatment for COVID19
88800196|NCT01047241|Experimental|Intranasal sufentanil/ketamine|Intranasal combination of sufentanil and ketamine. Dose of sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.
88800197|NCT03651856|Experimental|Atomoxetine|Atomoxetine 40mg daily for 2 weeks uptitration Atomoxetine 40mg BID for 4 weeks Atomoxetine 40mg daily for 1 week weaning off
88800198|NCT01012661|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face).
89233011|NCT03581318||Research Patients Cardiac and Non Cardiac|Adults with cardiac disease that will undergo MRI scans.
89233012|NCT03573648|Active Comparator|Endocrine Therapy|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
88800199|NCT01012661|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face.
88800200|NCT05298943|Other|Subjects with 4 walking situations|
88800201|NCT04325542|Other|HBSAG positive with rapid test|Newborns from woman who are positive with HBSAG rapid test got WHO recommended HBV vaccination at birth to avoid HBV transmission
88800202|NCT04353323||Covid area|
88800203|NCT04353323||Non-Covid area|
88800204|NCT05289583||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
88800205|NCT03016481|Active Comparator|the Community Health Worker -Personalized Support for Progress|Patients will work with a Community Health Worker (CHW) to complete a prioritization tool and meet as needed over the course of the next 6 months to navigate services and overcome barriers. In addition, patients will receive referrals to other professionals based on their prioritization and meet with the CHW at the time and place of their choice.
88800206|NCT03016481|Active Comparator|Care as Usual- Social Worker|Patients in the Care as Usual- Social Worker (CAU-SW) arm, will do intake with a social worker, who follows hospital procedures for intake and referrals, does a needs assessment, and offers safety planning in referral.
88800207|NCT02246803|Active Comparator|CABG+pulmonary vein isolation|CABG+pulmonary vein isolation procedure
88800208|NCT02246803|Active Comparator|Isolated CABG|Isolated CABG procedure
88800209|NCT02245919|Experimental|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
88800210|NCT03655444|Experimental|Phase I: Abemaciclib + Nivolumab|"Abemaciclib (150 mg) will be administered orally twice per day (with or without food) on Days 1 through 28 of every 4-week cycle~Nivolumab 480 mg will be given intravenously (IV) over 30 minutes on Day 1 of every 4-week cycle."
88800211|NCT03655444|Experimental|Phase II: Abemaciclib + Nivolumab|"Phase II Lead-in: Patients will be treated with abemaciclib monotherapy at the recommended phase II dose (150 mg) on Day -7 through Day -1 prior to starting Cycle 1 with the combination of abemaciclib and nivolumab. Patients will proceed directly from Day -1 to Cycle 1 Day 1 of combination abemaciclib + nivolumab, there is not a Day 0.~Patients will be treated with abemaciclib at the RP2D (150 mg) (Days 1 through 28) + nivolumab (480 mg, Day 1) of each 4-week cycle."
88800212|NCT03018977|Active Comparator|Sedative weaning protocol|We create the new sedative weaning protocol and then use the sedative weaning protocol.
88800213|NCT03018977|Placebo Comparator|Usual Care|no use sedative weaning protocol. Sedative or/and analgesic medications are adjusted base on physician
88800214|NCT03018821|Active Comparator|Standard CMF|"Standard Chinese medical formulas (CMF) for the corresponding TCM syndromes, plus an anti-virus treatment of western drugs (such as Entecavir or Tenofovir).~Yinchengao Decoction plus Ganlu Detoxification Pill for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao~Chaihu Shugan San for the TCM syndrome: Liver depression and qi stagnation~Xiaoyao powder for the TCM syndrome: Stagnation of liver qi and spleen deficiency.~Yiguan Decoction for the TCM syndrome: Yin deficiency of liver and kidney~Fuzilizhong Decoction plus Jinkui Shenqi Bolus for the TCM syndrome: Yang deficiency of spleen and kidney~Ge Xia Zhu Yu Decoction for the TCM syndrome: Internal blood stasis"
89119263|NCT05460169|Active Comparator|Immediate Renal Denervation Group (I-RDN-group)|Patients are randomized into (immediate) I-RDN-group and (delayed) D-RDN-group, respectively. All subjects in the I-RDN-group will undergo a diagnostic, renal angiogram immediately (based on clinical grounds to rule out renal artery stenosis), which should be per Institutional practice via femoral artery access. Renal Denervation procedure will be applied using the Paradise® Renal Denervation System. The Paradise® Renal Denervation System is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
89119264|NCT05460169|Other|Delayed Renal Denervation Group (D-RDN-group)|3 months after randomization, patients in the (delayed) D-RDN-group will undergo renal denervation procedure after undergoing a diagnostic, renal angiogram and will be followed for additional 36 months.
89119265|NCT05454852||Participants|Adult patients within 6 months of ART initiation or re-initiation
89119266|NCT05454839||Participants|Adult patients within 6 months of ART initiation or re-initiation
89119267|NCT05446545||ND-EOC or platinum-sensitive rEOC|"Newly diagnosed patients with advanced EOC (ND-EOC) who are eligible for radical surgery.~Patients relapsed from platinum-based therapy (rEOC) who are eligible for secondary cytoreductive surgery."
89119268|NCT05420662|Experimental|Vaginal Manipulator Group|In this group of patients, abdominal hysterectomy surgery will be performed with the vaginal manipulator. After cutting and suturing uterine arteries, cardinal and sacrouterine ligaments are preserved by using a vaginal manipulator. The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point of the vagina.
89119269|NCT05420662|Active Comparator|Classical Abdominal Hysterectomy Group|In this group of patients, abdominal hysterectomy surgery will be performed in a conventional way, by cutting the cardinal and sacrouterine ligaments.
89119270|NCT05393713|Experimental|Treatment (STI-3031)|Patients receive STI-3031 intra-lymphatically via the DoseConnect device over 1-8 hours QW on days 1, 8, 15, 22, 29, and 36 of cycle 1, and Q2W on days 1, 15, and 29 of cycle 2. Treatment repeats every 42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR at the end of cycle 2 receive 1-2 additional cycles in the absence of disease progression or unacceptable toxicity. Patients with PR or SD at the end of cycle 2 continue treatment for a total of 9 cycles in the absence of disease progression or unacceptable toxicity.
89119271|NCT05373342||iCount Device|A novel external device which can count the swabs and surgical tampons used during childbirth in an objective and validated manner.
89119272|NCT05373342||User Feedback Survey|"Feedback will be taken from 20 users including midwives/ doctors.~Users will be emailed an online survey or given the same survey as a printout to complete.~All 20 users will also then also be approached to have a semi-structured interview.~10 of the users who first express interest will be interviewed."
89119273|NCT05344066|Active Comparator|Best NHS Care|Best National Health Service (NHS) Care
88800215|NCT03018821|Experimental|Advanced CMF|"Advanced TCM formulas for corresponding TCM syndromes provided by famous TCM doctors who were national wide known in China, plus an anti-virus western drugs (such as Entecavir or Tenofovir).~Taohong Huazhuo Decoction for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao~Soothe the liver and regulate qi Decoction for the TCM syndrome: Liver depression and qi stagnation~Supplemented Ganbi Decoction for the TCM syndrome: Stagnation of liver qi and spleen deficiency.~Supplemented Zimu Dan for the TCM syndrome: Yin deficiency of liver and kidney~Guifu Erxian Decoction for the TCM syndrome: Yang deficiency of spleen and kidney~Supplemented Ganji Decoction for the TCM syndrome: Internal blood stasis"
88800216|NCT03018821|Experimental|Pure Entecavir or Tenofovir|Use an anti-virus western drug alone (such as Entecavir or Tenofovir).
88800217|NCT04322500|Other|Group A: conservative|conservative treatment
88800218|NCT04322500|Experimental|Group B: probiotics|in addition to the conservative treatment they receive a probiotics mixture (Streptococcus thermophilus ST10, Lactococcus lactis LLCO2 and Lactobacillus delbrueckii subsp. bulgaricus LDB01)
88800219|NCT01014455|Experimental|CO reminder|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
88800220|NCT01014455|Placebo Comparator|no CO reminder|a brief intervention that recommends fasting but does not mention that CO will be checked
88800221|NCT01047475|Active Comparator|MB-6+FOLFOX4|MB-6 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
88800222|NCT01047475|Placebo Comparator|Placebo+FOLFOX4|Placebo, 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
88800223|NCT03877432|Experimental|Dermatome stimulation|Check the effect of improving the function of bladder storage and bladder capacity before and after dermatome stimulation.
88800224|NCT03012451|Experimental|Advancing Adolescents|Received structured eight-week psychosocial sessions
88800225|NCT03012451|No Intervention|Control|Controls wait-listed for the intervention, matched for age and urban residence
88800226|NCT01047709|Experimental|positional therapy|Avoidance of supine positioning.
88800227|NCT01047709|No Intervention|Control|Position ad lib.
88800228|NCT03866434|Experimental|SPD422 + Omeprazole|Participants will receive 1 milligram (mg) of SPD422 (Anagrelide hydrochloride) (2*0.5 mg) capsule orally on Day 1 in fasted state (10 hours prior to and until 4 hours following administration of anagrelide), followed by 40 mg of Omeprazole capsule orally once daily (prior to breakfast) on Days 2 to Day 7, followed by 1 mg of Anagrelide in fasted state in combination with Omeprazole 40 mg on Day 8.
89119274|NCT05344066|Experimental|Intermittent Low Energy Diet|Intermittent Low Energy Diet
89119275|NCT05337540|Experimental|EVI-01 - low dose|4 mL, one single EVI-01 intra-articular injection
89119276|NCT05337540|Experimental|EVI-01 - high dose|6 mL, one single EVI-01 intra-articular injection
89119277|NCT05337540|Active Comparator|Synvisc-One|6 mL, one single intra-articular injection
89119278|NCT05336123|Experimental|Hatha Yoga|Participants will be invited to attend one 60-75 minute yoga class for 10 weeks in the prison facility where they reside. Each class will consist of: breathing exercises, brief guided centering meditation, warm-ups, standing postures, floor postures, an inversion, relaxation, and between-class practice assignments. Classes will emphasize mindfulness, including noticing emotions, thoughts, and physical sensations related to anger, and moderate physical activity. Classes will include some teaching of a relevant yoga theme, such as nonviolence (ahimsa).
89119279|NCT05336123|Active Comparator|Health Education|To match for attention, the control condition will be a 10-week program that consists of weekly 60-75 minute group classes. In classes, instructors will provide information about general health topics through a variety of means such as slides and handouts. There will be an emphasis on group discussion of relevant topics; instructors do not just lecture. The core rationale for this course is that good physical health is important for good mental health. Instructors will provide information and encourage questions but avoid psychotherapeutic techniques or personalized goal-setting. Instructors will give participants readings to explore on their own.
89119280|NCT05323149|Placebo Comparator|Group C|Group C, will be received saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
89119281|NCT05323149|Experimental|Group T|Group T, will be received TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
89119282|NCT05316532||Mechanically ventilated ECCO2R group|Adult, mechanically ventilated critically ill patients with respiratory failure and incapacity to sustain lung protective ventilation
89119283|NCT05316532||Awake spontaneously breathing ECCO2R group|Awake, spontaneously breathing critically ill patients suffering from respiratory exhaustion
89119284|NCT05293080|Experimental|Early rhythm control therapy|Patients with acute ischemic stroke and AF will receive either catheter ablation (mainly pulmonary vein isolation), or adequate antiarrhythmic drug therapy at an early time point. The initial therapy will be selected by the local investigator. In case of continuation or recurrence of AF, both modalities may be combined.
89119285|NCT05293080|Active Comparator|Usual care|Patients with acute ischemic stroke and AF will receive usual care following the current ESC guidelines for AF treatment.
89119286|NCT05273762|Experimental|FlowTriever|
89119287|NCT05270759||Hospitalized patients receiving hemodialysis/hemodialfiltration|"Adult patients hospitalized in the intensive care unit (ICU) or general ward receiving hemodiafiltration or hemodiafiltration treatments as least 3 times per week with ≥1L of fluid removal per session~Exclusion criteria:~Planned hospital discharge, death, or transition to comfort care within 48 hours according to the attending physician~End of active care (awaiting hospital discharge)"
88800229|NCT00962039|Experimental|Citalopram|Citalopram was initiated at 10 mg daily for one week, with dosage increased to 20 mg daily during week 2, with an optional increase to 40 mg daily at week 4 or thereafter if response was judged to be suboptimal (CGI-I or CGI-S > 2).
88800230|NCT00962039|Placebo Comparator|Placebo|Placebo administered in capsules identical to those containing citalopram using microcrystalline cellulose.
88800231|NCT03375385|Other|Hemodynamic parameters|
88800232|NCT03375385|Other|Ramsay sedation score|
88800233|NCT03375385|Other|Intraoperative side effects|
88800234|NCT03375385|Other|recovery of sedation|
89119288|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 1|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
89119289|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 2|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
89119290|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 3|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
89119291|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 4|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
89119292|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 5|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
89119293|NCT05262400|Experimental|Part 2A|PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior systemic therapy for advanced or metastatic disease, including CDK4/6 inhibitor treatment and Endocrine Therapy)
89119294|NCT05262400|Experimental|Part 2B|PF-07220060 + PF-07104091 + Fulvestrant (ER+/HER2- Breast Cancer with at least 1 prior endocrine therapy and up to 1 prior line of chemotherapy for advanced or metastatic disease and no prior treatment with any CDK4/6 inhibitor for advanced disease)
89119295|NCT05262400|Experimental|Part 2C|PF-07220060 + PF-07104091 + Letrozole (ER+/HER2- Breast Cancer with no prior treatment with any CDK4/6 inhibitor for advanced disease)
89119296|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 6|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
89119297|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 7|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
89119298|NCT05262400|Experimental|Part 1 Dose Escalation - Dose Level 8|PF-07220060 + PF-07104091 dose escalation (Breast Cancer or solid tumors)
89119299|NCT05253677|Experimental|CT-guided PCI strategy|"QAngio CT Research Edition is a software suite providing several functionalities for the analysis of coronary computed tomography angiography (CCTA) scans to extract and present relevant information on the coronary vasculature for further clinical investigation.~Also, QAngio CT Research Edition allows to export this information for later viewing during x-ray angiography (XA) procedures to help physicians plan and guide the interventional procedure."
89119300|NCT05253677|Active Comparator|intravascular ultrasound (IVUS)-guided PCI strategy|Intravascular ultrasound (IVUS) is an invasive intravascular imaging technique able to visualize the coronary vessel. The use of IVUS-guided PCI has been endorsed an recommended by the European Society of Cardiology. The device is considered part of standard of clinical care.
89119301|NCT05230914|Experimental|Simple imaging|NCCT and CTA will be used to screen patients for endovascular treatment
89119302|NCT05230914|Active Comparator|Standard imaging|NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
89119303|NCT05229900|Experimental|SGN-ALPV|SGN-ALPV monotherapy
89119304|NCT05220956|Other|Intermittent fasting|This arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks.
89119305|NCT05220956|Other|DGE diet|This control arm is not a subject to any time restrictions concerning eating, solely patients will be trained according to the 10 rules of healthy nutrition of the DGE.
89119306|NCT05213936|Experimental|Scalp cooling with hairstyle|Scalp cooling with hairstyle (braids, twists, cornrows) to minimize hair volume and increase scalp cooling cap to scalp contact
89119307|NCT05213936|Experimental|Scalp Cooling with conditioner and water emulsion|Scalp cooling after coating hair with conditioner and water emulsion to minimize hair volume and increase scalp cooling cap to scalp contact
89119308|NCT05213936|No Intervention|No Scalp Cooling|Control with no scalp cooling
89119309|NCT05209867|Experimental|CBD Intervention|Participants will self-administer CBD daily for 2 months.
89119310|NCT05185492||Cardiogenic shock cohort|Primary diagnosis of Cardiogenic Shock at the time of index evaluation. The clinical and hemodynamic criteria used to diagnose Cardiogenic Shock will be those as defined in the Society for Cardiovascular Angiography and Interventions clinical expert consensus statement on the classification of cardiogenic shock.
89119311|NCT05177484|Experimental|Ferric maltol|
89119312|NCT05177484|No Intervention|Standard Care|
89119313|NCT05164458|Experimental|IBI389|A dose escalation stage of IBI 389 monotherapy.
89119314|NCT05164458|Experimental|IBI 389 + sintilimab|A dose escalation stage of IBI 389 in combination with sintilimab.
89119315|NCT05155865|Experimental|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
89119316|NCT05155865|Active Comparator|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
89119317|NCT05149638|Active Comparator|Healthy volunteers|Healthy volunteers are those 18 years or older without prior diagnosis of adrenal insufficiency. Study participation by healthy volunteers helps us understand what cortisol levels should be in a healthy population. This information also helps us figure out what levels might be in people with adrenal insufficiency.
89119318|NCT05149638|Active Comparator|Patients with known adrenal insufficiency|This group consists of patients 18 years or older with an established diagnosis of adrenal insufficiency. Study participation by patients with adrenal insufficiency helps us understand what cortisol levels should be, in the new assays, among those with adrenal insufficiency.
89119319|NCT05149638|Active Comparator|Patients suspected to have adrenal insufficiency|This groups consists of patients 18 years or older who are suspected to have adrenal insufficiency. Study participation by this group will help us understand if the cortisol values we get from the new assay accurately diagnose adrenal insufficiency.
89119320|NCT05136170|Experimental|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF). in this arm one drop of cenegermin 20 mcg/mL will be instilled in both eyes TID for 28 consecutive days.
89119321|NCT05136170|Placebo Comparator|Vehicle|In this arm one drop of vehicle will be instilled in both eyes TID for 28 consecutive days.
89119322|NCT05118724|Experimental|Atezolizumab 840mg|Atezolizumab 840mg i.v. (q2w) for a total of 12 cycles (24 doses)
89119323|NCT05097820||Cisgender patients|All cisgender patients in which one or two testicular prostheses are to be implanted for various reasons.
88800235|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (A)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
89119324|NCT05097820||Transgender patients|All transgender patients in which one or two testicular prostheses are to be implanted for gender reassignment surgery.
89119325|NCT05093868|Experimental|FIRMap™ (Abbott Laboratories, Abbott Park, IL)|A 64-pole basket mapping catheter (FIRMap™, Abbott Laboratories, Abbott Park, IL) will be used to passively acquire electrical signals
89119326|NCT05066165|Experimental|Arm 1: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count <5%, administered by IV infusion following lymphodepleting chemotherapy.
89119327|NCT05066165|Experimental|Arm 2: NTLA-5001|Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count ≥5%, administered by IV infusion following lymphodepleting chemotherapy.
89119328|NCT05044286||40 Transgender and Gender Diverse for World Café Conversation|We will host two world cafe conversations. The first (n = 20) will be specifically or black transgender and gender diverse adults (18+), who are HIV-negative, and have indications for PrEP. The second (n = 20) will be open to transgender and gender diverse adults, who are HIV-negative, and have indication for PrEP.
89119329|NCT05044286||20 Other Key stakeholders for World Café Conversation|We will interview 20 other key stakeholders including medical providers, HIV prevention specialists, outreach workers, PrEP navigators/educators.
89119330|NCT05044286||500 Transgender and Gender Diverse for Survey|We will survey 500 TGD adults (18+), who are HIV negative, and have indications for PrEP.
89119331|NCT05040542||Infant Cohort|Healthy infants aged from 0-36 months.This is an observational trial so no intervention will be provided, with exception of study assessments, including fMRI.
89119332|NCT05040542||Preschooler Cohort|Healthy preschooler aged from 37-72 months.This is an observational trial so no intervention will be provided, with exception of study assessments, including fMRI.
89119333|NCT05018507||total knee arthroplasty patients|data collection only
89119334|NCT04994613|No Intervention|Control Group|The patient will be reserved a standard room in the preoperative area of main campus. This room will not include any additional sensory equipment. The child will be allowed to use any comfort items the family brought with them or offered a hospital iPad, as is current practice for all outpatient surgery patients.
89119335|NCT04994613|Experimental|Sensory Adaptive Environment Group|One of the three dedicated adaptive sensory rooms in the preoperative area of main campus will be set up by nursing and child life staff in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli. The equipment may include a portable popcorn tube with fiberoptic cart, handheld marble panel, color changing floor tiles, other sensory friendly objects, and individual sensory toys. This room will be set up prior to the patient's arrival the day of surgery and reserved for their use.
89119336|NCT04991480|Experimental|Part A1|Part A1 will evaluate ART4215 monotherapy administered in 21 day cycles. Up to 90 participants will participate in this dose escalation arm.
89119337|NCT04991480|Experimental|Part A2|Part A2 will evaluate ART4215 given in combination with talazoparib in 21 day cycles. Up to 50 participants will participate in this dose escalation arm.
89119338|NCT04991480|Experimental|Part B1|In Part B1 dose expansion, up to 30 participants with solid cancers that have been treated with a PARP inhibitor for an approved indication will receive ART4215.
89119339|NCT04991480|Experimental|Part B2|In Part B2 dose expansion, up to 20 participants with solid cancers with characteristics indicative of sensitivity to pol theta inhibition will receive ART4215.
89119340|NCT04991480|Experimental|Part B3|In Part B3, approximately 120 participants with HER2 negative BRCA breast cancers will be randomized 1:1 to either ART4215 in combination with talazoparib or talazoparib alone.
89119341|NCT04991480|Experimental|Part A3|Part A3 will evaluate ART4215 given in combination with niraparib in 21-day cycles. Up to 30 participants will participate in this dose escalation arm.
89119342|NCT04991467|Experimental|Parents of children receiving mental health treatment at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app .
89119343|NCT04991467|Experimental|Parents of children being treated for autoimmune disorders at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
89119344|NCT04991467|Experimental|Healthcare workers at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
89119345|NCT04975698|Other|HST-NEETs|HIV+ Participants that were treated with autologous hematopoietic stem cell transplant.
89119346|NCT04972123|Experimental|CPC Adminstration|Single dose of CPC will be given during tilt table test
89119347|NCT04972123|Placebo Comparator|Placebo Adminstration|Single dose of Placebo will be given during tilt table test
89119348|NCT04968652||IBS-C Group|Result of ROME VI marked as 'IBS-C'.
89119349|NCT04968652||Non IBS-C Group|Result of ROME VI marked as 'Non IBS-C'
89119350|NCT04965909|Experimental|Educational and therapeutic exercise program|Participants will receive a 3-month online physiotherapy program comprised of 'pain neuroscience education' (month 1) and 'gradual exposure to movement' (month 2 and 3). They will receive an informative booklet online.
89119351|NCT04965909|No Intervention|Passive control group (usual care)|Participants will receive the 'usual care'. They will receive an informative booklet online and the possibility of receiving the therapeutic program, once the study is completed.
89119352|NCT04958239|Experimental|Arm A: BI 765179|
88800236|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (B)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
88800237|NCT03867838|Experimental|Stroke survivors|Stroke survivors with upper extremity motor impairments
89119353|NCT04958239|Experimental|Arm B: BI 765179 + ezabenlimab|
89119354|NCT04925752|Experimental|Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF|"Participants will receive the following for at least 52 weeks:~Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily~Oral LEN 600 mg on Days 1 and 2~Participants will receive oral LEN if SC injections are not available"
89119355|NCT04925752|Experimental|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for at least 52 weeks:~SC LEN placebo every 26 weeks~Oral F/TDF 200/300 mg once daily~PTM Oral LEN on Days 1 and 2~Participants will receive oral LEN placebo if SC injections are not available"
88800238|NCT03018665|Experimental|Exenatide and Metformin|Exenatide in Combination With Metformin
88800239|NCT03018665|Active Comparator|BIAsp30 and Metformin|BIAsp30 in Combination With Metformin
89119356|NCT04925752|Experimental|LEN Open-Label Extension (OLE) Phase|"After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.~Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.~Participants randomized to F/TDF will receive SC LEN 927 mg on OLE Day 1, OLE Week 26, and will also receive oral LEN 600 mg on OLE Days 1 and 2."
89119357|NCT04925752|Experimental|PK Tail Phase|"At the completion of the LEN OLE phase, participants will transition into the PK Tail phase.~Additionally, participants that prematurely discontinue the study drug during blinded phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase are also eligible to transition to the PK Tail Phase.~Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks beginning 26 weeks after the last injection of LEN."
89119358|NCT04917796|Experimental|Electroacupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
89119359|NCT04917796|Placebo Comparator|Sham Acupuncture Arm|The study participants will include 250 cancer survivors who have completed neurotoxic agent containing chemotherapy at least three months prior and have persistent moderate to severe Chemotherapy-Induced Peripheral Neuropathy/CIPN pain randomized to one of two study arms.
89119360|NCT04872738||Vaccinated Breast Cancer Patients|Patients who enroll in the trial and decided to get the COVID-19 vaccine will complete surveys to indicate their experiences, side effects, location of vaccination (i.e. right arm, left arm, or leg). This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
89119361|NCT04872738||Unvaccinated Breast Cancer Patients|Patients who enroll in the trial and did not choose to receive the COVID-19 vaccine once it was available to them with complete a survey to indicate why they chose not to receive the vaccine. This information will be analyzed in conjunction with their breast cancer treatment history and lymphedema measurements.
89119362|NCT04857476|Other|skin psoriasis participants|Single arm study
89119363|NCT04846400|Experimental|ssNPA|self-supporting nasopharyngeal airway to be used nightly for approximately 8 weeks.
89119364|NCT04839497|Experimental|Volar Fibroblast Treatment|Volar fibroblasts are injected into the residual limb of transtibial amputees
89119365|NCT04839497|No Intervention|Cryoprotectant|Vehicle Control. Interdermal injection of cryoprotectant
89119366|NCT04835233|Experimental|methyldopa|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
89119367|NCT04835233|Active Comparator|captopril|postpartum exchange methyldopa for captopril 25 mg 01 tablet every 8 hours, doubling the dose depending on pressure levels, up to 15 days postpartum
89119368|NCT04827953|Experimental|Investigational treatment|Conventional Chemotherapy (Gemcitabine + nab-paclitaxel) plus NLM-001 plus Zalifrelimab
89119369|NCT04758533|Experimental|AloCELYVIR|Patients will received weekly infusion of AloCELYVIR during 8 weeks.
89119370|NCT04756232|Experimental|Anticholinergic Challenge|All participants will receive oral mecamylamine or IV scopolamine for 1 day
89119371|NCT04756232|Placebo Comparator|Placebo Challenge|All participants will receive oral placebo for 1 day
89119372|NCT04755127|Active Comparator|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
89119373|NCT04755127|Experimental|arthroscopic synovectomy|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
89119374|NCT04731298|Experimental|Emapalumab|"The first cohort of patients will receive a first infusion of 6 mg/kg at TD0, followed by a second infusion at 3 mg/kg after 3 days (treatment day 3 - TD3). Subsequent infusions of 3 mg/kg will be every 3 or 4 days from previous dose until dose 15 or until engraftment.~A maximum of 2 additional cohorts may be added to allow dosing regimen adaptation based on the PK/PD data observed from the previous cohort(s). Efficacy and safety data will also be considered before adding additional cohorts."
89119375|NCT04676412|Experimental|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
89119376|NCT04676412|Active Comparator|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
89119377|NCT04657120|Experimental|YEARS algorithm|Patients randomized to this arm will be evaluated according to the YEARS algorithm.
89119378|NCT04657120|Active Comparator|CTPA as single test|Patients randomized to this arm will undergo a contrast enhanced CTPA.
88800240|NCT03012763|Placebo Comparator|non-caloric water|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml non-caloric water 3 h thereafter
88800241|NCT03012763|Active Comparator|caloric drink|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml caloric drink 3 h thereafter
88800242|NCT03012763|Active Comparator|grapefruit juice|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml grapefruit juice 3 h thereafter
88800243|NCT01015781|Experimental|Arm 1|Progressive Tinnitus Management
88800244|NCT01015781|Other|Arm 2|Wait List Control
88800245|NCT03661762||Healthy Volunteers|All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
89119383|NCT04641975|Experimental|Mirabegron (5 to <12 Years)|Participants aged 5 to < 12 years received initial dose of 25 milligram (mg) of mirabegron orally once daily based on weight (pediatric equivalent dose of 25 mg [PED25]) on day 1. Participants with a body weight ≥ 35 kilogram (kg) received tablet and participants with a body weight< 35 kg or those who could not be dosed with the tablet received an oral suspension. At week 4, participants were up-titrated to the pediatric equivalent dose of 50 mg [PED50] based on the given dose titration criteria up to week 12. Urotherapy continued throughout the study treatment period until week 12.
89119384|NCT04641975|Placebo Comparator|Placebo (5 to <12 Years)|Participants aged 5 to < 12 years received placebo matched to mirabegron orally once daily based on weight PED25 on day 1. Participants with a body weight ≥ 35 kg received tablet and participants with a body weight< 35 kg or those who could not be dosed with the tablet received an oral suspension. At week 4, participants were up-titrated to the PED50 based on the given dose titration criteria up to week 12. Urotherapy continued throughout the study treatment period until week 12.
89119385|NCT04641975|Experimental|Mirabegron (12 to <18 Years)|Participants aged 12 to < 18 years received initial dose of 25 mg of mirabegron orally once daily based on weight PED25 on day 1. Participants with a body weight ≥ 35 kg received tablet and participants with a body weight< 35 kg or those who could not be dosed with the tablet received an oral suspension. At week 4, participants were up-titrated to the PED50 based on the given dose titration criteria up to week 12. Urotherapy continued throughout the study treatment period until week 12.
89119386|NCT04641975|Placebo Comparator|Placebo (12 to <18 Years)|Participants aged 12 to < 18 years received placebo matched to mirabegron orally once daily based on weight PED25 on day 1. Participants with a body weight ≥ 35 kg received tablet and participants with a body weight< 35 kg or those who could not be dosed with the tablet received an oral suspension. At week 4, participants were up-titrated to the PED50 based on the given dose titration criteria up to week 12. Urotherapy continued throughout the study treatment period until week 12.
89119387|NCT04633200|Experimental|Intervention|Participants in the intervention arm will receive a mobile app to support their daily PrEP adherence.
89119388|NCT04633200|No Intervention|Control|Participants in the control group will receive a 2-page PrEP patient education document based information about PrEP from on the CDC website.
89119389|NCT04616365|Experimental|Semi-Elective Lung Transplantation|Planned Semi-Elective Lung Transplantation Using 10°C Cold Static Preservation
89119390|NCT04603560|Experimental|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
89119391|NCT04603560|Experimental|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
89119392|NCT04603560|No Intervention|Control|No intervention will be provided to physicians in the control arm.
89119393|NCT04578041|Experimental|Arm 1: TRPMS + Aerobic Physical Activity Program|
89119394|NCT04578041|Active Comparator|Arm 2: TRPMS + Adaptive Cognitive Training|
89119395|NCT04558840|Active Comparator|Enhanced Recovery After Surgery (ERAS) Arm|"ERAS Arm will undergo multimodal regiment:~Before Surgery- gabepentin 300mg and celecoxib 400mg once the day before surgery and again 3 hours prior to surgery.~During surgery- subjects will receive ketorolac 30mg IV ketorolac once (15mg for patients age 64 years and above).~Post-operatively- Gabapentin 100mg three times daily for POD0-7, ketorolac 10mg four times daily for POD1-5 days, and ondansetron 4mg as needed for nausea; patients will also have a prescription for hydrocodone-acetaminophen 5/325mg tabs that they may fill if needed for emergency/breakthrough pain."
89119396|NCT04558840|Active Comparator|Current Practice Arm|The current practice arm will include: post-operatively, hydrocodone-acetaminophen 5/325mg tabs and ibuprofen 800mg, as needed for pain. Additionally, acetaminophen may be used in conjunction with the above regiment. Ibuprofen and acetaminophen can be taken as needed or alternating every 6 hours, scheduled.
89119397|NCT04557462|Experimental|LNP023|All participants are receiving 200 mg b.i.d
89119398|NCT04542031|Other|Survey|Survey to be distributed at 6 and 12 months
89119399|NCT04527432|Other|All participants|Survey at 6 and 12 months time with optional antibody tests
89119400|NCT04522895|Experimental|Consolidation Arm|Enasidenib (investigational product) will be started on day 1 for 28 days every 28 days for a maximum of 12 cycles. The starting dose of Enasidenib will be 100 mg once daily in every patient and may be reduced individually according to a dose modification scheme.
89119401|NCT04512131||Intermittent hemodialysis|patients who are going to undergo intermittent hemodialysis or patients who are going to switch dialysis mode to intermittent hemodialysis from continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate® platelet function analysis will be checked just before dialysis initiation and immediately after dialysis termination
89119402|NCT04512131||continuous renal replacement therapy|patients who are going to undergo continuous renal replacement therapy Laboratory test including complete blood count, prothrombin time, activated partial thromboplastin time, protein C, protein S and D-dimer, EXTEM of ROTEM and Multiplate platelet function analysis will be checked within 24 hours after dialysis initiation and 48 hours after taking first blood sample
89119403|NCT04509427|Active Comparator|Handouts Only (HO) group|The HO only group will receive program instructions via handouts and videoconferencing with a physical therapist who will provide intervention instruction, assist with program progression, and monitor participant quality of movement and safety.
89119404|NCT04509427|Active Comparator|Handouts plus web-based video (HO+) group|The HO+ group will receive the same intervention as the HO group but they will also have access to web-based videos that will lead them through all exercise/posture routines like a commercial exercise video.
89119405|NCT04494958|Experimental|Palbociclib + Binimetinib|
89119406|NCT04492033|Experimental|CTX-009 (ABL001) and Paclitaxel (P1b)|
89119407|NCT04492033|Experimental|CTX-009 (ABL001) and Irinotecan (P1b)|1 cycle = 4weeks
89119408|NCT04492033|Experimental|CTX-009 (ABL001) and Paclitaxel (P2)|1 cycle = 4weeks
89119409|NCT04490174||Healthy participants|Healthy adults without a current active COVID-19 infection or current symptoms consistent with COVID-19 at the first clinic visit
89119410|NCT04483505|Experimental|Rogaratinib + palbociclib + fulvestrant|
89119411|NCT04456920|Experimental|Experimental group 1|PRO (Patient Reported Outcomes) gathered via a phone consultation
89119412|NCT04456920|Experimental|Experimental group 2|e-PRO self-completed via connected objects (tablet/phone)
89119413|NCT04456920|No Intervention|Control group|group without e-PROs (standard care)
89119414|NCT04447768|Experimental|Venetoclax and Obinutuzumab|All patients will receive a minimum of 9 cycles (cycle = 28 days) of therapy with venetoclax and obinutuzumab during the treatment period. For patients who remain MRD positive at Cycle 9 of therapy, an additional 12 cycles of venetoclax monotherapy will be given.
89119415|NCT04368845|Active Comparator|Experimental Intervention Arm: Telerehabilitation|The treatment arm will be given up to 1-hour resistive training exercises, breathing exercises and aerobic exercises administered by an expert physiotherapist via teleconference (telerehabilitation). Every ten days one physiotherapist will record the individualized exercise program, will reevaluate the magnitude of exercise for each patient and reinforce to continue or increase exercise magnitude.
89119416|NCT04368845|No Intervention|No Intervention: Conventional teleconference|The usual care arm will receive standard communication via teleconference every ten days for a six-month period without any specific recommendations and exercise prescription for home training. The control arm will be subject to the same assessments as the experimental arm at the start, and at the 3 and 6 months period.
89119417|NCT04356989||Rivaroxaban|Adult NVAF patients with renal impairment, who are prescribed with rivaroxaban to prevent stroke or non-central nervous system (CNS) systemic embolism (SE).
89119418|NCT04326673||diurnal variation assessment|Assessment of diurnal variation in salivary testosterone adjusted for prandial state
89119419|NCT04326673||Glucose load measurements|Measurement of salivary and serum testosterone and related biomarkers before and after a standard 75g oral glucose load
89119420|NCT04261712|Experimental|Paltusotine|
89119421|NCT04234022||Zn-DDC|samples to be exposed with Zn-DDC (Imuthiol) alone
89119422|NCT04234022||Lenalidomide with Zn-DDC|samples to be exposed with Lenalidomide in combination with Zn-DDC
89119423|NCT04234022||Pomalidomide with Zn-DDC|samples to be exposed with Pomalidomide in combination with Zn-DDC
89119424|NCT04233866|Experimental|Arm A (gemcitabine, nab-paclitaxel)|Patients receive gemcitabine IV over 30 minutes and nab-paclitaxel IV over 30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89119425|NCT04233866|Experimental|Arm B (fluorouracil, leucovorin, liposomal irinotecan)|Patients receive fluorouracil IV over 46 hours starting on day 1. Patients also receive leucovorin IV over 90-120 minutes and liposomal irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89119426|NCT04228042|Experimental|Treatment (infigratinib, surgery)|Patients receive infigratinib PO QD on days 1-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. During weeks 8-9 (at least 48 hours after last dose of infigratinib), patients undergo surgery.
89119427|NCT04223492|Other|Neoadjuvant systemic treatment|All patients undergo standard neoadjuvant treatment and additional multi-parametric MRI and liquid biopsies during neoadjuvant treatment.
89119430|NCT04207060|Experimental|Oral indomethacin 50 mg po BID|The study intervention is oral indomethacin. Indomethacin is an FDA approved, commonly prescribed NSAID. Commercially available indomethacin will be utilized in this study. One capsule orally BID for 28 days. Those in the indomethacin arm will receive indomethacin 50 mg BID. Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication.
89119431|NCT04207060|Placebo Comparator|Placebo po BID|"Participants in both study arms will receive study medication, one capsule orally BID for 28 days. Those in the placebo arm will receive placebo capsules BID.~Participants will be advised not to make up missed doses. They will be advised to take a dose of study medication on the morning of their follow-up endoscopy, 2 hours prior to their scheduled procedure time, with a sip of water. At the time of follow-up endoscopy they will return any unused study medication."
89119432|NCT04196010|Experimental|Treatment (CI-CLAM, G-CSF)|Patients receive CI-CLAM consisting of cladribine and cytarabine via CIV on days 1-2, 1-3, 1-4, 1-5, or 1-6 depending on dose level assignment, and mitoxantrone via CIV on days 1-2 or 1-3 depending on dose level assignment. G-CSF may be added at the discretion of the treating physician, as per standard of care. Patients that do not achieve a response of MRD-negative CR after the first cycle are eligible to receive a second cycle of CI-CLAM. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.
89119433|NCT04195451|Experimental|Live Video-Supervised Exercise Intervention Arm|Patients randomized to exercise intervention at baseline will participate in live-video-supervised exercise sessions x3/week for 3 months, and then will follow a maintenance regimen for 6 months. During maintenance, patients will continue live-video-supervised exercise sessions, only x1/week, and will be instructed to exercise on their own x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
89119434|NCT04195451|Experimental|Live-Video-Supervised Exercise Control Arm|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the 3-month exercise intervention of live-video-supervised exercise sessions x3/week for 3 months.
89233013|NCT03573648|Active Comparator|Endocrine Therapy with Palbociclib|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
89233014|NCT03573310|Experimental|Part 1: Dose escalation and RP2D Selection|Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
89233015|NCT03573310|Experimental|Part 2:Dose Confirmation and Expansion|Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.
88800246|NCT03012607|Experimental|Perfect Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] once daily for 6 weeks
88800247|NCT03012607|Experimental|Moderate Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 4 times per week (Monday, Wednesday, Friday, and Saturday) for 6 weeks
88800248|NCT03012607|Experimental|Poor Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 2 times per week (Monday, Thursday) for 6 weeks
88800249|NCT03018509|Experimental|JTE-451 Dose 1|JTE-451 dose 1 for 28 days
88800250|NCT03018509|Experimental|JTE-451 Dose 2|JTE-451 dose 2 for 28 days
88800251|NCT03018509|Experimental|JTE-451 Dose 3|JTE-451 dose 3 for 28 days
88800252|NCT03018509|Experimental|JTE-451 Dose 4|JTE-451 dose 4 for 28 days
88800253|NCT03018509|Experimental|Placebo|Placebo for 28 days
88800254|NCT04316260|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
88800255|NCT04316260|Active Comparator|Treatment As Usual|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
88800256|NCT01048879|Other|ECMO alone|Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy (patients were already receiving oseltamivir and ECMO due to an illness)- Procedure/Surgery: pharmacokinetic blood sampling
88800257|NCT01048879|Other|CVVHD Alone|"Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir (Patients were already receiving oseltamivir and CVVHD as a result of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
89119435|NCT04190368|Other|Team Clinic Care: No VTC Groups|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient and yearly team visit as needed~• Providers will utilize a patient centered care approach to conducting appointments"
89119436|NCT04190368|Other|Team Clinic: Virtual Team Clinic Group|"Participants will be invited to participate in online/virtual thematic group sessions led by Team Clinic group facilitators (e.g., RD, SW, RN) aimed at improving glycemic control and treatment adherence, increasing social supports and diabetes care satisfaction, and aid in the transition from caregiver led treatment to self care.~o Patients and Family members attend their own online sessions: Energy Training, Proficiency Training, Resilience Training, Balance Training, Miscellaneous sessions - scheduled as needed"
88800258|NCT01048879|Other|CVVHD + ECMO|"Patient receiving oseltamivir and ECMO and CVVHD (patients were already receiving oseltamivir, ECMO, and CVVHD as part of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
88800259|NCT05272657|Experimental|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
88800260|NCT05272657|Experimental|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
88800261|NCT04296448|No Intervention|Traditional Otoscope|Pediatric trainees use a traditional otoscope to evaluate pediatric patient ears. Trainees' supervisors will also evaluate patients with the traditional otoscope. The study evaluates concordance of the exams.
88800262|NCT04296448|Experimental|Cellscope|Pediatric trainees use a cellphone otoscope (Cellscope) to evaluate pediatric patient ears. Trainees' supervisors will evaluate patients remotely with the video on the cellphone otoscope. The study evaluates concordance of the exams.
88800263|NCT05230771|Experimental|Palliative surgery after translational therapy|After randomization, patients received palliative surgery after translational therapy
88800264|NCT05230771|Active Comparator|Chemotherapy alone|After randomization, patients received chemotherapy alone
88800265|NCT05314738|Experimental|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 1 / Cohort 1|Riboflavin Solution + Exposure to NXL system to achieve total energy level 3
88800266|NCT05314738|Active Comparator|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 / Cohort 2A|Riboflavin Solution + Exposure to NXL system to achieve total energy level 1
88800267|NCT05314738|Active Comparator|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 / Cohort 2A|Riboflavin Solution + Exposure to NXL system to achieve total energy level 2
88800268|NCT05314738|Active Comparator|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 / Cohort 2A|Riboflavin Solution + Exposure to NXL system to achieve total energy level 3
88800269|NCT05314738|Active Comparator|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 3 / Cohort 2B|Riboflavin Solution + Exposure to NXL system to achieve total energy level 1
89233016|NCT03559634|Experimental|Intervention group|Using an electronic application, participants answer survey questions about their sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception. Then, based on survey answers, they will be able to watch more in-depth educational videos on methods that they qualify for. Participants will only be offered methods that are considered low risk and without any contraindication based upon responses to survey screening. This may include, contraceptive implant, medroxyprogesterone acetate injection, microgestin pills, xulane patch, or intravaginal ring. Participants will then be given the opportunity to initiate contraception in the ED. All participants will be referred for follow up outpatient health services. Subjects who have medical contraindications to certain contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s) while in the ED.
89233017|NCT03559634|Other|Control Group|Using an electronic application, participants answer survey questions about their background, sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception with brief pros and cons of each method. Then, based on participants medical history and contraceptive preferences they will be able to watch more in-depth counseling and educational videos on contraceptive methods that they qualify for. After these videos they will be given information on where they will be able to follow up to receive these contraceptive methods if they wish to start a method. Subjects who have medical contraindications to certain hormonal contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s), should this come up in future discussions with their providers.
89290068|NCT03935412|Sham Comparator|intrathecal morphine ITM|participant in the ITM group intrathecal injection of 10mg of hyperbaric bupivacaine 0.5 % in addition to 100 mcg of preservative-free morphine. Then, the parturient immediately placed in the supine position with 15° left tilt, and an oxygen mask was applied at 2 l.min-1. After ensuring sufficient anesthesia level, the surgical procedure was done with continuous hemodynamics monitoring and recording. While participants in the ITM group underwent sham blocks; Sham blocks consisted of a non-invasive ultrasound scan, while a blunt needle was gently pressed on both sides.
89290069|NCT01360918|Active Comparator|Usual care|
88800270|NCT05314738|Active Comparator|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 4 / Cohort 2B|Riboflavin Solution + Exposure to NXL system to achieve total energy level 2
88800271|NCT05314738|Active Comparator|Riboflavin Ophthalmic Solution and UV-A Irradiation Group 5 / Cohort 2B|Riboflavin Solution + Exposure to NXL system to achieve total energy level 3
88800272|NCT05314738|Sham Comparator|Placebo Group 2 / Cohort 2B|Sham Solution with no exposure to NXL System
88800273|NCT03010345|Experimental|Osmed self inflating tissue expanders|All patients will undergo a two-stage procedure ,second stage under General endotracheal anesthesia. The first stage will be placement of the expanders. The second stage will be 21 days later, with removal of the expanders, palatal revision, and closure of the oronasal fistula
88800274|NCT03010345|Experimental|Iliac bone graft|Placement of bone graft without the use of self inflating expanders
88800275|NCT04290676||DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).
88800276|NCT03112993|Experimental|Sugammadex group|2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
88800277|NCT03112993|Active Comparator|Neostigmine group|"50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.~Dosing will be based on actual body weight not ideal body weight."
88800278|NCT03670030|Experimental|ABI-009|In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.
88800279|NCT04271020|Experimental|UroLift|
88800280|NCT02924155|Experimental|SJP002|9 subjects received single dose of SJP002 and then received multiple dose of SJP002
88800281|NCT02924155|Placebo Comparator|Placebo|3 subjects received single dose of placebo and then received multiple dose of placebo
88800282|NCT01163461|Experimental|Immediate Treatment|individuals will receive 60 hours of speech therapy
88800283|NCT01163461|Experimental|Delayed Treatment|individuals will receive 60 hours of speech therapy after 6 week delay period
88800284|NCT03857230|Experimental|Sequence A: Primapur - Gonal-F|Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
88800285|NCT03857230|Active Comparator|Sequence B: Gonal-F - Primapur|Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
88800286|NCT02864485|Experimental|transplantation|Live donor liver transplantation for the treatment of unresectable colorectal cancer liver metastases
88800287|NCT02181127|Active Comparator|Glucagon-only Bionic Pancreas (active)|Glucagon-only Bionic Pancreas will deliver glucagon during 7 of the 14 days. The order of the glucagon days will be randomized in blocks of 2, with no more than 2 days in a row of glucagon.
88800288|NCT02181127|Placebo Comparator|Glucagon-only Bionic Pancreas (placebo)|Glucagon-only Bionic Pancreas will deliver placebo during 7 of the 14 days. The order of the placebo days will be randomized in blocks of 2, with no more than 2 days in a row of placebo.
88800289|NCT03670264|Experimental|Quitline Incentive|The incentive structure emphasizes engaging with the Quitline Delivered Treatment, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the Quitline, for maintaining involvement in the Quitline program (per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the Way to Health (WTH) platform.
88800290|NCT03670264|Experimental|Tobacco Cessation Incentive|The incentive structure emphasizes quitting regardless of engagement with the Quitline Delivered Treatment (though the Quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, compensation for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the WTH platform.
89119437|NCT04190368|Other|Standard Care: No VTC Groups|Appointments will continue as usually with provider (quarterly visits; 1 visit every 3 months), but will be referred for necessary care per usual methods (e.g., diabetes education or supportive services).
89119438|NCT04190368|Other|Standard Care: Virtual Team Clinic|"Appointments will continue as usually with provider (quarterly visits; 1 visit every 3 months), but will be referred for necessary care per usual methods (e.g., diabetes education or supportive services).~o Patients and Family members attend their own online sessions: Energy Training, Proficiency Training, Resilience Training, Balance Training, Miscellaneous sessions - scheduled as needed"
89119439|NCT04173104||Participants with Brain Cancer|Participants with new or suspected recurrent brain tumors
89119440|NCT04160546|Experimental|Ponatinib plus ASA treatment|Patients will be treated with ponatinib 15 mg/day plus 100 mg/day ASA for 104 weeks. After that, ponatinib and ASA will be stopped.
89119441|NCT04134000|Experimental|Atezolizumab + BCG|"Ten patient will be enrolled in first cohort, starting on level 0 (DL 0) receiving BCG 1 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w).~The next level of dose in case is necessary is BCG 1/2 instillation per week and Atezolizumab 1200 mg IV every three weeks (q3w)"
89119442|NCT04074044|Experimental|BHmApp users|Participants using BHmApp tor bladder education and training
89119443|NCT04066400|Placebo Comparator|wheat-based diet|The patients continue a wheat-based diet aiming at a reduction in bodyweight.
89119444|NCT04066400|Experimental|ATI reduced diet|Patients are counselled to reduce dietary gluten uptake.
89119445|NCT04050228|No Intervention|Standard Neoadjuvant Chemotherapy Monitoring|"Patients who will be randomized to the control arm with Standard Neoadjuvant Chemotherapy Monitoring will receive Phase I chemotherapy consisting of anthracycline-based treatment followed by Phase II chemotherapy consisting of taxane-based treatment.~Patients will be imaged but no modifications to treatment will occur in this trial arm depending on response by quantitative ultrasound."
88800291|NCT03670264|Placebo Comparator|No Financial Incentive|No financial incentive to engage in Quitline Delivered Treatment or report abstinence. Study procedures and reminders are managed through the WTH platform.
88800292|NCT04241146|Active Comparator|Standard Blind Technique of Tube placement|FDA approved technique of enteral nutrition tube placement
89119446|NCT04050228|Experimental|Adaptive Chemotherapy Monitoring|"Patients who will be randomized to the experimental arm Adaptive Chemotherapy Monitoring and demonstrate Response (+) will continue until standard chemotherapy is completed. For patients who do not demonstrate response after 4 weeks of chemotherapy, an early switch to the second phase of chemotherapy could occur (Phase II/Taxane) At the discretion of the treating medical oncologist.~Patients will undergo Quantitative Ultrasound on the following time points: Pre-treatment, Weeks 1, 4, 8, 12 and Pre-Operatively. These QUS time points correspond to the following chemotherapy times."
89119447|NCT04032704|Experimental|Part A: Non-randomized LV monotherapy|Monotherapy dosing schedule 1.
89119448|NCT04032704|Experimental|Part B: Non-randomized LV monotherapy|Monotherapy dosing schedule 2.
89119449|NCT04032704|Experimental|Part C - Arm 1: Randomized LV monotherapy|Monotherapy dosing schedule 3.
89119450|NCT04032704|Experimental|Part C - Arm 2: Randomized LV combination therapy|Combination dosing schedule 1.
89119451|NCT04032704|Experimental|Part C - Arm 3: Randomized LV combination therapy|Combination dosing schedule 2.
89119452|NCT04019288|Experimental|Arm I (batiraxcept, durvalumab)|Patients receive batiraxcept IV over 60 minutes on days 1, 15, and 29 of cycle 0, and on days 1 and 15 of subsequent cycles. Beginning cycle 1, patients also receive durvalumab IV over 60 minutes on day 1. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89119453|NCT04019288|Experimental|Arm II (durvalumab, batiraxcept)|Patients receive durvalumab IV over 60 minutes on days 1 and 22 of cycle 0 and on day 1 of subsequent cycles. Beginning cycle 1, patients also receive batiraxcept IV over 60 minutes on days 1 and 15. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89119454|NCT03984188|Experimental|Low-dose Theophylline Group|Participant in this group will receive low-dose theophylline in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment, over a one year period.
89119455|NCT03984188|Placebo Comparator|Placebo Group|Participant in this group will receive a placebo in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment.
89119456|NCT03957252||Training Cohort|Up to 1400 men from Alberta in addition to up to 2,500 men from external institutions, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with Total PSA greater than or equal to than 3 ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test.
89119457|NCT03957252||Validation Cohort|Up to 1400 men from Alberta in addition to up to 2,500 men from external institutions, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with Tota PSA greater than or equal to 3 ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test.
89119458|NCT03898362|Active Comparator|pneumatically powered wheelchair or scooter|participants will use pneumatic powered wheelchair or scooter
89119459|NCT03898362|Active Comparator|battery powered wheelchair or scooter|participants will use battery powered wheelchair or scooter
89119460|NCT03824106|Experimental|Arm1.Control|Participants randomized to the control arm will not receive any of the Frailty Rehabilitation Interventions. Participants in the control arm will receive Vitamin D.
89119461|NCT03824106|Experimental|Arm2.Group Exercise|Participants will attend the exercise program, twice-weekly, for 4-months with supplemental home exercise.
89119462|NCT03824106|Experimental|Arm3.Multi-modal Intervention|"Group Exercise/Supplemental Home Exercise: This will be delivered identically to Arm 2.~Nutrition, protein supplementation, and a medication review will also be implemented."
88800293|NCT04241146|Active Comparator|CORTRAK enteral access system (CEAS) placement|An electromagnetic device used to enable enteral nutrition tube placement
88800294|NCT03672370||Alloclassic® Variall® Cup|Subjects who received the Alloclassic® Variall® Cup Ceramic Bearing System
88800295|NCT01166347|Experimental|HeartWare® VAS|Implant of HeartWare® Ventricular Assist System
88800296|NCT01166347|Active Comparator|Control LVAD|Implant of FDA-approved LVADs approved for destination therapy
88800297|NCT04240678|Experimental|HBV Alert Group|
88800298|NCT04240678|No Intervention|Control Group|
88800299|NCT04332094|Experimental|Intervention|Early administration of tocilizumab associated with hydroxychloroquine and azithromycin.
88800300|NCT04332094|Active Comparator|Control|Treatment of SARS-COV-2 (COVID-19) infection with hydroxychloroquine and azithromycin.
88800301|NCT05122585|Experimental|Prospective MagTrace patients|All prospective patients will receive a MagSeed in the diagnosed breast cancer tumor. In addition, they will receive MagTrace to detect the sentinel lymph node during surgery. Since this is an experimental study, the patients will also be injected with the golden standard of Technetium tracer.
88800302|NCT04234672|Experimental|TAK-831 500 mg + [14C]TAK-831 50 μg + [14C]TAK-831 500 mg|TAK-831 500 mg, tablet, orally, once on Day 1, followed by [14C]TAK-831 50 micrograms (μg) [approximately 1 microcurie (μCi)], infusion, intravenously (IV), once on Day 1 of Treatment Period 1, followed by a washout period of 8 days, further followed by [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, once under fasted state on Day 1 of Treatment Period 2.
88800303|NCT05070715||Group 1: FGR group|Estimated fetal weight <10th percentile
88800304|NCT05070715||Group 2: Control group|Healthy pregnants who will give birth 37th and after gestational week
88800305|NCT02752243|Experimental|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
88800306|NCT02980081||Plain abdominal x-ray|All patients admitted to 2 EDs and with a prescription of an abdominal plain x-ray.
88800307|NCT03676972|Experimental|LithoVue ureteroscope system|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
88800308|NCT02335957|Other|Intentional irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast and nodal areas(axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
88800309|NCT02335957|Experimental|Incidental irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
88800310|NCT03681808|Experimental|Test|Soft Contact Lens
88800311|NCT03681808|Active Comparator|Control|Contact lens
88800312|NCT01166971|Experimental|ReSTOR +3|Bilateral Implantation of ReSTOR +3 Intraocular lenses after cataract extraction
88800313|NCT01166971|Active Comparator|Tecnis MF|Bilateral Implantation of Tecnis Multifocal Intraocular lenses after cataract extraction
88800314|NCT04208698|Experimental|CIN-102 Tablets Dose 1|CIN-102 tablets by mouth twice daily for 14 days
88800315|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 1|Placebo tablets by mouth twice daily for 14 days
88800316|NCT04208698|Experimental|CIN-102 Dose 2|CIN-102 tablets by mouth twice daily for 14 days
88800317|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 2|Placebo tablets by mouth twice daily for 14 days
88800318|NCT01167595|Experimental|PEP uP Protocol|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
88800319|NCT01167595|No Intervention|Standard Feeding Protocol|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
88800320|NCT03835078|Experimental|methalfilcon A contact lenses / fanfilcon A contact lenses|All subjects will first wear methafilcon A contact lenses for four (4) weeks of daily wear, then be refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
88800321|NCT02184169|Experimental|HLHS|Patients undergoing palliative repair.
88800322|NCT02184169|Active Comparator|TGA|Surgical repair of TGA.
88800323|NCT03681886|Experimental|Primary Implantation (Cohort 1)|Primary implantation with HMIOL through Month 1 visit, followed by study exit. 1 site followed up to Month 12.
88800324|NCT03681886|Experimental|Optic Exchange (Cohort 2)|Subset of Cohort 1 with optic exchange at Month 1 post primary implantation, followed up to Month 1 post optic exchange
88800325|NCT01167829|Experimental|Acyline and oral testosterone|
88800326|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 8 Weeks|Direct-acting antiviral (DAA)-naive participants without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 8 weeks.
88800327|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 12 weeks.
88800328|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
89119463|NCT03822468|Experimental|Ribociclib 400 mg|Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)
89119464|NCT03822468|Active Comparator|Ribociclib 600 mg|Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)
89119465|NCT03818503||OligoCare|Patients with oligometastatic disease treated with radical radiotherapy
89119466|NCT03818503||ReCare|Patients treated with high-dose Re-irradiation
89119467|NCT03816839|Experimental|SAR439859|administered orally once daily or twice daily as monotherapy in fasted or fed state
89119468|NCT03816319|Experimental|Group I (twice weekly UAE inhibitor TAK-243)|Patients receive UAE inhibitor TAK-243 IV over 10 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
89119469|NCT03816319|Experimental|Group II (once weekly UAE inhibitor TAK-243)|Patients receive UAE inhibitor TAK-243 IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
89119470|NCT03796598|Placebo Comparator|Placebo|Oral and rectal placebo at visit 2 Oral placebo at day 30
89119471|NCT03796598|Active Comparator|Group 3: Oral placebo and rectal FMT|Oral placebo and rectal FMT at visit 2 Oral placebo at day 30
89119472|NCT03796598|Active Comparator|Group 2: Oral FMT and rectal placebo|Oral FMT and rectal placebo at visit 2 Oral FMT at day 30
89119473|NCT03796598|Experimental|Group 1: Dual Oral and rectal FMT|Dual Oral and rectal FMT at visit 2 Oral FMT at day 30
89119474|NCT03746470|Experimental|insertion preserving|ACL reconstruction preserving insertion
89119475|NCT03746470|Active Comparator|insertion detaching|ACL reconstruction detaching insertion
89119476|NCT03731234|Experimental|Ibrutinib+R-CHOP|Screening phase for selection of Activated-B-Cell (ABC)-DLBCL Induction phase: R-CHOP21 x 5 cycles in combination with ibrutinib Maintenance phase: maintenance with Ibrutinib for 18 months for patients responding to the induction phase (CR or PR)
89119477|NCT03720197||Participants aged less than 14 years old|
89119478|NCT03720197||Participants aged 14 years old and older|
89119479|NCT03674593|Experimental|Mitral valve chordae prosthesis|"Patients of this group receive mitral valve chordae replacement performed in five stages:~Measure the required length of the chordae.~Forming loops.~Fixation of the loop group to the papillary muscles.~Fixation of chordal loops to the free edge of the valve.~Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse."
89119480|NCT03674593|Active Comparator|Mitral valve chordae translocation|"The technique of translocation of secondary chordae:~The method consists essentially of three stages:~Selection of the secondary chordae.~Fixation of secondary chordae to the free edge of the valve.~Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
89119481|NCT03635021|Experimental|Sequence 1|FOLFOX regimen panitumumab FOLFIRI regimen bevacizumab
89119482|NCT03635021|Experimental|Sequence 2|FOLFOX regimen bevacizumab FOLFIRI regimen panitumumab
89119483|NCT03631199|Experimental|canakinumab|canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy
89119484|NCT03631199|Other|canakinumab matching-placebo|canakinumab matching-placebo in combination with pembrolizumab and platinum-based doublet chemotherapy
89119485|NCT03610256|Experimental|SADI-S|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic SADI-S (laparoscopic Single-anastomosis duodeno ileal bypass with Sleeve gastrectomy).~SADI-S will be performed as a primary procedure or after failure of sleeve gastrectomy, defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
89119486|NCT03610256|Active Comparator|RYGB|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic RYGB (laparoscopic Roux-en-Y Gastric ByPass).~Similarly to the experimental group, RYGB will be performed as a primary procedure or after failure of sleeve gastrectomy, which is defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
89119487|NCT03587532|Experimental|Indocyanine Green Angiography|ICG based angiography after creation of the stomach graft and after thoracic pull-up of the graft. Dynamic digital images will be obtained starting immediately after intravenous bolus administration of 0.5 mg/kg of ICG.
89119488|NCT03513939|Experimental|T1D Cell Pouch Recipients|Eligible Type 1 Diabetes Mellitus (T1D) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch intervention
89119489|NCT03496181||Bilingual Participants with Glioma|"Bilingual (English and Spanish speaking) patients will be recruited from the clinical service of the Department of Neurosurgery of MSK. All patients on the Neurosurgery service scheduled to undergo a resection of a tumor in or adjacent to the primary language areas will be screened to participate in this study.~The study will be performed in concert with patient's regularly scheduled clinical care for his/her brain tumor. Clinical care (which will be performed whether or not the patient participates in the current study) will include: 1) pre-operative routine (anatomical) MRI and fMRI, 2) the surgery to remove the tumor, 3) intra-operative cortical stimulation to identify the essential motor and/or language areas. It should be stressed that neither the brain tumor surgery, nor the intra-operative cortical mapping will be changed in any way from routine practice."
89119490|NCT03496181||Healthy Volunteers|Normal, healthy volunteers who express interest in participation and who meet the eligibility criteria will be recruited for this study. It is anticipated that healthy volunteers will mostly consist of medical professionals. They will consist of 10 monolinguals (defined as native English speakers), 10 early bilinguals (defined as acquiring proficiency in the second language before 10 years of age), and 10 late bilinguals (defined as acquiring proficiency in the second language after 10 years of age).
89119491|NCT03473249|No Intervention|Retrospective Review|Comparison of CT and CEUS results from retrospective chart review of children who have had a CEUS for trauma at the Children's Hospital of Philadelphia (CHOP).
89119492|NCT03473249|No Intervention|Prospective Observation|Prospective observation of comparison of CT and CEUS results among children who are undergoing a CEUS and abdominal CT as part of clinical care.
89119493|NCT03473249|Other|Contrast-Enhanced Ultrasound using Lumason|Prospective intervention using contrast enhanced ultrasound with IV contrast Lumason.
89290070|NCT01360918|Active Comparator|Pulmonary vein isolation|
88800329|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
89119494|NCT03453268|Other|1: Interventional (drug reduction)|"STEP DOWN strategy.~Proposition of reduction of the number of antihypertensive medication according to:~the systolic blood pressure levels,~co-morbidities"
89119495|NCT03453268|Other|2: Control|Usual treatment
89119496|NCT03439137|Experimental|MT-6548|
89119497|NCT03439137|Active Comparator|Darbepoetin alfa|
89119498|NCT03425201|Experimental|Niraparib plus Cabozantinib|"Patients will receive niraparib and cabozantinib p.o. once daily in 28-day cycles.~In phase I, patients will be accrued to each dose level in cohorts of 6 patients. Escalation will continue until a dose-limiting toxicity (DLT) is observed or the highest dose-level is reached.~In phase II study patients will receive niraparib p.o. once daily and cabozantinib p.o. once daily in 28-day cycles at doses recommended in the phase I study.~If niraparib or cabozantinib need to be interrupted due to toxicity, patient can continue only with the other drug."
89119499|NCT03402386|Experimental|MT-6548|
89119500|NCT03389932|No Intervention|Standard of Care (Control)|For patients who are randomized to the control condition and who are or become potentially eligible for transplant during their enrollment in the study, they will not receive any additional interventions during the study period. Patients in this condition will only receive the education that is administered by the KPSC Kidney Transplant Program and will not receive any educational materials designed for the intervention group of this study.
89119501|NCT03389932|Experimental|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
89119502|NCT03349762||Observational 1|Radiotherapy or Chemotherapy
89119503|NCT03349762||Observational 2|Huaier Granule & Radiotherapy or chemotherapy
89119504|NCT03349762||Observational 3|Huaier Granules
89119505|NCT03337087|Experimental|Treatment (nal-IRI, leucovorin, fluorouracil, rucaparib)|"PHASE Ia: Patients receive liposomal irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.~PHASE Ib/II: Patients receive liposomal irinotecan IV over 90 minutes and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity."
89119506|NCT03329196|Experimental|MT-6548|
89119507|NCT03329196|Active Comparator|Darbepoetin alfa|
89119508|NCT03318900|Experimental|Treatment (T-cell infusion, aldesleukin, utomilumab)|Patients undergo leukapheresis. Patients then receive cyclophosphamide IV on day -2, CD8-positive T-lymphocyte via infusion on day 0, and aldesleukin SC every 12 hours for 14 days. Beginning 24 hours after CD8-positive T-lymphocyte, patients also receive utomilumab IV over 90 minutes on days 1, 29, 57, 85, 113, and 141 in the absence of disease progression or unacceptable toxicity.
89119509|NCT03315364|Experimental|Liporaxel® (oral paclitaxel)|"28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.~Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration."
89119510|NCT03315364|Active Comparator|Taxol® (IV paclitaxel)|"28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.~Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL."
89119511|NCT03285438|Experimental|Reduced dose of DOAC|A reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) during a mean follow-up period of 36 months (12 to 65 months)
89119512|NCT03285438|Active Comparator|Full dose of DOAC|A full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily) during a mean follow-up period of 36 months (12 to 65 months).
89119513|NCT03263559|Experimental|Haploidentical Transplantation|A conditioning regimen with Hydroxyurea, rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, and Mesna will be administered prior to Haploidentical Bone Marrow Transplantation.
89119514|NCT03204916||Observational (cancer care delivery analysis)|"CHART REVIEW: Patient medical record data is abstracted and treatment plans are reviewed for consistency to NCCN guidelines. For each patient, induction and post-induction care is recorded as either concordant with NCCN guidelines or non-concordant with NCCN guidelines.~SITE QUESTIONNAIRE: Participating sites complete a questionnaire which is designed to capture facility-oriented data.~FOCUS GROUPS: Healthcare providers participate in focus groups over 2-3 hours to discuss facilitators and barriers to AYA ALL guideline concordance. Participants provide responses which will be recorded on a flip-chart or white board, followed by discussion of the ideas for clarification"
89119515|NCT03118050|Experimental|RT in T2DM|Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training. Results of this arm will be compared to those previously obtained in healthy older subjects who participated in NCT02999802 (same training protocol) after 1:1 matching for age and sex.
89119516|NCT03118050|Experimental|BR in healthy subjects, LAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
89119517|NCT03118050|Experimental|BR in healthy subjects, HAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
89119518|NCT03118050|Experimental|BR in T2DM, LAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
89233018|NCT03556618|Experimental|Whole Person Care (WPC) Reentry Program - Post-Release|"In partnership with LA County Health Agency, Dr. Barnert is adapting the successful Transitions Clinic model developed for reentry adults, to assist recently incarcerated transition age youth link to needed health services and reduce substance use disorder relapse and recidivism. This adaption is informed by Dr. Barnert's prior research on the needs of incarcerated adolescents. The intervention, called the Whole Person Care (WPC) Reentry Program will consist of community health workers (i.e. network coaches) who are formerly incarcerated and formally trained in care coordination and social network coaching, who interact with justice-involved transition age youth pre- and post-release to increase youths' engagement in community SUD and mental health services. Participants in this branch will include youth exiting the adult justice system (ages 18-24) who receive PRE- and POST-release WPC services."
89233019|NCT03556618|No Intervention|Control|Participants in the control arm will receive PRE-release services only from Whole Person Care. They will not receive the POST-release WPC community health worker intervention. Participants in this branch will include youth exiting the adult jail system (ages 18-24).
89233022|NCT03523442|Experimental|Apalutamide|Participants will receive a single oral dose of apalutamide 240 milligram (mg) during pharmacokinetics (PK) Week Day 1 and will be monitored for one week (that is; PK Week) to assess PK and safety of drug. Subsequently, participants will further receive daily treatment of apalutamide from Cycle 1 Day 1 onwards until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. Each treatment cycle consists of 28 days. After final analysis (FA), participants who are receiving apalutamide in the open-label treatment phase may continue receiving single oral dose apalutamide 240 mg once daily in a long-term extension (LTE) phase if they continue to derive benefit from treatment (based on investigator assessment).
89233023|NCT03519451|Experimental|Group I (KickAsh smartphone mobile application)|Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks.
89233024|NCT03519451|Experimental|Group II (Breathe2Relax smartphone mobile application)|Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks.
88800330|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 3 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
88800331|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 3 (3 to < 6 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
88800332|NCT02066623||Implantation of ABSORB Scaffold|Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold
88800333|NCT04974151|Active Comparator|amlodipine (5mg/d)|Amlodipine besylate tablets (5mg/d)
88800334|NCT04974151|Experimental|amlodipine folic acid (5.8mg/d)|Amlodipine besylate and folic acid tablets (5mg:0.8mg)
88800335|NCT04974151|Experimental|amlodipine folic acid (5.8mg/d) + 5-MTHF (0.4mg/d)|Amlodipine besylate and folic acid tablets (5mg:0.8mg) with 0.4mg/d 5-MTHF
88800336|NCT04195594|Experimental|Nic's Keto Diet|
88800337|NCT04918693||Participant|All 15 participants must be anesthesiologists who are competent to perform UGRA independently. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified and licensed Medical Doctor.
88800338|NCT04918693||Trainee|All 15 trainees must be healthcare practitioners who are licensed to perform UGRA. In order to be eligible for the study, participants must be a U.S. board-eligible/board-certified health practitioner
88800339|NCT01924819|Experimental|Preoperative chemoradiotherapy|"2 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 3 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel~5 weeks preoperative chemoradiotherapy.~Gastric resection.~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
88800340|NCT01924819|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel~Gastric resection.~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine) OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
89233025|NCT03516812|Experimental|Treatment (olaparib, testosterone enanthate or cypionate)|Patients receive olaparib PO BID on days 1-28 and testosterone enanthate or cypionate IM on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88800341|NCT01168687|Experimental|Group A|Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
88800342|NCT01168687|Experimental|Group B|Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
88800343|NCT03685396|Experimental|Test Group|In the Test Group venous blood sampling was done in order to prepare PRF membranes used to cover the donor site of the connective tissue graft.
88800344|NCT03685396|Active Comparator|Control Group|In Control Group hemostatic agents with oxidized and regenerated cellulosa were used to cover the donor site.
88800345|NCT04214080|Experimental|Study Group (SG)|"In addition to feeding and oral motor intervention strategies, intensive neck and trunk stabilization exercises based on Neurodevelopmental treatment-Bobath (NDT-B) concept principles were applied to this group.~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
88800346|NCT04214080|Placebo Comparator|Control Group (CG).|"(NDT-B) concept approaches and feeding and oral motor intervention strategies were applied to this group in routine treatment.~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
88800347|NCT01169311|Experimental|HEEA Stapler|hemorrhoidopexy using Covidien EEA Hemorrhoid and Prolapse Stapling Set
89233026|NCT03505320|Experimental|zolbetuximab (Cohort 1A)|Participants will be treated with zolbetuximab on a 21-day cycle in which zolbetuximab will be administered as a single agent every 3 weeks until disease progression, toxicity requiring cessation, start of another anti-cancer treatment or other treatment discontinuation criteria are met.
89233027|NCT03505320|Experimental|mFOLFOX6 plus zolbetuximab (Cohort 2)|Participants will be treated with zolbetuximab and mFOLFOX6 on a 42-day cycle in which zolbetuximab is administered on days 1 and 22, and mFOLFOX6 is administered on days 1, 15 and 29; however, for the first cycle, zolbetuximab will be administered on day 3 (instead of day 1) to allow for pharmacokinetic collection. Participants will receive up to 12 mFOLFOX6 treatments (4 cycles). Beginning at cycle 5, participants may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab for the remainder of the study per investigator's discretion. mFOLFOX6 treatment includes oxaliplatin: intravenous [IV] infusion, leucovorin: IV infusion, fluorouracil bolus: IV bolus, fluorouracil infusion: continuous IV infusion.
89233028|NCT03505320|Experimental|Pembrolizumab plus zolbetuximab (Cohort 3A)|Participants will be treated with zolbetuximab and pembrolizumab on a 21-day cycle. Loading dose of zolbetuximab will be administered at cycle 1, day 1 followed by maintenance dose of zolbetuximab once every 3 weeks (Q3W). Pembrolizumab will be administered to 3 to 6 subjects at a intravenously on day 1 of every 21-day cycle and will be infused 1 hour after the zolbetuximab infusion is completed. Tolerability and safety of zolbetuximab in combination with pembrolizumab will be evaluated during the 3-week dose-limiting toxicity (DLT) assessment period. If this cycle 1 dose is not tolerable, a lower dose of zolbetuximab in combination with pembrolizumab will subsequently be evaluated.
89290071|NCT04162600|Experimental|Group 1|"Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10^9 vp vaccination intramuscularly.~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
88800348|NCT03688282|Sham Comparator|Sham Wearable belt|Device will be worn but not turned on for 30 minutes.
88800349|NCT03688282|Experimental|Wearable vibration belt (30)|Device will be worn and turned on for 30 minute treatment.
88800350|NCT01126255|Active Comparator|1|Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks
88800351|NCT01126255|Experimental|2|Progesterone 8%, topical application, once daily about 2 g, during 12 weeks
88800352|NCT04198948|Experimental|Omeprazole, Then Placebo|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.
88800353|NCT04198948|Experimental|Placebo, Then Omeprazole|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.
88800354|NCT01169467|Active Comparator|Standard-of-Care plus Precedex|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment.
88800355|NCT01169467|Placebo Comparator|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
88800356|NCT04186780|Experimental|Intervention group|Intervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days.
89290072|NCT04162600|Experimental|Group 2|"Volunteers will receive a standalone dose of ChAdOx2 RabG 2.5 x 10^10 vp vaccination intramuscularly.~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
88800357|NCT04186780|Placebo Comparator|Placebo group|Patients with borderline cholesterol consumed two placebo cereal bars for 66 days.
88800358|NCT04822363|Experimental|Group A: Healthy|Low Dose Aspirin - 81mg daily for 7 days
88800359|NCT04822363|Experimental|Group B: Healthy|High Dose Aspirin - 325mg daily for 7 days
88800360|NCT04822363|Experimental|Group C: Healthy|Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days
88800361|NCT04822363|Experimental|Group D: Obese|Low Dose Aspirin - 81mg daily for 7 days
88800362|NCT04822363|Experimental|Group E: Obese|Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days
88800363|NCT01170247|Experimental|Intranasal Ketamine|
88800364|NCT01170247|Active Comparator|Intramuscular Ketamine|
88800365|NCT04765423|Experimental|NaF PET/CT scan and F-18 fluciclovine PET/CT|"Visit 1: Participant receives a whole body [F-18] NaF PET/CT (diagnostic study)~Visit 2: Participant receives a whole body [F-18] fluciclovine PET/CT within 3 weeks of Visit 1"
88800366|NCT03700372|Experimental|IOWA Approach Cardiac Ablation|Subjects who are treated with the IOWA Approach Cardiac Ablation System for paroxysmal atrial fibrillation.
88800367|NCT04352257||ultrasonography|pelvic and transrectal ultrasound
88800368|NCT04182958|Experimental|(14C)-OPC-61815|
88800369|NCT01126099|Experimental|Prazosin|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
88800370|NCT01126099|Placebo Comparator|Placebo|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
88800371|NCT04176406|Active Comparator|rTMS over a node within the fronto-parietal network|excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.
88800372|NCT04176406|Sham Comparator|Sham rTMS over a node within the fronto-parietal network|electrical sham coil applied over a node within the fronto-parietal network.
88800373|NCT04176406|Active Comparator|rTMS over the DLPFC|excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.
88800374|NCT04176406|Sham Comparator|Sham rTMS over the DLPFC|electrical sham coil applied over the DLPFC.
88800375|NCT04171102|Active Comparator|Short term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-5 weeks post implantation
88800376|NCT04171102|Active Comparator|Mid term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-4 months post implantation
88800377|NCT04171102|Active Comparator|Long term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 6-8 months post implantation
88800378|NCT03807544|Experimental|TENS treatment arm|This study is a usability study, where all subjects will receive the same experimental treatment for their single visit.
89119519|NCT03118050|Experimental|BR in T2DM, HAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
89119520|NCT03118050|Experimental|BR in healthy subjects, PT|Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
89119521|NCT03118050|Experimental|BR in T2DM, PT|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
89119522|NCT03101995|Experimental|Gemcitabine|Gemcitabine doses: 300 mg/m2/week for 6 weeks.
89119523|NCT03093922|Experimental|Atezolizumab alone with Gemcitabine and Cisplatin|Atezolizumab alone for 2 cycles. One treatment cycle equals 21 days. Then patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 6 cycles. All 8 treatment cycles will take approximately 24 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator. This cohort is NO LONGER ACCRUING patients since 5/22/2018.
89119524|NCT03093922|Experimental|Atezolizumab with Gemcitabine and Cisplatin|Gemcitabine and Cisplatin for 2 cycles. One treatment cycle equals 21 days. After 2 cycles of Gemcitabine and Cisplatin patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 4 cycles. All 6 treatment cycles will take approximately 18 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
89119525|NCT03093922|Experimental|Atezolizumab alone for 1 cycle prior to gemcitabine, cisplatin|"Atezolizumab alone for 1 cycle. One treatment cycle equals 21 days. After 1 cycle of atezolizumab the patients will receive combined atezolizumab and gemcitabine, cisplatin for 4 cycles. All 5 treatment cycles will take approximately 15 weeks. Cisplatin dose can be given on day 1 or split over days 1 and 8 at the investigators discretion. Once the split-dose cisplatin is used, it should be used for the remainder of the chemotherapy treatment course."
89119526|NCT03034473|Other|Blood and tissue samples during therapy|Collection of blood and tissue samples during preoperative multimodal treatment (Radiochemotherapy (RCTx) followed by total mesorectal excision (TME) and Chemotherapy (CT)) in rectal cancer.
89119527|NCT02949219|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89119528|NCT02932280|Experimental|Neratinib|There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.
89119529|NCT02923570|Experimental|Photon intensity modulated radiation therapy (IMRT)|IMRT to standard dose of 60-66Gy
89119530|NCT02923570|Experimental|Proton beam radiotherapy (PBRT)|PBRT to standard dose of 60-66Gy
89119531|NCT02907099|Experimental|Treatment (CXCR4 antagonist BL-8040, pembrolizumab)|Patients receive CXCR4 antagonist BL-8040 SC on days 1-5 and 8-12 of cycle 1 and days 1, 4, 8, and 11 of subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over about 30 minutes on day 1. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
89119532|NCT02892201|Experimental|All subjects|"for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation~Pembrolizumab will be given at a constant dose of 200 mg every three weeks, for four cycles. Patients with resectable disease can then go on to surgery, and patients with unresectable disease can continue on pembrolizumab until progression or for up to 1 year."
89119533|NCT02873195|Experimental|Arm I (atezolizumab, bevacizumab, capecitabine)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89119534|NCT02873195|Active Comparator|Arm II (placebo, bevacizumab, capecitabine)|Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89119535|NCT02846987|Experimental|Abemaciclib (LY2835219)|Patients will be treated with abemaciclib 200 mg bid.
89119536|NCT02836015|Experimental|Shared Medical Visit Groups|All patients will be enrolled in the experimental group and will be involved in shared medical visits.
89119537|NCT02697396||with text messaging reminder system|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
89119538|NCT02697396||without text messaging reminder system|Participants in this arm will receive no additional vaccination reminders. However, the study staff will ask and record if the participant's pediatrician provides appointment reminder cards, emails and/or calls prior to each scheduled vaccination as captured in the Outcomes Survey.
89119539|NCT02643667|Experimental|Phase I: Ibrutinib|"Ibrutinib 840 mg by mouth once daily for 2 weeks.~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib."
88800379|NCT01170715|Experimental|Experimental Group|Enbrel (etanercept): started with self-injection of 50 mg subcutaneous twice weekly for 12 weeks, followed by self-injection of 50 mg subcutaneous weekly for 40 weeks.
88800380|NCT03809182|Experimental|Dexmedetomidine|After anesthesia induction, patients who were randomized to the Dexmedetomidine group received a bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
88800381|NCT03809182|Placebo Comparator|0.9% Sodium-chloride|After anesthesia induction, patients who were randomized to the Placebo group received a bolus and infusion of 0.9% normal saline at the same rate as the Dexmedetomidine group until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
88800382|NCT01170949|Experimental|Miltefosine|
88800383|NCT01170949|Placebo Comparator|Placebo|
88800384|NCT03805672|Active Comparator|Low Dose Enoxaparin|Subjects are randomized to receive or begin prophylactic dosing (30 mg BID) of enoxaparin for 6 weeks or until DVT resolution.
88800385|NCT03805672|Active Comparator|High Dose Enoxaparin|Subjects are randomized to begin therapeutic dosing (1 mg/kg body weight BID) of enoxaparin for 6 weeks or until DVT resolution.
88800386|NCT04555135|Experimental|Colonoscopy Procedure with EndoVigilant Software|Colonoscopy Procedure is performed with EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
88800387|NCT04555135|No Intervention|Colonoscopy Procedure without EndoVigilant Software|Colonoscopy Procedure is performed without EndoVigilant Software assisting the gastroenterologist during colonoscopy procedure.
88800388|NCT04158466|Experimental|Kalifilcon A Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb kalifilcon A daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
88800389|NCT04158466|Active Comparator|Biotrue ONEday Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb Biotrue ONEday daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
89119540|NCT02643667|Experimental|Safety Run-In and Phase II: Ibrutinib|"Ibrutinib 840 mg by mouth once daily for 4 weeks.~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
89119541|NCT02600156|Experimental|Single arm study|MR guided focal laser ablation of prostate cancer using the Visualase Thermal Therapy System.
89119542|NCT02473757||1/Cohort 1|Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.
89119543|NCT02422524|Experimental|Child-Pugh A (Mild hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
89119544|NCT02422524|Experimental|Child-Pugh B (Moderate hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
89119545|NCT02422524|Experimental|Child-Pugh C (Severe hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
89119546|NCT02422524|Experimental|Non-hepatically impaired controls|18 matched Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
89119547|NCT02268682|No Intervention|Standard of Care (Control)|Patients randomized to the standard of care condition will not receive any educational materials from our program and will only participate in the survey portion of the investigation. Dialysis providers will be asked to continue their current practices throughout the study period without change. While Control patients will be free to ask additional questions or solicit more information from their dialysis educators at any point during the study period, no additional educational interventions will be added to what is currently being done.
89119548|NCT02268682|Experimental|Patient-Guided|Over an 8-month period, patients in the Patient-Guided intervention condition will receive four educational modules and twelve transplant education postcards in the mail. Modules will be mailed once every other month and consist of an introductory letter, a transplant video, and printed resources. Transplant education postcard will be mailed every two weeks following the mailing of each module, for a total of three postcards over the course of 6-weeks.
89119549|NCT02268682|Experimental|Educator-Guided|Patients in the Educator-Guided intervention condition will receive the same intervention components as those in the Patient-Guided condition; however, the key difference in this condition is that Educator-Guided patients will also receive telephonic support from an experienced clinical social worker in the role of a Transplant Educator to maximally facilitate learning. Telephonic meetings with the Transplant Educator will occur after the mailing of each study module, for a total of four calls, each lasting 20-minutes, totaling 1 hour and 20 minutes. Finally, Patient-Guided and Educator-Guided patients will have the option of enrolling in an educational text messaging service designed to supplement the ET education they are receiving in the mail.
89119550|NCT02252887|Experimental|Gemcitabine, Trastuzumab, and Pertuzuma|The regimen will consist of gemcitabine at 1000mg/m^2 IV weekly days 1 + 8 q 3 weeks + trastuzumab every 3 weeks (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose followed by 420 mg every 3 weeks), all given intravenously (IV). Trastuzumab may be given IV weekly (4 mg/kg loading dose followed by 2 mg/kg weekly) in lieu of the every 3 week schedule. A loading dose of trastuzumab will not be required for patients who have received it < 6 weeks prior to Cycle 1 Day 1.
88800390|NCT03802864|Experimental|Liposomal Bupivacaine|Participants in this arm will have a single injection of liposomal bupivacaine admixed with standard bupivacaine (266mg liposomal bupivacaine mixed with 50mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
88800391|NCT03802864|Active Comparator|Standard Bupivacaine|Participants in this arm will have a single injection of standard bupivacaine (100mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
88800392|NCT03797872|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice. Commonly Initial therapy will be with methotrexate alone unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (sulfasalazine or leflunomide). In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
88800393|NCT03797872|Experimental|Local/IM steroid injections|Symptomatic therapy arm. The intervention will delay standard treatment with disease-modifying anti-rheumatic drugs (DMARDs) and use local injections of methylprednisolone or triamcinolone to affected joints instead. Oral non-steroidal anti-inflammatory drugs (NSAIDs) will also be allowed as concomitant medication. All active joints will be treated with injections. Injections can be either be given as an intra-articular injection or as an intra-muscular injection. If any joint requires more than 2 local injections of glucocorticoid within a 6 month period, then the patient is deemed to have failed symptomatic therapy and will be withdrawn from the treatment protocol and be treated as per usual care (in most cases with DMARD therapy).
88800394|NCT03782272|Experimental|AA-ORS|Those receiving enterade oral re-hydration solution with amino acids
89119551|NCT02205047|Active Comparator|Standard chemotherapy|Cisplatin/capecitabine or cisplatin/5-fluorouracil
88800395|NCT03782272|Placebo Comparator|Placebo|Those receiving placebo solution without amino acids or rehydration salts
88800396|NCT01127581|Experimental|MVI 200|MVI 200 mcg vaginal insert
88800397|NCT01127581|Active Comparator|Dinoprostone Vaginal Insert (DVI)|10 mg Dinoprostone vaginal insert
88800398|NCT03794752|Other|Vision Aided by a Head Mounted Device|A Head-Mounted Visual Enhancement Device developed by Evergaze Technology LLC has designed an electronic visual enhancement device that is compact and similar to glasses. It will be powered by a battery pack connected to the device. The electronic display will be affixed over only one of the user's eyes. The vision through the unobstructed eye will aid with the subject's balance and spatial orientation.
88800399|NCT04124536|Experimental|Intervention|In addition to standard partner notification services, the intervention arm will receive HIV self-test kits and structured counseling about HIVST, regardless of HIV status.
88800400|NCT04124536|No Intervention|Control|Standard partner notification services, regardless of HIV status.
89119552|NCT02205047|Experimental|Experimental arm 1|Cisplatin/capecitabine plus trastuzumab or cisplatin/5-fluorouracil plus trastuzumab
89119553|NCT02205047|Experimental|Experimental arm 2|cisplatin/capecitabine plus trastuzumab and pertuzumab or cisplatin/5-fluorouracil plus trastuzumab and pertuzumab
89119554|NCT02181114|Experimental|Expert System Coaching|Patients in the intervention group will receive coaching based off the answers provided in the computer-based Expert System that is designed to track their readiness level to pursue a living donor kidney transplant.
89119555|NCT02181114|No Intervention|Control|Patients in the control group will only receive the standard of care education that is offered at the UCLA Kidney and Pancreas Transplant Center which consists of a powerpoint presentation on their Evaluation Day appointment.
89119556|NCT02136238|Active Comparator|Prosthetic hand 1 (Hosmer 5XA)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 1
89119557|NCT02136238|Active Comparator|Prosthetic hand 2 (TRS Grip 3)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 2
89119558|NCT02136238|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
89119559|NCT02106611||Hodgkin Lymphoma Survivor|This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.
89119560|NCT02051062|Experimental|Blood sample collection|One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration, but within a maximum of 32 hours after administration.
89119561|NCT02026232|Active Comparator|hydroxychloroquine|hydroxychloroquine twice daily for 4 weeks
89119562|NCT02026232|Placebo Comparator|Placebo|hydroxychloroquine placebo twice daily for 4 weeks
89119563|NCT02008656|Experimental|INCT|Arm 1 will receive chemotherapy before chemoradiation. This is called induction neoadjuvant chemotherapy arm (INCT). The neoadjuvant chemotherapy regimen is prescribed specifically as 8 cycles of FOLFOX or 5 cycles of CapeOX over a period of approximately 15-16 weeks. Endoscopic exam (2-4 wks) after chemotherapy. If stable or response then pt will have radiation with either 5-FU or capecitabine.
89119564|NCT02008656|Experimental|CNCT|Arm 2 will receive chemoradiation before chemotherapy This is called the consolidation neoadjuvant chemotherapy arm (CNCT). Pt will have 6 weeks of chemoradiation therapy. Along with the radiation the pt will receive either 5-FU or capecitabine. 2-4 weeks after pt will have endoscopic exam and if stable or response pt will have will have 8 cycles of FOLFOX or 6 cycles of CapeOX.
88800401|NCT01127737|Placebo Comparator|Control|
89119565|NCT02008357|Experimental|Solanezumab/Solanezumab|"Participants received 400 milligram (mg) solanezumab followed by 800 mg solanezumab and then 1600 milligram solanezumab administered intravenously (IV) every 4 weeks (Q4W) for approximately 240 weeks in double-blind placebo-controlled period.~Participants begin open label extension and received 1600 mg solanezumab Q4W for 204 weeks (from week 240 to week 444)."
89119566|NCT02008357|Placebo Comparator|Placebo/Solanezumab|"Participants received placebo administered IV Q4W for approximately 240 weeks in double-blind period.~Participants begin open label extension period and received 1600 mg solanezumab Q4W for 204 weeks (from week 240 to week 444)."
89119567|NCT01983410||BRCAmut carrier relatives of a BRCAmut PDAC patient|Who themselves have no known prior or active personal history of non-PDAC malignancy (e.g. breast , ovarian cancer or prostate cancer)
89119568|NCT01983410||BRCAmut carrier relatives of a BRCA mutation PDAC|Patient who themselves have a known prior or active breast, ovarian cancer or prostate cancer
89119569|NCT01983410||BRCAmut carriers|who are not related to a BRCAmut PDAC patient
89119570|NCT01983410||AJ PDAC patients|who are proven non-BRCAmut carriers.
89119571|NCT01983410||AJ first or second degree relatives of an AJ PDAC patient from a multiplex family|A family with at least two first or second degree relatives w ho have had PDAC.
89119572|NCT01825603|Experimental|Treatment (ADH-1, cisplatin, gemcitabine hydrochloride)|Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride.
89119573|NCT01471483||patient will receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
89119574|NCT01471483||patients will not receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
89119575|NCT01290055|Experimental|Group 1a - Drink deuterated water on days 0 - 14 post-vaccination|Participants testing positive for human leukocyte antigen-A2 (HLA-A2) will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 2 weeks, on Days 0 through 14 post-vaccination.
89119576|NCT01290055|Experimental|Group 1b - Drink deuterated water on days 14 - 28 post-vaccination|Participants testing positive for HLA-A2 will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1b will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 2 weeks, on Days 14 through 28 post-vaccination.
89119577|NCT01290055|Experimental|Group 1c - Drink deuterated water on days 0 - 28 post-vaccination|Participants testing positive for HLA-A2 will be enrolled into one of the three Group 1 study arms. To assess the life span and decay of effector CD8+T cells, participants in group 1c will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water for 4 weeks, on Days 0 through 28 post-vaccination.
89119578|NCT01290055|Experimental|Group 2a - Drink deuterated water 2 months post-vaccination|To assess the homeostatic proliferation of Memory CD8 T cells, participants in group 2a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water 2 months post-vaccination.
89119579|NCT01290055|Experimental|Group 2b - Drink deuterated water 6 months post-vaccination|To assess the homeostatic proliferation of Memory CD8 T cells, participants in group 2b will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water 6 months post-vaccination.
89119580|NCT01290055|Experimental|Group 3 - Drink deuterated water for up to 8 weeks without vaccination|To assess homeostatic turnover of CD8+ T lymphocytes in general, unvaccinated participants will be asked to drink deuterium (70% enriched 2H2O) labeled water for up to 8 weeks.
89119581|NCT01290055|Experimental|Group 4a - Drink deuterated water on days 0 - 7 post-vaccination, with fine needle aspirate|To assess homeostatic turnover of monocytes participants in group 4a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water on Days 0 through 7 post-vaccination. Participants will undergo two fine needle aspirate (FNA) procedures to examine the immune response in the lymph nodes.
89119582|NCT01290055|Experimental|Group 4b - Drink deuterated water for 7 days without vaccination|To assess homeostatic turnover of monocytes participants in group 4b, unvaccinated participants will will be asked to drink deuterium (70% enriched 2H2O) labeled water for 7 days post enrollment.
89119583|NCT01266096|Experimental|newly diagnosed or recurrent head/neck melanoma|This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.
89119584|NCT00870129|Experimental|MRI|The advanced MRI studies will be obtained at the time of the routinely scheduled preoperative planning MRI and/or the routinely scheduled pre-RT planning MRI at approximately 3±2 weeks after surgery. The routine sequences obtained for the planning MRI are standard of care. The advanced MRI sequences may or may not be additional as some have already been adopted into the standard of care imaging at MSKCC.
89119585|NCT00836862||Arteriovenous Fistula|A tissue bank will be created to collect serum, whole blood, and vein specimens obtained from participants undergoing Arteriovenous Fistula (AVF) placement and revision. The planned specimen harvests will allow for both pre- and post-AVF placement specimens from both maturing and failing AVF.
88800402|NCT01127737|Active Comparator|Intervention|Educational intervention consisting of a mnemonic and a workbook used by kidney transplant recipients (KTRs) to assist with early detection of SCCs.
89233029|NCT03505320|Experimental|Zolbetuximab in combination with mFOLFOX6 and nivolumab (Cohort 4A/4B)|Participants will be treated with zolbetuximab and mFOLFOX6, nivolumab on a 42-day cycle. Cohort 4A: Loading dose of zolbetuximab in combination with nivolumab and mFOLFOX6 on cycle 1 day 1, followed by zolbetuximab in combination with nivolumab and mFOLFOX6 q2w [days 15 and 29] (1 cycle = 6 weeks). Tolerability and safety of zolbetuximab in combination with nivolumab, mFOLFOX6 will be evaluated during the 3-week DLT assessment period. If cycle 1 dose is not tolerable, a lower dose of dose zolbetuximab in combination with nivolumab and mFOLFOX6 will be subsequently evaluated. Cohort 4B: Subjects will be treated with the combination of zolbetuximab, mFOLFOX6 and nivolumab at the dose deemed tolerable in Cohort 4A. Subjects will receive up to 12 mFOLFOX6 treatments (4 cycles). For Cohorts 4A and 4B, beginning at cycle 5, subjects may continue on 5-FU and leucovorin or folinic acid along with zolbetuximab and nivolumab for the remainder of the study per investigator's discretion.
89233030|NCT03505320|Experimental|Zolbetuximab in combination with FLOT (Cohort 5)|"Participants will be treated with zolbetuximab & FLOT for a total of eight 2-week cycles. 4 cycles preoperatively & 4 cycles postoperatively 6-12 weeks after surgery.~Preoperative: Participants will receive zolbetuximab loading dose on cycle 1 day 1, followed by FLOT on cycle 1 day 2. For cycles 2-4, participants may receive zolbetuximab maintenance dose in combination with FLOT, dosed on day 1 of each cycle. However, dosing may be split over 2 days with zolbetuximab administration on day 1 & FLOT on day 2.~Post operative: Participants will receive zolbetuximab loading dose on cycle 5 day 1, followed by FLOT on cycle 5 day 2. For cycles 6-8, participants may receive zolbetuximab maintenance dose in combination with FLOT, dosed on day 1 of each cycle. However, dosing may be split over 2 days with zolbetuximab administration on day 1 and FLOT on day 2. For participants who experience a DLT during preoperative treatment on the loading dose, the postoperative loading dose may be lowered."
89233033|NCT03472586|Experimental|Treatment (ipilimumab, nivolumab, immunoembolization)|Patients receive ipilimumab IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Patients also undergo immunoembolization on day 2. Cycles repeat every 3 weeks for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive nivolumab IV on day 1 and undergo immunoembolization on day 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. The interval between treatments may be extended up to every 6 weeks at the discretion of the treating physician.
89233034|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 1 (Guselkumab)|Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
89233035|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 2 (Guselkumab)|Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
89233036|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 3 (Guselkumab)|Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
89233037|NCT03466411|Active Comparator|Phase 2 (GALAXI 1): Group 4 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
89233038|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
89233039|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
88800403|NCT03709810|Experimental|Test Denture Adhesive|Test denture adhesive will be applied directly from the tubes using a continuous strip pattern to the upper and lower denture which will then be placed in mouth of the participants.
88800404|NCT03709810|Other|Control|Participants will not apply any denture adhesive in this treatment arm.
88800405|NCT01128049|Active Comparator|Normal Patient Population|Non-Dry Eye patient population (intervention remains the same across all arms)
88800406|NCT01128049|Active Comparator|MGD Patient Population|Meibomium Gland Dysfunction population(intervention remains the same across all arms)
88800407|NCT01128049|Active Comparator|ADDE Population|Aqueous Deficient Dry Eye population(intervention remains the same across all arms)
88800408|NCT04498351|Placebo Comparator|cotrol group|
88800409|NCT04498351|Active Comparator|dexmedetomidine group|
88800410|NCT04498351|Active Comparator|magnesium sulphate group|
88800411|NCT04498351|Active Comparator|dexmedetomidine and magnesium sulphate group|
88800412|NCT03784300|Active Comparator|50 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.
88800413|NCT03784300|Placebo Comparator|50 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.
88800414|NCT03784300|Active Comparator|100 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.
88800415|NCT03784300|Placebo Comparator|100 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.
88800416|NCT03784300|Active Comparator|200 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.
88800417|NCT03784300|Placebo Comparator|200 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.
88800418|NCT02186665|Experimental|calcitriol ointment|calcitriol 3 mcg/g ointment
89233040|NCT03466411|Active Comparator|Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
89233041|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
89233042|NCT03457701|Experimental|rhEPO+57Fe followed by Daprodustat+58Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: Histamine [H2] receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
88800419|NCT02186665|Placebo Comparator|placebo|placebo comparator
88800420|NCT03713398|Experimental|T4C-SMI Group|Participants will receive the T4C-SMI intervention, in addition to standard prison mental health services
89233043|NCT03457701|Experimental|rhEPO+58Fe followed by Daprodustat+57Fe|Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
89233044|NCT03457701|Experimental|Daprodustat+57Fe followed by rhEPO+58Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
89233045|NCT03457701|Experimental|Daprodustat+58Fe followed by rhEPO+57Fe|Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.
89233046|NCT03455530|Experimental|Intervention Group|The intervention group will receive the IH-enhanced CHW intervention before (~3 months) the other arm (Delayed Intervention Group).
89233047|NCT03455530|Other|Delayed Intervention Group|The delayed intervention group will receive the IH-enhanced CHW intervention after (~3 months) the other arm (Intervention Group).
89233048|NCT03451851|Experimental|Part 1 Group 1: Guselkumab|Participants in Part 1a (age greater than or equal to (>=) 12 - less than (<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose >=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) Phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
89290073|NCT04162600|Experimental|Group 3|"Volunteers will receive a standalone dose of ChAdOx2 RabG 5 x 10^10 vp vaccination intramuscularly.~Optional extended follow-up, volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine."
89290074|NCT03935022|Experimental|Black rice Venere|Healthy volunteers will receive the black rice Venere in a cross-over randomized clinical trial (after 7 days wash-out).
89290075|NCT03935022|Experimental|Black rice Artemide|Healthy volunteers will receive the black rice Artemide in a cross-over randomized clinical trial (after 7 days wash-out).
88800421|NCT03713398|No Intervention|Control Group|The control group receives standard prison mental health services
88800422|NCT05313646|Experimental|batch 1 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101001.
88800423|NCT05313646|Experimental|batch 2 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101002.
88800424|NCT05313646|Experimental|batch 3 of Ad5-nCoV|Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202102003.
88800425|NCT01172197|Active Comparator|Ropivacaine|Local anaesthetic bolus and infusion
88800426|NCT01172197|Active Comparator|Levobupivacaine|Local anaesthetic bolus and infusion
88800427|NCT03771274|Experimental|Tecnis ZLB00 & Symfony IOL|The Tecnis multifocal ZLB00 and the Symfony IOLs are presbyopia correcting lenses designed to improve the vision at distance, intermediate and near reducing the need for glasses in patients undergoing cataract surgery.
88800428|NCT04420663|Experimental|Manometer Group|"Therapeutic thoracentesis will be performed in a sitting position. wide bore catheter as a pleural catheter will be inserted into the pleural cavity. simple water manometer will be connected to the pleural catheter via 3-way adapter.connected to the infusion lines with one draining into the drainage collection bottle and the other pre-flushed with normal saline hanging down till 40 cm below the puncture site and then rising up (forming a U) with the ascending arm taped to the IV stand. baseline pleural pressure will be registered before the beginning of pleural fluid withdrawal. Pleural pressure curve will subsequently be registered after the withdrawal of each 200 ml of pleural fluid up to a total volume of 1000 ml."
88800429|NCT04420663|No Intervention|Conventional Group|Therapeutic thoracentesis will be performed in a sitting position. The skin will be cleaned with betadine antiseptic solution. Pleural aspiration should take place in a clean area using full aseptic techniques. 5-10 cc Lidocaine 2% will be given as local anesthetic in the site of puncture. the IV cannula is advanced till fluid is aspirated. Then, the needle is withdrawn and the catheter is fixed to two 3-way adapters fixed in series placed in between. connected to the infusion lines with one draining into the drainage collection bottle.
88800430|NCT04141930|Other|Study Drug Eligible|Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant
88800431|NCT04374565|Experimental|Study participants|A total of 29 eligible subjects will be enrolled to receive high titer anti-SARS-CoV-2 plasma. Participants will be compared to a historical control group via retrospective chart review.
88800432|NCT01128829|Experimental|water-sucralose|"Subjects in this group drank water 10 min before drinking a glucose load on their first oral glucose tolerance test (OGTT) and drank sucralose 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
89119586|NCT00775463|Experimental|treprostinil diethanolamine|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
89119587|NCT00775463|Placebo Comparator|placebo (sugar pill)|Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
89119588|NCT00406640|Active Comparator|A|
89119589|NCT00406640|Active Comparator|B|
89119590|NCT00229931|Active Comparator|Laser therapy|If randomized to laser therapy at time of cataract surgery, laser therapy will be performed one month after cataract surgery. If macular edema does not respond an additional laser therapy will be performed. If macular edema persists after 2 lasers, then IVTA will be administered as per standard of care.
89119591|NCT00229931|Active Comparator|Triamcinolone therapy|"At time of cataract surgery, will have IVTA injection. If macular edema does not show improvement at 1 month, then can have repeat IVTA injection. If the macular edema is stil not improved after 2nd injection, participant will be considered treatment failure and will be given the option to have laser therapy."
89119592|NCT00150969|Experimental|phyloquinone|5 mg Vitamin K1
89119593|NCT00150969|Placebo Comparator|placebo|
89119594|NCT00770770|Experimental|Fluocinolone Acetonide 0.2 µg/day|0.2 µg/day
89119595|NCT00770770|Experimental|Fluocinolone Acetonide 0.5 µg/day|0.5 µg/day
89119596|NCT03656731|Experimental|Intervention group (n=50)|Patients in the intervention group will receive standard care and a 12-week exercise-based intervention.
89119597|NCT03656731|No Intervention|Control group (n=50)|Patient in the control group will receive standard care.
89119598|NCT00766636|Experimental|Gemcitabine + Erlotinib Without Radiation|"Gemcitabine + Erlotinib without radiation - Arm A: Gemcitabine 1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42.~Surgical removal of the pancreas and duodenum."
89119599|NCT00766636|Experimental|Gemcitabine + Erlotinib With Radiation|Gemcitabine + Erlotinib with radiation - Arm B: Gemcitabine 400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42. Radiation therapy 1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy. Surgical removal of the pancreas and duodenum.
89119600|NCT04103086|Experimental|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol). All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
89119601|NCT04103086|Placebo Comparator|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
89119602|NCT02580097||Stroke|Ischemic stroke patients with sympton onset in 24 hours and no contradiction to MRI scan
89119603|NCT05023681|Experimental|r-SAK treatment group|intravenous injection of single bolus 5 mg r-SAK in 3min
89119604|NCT05023681|Placebo Comparator|saline control group|intravenous injection of 10ml saline in 3min,r-SAK and saline are the same in appearance
89119605|NCT03297229|Experimental|Peer mentoring|Peers will be patients with hypertension that have already been adequately controlled within the last six months. They will be selected within each center by the staff of the center and invited to participate in the study.
89119606|NCT03297229|Experimental|Self-monitoring|Each participant will receive a blood pressure monitor. The study nurse will teach the participant on how to use the device.
89119607|NCT03297229|No Intervention|Control|Usual care
89119608|NCT03289585||Hidradenitis Suppurativa Cohort|Patients with Hidradenitis Suppurativa (ages 18-99 years old) will be asked to complete a series of questionnaires on how Hidradenitis Suppurativa impacts quality of life.
89119609|NCT02581969||Prophylaxis|Prophylaxis group: treatment is based on regularly repeated infusions of clotting factor, 20-30 IU/kg -3 times a week
89119610|NCT02581969||On-demand|On-demand group: treatment administered when bleeding episode occur
89119611|NCT00770692|Experimental|Eszopiclone 1 mg- Elderly|
89119612|NCT00770692|Experimental|Eszopiclone 2 mg- Elderly|
89119613|NCT00770692|Experimental|Eszopiclone 2 mg- Non-elderly|
89119614|NCT00770692|Experimental|Eszopiclone 3 mg- Non-elderly|
89119615|NCT02602054|Experimental|Surgical treatment|Implement surgical treatment for closure of patent ductus arteriosus
89119616|NCT02602054|Active Comparator|Control group|"- Indomethacin: Administer 1 full cycle (3 doses) of indomethacin (1 dose every 12 hours) for 2 days Dose 0.1 - 0.25 mg / kg~- Ibuprofen: Administer 1 full cycle (3 doses) of ibuprofen (1 dose every 24 hours) for 2 days Dose 05 - 10 mg / kg~- Acetaminophen: Administer 1 full cycle (12 doses) of acetaminophen (1 dose every 6 hours) for 3 days Dose 15 mg / kg"
89119617|NCT02816203|Experimental|Primary Hemostatic Intra-Uterine suction cup|Patients who present primary postpartum hemorrhage requiring administration of Nalador and the suction cup placed in the uterine cavity
89119618|NCT03248557||Study|Comatose survivors (GCS ≤8) after RoSC, in whom neurological prognosis is unknown at the time of admission. Neurological performance of patients from the study group (prospective and retrospective) will be categorized according to a risk score obtained from the multivariate spectral-based model.
89119619|NCT03248557||Control|Patients who are conscious (GCS=15) and whose neurological status is known and good at admission.
89119620|NCT04100668|Experimental|Data collection|Comparing radial arterial line, Sensifree's Alpha sensor and PPG sensor pressure waveforms
89119621|NCT02579551|Experimental|Treatment (surgical excision)|Patients undergo surgical excision of the skin lesion consisting of 1 and 2 mm circumferential margins during visit 1.
89119622|NCT04099732|Experimental|Part 1: Reference 1 followed by Test 1|Reference 1 - Rosuvastatin. Test 1 - Rosuvastatin + BI 1358894
89119623|NCT04099732|Experimental|Part 2: Reference 2 followed by Test 2|Reference 2 - Dabigatran etexilate. Test 2 - Dabigatran etexilate + BI 1358894
89119624|NCT04074655|Experimental|Intervention Arm|Participants of the study will play the driving simulator daily (5 days/week) for 15-20 minutes/day over a period of 2 consecutive weeks.
89119625|NCT02579785|Experimental|mhealth intervention|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number. Also receives Mobile phone based intervention for post-abortion contraceptive uptake.
89119626|NCT02579785|No Intervention|Standard Care|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number.
89119627|NCT03183115|Experimental|RFA group|"Balloon type RFA (12J/cm2, 1 application) will be applied for the entire speckled esophageal mucosa at the 3 months after complete ESD.~Oral prednisolone 30mg/day will be prescribed at day 3 after RFA procedure and continue for 28 days to prevent the post-RFA stenosis."
89119628|NCT03183115|No Intervention|Control group|No intervention; surveillance endoscopy alone
89119629|NCT04074499||Group-1|"The patients were classified based on the frequency of falls in the last 12 months.~Group-1 consists of COPD patients whose have at least one fall (fallers)"
89119630|NCT04074499||Group-2|"The patients were classified based on the frequency of falls in the last 12 months.~Group-2 consists of COPD patients whose have no history of falls (non-fallers)."
89119631|NCT02743897|Experimental|Direct-acting antiviral treatment for HCV|
89119632|NCT02743819|Experimental|Treatment|Treatment with the combination of pembrolizumab and ipilimumab.
89119633|NCT04074421|Active Comparator|Rifaximin group|Repeating treatment of Rifaximin
89119634|NCT04074421|Sham Comparator|Probiotics group|Sequential treatment of probiotics called Bacillus subtilis and Enterococcus faecium
89119635|NCT04074421|Placebo Comparator|Placebo group|Placebo control group
89119636|NCT02579707|Active Comparator|Treatment A: Unfed|Treatment A: Single oral dose of AG-120 at Hour 0 on Day 1, following a 10-hour overnight fast.
89119637|NCT02579707|Active Comparator|Treatment B: Fed|Treatment B: Single oral dose of AG-120 at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
89119638|NCT02579707|Experimental|Part 2 Single Dose|PART 2 is an open-label study to determine the safety and PK parameters of a single 1000-mg oral dose of AG-120.
89119639|NCT02713009|Experimental|Treatment 1|Pregnancy multivitamin + vitamin D daily from ~Week 12 gestation until delivery
89119640|NCT02713009|Placebo Comparator|Treatment 2|Pregnancy multivitamin + placebo daily from ~Week 12 gestation until delivery
89119641|NCT03085225|Experimental|Combination of trabectedin with durvalumab|"Trabectedin will be administered intraveinously, on day 1 of each cycle, every three weeks, as appropriate for assigned dose level.~Durvalumab will be administered intraveinously, at fixed doses of 1120 mg (equivalent to 15 mg/kg), on day 2 of each cycle, every three weeks."
89119642|NCT02580019|No Intervention|conventional stroke treatment|Control group without intervention, whereas they receive conventional stroke treatment that including rehabilitation
89119643|NCT02580019|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation accompanied with conventional treatment including rehabilitation
89119644|NCT02705287||Vitamin D dynamics-pregnant|Pregnant women recruited to measure Vitamin D dynamics during pregnancy.
89119645|NCT02705287||Vitamin D dynamics-nonpregnant|Non-pregnant women recruited to measure Vitamin D dynamics.
89119646|NCT01004822|Experimental|Active Drug|Weekly infusions of CVX-241 at specified doses
89119647|NCT03022279|Active Comparator|TAP blocks|TAP block group will receive three injections performed by an Anesthesiologist trained in the procedure, prior to initiation of the surgical procedure. Bilateral posterior transversalis fascial plane blocks and a right sided subcostal transverse abdominal plane block will be placed under ultrasound guidance. Normal saline will be used to confirm proper muscle layer placement before instillation of the local anesthesia. All patients will receive 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL (divided equally amongst the injection sites).
89119648|NCT03022279|Active Comparator|Local Wound Infiltration|Local wound infiltration (LWI) will be performed by the operative surgeon using 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL divided amongst the four port sites. 40% of the total dose will be given at the umbilicus, and 20% will be given at each of the other 3 ports. The majority of the anesthetic will be administered at the peritoneal level. Laparoscopic/robotic cholecystectomy will be performed with a port at the umbilicus and three smaller ports in a standard fashion in the subxiphoid and right upper quadrant regions. If conversion to open cholecystectomy occurs, the study data will still be collected, but the patient's data will be excluded from analysis.
89119649|NCT02578537|Experimental|Ticagrelor group|ticagrelor 180mg loading, followed by 90mg bid for 30 days
89119650|NCT02578537|Active Comparator|Clopidogrel group|clopidogrel 600mg loading, followed by 75mg/d for 30 days
89119651|NCT03011671|Experimental|Acetazolamide with Temozolomide|Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
89119652|NCT00628706|Experimental|A|Inhalation of THC, using a Volcano vaporizer
89119653|NCT00628706|Placebo Comparator|B|Inhalation of vehicle, using a Volcano vaporizer
89119654|NCT01001234|Experimental|Stage 1: rizatriptan|
89119655|NCT01001234|Placebo Comparator|Stage 1: placebo|
89119656|NCT01001234|Experimental|Stage 2: rizatriptan|
89119657|NCT01001234|Placebo Comparator|Stage 2: placebo|
89119658|NCT02870504|Experimental|corneoscleral limbus group|Laser spot locates on the corneoscleral limbus.
89119659|NCT02870504|Experimental|One spot group|Laser spot locates on one spot away from the corneoscleral limbus
89119660|NCT02870504|Experimental|Two spots group|Laser spot locates on two spots away from the corneoscleral limbus
89119661|NCT02649829|Experimental|Single Arm|dendritic cell vaccination plus chemotherapy
89119662|NCT04294082||Mindfulness based intervention|A shortened version of a mindfulness-based intervention originally developed by Jon Kabat-Zinn for management of chronic pain.
89119663|NCT04295642|Placebo Comparator|Part 1|Will include 4 subjects (3 active + 1 placebo) that will receive a single 15mg dose with approximately 48 hours of confinement and a follow-up after 7 days.
89119664|NCT04295642|Experimental|Part 2|"2A: will include 14 subjects to complete 12 with 28 days of dosing with 7 days (+/-2) of follow-up, with at least 14 days of confinement.~-or- 2B: will include 20 subjects to complete 12 with 2 dosing days and 5 days of washout with 7 days (+/-2) of follow-up, with 4 days of confinement (may be increased up to 12 days at the investigators discretion)."
89119665|NCT04297046|Active Comparator|QLB for total abdominal hysterectomy|Quadratus lumborum block (QLB) was performed bilaterally with 0,3 ml/kg 0.25% bupivacaine (maximum dose 3 ml/kg) solution injection on each side.Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
89119666|NCT04297046|Active Comparator|TAPB for total abdominal hysterect0my|The transversus abdominis plane block (TAPB)was performed bilaterally with 0.3 ml/kg of 0.25% bupivacaine (maximum dose 3 ml/kg) solution . Combine patient-controlled intravenous analgesia(same as PCA for TAH arm).
89119667|NCT02578459|Experimental|Intrathecal Drug Delivery (ITDD)|These subjects will have a Prometra System implanted and managed with the appropriate drug regimen to treat their pain.
89119668|NCT02578459|Active Comparator|Conventional Medical Management (CMM)|These subjects will be treated with conventional medical management to treat their pain.
89119669|NCT02578381|Experimental|Boston Scientific PW versus St Jude PW|Performance of Boston Scientific PW vs St Jude PW
89119670|NCT02578381|Experimental|Boston Sci PW vs Boston Sci PW|Boston Sci PW vs Boston Sci PW
89119671|NCT02578381|Active Comparator|St Jude PW versus St Jude PW|Performance of St Jude PW vs St Jude PW
89119672|NCT01004510|Experimental|Zoledronic Acid|Zometa administered as a 15 minute IV infusion of either 4 mg, 3.5mg, 3.3 mg or 3.0 mg every 4 weeks based on the patient's baseline calculated creatinine clearance(CrCl)using the Cockcroft-Gault formula.
89119673|NCT02578303|Experimental|Dementia group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).~ROC method will be used to find a threshold value of IAH that separates the two groups.~Interventions:~Vascular flow measurement by PC-MRI~Neuropsychological assessment~Registration of sleep apnea~Registration of blood pressure~ECG holters~Blood test~Geriatric standard evaluation"
89119674|NCT02578303|Other|control group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).~ROC method will be used to find a threshold value of IAH that separates the two groups.~Interventions:~Vascular flow measurement by PC-MRI~Neuropsychological assessment~Registration of sleep apnea~Registration of blood pressure~ECG holters~Blood test~Geriatric standard evaluation"
89119675|NCT04073953|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15mg of RPQ every day for 5 days. Cohort 2 will receive 22.5 mg of RPQ every day for five days.
89119676|NCT04073953|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15mg of SPQ every day for 5 days. Cohort 2 will receive 22.5 mg of SPQ every day for five days.
89119677|NCT04073953|Placebo Comparator|Placebo|Cohort 1 will receive placebo capsules every day for 5 days. Cohort 2 will receive placebo capsules every day for five days.
89119678|NCT02863783|Experimental|Fiducial Placement|EUS with Fiducial Placement into Tumor
89119679|NCT04073017|Experimental|Enterade|Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
89119680|NCT04073017|Experimental|Experimental|Non-Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
89119681|NCT02853175||Patients with both CF and ABPA|"Patients with both cystic fibrosis and allergic broncho-pulmonary aspergillosis (ABPA).~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
89119682|NCT02853175||Patients with CF and no ABPA|"Patients with both cystic fibrosis and no allergic broncho-pulmonary aspergillosis (ABPA).~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
89119683|NCT02849041|Experimental|Screening program|Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta. This population should accept to have a medical imaging Low-dose CT-scanner and an Identification of Circulating Tumor Cells on their blood. 30 first patients will be proposing to particpate to the psychologic sub-study by answering to a Psychological Questionnaires
89119684|NCT01004432|Experimental|Open-label (OL) Overall Group: Golimumab 50 mg SC + MTX|All enrolled and dosed participants receive golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks + Methotrexate (MTX) from Week 0 to Week 12.
89290076|NCT03935022|Sham Comparator|Complete white rice|Healthy volunteers will receive the complete white rice in a cross-over randomized clinical trial (after 7 days wash-out).
89119685|NCT01004432|Experimental|Double blind (DB) Group 2a: Golimumab 50mg SC & Placebo IV+MTX|Participants, who do not achieve Disease Activity Score in 28 joints (DAS28) good response at Week 16, will be randomly assigned to receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48, along with placebo matched to golimumab intravenous infusion (IV) at Week 16, 20, 28, 36, and 44.
89119686|NCT01004432|Experimental|DB Group 2b: Golimumab 2mg/kg IV & Placebo SC + MTX|Participants, who do not achieve DAS28 good response at Week 16, will be randomly assigned to receive golimumab 2 milligram per kilogram (mg/kg) intravenous infusion (IV) + MTX, at Week 16, 20, 28, 36 and 44, along with placebo matched to golimumab SC injection every 4 weeks from Week 16 to Week 48.
89119687|NCT01004432|Experimental|OL Group 1: Golimumab 50 mg SC + MTX|Participants, who achieve DAS28 good response at Week 16, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48.
89119688|NCT01004432|Experimental|OL Study Extension Group: Golimumab 50 mg SC + MTX|Participants who complete the main study (Week 0 to Week 52), do not meet lack of efficacy criteria, and participate in the OL study extension, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 52 to Week 72.
89119689|NCT02576275|Experimental|Duvelisib + Rituximab + Bendamustine|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Bendamustine is administered as an intravenous (IV) infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
89119690|NCT02576275|Placebo Comparator|Placebo + Rituximab + Bendamustine|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules of duvelisib.~Bendamustine is administered as an IV infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
89119691|NCT01000610|Experimental|single arm|
89119692|NCT04072939||Single arm|dilated fundus exam
89119693|NCT01877655|Experimental|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).
89119694|NCT01877655|Placebo Comparator|Placebo|Participants received 1 mL of 5 mg/mL of matching placebo via intramuscular injection in the deltoid muscle alternating sides with each dose on days -14 to -3 pretransplant, 14 to 40, 60, 90 and 180 in relation to the day of transplant (Day 0).
89119695|NCT04294238|Experimental|Post-exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage of peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
89119696|NCT04296968|Experimental|Expectation and experimental pain in humans|
89119697|NCT02871284|Experimental|Sensorimotor training (EI)|The participants of the experimental intervention arm will take part in a 45 minutes sensorimotor training class two times a week for a maximum of 24 weeks at the NCT (National Center for Tumor Diseases). Highly qualified exercise therapists will guide the class. Class size will be no bigger than 8 patients to ensure adequate individual supervision and guidance. Additionally, participants will be asked to perform one weekly 15 minutes home-based sessions without supervision. Participants who are not able to come to the NCT Heidelberg 2x/week will be offered a home-based sensorimotor program including the same exercises. At the beginning, participants will receive an appointment for an individual face-to-face counseling session at the NCT. During this appointment, the patient will receive an exercise manual for individualized home-based sensorimotor training and a practical introduction by the exercise therapist.
89119698|NCT02871284|Active Comparator|machine-based resistance training (AC)|Participants of the active control arm will receive machine-based resistance training. The supervised resistance exercise program will be undertaken twice weekly in small groups (not more than 12 people per group) of participants and will be guided by an exercise physiotherapist over a maximum of 24 weeks. All sessions will start with a warm-up and finish with a cool-down (comprising exercise on a cycle ergometer or treadmill at a relatively low intensity and stretching activities) and will take approximately 45 minutes. Additionally, participants will be asked to perform a weekly 15 minutes home-based resistance training session without supervision
89119699|NCT02871284|No Intervention|usual care|Participants will receive usual care with no additional exercise training or intervention
89119700|NCT02523469|Experimental|ALT-803 + Nivolumab dose escalation|"Up to 21 patients will receive ALT-803 + Nivolumab in the dose escalation phase to determine the maximum tolerated dose.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. The starting dose level for ALT-803 is 6 microgram (mcg)/kilogram (kg); the second dose level is 10 mcg/kg; the third dose level is 15 mcg/kg; and the fourth dose level is 20 mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
89119701|NCT02523469|Experimental|Arm A: ALT-803 + Nivo naive|"Patients who have not received PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) will be enrolled to Arm A in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
89119702|NCT02523469|Experimental|Arm B: ALT-803 + Nivolumab progressor|"Patients who have had PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) and progressed will be enrolled to Arm B in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
89119703|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 1|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 20 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
89290077|NCT03936504|Active Comparator|Control Group|Group received conventional exercise rehabilitation programs (CERP).
88800433|NCT01128829|Experimental|sucralose-water|"Subjects in this group drank sucralose 10 min before drinking a glucose load on their first OGTT and drank water 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
88800434|NCT01129141|Experimental|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
88800435|NCT01129141|Other|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
88800436|NCT03012139||Cancer with cachexia|Men and women (ages 35-80 years) with cancer cachexia (≥5% drop in body mass in less than 12 months)
88800437|NCT03012139||Cancer without cachexia|Men and women (ages 35-80 years) with cancer but without cachexia of similar age and sex as the group with cachexia
88800438|NCT03012139||No cancer|Men and women (ages 35-80 years) without cancer, but similar age and sex as groups with cancer.
88800439|NCT04138498|Experimental|Sequence 1 (ADBC)|Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.
88800440|NCT04138498|Experimental|Sequence 2 (BACD)|Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.
88800441|NCT04138498|Experimental|Sequence 3 (CBDA)|Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.
88800442|NCT04138498|Experimental|Sequence 4 (DCAB)|Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.
88800443|NCT03714256|Experimental|Children 6-17 months|"Device, patient mobility, powered:~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
88800444|NCT03714256|Experimental|Children 18 - 36 months|"Device, patient mobility, powered:~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
88800445|NCT03715426|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
88800446|NCT03715426|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
88800447|NCT05314192||Healthy|Healthy cohorts with no underlying systemic or periodontal disease
88800448|NCT05314192||stage 2 periodontitis|patients with periodontitis but no underlying systemic periodontal disease
88800449|NCT05314192||MI patients with stage 4 periodontitis|patients who had MI and having stage 4 periodontitis patients
88800450|NCT05314192||MI patients without periodontitis|patients who had MI without periodontitis
88800451|NCT01129531|Experimental|AGN-214868 3.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.
88800452|NCT01129531|Experimental|AGN-214868 16.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.
88800453|NCT01129531|Placebo Comparator|Placebo|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
88800454|NCT03746002|Active Comparator|Metolazone Pre-dosing|Metolazone 5 mg by mouth administered 60 minutes prior to furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
88800455|NCT03746002|Active Comparator|Metolazone Concurrent Dosing|Metolazone 5 mg by mouth administered at the same time as furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
88800456|NCT01172353|Experimental|sodium bicarbonate|hydration with sodium bicarbonate
88800457|NCT01172353|Active Comparator|saline|hydration with saline 1ml/Kg/h for 6 hours
88800458|NCT01129609||Participants with Successful Secondary Endovascular Treatment|
88800459|NCT04089982|Active Comparator|Varenicline|Varenicline BID
88800460|NCT04089982|Placebo Comparator|Placebo|
88800461|NCT00985088|Experimental|GSK2340274A F1_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 1 (F1) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
88800462|NCT00985088|Experimental|GSK2340274A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
88800463|NCT00985088|Experimental|GSK2340274A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
88800464|NCT00985088|Experimental|GSK2340274A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
88800465|NCT00985088|Experimental|GSK2340273A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
88800466|NCT00985088|Experimental|GSK2340273A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
88800467|NCT00985088|Experimental|GSK2340273A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm. Subjects above (>) 60 years old received an additional dose of Formulation 2 (F2) of GSK2340273A vaccine after Day 42, administered into the deltoid region of the non-dominant arm.
88800468|NCT00985088|Experimental|GSK2340273A F3_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 3 of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
89119704|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 2|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 10 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
89119705|NCT00586924|Experimental|5 mcg/kg|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
89119706|NCT00586924|Experimental|10 mcg/kg|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
89119707|NCT00586924|Experimental|20 mcg/kg|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
89119708|NCT00586924|Experimental|30 mcg/kg|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
89119709|NCT00586924|Experimental|40 mcg/kg|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
89119710|NCT00586924|Experimental|50 mcg/kg|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
89119711|NCT02578147|Experimental|Mighty Girls|Girls in this group complete 3 different activities after school: 6 classroom sessions, 4 DRAMA-RAMA game play sessions, and 4 short game experience surveys. Classroom sessions are 1 hour long, 3 days a week for 2 weeks. Topics include: goal setting, choices and their effects; defining what makes a behavior risky; learning how to not get talked into doing risky things by friends (e.g., going to a party at a house where parents are not home); and learning to be critical of TV shows and other media that make it seem like lots of teens are having sex. These sessions teach girls skills and strategies that help them score game points in DRAMA-RAMA. These are important skills and strategies that they can use in everyday life to make wise choices. Classroom sessions are designed to be fun.
89119712|NCT02578147|Active Comparator|Game Girls|Girls in this group take part in activities that can be done from home or anywhere they have Wi-Fi access: 4 Science Valley game play sessions and 4 short game experience surveys. Science Valley is a web based game in which girls explore a virtual world and experiment with objects in this world using a computer, tablet or cell phone. Girls will play this game for about 20-30 minutes. There are no classroom sessions required to be able to play Science Valley. Science Valley is designed to be fun and to give girls a chance to build skills important to doing well in school: her problem solving and critical thinking skills. Girls will be given a link to use to access Science Valley on the internet. At the end of the game, they do a short game experience survey that asks questions about how easy, how hard, how fun etc. it was to play Science Valley. This survey will appear on the screen at the end of the Science Valley game play session.
89119713|NCT01000376|Experimental|Group 1|
89119714|NCT01000376|Experimental|Group 2|
89119715|NCT01038635|Experimental|5-Azacytidine + Lenalidomide|5-Azacytidine 75 mg/m^2 by vein daily x 5 days on days 1 to 5. Lenalidomide starting dose 10 mg orally daily x 5 days on days 6 to 10.
88800469|NCT03783130|Experimental|Group 1: Trimer 4571 (100 mcg) IM with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
88800470|NCT03783130|Experimental|Group 2: Trimer 4571 (100 mcg) SC with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
89233049|NCT03451851|Placebo Comparator|Part 1 Group 2: Placebo for Guselkumab|Participants in Part 1a (age >= 12 - <18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose >=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
89233050|NCT03451851|Active Comparator|Part 1 Group 3: Etanercept|Participants in Part 1a (age >= 12 - <18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE phase of the study. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
89233051|NCT03451851|Experimental|Part 2: Guselkumab|Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter.
89233052|NCT03446612|Experimental|Participants receiving Daprodustat|Participants will receive 2 milligram (mg) daprodustat tablets once daily via oral route for a period of 41 days.
89233053|NCT03446612|Active Comparator|Participants receiving Darbepoetin alfa|Participants will receive Darbepoetin alfa solution for injection, administered as a single subcutaneous injection, once every two weeks (Days 1, 14 and 28).
89233054|NCT03438032||SSc-ILD|SSc-ILD subjects will be defined by those who fulfill 2013 American College of Rheumatology SSc criteria and have forearm modified Rodnan skin scores (mRSS) ≥1 (a validated, semi-quantitative scoring system for dermal fibrosis) and clinically relevant SSc-interstitial lung disease (ILD). A subject will be defined as having ILD if they have radiographic evidence for ILD and a forced vital capacity <70% on pulmonary function test (PFT).
88800471|NCT03783130|Experimental|Group 3: Trimer 4571 (500 mcg) IM with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
88800472|NCT03783130|Experimental|Group 4: Trimer 4571 (500 mcg) SC with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
89233055|NCT03438032||Control|Healthy control subjects recruited from the Northwestern community will complete demographic and basic medical forms to ensure health
89233056|NCT03434080||Autism Spectrum Disorder|The group with ASD (including all infants less than 3 years of age who are identified as being at high-risk for ASD)
89233057|NCT03434080||Cerebral Palsy|The group with CP (including all infants less than 18 months who are identified as being athigh-risk for CP)
89233058|NCT03434080||Typical Development toddlers infants|The control group will consist of 50 healthy volunteers with TD
89233059|NCT03433781|Experimental|Vitamin C 50 g|Patients will receive Vitamin C as a continuous intravenous infusion (CIVI) of 50 grams (g) daily over 24 hours for 5 days for total of 250 grams over 5 days up.
89233060|NCT03433781|Experimental|Vitamin C 75 g|Patients will receive Vitamin C as a continuous intravenous infusion (CIVI) of 75 grams (g) daily over 24 hours for 5 days for total of 375 grams over 5 days.
88800473|NCT00984542|Experimental|Bendamustine|
88800474|NCT00983918|Active Comparator|Desflurane|General Anesthesia with Desflurane
89233061|NCT03433781|Experimental|Vitamin C 100 g|Patients will receive Vitamin C as a continuous intravenous infusion (CIVI) of 100 grams (g) daily over 24 hours for 5 days for total of 500 grams over 5 days.
89233062|NCT03407079|Experimental|Study Arm 1|Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.
89233063|NCT03407079|Placebo Comparator|Study Arm 2|Participants will receive placebo capsules by mouth for 28 days.
89233064|NCT03401489|Experimental|PACESETTER|
89233065|NCT03401489|No Intervention|Healthy Lifestyle Intervention Group|
89233066|NCT03400410|Experimental|Education Arm|"This group will take a survey and be asked some sexual history questions including their contraceptive practices with their sexual partner(s). They will then watch the educational video on hormonal contraception and then be asked a few questions about the video. Then they will be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
89233067|NCT03400410|No Intervention|No Education Arm|"This group will take a survey and be asked some sexual history questions including contraceptive practices with their sexual partner(s). They will then be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
89290078|NCT03936504|Experimental|Experimental Group|Group received Tai Chi cardiac rehabilitation program(TCCRP).
88800475|NCT00983918|Active Comparator|Sevoflurane|General Anesthesia with Sevoflurane
88800476|NCT00983918|Active Comparator|Isoflurane|General Anesthesia with Isoflurane
88800477|NCT00983918|Active Comparator|Propofol|General Anesthesia with Propofol
88805866|NCT03012035|Other|comparator group|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
88800478|NCT03057782||Group A|"Plan for major surgery anticipated to cause pain and agitation (i.e. esophageal atresia treatment);~Patients who are anticipated to receive prolonged post-surgical neuromuscular blockade (NMB)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. These subjects will also receive EMG monitoring. Subjects in this group will also have video recordings that may be used for novel analysis such as subdermal blood flow or micro-movement."
88800479|NCT03057782||Group B|"Plan for major surgery anticipated to cause pain and agitation (i.e. bowel surgery);~Patients who are not anticipated to receive acute post-surgical NMB~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
88800480|NCT03057782||Group C|"Plan for minor surgery anticipated to cause pain and agitation (i.e. hernia repair)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
88800481|NCT03057782||Group D|"No plan for surgery~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
88800482|NCT01925924|Experimental|Resin-modified glass ionomer cement|Resin-modified glass ionomer cement is used to attach the fixed orthodontic brackets (brace) to the teeth.
88800483|NCT01925924|Active Comparator|Composite resin|Composite resin is used to attach fixed orthodontic brackets (brace)to the teeth.
88800484|NCT01926002|Experimental|Low-Dose MK-8351|Low-dose MK-8351 administered as single inhaled dose.
88800485|NCT01926002|Experimental|High-Dose MK-8351|High-dose MK-8351 administered as a single inhaled dose.
88800486|NCT01926002|Placebo Comparator|Placebo to MK-8351|Matching placebo to low-dose or high-dose MK-8351 administered as a single inhaled dose.
88800487|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
88800488|NCT01926080|No Intervention|Standard Bereavement Care|Those randomized to control group (no DVD) Standard Bereavement Care Arm receive the bereavement materials given to families as standard-practice of care in the NICU at SLCH following the death of an infant
88800489|NCT01926236|Active Comparator|Arm A: Active symptom control (ASC)|Active Symptom Control
88800490|NCT01926236|Experimental|Arm B: ASC with OxMdG chemotherapy|Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid & 5FU)
88800491|NCT03049826|Experimental|Stem cell transplantation (SCT)|Children undergoing stem cell transplantation (SCT)
88800492|NCT03049826|No Intervention|Home parenteral nutrition (HPN)|Children receiving home parenteral nutrition
88800493|NCT03049826|No Intervention|Healthy reference group|Healthy children
88800494|NCT01926314|Experimental|device|Patients in this group will be offered pelvic floor muscle rehabilitation program using PHENIX Neuromuscular Stimulation Therapy System device. The participants will start therapy once a week 42 days after delivery, and last 8 weeks.
88800495|NCT01926314|Active Comparator|usual home care without device|Patients in this group will receive usual home care without device.
88800496|NCT00983372|Active Comparator|Colchicine alone|-colchicine baseline pharmacokinetics
88800497|NCT00983372|Experimental|Colchicine with steady-state Diltiazem|-colchicine pharmacokinetics in presence of steady-state diltiazem
88800498|NCT01173211|Experimental|Arm 1: Fluarix®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluarix®.
88800499|NCT01173211|Experimental|Arm 3: Fluzone®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluzone®.
88800500|NCT01173211|Experimental|Arm 2: Agriflu®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Agriflu®.
88800501|NCT00983294|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
88800502|NCT00983294|Experimental|Colchicine with steady-state Azithromycin|colchicine pharmacokinetics in presence of steady-state azithromycin
88800503|NCT01926392|Experimental|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
88800504|NCT01926392|Active Comparator|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
88800505|NCT01129765||Parents of congested children|Parents of children less than six years of age with nasal congestion for which nasal suctioning and salt water irrigation is traditionally recommended.
89119716|NCT00619203|Active Comparator|A|Two active ingredients
89119717|NCT00619203|Active Comparator|B|One active ingredient
88800506|NCT05601830|Experimental|QN-030a|QN-030a in Adult subjects with MRD
89119718|NCT00619203|Active Comparator|C|One (other) active ingredient
88800507|NCT01175005||Fever and a central venous catheter|
89119719|NCT00619203|Placebo Comparator|D|
89119720|NCT04072471||Zurampic®|Patients exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) (lesinurad+XOI)
89119721|NCT04072471||Control group: xanthine oxidase inhibitor monotherapy|Patients exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat).
89119722|NCT04099654|Experimental|Core-Stabilization Exercise|
89119723|NCT04099654|Experimental|Counseling of physical activity|
89119724|NCT00619281||Oberservation|600 consecutive patients undergoing cardiac surgery
89119725|NCT01000064|Active Comparator|Vyvanse|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
89233068|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Intravenous (IV)|Participants will receive IV infusion of Talquetamab at minimum anticipated biologic effect level (MABEL)-based starting dose until the completion of the end of treatment visit. Subsequent dose levels will be selected based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and preliminary antitumor activity data.
88800508|NCT00982280|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
89233069|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Subcutaneous (SC)|Participants will receive Talquetamab SC. The dose levels will be selected to identify safe and tolerable putative RP2D(s).
89233070|NCT03399799|Experimental|Part 2: Dose Expansion (Talquetamab)|Participants will receive IV infusion or SC injection of Talquetamab at each putative recommended Phase 2 dose(s) (RP2D[s]) as determined in Part 1.
89233071|NCT03394066|Experimental|TMS|All participants will receive TMS to investigate acute modulations of brain activity by TMS
89233072|NCT03390504|Experimental|Cohort 1 (Arm 1A): Erdafitinib|Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision.
89233073|NCT03390504|Experimental|Cohort 1 (Arm 1B): Vinflunine or Docetaxel|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system.
89233074|NCT03390504|Experimental|Cohort 2 (Arm 2A): Erdafitinib|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision.
88800509|NCT01175317|Experimental|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
88800510|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
88800511|NCT01926470|Experimental|anteroposterior approach group|anteroposterior approach group
88800512|NCT01926470|Active Comparator|oblique approach group|oblique approach group
88800513|NCT01175395|Experimental|IBI-20089/Lucentis|Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
88800514|NCT03011905|Experimental|Dexamethasone|Single dose of dexamethasone (Dexagalen) 16 mg iv during operation.
88800515|NCT03011905|Placebo Comparator|Control|Single dose of NaCl, 4 ml, iv during operation.
88800516|NCT01926548|Experimental|CJ Imatinib 200mg|1 tablet(200mg) a day,PO,QD
88800517|NCT01926548|Active Comparator|Gleevec 100mg|2 tablet(100mg) a day,PO,QD
88800518|NCT01926704||healthy, young subjects|
88800519|NCT03011983||Adolescents With Concussion|Adolescents with a concussion (n=120) will undergo neuroimaging (MEG and MRI) and neuropsychology assessments at two time points in the acute and chronic periods after injury, respectively. Brain imaging injury measures will be compared to a control normative database we will create. These brain measures will also be associated with cognitive and clinical outcomes.
88800520|NCT03011983||Adolescents Without Concussion|Age- and gender-matched healthy controls (n=160) will be recruited to establish a normative database of whole-brain slow-wave maps from MEG resting-state data as well as white-matter diffusion measures from MRI.
88800521|NCT00981578|Experimental|ExAblate 2100 Treatment|ExAblate 2100 ablation for the treatment of painful bone metastases.
88800522|NCT01176877|Other|keloid scar|Those with a diagnosis of keloid scar.
88800523|NCT01176955|Experimental|Internet survey|Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.
88800524|NCT01176955|Placebo Comparator|Control|Subjects will receive standard-of-care treatment with the study medication, without internet surveys.
88800525|NCT00980798|Experimental|001|OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks
88800526|NCT00980798|Placebo Comparator|002|Placebo placebo tablet once daily for 16 weeks
88800527|NCT01177189|Other|Arm 1|Young healthy men and women aged 18-30
88800528|NCT01177189|Other|Arm 2|Older healthy men and women aged >70.
88800529|NCT01926860|Experimental|Study group - Prevenar®13 and Hepatitis A vaccines|Study group (group 1) - Prevenar®13 and Hepatitis A: one dose of each vaccine administered on Day 0
88800530|NCT01926860|Active Comparator|Pneumococcal conjugate vaccine -Control group - Prevenar®13|PCV -Control group (group 2) - Prevenar®13: one vaccine injection administered on Day 0
88800531|NCT01926860|Active Comparator|HepA -Control group - Hepatitis A vaccine|HepA -Control group (group 3) - Hepatitis A vaccine: one vaccine injection administered on Day 0
88800532|NCT01177735|Experimental|Pomalidomide|
88800533|NCT01135069|Active Comparator|Generic|treatment of acne for 12 weeks
88800534|NCT01135069|Active Comparator|Brand|Treatment of acne for 12 weeks
88800535|NCT01135069|Placebo Comparator|Placebo|Treatment if acne for 12 weeks as placebo
88800536|NCT01178281|Experimental|Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects or disease progression.~Participants who were RBC-transfusion independent or experienced clinical benefit (defined as a reduction from Baseline of ≥ 50% in RBC-transfusion frequency during the prior 84-day interval) could continue to receive pomalidomide until loss of RBC-transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
88800537|NCT01178281|Placebo Comparator|Placebo|"Participants received placebo taken by mouth once daily for at least 168 days unless there were unacceptable side effects or disease progression.~Participants who were RBC-transfusion independent or experienced clinical benefit could continue to receive placebo until loss of RBC- transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
88800538|NCT01178281|Experimental|China Extension: Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects, disease progression, or they received a RBC-transfusion.~Participants who experienced anemia response could continue treatment until the response was lost or other criteria for treatment discontinuation applied."
89119726|NCT01000064|Placebo Comparator|Placebo|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
89119727|NCT04102696|Experimental|The aromatherapy arm|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
89119728|NCT04102696|Placebo Comparator|The placebo arm|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
89119729|NCT02874053||Healthy|Healthy Volunteers
89119730|NCT01812603|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide and in open-label manner
89119731|NCT04292327||The ordinary COVID-19|Consistent with the diagnosis of ordinary COVID-19.
89119732|NCT04292327||The heavy COVID-19.|Consistent with the diagnosis of heavy COVID-19.
89119733|NCT04292327||The critical COVID-19|Consistent with the diagnosis of critical COVID-19
89119734|NCT02870270||Head and neck cancer patients|Patients with head and neck cancer who were ≥ 18 years old and had ≥ 16 teeth and no removable prosthesis or dental implants consisting of more than one teeth were included
89119735|NCT00766090|Experimental|GW685698X|
89119736|NCT04211805||Arm (A) TAF Group Comprised of Patients from 11 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Alafenamide (TAF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
89119737|NCT04211805||Arm (B) TDF Group Comprised of Patients from 11 Centers.|225 consecutive patients will be treated with local standard of care. The antiviral drug Tenofovir Disoproxil Fumarate (TDF) will be used to treat highly viremic chronic hepatitis B mothers from the gestational week 24-28 of pregnancy to delivery of infant at eleven centers across the People's Republic of China (PRC). Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.
89119738|NCT04303949|Experimental|Experimental|e-book for termination
89119739|NCT04303949|Other|Control|routine care Written form health education
89119740|NCT02871050||Castleman Disease Patients|Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease.
89119741|NCT02874287|Other|Hydroxychloroquine|Subjects are treated with hydroxychloroquine sulfate tablets.All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
89119742|NCT02874287|Other|placebo|Subjects are treated with placebo tablets. All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
89119743|NCT00628784|Experimental|Group 1|Specialized intestinal metaplasia (Barrett's esophagus) documented via endoscopic esophageal biopsy, with standard surveillance biopsies (four-quadrant biopsies obtained every 2-cm the entire length of the specialized intestinal metaplasia in the esophagus) performed within the past two years prior to study enrollment. Biopsies show either low grade dysplasia, indeterminate for dysplasia, or no dysplasia.
89119744|NCT00628784|Experimental|Group 2|Diagnosis of Barrett's esophagus and high grade dysplasia or intramucosal carcinoma. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). Endoscopic ultrasound* (EUS) demonstrating no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa (T1).
89119745|NCT00628784|Experimental|Group 3|Diagnosis of esophageal carcinoma (T1smN0 or T2N0 via EUS). Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement).
89119746|NCT00628784|Experimental|Group 4|Diagnosis of severe dysplasia within esophageal squamous mucosa on pathology review. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). EUS with no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa.
89119747|NCT04211493|Experimental|Experimental-Condition|"20 minutes whole-body-workout with simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout the muscles are simultaneously stimulated by those external electrodes with medium level (5) of stimulation intensity."
89119748|NCT04211493|Placebo Comparator|Placebo-Condition|"20 minutes whole-body-workout without simultaneous muscle stimulation (EMS).~Participants carry out easy whole-body-exercises while wearing a EMS-vest-belt-system with interwoven electrodes. During the workout they are stimulated with the lowest possible stimulation intensity (1). This is perceptible as a slight tingling sensation but the impulse intensity lies below the muscular threshold and therefore generates no muscular activity."
89119749|NCT02871362|Experimental|IQP-AS-118|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
89119750|NCT02871362|Placebo Comparator|Placebo|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
89119751|NCT00619593|Active Comparator|2|Standard follow-up in patients without appropriate ICD therapy
89119752|NCT00619593|Experimental|1|Following 1st appropriate ICD therapy, the patients have to be called to the clinic for intensified clinical diagnostics and, if necessary or useful, intensified therapy.
89119753|NCT00580801|Experimental|Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 2 to 50.
89119754|NCT00580801|Experimental|Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
89119755|NCT00580801|Active Comparator|Placebo+Pegylated-interferon-alfa-2a+Ribavirin|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa 2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
89119756|NCT04303481|Other|normal diet|
89119757|NCT04303481|Experimental|weight loss program kit|
89119758|NCT04303481|Experimental|weight loss program kit with A. muciniphila prebiotics|
89119759|NCT00628550|Experimental|1|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive vasopressin (0.8 units/kg) rescue as the second vasopressor medication.
89119760|NCT00628550|Active Comparator|2|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive standard dose epinephrine (0.01 mg/kg)rescue as the second vasopressor medication.
89119761|NCT02577913||FC patch low|Women taking FC Patch low, a transdermal patch releasing 60 micrograms gestodene/24 hours + 13 micrograms ethinyl estradiol/24 hours
89119762|NCT02577913||LNG-COC|Women taking levonorgestrel-containing COCs: 1) monophasic preparations containing 20 - 30mcg of ethinylestradiol; 2) multiphasic preparations containing up to 40mcg of ethinylestradiol
89119763|NCT01059539|Experimental|Cariprazine 3-12 mg/day for 16 weeks|Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator.
89119764|NCT00999908|Experimental|Indacaterol 150 μg-tiotropium 18 μg-placebo|Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89119765|NCT00999908|Experimental|Tiotropium 18 μg-placebo-indacaterol 150 μg|Patients received tiotropium 18 μg once. After a 5-9 days washout period, patients received placebo (matching indacaterol) once. After a second 5-9 days washout period, patients received indacaterol 150 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89119766|NCT00999908|Experimental|Placebo-indacaterol 150 μg-tiotropium 18 μg|Patients received placebo (matching indacaterol) once. After a 5-9 days washout period, patients received indacaterol 150 μg once. After a second 5-9 days washout period, patients received tiotropium 18 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89119767|NCT02576119|Experimental|Part 1: Sentinal Cohorts|Study is in 2 sequential cohorts (BMS-955176 or placebo) each to evaluate the safety, tolerability, and PK following multiple-dose administration of BMS-955176.
89119768|NCT02576119|Experimental|Part 2: Main QTc Study|3 period nested crossover study.
89119769|NCT02871518|Experimental|Two cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22)combine with IMRT
89119770|NCT02871518|Active Comparator|Three cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22 and D43)combine with IMRT
89119771|NCT00619749|Experimental|1|
89119772|NCT00619749|Placebo Comparator|2|
89119773|NCT00580723|Experimental|PRK 124|Topical PRK 124 (Pyratine-6)(0.125%) moisturizing lotion applied twice daily to the face for 48 weeks. Subjects will wash their faces prior to application. The applications will occur in the mornings and one hour before bedtime.
89119774|NCT00999596||FFDM (Full Field Digital Mammography)|Mammograms from the Philips Digital System
89119775|NCT04303754|Experimental|Diabetes-Specific Formula|Diabetes-Specific Formula
89119776|NCT04303754|Experimental|Bread and Spread|White bread with spread
89119777|NCT04303754|Experimental|Rice Porridge|Rice Porridge
88800539|NCT01135381|Experimental|CHF patients, IVR-Enhanced Care|Patients with congestive heart failure (CHF) who receive the interactive voice response (IVR) intervention.
88800540|NCT01135381|Experimental|COPD patients, IVR-Enhanced Care|Patients with chronic obstructive pulmonary disease (COPD) who receive the interactive voice response (IVR) intervention.
88800541|NCT01135381|No Intervention|CHF patients, Usual Discharge Care|Patients with congestive heart failure (CHF) who receive usual discharge care (no intervention).
88800542|NCT01135381|No Intervention|COPD patients, Usual Discharge Care|Patients with chronic obstructive pulmonary disease (COPD) who receive usual discharge care (no intervention).
88800543|NCT03994159|Experimental|PARO emotional robot|"Quasi-experimental before after study of the impact of the PARO robot on team dynamics among caregivers in geriatric wards caring for patients with dementia.~Pre intervention period: no PARO robot. Post-intervention period: with the PARO robot."
88800544|NCT01178827|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride), 60mg once daily for 10 days
88800545|NCT01178827|Active Comparator|Oxybutynin IR|Oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days
88800546|NCT01178827|Placebo Comparator|Oxybutynin IR placebo|Oxybutynin IR placebo three times daily for 2 days
88800547|NCT03012217||Specimens that meet inclusion criteria|
88800548|NCT01135537|Experimental|Thymoglobulin|Thymoglobulin 7.5 mg/kg/course prior to HSCT
88800549|NCT03011749|Experimental|FLT PET/CT|FLT PET/CT
88800550|NCT02181517|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
88800551|NCT02181517|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
88800552|NCT02181517|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
88800553|NCT01179217|Experimental|L-glutamine|Patients will be randomized to receive investigational product, L-Glutamine.
88800554|NCT01179217|Placebo Comparator|100% maltodextrin|Patients will be randomized to receive Placebo.
88800555|NCT02181829|Experimental|Whole Lung IMRT|This is a single institution study involving patients with synovial sarcoma who have completed all standard therapy (e.g. surgery +/- radiation to the primary site) +/- any adjuvant chemotherapy. The sequence and types of therapy offered prior to WLI will likely vary based on primary tumor site, tumor resectability, extent of metastatic disease, performance status, and comorbidity. Each patient's therapy will be determined by the disease management team irrespective of participation on this protocol.
88800556|NCT03010267|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
88800557|NCT03010267|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
88800558|NCT03977311|Experimental|MR-HIFU|-The study team will determine the tumor volume to be treated per standard-of-care diagnostic MRI or CT imaging. An array of scans will be used to align the participant with the HIFU system, optimize heat delivery to the patients, and/or monitor aspects related to the participant such as motion. Vendor-provided software will be used with the participant in each position to create a customized treatment plan for heat delivery. The HIFU device will then be used to apply clinical levels (41-42°C) of heat to the tumor volume. Regions will be heated to the 41-42°C for up to 60 minutes in one session (either before or after radiation) on one day per five to ten standard radiation therapy fractions, with a maximum of 6 days of hyperthermia over the course of their standard, indicated radiation therapy treatment.
88800559|NCT01181323|Experimental|Group 1: LAIV|0.2 ml of Live attenuated influenza vaccine (LAIV), Flumist® given intranasally (IN) and 0.5 ml of placebo given intramuscularly (IM) injection administered to 120 maternal subjects.
88800560|NCT01181323|Experimental|Group 2: TIV|0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM) and 0.2 ml of placebo given intranasally (IN) administered to 120 maternal subjects.
88800561|NCT03855943|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
89119778|NCT04301102|Experimental|Experimental|"Hemodynamic management will be based on the functional hemodynamic parameters provided by Hemosphere platform with the Acumen IQ sensor, including cardiac output, stroke volume, SVV and Acumen IQ specific parameters: maximal arterial pressure rise (dP/dtmax), dynamic arterial elastance (Eadyn) and HPI~As a pattern replacement of interstitial space, we will use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.~The protocol of action on the intravascular space will be based on the maintenance of systolic volume with colloids (hydroxyethyl starch - Voluvén®)."
89119779|NCT04301102|Other|Control|"Hemodynamic management will be based on the functional hemodynamic parameters provided by the HemoSphere platform® with the FloTrac® sensor, including cardiac output (CO), stroke volume (SV), and stroke volume variation (SVV)~As a pattern replacement of interstitial space, we use balanced crystalloid (Isofundin®) at 1-3 ml / kg / h in case of laparoscopic surgery and 5 to 7 ml / kg / h in case of open surgery.~The protocol action for the intravascular space will be based on a recently published hemodynamic optimization algorithm (Heming N, Moine P, Coscas R, Annane D. Perioperative fluid management for major elective surgery. British Journal of Surgery. 2020;107:e56-62). The fluid used will be hydroxyethyl starch (Voluven®)."
89119780|NCT04676867|Active Comparator|900 mg dose|Patients will receive Dalcetrapib 900 mg for 10 days
89119781|NCT04676867|Active Comparator|1800 mg dose|Patients will receive Dalcetrapib 1800 mg for 10 days
89119782|NCT04676867|Active Comparator|3600 mg dose|Patients will receive Dalcetrapib 3600 mg for 10 days
89119783|NCT04676867|Placebo Comparator|Placebo tablets|Patients will receive Placebo for 10 days
89119784|NCT00770224|Experimental|R-CHOP, tositumomab and rituximab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles~Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.~Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration."
89119785|NCT04301063||RV3278A arm|"study product RV3278A is applied twice a day on the face during the whole study.~In case of reaction resulting from the use of the product, the subject will inform the investigator who will explain to him/her what to do : application reduction or stop applications for a while"
89119786|NCT02389465|No Intervention|Control|This arm is for participants who are not depressed.
89119787|NCT02389465|Experimental|Experimental - treatment|Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.
89119788|NCT01057589|Experimental|Pemetrexed + Cisplatin + Cetuximab|"Participants will receive pemetrexed,cisplatin and cetuximab for up to 6 cycles (21 days per cycle) followed by optional maintenance of pemetrexed and cetuximab until disease progression. Optional maintenance therapy is permitted after at least 4 cycles of triplet combination therapy have been given. Cetuximab will be administered as an initial dose of 400 milligram per meter squared (mg/m^2) intravenous (IV) infusion and as a 250 mg/m^2 IV weekly dose thereafter.~As Standard of care dietary supplements included: 350 to 1000 micrograms (µg) oral Folic Acid 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed and 1000 µg vitamin B12 intramuscular injection (IM) during the week preceding the first dose of pemetrexed and every 9 weeks thereafter."
89119789|NCT02576197|Active Comparator|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
89119790|NCT02576197|Placebo Comparator|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
89119791|NCT02575885|Experimental|Arm I (different type of ENDS product at each visit)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with a different type of ENDS product at each visit (e-cigarette, disposable e-cigarette, eGo, personal vaporizer, e-cigar, and e-pipe) over 3.5-4 hours at least 7 days apart for 7 weeks. Participants are provided with cartridges of the same amounts of nicotine with regular (tobacco) or menthol flavor according to smoker's preference, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
89119792|NCT02575885|Experimental|Arm II (BLU e-cigarette ENDS product with different flavors)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with the BLU e-cigarette ENDS product with nicotine solution of one of five flavors over 3.5-4 hours at least 7 days apart for 6 weeks. Participants are provided with cartridges of maximum available amounts of nicotine and different flavors at each visit, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
89119793|NCT02575729|Experimental|Inject betamethasone by sonography|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease by sonography- guided. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
89119794|NCT02575729|Active Comparator|Inject betamethasone directly|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease directly. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
89119795|NCT02575651|Experimental|Fluzoparib|Each subject will receive a single dose of fluzoparib on day 1, and then subject will receive fluzoparib twice daily for 28 days during cycle 1.
89119796|NCT02575573||Admitted patients at the ED|
89119797|NCT01716117|Experimental|Surpass Flow Diverter|The objective of this study is to determine the safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus.
89119798|NCT00579553|Active Comparator|Intramuscular Progesterone|Intramuscular Progesterone
89119799|NCT00579553|Experimental|Vaginal Progesterone|Vaginal Progesterone
89119800|NCT01650831|Active Comparator|Clinical Suspicion of Hpylori|All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
89119801|NCT04211415|Experimental|Part 1: DS-2741a Cohort 1, 5 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 5 mg.
89119802|NCT04211415|Experimental|Part 1: DS-2741a Cohort 2, 15 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 15 mg.
89119803|NCT04211415|Experimental|Part 1: DS-2741a Cohort 3, 50 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 50 mg.
89119804|NCT04211415|Experimental|Part 1: DS-2741a Cohort 4, 150 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 150 mg.
89119805|NCT04211415|Experimental|Part 1: DS-2741a Cohort 5, 500 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 500 mg.
89119806|NCT04211415|Experimental|Part 1: DS-2741a Cohort 6, 1000 mg|Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 1000 mg.
89119807|NCT04211415|Placebo Comparator|Part 1: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
89119808|NCT04211415|Experimental|Part 2: DS-2741a Cohort 1, X mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a X mg, where X mg will be based on the maximum tolerated dose identified in Part 1.
89119809|NCT04211415|Experimental|Part 2: DS-2741a Cohort 1, Y mg (based on results of Part 1)|Participants will receive a single, subcutaneous injection of DS-2741a Y mg, where Y mg will be based on the maximum tolerated dose identified in Part 1.
89119810|NCT04211415|Experimental|Part 3: DS-2741a Cohort 1, Z mg (based on results of Part 1)|Participants will be randomized to receive a receive a single, subcutaneous injection of DS-2741a Z mg, where Z mg will be based on the maximum tolerated dose identified in Part 1.
89290079|NCT04109014|Other|FASTLANE II Group|Participants will participate in the FASTLANE II Intervention. Counseling sessions will focus on: 1) depressive symptoms, 2) methamphetamine use, and 3) sexual risk behaviors. Three sessions will be devoted to each topic area. Trained staff will use a client-centered approach and develop a goal for each area alongside the participant. Counseling sessions will remain confidential and will not be audio recorded.
88800562|NCT02246881|Active Comparator|Current Factor VIII|Optivate® (Human Coagulation Factor VIII)
89119811|NCT04211415|Placebo Comparator|Part 3: Placebo|Participants will be randomized to receive a single, subcutaneous injection of placebo.
89119812|NCT02577757|Other|healthy volunteers|achieving functional MRI
89119813|NCT02577757|Experimental|Eligible patients with awakened surgery|achieving functional MRI
89119814|NCT04209933|Active Comparator|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate 220 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
89119815|NCT04209933|Active Comparator|Colloidal pectin bismuth capsules containing quadruple therapy|Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
89119816|NCT04209933|Active Comparator|Colloidal pectin bismuth particles A quadruple therapy|Colloidal pectin bismuth particles 150 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
89119817|NCT04209933|Active Comparator|Colloidal pectin bismuth particles B quadruple therapy|Colloidal pectin bismuth particles 300 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
89119818|NCT00619905|Experimental|1|
89119819|NCT00619905|Placebo Comparator|2|
89119820|NCT04953273|Experimental|Vigitrauma|"Contact by phone at 3 weeks after the consultation in a clinical forensic medicine unit, and a second phone call if necessary.~If the subject is not contacted after the second phone call, he will receive a postcard."
89119821|NCT04953273|No Intervention|Control group|Usual follow-up.
89119822|NCT02579395|Experimental|With spouse/romantic partner|
89119823|NCT02579395|Experimental|Without spouse/romantic partner|
89119824|NCT02579395|Other|Control|No Intervention
89119825|NCT04072003||IVUS-guided PCI|In this group, intravascular ultrasound(IVUS) in addition to coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
89119826|NCT04072003||CAG-guided PCI|In this group, coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.
89119827|NCT04209699|Experimental|Treatment A: BMS-986165 alone, fasted|
89119828|NCT04209699|Experimental|Treatment B: BMS-986165 alone, fed|
89119829|NCT04209699|Experimental|Treatment C: BMS-986165 with famotidine pretreatment, fasted|
89119830|NCT00620295|Experimental|Gemcitabine / Bortezomib|"Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose on day 1 and day 8 of a 21 day cycle.~Bortezomib will be given 1 hour after gemcitabine by IVP over 3 to 5 seconds followed by a standard saline on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles."
89119831|NCT00581893|Experimental|1|Phenytoin administration
89119832|NCT00581893|Placebo Comparator|2|Placebo
89119833|NCT04211025|Experimental|Modest|This approach is feasible to integrate into workflows of a wide-range of clinics, and should have a minimal impact on human resources. Materials and strategies to support staff in this work will be provided. .
89119834|NCT04211025|Experimental|Intensive|This approach is more robust, and requires a greater commitment of human resources.
89119835|NCT04211103|Experimental|Pembrolizumab single agent|"Pembrolizumab single agent as neoadjuvant treatment before surgical conization and/or partial or radical vulvectomy.~Pembrolizumab 200 mg flat dose will be administered every 3 weeks for 5 cycles. Within 3 weeks from the last Pembrolizumab administration patients will be submitted to surgical conization or partial or radical vulvectomy."
89119836|NCT04209777|Active Comparator|Antibiotics|The antibiotic group is provided with amoxicillin capsules 500mg and metronidazole tablets 400mg three times a day for 7 days along with the placebo of probiotics twice daily for 30 days.
88800563|NCT02246881|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
88800564|NCT00980330|Experimental|TMC435 100 mg 12 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.
89119837|NCT04209777|Experimental|Probiotics|The probiotic group is provided with Lactobacillus-reuteri probiotics (2x10(8)CFU) twice daily after brushing for 30 days.
89119838|NCT01410123|Other|Treatment as Usual (TAU)|
89119839|NCT01410123|Other|Integrated Stepped Care (ISC)|
89119840|NCT00887523|Experimental|1|prone intensity-modulated radiotherapy
89119841|NCT00887523|Active Comparator|2|supine intensity-modulated radiotherapy
89119842|NCT02334865|Experimental|Group A (vaccine and week-4 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
89119843|NCT02334865|Experimental|Group B (vaccine and week-0 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 4, 6, 8, and 10 for up to 4 doses and then receive a booster in week 16. Beginning in week 0, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
89119844|NCT00620139||A|Some patients presenting with suspicious lesions of the oropharynx or oral cavity will need to undergo transoral biopsy in the clinic to confirm the diagnosis of carcinoma. Of those patients who choose to participate in the study, an extra piece of tumor will be harvested for investigational purposes related to this trial.
89119845|NCT04073719|Experimental|Apple Cider Vinegar + Coconut Water|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
89119846|NCT04073719|Experimental|Apple Cider Vinegar + Citric Soda|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
89119847|NCT04073719|Experimental|Apple Cider Vinegar + Lemonade|Patients will drink apple cider vinegar for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
89119848|NCT04073719|Experimental|Coconut Water + Apple Cider Vinegar|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
89290080|NCT01122654||Control|
89290081|NCT01122654||Experimental 1|
89290082|NCT01122654||Experimental 2|
89119849|NCT04073719|Experimental|Coconut Water + Citric Soda|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
89119850|NCT04073719|Experimental|Coconut Water + Lemonade|Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
89119851|NCT04073719|Experimental|Citric Soda + Apple Cider Vinegar|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
89119852|NCT04073719|Experimental|Citric Soda + Coconut Water|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
89119853|NCT04073719|Experimental|Citric Soda + Lemonade|Patients will drink citric soda for 7 days. After a washout period of 2 weeks, patients will then drink lemonade for 7 days.
89119854|NCT04073719|Experimental|Lemonade + Apple Cider Vinegar|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
89119855|NCT04073719|Experimental|Lemonade + Coconut Water|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink coconut water for 7 days.
89119856|NCT04073719|Experimental|Lemonade + Citric Soda|Patients will drink lemonade for 7 days. After a washout period of 2 weeks, patients will then drink citric soda for 7 days.
89119857|NCT04072081|Experimental|Drug-coated ballon|Treatment of in suit coronary lesions with drug-coated balloon
89119858|NCT04072081|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
89119859|NCT00379431|Experimental|Administration of rituximab and methylprednisolone|
89119860|NCT00620529|Experimental|1|20/50 fish oil, 1000mg capsules, Ocean Nutrition 2050,4g/day.
89119861|NCT00620529|Placebo Comparator|2|olive oil capsules
89119862|NCT04210323|Experimental|Shotblocker group|ShotBlocker® was used by an experienced registered nurse under the researcher supervision. The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
89119863|NCT04210323|Placebo Comparator|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
89119864|NCT04210323|No Intervention|Control group|Subcutaneous injection was performed with normal subcutaneous drug administration steps by an experienced registered nurse and no additional method was applied. The application process of each patient was managed by the researcher.
89119865|NCT04210167|Experimental|web-based training and telephone monitoring|The heart failure patients in the intervention group were given web-based training for three months after discharge and followed up by telephone at the first, fourth, eighth and 12th weeks. At the same time, a text message was sent once a week. Scale data were collected before the patient was discharged from the hospital and at the third month of discharge.
89119866|NCT04210479|Experimental|Filled-bladder|Bladder filling with 300ml diluted methylene blue.
89119867|NCT04210479|Active Comparator|non filled-bladder|
89119868|NCT04842201|Experimental|CM326|subcutaneous injection
89119869|NCT04842201|Placebo Comparator|Placebo|subcutaneous injection
88800565|NCT00980330|Experimental|TMC435 100 mg 24 Wks + PR48|Participants willl receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.
89119870|NCT00620217|Experimental|1|intramyocardial injection of bicistronic VEGF-A165/bFGF plasmid
89119871|NCT00620217|Placebo Comparator|2|intramyocardial injection of placebo plasmid
89119872|NCT04954989|Experimental|Erythropoietin injectable in a single subcutaneous application.|
89119873|NCT04954989|Active Comparator|Erythropoietin Eprex®|
89119874|NCT04187859|Other|Education Session|The participant will receive an education session in their home, lasting between 15-30 minutes from a District Nurse. The District Nurses will advise the participant on how to drink more fluids, the importance of hydration and the effects of dehydration.
89119875|NCT04187859|Other|Prompting Cup|Participants will receive a Droplet Cup with an electronic prompting device and a brief tutorial session from the District Nurse. The Droplet Cup will encourage the participant to stay hydrated during the day, by emitting a voice or light to encourage them to drink more.
89119876|NCT04187859|No Intervention|Control Group|There will be no change to the care the participant receives from the District Nurse.
88800566|NCT00980330|Experimental|TMC435 100 mg 48 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
89119877|NCT04187859|Other|Prompting Cup and Education|Participants will receive a Droplet Cup with an electronic prompting device and an education session on the importance of hydration and the effects of dehydration.
89119878|NCT05265663|No Intervention|best supportive care|Standard of care or best supportive care (or palliative care) is care that focuses on relieving symptoms caused by serious illnesses like cancer, in this case PDAC. It can be given at any point during a person's illness to help them feel more comfortable. For instance, prescription of medicines to help control or prevent nausea and vomiting or to help relieve pain. All patients will be treated with pancreatic enzymes like Creon and a proton pomp inhibitor. Current guidelines for best supportive care include follow-up visits at three-monthly intervals in order to optimize symptom relief.
89119879|NCT05265663|Experimental|stereotactic ablative radiotherapy|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
88800567|NCT00980330|Experimental|TMC435 150 mg 12 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.
88800568|NCT00980330|Experimental|TMC435 150 mg 24 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.
88800569|NCT00980330|Experimental|TMC435 150 mg 48 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
89119880|NCT00313989|Experimental|Evaluation of implants of patients receiving radiotherapy.|
89119881|NCT02691273|Experimental|breathing technique|this arm includes learning breathing technique using the patient's smartphone.
88800570|NCT00980330|Placebo Comparator|Placebo 48 Wks + PR48|Participants will receive Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
89119882|NCT00286533|Experimental|Placed implants|
89119883|NCT04209231||chronic periodontitis|
89119884|NCT04209231||chronic gingivitis|
89119885|NCT04209231||periodontally healthy|
89119886|NCT00621699|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg tacrolimus)
89119887|NCT00621699|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
89119888|NCT00621699|Active Comparator|B|administration of 1 capsule Prograf(R) (5 mg tacrolimus)
89119889|NCT04799769|Experimental|Test Device|Investigational Device Arm
89119890|NCT04209309|Experimental|leDLPFC|single session rTMS of the left dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F3)
89119891|NCT04209309|Experimental|riDLPFC|single session rTMS of the right dorsolateral prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the 10-20 EEG coordinate position F4)
89119892|NCT04209309|Sham Comparator|shamDLPFC|single session sham rTMS over the medial prefrontal cortex for 15 min (60 trains with 50 stimuli; 10 sec intertrain interval; 10 Hz; 110% RMT; 3000 pulses; coil positioning over the midline with tilted coil)
89119893|NCT00620841||A|Patients treated with tacrolimus and experiencing a drug interaction
88800571|NCT01138735|Active Comparator|adapalene/benzoyl peroxide|Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks
89119894|NCT00770146|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a week for 26 weeks.
89119895|NCT00770146|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
89119896|NCT04747899|Active Comparator|Traditional physical therapy|Traditional physical therapy ,Hot Pack, Muscle Stretching and Posture correction
89119897|NCT04747899|Experimental|Positional Release Technique|Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.
89119898|NCT03975153|Experimental|guselkumab treatment|Treatment with guselkumab for 20 weeks
89119899|NCT00915850|Experimental|Anticancer drug|docetaxel, cisplatin and 5-FU
89119900|NCT04208763|Experimental|Imipenem+Tigecycline+GM-CSF|
88800572|NCT01138735|Placebo Comparator|Topical Gel Vehicle|Topical Gel Vehicle applied topically once daily for 12 weeks
88800573|NCT01181479|Experimental|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel. Type of intervention is drug.
88800574|NCT01181479|Active Comparator|Lessina crossover to AG200-15|Lessina containing ethinyl estradiol and levonorgestrel for 6 cycles followed by AG200-15 for 6 cycles. Type of intervention is drug.
89119901|NCT04208763|Active Comparator|Imipenem+Tigecycline|
89119902|NCT04100356|Experimental|Normal diet|The group ingests normal diet, recommended by the health authorities
89119903|NCT04100356|Experimental|LCHF diet|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat
89119904|NCT04100356|Experimental|Normal diet + exercise|The group ingests normal diet, recommended by the health authorities in addition to exercise program 3x week.
89119905|NCT04100356|Experimental|LCHF diet + exercise|The group ingests LCHF diet, a modified Atkins diet with 70 energy percentage fat, in addition to exercise program 3x week.
89119906|NCT00620919|Experimental|1|Drug + MDCT
89119907|NCT00916552|Experimental|Erythropoeitin|40.000 IU, epoetin alfa; Janssen-Cilag
89119908|NCT03950037|Experimental|Medical intervention|Participants are hospitalized for 15-30 days while they receive the antiparasitic drug albendazole along with supportive drugs including dexamethasone and omeprazole.
89119909|NCT04188171|Experimental|Polidocanol foam sclerotherapy|"During the intervention period the participants are observed at 3-week intervals (maximum of 3 sessions).~The required number of polidocanol foam sclerotherapy sessions (maximum of 3) is determined by clinical and anoscopic evaluation (if the participant is non-symptomatic and/or there is no significant hemorrhoidal disease on anoscopy, the patient will not be a candidate for additional instrumental therapy moving directly to the follow-up period). After each session all patients were instructed to adopt dietary measures and adequate hydration maintaining therapy with systemic venotropic, topical and laxative if necessary.~After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
89119910|NCT00620997|Experimental|1|"patients randomized to 0.05% Proparacaine drops on a PRN basis for up to 7 days~Acetaminophen with Codeine for breakthrough pain~topical Gatifloxacin drops"
89119911|NCT00620997|Placebo Comparator|2|"placebo drops on a PRN basis for up to 7 days post injury~Acetaminophen with Codeine for breakthrough pain~Gatifloxacin drops"
89119912|NCT00622011|Experimental|1|zotepine , start from 50mg/day then titrate according to individual case
89119913|NCT00622011|Active Comparator|2|Risperidone, start from 1mg/day
89119914|NCT04663113|Other|Control group|Standard physiotherapy (1st Group): It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
89119915|NCT04663113|Experimental|Aerobic Exercises group|Aerobic exercise will be given with bicycle ergometer in addition to Standard physiotherapy (It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises)
89119916|NCT04663113|Experimental|the group in which the exercise protocol to be developed was applied|Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.
89119917|NCT00621075||1|Pulmonary Arterial Hypertension
89119918|NCT00621231|Placebo Comparator|1|
89119919|NCT00621231|Experimental|2|
89119920|NCT00622089|Experimental|1|150mg DIO-902 + 10mg Atorvastatin
89119921|NCT00622089|Experimental|2.|300mg DIO-902 + 10mg Atorvastatin
89119922|NCT00622089|Experimental|3|450mg DIO-902 + 10mg Atorvastatin
89119923|NCT05662449||Ankle fracture with syndesmosis injury|Syndesmosis fixation using bioabsorbable screw
89119924|NCT04208373|Experimental|Panel 1: JNJ 64417184 plus Itraconazole|Participants will receive single oral dose of JNJ 64417184 on Day 1 followed by itraconazole once daily on Days 6 to 13 along with a single dose of JNJ 64417184 on Day 9 orally.
89119925|NCT04208373|Experimental|Panel 2: JNJ 64417184 plus Etravirine|Participants will receive single oral dose of JNJ-64417184 on Day 1 followed by etravirine twice daily on Days 6 to 19 along with single dose of JNJ 64417184 on Day 15.
89119926|NCT04547751||Adult|Patients aged 18yrs and older hospitalized in the Emergency Department of the Mayotte Hospital Center after taking a chemical or other psychoactive substance and for whom a blood test is required
89119927|NCT04547751||Minor|Patients aged 14-17yrs and older hospitalized in the Emergency Department of the Mayotte Hospital Center after taking a chemical or other psychoactive substance and for whom a blood test is required
89119928|NCT00622245|Experimental|Lu AA34893: 4 mg|
89119929|NCT00622245|Experimental|Lu AA34893: 12 mg|
89119930|NCT00622245|Experimental|Lu AA34893: 18 mg|
89119931|NCT00622245|Other|Quetiapine fumarate|Active reference 300 mg
89119932|NCT00622245|Placebo Comparator|Placebo|
89119933|NCT04503057||COVID-19 positive|COVID-19-positive patients with pulmonary infection, ALI or ARDS
88800575|NCT00980174|Placebo Comparator|2|Subjects will receive placebo for denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab (SC injection every 6 months) for 1 year (open-label phase)
88800576|NCT00980174|Experimental|1|60 mg denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab(SC injection every 6 months) for 1 year (open-label phase). These subjects will be on denosumab for a total of 2 years.
89119934|NCT04503057||COVID-19 negative|COVID-19-negative patients with pulmonary infection, ALI or ARDS
89119935|NCT01056341|Experimental|Propranolol oral solution|
89119936|NCT01056341|Placebo Comparator|Placebo|
89119937|NCT00999518|Experimental|Group 1|
89119938|NCT00999518|Experimental|Group 2|
89119939|NCT00999518|Experimental|Group 3|
89119940|NCT00999518|Experimental|Group 4|
89119941|NCT00999518|Placebo Comparator|Group 5|
89119942|NCT00621387|Experimental|1|ofloxacin and roxithromycin
89119943|NCT00621387|Placebo Comparator|2|placebo
89119944|NCT00136149|Experimental|Immediate implants|
89119945|NCT03655743||Patients after refractive surgery|Patients have had any type of corneal or lens refractive surgery.
89119946|NCT03655743||Patients before refractive surgery|Patients will have any type of corneal or lens refractive surgery.
89119947|NCT02873273|Experimental|Dexamethasone delivery system|
89119948|NCT00627341|Experimental|Exposure and Response Prevention|Participants will receive Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa for 6 months.
89119949|NCT00627341|Active Comparator|Cognitive Behavior Therapy|Participants will receive cognitive behavioral therapy for anorexia nervosa for 6 months.
89119950|NCT04208841|No Intervention|Control - Patient|Participants who receive maternal health services at a facility not participating in the Quality Improvement Intervention or implementing the change package
89119951|NCT04208841|Experimental|Sustaining - Patients|Participants who received maternal health services at a facility where a quality improvement collaborative had been implemented
89119952|NCT04208841|Experimental|Spread - Patients|Participants who received maternal health services at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
89119953|NCT04208841|No Intervention|Control - Providers|Providers who work at a facility not participating in the Quality Improvement Intervention or implementing the change package
89119954|NCT04208841|Experimental|Sustaining - Providers|Providers who work at a facility where a quality improvement collaborative had been implemented
89119955|NCT04208841|Experimental|Spread - Providers|Participants who work at a facility that was provided a change package of ideas developed during the quality improvement collaborative (in phase 1) and used to make improvements on person-centered care
89119956|NCT01056263||Non-Interventional Study|Subjects participating in this observational study originally participated in study A4061012 [NCT00076011], and may have also have participated in study A4061008 [NCT00828919].
89119957|NCT00637143|Experimental|1|Oral
89119958|NCT00637143|Active Comparator|2|Oral
89119959|NCT04208451|Experimental|Experimental group|Patients on hemodialysis who consumed one month Standardized Aronia Melanocrpa extract
89119960|NCT01056107|Experimental|ROSE-010 30 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
89119961|NCT01056107|Experimental|ROSE-010 100 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
89119962|NCT01056107|Experimental|ROSE-010 300 mcg|A glucagon-like peptide-1 (GLP-1) analogue. A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
89119963|NCT01056107|Placebo Comparator|Placebo|Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
88800577|NCT01138969|Active Comparator|Esomeprazole plus clopidogrel group|esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
88800578|NCT01138969|No Intervention|Clopidogrel group|clopidogrel 75 mg qd for 6 months
88800579|NCT01926938||adults at risk|Latino adults with family history of type 2 diabetes
88800580|NCT01926938||controls|Latino adults without family history of type 2 diabetes and normal glucose tolerance
88800581|NCT01139515|Experimental|Treatment A|1 X 20 mg eletriptan
88800582|NCT01139515|Experimental|Treatment B|1 X 40 mg eletriptan
88800583|NCT01139515|Experimental|Treatment C|2 X 40 mg eletriptan
89119964|NCT03548805|Experimental|Trabeculectomy with Ologen|ologen® Collagen Matrix
89119965|NCT03548805|Active Comparator|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC (0.02%)
88800584|NCT01139515|Experimental|Treatment D|1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose
88800585|NCT00980018|Experimental|nilotinib|Participants received two 150 [a total of 300 mg at each dosing] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules [a total of 400 mg at each dosing] for patients enrolled prior to Protocol Amendment 1).
89119966|NCT01003886||Open Label|Adult male diagnosed with BPH and prescribed with Doxazosin mesylate GITS
89119967|NCT03541551|Experimental|CTT with ologen® Collagen Matrix|Experimental: Trabeculotomy with trabeculectomy with ologen implant
89119968|NCT03541551|Active Comparator|Trab Trab|Active Comparator: Trabeculotomy with trabeculectomy
89119969|NCT00627029|Experimental|Intervention|Care coordination, consisting variously (depending on the demonstration site)--nurse telephonic counseling, nurse in-person home visits, home telemonitoring equipment, and physician education and feedback.
88800586|NCT00987272|Experimental|Pataday+Pataday Vehicle|Olopatadine Hydrochloride Ophthalmic Solution 0.2%, 1 drop in 1 eye and Olopatadine 0.2% Vehicle in the contralateral eye
88800587|NCT00987272|Active Comparator|Patanol+Patanol Vehicle|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%, 1 drop in 1 eye and Olopatadine 0.1% Vehicle in the contralateral eye
88800588|NCT01182103||Major depressive patients|
88800589|NCT01182103||Healthy subjects|
89119970|NCT00627029|No Intervention|Control|Usual care in Medicare fee-for-service from beneficiaries' physicians and other health care providers
89119971|NCT00621465|Active Comparator|1|Participants will receive standard aftercare and community care services.
89119972|NCT00621465|Experimental|2|Participants will receive usual care and the Critical Time Intervention.
89119973|NCT04208607|Experimental|Study group|Patients with bronchiectasis
89119974|NCT01003184|Experimental|1|
88800590|NCT03010033|No Intervention|regular care|[Control group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary and regular rehabilitation-propaganda; postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time) and early ambulation unless serious patients.
88800591|NCT03010033|Experimental|pulmonary rehabilitation|[Study group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary, regular rehabilitation-propaganda and interventional pulmonary rehabilitation (preoperative part); postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time), early ambulation unless serious patients and interventional pulmonary rehabilitation (postoperative part).
88800592|NCT00986882|Experimental|SAF312A (2 doses in part B; 5 - 6 doses in part C)|
88800593|NCT00986882|Placebo Comparator|Placebo|
88800594|NCT00986882|Active Comparator|Ibuprofen|
88800595|NCT01927094|Active Comparator|Probiotic|"Saccharomyces boulardii 1 x 250 mg per day for 5 days, PO or Lactobacillus GG 1 x 10(9) CFU per day for 5 days or~Lactobacillus reuteri 1 x 10(8) CFU per day for 5 days"
88800596|NCT01927094|Active Comparator|Control|ORS-ad libitum
88800597|NCT00983060|Experimental|NIM811|
88800598|NCT00983060|Placebo Comparator|Placebo|
88800599|NCT05600816|Other|Pounce Venous Thrombectomy System|Subjects admitted for endovascular thrombus removal using the Pounce Venous Thrombectomy System
88800600|NCT05607914|Active Comparator|percussion massage group|Applying the hypervolt device to the hamstring muscle with the hard ball head for 5 minutes
88800601|NCT05607914|Active Comparator|static stretching group|Static stretching of the hamstring muscle for 5 minutes
88800602|NCT05607914|No Intervention|control group|no intervention
88800603|NCT04759352|Experimental|Telephone post-test genetic counseling|Post-test genetic counseling delivered by telephone
88800604|NCT04759352|No Intervention|In-person post-test genetic counseling|Post-test genetic counseling delivered in-person
88800605|NCT01927172|Other|AirSonea|Use of AirSonea to detect wheeze sounds.
88800606|NCT04759430|Active Comparator|Supervised Group|24 individuals will participate in the Supervised group. Patients in the supervised group will be treated individually by the researcher at the hospital. During the application, individuals will apply ten different stabilization exercises in company with a physiotherapist. Exercises will be applied under the supervision of a physiotherapist in the center where the work will be done for 20-30 minutes in each session, three days a week, for a total of 12 sessions for four weeks. The exercises program to be applied to the participants in the group is listed below: Supine position; Abdominal bracing, while continuing the abdominal bracing; heel slides, bridging, 90 degrees hip flexion. Quadruped position; Abdominal bracing while continuing the abdominal bracing; single arm lift, single leg lift, cross-arm leg raises activities. Standing position; Abdominal bracing.
89119975|NCT01003184|Active Comparator|2|
89119976|NCT05662761||symptomatic chronic obstruction|patients with symptomatic chronic obstruction of the femoroiliac and caval vein segments (VFC, VIE, VIC, VCI) treated with stent angioplasty.
89119977|NCT02446821|Experimental|VeraCept IUD System|All women will receive VeraCept.
89119978|NCT01029353|Active Comparator|Randomized Trial: Laparotomy|Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
89119979|NCT01029353|Active Comparator|Randomized Trial: Peritoneal drain placement|Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
89119980|NCT01029353|Active Comparator|Preference Cohort: Laparotomy|Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
89119981|NCT01029353|Active Comparator|Preference Cohort: Peritoneal drain placement|Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
89119982|NCT01008410|Experimental|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
89119983|NCT01008410|Placebo Comparator|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
89233075|NCT03390504|Experimental|Cohort 2 (Arm 2B): Pembrolizumab|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first.
88800607|NCT04759430|Experimental|Telerehabilitation Group|24 individuals will participate in the Telerehabilitation group. Patients in the telerehabilitation group will attend the treatment from their homes. The exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone. The same stabilization exercises will be applied to the participants in the supervised group. Exercises will be applied for 20-30 minutes in each session, three days a week, for a total of 12 sessions for four weeks.
88800608|NCT04759430|No Intervention|Control Group|
88800609|NCT00988052|Experimental|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
88800610|NCT04557800|Experimental|DNL151|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
88800611|NCT04557800|Placebo Comparator|Placebo|Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (10 days); Part C: Single-dose cohort; Part D: Additional multiple-dose cohort (28 days); Part E Multiple-ascending dose cohorts (14 days)
88800612|NCT05607836|Experimental|Intu-Brite|Use of new laryngoscope - IntuBrite for intubation
88800613|NCT05607836|Active Comparator|Macintosh|Use of standard laryngoscope with Macintosh blade for intubation
88800614|NCT04395170|Experimental|Convalescent plasma|Plasma from patients recovering from COVID-19.
88800615|NCT04395170|Experimental|Anti-COVID-19 human immunoglobulin|Anti-COVID-19 human immunoglobulin to be administered intravenously.
88800616|NCT04395170|Active Comparator|Standard (specific) therapy|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
88800617|NCT04394936|Experimental|Guselkumab|Guselkumab 100 mg/ml in prefilled syringe, subcutaneous injection, administered on day 0, 28 and 84.
88800618|NCT04394936|Placebo Comparator|Placebo|Sodiumchloride 0,9% solution for injection, subcutaneous injection, administered on day 0, 28 and 84.
88800619|NCT04394936|No Intervention|Healthy volunteers|Healthy volunteer cohort (observational)
88800620|NCT04394702|Experimental|One Shape Single-file rotary system|
88800621|NCT04394702|Active Comparator|Manual stainless steel K-file|
88800622|NCT04559516|Experimental|Mobile application-based home exercise intervention|"The exercise program will be administered over 12 weeks through the Ethica mobile app. Participants will perform exercise sessions at home guided by instructional video accessed via Ethica, six days per week. The program will include a combination of education, endurance, strength, and respiratory muscle training.~The Ethica mobile app will provide a daily alert and a daily exercise video. There will be background monitoring of step counts and actigraphy will be monitored for one week intervals at baseline, at week six, and at week twelve."
88800623|NCT04559516|Active Comparator|Standard care|No supervised exercise session will be performed. Symptoms and quality of life will be monitored in the same manner as the intervention group, and participants will receive the same educational message alerts through the Ethica app as the exercise intervention group.
88800624|NCT01927328|No Intervention|Control|Standard Care as determined by the clinical team
88800625|NCT01927328|Active Comparator|Iron isomaltoside 1000|Intravenous Iron Isomaltoside 1000 (Monofer®)will be administered in line with the summary of product characteristics.
88800626|NCT04552808|Experimental|Yimitasvir Phosphate Capsules|The mechanism of action of Yimitasvir is the specific inhibition of HCV non-structural protein NS5A
88800627|NCT04557566|Active Comparator|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
88800628|NCT04557566|No Intervention|Control|Wait list control
88800629|NCT05607602||1|Women with uterine fibroids, not requiring any medical or surgical treatment.
88800630|NCT05607602||1a|Women with uterine fibroids undergoing myomectomy or hysterectomy for uterine fibroids
88800631|NCT05607602||Group 2|Women with no uterine fibroids or uterine pathology on ultrasound scan
88800632|NCT01927406|Experimental|Prostaglandin Analog vs Timolol|In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.
88800633|NCT01927406|Experimental|Prostaglandin Analog|In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.
88800634|NCT05607524|Experimental|Probiotics|Probiotic capsules, 500 mg each, two daily for a total of 1000 mg for 4 weeks
88800635|NCT05607524|Placebo Comparator|Placebo|The placebo capsules had the same composition as the experimental capsules, except that they did not contain probiotics, and should be used for 4 weeks.
88800636|NCT01182493|Experimental|Insulin Pump Treatment|Patients will get an insulin pump
88800637|NCT01182493|No Intervention|Insulin treatment with MDI|patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day
88800638|NCT01927484|Experimental|methotrexate|25mg oral methotrexate tablets
88800639|NCT01927484|Placebo Comparator|placebo|25 mg/week placebo tablets
88800640|NCT01140295|Active Comparator|1, Miralax|Miralax colonoscopy preparation
88800641|NCT01140295|Active Comparator|2, senna|Senna colonoscopy preparation
88800642|NCT04551404|Experimental|Study Intervention(s) A|"TRNS bilateral temporal regions combined with AS for 20 minutes~Sham-tRNS bilateral temporal regions combined with Sham-AS for 20 minutes"
88800643|NCT04551404|Experimental|Study Intervention(s) B = Control Intervention|"TRNS bilateral temporal regions for 20 minutes~Sham-tRNS bilateral temporal regions for 20 minutes"
88800644|NCT01182805|Other|Single arm study.|
88800645|NCT01184755|Experimental|Resperate device used for 8 weeks|Participants to use Resperate device to guide breathing for 8 weeks. After the primary 8-week trial, this group is divided into two subgroups to examine 16-week data: one subgroup that stops using the device after 8 weeks, and one asked to continue to use the device for the full 16 weeks.
88800646|NCT01184755|Active Comparator|Relaxation control device|Participants use modified device to pace breathing in the 13/minute range for daily practice for 8 weeks and no device thereafter
88800647|NCT01184755|No Intervention|Usual Care|Participants continue their usual medication and other management for their hypertension. All participants (including UC) are given a home BP monitor and asked to take their BP in morning and evening 3 days/week.
88800648|NCT04275440|Experimental|Exercise group|Participants would be required to take part in an exercise plan, under the instruction and guidance of professional sports teachers.
88800649|NCT04275440|Experimental|Caloric restriction group|The caloric restriction plan will be designed based on individual basal metabolic rate.
88800650|NCT04275440|Experimental|Combined intervention group|Participants will receive both exercise and caloric restriction intervention at the same time.
89119984|NCT00627653|Experimental|1|
89119985|NCT01023269|Other|ON / OFF|Stimulation ON for 4 weeks, followed by stimulation OFF for 4 weeks.
89119986|NCT01023269|Other|OFF / ON|Stimulation OFF for 4 weeks, followed by stimulation ON for 4 weeks.
89119987|NCT02347917|Experimental|BBI608 puls pemetrexed and cisplatin|
89119988|NCT01972035|Experimental|ValAcyclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValA or ValG in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
89119989|NCT01972035|Active Comparator|ValGanciclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValG or ValA in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
89119990|NCT00622479|Experimental|Arm 1|
89119991|NCT05661903|Other|Patients with Implanted Devices on Minimal/No Stimulation Settings|Patients in this arm will be randomized to turn off their spinal cord stimulator (or to minimal settings).
89119992|NCT05661903|Other|Patients with Implanted Devices on Usual Stimulation Settings|Patients in this arm will be randomized to turn on their spinal cord stimulator to their usual stimulation settings.
89119993|NCT01207011|Experimental|1 AMR|
89119994|NCT01207011|Active Comparator|2 DOC|
89119995|NCT05264805|Experimental|Bupivacaine group|Patient receiving 20ml of inj. 0.25% Bupivacaine at laparoscopic port site
89119996|NCT05264805|No Intervention|Placebo group|No drug infiltration at laparoscopic port site
89119997|NCT04272411|Sham Comparator|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device
89119998|NCT04272411|Active Comparator|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device
88800651|NCT04275050|Experimental|TQB3303 Tablet|TQB3303 Tablet administered orally once. Then TQB3303 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.
88800652|NCT05607446|Experimental|TQC3564 tablets|Orally administer TQC3564 tablets for 14 days.
88800653|NCT05607446|Placebo Comparator|placebo tablets|Orally administer placebo tablets for 14 days.
88800654|NCT05607446|Experimental|TQC3564 tablets + montelukast sodium tablets|Orally administer TQC3546 tablets combined with Montelukast sodium tablets for 14 days.
88800655|NCT05607446|Placebo Comparator|placebo tablets + montelukast sodium tablets|Orally administer placebo tablets combined with Montelukast sodium tablets for 14 days.
88800656|NCT01141075|Experimental|Ataluren|"Cycle 1: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 5 mg/kg (morning), 5 mg/kg (midday), and 10 mg/kg (evening); there will then be an interval of 21 up to 42 days without treatment.~Cycle 2: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 10 mg/kg (morning), 10 mg/kg (midday), and 20 mg/kg (evening); there will then be an interval of 14 days without treatment."
88800657|NCT05607368||SLE group|"Voluntary signing of informed consent;~Age greater than 18 years old, less than 50 years old, gender is not limited;~Patients with SLE who meet diagnostic criteria."
88800658|NCT05607368||NPSLE epilepsy group|"Voluntary signing of informed consent.~Age greater than 18 years old, less than 50 years old, gender is not limited.~Patients with NPSLE epilepsy who meet diagnostic criteria."
88800659|NCT05607368||Healthy control group|"Voluntary signing of informed consent;~Healthy volunteers older than 18 years old and less than 50 years old, regardless of gender;~No systemic diseases and neurological symptoms and signs;~According to the judge's judgment, healthy volunteers matching the NPSLE epilepsy group in terms of gender, age, and education level were selected as the control group."
88800660|NCT01927952|Active Comparator|Kirschner wire|surgical fixation using a Kirschner wire
88800661|NCT01927952|Active Comparator|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
88800662|NCT01927952|Active Comparator|Stryker Smart-Toe implant|surgical fixation utilizing the Stryker Smart-Toe implant
88800663|NCT02185105|Experimental|comfilcon A MTO|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
89119999|NCT04272411|Active Comparator|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device
89120000|NCT05264493|Experimental|naloxone 5 mg IM autoinjector|participants will receive in random order, a single naloxone 5 mg IM autoinjector injection into the lateral thigh
89290083|NCT04073446|Active Comparator|Dorsal Column (DC) Perception|Use of DC Perception based programming
89233079|NCT03386734|Experimental|SLN biopsy only|Sentinel lymph node (SLN) biopsy only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
89233080|NCT03386734|Active Comparator|SLN biopsy + PLN dissection|SLN biopsy + full pelvic lymph node dissection (PLN) will be performed. The radical hysterectomy or trachelectomy will be done.
89233081|NCT03383978|Experimental|NK-92/5.28.z + Ezabenlimab|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8; intravenous infusion of Ezabenlimab 240mg q 3 weeks
89233082|NCT03377660||Sandostatin|This cohort will be the group who are undergoing routine clinical treatment with a long-acting somatostatin analogue to minimise abnormal gut hormone signalling, and thus reduce early satiety.
89233083|NCT03377660||Mirtazapine|This cohort will be the group who are undergoing routine clinical treatment with a tetracyclic antidepressant to stimulate appetite.
88800664|NCT02185105|Active Comparator|comfilcon A|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
88800665|NCT01928264|Experimental|Physical activity|Physical activity group program over 12 weeks; 1 hour sessions, 2 times a week
88800666|NCT01928264|No Intervention|Leisure time activities|Predominantly sedentary leisure time group activities, like playing board games, doing handicrafts, etc.; 12 weeks, 1 hour sessions, 2 times a week
88800667|NCT05606900|Experimental|Experiment group|Twenty volunteer patients between the ages of 18-65 who applied to the addiction polyclinic and were diagnosed with alcohol use disorder (AUD) constitute the sample of the experimental group. In addition to the standard alcohol addiction treatment (TAU) applied in the addiction polyclinic, the patients in the experimental group will be given addiction-focused eye movements, desensitization and reprocessing (AF-EMDR) psychotherapy. AF-EMDR consists of 3 sessions, with a total duration of 3 weeks. Each session will last between 1 and 1 and a half hours, depending on individual differences. Psychotherapy sessions will be conducted as face-to-face and individual sessions. TAU includes the medical treatment for AUD and motivational interviews if necessary, administered by the psychiatrist in the addiction polyclinic, where the research is conducted. Structured psychotherapy is not used in TAU practice.
88800668|NCT05606900|No Intervention|Control group|The sample of the control group consists of 20 volunteer patients between the ages of 18-65 who applied to the addiction polyclinic and were diagnosed with alcohol use disorder (AUD). Patients in the control group will be given standard treatment of alcohol use disorder (TAU). The duration and dosage of TAU are regulated by the psychiatrist in the polyclinic specific to the patient. During the duration of AF-EMDR to the experimental group, patients in the control group will be on the waiting list and will not receive AF-EMDR intervention. If AF-EMDR intervention is concluded as beneficial for the patients in the experimental group after the analysis of the final measurements (1-month follow-up measurements), the same AF-EMDR intervention will be applied to the patients in the control group.
88800669|NCT02185183|Experimental|AlequelTM|AlequelTM
88800670|NCT05606822||Anastomotic leakage after gastrointestinal surgery|No interventions will be administered, as this is an observational study.
88800671|NCT05606822||Esophageal perforation (Boerhaave syndrome, iatrogenic, trauma, other)|No interventions will be administered, as this is an observational study.
88800672|NCT02185339|Experimental|dNMB group|For patients randomized to the dNMB group, intravenous infusion of 0.6 mg/kg/h rocuronium will be administered 10 minutes after the administration of intubation dose or after the return of post-tetanic count (PTC), whichever comes first. Then, the infusion rate will be titrated according to PTC (target to keep PTC between 1 to 2). Infusion rate will be increased or be reduced at a rate of 0.1 mg/kg/h if PTC is > or < than 1-2 to maintain deep muscle relaxation throughout the surgery. Neuromuscular monitoring will be carried out by monitoring the adductor pollicis muscle in response to ulnar nerve stimulation. A dose of sugammadex (4 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
88800673|NCT02185339|Active Comparator|mNMB group|For patients randomized to the mNMB group, intravenous infusion of 0.2 mg/kg/h rocuronium will be administered 30 minutes after the administration of intubation dose or after the appearance of train-of-four (TOF) count >2, whichever comes first. Then, the infusion rate will be titrated according to TOF (target to keep TOF between 1 to 2). Infusion rate will be increased or reduced at a rate of 0.1 mg/kg/h if TOF is > or < than 1-2. A dose of sugammadex (2 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
88800674|NCT05606744|Active Comparator|Eccentric exercise|Only multi-joint eccentric exercise
88800675|NCT05606744|Experimental|Eccentric training with blood flow restriction|Multi-joint eccentric exercise with blood flow restriction
89233084|NCT03375320|Experimental|Arm I (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.
89233085|NCT03375320|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.
89233086|NCT03366168||Group 1|Ages 18-39 years
89233087|NCT03366168||Group 2|Ages 40-59 years
89233088|NCT03366168||Group 3|Ages 60 years old or older
89233089|NCT03353220|Experimental|Arm A|Participants receive lorcaserin (Belviq) 10 mg twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive placebo twice a day for 7 days.
89233090|NCT03353220|Experimental|Arm B|Participants receive placebo twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive lorcaserin (Belviq)10 mg twice a day for 7 days.
89233091|NCT03321630|Other|Lenvatinib & Pembrolizumab|
89290084|NCT04073446|Active Comparator|Dorsal Root (DR) Perception|Use of DR Perception based programming
88800676|NCT02980159||Before triage liaison physician|All patients admitted before the introduction of the function of triage liaison physician.
89120001|NCT05264493|Active Comparator|naloxone 2 mg IM|participants will receive in random order, a single naloxone 2 mg IM injection into the gluteus muscle
89120002|NCT05264493|Active Comparator|naloxone 2mg bolus IV|participants will receive in random order, a single naloxone 2 mg bolus IV injection
89120003|NCT00612261|Experimental|1|The group 1 patients receive AV sheathotomy for macular edema secondary to branch retinal vein occlusion.
89120004|NCT00612261|Active Comparator|2|The group 2 patients receive IVTA.
89120005|NCT00622791||CABG group|Patients undergoing coronary artery bypass graft with cardiopulmonary bypass
89120006|NCT00622791||OPCAB group|Patients undergoing off-pump coronary artery bypass graft
89120007|NCT02693379|Experimental|D-VIA|HPV high risk-positive (16, 18, 45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68) women had a cervical examination using acetic acid (VIA) application and visual inspection.
89120008|NCT02693457|Active Comparator|Drain|Intra-articular drain will be placed at closure of randomized knee for 24 hours
89120009|NCT02693457|Experimental|No Drain|No intra-articular will be placed in the contralateral knee of the same patient. A placebo drain will be placed so patient is unaware of which knee contains working drain.
89120010|NCT05261217|Experimental|The motion 3D II appliance|using The motion 3D II appliance on treating Class II orthodontic
89120011|NCT00636909|Experimental|1|Study treatment arm with G-CSF
89120012|NCT05260983|Active Comparator|Diabetes Prevention Education Only|A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Diseases Control and Prevention's National Diabetes Prevention Program.
89120013|NCT05260983|Experimental|Diabetes Prevention Education and Acceptance and Commitment Therapy|A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.
89120014|NCT02697201|Experimental|Intralipid Infusion, then Saline|Participants in this arm will first receive a lipid infusion. Then 4 weeks later the saline infusion.
89120015|NCT02697201|Sham Comparator|Saline Infusion, then Intralipid|Participants in this arm will first receive a saline infusion. Then 4 weeks later the lipid infusion.
89120016|NCT02697045|Other|ARIPIPRAZOLE|ABILIFY MAINTENA 400 MG LAI Aripiprazole 400mg, IM, Once a month
89120017|NCT02697357||Caregivers|This study is a pilot, single-arm intervention of Emotion Regulation Therapy for Cancer Caregivers (ERT-C). We plan to recruit a pilot sample 32 consented (24 evaluable) caregivers of patients diagnosed with cancer and measure their distress, anxiety, and other psychological outcomes at baseline. Caregivers will be consented into an 8-session ERT-C therapy (approximately 12 - 16 weeks).
89120018|NCT05661747|Experimental|Intervention Arm will use Vivos Grow/Vivos Way Device|This intervention will compare measurements prior to treatment with measurements post-treatment.
89120019|NCT01007942|Experimental|Everolimus + vinorelbine + trastuzumab|Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
89120020|NCT01007942|Placebo Comparator|placebo + vinorelbine + trastuzumab|Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only
89120021|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 10%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
89120022|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 25%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
89120023|NCT01023035|Experimental|Treated/Not Randomized|Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained >10 g/dL throughout the 28- or 48-week treatment period.
89120024|NCT01023035|Experimental|Ribavirin Dose Reduction|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
89120025|NCT01023035|Experimental|Erythropoietin Use|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
89120026|NCT04300361||Non-Western patients|Patients of non-Western descent with an indication for treatment with fluoropyrimidine-based chemotherapy. A patient is classified as non-Western if a one (1) of the parents or more than two (>2) of the grand parents are of non-Western descent.
89120027|NCT01028651||Portopulmonary hypertension|
89120028|NCT00627731|Active Comparator|1|mPSL 240 mg per day for 5 days
89120029|NCT00627731|Experimental|2|PSL 40mg per day for 10 days
89120030|NCT01028027|Experimental|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension
89120031|NCT01028027|Active Comparator|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension
88800677|NCT02980159||After triage liaison physician|All patients admitted after the introduction of the function of triage liaison physician.
88800678|NCT05603546||CFA treated by endarterectomy|Common femoral artery lesions undergo endometrial decortication
88800679|NCT05603546||CFA treated by transluminal extraction-atherectomy|Common femoral artery lesions are treated intravenously
88800680|NCT01186705|Experimental|MK-2206|This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.
89120032|NCT01007552|Experimental|Gemcitabine, Capecitabine and Bevacizumab|Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
89120033|NCT02870192|Experimental|Rectal Prolapse|Patients with rectal prolapse, who will underwent laparoscopic ventral mesh rectopexy. The implemented mesh may be synthetic or biological.
89120034|NCT04452890|Experimental|Sonourethrography|Ultrasound of the urethra (Sonourethrography - SUG): In this procedure, a Foley catheter is inserted into the top of the urethra and physiological serum is instilled into the urethra while a linear 7.5 MHz ultrasound probe is placed sagitally on the course of the urethra to detect a narrowing of the urethra.
89120035|NCT02869880|Active Comparator|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial.
89120036|NCT02869880|Experimental|Enhanced Pre-consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
89120037|NCT04204694||Patient in septic shock|
89120038|NCT04204694||blood donor tests|
89120039|NCT01007396|Other|new healthcare workers|doctors and nurses who were newly hired in 2008 at the Samsung Medical Center
89120040|NCT02869958|Active Comparator|1: Written action plan|Written action plan
89120041|NCT02869958|Experimental|2: Digital action plan|Written action plan + Digital action plan for asthma exacerbations Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
89120042|NCT02870036|Experimental|Pharmacokinetic data investigation of Simmitecan|To further determine the pharmacokinetic (PK) characteristics of Simmitecan monotherapy in patients with advanced solid tumors
89120043|NCT02870036|Experimental|Dose escalation study of Simmitecan combined therapy|To determine the maximum tolerated dose (MTD) of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced solid tumor
89120044|NCT02870036|Experimental|Dose extension study of Simmitecan monotherapy|To preliminarily evaluate the anti-tumor activity of Simmitecan monotherapy in patients with advanced solid tumors, and to determine the recommended phase II dose (RP2D)
89120045|NCT02870036|Experimental|Dose extension study of Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced/metastatic colorectal cancer (CRC), and to determine RP2D
89120046|NCT02870036|Experimental|Dose escalation&extension Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with gastrointestinal tumors, and to determine RP2D and MTD
89120047|NCT02870036|Experimental|Dose extension study of Simmitecan combined therapy|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with specific tumors
89120048|NCT04296422|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
89120049|NCT04296422|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
89120050|NCT04296422|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
89120051|NCT04296656|Active Comparator|Intervention group|"Mothers in the intervention group were taught the infant calming technique 5 S's, a part of The Happiest Baby (THB) method. THB is based on the theory that infants have an innate calming reflex that can soothe infant fussing, excessive crying and prolong sleep. This reflex is triggered by five activities that mimic the sensory milieu of the womb. The 5 S's include swaddling, side position, sound (white noise), swing and suck.~The intervention consisted of a 20-minute face-to-face guidance session with the researcher, executed individually in the mother's hospital room. Each mother was given a leaflet to take home that explained the 5 steps in short. Safety issues, such as safest sleep position (supine), allowing hips to flex and how to avoid overheating when swaddled, were addressed. The same researcher executed each guidance session to maintain standardization."
89120052|NCT04296656|No Intervention|Control group|Standard care on postpartum ward (breastfeeding and infant care guidance and support in recovering from childbirth and transitioning into parenthood).
89120053|NCT04296500||Decision tree algorithm training/testing|The investigators divided data of 67 patients into 5 groups to do 5 fold cross validation. Four groups were used to train decision tree algorithm and one group was used to test it.
89120054|NCT04293848|Experimental|music with low-sinusoidal sound (vibrations)|Participants will listen to music and low-sinusoidal sound (vibroacoustic therapy).
89120055|NCT04293848|Placebo Comparator|Control Group|Participants will listen to music alone.
89120056|NCT00998738|Experimental|Arm I (calcium gluconate, magnesium sulfate)|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after each ixabepilone administration.
89120057|NCT00998738|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 30 minutes immediately before and after each ixabepilone administration.
89120058|NCT00997334|Experimental|Erlotinib|Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.
89120059|NCT04293926|No Intervention|Control|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises.
88800681|NCT01928342|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
88800682|NCT01928342|Placebo Comparator|Placebo|Capsule without coenzyme A.
88800683|NCT01928498|Experimental|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon Angioplasty
89290085|NCT04073446|Active Comparator|Dorsal Root (DR) Sub-perception|Use of DR sub-perception based programming
88800684|NCT01928498|Active Comparator|Conventional uncoated balloon|Percutaneous Transluminal Angioplasty (PTA)
88800685|NCT04558502|Experimental|minocycline-based bismuth quadruple regimen for 14 days|Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days.
88800686|NCT04558502|Active Comparator|clarithromycin-based bismuth quadruple regimen for 14 days|Esomeprazole 20 mg,clarithromycin 500 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 14 days.
88800687|NCT04558502|Experimental|minocycline-based bismuth quadruple regimen for 10 days|Esomeprazole 20 mg, minocycline 100 mg, amoxicillin 1000 mg, and colloidal bismuth pectin 200 mg twice daily for 10 days.
88800688|NCT01218997|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
89120060|NCT04293926|Experimental|Exercise|This group will receive routine recommendations by the pediatrician, including specific lifestyle advises. In addition, a 8-week resistance exercise training program will be performed.
89120061|NCT04293770|Experimental|Indirect restorations luted with light-cured composite resin.|"Subjects for the study will be identified from patients who had treated with indirect adhesive restorations onlay or overlay during the period 2016 to 2017 was performed at Istanbul Okan University Faculty of Dentistry by an experienced clinician.~Local anesthesia was applied if necessary. After caries and/or failed restorations were removed, the preparations were performed according to defined principles for adhesive onlays/overlays. At least one cuspal coverage was required for each restoration. All undercuts were eliminated using composite resin. Following the cavity preparation, immediate dentin sealing was applied and polymerized prior to impression taking. Indirect restorations were designed and fabricated with CEREC system. Surface treatments and clinical protocols were performed under manufacturer's instructions. Adhesive cementation with composite resin procedure was carried out with the rubber-dam isolation."
89120062|NCT04295018|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
88800689|NCT01218997|Active Comparator|Oral naltrexone 50 mg|
88800690|NCT01928654|Experimental|Micropulse laser treatment|Sub-threshold laser treatment covering the area of retinal thickening with a dense pattern
88800691|NCT01928654|Active Comparator|Laser modified ETDRS|Macular treatment using the modified ETDRS protocol, with barely visible laser burns to close microaneurysms, or with a grid pattern in the area of retinal thickening.
88800692|NCT01219777|Experimental|Carboplatin|AUC 5.0 or 6.0
88800693|NCT01219777|Experimental|Bevacizumab|15 mg/kg
88800694|NCT01219777|Experimental|Paclitaxel|60-80 mg/m2
88800695|NCT05603156|Experimental|treatment arm|patients enrolled treated with the combination of Olverembatinib and Inotuzumab to clear the persistent MRD.
88800696|NCT05603078|Experimental|preoperative tumor-bed boost|The participants receive preoperative tumor-bed boost, oncoplastic surgery and adjuvant WBRT±RNI.
88800697|NCT04759742|Experimental|group Ropivacaine|The recommended administration concentration of ropivacaine in the subarachnoid space was 0.5% and the dose was 2-3ml (practical clinical anesthesiology). Based on previous clinical experience, the starting dose of ropivacaine was set at 12.5mg (2.5ml) and Dixon's up-and down method was adopted (Dixon WJ, Massey FJ Jr. Introduction to Statistical Analysis. NY: McGraw-Hill;1969. P. 344.) The dose of ropivacaine in the next patient was adjusted to 0.5mg (0.1 mL) according to the results of the previous patient's trial.
89120063|NCT04295096|Other|Experimental|Healthy donor
89120064|NCT04294940|Other|Group A: standard of care|The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.
89120065|NCT04294940|Other|Group B: standard of care + mobile application CardiCare™|The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™
89120066|NCT04296578|Experimental|Cohort 1: 5.5 mg selenite|Given orally, 5.5 mg selenite with food (within 30 mins of eating), for 5 weeks and monthly there after
89120067|NCT04296578|Experimental|Cohort 2: 11 mg selenite|Given orally, 11 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
89120068|NCT04296578|Experimental|Cohort 3: 16.5 mg selenite|Given orally, 16.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
89120069|NCT04296578|Experimental|Cohort 4: 22 mg selenite|Given orally, 22 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
89120070|NCT04296578|Experimental|Cohort 5: 27.5 mg selenite|Given orally, 27.5 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
89120071|NCT04296578|Experimental|Cohort 6: 33 mg selenite|Given orally, 33 mg selenite with food (within 30 mins of eating) for 5 weeks and monthly there after
89120072|NCT00996944|Experimental|Ropinirole IR|
89120073|NCT00996944|Placebo Comparator|Placebo|
89120074|NCT04296266|Experimental|Alda-341 treatment|Alda-341 treatment at 2 g/day for 14 days up until the day before regular medical care surgery.
89120075|NCT02869490||Patients with cervical cancer diagnosis|
89120076|NCT02869724|Active Comparator|Weekly divided delivery|Hospitalized for voluntary drug intoxications.
89120077|NCT02869724|Active Comparator|Monthly divided delivery|Hospitalized for voluntary drug intoxications.
89120078|NCT01002482|Experimental|CGAO-based Glucose Control|Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.
89120079|NCT01002482|Active Comparator|Standard-Care Glucose Gontrol|Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.
89120080|NCT01027949|Experimental|Oral Treprostinil|Subjects from previous studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405), TDE-PH-301 (NCT00325442), TDE-PH-302 (NCT00325403), or TDE PH-308 (NCT00887978). Subjects were instructed to take the appropriate amount of 0.125, 0.25, 0.5, 1, and/or 2.5 mg tablets based upon their prescribed dose. Investigators were instructed to increase the dose of oral treprostinil in the absence of dose limiting drug-related AEs to ensure each subject received the optimal clinical dose throughout the study
89120081|NCT01038323|Experimental|CBT and milnacipran|Subjects randomized to this group will receive a combination of eight telephone sessions of Cognitive Behavior Therapy (CBT) and a 21-week regimen of milnacipran.
89233092|NCT03301220|No Intervention|Arm A: Active Monitoring|Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.
89233093|NCT03301220|Experimental|Arm B: Daratumumab SC|Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.
89233094|NCT03269669|Experimental|Arm I (obinutuzumab, umbralisib)|CLOSED TO ACCRUAL: Patients receive obinutuzumab IV on day 1 and umbralisib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and ECHO or MUGA during screening, and PET/CT scans and collection of blood throughout the trial.
89233095|NCT03269669|Experimental|Arm II (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV on day 1 and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and ECHO or MUGA during screening, and PET/CT scans and collection of blood throughout the trial.
89233096|NCT03269669|Active Comparator|Arm III (obinutuzumab, combination chemotherapy)|"PRIOR BENDAMUSTINE-BASED CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, and prednisone PO on days 1-5. Treatment with obinutuzumab repeats every 21 or 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Treatment with combination chemotherapy repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~PRIOR CHOP CHEMOTHERAPY: Patients receive obinutuzumab IV on day 1, and bendamustine IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 or 12 cycles (bendamustine and obinutuzumab, respectively) in the absence of disease progression or unacceptable toxicity.~Patients undergo biopsy and ECHO or MUGA during screening, and PET/CT scans and collection of blood throughout the trial."
89233097|NCT03242642|Experimental|Primary Cohort- TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
89233098|NCT03242642|Experimental|Mitral Annular Calcification -TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
89233099|NCT03237858|Active Comparator|HeartLogic ON|ICD and CRT-D devices with HeartLogic alerts turned ON
89233100|NCT03237858|Placebo Comparator|HeartLogic OFF|ICD and CRT-D devices with HeartLogic alerts turned OFF
89290086|NCT04073446|Active Comparator|Dorsal Column (DC) Sub-perception|Use of DC sub-perception based programming
89290087|NCT03937882|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Thymosin beta 4
89290088|NCT03937882|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
88800698|NCT05602922|Active Comparator|basic treatment+ swallowing rehabilitation treatment|Swallowing function training mainly includes indirect training, direct training, and compensatory techniques, once a day for 20 minutes each time. In addition, a low-frequency electric VitalStim swallowing therapy device (produced by Chattanooga, USA) was also used for electrical stimulation therapy. The treatment parameters were 700ms in width, two-way square wave, 0～25mA in amplitude, and 30～80Hz in fixed frequency. The A electrode of channel 1 is placed above the hyoid bone, and the B electrode is placed above the notch on the thyroid cartilage. The channel 2 electrode C and electrode D of the therapeutic apparatus are arranged vertically and equidistantly according to the electrode A and electrode B. After the electrodes are placed, turn on the power. The stimulation intensity is based on the maximum stimulation that the patient can tolerate. 1 time a day, 30min each time, a total of 4 weeks.
88800699|NCT05602922|Experimental|basic treatment+ swallowing rehabilitation treatment+ Liu-Zi-Jue|"On the basis of the control group, the Liu-Zi-Jue exercises were performed, including Xu, He, Hu, Si, Chui, Xi, 6 times each time, 5 times a week, each exercise for 30 minutes, and continuous treatment for 4 weeks."
88800700|NCT03361826|Other|DBT Only|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder.
88800701|NCT03361826|Experimental|MagPro MST with Cool TwinCoil + DBT|MST treatments will be administered using the MagPro MST with Cool TwinCoil. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
88800702|NCT01928810|Experimental|70% VO2max|"Cognitive Behavioural Therapy (CBT)~+ aerobic exercise (30 minutes, 70% VO2max) prior to 5 in-vivo exposure sessions"
88800703|NCT01928810|Active Comparator|30% VO2max|"Cognitive Behavioural Therapy (CBT)~+ placebo exercise (30 minutes, 30% VO2max) prior to 5 in-vivo exposure sessions"
88800704|NCT01928888|Experimental|Arm HFP|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Famotidine, 3rd heartburn episode Placebo
88800705|NCT01928888|Experimental|Arm HPF|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Placebo, 3rd heartburn episode Famotidine
88800706|NCT01928888|Experimental|Arm FHP|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Placebo
88800707|NCT01928888|Experimental|Arm FPH|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Placebo, 3rd heartburn episode Hydrotalcid
89290089|NCT01125384|No Intervention|nurse swabbing|
89290090|NCT01125384|Experimental|"accurate swabbing by a physician"|
88800708|NCT01928888|Experimental|Arm PHF|1st heartburn episode Intervention Placebo, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Famotidine
88800709|NCT01928888|Experimental|Arm PFH|1st heartburn episode Intervention Placebo, 2nd heartburn episode Famotidine, 3rd heartburn episode Hydrotalcid
88800710|NCT04557722|Active Comparator|Group 1: 0-30° technique.|Procedure: 0-30° Biplanar Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
88800711|NCT04557722|Active Comparator|Group 2: new 0-90° technique.|Procedure: new 0-90° Fluoroscopic Puncture Technique for Percutaneous Nephrolithotomy.
88800712|NCT01928966|Active Comparator|Group I - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four weeks of study: receive 1.5 ounces of pumpkin seeds per day for consumption; Third four weeks of the study: consume their perceived normal diet.
88800713|NCT01928966|Active Comparator|Group II - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four week period: consume perceived normal diet; Third four week period: receive 1.5 ounces of pumpkin seeds per day for consumption.
88800714|NCT04556084|Experimental|Blinatumomab|Up to 2 cycles of continuous infusion blinatumomab will be given based on the end of Cycle 1 disease response. Cycle 2 of blinatumomab can be given to subjects who have achieved remission (< 5% marrow blasts) after Cycle 1 but have persistent disease identified by multi-parameter flow cytometry (minimal residual disease (MRD) positive ≥ 0.01%) after Cycle 1.
88800715|NCT04394780|No Intervention|Peritoneal dialysis at 37 C|Patients underwent peritoneal dialysis with the standard temperature.
88800716|NCT04394780|Active Comparator|Peritoneal dialysis at 32 C|Patients started on continuous ambulatory peritoneal dialysis using a peritoneal dialysate cooled to between 32-33 degrees centigrade, at a pre-determined and precisely controlled temperature for the 4 hour duration treatment.
88800717|NCT04395326||24 months follow-up|"Single-group study Patients have been included for up to 4 weeks after the initiation of Second Generation Antipsychotic (SGA) treatment (baseline)~Patients under 18 years of age, previously naïve of antipsychotics, starting an SGA or who started an SGA treatment for less than 4 weeks, followed longitudinally at one of the selected recruiting centers, regardless of the diagnosis that motivated the prescription. Comedications and combination of APs are allowed, as this is an observational study.~The exclusion criteria are the following: participants diagnosed before or at the baseline with diabetes, dyslipidemia, high blood pressure, thyroid dysfunction, hepatic disease, a disorder that can lead to hyperprolactinemia or another disorder that may interfere with the development of the side effects studied in this research, participants taking a drug intended to treat one of the conditions mentioned above before starting the SGA treatment, and pregnancy."
88800718|NCT01929122|Placebo Comparator|Placebo-Control|Randomized participants consume 1 meal and 1 snack per day that does not include either rice bran or navy bean powder for 28 days.
88800719|NCT01929122|Experimental|Cooked Navy Bean Powder|Randomized participants consume 1 meal and 1 snack per day containing cooked navy bean powder (35 g/day) for 28 days.
88800720|NCT01929122|Experimental|Rice Bran|Randomized participants consume 1 meal and 1 snack per day containing rice bran (30 g/day) for 28 days.
88800721|NCT04394234||Treatment Group|Participants data who are new users of rivaroxaban, apixaban and dabigatran with prior Non-valvular atrial fibrillation/Venous thromboembolism/Total hip replacement (NVAF/VTE/THR) or Total knee replacement (TKR) in a nationally representative population of insured participants in the United States (US) will be compared pairwise.
88800722|NCT04394234||Comparator Group|Participants data who are new users of warfarin, apixaban, and dabigatran with prior NVAF/VTE/THR or TKR in a nationally representative population of insured participants in the US will be compared pairwise.
89120082|NCT01038323|Placebo Comparator|CBT and placebo|Subjects randomized to this arm will receive a series of eight telephone sessions of Cognitive Behavioral Therapy (CBT) along with a 21-week regimen of a placebo(sugar pill)medication.
89120083|NCT01038323|Active Comparator|Educational with milnacipran|Subjects randomized to this group will receive a series of eight educational phone calls regarding fibromyalgia along with a 21-week regimen of milnacipran.
89120084|NCT05031221|Experimental|Yoga + behavioral weight loss|In person and virtual yoga + 150 minutes of moderate-to-vigorous physical activity/week + weekly instruction on dietary strategies for weight loss
89120085|NCT01027871|Experimental|LY2605541 Dosing Algorithm 1|Participants took both LY2605541 and their pre-study insulin for first several days
89120086|NCT01027871|Experimental|LY2605541 Dosing Algorithm 2|Participants took only LY2605541 with first dose doubled
89120087|NCT01027871|Active Comparator|Insulin glargine|
89120088|NCT02873507|Experimental|MRI of donor liver|MRI evaluation of graft steatosis in donor liver prior to transplantation
89120089|NCT04301375|Experimental|Study treatment|
89120090|NCT04300439|Active Comparator|Arm A: metallic reusable ancillary.|This control group will be constituted of patients who will have the GMK® prosthesis with metallic reusable ancillary.
89120091|NCT04300439|Experimental|Arm B: Efficiency single use ancillary.|This group will be constituted of patients who will have the GMK® prosthesis with Efficiency single use ancillary.
89120092|NCT04300907|Experimental|Provant Infinity Therapy|Open-label treatment with Provant Infinity Therapy
89120093|NCT04300829|Experimental|Simple hygiene rules of the site + Cicaderma ointment|Hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and Cicaderma ointment application)
89120094|NCT04300829|Active Comparator|Preventive standard cares|Preventive standard cares of the site including hygiene rules (use of a neutral soap, no bath, use of non-alcoholic products, delicate drying of the skin, wearing of cotton clothing) and a maximum of one topical treatment
89120095|NCT01021553|Placebo Comparator|placebo|placebo
89120096|NCT01021553|Active Comparator|50 mg|50 mg GSK557296
89120097|NCT01021553|Active Comparator|150 mg|150 mg GSK557296
89120098|NCT01026389|Active Comparator|Gadovist|Patient received contrast-enhanced MRA with Gadovist
89120099|NCT01026389|Experimental|Dotarem, interventional|Patients received contrast-enhanced MRA with Dotarem
89120100|NCT04300517|Experimental|protein supplement|Intervention patients will be received protein diet (1.2 g/kg/day) and protein supplement (36 g/day) for 1 month after surgery.
89120101|NCT04300517|Placebo Comparator|maltodextrin|Control patients will be received protein diet (1.2 g/kg/day) and maltodextrin for 1 month after surgery.
89120102|NCT01006616|Experimental|Navarixin 10 mg|Participants receive navarixin 10 mg, as one navarixin 10 mg capsule and two placebo capsules, administered orally once daily (QD) for up to 2 years
89120103|NCT01006616|Experimental|Navarixin 30 mg|Participants receive navarixin 30 mg, as one navarixin 30 mg capsule and two placebo capsules, administered orally QD for up to 2 years
89120104|NCT01006616|Experimental|Navarixin 50 mg|Participants receive navarixin 50 mg, as two navarixin 10 mg capsules and one navarixin 30 mg capsule, administered orally QD for up to 2 years
89120105|NCT01006616|Placebo Comparator|Placebo|Participants receive placebo to navarixin, as three placebo capsules, administered orally QD for up to 2 years
89120106|NCT04261166|Experimental|Single dose|Single dose in fasted state of : A1, A2,A3, A4, A5, B1, B2, B3, B4
88800723|NCT05602844|Experimental|PSI Lapidus|Design of PSI, 3D printing of PSI, PSI-assisted Lapidus Surgery.
88800724|NCT05602844|Active Comparator|Conventional Lapidus|Lapidus Surgery: exposure of the 1TMTJ via a 3-5cm medial longitudinal skin incision and capsulotomy. Freehand creation of the fusion surface with fluoroscopic assistance. Fixation of the Lapidus arthrodesis will be performed with two 3.5mm headless compression screws.
88800725|NCT04552652|Experimental|High-intensity interval training - telerehabilitation|12 weeks of high-intensity interval training. Three sessions per week will be performed (36 total sessions).
88800726|NCT04552652|Active Comparator|Moderate-intensity continuous training - telerehabilitation|12 weeks of moderate-intensity continuous training. Three sessions per week will be performed (36 total sessions).
88800727|NCT02569710|Experimental|Cohorts 1 and 2 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic Hepatitis C virus (HCV)-infected participants will receive AL-335 and Odalasvir (ODV) with Simeprevir (SMV) for 8 weeks.
88800728|NCT02569710|Experimental|Cohort 1b (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV for 8 weeks.
88800729|NCT02569710|Experimental|Cohort 3 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV for 6 weeks.
88800730|NCT02569710|Experimental|Cohort 4 (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV up to 8 or 12 weeks.
88800731|NCT02569710|Experimental|Cohort 5 (Without Cirrhosis) : AL-335+ODV + SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV up to 8 or 12 weeks.
88800732|NCT02569710|Experimental|Cohorts 6, 7, 8 and 12 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 8 weeks.
88800733|NCT02569710|Experimental|Cohorts 9, 10 and 11 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 12 weeks.
89120107|NCT04261166|Experimental|Cross-Over food effect|2 doses: fasted and fed state with the same product: A1, A4, A5, B4
89120108|NCT04261166|Experimental|Cross-Over product comparison|2 doses: in fasted state comparing A1 to A4
89120109|NCT04261166|Experimental|Cross-over route of administration comparison|2 doses: in fasted state comparing oral administration to sublingual administration of A4
89120110|NCT00996632|Experimental|A|Patients were operated using an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
89120111|NCT00996632|Active Comparator|B|Patients were operated using a conventional diarthermy knife
89120112|NCT01025843|Experimental|Pbo → 5 mg → Candesartan → 24 mg → 38 mg|Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
89120113|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Candesartan → Pbo|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.
89120114|NCT01025843|Experimental|1 mg → Candesartan → Pbo → 24 mg → 38 mg|1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
89120115|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Pbo → Candesartan|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
89120116|NCT01025843|Experimental|Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan|Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
89120117|NCT01025843|Experimental|2 mg→Pbo → Candesartan → Pbo fed→38 mg|2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
89120118|NCT01025843|Experimental|2 mg→Candesartan→Pbo→Candesartan fed→38 mg|2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
89120119|NCT01025843|Experimental|2 mg → 8 mg → 18 mg → 2 mg fed → Pbo|2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.
89120120|NCT01025843|Experimental|Candesartan→8 mg→ 18 mg →2 mg fed→38 mg|Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
89120121|NCT01025843|Experimental|Candesartan→Pbo → 12 mg → 24 mg→38 mg|Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
89120122|NCT02873351|Experimental|carbidopa-levodopa 25-100 mg|Treatment with carbidopa-levodopa 25-100 mg tablets dosed once daily at bedtime for 45 +/- 5 days followed by carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
89120123|NCT02873351|Placebo Comparator|Placebo for carbidopa-levodopa 25-100 mg|Treatment with placebo for carbidopa-levodopa 25-100 mg in identical tablets dosed once daily at bedtime for 45 +/- 5 days followed by placebo for carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
89120124|NCT04301999|Active Comparator|PDT group|Patients in PDT group underwnt PDT
89120125|NCT04301999|Experimental|RFA group|Patients in RFA group underwent RFA
89120126|NCT04302155|Experimental|Nintendo Wii|Balance-specific exer-games focusing on dynamic aspects of center of pressure (COP) on Wii fit system.
89120127|NCT04302155|Experimental|Traditional|Mini trampoline two balance exercises of 6 minutes on mini trampoline for a total duration of 3 min on each leg Inflatable discs 4 balance exercises of 12 minutes on BOSU ball 6 minutes on rounded side and 6 minutes on rigid side.
89120128|NCT01021007|Placebo Comparator|A|control mouthrinse
89120129|NCT01021007|Experimental|B|new prototype mouthrinse
89120130|NCT02872883|Experimental|Expectant management and minimal vaginal examinations|Expectant management up to approximately 96hours and vaginal examinations only when necessary during active labour
89233101|NCT03234972|Experimental|Arm A: Daratumumab, Velcade, and Dexamethasone (DVd)|Participants will receive daratumumab weekly for the first 3 cycles, every 3 weeks (q3w) on Day 1 of Cycles 4-9 as an intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) or will have the option to switch to daratumumab subcutaneously (SC) on Day 1 of any cycle, and then every 4 weeks (q4w) thereafter, Velcade at a dose of 1.3 milligram per square meter (mg/m^2) subcutaneous (SC) on Days 1, 4, 8 and 11 of each 21-day cycle (up to 8 treatment cycles) and dexamethasone (Dex) orally (PO) at 20 milligram (mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the 8 Velcade treatment cycles.
89233102|NCT03234972|Experimental|Arm B: Velcade and Dexamethasone (Vd)|Participants will receive Velcade SC at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle and Dex 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12 (up to 8 cycles). Participants who have sponsor-confirmed disease progression while being treated with Vd or on observation, will be offered the option for treatment with daratumumab monotherapy (16 mg/kg weekly for Cycles 1 and 2, every other week for Cycles 3 to 6, and every 4 weeks for Cycles 7 and onwards until disease progression, unacceptable toxicity, pregnancy, loss of follow-up, withdrawal of consent, or death [each cycle is 28 days]), if recommended by the site investigator.
89233103|NCT03233399|Active Comparator|Healthy Patients|All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).
89233104|NCT03233399|Active Comparator|PMD/PNES patients|PMD and PNES subjects will be referred by the treating
89233109|NCT03218488||Participants 6-18 years of Age With Moderate to Severe Plaque Psoriasis|All Participants diagnosed with moderate to severe plaque psoriasis who will either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study as per routine clinical practice, will be monitored for the long-term safety of ustekinumab and long-term effects of ustekinumab on growth and development. The primary data source for the study will be the medical records of participants and standardized questionnaires (completed by the physician and by the participant/parent).
89233110|NCT03217812|Active Comparator|Treatment A: VMP Alone|Participants will receive Velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is greater than [>]2 milligram per deciliter [mg/dL] at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2) orally, once daily (on Days 1 to 4) and prednisone 60 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
89233111|NCT03217812|Experimental|Treatment B: D-VMP|Participants will receive Velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2), orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 milligram per kilogram (mg/kg) as intravenous (IV) infusion or daratumumab Subcutaneously (SC) at the discretion of the investigator, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycles 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study. Participants will receive pre-infusion medications before each daratumumab infusion.
88800734|NCT02569710|Experimental|Cohorts 12 to 15: AL-335+ODV With/without SMV|Based on safety, pharmacokinetic (PK), and viral load data, the treatment duration (4 to 12 weeks) and dose levels (AL-335: 400-1,200 milligram [mg], ODV: 25-50 mg with/without SMV: 75-150 mg) may be changed for ongoing and future cohorts (up to 15) after obtaining agreement from the Sponsor and the Principal Investigator.
88800735|NCT04550624|Experimental|Interventional Arm|This is an open-label, multi-center, phase II trial of lenvatinib in combination with pembrolizumab in patients with Advanced Biliary Tract Carcinoma (BTC) who have progressed on standard systemic therapy. All participants will be administered Pembrolizumab 200mg IV on day 1 and Lenvatinib 20mg PO daily days 1-21 of each cycle (21 days).
88800736|NCT03379064|Experimental|culturally adapted Cognitive Behavior Therapy|We will use The STreSS CBT manual developed by Schroder and his colleagues
88800737|NCT03379064|No Intervention|Treatment As Usual|The Treatment As Usual (TAU) group will receive regular treatment they have been receiving already as prescribed by the physician.
88800738|NCT04550546|Experimental|Nystatin treatment|Participants will be given 1-week supply of nystatin suspension (6ml 600,000 U/mL) and be instructed to rinse the mouth with nystatin for 1 minute and spit out the suspension, at a frequency of four times a day, for a duration of 1 week. Participants will be instructed to spit the suspension after the oral rinse and do not swallow the suspension, and they will be instructed to avoid eating, drinking and brushing their teeth for 30 minutes.
88800739|NCT01929200|Experimental|1-year treatment with icotinib|Patients will receive 1-year treatment with icotinib after operation.
88800740|NCT01929200|Experimental|2-year treatment with icotinib|Patients will receive 2-year treatment with icotinib after operation.
88800741|NCT04394312|Experimental|Intervention|Participants will attended a 75 minute physical literacy workshop (Parent PLAYSHOP). A questionnaire will be completed at the beginning of the workshop and the end of the workshop to measure if there is a difference in parent's knowledge and confidence levels in regard to engaging in meaningful physical activity with their children.
88800742|NCT04394312|No Intervention|Control|Participants will complete the 2 questionnaires online, one week or more apart. Once questionnaires are completed they will be invited to attended the 75 minute physical literacy workshop. The workshop content and delivery will be the same as the intervention group but will not include questionnaires.
88800743|NCT04394078||Turkish society|Individuals speak Turkish and lives in Turkey, ages between 15 - 65, literate and with internet access
89120131|NCT02872883|Experimental|Expectant management and routine vaginal examinations|Expectant management up to approximately 96hours and routine vaginal examinations during active labour
89120132|NCT02872883|Experimental|Active management and minimal vaginal examinations|Induction of labour at approximately 24hours and vaginal examinations only when necessary during active labour
89120133|NCT02872883|Active Comparator|Active management and routine vaginal examinations|Induction of labour at approximately 24hours and routine vaginal examinations
89120134|NCT02872961||SIBO Positive|Positive small bowel aspirate culture and/or positive glucose breath test
89120135|NCT02872961||SIBO Negative|Negative small bowel aspirate culture and negative glucose breath test
89120136|NCT02873117||5 alpha reductase inhibitor|
89120137|NCT02873117||Any other drug for benign prostate hyperplasia|
89120138|NCT02872415|Experimental|The forearm as blood puncture site|The child receives a puncture blood on the forearm
89120139|NCT02872415|Placebo Comparator|Fingers like blood puncture site|Premature receiving a puncture blood on the finger
89120140|NCT04300283|Experimental|Pre-operative hypnosis|
89120141|NCT04299971|Active Comparator|methotrexate|This group of 38 TAK cases are prescribed with methotrexate tablets (Dose: 15.0 mg. qw. p.o.) for 24 weeks.
89120142|NCT04299971|Experimental|Tofacitinib|This group of 38 TAK cases are prescribed with tofacitinib tablets (Dose: 5.0 mg. bid. p.o.) for 24 weeks.
89120143|NCT01020773|Active Comparator|SBT group|In the SBT group, the patients underwent a 1 hr SBT with inspiratory PS of 7 cmH2O with other settings remaining constant (FiO2, PEEP, trigger sensitivity). The patients who tolerated the SBT underwent immediate extubation.
89120144|NCT01020773|No Intervention|no-SBT group|In no-SBT group, as soon as a patient met readiness criteria, he or she underwent extubation without SBT process.
89120145|NCT01020305|Experimental|Temsirolimus + Bicalutamide|"Temsirolimus 25 mg administered intravenously (IV) once weekly for 12 weeks~Casodex (bicalutamide) administered 50 mg/day orally (PO)"
89120146|NCT00627575|Active Comparator|Lamotrigine|Subjects will receive 40 milligram (mg) of Atrovastatin from Days 1-7, from Days 8-56 subjects will receive Lamotrigine and Subjects will receive 300 mg/day of Lamotrigine and 40 mg/day of atorvastatin each morning on Days 57-77.
89120147|NCT00627575|Active Comparator|phenytoin|Subjects will receive 40 mg of Atrovastatin from Days 1-7, from Days 8-28, subjects will receive 4mg/kg/day of phenytoin in the morning and will continue to take 40 mg/day of atorvastatin each morning. Subjects will receive taper dose of phenytoin from Days 29-30.
89120148|NCT01036529|Experimental|Precision Spinal Cord Stimulator|Spinal Cord Stimulation
89120149|NCT01036529|Active Comparator|Back Surgery|Discectomy, laminotomy, laminectomy, foraminotomy, fusion with or without instrumentation
89120150|NCT00627809|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
89120151|NCT00627809|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
89120152|NCT01024751|Experimental|Bausch & Lomb Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
89120153|NCT01024751|Active Comparator|Ciba's Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
89120154|NCT02872649|Experimental|study medication|Dabigatran 110mg twice daily with normal renal function (glomerular filtration rate >80 ml/min) Dabigatran 75mg twice daily with impaired renal function (glomerular filtration rate between 80 and 30 ml/min)
89120155|NCT02872649|Active Comparator|control group|Phenprocoumon dosage according to INR
89120156|NCT04299737||First patient in the case pair|This patient will receive the treatment bundle. S. aureus transmission surveillance will be conducted.
89120157|NCT04299737||Second patient in the case pair|This patient will receive usual care. S. aureus transmission surveillance will be conducted.
88800744|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 60µg|
89120158|NCT04301921|Other|Group 1|Traditional puncture site + no anticoagulation
89120159|NCT04301921|Other|Group 2|Traditional puncture site + ACT-guided anticoagulation
89120160|NCT01019369|Experimental|Self Administration of DMPA|Self administration of subcutaneous depot medroxyprogesterone acetate
89120161|NCT01019369|Active Comparator|Clinic administration of DMPA|Clinic administration (routine care) of DMPA
89120162|NCT01019135|Active Comparator|Women-Only Cardiac Rehabilitation|The women-only CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format, wherein participants engage in on-site female-only group exercise sessions, as well as female-only group education sessions.
89120163|NCT01019135|Active Comparator|Co-ed Cardiac Rehabilitation|The traditional hospital-based co-ed CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format.
89120164|NCT01019135|Active Comparator|Home-Based Cardiac Rehabilitation|In the monitored home-based programs, patients attend an intake appointment where an exercise test is performed as the basis for exercise prescription. Patients are given written guidelines for aerobic conditioning based on their treadmill test. Patients are cautioned about symptoms, and taught how to check their heart rate during walking sessions. Patients are provided with reading materials regarding CVD, risk factors and lifestyle modification. These are discussed with an allied health professional from the home-based CR program by telephone during weekly scheduled telephone calls.
89120165|NCT01018979|Experimental|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
89120166|NCT01018979|Experimental|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
89120167|NCT01572493|Experimental|Arm A1 (Dose Escalation, 10-day Dosing)|Maximum tolerated dose (MTD) determination in subjects with metastatic cancers receiving recombinant human Interleukin-15 (rhIL-15) intravenous (IV) for 10 consecutive days
89120168|NCT01572493|Experimental|Arm A2 (Dose Expansion, 10-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving recombinant human Interleukin-15 (rhIL-15) intravenous (IV) for 10 consecutive days
89290091|NCT01122732||US Group|Interscalene catheter will be placed with US guidance without any nerve stimulation guidance.
89120169|NCT01572493|Experimental|Arm B1 (Dose Escalation, 5-day Dosing)|Maximum tolerated dose (MTD) determination in subjects with metastatic unresectable cancers receiving recombinant human Interleukin-15 (rhIL-15) intravenous (IV) for 5 consecutive days
89120170|NCT01572493|Experimental|Arm B2 (Dose Expansion, 5-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving recombinant human Interleukin-15 (rhIL-15) intravenous (IV) for 5 consecutive days
89120171|NCT02315443|Experimental|Nerinetide (NA-1)|2.60 mg/kg of nerinetide (up to a maximum dose of 270 mg) administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
89120172|NCT02315443|Placebo Comparator|Placebo|Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
89120173|NCT01018511|Placebo Comparator|Placebo|Participants received 3 tablets once a day for 12 weeks. Placebo tamsulosin hydrochloride oral controlled absorption system (OCAS) 0.4 mg tablet; Placebo fixed dose combination (FDC) tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
89120174|NCT01018511|Active Comparator|TOCAS 0.4 mg|Participants received 3 tablets once a day for 12 weeks. Tamsulosin hydrochloride OCAS (TOCAS) 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
89120175|NCT01018511|Experimental|FDC 0.4 mg/6 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
89120176|NCT01018511|Experimental|FDC 0.4 mg/9 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
89120177|NCT02577367|Experimental|Levothyroxine on empty stomach|Levothyroxine will be given on empty stomach, by holding enteral feeding for 2 hours before and 2 hours after Levothyroxine administration
89120178|NCT02577367|Active Comparator|Levothyroxine during feeding|Levothyroxine will be given while the enteral feeding is running
89120179|NCT04071067||Emergency Clinical County Hospital Group|
89120180|NCT04071067||Municipal Clinical Hospital Group|
89120181|NCT00996476|Experimental|TMC12/PR24 50 mg|Participants received TMC435 50 mg once daily with PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24 Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
89120182|NCT00996476|Experimental|TMC12/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
89120183|NCT00996476|Experimental|TMC24/PR24 50 mg|Participants received TMC435 50 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435, PR) at Week 24. All other participants continued PR until Week 48.
89120184|NCT00996476|Experimental|TMC24/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
89120185|NCT00996476|Experimental|PR48 Control|Participants received PegIFNa-2a and ribavirin (PR) for 48 weeks (PR48 control group)
89120186|NCT04070911|Experimental|patients in the water group|water group: Patients in the water group were performed oral water after their accession to PACU.
89120187|NCT04070911|Experimental|patients in the ice group|ice group, Patients in the ice group were performed oral ice popsicle after their accession to PACU.
89120188|NCT04070911|No Intervention|no intervention group|control group, the control group patients have performed rutin treatment and care without any other intervention
89120189|NCT04277078||Intubated asthma attack|Patients who had been hospitalised with asthma attack, then intubated during hospitalisation.
89120190|NCT04277078||Non-Intubated asthma attack|Patients who had been hospitalised with asthma attack without intubation during hospitalisation.
89120191|NCT04296344|Experimental|Treatment|Participants with chronic pain to receive acupuncture therapy treatments and yoga therapy sessions.
89120192|NCT04258904|Experimental|Intervention|Skin Care Program
89120193|NCT04258904|No Intervention|Control|Usual Treatment
89120194|NCT00628940|Experimental|1|18F-fluoromethylcholine
89120195|NCT04294706|Experimental|Hemp arm|Randomly assignment to Hemp arm (60 mg/day of hemp oil extract x 6 weeks)
89120196|NCT04294706|Placebo Comparator|Placebo arm|Randomly assigned to Placebo arm (60 mg/day of cellulose x 6 weeks)
89120197|NCT02869022|Experimental|Custodiol-N|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
89120198|NCT02869022|Active Comparator|Custodiol|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
89120199|NCT04201340||Subjects Presenting with Normal Eyes|Subjects with no known ocular diseases will be imaged on the DRI OCT Triton with SS-OCT Angio software, Zeiss Cirrus HD-OCT 5000, and TRC-50DX
89120200|NCT04201340||Subjects with retinal pathology present in the vasculature|Subjects with retinal pathology likely to present in the vasculature will be imaged on the DRI OCT Triton with SS-OCT Angio software, Zeiss Cirrus HD-OCT 5000, and TRC-50DX
89120201|NCT04293692|Experimental|UC-MSCs treatment group|Participants will receive conventional treatment plus 4 times of 0.5*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7).
89120202|NCT04293692|Placebo Comparator|Control group|Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day1, Day3, Day5, Day7.
89120203|NCT04299815|Active Comparator|Oral lactate|Sodium D/L lactate solution, 25g/L in 300mL water
89233112|NCT03213977|Active Comparator|Arm I:R-DA-EPOCH|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
89233113|NCT03213977|Experimental|Arm II:R-CEOP90|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
89233114|NCT03206099||Biological relatives|Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
89233115|NCT03206099||Healthy volunteers|Select internal controls
89233116|NCT03206099||Probands|Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
89233117|NCT03190928||1|Patients with grades 1-2 or 3a follicular lymphoma (FL)
89233118|NCT03178643|Active Comparator|Proguanil Oral Tablet|Proguanil is the current standard of care for chemoprevention of malaria in children with SCA in Kenya. This medication will be taken on a daily basis
88800745|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 90µg|
88800746|NCT01219855|Placebo Comparator|Cohort 1: Sugar Capsule|
89233119|NCT03178643|Active Comparator|Sulfadoxine/Pyrimethanine-Amodiaquine|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ) is a combination therapy comprised of sulfadoxine and pyrimethamine (two antifolate antimicrobials) co-administered with amodiaquine. This medication is taken on a monthly basis.
89233120|NCT03178643|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|DP is an artemisinin-combination therapy consisting of the artemisinin derivative dihydroartemisinin and the bisquinoline piperaquine. This medication is taken on a monthly basis.
89233121|NCT03176173|Experimental|Immunotherapy plus Image-guided Radiation Therapy|Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while continuing their prior treatment with the treating physician's choice of regular medical care immunotherapy.
89233122|NCT03176173|Active Comparator|Immunotherapy Alone (Regular Medical Care)|Patients who decline to undergo radiation therapy will continue their prior treatment with the treating physician's choice of regular medical care immunotherapy.
89233123|NCT03158805|Active Comparator|Active drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
89233124|NCT03158805|Placebo Comparator|Placebo|Placebo (no active drug)
89233125|NCT03153475|Other|ATTUNE Revision Knee System|The ATTUNE Revision system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in revision knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
88800747|NCT01219855|Experimental|Cohort 2: CTAP101 Capsules 30µg|
88800748|NCT01219855|Placebo Comparator|Cohort 2: Sugar Capsule|
88800749|NCT02984072|Active Comparator|Menthol|5% menthol in aqueous cream (Dermacool Forte)
88800750|NCT02984072|Placebo Comparator|Placebo|Aqueous cream
88800751|NCT05506410||Arms|Experimental:Rituximab、Bendamustine、Cytarabine、Prednisone （R-BAP） combined with BTK inhibitors To observe the efficacy and safety of R-BAP combined with BTK inhibitors in the treatment of newly-treated patients with mantle cell lymphoma (MCL)
88800752|NCT05506332|Experimental|Venetoclax and 6-mercaptopurine|Single arm study with venetoclax and 6-mercaptopurine administered in two to six cycles of 28 days. Venetoclax is given at a dosage of 600mg with dose reduction in case of interaction with a moderate or strong CYP3A4 inhibitor. 6-mercaptopurine is given at a dosage of 100mg.
88800753|NCT01220869|Experimental|Degarelix|
88800754|NCT04124666|Experimental|Granulocytes infusion only|Fresh, non-irradiated granulocytes from ABO, Rh, CMV compatible, unrelated donors; bioactivity of anti-cancer ability meets the criteria.
88800755|NCT05511402|Experimental|Aerobic exercise|This group will participate in an aerobic training program (8-week, 3 times weekly, and 30-min each time) and conventional physiotherapy program (8-week, 3 times weekly, and 45-min each time).
88800756|NCT05511402|Active Comparator|Conventional physiotherapy|This group will participate in a conventional physiotherapy program (8-week, 3 times weekly, and 45-min each time).
88800757|NCT04124354|Experimental|Immediate Experimental Group|Participants will immediately begin an experimental supervised moderate-intensity treadmill walking intervention program.
88800758|NCT04124354|No Intervention|Delayed Intervention Control Group|Participants will be asked to maintain their usual physical activity during the initial 8-week intervention period but will undergo all data collection procedures. Following the initial intervention period, these participants will be given the option to complete the 8-week intervention, with identical data collection procedures employed.
88800759|NCT05600192|Experimental|Exercise arm|Subjects perfom aerobic or anaerobic exercise in the morning or in the afternoon
89233126|NCT03153449|Other|ATTUNE Revision knee system|The ATTUNE Revision knees system is complementary to the ATTUNE primary knee portfolio and includes both rotating platform (RP) and fixed bearing (FB) configurations. The system includes a full compliment of implants designed to address the challenges faced in complex primary knee surgeries. These implants include Stemmable tibial and femoral components, augments, sleeves and offsets
89233127|NCT03151564|Experimental|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
89233128|NCT03151564|Experimental|Computed tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
89233129|NCT03151564|Experimental|Deep Learning Image Reconstruction (DLIR)|DLIR is available in both single (SE) and dual/multi energy (DE) CT scanning modes. DLIR SECT and DLIR DECT reconstructions have yet to be compared.
88800760|NCT01927874|Active Comparator|Infiltration, analgesic effect|10ml 0.5% bupivacaine each side Block Injection of local anesthetic at pudendal nerve
88800761|NCT01927874|Active Comparator|Spinal block|10 mg of hyperbaric 0.5% bupivacaine Injection of anesthetic at subarachnoidal space
88800762|NCT05604716||SPN patients|
88800763|NCT04124276|Experimental|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day) for 6 weeks
88800764|NCT04124276|Placebo Comparator|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
88800765|NCT04124510|Experimental|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
89120204|NCT04299815|Placebo Comparator|Iso-lactic intravenous lactate infusion|iv sodium D/L lactate to elevate [lactate] to the same levels as measured on day 1 + oral sodium chloride, 300 mL
89120205|NCT02269267|Other|Discontinuation of TKI medication|Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years.
89120206|NCT02575495|Experimental|7 days course of antibiotic treatment|To assign the 7 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
89120207|NCT02575495|Active Comparator|14 days course of antibiotic treatment|To assign the 14 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
89120208|NCT02575261|Experimental|Experimental:CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen by infusion.
89120209|NCT02575261|No Intervention|No Intervention|
89120210|NCT01017731|Experimental|IMC-1121B|"Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period.~For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab [10 milligrams per kilogram (mg/kg)] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between."
89120211|NCT02575417|Experimental|Patient Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Patient Only Groups:~are 18 years or older~speak and read English~have at least one chronic illness (cancer, chronic pulmonary disease, coronary artery disease, congestive heart failure, peripheral vascular disease, severe chronic liver disease, diabetes with end organ damage, renal failure)~have not completed an advance directive within the past 18 months~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required surveys"
89120212|NCT02575417|Experimental|Caregiver Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Caregiver Only Groups:~are 18 years or older~speak and read English~have been an unpaid caregiver for an adult over the age of 18 in the last 12 months. Being an unpaid caregiver may include helping with personal needs or household chores, managing a person's finances, arranging for outside services, or visiting regularly to see how they are doing. This person need not live with participants in order for them to identify as caregivers;~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required survey~care recipient is capable of discussing medical issues~care recipient has not completed an AD in past 18 months"
89120213|NCT02575417|Experimental|Surrogate Decision Maker with Patient|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Surrogate Decision Maker and Patient Group:~considers themselves a surrogate decision maker for an adult with a chronic illness (defined in Patient Only Group)~are 18 years or older~speak and read English~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required surveys~both patient and surrogate decision maker are able to attend study session together~patient must meet eligibility criteria defined in Patient Only group"
89120214|NCT02577289|Active Comparator|Control group ( Hydroxyappetite)|Patients will undergo open sinus lift using nano crystalline hydroxyapatite as augmentation material and placing implants simultaneously then evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)
89120215|NCT02577289|Experimental|Test group (PRF)|Patients will undergo open sinus lift using PRF as sole augmentation material and placing implants simultaneously then Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)
89120216|NCT04302233|Experimental|New pharmaceutical support (NPS)|"An NPS is an interview comprising the following elements:~The delivery of the identification sheet of their implants with:~a quiz to focus the patient's attention~a description of the characteristics of their prosthesis using a specific photo of their implant~a presentation of the medical device vigilance.~an explanation of the value of the identification sheet for their implant, An in-depth presentation of an information booklet on living at home with their prosthesis and on medical and paramedical monitoring.~For patients in orthopedic surgery: a booklet specific to their prosthesis and the surgical approach For plastic surgery patients, the information sheets published by the French Society of Plastic Reconstructive and Aesthetic Surgery (SOF.CPRE).~A time to answer any questions the patient may have"
89120217|NCT04302233|No Intervention|Usual pharmaceutical support (UPS)|"An UPS is an interview comprising the following elements:~The delivery of the same patient-implant sheet as in arm 1, but without additional oral information.~The delivery and oral presentation of the same booklet as practiced in the arm 1 (NPS).~And a time to answer any questions from the patient months"
89120218|NCT02575183|Experimental|Varenicline (Chantix)|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: 0.5 mg orally once a day Days 4 to 7: 0.5 mg orally twice a day Days 8 to end of treatment: 1 mg orally twice a day. Intervention 'Varinecline (Chantix)' and Intervention 'Behavioral Therapy'"
89233130|NCT03147612|Experimental|Treatment (chemotherapy, ponatinib, blinatumomab)|See Detailed Description.
89233131|NCT03145181|Experimental|Part 1: Dose Escalation (IV)|Participants will receive Teclistamab intravenously (IV).
88805867|NCT00289718|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the long term follow-up."
89233132|NCT03145181|Experimental|Part 2: Dose Expansion (IV)|Participants will receive Teclistamab IV.
89233133|NCT03145181|Experimental|Part 1: Dose Escalation (SC)|Participants will receive Teclistamab subcutaneously (SC).
89233134|NCT03145181|Experimental|Part 2: Dose Expansion (SC)|Participants will receive Teclistamab SC.
89233135|NCT03141671|Experimental|GnRH + Bicalutamide|"GnRH agonist injection monthly or every 3 months for 6 months~Bicalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
89233136|NCT03141671|Experimental|GnRH+Abiraterone+Apalutamide+Prednisone|"GnRH agonist injection monthly or every 3 months for 6 months~Abiraterone acetate by mouth once/day for 6 months~Prednisone by mouth once/day for 6 months~Apalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
89233137|NCT03118986|Active Comparator|Olanzapine|Standard antiemetics plus olanzapine
89233138|NCT03118986|Placebo Comparator|Placebo Oral Tablet|Standard antiemetics plus placebo
89233139|NCT03114462|Experimental|Stereotactic Hypofractionated Radioablation (HYDRA)|"Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.~Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years."
89233142|NCT03090165|Experimental|Arm A - Phase I|"Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle.~Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle.~Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle.~Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 25 patients."
89233143|NCT03076554|Experimental|Arm 1 Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
89233144|NCT03056755|Experimental|Cohort A: Pre-treated with CDK 4/6i + AI|Participants who received any Cyclin-Dependent Kinases 4 and 6 inhibitor (CDK 4/6i) plus aromatase inhibitor (AI) as immediate prior treatment will receive alpelisib + fulvestrant
88800766|NCT05604638|Experimental|Tenecteplase plus Tirofiban|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds). Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min, if there was no parenchymal hemorrhage or extensive subarachnoid hemorrhage beyond the Sylvian fissure on the posttreatment computed tomography scan. Aspirin (100 mg/d) will be given orally at 4 hours before the end of infusion and continued for at least 3 months after intravenous thrombolysis .
88800767|NCT05604638|Placebo Comparator|Tenecteplase plus Placebo|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds). Patients will receive a continuous intravenous infusion of placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min, if there was no parenchymal hemorrhage or extensive subarachnoid hemorrhage beyond the Sylvian fissure on the posttreatment computed tomography scan. Aspirin (100 mg/d) will be given orally at 4 hours before the end of infusion and continued for at least 3 months after intravenous thrombolysis .
88800768|NCT04123808|Experimental|IpsiHand Treatment|All participants will receive treatment with IpsiHand device
88800769|NCT02999438||Patients with hemodynamically significant heart disease|"Patients with either:~Single ventricle physiology s/p Fontan~Heart failure diagnosed by a cardiologist~Pulmonary hypertension diagnosed by cath"
88800770|NCT02999438||Controls|Healthy controls as defined in inclusion- exclusion criteria
89233145|NCT03056755|Experimental|Cohort B: Pre-treated with CDK 4/6i + fulvestrant|Patients who received any CDK 4/6i plus fulvestrant as immediate prior treatment will receive alpelisib + letrozole
89233146|NCT03056755|Experimental|Cohort C: Pre-treated with systemic chemotherapy or ET|Participants who received systemic chemotherapy or endocrine therapy (ET) (as monotherapy or in combination with targeted treatment except CDK 4/6i + AI) as immediate prior treatment will receive alpelisib + fulvestrant.
89233147|NCT03037671||CGM Monitored Cohort|The continuous glucose monitor (CGM) used during this study will be the Abbot Freestyle Libre Professional Continuous Glucose Monitoring System.
89290092|NCT01122732||NS Group|Catheter will be placed using nerve stimulation guidance
89290093|NCT03783780|Experimental|INVSENSOR00031|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00031 sensor during motion and non-motion.
89290094|NCT03869866|Experimental|MenACYW conjugate vaccine|MenACYW conjugate single injection at Day 0
89233155|NCT02968212|Experimental|clofazimine|Participants receive lamprene
89233156|NCT02968212|Placebo Comparator|sugar pill|Participants receive placebo
89233157|NCT02938923|Experimental|Exercise + Testosterone (EX + T)|Supervised exercise training 2 times per week and topical testosterone 1% gel (12.5 mg per pump depression) daily, both for six months duration.
89233158|NCT02938923|Placebo Comparator|Exercise + Placebo (EX + P)|Supervised exercise training 2 times per week and placebo gel daily, both for six months duration.
89233159|NCT02938923|Other|Enhanced Usual Care (EUC)|Home exercise program 3 times per week and monthly health education modules, both for six months duration.
88800771|NCT01016483|Experimental|Safety Run-in Part: Regimen 1|Subjects will receive pimasertib capsule orally once daily (qd) doses of 15, 30, 45, 68, 90, and 120 milligram (mg) on Day 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15,16, 17, 18, 19, 22, 23, 24, 25, 26 and gemcitabine 1000 milligram per square meter (mg/m^2) intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks).
88800772|NCT01016483|Experimental|Safety Run-in Part: Regimen 2|Subjects will receive pimasertib capsule orally twice daily (bid) doses of 60 and 75 mg continuously for a 28-day cycle and gemcitabine 1000 mg/m^2 intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks) (bid - continuous regimen).
88800773|NCT01016483|Active Comparator|Phase II: Arm 1 (Gemcitabine + Placebo)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion on for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and placebo matched to pimasertib orally bid - continuous regimen.
88800774|NCT01016483|Experimental|Phase II: Arm 2 (Gemcitabine + Pimasertib)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and pimasertib capsule orally bid - continuous regimen.
88800775|NCT04123730|Active Comparator|Fixed dose oxygen|O2Matic deliver the usual fixed-dose oxygen treatment during walking.
88800776|NCT04123730|Experimental|Automated oxygen titration|O2Matic deliver a variable oxygen dosage set at an SpO2-target of 90 to 94 % and a O2-flow of 0 - 15 liters/min during walking.
88800777|NCT05603780|Other|group 1|one cohort
88800778|NCT02569476|Experimental|Zanubrutinib and Obinutuzumab|In the dose-escalation part, dose levels and regimens were evaluated. In the indication-specific expansion cohorts, participants were assigned to different cohorts based on histology type.
88800779|NCT04123028||eosinophilic COPD patient|COPD patient with blood eosinophil equal or > 300 cells/µL
88800780|NCT04123028||non-eosinophilic COPD patient|COPD patient with blood eosinophil < 300 cells/µL
88800781|NCT00963677|Experimental|Intubation without difficulty|The patients are not predicted for difficult intubation
88800782|NCT00963677|Experimental|Difficult intubation|The patients will be anticipated for difficult intubation without difficult ventilation
88800783|NCT05603234|Experimental|Symptom Monitoring Intervention|This group reported their symptoms every day for 14 days.
88800784|NCT05603234|No Intervention|Control|This group did not monitor their symptoms every day for the 14 day period, however they did report their symptoms at the beginning and end of the 14 day period
88800785|NCT04393064|Other|full term and preterm|75 preterm and 75 fullterm will be recruited in this study; all will be hemodynamically stable on discharge doing FEES
89233160|NCT02933736|Experimental|Administration of ribociclib|"Subjects will be administered ribociclib prior to surgical resection of their tumor. All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:~Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection~Cohort 2: last ribociclib dose 6-8 hours prior to craniotomy for tumor resection~Cohort 3: last ribociclib dose 23-25 hours prior to craniotomy for tumor resection"
88800786|NCT00955253|Experimental|Guanfacine (Day 2) then Placebo (Day 4)|All patients received a single dose of guanfacine on Day 2 and a single dose of placebo on Day 4.
88800787|NCT00955253|Experimental|Placebo (Day 2) then Guanfacine (Day 4)|All patients received a single dose of placebo on Day 2 and a single dose of guanfacine on Day 4.
88800788|NCT04392986|No Intervention|Baseline|Baseline measurement
88800789|NCT04392986|Experimental|Intervention|Sunlight intervention
88800790|NCT00963911|Experimental|Included patients|Screening tests (G8 and VES-13)
88800791|NCT04123106|Experimental|ESP block|Ultrasound-guided, performed below erector spinae plane (ropivacaine 0.5% 20 mL each side).
88800792|NCT04123106|Active Comparator|Wound infiltration|Ropivacaine 0.5% 20-40 mL, performed by surgeon.
88800793|NCT04079504|Active Comparator|Ligation|Ligation of indirect inguinal hernia sac in inguinal hernioplasty patients
88800794|NCT04079504|Experimental|Non-ligation|Non-Ligation of Indirect inguinal hernia sac/ simple inversion/reduction of indirect inguinal hernia sac in inguinal hernioplasty patients
88800795|NCT00963989|Experimental|Penumbra Device Arm|
88800796|NCT05609006|Experimental|Group A: High-Energy, Low-Volume ONS // High-Energy Standard ONS|Intervention: high-energy low-volume ONS (2.4kcal/ml; 125ml) for 28 days followed by high-energy standard ONS (2.0kcal/ml; 200ml) for 28 days
88800797|NCT05609006|Experimental|Group B: High-Energy Standard ONS // High-Energy, Low-Volume ONS|Intervention: high-energy standard ONS (2.0kcal/ml; 200ml) for 28 days followed by high-energy low-volume ONS (2.4kcal/ml; 125ml) for 28 days
88800798|NCT05608928|Experimental|Vivomixx|Vivomixx also known as VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
88800799|NCT05608928|Experimental|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
88800800|NCT05608850|Other|Exercise Then Stretch|Participants in AB will perform the experimental (exercise) intervention first and the control (stretch) intervention second
88800801|NCT05608850|Other|Stretch Then Exercise|Participants in BA will perform the experimental (exercise) intervention second and the control (stretch) intervention first
88800802|NCT01016873|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
88800803|NCT01016873|Sham Comparator|Sham 16 Gy IRay|Sham 16 Gy IRay + PRN Lucentis®
88800804|NCT01016873|Experimental|24 Gy IRay|24 Gy IRay + PRN Lucentis®
88800805|NCT01016873|Sham Comparator|Sham 24 Gy IRay|Sham 24 Gy IRay + PRN Lucentis®
88800806|NCT04120454|Experimental|Treatment (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
88800807|NCT03018431||Physician routine evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon clinical and biological, associated with standard radiographs, performed by the physician in chrage of the patient.
88800808|NCT03018431||independent evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon early CT scan, and repeated lung ultrasonography, performed by an independent operator.
88800809|NCT04122404|Other|Intervention|"Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture) + Intervention~Intervention: LF-LAM is made available at the study site for the clinical staff to use; Training of clinical staff in national TB guidelines and LF-LAM use together with staff from the National TB Programme in Ghana"
88800810|NCT04122404|No Intervention|Standard of care|Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture)
88800811|NCT01017497|Experimental|1mm margin|GTV expanded by 1 mm
88800812|NCT01017497|Experimental|3mm margin|GTV expanded by 3 mm
88800813|NCT01017653|Experimental|Panitumumab and irinotecan|
88800814|NCT00965237|Other|Multifocal CL / Single vision CL + reading glasses|Lotrafilcon B multifocal contact lenses (CL) worn first, with lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
88800815|NCT00965237|Other|Single vision CL + reading glasses / Multifocal CL|Lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn first, with lotrafilcon B multifocal contact lenses (CL) worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
88800816|NCT00966641|Experimental|PL 3100|Active experimental drug
88800817|NCT00966641|Active Comparator|Naproxen|Active comparator
88800818|NCT02565576|Active Comparator|CFZ533|CFZ533
88800819|NCT02565576|Placebo Comparator|Placebo|Placebo
88800820|NCT03018743||dapoxetine treatment group|Consecutive patients who seek medical treatment for PE will be enrolled in the study.
88800821|NCT03018119|Active Comparator|Anesthesiologists|Total: 11 Intervention: Survey
88800822|NCT03018119|Active Comparator|Obstetricians|Total: 11 Intervention: Survey
88800823|NCT03018119|Active Comparator|Registered Nurses|Total: 10 Intervention: Survey
88800824|NCT03018119|Active Comparator|Surgical Technicians|Total: 6 Intervention: Survey
88800825|NCT05395949|Experimental|Steroid combined with methotrexate|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
89233165|NCT02919683|Experimental|Nivolumab With Ipilimumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Ipilimumab to be delivered at a pre-determine dose for one week~Blood Sample Collected~Standard of Care Surgery"
88800826|NCT05395949|No Intervention|Extensive lesion excision|Patients in the control group underwent wide local excision, make sure the margin is negative. Irrigation and mammoplasty were performed in the same way as in the observation group.
88800827|NCT03018197|Experimental|Medication Education|Patients will receive training on the use of the personal health record and health education via the personal health record.
88800828|NCT03018197|No Intervention|No Medication Education|Patients will receive the current standard of care for the personal health record. Patients will not receive training on the use of the personal health record or health education via the personal health record.
88800829|NCT03018275|Experimental|1|"Vials of lyophilized R mucosa (103, 104, or 105 CFU)"
88800830|NCT05395637||Assessed with the remote assessment of Longshi Scale first and then with bedside assessment|
89233166|NCT02919683|Experimental|Nivolumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Blood Sample Collected~Standard of Care Surgery"
89120219|NCT02575183|Placebo Comparator|Placebo|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive a Placebo for Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: a placebo (matched to 0.5 mg of Varenicline) orally once a day Days 4 to 7: a placebo (matched to 0.5 mg of Varenicline) orally twice a day Days 8 to end of treatment: a placebo (matched to 1 mg of Varenicline) orally twice a day.~Intervention 'Placebo (for Varenicline)' and Intervention 'Behavioral Therapy'"
89120220|NCT01035905|Experimental|Nelfilcon A|Nelfilcon A contact lens
89120221|NCT01035905|Active Comparator|Narafilcon A|Narafilcon A contact lens
88800831|NCT05395637||Assessed with the bedside assessment of Longshi Scale first and then with remote assessment|
89120222|NCT04565821|Experimental|Feasibility of trans-nasal IPD probe|The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability
89120223|NCT02255305|Experimental|FMT Group (Intervention Arm)|Patients randomized to the FMT group will have antimicrobials targeting C. difficile discontinued at least 6 hours prior to undergoing an FMT via retention enema. A second FMT via retention enema will be administered at 24 hours if diarrhea persists.
89120224|NCT02255305|Active Comparator|Antimicrobial Group (Control Arm)|Patients randomized to the antimicrobial group will be treated with antibiotics targeting C. difficile according to the Society for Healthcare Epidemiology of America (SHEA) Clinical Practice Guidelines for CDI. FMT will be offered to this group after 90 days if they experience relapsing CDI.
89120225|NCT00779584|Experimental|MK-8776 10mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 10 mg/m^2 given as monotherapy as an intravenous (IV) infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120226|NCT00779584|Experimental|MK-8776 20mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 20 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120227|NCT00779584|Experimental|MK-8776 40mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 40 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120228|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120229|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120230|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120231|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120232|NCT00779584|Experimental|MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 150 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120233|NCT00779584|Experimental|MK-8776 200mg+Gemcitabine 1000mg/m^2|Participants received MK-8776 200 mg given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
89120234|NCT04073641||Survey population|Adults with type 1 and type 2 diabetes and caregivers of people with diabetes including parents of children and young people with diabetes.
89120235|NCT00995930|Placebo Comparator|Placebo|subcutaneous (SQ) monthly
89120236|NCT00995930|Experimental|ACZ885|150 mg SQ monthly
89120237|NCT02577133|Active Comparator|Lactobacillus reuteri group|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
89120238|NCT02577133|Placebo Comparator|Placebo group|Placebo (5 drops) for 28 days
89120239|NCT00779506|Experimental|Quetiapine Fumarate XR|Seroquel XR 400-800mg
89120240|NCT04292132|Active Comparator|Conventional loading|Loading of 4 interforaminal implants three months after surgery.
89120241|NCT04292132|Experimental|Immediate Loading|Loading of 4 interforaminal implants immediately after surgery.
89120242|NCT02575027|Experimental|Treatment (4pi radiotherapy)|Patients undergo 4pi radiation simulation and planning followed by 5 to 10 daily fractions of 4pi palliative radiotherapy. If an acceptable plan cannot be achieved using 4pi planning, then the patient will be treated with standard radiation therapy planning for palliative re-irradiation.
89120243|NCT04099420||Italian university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
89120244|NCT04099420||Spanish university students|university students, doctoral students, post-docs and post-graduate students in biomedical and pharmaceutical sciences (N = 100)
89120245|NCT02577211|Experimental|Hipocaloric enteral nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
89120246|NCT02577211|Active Comparator|Normocaloric enteral nutrition|25 kcal per kg of body weight and 1.7 grams of protein per kg.
89120247|NCT00995774|Experimental|Robotic then Conventional|robotic arm therapy first, conventional therapy second
89120248|NCT00995774|Experimental|Conventional then Robotic|conventional therapy first, robotic therapy second
89120249|NCT00765388|Experimental|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
88800832|NCT05395403|Experimental|Office Blood Pressure Measurement (OBPM)|Traditional office blood pressure monitoring in the primary care clinical environment.
88800833|NCT05395403|Experimental|Automated Office Blood Pressure Measurement (AOBPM)|Blood pressure measurement using a validated BpTRU device
88800834|NCT05395403|Experimental|Home Blood Pressure Measurement (HBPM)|Blood pressure measurement at patient's home using home monitoring device.
89120250|NCT00765388|Active Comparator|hollister Uro|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive
89120251|NCT02577055|Active Comparator|myomectomy|Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route
89120252|NCT02577055|Experimental|embolisation|Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter > 500µm)
89120253|NCT02868866|Experimental|Immediate intervention|Training of church committee followed by 12 months of technical assistance phone calls.
89120254|NCT02868866|No Intervention|Delayed intervention|20 churches are followed but receive no intervention.
89120255|NCT01385059|Experimental|Arm I (neoadjuvant enzyme inhibitor and prostatectomy)|Patients receive axitinib PO BID on days 1-28. Patients then undergo prostatectomy and pelvic lymph node dissection. Treatment continues in the absence of disease progression or unacceptable toxicity.
89120256|NCT01385059|Active Comparator|Arm II (surgery)|Patients undergo prostatectomy and pelvic lymph node dissection at 5-6 weeks after biopsy confirmation of prostate cancer.
89120257|NCT04292366|Experimental|Intervention arm I|pre-notification approximately ten days prior to intervention, invitation and one reminder (three-staged intervention)
89120258|NCT04292366|Experimental|Intervention arm II|invitation, one reminder after 45 days and a second reminder three months after invitation (three-staged invitation procedure)
89120259|NCT04292366|Experimental|Intervention arm III|pre-notification, invitation, reminder after 45 days and reminder after three months (four-staged invitation procedure)
89120260|NCT04292366|Active Comparator|Control group|invitation and one reminder after 45 days (usual care)
89120261|NCT04551157|Experimental|Video Viewing|Participants will receive the intervention where they will view two patient information videos. The first video will be viewed within the first week of their inpatient stay and the second video will be viewed just before discharge.
89120262|NCT04551157|No Intervention|Treatment as usual|No change to routine care.
89120263|NCT00769132|Experimental|A|ER niacin/laropiprant + Placebo to laropiprant
89120264|NCT00769132|Active Comparator|B|ER niacin + Placebo to laropiprant
89120265|NCT00769132|Experimental|C|laropiprant + Placebo to ER niacin/laropiprant
89120266|NCT00769132|Placebo Comparator|D|Placebo
89120267|NCT04527523||Endothelial Dysfunction Cohort|All patients enrolled in the study will receive a baseline Optical Coherence Tomography scan (OCT) within 4 weeks prior to surgery. Two additional OCT scan will be performed 6 weeks and 3 months after surgery.
89120268|NCT04070755|Experimental|FMX-101|
89120269|NCT02576821|Other|Patients with Hippocampal sclerosis non AD|Patients with Hippocampal sclerosis non AD (n=40)
89120270|NCT02576821|Other|Patients with Alhzeimer's Disase|Patients with Alhzeimer's Disase (n=40)
89120271|NCT02576821|Other|Patients with DLFT|Patients with DLFT (n=20)
89120272|NCT02576821|Other|Patients with CBD/PSP|Patients with CBD/PSP (n=20)
88800835|NCT05395169|Experimental|medical treatment|Control group:Will be consisted of 25 females suffering from PMS will receive medical treatment in form of vit, B6, ca supplements and minerals (vitatron), once daily(1capsule), for 12 weeks.
89120273|NCT02576821|Other|Normal controls|Normal controls (n=20)
89120274|NCT04100434|Experimental|the evolocumab plus statin therapy|Patients with ACS are treated with atorvastatin (20mg) daily and evolocumab (140 mg) every two weeks throughout the study period
89120275|NCT04100434|No Intervention|the statin alone therapy|Patients with ACS are treated with atorvastatin (20mg) daily throughout the study period.
89120276|NCT00991952|Experimental|Arm A (irinotecan hydrochloride, alvocidib)|Patients receive irinotecan hydrochloride IV over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89120277|NCT00991952|Active Comparator|Arm B (irinotecan hydrochloride)|Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89120278|NCT04522921|No Intervention|Control Group (CG)|Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and regular follow-up.
89120279|NCT04522921|Experimental|Follow-up group (FUG)|Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and increased follow-up.
89120280|NCT04522921|Experimental|Intervention group (IG)|A higher protein diet (25E%/day) for the 10 weeks they attend the camp and increased follow-up.
89120281|NCT00779038|Experimental|Fentanyl ITS|40 microgram (mcg) per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an Iontophoretic Transdermal System (ITS). Total duration of treatment will be 72 hours.
89120282|NCT04293380|Other|normal karyotype|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
89120283|NCT04293380|Other|down syndrome|During the prenatal evaluation, IMA and cytokine values in amniotic fluid will be compared in cases with down syndrome and normal karyotype.
89120284|NCT02575105||Pediatric Hydrocephalus|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
89120285|NCT02575105||Pediatric Control|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
89120286|NCT02575105||Adult Hydrocephalus|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
89120287|NCT02575105||Adult Control|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
89120288|NCT04292990|Experimental|Fentanyl|Intervention: Drug: Fentanyl Transdermal Patch
89120289|NCT04292990|Active Comparator|Morphine|Intervention: Drug: Morphine Controlled-Release Tablets
89120290|NCT04100278|No Intervention|Traditional therapy group|All patients in this group will be given routine diabetes management, including lifestyle education, health guidance, monitoring blood sugar guidance and drug adjustment.
89120291|NCT04100278|Active Comparator|Shared Care group|The patients download the Shared Care mobile application and connect with the smart-glucometer Bg1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
89120292|NCT02197351|Experimental|Gastric Symptoms|Patients with gastric symptoms including dyspepsia undergoing upper endoscopy will undergo white light biopsy narrow band imaging guided biopsy protocolled biopsy
89120293|NCT02869568||Patients with ovarian cancer diagnosis|
89120294|NCT00916474||Cohort A|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
89120295|NCT00916474||Cohort B|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
89120296|NCT04291742|Experimental|0: cognitive|target prostate biopsies by cognitive fusion
89120297|NCT04291742|Experimental|1: software|target prostate biopsies by software
89120298|NCT04293068||Control group|Related tests were normal, because the male factor alone required the first IVF/ICSI cycle; Follow-up of included patients was conducted to determine whether embryo transplantation was performed, and the score of transferred embryos was recorded, and the final control group would be confirmed after achieving clinical pregnancy
89120299|NCT04293068||Recurrent implantation failure|Previous ≥3 consecutive embryo transfer failures
89120300|NCT04293068||Recurrent spontaneous abortion(miscarriage)|≥2 consecutive spontaneous abortions or embryo damage
89120301|NCT00629174|Experimental|1|Exercise
89120302|NCT00629174|Experimental|2|Mental training (computer lessons)
89120303|NCT00629174|No Intervention|3|
89120304|NCT02868710|Experimental|Individualized method|"3 days a week of exercise at the following intensity and energy expenditure:~Week 1: HR > VT1; 5.6 kcal/kg/wk Week 2: HR > VT1; 8.4 kcal/kg/wk Week 3: HR > VT1; 11.2 kcal/kg/wk Week 4: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 5-6: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 7: HR ≥ VT1 to <VT2; 12.6 kcal/kg/wk Week 8: HR ≥ VT1 to <VT2; 14 kcal/kg/wk Week 9-10: HR ≥ VT2; 14 kcal/kg/wk Week 11-12: HR ≥ VT2; 15.4 kcal/kg/wk"
89120305|NCT02868710|Experimental|Standardized method|"3 days a week of exercise at the following intensity and energy expenditure:~Week 1: 40-45% HRR; 5.6 kcal/kg/wk Week 2: 40-45% HRR; 8.4 kcal/kg/wk Week 3: 40-45% HRR; 11.2 kcal/kg/wk Week 4: 50-55% HRR; 11.2 kcal/kg/wk Week 5-6: 55-60% HRR; 11.2 kcal/kg/wk Week 7: 55-60% HRR; 12.6 kcal/kg/wk Week 8: 55-60% HRR; 14 kcal/kg/wk Week 9-10: 60-65% HRR; 14 kcal/kg/wk Week 11-12: 60-65% HRR; 15.4 kcal/kg/wk"
89120306|NCT02868710|No Intervention|Control|"non-exercise control group~Testing at baseline and post-program (12 weeks)"
89120307|NCT00629096|Experimental|1|All included patients are assigned to arm 1, in which they are treated by the intervention
89120308|NCT02868632|Experimental|Cohort A: MEDI4736 + SBRT|MEDI4736 10 mg/kg IV every 2 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
89120309|NCT02868632|Experimental|Cohort B:Tremelimumab + SBRT|Tremelimumab 10 mg/kg IV every 4 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
89120310|NCT02868632|Experimental|Cohort C: MEDI4736 + Tremelimumab + SBRT|MEDI4736 + Tremelimumab (recommended phase 2 IV dose for combination) plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 16 Subjects
89120311|NCT00765076|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0
89120312|NCT00765076|Active Comparator|Fluarix elderly Group|Subjects aged >= 65 years receiving 1 dose of Fluarix vaccine at Day 0
89120313|NCT00765076|Active Comparator|Fluarix young Group|Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0
89120314|NCT04021498|Placebo Comparator|Placebo|"placebo~1 year"
89120315|NCT04021498|Experimental|Simvastatin|"40 mg~1 year"
89120316|NCT00994682|Active Comparator|Pioglitazone|After all patients receive dietary counseling at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
89120317|NCT00994682|Placebo Comparator|Placebo|After dietary counseling to all patients at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
89120318|NCT00768898||2.5 microliters lissamine green|
89120319|NCT00768898||5.0 microliters lissamine green|
89120320|NCT00768898||10.0 microliters lissamine green|
89120321|NCT00994448|Experimental|Bupropion|
89120322|NCT00994448|Placebo Comparator|Placebo (sugar pill)|
89120323|NCT00991406|Experimental|Arm 1: FES|Case-control study: pre- and post-stimulation (FES).
89120324|NCT04292444|Experimental|RAGE polymorphism (TT)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TT) will be selected and scanned twice.
89120325|NCT04292444|Experimental|RAGE polymorphism (TA/AA)|30 participants with the RAGE polymorphism (-374 T/A: rs1800624; TA/AA) will be selected and scanned twice.
89120326|NCT01017575|Experimental|Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
89120327|NCT01017575|Experimental|Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
89120328|NCT01017575|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
89120329|NCT01017575|Experimental|Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)|Non-Responder
89120330|NCT01017575|Experimental|Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Non-Responder
89120331|NCT01017263|Active Comparator|Open label Vyvanse|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
89120332|NCT02872181|Experimental|BMI <30|Pregnant women undergoing C/S with BMI <30
88800836|NCT05395169|Experimental|the same medication, in addition to DASH diet and aerobic exercise|Study group: Will be consisted of 25 females suffering from PMS will Receive the same medication as in group (A) in addition to the DASH diet and aerobic exercise for 30 minutes,3 times/week,for 12 weeks.
88800837|NCT05394857|Experimental|Treatment group|SHR-1314 s.c
88800838|NCT00970073|Experimental|Delayed CNI Group 1|Thymoglobulin 3mg total, administered on Days 0 and 2 (after transplant), plus MMF and corticosteroids. CNI administration delayed until 10 days post transplant. tacrolimus 3-8 (trough concentration)
88800839|NCT00970073|Experimental|Delayed CNI Group 2|Thymoglobulin 4.5mg total, plus MMF and corticosteroids. CNI therapy delayed until 10 days post transplant.tacrolimus 3-8 (trough concentration)
88800840|NCT00970073|Active Comparator|Early CNI / Control Arm|Standard post liver transplant therapy to include: tacrolimus 8-12 (trough concentration) initiated within 48 hours post-transplant, plus mycophenolate mofetil (MMF) and corticosteroids to be administered within 24 hours after transplant (Day 0).
89120333|NCT02872181|Experimental|BMI 30-40|Pregnant women undergoing C/S with BMI 30-40
89120334|NCT02872181|Experimental|BMI >40|Pregnant women undergoing C/S with BMI >40
89120335|NCT00768664|Experimental|A|
89120336|NCT04097782|No Intervention|Control Group|"Prior to the study, primiparous pregnant women presented to the outpatient clinic for routine pregnancy control were introduced with free prenatal education classes and they were invited to participate in the study.~Primiparous women who volunteered to participate in the study and met the inclusion criteria were included in the study and they formed the experimental and control group. Control group did not receive antenatal education and they received prenatal care service routinely provided at the polyclinics of the same hospital."
88800841|NCT00970853|Active Comparator|Control|Control group
88800842|NCT00970853|Experimental|MOM Program home visiting|Mixed professional support home visiting program.
88800843|NCT02569398|Experimental|Group 1|Participants will receive one atabecestat, 5 milligram (mg) tablet orally once daily up to 54 months.
88800844|NCT02569398|Experimental|Group 2|Participants will receive one atabecestat, 25 mg tablet orally once daily up to 54 months.
88800845|NCT02569398|Experimental|Group 3|Participants will receive one matching placebo tablet orally once daily up to 54 months.
88800846|NCT00971633|Experimental|1|Treatment Sequence A-B-C
88800847|NCT00971633|Experimental|2|Treatment Sequence B-C-A
88800848|NCT00971633|Experimental|3|Treatment Sequence C-A-B
88800849|NCT00971633|Experimental|4|Treatment Sequence A-C-B
88800850|NCT00971633|Experimental|5|Treatment Sequence B-A-C
88800851|NCT00971633|Experimental|6|Treatment Sequence C-B-A
88800852|NCT05506176|Experimental|SIM-0417|orally administrated SIM0417+ ritonavir
88800853|NCT05506176|Placebo Comparator|Placebo|Placebo
88800854|NCT05511168|Other|Craniosynostosis patients|Craniosynostotic patients aged more than 3months
88800855|NCT00971789|Experimental|Sirolimus Patients|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.
88800856|NCT05510934||Shared-care Group|The Shared-care Group will comprise of patients who are receiving long term follow-up care for their condition by their PCP.
88800857|NCT05510934||Control Group|The Control Group will be made of patients who are receiving long term follow-up care for their condition of low-risk DTC at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC).
88800858|NCT05510778|Experimental|Charcocaps|2 capsules 15 minutes before meal and 2 additional capsules 2 hours after meal
89120337|NCT04097782|Experimental|Experimental Group|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
89120338|NCT02600962||STEMI|Patients discharged with STEMI
89120339|NCT02600962||NSTEMI|Patients discharged with NSTEMI
89120340|NCT00778336||Limb Ischemia|Patients presenting with limb ischemia for treatment
88800859|NCT05510778|Placebo Comparator|Placebo|2 capsules 15 minutes before meal and 2 additional capsules 2 hours after meal
88800860|NCT05510622||Recurrent pregnancy loss|Women with history of recurrent pregnancy loss
88800861|NCT05510622||Control|Normal fertile women
88800862|NCT00972335|Experimental|Combination Therapy|"Everolimus; this drug will be dosed at 10 mg orally DAILY for the duration of the study.~Bevacizumab; this drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study"
88800863|NCT03341156|Experimental|Kcentra (PCC)|Half of subjects enrolled will be randomized to the Kcentra (PCC) group.
88800864|NCT03341156|Active Comparator|Frozen Plasma Product, Human|Half of subjects enrolled will be randomized to the standard transfusion group and receive fresh frozen plasma intra-operatively.
88800865|NCT02983994||Patients with asthma with an inhaled steroid|Patients with a diagnosis of asthma with indication of Treatment with an inhaled steroid (CI)
88800866|NCT02983994||Patients with asthma with an inhaled Beta agonist|Patients with a diagnosis of asthma with indication of Treatment with an inhaled Beta agonist (LABA)
88800867|NCT04122560|Experimental|Obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
88800868|NCT04122560|Active Comparator|Non-obese subjects|"Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg~Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg"
88800869|NCT04122326|Experimental|Posture Sequence|Participants will complete computer work on a provided monitor and keyboard for two hours. During the first hour, the research personnel will alter the workstation every ten minutes to test various different postures of the neck, shoulder, arms, and trunk. The sequence will include 3 seated postures and 3 standing postures. At the end of the first hour, the participant will be instructed to adjust the workstation independently and continue to work for 60 minutes for an observational session.
89120341|NCT00778336||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
89120342|NCT00778336||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
89120343|NCT00778336||Other Thrombotic Conditions|Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.
89120344|NCT04097938|Experimental|GLPG3667 SAD|Single doses of GLPG3667 at up to 6 dose levels in ascending order
89120345|NCT04097938|Placebo Comparator|Placebo SAD|Single doses of placebo
89120346|NCT04097938|Experimental|GLPG3667 MAD|Multiple doses of GLPG3667 at up to 3 dose levels in ascending order, daily for 13 days
89120347|NCT04097938|Placebo Comparator|Placebo MAD|Multiple doses of placebo
89120348|NCT04097938|Experimental|GLPG3667 FE fasted|Single dose of GLPG3667 in fasted state
89120349|NCT04097938|Experimental|GLPG3667 FE fed|Single dose of GLPG3667 in fed state
89120350|NCT04097938|Experimental|GLPG3667 oral suspension rBA-FE fed|Single dose of GLPG3667 oral suspension in fed state
89120351|NCT04097938|Experimental|GLPG3667 capsules rBA-FE fasted|Single dose of GLPG3667 capsules in fasted state
89120352|NCT04097938|Experimental|GLPG3667 capsules rBA-FE fed|Single dose of GLPG3667 capsules in fed state
89120353|NCT02576743||Healthy subjects|Subjects with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning. 7 Tesla MRI
89120354|NCT02576743||Patients|Patients with an unruptured brain aneurysm or an unruptured arteriovenous malformation (AVM) with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning 7 Tesla MRI
89120355|NCT04840069|No Intervention|MRI-guided radiotherapy|Patients will undergo standard of care MRI-guided radiotherapy.
89120356|NCT04840069|Experimental|MRI + Fluciclovine PET-guided radiotherapy|Patients will undergo MRI + Fluciclovine PET-guided radiotherapy
89120357|NCT02574949|Active Comparator|Conventional rate fluoroscopy|Radiation: 15 FPS Cine 15 PPS
89120358|NCT02574949|Experimental|Intermediate frame rate 7.5 fps|Radiation: 7.5 low Frame rate
89120359|NCT02574949|Experimental|Low frame rate|Low Cine 10 PPS
89120360|NCT01253161|Experimental|Pasireotide LAR Treatment|The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.
89120361|NCT00581113|Active Comparator|1|Standard Whole Brain Radiotherapy
89120362|NCT00581113|Experimental|2|Neural Stem Cell-Preserving Whole Brain Radiotherapy
89120363|NCT00709423|Active Comparator|1|
89120364|NCT00709423|Placebo Comparator|2|
89120365|NCT02574871||Single Group|Psychological and biological data collection
89120366|NCT00627887|Experimental|ECT+pharmacotherapy|Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.
89120367|NCT00627887|Active Comparator|pharmacotherapy|Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.
89120368|NCT02576665|Experimental|Toca 511/Toca FC|"Toca 511: 14 mL intravenously daily for 3 days followed by up to 4 mL intratumorally or into resection cavity walls following biopsy or resection. Cutaneous melanoma patients may receive intralesional injections (up to 4 mL) daily for 5 days.~Toca FC: 220 mg/kg/day orally starting at Week 5-6. Cycles are 5- to 7- day courses of treatment every 4 to 6 weeks."
89120369|NCT00627965|Experimental|1|Sildenafil citrate
89120370|NCT00627965|Placebo Comparator|2|Placebo
89120371|NCT01207141||rATG induction|Liver transplant recipients who receive induction with rATG prior to transplantation.
89120372|NCT01207141||no rATG induction|Liver transplant recipients who do not receive rATG induction therapy prior to transplantation.
89120373|NCT02574559|Experimental|Caregiver of Child With Autism Spectrum Disorder|Caregivers attending eight weekly sessions of Cognitive Based Compassion Training Sessions and Meditation.
89120374|NCT00709501|Experimental|1|"Participants in the intervention condition are encouraged to access the Achieve Together website at least once each week. During each login, the following activities will occur:~Users will enter their weight and height, how well their plan for a healthy weight has been going, and clarify their goal weight.~Users will answer questions about each habit they are using to lose weight~Users will receive automated feedback about each habit and will be encouraged to change or delete habits that are being used but not helpful, more consistently use habits that are helpful but not used being used and to continue to use habits that are helpful and being used consistently.~Users are encouraged to search for habits that have helped people of similar age and gender to themselves."
89120375|NCT00709501|No Intervention|2|Participants in the control condition will have to wait 12 weeks before accessing the Achieve Together website. These participants will be a given a log where they can document weekly weight measurements (this part did not happen).
89120376|NCT02576353|Experimental|Cohort 1|After a 10-hour fast, the 10 participants in this cohort are randomized to receive Fentanyl Sublingual (under the tongue) Spray (FSS) 100 mcg (n=8), or Fentanyl Citrate Intravenously (FCIV) 50 mcg (n=2).
89120377|NCT02576353|Experimental|Cohort 2|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 200 mcg (n=8), or FCIV 50 mcg (n=2).
89120378|NCT02576353|Experimental|Cohort 3|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 400 mcg (n=8), or FCIV 50 mcg (n=2).
89120379|NCT02576353|Experimental|Cohort 4|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 600 mcg (n=8), or FCIV 50 mcg (n=2).
89120380|NCT02576353|Experimental|Cohort 5|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 800 mcg (n=8), or FCIV 50 mcg (n=2).
89120381|NCT04473235|Experimental|Literacy training|The basic-literacy training will be given for two hours/day for four days/week for 6 months. At baseline, participants will be randomized into four classes of 30. An expert in adult education will oversee the classes and meet the teachers periodically, and each class will count with a certified and experienced lead teacher and teacher aid. The intervention group will receive literacy training based on analytical and phonemic methods for enabling reading and writing
89120382|NCT04473235|Active Comparator|Non-literacy training|The comparator group will have access to non-literacy classes offered at the adult school, including geography, history, informatics, and sciences, but no literacy-training, for two hours/day for four days/week for 6 months. After 6 months, the groups switch, so the comparator receives the specific reading and writing training, and the intervention group receives the lessons on other themes.
89120383|NCT01016015|Experimental|Treatment (cixutumumab and temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89120384|NCT00709579|Placebo Comparator|placebo|
89120385|NCT00709579|Active Comparator|RV3391A|
89120386|NCT00628043|Experimental|EPOCH|
89120387|NCT00628043|Placebo Comparator|placebo|
89120388|NCT00709657|Experimental|1|patients with age-related macular degeneration, which are already scheduled for intravitreal anti-VEGF therapy in one eye are measured before and after treatment.
89120389|NCT04073173|Experimental|LISA-analgesic|Less Invasive Surfactant Administration (LISA) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
89120390|NCT04073173|Experimental|LISA-no analgesic|Less Invasive Surfactant Administration (LISA) without an analgesic drug.
89120391|NCT04073173|Experimental|INSURE-analgesic|INtubation-SURfactant-Extubation (INSURE) with remifentanil (0.5-2 micrograms/kg/dose) as the analgesic drug.
89120392|NCT04073173|Experimental|INSURE-no analgesic|INSURE without an analgesic drug.
89120393|NCT01015703|Experimental|CoVaccine HT|
89120394|NCT00628121|Experimental|Cetrorelix 1 mg|
89120395|NCT00628121|Experimental|Cetrorelix 2 mg|
89120396|NCT00628121|Experimental|Cetrorelix 3 mg|
89120397|NCT04073251|Experimental|KalobaTuss children|KalobaTuss children syrup 5 ml for 4 times a day supplied for 8 consecutive days.
89120398|NCT04073251|Placebo Comparator|Placebo|Placebo syrup 5 ml for 4 times a day supplied for 8 consecutive days.
89120399|NCT00709813|No Intervention|1|
89120400|NCT00709813|Experimental|2|
89120401|NCT04634929||bariatric surgery participants|participants with obesity planning to undergo bariatric surgery
89120402|NCT04634929||conservative diet participants|participants with obesity planning to controlled conservative behavioral weight loss program
89120403|NCT04439071|Experimental|PTC299 + Standard of Care (SOC)|"Participants will receive PTC299 at 200 milligrams (mg), administered orally, twice daily (BID) on Days 1 to 7, then at 50 mg administered orally, once daily (QD) on Days 8 to 14.~SOC will also be administered according to local, written policies or guidelines."
89120404|NCT04439071|Placebo Comparator|Placebo + SOC|"Participants will receive PTC299-matching placebo administered orally, BID on Days 1 to 7, then administered orally, QD on Days 8 to 14.~SOC will also be administered according to local, written policies or guidelines."
89120405|NCT04069975||No sedation|The group of patients who did endoscopies without sedation.
89120406|NCT04069975||Sedation|The group of patients who did endoscopies with sedation.
89120407|NCT00709969|Experimental|1|Artemether-lumefantrine
89120408|NCT00710047|Experimental|1|Fasting state
89120409|NCT00710047|Experimental|2|after high-fat breakfast
89120410|NCT04070677|Experimental|Ziverel arm|Patients included will receive treatment with ZIVEREL®, initially 10 mL every 8 hours, 30 minutes after meals, to avoid physical entrainment by food, during a minimum of 8 weeks, recruited during a period of 12 months. The treatment will be indicated when the patient develops a radiation-induced esophagitis of degree ≥ 2.
89120411|NCT02578927|Experimental|GT+Ex|Ingestion of one dose of 2 g of green tea (GT) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
89120412|NCT02578927|Placebo Comparator|PL+Ex|Ingestion of one dose 2 g of placebo (PL) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
89120413|NCT02578927|Active Comparator|Green Tea|Ingestion of one dose 2g of green tea (GT) at 10 minutes after the period of rest. In this section the volunteers does not practice aerobic exercise.
89120414|NCT00714337|Experimental|1|fasting state
89120415|NCT00714337|Experimental|2|fasting state
89120416|NCT00714337|Experimental|3|non-fasting state
89120417|NCT00714337|Experimental|4|fasting state
89120418|NCT00714337|Experimental|5|non-fasting state
89120419|NCT00710125|Experimental|GPX-150 for Injection|GPX-150 is administered IV on Day 1, followed by a 20 day rest period, every 3 weeks.
89120420|NCT02573701|Experimental|1 Guideline treatment|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
89120421|NCT02573701|Active Comparator|2 Treatment as Usual|Participants will receive the Treatment as Usual (atypical antipsychotic) plus psychosocial treatment decided by clinician
89120422|NCT01017029|Active Comparator|Immediate introduction of everolimus|
89120423|NCT01017029|Experimental|Delayed introduction of everolimus|delayed introduction) + Cyclosporin + steroids
89120424|NCT00714649|Other|I-1|"This is a phase I/II trial. PhaseI: The delay between the last administration of cetuximab and surgery will be progressively reduced. Five delay schedules are pre-defined before final administration of 3 preoperative doses of cetuximab with a 24-hour delay between the last dose of cetuximab and surgery. The cohort size is 3 patients per delay schedule, extended to 6 patients if one limiting toxicity is observed.~Phase II: will proceed if delay schedule V is safe. The patients included in delay schedule V of the Phase I part of the study will be involved in the phase II analysis. Recruitment of a total of 12 patients (3-6 of delay schedule V in phase I plus an additional 3-9 patients)."
89120425|NCT00710281|Other|2D/3D Phase contrast MR|
89120426|NCT00710359|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
89120427|NCT00710359|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
89233167|NCT02919592|Experimental|Primary Breast Augmentation|Participants who meet the requirements for primary breast augmentation (have not had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
89120428|NCT05673343||Complete blood count|"Complete blood count with differential should be done within 2 weeks before starting CCRT. We will calculate NLR as total neutrophilic count divided by total lymphocytic count for each patient before starting the treatment.~Two protocols of the treatment: first is by starting with CCRT then surgery (Total Neoadjuvant Therapy), second is CCRT then surgery then continue chemotherapy: FOLFOX , Xeloda or CAPOX.~Radiotherapy dose: long course radiation therapy at the dose of 45 to 50 Gray (Gy) in 25 to 28 fractions to the pelvis by NCCN recommendation. Short-course radiation therapy (25 Gy in 5 fractions).~Patients should be kept on follow up after complete their treatment every three months till disease progression occur, death of the patient or at least 12 months of follow up."
89120429|NCT00714727|Other|1|
89120430|NCT02578849||PD_no_LID|Patients with Parkinson´s disease without dyskinesia
89120431|NCT02578849||PD_LID|Patients with Parkinson´s disease with L-DOPA induced dyskinesia
89120432|NCT02578849||HC|Health controls, age-mathced.
89120433|NCT00710437||1|Dexmedetomidine - used
89120434|NCT00710437||2|Dexmedetomidine - not used
89120435|NCT02573623||HIV-infected children with confirmed TB|Hospitalized children with TB confirmed by culture or GeneXpert
89120436|NCT02573623||HIV-uninfected children aged<5 years with confirmed TB|Hospitalized children aged<5 years with TB confirmed by culture or GeneXpert
89120437|NCT02573623||HIV-uninfected children aged>4 years with confirmed TB|Hospitalized children aged>4 years with TB confirmed by culture or GeneXpert
89120438|NCT02573623||HIV-infected control children|Children hospitalized in the surgery ward without any evidence of tuberculosis infection
89120439|NCT02573623||HIV-uninfected controls aged <5 years|Children <5 years hospitalized in the surgery ward without any evidence of tuberculosis infection
89120440|NCT02573623||HIV-uninfected controls aged >4 years|Children >4 years hospitalized in the surgery ward without any evidence of tuberculosis infection
89120441|NCT00710515|Experimental|1|with food
89120442|NCT00710515|Experimental|2|without food
89120443|NCT02574715||Levonorgestrel (Jaydess, BAY86-5028)|women aged 18 to 29 years following 6 (±1) months of Jaydess® use as their contraceptive method.
89120444|NCT00714805||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
89120445|NCT00714805||Healthy Control|Subjects having no known ailment.
89120446|NCT00710671||Phase 1|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from four participating AMTU sites.
89120447|NCT00710671||Phase 2|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from all fifteen AMTU sites.
89120448|NCT00710827|Experimental|Arm 1|
89120449|NCT00710827|Placebo Comparator|Arm 2|
89120450|NCT00994214|Experimental|BIM 23A760 1 mg|
89120451|NCT00994214|Experimental|BIM 23A760 2 mg|
89120452|NCT00994214|Experimental|BIM 23A760 4 mg|
89120453|NCT00994214|Experimental|BIM 23A760 6 mg|
89120454|NCT01034657|Experimental|LBH589|During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months.
89120455|NCT01034657|Experimental|LBH589 + Epoetin Alfa|During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months.
89120456|NCT02041585||Elder discharge cohort|There will be no intervention in this observational survey research.
89120457|NCT02867696|Active Comparator|Standard Care|Standard Care serves as the no treatment control in this project. Participants in this group will receive the typical care from their surgeon following bariatric surgery. No additional interventions will be given to participants randomized to this group.
89120458|NCT02867696|Experimental|Technology-based Intervention (TECH)|TECH is the experimental group in this project. A minimal-contact technology-based intervention for weight management will be given to this group in addition to the standard or typical care received from their surgeon following bariatric surgery.
89120459|NCT01014767|Experimental|Standard Arm (1)|Alternating chemotherapy cycles with etoposide 100 mg/m2 over 1 hour on days 1-5, carboplatin 350 mg/m2 over 2 hours on day 2 and 3, vincristine 1.5 mg/m2 on day 5 alternating with: etoposide 100 mg/m2 over 1 hour on days 1-5, cyclophosphamide 1 g/m2 over 1 hour on day 2 and 3, vincristine 1.5 mg/m2 on day 5. Six blocks are given in 4 week intervals (day1 to day1). Radiation is given between the second and the third cycle only to a small subgroup of patients defined by age histology staging and response to the first to cycles of chemotherapy.
89120460|NCT01014767|Experimental|Doxorubicin/cisplatin arm (2)|Doxorubicin 25 mg/m²/day over 12 hrs on days 1-3, Dactinomycin 45 µg/kg/day (max. 2 mg), i.v. on day 1, and Cisplatin 70 mg/m²/d over 6 hrs on day 4, and Vincristine 1.5 mg/m²/day (max. 2 mg), i.v. on days 8, 15. An identical second cycle is started on day 28 if the side effects allow it. The further treatment is identical to the standard arm with four more cycles of chemotherapy following radiation in some of the patients in all treatment arms.
89120461|NCT01014767|Experimental|Methotrexate Arm (3)|Methotrexate 5g/m^2 over 24 hours with leucovorin rescue at hour 42 given three times on days 1 15 and 29. The further treatment is identical in all four treatment arms.
89120462|NCT01014767|Experimental|Temozolomide Irinotecan arm (4)|Temozolomide is given at 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day x 5 days as one hour infusions. Two of these cycles are followed by the common radiation - four cycle chemotherapy protocol.
89120463|NCT02016781|Active Comparator|Transplant|Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT)
89120464|NCT02016781|Active Comparator|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
89120465|NCT01014689|Active Comparator|Adapalene 0.1% / BPO 2.5% gel|
89120466|NCT01014689|Placebo Comparator|Adapalene 0.1% / BPO 2.5% Vehicle Gel|
89120467|NCT01014533|Placebo Comparator|Placebo|After 3 nights in the UM sleep lab and randomization, this arm receives placebo for one week. They then return to the sleep lab for the same procedures.
88800870|NCT02569242|Experimental|Nivolumab Arm|Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
88800871|NCT02569242|Active Comparator|Active Comparator Arm （Docetaxel/Paclitaxel）|"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~OR~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
88800872|NCT04122014|Experimental|Control group|Usual daily activities
88800873|NCT04122014|Experimental|Training group|Each subject will participate in 2 sessions each week during 3 months.
88800874|NCT05608382|Placebo Comparator|sterile Phosphate Buffer Saline (PBS)|
88800875|NCT05608382|Experimental|SGW13|
88800876|NCT05501808|Experimental|Enamic group|patient in this group received a restoration with enamic material
88800877|NCT05501808|Active Comparator|Cerasmart group|patient in this group received a restoration with Cerasmart material
88800878|NCT04122248||M6-C|Subjects treated with an M6-C device
88800879|NCT04122248||ACDF|Subjects treated with Anterior Cervical Discectomy and Fusion (ACDF)
89120468|NCT01014533|Active Comparator|Gabapentin|After spending 3 baseline nights in the UM sleep lab, alcohol dependent subjects are randomized. This arm receives gabapentin . On nights 1 and 2 of medication, the dose is 600 mg by mouth 30 min before bedtime. On nights 3-10, the dose is 1200 mg by mouth 30 min before bedtime. On nights 8-10 of medication, subjects return to the UM sleep lab and complete 3 sleep nights with the same procedures. On night 11, the dose is reduced to 600 mg by mouth 30 min before bedtime, and then stopped.
89120469|NCT02013427|No Intervention|Observational|Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
89120470|NCT02013427|Active Comparator|Naproxen & Omeprazole|Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
89120471|NCT02013427|Placebo Comparator|Placebo Only|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
89120472|NCT00628277|Experimental|1|Arm 1: high caloric expenditure exercise plus dietary counseling
89120473|NCT00628277|Active Comparator|2|Arm 2: low caloric expenditure exercise plus dietary counseling
89120474|NCT01014143|Placebo Comparator|Fluoride toothpaste|Negative control
89120475|NCT01014143|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste
88800880|NCT05501730||Pre-Quantra|Patients undergoing cardiac surgery prior to the introduction of the Quantra.
89120476|NCT01014143|Active Comparator|Chlorhexidine Oral Rinse|Positive Control mouthrinse
89120477|NCT00710983|Active Comparator|A|Oral polio vaccine
89120478|NCT00710983|No Intervention|B|No oral polio vaccine
89120479|NCT00714961|Experimental|1|
89120480|NCT00714961|Placebo Comparator|2|
88800881|NCT05501730||Post-Quantra|Patients undergoing cardiac surgery after the introduction of the Quantra.
88800882|NCT05501496|Other|Casting|Displaced fracture will be treated with closed reduction and long leg cast under general anesthesia
88800883|NCT05501496|Active Comparator|intramedullary nailing|Displaced fracture will be treated with closed or open reduction and flexible intramedullary nailing
88800884|NCT05501418|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after COVID-19 infection.
88800885|NCT05501418|Placebo Comparator|Placebo|Normal saline will be administered to patients after COVID-19 infection.
88800886|NCT02983838||depression with cognitive impairment|depression onset after 60 years old with subjective cognitive impairment
88800887|NCT02983838||depression without cognitive impairment|depression onset after 60 years old without subjective cognitive impairment
88800888|NCT02983838||normal control|older than 65 years, free from other neurocognitive disorder
88800889|NCT05501340|Experimental|PRaG combined PD-1 inhibitor intraperitoneal injection|PRaG(PD-1 inhibitor,Radiotherapy and GM-CSF) combined with PD-1 inhibitor intraperitoneal injection
88800890|NCT00972725|Experimental|GSK732461+Nivaquine Group|Subjects received a single dose of Nivaquine® tablets orally, 2 days prior to receiving a booster dose of the GSK732461 vaccine.
88800891|NCT00972725|Active Comparator|GSK732461 Group|Subjects received a booster dose of the GSK732461 vaccine intramuscularly, in the deltoid region of the non-dominant arm.
89120481|NCT00711061||1|18-25 year old males, growth hormone deficient, who completed growth hormone treatment 3-5 years prior to enrollment in study
88800892|NCT05501262|Active Comparator|Standard of Care|Steroid and lidocaine injection
88800893|NCT05501262|Experimental|Study|Steroid and lidocaine injection with cryoablation
88800894|NCT04394000||Before or control group|All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
89120482|NCT00711061||2|18-25 year old males, healthy, never treated with growth hormones.
88800895|NCT04394000||After or intervention group|On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
89120483|NCT02574403|Experimental|without eculizumab|
89120484|NCT01013753|Experimental|Olodaterol (BI 1744) low|Low dose inhaled orally once daily from the Respimat inhaler
89120485|NCT01013753|Experimental|Olodaterol (BI 1744) very low|Very low dose inhaled orally once daily from the Respimat inhaler
89120486|NCT01013753|Experimental|Olodaterol (BI 1744) medium|Medium dose inhaled orally once daily from the Respimat inhaler
88800896|NCT05600660|Experimental|OR-MTX|Experimental arm will be treated with OR-MTX regimen(Orelabrutinib plus Rituximab and Methotrexate) for 6 cycles as initiate induction. After 6 cycles of induction chemotherapy, autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be performed for transplantation eligible patients . Thereafter, Orelabrutinib maintenance chemotherapy will be given up to one year. Follow-ups should be taken up to the first 2 years. The primary endpoint is objective response rate (ORR) and secondary endpoint includes Progression free survival (PFS), overall survival (OS), and adverse events.
88800897|NCT03830762|Experimental|Cohort 1 / Cohort 2 (Active)|20mg or 30mg capsules of Xanamem respectively, to be administered PO once daily.
88800898|NCT03830762|Placebo Comparator|Cohort 1 / Cohort 2 (Placebo)|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
88805868|NCT00290654|Experimental|Lumpectomy with Brachytherapy|Patients with ductal carcinoma in situ (DCIS, a non-invasive form of breast cancer) treated with standard lumpectomy/brachytherapy following by radiation using the MammoSite (FDA approved a balloon-catheter device placed in the lumpectomy cavity through which high dose radiation is delivered). Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient.
88805869|NCT00290810|Experimental|Treatment (monoclonal antibody therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89120487|NCT01013753|Experimental|Olodaterol (BI 1744) high|High dose inhaled orally once daily from the Respimat inhaler
89120488|NCT01013753|Active Comparator|Formoterol 12 mcg|12mcg inhaled twice daily from the Aerolizer inhaler
89120489|NCT01013753|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
89120490|NCT00711139||1|AFFITOPE AD01
89120491|NCT00711139||2|AFFITOPE AD01 + Adjuvant
89120492|NCT00715039|Active Comparator|lorazepam|
89120493|NCT00715039|Placebo Comparator|placebo|
89120494|NCT00715039|Active Comparator|paroxetine|
89120495|NCT00715195|Experimental|1|Cognitive-behavioral therapy : 50 patients planned
89120496|NCT00715195|No Intervention|2|50 patients planned
89120497|NCT00711217|Experimental|#1 Medical food|
89120498|NCT00711217|Placebo Comparator|#2 Control|
89120499|NCT00711295|Experimental|Cohort 1, Treatment Arm 1|"Stratum A (18-59 ys)/B(>=60 ys): 120 healthy volunteers per stratum will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Among Stratum A volunteers, 60 will participate in antibody kinetics evaluation and 30 in cellular immunity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio. Subjects in Treatment Arm 1 will be included in the immunologic determination of lot-to-lot consistency."
89120500|NCT00711295|Experimental|Cohort 1, Treatment Arm 2|"Stratum A (18-59 ys)/B(>=60 ys): 60 healthy volunteers per stratum will receive 2 vaccinations with 3.75 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio."
89120501|NCT00711295|Experimental|Cohort 1, Treatment Arm 3|"Stratum A (18-59 ys): 2060 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in safety evaluation only.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine."
89120502|NCT00711295|Experimental|Cohort 2, Treatment Arm 1|"300 immune compromised individuals 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21.~100 will participate in immunogenicity evaluation and 30 in cellular immunity evaluation."
89120503|NCT00711295|Experimental|Cohort 3, Treatment Arm 1|300 chronically ill patients 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.
89120504|NCT00711295|Experimental|Cohort 1, Treatment Arm 4|"Stratum A (18-59): 540 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity assessment.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine.~Subjects in Treatment Arm 4 will be included in the immunologic determination of lot-to-lot consistency."
89120505|NCT00757042|Experimental|Tezepelumab|Participants will receive a single dose of tezepelumab administered subcutaneously or intravenously. The starting dose will be 2.1 mg tezepelumab.
89120506|NCT00757042|Placebo Comparator|Placebo|Participants will receive matching placebo administered subcutaneously or intravenously.
89120507|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 1|alveolar recruitment maneuvers by CPAP then alveolar recruitment maneuvers by eSigh
89120508|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 2|alveolar recruitment maneuvers by eSigh then alveolar recruitment maneuvers by CPAP
89120509|NCT00711373|Experimental|Unilateral and Bilateral Amputees|
89120510|NCT04099186|Experimental|hydro-mechanical pulmonary embolism fragmentation|Those patients will undergo catheter directed fragmentation followed by injection of 100 ml of heparinized saline via power injector
89120511|NCT04099186|No Intervention|thrombolytic treated arm|patients with high risk and intermediate high risk PE who received thrombolysis as only treatment modality
89120512|NCT02871869|Active Comparator|Control group A|Control group A was treated with single R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
89120513|NCT02871869|Experimental|Trial group A|Trial group A was treated with Cinobufacini Tablets combined with R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
89120514|NCT02871869|Active Comparator|Control group B|Control group B was treated with single CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
89233168|NCT02919592|Experimental|Revision Breast Augmentation|Participants who meet the requirements for revision breast augmentation (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast implants
89233169|NCT02919592|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
89233170|NCT02919592|Experimental|Revision Breast Reconstruction|Participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor MemoryGel® Breast Implants or MemoryShape® Breast Implants
89233171|NCT02919592|Active Comparator|Other Aesthetic Surgery|Participants who meet the requirements for other aesthetic surgery procedures, which may not include silicone implants (breast or otherwise)
89233172|NCT02816021|Experimental|Arm A: Metastatic Melanoma - PD-1 Naive|"Thirty-six participants with metastatic melanoma that are PD-1 naïve enrolled in treatment Arm A.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
88800899|NCT04759118|No Intervention|Control group|The participant in his group is a pregnant woman. The facilitators of the control groups were midwives who are already providing prenatal education classes at the clinics. The classes followed the government curriculum, which consists of three classes per month and does not invite husbands to participate. However, in this study, participants in the control group have four classes over a one-month period to better match the program of the intervention group. The material for the standard curriculum includes anatomical and physiological changes during pregnancy, pregnancy care, birth, and postpartum care. The classes also address family planning after giving birth, newborn care, preventing infectious disease, and procedures for obtaining a birth certificate. The midwives also discuss and debunk unhealthy local myths, beliefs, and cultural practices surrounding pregnancy, childbirth and the postpartum period
88800900|NCT04759118|Experimental|Experimental group|The modified childbirth education program was applied in the experimental group. the intervention covered modification of content material, learning methods, and involving husband or other relatives during the class.
89233173|NCT02816021|Experimental|Arm B: Metastatic Melanoma - Post PD-1 Progression|"Thirty-five participants with metastatic melanoma that have progressed on PD-1 directed therapy enrolled in treatment Arm B.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
88800901|NCT04121702|Active Comparator|PEP-H|Physical exercise program at a hospital
88800902|NCT04121702|Experimental|PEP-PSC|Physical exercise program with tele-monitoring in a public sport centre
88800903|NCT00972959|Experimental|Bortezomib/Dexamethasone/Zoledronic Acid|"For this study, Velcade will be administered at the standard dose of 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle.~Dexamethasone will be administered at a dose of 12 mg/m2 p.o., on days 1-2, 4-5, 8-9 and 11-12 of the same cycle.~Zoledronic acid will be administered at a dose of 4 mg, iv (15-minute infusion), every 28 days for up to 8 cycles, and then every 28 days for the next 18 months"
88800904|NCT05609318||iron-deficient|patients prescribed intravenous iron infusion for the treatment of iron deficiency as part of standard clinical care
88800905|NCT00973739|Experimental|Lapatinib|"Lapatinib PO dosed according to age:~Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily~Adults (18 years of age or older): 1,500 mg PO once daily~Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment."
88800908|NCT00974051|Active Comparator|Control|Subjects complete the same exercise routine, however no treatment is given at 9:00pm.
88800909|NCT00974051|Experimental|Terbutaline|Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered.
88800910|NCT00974051|Experimental|20% Basal Insulin Reduction|All subjects complete the same exercise session. At 9:00pm, subject's basal rate is decreased by 20% for six hours.
88800911|NCT04129814|Experimental|test group|Non-surgical periodontal treatment consisted of oral hygiene instructions (OHI), single session full-mouth scaling and root planing (SRP)
88800912|NCT04129814|No Intervention|control group|no periodontal treatment was performed during the follow-up period in the control group.
88800913|NCT00974363|Experimental|Group A|Subjects who received GSK Biologicals' meningococcal vaccine 134612 in the primary vaccination study 109069.
88800914|NCT00974363|Active Comparator|Group B|Subjects who received MencevaxTM ACWY in the primary vaccination study 109069.
88800915|NCT04129892|Experimental|Course participants|Students that enroll in the Resilience-based course during their Bachelor of science or Bachelor of social studies.
88800916|NCT04129892|No Intervention|Control group- no intervention|Students in their Bachelor of science or Bachelor of social studies that did not attend the course, but agreed to fill out the study questionnaires.
88800917|NCT05604248|Other|Lactating mother-infant pair|"8 arms of 7 lactating women for a total of 56 women following a study design integrating a model-based compartmental analysis with the Retinol Isotope Dilution (RID) technique using a Wonder women approach.~For infants, the RID test will start at day 14. After the baseline blood, they will receive 1.0 μmol 13C2-retinyl acetate and will have a second blood sample at day 28."
88805870|NCT04042142|Active Comparator|Healthy overweight subjects|MR spectroscopy verified no steatosis
88805871|NCT04042142|Active Comparator|Subjects with non-alcoholic fatty liver disease|MR spectroscopy verified steatosis, no steatohepatitis on liver biopsy
89233174|NCT02808780||Simponi-exposed cohort|Participants receiving Simponi at enrollment and are still receiving Simponi after participation in a therapeutic trial or participants scheduled to receive Simponi within 30 days after enrollment. Participants in this cohort may be receiving Simponi alone or in combination with thiopurines but must not be receiving other approved biologics or investigational agents at enrollment. Participants may have received other approved biologics or investigational agents prior to enrollment.
89233175|NCT02808780||Thiopurine cohort|Participants currently receiving thiopurines, having received at least 12 consecutive weeks of therapy prior to registry entry. Participants must not be receiving approved biologic agents, including Simponi, or investigational agents at enrollment. These patients may have received biologics other than Simponi or investigational agents prior to enrollment.
89233176|NCT02755584||Healthy Volunteers|between the ages of 20-39 years and 70 years old and older
89233177|NCT02728336|Active Comparator|Heart Failure Patients|patients who are scheduled to undergo clinically ordered CRT for heart failure complicated by dyssynchrony
89233178|NCT02728336|Active Comparator|Control|20 matched control subjects
89233179|NCT02724371|Experimental|Primary Breast Reconstruction|Participants who meet the requirements for primary breast reconstruction (have not had previous silicone or saline breast implants, not including tissue expanders) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
88800918|NCT03017963|Experimental|dose-escalation cohort|Patients are divided in 6 groups of 3 patients to receive the following intervention: 0 gram (g), 2.5 g, 5 g, 10 g, 12.5 g and 15 g of sodium thiosulfate pentahydrate (STS) intravenous. The first dose is given in 15 min immediately after inclusion at the cath-lab. In the absence of dose-limiting toxicity (DLT), a second gift of STS is given in 30 min, 6 hours later at the coronary care unit (CCU). When no DLT is observed in any of the patients after 2 gifts of the same dose an extra 3 subjects are enrolled into the next higher dose cohort. If 1 out of 3 patient develops DLT at a specific dose, an extra 3 subjects are enrolled into the same dose cohort. When more than 1 out of 6 patients develop DLT the trial will be terminated because the maximum tolerable dose (MTD) has been exceeded.
88800919|NCT04121390||Newborn Parenting Class|New Mother who attended the Newborn Parenting Class
88800920|NCT04121390||New Mothers|New Mothers who expressed interest, but did not attend the Newborn Parenting Class
88800921|NCT03018353|Other|Navigation services with sof/vel therapy|This a single group demonstration project in which, patients are treated with the FDA-approved drug, Sofosbuvir/Velpatasvir (Epclusa). If a patients is released during their treatment regimen, they will receive patient navigation services to continue their care and treatment in the community.
88800922|NCT04120844|Experimental|Intervention|Patients in the intervention group (n=117) received a four-session PEP in small groups over one month by trained nurses and doctors.
88800923|NCT04120844|Placebo Comparator|Control|The control group (n=108) received the traditional lecture-style health education on Diabetes Mellitus.
88800924|NCT00977171|Experimental|Droxidopa|
88800925|NCT04121000|Experimental|Erector Spinae Block for VATS Group|40 patients who had VATS will receive erector spinae block for postoperative pain management. All patients will receive IV Midazolam (0.05mg/kg) premediacation. Standard monitorization of EKG, non- invasive blood pressure and pulsoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the induction and in the prone positon the ESB procedure will be done. 10 % povidon- iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done at the 8th thoracic vertebra line. The USG probe will be replaced 2-3 cm lateral to the spinous process in sagittal plane. When the erector spinae muscle is identified in the USG the needle will be guided caudally.0.5-1 ml local anesthetics will be given in order to confirm the needle is in the right place. After confirmation with 20 mL %0.25 bupivacaine the procedure will be performed.
88800926|NCT04121000|Experimental|Patient - Controlled Analgesia for VATS Group|40 patients who had VATS will receive IV PCA for postoperative analgesia managemnet.
88800927|NCT04129424|Experimental|Type 1 diabetes mellitus_7-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800928|NCT04129424|Experimental|Type 1 diabetes mellitus_14-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800929|NCT04129424|Experimental|Type 1 diabetes mellitus_28-day group|Type 1 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800930|NCT04129424|Experimental|Type 2 diabetes mellitus_7-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800931|NCT04129424|Experimental|Type 2 diabetes mellitus_14-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800932|NCT04129424|Experimental|Type 2 diabetes mellitus_28-day group|Type 2 diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800933|NCT04129424|Experimental|Gestational diabetes mellitus_7-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800934|NCT04129424|Experimental|Gestational diabetes mellitus_14-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800935|NCT04129424|Experimental|Gestational diabetes mellitus_28-day group|Gestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
89233180|NCT02724371|Experimental|Revision Breast Reconstruction|participants who meet the requirements for revision breast reconstruction (have had previous silicone or saline breast implants) and have been implanted with Mentor Larger Size MemoryGel Ultra High Profile Breast implants
88800936|NCT04129424|Experimental|Pregestational diabetes mellitus_7-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800937|NCT04129424|Experimental|Pregestational diabetes mellitus_14-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800938|NCT04129424|Experimental|Pregestational diabetes mellitus_28-day group|Pregestational diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800939|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _7-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800940|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _14-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800941|NCT04129424|Experimental|Pancreatogenic diabetes mellitus _28-day group|Pancreatogenic diabetes mellitus patients aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800942|NCT04129424|Experimental|Diabetes patients in perioperative period _7-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 7 days. After 7 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800943|NCT04129424|Experimental|Diabetes patients in perioperative period _14-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 14 days. After 14 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800944|NCT04129424|Experimental|Diabetes patients in perioperative period _28-day group|Diabetes patients in perioperative period aimed to reach goal blood glucose in 28 days. After 28 days, CGM was planed to apply for another 6 days to evaluate their blood glucose level and adjust insulin dose if necessary.
88800945|NCT00955487|Experimental|Inhaled Nitric Oxide (iNO)|Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.
88800946|NCT00955487|Placebo Comparator|Nitrogen (placebo)|Participants will receive nitrogen (placebo) while in the hospital.
88800947|NCT04120922|Other|calcium carbonate|"Calcium based P-binder - calcium carbonate: Typical dose is 500mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
88800948|NCT04120922|Other|sevelamer carbonate|"Calcium (Ca) free P-binder - sevelamer carbonate: Typical dose is 800mg, orally, three times a day but this can be adjusted as per individual patient requirements at the clinician's discretion.~All participants will be given sevelamer carbonate (Ca-free P-binder) for up to 16 weeks and then calcium carbonate (Ca-based P-binder) for 12 weeks, administered orally. No wash out period is possible as the children must always be on a P-binder. The Ca-free P-binder may be administered for less than 16 weeks if it is clinically necessary to resume the Ca-based P-binder early based on serial monitoring of serum Ca levels."
89233184|NCT02675764|Experimental|Experimental|The experimental group receives the wrist subthreshold vibrotactile stimulation during therapy.
89233185|NCT02675764|Active Comparator|Placebo|"The control group will wear the vibration device with no vibration.~Both groups cannot feel the vibration since the vibration intensity is set below the perceptible level.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
88800949|NCT01663740|Experimental|Cohort A: Partcipants who Received Valganciclovir|Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant.
88800950|NCT01663740|No Intervention|Cohort B: Untreated Participants|Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.
88800951|NCT04758884|Experimental|Telemedicine group|"Visits by videoconference in months 0, 1, 2, 3, 4 and 6. Additionally, availability to send intermediate messages with a response from the endocrine in less than 72 hours.~The videoconference will be held safely through the SocialDiabetes® App. Patients will be provided with a glucometer that transfers the data directly to the App without the patient having to enter it to avoid bias in time and value. Videoconferences will NOT be recorded.~Patients with CGM will additionally have all their values on the platform that corresponds to their sensor (Libreview® for the Freesyle libre® sensor and Clarity® for the Dexcom G5 sensor)."
88800952|NCT04758884|No Intervention|Conventional management group|Initial visit, 3 and 6 months.
89233186|NCT02639299||Healthy volunteer|healthy, malaria-na(SqrRoot) ve US adults
89233187|NCT02636569|Active Comparator|diclofenac once daily|Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
89233188|NCT02636569|Placebo Comparator|placebo|The topical medication will will be applied onto the skin of one arm, once daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
89233189|NCT02632123||Development cohort|Patients newly diagnosed with idiopathic pulmonary fibrosis
88800953|NCT04129190|Experimental|Single|
88800954|NCT02984228|Active Comparator|Platelet-rich plasma (PRP)|Patients will receive an injection of PRP.
88800955|NCT02984228|Active Comparator|Hyaluronic Acid|Patients will receive an injection of hyaluronic acid.
88800956|NCT05501184|Experimental|Synchronous Telerehabilitation Group|The exercise program was applied to groups that include three participants of the synchronous group 3 days per week by video conference method on an online platform (Zoom) with the supervision of a physiotherapist. The time of the group session was organized according to the availability of participants in that group and the physiotherapist using shared calendar availability (Doodle). The physiotherapist sent a reminder to participants one hour prior to each session including the video conference meeting link. Each exercise session lasted approximately 40 minutes. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist demonstrated the exercises as needed, supervised the group by giving real-time feedback, and progressed the exercise program according to the needs of each group.
88800957|NCT05501184|Active Comparator|Asynchronous Telerehabilitation Group|The exercise program was prescribed and followed up 3 days per week via the mobile application (FizyoTr). A notification was sent to participants' phones via mobile application prior to each session and attendance to the exercise program was recorded. For 8 weeks, a total of 24 exercise sessions were performed. The physiotherapist progressed the exercise program according to the assessment at 4 weeks and the needs of each participant.
88800958|NCT00979121|Active Comparator|Rosuvastatin|"Half of the subjects were randomized to the active drug (Rosuvastatin).~Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy.~Duration: drug was administered daily until:~28 days after randomization or 3 days after ICU discharge (whichever comes first),~Discharge from study hospital,~Death"
88800959|NCT00979121|Placebo Comparator|Placebo|"Half of the subjects were randomized to placebo.~10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug."
88800960|NCT03828032|Experimental|Mannitol injection|The participant receive mannitol injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
88800961|NCT03828032|Experimental|Hypertonic saline injection|The participant receive hypertonic saline of specific concentration injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
88800962|NCT03827876|Experimental|Open Label Enstilar|once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
88800963|NCT02960282||Ancillary-Correlative (gut microbiome analysis)|Patients undergo collection of fecal specimens at baseline, prior to start of each course of chemotherapy or immunotherapy, at the end of weeks 2, 4, 6, and 8, at the end of course 3 and courses thereafter of chemotherapy or immunotherapy, and at the time of disease progression or going off-treatment. Fecal specimens are analyzed via 16S ribosomal RNA gene sequencing, meta-transcriptomics analysis, and meta-proteomics analysis.
88800964|NCT01960127|Experimental|Aerobic Exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
88800965|NCT01960127|Placebo Comparator|Usual Care Group|These patients will continue with their normal daily activity ad will not be provided with supervised aerobic exercise training during the study period.
88800966|NCT03898934|Experimental|Vitamin D group|These patients will receive 6000IU daily for 8 weeks then 2000IU maintenance till pregnancy or end of study
88800967|NCT03898934|Placebo Comparator|Placebo group|These group will receive placebo for the same periods of study group
88800968|NCT00979199|Other|Non invasive cardiac imaging|Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.
88800969|NCT04128800|Experimental|Apatinib and S-1 group|
88800970|NCT04129112||Patients without body movements|Patient who, under general anesthesia without curare agents, during surgery has no body movements
89233190|NCT02632123||Validation cohort|Patients newly diagnosed with idiopathic pulmonary fibrosis
88800971|NCT04129112||Patients with body movements|Patient who, under general anesthesia without curare agents, during surgery has any body movements that are no reflexes movements
88800972|NCT01608893|Active Comparator|Metoprolol|The metoprolol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and metoprolol is dose titrated from 25 mg bid to a maximum of 50 mg bid over one month then patients are followed for 6 months.
88800973|NCT01608893|Active Comparator|Carvedilol|The carvedilol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and carvedilol is dose titrated from 3.25 mg bid to maximum dose of 25 mg bid over one month then patients are followed for 6 months.
88805872|NCT04042142|Active Comparator|Subjects with non-alcoholic steatohepatitis|MR spectroscopy verified steatosis, steatohepatitis on liver biopsy
89120515|NCT02871869|Experimental|Trial group B|Trial group B was treated with Cinobufacini Tablets combined with CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
89120516|NCT02573545|Experimental|Test group: with IFE|Patients treated with IFE software
89120517|NCT02573545|Active Comparator|Test group: without IFE|Patients treated with Numaris 4 software
89120518|NCT01013597|Experimental|LBH589|
89120519|NCT04548947|Experimental|Cold snare polypectomy with a submucosal injection|The procedure will include a cold snare polypectomy with a submucosal injection done prior to the resection.
89120520|NCT00715273|Active Comparator|1 - single therapy group|Participants will receive atorvastatin, placebo niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the single therapy group.
89120521|NCT00715273|Experimental|2 - double therapy group|Participants will receive atorvastatin, niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the double therapy group.
89120522|NCT00715273|Experimental|3 - triple therapy group|Participants will receive atorvastatin, niacin, and colesevelam. The treatment target for LDL-C will be ≤60 mg/dl for the triple therapy group
89120523|NCT01013285|Experimental|bevacizumab, temozolomide, external beam radiation|
89120524|NCT00715351||A|
89120525|NCT00715351||B|
89120526|NCT00711451|Active Comparator|manual|Manual removal of placenta
89120527|NCT00711451|Active Comparator|expressed|expressed placental removal
89120528|NCT04018885|Experimental|ALA 2.5% 0.5h|Topical application of 2.5% ALA for 0.5 hour
89120529|NCT04018885|Experimental|ALA 2.5% 1.5h|Topical application of 2.5% ALA for 1.5 hours
89120530|NCT04018885|Experimental|ALA 2.5% 3h|Topical application of 2.5% ALA for 3 hours
89120531|NCT04018885|Experimental|ALA 5% 0.5h|Topical application of 5% ALA for 0.5 hour
89120532|NCT04018885|Experimental|ALA 5% 1.5h|Topical application of 5% ALA for 1.5 hours
89120533|NCT04018885|Experimental|ALA 5% 3h|Topical application of 5% ALA for 3 hours
89120534|NCT04018885|Experimental|ALA 10% 0.5h|Topical application of 10% ALA for 0.5 hour
89120535|NCT04018885|Experimental|ALA 10% 1.5h|Topical application of 10% ALA for 1.5 hours
89120536|NCT04018885|Experimental|ALA 10% 3h|Topical application of 10% ALA for 3 hours
89120537|NCT02574325|Placebo Comparator|Placebo|Placebo
89120538|NCT02574325|Experimental|ARI-3037MO|ARI-3037MO
89120539|NCT03912181||Familial chylomicronaemia syndrome (FCS)|"Patient homozygous or compound heterozygous mutation in lipoprotein lipase (LPL) gene~Patient homozygous or compound heterozygous mutation in any Apolipoprotein A5 (Apo A5), glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2), genes and heterozygous (het) mutation in LPL gene"
89120540|NCT03912181||Multifactorial chylomicronemia syndrome|"Patient with heterozygous mutation in lipoprotein lipase (LPL) , Apolipoprotein A5 (Apo AV), GPI HBP1, LMF1, ApoC2 genes and any additional combination of functional variant~Patient with any additional combination of functional variant in LPL gene Apo AV, glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 (GPI HBP1), lipase maturation factor 1 (LMF1), Apolipoprotein C2 (ApoC2) genes"
89120541|NCT00715507||1|For the phase of the study in which the utility of the graphical medication monitor is assessed, the monitor will not be shown to anesthesiologists placed in the control condition.
89120542|NCT00715507||2|In the experimental condition, anesthesiologists will be shown the medication monitor to aid their expertise and decision-making.
89120543|NCT02573389|No Intervention|"Retrospective and prospective non-stented"|Non-stented patients undergoing distal pancreatectomy retrospectively (2008-2015) and prospectively from 2015 to 2017.
89120544|NCT02573389|Experimental|"Prospective stented"|Patients who undergo prophylactic pancreatic duct stenting prior to a distal pancreatectomy starting approximately September 2015.
89120545|NCT00711841|Placebo Comparator|saline solution|Placebo (saline solution), 2 mL, intravenous, every 12 hours, for 48 hours
89120546|NCT00711841|Active Comparator|Dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
89120547|NCT00711919|Active Comparator|1|Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months. After administration, serum LDL-cholesterol should be kept between 100 and 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
89120548|NCT00711919|Active Comparator|2|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months. After administration, serum LDL-cholesterol should be kept under 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
89120549|NCT04073095|Active Comparator|Group T = mTLIP block group|In group T, mTLIP block will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).
89120550|NCT04073095|Active Comparator|Group E = ESPB group|In group E, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).
89120551|NCT04073095|No Intervention|Group C = Control group|Patients in control group will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
89120552|NCT00715585|Active Comparator|Active Control|patients receive 3 individualized visits with a health educator for education on general diabetes and health promotion
88800974|NCT04128878||Atrial Fibrillation Cohort|Adult patients with known or new diagnosis of either paroxysmal or persistent atrial fibrillation seen at the electrophysiology outpatient clinic and admitted to the electrophysiology service for initiation of anti-arrhythmic medications (dofetilide or sotalol).
88800975|NCT00979745|Experimental|Afamelanotide|
88800976|NCT00979745|Placebo Comparator|Placebo|
88800977|NCT04120532|Experimental|Education group|
88800978|NCT04120532|No Intervention|Usual care group|
88800979|NCT03828110||Children with neurological impairment|
88800980|NCT03827954|Experimental|Experimental Treatment|HeartMapp+CT
88800981|NCT00980681|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg.
88800982|NCT00980681|Other|Time Of Flight|Each subject will undergo a TOF Magnetic Resonance Angiography
88800983|NCT03828188|Experimental|group A|"Red Ginseng Concentrated Powder in 12 weeks → rest in 4 weeks → Placebo 12 weeks.~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
88800984|NCT03828188|Experimental|group B|"Placebo 12 weeks→ rest in 4 weeks → Red Ginseng Concentrated Powder in 12 weeks.~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
88800985|NCT04759040|Active Comparator|MigraineGuard|Active supplement treatment , MigraineGuard capsule containing Coq10 , Magnesium ,Vit B2 , Skullcap Extract , Feverfew Extract , Piperine
88800986|NCT04759040|Placebo Comparator|Placebo for MigraineGuard|Placebo capsules non identifiable from Migraineguard capsules were used as control comparator
88800987|NCT04759196|Active Comparator|NESIS - Levetiracetam|"Participant with a score NESIS of 4 or more (increased risk of having cortical depression).~Levetiracetam is an anti-epileptic drug known to be inefficient in other condition with cortical depression. It will be use as an active comparator."
88800988|NCT04759196|Experimental|NESIS - Topiramate|"Participant with a score NESIS of 4 or more (increased risk of having cortical depression).~Topiramate is an anti-epileptic drug known to be efficient in other condition with cortical depression. The investigators want to test his efficacy in chronic subdural hematoma with probable cortical depression."
88800989|NCT04759196|Active Comparator|Non NESIS - Levetiracetam|"Participant with a score NESIS of 3 or less (increased risk of having epileptic discharges).~Levetiracetam is an anti-epileptic drug known to be inefficient in other condition with cortical depression. It will be use as an active comparator.~Levetiracetam should be as efficient as Topiramate in a group a participant with epileptic discharges."
88800990|NCT04759196|Experimental|Non-NESIS - Topiramate|"Participant with a score NESIS of 3 or less (increased risk of having epileptic discharges).~Topiramate is an anti-epileptic drug known to be efficient in other condition with cortical depression. The investigators want to test his efficacy in chronic subdural hematoma with probable cortical depression.~Topiramate should be as efficient as Levetiracetam in a group a participant with epileptic discharges."
88800991|NCT05506020|Experimental|ICG group|indocyanine green (ICG) fluorescence cholangiography
88800992|NCT05506020|No Intervention|non ICG group|no intervention
88800993|NCT04128332|Other|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) delivering 35Gy in five fractions (7Gy/fraction) over 5 days.
88800994|NCT05501106|No Intervention|Comparison Arm|All hospitals will receive general interventions (comparison program), including: recommendation for implementing quality improvement programs to reduce vaginal delivery complications; trainings on obstetric quality management and clinical skills on the prediction and treatment of vaginal delivery complications (3 times a year); monitoring postpartum hemorrhage after vaginal delivery and reporting data to the NCHQMO by monitoring platform every month.
88800995|NCT05501106|Experimental|Experimental Arm|The hospitals in the experimental group will receive general interventions and additionally implement integrated improvement strategies which include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases (detailed in the Intervention Description).
88800996|NCT04274114|Experimental|Experimental group|Patients in this group will receive flexible doses of L-glutamine ranging from 5 to 25 grams once daily for 8 weeks. L-glutamine is administered as a powder dissolved in water.
88800997|NCT04274114|Placebo Comparator|Placebo group|Patients in this group will receive flexible doses of placebo ranging from 5 to 25 grams once daily for 8 weeks. Placebo is administered as a powder dissolved in water.
88800998|NCT05501028||Patients scheduled for consult with gastroenterologist|
88800999|NCT05501028||Patients scheduled for diagnostic endoscopy|
88801000|NCT04737642|Experimental|Papillary ballon dilatation|
88801001|NCT04128410||T1|At 5 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
89120553|NCT00715585|Experimental|Intervention 1|patients receive 3 individualized visits with an rd-cde for education focused on modified plate method
89120554|NCT00715585|Experimental|intervention 2|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
89120555|NCT01033643|Experimental|MK-3614 0.25 mg (Panel A)|Participants received 0.25 mg of MK-3614 twice daily (BID) every 12 hours orally for 10 days.
89120556|NCT01033643|Experimental|MK-3614 0.50/0.25 mg (Panel B)|Participants received 0.50 mg of MK-3614 in the morning (AM) and 0.25 mg of MK-3614 in the evening (PM) 12 hours apart orally for 10 days.
89120557|NCT01033643|Experimental|MK-3614 0.50/0.25 mg (Panel C Repeat)|Participants were to receive 0.75 mg of MK-3614 BID every 12 hours orally for 10 Days. Per protocol amendment, the Panel B dose was repeated, and participants received instead 0.50 mg of MK-3614 in the AM, and 0.25 mg of MK-3614 in the PM, 12 hours apart orally for 10 days.
89120558|NCT01033643|Experimental|MK-3614 0.50 mg (Panel D)|Participants received 0.50 mg of MK-3614 three times a day (TID) orally every 8 hours on Day 1 followed by a wash out period for Days 2, 3 and 0.50 mg of MK-3614 every 12 hours orally for 10 days (Days 4-13).
89120559|NCT01033643|Experimental|MK-3614 0.50 mg (Panel E)|Participants were to receive orally 0.50 mg of MK-3614 BID every 12 hours on Day 1 followed by 3 doses (0.50/0.50/0.25 mg) of MK-3614 each 8 hours apart on Day 2; three doses of 0.50 mg of MK-3614 8 hours apart on Days 3,4; and 0.75 mg of MK-3614 BID every 12 hours on Days 5-14. No participants were enrolled in this group.
89120560|NCT01033643|Placebo Comparator|Placebo (All Panels)|Participants received a dose matched placebo orally according to randomization.
89120561|NCT00715663||A|
89120562|NCT04070599|Experimental|Single arm|Study of lymphocyte subpopulations, cytokine assays, identification of autoantibodies, study of CD40 platelet ligand, thrombopoietin assay
89120563|NCT00712231||phakic eyes|the cases did not accept any intraocular surgery
89120564|NCT00712231||pseudophakic eyes|tht cases did not accept any intraocular surgery expect for cataract surgery
89120565|NCT01013207|Experimental|Nexus (S9) CPAP device|"Fifty subjects with obstructive sleep apnea (OSA), established on CPAP therapy (≥ 6 months) were recruited into this study. These patients use their CPAP device every night while sleeping to treat their OSA.~Nexus (S9) is a new CPAP device with improved humidification system (heated tube and climate control), reduced noise, improved comfort of breathing and new user interface. During the study, patients will use this CPAP every night in place of their own CPAP for a period of 4 weeks. Compliance data from the Nexus will then be compared to the patient's usual CPAP pre trialling Nexus and post trialling Nexus."
89120566|NCT00715897|Experimental|Treatment- HBOT|HBOT treatment: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
89120567|NCT00715897|No Intervention|control-HBOT|Cross group: Patients in the cross group were evaluated three times-baseline, after 2 months control period of no treatment and after a consequent 2 month of HBOT
89120568|NCT00712309|Active Comparator|1|Percutaneous transluminal angioplasty (PTA)
89120569|NCT00712309|Active Comparator|2|Primary stenting
89120570|NCT02574091|Experimental|Cohort 1-Experimental|"4 healthy adult participants will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
89120571|NCT02574091|Placebo Comparator|Cohort 1-Placebo|"2 healthy adult participants will be randomized to receive placebo (blank cream), applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
89120572|NCT02574091|Experimental|Cohort 2-Experimental|"4 healthy adult participants will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
89120573|NCT02574091|Placebo Comparator|Cohort 2-Placebo|"2 healthy adult participants will be randomized to receive matching placebo, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
89120574|NCT02574091|Experimental|Cohort 3-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
89120575|NCT02574091|Placebo Comparator|Cohort 3-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
89120576|NCT02574091|Experimental|Cohort 4-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
89120577|NCT02574091|Placebo Comparator|Cohort 4-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
89120578|NCT00712387|No Intervention|A|General surgical trainees who will receive the 'traditional' training programme; i.e. will receive whatever clinical training on a patient their supervising consultant deems appropriate. This is the way junior surgeons are currently trained. They will also receive the standard didactic teaching on the School for Surgeons e-learning resource.
89120579|NCT00712387|Active Comparator|B|Surgical trainees who are assigned to the 'proficiency-based progression' training programme. These trainees will be required to train on the virtual reality simulator (Lap Sim™) for a laparoscopic cholecystectomy. Trainees will have objectively set goals to reach on the simulator and will have to demonstrate proficiency before they are permitted to progress to the next, more challenging level. Group B will also receive the standard School for Surgeons instruction but, unlike Group A, they will have to demonstrate proficiency on the didactic module before they progress to the operating theatre
89120580|NCT00712465|Experimental|1|AZD1305 tablet
89120581|NCT00712465|Experimental|2|AZD1305 tablet + digoxin
89120582|NCT00712465|Active Comparator|3|Digoxin
89120583|NCT00715975|Experimental|1|The patients will be treated with halobetasol once a day for 15 days.
89120584|NCT00715975|Experimental|2|The patients will be treated with clobetasol once a day for 15 days.
89120585|NCT01033487|Placebo Comparator|Placebo|
89120586|NCT01033487|Active Comparator|active comparator|
89120587|NCT01033487|Experimental|PF-03635659|
89120588|NCT00716053|Experimental|BLVR|
89120589|NCT00716053|Sham Comparator|Saline|
89120590|NCT04018963||Uninostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the single nostril approach.
89120591|NCT04018963||Binostril group|Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the bilateral nostril approach.
89120592|NCT02572687|Experimental|Ramucirumab + MEDI4736 (NSCLC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given intravenously (IV) every 3 weeks (q3w) of a 21 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q3w. Participants may continue to receive study treatment until discontinuation criteria are met."
89120593|NCT02572687|Experimental|Ramucirumab + MEDI4736 (Gastric/GEJ)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV every 2 weeks (q2w) of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
89120594|NCT02572687|Experimental|Ramucirumab + MEDI4736 (HCC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV q2w of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
89120595|NCT00716131||ALS|Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
89120596|NCT00716131||Neuro|Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
89120597|NCT00716131||Healthy|Normal Controls
89120598|NCT00716131||Autopsy|
89120599|NCT00712621|Other|I|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm I: Quality of life is assessed at baseline and at 3 and 6 months."
89120600|NCT00712621|Other|II|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm II: Quality of life is assessed at baseline and at 3 and 6 months."
89120601|NCT01033019|Experimental|LDE225 0.75%|Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
89120602|NCT01033019|Placebo Comparator|Vehicle|Participants topically applied matching placebo cream twice daily for 6 weeks.
89120603|NCT04205279|Experimental|Treadmill training|Subjects randomly assigned to the treadmill training, would undergo either a stance or walking perturbation training protocol. The stroke subjects and older adults would be assigned to either the stance or walking perturbation training protocol. All the participants would be asked to perform voluntary stepping, backward and forward with both limbs pre and post perturbation training. Also, all the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd.
89120604|NCT04205279|Experimental|Overground training|Subjects randomly assigned to overground slip will be made to walk at their comfortable natural walking speeds either for 5-8 trials on the instrumented walkway (7 m 1.5 m) at their self-selected preferred speed. All the participants would perform walking trials with head mounted virtual reality system under three conditions: ice, beach and crowd. After establishing baseline walking ability, a slip will be introduced without warning which will comprise the baseline slip test followed by a trip in the form of the trip plate. This is followed by a block of 8 trials for slip training, block of 8 trials for trip training and then the mixed block consisting of slip and trip trials interspersed with walking trials. Slips and trips could be induced under either of the limbs.
89120605|NCT04205279|Experimental|Surefooted training|"Subjects randomly assigned to Surefooted (Surefooted LLC) would be donned a safety harness and instructed that when you experience slip-like or trip-like movements, try to keep walking on the platform. Subjects would undergo 4-minute training block on each of the 6 different conditions. The first 3 training blocks would be unidirectional perturbation (either slip or trip) followed by 3 training blocks of mixed directional perturbations while the subjects are walking on the platform. 3 surface conditions- slippery (vinyl surface plate), normal friction with obstacles (surface plate with 6 tall structures embedded), and a foam surface with obstacles embedded would be used."
89120606|NCT00716209||1|Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)
89120607|NCT00712777|Active Comparator|1|homozygote mutant: Insertion/Insertion (40 patients)
89120608|NCT00712777|Active Comparator|2|homozygote mutant: Deletion/Deletion (40 patients)
89120609|NCT00603447|Experimental|Carfilzomib + Lenalidomide + Dexamethasone|Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
89120610|NCT00718627|Experimental|HHLivC Therapy Group|
89120611|NCT03989167|Experimental|Intervention group|Group receiving the Clinical decision support
89120612|NCT03989167|No Intervention|Control group|Group receiving standard care
89120613|NCT00718705|Experimental|1|josamycin
89290095|NCT03783702|Experimental|Experimental group|Patients in the experimental group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is ibuprofen (600mg tablet by mouth every 6 hours). Oxycodone (5mg tablet by mouth every 4 hours) will be the third-line medication to be used if acetaminophen and ibuprofen do not sufficiently control the pain.
89290096|NCT03783702|Active Comparator|Control group|Patients in the control group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is oxycodone (5mg tablet by mouth every 4 hours).
89120614|NCT00718705|Placebo Comparator|2|Placebo
89120615|NCT02687685|Experimental|Skin to skin contact immediate|At birth, the baby will be placed and dried on the breast of his mother where thermoregulation manoeuvres will be applied and once the cord clamping procedure has taken place; the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least one hour or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, it will be allowed again after these interventions. During immediate SSC, mother and baby receive continuous monitoring by the health staff
89120616|NCT02687685|Active Comparator|skin to skin contact early|At birth, the baby will be dried and placed on the abdomen and chest of his mother where thermoregulation manoeuvres are applied once there is an indication that the cord clamp procedure has been completed. At this time the baby will go to the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby who has 60 minutes of life, will proceed with the initiation of SSC for at least one hour or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC the mother and baby will receive monitoring by health personnel
89120617|NCT00716287||1|Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.
89120618|NCT00639015|Experimental|1|Phenylephrine
89120619|NCT00639015|Active Comparator|2|Norepinephrine
89120620|NCT00718783||Retinoblastoma|
89120621|NCT04186143|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, closed cinetic chain exercises were applied for 12 weeks.
89120622|NCT04186143|Active Comparator|Active Comparator|In addition to the conservative treatment of the control group, opened cinetic chain exercises were applied for 12 weeks.
89120623|NCT04186143|Other|Control Group|Conservative treatment was applied for 12 weeks.
89120624|NCT00712855|Experimental|A|mapatumumab and sorafenib
89120625|NCT04185987|Experimental|Microbial colonisation|microbial sample collection was done at the end of the time periods T1 (6 weeks after bonding ), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
89120626|NCT04185987|Experimental|Plaque index|Plaque index was measured prior to bonding (T0), 6 weeks after bonding (T1),10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
89120627|NCT04185987|Experimental|Gingival index|Gingival index was measured prior to bonding (T0), 6 weeks after bonding (T1), 10 weeks after bonding (T2), 14 weeks after bonding (T3), 18 weeks after bonding (T4)
89120628|NCT04185987|Experimental|surface roughness|surface roughness was measured before usage and after 4-weeks usage
89120629|NCT02537925|Active Comparator|concurrent_radiochemotherapy|Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
89120630|NCT02537925|Experimental|celecoxib_radiochemotherapy|Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
89120631|NCT00713011|Experimental|Arm 1|
89120632|NCT00713011|Active Comparator|Arm 2|
89120633|NCT02687295|Placebo Comparator|Control group|Control group subjects received the same diet restriction intervention as treatment group. However, their food products did not contain any active component.
89120634|NCT02687295|Active Comparator|Thylakoid group|Thylakoid group subjects received the same diet restriction intervention as the control group. However, their food products did contain an active component in the form of thylakoid powder.
89120635|NCT00716365|Experimental|HemCon|"The purpose of this trial is to test HemCon pad after diagnostic percutaneous coronary angiography as an adjunct to manual compression to better control vascular access site bleeding and reduce time-to-hemostasis.~The HemCon bandage (containing a carbohydrate called chitosan, found in the shells of shrimp, lobster and beetles) will be used to shorten the time needed to achieve hemostasis, time to patient's ambulation, and patient's."
89120636|NCT02537769|Experimental|LVAD+TVR|In addition to left ventricular assist device (LVAD) placement with the inflow cannula in the left ventricular apex and outflow cannula placed in the ascending aorta, a repair of the regurgitating tricuspid valve will be performed. A Patent Foramen Ovale, if present, will be closed primarily. Echocardiographic parameters relevant to study will be collected throughout the procedure.
89120637|NCT02537769|Active Comparator|LVAD only|LVAD placement will be performed without additional tricuspid valve repair (TVR). The inflow cannula will be sutured to the left ventricular apex followed by the outflow cannula placed in the ascending aorta. This will be performed under cardiopulmonary bypass. Echocardiographic parameters relevant to study will be collected throughout the procedure.
89120638|NCT04185675|Active Comparator|Macintosh laryngoscope|
89120639|NCT04185675|Experimental|nonadjustable videolaryngoscope|
89120640|NCT04185675|Experimental|adjustable videolaryngoscope|
89120641|NCT04208061|Experimental|Panel 1: Dabigatran etexilate +DRV/COBI|Participants will receive Treatment A (single dose of Dabigatran etexilate orally) on Day 1 followed by Treatment B (single dose of Darunavir/ cobicistat [DRV/COBI] as fixed dose combination tablet orally and single dose of dabigatran etexilate) on Day 4 followed by Treatment C ([DRV/COBI] as fixed dose combination tablet orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
89120642|NCT04208061|Experimental|Panel 2: Dabigatran etexilate +DRV+rtv|Participants will receive Treatment D (single dose of dabigatran etexilate orally) on Day 1 followed by Treatment E (single doses of Darunavir, and ritonavir [rtv], and single dose of dabigatran etexilate on Day 4), followed by Treatment F (DRV and rtv orally once daily from Day 5 to Day 20 and single dose of dabigatran etexilate on Day 18).
89120643|NCT02687373|Experimental|Part 1: Grp 1A - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination."
89120644|NCT02687373|Placebo Comparator|Part 1: Grp 1A - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination."
89120645|NCT02687373|Experimental|Part 1: Grp 1B - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120646|NCT02687373|Placebo Comparator|Part 1: Grp 1B - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89290097|NCT01319734|Experimental|Vitamin C supplementation plus oral hypoglycemic agents arm|This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.
88801002|NCT04128410||T2|At 10 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
88801003|NCT04128410||T3|At 15 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
88801004|NCT04128410||T4|At 20 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
88801005|NCT04128410||T5|At 25 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
88801006|NCT04128410||T6|At 30 minutes after flurbiprofen axetil injected intravenously, 14 patients' samples were required to be collected,including 7 younger patients
88801007|NCT04128410||T7|At 35 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
88801008|NCT04128410||T8|At 40 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
88801009|NCT04128410||T9|At 45 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
88801010|NCT04128410||T10|At 50 minutes after flurbiprofen axetil injected intravenously, 7 aged patients' samples were required to be collected
88801011|NCT04286334|Active Comparator|Group A - control Group|Customized titanium mesh without collagen membrane 15 patients will undergo bone regeneration with custom-made mesh without a collagen membrane. (Meshes - 3D-mesh BTK, Biotec, Vicenza, Italy.) Digitally designed by an operator before the surgery (digital technique).
88801012|NCT04286334|Experimental|Group B - Test Group|Customized titanium mesh with collagen membrane 15 patients will undergo bone regeneration with a custom-made titanium mesh (BTK, Biotec- Vicenza, Italy). Digitally designed by an operator before the surgery (digital technique), covered by collagen membrane (Cytoplast RTM, Osteogenics, deore materials, Verona, Italy).
88801013|NCT04274036||Fibromyalgia Patients|Fibromyalgia patients diagnosed according to the 2016 American College of Rheumatology criteria.
88801014|NCT04274036||Healthy-Controls|Healthy controls without pain or chronic illness
88801015|NCT04128254|Experimental|Apixaban|
88801016|NCT04128254|Placebo Comparator|Placebo|
88801017|NCT04128020|Experimental|Nivolumab|Nivolumab: 0.3, 0.5, or 1.0 mg/kg IV, days 1 & 15
88801018|NCT04128020|Experimental|Nivolumab + Azacitidine|Azacitidine 8,16, 24 mg/m^2, days 1-5 Nivolumab @MTD (1.0 mg/kg or lower), days 8 & 15
88801019|NCT05510388|Experimental|High-flow nasal cannula oxygenation group|
89120647|NCT02687373|Experimental|Part 1: Grp 1C - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120648|NCT02687373|Placebo Comparator|Part 1: Grp 1C - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120649|NCT02687373|Experimental|Part 1: Grp 2A - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
89120650|NCT02687373|Placebo Comparator|Part 1: Grp 2A - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
89120651|NCT02687373|Experimental|Part 1: Grp 2B - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
89290098|NCT01319734|Active Comparator|Type 2DM patients receiving oral hypoglycemic agents alone|this group is the control group who receive oral hypoglycemic agents alone
89290099|NCT01121016|Active Comparator|combination therapy|combination therapy with inhaled budesonide and oral montelukast
89290100|NCT01121016|Placebo Comparator|monotherapy|monotherapy with inhaled budesonide and placebo of montelukast
89290101|NCT03685240|Experimental|Intervention|AI-enabled camera fall detection with Human-in-the-Loop (HIP) review
89290102|NCT03685240|No Intervention|Control|No camera detection
88801020|NCT05510388|Active Comparator|Regular nasal cannula oxygenation group|
88801021|NCT03827642|Experimental|Cohort 1: Treatment Sequence A-D-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment D on Day 1 of Period 2, Treatment C on Day 1 of Period 3 and Treatment B on Day 1 of Period 4.
88801022|NCT03827642|Experimental|Cohort 2: Treatment Sequence B-C-D-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, Treatment D on Day 1 of Period 3 and Treatment A on Day 1 of Period 4.
88801023|NCT03827642|Experimental|Cohort 3: Treatment Sequence C-A-B-D|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, Treatment B on Day 1 of Period 3 and Treatment D on Day 1 of Period 4.
88801024|NCT03827642|Experimental|Cohort 4: Treatment Sequence D-B-A-C|Participants received Treatment D on Day 1 of Period 1, Treatment B on Day 1 of Period 2, Treatment A on Day 1 of Period 3 and Treatment C on Day 1 of Period 4.
88801025|NCT03827720|Experimental|Control|Healthy volunteers monitored with Sense Device
88801026|NCT03827720|Experimental|Intracranial Hemorrhage|Intracranial hemorrhage patients monitored with Sense Device
88801027|NCT03827720|Experimental|Acute Ischemic Stroke with LOV|Acute Ischemic Stroke patients that have large vessel occlusion monitored with SENSE Device
88801028|NCT03827720|Experimental|AIS without LOV|Ischemic Stroke patients that do not have large vessel occlusion monitored with SENSE device
88801029|NCT05505786|Active Comparator|Normal stance width|Those assigned to this group will complete their pre-season training as normal i.e. when performing their squat exercises they will do so using their habitual (self-selected) stance width.
88801030|NCT05505786|Experimental|Wide stance width|Those assigned to this (i.e. experimental) group will also complete their pre-season training as normal, the only exception will be that when performing their squat exercises they will increase their stance width by 20% compared to their self-selected stance width.
88801031|NCT03827486|Active Comparator|Standard of care|
88801032|NCT03827486|Experimental|Domicilary exercise program|
89120652|NCT02687373|Placebo Comparator|Part 1: Grp 2B - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
89120653|NCT02687373|Experimental|Part 1: Grp 2C - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
89120654|NCT02687373|Placebo Comparator|Part 1: Grp 2C - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
89120655|NCT02687373|Experimental|Part 1: Grp 2D - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120656|NCT02687373|Placebo Comparator|Part 1: Grp 2D - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120657|NCT02687373|Experimental|Part 1: Grp 2E - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120658|NCT02687373|Placebo Comparator|Part 1: Grp 2E - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120659|NCT02687373|Experimental|Part 1: Grp 3A - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
89120660|NCT02687373|Placebo Comparator|Part 1: Grp 3A - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
89120661|NCT02687373|Experimental|Part 1: Grp 3B - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
89120662|NCT02687373|Placebo Comparator|Part 1: Grp 3B - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
89120663|NCT02687373|Experimental|Part 1: Grp 3C - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
89120664|NCT02687373|Placebo Comparator|Part 1: Grp 3C - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
89120665|NCT02687373|Experimental|Part 1: Grp 3D - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120666|NCT02687373|Placebo Comparator|Part 1: Grp 3D - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120667|NCT02687373|Experimental|Part 1: Grp 3E - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
89120668|NCT02687373|Placebo Comparator|Part 1: Grp 3E - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
88801033|NCT05510310|Experimental|Breast stimulation|Breast pump for breast stimulation: The suction cup will be placed on the breast, held by the patient or a strap, alternated between nipples every 15 minutes, with a pause of 15 minutes after each 30 minutes. Suction intensity will be adjusted to the maximum tolerated by the patient while avoiding causing pain or discomfort. Treatment will be continued for a maximum of 12 hours.
88801034|NCT05510310|Active Comparator|Low-dose oxytocin|Low-dose oxytocin will be administered intravenously, starting at a dose of 0.5-2 milliunits\minute, and increasing incrementally by 1-2 milliunites\minute every 15-40 minutes. Treatment will be continued for a maximum of 12 hours.
88801035|NCT04129034|Experimental|Treatment|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
88801036|NCT05510232|Experimental|A treatment group that will watch a non-VR video via an iPad|"Demographic appropriate screening for inclusion ( including age and available past medical history)~Patient consent (before randomization),~iPad administration (description below),~cast sawing,~physical examination (before and after procedure),~pulse oximetry application (HR measured 3 minutes pre-procedure and throughout entire procedure),~NRS VAS pain administration (3 minutes pre-procedure and immediately post-procedure) in patients over 8 years(Will mark on scale),~VAS Faces pain administration (3 minutes pre-procedure and immediately post-procedure) in patients under 8 years (Will point to face),~NRS VAS anxiety administration (3 minutes pre-procedure and immediately post-procedure)(Will mark on scale),~VAS Faces anxiety scale administration in patients under 8 years(Will point to face),~Patient/parent satisfaction administration (post-procedure)."
88801037|NCT05510232|Experimental|A treatment group that will have headset on and will watch a non-VR video|"Demographic appropriate screening for inclusion ( including age and available past medical history)~Patient consent (before randomization),~Video administration via headset(description below),~Cast sawing,~Physical examination (before and after procedure),~Pulse oximetry application (HR measured 3 minutes pre-procedure and throughout entire procedure),~NRS VAS pain administration (3 minutes pre-procedure and immediately post-procedure) in patients over 8 years(Will mark on scale),~VAS Faces pain administration (3 minutes pre-procedure and immediately post-procedure)in patients under 8 years(Will point to face),~NRS VAS anxiety administration (3 minutes pre-procedure and immediately post-procedure)(Will mark on scale),~VAS Faces anxiety administration (3 minutes pre-procedure and immediately post-procedure) in patients under 8 years (Will point to face),~Patient/parent satisfaction administration (post-procedure)."
88801038|NCT05510232|Experimental|A treatment group that will be immersed in the VR game (Bear Blast) via the headset.|"Demographic appropriate screening for inclusion ( including age and available past medical history)~Patient consent (before randomization)~VR assembly and administration (description below)~Cast sawing,~physical examination (before and after procedure) ,~pulse oximetry application (HR measured 3 minutes pre-procedure and throughout entire procedure),~NRS VAS pain administration (3 minutes pre-procedure and immediately post-procedure) in patients over 8,-(Will mark on scale)~VAS Faces pain administration (3 minutes pre-procedure and immediately post-procedure) in patients under 8 years(Will point to face),~NRS VAS anxiety administration (3 minutes pre-procedure and immediately post-procedure)(Will mark on scale),~VAS Faces anxiety scale administration (3 minutes pre-procedure and immediately post-procedure) in patients under 8 years(Will point to face),~Patient/parent satisfaction administration (post-procedure)."
88801039|NCT04123574|Experimental|Single Arm|BXCL701 will be administered for one week at a dose of 0.2 mg, twice daily (BID). If BXCL701 is well-tolerated after the first week of treatment, the dose will be increased to 0.3mg BID for a total daily dose of 0.6mg to all patients for the second week of treatment.
88801040|NCT05500950||Patients with space occupying lesions completed CDU and CT-DCG or CT|Patients who had completed CDU and CT-DCG or CT examination before surgery and were diagnosed with lacrimal sac space occupying lesions during surgery were selected to be included in this study.
88801041|NCT05500872|Experimental|BFR Group|Cross-education will be performed for 8 weeks with blood flow restriction in the unaffected extremity in the isokinetic system.
88801042|NCT05500872|Active Comparator|Control Group|Cross-education will be performed for 8 weeks without applying blood flow restriction in the isokinetic system.
88801043|NCT04127552||Patients with non-functioning adrenal adenoma|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels lower than 50 nmol/L
88801044|NCT04127552||Patients with pACS receiving conservative management|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving conservative management
88801045|NCT04127552||Patients with pACS receiving adrenalectomy|Patients with incidentally discovered adrenal mass with 1mg-DST serum cortisol levels greater than 50 nmol/L receiving adrenalectomy according to the 2016 European Society of Endocrinology guidelines
88801046|NCT04127552||Healthy controls|Patients without adrenal masses
89120669|NCT02687373|Experimental|Part 2: Group 1 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10^6 PfSPZ per dose."
89120670|NCT02687373|Experimental|Part 2: Group 2 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10^5 PfSPZ per dose."
89120671|NCT02687373|Experimental|Part 2: Group 3 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10^5 PfSPZ per dose."
89120672|NCT02687373|Placebo Comparator|Part 2: Group 4 - Normal Saline|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals."
89120673|NCT00778258|Experimental|Milk-allergic; Non-consumption|Subjects in this arm reacted to the lowest baseline dose of baked milk (muffin) and will continue strict milk avoidance, returning for re-evaluation with laboratory tests at 12 and 24 months and baked milk challenge at 36 months. Individual participants may be challenged at 12 and or 24 months.
89120674|NCT00778258|Experimental|Tolerated Muffin, Reacted to Pizza|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin but react to ingesting the amount of baked milk in a standardized portion of pizza. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
89290103|NCT03677752|Experimental|GP_Posit|Participants allocated to this arm will receive the GP_Posit intervention.
89290104|NCT03677752|No Intervention|Control|Participants in the control arm will receive usual care.
89290105|NCT01219608|Active Comparator|Glutamine 0.5 g/kg/day|
89120675|NCT00778258|Experimental|Reacted to Rice Pudding|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin and a standardized portion of pizza but react to a standardized dose of baked milk in rice pudding. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
89120676|NCT00778258|Experimental|Reacted to Non-baked Milk|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin, pizza and rice pudding but react to a standardized dose of non-baked milk. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
88801047|NCT05500794|Experimental|MBSR (Mindfulness-Based Stress Reduction) group|MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.
88801048|NCT05500794|No Intervention|Standard group|No intervention in this group which will be followed according to the standard care
88801049|NCT00981227|Experimental|ESL 400 mg twice-daily|ESL 400 mg twice-daily
88801050|NCT00981227|Experimental|ESL 800 mg once-daily|ESL 800 mg once-daily
88801051|NCT00981227|Experimental|ESL 600 mg twice daily|ESL 600 mg twice daily
88801052|NCT00981227|Experimental|ESL 1200 mg once daily|ESL 1200 mg once daily
88801053|NCT00981227|Experimental|ESL 800 mg twice daily|ESL 800 mg twice daily
88801054|NCT00981227|Placebo Comparator|placebo|placebo
88801055|NCT05505708|Active Comparator|Group (V)|Group (V): will receive hydroxyethyl starch (voluven) Pfizer Inc 500ml over 30 minutes
88801056|NCT05505708|Active Comparator|Group (R)|Group (R): will receive ringer acetate 500ml over 30 minutes
88801057|NCT00981305|Experimental|Lactate-containing Vaginal Lubricant|apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
88801058|NCT00981305|Placebo Comparator|Placebo|apply 3cc of placebo vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
88801059|NCT04525404||Troponin Substudy|Participants with new COVID-19 infection will undergo high-sensitivity Troponin testing; participants with elevated Troponin will undergo MRI, bloodwork, and olfaction testing at Baseline, then repeat MRI, bloodwork and all functional testing at the Recovered (ie 12weeks post diagnosis) phase. Participants with normal Troponin will undergo only olfaction testing and bloodwork at baseline, then MRI, bloodwork and all functional testing at the Recovered phase.
88801060|NCT04525404||Late Cross-Sectional Substudy|Participants with a COVID-19 diagnosis at least 3 months prior to enrollment will undergo MRI, bloodwork and all functional testing at the Recovered phase only.
88801061|NCT04127708|Placebo Comparator|sham acupuncture|Ten acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
88801062|NCT04127708|Active Comparator|acupuncture|en acupuncture sessions were applied over five weeks. In this study, acupuncture style is the traditional Chinese model, acupuncture was performed on 11 acupuncture points (TE21, SI19, GB2, TE22, ST7, TE17, GB20 of the affected side, and GB20, TE05, KI3 of both sides) using sterile, single-use, 0.25 mm thick, 40 mm long needles (Dongbang Medical Co., Boryeong, Korea). The acupuncture points were selected by taking previous studies as reference. The depth of the needle differed depending on the anatomical structure of the participant and the nature of the acupuncture points, but it was approximately 5-10 mm. The acupuncture needles were applied until the participant experienced de-qi and removed after 20 minutes.
88801063|NCT02246231|Experimental|NF2 who has an auditory implant|
88801064|NCT04125368|Experimental|Intervention|A&T intervention areas: intensified maternal nutrition behavior change interventions during antenatal care delivered through government health facilities and in the community
88801065|NCT04125368|No Intervention|Control|Comparison areas: standard antenatal care services delivered at government health facilities and in the community
88801066|NCT01022567|Active Comparator|Operative treatment|Regular open appendicectomy
88801067|NCT01022567|Active Comparator|Antibiotic treatment|Ertapenem 1 g i.v. x 1 three days
88801068|NCT03831308||Breast cancer new diagnosis|group will include volunteer women, diagnosed with breast cancer, in any stage, aged 18y or more; at least 100 patients will be recruited in medical oncology appointments; all subjects should be periodically submitted to non-invasive evaluation tests - that is, clinical test/clinical and physical assessment to collect information on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
88801069|NCT03827096|Experimental|Human AMSC (passage 3) 3P in 1.5 mL|Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL
88801070|NCT05510076||Group A|in which full-thickness vertical compression suture combined with inflated intrauterine balloon are used to control bleeding
88801071|NCT05510076||Group B|in this group, a resective-reconstructive technique is used, which involves resecting the invasive accreta area followed by immediate uterine reconstruction and bladder reinforcement
88805873|NCT01137539|Experimental|Gynecare TVT-SECUR system|All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
89290106|NCT01219608|Active Comparator|Glutamine 1 g/kg/day|
89290107|NCT01219608|Placebo Comparator|Enteral Nutrition|
89290108|NCT03575572|Experimental|Colchicine|Colchicine will be given at 0.6 mg once daily for the duration of chest tube output plus 24 hours after chest tube removal with a maximum of 4 weeks duration.
88805874|NCT01892930|Experimental|Treatment (SBRT, nephrectomy)|Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29.
89120677|NCT00778258|Experimental|Tolerant to Baked and Non-baked Milk|"Biological/Vaccine: Baked Milk At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.~Biological/Vaccine: Non-baked Milk Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk."
89120678|NCT00778258|No Intervention|Non-Interventional Comparison|Thirty subjects who fulfill inclusion criteria but are unwilling to participate in the full protocol will be enrolled as a comparison group to the active arms.
89120679|NCT00988208|Experimental|Docetaxel, Prednisone, Lenalidomide (DPL)|25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle
89120680|NCT00988208|Experimental|Docetaxel and Prednisone (DP)|Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle
89120681|NCT04185597|Experimental|HFP Intervention: Delivery by Community Farmers|"HFP- Delivered by community farmers, supported by the study and linked to eligible households to educate on growing nutritious food and poultry rearing or fish culture~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female community nutrition promoters (CNPs) will refer PLW to service delivery points; gradually this will be completed by peer leaders~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will later be replaced by peer leaders"
89120682|NCT04185597|Experimental|HFP Intervention: Delivery by agricultural Retailers|"HFP- Delivered by agricultural Retailers, supported by the study and linked to eligible households to educate on growing nutritious food and either poultry raring or fish culture~Strengthen referrals to health services- Improvements to referral networks will be implemented. Female CNPs will refer PLW to service delivery points; gradually this will be completed by peer leaders~Improving quality of health services- Health-related service providers will be trained and supervised on nutrition best practices~SBCC- Primary target is PLW. Delivered using traditional and digital channels. Voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for different weekly messages. Mothers' groups consisting of ten or fewer will be established. Female CNPs will deliver SBCC during monthly mothers' group meetings, household visits, and in health facilities. CNP's role will be replaced by peer leaders"
89120683|NCT04185597|Active Comparator|Standard of Practice|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
89120684|NCT05368779|Experimental|Internet-based Psychosocial Intervention Group|The internet-based psychosocial intervention, which was based on Social Learning Theory and Cognitive Behavioral Therapy techniques, was delivered individually and electronically to the participants in the experimental group in eight sessions, each lasting up to 120 minutes, using videoconferencing.
88801072|NCT05510076||Group C|In this group, bilateral uterine artery ligations combined with cervical tamponade which is performed by elevating the cervix into the uterine cavity with Allis forceps, then suturing the anterior and/ or posterior cervical lip(s) into the anterior and/ or posterior uterine segment(s) depending on the site of bleeding with two or three simple interrupted stitches, with the patency of the cervical canal confirmed, followed by closure of the uterine incision
88801073|NCT04411524|Experimental|Treatment Arm|A total of 50 MSI-H LARC patients will receive 2 cycles of PD-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of PD-1 antibody, finally received the total mesorectal excision (TME) and 6 cycles of adjuvant chemotherapy of XELOX.
89120685|NCT05368779|No Intervention|Control Group|No intervention was applied to the participants in the control group.
89120686|NCT00639249|Placebo Comparator|P|Placebo
89120687|NCT00639249|Experimental|A1|SA4503
89120688|NCT00639249|Experimental|A2|SA4503
89120689|NCT04185831|Experimental|NF1/MAP2K1|Cobimetinib, 60mg po daily. 28 day cycle; day 1-21 60mg daily, day 22-28 rest period.
89120690|NCT04185831|Experimental|MTOR/TSC1/TSC2|Everolimus, 10mg po daily.
89120691|NCT04185831|Experimental|Mutation burden|Atezolizumab. 1200mg iv every 3 weeks.
89120692|NCT04185753||Obese adolescents with CI|Obese adolescents with chronotropic incompetence
89120693|NCT04185753||Control group|Obese adolescents without chronotropic incompetence
89120694|NCT04108065||Patients with gestational diabetes mellitus (GDM)|GDM diagnosed according to current Danish guidelines (plasma glucose (PG) concentration at 120 min after a 75 g oral glucose tolerance test (OGTT) ≥9.0 mM)
89120695|NCT04108065||Pregnant women with normal glucose tolerance (control group)|Pregnant women with normal glucose tolerance (fasting plasma glucose (PG) concentration ≤6.0 mM and PG concentration at 120 min after a 75 g-OGTT <7.8 mM)
89120696|NCT04185519|Experimental|AI (model)|This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose.
89120697|NCT04185519|No Intervention|DR1|Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl.
89120698|NCT02686983|Experimental|Active|Betamethasone and local anesthetic.
89120699|NCT02686983|Placebo Comparator|Placebo|Saline with local anesthetic.
89120700|NCT02687061||Chronic hepatitis B|Patients diagnosed with chronic hepatitis B
88801074|NCT02983916||Group 1: adhesiolysis|Group 1 (the operative group) consisted of all patients who underwent laparoscopy and/or laparotomy. Typically patients had positive cine-MRI. A few patients with inconclusive cine-MRI who underwent diagnostic laparoscopy are also included in this group. Patients with no adhesions found during operation remain in group 1, because analysis is performed on intention-to-treat basis.
88801075|NCT02983916||Group 2: Adhesions, conservative|Patients with evidence of adhesions based on cine-MRI who did not undergo laparoscopy or laparotomy.
89120701|NCT02687061||Chronic hepatitis C|Patients diagnosed with chronic hepatitis C
89120702|NCT02686905|Experimental|Topical vitamin patch|Dietary Supplement: PatchMD Vitamin D3/Calcium Patch Dietary Supplement: PatchMD Multivitamin Patch Dietary Supplement: PatchMD B12 Energy Plus Patch
89120703|NCT02686905|Experimental|Oral vitamins|Dietary Supplement: Chewable Multivitamin with Iron Dietary Supplement: Chewable Calcium Dietary Supplement: Quick Dissolve B12
89120704|NCT00990704|Experimental|Paricalcitol|2 mcg adjusted by +/- 1 mcg, up to a maximum of 7 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
89120705|NCT00990704|Active Comparator|Maxacalcitol|5 or 10 mcg adjusted by +/- 2.5 mcg, up to a maximum of 20 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
89120706|NCT00639327|Experimental|A|CPT-11+ S-1
89120707|NCT00639327|Active Comparator|B|CPT-11
89120708|NCT02867774|Experimental|Intervention|This pilot study will enroll 25 women age 18-65 with greater than six months of noncyclic pelvic pain. Subjects will participate in an 8-week physical activity program specifically designed for patients with chronic pain and supervised by personal trainers and exercise physiologists in a rehab-focused, medically-based fitness center. Subjects will complete web-based assessment tools at the start of the program, immediately after completion of the 8-week program and four weeks after the conclusion of the program (at the 12-week time point).
89120709|NCT02686749|Active Comparator|AF catheter Ablation|Pulmonary Vein Isolation catheter ablation for treatment of AF. AF catheter ablation is an FDA approved treatment for AF
89120710|NCT02686749|Active Comparator|FDA approved anti arrhythmic drug|FDA approved anti arrhythmic drug for the treatment of AF will be based on treating physicians' preference in accordance to guidelines.
89120711|NCT04089553|Experimental|Module 1 (AZD4635 75 mg + Durvalumab 1500 mg)|Participants will receive monotherapy of AZD4635 75 mg orally once daily (QD) for first 14 days and thereafter will continue to receive 75 mg orally QD in combination with durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W) until will derive clinical benefit as judged by the investigator, confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
89120712|NCT04089553|Experimental|Module 2 (AZD4635 50 / 75 mg + Oleclumab 1500 mg)|Participants will receive combination therapy of AZD4635 (50 mg / 75 mg orally QD) and oleclumab 1500 mg IV (every 2 weeks of 28-day cycle for the first 4 doses and Q4W thereafter) until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
89120713|NCT00639405||1|subjects who are diagnosed with parathyroid adenomas. There will be 6 subjects who have not had surgery and 25 subjects who have had surgery.
89120714|NCT02867852|Experimental|Abiraterone acetate|Abiraterone acetate 1 g/day must be taken as four 250-mg tablets daily on an empty stomach. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least 1 hour after the dose of abiraterone acetate is taken. Prednisone (prednisolone when prednisone is not available) 5 mg will be given orally twice a day.
89120715|NCT02686827|Experimental|Paricalcitol (Vitamin D3)|paricalcitol, (Zemplar® 5 μg/ml Abbvie), will be administered via the subcutaneous route 4 times at 0.5 ml (registered dose of 5 μg/ml, thus 2.5 μg per sub-cutaneous injection). The minimum time interval between two injections is 4 days, which is a significantly lower frequency than the prescribed maximum of 3 times a week or every other day.
89120716|NCT02686827|Active Comparator|Placebo|Placebo, the same constituents as Zemplar (propylene glycol 30% (v/v) alcohol 20% (v/v)) but no paricalcitol, same dosage as verum-arm.
89120717|NCT04292678|Experimental|Relaxation|Caregivers of patients with advanced cancer will apply 20 minutes of progressive muscle relaxation exercise twice a week, for 8 weeks with a group session.
89120718|NCT04292678|Active Comparator|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
89120719|NCT00713089||1|75 subjects randomised into the placebo arm of an ongoing randomised double-blind placebo controlled clinical trial at National University Hospital, Singapore
89120720|NCT00713089||2|The expecting mothers visiting at the well mother clinics at Gadjah Mada University Hospital were invited to participate in the study
89120721|NCT02868320|Experimental|Intervention group|This group received a diabetes instruction booklet in addition to daily educational SMS messages and weekly reminders
89120722|NCT02868320|Active Comparator|Control group|This group only received a diabetes instruction booklet
89120723|NCT00713167|Experimental|Grape Seed Extract|Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules
89120724|NCT00713167|Placebo Comparator|Placebo|Placebo enrolled patients who are randomly assigned to receive placebo of Grape Seed Extract
89120725|NCT04185129|Experimental|Foster|uncontrolled asthma patients were randomized into Foster treatment group
89120726|NCT04185129|Active Comparator|Relvar|uncontrolled asthma patients were randomized into Relvar treatment group
89290109|NCT01125462||Subjects previously treated with Gonal-f|Subjects who had undergone at least one treatment cycle with Gonal-f powder and solvent for solution for injection within the past 12 months (equivalent to 75 IU/ml, 450 IU/0.75ml or 1050 IU/1.75 ml)
89290110|NCT01125462||Subjects previously treated with urine-derived FSH|Subjects which had undergone at least one treatment cycle with urine-derived FSH therapy with vials within the past 12 months
89290111|NCT01374100|Active Comparator|Standard Exercise|See methods below - standard strength and endurance training
88801076|NCT02983916||Group 3: No adhesions|Patients in whom no evidence of adhesions was found on cine-MRI, and who did not undergo laparoscopy or laparotomy .
89290112|NCT01374100|Experimental|Qigong exercise|See methods below - medical QiGong therapy session
89120727|NCT05368701|Experimental|App-based volitional help sheet (VHS) for self-harm|"A smartphone-based app version of the adapted VHS for self-harm. Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with ten 'high risk' situations (temptations). By selecting an appropriate situation, 10 appropriate responses (processes of change) are suggested (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
89120728|NCT05368701|Active Comparator|App-based pencil-and-paper VHS|"The app will deliver a .pdf file (for printing) worksheet of the VHS for self-harm, with no integration into the app.~Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response by drawing a line between the situation and response."
89120729|NCT05368701|No Intervention|App with no VHS component|"An app with no VHS component that collects questionnaire survey data.~In this control condition, the app only contains the survey questions and links to helplines contained in the other two conditions.~A free text entry box will ask participants to think of important situations where they might self-harm. A second box asks participants to think of alternative plans that they can do instead of self-harming. Participants are not guided to make links between the situations and responses."
89120730|NCT00716521|Placebo Comparator|Placebo|groups of 3-4 subjects for overnight polysomnography assessments
89120731|NCT00716521|Experimental|Low dose Zolpidem|
89120732|NCT00716521|Experimental|High dose zolpidem|
89120733|NCT00716599|No Intervention|Control|Health centers continue with standard-of-care empiric case management
89120734|NCT00716599|Experimental|RDT training|Health centers randomly selected to receive training and RDTs, for use in routine patient case management
89120735|NCT00612417|Experimental|1|recombinant FVIII
89120736|NCT00612417|Placebo Comparator|2|Placebo
89120737|NCT00716677||1|
89120738|NCT00716677||2|
89120739|NCT02689635|Active Comparator|Sodium Restricted Diet|Low Salt (cardiac) diet
89120740|NCT02689635|Active Comparator|Regular Diet|Non-Cardiac diet
89120741|NCT02572219|Active Comparator|Nutraceutical|Treated with nutraceutical compound
89120742|NCT02572219|Placebo Comparator|Placebo|Treated with placebo
89120743|NCT00718939|Other|Rheos ON|Study participants in this arm will have the device turn on for six months and remains on.
89120744|NCT00718939|Other|Rheos OFF|Study participants in this arm will have the device turned off for 6 months and then turned on.
89120745|NCT00716833|Active Comparator|Preemptive|Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose
89120746|NCT00716833|Placebo Comparator|Postoperative|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.
89120747|NCT00993668|Placebo Comparator|Placebo|Placebo
89120748|NCT00993668|Experimental|Cimzia|Certolizumab pegol
89120749|NCT00778102|Experimental|1|
88801077|NCT05500638|Experimental|Virtual Reality Group|Firstly, the intervention group was administered the pretest, then the training program (VR-ESMEPP), and a posttest immediately following the training. The participants were monitored on the 15th day.
89120750|NCT00778102|Active Comparator|2|
89120751|NCT00713557||1|patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
89120752|NCT00713557||2|patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
89120753|NCT00713557||3|patients with non-ST-elevation ACS treated by immediate PCI
89120754|NCT00713557||4|patients with non ST-elevation ACS treated by elective PCI
89120755|NCT00713557||5|STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
89120756|NCT00713557||6|STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).
89120757|NCT00719017|Experimental|Vaginectomy group|Upper vaginectomy
89120758|NCT00719017|Experimental|Brachytherapy group|Post-operative brachytherapy
89120759|NCT00719017|Active Comparator|Control group|Standard treatment
89120760|NCT03824145|Experimental|Immediate Intervention|"The experimental arm will receive a 16-week lifestyle intervention that promotes nutritional and physical activity changes concordant with those contained in the ACS nutrition and physical activity guidelines for cancer survivors. The 16-week intervention includes:~1) a curriculum binder covering weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 16-weeks, with in-person or virtual supervised exercise sessions and telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to cooking classes emphasizing plant-based eating."
89120761|NCT03824145|Other|Attention Control|"The attention control participants will receive a home/work organization intervention:~Participants will receive a book with overview of home/work organization program with 16 weekly topics with an overview of each chapter.~Virtual or weekly phone calls- with a home organization coach with standard prompts.~Text messages supporting home/work organization."
89120762|NCT00719095|Experimental|1-week buprenorphine taper|1-week buprenorphine taper + behavioral therapy + urine toxicology
89233198|NCT02609776|Experimental|Part 1:Amivantamab Monotherapy+Combination Dose Escalations|The first cohort of participants will receive intravenous (IV) infusions of Amivantamab 140 milligram (mg) as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level. Dose escalation will continue until maximum tolerated dose is reached or all planned doses are administered. Participants will receive IV infusion of Amivantamab once weekly during cycle 1 and once every 2 weeks during subsequent cycles (duration of each treatment cycle is 28 days). Participants will receive lazertinib and Amivantamab on Cycle 1 Day 1 (C1D1) prior to initiation of Amivantamab (C1D1) at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily thereafter, on 28-day Amivantamab treatment cycle. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with standard of care carboplatin and pemetrexed.
89233199|NCT02609776|Experimental|Part 2:Amivantamab Monotherapy+Combination Dose Expansion|Participants will receive IV infusion of Amivantamab as monotherapy at Phase 2 dose (RP2D) regimen or in combination lazertinib at the recommended Phase 2 combination dose (RP2CD) regimen as determined in Part 1. The purpose of dose expansion is to further evaluate safety, tolerability, pharmacokinetic, and to assess preliminary efficacy in monotherapy and combination therapy cohorts.
89233200|NCT02603432|Experimental|Arm A|Avelumab plus Best Supportive Care (BSC)
89233201|NCT02603432|Other|Arm B|"Best Supportive Care (BSC) alone~Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the watch and wait part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone. All patients who choose not to receive Avelumab will be discontinued."
89233202|NCT02592317|Experimental|JNJ 56021927|Participants will receive drug cocktail (comprising of midazolam [2 milligram {mg}], warfarin [10 mg], vitamin K (10 mg), omeprazole (40 mg), and fexofenadine [30 mg]) orally on Study Day 1 and 43 (Cycle 2 Day 1). On Study Day 8 and 50, pioglitazone 15 mg will be administered orally and on Study Day 9 and 51, rosuvastatin 10 mg will be administered orally. JNJ 56021927, 240 mg once daily will be administered on Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
89233203|NCT02581787|Experimental|(Phase 1) Fresolimumab 3 mg/kg|Patients receive fresolimumab 3 mg/kg IV on days 1, 15, and 36 and undergo SABR in 4 fractions between days 8 and 12.
89233204|NCT02581787|Experimental|(Phase 1) Fresolimumab 1 mg/kg|Patients receive fresolimumab 1 mg/kg IV on days 1, 15, and 36 and undergo SABR in 4 fractions between days 8 and 12.
89233205|NCT02581787|Experimental|(Phase 2) Fresolimumab|Fresolimumab will be administered IV at the dose selected in the preceding Phase 1 on Days 1, 15 and 36 and SABR will be administered in 4 fractions between Days 8 and 12.
89233206|NCT02555189|Experimental|Enzalutamide + Ribociclib|Patients receive enzalutamide PO QD on days 1-28 and ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89233207|NCT02544009||1|16 subjects who previously participated in the Biggest Loser study
89233209|NCT02531880|Experimental|1|Patients will be given the study drug
89233210|NCT02531516|Experimental|Apalutamide|Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
89290113|NCT01122888|Experimental|Arm I (course 1)|Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
88801078|NCT05500638|No Intervention|Control Group|For the control group, a pretest, routine outpatient clinical practices, and a posttest were carried out; and the participants were monitored on day 15. They took usual care.
88801079|NCT04127396|Experimental|lenvatinib and TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
88801080|NCT04127396|Active Comparator|Sorafenib and TACE|Patients in Sorafenib + TACE group will take oral sorafenib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.
88801081|NCT04127474||Group I|25 Generalized chronic periodontitis subjects without coronary heart disease.
88801082|NCT04127474||Group II|25 Generalized chronic periodontitis subjects diagnosed with coronary heart disease.
88801083|NCT04127474||Group III|25 Periodontally healthy subjects diagnosed with coronary heart disease.
88801084|NCT04120064|Experimental|Large bolus|
88801085|NCT04120064|Active Comparator|Standard|
88801086|NCT05505318||parotid gland neoplasm in upper Egypt|
88801087|NCT04127630||mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
88801088|NCT00982007|Experimental|Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
88801089|NCT00982007|Active Comparator|Cohort 1 (Group B) - Ferrous Sulfate|Oral iron - Ferrous Sulfate tablets
88801090|NCT00982007|Active Comparator|Cohort 2 (Group D) - IV Iron (standard of care)|Other IV iron
88801091|NCT00982007|Experimental|Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
88801092|NCT04274582|Experimental|Chokeberry extract consumption|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
88801093|NCT04274348|Other|Skin biopsies and blood samples|
88801094|NCT03826862|Experimental|intervention group|All patients receive CT three-dimensional reconstruction before surgery.
88801095|NCT03826862|No Intervention|control group|All patients did not receive CT three-dimensional before surgery
88801096|NCT04346732|Experimental|Vapocoolant spray|Vapocoolant spray was applied to the donors in the vapocoolant spray group.
88801097|NCT04346732|No Intervention|Control|The donors in the control group were not given any intervention during the blood collection process.
88801098|NCT03826784|Experimental|BHA|Subjects treated with BHA + standard of care
88801099|NCT03826784|No Intervention|Control|Subjects treated as per standard of care
89120763|NCT00719095|Experimental|2-week buprenorphine taper|2-week buprenorphine taper + behavioral therapy + urine toxicology
89120764|NCT00719095|Experimental|4-week buprenorphine taper|4-week buprenorphine taper + behavioral therapy + urine toxicology
89120765|NCT00916630|Other|Single-arm treatment|Dose finding study
89120766|NCT02572375|Experimental|Codeine Phosphate/Guaifenesin ER Tablet|Patients receiving an extended release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin twice a day for 6 and a half days total. Total dosage [2 tablets] is 60 mg Codeine Phosphate and 1200 mg Guaifenesin twice a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
89120767|NCT02572375|Active Comparator|Codeine Phosphate/Guaifenesin IR Tablet|Patients receiving an immediate release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin six times a day for 6 and a half days total. Dosage is 20 mg Codeine Phosphate and 400 mg Guaifenesin six times a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
89120768|NCT05259111|No Intervention|Control, Care in the Hospital|After bariatric sleeve gastrectomy, patients receive their care in the hospital, as usual.
89120769|NCT05259111|Experimental|Intervention, Care in the Home|After bariatric sleeve gastrectomy, patients receive their care in the home.
89120770|NCT00719173|Experimental|Arm I|Patients receive aprepitant 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving aprepitant, patients receive an infusion of cyclophosphamide on day 1. During course 2, patients crossover and receive treatment as in arm II.
89120771|NCT00719173|Experimental|Arm II|Patients receive a placebo 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving the placebo, patients will receive an infusion of cyclophosphamide infusion on day 1. During course 2, patients crossover and receive treatment as in arm I.
89120772|NCT00756886|Active Comparator|Atorvastatin|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
89120773|NCT00756886|Placebo Comparator|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
89120774|NCT00713635||1|Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
89120775|NCT00713635||2|Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
89120776|NCT00713635||3|Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
89120777|NCT00713635||4|Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
89120778|NCT05215041||Cesarean section group|
89120779|NCT05215041||Non-cesarean section group|
89120780|NCT02574013|Experimental|sponge-assisted surgery group|Patients offered surgery with use of the retractor sponge
89120781|NCT02574013|No Intervention|Control group|Patients receiving standard care, i.e. surgery in Trendelenburg position
89120782|NCT02686359|Experimental|Burning Mouth Syndrome Patients|saliva, blood and urinary samples
89120783|NCT02686359|Active Comparator|controls|saliva, blood and urinary samples
89120784|NCT00756730|Other|Switch to DRV/r (800mg/100mg) QD|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
89120785|NCT00756730|Other|Switch to ATV/r (300mg/100mg QD)|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study
89120786|NCT00713713|Experimental|1|Two different tidal volumes (6 and 12 ml.kg-1 of ideal weight) are alternatively delivered to patients 30 minutes each one. The order of the two tidal volumes is randomized. Between the two study tidal volumes, patient returns for 30 minutes to the tidal volume used before the study recruitment.
89120787|NCT02573935|Experimental|Clarithromycin|Clarithromycin combined with VCD induction therapy
89120788|NCT02573935|Placebo Comparator|Placebo|Placebo combined with VCD induction therapy
89120789|NCT00984620|Experimental|short arm|patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
89120790|NCT00984620|Experimental|long arm|patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
89120791|NCT00717145|Experimental|1|One risedronate 20 mg DR tablet taken following an overnight fast, followed by a 4-hour fast.
89120792|NCT00717145|Experimental|2|One risedronate 20 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
89120793|NCT00717145|Experimental|3|One risedronate 35 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
89120794|NCT00717145|Experimental|4|One risedronate 35 mg IR tablet taken following an overnight fast, 30 minutes before ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
89120795|NCT02686281|Experimental|Cohort A (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Other: Placebo"
89120796|NCT02686281|Experimental|Cohort B (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Other: Placebo~The dose administered in Part A (fed) was based on the outcome of Part A (fasted)."
89120797|NCT02600728|Experimental|experimental group (EG)|The experimental training (ET) consisted of eight gait training sessions, twice a week, using the declarative memory cues strategy (DMCS).
89120798|NCT02600728|Active Comparator|control group (CG)|The control training (CT) consisted of a similar gait training without DMCS.
89120799|NCT00713791|Experimental|1|There are 5 variations of the ZD4054 (Zibotentan) 10mg tablet - A, B, C, D, and E. A minimum washout period of 1 week will occur between each treatment period.
88801100|NCT05042934|Experimental|Treatment (lurbinectedin, fine-needle aspiration, irinotecan)|Patients receive lurbinectedin IV over 60 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo fine-needle aspiration on days 2-6 of cycle 1. Beginning in cycle 2, if the biopsy shows suppression of NR0B1, then patients receive irinotecan IV over 1 hour on the day of maximum NR0B1 suppression on cycle 2. If the duration of NR0B1 suppression from lurbinectedin alone exceeds 48 hours, or if the duration of NR0B1 suppression from lurbinectedin and irinotecan exceeds 48 hours and is longer than that seen with lurbinectedin alone, then patients may receive a second dose of irinotecan during the extended period of NR0B1 suppression.
88801101|NCT05505006|Experimental|Cancer patients with anemia (i.e. Hb <12 g/dl if females, <13 g/dL if males)|"Cancer patients eligible for surgery with anemia will be managed as follows:~s-ferritin <100 mcg/l or s-ferritin <500 mcg/l + TSAT<20% = i.v. iron (ferric carboxymaltose, dosage according to body weight and Hb level)~folate < 5 ng/ml = folate 5 mg per day for 1 month~B12 < 200 pg/ml = B vitamin complex 1 tablet per day for 1 month~Patients will receive combined treatment if they have multiple deficiencies simultaneously.~Patients without correctable deficiencies will not receive any treatment."
88801102|NCT03826706|Active Comparator|C-MAC Videolaryngoscope D blade|Patients was intubated with C-MAC videolaryngoscope D blade.
88801103|NCT03826706|Active Comparator|McGrath MAC Videolaryngoscope X3 blade|Patients was intubated with McGrath MAC Videolaryngoscope X3 blade
88801104|NCT05509920|Active Comparator|patients with root carious lesions will be treated by SDF varnish|Silver diamine fluoride (SDF) contains high concentrations of silver and fluoride ions, which prevents and arrests root caries, as well as dentin caries in the primary teeth of young children. Unlike other fluoride products that mainly reduce the formation of new carious lesions, 38% SDF is an effective agent that can efficiently arrest the carious process, remineralize the decayed dental tissues, and protect the tooth structure against the for-mation of new caries lesions. The use of SDF can result in more caries-resistant tooth structures.
88801105|NCT05509920|Experimental|patients with root carious lesions will be treated by PRG barrier coat.|PRG barrier coat is a Giomer varnish from Shofu. It is a light cured Surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix. It has an immediate and long lasting effect. The (S-PRG) favors the re-lease of fluoride ions and its recharging that aid in remineraliza-tion and protection of the tooth structure in a way similar to the glass ionomer. The fluoride ions aid in the neutralization of the acidity of the oral cavity and decrease the plaque accumulation
88801106|NCT04392518|Active Comparator|Hospital based rehabilitation group|This group will perform the exercises in the hospital under the supervision of a physiotherapist
88801107|NCT04392518|Active Comparator|Telerehabilitation group|This group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection
88801108|NCT05509764||group 0|control group
88801109|NCT05509764||group 3|3 Lt/min Oxygen therapy via nasal cannula
88801110|NCT05509764||group 6|6 Lt/min Oxygen therapy via Simple face mask
88801111|NCT05509686|Experimental|A single-session intermittent theta burst stimulation (iTBS)|The classical 600-pulse iTBS protocol is delivered to the motor hotspot over the ipsilesional hemisphere.
88801112|NCT05509686|Sham Comparator|A single-session sham intermittent theta burst stimulation (iTBS)|The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp.
88801113|NCT04392752|Experimental|Participants|The participants are recruited via the University of Jyväskylä and Finnish Fitness Sports Association web page and social media channels. An online pre-study questionnaire are sent to randomly chosen athletes and control group candidates who claim to fulfill the inclusion criteria and volunteer for the study. The participants selected for the study filled an additional questionnaire which is subsequently reviewed by the physician of the study to confirm that they will meet inclusion criteria relating to health.
88801114|NCT04392752|No Intervention|Control|The target is 15 male ja 15 female participants for both the control and intervention groups. To be included, participants need to be with two or more years of resistance training experience, similar to our previous study in females (Hulmi et al. 2017). If more than 15+15 control participants sign up for the study, the final group will be matched to the intervention group based on age, height, weight, and training experience reported on the pre-study questionnaire. The control group maintain their normal nutrition and training during the study.
88801115|NCT03018392|Experimental|Tritanium|TLIF with Tritanium® PL cage and pedicle screw fixation
88801116|NCT01663506||Cohort|
88801117|NCT02979548|Experimental|Group A : Aprepitant (Add on therapy)|Aprepitant group will receive aprepitant capsules 1 h prior to chemotherapy on days 1-3 in addition to 5HT3 RA (Ondansetron). The dose of aprepitant will be given based on weight groups Weight 15-40 kg : Aprepitant 80 mg on days 1-3 Weight > 41kg: Aprepitant 125 mg on day 1 followed by 80 mg on days 2-3 Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
88801118|NCT02979548|Active Comparator|Group B : 5HT3 RA (Ondansetron)|"On the day of chemotherapy, ondansetron will be administered to all patients as per our institutional practice in a dose of 0.15 mg/kg as an intravenous bolus 30 minutes before chemotherapy followed by every 8 hourly for 8 days.~Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day."
88801119|NCT03012776|Experimental|TOPS System|Investigational surgical treatment using TOPS System
88801120|NCT03012776|Active Comparator|Transforaminal Lumbar Interbody Fusion (TLIF)|Control surgical treatment using interbody fusion and placement of posterolateral instrumentation
88801121|NCT05504928|Experimental|Experimental: Implementation of a dedicated school nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
88801122|NCT02568384|Experimental|Users of Onyx BG Meter / App System|"Subjects with diabetes used the Onyx Blood Glucose (BG) Meter / App System at home. The enrollment goal for the intended use population:~40 to 70% of subjects will have type 1 diabetes~Not more than 30% of subjects will use an insulin pump"
89120800|NCT00639483|Experimental|A|
89120801|NCT00639483|Placebo Comparator|B|
89120802|NCT00719251|Experimental|HVG|The patients received standard nursing care and HVPC
89120803|NCT00719251|Experimental|LG|These patients received standard nursing care and LLLT
89120804|NCT00719251|Active Comparator|CG|The control group only was treated with standard nursing care
89290114|NCT01122888|Other|Arm II (course 1)|Patients do not receive treatment and undergo a 2-week rest period.
88801123|NCT03821558|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak exercise performance) and low-intensity intervals (60-70% of peak exercise performance).
88801124|NCT03821558|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo moderate continuous exercise training at 75% of peak exercise performance.
88801125|NCT05509530|Experimental|anti BCMA/GPRC5D CAR-T|Enrolled patients will receive prespecified dose of autologous anti BCMA/GPRC5D CAR-T cells.
88801126|NCT03826472|Experimental|Almond Butter|Participants will consume one ounce per day (~32 g) of almond butter as an evening snack (i.e., after dinner and before sleep).
88801127|NCT03826472|No Intervention|No-snack Control|Participants will consume nothing besides water after dinner/bed sleep.
88801128|NCT05499936|Experimental|68Ga-FAPI PET/CT|Imaging was performed 30-60 minutes after injection of 2-4mci 68Ga-FAPI tracer
88801129|NCT03826316|Experimental|Mutonpain Injection 10 mg/ml|
88801130|NCT04393610|Active Comparator|Group (L)|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group)
88801131|NCT04393610|Active Comparator|Group M|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
88801132|NCT04393610|Active Comparator|Group F|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
88801133|NCT03825926||Gestational Diabetes Mellitus|The diagnosis of GDM is based on a 75-g oral glucose tolerance test (OGTT) performed between 24 and 28 gestational weeks, according to the American diabetes association (ADA) criteria (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L, 2 h ≥ 8.5 mmol/L). Recruited patients were accepted the standard of treatment of GDM according to the American college of obstetricians and gynecologists (ACOG) practice bulletin on gestational diabetes mellitus.
88801134|NCT03825926||Non-Gestational Diabetes Mellitus|normal group
89120805|NCT02867540|Experimental|experimental group|Patient's with Crohn's disease who have had ileocolic resection
89120806|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 5 mg|Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
89120807|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 10 mg|Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
89120808|NCT00777946|Active Comparator|Aliskiren 300 mg|Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
89120809|NCT04068883|Experimental|Collar group|group of athletes that will wear the collar device
89120810|NCT04068883|No Intervention|Non Collar group|group of athletes that will not wear the collar device
89120811|NCT02686047|Experimental|the HYAJOINT Plus group|the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
89120812|NCT02686047|Active Comparator|The Synvisc-One group|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
89120813|NCT00717223||Parents with children with diabetes|parents who have children 18 or younger with diabetes
89120814|NCT00639561|Experimental|A|diet composed of 10g of fibre per day
89120815|NCT00639561|Experimental|B|diet composed of 40g of fibre per day
89120816|NCT00916084|Experimental|Group A|
89120817|NCT00916084|Experimental|Group B|
89120818|NCT00713869||1|Patients between the ages of 21 and 35 undergoing in-vitro fertilization will be included in this study.
89120819|NCT00713869||2|Recipients using only frozen donor eggs
89120820|NCT00713947|Active Comparator|A|Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
89120821|NCT00713947|Experimental|B|Pantoprazole
89120822|NCT00713947|Placebo Comparator|C|Placebo
89120823|NCT00990314|Experimental|B.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, B.I.D (twice a day dosing)
89120824|NCT00990314|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, q.i.d (four times a day dosing)
89120825|NCT00756652||MemoryGel Breast Implant Participants|MemoryGel Breast Implant Participants received Mentor Silicone Gel-Filled Breast Implants (MemoryGel) during their Breast Augmentation, Breast Reconstruction, or Revision surgery
89120826|NCT00756652||Saline Breast Implant Control Participants|Saline Breast Implant Control Participants received Saline Filled Breast Implants during their Breast Augmentation, Breast Reconstruction, or Revision surgery
89120827|NCT00717301||Head Trauma|Patients presenting to any of the AHCC/ERNES Emergency Departments with head trauma.
89120828|NCT00717301||Control subjects|Patients presenting to the Univ of Rochester Medical Center/Strong Memorial Hospital Outpatient Laboratory for routine blood draw.
89120829|NCT04097626|Experimental|experimental|This group will receive nutrition education during the first week of the study. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
89120830|NCT04097626|Active Comparator|control|This group will receive no nutrition education. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
89120831|NCT00717379|Active Comparator|1|steroid regimen 1
89120832|NCT00717379|Experimental|2|steroid regimen 2
89120833|NCT02685813||Pregnant women in Denmark|Pregnant women in Denmark participating in prenatal screening. This counts for approximately 50000 pregnancies/year and covers >95% of all pregnancies nationally.
89120834|NCT04097392|Experimental|Diaphragm biofeedback reeducation plus inspiratory training|
89120835|NCT04097392|Active Comparator|Isolated high-intensity inspiratory muscle training|
89120836|NCT02867228|Other|Single Observational Group|Patients receiving mechanical ventilation and subject to the intervention: changes in ventilator settings.
88801135|NCT03826238||ARBD and depression|10 patients with ARBD and at least moderate depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale ≥ 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
88801136|NCT03826238||ARBD and no depression|10 patients with ARBD and no clinically relevant depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale < 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
88801137|NCT03826238||Healthy|10 healthy controls (no ARDB, no depression, no cognitive deficit). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
88801138|NCT03820466|Active Comparator|Aspirin|Aspirin 100 mg once daily and Placebo Atorvastatin once daily
88801139|NCT03820466|Active Comparator|Atorvastatin|Atorvastatin 20 mg once daily and Placebo Aspirin once daily
88801140|NCT03820466|Experimental|Aspirin-Atorvastatin|Aspirin 100 mg once daily and Atorvastatin 20 mg once daily
88801141|NCT03820466|Placebo Comparator|Placebo|Placebo Aspirin once daily and Placebo Atorvastatin once daily
88801142|NCT03826004|Placebo Comparator|Placebo|Saline solution 2ml before anesthetic induction
88801143|NCT03826004|Experimental|Clemastine|Clemastine fumarate 2mg/2ml before anesthetic induction
88801144|NCT04127240|Experimental|Meat assignment in DASH intervention|Participants consumed 3 ounces of red meat per day as a part of the DASH diet.
88801145|NCT04127240|Experimental|Meat allocation in DASH intervention|Participants consumed 6 ounces of red meat per day as a part of the DASH diet.
88801146|NCT03097094|Active Comparator|Male dog|Male dog extract used for skin prick test and conjunctival provocation
89120837|NCT02867306|Experimental|ASP1707 and methotrexate (MTX)|On day 1 patients will receive prescribed dose of MTX. On Days 3 through 8, patients will receive ASP1707 (twice daily). On Day 9, patients will receive a single dose in the morning. A single dose of MTX will be coadministered on Day 8.
89120838|NCT00777556|Experimental|DR-104|One tablet for emergency contraception
89120839|NCT00602979|Other|Macintosh laryngoscope|Macintosh laryngoscope (control group/direct laryngoscopy) - current standard
89120840|NCT00602979|Other|Airtraq Optical Laryngoscope|Airtraq® Optical Laryngoscope (an experimental group/indirect laryngoscopy)
89120841|NCT00602979|Other|Storz DCI Video Laryngoscope|Storz DCI Video Laryngoscope® (an experimental group/indirect laryngoscopy)
89120842|NCT00602979|Other|GlideScope Video Laryngoscope|GlideScope® Video Laryngoscope (an experimental group/indirect laryngoscopy)
89120843|NCT00602979|Other|McGRATH Video Laryngoscope|McGRATH® Video Laryngoscope (an experimental group/indirect laryngoscopy)
89120844|NCT02867462|Other|A-Standard Care|standard care
89120845|NCT02867462|Experimental|B-manipulator consultation radiotherapy added to standard care|manipulator consultation radiotherapy added to standard care
89120846|NCT04097080|Experimental|NBTX-001|30% medical grade xenon/70% Oxygen
89120847|NCT04097080|Placebo Comparator|Standard of Care|Reconstituted air
89120848|NCT04081363|Experimental|Swallowed Capsules Cohort|Participants swallowed two capsules of centanafadine (one containing a 50-milligram [mg] dose as extended release beads and other containing a 5-mg dose as immediate-release [IR] beads), total dose of 55 mg, orally in the morning of Day 1 following a minimum 8-hour fast.
88801147|NCT03097094|Active Comparator|Female dog|Female dog extract used for skin prick test and conjunctival provocation
88801148|NCT02338076|Experimental|Interventional arm|petrolatum application under occlusion
88801149|NCT04126772||Active MS patients|10 MS patients with an active lesion of 0,5 cm diameter
88801150|NCT04126772||Healthy controls|20 healthy controls
88801151|NCT04126772||SPMS patients|10 SPMS patients
88801152|NCT03829670||Delirium Group|"UBACC: University of California, San Diego Brief Assessment of Capacity to Consent.~The participant may decline participation after this UBACC (University of California, San Diego Brief Assessment of Capacity to Consent) assessment and will be removed from the study.~The Short IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) is administered to the legally authorized representative or caregiver by Dr. Schmidt. If the potential participant scores 3.3 or lower, the participant will continue in the delirium group. If higher, patient likely with pre-existing dementia. These patients are not eligible for study participation.~Delirium Rating Scale 98 will be performed on the ALGH (Advocate Lutheran General Hospital) rehabilitation unit~Cytochrome P450 testing~Delirium Status: Admission, Hospital Discharge, Outpatient Visit~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
89120849|NCT04081363|Experimental|Sprinkled Onto Applesauce Cohort|Participants were administered centanafadine 55 mg, contents of 2 capsules (one containing a 50-mg dose as beads and other containing a 5-mg dose as IR beads) sprinkled on a tablespoon of applesauce, orally in the morning of Day 1 following a minimum 8-hour fast.
89120850|NCT02685657|Experimental|AC followed by Docetaxel with Selumetinib|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle, 75 mg of SELUMETINIB twice a day PO on days 1-21 of every 3 week cycle
89120851|NCT02685657|Active Comparator|AC followed by Docetaxel|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle
89120852|NCT04290884|Experimental|Local administration of tranexamic acid|"All patients hip fracture will be treated according to the hospital standard procedure~Check complete blood count on admission and Day 3 post-operation.~10ml tranexamic acid injected under the deep fascia around the fracture site under x-ray control~Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.~Transfusion when clinically indicated or Hb < 8g/dL~Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)~Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.~After discharge, patients will be seen in 6 weeks and 3 months"
89290115|NCT01214928|Active Comparator|Cholecalciferol|Cholecalciferol 50,000IU po once weekly for 12 continuous weeks.
88801153|NCT03829670||Patients without delirium|"Cytochrome P450 testing~Delirium Status: Admission, Hospital Discharge, Outpatient Visit~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
88801154|NCT03829826||Patients receiving IVIg|Patients are currently receiving IVIg regularly for at least every 6 weeks and exhibit a favorable response will be recruited into the study (11 patients). They will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their impairment using the previously validated Stiffness and Sensitivity scales and quality of life questionnaire (QoL) at weeks 0, 4, 8, 12. At week 12, prior to the first SCIg infusion, blood will be drawn for humoral (immunological) studies. One week following the last dose of IVIg (at week 13), the participants will be started on SCIg at a total dose equivalent to the monthly dose of IVIg they have been receiving.
88801155|NCT03829826||de novo SCIg patients/IVIg-Naive Group|This other arm of the trial will include 11 patients naïve to IVIg who do not receive other immunotherapies while being symptomatic. These patients after a 12-week observation period will start directly on SCIg drug (HYQVIA), following the same schedule as described above for the previous group.
88801156|NCT04126694|Experimental|CBT with smartphone application|12 weeks of CBT with SenseSupport smartphone application
88801157|NCT02978534||Quetiapine|Patients taking quetiapine during pregnancy are eligible to participate in the study. Their dose and plasma concentration levels of quetiapine will be monitored throughout pregnancy and up to three months postpartum.
88801158|NCT03829982|Experimental|bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
88801159|NCT03829982|Experimental|dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
88801160|NCT02983760|Active Comparator|Planar V/Q-based strategy|Control arm
88801161|NCT02983760|Active Comparator|CTPA-based strategy|Control arm
88801162|NCT02983760|Experimental|V/Q SPECT-based strategy|Experimental arm
88801163|NCT01222117|Experimental|Plasmin Open-label Treatment Group A|Open-label 150 mg Plasmin administered without initial proximal pulse; 5-hour infusion using 10 mL/hour infusion rate.
88801164|NCT01222117|Experimental|Plasmin Open-label Treatment Group B|Open-label 150 mg Plasmin administered with initial proximal pulse; 5-hour infusion using 15 mL/hour infusion rate
88801165|NCT01222117|Experimental|Plasmin Open-label Treatment Group C|Open-label 150 mg Plasmin administered with proximal pulse; 5 hour infusion using 30 mL/hour infusion rate.
88801166|NCT01222117|Experimental|Plasmin Open-label Treatment Group D|Open-label 150 mg Plasmin administered with proximal pulse; 2-hour infusion using 35 mL/hour infusion rate
88801167|NCT01222117|Active Comparator|Plasminogen Activator Blinded Group E|PA administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice
88801168|NCT01222117|Placebo Comparator|PA Placebo Blinded Treatment Arm F|PA placebo (normal saline for injection) administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice for PA administration
88801169|NCT01222117|Experimental|Plasmin Open-label Treatment Group G|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 60 mL/hour infusion rate
88801170|NCT01222117|Experimental|Plasmin Open-label Treatment Group H|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 75 mL/hour infusion rate
88801171|NCT01222117|Experimental|Plasmin Open-label Treatment Group I|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
88801172|NCT01222117|Experimental|Plasmin Open-label Treatment Group J|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 35 mL/hour infusion rate with balloon occlusion catheter
88801173|NCT01222117|Experimental|Plasmin Open-label Treatment Group M|Open-label 250 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
88801174|NCT04392830|Experimental|ALZ002 DS|"SAD: 6 cohorts of subjects are planned to be orally dosed, ranging from 15 mg - 800 mg.~MAD: 3 cohorts of subjects are planned to be orally dosed once or twice daily for 7 consecutive days, ranging from 300 mg - 600 mg."
88801175|NCT04392830|Placebo Comparator|Placebo|Placebo
88805875|NCT01138475|Active Comparator|Paricalcitol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules,cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
89120853|NCT04290884|No Intervention|Control group|"All patients hip fracture will be treated according to the hospital standard procedure~Check complete blood count on admission and Day 3 post-operation.~10ml normal saline injected under the deep fascia around the fracture site under x-ray control~Sealed envelope system: Operation room nurse will open a sealed envelope for treatment allocation. The medications are prepared by the nurse according to the instruction inside the envelop.~Transfusion when clinically indicated or Hb < 8g/dL~Blood Loss calculation (formula of Nadler, Hidalgo and Bloch)~Blood taken at Day 3 post-operation will be used for measure of postoperative haematocrit. By this time postoperatively fluid shift has settled and the patient is haemodynamically stable.~After discharge, patients will be seen in 6 weeks and 3 months"
89120854|NCT00719407|Experimental|A|All enrolled patients will be in this single arm, who will receive experimental drug treatment.
89120855|NCT00639795|Active Comparator|A|Patients randomized to receive thoracic paravertebral nerve blockade in addition to general endotracheal anesthesia during video assisted thoracoscopy procedure
89120856|NCT00639795|Sham Comparator|B|Patients randomized to receive sham single-injection thoracic peripheral nerve blockade (no injection) in addition to general endotracheal anesthesia
89120857|NCT00714025|Experimental|I|40 patients with metastatic or locally advanced transitional bladder cancer with failed platinum-based chemotherapy receiving RAD001 10mg daily PO.
89120858|NCT02869412|Experimental|Group I (BCG website)|Patients use the BCG website which will collect personal information including individual health priorities/goals, demographics (i.e. age, ethnicity), health information (i.e. weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences. Patients then receive a report with a personalized physical activity plan.
89120859|NCT02869412|Active Comparator|Group II (passive website)|Patients use a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors).
89120860|NCT02685345|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablets, orally, once daily (QD) for up to 28 days
89120861|NCT02685345|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg tablets, orally, once daily (QD) for up to 28 days
89120862|NCT02685345|Placebo Comparator|placebo|placebo tablets, orally, once daily for up to 28 days
89120863|NCT04102384|No Intervention|Control Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using an electronically link sent via email. Additionally, participants will be asked to fill out one survey once a week during the study period.
89120864|NCT04102384|Experimental|Intervention Group|Participants will be enrolled for a period of 4 weeks. At baseline, we will collect demographic information on participants. During the study, participants will be asked to fill out daily and weekly surveys using the e-PRO app. Additionally, participants will be asked to fill out one survey once a week during the study period. A subgroup of these participants will be asked to complete an additional interview to collect more information on their experiences using the mobile app.
89120865|NCT02869100|Experimental|Spondyloarthritis Patients|
89120866|NCT04033965||women <35 with early breast cancer|
89120867|NCT04033965||women>65 years old with early breast cancer|
89120868|NCT04096768|Experimental|Dexmedetomidine + Ketamine|
89120869|NCT04096768|Placebo Comparator|Dexmedetomidine + Placebo|
89120870|NCT00717613||1|Observational cohort study
89120871|NCT04102462|Experimental|Multiple rising dose part|
89120872|NCT04102462|Experimental|Midazolam part|
89120873|NCT00714103|Experimental|8-Chloro-Adenosine|Starting dose for first cohort of patients 45 mg/m2 intravenous over 1 hr daily for 5 days every 4 weeks (± 3 days).
89120874|NCT02685501||Combat women soldiers|Women soldiers in combat units
89120875|NCT02685501||Non combat women soldiers|Women soldiers in non-combat units
89120876|NCT02601430|Experimental|BOLD-MRI|Blood Oxygen Level Dependent (BOLD)-MRI assessment of limb perfusion before and after standard of care endovascular therapy.
89120877|NCT02685423|Experimental|Visual Deprivation - 10 days|10 days of visual deprivation followed by vision training
89120878|NCT02685423|Active Comparator|Vision Training Only|Vision training without visual deprivation
89120879|NCT04290962|Experimental|Supportive Care (web-based lifestyle intervention)|Participants complete the 12-month Precision Nutrition Coaching Program web-based lifestyle intervention consisting of physical activity at home or a local gym, nutritional/lifestyle habit with a new focus biweekly, and educational lessons about health, nutrition, fitness, or behavior change.
89120880|NCT00719485|Experimental|1|Educational program
89120881|NCT00719485|No Intervention|2|Standard care
89120882|NCT02600806|Other|Azithromycin/levofloxacin|Azithromycin or levofloxacin are given according to serum procalcitonin levels
89120883|NCT00639873|Experimental|AS 2mg/kg|Artesunate monotherapy 2mg/kg/day for 7 days
89120884|NCT00639873|Experimental|AS 4mg/kg|Artesunate monotherapy 4mg/kg/day for 7 days
89120885|NCT00639873|Active Comparator|QD Control|Quinine-doxycycline for 7 days
89120886|NCT02572921|Experimental|Positive Psychotherapy|Experimental Group (Positive Psychotherapy)
89120887|NCT02572921|Active Comparator|Cognitive Behavioral Therapy|Active Control Group (Cognitive Behavioral Therapy)
89120888|NCT04291118|Other|Medical Management and Sinus Surgery in private system|These patients will first receive medical management for their symptoms and then will undergo sinus surgery much earlier than the other group as they will include patients being operated in the private system.
89120889|NCT04291118|Other|Medical Management and Sinus Surgery in public system|These patients will first receive medical management for their symptoms, and then will undergo sinus surgery after a waiting period of at least 1 year since they are on the public wait-list.
89120890|NCT04291118|Other|Medical Management Only|These patients will only receive medical management for their symptoms as they will not require sinus surgery.
89120891|NCT04096612|Experimental|Orbital decompression combined MPT|Orbital decompression was performed by the same doctor with rich clinical experience. MPT should be implemented in the patients with obvious thyroid disorder before orbital decompression surgery which should only be performed when thyroid function was stabilized. The surgery was performed under general anesthesia. An arcuate incision was made in the skin 2 mm below the lower eyelid margin, and the tissue under the incision were separated to the periorbita and orbital septum. Part of the medial orbital wall, inferior orbital wall and partial tissue of ethmoidal sinus were removed, and an appropriate amount of adipose tissue was excised. MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
89120892|NCT04096612|Experimental|Separate MPT|MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
89120893|NCT04069351|Experimental|Overfeeding Plus Resistance Training Arm|6-week overfeeding plus resistance training arm
89120894|NCT04291586|Experimental|Virtual Reality|The Virtual Reality group will perform personalized activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
89120895|NCT04291586|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalized to their deficits and generated automatically through a Task Generator.
89120896|NCT00719641||Phase 1: Single Colonoscopy|Feasibility testing using the segmental stiffening wire
89120897|NCT00719641||Phase 2; Not randomized|Phase 2 participants who did not have looping during first colonoscopy
89120898|NCT00719641||Phase 2: Randomized to SSW during first colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to subsequent use of segmental stiffening wire, then colonoscopy with no segmental stiffening wire upon repeat colonoscopy the next day.
88801176|NCT02976428|Active Comparator|Standard Soft Tissue Balancing|In the control group where the sensor device is not used in optimization of knee balance and alignment, definitive implants will be cemented in place and the sensor trial inserted using a thickness based on prior standard bearing insert trialing. Peak load data will be captured intraoperatively through full ROM. Custom shims will be affixed to the sensor to replicate thickness of the standard trial. The knee will then be cycled and loads recorded in the medial and lateral compartments at 10, 45 and 90 degrees of flexion. The surgeon will be blinded to the sensor output and the system will be located outside of their visual field.
88801177|NCT02976428|Experimental|Sensor Guided Soft Tissue Balancing|In the experimental group where the sensor device is used to optimize balance and alignment, the sensor trial will be inserted and tibial baseplate rotated until medial and lateral femoral contact points are parallel on the sensor output. Quantitative balance is defined as a mediolateral intercompartmental loading difference of ≤15 pounds. Flexion balance is achieved when femoral contact point position is within the midposterior third of the tibial insert and intercompartmental loads are balanced. Loads in the medial and lateral compartments are recorded at 10, 45 and 90 degrees. If compartment loads differ by >15 lbs between compartments, unbalanced, further soft tissue release/bone resection will be done to achieve a side to side compartment pressure difference of <15 lbs through ROM.
88801178|NCT01222195|Experimental|Lenalidomide + Darbepoetin alfa|Lenalidomide 10 mg/day orally days 1-21 and Darbepoetin alfa 200 mcg subcutaneously every 2 weeks of 28 day cycle
88801179|NCT04126616|Experimental|patients with COPD and PH|
88801180|NCT04126616|Active Comparator|patients with COPD without PH|
88801181|NCT04126616|Active Comparator|healthy subjects|
88801182|NCT01222273|Other|Open label|open label Vitamin D
88801183|NCT04126460|Experimental|Toripalimab|Injection; dosage form: 6ml: 240mg; frequency: 240mgQ3W; duration: 17cycles (12 months) or randomization to the date of the first documented progression
88801184|NCT03161912||DME/naïve|patients with pre-treatment in diabetic macular edema (DME)
88801185|NCT03161912||DME/pre-treatment|patients without pre-treatment in DME
88801186|NCT03161912||RVO/pre-treatment|Macular edema secondary to RVO with prior treatment
88801187|NCT03161912||RVO/naïve|Macular edema secondary to RVO without prior treatment
88801188|NCT01222585|Experimental|Treatment|Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours
88801189|NCT04126382|Active Comparator|INSURE|Intubate-Surfactant-Extubate(INSURE) technique is a Important treatment in premature infants with RDS.
88801190|NCT04126382|Experimental|LISA|Less invasive surfactant administration(LISA) technique is a Important treatment in premature infants with RDS.
88801191|NCT03829592|Placebo Comparator|misoprostol in neutral media|Intervention : misoprostol in a neutral media will be given to women to induce labour
88801192|NCT03829592|Active Comparator|Misoprostol in acidic media|Intervention : misoprostol in acidic media will be given to induce labour
88801193|NCT03829592|Sham Comparator|Misoprostol in alkaline media|Intervention : misoprostol in alkaline media will be given to induce labour
88801194|NCT01142323|Experimental|Fenofibrate|fenofibrate 160 mg po daily
89120899|NCT00719641||Phase 2: Randomized to SSW during second colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to no subsequent use of the segmental stiffening wire that day, then colonoscopy with segmental stiffening wire upon repeat colonoscopy the next day.
89120900|NCT02868164|Experimental|Fecal Microbiota Transplantation (FMT)|
89120901|NCT02868164|Active Comparator|Weight Reduction|
89120902|NCT03352011|Experimental|Primary Care Brief Mindfulness Training|group-based mindfulness training
89120903|NCT03352011|Active Comparator|PTSD Psychoeducational Class|group-based psychoeducation class
89120904|NCT00717691|Experimental|1|Immediate fitting with dynamic splinting following diagnosis of hallux limitus.
89120905|NCT00717691|No Intervention|2|Control arm; patients only treated with standard of care following diagnosis of hallux limitus.
89120906|NCT02867072|Active Comparator|Open appendectomy|Subjects that underwent open surgery for appendicitis
89120907|NCT02867072|Active Comparator|Laparoscopic appendectomy|Subjects that underwent laparoscopic surgery for appendicitis
89120908|NCT04272710||ACEI treatment|hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
89120909|NCT04272710||Control|hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
89120910|NCT04068337||Hemiarch|Patients with Freestyle aortic root implantation receiving a hemiarch replacement by open anastomosis technique with axillary cannulation and antegrade cerebral perfusion
89120911|NCT04068337||Non-Hemiarch|Patients with Freestyle aortic root implantation without hemiarch replacement with normal systemic perfusion
89120912|NCT02866916|Experimental|Dose escalation|"The standard method 3+3 will be used for dose escalation: the first 3 patients will be treated at level 1; consecutive cohorts of 3 to 6 patients will be treated with increasing doses of SXL01.~Treatment will be administered until patient experiences unacceptable toxicity, PSA raising, progressive disease and/or treatment is discontinued at the discretion of the investigator or withdrawal of consent.~Additional patients will be included at the Recommended Phase II Dose (RP2D) in the expansion phase."
89120913|NCT04068571|Active Comparator|I-PUSH intervention sites|Clusters with I-PUSH intervention
89120914|NCT04068571|No Intervention|No I-PUSH intervention sites|Clusters with no I-PUSH intervention
89120915|NCT00777088|Experimental|Pipeline|Placement of Pipeline Embolization Device in the parent artery at the aneurysm location
89120916|NCT02868944|Experimental|experimental group|sequential combined spinal epidural with local anesthetic injection associated with morphine
89120917|NCT02868944|Active Comparator|control group|sequential combined spinal epidural with local anesthetic injection alone
89120918|NCT04067323|Placebo Comparator|LCT consumption|20g soy oil (containing mainly long chain triglycerides - LCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
89120919|NCT04067323|Experimental|MCT consumption|20g MCT oil (containing 100% MCT) together with 100g yogurt) will be provided in lunch-daily meal for a period of 4 months.
89120920|NCT03292809|Experimental|CyclASol Ophthalmic Solution|Cylclosporine A solution in vehicle
89120921|NCT03292809|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle only
89120922|NCT00722839|Experimental|Group A|Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
89120923|NCT00722839|Experimental|Group B|Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909 adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
89120924|NCT02868008|Experimental|fMRI guided AVM resection|fMRI guided microsurgical resection of brain AVMs
89120925|NCT04096924|Experimental|Treatment Group|Experimental group is allocated to use novel interventional guidewire for the echocardiography guided percutaneous interventions for ASD.
89120926|NCT04096924|Active Comparator|Control Group|Control Group is allocated to use Cook lunderquist guidewire for the echocardiography guided percutaneous interventions for ASD.
89120927|NCT04069195|Active Comparator|DHA supplement|Patients in the intervention group will recieve a ~1000mg capsule containing ~400mg of DHA. This is not standard of care and is being done for research purposes only. Patients will take this capsule once daily begining between 8-14 weeks of pregnancy until delivery of their infant.
89120928|NCT04069195|Placebo Comparator|corn oil: Soybean oil placebo|Patients in the Placebo group will recieve a ~1000mg capusle containing no DHA and filled with 50:50 mix of corn and soybean oils. This oil is ubiquitous in the american diet and only a very small amount of additional oil will be ingested for study purposes. Giving pregnant women this oil is not standard of care and is being done for research purposes only. Patients will continue taking this placebo from enrollment at 8-14 weeks of pregnancy until time of delivery.
89120929|NCT04290728|Experimental|High flow|Apply high-flow nasal oxygenation during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
89120930|NCT04290728|Active Comparator|Control|Apply nothing during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
89120931|NCT04096690|Experimental|Anti-PD-1 antibody plus pegaspargase|Participants will receive induction treatment for six cycles of Anti-PD-1 antibody plus pegaspargase (21-day cycle) and Anti-PD-1 antibody monotherapy maintenance treatment for about 2 years (21-cycle)
89120932|NCT00717847||1|Any patient with NSCLC receiving erlotinib or gefitinib
89120933|NCT00717847||2|Patients with unexpected and/or severe treatment related toxicity whilst receiving EGFR TKI.
89120934|NCT02868086|Experimental|Tested patients|Patients treated with anti-angiogenics for ARMD : monitoring using optical coherence tomography angiography
89120935|NCT02868086|Active Comparator|Control patients|Patients treated with anti-angiogenics for ARMD : monitoring during common practice via optical coherence tomography B scans
89120936|NCT00763282|Experimental|SM+MI|Self Management (SM) + Motivational Interviewing (MI). Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. Motivational Interviewing (MI) is an evidence-based form of counseling to help individuals to engage in behavior change. Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
89120937|NCT00763282|Active Comparator|ED|Education (ED). An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures. The ED intervention will differ only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
89120938|NCT00639951|Active Comparator|A Normal dose Group|20 vials up front in a Single Dose of Antivipmyn in 500 ml of solution IV, administered in 60 minutes. After 12 hours, it has to be perfomed a clinical evaluation of the patient. Each patient is going to have clinical studies of coagulation time and also the fibrinogen measures, this at 2, 4, 6, 8, 10, 12, 48, 72, 96 hours.All patients who have received at least one dose of medication study will be contacted by telephone to investigate the presence of symptoms suggestive of continuing with effect snake venom, or the presence of an adverse event, or any signs or symptoms indicating the presence of a hypersensitivity response to Antivipmyn® including serum sickness. If symptoms suggestive of an adverse event were discovered, the patient will referred for appropriate treatment.
89120939|NCT00639951|Placebo Comparator|B Placebo Group|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®. The treatment schedule for each subject is a dose of 5 vials Antivipmyn® every 2 hours to complete 20 vials, the total duration is 6 hours of the treatment. Each dose IV shall apply in physiological solution 250ml, and finish its application in 15 minutes. For pediatric patients the volume administered should not exceed the recommended fluid volume according to your body weight. After the assessment at 12 hours, it can be administered at the discretion of more antivenom attending by the physician.
89120940|NCT00988598|Active Comparator|PF-04447943|
89120941|NCT00988598|Placebo Comparator|Placebo|
89120942|NCT04184739|Active Comparator|Group A|Standard treatment information (verbal and written) and access to a basic version of the App with a toothbrushing timer. The timer is necessary as the health behaviour outcome is toothbrushing duration.
89120943|NCT04184739|Experimental|Group B|As for group A, however, additionally the App will provide generic treatment information (a combination of videos and text)
89120944|NCT04184739|Experimental|Group C|As for group B, however, the patients will have access to the full functionality of the App and the App will allow patients to input their own personalised treatment information (including progress photographs), set goals, develop plans for achieving these and provide the patient and clinicians with appropriate dashboards to monitor progress.
89233211|NCT02531516|Active Comparator|Control group|Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
89233212|NCT02526186|No Intervention|Standard of Care|Standard of Care only
89233213|NCT02526186|Experimental|Battlefield Auricular Acupuncture|Standard of Care plus Battlefield Auricular Acupuncture
89233215|NCT02494986|Experimental|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other antiretrovirals (ARVs).
88801195|NCT04126226|Experimental|Study group|
88801196|NCT04126226|No Intervention|Control Group|
88801197|NCT01142947|Other|beclomethasone dipropionate (BD)|Patients who meet eligibility criteria will be treated with 6 weeks of beclomethasone dipropionate to assess change in pulmonary function and asthma control. These change will be used as phenotypes in a genetic association study. There is no placebo group.
88801198|NCT02972294|Experimental|TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and tranexamic acid
88801199|NCT02972294|Experimental|Placebo TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and Placebos tranexamic acid
88801200|NCT02972294|Experimental|TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and tranexamic acid
88801201|NCT02972294|Experimental|Placebo TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and Placebos tranexamic acid
88801202|NCT02983214|Active Comparator|Clopidogrel|Clopidogrel 75 mg/day
88801203|NCT02983214|Active Comparator|Clopidogrel plus cilostazol|Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day
88801204|NCT03825068|Active Comparator|ESP block group|patients receive ESP Bock with local anaesthetics
88801205|NCT03825068|Placebo Comparator|control group|general anaestesia
88801206|NCT04393688|Experimental|Experimental: Tri-wire Peripheral Balloon Dilatation Catheter|Percutaneous transluminal angiography (PTA) will be performed using the Tri-wire Peripheral Balloon Dilatation Catheter. Interventions: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter; Procedure: Percutaneous Transluminal Angiography.
88801207|NCT04393688|Active Comparator|Active Comparator: OHICHO Ⅱ PTA Balloon Catheter.|Percutaneous transluminal angiography (PTA) will be performed using OHICHO Ⅱ PTA Balloon Catheter, a commercially available high-pressure PTA balloon. Multiple balloons, inflations and/or prolonged inflation may be used. Interventions: Device: OHICHO Ⅱ PTA Balloon Catheter. Procedure: Percutaneous Transluminal Angiography.
88801208|NCT03824678|Experimental|Administration of CC-220|All subjects will receive one 1-mg CC-220 capsule administered orally with approximately 240 mL of non-carbonated, room temperature water, and administered by trained clinical staff.
88801209|NCT02085356|Experimental|Intervention women with partners|Women will enroll with male partners and both members of the couple will attend the Protect your Family intervention
88801210|NCT02085356|Experimental|Intervention women without partners|Women will enroll alone and will attend the Protect your Family Intervention without a partner
88801211|NCT02085356|No Intervention|Control women with partners|Women will enroll with male partners and both members of the couple will attend time-matched video sessions
88801212|NCT02085356|No Intervention|Control women alone|Women will enroll alone and will attend time-matched video sessions
88801213|NCT03824834|Experimental|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) with supervised exercise training.
88801214|NCT03824834|Placebo Comparator|Exercise training with placebo|Placebo treatment with supervised exercise training.
88801215|NCT03829124|Experimental|ketamine + propofol group|use ketamine + propofol for ECT induction
89233217|NCT02446132|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 52-week period
89233218|NCT02446132|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 52-week period
89233219|NCT02446132|Experimental|AVP-786 (dose 3)|AVP-786 dose 3; capsules administered twice a day over a 52-week period
89233220|NCT02435212|Active Comparator|Arm 1|
89233221|NCT02435212|Experimental|Arm 2|
88801216|NCT03829124|Active Comparator|propofol group|use propofol only for ECT induction
88801217|NCT03828890|Other|Single Arm Trial|Intervention includes screening eye exam using Optos technology
88801218|NCT03829202|Experimental|A-B-A Group|Daily use of own mechanical knee for 4 weeks (A), followed by RheoKnee microprocessor prosthetic knee for 4 weeks (B), and concluding with own mechanical knee for 4 weeks (A).
88801219|NCT03829202|Experimental|B-A-B Group|Daily use of RheoKnee microprocessor prosthetic knee for 4 weeks (B), followed by own mechanical knee for 4 weeks (A), and concluding with RheoKnee microprocessor prosthetic knee for 4 weeks (B).
88801220|NCT03011216|Experimental|Adaptive emotional cognitive control training|"Adaptive emotional n-back task: On each trial of this task, participants are presented with an emotional facial expression. Participants have to indicate whether the emotion presented in the current trial is the same as n trials back. In order to train participants at their individual ability level, the n-level varies by trial block based on participants' performance on the previous block.~The adaptive emotional n-back task is assumed to train the ability to continuously update emotional material in working memory."
89290116|NCT01214928|Placebo Comparator|Placebo|Matching placebo po once weekly for 12 continuous weeks
89290117|NCT02625766|Experimental|Operative|Patients enrolled in the operative treatment group will undergo surgical intervention for their pelvic fracture. The surgeon will decide the best surgical technique as per standard of care for the patient's injury. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
88801221|NCT03011216|Active Comparator|Placebo training|"Adaptive non-emotional feature match task: On each trial of this task, participants are presented with two panels containing 8-12 shapes each. Participants are asked to compare the two panels and decide whether or not they are identical. The panels contain a minimum of 8 shapes and a maximum of 12 shapes, depending on participants' performance on the previous block.~The adaptive non-emotional feature match task is assumed to train the speed of responding (involving processes like visual search and concentration). It does not trait working memory updating."
88801222|NCT03828578|Experimental|High flow oxygen therapy|"Patients allocated to the intervention group will receive high flow oxygen therapy via the tracheostomy tube from cessation of mechanical ventilation. The HFOT will provide oxygen therapy at a flow rate of 50-60 litres per minute at a FiO2 titrated by the bedside clinician to maintain a peripheral oxygen saturation of 95% of more (unless otherwise clinically indicated and documented by an appropriate consultant).~Once transferred to the ward patients will continue to receive HFOT 24 hours per day at a rate of 50-60 litres per minute at a maximum oxygen concentration of 40% to achieve oxygen saturations 95% and above (unless otherwise documented).~Patients may be disconnected from the HFOT for short periods for toileting, mobilising etc. Tracheostomy weaning will continue as per standard practice with an aim of cuff deflation followed by decannulation once clinically appropriate. systems. Following decannulation patients will resort to standard oxygen therapy as needed."
88801223|NCT03828578|No Intervention|Standard Care|Patients randomised to the standard care study arm will receive routine post-operative care as currently performed within the host organisation. Following cessation of mechanical ventilation, oxygen therapy will be delivered using equipment and rates appropriate to the clinical picture. On transfer to the ward patients will continue with existing methods of oxygen therapy and will be weaned from these accordingly. Patients will continue to use heat moisture exchanges (e.g. Swedish nose or Buchannan protectors) as clinically indicated, as well as having saline nebulisers prescribed and administered as per standard. Tracheostomy weaning will continue in accordance with current practice. Data on all of the applied procedures will be recorded.
88801224|NCT02965976|Experimental|Arm I (botulinum toxin type A, esophagectomy)|Patients receive botulinum toxin type A injection IM while undergoing standard minimally invasive esophagectomy.
88801225|NCT02965976|Active Comparator|Arm II (esophagectomy)|Patients undergo standard minimally invasive esophagectomy.
88801226|NCT03824288|Active Comparator|The landmark technique|PTA a needle aspiration attempted according to the landmark technique is conducted. If the initial aspiration is unsuccessful, two additional attempts are made in the middle and lower pole of the tonsil.
88801227|NCT03824288|Experimental|Ultrasound-guided aspiration|An intraoral ultrasound is conducted with a Burr-Hole N11C5s transducer (BK Ultrasound) and if an abscess cavity is suspected, an ultrasound-guided aspiration is performed with an in-plane needle guide attached to guide the needle.
88801228|NCT00982397|Experimental|Single-chamber detetction|Patients implanted with a Protecta VR-ICD.
88801229|NCT00982397|Experimental|Dual-chamber detection|Patients implanted with a Protecta DR-ICD or CRT-D.
88801230|NCT03828656|Experimental|Open Label Treatment Arm|Open-label Intervention with the NightWare Therapeutic System every night.
88801231|NCT04125680|Other|ESL Health Literacy Classes|The program will last 8 weeks with classes held online during evening hours. The curriculum will focus on using pedagogies for health literacy as a practice. Assessments will be administered pre-post intervention.
88801232|NCT04392596|Experimental|patients|40
88801233|NCT05394389|Active Comparator|sensory-stimulating therapy|
88801234|NCT05394389|Active Comparator|social interaction|
88801235|NCT05394389|Experimental|combined sensory-stimulating therapy and social interaction.|
88801236|NCT02963948||Clinic A1|
88801237|NCT02963948||Clinic A2|
88801238|NCT02963948||Clinic B1|
88801239|NCT02963948||Clinic B2|
88801240|NCT02963948||Clinic B3|
88801241|NCT02963948||Clinic B4|
88801242|NCT03828812|Active Comparator|Breakfast promotion|Receiving the recommendation of daily breakfast
88801243|NCT03828812|Active Comparator|Nighttime snack reduction|Receiving the recommendation of reducing nighttime snack frequency
89120945|NCT04105803||De novo HTx|"Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography and coronary angiography is part of the scheduled standard HTx follow-up visits."
89120946|NCT04105803||Longterm HTx|"Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
89120947|NCT04105803||PET-scan de novo HTx|"Radiation: Two PET-scans with 11C-acetate tracer will be performed.~Procedure: Two perprocedural biopsies under transplantation is performed from the left ventricular septum.~Procedure: Endomyocardial biopsies from the right ventricular septum, taken at scheduled standard HTx follow-up visits at our department (protocol is to take 4-5 biopsies, two additional biopsies will be taken at this visit).~Procedure: Coronary Angiography is part of the scheduled standard HTx follow-up visits. This recording will be used for CAV evaluation. In addition to the protocol procedure, we will evaluate the hemodynamic status in the patients.~Diagnostic test: Echocardiography is part of the scheduled standard HTx follow-up visits. No additional examinations will be performed. We will use the standard recordings to calculate the desired parameters."
89120948|NCT00719797|Experimental|Arm I (FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
88801244|NCT03828812|Experimental|Breakfast promotion + nighttime snack reduction|Receiving the recommendation of daily breakfast + reducing nighttime snack frequency
88801245|NCT04393220|Experimental|Bevacizumab and anti-PD-1 therapy|
88801246|NCT04393220|Active Comparator|Bevacizumab|
88801247|NCT04393220|Active Comparator|anti-PD-1|
88801248|NCT01025453|Experimental|Pts getting Temsirolimus and Sorafenib|We propose a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). A maximum of 36 subjects will be evaluated during the study. Restaging scans, with evaluation of response, will be done every 2 cycles (8 weeks of treatment). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 4 weeks, or at the discretion of the treating physician or patient.
88801249|NCT04125602|Experimental|High fat low carbohydrate diet|
88801250|NCT04125602|Experimental|Low fat high carbohydrate diet|
88801251|NCT05394311|Experimental|Intervention arm - sport based mental health promotion program|The experimental arm will receive an intervention for around 10 months' period after baseline data collection.
88801252|NCT05394311|No Intervention|Control group - treatment as usual|This group receive the intervention available in the existing health care and education system in the study area.
88801253|NCT03824054||colorectal resection arm|Patients affected by symptomatic deep infiltrating endometriosis involving the bowel and submitted to colo-rectal resection
88801254|NCT05394233|Experimental|tislelizumab combined with bevacizumab and platinum plus pemetrexed|"Drug:~Induction Phase:~Bevacizumab: 7.5 mg/kg administered as an IV infusion on Day 1 of each 3-week cycle for 4 cycles Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours every 3 weeks for 4 cycles.~Pemetrexed, 500 mg/m2, intravenously, every 3 weeks for 4 cycles~Maintenance phase:~Tislelizumab, 200 mg IV every 3 weeks;until disease progression or intolerance Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle;until disease progression or intolerance"
88801255|NCT03824210||Stage 1|School children age 11-18 (from two nominated schools) and young carers 11-18
88801256|NCT03824210||Stage 2|Young carers from Young Carers in Herts 11-18
88801257|NCT00982553|Experimental|Phase 1_ribavirin|Treatment with Single dose ribavirin (800 mg) administered on day 1
88801258|NCT00982553|Experimental|Phase2_raltegravir|Treatment with Raltegravir (400 mg twice daily) administered from days 15-19
88801259|NCT00982553|Experimental|Phase3_ribavirin+raltegravir|Treatment with Ribavirin (800 mg) and Raltegravir (400 mg) administered day 20
89120949|NCT00719797|Experimental|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
89120950|NCT00979628|Experimental|Basal Plus Regimen|glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed
89120951|NCT00979628|Experimental|Basal Bolus|glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)
89120952|NCT00979628|Active Comparator|sliding scale regular insulin (SSRI)|sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.
89120953|NCT04096534|Experimental|Normotonic partial nephrectomy|Performing a partial nephrectomy under normal body blood pressure
89120954|NCT04096534|Active Comparator|Hypotonic partial nephrectomy|Performing a partial nephrectomy under hypotonic body blood pressure
89120955|NCT02868788|Other|high fat high calorie|Subjects in this arm will receive high fat high calorie meal
89120956|NCT02868788|Experimental|high fat high calorie plus fiber|Subjects in this arm will receive high fat high calorie meal plus dietary fiber supplementation
89120957|NCT00719875|Experimental|1|
89120958|NCT02685111|Active Comparator|A. Pegfilgrastim|D2 once a cycle pegfilgrastim arm
89120959|NCT02685111|Experimental|B. Filgrastim|Intermittent Every Other Days of 5 Shot (D3-11) filgrastim arm
89120960|NCT00762970|Experimental|Test Lens 1|Investigational soft contact lenses worn daily.
89120961|NCT00762970|Experimental|Test Lens 2|Investigational soft contact lenses worn daily.
89120962|NCT00762970|Active Comparator|Control lens|Spectacle lenses worn daily.
89120963|NCT00717925|Experimental|1|
89120964|NCT00988442|Experimental|Enhanced nursing telephone support with standard care|Participants received enhanced nursing telephone support plus care as usual.
89120965|NCT00988442|Active Comparator|Standard care|Participants received care as usual.
89120966|NCT00718003||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
89120967|NCT00640029|Experimental|1|Cervical - Arthroplasty
89120968|NCT00640029|Active Comparator|2|Cervical - Arthrodesis
89120969|NCT00640029|Experimental|3|Lumbar - Over 50 years - Arthroplasty
89120970|NCT00640029|Active Comparator|4|Lumbar - Over 50 years - Arthrodesis
89120971|NCT00640029|Experimental|5|Lumbar - Under 50 years - Arthroplasty
89120972|NCT00992186|Experimental|Carlumab|
89120973|NCT04184817||Medical data collection|The medical data of patients diagnosed by Achondroplasia will be collected. The radiological data will analyse to evaluate the severity of stenosis as well as its clinical tolerance and evolution.
89120974|NCT02684799|Experimental|Part 1 Group 1 (Cenicriviroc)|Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.
89120975|NCT02684799|Active Comparator|Part 1 Group 1 (Omeprazole)|Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.
89120976|NCT02684799|Experimental|Part 1 Group 2 (Cenicriviroc)|Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.
89120977|NCT02684799|Active Comparator|Part 1 Group 2 (Famotidine)|Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.
89120978|NCT02684799|Experimental|Part 2 (Cenicriviroc)|Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.
89120979|NCT02684799|Active Comparator|Part 2 (Omeprazole)|Part 2 (24 subjects) will receive Omeprazole from Days 11-20.
89120980|NCT02685189||0.75 mg/kg Previous exposure to stannsoporfin|Previous exposure 0.75 mg/kg
89120981|NCT02685189||1.5 mg/kg Previous exposure to stannsoporfin|Previous exposure 1.5 mg/kg
89120982|NCT02684877||Intensive care survivors|Observational study
89120983|NCT00992108|Active Comparator|Lidocaine|lidocaine injection group
89120984|NCT00992108|Experimental|Botulinum|
89120985|NCT02684721|No Intervention|Control group|Patients in the control group receive usual care as a minimum. This includes 3-5 days of hospitalisation where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.
89120986|NCT02684721|Experimental|Exercise group|8-week home-base exercise programme: Patients in the intervention group receive the same usual care as patients in the control group. In addition the patients participate in an 8 week home-based exercise programme, including follow-up telephone calls with the physiotherapist after 1 week, 2 weeks and 4 weeks. Briefly put, the patients are required to exercise for a minimum of 3 times per week for 30-60 minutes, and with 3-4 intervals of approximately 1 minute at a high intensity level. Total exercise time and intervals increase during the 8 week programme. The patients can choose whatever type of exercise they prefer, and they are generally encouraged to choose something they already do, or something that they have previously had positive experiences doing.
89120987|NCT00752986|Experimental|Vandetanib at the dose of 100 mg|vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
89120988|NCT00752986|Experimental|Vandetanib at the dose of 300 mg|vandetanib at the dose of 300 mg orally once-daily plus placebo to match vandetanib 100 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
89120989|NCT00752986|Placebo Comparator|Placebo to match vandetanib 100 mg and 300 mg|placebo to match vandetanib 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3).
89120990|NCT02684487|Active Comparator|vitamin D3|Patients will be given single dose of vitamin D3 within 24 hours of new-onset severe sepsis, followed by weekly doses of vitD3 (25,000 IU) up to 90 days to assess clinical outcomes and key biomarkers.
89120991|NCT02684487|Sham Comparator|Placebo|Patients will be given placebo intervention within 24 hours of new onset severe sepsis followed by or placebo for up to 90 days to assess clinical outcomes and key biomarkers.
89120992|NCT02601274|Experimental|Single Group Assignment|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 7 dose cohorts,including120mg/160mg/200mg/220mg/300mg/400mg/500mg, QD in the dose escalation stage .
89120993|NCT02684409|Experimental|PROT-CL-NP101-015.01|
89120994|NCT00762892|Active Comparator|Raltegravir|Raltegravir in combination with truvada (tenofovir and emtricitabine)
89120995|NCT00762892|Active Comparator|Atazanavir|Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
89120996|NCT04290416|Experimental|Microwire electrodes|Activity of individual neurons will be recorded via microwire contacts. These microwire electrodes do not interfere with the macrowire clinical recordings.
89120997|NCT04290572|Experimental|Isotretinoin 10 mg/day|One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.
89120998|NCT04290572|Experimental|Isotretinoin 20 mg/day|One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.
89120999|NCT04290572|Active Comparator|Isotretinoin 30 mg/day|One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.
89121000|NCT04098562|Experimental|Treatment|0.5 mg/mL LL-37 cream, administered twice a week for 4 weeks
89121001|NCT04098562|Placebo Comparator|Placebo|Placebo cream, administered twice a week for 4 weeks
89121002|NCT04069429|Experimental|Healthy Controls|7 controls (subjects without GI symptoms and known GI disease), subjects will receive the radiopharmaceutical agent orally
89121003|NCT04069429|Experimental|Eosinophilic Esophagitis Patients|10 patients with diagnosed EoE (greater than 15 eosinophils per HPF) on esophageal biopsy will be included as the diseased population, subjects will receive the radiopharmaceutical agent orally
89121004|NCT04290650|Other|Modified CBT for insomnia|All patients admitted to one of the psychosis ward will be offered the same customized treatment focusing on sleep in addition to treatment as usual.
89121005|NCT04290650|Other|Treatment as usual|All patients admitted to the other two psychosis wards will only receive treatment as usual.
89121006|NCT02572999||Valvular heart disease|All patients aged 70 years or older, consecutively admitted for elective heart valve surgery or if admitted for elective transcatheter aortic valve implantation, or if a patient presents with symptomatic moderate to severe valvular heart disease on hospital admission as evidenced by moderate to severe valve regurgitation or stenosis will be included in this cohort. Participants will be observed up to 30 days post-hospital discharge
89121007|NCT04068025|No Intervention|No Intervention: Control group|Patients in the control group were given usual care by a health professional who was not involved in the study and who worked in the Department of Urology. After the end of the study, the patients in the control group were also given structured bladder training similar to the patients in the intervention group.
89121008|NCT04068025|Active Comparator|the IMB model|Structured bladder training was applied to the patients in the intervention group via the IMB model.
89121009|NCT00755716|Placebo Comparator|Placebo (sugar pill)|Person receives an inactive placebo
89121010|NCT00755716|Active Comparator|Topiramate|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day for a total time of 10 weeks.
89121011|NCT00755716|Active Comparator|Topiramate and Nicotine patch|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day and one week taper for a total time of 10 weeks. On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
89121012|NCT00629252|Experimental|1|Schizophrenic patients treated with sertindole
89121013|NCT00629252|Active Comparator|2|Schizophrenic patients treated with risperidone
89121014|NCT00629252|No Intervention|3|Healthy controls without any treatment.
88801260|NCT03823898|Experimental|Supervised exercise|"Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants were involved in two supervised exercise sessions per week plus healthy lifestyle interactive sessions.~The experimental intervention consisted of: a) monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study; b) The supervised exercise sessions were prescribed using an aerobic mode performed at a moderate-to-vigorous intensity during 45 minutes, twice a week, preferably during the weekends."
88801261|NCT03823898|Active Comparator|Control Group|Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants received no intervention
88801262|NCT03823898|Experimental|Monthly behavioral sessions|"Participants in this group received a lifestyle intervention from baseline to 4 months and then from 4 to 16 months participants were involved in non-supervised exercise group sessions with monthly behavioral sessions.~The experimental intervention consisted of monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study"
88801263|NCT02945384|Experimental|Creating Connections|Dual-generation intervention: child component delivered in classroom setting, parent component delivered in small-group setting
88801264|NCT02945384|No Intervention|Head Start as usual|Regular Head Start curriculum
88805876|NCT01138475|Active Comparator|cholecalciferol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
88805877|NCT01138475|Placebo Comparator|placebo|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
88805878|NCT01896830|Experimental|Vaccine Group|Participants will receive the candidate C. difficile toxoid vaccine
89121015|NCT04290338|Experimental|PIOMI Group|Patients in this group will receive the intraoral and extraoral stimulations provided by the PIOMI protocol. These stimulations will last 5 minutes and will be performed once a day for 7 consecutive days for each patient.
89121016|NCT04290338|No Intervention|Control Group|Patients in this group will receive classic care.
89121017|NCT04067167|Sham Comparator|WB-EMS (Sham-intervention)|Low-theshold WB-EMS combined with nutritional therapy
89121018|NCT04067167|Experimental|WB-EMS|WB-EMS combined with nutritional therapy
89121019|NCT04067167|Experimental|Free WB-EMS|WB-EMS using a mobile System combined with nutritional therapy
89121020|NCT04067167|Experimental|Flexi Band Resistance Training|Flexi band resistance Training combined with nutritional therapy
89121021|NCT04093726|Experimental|lollipop|
89121022|NCT04093726|No Intervention|control|
89121023|NCT02866994|Experimental|Project Connect Online (PCO)|Creation of personal website to share breast cancer experience with friends and family
89121024|NCT02866994|Experimental|PCO PLUS|Creation of personal website to share breast cancer experience with friends and family, as well as other women diagnosed with breast cancer
89121025|NCT02572531|Active Comparator|L. reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 2 weeks
89121026|NCT02572531|Placebo Comparator|Placebo|Placebo lozenges three times daily for 2 weeks
89121027|NCT04096144|Experimental|Neostigmine|This is the standard Neuromuscular reversal drug that has been in standard care for the past thirty years. Dose: -Neostigmine: 0.03-0.07 mg/kg by intravenous route.
89121028|NCT04096144|Experimental|Sugammadex|"Used for Neuromuscular reversal; Sugammadex is devoid of the parasympathetic effects caused by Neostigmine.~Dose: -Sugammadex: 2-4 mg/kg (4 mg/kg if no twitch responses after initial stimulation), intravenous route."
89121029|NCT02866604|Active Comparator|Strerofundin|Days of intervention: 3 days
89121030|NCT02866604|Active Comparator|0.9% saline|Days of intervention: 3 days
89121031|NCT00722995|Active Comparator|1|Sleeve gastrectomy
89121032|NCT00722995|Active Comparator|2|Gastric Bypass
89121033|NCT04095754|Other|Group I (control group)|Patients will be positioned supine.
89121034|NCT04095754|Experimental|Group II|patients will be positioned 10° anti-trendelenburg position.
89121035|NCT04095754|Experimental|Group III|patients will be positioned 20° anti-trendelenburg position.
89121036|NCT03989245||Target arm: UCC (Cognitive Behavioural Unit)|Patients receiving care in Cognitive Behavioural Unit (UCC )
89121037|NCT03989245||Control arm: SSR (Geriatric Follow-up and Rehabilitation Unit)|Patients receiving care in Geriatric Follow-up and Rehabilitation Care Unit (SSR)
89121038|NCT00755326|Active Comparator|Huo-Luo-Xiao-Ling|Active herb Huo-Luo-Xiao-Ling (HLXL) The subjects in the HLXL group received the medium dose of HLXL (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/day) for the subsequent 6 weeks.
89121039|NCT00755326|Placebo Comparator|Placebo|Placebo Huo-Luo-Xiao-Ling (HLXL): Subjects in the placebo group received an equal number of placebo capsule.
89121040|NCT00720265|Active Comparator|1|
89121041|NCT00720265|Experimental|2|
89121042|NCT02600650|Experimental|Experimental|Receive daily authentic Testosterone boosting supplement
89121043|NCT02600650|Placebo Comparator|Placebo|Receive daily placebo supplementation
89121044|NCT03084471|Experimental|Combination therapy|"Combination therapy (durvalumab + tremelimumab) : Patients will receive the combination therapy followed by monotherapy via intravenous (IV) infusion once Q4W:~Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) and~Durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab."
89121045|NCT03084471|Experimental|Monotherapy|Monotherapy (Durvalumab 1,500 mg): Patients will receive durvalumab 1,500 mg via IV infusion Q4W on Week 0.
89121046|NCT00723151|Experimental|Low Intensity|One hour of intervention per week
89121047|NCT00723151|Experimental|High Intensity|Five hours of intervention per week, one hour per day for five days per week
89121048|NCT00718393||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
89121049|NCT04095910|Experimental|Planet Nutrition program|multidisciplinary school- based program
89121050|NCT04095910|No Intervention|Control Group|Normal curricular classes
89121051|NCT00718471|Experimental|1|Enoxaparin
89121052|NCT00718471|Active Comparator|2|UFH
89121053|NCT00916708|Experimental|Intensive follow up|Intensive follow up in low-risk patients Intensive follow up in high-risk patients
89121054|NCT00916708|Experimental|Minimalist follow up|Minimalist follow up in low-risk patients Minimalist follow up in high-risk patients
89121055|NCT00723307|Experimental|Metformin|
89121056|NCT00723307|Placebo Comparator|Placebo|
89121057|NCT00723385|Placebo Comparator|Placebo|Placebo administration for 12 weeks with repeated 25-OH D determinations over 12 weeks, dietary, sunshine questionnaire recording
89121058|NCT00723385|Experimental|Vitamin D|Vitamin D (1000 or 2000 IU/day)
89121059|NCT02684565|Active Comparator|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
89121060|NCT02684565|Active Comparator|BCAA Low Protein Supplement|Subjects will be randomly assigned to take low BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
89121061|NCT00754936|Experimental|Escitalopram|12 week open label with 2 week placebo period (14 weeks total)
89121062|NCT02684643|Experimental|enhanced individualised therapy|Patients' dialysis dosage, medication as well as dietary plan will be modified.
89121063|NCT02684643|Experimental|non-enhanced individualised therapy|Patients' medication as well as dietary plan will be modified without alteration of dialysis dosage.
89121064|NCT02684643|Experimental|regular intervention|Phosphate binders and calcitriol will be prescribed and adjusted without altering patients' diet habit.
89121065|NCT04095988|Experimental|Verum-AMR|Patients receiving Verum-Allogeneic Microbiota Reconstitution via gastroscopy
89121066|NCT04095988|Placebo Comparator|Placebo-AMR|Patients receiving Placebo(Saline)-Infusion via gastroscopy
89121067|NCT02684019|Active Comparator|Dexmedetomidine|1microgram/kilogram loading dose followed by 0.5 microgram/kilogram/hour IV
89121068|NCT02684019|Active Comparator|Magnesium sulphate|40milligram/kilogram loading dose followed by 10milligram/kilogram/hour IV
89121069|NCT00720421|Other|1|AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy
89121070|NCT00720421|Other|2|AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 1mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy
89121071|NCT00720421|Other|3|AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy
89121072|NCT00720421|Other|4|AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy
89121073|NCT02684175|Active Comparator|In-Person CI Counseling Session|Participants (n=6) randomized to receive an in-person CI counseling session will receive what normally occurs with patients pursuing cochlear implantation. The counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, an explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
89121074|NCT02684175|Experimental|Remote CI Counseling Session|Participants (n=6) randomized to receive a remote CI counseling session will be receiving the counseling session remotely. The participants will be counseled remotely by the audiologist located in Lexington, KY via the telemedicine system (intervention). This counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
89121075|NCT04068259|Experimental|Cohort 1, Dose 1 of PBI-4547 or Placebo|Dose 1 of PBI-4547 or matching Placebo tablets by mouth
89121076|NCT04068259|Experimental|Cohort 2, Dose 2 of PBI-4547 or Placebo|Dose 2 of PBI-4547 or matching Placebo tablets by mouth
89121077|NCT04068259|Experimental|Cohort 3, Dose 3 of PBI-4547 or Placebo|Dose 3 of PBI-4547 or matching Placebo tablets by mouth
89121078|NCT04068259|Experimental|Cohort 4, Dose 4 of PBI-4547 or Placebo|Dose 4 of PBI-4547 or matching Placebo tablets by mouth
89121079|NCT04068259|Experimental|Cohort 5, Dose 5 of PBI-4547 or Placebo|Dose 5 of PBI-4547 or matching Placebo tablets by mouth
89121080|NCT00762502|Active Comparator|senofilcon A toric bilaterally|senofilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
89121081|NCT00762502|Active Comparator|balafilcon A toric bilaterally|balafilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
89121082|NCT00762502|Active Comparator|senofilcon A/balafilcon A contralaterally|senofilcon A lens worn in one eye and balafilcon A lens worn in the other eye (contralaterally), daily for 3 months, replaced weekly.
89121083|NCT02684331||T2DM|
89121084|NCT00723463|Experimental|A|To determine if apparent diffusion coefficient values can differentiate tumors from normal tissues using a 3T MRI scan.
89121085|NCT00723541|Experimental|A|Develop a computer-aided diagnostic system that will aid in the screening and detection of breast abnormalities/cancer
88801265|NCT02939300|Experimental|Combination Of Nivolumab with Ipilimumab|"All patients will be treated based on their primary tumor diagnosis with a combination regimen of Nivolumab and Ipilimumab. Each treatment cycle is 6 weeks; exceptions below.~Melanoma:~Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg, every 3 weeks for 4 doses.~Followed by Nivolumab 480 mg every 4 weeks until disease progression. Each cycle of monotherapy is defined as 8 weeks.~Non-small Cell Lung Cancer / Head and Neck Cancer:~- Nivolumab 3 mg/kg every 2 weeks, and Ipilimumab 1 mg/kg every 6 weeks.~Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg, every 3 weeks for 4 doses.~Followed by Nivolumab 240 mg every 2 weeks until disease progression.~Renal Cell Carcinoma / Other Solid Tumors (not listed above):~Nivolumab 3 mg/kg and Ipilimumab 3 mg/kg, every 3 weeks for 4 doses.~Followed by Nivolumab 480 mg every 4 weeks until disease progression. Each cycle of monotherapy is defined as 8 weeks."
88801266|NCT03823664||Type 2 Diabetic|"Fasting Plasma Glucose ≥126 mg/dL (7.0 mmol/L). OR * A1C ≥6.5% (48 mmol/mol). OR * Patients with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).OR* 2-h Plasma Glucose ≥200 mg/dL (11.1 mmol/L) during oral glucose tolerance test*~* American Diabetes As. (ADA) type 2 diabetes diagnosis criteria"
88801267|NCT03823664||Prediabetic|"Fasting Plasma Glucose 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (Impaired Fasting Glucose)* OR A1C 5.7-6.4% (39-47 mmol/mol)* OR 2-h Plasma Glucose during 75-g Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (Impaired Glucose Tolerance)*~* ADA prediabetes criteria"
88801268|NCT03823664||Healthy|Healthy glucose metabolism and according to endocrinology visit no health problems related or affect cardiorespiratory fitness and other parameters examined in this study.
88801269|NCT03823508|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (left dorsolateral prefrontal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
88801270|NCT03823508|Placebo Comparator|sham tDCS|Patients will receive sham tDCS (15 secondes of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
88801271|NCT02910986|No Intervention|Usual Care|Breast density notification using standard language reporting for dense and non-dense breasts within the mammogram results notification letter
88801272|NCT02910986|Active Comparator|Enhanced|Usual Care plus a written educational brochure
88801273|NCT02910986|Active Comparator|Interpersonal|Usual Care plus Enhanced plus interaction with a promotora (lay health educator)
88801274|NCT03822260||Sur1/ Trpm 4 acitivities at SAH|only after collecting sample,
88801275|NCT04392128|Experimental|Treatment arm|Patients enrolled in the experimental arm will receive hydroxychloroquine (200mgx3 tablets per day during 10 days) and azithromycine (500 mg at day 1 (2 capsules taken at the same time) then 250mg per day (1 capsule per day) during 4 days).
88801276|NCT04392128|Placebo Comparator|Control arm|Patients enrolled in the control arm will receive a placebo of hydroxychloroquine (3 tablets per day during 10 days) and a placebo of azithromycine (2 capsules taken at the same time at day 1, then 1 capsule per day during 4 days)
89121086|NCT00762268|Experimental|SAMe|"SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
89121087|NCT00762268|Placebo Comparator|placebo|"Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day rest-period, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period."
89121088|NCT02689713|Experimental|Topical Voriconazole Study Drug Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Voriconazole study drug placed on graft site.
89121089|NCT02689713|Placebo Comparator|Topical Sterile Water Placebo Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Sterile Water Placebo placed on graft site.
89121090|NCT00723619||1|Children and adolescent from German schools in the region Wesel, Hannover and Düsseldorf, selected via special school lists
89121091|NCT05373589|Experimental|group C|
89121092|NCT05373589|Experimental|group PS|
89121093|NCT04187313|Experimental|Intervention|The intervention arm will comprise study participants who receive intervention package (i.e. private practitioners in the selected areas who agree to participate).
89121094|NCT04187313|No Intervention|Control|Private practitioners in the control areas will receive no intervention.
89121095|NCT02601508|Active Comparator|Modarate Blockade Group|Neuromuscular blocking agent, cis-atracurium will be administered after skin incision and reversal agents, pyridostigmine & glycopyrrolate will be given for the recovery.
89121096|NCT02601508|Experimental|Deep Blockade Group|Neuromuscular blocking agent, rocuronium will be administered after skin incision and reversal agent, Sugammadex will be given for the recovery.
89121097|NCT00723775|Other|Part 1|GSK706769 new vs. current formulation; GSK706769 alone vs. GSK706769 plus Kaletra
89121098|NCT00723775|Other|Part 2|GSK706769 alone for 10 days; GSK706769 + Kaletra for 14 days
89121099|NCT04187157||Blue-light filtering intraocular lens (IOL)|Bilateral implantation of blue-filtering intraocular lens. Blue-IOL, in addition to ultraviolet, also impede the transmission of the lower visible blue spectrum between 400 and 500nm.
89121100|NCT04187157||Conventional intraocular lens (IOL)|Bilateral implantation of conventional ultraviolet light-blocking intraocular lens
89121101|NCT04184193||Pulmonary Rehabilitation|
89121102|NCT02570581|Placebo Comparator|Plain jelly control|Plain jelly control
89121103|NCT02570581|Active Comparator|Jelly with: Paracetamol|"Jelly with:~Paracetamol"
89121104|NCT02570581|Active Comparator|Jelly with Furosemide|Jelly with Furosemide
89121105|NCT02570581|Active Comparator|Jelly with Levothyroxine sodium salt|Jelly with Levothyroxine sodium salt
88801277|NCT03822026|Other|patients with severe TBI|Patients with severe TBI enrolled in the study undergo an hyperventilation test, in which the alveolar ventilation is increased by a stepwise increase in tidal volumes and respiratory rate until a reduction of etCO2 of 0.7 kPa is achieved.
88801278|NCT04125056|Experimental|test group|Hydronidone capsules (Specification: 30 mg / capsule）
88801279|NCT04125056|Placebo Comparator|Control group|Hydronidone capsules (Specification: 15 mg / capsule）
88801280|NCT02565186|Experimental|Lasmiditan 100mg|Participants received oral dose of 100 milligrams (mg) Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
88801281|NCT02565186|Experimental|Lasmiditan 200mg|Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
88801282|NCT03823352|Experimental|Antroquinonol|Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
88801283|NCT03823586||Children|
88801284|NCT03823586||Adolescents|
88801285|NCT04124978|Experimental|Intervention group|prospective, single armed, single centre trial study using the MyTAP device on a daily basis for a period of 3 months
88801286|NCT04758494||Stroke1-hemiparesis|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical hemiparesis.
88801287|NCT04758494||Stroke 2-mild stroke|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of a mild stroke.
88801288|NCT04758494||Stroke 3-speech disorder|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of a speech disorder.
88801289|NCT04758494||Stroke 4-hemiparesis mainly of upper limb|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical hemiparesis mainly of upper limb.
88801290|NCT04758494||Stroke 5-memory loss and depression|Patients diagnosed with an ischemic/hemorrhagic stroke and clinical symptoms of memory loss and depression.
88801291|NCT04758494||Multiple Sclerosis|Patients diagnosed with multiple sclerosis.
88801292|NCT04274504||patients|metatstatic breast
88801293|NCT04274816|Experimental|Tremelimumab|Intradermal injection of tremelimumab at the primary melanoma excision site, 7 days prior to sentinel node biopsy (SNB), with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
88801294|NCT05509374|Experimental|A study of carfilzomib, pomalidomide and dexamethasone administration after KRd administration|Patients with RRMM who progressed after receiving lenalidomide monotherapy for at least 6 months after administration of KRd will receive KPD therapy every 4 weeks until disease progression.
88801295|NCT04124744|Experimental|Intervention|Will receive the Health Champion intervention
88801296|NCT04124744|Active Comparator|Control|Treatment as usual
88801297|NCT04124822|No Intervention|control|group 1 , is no intervention group in which root canal procedure will be done without drug as ideal protocol .
88801298|NCT04124822|Experimental|Piroxicam|group 2 is given Piroxicam 20 mg half an hour before root canal treatment to manage post operative pain.
88801299|NCT04124822|Experimental|Prednisolone|group 3 is given Prednisolone 20mg half an hour before root canal treatment to manage post operative pain.
88801300|NCT01453790|Experimental|Parent-Specific Depression Education-Motivation|Mothers receive depression education (verbal and written) with messages targeted to parent status which are drawn from previous research. They also receive motivational messages at 2 days via telephone.
88801301|NCT01453790|Active Comparator|General Depression Education|Mothers receive general depression education (verbal and written) which are drawn from previous research. They also receive attention control telephone calls at 2 days.
88801302|NCT04802226|Experimental|optimized self-exclusion procedure A|optimized self-exclusion procedure including content optimization with brief intervention, normative feedback, motivational approach, a personal story of a peer who had a positive experience using the tool, re-contact before the end of the self-exclusion period to propose an extension of the period outside the gambling plateform
88801303|NCT04802226|Other|standard self-exclusion B|standard self-exclusion with a single neutral notification email
88801304|NCT05504694|Experimental|Ofatumumab|The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.
88801305|NCT02854670|Experimental|Capsaicin patch|Cuttable capsaicin patch. 2 patches of 4 cm² (2 x 2cm), for a total of 2.5 mg of capsaicin.
88801306|NCT01453868|Active Comparator|Active non impact aerobics|This group will be performing a 12 week non impact aerobics program twice a week.
88801307|NCT01453868|Active Comparator|Control group: Passive lecture series|The control group will also be measured for balance and then attend a 12 week lecture series with no exercise. They will then also be remeasured post lectures series
88801308|NCT02843282|Experimental|Cognitive training|Advanced reasoning training
88801309|NCT01454024||Total study population|
88805879|NCT01896830|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
89121106|NCT02570581|Active Comparator|Jelly with memantine|Jelly with memantine
89121107|NCT02570581|Active Comparator|jelly with zopiclone|Jelly with zopiclone
89121108|NCT02570581|Active Comparator|jelly with alprazolam|elly with alprazolam
89121109|NCT02570581|Active Comparator|jelly with Oxazepam|Jelly with Oxazepam
89121110|NCT02570581|Active Comparator|jelly with donepezil|jelly with donepezil
89121111|NCT02570581|Active Comparator|Jelly with clopidogrel|jelly with clopidogrel
89121112|NCT02570581|Active Comparator|jelly with ramipril|jelly with ramipril
89121113|NCT02570581|Active Comparator|jelly with Paracetamol + Furosemide + Levothyroxine sodium sa|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
89121114|NCT02570581|Placebo Comparator|Plain apple compote control|Plain apple compote control
89121115|NCT02570581|Active Comparator|Apple compote Paracetamol|Apple compote Paracetamol
89121116|NCT02570581|Active Comparator|Apple compote Furosemide|Apple compote Furosemide
88801310|NCT02565108|Experimental|GWP42003-P 20 mg/kg/Day Dose|"Participants received GWP42003-P 20 milligrams [mg]/kilogram [kg]/day orally, twice daily immediately after their clobazam (CLB) dose. Participants titrated GWP42003-P to 20 mg/kg/day over 10 days and remained at this dose for the 21-day treatment period. Participants who then did not enter the open-label extension (OLE) or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their GWP42003-P treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an Investigational Medicinal Product (IMP), for the duration of this study."
88801311|NCT02565108|Placebo Comparator|Placebo|"Participants received placebo (0 mg/milliliter [mL] GWP42003-P) orally, twice daily immediately after the participant's CLB dose. Participants titrated the placebo dose over 10 days, followed by a 21-day treatment period. Participants who then did not enter the OLE or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an IMP, for the duration of this study."
88801312|NCT03821168|Active Comparator|intravitreal injection of bevacizumab and erythropoietin|erythropoietin:
89121117|NCT02570581|Active Comparator|Apple compote Levothyroxine sodium salt|Apple compote Levothyroxine sodium salt
89121118|NCT02570581|Active Comparator|Apple compote Memantine|Apple compote Memantine
89121119|NCT02570581|Active Comparator|Apple compote Zopiclone|Apple compote Zopiclone
89121120|NCT02570581|Active Comparator|Apple compote Alprazolam|Apple compote Alprazolam
89121121|NCT02570581|Active Comparator|Apple compote Oxazepam|Apple compote Oxazepam
89121122|NCT02570581|Active Comparator|Apple compote Donepezil|Apple compote Donepezil
89121123|NCT02570581|Active Comparator|Apple compote Clopidogrel|Apple compote Clopidogrel
89121124|NCT02570581|Active Comparator|Apple compote Ramipril|Apple compote Ramipril
89121125|NCT02570581|Active Comparator|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopi|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopiclone Alprazolam
89121126|NCT00640263|Experimental|1|infant peri-exposure prophylaxis with lopinavir/ritonavir
89121127|NCT00640263|Active Comparator|2|infant peri-exposure prophylaxis with lamivudine
89121128|NCT02683863|Other|Group 1|"There will be 4 CSF sampling groups at the Week 6 visit for PK assessment:~1. Four subject for CSF samples 3 hours after dosing"
89121129|NCT02683863|Other|Group 2|2. Four subjects for CSF samples 5 hours after dosing
89121130|NCT02683863|Other|Group 3|3. Four subjects for CSF samples 7 hours after dosing
89121131|NCT02683863|Other|Group 4|4. Four subjects for predose CSF samples
89121132|NCT00975884|Experimental|GSK2340272A (D21) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21 (D21).
89121133|NCT00975884|Experimental|GSK2340272A (M6) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Month 6 (M6).
89121134|NCT02865668|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with one Extended Release (XR) tablet of metformin of 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with one metformin (XR) tablets of 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89121135|NCT02865668|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89121136|NCT02865668|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89121137|NCT02865668|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89121138|NCT04006808|Experimental|PED-HZ/su 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, receiving 2 doses of the investigational vaccine (PED HZ/su)
89121139|NCT04006808|No Intervention|Control 12-17 Group|Paediatric renal transplant recipients aged 12 to 17 years old, not receiving the investigational vaccine but being treated according to the local standard of care
89121140|NCT04006808|Experimental|PED-HZ/su 1-11 Group|"Paediatric renal transplant recipients aged 1 to 11 years old, receiving 2 doses of the investigational vaccine (PED HZ/su).~Enrolment into this group will be in a staggered manner. Following enrolment into the PED-HZ/su 12-17 group, a safety evaluation of data collected up to visit month 2 will be performed. Upon favourable outcome of the evaluation, enrolment into this group will begin."
89121141|NCT04006808|No Intervention|Control 1-11 Group|Paediatric renal transplant recipients aged 1 to 11 years old, not receiving the investigational vaccine but being treated according to the local standard of care
89121142|NCT02689791|No Intervention|Control (SWF)|Standard Wheat Flour (SWF) Muffins
89121143|NCT02689791|Experimental|Resistant Starch Type 4|Resistant Wheat Starch Muffins
88801313|NCT03821168|Active Comparator|intravitreal injection of bevacizumab|bevacizumab:1.25 mg
88801314|NCT01454180|Active Comparator|Arm A|Control treatment arm will be treated with any of the schemes used in the study according to the discretion of the physician responsible
88801315|NCT01454180|Experimental|Arm B|treatment guided by the therapeutic targets
88801316|NCT03820934|Other|Patients undergoing Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these test. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
88801317|NCT02564952|Experimental|GWP42003-P|"Participants who transferred from the DB phase (NCT02565108) to the OLE (still blinded at that stage) tapered off their GWP42003-P or placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P to 20 mg/kg/day initially for the OLE; doses could then be adjusted up or down, dependent on investigator opinion, to a maximum of 30 mg/kg/day GWP42003-P.~Clobazam (CLB) was administered in line with the physician's preferred CLB dosing regimen for each participant."
88801318|NCT01454336|Experimental|Cirrhotic Patients|3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy
88801319|NCT03820856|Experimental|acupuncture plus fire needle group|
89121144|NCT04586595|Experimental|Intervention arm|GP trainees in this arm will receive the REVISiT intervention which will involve having their prescribing reviewed and feedback provided, at two time points (approximately 100 prescriptions at each time point) separated by approximately a 3-month time period.
89121145|NCT04586595|No Intervention|Control arm|GP trainees in this arm will continue with training as usual and will have their prescribing (approximately 200 prescriptions) reviewed once but representing two time points - separated by an approximate 3-month time period. Feedback will occur at one time point, to cover the review for the 200 prescriptions.
89121146|NCT02867930|Active Comparator|Group D|Dexmedetomidine- drug used for moderate sedation prepared as 200 mic in 20 ml syringe.with intravenous loading dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
89121147|NCT02867930|Active Comparator|Group KF|Ketamine+Propofol -drugs used for sedation-as ratio 1:3with 19ml of 1% propofol + 1.3ml ketamine(50mg/ml) as loading intravenous infusion dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
89121148|NCT02570893|Experimental|adjuvant chemoradiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
89121149|NCT02570893|Experimental|adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
89121150|NCT02538081|Active Comparator|Risperidone plus placebo|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus placebo
89121151|NCT02538081|Active Comparator|Risperidone plus DMXB-A|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus DMXB-A
89121152|NCT02570971|No Intervention|Control|Patients will receive supportive care measures.
89121153|NCT02570971|Experimental|Investigational|Patients will receive 500mL of 20% mannitol
89121154|NCT02866292||non-pregnant nulliparous|Nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
89121155|NCT02866292||primigravid|Pregnant women on her first pregnancy and gestational age above 14 weeks. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
89121156|NCT02683629|Experimental|NTCELL|NTCELL Implantation
89121157|NCT02683629|Sham Comparator|Sham Surgery|Sham Surgery
89121158|NCT02866214|Experimental|Group I|This Group of Patients will receive Febuxostat Drug along with their Standard Treatment.
89121159|NCT02866214|Placebo Comparator|Group II|This Group of Patients will receive Placebo along with their standard Treatment.
89121160|NCT04290182|Experimental|Single arm: MSC administration to vocal fold scar|1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)
89121161|NCT02866448|Placebo Comparator|Vehicle control|"Subjects will consume~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid~1 x 75mg cellulose pill"
89121162|NCT02866448|Experimental|Isoquercetin|"Subjects will consume~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid~1 x 75mg cellulose pill"
89121163|NCT02866448|Active Comparator|Aspirin|"Subjects will consume~1 x 75mg dispersible aspirin~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid"
89121164|NCT02866448|Experimental|Isoquercetin plus Aspirin|"Subjects will consume~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg folic acid~1 x 75mg dispersible aspirin"
89121165|NCT00578227|Experimental|Cervarix™ & Twinrix™ Group|Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A & Hepatitis B (HAB) vaccine (Months 0, 1 & 6).
89121166|NCT00578227|Experimental|Cervarix™ Group|Subjects received 3 doses of HPV vaccine (Months 0, 1 & 6).
89121167|NCT00578227|Active Comparator|Twinrix™ Group|Subjects received 3 doses of HAB vaccine (Months 0, 1 & 6).
89121168|NCT02571127|Experimental|Only treatment|two weekly applications (monday and thursday or tuesday and friday) for 12 weeks
89121169|NCT00723853|Experimental|Group 1|Reach-Out Program, Nutritional and Exercise Intervention
88801320|NCT03820856|Active Comparator|acupuncture group|
88801321|NCT05504538|Experimental|patient with Acute acromioclavicular joint injury|patient with Acute acromioclavicular joint injury
89121170|NCT00723853|Active Comparator|Group 2|Reach-In Program, Standard of Care
89121171|NCT00720577|Active Comparator|1|
89121172|NCT00720577|Active Comparator|2|
89121173|NCT00720577|Active Comparator|3|
89121174|NCT00978380|Experimental|A|
89121175|NCT02572297||video-EEG|Patients suffering from drug-resistant partial epilepsy for whom a video-EEG monitoring of their seizures was scheduled as part of pre-surgical assessment
89121176|NCT04005794|Active Comparator|VR Social Skills Training|Participants will undergo a virtual reality social skills training program for 10 sessions. Each session takes about an hour. Participants visit the lab twice a week. Therefore, the training duration is 5 weeks.
89121177|NCT04005794|Other|Cognitive training game|If there is a significant improvement in social skills for the active treatment condition, the reason might be that the participants were exposed to social environment by coming to the lab and interacting with the research staff twice a week for 5 weeks and/or they used a computerized training tool twice a week for 5 weeks. In order to control for these potential confounds, we included a cognitive training arm. Participants will undergo a commercially available cognitive training program for ten 1-hour sessions (twice a week for 5 weeks).
89121178|NCT04005794|No Intervention|Healthy Controls|Healthy controls are recruited to yield comparison data. They do not undergo training.
89121179|NCT05373277|Placebo Comparator|Placebo|The subjects will be given orally placebo twice a day for 2 days, and a single 10 mg dose of rosuvastatin.
89121180|NCT05373277|Active Comparator|Ticagrelor|The subjects will be given orally 90 mg ticagrelor twice a day for 2 days, and a single 10 mg dose of rosuvastatin.
89121181|NCT01639105|Experimental|treated half of the scar|
89121182|NCT01639105|No Intervention|untreated half of the scar|
89121183|NCT00720655|Experimental|Fatty fish|
89121184|NCT00720655|Experimental|Lean Fish|
89121185|NCT00720655|Placebo Comparator|Control diet|
89121186|NCT00724087|Experimental|5.5-hour bedtime|
89121187|NCT00724087|Experimental|8.5-hour bedtime|
89121188|NCT00724165|Experimental|1|
89121189|NCT00724165|Active Comparator|2|
89121190|NCT00724321|Other|Iloprost and placebo|Each participant will undergo testing at sea level and altitude after inhalation of iloprost and placebo, sequence is randomly assigned.
89121191|NCT00724399||Observations|Women attending screening mammography and gynecology visit
89121192|NCT00724399||A|Women attending their annual screening mammography and gynecology clinic visits.
89121193|NCT00724555||1|Adults living in DC neighborhoods with high proportions of underserved adults. The age of the cohort members will reflect the age of DC residents who suffer most from stroke.
89121194|NCT00720733|Experimental|1|Skills Building Group
89121195|NCT00720733|Active Comparator|2|Personal Interview Group
89121196|NCT00720811|Experimental|ACT, antibiotic, paracetamol|CHWs will test children with acute febrile illness for malaria using RDTs, and for pneumonia by counting their respiratory rate with RRTs. Treatment will then be provided on the basis of the test results, in line with national guidelines. Children with a positive RDT will receive artemether-lumefantrine in Burkina Faso and Uganda, and artesunate-amodiaquine in Ghana. Children with a cough and a high respiratory rate will receive amoxicillin in Ghana and Uganda, and cotrimoxazole in Burkina Faso. Additionally, paracetamol (PCT) will be provided to all children with an axillary temperature > 38.5°C.
89121197|NCT00720811|No Intervention|Presumptive fever management|Presumptive treatment of malaria with ACTs. No antibiotic treatment available
89121198|NCT00720889||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
89121199|NCT00720889||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
89121200|NCT05338099|Experimental|Dose group A (Low dose)|Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m^2) + Chlorpheniramine (1 mg for 2~6 years old; 2 mg for 6~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.
89121201|NCT05338099|Experimental|Dose group B (High dose)|Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m^2) + Chlorpheniramine (1 mg for 2~6 years old; 2 mg for 6~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.
89121202|NCT04292210|Experimental|CAPD handling|"A connecting device simplifying the steps during a cycle of Peritoneal dialysis. Instead of directly doing a manual connection and manually breaking a frangible, the device assist in connecting and breaking the frangible.~This study was done demonstrating a continuous ambulatory peritoneal dialysis (CAPD)"
89121203|NCT00720967|Active Comparator|1|Control Group (Open heart surgery alone)
89121204|NCT00720967|Experimental|2|Intraoperative Modified Ultrafiltration (MUF) Group (Open heart surgery with intraoperative MUF)
89121205|NCT00720967|Experimental|3|Preoperative Hemodialysis Group (Open Heart Surgery after preoperative hemodialysis)
89121206|NCT00724633|Other|1|standard dialysate Na 140 mEq/L
89121207|NCT00724633|Active Comparator|2|dialysate sodium equal to patient's predialysis serum Na
89121208|NCT00724633|Active Comparator|3|dialysate sodium lower than patient's predialysis plasma sodium
89121209|NCT00577993|Active Comparator|1: FND + Rituximab Followed by Interferon|Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon
89121210|NCT00577993|Active Comparator|2: FND Followed by Interferon & Rituximab|Fludarabine/Novantrone/Decadron Followed by Interferon & Rituximab
89121211|NCT00577993|Active Comparator|3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon|Cyclophosphamide/Vincristine/Doxorubicin/Bleomycin (1st Sequence) + Rituximab; Etoposide/Cisplatin/Ara-C/Methyl-Prednisol (2nd Sequence); Novantrone/Vincristine/Procarbazine/Prednisone + Rituximab (3rd Sequence) Followed by Interferon
89121212|NCT00975806|Experimental|Cohort A|Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle
89121213|NCT00975806|Experimental|Cohorts F and G|Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle
89121214|NCT00725023|Experimental|1|Treatment: TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
89233224|NCT02354014|Experimental|TMC207/Background Regimen (BR)|There will be 4 age-based cohorts. Participants will be enrolled concurrently in Cohorts 1 and 2 followed by sequential enrollment of Cohorts 3, 4. Cohort 1: >= 12 to < 18 years: bedaquiline (TMC207) tablet orally as 400 mg, once daily(qd),for first 2 weeks, followed by TMC207, 200 mg 3 times per week (tiw) for 22 weeks; Cohort 2: >=5 to <12 years: TMC207 tablet given orally as 200 mg, qd, for first 2 weeks, followed by TMC207, 100 mg, tiw for 22 weeks. Cohort 3: >=2 to <5 years: TMC207 8 milligram per kilogram (mg/kg) qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw for 22 weeks. Cohort 4: 0 months to <2 years: TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3. TMC207 will be given in combination with Background Regimen for Multidrug Resistant Tuberculosis (MDR-TB) according to WHO/National Tuberculosis Program (NTP) guidelines/current standard of care.
89233225|NCT02339571|Experimental|Arm A (nivolumab, ipilimumab, sargramostim)|"INDUCTION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle, ipilimumab IV over 30 minutes on day 1 of each cycle, and sargramostim SC on days 1-14 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive nivolumab and sargramostim as in Induction therapy. Patients with PR, SC, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT scan, and blood sample collection throughout the study. Patients may also undergo a MUGA during screening, as well as an ECHO throughout the trial as clinically indicated."
89233226|NCT02339571|Experimental|Arm B (nivolumab, ipilimumab)|"INDUCTION THERAPY: Patients receive nivolumab and ipilimumab as in Arm I. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive nivolumab as in Induction therapy. Patients with PR, SD, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT scan, and blood sample collection throughout the study. Patients may also undergo a MUGA during screening, as well as an ECHO throughout the trial as clinically indicated."
89233227|NCT02316106|Experimental|Arm A (Long Intense)|
89233228|NCT02316106|Experimental|Arm B (Intermediate)|
89233229|NCT02316106|Experimental|Arm C (Short Intense)|
89233230|NCT02310321|Experimental|Phase 1 Dose Evaluation Part|In the dose-evaluation part in Phase 1 part, subjects will receive ASP2215 at assigned single dose for determination of MTD and/or RED. Treatment of AML in this study is composed of 3 periods of therapy: remission induction (42-day cycles x 2 at maximum), consolidation (28-day cycles x 3 at maximum), and maintenance (28-day cycles x 26 at maximum). The decision of whether or not to proceed to the next dose will be made based on the occurrence of DLT during Cycle 1 of the induction period.
89233231|NCT02310321|Experimental|Phase 1 Dose Expansion Part|In the dose expansion part in Phase 1 part, subjects will receive ASP2215 at RED that has been determined in the dose-evaluation part, and the safety will be assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.
89233232|NCT02310321|Experimental|Phase 2 Part|Subjects will receive ASP2215 at the recommended dose established in Phase 1 part.
89233233|NCT02303678|Experimental|D2C7-IT|Recurrent malignant glioma patients will receive D2C7-IT, delivered intratumorally by CED following confirmatory diagnostic biopsy.
88801322|NCT05564286|Experimental|fosaprepitant group|Intravenous fosaprepitant of 150mg was given before cisplatin administration on day 1. All patients received tropisetron 5mg and dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
88801323|NCT05564286|Active Comparator|control group|The control group was delivered tropisetron 5mg and dexamethasone 5mg only.
88801324|NCT03820700|No Intervention|Control group|[Randomized] Patients in control group will receive regular nursing care but no behavioral therapy intervention.
88801325|NCT03820700|Experimental|Hypnosis (Hypn)|[Randomized] Patients will receive a hypnosis recorded audiotape.
88801326|NCT03820700|Experimental|Virtual reality (VR)|[Randomized] Patients will see a 3D movie with a beautiful landscape.
88801327|NCT03820700|Experimental|Virtual reality hypnosis (VRH)|[Randomized] Patients will see the same 3D film combined with a hypnotic voice.
88801328|NCT05504460|Experimental|test group|The test group will use the investigational device Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd.) + basic treatment (supportive treatment determined by the investigator based on the condition of the patients)
88801329|NCT05504460|Active Comparator|Control Group|the control group will use basic treatment only
88801330|NCT01454804|Experimental|Arm A: Pazopanib + Lapatinib|Oral Pazopanib 200 mg every other day starting on day 1 and oral Lapatinib 500 mg daily starting day 1, both for 28 days.
88801331|NCT01454804|Experimental|Arm B: Pazopanib + Trastuzumab|Oral Pazopanib 200 mg daily for 28 day cycle and Trastuzumab (Herceptin®) 4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1, with a maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.
88801332|NCT03820622|Experimental|DIOR group|in this group, patients will be treated with Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
88801333|NCT03820622|Active Comparator|Bingo group|in this group, patients will be treated with Paclitaxel-Eluting Balloon (Bingo)
88801334|NCT05504382|Experimental|study group 1|receive especially electrical acupuncture on the knee joint
88801335|NCT05504382|Experimental|study group 2|receive naproxen phonophoresis on the knee joint
89233234|NCT02233868|Experimental|Phase I|PET scan with [11C]PBR28 followed by PET scan with FDG and MRI.
89233235|NCT02233868|Experimental|Phase II|After 3 weeks of abstinence or non-abstinence, PET scan with [11C]PBR28 followed by PET scan with FDG and MRI are repeated.
88801336|NCT04391972|Other|SAV multifocal IOL|Subjects who have cataract surgery with SAV multifocal IOL
88801337|NCT03823040|Active Comparator|Tinox® group|Male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1%.
88801338|NCT03823040|Experimental|Oxiconazole nitrate SLNs loaded gel group|13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel
88801339|NCT04282980|Experimental|DCC-2618|DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle.
88801340|NCT03823196|Experimental|Verum900|The arm will receive 900 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
89121215|NCT00725023|Other|2|Treatment: Dummy TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
89121216|NCT00721045|Active Comparator|A1|15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping.
89121217|NCT00721045|Sham Comparator|A2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
89121218|NCT00721045|Active Comparator|B1|15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping.
89121219|NCT00721045|Sham Comparator|B2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
89121220|NCT00721045|Active Comparator|C1|15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping.
89121221|NCT00721045|Sham Comparator|C2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
89121222|NCT02865512|Active Comparator|supine position|thoracic epidural catheterization with supine position
89121223|NCT02865512|Active Comparator|flexed lateral position|thoracic epidural catheterization with flexed lateral position
89121224|NCT04288076|Experimental|PEEP Titration Arm|
89121225|NCT02865278|Experimental|Polyphenol-rich drink|The participants consume the polyphenol-rich drink. After 3 hours they consume a standard meal to evaluate whether the metabolic response may be influenced by polyphenols.
89121226|NCT02865278|Placebo Comparator|Placebo drink|The participants consume the control drink.After 3 hours they consume a standard meal to evaluate the metabolic response after a placebo.
89121227|NCT02866370|Experimental|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously
89121228|NCT02866370|Active Comparator|Chemotherapy|"Ovarian Cancer Patients:~Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days Topotecan (4mg/m2) IV Day 1, 8, 15 every 28 days~Endometrial Cancer Patients:~Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days Doxorubicin IV (60mg/m2) every 21 days~Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
89121229|NCT05182801|Placebo Comparator|Placebo sachet|
89121230|NCT05182801|Experimental|Banana flower extract sachet|
89121231|NCT00721435|Experimental|3D Tomosynthesis & 3D Ultrasound for breast masses|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
89121232|NCT00721435|Experimental|3D Tomosynthesis/ 3D Ultrasound for healthy subjects|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
89121233|NCT00725179||1|Patients receiving oral NAC treatment
89121234|NCT00725179||2|Patients receiving IV NAC treatment
89121235|NCT00978068|Active Comparator|Lopinavir/ritonavir (LPV/r) +2 NRTI|Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
89121236|NCT00978068|Active Comparator|Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI|Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)
89121237|NCT02863952|Other|EARLY POST-STRESS EF CHANGE|There is only a single arm. All patients undergoing the routine myocardial perfusion SPECT study will also have additional (earlier) image acquisition in order to assess the relation of early wall motion abnormalities to the severity of myocardial ischemia.
89121238|NCT00725257|Active Comparator|1|Low-carbohydrate, energy-restricted, Mediterranean-type diet
89121239|NCT00725257|Active Comparator|2|Low-fat diet
89121240|NCT04289558|Experimental|Sodium Nitrite|Single 60-minute intravenous infusion of sodium nitrite in 0.9% sodium chloride at up to 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute)
89121241|NCT00725335|Experimental|group A,non-pringle group|Intervention of curative resection of HCC Without pringle manoeuvre in this arm
89121242|NCT00725335|Active Comparator|pringle group(B)|when the curative resection of HCC performed, the pringle manoeuvre will be routinely applied.
89121243|NCT00629642|Experimental|I.Solifenacin succinate 10mg (2x5mg 1/day)|Oral
89121244|NCT00629642|Experimental|II.Solifenacin succinate 5mg (5mg 1/day)|Oral
89121245|NCT00629642|Active Comparator|III.Oxybutynin hydrochloride 15mg (5mg 3/day)|Oral
89121246|NCT00629642|Placebo Comparator|IV. Placebo|Oral
89121247|NCT02571751|Experimental|Breast Augmentation|
89121248|NCT02865356|Experimental|Cyclosporine 5% Solution|"SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas.~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
89121249|NCT02865356|Placebo Comparator|Placebo|"SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas.~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
89121250|NCT00721591||A|Subjects opting for treatment with unfractionated heparin
89121251|NCT00721591||B|Subjects opting for treatment with low molecular weight heparin
89121252|NCT04287686|Experimental|rhACE2 group|0.4 mg/kg IV BID for 7 days (unblinded) + standard of care
89121253|NCT04287686|No Intervention|Control group|Standard of care; no placebo
89121254|NCT02865200|Experimental|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique. The needles were kept on the body for 20 minutes and at the 10th minute, the needle was rolled and re-stimulation was enabled. The treatment was applied twice a week, which is equal to 6 sessions in total.
89233236|NCT02233829|Active Comparator|Evening MRI/PET/Raclopride/IV Methylphenidate Session|The PET [11C] raclopride scan will be done between 5-7 PM. After iv catheters are inserted blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plus-infusion method for [11C]raclopride and the administration of intravenous MP (0.5 mg/kg) forty-five minutes after initial bolus injection of [11C]raclopride. Scan to be done for a total of 100 minutes.
89233237|NCT02233829|Active Comparator|Morning MRI/PET/Raclopride/IV Methylphenidate Session|Morning Session [11C]raclopride PET scan: To be started between 7-8 AM. After iv catheters are inserted, genetic blood samples are drawn and then blood sampling starts and continues throughout study. Cardiac monitoring is initiated and continues until physician discontinues post PET scan. Bolus-plusinfusion method for [11C]raclopride and the administration of intravenous MP (0.25 mg/kg) fortyfive minutes after initial bolus injection of [11C]raclopride. Scan to be done for a total of 100 minutes.
89233238|NCT02211768|Experimental|1/FDG and FLT PET scans|Subjects will undergo FDG-PET and FLT-PET scans at least one day apart
89233239|NCT02211768|Other|2/FDG-PET scan|Subjects will undergo FDG-PET scan
89233240|NCT02203526|Experimental|Arm 1-A (original study design - prior to Amendment G)|TEDD-R (cycle 1) with ibrutinib; TEDDI-R with cytarabine (cycles 2-6)
89233241|NCT02203526|Experimental|Arm 1-B (original study design-prior to Amendment G)|TEDDI-R with cytarabine
89233242|NCT02203526|Experimental|Arm 2 (Dose Escalation; prior to Amendment 06/04/2021)|TEDDI-R with cytarabine, and isavuconazole
88801341|NCT03823196|Experimental|Verum1800|The arm will receive 1800 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
88801342|NCT05504226|Experimental|Teneligliptin 20 mg|Once daily for 24 weeks
88801343|NCT05504226|Placebo Comparator|Teneligliptin placebo|Once daily for 24 weeks
88801344|NCT03822806|Experimental|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise (using the videogame JustDance) for the first 30 minutes of those 2 hours using the video game (continuing to wear the patch for 90 minutes after exercise).
88801345|NCT05508828||The study group|We retrospectively analysis of 8 consecutive patients with SAP and IPN. SAP was diagnosed with persistent organ failure >48h. IPN was considered when the following situations occur: ≥38.5℃; increasing WBC, CRP or procalcitonin; rapid clinical deterioration; signs of gas was present in areas of necrosis.
88801346|NCT01454882||Behavioral effects of clothing and temperature|In this first study, we will determine how variations in clothing and ambient temperature influence the accuracy of EE determined from measurements of total heat production. 65 individuals will be studied. This will be a randomized cross-over trial with two within subject factors: 1) ambient temperature and 2) amount of clothing. There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
88801347|NCT01454882||Behavioral effects of age, sex, and adiposity|THe aim of this study is to Determine how age, sex, and adiposity influence the accuracy of EE determined from measurements of total heat production . This will be a randomized study with two within subject conditions(high and low physical activity levels). A heterogenous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age range (≥ 18 yrs).
88801348|NCT01454882||Effects of free living energy expenditure|The primary aim of this study is to compare the accuracy of measuring free-living energy expenditure in humans measured using portable direct calorimetry. This will be a comparison study; TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age (>18 yrs).
88801349|NCT02929160|Experimental|PCN|Percutaneous nephrostomy
88801350|NCT02929160|Experimental|JJ Stent|Retrograde ureteric JJ stent
88801351|NCT05504148|Experimental|Crocin group|The chemotherapy/radiotherapy protocols are made by oncologists adopted for patients depending on specific conditions , take saffron total glucosides tablets(provided by Reyoung Pharmaceutical Co., Ltd.) for 8 days during each chemotherapy (started on the 1st day before chemotherapy), 4 tablets/time, 3 times a day.
88801352|NCT05504148|Placebo Comparator|placebo group|Undergoing chemotherapy/radiotherapy protocols as planned, take placebo piece during(the same appearance of crocin tablets, production unit:Reyoung Pharmaceutical Co., Ltd.) for 8 days during each chemotherapy (started on the 1st day before chemotherapy), 4 tablets/time, 3 times a day
88801353|NCT02566902|Active Comparator|T-piece Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental T-piece Nebulizer (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
88801354|NCT02566902|Experimental|Breath-Enhanced Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental Breath-Enhanced Nebulizer (NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer Salter Labs®, Arvin, CA). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
88801355|NCT01454960|Experimental|SA, AJ, PC|"Participants are given all 3 interventions:~Suggested Alternatives, Accountable Justification, and Peer Comparison."
88801356|NCT01454960|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
89233243|NCT02203526|Experimental|Arm 3 (Dose Expansion; prior to Amendment 06/04/2021)|TEDDI-R with cytarabine and isavuconazole
88801357|NCT01454960|Experimental|SA, PC|Participants receive the Suggested Alternatives and Peer Comparison interventions, but not the Accountable Justification intervention.
88801358|NCT01454960|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternatives intervention.
88801359|NCT01454960|Experimental|Peer Comparison|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
88801360|NCT01454960|Experimental|Suggested Alternatives|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
89121255|NCT02865200|Experimental|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again. The period of treatment was 6 sessions in total with 25 minutes of each.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
89121256|NCT00725569|Active Comparator|A|Bellis perennis and Staphysagria (C6)
89121257|NCT00725569|Active Comparator|B|Bellis perennis and Staphysagria (C30)
89121258|NCT00725569|Placebo Comparator|C|Placebo Remedy
89121259|NCT04287842|No Intervention|control|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. This provides complete suppression of animal responses to pain, fixation, tracheal intubation. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed.
89121260|NCT04287842|Experimental|training ischemia|Induction of anesthesia: Chloralhydrat intraperitoneal 300 mg/kg. Comparison of a total GSK-3 and phosphorytated (Ser9) GSK-3beta (pGSK3b) in brain tissuesupracardiac bundle of vessels by means of a special hook after cardiac arrest and absence of ventilation lasts 10 min.
89121261|NCT04287842|Active Comparator|desflurane|Intervention. Drug: Desflurane. Desflurane 8 vol% anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Surgery: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
89121262|NCT04287842|Active Comparator|sevoflurane|Sevoflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
89121263|NCT02864186|Active Comparator|control|Women wont use support bra for six months
89121264|NCT02864186|Active Comparator|surgical support bra|Women will use surgical support bra 24 hours a day for six months
89121265|NCT02864186|Active Comparator|common support bra|Women will use common support bra 24 hours a day for six months
89121266|NCT00725647||Treated PDA|Infants who had a PDA which the attending physicians treated medically or surgically.
89121267|NCT00721747|Experimental|Unique arm|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
89121268|NCT00721825|Active Comparator|1|Neuroaid
89121269|NCT00721825|Placebo Comparator|2|Neuroaid matched placebo
89121270|NCT04859803|Active Comparator|RISS group|patients will receive rhomboid intercostal block under ultrasound guidance.
89121271|NCT04859803|Active Comparator|Control group|Patients will received the conventional intravenous analgesia
89121272|NCT00603525|Experimental|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
89121273|NCT00603525|Placebo Comparator|1000 ml Saline|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
89121274|NCT02570191|Experimental|Peginterferon alfa-2a|Participants received 180 micrograms (uG) of Pegasys (0.5 milliliter [mL] solution) once a week subcutaneously for 48 weeks.
89121275|NCT03680287|Active Comparator|Uninterrupted Sleep|Participants will be permitted to sleep without interruption for 8 hours.
89121276|NCT03680287|Experimental|Sleep Disruption|Participants will be repeatedly awakened throughout the night according to a standardized protocol.
89121277|NCT02689401|Experimental|Ferumoxtyol (Feraheme) with MRI|Patients will undergo a pre-contrast MRI followed by a pre determined dose of of IV Ferumoxyto. Post-contrast MRI imaging will be performed immediately following Ferumoxytol infusion and 48 hours after Ferumoxytol administration with subsequent image analysis.
89121278|NCT02570659|No Intervention|Information Folder|A folder with advise and exercises used by physiotherapeutic clinic of Södersjukhuset Hospital (Treatment as usual)
89121279|NCT02570659|Experimental|Information Video|A multiprofessional information video
89121280|NCT02683551||Ligasure|Patients underwent to Sutureless Thyroidectomy with Ligasure SmallJaw
89121281|NCT02683551||Harmonic|Patients underwent to Sutureless Thyroidectomy with Harmonic FOCUS
89121282|NCT00726115|Placebo Comparator|1|arm placebo
89121283|NCT00726115|Experimental|2|arm drug
89121284|NCT00726193||1 - standard films|Tibia reconstruction surgery with OsteoGen™ with standard radiographs
89121285|NCT00726193||2 - Standard films plus CT|Tibia reconstruction surgery with OsteoGen™ with standard radiographs and additional CT scan at 10 and 18 weeks.
89121286|NCT00640497|Experimental|1|Treatment arm
89121287|NCT00726271|Experimental|active|"Subjects will complete the Zung Depression and Anxiety Scales. At the first visit the subject's medication list, weight, height, and waist measurement will be obtained. The goal is to recruit a minimum of 20 patients.~Subjects will receive light olive oil, and capsules of fish oil and flaxseed oil, to take daily at home with weight based dosing, based on the doses recommended in Dr. Roberts' work. Doses are within the recommended dietary ranges to improve intermediate outcomes for coronary artery disease subjects.~They will return weekly for measurement of weight, waist measurements, discussion of any problems with the oils, and dose adjustment of the oils."
88801361|NCT01454960|Experimental|Accountable Justification|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
88801362|NCT01454960|No Intervention|Control|Participants do not receive any of the 3 interventions.
88801363|NCT03820154|Active Comparator|Skin Prick Test TAPE|"The Skin Prick Test Tape is an innovative sterile all-in drug carrying 8 allergens and 2 control solutions including prick needles in one Tape for easy use and standardization. Single use. Reading of wheal reactions after 15 minutes, facilitated by stripes with the allergen names."
88801364|NCT03820154|Active Comparator|Skin Prick Test|The conventional SPT is the world-wide standard in allergy Type 1 diagnosis for inhalant and food allergens. Drops of allergens are applied to the forearm and, with the help of a lancet, brought into the skin. Reading of wheal reactions after 15 minutes.
88801365|NCT05508516|Experimental|Shugan Dingtong decoction|Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
88801366|NCT05508516|Active Comparator|duloxetine hydrochloride|Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
88801367|NCT03820076|Experimental|dose 1|AZT-04
88801368|NCT03820076|Experimental|dose 2|AZT-04
89121288|NCT03907189||Emergent Inflammation|Subjects with emergent inflammation detected by Podimetrics RTM Mat within the last week.
89121289|NCT03907189||No Inflammation|Subjects with no emergent inflammation detected by Podimetrics RTM Mat within the last week.
89121290|NCT00640575|Experimental|A|Local
88801369|NCT03820076|Experimental|dose 3|AZT-04
88801370|NCT05563740|Experimental|Intervention Group|"All received care for alcohol withdrawal state as is routinely provided at the centre by their respective treating doctors and followed up as directed. All treatment and follow up decisions were made by the respective treating doctors. Study team did not have any role in it.~In addition all received a session of Brief Intervention (BI) for alcohol, at the time of recruitment and again after completing detoxification. Further, patient or designated caregiver received daily phone calls and Information was provided regarding any queries related to their withdrawal or detoxification process. Adverse outcomes such as sedation, seizure, confusion were enquired for and records were kept. Patient was encouraged to continue the treatment and report back for scheduled follow ups and in case of any adverse outcomes patient was asked to report back to the treating doctor and an appointment was facilitated. Phone calls were discontinued once detoxification (CIWA < 8) was complete."
88801371|NCT05563740|No Intervention|Control Group|All participants received care for alcohol withdrawal state as is routinely provided at the centre by their respective treating doctors and followed up as directed. All treatment and follow up decisions were made by the respective treating doctors. Study team did not have any role in it.
88801372|NCT01455038||Control group|Healthy controls had no history of psychiatric disorder and had no psychiatric symptom when interviewed by a board-certified psychiatrist.
88801373|NCT01455038||Bipolar group|individual patient as being in subsyndromal depressive phase when the patient had a Montgomery-Åsberg depression rating scale score of 10 or less and Clinical Global Impression severity of 3 or less for last one month.
88801374|NCT05503914|Experimental|low-dose radiotherapy group|Neoadjuvant chemotherapy combined with low-dose radiotherapy sequential concurrent chemoradiotherapy
88801375|NCT05503914|No Intervention|control group|Neoadjuvant chemotherapy sequential concurrent chemoradiotherapy
88801376|NCT01455506|Experimental|Decitabine with fludarabine and busulfan|decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation
88801377|NCT05563428|Active Comparator|Free gingival graft|Free gingival graft will be conducted.
88801378|NCT05563428|Active Comparator|Connective tissue graft|The recession will be treated with the pouch technique using a connective tissue graft.
88801379|NCT03821012||CSCAP-1|STEMI with symptom onset within 12 h regardless of whether receiving reperfusion or symptom onset within 12-24 h of needing PPCI
88801380|NCT03821012||CSCAP-2|STEMI patients with symptom onset within 30 days
88801381|NCT03821012||CSCAP-3|STEMI patients with symptom onset within 30 days
88801382|NCT05508438|Other|Treatment Group|
89121291|NCT00640575|Active Comparator|B|Systemic
89121292|NCT04067791|Experimental|Prolonged-Release melatonin then Immediate-release melatonin|
89121293|NCT04067791|Experimental|Immediate-Release Melatonin then Prolonged-Release Melatonin|
89121294|NCT00762034|Experimental|Pem/Carbo/Bev|Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab
89121295|NCT00762034|Active Comparator|Pac/Carbo/Bev|Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab
89121296|NCT02683317|Experimental|DHA group|Experimental group will receive 75 mg of docosahexaenoic acid per kilo of baseline weight in one dose per day, administered by enteral feeding throughout 14 days.
89121297|NCT02683317|Sham Comparator|Control group|"Control group will receive sunflower oil, the excipient of the DHA in our intervention.~They will receive it once a day, administered by enteral feeding throughout 14 days."
89121298|NCT02571829|Experimental|ribociclib|single arm ribociclib Oral 600 mg x 1 a day duration according to response.
89121299|NCT02683395|Experimental|Treatment Group A|Open label, sequential PLX51107 dose escalation in approximately 30 solid tumor subjects.
89121300|NCT02683395|Experimental|Treatment Group B|Open label, sequential PLX51107 dose escalation in approximately 30 subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
89121301|NCT00721903|Active Comparator|Healthy Subjects|Ultrasound scan
89121302|NCT00721903|Active Comparator|Cancer|120 women diagnosed by biopsy to have breast cancer will have an ultrasound scan
89121303|NCT00721981||1|Regular treatment for non-small cell lung cancer (NSCLC)
89121304|NCT00722059|Experimental|1|Subjects will undergo a 3D breast Tomosynthesis imaging scan. This is a one time breast imaging scan will last approximately 15 minutes.
89121305|NCT02386995||BIS and Entropy monitoring|Depth of anesthesia monitoring (BIS and entropy) are compared with standard clinical monitoring in patients with deep brain stimulators inserted at internalization whilst they are having a general anesthesia.
89121306|NCT03148951||Group 1|Group 1: patients receiving general anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
89233244|NCT02203526|Experimental|Arm 4 (Dose Expansion; Amendment 06/04/21)|TEDDI-R, cytarabine or methotrexate, isavuconazole, ibrutinib for 10 days
88801383|NCT03822104|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
88801384|NCT03822104|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
89233258|NCT02146170||Single group|Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET
89233259|NCT02123758|Experimental|Cohort 1|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.
89233260|NCT02123758|Experimental|Cohort 2|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
88801385|NCT02564796|Placebo Comparator|Control|Group II (non-treatment group): Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
88801386|NCT02564796|Experimental|Epoetin alfa and iron supplements|Group I (treatment group): Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
88801387|NCT03826160||Tesamorelin|Individuals who plan to initiate tesamorelin clinically
88801388|NCT03826160||No Treatment|Individuals who decline to initiate tesamorelin despite a clinical indication
88801389|NCT01455584|Experimental|HM781-36B|HM781-36B
88801390|NCT04273100|Experimental|Treatment group|The participants will receive the combined treatment of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE, lobaplatin and epirubicin and anti-angiogenic therapy (lenvatinib)
89121307|NCT03148951||Group 2|Group 2: patients receiving general anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
89121308|NCT03148951||Group 3|Group 3: patients receiving regional (spinal) anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
89121309|NCT03148951||Group 4|Group 4: patients receiving spinal anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
89121310|NCT00726349||Observation|Patients undergoing isolated elective total hip or knee arthroplasty (primary or revision surgery for a non-malignant condition), aged 60 years or older and able to walk prior to surgery.
89121311|NCT00726427|Experimental|1|8 increasing oral single doses given to 8 groups (3 on active and 1 on placebo in each group)
89121312|NCT00726427|Experimental|2|2 oral doses of AZD1656 given to 2 groups together with food
89121313|NCT00761956|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen CR-Flex Fixed Bearing Knee.
89121314|NCT00761956|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen CR Knee.
89121315|NCT04183881|Experimental|Brodalumab 210mg SC|Brodalumab 210mg subcutaneous injection
88801391|NCT01457222|Active Comparator|Mindfulness|Mindfulness intervention 10 minutes daily
89121316|NCT00638313|Placebo Comparator|Placebo|
89121317|NCT00638313|Experimental|PF-04603629|
89121318|NCT02600572|Experimental|Isometric exercise|Subjects performing the isometric exercises intervention
89121319|NCT02600572|Experimental|Eccentric exercise|Subjects performing the eccentric exercises intervention
89121320|NCT04093648|Experimental|TEGAR T cells + Fludarabine and Cytoxan|GPC3-CAR (TEGAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
89121321|NCT04184115|Experimental|DPI-386 Nasal Gel + placebo patch|DPI-386 Nasal Gel: Each 0.12 gram of the gel contains 0.2 mg of scopolamine HBr
89121322|NCT04184115|Placebo Comparator|Placebo nasal gel + Placebo patch|Placebo
89121323|NCT04184115|Active Comparator|placebo nasal gel + TDS patch|Transderm Scop® is a commercial transdermal scopolamine (TDS) patch worn behind the ear containing a 1.5 mg reservoir of scopolamine to be delivered over a 72-hour period.
89121324|NCT00722215|Placebo Comparator|1|Placebo control arm of study
89121325|NCT00722215|Experimental|2|BQ-123 arm of study
89121326|NCT00722215|Active Comparator|3|Nifedipine arm of study
89121327|NCT02571595|Experimental|Immediate dCBT-I group|Digital cognitive behavioural therapy for insomnia (dCBT-I) is a 6 session training program (spanning 6 to 12 weeks) designed to improve sleep. Participants in the immediate dCBT-I group will receive the Sleepio intervention shortly after enrollment.
89121328|NCT02571595|Experimental|Waitlist control group|Participants in the waitlist control group will receive sleep hygiene recommendations from validated online resources for HIV patients (http://www.catie.ca/en/positiveside/winter-2013/sleep-tight) around the time of enrollment. They will start the digital cognitive behavioural therapy for insomnia (dCBT-I) intervention 12-14 weeks after the initial enrollment.
89121329|NCT00640809|Experimental|A|
89121330|NCT00640809|Placebo Comparator|B|
89121331|NCT00640809|Active Comparator|C|
89121332|NCT00754624|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
89121333|NCT00722293|Experimental|Arm A|once daily oral administration of pazopanib for Days 1-21 days in combination with epirubicin given as a bolus intravenous administration on Day 3
89121334|NCT00722293|Experimental|Arm B|once daily oral administration of pazopanib for Days 1-8 of a 3-week cycle in combination with epirubicin (bolus intravenous administration) on Day 3
89121335|NCT00722293|Experimental|Arm C|epirubicin (bolus intravenous administration) on Day 1 with once-daily oral administration of pazopanib for Days 14-21 of a 3-week cycle
89121336|NCT00722293|Experimental|Arm D|once-daily oral administration of pazopanib (according to schedule selected from either Arm A, B, or C) (3 week cycle) in combination with doxorubicin (bolus intravenous administration) on Day 1 or 3, depending on the schedule selected from either Arm A, B, or C
89121337|NCT02570737||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
89121338|NCT02570737||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
89121339|NCT04187235||Keyhole rapair|74 patients who undervent parastomal hernia repair with keyhole technique 1997-2009
89121340|NCT04187235||Sugarbaker repair|61 patients who undervent parastomal henia repair a.m. Sugarbaker 2009-2015
89121341|NCT00726505|Active Comparator|Group 1|Subjects with T2DM - Dapagliflozin 5 mg
89121342|NCT00726505|Active Comparator|Group 2|Subjects with T2DM - Dapagliflozin 20 mg
89121343|NCT00726505|Active Comparator|Group 3|Healthy Subjects - Dapagliflozin 20 mg
89121344|NCT02683005|Experimental|Ledipasvir/Sofosbuvir|Hepatitis C treatment will be initiated with ledipasvir (400 mg) and sofosbuvir (90mg) fixed dose combination, one pill, once daily for 12 weeks.
89121345|NCT02689323|Experimental|Open label|Participants will undergo 5 sessions of active rTMS
89121346|NCT00726583|Experimental|Investigational Drug|Dose Escalation
89121347|NCT04183959|Active Comparator|Group- video stylet intubation (VS)|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
89121348|NCT04183959|Active Comparator|Group- fiberoptic intubation (FO)|: intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
89121349|NCT02176863|Experimental|Stage 1 Arm 1: 2 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 2 g/kg of body weight administered via intravenous infusion over 2 consecutive days (Flebogamma 5% DIF 1 g/kg infused on Day 1 and Flebogamma 5% DIF 1 g/kg infused on Day 2) every 4 weeks for 52 weeks.
88801392|NCT01457222|Active Comparator|Music relaxation|Music intervention 10 minutes daily
88801393|NCT01457222|No Intervention|Business as usual|No intervention - control group.
89121350|NCT02176863|Experimental|Stage 1 Arm 2: 1 g/kg Flebogamma 5% DIF|Flebogamma 5% DIF 1 g/kg of body weight administered via intravenous infusion on Day 1 and 20 mL/kg of body weight of normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will also be administered on a separate day, for a total dosing period of 2 consecutive days. every 4 weeks for 52 weeks. The order of 1 g/kg of body weight of Flebogamma® 5% DIF or 20 mL/kg of body weight normal saline solution infused on 2 consecutive days will be randomly determined for each participant by the Interactive Web Response System (IWRS), which will remain the same for the participant for all infusion visits during the treatment period.
88801394|NCT02564718|Experimental|Arm 1|Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
88801395|NCT01453946|Other|Entocort|Study Medication
88801396|NCT05503758||Group A|9 participants have exposed to midline epidural anaesthesia for cesarean delivery.
88801397|NCT05503758||Group B|22 participants have exposed to midline spinal anaesthesia for cesarean delivery.
89121351|NCT02176863|Placebo Comparator|Stage 1 Arm 3: Placebo|Normal saline solution total dose of 40 mL/kg of body weight (equivalent volume of 2 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered over 2 consecutive days. On Day 1, a dose of 20 mL/kg of body weight Normal Saline Solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered and on Day 2, the second dose of 20 mL/kg of body weight. Normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered, every 4 weeks for 52 weeks.
88801398|NCT05503758||Group C|10 participants underwent general anesthesia for cesarean delivery.
89121352|NCT02176863|Experimental|Stage 2 Arm 1: Flebogamma 5% DIF|The dose of Flebogamma® 5% DIF selected from Stage 1 will be administered over 2 consecutive days every 4 weeks for 52 weeks.
89121353|NCT02176863|Placebo Comparator|Stage 2 Arm 1: Placebo|Normal saline solution total dose of 40 mL/kg of body weight (equivalent volume of 2 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered over 2 consecutive days. On Day 1, a dose of 20 mL/kg of body weight normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered and on Day 2, the second dose of 20 mL/kg of body weight normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will be administered, every 4 weeks for 52 weeks.
89121354|NCT04237207|Other|Aidable Residual Hearing (ARH) Cohort|Control Device followed by experimental Device.
89121355|NCT04237207|Other|Electric Only (EO) Cohort|Control Device followed by experimental Device.
89121356|NCT02682849||Retrospective cohort|
89121357|NCT02682849||Prospective PleuralFlow cohort|
89121358|NCT02571283|Experimental|Randomized Group A [Cocktail Injection]|"COCKTAIL INJECTION:~Cocktail Injection Consists of:~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1 mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose"
89121359|NCT02571283|Experimental|Randomized Group B [Cocktail Injection Plus Exparel]|"COCKTAIL INJECTION PLUS EXPAREL:~Cocktail Injection Consists of:~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
89121360|NCT02571283|Experimental|Randomized Group C [Marcaine Plus Exparel]|"MARCAINE PLUS EXPAREL:~Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution Frequency: Single dose~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
89121361|NCT02682693|Experimental|Denosumab|Denosumab every 4 weeks for 6 cycles.
89121362|NCT02682693|Experimental|nab-Paclitaxel weekly|nab-Paclitaxel weekly for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin in parallel to nab-paclitaxel.
88801399|NCT05503758||Group D|22 participants were in the control group (no previous pregnancy or anaesthesia).
88801400|NCT01455662||all patients after cardiac arrest|
88801401|NCT05508126||Primary staging group I|All patients will be treated according to standard practice. Patients in group I are patients that will be stratified for radical gastrectomy or endoscopic resection. Group I will undergo only a primary staging. All patients will take DECT and mpMRI examination within 1 week before surgery.
88801402|NCT05508126||Restaging group II|"Patients in group II are patients that will be stratified for neoadjuvant chemotherapy.~Group II will undergo a primary staging (DECT and mpMRI) and 1-2 times restaging (DECT and mpMRI)."
88801403|NCT01455896|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
88801404|NCT01455896|Other|ITCA placebo|
88801405|NCT05503602|Other|Control Group|An average of 20 people will be taken into the control group.
88801406|NCT05503602|Experimental|IASTM Treatment Group|An average of 20 people will receive IASTM application treatment.
88801407|NCT05503602|Experimental|Foam Roller Treatment Group|An average of 20 people will receive Foam Roller application treatment.
88801408|NCT05508048|Experimental|Experimental Group|The existential approach and logotherapy-based psychosocial support program intervention
88801409|NCT05508048|No Intervention|Control Group|
88801410|NCT01455740|Experimental|Provider Visit Incentive (PVI)|"Participants were told that they would receive $30 after attending each scheduled provider visit (a CCT).~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 21 individuals to the PVI arm."
88805880|NCT05076539|Other|Geospatial|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery)
89121363|NCT02682693|Experimental|nab-paclitaxel 2 of 3 weeks|nab-Paclitaxel day 1,8 q22 for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin weekly in parallel to nab-paclitaxel.
89121364|NCT02682693|Experimental|EC every two weeks or every three weeks|Epirubicin and Cyclophosphamide 600mg/m² for 4 times. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab.
89121365|NCT02571517|Experimental|Glucocorticoids|"methylprednisolone intravenous administration of 2mg/kg/day (divided in two doses) and/or oral prednisolone 2,5 mg/kg/day (in two divided doses) during 7 days.~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis"
89121366|NCT02571517|Placebo Comparator|Placebo|"will receive iv/oral glucose 5% solution as placebo of 2mg/kg/day and/or 2,5 mg/kg/day (divided in two doses) during 7 days.~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis."
89121367|NCT04066543|Active Comparator|TACE group|Device: Transcatheter arterial chemoembolization(TACE)
89121368|NCT04066543|Experimental|TACE+Anlotinib group|Device: Transcatheter arterial chemoembolization Drug: Anlotinib Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
89121369|NCT00586846|Experimental|1|
89121370|NCT04098640|Other|FMI|FoundationOne CDx will be performed using archival tumor tissue
89121371|NCT02570269|Active Comparator|AuraGain|The patient will get a fiberoptic Intubation via the AuraGain larynxmask
89121372|NCT02570269|Placebo Comparator|Slotted Guedeltubus|The patient will get a fiberoptic intubation via the slotted Guedeltubus
89121373|NCT00973700|Experimental|2x7.5adj|Two doses of MF59 adjuvanted (adj) A/H1N1
89121374|NCT00973700|Experimental|7.5adj_1_8|MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
89121375|NCT00973700|Experimental|7.5adj_1_22|MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
89121376|NCT00973700|Experimental|15_1_22|A/H1N1 on study days 1 and 22
89121377|NCT00973700|Experimental|2x15_1_22|Two doses of A/H1N1 (one in each arm) on study days 1 and 22
89121378|NCT04144465|Active Comparator|NORADRENALIN|NORADRENALINE INFUSION
89121379|NCT04144465|Active Comparator|PHENYLEPHRINE|PHENYLEPHRINE INFUSION
89121380|NCT00754390|Experimental|Overall Study|Participants consumed 4 experimental diets for 4 weeks each in randomized order
89121381|NCT04066621|Experimental|CRO-SBT|Ceftriaxone Sodium and Sulbactam Sodium for Injection(2:1)
89121382|NCT02883517||Aggressive primary cutaneous lymphomas|"Mycosis fungoides ≥ T2b~Primary cutaneous T helper follicular lymphoma ≥ T2~Primary cutaneous diffuse large B-cell lymphoma, leg type Genetic: Cytogenetic and molecular studies Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome."
89121383|NCT00754234|Experimental|MyPyramid Menu Days 1-7|Iron absorption measured from one of the 7 different USDA MyPyramid menus for 1 day each, in randomized order for each subject, separated by 2 weeks
89121384|NCT00629330|Experimental|Multi-component Academic Detailing|Includes an interactive, digitized CDROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients.
89121385|NCT02600416|Other|AV port reversal|Patients undergoing citrate CVVH.
89121386|NCT04289012|Experimental|Helicobacter Screening|All patients with confirmed MI (both STEMI and NSTEMI) will be tested for Hp infection with bedside UBT.
89121387|NCT04094896|Experimental|Arm A: TCHP|docetaxel/carboplatin/trastuzumab/Pertuzumab
89121388|NCT04094896|Active Comparator|Arm B: EC-THP|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab
89121389|NCT04289168|Experimental|Music Class|Music Class attendance
89121390|NCT04289168|No Intervention|Play Class|Play date class attendance
89121391|NCT02675491|Experimental|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
89121392|NCT03980158||Upper airway stimulation group|
89121393|NCT03980158||OSA group with conservative / no treatment|
89121394|NCT03980158||Test group without OSA|
89121395|NCT05592626|Experimental|Phase 1: Advanced Solid Tumors|Dose Escalation; Intervention: Drug: STAR0602
89121396|NCT05592626|Experimental|Phase 2: Advanced Solid Tumors|Dose Expansion; Recommended Phase 2 Dose (RP2D) identified from Phase 1 will be used in Phase 2; Intervention: Drug: STAR0602
89121397|NCT00629564|Active Comparator|1|20mg oral
89121398|NCT00629564|Active Comparator|2|15 minute intravenous infusion
89121399|NCT00753922|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
89121400|NCT00753922|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
89121401|NCT00753922|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
89121402|NCT00753922|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
89121403|NCT02407795|Active Comparator|Arm 1|Conventional radiotherapy, 1x8Gy
89121404|NCT02407795|Experimental|Arm 2|Stereotactic radiotherapy, 1x20Gy
89121405|NCT04289948|Experimental|Phage|
89121406|NCT04289948|Placebo Comparator|Placebo|
89121407|NCT00761176|No Intervention|Standard of Care|Standard of Care will be utilized without the device.
89121408|NCT00761176|Other|The Provant Therapy System|Thirty minutes, twice daily treatment
89121409|NCT04287296|Experimental|App users|The app users who are at least 18 years old.
89121410|NCT01613989|Active Comparator|Treatment 1|Reference group, installation of hip prothesis following standard procedure
89121411|NCT01613989|Active Comparator|Treatment 2|:treatment group,installation of hip prosthesis with assistance by computer based on imaging EOS
88801411|NCT01455740|Experimental|Incentive Choice (IC)|"Participants were given a choice between the CCT described in the PVI arm and a commitment contract, which made the $30 payment conditional on the patient attending the provider visit AND meeting an ART adherence threshold.~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 19 individuals to the IC arm."
88801412|NCT01455740|No Intervention|Passive Control (PC)|The study also included 70 individuals in a PC arm, who did not receive financial incentives. Individuals in the PC arm were not enrolled in the randomized trial but met basic study eligibility criteria during the same time period.
88801413|NCT03829748|Experimental|Intermittent aspiration|Empty syringe of 10cc and intermittent aspiration during puncture
89121412|NCT05437276||People with mild to moderate Multiple Sclerosis and gait deficit|"All enrolled subjects will go through 14 weeks therapy: Phase 1 (2-week in-clinic supervised PoNS therapy) followed by Phase 2 (12-week period of at-home unsupervised - PoNS therapy).~Six-Month Observation: subjects will be asked to return to the clinic six months after the end of the 14-week course of therapy for an observation visit.~Individual subjects could receive, upon investigator's opinion of need, an ad hoc second 12-week course of PoNS therapy."
89121413|NCT02865824|Active Comparator|Continue thienopyridine|Patients continue dual antiplatelet therapy (DAT) before colonoscopy and all polyps are removed by cold snare polypectomy.
89121414|NCT02865824|Experimental|Discontinue thienopyridine|Patients discontinue thienopyridines for 1 week before colonoscopy and all polyps are removed by cold snare polypectomy.
88801414|NCT03829748|No Intervention|Continous/standard aspiration|Empty syringe of 10cc and continous aspiration during puncture
88801415|NCT03829358|Experimental|Probiotic|Lactobacillus plantarum IS-10506
89121415|NCT02570035||Mirabegron group|Subjects with overactive bladder and cardiovascular disease prescribed mirabegron
89121416|NCT02865980|Experimental|inflammation|The effect of washing with betadine and clove extract on incidence of inflammation place logging shaldon catheter in the hemodialysis patients
89121417|NCT02865980|Experimental|infection|The effect of washing with betadine and clove extract on incidence of infection place logging shaldon catheter in the hemodialysis patients
89121418|NCT04098796|Experimental|Experimental: Anti-PD-1 antibody＋XELOX|Every patient will receive anti-PD-1 antibody (200 mg intravenous drip every 3 weeks) and XELOX regimen chemotherapy (Oxaliplatin 130 mg/m2, intravenous drip, d1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14;every 21 days). Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years. XELOX will be administered 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
89121419|NCT00522145|Experimental|Group 1|
89121420|NCT02864030|Other|Single arm with Eribulin mesylate|
89121421|NCT00726817|Placebo Comparator|1|enemas, once daily, containing saline
89121422|NCT00726817|Experimental|2|enemas, once daily, containing 50mM butyrate
89121423|NCT00726817|Experimental|3|enemas, once daily, containing 100mM butyrate
89121424|NCT02599870|Experimental|NeuroIDgenetix Test Panel Intervention|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
89121425|NCT02599870|No Intervention|Control|The medical provider for the control group will not receive the NeuroIDgenetix Test Panel results and will make post-operative pain management recommendations based as usual. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
89121426|NCT00726973|Experimental|1|Reduced fluence (3300mW/cm2-50% standard fluence) PDT + ranibizumab
89121427|NCT00726973|Active Comparator|2|Ranibizumab monotherapy
89121428|NCT02956603|Experimental|Neuroma Graft|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The investigators will place small electrodes percutaneously into the muscle grafts to record EMG signals and electrically stimulate the implanted nerves.
89121429|NCT02956603|Experimental|Prosthetic Control Graft|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the investigators will place small electrodes percutaneously into the muscle grafts to record EMG signals and electrically stimulate the implanted nerves.
89121430|NCT02956603|Experimental|Able Bodied|The investigators will place small electrodes percutaneously into intact muscles in the arm to record EMG signals and electrically stimulate the intact nerves nearby.
89121431|NCT00760552|Active Comparator|Arm 1|VA patients with uncontrolled HTN.
89121432|NCT00760552|Active Comparator|Arm 2|VA patients with uncontrolled HTN.
89121433|NCT04287140|Experimental|Saline|1000 ml of 0.9% normal saline bolus over one hour.
88801416|NCT03829358|Placebo Comparator|Placebo|Placebo
88801417|NCT01452308|Experimental|Cohort 1|Participants will receive simtuzumab at a dose of 10 mg/kg by intravenous (IV) infusion every other week for a total of 3 infusions.
88801418|NCT01452308|Experimental|Cohort 2|Participants will receive simtuzumab IV every other week for a total of 3 infusions. The dose will depend on the safety and tolerability of simtuzumab seen in Cohort 1 but will not exceed 20 mg/kg.
88801419|NCT05562882|Experimental|Intervention|Daratumumab once a week x 8 doses
88801420|NCT03825146|Experimental|Treatment Arm (AMPC)|AMPC will be intravenously infused.
88801421|NCT05561634|Sham Comparator|SHHI then follow-up|
88801422|NCT05561634|Experimental|SHHI then radiotherapy|
88801423|NCT02579174|Other|Manual (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for both the tibia component and the femur component
88805881|NCT01894958|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
89121434|NCT04287140|No Intervention|No Saline|10 ml of 0.9% normal saline over one hour.
89121435|NCT00727051||1|Liver and lung transplant candidates referred for coronary angiography will be invited to participate in the study.
89121436|NCT00753766|Experimental|Multifactorial Intervention|Mulitfactorial intervention - addressing glucose, blood pressure, lipids, smoking, nutrition and exercise.
89121437|NCT00753766|No Intervention|Usual care|Control group
88801424|NCT02579174|Other|Manual (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for the tibia component and custom instrumentation for the femur component
88801425|NCT02579174|Other|Custom (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for both the tibia component and the femur component
88801426|NCT02579174|Other|Custom (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for the tibia component and manual instrumentation for the femur component
88801427|NCT05560542|Other|Dexamethasone group (D)|Patients will receive intrathecal hyperbaric bupivacaine 0.5% in a dose of 12.5 mg (2.5 ml) mixed with morphine in a dose of 200 µg (0.5 ml was withdrawn from a syringe containing 4 mg morphine sulfate diluted in 10 ml normal saline) [Total volume 4 ml], followed by intrathecal dexamethasone 4 mg (1ml).
88801428|NCT05560542|Other|Atropine group (A)|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg (2.5 ml 0.5%) mixed with morphine 200 µg (0.5 ml) and atropine100 µg (0.5 ml was withdrawn from a syringe containing 2 mg atropine sulfate diluted in 10 ml normal saline) [Total volume 3.5 ml].
88801429|NCT05560542|Other|Dexamethasone and Atropine group (DA)|Patients will receive intrathecal hyperbaric bupivacaine in a dose of 12.5 mg (2.5 ml) mixed with morphine 200 µg (0.5 ml) and atropine 100 µg (0.5 ml), followed by intrathecal injection of dexamethasone 4 mg (1 ml) [Total volume 4.5 ml] .
88801430|NCT01455974|Experimental|Dialysate sodium set at 136 mmol/L|
88801431|NCT05560308|Experimental|Trastuzumab Emtansine for Injection；Pyrotinib Maleate Tablets|Trastuzumab Emtansine for Injection: 3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle; Pyrotinib Maleate Tablets: The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle; Efficacy was assessed every two cycles and treatment was continued until disease progression or intolerable toxicity or death.
88801432|NCT04782726|Placebo Comparator|Control Arm|After consent and study enrollment the subject will be scheduled for CT simulation for radiation treatment planning. At the time of CT simulation, they will be immobilized by means of a thermoplastic mask. For patients in the control arm, the radiation treatment planning will proceed as normal. Treatment planning is performed on Pinnacle. The patient will return for validation of the radiation plan. Validation involves collecting on-table X-rays or cone beam CTs when the patient is in position for treatment, which is the standard of care. Most often, the date of validation will happen within 5 business days of the CT simulation.
88801433|NCT04782726|Experimental|Research Arm|After consent and study enrollment the subject will be scheduled for CT simulation for radiation treatment planning. At the time of CT simulation, they will be immobilized by means of a thermoplastic mask. For patients in the research arm, a theoretical plan will be created after physician's segmentation and will be used as a guide for the final plan. The patient will return for validation of the radiation plan. Validation involves collecting on-table X-rays or cone beam CTs when the patient is in position for treatment, which is the standard of care. Most often, the date of validation will happen within 5 business days of the CT simulation.
88801434|NCT03822494|Experimental|Dose Escalated CyberKnife SBRT|
89121438|NCT04287452|Placebo Comparator|Control|Emergency department patients enrolled in the control arm will receive usual care. Emergency department providers enrolled in the control arm will work their shift as usual.
89121439|NCT04287452|Active Comparator|Intervention|Emergency department patients and providers in the intervention arm will be exposed to and/or interact with a certified therapy dog and handler
89121440|NCT02865902|Experimental|Test Group|In Test group, the free gingival graft donor sites of each experimental group received low-level laser therapy by Ezlase; Biolase® at doses of 8.6 J/cm2.
89121441|NCT02865902|Sham Comparator|Control Group|In Control Group, the low-level laser therapy by Ezlase; Biolase® was performedin a same manner with test group at free gingival graft donor sites. However, no irradiation was occurred because of not pushing the start button.
89121442|NCT02571361|Active Comparator|Treatment A:|Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
89121443|NCT02571361|Active Comparator|Treatment B:|Paracetamol 1g + placebo orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
89121444|NCT02571361|Active Comparator|Treatment C:|Placebo + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
89121445|NCT02571361|Active Comparator|Treatment D:|Paracetamol 0,5 g + ibuprofen 200 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
89121446|NCT04093102||cases|cases with obsrtuctive sleep apnea
89121447|NCT04093102||control|cases without obstructive sleep apnea.
89121448|NCT04290260|Experimental|Use of breast bra|Patients allocated on this group wear a breast bra from admission to hospital discharge.
89121449|NCT04290260|Active Comparator|Usual care|Usual care: participants will not wear a breast bra until discharge from the hospital
89121450|NCT04095130||Healthy subjects|those without a condition
89121451|NCT04095130||Psoriasis patients|those with a condition
89121452|NCT00722605|Experimental|1|cone-beam CT based
88801435|NCT04779528|Experimental|Group S|Patients will undergo fiberoptic intubation in supine position.
88801436|NCT04779528|Experimental|Group L|Patients will undergo fiberoptic intubation in lateral position.
88801437|NCT04273568|Experimental|Group1 (PNF group)|Scapular PNF and exercise program was applied to the PNF group.
88801438|NCT04273568|Active Comparator|Group 2 (Exercise group)|Exercise program was applied to the exercise group
89121453|NCT04290104|Experimental|1gr oral ampicillin/sulbactam group|The group to be prescribed 1 g oral ampicillin/sulbactam twice a day while discharged after laparoscopic cholecystectomy due to ACC.
89121454|NCT04290104|No Intervention|Antibiotic not prescribed group|Antibiotics not prescribed when discharged after laparoscopic cholecystectomy due to ACC.
89121455|NCT04290026|Active Comparator|metoclopramide versus granisetron|Ultrasound assessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section: A randomized, double-blind, placebo-controlled study
89121456|NCT01921803|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
88801439|NCT05507736|Experimental|Experimental|"Pre-Post feasibility treatment On the first cycle of irinotecan, the patient does not receive any intervention, we only collect data. This is the control cycle.~There will be a single study group that will be used at the same time as your own control. On the second cycle of irinotecan, the patient receives acupuncture. There will be a single study group that will be used at the same time as your own control."
88801440|NCT04847726|Experimental|CEUS with perfluorobutane and sulfur hexafluoride|Contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride for the hepatic lesion.
88801441|NCT05475834|Experimental|SIM0417|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
88801442|NCT04273646|Experimental|UC-MSCs Treatment Group|"Conventional treatment plus UC-MSCs:~Participants will receive conventional treatment plus 4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1，Day 3，Day 5，Day7)."
88801443|NCT04273646|Placebo Comparator|Conventional Control Group|"Conventional treatment plus Placebo:~Without UC-MSCs Therapy but conventional treatment should be received. Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day 1，Day 3，Day 5，Day7)."
88801444|NCT05436522|Experimental|Remimazolam TIVA|Induction: Remimazolam, sufentanil, cisatracurium. Maintenance: Remimazolam, remifentanil, cisatracurium.
88801445|NCT05436522|Active Comparator|Propofol TIVA|Induction: Propofol, sufentanil, cisatracurium. Maintenance: Propofol, remifentanil, cisatracurium.
88801446|NCT04273334|Experimental|68Ga-NEB injection and PET/CT scan|Patients for lymphatic disorders imaging: The patients were subcutaneously injected with 68Ga-NEB and underwent PET/CT scan 20~40min after the injection.
88801447|NCT01456286|Experimental|Sapropterin|5 mg/kg daily first week; 10 mg/kg daily second week of treatment
88801448|NCT01456286|Placebo Comparator|placebo|
88801449|NCT05349240|Experimental|Study Intervention|All subjects will receive treatment with the study device.
88801450|NCT03780010|Experimental|TRC105 + B + P + C|TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
88801451|NCT03826550|Experimental|Diclofenac Sodium Gel3%|Diclofenac Sodium Gel 3%, dosed twice daily for 60 days.
88801452|NCT03826550|Active Comparator|Solaraze|Solaraze Gel dosed twice daily for 60 days.
88801453|NCT03826550|Placebo Comparator|Placebo|Placebo Gel dosed twice daily for 60 days.
88801454|NCT05325762|Experimental|Propofol|
88801455|NCT05325762|Active Comparator|Dexmedetomidine|
88801456|NCT05325762|Placebo Comparator|saline|
88801457|NCT04391738||BMI SARS-CoV-2|Patients admitted to Intensive Care Unit with SARS-CoV-2
88801458|NCT05313568|Active Comparator|static stretching group|The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
88801459|NCT05313568|Experimental|self massage group|In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
88801460|NCT05313568|Experimental|Manual Stimulation Group|"In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each)."
88801461|NCT05498142||SICS I|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT02912624)
88801462|NCT05498142||SICS II|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT03577405)
88801463|NCT05498142||AFIB-ICU|An international inception cohort study.
88801464|NCT05498142||Emmen|Patients admitted to the ICU of a community hospital in the Netherlands.
88801465|NCT04391582|Experimental|Test - Tilapia Skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage.
88801466|NCT04391582|Active Comparator|Control - Silver sulfadiazine|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and band
88801467|NCT03768856|Experimental|Temporally Feathered Radiation Therapy (TFRT)|"Temporally feathered radiation therapy is designed for targets within close proximity to multiple organs at risk. The foundation of this planning technique is the rotation of radiation dose to the nearby organs at risk on a daily basis, and hence the term feathering."
88801468|NCT04845386||TOF Cuff on arm and TOF Scan on corrugator supercilii|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
88801469|NCT04845386||TOF Cuff on lower leg and TOF Scan on adductor pollicis|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
88801470|NCT04845386||TOF Scan on adductor pollicis and TOF Scan on toe|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
88801471|NCT04845386||TOF Scan on adductor pollicis and TOF Cuff on arm|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
88801472|NCT04845386||TOF Scan on adductor pollicis and TOF Scan on corrugator supercilii|Patients undergoing surgery with intubation and receiving a intubation dose of mivacurium (0.2 mg/kg) and repeated dose of mivacurium (2mg) depending of needing under, routine gas anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
89121457|NCT01921803|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
88801473|NCT03767062|Active Comparator|Topiramate|Topiramate will be introduced 25 mg/day b.i.d. for the first week and increased to 100 mg/day b.i.d. for the second week.
88801474|NCT03767062|Active Comparator|Greater Occipital +Supratrochlear Nerve Block|"Greater occipital nerve block (GONB) will be applied to medial of the occipital artery which localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg) and 1 ml 0,9% sodium chloride (NaCl). The injection is performed using a 22 gauge (G) × 1¼ (0.7 × 40mm) injector when the patient is lying prone on the table. The scalp is cleaned with iodine before procedure and injections are performed bilaterally with a volume of 2 mL after negative aspiration for blood. Supratrochlear nerve block (STNB) is applied 1 cm medial to superior orbital fissure using a mixture of 8 mg bupivacaine and 1.4 ml 0,9% NaCl. STNB is performed bilaterally with a volume of 1.5 mL after negative aspiration for blood."
88801475|NCT01456364|Active Comparator|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
88801476|NCT01456364|Active Comparator|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
88801477|NCT05497986|Experimental|High Flow Nasal Cannula|
88801478|NCT05497986|Active Comparator|Conventional Oxygenation with low flow cannula|
88801479|NCT02901314|Experimental|MyRoad|Receives usual care heart failure education before discharge AND a card at discharge that provided pre-recorded audio messages that can be played back on-demand on 4 themes: heart failure signs/symptoms assessment, medications, activity and exercise and diet and a general message about the importance of follow-up post discharge and following the plan of care.
88801480|NCT02901314|No Intervention|Usual care|Receives usual care heart failure education before discharge
88801481|NCT04281420|Experimental|ATG-019 Alone|A starting does of 30 mg QoD×3 ATG-019
88801482|NCT04281420|Experimental|ATG-019 + Niacin ER|A starting dose of 60 mg ATG-019 and 500 mg niacin ER
88801483|NCT03765502|Experimental|Nasal Glucagon Device (NG)|Empty NG device administered to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
88801484|NCT03765502|Active Comparator|Glucagon Emergency Kit (GEK)|Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
88801485|NCT04845230|Active Comparator|Enhanced Usual Care|"The control group in this study will still receive some services above and beyond the usual standard of care offered to pregnant women on Medicaid. In addition to the case management services offered through their managed care provider, Operation Food Search will offer this group access to the hunger hotline, a service provided by Operation Food Search to help them find food assistance around St. Louis; assistance in enrolling in public nutrition assistance programs like SNAP and WIC; and guidance on food pantry access in St. Louis."
88801486|NCT04845230|Experimental|Treatment 1: Nutrition Services|"This treatment group will receive all the services offered to the control group, as well as the following services:~Weekly food deliveries of fresh food meal kits with step-by-step recipes from the time of program enrollment through 60 days post-partum. Access to necessary cooking tools for their kitchen (e.g., spatulas, cutting boards , etc.), should they need them. Access to online cooking resources to help guide them on culinary skills and recipe preparation. Nutrition education and counseling provided by a registered dietitian."
88801487|NCT04845230|Experimental|Treatment 2: Integrated Care Services|This treatment group will receive all the services offered to Treatment Group 1, as well as the services of a Licensed Masters Social Worker who will provide trauma-informed integrative care services to participants. These services will focus on an array of potential needs that may emerge in participants' lives, such as assistance in finding stable housing, assistance navigating social services, connections with other community organizations, and other needs.
88801488|NCT04455828||Hospitalized Heart Failure subjects|Subjects hospitalized for heart failure exacerbation will be enrolled, prior to discharge from hospital, to wear the WHOOP device for 90 days.
88801489|NCT04455828||Non-hospitalized Heart Failure subjects|Subjects who have not been hospitalized in the past 1 year, but have a diagnosis of heart failure, will be enrolled during routine outpatient care to wear the WHOOP device for 90 days.
88801490|NCT04587492||Children with SMA|All children with SMA are eligible for the study
88801491|NCT03761368|Experimental|RIPC group|The RIPC group underwent Remote Ischemic Preconditioning.
88801492|NCT03761368|Sham Comparator|Control group|Patients from control group had sham Remote Ischemic Preconditioning.
88801493|NCT04841642|Experimental|Manual therapy and a telerehabilitation program|"In the experimental group, an intervention based on manual therapy and a telerehabilitation program based on exercises will be carried out.~The investigators will apply manual therapy for ten minutes a week based on cervical mobilizations and suboccipital inhibitions.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need."
89121458|NCT00722683|Experimental|Ultrasound Imaging|Ultrasound Imaging with Contrast
89121459|NCT04287374|Experimental|Multi-component Well-being Intervention|Reading and writing activities based on cognitive restructuring (rephrasing automatic negative thoughts), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities)
89121460|NCT04287374|Sham Comparator|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
89121461|NCT00640887|Experimental|1|RBT associated with EFV based ART
89121462|NCT00640887|Experimental|2|RBT associated with NVP based ART
89121463|NCT00640887|Experimental|3|RBT associated with LPV/r based ART
89121464|NCT04067869|Experimental|Single arm|Patient with confirmed HIV-1 infection
89121465|NCT04183647|Active Comparator|Local Vibration / Whole body vibration|"Local vibration will be sequentially applied to the bilateral gastrosoleus complex with the Vibrasens © device. Application, the largest part of the muscle, each limb 5'er for a total of 10 minutes, static semi-squat position will be done.~The vibration frequency is 80 Hz and the amplitude is 1 mm."
88801494|NCT04841642|Active Comparator|Manual therapy and recommendations for home exercises|"In the control group, the same manual therapy intervention and recommendations for home exercises will be applied.~This exercises recommendations will be based on a simulation of the exercise in the same session of the manual therapy of each week."
88801495|NCT03774134||CME group|The CME group consisted of patients, who underwent elective CME for sigmoid colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2014.
88801496|NCT03774134||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for sigmoid adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
88801497|NCT03758716|Experimental|FB825|Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.
88801498|NCT05285124|Experimental|tDCS and melatonin intervention|In real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes. Participants were given a 3-mg fast-release oral dose of melatonin.
88801499|NCT05285124|Experimental|tDCS intervention|In real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
88801500|NCT05285124|Experimental|Melatonin intervention|Participants were given a 3-mg fast-release oral dose of melatonin.
88801501|NCT05285124|Placebo Comparator|Control|Patients were treated with the placebo and sham-tDCS.
89121466|NCT04183647|Active Comparator|Whole body vibration/local vibration|Whole body vibration application will be done with Compex® Winplate device. During this application, patients will be asked to continue static semi-squat position with 5 minutes of vibration and then 5 minutes of vibration.Vibration frequency, 30 Hz amplitude will be selected 2 mm.
89121467|NCT04067947|Experimental|XG005|XG005 in 4 dose levels
88801502|NCT01450046|Experimental|Phase I Dose Escalation|Each investigator will be provided with adequate supplies of Vitamin E δ -Tocotrienol, which will be supplied as 100-mg, 200-mg, and 400-mg capsules. Vitamin E δ-Tocotrienol will be administered orally once. The dose administered to each subject will be fixed and based on cohort assignment. Doses will be administered at the clinical site during each protocol-defined visit.
88801503|NCT03757312|Experimental|Fontan|Patients undergoing Fontan procedure to redirect blood flow from the lower body to the lungs.
88801504|NCT03757312|Active Comparator|Non-Fontan|Patients undergoing other cardiac surgeries requiring cardiopulmonary bypass.
88801505|NCT01450124|Experimental|Boswellic acids (BOSWELAN)|Baseline to treatment single arm - 4 months baseline and 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg of BOSWELAN.
89121468|NCT04067947|Placebo Comparator|Placebo|Placebo in all cohort
89121469|NCT04183569||Primary diffuse cutaneous B-cell lymphoma, leg type|Cohort of 32 patients LBC-TJ treated with R-chemotherapy for which data collection was carried out in homogeneous and prospectively followed according to international standards through RCP monthly cutaneous lymphomas managed by Professor Beylot-Barry and inclusion of cases in the national database of rare cancer network French Study Group of Cutaneous Lymphomas in Bordeaux managed by Prof. Beatrice Vergier.
89121470|NCT02682771|Active Comparator|Control|Individuals were treated with Conventional Respiratory Physiotherapy (CRP), twice in immediate postoperative day and three times in first postoperative day.
89121471|NCT02682771|Experimental|Bilevel positive airway pressure|Individuals were treated with positive pressure, in the BIPAP mode (bilevel positive airway pressure, with inspiratory pressure:12 cmH20 and expiratory pressure: 8 cmH20) twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each
89121472|NCT02682771|Experimental|Load inspiratory breathing exercises|Individuals were treat with PowerBreathe, a device for inspiratory muscle, with 40% maximal inspiratory pressure, measured at preoperative, twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each.
89121473|NCT00730093|Other|A|
89121474|NCT02682615||requirement of norepinephrine|requirement of norepinephrine <0,1 µg/kgKG/min versus ≥0,1 µg/kgKG/min
88801506|NCT05587166|Active Comparator|The transverse short-axis group|
88801507|NCT05587166|Experimental|The oblique short-axis group:|
88801508|NCT05587088|Experimental|Metastatic gastrointestinal tumors and acute leukemia patients|Patients with metastatic gastrointestinal tumors (colon, pancreas, stomach, and bile ducts) and newly diagnosed/relapse acute leukemias who meet the inclusion criteria will take the anamu extract with chemotherapy to evaluate the adverse drug-related side effects.
88801509|NCT05587088|Experimental|Stage II Metastatic gastrointestinal tumors including pancreas|For solid metastatic tumors, 30 patients will be recruited, which can be from the colon, pancreas, stomach, and bile ducts, divided into two groups of 15 patients, an intervention group and a placebo group. The intervention group will receive the Esperanza extract at DMT for three continuous treatment cycles (approximately 12 weeks), and the other group will receive the placebo.
88801510|NCT05587088|Placebo Comparator|Stage II Placebo Metastatic gastrointestinal tumors including pancreas|For solid metastatic tumors, 30 patients will be recruited, which can be from the colon, pancreas, stomach, and bile ducts, divided into two groups of 15 patients, an intervention group and a placebo group. The intervention group will receive the Esperanza extract at DMT for three continuous treatment cycles (approximately 12 weeks), and the other group will receive the placebo. Both groups will receive standard chemotherapy treatment for their underlying disease. The safety evaluation will be carried out in each treatment cycle, and the efficacy evaluation will be carried out at the end of the three cycles.
88805882|NCT01894958|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water
88805883|NCT05073497|Experimental|Experimental Group|One minute before the procedure the children in the experimental group will start to play with finger puppets under the direction of the researcher. The researcher will continue to distract the child's attention during the procedure with finger puppets.
89121475|NCT00976898|Experimental|Proton Beam Irradiation|This is a single arm study. All study participants will receive proton radiation therapy.
89121476|NCT04183725|Experimental|Experimental group|Reduning injection +Oseltamivir phosphate granule simulants
89121477|NCT04183725|Active Comparator|Control group|Oseltamivir phosphate granules+ Reduning injection simulants
89121478|NCT00730249|Active Comparator|1|
89121479|NCT00730249|Placebo Comparator|2|
88801511|NCT05587088|Experimental|Acute leukemia (Newly/Relapse)|"For newly diagnosed hematological tumors, 28 patients will be recruited and will receive the Esperanza extract at DMT. The intervention group will continuously receive the Esperanza extract at DMT for four weeks with the standard chemotherapy regimen for their underlying disease. The safety and efficacy evaluation will be carried out at the end of the treatment cycle.~Patients with relapsed or refractory acute leukemias will be admitted to receive the calculated DMT in phase Ib; A total of 6 patients will be recruited, and safety and efficacy evaluations will be performed during three treatment cycles or progression and death of the patient.~For the analysis of the response in patients with acute leukemia, a comparison will be made with a group followed historically. A propensity score matching will be performed for statistical analysis in case of differences in their baseline characteristics."
88801512|NCT01450202|Placebo Comparator|Air insufflation, colonoscopy, esophagogastroduodenoscopy|
88801513|NCT01450202|Active Comparator|CO2 insufflation, colonoscopy, esophagogastroduodenoscopy|
88801514|NCT03748264|Active Comparator|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant. Therapy information is available continuously to site staff personnel in the standard care arm.
88801515|NCT03748264|Experimental|DreamMapper Application|The DreamMapper Application group will receive the site's therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. Participants in this group will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously as well
88801516|NCT03748264|Experimental|DreamMapper Application with Therapist Assist|The DreamMapper Application wit Therapist Assist group will not receive the site's therapy initiation standard of care but will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, and their Philips Respironics mask. and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously as well
88801517|NCT03751124|Experimental|Relugolix plus E2/NETA|Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 52 weeks.
88801518|NCT03751124|Placebo Comparator|Placebo tablets and capsules|"Placebo for relugolix co-administered with placebo for E2/NETA for up to 52 weeks or until heavy menstrual bleeding returns.~Retreatment with open-label relugolix with E2/NETA will be offered if heavy menstrual bleeding returns."
89121480|NCT02682537||Female, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 Years
89121481|NCT02682537||Female, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
89121482|NCT02682537||Female, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
88801519|NCT01450280|Experimental|Group 1A|AdCh63 CS 5x10^9 vp
88801520|NCT01450280|Experimental|Group 1B|ChAd63 CS 5x10^9 vp Day 0; MVA CS 2x10^8 pfu Day 56
88801521|NCT01450280|Experimental|Group 2A|AdCh63 CS 5 x 10^10 vp
88801522|NCT01450280|Experimental|Group 2B|ChAd63 CS 5x10^10 vp Day 0; MVA CS 2x10^8 pfu Day 56
88801523|NCT01456598|Experimental|Laparoscopic gastrectomy|Laparoscopic subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
88801524|NCT01456598|Active Comparator|Open gastrectomy|Open subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
88801525|NCT02859116||Collection of digestive tissues|Digestive tissues will be collected from participants undergoing scheduled (non-emergent) gastrointestinal surgery.
88805884|NCT05073497|No Intervention|Control Group|No intervention will perform to reduce pain in the control group.
89121483|NCT02682537||Female, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
89121484|NCT02682537||Female, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
89121485|NCT02682537||Female, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
89121486|NCT02682537||Female, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
89121487|NCT02682537||Female, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
89121488|NCT02682537||Female, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
89121489|NCT02682537||Male, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 years
89121490|NCT02682537||Male, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
89121491|NCT02682537||Male, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
89121492|NCT02682537||Male, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
89121493|NCT02682537||Male, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
89121494|NCT02682537||Male, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
89121495|NCT02682537||Male, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
89121496|NCT02682537||Male, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
89121497|NCT02682537||Male, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
89121498|NCT02570347|Active Comparator|Routine use arm|"All participants allocated to this arm will be given~Injection Tetanus toxoid 0.5 ml intramuscularly Stat~Antibiotic (Co-amoxiclav) will be given to all patients for a minimum duration of 5 days.~Daily clinical assessment would be done. Change of antibiotics is allowed if clinical failure occurs.~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
89121499|NCT02570347|Experimental|Clinically-directed use arm|"Participants allocated to this arm will be given~Injection Tetanus toxoid 0.5 ml intramuscularly Stat~Daily clinical assessment would be done. Antibiotic (Co-amoxiclav) will be started only if clinical failure occurs.~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
89121500|NCT01632657|Experimental|Sumatriptan|Subcutaneous injection of sumatriptan (6 mg)
89121501|NCT01632657|Placebo Comparator|Placebo|Matching placebo (0.9% saline)
89121502|NCT00727285||A|CF patients followed by the Adult CF Program at National Jewish Health meeting criteria for an acute pulmonary exacerbation.
89233261|NCT02114372||CogState Brief Battery|Enrolled participants will be randomized in a balanced manner to CogState brief battery in both the Main Study and the SubStudy. CogState consists of four tasks that respectively measure the functions of attention, processing speed, visual learning, and working memory. The CogState Brief Battery is an approximately 15 minute computerized battery with demonstrated reliability, validity, and short term stability, that was developed expressly for maximal sensitivity to detect change. CogState can be administered via the internet or on a stand-alone computer and is available in over 50 languages.
89233262|NCT02114372||Cognitive Drug Research Assessment System (CDR-AS)|Enrolled participants will be randomized in a balanced manner to CDR-AS in both the Main Study and the SubStudy. CDR-AS is fully automated system that targets the core aspects of cognitive function crucial for everyday behavior which are vulnerable to numerous insults including aging, fatigue, disease, pathology, trauma, diet, and pharmaceuticals. CDR-AS is an approximately 20-minute computerized battery designed to reliably measure changes in cognitive function in clinical trial situations.
89233263|NCT02114372||Delis Kaplan Executive Function System (DKEFS)|Enrolled participants will be randomized in a balanced manner to DKEFS in the Main Study and at one site of the SubStudy. The DKEFS is a paper and pencil measure of verbal and nonverbal executive functions that has been normed and validated for children and adults from 8-89 years of age. The measure consists of nine subtests. For the purposes of this study, the Trail Making Test (TMT) and Verbal Fluency subtests will be used.
89233264|NCT02114372||COGNITO|Enrolled participants will be randomized in a balanced manner to COGNITO at the other site of the SubStudy. COGNITO is an approximately 45 to 60 minute computerized neuropsychometric examination based on well-known cognitive tests designed for both cognition research and clinical assessment. COGNITO assesses reaction time, primary and working memory, visuospatial and verbal secondary memory, implicit learning, language skills, functional and semantic categorization of visual data, focused and divided attention, and crystallized intelligence. Responses are made via a tactile screen which permits the recording of response latency (deducting reaction time provides an estimation of information processing time).
89233265|NCT02078648|Experimental|SL-701 + GM-CSF + Imiquimod|"Patients will receive SL-701 with the vaccine adjuvants granulocyte macrophage-colony stimulating factor (GM-CSF) injection and imiquimod topical cream.~A complete dose of study drug consists of the administration of a sequence of 3 agents, SL-701 emulsion SC injection, GM-CSF SC injection, and imiquimod topical cream, within a 5-minute time frame. Topical application of imiquimod cream at the injection site is repeated at 24 hours after each SL-701 emulsion injection. For each patient, SL-701 emulsion (SL-701 in Montanide®) will be administered by SC injection beginning on Day 1 with imiquimod topical cream 5% applied immediately (within 5 minutes after SL-701 emulsion injection) to the SL-701 emulsion injection site.~In addition to the SL-701 emulsion injection, the patient will receive a SC injection of GM-CSF 150 μg close to the injection site of SL-701 emulsion. An additional dose of imiquimod cream will be applied at the same site by the patient 24 hours later."
89233266|NCT02078648|Experimental|SL-701; poly-ICLC 1.6mg; bevacizumab|SL-701 emulsion and the adjuvant poly-ICLC will be administered twice weekly for the initial 2 weeks, every 7 days during the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) through Week 22, and every 4 weeks thereafter. Bevacizumab will be administered every 2 weeks, subsequent to the administration of SL-701/poly-ICLC.
88801526|NCT02563548|Experimental|GAC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma (GAC) will receive PEGPH20 1.6 micrograms/kilogram (µg/kg) or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 milligrams/kilogram (mg/kg) every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory locally advanced or metastatic GAC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks).
88801527|NCT02563548|Experimental|NSCLC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory Stage IIIB or IV non-small cell lung cancer (NSCLC) will receive PEGPH20 1.6 µg/kg or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 mg/kg every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory Stage IIIB or IV NSCLC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 46 weeks).
88801528|NCT01450358|Active Comparator|Pathogen detection by Multiplex PCR|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. Multiplex PCR will be immediately undertaken and its results will be reported to prompt medical researcher (6-12 hours).The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR.
88801529|NCT01450358|No Intervention|Pathogen detection by blood culture|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. The results of multiplex PCR will be not informed to the medical researcher, being focused care as a result of blood culture (at least after 72 hours).
88801530|NCT04081324|Placebo Comparator|Placebo|Participants received placebo administered orally on Day 1 and repeated doses on Days 4 to 10 (7 days of dosing).
88801531|NCT04081324|Experimental|50 milligram (mg) Lasmiditan|Participants received 50 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 50 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
89233268|NCT02052648|Experimental|Phase 1b Cohort 1|"Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.~Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity."
89233269|NCT02052648|Experimental|Cohort 2a|Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
89233270|NCT02052648|Experimental|Cohort 2b|"Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.~Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg."
89233271|NCT02052648|Experimental|Cohort 2c|Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
89233274|NCT01998971|Experimental|Daratumumab + VD|Daratumumab will be administered with Velcade-dexamethasone (VD).
88801532|NCT04081324|Experimental|100 mg Lasmiditan|Participants received 100 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 100 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
89233275|NCT01998971|Experimental|Daratumumab + VMP|Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).
89233276|NCT01998971|Experimental|Daratumumab + VTD|Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).
89233277|NCT01998971|Experimental|Daratumumab + Pom-dex|Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).
89233278|NCT01998971|Experimental|Daratumumab + CFZ-dex|Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.
89233279|NCT01998971|Experimental|Daratumumab + KRd|Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.
89233280|NCT01961986|Active Comparator|TSR: traditional subscap release|"TSR - traditional subscapularis release approach~Subscapularis tendon release technique TSR"
89233281|NCT01961986|Experimental|TSR: rotator cuff sparing|Rotator cuff sparing technique TSR
88801533|NCT04081324|Experimental|200 mg Lasmiditan|Participants received 200 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 200 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
88801534|NCT01456676|Experimental|Nilotinib + LDE225|The planned dose of nilotinib 400 mg b.i.d (twice a day) was selected for the combination as this is the dose approved for the treatment of the patient population that will be included in the present study. The starting dose for LDE225 chosen for the current study is 400 mg once daily(q.d.). The maximum dose of LDE225 that will be tested in combination with nilotinib is 800 mg once dail.y
88801535|NCT01456754|Experimental|High feeding frequency (14x)|
88801536|NCT01456754|Experimental|low feeding frequency (3x)|
88801537|NCT04391426||Patients who will undergo ERCP (case group)|
88801538|NCT04391426||Living liver transplantation donors (control group)|
88801539|NCT04424706||Normal people|No diabetes and atherosclerosis
89233282|NCT01933620||Patient|Patients who might become colonized or infected with a multidrug-resistant organism
89233283|NCT01878045||American Indians with type 2 diabetes|previously enrolled in OH95-DK-N037
89233284|NCT01875588||DOD|Participants that are from IDCRP
89233285|NCT01875588||HIV negative controls|Participants that do not have HIV infection
89233286|NCT01875588||HIV positive|Participants that have HIV infection
88801540|NCT04424706||type 2 diabetes mellitus without atherosclerosis|Newly diagnosed type 2 diabetes without atherosclerosis
88801541|NCT04424706||type 2 diabetes mellitus with atherosclerosis|Newly diagnosed type 2 diabetes with atherosclerosis
88805885|NCT05045807|Experimental|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with sodium nitrate as an additive.
89233290|NCT01840072|Experimental|Active antihypertensive treatment|Active antihypertensive treatment
89233291|NCT01840072|No Intervention|Usual care|Discontinue all home BP medications.
88801542|NCT04042324|Experimental|Triferic post-dialyzer; UFH via continuous infusion|Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.
89121503|NCT01460589|Experimental|early commencement|Individuals who initiate the adjuvant chemotherapy from 10 to 14 days after surgery
89121504|NCT01460589|Active Comparator|conventional commencement|Individuals who initiate the adjuvant chemotherapy after 14 days after surgery
89121505|NCT03950791|Experimental|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials.
89121506|NCT03950791|Placebo Comparator|Health Education|A 2-hour in-person informational session about general health education. Participants receive a list of resources in the community.
89121507|NCT02682459|Experimental|Lisinopril|Patients will receive, in addition to standard immunosuppressive therapy, lisinopril starting with 5 mg/day, then progressively up-titrated to reach the maximum tolerable dose (target dose) for 18 months.
89121508|NCT02682459|No Intervention|No intervention|Patients will receive only the standard immunosuppressive therapy.
89121509|NCT00727363|Placebo Comparator|1|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital. Patients fed through NG tube will be administered 5 drops of placebo through the NG tube followed by a 0.5 cc of a normal saline flush. Patients taking PO feeds will be administered 5 drops of placebo in posterior oropharynx after secretions have been suctioned.
89121510|NCT00727363|Experimental|2|5 drops of Lactobacillus reuteri DSM 17938 from an oil based suspension will be administered once a day until death or discharge home. Patients with NG feeds will be administered the probiotic in the amount of 5 drops through the NG tube followed by 0.5 cc of a normal saline flush. Patients with PO feeds will be administered 5 drops of the probiotics in the posterior oropharynx after secretions have been suctioned. If feeds are temporarily suspended because of feeding intolerance or NEC, the probiotic may be re-started once feeds are re-started.
89121511|NCT00640965|Experimental|A|DP-VPA
89121512|NCT00640965|Placebo Comparator|B|
89121513|NCT01320657|Active Comparator|InOvation C|Active Self-ligating Bracket
89121514|NCT01320657|Placebo Comparator|Ovation|Conventional Bracket
89121515|NCT01320657|Experimental|Damon Q|Self-ligating bracket
89121516|NCT02682303|Experimental|elastic bandage|In this study, Idealplast C® (6cm*2.5m) was used.
89121517|NCT02682303|Placebo Comparator|Non-standardized tape (NST)|In the NST group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used.
89121518|NCT02620579|Experimental|Personalized Pharmaceutical and Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive the pain processing education modules as the combined intervention for this arm.
89121519|NCT02620579|Placebo Comparator|Placebo Pharmaceutical, General Education|This group will have the placebo pharmaceutical administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
89121520|NCT02620579|Active Comparator|Placebo Pharmaceutical, Personalized Education|This group will have the placebo pharmaceutical administered orally and receive the pain processing education modules as the combined intervention for this arm.
89121521|NCT02620579|Active Comparator|Personalized Pharmaceutical, General Education|This group will have propranolol (Propranolol LA) 60 mg administered orally and receive general shoulder anatomy education modules as the interventions for this arm.
89121522|NCT02682225|Experimental|Sequence 1: Qualification Session|Participants will receive Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 1 and Treatment B (0.5 milligram per kilogram (mg/kg) of intravenous racemic ketamine and intranasal placebo concurrently) on Day 2.
89121523|NCT02682225|Experimental|Sequence 2: Qualification Session|Participants will receive Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo concurrently) on Day 1 and Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 2.
89121524|NCT02682225|Experimental|Sequence 3: Treatment Phase|Participants in Sequence 3 will receive Treatment A (intravenous placebo and intranasal placebo) on Day 1 of period 1, Treatment D (intravenous placebo and intranasal 112 milligram (mg) of esketamine as 4 devices, each with 28 mg esketamine) on Day 1 of period 2, Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo) on Day 1 of period 3, Treatment C (intravenous placebo and intranasal 84 mg esketamine as 3 devices, each with 28 mg esketamine followed by 1 device with placebo) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
89121525|NCT02682225|Experimental|Sequence 4: Treatment Phase|Participants in Sequence 4 will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
89121526|NCT02682225|Experimental|Sequence 5: Treatment Phase|Participants in Sequence 5 will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment D on Day 1 of period 3, Treatment A on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
89121527|NCT02682225|Experimental|Sequence 6: Treatment Phase|Participants in Sequence 6 will receive Treatment D on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment B on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
89121528|NCT04066231|Experimental|VIPUN GMS|Single arm study.
89121529|NCT00727519|Experimental|PG|
89121530|NCT00727519|Experimental|PL|
89121531|NCT04183491|Experimental|Arm A: Interferon beta-1a low dose|Single dose of interferon beta-1a 7.5 µg intramuscular (IM)
89121532|NCT04183491|Experimental|Arm B: Interferon beta-1a intermediate dose|Single dose of interferon beta-1a 15 µg IM
89121533|NCT04183491|Experimental|Arm C: Interferon beta-1a high dose|Single dose of interferon beta-1a 30 µg IM
89121534|NCT04183491|Experimental|Arm D: Peginterferon beta-1a low dose|Single dose of peginterferon beta-1a 31.25 µg subcutaneous (SC)
89121535|NCT04183491|Experimental|Arm E: Peginterferon beta-1a intermediate dose|Single dose of peginterferon beta-1a 62.5 µg SC
89121536|NCT04183491|Experimental|Arm F: Peginterferon beta-1a high dose|Single dose of peginterferon beta-1a 125 µg SC
89121537|NCT04183491|Placebo Comparator|Arm G: Placebo|Single dose of placebo
89121538|NCT03702283|Experimental|Penicillin Allergic ICU Patients|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
89121539|NCT00727675|Other|1|Integrated Cognitive Behavioral Therapy for pain reduction and opioid dependence.
89121540|NCT02681835|Experimental|Position 1|Standard position during intubation. Intubator is behind head of the victim, propped up on both elbows
89121541|NCT02681835|Experimental|Position 2|Intubator is behind head of the victim, lies on the left side
89121542|NCT02681835|Experimental|Position 3|Intubator stands astride the victims, intubated using the face-to-face
89121543|NCT00727753||Ranibizumab|
89121544|NCT00727753||Bevacizumab|
89121545|NCT00727753||Dry AMD|
89121546|NCT02569567||US elastography|"Participants who have the plan of liver transplantation or liver biopsy within 4 weeks will be screened from the outpatient clinic.~Two types of ultrasonographic elastography(US elastography) techniques including Smart-Shear Wave(SSW) imaging and transient elastography(TE) will be performed as a diagnostic method for hepatic fibrosis."
89121547|NCT00641199|Active Comparator|1|Jarrow-Dophilus EPS
89121548|NCT00641199|Placebo Comparator|2|Placebo
89121549|NCT02681991|Experimental|test|Renamezin capsule 2g, tid, PO
89121550|NCT00727987|Experimental|CNTO 148 50 mg + methotrexate|
89121551|NCT00727987|Experimental|CNTO 148 100 mg + methotrexate|
89121552|NCT00727987|Placebo Comparator|Placebo + methotrexate|
89121553|NCT05664321||Normal weight|Body mass index (BMI) between 18.50 and 24.99 kilograms per square meter
89121554|NCT05664321||Obese|Body mass index (BMI) of more than 30 kilograms per square meter
89121555|NCT00733915|Experimental|Single arm|Cohort of total knee replacements with LCS Complete knee implants
89121556|NCT02681913|No Intervention|standard cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.~The cardioplegic maintenance solution consists of a 500 ml normal saline (0.9% NaCl) infusion bag. Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.~This arms receives standard intermittent 20:1 diluted warm blood cardioplegic solution.~Intervention: n/a"
89121557|NCT02681913|Experimental|adenosine enriched cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.~The cardioplegic maintenance solution consists of a 1000 mg = 500 ml adenosine infusion bag (2 mg/ml). Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.~This arms receives adenosine enriched, intermittent 20:1 diluted warm blood cardioplegic solution.~Intervention: Drug: Adenosine"
89121558|NCT04065217|Other|Iraqi patients with face hemangioma|Diode laser 980-nm in the diseased group only while we no need the comparator group because we compared between lesion before and after. The administration of laser is scheduled to start treatment. Patients will take laser therapy as a 12 session at two week-interval. In case of intolerance, session number reduction by 10, 8, 6, 4 allowed. Adherence to treatment will be assessed at each interval for undesired side effects or complications. The intervention should continue also after complete session, or during temporary interval withdrawal due to reached maximal cumulative response or side effects from laser therapy.
89121559|NCT02681679|Experimental|0.1% bromfenac ophthalmic solution|Patients received 0.1% bromfenac ophthalmic solution twice a day for 3 days before surgery.
89121560|NCT02681679|Placebo Comparator|control physiological normal saline|Patients received control physiological normal saline twice a day for 3 days before surgery.
89121561|NCT00728065|Experimental|1|White Bread (control)
89121562|NCT00728065|Experimental|2|White Bread (control)
89121563|NCT00728065|Experimental|3|White bread with 7.32 grams Salba hispanica
89121564|NCT00728065|Experimental|4|White bread with 15.58 grams Salba hispanica
89121565|NCT00728065|Experimental|5|White bread with 24 grams Salba hispanica
89121566|NCT00728065|Experimental|6|Rice Milk (control)
89121567|NCT00728065|Experimental|7|Rice Milk (control)
89121568|NCT00728065|Experimental|8|Rice Milk with 7.32 grams Salba hispanica
89121569|NCT00728065|Experimental|9|Rice Milk with 15.58 grams Salba hispanica
89121570|NCT00728065|Experimental|10|Rice Milk with 24 grams Salba hispanica
89121571|NCT00753688|Placebo Comparator|PLACEBO|matching placebo 800 mg once daily orally
89121572|NCT00753688|Experimental|PAZOPANIB|800 mg once daily orally
89121573|NCT04033887||HCV-only infected|"Archived frozen plasma samples from individuals that were characterised to be HCV-antibody positive or HCV-antibody negative (HCV-only infected). These samples are characterised for their HIV status (negative)."
89121574|NCT04033887||HCV/HIV co-infected|"Archived frozen plasma samples from HCV-positive or HCV-negative individuals who are HIV infected (HCV/HIV co-infected)."
89121575|NCT00730561|No Intervention|1|
89121576|NCT00730561|Experimental|2|Hematopoietic stem cell transplantation
89121577|NCT04183257|Experimental|vitamin D|vitamin D arm will receive oral vitamin D in escalating dosage.
89121578|NCT04183257|No Intervention|Conventional|This arm will receive conventional treatment only.
89121579|NCT01558921|Experimental|B: 5x5Gy -> CAPOX -> surgery|experimental group (arm B) M1 scheme
89121580|NCT01558921|Active Comparator|A: 5 weeks chemoradiation -> surgery|control group (arm A) standard long course chemoradiotherapy
89121581|NCT04182945|Other|Unobtrusive data collection|Unobtrusive data collection using noninvasive sensor systems.
89121582|NCT02681445||Group 1 Healthy Non Smokers|No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray Non-Smoker
89121583|NCT02681445||Group-2 Smokers|No TB History No TB Symptoms No TB History Negative Mantoux test Smoker 10 + Cigarettes/day
89121584|NCT02681445||HIV Positive|"No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray HIV Positive~CD4 count >200"
89121585|NCT02681445||TB Suspect Group|WHO Screening Recommendation Protocls Unexplained Cough Sputum production Fever Weight Loss or loss of appetite Night Sweats
89121586|NCT02681445||Lower Respiratory Track Infection|TB Lab test Negative Ab Normal Chest X-ray HIV Negative
89121587|NCT04094740|Experimental|Needle-free Jet Injector|Subjects will be instructed to use a needle-free syringe to inject insulin during the study period. The dosage and frequency of insulin are determined by the responsible physician according to the patient's condition.
89121588|NCT04094740|No Intervention|Conventional Insulin Pen|Patients allocated to the control group will be instructed to use conventional insulin pens to inject insulin. Except for the syringe, all of them are the same as the experimental group.
89121589|NCT04094740|No Intervention|Routine Care|Subjects can receive the education provided by health-care professionals and training in the outpatient department and inpatient departments.
89121590|NCT00728143|Active Comparator|1|Healthy subjects
89121591|NCT00728143|Experimental|2|Diabetic subjects
89121592|NCT00641433|Experimental|experimental|Subjects will daily dress their nail bed with oxidized regenerated cellulose collagen-silver, until healing occurs.
89121593|NCT00641433|Active Comparator|Control|Topical silver sulfadiazine cream will be applied daily to the wound bed until healing has occured.
89121594|NCT00734227|Active Comparator|A|"Randomization: By the blind card method to TIPS or emergency portacaval shunt. Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 24 hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong data collection on line, analysis by biostatistician Florin Vaida, PhD. External Advisory, Data Monitoring and Safety Committee by 3 senior academicians.~Procedure: Emergency portacaval shunt."
89121595|NCT00734227|Active Comparator|B|Procedure: Emergency TIPS.
89121596|NCT00641511|Experimental|1 (Medication arm - SYN117 aka Nepicastat)|"Veterans will be receiving the study medication Nepicastat initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily; During the 8 weeks (weeks: 7-14) extension phase, those from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed for an additional 8 weeks. Those who have a prior defined positive clinical response to the study medication, Nepicastat, will be continued on open label Nepicastat at 120mg once daily, in order to assess further improvement and safety; those who do not have a positive clinical response during the 6 weeks RCT will be offered the addition of the standard first-line PTSD pharmacotherapy, Paroxetine. Paroxetine is an allowed concomitant medication (i.e. rescue medication) and is not considered a research medication or subject of a research question during the 8 weeks extension phase."
89121597|NCT00641511|Placebo Comparator|2 (Placebo arm)|During the 6 weeks ( weeks: 1-6) double- blind, randomized clinical trial (RCT) phase, the veterans who have been randomized to the placebo treatment group will be receiving placebo pills. During the 8 weeks (weeks: 7-14) extension phase, all veterans from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed by the study team for an additional 8 weeks. The veterans on the placebo during the RCT will receive the study medication at end of the study week 6, the medication will be initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily for 8 weeks until the end of the study.
89121598|NCT00728221|Placebo Comparator|1|Placebo capsules (3g)
89121599|NCT00728221|Experimental|2|Whole Korean Red Ginseng root (3g)
89121600|NCT00728221|Experimental|3|Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root
89121601|NCT00728221|Experimental|4|Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root
89121602|NCT02681367|No Intervention|fresh embryo transfer|Patient with RIF underwent ICSI cycle followed by Day 5 fresh embryo transfer.
89121603|NCT02681367|Experimental|Freeze all|Patient with RIF. All of them underwent ICSI cycle, all their embryos were cryopreserved at Day 5 and transferred in a consecutive natural cycle.
89121604|NCT04065997||Patients implanted with HVAD System|Patients intended to be implanted with a HeartWare HVAD per the current (local) guidelines, are eligible for enrollment into Apogee International and must be consented for Apogee International prior to the HVAD implant.
89121605|NCT05664165|Experimental|Dry needling|It was performed using a deep dry needling technique using 0.25x25 mm disposable sterile steel acupuncture needles (HuaLong, China) while patient was in prone position. The needle inserted in the trigger point and stimulation was performed by manipulating it up and down several times. The needle was kept in the trigger point for 1-3 minutes and removed after the muscle spasm regressed . One session per week, a total of 3 sessions were applied.
89121606|NCT05664165|Experimental|Cold spray and stretching|The patient was placed on the chair with the head and body upright in the most comfortable position possible and voluntary relaxation was achieved. One end of the muscle was fixed in order to apply passive stretching. The cooler spray (in its content; 0.06% menthol, 2.06% isopropyl alcohol, 2% isopropyl alcohol) was sprayed to the surface at an angle of 30° from a distance of approximately 30-50 cm, while passive stretching was applied. One session per week, a total of 3 sessions were applied
89121607|NCT00734383|Experimental|1|Propofol Cardioprotection
89121608|NCT00734383|Experimental|2|Volatile Anesthesia Preconditioning
89121609|NCT02681133||patients with knee pain|
89121610|NCT00728299|Experimental|1|
89121611|NCT00728299|Placebo Comparator|2|
89121612|NCT02681289|Experimental|physiotherapy group|Early goal directed neuromotor therapy applied by physiotherapist
89121613|NCT02681289|Experimental|family group|Early goal directed neuromotor therapy applied by family
89121614|NCT00586612|Experimental|Preterm group|Subjects born after a gestation period of less than or equal to 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
89121615|NCT00586612|Active Comparator|Full-term group|Subjects born after a gestation period of more than 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
89121616|NCT00728377|Active Comparator|Heath & Wellness|
89121617|NCT00728377|Experimental|Exercise|
89121618|NCT00728455|Experimental|A|
89121619|NCT00728455|Experimental|B|
89121620|NCT00728455|Experimental|C|
89121621|NCT00728455|Experimental|D|
89121622|NCT00728455|Experimental|E|
89121623|NCT02680977|Experimental|MP-Equivalent; MP-Low; MP+DDCI|"MP-Equivalent: Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI (for example 100mg of Madopar corresponds to 500mg of Levodopa in MP).~MP-Low: Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 350mg of Levodopa in MP) MP+DDCI: Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 100mg of Levodopa in MP plus 25mg of Benserazide)"
89121624|NCT02680977|Active Comparator|LD+DDCI; LD-DDCI|"LD+DDCI: Levodopa plus Benserazide (dispersible formulation). The dose is calculated as 3.5mg per kg of body weight.~LD-DDCI: Levodopa without any dopa decarboxylase inhibitor (galenic formulation). The dose is 5-fold than LD+DDCI."
89121625|NCT02680977|Placebo Comparator|Placebo|Powder of groundnuts
89121626|NCT04064905|Experimental|mRNA-1893|
89121627|NCT04064905|Placebo Comparator|Placebo|0.9% sodium chloride
89121628|NCT02680899|Experimental|Curricular Intervention|The intervention is a novel science education curriculum in mental health and addiction called My Mind, My Body.
89121629|NCT00728533|Experimental|1|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~Maintenance doses of 360 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months"
89121630|NCT00728533|Experimental|2|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~Maintenance doses of 480 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months."
89121631|NCT00734695|Experimental|1|Baruch Pade Medical Center
89121632|NCT00734695|Active Comparator|2|Rambam Medical Center
89121633|NCT00734695|Active Comparator|3|Soroka Medical Center
89121634|NCT00586690|Experimental|NK Cell Infusion|Natural Killer (NK) Cell infusion using CD56 monoclonal antibody
89121635|NCT00586690|Other|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
89121636|NCT04182711|Experimental|Device Arm|The aim in the 1st phase is to benchmark the device against manual counting of respiration (number of breaths per minute). The aim in the 2nd phase is to benchmark the device against existing technologies, namely lead-based-ECG sensing, acoustic sensing and capnography. This phase can have a mix of patients having either COPD, asthma, pneumonia or any other respiratory diseases
89121637|NCT00728611|Experimental|1|
89121638|NCT00728611|Active Comparator|2|
89121639|NCT00728611|Placebo Comparator|3|
89121640|NCT02680509|Experimental|All|All patient will undergo a unilateral sympathicotomy R3. After this left and right will be compared
89121641|NCT00728767|Experimental|1|
89121642|NCT00728767|Placebo Comparator|2|
89121643|NCT05663775|Experimental|Prophylactic Mesalamine in combination of Immunotherapy (Nivolumab/Ipilimumab)|Participants will receive 500mg of Mesalamine QID (four times a day) in combination with standard of care Immunotherapy
89121644|NCT05616715|Experimental|Subjects with gummy smile and with upper lip hypermobility|Periodontal plastic surgery for peek device implantation with 4 screws in the anterior maxillary area
89121645|NCT05616715|Experimental|Subjects with gummy smile and with short teeth and upper lip hypermobility|Gingivectomy/crown lengthening and device implantation in the anterior maxillary area. First crown lengthening procedure (CLP) will be performed creating a distance of 3mm between cementoenamel junction (CEJ). Next peek device will be position with 4 screws
89121646|NCT05616715|Experimental|Patiens who refuse device implantation - control group|Gingivectomy/crown lengthening procedure
89121647|NCT00976820|Experimental|Arepanrix/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh [for children under (<) 12 months of age]. The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
89121648|NCT00976820|Experimental|Arepanrix/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
89121649|NCT00976820|Experimental|GSK2340273A/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
89121650|NCT00976820|Experimental|GSK2340273A/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
88801543|NCT04042324|Experimental|UFH and Triferic admixture|"Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer heparin line. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis."
88801544|NCT04042324|Experimental|UFH via continuous infusion pre-dialyzer|Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis
88801545|NCT04391660|Active Comparator|0.5% sodium hypochlorite solution|
88801546|NCT04391660|Active Comparator|0.5% sodium hypochlorite solution and 70% ethanol|
88801547|NCT05497440|Experimental|All'InCath CBC 035M Balloon Dilatation Catheter|All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
88801548|NCT04842422|Experimental|Earliest Stage Treatment of Aktinic Keratosis|
88801549|NCT05497362|Experimental|Real tDCS|Group 1 (n = 5) received anodal tDCS stimulation and intensive speech and voice therapy; tDCS and speech therapy was applied in 10 daily sessions during a 2-week period, administered on Monday to Friday. The anodal stimulation was delivered to the primary motor cortex (SM1) of the orofacial area.
88801550|NCT05497362|Sham Comparator|Sham tDCS|Group 2 (n = 4) received sham tDCS stimulation and intensive speech and voice therapy. For the sham tDCS group, the same setting of tDCS electrodes was applied on the scalp, but the stimulation only lasted for 30 sec in order to cause a similar sensation on the scalp. tDCS and speech therapy was applied in 10 daily sessions during a 2-week period, administered on Monday to Friday.
88801551|NCT04066426|Experimental|naproxen sodium+codeine phosphate|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Codeine phosphate is an opioid analgesic which has similar applications to those of morphine. However, it is significantly less potent as an analgesic and has only mild sedative effects. The drug's principal site of action is at the µ-opioid receptors (MOR) which are distributed in the central nervous system. Peak effect is reached within 2 hours and analgesic action continues for approximately 4 hours. Naproxen sodium (550 mg)+codeine phosphate (30 mg) was used twice daily in this study.
88801552|NCT04066426|Experimental|naproxen sodium+dexamethasone|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily + dexamethasone (8 mg) was used once daily in this study.
88801553|NCT04066426|Experimental|naproxen sodium|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily in this study.
88801554|NCT04066426|Active Comparator|paracetamol|Paracetamol is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhoea.
88805886|NCT05045807|Experimental|Meat with added nitrate plus vegetables|"The same intervention as of Arm meat with added nitrate consumed together with mixed vegetables."
89121651|NCT00909987|Experimental|Single arm|"Neoadyuvant chemotherapy with XELOX: Xeloda 1000mg/m2/12h dayly, day one in the afternoon until day 15 in the morning; plus oxaliplatin 130mg/m2 (day 1); and Bevacizumab 7.5 mg/kg (day 1)during 3 cycles (each cycle of 3 weeks).~Followed by a selective use of chemoradiotherapy with radiotherapy (50.4Gy, 28 sesions of 1.8Gy during 5 weeks) plus Xeloda 825mg/m2/12h dayly."
89121652|NCT00729001|Experimental|Group A|Human Rotavirus Vaccine - Formulation 1
89121653|NCT00729001|Experimental|Group B|Human Rotavirus Vaccine - Formulation 2
89121654|NCT00729001|Placebo Comparator|Group C|
89121655|NCT04182789|Experimental|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
89121656|NCT00730795|Experimental|Group A|Subjects receiving the low-dose antigen candidate TB vaccine
89121657|NCT00730795|Experimental|Group B|Subjects receiving the high-dose antigen candidate TB vaccine
89121658|NCT05663619|Experimental|Virtual Reality distraction (VRD)|In the VRD group, participants wore a VRD device and watched a previously selected favorite cartoon during the prophylactic dental treatment.
89121659|NCT05663619|Active Comparator|control group|In the control group, participants received their treatment while watching a previously selected favorite cartoon on a regular screen.
89121660|NCT00730873|Experimental|A|continuous positive airway pressure
89121661|NCT00730951|Experimental|1|0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules)
89121662|NCT00730951|Experimental|2|1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules)
89121663|NCT00730951|Experimental|3|3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules)
89121664|NCT00730951|Experimental|4|6g Korean Red Ginseng (12 capsules)
89121665|NCT00730951|Experimental|5|6g Corn Starch Control (12 capsules)
89121666|NCT02680275|Experimental|Doxycycline,Dead Sea Peloid Gel,placebo|"Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by Dead Sea Peloid Gel , 60 ml per day fo 12 days, intravaginally~Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by placebo gel, 60 ml per day fo 12 days, intravaginally"
89121667|NCT00760474|Experimental|Pregabalin, then placebo|
89121668|NCT00760474|Experimental|Placebo, then pregabalin|
88801555|NCT04232982|Experimental|MicroPulse Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered by micropulse waves will be given 4-8 weeks before the Boston keratoprosthesis surgery.
88801556|NCT04232982|Experimental|G-Probe Treatment|Prophylactic transscleral cyclophotocoagulation treatment, delivered with a diode laser using the G-Probe device, will be given 4-8 weeks before the Boston keratoprosthesis surgery.
88801557|NCT04232982|No Intervention|Historical Cohort|"An historical cohort composed of patients who received a Boston keratoprosthesis between january 2017 and january 2019 will be included. Only patients who did not receive any glaucoma treatment 3 months before their surgery will be included. A total of 10 patients will be selected with the goal of matching the preoperative characteristics of the interventional patients.~This group will serve as the control group in our study. Retrospective chart review will be performed for this branch."
88801558|NCT01456832||Renal Transplant Patients with Post-operative Hypoatremia|All renal transplant recipients at the Mayo Clinic of Florida from 1/1/2010 through 8/19/2011 who received a kidney from either a living or cadaveric donor.
88801559|NCT01450514|Placebo Comparator|Placebo|Sugar pill
88801560|NCT01450514|Experimental|Pipamperone|15 mg once daily
89121669|NCT00731029|Experimental|Group A|The subjects in this group will be 18-60 years.
89121670|NCT00731029|Experimental|Group B|The subjects in this group will be > 60 years.
89121671|NCT00731029|Active Comparator|Group C|The subjects in this group will be 18-60 years.
89121672|NCT00731029|Active Comparator|Group D|The subjects in this group will be > 60 years.
89121673|NCT02680353|Active Comparator|Study group|Patients received bilateral superficial cervical plexus block before operation
89121674|NCT02680353|No Intervention|Control group|Patients received no intervention before operation
89121675|NCT02680119|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
89121676|NCT02680119|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
89121677|NCT04182165|Experimental|Subjects measured by the study staff|Subjects measured by the study staff via the investigational device at the hospital (up to 50 subjects).
89121678|NCT04182165|Experimental|Subjects measuring themselves autonomously|Subjects measuring themselves autonomously with the investigational device at their homes (up to 10 subjects from the first arm).
89121679|NCT04065061|Experimental|Experimental|Erinacine A-enriched Hericium Erinaceus Mycelia dietary supplement from week 0 to week 49.
89121680|NCT04065061|Placebo Comparator|Placebo|Placebo dietary supplement from week 0 to week 49.
89121681|NCT04182243|Other|Emergency Health Care Provider|Working in emergency health services in Northern Cyprus
89121682|NCT00731107|Active Comparator|1|Veress Needle laparoscopic entry
89121683|NCT00731107|Active Comparator|2|XCEL bladeless trocar laparoscopic entry
89121684|NCT04289090|Experimental|Group A|Group A will begin anesthesia maintenance with sevoflurane-only, then will be switched after 30 minutes to anesthesia with propofol-only.
89121685|NCT04289090|Experimental|Group B|Group B will begin anesthesia with propofol-only then will be switched to sevoflurane-only.
89121686|NCT02680197|Experimental|CHF5259 12.5 μg total daily dose|"CHF5259 or Placebo administration:~Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI matched placebo twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
89121687|NCT02680197|Experimental|CHF5259 25 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI 6.25μg twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
89121688|NCT02680197|Experimental|CHF5259 50 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 12.5 μg + 1 puff of CHF5259 DPI 12.5 μg twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
89121689|NCT02680197|Experimental|CHF5259 100μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment :1 puff of CHF5259 DPI 25 μg + 1 puff of CHF5259 DPI 25 μg twice a day~Interventions :~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
88801561|NCT04279314|Experimental|Trofinetide|
88801562|NCT04059250|Experimental|Nobio flange|On the Nobio flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it the Nobio composite.
88801563|NCT04059250|Placebo Comparator|Traditional composite flange|On the traditional composite flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it a traditional composite.
88801564|NCT01456910|Experimental|Working group|G1 intervention group of 20 participants aged 14-36 years old and mild to severe intellectual disability of both gender.
88801565|NCT01456910|Active Comparator|Daily Living|G2 control group continue usual routine
88801566|NCT01450592||Group 1|
88801567|NCT01450592||Group 2|
89121690|NCT02680197|Placebo Comparator|CHF5259 matched Placebo BID|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 2 puffs of CHF5259 DPI matched placebo twice a day~Interventions :~Day 1 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
89121691|NCT00735163|Experimental|A|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
89121692|NCT04286984||Pre-upPBM|Patients with a diagnosis of gastric cancer before the upPBM implementation in their attending center
89121693|NCT04286984||Post-upPBM|Patients with a diagnosis of gastric cancer after the upPBM implementation in their attending center
89121694|NCT00731263|Experimental|1|The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
89121695|NCT02680431||Neurofibromatosis 1|10 mL venous blood sample taken from patients with type 1 neurofibromatosis
89121696|NCT02680431||Control|10 mL venous blood sample taken from age- and gender-matched healthy controls
89121697|NCT00975416|Placebo Comparator|Methadone|Intranasal oxytocin administered in the context of cognitive behavioral therapy to methadone dependent outpatients
89121698|NCT00975416|Placebo Comparator|Outpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent outpatients
89121699|NCT00975416|Placebo Comparator|Inpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent inpatients
89121700|NCT00729079|Active Comparator|1|Subject will be randomly assigned to work with providers at Clinton Medical Associates
89121701|NCT00729079|Active Comparator|2|Subjects will be randomly assigned to work with providers at 1655 Elmwood AVe, Suite 125
89121702|NCT02679963|Experimental|Maintenance Olaparib|Olaparib (experimental arm): 600 mg daily (2 doses of 300 mg (2*2 tablets of 150 mg) taken approximately 12 hours apart) po, administered until disease progression or toxicity requiring its interruption. Olaparib has to be started no later than 6 weeks after the last administration of induction chemotherapy, and no later than 3 weeks after the CT scan confirming response to induction chemotherapy
89121703|NCT02679963|Placebo Comparator|Placebo|Placebo (control arm): 2 doses of 300 mg per day (2*2 tablets of 150 mg) taken approximately 12 hours apart
89121704|NCT00760084|Experimental|A|Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.
89121705|NCT00729235|Experimental|1|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
89121706|NCT00729235|Experimental|2|Slow VT zone programmed with ATP therapies (therapy arm).
89121707|NCT04289636|Experimental|Weight loss and self-compassion|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week mindfulness-based self-compassion program which combines the skills of mindfulness and self-compassion as a means for improving emotional resilience, well-being, and weight control.
89121708|NCT04289636|Active Comparator|Weight loss and nutrition/cooking education|Participants will receive a 15-week behavioral weight loss program which teaches strategies for changing diet and exercise behaviors. This will consist of a combination of group and individual sessions. Group classes will be delivered remotely via a video-conferencing platform. This will be followed by an 8-week nutrition and cooking education program which will provide basic nutrition knowledge and cooking skills for healthy eating.
89121709|NCT02679651||Control group|Healthy Adults without foot pain
89121710|NCT02679651||DIsease group|Adults diagnosed with fat pat atrophy and report symptoms of foot pain and have participated in clinical trial to treat fat pad atrophy.
89121711|NCT04286828||Females with Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
89121712|NCT04286828||Healthy Females|20 healthy volunteers with matching ages and genders.
89121713|NCT00641823||1|
89121714|NCT00641823||2|
89121715|NCT00641823||3|
89121716|NCT00729313|Experimental|1|"Drug: Lanreotide 30 mg microparticle formulation~One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h~For non-responders patients lanreotide will be stopped."
89121717|NCT00729313|Placebo Comparator|2|"One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.~Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment."
89121718|NCT00641901||Observation|Pregnant women with gingivitis
89121719|NCT00735319|No Intervention|A|In the 7 control Capital Health community health centers, babies will be followed up according to the current policy. Bilirubin determinations will be performed at the discretion of the visiting nurse if the infant is inappropriately jaundiced or at the request of the physician if risk factors are present. Transcutaneous Bilirubinometers will not be available in each of these 7 centers for all the duration of the study.
89121720|NCT00735319|Experimental|B|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained.Depending on the level of bilirubin obtained and whether risk factors (gestational age < 38 weeks, blood group incompatibility with DAT positive) are present or not, a different management plan will apply. The algorithm is based on curves established by Bhutani et al to predict the risk of significant hyperbilirubinemia based on predischarge bilirubin measurements.
89121721|NCT00641979|Experimental|1|Rhinocort
89121722|NCT00641979|Placebo Comparator|2|
88801568|NCT04840706|Active Comparator|Airvo|Patients allocated to use Airvo device
88801569|NCT04840706|Placebo Comparator|Control|Patients not using Airvo, standard care
88801570|NCT04424472|Experimental|Ultrasonography|Patient will be scheduled to undergo an additional US by a blinded sonographer within 4 weeks of their most recent cross-sectional imaging that indicated a recurrence
88801571|NCT04758728|Active Comparator|Group A|Group A - great saphenous vein stripping with local adrenaline use for hemostasis
88801572|NCT04758728|Sham Comparator|Group B|Group B - great saphenous vein stripping with local normal saline use for hemostasis
88801573|NCT04758728|Sham Comparator|Group C|Group C - great saphenous vein stripping with traditional hemostatic practice
88801574|NCT01450670||Dialysis patients|
88801575|NCT01450748|Experimental|Sodium alginate|oral suspension, 50 mg/ml
88801576|NCT01450748|Placebo Comparator|Placebo|oral suspension without active ingredient
88801577|NCT01457066|Experimental|Intervention|This group will receive the peer navigator intervention.
88801578|NCT01457066|No Intervention|Control|This group will receive usual care.
88801579|NCT03808948|Experimental|All Patients|VFI dose: 47 mg / 3 mL Number of doses: 2 Route of administration: intravenous
88801580|NCT02559570|Placebo Comparator|Placebo|Participants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.
88801581|NCT02559570|Experimental|LIN Dose A (9 ug or 18 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
88801582|NCT02559570|Experimental|LIN Dose B (18 ug or 36 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
88805887|NCT00293540|Active Comparator|A|Surgical oophorectomy in history-estimated mid-luteal phase of menstrual cycle plus Tamoxifen
89121723|NCT02679417|Active Comparator|aerobic exercise|Each participant reach a minimum of 50 minutes of some form of aerobic exercise including running on a treadmill 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
89121724|NCT02679417|Active Comparator|resistant exercise|Each participant reach a minimum of 50 minutes of some form of strength training involving repetitions of a resistance training exercise for each major muscle group at an intensity for at least 60% of a one-repetition max, 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
89121725|NCT02679339|Experimental|CNTX-2022 (lidocaine gel, 40%)|Application of 1mL CTNX-2022 (40% Anhydrous Lidocaine Gel) topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
89121726|NCT02679339|Placebo Comparator|Placebo|Application of 1mL placebo topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
89121727|NCT02679261|Experimental|Atorvastatin|Oral administration Atorvastatin 20 mg per day
89121728|NCT02679261|Placebo Comparator|Control|Oral administration of Placebo
89121729|NCT02679183|Placebo Comparator|Control 0|No Intervention. This group received Premature Milk Formula. This group did not receive any Medically-Graded Honey.
89121730|NCT02679183|Experimental|Group 1|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 5 gram/day) for 2 weeks
89121731|NCT02679183|Experimental|Group 2|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 10 gram/day) for 2 weeks
89121732|NCT02679183|Experimental|Group 3|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 15 gram/day) for 2 weeks
89121733|NCT02679027|Active Comparator|Easy intubation|Intubation difficulty score <5
89121734|NCT02679027|Active Comparator|Difficult intubation|Intubation difficulty score >5
89121735|NCT00752206|Active Comparator|Saracatinib|Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be 13 cycles.
89121736|NCT00752206|Placebo Comparator|Placebo|Placebo will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with placebo will be 13 cycles.
89121737|NCT02679105|Placebo Comparator|ALK diluent|Human albumin
89121738|NCT02679105|Active Comparator|ALK Alutard birch or 5-grasses|Grass pollen suspension or birch pollen suspension
89121739|NCT04182009|Other|Omron|Omron group will undergo sputum induction with the Omron nebuliser at Visit 1, followed by the Akita Jet nebuliser at Visit 2.
89121740|NCT04182009|Active Comparator|Akita|Akita group will undergo sputum induction with the Akita Jet nebuliser at Visit 1, followed by the Omron nebuliser at Visit 2.
89121741|NCT05663229||Experimental group-with rehabilitation intervention|We evaluate the static or dynamic posture stability of patients with rehabilitation intervention
89121742|NCT05663229||Control group-without rehabilitation intervention|We evaluate the static or dynamic posture stability of patients without rehabilitation intervention
89121743|NCT02678949|Experimental|Inhaled Fluticasone 50 mcg/twice day|Group 2; Inhaled fluticasone. 50 mcg/twice day for a period of 4 weeks.
89121744|NCT02678949|Experimental|Inhaled Fluticasone 100 mcg/twice day|Group 3;Inhaled fluticasone. 100 mcg/twice day for a period of 4 weeks
89121745|NCT02678949|Experimental|Inhaled Albuterol|Group 2 and group 3, inhaled albuterol one dose of 400 mcg.
89121746|NCT00642135|Active Comparator|1|Premature newborns and neonates treated using Phenylephrine and tropicamide eyedrops
89121747|NCT00642135|Active Comparator|2|Premature newborns and neonates treated using insert Mydriasert®
89121748|NCT04094272||Chronic hepatitis C participants|Participants with a newly started DAA medication for HCV infection were included in the study.
89121749|NCT02678559|Experimental|TEE monitory system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
89121750|NCT02678559|Experimental|mini-invasive monitoring system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
89121751|NCT04093960|Experimental|escitalopram plus128|escitalopram (10 mg daily) plus PS128(a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily)
89121752|NCT04093960|Active Comparator|escitalopram|10 mg/d of escitalopram
89121753|NCT00642291|Experimental|1|Treatment naive pediatric patients (Group 1: ages 3 to 24 months)were to receive emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
89121754|NCT00642291|Experimental|2|Treatment naive or experienced pediatric patients (Group 2: ages 7 to 12 years; Group 3: ages 13-17 years) received emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
89121755|NCT02600260|Other|enoxaparin|A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery through the application of a thromboprophylaxis protocol with risk assessment score.The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in both groups.
89121756|NCT02600260|Other|no intervention|Pregnant women admitted in hospital for clinical treatment and/or delivery and that does not score for thromboprophylaxis.
89121757|NCT02678325|Active Comparator|Standardized normal protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 20% of the total caloric intake
89121758|NCT02678325|Experimental|Standardized high protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 33% of the total caloric intake
89121759|NCT04181931|Experimental|neo-TACE-HAIC with surgery|neoadjuvant TACE-HAIC with surgery for HCC patients with PVTT
89121760|NCT04181931|Active Comparator|surgery alone|surgery alone for HCC patients with PVTT
89121761|NCT04094116|Active Comparator|ear wax syringing with pre ear oil treatment|patients in Fanling Family Medicine Centre with ear wax will be given ear oil one week before performing ear syringing.
89121762|NCT04094116|Sham Comparator|ear wax syringing without pre ear oil treatment|Patients in Wong Siu Ching Clinic and Tai Po Clinic who are found to have ear wax after physical examination will have ear syringing done, without pre-ear oil application.
89121763|NCT02678481|Experimental|MR-targeted biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MR imaging two targeted biopsy cores will be taken.
89121764|NCT02678481|Experimental|TRUS-guided biopsy|Patients of arm B receive a saturation TRUS-guided prostate biopsy.
89121765|NCT00643305|Experimental|1|Skills Building with Motivational Interviewing (SB-MI)- combines education and general skills-building participants can use to reduce their at-risk behavior for HIV with increasing motivation to change HIV risk behaviors
89121766|NCT00643305|Active Comparator|2|Skills Building (SB) - provides education and general skills-building for reduction of HIV risk behaviors.
89121767|NCT02675985|Experimental|Intervention arm|Early intensive physical therapy will be the intervention arm. There is not a control group.
89121768|NCT02676063||neonatal Hypoxic Ischemic encephalopathy|moderate or severe HIE among term and late preterm newborn
89121769|NCT04020562|Experimental|Mild Resistive Expiratory Technique|Mild resistive Expiratory Technique from EMST150- five-week training protocol.
89121770|NCT04020562|Active Comparator|Conventional Training|Breathing exercise, Assistive Coughing, ROM Exercises, Sustained stretching, Splinting, Bracing, Functional Mobility, Tilt table standing
89121771|NCT00976508|Experimental|1|
89121772|NCT02600104|Experimental|all subjects|will receive up to four (4) facial treatments in 3-8 weeks interval, with the PicoWayTM device-fractional hand piece 1064nm and/or 532nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
89121773|NCT02866058||Cesarean|Mothers delivered by cesarean section
89121774|NCT02866058||Vaginal|Mothers delivered by vaginal delivery
89121775|NCT02675673|Active Comparator|GJ-Tube arm|Patients randomized to his arm would usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made into the stomach through the frozen skin. The feeding tube is placed through this puncture into the stomach and the tube tip is placed in the small bowel. Once the GJ-tube has been inserted, the tube in the nose is removed.
89121776|NCT02675673|Active Comparator|G-Tube arm|Patients who are randomized to this arm will usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made through the frozen skin. A small guiding tube or catheter is placed through this puncture into the stomach, and is advanced up the esophagus and out of the mouth. The feeding tube is then pulled into the mouth, down the esophagus, and positioned through the abdomen with its inside tip in the stomach.
89121777|NCT04289246|Experimental|Treatment Group (TG)|On the first day of the intervention phase, research assistants visited TG's participants to introduce the MAD in the presence of caregivers. After the training session, which lasted 40 min approximately, the MAD was personalized according to the participant's prescriptions and through discussions with them on an appropriate schedule for presenting the reminders. Research assistants used the MAD administrator sub-system to enter the medication names, health problems to address, timetables, and the frequency at which medications should be taken. Then, they attached and configured NFC tags to each of the pill containers, which included selecting the images that best represented the pills and their containers to be used to form the visual reminders. Afterward, the MAD was placed in the homes' area where participants reported taking medications. MAD was used for 5 weeks during which data on medication adherence and system adoption was collected from the TG.
89121778|NCT04289246|No Intervention|Control Group (CG)|Participants in the CG followed their medication routine as usual. During 5 weeks data on medication adherence was collected.
89121779|NCT02537379||SOF+COPE|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+COPE as part of routine clinical care at a participating clinical site.
89121780|NCT00973622|Experimental|Smokers|Healthy adult smokers aged 19-55 who are not currently interested in quitting smoking.
89121781|NCT00973622|Experimental|Non-smokers|Healthy adult non-smokers aged 19-55
89121782|NCT00916786||OROS-methylphenidate|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
89121783|NCT00916786||Atomoxetine group|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
89121784|NCT00916786||Control group|Healthy controls matching for the distribution of age and sex of the case groups
89121785|NCT04180137|Experimental|Surgical treatment with subsequent pharmacotherapy|
89121786|NCT04180137|Other|Isolated surgical treatment|
89121787|NCT02865746|Active Comparator|Group betamethasone|Active Comparator: betamethasone disodium phosphate at a concentration of 4 mg / ml - dosage of 0.05 mg / kg
89121788|NCT02865746|Placebo Comparator|Group placebo|sterile saline solution (sodium chloride 0.9% - 1 ml ampoules) - dosage of 0.05 mg / kg
89121789|NCT04093804|Active Comparator|32mm Glenosphere|The control group will receive the standard 32mm glenosphere.
89121790|NCT04093804|Experimental|36mm Glenosphere|The experimental group will receive a 36mm glenosphere.
89121791|NCT00629486|Experimental|cytokines were determined|prevalence of genetic polymorphisms of interleukin 1B was measured in HBV-related hepatocellular carcinoma
89121792|NCT04179747|Experimental|Group A|The cognitive behavior psychotherapy was administered to participants in this treatment arm.
89121793|NCT04179747|Active Comparator|Control Group|This group received the administration of pharmacotherapy (PDE5i) for treatment of Erectile Dysfunction.
89121794|NCT02600026|Experimental|Video Camera: Intervention|DriveCam video event recorder with feedback
89121795|NCT02600026|Placebo Comparator|Video Camera: Monitoring|DriveCam video event recorder with no feedback
89121796|NCT02675127|Experimental|A Test|Test drug (Daktavira, European Egyptian Pharmaceutical Industries)1 tablet contains 60 mg Daclatasvir
89121797|NCT02675127|Active Comparator|B Reference|Reference drug (Daklinza, (Bristol-Myers Squibb Pharma, UK)) 1 tablet contains 60 mg Daclatasvir
89121798|NCT04044716|Experimental|Auricular acupressure Group|The Auricular acupressure (AA) nurses will place the acupressure pellet pads on the participants in this group post-operatively.
89121799|NCT04044716|Active Comparator|Standard of care Group|Participants in this group will receive standard of care pain management by the treating physician.
89121800|NCT04044716|No Intervention|Nurse Interventionists|Nurses who were trained to apply the auricular acupressure pads/pellets in the the holding room prior to surgery.
89121801|NCT02675283|Other|coeliac disease point of care test|Patients will be consented for a finger prick point of care test, Simtomax, at the pharmacy.
89121802|NCT02675205|Active Comparator|clopidogrel-aspirin|clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.
89121803|NCT02675205|Experimental|ticagrelor-aspirin|Ticagrelor: 90 mg bid and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery
89121804|NCT04041284|Experimental|fremanezumab|monthly 225 mg. In the open-label extension phase starting at week 12, all participants will receive active treatment with a quarterly dose of 675 mg sc
89121805|NCT04041284|Placebo Comparator|Placebo|
89121806|NCT00753454|Experimental|CDP870|Patients having completed the week 34 assessment in C87077 (NCT00580840) or patients having been randomized at Week 18 and having met the pre-defined criteria for flare, will be given the option to enroll in C87084 and receive: 400 mg CZP at Entry, Week 2, and Week 4 followed by 200 mg every two weeks in combination with MTX until the drug is commercially available for the indication of RA in the patient's country or region (or until further notice from UCB).
89121807|NCT05277129||Stroke patients|
89121808|NCT02675361|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses.
89121809|NCT02675361|No Intervention|Comparison group|"Participants allocated to this group will receive usual care, which includes follow-up visits according to the complexity of the congenital heart disease. Usual care can vary across clinics, however, they all include meeting with a nurse and a physician.~This is established as a comparison group since there is the risk of contamination in this group."
89121810|NCT02675361|No Intervention|Control group|"Participants in this group will receive usual care. Follow-up visits will depend on the complexity of the disease.~Five clinis comprise this section of the study and will be part of an longitudinal, observational study, which investigators will use as a control group."
89121811|NCT00976274|Placebo Comparator|starch capsule|
89121812|NCT00976274|Experimental|Korea red ginseng|
89121813|NCT00643461||Adhesive A|
89121814|NCT00643461||Adhesive B|
89121815|NCT00643461||Adhesive C|
89121816|NCT02863016||Concentrate SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution: first of all concentrate SelectBag One (with 3 mM of acetic acid and 0 mM of citrate)
89233296|NCT01809288||1|Healthy African, African-American, and white women between 30 and 65 years of age who are federal employees or contractors.
89233297|NCT01805869||Healthy volunteers|Male or female ages 16-50
89233298|NCT01804686|Experimental|Ibrutinib|
89233299|NCT01804634|Experimental|Reduced intensity conditioning|Fludarabine IV infusion over 30 minutes on D-7 to D-3. The dose will be 30 mg/m2/dose (adjusted for renal function). Melphalan: IV infusion over 30-60 minutes, depending on volume, on D-2. The dose will be 100mg/m2.Total body irradiation: 200 cGy AP/PA with 4MV or 6MV photons at 8 12 cGy/min at the point of prescription (average separation of measurements at mediastinum, abdomen, and hips) will be administered in a single fraction on day -1. Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant. Tacrolimus begins on Day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 3 hours every 12 hours. Mycophenolic acid mofetil (MMF) F will be given at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).
89233300|NCT01780168||healthy volunteers|Healthy volunteers
89233301|NCT01780168||Inborn errors of metabolism/mitochondrial disease|patients with inborn errors of metabolism including those with mitochondrial disease
88801583|NCT02559570|Experimental|LIN Dose C (36 ug or 72 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
88801584|NCT02559570|Experimental|LIN 145 µg|Participants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
88801585|NCT01457144|Experimental|RiBVD|Rituximab Bendamustine Velcade® Dexamethasone 6 cycles every 28 days
88801586|NCT01450904|Experimental|Group A|The length of Quadriceps incision was less than 2 cm.
88801587|NCT01450904|Experimental|Group B|The length of Quadriceps incision was 2 to 4 cm.
88801588|NCT01450904|Experimental|Group C|The length of Quadriceps incision was more than 4 cm.
88801589|NCT04051684|Experimental|TAP, Bupivacaine|This group will receive general anesthesia and at the end of the operation, but still in the operating room, a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
88801590|NCT04051684|No Intervention|No intervention|General anesthesia
88801591|NCT02854124||Patients with stage Ib and II melanoma|Melanoma and peritumoral skin excision
88801592|NCT04057768|Other|Intervention|Device: Venus Viva
88801593|NCT01457300||District Rehabilitation Centre (Model 1)|Patients admitted to Primary Health Care Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited continuously at Entrance to the Rehabilitation Centre.
88801594|NCT01457300||Standard PHC Rehabilitation (Model 2)|Patients admitted to Standard Primary Health Care (PHC) Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited Continuously at Entrance to the Short Term Rehabilitation Beds in Nursing Homes or at the Beginning of Rehabilitation in their Own Homes.
88801595|NCT04052542|Active Comparator|Traditional online continuing education|
88801596|NCT04052542|Active Comparator|Interprofessional education|
88801597|NCT04052542|Active Comparator|Just-in-time education|
89233302|NCT01747213|Experimental|BNC|Bisnorcymserine tartrate
89233303|NCT01747213|Placebo Comparator|Placebo|microcrystalline celluose
89233304|NCT01736293||Affected Participants|Participants with ABCA4-related retinopathies.
89233305|NCT01734369||Healthy Control Subjects|Military service members active duty or no longer in duty, military contractors, and civilians working for the military. Controls should be without a recognized autoimmune or chronic muscle disease.
89233306|NCT01734369||Myositis Subjects|Diagnosis of myositis during military service or service as a military contractor or civilian working for the military with polymyositis, dermatomyositis, or inclusion body myositis.
88801598|NCT04840238|Experimental|Cholecalciferol|Cholecalciferol 30,000IU weekly orally
88801599|NCT04840238|Placebo Comparator|Placebo|Placebo tablets weekly orally
88801600|NCT01450982|Experimental|001|JNJ-38518168 / MTX Day 1: MTX: Route=oral use single dose of participant's weekly MTX dose Days 2-15: MTX: Route=oral use single dose of participant's weekly MTX dose and of JNJ-38518168 Type=exact unit=mg number=100 form=capsule route=oral use administered daily.
88801601|NCT05015010|Experimental|Alectinib|The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 96 weeks. Treatment will be discontinued in case of unacceptable toxicity or disease progression.
88801602|NCT03829618|Active Comparator|Topical Lidocaine|16 ml of 1% lidocaine sprayed in 4 ml aliquots to vocal cords, midtrachea, left main stem bronchus and right main stem bronchus.
88801603|NCT03829618|Active Comparator|Nebuliser Solution|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via jet nebulizer in operating room over ten minutes.
88801604|NCT03829618|Active Comparator|Nebuliser Suspension|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via vibrating mesh nebulizer in operating room over ten minutes.
88801605|NCT01457378||Healthy volunteers|100 healthy volunteers
88801606|NCT01457378||IBS Subjects|100 IBS Subjects
88801607|NCT04272788||CD patients|CD patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.CD patients are followed for 14 weeks after the first administration of infliximab. At week 14 of Infliximab treatment, CD patients are classified as remission group (CDAI<150 and endoscopic mucosal healing, R group) and non-remission group (CDAI≥150 and/or mucosal non-healing group, N group).
88801608|NCT04272788||Healthy controls|Healthy controls without Crohn's Disease.
88801609|NCT01457690|Experimental|Tocofersolan: Vitamin E water-soluble|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
88801610|NCT01457690|Active Comparator|Tocopherol alpha: Vitamin E conventional fat-soluble form|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
88801611|NCT01457690|Active Comparator|volunteers|
88801612|NCT04390880|Experimental|PEt/CT arm|Subjects receive a PET/CT scan.
88801613|NCT02913092|Experimental|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed and responded to (e.g. outreach worker contacts the participant for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide asthma education over the phone
88801614|NCT02913092|No Intervention|Usual Care|Usual care group will receive the electronic tracker but the sensor-generated alerts will not be delivered. If the usual care group rescue inhaler data reveals frequent use of rescue medication (daily use for >3 days) investigators will reach out (via app or phone call) to advise the participant to see their physician
88801615|NCT03741088|Experimental|VORTX Rx treatment|Focused ultrasound ablation of liver tumors.
88801616|NCT05497128|Experimental|Ultrahigh-speed cut rate 27-gauge system|Patients will receive the pars plana vitrectomy in the macular disease with the 27-gauge vitrectomy systems with 20,000 cpm probes.
89121817|NCT02863016||Concentrate SelectBag Citrate|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution, then with SelectBag Citrate (with 0 mM of acetic acid and 1 mM of citric acid)
89121818|NCT00643539|Experimental|1|
89121819|NCT00643539|Experimental|2|
89121820|NCT00759148|Experimental|Moxifloxacin AF|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days
89121821|NCT00759148|Placebo Comparator|Vehicle|Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days
89121822|NCT02864810|Experimental|[18F]GP1 PET/CT imaging|"Maximally 10 patients with deep vein thrombosis, pulmonary embolism, or arterial thromboembolism, respectively will be enrolled in the study (plus replacements for drop-outs).~Intravenous injection and PET/CT scanning of [18F]GP1"
89121823|NCT00910065|Experimental|Arm 1|
89121824|NCT00910065|Experimental|Arm 2|
89121825|NCT00910065|Active Comparator|Arm 3|
89121826|NCT02601040|Experimental|Attenuated Hepatitis A Vaccine, H2 Strain|Health subjects received attenuated Hepatitis A vaccine intramuscularly in the deltoid region.
89121827|NCT02601040|Experimental|Inactivated Hepatitis A Vaccine, Lu8 Strain|Health subjects received inactivated Hepatitis A vaccine intramuscularly in the deltoid region.
89121828|NCT02601040|Placebo Comparator|Group A Meningococcal Polysaccharide vaccine|Health subjects received Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.
89121829|NCT04288934|Active Comparator|patients with complete transection of the spinal cord|This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.
89121830|NCT04288934|Active Comparator|patients with SCI without total transaction.|This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla.
88801617|NCT05497128|Active Comparator|Standard cut rate 27-gauge system|Patients will receive the pars plana vitrectomy in the macular disease with the 27-gauge vitrectomy systems with 10,000 cpm probes.
88801618|NCT01451138|Experimental|Treated|
88801619|NCT01143181|Experimental|Brincidofovir|Subjects received either a weight-based or a fixed-dose of oral brincidofovir (BCV) once weekly or twice weekly for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer.
88801620|NCT04199676||Intervention|75g glucose tolerance test to be administered during postpartum hospitalization
89121831|NCT02864966|Other|Other|This is a safety study where a marketed product will be placed on healthy adult skin.
89121832|NCT04179435|Other|Tourette syndrome|Patients with Tourette syndrome aged 13 - 18 y.o. Interventions : Brain scans, cognitive testing, TMS measures
88801621|NCT03740152|Experimental|Transcranial Light Therapy|All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.
88801622|NCT03739684|Experimental|18F-DCFPyL Injection|9 mCi (333 MBq) IV injection of 18F-DCFPyL
88801623|NCT04819620|Experimental|Single Dose|Single dose administration
88801624|NCT04819620|Experimental|Multiple Dose|Multiple dose administration
88801625|NCT04819620|Experimental|Solid Dose Comparison|Solid dose administration
89121833|NCT04179435|Other|Controls|Controls matched to Tourette syndrome group nterventions : Brain scans, cognitive testing, TMS measures
89121834|NCT04179513|Experimental|GB224 10mg|GB224 10mg
89121835|NCT04179513|Experimental|GB224 20mg|GB224 20mg
89121836|NCT02863640||Exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA above the 59th percentile of the population
89121837|NCT02863640||Non exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA below the 41th percentile of the population
89121838|NCT05460507|Experimental|Retreatment with Rhenium Liposome|Each participant will receive a single administration of 186RNL. The proposed dose is up to 8.8 mL as a single administration with an administered dose of 22.3 mCi.
89121839|NCT02865044|Active Comparator|Wax Ester Marine Oil|Active: Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules)
89121840|NCT02865044|Other|Ethyl Ester Marine Oil|Control: Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule)
89121841|NCT02675049|Placebo Comparator|0.9% saline|Patients were assigned to receive 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
89233307|NCT01728402||Blood Draw|
89233308|NCT01712672||1|Healthy participants
89121842|NCT02675049|Experimental|dexmedetomidine 1 µg.kg-1|Patients were assigned to receive 1µg.kg-1dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
89121843|NCT02675049|Experimental|dexmedetomidine 1.5 µg.kg-1|Patients were assigned to receive 1.5µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
88801626|NCT01143649|Experimental|active tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday).
89121844|NCT02675049|Experimental|dexmedetomidine 2 µg.kg-1|Patients were assigned to receive 2µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
89121845|NCT04179201||IBD with CDI|Inflammatory bowel disease with clostridium difficile infection
89121846|NCT04179201||IBD without CDI|Inflammatory bowel disease without clostridium difficile infection
89121847|NCT04179279||Pilot|
89121848|NCT04179279||Pivotal|
89121849|NCT02794285|Experimental|Anifrolumab|Anifrolumab
89121850|NCT02794285|Placebo Comparator|Placebo|Placebo
89121851|NCT00643695|Experimental|1|Home-based walking program
89121852|NCT00643695|Other|2|educational intervention
88801627|NCT01143649|Experimental|active tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT)
88801628|NCT01143649|Experimental|tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one session of treatment with active tACS (in which the order in which they receive either sham or active transcranial alternating current stimulation (tACS) stimulation will be randomized).
88801629|NCT01143649|Sham Comparator|sham tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday). For the sham session, tDCS is turned off after 30seconds.
88801630|NCT01143649|Sham Comparator|sham tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT). The sham stimulation consists of 30 seconds of stimulation at the beginning of the 40 min of treatment.
88801631|NCT01143649|Sham Comparator|sham tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one day of treatment with sham tACS. All participants received active and sham stimulation in a randomized order.
89121853|NCT02674737|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both sedative and analgesic(dexmedetomidine, tramadol and flurbiprofen) are applied to this group of patients.
89121854|NCT02674737|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(tramadol and flurbiprofen) are applied to this group of patients.
89121855|NCT02674893|Experimental|type 2 diabetics treated with GLP1 analogue|
89121856|NCT02674893|Active Comparator|Type 2 diabetics not treated with incretins|
89121857|NCT02674893|Other|Healthy subjects|
89121858|NCT02674815|Experimental|Intervention|Patients within this arm will perform two weeks of high intensity interval training prior to colorectal/thoracic surgery. Exercise intensity will be 100% of the peak power output (PPO) during maximal cardiopulmonary exercise testing. Patients will exercise for 15 seconds at 100% PPO and rest for 15 seconds (passive) for 30 minutes or until exhaustion. This will be performed 5 days a week for 2 weeks.
89121859|NCT04100421||Mild renal injury|CKD patients with eGFR ≥ 60 ml∙min-1∙ (1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
89121860|NCT04100421||Moderate renal injury|CKD patients with eGFR between 30 ml∙min-1∙(1.73 m2)-1 to 60 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
89121861|NCT04100421||Severe renal injury|CKD patients with eGFR < 30 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).
89121862|NCT04100421||Hemodialysis|uremic patients on hemodialysis therapy
89121863|NCT04100421||Peritoneal dialysis|uremic patients on peritoneal dialysis
88801632|NCT03937570|Experimental|EO GROUP|Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.
89121864|NCT04100421||Healthy control|Healthy volunteers with no history of kidney diseases or any chronic diseases which may lead to renal injury.
89121865|NCT02717455|Experimental|Treatment (STRATUM 1)|Patients with recurrent/progressive DIPG will be enrolled at the time of progression. All patients will take the study drug panobinostat (LBH589).
89121866|NCT02717455|Experimental|Treatment (STRATUM 2)|Patients with non-progressed DIPG or H3K27M+ Thalamic DMG will be enrolled. All patients will take the study drug panobinostat (LBH589).
89121867|NCT00643773|Experimental|A|Leucine supplement
89121868|NCT00643773|Placebo Comparator|B|Wheat flour
89121869|NCT02674425||Young adults (18-40)|Healthy adult volunteers, aged between 18 and 40, with no prior/current eye problems or family history of genetic eye diseases and good general health.
89121870|NCT02674425||Older adults (50-70)|Healthy adult volunteers, aged between 50 and 70, with no prior/current eye problems or family history of genetic eye diseases and good general health.
89121871|NCT00729391|Experimental|1|Women's CoOp
89121872|NCT00729391|Active Comparator|2|Nutrition (Attention-Control)
89121873|NCT00729391|Active Comparator|3|Voluntary Counseling and Testing
89121874|NCT02674581|Experimental|Healthy Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
89121875|NCT02674581|Experimental|Mild Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
89121876|NCT02674581|Experimental|Moderate Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
89121877|NCT02674581|Experimental|Severe Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
88801633|NCT03937570|No Intervention|CONTROL GROUP|Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.
88801634|NCT01143727|Active Comparator|A|Santyl
88801635|NCT01143727|Active Comparator|B|Tegaderm Hydrogel
88801636|NCT05496816||Sepsis|
88801637|NCT05496816||Septic shock|
88801638|NCT03738826|Experimental|Intervention arm|Lupus clinic providers will use Surescripts refill information to assess adherence level and address adherence barriers. We will assess the feasibility and acceptability of the intervention.
88801639|NCT01451216||ABI 50-70 y|patients suffering from acquired brain injury aged 50-70 years old
88801640|NCT01451216||ABI 25-50y|Patients suffering from acquired brain injury aged 25-50 years oled
88801641|NCT03011827|Experimental|Prospective cohort|Fibrinogen and/or platelet administration
88801642|NCT05496660|Experimental|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
88801643|NCT05496660|Sham Comparator|NHE|the Nordic hamstring exercise plus taping wihout tension during 4-week consisting 12 sessions
88801644|NCT05496582||Asthma|Previously disgnosed asthma patients
88801645|NCT05496582||Control|Healthy participants
88801646|NCT03735862||Observations Group|Patients who have undergone a hiatal hernia repair with MIROMESH.
88801647|NCT01143883|Experimental|Silverlon Dressing|The Silverlon(Cura Surgical, Geneva, IL) dressing is applied to the surgical wound postoperatively. This dressing is coated with silver nylon.
88801648|NCT01143883|Active Comparator|Standard of Care Dressing|The standard plain gauze is used to dress the wound postoperatively
89121878|NCT02674581|Experimental|End Stage Renal Disease Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
89121879|NCT04065919|Active Comparator|Exparel|"administration of liposomal bupivacaine 266mg/20mL+ 40 mL bupivacaine 0.25% bupivacaine~."
88801649|NCT01451294|Active Comparator|Ephedrine|
88801650|NCT01451294|Active Comparator|Phenylephrine|
88801651|NCT01187017|Experimental|Fludarabine/Cyclophosphamide in Participants with Severe Aplastic Anemia|Participants with Severe Aplastic Anemia will receive Fludarabine at 125 mg/m squared plus Cyclophosphamide at 60 mg/kg (Flu/Cy).
88801652|NCT02896088|Other|test tooth groups|test tooth groups
88801653|NCT02896088|Other|control tooth groups|control tooth groups
88801654|NCT04553094|No Intervention|Group 1|No physical training
88801655|NCT04553094|Experimental|Group 2|Endurance training
88801656|NCT04553094|Experimental|Group 3|Muscle building training
89121880|NCT04065919|Active Comparator|Standard of Therapy|administration of 0.25% bupivacaine with epinephrine at 1cc/kg total dose
89121881|NCT02674347|Experimental|Cohort 1: 3 g or 6 g of Zidebactam|"Cohort 1 (Zidebactam): 3 g of Zidebactam (1 g every 8 hours [q8h]) (n=8) IV infusions administered over 60 minutes.~Cohort 2 (Zidebactam or placebo): 6 g of Zidebactam (2 g q8h) (n=8) IV infusions administered over 60 minutes."
89121882|NCT02674347|Placebo Comparator|Placebo|"Cohort 1: Placebo every 8 hours [q8h] (n=2) IV infusions administered over 60 minutes.~Cohort 2: Placebo every q8h (n=2) IV infusions administered over 60 minutes."
89121883|NCT04065529|Experimental|Gelatin tannate (GT)|Gelatin tannate (GT)
88801657|NCT04553094|Experimental|Group 4|Training combining endurance + muscle building
88801658|NCT01145833|Active Comparator|Immediate treatment group|The immediate treatment group begins the 5-month treatment immediately after baseline assessment.
88801659|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group serves as the control group. This group starts treatment 5 months after the baseline assessment. No intervention is involved during this 5-month waiting period. After 5 months, the delayed group is assessed for the second time and then begins the 5-month treatment.
88801660|NCT04035694|Experimental|Intervention|Participants will receive access to Media Aware.
88801661|NCT04035694|No Intervention|Delayed-Intervention Control|Participants will receive their regular health education programming not related to sexual health education or media literacy education.
88801662|NCT04391192|Experimental|Participants|All participants will be given the phone number and encouraged to call any time they plan to use substances alone
88801663|NCT01451450|Experimental|QGE031 A|
88801664|NCT01451450|Experimental|QGE031 B|
88801665|NCT01451450|Experimental|QGE031 C|
88801666|NCT01451450|Experimental|QGE031 D|
88801667|NCT01451450|Placebo Comparator|Placebo A|
88801668|NCT01451450|Placebo Comparator|Placebo B|
88801669|NCT01451450|Placebo Comparator|Placebo C|
88801670|NCT01451450|Placebo Comparator|Placebo D|
88801671|NCT05491122|No Intervention|Habitual period|8 consecutive days where participants will drink fluids as they do habitually (habitually low TFI = ≤ 1.6 L/day, women ≤ 1.5 L/day, or habitually high TFI = men ≥ 2.9 L/day, women ≥ 2.5 L/day)
88805888|NCT00293540|Active Comparator|B|Surgical oophorectomy in history-estimated mid-follicular phase of menstrual cycle plus Tamoxifen
88805889|NCT03012113|Other|Short term mild cooling|Subjects will undergo a short term mild cooling protocol consisting of personalized water cooling method for approximately 2 hours.
89121884|NCT04065529|Placebo Comparator|Placebo|Placebo
89121885|NCT04179045|Experimental|Bioheart|Subjects have CAD with one or two de novo native coronary artery lesions and will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System. There will be only one arm in this study.
89121886|NCT00731419|Active Comparator|SEMS|Self expanding metal stent compared to plastic stent. Both recognised forms of treatment for condition
89121887|NCT00731419|Active Comparator|Plastic stent|
89121888|NCT02674269|Experimental|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
89121889|NCT02674269|Experimental|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
89121890|NCT02674269|Placebo Comparator|TC-3 Gel|One intravesical instillation of 60 ml TC-3 gel
89121891|NCT00731497|Active Comparator|1|children in households/villages using Solar Water Disinfection (SODIS) method of disinfecting household drinking water
89121892|NCT00731497|No Intervention|2|children in households/villages where Solar Water Disinfection (SODIS) has not been implemented
89121893|NCT00643929||Observational|Subjects who have participated in a prior eltrombopag study, receiving either placebo or eltrombopag
89121894|NCT00735631|Experimental|1|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
89121895|NCT00970268|Experimental|1|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
89121896|NCT00970268|Experimental|2|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
89121897|NCT00729547|Placebo Comparator|2|Psychotherapy placebo session
89121898|NCT00729547|Experimental|1|Neurofeedback training which enhance left frontal alpha wave.
89121899|NCT02673957||Blood pressure cuff protocol|All participants receive a baseline control blood test, and all participants receive the blood pressure cuff inflation protocol and blood sampling following the cuff protocol.
89121900|NCT00644007|Placebo Comparator|Group 1|
89121901|NCT00644007|Experimental|Group 2|
89121902|NCT00735865|Active Comparator|1|
89121903|NCT00735865|Active Comparator|2|
89121904|NCT00735865|Active Comparator|3|
89121905|NCT00735865|Active Comparator|4|
89121906|NCT00910143||1|patients operated before summer 1995, that is before the introduction of TME
89121907|NCT00910143||2|patients operated after summer 1995, that is after the introduction of TME.
89121908|NCT03732560||Patients undergoing treatment with nivolumab and ipilimumab|
89121909|NCT03732560||Patients undergoing treatment with nivolumab|
89121910|NCT02674113|Active Comparator|regional anesthesia bupivacaine|regional anesthesia (a single shot fascia iliaca block using bupivacaine) prior to hip arthroscopy
89121911|NCT02674113|Placebo Comparator|regional anesthesia placebo|subcutaneous injection procedure placebo (0.9% sodium chloride in water)
89121912|NCT04286672||Group 1:|• 35 bladder cancer patients diagnosed by biopsy before treatment.
89121913|NCT04286672||Group 2:|35 apparently healthy individuals who were matched by age and sex .
89121914|NCT00729703|Experimental|1|Dual-chamber detection and activated treatment (at least ATP) in the slow VT-zone plus activated AAIsafeR pacing (basic rate 60 bpm).
89121915|NCT00729703|Experimental|2|Single-chamber ICD following clinical practice but with a monitoring zone active to allow the documentation of all occurring ventricular arrhythmias
89121916|NCT00644085|Experimental|1|oral administration of aspirin 100 mg
89121917|NCT00644085|Placebo Comparator|2|oral administration of placebo
89121918|NCT02674191|Experimental|Group 1|Device: mini-plates supported molar intrusion (Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence Procedure/Surgery: Application of ULTRACARE benzocaine 20%, topical anesthesia (Ultradent Products, Inc) Procedure/Surgery: Administration of , Mepivacaine-l local anesthesia Procedure/Surgery: BETADINE povidone-iodine 10% a local disinfectant Drug: (150g Clindamycin/tds) for 1 week Postoperative antibiotic Drug: (Cataflam 25mg), are prescribed post-operatively an analgesic
89121919|NCT02674191|No Intervention|Group 2|hyperdivergent adolescence with no intervention
89121920|NCT00731809|Other|1|PET CT
89121921|NCT00969332|Experimental|Omegaven|0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
89121922|NCT00736021|Experimental|A|Single arm (open label study): Provide twelve weeks of treatment with high does (40 mg daily) of escitalopram to trauma survivors with chronic PTSD.
89121923|NCT04178655|Experimental|Tranexamic Acid Treatment|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
89121924|NCT04178655|Placebo Comparator|Placebo|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
89121925|NCT02863094|Active Comparator|Real Stimulation|The continuous theta burst stimulation (cTBS) protocol lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. In the cTBS session, this 40s protocol was repeated for three times (1800 pulses in total) separated by two 15 min breaks (controlled by a stopwatch). MRI dataset should be acquired before the first cTBS session and after the last cTBS session.
89121926|NCT02863094|Sham Comparator|Placebo Stimulation|The procedure of this protocol was performed by a placebo coil. Each session lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first sham TBS session and after the last sham TBS session.
89121927|NCT00738517|Active Comparator|1|Immunoadsorption with subsequent immunoglobulin substitution
89121928|NCT00738517|No Intervention|2|
89121929|NCT04178577|Experimental|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
89121930|NCT02568787|Experimental|Rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
89121931|NCT02568787|Placebo Comparator|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
89121932|NCT02673879|Active Comparator|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase.
89121933|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated.
89121934|NCT03692468|Experimental|Intervention Group|Participants will engage in a 5 session psychotherapy intervention focused on improving pain and mood.
89121935|NCT03692468|No Intervention|Control Group|Patients will receive treatment as usual from their care providers.
89121936|NCT02674035|Active Comparator|Device: 2-0 monofilament nylon suture|Plication of the anterior rectus sheath (correction of diastasis of the rectus abdominis muscles) was performed in two layers with Device 2-0 monofilament nylon suture (control group). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
88801672|NCT05491122|Experimental|Intervention period|1-week where the fluid intake will be modified. Habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI.
88801673|NCT01451528|Experimental|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation
89121937|NCT02674035|Active Comparator|Device: Single layer 2-0 monofilament|Single layer with a Device 2-0 monofilament nylon suture (correction of diastasis of the rectus abdominis muscles) (group I). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
89121938|NCT02674035|Active Comparator|Device: Barbed suture Quill Nylon 1|Using a continuous Device Barbed suture Quill Nylon 1 (correction of diastasis of the rectus abdominis muscles) (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
89121939|NCT00738595|Experimental|1|EVT 302, 5 mg once Daily
89121940|NCT00738595|Placebo Comparator|2|Placebo once daily
89121941|NCT00738595|Experimental|3|EVT 302 plus open label Nicotine replacement
89121942|NCT00738595|Active Comparator|4|Placebo plus nicotine replacement therapy
89121943|NCT04016493||Control group (CAF+CTG; N=20)|
89121944|NCT04016493||Test group (TUN+CTG; N=20)|
89121945|NCT04099719||Anyone (>16 years old) registered with services providing drug|retrospective data, no intervention to be administered
89121946|NCT02673723|Experimental|Dezocine|Dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
89121947|NCT02673723|Placebo Comparator|Controlled|The same amount of saline is given for 10 seconds after surface anesthesia
89121948|NCT00968864|Experimental|CliniMACS® (T cell depletion)|Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
89121949|NCT00644163|Experimental|1|Participants will receive Eban HIV/STD Risk Reduction Intervention.
89121950|NCT00644163|Active Comparator|2|Participants will receive Eban Health Promotion Intervention.
89121951|NCT04016337|Experimental|Intervention with beverage added with sucralose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with sucralose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener sucralose was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
89121952|NCT04016337|Experimental|Intervention with beverage added with saccharose|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with saccharose was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener saccharose was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
89121953|NCT04016337|Experimental|Intervention with beverage added with stevia|"A beverage (330 mL) made with lemon and maqui extracts and sweetened with stevia extract was taken by participants, during 60 days. Beverages were made in a semi-industrial process in a pilot plant. Microbiological tests, quality controls and shelf-life assays were performed following legislation on beverages.~Concentrations of lemon and maqui extract are under industrial secret. The sweetener stevia was added within the ranges established by law as maximums.~The beverage was carried out in the pilot plant of a company (Nutracitrus) with all the safety systems, tested by an external lab (Ecosur), apart from the routine controls themselves.~All ingredients were suitable for consumption and purchased from different companies with their respective certificates and conservation was at 5 º C for a maximum of 7 days, prior to administration to volunteers."
89121954|NCT04285970||Medullary injured|Injured Medullary users of manually driven wheelchairs for daily locomotion
89121955|NCT04285970||Healthy volunteers|Healthy volunteer with at least 2 hours' experience using a manual wheelchair
89121956|NCT04177407|Experimental|BPF group|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
89121957|NCT04177407|No Intervention|control group|Regarding to the pelvic peritoneum reconstruction, in control group, the pelvic peritoneum will be closed with running suturing. If not possible, the peritoneum covering the surface of the bladder will be secured on the anterior surface of the sacrum with nonabsorbable sutures at the level where the anatomic structure obliterates the pelvic entrance. If neither method was feasible, the pelvic peritoneum defect will be left unclosed.
89121958|NCT05273775|Experimental|single arm|HRS5091 + probe drugs (Midazolam Maleate Tablets+Warfarin Sodium Tablets+ Omeprazole Enteric Capsules+ Digoxin Tablets+ Rosuvastatin Calcium) + Vitamin K1 Tablets
89121959|NCT04177017|Experimental|Experimental group|The experimental group is the one that participates in the intervention
89121960|NCT04177017|No Intervention|Control group|The control group belonged to the same school but did not participate in the intervention. Instead, they continued with regular curricular classes
89121961|NCT04177485|Experimental|Standard of Care + SMS text reminders|Standard of Care + SMS text reminders to be sent to caregivers for each of their subsequent vaccination visits, as per the EPI schedule (Penta2/OPV2/PCV2, Penta3/OPV3/PCV3, and MCV)
88801674|NCT01224145|Experimental|Drug: Bupivacaine Collagen Sponge|bupivacaine collagen sponges
88801675|NCT05496426|Experimental|KL130008 capsule High Dose|KL130008 capsule administered orally
88801676|NCT05496426|Experimental|KL130008 capsule Middle Dose|KL130008 capsule administered orally
89121962|NCT04177485|No Intervention|Standard of Care|*Standard of care was defined as the health worker providing vaccination cards (home based records) to caregivers, as available, and providing verbal instruction of when to return for the next visit.
89121963|NCT02671851||Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs at the level of T3-T4 with 20 mL bupivacaine 0.375% as an adjunct to general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
89121964|NCT02671851||IV metamizole sodium, paracetamol|Patients received only standardized general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
89121965|NCT02672163|Experimental|AACD-Therapy group|6 patients are recruited to the AADC-therapy group. Autologous atrial appendage derived cells (AADCs) are harvested from the appendage tissue removed during the venal cannulation of bypass. The cells and their extracellular matrix are placed with tissue clue to Cormatrix-sheet and further on top of the myocardium in the area of infarction scar. The procedure is done simultaneously with CABG surgery. The patients will be carefully monitored after the operations and cardiac MRI and echocardiogram will be performed previously to surgery as well as during the follow ups.
89121966|NCT02672163|Active Comparator|Control group|20 patients are recruited to form the control group. They are patients scheduled for elective CABG surgery and they meet the same inclusion and exclusion criteria as the therapy group. There patients are followed as the hospital protocol with out any additional imagination or blood tests.
89121967|NCT04176861|Experimental|Home based intervention|Participants using hBET technology at home (all participants).
89121968|NCT02671695|Experimental|Group 1|chelation therapy plus Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
89121969|NCT02671695|Experimental|Group 2|chelation therapy plus Amlodipine in a dose of 5 mg/day orally for 3 months
89121970|NCT04087785||Positive metastasis|Positive occult lymph node metastasis pathology
89121971|NCT04087785||Negative metastasis|Without lymph node metastasis pathology
89121972|NCT00736177|Active Comparator|Control|Patients in the control group will undergo conventional IVF cycles with fresh blastocyst transfer.
89121973|NCT00736177|Experimental|Test group|Patients in the Test group will have their embryos cryopreserved for transfer in a second cycle.
89121974|NCT02671617|No Intervention|Control|Control: This group of patients will receive 'current best practice' as per UK NHS recommendations for their specific cancer management prior to surgery.
89121975|NCT02671617|Experimental|High intensity interval training|"Exercise: Participants in this group will attend 3-4 times per week to complete HIIT training during the period from diagnosis to surgery.~High intensity interval training (HIIT)"
89121976|NCT00736411|Active Comparator|1|IVF
89121977|NCT00736411|Other|II|treatment
89121978|NCT02671773||BTS Step 2 Asthmatic patients|Group of 20 asthmatic patients on British Thoracic Society (BTS) treatment step 2 - regular low dose inhaled corticosteroids (dose of <400 micrograms/day BDP equivalent)
89121979|NCT02671773||BTS Step 4 Asthmatic patients on treatment with fluticasone|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled fluticasone (dose of >500 micrograms/day)
89121980|NCT02671773||BTS Step 4 Asthmatic patients on treatment with budesonide|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled budesonide (dose of >800 micrograms/day)
89121981|NCT02671539|Experimental|open label injection of rAAV2.REP1|This is an open label, single arm interventional trial with subretinal injection of rAAV2.REP1 and fellow eye comparison
89121982|NCT00731965|Experimental|1|Measles, mumps, rubella booster vaccination within 3 months after randomisation
89121983|NCT00731965|No Intervention|2|Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation
89121984|NCT00644631|Active Comparator|Arm 1|
89121985|NCT00644631|Placebo Comparator|Arm 2|
89121986|NCT02671383|Active Comparator|Darunavir|Darunavir/Ritonavir 400/100mg once daily
89121987|NCT02671383|Active Comparator|Lopinavir|Lopinavir/Ritonavir 400/100mg twice daily
89121988|NCT00738751|Experimental|Dose Escalation Followed by Expansion|Eligible participants were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at 4 planned dose levels (DLs).
89121989|NCT05243823||Danish cohort|Danish cohort starts on 1 January 2000 and ends on 31 December 2019. It consists of new users of low dose vaginal estrogens (LDVE) (split into Vagifem® and other LDVE products) in the study period, and a comparator group consisting of women using no hormone replacement therapy.
89121990|NCT05243823||US cohort|US cohort starts on 1 January 2007 and ends on 31 December 2019. It consists of new users of low dose vaginal estrogens (LDVE) (split into Vagifem® and other LDVE products) in the study period, and a comparator group consisting of women using no hormone replacement therapy.
89121991|NCT00736801|Experimental|A|Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.
89121992|NCT00738829|Experimental|Treatment Arm|Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy
89121993|NCT02671227|Active Comparator|intrathecal bupivacaine + Mg sulfate|intrathecal bupivacaine 15 mg + intrathecal Mg sulfate 50 mg. in gynecologic laparoscopic surgeries.
89121994|NCT02671227|Active Comparator|intrathecal bupivacaine|intrathecal bupivacaine 15 mg in gynecologic laparoscopic surgeries.
89121995|NCT00644709|Experimental|Arm A|
89121996|NCT00738985|Placebo Comparator|ezetimibe/simvastatin 10/20 mg + placebo|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe (+) simvastatin 10/20 mg + placebo for 12 weeks. Safety and efficacy parameters are measured at baseline and 12 weeks later
88801677|NCT05496426|Experimental|KL130008 capsule Low Dose|KL130008 capsule administered orally
88801678|NCT05496426|Placebo Comparator|Placebo|Placebo administered orally
88801679|NCT01458002|No Intervention|Control|Assessment only
88801680|NCT01458002|Other|Tailored Internet Communications|TTM expert system only
88801681|NCT01458002|Experimental|Tailored Internet Communication with Relational Agent|TTM expert system plus relational agent
89121997|NCT00738985|Active Comparator|ezetimibe/simvastatin 10/20 mg + MK0524A|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe/simvastatin 10/20 mg + MK0524A 1 gr for 6 weeks, if efficacy achieved will continue with ezetimibe (+) simvastatin 10/20 mg + MK0524A 1 gr + placebo; if not achieved, will receive ezetimibe (+) simvastatin 10/20 mg + MK0524A 2 gr for 6 weeks.
89121998|NCT05216211|Active Comparator|Group Caudal|Caudal block with 1 ml / kg, % 0.25 bupivacaine
89121999|NCT05216211|No Intervention|Group Control|No intervention
89122000|NCT00732043|Experimental|1|
89122001|NCT00732043|Experimental|2|
89122002|NCT00732043|Placebo Comparator|3|
89122003|NCT02670993|Experimental|Control group : Singing sessions.|Patients will participate to singing working sessions. They will continue to take their usual treatments during the study period.
89122004|NCT02670993|Active Comparator|Control group : Painting sessions.|Patients will continue to participate to painting work sessions, and to take their usual treatments during the study.
89122005|NCT00732121|Active Comparator|1|Sitagliptin
89122006|NCT00732121|Placebo Comparator|2|Placebo arm
89122007|NCT02537223|Experimental|BYL719, Cisplatin, and Radiation Therapy|BYL719, orally, at a starting dose of 200-350 mg, once daily, for 7 weeks. Cisplatin, intravenously, at 100 mg/m2 over 1 hour, every 3 weeks for 3 doses. Radiation therapy, Monday to Friday, for 7 weeks.
89122008|NCT04176237|Experimental|Intervention|Schools receive 3 one hour lessons on sun safety, followed by a 1 hour UV dosimtery laboratory session.
89122009|NCT04176237|No Intervention|Control|Schools receive 3 one hour lessons on sun safety.
89122010|NCT04176237|No Intervention|Observation|Schools do not receive any lessons.
89122011|NCT02671149|Experimental|Drink water|Participants will receive two 150ml drinks of water during the dehydration protocol
89122012|NCT02671149|No Intervention|Drink nothing|Participants will drink nothing during the dehydration protocol
89122013|NCT00732277|Experimental|Treatment|Patients in this arm will be given the following IMP intraveneously at 6 hour intervals - hydrocortisone (100mg/m2/24 hours)
89122014|NCT00732277|No Intervention|Control|in each phase of study 15 patients will receive no IMP as control arm
89122015|NCT04084509||Healthy Controls|
89122016|NCT04084509||Idiopathic Parkinson's Disease|
89122017|NCT04084509||Symptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
89122018|NCT04084509||Asymptomatic Genetic Carriers (SNCA, Parkin or PINK1)|
89122019|NCT00737035|Experimental|1-Intervention|For 16 weeks, participants will have access to an interactive healthcare communication application (IHCA).
89122020|NCT00737035|Active Comparator|2- Control|For 16 weeks, participants will have access to generally available Internet-based information about parenting, trauma, and child development.
89122021|NCT04176315|Active Comparator|Conventional Rehabilitation Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty autonomously
89122022|NCT04176315|Experimental|ReHub Group|Participants follow the usual exercise plan designed at Presidio San Camillo for Total Hip Arthroplasty but use the telerehabilitation platform ReHub to do the exercises at home and to have their progress monitored.
89122023|NCT02569333|Experimental|Educational Video|Subjects to have access to educational video during hospital stay
89122024|NCT02569333|No Intervention|Usual Care|Patients to receive usual care and will not have access to educational video.
89122025|NCT04176471|Experimental|Therapeutic Hypothermia|Therapeutic hypothermia will be achieved using a servo-controlled temperature regulating blanket that is approved for use in neonates and is currently used for the treatment of neonates with moderate-severe HIE. The goal target temperature is 33.5°C ± 0.5°C for 72 hours and the subject will then be rewarmed at a rate of 0.5°C per hour to a goal of 36.5°C.
89122026|NCT04176471|Active Comparator|Normothermia|Normothermia will be achieved using a servo-controlled temperature regulating blanket with the temperature goal of 36.5-37.3°C for 72 hours.
89122027|NCT00732355||I|known syphilis infected patients
89122028|NCT00732355||U|presumed uninfected patients
89122029|NCT00739219|Active Comparator|eNO group|eNO measurement is used to inform asthma management decisions
89122030|NCT00739219|No Intervention|control group|Asthma is managed according to existing standard of care
89122031|NCT00739453|Experimental|Schedule 1|OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
89122032|NCT00739453|Experimental|Schedule 2|OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
89122033|NCT00739453|Experimental|Schedule 3|OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.
89122034|NCT02668575|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality CF care provided to all patients at the UPMC CF Center.
89122035|NCT02668575|Experimental|Supportive Care Intervention|Patients randomized to the intervention arm will receive a protocolized supportive care intervention from a palliative care nurse practitioner.
89122036|NCT02668497|Experimental|De-novo PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
89122037|NCT02668497|Experimental|L-dopa PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
89122038|NCT00737191|Active Comparator|Arm I|Patients receive oral opioid and oral placebo once daily for 4 weeks.
89122039|NCT00737191|Experimental|Arm II|Patients receive oral opioid and 2.5 mg oral olanzapine once daily for 4 weeks.
89122040|NCT00737191|Experimental|Arm III|Patients receive oral opioid and 5 mg oral olanzapine once daily for 4 weeks.
89122041|NCT00758680|Experimental|MK-1006 20 mg Once Daily (Panel A)|After a 2-week run-in/wash-off period, participants received single daily doses (q.d.) of 20 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the Clinical Research Unit (CRU).
89122042|NCT00758680|Experimental|MK-1006 40 mg Once Daily (Panel B)|After a 2-week run-in/wash-off period, participants received single daily doses of 40 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
89122043|NCT00758680|Experimental|MK-1006 80 mg Once Daily (Panel C)|After a 2-week run-in/wash-off period, participants received single daily doses of 80 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
89122044|NCT00758680|Experimental|MK-1006 120 mg Once Daily (Panel D)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
89122045|NCT00758680|Experimental|MK-1006 20 mg Twice Daily (Panel E)|After a 2-week run-in/wash-off period, participants received twice-daily doses (b.i.d.) of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
89122046|NCT00758680|Experimental|MK-1006 30 mg Twice Daily (Panel F)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 30 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
89122047|NCT00758680|Experimental|MK-1006 50 mg Twice Daily (Panel G)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
89122048|NCT00758680|Experimental|MK-1006 120 mg Once Daily Outpatient (Panel H)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
89122049|NCT00758680|Experimental|MK-1006 50 mg Twice Daily Outpatient (Panel I)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
89122050|NCT00758680|Placebo Comparator|Placebo|After a 2-week run-in/wash-off period, participants received dose-matched placebo to MK-1006 over a multiple-dosing period while remaining domiciled in the CRU.
89122051|NCT00732433|Experimental|digital mammogram|"Digital mammography is a non-invasive imaging technique to obtain an x-ray image of the breast.~Two-view digital mammogram of the breast with a lesion that has been recommended for biopsy during the subject's regular clinical care. The digital mammogram is then analyzed by a computer program."
89122052|NCT04175067||Endometrium cancer|stage I endometrium cancer n=57
89122053|NCT04175067||Healthy controls|Healthy volunteers n=60
89122054|NCT02668107|Active Comparator|Intervention Group (Hammock positioning)|Babies in the intervention group (IG), will be positioned supine in a hammock in the incubator, with the appropriate postural adjustments.
89122055|NCT02668107|No Intervention|Control Group|Those selected for the control group (CG) will be placed in the incubator following the service routine.
89122056|NCT02668029|Experimental|oxygen|oxygen administered through a nasal cannula at a personalized, fixed flow
89122057|NCT02668029|Placebo Comparator|medical air|Medical air administered through a nasal cannula at the same flow
89122058|NCT00645489|Other|1|Control condition is wait-list control.
89122059|NCT00645489|Experimental|2|Active treatment condition: psychoeducational intervention for patients with HF
89122060|NCT00758602|Active Comparator|MMF, Standard Dose Tacrolimus|Participants received mycophenolate mofetil (MMF) 0.75 to (-) 1 gram (g), orally (PO), twice daily (BID) from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 milligrams per kilogram (mg/kg), PO, BID to reach a target trough dose of 8-10 nanograms per milliliter (ng/mL) from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
89122061|NCT00758602|Experimental|MMF, Low Dose Tacrolimus|Participants received MMF 0.75-1 g, PO, BID from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 mg/kg, PO, BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to 0.05-0.08 mg/kg, PO, BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
89122062|NCT02667717|Experimental|Experimental group : Mirror Therapy|Experimental group will perform mirror therapies during 16 weeks, added to the usual care. Therapy mirror sessions will take place at hospital units but also at home.
89122063|NCT02667717|Active Comparator|Control group : Usual care|The control group will benefit from the usual care during 16 weeks. No mirror therapies will be performed to this group.
89122064|NCT02667795|Experimental|Monitored walking based exercise|Participants will be given a personalised daily exercise target. Participants will be given an activity tracker (a Fitbit ZipTM). The participants will be asked to wear the device all day to monitor their activity. Once a day the participants will be asked to complete the walking target they have been given at completion of their baseline assessment. This target should be completed in one go. The walking programme will last a minimum of 2 weeks and a maximum duration of 4 weeks. The length of time will depend on the length of time between recruitment and when the participant is scheduled to have their surgery.
89122065|NCT02667795|No Intervention|Control|No intervention
89122066|NCT02601118|Experimental|training group|41 training students were pre-tested before education with Micro Expression Training Tool (METT) and Subtle Expression Training Tool (SETT) at baseline and then, took second METT and SETT tests after a 1-hour class about interpreting micro and subtle expressions.
89122067|NCT02601118|No Intervention|control group|41 control students were pre-tested before education with METT and SETT at baseline and then, took the second tests without attend the training class.
89122068|NCT02667561|Experimental|Testosterone gel 1% 2.2 mg|Testosterone gel 1% Topical use 2.2 mg (220 mg of gel) once daily duration of treatment: 28 days
89122069|NCT02667561|Experimental|Testosterone gel 1% 4.4 mg|Testosterone gel 1% Topical use 4.4 mg (440 mg of gel) once daily duration of treatment: 28 days
89122070|NCT02667561|Experimental|Testosterone gel 1% 8.8 mg|Testosterone gel 1% Topical use 8.8 mg (880 mg of gel) once daily duration of treatment: 28 days
89122071|NCT02667561|Placebo Comparator|Placebo of Testosterone Gel 1%|Placebo of Testosterone Gel 1% Topical use Approximately 550 mg of gel Once daily duration of treatment: 28 days
89122072|NCT02667405|Experimental|Whirlpool|Immersion in Whirlpool during therapy
89122073|NCT02667405|Active Comparator|Hot Pack|Hot Pack Application during therapy.
89122074|NCT00732511|Experimental|1|Coreg Cr will be up-titrated as needed to achieve blood pressure <130/80
89122075|NCT00732511|Active Comparator|2|Toprol XL will be up-titrated at weekly intervals to achieve a blood pressure <130/80 mm Hg
89122076|NCT02667249||check list|clinical pathway using a paper based check-list
89122077|NCT02667249||integrated clinical pathway|clinical pathway in form of a clinical pathway integrated into the paper based medical treatment and nursing documentation
89122078|NCT00739531||Asthmatics|Subjects with asthma
89122079|NCT05047887|Experimental|Study group (in one side)|Modified socket shield technique with autogenous dentin graft
89122080|NCT05047887|Active Comparator|Control group (in contrlateral side)|Modified socket shield technique with alloplast
89122081|NCT04174599|Experimental|F-627|Subjects will receive F-627 (20 mg/dose, s.c.) on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
89122082|NCT04174599|Active Comparator|GRAN®|Subjects will receive GRAN® [5 μg/kg/day, s.c., once daily (± 4 h) up to 2 weeks or until neutrophil count returns to 5.0 ×109/L] on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
89122083|NCT00739609|Experimental|1|
89122084|NCT00739687|Experimental|ALT-711|Alagebrium 200 mg BID
89122085|NCT00739687|Experimental|Placebo|Placebo
89122086|NCT00645723|Experimental|A|Intravenous colistin and nebulized colistin
89122087|NCT00645723|Placebo Comparator|B|intravenous colistin and saline solution nebulized
89122088|NCT00737347|No Intervention|1|usual care. Subjects had one 90 minute visit with registered dietitian
89122089|NCT00737347|Active Comparator|2.|Standard care. Subjects had 4 sessions with registered dietitian
89122090|NCT00737347|Active Comparator|3|Intensive care. subjects had 10 visits with registered dietitian
89122091|NCT02568865||Major Depressive Disorder|
89122092|NCT02568865||Healthy Volunteers|
89122093|NCT04991337|Experimental|Detraining group|Will be instructed to avoid high-intensity exercise corresponding to a heart rate >75% of maximum heart rate, and a total duration of exercise (hours/week) corresponding to >80% of the self-reported average weekly amount of exercise (hours/week) during the past six months, for a period of 16 week.
89122094|NCT04991337|Experimental|Control group|Will be instructed to perform at least three weekly sessions of high intensity exercise, corresponding to a HR ≥85% of maximum heart rate, and otherwise continue endurance exercise as usual.
89122095|NCT00711529|Experimental|Hypnotherapy|"Patients randomized to the experimental arm were scheduled for three one-hour inductions by a single hypnotherapist, each one week apart. Standardized outlines were used for each induction. The second and third sessions also began with a standardized induction, followed by the establishment of an anchor, or physical reference point (forefinger to thumb), used to invoke images of coolness, which were individualized according to patient preference.~Patients were also instructed by the same hypnotherapist in self-hypnosis and guided imagery techniques to be used at home with the assistance of standardized audio compact disks. Participation lasted eight weeks."
89122096|NCT00711529|Active Comparator|Gabapentin|Patients randomized to the gabapentin arm were prescribed 900mg of the drug daily (300 mg by mouth three times daily).
89122097|NCT02667171|Active Comparator|Control group|The control group will receive standardized conventional supervised COPD rehabilitation, delivered in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks.
89122098|NCT02667171|Experimental|Online COPD rehabilitation|Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks.
89122099|NCT02667327|Active Comparator|Granexin gel plus Standard of Care|Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.
89122100|NCT02667327|Placebo Comparator|Vehicle gel plus Standard of Care|Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.
88801682|NCT01187095|Experimental|counselling|Does couples in IVF treatment benefit from emotional disclosure
89122101|NCT02667327|No Intervention|Standard of Care|Standard of Care includes cleaning and irrigating ulcer, non-surgical debridement, pain management, ulcer dressing, off-loading, and nutritional assessment.
89122102|NCT00732589|Experimental|A|Suprascapular nerve block
89122103|NCT00732589|Experimental|B|therapeutic ultrasound
89122104|NCT00737425|Active Comparator|1|
89122105|NCT00737425|Sham Comparator|2|
89122106|NCT02569099|Experimental|Intervention using standardised care|"Caregiver training /standardised care: where the participants (caregivers)s are trained on caring for relative who has survived a stroke once only for one hour using a developed curriculum.~Plus Conventional care: where the participants continue to receive the usual care as offered in protocols for treatment of stroke in Zimbabwe."
89122107|NCT02569099|No Intervention|Control|No training offered to caregivers but conventional care only where the people who have survived a stroke receive the usual care as offered in protocols for treatment of stroke in Zimbabwe.
89122108|NCT04064203|Experimental|Totally pancreatectomized patients|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
89122109|NCT04064203|Experimental|Healthy controls|Oral glucose tolerance test + insulin-induced hypoglycaemic clamp followed by an oral glucose tolerance test
89122110|NCT02667015|Experimental|Anxiety Sensitivity Intervention|Group receives the 3-week, 6-session Anxiety Sensitivity Intervention. This is a 6-session psychotherapy occurring twice weekly (60-90 minutes) for three weeks. This psychotherapeutic treatment is focused on reducing anxiety sensitivity and includes many components, but primarily consists of psychoeducation about the relationship between anxiety and substance use disorders, interoceptive exposures, in vivo exposures, and cognitive challenging.
89122111|NCT02667015|No Intervention|Control Group|Receives only treatment as usual
88801683|NCT01187095|Active Comparator|Control|Neutral writing exercise
88801684|NCT01451840|Active Comparator|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of intravenous remifentanil before emergence of a desflurane-based anesthesia
89233311|NCT01639950||Adults Group 1|Adults patients with cancer or neurofibromatosis 1 (NF1)
89233312|NCT01639950||Adults Group 2|Adults with sickle cell disease (SCD)
88801685|NCT01451840|Experimental|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
88801686|NCT05496270||TME|patients only underwent TME
88801687|NCT05496270||nCRT+TME|patients underwent TME following neoadjuvant treatment
88801688|NCT01451918|Active Comparator|Resveratrol|
88801689|NCT01451918|Placebo Comparator|Placebo|
88801690|NCT01187329|Experimental|hyperinsulinemic normoglycemic clamp (HNC)|Patients will be randomized to receive treatment with HNC during cardiac surgery.
88801691|NCT01187329|Placebo Comparator|standard glucose management|Patients will be randomized to receive treatment with standard glucose management during cardiac surgery.
88801692|NCT04758182|Experimental|Experimental group|Experimental group: HILT + sham ultrasound therapy In the experimental group, participants received HILT treatment 1 session per day over a period of 2 consecutive weeks (5 days/week); total 10 sessions. In this study we used HIRO 3.0 device applied to the hemiplegic shoulder and the area of following muscles include upper trapezius, supraspinatus, deltoid, pectoralis minor muscles and the tender points. The treatment consisted of high peak power (3kW), a wavelength of 1064 nm. Two phases of treatment were performed according to Rotator cuff tendinopathy protocol of the device. The total energy administered will be approximately 2500 J. The total treatment time was approximately 10 minutes. They also received sham ultrasound therapy, which performed by applying probe with gel without turning on the device, for 10 minutes.
88801693|NCT04758182|Active Comparator|Control group|"Control group: sham HILT + ultrasound therapy In control group, participants received continuous ultrasound therapy for 10 minutes in the same area as an experimental group with Chattanooga intellect mobile ultrasound device. The device was operated at the frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100% in the same area of the HILT group. They also received sham HILT, by applying the applicator with pre-recorded sound without starting the device, for 10 minutes. Ultrasound therapy and sham ultrasound were delivered according to the predefined protocol by the physiotherapists.~Both groups received 3 ROM exercise sessions per day. Participants and their caregiver were educated about proper positioning and manual handling"
88801694|NCT02847728||Single Arm Design|The study encompasses a single arm design with 417 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 772 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.
88801695|NCT01146379|Experimental|Low Movement Dose, 3200 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
88801696|NCT01146379|Experimental|Medium Movement Dose, 6400 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
88801697|NCT01146379|Experimental|High Movement Dose, 9600 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
88801698|NCT01146379|Experimental|Individual Maximum High Movement Dose|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
88801699|NCT05490966|Experimental|Isometric fatigue|Fatiguing intermittent isometric exertions of trunk extensor muscles will be performed.
89233313|NCT01639950||Children|Children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
89233314|NCT01639950||Parents|Parents of children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
89233315|NCT01631617|Active Comparator|1A/Cephalexin|Cephalexin + Placebo bleach
89233316|NCT01631617|Active Comparator|1B/TMP/SMX|TMP/SMZ DS 800 /160 orally every 12 hours for 14 days
89233317|NCT01631617|Active Comparator|1C/Doxycycline 100|Doxycycline 100 mg orally every 12 hours for 56 days
89233318|NCT01631617|Active Comparator|1D/Doxycycline 20|Doxycycline 20 mg orally every 12 hours for 56 days
89233319|NCT01631617|Active Comparator|2A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
89233320|NCT01631617|Placebo Comparator|2B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
89233321|NCT01631617|Placebo Comparator|2C/Placebo capsules + Dilute bleach|Placebo capsules + dilute bleach study bath liquid
89233322|NCT01631617|Placebo Comparator|2D/Placebo capsules + Placebo bleach|Placebo capsules + placebo study bath liquid
89233323|NCT01631617|Active Comparator|3A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
88801700|NCT00378196|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
88801701|NCT00378196|Experimental|B|0.5 mg /0.05 ml dose of ranibizumab
88801702|NCT01188109|Experimental|Gemcitabine / Cisplatin|Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.
88801703|NCT01458080||Patients w/secondary thrombocytopenia related to hepatitis C|Patients w/secondary thrombocytopenia related to hepatitis C
88801704|NCT03980470|Other|Normal-dose versus Low-dose|"The standard intervention consists of the routinely performed cardiac CT datasets reconstructed with a standard iterative reconstruction algorithm (ASIR-V). Median radiation dose is about 0.5 mSv, range between about 0.2 and 1.2 mSv; median contrast agent administration about 45 mL, range between 35 and 55 mL.~The experimental intervention is an additional CT scan with a lower dose (about 20 to 50% decrease) and a similar contrast agent administration that is reconstructed with a deep-learning image reconstruction immediately after the clinical CT scan. The additional time required is about 5 minutes."
88801705|NCT01458158||Diabetic nephropathy|Diabetic nephropathy in patients with type 2 diabetes
89122112|NCT00737503|Experimental|1|All eligible children in the experimental arm will be vaccinated with the Rotavirus vaccine
89122113|NCT00737503|No Intervention|2|Children will not be vaccinated with rotavirus vaccine.
89122114|NCT00645879|Experimental|OKG, Glutamine, and Disodium Citrate|Ornithine Alpha Ketoglutarate for 4 weeks, followed by 2 week washout period. 4 weeks Glutamine, followed by 2 week washout period. 4 weeks Disodium Citrate, followed by 2 to 12 week washout period. Then continue an additional 30 weeks on Disodium Citrate (drug producing the best increment in plasma glutamine levels).
89122115|NCT04174287|Experimental|F-18-AV45|F-18-AV45 imaging
89122116|NCT00737659|Experimental|1|Concentration Controlled (CC)group will receive an individually adjusted MMF dosing regimen based on the plasma concentrations of mycophenolic acid (MPA,the active metabolite of mycophenolate mofetil).
89122117|NCT00737659|Active Comparator|2|Fixed dose (FD) group will receive an a priori set dose of 2mg\day MMF, the recommended dose, with a possible secondary adaptation by the clinician based on criteria of clinical efficacy, toxicity or interactions with other medications.
89122118|NCT02666703|Experimental|Study (CytoSorb)|In the study group (20 patients) the CytoSorb filter will be installed in the CPB in a parallel circuit. An additional roller pump will drive the blood through the filter with a constant flow of 400 ml/min (max flow).
89122119|NCT02666703|No Intervention|Control|In the control group (20 patients) no filter will be installed on the CPB.
88801706|NCT01458158||chronic glomerulonephritis|chronic glomerulonephritis in patients without diabetes mellitus
88801707|NCT01458158||controls|participants without diabetic nephropathy and chronic glomerulonephritis
88801708|NCT01458236|Experimental|BPS-314d-MR|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration.
88801709|NCT01458236|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group.
88801710|NCT01146457|Placebo Comparator|Placebo|
88801711|NCT01146457|Active Comparator|Morphine 25|
88801712|NCT01146457|Active Comparator|Morphine 50|
88801713|NCT01146457|Active Comparator|Morphine 75|
88801714|NCT01146457|Active Comparator|Morphine 100|
88801715|NCT04018924|Experimental|T - Treated|After standard cleansing or debridement of all wounds, on wound or portion of wound selected for treatment is treated with EmoLED device. Then covered with hydro fibre medication and dressing or compressive dressing when needed on the whole wound (SOC). Treatment is repeated once a week.
88801718|NCT05496114|Experimental|Intervention group: with checklist|When starting the scenario, a checklist will be given to the emergency physician. The checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
88801719|NCT05496114|No Intervention|Control group: without checklist|Emergency physicians will be asked to perform the scenario as they would in their daily practice. They will be allowed to use their usual cognitive aids (eg, phone, internet) but not allowed to request help from others.
88801720|NCT01452230|Experimental|Supervised physical activity|
88801721|NCT01452230|No Intervention|Usual care|
89122120|NCT02666703|Active Comparator|Corticosteroid|In the corticosteroid group (20 patients), 1 gram of methylprednisolone will be added in the priming solution of CPB machine. No filter will be installed on the CPB.
89122121|NCT04071249||Control|Patients who use symptomatic medication as therapy for their allergic rhinoconjuntivitis as recommended by their physician
89122122|NCT04174209|Experimental|Cohort 1|70 patients are involved and will perform the three conditions.
88801722|NCT04011436|Experimental|Core, Hip and knee.|Physical Exercises to strengthen the core, hip and knee.
88801723|NCT04011436|Sham Comparator|Hip and Knee|Physical Exercises to strengthen the hip and knee.
88801724|NCT04272866|Active Comparator|Group 1|Teeth in this group will be sealed with clinpro sealant
88801725|NCT04272866|Experimental|Group2|Teeth in this group will be sealed with embrace wetbond sealant
88801726|NCT04272866|Experimental|Group3|Teeth in this group will be sealed with triage sealant
88801727|NCT04267536||Participants treated with upadacitinib monotherapy|Participants will receive upadacitinib for 12 months as prescribed by the physician
89122123|NCT02666859|Experimental|Unilateral Transradial Amputation|This group includes people with a unilateral transradial amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
89122124|NCT02666859|Experimental|Unilateral Transhumeral Amputation|This group includes people with a unilateral transhumeral amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
89122125|NCT02666625||Patients treated for cancer in childhood|
89122126|NCT02666937||ICU-patients (prospective)|Critically ill patients (18 years and older) on mechanically ventilation who have an arterial line and require bloodgasanalysis for medical reasons
89122127|NCT02666937||Emergency Department (prospective)|Patients (18 years and older), who are presented to the Emergency Department, and require bloodgasanalysis for medical reasons
89122128|NCT02666937||Pulmonary department (prospective)|Patients (18 years and older) who visit the outpatient clinic of the pulmonary department for different pulmonary functional test and require bloodgasanalysis for medical reasons
89122129|NCT02666937||Pulmonary department (retrospective)|Patients (18 years and older) who visited the outpatient clinic of the pulmonary department in the past of the VU medical centre in Amsterdam or the Medical Centre Alkmaar for different pulmonary functional test and required bloodgasanalysis for medical reasons
89122130|NCT04936815|Experimental|Echocardiographic screening|Echocardiographic screening for the detection of latent structural heart disease
89122131|NCT04936815|No Intervention|Control arm|Routine antenatal care
89122132|NCT00645957|Active Comparator|2|This group will have a red rubber drain(s) placed during surgery. This drain(s) will be irrigated intra and post-operatively
89122133|NCT00645957|Active Comparator|1|This group will have a penrose drain(s) placed during surgery to facilitate drainage post-operatively. This drain (s) will not be irrigated.
89122134|NCT02666391|Experimental|UCMSCs|Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)
89122135|NCT02666391|No Intervention|controls|Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion
89122136|NCT02537067|Experimental|Autologous cultured Chondrocyte|Subjects who give consent will be screened and those who meet trial criteria will receive CHONDRON (Autologous cultured Chondrocyte) by transplant.
89122137|NCT04174131|Experimental|Treatment A (right) B (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
89122138|NCT04174131|Experimental|Treatment B (right) A (left)|Subjects will receive Restylane + Lidocaine and Restylane Lyft. One product will be randomized, per NLF.
89122139|NCT04173897|Experimental|Intervention arm|12 weeks access to LIBERATE online supportive intervention (dose not specified) including symptom monitoring questionnaire component, with questionnaire results integrated within electronic medical records for clinician review.
89122140|NCT04173897|No Intervention|Waiting list control arm|Care and support as usual; no access to intervention. Placed on waiting list to receive intervention following study completion.
89122141|NCT04174053|Experimental|Temperature measurement|"enteric capsule will be ingested every 24 hours during aplasia. Temperature measurement will be made continuously during aplasia.~In parallel, auricular temperature will be measure every 4 hours during aplasia."
89122142|NCT00646035|Placebo Comparator|A|
89122143|NCT00646035|Placebo Comparator|B|
89122144|NCT02666469|Active Comparator|Group A Hyperbaric Oxygen Therapy and Exercise Program|Group A: Hyperbaric Oxygen Therapy (HBOT) and Exercise with HBOT sessions for 90 minutes, once daily, 5 times a week for 8 consecutive weeks. HBOT will be provided with 100% oxygen at 2.0 ATA. Patients will exercise in the multiplace hyperbaric chamber while receiving hyperbaric oxygen.
89122145|NCT02666469|Active Comparator|Group B Exercise Program|Group B: Exercise Program in the hyperbaric medical unit without exposure to HBOT
89122146|NCT02666235|Active Comparator|Remote ischaemic conditioning|Intermittent inflation of a forearm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a curtain.
89122147|NCT02666235|Sham Comparator|Control group|Sham intervention: Arm cuff placement but without inflation during a 40 minute period. A curtain will obscure the patient from the clinical team during this time. Arm cuff placement, no inflation.
89122148|NCT04068909||acute coronary syndrome|All patients should receive standard therapy for acute coronary syndrome and concomitant diseases. All drugs are prescribed according current guidelines and approved indications.
89122149|NCT00646191|Active Comparator|A|
89122150|NCT00646191|Active Comparator|B|
88805890|NCT03012113|Active Comparator|Mirabegron|Subjects will receive one dosage of 200 mg Mirabegron (Astellas Pharma).
89122151|NCT00646191|Active Comparator|C|
89122152|NCT02666079|Experimental|Treatment arm|Wide local excision (WLE) for breast cancer with intra-operative use of the LightPath® Imaging System.
89122153|NCT02666157|Active Comparator|Dabigatran|oral dabigatran etexilate capsule 110 or 150 mg (110 mg in specific population) bid for entire study period
89122154|NCT02666157|Active Comparator|Rivaroxaban|oral rivaroxaban film-coated tablet 15 or 20 mg (10 or 15 mg in specific population) qd for entire study period
89122155|NCT02666157|Active Comparator|Apixaban|oral apixaban 5 mg (2.5 mg in specific population) bid for entire study period
89122156|NCT04067973||patients|"Premature subjects benefit from the examinations described in the protocol, namely automated refractometry, intraocular air pressure, biometrics (with axial length and pachymetry (corneal thickness) performed by the same machine at the same time), a photo of the fundus (retinophotography) and an OCT RNFL. These examinations are necessary for the follow-up of premature children.~All children examined at Nantes University Hospital benefit systematically from: automated refractometry, intraocular pressure in the air and a photo of the fundus."
89122157|NCT04067973||control|"controls benefit from two additional tests: RNFL OCT and biometrics. The duration of the RNFL OCT is about 2 minutes, with a total of 10 seconds per eye, the rest being computer manipulation.~The biometrics take about 2 minutes to complete, with a total of 30 seconds per eye, the rest being computer manipulation.~These two reviews are conducted on the same day as the initial consultation and directly following the consultation."
89122158|NCT00646269|Active Comparator|1|
89122159|NCT00646269|Experimental|2|
89122160|NCT00646269|Experimental|3|
89122161|NCT00646269|Experimental|4|
89122162|NCT02666001|Experimental|Part 1 (BMS-663068+methadone)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of methadone
89122163|NCT02666001|Experimental|Part 2 (BMS-663068+buprenorphine and norbuprene)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of buprenorphine and norbuprenorphine
89122164|NCT02665845|Experimental|5-ASA group|Patients will receive corticosteroids with optimized 5-ASA.
89122165|NCT02665845|Active Comparator|Control group|Patients will receive corticosteroids alone.
89122166|NCT00646347|Experimental|A|Conventional stroke upper limb rehabilitation is given
89122167|NCT00646347|Active Comparator|B|Neuro Hand Orthosis Program is given
89122168|NCT00646425|Experimental|1|Basiliximab
89122169|NCT00646425|Placebo Comparator|2|
89122170|NCT02665767|No Intervention|On-site sonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an onsite expert.
89122171|NCT02665767|Active Comparator|Smartphone-based Telesonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an offsite expert.
89122172|NCT04173351|Experimental|Intervention|Pregnant women in intervention group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Date of the next antenatal follow-up of the participants in the intervention group was recorded and they were given an appointment for the antenatal education. Women, whose date of next antenatal follow-up was unknown, were asked to inform the researchers about their appointment. Following the antenatal follow-up, the pregnant women in the intervention group were given an antenatal childbirth education and an educational brochure after the education. Also, provided telephone counseling to the intervention group one week after the education. Participants in the intervention group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
89122173|NCT04173351|No Intervention|Control|Pregnant women in control group completed the PIQ, W-DEQ-A and CAQ between the 28th and the 34th gestational weeks. Participants in the control group filled the W-DEQ-A and CAQ during the 38th and the 40th gestational weeks. Finally, were completed the W-DEQ-B during the first and the second postnatal days.
89122174|NCT02665533|Active Comparator|Dexamethasone|Dexamethasone 8 mg, one capsule single preoperative dose.
89122175|NCT02665533|Experimental|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg, one capsule single preoperative dose.
89122176|NCT02665611|Experimental|intervention group|"intervention for improvement of treatment adherence Intervention group- This group will be followed by the MOMA call center (By the MOMA nures every couple weeks and by the study coordinatore and the treating Doctor at special visits as the study required.) The group will be monitored according to number of parameters, including treatment Adherence."
89122177|NCT02665611|Experimental|control group|"treatment as usual Control group- Treatment will continue as usual by the Doctor.(This group will allso be followed by the Study Coordinator at the same visits as the Intervention group.The group will be monitored according to number of parameters, including treatment Adherence."
89122178|NCT00646503|Experimental|1|600 mg/day, oral telbivudine for 52 weeks
89122179|NCT04173039|Other|Controls|Patients with psoriasis and without psoriatic arthritis.
89122180|NCT04173039|Other|Cases|Patients with psoriatic arthritis and with personal or familial psoriasis.
89122181|NCT02663661|Other|Autoantibody negative subjects|Subjects who are relatives of persons with T1DM and have tested negative for autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test.
89122182|NCT02663661|Other|One autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for one autoantibody will have a Metabolic Challenge Admission followed by a CGM home test..
89122183|NCT02663661|Other|Two or more autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for two or more autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test..
89122184|NCT00648531|Experimental|1|Balsalazide Disodium Capsules 750 mg
89122185|NCT00648531|Active Comparator|2|Colazal® Capsules 750 mg
89122186|NCT04171713|Experimental|Grup 1|MBHP protocol + TAU
89122187|NCT04171713|Experimental|Grup 2|ABCT protocol + TAU
89122188|NCT04171713|Active Comparator|Grup 3|TAU
89122189|NCT04171401||Participants post stroke|Severly affected patients in the subacute phase post stroke that are unable to walk without the help of one or two therapists to assist for balance and weight-carrying. Participants were able to sit independently for two minutes. Participants post stroke performed limits of stability testing in sitting, and tests for trunk control and functional balance.
89122190|NCT04171401||Healthy controls|Healthy control subjects who matched patients post stroke for age and gender, and had no limitations to perform measurements. Healthy controls performed limits of stability measurements and a clinical measurements for balance.
89122191|NCT00648609||Home-based palliative care services|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
89122192|NCT00648609||Standard of care|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
89122193|NCT00648687|Experimental|I|this group will receive oral water and glucose prior to eye exam
89122194|NCT00648687|No Intervention|II|this group is the control group.
89122195|NCT00648765|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
89122196|NCT00648765|Active Comparator|2|Agrylin® Capsules 1 mg
89122197|NCT04171557||Patients with diabetes at the baseline assessement in EPIC|Self-reported and confirmed diabetes (validated by a second source (at least 1), including repeated self-report, contact with physician, linkage to register later point, intake of diabetes medicine, registration of diabetic chiropody, baseline glycated hemoglobin>=6.0%, five annual blood glucose measurements or two blood glucose measurements per year for five consecutive years) cases were included in the analyses. No information is available to distinguish between type 1 and type 2 diabetes across the population but type 1 is rare by comparison.
89122198|NCT02663583||Intensity-Modulated Proton Therapy or( IMPT) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
89233324|NCT01631617|Placebo Comparator|3B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
89122199|NCT02663583||TransOral Robotic Surgery (TORS) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
89122200|NCT04171245|Experimental|Experimental|One minute laughter prescription 3x a day Tracking sleep using equipment
89122201|NCT04171245|Active Comparator|Control|Tracking sleep using equipment
89122202|NCT02663427|Experimental|PG(-) and Hp(-) Group|PG negative （pepsinogen（PG）Ⅰ > 70ng/ml or PGⅠ/PGⅡ >7.0）and Hp (helicobacter pylori) negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
89122203|NCT02663427|Experimental|PG(-) and Hp(+) Group|PG negative and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
89122204|NCT02663427|Experimental|PG(+) and Hp(-) Group|PG positive (PGⅠ ≤ 70ng/ml and PGⅠ/PGⅡ≤7.0) and Hp negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
89122205|NCT02663427|Experimental|PG(+) and Hp(+) Group|PG positive and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
89122206|NCT02663505||Group 1|Patients receiving either elective or emergency surgery.
89122207|NCT00648843|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
89122208|NCT00648843|Active Comparator|2|Ditropan XL® Tablets 5 mg
89122209|NCT02663115||Arm 1|Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by ischemic or dilatative myocardiopathy with indication for left ventricular assist device (LVAD) therapy
89122210|NCT02663115||Arm 2|Patients (age 40-70 years) with the indication for elective bypass surgery and normal left ventricular function (EF>50%)
89122211|NCT02663193||Enzalutamide Group|Participants who are receiving enzalutamide in a clinical practice setting will be observed for tolerability and quality of life.
89122212|NCT02663193||Abiraterone Acetate plus Prednisone group|Participants who are receiving abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
89122213|NCT02663037||1|"Subjects will be recruited from a pool of elderly patients who present to the Emergency Department.~To be eligible for participation in the study, patients must meet ALL of the following criteria:~Age ≥ 55 years old~Triaged as P2 or P3 in the Emergency Department~Singapore citizen or Permanent Resident~Provision of Informed consent~Not previously already enrolled in this study"
89122214|NCT02662959|Experimental|Irinotecan|In the experimental arm, patients receive single agent of irinotecan as third line treatment in metastatic gastric cancer.
89122215|NCT02662647|Experimental|DCAG plus HLI|Patient will be treated with decitabine and modified CAG regimen followed by HLA haploidentical peripheral mononuclear blood cells infusion.
89122216|NCT02662647|Experimental|DCAG|Patient will be treated with decitabine combining modified CAG regimen without other treatments.
89122217|NCT02662725|Experimental|ipilimumab + Stereotactic Radiosurgery|ipilimumab combined with a Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases
89122218|NCT00648921|Experimental|1|Olanzapine Tablets 5 mg
89122219|NCT00648921|Active Comparator|2|Zyprexa® Tablets 5 mg
89122220|NCT02662803|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
89122221|NCT02662803|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
89122222|NCT02662491|Experimental|vitamin D and calcium|daily oral vitamin D(3) (2000 IU) and calcium (600 mg) for 6 months
89122223|NCT02662491|Experimental|Calcium supplement|daily oral calcium (600 mg) for 6 months
89122224|NCT02662491|Experimental|vitamin D supplement|daily oral vitamin D(3) (2000 IU) for 6 months
89122225|NCT02662491|Placebo Comparator|Placebo|daily placebo tablet for 6 months
89122226|NCT04171011|Experimental|Nerve Stimulation|Participants will undergo brief NVB stimulation during the esophagectomy procedure.
89122227|NCT02662335|Experimental|Arm I (computer-assisted cognitive training)|Patients complete a computerized working memory training program (Cogmed) over 35 minutes a day, 5 times a week for 6 weeks.
89122228|NCT02662335|Active Comparator|Arm II (wait-list)|Patients undergo standard follow-up care for 6 weeks. Following standard follow-up care, patients may complete Cogmed as in the Intervention Group in weeks 7-13.
89122229|NCT02662101|Experimental|Single arm, exsalt application|
89122230|NCT00648999|Active Comparator|1|
89122231|NCT00648999|Active Comparator|2|
89122232|NCT02662179||Elderly patients with solid tumors|The group will include elderly patients with a malignant solid tumor: ovary cancer, breast cancer, digestive cancer (colo-rectal, pancreas), lung cancer or urinary tract cancer (including bladder cancer).
89122233|NCT02661945|Experimental|Near focus with narrow band imaging|Near focus with narrow band imaging is used for marking the tumor margin.
89122234|NCT02661945|No Intervention|Indigo carmin|After indigo carmine was sprayed over the lesion, marking is performed.
89122235|NCT02661867||VD|Vaginal delivery group - women who gave birth of offspring through the vagina without the use of special instruments such as forceps or a vacuum extractor (instrumental vaginal delivery)
89122236|NCT02661867||CS|Cesarean section group - women delivered by surgical procedure in which one or more incisions are made through a mother's abdomen and uterus to deliver a baby. Cesarean section is performed when a vaginal delivery would put the baby's or mother's life or health at risk.
89122237|NCT02661711|Experimental|Aflibercept (Eylea)|All patients recruited to the study will receive 3 loading intravitreal injections of Aflibercept (Eylea) at monthly intervals followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow-up will occur when there is evidence of OCT stability in the view of the investigator i.e. there is no further reduction in macular fluid compared to the previous visit. All patients will receive 5 injections before considering them non-responders.
89122238|NCT02661789|Active Comparator|GnRHa|Goserelin 3.6 mg implant
89122239|NCT02661789|Placebo Comparator|Placebo|Injection of saline
89122240|NCT02661555|Experimental|Aerobic exercise|Aerobic exercise two times per week for 24 weeks.
89122241|NCT02661555|No Intervention|Habitual lifestyle|Habitual lifestyle the first 24 weeks. Will be offered the same exercise intervention after 24 weeks.
89122242|NCT02661633||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
89122243|NCT02661633||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
89122244|NCT02661477|Other|pegylated interferon + placebo|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ). Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will receive subcutaneous placebo (0,9% NaCl) injection once a week, two times.
89122245|NCT02661477|Other|placebo + pegylated interferon|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive will receivesubcutaneous placebo(0,9% NaCl) injection once a week, two times. Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).
89122246|NCT02661243|Other|Dentate Sjogren's syndrome arm|30 human adults affected by SS with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
89122247|NCT02661243|Other|Dentate healthy controls arm|30 healthy human adults with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
89122248|NCT02661243|Other|Edentulous Sjogren's syndrome arm|30 human edentulous adults affected by SS with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
89122249|NCT02661243|Other|Edentulous healthy controls arm|30 healthy human edentulous adults with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
89122250|NCT02661087|Experimental|Bipolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of bipolar energy
89122251|NCT02661087|Active Comparator|Monopolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of monopolar energy
89122252|NCT02661009||Plasma and tissue matching|
89122253|NCT02661009||predicting clinical efficacy|
89122254|NCT04170699|Experimental|PECS 1 Block|40 patients who had PECS 1 block for peroperative analgesia in port-a-cath replacement. All patients will receive IV Midazolam (0.05mg/kg) premedication. Standard monitorization of EKG, non- invasive blood pressure and pulseoximeter will be done and recorded in every 5 minutes. After sedation and standard monitorization, 20 minutes before the intervention and in the supine positon the PECS 1 block will be done. 10 % povidone - iodin will be used for sterilization and the USG probe will be covered with sterile sheath. The block will be done as a single injection of local anaesthetic between pectoralis major and pectoralis minor muscles at the level of the 3rd rib to anaesthetise the lateral and medial pectoral nerves. The USG probe will be replaced inferior to the clavicle. Identify the pectoralis muscles with the axillary artery and axillary vein on sonography. The brachial plexus should be visible underneath. After confirmation with 20 mL %0.25 bupivacaine will be administered.
89122255|NCT04170699|Experimental|Infiltrative Anesthesia|40 patients who had port-cath replacement will receive infiltrative anesthesia.
89122256|NCT00601419||Somatropin|Patients administered Somatropin.
89122257|NCT04170387|Experimental|Relaxometer fibromyalgia cases|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
89122258|NCT04170387|Active Comparator|Relaxometer controls|Repetition 6 minutes pre-set programme with the relaxometer 60 seconds 34 movements/minute 3 seconds 55 movements/minute 60 seconds 34 movements/minute 60 seconds 55 movements/minute 90 seconds 34 movements/minute 5 seconds 55 movements/minute 90 seconds 34 movements/minute
89122259|NCT02660931|Experimental|AKI Risk Notification|Patients randomized to this arm will be eligible for an acute kidney injury risk notification, if their calculated risk exceeds the threshold during their inpatient encounter.
89122260|NCT02660931|No Intervention|Usual Care|These patients will receive usual clinical care, with no acute kidney injury risk notification.
89122261|NCT02660697|Active Comparator|Test - Extraction site development group|In the test group 29 healthy patients presenting 33 single rooted teeth scheduled for extraction with Extraction Defect Sounding (EDS) Class 3-4 type buccal bony dehiscences were included. 29 maxillary single rooted teeth and 4 single rooted teeth in the mandible (27 incisors, 2 canines and 4 premolars) were removed and treated by the novel extraction site development method. Pre- and postoperative ConeBeam Computer Tomography (CBCT) data were collected for further analysis.
89122262|NCT02660697|No Intervention|Control - Spontaneous healing group|In the control group. pre- and postextraction CBCT data sets of 14 patients with 21 extracted teeth were collected. 11 maxillary single rooted teeth and 10 single rooted teeth in the mandible (13 incisors, 2 canines and 6 premolars) were extracted and left for spontaneous healing.
89122263|NCT02660541|Active Comparator|Betafoam|Brand name: Betafoam® This is a medicated device (dressing) consisting of 3% povidone iodine.
89122264|NCT02660541|Active Comparator|Allevyn Silver dressing|Brand name: Allevyn® Silver
89122265|NCT00649077|Experimental|1|Meloxicam Tablets 15 mg
89122266|NCT00649077|Active Comparator|2|Mobic® Tablets 15 mg
89122267|NCT02660619||Low-risk patients|These will be patients with a prescription for opioids for chronic pain for at least 30 days, recruited from university-affiliated pain and rehabilitation medicine clinics that routinely employ precautions to avoid prescribing such medication to individuals seeking it for non-therapeutic reasons
89122268|NCT02660619||High-risk patients|These patients will be in treatment for addiction to opioids and have (or have had) a prescription of opioids to treat pain.
89122269|NCT02660307|Experimental|PROGRESS group|this group received the intervention based in meditation in the first 8 weeks. They were instructed to practice at least 5 times a week for up to half an hour a day. During the second 8 week period this group were left to manage their practice on their own.
89122270|NCT02660307|Other|control group|this group received no intervention in the first 8 weeks. During the second 8 week period, this group received the same intervention based in meditation that received PROGRESS group.
89122271|NCT02656251|Active Comparator|0.12% Clorhexidine with alcohol|0.12% Clorhexidine with alcohol, 15ml every 12 hour for 4 days
89122272|NCT02656251|Experimental|0.12% Clorhexidine without alcohol|0.12% Clorhexidine without alcohol, 15ml every 12 hour for 4 days
89122273|NCT02656251|Placebo Comparator|control|placebo 15ml every 12 hour for 4 days
89122274|NCT00649935|Experimental|1|Azithromycin Tablets 600 mg
89122275|NCT00649935|Active Comparator|2|Zithromax® Tablets 600 mg
89122276|NCT02655939|Active Comparator|Reflex Plus|Reflex Plus TM, Sachets to be taken once in a day Before breakfast for the study duration
89122277|NCT02655939|Placebo Comparator|Placebo|Placebo Sachets to be taken once in a day Before breakfast for the study duration
89122278|NCT02655783|Active Comparator|control|normal saline, 250 ml/h, until expulsion of placental
89122279|NCT02655783|Experimental|intervention|normal saline + 5% dextrose, 250 ml/h, until expulsion of placental
89122280|NCT04421313|Experimental|Rhumatoid Arthritis|The patients with Rheumatoid arthritis receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
89122281|NCT04421313|Placebo Comparator|Control Subjects|The patients with Control Subjects receive 12 g/day of INULIN or 10,5g/day of maltodextrine during 30 days
89122282|NCT02655705|Active Comparator|Cyclosporine A|Cyclosporine 200 mg/day (male) and 150 mg/day (female) orally, divided twice daily for 16 weeks
89122283|NCT02655705|Active Comparator|Methotrexate|Methotrexate was started with 10 mg/week orally as a single dose, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
89122284|NCT02655861||Ichthyosis|
89122285|NCT02655627|Experimental|Group A|Usual Care Group: A brochure which emphasis the importance of physical activity and exercise in Type 2 DM will be given to the patients in this group after the evaluation.
89122286|NCT02655627|Experimental|Group B|Supervised Clinical Exercise Training Group: Patients in this group will continue group exercise training includes aerobic and resistance training, 1 hour in a day, 3 times in a week for 8 weeks with the supervision of a researcher physiotherapist.
89122287|NCT02655627|Experimental|Group C|Internet Based Exercise Training Group. the patients to this group will be a member of the web site named www.diyabetvehareket.com. The participation of the patients will be provided with the videos directing them to 1 hour in a day, 3 times in a week for 8 week both aerobic and resistance exercise training from the researcher physiotherapist.
89122288|NCT02655471|Experimental|HTLV-1 plus Tropical Spastic paraparesis|"Patients with recent onset of Tropical Spastic paraparesis due HTLV-1 will receive combination of Raltegravir and Zidovudine during 48 weeks"
89122289|NCT04418037|Experimental|Single arm using the Digital Health Feedback System|This protocol is designed to evaluate a novel technology that employs an ingestible sensor to detect medication ingestion for use by persons initiating or restarting antiretroviral (ARV) treatment for HIV infection during a hospital admission.
89122290|NCT02655549|Experimental|Cohort 1 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
89122291|NCT02655549|Experimental|Cohort 2 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
89122292|NCT02655549|Experimental|Cohort 3 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
89122293|NCT04168749||local compounding group|the first 100 preterm babies born as from January 1 2015 with a birth weight between 1250-2000g that received at least 10 days of TPN.
89122294|NCT04168749||Numeta G13 group|the first 100 preterm babies as from January 1 2017 with a birth weight between 1250-2000g that received at least 10 days of TPN
89122295|NCT00650013|Experimental|1|Midodrine HCl Tablets 5 mg
89122296|NCT00650013|Active Comparator|2|ProAmatine® Tablets 5 mg
89122297|NCT02655159||Abraxane® treatment in patients with metastatic breast cancer|Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.
89122298|NCT04168905|Experimental|Active arm|After receiving standard treatment and AOTI Inc. TWO2 topical oxygen therapy equipment training, patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
89122299|NCT04168905|Placebo Comparator|Controlled arm|patients receive standard treatment.
89122300|NCT00712933|Experimental|1|1 mg/kg dose of belimumab given IV every 28 days.
89122301|NCT00712933|Experimental|2.|10 mg/kg dose of belimumab given IV every 28 days.
89122302|NCT02654847|Active Comparator|Norepinephrine 3 micrograms/mL|1mL of a solution of norepinephrine, containing 3 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
89122303|NCT02654847|Active Comparator|Norepinephrine 4 micrograms/mL|1mL of a solution of norepinephrine, containing 4 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
89122304|NCT02654847|Active Comparator|Norepinephrine 5 micrograms/mL|1mL of a solution of norepinephrine, containing 5 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
89122305|NCT02654847|Active Comparator|Norepinephrine 6 micrograms/mL|1mL of a solution of norepinephrine, containing 6 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
89122306|NCT02654847|Active Comparator|Norepinephrine 7 micrograms/mL|1mL of a solution of norepinephrine, containing 7 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
89122307|NCT02654847|Active Comparator|Norepinephrine 8 micrograms/mL|1mL of a solution of norepinephrine, containing 8 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
89122308|NCT02654925||Young Men|men 21-40 years of age
89122309|NCT02654925||Young Women|women 21-40 years of age; young women will be premenopausal and eumenorrheic, not on hormonal contraceptive therapy.
89122310|NCT02654925||Older Men|men 55-100 years of age
89122311|NCT02654925||Older Women|women 55-100 years of age; older women will be postmenopausal who are at least 12 months past the final menstrual period (FMP).
89122312|NCT02536209|Experimental|Regimen 1|Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing
88801728|NCT04267536||Participants treated with upadacitinib in combination with MTX|Participants will receive upadacitinib in combination with MTX as prescribed by the physician for 12 months
89122313|NCT02536209|Experimental|Regimen 2|Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing
89122314|NCT02536209|Experimental|Regimen 3|Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing
89122315|NCT02536209|Experimental|Regimen 4|Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing
89122316|NCT02568631|Experimental|serious game JeStiMulE|"Evaluation of the social cognition for adults with autism.~The objective of the players of JeStiMulE (Educational Game for Multisensory Stimulation of Children with developmental disorders) will be to end the game after a period of learning and two periods of game (with emotional words and with idiomatic expressions understanding each three modules). The session ends when the module is carried out, what corresponds approximately at 1 am by module, that is 6 sessions of game.~Evaluation of the social cognition for adults with autism."
89122317|NCT02568631|Placebo Comparator|control video game|"Evaluation of the social cognition for adults with autism.~The objective of the players of the control video game will be to play 6 sessions of one hour.~Evaluation of the social cognition for adults with autism."
89122318|NCT02655003|Experimental|INH (Intervention Nursing Homes)|TIME consists of a manual based multicomponent program which includes a rigorous assessment, the treatment, and the evaluation of NPS. The staff, physicians and nursing home managers in the intervention nursing homes will receive a one-day education program. Three nurses from each unit will receive further education including practical and theoretical training for three hours.
89122319|NCT02655003|Active Comparator|CNH (Control Nursing Homes)|A brief two hours education-only intervention about dementia and NPS will be given to the staff in for the control nursing homes (CNH). The staff and physicians in the control nursing homes continue practice as usual.
89122320|NCT00739921|Experimental|1|"Patients with sinusitis compared to patients without.~To find out if any specific type of fungus or mold is correlated with chronic sinus disease. The study will add new information about the different types of fungus and mold found in the human nose."
89122321|NCT02655081|Experimental|Dietary supplement|Subjects will receive high arginine nutritional supplement (Nestle's Impact AR), prior to cystectomy
89122322|NCT04168827||Relatives of severe traumatized child|Relatives of a child who has been hospitalized in intensive care of Necker hospital following a severe trauma
89122323|NCT00740155|Experimental|Group 1|
88801729|NCT04346498|Experimental|CB-SSC|The participant received CB-SSC for 2 hours per day for three consecutive days
88801730|NCT04346498|Placebo Comparator|CC-SSC|Following a 30 minute washout time, the same participant would continue to receive chest-to-chest (CC) SSC for 2 hours. This was also conducted for three consecutive days
89122324|NCT00740155|Experimental|Group 2|
89122325|NCT00740155|Experimental|Group 3|
89122326|NCT00740155|Experimental|Group 4|
89122327|NCT00740155|Active Comparator|Group 5|
89122328|NCT00732745|Experimental|Phase II arm I|Patients receive docetaxel IV over 1 hour on days 1 and 8, oxaliplatin IV over 2 hours on day 1, and oral vandetanib (at the maximum tolerated dose determined in phase I) once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
89122329|NCT00732745|Active Comparator|Phase II arm II|Patients receive docetaxel and oxaliplatin as in arm I. Patients also receive an oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
89122330|NCT02654457||Women with Breast Cancer #1|IVD Study
89122331|NCT02654457||Women with Breast Cancer #2|IVD Study
89122332|NCT02654457||Women with Breast Cancer #3|IVD Study
89122333|NCT00732823|Placebo Comparator|Profile A|No device worn
89122334|NCT00732823|Active Comparator|Profile B|Foot 40 mmHg, ankle 40 mmHg, mid-calf 35 mmHg, upper calf 30 mmHg
88801731|NCT02892890|Experimental|patients with CIDP|
88801732|NCT05495958|Placebo Comparator|Prescribe topical placebo eye drop|
88801733|NCT05495958|Active Comparator|Prescribe topical Vitamin D eye drop|
88805891|NCT03012113|Placebo Comparator|Placebo|Subjects will receive one dosage of Placebo, which is packed and labeled to mach the active compound.
89122335|NCT00732823|Active Comparator|Profile C|Foot 50 mmHg, ankle 50 mmHg, mid-calf 45 mmHg, upper calf 40 mmHg
89122336|NCT00732823|Active Comparator|Profile D|Foot 60 mmHg, ankle 60 mmHg, mid-calf 55 mmHg, upper calf 50 mmHg
89122337|NCT02654613|Active Comparator|Quality Improvement Intervention|In intervention clinics, staff will follow QI methodology to undertake a detailed assessment of their HIV-TB care and to prioritize the steps to improve treatment outcomes. A senior nurse will be identified to be the QI champion and will be trained by the study team to fulfil this role. The QI champion in the clinic then provides peer-leadership, mentorship and support for the implementation of the prioritized changes until the checklist is complete and all integrated HIV-TB service components meet the required standard.
89122338|NCT02654613|No Intervention|Control Standard of Care|The control arm will continue with the usual support that is received for HIV-TB service integration
89122339|NCT00737815|Active Comparator|A|Magnesium citrate: a total of 500 mg of elemental magnesium
89122340|NCT00737815|Placebo Comparator|B|Placebo pills
88801734|NCT04011592|Experimental|Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)
88801735|NCT04011592|Experimental|Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)
88801736|NCT01452386||Experimental Group|
89122341|NCT02654379||Cohort|Cohort consisting of participants who are in the center to receive an infusion for rituximab for a non-oncology indication.
89122342|NCT04065373|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored a common peripheral IV site over a 24 hour observation period.
89122343|NCT00732979|Experimental|A|Infrahepatic inferior vena cava clamping The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
89122344|NCT00732979|Active Comparator|B|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
89122345|NCT02654301|Placebo Comparator|Control group|sucrose drink (Control, sucrose 50g + deionized water 100g)
89122346|NCT02654301|Active Comparator|5 g xylose group|5 g xylose (Test 1, sucrose : xylose = 10:1),
89122347|NCT02654301|Active Comparator|3.33 g xylose group|3.33 g xylose (Test 2, sucrose : xylose = 15:1)
89122348|NCT02654301|Active Comparator|2.5 g xylose group|2.5 g xylose (Test 3, sucrose : xylose = 20:1)
89122349|NCT04349007|Active Comparator|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in
89122350|NCT04349007|Experimental|School food ready-to-use|peanut-based school food ready-to-use
89122351|NCT04349007|Experimental|School food ready-to-use plus Milk|peanut-based school food ready-to-use with milk
89122352|NCT04341129|Experimental|Abbreviated MRI using Dotarem|Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. The shorter imaging times achieved with the abbreviated DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol using Dotarem® (Gadoterate Meglumine) by comparing the diagnostic accuracy of dynamic contrast-enhanced breast MRIs performed with an abbreviated protocol versus a full protocol.
89122353|NCT00712543|Experimental|1|Kristalose®, as prescribed, for 7 days.
89122354|NCT00712543|Experimental|2|Liquid lactulose, as prescribed, for 7 days.
89122355|NCT00740311|Experimental|Filling|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
89122356|NCT00740311|No Intervention|Without filling|
89122357|NCT00650169|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
89122358|NCT00650169|Active Comparator|2|Plavix® Tablets 75 mg
89122359|NCT04064125|Experimental|FMX-101|
89122360|NCT02653989|Experimental|MDV9300|
89122361|NCT04168515||Patient|
89122362|NCT04168515||Caregiver|
89122363|NCT04168515||Healthcare provider|
89122364|NCT00740545|Placebo Comparator|2|
89122365|NCT00740545|Experimental|1|
89122366|NCT02653833|Experimental|Healthy Controls (HC)|Healthy men currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. This is repeated at baseline and shortly after taking beetroot juice extract.
88801737|NCT01452386||Control Group|
89122367|NCT02653833|Experimental|Becker Muscular Dystrophy (BMD)|"currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. Using a lower body negative pressure (LBNP) chamber, the subjects are tested for impaired exercise induced vasodilation to the skeletal muscle or functional sympatholysis. This is repeated at baseline and shortly after taking beetroot juice extract."
89122368|NCT00733057|Experimental|1|Minocycline treatment
89122369|NCT00733057|Placebo Comparator|2|Placebo
89122370|NCT04168359|Experimental|Semi-barbed Sutures Localization Group|Patients with pulmonary nodules requiring CT-guided puncture positioning before thoracoscopic surgery
89122371|NCT04168593|Sham Comparator|A- Placebo|Sham Acupuncture and Sham Cupping
89122372|NCT04168593|Active Comparator|B -Cupping|Sham Acupuncture and Real Cupping
89122373|NCT04168593|Active Comparator|C - Acupuncture|Real Acupuncture and Sham Cupping
89122374|NCT04168593|Active Comparator|D - Acupuncture + Cupping|Real Acupuncture and Real Cupping
89122375|NCT02569021||Biphasic DBS stimulations|Subjects in this group will have Biphasic DBS stimulation setting performed, Unified Parkinson's Disease Rating Scale (UPDRS), Tremor Rating Scale (TRS), kinesia accelerometer assessment, Trigno wireless system (EMG) assessment and GaitRite walking assessment performed.
89122376|NCT04168281|Experimental|PCI- free after response to radical chemoradiotherapy|Patients with no metastases will be followed-up with MRI: at the qualifying visit before MRI-1, and then every 6 months +/- 2 weeks), the patients will have a cognitive examination performed using dedicated neuropsychological tests and QoL assessment using the QLQ-C30 questionnaire. The tests will be conducted in the following order: California verbal learning test (CVLT) with a delay of 15 min, Color connection test (CTT), CVLT (after delay), Benton visual memory test (BNRT), Verbal fluency test by the certified psychologist.
89122377|NCT00737971|Active Comparator|A|Avastin intravitreal injection D0, Week 4, Week 8
89122378|NCT00737971|Active Comparator|B|Triamcinolone intravitreal injection
89122379|NCT00737971|Active Comparator|C|Avastin + Triamcinolone intravitreal injection simultaneously
89122380|NCT02653911|Experimental|acupuncture group|"Bilateral ST25, EX-CA1, CV4 and SP6 will be selected for treatment. After routine sterilization of the local skin, bilateral ST25, EX-CA1, CV4 and SP 6 will be inserted by the needles (0.30 mm in diameter, 40 mm in length) to a depth of 25-30 mm to the abdominal muscle layer with the manipulation of lifting, thrusting and rotating until de qi. Each session will last for 30 minutes, and the manipulation of lifting, thrusting and rotating evenly three times will be used for CV 4 and SP 6 every 10 minutes. If the date of treatment is during the menstrual circle, the treatment will be continued as usual. Participants will be treated three times a week for 12 weeks with 36 sessions."
89122381|NCT02653911|Sham Comparator|Sham-acupuncture group|The sham ST25, EX-CA1, CV4 and SP 6, which are 1 cun (25 mm) outward to ST25, EX-CA1, CV4 and SP 6, will be inserted to 2-3 mm with needles with a diameter of 0.30 mm and a length of 13 mm. The needles will be inserted without de qi or any manipulation. The treatment sessions will be the same as those in the acupuncture group.
89122382|NCT02653677|Active Comparator|commercial bread, wheat flour|Intake of the specific kind of bread
89122383|NCT02653677|Experimental|wheat, organic flour|Intake of the specific kind of bread
89122384|NCT02653677|Experimental|wheat, supermarket flour|Intake of the specific kind of bread
89122385|NCT02653677|Experimental|einkorn, organic flour|intake of the specific kind of bread
89122386|NCT02653521|Experimental|adaptive radiation therapy (ART)|40 patients treated with ART, using dose adaptation method to match the change of PTV and movement of OARs and achieve an optimal dose distribution using online CBCT images.
89122387|NCT02653521|No Intervention|the control group|40 patients treated with original plan for full treatment course.
89122388|NCT04064281|Experimental|the healthy Cantonese diet|Based on the typical Cantonese diet, the healthy Cantonese diet is developed according to the DASH diet and the balanced dietary pattern of the Chinese Dietary Guidelines 2016. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set to achieve the healthy goal. Compared with the typical Cantonese diet, the healthy Cantonese diet is increased in fruit, vegetables, low-fat dairy products, whole grains, nuts and seeds, and reduced in salt, oil and sweets.
89122389|NCT04064281|Placebo Comparator|the typical Cantonese diet|The typical Cantonese diet is a diet of what many Cantonese eat. In this diet, the main nutrients, dietary fiber, sodium, calcium, magnesium and potassium are set at the average dietary intake levels in Guangdong.
89122390|NCT00740701|Sham Comparator|Sham TMS|A Sham TMS coil, designed to elicit sham cerebellar transcranial magnetic stimulation, is used to administer sham TMS pulses after letters are presented.
89122391|NCT00740701|Experimental|TMS|A genuine TMS coil is used to administer cerebellar transcranial magnetic stimulation pulses after letter presentation.
89122392|NCT00650247|Experimental|1|Sumatriptan Succinate Tablets 100 mg
89122393|NCT00650247|Active Comparator|2|Imitrex® Tablets 100 mg
89122394|NCT02568709|Active Comparator|Interventional|40 IU Oxytocin
89122395|NCT02568709|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
89122396|NCT04168047|Other|Healthy volunteers|
89122397|NCT04168047|Other|Patients with insomnia|
89122398|NCT04168047|Other|Patients with irritable bowel syndrome|
89122399|NCT04168047|Experimental|Patients with irritable bowel syndrome and insomnia|
89122400|NCT02653365||Non-invasive ventilation|All patients eligible for inclusion in the study were treated with Non-invasive ventilation.
89122401|NCT00740935|Other|1|Cohort of vaccinated infants against rotavirus
89122402|NCT04647175|Other|Fermented aronia - aronia - placebo|The participants receive each intervention for 8 weeks in the stated order.
89122403|NCT04647175|Other|Fermented aronia - placebo - aronia|The participants receive each intervention for 8 weeks in the stated order.
89122404|NCT04647175|Other|Placebo - aronia - fermented aronia|The participants receive each intervention for 8 weeks in the stated order.
89122405|NCT04647175|Other|Placebo - fermented aronia - aronia|The participants receive each intervention for 8 weeks in the stated order.
89122406|NCT04647175|Other|Aronia - placebo - fermented aronia|The participants receive each intervention for 8 weeks in the stated order.
89122407|NCT04647175|Other|Aronia - fermented aronia - placebo|The participants receive each intervention for 8 weeks in the stated order.
89122408|NCT02653209|Experimental|Sitagliptin - DPP4i|
89122409|NCT02653209|Experimental|Canagliflozin - SGLT2i|
89122410|NCT02653209|Experimental|Pioglitazone - TZD|
89122411|NCT02653131|Experimental|DPP-4|The administration of the DPP-4 inhibitor in the form of a pill once per day
89122412|NCT02653131|No Intervention|NO DPP|no therapy
89122413|NCT04288011||Clinical EDSS|The Kurtzke EDSS, is a clinical rating scale for multiple sclerosis having scores between 0 to 10 that are assigned by a trained clinician. Smaller impairments are assessed at lower scores and disability is assessed at higher scores. It is important to note, however, that despite being denoted on an ordinal scale, each level on the scale is not indicative of an equal change in disability.
89122414|NCT04288011||MLA EDSS|The Kurtzke EDSS, is a clinical rating scale or multiple sclerosis having scores between 0 to 10 that are assigned by a technique based upon several different Machine Learning Algorithms that are combined to produce a single score
89122415|NCT00738205||1|
89122416|NCT00738205||2|
89122417|NCT02652897||Exposure to glioma resection surgery|Patients undergoing elective glioma resection
89122418|NCT02652897||Exposure to colon resection surgery|Patients undergoing elective colon cancer resection
88801738|NCT04416828||Suspected ganglion cyst of the wrist or hand|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging AND cart-based ultrasound imaging before surgery.
88801739|NCT05024162|Experimental|Prospective Cohort|Sixty patients with a new diagnosis of prostate cancer that meet eligibility criteria. The group will have two standard MRI-P's completed. The first MRI-P will be acquired as standard of care and the second will be an additional investigation for the purposes of this study. The efficacy of the MRT will be compared at both time points, evaluating if the MRT demonstrates clinically sufficient stability in its findings (i.e., does the MRT report an accurate and similar result at both time points).
89122419|NCT04168125|Experimental|Tilapia skin|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a tilapia skin as an occlusive biological dressing for palatal wound healing.~Device: Tilapia skin. A xenogeneic collagen dressing will be placed over palate wound and stabilized with sutures during the healing process."
89122420|NCT04168125|Active Comparator|Surgical Wound Dressing|"Procedure/Surgery: Free gingival graft harvesting from hard palate. After gingival graft harvesting from hard palate, it will be placed a surgical wound dressing as a mechanical protection during palatal wound healing.~Device: Surgical wound dressing A surgical wound dressing will be placed over palate wound during the healing process to provide mechanical protection."
89122421|NCT00733603|Sham Comparator|Global Therapeutic Massage (GTM)|Non-specific somatic treatment with full-body Western massage.
89122422|NCT00733603|Active Comparator|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
89122423|NCT02652585|Active Comparator|Naltrexone|"1 capsule naltrexone 25 mg per day, oral use, day 1 to day 3;~1 capsule naltrexone 50 mg per day, oral use, day 4 to day 28"
89122424|NCT02652585|Placebo Comparator|Placebo|1 capsule placebo, oral use, day 1 to day 28
89122425|NCT00733681|Experimental|PFC Sigma RP TC3 Revision Knee System|Revision knee surgery with the PFC Sigma RP TC3 Revision Knee System (mobile bearing).
89122426|NCT02652819|Experimental|FG-4592|Intervention is investigational treatment FG-4592
89122427|NCT02652819|Placebo Comparator|Placebo|Double blinded placebo control
89122428|NCT00741169|Experimental|Treatment Sequence ABC|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence will consist of Treatment A (TMC435350 200 mg once daily for 7 days), Treatment B (rifampin 600 mg once daily for 7 days), and Treatment C (TMC435350 200 mg once daily+rifampin 600 mg once daily for 7 days). Participants will receive 1 treatment (A, B, or C) during each treatment session. There will be 3 treatment sessions, each treatment session will be separated by 10 days.
89122429|NCT00741169|Experimental|Treatment Sequence BCA|
89122430|NCT00741169|Experimental|Treatment Sequence CAB|
89122431|NCT00741169|Experimental|Treatment sequence CBA|
89122432|NCT00741169|Experimental|Treatment Sequence BAC|
89122433|NCT00741169|Experimental|Treatment Sequence ACB|
89122434|NCT02652975|Experimental|Category 1|Examination of participants prior to chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
89122435|NCT02652975|Experimental|Category 2|Examination of participants immediately after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
89122436|NCT02652975|Experimental|Category 3|Examination of participants one year after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
89122437|NCT00741325||G-CSF plus plerixafor|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received plerixafor, prior to undergoing apheresis.
89122438|NCT00741325||G-CSF plus placebo|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received placebo, prior to undergoing apheresis.
89122439|NCT02652663||ECA-MRI group|ECA-MRI group (patients who underwent conventional MRI using extracellular contrast agent [ECA])
89122440|NCT02652663||Gd-EOB-MRI group|Gd-EOB-MRI group (patients who underwent gadoxetic acid-enhanced MRI)
89122441|NCT00741403|Experimental|A|IV Infusion of CPI-613 on Days 1,4,8,11,15,18 of 28 day cycle in patients with advanced malignancies
89122442|NCT02652741|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
89122443|NCT05741281|Experimental|STUDY GROUP|Physical exercises will be carried out for patients in the study group . The physical exercise intervention phase will take three weeks for each patient (three sessions per week for three weeks - Nine sessions for each group). It will be applied for two groups each week for three weeks (one group / day - 3 sessions /week for each group - six days/ week for the two groups).
89122444|NCT05741281|Active Comparator|Control group|Those in the control group will be left to undergo the usual hospital routine
89122445|NCT02652507|Other|Anesthesia for MRI|"All patients will receive the same drugs.~A loading dose of dexmedetomidine of 2 mcg/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h. Bolus dose 2 mg/kg of ketamine will be given after the initial set of research images have been taken."
89122446|NCT00738127|Experimental|1|Group I (treatment with our technique) Eighteen patients (18 wrists) were available for long-term follow-up at an average of 47.8 months after surgery. There were 11 men and seven women. Their mean age at the time of surgery was 35.4 years (range, 22 to 56 years). The dominant hand was involved in 12 patients and the nondominant hand, in six.
89122447|NCT00738127|Experimental|2|Group II (treatment with Inoue et al.'s technique) Fifteen patients (15 wrists) were evaluated at an average of 51 months. Nine patients were men and 6 were women. The mean age of the group at the time of surgery was 37.5 years (range, 24 to 58 years). The dominant hand was involved in 10 and nondominant hand, in seven.
89122448|NCT02652273|Experimental|Abatacept|Abatacept 125mg administered via subcutaneous injection once a week for 24 weeks
89122449|NCT05741203||children with LRTI|
89122450|NCT00650325|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
89122451|NCT00650325|Active Comparator|2|Zoloft® Tablets 100 mg
89122452|NCT02652351|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
89122453|NCT04032873|Other|Provider Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by the orthopaedic surgeon before the decision for immobilization has been made.
89122454|NCT04032873|Other|Research Team Cost|The subject will be given information about the cost of casting and splinting for treatment of the buckle fracture by a member of the study team after the decision for immobilization has been made.
89122455|NCT00923611|Placebo Comparator|Placebo|3 tablets of placebo will be taken 30minutes after breakfast for 8 weeks
89122456|NCT00923611|Active Comparator|Fimasartan 20mg|2 tablets of placebo and 1 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
89122457|NCT00923611|Active Comparator|Fimasartan 60mg|3 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
89122458|NCT00923611|Active Comparator|Fimasartan 120mg|3 tablets of fimasartan 40mg will be taken 30minutes after breakfast
89122459|NCT00923611|Active Comparator|Fimasartan 240mg|3 tablets of fimasartan 80mg will be taken 30minutes after breakfast for 8 weeks
89122460|NCT00650403|Experimental|1|Paroxetine hydrochloride 40 mg tablet
89122461|NCT00650403|Active Comparator|2|Paxil® 40 mg Tablet
89122462|NCT00733837|Experimental|A|This is a repeated measures study. All participants experience the same conditions.
89122463|NCT02648373|Experimental|Education|Patients receive an educational video about low back pain based on the Consumer Reports Choosing Wisely recommendation for patients with back pain to avoid early imaging and remain as active as possible. After the video the evaluator and patient discussed key themes from the video and the patient was able to ask any questions. Previously scheduled physical therapy then began with treatment at the therapist's discretion.
89122464|NCT02648373|Active Comparator|Control|Previously scheduled physical therapy was provided with treatment at the therapist's discretion. No educational intervention was provided before beginning physical therapy
89122465|NCT02568319|Experimental|LIPO-202|Experimental arm
89122466|NCT02568319|Placebo Comparator|Placebo|Placebo comparator
89122467|NCT02648451|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES Rome for a period of 9 days
89122468|NCT02648607|Experimental|Customised Orthosis|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
89122469|NCT00920803|Active Comparator|5g SRT501|5.0 g of SRT501 will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, SRT501 will be administered approximately 15-30 minutes following the consumption of a standardized breakfast. On all other days, SRT501 will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of SRT501 administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive SRT501 for a minimum of 10 days and a maximum of 21 days.
89122470|NCT00920803|Placebo Comparator|Placebo|Placebo will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, placebo will be administered approximately 15-30 minutes following the consumption of a standardized breakfast to allow for PK sample collection. On all other days, placebo will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of placebo administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive placebo for a minimum of 10 days and a maximum of 21 days.
89122471|NCT02648529|Experimental|Patients with BCECTS|Patients with BCECTS on which MRI, fMRI and neuropsychological assessment will be performed
89122472|NCT02648529|Other|Healthy volunteers|Healthy volunteers on which MRI, fMRI and neuropsychological assessment will be performed
89122473|NCT02648685||normal glycaemic metabolism|100 subjects
89122474|NCT02648685||Type 2 Diabetes|300 subjects
89122475|NCT04063423||hemodialysis study session|"4h hemodialysis session using standard polysulphone dialyzer and Nikkiso dialysis monitors~Minimal dose of unfractionated heparin (UFH) with loading dose 500IE and maintenance 500IE/h, stopped 60 minutes before session end in case of AVF use.~Standard bicarbonate-based ultrapure dialysate. Na, K, Ca, bicarbonate concentrations according to the patient's routine dialysis prescription.~The blood flow rate maximized as per routine nursing care.~Dialysate flow rate fixed at 500 ml/min.~Dialysate temperature between 35.5°C and 36.5°C.~Ultrafiltration according to patient's dry weight and supported ultrafiltration rate.~At the end of the dialysis session the blood will be returned (100ml/min) to the patient."
89122476|NCT05742061|Active Comparator|OA group injected by corticosteroid|Group l include 50 patients who will be injected with one intra_articular injection of 2 ml of methylprednisolone acetate 40 mg/ml mixed with 2ml of lidocaine
89122477|NCT05742061|Active Comparator|OA group injected by Platelet Rich Plasma|Group lI include 50 patients who will be injected with a single 5 ml intra_articular injection of PRP prepared in our hospital
89122478|NCT04316169|Experimental|Abemaciclib and HCQ 200 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
89122479|NCT04316169|Experimental|Abemaciclib and HCQ 400 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
89122480|NCT04316169|Experimental|Abemaciclib and HCQ 600 mg b.i.d.|HCQ will have a dose escalation of a 3 + 3 design.
89122481|NCT04316169|Experimental|Abemaciclib + HCQ (Optimal Dose) + endocrine therapy|"This group will be divided into two cohorts:~eligible participants who are endocrine therapy naive.~eligible participants who had one prior line of endocrine therapy."
89122482|NCT02536287|Experimental|total PTX without autotransplantation|all parathyroid glands were found and removed
89122483|NCT02536287|Active Comparator|total PTX with autotransplantation|all parathyroid glands were found and removed,and then a portion of it is sliced into 1*1*1 mm pieces for autotransplantation
89122484|NCT05538949|Experimental|Test group|Participants received 1%, 2%, 4%, 8% of EB-203 eye drops. Group A : EB-203 1% eye drops, Group B : EB-203 2% eye drops, Group C : EB-203 4% eye drops, Group D : EB-203 8% eye drops
89122485|NCT05538949|Placebo Comparator|Placebo group|Participants received Placebo eye drops. Group A : Placebo eye drops, Group B : Placebo eye drops, Group C : Placebo eye drops, Group D : Placebo eye drops
89122486|NCT02648139|Experimental|Experimental dentifrice|Dentifrice containing the extract of Eugenia uniflora rip fruit. Each 10 ml of E. uniflora L. dentifrice comprises the following components: Hydroalcoholic extract of the ripe fruit of E. uniflora L. (3.0%), preservatives (parabens; 0.02 g), and dentifrice base (silicon dioxide, sodium lauryl sulfate, white dye, aromatic compounds, sodium saccharin, and Gangrez sodium salt; q.s.p.). Intervention protocol: three times per day (pea-like amount), for seven consecutive days.
89122487|NCT02648139|Active Comparator|Control Dentifrice|"Control dentifrice - Colgate total 12 (fluoride, 1500 ppm and triclosan, 0.3%)~Intervention protocol: three times per day (pea-like amount), for seven consecutive days."
89122488|NCT00651339||A|
89122489|NCT05740969|Active Comparator|5-Fluorouracil|Patients will be asked apply a 40 mg/g creme containing 5-Fluorouracil once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
89122490|NCT05740969|Active Comparator|Imiquimod|Patients will be asked apply a 50 mg/g creme containing imiquimod thrice a week on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
89122491|NCT05740969|Experimental|Melatonin|Patients will be asked apply a 25 mg/g creme containing melatonin once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
89122492|NCT05740969|No Intervention|Control|A biopsy will be taken from the patient and the patient will be refered to a dermatologist for further treatment, if necessary.
89122493|NCT02647983|Experimental|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection to be used a MRI contrast agent.
89122494|NCT00651417|Active Comparator|1|Organic Germanium tablets 5 times a day
89122495|NCT00651417|Placebo Comparator|2|Placebo tablets 3 -5 times per day
89122496|NCT02568241|Experimental|interferon Alfa-2b|High-risk acute leukemia patients after hematopoietic stem cell transplantation receive interferon Alfa-2b after prophylactic DLI
89122497|NCT05551897|Experimental|Treatment Arm|Subjects will receive a single oral dose of Camizestrant on Day 1 of treatment period 1. Following washout period of 7 to 10 days, subjects will receive Itraconazole on Days 1, 2, and 3 of treatment period 2, and single oral dose of Camizestrant plus a dose of Itraconazole on Day 1, followed by Itraconazole alone on Day 2 and Day 3 of treatment period 3.
89122498|NCT02647671|Experimental|Aquamin®|Experimental: Aquamin® (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
89122499|NCT02647671|Active Comparator|Calcium Carbonate|Active Comparator: Calcium Carbonate (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
89122500|NCT02647671|Placebo Comparator|Placebo|Placebo (Maltodextrin) - 4 capsules; 2 to be taken in the morning and 2 in the evening
89122501|NCT05740891|Experimental|Treatment Group|Refractory and relapsed multiple myeloma
89122502|NCT00651495|Experimental|1|Participants receive a $50 financial incentive if they view at least 3 of 5 patient decision aids in a group screening.
89122503|NCT00651495|Active Comparator|2|No financial incentive for watching patient decision aids in group screenings
89122504|NCT04578613|Experimental|ICP-022|ICP-022 will be orally administered until disease progression or unacceptable toxicity.
89122505|NCT04578613|Active Comparator|Chlorambucil combined with Rituximab|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles.
89122506|NCT02647515|Experimental|ranibizumab|
89122507|NCT02647593||gallstone hepatitis group,|gallstone hepatitis group (Among patients diagnosed as CBD stone who displayed above 400 IU/L of aminotransferase without cholangitis),
89122508|NCT02647593||control group|control group (Among patients diagnosed as CBD stone who showed the normal value of aminotransferase)
89122509|NCT04064047|Active Comparator|External Anal application - 5 minutes exposure|Anal application of lidocaine cream 5% for 5 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
89122510|NCT04064047|Active Comparator|External Anal application - 10 minutes exposure|Anal application of lidocaine cream 5% for 10 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
89122511|NCT04064047|Active Comparator|External Anal application - 20 minutes exposure|Anal application of lidocaine cream 5% for 20 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
89122512|NCT04064047|Active Comparator|External Anal plus intrarectal - 5 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 5 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
89122513|NCT04064047|Active Comparator|External Anal plus intrarectal - 10 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 10 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
89122514|NCT04064047|Active Comparator|External Anal plus intrarectal - 20 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 20 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
89122515|NCT04064047|Sham Comparator|Control group|No anal application of lidocaine cream prior to probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
89122516|NCT03818763|Experimental|Autologous CD34+PBSC transduced with a lentiviral vector|Patients will receive a patient specific (autologous) cytokine mobilized CD34+Peripheral Blood Stem Cells (PBSC) transduced ex vivo with a lentiviral vector containing cDNA encoding the human B-domain deleted FVIII protein.
89122517|NCT02647125|Experimental|Huachansu Arm|Patients in this arm will receive a treatment of Huachansu combined with thoracic radiotherapy.
89122518|NCT02647125|Active Comparator|Control Arm|Patients in this arm will receive thoracic radiotherapy alone.
89122519|NCT02647047|Experimental|Spinal|Patients will receive spinal analgesia (morphine 0.2 mg) before general anesthesia for minor laparotomic liver resection.
89122520|NCT02647047|Active Comparator|Epidural|Patients will receive epidural analgesia (bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL) before general anesthesia for minor laparotomic liver resection.
89122521|NCT02646813|Active Comparator|Intraluminal Placement|These patients will have the Arndt endobronchial blocker placed within the endotracheal tube for lung isolation during their thoracic surgery. The observer will measure time required to place blocker correctly prior to surgery.
89122522|NCT02646813|Experimental|Extraluminal Placement|These patients will have the Arndt endobronchial blocker placed outside of the endotracheal tube for lung isolation during their thoracic surgery. The investigator will measure the time required for placement.
89122523|NCT00651651|Experimental|1|Symbicort
89122524|NCT00651651|Active Comparator|2|budesonide
89122525|NCT00651651|Active Comparator|3|formoterol
89122526|NCT00709111|Experimental|Maraviroc|Maraviroc (MVC) was taken for 24 weeks, in addition to the subject's current antiretroviral therapy (ART) drug regimen. At week 24, subjects discontinued MVC and were followed for an additional 24 weeks off MVC, but still on current ART drug regimen.
89122527|NCT00651729|Experimental|1|Botulinum Toxin Type A
89122528|NCT02646735|Experimental|Fulvestrant|Fulvestrant 500 mg
89122529|NCT02646735|Active Comparator|Exemestane|Exemestane 25mg
89122530|NCT02646579|Experimental|Spinal and Peripheral Dry Needling|Participants will receive dry needling to the low back and painful areas in the leg.
89122531|NCT02646579|Active Comparator|Peripheral Dry Needling|Participants will receive dry needling to painful areas in the leg.
89122532|NCT02646501|Experimental|group A+PSGB|(Antiarrhythmic drug + percutaneous stellate ganglion block) group
89122533|NCT02646501|Active Comparator|group A|Antiarrhythmic drug group
89122534|NCT04063891|Placebo Comparator|Placebo-Controlled|Placebo group will have placebo treatment by standing on the LMHFV platform for 20 minutes/day
89122535|NCT04063891|Experimental|Vibration Group|Vibration group is treated with LMHFV at 35Hz, 0.3g, for 20 minutes/day, 5 times/week
89122536|NCT02646657|Other|Early UC|Patients with 'early UC' defined as disease duration < 4 years and no other treatments than aminosalicylates and/or corticosteroids
89122537|NCT02646657|Other|Late UC|Patients with 'late UC' defined as active disease despite treatment with immunosuppressives (IS) and/or anti-TNF. Patients wih intolerance to IS AND anti-TNF will also be allowed in the latter group.
89122538|NCT00652041|Experimental|1|Induction: 6 alternating cycles Bortezomib-Melfalan-Prednisone or Bortezomib- Adriamycine-Melfalan-Prednisone and Thalidomide-Cyclophosphamide-Dexamethasone, followed by other 6 maintenance cycles
89122539|NCT02646111|Experimental|Genotype 1b without cirrhosis|12 weeks without Ribavirin
89122540|NCT02646111|Experimental|Genotype 1b with cirrhosis|12 weeks with Ribavirin
88801740|NCT04098172|Experimental|Pressure Guidewire test subject|Stable patients with suspected or known CAD, who are scheduled for diagnostic angiography and pressure wire assessment, and signed the informed consent, will be screened for enrollment in this study.
88801741|NCT01458470|Active Comparator|Memantine|NMDA Receptor Antagonist
88801742|NCT01458470|Placebo Comparator|Sugar pill|
88801743|NCT04019626|Active Comparator|Continue-smoking|The subject's usual brand of combustible cigarette
88801744|NCT04019626|Experimental|myblu Tobacco 2.5%|myblu e-cigarette system with Tobacco flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
88801745|NCT04019626|Experimental|myblu Tobacco 4.0%|myblu e-cigarette system with Tobacco flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
89122541|NCT02646111|Experimental|Genotype 1a without cirrhosis|12 weeks with Ribavirin
89122542|NCT02646111|Experimental|Genotype 1a with cirrhosis|24 weeks with Ribavirin
89122543|NCT00652119|Experimental|Paclitaxel + Carboplatin + Avastin|"Paclitaxel Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.~Carboplatin Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.~Avastin Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle."
89122544|NCT05740657||KISPI 000|Patients of the group received one or multiple clinically approved opioids, namely; Fentanyl, Remifentanil, Sufentanil, Hydrocodone, Oxycodone and Morphine
89122545|NCT02646345||Pre Checklist|All surgical encounters before surgical checklist implementation
89122546|NCT02646345||Post Checklist|All surgical encounters after surgical checklist implementation
89122547|NCT05741749|Experimental|Socket Seal Abutment|
89122548|NCT05741749|Active Comparator|Conventional Healing abutment|
89122549|NCT04166955|Experimental|(Intervention)|Participants will be provided with weekly messages including information for promoting physical activity.
89122550|NCT04166955|No Intervention|(Control)|Participants will be evaluated without providing any intervention.
89122551|NCT02646267|Experimental|standard intensity warfarin group|standard intensity warfarin group， target international normalised ratio(INR) was 2.1-3.0, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(2.1-3.0)
89122552|NCT02646267|Experimental|low intensity warfarin group|low intensity warfarin group， target international normalised ratio(INR) was 1.7-2.2, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(1.7-2.2)
89122553|NCT02646267|Active Comparator|dabigatran etexilate group|110mg dabigatran etexilate was administrated twice a day
89122554|NCT00710749|Experimental|Disposable device first, then Digital device|
89122555|NCT00710749|Experimental|Digital device first, then Disposable device|
89122556|NCT02646189|Experimental|REP 2139-Ca + immunotherapy|"REP 2139-Ca is the calcium chelate complex formulation of REP 2139.~Zadaxin is thymosin alpha 1~Pegasys is pegylated interferon alpha 2a~Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is > 2000 copies / ml.~After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys."
89122557|NCT02646033||robotic surgery|all those patients aged 40 - 60 years undergoing robotic surgeries, who does not have any ophthalmic complains.
89122558|NCT02645877||Prehospital care|All pre-hospital service data were collected from January 2005 to December 2014 from the Beijing Emergency Center and Beijing Red Cross Emergency Center, which oversee all pre-hospital care in Beijing. The major illnesses were classified into 34 disease spectrum categories according to the Medical Priority Dispatch System (MPDS) which total includes 34 diseases. Data on pre-hospital emergency demand and first aid-related time intervals were analyzed to determine trends over the period.
89122559|NCT05741671||natural course|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Natural behaviour - 1 year"
89122560|NCT05741671||during long-term use of exogenous hormone exposure|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Long-term exogenous hormonal exposure - 1 year"
89122561|NCT05741671||Selective progesterone receptor modulators treatment or GnRH-analogues treatment|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: SPRMs or GnRH-analogues - 3 months"
89122562|NCT05741671||after initiation exogenous hormonal exposure|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Initiation of exogenous hormonal exposure - 1 year"
89122563|NCT05741671||embolization therapy|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Embolization - 6 months"
89122564|NCT05741671||ablation therapy|"To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRMs or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy .~Primary outcome: Ablation therapy - 6 months"
89122565|NCT02645799|Active Comparator|LABR-312|"LABR-312 will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.~Three (3) doses will be tested:~Group 1: Low dose -> 0.01 mg LABR-312 Group 2: Intermediate dose-> Up to 0.03 mg LABR-312 Group 3: High dose-> Up to 0.08 mg LABR-312 The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.~OCT follow-up will be performed at 9 months."
89122566|NCT02645799|Placebo Comparator|saline|"Placebo will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.~Three (3) doses will be tested:~Group 1: Low dose -> placebo (saline) equivalent to 0.01 mg LABR-312. Group 2: Intermediate dose-> placebo (saline) equivalent to up to 0.03 mg LABR-312 Group 3: High dose-> placebo (saline) equivalent to up to 0.08 mg LABR-312. The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.~OCT follow-up will be performed at 9 months."
89122567|NCT04063735|Experimental|Experimental group|supplement was given for 3 months.
89122568|NCT04063735|Placebo Comparator|Placebo group|Placebo was given for 3 months.
89122569|NCT04063813|Experimental|40 minute up trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree incline and at 75% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
89122570|NCT04063813|Experimental|40 minute down trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree decline and at 45% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
89122571|NCT04063813|Experimental|Two 20 minute up trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 75% of maximal effort, the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h..Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
89122572|NCT04063813|Experimental|Two 20 min down trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 45% of maximal effort , the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
89122573|NCT04063813|Active Comparator|Sedentary trial|No exercise day with isocaloric meals provided at 7:00, 13:00. and 19:00 h.
89122574|NCT02645955||Control group, disease history|people who didn't have disease history of Maintenance Hemodialysis
89122575|NCT02645955||The MHD patient group, diseases history|Maintenance Hemodialysis Patients
89122576|NCT00652197||Extraventricular Drainage|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
89122577|NCT02645721|Experimental|Extended self-help program with guidance|The program is a comprehensive CBT program lasting 12 weeks, with as many modules. The modules are quite extensive. A guide with basic education in psychotherapy assists and counsels participants online.
89122578|NCT02645721|Active Comparator|Briefer Self-help program, no guidance|This self-help program also lasts 12 weeks but contains only 9 modules; a pause occurs during the final weeks of the program for self-testing of acquired skills. The modules are quite brief. Participants receive no guidance.
89122579|NCT02645721|Other|WL: Extended self-help program, choice of guidance intensity|Participants will be put on a waiting list. After 12 weeks on the waiting list, participants will receive access the the extended self-help program used in the experimental arm. However, participants will be offered a choice between three guidance options of varying intensity: proactive guidance, reactive guidance (only at participant request) or no guidance.
89122580|NCT02645565|Active Comparator|Low dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
89122581|NCT02645565|Active Comparator|High Dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 750mg/m2 intravenous 4 weekly for 6 months followed by azathioprine 2mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
89122582|NCT02645643|Experimental|intervention group|Medical students rolled into this group would accept education of medical humanities.
89122583|NCT02645643|No Intervention|control group|Medical students rolled into this group would not gain education of medical humanities.
89122584|NCT00652275|Experimental|A|"Biological/Vaccine: 189 volunteers will receive the Malaria vaccine MSP3 Long Synthetic Peptide (LSP)~Arms: MSP3 LSP vaccine Biological/Vaccine:MSP3 LSP 30 micrograms of MSP3 LSP~Arms: I, MSP3 LSP vaccine"
89122585|NCT00652275|Active Comparator|B|189 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
89122586|NCT00699907|Active Comparator|Treatment Arm|Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
89122587|NCT00699907|No Intervention|High Risk Arm|High risk patients underwent risk-reducing salpingo-oophorectomy.
89122588|NCT00699907|No Intervention|Low Risk Arm|Low risk patients underwent salpingo-oophorectomy for a medical indication.
89122589|NCT00652353|Experimental|Intervention|Participants will be given a standardized information sheet providing a mnemonics to help remember the Ottawa Ankle and foot Rules.
89122590|NCT00652353|Placebo Comparator|0|control group
89122591|NCT00652509|Experimental|1|IDEA
89122592|NCT00652509|Active Comparator|2|IE
89122593|NCT00652509|No Intervention|3|UC: Patients receive no research intervention.
89122594|NCT02645097|Active Comparator|Proximal saphenous nerve block|The anesthesiologist will administer a saphenous proximal nerve block if specified in the randomization envelope.
89122595|NCT02645097|Active Comparator|Distal saphenous nerve block|The anesthesiologist will administer a saphenous distal nerve block if specified in the randomization envelope.
89122596|NCT02645175|Experimental|TW1025|TW1025 oral solution, 20ml, 3 times per day (daily dose: 60 ml)
89122597|NCT02645175|Placebo Comparator|Placebo|TW1025 oral solution matched placebo, 20ml, 3 times per day
89122598|NCT03182361|Experimental|Study group|Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants
89122599|NCT00710593|Active Comparator|A: HAART naive or no HAART in past 6 months|Participants who are ART naïve or, if ART-exposed, have not received highly active antiretroviral therapy (HAART) for at least the six months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
89122600|NCT00710593|Active Comparator|B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months|Participants who have been receiving highly active antiretroviral therapy (HAART) for at least six months at the time of study entry, with two HIV-1 RNA plasma viral loads < 400 copies/ml on two previous clinical visits within the 6 months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
89122601|NCT00599313|Experimental|Sunitinib Malate|Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)
89122602|NCT00708175|Experimental|Pioglitazone|
89122603|NCT00708175|Placebo Comparator|Placebo|
89122604|NCT02641509|Experimental|NBI to perform the polipectomy|this arm will undergo polypectomy with the use of NBI to define the margins of the lesion
89122605|NCT02641509|Experimental|no NBI to perform the polypectomy|this arm will undergo polipectomy without the use of NBI to define the margins of the lesion
89122606|NCT05740345||Hyperglycemia/Normoglycemia|
89122607|NCT05740345||Treated/No treated|
89122608|NCT02641431|Experimental|mapping/ablation|Epicardial substrate identification consisted in mapping the entire RV epicardial surface under baseline conditions and after ajmaline infusion (1mg/kg in 5 minutes).We obtained 3 groups of RV epicardial maps using CARTO3 system: 1) bipolar/unipolar voltage map, 2) local activation time map (LAT), and 3) potential duration map (PDM), in which abnormal long-duration bipolar electrograms were defined as low-frequency (up to 100 Hz) prolonged duration (> 200 ms) bipolar signals with delayed activity extending beyond the end of the QRS complex. Epicardial ablation was performed during sinus rhythm using a stepwise strategy in a descending order of abnormal potential duration as displayed on the map and beginning from the longest potentials.
89122609|NCT02641275|Experimental|Intervention|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions.
89122610|NCT02641275|No Intervention|Control group|no intervention other than existing support (see exclusion criteria). However, intervention will be offered and studied secondary as well (after 1 1/2 year of no intervention).
89122611|NCT04063345|Experimental|IVUS-guided PCI|Percutaneous intervention under IVUS-guidance
89122612|NCT04063345|Active Comparator|Angiography-guided PCI|Percutaneous intervention under angiograhy-guidance only
89122613|NCT02641197|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after brachial artery occlusion by a standard upper arm pneumatic blood pressure cuff. The procedure is non-invasive and does not employ ultrasound.
89122614|NCT00733525|Experimental|Stepped Care|Participants will receive guided self-help with nine clinician checkups, followed by fluoxetine if nonresponsive, followed by cognitive behavioral therapy if still nonresponsive.
89122615|NCT00733525|Active Comparator|Cognitive Behavioral Therapy|Participants will receive 20 sessions of cognitive behavioral therapy with the addition of fluoxetine at interim points.
89122616|NCT05740267|No Intervention|Conventional laparoscopy group|The investigators can select either the intracorporeal or extracorporeal method to create bowel anastomoses. For the extracorporeal way, a mini-laparotomy wound is created and exteriorizes the bowel to do the anastomosis. The specimen is removed via the mini-laparotomy wound after the anastomosis is accomplished for the intracorporeal approach.
89122617|NCT05740267|Experimental|NOSE group|After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
89122618|NCT00653601||1|Patients who receive bridge therapy with tirofiban who were previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures
89122619|NCT00653601||2|"Patients who do NOT receive bridge therapy previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures. This will entail of a matching case-control for the following characteristics.~# of RF for stent thrombosis~types of stents~time frame when the stents were placed~procedure type"
89122620|NCT02568085|Experimental|1|thyroidectomy + Arista
89122621|NCT02568085|No Intervention|2|Thyroidectomy
89122622|NCT02568085|Experimental|3|Thyroidectomy with neck + Arista
89122623|NCT02568085|No Intervention|4|Thyroidectomy with neck
89122624|NCT02641119||Albumin|Patients receiving any amount of 5% albumin during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician.
89122625|NCT02641119||Saline-only|Patients receiving only saline during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician
89122626|NCT02641041|Experimental|Cohort 1|A single IV dose of 10 mg/kg BIIB033 or placebo given on Day 1
89122627|NCT02641041|Experimental|Cohort 2|A single IV dose of 30 mg/kg BIIB033 or placebo given on Day 1
89122628|NCT02641041|Experimental|Cohort 3|One IV dose of 100 mg/kg BIIB033 or placebo given on Days 1 and 15
89122629|NCT02567149|Experimental|Cidofovir|Cidofovir clinical resolution of treated warts as evaluated by the investigators
89122630|NCT00707239|Experimental|A|
89122631|NCT00707239|Experimental|B|
89122632|NCT00707239|Active Comparator|C|
89122633|NCT00968708|Experimental|Placebo|Alogliptin placebo matching tablets, orally, once daily. Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
89122634|NCT00968708|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg, tablets, orally, once daily for participants with moderately impaired renal function (eGFR ≥30 and <60 mL/min). Alogliptin 6.25 mg, tablets, orally, once daily for participants with severely impaired renal function or end stage renal disease (eGFR <30 mL/min). Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
89122635|NCT00920881||Diabetes|
89122636|NCT05735821|No Intervention|control group|The control group will be pre-tested with data collection tools and a post-test will be applied 1 month later. No intervention will be made.
89122637|NCT05735821|Experimental|video group|A pre-test will be applied to the video group. Afterwards, a video containing the breastfeeding education prepared by the researcher will be watched. A post-test will be administered after the training. After 1 month, contact will be made and the test will be done again.
89122638|NCT05735821|Experimental|simulator group|A pre-test will be applied to the simulator group. Afterwards, a training will be given by the researcher with a breastfeeding simulator. A final test will be given after the training. After 1 month, the contact will be made and the test will be done again.
89122639|NCT05733793||Cohort A (Retrospective):|"Cohort A (Retrospective):~• All consecutive patients diagnosed with gynecological malignancies who have performed an NGS analysis on tumor sample as for clinical practice or as part of a clinical study from the January 1st 2015 until the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients) will be enrolled."
89122640|NCT05733793||Cohort B (Prospective):|• All consecutive patients diagnosed with a gynecological malignancy who perform an NGS analysis on tumor sample as for clinical practice or as part of a clinical practice from the date in which the study is approved by the local ethical committee (Investigator is allowed to enroll patients) until 1st January 2025.
89122641|NCT00921037|Experimental|Erbium YAG Laser|Patients with Neurofibromatosis Type 1 (Recklinghausen)
89122642|NCT02567071|Experimental|Intervention Group|75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.
89122643|NCT02567071|Placebo Comparator|Placebo Group|75 children born by planned C-section will be exposed to clean swab.
89122644|NCT02567071|No Intervention|Control Group|75 children born vaginally.
89122645|NCT05732545|Experimental|enteral nutrition program by intra-abdominal pressure|enteral nutrition program for patients with intra-abdominal hypertension guided by intra-abdominal pressure
89122646|NCT05732545|No Intervention|Routine nursing measures|Routine nursing measures
89122647|NCT04062565|Experimental|Experimental|Treprostinil and Riociguat
89122648|NCT00967694|Experimental|Nitrous oxide administration|All 20 healthy volunteers had their intraocular pressure (IOP) measured at baseline and then after 3, 6, 9, and 12 minutes of nitrous oxide administration, and then after 5, 10, and 15 minutes of breathing room air. There was therefore only one study arm, with each individual serving as their control for baseline and then intervention values of IOP measurement.
88801746|NCT04019626|Experimental|myblu Honeymoon 2.5%|myblu e-cigarette system with Honeymoon flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
88801747|NCT04019626|Experimental|myblu Honeymoon 4.0%|myblu e-cigarette system with Honeymoon flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
89122649|NCT04288388|Experimental|massage group|Immediately before the episiotomy repair was started (after exit of placenta and applying local anesthetic agent), women assigned to the study (massage) group were asked to place plastic gloves filled with ice pieces in the LI4 point on hand. This application was made for 5 minutes to the right hand and for 5 minutes to the left hand. The episiotomy was opened by the same midwife as all the women to the right mediolateral and repaired by the same midwife with the same technique and material.The ice massage was repeated until the episiotomy repair was over; total massage time and episiotomy repair time were recorded. Women were asked to mark the perceived pain level before the application and at the end of the application using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair).
89122650|NCT04288388|No Intervention|Control group|I the control group women were not excluded from routine practice; women were asked to mark the perceived pain level before episiotomy repair begin and at the end the repair using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair) like the study (massage) group.
89122651|NCT04288700|Active Comparator|Group A|
89122652|NCT04288700|Active Comparator|Group B|
89122653|NCT04288700|Active Comparator|Group C|
89122654|NCT04288700|Active Comparator|Group D|
89122655|NCT02863406|Experimental|Healthy volunteers|Bronchoalveolar lavage in healthy volunteers
89122656|NCT02863406|Experimental|Patients suffering from sarcoidosis|Bronchoalveolar lavage in patients suffering from sarcoidosis
89122657|NCT03664232|Experimental|JNJ-42165279|Participants will self-administer 25 milligram (mg) JNJ-42165279 tablets orally twice daily for 12 weeks.
89122658|NCT03664232|Placebo Comparator|Placebo|Participants will self-administer matching placebo tablets orally twice daily for 12 weeks.
89122659|NCT04286048|Experimental|Experimental group|"Each session will last 15 minutes, taking place for 2 days a week, over a period of 4 weeks. The intervention will take place at the beginning of the training session.~Prior to training, each pitcher will perform his normal warm-up routine, notifying the investigator when he feels ready to perform the training. The intervention through weight implements will consist in the application of the protocol described by Fleising et al. The objective of the application of the technique is to produce an increase in the speed of the throws."
89122660|NCT04286048|No Intervention|Control group|Athletes included in the control group will conduct their training and activities on a daily basis
89122661|NCT02863562|Experimental|Group 1|"This group included 16 subjects. They received kinesio taping for both ankle joints and and performed proprioceptive exercises.~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training."
89122662|NCT02863562|Experimental|Group 2|"This group received placebo kinesio taping for ankle joint (no tension) and performed proprioceptive exercises.~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training in the same way as before but with no tension. It was removed on the second day of training."
89122663|NCT02863562|Experimental|Group 3|This group received kinesio taping for ankle joint. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training.
89122664|NCT00967616|Active Comparator|FOLFIRI|"Participants who received irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). FOLFIRI was administered by intravenous (IV) injection once every 2 weeks. The FOLFIRI regimen consisted of:~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
89122665|NCT00967616|Experimental|CS7017+FOLFIRI|"Participants who received CS7017 plus irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). Two CS-7017 tablets were administered by mouth (PO) twice a day (BID) every 12 hours. FOLFIRI was administered IV once every 2 weeks. The FOLFIRI regimen consisted of:~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
89122666|NCT00629876|Experimental|Peginesatide|
89122667|NCT04288232|Experimental|Intravitreal aflibercept|Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.
89122668|NCT04288466|Active Comparator|Adults|Adults < 60 years-old maltodextrin solution 450ml
89122669|NCT04288466|Active Comparator|Elders|Elders 65 or more years-old maltodextrin solution 450ml
89122670|NCT02864264|Experimental|Single Ascending Dose (SAD) - IV Panel|Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184
89122671|NCT02864264|Experimental|Single Ascending Dose (SAD) - SC Panel|Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184
89122672|NCT02864264|Experimental|Multiple Ascending Dose (MAD) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
89122673|NCT02864264|Experimental|Proof of Mechanism (POM) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
88801748|NCT04019626|Active Comparator|JUUL 5%|JUUL® system with Virginia Tobacco Flavor JUULpod, 5.0% nicotine. This arm is only included in the PK sub-study.
88801749|NCT01452464||MenACYW-CRM vaccinated adolescents|All adolescent recipients of MenACYW-CRM vaccines during the study period. Among these, adolescents who have additionally experienced an event of interest within the 1-year observation period following vaccination will be included in the self-controlled case series.
88805892|NCT01139411|Experimental|Behavioral Weight Control with Enhanced Parent Involvement|This treatment arm included periodic dyadic sessions with adolescents and their parents, focusing on weight-related communication combined with standard behavioral weight control.
89122674|NCT00971204|Experimental|Treatment with HeartLight System|Treatment of paroxysmal atrial fibrillation (PAF) with HeartLight System
89122675|NCT03914378||Discovery Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
89122676|NCT03914378||Discovery Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
89122677|NCT03914378||Validation Phase - Radiotherapy only|25 patients undergoing radiotherapy only for head / neck cancer
89122678|NCT03914378||Validation Phase - Radiotherapy plus chemotherapy|25 patients undergoing radiotherapy plus chemotherapy for head / neck cancer
89122679|NCT03914378||Retrospective Cohort|50 patients who previously received unilateral radiotherapy for head / neck cancer up to 5 years post-treatment
89122680|NCT03914378||Normal Hearing Controls for Retrospective Cohort|50 controls with normal hearing, age- and sex-matched to retrospective cohort
89122681|NCT03914378||Hearing Impaired Controls for Retrospective Cohort|50 controls with impaired hearing, age-, sex-, and audiogram-matched to retrospective cohort
89122682|NCT02640963|Experimental|Intervention: the GrACE programme|The programme included several weight-bearing exercises (using body weight and dumbbells) and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. While developed for respite care older adults, the GrACE programme was slightly modified for the RAC setting; using reduced range of motion and resistance, and an extended conditioning/familiarisation phase. The conditioning phase lasted for three weeks and focus on the development of correct technique. After concluding the conditioning phase, participants started to use light dumbbells. Participants performed the exercises twice per week for 12 weeks. Training sessions lasted approximately 45 minutes, were separated by at least 48 hours and were delivered by an experienced allied health professional.
89122683|NCT02640963|Placebo Comparator|Control Group|All subjects assigned to the control group were given the option to engage in other activities that were offered by the facility during the 12-week intervention period. Activities were facility specific, and included Zumba aerobic exercise and walking, however no specific resistance exercises were offered.
89122684|NCT02640885|Experimental|Foley's cather tamponade|Balloon tamponade with 2-way Foley's Cather was successfully used during cesarean section due to sever postpartum haemorrhage after failure of medical treatment.
89122685|NCT02640729|Experimental|Nelotanserin|Nelotanserin 40mg then nelotanserin 80 mg
89122686|NCT02640729|Placebo Comparator|Placebo|Placebo
89122687|NCT02640651|Experimental|DC-Stimulator (PLUS version)|For tDCS stimulation, anodal stimulation of the right dorsolateral prefrontal cortex will be performed for twenty minutes at 2mA. The current will be applied by a battery-driven tDCS stimulator via a pair of saline-soaked sponge electrodes (25 cm2 surface). The anodal electrode will be placed on the scalp at the F4 position according to the international 10-20 EEG coordinate system. 20 minute tDCS sessions will be conducted ten times over a two week period
89122688|NCT02640417|Experimental|Nucleotides + B12|Nucleotides + Vitamin B12 Dose: two capsules, three times per day + placebo corresponding to Group B treatment
89122689|NCT02640417|Active Comparator|B vitamins|Vitamin B1 + Vitamin B6 + Vitamin B12 Dose: one tablet, three times daily + placebo corresponding to Group A treatment
89122690|NCT02640495||Study subjects|Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
89122691|NCT02640339||Parkinson Disease|Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, with alpha-synuclein deposits in neurons which aggregate into Lewy bodies.
89122692|NCT02640339||Mutiple system atrophy|is a degenerative neurological disorder. MSA is associated with the degeneration of nerve cells in specific areas of the brain. This cell degeneration causes problems with movement, balance, and autonomic functions of the body such as bladder control or blood-pressure regulation. Neuronal death probably occurs as a consequence of alpha-synuclein aggregation in oligodendroglia.
89122693|NCT02640339||REM sleep behavior disorder|a sleep disorder in which you physically act out vivid, often unpleasant dreams with vocal sounds and sudden, often violent arm and leg movements
89122694|NCT02640339||dementia with Lewy bodies|"causes a progressive decline in mental abilities.~It may also cause visual hallucinations, which generally take the form of objects, people or animals that aren't there. This can lead to unusual behavior such as having conversations with deceased loved ones.~Another indicator of Lewy body dementia may be significant fluctuations in alertness and attention, which may include daytime drowsiness or periods of staring into space. And, like Parkinson's disease, Lewy body dementia can result in rigid muscles, slowed movement and tremors."
89122695|NCT02640339||Pure autonomic failure|Pure autonomic failure is dysfunction of many of the processes controlled by the autonomic nervous system, such as control of blood pressure•Blood pressure may decrease when people stand, and they may sweat less and may have eye problems, retain urine, become constipated, or lose control of bowel movements
89122696|NCT02640339||Healthy controls|Healthy normals with no neurological involvement
89122697|NCT02640261||Group 1|Single embryo transfer on day 5, according to standard embryo morphological criteria
89122698|NCT02640261||Group 2|Single embryo transfer on day 5, chosen on the basis of both embryo morphological criteria and levels of cytokines measured in the individual FF.
89122699|NCT02535897|Placebo Comparator|CON|500 ml of flavoured water
89122700|NCT02535897|Active Comparator|CHO|500 ml of flavoured water containing 80 g carbohydrate
89122701|NCT02535897|Active Comparator|CHO-PRO|500 ml of flavoured water containing 40 g carbohydrate and 40 g whey protein
89122702|NCT02640183|Experimental|Group A (EMLA)|3 mL EMLA® cream 5% will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
89122703|NCT02640183|Placebo Comparator|Group B (Placebo)|3 mL of ultrasonic gel will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
89122704|NCT02640027|No Intervention|Treatment in the Clinic Only|Patients in Group A will receive their follow-up care entirely at the investigators institution
88801750|NCT01452542|Experimental|Sequence 1|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: TRTR, with a 7-day washout between dosing in each period.
89122705|NCT02640027|Experimental|Treatment in the Clinic and at Home|Cast removal at home using a telemedicine tool
89122706|NCT02639949|Experimental|Group CBT|
89122707|NCT02639949|Active Comparator|Standard Care|
89122708|NCT02639871||healthy volunteers|31P-MR Spectroscopy and CEST for Validation of MRI/MRS methods
89122709|NCT02639871||HD presymptomatic individuals|General medical exam Clinical assessment with illness rating scales: Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS) and Total Functional Capacity (TFC), 31P-MR Spectroscopy and CEST
89122710|NCT02639871||early affected HD patients|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
89122711|NCT02639871||Controls|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
89122712|NCT02639793|Active Comparator|manual radiofrequency ablation|Radiofrequency catheter ablation using manual catheter manipulation will be used as an ablation technique.
89122713|NCT02639793|Active Comparator|magnet navigation ablation|Radiofrequency catheter ablation using remote magnet navigation will be used as an ablation technique.
89122714|NCT02639793|Active Comparator|cryoablation|Catheter ablation using cryoablation technique will be used as an ablation technique of atrial fibrillation.
89122715|NCT02639403|Experimental|RT for Obstructing Rectal Cancer|Conformal three-dimensional RT was planned (3D-RT) in patients with obstructing rectal cancer not amenable for curative resection
89122716|NCT02639481|Active Comparator|Control group standard physiotherapy|Patients will receive standard physiotherapy for 60 minutes, including the goal of verticalization and stimulation of the patient but without the use of the robotic Erigo®Pro device.
89122717|NCT02639481|Active Comparator|Erigo®Pro group without FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device but without functional electrical stimulation (FES) of the leg muscles.
89122718|NCT02639481|Active Comparator|Erigo®Pro group with FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device including functional electrical stimulation (FES) of the leg muscles.
89122719|NCT04164927|Active Comparator|Kinesio Taping|Lymphatic correction method is applied via Kinesiotaping depending on the size of the leg two or three fan-cut tape was applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Certified Kinesio Tape practitioner applied Kinesiotaping on the second day (day 2) post-surgery and once a week.
89122720|NCT04164927|Active Comparator|Manual Lymphatic Drainage|A standardized 30-minute manual lymphatic drainage (MLD) treatment is applied to MLD group. On the second day (day 2) post-surgery, patients allocated to the MLD group underwent a standardized 30 minute MLD treatment on the operated limb by an experienced remedial massage therapist trained in delivering MLD.
89122721|NCT04164927|No Intervention|Control|Standard postoperative rehabilitation program is applied to Control Group. Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures.
89122722|NCT00654225|Experimental|1|Rosuvastatin
89122723|NCT00654225|Active Comparator|2|Atorvastatin
89122724|NCT00974090|Placebo Comparator|Placebo / Teneli + SU|
89122725|NCT00974090|Experimental|Teneli / Teneli + SU|
89122726|NCT00654303|Experimental|1|Rosuvastatin
89122727|NCT02639169|Experimental|music|Apply live music through techniques music therapy in group experimental and evaluation through the visual analog scale (VAS) and numeric.
89122728|NCT02639169|No Intervention|Comparative|Apply the visual analog scale (VAS) and numeric.
89122729|NCT02863484|Active Comparator|Conventional surgery intra-dural|This arm will be surgically operated by direct attack of the tumour after opening the dura
89122730|NCT02863484|Experimental|Pealing surgery extra-dural|This arm the pealing of the outer layer of the lateral wall of the cavernous sinus will be done before the dura is opened. After the pealing is completed, the middle meningeal artery will be divided at the foramen spinosum. Then, the dura will be opened and the tumour attacked.
89122731|NCT02639091|Experimental|BAY 94-9343 + Pemetrexed + Cisplatin|Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
89122732|NCT04286750|Experimental|ACT-1004-1239 Dose level 1 (30 mg) to 5|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
89122733|NCT04286750|Placebo Comparator|Placebo|Each dose level will be investigated in a group of 10 male and female subjects (ratio 1:1, male:female), with 8 subjects being administered ACT-1004-239 and 2 subjects matching placebo (ratio 1:1, male:female). Sentinel dosing will be applied at each dose level, i.e., in each group two subjects (ratio 1:1, male:female) will initially receive study treatment (1 on active treatment and 1 on placebo).
89122734|NCT02638935|Other|BI-RADS 3|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
89122735|NCT02638935|Other|BI-RADS 4a|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
89122736|NCT02638935|Other|BI-RADS 4b|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
89122737|NCT02638935|Other|BI-RADS 4c|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
89122738|NCT02864654|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate Adipose-derived regenerative cells (ADRC). After isolation 10 mL of autologous ADRC suspension will be injected intramuscularly, close to the site of muscle injury. 10 to 20 injections will be performed so as to infiltrate the injured muscle
89122739|NCT02639013|Experimental|ttransducer technique|the nurses will measure intraabdominal pressure at each shift during the day by using transducer technique
89122740|NCT00971048|Experimental|HP828-101|
89122741|NCT00971048|Active Comparator|Standard of Care|For DFU SoC is a hydrogel. For PU SoC is a hydrocolloid gel.
89122742|NCT02535819|Experimental|Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
89122743|NCT02535819|Other|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
89122744|NCT00911001||Group 1|
89122745|NCT00654459||A|
89122746|NCT00654459||B|
89122747|NCT02863250||Massively transfused patients|Patients (18+ years) who have had a critical bleeding event that necessitated a massive transfusion (defined as 5 or more units of red cells in any 4 hour period)
89122748|NCT02638779|Experimental|Blood sampling|Blood sampling will be performed in all patients and healthy volunteers
89122751|NCT00654537|Experimental|1|Rosuvastatin
89122752|NCT00654537|Active Comparator|2|Atorvastatin
89122753|NCT00654537|Active Comparator|3|Pravastatin
89122754|NCT00654537|Active Comparator|4|Simvastatin
89122755|NCT02638857|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization(TACE) treatment:patients will receive lipiodol,Mitomycin (MMC),Epirubicin（EADM） hepatic arterial infusion,3 cycles.
89122756|NCT02638857|Experimental|DC-PMAT cells|After accepting concurrent TACE treatment,patients will receive 3 cycles of Dendritic Cell -Precision Multiple Antigen T (DC-PMAT) cells treatment.
89122757|NCT02638545|Experimental|dexmedetomidine|
89122758|NCT00654693||monitored|patients hospitalized for longer than 24 hours and are located on the 4th, 5th, and 6th floors of the Vanderbilt University Medical Center Round Wing
89122759|NCT02638467|Experimental|Bosutinib and Bone Marrow Transplant|Subjects will receive 400mg of bosutinib from day at least -45 to day -15 to assess the sensitivity of patient Chronic Myeloid Leukemia (CML) to this TKI. Patients will be transplanted with the aim to transplant > 3 x 106 CD34+ cells/kg Body Weight (BW) recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow. Then, subjects will receive 400mg of bosutinib once daily from day +30 after transplant.
89122760|NCT02864420|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vitals and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
89122761|NCT02864420|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
89122762|NCT00654771||1|women undergoing evaluation for pre-eclampsia
89122763|NCT03883802|Experimental|Foxy-5|Arm will receive Foxy-5 as neo-adjuvant therapy prior to surgical removal of tumour and afterwards until initiation of FOLFOX 6 months regimen
89122764|NCT03883802|Active Comparator|Standard therapy|Surgical removal of tumour followed by 6 months FOLFOX regimen
89122765|NCT02638233|Other|Sofosbuvir 400mg/Ledipasvir 90 mg|Subjects will receive sofosbuvir 400mg q.d p.o and ledipasvir 90 mg q.d p.o (FDC) for 8 weeks
89122766|NCT00654849|Experimental|1|compare security and effectiveness of use Electrosurgical Bipolar Plasmakinetic Vessel Sealing
89122767|NCT00654849|Active Comparator|2|traditional abdominal hysterectomy technique with the use of sutures
88805893|NCT01139411|Placebo Comparator|Behavioral Weight Control with Minimal Parent Involvement|This treatment arm included standard behavioral weight control delivered to the adolescent with minimal parent involvement.
89122768|NCT04285268|Experimental|Treatment (rituximab, venetoclax, bortezomib)|Patients receive rituximab IV on day -1 of cycle 1, then on day 1 of cycles 2-6. Patients also receive venetoclax PO QD on days 1-14 and bortezomib IV or SC on day -1 of cycle 1, then on days 1, 8, and 15 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles for rituximab and up to 26 cycles for venetoclax and bortezomib in the absence of disease progression or unacceptable toxicity.
89122769|NCT02502435||Patients with Night-Eating Syndrome|Individuals diagnosed with Night Eating Syndrome (NES); 18-65 years of age; eating 30% of their caloric intake after dinner with nocturnal awakenings to eat at a frequency of ≥ 5 times per week
89122770|NCT02502435||Matched Healthy Controls|Healthy volunteers; 18-65 years of age; eating <25% of their caloric intake after dinner; no nocturnal ingestions
89122771|NCT04285190|Experimental|The T89 treatment group|Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID(every morning and evening), for 10 days (Depending on clinical need and practicability, the use can be extended for up to 14 days).
89122772|NCT04285190|No Intervention|The blank control group|All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
89122773|NCT00699751|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
89122774|NCT00699751|Placebo Comparator|Placebo|Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
89122775|NCT01842399|Placebo Comparator|Placebo Comparator|2x/day orally
89122776|NCT01842399|Experimental|Resveratrol 1|75 mg, 2x/day orally
89122777|NCT01842399|Experimental|Resveratrol 2|150 mg, 2x/day orally
89122778|NCT02638155||Food Addiction Group|Those participants identified as having food addiction by the Yale Food Addiction Scale.
89122779|NCT02638155||No Food Addiction Group|Those participants with no identified food addiction
89122780|NCT01585857|Experimental|Group 1|2 x 10E6 ASC intra-articular injection (5 ml)
89122781|NCT01585857|Experimental|Group 2|10 x 10E6 ASC intra-articular injection (5 ml)
89122782|NCT01585857|Experimental|Group 3|50 x 10E6 ASC intra-articular injection (5 ml)
89122783|NCT00970502|Experimental|erlotinib + celecoxib|
89122784|NCT01329081|Experimental|Six weeks strength training in teams and patient education|
89122785|NCT01329081|Experimental|Supervised home training with focus on activities|
89122786|NCT04286204|Experimental|Basic Life Support Training based on ICTs|It will be conformed with students from one highschool random selected. They will receive a basic life support training based on Information and communication technologies.
89122787|NCT04286204|Active Comparator|Classic Basic Life Support Training|It will be conformed with students from another highschool random selected. They will receive a full and conventional basic life support training based on American and Hear Association recommendations.
89122788|NCT02635815||Group I|twenty six patients with history of bleeding or had an attack of bleeding during one year follow-up. All underwent upper gastrointestinal endoscopy.
89122789|NCT02635815||Group II|thirty four patients without bleeding. All underwent upper gastrointestinal endoscopy.
89122790|NCT04267406||Cirrhosis|Patients who diagnosed as cirrhosis. 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
89122791|NCT04267406||Non-cirrhotic portal hypertension|Patients who diagnosed as extrahepatic portal hypertension (due to portal vein thrombosis). 2 ml EDTA blood sample was taken from patients during their routine controls or at the time of diagnosis. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
89122792|NCT04267406||Control|Healthy volunteers, who admitted to our hospital for any complaints, but was not determined any organic disease. 2 ml EDTA blood sample was taken from healthy volunteers, during their hospital admition. Samples will be tested for ADAMTS-13 and vWF levels and activity at the end of study.
89122793|NCT02635893|Active Comparator|D-Cycloserine/Placebo + Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation.
89122794|NCT02635893|Active Comparator|Training+Med/Placebo+Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation followed by training.
89122795|NCT02635893|Active Comparator|Training+Med+Stimulation/Placebo Stim|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation or placebo stimulation followed by training.
89122796|NCT02635581|Experimental|DELTA TT|
89122797|NCT02861456|Active Comparator|Standard Care Group|Patient in the treatment arm will receive the Standard Model of Care as prescribed for their condition by their physician including but not limited to Advanced imaging, Rest, Bracing, Physical Therapy, and Medication.
89122798|NCT02861456|Experimental|Functional Progression Group|Patients who are randomized to the alternative model of care to guide treatment will not have advanced imaging done and will be referred directly to physical therapy care . If the patient is able to functional progress through phase I and II of physical therapy within 3 weeks and phase III within 5 weeks then they return to sport. If patient are unable to progress the are put on rest as a presumed vertebral injury (spondylolysis).
89122799|NCT04162509|Experimental|Exposure|The experimental intervention in the experimental group consists of six 30-minutes AR exposures as home training (total duration in AR: 3 hours) within two weeks.
89122800|NCT04162509|No Intervention|Control|The control group will not receive any active treatment (untreated comparison group).
89122801|NCT02635503|Experimental|transrectal specimen extraction|Laparoscopic colorectal resection with natural orifice specimen extraction will be performed for patients in this group.
89122802|NCT02635503|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
89122803|NCT02635269|Experimental|Sugar|The subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max.
89122804|NCT02567773|Experimental|Part A: GSK2881078|The first cohort subjects will receive GSK2881078 1.5 mg (for males) or 0.75 mg (for females) twice daily for 3 days followed by once daily for 25 days. The subsequent cohort subjects will receive GSK2881078 doses selected after reviewing the unblinded data from at least 2 weeks of dosing of at least 6 subjects in the first cohort. Each cohort subjects will receive GSK2881078 dose twice daily for the first 3 days followed by 25 days of once daily.
89122805|NCT02567773|Placebo Comparator|Part A: Placebo|Subjects will receive placebo twice daily for 3 days followed by once daily for 25 days.
89122806|NCT02567773|Experimental|Part B: GSK2881078-Itraconazole|Subjects will receive GSK2881078 (dose level will be determined based on the results from Part A) on Day 1 of Period-1 and Day 6 of Period-2. Subjects will also receive itraconazole 200 mg twice daily on Day1 of Period-2 and 200 mg once daily on Days 2-34 of Period-2.
88801751|NCT01452542|Experimental|Sequence 2|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: RTRT, with a 7-day washout between dosing in each period.
88801752|NCT04022668||STEMI|Current international ECG criteria (New ST-segment elevation at the J-point in two contiguous leads with the cut-points: ≥0.1 mV millivolts (mV) in all leads other than leads V2-V3; for leads V2-V3: ≥2 mm in men ≥40 years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age) with troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia.
89122807|NCT04162197|Experimental|Experimental 1: Gait Group (GG)|Gait Group (GG) will perform, in addition to conventional therapy, gait training using only an end effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 12 sessions/month. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/ h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
89122808|NCT04162197|Experimental|Experimental 2: Balance Group (GHG)|Balance Group (GHG) will receive, in addition to conventional therapy, a combined robotic treatment program with the same end-effector robotic system and a robotic proprioceptive platform, 3 times/week for 12 sessions/month. The time of the single session (45 minutes) is dived in gait training and balance training. The balance training will consist in static and dynamic exercises during sitting and standing position, dual-task exercises and exercises aimed to improve trunk control.
89122809|NCT00967226|Experimental|propranolol for treatment of hemangiomas|Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
89122810|NCT00967226|Active Comparator|Prednisolone|Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
89122811|NCT00706381|Experimental|1: Carb meal, fat meal, sincalide, placebo, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, and IV placebo + PO Ursodiol 15mg/kg day 5
89122812|NCT00706381|Experimental|2: Fat meal, carb meal, sincalide, placebo, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
89122813|NCT00706381|Experimental|3: Carb meal, fat meal, placebo, sincalide, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
89122814|NCT00706381|Experimental|4: Fat meal, carb meal, placebo, sincalide, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, the IV placebo + PO Ursodiol 15mg/kg day 5
89122815|NCT04283474|Experimental|XG005-03|XG005-03 in 3 dose levels
89122816|NCT04283474|Placebo Comparator|Placebo|Placebo in all cohort
89122817|NCT05727865|Experimental|Online CBT following cardiac surgery|The treatment lasts for five weeks and will be provided as an early intervention following cardiac surgery ≥ eight weeks to nine months before assessment. The intervention is psychologist-guided (clinical psychologist and/or resident psychologist under supervision) and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease.
89122818|NCT05727553||Breast cancer patients|Breast cancer patients treated with postoperative radiotherapy in an online adaptive workflow on Ethos.
89122819|NCT05723185||Internal medicine model|This group of patients will be treated at the outpatient clinic which is run by internal medicine specialists
89122820|NCT05723185||Specialist model|This group of patients will be treated at the outpatient clinic which is run by cardiologists and/or diabetologists
89122821|NCT05721469|No Intervention|kontrol group|Pretest and posttest application
89122822|NCT05721469|Experimental|experimental group|Art therapy application to the experimental group
89122823|NCT05721469|No Intervention|Posttest phase|Applying posttest to the experimental and control groups
89122824|NCT00964886|Experimental|Arm 1|desipramine hydrochloride
89122825|NCT00964886|Experimental|Arm 2|cognitive behavioral therapy
89122826|NCT00964886|Experimental|Arm 3|desipramine hydrochloride and cognitive behavioral therapy
89122827|NCT00964886|Placebo Comparator|Arm 4|anticholinergic medication; active placebo
89122828|NCT02861222|Experimental|MYOCET|2 treatments of doxorubicin are administered at 60 mg/m²/day or 75 mg/m²/day in single dose in 1-hour perfusion each 21 days. A maximum of 6 treatments/patient is administered.
89122829|NCT04062019|Experimental|interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 once every other day, for 3 months.
89122830|NCT02862158|Experimental|Experimental|FDT visual field will be compared to standard HVF in detecting glaucomatous visual field loss
89122831|NCT04061863|Experimental|ER+/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
89122832|NCT04061863|Experimental|ER-/HER2- breast cancer|will be treated with a combination of eribulin and nivolumab
89122833|NCT02862236|Experimental|Hypericum perforatum (Remotiv, 250 mg)|
89122834|NCT02862236|Experimental|Hypericum perforatum (Remotiv, 500 mg)|
89122835|NCT04063111|Active Comparator|group A|Group A will be treated with vacuum assistant closure
89122836|NCT04063111|Active Comparator|group B|Group B will be treated with conventional dressing
89122837|NCT04284878||A|patients with inflammatory bowel disease
89122838|NCT04284878||B|healthy subjects
89122839|NCT04285502|No Intervention|CONTROL GROUP|patients without a drain
89122840|NCT04285502|Experimental|CASE GROUP|Patients a drain inserted
89122841|NCT02568163|Other|questionary|
89122842|NCT02861378|Experimental|Phentolamine mesylate|Once anesthesia is confirmed, subjects in the Phentolamine mesylate group will receive 1 injection of 1ml of a solution containing 0.24 mg of phentolamine mesylate in the same site that was previously anaesthetized (not as a part of the study).
89122843|NCT02861378|Placebo Comparator|Water|Once anaesthesia is confined, the subjects in the water group will receive 1 injection of 1 ml of sterile physiological water in the same site that was previously anaesthetized (not as a part of the study).
89122844|NCT04119206||Control|Normonatremic control, no intervention.
89122845|NCT04119206||Fluid restriction|Hyponatremic patients (serum sodium <135mmol/L): restriction of fluid intake < 1L
89290118|NCT02625766|Experimental|Non-operative|Patients enrolled in the non-operative treatment group will not undergo surgical intervention for their pelvic fracture. They will mobilize as per the surgeon's instructions according to standard of care of for this injury. X-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly or if the pelvis has shifted and may warrant surgical intervention. If complications arise and/or surgery is required, crossover will be allowed and recorded within study follow-up forms.
89290119|NCT03934788|Experimental|Oxysoft|olifilcon C, daily disposable soft contact lens, 1 month
89290120|NCT03934788|Active Comparator|SiHy|olifilcon B, dialy disposable soft contact lens, 1 month
89290121|NCT01122966|Other|trabeculectomy|Subjects who have trabeculectomies with intraocular bevacizumab injection
88801753|NCT04022668||NSTEMI|Troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia without abovementioned criteria.
89122846|NCT04119206||Tolvaptan 3.75mg|Hyponatremic patients (serum sodium <135mmol/L): tolvaptan 3.75 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
89122847|NCT04119206||Tolvaptan 7.5mg|Hyponatremic patients (serum sodium <135mmol/L): tolvaptan 7.5 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
89122848|NCT04062955|Experimental|Prevention (dietary intervention)|"DIETARY INTERVENTION: Participants receive dietary counseling with a dietitian in person or via telephone to support adherence to a diet based on the AHEI guidelines once weekly for up to 12 weeks.~DXA ONLY STUDY: Participants undergo DXA scan for breast density measurement at baseline and at 12 weeks."
89122849|NCT03601832|Experimental|4-D navigated stereotactic radiosurgical ablation|The patients enroled to this arm of the study will undergo 4-D navigated stereotactic radiosurgical ablation.
89122850|NCT00705757|Active Comparator|Lumigan|Patients assigned to Lumigan/bimatoprost one drop before bedtime (qhs) to affected eye(s)
89122851|NCT00705757|Active Comparator|Xalatan|Patients assigned to Xalatan/latanoprost one drop before bedtime (qhs) to affected eye(s)
89122852|NCT00705757|Active Comparator|Travatan|Patients assigned to Travatan/travoprost one drop before bedtime (qhs) to affected eye(s)
89122853|NCT00629954||I|
89122854|NCT04284644|Experimental|Group P|Patient received a dose of 1.5 mg/kg of Propofol slowly over 2 minutes for induction.
89122855|NCT04284644|Experimental|Group S|Patient received 8% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen.
89122856|NCT04284644|Experimental|Group C|Patient received 4% sevoflurane through sealed plastic facemask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
89122857|NCT05330143|Experimental|ASC22 1mg/kg|ASC22 Injection of 1mg/kg and anti-retroviral therapy for 12 weeks
89122858|NCT05330143|Experimental|ASC22 2.5mg/kg|ASC22 Injection of 2.5mg/kg and anti-retroviral therapy for 12 weeks
89122859|NCT05330143|Placebo Comparator|Placebo|0.9% Saline and anti-retroviral therapy for 12 weeks
89122860|NCT04284956|Experimental|Proximal group|Proximal segment of saphenous veins are harvested from the thigh by No-Touch technique and randomized to bypass the left or right territory of coronary system
89122861|NCT04284956|Active Comparator|Distal group|Distal segment of saphenous veins are harvested from the shank of the ipsilateral leg by No-Touch technique and used to bypass the right or left territory of coronary system (depending on the randomizing result of the proximal segments)
89122862|NCT02566837|Active Comparator|ELEC|electrical stimulation guidance
89122863|NCT02566837|Experimental|ECHO|ultrasound guidance
89122864|NCT04284722|Active Comparator|Metformin +|The study intervention involves the self-administration of metformin in the same dosage as the patient's regular dosage according to regular dosing schedule and randomization.
89122865|NCT04284722|No Intervention|Metformin -|The control group involves no intervention, which means cessation of oral metformin therapy 24 hours prior to surgery according to the local guidelines of the anesthesia department and the national anesthesiology guidelines.
89122866|NCT04283240|Active Comparator|Sildenafil|50 mg sildenafil oral. One dose
89122867|NCT04283240|Placebo Comparator|Placebo|Placebo pill. One dose
89122868|NCT02862314|Experimental|procalcitonin group|The procalcitonin concentration is measured at inclusion.
89122869|NCT02862314|No Intervention|control group|Concentrations of procalcitonin are not measured. .
89122870|NCT03588884|Active Comparator|CTAP101|CTAP101/Calcifediol Capsules 60 micrograms (mcg) once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
89122871|NCT03588884|Experimental|Immediate-release (IR) calcifediol|Immediate-release (IR) calcifediol/266 micrograms (mcg) capsule before breakfast on the mornings of Day 1 and Day 29
88801754|NCT04022668||Normal|Emergency department admission with a clinical picture compatible with acute coronary syndrome, but no change in serial ECGs and no rise in cardiac biomarkers
88805894|NCT01139801|Active Comparator|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
89122872|NCT03588884|Experimental|Cholecalciferol|Cholecalciferol/Capsules 300,000 International Units (IU) (high-dose) before breakfast on the mornings of Day 1 and Day 29
89122873|NCT03588884|Active Comparator|Paricalcitol|Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and29 when dosing will occur before breakfast
89122874|NCT04285736|Experimental|Group A Ivabradine Group|
89122875|NCT04285736|Active Comparator|Group B Control Group|
89122876|NCT02862704|Experimental|MG7-CART|A single dose of MG7-CART cells will be administered by intra-tumor injection under ultrasound guidance. The dose is 1-6x108 MG7-CAR positive T cells. The infusion will be scheduled to occur 2 days after two doses of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. The cells perfusion process would lasts 1min to 2min, and an interventional radiologist would operate the cell infusion.
89122877|NCT02862860|Experimental|patients with type-1 diabetes|
89122878|NCT02862860|Placebo Comparator|Controls|
89122879|NCT02862782|Experimental|hCG|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono)
89122880|NCT02862782|Experimental|hCG + GnRH agonist|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono) and GnRH agonist - Gonadotropin - releasing hormone (Decapeptyl 0.2mg - Ferring Gmgh)
88805895|NCT01139801|Experimental|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
89233326|NCT01603316|Active Comparator|Food Voucher Program (Voucher)|Food Voucher arm, each participant will receive a debit card specifically created for this program. Each month for the duration of study participation (6 months), the debit card will be credited with $128 & given to the patient in person or via mail. Patients will be instructed to use these cards only for food purchases. If patients are not able to use the debit card at their local grocery stores, patients will be provided with a money order of the same dollar value instead of the debit card. They will be counseled on using their vouchers only for healthful foods, in a way that stretches their food dollars. Purchases will be tracked by having patients bring their receipts in for review each month when they come in to pick-up their next monthly vouche, or by providing electronic copies of receipts. Patients will be provided with a receipt holder to assist in storing receipts for review. For voucher cards sent via mail, patients will receive a mailing letter accompanying each card.
89233327|NCT01603316|Experimental|Home Grocery Delivery (Delivery)|"In the Home Grocery Delivery arm, each participant will receive home grocery delivery from PeaPod grocery delivery service or from FreshDirect (depending on the participants zip code), worth $128 per month, for the duration of study participation (6 months). Patients in the Delivery arm will review a list of food categories and a subset of items in each category with a COA."
89233328|NCT01603316|Experimental|Medically-Tailored Hospital-Based Food Pantry (Pantry)|Patients in this arm will have access to the pantry for the duration of their study participation (6 months). Those accessing the medically-tailored food pantry will pick-up a pantry bag weekly or bi-weekly (per patient preference) at the hospital, either during one of their medical appointments or at another preferred time. Each patient's food prefereces will be assessed once during baseline and they will be given food bags, tailored when possible and when available to these preferences and to their medical needs and cultural preferences.
89233329|NCT01571752||CMU|Current marijuana users
89233330|NCT01571752||Cohort 1 - NIH Negative|HIV negative adults
89233331|NCT01571752||Cohort 1- HIV Positive|HIV positive adults
89233332|NCT01571752||Cohort 2 Seeds-Wave 0|HIV positive adults
89233333|NCT01571752||Cohort 2 Wave 1|HIV negative adults or HIV positive adults
89233334|NCT01571752||Cohort 2 Wave 2|HIV negative adults or HIV positive adults
89233335|NCT01571752||COSU|Current opioid/stimulant users
89233336|NCT01571752||COSU-NTS|Non-treatment seekers
89233337|NCT01571752||COSU-TS|Treatment seekers
89233338|NCT01571752||NDU|Non-drug-users
89233339|NCT01571752||Unclassified|
89233342|NCT01534598|Experimental|Single Arm|FdCyd + THU administered on an intermittent schedule in 21-day cycles per dose escalation table. THU will be administered orally at a fixed dose of 3000 mg 30 minutes prior to FdCyd.
89233344|NCT01503086|Experimental|Arm I (interactive training program)|Patients undergo a home-based, computerized, interactive training program comprising 3-5 sessions of 15-45 minutes every week for 5-9 weeks. The program contains twelve visually engaging and interesting exercises that target skills involving visual-spatial and verbal WM. The program is adaptive in a way that each difficulty task is automatically adjusted on a trial-by-trail basis to match a patient's current WM. Each patient has an interventional coach who has online access to patient's training sessions and outcomes (pass or fail). Coaches are able to modify the training sequence or make suggestions to patients and/or parents about how progress can be maximized. Coaches also have telephone meetings with patients and/or families once a week to ensure compliance, track progress, provide feedback, and answer questions that arise during training.
89233345|NCT01503086|Experimental|Arm II (non-adaptive training program)|Patients undergo a home-based, computerized, interactive, non-adaptive training program comprising 3-5 sessions of 15-45 minutes a week for 5-9 weeks. Each patient also has an interventional coach as in arm I. Patients in both arms complete a brief neuropsychological/behavioral assessment comprising the WIS-IV, the CMS, and the CVLT-C at baseline, after completion of study, and at 6 months after completion of study. Additionally, parents complete a parent-report questionnaire to gather information about patient's behaviors, thoughts, emotions, adaptive skills, and social and functional impairment. Parents and children also complete surveys about the program regarding technical feasibility, adherence, ease-of-use, and satisfaction.
89233346|NCT01498263||Alzheimers related dementias (family)|Enrollment was open to family members of persons diagnosed with Alzheimers (/related dementia) in specific communities around Memphis, TN.
89233347|NCT01498263||Inherited inflammatory condition (family)|Enrollment open to family members of persons diagnosed with inherited inflammatory conditions. Participation at NIH or remote (internet/phone); request referral of family for remote participation.
89233348|NCT01498263||Inherited metabolic conditions (family)|Enrolls family members of persons diagnosed with inborn errors of metabolism / mitochondrial disorders. Study at NIH or remote (internet/phone); request family-referrals for remote participation.
89233349|NCT01498263||Inherited neurodegenerative disorders (family)|Open to family members of persons diagnosed with genetically-defined neurodegenerative conditions. Study at NIH or (internet/phone); request referral of family members for remote participation.
89233350|NCT01498263||Typically developing (family) = Healthy Volunteers|Open to parents of typically-developing child/ren <18yrs (*when age-matched child is full-time resident of parent's home). Study at NIH; request family-referrals for remote participation.
89233351|NCT01498263||Undiagnosed conditions (family)|Enrollment open to family members referred in from the Undiagnosed Disease Network. Participation at NIH or remote (internet/phone); request referral of family members for remote participation
89233355|NCT01445314||1/Patients|Infants, children, adolescents, and adults who have taken neurobehavioral assessments as part of a past, current, or future IRB-approved protocol.
88801755|NCT05027204|Experimental|Docetaxel combined with Nivolumab|"Phase Ib: The eligible patients with SCCHN will received Docetaxel for Injection (Albumin-bound) 75 mg/m^2 or 100 mg/m^2 sequentially in combination with Nivolumab 360 mg to evaluate safety and efficacy and explore RP2D.~Phase II: According to the RP2D determined in the phase Ib study, patients will be treated with Docetaxel for Injection (Albumin-bound) combined with Nivolumab until participants meet the criteria for termination or withdrawal criteria, for a maximum of 2 years."
88801756|NCT01458626|Active Comparator|Add-on therapy|mirtazapine 30mg QD and paroxetine 20mg QD
88801757|NCT01458626|Active Comparator|mirtazapine monotherapy|mirtazapine 30mg QD
89122881|NCT00630188|Experimental|1|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with physician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
89122882|NCT00630188|Active Comparator|2|Highway Safety video
89122883|NCT04283162|Experimental|conventional treatment plus calcium dobesilate|maintain lifestyle habits and the usual treatment, plus the use of calcium dobesilate (500 mg, orally, 3 times per day) for 12 months
89122884|NCT04283162|Active Comparator|conventional treatment group|maintain lifestyle habits and the usual treatment for 12 months
89122885|NCT02861924|Experimental|microcirculatory responses|"Measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle).~A pressure is applied to the subject's arm. this causes a localized ischemia. the measures responses to this ischemia will be made by the imager speckle (LSCI) give the microvascular perfusion data."
89122886|NCT04282772||Ectopic Eruption|The ectopic eruption of PFMs were classified in two ways: impacted and self-corrected.
89122887|NCT02859818|Other|adolescents with type 1 diabetes|adolescents with type 1 diabetes following their participation in therapeutic education program
89122888|NCT02860052|Experimental|SB208 2%|Apply once daily to one or both feet for 14 days
89122889|NCT02860052|Experimental|SB208 4%|Apply once daily to one or both feet for 14 days
89122890|NCT02860052|Experimental|SB208 16%|Apply once daily to one or both feet for 14 days
89122891|NCT02860052|Placebo Comparator|Vehicle Gel|Apply once daily to one or both feet for 14 days
89122892|NCT02861066|Experimental|Mindfulness-based Intervention|6 week, abbreviated group MBI treatment for depression and anxiety
89122893|NCT04281602||Rheumatoid arthritis patients|Adult patients suffering from rheumatoid arthritis, diagnosed according to American College of Rheumatology/European League Against Rheumatism 2010 criteria and requiring a anti-IL-6 treatment
89122894|NCT04281602||Healthy controls|Healthy controls not suffering from acute or chronic inflammatory disease at inclusion.
89122895|NCT00960752|Active Comparator|Group 1: gp100 and MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
89122896|NCT00960752|Active Comparator|Group 2: gp100 and MAGE-3|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
89122897|NCT00960752|Active Comparator|Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
89122898|NCT04281524|Experimental|CSL312 Cohort 1 (Dose 1)|CSL312 administered as IV infusion
89122899|NCT04281524|Experimental|CSL312 Cohort 2 (Dose 2)|CSL312 administered as IV infusion
89122900|NCT04281524|Experimental|CSL312 Cohort 3 (Dose 3)|CSL312 administered as IV infusion
89122901|NCT04281524|Experimental|CSL312 Cohort 4 (Dose 4)|CSL312 administered as IV infusion
89122902|NCT04281524|Placebo Comparator|Placebo|Placebo administered as IV infusion
89122903|NCT02859740||permanent prosthesis|
89122904|NCT02859740||Temporary prosthesis|
89122905|NCT00758524|Experimental|Core Period: LCI699 0.25 mg QD|Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.
89122906|NCT00758524|Experimental|Core Period: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.
89122907|NCT00758524|Experimental|Core Period: LCI699 1.0 mg QD|Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.
89122908|NCT00758524|Experimental|Core Period: LCI699 0.5 mg BID|Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
89122909|NCT00758524|Active Comparator|Core Period: Eplerenone 50 mg BID|Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.
89122910|NCT00758524|Placebo Comparator|Core Period: Placebo|Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.
89122911|NCT00758524|Experimental|Withdrawal Period: LCI699 0.25 mg QD|Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
89122912|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.25 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
89122913|NCT00758524|Experimental|Withdrawal Period: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
89122914|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.5 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
89122915|NCT00758524|Experimental|Withdrawal Period: LCI699 1.0 mg QD|Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
89122916|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 1.0 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
89122917|NCT00758524|Experimental|Withdrawal Period: LCI699 0.5 mg BID|Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
89122918|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.5 mg BID Placebo|Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
89122919|NCT00758524|Active Comparator|Withdrawal Period: Eplerenone 50 mg BID|Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
89122920|NCT00758524|Placebo Comparator|Withdrawal Period: Eplerenone 50 mg BID Placebo|Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
89122921|NCT00758524|Placebo Comparator|Withdrawal Period: Placebo|Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).
89122922|NCT05466292||Healthcare Professionals (HPs) employed at the Local Health Authority of Reggio Emilia,|HPs will be included if they are employed at the Health Care Authority of Reggio Emilia. They will receive a closed-ended questions survey.
89122923|NCT05466292||Local Health Authority's Managers/Wards Heads|Managers/Heads who formally supported and promoted the intervention or have been contacted during the dissemination process will be interviewed by semi-structured interview.
89122924|NCT05466292||Clinical Ethics Committee (CEC)'s members|CEC's members will be interviewed by semi-structured interview.
89122925|NCT05466292||Healthcare Professionals who submitted an ethics consultation request|Healthcare Professionals who submitted an ethics consultation request will be interviewed by semi-structured interview.
89122926|NCT05466292||Healthcare Professionals who attended the training provided by the Clinical Ethics Committee|Healthcare Professionals who attended at least one of the five training courses on ethics consultation provided by the Clinical Ethics Committee. They will receive a survey of 20 multiple-choice questions and supplemented by free-text questions.
89122927|NCT02601196|Other|Ulipristal acetate treatment|Women who receive UPA treatment before another IVF cycle.
89122928|NCT00757588|Experimental|Saxagliptin, 5 mg + insulin|Saxagliptin, 5 mg, plus insulin, administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
89122929|NCT00757588|Placebo Comparator|Placebo + insulin|Placebo administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
89122930|NCT02597764|Active Comparator|Standard Urotherapy (SU)|Standard Urotherapy (SU): A non-invasive therapy combining cognitive, behavioral and physical therapy. The study team will explain the problem to the children and their parents and educate them on the following: proper voiding mechanics, sitting, standing positions, how and when to void, techniques on relaxing pelvic floor muscles, and avoiding straining. An assessment of bowel habits will be done and their diet and drinking/voiding habits will be modified to maintain proper hydration with timed voiding. Voiding diaries will be provided for the assessment of the bladder and bowel habits.
89122931|NCT02597764|Experimental|Standard Urotherapy (SU) + Diaphragmatic Beathing (DB)|"Standard Urotherapy (SU) with the addition of Diaphragmatic Breathing (DB):~A non-invasive breathing technique that is performed by a marked expansion of the abdomen (contracting diaphragm) rather than chest cavity during inspiration and tightening of the stomach muscles during expiration. Participants will lie on their back on a flat surface. Head is supported with a pillow and knees are bent forward supported by another pillow. Participants will place one hand on chest and the other on the abdomen, then start inhalation by moving their abdomen out against their hand, breathing in through their nose while keeping their chest and the other hand as still as possible. During expiration, the participants will tighten their abdominal muscles by forcing them inward and breathe out through pursed lips while keeping the hand on the chest as still as possible. Participants will be asked to perform this exercise for 10 minutes 3 times daily for 3 months."
89122932|NCT04092712|Experimental|Investigational Product|[14C]-CTP-543
89122933|NCT04090294|Experimental|Roflumilast -non roflumilast|"35 patients will receive Roflumilast for three months and improvement regarding dyspnea scales , Pulmonary function Test , Six minutes walking test and bronchectasis severity index (FACED) score pre and post therapy will be assessed.~patients will receive Roflumilast 500 Mcg. Tablet Once daily for Three months and then base line assessment will be repeated to evaluate improvement."
89122934|NCT04090372|Active Comparator|Control group|Control group will be assessed by standard preop planning using implants templates.
89122935|NCT04090372|Active Comparator|TraumaCad Group|TraumaCad Group will be assessed by preop planning using Traumacad
89122936|NCT00744796||DSAEK: Outcomes in patients with corneal edema|Best spectacle corrected visual acuity and anterior segment optical coherence tomography (OCT) at minimum will be performed in patients who have undergone DSAEK for corneal edema secondary to corneal endothelial dysfunction.
89122937|NCT00917254|Experimental|YM150 group-1|YM150 low dose group
89122938|NCT00917254|Experimental|YM150 group-2|YM150 high dose group
89122939|NCT00917254|Placebo Comparator|Placebo group|
89122940|NCT00917254|Active Comparator|Enoxaparin group|
89122941|NCT02599792|Experimental|CTP-656, 150 mg|Single Oral Dose
89122942|NCT02599792|Active Comparator|Kalydeco, 150 mg|Single oral dose
89122943|NCT02599792|Experimental|CTP-656, 75 mg or matching placebo|Subjects will be administered 75 mg CTP-656 for 7 days.
89122944|NCT02599792|Experimental|CTP-656, 150 mg or matching placebo|Subjects will be administered 150 mg CTP-656 for 7 days.
89122945|NCT02599792|Experimental|CTP-656, high dose or matching placebo|Subjects will be administered up to 300 mg CTP-656 for 7 days.
89122946|NCT00705679|Experimental|1|TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
89122947|NCT00705679|Experimental|2|TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
89122948|NCT00705679|Experimental|3|TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
89122949|NCT00705679|Experimental|4|Application of tenofovir 1% vaginal gel once daily
89122950|NCT00705679|Experimental|5|Application of tenofovir placebo gel once daily
89122951|NCT02597608|Experimental|UPPR: Control|No interventions are provided.
89122952|NCT02597608|Experimental|UPPR: Livelihoods only|Livelihoods programmes offered by UPPR.
89122953|NCT02597608|Experimental|UPPR: Livelihoods plus nutrition|Livelihoods programmes offered by UPPR, plus nutrition programmes offered by UPPR.
89122954|NCT02597608|Experimental|CLP: Livelihoods only|Livelihoods programmes offered by CLP.
89122955|NCT02597608|Experimental|CLP: Livelihoods plus nutrition|Livelihoods programmes offered by CLP, plus nutrition programmes offered by CLP.
89122956|NCT02597608|Experimental|Shiree: Livelihoods only|Livelihoods programmes offered by Shiree.
89122957|NCT02597608|Experimental|Shiree: Livelihoods plus nutrition|Livelihoods programmes offered by Shiree, plus nutrition programmes offered by Shiree.
89122958|NCT04062487|Experimental|Lumbar pedicle screws implantation of traditional procedure|traditional method of lumbar pedicle screws implantation
89122959|NCT04092868||cardiac surgery with extracorporeal circulation|"during the operation~Intervention Blood sample :~- Choay Heparin (pharmacokinetic) concentration: t = 5, 15, 30 minutes after the start of the heparin injection + t = 5, 30, 60 minutes after the start of extracorporeal circulation~protamine dosage: t = 2, 5, 8, 10 and 15 min after protamine injection~anti-X activity t = 0 before administration and at time 2, 5, 8, 10 and 15 min then at time 1, 3, 5, 6 and 7 hours after protamine injection~thrombin generation test (TGT) activity (thrombinography) : t = 2, 5, 8, 10 and 15 min after protamine injection"
89122960|NCT04092556|Active Comparator|tDCS (M1)|The participants will be submit to tDCS applied over the motor cortex (M1)
89122961|NCT04092556|Active Comparator|tDCS (Cerebellar cortex)|The participants will be submit to tDCS applied over the cerebellar cortex
89122962|NCT04092556|Sham Comparator|Sham stimulation|The participants will be submit to sham stimulation
89122963|NCT03977818||patients with metastatic softtissue sarcomas diagnosed between 1990 and 2013|
89122964|NCT02598544|Other|lean men|
89122965|NCT02598544|Other|Obese men without type 2 diabetes|
89122966|NCT02598544|Other|Obese men with type 2 diabetes|
89122967|NCT00916942|Experimental|NGX-4010 patch|
89122968|NCT00916942|Experimental|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
89122969|NCT05672485|Experimental|Patients diagnosed with prostate cancer|
89122970|NCT00751348|Experimental|PRIORIX-TETRA GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra® vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.
89122971|NCT00751348|Active Comparator|PRIORIX + VARILRIX GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.
89122972|NCT00920959|Experimental|Fluticasone propionate/salmeterol combination|study drug
89122973|NCT00920959|Experimental|Fluticasone propionate|study drug
89122974|NCT00920959|Experimental|Placebo|placebo
89122975|NCT04092322||Patients with subacute chronic stroke|Patients with subacute chronic stroke between the ages of 40-80
89122976|NCT04090138|Active Comparator|Setria performance blend|l-citrulline + glutathione
89122977|NCT04090138|Placebo Comparator|Placebo|
89122978|NCT02597530|Experimental|Long-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.Patients in Long-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and continued until the end of the surgery with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
89122979|NCT02597530|Other|Short-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.The patients in Short-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
89122980|NCT02597530|Placebo Comparator|Sham group|Patients in sham group will be pasted electrodes 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
89122981|NCT00751114|Experimental|Insulin Glargine|Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL<FPG≤100mg/dL (3.9mmol/L<FPG≤5.5mmol/L).
89122982|NCT00751114|Active Comparator|Sitagliptin|Dose of 100 mg once a day administered with or without food.
89122983|NCT00960440|Experimental|Sequence 1|
89122984|NCT00960440|Experimental|Sequence 2|
89122985|NCT00960440|Placebo Comparator|Sequence 3|
89122986|NCT00960440|Placebo Comparator|Sequence 4|
89122987|NCT04092478||Traditional Sitting Position|We are going to use the Traditional Sitting Position on each patients.
89122988|NCT04092478||Lateral Decubitis Position|We are going to use the Lateral Decubitis Position on each patients.
89122989|NCT04092478||Abdominal Crunch Position|We are going to use the Abdominal Crunch Position on each patients.
89122990|NCT04089436||patients with encephalitis|children above 28days and adults with suspected encephalitis Hospitalized in 4 different Hospitals, Kantha Bopha IV children's Hospital, Phnom Penh, Cambodia, National paediatrics Hospital, Hanoi, Vietnam and Mahosot Hospital, Vientiane, Lao PDR, and Yangon Children Hospital, Yangon, Myanmar
89122991|NCT02598466||Abatacept|
89122992|NCT05973461|Experimental|Cycle Ergometer and Virtual Reality|30 min ride on cycle ergometer while viewing neighborhood scenes using virtual reality
89122993|NCT05973461|Experimental|Cycle Ergometer|30 min ride on cycle ergometer
89122994|NCT05973409|Experimental|Habitual Soft Lens Wearers|Each group will be a prospective, randomized, double masked, cross-over, 1-month per arm, daily wear study. Each participant will be active in the study for at least 2 months.
89122995|NCT05973409|Experimental|Non Contact Lens Wearers|Each group will be a prospective, randomized, double masked, cross-over, 1-month per arm, daily wear study. Each participant will be active in the study for at least 2 months.
89122996|NCT05973396|Active Comparator|Control: Physical Fatigue only|Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort
89122997|NCT05973396|Experimental|Experiment: Mental and Physical Fatigue|Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort with mentally fatiguing task during low intensity effort pace with stroop testing during 50 seconds
89122998|NCT05973370|Placebo Comparator|Control|Participants in this arm will receive Placebo with the current DMARDs treatments for rheumatoid arthritis for 24 weeks.
89122999|NCT05973370|Active Comparator|Ursodeoxycholic acid (UDCA)|Participants in this arm will receive ursodeoxycholic acid (UDCA) 500 mg/day + DMARDs for 24 weeks.
89123000|NCT05973357|Experimental|Sub-crestal group|Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization
89123001|NCT05973357|Experimental|Equi-crestal grouo|Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
89123002|NCT05973331||prospective general opulation cohort|Males and females age >= 40 years, without a personal history of PDAC or current PDAC, with at least 2 clinical encounters to the HCO within the year prior to the study start date.
89123003|NCT05973318|Experimental|Patients with primary open-angle glaucoma receiving Dorzotimol eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d., 12 weeks
89123004|NCT05973318|Active Comparator|Patients with primary open-angle glaucoma receiving Cosopt eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d., 12 weeks
89123005|NCT05973305|Experimental|Patients with primary open-angle glaucoma receiving Dorzol 20 mg/ml|Dorzol 20 mg/ml eye drops, dosing schedule t.i.d, 12 weeks
89123006|NCT05973305|Active Comparator|Patients with primary open-angle glaucoma receiving Trusopt 20 mg/ml|Trusopt 20 mg/ml eye drops, dosing schedule t.i.d, 12 weeks
89123007|NCT05973292|Experimental|Group ZA|Participants received Zirconia anterior endocrowns. Endocrowns were cemented with MDP-containing primer+ MDP-containing resin cement.
89123008|NCT05973292|Experimental|Ggroup ZB|Participants received Zirconia anterior endocrowns. Endocrowns were cemented with MDP-containing primer+ Non-MDP-containing resin cement.
89123009|NCT05973292|Experimental|Group EA|Participants received E-max anterior endocrowns. Endocrowns were cemented with MDP-containing primer+ MDP-containing resin cement.
89123010|NCT05973292|Experimental|Group EB|Participants received E-max anterior endocrowns. Endocrowns were cemented with MDP-containing primer+ Non-MDP-containing resin cement.
89123011|NCT05973253|Experimental|eyes that recieved medroxy progestrone at the end of surgery|eyes that received one drop of medroxy progesterone at the end of the photorefractive keratectomy(PRK)
89123012|NCT05973253|No Intervention|eyes did not recieved moderxy progestrone|eyes that did not receive drop medroxy progesterone at the end of photorefractive keratectomy(PRK)
89123013|NCT04285424|Experimental|HSCT patients with acute steroid-resistant GI-related GVHD|Patients will receive 500ml fecal microbiota which were sprayed evenly on the entire colon through colonscopy or duodenal nutrition tube injection which collected from one unrelated healthy donors. Patients receiving FMT treatment will be followed for at least 1,3,5,7 days.Stool, blood and colonic mucosa samples will be serially collected and tested (before pre-treatment, 1,3,5,7 days after FMT).
89123014|NCT05973201|Experimental|interventional arm|Fibroscopy performed under local anesthesia with immersion in a virtual reality scenario
89123015|NCT05973201|No Intervention|Conventional arm|Fibroscopy performed under local anesthesia without immersion in a virtual reality scenario
89123016|NCT05973188|Active Comparator|Group A, warfarin group|Patients started on warfarin, dose will be adjusted according to patient target INR (2-3)
89123017|NCT05973188|Experimental|Group B, Rivaroxaban (Xcept)|Patients started on rivaroxaban 20mg single dose in 24hours
89123018|NCT05973188|Experimental|Group C, Apixaban ( Apixaget)|Patients started on Apixaban 5mg or 2.5mg (12hours apart)
89123019|NCT05973175||Women with PCOS|"The following inclusion criteria need to be met for the PCOS Study participants:~Women with a confirmed diagnosis polycystic ovary syndrome with androgen excess on clinical or biochemical grounds~BMI 20-40kg/m2~Age range 18-50 years~Ability to provide informed consent"
89123020|NCT05973175||Women without PCOS (controls)|"The following inclusion criteria need to be met for the control Study participants:~No clinical features of possible polycystic ovary syndrome (absence of clinical features of androgen excess and ovulatory dysfunction).~BMI 20-40kg/m2~Age range 18-50 years~Ability to provide informed consent"
89123021|NCT05973149|Experimental|QLH12016 dose escalation|Daily dosages are predetermined by Safety Monitoring Committee after the initial starting dose cohort at the end of Cycle 1 (each cycle is 28 days)
89123022|NCT05973149|Experimental|QLH12016 in mCRPC with specific biomarkers|Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A
89123023|NCT05973149|Experimental|QLH12016 in mCRPC without specific biomarkers|Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A
89123024|NCT05973149|Experimental|QLH12016 in less pretreated mCRPC|Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A
89123025|NCT05973136|Experimental|Intervention group|Group of participant receiving the hybrid telerehabilitation intervention
89123026|NCT05973123|Experimental|BLOOM Group Outings|6 weeks of nature based anxiety intervention for families with children who have at least one ACE and higher than average anxiety. Three of the outings will be group outings; the family will conduct 3 of the outings on their own independently.
89123027|NCT05973123|Experimental|BLOOM Independent Outings|This group receives text support in going outdoors as a family once a week for 6 weeks to gain skills in managing anxiety.
89123028|NCT05973123|No Intervention|Control|Wait listed control. Receives standard of care referral to mental health resources on enrollment. At the end of study receives information on health benefits of being outdoors in nature and an invitation to group outings through the SHINE program at UCSF Benioff Children's Hospital Oakland.
89123029|NCT05973097|Active Comparator|total glucosides of paeony treatment|Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
89123030|NCT05973097|Active Comparator|photodynamic therapy treatment|Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.
89123031|NCT05973097|Experimental|glucosides of paeony and photodynamic therapy combined treatment|Glucosides of paeony and photodynamic therapy are combined for the treatment
89233359|NCT01420250|Experimental|Cabazitaxel with Intensity Modulated Radiation Therapy (IMRT)|Weekly Cabazitaxel with concurrent IMRT
89233361|NCT01361711|Experimental|Treatment (monoclonal antibody therapy)|Patients receive alemtuzumab SC three times a week in weeks 1-18 and ofatumumab IV over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and 17.
89233362|NCT01358058|Experimental|Proton radiation therapy|Single arm study delivering fractionated proton therapy over 6 week (54-59.4 Gy(RBE))
89233364|NCT01313442||1/ Cohort 1|Subjects with a diagnosis of cancer
89233365|NCT01306019|Other|cohort a|First 8 Patients Treated
89233366|NCT01306019|Other|cohort b|Patients 9 and Beyond
89233367|NCT01294332|Experimental|Exercise|Aerobic exercise performed for 12 weeks
89233368|NCT01287156||1|Subjects with diagnosed or suspected TBI or postconcussive syndrome
88801758|NCT01458626|Active Comparator|paroxetine monotherapy|paroxetine 20mg QD
88801759|NCT04281186||Cross-sectional cohort|Up to 720 type 2 diabetic patients (>5 years duration), older than 65 years of age are expected to be recruited in orfer to asure the sample of 168 patients with MCI and 63 normocognitive fulfilling criteria for the prospective study.
88801760|NCT04281186||Prospective study-MCI|Target 168 Patients from the cross-sectional cohort diagnosed with mild cognitive impairment during the cross-sectional evaluation
88801761|NCT04281186||Prospective study normocognitive|63 Patients from the cross-sectional cohort without mild cognitive impairment evaluated during the cross-sectional evaluation
88801762|NCT03725098|Experimental|HEMOBLAST Bellows (Hemostatic Device)|Bleeding sites will be treated with HEMOBLAST Bellows per its approved Indications for Use
88801763|NCT03725098|Active Comparator|FLOSEAL (Hemostatic Device)|Bleeding sites will be treated with FLOSEAL per its approved Indications for Use
88801764|NCT04179708|Experimental|pain neuroscience education|
88801765|NCT04179708|Active Comparator|Conventional education|"patient receiving a classical education on spinal physiology and ergonomics"
88801766|NCT04111276|Experimental|Subjects diagnosed with osteoarthritis of the knee|Subjects must be diagnosed with marked unicompartimental degenerative joint space narrowing.
88801767|NCT05495724|Experimental|Disitamab Vedotin and Tislelizumab|Disitamab Vedotin 120mg IV on day 1 in combination with Tislelizumab 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
88801768|NCT05495724|Other|Disitamab Vedotin|Disitamab Vedotin 120mg IV on day 1 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
88801769|NCT02559414|No Intervention|Control|This arm of 10 subjects will be assigned randomly via a computer generated treatment sequence, and then be given no antiplatelet medication.
88801770|NCT02559414|Active Comparator|Aspirin|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given aspirin.
88801771|NCT02559414|Active Comparator|Clopidogrel|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given clopidogrel.
88801772|NCT03527264|Experimental|Cohort 1A|Nivolumab during Chemo/RT with whole pelvic RT
88801773|NCT03527264|Experimental|Cohort 1B|Nivolumab during Chemo/RT with extended field
88801774|NCT03527264|Experimental|Cohort 2|Chemoradiation followed by Nivolumab Maintenance
88801775|NCT03527264|Experimental|Cohort 3|Nivolumab during chemoradiation and then as maintenance
88801776|NCT04160260|Experimental|Omadacycline: Omadacycline Tablets|
88801777|NCT04713904|Experimental|Clormadinone Ethinyl estradiol Test Product|
88801778|NCT04713904|Active Comparator|Clormadinone Ethinyl estradiol Reference Product|
88801779|NCT01452620||EVAR cohort|All consecutive patients undergoing endovascular AAA repair (EVAR) in our community setting were followed for outcomes.
88801780|NCT04081818|Active Comparator|Intervention group (Nutritious Mushrooms)|
88801781|NCT04081818|No Intervention|Control group|
88801782|NCT01458704||fresh frozen tumor tissue|patients providing fresh frozen tumor tissue
88801783|NCT04054908||Cohort A|Patients treated with oral fluoropyrimidine (Capecitabine (CAP)) as part of standard of care (SOC) chemotherapy
88801784|NCT04054908||Cohort B|Patients treated with Trifluridine/Tipiracil (TAS-102) including those receiving it in combination with Y-90 radioembolization as part of a clinical trial
89233372|NCT01273168|Experimental|1|Z-endoxifen will be administered orally once a day in 28-day cycles
89233377|NCT01237093|Experimental|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda for 12 weeks
89233378|NCT01237093|Experimental|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish for 12 weeks
89233379|NCT01237093|Experimental|4. Meat and fish and soda|weight maintaining diet with meat, fish, and soda for 12 weeks
89233380|NCT01237093|Experimental|5. Fish, no meat or soda|weight maintaining diet with meat, fish, and soda for 12 weeks
89233381|NCT01237093|Experimental|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat for 12 weeks
89233382|NCT01237093|Experimental|7. No meat, fish, or soda|no fish, and no soda (vegetarian) for 12 weeks
89233383|NCT01237093|Experimental|8. Soda, no meart or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda) for 12 weeks
89233384|NCT01237093|Experimental|Meat and fish, no soda|weight maintaining diet with meat and fish but no soda for 12 weeks
89233385|NCT01231932||Cancer survivors|Individuals recently completed primary treatment for cancer
89123032|NCT05973071|Experimental|Tuune|Participants complete the Tuune contraceptive decision aid health questionnaire as part of their standard OBGYN clinic appointment.
89123033|NCT05973071|Active Comparator|Control|Participants will complete a standard OBGYN clinic appointment without using the Tuune contraceptive decision aid health questionnaire.
89123034|NCT05972980||Non-COVID-19 cohort|"Patients with Ventilator Acquired Pneumonia without COVID-19.~The patients belonging to the NON-COVID cohort were admitted to three intensive care units at Molinette Hospital (Turin, Italy):~General Intensive Care Unit - admitting primarily medically critical patients and a smaller proportion of surgical patients, originating from the Hospital's Emergency Department or other Intensive Care Units in Piedmont. It serves as the regional referral center for Extracorporeal Membrane Oxygenation (ECMO).~Emergency Department - Intensive Care Unit (PSAR) - admitting both medical and surgical patients in urgent conditions.~Cardiac - Intensive Care Unit- admitting patients undergoing elective or emergency cardio-surgical interventions, and serving as a referral center for heart and lung transplants and the implantation of external ventricular assists."
89123035|NCT05972980||COVID-19 cohort|"Patients with Ventilator Acquired Pneumonia with COVID-19. Confirmation of pneumonia was achieved by using the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) technique on a sample collected from the lower respiratory tract.~The COVID-19 cohort consists of patients admitted at the Città della Salute e della Scienza University Hospital (Turin, Italy) in two intensive care units at Molinette Hospital, dedicated to treating critically ill patients with COVID-19."
89123036|NCT05972967|Experimental|OMS906 Study Drug - 3 mg/kg IV with Ravulizumab IV|Up to 6 doses of 3 mg/kg at 8-week intervals
89123037|NCT05972967|Experimental|OMS906 Study Drug - 5 mg/kg IV with Ravulizumab IV|Up to 6 doses of 5 mg/kg at 8-week intervals
89123038|NCT05972928|Experimental|Sitagliptin|Sitagliptin at a dose of 100 mg every 24 hours for 3 months
89123039|NCT05972928|No Intervention|control|patient won't receive medication
89123040|NCT05972902|Experimental|Dydrogesterone|For pituitary suppression, the patients receives Dydrogesterone (Duphaston 10 mg/twice daily, Abbott Healthcare, America) orally since day 2-3.
89123041|NCT05972902|Active Comparator|GnRH antagonist|For pituitary suppression, the patients receives GnRH antagonist (CETROTIDE 0.25MG , MERCK SERONO, Germany) 0.25 mg/day subcutaneously since the dominant follicles reached the diameter of 12-14 mm till trigger day.
89123042|NCT05972902|Active Comparator|GnRH agonist|For pituitary suppression, the patients receives (Decapeptyl, sc 0.1 mg/day) beginning in the afternoon of the 21st day of the cycle prior to stimulation
89123043|NCT05972876|Experimental|Blood flow restriction training (BFRT)|Patients in the BFRT group will perform four sets (30, 15, 15 and 15 repetitions, respectively) of unilateral leg press, seated leg extension, deadlift and squat exercises with 30s inter-set rest periods throughout a 0-90° range of motion at 30% one-repetition maximum
89123044|NCT05972876|Active Comparator|Resistance training (RT)|Patients in the resistance training group will perform 3x10 reps (30s inter-set rest) of unilateral leg press, seated leg extension, deadlift and squat exercises exercise throughout a 0-90° range of motion with incremental increase in external-load up to 70% of patients' one-repetition maximum
89123045|NCT05972837|Experimental|SES combined with telemedical support|SES device for personal use will be provided for participants in addition to remote medical support.
89123046|NCT05972837|Active Comparator|SES|Participants in this group will also attend an appointment via a video call with a rehabilitation doctor in the first week but no weekly telehealth visits. Only SES device for personal use and a user manual will be provided.
89123047|NCT05972837|No Intervention|No intervention|Participants in this group will not be provided either SES device or weekly telehealth visits. They are only required to attend a session of video call with a rehabilitation doctor in the first week.
89123048|NCT05972798|Experimental|Omega-3 fatty acids|"Age > 60 years.~Previous major depressive disorder (MDD), single or recurrent.~Mood is relatively stable for at least 3 weeks and the score of 17-item Hamilton Depression Rating Scale (HAMD-17) less than 10"
89123049|NCT05972798|Placebo Comparator|Soybean oil|"Age > 60 years.~Previous major depressive disorder (MDD), single or recurrent.~Mood is relatively stable for at least 3 weeks and the score of 17-item Hamilton Depression Rating Scale (HAMD-17) less than 10"
89123050|NCT05972785||No AHT|Women with HTN with no AHT use
89123051|NCT05972785||AHT but non-CCB|Women with HTN exposed to other antihypertensive medicines but not exposed to calcium channel blockers
89123052|NCT05972785||CCB only|Women with HTN exposed to calcium channel blockers but not exposed to other antihypertensive medicines
89123053|NCT05972785||Both CCB and non-CCB|Women with HTN exposed to both calcium channel blockers and other antihypertensive medicines.
89123054|NCT05972746|Experimental|Telemonitoring program with electronic alerts + Standard of care|
89123055|NCT05972746|Placebo Comparator|Standard of care|
89123056|NCT05972694|Experimental|Freeze-dried Grape powder intervention|participants will be supplemented with 46g/d freeze-dried grape powder consumed as 22.5g packets twice daily for 28 days.
89123057|NCT05972668|Experimental|Intervention Group|Intervention group needs to download the smartphone apps and follow research protocol
89123058|NCT05972668|No Intervention|Control group|
89123059|NCT05972642|Experimental|HIFU treatment|Eligible patients will be treated with HIFU instrument.
89123060|NCT05972616||NMP|"Have clinical or radiological evidence of degenerative disc disease of the lumbar spine.~Have been treated with NMP™ during a lumbar spinal fusion procedure."
89123061|NCT05972603|Experimental|0,35% povidone-iodine solution lavage|0,35% povidone-iodine solution lavage left in wound for 3 minutes following final implantation.
89123062|NCT05972603|Experimental|1.0 g Vancomycin powder into the wound|additional 1.0 g Vancomycin powder into the wound
89290122|NCT01123044|Experimental|corneal stem cell transplant|
89123063|NCT05972577|Experimental|Supportive care (GO!)|Patients undergo personalized GO! plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.
89123064|NCT05972538|Active Comparator|Group I|patients received ball and socket retained mandibular implant overdentures restoring complete edentulous mandible.
89123065|NCT05972538|Experimental|Group II|patients received cement retained mandibular implant overdentures restoring complete edentulous mandible.
89123066|NCT05972499|Placebo Comparator|Group A (control group)|"The children in this group will receive physical therapy exercises to improve gross motor function and functional performance for 30 minutes per session ,3 times per week for three successive months as the following:~Forward and sideways walking between parallel bars, as well as walking training with a stepper. Obstacles such as rolls and wedges are placed across the walking track during gait training in an open manner"
89123067|NCT05972499|Active Comparator|Group B (study group)|"Task-oriented training with pretend play treatment:~Individual interviews will be conducted with subjects and their parents to find their favorite story and to set up a pretend play situation for each subject. The child will have his specific script, will be constructed from his favorite story. The physical therapist will use modeling, prompts, and encouragement to initiate pretend play. Actions and verbalization on the scripts will be constructed to describe the performance of activities based on task-oriented training which include:~Forward, sideways and backward walking. Walking through obstacle course. Walking up and down stairs. Walking up and down ramps. Running. Jumping. Each task will be given for 4 minutes and one minute rest. The child will be encouraged to complete the task and will be verbally cued during training. Tasks will be progressed according to each child's performance. These progressions included increasing the number of repetitions, and speed."
89123068|NCT05972460|Experimental|IMM2510 in Advanced Solid Tumors|"IMM2510 Phase 1a Dose Escalation: 0.007 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 6.0 mg/kg, 10 mg/kg, 20 mg/kg, or higher dose, through intravenous administration every 2 weeks up to 52 weeks.~Phase 1b Cohort Expansion: multiple cohorts are planned, including, but not limited to: non-small cell lung cancer, liver cancer, cervical cancer, cholangiocarcinoma, pancreatic cancer and renal cell carcinoma, with at least 12 patients enrolled in each cohort to further explore the safety and efficacy of IMM2510 in different tumors. The dose for expansion is given by intravenous infusion up to 52 weeks."
88801785|NCT04054908||Cohort C|Patients receiving CAP plus immunotherapy (pembrolizumab) and bevacizumab as part of a clinical trial.
88801786|NCT03995680|Experimental|Chewable tablet of mebendazole|"3-5 year olds allocated to the swallowable tablet arm will be given the crushed tablet on a spoon mixed with a small amount of clean water;~6-12 year olds allocated to the swallowable tablet arm will be given the whole tablet to swallow with a glass of clean water;"
88801787|NCT03995680|Active Comparator|Swallowable tablet of mebendazole|"3-5 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and swallow it without water; if they cannot chew it then a small amount of water will be added to the tablet in a spoon;~6-12 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and then swallow it without water."
88801788|NCT01452698|Experimental|TAK-438 20 mg QD|
88801789|NCT01452698|Active Comparator|AG-1749 30 mg QD|
88801790|NCT04005586|Experimental|Light Delivery Device (LDD)|Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.
88801791|NCT01458860||GROUP A|patients had a CT
88801792|NCT01458860||GROUP B|patients with severe carotid artery stenosis
89123069|NCT05972447|Other|non-restorable mandibular molar teeth|patients with non restorable mandibular molar teeth without any periapical pathosis to be extracted and implanted immediately using ultrawide diameter dental implants
89123070|NCT05972434|Experimental|Group 1: Sunscreen A|Eligible study participants will receive a standard liquid soap to be used on the face and forearms for 3 full days for an initial washout period in place of their usual soap. On their next visit to site an amount of IP will be topically applied to malar on one side of the participant's face by a qualified technician and other side of face will remain without product application (used for control). Six areas will also be marked on inner side of participant's forearms, approximately 5 centimeter (cm) from cubital region. These areas will be randomized, with 1 area for control (without product application) and other 5 areas for product application, being each of them for 02 IPs (Facial Sunscreen A and Face Sunscreen B) and 3 benchmarks. The products will be applied topically only once in marked areas. Next, participants will use Facial Sunscreen A in normal conditions at home for 28 +/- 2 days and then make the last study visit to complete the final analysis.
89123071|NCT05972434|Experimental|Group 2: Sunscreen B|Eligible study participants will receive a standard liquid soap to be used on the face for 3 full days for an initial washout period in place of their usual soap. On their next visit to the Site an amount of the IP will be topically applied to the malar on one side of the participants' face by a qualified technician and the other side of the face will remain without product application (used for control). On their next visit to the Site an amount of the IP will be topically applied to the malar on one side of the participants' face by a qualified technician and the other side of the face will remain without product application (used for control). From Visit 2 to visit 4 participants will use the IP (Face Sunscreen B) at home until 56 +/-2 days of use.
89123072|NCT05972421|Experimental|High Intensity Proactive Outreach|"Patients will receive a mailed letter as well as proactive outreach by phone. The objective of the letter and phone outreach is to describe the Flex Nutrition Program and offer enrollment.~Letters will be written in the primary language spoken by the patient. The letter will contain a call back phone number as well as a primary email contact. Patients will be provided with the phone number of Interpreter Services to utilize if needed.~1 week following the mailing of the letter, patients will receive 3 phone calls within 10 business days, occurring at different times of day. Patients will be provided a call back number. Phone calls will be made to patients in their primary languages, with the use of Interpreters as needed."
89123073|NCT05972421|Experimental|Low Intensity Proactive Outreach|"Patients will receive a mailed letter. The objective of the letter is to describe the Flex Nutrition Program and offer enrollment.~Letters will be written in the primary language spoken by the patient. The letter will contain a call back phone number as well as a primary email contact. Patients will be provided with the phone number of Interpreter Services to utilize if needed."
88801793|NCT01452776|Experimental|TAK-438 10 mg QD|
88801794|NCT01452776|Experimental|TAK-438 20 mg QD|
88801795|NCT03990298|Other|All subjects|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages.
88801796|NCT05029856|Experimental|Group A- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|2 doses of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
88805896|NCT01139879|Experimental|P400 support surface|All patients will receive the P400 mattress
89123074|NCT05972421|No Intervention|No Outreach; Usual Care|Patients will not receive any proactive outreach and will serve as a comparison group. These patients may be referred to the Flex Nutrition Program through their Care Managers.
89123075|NCT05972395||Localized CLBP|Chronic low back pain >3 months with localized pressure pain hyperalgesia
89123076|NCT05972395||Widespread CLBP|Chronic low back pain >3 months with widespread pressure pain hyperalgesia
89123077|NCT05972382||Cervicogenic Headache|Individuals with chronic cervicogenic headache (>3 months duration)
89123078|NCT05972369||Exercise Responders|≥30% improvement in pain with 12 weeks of prescribed exercise
89123079|NCT05972369||Exercise Non-responders|<30% improvement in pain with 12 weeks of prescribed exercise
89123080|NCT05972317|No Intervention|Non-IBS|Participants which are not suffering from IBS symptoms.
89123081|NCT05972317|Experimental|IBS -low FODMAP|individuals that are diagnosed with IBS according to Rome IV criteria
89123082|NCT05972317|No Intervention|FODMAP graduates|Individuals who have practiced a low-FODMAP diet in the past
89123083|NCT05972304|Experimental|Intervention Group|Patients undergoing endoscopic procedures receiving oxygen supplementation through nasal positive airway pressure system ( 10 litters/minute).
89123084|NCT05972304|No Intervention|Control Group|Patients undergoing endoscopic procedures receiving conventional oxygen supplementation through nasal cannula (6 litters/minute).
89123085|NCT05972252|Experimental|Experimental Group|Patients with acute ischemic stroke will receive interventional procedure by the Cerebrovascular Interventional Procedural Control System.
89123086|NCT05972239|Active Comparator|Control|Educational interventions, aerobic and strenght training, flexibility exercises.
89123087|NCT05972239|Experimental|Intervention|Educational interventions, aerobic and strenght training, balance training.
89123088|NCT05972096|Experimental|Combination of DBT-ST, self-compassion, and contextual-based skills.|Combination of DBT-ST, self-compassion, and contextual-based skills.
89123089|NCT05972096|Placebo Comparator|Control Group|Treatment as usual. Although these individuals did not receive any new specific psychotherapeutic intervention for BPD, they valued the higher frequency of psychiatric visits, attention in crisis, family care, and greater experience and sensitivity in the management of BPD.
89123090|NCT05972070||Cardiac patients|Adult patients who have undergone surgical or percutaneous coronary revascularization due to atherosclerotic coronary artery disease.
89123091|NCT05971992|Experimental|Prebiotic|Adult women and men (N = 35) with mild psoriasis (Psoriasis Area and Severity Index; PASI < 10) will receive 15g of prebiotic (chicory-derived inulin-type β-fructans) daily for 8 weeks
89123092|NCT05971992|Placebo Comparator|Placebo|Adult women and men (N = 35) with mild psoriasis (Psoriasis Area and Severity Index; PASI < 10) will receive 15g of placebo (maltodextrin) daily for 8 weeks
89123093|NCT05971992|No Intervention|Control|Healthy adult women and men (N = 30) will not receive any dietary intervention
89123094|NCT05971901||BV use cases|cases in whom BV was ordered
89123095|NCT05971901||BV non-use cases|cases in whom BV was not ordered
89123096|NCT05971862|Experimental|SKI-G-801(Denfivontinib) 100mg QD|Administered orally
89123097|NCT05971862|Experimental|SKI-G-801(Denfivontinib) 150mg QD|Administered orally
89123098|NCT05971862|Experimental|SKI-G-801(Denfivontinib) 225mg QD|Administered orally
88801797|NCT05029856|Experimental|Group B- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|2 doses of 5 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
89123099|NCT05971862|Experimental|SKI-G-801(Denfivontinib) 300mg QD|Administered orally
89123100|NCT05971862|Experimental|SKI-G-801(Denfivontinib) 400mg QD|Administered orally
89123101|NCT05971862|Experimental|SKI-G-801(Denfivontinib) 500mg QD|Administered orally
89123102|NCT05971836||Subjects with Reproductive Disorders|Individuals with reproductive disorders and their affected and unaffected family members
89123103|NCT05971771|Experimental|Active: Sleep Supplement containing Magnesium and Saffron Extract|Powder that is to be mixed into 3oz. of water, 30-60 minutes before going to bed
89123104|NCT05971771|Placebo Comparator|Placebo|Placebo that is 2 softgels that will be taken with water, 30-60 minutes prior to going to bed.
89123105|NCT05971758|Active Comparator|Fimepinostat 60mg|two 30mg capsules once a day, 10 subjects
89123106|NCT05971758|Active Comparator|Fimepinostat 30mg|single 30mg capsule daily in 10 subjects
89123107|NCT05971706|Experimental|ozone|Gaseous ozone was applied immediately after non-surgical periodontal treatment
89123108|NCT05971706|Active Comparator|control|Only non-surgical periodontal treatment was applied
89123109|NCT05971680|Experimental|Vitamin B 1|VITAMIN B1 (High Potency) 500mg
89123110|NCT05971680|Other|control|patient not subjected to treatment . only follow up
89123111|NCT05971654|Experimental|Azithromycin|azithromycin.:500 mg PO once for 5 days every month
89123112|NCT05971654|No Intervention|control|pregnant woman at risk of preterm delivery
89123113|NCT05971628|Experimental|Liver transplantation with the RAPID procedure|Liver transplantation for hepatocellular carcinoma according to the RAPID protocol. This protocol is an auxiliary liver transplantation of a partial graft with total hepatectomy in two stages (2 successive operations).
89123114|NCT05971628|No Intervention|Comparator group with standard liver transplantation (whole graft)|Orthotopic liver transplantation with whole organ from deceased donor for hepatocellular carcinoma. Data will be provided by Biomedicine Agency, following pairing rules.
89123115|NCT05971615|Other|Peripheral Venous Blood Gases|
89123116|NCT05971589|Experimental|Intravenous of LM103|≥5×10^9 cells (LM103) will be infused i.v. to patients after non-myeloablative lymphodepletion treatment with Cyclophosphamide for Injection and Fludarabine Phosphate for Injection.
89123117|NCT05971576|Experimental|Intravenous of LM103|≥5×10^9 cells (LM103) will be infused i.v. to patients after non-myeloablative lymphodepletion treatment with Cyclophosphamide for Injection and Fludarabine Phosphate for Injection.
89123118|NCT05971563|Active Comparator|Casein|
89123119|NCT05971563|Active Comparator|Glycomacropeptide|
89123120|NCT05971563|Active Comparator|L- amino acids|
89123121|NCT05971550|Experimental|Patients : Absence of antibiotic treatment|
89123122|NCT05971550|Active Comparator|Patients : Ceftriaxone|
89123123|NCT05971524|Placebo Comparator|Placebo|An oral placebo capsule once daily for 4 weeks
89123124|NCT05971524|Experimental|2mg 6-BT|2 mg of 6-BT as an oral capsule once daily for 4 weeks
89123125|NCT05971524|Experimental|4mg 6-BT|4 mg of 6-BT as an oral capsule once daily for 4 weeks
89123126|NCT05971524|Experimental|8mg 6-BT|8 mg of 6-BT as an oral capsule once daily for 4 weeks
89123127|NCT05971472|Active Comparator|Arthroscopic Repair|Arthroscopic Repair for medial meniscus posterior root tears
89123128|NCT05971472|Active Comparator|High tibial osteotomy|Open wedge High tibial osteotomy for medial meniscus posterior root tears
89123129|NCT05971459|Experimental|Individuals with PD|One music therapy session of 30 minutes
89123130|NCT05971459|Active Comparator|Healthy Individuals|One music therapy session of 30 minutes
89123131|NCT05971446||Participants with HIE|
89123132|NCT05971446||Healthy participants|
89123133|NCT05971420|Experimental|VR group|VR activity-based training
89123134|NCT05971420|Active Comparator|Exercise group|Exercise-based training (Baduanjin)
89123135|NCT05971394|Experimental|IBS Titan|Subjects treated with IBS Titan™.Participants will be included in this arm.
89123136|NCT05971342|Experimental|Gelatin sponge-loaded apoptotic vesicle complex|4 * 10^10 apoptotic vesicles derived from umbilical cord mesenchymal stem cells were loaded in a gelatin sponge（Kuaikang®）. A piece of gelatin sponge-loaded apoptotic vesicle complex was placed in an extraction socket after tooth extraction.
89123137|NCT05971342|Active Comparator|Gelatin sponge only|A piece of gelatin sponge（Kuaikang®）was placed in an extraction socket after tooth extraction.
89123138|NCT05971316|Experimental|Warm-up + Foam Roller|General Warm-up + Warm-up with Foam Roller
89123139|NCT05971316|No Intervention|Warm-up Only|General Warm-up only
89123140|NCT05971290|Experimental|Continuous Positive Airway Pressure use|
89123141|NCT05971290|Sham Comparator|Ambient air|
89123142|NCT05971264|Experimental|Single Arm|
89123143|NCT05971238|Experimental|Eye-tracking, pupillometry and scene rating indoors & outdoors|
89123144|NCT05971212|Experimental|Intervention|Access to Sleep Clinic immediately
89123145|NCT05971212|Experimental|Control|Access to Sleep Clinic delayed
89123146|NCT05971199|Experimental|treatment|Fruquintinib+sintilimab+TACE
89123147|NCT05971186|Active Comparator|Ibuprofen|"Fifteen participants were randomly selected to form the third intervention group. Each subject in this arm received a single tablet of Ibuprofen, with a dosage of 400 mg. Similar to the other arms, they were given a 15-minute window to take the Ibuprofen tablet.~Prior to administering the Ibuprofen, the pain intensity of the participants was measured using the standardized Numeric Rating Scale (NRS). Additionally, the pain intensity was measured again two hours after the consumption of the Ibuprofen tablet, using the same Numeric Rating Scale (NRS)."
89123148|NCT05971186|Active Comparator|Young Coconut Water|"Fifteen participants were randomly selected to join the intervention group. Each subject in this arm received a single dose of 330 ml of young coconut water. To ensure uniformity, they were given a 15-minute window to consume the entire 330 ml of the young coconut water intervention.~Before administering the young coconut water, the pain intensity of the participants was measured using a standardized Numeric Rating Scale (NRS). Additionally, the pain intensity was reevaluated two hours after the consumption of the young coconut water, using the same Numeric Rating Scale (NRS)."
89123149|NCT05971186|Active Comparator|Dark Chocolate Bar|"Fifteen participants were also randomly chosen for the second intervention group. In this arm, each subject received a single 70% dark chocolate bar weighing 35 grams. Similar to Arm 1, they were given a 15-minute timeframe to consume the entire dark chocolate bar intervention.~Prior to giving the dark chocolate bar, the pain intensity of the participants was measured using the Numeric Rating Scale (NRS). Subsequently, the pain intensity was reassessed two hours after the consumption of the dark chocolate bar, using the same Numeric Rating Scale (NRS)."
89123150|NCT05971134|Experimental|experimental group|Intervention group 1 consisted of patients with brescia-cimino fistula Intervention group 2 consisted of patients with snuff-box fistula Intervention group 3 consisted of patients with antecubital fistula.
89123151|NCT05971134|No Intervention|Control Group|Control group 1 consisted of patients with brescia-cimino fistula Control group 2 consisted of patients with snuff-box fistula Control group 3 consisted of patients with antecubital fistula.
89123152|NCT05971121||ciprofol group|Hypotensive ICU patient sedated with ciprofol
89123153|NCT05971121||propofol group|Hypotensive ICU patient sedated with propofol
89123154|NCT05971095|Experimental|Neuromodulation group|"The maximum isometric contraction force of the quadriceps will be measured prior to the neuromodulation program using a hand dynamometer.~The percutaneous neuromodulation program will begin using the EPTE® Bipolar System device. The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts.~The low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to.~The surgical intervention will be carried out by subarachnoid block with local anesthetic in accordance with the usual practice.~After its completion, a single injection block of the femoral nerve will be performed with a long-acting local anesthetic , a regional anesthesia technique included in routine clinical practice."
89123155|NCT05971095|No Intervention|Control group|The neuromodulation program will not be carried out. Only the maximum contraction force of the quadriceps prior to subarachnoid block will be measured. After the intervention, the femoral nerve block will be performed following the usual clinical practice.
89123156|NCT05971069|Experimental|Group1|Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
89123157|NCT05971069|Experimental|Group2|Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
89123158|NCT05971069|Experimental|Group3|No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
89123159|NCT05971030|Experimental|CBS for mPFC and dlPFC|Case series of AD patients who accept CBS for mPFC and dlPFC
89123160|NCT05971017|Placebo Comparator|Control group|To the control group was assigned lettuce without any biostimulation but with the same characteristic of biostimulated lettuce (soil, water, harvesting time)
89290123|NCT01123044|No Intervention|conservative medical therapy|
89123161|NCT05971017|Experimental|Biostimulated Group|experimental: Biostimulated group: To the intervention group was assigned the biostimulated lettuce.
89123162|NCT05971004|Experimental|Collagen Peptide Group|The Collagen Peptide Group (31 patients) received oral pain relievers (paracetamol and anti-inflammatory NSAIDs) for 3-7 days (if the pain was severe) and one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point (femoral condyle).
89123163|NCT05971004|Active Comparator|Cortison Group|The Cortison Group (31 patients) received oral painkillers (paracetamol and anti-inflammatory NSAIDs) for 3-7 days (if the pain was severe) and one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
89123164|NCT05970991|Active Comparator|MBC Controls|Control group clinicians will complete the Brief Online Training (BOLT) for Measurement-Based Care (MBC) and consultation packages (4 online training modules supported by two 1-hour long, live post-training consultation sessions and expert-facilitated asynchronous online discussion board).
89123165|NCT05970991|Experimental|MBC + VIBRANT|Experimental condition clinicians will complete the same online training modules for MBC (BOLT) as the control group, but also complete the Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT) module (45 minutes). They will also receive two 1-hour long, live post-training consultation sessions and expert-facilitated asynchronous online discussion board.
89123166|NCT05970276|Experimental|Deep Sleep Enhancement with TES|Transcranial Electrical Stimulation, 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
88801798|NCT05029856|Experimental|Group C- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|1 dose of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
89123167|NCT05968534|Other|MOSAIC Plus|This is a single-arm open-trial to evaluate and refine the feasibility and acceptability of training and recruitment methods. Data from this phase will be used to refine and inform study procedures for the subsequent RCT.
89123168|NCT05968313||NSSI|
89123169|NCT05968313||HC|
89123170|NCT05967143||Patients with unresectable HCC or unresectable liver metastases from mCRC|This cohort will include patients with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy, who have been prescribed selective internal radiation therapy (SIRT) with SIR-Spheres per medical decision.
89123171|NCT05966909||Solid cancer patients|Patients with solid cancer who underwent the placement of a PICC or PICC-PORT for chemotherapy.
89123172|NCT05966298|Experimental|Core stabilization group|Individuals included in this group will receive 20 minutes of core stabilization training in addition to 40 minutes of standard rehabilitation. Patients will be trained 5 days a week for first 3 weeks(standart rehabilitation + core stabilization training) then will be trained 3 days a week on 4-6 week (only core stabilization training). The next 6 weeks will be given a home exercise program including shoulder exercises and core stabilization training.
89123173|NCT05966298|Other|Control group|Individuals included in this group will receive only 40 minutes of standard rehabilitation. Patients will be trained 5 days a week for first 3 weeks(only standart rehabilitation). The next 9 weeks will be given a home exercise program including shoulder exercises.
89123174|NCT05966103|Active Comparator|Conventional Exercise Group (Control Group)|Conventional neck exercises were applied to the control group.
89123175|NCT05966103|Experimental|Scapulothoracic Exercise (Treatment Group)|In the treatment group, scapulothoracic exercises were applied in addition to conventional neck exercises.
89123176|NCT05964517|No Intervention|Control Group|The control group refers to patients with tension-type headache who will not be treated. These patients are only evaluated during follow-up.
89123177|NCT05964517|Active Comparator|Study Group|Patients with tension-type headache in the study group are treated. Evaluations are made before and after treatment.
89123178|NCT05964478|Experimental|Intervention arm of schools in Nigeria and Palestine|The participating schools in this arm will receive the multi-component hand hygiene intervention package for a duration of one year
88801799|NCT05029856|Experimental|Group D - SII B.1.351 Vaccine / Matrix-M1 Adjuvant|1 dose of 5 μg SII B.1.351 Vaccine + 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
88801800|NCT05029856|Experimental|Group E -SII Bivalent Vaccine / Matrix-M1 Adjuvant|2 doses of 6 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
88801801|NCT05029856|Experimental|Group F- SII Bivalent Vaccine / Matrix-M1 Adjuvant|2 doses of 10 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
89123179|NCT05964478|No Intervention|Control arm of schools in Nigeria and Palestine|The participating schools in this arm will not receive the multi-component hand hygiene intervention package until the conclusion of the study, which occurs one year after the completion of data collection at the endline assessment
89123180|NCT05962866|Experimental|Experiment: Have pregnant women perform the 1st and 2nd Leopold Maneuvers|Voluntary information form will be read to those who want to participate in the research, verbal and written permissions will be obtained and information will be given about fetal development and Leopold maneuvers in the pregnant follow-up room of the family health center. This transaction is 28-32. 32-38 at the next follow-up at gestational weeks. Pregnancy will be carried out with the same procedure.
89123181|NCT05962866|No Intervention|Control: Assigned Interventions standard care group|No intervention will be made.
89123182|NCT05956951|Experimental|Experimental: Night three- sham, night four - active|"This arm will receive sham auditory stimulation for the first 3 nights and active auditory stimulation for the fourth night.~Night one - sham auditory stimulation, night 2 - sham auditory stimulation, night 3 - sham auditory stimulation, night 4 - active auditory stimulation"
89123183|NCT05956951|Experimental|Experimental: Night three - active, night four - sham|"This arm will receive sham auditory stimulation for the first two nights, active auditory stimulation for the third night, and sham auditory stimulation for the fourth night.~Night one - sham auditory stimulation, night two - sham auditory stimulation, night three - active auditory stimulation, night four - sham auditory stimulation"
89123184|NCT05954715|Experimental|IPC (Ischaemic Preconditioning)|IPC will be administered to the upper limb using cuff inflation pressures of 200 mmHg or 60mm Hg above the systolic BP (whichever is higher). Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
88801802|NCT05029856|Experimental|Group G- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant|2 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
89123185|NCT05954715|Sham Comparator|Sham|The Sham intervention will be administered with a BP cuff over the upper arm being inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles will comprise of four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation.
89123186|NCT05952583||sFGR cohort|Monochorionic diamniotic twin pregnancies complicated by sFGR (diagnosed before 28 weeks of gestational age)
89123187|NCT05944263|Experimental|The gratitude, kindness and hope (GKH) program|"This gratitude, kindness and hope (GKH) program will be a structured manual-based intervention that has been adapted and contextualized from the previous work that has been done in this field. Each intervention session will be conducted in the school and community settings by 2 youth trainers aged 18 - 24 and who will be trained in the delivery of the intervention.~The sessions will be held twice a week, concurrently in schools and in the community. Fifty per cent of the sessions will be supervised by master trainers (who are experts in charge of training the youth trainers on the intervention). The rest of the sessions will be audio-recorded and reviewed randomly during supervision meetings.~The total duration of each session will be 45 minutes distributed as shown below:~iv. 5 minutes warm up activity v. 30 minutes practice and explanation of concepts through interactive activities and discussions vi. 10 mins answering questions and designing homework"
89123188|NCT05944263|Active Comparator|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|"The program delivered to the control group is adapted from the Stan Kutcher Teen Mental Health Curriculum. It was initially developed to help enhance the mental health literacy of students and was developed for ages 13 to 15 years which was further adapted for a slightly lower age group (12-14 yrs) as that targeted in this study through simplification of terminologies to ensure age-appropriate content.~Just like the GKH program, the TMH sessions will be delivered by 2 trained youth trainers in the school and community settings. The program will be delivered over 8 sessions, two sessions a week (i.e. over a span of 4 weeks). Half of the sessions will be supervised by master trainers. Like the GKH program, each session will go for 45 minutes each ."
89123189|NCT05938062|Experimental|grup 1: the group without fibrinogen concentrate (GNF)|grup 1: the group without fibrinogen concentrate (GNF)
89123190|NCT05938062|Experimental|Grup 2: the group with fibrinogen concentrate|Grup 2: the group with fibrinogen concentrate
89123191|NCT05930808|Experimental|First Test Concor (Fasted), Then Reference Concor (Fasted)|Participants will receive a single oral dose of Test Concor tablet on Day 1 in treatment period 1 followed by single oral dose of reference Concor tablet on Day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period.
89123192|NCT05930808|Experimental|First Reference Concor (Fasted), Then Test Concor (Fasted)|Participants will receive a single oral dose of Reference Concor tablet on Day 1 in treatment period 1 followed by single oral dose of Test Concor tablet on day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period.
89123193|NCT05930808|Experimental|First Test Concor (Fed), Then Reference Concor (Fed)|Participants will receive a single oral dose of Test Concor tablet on Day 1 in treatment period 1 followed by a single oral dose of Reference Concor tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
89123194|NCT05930808|Experimental|First Reference Concor (Fed), Then Test Concor (Fed)|Participants will receive a single oral dose of Reference Concor tablet on Day 1 in treatment period 1 followed by a single oral dose of Test Concor tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period.
89123195|NCT05928676|Experimental|Vascanox® HP|
89123196|NCT05921162||Observation of Participants exposed to 1.2E11gc/eye of vMCO-I|This is a long-term follow-up observational study of participants who previously received 1.2E11gc/eye of vMCO-I No investigational product will be administered in this study.
89123197|NCT05921162||Observation of Participants exposed to 0.6E11gc/eye of vMCO-I|This is a long-term follow-up observational study of participants who previously received 0.6E11gc/eye of vMCO-I No investigational product will be administered in this study.
89123198|NCT05916352|Active Comparator|Caffeine Group|5 mg/kg caffein supplement will be given
89123199|NCT05916352|Placebo Comparator|Placebo Group|Placebo will be given
89123200|NCT05898789|Experimental|CaRE@Home intervention|
89123201|NCT05898789|No Intervention|Usual Care group|
89123202|NCT05894460||Chocolate balloon|
89123203|NCT05894460||Conventional ballon|
89123204|NCT05892211||Group 1 (vasomotor symptoms present)|Participants who have vasomotor symptoms. Sleep is recorded by polysomnography for a night. Hot flashes during sleep are recorded by two electrodes measuring the skin conductance near sternum. Any hot flashes reported subjectively by the patient during the recording is noted. Their blood samples are obtained.
89123205|NCT05892211||Group 2 (vasomotor symptoms absent)|Participants who don't have vasomotor symptoms. Sleep is recorded by polysomnography for a night. Hot flashes during sleep are recorded by two electrodes measuring the skin conductance near sternum. Any hot flashes reported subjectively by the patient during the recording is noted. Their blood samples are obtained.
89123206|NCT05889637||Group G: Patients taking GLP-1receptor agonists|
89123207|NCT05889637||Group C: Patients not taking GLP-1 receptor agonists (control group)|
89123208|NCT05875922|Experimental|IOL implantation experimental|Experimental arm: Premium monofocal intraocular lens.
89123209|NCT05875922|Active Comparator|IOL implantation active comparator|Comparator arm: EDOF intraocular lens.
89123210|NCT05866445|Experimental|Hypertensive|Hypertensive patients
89123211|NCT05866445|Experimental|Normotensive participants|Normotensive participants with no high blood pressure
88801803|NCT05029856|Experimental|Group H- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant|1 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose on Days 0.
89123212|NCT05862727|Experimental|PASS Arm1|Caregivers will receive sessions of evidence-based behavioral parent training which focuses on improving behaviors, such as establishing daytime and bedtime routines, through enhancement of positive parenting skills, including modifying antecedents, applying/withdrawing positive attention as a consequence, and shaping behavior using salient rewards.
88801804|NCT05490498|Experimental|Breastfeeding mother|Breastfeeding mother with infants between 1 and 89 days of age who presented with suspected neonatal bacterial sepsis due to the presence of a fever.
89123213|NCT05862727|Active Comparator|PASS Arm2|Caregivers will receive sessions of evidence-based behavioral parent training which focuses on improving behaviors, including in home and public settings, through enhancement of positive parenting skills, including modifying antecedents, applying/withdrawing positive attention as a consequence, and shaping behavior using salient rewards.
89123214|NCT05852340|Active Comparator|Treatment A|ritlecitinib 1 x 30 milligram (mg) intact blend-in-capsule (BiC) in fasted state
89123215|NCT05852340|Active Comparator|Treatment B|contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on strawberry jam in fasted state
89123216|NCT05852340|Active Comparator|Treatment C|contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on yoghurt in fasted state
89123217|NCT05852340|Active Comparator|Treatment D|contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on applesauce in fasted state
89123218|NCT05852340|Active Comparator|Treatment E|ritlecitinib 1 x 30 mg intact BiC given with high fat meal
89123219|NCT05850442||FIBROMIYALGIA GROUP|Patients aged between 18-65 who are diagnosed as FMS according to AACR 2016 criterias willing to take part in the study.
89123220|NCT05847465||Case group (exercise heat stroke patients)|Participants enrolled in the case group have been experiencing exercise heat stroke and are participating in the main EXPLO-CCE study.
89123221|NCT05847465||Control group (healthy individuals)|Participants enrolled in the control group are healthy individuals who are participating in the main EXPLO-CCE study.
89123222|NCT05837390||High risk singleton pregnancy for preterm birth|
89123223|NCT05834400|Experimental|The Optimal Lymph Flow (TOLF)|Participants in this arm perform lymphatic exercise training AND daily monitoring of fluid overload symptoms for 4 weeks
89123224|NCT05834400|Active Comparator|Daily Monitoring|Participants in this arm will only perform daily monitoring of fluid overload symptoms including weight, heart rate, and blood pressure for 4 weeks. Participants will NOT perform TOLF in this arm.
89123225|NCT05833334|Active Comparator|Public health infographic (AIM 3)|Participants will view a standard public health infographic about home air radon testing and will receive information about requesting a free home air radon test kit from their state radon program.
89123226|NCT05833334|Experimental|Online health promotion intervention tailored by smoking status (AIM 3)|Participants will view an online health promotion intervention about home air radon testing, with messaging tailored based on whether the participant smokes or does not smoke. Participants will also receive information about requesting a free home air radon test kit from their state radon program.
89123227|NCT05833334|Experimental|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Participants will view an online health promotion intervention about home air radon testing, with messaging tailored based on whether the participant smokes or does not smoke. Participants will also receive information about requesting a free home air radon test kit from their state radon program, as well as reminder messages about radon testing for about two months after initially viewing the online intervention component.
89123228|NCT05833334|Experimental|Focus group with educational overview (AIM 1)|Participants will participate in a focus group discussion about radon testing and will receive a brief educational overview about radon testing.
89123229|NCT05821660|Experimental|Five-day hypocaloric and ketogenic programme|The group will receive a five-day remotely delivered hypocaloric and ketogenic programme followed by a four-day food reintroduction period
89123230|NCT05821660|No Intervention|Control|The group will maintain their habitual diet
89123231|NCT05813964|Active Comparator|Event-driven PrEP with TDF/FTC|Participants randomly assigned to the event-driven TDF/FTC arm will be instructed to take a loading dose of two single tablets containing coformulated TDF/FTC (300/200mg) 2 to 24 hours before sexual intercourse, followed by a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourses, they will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills.
89123232|NCT05813964|Experimental|Event-driven PrEP with TAF/FTC|Participants randomly assigned to the event-driven TAF/FTC arm will be instructed to take one single tablet containing coformulated TAF/FTC (25/200mg) with or without food 2 to 24 hours before sexual intercourse followed by a second pill 24 hours after the first drug intake. In case of daily sexual intercourses, they will be instructed to take one pill per day until the last sexual intercourse and then a last pill 24 hours later.
89123233|NCT05797636|Experimental|Transcranial magnetic stimulation participants|All participants will be recruited into a single arm where, across two sessions they will receive transcranial magnetic stimulation in separate session to either the dorsolateral prefrontal cortex or the angular gyrus. Session order will be counter-balanced across participants, and stimulation target will be blinded to the participants until after their participation is complete.
89123234|NCT05777889||Study CRPS Group|"Enrolled patients with complex regional pain syndrome undergoing a surgical procedure that requires spinal cord stimulation.~All participants in the group will have an image of their feet taken perpendicularly with a 1-inch space from all four sides using a FLIR T420 or T62101 camera with 320*240 resolution.~All participants will also answer questionnaires about: their average pain score, CRPS severity, quality of life, and neuropathic pain."
89123235|NCT05771103|Active Comparator|Stellate ganglion block with alcohol injection|Stellate ganglion block with alcohol injection by ultrasound guidance and C7 level confirmation by fluoroscopy.
89123236|NCT05771103|Active Comparator|thermal RF neurolysis of Stellate ganglion|Stellate ganglion RF therapy will be done under fluoroscopy, integrated by ultrasound guidance
89123237|NCT05750732||Study group|Age range 20-50, BMI range of 25-40 kg/m2
89123238|NCT05750732||Control group|Age range 20-50, BMI range18.5-24.9 kg/m2
89123239|NCT05743647||Young|40 right handed healthy subject aged between 18 and 40
89123240|NCT05743647||Old|40 right handed healthy subject aged between 41 and 75
89123241|NCT05739006|Experimental|Group 1|BCD-201 200 mg by intravenous infusions once every 3 weeks
89123242|NCT05739006|Active Comparator|Group 2|Keytruda 200 mg by intravenous infusions once every 3 weeks
89233386|NCT01231932||Individuals receiving cancer treatment|Individuals receiving cancer treatment
89233387|NCT01231932||Individuals with cancer|Individuals with cancer
88801805|NCT03505372|Experimental|Contrast enhanced mammography|"The CESM images will be performed according to clinical protocol~Images will be acquired within approximately 2-12 minutes of contrast injection~A total of four images per breast will be acquired with low and high energy~Two radiologists will prospectively review the CESM, and will use a third as tie-breaker~The CESM will be evaluated for the biopsy site and up to two additional findings in either breast~The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement"
88801806|NCT05495412|Other|Rebound therapy|Exercise therapy which uses a full sized trampoline to provide opportunities for movement, therapeutic exercise and recreation for children and young people.
88801807|NCT03429712|Experimental|Dose Split CT|
89123243|NCT05725824|Active Comparator|Third-party control|Ear canal impressions will be will be packaged and sent to a professional third-party manufacturer for fabrication in an acrylic material-type. These will serve as the control earmolds, by which the in-house study/intervention earmolds will be compared against. To control for style of earmolds, all earmolds will be made in a skeleton style with a sound bore that accommodates size #13 tubing and a separate select-a-vent (SAV).
89123244|NCT05725824|Experimental|In-house Study group_Resin|Custom earmold impressions will be scanned and edited using computer-aided design software. These 3D earmold meshes will then be converted to g-code using licensed software and sent to a stereolithography 3D printer for fabrication. Participants will only wear these study earmolds for the duration of testing.To control for style of earmolds, all earmolds will be made in a skeleton style with a sound bore that accommodates size #13 tubing and a separate select-a-vent (SAV).
89123245|NCT05725824|Experimental|In-house Study group_PLA|Custom earmold impressions will be scanned and edited using computer-aided design software. These 3D earmold meshes will then be converted to g-code using licensed software and sent to a fused deposition modeling 3D printer for fabrication. Participants will only wear these study earmolds for the duration of testing. To control for style of earmolds, all earmolds will be made in a skeleton style with a sound bore that accommodates size #13 tubing and a separate select-a-vent (SAV).
89123246|NCT05720013|Experimental|Beetroot Juice Supplement|140 mL of beetroot juice supplement will be ingested orally (Beet-It Nitrate 400, James White Co).
89123247|NCT05720013|Placebo Comparator|Placebo Supplement|140 mL of placebo supplement will be ingested orally (Beet-It Nitrate 400, James White Co).
89123248|NCT05713383|No Intervention|Walking|Walking normally without restriction
89123249|NCT05713383|Experimental|Walking Quietly|Participants instructed to make little noise while walking.
89123250|NCT05695027|Experimental|Nicotinamide and Pyruvate|The N&P group will receive nicotinamide and pyruvate for 87 weeks (20 months).
89123251|NCT05695027|Placebo Comparator|Placebo|The placebo group will receive placebo for 87 weeks (20 months).
89123252|NCT05694182|Experimental|Oral superfruits supplement|Participants will consume oral superfruits supplement once daily for 6 weeks.
89123253|NCT05676580|Other|Abstention|After keratoconus diagnosis the patient won't be assigned to intervention
89123254|NCT05676580|Other|Intervention (cross-linking surgery or intra corneal ring)|After keratoconus diagnosis the patient was assigned to cross linking surgery or intra corneal ring surgery
89123255|NCT05631795|Experimental|Alpelisib + fulvestrant|Alpelisib 300 mg orally once daily starting on Cycle 1 Day 1 in combination with fulvestrant (intramuscular injection) 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28 day cycle.
89123256|NCT05629637|Experimental|Mindfulness-Based Resilience Training (MBRT)|MBRT is an 2.5-day program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive-behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
89123257|NCT05623865|Experimental|Experimental group|"After the initial evaluation, the patients will be randomly divided into two groups as the Experimental group and the control group.Experimental group will receive kinesiotape treatment in addition to those applied in the control group.~Kinesiotape to the kinesio tape group will be done by a PM&R spesialist doctor who has a certificate of kinesiotaping, in accordance with the literature, using the lymphedema method."
89123258|NCT05623865|Other|Control group|Elevation and cold application, which is applied in the prevention and treatment of classical edema, will be recommended to the control group. In addition, wrist, elbow, finger range of motion and stretching exercises will be taught as a home exercise program.
89123259|NCT05619107|Active Comparator|Active transauricular nerve stimulation|Using a training device, two conductive clips are placed securely on both the left and right tragus areas of the outer ear. Using parameters we have identified through systematic review, electrical stimulation (pulse width:200μs; frequency:30Hz) is initiated at 10mA, until the participant feels a 'tingling' sensation within 20s of commencing. At this point the current is reduced to a level just below this perceptible threshold (20-60 mA), which is defined as the 'prescription dose'. The participant then receives another active device set at the 'prescription dose'.
89123260|NCT05619107|Sham Comparator|Sham transauricular nerve stimulation|Using a training device, two conductive clips are placed securely on both the left and right tragus areas of the outer ear. Using parameters we have identified through systematic review, electrical stimulation (pulse width:200μs; frequency:30Hz) is initiated at 10mA, until the participant feels a 'tingling' sensation within 20s of commencing (Figure 2). At this point the current is reduced to a level just below this perceptible threshold (20-60 mA), which is defined as the 'prescription dose'. The participant then receives another device set at the 'prescription dose' but this sham device is disabled from delivering any current .
89123261|NCT05608668|Experimental|Active inspiratory muscle rehabilitation (IMR) group|"Each participant will be provided a PrO2™ device and trained on its use and its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal).~The research team will implement biofeedback signals at a specific inspiratory resistance to provide a precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP."
88801808|NCT02881970|Experimental|Neonatal hypoxic-ischaemic encephalopathy|
89123262|NCT05608668|Active Comparator|SHAM|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition.
89123263|NCT05607069||COVID-19 previous infection|
89123264|NCT05605483||Schools with salad bars|Schools with salad bars
89123265|NCT05605483||Schools without salad bars|Schools without salad bars
89123266|NCT05605483||Schools with salad parts post COVID-19|A subset schools with salad bars that were examined pre-COVID-19 will undergo methods again.
89123267|NCT05602662|Experimental|Music therapy during mechanical ventilation in the iCU.|Headphones with music.
89123268|NCT05602662|Sham Comparator|Comparator|Headphones only.
89123269|NCT05598528||EGFR-positive lung patients recieving 3rd generation EGFR-TKIs as first-line therapy|Stage III-IV EGFR-positive lung patients receiving 3rd generation EGFR-TKIs (Osimertinib 80mg/Qd or Almonertinib 110mg/Qd or Furmonertinib 80mg/Qd) as first-line therapy.
89123270|NCT05598034|Experimental|Left DLPFC tDCS|Participants randomized to this arm will receive tDCS at the left DLPFC brain region.
89123271|NCT05598034|Experimental|Left DLPFC tDCS + task|Participants randomized to this arm will receive tDCS at the left DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
89123272|NCT05598034|Experimental|Right DLPFC tDCS|Participants randomized to this arm will receive tDCS at the right DLPFC brain region.
89123273|NCT05598034|Experimental|Right DLPFC tDCS + task|Participants randomized to this arm will receive tDCS at the right DLPFC brain region. Additionally, participants will be asked to perform a mental task (2-back working memory) at the same time.
89123274|NCT05597462|Experimental|DFD-29|DFD-29 (minocycline hydrochloride) capsules, 40 mg will be administered orally once daily for 16 weeks.
89123275|NCT05597462|Placebo Comparator|Placebo|Placebo capsules will be administered orally once daily for 16 weeks.
89123276|NCT05595135|Experimental|Health services research (text messages, smart pill bottle)|Patients receive interactive text messages to help with adherence to medications and a smart pill bottle with medication reminders on study.
89123277|NCT05588986||with IUGR|Pregnant women who received antenatal corticosteroid therapy and complicated with intrauterine growth retardation
89123278|NCT05588986||without IUGR|Pregnant women who received antenatal corticosteroid therapy and were not complicated by intrauterine growth retardation
89123279|NCT05578118||ICSI + AOA|Children born after ICSI + AOA
89123280|NCT05578118||Control|Children born after ICSI
89123281|NCT05572671|Experimental|fMRI smoking lapse task|
89123282|NCT05571384|Experimental|high intensity body-weight circuit (HIBC)|HIBC Exercise Protocol- circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10), and modified push-ups (5). The exercise sessions will involve repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Three sessions per week will be completed at home. After three weeks of training, participants will be asked to add a fourth session each week. Initially, the HIBC sessions will be five minutes long, and the duration of the sessions will increase by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session (warm up not included in this timing) as early as the eighth week of training. Session duration will be capped at 10-minutes.
89123283|NCT05571384|Active Comparator|traditional exercise intervention (TEI)|TEI Protocol- The American College of Sports Medicine (ACSM) and the American Diabetes Association (ADA) joint position stand on exercise prevention for T2DM recommends participants undertake at least 150 min/week of moderate to vigorous activity in high-risk adults 5,13. Therefore, this intervention will initially consist of three sessions per week of 40 minutes of continuous physical activity, and increase to a fourth weekly session following the third week. The TEI modality will consist of walking exercise at a moderate intensity of 40- 60% heart rate reserve (([maximal heart rate - resting heart rate] x 0.4-0.6) + resting heart rate). Participants will continue this protocol for 16-weeks.
89123284|NCT05564559|Experimental|MFGP intervention|This group will provide 8 weeks of multi-family psychoeducation to the families of people living with a diagnosis of substance abuse disorder.
89123285|NCT05564559|No Intervention|Wait list-control group|This group will provide 8 weeks of multi-family psychoeducation to the families of people living with a diagnosis of substance abuse disorder after the intervention group is completed. This group is the control group on the waiting list.
89123286|NCT05526105|Experimental|Standard ASA NPO Protocol|Patients will be made NPO at midnight prior to date of surgery.
89123287|NCT05526105|Experimental|Liberal Feeding Protocol|Patients will be fed enterally up until call to OR at which time their stomachs will be decompressed with a pre-existing gastric tube.
89123288|NCT05514067|Experimental|Electro-acupuncture (EA) arm|Patients with stable CAD going for coronary artery bypass graft (CABG) surgery randomized to receive EA before surgery.
89123289|NCT05514067|No Intervention|Standard Care arm|Patients with stable CAD going for coronary artery bypass graft (CABG) surgery.
89123290|NCT05508932||Beta-thalassemia|Patients with Beta-thalassemia undergoing a cardiological evaluation
89123291|NCT05506358|Other|1) HbSS; 2) HbAS; 3) HbS/β-thalassemia; 4)Hbβ/β-thalassemia; 5) HbA/β- thalassemia; 6) HbAA|"Around 20 participants each (in Nepal):~with the homozygous form of sickle cell disease (HbSS)~with the heterozygous form of sickle cell disease (HbAS)~with the compound heterozygous form of sickle cell disease (HbS/β-thalassemia)~with the carrier form of β-thalassemia (HbA/β-thalassemia)~with the carrier form of β-thalassemia (HbA/β-thalassemia)~without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc.~Around 30 participants each (in Canada):~with the homozygous form of sickle cell disease (HbSS)~with the heterozygous form of sickle cell disease (HbAS)~without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc."
88801809|NCT03950310|Experimental|ELCA|On the antegrade delivery of the laser catheter after wiring, we used safe laser techniques and injected saline before and during the laser procedure at a 0.5 mm/sec catheter advancement rate. Whether to perform a retrograde laser method depended on each operator. After ablation by ELCA, patients undergo balloon dilation via standard techniques, and as appropriate, receive drug-eluting stent deployment.
89123292|NCT05501171|Experimental|DREAMLAND|"Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA.~Participants will use DREAMLAND and during hospitalization for treatment of AML to learn how to cope most effectively with the diagnosis of AML using an iPad provided by the study team or participant's own iPad.~Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days."
89123293|NCT05501171|Active Comparator|CERENA|"Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA.~Participants will use the mobile app CERENA during hospitalization for treatment of AML to learn how to best care for themselves using an iPad provided by the study team or participant's own iPad.~Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days."
89123294|NCT05484687|Experimental|Lidocaine is used in radical resection of colorectal tumors.|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
89123295|NCT05481892|Experimental|Cellular Home blood pressure (BP) monitoring with minimal support|Patients will be instructed to write down their blood pressures (BP) in a BP log that will be provided to them at the time of enrollment. Study staff will access the patient's home BP measurements on the BP device dashboard and send a summary of the home BP measurements (mean, median, % of BP measurements at goal) to the primary care provider in a telephone encounter (TE) 3 to 5 days prior to the next scheduled visit.
89123296|NCT05481892|Active Comparator|Cellular Home blood pressure (BP) monitoring with pharmacist support for treatment intensification|For patients randomized to this intervention arm, a pharmacist will review the home blood pressure (BP) measurements and use an evidence-based algorithm to make recommendations for medication intensification. If the patient has a primary care provider (PCP) appointment within 2 weeks, the pharmacist will send a telephone encounter (TE) with BP measurements and medication recommendations to the PCP 3 -5 days prior to the scheduled appointment. If the patients has no appointment scheduled within two weeks, the pharmacist will call the patient and prescribe medication intensification if the patient is amenable.
89123297|NCT05481892|No Intervention|Non-randomized usual care|To compare the two intervention arms with usual care, investigators will extract electronic health record (EHR) data on active San Francisco Health Network (SFHN) adult patients (age 18+) with diagnosis of hypertension who made at least one primary care visit during the study period.
89123298|NCT05480384|Experimental|Starting Trastuzumab Deruxtecan Dose|Trastuzumab deruxtecan, 6.4 mg/kg IV every 3 weeks for 17 doses (12 months)
89123299|NCT05480384|Experimental|First Trastuzumab Deruxtecan Dose Reduction|Trastuzumab deruxtecan, 5.4 mg/kg IV every 3 weeks for 17 doses (12 months)
89123300|NCT05480384|Experimental|Second Trastuzumab Deruxtecan Dose Reduction|Trastuzumab deruxtecan, 4.4 mg/kg IV every 3 weeks for 17 doses (12 months)
89123301|NCT05476484||Allergic rhinitis patients with and without asthma treated with SQ SLIT-tablet|
89123302|NCT05476484||Allergic rhinitis patients with and without asthma not treated with SQ SLIT-tablet|
89123303|NCT05474235||ALS or Suspected ALS Patient|Subjects with clinical diagnosis of possible, laboratory-supported probable, probable or definite, ALS or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features or a blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features.
89123304|NCT05474235||Blood Relative of ALS Patient|Subjects with family history (first, second or third degree blood relative) of ALS or other motor neuron disease.
89123305|NCT05474235||Healthy Control|Subjects with no personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease
89123306|NCT05471154|Experimental|Active HD-tDCS|Half of all subjects will receive active HD-tDCS (randomly assigned): anodal stimulation on the right dorsolateral prefrontal cortex. Stimulation will consist of 20 minutes 2mA anodal stimulation of the right dorsolateral prefrontal cortex.
89123307|NCT05471154|Sham Comparator|Sham HD-tDCS|Half of all subjects will receive sham HD-tDCS (randomly assigned). A ramp-up of 1 minute will be used to induce the same feelings as during the active tDCS, but will then stop the stimulation. A short ramp up is repeated in the last minute of the protocol.
89123308|NCT05465382|Experimental|Intra-articular saline lavage|"Subjects in Group 1 will then undergo saline joint lavage as follows:~Subjects will undergo aspiration of the injured ankle joint via the standard anteromedial arthroscopy portal approach. This will be performed with sterile technique using a 16-gauge needle attached to a 10cc syringe. After synovial fluid aspiration, three 10cc syringes will be filled with 10cc of sterile 0.9% normal saline. Normal saline will be injected into the ankle joint and withdrawn from the joint via the existing anteromedial 16 gauge needle. After three rounds of lavage, 10cc of 1% lidocaine without epinephrine will be injected into the joint via the existing anteromedial 16-gauge needle. Subjects will undergo a period of soft tissue rest to allow for the resolution of soft tissue swelling. At the time of surgical fixation subjects will again undergo intra-articular aspiration of the injured ankle joint."
89123309|NCT05465382|No Intervention|No intra-articular saline lavage|"Subjects in group 2 will not undergo normal saline lavage as follows:~Subjects will undergo aspiration of the injured ankle joint via the standard anteromedial arthroscopy portal approach. This will be performed with sterile technique using a 16-gauge needle attached to a 10cc syringe. After synovial fluid aspiration, they will undergo intra-articular injection of 10cc of 1% lidocaine without epinephrine via the existing anteromedial 16-gauge needle. Subjects will undergo a period of soft tissue rest to allow for the resolution of soft tissue swelling. At the time of surgical fixation, subjects will again undergo intra-articular aspiration of the injured ankle joint."
89123310|NCT05462392|Experimental|the Micro Hand S robot group|68 patients were randomly allocated in the Micro Hand S robot group and partial nephrectomy, radical cystectomy, and radical prostatectomy will be performed using the Micro Hand S robot.
89123311|NCT05462392|Other|the da Vinci robot group|68 patients were randomly allocated in the da Vinci robot group and partial nephrectomy, radical cystectomy, and radical prostatectomy will be performed using the da Vinci robot.
89123312|NCT05434013|Experimental|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
89123313|NCT05434013|Experimental|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
89123314|NCT05434013|Experimental|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
89123315|NCT05427201|Experimental|DLPFC-rTMS + ACT|Active DLPFC-rTMS with ACT treatment
89123316|NCT05427201|Active Comparator|Sham-rTMS + ACT|Sham delivered rTMS with ACT treatment
89123317|NCT05426655|Experimental|Self management|Intervention group: education in pain neuroscience + self-massage + exercises + advice and recommendations.
89123318|NCT05425550|Experimental|Arm A|Experimental group is using the medidux™ app
89123319|NCT05425550|No Intervention|Arm B|
89123320|NCT05416632|Experimental|Arthrometer|
89123321|NCT05399784|Experimental|Early & Often Postpartum Care|Visit at 2-3 and 6 weeks postpartum.
89123322|NCT05399784|Placebo Comparator|Standard Postpartum Care|Visit at 6 weeks postpartum.
89123323|NCT05397704|Experimental|desaturation|Controlled desaturation studies are conducted by changing the alveolar oxygen tension (or pressure, PAO2). This is achieved by a dedicated gas delivery system, RespirAct RAMR (Thornhill Research, Toronto, ON). The attained PAO2 then determines the arterial oxygen tension (PaO2) at the alveolar-arterial interspace in the lung. The arterial oxygen tension (PaO2) will then determine the arterial oxygen saturation (SaO2) and in turn, the pulse oximeter oxygen saturation (SpO2). The step down changes in the alveolar oxygen tension (PAO2) will result in the corresponding step down changes in SaO2/SpO2 from 100 to 70%.
89123324|NCT05396222|Experimental|3D-printed|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
89123325|NCT05392855|Experimental|Symptom driven|Symptom driven performance of airway clearance regimen
89123326|NCT05392855|Active Comparator|Continuous|Continuous performance of baseline daily airway clearance regimen
89123327|NCT05388149|Experimental|Neratinib Arm|Standard T-DM1 (3.6mg/kg) IV infusion every 3 weeks administered with Neratinib (160 mg) orally once daily up to 1 year.
89123328|NCT05380115|Experimental|CBT|All subjects enrolled received CBT for 10 weeks.
89123329|NCT05374642|Experimental|cognitive training|
89123330|NCT05374642|Active Comparator|active control|
89123331|NCT05351255|Experimental|rTMS Intervention|In aim 2 of the study, participants receive a repetitive transcranial magnetic stimulation intervention called theta burst stimulation (TBS) to study its effect on motor learning behavior. All participants will complete 3 sessions in which they will receive continuous TBS, intermittent TBS, or sham TBS before completing a behavioral motor learning task. The order of TBS sessions will be counter-balanced across participants.
89123332|NCT05349656|Experimental|trans muscular quadratus lumborum (TQL) block|after induction of general anesthesia (GA), the participant will be placed in the lateral position, and a high-frequency linear ultrasound probe (5-13 MHz) will be placed on the anterior iliac crest. The Petit's triangle (formed of the iliac crest inferiorly and the borders of external abdominal oblique anteriorly and latissimus dorsi (LD) posteriorly) will be identified and then Tracing dorsally from Petit's triangle, the external oblique, and the internal oblique are seen disappearing into an aponeurosis as the quadratus lumborum (QL) appears beneath the LD (anteriorly), and going farther dorsally, the QL, erector spinae, and psoas major (PM) muscles around the transverse process of lumbar vertebra L4 are seen. A 22-gauge needle will be inserted using an in-plane technique along the posterior edge of the probe in the anteromedial direction. The needle tip will be placed between the QL muscle and the PM muscle, then 0.5 ml/kg of 0.25% bupivacaine will be injected.
89123333|NCT05349656|Experimental|Pericapsular nerve group (PENG) block|After induction of GA, the participant will be in the supine position. A linear high-frequency ultrasound probe (5-13MHz) will be initially placed in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees; In this view, the ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle Will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution of 0.25% bupivacaine will be injected in 5-mL increments while observing for an adequate fluid spread in this plane for a total volume of 0.5 ml/kg.
89123334|NCT05343455|Experimental|DFD-29|DFD-29 (40 mg) extended release capsules
89123335|NCT05343455|Active Comparator|Doxycycline 40 mg|Doxycycline 40 mg modified release capsules
89123336|NCT05343455|Placebo Comparator|Placebo|Placebo capsules matching DFD-29
89123337|NCT05312710|Experimental|APG-157|Two pastilles (100 mg) taken three times a day (i.e. before meal time).
89123338|NCT05310240||Hip arthroscopy|Patients that underwent hip arthroscopy at this department between 2013 and 2021.
89123339|NCT05303324|Experimental|Sequence 1 (AB)|"Participants received ALXN1840 once in each Period as a single oral dose under fasted conditions as follows:~Period 1: ALXN1840 as a single EC tablet (Treatment A, reference). Period 2: ALXN1840 as three EC tablets (Treatment B, test).~Participants were discharged following the 240-hour post-dose procedures (approximately 10 days after dosing in each period) unless it was medically necessary to extend the confinement.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89123340|NCT05303324|Experimental|Sequence 2 (BA)|"Participants received ALXN1840 once in each Period as a single oral dose under fasted conditions as follows:~Period 1: ALXN1840 as three EC tablets (Treatment B, test). Period 2: ALXN1840 as a single EC tablet (Treatment A, reference).~Participants were discharged following the 240-hour post-dose procedures (approximately 10 days after dosing in each period) unless it was medically necessary to extend the confinement.~There was a washout period of at least 14 days between each ALXN1840 dosing."
89123341|NCT05284838|Experimental|Error Management Training (Difficult)|Participants receive the learning strategy Error Management Training and encounter difficult questions.
89123342|NCT05284838|Experimental|Error Management Training (Easy)|Participants receive the learning strategy Error Management Training and encounter easy questions.
89123343|NCT05284838|Active Comparator|Error Avoidance Training|Participants receive the learning strategy Error Avoidance Training.
89123344|NCT05268198|Experimental|Intervention/Treatment|Single dose, oral inhalation (nebuliser solution)
89123345|NCT05268198|Placebo Comparator|Placebo|Placebo
89123346|NCT05252052||Adolescents 14-24 years old|Adolescents 14-24 years old
89123347|NCT05252052||Health care providers in rural Haiti|Health care providers in rural Haiti
89123348|NCT05249816|Experimental|NVX-CoV2373|NVX-CoV2373 (5 μg): Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg antigen and 100 μg adjuvant per mL. The vaccination regimen will comprise of 1 intramuscular (IM) injection on Day 0 of 0.5 mL injection volume at a dose of 5 μg of antigen with 50 μg Matrix-M adjuvant.
89123349|NCT05249816|Active Comparator|BBIBP CorV|Sinopharm BBIBP-CorV vaccine administered per manufacturer instructions as a single intramuscular injection.
89123350|NCT05238207|Experimental|BBI-001|BBI-001: Oral administration immediately prior to a meal enriched with stable iron isotope Fe57
89123351|NCT05238207|Placebo Comparator|Placebo|Placebo: Oral administration immediately prior to a meal enriched with stable iron isotope Fe58
89123352|NCT05230693|Experimental|SPARC Group|
89123353|NCT05230693|Active Comparator|Enhanced Standard Care Control Group|
89123354|NCT05223439||Individuals diagnosed with neuropathic pain due to lumbar disc degeneration|Individuals with neuropathic pain due to lumbar disc degeneration were included in this group.
89123355|NCT05223439||Individuals with lumbar disc degeneration but no neuropathic pain|Individuals without neuropathic pain due to lumbar disc degeneration were included in this group.
89123356|NCT05223439||Healthy Controls|Healthy individuals who did not have any problems that would affect gait were included.
89123357|NCT05213104|Experimental|group 1 - Flecainide 150 mg 6 months|Flecainide 150 mg 6 months in addition to standard of care
89123358|NCT05213104|Experimental|group 2 - Flecainide 150 mg 3 months|Flecainide 150 mg 3 months in addition to standard of care
89123359|NCT05213104|No Intervention|group 3 - no Flecainide|to receive no additional treatment (standard of care only).
89123360|NCT05208710|Experimental|PANHPVAX 10µg|PANHPVAX 10µg plus c-di AMP in escalating doses
89123361|NCT05208710|Experimental|PANHPVAX 40µg|PANHPVAX 40µg plus c-di AMP in escalating doses
89123362|NCT05208710|Experimental|PANHPVAX 100µg|PANHPVAX 100µg plus c-di AMP in escalating doses
89123363|NCT05195177|Experimental|Study group|
89123364|NCT05192577|Experimental|Study group|
89123365|NCT05165433|Experimental|All cohorts|NG-350A and pembrolizumab
89123366|NCT05150431|Experimental|Parecoxib|Parecoxib 40mg will be administered to this group 15 minutes before the end of the surgery.
89123367|NCT05150431|Placebo Comparator|Placebo|2ml normal saline will be administered to this group 15 minutes before the end of the surgery.
89123368|NCT05148923|Active Comparator|Rational energy algorithm|150 J, 360 J, 360 J biphasic DCCV
89123369|NCT05148923|Active Comparator|Maximum fixed energy algorithm|3x 360 J biphasic DCCV
89123370|NCT05138601|No Intervention|Usual Care with Education|The participant will be provided with educational material and a home BP monitor. Control participants will continue to see their physicians for their usual care for BP management (their BP data will not be reviewed by pharmacists and the patients will not have support from vCCC pharmacists)
89123371|NCT05138601|Experimental|Virtual Collaborative Care Clinic|Participants will partake in the virtual collaborative care clinic
89123372|NCT05130255|Experimental|GD2-SADA:177Lu-DOTA Complex|"GD2-SADA IV. infusion followed by 177Lu-DOTA IV. infusion (The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA ).~1 treatment cycle in Part A, 2 treatment cycles in Part B and up to 5 treatment cycles in Part C"
89123373|NCT05119764|No Intervention|Control Group|Standard pre- and postoperative physical therapy without manual lymphatic drainage.
89123374|NCT05119764|Experimental|Manual lymphatic drainage before and after knee replacement|Manual lymphatic drainage before and after knee replacement
89123375|NCT05119764|Experimental|Manual lymphatic drainage after knee replacement|Manual lymphatic drainage after knee replacement
89123376|NCT05115851|Experimental|Anodal tDCS cerebellar stimulation group:|Anodal tDCS cerebellar stimulation
89123377|NCT05115851|Experimental|Anodal tDCS cerebral (M1) stimulation group:|Anodal tDCS cerebral (M1) stimulation
89123378|NCT05115851|Sham Comparator|Sham Group|Sham
89123379|NCT05057637||Complete cohort|In all patients included in the study subsequent optical coherence tomography (OCT) measurements will be performed pre and post stent placement.
89123380|NCT05013502|Experimental|Empagliflozin 10mg PO daily for 12 weeks|Single arm trial
89123381|NCT05007392|Experimental|Drug: Dotinurad + Febuxostat Matched Placebo|Participants will receive one dotinurad 1 mg tablet and one febuxostat 20 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then one dotinurad 2 mg tablet and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two dotinurad 2 mg tablets and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
89233393|NCT01174121|Experimental|1/CD8+ Enriched TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young CD8+ enriched TIL + high-dose aldesleukin (CLOSED)
88801810|NCT03950310|No Intervention|non ELCA|In non ELCA group, the conventional PCI procedure, including thrombus aspiration, POBA, and stent implantation was performed. The indication for aspiration was at the discretion of the physician based on angiographic, intravascular ultrasound, or optical coherence tomography/Optical Frequency-Domain Imaging.
88801811|NCT05314348|Active Comparator|Motor Neuron Disease|High-density surface EMG Ultrasound
88801812|NCT05314348|Active Comparator|Healthy controls|High-density surface EMG Ultrasound
88801813|NCT04424628|Active Comparator|Radiotherapy 3 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (0.5 Gy in 6 fractions alternating days).~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be randomized to 3 or 6 Gy again"
89123382|NCT05007392|Active Comparator|Drug: Febuxostat + Dotinurad Matched Placebo|Participants will receive one febuxostat 20 mg tablet and one dotinurad 1 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then two febuxostat 20 mg tablets and one dotinurad 2 mg matched placebo tablet, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two febuxostat 20 mg tablets and two dotinurad 2 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
89123383|NCT05000749|Experimental|DBT-SG plus VHA treatment as usual|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
89123384|NCT05000749|Active Comparator|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
89123385|NCT04979429|Experimental|PePS|4 sessions of telephone CBT-based pain self-management in addition to standard perioperative care.
89123386|NCT04979429|No Intervention|Standard Care|Standard perioperative care.
89123387|NCT04958434|Experimental|Part A - Dose Escalation|Dosed every 3 weeks IV with TST005, starting dose is 1 mg/kg, and 5 dose levels will be tested.
89123388|NCT04958434|Experimental|Part B - Dose Expansion|Participants with any kind of advanced or HPV metastatic solid tumors dosed Q3W with the Part A Q3W recommended dose of TST005
89123389|NCT04948099|Experimental|VIB1116|"Single dose of VIB1116, SC or IV administration.~Multiple doses of VIB1116, SC administration."
89123390|NCT04948099|Placebo Comparator|Placebo|"Single dose of Placebo, SC or IV administration.~Multiple doses of Placebo, SC administration."
89123391|NCT04922112|Experimental|Research group|Sleep apnea testing will be performed with this group, in the form of quality of life and sleep questionnaires, home sleep study results, as well as information collected from their electronic medical record. The investigator will also obtain blood laboratory specimens to measure serum TNF-alpha and IL-6.
89123392|NCT04911751|Experimental|Low dose group|39 subjects for low dose group. 26 subjects on KBL697, 13 subjects on placebo.
89123393|NCT04911751|Experimental|High dose group|39 subjects for high dose group. 26 subjects on KBL697, 13 subjects on placebo.
89123394|NCT04909853|Experimental|PF-07321332|PF 07321332/ritonavir
89123395|NCT04902573||Asthma patients|Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.
89123396|NCT04898348|Placebo Comparator|Placebo|3 capsules twice a day dosing of Placebo
89123397|NCT04898348|Experimental|KBL697|3 capsules twice a day dosing of KBL697
89123398|NCT04878354|Placebo Comparator|Placebo|Gelatine (fish source), mannitol and sodium hydroxide
89123399|NCT04878354|Experimental|Intervention/treatment|Sublingual allergy immunotherapy tablet, for daily administration SQ tree SLIT-tablet
89123400|NCT04849507|Active Comparator|active taVNS|We will deliver taVNS via the BabyStrong system, with pulses paired with oral feeding, off with rest during 2 feeds a day. Current will be delivered at 0.1milliAmpere (mA) < perceptual threshold (PT), 500microseconds, 25 Hertz (Hz).The ear electrode will be positioned on left tragus for active taVNS.
89123401|NCT04849507|Sham Comparator|sham taVNS|The ear electrode positioned on left tragus as for active taVNS. We will test the PT with active stimulation, and then program a sham setting on the BabyStrong unit to deliver no current after the PT is determined.
89123402|NCT04825574|Experimental|Patients with GIST previously enrolled in avapritinib clinical trials|
89123403|NCT04811664|Experimental|Immediate Vaccination|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml Intramuscular into the deltoid muscle on Day 1 and Day 29.
89123404|NCT04811664|Experimental|Standard of care|Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml Intramuscular into the deltoid muscle on Day 113 and Day 141.
89123405|NCT04811664|No Intervention|Vaccine Declined|Participants who prefer not to be vaccinated, If requested, participant will be offered vaccine if they have not received vaccine outside of the study
89123406|NCT04811261|Experimental|3+3 dose escalation|The first 3 subjects' patients will be administered 50 x 10^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
89123407|NCT04795674|Experimental|ADHD EWM|Participants will receive EWM training sessions.
89123408|NCT04795674|Placebo Comparator|ADHD Placebo|Participants will receive placebo training sessions.
89123409|NCT04782570|Experimental|Verum TMS|ITBS (intermittent Theta Burst Stimulation) over left frontal cortex
89123410|NCT04782570|Sham Comparator|Sham TMS|Sham TMS over left frontal cortex
89123411|NCT04771780|Experimental|KHK7791|"During the dosing period, subjects administer KHK7791 twice daily just before meals.Subjects will be underwent tests at scheduled visits at least weekly until Week 12, at least once every 2 weeks after completion of Week 12 test.~KHK7791 and phosphate binders are adjusted with the goal of controlling serum phosphorus concentration within a certain range based on the dose adjustment criteria described in the study protocol.It should be considered that phosphorus adsorbent should be switched to KHK7791 whenever feasible."
89123412|NCT04733534|Active Comparator|Dasatinib plus Quercetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16^INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 will assess the permanence of change after completion of the trial."
88801814|NCT04424628|Active Comparator|Radiotherapy 6 Gy|"Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (1 Gy in 6 fractions alternating days).~Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be treated with 6 Gy again"
89123413|NCT04733534|Active Comparator|Fisetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 to will assess the permanence of change after completion of the trial."
89123414|NCT04732689||Groups/Cohorts|The investigators propose to conduct a prospective observational cohort which will include all consecutive adult liver transplant recipients in each center during a one-year period but will exclude same patients who undergo a retransplantation during the same period of observation.
89123415|NCT04727307|Experimental|Neoadjuvant Atezolizumab before radiofrequency ablation then adjuvant Atezolizumab + Bevacizumab|Neoadjuvant atezolizumab and adjuvant atezolizumab + bevacizumab in combination with percutaneous radiofrequency ablation
89123416|NCT04727307|Active Comparator|Percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation, standard treatment
89123417|NCT04726930||Intercostal nerve block with surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.~Code name: ICNB-INUS-check"
89123418|NCT04726930||Paravertebral block with surface ultrasound|Number of participants: 10 Paravertebral blocks will be performed under guidance of surface ultrasound. After we reach the injection site, the puncture stylet will be replace by Intra-needle ultrasound transducer (INUS). Collect signal from Intra-needle ultrasound transducer and then inject local anesthetics.
89123419|NCT04726930||Intercostal nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Intercostal blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.~Code name: ICNB-INUS-guide"
89123420|NCT04726930||Paravertebral nerve block with intra-needle and surface ultrasound|"Number of participants: 10 Paravertebral blocks will be performed under guidance of intra-needle and surface ultrasound. The intra-needle transducer will be placed inside the puncture needle and it will be the primary guidance to reach target injection site. Surface ultrasound will be the secondary image guide for simultaneous comparison. Collect signal from both Intra-needle ultrasound transducer and surface ultrasound, and then inject local anesthetics.~Code name: PVB-INUS-guide"
89123421|NCT04725773||PD DBS|Patients with Parkinson's disease and deep brain stimulation
89123422|NCT04683939|Experimental|Part 1A - BNT141 monotherapy escalation|Administration once every three weeks (Q3W)
89123423|NCT04683939|Experimental|Part 1B - BNT141 in combination with nab-paclitaxel and gemcitabine|BNT141 will be administered once every three weeks (Q3W). Nab-paclitaxel and gemcitabine will be administered on three days of each 28-day cycle.
89123424|NCT04680598||high HBV-DNA group|patients with HBV-DNA >500 IU/ml
89123425|NCT04680598||low HBV-DNA group|patients with HBV-DNA≤500 IU/ml
89123426|NCT04669340|Experimental|Intervention group|"Participants in the intervention group will receive patient education through an e-learning program at home. A study nurse will introduce patients to the program and they will be asked to accomplish the program within four weeks. Furthermore, they will be encouraged to go through the program as many times as necessary and involve family and relatives if they like.~Both groups will receive one planned phone call regarding medication 2-3 weeks after they started taking the medicine. Furthermore, both groups will be referred to a physiotherapist if needed. All patients have access to contact the out-patient clinic as needed throughout the study period."
89123427|NCT04669340|Active Comparator|Control group|"Participants in the control group will receive conventional patient education from a nurse in the out-patient clinic within four weeks after inclusion. Relatives can take part in the conversation.~Both groups will receive one planned phone call regarding medication 2-3 weeks after they started taking the medicine. Furthermore, both groups will be referred to a physiotherapist if needed. All patients have access to contact the out-patient clinic as needed throughout the study period."
89123428|NCT04669002|Experimental|Phase 2A Cohort 1|Patients with advanced platinum resistant ovarian cancer who have received no more than 1 prior line of therapy which must be platinum-based chemotherapy
89123429|NCT04669002|Experimental|Phase 2A Cohort 2|Patients with advanced ovarian cancer who have received at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by a PARP inhibitor as maintenance treatment as their last treatment regimen
89123430|NCT04655079|Experimental|Real tDCS group|Participants receive anodal tDCS on the left dlPFC for 5 days/week for 2 weeks
88801815|NCT01452932|Experimental|Physiotherapy|Group of participants who recive physiotherapy treatment using Kabat technique for the upper limbs resistance training during 12 weeks
88801816|NCT01452932|Other|Yoga|Group of participants who recive Yoga sessions during 12 weeks
88801817|NCT00377416|Experimental|1|rAAV2-CB-hAAT Gene Vector
88801818|NCT01458938||Healthy volunteers|
88801819|NCT01458938||surgery for spinal radiculopathy|
88801820|NCT01458938||surgery for axial spine pain|
88801821|NCT01458938||myelography for spinal pain|
89123431|NCT04655079|Sham Comparator|Sham group|Participants receive sham stimulation on the left dlPFC for 5 days/week for 2 weeks
89123432|NCT04640493|Experimental|SGLT2-SDB|Patients with newly diagnosed SDB will be given dapagliflozin (standard dosage, 10mg)
89123433|NCT04617262|Experimental|Remote Problem Management Plus|Five individual sessions of low-intensity psychological intervention
89123434|NCT04612933|Experimental|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
88801822|NCT05490342||tacrolimus-based immunosuppresion|The TAC-based group will include any patient on tacrolimus monotherapy and patients taking multiple IS medications with blood tacrolimus levels > 5 ng/mL
88801823|NCT05490342||NON-tacrolimus-based immunosuppresion|The NON-TAC-based group will include any patient on TAC-free therapy and patient taking multiple IS medications with blood tacrolimus levels < 5 ng/mL
89123435|NCT04612933|No Intervention|No intervention|"All appointments, scheduled and non-scheduled are by face-face communication with the health care professionals.~Patients will receive their usual treatment."
89123436|NCT04597112|Experimental|Myofascial Release Group|Intervention group, who received conventional therapy and myofascial release therapy.All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. In the intervention group, the myofascial release technique will be applied to the wrist flexors and extensors, elbow flexors and extensors, pectoralis, supraspinatus, infraspinatus, trapezius muscles, starting from the fingers after the conventional treatment, 3 days a week for 4 weeks.
89123437|NCT04597112|Active Comparator|Exercise Group|The control group will consist of patients who received conventional therapy and exercise therapy. All participants will be given conventional treatment 3 days a week for 4 weeks. Conventional treatment will include 20 minutes hotpack, 5 minutes ultrasound, 20 minutes Transcutaneous Electrical Stimulation. After conventional treatment, a program consisting of neck extension, lateral flexion and rotation range of motion, stretching of the trapezius muscles and strengthening of the neck extensor muscles will be applied to the control group in the presence of a physiotherapist 3 days a week for 4 weeks.
89123438|NCT04553432|Experimental|Omnigen + OmniLenz|Omnigen amniotic membrane 17mm disk with 6mm central aperture place under 18mm OmniLenz bandage contact lens
89123439|NCT04553432|Active Comparator|OmniLenz|Bandage contact lens alone
89123440|NCT04552704|Experimental|Phase I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 with standard of care (i.e., steroids per treating physician and best supportive care) in the absence of disease progression or unacceptable toxicity.
89123441|NCT04552704|Experimental|Phase II, Arm I (CD24Fc)|Patients receive CD24Fc IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
89123442|NCT04552704|Placebo Comparator|Phase II, Arm II (placebo)|Patients receive placebo IV over 60 minutes on days 1, 14, and 28 in addition to standard of care treatment for irAE in the absence of disease progression or unacceptable toxicity.
89123443|NCT04528173|Active Comparator|Traditional Care Group (TCG)|Traditional anesthetic with opioids group will receive institutional standard clinical care for tonsillectomy, including a standardized opioid dose at the beginning of the case and again at the end if needed. Dexmedetomidine and Ketorolac will not be used intra-operatively in this cohort to prevent confounding.
89123444|NCT04528173|Experimental|Opioid-Free Group (OFG)|Opioid-Free group will receive institutional standard clinical care for tonsillectomy, without opioids, but including Dexmedetomidine and Ketorolac.
89123445|NCT04519944||NVAF patients undergoing PCI|Patients with non-valvular atrial fibrillation (NVAF) who had successful percutaneous coronary intervention (PCI).
89123446|NCT04519801|Other|REHAB|Standard post-operative rehabilitation regimen (REHAB) (Control)
89123447|NCT04519801|Experimental|REHAB + BFR|Standard rehabilitation regimen with BFR therapy (REHAB + BFR) (Experimental)
89123448|NCT04497376|Experimental|Upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo ethanol infusion in the vein of Marshall (EI-VOM) followed by the '2C3L' ablation step which includes bilateral circumferential PV antral ablation and linear ablations across the left atrial roof, mitral isthmus (MI), and cavotricuspid isthmus (CTI).
89123449|NCT04497376|Active Comparator|Pulmonary vein antral isolation (PVI)|Patients randomized to the PVI arm will undergo right PV antrum ablation, followed by the left PVA ablation. Radiofrequency should be applied 1 cm proximal to the PV ostia in a wide-area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished.
89123450|NCT04495751|Experimental|Muscadine Grape Extract Arm|Muscadine grape extract pill (12 week supply)
89123451|NCT04495751|Placebo Comparator|Placebo Arm|Placebo provided (12 week supply)
89123452|NCT04495582||Non-Interventional Study group|Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.
89123453|NCT04485728|Experimental|Sleep Improvement Intervention|
89123454|NCT04485728|No Intervention|Standard of Care (Control)|
89123455|NCT04455074|Experimental|PD patients with motor fluctuations|FN scale is an autoquestionnaire consisting of 20 questions, to be answered in On-med and OFF-med condition
89123456|NCT04453553|Active Comparator|Standard of care|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14
89123457|NCT04453553|Experimental|Near Patient Testing|Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system
89123458|NCT04449666||Experimental group|Patients undergoing neurological rehabilitation after aneurysmal subarachnoid hemorrhage
88801824|NCT03352882|Other|Open Label|All enrolled participants will undergo hepatic ultrasound with acoustic radiation force impulse (ARFI) before and 30 days after creation of TIPS.
88801825|NCT01459094|Experimental|Treatment Sequence AB|
88801826|NCT01459094|Experimental|Treatment Sequence BA|
88801827|NCT05495100|Experimental|Mitoxantrone liposome combined with Chidamide and Azacitidine|
89123459|NCT04449666||Control group|Healthy adults controlled for age, gender and educational status
89123460|NCT04445649||ICU patients|Patients with impaired consciousness admitted to intensive care unit after severe brain injury
89123461|NCT04430452|Experimental|Arm I (hypofractionated RT, durvalumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89233394|NCT01174121|Experimental|2/Unselected TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin (CLOSED)
88801828|NCT03325114|Other|Chlorthalidone|Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks
89123462|NCT04430452|Experimental|Arm II (hypofractionated RT, durvalumab, tremelimumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with durvalumab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who complete the first dose of tremelimumab and demonstrate clinical benefit based upon radiographic tumor regression and/or other clinical response without progression for at least 6 cycles or 6 months on treatment, whichever is shorter, and subsequently have evidence of progressive disease during the durvalumab monotherapy portion may receive a repeat dose of tremelimumab at the next scheduled cycle of treatment with durvalumab per physician discretion.
88801829|NCT01453244||SVR group|A patients who achieved SVR (sustained virologic response)
89123463|NCT04430257|Experimental|PrEP for health|Participants in the PrEP (pre-exposure prophylaxis) for health arm will receive theory informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation.
89123464|NCT04430257|Active Comparator|Standard of care|Participants in the standard of care arm will receive PrEP information and referrals.
89123465|NCT04353661|Experimental|Arm A Open-label: azithromycin + SOC therapy|Participants will receive azithromycin and SOC theraphy for 52 weeks.
89123466|NCT04353661|Active Comparator|Arm A Open-label: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
89123467|NCT04353661|Active Comparator|Arm B Observational: SOC therapy|Participants will receive SOC theraphy for 52 weeks.
89123468|NCT04346225|Experimental|Cohort A: Hyperpolarized C13 MRI at a single time point|Participants will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at a single time point and will receive up to two 13C pyruvate (C-1 and C-2 labeled 13C pyruvate) investigational medicinal product (IMP) injections on the day of imaging (2nd injection is optional), as well as optional MR- or CT- guided tumor biopsies at baseline and at the time of disease progression following completion of HP C-13 MRI at the corresponding time point
89123469|NCT04346225|Experimental|Cohort B: Hyperpolarized C13 MRI at multiple time points|Participants will undergo hyperpolarized (HP) C13 MRI at baseline and 12 weeks (+/- 8 weeks). Participants in Cohort B may undergo additional optional MR imaging at the time of disease progression. the same sequence of injections (C-1 labeled pyruvate first, C-2 labeled pyruvate second) will be used for subsequent scan time points as well.
89123470|NCT04340154|Experimental|chimeric antigen receptor T cell treatment|
88801830|NCT01453244||non-SVR group|A patients who not achieved SVR (sustained virologic response)
88801831|NCT05495022|Experimental|MBSR group|Mindfulness-based stress reduction (MBSR) program
89123471|NCT04305366||Head and Neck Cancers|This study will target patients with a diagnosis squamous cell carcinoma in the head and neck. In addition, this study will also target patients undergoing tonsillectomy or sleep surgery as the control group. This study will aim to enroll an equal number of patients into both the study group and control group. However, this will be dependent on patient encounters within the adult ENT clinic.
89123472|NCT04296539||Sedentary|Involving little exercise or physical activity
89123473|NCT04296539||Exercise|Subjects who were performing regularly pilates exercises for at least six months
89123474|NCT04223102|Other|Tissue collection|Tissue collection
89123475|NCT04222998|Experimental|Intervention group|Household receives the home-based growth chart
89123476|NCT04222998|Active Comparator|Control group|Household does not receive the home-based growth chart
89123477|NCT04214093|Experimental|Arm A|Dose escalation for patients with solid tumors, lymphoma and multiple myeloma with low risk of TLS. Each cohort within Arm A will test a single dose level.
88801832|NCT05495022|No Intervention|Control group|standard care group
89123478|NCT04214093|Experimental|Arm B|Dose escalation for patients with hematologic malignancies with an intermediate to high risk of TLS. Intrapatient dose ramp-ups within each cohort will be used.
89123479|NCT04199091|Experimental|Craniosacral self-help techniques (CST)|The experimental group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. The course starts with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients will also receive a script with theoretical CST basics and descriptions of the techniques, which should facilitate the correct practice at home.
89123480|NCT04199091|Active Comparator|Progressive muscle relaxation (PMR)|The active control group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. Every week patients will meet for 2 TUs. The patients will also receive a script with theoretical basics and descriptions of the PMR techniques, hich should facilitate the correct practice at home.
89123481|NCT04196803|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
89123482|NCT04196803|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
89123483|NCT04196803|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
89123484|NCT04196803|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
88801833|NCT05494944|Other|ThuLEP group|
88801834|NCT01453400|Experimental|Arm 1|
88801835|NCT01453400|Active Comparator|Arm 2|
88801836|NCT01453400|Placebo Comparator|Arm 3|
88801837|NCT05490186|Active Comparator|Manual Adjusted Mechanical Alignment|"Usual care:~Midline incision, no tourniquet, medial Parapatellar arthrotomy, resect anterior osteophytes~Distal femoral cut with 3-5 degrees of valgus from the anatomical axis (Based on the angle measurement on the 4 foot standing Xray). Correct for flexion contracture.~Measure the femoral size with the anterior referencing guides. Use 3 degrees external rotation to the Posterior condylar axis~Perform anterior, posterior and chamfer cuts with the 4 in 1 in appropriate external rotation~Extramedullary tibial alignment guide with 3-5 degrees posterior slope, and orthogonal cut to the tibial axis.~Resect posterior osteophytes~Place trial components and perform appropriate release/balance the gaps~Patellar replacement based on surgeon's discretion~Cementing the components with tourniquet inflation"
89123485|NCT04169568||OI manual cuff BP|Patients with diagnosis of Osteogenesis Imperfecta from ages 1 to 35 who are admitted to our institution to the inpatient, non-ICU setting, following orthopedic surgery for spine surgery, upper or lower extremity realignment and IM rodding
89123486|NCT04154982|Experimental|Pharmacological treatment|Patients are treated with NAC prior to carrying out CAP.
89123487|NCT04154982|No Intervention|Standard procedure|Patients are not treated with NAC. No placebo treatment is performed.
89123488|NCT04141449|Experimental|Potlako intervention|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation~Community-led cancer symptom awareness campaign to educate residents on methods and importance of early detection of cancer~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer.~Cross-sectional community-facing activities partnered with longitudinal clinic-based targeted educational program~Remote phone/SMS-based cancer suspect navigation program to support and expedite evaluation for symptoms/signs of possible cancer."
89123489|NCT04141449|Active Comparator|Enhanced Care|"Provider oncology training focused on detection of cancer symptoms/signs and performance of appropriate diagnostic evaluation.~Support/counselling call after initial clinician recognition that patient requires evaluation for possible cancer."
89123490|NCT04124029||Younger mild Traumatic Brain Injury|mTBI subjects aged 30-59 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the Test of Memory Malingering (TOMM) and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
89123491|NCT04124029||Older mild Traumatic Brain Injury|mTBI subjects aged 60- 90 yo will be recruited who have a physician diagnosis of 1 or more mTBI episodes without concomitant moderate or severe TBI diagnosis (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). mTBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
89123492|NCT04124029||moderate Traumatic Brain Injury|TBI control subjects, age-, education- and sex-matched with mTBI subjects (aged 30-90) will be recruited who have a physician diagnosis of 1 or more moderate TBI episodes (loss of consciousness greater than 30 minutes, posttraumatic amnesia greater than 24 hours, or altered mental status greater than 24 hours). Moderate TBI subjects must pass effort measures on the TOMM and have intact color vision and visual acuity of 20/30 or better in order to be included in the study.
89123493|NCT04124029||Mild Cognitive Impairment (MCI)|MCI control subjects, age-, education- and sex-matched with older mTBI subjects (aged 60-90) will be recruited if they meet diagnostic criteria for MCI (without a history of TBI) based on the judgement of a behavioral neurologist following the 2011 MCI criteria. Specifically, subjects will test in the impaired range on one or more cognitive domains on neuropsychological testing and will not have impairments in function (i.e. will not meet diagnostic criteria for dementia). MCI subjects will be matched for their Montreal Cognitive Assessment (MoCA) score with older mTBI subjects. Of note, subjects with MCI may or may not meet diagnostic criteria for MCI due to AD. The intent of this control group is to recruit a broad range of MCI subjects without TBI as controls for subjects with cognitive impairment who have a history of mTBI.
89123494|NCT04124029||Younger Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with younger mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
89123495|NCT04124029||Older Healthy Controls|Cognitively normal control subjects, age-, education- and sex-matched with older mTBI subjects, but lacking and mTBI history. All subjects must be within 1 standard deviation of normal on all neuropsychologic testing in order to be enrolled.
89123496|NCT04119414|Experimental|S&S + LFLS Group|300 expecting couples totaling 600 participants will be completing the S&S program followed by the LFLS Program.
89123497|NCT04040231|Experimental|Malignant Pleural Mesothelioma (MPM)|Participants with previously treated Malignant Pleural Mesothelioma/MPM
89123498|NCT04026256|Active Comparator|Teriparatide only|daily subcutaneous injection teriparatide for 3 months
89123499|NCT04026256|Active Comparator|Denosumab only|one dose of subcutaneous injection denosumab
89123500|NCT04026256|Active Comparator|Denosumab and teriparatide|daily subcutaneous injection teriparatide for 3 months plus one dose of subcutaneous injection denosumab
89123501|NCT03984643|Experimental|Deep Brain Stimulation|Subjects in this study will have been implanted with a DBS lead in the VIM as part of their routine clinical care and have an existing set of brain MRI's.
89123502|NCT03967600||Hidradenitis Suppurativa Patients|Patients with physician diagnosed Hidradenitis Suppurativa
89123503|NCT03967600||Healthy Volunteers|Healthy volunteers without any skin conditions or recent history of antibiotic use.
88806108|NCT00241904|Active Comparator|Comprehensive Intervention Group|The NP/CHW intervention focused on behavioral interventions to affect therapeutic lifestyle changes and adherence to medications and appointments as well as the prescription and titration of medications for one year. The NP and CHW worked as a team. The NP oversaw the initial assessment and, in collaboration with the CHW, tailored the intervention plan, conducted the intervention including lifestyle modification counseling and medication titration and prescription, consulted with the physician, and supervised the CHW. Specific algorithms for drug treatment of hyperlipidemia, hypertension (HBP), hyperglycemia, ACE, and β-blocker therapy were developed for this study based on current guidelines and standards of care.
89123504|NCT03954717||Participants in the Shepherd CAN DO Program|People with MS enrolled into the Shepherd CAN DO Program.
89123505|NCT03954717||Control Group-Shepherd (CG-S)|People with MS who are current patients of the MS Institute at the Shepherd Center.
89123506|NCT03954717||Control Group-iConquerMS (CG-iCMS)|iConquerMS members
89123507|NCT03954717||Support partners of CAN DO|Support partners of the participants in the Shepherd CAN DO Program group
89123508|NCT03954717||CG-S support partners|Support partners of the people with MS in the CG-S group.
89123509|NCT03954717||CG-iCMS|Support partners of the people with MS in the CG-iCMS group
89123510|NCT03928288|Experimental|Intervention|Cabergoline 0.5 mg PO twice weekly for 6 months
89123511|NCT03928288|Placebo Comparator|Placebo|Placebo capsule PO twice weekly for 6 months
89123512|NCT03925883|Active Comparator|Patient Navigation|Patients randomized to this arm will receive patient navigation with the goal of completing a follow-up colonoscopy within 12 months of a positive FIT result.
89123513|NCT03925883|No Intervention|Usual Care|Patients will receive usual care screening opportunities
89123514|NCT03808402||High dose surfactant|Infants who receive a first dose of surfactant between 170 and 200 mg/kg
89123515|NCT03808402||Low dose surfactant|Infants who receive a first dose of surfactant between 100 and 130 mg/kg
89123516|NCT03789604|Experimental|CS1001 monoclonal antibody|
89123517|NCT03789604|Placebo Comparator|CS1001 placebo|
89123518|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection in superficial tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors
89123519|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection in deep/visceral tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in deep/visceral tumors
89123520|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV) in superficial tumors|Doses of RP1 (IT) in superficial tumors with nivolumab (IV)
89123521|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV) in deep/visceral tumors|Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV)
89123522|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma
89123523|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors
89123524|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer
89123525|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1 Failed Cutaneous Melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy
89123526|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer who have been previously treated with anti-PD1/PD-L1 therapy
89123527|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NSCLC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non small cell lung cancer who have been previously treated with anti-PD1/PD-L1 therapy
89123528|NCT03765307|Experimental|SyMap Bronchial Ablation Group|The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3).
89123529|NCT03765307|Active Comparator|Boston Scientific Bronchial Thermoplasty Group|The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
89123530|NCT03762265|Placebo Comparator|Placebo Then Rilzabrutinib|In BT period, participants received placebo orally twice daily (BID) up to 37 weeks along with sponsor-provided corticosteroids (CS). After at least two weeks of control of disease activity (CDA; no new lesions and established lesions begin to heal), based on protocol-specified clinical criteria, investigators could decrease the CS dose to a minimum of 5 milligrams (mg) prednisone/prednisolone per day from Week 29 to Week 37. Post completion of BT period, eligible participants received rilzabrutinib 400 mg BID up to Week 61 in OLE period and those who were eligible after OLE period completion, continued the same treatment until Week 109 in LTE period according to protocol-specified criteria.
89123531|NCT03762265|Experimental|Rilzabrutinib Then Rilzabrutinib|In BT period, participants received rilzabrutinib 400 mg orally BID up to 37 weeks along with sponsor-provided CS. After at least two weeks of CDA (no new lesions and established lesions begin to heal), based on protocol-specified clinical criteria, investigators could decrease the CS dose to a minimum of 5 mg prednisone/prednisolone per day from Week 29 to Week 37. Post completion of BT period, eligible participants received rilzabrutinib 400 mg BID up to Week 61 in OLE period and those who were eligible after OLE period completion, continued the same treatment until Week 109 in LTE period according to protocol-specified criteria.
89123532|NCT03735420|Experimental|Xanthohumol|Participants will receive 24 mg of 98% pure xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
89123533|NCT03735420|Placebo Comparator|Placebo oral capsule|Participants will receive vehicle (rice protein) by mouth once daily with the first daily meal.
89123534|NCT03721393||Group 1: Syncope patients|Patients that have undergone an ARS assessment and diagnosed with orthostatic hypotension or reflex syncope.
89123535|NCT03721393||Group 2: Control patients|Patients that have undergone an ARS assessment and are control subjects.
89123536|NCT03718832|Experimental|Treatment Group-Begin Now|"Group 1- Will be randomized to the treatment (Begin Now) group for the Fresh Food Farmacy program. Subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program right away when the program opens in their geographic area. Data will be collected during the first 12 months of subject participation and EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total)."
89123537|NCT03718832|No Intervention|Control Group-Begin Later|"Group 2- Will be randomized to the control (Begin Later) group for the FFF program. These subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program approximately 6 months after the program opens in their geographic area. Data will be collected during the first 6 months of subject participation and used as control data for the study. EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total from the start of the trial)."
89123538|NCT03662074|Experimental|Treatment (gemcitabine, nivolumab)|Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity
89123539|NCT03642938|Experimental|Low Dose Exercise|The Low Dose Exercise group will perform treadmill walking exercise, three times per week for one week.
89123540|NCT03642938|Experimental|Moderate Dose Exercise|The Moderate Dose Exercise group will perform treadmill walking exercise, five times per week for one week.
89123541|NCT03642938|Experimental|High Dose Exercise|The High Dose Exercise group will perform treadmill walking exercise, ten times per week for one week.
89123542|NCT03642938|Sham Comparator|Control|The Control group will perform quiet rest, three times per week for one week.
89123543|NCT03635632|Experimental|Arm A: High-risk group of patients with lung metastases|"Patients will be treated at 2 dose levels without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated at the next dose level with C7R.GD2.CART cell infusion without lymphodepletion chemotherapy.~The protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Each arm will undergo separate dose escalation."
89123544|NCT03635632|Experimental|Arm B: Standard risk group of all other patients|"Patients will be treated at 2 dose levels without lymphodepletion chemotherapy. Three patients will be evaluated and if safety is confirmed patients will be treated at the next dose level with C7R.GD2.CART cell infusion without lymphodepletion chemotherapy.~The protocol is divided into two arms, a high-risk group of patients with lung metastases (Arm B) and a standard risk group of all other patients (Arm A). The standard risk Arm A includes osteosarcoma patients without pulmonary disease. Each arm will undergo separate dose escalation."
89123545|NCT03602859|Placebo Comparator|Participants receiving SOC+placebo|Participants in this arm will receive SOC (carboplatin+paclitaxel+/-bevacizumab) in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/-bevacizumab along with niraparib placebo and dostarlimab placebo.
89123546|NCT03602859|Active Comparator|Participants receiving SOC+niraparib|Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of +/- bevacizumab with niraparib and dostarlimab placebo.
89123547|NCT03602859|Experimental|Participants receiving SOC+dostarlimab+niraparib|Participants in this arm will receive SOC in cycle 1 (each cycle is of 21 days) followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of +/-bevacizumab with niraparib and dostarlimab.
89123548|NCT03580655|Experimental|Avapritinib|Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles
89123549|NCT03562767|Experimental|Group-based Cognitive Behavioral Intervention|Subjects receiving the group-based CT-CB intervention
89123550|NCT03562767|Experimental|Web-based Cognitive Behavioral Intervention|Subjects receiving the web based CT-CB intervention
89123551|NCT03562767|Placebo Comparator|Usual Care|Subjects receiving usual care from their primary care providers
89123552|NCT03558893|Experimental|Forced Desynchrony|All participants will undergo a forced desynchrony protocol.
89123553|NCT03542175|Experimental|Rucaparib Administered With Radiation|"Treatment will consist of rucaparib at one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.~Radiotherapy will consist of 50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician."
89123554|NCT03519230|Experimental|Treatment arm|
89123555|NCT03519230|Placebo Comparator|Placebo arm|
89123556|NCT03508479|Experimental|RG-HRV16 Inoculation|While wearing a dental bib, subjects will be asked to blow the nose prior to inoculation. With the head tilted back, a total of 0.5 mL (0.25 mL/nostril) will be administered using the MAD Nasal™ Intranasal Mucosal Atomization Device. Subjects instructed not to blow nose for 30 minutes afterwards.
89123557|NCT03485014|Experimental|Experimental: EXPAREL 4 mg/kg|Single dose of EXPAREL 4 mg/kg
89123558|NCT03402503|Experimental|Group A|Montelukast buccal film, administered 10-mg once or 30-mg twice daily (once in the morning and once in the evening) for 26 weeks.
89123559|NCT03402503|Placebo Comparator|Group B|Placebo buccal film, administered once or twice daily (once in the morning and once in the evening) for 26 weeks.
89123560|NCT03389412|Experimental|Treatment without evaluating the home recordings, medicin.|Children will receive desmopressin without evaluating the home recordings.
89123561|NCT03389412|Experimental|Treatment without evaluating the home recordings, alarm.|Children will receive conditional alarm without evaluating the home recordings.
89123562|NCT03389412|Active Comparator|Treatment based on home recordings, polyuria.|Children with polyuria based on the home recordings will receive desmopressin.
89123563|NCT03389412|Active Comparator|Treatment based on home recordings, reduced bladder capacity.|Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
89123564|NCT03389412|Active Comparator|Treatment based on home recordings, both.|Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
89123565|NCT03389412|Active Comparator|Treatment based on home recordings, none.|Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.
89123566|NCT03334942|Experimental|CFTSI|Youth and caregivers randomized to the Violence Intervention Program (VIP) and Child and Family Traumatic Stress Intervention (CFTSI) arm will receive 5 to 8 CFTSI sessions with a trained clinician and be enrolled in VIP. VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
89123567|NCT03334942|No Intervention|Violence Intervention Program|Youth and caregivers randomized to the VIP-only condition will complete a baseline assessment prior to randomization and then be enrolled in the Violence Intervention Program (VIP). VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
89123568|NCT03334500|Experimental|Cohort 1|Gleason 6 (n=10)
89123569|NCT03334500|Experimental|Cohort 2|Gleason 7-8 (n=10)
89123570|NCT03334500|Experimental|Cohort 3|Gleason 9 or oligometastic disease (n=10)
89123571|NCT03333941||RES (Regenerative Epithelial Suspension)|
88801838|NCT05490186|Experimental|Robotic Assisted Adjusted Mechanical Alignment|"Midline incision, no tourniquet, medial Parapatellar arthrotomy, resect anterior osteophytes~Place the femoral pins in the proximal incision and the tibial pins 4 finger breadths under the joint line~Map the knee and perform evaluation~Assess gaps, adjust the femoral axis to decrease soft tissue release (+/- 2 degrees), correct for flexion contracture~Verify and perform distal femoral cut, proximal tibial cut orthogonal (90 Degrees) to the tibial axis~Assess and balance extension gap with appropriate releases~Remap the posterior condylar axis, assess the flexion space, 3 degrees external rotation to the posterior condylar axis~Perform anterior, posterior and chamber cuts with the 4 in 1 (appropriate external rotation), followed by posterior osteophyte resection~Place trial components and balance the knee, soft tissue releases (1-2 mm)~Patellar replacement based on surgeon's discretion~Cementing the components with tourniquet inflation"
89123572|NCT03315754|Experimental|TOOKAD Soluble 4 mg/kg|TOOKAD® Soluble VTP treatment consist of the combination of a single, 10-minute IV infusion of TOOKAD® Soluble at the dose of 4 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
89123573|NCT03260023|Experimental|TG4001/Avelumab|
89123574|NCT03260023|Experimental|Avelumab|Applicable for Phase II part 2.
89123575|NCT03220477|Experimental|pembrolizumab plus guadecitabine and mocetinostat|Pembrolizumab given IV; guadecitabine given SQ, mocetinostat given PO.
89123576|NCT03215199|No Intervention|Usual Care Group|The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
89123577|NCT03215199|Active Comparator|NAPT Group|The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
89123578|NCT03186898|Experimental|Proton Therapy (Radiation Therapy)|Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.
89123579|NCT03186898|Experimental|Photon Therapy (Radiation Therapy)|Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.
89123580|NCT03182998|Experimental|Arm A (Knowing Your Options)|"Arm A (Knowing your Options) Patients receive Knowing your Options decision aid before their consultation visit."
89123581|NCT03182998|Experimental|Arm B (Prostate Choice)|"Patients receive Prostate Choice decision aid during their consultation visit."
89123582|NCT03182998|Active Comparator|Arm C (Usual Care)|Patients undergo usual care.
89123583|NCT03161067|Experimental|Surgical implantation of BiCNS|
89123584|NCT03151798|Experimental|Phase I: Observational studies|Patients are eligible who are undergoing either bariatric surgery or a liver biopsy for the diagnosis of nonalcoholic fatty liver disease
89123585|NCT03151798|Experimental|Phase II: Lifestyle treatment|Subjects will undergo lifestyle modification to cause weight loss and improved fitness
89123586|NCT03151798|Placebo Comparator|Phase II: Control treatment|Subjects will be given dietary advice and a stretching program.
89123587|NCT03146546||Sepsis|Patients with sepsis as defined by the Sepsis-3 criteria
89123588|NCT03146546||Control|Patients without sepsis, as defined by the Sepsis-3 criteria
89123589|NCT03126266|Experimental|Patients receiving re-irradiation|Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
89123590|NCT03095612|Experimental|Selinexor Monotherapy and in Combination with Docetaxel|"For the selinexor monotherapy cohort, 6 patients each will be treated in two dosing cohorts (weekly and biweekly). Selinexor once weekly oral (40mg, 60mg, 80mg) OR Selinexor twice weekly oral (60mg, 40mg, 60mg weekly).~Selinexor will be administered once weekly starting one week before chemotherapy initiation in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Selinexor dose escalation: 60, 80, 40 mg once weekly. Docetaxel 75 mg/m2 IV, 60 every 3 weeks."
89123591|NCT03083288|Experimental|Single Arm|
89123592|NCT03075748|Experimental|Primary study|Patients meeting primary inclusion/exclusion criteria will be enrolled in primary study arm and be treated with the TAAA Debranching Stent Graft System.
89123593|NCT03075748|Experimental|Expanded selection|Patients who fail to meet inclusion criteria for the primary study arm may be enrolled under the expanded selection arm and be treated with the TAAA Debranching Stent Graft System.
89123594|NCT03028350|Experimental|Ifetroban Oral Capsule|Oral ifetroban, 200 mg daily for 8 weeks
89123595|NCT03028350|Placebo Comparator|Placebo Oral Capsule|Oral placebo daily for 8 weeks
89123596|NCT03022825|Experimental|BCG+N-803|
89123597|NCT02918370|Experimental|Aripiprazole|Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
89123598|NCT02918370|Placebo Comparator|Placebo|Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
89123599|NCT02914405|Experimental|Treatment|"The dose and schedule of 131-I mIBG will be constant, and the doses of ch14.18/ CHO and Nivolumab determined by cohort:~Cohort I: 3 mg/kg Nivolumab (100% adult dose). No ch14.18/CHO. (3-6 patients)~Cohort II: 50mg/m2/cycle ch14.18/CHO (50% established Long Term Intervention (LTI) dose) and 3 mg/kg Nivolumab (100% adult dose) (3-6 patients)~Cohort III: 100mg/m2/cycle ch14.18/CHO (100% established LTI dose) and 3 mg/kg Nivolumab (100% adult dose) (initial 3-6 patients, expanded to 15 patient cohort if tolerated)"
89123600|NCT02868567|Experimental|Ampyra|Ampyra open label
89123601|NCT02761811|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
89123602|NCT02761811|Sham Comparator|Masked Procedure|Percutaneous renal artery angiography
88801839|NCT05490186|Experimental|Robotic Assisted Kinematic Alignment: (Joint line restoration)|"-- Midline incision, no tourniquet, medial parapatellar arthrotomy, resect anterior osteophytes~Place femoral pins in proximal incision, tibial pins 4 finger breadths under joint line~Map and evaluate the knee, ROM, varus valgus testing at 0 & 90 degrees flexion~Distal femoral cut based on cartilage loss on medial and lateral femoral condyle (9mm total cut/condyle).~Perform distal femoral cut, maintain the joint line (femoral axis +/- 5 degrees)~Perform proximal tibial cut within +/- 3 degrees, balance the gaps, differential between medial and lateral gaps = 1- 3mm.~Assess extension space, resect posterior osteophytes~Remap posterior condylar axis, place 4 in 1 at 0 degrees to the post condylar axis (aim = 9mm posterior condylar cuts)~Resect posterior osteophytes, place trial components. Adjust cuts to achieve a balanced knee, maintain HKA axis +/- 3 degrees~Patellar replacement per surgeon discretion~Cement the components with tourniquet inflation"
88801840|NCT05023850|Active Comparator|Group TLIP|"Patients will receive a Thoracolumbar Plane Block (TLIPB) under ultrasound guidance while under general anesthesia.~Intervention: Patients will receive a TLIPB with 20mls 0.25% Bupivicaine bilaterally."
88801841|NCT05023850|Experimental|Group ESP|"Patients will receive an Erector Spinae Plane Block (ESPB) under ultrasound guidance while under general anesthesia.~Intervention: Procedure: Patients will receive an ESPB with 20 ml 0.25% Bupivacaine bilaterally."
88806109|NCT00241904|Active Comparator|Less Intensive Intervention Group|Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians. Patients and their providers in the received the results of baseline lipids, BP, and HbA1c along with the recommended goal levels and a pamphlet on controlling risk factors published by the American Heart Association. In addition, providers received copies of the AHA/ACC Guidelines for Secondary Prevention.
89123603|NCT02723955|Experimental|Part 1A: Dose escalation feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.
89123604|NCT02723955|Experimental|Part 1B: Expansion feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.
89123605|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
89123606|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.
89123607|NCT02723955|Experimental|Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy)|Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.
89123608|NCT02723955|Experimental|Part 2B: Expansion-feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
89123609|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.
89123610|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.
89123611|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.
89123612|NCT02637934|Experimental|Biodistribution|"The Biodistribution cohort will include up to 4 patients who will undergo a series of vertex to mid-thigh biodistribution [18F]FTT PET/CT scans over a period of approximately 4 hours.~Up to 10 subjects were initially planned for this cohort, however, the first 4 subjects have been enrolled and initial data analysis for these completed. The decision was made to close enrollment for this cohort as we do not believe that we need to complete the up to 10 subjects originally planned for this cohort as the initial data shows consistent and repeatable data that we do not believe would change significantly with the addition of 6 more subjects."
89123613|NCT02637934|Experimental|Dynamic|The Dynamic cohort will include up to 36 patients who will undergo 1 static skull base to mid-thigh scans imaging post injection of [18F]FTT.
89123614|NCT02632175|Experimental|Subjects receiving Adalimumab|Subjects receiving Adalimumab up to 288 weeks
89123615|NCT02566304|Experimental|RIC HSCT, GVHD prophylaxis|"RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -6.~TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
89123616|NCT02495090|Other|Hypospadias|Familial hypospadias trios (patients + parents)
89123617|NCT02440711|Experimental|mRSF-ESF|Study participants in Arm 1 will first receive the Modified running specific foot (mRSF) and then the Energy storing foot (ESF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
89123618|NCT02440711|Experimental|ESF-mRSF|Study participants in Arm 2 will first receive the Energy storing foot (ESF) and then the Modified running specific foot (mRSF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
89123619|NCT02266758|Other|GDM Screening Method 1|GDM Screening Methods
89123620|NCT02266758|Other|GDM Screening Method 2|GDM Screening Methods
89123621|NCT02223767|Experimental|Verum transcranial magnetic stimulation (TMS)|10 Hz TMS over medial prefrontal cortex
89123622|NCT02223767|Experimental|Sham transcranial magnetic stimulation (TMS)|10 Hz sham TMS over medial prefrontal cortex
89123623|NCT02177617|Active Comparator|Botox only|Participants randomized to receive Botox injections alone.
89123624|NCT02177617|Active Comparator|Botox plus Physical Therapy|Participants randomized to receive Botox injection combined with Physical Therapy
89123625|NCT02145741|Experimental|Xentuzumab|Patients to receive low, middle, and high doses of Xentuzumab intravenously (IV)
89123626|NCT01956773|Experimental|MeTree - Patient|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to patients as clinical decision support.
89123627|NCT01956773|Experimental|MeTree - Provider|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to providers as clinical decision support.
89123628|NCT01946529|Active Comparator|Group A (Standard Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.
89123629|NCT01946529|Active Comparator|Group B (High Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.
89123630|NCT01876524|Experimental|tRNS over Anterior Cingulate|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the disease-specific Anterior Cingulate Cortex (ACC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
89123631|NCT01876524|Experimental|tRNS applied over DLPFC|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the dorso-lateral-prefrontal-cortex (DLPFC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
89123632|NCT01876524|Sham Comparator|Sham Group|75 patients will be receive tRNS sham 35 sessions.
89123633|NCT01760915||Severe asthma|Subjects with severe asthma (SARP protocol definition)
89123634|NCT01760915||Well controlled asthma|Subjects with well controlled asthma
89123635|NCT01760915||Normal control|Subjects that are healthy normals
89123636|NCT01695863|Experimental|miralax|miralax with dulcolax and gatorade efficacy evaluated by colonoscopy and patient satisfaction evaluated by patient questionnaire
89123637|NCT01695863|Experimental|moviprep split dose|Efficacy of split dose moviprep on cleansing colon for colonoscopy and patient satisfaction with the regimen
89123638|NCT01666808|Experimental|FACBC PET scan|A trial group in which anti-3-[18F]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.
89123639|NCT01666808|Active Comparator|Conventional-Only Imaging|A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.
89123640|NCT01539122|Active Comparator|TM Glenoid|Zimmer TM glenoid shoulder replacement component will be used for the glenoid component of the total shoulder replacement.
89123641|NCT01539122|Active Comparator|Cemented Glenoid|Cemented glenoid shoulder replacement component
89123642|NCT00897286||Tumor/Tissue Sample|Tumor material collected prospectively from a clinically well characterized patient cohort
88806110|NCT01791296|Experimental|Dexmedetomidine|Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
89123643|NCT00878254|Experimental|R-MACLO/IVAM|"Four 21-day cycles, followed by Maintenance Therapy as follows:~Cycles 1 and 3: Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Methotrexate, Leucovorin, and G-CSF per study protocol.~Cycles 2 and 4: Rituximab, Cytarabine, Ifosfamide, Mesna, Etoposide, and G-CSF per study protocol.~Maintenance Therapy: Rituximab: For study participants in complete remission. Every 6 months for up to 3 years, per study protocol."
89123644|NCT00813423|Experimental|Treatment (sunitinib malate, hydroxychloroquine)|Patients receive sunitinib malate PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-42 (beginning day 4 of course 1). Treatment repeats every 42 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89123645|NCT00760656||Research Participants|Participants with a diagnosis of childhood malignancy treated or followed at SJCRH
89123646|NCT00760656||Control Participants|Siblings, parents, relatives or friends of St. Jude patients or former patients or SJCRH employees who are not SJLIFE study team members or supervised by a SJLIFE study team members
89123647|NCT00591500||Control|The control group comprises patients with a first primary melanoma diagnosed in a twelve-month period.
89123648|NCT00591500||Cases|Cases are patients diagnosed with a second or higher order primary in a six-year period.
89123649|NCT00017953|Experimental|Lifestyle Intervention|Participants in the lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain weight loss.
89123650|NCT00017953|Active Comparator|Diabetes Support and Education|The diabetes support and education arm provides group sessions on diabetes management and social support.
89123651|NCT04015882|Active Comparator|exercise|the exercise group will applied virtual reality exercises by Nintendo Wii Fit Plus System Game Console.
89123652|NCT04015882|No Intervention|control|No exercise applied the control group.
89123653|NCT04089592|Experimental|Dex Group|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
89123654|NCT04089592|Experimental|Fent Group|intravenous fentanyl at 2mcg/kg in 100ml saline
89123655|NCT04092400||Micro-Invasive Glaucoma Surgical devices|Patients implanted With Micro-invasive Glaucoma Surgical (MIGS) devices at the National University Hospital, Singapore
89123656|NCT00964028|Experimental|INFANRIX-IPV/HIB M2-M3-M4 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age (M2-M3-M4), administered intramuscularly into the upper right side of the thigh.
89123657|NCT00964028|Experimental|INFANRIX-IPV/HIB M3-M4-M5 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age (M3-M4-M5), administered intramuscularly into the upper right side of the thigh.
89123658|NCT02862002|Experimental|"Therapeutic Patient Education (E.T.P)of type caratif"|Patients in arm E.T.P benefit of the nursing consultation E.T.P,
89123659|NCT02862002|Active Comparator|standard care|patients receiving standard care of cancer pain.
89233395|NCT01174121|Experimental|3/Unselected TIL + Pembro Prior to Cells|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
88806111|NCT01791296|Placebo Comparator|Placebo|Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
89123660|NCT02861144|Other|Intervention|"Patient participants in the intervention arm will receive diabetes self-management program, Ma ka hana ka ̒ike which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 4.5 months. After 4.5 months, the patient will receive 4 monthly boosters by mail that will reinforce information from the Ma ka hana ka ̒ike program. Completion of diabetes process and glycemic outcomes will trigger the modest financial incentives.~Health care provider participants in the intervention arm will receive educational resources, Hanapū Provider Toolbox to guide their patients to optimal glycemic control.They will receive modest financial incentives when their patients complete clinical tests and achieve glycemic target."
89123661|NCT02861144|No Intervention|Usual Care|"Patient participants in the usual care arm will receive 5 mail-out diabetes self management education booklets endorsed by the American Diabetes Association (ADA) and the National Institute for Diabetes, Digestive and Kidney disease for 4.5 months. Patients will see their doctor according to usual care practice. After 4.5 months, the patients will receive 4 monthly boosters in mail reinforcing the previous mail-out diabetes self-management program materials.~Health care provider participants in the usual care arm will receive the latest ADA guidelines to use in their treatment plan of their patients."
89123662|NCT00960206|Experimental|Trident®System|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
89123663|NCT00960206|Experimental|ABC System|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
89123664|NCT00960206|Active Comparator|Control|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
89123665|NCT00751036|Experimental|Nilotinib|Patients who were assigned to this treatment group received 400 mg. nilotinib bid.
89123666|NCT00751036|Active Comparator|Imatinib|Patients who were assigned to this treatment group received 400 mg. imatinib bid.
89123667|NCT00961298|Experimental|Duloxetine|Two weeks of placebo run in followed by 12 weeks of Duloxetine.
89123668|NCT00744328|Experimental|Transdermal Estradiol|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains transdermal estradiol ranging in dose from 50 to 200 mcg/day
89123669|NCT00744328|Active Comparator|Sertraline|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The skin patch contains no active ingredients, though packaging is designed to match active patches. The capsules contain sertraline ranging in dose from 25 to 200mg/day
89123670|NCT00744328|Placebo Comparator|Placebo|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains no active ingredients, though packaging is designed to match active patches.
89123671|NCT00917332|Experimental|intervention|"55 third trimester women will receive a CD of relaxation and guided imagery (of safe place), to practice daily at home until childbirth"
89123672|NCT00917332|No Intervention|control|55 third trimester women who does not receive the relaxation and guided imagery CD.
89123673|NCT04019782|Experimental|Collagen-PVP|Collagen-polyvinyl pyrrolidone (collagen-PVP).
89123674|NCT04019782|Active Comparator|Hylan G-F 20|Hylan G-F 20.
89123675|NCT04092088|Active Comparator|tDCS-r+TENS-r|Real transcranial direct current stimulation (tDCS-r) + real transcutaneous electrical nerve stimulation (TENS-r)
89123676|NCT04092088|Experimental|tDCS-r+TENS-s|Real transcranial direct current stimulation (tDCS-r) + sham transcutaneous electrical nerve stimulation (TENS-s)
89123677|NCT04092088|Experimental|tDCS-s+TENS-r|Sham transcranial direct current stimulation (tDCS-s) + real transcutaneous electrical nerve stimulation (TENS-r)
89123678|NCT04092088|Sham Comparator|tDCS-s+TENS-s|Sham transcranial direct current stimulation (tDCS-s) + sham transcutaneous electrical nerve stimulation (TENS-s)
89123679|NCT02599480|Active Comparator|mirabegron|Patients will be orally administererd with 50 mg of mirabegron once a day during 12 months.
89123680|NCT02599480|Placebo Comparator|Placebo|Patients will be orally administererd with a placebo once a day during 12 months.
89123681|NCT04091854||HMS5552 treatment|
89123682|NCT03245840|Experimental|Budesonide Oral Suspension|Participants received 10 milliliters (mL) of budesonide oral suspension at a concentration of 0.2 milligram per milliliter (mg/mL), twice daily, for up to 4 years 5 months.
89123683|NCT04090216||Addict patients|patients with substance use disorders presented with STEMI & undergoing Primary PCI
89123684|NCT04090216||Non Addict patients|patients without substance use disorders presented with STEMI & undergoing Primary PCI
89123685|NCT04091698|Active Comparator|topical Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
89123686|NCT04091698|Placebo Comparator|topical corticosteroid|will receive topical corticosteroid (kenacort A Orabase: triamcinolone acetonide 0.1%5gram adhesive paste - dermapharm), 4 times daily for 3months.
89123687|NCT02598232|Experimental|1,414nm Nd:YAG laser|It has high absorption coefficient in water and a short pulse width.
89123688|NCT04281290|Experimental|Experimental group|Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
89123689|NCT04091932|Experimental|Pembrolizumab treatment|Pembrolizumab dosage form:100mg/4ml dosage:2mg/kg weight frequency: once per 4 weeks duration:12 weeks
89123690|NCT04090840|Experimental|Intermittent Fasting|Patients will follow intermittent fasting for 16 hours with time restricted eating during an 8 hour window. The subjects are also advised to minimize sugar intake to <15g per serving.
89123691|NCT00959894|Experimental|Etravirine 400 mg once daily|Etravirine 400 mg once daily with fixed dose tenofovir/emtricitabine (Truvada) one tablet once daily
89123692|NCT00917566|Active Comparator|Airtraq group|Use Airtraq for intubation
89123693|NCT00917566|Active Comparator|Macintoch gorup|Use Macintoch laryngoscope for intubation
89123694|NCT04019938||Diabetic adults|
89123695|NCT04091620|Experimental|Transanal Total Mesorectal Excision|For transanal total mesorectal excision, a two team approach will be adopted. One surgical team will be performing the abdominal phase dissection using standard laparoscopic approach, while the other will be simultaneously performing the transanal dissection and total mesorectal excision in a 'down-to-up' fashion using laparoscopic instruments.
89290124|NCT01219686|Experimental|escitalopram 20mg + pindolol 15mg|Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
88801842|NCT03992014|Experimental|Linerixibat + [14C]-linerixibat|Subjects will receive a single oral dose of linerixibat 90 milligram (mg) (2*45 mg) tablets concomitantly with [14C]-linerixibat 100 microgram (approximately 9.25 kilobecquerel; 250 nano curie) IV infusion for 3 hours, after an overnight fast that continues for 2 hours after the oral dose/start of IV infusion, small standard high-fat meal will be given on Day 1 in treatment Period 1; followed by a single oral dose of [14C]-linerixibat 90 mg (approximately 4.96 megabecquerel; 134.1 micro curie) solution on Day 1 in treatment Period 2. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
89123696|NCT04091620|Active Comparator|Robotic Total Mesorectal Excision|For robotic total mesorectal excision, a fully robotic approach will be adopted. Left-sided colonic mobilization, division of lymphovascular pedicle, and 'top-to-down' total mesorectal excision will be performed using the robotic platform.
89123697|NCT02859350|Experimental|Group 1a (PfSPZ Vaccine)|18-35 years; n= 20; 3 doses of 2.7x10^6 PfSPZ Vaccine given eight weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
89123698|NCT02859350|Placebo Comparator|Group 1a (normal saline)|18-35 years; n=6; 3 doses of normal saline given 8 weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
89123699|NCT02859350|Experimental|Group 1b (PfSPZ CVac)|18-35 years; n=20; 3 doses of 1.0x10^5 PfSPZ Challenge given every four weeks. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
89123700|NCT02859350|Placebo Comparator|Group 1b (normal saline)|18-35 years; n=6; 3 doses of normal saline given 4 weeks apart. Group 1b will start 8 weeks after Group 1a. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
89123701|NCT02859350|Experimental|Group 2 (PfSPZ Vaccine)|36-65 years; n=12; 3 doses of 2.7x10^6 PfSPZ Vaccine given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
89123702|NCT02859350|Placebo Comparator|Group 2 (normal saline)|36-65 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
89123703|NCT02859350|Experimental|Group 3 (PfSPZ Vaccine)|11-17 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
89123704|NCT02859350|Placebo Comparator|Group 3 (normal saline)|11-17 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
89123705|NCT02859350|Experimental|Group 4 (PfSPZ Vaccine)|6-10 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
89123706|NCT02859350|Placebo Comparator|Group 4 (normal saline)|6-10 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
89123707|NCT02859350|Experimental|Group 5 (PfSPZ Vaccine)|1-5 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
88801843|NCT05490108|Experimental|ZR202-CoV - Phase 1|Two doses of SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype), 1 dose each on Day 0 and 28.
89123708|NCT02859350|Placebo Comparator|Group 5 (normal saline)|1-5 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
89123709|NCT02859350|Experimental|Group 6a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 9.0x10^5 PfSPZ Vaccine. Group 6a will start 7 weeks after Group 1a.
89123710|NCT02859350|Experimental|Group 6b (PfSPZ Vaccine)|6-11 months; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
89123711|NCT02859350|Placebo Comparator|Group 6b (normal saline)|6-11 months; n=4; 3 doses of normal saline given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
89123712|NCT02597218||Patients following hepatectomy|"Patients following hepatectomy of any type, any gender. Roughly, we will describe: type of resection, presence of cancer,use of mechanical/pharmacological prophylaxis, major/minor bleedings ocurring during observation period.~Outcomes: Venous thromboembolism (VTE)[deep vein thrombosis (DVT) and pulmonary embolism (PE)] and portal thrombosis (PT)."
89123713|NCT00630422||64|All Patients
89123714|NCT02859428||Patients with hereditary spastic paraplegia (HSP)|Patients with hereditary spastic paraplegia types 3A, 4 and 31.
89123715|NCT04284176|Experimental|Mirrow therapy and action-observation therapy|The intervention include 20 hours, applied during a four-week period (1 hour per day from Monday to Friday) at home. The first 15 minutes will include myrror therapy 6 activities and the remaing 45 minutes both unimanual and bimanual action-observation therapy activities.
89123716|NCT04284176|Experimental|Action-observation therapy|The intervention include 20 hours, applied during a four-week period (1 hour per day from Monday to Friday) at home. There protocol includes both unimanual and bimanual action-observation therapy activities.
89123717|NCT00750880|Experimental|1|
89123718|NCT02599168|Active Comparator|Dexmedetomidine group|Patients will receive a pre-induction loading dose of dexmedetomidine 1-µ/kg over 10 minutes followed by an intraoperative infusion of 0.5-µ/kg/hour . Over and above the use of study drug dexmedetomidine propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
89123719|NCT02599168|Placebo Comparator|Non-Dexmedetomidine group|Patients will receive a pre-induction loading dose of 0.9% saline solution over 10 minutes followed by an intraoperative infusion.Over and above the use of 0.9% saline solution propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
89123720|NCT00746590|Experimental|1|
89123721|NCT02599012|Experimental|Subjects|
89123722|NCT01032629|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
88801844|NCT05490108|Experimental|ZR202a-COV - Phase 1|Two doses of SARS-CoV-2 adjuvanted recombinant protein vaccine (variant), 1 dose each on Day 0 and 28.
88801845|NCT05490108|Active Comparator|Comirnaty® - Phase 1|Two doses of Comirnaty® (Pfizer-BioNTech), 1 dose each on Day 0 and 28.
88801846|NCT05025644|Experimental|Preoperative Transesophageal Echocardiogram (TEE) PG under anesthesia <50mmHg (Group A)|"Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG under DBT stress test at 5, 10, 15 and 20 mcg/kg/min or until a PG ≥ 50mmHg is achieved, will be recorded.~Post-CPB (post-myectomy) echocardiographic parameters: PG at DBT peak dose (DBT-pd) will be recorded.~If LVOT PG post myectomy are >16 mmHg, the surgeon will be advised, for surgical management considerations."
88801847|NCT05025644|Experimental|Preoperative PG under anesthesia ≥ 50mmHg (Group B)|"Pre-cardiopulmonary bypass (CPB) (pre-myectomy) echocardiographic parameters: PG without DBT stress test will be recorded.~Post-CPB (post-myectomy) echocardiographic parameters: PG at 5, 10, 15, 20 mcg/kg/min DBT stress test or until the postoperative provocable PG is >16 mmHg will be recorded."
88801848|NCT02558790|Experimental|L-Threonic Acid Magnesium Salt (L-TAMS)|Subjects received open label L-Threonic acid Magnesium salt for 12 weeks. Subjects took MMFS202 (6-hour release) and MMFS302 (12-hour release) by mouth each day, up to three times a day.
88801849|NCT01459172|Experimental|Limonene intervention|
88801850|NCT05494710|Experimental|Bleomycin electrosclerotherapy treatment|Bleomycin electrosclerotherapy treatment administered. The combination of Bleomycin and electroporation of the treated area is called electrochemotherapy (ECT).
89123723|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 100 mg|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
89123724|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 300 mg|Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study
89123725|NCT04205201|Experimental|Group A|Latanoprost
89123726|NCT04205201|Other|Group B|Brimonidine
89123727|NCT02873897|Other|"Group meals on wheels at home"|
89123728|NCT02873897|Other|"Group residents of old people's homes - EHPAD"|
89123729|NCT00749944|Experimental|varenicline|
89123730|NCT00749944|Placebo Comparator|placebo|
89123731|NCT04091230|Experimental|novel needle|TRUSbx using the 18 gauge (G) 25 centimeter(cm) novel needle with 19 millimeter (mm) sample notch and a new actuator. 12 biopsies / patient.
89123732|NCT04091230|Active Comparator|standard tru cut needle|TRUSbx using a standard tru cut biopsy needle (Mermaid Medical M-biopsy 18G 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator ( Moller Medical Blue RBG-1000-10-1000). 12 biopsies/ patient.
89123733|NCT00917410|Experimental|SMS intervention|
89123734|NCT02597140|Experimental|Lidocaine group|Patients will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
89123735|NCT02597140|Placebo Comparator|Control group|Patients will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous normal saline infusion of 2 mg/kg/hr.
88801851|NCT03810066|Experimental|Osimertinib|
88801852|NCT03992482|Experimental|IVIG-Eye Drop|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
88801853|NCT03992482|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl)
88801854|NCT04390490|No Intervention|control|Automatic chemiluminescence analyzer will be used for dectecting the concentration of cardiac troponin I as control group.
88801855|NCT04390490|Experimental|Photoelectrochemical immunosensor|Photoelectrochemical immunosensor will be used for dectecting the concentration of cardiac troponin I as test group.
88801856|NCT03793920|Experimental|PEA patients without alcohol disorder|A group of 36 PEA patient without alcohol-dependence (AD), performing 6 behavioral tasks.
89123736|NCT02598310|Experimental|nab-paclitaxel plus trastuzumab|Four cycles of nab-PTX 260 mg/m2 with trastuzumab 6 mg/kg (8 mg/kg as the loading dose). One year of adjuvant trastuzumab will be administrated. Anthracycline regimens may be administered by physician's choice for the case expected to have a high risk of recurrence based on the pathological findings of surgical specimen. Adjuvant endocrine therapy may be administrated for the case with weakly hormone-sensitive (1-9% of positive cells) tumor.
89123737|NCT04091074|Active Comparator|aspirin + ticagrelor before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + ticagrelor 90mg for 15 days before carotid stenting
89123738|NCT04091074|Active Comparator|aspirin + clopidogrel before carotid stenting|patients undergoing carotid stenting take aspirin 150 mg + clopidogrel 75 mg for 15 days before carotid stenting
89123739|NCT00749398||Infliximab|Subjects with moderate-to-severe psoriasis who are treated with infliximab in daily clinics according to local country regulations and reimbursements.
89123740|NCT04089670|Active Comparator|Online Acceptance and Commitment Therapy Intervention|"This online Acceptance and Commitment Therapy intervention is delivered over 8 weeks, in 8 15-minute modules. Each module has a practice assignment at the end with the goal of having the participant engage in the material over the next week. Additionally, each participant will receive a weekly call for the duration of the intervention (i.e., 9 phone calls, one introduction phone call, 8 module related phone calls) from a Master's-level clinical student who will serve as the participants phone coach. During the call the clinical student will be able to help troubleshoot any technical difficulties being experienced, as well as clarify any questions about the material being taught in the intervention."
89290125|NCT01219686|Active Comparator|Escitalopram 30 mg|Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
88801857|NCT03793920|Sham Comparator|PEA patients with alcohol disorder|A group of 36 PEA participants, currently alcohol-dependent, performing 6 behavioral tasks.
88801858|NCT03793920|Sham Comparator|Healthy controls with AD father|A group of 36 non-alcohol-dependent controls whose father was alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
88801859|NCT03793920|Sham Comparator|Healthy controls without AD father|A group of 36 non-alcohol-dependent controls whose father was not alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
88801860|NCT01453478|Experimental|GSK1325756 Immediate Release 50 mg|Administered to volunteers in the fasted and fed states
88801861|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 1 50 mg|Administered to volunteers in the fasted and/or fed states
88801862|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 2 50 mg|Administered to volunteers in the fasted and/or fed states
88801863|NCT01459250|Experimental|AGO178C|
88801864|NCT03747588|Experimental|Minimally-invasive Pancreaticoduodenectomy|MIPD
88801865|NCT03747588|Placebo Comparator|Open Pancreaticoduodenectomy|OPD
88801866|NCT03269968|Experimental|Negative pressure wound therapy (NPWT)|Women receiving NPWT will have a PREVENA Incision Management Therapy System applied directly onto their skin over the closed incision after delivery.
88801867|NCT03269968|Placebo Comparator|Standard dressing|Standard dressing
88801868|NCT01453556|Experimental|Intracorpopreal anastomosis|Intracorporeal mechanical anastomosis
88801869|NCT01453556|Active Comparator|Extracorporeal anastomosis|Extracorporeal mechanical anastomosis
88801870|NCT04390412|Experimental|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA fashion
88801871|NCT04166032|Experimental|ANICGM|non-invasive continuous glucose monitoring device
88801872|NCT02556138|Experimental|Orbera Intragastric Balloon|All subjects will be receiving the ORBERA Intragastric Balloon
88801873|NCT04303156|Experimental|Severe Renal Impairment|Participants with severe renal impairment received a single oral dose of 60 mg MK-8591 (Islatravir) administered in capsule form.
88801874|NCT04303156|Experimental|Healthy|Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.
88801875|NCT04390334|Experimental|Treatment A: Daridorexant|Single dose of 50 mg daridorexant
88801876|NCT04390334|Experimental|Treatment B: Famotidine & daridorexant|Single dose of 40 mg famotidine followed 3 h later by a single dose of 50 mg daridorexant
89123741|NCT04089670|No Intervention|Control|Participants in this arm of the study will complete the same sleep diaries and questionnaires at the same time points as the intervention group, but will not be administered the intervention modules and will not receive any phone coaching. When they have completed the 1-month follow-up they will be offered the intervention.
89123742|NCT04090996|Experimental|DT patients|
89123743|NCT04091152||old patients|"Patient will freely use Ardoiz during their hospitalisation for a maximum of 9 days.~After this use, a survey concerning the usability of Ardoiz will be administered to the patient, before their discharge from hospital."
89123744|NCT04091152||relatives / unformal caregivers|"Unformal caregivers will freely use Ardoiz during the hospitalization of their relatives and a maximum of 9 days.~After this use, a survey concerning the usability of Ardoiz will be administered to the unformal caregivers, before the discharge of their hospitalized relatives from hospital."
89123745|NCT04091152||profesionnal caregivers|"After the inclusion of all expected patients and relatives, a survey concerning the usability of Ardoiz will be administered to professional caregivers."
88801877|NCT04390334|Experimental|Treatment C: Efavirenz|600 mg efavirenz once daily in the evening from Day 5 to Day 14
89123746|NCT00746356|Experimental|Promote RF CRT-D|Patients with CRT-D device will have the autocapture features of the device tested.
89123747|NCT00746356|Experimental|Current RF ICD|Patients with ICD device will have the autocapture features of the device tested.
89123748|NCT01012973|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.
89123749|NCT01012973|Sham Comparator|Sham treatment|Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.
89123750|NCT00748540|Experimental|Implanted|Implanted with Vibrant Soundbridge
89123751|NCT01012739|Experimental|Indacaterol 150μg-placebo-Indacaterol 60μg-Indacaterol 120μg|In treatment period 1, patients received indacaterol 150 μg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 μg via the Simoon DPI; and in treatment period 4, patients received indacaterol 120 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89233396|NCT01174121|Experimental|4/Unselected TIL + Pembro at POD|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab within 4 weeks of progressive disease for up to 8 doses every 3 weeks
88801878|NCT04390334|Experimental|Treatment D: Daridorexant & efavirenz|Single dose of 50 mg daridorexant in the morning of Day 15 followed by a single dose of 600 mg efavirenz in the evening of Days 15 and 16
88801879|NCT02880020|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88801880|NCT02880020|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes every 6 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88801881|NCT05494554||Pressure control mode group|On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio).
88801882|NCT05494554||Volume control mode group|Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. In this way, two dependent groups were formed.
88801883|NCT01453634|Experimental|Lunacalcipol 180|180 µg (n=4)Lunacalcipol Injection
88801884|NCT01453634|Experimental|Lunacalcipol 270|270 µg (n=8)Lunacalcipol Injection
88801885|NCT05494476|Active Comparator|2mm under bone level|implant platform will be submerged 2mm under bone level
88801886|NCT05494476|Active Comparator|1mm under bone level|implant platform will be submerged 1mm under bone level
88801887|NCT03150160|Experimental|Simbrinza + Travatan|Brinzolamide 1%/brimonidine 0.2% fixed combination + travoprost 0.004% ophthalmic solution
88801888|NCT03150160|Placebo Comparator|Placebo + Travatan|Placebo + travoprost 0.004% ophthalmic solution
88801889|NCT01459406|Experimental|Glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g glucose
88801890|NCT01459406|Experimental|Fructose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose
88801891|NCT01459406|Experimental|Fructan drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructan
88801892|NCT01459406|Experimental|Fructose and glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose and 40 g glucose
88801893|NCT01453712|No Intervention|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
88801894|NCT01453712|Experimental|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
88801895|NCT03988426|Experimental|Octanorm|Human Normal Immunoglobulin for Subcutaneous Administration (Octanorm) is a liquid formulation of normal human IgG at a concentration of 16.5% administered as a SC infusion at weekly intervals (either done at the study center [during first training sessions and then for every 4th administration] or at home by the patient or caregiver). The initial weekly dose was determined based on subjects' previous IVIG treatment.
88801896|NCT01890356|Experimental|Transcranial electrical stimulation|
88801897|NCT05489952|Experimental|iron supplement group|
88801898|NCT05489952|No Intervention|control group|
88801899|NCT03123328|Experimental|Test Subjects|Each test subject will receive a Radical-7 Pulse CO-Oximeter and sensor that will remain on the subject for the first 24 hours following ED admission or discharge from the ICU/IMU.
88801900|NCT04272398|Active Comparator|Treatment|Used dynamic elastomeric fabric orthoses with physiotherapy and rehabilitation program
88801901|NCT04272398|Experimental|Control|Only physiotherapy and rehabilitation program
88801902|NCT01459640|Active Comparator|Hyaluronic acid|
88801903|NCT01459640|Experimental|Bone marrow mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells
88801904|NCT04257396|Experimental|Arm 1 CARA Positioning|Arm 1 patients will receive CARA breast support. The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning. No known risks to using CARA have been identified.
88801905|NCT04257396|No Intervention|Arm 2 Standard of Care|Arm 2 patients will not receive CARA breast support. Patients in arm 2 may be treated with no breast support, a small foam wedge, a thermoplastic shell or alternate supine breast support method according to the current standard of care at the treating centre. These methods have entered RT clinical practice over decades of practice without published evidence of impact on rates of MD. Published rates of MD for the control arm thus pertain to a cross section of these methods. The control arm of this study will look at all of these methods combined. There may be centre specific preference for the control method and stratification by centre will be done.
88801906|NCT01500772|Experimental|Alisporivir|ALV 400 mg twice daily (BID), plus PEG and RBV for 48 weeks
89123752|NCT01012739|Experimental|Indacaterol 60μg-Indacaterol 150μg-Indacaterol 120μg-placebo|In treatment period 1, patients received indacaterol 60 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 150 μg via the Concept1 DPI; in treatment period 3, patients received indacaterol 120 μg via the Simoon DPI; and in treatment period 4, patients received placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89123753|NCT01012739|Experimental|Indacaterol 120μg-Indacaterol 60μg-placebo-Indacaterol 150μg|In treatment period 1, patients received indacaterol 120 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 60 μg via the Simoon DPI; in treatment period 3, patients received placebo to indacaterol via the Concept1 DPI; and in treatment period 4, patients received indacaterol 150 μg via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89123754|NCT01012739|Experimental|Placebo-Indacaterol 120μg- Indacaterol 150μg- Indacaterol 60μg|In treatment period 1, patients received placebo to indacaterol via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 120 μg via the Simoon DPI; in treatment period 3, patients received indacaterol 150 μg via the Concept1 DPI; and in treatment period 4, patients received indacaterol 60 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89123755|NCT04298645|Experimental|High GI carbs breakfast / dinner|Participants will receive a meal rich in high GI carbohydrates for breakfast (day 5) first. After the wash-out day (day 6), the identical meal will be provided for dinner (day 7).
89123756|NCT04298645|Experimental|High GI carbs dinner / breakfast|Participants will receive a meal rich in high GI carbohydrates for dinner (day 5) first. After the wash-out day (day 6), the same meal will be provided for breakfast (day 7).
89123757|NCT04299035|Experimental|Thoracic surgery + ESPblock|Thoracic surgery + ESPblock + standard pain management
89123758|NCT04299035|Experimental|Abdominal surgery + ESPblock|Abdominal surgery + ESPblock + standard pain management
89123759|NCT04299035|Experimental|Spinal surgery + ESPblock|Spinal surgery + ESPblock + standard pain management
89123760|NCT04299035|No Intervention|Thoracic surgery|Thoracic surgery + standard pain management
89123761|NCT04299035|No Intervention|Abdominal surgery|Abdominal surgery + standard pain management
89123762|NCT04299035|No Intervention|Spinal surgery|Spinal surgery + standard pain management
89123763|NCT00742924|Experimental|Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery .~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
89123764|NCT00742924|Experimental|Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
89123765|NCT00742924|Experimental|Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
89123766|NCT00742924|Experimental|Chemotherapy and 2.3 mg/m2 Zoledronic Acid after MTD|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
89123767|NCT04090606||FTC Method|
89123768|NCT04090606||Massachusetts Method|
89123769|NCT04090606||Health Canada Intense Method|
89123770|NCT02596984|Experimental|caspofungin|Caspofungin will be administered according to the international recommendation.
89123771|NCT00698815|Experimental|Arm I (pemetrexed)|Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive sunitinib malate as in Arm II as third-line therapy.
89123772|NCT00698815|Experimental|Arm II (sunitinib)|Patients receive sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive pemetrexed disodium as in Arm I as third-line therapy.
89123773|NCT00698815|Experimental|Arm III (pemetrexed and sunitinib)|Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1 and sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive third-line therapy at the discretion of the treating physician.
89123774|NCT04089124|Other|repair using General anesthesia ( control group)|Surgery repair zone II under GA
89123775|NCT04089124|Other|repair using Walant|Surgery repair zone II under WALANT
89123776|NCT04019860|Experimental|High Intensity Interval Training|High intensity interval training for seven weeks. Three weekly, supervised training sessions.
89123777|NCT04019860|Experimental|Time-Restricted Eating|Time-restricted eating for seven weeks. Maximal daily eating window of 10 hours.
89123778|NCT04019860|Experimental|High Intensity Interval Training & Time-Restricted Eating|
89123779|NCT04019860|No Intervention|Control|Will be given information about the recommended level of physical activity for health benefits and a healthy diet.
89123780|NCT02599090|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
89123781|NCT02599090|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
89123782|NCT02599090|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
89123783|NCT02599090|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
89123784|NCT02566915|No Intervention|CPET submaximal without EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). During the visit without EPAP will be maintained using the facial mask applied without resistance.
89233397|NCT01150708||Chiari 1 with syringomyelia|Chiari I malformation with syringomyelia.
89233398|NCT01150708||Chiari 1 without syringomyelia|A Chiari I Malformation without syringomyelia is defined as descent of the cerebellar tonsils > 5 mm below the foramen magnum 79 without associated syringomyelia.
89233399|NCT01150708||Syringomyelia without chiari|A syrinx or syringomyelia is defined as an intramedullary cyst that extends / length > 1spinal segment.
89233400|NCT01144468||MAP3 Participants|study participants in the MAP.3 study are randomly assigned to either placebo or 25 mg exemestane daily for 5 years. Allocation is blinded. We are following 354 of these study participants and are blinded to treatment allocation.
88801907|NCT02840630|No Intervention|Non-diabetic group|Non-diabetic volunteers will be recruited for baseline data. They will only be required to provide dried blood samples (DBS) samples and information at week 0. They have to collect finger prick DBS, weigh themselves and fill in food frequency questionnaire only at one time point.
89233406|NCT01132937||Healthy Controls|Accrual Ceiling: 20. Healthy, uninjured, subjects are used to match to those suspected of head injury. 10 subjects have been enrolled to date in the PET arm
88801908|NCT02840630|No Intervention|Diabetic control intervention group|The diabetic control group will provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16. This group will not be receiving tinned mackerel and will be asked to continue with their habitual diet and lifestyle.
88801909|NCT02840630|Active Comparator|Diabetic fish intervention group|This intervention group will receive two 125 g portion of tinned mackerel fish (containing 7.8 g n-3 LCPUFA) per week from week 0 until 16 and a mackerel recipe book each. They will be required to provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16.
88801910|NCT04257162|Other|Experimental Arm|Patients treated with Trastuzumab Deruxtecan (T-DXd; DS-8201a)
88801911|NCT04272476|Experimental|Acupuncture and moxibustion|Acupuncture points: Baihui(GV 20), Mingmen(GV 4), Bilateral Neiguan(PC 6), Bilateral Shenmen(HT 7), Bilateral Hegu(LI 4), Bilateral Zusanli(ST 36), Bilateral Taichong(LR 3). Each treatment takes about thirty minutes,3 times a week(treatment on Monday, Wednesday and Friday) for 8 weeks.
88801912|NCT04272476|Active Comparator|Western medicine|Fluoxetine 20 mg capsule by mouth every day for 8 weeks.
88801913|NCT03276390|Active Comparator|Intervention study site|"Exposure to the intervention, which is the Northwestern Medicine (TM) Hispanic Kidney Transplant Program, a culturally targeted program for Hispanic potential recipients for transplant evaluation that is implemented into the 2 study sites.~The intervention study site will provide the intervention to its Hispanic patients.~The intervention study will will also provide the routine care (control arm) to all other patients.~For the purposes of this study, Hispanic potential recipients recruited into the study will be exposed to this intervention. Non-Hispanic Whites recruited into the study will not be exposed to this intervention."
88801914|NCT03276390|No Intervention|No intervention study site|Exposure to routine transplant evaluation at the two control sites.
88801915|NCT03984838|Experimental|Subjects receiving Dolutegravir and Rilpivirine FDC|Subjects will receive Dolutegravir/Rilpivirine 50mg/25mg fixed dose combination (FDC) tablet as a single oral dose in a fed state.
88801916|NCT01890668|Experimental|Osteopathic Manipulative Treatment|Randomization and first OMT will take place at discharge (Day 3); second osteopathic therapy will be performed by the same osteopath practitioner at Day10.
88801917|NCT01890668|Placebo Comparator|Control group|Control group consists in classical medical and paramedical breastfeeding support. OMT on the newborn will be realized by osteopath dissimulated behind a screen. Placebo OMT consists to mimic, without the knowledge of parents, osteopathic techniques on a dolly.
88801918|NCT01890824||Breast Cancer Patients|Breast cancer patients to be studied before and after chemotherapy
88801919|NCT01890824||Healthy Female Controls|Healthy female controls will be compared to breast cancer patients before and after chemotherapy and to healthy male controls
88801920|NCT01890824||Healthy Male Controls|Healthy male controls will be compared to healthy female controls to determine gender differences
88801921|NCT01890902|Experimental|Impracor (Ketoprofen 10% Cream)|Topical Cream over a period of 14 days
88801922|NCT01890902|Placebo Comparator|Placebo Cream:|Topical Cream over a period of 14 days
88801923|NCT04423926|Experimental|Lenalidomide+CHOP|
88801924|NCT03979066|Active Comparator|Atezolizumab|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
89233407|NCT01132937||Suspected of Head Injury|Accrual Ceiling: 1000. Subjects enrolled with 48hrs of suspected head injury in emergency department of local hospitals, Suburban Hospital Center or Washington Hospital Center
89233412|NCT01102556||Surgery Patients/High-risk Patients|Patients who have undergone surgery for pancreatic cancer or pre-neoplastic lesions of the pancreas will be accrued to the study. In addition, patients who are determined to be at high-risk for pancreatic cancer (with a significant family history) will also be recruited for study enrollment.
89233414|NCT01071577||Healthy Volunteers|Healthy volunteers wanting to donate BMSC for allogeneic use
89233415|NCT01071577||Patients|Patients donating BMSC for autologous use
89233416|NCT01031407||Group 1|Healthy Volunteers
89233417|NCT01031407||Group 2|Individuals with Autism Spectrum Disorders
89233418|NCT01031407||Group 3|Parents of Healthy Volunteers, or Individuals with Autism Spectrum Disorders
89233419|NCT01030913||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
89233420|NCT01028430||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
89233421|NCT00942981||healthy volunteers|healthy volunteers
88801925|NCT03979066|Experimental|Atezolizumab in combination with PEGPH20|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery in combination with PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
88801926|NCT05021432|Experimental|Virtual Reality Group|Virtual Reality group will receive video based games training.
88801927|NCT05021432|Active Comparator|Circuit Training Group|They will receive Task-oriented Circuit training exercise program
88801928|NCT02831348||Uncontrolled asthma|Indicated by an asthma control test (ACT) score of <20 and asthma symptoms of cough, wheeze, or chest tightness for more than 2 days in the prior 2 weeks, OR current asthma exacerbation indicated by the prescription of a short course (3-5 days) of systemic corticosteroids by treating provider at the time of visit.
88801929|NCT02831348||Controlled asthma|Indicated by an ACT score of >19, or spirometry results within 10% of year's best value (based on FEV1).
89123785|NCT02566915|Experimental|CPET submaximal with EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). The application of EPAP (10cmH2O) via face mask (Vital RHDSON Signs®, New Jersey, USA) will be randomized with the help of opaque envelopes to be given in one visit. IC serial measurements will be carried out before, during and immediately after the exercise.
89123786|NCT00745498|Experimental|Preop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 14 days before vitrectomy
89123787|NCT00745498|Experimental|Intraop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
89123788|NCT00745498|No Intervention|No IVB|Patients will not receive bevacizumab before nor during vitrectomy
89123789|NCT04089748||Patients enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort
89123790|NCT04089748||Patients from St Louis cohort not enrolled in VESPER study|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort
89123791|NCT00917098|Experimental|Behavior Therapy|Participants will receive behavior therapy during Phases 1 and 2.
89123792|NCT00917098|Placebo Comparator|Supportive Counseling|Participants will receive supportive counseling during Phase 1 and will not participate in Phase 2.
89123793|NCT05270473|Active Comparator|group A: b lynch|B lynch uterine compressive suture was done
89123794|NCT05270473|Active Comparator|group B : Nusicaa suture|Nusicaa uterine compressive suture was done
88801930|NCT02831348||Pneumonia|Indicated by an admission diagnosis of pneumonia with chest X-ray consistent with the diagnosis, based on attending radiologist's interpretation.
88801931|NCT02831348||Controlled allergic rhinitis|Indicated by a rhinitis control assessment test (RCAT) score of >= 21.
88801932|NCT02831348||Uncontrolled allergic rhinitis|Indicated by an RCAT score of <21.
88801933|NCT02831348||Cystic fibrosis (exacerbated)|Indicated by treating physician's assessment of cystic fibrosis respiratory exacerbation within 24 hours of initial antibiotic therapy.
88801934|NCT02831348||Cystic fibrosis (stable)|Indicated by diagnosis of cystic fibrosis with baseline symptoms and with spirometry results (based on FEV1) within 5% of year's best value.
88801935|NCT02831348||Control|Indicated by a negative history of any of the conditions characterizing the other groups.
89123795|NCT00917176|Experimental|Effective stimulation|Effective stimulation at sub-threshold level
89123796|NCT00917176|Placebo Comparator|Placebo stimulation|Stimulation at non-effective strength
89123797|NCT02596828|Experimental|RIST|
89123798|NCT02598856|Experimental|Intranasal naloxone 1x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
88801936|NCT03968848|Experimental|Subjects with Severe Hepatic Impairment|Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.
89123799|NCT02598856|Active Comparator|Intranasal naloxone 2x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
89123800|NCT02598856|Active Comparator|Intravenous naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
89123801|NCT02598856|Active Comparator|Intramuscular naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
89123802|NCT04061551|Experimental|EC Clinic Support|Whole of practice interventions delivery through nurse-led model
89123803|NCT04815031||COMIRNATY|COVID-19 mRNA vaccine (nucleoside-modified)
89123804|NCT00744874|Experimental|Ablated Patients|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
89123805|NCT02595658|Experimental|1|Carbohydrate only meal: Participants will consume a standardised carbohydrate meal (80 g of carbohydrates, 25 g protein, 0 g fat: meal composition, white rice, chicken, curry sauce; 420 kcal) and will self-administer (into the subcutaneous tissue of the abdomen, as per their regular routine) a rapid-acting insulin dose calculated as per the carbohydrate-counting ratio (e.g. 1 IU of insulin per 10 g of carbohydrates).
89123806|NCT02595658|Experimental|2|Participants will replicate Trial 1, but on this occasion the meal consumed will have an additional 50 g of fat (via addition of Ghee). This fat will be added to the sauce within the meal (80 g of carbohydrates, 25 g of protein, 50 g of fat; 735 Kcal). Participants will administer their rapid-acting insulin as per the carbohydrate counting method (i.e. the same IU of insulin as per Trial 1).
89123807|NCT02595658|Experimental|3|Trial 3) Participants will replicate Trial 2, but will administer a rapid-acting insulin dose that has been increased by 30%.
89123808|NCT02595658|Experimental|4|Participants will replicate Trial 2, but will administer an additional rapid-acting insulin dose of 30% 3 hrs post-meal.
89123809|NCT00576901|Experimental|1|
89123810|NCT02598154||Study population|The study population consists of patients whose age is between 20 and 75 years and who experienced a supra-tentorial ischemic or hemorrhagic stroke. The study covers inpatients or patients consultating in the neurological rehabilitation service (NHS) at the Grau du Roi Medical Center, Nîmes University Hospital.
89123811|NCT02596672|Experimental|Intervention|They will complete a 12-week peer-led walking programme. Participants will be paired together as walking partners and will be given a pedometer and step count logs for self-monitoring. The walking co-ordinators will facilitate walking groups two times a week in the local areas, lasting for 30 minutes. The nature of the walks will be tailored to the participants stated preferences of types of activity. Participants will also receive local walking route maps. After 12 weeks, the formal peer-led component will finish and participants will be encouraged to continue walking with their walking partners other activity programmes organised in the fold in order to maintain activity levels.
89123812|NCT02596672|No Intervention|Control|"Folds assigned to the control group will not receive any additional support to change their physical activity behaviour over the course of the intervention period.~At the six-month data collection point they will be offered a referral to a local walking group in their area or advice on beginning a self-directed walking programme (similar to Public Health Agency www.choosetolivebetter.com/content/getting-active). They will be asked to complete outcome measures at baseline and follow up time-points. Post-study a sample of control participants will be asked to attend a focus group, exploring their views on social activity as form of physical activity for older adults in folds."
89123813|NCT02566681|Experimental|MSC construct for Osteonecrosis|Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM).
89123814|NCT02595736|Placebo Comparator|Placebo (SC)|Single subcutaneous (SC) dose of placebo
89123815|NCT02595736|Experimental|LY3200327 (SC)|Single escalating subcutaneous (SC) dose of LY3200327
89123816|NCT02595736|Experimental|LY3200327 (IV)|Single intravenous (IV) dose of LY3200327
89123817|NCT02595736|Placebo Comparator|Placebo (IV)|Single intravenous (IV) dose of placebo
89123818|NCT00917488|Experimental|A|Four concentrations of Glycyphagus domesticus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, was tested in every patient in duplicate on the volar surface of the forearm.
89123819|NCT03971344||Family members of newborns extremely premature|Parents and siblings (if any) of infants born at 30 weeks gestational age or less, or with a birthweight less than 1500 grams.
89123820|NCT03971344||Family members of new pediatric oncology patients|Parents and siblings (if any) of patients with new onset (not relapses) pediatric oncologic diagnoses including liquid, solid, and brain cancer.
89123821|NCT03971344||Family members of critical congenital heart defect patients|Parents and siblings (if any) of newborns with critical congenital heart defects who typically undergo surgery by 12 months of life.
89123822|NCT03971344||Family members of children with severe neurological impairment|Parents and siblings (if any) of patients with severe neurologic impairments, associated with substantial functional impairment, relentless progressive deterioration, or substantially shortened life-spans.
89123823|NCT02597842|Experimental|shuangxuezu|Patients were given 30min of TEAS before induction until the end of the operation at two acupoints.
89123824|NCT02597842|Experimental|neiguanxuezu|Patients were given TEAS at neiguan acupoint.
89123825|NCT02597842|Experimental|zusanlixuezu|Patients were given TEAS at Zusanli acupoint.
89123826|NCT02597842|Sham Comparator|duizhaozu|Patients were not given TEAS at two acupoints.
89123827|NCT02597686|Experimental|SD-PB training|
89123828|NCT04088812|Placebo Comparator|Placebo meat derivative + Placebo satiating compound|60 g Placebo meat derivative 25 g Placebo satiating compound
89123829|NCT04088812|Experimental|Placebo meat derivative + Satiating compound|60 g Placebo meat derivative 25 g Satiating compound
89123830|NCT04088812|Experimental|Experimental meat derivative + Placebo satiating control|60 g Experimental meat derivative 25 g Placebo satiating compound
89123831|NCT00699283|Experimental|Brivaracetam (BRV) 1|50 mg daily
89123832|NCT00699283|Experimental|Brivaracetam (BRV) 2|100 mg daily
89123833|NCT00740584|Experimental|Open Label, only arm|3%w/w SPL7013 vaginal gel (VivaGel)
89123834|NCT02596438||Asian Americans|Foreign born or children of foreign born Asian American from Hepatitis B endemic areas residing in Sacramento, CA.
89123835|NCT04062721|Experimental|Chemotherapy + RFA + in situ immunotherapy|Patients with non-resectable CRC liver-only metastases.
89123836|NCT04062643||Patients with obesity|Obesity in those with BMI ≥30 kg/m2
89123837|NCT04062643||Patients without obesity|Normal weight was considered in the patients with BMI <30 kg/m2
89123838|NCT01023815|Experimental|Group A -Once-a-day regimen|"Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12.~Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL.~Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning."
89233422|NCT00942981||patients|patients with schizophrenia, schizoaffective disorder or other psychotic disorders aged18-60
89233423|NCT00902447||Human Blood Cell Disorders|Human Blood Cell Disorders Tissue Bank
89233424|NCT00896298|Active Comparator|1 Leptin|Active Comparator for 4 months, then for 8 months.
89233425|NCT00896298|Placebo Comparator|2 Sugar pill|Placebo for 4 months, then active comparator for 8 months.
88801937|NCT03968848|Experimental|Matched-Control Subjects|Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.
88801938|NCT05494086|Experimental|DPLDG arm|Dual-port laparoscopic distal gastrectomy
88801939|NCT05494086|Active Comparator|LDG arm|Laparoscopic distal gastrectomy
88801940|NCT02829242||Prostatic Surgery|Patient scheduled for a robotic assisted laparoscopic prostatic surgery.
88801941|NCT02829242||Colorectal Surgery|Patient scheduled for a robotic assisted laparoscopic colorectal surgery.
88801942|NCT01484314|Experimental|Migration Arm|Administration of eltrombopag to support platelets during chemotherapy
88801943|NCT05023148|Active Comparator|Electroacupuncture with dietary intervention|"Acupoints stimulation with an electric stimulator on CV12 Zhongwan, CV9 Shuifen, CV6 Qihai, CV4 Guanyuan, ST25 Tianshu bilateral, SP15 Daheng bilateral, ST40 Fenglong bilateral using continuous 2 Hz for 30 minutes. Therapy sessions are three times a week for four weeks (total 12 times).~Dietary intervention means reducing 500 calories from usual calorie consumptions and will be done twice, at the beginning and 2 weeks after."
88801944|NCT05023148|Active Comparator|Thread embedded acupuncture with dietary intervention|"Acupoints stimulation by embedding PDO thread in CV12 Zhongwan penetrating to CV9 Shuifen using 27G x 60 mm, CV4 Guanyuan penetrating to CV6 Qihai using 27G x 40 mm, ST25 Tianshu penetrating to SP15 Daheng using 27G x 40 mm, and perpendicular in ST40 Fenglong bilateral using 31G x 25 mm. Therapy will be done only once.~Dietary intervention means reducing 500 calories from usual calorie consumptions and will be done twice, at the beginning and 2 weeks after."
88801945|NCT05493930||development set;|RC patients from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College
88801946|NCT05493930||external validation sets 1|RC patients from Changhai Hospital, Naval Medical University
88801947|NCT05493930||external validation sets 2|RC patients from the Second Affiliated Hospital of Harbin Medical University
88801948|NCT03020446|Experimental|Sorbion dressing to venous leg ulcer|any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed
88801949|NCT01459952|Experimental|Rose hip Liquid|20 ml Rose hip Liquid BID
88801950|NCT01459952|Placebo Comparator|Placebo|20 ml placebo liquid BID
88801951|NCT01479010|Experimental|Anakinra|
88801952|NCT01452074|Other|Exercise Training with Weight Loss|"During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week~After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight"
88801953|NCT01472692|Active Comparator|Febuxostat|
88801954|NCT01472692|Placebo Comparator|Placebo|
88801955|NCT05028764||18 to 30 years of age group|Consisting of at least 13 males and 13 females
88801956|NCT05028764||31 to 50 years of age group|Consisting of at least 13 males and 13 females
89233429|NCT00867269||Blood Relatives|Blood Relatives of ICL subjects
89233430|NCT00867269||Household Contacts|Household contacts of ICL subjects
89233431|NCT00867269||ICL Subjects|Patients with confirmed idiopathic CD4 lymphocytopenia
88801957|NCT01891136|Experimental|Peanut protein|Subjects to receive varying amounts of peanut protein as peanut oral immunotherapy.
88801958|NCT01891214||Ulcerative Colitis and Crohn's Disease|
88801959|NCT05020808|Sham Comparator|Nonessential amino acid formulation (NEAA)|"Novel non-essential amino acid blend dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.~Product Number: NEAA56812"
88801960|NCT05020808|Active Comparator|Plant Protein Isolate (PPI)|"Plant protein isolate (Fava bean) dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.~Product Number: FP2011273"
88801961|NCT02558400|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
88801962|NCT02558400|Active Comparator|AR-13324 Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
88801963|NCT02558400|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
88801964|NCT02825264||STARflo|Patients who have been implanted with STARflo implant
88801965|NCT05493696|Experimental|Group 1 (ALG+TPTP)|Patients received Antigravity treadmill training + Traditional physical therapy program
88801966|NCT05493696|Active Comparator|Group 2 (TPTP)|Patients received a Traditional physical therapy program
89233437|NCT00852111||Patients|Prostate cancer patients
89290126|NCT01219686|Active Comparator|escitalopram 20 mg|days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo
88801967|NCT04359732|Other|Hybrid PET/MRI|For the purposes of the study, in addition to standard imaging (EUS and CT scan), a fully integrated hybrid PET/MRI (PET/MRI) study with FDG will replace the Standard PET (pre-surgical evaluation) used for evaluating distant metastases and will be considered as the add-on procedure at three time points. The additional evaluation for patients is that during nCRT treatment.
88801968|NCT04758260|Experimental|Antioxidant Treatment|Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men
88801969|NCT01446250|Experimental|Alisporivir|At the time of partial clinical hold, participants randomized to original treatment arms A and B (Alisporivir triple therapy arms with Peginterferon alfa-2a and Ribavirin) discontinued alisporivir treatment immediately while continuing their treatments with the other two therapies. These participants were combined into the same arm because they received the same dose of alisporivir 400 mg twice per day (BID) for the same duration. Amendment 1 offered them the opportunity to continue in the study receiving boceprevir triple therapy.
88801970|NCT01446250|Active Comparator|Boceprevir|Participants randomized to boceprevir triple therapy with Peginterferon alfa-2a and Ribavirin (the original treatment arm C).
88801971|NCT05493618|Experimental|Single-arm, multi-institution|"Study Arm:~Pembrolizumab 200 mg IV q3 weeks Belantamab 2.5 mg/kg IV q3 weeks. Dex 40 mg IV q3 weeks (20 mg if patient >75) Treatment will be administered on a 21-day cycle and will be continued until unacceptable toxicity or disease progression for up to 2 years (35 cycles)"
88801972|NCT02936206|Experimental|Fulvestrant|750 mg injection in 3 divided doses
88801973|NCT02936206|Active Comparator|Tamoxifen|20mg orally
89123839|NCT01023815|Experimental|Group B - Steroid Withdrawal group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12.~Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks."
89123840|NCT01023815|Active Comparator|Group C - Standard twice-a-day group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12.~Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning."
89123841|NCT01023815|Experimental|Not Randomized Population (NRP)|"NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90. This group was addressed as not randomized patients (NRP) and described with respect to baseline characteristics, treatment and outcome variables."
89123842|NCT03967366||plasma melatonin 1|Quartile 1 of plasma melatonin
89123843|NCT03967366||plasma melatonin 2|Quartile 2 of plasma melatonin
89123844|NCT03967366||plasma melatonin 3|Quartile 3 of plasma melatonin
89123845|NCT03967366||plasma melatonin 4|Quartile 4 of plasma melatonin
89123846|NCT04062331|Placebo Comparator|Placebo group|This group will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) without any frequency (device doesn't running; it means, device turned off) but the same duration of sessions.
88801974|NCT05020106||Alzheimer's disease|Criteria for AD according to the 2011 NIA-AA
88801975|NCT05020106||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
88801976|NCT05020106||Non-AD dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or vascular dementia (VaD); or corticobasal degeneration (CBD); or dementia not otherwise specified.
88801977|NCT05020106||Cognitively normal controls|Individuals with normal cognitive function
88801978|NCT01891526||Hepatic patients|patients with hepatic insufficiency
88801979|NCT01891526||Healthy Controls|Healthy adults
88801980|NCT01426516|No Intervention|Treatment as usual (TAU)|Subjects will give DNA sample for genetic testing but will not receive genetic results and will therefore receive treatment as usual.
89123847|NCT04062331|Experimental|Group under TMS 1 Hertz treatment|1 Hertz group (1 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 1 Hertz.
89123848|NCT04062331|Experimental|Group under TMS 5 Hertz treatment|5 Hertz group (5 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 5 Hertz .
89123849|NCT02595580|Experimental|GlucoPred|
89123850|NCT02567383|Experimental|Hyperthermia|Hyperthermia; Thermotron RF-8, radiation, Cisplatin and Taxotere
89123851|NCT01023659|Active Comparator|Bupropion + motivational emails|participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
89123852|NCT01023659|Active Comparator|Varenicline + motivational emails|participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
89123853|NCT01023659|Active Comparator|Motivational emails|participants receive weekly motivational emails for 12 weeks.
89123854|NCT04062253||HCV or HIV negative|Individuals who test negative for HCV or HIV are given information regarding ways of transmission.
89123855|NCT04062253||HCV and HIV positive|Individuals with a positive test for HCV o HIV are offered delivery or accompaniment to specialist health care.
89123856|NCT00917800||suspected coronary artery disease|patients referred to angiography because of suspected coronary artery disease
89123857|NCT02567617|Active Comparator|Intervention group|Group receiving capsules with polyphenols.
89123858|NCT02567617|Placebo Comparator|Placebo controlled group|Group receiving capsules with starch.
89123859|NCT00740116|Active Comparator|The Tranexamic acid group|The group of women receiving Tranexamic acid intravenously immediately before the surgery
89123860|NCT00740116|Placebo Comparator|The placebo group|The group of women receiving saline solution (0.9% NaCl) intravenously immediately before the surgery
89123861|NCT02567461|Experimental|DAPT plus high-dose edoxaban|High-dose edoxaban will be represented by edoxaban 60mg od, which will be reduced to 30mg od in patients with ClCr ≤50mL/min.
89123862|NCT02567461|Experimental|DAPT plus low-dose edoxaban|Low-dose edoxaban will be defined as edoxaban 30mg od, which will be reduced to 15mg od in patients with ClCr ≤50mL/min.
89123863|NCT02567461|Active Comparator|DAPT|Aspirin 81 mg od plus clopidogrel 75 mg od
88801981|NCT01426516|Experimental|Genecept Assay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account.
88801982|NCT02983136|Experimental|Study site|The study arm will consist of managers and staff at at the operating department of a University hospital in western Sweden' The intervention is based on partnership, dialogue and inter-professional learning
88801983|NCT02983136|No Intervention|Control site|The Control arm will consist of managers and staff at at the operating department of a University hospital in south Sweden
89123864|NCT03966274||Delirium positive|
89123865|NCT03966274||Delirium negative|
89123866|NCT00698581|Experimental|Brivaracetam 50 mg|50 mg/day
89123867|NCT00698581|Experimental|Brivaracetam 100 mg|100 mg/day
89123868|NCT02595346|Experimental|hydroxychlorquine|hydroxychloroquine 200 mg twice a day for 6 months
89123869|NCT02595346|Placebo Comparator|control|placebo 2 pills a day for 6 months
89123870|NCT05380258|Experimental|chewing gum|Pregnant women with 4-5 cm cervical dilatation started chewing gum as soon as their contractions came and they chewed gum for 20 minutes. and when the cervical dilation was 6-8 cm, they chewed gum again for 20 minutes.
89123871|NCT05380258|Experimental|stress ball|Pregnant women with 4-5 cm cervical dilatation were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes when their contractions came, and when the cervical opening was 6-8 cm, they were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes.
89123872|NCT05380258|No Intervention|Control Group|standard care
89123873|NCT02596594|Experimental|Port intervention|"The subcutaneous intraumbilical port-system will be implanted in IUGR patients with the cerebroplacental ratio less than 1 (cerebroplacental ratio= PI in the middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.~The fetuses will receive AAs and glucose supplementation via a subcutaneously implanted intraumbilical perinatal port system till the delivery. Control by doppler and cardiotocogram"
89123874|NCT02596594|No Intervention|control|"IUGR patients with the cerebroplacental ratio less than 1 (CPR= PI middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.~Control by doppler and cardiotocogram"
89123875|NCT04061395|Experimental|Guselkumab|Guselkumab 200 mg Q4W; subcutaneous injections; duration of 16 weeks.
89123876|NCT02566603|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between three and six patients will be enrolled per intervention level. Intervention levels range from 3 to 24 micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after initiation of PRTX-100 dosing for safety management.
89123877|NCT02566447||Symptomatic|Subjects will be categorized by the clinician as symptomatic for Trichomonas vaginalis infection.
89123878|NCT02567695|Experimental|Treatment Sequence 1|Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 1 followed by Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 2.
89290127|NCT03116698|Experimental|Low dose DFD07 once daily|
88801984|NCT02819908|Active Comparator|Imprimis Dropless|TriMoxiVanc 0.2cc intravitreal one time
88801985|NCT02819908|Active Comparator|Imprimis Less Drops|Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.
88801986|NCT01453010|Experimental|8 individual case reviews|SaeboFlex Self-directed training
88801987|NCT02678858|Experimental|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) shall target expressive and interactional behavior skills together with those social cognitive domains (facial and prosodic affect recognition, social perception, theory-of-mind) known to be most impaired (Savla, 2012) and most closely associated with functional outcome (Fett, 2012) in schizophrenia.
89123879|NCT02567695|Experimental|Treatment Sequence 2|Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 1 followed by Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 2.
89123880|NCT05214859|Experimental|Intervention|Participants in the intervention arm will receive Dyadic Expressive Arts Group Therapy as an intervention.
89123881|NCT05214859|No Intervention|The Treatment-as-usual Waitlist Control Group|Participants in the control group will continue their routine healthcare and social services. Upon completion of the 8-month study period, participants will be invited to a similar intervention group program.
89123882|NCT01023581|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
89123883|NCT01023581|Experimental|Alogliptin 25 QD|Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
89123884|NCT01023581|Experimental|Alogliptin 12.5 BID|Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
89123885|NCT01023581|Active Comparator|Metformin 500 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
89123886|NCT01023581|Active Comparator|Metformin 1000 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
89123887|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 500 BID|Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
89123888|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 1000 BID|Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.
89123889|NCT05571787|Experimental|Treatment A|Subjects in treatment A will fast overnight for at least 10 hours prior to HMPL-523 dosing.
89123890|NCT05571787|Experimental|Treatment B|Subjects in treatment B will receive a standardized high-fat meal approximately 30 minutes before HMPL-523 administration
89123891|NCT05571787|Experimental|Treatment C|Subjects in treatment C will receive a standardized low-fat meal approximately 30 minutes before HMPL-523 administration
89290128|NCT03116698|Experimental|High dose DFD07 once daily|
89123892|NCT05571787|Experimental|Treatment D|Subjects in treatment D will receive rabeprazol 1 hour prior to receiving a standardized low-fat meal. On Day 26 subjects will also receive HMPL-523 approximately 30 minutes after the standardized low-fat breakfast
89123893|NCT04063189|Experimental|First Relapsed Multiple Myeloma|
89123894|NCT02567929|Active Comparator|propofol group|The patient who anesthetized by using propofol.
89123895|NCT02567929|Active Comparator|sevoflurane group|The patient who anesthetized by using propofol
89123896|NCT04298489|Experimental|stage III/IV gastrointestinal cancer patients|The study group (Personalized drug sensitivity test) was treated according to the physician's opinion. Tumor tissues are obtained during the surgery or via biopsy with informed consent, for the purpose of ex vivo assay.
89123897|NCT05190523|Experimental|ASC42 tablets of 5mg|ASC42 tablets 5mg for 12 weeks
89123898|NCT05190523|Experimental|ASC42 tablets of 10mg|ASC42 tablets 10mg for 12 weeks
89123899|NCT05190523|Experimental|ASC42 tablets of 15mg|ASC42 tablets 15mg for 12 weeks
89123900|NCT05190523|Placebo Comparator|Placebo|Placebo for 12 weeks
89123901|NCT04298333|Experimental|BP-C1|BP-C1 will be used as supportive care
89123902|NCT05188417|Experimental|Tirofiban 0.25μg/kg/min(0.005ml/kg/min) group|The tirofiban hydrochloride sodium chloride injection is pumped intravenously at a constant rate of 0.25μg/kg/min (0.005 ml/kg/min) for 30 minutes, and then pumped intravenously at a constant rate of 0.1 μg/kg/min (0.002 ml/kg/min) for 24 hours.
89123903|NCT05188417|Experimental|Tirofiban 0.4μg/kg/min(0.008ml/kg/min) group|The tirofiban hydrochloride sodium chloride injection is pumped intravenously at a constant rate of 0.4 μg/kg/min (0.008 ml/kg/min) for 30 minutes, and then pumped intravenously at a constant rate of 0.1 μg/kg/min (0.002 ml/kg/min) for 24 hours.
89123904|NCT05188417|Placebo Comparator|0.9% sodium chloride solution|The placebo is pumped intravenously at a constant rate of 0.008 ml/kg/min for 30 minutes, and then pumped intravenously at a constant rate of 0.002 ml/kg/min for 24 hours.
89123905|NCT00962780|Experimental|1|3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
89123906|NCT02567851|Experimental|Brentuximab Vedotin|brentuximab vedotin will be administered at an initial dose of 1.8 mg/kg every 3 weeks as a 30-minute outpatient i.v. infusion. A maximum of 16 cycles
89123907|NCT02566291||Supreme Group|Measuring Success rate and Insertion Time
89123908|NCT02566291||Gain Group|Measuring Success rate and Insertion Time
89123909|NCT02566213|Other|Motor skills measurements|
89123910|NCT00739882|Active Comparator|Efalizumab|
89123911|NCT00739882|Placebo Comparator|Placebo|
89123912|NCT04281056|No Intervention|Control|
89123913|NCT04281056|Experimental|Tooth removal|Tooth removal and their replacement by means of a denture Teeth have been removed and replaced by means of dentures for at least one year
89123914|NCT00961220|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour and apply topical carmustine to the total skin surface (excluding the lips, eyelids, and ulcerated lesions) 1 hour after completing O6-benzylguanine infusion on days 1-2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89123915|NCT00734656|Placebo Comparator|Placebo medication + placebo alcohol|
89123916|NCT00734656|Experimental|Placebo Medication + 0.8 gr/kg Ethanol|
89123917|NCT00734656|Experimental|4 mg Dutasteride + Placebo Alcohol|
89123918|NCT00734656|Experimental|4 mg Dutasteride + 0.8 gr/kg Ethanol|
89123919|NCT04644289|Other|cohort A - olaparib monotherapy|Olaparib tablets 2 × 300 mg per day for 3 weeks prior to surgery until one day prior to surgery or withdrawal of informed consent and as long as the patient has received all possible licensed treatment regimens according to national guideline or for whom further licensed treatment options are contraindicated, offered as investigational maintenance therapy for 24 months after completion of primary therapy (chemotherapy).
89123920|NCT04644289|Other|cohort B - olaparib + durvalumab combination|Olaparib tablets 2 × 300mg per day for 4 weeks plus durvalumab 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle).
89123921|NCT00921271||At risk for compartment syndrome.|"Patients admitted to Selly Oak Hospital, Birmingham, Uk, meeting one or more of the following inclusion criteria:~Patients with one or more of the following injuries:~tibial fracture.~crush injury/soft tissue injury to lower limb without fracture.~pelvic fracture.~major vascular injury below the aortic bifurcation.~2 or more long bone fractures.~Any patient sustaining a traumatic injury with a base deficit ≥ 6 mEq/L within 12 hours of Hospital admission.~Any patient receiving ≥ 6 units packed red blood cells within 12 hours of hospital admission."
89123922|NCT02565979|Active Comparator|Resveratrol|resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
89123923|NCT02565979|Placebo Comparator|Placebo|placebo will be given for 6 months, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
89123924|NCT04062175|Active Comparator|cephalosporin arm|72 women will receive single antibiotic chemotheraby first generation cephalosporin (cefazolin) 2 gm iv within 30 minutes before skin incision
89123925|NCT04062175|Active Comparator|cephalosporin +azithromycin arm|72 women will receive combined antibiotic chemotherapy azithromycin (Azrolid) 1 gm single oral dose 2 hours before cesarean delivery + cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
89123926|NCT02859584|Other|no serious acute hepatitis|
89123927|NCT02859584|Other|Serious acute hepatitis|
89123928|NCT02859584|Other|Healthy volunteers|
89123929|NCT02859584|Other|Surrenal insufficiency|
89123930|NCT02567305||Actual Sepsis|"For infants below 44 weeks inclusive of corrected age clinical sepsis is defined, according to the Expert Meeting on Neonatal and Pediatric Sepsis (Report on the Expert Meeting on Neonatal and Pediatric Sepsis - 8 June 2010, EMA London). Confirmed sepsis is defined as positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)~For children above 44 weeks corrected age clinical sepsis is defined according to the Goldstein criteria (Goldstein et al, 2005). Confirmed sepsis: positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)"
89123931|NCT02567305||Suspected Sepsis|None of the above.
89123932|NCT04391569|Placebo Comparator|IV Placebo|Placebo bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
89123933|NCT04391569|Experimental|IV ganaxolone active|Ganaxolone bolus dose followed by continuous infusion for 36 hours, followed by 12 hour taper
89123934|NCT05324917||lymphoma patients|Patients with Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and other mature B-lymphoma patients. Patients were randomly divided into two groups for PK blood collection. There were 12 blood sampling sites in each group.
89123935|NCT05324917||Patients with B lymphoproliferative diseases|Patients with hematopoietic stem cell transplantation and Epstein-Barr virus associated b-cell lymphoproliferative diseases, b-cell lymphoproliferative changes, immune thrombocytopenia, and autoimmune hemolytic anemia. Patients were randomly divided into two groups for pharmacokinetics blood collection. There were 12 blood sampling sites in each group.
89123936|NCT00739648|Placebo Comparator|Placebo|Placebo inhaled twice daily via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
89123937|NCT00739648|Experimental|MP-376 240 mg Twice Daily (BID)|MP-376 240 mg BID inhaled via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
89123938|NCT02566057|Experimental|PGx testing guided treatment (PGT)|Results of the GeneceptTM Assay will be provided to their prescribers who may use the knowledge to guide medication management.
89123939|NCT02566057|No Intervention|Treatment as usual condition (TAU)|Patients will also utilize the GeneceptTM Assay but the results will not be provided back to their prescribers, who will treat the patients without the knowledge of pharmacogenetic testing results.
89123940|NCT01032239|Active Comparator|ITB therapy|Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
89123941|NCT01032239|No Intervention|Best Medical Treatment (BMT)|Use one or a combination oral antispastic medication.
89123942|NCT04061629||Group C|Size of the cuffed ETT based on the Cole formula = (Age/4) + 4.
89123943|NCT04061629||Group D|size of the cuffed ETT based on the Duracher formula = (Age/4) + 3 + 0.5 mm.
89123944|NCT04061629||Group K|size of the cuffed ETT based on the Khine formula = (Age/4) + 3.
89123945|NCT05139901|Active Comparator|4% saline|4% Saline inhalations twice daily
89123946|NCT05139901|Experimental|Pulmosyme|DNAse alpha inhalations twice daily
89123947|NCT02871713|Active Comparator|Intrathecal morphine|Intrathecal morphine 100 mcg
89123948|NCT02871713|Experimental|Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg)
89123949|NCT02871713|Experimental|Intrathecal morphine + Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg) + Intrathecal morphine 100 mcg
89123950|NCT04298801|Experimental|Nurse-driven HIV screening for key populations+UD|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing (UD)
89123951|NCT04298801|Active Comparator|Physician-directed diagnostic testing alone|
89123952|NCT05112835||brolucizumab|brolucizumab intravitreal injections in patients with nAMD treated in the UK
89123953|NCT00734578|Experimental|SPD503-AM|SPD503 (Guanfacine Extended Release)
89123954|NCT00734578|Experimental|SPD503-PM|SPD503 (Guanfacine Extended Release)
89123955|NCT00734578|Placebo Comparator|Placebo|
89123956|NCT04298411|Experimental|Experimental Arm|Participants will take part in 12 one-hour rehabilitation sessions over 12 weeks in the clinic at Holland Bloorview Kids Rehabilitation Hospital and Institut de réadaptation en déficience physique de Québec, during which they will play games developed for the Novint Falcon.
89123957|NCT00628433|Placebo Comparator|1|Placebo
89123958|NCT00628433|Experimental|2|HE3286 5 mg daily
89123959|NCT00628433|Experimental|3|HE3286 10 mg daily
89123960|NCT00628433|Experimental|4|HE3286 20 mg daily
89123961|NCT00628433|Experimental|5|HE3286 4 mg daily
89123962|NCT02596282|Active Comparator|Clinical Officer (CO),|COs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
89123963|NCT02596282|Experimental|Nurse Midwife (NMW)|NMWs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
89123964|NCT04630301||Measurement of pleural pressure|a. Patients admitted to the Johns Hopkins Hospital with spontaneous, iatrogenic, or tension pneumothorax referred to the Division of Interventional Pulmonology for thoracostomy will be recruited. Using standard sterile technique, a 14fr catheter will be inserted into the pleural space. An electronic manometer (Compass, Medline Industries, Inc.) will be connected in-line to the introducer needle and Ppl will be recorded for 3-5 respiratory cycles. After measurement, the manometer will be removed and the catheter will remain in place per routine standards of practice.
89123965|NCT00739102|Experimental|1|S.M.A.R.T.® Nitinol Self-Expandable Stent System
89123966|NCT02596360|Experimental|Dextromethorphan|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
89123967|NCT02596360|Placebo Comparator|Placebo|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
89123968|NCT02593708|Experimental|Cohort 0|"Neratinib: 80 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
89123969|NCT02593708|Experimental|Cohort 1|"Neratinib: 120 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
89123970|NCT02593708|Experimental|Cohort 2|"Neratinib: 160 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
89123971|NCT02593708|Experimental|Cohort 3|"Neratinib: 200 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
89123972|NCT00959192|Experimental|ACC-001 + QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
89123973|NCT00959192|Placebo Comparator|QS-21|Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
89233441|NCT00687115|Other|Overfeeding|an inpatient overfeeding arm in which obesity resistant individuals are prescribed a 150% increase in a weight maintenance calorie diet for 6 weeks which (by random assignment) is either low in protein (6%) content. Overfeeding or Overfeeding Low Pro or with normal (20%) protein content
89233442|NCT00687115|Other|Weight Loss|a weight loss arm in which obese individuals are placed on a 50% decrease from a weight maintenance calorie diet for 6 weeks which (by random assignment) is either a standard 50% decrease in energy intake with all macronutrients held at the same percentage (20% protein, 50% carbohydrate, 30% fat) or a 50% decrease in energy intake with the same absolute protein content (in grams) as the weight maintaining diet while on our clinical research unit then followed as outpatients monthly for 10 months
89233443|NCT00678821|Experimental|1|Patients with PH will be randomized to either aerobic exercise training plus education (AET) or education only (Ed-only) treatments
89233444|NCT00678821|Active Comparator|2|A comparison group of patients with ILD who do not have secondary PH (ILD-only) will also undergo the AET arm
89233445|NCT00663611|Experimental|Study I and IB|Each involve six subjects and are designed to test the hypothesis that pulsatile subcutaneous infusion of GH via a subcutaneous infusion pump will yield a reasonable pulsatile GH pattern. The dose of GH used in Study IB will be three-fold higher than that in Study I. Study I and IB will be done first before proceeding to Study II
89233446|NCT00663611|Experimental|Study II|Is a randomized, double-blinded, placebo-controlled 12 week study involving 26 subjects divided into 2 groups: Group A and Group B. Group A will involve 13 subjects receiving pulsatile GH or placebo infusion for 4 weeks with 8 week washout after intervention. Group B will involve 13 subjects receiving conventional once a day subcutaneous infusion of GH or placebo for 4 weeks with 8 week washout after intervention.
89233447|NCT00606346||Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
89233448|NCT00606346||No Biologics|Treatments will be prescribed according to investigator judgement.
89233450|NCT00542230||Healthy Volunteers|Healthy Volunteers
89233451|NCT00542230||Sickle Cell Trait|Patient with sickle cell trait or disease
89233452|NCT00508547||Guselkumab|Participants will receive guselkumab as prescribed by a physician according to standard of care for psoriasis.
89233453|NCT00508547||Infliximab|Participants will receive infliximab as prescribed by a physician according to standard of care for psoriasis.
89233454|NCT00508547||Ustekinumab|Participants will receive ustekinumab as prescribed by a physician according to standard of care for psoriasis.
89233455|NCT00508547||Biological Therapies|Participants will receive biological therapies other than infliximab, ustekinumab, guselkumab, and IL-17 inhibitors as prescribed by a physician for psoriasis. Participants will not receive any intervention as a part of this study.
89233456|NCT00508547||Conventional Systemic Agents|Participants will receive conventional systemic agents as prescribed by a physician for psoriasis. Participants will not receive any intervention as a part of this study.
89233457|NCT00508547||IL-17 Inhibitor|Participants will receive an IL-17 inhibitor as prescribed by a physician according to standard of care for psoriasis.
89233458|NCT00500994|Experimental|fMRI study|subjects receiving MRI
89233470|NCT00397280||1|Any healthy donors meeting inclusion/exclusion criteria
89233473|NCT00341874||1|Subjects with hearing loss consisting of both nonsyndromic and syndromic forms of deafness of genetic etiology
89233475|NCT00340132||Adult volunteers|Volunteers aged 18-55 who are healthy as determined by medical history, physical examination, and laboratory tests
89233476|NCT00339911||1/ single cohort|Healthy NCI Frederick Cancer Research and Development Center employees
89233477|NCT00329771||Episodic migraineurs|Eligible subjects with episodic migraine (with or without aura)
89233481|NCT00302146||Asymptomatic|Unaffected at-risk individuals with or without a first degree family member with parkinsonism, GD with and without a family history of PD, Gaucher carriers with and without a family history of PD.
89233482|NCT00302146||Control|Controls will include subjects without GBA mutations, with sporadic PD and healthy volunteers who do not have a family history of parkinsonism or Gaucher disease.
89233483|NCT00302146||PD|Subjects with parkinsonism to better characterize the parkinsonian phenotype (e.g.,GD/PD, Sporadic PD, Gaucher carrier PD).
89233485|NCT00104325||1|white blood cells obtained through cytapheresis by healthy males and females 18 years and older
89123974|NCT00696787|Placebo Comparator|Placebo|In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.
89123975|NCT00696787|Experimental|DVS SR|In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.
89123976|NCT00696787|Active Comparator|Pregabalin|In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.
89123977|NCT01012037|Experimental|linagliptin low dose|linagliptin low dose twice daily
89123978|NCT01012037|Placebo Comparator|placebo|placebo matching linagliptin
89123979|NCT01012037|Experimental|linagliptin medium dose|linagliptin medium dose once daily
89123980|NCT04284566|Experimental|TAU + multicomponent treatment FIBROWALK|FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
89123981|NCT04284566|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option. Patients were offered the opportunity to participate in the next wave of group intervention at the end of the study (3 months).
89123982|NCT00630110|Active Comparator|docetaxel|docetaxel (75 mg/m2)
89123983|NCT00630110|Experimental|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
89123984|NCT00734032|Placebo Comparator|Placebo Group|Matched Placebo
89123985|NCT00734032|Experimental|SB480848 40mg Group|SB480848 40mg/day
89123986|NCT00734032|Experimental|SB480848 80mg Group|SB480848 80mg/day
89123987|NCT00734032|Experimental|SB480848 160mg Group|SB480848 160mg/day
89123988|NCT04284098|Placebo Comparator|GA group|Group I (GA group): Standard general anesthesia (GA) .
89123989|NCT04284098|Active Comparator|Bupivacaine group|Group II (B group): ultrasound-guided PECS block using bupivacaine 0.25% + standard GA.
89123990|NCT04284098|Active Comparator|Dexmedetomidine&bupivacaine group|Group III (D group): ultrasound-guided PECS block using bupivacaine 0.25% and Dexmedetomidine 1µg/kg+standard GA.
89123991|NCT01010633|Experimental|Loteprednol Etabonate|Loteprednol etabonate
89123992|NCT01010633|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate
89123993|NCT00733954|Active Comparator|clobetasol propionate spray|clobetasol propionate spray 0.05%
89123994|NCT00733954|Active Comparator|clobetasol propionate ointment|clobetasol propionate ointment 0.05%
89123995|NCT04283006|Experimental|Administration of CD20/CD22 dual Targeted CAR T-cells|A dose levels of 3-5*10E6/kg are administrated for each subject.
89123996|NCT04297943|Active Comparator|3D Orthosis|See summary
89123997|NCT04297943|Active Comparator|Custom Thermoplastic Orthosis|See summary
89123998|NCT04280900|Experimental|cybertherapy|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
89123999|NCT04280900|Other|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
89124000|NCT04297865|Experimental|A dose as CJ-15314 or placebo|Oral administration of A as CJ-15314 or placebo once a day
89124001|NCT04297865|Experimental|B dose as CJ-15314 or placebo|Oral administration of B as CJ-15314 or placebo once a day
89124002|NCT04297865|Experimental|C dose as CJ-15314 or placebo|Oral administration of C as CJ-15314 or placebo once a day and once daily for 7 days
89124003|NCT04297865|Experimental|D dose as CJ-15314 or placebo|Oral administration of D as CJ-15314 or placebo once a day and once daily for 7 days
89124004|NCT04297865|Experimental|E dose as CJ-15314 or placebo|Oral administration of E as CJ-15314 or placebo once a day and once daily for 7 days
89124005|NCT04297865|Experimental|F dose as CJ-15314 or placebo|Oral administration of F as CJ-15314 or placebo once a day and once daily for 7 days
89124006|NCT03368833||Caudal block|Patients that receive regional anesthesia in the form of a caudal block prior to surgery as part of their standard of care.
89124007|NCT03368833||Control|Patients who do not receive a caudal block.
89124008|NCT04283084|Experimental|Study group|Number of participants in this group is anticipated to be 25. Participants in this group will be receiving 10 minutes of exercise with the virtual reality based balance and coordination training system (MARBES). In the MARBES system two exercises (1. Balance exercise, 2. Coordination exercise) will be played for 5 minutes each.
89124009|NCT02595268|Experimental|Pitavastatin Then JNJ-63623872|Participants will sequentially receive single oral dose of pitavastatin 1 milligram (mg) on Day 1, followed by JNJ-63623872 600 mg twice daily on Days 4 through 12 with a single oral dose of pitavastatin 1 mg administered in the morning of Day 9. All study drug intakes will be taken orally, under fed conditions (within approximately 10 minutes after completion of a meal).
89124010|NCT00921505|Active Comparator|Ibuprofen 400 mg|Ibuprofen oral single dose
89124011|NCT00921505|Active Comparator|Ibuprofen 1200 mg|Ibuprofen oral single dose
89124012|NCT00921505|Active Comparator|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) oral single dose
89124013|NCT00921505|Active Comparator|Ibuprofen 400 mg + paracetamol 1000 mg|Paracetamol (acetaminophen) + ibuprofen oral single dose
89124014|NCT00628511||observation|
89124015|NCT04280588|Experimental|Treatment group|
89124016|NCT04280588|No Intervention|Control group|
89124017|NCT02593552|Experimental|Video camera|DriveCam video event recorder with counseling feedback
89124018|NCT04298021|Experimental|AZD6738 + Durvalumab|"Durvalumab 1500 mg iv on D1~AZD6738 240 mg bid on D15-D28 Every 4 weeks C1D1 dose of durvalumab will be delivered, and AZD6738 of 240 mg bid will be dosed at D15-D28. Every cycle consists of 4 weeks."
89124019|NCT04298021|Experimental|AZD6738 + Olaparib|"AZD6738 160 mg qd on D1-D7~Olaparib 300 mg bid on D1-D28 Every 4 weeks Every cycle consists of 4 weeks. AZD6738 of 160 mg qd will be administered on D1-D7. Olaparib will be delivered as 300 mg bid dose on D1-D28."
89124020|NCT02595190|Experimental|surgery group|sacral canal cyst microscopic tamponade treatment; resting state functional magnetic resonance imaging (rfMRI)
89290129|NCT03116698|Experimental|High dose DFD07 twice daily|
88801988|NCT02678858|Active Comparator|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Therapy (NCRT) shall target impairments in attention, memory, and executive functions as an active comparator to the ISST.
89124021|NCT02595190|Experimental|drug group|gabapentin + tramadol tablets; resting state functional magnetic resonance imaging (rfMRI)
89124022|NCT02595190|Placebo Comparator|control group|resting state functional magnetic resonance imaging (rfMRI)
89124023|NCT04061473|Placebo Comparator|Pancreatectomized + Placebo|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 placebo tablets will be administered orally."
89124024|NCT04061473|Active Comparator|Pancreatectomized + DPP-4 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 DPP4-inhibitor tablets will be administered orally."
89124025|NCT04061473|Active Comparator|Pancreatectomized + SGLT-2 inhibitor|"During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.~Before the meal (1 h and 12 h) 1+1 SGLT-2 tablets will be administred orally."
89124026|NCT04061473|Placebo Comparator|Healthy + Placebo|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
89124027|NCT04061473|Active Comparator|Healthy + DPP-4 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
89124028|NCT04061473|Active Comparator|Healthy + SGLT-2 inhibitor|During the experimental day the participant will ingest a standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
89124029|NCT02595112|Experimental|Patient undergoing otorhinolaryngologic surgery|Staphylococcus aureus carriage is measured in the vestibulum nasi and posterior nasal cavity. Posterior nasal cavity is measured during endoscopic procedure.
89124030|NCT00733408|Experimental|Tx (chemo, MoAb, and enzyme inhibitor)|"INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity."
88801989|NCT04078230|Experimental|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
88801990|NCT04078230|No Intervention|Regional LymphAdenectomy|Regional lymph node dissection for intrahepatic cholangiocarcinoma included station 12.
89124031|NCT01010867|Experimental|Lactobacillus plantarum|There is a single intervention arm in this study. Target accrual for the intervention is 30 subjects. Subjects receive supplementation with Lactobacillus plantarum strains 299 and 299v.
89124032|NCT05270122|Experimental|ThrombX Retriever|Access to the involved vasculature and preform mechanical thrombectomy using the ThrombX Retriever.
89124033|NCT04297163|Active Comparator|Hospital management|Patient's receive no intervention, the follow up is the usual for a patient following CPAP therapy.
89124034|NCT04297163|Experimental|Telemedicine management|CPAP remote monitoring of patients, including a mobile application and a voicemail.
89124035|NCT04296383|Experimental|Azithromycin plus Xiyanping injection group|
89124036|NCT04296383|Active Comparator|Azithromycin group|
89124037|NCT04297553|Active Comparator|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
88801991|NCT01891682||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
88801992|NCT01406860|Experimental|Droperidol|
88801993|NCT01406860|Active Comparator|Metoclopramide + Diphenhydramine|
88801994|NCT04138212|Active Comparator|Chemotherapy group|Patients in this group will receive neoadjuvant chemotherapy.
88801995|NCT04138212|Experimental|Chemoradiation group|Patients in this group will receive neoadjuvant chemoradiation therapy.
88801996|NCT02813954||Study Group|Neonates with respiratory distress
88801997|NCT02813954||Control Group|Healthy Infants
88801998|NCT05493384|Experimental|Telerehabilitation group|The Telerehabilitation Group will be performed exercise program including stretching, strengthening, posture and relaxation exercises by an experienced physiotherapist for 3 times a week for 8 weeks via Zoom.
89124038|NCT04297553|Active Comparator|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
89124039|NCT00576823|Experimental|Alfuzosin solution - 2-7 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children 2-7 years of age.
89290130|NCT03116698|Placebo Comparator|Placebo twice daily|
89233488|NCT00059748||Patients affected with autoinflammatory diseases|Subjects with known or suspected diagnosis of NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still s disease, Behcet s disease, JDM, and other autoinflammatory diseases.
89233495|NCT00027274||1|All families with a member who has one of the relevant syndromes.
89233496|NCT00026663||1/Patients with cancer|Cancer patients providing tissue for research studies
88801999|NCT05493384|No Intervention|No Intervention group|No additional therapy will be performed to the Control Group and they were suggested to continue their usual physical activity.
89233497|NCT00026663||2/Normal Volunteers|normal volunteers providing samples for research studies
89233501|NCT00005927||Hyperaldosteronism and cushing participants|Subjects with Hyperaldosteronism and cushing. Adults, pediatric subjects and family members (DNA collection only for family members).
89233506|NCT00004571||Healthy volunteers|Healthy subjects from the community
89233507|NCT00004571||Schizophrenia|Patients with schizophrenia and psychosis
88802000|NCT02773576|Experimental|2x360 mg risperidone implant|2, 360 mg risperidone implants
88802001|NCT02773576|Experimental|3x300 mg risperidone implant|3, 300 mg risperidone implants
89233508|NCT00004571||Williams Syndrome|Individuals with copy number variation in the Williams Syndrome Region
89233515|NCT00001721||Patients|Patients diagnosed with SLOS
89233516|NCT00001645||Diarrhea GI parasite|Subjects infected with a GI parasite
89233517|NCT00001645||Echinococcus|Subjects infected with echinococcus
89233518|NCT00001645||Intestinal worm|Subjects infected with parasitic intestinal worm
89233519|NCT00001645||Malaria|Subjects infected with malaria
89233520|NCT00001645||Parasitic infection|Subjects infected with a parasitic infection that is not included in the other cohorts
89233521|NCT00001620||Subjects undergoing screening|Adults and children being screened for an active NHLBI protocol
88802002|NCT01891058|Active Comparator|drug-shock vs shock only|For ED patients with RAFF, Investigators will compare conversion to normal sinus rhythm between the two strategies of i) attempted pharmacological cardioversion with intravenous procainamide followed by DC cardioversion if necessary (Drug-Shock), and ii) DC cardioversion alone (Shock Only).
88802003|NCT01891058|No Intervention|pad positions|For ED RAFF patients undergoing DC cardioversion, Investigators will compare conversion to normal sinus rhythm between the i) antero-posterior and ii) antero-lateral pad positions.
88802004|NCT01891838|Active Comparator|Volume controlled ventilation|Volume controlled ventilation: tidal volume of 7 mL/kg ideal body weight, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Ventilatory frequency is changed if necessary to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg.
88802005|NCT01891838|Experimental|Pressure-controlled ventilation|initial pressure of 15 cm H2O, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Pressure is modified to maintain a tidal volume of 7 mL/kg of ideal body weight and frequency ventilation is modified to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg
88802006|NCT05489094|Active Comparator|Intervention Group|First group will be given nutrition education and iron intake from growing up milk approximately 2 - 3 servings/day for four months intervention period
89233523|NCT00001529||Group 1|Healthy volunteers
89233524|NCT00001506||Patients|With dermatologic diseases and systemic diseases with cutaneous manifestations
89233525|NCT00001505||1/Single Cohort|Healthy individuals (including employees and other patients) and patients with selected skin or other diseases
89233526|NCT00001481|Placebo Comparator|Group 1, Hormone and Placebo Group|8 weeks of hormonal addback plus 4 weeks of placebo
89233527|NCT00001481|Active Comparator|Group 2, Continued Replacement Group|12 weeks of hormone addback
89233528|NCT00001471||Healthy Volunteers|Healthy Volunteers
89233529|NCT00001471||HIV-infected|HIV-infected individuals
89233530|NCT00001471||ICL|Idiopathic CD4 lymphopenia
88802007|NCT05489094|Placebo Comparator|Control Group|Second group will be given nutrition education only for four months intervention period
88802008|NCT01394926|Experimental|Arm Number 1|
89124040|NCT00576823|Experimental|Alfuzosin solution - 8-16 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children and adolescents 8-16 years of age who were not able to swallow tablets or preferred to take the solution or had a body weight < 30 kg.
89124041|NCT00576823|Experimental|Alfuzosin tablet - 8-16 years|Alfuzosin tablet, daily dose divided in 2 doses given at breakfast and dinner to children and adolescents 8-16 years of age who were able to swallow tablets and had a body weight ≥ 30 kg.
89124042|NCT00732940|Experimental|Belimumab Q2WKS|Every other week: 100 mg of belimumab (1 injection) subcutaneous (under the skin) on days 0, 7, and 14, then every other week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
89124043|NCT00732940|Experimental|Belimumab 3X/WK|Three times weekly: 200 mg of belimumab (2 injections of 100 mg each) subcutaneous (under the skin) on days 0, 2, and 4 then 100 mg three times a week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
89124044|NCT00962390|Experimental|150mg S-equol|
89124045|NCT00962390|Experimental|50mg S-equol|
89124046|NCT00962390|Experimental|10 mg S-equol|
89124047|NCT00962390|Placebo Comparator|Placebo|
89124048|NCT00742729|Experimental|Arm 1|Educational small group session with free FOBT kit
89124049|NCT00742729|Experimental|Arm 2|Educational small group session with no FOBT kit
89124050|NCT00742729|Sham Comparator|Arm 3|Control
89124051|NCT02860754|Other|Six-minute walk test|All patients will perform six-minute walk test before surgery, in the preoperative clinic
89124052|NCT02594956|Active Comparator|With Nasogastric Decompression|This group will receive conventional care according to the protocol of the service in place with removal of the nasogastric tube the 3rd postoperative day if the flow is < 500ml / 24h, if not removal will take place on the 5th postoperative day.
89124053|NCT02594956|Experimental|Without Nasogastric decompression|The nasogastric tube will be take off at the end of the surgery, just after the extubation.
89124054|NCT02564575|Experimental|Cohort 1|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^6 PFU/mL of the HPIV3-EbovZ GP vaccine.
89124055|NCT02564575|Experimental|Cohort 2|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^7 PFU/mL of the HPIV3-EbovZ GP vaccine.
89124056|NCT03317678|Experimental|BioKefir (BKP)|BioKefir™ (Lifeway Foods) is a lactose-free fermented milk drink containing 12 different species of bacteria within the lactobacillus, bifidobacterium, and streptococcus generas totaling approximately 20 CFU per 3.5 ounce serving. The product also contains 2 g of fiber, including pectin and inulin. These fibers, especially inulin, are prebiotics that may function along with the probiotic species to support gastrointestinal health. The product is available commercially. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The probiotic will be provided in individual 3.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
89124057|NCT03317678|Placebo Comparator|Non-fermented Milk (NFM)|The NFM is dairy-based product ultra-filtered to remove lactose. In addition to being matched to lactose, the NFM contains similar energy, fat, and protein content as the probiotic. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The NFM control will be provided in 11.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
89124058|NCT02564341|Experimental|TEACH Collaborative Care Intervention|Physicians randomized to the intervention will receive: 1) collaboration with an IT enabled nurse care manager; 2) physician education and academic detailing; and 3) facilitated access to a specialist in addictions to help manage the most challenging HIV-infected patients on COT.
89124059|NCT02564341|No Intervention|Standard of Care Control|Physicians in the control group will receive information summarizing guidelines for COT but will not have access to the support of the TEACH intervention.
88802009|NCT05489016|Experimental|Yuekang Huoxin Pills (concentrated pills)|2 pills at a time, 3 times a day
88802010|NCT05489016|Placebo Comparator|Yuekang Huoxin Pills (concentrated pills) simulant|2 pills at a time, 3 times a day
88802011|NCT05021978|Experimental|Part A: Open-label 20 and 40 mg PRAX-944|Once daily, oral dosing with 7 days of 20 mg and 7 days of 40 mg
89124060|NCT04280510||Active coeliac patients|Patients with active coeliac disease
89124061|NCT04280510||Treated coeliac patients|Patients with coeliac disease on gluten free diet
89124062|NCT04280510||Sprue type I|Patients with refractory coeliac disease of type I
89124063|NCT04280510||Sprue type II|Patients with refractory coeliac disease of type II
89124064|NCT04280510||Intestinal Lymphoproliferations|Patients with intestinal lymphoproliferations
89124065|NCT04280510||Non coeliac enteropathies|Patients with non coeliac immune-mediated enteropathy
89124066|NCT04280510||Patients without neoplastic or inflammatory intestinal disease|Patients without neoplastic or inflammatory intestinal disease
89124067|NCT03883867||Normal|The subject population will involve 10 non-pregnant women. The tactile imaging reprifucibility sub-group will include 5 non-pregnant subjects with 2 tactile imaging examinations completed in one session. All other subjects will have a single tactile imaging examination.
89124068|NCT03883867||Pregnant|The subject population will involve 10 pregnant women without known complications at 36-37 weeks of pregnancy scheduled for a regular examination. All pregnant subjects should be examined weekly after completing 36th week of an uncomplicated pregnancy. Routine gynecologic examination includes external and internal obstetrical examination.
89124069|NCT02858960|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO~Constant Treadmill Load Test (CTLT) using HFNCO"
89124070|NCT02858960|Active Comparator|The Venturi Mask|"Incremental Load Treadmill Test (ILTT) using venturi mask~Constant Treadmill Load Test (CTLT) using venturi mask"
89233531|NCT00001465||LAM|Patients with tissue diagnosis of LAM may be admitted for evaluation every six months, or as deemed necessary for research
88802012|NCT05021978|Experimental|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded PRAX-944|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
88802013|NCT05021978|Active Comparator|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded placebo|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 14 days of 120 mg, 14 days placebo
88802014|NCT04280406|Active Comparator|Test|- 500mg of azithromycin one hour before implant placement
88802015|NCT04280406|Placebo Comparator|control|- identical placebo one hour before implant placement
88802016|NCT05599828|Experimental|AMG 510 + Omeprazole + Famotidine|Participants will receive AMG 510 on Day 1, famotidine on Day 3, AMG 510 and famotidine on Day 4, omeprazole on Days 6 through 10, and omeprazole and AMG 510 on Day 11.
88802017|NCT02675270|Experimental|Phonological, Orthographic, Untrained|
88802018|NCT02675270|Experimental|Semantic, Lexical, Untrained|
88802019|NCT01350232|Experimental|HSCT|"Subjects receive the preparative regimen in 2 steps. The first step will be with fludarabine and cytarabine and a low dose of total body irradiation. This will be followed by the first step of the transplant graft - the donor lymphocytes. The second step of the chemotherapy will be two doses of cyclophosphamide. This will then be followed by the second step of the transplant graft - the stem cells.~Only subjects with prior alloimmunization against donor will receive desensitization. Subjects who demonstrate alloimmunization against the HLA of the donor will receive bortezomib and rituximab in combination with plasmapheresis prior to the admission for transplant."
88802020|NCT01895660|Experimental|Group with continuous constraint and daily therapy|
88802021|NCT01895660|Experimental|Group with continuous constrainit and 3 days a week therapy|
88802022|NCT01895660|Experimental|Group with part-time constraint and daily therapy|
88802023|NCT01895660|Experimental|Group with part-time constraint and 3 days a week therapy|
88802024|NCT01895660|Active Comparator|Usual and customary treatment group|
88802025|NCT01890044||Moderate to highest risk for VTE|Patients admitted to the hospital for care of traumatic injuries who have from a moderate to highest level of VTE risk. These risk levels are assessed within the first 24 hours following hospital admission as mandated by the Surgical Quality Improvement Project (SCIP) Guidelines. Individual risk level will be assessed and determined according to each individual reporting institution's risk assessment protocol. This will be a prospective registry of trauma patients without any study based interventions.
88802026|NCT05493228|Experimental|patient is receiving dexmedetomidine|dexmedetomidine infusion at the rate of 0.5 μg kg-1 hr-1, started after the induction of general anesthesia without a loading dose
88802027|NCT05493228|Placebo Comparator|standard treatment (saline)|saline injection only after the induction of general anesthesia
88802028|NCT02758132|Active Comparator|Alliance A031201|Denosumab plus enzalutamide, abiraterone and prednisone
88802029|NCT02758132|Active Comparator|Standard of Care|Denosumab plus enzalutamide alone
88802030|NCT04107636|Experimental|Assigned Interventions|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location. After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
88802031|NCT01891916|No Intervention|extensively hydrolysed casein formula|extensively hydrolysed casein formula
88802032|NCT01891916|Active Comparator|Extensively hydrolyzed casein formula + LGG|Extensively hydrolized formula plus LGG
88802033|NCT01892072||HCC patients|Hepatocellular carcinoma patients treated by surgical treatment
88802034|NCT01313416|Experimental|Single arm|Combination CT-011 and Gemcitabine
88802035|NCT05599360|Experimental|Vyxeos|
88802036|NCT05499234|Experimental|High concentration|Epidural analgesia with 20 mL of 0.125% bupivacaine + 2 mcg/mL fentanyl solution
88802037|NCT05499234|Experimental|Low concentration|Epidural analgesia with 20 mL of 0.0625% bupivacaine + 2 mcg/mL fentanyl solution
88802038|NCT01269034|Experimental|Part A|Exenatide and long acting insulin before the boost.
88802039|NCT01269034|Active Comparator|Part B|Rapid and long acting insulin before the boost
88802040|NCT01269034|Active Comparator|Part C|long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost
89233532|NCT00001452||1|families with PPNAD and/or Carney complex
89233533|NCT00001406||1|Volunteers with elevated eosinophil counts in the peripheral blood or tissues; or a relative of a volunteer with eosinophilia
88802041|NCT01269034|No Intervention|Healthy controls|healthy controls without any medication before the boost.
88802042|NCT05499156|Experimental|exosome therapy|placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. These vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti-inflammatory properties by using paracrine effects. Exosomes, as a vehicle for signaling, are responsible for a significant part of cell-to-cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC-derived exosome treatment on various fistulas and inflammatory bowel disease. In this study, we aimed to evaluate the safety and effectiveness of PlacentaMSCs derived exosomes in the treatment of patients with complex preanal fistula (Crohn's) in phases I and II of the clinical trial
88802043|NCT05499156|Experimental|placebo|placebo
88802044|NCT02670512|Experimental|Telehome Monitoring|Patients in this arm will use the telehome monitoring device (a mobile tablet) to support them with their peritoneal dialysis (communication, treatment tracking, supply tracking, appointment reminders, educational content).
88802045|NCT02670512|No Intervention|Standard of Care|Patients in this arm use the standard of care for peritoneal dialysis, which is simple telephone communication and using pen and paper log to track their treatments and supplies.
88802046|NCT05599126|Experimental|Mianserin with escitalopram|
89233534|NCT00001405||Healthy Volunteers|Healthy Adult Volunteers
89233535|NCT00001405||Patients|Pts with PID or other blood disorder or clinical history consistent with PID or other blood disorder. Pts are able to volunteer as patient for research collection only per PI discretion.
88802047|NCT05599126|Active Comparator|Lorazepam with escitalopram|
88802048|NCT02669498|Active Comparator|Surgery with fallopian tube removal|Patients receiving routine fallopian tube removal during pelvic surgery after randomization.
89233553|NCT00001223||CF Patients|cystic fibrosis patients
89233554|NCT00001223||CF Relatives|relatives of cystic fibrosis patients
89233555|NCT00001215||Control|healthy volunteers
89233556|NCT00001215||Family Member|a family member of a documented proband
89233557|NCT00001215||Patient|the participant on initial screening must be found to have or be a carrier of a documented lysosomal storage disorder
88802049|NCT02669498|No Intervention|Surgery without fallopian tube removal|Fallopian tubes are not removed during pelvic surgery after randomization.
88802050|NCT05313178|Placebo Comparator|Milk Protein|25-gram dose of milk protein concentrate
88802051|NCT05313178|Experimental|Milk Protein and Probiotic|25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086
88802052|NCT01892150|Experimental|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
88802053|NCT02663752|Other|Deferasirox|All patients are already on commercial deferasirox before entering the study.
88816404|NCT04187378|No Intervention|Control Group|Body temperature of the patients will be measured in the pre-operative service and in the waiting room. Sociodemographic characteristics form, preoperative, intra and postoperative evaluation forms will be completed. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
89290131|NCT01219764|Active Comparator|Full Dose|Full dose of Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
89290132|NCT01219764|Experimental|Half dose|Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
89290133|NCT02565004||1|Patients who were enrolled on protocol 09-C-0079, or family members of patients who were enrolled on protocol 09-C-0079
89290134|NCT02565004||2|Individuals found to harbor a germline APC promoter 1B variant not previously enrolled in Cohort l.
89290135|NCT01219842|Active Comparator|INVASIVE (INV) group|Modern endovascular and/or open revascularization according to the recommendations in the TASC II document.
89290136|NCT01219842|Active Comparator|NON-INVASIVE (NON) group|Patients receiving only best medical treatment (BMT).
89290137|NCT01328730|Experimental|Firebird 2 stent group|patients who were implated with Firebird 2 SES
89290138|NCT01328730|Active Comparator|Cypher Stent Group|patients who were implanted with Cypher SES
89290139|NCT03936426|Experimental|SARTATE|All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.
89290140|NCT01125618|Experimental|MVP village|Wealth stratified and randomly selected households residing in a village exposed to the Millennium Villages Project intervention (or health and development intervention package)
89290141|NCT01125618|Active Comparator|Comparison village|Villages receiving routine services through established programs
89124071|NCT04060615|Other|Patients with chronic total occlusion of the coronary artery|In each patient before the PCI procedure, the investigators will assess myocardial viability, functional parameters of collateral blood vessels, and quality of life. 24h and 6 months after the procedure these parameters will be reevaluated as well as functional parameters of the treated coronary artery.
89124072|NCT04282928|Active Comparator|Routine treatment group|"Participants will receive the treatment according to the treatment principle of severe and critical cases in Influenza diagnosis and treatment plan (2019 version)"
89124073|NCT04282928|Experimental|HUC-MSCs adjuvant Group|Participants will receive intravenous infusion of definitive HUC-MSCs (1×10^6 cells/Kg × body weight(kg), which was selected by immunomodulatory assay through coculture with BV2 cell) on the basis of the routine treatment.
89124074|NCT00743041|Experimental|1|Standard of Care plus EFT (Emotional Freedom Techniques)
89124075|NCT00743041|No Intervention|2|Standard of Care (SOC)
89124076|NCT02859194|Experimental|Veno-veno-arterial ECMO group|
89124077|NCT02565277|Active Comparator|Influenza Vaccine|Fluzone injection once IM
89124078|NCT02565277|Placebo Comparator|Placebo|Saline Injection once IM
89124079|NCT03891745||prone group|prone extubation
89124080|NCT03891745||supine group|supine extubation
89124081|NCT00732472|Experimental|7 day repeat dose|7 day repeat dose
89124082|NCT00960986|Experimental|Duloxetine 60 mg with food|Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks
89124083|NCT00960986|Experimental|Duloxetine 60 mg without food|Duloxetine 60 mg capsule po QD without food for 8 weeks
89124084|NCT00960986|Experimental|Duloxetine 30 mg with food|Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks
89124085|NCT00960986|Experimental|Duloxetine 30 mg without food|Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks
89124086|NCT00732238|Experimental|Arm 1|Removal of Bladder Catheter. Urine Culture Post Catheter Removal. Shorter Duration of Antibiotic Therapy.
89124087|NCT00732238|Active Comparator|Arm 2|Urinary Catheter Is Not Exchanged. Antibiotic Therapy Is Based On Culture Obtained From Existing Catheter. Longer Duration of Antibiotic Therapy.
89124088|NCT00958880|Placebo Comparator|Sugar Pill|Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy
89124089|NCT00958880|Experimental|Yohimbine Hydrochloride|Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy
89124090|NCT02860910|Experimental|Cognitive Behavioral Group Therapy|"The six CBGT sessions are outlined in the manual entitled: Managing Hot Flushes with Group Cognitive Behaviour Therapy: An Evidenced-Based Treatment Manual for Health Care Professionals (Hunter & Smith, 2015) as follows:~Session 1: Psycho-education and the cognitive behavioural model Session 2: Stress management, improving wellbeing and identifying precipitants Session 3: Managing hot flushes using a cognitive behavioural approach Session 4: Managing night sweats and improving sleep (part one) Session 5: Managing night sweats and improving sleep (part two) Session 6: Review and maintaining changes (One alteration: Open discussion about mood disorders, anxiety and the psychological impact instead of the psychological impact of breast cancer)"
89124091|NCT00732160|Experimental|HS-V/A; LS-V/A|High Sodium diet- Vehicle infusion then Aldosterone infusion Low Sodium diet- Vehicle infusion then Aldosterone infusion
89124092|NCT00732160|Experimental|HS-A/V; LS-A/V|High Sodium diet- Aldosterone infusion then Vehicle infusion Low Sodium diet- Aldosterone infusion then Vehicle infusion
89124093|NCT00732160|Experimental|LS-V/A; HS-V/A|Low Sodium diet- Vehicle infusion then Aldosterone infusion High Sodium diet- Vehicle infusion then Aldosterone infusion
89124094|NCT00732160|Experimental|LS-A/V; HS-A/V|Low Sodium diet- Aldosterone infusion then Vehicle infusion High Sodium diet- Aldosterone infusion then Vehicle infusion
89124095|NCT04088344|Placebo Comparator|Isocaloric diet (7 days)|Protocole A
89124096|NCT04088344|Experimental|Hypercaloric diet enriched with carbohydrate food (7 days)|Protocole B
89124097|NCT02595034|Experimental|Clindamycin/BP Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%/5% applied twice daily (morning and evening) for 70 days (10 weeks).
89124098|NCT02595034|Active Comparator|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel applied twice daily (morning and evening) for 70 days (10 weeks).
89124099|NCT02595034|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied twice daily (morning and evening) for 70 days (10 weeks).
89124100|NCT03969940||Thermo|Buruli ulcer patients receiving thermotherapy
89124101|NCT03969940||Chemo|Buruli ulcer patients receiving chemotherapy
89124102|NCT00958724|Experimental|Neratinib and Vinorelbine|Neratinib: 240 mg administered daily by mouth continuously, Vinorelbine: 25 mg/m^2 administered IV on Day 1 and 8 of 21 day cycle
89124103|NCT02858570|Experimental|MenCC-BIO Vaccine|Vaccine against meningococcus serogroup C conjugated to tetanus toxoid produced by Bio-Manguinhos / FIOCRUZ (MenCC-Bio). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old)For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
89124104|NCT02858570|Active Comparator|combined - CRM197|Adsorbed vaccine meningococcal C (combined - CRM197) produced by the Foundation Ezequiel Dias (FUNED). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old). For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
89124105|NCT04280432||Cesarean|Women hospitalized for cesarean section
89124106|NCT00738400|Experimental|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets PRN (pro re nata) for 4 weeks, Vardenafil 5 mg/10 mg/20 mg tablets PRN for consecutive 4 weeks
89124107|NCT00738400|Placebo Comparator|Placebo|Matching placebo tablets PRN (pro re nata) for 4 weeks, placebo tablets PRN for consecutive 4 weeks
89124108|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
89124109|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
89124110|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
88802054|NCT04389944|Experimental|convalescent plasma treatment|"After confirmation of negative SARS-CoV-2 polymerase chain reaction (PCR) in two consecutive nasal swabs or 28 days after resolution of symptoms, donor check is performed and plasma donation occurs by apheresis. The plasma is photochemically pathogen reduced using the INTERCEPT Blood System.~In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up."
88802055|NCT02654782|Active Comparator|Lactated Ringer's|Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
89124111|NCT01009463|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
89124112|NCT00958568|Experimental|Olanzapine and Fluoxetine combination (OFC)|
89124113|NCT00958568|Active Comparator|Fluoxetine|
89124114|NCT04284020|Experimental|Educational program & pelvic floor muscle training|"The educational strategy will consist of explaining a healthy lifestyle guide with videos, mobile apps and activities about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, high impact sports, constipation, smoking, or drinking too much caffeine and alcohol. They will also instruct in toilet habits.~The pelvic floor muscle training (PFMT) protocol will be applied. Participants will perform exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
89124115|NCT04284020|Active Comparator|PFMT group|"They will receive a basic behavioral educational strategy in the first session including pelvic anatomy and physiology, recommendations to avoid risk factors and toilet habits.~The PFMT protocol will be applied. Participants will perform PFMT exercises with anal biofeedback, perineal and erectile dysfunction electrotherapy protocol and surface electromyography. They will perform PFMT in supine position, sitting, standing and walking. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30/40 minutes.~If the patients have overactive bladder symptoms they will perform transcutaneous tibial nerve stimulation (TTNS) protocol. The intervention will last 5 weeks, 2 sessions per week. Each session will last 30 minutes."
89124116|NCT04283630|Active Comparator|Randomization and Dietary supplement Interventions|The dietary nitrate supplement was provided in the form of commercial beetroot juice (Sport Beet IT shot, Heartbeet Ltd) for all participants, whereas vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the concentrated beetroot juice with breakfast meals, and then the vitamin C supplement (1000 mg)or placebo at the same time one-hour post beetroot juice supplementation
89124117|NCT04283630|Placebo Comparator|Placebo|Vitamin C placebo was matched with the active vitamin c capsules in shape, color, and size.
89124118|NCT04283708|Experimental|Skeletal chin deficiency|Advancement genioplasty with submental liposuction
89124119|NCT04282538|Active Comparator|Group A - Active|Active rTMS for Gait Dysfunction of Hemiplegia
89124120|NCT04282538|Sham Comparator|Group A - Sham|Sham rTMS for Gait Dysfunction of Hemiplegia
89124121|NCT04282538|Active Comparator|Group B - Active|Active tDCS for Frontal Gait Dysfunction
89124122|NCT04282538|Sham Comparator|Group B - Sham|Sham tDCS for Frontal Gait Dysfunction
89124123|NCT00958412|Experimental|Proellex®|25 mg Proellex®
89124124|NCT00630500|Active Comparator|Memantine|Active treatment with memantine
89124125|NCT00630500|Placebo Comparator|Placebo|Placebo matching active study drug
88802056|NCT02654782|Active Comparator|5% Human Albumin|Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
89124126|NCT02860676|Experimental|Cirmtuzumab|
89124127|NCT02858804|Experimental|Etoposide|50 mg/m2, IV, d1-4
89124128|NCT02858804|Experimental|Doxorubicin|10 mg/m2, IV, d1-4
89124129|NCT02858804|Experimental|Dexamethasone|30 mg/d, d1-5
89124130|NCT02858804|Experimental|Vincristine|0.4 mg/m2, IV, d1-4
89124131|NCT02858804|Experimental|Cyclophosphamide|750 mg/m2 ,d5
89124132|NCT02858804|Experimental|Cytarabine|2g/m2, q12h, d1
89124133|NCT02858804|Experimental|Cisplatin|100mg/ m2,IV, d1
89124134|NCT02858804|Experimental|Rituximab|375 mg/m2 IV, d1
89124135|NCT02858804|Experimental|Thalidomide|50-150mg/d, po, d1-28
89124136|NCT02858804|Experimental|Prednisone|0.5mg/Kg, po, qod
89124137|NCT02858648|Experimental|Behavior intervention with smart phone based self-monitoring|Patients in this group were asked to attend 11 group and 1 individual session over 6 months, and received a smartphone with two downloaded applications to monitor diet, physical activity, weight, and blood glucose (connected with a blue tooth glucometer) throughout 6 months.
89124138|NCT02858648|Experimental|Behavior intervention with paper diary based self-monitoring|Patients in this group were asked to attend 11 group sessions and 1 individual session over 6 months, and received paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer to monitor diet, physical activity, weight, and blood glucose throughout 6 months.
89124139|NCT02858648|No Intervention|Usual care|Patients in this group received no intervention, they continue to receive usual diabetes care and education from the recruitment clinic.
89124140|NCT00958256|Experimental|Bortezomib with Cyclophosphamide and Rituximab|Bortezomib 1.3 mg/m^2 intravenously (IV) on Days 1, 4, 8, and 11 of the cycle; Cyclophosphamide 300 mg/m^2 IV every 12 hours on Days 2, 3, and 4, and Rituximab 375 mg/m^2 IV on Day 1. Mesna 600 mg/m^2 for 3 days, G-CSF 5 micrograms/kg subcutaneously daily for 7 days after last dose of Bortezomib. Cycles repeated every 21 days for up to six cycles.
89124141|NCT02860442|Experimental|Smartphone brief intervention (SP-BI)|
89124142|NCT02860442|Placebo Comparator|Enhanced Usual Care (EUC)|
89124143|NCT02860598||Group 1|Patient with AML de novo or secondary myelodysplasia, in Complete Remission (CR) after induction and / or salvage therapy and candidate to receive a consolidation therapy
89124144|NCT02860598||Group 2|Patient with hematologic malignancies (ALL, AML, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, myeloma, myeloproliferative syndrome (MDS)) and candidate for blood marrow or stem cell or placental blood transplantation.
89124145|NCT00696709|Experimental|Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine|Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered ~30 days apart.
89124146|NCT00696709|Experimental|Part 1: Gamma- Irradiated VZV Vaccine A|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered ~30 days apart.
89124147|NCT00696709|Placebo Comparator|Part 1: Placebo|Participants received a 4-dose placebo regimen administered ~30 days apart.
89124148|NCT00696709|Experimental|Part 2: Gamma- Irradiated VZV Vaccine B|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered ~30 days apart.
89124149|NCT00696709|Experimental|Part 2: Gamma- Irradiated VZV Vaccine C|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered ~30 days apart.
89124150|NCT01006265|Experimental|ACT-128800 Dose 1|ACT-128800 Dose 1
89124151|NCT01006265|Experimental|ACT-128800 Dose 2|ACT-128800 Dose 2
89124152|NCT01006265|Experimental|ACT-128800 Dose 3|ACT-128800 Dose 3
89124153|NCT01006265|Placebo Comparator|Placebo|Matching placebo
89124154|NCT04280120|Experimental|Neural Mobilisation Group|"Massage therapy.~Faradic electrical stimulation.~Exercises in front of the mirror.~Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest."
89124155|NCT04280120|Active Comparator|Conservative group|"Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.~Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.~Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes."
89124156|NCT02861690|Experimental|Treatment group|patients received Liposomal Paclitaxel and Nedaplatin every 21 days until the presence of progressive disease or unacceptable toxicity
89124157|NCT02565745|Experimental|Skin Dressing|Hydrocolloid dressings applied during hospitalization
89124158|NCT02565745|Active Comparator|Moisturizing cream|Use of moisturizing cream, as part of conventional skin care
89124159|NCT04281836|Experimental|Breathing awareness through use of virtual reality breathing|Healthy participants were recruited in this group.
89124160|NCT04281836|Active Comparator|Traditional breathing awareness|Healthy participants were recruited in this group.
89124161|NCT02858882||Swimmers|Screening of elite athletes
89124162|NCT02565121|Experimental|Olfactory disorder after brain trauma|Recruited from 250 patients with moderate to severe traumatic brain injury in the Hodeskadeprosjektet (TBI) cohort. Treatment with (first) corticosteroids and (second) olfactory stimulation.
89124163|NCT05141552|Experimental|dapa group|subjects will be treated with dapagliflozin (10mg per day) and standard anti-heart failure therapy (including RAS inhibitors, beta-blocker, Aldosterone inhibitors)
89124164|NCT05141552|No Intervention|control group|subjects will be treated with standard anti-heart failure therapy (including RAS inhibitors, beta-blocker, Aldosterone inhibitors)
89124165|NCT02564107|Experimental|Ibandronate|Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.
89124166|NCT04297475||rheumatoid arthritis|The patients are diagnosed with RA according to the American College of Rheumatology (ACR) criteria, and the current clinical state was in-active or relapse. The patients receive final diagnosis and disease evaluation by two experienced rheumatologists
89124167|NCT00628667|Experimental|1|
89124168|NCT00628667|Placebo Comparator|2|
89124169|NCT04281758|Active Comparator|Caffeine beverage (control)|Flavored still beverage with caffeine 100 mg
89233560|NCT01021605|Experimental|Hemolung Respiratory Assist System|
89233561|NCT00640835|Experimental|Sublingual administration|Buprenorphine/naloxone film strip administered sublingually
89124170|NCT04281758|Experimental|Caffeine beverage plus bioactive 1|Flavored still beverage with caffeine 100 mg + quercetin 250 mg
89124171|NCT04281758|Experimental|Caffeine beverage plus bioactive 2|Flavored still beverage with caffeine 100 mg + curcumin 80 mg
89124172|NCT04281758|Experimental|Caffeine beverage plus bioactive 3|Flavored still beverage with caffeine 100 mg + methylliberine 75 mg
89124173|NCT00743353|Experimental|A|16 subjects to be enrolled; Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
89124174|NCT02858258|Active Comparator|Standard Arm A|"R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM"
89124175|NCT02858258|Experimental|Experimental Arm A+I|"R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)"
89124176|NCT02858258|Experimental|Experimental Arm I|"R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)"
89124177|NCT02564185|Active Comparator|Control|"The control group will follow usual practice."
89124178|NCT02564185|Experimental|Education program|"The Education program group benefit in addition of a therapeutic education program including nursing follow-up at 1, 3 and 6 months."
89124179|NCT01008995|Experimental|001|placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16
88802057|NCT02821364|Other|Advanced Life Support|ALS providers are trained and able to perform certain procedures such as intubation with endotracheal tubes and placement of intravenous catheters. Endotracheal intubation is often performed by pre-hospital providers in critically ill trauma patients because it is believed that it allows for protection of the airway and better delivery of oxygen. However, most studies actually show that intubation does not provide a survival advantage to this patient population and actually could result in worse outcomes. Intravenous catheter placement and administration of intravenous fluids is also routinely performed however, studies have shown that it is also not helpful.
88802058|NCT02821364|No Intervention|Basic Life Support|Subjects randomized to the study group will receive basic life support (BLS) level care. This means that pre-hospital procedures such as endotracheal intubation and intravenous fluid administration will not be carried out. However, passive oxygen and needle thoracostomy, if required for tension pneumothorax, will be permitted if medically necessary.
89124180|NCT01008995|Experimental|002|placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16
89124181|NCT04295993|Experimental|methylene blue group|The patients in this group will receive methylene blue bolus in addition to the norepinephrine infusion.
89124182|NCT04295993|Active Comparator|Norepinephrine group|The patients in this group will receive norepinephrine infusion.
89124183|NCT00743587|Placebo Comparator|A|
89124184|NCT00743587|Active Comparator|B|
89124185|NCT00743587|Active Comparator|C|
89124186|NCT00743587|Active Comparator|D|
89124187|NCT04205123||sickle cell syndrome|Inclusions of sickle cell patients aged over 17 years followed regularly in the participating centers.
89124188|NCT04190251|Other|Intervention group A|Intervention group A will benefit of the medication adherence support program during 12 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
89124189|NCT04190251|Other|Intervention group B|Intervention group A will benefit of the medication adherence support program during 6 months. Adherence will be monitored using an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd.) during 24 months. At each pharmacy visits, the pharmacist will conduct an 15 minutes, semi-structured interview based on Fisher's sociocognitiv model with the patients. A summary and the adherence graph will be send to all the involved health professionals
89124190|NCT00957944|Experimental|Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)|Two single applications of rotigotine patches from two different manufacturing sites in the order A-B separated by a washout phase of at least 5 days
89124191|NCT00957944|Experimental|Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)|Two single applications of rotigotine patches from two different manufacturing sites in the order B-A separated by a washout phase of at least 5 days
89124192|NCT02871323|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over approximately 1 hour on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with SD, no new inter-current illness, and no unacceptable toxicity, may continue treatment beyond 3 courses.
89124193|NCT04296149|Experimental|Y-90-DOTATOC|Patients affected by Small Intestine neuroendocrine tumors
89124194|NCT02861612||Nerve Transfer|This is an observational study that looks at function and quality of life in patients before and after nerve transfer surgery.
89124195|NCT01005875|Experimental|Radiation followed by Sorafenib|Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
89124196|NCT04296929|Experimental|Affected arm in lymphedema patients|Complex decongestive physiotherapy treatment will be applied to the arm (affected arm) that develops lymphedema after unilateral breast cancer treatment.
89124197|NCT04296929|No Intervention|Unaffected arm in lymphedema patients|After unilateral breast cancer treatments, the non-lymphedema side in the upper extremities, is the unaffected arm. No treatments will be applied to the unaffected side.
89124198|NCT02701088|Experimental|Concomitant chemotherapy and radiotherapy|Chemoradiotherapy with two cycles of 5FU and Mitomycin-C plus radiotherapy by SIB-IMRT (for simultaneous integrated boost intensity modulated radiation therapy) day 1 to day 50 in 36 fractions
89124199|NCT04060225|Experimental|Participants|Participants will be asked to participate in a single arm study with three phases (washout phase, abstinence phase, and exposure phase). These participants will first be asked to abstain from drinking any caffeinated food or beverages for 72 hours (known as the washout phase). Following the first phase, participants will then wear a blood pressure cuff to collect diastolic and systolic blood pressure for 24 hours (abstinence phase) wherein they will be asked to refrain from caffeinated products. Participants will then drink the coffee intervention and collect blood pressure measurements for 24 hours (exposure phase).
89124200|NCT04279106|Experimental|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
89124201|NCT04279106|Active Comparator|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
89124202|NCT04279106|Active Comparator|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
89124203|NCT04279106|Placebo Comparator|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
89124204|NCT00743743|Experimental|1|receive 1 Longevinex brand capsule daily containing 215 mg of resveratrol active ingredient
89124205|NCT00743743|Placebo Comparator|2|Receive 1 capsule daily for 52 weeks containing placebo for comparison to experimental arm
88802059|NCT02820194|Active Comparator|Stereotactic body radiation therapy|Patients are treated with Stereotactic Body Radiation Therapy, a methodology for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule.
89124206|NCT02641496|Experimental|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
89124207|NCT02641496|Active Comparator|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
89124208|NCT01005719|Experimental|Zegerid|Participants receiving Zegerid (omeprazole/sodium bicarbonate) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
89124209|NCT01005719|Active Comparator|Prevacid®|Participants receiving Prevacid® (lansoprazole) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
89124210|NCT01005719|No Intervention|No treatment|Participants receiving No treatment in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants took approximately 2 oz of water once daily for 7 days.
89124211|NCT00630578|Active Comparator|1|Cognitive Processing Therapy
89124212|NCT00630578|No Intervention|2|Arm 2 participants will monitor their symptoms for a period of 10 weeks, prior to being crossed over into active treatment. This will allow investigators to account for the passage of time without intervention when tracking symptoms.
89124213|NCT00743821||TBI Patients|Individuals who have suffered a mild traumatic brain injury and have persistent post-concussive symptoms (PCS)
89124214|NCT00743821||Normals|Individuals of comparable age and education who have not suffered a traumatic brain injury
89124215|NCT02858102|Active Comparator|Active treatment group|Physical activity program: 36 sessions of physical activity lasting between 30-60 minutes for 12 weeks, three days per week.
89124216|NCT02858102|No Intervention|Control group|No physical activity program
89124217|NCT02856854|Experimental|EMB-001 (oral)|EMB-001 will be orally administered for 7 consecutive days, twice daily for 6 days followed on the last day by one EMB-001 oral dose (QD) in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
89124218|NCT02856854|Placebo Comparator|Placebo (oral)|PLB-to-match EMB-001 will be orally administered for 7 consecutive days, BID for 6 days, followed on the last day by one PLB oral dose in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
89124219|NCT00921583||1|Examination of dental implants 20 years in function
89124220|NCT04088383|Other|Amnios™ RT|
89124221|NCT04088383|Placebo Comparator|Saline|
89124222|NCT02857166|Experimental|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
89124223|NCT04297085|Experimental|Cases|
89124224|NCT04061005|Active Comparator|Hot snare polypectomy (HSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). According to the randomized group, patients with HSP group were treated with HSP to excise 5-15 mm colorectal polyps. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopist carefully observed the edge of the resection to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
89124225|NCT04061005|Experimental|Cold snare polypectomy (CSP)|The polyp size was measured using the tip of the snare catheter (2.5 mm). After randomization, patients in the CSP group will be treated with CSP to remove colorectal polyps of 10-15 mm size. After resection, the jet stream will be used to thoroughly clean the mucosal defect. After the endoscopic surgeon carefully observed the resection margin to complete the polypectomy, a 2- or 4-quad biopsy was performed from the symmetrical margin of the mucosal defect to confirm the presence or absence of residual lesions.
88802060|NCT02820194|Active Comparator|Microwave Ablation|Patients are treated with Microwave Ablation,a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis.
88802061|NCT01253668|Experimental|Arm 1|Patients receive oral brivanib alaninate daily in the absence of disease progression or unacceptable toxicity.
89124226|NCT02856932|Experimental|Glass Ionomer with Glass Hybrid technology|Intervention
89124227|NCT02856932|Active Comparator|Conventional high viscosity Glass Ionomer|Comparator
89124228|NCT02564965|Other|Greater than 50% Necrosis|Subjects who have greater than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
89124229|NCT02564965|Other|Less than 50% Necrosis|Subjects who have less than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
89124230|NCT02563951|Experimental|GNS Spray 0.5mg|One spray of GNS 0.5mg/spray into right nostril.
89124231|NCT02563951|Experimental|GNS Spray 1.0mg|One spray of GNS 0.5mg/spray into both left and right nostril.
89124232|NCT02563951|Experimental|GNS Spray 2.0mg|One spray of GNS 1.0mg/spray into both left and right nostril.
89124233|NCT02563951|Active Comparator|Kytril 1mg (IV injection)|A dose of 1mg of Granisetron IV injection (kytril 1mL, 3mg/mL/vial) will be administered as a slow IV injection (over 30 seconds)
89124234|NCT02563951|Active Comparator|Kytril 1mg (Tablet)|a single dose (kytril 1mg, one tablet) orally administered with 240mL of water
89124235|NCT00743899|Experimental|1|The aggressive group
89124236|NCT00743899|Experimental|2|The conservative group
88802062|NCT01890200|Experimental|TCM-700C (low dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
88802063|NCT01890200|Experimental|TCM-700C (high dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
88802064|NCT01890200|Placebo Comparator|Placebo|placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
88802065|NCT01662648|Experimental|Paliperidone ER: Lack of efficacy|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of efficacy.
88802066|NCT01662648|Experimental|Paliperidone ER: Lack of tolerability, compliance or other|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of tolerability, compliance or other reasons.
88802067|NCT05586620|Active Comparator|3-snip punctoplasty|
88802068|NCT05586620|Active Comparator|3-snip punctoplasty with mitomycin C|
88802069|NCT01893788|Active Comparator|Aliskiren|Aliskiren group treated with 150-300mg daily aliskiren without diuretics or ACE inhibitors or angiotensin receptor blockers.
88802070|NCT01893788|Active Comparator|Eplerenone|Eplerenone group treated with 50-100mg daily eplerenone without diuretics or ACE inhibitors or angiotensin receptor blockers
88802071|NCT01231750|Active Comparator|0.1% Capsaicin Cream|0.1% capsaicin cream spread 8cm x 15cm on abdomen, once, 45 minutes prior to exercise
88802072|NCT01231750|Placebo Comparator|Placebo Cream|Inactive cream, 4cm spread 8cm x 15cm on the abdomen, once, 45 minutes prior to exercise
89124237|NCT00953576|Experimental|Phase I Dose Level 1 (DL1): KHAD+L (250 mg)|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
89124238|NCT00953576|Experimental|Phase I Dose Level 2 (DL2): KHAD+L (500 mg)|"For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day"
89124239|NCT00953576|Experimental|All Phase I Participants|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: according to the established dose escalation schedule~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
89124240|NCT00743977|Active Comparator|A|
89124241|NCT00743977|Experimental|B|
89124242|NCT02565823|Experimental|Exercise intervention|Subjects will undergo an acute bout of exercise for 45 mins at 75% of peak aerobic capacity
89124243|NCT02857088|Experimental|depressed patients|patient with a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
89124244|NCT02857088|Experimental|non depressed subject|subject without a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
89124245|NCT02563873|No Intervention|Standard pacemaker settings|Standard pacemaker settings will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange
88802073|NCT05488860|Active Comparator|Traditional injection|Intralesional injection of drug by traditional injection needle. This is the traditional approach for drug delivery recommended by international guidelines for each skin diseases.
88802074|NCT05488860|Experimental|Piezoelectric drived microneedling|Intralesional injection of drug by piezoelectric drived microneedles.
89124246|NCT02563873|Experimental|Tailored pacemaker settings|The pacemaker settings will be altered to match optimal heart rate range with respect to cardiac contractility, as determined by echocardiography. This will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange.
89124247|NCT00744133|Experimental|Group 1: 1, 3, or 5 bites|Part A: 18 subjects receive 1, 3, or 5 bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
89124248|NCT00744133|Experimental|Group 2: N bites|Part B: 20 subjects receive N bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
89124249|NCT01005329|Experimental|Treatment (IMRT, cisplatin,bevacizumab,carboplatin,paclitaxel)|Patients undergo pelvic IMRT once daily, 5 days a week, for 5 weeks. Patients may also undergo optional nodal boost radiotherapy and/or vaginal brachytherapy boost. Patients also receive concurrent cisplatin IV over 1 hour on days 1 and 29 and bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Beginning 4-6 weeks after completing IMRT, cisplatin, and bevacizumab, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment with carboplatin and paclitaxel repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89124250|NCT00921349|Experimental|Ligation+Nadolol|"Multi-ligators were applied. Patients received regular ligation treatment at an interval of 3-4 weeks until variceal obliteration.~Intervention; ligation of varices plus beta blockers (Nadolol)."
89124251|NCT00921349|Active Comparator|Nadolol only|
89124252|NCT01005251|Experimental|60 mg|PPI+lesogaberan (AZD3355) 60 mg bid
88802075|NCT02549716|Experimental|IV acetaminophen + oral placebo|Patients in this group will receive IV acetaminophen and an oral placebo. The IV formulation will be given using the FDA approved OFIRMEV which comes in a single glass bottle at a concentration of 1000mg/100ml (10mg/ml) containing a total of 1 gram of acetaminophen.
88802076|NCT02549716|Experimental|Oral acetaminophen + IV placebo|Patients in this group will receive oral acetaminophen and a saline solution placebo through their IV. The enteral formulation will be in the standard tablet form of 500mg per pill. Patients will receive two pills, or 1 gram of acetaminophen.
89124253|NCT01005251|Experimental|120 mg|PPI+lesogaberan (AZD3355) 120 mg bid
88802077|NCT02540434|Active Comparator|RiaSTAP Arm|Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
88802078|NCT02540434|Active Comparator|Cryopreciptiate Arm|Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
89124254|NCT01005251|Experimental|180 mg|PPI+lesogaberan (AZD3355) 180 mg bid
89124255|NCT01005251|Experimental|240 mg|PPI+lesogaberan (AZD3355) 240 mg bid
89124256|NCT01005251|Placebo Comparator|Placebo|PPI+ Placebo
89124257|NCT03048578|Experimental|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
89124258|NCT03048578|Placebo Comparator|Placebo|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
89124259|NCT04295369|Experimental|Lifestyle Medicine Group|
89124260|NCT04295369|No Intervention|Waitlist Control Group|Participants in the waitlist control group will receive the intervention after the immediate post-treatment assessment.
89124261|NCT02856464|Experimental|Experimental|
89124262|NCT02856464|Other|Control|
89124263|NCT04282889||Liver transplantation group|"The study population will include 20 adults (age range of 18 - 75 years) who are undergoing liver transplantation. Inclusion criteria are patients undergoing liver transplantation with English as their native language.~Exclusion criteria include patient's refusal, or on medical anticoagulation therapy. Informed consents will be obtained from the patients who agree to participate in this clinical study."
89124264|NCT04282889||Healthy volunteer|The control population will include 20 adult volunteers (age 18-65 years) who meet the in the American Society of Anesthesiologists (ASA) Physical Status (PS) Classes 1 criteria. Exclusion criteria will be refusal, volunteers on any medication or significant history of bleeding.
89124265|NCT02858414|Experimental|blood sample|
89124266|NCT02856776|Experimental|Arm 1: 600 IU vitamin D|Subject will receive 600 IUs of vitamin D3/day for 24 weeks.
89124267|NCT02856776|Experimental|Arm 2: 4,000 IU vitamin D|Subject will receive 4,000 IUs of vitamin D3/day for 24 weeks
89124268|NCT02856776|Experimental|Arm 3: 10,000 IU vitamin D|Subjet will receive 10,000 IUs of vitamin D3/day for 24 weeks
89124269|NCT02856776|Experimental|Arm 4: Mixed vitamin D dosages|Subject will receive 600 IUs of vitamin D3/day for the first 8 weeks, 4,000 IUs of vitamin D3/day for the next 8 weeks, and 10,000 IUs of vitamin D3/day for the final 8 weeks.
89124270|NCT04296851|Experimental|niclosamide|650mg daily
89124271|NCT04296851|Placebo Comparator|placebo|identical- appearing placebo
89124272|NCT02615600|Experimental|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
89124273|NCT01008449|Active Comparator|Absorbable Subcuticular Surgical Suture|Patients in this arm will receive absorbable subcuticular suture for wound closure of cesarean deliveries.
89124274|NCT01008449|Active Comparator|Surgical staples|Patients in this arm will receive surgical staples for wound closure.
89124275|NCT02858024|Active Comparator|Cohort I|In Cohort I, eligible participants will be randomly assigned to one of two treatment sequences (ABE or BAE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
89124276|NCT02858024|Active Comparator|Cohort II|In Cohort II, eligible participants will be randomly assigned to one of two treatment sequences (CDE or DCE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
89124277|NCT04297007|Active Comparator|Group P = PECS-II group|In group P, PECS will be performed with patients in the supine position at the end of the surgery before extubation by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions the high frequency linear probe (11-12 MHz) will be covered with a sterile sheath and a 22G, 50 mm block needle will be used. US probe will be placed on the 4th rib. The muscles PMm, Pmm and Sam will be visualized. At the anterior axillary level or mid-axillary level, via the in-plane technique, Pecs II will be applied by injecting 20 mL of 0.25% bupivacaine in a cephalad to caudad direction to the fascia on Sam.
89124278|NCT04297007|Active Comparator|Group R = RIB group|In group R, RIB block will be performed with patients in the lateral decubitus position at the end of the surgery before extubation. The linear high frequency probe will be placed in sagittal plane medially on the medial border of the scapula at T5-6 level. The trapezius muscle, rhomboid major muscle, intercostal muscle, ribs and the pleura will be visualized. The needle will be inserted into the fascial plane between the rhomboid major and intercostal muscles in a cranio-caudal direction. A dose of 20 ml 0,25% bupivacaine will be injectted into the fascial plane.
89124279|NCT04297007|No Intervention|Group C = Control group|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
89124280|NCT02857946|Experimental|A Test|Test drug (Prevaglip) 1 tablet contains 5 mg linagliptin
89124281|NCT02857946|Active Comparator|B Reference|Reference drug (Trajenta) 1 tablet contains 5 mg linagliptin
89124282|NCT02857712|Experimental|Axitinib|Axitinib will be administered at 5 mg BID (starting dose); in case of no adverse events above CTCAE version 4.0 Grade 2 for a consecutive 2-week periods, the dose may be increased to 7 mg BID and further to 10 mg BID using the same criteria until tumor progression, unacceptable toxicity or other criteria for discontinuation is met.
89124283|NCT00696241|Experimental|Azilsartan Medoxomil 20 mg QD|
89124284|NCT00696241|Experimental|Azilsartan Medoxomil 40 mg QD|
88802079|NCT05492760||ablation group|
88802080|NCT05488704||CONTROL GROUP|Control Group [NST device volume turned off]
88802081|NCT05488704||Intervention Group I|Intervention Group I [NST device volume 1-35 dB(A)]
88802082|NCT05488704||Intervention Group II|Intervention Group II [NST device volume 36-60 dB(A)]
88802083|NCT05488704||Intervention Group III|Intervention Group III [61 dB( A) and above]
89124285|NCT00696241|Experimental|Azilsartan Medoxomil 80 mg QD|
88802084|NCT01207726|Experimental|Arm I (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-5 and 8-10 and entinostat PO QD on days 3 and 10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88802085|NCT01207726|No Intervention|Arm II (standard of care)|Patients receive standard of care.
89124286|NCT00696241|Active Comparator|Olmesartan 40 mg QD|
89124287|NCT00696241|Placebo Comparator|Placebo QD|
89124288|NCT04941365|Experimental|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
89124289|NCT00957008|Experimental|A - GWL|Group Weight Loss Program (GWL) - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator.
89124290|NCT00957008|Experimental|B - GWL+SWA|Group weight loss program plus use of the Senseware Armband - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator and wore a SenseWear Armband. The SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
89124291|NCT00957008|Experimental|C - SWA Alone|Use of the senseware armband alone program - The intervention for the SWA Alone group was the SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
89124292|NCT00957008|No Intervention|D - Standard Care|Standard Care - Participants in this group received a self-directed weight loss manual that focused on cognitive and behavior change principles and learning activities based on Active Living Every Day and Healthy Eating Every Day
89124293|NCT02565667|Experimental|KOL group|KOL stapler was used for rectal anastomosis
89124294|NCT02565667|Active Comparator|traditional stapler group|traditional stapler was used for rectal anastomosis
89124295|NCT00744289|No Intervention|Arm 1|Participants in Arm 1 will not receive any financial incentive after the second and third dose of hepatitis B vaccine have been administered.
89124296|NCT00744289|Other|Arm 2|Participants in Arm 2 will receive a small financial incentive after the second and third dose of the hepatitis B vaccine
89124297|NCT03968809||Standard Coronary Artery Disease Screening|All patients presenting for standard coronary artery disease screening will undergo additional imaging with CardioFlux MCG. These patients will be followed longitudinally for short and long term MACE.
89124298|NCT00952484|Active Comparator|2 mg/kg|2 mg/kg subcutaneous injection three times per week.
89124299|NCT00952484|Active Comparator|3 mg/kg|3 mg/kg subcutaneous injection three times per week.
89124300|NCT02484079|Active Comparator|Cold polypectomy|"Patients in this arm will have their polyps removed by cold polypectomy, i.e. a metal sling that is closed around the basis of the polyp, and the polyp is cut off.~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
89124301|NCT02484079|Active Comparator|Hot polypectomy|"Patients in this arm will have their polyps removed by hot polypectomy, i.e. a metal sling taht is closed around the basis of the polyp, electrical currents is applied, and the polyp is cut off.~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
89124302|NCT03889951||group 1|group of ALL patients with IKZF1 deletion mutation.
89124303|NCT03889951||group 2|group of ALL patients with no detected mutation
89124304|NCT01974362||Monolithic Zirconia with Buccal Veneer (MZ)|Patients that have a full-mouth (maxilla and/or mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial with buccal veneers
89124305|NCT01974362||Monolithic Zirconia full-contour (FCMZ)|Patients that have a full-mouth (maxilla and/or mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial full contour (without veneer)
89124306|NCT01974362||Zirconia-Feldspathic (PVZ)|Patients that have a full-mouth (maxilla and/or mandible) implant supported rehabilitation restored with zirconia substructure and feldspathic veneered biomaterial
89124307|NCT00689611|Placebo Comparator|P|Half of patients will receive placebo for 9 weeks.
89124308|NCT00689611|Active Comparator|A|Half of patients will receive bupropion for 9 weeks.
89124309|NCT02859974|Experimental|Respiratory retraining for PVFMD|Single arm study
89124310|NCT04278170||Case group|Rheumatoid arthritis patients who met the American College of Rheumatology (ACR) 2010 RA classification
89124311|NCT02563795||Group I|Pregnant with BMI<30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
89124312|NCT02563795||Group II|Pregnant with BMI<30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
89124313|NCT02563795||Group III|Pregnant with BMI>30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
89124314|NCT02563795||Group IV|Pregnant with BMI>30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
88802086|NCT05498844|Active Comparator|Treatment as usual|Control group participants will receive usual medical, physical activity, and standard in-person nutrition counseling (IPNC) on site.
89124315|NCT04281680||Pasireotide|Patients who received pasireotide perioperatively
89124316|NCT04281680||Octreotide|Patients who received perioperative octreotide
89124317|NCT04281680||Control|Patients who received no additional medication in the timely cohort
89124318|NCT00744445|Active Comparator|0800|r-HuEPO administered at 0800 hrs
89124319|NCT00744445|Active Comparator|1500|r-HuEPO administered at 1500 hrs
89124320|NCT00744445|Active Comparator|2200|r-HuEPO administered at 2200 hrs
89124321|NCT02857868|Experimental|ABL001|
89233562|NCT00640835|Experimental|Buccal administration|Buprenorphine/naloxone film strip administered buccally
89233563|NCT03839355|Active Comparator|Eliquis|
89233564|NCT03839355|Active Comparator|Warfarin|
89290142|NCT01121328|Experimental|Autologous cord blood transfusion|Collected cord blood at birth will be transfused for the preterm neonate
89124322|NCT00921427|Active Comparator|VRT and active tDCS|Patients will receive tDCS (noninvasive brain stimulation) concurrently with vision restoration therapy. TDCS is delivered using a small battery-operated device. Electrical leads from the device are connected to saline soaked sponges that are placed at strategic locations on the skull corresponding to areas of the brain that need to be stimulated (in this case, the visual cortex). The dosage will be set to 2 mA/min for 30 minutes, twice a day for 3 days a week for 12 weeks.
89124323|NCT00921427|Sham Comparator|VRT combined with sham tDCS|Patients will receive sham tDCS concurrently with vision restoration therapy. Electrical leads from the tDCS device will be connected to saline soaked sponges placed at strategic locations on the skull, in a similar maner as in the active tDCS group. Current will be turned on for 30 seconds but will be slowly ramped down and turned off. Treatment will continue for 3 days a week for 12 weeks.
89124324|NCT02860208||3 years follow-up|all patients who received surgical treatment for peri-implantitis during a Randomized and Controlled Trial registered in ClinicalTrials.gov NCT NCT01857804
89124325|NCT00744601||1|Patients with Cocaine Addiction
89124326|NCT00744601||2|Healthy Control Volunteers
88802087|NCT05498844|Experimental|Intervention-remote nutrition councelling|Intervention group participants will receive remote, web-based nutrition counseling (WBNC) in addition to the standard medical counseling and on-site physical activity.
88802088|NCT05498688|Experimental|Low carbohydrate|The intervention meal is a low-carbohydrate meal composed of 15 E% carbohydrates, 20 E% protein and 65 E% fat
88802089|NCT05498688|No Intervention|Control meal|The control meal is a regular diabetes meal according to the official Danish dietary guidelines composed of 50 E% carbohydrates, 20 E% protein and 30 E% fat
89124327|NCT02983370|Experimental|Blind volunteer|Blind volunteers will be implanted with our existing vision neuroprosthetic system, which utilizes a FDA cleared microelectrode array, using a minicraniotomy. The array will be implanted near the occipital pole or in extra striate areas. The investigators will collect descriptive feedback regarding thresholds, evoked perceptions and stimulation parameters leading to recognizable patterns.
89124328|NCT02854748|Experimental|Empagliflozin / Lobeglitazone / Empa.+Lobe.|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
89124329|NCT02854748|Experimental|Empagliflozin / Empa.+Lobe. / Lobeglitazone|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
89124330|NCT02854748|Experimental|Lobeglitazone / Empagliflozin / Empa.+Lobe.|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
89124331|NCT02854748|Experimental|Lobeglitazone / Empa.+Lobe. / Empagliflozin|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
89124332|NCT02854748|Experimental|Empa.+Lobe. / Empagliflozin / Lobeglitazone|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
89124333|NCT02854748|Experimental|Empa.+Lobe. / Lobeglitazone / Empagliflozin|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
89124334|NCT00689299|Placebo Comparator|Dose Group C|Standardized Allergenic Extract, Cat Hair (Felis domesticus) placebo
89124335|NCT00689299|Active Comparator|Dose Group A|Standardized Allergenic Extract, Cat Hair (Felis domesticus) 0.21 Units
89124336|NCT00689299|Active Comparator|Dose Group B|Standardized Allergenic Extract, Cat Hair (Felis domesticus)2.1 units
89124337|NCT02506244|Experimental|Immediate Monitoring|"Individuals randomized to immediate monitoring will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of the 4 month monitoring period of time 0 to 4 months.~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) continuously over the 4 month monitoring period."
89124338|NCT02506244|Active Comparator|Delayed Monitoring|"Individuals randomized to delayed monitoring will receive usual care for 4 months after which they will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of study months 4 through 8.~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) daily for months 4 through 8."
89124339|NCT02565043|Experimental|RENASYS TOUCH Negative Pressure Wound Therapy Device|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the intermittent/variable therapy mode, for up to 28 days of therapy."
89124340|NCT02565043|Active Comparator|RENASYS TOUCH Negative Pressure Wound Therapy System|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the continuous therapy mode for up to 28 days of therapy."
89124341|NCT00948974|Active Comparator|cognitive therapy|cognitive therapy and exposure
89124342|NCT00948974|Active Comparator|acceptance and committment therapy|acceptance and commitment therapy and exposure
89124343|NCT02564809|Experimental|Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a cognitive training program (Fit Brains training) 6 hours a week for 8 weeks.
89124344|NCT02564809|Experimental|Exercise + Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a combination of aerobic exercise and a cognitive training program (Fit Brains training) for 6 hours a week over 8 weeks.
89124345|NCT02564809|Sham Comparator|Balanced And Tone|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will complete 3 weekly training sessions of 1 hour for 8 weeks.
89124346|NCT02563717|Active Comparator|Reference Device: T-piece System|
89124347|NCT02563717|Active Comparator|Investigational Device: The New System|
88802090|NCT02534038|Placebo Comparator|Placebo|Placebo drug to be taken twice a day for 6 weeks
88802091|NCT02534038|Active Comparator|AVP-786|Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.
88802092|NCT00379678||Information not available|
88802093|NCT01202110|Experimental|Propranolol|Propranolol 1mg iv
88802094|NCT01202110|No Intervention|Control|Routine care
88802095|NCT02556918|Experimental|Sitagliptin|"Subjects undergoing cardiac surgery with type 2 diabetes (T2D) will be randomized to receive one tablet of sitagliptin once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Sitagliptin Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
88802096|NCT02556918|Placebo Comparator|Placebo|"Subjects undergoing cardiac surgery with type 2 diabetes will be randomized to receive one tablet of placebo once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Placebo Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
88802097|NCT00379756|Active Comparator|Levitra|10mg x 4 weeks, with option to increase to 20mg aat that time if desired
88802098|NCT00379756|Placebo Comparator|placebo|
88802099|NCT05492292|Experimental|Long Covid19 patient group|Patients with Long Covid19 undergoing perfusion brain scintigraphy
88802100|NCT02518750|Experimental|Study Participants|"Participants with ALL will receive the following interventions in three treatment blocks:~Block A: Dexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples.~Block B: High-dose methotrexate, 6-mercaptopurine, intrathecal triples, high-dose cytarabine.~Block C: Nelarabine or clofarabine, cyclophosphamide, etoposide."
88802101|NCT05592964||Group A|Standard fasting group.
88802102|NCT05592964||Group S|The patient group who were given oral 5 ml/kg (maximum 250 ml) of water 1 hour ago.
88802103|NCT05592964||Group K|The patient group who were given an oral 5 ml/kg (maximum 250 ml) carbohydrate rich clear liquid 1 hour ago.
88802104|NCT05492058|Experimental|maternal touch|maternal touch
88802105|NCT05492058|Experimental|music group|music group
88802106|NCT05492058|Experimental|virtual reality group|virtual reality group
89124348|NCT00744679|Experimental|Natalizumab 300 mg|Natalizumab infused at 300 mg every 28 days during the screening and assessment periods of the study which continues the therapy of the previous 12 months and maintains steady-state pharmacokinetics.
89124349|NCT02565589||ICU patient|Critically ill patients who were enrolled less than 24 hours after ICU admission.
89124350|NCT02565589||Control|Age-, sex-, and BMI-matched healthy subjects.
88802107|NCT05492058|No Intervention|control|
88802108|NCT05498532||PUJS patients|Patients between 0 and 17 years old treated or followed for pyelo-ureteral junction syndrome.
89124351|NCT03811171|Experimental|Treatment|The arm receives the investigational Break Wave procedure.
89124352|NCT04060459|Experimental|Treatment plan|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
89124353|NCT00744835|Experimental|1|Ablation Management
89124354|NCT01007435|Experimental|(A) Tocilizumab 8 mg/kg + placebo to methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
89124355|NCT01007435|Experimental|(B) Tocilizumab 8 mg/kg + methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
89124356|NCT01007435|Experimental|(C) Tocilizumab 4 mg/kg + methotrexate|Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
88802109|NCT01194856|Active Comparator|Efavirenz 600 mg|Serving as the Control Arm - patients will maintain EFV-containing antiretroviral regimen
88802110|NCT01194856|Experimental|Arm B - Atazanavir/Ritonavir|Atazanavir 300 mg orally with Ritonavir 100 mg orally once daily for 96 wks
89124357|NCT01007435|Active Comparator|(D) Placebo to tocilizumab + methotrexate|Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.
89124358|NCT00948896|Experimental|1|
89124359|NCT00948896|Experimental|2|
88802111|NCT05488392|Experimental|Intrajugular cooling group|The safety and tolerability of hypothermia with intrajugular cooling will be investigated using 3+3 dose-escalation trial design.
88802112|NCT01182610|Experimental|Treatment group|"Panitumumab 9mg/kg on Days 1, 22, and 43~Paclitaxel 200mg/m2 on Days 1 and 22~Carboplatin AUC=6 on Days 1 and 22~5FU 225mg/m2/day on Days 1-15 and 22-36"
88802113|NCT05491902||Early onset mild to moderate AD|Patients aged 50 to 69
88802114|NCT05491902||Late onset mild to moderate AD|Patients aged 70 and above
88802115|NCT05491902||Older Healthy Volunteer|Aged 50 to 69
88802116|NCT05491902||Younger Healthy Volunteer|Aged 18 - 25
88802117|NCT05488158|Active Comparator|MD|Allopathic physicians in one arm of the study were treated with OMT to alleviate pain and somatic disfunction. The amount of pain they were experiencing before treatment was recorded using a Likert pain scale.
88802118|NCT05488158|Active Comparator|DO|Osteopathic physicians in one arm of the study were treated with OMT to alleviate pain and somatic disfunction. The amount of pain they were experiencing before treatment was recorded using a Likert pain scale.
88802119|NCT05491824||Stroke|
88802120|NCT05491824||Non-stroke|
89124360|NCT00948896|Experimental|3|
89124361|NCT00948896|No Intervention|4|
89124362|NCT01004159|Experimental|cetuximab with irinotecan|
89124363|NCT00948818|Experimental|Linaclotide|Linaclotide 290 micrograms
89124364|NCT00948818|Placebo Comparator|Placebo|Matching placebo
89124365|NCT02854592||rtPA|Intravenous rt-PA thrombolysis shall be administered within 4.5 h after symptom onset, at a dose of 0.9 mg/kg body weight (maximum, 90 mg), with 10% of the dose given as a bolus over 1 min and the remaining 90% infused over 60 min.
89124366|NCT02854592||urokinase|1,000,000-1,500,000 units of urokinase intravenous infused over 30 minutes within 4.5 h of stroke onset .
89124367|NCT00948506|Placebo Comparator|1% topical cidofovir|1% topical cidofovir to one side of the face and placebo to the other side of the face
89124368|NCT00948506|Placebo Comparator|3% topical cidofovir|3% topical cidofovir to one side of the face and placebo to the other side of the face
89124369|NCT00955682|Experimental|Group A|Subjects who received GSK vaccine 134612 in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
89124370|NCT00955682|Active Comparator|Group B|Subjects who received Meningitec™ vaccine in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
89124371|NCT00689221|Experimental|Cilengitide + Temozolomide + Radiotherapy|
89124372|NCT00689221|Active Comparator|Temozolomide + Radiotherapy|
89124373|NCT02007733||Derivation Cohort|The derivation cohort includes patients enrolled in the first phase of the study, from February 2014 to June 2014. All children enrolled in this study will receive the same interventions, which include collection of regular weights to establish percent weight change with rehydration, clinical assessment of dehydration status, and ultrasound of the IVC and aorta.
89124374|NCT02007733||Validation Cohort|The validation cohort includes patients enrolled in the second phase of the study, from March 2015 to May 2015. All children enrolled in this study will receive the same interventions, which include collection of regular weights to establish percent weight change with rehydration, clinical assessment of dehydration status, and ultrasound of the IVC and aorta.
89124375|NCT04060771|Experimental|Group P|During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.
89124376|NCT04060771|Active Comparator|Group D|During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.
89124377|NCT00744913|Experimental|1|
89124378|NCT00744913|Active Comparator|2|
89124379|NCT01875445|Placebo Comparator|Placebo|Matched dosage of inositol daily.
89124380|NCT01875445|Active Comparator|Inositol|Powder form, 2g TID up to 6g TID
89124381|NCT02564653|Other|Technical Assistance, training,clinical reminders|provider adherence to tobacco use treatment guidelines
89124382|NCT02564653|Other|TTC + help of community health workers|We will assess this secondary aim by comparing smoking cessation outcomes among smokers who receive brief provider counseling alone only vs. smokers who receive provider counseling + community health worker counseling. The purpose of this assessment is to specifically analyze the impact of the community health worker counseling component of the intervention using a quasiexperimental design that leverages the larger RCT.
89124383|NCT04060537||Research|Patients with Renal Cell Carcinoma who have had previous systemic treatment, with adequate tissue samples and radiological data
89124384|NCT03763591|Experimental|Psychological Skills Group (e.g., Active Intervention)|10-week Psychological Skills Group.
89124385|NCT00745147|Experimental|A|Chinese herbal formula + Placebo of duphalac
89124386|NCT00745147|Active Comparator|B|Duphalac + Placebo of Chinese herbal formula
89124387|NCT00688909|Experimental|Letrozole|Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.
89124388|NCT00948428|Active Comparator|Generic Imiquimod|imiquimod cream, 5%
89124389|NCT00948428|Active Comparator|Aldara™|Aldara™ (imiquimod) cream, 5%
89124390|NCT00948428|Placebo Comparator|Vehicle cream|Vehicle cream (Actavis)
89124391|NCT02856308|Experimental|Hairstetics hair implant device|Subjects will undergo the Hairstetics prosthetic hair implantation starting with a test of up to 100 fibers and up to 2 additional implantation sessions with up to 1500 fibers overall per subject. The implantation will be carried out according to the device IFU.
89124392|NCT02854982||Prostate Cancer|Group drawn of the case group of the case control study, entitled EPICAP
89124393|NCT02854982||No Prostate Cancer|Group drawn of the control group of the case control study, entitled EPICAP
89124394|NCT00948194|No Intervention|No nitric oxide|This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics
89124395|NCT00948194|Experimental|Nitric Oxide|Will receive Nitric oxide and other standard inhaled anesthetics
89124396|NCT00691483|Placebo Comparator|placebo|
89124397|NCT00691483|Experimental|varenicline|
89124398|NCT02565433|Experimental|questionnaire administration|Quality of life questionnaires administration (EORTC QLQ C30 and BN20 / IADL / HADS / MoCa Edmonton Symptom Assessment Scale)
89124399|NCT00691093||fesoterodine|
89124400|NCT03646825||Treatment group|Male patients exposed to antioxidant for 12 weeks
89124401|NCT00745225|Experimental|Active intervention arm|Peroxisome proliferator activator receptor gamma treatment, Pioglitazone
89124402|NCT00745225|Placebo Comparator|placebo pill|placebo comparator
89124403|NCT00745303||1|Subjects in this group received TCC training for 3 months
89124404|NCT00745303||2|Subjects in this group received no TCC training within 3 months
89124405|NCT00947882|Placebo Comparator|Placebo|
89124406|NCT00947882|Experimental|Degarelix 10 mg|
89124407|NCT00947882|Experimental|Degarelix 20 mg|
89124408|NCT00947882|Experimental|Degarelix 30 mg|
89124409|NCT00745381||1|This registry will be open to all patients with GEPNET or NET of unknown primary.
89124410|NCT00745459|Experimental|N|20 mL NPO-11
89124411|NCT02856386|Experimental|polyphenol supplement|Dietary supplement administered 8 mL once daily
89124412|NCT04204226|Experimental|Social Worker vs Autism Behavioral Health Navigation (ABHN)|"Phase 1: Families providing informed consent will then be randomized to social work consultation or to the Autism Behavioral Health Navigation (ABHN) intervention.~Non-responders to ABHN will move to ABHN + Complex Autism Program (CAP)."
89124413|NCT04204226|Experimental|Social work + ABHN vs Social work + ABHN + CAP|"At 3 months, children who are considered to be responders to their current treatment will continue; children who are nonresponders in the social work arm of the study will be randomized to either ABHN or ABHN+CAP. Children in the ABHN arm who are non-responders will receive ABHN + CAP"
89124414|NCT02857634||Bladder tumor resection|
89124415|NCT04277390||Controls|145 systemically and periodontally healthy pregnant women Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
88802121|NCT01165450|Active Comparator|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
88802122|NCT01165450|Placebo Comparator|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
88802123|NCT05485896|Experimental|Advanced Renal Cell|Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation and patients need to continue taking the drug for a year after surgery.
88802124|NCT01148056|Experimental|Short course IMRT|Patients will receive short course IMRT (Intensity Modulated Radiation Therapy) prior to surgery. Dose will be 5 Gy x 5, followed by surgery the week after
88802125|NCT05488002|Experimental|Intervention|"This arm will receive pharmaceutical interventions.~Hypertensive patients will receive pharmacist recommendations on hypertension Diabetic patients will receive pharmacist recommendations on diabetes Obese patients will receive pharmacist recommendations on obesity"
88802126|NCT05488002|No Intervention|Control|This arm will receive standard care
88802127|NCT05485818|Experimental|Low Dose|Patients in this treatment group will receive NL005 for 0.25 ug/kg respective.Continuous administration for 7 days.
88802128|NCT05485818|Experimental|Middle Dose|Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
88802129|NCT05485818|Experimental|High Dose|Patients in this treatment group will receive NL005 for 2.0 ug/kg respective.Continuous administration for 7 days.
88802130|NCT05485818|Placebo Comparator|Placebo|Patients in this treatment group will receive placebo respective. Continuous administration for 7 days.
89124416|NCT04277390||Group A|"Group A-100 Systemically healthy pregnant women with chronic periodontitis.~Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155."
89124417|NCT04277390||Group B|Group B- 100 Preeclamptic pregnant women with chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
89124418|NCT04277390||Group C|Group C-100 Preeclamptic pregnant women without chronic periodontitis. Subgingival samples and placental tissue samples(postpartum) were collected for microbial analysis and check for the levels of MIR155.
89124419|NCT00688753|Experimental|RAD001|two 5 mg tablets of everolimus orally, once daily
89124420|NCT02854514||aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated with endometrial secretion then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
89124421|NCT04204382|Experimental|test group|"CKI was injected intravenously for 7 days, once a day, 20ml each time；~Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time,"
89124422|NCT04204382|Other|control group|Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time.
89124423|NCT00745537|Experimental|Adolescent Mother|aged less than 17 years old and recently gave birth
89124424|NCT02856152|Experimental|Treatment A Then B Then D Then C|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment A on Day 1 of first intervention period, followed by Treatment B on Day 1 of second intervention period, followed by Treatment D on Day 1 of third intervention period, and then Treatment C on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
89124425|NCT02856152|Experimental|Treatment B, Then C, Then A, Then D|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment B on Day 1 of first intervention period, followed by Treatment C on Day 1 of second intervention period, followed by Treatment A on Day 1 of third intervention period, and then Treatment D on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
89233565|NCT00382018|Active Comparator|Group 1|Patients continue to receive regular treatment without change at the discretion of the physician. Patients are eligible for other first-line chemotherapy trials. No further blood is collected.
88802131|NCT05507398|Placebo Comparator|control group|30 patients who will serve as a control group and will receive placebo tablets
88802132|NCT05507398|Active Comparator|metformin group|30 patients who will receive metformin 1000 mg/day.
88802133|NCT05507398|Active Comparator|atorvastatin group|30 patients who will receive atorvastatin 20 mg/day.
88802134|NCT05487612|Active Comparator|Minimal Invasive Extracorporeal Circulation (MiECC)|Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with Minimal Invasive Extracorporeal Circulation (MiECC).
88802135|NCT05487612|Active Comparator|Conventional Cardiopulmonary Bypass (cCPB)|Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with conventional cardiopulmonary bypass (cCPB)
88802136|NCT02414698|Active Comparator|Percutaneous Hydrodiscectomy|Percutaneous Hydrodiscectomy with the SpineJet Hydrodiscectomy System
88802137|NCT02414698|Active Comparator|TESI|Transforaminal Epidural Steroid Injections
89233566|NCT00382018|Experimental|Group 2|Patients continue to receive their current chemotherapy regimen without change.
89233567|NCT00382018|Active Comparator|Group 3, Arm I|Patients continue with their current chemotherapy regimen without change.
89233568|NCT00382018|Experimental|Group 3, Arm II|Patients switch to a different chemotherapy regimen. Selection of a new chemotherapy regimen is made by the patient's doctor.
89124426|NCT02856152|Experimental|Treatment C, Then D, Then B, Then A|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment C on Day 1 of first intervention period, followed by Treatment D on Day 1 of second intervention period, followed by Treatment B on Day 1 of third intervention period, and then Treatment A on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
89124427|NCT02856152|Experimental|Treatment D, Then A, Then C, Then B|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment D on Day 1 of first intervention period, followed by Treatment A on Day 1 of second intervention period, followed by Treatment C on Day 1 of third intervention period, and then Treatment B on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
89124428|NCT02856230|Experimental|Ranger SL DEB angioplasty|patients filling general and angiographic inclusion/exclusion criteria will have an BTK angioplasty using one or several Ranger SL drug-eluting balloons
88802138|NCT05485506|Experimental|Intervention group|Intervention group will add to their training routine a multimodal exercise program (two days per week, during six weeks). This program will include running technical drills, exercises for lumbopelvic stabilization and resisted sprints by using sled.
89124429|NCT02563483|Experimental|Yoga and compassion meditation program|"The duration of this group was 8 weeks. The program included sessions 3 times per week, with each session lasting 1 hour and 15 minutes. The volunteers performed yoga classes composed of asana (poses), pranayama (breathing exercise) and meditation."
89124430|NCT02563483|No Intervention|control|this group was a non treatment group.
89124431|NCT02855996|Experimental|Intervention|"Fathers will be randomly assigned to participate in the Fathers in Action/Padres Activos (FA/PA) intervention program to support fathers' healthy relationships with their children and support their co-parenting skills."
89124432|NCT02855996|No Intervention|Control|"Fathers waitlisted for participation in the Fathers in Action/Padres Activos (FA/PA) program."
89124433|NCT00631046|Experimental|Fish Oil|containing n-3 LCPUFA
89124434|NCT00631046|Placebo Comparator|Sunflower oil|containing n-6 PUFA
89124435|NCT00631124|Experimental|Arm 1|
89124436|NCT00631124|Experimental|Arm 2|
89124437|NCT02855762|Other|Dietary Intervention Group|Subject will be guided to eat a high polyunsaturated fatty acid diet.
89124438|NCT04275206|Experimental|Medicinal water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in tap water.)
89124439|NCT04275206|Placebo Comparator|Tap water treated group|3-week-long inward rehabilitation, in a bath tab, for 30 min, 5 days a week. (After 6 months treatments will be repeated in medicinal water.)
89124440|NCT04275128||Conventional Genicular Ablation|This group is scheduled to receive conventional genicular ablation to treat their chronic knee pain.
89124441|NCT04275128||Cooled radiofrequency Ablation|This group is scheduled to receive cooled radiofrequency ablation to treat their chronic knee pain.
89124442|NCT02854202|Experimental|Arm 1-Whey protein|In the Arm 1-Whey protein Breakfast the participant will consume 42 g protein at breakfast mainly from whey
89124443|NCT02854202|Active Comparator|Arm 2 Breakfast- other proteins|In the Arm 2 Breakfast- other proteins sources (No Whey) the participants will consume 42 g protein from other sources (no Whey) at breakfast
89124444|NCT02854202|Placebo Comparator|Arm 3 Breakfast- low protein|In the Arm 3: breakfast with low proteins content, the participant will consume 22 g protein at breakfast
89124445|NCT02854280|Active Comparator|Chronic Obstructive Pulmonary Disease (COPD)|18 patients
89233569|NCT03838731|Experimental|REGN1908-1909|
89233570|NCT03838731|Placebo Comparator|Placebo|
88802139|NCT05485506|No Intervention|Control group|Control group will maintain their training routine.
88802140|NCT02415166|Experimental|VACCINE MDD|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
88802141|NCT02415166|Placebo Comparator|PLACEBO MDD|SALINE (0.5ML) DELIVERED I.M.
89124446|NCT02854280|Active Comparator|Sleep Apnea Obstructive (OSA)|18 patients
89124447|NCT02854280|Active Comparator|Healthy Volunteers|36 control patients
89124448|NCT02855684|Experimental|Toujeo - insulin glargine (U300)|Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
89124449|NCT02855684|Active Comparator|Lantus - insulin glargine|Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
89124450|NCT02855840||systemic lupus erythematous|
89124451|NCT02855840||systemic sclerosis|
89124452|NCT02855840||inflammatory myopathy|
89124453|NCT02857556|Other|group with stage 3 kidney failure (diabetic or not)|
89124454|NCT02857556|Other|group with stage 5 kidney failure (diabetic or not)|
89124455|NCT02854358|Active Comparator|control|In the control group, patients received Hypozalix (artificial saliva)spray three times per day for a period of four weeks.
89124456|NCT02854358|Experimental|intervention|Patients in intervention group received sachets containing 4 grams of mixed powder of A. digitata and M. sylvestris (in a proportion of 1:1), three times per day for a period of four weeks
89124457|NCT01667744|Placebo Comparator|Placebo|Placebo pill
89124458|NCT01667744|Experimental|Citalopram|Drug
89124459|NCT00951080|Experimental|SNaP Wound Care System|
89124460|NCT00951080|Active Comparator|Traditional NPWT System|
89233571|NCT02551133|Active Comparator|0.1 mg/kg dexamethasone|0.1 mg/kg dexamethasone intravenous will be given 1 h before surgery.
89124461|NCT04269980|Active Comparator|Group (PHN)|Group (PHN) (n=15): will receive hypotensive anesthesia with phentolamine infusion (Rogitamine, Egypharma) via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure
89124462|NCT04269980|Active Comparator|Group MG|Group MG (n=15): will receive hypotensive anesthesia with 40 mg/kg Magnesium sulphate as bolus in 15 min with infusion later on till end of surgery at the rate of 10 mg/kg/hr .
89124463|NCT02351492|Active Comparator|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography (IOC) to investigate bile ducts.
89124464|NCT02351492|Active Comparator|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography (MRCP) first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
89124465|NCT00946322|Experimental|Arm 1: CTAP|Couple-Based Treatment for Alcohol Use Disorders and PTSD
89124466|NCT02331290||All patients|20 newly diagnosed patients with small-cell lung cancer and adenocarcinoma of the lung stage III or IV
89124467|NCT04274270|Experimental|experimental group|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
89124468|NCT02857322|Other|subjects with documented psychiatric pathology|
89124469|NCT02855372||Lung transplanted patients|
89124470|NCT02855528|Experimental|Reduction of radiation dose and diagnostic accuracy|Reduction of radiation dose during coronary artery calcium scoring with the use of a tin filter system.
89124471|NCT02855294|Active Comparator|Oral contraceptive pills users|The participants received treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of ring/pill treatment followed by a 1-week pill-free period. The women were randomized in a 1:1 ratio to receive the COC containing 30 μg of EE and 3mg of drospirenone (Yasmin; Schering AG, Berlin, Germany)
89124472|NCT02855294|No Intervention|control|no drugs
89124473|NCT02855216|Experimental|Manual technique of sub-occipital inhibition|"The technique applied to Manual Group was performed with the patient supine position. Physiotherapist in a sitting position at the head of the subject with forearms resting on the table . Suboccipital region was located , and flexing the metacarpophalangeal joints 90º a pressure was made ventrally , relaxing the rest of the head in the heel of the hand.~The technique was performed for 5 minutes"
89124474|NCT02855216|Experimental|Self-treatment by way of Occipivot®|The technique applied to the Instrumental Group was performed with the patient supine in the same position as the Manual Group . It was previously instructed the subject how to proceed with the cushion Occipivot® , indicating the installation location and method of affixing , correcting him if the application was inadequate. The subject placed the cushion Occipivot® under the suboccipital region and told him he had to stay in that position for 5 minutes. A physiotherapist warned the patient at the end of the application time so that the subject had to be aware not to control it.
89124475|NCT00950690||Study Drug - Xalatan 0.005% eye drops|
89124476|NCT01535066|Experimental|Arm I|Patients receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
89124477|NCT01535066|Sham Comparator|Arm II|Patients receive sham acupuncture twice weekly for 6 weeks and then once weekly for 6 weeks.
89124478|NCT01535066|No Intervention|Arm III|Patients are assigned to a waiting list for 12 weeks with standard follow-up care.
89124479|NCT02855138|Active Comparator|study group|The study group consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended the obstetrics and gynecology clinic for the treatment of menstrual irregularities and hirsutism.The patients were treated with 0.6-0.8 mg/kg oral isotretinoin up to a total dose of 120-150 mg/kg. Treatment was started at 20 mg/day and gradually increased to the maximum of 40 mg/day. The patients were monitored monthly during isotretinoin treatment.
89124480|NCT02855138|No Intervention|control group|The control group of this study was pretreatment period of the same volunteer patients.
89124481|NCT00694369|Experimental|1|etoricoxib 90 mg
89124482|NCT00694369|Experimental|2|etoricoxib 120 mg
89124483|NCT00694369|Active Comparator|3|ibuprofen 2400 mg
89124484|NCT00694369|Active Comparator|4|acetaminophen 2400 mg/codeine 240 mg
89124485|NCT00694369|Placebo Comparator|5|Matching Placebo
89124486|NCT00745693|Experimental|1|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
89124487|NCT00745693|Experimental|2|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
89124488|NCT00745693|Experimental|3|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
89124489|NCT00745693|Experimental|4|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
89124490|NCT02563405|Active Comparator|doxazosin|To observe the effects of doxazosin (4 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
89124491|NCT02563405|Active Comparator|nifedipine|To observe the effects of nifedipine (30 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
89124492|NCT02564419|Experimental|Medtronic Activa PC+S|"Objective of this pilot phase early feasibility study is to assess the safety and feasibility of Medtronic Activa PC+S implant (device) by;~Evaluating the ability of the Activa PC+S system to sense ECoG signals in subjects living with quadriplegia (C5 or C6 level).~Assessing the feasibility of activating fundamental upper extremity muscles to reproduce hand grasp.~These are important first steps towards creating and designing a device that can enhance or assist in performing activities of daily living (ADL) in the life of these subjects. Attachment 15.3"
89124493|NCT00513019|Active Comparator|1|Lamictal (lamotrigine)
89124494|NCT00513019|Placebo Comparator|2|Placebo
89233572|NCT02551133|Active Comparator|0.2 mg/kg dexamethasone|0.2 mg/kg dexamethasone intravenous will be given 1 h before surgery.
89233573|NCT00814853||Extubation readiness testing|Patients who pass the ERT.
89233574|NCT00818285|No Intervention|1|Physicians in this arm will be using the standard electronic prescription interface.
89233575|NCT00818285|Experimental|2|In addition to the standard electronic prescription module, physicians in this arm will receive targeted drugs alert and decision support for psychotropic drug management
89233576|NCT00452439|Active Comparator|Actonel|Actonel (Risedronate) + Vitamin D + Calcium
89233577|NCT00452439|Placebo Comparator|Placebo|Placebo + Vitamin D + Calcium
89233578|NCT02550899|Active Comparator|Bulkamid injection treatment group 1|Injection at four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
89233579|NCT02550899|Active Comparator|Bulkamid injection treatment group 2|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
89233580|NCT02550899|Active Comparator|Bulkamid injection treatment group 3|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
89233581|NCT00814931|Experimental|1|Treatment Group
89233582|NCT00814931|Placebo Comparator|2|
89233583|NCT01023087||Treatment|Patients with sepsis treated with polymyxin E (colistin)
89233584|NCT01023087||Control|Patients with sepsis treated with other, non-nephrotoxic antibiotic medication
89233585|NCT00815009|No Intervention|A (Std of Care)|Standard of Care/Control, including Lifestyle Advice (attend a basic healthy nutrition class as well as follow up appointments with GI MD).
89233586|NCT00815009|Experimental|B (Low Fat)|Standard of Care, plus Low Fat Diet and Moderate Exercise
89233587|NCT00815009|Experimental|C (Mod Fat)|Standard of Care, plus Moderate Fat/Low Processed Carbohydrate Diet and Moderate Exercise
89233588|NCT00815009|Experimental|D (Exercise only)|Standard of Care plus Moderate Exercise only
89233589|NCT00381940|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy)|"Patients receive ifosfamide IV continuously over days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, bortezomib IV on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy."
89233590|NCT00818597|Experimental|EISS-treatment|In this arm patients receive additional treatment with the EISS-bioreactor
89233591|NCT00818675|Experimental|Ridaforolimus|
89233592|NCT00818675|Placebo Comparator|Placebo|
89233593|NCT00364156|Experimental|Extended Patch Treatment|Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.
89233594|NCT00364156|Active Comparator|Standard Patch Treatment|Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.
89233595|NCT00452361|Experimental|1|Sirolimus therapy
89233596|NCT00452361|Active Comparator|2|Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
89233597|NCT03334318||Allopurinol-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to allopurinol
89233598|NCT03334318||Placebo-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to placebo
89233599|NCT00640289|Experimental|A|Treatment
89233600|NCT00818909|Experimental|Systane|Systane ocular product
89233601|NCT01049932|Experimental|All subjects|TMC278LA 600mg injected intramuscularly (i/m)
89233602|NCT00818987|Other|Operative|Treatment arm - intervention = Open Reduction Internal Fixation or Reduction & Immobilization
89233603|NCT00818987|No Intervention|Non Operative|Placebo arm
89233604|NCT01047670|Experimental|1|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
89233605|NCT01047670|Placebo Comparator|2|placebo
89233606|NCT00819065|Active Comparator|1-BTA Lanzhou/Allergan|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
89233607|NCT00819065|Active Comparator|2. BTA Allergan/Lanzhou|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.
89233608|NCT01047748|Active Comparator|intra-fetal injection|Subjects will receive an intra-fetal digoxin injection one day prior to their second-trimester surgical abortion
89233609|NCT01047748|Active Comparator|intra-amniotic injection|Subjects will receive an intra-amniotic digoxin injection one day prior to their second-trimester surgical abortion
89233610|NCT01047826|Experimental|M.I.P.O. Group|subjects who have been randomized to the M.I.P.O. group
89233611|NCT01047826|Experimental|Intramedullary Nail group|Subjects who have been Randomized to the I.M. group
89233612|NCT00568451|Experimental|PC (previously treated)|Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
89233613|NCT00568451|Experimental|PC (chemo naive)|Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
89233614|NCT00568451|Experimental|TMZ (previously treated)|Previously chemotherapy treated cohorts: Temozolomide (TMZ)
89233615|NCT00568451|Experimental|TMZ (chemo naive)|Chemotherapy-naive cohorts: Temozolomide (TMZ)
89233616|NCT00459537|Experimental|Terbinafine|10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
89233617|NCT00459537|Active Comparator|Amorolfine|5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
89233618|NCT00819299|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay ACI 7000PDT in emmetropic presbyopic patients.
89233619|NCT03850509|Experimental|OPS-2071 150 mg BID|Participants were to receive OPS-2071 150 mg, tablets, orally, twice daily (BID) in the morning and evening (8 to 12 hours apart) with 240 milliliters (mL) of water for up to 12 weeks.
89233620|NCT03850509|Experimental|OPS-2071 300 mg BID|Participants received OPS-2071 300 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 6 weeks.
89290143|NCT01215084|Experimental|Chinese Subpopulation: Fampridine-PR 10 mg|Chinese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
88802142|NCT02415166|Experimental|VACCINE HC|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
89124495|NCT00053677|Placebo Comparator|Naltrexone|17 weeks of double-blind Naltrexone. Subjects were randomized into one of these three conditions (if they weren't randomized to placebo): naltrexone 50mg/day, 100mg/day, 150mg/day. To minimize nausea, treatment for all subjects was initiated at 25mg/day naltrexone for two days, then the dose was increased to 50mg/day. At week 3, subjects were randomly assigned to 50mg/day continued at that dose, while subjects who were randomized to naltrexone 100mg/day or 150mg/day were raised to the higher doses.
88802143|NCT02415166|Placebo Comparator|PLACEBO HC|SALINE (0.5ML) DELIVERED I.M.
88802144|NCT02403154|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be internal fixator.
88802145|NCT02403154|Experimental|Randomized to External Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be external fixator.
88802146|NCT02403154|Other|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the internal fixator intervention based on their preference for the specific case or the patient chose the internal fixator.
88802147|NCT02403154|Other|Observational - External Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the external fixator intervention based on their preference for the specific case or the patient chose the external fixator.
88802148|NCT02381626|Experimental|Intervention Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. At the end of the initial two weeks, portable HEPA air purifiers (136) will be placed in the Intervention Group drivers' cars and the air monitoring and biological parameters will be repeated for another 2-week period, to determine changes in PM levels and physiological measurements as a result of this targeted intervention.
88802149|NCT02381626|Experimental|Wait-list Control Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. The Wait-list Control Group drivers will not receive a HEPA air purifier at this time, but will also have the air monitoring and biological parameters repeated for another 2 weeks. At the end of the 1 month period of measurements for both groups of drivers, the Wait-list drivers will then receive a HEPA air purifier, so that they may also potentially benefit from the intervention being tested in this study, but no further measurements will be taken.
88802150|NCT05487300|Other|Testing on-levodopa|Participants will undergo autonomic testing one hour after taking their regular morning dose of levodopa.
88802151|NCT05487300|Other|Testing off-levodopa|Participants will undergo autonomic testing at least twelve hours after taking their last dose of levodopa.
89124496|NCT00053677|Placebo Comparator|Placebo|Subjects who were assigned to placebo in the 17 week double-blind phase.
88802152|NCT01147042|Active Comparator|gp91 CGD with relatively high baseline superoxide|"Patients with X-linked Chronic Granulomatous Disease (CGD) with a missense gp91phox mutation and relatively high baseline superoxide production.~IFN-gamma was the administered intervention."
88802153|NCT01147042|Active Comparator|Autosomal Recessive CGD with p47|Patients with Autosomal Recessive Chronic Granulomatous Disease (CGD) with p47 phox mutation. IFN-gamma was the administered intervention.
89124497|NCT03385681|Experimental|Intervention Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate. Tailored Educational Intervention is administered to this group.
89124498|NCT03385681|No Intervention|Control Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate in the study.
89124499|NCT00954512|Experimental|Regimen A: FOLFIRI (± Cetuximab) + Robatumumab|Participants with colorectal adenocarcinoma receive FOLFIRI (Irinotecan 180 mg/m^2+ folinic acid 400 mg/m^2+ 5-fluorouracil [5-FU] 400 mg/m^2 bolus followed by 2400 mg/m^2 intravenous [IV] infusion over 46 hours) (± cetuximab initial dose of 400 mg/m^2 IV followed by once-weekly doses of 250 mg/m^2 IV) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 2-week cycle.
89124500|NCT00954512|Experimental|Regimen B: Carboplatin + Paclitaxel + Robatumumab|Participants with non-small cell lung cancer receive carboplatin administered at an area under the curve (AUC) of 6 mg/mL/min IV PLUS paclitaxel 225 mg/m^2 IV PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
89124501|NCT00954512|Experimental|Regimen C: Epirubicin + Cisplatin + 5-FU + Robatumumab|Participants with gastric adenocarcinoma receive epirubicin 50 mg/m^2 IV PLUS cisplatin 60 mg/m^2 IV PLUS 5-FU 200 mg/m^2/day administered via a 21-week continuous IV infusion PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
89124502|NCT00954512|Experimental|Regimen D: Trastuzumab + Robatumumab|Participants with human epidermal growth factor receptor 2 positive (Her2+) breast cancer receive trastuzumab 4 mg/kg IV once every week PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
89124503|NCT00954512|Experimental|Regimen E: mTor Inhibitor (Everolimus) + Robatumumab|Participants with renal cell cancer receive mammalian target of rapamycin (mTor) inhibitor (everolimus) 10 mg orally once per day PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
89124504|NCT00954512|Experimental|Regimen F: Gemcitabine (± Erlotinib) + Robatumumab|Participants with pancreatic adenocarcinoma receive gemcitabine 1000 mg/m^2 IV on Days 1, 8, 15, 22, 29, 36, and 43 in Cycle 1 and on Days 1, 8 and 15 in subsequent cycles (± erlotinib 100 mg per day orally) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle. (Cycle 1 is 8 weeks.)
89124505|NCT00741481||1|all study population
89233621|NCT03850509|Experimental|OPS-2071 600 mg BID|Participants were to receive OPS-2071 600 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 12 weeks.
88821362|NCT04425902|Experimental|Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254|All participants will receive a single dose of treatment A: Probe substrates (caffeine 200 milligram [mg], metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1; followed by treatment B- GSK3640254 200 mg on Days 11 to 20; further followed by treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.
89124506|NCT02565355|Other|Lifestyle Modification/Dietary Exclusion|In the lifestyle modification group, where specific IgG antibodies to foods are identified, the intervention is appropriate dietary elimination. The IgG antibody results will be disclosed and specific dietary elimination advice will be provided by an experienced dietician; provide diet alternatives to prevent nutritional deficiencies and improve adherence to diet. To improve compliance, a maximum of 2 high IgG positive foods will be eliminated at any one time in each 4 week period. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
89124507|NCT02565355|Other|The Standard Treatment Group|The standard therapy group will not receive results of IgG antibody testing. The patients will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relief as appropriate. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
89124508|NCT02853890||pregnant woman|
89124509|NCT00745771|Active Comparator|1|200 mg Ketoprofen
89124510|NCT00745771|Active Comparator|2|100 mg Ketoprofen
89124511|NCT00745927|No Intervention|Room air insufflations|Room air will be used for insufflations during colonoscopy
89124512|NCT00745927|Active Comparator|CO2 insufflations|CO2 will be used for insufflations during colonoscopy
89124513|NCT00746005|Experimental|1|3 g EPA-DHA
89124514|NCT00746005|Placebo Comparator|2|Placebo: sunflower oil
89124515|NCT00746083|Experimental|Intervention group|
89124516|NCT00746083|No Intervention|Control group|
89124517|NCT00746161|Active Comparator|1|Roux-en-Y
89124518|NCT00746161|Experimental|2|double tract reconstruction
89124519|NCT00746317|Experimental|1|
89124520|NCT00741559|Experimental|1|
89124521|NCT03885193||HMS plus group|HMS plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
89124522|NCT03885193||ACT plus group|ACT plus device is employed to assess anticoagulation and ensure adequate heparin and protamine dosing during cardiopulmonary bypass (CPB).
89124523|NCT05319145|Active Comparator|Control group|Treatment as usual. Mainly based on standard physical rehabilitation.
89124524|NCT05319145|Experimental|Intervention group|Based on the results of the CGA, a tailored multidisciplinary intervention will be proposed, focused on a multicomponent physical exercise program with nutritional recommendations.
89124525|NCT00691015|Experimental|Chemotherapy or chemotherapy + total body irradiation|"Standard of care (SOC) chemotherapy or ( SOC) chemotherapy + total body irradiation (TBI) of one of the following regimens:~Regimen I: Patients receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV;anti-thymocyte globulin IV.~Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV; anti-thymocyte globulin IV.~Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen V: Patients receive carmustine IV, etoposide IV, cytarabine IV, and melphalan IV. Some patients also receive rituximab IV; anti-thymocyte globulin IV.~Regimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI; anti-thymocyte globulin IV."
89124526|NCT00741637|Experimental|Vaccine|Live attenuated oral CholeraGarde® (5x107 to 1x109 CFU) vaccine
89124527|NCT00741637|Placebo Comparator|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
89124528|NCT00950300|Active Comparator|Herceptin IV + Chemotherapy|Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
89124529|NCT00950300|Experimental|Herceptin SC + Chemotherapy|Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.
89124530|NCT00949988|Active Comparator|Dasatinib - 100 mg (Phase I)|Dasatinib - 100 mg (Phase I)
89124531|NCT00949988|Active Comparator|Dasatinib - 70 mg (Phase I)|Dasatinib - 70 mg (Phase I)
89124532|NCT00731692|Experimental|FTY720D 0.5 mg|Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment
89124533|NCT00731692|Placebo Comparator|Placebo|Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization
89124534|NCT00731692|Experimental|FTY720D 1.25 mg switch to 0.5 mg|Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009
89124535|NCT02593474|Other|Detoxification / induction|The detoxification / induction procedure consists of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection. Participants then receive a second injection 4 weeks after the first.
89124536|NCT00687193|Placebo Comparator|Placebo|
89124537|NCT00687193|Experimental|CP-690,550, 10mg|
89124538|NCT00687193|Experimental|CP-690,550, 15mg|
89124539|NCT00687193|Experimental|CP-690,550, 1mg|
89124540|NCT00687193|Experimental|CP-690,550, 3mg|
89124541|NCT00687193|Experimental|CP-690,550, 5mg|
89124542|NCT02594878|Experimental|Pamidronatdinatrium 3mg/ml|Pamidronatdinatrium 1 mg/kg max 60 mg for 3 days every 3 month in total of 3 series (0,3,6 month). First day first series 0,5mg/kg max 30 mg.
89124543|NCT02594878|Placebo Comparator|Natrium chloride 9 mg/ml|Natrium chloride 9 mg/ml volume equals experimental drug
89124544|NCT00917878|Experimental|Milk|500 mL low-fat milk added to high-fat meal
89124545|NCT00917878|Experimental|Protein|Milk protein in 500 mL water added to high-fat meal
89124546|NCT00917878|Experimental|Calcium|Milk calcium in 500 mL water added to high-fat meal
89124547|NCT00917878|Experimental|Control|Lactose in 500 mL water added to high-fat meal (control condition)
89124548|NCT00749281||1|Patients with angiographically confirmed significant CAD
89124549|NCT00749281||2|Patients without significant CAD
89124550|NCT00730912|Experimental|Pediatrics 3 to 6 years|Pediatrics 3 to 6 years
89124551|NCT00730912|Experimental|Pediatrics 7 to 15 years|Pediatrics 7 to 15 years
89124552|NCT00730912|Experimental|Adults 16 to 64 years|Adults 16 to 64 years
89124553|NCT04059601||Patients with acute cholecystitis|All patients with acute cholecystitis are included in the study cohort during year 2019. MRCP and IOC will be performed to all patients whenever feasible.
89124554|NCT00746473||1|15 HIV-1 infected individuals, with or without AIDS, who had never received ARV. These patients had not yet been indicated for ARV, or had had HIV-1 infection diagnosed a few days before inclusion in this study.
89124555|NCT00746473||2|"27 HIV-1 infected individuals, sick or not, on ARV treatment, five with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and one nonnucleoside reverse transcriptase inhibitor (NNRTI), and 22 on HAART with two NRTI, or one NRTI and one NNRTI, and one protease inhibitor (PI), and VL equal to or greater than 50 copies of plasma RNA/mL.~Treatment duration in this group varied between three and 145 months (mean 53.62 months; median 42 months)."
89124556|NCT00746473||3|31 HIV-1 infected individuals on ARV treatment, 16 on HAART with two NRTI, or one NRTI and one NNRTI, and one PI, and 15 with two NRTI and one NNRTI. All G3 patients had undetectable VL for at least the past 6 months. Treatment in this group varied between five to 108 months (mean 48.13 months; median 42 months).
89124557|NCT00746473||4|20 blood donors without clinical complaints and negative for anti-HIV-1/2 antibodies. None of them showed any sign of disease.
89124558|NCT00730756|Active Comparator|Arm A|Fluticasone Furoate Nasal Spray 110mcg intranasally once daily
89124559|NCT00730756|Placebo Comparator|Arm B|Matching placebo nasal spray intranasally once daily
89124560|NCT00730132||New Statin|Group 1 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by transition to a new statin treatment
89124561|NCT00730132||Statin Dose Titration|Group 2 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by increasing the dose of ongoing statin treatment
89124562|NCT00730132||Ezetimibe added to existing statin|Group 3 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and whose lipid-lowering therapy was modified by the addition of ezetimibe to ongoing statin treatment
89124563|NCT00737464|Experimental|Mircera|Participant with chronic renal anemia will receive methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.
89124564|NCT02594722|Experimental|One single arm group|"COPD included in a pulmonary rehabilitation program~Intervention:~Investigators used a bedside cycloergometer with electrical stimulation. COPD perform 2 measure of oxygen uptake during exercise for compare aerobic capacities:~Functional Electrical Stimulation Cycling (FES-cycling)~Classic Cycloergometer endurance training with a sham electrical stimulation"
89124565|NCT00729586|Experimental|Arm I (temsirolimus)|Patients receive temsirolimus IV over 30 minutes once weekly for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89124566|NCT00729586|Experimental|Arm II (temsirolimus, megestrol acetate, tamoxifen citrate)|Patients receive temsirolimus as in Arm I and megestrol acetate PO BID for 3 weeks alternating with tamoxifen citrate PO BID for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89124567|NCT00949910|Experimental|Erlotinib|Erlotinib will be given as a single agent in this expanded access program (EAP) to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Treatment will continue until unacceptable toxicity, disease progression, or withdrawal for any other reason.
89124568|NCT04313543|Experimental|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. There is 3 days for wash out period. These tests will be repeated for 3 times for baseline glucose calculation. After that, volunteers take 50 g of longan syrup in 250 ml of water in 5 minutes.Then, they are tested blood glucose levels (taken from the fingertips) at 15, 30 ,45, 60, 90, and 120 minutes. Glycemic index of longan syrup is calculated from area under the curved of blood glucose after longan syrup taking divided to mean of area under the curved of blood glucose after glucose taking
89124569|NCT02594800|Active Comparator|standard dose|Drug: Rosuvastatin rosuvastatin 10 mg daily for 52 weeks.
89124570|NCT02594800|Experimental|intensive dose|Drug: Rosuvastatin rosuvastatin 20 mg daily for 52 weeks.
89124571|NCT02593162|Experimental|Group 1|12 weeks of Faldaprevir plus low dose TD-6450 plus Ribavirin
89124572|NCT02593162|Experimental|Group 2|12 weeks of Faldaprevir plus high dose TD-6450 plus Ribavirin
89124573|NCT00686959|Experimental|Arm A: Pemetrexed + Cisplatin and TRT|"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (Concurrent Phase) for three 21-day cycles, followed by a 3-5 week Recovery Period, then treated with consolidation chemotherapy with pemetrexed (Consolidation Phase) for up to four 21-day cycles~Concurrent Phase:~Pemetrexed: 500 milligrams per meter squared (mg/m^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.~Cisplatin: 75 mg/m^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray [Gy] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.~Consolidation Phase:~Pemetrexed: 500 mg/m^2, IV on Day 1 of each 21-day cycle up to 4 cycles"
89233622|NCT03850509|Placebo Comparator|Placebo|Participants received OPS-2071-matched placebo, tablets, orally, BID in morning and evening (8 to 12 hours apart) with 240 mL of water for up to 4 weeks.
89233623|NCT00635999|Experimental|Purely Behavioral therapy|Participants will receive treatment with progressive and applied relaxation and self-control desensitization.
89124574|NCT00686959|Active Comparator|Arm B: Etoposide + Cisplatin and TRT|"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (Concurrent Phase) for two 28-day cycles, followed by a 3-5 week Recovery Period, then received consolidation treatment with cytotoxic chemotherapy of choice (Consolidation Phase) for up to 2 cycles~Concurrent Phase:~Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m^2, IV on Days1, 8, 29, and 36~Consolidation Phase options:~Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"
89124575|NCT02594566|Experimental|Research Subjects|A total of 3 injections of the vaccine (CyMVectin) will be given at Days 0, 28 (+4 days), and 56 (+4 days).
89124576|NCT04088110|Experimental|Pyrotinib and trastuzumab plus aromatase inhibito|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89124577|NCT02594488|Active Comparator|Remote monitoring|Remote cardiac monitoring by the Reveal® LINQ implantable cardiac monitor
89124578|NCT02594488|No Intervention|Control arm|Follow-up at the same frequency, but with no implantable cardiac monitor
89124579|NCT04087954|Experimental|Intervention vs control|
89124580|NCT04087954|No Intervention|Control|
89124581|NCT04088266|Other|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA® sublingual film 16 mg buprenorphine with 4 mg naloxone
89124582|NCT05311579|Experimental|Ovarian cancer patients with increased CA125|Patients with CA125 >35 U/ml or increased to 2 x nadir, and with no evidence of imaging recurrence after completion of 1st-line platinum-based chemotherapy
89124583|NCT02853968||Castleman's Patients|Castleman's patients with HHV8 negative multicentric MCD
89124584|NCT02853968||Related Disease Controls|Controls with inflammatory diseases similar to idiopathic multicentric Castleman's: i.e. HHV8+ MCD, HLH, Hodgkin disease
89124585|NCT02853968||Healthy Donor Controls|Healthy subjects used for controls. These healthy subjects have no history of autoimmune disorders.
89124586|NCT00749359|Experimental|open label treatment|On each treatment period, subjects will receive controlled release paroxetine 37.5 milligram (mg) on Day 1.
89124587|NCT02854046||Calciphylaxis Cases|Adult patients with advanced chronic kidney disease (DFG estimation < 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes
89124588|NCT02854046||Witness cases|"Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint onset of the lesions and REIN regions belonging"
89124589|NCT02562079|Experimental|subjects SSc diagnosed|
89124590|NCT02562079|Experimental|subjects Localised sclerosis diagnosed|
89124591|NCT02562079|Experimental|subjects Sc|
89124592|NCT00946088|Active Comparator|Progesterone|Progesterone 400mg per vagina qhs.
89124593|NCT00946088|Placebo Comparator|Polyethylene glycol&hydrogenated vegetable oil|Polyethylene glycol&hydrogenated vegetable oil per vagina
89124594|NCT02562313|Experimental|BioChaperone insulin lispro|
89124595|NCT02562313|Active Comparator|Humalog®|Insulin lispro
89124596|NCT00736996|Experimental|Pioglitazone|"Pioglitazone~30 - 45mg tablet daily for 6 months"
89124597|NCT00736996|Active Comparator|Endurance Exercise Training|Endurance Exercise Training (EET) Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
89124598|NCT00736996|Placebo Comparator|Placebo|Placebo matching tablet sugar pill daily for 6 months
89124599|NCT00741949|Experimental|1|
88821363|NCT04421586|Experimental|Pregnant women receiving VISTA counseling|Up to 30 pregnant women are screened and counseled for vaccine concerns using VISTA
89124600|NCT00741949|Placebo Comparator|2|
89124601|NCT01410344|Other|Allogeneic Transplant|One regimen from either reduced-intensity conditioning (RIC) (Fludarabine and Busulfan; or Fludarabine and Melphalan) or myeloablative conditioning (MAC) (Busulfan and Fludarabine; or Cyclophosphamide and Total Body Irradiation) will be administered prior to allogeneic hematopoietic cell transplantation (HCT).
89124602|NCT02594410|Experimental|Treatment|patients receiving renal artery stenting and anti-hypertension drug for renal artery atherosclerosis
89124603|NCT00746629|Active Comparator|Prescribed Skills|Behavioral skills are all prescribed and considered necessary tools expected to be used consistently, completely, and uniformly by all participants throughout treatment
89124604|NCT00746629|Experimental|Self-Directed Skills|Behavioral skills are considered a tool box from which families are encouraged to select skills that best apply to that family's situation in attempts to help their child make eating and activity change.
89124605|NCT00746707|Experimental|1|use of octyl-2-cyanoacrylate adhesive glue for perineal tear grade 1 in 80 women
89124606|NCT00746707|Active Comparator|3|use of traditional suturing for perineal tear grade 1 in 50 women
89124607|NCT02562001|Experimental|Outpatient active group|This group will receive active tDCS, combined with Lokomat gait training
89124608|NCT02562001|Experimental|Inpatient active group|This group will receive active tDCS, combined with Lokomat gait training
89124609|NCT02562001|Experimental|Outpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
89124610|NCT02562001|Experimental|Inpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
89233624|NCT00635999|Experimental|Cognitive-Behavioral Therapy|Participants will receive treatment with cognitive therapy, progressive and applied relaxation, and self-control desensitization
89233625|NCT00635999|Experimental|Cognitive Therapy (CT)|Participants will receive purely cognitive therapy including identification of maladaptive thought processes and training in cognitive restructuring.
89290144|NCT01215084|Experimental|Japanese Subpopulation: Fampridine-PR 10mg|Japanese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
89290145|NCT01215084|Experimental|Caucasian Subpopulation: Fampridine-PR 10mg|Caucasian ethnic participants were administered a single dose of Fampridine-PR 10 mgs
89233626|NCT03866421||Kidney transplanted patients|"Number of patients: 16~Patients on the waiting list for kidney transplantation with a living donor. The patients are screened with an OGTT before participation in the study, thereby excluding patients with diabetes mellitus.~Patients in this group are examined three times (baseline (before transplantation) and after three and twelve months after transplantation).~Same interventions as in the control Group.~Including/ Exclusion criteria are listed under the section Eligibility"
89233627|NCT03866421||Control group|"Number of patients: 16~Participants in this group are matched on age and BMI according to the kidney transplanted patients.~Participants are screened with an OGTT before participation since only persons with normal glucose tolerance may be included in the study.~Furthermore, participants have to have normal kidney function.~Participants in this group are only examined once. Same interventions as in the kidney transplanted patient group"
89233628|NCT00819377|Placebo Comparator|Normal saline|Normal saline by inhalation over 15 min
89233629|NCT00819377|Active Comparator|Milrinone|Inhaled milrinone 5 mg(as for the injectable solution)
89233630|NCT01023165|Experimental|IV bolus insulin, metabolic integrity|Diabetic patients will complete diagnostic testing and complete quality of life questionnaires at baseline and every six months thereafter while enrolled in the study to monitor and assess progress with metabolic integrity and complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months thereafter. Supervising physician may request testing be performed more frequently as deemed medically necessary, testing may include retinal photography, nerve conduction and labs. Meds and medical intervention information is collected weekly at the Intravenous Bolus Insulin treatment sessions. An annual evaluation is performed to review clinical data collected and evaluate progress for analysis and comparison.
89233631|NCT01025895|Active Comparator|single bundle|acl reconstruction - single bundle technique
89233632|NCT01025895|Experimental|double bundle|acl reconstruction - double bundle technique
89233633|NCT01023243|Placebo Comparator|1 CAre of the Feet for Those at Risk|secular trends for physician documentation in the medical record for care of the feet for high risk patients
89233634|NCT01023243|Active Comparator|Care of the feet for those at risk|the impact of 1) patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam and 2) patient education material: Care of the Foot For Those at Risk, on documentation of foot examination in the medical record
89233635|NCT01023243|Active Comparator|Impact of Quality Survey|Impact of patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam in the medical record
89233636|NCT01025973||Diabetes Mellitus|Patients with type 1, type 2 or gestational diabetes mellitus
89233637|NCT01025973||Normal pregnancy|Patient without diabetes mellitus
88802154|NCT03840486|Active Comparator|Non-rebreather mask (NRBM)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-rebreather mask (NRBM) overlying the sensor. The participants will be randomized to the order of their treatment sequence as follows: oxygen at 15 liters per minute (LPM) for 3 minutes, at 35 LPM for 3 minutes, or at flush rate (55 LPM) for 3 minutes. The maximal reading at the end of this will be recorded, then the study subjects will be allowed to rest until their EtO2 returns to their baseline. They will then be placed back on NRBM at flush rate, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
88802155|NCT03840486|Active Comparator|Non-invasive ventilator mask (NIV)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-invasive ventilator mask (NIV) overlying the sensor. Participants will be randomized to the order of their treatment sequence as follows: NIV at 50% fraction of inspired oxygen (FiO2) for 3 minutes, NIV at 75% FiO2 for 3 minutes, NIV at 100% FiO2 for 3 minutes, the maximal reading at the end of this trial will be recorded. The study subjects will be allowed to rest until their EtO2 returns to their baseline, then they will be placed back on NIV at 100% FiO2, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
88802156|NCT05485350|Experimental|Anlotinib combined with SBRT and penpulimab|
88802157|NCT01136668|Experimental|Treatment group|Bupivacine-TAP block
88802158|NCT01136668|Active Comparator|Control Group|Bupivacaine- wound infiltration
88802159|NCT05487222||• Liberal fluid group (L group) using traditional technique of fluid administration|
88802160|NCT05487222||• Goal directed fluid group(G group) using stroke volume optimization|
88802161|NCT05485272|Experimental|Intervention 1|Silver Diamine Fluoride combined with Potassium Iodide (Riva Star), under High-Viscosity Glass Ionomer (EQUIA).
88802162|NCT05485272|Experimental|Intervention 2|Silver Diamine Fluoride (SDF), under High-Viscosity Glass Ionomer (EQUIA).
88802163|NCT05485272|Active Comparator|The comparator|High-Viscosity Glass Ionomer (EQUIA).
88802164|NCT01108666|Experimental|Proton RT and Nelfinavir|
88802165|NCT02317276|Experimental|Treatment|Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
88802166|NCT01662492|Experimental|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
88802167|NCT01662492|Experimental|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
88802168|NCT01662492|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
89233638|NCT01023321|Experimental|1|single ascending doses
88802169|NCT00378976|Experimental|1|
88802170|NCT00378976|Placebo Comparator|2|
88802171|NCT05485116||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
88802172|NCT05485116||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
88821364|NCT04421586|No Intervention|Pregnant women receiving usual care|Up to 30 pregnant women receiving usual care
88821365|NCT04413799|Active Comparator|lidocaine/ ketamine infusion|Lidocaine/ ketamine infusion will be monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
89233639|NCT01023321|Placebo Comparator|2|single dose placebo
89233640|NCT01023321|Experimental|3|multiple dose, 7 or 14 days, oral solution
89233641|NCT01023321|Placebo Comparator|4|multiple dose, 7 or 14 days, oral solution
89233642|NCT00469209|Active Comparator|No Bortezomib|Arm 1: Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
89233643|NCT00469209|Active Comparator|Bortezomib 1.0 mg/m^2|Arm 2: Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
89233644|NCT00469209|Active Comparator|Bortezomib 1.5 mg/m^2|Arm 3: Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
89233645|NCT01322919|Experimental|Myopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a myopic condition of the eye in conjunction with a presbyopic condition
89233646|NCT01322919|Experimental|Hyperopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a hyperopic condition of the eye in conjunction with a presbyopic condition
89233647|NCT00635219|Placebo Comparator|Placebo|
89233648|NCT00635219|Experimental|Vortioxetine: 2.5 mg|
89233649|NCT00635219|Experimental|Vortioxetine: 5 mg|
88802173|NCT02297230|Experimental|Arm 1 Capecitabine and RT|Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
88802174|NCT02297230|Experimental|Arm 2 Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients. The first dose will be 4mg/kg given IV over 90 minutes. Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
88802175|NCT02297230|Experimental|Arm 3: Paclitaxel and RT|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
88802176|NCT02297230|Experimental|Arm 4: Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery & thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
88802177|NCT02282332|Experimental|Patiens Discharged on Ticagrelor|Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.
88802178|NCT04016844|Experimental|tDCS first then SHAM effects on glucose uptake in leg muscles|"tDCS Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time tDCS will be applied to the motor cortex (M1) corresponding to the more-affected leg.~Sham Block: The subject will walk for 20 min on a treadmill at a self-selected speed during which time SHAM will be applied to the motor cortex (M1) corresponding to the more-affected leg."
88802179|NCT02287636|Experimental|Diagnostic (fludeoxyglucose F 18 PET/CT and PET/MRI)|Patients undergo fludeoxyglucose F 18 PET/CT followed by PET/MRI.
88802180|NCT05479500|No Intervention|Group 1|"Control group will consist of 12 patients with diagnosed Plantar Fasciitis, aged between 30-60 years. Only conventional physiotherapy program will be applied to this group.~Conventional treatment will consist of foot intrinsic muscles strengthening, plantar fascia, achilles and hamstring stretching exercises. The exercises will be performed as 10 repetitions and 3 sets. Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 20-40 minutes."
88802181|NCT05479500|Experimental|Group 2|Experimental group will consist of 12 patients with diagnosed Plantar Fasciitis, aged between 30-60 years. In addition to the conventional physiotherapy program, local release techniques will be applied to this group. Local Release Techniques will be applied as Gastro-solues trigger point myofascial release and Plantar fascia myofascial release. Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 20-40 minutes.
89233650|NCT00635219|Experimental|Vortioxetine: 10 mg|
89233651|NCT00635219|Other|Duloxetine: 60 mg|Active reference
89233652|NCT03987477|Experimental|Experimental group|The experimental group will be exposed to a brief online program aimed at the modification of negative emotional cognitive biases. The program consists of an introduction and four 1-hour sessions, in video format. In each session, participants are required to complete some open questions and scales about the type of cognitive bias addressed in each session. All sessions are structured in four parts: 1) description and examples of some specific cognitive biases; 2) information about negative consequences of each bias; 3) explanation of adaptive strategies to modify cognitive biases (i.e., the four-questions approach used in standard Cognitive behavioral therapy); and 4) use of some practices to familiarize participants with the use of those strategies.
89233653|NCT03987477|Other|Waiting list group|The control group will be composed of individuals waiting for the treatment. Participants will not be exposed to the experimental program or any other between the pre-evaluation and the post-evaluation sessions. Participants in this group will have access to the potential benefits of the intervention after the post-evaluation of both groups.
89233654|NCT00363766|Experimental|LY573636|
89233655|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
89233656|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
89233657|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
89233658|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
89233659|NCT01026129|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia.
89124611|NCT03963700||Cancer patients with Paraneoplastic neurological syndromes|"Cancer patients with Paraneoplastic neurological syndromes presenting various autoimmune anomalies:~Anti-Hu also known as anti-Neuron specific cell Nuclear Antibodies (anti-ANNA1) (350 patients), uncommon form of brain inflammation associated with an underlying cancer~anti-Yo (130 patients), antibody associated with paraneoplastic cerebellar degeneration~anti-Ma2 (50 patients), antibody associated with paraneoplastic encephalitis~anti-N-methyl-d-aspartate (NMDA) Receptor (350 patients), autoimmune disorder in which antibodies attack N-methyl-D-aspartate-type glutamate receptors~anti-gamma-aminobutyric acid-B (GABAb) receptor (35 patients), autoimmune disorder in which antibodies attack gamma-aminobutyric acid-B receptors~anti-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor (15 patients), autoimmune disorder in which antibodies attack alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors~without antibodies (50 patients)."
89124612|NCT00954122|Experimental|Quetiapine XR|Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.
89124613|NCT02563171|Placebo Comparator|Healthy periodontium without obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
89124614|NCT02563171|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
89290146|NCT01123122|Active Comparator|Strict glucose control|
88802182|NCT05479500|Experimental|Group 3|"Experimental group will consist of 12 patients with diagnosed Plantar Fasciitis, aged between 30-60 years. In addition to the conventional physiotherapy program, myofascial chain release techniques will be applied to this group.~Myofascial release technique will be applied to the center of coordination points in the superficial back line myofascial chain of the body. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.~Participants will be treated for a total of 6 weeks, 2 days a week. Each treatment session will last 20-40 minutes."
88802183|NCT05486988||2 cycles chemotherapy combined with PD-1/PD-L1 inhibitors|Participants receive 2 cycles chemotherapy combined with PD-1/PD-L1 inhibitors, after achieving CR/PR/SD according to RECIST v1.1, then will continue immune monotherapy maintenance therapy.
88802184|NCT05486988||4-6 cycles chemotherapy combined with PD-1/PD-L1 inhibitors|Participants receive 4~6 cycles chemotherapy combined with PD-1/PD-L1 inhibitors, after achieving CR/PR/SD according to RECIST v1.1, then will continue immune monotherapy maintenance therapy.
88802185|NCT01083472|Active Comparator|Strattice(TM) TM repair|Strattice(TM) TM will be placed in the intraperitoneal or retrorectus position to support the repair of abdominal wall defect
88802186|NCT01083472|Active Comparator|Standard of Care repair|Abdominal wall defect will be repaired using current standard of care techniques of either suture alone or suture with absorbable surgical mesh
88802187|NCT05479266|Experimental|Muscle Energy Techniques|Muscle Energy Techniques and Conventional Physical Therapy
88802188|NCT05479266|Experimental|Myofascial Release|Myofascial Release and Conventional Physical Therapy
88802189|NCT00378664|Experimental|Intervention|All enrollees are included in the intervention - lumbar to sacral ventral nerve re-routing procedure surgical nerve re-routing procedure.
88802190|NCT05486754|Experimental|Cognitive behavioral stress management group|Participants received the cognitive behavioral stress management intervention for 10 weeks.
88802191|NCT05486754|Active Comparator|Health promotion group|Participants received the health promotion group for one day.
88802192|NCT02253394|Active Comparator|AMB + Spiro, Cardiopulmonary fitness|Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
88802193|NCT02253394|Placebo Comparator|Placebo Cardiopulmonary fitness|Placebo mimics spironolactone 50 mg and will be taken QD
88802194|NCT05479110|Experimental|Experimental group|The experimental group was given four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
88802195|NCT05479110|Active Comparator|Control group|The control group was given case studies(text).
88802196|NCT05312788|Placebo Comparator|Whole wheat bread|Whole wheat bread will be used as control bread.
88802197|NCT05312788|Experimental|Barley supplemented wheat bread|Barley supplemented wheat bread (50% substitution) will be used as experimental bread.
88802198|NCT02236546|Experimental|FDG-PET/CT|Patients undergo [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84). Molecular assays on biopsied tissue obtained from a subset of patients will also undergo molecular assays, the results from which will be correlated with FDG-PET/CT data.
88802199|NCT05484726|Experimental|Intervention group (Group 1)|"Maternal involvement shall be in three stages for the intervention group as~Observer status~Performing under supervision~Independent~Study groups for sensory motor stimulation (5 minutes) + pacifier (2 minutes)~Intervention group (Group I): by mothers~T1: Nurses performing all steps while mother observer status~T2: Nurses perform all steps in front of the mother and a pacifier will be offered by the mother~D1: Mother performs all steps and oral milk shall be offered by the nurse while the mother observes.~D2: Mother performing all steps and offering oral milk while the nurse is supervising~D3: Mother performing all steps independently"
88802200|NCT05484726|Sham Comparator|Control group (Group 2)|All steps will be the same as the intervention group and shall be performed by staff nurses
88802201|NCT02175628|Experimental|Acoustic Angiography|All breast patients will be included in the experimental group.
88802202|NCT02175628|Experimental|Healthy Volunteers|A volunteer group was added to the study to perfect the image acquisition techniques.
88802203|NCT05484648|Experimental|Group A|Patients allocated to group A will receive ultrasound guided FICB with 0.375% ropivacaine 38 cc along with 8 mg dexamethasone in 2cc making a total injection volume of 40 cc.
88802204|NCT05484648|Experimental|Group B|Patients allocated to group B will receive ultrasound guided FICB with 0.375% ropivacaine 38 cc along with 1 µg/kg dexmedetomidine in 2cc dilution making a total injection volume of 40 cc.
88802205|NCT05484648|No Intervention|Group C|Patients allocated to group C will receive ultrasound guided FICB with 0.375% ropivacaine 38 cc along with 2 cc normal saline making a total injection volume of 40 cc. This will serve as the control arm.
88802206|NCT02184520|Active Comparator|TRANSITION|Stabilization System
89124615|NCT02563171|Placebo Comparator|Healthy periodontium with obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
89124616|NCT02563171|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
89124617|NCT00586066|Placebo Comparator|Placebo|Placebo-matching memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to placebo-matching memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to placebo-matching memantine 5 mg in the morning and placebo-matching memantine 10 mg in the evening in Week 3; dose increase if tolerated to placebo-matching memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
89124618|NCT00586066|Experimental|Memantine|Re-purposed Alzheimer's drug to treat cognitive dysfunction associated with bipolar disorder. Memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to memantine 5 mg in the morning and memantine 10 mg in the evening in Week 3; dose increase if tolerated to memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
89124619|NCT00742105|Experimental|BGT226|
89124620|NCT00749593||CaHASE 1|Adults with CAH
89124621|NCT05259826|Experimental|patients with food hypersensitivity|
89124622|NCT05259826|Experimental|healthy controls|
89124623|NCT04273958|Experimental|Virtual reality|The intervention will consist of the use of a virtual reality helmet during the painful medical procedure. The content has been developed by a private company with the goal of providing a relaxing and soothing exploration of a virtual world.
89124624|NCT04273958|Active Comparator|Computer screen|The comparator will consist in the screening of the same virtual world on the computer screen.
89124625|NCT00630890|Experimental|1|External beam radiation with Cyberknife radiosurgery boost and concurrent capecitabine
89124626|NCT04260074||Oral Cancer group|20 consecutive patients with oral squamous cell carcinoma referred to the Department of Otolaryngology - Head and Neck Surgery
89124627|NCT04260074||Healthy oral mucosa group|20 controls with normal buccal mucosa upon examination.
89124628|NCT00728494||Treatment and Patient Assistance Program|Patient assistance program was provided to the participants treated with PegIntron/Rebetol. The support program consisted of training by physicians or specialized nurses on the significance of treatment compliance, methods for managing adverse events, and correct drug administration, as well as informational materials and assistance in the management of adverse events.
89124629|NCT00728494||Treatment Alone|PegIntron/Rebetol treatment only.
89124630|NCT02854904|Experimental|Dexmedetomidine intervention|Dexmedetomidine (1 ug/kg/hr) during anesthesia.
89124631|NCT02854904|Placebo Comparator|Placebo|Infusion of normal saline during anesthesia.
89124632|NCT04269746||Control group|The control population comprised normal healthy individuals.
89124633|NCT04269746||Precancerous group|patients with precancerous colorectal diseases
89124634|NCT04269746||CRC group|patients with colorectal cancer
89124635|NCT00728416|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
89124636|NCT00728416|Placebo Comparator|Arm 2|Matching placebo nasal spray
89124637|NCT02854826||UCLA Ronald Reagan Medical Center|"Site 1 (UCLA Regan Medical Center): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
89124638|NCT02854826||Huntington Hospital|"Site 2 (Huntington Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research Council/ Evidence Based Practice will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
89124639|NCT02854826||Torrance Memorial Hospital|"Site 3 (Torrance Memorial Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/ Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
88802207|NCT02184520|Active Comparator|REVERE|Stabilization System
89124640|NCT02853734|Experimental|SEVERE PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
89124641|NCT02853734|Other|NO PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
89124642|NCT00602264||1|Treatment-naïve patients with a recent diagnosis of anorexia nervosa
89124643|NCT00602264||2|The weight recovered subgroup of group 1
89124644|NCT00602264||3|Recovered patients with a previous history of anorexia nervosa but normal menstrual cycles and body weight at the present time
89124645|NCT00602264||4|Control group
89124646|NCT00728182|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
89124647|NCT00728182|Placebo Comparator|Placebo|
89124648|NCT00941330|Experimental|A: Exemestane|ARM A: Patients will be treated with exemestane.
89124649|NCT00941330|Active Comparator|B: Docetaxel and Cytoxan|ARM B: Patients will be treated with docetaxel and cytoxan.
89290147|NCT01123122|No Intervention|Standard glucose control|
89124650|NCT02594332|Experimental|Mepolizumab|100 mg SC every 4 weeks for 13 injections
89124651|NCT02594332|Experimental|Placebo|Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
89124652|NCT02852642|Experimental|Exercise|Power training model based in the potentiation of the stretch-shortening cycle.
89124653|NCT02852642|No Intervention|Control|Maintaining daily activities
89124654|NCT02857478|Experimental|Safety of a Sunscreen product|Sunscreen product safety evaluation under supervised out-door conditions on sport users.
89124655|NCT02593084|Experimental|Higher Intensity Resistance Training|Participants will take part in a 12-week higher-intensity resistance training protocol.
89124656|NCT02593084|Active Comparator|Lower Intensity Resistance Training|Participants will take part in a 12-week lower-intensity resistance training protocol that will serve as the active comparator.
89124657|NCT00686881|Experimental|PegIFN-2b|Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.
89124658|NCT00686881|Active Comparator|SNMC|Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.
89124659|NCT02857244|Other|Open-Label Treatment Arm|"Each patient will take Duloxetine 30mg for 1 week, followed by 60mg qam for 1 week, 90mg qam for 1 week, and 120mg qam for 1 week, if tolerated. The patient will be taking Duloxetine for a total of 4 weeks. The dose of Duloxetine will be reduced if the patient cannot tolerate. Donepezil will then be added to Duloxetine 120mg qam (or the highest dose the patient can tolerate) by 5mg qd for 1 week, followed by 10mg qd for 1 week.~After a 4-week washout period, each patient will take Modafinil 100mg qam for one week, followed by 200mg qam for 1 week.~Patients will come into the medical center on 5 occasions, 1 for screening/baseline, 1 after completion of duloxetine, 1 after completion of duloxetine+donepezil, 1 after four-week washout, 1 after completion of modafinil."
89124660|NCT04273256|Experimental|Myo-inositol arm|Patients will be supplemented with 2 grams of Myo-inositol + at least 400 μg of folic acid (received from routinely prescribed multivitamins) every day for 3 months before the IVF cycle.
89124661|NCT04273256|No Intervention|Control arm|Patients will receive at least 400 μg of folic acid from routinely prescribed multivitamins every day for 3 months before the IVF cycle.
89124662|NCT00921661|Experimental|AVE0005 (aflibercept)|
89124663|NCT00749827|Active Comparator|1|Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours
89124664|NCT00749827|Active Comparator|2|Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
89124665|NCT04088032|Experimental|Active|Experimental treatment
89124666|NCT04259372||Primary Diagnosis|Analysis of patient blood at primary diagnosis of AML
89124667|NCT04259372||Relapse|Analysis of patient blood at time point of relapse after allo-HCT
89124668|NCT04259372||Remission|Analysis of patient blood during remission after allo-HCT
89124669|NCT00742261|Experimental|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
89124670|NCT00727558|Active Comparator|narafilcon A|spherical soft contact lens worn as a daily disposable modality for one week
89124671|NCT00727558|Active Comparator|nelfilcon A|spherical soft contact lens worn as a daily disposable modality for one week
89124672|NCT02852408||Study|liver cauterized during laparoscopic cholecystectomy.
89124673|NCT02852408||Control|liver not-cauterized during laparoscopic cholecystectomy.
89124674|NCT02852096|Experimental|Dual or Multiple Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with Dual or Multiple Tumor Tissue Paraffin Blocks
89124675|NCT02852096|Active Comparator|One Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with One Tumor Tissue Paraffin Blocks
89124676|NCT02853266||patients KD|adults with a history of KD in childhood
89124677|NCT02853266||control group|healthy adults volunteers
89124678|NCT00688597|Experimental|Cohort 1|Regimen 1: Low-dose duvoglustat (2.5 grams [g]) once a day (QD) for 3 days, followed by no drug for 4 days, for 11 weeks.
89124679|NCT00688597|Experimental|Cohort 2|Regimen 1: High-dose duvoglustat (5.0 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks.
89124680|NCT00688597|Experimental|Cohort 3|Regimen 2: High-dose duvoglustat (5.0 g) QD for 7 days, followed by no drug for 7 days, for 11 weeks.
89124681|NCT00735904|Experimental|AG-013736/Cisplatin/Gemcitabine|
89124682|NCT00602732|Experimental|1|Participants assigned to the ROSE program
89124683|NCT00602732|Active Comparator|2|Participants assigned to enhanced care as usual
89124684|NCT02561923|Experimental|Rivaroxaban|Participants will be administered a single 20 milligram (mg) dose of rivaroxaban orally on Day 1 in Part 1.
89124685|NCT02561923|Experimental|Rivaroxaban plus tranexamic acid (TXA)|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.
89124686|NCT02561923|Experimental|Rivaroxaban plus Kcentra|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, participants will be randomized to receive a single dose of Kcentra (a 4-factor PCC), 50 international units per kilogram (IU/kg), intravenously administered (maximum rate of 210 [international units per minute] IU/min) on Day 4 in Part 2.
89124687|NCT02561923|Experimental|Rivaroxaban plus Saline|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, saline [Kcentra saline control or TXA saline control] on Day 4 in Part 2.
89233660|NCT01026129|Experimental|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia.
89233661|NCT01026129|Active Comparator|Lidocaine|Bolus dose of intravenous remifentanil 1mg/kg given once before emergence of general anesthesia.
89124688|NCT02852174|Experimental|Mindfulness group|The treatment groups will participate in a mindfulness intervention training that will meet for 2 hours once a week for eight weeks. The 8-week program provides participants with 2-hour weekly instruction designed to teach specific skills and how to apply them during stressful situations (e.g., when caring for or advocating for the veteran).Mindfulness training also requires that participants engage in daily home practice for 30 to 40 minutes. Participants will be required to record the duration of the meditation in log sheets.
89124689|NCT02852174|No Intervention|Control|Participants in the control may receive the mindfulness training after the wait period ends at which point they may receive the treatment as described above.
89124690|NCT00918190|Active Comparator|Ondansetron-Dexa group|Use 2 different antiemetics
89124691|NCT00918190|Active Comparator|Midazolam, Dexa group|use of midazolam and dexamethasone
89124692|NCT00918190|Placebo Comparator|Placebo|Saline will be given
89124693|NCT02852018||Appropriate treatment|Patients who have a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation
89124694|NCT02852018||No event|Patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive appropriate treatment during the follow up period of the study.
89124695|NCT00749905|Experimental|1|Low fiber diet for 5 days prior to procedure
89124696|NCT00749905|Active Comparator|2|regular diet
89124697|NCT02563327|Active Comparator|Standard Therapy|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
89124698|NCT02563327|Experimental|Rifapentine-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
89124699|NCT02563327|Experimental|Rifapentine- and Moxifloxacin-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg."
89124700|NCT04268186|Experimental|Direct tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target mid-cingulate cortex directly.
89124701|NCT04268186|Experimental|Indirect tDCS|Transcranial direct current stimulation (tDCS) was computationally optimized to target the middle frontal gyrus, a brain area connected to mid-cingulate cortex.
89124702|NCT04268186|Experimental|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be individually optimized to simultaneously stimulate key nodes connected to mid-cingulate cortex, including anterior insula, MFG and supramarginal gyrus.
89124703|NCT04268186|Sham Comparator|Sham tDCS|Placebo transcranial direct current stimulation (tDCS) will be applied.
89124704|NCT00918034|Experimental|LS11 (talaporfin sodium)|
89124705|NCT04272164|Active Comparator|technical taekwondo training|Light jogging,running, Stretching exercises,Pushups and sit ups, Punches,Kicks
89124706|NCT04272164|Experimental|weighted rope taekwondo training|weighted rope jump training along with tachnical taekwando training
89124707|NCT02593942|Experimental|group I|remifentanil
89124708|NCT02593942|Experimental|group II|remifentanil, propofol
89124709|NCT05381870|Experimental|Test preparation|Ezetimibe tablets: specification: 10mg; Package specification: 7 pieces / plate, 1 plate / box; Produced and provided by Changzhou Pharmaceutical Factory Co., Ltd.
89124710|NCT05381870|Active Comparator|Reference preparation|Ezetimibe Tablets：Ezetrol ®， Specification: 10mg, packaging specification: 10 pieces / plate, 1 plate / box; Licensee: MSD Pharma (Singapore) PTE. Ltd.
89124711|NCT00749983|Experimental|1|creatine intake
89124712|NCT00749983|Placebo Comparator|2|placebo (dextrose) intake
89124713|NCT02593240|Experimental|Human Performance Institute©|These participants will be part of the intervention sites and will receive the Human Performance Institute© intervention for the duration of the study (18 months).
88802208|NCT05486598|Experimental|AL8326(Fasting）|After screening, the subjects were randomly assigned to two sequence groups A and B. after fasting at least 10 hours overnight, they took al8326 tablets according to the requirements of two sequence groups A and B.
88802209|NCT05486598|Experimental|AL8326（Postprandial）|After screening, the subjects were randomly assigned to two sequence groups A and B. after fasting at least 10 hours overnight, they took al8326 tablets according to the requirements of two sequence groups A and B.
88802210|NCT01011634|Active Comparator|Moderate sedation|
89124714|NCT02593240|Experimental|The iDiet® with Voucher|These participants will be part of the intervention sites and will receive the iDiet® with Voucher for the duration of the study (18 months).
89124715|NCT02593240|Experimental|The iDiet® with Food|These participants will be part of the intervention sites and will receive the iDiet® with Food for the duration of the study (18 months).
89124716|NCT02593240|No Intervention|Wait-listed control|These participants will be part of the control sites and will participate in outcome assessments for a 6-month period only.
89124717|NCT00604292||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases
89124718|NCT00742339|Active Comparator|1|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 1.
89124719|NCT00742339|Experimental|2|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 2.
88802211|NCT01011634|Active Comparator|Oral medication|
88802212|NCT02137096|Experimental|High Dose Conditioning|Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation
88802213|NCT02132884|Active Comparator|Arm A (standard of care treatment)|Patients receive standard of care treatment based on the discretion of the treating physician.
89124720|NCT02594020|Other|dental bur versus air abrasion|1 tooth prepared with air abrasion versus one prepared tooth with dental bur
89124721|NCT02594020|Other|sono abrasion versus dental bur|1 tooth prepared with sono abrasion ans 1 tooth prepared with dental bur
89124722|NCT02594020|Other|air abrasion versus sono abrasion|1 tooth prepared with air abrasion versus 1 tooth prepared with sono abrasion
89124723|NCT02592928||Lleida Health Sector|"Lleida (168k inhabitants and 21 Primary Care centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
89124724|NCT02592928||Vic Health Sector|"Vic (49k inhabitants and 11 Primary Care Centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
89124725|NCT02592928||AISBE Health Sector|"Atenció Integral en Salut Barcelona Esquerra (AISBE) (540k inhabitants and 19 Primary Care centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
89124726|NCT02563249|Other|Dexterity, Coordination,Perception measurements|Dexterity, Hand-eye Coordination and Perception of Orientation and Distances
89124727|NCT02592772|Experimental|Reduced Nicotine Non-Menthol (RNC)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine non menthol cigarettes (RNC: NRC 200; 0.07 mg nicotine yield cigarettes without menthol) during the 6 week experimental phase.
89124728|NCT02592772|Experimental|Reduced Nicotine Menthol (RNC-Men)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine menthol cigarettes (RNC-Men: NRC 201; 0.07 mg reduced nicotine content menthol cigarettes) during the 6 week experimental phase.
89124729|NCT02592772|Experimental|Conventional Nicotine Non-Menthol (CN)|Study participants will be randomized from their own brand of menthol cigarettes to the regular/conventional nicotine non menthol cigarettes (CN: NRC 600; 0.8 mg nicotine content) during the 6 week experimental phase.
89124730|NCT02853188|Experimental|cancer of lung|
89124731|NCT00688519|Experimental|U0267 Foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
89124732|NCT00688519|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
89124733|NCT02851862||Late Onset GM2 Gangliosidosis|10-15 subjects with Late Onset GM2 Gangliosidosis
89124734|NCT02594176|Experimental|Test Product|2.2 g FLEXISEQ® twice daily
89124735|NCT02594176|Placebo Comparator|Placebo|2.2 g placebo twice daily
89124736|NCT00631202|Experimental|I|Treatment arm
89124737|NCT00747019|Experimental|PBPA|
89124738|NCT00747019|Active Comparator|PE|
89124739|NCT04269122||Part 1|30 eligible subjects will be asked to participate in 3 inpatient visits, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
89124740|NCT04269122||Part 2|90 eligible subjects will be asked to participate in 1 inpatient visit, each lasting up to 3 days (Day -1 to Day 2). Each visit will assess 24-hour ammonia levels in plasma and rate of urea production for 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis.
89124741|NCT02851784|Active Comparator|MWA only|The HCC patients will be treated only by MWA.No adoptive immunotherapy will be used.
89124742|NCT02851784|Experimental|MWA combined with immunotherapy|The HCC patients will be treated firstly by MWA, and then treated by courses of adoptive immunotherapy.
89124743|NCT02851628|Experimental|Alternative sizing model trial mask|In this arm participants who are randomized to the alternative sizing model based mask will be given the alternative sizing model based mask to use in home for the duration of this arm.
89124744|NCT02851628|Active Comparator|Prototype Full Face Mask (PFFM)|In this arm, participants who are randomized to the PFFM will be given the PFFM to use in-home for the duration of this arm.
89124745|NCT00721630|Experimental|1|The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.
89124746|NCT00602966||Slow Freeze|
89124747|NCT00602966||Vitrification|
89124748|NCT00686725|Active Comparator|Temozolomide + Radiation|"Standard therapy regimen:~Treatment will start 4 weeks after surgery. Temozolomide will be administered concomitantly with radiotherapy, at 75 mg/m^2/day orally for 42 days. Four weeks after completing concomitant radiotherapy, temozolomide will be administered for an additional six cycles. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m^2/day, and may be increased to 200 mg/m^2/day for Cycle 2 and subsequent cycles depending on nonhematological toxicity observed and neutrophil and platelet count values. Capsules containing 20 mg or 100 mg of temozolomide will be used.~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
89233662|NCT01026207||Chronic Obstructive Pulmonary Disease|Patients recruited from the Pneumology Clinic of UNIFESP, diagnosed with COPD stage II and III of Global Initiative for Chronic Obstructive Lung Disease, stable for three months, and with symptoms suggestive of Obstructive Sleep Apnea Syndrome.Patients has been underwent one night by polysomnography and one night with portable monitoring.
88802214|NCT02132884|Experimental|Arm B (genetic sequencing and targeted therapy)|Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing.
88802215|NCT02130622|Experimental|Promethazine|Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
88802216|NCT02130622|Placebo Comparator|Sugar Pill|Placebo P.O. t.i.d. for 4 weeks
89124749|NCT00686725|Experimental|Temozolomide alone, then Temozolomide + Radiation|"Early postsurgery temozolomide chemotherapy plus standard regimen:~Treatment with temozolomide alone will start 2 weeks after surgery at 75 mg/m^2/day orally for 14 days. Then, starting on Day 29 after surgery, temozolomide will be administered according to standard treatment as described for the temozolomide + radiation arm (standard therapy regimen).~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
89124750|NCT04204070|Experimental|Group I Accuro|epidural catheter insertion using the Accuro ultrasound imaging assisted technique
89124751|NCT04204070|Experimental|Group II APAD|epidural catheter insertion using the real time ultrasound guided technique combined with the use of the acoustic puncture assist device (APAD) technique.
89124752|NCT00727402||Observational|healthy patients fit into lotrafilcon A contact lenses for continuous wear
89124753|NCT04055623|Experimental|Intravenous infusion of Treg cells + Interleukin-2 injections|For the first six months: T-regulatory cells taken from a participant will be increased in numbers outside the body in a lab and then returned back to the same participant through intravenous (IV) infusions once per month. The participant will also take Interleukin-2 (IL2) injections three times per week.
89124754|NCT04055623|Placebo Comparator|Intravenous infusion w/Placebo + matching placebo injections|For the first six months: Participants will receive matching placebo or inactive intravenous (IV) infusions once per month. The participant will also take a matching inactive placebo injection three times per week.
89124755|NCT04055623|Experimental|2nd 6-months Open Label: Treg Infusions + IL-2 injections|For second six months: All participants will receive their own expanded/increased in numbers Treg cells by monthly infusion plus 3 times per week subcutaneous injections of IL-2.
89124756|NCT00604370||1|Acutely ill medical and surgical patients who were hospitalized at BWH, and at-risk for VTE, but were not treated with prophylaxis at hospital discharge.
89124757|NCT00604370||2|Acutely ill medical and surgical patients who were at risk for VTE at time of hospital discharge and prescribed a prophylaxis strategy.
89124758|NCT02561845||rosuvastatin group|patients who received rosuvastatin
89124759|NCT05381636|Active Comparator|Control group|Systemic intravenous chemotherapy with albumin paclitaxel 125 mg / m2 for D1, D8 + cisplatin 75 mg / m2 for D1, every 3 weeks for 1 cycle
89124760|NCT05381636|Experimental|Study group|esophageal arterial infusion chemotherapy
89124761|NCT00727246|Experimental|CDP-Choline|Treatment with CDP-Choline
89124762|NCT00727246|Placebo Comparator|Placebo|Treatment with Placebo
89124763|NCT04055701|Other|dichorionic diamniotic twin pregnancy|rutin examination: the assesment of fetal thymus volume at all cases.
89124764|NCT05381558|Experimental|spasmotic flatfoot patient|
89124765|NCT04055233|Experimental|Subcutaneous irrigation with 0.04% polyhexanide solution|"Intervention: after closure of abdominal fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml antiseptic solution (0.04% polyhexanide) will be done once for ten minutes.~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
89124766|NCT04055233|Active Comparator|Subcutaneous irrigation with NaCl (saline)|"Intervention: after closure of fascia, an intraoperative irrigation of the subcutaneous tissue with 250 ml NaCl (saline) will be done once for one minute.~No subcutaneous suture. Closure of skin with either staples, interrupted sutures or running suture."
89124767|NCT02592850|Experimental|Osteopathic Manipulative Treatment|Active manipulative treatment.
88802217|NCT02134912|Experimental|Arm I (crizotinib, pemetrexed disodium)|Patients receive crizotinib PO BID on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.
88802218|NCT02134912|Experimental|Arm II (pemetrexed disodium)|ARM II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Upon disease progression or symptomatic deterioration, patients may crossover to Arm I.
89124768|NCT02592850|Sham Comparator|Sham Osteopathic Manipulative Treatment|Sham manipulative treatment.
89124769|NCT00604448|Experimental|Pulse group|a group receiving a meal with pulses (5 cups/week) for 8 weeks
89124770|NCT00604448|Experimental|Energy-restricted group|a group with a diet restriction of 500 kcal/day for 8 weeks
89124771|NCT04268966|Experimental|CMX001|Initial dose of 200mg followed by 4 doses of 100mg
89124772|NCT04086706||Consecutive Patients with complete colonoscopy|Inclusion criteria were as follows: Patients older than 18 years, with a complete colonoscopy, for CRC screening or post-polypectomy surveillance or diagnostic assessment. Exclusion criteria precluded patients with previous colectomy or an abdominal surgery in the last 6 months, patients with polyposis syndromes or inflammatory bowel diseases and if they were unfit for polypectomy or the polyp specimen was not retrieved for histology.
89124773|NCT04269278||0 ng/ml|Blood specimen which was added 0 ul of dexmedetomidine
89124774|NCT04269278||0.5 ng/ml|Blood specimen which was added 0.25 ul of dexmedetomidine
89124775|NCT04269278||1.0 ng/ml|Blood specimen which was added 0.5 ul of dexmedetomidine
89124776|NCT04269278||1.5 ng/ml|Blood specimen which was added 0.75 ul of dexmedetomidine
89124777|NCT02562937|Experimental|Intervention|text messages related to sedentary behaviour
89124778|NCT02562937|No Intervention|Control|text messages unrelated to sedentary behaviour.
89124779|NCT02592616|Experimental|CON|Control (CON).
89124780|NCT02592616|Experimental|CW|Continuous Walking (CW).
89124781|NCT02592616|Experimental|IW|Interval Walking (IW).
89124782|NCT02853578|Experimental|Busonid (budesonide 200mcg and 400mcg)|"It´s a capsule with inhalatoin powder composed of budesonide 200mcg or 400mcg. The experimental drug will be dispensed in a cartridge containing 60 capsules of 200 mcg or 400 mcg and an inhaler. It should be stored at room temperature (between 15 and 30°C) and protected from moisture.~Regarding the dosage, the 80 study participants will perform an inhalation 200mcg every 12 hours (400 mcg / day). During follow-up visits (V1 and V2) the attending physician will assess the need for increased PSI dose to 400 mcg every 12 hours (800mcg / day). Study participants should rinse the mouth with water and / or brush your teeth immediately after use of the drug.~The duration of treatment may be 12 weeks."
89124783|NCT02562781|Active Comparator|Supplemental Oxygen|Inspired oxygen fraction > 0.5 and SpO2 = 98-100%
89124784|NCT02562781|Experimental|Air or supplemental oxygen|Air or lowest possible inspired concentration of oxygen to maintain SpO2 > 90%
89124785|NCT02591680|Experimental|Neuromuscular training|Neuromuscular, this arm will receive neuromuscular training and muscle strengthening.
89124786|NCT02591680|Active Comparator|Strength|Strength, this arm will receive only muscle strengthening.
89124787|NCT02562859|Experimental|GLPG1837 as oral suspension fasted|Single dose of 500 mg GLPG1837 as oral suspension after an overnight fast
89124788|NCT02562859|Experimental|GLPG1837 as oral tablet fasted|Single dose of 500 mg GLPG1837 as oral tablet after an overnight fast
89124789|NCT02562859|Experimental|GLPG1837 as oral tablet fed|Single dose of 500 mg GLPG1837 as oral tablet after a high-fat high-calorie breakfast
89124790|NCT00918268|Experimental|Influenza vaccine|
89124791|NCT02851238|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 6mL/kg of ideal body weight and positive end expiratory ventilation of 5cmH2O during one-lung ventilation
89124792|NCT02851238|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
89124793|NCT02592694|Experimental|Cocktail with thrombus aspiration|Intracoronary cocktail (tirofiban, bivalirudin, tenecteplase) injection combined with thrombus aspiration
89124794|NCT02592694|Active Comparator|Thrombus aspiration|Thrombus aspiration alone
89124795|NCT02591836|Experimental|Gemcabene 300 mg|Gemcabene 300 mg QD
89124796|NCT02591836|Experimental|Gemcabene 600 mg|Gemcabene 600 mg QD
89124797|NCT02591836|Experimental|Gemcabene 900 mg|Gemcabene 900 mg QD
89124798|NCT02591836|Placebo Comparator|Placebo|
89124799|NCT02591836|Active Comparator|Atorvastatin 10 mg|
89124800|NCT02591836|Active Comparator|Atorvastatin 40 mg|
89124801|NCT02591836|Active Comparator|Atorvastatin 80 mg|
89124802|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 10 mg|
89124803|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 40 mg|
89124804|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 80 mg|
89124805|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 10 mg|
89124806|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 40 mg|
89124807|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 80 mg|
89124808|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 10 mg|
89124809|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 40 mg|
89124810|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 80 mg|
89124811|NCT00603122|Experimental|1|fast ascent
89124812|NCT00603122|Active Comparator|2|slow ascent
89124813|NCT04056871||Fried Frailty Phenotype|This group of patients will be assess by using 5 characteristics of Frailty which are weight loss, weakness, exhaustion, low activity and physical fitness of the patients. Patients classify as frail will have more than 3 criteria, intermediate or pre-frail will be 1 or 2 criteria present and robust will not have criteria.
89124814|NCT04056871||Groningen Frailty Index|GFI is a simple questionnaire consisting of 15 items which are classified into 8 groups, consistent of 4 domains of functioning. A score of 4 or more indicates a higher risk for frailty and possible delirium.
89124815|NCT02851472|Experimental|Inhaled Nitric Oxide|iNO will be given at 20 ppm, continuous, via inhalation before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
89124816|NCT02851472|Active Comparator|Placebo|Placebo gas (nitrogen) will be given continuous, via inhalation at the same ppm, before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
89124817|NCT02562703|Active Comparator|ACTIVE tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
89124818|NCT02562703|Sham Comparator|SHAM tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be turned off after 60 seconds following previous trials.
89124819|NCT04268030||GBA mutation carriers with PD undergoing STN-DBS|
89124820|NCT04267952|Experimental|first group|Hand hygiene intervention program prepared by using planned behavior theory will be applied to the students in this group.
89124821|NCT04267952|Active Comparator|second group|Students in this group will be given classic hand hygiene training
89124822|NCT00687973|Experimental|Valsartan/amlodipine 160/10 mg|Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
89124823|NCT00687973|Active Comparator|Atenolol/amlodipine 100/10 mg|Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
89124824|NCT00747097|Experimental|1|gemcitabine+cetuximab
89124825|NCT00747253|Experimental|Single Active Arm|Only Arm. Patients treated using AutoLITT System.
89124826|NCT00747331|Experimental|A|
89124827|NCT00747331|Placebo Comparator|B|
89124828|NCT00747409|Active Comparator|Hum|use of human regular insulin and NPH insulin
89124829|NCT00747409|Active Comparator|Ana|use of insulin aspart and insulin detemir
89124830|NCT00752011|Experimental|Carboplatin + TAS-106|Carboplatin starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle. TAS-106 starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
89124831|NCT00721396|Experimental|B+R246|Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.
89124832|NCT00721396|Experimental|B246_R357|Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.
89124833|NCT00721396|Experimental|B+R234|Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.
89124834|NCT00721396|Active Comparator|R234|Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.
88802219|NCT01226485|Experimental|Taladegib|"Part A Cohort 1: 50 milligram (mg) taladegib administered orally QD on a 28-day cycle.~Part A Cohort 2: 100 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 3: 200 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 4: 400 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 5: 600 mg taladegib administered orally QD on a 28-day cycle.~Part C: 400 mg taladegib administered orally QD. Participants with advanced solid tumors.~Part D: 400 mg taladegib administered orally QD. Participants with advanced basal cell carcinoma (BCC)."
88802220|NCT05486442|Experimental|Experimental group|Participants in the experimental group received ACT training in the group setting aiming to reduce weight-related experiential avoidance. This included 6 sessions in total. Each session was completed approximately in 80 mins.
89124835|NCT00943826|Experimental|Bevacizumab + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy (RT) in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab 10 mg/kg IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they receive six 28-day cycle of bevacizumab 10 mg/kg IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive bevacizumab 15 mg/kg IV q3w until disease progression/unacceptable toxicity.
89124836|NCT00943826|Placebo Comparator|Placebo + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they will receive six 28-day cycle of placebo IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive placebo IV q3w until disease progression/unacceptable toxicity.
89124837|NCT00603200||Group 1|Patients with cirrhosis, who have refractory ascites requiring large volume paracentesis
89124838|NCT04268888|Active Comparator|TACE/TAE Alone|Transarterial Chemoembolisation (TACE) and/or Transarterial Embolisation (TAE) Alone.
89124839|NCT04268888|Experimental|TACE/TAE and Nivolumab|As above for TACE/TAE. Nivolumab adminstered as a flat dose of 480mg IV.
89124840|NCT00603356|Experimental|1|Dose Escalation
89124841|NCT02853110|Experimental|Hypo-FLAME|External beam radiotherapy, 5 additional MRI scans, blood sampling
89124842|NCT02852954||study group1|20 paraffin embedded blocks which was diagnosed endometrial cancer
89124843|NCT02852954||control group|20 paraffin embedded blocks of healthy women
89124844|NCT02852954||study group2|20 paraffin embedded blocks which was diagnosed endometrial hyperplasia
89124845|NCT02851316|Experimental|Whole Body Vibration|The WBV intervention consists of 6 bouts of 60 seconds vibration with 2 minutes of rest in between (30Hz, 2g acceleration) while participants stand on a vibrating platform with their knees bent.
89124846|NCT02851316|No Intervention|Control|The control intervention consists of 6 bouts of 60 seconds with 2 minutes of rest in between while participants stand with their knees bent (no vibration applied).
89124847|NCT02851394|Active Comparator|Levobupivacaine group|
89124848|NCT02851394|Experimental|Levobupivacaine + tramadol group|
89124849|NCT02851160||Patients requiring lung cancer chemotherapy|30 major Patients with lung cancer requiring chemotherapy either as palliative or adjuvant as surgical treatment having a semi-structured interview conducted by a clinical psychologist
89124850|NCT02851160||Family of lung cancer patients receiving chemotherapy|30 Family of lung cancer patients receiving chemotherapy having a semi-structured interview conducted by a clinical psychologist
89124851|NCT02851160||doctors caring for lung cancer patients receiving chemotherapy|15 doctors caring for lung cancer patients receiving chemotherapy 15 have a semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
89124852|NCT00603434|Experimental|1|Osmotic-Release Methylphenidate
89124853|NCT00603434|Experimental|2|Osmotic-Release Methylphenidate
88802221|NCT05486442|No Intervention|Control group|Participants in the control group did not receive any manipulation
88821366|NCT04413799|Active Comparator|paravertebral block with ropivacaine|Paravertebral block catheter will be placed by Anesthesiology led Acute Pain Service. Once the catheter is inserted, a ropivacaine bolus and infused with ropivacaine, monitored and titrated as necessary by Anesthesiologist led Acute Pain Service.
89124854|NCT00603434|Experimental|3|Osmotic-Release Methylphenidate
89124855|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group A (Fasting)|Participants will receive single dose of ASP2151 assigned to Group A on day 1
89124856|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group B (Fasting)|Participants will receive single dose of ASP2151 assigned to Group B on day 1
89124857|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group C (Fasting)|Participants will receive single dose of ASP2151 assigned to Group C on day 1
89124858|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group D (Fasting)|Participants will receive single dose of ASP2151 assigned to Group D on day 1
89124859|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group E (Fasting)|Participants will receive single dose of ASP2151 assigned to Group E on day 1
89124860|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group F (Fasting)|Participants will receive single dose of ASP2151 assigned to Group F on day 1
89124861|NCT02852876|Placebo Comparator|Part 1: Placebo Single Ascending Dose (Fasting)|Participants will receive single dose of matching placebo on day 1
89124862|NCT02852876|Experimental|Part 2: ASP2151 (Fasting)|Participants will receive a single dose of ASP2151 under fasted conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
89124863|NCT02852876|Experimental|Part 2: ASP2151 (Fed)|Participants will receive a single dose of ASP2151 under fed conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
89233663|NCT01026285||antipsychotic treatment|Risperidone Long-Acting injectable or oral antipsychotics According to label
88802222|NCT05484336|Experimental|Glucose as reference food|Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
88802223|NCT05484336|Experimental|Glucose beverage containing 4 g spirulina|Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
88802224|NCT05484336|Experimental|Glucose beverage containing 6 g spirulina|Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
88802225|NCT05484336|Experimental|Glucose beverage containing 8 g spirulina|Thirteen healthy young adults, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, two times, in different weeks as reference food along with 300 mL water; and 50 g available carbohydrates from beverages containing 4, 6 and 8 g spirulina, tested once, in different visits, along with 300 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120min postmeal. The first glucose sample was taken exactly 15min after the beginning of the consumption of the tested food.
88802226|NCT02094352|Experimental|Ketamine Infusion + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of KETAMINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three ketamine booster infusions over the course of three months."
89124864|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group G (Fasting)|Participants will receive single dose of ASP2151 assigned to Group G on day 1
89124865|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group H (Fasting)|Participants will receive single dose of ASP2151 assigned to Group H on day 1
89124866|NCT02851082|Experimental|Haemophilia A patients|Patients will perform endurance training program on 6 consecutive weeks
89124867|NCT01004003|Experimental|BIBF 1120|Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
89124868|NCT01004003|Active Comparator|Sorafenib|
89124869|NCT02871245|Active Comparator|Comparator Group|Patients received gastrointestinal neoplasms laparoscopic surgery but no acupuncture therapy.
89124870|NCT02871245|Experimental|Acupuncture Therapy Group|Patients received gastrointestinal neoplasms laparoscopic surgery and acupuncture therapy. Finish surgery up to 24 hours electricity acupuncture treatment, treatment 1 times a day, every time lasted 30 minutes, 5 days in a row
89124871|NCT00943670|Experimental|T-DM1 / T-DM1 + pertuzumab|"Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.~From Cycle 4, participants with early progressive disease (demonstrated prior to the end of Cycle 6) could receive combined pertuzumab and trastuzumab emtansine. Pertuzumab was administered after trastuzumab emtansine by IV infusion at a loading dose of 840 mg on Day 1, starting at the cycle after tumor progression was determined, followed by 420 mg IV infusion every 3 weeks in subsequent cycles.~Participants who met criteria for ongoing clinical benefit were allowed to continue study treatment in the absence of disease progression or unacceptable toxicity for up to 1 year."
89124872|NCT02851004|Experimental|BBI608 + Pembrolizumab|BBI608 and Pembrolizumab
89124873|NCT02850692|Experimental|Cystic fibrosis with portal hypertension|Mucoviscidosis with portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
89124874|NCT02850692|Experimental|Muco without portal hypertension|Mucoviscidosis without portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
89124875|NCT02850692|Experimental|Portal hypertension without muco|Portal hypertension without Mucoviscidosis. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
89124876|NCT02850692|Experimental|Healthy volunteers|Healthy volunteers. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®).
89124877|NCT00938366|Experimental|Cladribine followed by Cladribine + Pantoprazole|Subjects will receive a single dose of cladribine10 milligram (mg) orally on Day 1. After a wash out period of 10-25 days, subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose.
89124878|NCT00938366|Experimental|Cladribine + pantoprazole followed by Cladribine|Subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose. After a wash out period of 10-25 days, subjects will receive a single dose of cladribine 10 mg orally.
89124879|NCT00943592|Experimental|Treatment|
89233664|NCT01026363|Experimental|ergocalciferol|Ergocalciferol intervention arm
89124880|NCT00943124|Experimental|MK0524B then Simvastatin + MK0524A|"Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).~Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets."
89233665|NCT01026363|Experimental|calcitriol|calcitriol intervention arm
88802227|NCT02094352|Placebo Comparator|Control Group + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of SALINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three saline booster infusions over the course of three months."
88802228|NCT05486364|Experimental|Study group|All subjects will receive both standard of care monitoring and digital rhythm monitoring using a PPG based smartphone application for AF recurrence after the PVI procedure.
88802229|NCT05478876|Experimental|carbon ion radiotherapy|Patients affected by pelvic recurrence of gynecological cancer, who had not undergone to previous pelvic irradiation, will be enrolled on this study. After enrollment, patients undergo baseline exams, simulation CT and MRI and then carbon ion radiation therapy treatment will be performed, according to trial indications.
88802230|NCT02552238|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
88802231|NCT01188421|Active Comparator|buprenorphine|Sublingual buprenorphine/naloxone tablets (or placebo)
88802232|NCT01188421|Active Comparator|clonidine|Oral clonidine tablets (or placebo)
88802233|NCT01188421|Experimental|tramadol ER|Oral tramadol tablets (or placebo)
88802234|NCT04424082|Other|dead space removal|external dead space will be removed and Vcap parameters (VCO2, PaCO2 and alveolar dead space) recorded before and after.
89124881|NCT00943124|Experimental|Simvastatin + MK0524A then MK0524B|"Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.~Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg)."
89124882|NCT05381246|Experimental|Acupressure group|A total of 18 minutes of compression will be applied to each point for three minutes, as the Heart Meridian is at the 7th point (HT7), the Large Intestine Meridian is at the 4th point (LI4) and the pericardial meridian is at the 6th point (PC6).
89124883|NCT05381246|Experimental|Reiki group|In the reiki group the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
89124884|NCT05381246|No Intervention|Control group|
89124885|NCT02850926|Experimental|Soccer head gear|Subjects who are wearing soccer head gear during the practices and games during the soccer season.
89124886|NCT02850926|No Intervention|Control|Subjects who are not wearing soccer head gear during the practices and games during the soccer season.
89124887|NCT00285974|Experimental|hip prosthesis|
89124888|NCT00726622|Active Comparator|Arm 1: Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection. The standard form of surgery is open laparotomy rectal resection. During open laparotomy, the surgeon makes a large incision or cut in the abdomen, and goes in through that cut to remove the tumor and lymph nodes from the rectum.
89124889|NCT00726622|Experimental|Arm 2: Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection. Laparoscopic-assisted rectal resection is performed using small instruments on long handles introduced into the abdomen through small ports called trocars in 3 - 6 positions on the abdomen through incisions measuring 5 -10 mm, under the guidance of a video camera. The abdominal wall is held up with carbon dioxide under pressure. The piece of bowel or intestine is removed through another incision (about 8 centimeters), and the ends of the intestine are reconnected to provide normal bowel function.
89124890|NCT04086394|Experimental|PECS Block|Group who was randomly selected to receive the intraoperative nerve block.
89124891|NCT04086394|Sham Comparator|Control|Patient who was randomly selected not to receive intraoperative nerve block
89124892|NCT03953872||ARB|Group of angiotensin receptor blockers(ARB) monotherapy users. A subject was considered as an ARB user when the total prescription days of ARB monotherapy was at least 30.
89124893|NCT03953872||combination of CCB and ARB|Group of calcium channel blockers(CCB) and angiotensin receptor blockers(ARB) combination users. A subject was considered as a CCB and ARB combination user when the total prescription days of CCB and ARB combination therapy was at least 30.
89124894|NCT03953872||CCB|Group of calcium channel blockers(CCB) monotherapy users. A subject was considered as a CCB user when the total prescription days of CCB monotherapy was at least 30.
89124895|NCT03953872||No treatment|Group of nonusers of antihypertensives. A subject was considered as a nonuser never received regular antihypertensive treatment or total prescription days of antihypertensives was less than 30.
89124896|NCT00940316|Experimental|Arm A: Erlotinib + Panitumumab + Irinotecan|Patients receive oral erlotinib hydrochloride once daily on days 1-14, panitumumab IV over 30-90 minutes on day 1, and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
89124897|NCT00940316|Experimental|Arm B: Erlotinib + Panitumumab|Patients receive oral erlotinib hydrochloride once daily on days 1-14 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients receive irinotecan hydrochloride as in arm A.
89124898|NCT00940316|Experimental|Arm C: Erlotinib + Panitumumab|Patients receive erlotinib hydrochloride and panitumumab as in arm B.
89124899|NCT02850770|Other|Control|Pedometers and walking logs
89124900|NCT02850770|Experimental|Phone Messaging|Phone Messaging
89124901|NCT02850770|Experimental|Phone Messaging + Family/Friend Support|Phone Messaging + Family/Friend Support
89124902|NCT02850614|Active Comparator|Control|Fifty participants in the control condition will each receive a FitBit to track their physical activity. Instead of interfacing with a gaming app on their Chromebooks to track physical activity, control condition participants will interface with a minimalist activity tracker showing them only how many minutes of MVPA they've done over the course of the day. It is expected that after several weeks of baseline use, control condition participants will no longer find the FitBit novel. In order to encourage control condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
89233666|NCT01026441|Other|Treatment for cellulite and circumference reduction|All subjects will be treated with the device
89290148|NCT03933228||Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
89124903|NCT02850614|Experimental|Intervention|Fifty participants will be randomized to the intervention condition, which will use a gaming application to encourage physical activity, as physical activity goal achievement will translate into rewards in the game. Physical activity will be tracked using a FitBit activity monitor and in order to encourage intervention condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
89124904|NCT02850848|Experimental|Entigin Film Coated Tablet 0.5mg|Entigin Film Coated Tablet 0.5mg Dosing Regimen: Single dosing of two tablets
89124905|NCT02850848|Active Comparator|Baraclude 0.5mg Tablets|Baraclude 0.5mg Tablets Dosing Regimen: Single dosing of two tablets
89124906|NCT00604526|Experimental|1|Questionnaires, Iridium 192 radioactive seeds
89124907|NCT05381168|Experimental|Calcium from fish bone|The volunteer will receive calcium from fish bone 4 capsules per day for 6 months.
89124908|NCT05381168|Active Comparator|Calcium carbonate|The volunteer will receive calcium carbonate 2 tablets per day for 6 months.
89124909|NCT00263432|Experimental|1|Implantation of fresh human allogenic chondrocytes
89124910|NCT00604604|No Intervention|1|Control group (usual postpartum care)
89124911|NCT00604604|Experimental|2|Experimental group (usual postpartum care plus telephone-based support from an experienced mother who has participated in a 4-hour training session)
89124912|NCT05383040|Experimental|percutaneous release|Percutaneous release of A1 pulley release will be performed in the well-managed operation theater set up, using an 18 gauge hypodermic needle, after preparation of the skin and injection of 1ml 2% plain lidocaine. The proper location of the pulley will be defined using surface landmarks in each digit after waiting a few minutes to allow the anesthetic to take effect the 18 gauge needle will be longitudinally moved to keep the level of the needle parallel with the tendon grating sensation will be elucidated confirming the cut of pulley until there is no grating sensation felt and improvement of symptoms. A sterile dressing will be placed.
89124913|NCT05383040|No Intervention|Steroid injection|The steroid injection mixed with 1 ml of methyl prednisone (40mg) with 0.5 ml of 2% plain lidocaine will be inserted into the flexor tendon sheath over the A1 pulley, which will also be performed in the operation theater for patient safety.
89124914|NCT04268810|Experimental|Chondroitin sulphate 2%|chondoritin sulphate 2% ( Uracyst) for bladder instillation. One bladeer instillation per week during 6 weeks.
89124915|NCT04268810|Active Comparator|DMSO 50%|DMSO 50% in saline for bladder instillation. One bladder instillation per week during 6 weeks
89124916|NCT00726388|Experimental|A|IV administration of multiple doses of DIC075V (intravenous diclofenac sodium) over multiple days
89124917|NCT00572455|Experimental|Stage 1: PF-04217329 - Lowest Dose|
89124918|NCT00572455|Experimental|Stage 1: PF-04217329 - Low Dose|
89124919|NCT00572455|Experimental|Stage 1: PF-04217329 - Middle Dose|
89124920|NCT00572455|Experimental|Stage 1: PF-04217329 - High Middle Dose|
89124921|NCT00572455|Experimental|Stage 1: PF-04217329 - High Dose|
89124922|NCT00572455|Experimental|Stage 1: PF-02417329 - Highest Dose|
89124923|NCT00572455|Experimental|Stage 1: PF-04217329 - Vehicle|
89124924|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost Vehicle|
89124925|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost Vehicle|
89124926|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost Vehicle|
89124927|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost 0.005%|
89124928|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost 0.005%|
89124929|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost 0.005%|
89124930|NCT00572455|Experimental|Stage 2: PF-04217329 - Vehicle + Latanoprost 0.005%|
89124931|NCT01003691|Experimental|Arm 1|
89124932|NCT00752167||Case|all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff
89124933|NCT00752167||Control|control athletes (ie, not currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff and/or not currently using asthma medications) from the same sport
89124934|NCT00752323|Experimental|Arm I: Newly diagnosed GBM 10mg/kg|Arm I: Newly diagnosed GBM patients receive oral aminolevulinic acid(10mg/kg)at 6 hours before the midpoint of surgery.
89124935|NCT00752323|Experimental|Arm II: Newly diagnosed GBM 20mg/kg|Arm II: Newly diagnosed GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
89124936|NCT00752323|Experimental|Arm III: Recurrent GBM 10mg/kg|Arm III: Recurrent GBM patients receive oral aminolevulinic acid (10mg/kg)at 6 hours before the midpoint of surgery.
89124937|NCT00752323|Experimental|Arm IV: Recurrent GBM 20mg/kg|Arm IV: Recurrent GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
89124938|NCT00686335|Experimental|Lodotra|After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.
89124939|NCT00686335|Active Comparator|Cortancyl|During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.
89124940|NCT01002989||All eligible patients|"Subjects assessed for hypertension, were subjected to the measurement of ankle brachial index (ABI) by two methods:~Doppler~WatchBP Office oscillometric The order for performing the two methods was randomized."
89124941|NCT00685945|Experimental|Control (bradykinin infusion)|Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)
89124942|NCT00685945|Experimental|L-NMMA + bradykinin|N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)
89124943|NCT00685945|Experimental|Isosorbide + L-NMMA + bradykinin|Isosorbide (NO donor)
89124944|NCT00685945|Experimental|Sildenafil + L-NMMA + bradykinin|Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor
89124945|NCT00628823|No Intervention|A1|Gluten-containing diet
88802235|NCT01006018|Experimental|Sitagliptin + Pioglitazone PLACEBO|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone PLACEBO daily by mouth"
88802236|NCT01006018|Experimental|Sitagliptin + Pioglitazone|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone (TZD) 15 mg daily by mouth"
88802237|NCT01006018|Placebo Comparator|PLACEBO|"Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth~+ pioglitazone (TZD) PLACEBO daily by mouth"
89124946|NCT00628823|Active Comparator|A2|Gluten-free diet
89124947|NCT04296461|Experimental|Welgenaleucel (UWC19)|Part I The safety and efficacy of Welgenaleucel (UWC19) will be evaluated in a standard 3+3 dose escalation approach.The planned dose escalation cohort levels for Welgenaleucel (UWC19) are 4, 8, 12, 16 and 20 x10^6 CAR-T cells/kg administered intravenously once.
89124948|NCT00747487|Experimental|1|Idebenone
89124949|NCT00747487|Placebo Comparator|2|Placebo
89124950|NCT00747175|Experimental|1|3 (alt.4) gradually increasing repeated oral doses of AZD1656 given to 3 (alt.4) groups (6 on active and 2 on placebo in each group)
89124951|NCT00747175|Experimental|2|Oral dose of AZD1656 titrated during 3 days to a tolerable dose (15 on active and 5 on placebo)
89124952|NCT01007123|Experimental|A3309 low dose|Administered once daily for the duration of the study
89124953|NCT01007123|Experimental|A3309 intermediate dose|Administered once daily for the duration of the study.
89124954|NCT01007123|Experimental|A3309 high dose|Administered once daily for the duration of the study
89124955|NCT01007123|Placebo Comparator|Placebo|Administered once daily for the duration of the study
89124956|NCT00687739|Placebo Comparator|1|GnRH agonist + placebo
89124957|NCT00687739|Active Comparator|2|GnRH agonist + placebo + exercise
89124958|NCT00687739|Experimental|3|GnRH agonist + Estradiol
89124959|NCT00687739|Experimental|4|GnRH agonist + Estradiol + exercise
89124960|NCT00752401|Active Comparator|1|6800 IU/day of Cholecalciferol (Vitamin D3) orally for one year
89124961|NCT00752401|Placebo Comparator|2|Oral placebo solution daily for one year
89124962|NCT02871089|Experimental|24/7 Closed loop delivery|Unsupervised home use of day and night automated closed-loop insulin delivery system FlorenceM (Medtronic 640G insulin pump, guardian 3 CGM and Android smartphone) of CamAPS FX (Dana insulin pump, Dexcom G6 CGM and App on Android smartphone) until 24 months after diagnosis
89124963|NCT02871089|Active Comparator|Multiple Daily Injections|Participants will apply standard insulin therapy using multiple daily injections via insulin pens during the 24 months control period
89124964|NCT00750451|Experimental|LMWH|Women in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone
89124965|NCT00750451|Active Comparator|Control|Women in the control arm are administered routine luteal phase support without the addition of LMWH
89124966|NCT00747721|Experimental|1|Dexmedetomidine
89124967|NCT01006889|Experimental|Exenatide (twice daily)|Patients with T2DM well-controlled on an intensified insulin regimen for the previous 6 months by the will have their insulin aspart discontinued and replaced for exenatide twice daily while continuing the bedtime detemir insulin. Safety and efficacy parameters will be measured before and after 6 months of treatment.
89124968|NCT02561767|Experimental|MSCs group|"Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.~The third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx."
89124969|NCT02561767|Placebo Comparator|Control group|Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
89124970|NCT04060069||Before pneumoperitoneum|Fluid administration
89124971|NCT00747799|Experimental|1|Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
89124972|NCT04294823||FRANCE - CHU creteil|An internal physical examination including vital signs measurements and a 13C-UBT with the standard test meal (Helicobacter Test INFAI) will be performed. Patients with a positive UBT will undergo upper endoscopy. All biopsy samples will be analysed in the local laboratory of the centre. Patients with a negative UBT will undergo also upper endoscopy. Endoscopic procedures and subsequent investigations will be identical in patients with a positive and with a negative UBT. H. pylori positive and negative patients will perform the 13 C-UBT breath tests with new test meal on Day 30. The study will be conducted in outpatients. Starting on Day 1, H. pylori positive and negative patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast. Patients will return to the hospital/medical practice for UBT breath tests with new test meal on Day 30. Patients will be followed-up for 7 days after discontinuation of PPI treatment.
89124973|NCT02870543|Placebo Comparator|Placebo|Placebo
89124974|NCT02870543|Active Comparator|Phytolacca decandra|The Phytolacca decandra with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
89124975|NCT02870543|Active Comparator|Melissa officinalis|The Melissa officinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
89124976|NCT02870543|Experimental|Phyt.decandra + Melissa offic.|The combination of Phytolacca decandra with Melissa offcicinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
89124977|NCT04294433|Active Comparator|Infanrix-hexa+Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2, 4 and 18 months with a standard dose of Infanrix-hexa
89124978|NCT04294433|Experimental|Infanrix-hexa+Infanrix-hexa|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa
89124979|NCT04294433|Experimental|Infanrix-hexa+Twinrix|Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa and a standard dose of Infanrix-Junior, respectively
89124980|NCT04294511|Experimental|Experimental|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
89124981|NCT01001429|Active Comparator|Propofol|propofol 1mg/kg as a bolus intravenously followed by an infusion of 25-100 ug/kg/min
88802238|NCT05478642||retrospective analysis|A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
88802239|NCT05478642||prospective study|Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022
89124982|NCT01001429|Experimental|dexmedetomidine infusion|Subject will receive a bolus of0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug.
89124983|NCT04294121|Experimental|Children|"Children aged 5-13 years, all genders, will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Children will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Children will also be asked to rank the cereals in order of their preference (i.e., Most (1) to Least (6)). Children will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
89124984|NCT04294121|Experimental|Parents|"Parents or guardians of the children in the study will be exposed to a set of breakfast cereals displaying varying child-appealing and parent-appealing marketing techniques as well as varying degrees of child-appealing marketing power on their packaging. Parents will be asked to determine if each individual cereal is child-appealing (i.e., yes or no). Parents will also be asked to rank the cereals in order of which they would be most likely to purchase for a child (i.e., Most (1) to Least (6)). Parents will then participate in a focus group discussion about the why they classified/ranked the cereals the way that they did."
89124985|NCT01000961|Experimental|RP103 Q12H|
89124986|NCT01000961|Active Comparator|Cystagon® Q6H|
89124987|NCT01000805|Experimental|Duloxetine|
89124988|NCT01000805|Placebo Comparator|Placebo|
89124989|NCT02870387|Active Comparator|Usual Inpatient Care|Usual Inpatient Care: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
89124990|NCT02870387|Experimental|Comprehensive Care with Inpatient Consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
89124991|NCT00684307|Experimental|1|AZD0837 450 mg
89124992|NCT00684307|Experimental|2|AZD0837 200 mg
89124993|NCT00684307|Experimental|3|AZD0837 300 mg
89124994|NCT00684307|Experimental|4|AZD0837 150 mg
89124995|NCT00684307|Active Comparator|5|Vitamin-K antagonist at INR 2-3
89124996|NCT00683917|Experimental|Proellex 25 mg|Proellex 25 mg
89124997|NCT00683917|Experimental|Proellex 50 mg|Proellex 50 mg
89124998|NCT00683917|Active Comparator|Lupron|Lupron Depot
89124999|NCT00750529|Experimental|Galantamine|
89125000|NCT04053595|Experimental|Estimated Oxygen Extraction|
89125001|NCT04053595|Active Comparator|Dynamic Parameters|
89125002|NCT02561689|Experimental|Fissure sealant material 1|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
89125003|NCT02561689|Experimental|Fissure sealant material 2|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
89125004|NCT00747877|Experimental|Arm I|Patients receive high-dose melphalan IV on day -1 followed by autologous stem cell transplantation (ASCT) on day 0.
89125005|NCT00747877|Experimental|Arm II|Patients receive low-dose cyclophosphamide IV or orally once a week for 12-20 weeks for a total of 12 courses.
89125006|NCT00750763|Active Comparator|1|PEG (Colonlytely) - 4 litres
89125007|NCT00750763|Active Comparator|2|Picosulphate (Picolax/Picoprep) - 2 sachets
89233667|NCT01322997|Experimental|Myomo + RTP|This group will be administered a regimen comprised of repetitive task specific practice (RTP) in conjunction with use of the robotic brace described elsewhere in this record.
89125008|NCT00750763|Active Comparator|3|Sodium Phosphate (Fleet) - 2 bottles
89125009|NCT04056091|Experimental|Back rub stimulation|
89125010|NCT04056091|Active Comparator|Foot flicks stimulation|
89125011|NCT00752713||1|Patients presenting to hospital with AMI
89125012|NCT00752713||2|healthy volunteers as control group
89125013|NCT02562391|Active Comparator|PVI+Box lesions|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.
89233668|NCT01322997|Active Comparator|Myomo|Patients in this group will only be administered the robotic brace described elsewhere in this record.
89233669|NCT01322997|Active Comparator|RTP only|Patients in this group will be administered repetitive task specific practice (RTP), emphasizing use of their affected arms during performance of valued, functional tasks.
89290149|NCT03933228||Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
89125014|NCT02562391|Experimental|PVI+Box lesions+LAA cutting|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.The left atrial appendage was removed by stapling and then cutting.
89125015|NCT00748111|Experimental|1|Sudden cardiac death hospitalized
89125016|NCT00748111|Experimental|2|Acute myocardial infarction
89125017|NCT00748111|Experimental|3|Angioplasty procedures programmed
89125018|NCT00748111|Experimental|4|Sudden cardiac death hospitalized without coronary syndrome
89125019|NCT00750997||Hypertonic saline|Hypertonic resuscitation
89125020|NCT00750997||Control: normal saline|Normal saline resuscitation
89125021|NCT00748345|Experimental|1|Caspofungin (drug)
89125022|NCT00752869|Placebo Comparator|B|This group will meet the same inclusion and exclusion criteria as the group receiving the study drug
89125023|NCT00752869|Active Comparator|A|This arm will receive the active medication dutasteride
89125024|NCT00748423|Experimental|1|Nitric Oxide in nitrogen
89125025|NCT00748423|Placebo Comparator|2|Nitrogen
89125026|NCT00751309||1|Lung and heart-lung transplanted subjects.
89125027|NCT00751387||1|
89125028|NCT00751465|Active Comparator|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997)
89125029|NCT00751465|Active Comparator|Standard CBT|standard Cognitive Behavior Therapy, standard CBT following the model of Clark and Wells (1995).
89125030|NCT00751465|No Intervention|Wait list control|Wait list control group
89125031|NCT00687271|Experimental|MK-6213 160 mg + Atorvastatin 20 mg|1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks
89125032|NCT00687271|Active Comparator|Atorvastatin 20 mg|1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks
89125033|NCT00687271|Experimental|MK-6213 160 mg|1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks
89125034|NCT00687271|Placebo Comparator|Placebo|1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks
89125035|NCT02562625|Experimental|Pembrolizumab Alone|If the patient is randomised to the Pembrolizumab Arm Only then they will receive 200mg of pembrolizumab every 3 weeks.
89125036|NCT02562625|Experimental|Pembrolizumab plus Radiotherapy|If The patient is randomised to this arm they will receive 200mg of pembrolizumab every 3 weeks in combination with a radiotherapy dosage of 24Gy in 3 fractions to be given over 3 consecutive days (only).
89125037|NCT00752947|Experimental|A|
89125038|NCT00752947|Active Comparator|B|
89233670|NCT01023399|Experimental|Artesunate + Amodiaquine|"Oral fixed combination of artesunate (AS) and amodiaquine (AQ)~Once daily, dose according to age~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)~Adults: >= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)~3 day-treatment"
89233671|NCT01026519|Experimental|Dose 1|Active dose
89125039|NCT04617275|Experimental|Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 120 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
89125040|NCT04617275|Experimental|Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
89125041|NCT04617275|Experimental|Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 80 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
89125042|NCT04617275|Experimental|Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
89125043|NCT04617275|Placebo Comparator|Arm 5 - Placebo in subjects with T2DM and Obesity|Matching Placebo tablets taken twice a day (BID)
89125044|NCT04617275|Experimental|Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
89125045|NCT04617275|Experimental|Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
89125046|NCT04614545|Experimental|Virtual Visits|"All patients will be seen face to face on visit 1. Patient will be evaluated by an obesity-medicine specialist and also by a registered dietitian and exercise physiologist via telemedicine. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated), and will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored remotely and patients will receive a remote scale and a remote blood pressure cuff.~Subjects will then initiate 3 one to one virtual visits with the obesity specialist. On each of this visit the five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. A personalized nutrition and exercise program will be developed. If felt relevant by the provider, subjects may also be referred to a mental health specialist and/or sleep clinic. All medical care will be provided virtually."
89125047|NCT04614545|Active Comparator|Face to face visits|"All patients independently of the randomization arm will be seen face to face on visit 1. Patients will be evaluated by an obesity-medicine specialist and patient will also be seen face to face by a registered dietitian and exercise physiologist. Subjects will be prescribed phentermine (37.5 mg po daily; dose may be reduced if not tolerated). Patients will choose one of two dietary programs (Mediterranean or Keto diet). Weight and vital signs will be monitored in each of the visits.~Subjects will then initiate 3 face to face visits with the obesity specialist provider every 4 weeks. The five pillars of weight management will be discussed including nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress.~The patient will be provided a personalized nutrition and exercise program and may be referred to a mental health specialist and/or sleep clinic per provider discretion. All medical care will be provided via a face-to-face manner."
89125048|NCT04611503|Experimental|Subretinal injection of rAAV.hPDE6A|Single subretinal injection of rAAV.hPDE6A
89125049|NCT01031537|Other|FSME-IMMUN 0.5mL Baxter|FSME-IMMUN 0.5mL Baxter is non-US licensed vaccine for tick-borne encephalitis virus. The FSME-IMMUN 0.5mL Baxter is available as 0.5mL in a pre-loaded vaccine syringe. All participants received active vaccine using a rapid immunization schedule, with vaccine administration on Days 0, 14, 161 and 245. Participants that tested seropositive for tick-borne encephalitis virus or subjects that developed positive viral neutralizer titers after the 3rd or 4th vaccine were given a booster of FSME-IMMUN 0.5mL Baxter vaccine at 3, 6 and 9 years after enrollment.
89125050|NCT01031381|Other|Rad001/Bevacizumab|Patients will receive RAD001 by mouth everyday and Bevacizumab IV every 14 days until clinical progression.
89125051|NCT00685399|Experimental|Cohort 1|Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.
89125052|NCT00685399|Experimental|Cohort 2|Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.
89125053|NCT00685399|Experimental|Cohort 3|Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.
89125054|NCT00685399|Experimental|Cohort 4|Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.
89125055|NCT00685399|Experimental|Cohort 5|Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.
89125056|NCT00685399|Experimental|Cohort 6 Arm 1|Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).
89125057|NCT00685399|Experimental|Cohort 6 Arm 2|Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).
89125058|NCT00685399|Experimental|Cohort 6 Arm 3|Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.
89125059|NCT00753025|Experimental|CD133|
89125060|NCT00753025|Experimental|TNC|
89125061|NCT00753025|Placebo Comparator|Placebo|
89125062|NCT00751699|Experimental|1|Asacol 6x400 mg Q24h at 7 am for 7 days
89125063|NCT00751699|Experimental|2|Asacol 2x400 mg Q8h at 7 am, 3 pm, and 11 pm for 7 days
89125064|NCT00751699|Experimental|3|Lialda 2x1.2g Q24h at 7 am for 7 days
89125065|NCT00753103|Experimental|1|Patients with active vasculitis who receive infliximab in addition to standard immunosuppressive therapy
89125066|NCT00753103|Active Comparator|2|Patients with active ANCA associated vasculitis who receive standard immunosuppression but no infliximab
89125067|NCT00753181|Experimental|A1|Diabetes Meal Plan with Experimental Diabetes-Specific nutritional shake
89125068|NCT00753181|Active Comparator|A2|Usual diet
89125069|NCT00753181|Experimental|A3|Diabetes Meal Plan with Experimental Diabetes-Specific Nutritional Shake, diabetes specific Cereal, and diabetes specific snack bars.
89125070|NCT02562547||All Vaginal Births|The application of the Hem-Avert Perianal Stabilizer
89125071|NCT00748735||A1|heart failure patients undergoing CRT implantation
89125072|NCT00748813|Other|1|
89125073|NCT00748891|Experimental|1|Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression
89125074|NCT00685165|Experimental|Primidone 50 mg Tablets|A single dose of primidone 50 mg administered after an overnight fast of at least 10 hours.
89125075|NCT00685165|Experimental|Primidone (Mysoline®) 50 mg Tablets|A single dose of Mysoline® 50 mg administered after an overnight fast of at least 10 hours.
89125076|NCT00749047|Experimental|1|Open label arm
89125077|NCT00753259|Experimental|AF Clinic|
89125078|NCT00753259|Active Comparator|Care as Usual|
89125079|NCT04052815|Experimental|Diabetes prevention program culturally tailored|Adult females with Hispanic background
89125080|NCT00683449|Experimental|IV infusion of MN-221|MN-221 total dose of 240 mcg
89125081|NCT00683449|Placebo Comparator|MN-221 PLACEBO|i.v. infusion of MN-221 Placebo for 15 min
89125082|NCT02561533|Experimental|BRAF immunohistochemistry (IHC)|
89125083|NCT00751855|Active Comparator|1|Prolonged Exposure therapy with Hydrocortisone
89125084|NCT00751855|Placebo Comparator|2|Prolonged Exposure therapy with placebo
89125085|NCT00755833||A|
89125086|NCT00753493|Experimental|1|This is a one arm pharmacokinetic and safety study.
89125087|NCT00753571|Active Comparator|1|1,CTG,po
89125088|NCT00753571|Placebo Comparator|2|
89125089|NCT02561143|Experimental|Intervention group|Patients in the intervention group will be given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
89125090|NCT02561143|Placebo Comparator|Control group|Patients in the control group will be given whole wheat flour (100 g) daily along with nutritional counseling and physical activity counseling for six months.
89125091|NCT04055857||NIID|NIID patients
89125092|NCT04055857||HC|healthy control
89125093|NCT00683293|Active Comparator|1|Randomized group of patients receiving conventional laparoscopic hysterectomy
89125094|NCT00683293|Active Comparator|2|Randomized group of patients receiving robot-assisted laparoscopic hysterectomy
89125095|NCT02561611|No Intervention|Control Group|"Usual Working Condition Group (UWC)~The no-intervention control condition will be asked to maintain their usual work and lifestyle throughout the study. Participants may be contacted by Pennington Biomedical staff during the intervention."
89125096|NCT02561611|Experimental|Intervention Group|"Combined Intervention (Walk More and Pedal Desk; WMPD)~Participants in the WMPD condition will engage in both step-counting (Walk More, WM) and pedal desk (PD) intervention components."
89125097|NCT00755989|Placebo Comparator|1|group to receive topical gel without morphine
89125098|NCT00755989|Experimental|2|Morphine gel
89125099|NCT00756067|Experimental|Formulation 1|
89125100|NCT00756067|Experimental|Formulation 2|
89125101|NCT00756067|Experimental|Formulation 3|
89125102|NCT00756067|Experimental|Formulation 4|
89125103|NCT00756067|Experimental|Formulation 5|
89125104|NCT00756067|Experimental|Formulation 6|
89125105|NCT00756067|Active Comparator|23 valent pneumococcal vaccine|
89125106|NCT00726232|Experimental|Ruxolitinib 10 mg BID|Participants received 10 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
89125107|NCT00726232|Experimental|Ruxolitinib 25 mg BID|Participants received 25 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
89125108|NCT00726232|Experimental|Ruxolitinib 50 mg QD|Participants received 50 mg Ruxolitinib orally once a day (QD) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
89125109|NCT05434975|Experimental|Blocked|All participants will have single-shot interscalene brachial plexus block with same technique. There is no comparing.
89125110|NCT05354596|Experimental|STRICT LUNG|Central Tumors in the Lung The tumor is considered central when the tumor is located within 0.5 -2.5 cm in all directions of the PBT or the esophagus. The PBT includes trachea, main bronchi and intermediate bronchus and 5 lobar bronchi. In addition, the tumor is also considered central, if it is located <0.5 cm from the spinal cord, heart and aorta.
89125111|NCT05354596|Experimental|STAR LUNG|Ultra-Centrally Tumors in the Lung Ultra-centrally located tumors are tumors located within the 0.0 to 0.5 cm zone of trachea, main bronchi or intermediate bronchus. The patient will be excluded if the tumor invades the trachea, bronchi, esophagus, or pericardium/heart (radiological or by bronchoscopy assessment).
89125112|NCT04053205|Experimental|1 Gentuximab+ Paclitaxel|8 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
89125113|NCT04053205|Experimental|2 Gentuximab+ Paclitaxel|12 mg/kg Gentuximab administered intravenously (IV) on D1 and D15（28 days every cycle）+ 80 mg/m² paclitaxel administered IV on D1, D8 and D15
89125114|NCT02559973|Experimental|RBP-6000 - Light MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a light molecular weight (MW) polymer.
89125115|NCT02559973|Experimental|RBP-6000 - Heavy MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a heavy molecular weight (MW) polymer.
89125116|NCT02559973|Active Comparator|RBP-6000 - Intermediate MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with an intermediate molecular weight (MW) polymer (reference).
89125117|NCT00753883|Active Comparator|1|simvastatin 20 mg/qd for 8 weeks, and then add on ezetrol 10mg (if ldl-c . 160mg/dl) for another 8 weeks.
89125118|NCT00753883|Active Comparator|2|ezetrol 10 mg/qd for 8 weeks, and then add on simvastatin 20 mg qd (if ldl-c . 160mg/dl) for another 8 weeks
89125119|NCT00753961|Active Comparator|1|fermented dairy product
89125120|NCT00753961|Placebo Comparator|2|non fermented acidified dairy product.
89125121|NCT02561377|Experimental|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
89125122|NCT02561377|Experimental|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
89125123|NCT02561377|No Intervention|standard care|standard care complied with the daily lifestyle.
89125124|NCT00720382|Experimental|1|0.15% azelastine hydrochloride 1644 mcg
89125125|NCT00720382|Experimental|2|Mometasone furoate 200 mcg
89125126|NCT00754039|Experimental|1|Welchol + TriCor
89125127|NCT00754039|Placebo Comparator|2|Welchol + placebo
89125128|NCT00756145|Experimental|1|Injection of LMWH at the start of the hemodiafiltration session, at the inlet bloodline
89125129|NCT00756145|Experimental|2|Injection of LMWH 5 minutes after the start of the hemodiafiltration session, at the inlet bloodline
89125130|NCT00756145|Experimental|3|Injection of LMWH at the start of the hemodiafiltration session, at the outline bloodline
89125131|NCT02592538|Experimental|RFA+stent+S-1|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.
89125132|NCT02592538|Placebo Comparator|RFA+stent|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
89125133|NCT02560909|Experimental|Experimental|The experimental group will receive one dose MF59 adjuvanted intramuscular vaccine.
89125134|NCT02560909|Active Comparator|Control|The control group will receive one dose of the standard 2015-2016 nonadjuvanted vaccine.
89125135|NCT00756223|Experimental|Arm A|BI 831266 24h infusion on day 1 and day 15 every 4 weeks
89125136|NCT00756223|Experimental|Arm B|BI 831266 24h infusion on day 1 every 3 weeks
89125137|NCT02592226|Active Comparator|Control group|
89125138|NCT02592226|Experimental|Protocol Group|
89125139|NCT00756301|Active Comparator|Traditional Technique|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
89125140|NCT00756301|Experimental|Alternative Technique|Local anesthetic (Lidocaine) injected using an alternative technique (inserting the numbing needle into the deeper tissues first and injecting numbing medication from there up to the skin).
89125141|NCT00756301|No Intervention|No Anesthetic|No local anesthetic is used.
89125142|NCT00756535|Experimental|1|Group-based exercise training during hospitalization
89125143|NCT00756535|Active Comparator|2|Usual treatment and rehabilitation during hospitalization
89125144|NCT04086628||Asthmatic children vaccinated|
89125145|NCT04086628||Asthmatic children unvaccinated|
89125146|NCT00756691||1|First 5 consecutive 18F-FAZA avid subjects that undergo up to 5 PET scans, 13 blood and 2 urine samples over 4.5 hours
89125147|NCT00756691||2|Next 5 consecutive 18F-FAZA avid subjects that undergo up to 4 PET scans, 8 blood and 2 urine samples over 5.5 hours
89125148|NCT00720226|Experimental|Losartan|Losartan 100 mg daily
89125149|NCT00720226|Placebo Comparator|Placebo|Placebo 1 pill daily
89125150|NCT04049929|Experimental|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
89125151|NCT00754117||All patients|All patients
89125152|NCT05434507|Experimental|K-clipTM transcatheter annuloplasty system|
89125153|NCT00725920|Experimental|Topiramate|patients receiving the active drug: topiramate
89125154|NCT00725920|Placebo Comparator|Placebo Control group|patients received pills content placebo, that were identical to the pills content active drug
89125155|NCT00754195|Active Comparator|1|Insertion distance of thoracic epidural catheter: 3 cm
89125156|NCT00754195|Active Comparator|2|Insertion distance of thoracic epidural catheter: 5 cm
89125157|NCT00754195|Active Comparator|3|Insertion distance of thoracic epidural catheter: 7 cm
89125158|NCT00754273||1|PAL samples collected for pneumonia evaluation
89125159|NCT00725842||Peg-IFN alfa-2b + ribavirin|Participants with chronic hepatitis C (CHC) treated with Peg-IFN alfa-2b + ribavirin as first treatment, in common clinical practice, who had negative hepatitis-C virus (HCV)-ribonucleic acid (RNA) by the end of treatment (24 or 48 weeks per product labeling).
89125160|NCT04051723|Experimental|The dexamethasone plus ropivacaine group|Patients in the dexamethasone plus ropivacaine group will receive a peri-incisional scalp infiltration with 0.025% dexamethasone and 0.2% ropivacaine and normal saline miscible liquids.
89125161|NCT04051723|Active Comparator|The ropivacaine group|Patients in the ropivacaine group will receive a peri-incisional scalp infiltration with 0.2% ropivacaine and normal saline miscible liquids.
89125162|NCT00756847|Experimental|1|
89125163|NCT02591602|Experimental|CASI|Teleradiology service for patients residing at home or in nursing homes
89125164|NCT02591602|No Intervention|CONTROLLI|X-ray hospital department
89125165|NCT04051567|Experimental|LDA group|
89125166|NCT04051567|No Intervention|NC group|
89125167|NCT00756925||1|Cocaine dependent females
89125168|NCT00756925||2|Cocaine dependent males
89125169|NCT05427097|Active Comparator|Active|"The treatment consisted of placing 10 active Helical patches spread as follows:~Two in the upper cervical area (suboccipital);~Two in the lower cervical area (near the 5th and 6th vertebrae);~Two in the upper trapezius muscle area (between neck and shoulder);~Four in the tender point area (as reported by the patient)."
89125170|NCT05427097|Placebo Comparator|Placebo|"The treatment consisted of placing 10 placebo Helical patches spread as follows:~Two in the upper cervical area (suboccipital);~Two in the lower cervical area (near the 5th and 6th vertebrae);~Two in the upper trapezius muscle area (between neck and shoulder);~Four in the tender point area (as reported by the patient)."
89125171|NCT00757081|Experimental|1|
89125172|NCT00757159|Experimental|1|
89125173|NCT00757159|Active Comparator|2|
89125174|NCT00757315|Experimental|1|
89125175|NCT00757315|Active Comparator|2|
89125176|NCT00757393|Active Comparator|1|
89125177|NCT00757393|Experimental|2|
89125178|NCT00754351|Experimental|1|Bevacizumab->Docetaxel->Gemcitabine
89125179|NCT02561065|Experimental|Lifestyle intervention high risk group.|Participants in the intervention group will receive the intervention on top of standard care.
89125180|NCT02561065|No Intervention|Standard care high risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
89125181|NCT02561065|Experimental|Lifestyle intervention low risk group.|Participants in the intervention group will receive the intervention on top of standard care.
89125182|NCT02561065|No Intervention|Standard care low risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
89125183|NCT00725764|Experimental|Single Arm|Participants who qualified for study entry received 240 mg of GSK1363089 (foretinib) on a 5-day on 9-day off schedule every 2 weeks.
89125184|NCT00754429|Experimental|A|Losartan 50mg qd for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
89125185|NCT00754429|Active Comparator|B|Amlodipine 5 mg q.d for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
89125186|NCT00754507|Experimental|1|colesevelam tablets and atorvastatin tablets
89125187|NCT00754507|Placebo Comparator|2|colesevelam HCl placebo tablets and atorvastatin tablets
89233672|NCT01026519|Experimental|Dose 2|Active dose
89233673|NCT01026519|Experimental|Dose 3|Active 3
89125188|NCT00754585||I|"All participants will perform the five Chair Support tasks: (1) quiet standing, sitting, (2) upper back unsupported, (3) sitting, upper back unsupported with Logic Back in place, (4) sitting in a standard ergonomic chair, and (5) sitting in a standard ergonomic chair with Logic Back in place. Aside from the Quiet Standing trials which will be performed first, the order of Chair Support will be randomized. Participants will perform the Chair Support task for 30 minutes while quietly watching a movie DVD of their choice. The DVDs provided will the light in content without a lot of suspense or emotion. Data will be collected for the final two minutes of each 30-minute trial."
89125189|NCT00725608||Patients|Opioid dependent patients currently in maintenance treatment with another medication who are switched to Suboxone (buprenorphine plus naloxone)
89125190|NCT00757471|Active Comparator|Group 1|Brillant Blue
89125191|NCT00757471|Active Comparator|Group 2|Indocyanine Green
89125192|NCT00725452||Infliximab|Subjects with plaque psoriasis will receive Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
89125193|NCT00725296||Remicade (Infliximab)|Participants with active and progressive PsA who have responded inadequately to disease-modifying anti-rheumatic drugs will receive induction infusions of Remicade at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. Whole observation period cannot exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in the Summary of Product Characteristics (SPC) is taken into consideration.
89125194|NCT02591524|Experimental|Cystic fibrosis airway colonization|Flexible bronchoscopy via the nasal route on the date of baseline visit, nasal lavage at baseline and after 6 month
89125195|NCT03957616||Paraneoplastic neurological syndromes patients|Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.
89125196|NCT02591368|Active Comparator|Ligament reconstr. tendon interposition|Ligament reconstruction, tendon interposition.
89125197|NCT02591368|Active Comparator|Mini Tight rope with one-suture|Mini Tight rope with one suture
89125198|NCT02591368|Active Comparator|Mini Tight rope with two-suture|Mini Tight rope with two sutures
89125199|NCT04019392|Active Comparator|Wetted ice with elastic wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied to each participants' lower leg for 30 minutes using an elastic wrap. The elastic wrap will be applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half. The elastic wrap application will consist of pulling the wrap to its full tension, measuring the length of the wrap, and calculating 75% of the total length to apply to the body part.
89125200|NCT04019392|Active Comparator|Game Ready|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
89125201|NCT00719680|Experimental|IgPro20|The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)
89125202|NCT02592460|Experimental|poor-polyamines diet|
89125203|NCT02592460|Active Comparator|high-polyamines diet|
89125204|NCT02592304|Other|dual energy ct|
89125205|NCT00719212|Experimental|AMG 479|AMG 479 administered on day 1 of each 21-day cycle up to disease progression, unacceptable toxicity, withdrawal of consent or sponsor decision to stop the study.
89125206|NCT02592148||Health subjects|Male and female
89125207|NCT00585052|Experimental|Paclitaxel and lovastatin|Paclitaxel given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly. Lovastatin self-administered at 80mg daily.
89125208|NCT00724282|Other|Eszopiclone or Placebo|Subjects receive either eszopiclone or placebo for 9 days, followed by 3 week washout, then crossover to opposite treatment. Treatment is double-blinded.
89125209|NCT04086238|Other|Formulation A Fasted|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
89125210|NCT04086238|Experimental|Formulation A Fed|EPI01 Formulation A (moderate release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
89125211|NCT04086238|Other|Formulation B Fasted|EPI01 Formulation B (slow reelase): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
89125212|NCT04086238|Experimental|Formulation B Fed|EPI01 Formulation B (slow release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
89125213|NCT04086238|Other|Formulation C Fasted|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fasting conditions. Single oral administration with 250mL of water.
89125214|NCT04086238|Experimental|Formulation C Fed|EPI01 Formulation C (retarded release): 3 capsules each containing decitabine (5 mg) and THU (250 mg) administered under fed conditions. Single oral administration with 250mL of water.
89125215|NCT02591992|Active Comparator|Cardiac CT|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo computed tomography angiography (cardiac CT) as the first-choice imaging diagnostics
89125216|NCT02591992|Active Comparator|Invasive coronary angiography|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo invasive coronary angiography
89125217|NCT00724126|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
89125218|NCT00724126|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
89125219|NCT04085926|Experimental|Sealed shoe|"Therapeutic footwear including off-the-shelf therapeutic shoes and custom-made insoles. The shoe on the ulcerated foot is sealed, i.e., made irremovable, with a plastic band."
89125220|NCT04085926|Active Comparator|Total contact cast|A irremovable custom-made total Contact cast enclosing the foot and shin
89125221|NCT04086004|Experimental|Group I Experimental Motor Imagery|Motor imagery practice
89125222|NCT04086004|Experimental|Group II Dual Task Training|Dual-task balance training
89125223|NCT02592070|Experimental|30 minute treadmill walking|All participants will walk on the treadmill for 30 minutes and perform a battery of cognitive tasks immediately prior, immediately after, and one hour after completion of the 30 minute walking period.
89125224|NCT02591212|Active Comparator|#ConnectDots|"Green Dot Intensive Bystander Training (INT Condition) (Randomized):~Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.~Administered by: UK VIP Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training."
89125225|NCT02591212|Placebo Comparator|#ConnectWell|"Wellness Initiatives for Student Empowerment delivered by UK's Student Wellness Office Programming: Addresses elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.~Administered by: UK VIP/Student Wellness Ambassadors Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training"
89125226|NCT00723892||PegIntron/Rebetol and psychotherapy support program|Participants receiving a psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
89125227|NCT00723892||PegIntron/Rebetol alone (no psychotherapy)|Participants receiving no psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
89125228|NCT00718666|Experimental|Group A|Subjects who were previously vaccinated with one dose of GSK134612 at 12 months of age.
89125229|NCT00718666|Experimental|Group B|Subjects who were previously vaccinated with two doses of GSK134612, one each at 9 and 12 months of age.
89125230|NCT00718666|Experimental|Group C|Subjects aged 5-6 years not previously administered meningococcal vaccine.
89125231|NCT04086940|Active Comparator|esmolol(breviblock) group|Patients in group E received a loading dose of esmolol(breviblock) 1 mg/kg in 50 ml isotonic saline over 30 minutes before induction of anesthesia, then followed by an infusion of esmolol 10 µg/kg/min until the end of the surgery.
89125232|NCT04086940|Active Comparator|non esmolol group|Patients in group N received 50 ml of isotonic saline over 30 min, followed by an infusion of isotonic saline at same rate of group E till the end of the surgery.
89125233|NCT04085692|Experimental|Intervention|"The intervention group begins LDHF dispatcher training with one introduction week followed by twelve weeks of LDHF training.~During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs."
89125234|NCT04085692|No Intervention|Comparison|During the study period, all regular quality improvement (QI) activities, such as self-audits, case reviews, mentor groups, and status meetings will continue for all EMDs.
89125235|NCT00718510|Active Comparator|L-arginine first/placebo second|Patients with diagnosis of schizophrenia will be randomised to receive L-arginine first/placebo second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
89125236|NCT00718510|Placebo Comparator|Placebo first/L-arginine second|Patients with diagnosis of schizophrenia will be randomised to receive placebo first/L-arginine second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
89125237|NCT02590900||at delivery|women who underwent cesarean at delivery, and needed iv paracetamol as part of multimodal analgesia. In these cases, paracetamol was administered q6h (2g loading dose, 1g q6h for 24 h), and blood and urine samples were collected to describe paracetamol disposition at delivery.
89125238|NCT02590900||postpartum|a subgroup of 8 women initially included in at delivery, underwent a second PK study 2-3 months postpartum and another PK study about 1 year after delivery. This PK study was based on a single iv paracetamol administration (2 g), and blood and urine samples were collected to describe paracetamol disposition in postpartum
89125239|NCT02590900||healthy female volunteers|"a group of 8 young healthy women not on oral contraceptives underwent a single PK study (2 g intravenous paracetamol) and blood and urine samples were collected to described paracetamol disposition in healthy female volunteers, not on oral contraceptives.~Raw data as published by Gregoire et al (Clin Pharm Ther 2007) were available in 14 young women, all on contraceptives."
89125240|NCT00585286|Experimental|Fractional carbon dioxide laser system|Thirty total healthy subjects from two research centers with skin type I-IV of moderate to severe acne scarring received treatment with the 10,600 nm fractional carbon dioxide laser system.
89125241|NCT02591914|Experimental|Altering regimens of Fovista™and Anti-VEGF Therapy|"All subjects will be treated with Fovista™ 1.5 mg/eye in combination with anti-VEGF therapy.~The following doses of Anti-VEGF therapy will be delivered based on the Investigator's discretion:~Lucentis® 0.5 mg/eye~Avastin® 1.25 mg/eye~Eylea® 2 mg/eye~Subjects will be treated with Fovista™ and Anti-VEGF therapy every month for the first three months.~The regimen for administration of each intravitreal agent will be as follows:~Injection Day #1-Administration of Fovista™ 1.5mg/eye~Injection Day #2-Administration of Fovista™ 1.5mg/eye followed by anti-VEGF therapy after Fovista™ injection~The same regimen will be delivered monthly until the subject reaches maximum visual acuity benefit. Maximum visual acuity is defined as no increase in ETDRS visual acuity at two consecutive visits.~Subsequent re-treatment with the Anti-VEGF therapy will use a PRN (as-needed) regimen based on protocol specified retreatment criteria."
89125242|NCT00723190|Experimental|Arm A|CLONICEL (Clonidine HCl sustained release)
89233674|NCT01026519|Placebo Comparator|Dose 4|Placebo dose
89233675|NCT00451191|Active Comparator|1|100 units botulinum toxin type A (BoNT/A)
89233676|NCT00451191|Active Comparator|2|300 units botulinum toxin type A (BoNT/A)
89290150|NCT01215162|Experimental|Single arm study|Patients with stage T1/T2No breast cancer receiving breast conserving treatment
89125243|NCT02591758||Stable Angina with coronary angiogram|This study aims to correlate the biometric data collected and derived from the Hexoskin with the standard physiological assessment, in patients referred for coronary angiography for limiting angina. Afterwards, the clinician will decide of the best treatment strategy for the patient: coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) or no revascularization.
89125244|NCT00722800|Experimental|A|drospirenone and ethinyl estradiol
89125245|NCT00722800|Placebo Comparator|B|Placebo
89125246|NCT00718042|Experimental|1|All subjects will have their blood tested by the investigational Chagas screening assay.
89125247|NCT00718042|Experimental|2|Testing of blood donor samples with the investigational Chagas screening assay. Samples that test positive will be also tested with the Chagas confirmatory assay.
89125248|NCT04087252|Experimental|vaccinated group|Neoantigen vaccination will be performed with 6 doses in total, once per week
89125249|NCT00741598|Experimental|Galantamine-ER|Participants will receive treatment with extended release galantamine
89125250|NCT00741598|Placebo Comparator|Galantamine placebo|Participants will receive treatment with placebo.
89125251|NCT02590978|Experimental|Early cholecystectomy|Cholecystectomy within the first 72 hours of admission.
89125252|NCT02590978|Other|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy is delayed until normalization of laboratory values, abdominal pain resolves and oral intake is restored.
89125253|NCT04084600|Experimental|Intervention Group|Once a week for 6 consecutive weeks, this group will receive a manual therapy protocol with an approach based on Taylor et al., 1990; Schleip et al., 2012; Bienfait, 1999 and Myers, 2016, lasting 20 minutes, focused on the upper quadrant homolateral to the surgery. Shortly thereafter, this group will participate in a kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
89125254|NCT04084600|Sham Comparator|Sham Group|Once a week for 6 consecutive weeks, this group will receive a soft and shallow traditional massage, lasting 20 minutes. Shortly thereafter, this group will participate to the same kinesiotherapy protocol with stretching, mobility and strengthening exercises, also for 20 minutes. All sessions will be individual.
89125255|NCT00717886|Experimental|1|Patients with documented axillary metastases (Stage II breast cancer) will undergo subdermal injection of technetium sulfur colloid (TSC) into the ipsilateral upper extremity approximately 3 hours before surgery.
89125256|NCT04085770|Experimental|Alfacalcidol|Patients allocated to the alfacalcidol group received 2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay.
89125257|NCT04085770|No Intervention|Control|Control group were exposed to the same conditions as the treatment group except they were not given one-alfacalcidol.
89125258|NCT03941392||Healthy children between 1 and 9 years old|A sample of 1500 apparently healthy children between 1 to 9 years old from urban areas from different regions of Spain.
89125259|NCT02589886|Active Comparator|intervention|This arm will receive the education and self-help internet intervention added to usual care
89125260|NCT02589886|No Intervention|control|This arm will receive usual care only
89125261|NCT00741286|Placebo Comparator|Asprin (100mg) plus placebo|Asprin (100mg) plus placebo
89125262|NCT00741286|Active Comparator|Asprin (100mg) plus cilostazol (200mg)|Asprin (100mg) plus cilostazol (200mg)
89125263|NCT02596204|Active Comparator|Data Upload|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. Subjects will continue to receive usual diabetes care. Phone calls and emails to the diabetes clinic will be initiated by the family.
89125264|NCT02596204|Experimental|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (diabetes educator, nurse practitioner and/or physician) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
89125265|NCT02589730|Experimental|online mutual management|The patients received the online coaching of a doctor and diabetes educator via smart phone based welltang app.
89125266|NCT02589730|Experimental|online self-management|The patients received the online coaching of a doctor alone via smart phone based welltang app.
89125267|NCT02589730|No Intervention|hospital regular management|The patients received usual care and did not use smart phone.
89125268|NCT02596048|Other|Iomeron|Patients will undergo a injection of Iomeron if they are scheduled to undergo an elective thoraco-abdominal aorta, carotid, pulmonary or peripheral MDCTA examination
89125269|NCT04085302|Experimental|All subjects|
89125270|NCT05684770|Experimental|4G Tablet|
89125271|NCT03946540||L-FED sample|All young people treated in Maudsley Child and Adolescent Eating Disorder Service between 1/8/2009 and 31/1/2014.
89125272|NCT04085224|Active Comparator|1|
89125273|NCT04085224|Experimental|2|
89125274|NCT04085224|Experimental|3|
89125275|NCT05282524|Experimental|Simulated patient|Women recruited from a general population subject to inclusion/exclusion criteria, who will participate at a minimum four times in the study
89125276|NCT05282524|Experimental|Naive patient|Women recruited from a general population subject to inclusion/exclusion criteria, who will participate only once in the study
89125277|NCT02590744|Experimental|eye patch|cover the sick eye with eye patch for 3 hours preoperatively.
89125278|NCT02590744|Placebo Comparator|non-eye patch|do not cover the sick eye before surgery.
89125279|NCT04084132|Experimental|Early re-valving|60 patients who are assigned to early re-valving undergo pulmonary valve replacement within 3 months from randomization.
89125280|NCT04084132|Experimental|Later re-valving|60 patients who are assigned to later re-valving undergo pulmonary valve replacement when the current European guideline criteria are met.
89125281|NCT05040334|Active Comparator|group(1)|69 patients receiving a single dose of oral doxycycline (200 mg) and metronidazole (500 mg)tablets
89125282|NCT05040334|Placebo Comparator|Group (2)|69 patients receiving placebo
89125283|NCT00716092|Placebo Comparator|Placebo|Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
89125284|NCT00716092|Experimental|Linagliptin|Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
89125285|NCT00716092|Active Comparator|Sitagliptin|Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.
89125286|NCT02590510|Experimental|The small dose of group|The dose of methotrexate is 10 mg
89125287|NCT02590510|Active Comparator|The high dose of group|The dose of methotrexate is 15 mg
89125288|NCT05245864|Experimental|physical therapy with blood flow restriction|
89125289|NCT05245864|Other|physical therapy without blood flow restriction|Standard of care.
89125290|NCT02590666|Experimental|Bipolar electrode|Polyps resection with bipolar electrode
89125291|NCT02590666|Active Comparator|Microscissors or graspers|Polyps resection with microscissors or graspers
89125292|NCT00919204|Experimental|Cohort 1|
89125293|NCT00715624|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
89125294|NCT00715624|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
89125295|NCT02589574|No Intervention|Control|Subjects of the control group will receive the usual announcement on the dates and times of offering free influenza vaccination, and reminder from hospital, and access to informational flyers posted at the hospital
89125296|NCT02589574|Experimental|Intervention|Subjects of the intervention group besides the usual information same as those stated in the control group, will receive four reminders on dates and details for free influenza vaccine. Together with the reminder, electronic text messages of educational information will be received
89125297|NCT00919282|Experimental|Gemcitabine/folinic acid/5-FU|Gemcitabine 1g/m² 5-FU 750mg/m² FS 500 mg/m²
89125298|NCT02590276|Experimental|Evaluation|Characterization
89125299|NCT00754663|Active Comparator|1|exercise training
89125300|NCT00754663|Placebo Comparator|2|control arm: normal behavior, no additional exercise will be advised
89125301|NCT05398159|Experimental|treatment|3 bi-weekly treatments
89125302|NCT00576199|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks and within 24-48 hours prior to each transarterial chemoembolization (TACE) until disease progression or unmanageable toxicity. TACE was conducted for 4 sessions at 8-10 week intervals.
89125303|NCT02560831|Experimental|Therapeutic exercise and Pompage|strengthening exercises, balance training and knee's pompage
89125304|NCT02560831|Active Comparator|Control|Educational lectures.
89125305|NCT00754819|Active Comparator|1|Colchicine 1mg daily oral
89125306|NCT00754819|Placebo Comparator|2|Placebo 1 capsule daily oral
89125307|NCT00715078|Active Comparator|Cohort A|Sipuleucel-T with the concentration of 10 μg/mL PA2024 in a cell suspension of 1 x 10^7 peripheral blood mononuclear cells (PBMCs) per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
89125308|NCT00715078|Active Comparator|Cohort B|Sipuleucel-T with the concentration of 5 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
89125309|NCT00715078|Active Comparator|Cohort C|Sipuleucel-T with the concentration of 2 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
89125310|NCT02589652||Switch group|Patients who have been assigned to pegylated interferon alfa-2a.
89125311|NCT02589652||Sequential combination group (S-C group)|Patients who have been assigned to pegylated interferon alfa-2a plus entecavir.
89125312|NCT02589652||ETV group|Patients who have been assigned to entecavir monotherapy.
89125313|NCT02590042|Experimental|ADSC-SVF-002|Cells will be administered at 1x10^6 cells/mL of defect. If administered with fat, the cells will be administered at 1.2x10^6 cells/mL of defect.
89125314|NCT00679627|Experimental|Galantamine|Galantamine 8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
89125315|NCT00679627|Placebo Comparator|Placebo|Matching placeco
89125316|NCT00714688|Experimental|001|prolonged release (PR) OROS methylphenidate 54 mg 18+36mg once daily for 13 weeks
89125317|NCT00714688|Experimental|002|prolonged release (PR) OROS methylphenidate 72 mg 2x36mg once daily for 13 weeks
89125318|NCT00714688|Placebo Comparator|003|Placebo 2xplacebo once daily for 13 weeks
89125319|NCT05165212|Experimental|Patients receiving one dose of amoxicillin.|Patients receiving one dose of amoxicillin and then observed for one hour for signs/symptoms off allergic reaction.
89125320|NCT00679549|Experimental|DEVICE|Provided CPAP as an inpatient
89125321|NCT00679549|No Intervention|Control|No device provided
89125322|NCT00754897||1|"We will do a database search to identify children less than 1 year of age that have undergone inguinal hernia surgery during the years of 1999-2007, and children who have had inguinal hernia surgery between the ages of 1 and 3 years during the years 1999-2007.~We will then do a telephone interview of the parents of these children to determine if there are siblings that are within three years of age and have not have any exposure to anesthetics agents or sedatives before their 3rd birthday."
89125323|NCT00754975|Experimental|I|JACTAX LD DES
89125324|NCT00754975|Active Comparator|II|TAXUS™ Libertè™ DES
89125325|NCT05163418|Experimental|Flat feet|People with flat feet according to foot posture index (validated by clinical assessment)
89125326|NCT05163418|Experimental|High arches feet|People with high arches feet according to foot posture index (validated by clinical assessment)
89125327|NCT05163418|No Intervention|Normal arches feet (control group)|Control group
89125328|NCT04051099|Experimental|bilateral cervical plexus block|bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 0.25% bupivacaine 16 mg)
89125329|NCT04051099|Experimental|General anesthesia|General anesthesia with endotracheal intubation under total intravenous anesthesia (TIVA)
89125330|NCT02589418|Experimental|Healthy subjects|All subjects participate at 3 experimental conditions (Acupuncture, Sham-Acupuncture and No Acupuncture) at 3 different days in a randomized order.
89290151|NCT03932838|Experimental|clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
88802240|NCT04424238|No Intervention|Standard Clinic Prenatal Care (Control Group)|pregnancy's prenatal care appointment would be changed to once every two weeks when diagnosed with GDM. Doctors generally ask GDM women record their daily diet, exercise, weight, BG and blood pressure for at least three days between two visits and give lifestyle guidance according to the records. If they fail to show diaries, doctors would ask them come back with record next week. If BG control is poor, medicine intervention would be considered.
89125331|NCT01031069|Experimental|HIV+/Cervarix Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
89125332|NCT01031069|Active Comparator|HIV+/Gardasil Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
89125333|NCT01031069|Experimental|HIV-/Cervarix Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
89125334|NCT01031069|Active Comparator|HIV-/Gardasil Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
89125335|NCT04084912|Active Comparator|Dexamethasone group|this group will receive one ampoule Intravenous injection of Dexamethasone Sodium Phosphate 2 ml . 8 mg once by the anesthesiologist immediately before skin incision
89125336|NCT04084912|Placebo Comparator|Placebo group|this group will receive one ampoule Intravenous injection of Saline once by the anesthesiologist immediately before skin incision
89125337|NCT00679081|Experimental|CelTx|CelTx
89125338|NCT00679081|Active Comparator|Autologous CTG|Autologous sub-epithelial connective tissue graft
89125339|NCT05325892||IDH|Diabetic patients with maintenance hemodialysis who developed hypotension during hemodialysis therapy.Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by ≥10 mm Hg associated with symptoms that include: abdominal discomfort; yawning; sighing; nausea; vomiting; muscle cramps; restlessness; dizziness or fainting; and anxiety.
89125340|NCT05325892||non-IDH|Diabetic patients with maintenance hemodialysis who did not develop hypotension during hemodialysis treatment.Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by ≥10 mm Hg associated with symptoms that include: abdominal discomfort; yawning; sighing; nausea; vomiting; muscle cramps; restlessness; dizziness or fainting; and anxiety.
89125341|NCT02560675||120 healthy subjects|"One hundred and twenty healthy subjects (range 20-79; 20 subjects per age decade, 10 M and 10 F) will participate in the first phase of the study aimed to collect normative data from healthy population.~Study design Phase I - Normative data collection for the inhibitory and excitatory pain modulation responses, a study on healthy subjects (no blood tests)"
89125342|NCT02560675||750 subjects wuith acute whiplash-injury|"Seven hundred and fifty acute whiplash-injury based mild TBI will participate in this study.~Phase II - Multi-modal assessment of acute mild TBI whiplash patients and follow-up"
89125343|NCT00757939|Experimental|AD Participants|Participants with a diagnosis of mild-to-moderate AD
89125344|NCT00757939|Experimental|Cognitively Normal Elderly Participants|Elderly participants with no cognitive impairment
89125345|NCT00755053|Active Comparator|Clotrimazole tablet (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
89125346|NCT00755053|Experimental|Clotrimazole ovule (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
89125347|NCT02590198||ANAES algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
89125348|NCT02590198||PCT algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
89125349|NCT00755209|Placebo Comparator|Transamin|"Drug: tranexamic acid~Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours"
89125350|NCT02589340|Experimental|Buspirone|Two week titration up to 10 mg tablet/3 times a day for 7 days
89125351|NCT02589340|Placebo Comparator|Placebo|Two week titration up to 3 tablets/3 times a day for 7 days
89125352|NCT00682435|Experimental|Hydromorphone|1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
89125353|NCT04294979|Experimental|Rehabilitation|Conventional Physical Therapy
89125354|NCT00758017|Experimental|Acupuncture 1|
89125355|NCT00758017|Active Comparator|Acupuncture 2|
89125356|NCT05340205|Active Comparator|Tranexamic acid group|Patients will receive 1 gm (10 ml) tranexamic acid diluted in 20 ml of Glucose 5% (administered as IV infusion over 5 minutes, at least 15 minutes prior to skin incision). Following the delivery of the baby, patients will additionally receive a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).
89125357|NCT05340205|Active Comparator|Misoprostol group|Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and swabbing the uterine cavity. Patients will additionally receive a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).
89125358|NCT05340205|Active Comparator|Oxytocin only (control) group|Patients will receive only an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
88802241|NCT04424238|Experimental|m-health group (Intervention Group)|participants were managed continuously through WeChat group chat.
88802242|NCT04424160|Experimental|Endometrial PRP|Patients in whom endometrial PRP was performed
88802243|NCT00996502|Experimental|Combination regimen|"Bevacizumab, Erlotinib, Docetaxel, Prednisone (dose escalation)~Phase I:~Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid"
88802244|NCT05484102|Experimental|lactobacillus paracasei CBA L74|100 enrolled children will receive milk fermented with lactobacillus paracasei CBA L74 daily for 3 months.
89290152|NCT03936348|Experimental|FB group|Participants who performed an exercise training program for 8 weeks using a nasal restriction device for inspiratory muscle training, called Feelbreathe®
89125359|NCT00713830|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
88802245|NCT05484102|Placebo Comparator|placebo|100 enrolled children will receive placebo milk formula containing maltodextrins daily for 3 months.
89125360|NCT00713830|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
89125361|NCT00681811|Experimental|HGT-1111 100 U/kg|
89125362|NCT00681811|Experimental|HGT-1111 200 U/kg|
89125363|NCT00755443|Experimental|2|
89125364|NCT00755443|Placebo Comparator|1|Bare metal stent
89125365|NCT05159440|Experimental|Monotherapy Dose Dose Finding - Part 1|TORL-2-307-MAB
89125366|NCT05159440|Experimental|Expansion as Monotherapy - Part 2|TORL-2-307-MAB
89125367|NCT02589184|Experimental|hypergravity WITH isometric load|Patient performing rehabilitation exercises under hypergravity as well as loaded isometric squats
89125368|NCT02589184|Experimental|hypergravity WITHOUT isometric load|Patient performing rehabilitation exercises under hypergravity
89125369|NCT02589184|Experimental|normal gravity WITH isometric load|Patient performing rehabilitation exercises under normal gravity as well as loaded isometric squats
89125370|NCT02589184|Active Comparator|normal gravity WITHOUT isometric load|Patient performing rehabilitation exercises under normal gravity
89125371|NCT05685160|Experimental|Patient group|Patients with intermetatarsal pain have ultrasound and MRI done
89125372|NCT05685160|Active Comparator|Control group|Healthy individuals (no forefoot pain) undergo ultrasound and MRI scan of the forefoot.
89125373|NCT00918970||SNA group|This group will have a real-time analysis of autonomic nervous system activity during its intensive care hospitalisation
89125374|NCT00918970||Clinical group|This group will have a conventional clinical analysis during its intensive care hospitalisation
89125375|NCT00755521|No Intervention|B|
89125376|NCT00755521|Experimental|A|adding Etoricoxib to the basic therapeutic regimen
89125377|NCT05156866|Experimental|Monotherapy Dose Dose Finding - Part 1|TORL-2-307-ADC
89125378|NCT05156866|Experimental|Expansion as Monotherapy - Part 2|TORL-2-307-ADC
89125379|NCT03939676||Major Depressive Disorder or Bipolar Disorder|All eligible participants will be included in this single study arm.
89125380|NCT05684536|Active Comparator|ligasure throidectomy|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall, with dissection around ligament of berry and inferior thyroidal artery
89125381|NCT05684536|No Intervention|conventional thyroidectomy|with dissection around ligament of berry and inferior thyroidal artery through ligation with vicryl and hemoclips
89125382|NCT00755599|Active Comparator|1|Vaginal speculum examinations done without stirrups.
89125383|NCT00755599|Active Comparator|2|Speculum examination with feet in stirrups.
89125384|NCT00681109|Active Comparator|Treatment Arm 1|2.5% IL-1Ra
89125385|NCT00681109|Placebo Comparator|Placebo|Artificial Tear
89125386|NCT00681109|Active Comparator|Treatment Arm 2|5% IL-1Ra
89125387|NCT00755677|Other|pulses|Interventional. Participants are registered sequentially to undergo daily consumption of pulses for eight weeks
89125388|NCT02588950|Experimental|Part A: U-500R Single Injection|Bolus of U-500R administered via single subcutaneous (SC) injection.
89125389|NCT02588950|Experimental|Part A: U-500R CSII|Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII).
89125390|NCT02588950|Experimental|Part B: U-500R TID|U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days
89125391|NCT02588950|Experimental|Part B: U-500R BID|U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days
89125392|NCT02588794|Active Comparator|intervention|Standart CVVHD plus CytoSorb 300 ml device (3804606CE01)
89125393|NCT02588794|No Intervention|control|Standart CVVHD
89125394|NCT00680407|Experimental|silymarin 420 mg|420 mg Legalon (silymarin) three times daily
89125395|NCT00680407|Experimental|silymarin 700 mg|700 mg of Legalon (silymarin) three times daily
89125396|NCT00680407|Placebo Comparator|Placebo|Placebo (lactose pill)
89125397|NCT02560285||Development / 2000 participants|"Age >18 years;~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
89125398|NCT02560285||Validation / 1000 participants|"Age >18 years;~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
89125399|NCT03941470||unexplained recurrent pregnancy loss|peripheral blood sample examined by flowcytometry
89125400|NCT03941470||control fertile multipara|peripheral blood sample examined by flowcytometry
89125401|NCT00758251||1|Adult schizophrenia patients already on Seroquel XR therapy
89125402|NCT05322616|Active Comparator|JK07|Single dose of intravenous JK07 administered by intravenous infusion over 60 minutes.
89125403|NCT05322616|Placebo Comparator|Matching Placebo|Single dose of vehicle control administered by intravenous infusion over 60 minutes
89125404|NCT02560519|Active Comparator|Ringers acetate solution|Ringer-Acetat Baxter Viaflo® (Baxter Finland, Finland): Ringer-Acetat is iso-oncotic solution.Pharmacodynamic and pharmacokinetic properties: The osmotic effect is approximately the same as that of blood plasma. Electrolytes are given to receive or to keep normal osmotic conditions in the extracellular as well as the intracellular compartment. Acetate is oxidized into bicarbonate, mainly in the muscles and peripheral tissues and gives a weak alkalizing effect. Qualitative and quantitative list of composition: 1000 ml of Ringer-Acetat Baxter Viaflo contains 5.86 g sodium chloride, 0.30 g potassium chloride dihydrate, 0.29 g, 0.20 g magnesium chloride hexahydrate, 4.08 g sodium acetate trihydrate. List of excipients: Water for injections, Hydrochloric acid.
89125405|NCT02560519|Experimental|Albumin solution|Albuman® 200g/L (Sanquin, the Netherlands) is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.The solution contains 100 mmol/l of sodium (2.3 g/L). Pharmacodynamic properties: Albumin stabilises circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Pharmacokinetic properties. Under normal conditions, the average half-life of albumin is about 19 days. Albuman® 40g/L is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin. The solution contains 140 mmol/l of sodium (3.2 g/L).
89125406|NCT00918658||Patients with hematologic cancer|Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma
89125407|NCT00918658||Patients without cancer|Patients who do not have cancer.
89125408|NCT02560441|Other|chemotherapy followed by radiotherapy|Patients receive 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy followed by radiotherapy.
89125409|NCT02560441|Other|radiotherapy followed by chemotherapy|Patients receive radiotherapy followed by 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy.
89125410|NCT02560441|Other|IPGDP regimen chemotherapy|Patients receive 6 cycles of ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6. 6 cycles, every 3 weeks one cycle.
89125411|NCT02560363|Experimental|Treatment sequence 1|Period 1:Fast ER formulation of AZD9977 Period 2:Intermediate ER formulation of AZD9977 Period 3:Slow ER formulation of AZD9977 Period 4:IR formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
89125412|NCT02560363|Experimental|Treatment sequence 2|Period 1:Intermediate ER formulation of AZD9977 Period 2:IR formulation of AZD9977 Period 3:Fast ER formulation of AZD9977 Period 4:Slow ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
89125413|NCT02560363|Experimental|Treatment sequence 3|Period 1:Slow ER formulation of AZD9977 Period 2:Fast ER formulation of AZD9977 Period 3:IR formulation of AZD9977 Period 4:Intermediate ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
89125414|NCT02560363|Experimental|Treatment sequence 4|Period 1:IR formulation of AZD9977 Period 2:Slow ER formulation of AZD9977 Period 3:Intermediate ER formulation of AZD9977 Period 4:Fast ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
89125415|NCT00758329||1|
89125416|NCT04007809|Experimental|New-onset Type 1 diabetes|
89125417|NCT03878251|Other|X fragile syndrome patients|
89125418|NCT03878251|Other|Angelman syndrome patients|
89125419|NCT03878251|Other|Rett syndrome patients|
89125420|NCT03878251|Other|Patients with other genetic rare syndromes with intellectual d|
89125421|NCT02589964|Active Comparator|Probiotic|"Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The treatment is Florajen-3. The ingredients in Florajen-3 are:~Lactobacillus acidophilus-over 7.5 billion Bifidobacterium lactis-over 6.0 billion Bifidobacterium longum-over 1.5 billion"
89125422|NCT02589964|Placebo Comparator|Placebo|"Placebo will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The ingredients in the placebo are:~Rice maltodextrin"
89125423|NCT00919360||Controls|Gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, mode of delivery, maternal age, and race.
89125424|NCT00919360||Preeclamptics|Gravidas at 32-42 weeks gestation, delivered by Caesarean Section, who have preeclampsia as defined by Sibai et al, 1997.
89125425|NCT04083664||Control healthy subjects without anemia.|"Adults > 18 years.~Age and sex matched.~No active infection or inflammation."
89125426|NCT04083664||ESRD with Hgb <11 g/dl.|"Adults > 18 years.~ESRD patients on regular hemodialysis.~Hgb < 11g/dl.~No apparent infection or inflammation."
89125427|NCT04083664||ESRD with Hgb ≥ 11 g/dl|"Adults > 18 years.~ESRD patients on regular hemodialysis.~Hgb ≥ 11g/dl.~No apparent infection or inflammation."
89125428|NCT05202730|Other|Traditional injection site and traditional local anesthetic formulation|
89125429|NCT05202730|Experimental|Traditional injection site and new local anesthetic formulation|
89125430|NCT05202730|Experimental|New injection site and traditional local anesthetic formulation|
89125431|NCT05202730|Experimental|New injection site and new local anesthetic formulation|
89125432|NCT05201950|Experimental|Virtual simulation|- Virtual simulation group: Participants will log in to the virtual simulation software from home and play 2 cases (1 case of sepsis, 1 case of trauma). Learners are instructed to play each case as many times as they like within 70 minutes, to reach the highest score possible in that time. This process is proctored, with participants sharing their screen over video conferencing with study team members (JCL or LZY) to ensure adherence to time limit and cases played.
89125433|NCT05201950|Active Comparator|Team based in situ simulation|- Team based in situ simulation group: Faculty observing and debriefing learners at the mock code will be variable and consist of a wide range of NUH emergency department faculty outside of this study, due to logistical constraints in having the same faculty being present consistently in the entire year. The in situ simulation will cover 1 case of sepsis, and 1 case of trauma, with case content matched to the cases in the virtual simulation group, and time matched at 70 minutes.
89125434|NCT00677365|Placebo Comparator|Placebo|Placebo inhaled either once or twice daily via the PARI eFlow nebulizer for 28 days
89125435|NCT00677365|Experimental|MP-376 120 mg QD|MP-376 120 mg inhaled Once Daily (QD) via the PARI eFlow nebulizer for 28 days
89125436|NCT00677365|Experimental|MP-376 240 mg QD|MP-376 240 mg inhaled QD bia the PARI eFlow nebulizer for 28 days
89125437|NCT00677365|Experimental|MP-376 240 mg BID|MP-376 240 mg inhaled twice daily (BID) via the PARI eFlow nebulizer for 28 days
89125438|NCT00919048||Urodynamic patients|Uroflow studies of patients who underwent urodynamics as part of an incontinence work-up.
89125439|NCT05155657|Experimental|Low dose umbilical cord mesenchymal stem cells (UCMSCs)|
89125440|NCT05155657|Experimental|Medium dose UCMSCs|
89125441|NCT05155657|Experimental|High dose UCMSCs|
89125442|NCT02559193||No treatment.|Data collection only trial design.
89125443|NCT05196958|Experimental|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
89125444|NCT05039944|Experimental|SI-B001_A|Patients with unresectable or metastatic gastric cancer, HER2-negative and without standard treatment were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
89125445|NCT05039944|Experimental|SI-B001_B|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed conventional chemotherapy combined with EGFR mab were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
89125446|NCT05039944|Experimental|SI-B001_C|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed multiple lines of conventional chemotherapy (excluding EGFR monoclonal antibody) were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
89125447|NCT05039944|Experimental|SI-B001 combined with irinetecan_D|Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed to receive anti-PD-1 (L1) mab (excluding EGFR mab) in the first or second line were treated with SI-B001 in combination with irinetecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
89125448|NCT05039944|Experimental|SI-B001 combined with FOLFIRI or FOLFOX_E|Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed first-line anti-PD-1 (L1) mab were treated with SI-B001 in combination with FOLFIRI or FOLFOX for second-line treatment.SI-B001 is administered by intravenous drip twice weekly (Q2W).
89125449|NCT05039944|Experimental|SI-B001 combined with irinetecan_F|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed standard first-line treatment containing oxaliplatin or irinotecan plus fluorouracil plus or minus bevacizumab were treated with SI-B001 plus irinotecan in the second-line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
89125450|NCT03719131|Active Comparator|Arm A (standard of care)|This is standard of care arm: induction with 4 cycles (21 days each) of Ipilimumab and nivolumab followed by continuation with nivolumab alone every month X1 year (13 doses).
89125451|NCT03719131|Experimental|Arm B (rituximab, hyaluronidase human)|This includes induction with 4 cycles of ipilimumab and nivolumab X 4 cycles followed by continuation with nivolumab alone every month for 1 year as in standard of care arm. Each induction cycle is 21 days and includes ipilimumab on day 1 plus nivolumab on day 1. In addition, patients will receive 4 weekly doses of Rituxan (first dose intravenously and then 3 weekly doses subcutaneously). First dose of Rituxan will be administered one week following the start of cycle 1 of ipilimumab and nivolumab. All treatments will have a +/-3 business day window for administration.
89125452|NCT05684458|Experimental|Reiki Group|Patient Descriptive Information Form, Edmonton Symptom Diagnosis Scale (ESTO), and European Association for Cancer Research and Treatment BR23 Quality of Life Scale (EORTC-QLQ-BR232) will be administered to the Reiki group. Then, under the guidance of a researcher holding a Usui Reiki Master & Teacher degree, a total of 26 patients in the intervention group will be given a short 30-minute application to energy centers by researchers with a second-degree Reiki practitioner. On the second and on third days, 30 minutes of short Reiki will be done remotely. After 3 days and 10 days after the patients were included in the study, the post-tests will be performed by calling the patients.
89125453|NCT05684458|No Intervention|Control Group|Patient Descriptive Information Form, Edmonton Symptom Diagnosis Scale (ESTO), and European Association for Cancer Research and Treatment BR23 Quality of Life Scale (EORTC-QLQ-BR232) will be administered to the control group. No treatment will be applied to the patients. Post-tests will be applied to all patients 3 days and 10 days after they were included in the study.
89125454|NCT00921739|Experimental|IMRT concurrent with chemotherapy|6 fractions of esophageal sparing IMRT weekly for 5-6 weeks (dependent on dose cohort) concurrent with standard chemotherapy: Cisplatin 50 mg/m2 /d intravenously (IV) on days 1, 8, 29, and 36. Etoposide 50 mg/m2 /d IV on days 1 through 5 and 29 through 33.
89125455|NCT04083352|Experimental|6-week ketone supplementation|Participants took a ketomax ketone salt supplementation for 6-weeks. They took 2 servings per day.
89125456|NCT04083352|Placebo Comparator|6-week placebo supplement|Participants took a placebo supplement for 6-weeks. The placebo was calorie, sodium, and flavor-matched to the experimental supplement.
89125457|NCT05435599|Other|Chronic Hepatitis B|Measurement of serum regucalcin level
89125458|NCT05435599|Other|Healthy Volunteers|Measurement of serum regucalcin level
89125459|NCT05435521|Experimental|People living with HIV group 40 participants|40 participants with HIV
89125460|NCT05435521|Active Comparator|People without HIV|20 participants without HIV
89125461|NCT05195164||Older transgender women|This cohort will consist of healthy transgender women aged 45 and above who have not undergone but desire orchiectomy, who have been on estrogen (history of oral, transdermal or injectable) and spironolactone for at least one year.
89125462|NCT05195164||Younger transgender women|This cohort will consist of healthy transgender women aged 18-44 who have not undergone but desire orchiectomy, who have been on estrogen (history of oral, transdermal or injectable) and spironolactone for at least one year.
89125463|NCT05118022|Experimental|Intervention|Patients randomized to intervention will be cared by physicians under AI-ECG support.
89125464|NCT05118022|No Intervention|Control|Patients randomized to control will be cared by routine practice.
89125465|NCT02588560||HCV lymphoma patients with chemotherapy|Lymphoma patients who are positive for anti-HCV and are planning to receive chemotherapy for lymphoma
89125466|NCT00680017|Experimental|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
89125467|NCT00680017|Active Comparator|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
89125468|NCT04083040|Other|TAVI patients|Patient undergone TAVI
89125469|NCT05029570|Experimental|Conduction System Pacing and AV node ablation|Atrioventricular node ablation and subsequent conduction system pacing
88821367|NCT04410575|Experimental|Intervention Group (Standard Pharmacist Care + Pharmacist Interventions)|Participants enrolled in the intervention group will receive pharmacist interventions, in addition to standard care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians), at enrollment (month 0) and at 1, 3, and 6 month in-person follow-up appointments
89125470|NCT05029570|No Intervention|Medical treatment for rate control of AF|Pharmacological rate control based on clinical practice guidelines
89125471|NCT00919516|Experimental|Stem Cell Implantation|
89125472|NCT05024500|Experimental|ADRSNet protocol|ARDSnet protocol is the current, standard of care for ARDS. Its used by setting PEEP and the fraction of inspired oxygen (FiO2) to achieve the oxygenation goal (SpO2 ≥ 93% - accepting the range of 90-96%)
89125473|NCT05024500|Experimental|Driving Pressure (DP)|setting PEEP after performing a modified alveolar recruitment maneuver followed by a decremental PEEP titration electing the level correspondent to the lowest driving pressure.
89125474|NCT05024500|Experimental|Electrical Impedance Tomography (EIT)|After performing a modified alveolar recruitment maneuver, the PEEP decremental titration guided by the EIT will be set at the level above the intersection of the curves representing relative alveolar overdistention and collapse.
89125475|NCT00676663|Experimental|Exemestane 25 mg + Entinostat 5 mg|Exemestane (Aromasin®) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
89125476|NCT00676663|Placebo Comparator|Exemestane 25 mg + Placebo|Exemestane (Aromasin®) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
89125477|NCT02559583||Participants with Chronic Lymphocytic Leukemia (CLL)|This is an observational study. Data will be captured for Participant's with diagnosis of Chronic Lymphocytic Leukemia according to hospital records in the questionnaire provided by the Sponsor.
89125478|NCT02559583||Participants with Multiple Myeloma (MM)|This is an observational study. Data will be captured for Participant's with diagnosis of Multiple Myeloma (MM) according to hospital records in the questionnaire provided by the Sponsor.
89125479|NCT02559583||Participants with Non-Hodgkin's lymphoma (NHL)|This is an observational study. Data will be captured for Participant's with diagnosis of non-Hodgkin's lymphoma (NHL) data according to hospital records in the questionnaire provided by the Sponsor.
89125480|NCT03590041|Active Comparator|Standardized SMA|The standardized SMA model includes the same TTIM curriculum as in the patient-driven model, but it is delivered in a standardized way (order of and time spent on topics are set) across all participating practices.
89125481|NCT03590041|Active Comparator|Patient-driven SMA|In the patient-driven SMA model, patients receive the same TTIM curriculum, but patients at each practice are able to set the order of the curriculum and dictate how long to spend on each topic.
89125482|NCT02589028|Experimental|premeal protein bar first|"intervention: premeal protein-enriched bar intake~protein enriched bar(total serving: 30g, 43.28% carbohydrate; 1.29% fat; 40.39% protein; 42.63% fiber) will be given 30 minutes before breakfast~protein enriched bar is provided with 150 ml of water~amount of protein bar : 30g~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
89125483|NCT02589028|Other|breakfast first|"intervention: breakfast follows by protein bar~protein enriched bar is provided with 150 ml of water shortly after breakfast~amount of protein bar : 30g~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
89125484|NCT02559427|Active Comparator|Immediate SPA treatment|3-week immediate SPA treatment (soon after randomization)
89125485|NCT02559427|Sham Comparator|Late SPA treatment|3-week late SPA treatment (soon after primary endpoint at 4 1/2 months visit)
89125486|NCT02560207|Active Comparator|Intermittent cefotaxime|Cefotaxime 1 gram (1000 mg) is to be administered 4 times daily for 4 days
89125487|NCT02560207|Experimental|Continuous cefotaxime|After a 1 gram (1000 mg) Cefotaxime loading dose, Cefotaxime 4 gram (4000 mg) is to be administered as a continuous infusion in 24h for 4 days .
89125488|NCT02559661||Medical students|Students with limited knowledge of the anatomy and pathology of the eye.
89125489|NCT02559661||Ophthalmological trainees|The trainees have never done eye surgery but have a better understanding of the eyes pathology and anatomy than the medical students.
89125490|NCT02559661||Vitreoretinal surgeons|The vitreoretinal surgeons knows the eyes anatomy and pathology well and have training and skills in vitreoretinal surgery.
89125491|NCT00678691|Experimental|A,1|armodafinil
89125492|NCT00678691|Placebo Comparator|A,2|placebo
89125493|NCT05003752|Other|Hypofractionated EBRT plus HDR-BT boost|Primarily hypofractionated EBRT consisting of 12 x 3 Gy/fraction, TD 36 Gy will be administered. Followed by HDR-BT boost of the prostate, TD 14 Gy.
89125494|NCT02588014||Schizophrenia|Individuals with schizophrenia
89125495|NCT02588014||Control|Neurotypical individuals
89125496|NCT00679939|Active Comparator|Arm 1 Treatment A|rosiglitazone up to 8mg/day
89125497|NCT00679939|Active Comparator|Arm 2 Treatment B|metformin up to 2000mg/day
89125498|NCT05094856||Effect of volume expansion by albumin on the correction of peripheral tissue hypoperfusion|Effect of volume expansion by albumin on the correction of peripheral tissue hypoperfusion by measuring the proportion of patients who normalized their cutaneous re-coloring time (CRT) measured at the index level, defined by a value <3 seconds at H1. The clinical measurement method has been standardized in the participating departments and has been used for several years in clinical practice.
89125499|NCT05094856||Effect of volume expansion by saline on the correction of peripheral tissue hypoperfusion|Effect of volume expansion by saline on the correction of peripheral tissue hypoperfusion by measuring the proportion of patients who normalized their cutaneous re-coloring time (CRT) measured at the index level, defined by a value <3 seconds at H1. The clinical measurement method has been standardized in the participating departments and has been used for several years in clinical practice.
89125500|NCT04082260||De novo patients with alemtuzumab|De novo patients prior and after alemtuzumab treatment initiation
89125501|NCT04082260||Alemtuzumab treatment|Patients under alemtuzumab treatment
89125502|NCT04082260||Extended alemtuzumab treatment|Patients requiring more than two alemtuzumab infusions
89125503|NCT02587390|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
89125504|NCT02587390|Active Comparator|Simvastatin 80 mg|Simvastatin 80 mg
89125505|NCT00760903||> 18 years moderate head trauma|Group I: (Pilot group): 5-10 patients > 18 years old, gender and race indifferent with moderate head trauma.
89125506|NCT00760903||> 18, gender and race indifferent|Group II: 30 patients > 18 years old, gender, and race indifferent with moderate head trauma
89125507|NCT00760903||Pediatric|Group III: 30 patients < 18 years old, gender and race indifferent with moderate head trauma (pediatric patient group)
89125508|NCT00760903||Pre-evaluated|Group IV: 10-20 patients age, gender and race indifferent with moderate head trauma that have been examined with conventional MRI of the brain, MRS and DTI as clinically requested. The images of these patients will be evaluated retrospectively for data- point collection.
89125509|NCT00760903||Control Group|Group V (control group): 20 volunteers without prior history of traumatic brain injury or neurological problems.
89125510|NCT00760981|Experimental|Imatinib|200 mg orally daily and 400 mg orally daily for 4 weeks.
89125511|NCT00919906|No Intervention|Handwriting without Tears|Standard practice
89125512|NCT00919906|Experimental|Haptic guidance|
88821368|NCT04410575|Active Comparator|Control Group (Standard Pharmacist Care)|Patients randomized to the usual care group will receive standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians) and physician care, at enrollment (month 0) with no specific interventions for the duration of 6 months, until the 6 month in-person follow-up appointment
89125513|NCT00761059|Active Comparator|Glucose 20%|
89125514|NCT00761059|Placebo Comparator|placebo|
89125515|NCT02588638||Adult patients|Unclear movement disorder, unclear cognitive decline
89125516|NCT02588638||Patients < 18 years|Patients with (penetrating) suspected cerebral neurogenetic diseases
89125517|NCT02588716|Active Comparator|Terlipressin|Terlipressin will be given at the beginning of surgery as an initial bolus dose of (1 mg over 30 mins) followed by a continuous infusion of 2μg/kg/h to be continued throughout the surgery then gradually withdrawn over 4 hours
89125518|NCT02588716|Placebo Comparator|Control|same volumes of normal saline with the same rate of infusion, throughout the operation then gradually withdrawn over 4 hours.
89125519|NCT00673933|Experimental|1|PDT using MAL crem
89125520|NCT00673933|Placebo Comparator|2|PDT using Placebo cream
89125521|NCT02587858||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI, other clinical findings, and PANK2 gene sequencing.
89125522|NCT02587858||PLAN|This group consists of individuals diagnosed with PLAN using a combination of MRI, other clinical findings and PLA2G6 gene sequencing.
89125523|NCT02587858||BPAN|This group consists of individuals diagnosed with BPAN using a combinatino of MRI, other clinical findings, and WDR45 gene sequencing.
89125524|NCT00761449|Experimental|1|1. lenalidomide
89125525|NCT04968106|Other|Standard Arm A: treatment by neoadjuvant chemotherapy|Treatment by doxorubicin and ifosfamide followed by surgery
89125526|NCT04968106|Experimental|Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab|Treatment by doxorubicin, ifosfamide and retifanlimab followed by surgery
89125527|NCT00761683||1|Patients diagnosed with endometriosis
89125528|NCT00919594|Experimental|Interpersonal Psychotherapy for Mothers|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
89125529|NCT00919594|Active Comparator|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
89125530|NCT04957966|Experimental|Music listening vs. No music listening|Random assignment (50:50) of every participant to one of the following two conditions: Music listening after a stressful/discriminatory event (i.e., intervention condition) or no music listening after a stressful/discriminatory event (i.e., control condition).
89125531|NCT02587780||Inactive|people who perform < 30mins.day physical activity at a 'moderate' level of intensity.
89125532|NCT02587780||Active|people who perform 30mins-60 mins.day of physical activity at a 'moderate' level of intensity.
89125533|NCT02587780||Very active|People who perform > 60 mins.day of physical activity at a >moderate level of intensity.
89125534|NCT00919438||Dialysis|
89125535|NCT04082182|Experimental|DC immunotherapy|Intra-patient dose escalation of intravenous MIDRIX4-LUNG autologous DC vaccine
89125536|NCT00571519|Experimental|1|rivoglitazone HCl 0.5mg
89125537|NCT00571519|Experimental|2|rivoglitazone HCl 1.0 mg
89125538|NCT00571519|Experimental|3|rivoglitazone HCl 1.5 mg
89125539|NCT00571519|Placebo Comparator|4|placebo matching rivoglitazone HCl tablets
89125540|NCT00571519|Active Comparator|5|pioglitazone HCl 15 mg
89125541|NCT00571519|Active Comparator|6|pioglitazone HCl 30 mg
89125542|NCT00571519|Active Comparator|7|pioglitazone HCl 45 mg
89125543|NCT00571519|Placebo Comparator|8|matching placebo for pioglitazone
89125544|NCT00761839|Experimental|Arm 1|These patients receive the experimental intervention--the after-care summary.
89125545|NCT00761839|Active Comparator|Arm 2|These patients are the control group and receive usual care.
89125546|NCT00761917||1: Normal|Subjects without dry eye symptoms based on questionnaire.
89125547|NCT00761917||2: Dry Eye|Subjects with dry eye symptoms based on questionnaire.
89125548|NCT02587702|Experimental|Improved Infant Formula Group|Containing β-Palmitate Content
89125549|NCT02587702|Placebo Comparator|General Infant Formula Group|Excluding β-Palmitate Content
89125550|NCT02587702|Active Comparator|Human Milk Group|Containing β-Palmitate Content Naturely in Human Milk
89125551|NCT02558647|Experimental|CBT for insomnia (CBT-I)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) comprises a fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention
89125552|NCT02558647|Active Comparator|Psychoeducation about Sleep (PE)|The PE intervention gives participants access to a website with information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
89125553|NCT00919672|Active Comparator|Sacral nerve stimulation ON-OFF|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
89125554|NCT00919672|Active Comparator|Sacral nerve stimulation OFF-ON|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
89125555|NCT00761995|Active Comparator|Azopt|topical eye drop dosed 1 drop 3 times daily
89125556|NCT00761995|Active Comparator|Cosopt|topical eye drop
89125557|NCT00762151|Placebo Comparator|Negative Control|Regular Toothpaste
89125558|NCT00762151|Active Comparator|Positive Control|Standard anti-plaque and anti-bacterial toothpaste.
89125559|NCT00762151|Active Comparator|Prototype|AN0128 Toothpaste
89125560|NCT02558413|Active Comparator|BTA-C585 oral capsules|25 or 100 mg oral capsules; Single ascending doses (SAD) from 50 mg to 800 mg
89125561|NCT02558413|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
89125562|NCT04082026|Experimental|Early Adolescent Skills for Emotions (EASE)|EASE has four core features: Seven group sessions for young adolescents and three for their caregivers; Delivered by non-specialists; Trans-diagnostic: addressing depression, anxiety, distress, and other problems as defined by the young people themselves; and Designed for young people and their caregivers in low- and middle-income countries living in communities affected by adversity.
89125563|NCT04082026|Placebo Comparator|Enhanced Treatment As Usual (ETAU)|The Enhanced Treatment as Usual (ETAU) consisted of a single psychoeducation individual session, jointly for eligible adolescents and their caregivers, that included information on: (i) the results of the screening; (ii) self-care strategies; and, (iii) seeking services from local health or community services offering psychosocial / mental health care support.
89125564|NCT02559037|Experimental|Acupuncture-moxibustion group|Receiving acupuncture and moxibustion treatment.
89125565|NCT02559037|Sham Comparator|Sham acupuncture-moxibustion group|Receiving sham acupuncture and sham moxibustion.
89125566|NCT00921973|Active Comparator|VAX102|Simultaneous administration of VAX102 1 ug i.m. plus TIV
89125567|NCT00921973|Placebo Comparator|Placebo|
89125568|NCT00676195|Experimental|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
89125569|NCT02558959|Experimental|Irinotecan and Capecitabine|irinotecan 180mg/m2 d1, capecitabine 1000mg/m2 bid d1-10, q2w
89125570|NCT02558959|Active Comparator|Irinotecan|irinotecan 180mg/m2 d1, q2w
89125571|NCT02558881||Virtual colonoscopy|"With virtual colonoscopy, the patient does not need to be hospitalized for examination, which is usually done without hospitalization. A bowel preparation is necessary. It may vary from site to site, but it generally comprises polyethylene glycol or sodium phosphate. The residual stools are marked by ingestion of a radiopaque product to differentiate colic lesions. But no contrast agent is injected intravenously. The patient should be supine and a rectal probe is set up to inject either air or CO2. The vesting period does not exceed thirty seconds apnea, and overall completion time of the examination (patient table) is about 10 minutes."
89125572|NCT02558881||Colon capsule|The colon capsule comprises two cameras located at both ends. Image acquisition is set between four to thirty-five images per second. It begins immediately after ingestion of the capsule which allows recording of esophageal and gastric images. She paused for 2 hours (to save batteries) while crossing the small intestine. It is reactivated in the terminal ileum. The films analysis time is approximately 1 hour, and the capsule remains on average 3 hours in the colon.
89125573|NCT02674945||Wireless Activity tracker: Fitbit|Patients with brain tumor(s) will be give a wireless activity tracker (fitbit flex) to use during treatment. They will complete quality of life surveys and a sleep survey.
89125574|NCT02558725|No Intervention|one capsule of iron supplement|instructed to take one capsule at least 2 hours after consumption of dairy products
89125575|NCT02558725|Active Comparator|two capsules of iron supplement|instructed to take two capsules of Aktiferrin F at least 2 hours after consumption of dairy products
89125576|NCT04801732|Experimental|mulligan group|Patients in the study group will treated with SNAGS techniques on thoracic spine with traditional treatment consist of ice application, supervised exercises (stretching and strengthening exercise) for 3 times/week for one month.
89125577|NCT04801732|Active Comparator|exercising group|will receive only traditional treatment (ice application and supervised exercise ) for 3 times/week for one month.
89125578|NCT04082962|Experimental|Treatment Group|Participants receiving dexamethasone implant.
89125579|NCT04082962|No Intervention|Non-treatment group (control)|Participants not receiving dexamethasone implant.
89125580|NCT00675103|Experimental|pegloticase|
89125581|NCT02471833|Experimental|Telmisartan 20mg|African American participants with and without hypertension and at high risk for Alzheimer's disease randomly assigned to receive telmisartan 20mg once a day orally.
89125582|NCT02471833|Experimental|Telmisartan 40mg|African American participants with and without hypertension and at high risk for Alzheimer's disease randomly assigned to receive telmisartan 40mg once a day orally.
89125583|NCT02471833|Placebo Comparator|Placebo|African American participants with and without hypertension and at high risk for Alzheimer's disease randomly assigned to receive a placebo to match telmisartan once a day orally.
89290153|NCT03936348|Experimental|ONB group|Participants who performed an exercise training program for 8 weeks with oronasal breathing without FB
89125584|NCT05680168|Active Comparator|Group A: Extracorporeal Magnetic stimulation|Group (A): will receive rehabilitation program with exposure to ExMS, Patients will receive regular sessions of electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia). Each session will last for 20 minutes. Patients will receive three weekly sessions for total of 20 sessions starting one month after catheter removal.
88821369|NCT04408599|Experimental|NC410 3mg|3mg of NC410 for IV infusion administered in 14 day dosing cycles
89125585|NCT05680168|Active Comparator|Group B: Extracorporeal Magnetic stimulation and pelvic floor exercises|Group (B): This group will receive a rehabilitation program depending ExMS with the protocol described above. In addition, this group will be advised for pelvic floor muscle training in serial training sessions with our therapist for PME.
89125586|NCT05680168|Active Comparator|Group C: Pelvic floor exercises|Group (C): This will be the control group. This group will be advised to do PME only. The pelvic floor exercises will consist of advice to the patients to contract the anal sphincter muscles in successive way as if holding flatus. The pelvic floor muscle training schedule and therapist in group B and group C will be the same.
89125587|NCT04895410|Experimental|Dose Escalation: Lemzoparlimab|Participants will receive lemzoparlimab in 28 day cycles.
89125588|NCT04895410|Experimental|Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone|Participants will receive lemzoparlimab + pomalidomide + dexamethasone in 28 day cycles.
89125589|NCT04895410|Experimental|Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone|Participants will receive lemzoparlimab + carfilzomib + dexamethasone in 28 day cycles.
89125590|NCT04895410|Experimental|Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone|Participants will receive lemzoparlimab + daratumumab + dexamethasone in 28 day cycles.
89125591|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion in 28 day cycles.
89125592|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab + Dexamethasone|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + dexamethasone in 28 day cycles.
89125593|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + pomalidomide + dexamethasone in 28 day cycles.
89125594|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + carfilzomib + dexamethasone in 28 day cycles.
89125595|NCT04895410|Experimental|Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone|Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + daratamumab + dexamethasone in 28 day cycles.
89125596|NCT00675025|Experimental|Prior Donepezil-DB|All participants started with a dose of 2.5 mg/day (2.5 mL/day). Dose escalations occurred in 2.5 mg/day increments every 2 weeks (steady state levels assumed to have been reached) to a maximum dose of 10 mg/day, according to the participant's weight schedule and the Investigator's judgment of safety and tolerability. Re-titration was done to maintain the blinding of the double-blind study (E2020-A001-219). Doses could be decreased due to tolerability and could be increased or decreased to maintain a maximum dose of 0.1 to 0.2 mg/kg/day based on the participant's weight at clinic visits during the study duration.
89125597|NCT01772329|Experimental|4 weekly CT sessions - in person|4 weekly CT sessions; all will be 1-hr individual cognitive therapy sessions with the psychology staff (under the supervision of John Burns, PhD).
89125598|NCT01772329|Experimental|8 weekly CT sessions|"8 weekly CT sessions; 1st and 8th will be 1-hr individual cognitive therapy session with the psychology staff (under the supervision of John Burns, PhD). The intermediate CT sessions will be by telephone call or video/Skype. Our group will purchase and setup a web camera and headphone/microphone for the subjects in the CT groups that use Skype. The 1-hr CT protocol was adapted from Dr. Beverly E. Thorn's CT manual (Cognitive Therapy for Chronic Pain: A Step-by-Step Guide; Thorn, 2004; with the Client and Therapy Workbooks."
89125599|NCT01772329|Experimental|4 weekly CT sessions - Tele-video|"4 weekly CT sessions; 1st and 4th will be 1-hr individual cognitive therapy session with the psychology staff. The intermediate CT sessions will be by telephone call or video/Skype."
89125600|NCT01772329|Placebo Comparator|Routine care|Routine care; no CT sessions
89125601|NCT04049461||PDAC Group|Radical operations were performed through central abdominal incisions. The postoperative pathology was pancreatic ductal adenocarcinoma.
89125602|NCT04049461||Benign Group|The abdominal midline incision was performed and the postoperative pathology was benign.
89125603|NCT02587624||RMN AF ablation|Consecutive patients with class I or class IIa indication for catheter ablation for symptomatic atrial fibrillation according to the current guidelines.
89125604|NCT01275313|Experimental|Custom-Fitted Lightweight Wheelchair & Cushion|Receive a new custom-fitted lightweight wheelchair, skin protection cushion and wheelchair skills training
89125605|NCT01275313|Other|Cushion Only|Receive a skin protection cushion and wheelchair training, but remain in facility-issued wheelchair
89125606|NCT00758407|Active Comparator|1|
89125607|NCT00758407|Placebo Comparator|2|
88821370|NCT04408599|Experimental|NC410 6mg|6mg of NC410 for IV infusion administered in 14 day dosing cycles
88821371|NCT04408599|Experimental|NC410 15mg|15mg of NC410 for IV infusion administered in 14 day dosing cycles
88821372|NCT04408599|Experimental|NC410 30mg|30mg of NC410 for IV infusion administered in 14 day dosing cycles
89125608|NCT02587078|Active Comparator|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
89125609|NCT02587078|Active Comparator|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
89125610|NCT00758641|Experimental|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
89125611|NCT00758641|Active Comparator|Steroid Injection|Corticosteroid injections
89125612|NCT02587546|Experimental|laryngeal carcinoma|patients with T1-T2 (some T3) laryngeal carcinoma will undergo treatment using thulium contact laser surgery - tumour resection
89125613|NCT02587546|Experimental|bilateral vocal cord paralysis|patients with bilateral vocal cord paralysis treated with partial arytenoidectomy will be treated using thulium laser surgery and laterofixation
89125614|NCT02587546|Experimental|subglottic stenosis|patients with subglottic stenosis treated endoscopically (incisions and dilatation) will be treated with thulium laser surgery
89125615|NCT04081870||ICSI cases|All women underwent long agonist protocol for controlled ovarian hyperstimulation The GnRH agonist was started in the previous mid-luteal phase . After the confirmation of pituitary down regulation , the HMG ampoules were started by 225 IU/day . During the follow up of overstimulation, the doses were adjusted according to the response of patient. All women underwent serial TVS until at least three dominant follicles were reached in every woman. When the dominant follicles reached 18-20 mm, HCG 10000 was administered. Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration. The luteal phase was supported by progesterone 300 mg per day . Five days following ovum pick up, the embryos were transferred at the blastocyst stage.
89125616|NCT04786990|Experimental|Open-Label Treatment|"Subjects 6-11 years of age: 100 to 400mg SPN-812 (100 mg oral capsule)~Subjects 12-17 years of age: 100 to 600mg SPN-812 (100, 200 mg oral capsule)"
89125617|NCT04082494|No Intervention|Regular Treatment|"No intervention is planned for the first period. Baseline treatment assesment."
89125618|NCT04082494|Experimental|Music|Optional music via internet and noise canceling headphones will be offered.
89125619|NCT04082494|Experimental|Music and Beverages|Additionally to the offered optional music via internet and noise canceling headphones, there will be beverages optionally offered (with and without sugar, warm or cold).
89125620|NCT00758797|Experimental|1|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
89125621|NCT02558803|No Intervention|Usual Care|The clinical team will be left to identify the need for a follow-up HPV vaccine through existing mechanisms
89125622|NCT02558803|Experimental|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
89125623|NCT00759265|Experimental|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
89125624|NCT00759265|No Intervention|control|No intervention was prescribed
89125625|NCT05683210|Experimental|Cup feeding|The infants in the control group were fed with a cup. During feeding, all infants in this group were placed in semi-elevated supine position. The position of the infant was adjusted so that when the milk reached the tongue, the infant would start foraging, dip his/her tongue into the milk by dimpling and slurp the milk with his/her tongue through a negative pressure, swallow as much as he/she wants and leave the rest back to the cup. The stopwatch was activated when the infant began to drink the milk from the cup, and the stopwatch was stopped when the infant no longer slurped the milk, and the feeding process was completed. When the infant was physiologically (HR of 120-160/min, SpO2 ≥90) and behaviourally ready, feeding was resumed and the infant was prevented from getting tired during feeding and actively participated in feeding. Feeding time was limited to 30 minutes in either group, including the infants' resting time.
89125626|NCT05683210|Experimental|Bottle feeding|The infants in the experimental group were fed with a bottle. The teat of the feeding bottle was selected to be smaller in size, softer and with a smaller hole than the teat of the term infant and suitable for preterm infants. The same brand and model of bottle and teat were used for each infant. All infants in this group were fed in a semi-elevated side-lying position, as it was more similar to the position in which the infant suckled the mother's breast. The infant's lips were tapped with the bottle teat for stimulating to feed, and when the infant opened his/her mouth and drooped his/her tongue, the teat of the bottle was put into his/her mouth. The time elapsed from when the infant started to suck the bottle until he/she released the bottle from his/her mouth was considered as the feeding phase.
89125627|NCT00759421|Experimental|1|
88821373|NCT04408599|Experimental|NC410 60mg|60mg of NC410 for IV infusion administered in 14 day dosing cycles
89125628|NCT00759421|Active Comparator|2|
89125629|NCT04081948|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
89125630|NCT04081948|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
89125631|NCT00759499||Debridement|The intent of this protocol is to salvage wound material that is normally destined for destruction, so it can be used in wound-related scientific studies. This clinical wound material can be studied in order to better understand the molecular, cellular, or ecological components of the wound system. These studies may be able to provide important insights into the keys of wound healing, wound persistence, or wound deterioration.
89125632|NCT00762775|Experimental|1|Calcium supplementation and placebo
89125633|NCT00762775|Experimental|2|Vitamin D supplementation and placebo
88821374|NCT04408599|Experimental|NC410 100mg|100mg of NC410 for IV infusion administered in 14 day dosing cycles
88821375|NCT04408599|Experimental|NC410 200mg|200mg of NC410 for IV infusion administered in 14 day dosing cycles
88821376|NCT04407234|Experimental|Tirzepatide + Acetaminophen|Participants received 5mg tirzepatide on Day 1 and Day 8; 10 mg tirzepatide on Day 15, 22 and 29; 15 mg tirzepatide on Day 36 administered subcutaneously (SC) and 160 mg acetaminophen administered orally on Day -1, Day 2 and Day 37.
88821377|NCT04361955|Other|PD with DBS on|intervention is EEG while at rest and performing tasks, on anti PD medications and off anti PD medications
89125634|NCT00762775|Experimental|3|Calcium and Vitamin D supplementation
89125635|NCT00762775|Placebo Comparator|4|Placebos only
89125636|NCT02587468|Experimental|Juice Plus+(R)|Check of phenolic absorption between baseline and after 8wks of intake before-after comparison
89125637|NCT00763087|Active Comparator|nonweightbearing exercise|
89125638|NCT00763087|Placebo Comparator|nonexercising control|
89125639|NCT00763087|Experimental|weightbearing exercise|
89125640|NCT00763165|Active Comparator|A|
89125641|NCT00763165|Placebo Comparator|B|
89125642|NCT00919750||Ancillary-Correlative (tissue and blood sample collection)|Brain tumor tissue and blood specimens are collected from patients and banked for future study.
89125643|NCT04049227|Experimental|Treatment (letrozole, abemaciclib)|Patients receive letrozole PO QD and abemaciclib PO BID on days 1-14. Patients then undergo standard of care hysterectomy on day 15.
89125644|NCT04752007|Active Comparator|RSA group|Conventional RSA to measure the movement in th SI joint.
89125645|NCT04752007|Active Comparator|CT group|Low dose CT to measure the movement in th SI joint.
89125646|NCT04683250|Experimental|TAS0953/HM06 Phase 1|Dose escalation and dose expansion until recommended Phase 2 dose determined
89125647|NCT04683250|Experimental|TAS0953/HM06 Phase 2|Treatment phase at recommended Phase 2 dose in three different populations
89125648|NCT02558257||Palliative Care Survey|Initial consultation visit followed by phone survey within 1 week +/- 4 days of initial consultation.
89125649|NCT04081558|Experimental|Electronic follow-up|
89125650|NCT00763399|Experimental|97-0549B|
89125651|NCT00763477|Placebo Comparator|saline injections|
89125652|NCT00759733||1|Pregnant women with a history of cardiac disease (study group)
89125653|NCT00759733||2|Pregnant women with no history of heart disease (control group)
89125654|NCT04777864|No Intervention|Usual Care|
89125655|NCT04777864|Experimental|Decision Aid|Usual care, plus introduction of a decision aid
88821378|NCT04361955|Other|PD with DBS off|intervention is EMG while at rest and performing tasks, on anti PD medications and off anti PD medications
89125656|NCT00759889||wound biopsy|diabetic foot,venous leg ulcer, decubitus ulcer
89125657|NCT02586532||1|Residents of towns participating in China Demonstration Project.
89125658|NCT00760045|Experimental|1|AL-43546 0.15%
89125659|NCT00760045|Experimental|2|AL-43546 0.25%
89125660|NCT00760045|Active Comparator|3|AL-43546 0%(Vehicle)
89125661|NCT00760045|Active Comparator|4|0.1% sodium hyaluronate ophthalmic solutio
89125662|NCT00760123|Experimental|1|Early Physical Therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
89125663|NCT00760123|Other|2|Educational Strategy: instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
89125664|NCT00760201||1|Hospital executives, physician administrators and hospital legal counsel
89125665|NCT04049305|Experimental|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM.
89125666|NCT04049305|Active Comparator|Conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy.
89125667|NCT04049305|Active Comparator|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, with endoscopic instruments to performed nipple sparing mastectomy.
89125668|NCT04080154|Experimental|Anlotinib|Anlotinib p.o., qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
89125669|NCT02584348|Experimental|Gastric Ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed
89125670|NCT00678379|Placebo Comparator|Normal Saline|1.5 ml injection of Normal Saline into each tonsillar fossa pre-tonsillectomy
89125671|NCT00678379|Active Comparator|Lidocaine (1%) + Bupivacaine 0.5%|Submucosal injection of 1.5 mL Lidocaine (1%) + Bupivacaine 0.5% into the tonsillar fossa, pre-tonsillectomy
89125672|NCT00678379|Experimental|Lidocaine + Bupivacaine + Clondine|Submucosal injection of 1.5 mL Lidocaine 1% + Bupivacaine 0.5% + Clondine 25mcg into the tonsillar fossa, pre-tonsillectomy
89125673|NCT00674323|Experimental|Verteporfin and Ranibizumab|Photodynamic therapy with verteporfin in combination with ranibizumab injection. Patients received one treatment at baseline with verteporfin photodynamic therapy (PDT) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
89125674|NCT00674323|Active Comparator|Verteporfin monotherapy|Patients received one treatment at baseline with verteporfin photodynamic therapy in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab placebo (sham intravitreal injection) on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
88821379|NCT04361955|Other|ET with DBS on|intervention is EEG while performing tasks and at rest
88821380|NCT04361955|Other|ET with DBS off|intervention is EEG while performing tasks and at rest
89125675|NCT00674323|Active Comparator|Ranibizumab monotherapy|Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
89125676|NCT00763633|Active Comparator|highB6|high vitamin B6
89125677|NCT00763633|Active Comparator|lowB6|low vitamin B6
89125678|NCT03935542||MPI arm|For the MPI arm, patients with severe jailed diagonal branch disease with available MPI in 3 months were selected from the Seoul National University Hospital Cardiac Catheterization and MPI database.
89125679|NCT03935542||CCTA arm|For the CCTA arm, patients from a previous multicenter prospective CCTA registry were retrospectively reviewed for a post-hoc analysis.
89125680|NCT00763711|Experimental|Injection with Needle Guide|
89125681|NCT04586140||Patients with COVID-19 infection|This study will be carried out on patient data usually collected as part of their care. The patients were infected with COVID-19 and hospitalized between 03/25/2020 and 05/07/2020, and who benefited from GAREC's intervention.
89125682|NCT04586140||Nursing staff AND GAREC Members|This study also concerns data collected in the context of semi-structured interviews with health professionals, in a prospective manner. These are caregivers who are members of GARED or who called on GAREC between 25/03/2020 and 07/05/2020.
89125683|NCT02558179||Nugent Score >/= 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Diagnosis of bacterial vaginosis (study group) according to Nugent score and/or diagnosis of vulvovaginal candidiasis; and/or diagnosis of Trichomonas vaginalis.
89125684|NCT02558179||Nugent Score< 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Bacterial vaginosis not diagnosed according to Nugent score (<7).
89125685|NCT00763789|Experimental|1|Local anaesthesia and remifentanil sedation
89125686|NCT00763789|Other|2|Total intravenous anaesthesia
89125687|NCT04081402|Experimental|HU-014 Inj|
89125688|NCT04081402|Active Comparator|Botox Inj|
89125689|NCT00763945||1|Patients representing to the hospital with acute coronary syndrome
89125690|NCT00760357||Retrospective Anaylsis|Once the patients are identified that have a full thickness wound on a limb clearly identified as having critical limb ischemia, these patients will be evaluated
89125691|NCT04115956|Experimental|Melflufen and dexamethasone in combination|Intravenous infusion of melflufen Day 1 of 28 day cycles, in combination of dexamethasone on Days 1 and 2 of each 28-day cycle.
89125692|NCT02584192|Experimental|the rehabilitation group|entailing an early home-based CR program
89125693|NCT02584192|Other|the control group|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
89125694|NCT02587156|Experimental|Meal serving at high dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount above 1.5 g protein/kg/day
89125695|NCT02587156|Active Comparator|Meal serving at low dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount below 0.8 g protein/kg/day
89125696|NCT04579042|Experimental|Septoplasty Using Cartilaginous Batten Graft|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
89125697|NCT04079608|Experimental|FLASH curriculum|Students who will receive the FLASH high school curriculum.
89125698|NCT04079608|Active Comparator|Sexual Health Education for Adolescents|Students will receive a five-session knowledge-based sexual health curriculum designed for classroom settings.
89125699|NCT04081480|Other|Valacyclovir oral solution|Valacyclovir oral solution as administered in standard of care. Dosage: 10 mg/kg BID for children weighing less than 40 kg and 500 mg BID for children weighing 40 kg or more.
89125700|NCT00678301|Experimental|SYNFLORIX™ + ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Synflorix™ vaccine, according to a 3-dose schedule at 6-10-14 weeks of age co-administered with 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to the same schedule. The Synflorix™ and Zilbrix™ Hib vaccines were administered by intramuscular injection, in the right and left thigh respectively. The Polio Sabin™ vaccine was administered orally.
89125701|NCT00678301|Experimental|ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to a 3-dose schedule at 6-10-14 weeks of age. The Zilbrix™ Hib vaccine was administered by intramuscular injection, in the left thigh. The Polio Sabin™ vaccine was administered orally.
88821381|NCT04349514||Friedreich ataxia|Individuals with a diagnosis of Friedreich ataxia.
88821382|NCT04349514||Control|Individuals without a diagnosis of Friedreich ataxia.
89125702|NCT02586454|Experimental|Transmuscular quadratus lumborum (QL) block|Bilateral QL block using 20 ml 0.375% ropivacaine in each side (to a maximum dose 3 mg/kg) plus patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
89125703|NCT02586454|Active Comparator|Control|Patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
89125704|NCT02586376|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
89125705|NCT02586376|Experimental|4J LLLT|The Laser radiation will be made with 4J by spot.
89125706|NCT02586376|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
89125707|NCT02586376|Experimental|8J LLLT|The Laser radiation will be made with 8J by spot.
89125708|NCT02586298|Experimental|ICSI with mitochondria|Half of the Metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and autologous mitochondria from the patient's ovarian cortex will be introduced into the oocyte during the intracytoplasmic sperm injection in the vitro fertilization treatment.
89125709|NCT02586298|Active Comparator|Control ICSI without mitochondria|The other half of the metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and will not receive autologous mitochondria during the intracytoplasmic sperm injection (ICSI) in the vitro fertilization treatment. Control Group
89125710|NCT00939770|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89125711|NCT03931486||Operatively treated patients with Achilles tendon rupture|Cohort of operatively treated patients with acute Achilles tendon rupture.
89125712|NCT02558569|Experimental|Levobupivacaine|Scalp nerve block with 0.5% Levobupivacaine adds up to intravenous fentanyl for intraoperative pain control during supratentorial craniotomy with brain tumor removal. The scalp block includes 4-6 nerves which give sensory supply to related location with the use of total 10-15 ml of 0.5% Levobupivacaine. Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given. is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
89125713|NCT02558569|Sham Comparator|NSS|Scalp nerve block with 10-15 ml of 0.9% sodium chloride(NaCl), or normal saline (NSS) includes 4-6 nerves which give sensory supply to related location (sham block). Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
89125714|NCT04079530|Experimental|Treatment A|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
89125715|NCT04079530|Experimental|Treatment B|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
89125716|NCT04079530|Experimental|Treatment C|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
89125717|NCT04079530|Experimental|Treatment D|Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
89125718|NCT04079530|Experimental|Treatment E|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
89125719|NCT04079530|Experimental|Treatment F|Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
89125720|NCT04079530|Experimental|Treatment G|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
89125721|NCT04079530|Experimental|Treatment H|Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
89125722|NCT04079530|Experimental|Treatment I|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
89125723|NCT04079530|Experimental|Treatment J|Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
89125724|NCT04079530|Experimental|Treatment K|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
88821383|NCT04340063|Active Comparator|Treadmill group|Participants randomized to the Treadmill group will complete high intensity gait training on a treadmill.
89125725|NCT04079530|Experimental|Treatment L|Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
89125726|NCT00764023||No treatment|
89125727|NCT00764023||human samples|
89125728|NCT00939692|Experimental|Torrent Topiramate|tablet containing 25 mg of topiramate (Torrent Pharmaceuticals)
89125729|NCT00939692|Active Comparator|Topamax|tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)
89125730|NCT00920608|Experimental|A|AZD9056 400 mg and Methotrexate
89125731|NCT04674514|Experimental|Arm A (Single agent)|Dose escalation APG-2575 at 3 dose levels 3+3 design.
89125732|NCT04674514|Experimental|Arm B (combo)|Dose escalation APG-2575 at 3 dose levels in combination with Rd, 3+3 design.
89125733|NCT02586220||normal pregnant women|150 normal pregnant women (28-32 weeks' gestation)
89125734|NCT02586220||pregnant women with gestational|100 pregnant women with gestational diabetes (28-32 weeks' gestation)
89125735|NCT04672252|Experimental|Cohort 1 - CBD|
89125736|NCT04672252|Placebo Comparator|Cohort 2 - Placebo|
89125737|NCT04081012|Experimental|N-acetyl Cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before endarterectomy or balloon angioplasty.
89125738|NCT04081012|Placebo Comparator|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals. All study medications will be prepared by the Pharmacology department, which is not involved in patient care; the name of the medication and dose of the original ampule will be erased and also an identification label will be placed with the name, registration number, bed number, date and will be indifferent for groups with the same type of ampoule, with the same type of labeling
88821384|NCT04340063|Experimental|Movement Amplification group|The locomotor training protocol described for the Treadmill group will be used for the Movement Amplification group with one exception. The Movement Amplification group will perform all gait training within the movement amplification environment.
89125739|NCT02584114|Experimental|Memory training group|The intervention is self-administration of 4 hours of memory training over 4 days per week, for 3 weeks (12 hours total). Memory training will be done with the Peak app for memory training http://www.peak.net.
89125740|NCT02584114|Active Comparator|Non-memory training group|The intervention is self-administration of 4 hours of training of games that do not involve memory such as language and card games over 4 days per week, for 3 weeks (12 hours total).
89125741|NCT02584036||Receiving Influenza Vaccine|Patients who receive an influenza vaccine at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
89125742|NCT04760002||Atrial Fibrillation Patients|"Atrial fibrillation patients are to be investigated for sleep apnea by the a home-monitoring device.~Other inclusion criteria are:~>18 years <90 years"
89125743|NCT00584740|Experimental|AIN457|AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.
89125744|NCT00584740|Placebo Comparator|Placebo|Matching placebo to AIN457 was given as an infusion at day 1 and day 22.
89125745|NCT04081090|Experimental|Brain HQ adaptive Cognitive Therapy Modules|Brain HQ licensed modules that adapt to each individuals unique strengths and weaknesses to address deficits and improve neuroplasticity.
89125746|NCT04081090|Active Comparator|Brain HQ Active Control Modules|Participants in this arm will complete puzzles such as crossword puzzles, Sudoku, etc.
89125747|NCT00942968|Experimental|1|
89125748|NCT00942734|Experimental|RAD001 + Erlotinib|RAD001 1 tablet (5 mg) by mouth every day of each 28 day study cycle. Erlotinib one tablet (150 mg) by mouth every day of each 28 day study cycle.
89125749|NCT00584194|Experimental|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
89125750|NCT02586142|Experimental|Botulinum toxin type A(BTX-A) injection|To inject Botulinum toxin type A on the spasticity lower extremities for participants by ultrasounds guidance.
89125751|NCT02586142|Active Comparator|BTX-A injection plus stretching exercise|Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.
89125752|NCT00919984|Experimental|IP Chemotherapy|Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
89125753|NCT00942422|Experimental|defined green tea catechin extract / correlative analysis|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89125754|NCT02585986|Active Comparator|Probiotic|daily intake of 1 capsule containing probiotic.
89125755|NCT02585986|Placebo Comparator|Placebo|daily intake of 1 capsule containing placebo
89125756|NCT00603824|Experimental|A|Fondaparinux
89125757|NCT00603824|Active Comparator|B|Direct thrombin inhibitor
89125758|NCT00677833|Experimental|1|
89125759|NCT00677833|Experimental|2|
89125760|NCT05086874||Exposed group|A group of patients with ischemic stroke, treated with butylphthalide
89125761|NCT05086874||Non-exposed group|A group of patients with ischemic stroke, treated with Urinary Kallidinogenase
89125762|NCT04204148||Clinical characteristics of the patients|including sex,age,smoking history,tumor location and tumor diameter
89125763|NCT04204148||Logistic regression analysis of influencing factors of c|The Leicester Cough Questionnaire in Mandarin Chinese (LCQ-MC) was used to evaluate the degree of cough in patients. The LCQ-MC is divided into three dimensions: physical, psychological and social. There are a total of 19 questions, and each question has seven options (positive scoring, grades 1-7; the higher the score is, the lighter the cough).
89125764|NCT02586766|Experimental|Behavioral: Project Sync|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care
89125765|NCT02586766|No Intervention|Comparison Group|This group did not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
89125766|NCT04268108||group 1|"arm 1: secondary resistance to anti-PD-1 therapy: this patients group received liquid tumor infiltrating lymphocytes combined anti-PD-1 therapy.~arm 2: primary resistance to anti-PD-1 therapy: this patients group received FC preconditioning before received liquid tumor infiltrating lymphocytes"
89125767|NCT05466838|Experimental|PERT plus Standard of Care|Initiation of PERT at time of discharge post pancreaticoduodenectomy with dose escalation upon symptom presentation
88821385|NCT04336969|Other|T1D Patients|Participants will wear a Continuous Glucose Monitor (CGM) with remote data monitoring
89125768|NCT05466838|Other|Standard of Care|Standard of care (no PERT) until presentation of PEI symptoms.
89125769|NCT00764101|Experimental|1|9 sessions of attentional bias modification (computerized training program)
89125770|NCT00764101|Placebo Comparator|2|Attentional control condition (placebo training program)
89125771|NCT00764179|Experimental|1|hyperproteinic milk
89125772|NCT00764179|Active Comparator|2|Normoproteinic milk
89125773|NCT04048915|Experimental|Long live drama|Primary school students watched an interactive long live drama (90 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
89125774|NCT04048915|Experimental|Short live drama|Primary school students watched an interactive short live drama (60 minutes) in schools. DVD and worksheets were also distributed to students and asked them to watch the DVD and finish the worksheets with their parents.
89125775|NCT04048915|No Intervention|Waitlist control|Primary school students received no intervention during the 3-month study period. After the study finished, the students watched either short or long live drama, and DVD with worksheets were distributed to students and they were invited to share with their parents.
89125776|NCT04652830|Active Comparator|Naprapathy training|Training program for three months
89125777|NCT04652830|Placebo Comparator|Control group|No change of daily routines
89125778|NCT00764257|Experimental|PREVELLE Shape|
89125779|NCT00764257|Active Comparator|Restylane|
89125780|NCT02585908|No Intervention|Experimental Group A(control group)|regular treatment and follow up
89125781|NCT02585908|Experimental|Experimental Group B|CIK will be used against tumor cells.
89125782|NCT02585908|Experimental|Experimental Group C|γδ T will be used against tumor cells.
89125783|NCT02585908|Experimental|Experimental Group D|CIK and γδ T will be used against tumor cells.
88821386|NCT04329312||Pulmonary arterial hypertension (PAH)|The patients with PAH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
89125784|NCT00764335||unilateral normal|total hip arthroplasty one side, normal offset of medial femoral head
89125785|NCT00764335||bilateral normal|total hip arthroplasty both sides, normal offset of medial femoral head
89125786|NCT00764335||bilateral abnormal offset|total hip arthroplasty both sides, abnormal offset of medial femoral head
89125787|NCT00764335||controls|Healthy, age-matched control group
89125788|NCT00760825|Experimental|Vaccine|killed bivalent (O1 and O139)whole cell oral cholera vaccine(Shanchol™)
89125789|NCT02585752|Experimental|Single centre, single arm|Noninvasive ventilation with expiratory modulation. Assessment of comfort and blood gases.
89125790|NCT00764803||2|Subjects who meet the indications for use and are implanted with the Encore MJS™ Knee System.
89125791|NCT00764803||1|Subjects who meet the indications for and are implanted with the Encore 3DKnee™ system.
89125792|NCT02585674|Experimental|MyStar DoseCoach|MyStar DoseCoach - Device-supported treat-to-target regimen. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
89125793|NCT02585674|Active Comparator|Routine Titration|Routine Titration - Routine titration defined by the Investigator. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
89125794|NCT00942266|Experimental|Arm I|Patients receive low-dose oral vorinostat once daily on days 1-3, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV over 46 hours on days 2 and 3. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
89125795|NCT00942266|Experimental|Arm II|Patients receive high-dose oral vorinostat once daily on days 1-3 and leucovorin calcium and fluorouracil as in arm I. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
89125796|NCT04519294|Active Comparator|SURE|
89125797|NCT04519294|Active Comparator|Standard Ureteroscopy (Basketing)|
89125798|NCT04079374|Experimental|Etanercept|Patients receive Etanercept in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
89125799|NCT04079374|Active Comparator|Enbrel|Patients receive Enbrel in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
89125800|NCT03930004||Type 1 diabetic patients|"Patients diagnosed with type 1 diabetes mellitus with criteria for cardiovascular autonomic neuropathy, asymptomatic, normotensive, with negative medical history of cardiovascular disease.~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
89125801|NCT03930004||Control - Healthy subjects|"Fifteen age- and sex-matched healthy control subjects, asymptomatic, normotensive, with negative medical history of cardiovascular disease.~Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function."
89125802|NCT00942188|Experimental|0.6 milligrams (mg) LY2189102|
89125803|NCT00942188|Experimental|18 mg LY2189102|
89125804|NCT00942188|Experimental|180 mg LY2189102|
89125805|NCT00942188|Placebo Comparator|Placebo|0.9% Sodium Chloride
89125806|NCT00673231|Experimental|1|2.5mg
89125807|NCT00673231|Experimental|2|5mg
89125808|NCT00673231|Experimental|3|10mg
89125809|NCT00673231|Placebo Comparator|4|
89125810|NCT02583958|Experimental|Device Urgo 3103166|Soft-adherent hydro-desloughing dressing
89125811|NCT02583958|Active Comparator|Device Aquacel Extra|Hydrofibre dressing
89125812|NCT00604058|Experimental|Group A|
89125813|NCT00604058|Active Comparator|Group B|
89125814|NCT02586610|Experimental|Neoadjuvant Treatment|"All subjects will receive concurrent chemoradiation and pembrolizumab neoadjuvant treatment for 6 weeks:~Pembrolizumab 200 mg IV Days 1, 22 and 43~Capecitabine 825 mg/m2 PO in twice daily doses (total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days~Radiation therapy 50.4 GY. Daily fractions of 1.8 Gy over a 6 week interval, excludes weekends"
89125815|NCT05071040|Experimental|Exercise group|Participants will follow a strength exercise program monitored through the use of a specifically designed smartphone application.
89125816|NCT05071040|No Intervention|Control group|Continue their daily routine without exercise prescription.
89125817|NCT00604682|Experimental|Administration of CC10004|
89125818|NCT00672841|Active Comparator|2|Standard care/empiric therapy group
89125819|NCT00672841|Experimental|1|Active surveillance/ preemptive therapy group
89125820|NCT00920296|Experimental|Cohort 1|All subjects
89125821|NCT04080388|Active Comparator|Control Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The control group (half of the patients) will be discharged without additional intervention.
89125822|NCT04080388|Active Comparator|Interventional Group|Patients prior to discharge for acute heart failure admission will be examined with a lung impedance device for their suitability for discharge according to their level of pulmonary congestion. Only patients who are unsuitable for discharge according to the lung impedance assessment will be enrolled in the study. The interventional group (half of the patients) will continue anti-congestive treatment while hospitalized until achieving a suitable level of decongestion.
89125823|NCT00764959||Linear Hip|Encore Linear Hip System
89125824|NCT02585596|Experimental|YH23537 1000mg/day|YH23537 500mg 1 tab, placebo 500mg 2tab twice a day (before morning,evening meal) during 12 weeks
89125825|NCT02585596|Experimental|YH23537 2000mg/day|YH23537 500mg 2tab, placebo 500mg 1tab twice day (before morning,evening meal) during 12 weeks
89125826|NCT02585596|Experimental|YH23537 3000mg/day|YH23537 500mg 3tab a day twice day (before morning,evening meal) during 12 weeks
89125827|NCT02585596|Experimental|YH23537 3000mg/day loading 1000mg/day|YH23537 500mg 3tab twice a day (before morning,evening meal) during 4weeks and YH23537 500mg tab twice a day (before morning,evening meal) during 8weeks
89125828|NCT02585596|Placebo Comparator|Placebo|YH23537 500mg placebo 3tab twice a day
89125829|NCT00765115|Experimental|1|100 mg LY 450139 oral
89125830|NCT00765115|Experimental|2|140 mg LY450139 oral
89125831|NCT00765115|Experimental|3|280 mg LY450139 oral
89125832|NCT00765115|Experimental|4|Placebo
89125833|NCT04080622|Placebo Comparator|Placebo|Usual care
89125834|NCT04080622|Active Comparator|Selenium|Usual care + selenium 300 µg/day (IV infusion)
88802246|NCT05484024|Experimental|iTNT group|The intervention of iTNT group is Short-course radiotherapy followed by neoadjuvant chemotherapy and PD-1 inhibitor, which consists of a short-course radiotherapy(SCRT, 5 Gy x 5 alone), then after 14 days of radiotherapy completed, four cycles of PD-1 inhibitor and four cycles of CAPOX or six cycles of mFOLFOX will be performed. The regimen of PD-1 inhibitor and CAPOX treatment includes Sintilimab 200 mg IV, day 1，Oxaliplatin 130 mg/m2 IV day 1，Capecitabine 1000 mg/m2 twice daily PO for 14 days(3 weeks per cycle). The regimen of PD-1 inhibitor and mFOLFOX treatment includes Sintilimab 200 mg IV day 1(3 weeks per cycle), Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion(2 weeks per cycle), then followed by a total mesorectal excision(TME) or Watch & Wait strategy for clinical complete remission voluntary patients.
88802247|NCT05484024|Active Comparator|TNT group|The intervention of TNT group is Short-course radiotherapy followed by neoadjuvant chemotherapy, which consists of a short-course radiotherapy(SCRT, 5 Gy x 5 alone), then after 14 days of radiotherapy completed, four cycles of CAPOX or six cycles of mFOLFOX will be performed. The regimen of CAPOX treatment includes Oxaliplatin 130 mg/m2 IV day 1，Capecitabine 1000 mg/m2 twice daily PO for 14 days(3 weeks per cycle). The regimen of mFOLFOX treatment includes, Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion(2 weeks per cycle), then followed by a total mesorectal excision(TME) or Watch & Wait strategy for clinical complete remission voluntary patients.
89125835|NCT02585518||Obese|Children and adolescents with a BMI at or above the 85th percentile for age and sex
89125836|NCT02585518||Healthy control|Children and adolescents with a BMI below the 85th percentile for age and sex
89125837|NCT03928912||without fracture nonunion|The patients who undergone surgery after tibial shaft fracture did not exist fracture nonunion
88802248|NCT02027272|Active Comparator|Dexamethasone|Dexamethasone 12 mg, 2 doses, 12 hours apart.
88802249|NCT02027272|Placebo Comparator|Placebo|Placebo, 2 doses, 12 hours apart
89125838|NCT03928912||with fracture nonunion|The patients who undergone surgery after tibial shaft fracture existed fracture nonunion
89125839|NCT04079140|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
89125840|NCT04079140|Placebo Comparator|placebo|one tablet of placebo self-administered by the patient 12 hours before IUD insertion.
89125841|NCT00673465|Experimental|Treatment sequence 1: SCH 497079 → Placebo → Metformin|Participants received SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks followed by metformin daily for 4 weeks.
89125842|NCT00673465|Experimental|Treatment sequence 2: Placebo → Metformin → SCH 497079|Participants received placebo daily for 4 weeks followed by metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
89125843|NCT00673465|Experimental|Treatment sequence 3: Metformin → SCH 497079 → Placebo|Participants received metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks.
89125844|NCT00673465|Experimental|Treatment sequence 4: SCH 497079 → Metformin → Placebo|Participants received SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks followed by placebo daily for 4 weeks.
89125845|NCT00673465|Experimental|Treatment sequence 5: Placebo → SCH 49709 → Metformin|Participants received placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks.
89125846|NCT00673465|Experimental|Treatment sequence 6: Metformin → Placebo → SCH 497079|Participants received metformin daily for 4 weeks followed by placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
89125847|NCT00764413|Active Comparator|1|Both study arms receive both active treatment = methylprednisolone and an inactive treatment = Sodium chlorid (dummy)
89125848|NCT00764413|Active Comparator|2|Both arms receives both active treatment and inactive treatment = dummy. Active treatment is methylprednisolone, inactive treatment is sodium chlorid.
89125849|NCT02583490|Experimental|Low Pulse Amplitude ECT (LAP)|Right Unilateral LAP ECT
89125850|NCT02583490|Active Comparator|standard Right Unilateral ECT|standard Right Unilateral ECT
89125851|NCT04078984||Experimental|Experimental group is composed by patients that enter the weaning phase following a moderate to severe Acute Respiratory Distress Syndrome (ARDS) equiped with a nasogastric allowing measures of Electrical Activity of diaphragm (EAdi) will be included. Driving Pressure will be measured following the method used by Bellani et al. A weaning test will be conducted daily.
89125852|NCT00941798|Experimental|QMF149 Twisthaler® 500/400|QMF149 Twisthaler® (indacaterol maleate 500 µg/mometasone furoate 400 µg), once daily (QD)
89125853|NCT00941798|Active Comparator|Mometasone Twisthaler®|Mometasone Twisthaler®, 400 µg QD
89125854|NCT00604760|Experimental|A|
89125855|NCT00604760|Experimental|B|
89125856|NCT00604760|Experimental|C|
89125857|NCT00604760|Placebo Comparator|D|
89125858|NCT00583102|Experimental|Lovastatin followed by Cytarabine|The subject will receive high dose cytarabine as well as lovastatin. The subject will take doses of lovastatin twice a day, about 12 hours apart. On the third day, the subject will begin high-dose cytarabine IV over 3 hours, twice a day, starting 1 hour after the lovastatin dose for 5 days.
89125859|NCT02585440|Experimental|Group A|CMX157, tablet, 5 mg, QD, 14 days versus CMX157 placebo, 5 mg, tablet, QD, 14 days
89125860|NCT02585440|Experimental|Group B|CMX157, tablet, 10 mg, QD, 14 days versus CMX157, placebo tablet, 10 mg, QD, 14 days
89125861|NCT02585440|Experimental|Group C|CMX157, tablet, 25 mg, QD, 14 days versus placebo CMX157, placebo tablet, 25 mg, QD, 14 days
89125862|NCT02585440|Experimental|Group D|CMX157, tablet, 50 mg, QD, 14 days versus CMX157, placebo tablet, 50 mg, QD, 14 days
89125863|NCT02585440|Experimental|Group E|CMX157, tablet, 100 mg, QD, 14 days versus CMX157, placebo tablet, 100 mg, QD, 14 days
89125864|NCT04266860|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
89125865|NCT04266860|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
89290154|NCT03936348|No Intervention|control group (CG)|Participants who received the standard medical recommendations for patients with COPD, but not participated in the exercise intervention program
89290155|NCT01125696|Active Comparator|Standard of Care|
89125866|NCT05536726|Experimental|608 160 mg W0+80 mg Q2W+80 mg Q4W|Participants will receive starting dose of 160 milligrams (mg) 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection during induction period (12 weeks). During the maintenance period, participants will receive 80mg 608 once every four weeks (Q4W).
89125867|NCT05536726|Experimental|608 160 mg Q4W+160 mg Q8W|Participants will receive 160mg 608 once every four weeks (Q4W) by subcutaneous injection during induction period (12 weeks) followed by 160mg 608 once every eight weeks (Q8W) during maintenance period.
89125868|NCT05536726|Placebo Comparator|Placebo|Participants will receive Placebo by subcutaneous injection during induction period and then, will be re-randomized to either receive starting dose of 160mg 608 at week 12 followed by 80mg 608 once every four weeks (Q4W) or 160mg 608 once every eight weeks (Q8W) during maintenance period.
89125869|NCT00605852|Experimental|Subjects receiving treatment in cohort I|Eligible subjects will receive three single doses of GSK835726 and one single dose of placebo in cohort I.
89125870|NCT00605852|Experimental|Subjects receiving GSK835726 in cohort II|Eligible subjects will receive repeat doses of GSK835726 once daily for 7 days.
89125871|NCT00605852|Placebo Comparator|Subjects receiving placebo in cohort II|Eligible subjects will receive repeat doses of placebo once daily for 7 days.
89125872|NCT00605852|Experimental|Subjects receiving treatment in cohort III|Eligible subjects will receive two single doses of GSK835726 and one single dose of placebo in cohort III.
89125873|NCT03931954||Study population|Patients completing the inclusión criteria
89125874|NCT00605930|Active Comparator|Pyruvate, creatine, niacinamide|Pyruvate, creatine, niacinamide administered
89125875|NCT00605930|Placebo Comparator|Placebo|placebo
89125876|NCT00602186|Experimental|1|taking Tamsulosin
89125877|NCT00602186|Active Comparator|2|taking prasosin
89125878|NCT04204304|Experimental|Isotretinoin-induced adverse effect group|Patients receiving isotretinoin with dose of 0.5-1 mg/kg/day and had musculoskeletal adverse effects
89125879|NCT04204304|Active Comparator|Control group|Pateients receiving isotretinoin with dose of 0.5-1 mg/kg/day had no musculoskeletal adverse effects
89125880|NCT02586688|Active Comparator|Phase I TMS Active|Blinded Active TMS coil (Phase I). Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
89125881|NCT02586688|Sham Comparator|Phase I TMS Sham|Blinded Sham TMS coil (Phase I) Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
89125882|NCT02586688|Other|Phase II Open Label Active TMS|Open label active TMS coil. Open label active NeuroStar® TMS.
89125883|NCT02586688|Other|Phase III Long-Term Follow up TMS Active|Long term follow up with open label active TMS for retreatment as needed. Open label active NeuroStar® TMS.
89125884|NCT05380778|Experimental|Shallow Anesthesia|Experimental: Shallow Anesthesia Standard anesthesia with fentanyl, propofol for shoulder surgery together with an interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
89125885|NCT05380778|Experimental|Deep Anesthesia|Experimental: Deep Anesthesia Standard anesthesia with fentanyl, propofol for shoulder surgery together with an interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS < 45 (group 1, deep anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below a BIS level of 45 were counted.
89125886|NCT02585362|Active Comparator|Intervention group|Participants will receive physical exercise, nutrition counseling and a whey protein Supplement over 12 weeks
89125887|NCT02585362|No Intervention|Control group|Participants will receive standard care
89125888|NCT02852720|Experimental|Pharmacokinetics|A bilateral TAP block will be performed with 20 ml levobupivacaine 0,25% and epinephrine (5ug/ml). After the blockade, venous blood samples will be taken on predefined times.
89125889|NCT00604838|Experimental|I|
89125890|NCT05857683|Active Comparator|extension pin block|this is the technique for mallet finger where 2 pins are used, one for the extension block and other intramedullary for the extension posture
89125891|NCT05857683|Active Comparator|pin orthosis- extension block pin|this is the technique for mallet finger where only 1 pin is used for extension block and an orthosis is applied for the extension posture
89125892|NCT05857618||Patients who have undergone exposer to General Anesthesia|Patients who have undergone general anesthesia at the University of Chicago Medical Center more than 20 times or patients who have general anesthesia 5 or fewer times in the past.
89125893|NCT05857605|Active Comparator|Standard Physical Therapy exercise instructions for Knee Osteoarthritis|"Participants enrolled in the control group will be provided standard physical therapy exercise instruction based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis. During their first visit, the participants will meet the trained research staff to trial a series of therapeutic exercises for medial knee OA. They will be provided a handout with pictures of these exercises after they have demonstrated the ability to complete them at the initial visit. The participants will then complete this program on their own for 8 weeks; performing the exercises 3 times per week.~Apart from these home-based exercise sessions participants in this group will complete 3 separate evaluation sessions onsite at the beginning, interim, and end of the study where they will complete a series of functional tests and fill standard questionnaires evaluating their pain, symptoms and knee function followed by thigh muscle strength testing."
89233677|NCT00451035|Experimental|Panobinostat (LBH589)|Participants were administered panobinostat 20 milligram (mg) orally once a day (OD) three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat were administered at the same time each morning with 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue treatment until they experienced unacceptable toxicity or disease progression.
89290156|NCT01125696|Experimental|Tenofovir|
89290157|NCT03932916|Experimental|experimental group 1|HHT201 17mg injection
89290158|NCT03932916|Experimental|experimental group 2|HHT201 34mg injection
89290159|NCT03932916|Active Comparator|experimental group 3|Donepezil Hydrochloride oral tablet 5mg
89290160|NCT03931980|Experimental|Robotic surgery|Patients undergoing robotic surgery for removal of rectal cancer.
89125894|NCT05857605|Experimental|Standard Physical Therapy exercise instructions for Knee Osteoarthritis + seated elliptical device|"Participants in the intervention group will be provided physical therapy (PT) exercise instruction based on Arthritis Foundation guidelines for physical activity specific to individuals with knee OA. Participants will be provided a handout with pictures of these exercises after they have demonstrated the ability to complete them at the initial visit. They will then complete this program on their own for 8 weeks; performing the exercises 3 times per week. This group will also receive a compact seated elliptical device which they will be expected to use for a min of 30 min for 5 days per week in conjunction with PT exercise instruction.~Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions on-site at the beginning, interim, and end of the study where they will complete a series of functional tests and fill standard questionnaires evaluating their pain, symptoms, and knee function followed by thigh muscle strength testing."
89125895|NCT05857579|Experimental|MBE-IPL-MGX treatment and home-based therapy.|In this arm, participants received three sessions of MBE-IPL-MGX treatment and home-based therapy.
89125896|NCT05857579|Active Comparator|Home-based therapy|In this arm, participants received home-based therapy alone.
89125897|NCT05857488|Experimental|Trans Nasal Endomicroscopy Imaging|The subject will have the transnasal introduction tube inserted, and OCT images will be acquired using the OCT compact imaging system. The subject may also undergo a microbiome brushing and/or intestinal potential difference measurement procedure during the study visit.
89125898|NCT05857462|Experimental|Post-admission FICB|Post-admission FICB, drug 0.33% bupivacaine 30 ml + Pre-operative FICB 0.33% bupivacaine 30 ml. Peri-operative pain management protocol : paracetamol + opioid.
89125899|NCT05857462|No Intervention|Only preoperative FICB|No post-admission FICB + Pre-operative FICB 0.33% bupivacaine 30 ml. Peri-operative pain management protocol : paracetamol + opioid.
89125900|NCT05857449|Experimental|Part A|Each subject receive the same dose(X1mg) of LPM3480392 in 15minutes in the first cycle, 5 minutes in the second cycle, and 2 minutes in the third cycle .
89125901|NCT05857449|Experimental|Part B|Each subject receive LPM3480392 X2mg in the first cycle and LPM3480392 X3mg in the second cycle .
89125902|NCT05857436|Experimental|apical periodontitis|60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
89125903|NCT05857436|Experimental|control|A total of 30 volunteers who were determined to be systemically and orally healthy (not having AP indication), were included in the study as the control group.
89125904|NCT05857423|Other|Control Group|Preterm infants who are applied gentle human touch by nurses
89125905|NCT05857423|Experimental|Experimental Group|Preterm infants who are applied gentle human touch by mother
89125906|NCT05857410|No Intervention|control group (group N)|
89125907|NCT05857410|Active Comparator|heating group (group T)|
89125908|NCT05857410|Active Comparator|DEX group (group D)|
89125909|NCT05857410|Experimental|heating combined with DEX group (group TD)|
89125910|NCT05857319||General Cohort|The General Cohort includes all participants of the study. These are enrolled in the RNPC Program and will provide clinical and biological data usually collected in the RNPC centers, enriched by data from additional clinical and biological examinations as well as by self-questionnaires completed by the participants.
89125911|NCT05857319||Connected Objects Group|"Depending on the RNPC center in which the participant is followed, he/she will be offered to be part of the Connected Objects subgroup, with specific additional examinations on inclusion as well as at certain key times of the intervention:~Measurement of anthropometric parameters and evaluation of arterial stiffness using the Body Cardio connected scale (Withings).~Sleep evaluation using the Sleep Analyzer (Withings); Measurements taken at the participant's home."
89125912|NCT05857319||Obstructive Sleep Apnea Syndrome (OSAS) Group|"Depending on the RNPC center in which the participant is followed, he/she will be offered to be part of the OSAS subgroup, with specific additional examinations on inclusion as well as at certain key times of the intervention:~Sleep assessment and diagnosis of OSAS (if applicable) via the Sunrise device. Measurements taken at the participant's home."
89125913|NCT05857319||Neuropathies Group|"Depending on the RNPC center in which the participant is followed, he/she will be offered to be part of the Neuropathies subgroup, with specific additional examinations at each visit:~Detection of diabetic neuropathies using SUDOSCAN/EZSCAN technology (Withings). Measurements taken at the center."
89125914|NCT05857306|Active Comparator|Olvanil|
89125915|NCT05857306|Placebo Comparator|Placebo|
89125916|NCT05857293|Experimental|Cyanotic neonate|Cyanotic neonates with PDA dependent pulmonary circulation will be treated with catheter guided PDA stent implantation to keep duct patency and improve oxygen saturation
89125917|NCT05857280|Active Comparator|EXOPULSE Mollii Suit Stimulation Active|This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes.
89125918|NCT05857280|Sham Comparator|EXOPULSE Mollii Suit Stimulation Sham|This will be the EXOPULSE Mollii Suit Sham Stimulation. Stimulation will go on for 1 minute then it turns off while the control unit will remain on for total of 60 minutes.
89125919|NCT05857267|Experimental|Dorzolamide+Timolol PF|Glaucotensil TD LC, Laboratorios Poen
89125920|NCT05857267|Experimental|Dorzolamide + Timolol BAK|Glaucotensil TD, Laboratorios Poen
89125921|NCT05857215|Experimental|A- amilo-5MER solution for subcutaneous administration or matching placebo- 10 mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 10 mg
89125922|NCT05857215|Experimental|B- amilo-5MER solution for subcutaneous administration or matching placebo- 30 mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 30 mg
89125923|NCT05857215|Experimental|C- amilo-5MER solution for subcutaneous administration or matching placebo- 90 mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 90 mg
89125924|NCT05857215|Experimental|D- amilo-5MER solution for subcutaneous administration or matching placebo- 180 mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 180 mg
89125925|NCT05857215|Experimental|E- amilo-5MER solution for subcutaneous administration or matching placebo- 360mg|Amilo-5MER solution for subcutaneous administration or matching placebo at a dose of 360 mg
89125926|NCT05857202||Operated laryngeal cancer patients treated with non narcotic|Operated laryngeal cancer patients who were administered non narcotic drugs postoperative for pain management
88802250|NCT05475444|Experimental|Paste and solution of ciprofloxacin as Conventional Treatment|Paste and solution of ciprofloxacin as conventional dosage forms and drugs used to treat endodontics infections. For ciprofloxacin solution is used once daily while the paste form used weekly.
88802251|NCT05475444|Experimental|Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel|Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel dosage forms treat endodontics infections
88802252|NCT02012608|Active Comparator|Glutamine|Powdered Glutamine, 10.0 grams by mouth three times a day (TID) for 30 days, so that daily dose is 30 grams per day
88802253|NCT02012608|Placebo Comparator|Placebo|Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day
88802254|NCT05478486|Experimental|MSP008-22 treatment arm|"Oral Escalating doses of MSP008-22- total five doses, each in form of a single dose oral formulation/tablet.~Each trial participant will receive only one single oral dose of 05 identified dose levels of MSP008-22. Intra-patient dose escalation will not be carried out"
88802255|NCT01996852|Active Comparator|Standard ED Care|Standard medical treatment of erectile dysfunction (ED) including administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)
88802256|NCT01996852|Experimental|Standard ED Care + Cognitive-Behavioral Intervention|standard medical treatment of ED (administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)) in addition to cognitive-behavioral meetings
88802257|NCT01996852|No Intervention|Usual Care (UC)|Study participants will not receive any study intervention, but will continue with standard care.
88802258|NCT05478408||Questionnaires assessed general population|"① Internet users over the age of 18；~② Be able to read and communicate in Chinese."
88802259|NCT05478330|Experimental|Group A (Flutamide group)|"Flutamide was supplied in the form of yellow powder and obtained from Sigma Pharmaceutical Industries, Egypt.~Tween 80 and Propylene glycol were obtained from Sigma Pharmaceutical Industries, Egypt.~Oleic acid was purchased from El Gomhouria Company for Trading Chemicals and Medical Appliances, Egypt."
88802260|NCT05478330|Placebo Comparator|Group B (control group)|"Tween 80 and Propylene glycol were obtained from Sigma Pharmaceutical Industries, Egypt.~Oleic acid was purchased from El Gomhouria Company for Trading Chemicals and Medical Appliances, Egypt."
89125927|NCT05857202||Operated laryngeal cancer patients treated with non narcotic and opioids|Operated laryngeal cancer patients who were administered non narcotic and opioids postoperative for pain management
89125928|NCT05857202||Operated laryngeal cancer patients treated with opioids|Operated laryngeal cancer patients who were administered opioids postoperative for pain management
89125929|NCT05857189|Experimental|Experimental group|
89125930|NCT05857189|Active Comparator|Control group|
89125931|NCT05857189|Other|Healthy control group|patients in this group will be observed as a normal reference group
89125932|NCT05857137|Experimental|Active TMS|Participants will receive single-session administration of TMS. Functional MRI will be acquired before and immediately after the intervention.
89125933|NCT05857137|Placebo Comparator|Placebo TMS|Participants will also receive single session administration of placebo TMS (at least two days apart from the day of the active TMS). Functional MRI will be acquired before and immediately after the intervention.
89125934|NCT05857124|Experimental|Active treatment devices|Vielight Neuro RX Gamma active device
89125935|NCT05857124|Sham Comparator|Sham devices|Vielight Neuro RX Gamma sham device
89125936|NCT05857111||Study population|An estimate of 255 adult women (≥ 18 years old) who come to consult at the Breast Pathology Unit of La Paz Hospital (Madrid, Spain), because of discomfort, breast symptoms, or because they have been sent for specialized evaluation because of a diagnostic doubt will be included.
89125937|NCT05857085|Active Comparator|GLP 1 agonist|semaglutide in titrating doses 0,25 to 1,0 mg - duration of treatment12 weeks adding to insulin sheme (MDI or CII)
89125938|NCT05857085|Active Comparator|SGLT 2 inhibitor|empagliflozin 25 mg - duration of treatment 12 weeks adding to insulin sheme (MDI or CII or hybride system)
89125939|NCT05857085|No Intervention|comparator|continuing treatment only with insulin sheme (MDI or CII or hybride system)
89125940|NCT05857033|Experimental|Direct local anesthesia with Buzzy|
89125941|NCT05857033|Experimental|Indirect local anesthesia with Buzzy|
89125942|NCT05857033|Active Comparator|Direct local anesthesia|
89125943|NCT05857033|Active Comparator|Indirect local anesthesia|
89125944|NCT05856968|Active Comparator|continuous subcutaneous tissue closure|continuous subcutaneous tissue closure
89125945|NCT05856968|Active Comparator|Interrupted subcutaneous tissue closure|Interrupted subcutaneous tissue closure
89125946|NCT05856955|Active Comparator|Enhanced Usual Care|The active comparison group will receive a smartphone with the WebMD® health information application preloaded and a BP monitor. After recruitment, participants will receive a confirmatory interview, informed consent, and baseline device training via telephone, delivered by an experienced research assistant. Participants will be encouraged to complete 1 morning BP reading daily, irrespective of study arm. BP readings are automatically uploaded via Bluetooth to a centralized, secure platform to be accessible to the study PI.
89125947|NCT05856955|Experimental|Behavioral mHealth Coaching Intervention|Those randomized to the intervention group will receive a smartphone with the intervention program preloaded in addition to a BP monitor. After recruitment, participants will receive a confirmatory interview, informed consent, and baseline device training via telephone, delivered by an experienced research assistant. Participants will be encouraged to complete 1 morning BP reading daily, irrespective of study arm, however, only the intervention group will receive reminders from the mHealth coaching intervention to check BP daily. BP readings are automatically uploaded via Bluetooth to a centralized, secure platform to be accessible to the study PI.
89125948|NCT05856929||Renal transplant group|
89125949|NCT05856825||Sun Yat-sen Memorial Hospital|
89125950|NCT05856825||Renji Hospital, Shanghai Jiaotong University School of Medicine|
89125951|NCT05856825||The Third Medical Centre of Chinese PLA General Hospital|
89125952|NCT05856825||The First Affiliated Hospital of Zhengzhou University|
89125953|NCT05856825||Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College|
88802261|NCT00978874|Experimental|All subjects|
89125954|NCT05856825||Southwest Hospital, Third Military Medical Hospital (Army Medical University)|
89125955|NCT05856825||Tongji Hospital Affiliated to Tongji Medical College Hust|
89125956|NCT05856825||The First Affiliated Hospital of Xi'an Jiaotong University|
89125957|NCT05856825||The First Affiliated Hospital of Navy Medical University|
89125958|NCT05856825||The First Affiliated Hospital of Nanchang University|
89125959|NCT05856825||Zhongda Hospital Southeast University|
89125960|NCT05856825||The Second Xiangya Hospital, Central South University|
89125961|NCT05856825||The First Affiliated Hospital of Nanjing Medical University|
89125962|NCT05856825||Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital|
89125963|NCT05856825||Gansu Provincial Hospital|
89125964|NCT05856825||The Affiliated Yantai Yuhuangding Hospital of Qingdao University|
89125965|NCT05856825||West China Hospital, Sichuan University|
89125966|NCT05856825||The First Hospital of China Medical University|
89125967|NCT05856825||The Third Xiangya Hospital of Central South University|
89125968|NCT05856825||General Hospital of Central Theater Command|
89125969|NCT05856825||Kunming First People's Hospital|
89125970|NCT05856825||The East Campus of Qingdao Municipal Hospital|
89125971|NCT05856825||The second Affiliated Hospital of Kunming Medical University|
89290161|NCT03931980|Experimental|Laparoscopic surgery|Patients undergoing laparoscopic for removal of rectal cancer
88821387|NCT04329312||PH due to left-heart disease (PH-LHD)|The patients with PH-LHD received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
88821388|NCT04329312||Chronic thromboembolic pulmonary hypertension (CTEPH)|The patients with CTEPH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
89125972|NCT05856825||Second Hospital of Dalian Medical University|
89125973|NCT05856825||The Second Affiliated Hospital of Xi'an Jiaotong University|
89125974|NCT05856825||The First Hospital of Jilin University|
89125975|NCT05856825||Zhejiang Cancer Hospital|
89125976|NCT05856825||Peking University Third Hospital|
89125977|NCT05856825||Changzheng Hospital, Naval Medical University|
89125978|NCT05856825||Peking Union Medical College Hospital|
89125979|NCT05856825||The First Affiliated Hospital of Chongqing Medical University|
89125980|NCT05856825||Beijing United Family Hospital and Clinics|
89125981|NCT05856799|Active Comparator|Leadless Pacemaker|Implantation with a leadless pacemaker
89125982|NCT05856799|Active Comparator|Transvenous pacemaker|Implantation with a transvenous pacemaker
89125983|NCT05856734||University students living at home|Group of university students
89125984|NCT05856734||University students living in private accommodation|Group of university students
89125985|NCT05856734||University students living in the halls of residence|Group of university students
89125986|NCT05856734||Non-university participants living in Aberdeen|Group of age-matched volunteers living in the same city
89125987|NCT05856721|Active Comparator|cases group|One hundred patients with liver cirrhosis and GIT complaints
89125988|NCT05856721|Active Comparator|control group|One hundred patients with GIT complaints but not have any cormobidity
89125989|NCT05856682|Active Comparator|Pre-incision TAP (PITAP) and Rectus Sheath block|Pre-incision TAP block and Rectus sheath block will be performed after induction of anesthesia, just after prep and drape by Blind double pop technique by Anesthetist/Anesthesia trainee.Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be Immediate right subcostal region , 3 cm medially to mid axillary line The intervention and the control group will receive TAP block and rectus sheath block with Rupivacaine (3mg/kg). 1 ampule is of 10 ml and consists of 50mg /10ml, maximum dose will be 300mg. will use a of minimum volume of solution 50ml which will be made by 3 ampules of Rupivacaine and it will be diluted to a total of 20ml of injectate( distilled water )which is then divided between the four rectus block sites (5ml each) and one TAP block site(30ml ).
89125990|NCT05856682|Active Comparator|Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block|Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee.Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be Immediate right subcostal region , 3 cm medially to mid axillary line The intervention and the control group will receive TAP block and rectus sheath block with Rupivacaine (3mg/kg). 1 ampule is of 10 ml and consists of 50mg /10ml, maximum dose will be 300mg. will use a of minimum volume of solution 50ml which will be made by 3 ampules of Rupivacaine and it will be diluted to a total of 20ml of injectate( distilled water )which is then divided between the four rectus block sites (5ml each) and one TAP block site(30ml each).
89125991|NCT05856643|Experimental|SZ011 CAR-NK|
89125992|NCT05856630|Experimental|LY01022|
89125993|NCT05856630|Active Comparator|Zoladex®|
89125994|NCT05856604|Experimental|Experimental|Improvisational Music Therapy - 45min, one 2 one intervention.
89125995|NCT05856604|Active Comparator|Active Control|Storytelling activity - 45min, one 2 one intervention.
89125996|NCT05856578|Experimental|Mulberry Twig Alkaloid Tablet|Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet
89125997|NCT05856578|Active Comparator|Canagliflozin|Canagliflozin
89125998|NCT05856565||Retrospective|Photograph
89125999|NCT05856565||Prospective|
89126000|NCT05856396|Active Comparator|Pregnant women|Pregnant women will receive one dose of Pertussis-containing vaccine during pregnancy.
89126001|NCT05856396|Active Comparator|Non pregnant women|Non-Pregnant women will receive one dose of Pertussis-containing vaccine.
89126002|NCT05856396|Active Comparator|Infants born to Tdap-vaccinated mothers|Infants whose mothers have been immunized during pregnancy with Tdap vaccine. Infants will receive three doses of Pertussis-containing vaccine (with 28 days interval starting at two months of age).
89126003|NCT05856396|Active Comparator|Infants born to non Tdap-vaccinated mothers|"Infants whose mothers have not been immunized during pregnancy with Tdap vaccine.~Infants will receive three doses of Pertussis-containing vaccine (with 28 days interval starting at two months of age)."
89126004|NCT05856383||Group of ues of inetetamab combined with pyrotinib and vinorelbine|Group of ues of inetetamab combined with pyrotinib and vinorelbine
89233678|NCT00468585|Experimental|1 Capecitabine and Bevacizumab|The Phase II trial has a Simon mini-max two-stage design. Twenty-seven patients will be enrolled to the first stage of the Phase II trial, with a target accrual of 40 patients. The treatment dose of capecitabine as determined in the Phase I portion of this trial will be administered orally in two divided doses daily on Days 1 through 7 and Days 15 through 21 in a 28 day cycle. Phase II patients will receive bevacizumab 10 mg/kg intravenously every 2 weeks concurrently with oral capecitabine. Patients will be evaluated for toxicity between Days 3 to 5 (complete blood count only), Day 8, Day 15, and Day 22 during cycle #1. Thereafter, toxicity will be assessed on Days 1 and 15. Efficacy will be assessed with every other week physical examination and radiographic scans of measurable disease every 12 weeks.
89233679|NCT01021839|Active Comparator|Bovine Carotid Artery Graft|
89233680|NCT01021839|Active Comparator|Expanded Polytetrafluoroethylene Grafts|
89233681|NCT01026597|Experimental|Cohort 1|Dose 1 versus placebo
89233682|NCT01026597|Experimental|Cohort 2|Dose 2 versus placebo
89233683|NCT01026597|Experimental|cohort 3|Dose 3 versus placebo
89233684|NCT01026597|Experimental|cohort 4|Dose 4 versus placebo
89233685|NCT01026597|Experimental|cohort 5|Dose 5 versus placebo
89233686|NCT00450801|Experimental|R-MACLO-IVAM-T|Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.
89233687|NCT01023555|No Intervention|0.5cc 2 Bottles|
89233688|NCT01023555|Active Comparator|1cc single bottle|
89233689|NCT01023633|Active Comparator|Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)|The arm A (FOLFOX4 continuous arm):receive FOLFOX4 every 2 weeks until progression or for maximum 24 cycles.
89233690|NCT01023633|Experimental|Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)|The arm B will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles
89233691|NCT01026675||Pregnant women 6-13 weeks|
88802262|NCT05478096|Experimental|We-based intervention for procrastination|GetStarted is a guided e-health application, based on cognitive-behavioral therapy (CBT). It comprises 5 main and 4 optional modules that are delivered weekly via computer, laptop, tablet, or mobile phone. Every week a trained e-coach will provide feedback on the progress of the program and the exercises via e-mail. The main modules are (1) psycho-education about procrastination (2) getting insight into one's own procrastination behavior, (3) uncovering unhelpful thoughts underlying procrastination and (4) replacing these unhelpful thoughts with helpful ones. Each module takes approximately 40 minutes to complete and participants will receive provide asynchronous written personalized feedback from their e-coaches within 48 hours (counting workdays only) after session completion.
88802263|NCT05478096|No Intervention|Wait list|Participants in the waiting list condition will receive no treatment for four weeks post-randomization. Following this, they can start the program if they choose to do so.
88802264|NCT04331626|Experimental|Low-dose Gemcitabine Combined With nivolumab|Bristol-myers squibb (BMS) company's nivolumab injection liquid (trade name: odiwal). Recommended dosage: 3mg/kg, intravenously injected once every 2 weeks for 60 minutes. As long as clinical benefit is observed, continue treatment with this product for up to 6 courses. Gemcitabine hydrochloride injection from eli lilly. Use 50% of the recommended dose, i.e. 500mg/m2, intravenously for 30 minutes. Day 1 and day 8 administration. Depending on the patient's tolerance to gemcitabine, a reduced dose may be considered for each treatment cycle or one treatment cycle. Use for 1 year. If a Ⅲ magnitude of adverse reactions, it is necessary to permanently discontinued.
88802265|NCT00970606|Placebo Comparator|Placebo tablet|Placebo
88802266|NCT00970606|Experimental|Rosuvastatin (crestor)|Experimental arm
89233692|NCT00458211|Experimental|Experimental|Open label change to ziprasidone
89233693|NCT00450723|Experimental|Sentinel Lymph Node Biopsy|
89233694|NCT01026753|No Intervention|FOBT by laboratory requisition or directly by PCP|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit.
89233695|NCT01026753|Experimental|FOBT by lab req. or directly from PCP + study magnet|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address.
89233696|NCT00467961|Experimental|Miltenyi system transplant recipients|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. Determine appropriate level of post transplant immunosuppression
88802267|NCT01973062|Experimental|rituximab and yttrium Y 90 ibritumomab tiuxetan|Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
88802268|NCT00981370|Other|Single Arm study|Single Arm study, all subjects to receive study medication, deferasirox (Exjade).
88802269|NCT00979810|Experimental|18F-FLT PET scan|This is a pilot study intended to collect preliminary data on 15 patients diagnosed with untreated high-grade glioma who are scheduled to undergo surgical resection.
89233697|NCT03996213|No Intervention|supine group|induction of anesthesia will be initiated while patient in supine position
89233698|NCT03996213|Active Comparator|head down|induction of anesthesia will be initiated while patient in head down position
89233699|NCT03996213|Active Comparator|leg elevation|induction of anesthesia will be initiated while patient in leg elevation position
89233700|NCT04889157|Experimental|PF-06882961|Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg
89233701|NCT04889157|Placebo Comparator|Placebo|Placebo
89233702|NCT00457821|Experimental|Ivacaftor Group A|Subjects in Part 1 who first received 25 mg or 75 mg of ivacaftor every 12 hours (q12h) for 14 days, then crossed over to receive the alternate dose for another 14 days.
89290162|NCT03116152|Experimental|IBI308|IBI308 200mg Intravenous drip every three weeks
89126005|NCT05856344|Experimental|Spherical tip noncompliant balloon|Enrolled patients who were randomly assigned to this group underwent stent postdilation using the spherical tip non compliant balloon(APT Medical Inc，CONQUEROR NC Pro). The selection of balloon size is based on the expected target lesion stent diameter, and the length range is restricted among 8-12mm. It will be defined as balloon passage failure if it fails to pass the target lesion after three attempts. After that, based on the purpose of completing the surgery, alternative options can be selected based on the surgeon's experience, including double-guide wire assistance, 5in6 support, the use of regular noncompliant balloon and so on.
89126006|NCT05856344|Active Comparator|Regular noncompliant balloon|Enrolled patients who were randomly assigned to this group underwent stent postdilation using the regular noncompliant balloon(tapered-tip). The selection of balloon size is also based on the expected target lesion stent diameter, and the length range is restricted among 8-12mm. It will be defined as balloon passage failure if it fails to pass the target lesion after three attempts. After that, based on the purpose of completing the surgery, alternative options can be selected based on the surgeon's experience, including tip modification, double-guide wire assistance, 5in6 support, the use of spherical tip non compliant balloon(APT Medical Inc，CONQUEROR NC Pro) and so on.
89126007|NCT05856318||Pregnancy ~3000 participants|Actively planning to conceive within approximately 12 months of study registration. No previous pregnancies.
89126008|NCT05856318||Non-Pregnancy ~500 participants|Not planning to conceive within 18 months of study registration. No previous pregnancies.
89126009|NCT05856292|Experimental|Teach-Back|The intervention group were educated using the standard educational method with the addition of Teach-back enhancement. It consists of 5 steps: Triage, Tools, Take Responsibility, Tell Me, and Try Again. The Triage, Tools, and Try Again focus on effective information delivery, while the Take Responsibility and Tell Me evaluate the patient's ability to receive the information
89126010|NCT05856292|Placebo Comparator|Non-Teach-Back|No educational intervention, just standard educational methods
89126011|NCT05856253||ERAS group|
89126012|NCT05856253||Control group|
89126013|NCT05856240|Experimental|Group-Based Psychological Intervention|Single-arm feasibility trial, so all participants will receive the intervention.
89126014|NCT05856201|Active Comparator|laparoscopic cervicosacropexy (CSP)|
89126015|NCT05856201|Active Comparator|Shull technique via V-NOTES (VNS)|
89126016|NCT05856188|Experimental|Group I (Test group):|Will include twenty patients receiving Glutamine oral suspension (5 grams of glutamine and 5 g maltodextrin dissolved in cold water) 30 min before a meal, 3 times per day through swish and swallow technique25 throughout the radiotherapy period.
89126017|NCT05856188|Placebo Comparator|Group II (Control group)|Included twenty patients receiving maltodextrin oral suspension (5 g maltodextrin dissolved in cold water) 30 min before a meal, 3 times per day through swish and swallow technique throughout the radiotherapy period along with general measures as well as analgesic drugs according to the WHO scale.
89126018|NCT05856175||PT patients with postoperative recurrence|participants in this group undergo ultra-high resolution CT, vessel wall MR, 4D Flow MR and ASL MR imaging technology before and after surgery.
89126019|NCT05856175||PT patients without postoperative recurrence|participants in this group undergo ultra-high resolution CT, vessel wall MR, 4D Flow MR and ASL MR imaging technology before and after surgery.
89126020|NCT05856149|Experimental|STEPS|Participants will have access to the mobile, web-based diabetes prevention program-- STEPS--for a total of three months or twelve weeks. They will be able to access all program modules and tools during this period.
89126021|NCT05856149|No Intervention|Usual Care|Participants in the Usual Care control group will not receive an intervention.
89126022|NCT05856097|Experimental|kinesio taping with diaphragmatic breathing|kinesio taping application with diaphragmatic breathing
89126023|NCT05856097|Active Comparator|kinesio taping without diaphragmatic breathing|kinesio taping application without diaphragmatic breathing
89126024|NCT05856045|Experimental|PNF intervention group|Proprioceptive neuromuscular facilitation (PNF) is a therapeutic approach that uses cutaneous, proprioceptive and auditory input to produce functional improvement in motor output.
89126025|NCT05856045|Experimental|PBBT(pertubation based balance training) intervention group|Perturbation-based balance training (also referred to as reactive balance training or perturbation training) utilizes a task-specific approach to balance training, applying repeated exposure to unpredictable mechanical perturbations that mimic balance disturbances experienced in daily life.
89126026|NCT05856045|Experimental|PNF and PBBT intervention group|both techniques will be used
89126027|NCT05856032|Experimental|Use of Acapella device|"Experimental group will receive treatment with Acapella device twice a day for 6 days post-operatively.~Participants in this group will also receive conventional chest physiotherapy protocol as: incentive spirometry, Active Cycles of Breathing Technique (ACBT), Diaphragmatic breathing exercises except manual chest physiotherapy techniques."
89126028|NCT05856032|Active Comparator|Conventional treatment|•Participants in control or comparative group will receive conventional chest physiotherapy protocol as incentive spirometry, ACBT's, Diaphragmatic breathing exercises along with manual chest physiotherapy techniques as percussion and vibration.
89126029|NCT05855993|Experimental|Nerve Glide Exercise with Ultra Sound|
89126030|NCT05855993|Active Comparator|Nerve Glide Exercise without Ultra Sound|
89126031|NCT05855980|Active Comparator|Closed wound|Wound is closer immediately after amputation (instead healing secondarily)
89126032|NCT05855980|No Intervention|Open wound|Wound is left to heal secondarily
89126033|NCT05855954|Experimental|intervention group|"First,20min after the end of cardiopulmonary bypass, on the basis of ensuring that the mean arterial pressure (MAP) ≥ 60mmHg, the patients will accept dorsal elevated position.~After that, if the patient's CVP is less than 10mmHg, nitroglycerin will be pumped at 0.2ug/ (kg * min). If the patient's CVP is still greater than or equal 10mmHg, we increase the dose by 0.2ug/ (kg * min) and pump again for 5min, and the like. Until the patient's CVP is less than 10mmHg or the dose of nitroglycerin increases to 1ug/ (kg * min), the current dose is maintained until the end of surgery."
89126034|NCT05855954|No Intervention|control group|no intervention measures
89126035|NCT05855928|Other|Electrical Stimulation and Mime Therapy|
89126036|NCT05855928|Experimental|Electrical Stimulation and PNF Technique|
89126037|NCT05855915|Experimental|Kinesio taping|Kinesotaping will be applied with routine physical therapy
89233703|NCT00457821|Experimental|Ivacaftor Group B|Subjects in Part 1 who first received 75 mg or 150 mg of ivacaftor q12h for 14 days then crossed over to receive the alternate dose for another 14 days.
89233704|NCT00457821|Experimental|Ivacaftor Group C|Subjects in Part 2 who received 150 mg or 250 mg of ivacaftor q12h for 28 days.
89233705|NCT00457821|Placebo Comparator|Placebo|Subjects who received placebo in Part 1 and subjects who received placebo in Part 2.
89233706|NCT00633893|Experimental|1|2.5 mg
89233707|NCT00633893|Experimental|2|5.0 mg
89233708|NCT00633893|Active Comparator|3|0 mg
89233709|NCT02550665|Experimental|donepezil 15mg titration|donepezil 15mg during the first 4 weeks before escalation to 23mg
89233710|NCT02550665|Experimental|donepezil 10mg & 23 mg alternating|alternating donepezil 10mg and 23mg during the first 4 weeks before escalation to 23mg
89233711|NCT02550665|Active Comparator|no titration of donepezil|no titration and direct escalation to 23mg donepezil
89233712|NCT00819455|Active Comparator|2|In person lifestyle advice at baseline, 6, 12, 18 months.
89233713|NCT00819455|Experimental|1|In person lifestyle advice at baseline, 6, 12, 18 months. Receive reminders by internet based, mobile phone text messaging (Frequency, time and number(s) of messages according to participants requirement)
89233714|NCT00819533|Experimental|sensor|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
89233715|NCT00819611|Experimental|Working memory training|
89233716|NCT00819611|Sham Comparator|Control version of working memory training|
89233717|NCT04044677|Experimental|tDSC-active|"The TDCS-active will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend) during the practice of VR games, TDCS-active will be performed with a current of 1 mA and 20 min of duration (20 seconds of ramp-up and ramp-down). The stimulation target will be the M1 area, choosing the more functional side of the participant (C3 or C4).~This group will perform the tDCS-sham after one-month washout."
89233718|NCT04044677|Sham Comparator|tDCS-sham|"The TDCS-sham will be performed over ten consecutive sessions per weekday (i.e. one session daily, no stimulation during the weekend). However, the electrodes will be positioned at the same sites of the tDCS-active and the device will be switched on for 20 seconds (with ramp-up and ramp-down), giving the children the initial sensation of the 1 mA current, but with no stimulation administered during the rest of the time. This sham protocol is already programmed in the device prior to data collection.~This group will perform the tDCS-active after one-month washout."
89233719|NCT00819845|Experimental|Ramipril|
89233720|NCT00819845|Experimental|Carvedilol|
89233721|NCT00819923|Experimental|1|Patients receiving bio-active stent during the intervention
88802270|NCT00947284|Experimental|Women|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm.
88802271|NCT00947284|Experimental|Men|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm
88802272|NCT04547556|Experimental|Intervention|
88802273|NCT04547556|No Intervention|Standard of Care|
88802274|NCT01946542|Placebo Comparator|placebo|placebo drink, single dose, taste and color-matched to experimental drink
89233722|NCT00819923|Active Comparator|2|Patients receiving everolimus-eluting stent during the intervention
89233723|NCT00820001|Experimental|Acute Treatment Protocol Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in the booster dose of treatment. The treatment provided in this arm includes specific booster treatment based on the 8 modules of the initial treatment study. Saliva samples were also collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
89233724|NCT00820001|Experimental|Acute Treatment Protocol No-Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in assessments only thus not receiving any additional booster treatment. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
89233725|NCT00820001|Active Comparator|Treatment As Usual|Child participants in this arm were initial participants enrolled in the parent study in the clinically referred Treatment As Usual comparison group. These participants were initially enrolled in treatment services with identified providers and received treatment services as provided in that community agency. In this continuation study, the participants were enrolled at the 36 month assessment and participated in the ongoing follow-up assessments only. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
89233726|NCT00820001|Other|No Intervention Healthy Comparison|The Healthy Control subjects enrolled initially in the parent study are incorporated in a related project designed to evaluate the role of biological measures in differentiating antisocial and normal children. All Healthy Control participants were initially matched to cases in the clinical sample (both the acute treatment and the clinically referred Treatment as Usual).
89233727|NCT00457743|Experimental|SU011248|25 , 50 or 75 mg/day of SU011248
89233728|NCT00820079|Experimental|ADX10059 120 mg|Twice-daily
88802275|NCT01946542|Experimental|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
88806112|NCT01479127|Experimental|Levodopa-carbidopa intestinal gel|"Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks.~The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms."
88806113|NCT03917966|Experimental|SHR-1210+Docetaxel+nedaplatin|SHR-1210+Docetaxel+nedaplatin
89126038|NCT05855915|Experimental|Sham taping|Sham taping will be applied with routine physical therapy
89126039|NCT05855902||Adults with OCD|Adults with OCD in an intensive treatment program will participate in weekly Art Therapy sessions during their enrollment in the program. Each group is 1.5 hours long. Each participant will be asked to fill out one survey after their first Art Therapy group, and one at the end of the time in the program. Both surveys pertain to their perceptions of the value of Art Therapy within the program.
89126040|NCT05855824|Placebo Comparator|Placebo - 0 mg carotenoids / d|"The placebo 0 mg/d group consumes 1-90 g pouch of applesauce providing 0 mg carotenoids/d (Unsweetened Applesauce Pouches) daily for 4 weeks."
89126041|NCT05855824|Experimental|Low - 2.5 mg carotenoids / d|"The low 2.5 mg/d group will consume alternating pouches of the applesauce (0 mg carotenoids/90 g pouch) and a 120 g pouch of fruit-vegetable puree blend providing 5 mg mixed carotenoids (Carrot, Banana, Mango, & Sweet Potato pouch) daily for 4 weeks."
89126042|NCT05855824|Experimental|High - 5 mg carotenoids / d|"The high dose 5 mg/d group will be provided one 120 g pouch/day of the fruit-vegetable puree blend (Carrot, Banana, Mango, & Sweet Potato pouch) daily for 4 weeks."
89126043|NCT05853978|Experimental|BSS Plus|
89126044|NCT05853978|Active Comparator|BSS|
89126045|NCT05853510||Unilateral developmental dysplasia of the hip|Diagnosed with developmental dysplasia of the hip and treated with a hip abduction brace in one hip.
89126046|NCT05853510||Bilateral developmental dysplasia of the hip|Diagnosed with developmental dysplasia of the hip and treated with a hip abduction brace in two hips.
89126047|NCT05853328|Active Comparator|Epley Maneuver|"The SOC therapy for this patient population is Physical Therapy. No medication or medical device therapy was included. In addition to SOC, patients in this arm were allocated to Epley Maneuver. The first treatment maneuver was performed once by a physician according to the assigned treatment group. The patient simultaneously received verbal instructions on how to perform the maneuver. Fifteen minutes after the first diagnostic maneuver, a second diagnostic maneuver was carried out in order to evaluate the effect of a single maneuver.~For the self-maneuvers, patients received written instructions with figures on how to perform the EM independently in a home environment. For the self-maneuver at home, the modified Epley self-maneuver was done by the patient with a pillow under the shoulders.~The frequency at home was three times in the morning, three times at noon, and three times in the evening, i.e., nine times per day."
89126048|NCT05853328|Active Comparator|SemontPLUS Maneuver|"The SOC therapy for this patient population is Physical Therapy. No medication or medical device therapy was included. In addition to SOC, patients in this arm were allocated to the SemontPLUS Maneuver. The first treatment maneuver was performed once by a physician according to the assigned treatment group. For the SM+, the angle of the 60° overextended head and body was measured by an inclinometer application. The patient simultaneously received verbal instructions on how to perform the maneuver. Fifteen minutes after the first diagnostic maneuver, a second diagnostic maneuver was carried out in order to evaluate the effect of a single maneuver.~For the self-maneuvers, patients received written instructions with figures on how to perform the SM+ independently in a home environment.~The frequency at home was three times in the morning, three times at noon, and three times in the evening, i.e., nine times per day."
89126049|NCT05852678||Patient registry|The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
89126050|NCT05852379|Experimental|Active transcutaneous auricular vagus nerve stimulation|PtaVNS, twice daily, 30 minutes each time over 6 months. Followed by 6 months home excercice program, physiotherapy twice a week, and continuous low frequency antidromic pelvic neuromodulation (CAPN).
89126051|NCT05852379|Sham Comparator|Sham transcutaneous auricular vagus nerve stimulation|Sham PtaVNS (fictive stimulation), twice daily, 30 minutes each time over 6 months. Followed by 6 months home excercice program, physiotherapy twice a week, and continuous low frequency antidromic pelvic neuromodulation (CAPN).
89126052|NCT05851313|Experimental|Vitamin D supplementation for 16 weeks|The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
89126053|NCT05851313|Placebo Comparator|Placebo|The control group took a placebo prepared with the same shape and size of supplements.
89126054|NCT05850676||Idiopathic Hypersomnia|Men and women with a current diagnosis of Idiopathic Hypersomnia
89126055|NCT05850676||Hypersomnia Associated with a Psychiatric Disorder|Men and women with a current diagnosis of Hypersomnia Associated with a Psychiatric Disorder
89126056|NCT05850065|Other|Hu-Friedy 212 clamp|Hu-Friedy 212 clamp will used for the retraction.
89126057|NCT05850065|Other|dental floss using the simple knot tie method|Dental floss using the simple knot tie method will used for the retraction.
89126058|NCT05850065|Other|Using Hu-Friedy 212 clamp and dental floss using the simple knot tie method together|Using Hu-Friedy 212 clamp and dental floss using the simple knot tie method together will used for the retraction.
89126059|NCT05850065|Other|Coltene B4 clamp|Coltene B4 clamp will used for the retraction.
89126060|NCT05848999|Experimental|Arm of UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)|Anti-mesothelin CAR-T cells Injection Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by Anti-mesothelin CAR-T cells injection.
89126061|NCT05848882|Experimental|Elastodontic removable device|Patients in this group will be treat with an elastodontic device adapted to the patient according to the shape of the dental arches. This device is similar to a mouthguard and embraces both dental arches. This appliance is worn overnight and the patient will be checked every month. The distance between the palatal cusps of the first upper premolars will be taken at T0( before the start of the therapy), at T1 (after six months)and at T2 (after one month). All the dental recors will be taken by the same operator with an intraoral scanner 3D.
89126062|NCT05848882|Experimental|Schwarz removable device|Patients in this group will be treat with a Schwarz removable device constructed individually by the dental technician.This device has a resin baseplate with an activation screw in the center and Adams hooks on the upper first molars and it works by turning the expansion screw in the center of the palate one-quarter turn, once or twice a month by the ortodontist. This appliance is worn overnight and some hours during the day (totally 16 hours).The distance between the palatal cusps of the first upper premolars will be taken at T0( before the start of the therapy), at T1 (after six months)and at T2 (after one month). All the dental recors will be taken by the same operator with an intraoral scanner 3D.
89233729|NCT00820079|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
88802276|NCT05483790|Experimental|multidomain intervention|The intervention group receives four intervention components including cognitive, physical exercise, healthy lifestyle, and computerized cognitive training. (1) cognitive training includes memory methods and strategies, attention training, etc; (2) healthy lifestyle includes nutrition recommendations, sleep guidance, emotional regulation, etc; (3) physical exercise includes activities preferred by each participant (5 times per week, 30 minutes per time), such as Tai Ji, Baduanjin, elastic band gymnastics or yoga, etc; (4) computerized cognitive training is a kind of computer program-based cognitive training guided by professional staff at the study site, conducted in 6 weeks, 3 times per week, 20-30 minutes per session, and 12 sessions. The web-based training program includes several tasks: spatial cognition, brain balance, clock, and ATM simulation. The sessions with educational content on cognitive and healthy lifestyles perform once times per week, 90 min per session, 6 weeks.
88802277|NCT05483790|No Intervention|the control|The control group received regular health advice weekly for 6 weeks.
88802278|NCT01921114|Active Comparator|BioFlo™ PICC|BioFlo™ Peripherally Inserted Central Catheter (PICC)
88802279|NCT01921114|Active Comparator|Bard® PowerPICC SOLO2®|Bard® Dual-Lumen PowerPICC SOLO2®
88802280|NCT00932152|Active Comparator|Arm B, Group 1|Best supportive care only: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support PRN
88802281|NCT00932152|Active Comparator|Arm B, Group 2|Best supportive care and Bevacizumab 15mg/kg every 21 days
88802282|NCT00932152|Experimental|Arm A, Group 1|Fulvestrant and anastrozole only
88802283|NCT00932152|Experimental|Arm A, Group 2|Fulvestrant, anastrozole and Bevacizumab
88806114|NCT03917966|Experimental|SHR-1210+Apatinib|SHR-1210+Apatinib
88806115|NCT00242684||Group 1|older patients admitted to a TCU unit
89126063|NCT05847556|Experimental|Monitoring of ototoxicity|Video game hearing tests will be used to determine if they can effectively monitor changes in hearing function over time remotely.
89126064|NCT05847556|No Intervention|Tablet-based audiometry validation|Further validation of tablet-based audiometry compared to formal sound-booth audiometry.
89126065|NCT05847556|Experimental|Audio-training - intervention arm|Audio-training with video game hearing tests will be used to determine if it can improve spatial hearing perception.
89126066|NCT05847556|No Intervention|Audio-training - control arm|No audio-training but video game hearing tests will be used as a comparator arm to identify if audio-training can improve spatial hearing perception.
89126067|NCT05844813|Experimental|The Neoadjuvant Therapy Group|Neoadjuvant chemotherapy + Target therapy+ Radical resectional Surgery Drugs: Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide 1g/㎡ d1-5, Anlotinib10mg d1-14 Q3weeks * 3 Circles, Watch-Wait 4-6 weeks
89126068|NCT05844813|Active Comparator|The Surgery only Group|Procedure: Radical resectional surgery
89126069|NCT05842928|Experimental|Intervention Arm|Intensified and patient-centred cooperation between GPs and pharmacists including patient empowerment
89126070|NCT05842928|Active Comparator|Control Arm|Extended routine care
89126071|NCT05842863|Experimental|Dialectical Behavior Therapy + Cognitive Behavioral Therapy for Insomnia|
89126072|NCT05842863|Active Comparator|Dialectical Behavior Therapy Only|
89126073|NCT05837338|Experimental|Sequence A|Single topical application of BXP154 6ml (right leg), treatment period 1; single topical application of Placebo 6ml (left leg), treatment period 2
89126074|NCT05837338|Experimental|Sequence B|Single topical application of Placebo 6ml (right leg), treatment period 1; single topical application of BXP154 6ml (left leg), treatment period 2
89126075|NCT05837338|Experimental|Sequence C|Single topical application of BXP154 6ml (left leg), treatment period 1; single topical application of Placebo 6ml (right leg), treatment period 2
89126076|NCT05837338|Experimental|Sequence D|Single topical application of Placebo 6ml (left leg), treatment period 1; single topical application of BXP154 6ml (right leg), treatment period 2
89126077|NCT05829681|Experimental|Medial Prefrontal Cortex (MPFC)|Intermittent theta-burst stimulation (iTBS) of MPFC at up to 100% resting motor threshold (RMT), with lower extremity RMT established for the MPFC target.
89126078|NCT05829681|Active Comparator|Right Prefrontal Cortex (rPFC)|Continuous theta-burst stimulation (cTBS) of rPFC at up to 110% of RMT, with upper extremity RMT established for the rPFC target.
89126079|NCT05820204|Experimental|Pain reprocessing therapy (PRT)|"PRT has 5 components: 1) education about the origin of pain in the brain, its reversibility, and the pain-fear cycle; 2) reinforcing education using personal biography; 3) somatic tracking of pain through mindfulness and reappraisal of pain sensations as non-dangerous; 4) lowering the level of personal threat that may trigger pain sensation; and 5) inducing positive affect in periods of pain. Patients will attend 1 assessment and education telehealth session with a physician followed by 8, 50-minute, therapist-led sessions. Pacing will be flexible, ranging from 5-12 weeks, to increase accessibility. Treatment will be provided by experienced PRT clinicians. All PRT sessions will be remotely-delivered."
89126080|NCT05820204|Active Comparator|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|CBT-CP, considered the leading psychological treatment for chronic pain, is a structured, time-limited intervention that aims to teach patients how to better manage chronic pain and improve their quality of life. Participants will receive 9, 50-minute sessions of CBT-CP over 5 - 12 weeks. The VA CBT-CP protocol contains an initial orientation involving education and familiarization with the CBT-CP approach to chronic pain. The protocol then includes sessions that focus on topics such as exercise, relaxation, pleasant activities, cognitive coping, and sleep. All CBT-CP sessions will be remotely-delivered.
89126081|NCT05820204|Active Comparator|Usual Care|Participants will be asked to continue whatever they are already doing to care for their back pain. Length of the usual care condition will be 5 weeks, the expected mean completion time of the PRT and CBT arms, and may be adjusted at mid-enrollment to match treatment arm length more closely.
89126082|NCT05813574||COVID-19 survivors|COVID-19 survivors: patients (≥18 years old) who were tested positive for SARS-CoV-2 infection as confirmed by polymerase-chain-reaction (PCR) testing and were subsequently hospitalised, were followed after discharge from hospitals in Enschede (MST), Hengelo or Almelo (ZGT).
89126083|NCT05812417|Active Comparator|Normal renal function|eGFR >=90 mL/min/1.73m^2
89126084|NCT05812417|Experimental|Mild renal impairment|eGFR 60~89 mL/min/1.73m^2
89126085|NCT05812417|Experimental|Moderate renal impairment|eGFR 30~59 mL/min/1.73m^2
89126086|NCT05812417|Experimental|Severe renal impairment|eGFR 15~29 mL/min/1.73m^2
89126087|NCT05800158||SARS-CoV-2|Nasopharyngeal and anterior nasal swabs collected from symptomatic individuals suspected of COVID-19 by their health care provider.
89126088|NCT05770427|Experimental|Intervention group|
89126089|NCT05768555|Active Comparator|Whole body vibration intervention at 40 Hz|40 Hz frequency WBVT
89126090|NCT05768555|Active Comparator|Whole body vibration intervention at 25 Hz|25 Hz frequency WBVT
89126091|NCT05768555|Active Comparator|Whole body vibration intervention at 0 Hz|0 Hz frequency WBVT
89126092|NCT05766540|Experimental|Aripiprazole|This group will receive Aripiprazole 10 mg/day for 6 months along with Clozapine and Metformin
89126093|NCT05766540|Placebo Comparator|Treatment as usual|This group will receive Clozapine and Metformin.
89126094|NCT05747131|Experimental|Emotion Detectives In-Out|Emotion Detectives In-Out consists of 15 weekly sessions with the children (9 face-to-face group sessions, 4 online sessions and 2 videoconference sessions).
89126095|NCT05747131|Active Comparator|Coping Cat|Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents.
89126096|NCT05746806|Experimental|Single arm|Patients with locally recurred prostate cancer will receive a ultrahypofractionated stereotactic radiotherapy to the radiologically identified lesion (Dose: 5 fractions with 7Gray every second work week day) combined with an androgen deprivation therapy (LHRH-agonist / -antagonist) for 6 months.
89126097|NCT05740202|Experimental|SHR-7367|
89126098|NCT05736120||Phase I|Online bulletin boards (OBB)
89126099|NCT05736120||Phase II|Virtual focus groups (real-time)
89126100|NCT05734118|Experimental|Intraoperative perfusion assessment using ICG-FA|Surgical procedure within standard of care. Intraoperatively, the vitality of the bowel will be assessed visually (the conventional method). Afterwards, participants will be administered indocyanine green intravenously.
89126101|NCT05733715|Experimental|A: Pembrolizumab + Lenvatinib|Subjects will receive Pembrolizumab + Lenvatinib. Pembrolizumab 200 mg or 400 mg will be administered as a 30-minute IV infusion every 3 weeks. Lenvatinib 20 mg daily will be self-administered PO by subject for 28 consecutive days, beginning Day -7.
89126102|NCT05733715|Experimental|B: Pembrolizumab|Subject will receive Pembrolizumab 200 mg or 400 mg will be administered as a 30-minute IV infusion every 3 weeks.
89126103|NCT05730179|Active Comparator|Mechanical stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 5/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
89126104|NCT05730179|Active Comparator|Repeated mechanical stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 2/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be performed for 2 minutes 4 times with 1 minute rest."
89126105|NCT05730179|Active Comparator|Repeated mechanical stimulation at different locations|"Mechanical compression is applied with the thumb. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 2/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. Stimulation will be performed for 2 minutes, 4 times, at four different sites (left and right upper trapezius and left and right lumbar paravertebral) with 1 minute of rest."
89126106|NCT05730166|Experimental|Mechanical stimulation at moderate pain intensity|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 5/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
89126107|NCT05730166|Active Comparator|Mechanical stimulation at mild pain intensity|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 2/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
89126108|NCT05730166|Active Comparator|Painless mechanical stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 0/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
89126109|NCT05730127|Experimental|Mechanical pressure stimulation|"Mechanical compression is applied with the thumb to the upper trapezius muscle on the non-dominant side at the midpoint between the acromion and C7. The intensity of this will be regulated by the pain it causes the patient, trying to ensure that it is at all times approximately 5/10 on the numerical pain rating scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable. The stimulation will be carried out for 2 minutes."
89126110|NCT05730127|Active Comparator|Electrical stimulation|To perform this procedure a TENS will be used applying a biphasic current, since it is the most used and studied type of electrotherapy. A frequency of 100hz and a bandwidth of 150 will be used. The intensity will be increased and decreased with the patient's feeback in order to provoke a pain of approximately 5/10 in the NPRS. The stimulation will be performed for 2 minutes on the upper trapezius of the non-dominant side at the midpoint between acromion and C7.
89126111|NCT05730127|Active Comparator|Cold pressor task|The non-dominant hand shall be placed in a bucket of cold water at 10.5° for 2 minutes.
89126113|NCT05709691|Experimental|Experimental|Oculomotor therapy and adapted yoga.
89126114|NCT05709691|Active Comparator|Active Comparator|Adapted yoga.
89233730|NCT00820157|Active Comparator|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE
89233731|NCT00820157|Experimental|TACE|TACE alone
88802284|NCT01916590|Active Comparator|Bupivacaine|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine)through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
88802285|NCT01916590|Placebo Comparator|Placebo|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine) through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with saline solution, and the infusion will be started at 6 ml/hr. gh the catheter.
88821389|NCT04329312||PH due to emphysema (PH-LD-Emphys)|The patients with PH-LD-Emphys received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
89126115|NCT05709145|Experimental|Written recommendation|Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within 1 year.
89126116|NCT05709145|No Intervention|Non Written recommendation|Patients in the control group will receive a report of the colonoscopy without a written recommendation that the colonoscopy should be repeated within 1 year.
89126117|NCT05702177|Experimental|Daridorexant 25 mg|Subjects will receive a daridorexant 25 mg tablet for oral administration.
89126118|NCT05702177|Experimental|Daridorexant 50 mg|Subjects will receive a daridorexant 50 mg tablet for oral administration.
89126119|NCT05702177|Placebo Comparator|Placebo|Subjects will receive a daridorexant-matching placebo tablet for oral administration.
89126120|NCT05691075||Metatarsophalangeal arthrodesis of the hallux with large diameter screws|Patient who can benefit from first-line arthrodesis using large-diameter screws
89126121|NCT05691075||Metatarsophalangeal arthrodesis of the hallux by plate|Patient who can benefit from a first intention arthrodesis by dorsal plate
89126122|NCT05687955|Experimental|Hip Exercise Program|A 12-week strength exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance.
89126123|NCT05683067||Fontan Survivors|The investigator will include Fontan survivors between 16-50 years of age for the study.
89126124|NCT05683067||People operated for congenital heart diseases|The investigator will include people operated for other types of congenital heart diseases such as tetralogy of Fallot, transposition of great arteries between 16 and 50 years of age
89126125|NCT05683067||Healthy volunteers|The investigator will include healthy volunteers between 16 to 50 years of age for comparison purpose.
89126126|NCT05682560|Experimental|RegeneCyte|HPC, Cord Blood
89126127|NCT05682560|Placebo Comparator|Placebo|Normal Saline
89126128|NCT05678647|Experimental|Oral sucrosomial Iron (SiderAl Forte®)|Oral sucrosomial Iron (SiderAl Forte®) is given to blood donors after blood donation
89126129|NCT05678647|Active Comparator|Oral iron sulphate (Duroferon®)|Oral iron sulphate (Duroferon®) is given to blood donors after blood donation
89126130|NCT05676008|No Intervention|Waitlist control|
89126131|NCT05676008|Experimental|Treatment|
89233732|NCT00820313|Other|Lifestyle Intervention|Comprehensive lifestyle intervention for reversal of heart disease
89233733|NCT04044599|Experimental|Study|THE GROUP THAT WİLL RECİEVE VAGİNAL LACTOBACİLLUS
88821390|NCT04329312||PH due to lung fibrosis (PH-LD-Fibr)|The patients with PH-LD-Fibr received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
89126132|NCT05665101|Experimental|EVAR with SE|Patients in the EVAR-SE arm will receive EVAR with additional coil embolization of the aneurysm sac.
89126133|NCT05665101|No Intervention|standard EVAR|Patients in the standard EVAR arm will receive EVAR without additional coil embolization of the aneurysm sac.
89126134|NCT05639907|Experimental|K21 Cavity cleanser-coated TAD|A TAD to be placed is coated with K21 solution. The solution is allowed to evaporate to dryness, leaving a K21-rich film. The TAD is placed following the University TAD placement protocol.
89126135|NCT05639907|Placebo Comparator|Ethanol Control|A TAD to be placed is coated with ethanol solution. The solution is allowed to evaporate to dryness (no residue is expected). The TAD is placed following the University TAD placement protocol.
89126136|NCT05626894|Experimental|StrokeWear Motor and Behavioral Intervention|
89126137|NCT05626894|Sham Comparator|Usual Care|
89126138|NCT05622344|Active Comparator|Traditional VPT JHU|Subjects that have had their eighth cranial nerve resected will receive traditional vestibular rehabilitation exercises at Johns Hopkins University (JHU) site.
89126139|NCT05622344|Experimental|SWAN VPT JHU|Subjects that have had their eighth cranial nerve resected will receive the automated vestibular rehabilitation method
89126140|NCT05622344|Experimental|SWAN Motion Sick Dayton|Healthy control subjects that meet similar similar physical characteristics of astronauts will receive the automated vestibular rehabilitation method post motion sickness.
89126141|NCT05622344|No Intervention|Traditional Motion Sick Dayton|Typically, the suggestion for treating motion sickness once it has started is to avoid motion. Therefore, healthy control subjects that meet similar similar physical characteristics of astronauts will not receive any post motion sickness treatment.
89126142|NCT05619276|Active Comparator|Standard serving utensil toolkit|Participants will self-serve and condiment a cold meal in the laboratory using standard kitchen utensils, including 2 nylon serving spoons and a simple glass oil dispenser. Participants will complete an eye-tracking test before eating, and will fill in questionnaires and provide blood samples during and after the meal. At 2h post-meal, they will complete a computerized memory reconstruction task related to the meal. After leaving the laboratory participants will keep a food diary, and will complete an on-line learning test before bedtime.
89233734|NCT04044599|No Intervention|Control|Control group
89233735|NCT01023867|Experimental|Alzheimer's disease group|Patients with Alzheimer's disease treated donepezil
89233736|NCT01023867|Experimental|Mixed Dementia group|Patients with Mixed Dementia treated donepezil
89233737|NCT00820391|Experimental|KIDNET|Narrative Exposure Therapy for Children
89233738|NCT00820391|Experimental|Meditation/Relaxation|
89233739|NCT03696303||Cases|Suspected community-acquired bacterial pneumonia
89233740|NCT03696303||Controls|Healthy children, age-matched to enrolled cases
89126143|NCT05619276|Experimental|Optimised portion-control toolkit|Participants will self-serve and condiment a cold meal in the laboratory using an optimised portion control toolkit. This toolkit will include two calibrated serving spoons, one for vegetables (slotted) and one for starch (solid), and a calibrated oil dispenser. Both spoons have a volume capacity of 155 ml with a 121 ml mark. The oil dispenser has a volume capacity of 250ml and allows pre-portioning of the oil via a sucking device in amounts ranging from 5-20 millilitres, 1-3 teaspoons or 0.5 to 1 tablespoon, prior to serving. Participants will complete an eye-tracking test before eating, and will fill in questionnaires and provide blood samples during and after the meal. At 2h post-meal, they will complete a computerized memory reconstruction task related to the meal. After leaving the laboratory participants will keep a food diary, and will complete an on-line learning test before bedtime.
89126144|NCT05614115|Experimental|Empagliflozin 10mg|Empagliflozin10mg oral: Those randomized to 10 mg daily dose will be treated with 10 mg QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
89126145|NCT05614115|Experimental|Empagliflozin 25mg|Empagliflozin 25 mg oral: Those randomized to 25 mg daily dose will be treated with 10 mg QD for the first 2 weeks before escalating the dose to 25 mg QD in week 3, based on tolerability. At the end of the dose-escalation phase (weeks 3-4), participants will continue the randomized assignment for additional 8 weeks (weeks 5-12, treatment phase), for a total of 12 weeks.
89126146|NCT05614115|Placebo Comparator|Placebo|Encapsulated placebo with an identical appearance to empagliflozin: Those randomized to placebo will be treated with an oral placebo QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
89126147|NCT05610930|No Intervention|Control arm|"Participants received a questionnaire including 3 sets of images of food packaging, (brand blinded), categorized by food groups: 8 cookies, 7 breakfast cereals, and 7 ready-to-eat meals, but without front-of-pack nutritional label (in case the original Nutri-Score was displayed on the product, it was hidden by the investigators). They had the possibility to check the back-of-pack nutrition facts and ingredient information. First, they were asked which product they would intend to purchase in each category, and which product they thought to be the healthiest. Then, participants were asked 1) to rank them according to their nutritional quality by identifying the first, the second and the third products with the best nutritional quality (in this order) and 2) to identify those that were ultra-processed."
89126148|NCT05610930|Experimental|Experimental arm|"Participants received a questionnaire including 3 sets of images of real food product packaging (brand blinded), categorized by food groups: 8 cookies, 7 breakfast cereals, and 7 ready-to-eat meals, with the Nutri-Score 2.0 displayed on the front-of-pack of each product. First, they were asked which product they would intend to purchase in each category, and which product they thought to be the healthiest. Then, participants were asked 1) to rank them according to their nutritional quality by identifying the first, the second and the third products with the best nutritional quality (in this order) and 2) to identify those that were ultra-processed. Last, a series of questions evaluated how participants of this arm perceived the Nutri-Score 2.0 and whether they found it helpful."
89126149|NCT05604794|Experimental|Clients|Adult patients coping with symptoms of depression, anxiety, and post traumatic stress
89126150|NCT05602025|Experimental|Participants receiving depemokimab via a SSD|
89126151|NCT05602025|Experimental|Participants receiving depemokimab via an autoinjector|
89126152|NCT05575310||No Persistent Post Surgical Pain|The grouping variable will be the presence or not of persistent post-surgical pain. This will be a dichotomous variable obtained from the evaluation of pain intensity at 3 months after surgery. The tool used will be a 100mm Visual Analog Scale (VAS) (0 = no pain, 100 = worst pain imaginable) (25). Those with a VAS < 30 will be considered as patients with no persistent pain, while those with a VAS ≥ 30 will be considered as patients with persistent pain. This cut-off point has been determined by numerous authors in previous studies.
89126153|NCT05575310||Persistent Post Surgical Pain|While those with a VAS ≥ 30 will be considered as patients with persistent pain. This cut-off point has been determined by numerous authors in previous studies
89126154|NCT05574452|Experimental|Pilot group|Pilot group undergoing ACL reconstruction using the SONAR Femoral Aimer PSI
89126155|NCT05565404|Experimental|Test group|Scaling and root planing, interdental brushing demonstration and regular text messages in type 2 embrasure patients.
89126156|NCT05565404|Active Comparator|Control group|Scaling and root planing, interdental brushing demonstration in type 2 embrasure patients.
89126157|NCT05561088|Experimental|experimental group|Mechanical thrombectomy was followed by acupuncture and guideline-based conventional treatment
89126158|NCT05561088|Experimental|control group|Conventional treatment based on guidelines was administered after mechanical thrombectomy
89126159|NCT05548413|Active Comparator|Patients - Attention Only|Patients with a confirmed diagnosis of heart failure.
89126160|NCT05548413|Active Comparator|Care Partners - Attention Only|Care partners of patients with a confirmed diagnosis of heart failure.
89126161|NCT05548413|Experimental|Patients - FamLit|Patients with a confirmed diagnosis of heart failure.
89126162|NCT05548413|Experimental|Care Partners - FamLit|Care partners of patients with a confirmed diagnosis of heart failure.
89126163|NCT05542134||V-A ECMO without P2Y12 inhibitors|control group
89126164|NCT05542134||V-A ECMO with P2Y12 inhibitor at the time of ECMO|observational group 1
89126165|NCT05542134||V-A ECMO already recieving P2Y12 inhibitors|observational group 2
89126166|NCT05541939|Experimental|Treatment Arm A|Subjects will receive two separate single doses (Period 1 and Period 2) of encapsulated mizagliflozin
89126167|NCT05541939|Experimental|Treatment Arm B|Subjects will receive one dose of liquid formulation (Period 1), and one dose (optional) of encapsulated mizagliflozin (Period 2)
89126168|NCT05514002|Active Comparator|Recombinant Influenza Vaccine (RIV)|
89126169|NCT05514002|Active Comparator|Standard-Dose Inactivate Influenza Vaccine (SD IIV)|
89126170|NCT05510583||Group 1|Pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
89126171|NCT05510583||Group 2|Pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
89126172|NCT05498415|Active Comparator|Education|Participants will receive basic education information on physical activity, sedentary behavior, and sleep for 8 weeks.
89126173|NCT05498415|Experimental|Education + Health Coaching + Activity Monitor|Participants will receive education information on physical activity, sedentary behavior and sleep plus health coaching plus a Fitbit activity monitor for 8 weeks.
89126174|NCT05495880|Experimental|Forearm-supported|forearm-supported head extension during direct laryngoscopy
89126175|NCT05495880|Active Comparator|Control|without forearm-support for head extension during direct laryngoscopy
89126176|NCT05495789|Experimental|Virtual Reality Group|In addition to the routine procedure, virtual reality glasses will be applied to the high-risk pregnant in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After the NST device is connected and, the high-risk pregnant included in the experimental group will be made to watch a video lasting an average of 40 minutes with virtual reality glasses until the procedure is completed.
89126177|NCT05495789|Experimental|Music Group|In addition to the routine procedure, the high-risk pregnant women in the music group of the research will listen to the relaxing music used in the virtual reality application with headphones.
89126178|NCT05495789|No Intervention|Control Group|The high-risk pregnants in the control group of the study will not be subjected to any treatment other than the routine procedure.
89126179|NCT05487534||Sugar Swing +|Patients with type 1 diabetes with a high glucose variability (i.e., a coefficient of variation > 36% over a 10-day continuous glucose monitoring)
89126180|NCT05487534||Sugar Swing -|Patients with type 1 diabetes with low glucose variability (i.e., a coefficient of variation < 36% over a 10-day continuous glucose monitoring)
89126181|NCT05477407|Experimental|Pathogenesis study|This pathogenesis study aimed to evaluate potential changes in adipose tissue after switching from an INSTI-based regimen (RAL or DTG or BIC) to TDF/FTC/DOR.
89126182|NCT05476861||Having omit insulin|Patients with type 1 diabetes who responded to the BETTER survey that they intentionally forgot their insulin.
89126183|NCT05476861||Not intentionally omit insulin|Patients with type 1 diabetes who responded to the BETTER survey that they did not intentionally omit their insulin, but they did omit it.
89126184|NCT05466253|Experimental|Group 1 EARLY|In experimental group Orthodontic treatment will be started (early) 10 days after periodontal surgery
89126185|NCT05466253|Experimental|Group 2 DELAYED|control group will receive orthodontic intervention(delayed) 3 months after periodontal surgery
89126186|NCT05457478|Active Comparator|Cohort 2 (no weighing)|"Patients do not weigh themselves using the Smart scale during standard radiation therapy."
89126187|NCT05457478|Experimental|"Cohort I ('Smart scale weighing)"|"Patients weigh themselves daily using the Smart scale over 5-8 weeks during standard radiation therapy."
89126188|NCT05455190|Experimental|Fit Together|Participants in the intervention arm will receive standard of care obesity treatment from their provider and be able to participate in the Fit Together program and attend activity sessions throughout the duration of their 12 month participation.
89126189|NCT05455190|Active Comparator|Control|Participants in the control arm will receive standard of care obesity treatment from their provider and a healthy cooking magazine mailed to them at a regular interval throughout the duration of their 12 month participation
89126190|NCT05440812|Experimental|Care As Usual plus STAIRS|Care as usual added with a eight week STAIRS-training
89126191|NCT05440812|No Intervention|Care As Usual|Care as usual added with three information letters
89126192|NCT05436262|Other|Real time neurofeedback with task|Participants will undergo a real-time fMRI scan during which two distinct tasks will be performed.
89126193|NCT05436262|Other|Overt tapping and/or motor imagery practice|Participants will undergo an overt tapping task at baseline. Participants are assigned to a group where the participants will then perform respective motor and/or imagery tasks at home for 3 weeks.
89126194|NCT05433324||Group A|Persons previously infected with COVID-19 experiencing CNS-PASC within 6 months of recovery
89126195|NCT05433324||Group B|Persons previously infected with COVID-19 without CNS-PASC symptoms within 6 months of recovery
89126196|NCT05433324||Group C|A control group of persons not previously infected with COVID-19.
89126197|NCT05432362|Experimental|Verum Normal Weight|Normal weight participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
89126198|NCT05432362|Experimental|Verum Obesity|Adipose participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
89126199|NCT05432362|Experimental|Verum Depression|Depressive participants receiving polyphenol-rich Aronia juice (verum) (n=20) The aronia juice is derived from a local producer, a common food and commercially available.
89126200|NCT05432362|Placebo Comparator|Placebo Normal Weight|"Normal weight participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free."
89126201|NCT05432362|Placebo Comparator|Placebo Obesity|"Obese participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free"
89126202|NCT05432362|Placebo Comparator|Placebo Depression|"Depressive participants receiving placebo (control) (n=20)~The placebo drink is prepared according to a published recipe and contains nutrients such as sugars, vitamins and minerals. It has a comparable nutrients profile as the aronia juice but is completely polyphenol-free"
89126203|NCT05422768||Warrior Renew|Warrior Renew is a program for military sexual trauma (MST).
89126204|NCT05422768||Warrior Renew + EAL|Warrior Renew and EAL are combined into one program for military sexual trauma (MST).
89126207|NCT05408143|Active Comparator|usual CC (with conventional telemedicine)|
89126208|NCT05408143|Experimental|comprehensive care (CC) augmented with enhanced telemedicine (ETM)|
89126209|NCT05396105|Experimental|Part A: Low dose|Single low dose of deucrictibant
89126210|NCT05396105|Experimental|Part A: Medium dose|Single medium dose of deucrictibant
89126211|NCT05396105|Experimental|Part A: High dose|Single high dose of deucrictibant
89126212|NCT05396105|Experimental|Part B: Selected dose|Single dose of deucrictibant
89126213|NCT05389371|Active Comparator|Alberta Healthy Living Program|An integrated community-based chronic disease management program available to residents of Alberta.
89126214|NCT05389371|Experimental|Alberta Obesity Centre Program|Evidence-based medical management of obesity using a multidisciplinary approach.
89126215|NCT05368311|Experimental|Group receiving dietary recommendations including protein enriched bars .|Experimental group will consume two protein enriched bars per day during 12 weeks. First bar will be consumed 45 minutes before lunch and second bar will be consumed 45 minutes before dinner.
89126216|NCT05368311|Placebo Comparator|Group receiving dietary recommendations without protein enriched bars.|Placebo group will follow just dietary recommendations during 12 weeks.
89126217|NCT05366829|Experimental|Tislelizumab in conjunction with radiation therapy|"Participants will receive local therapy including TACE+ RT or Ablation (tumors with incomplete ablation) + RT or RT alone (for patients not eligible for TACE or Ablation) and will be screened for eligibility prior to enrollment.~Once eligibility has been confirmed, Tislelizumab will be started before radiation therapy and will continue after radiation therapy.~Participants who do not receive Tislelizumab for a total of two cycles will be replaced and interpreted for only toxicity analysis."
89126218|NCT05348499||People with T1D participating in the NHS funded pilot of HCL therapy|"The questionnaires to be administered to people with type 1 diabetes, over 3 months after starting hybrid closed loop insulin pump therapy as part of the NHS pilot are:~Gold Score~Patient health questionnaire-9 (PHQ-9)~Diabetes distress score-T1~Hypoglycaemia confidence scale~INSPIRE survey~EQ5D5L~Diabetes Treatment Satisfaction Questionnaire (DTSQs) and Diabetes Treatment Satisfaction Questionnaire change (DTSQc) version~Bespoke questionnaire using domains that are important to people with diabetes~System usability scale~Approximately 15 participants with type 1 diabetes will be asked to participate in semi-structured qualitative interviews at >3 months after the person with type 1 diabetes starts the HCL."
89126219|NCT05348499||Partners of people with T1D participating in the NHS funded pilot of HCL therapy|"Partners of people with type 1 diabetes will be invited to complete three validated questionnaires that have been specifically developed for partners and one bespoke questionnaire:~Diabetes distress score - partner~Hypoglycaemia confidence scale - partner~INSPIRE - partner~Bespoke questionnaire~Approximately 15 partners of people with type 1 diabetes will be asked to participate in semi-structured qualitative interviews at >3 months after the person with type 1 diabetes starts the HCL."
89126220|NCT05342025|Experimental|PNF group|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases. The physiotherapist will apply patterns over the 2nd and 3rd ribs in a bilateral anterior manner including intercostal stretches.
89126221|NCT05342025|Active Comparator|Control Group|"Individuals in this group will be taught breathing exercises (diaphragmatic breathing, thoracic expansion, pursed-lip breathing, and respiratory control) after the assessments, and they will be informed about performing breathing exercises for 15 minutes a day, every day of the week. Patients will be asked to keep a treatment diary to control regular breathing exercises. Individuals will be re-evaluated after 2 months."
89126222|NCT05327504|Experimental|Written Exposure Therapy|Written Exposure Therapy (WET) plus Treatment As Usual (TAU). WET is a 5 session, evidence-based trauma-focused written narrative exposure treatment. At each session, patients are instructed to write about the same trauma event and therapists provide feedback about adherence and offer suggestions. The first session includes psychoeducation about PTSD and a treatment rationale prior to general trauma narrative writing instructions, and specific instructions for completing the first writing session, before completing the first writing (30 minutes) session. Participants are instructed to write about the same trauma event at each following session, with an emphasis on delving into their deepest emotions and thoughts, in as much detail as possible, about the event. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
89126223|NCT05327504|Active Comparator|Neutral Topic Writing|Treatment As Usual (TAU) augmented by a neutral topic writing condition. The neutral topic writing condition involves writing about an assigned topic during each of the five writing sessions. As opposed to writing about trauma, the specific focus of this condition is on writing for 30 minutes about topics related to their life without writing about emotions or opinions. Rather, they are asked to write about specific objects or events in detail, as accurately as possible, and with as much description as possible. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
89126224|NCT05321953|Active Comparator|Standard of Care Physical Therapy With No Study Intervention|Participants will receive 6 weeks of standard physical therapy and have reported satisfaction and respond with a numerical value of ≤3 on a chronic constipation numeric scale. Participants will receive no additional study interventions.
89126225|NCT05321953|Experimental|Standard of Care Physical Therapy With Study Intervention|Participants who receive 6 weeks of standard physical therapy and have reported non satisfaction and respond with a numerical value of >3 on a chronic constipation numeric scale and have been cleared of pelvic floor muscle dyssynergia. Participants will receive an additional 8 weeks of study intervention.
89126226|NCT05319509|Experimental|gameChange|
89126227|NCT05310292|Experimental|Subjects diagnosed with IKH|10 patients, diagnosed with IKH
89126228|NCT05310292|Experimental|Healthy control subjects|10 subjects, healthy, matched for gender, BMI, age
89126229|NCT05305248|Experimental|Remimazolam group|Sedation with remimazolam during spinal anesthesia
89126230|NCT05305248|Active Comparator|Dexmedetomidine group|Sedation with dexmedetomidine during spinal anesthesia
89126231|NCT05291741|Active Comparator|Very Low Calorie Diet (VLCD)|VLCD
89126232|NCT05291741|Placebo Comparator|Standard care|Standard care
89126233|NCT05286996|Experimental|Iovera|Cryoneurolysis + standard of care: Usual intervention plus pre-operation Iovera treatment. Patients will receive local anaesthesia unilaterally to the affected knee prior to the treatment and then the anesthesiologist will administer the freezing cold therapy (Iovera device) to the affected knee.
89126234|NCT05286996|Placebo Comparator|Placebo|Placebo: Usual intervention plus pre-operation placebo. The placebo group will receive short-acting local anaesthesia injection unilaterally to the affected knee.
88806116|NCT00243152|Active Comparator|Lamotrigine to Placebo Crossover|The drug lamotrigine will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, placebo (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for placebo will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
89126235|NCT05286710|Experimental|modified access group|modified access: PMT was performed via distal calf venous access or contralateral femoral access
89126236|NCT05286710|Active Comparator|traditional access group|traditional access: PMT was performed via ipsilateral popliteal venous access
89126237|NCT05284123|Experimental|Self-compassion intervention|Brief (20-minute) workshop with a self-compassion writing exercise and information about mental health resources available to students.
89126238|NCT05284123|Experimental|Mental health literacy intervention|Brief (20-minute) workshop with information and a written reflection about common mental disorders, and information about mental health resources available to students.
89126239|NCT05284123|Active Comparator|Control|Brief (7-minute) workshop with information about mental health resources available to students.
89126240|NCT05273060|No Intervention|Standard of Care Nasal Reconstruction Planning|Subjects undergoing nasal reconstruction will have standard planning for procedure.
89126241|NCT05273060|Experimental|3D Nasal Reconstruction Planning|Subjects undergoing nasal reconstruction will have 3D planning utilized by the surgical team for the procedure.
89126242|NCT05269823|Active Comparator|Ice-therapy|Ice therapy will be provided prior to the provision of the intravitreal injection
89126243|NCT05269823|Placebo Comparator|No Ice-therapy|No ice therapy will be provided prior to the provision of the intravitreal injection
89126244|NCT05260723|Experimental|Sit Less|The primary goal of the Sit Less arm is to reduce the total amount of time spent sitting each day and break up prolonged bouts of sitting.
89126245|NCT05256394|Active Comparator|Pain Manager + tailored implementation support Pain Manager|Pain Manager is a decision support tool. All study clinics will begin the trial with Pain Manager integrated and available in their EHR. Consistent with the stepped-wedge design, intensive implementation support (e.g, administrative support, technical support)will be provided to two clinics at once by a multidisciplinary team.
89126246|NCT05256394|No Intervention|Pain Manager implementation in EHR|Pain Manager is a decision support tool. All study clinics will begin the trial with Pain Manager integrated and available in their EHR. The other 6 clinics will have no additional tailor support.
89126247|NCT05250830|Experimental|TrueRelief device|Patients receive an experimental procedure using a TrueRelief device.
89126248|NCT05250830|Sham Comparator|Sham TrueRelief device|Patients receive a placebo procedure using a sham TrueRelief device that looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
89126249|NCT05242952|Experimental|Immediate Intervention Group|Participants will enter an online game and learn about how to prevent cardiovascular and metabolic conditions.
89126250|NCT05242952|Other|Waitlist Control Group|Participants will enter an online game at a later date after the immediate intervention group and learn about how to prevent cardiovascular and metabolic conditions.
89126251|NCT05232669|Active Comparator|Cocoa extract + multivitamin|
89126252|NCT05232669|Active Comparator|Cocoa extract + multivitamin placebo|
89126253|NCT05232669|Active Comparator|Cocoa extract placebo + multivitamin|
89126254|NCT05232669|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
89126255|NCT05222815|Experimental|CGM (continuous glucose monitoring)|"Use CGM, with availability of Ambulatory Glucose Profile (AGP) data, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using usual care resources."
89126256|NCT05222815|Active Comparator|SMBG (Self-monitoring of blood glucose)|"Use SMBG, as currently used in primary care, to monitor and manage glucose over 12 months, in individuals with type 2 diabetes on insulin with or without other glycemic therapies. Glucose management over the 12 months study period will be in primary care, using usual care resources."
89126257|NCT05210166|Active Comparator|Active tSCS and Lokomat|"20 sessions, 5 sessions per week of active transcutaneous spinal cord stimulation (tSCS) combined with Lokomat will be performed.~The duration of Lokomat will be 30 minutes, of which the first 20 minutes tSCS will be applied at the beginning of each session."
89126258|NCT05210166|Placebo Comparator|Sham tSCS and Lokomat|"20 sessions, 5 sessions per week of sham transcutaneous spinal cord stimulation (sham-tSCS) combined with Lokomat will be performed.~The duration of Lokomat will be 30 minutes, of which the first 20 minutes sham-tSCS will be applied at the beginning of each session."
89126259|NCT05208866|Experimental|Lixivaptan|Lixivaptan capsules 100-200mg twice daily
89126260|NCT05197530|Experimental|Early RA (<1 year of disease)|In this single center study, early RA subjects (<1 year of disease) who are MTX inadequate responders or experience a flare (see inclusion criteria for detail) on MTX and are starting an anti-TNF therapy will be invited to participate to receive ICG injections at Baseline (prior to the start of medication), week 16 and week 52. NIR-ICG imaging will be done immediately post injection and 1 week later for a total of three injection/imaging visits and three imaging visits without injections. See schedule of events for more detail. Total length of participation will be up to 53 weeks (+3days).
89126261|NCT05197530|Experimental|Established RA (> 10 years of disease)|Patients with symptomatic established RA (>10 years) will be invited to participate in an ICG injections followed by NIR-ICG imaging and NIR-ICG imaging visit 1 week later. Total length of participation will be up to 1 week (+3 days)
89126262|NCT05190666|Experimental|PACE Weight Loss Program|Participants randomized to this arm will receive personalized diet, activity, and weight loss goals as well as tools to self-monitor behaviors and weight. To facilitate changes, participants will receive coaching calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
89126263|NCT05190666|Sham Comparator|Chronic Disease Self-Management Program|Participants randomized to this arm will receive a chronic disease self-management program including a self-management book. Participants will receive regular calls weekly during months 1-4, biweekly during months 5-6, and monthly during months 7-12.
89126264|NCT05178069|Placebo Comparator|Placebo Comparator: Placebo for Probiotic|Placebo capsule that matches the probiotic capsule in appearance will be given once daily for 180 days.
89126265|NCT05178069|Active Comparator|Active Comparator: Lactobacillus Rhamnosus GG|Dietary supplement capsule (Lactobacillus Rhamnosus GG) will be given once daily for 180 days.
89126266|NCT05174910|Active Comparator|With Obsidian ASG|Anastomosis treatment using standard procedure and Obsidian ASG
89126267|NCT05174910|No Intervention|Without Obsidian ASG|Anastomosis treatment using standard procedure
89126268|NCT05173740|Experimental|Individually tailored rehabilitation intervention + usual care|A comprehensive neurocognitive assessment and a thorough individual assessment of rehabilitation needs will be conducted to inform the individually tailored intervention plan. Core intervention elements are: 1) comprehensive assessment of individual rehabilitation needs including neuropsychology tests in order to make a individually tailored intervention plan coordinated with the multidisciplinary rehabilitation team, 2) providing strategies to lessen impact for the individual cognitive impairment, 3) educating survivors and relatives about the impact of a cardiac arrest and consequences on daily life, 4) work preparation, including establishment of routines and opportunities to practice work skills and 5) collaboration with the local municipality's job centre and employers to plan, support and monitor graded RTW, 6) short term therapy by psychologist dealing with thoughts and behaviour in relation to cardiac arrest.
89126269|NCT05173740|Active Comparator|Usual care|All participants including those allocated to the usual care group will be seen by an occupational therapist if their MoCA screening score ≤26. Furthermore, if considered relevant by the discharging unit, survivors are referred for rehabilitation provided and delivered in the local municipality where the participant is resident. The content of the rehabilitation will typically be based on the content of the rehabilitation plan from the discharging hospital unit and an individual assessment of the survivors' expressed needs, within the local municipality where the participant is resident.
89126270|NCT05161455|Experimental|A-PRF|
89126271|NCT05161455|Experimental|A-PRF+ allograft bone|
89126272|NCT05161455|Active Comparator|allograft bone+crosslinked collagen membrane|
89126273|NCT05161455|Sham Comparator|collagen plug|
89126274|NCT05158153|Experimental|ORKID Bundled Intervention|
89126275|NCT05156840||Telehealth|Patients/Caregivers who received a telehealth follow-up visit from a pediatric hospitalist following hospital discharge.
89126276|NCT05156840||Usual Care|Patients/Caregivers who did not receive a telehealth follow-up visit from a pediatric hospitalist following hospital discharge.
89126277|NCT05152992|Experimental|Video and stimulation-based induction of emotion|Participants viewed visual stimuli while undergoing stimulation of brain regions involved in emotion during their inpatient hospitalization at the University of California, San Francisco (UCSF).
89126278|NCT05149859||BED+ : Participants with obesity and binge eating disorder|Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 positive score and a Binge Eating Scale score >16
89126279|NCT05149859||BED-: Participants with obesity but without binge eating disorder|Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 negative score and a Binge Eating Scale score < 12
89126280|NCT05147558|Experimental|Pembrolizumab With Lenvatinib|Lenvatinib (20mg once daily orally) in combination with Pembrolizumab (200mg every 3 weeks, intravenously)
89126281|NCT05133362|Active Comparator|Standard Care with Ekso Group|Participants in the SCG (n=31) will attend two 45-minute treatment sessions per week for a minimum of 8 and a maximum of 10 total sessions. For each participant, an individualized plan of care consistent with evidence-based practice standards will be provided based on rehabilitation goals. The interventions during each treatment session will include forward gait training with EksoNR, neuromuscular movement-related tasks, mobility tasks, and interventions using products and technology, and education for caregivers, family, and friends.
89126282|NCT05133362|Experimental|Standard Care with Ekso and Backward Walking Group|Participants in the SCBWG (n=31) will attend two 45-minute treatment sessions per week for a minimum of 8 and a maximum of 10 total sessions. Once a week, each participant will receive standard care as described in the standard care with Ekso group.Once a week, each participant will receive backward walking training with EksoNR during their treatment session.
89126283|NCT05118815|Active Comparator|Conventional straight esthetic abutment|After implant surgery, 30 patients will have a 3 mm high conventional straight esthetic abutment placed. The implant placement will follow the manufacturer's instructions and the operator's expertise to achieve stability with an insertion torque of at least 40 N, recording the final torque with a calibrated torque wrench. The implant will be placed whenever bone and gingival availability allows it, juxta-osseous to avoid collateral damage in the peri-implant perimetral soft tissue excision (donut). The abutment will be placed at 30 N as indicated by the manufacturer. After removal of the donut, a new abutment will be placed and left in place up to 3 months to allow healing and complete osseointegration. Patients will receive prosthodontic loading following standard metal-ceramic rehabilitation protocols and the manufacturer's recommendation. The prosthesis will be screw-retained, on the abutment placed after excision of the donut, screwed at 25 N.
89126284|NCT05118815|Experimental|Slim (New Slim) transepithelial abutment|After surgery, 30 patients will have a 3 mm high transepithelial New Slim abutment placed. The implant placement will follow the manufacturer's instructions and the operator's expertise to achieve stability with an insertion torque of at least 40 N, recording the final torque with a calibrated torque wrench. The implant will be placed whenever bone and gingival availability allows it, juxta-osseous to avoid collateral damage in the peri-implant perimetral soft tissue excision (donut). The abutment will be placed at 30 N as indicated by the manufacturer. After removal of the donut, a new abutment will be placed and left in place up to 3 months to allow healing and complete osseointegration. Patients will receive prosthodontic loading following standard metal-ceramic rehabilitation protocols and the manufacturer's recommendation. The prosthesis will be screw-retained, on the abutment placed after excision of the donut, screwed at 25 N
89126285|NCT05117073||spontaneous bacterial peritonitis|cirrhotic patients diagnosed with SBP
89126286|NCT05117073||spontaneous fungal peritonitis|irrhotic patients diagnosed with SFP
89126287|NCT05114733|Experimental|InVEST|4 month treatment condition
89126288|NCT05114733|No Intervention|delayed invest|participants in delayed invest wait four months and are reassessed before taking part in the intervention
89126289|NCT05098366|Experimental|Furosemide|Participants will receive a 20mL/kg (max 1000mL) IV fluid bolus and a 0.1mg/kg (max 5mg) furosemide dose
89126290|NCT05098366|Placebo Comparator|IV fluids|Participants will receive a 20mL/kg (max 1000mL) IV fluid bolus and an IV fluid flush
89126291|NCT05095363|Experimental|PCplanner mobile app platform|Participants who are randomized to the intervention arm will complete surveys at 3 timepoints and will be given resources on advance care planning via PCplanner, the mobile app platform. They will receive a telephone call by the study team about a week after enrollment to answer any questions about the resources provided. If needs and questions are not resolved quickly after the clinic visit, then another layer of patient support with a telephone call by a palliative care specialist will be provided to the participant to help develop potential management plans.
89126292|NCT05095363|No Intervention|Usual Care|Participants who are randomized to the usual care arm will complete surveys at 3 timepoints and receive usual care by pulmonary clinician.
89126293|NCT05090046||Christchurch Health and Development Study (CHDS)|The Christchurch Health and Development Study (CHDS) is a birth cohort study comprising 1265 people born in Christchurch in 1977. Participants have been followed to age 40, with 75-80% retention at data collection points.
89126294|NCT05089331||Participants will be recruited from the GERFHS/ROSE Study|Participants will be recruited who have had a hemorrhagic stroke and have been enrolled into the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study/Recovery and Outcomes from Stroke study, who live in the area of University of Cincinnati, University of Maryland, Duke University, Columbia University and University of Chicago Illinois, Baptist Health Louisville and Houston Methodist. The participant's age must be18 years or greater. The participant or legal representative must be able to provide informed consent, and the racial/ethnic category of participants should be Caucasian, African American or Hispanic.
89126295|NCT05082480|Experimental|Hyaluronic acid (HA)|Hyaluronic acid (HA)
89126296|NCT05082480|Placebo Comparator|Saline|Saline
89126297|NCT05073302|Experimental|Treatment Group|Implantation of the Device-Less sentinel units. Ultrasound Monitoring. Islet Transplantation. Explantation of Device-Less Sentinels. Standard of Care. Concomitant Care. Post Transplant Testing and Visits. Participant Retention (nine month follow up assessment).
89126298|NCT05073250|Experimental|Experimental arm|Enrolled patients will be administered IBI376 plus rituximab, induction therapy for 6 cycles (28-day cycle). Patients assessed as partial response (PR) after 6 cycles of induction therapy will receive another 6 cycles of IBI376 combined with rituximab induction therapy.
89126299|NCT05061810|Experimental|Group A: Arm 1|Arm 1, group A will receive standard respiratory outpatient care such as routine virtual visits to the respiratory clinic at 6 and 12 months along with the use of a smartphone app self-management programme with follow up monthly phone calls. They will be asked to use the spirobank spirometer (measures lung function, FEVI), pulse oximeter (measures oxygen saturations, SP02) and input the dyspnoea score (m MRC), step count and view the educational videos on the app twice a week for twelve months. The smartphone app self-management programme will prompt the patient once a week to remind them to input their data. Furthermore, they will receive motivational messages weekly via the app. At the routine visits they will complete questionnaires on engagement, quality of life, m MRC scale and self-efficacy at these visits over the phone. They will inform the research team of self-reported GP visits or hospital admissions due to an exacerbation of COPD.
89126300|NCT05061810|Experimental|Group B: Arm 2|Those allocated to the intervention groups B will receive standard respiratory outpatient care such as routine virtual visits at 6 and 12 months to the respiratory outpatient clinic along with the use of a smartphone app self-management programme. They will be asked to use the spirobank spirometer (measures lung function, FEV1), pulse oximeter (measures oxygen saturations, SP02) and input the dyspnoea score (m MRC), their step count and view the educational videos on the app twice a week for twelve months. The smartphone app self-management programme will prompt the patient once a week to remind them to input their data. Furthermore, they will receive motivational messages weekly via the app. At the routine visits they will complete questionnaires on engagement, quality of life, m MRC scale and self-efficacy at these visits over the phone. They will inform the research team of self-reported GP visits or hospital admissions due to an exacerbation of COPD.
89126301|NCT05061810|Active Comparator|Group C: Arm 3 Control group|Participants in group C the control group will receive standard outpatient respiratory care which involves attending the routine visits as outlined above and informing the research team of an GP visits and or hospital admissions relating to an exacerbation of COPD. They will complete questionnaires on quality of life, m MRC scale and self-efficacy at these visits over the phone.
89126302|NCT05043831|Experimental|Direct Selective Laser Trabeculoplasty (DSLT)|Subjects will be treated with DSLT
89126303|NCT05043831|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects will be treated with SLT
89126304|NCT05041270|Placebo Comparator|control group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
89126305|NCT05041270|Active Comparator|dexmedetomidine group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)
89126306|NCT05041270|Active Comparator|nalbuphine group|patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)
89126307|NCT05039736|Experimental|cabozantinib|cabozantinib by mouth every day for 6 weeks
89126308|NCT05039736|Experimental|nivolumab|nivolumab by vein every 4 weeks for up to 2 years
89233741|NCT03696303||Controls with URI|Children 5 years of age or younger with upper respiratory infection (URI) (controls with URI)
89233742|NCT00820469|Experimental|1|Patients treated by rituximab
89233743|NCT00820469|Experimental|2|Patients treated by rituximab and plasma exchange
89233744|NCT00450411|Experimental|Brachytherapy|Prostate brachytherapy delivered using either 125-iodine (I-125) or 103-palladium (Pd-103)
89126309|NCT05030753|Experimental|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
89126310|NCT05030753|Active Comparator|Patient Education (PE)|he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
89126311|NCT05014035|Experimental|Exercise Intervention|
89126312|NCT05010590|Active Comparator|Romosozumab and denosumab|
89126313|NCT05010590|Active Comparator|Romosozumab|
89126314|NCT04940637|Experimental|Niraparib and Dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
89126315|NCT04911660|Active Comparator|Empagliflozin + Placebo|1 capsule containing 25 mg empagliflozin per day for 14 days, followed by a 14-42 days wash-out phase and a second treatment phase with 1 capsule containing placebo for 14 days.
89126316|NCT04911660|Placebo Comparator|Placebo + Empagliflozin|1 capsule containing placebo per day for 14 days, followed by a 14-42 days wash-out phase and a second treatment phase with 1 capsule containing 25 mg empagliflozin for 14 days.
89126317|NCT04895644|Experimental|No Hard Collar|Patient randomised to not wearing a Hard Collar for 12 weeks
89126318|NCT04895644|No Intervention|Standard Care Arm - Hard Collar|Patient randomised to wearing a Hard Collar for 12 weeks - standard care
89126319|NCT04886544|Experimental|Test group|Hyaluronic acid dermal filler at Week 0
89126320|NCT04886544|No Intervention|Control group|Remain untreated until Week 26
89126321|NCT04881682|Experimental|Immunoadsorption|3 cycles of immunoadsorption in week 1, 7, and 13 after randomization. One cycle consists of 5 sessions on 5 consecutive days with processing of the 2-fold plasma volume on the first day and the 2.5-fold plasma volume on consecutive days, using regenerative adsorbers (Therasorb, Miltenyi Biotec, Bergisch Gladbach)
89126322|NCT04881682|Active Comparator|Immunoglobulins|5 cycles of intravenous immunoglobulins in week 1, 4, 7, 10, and 13 after randomization. The first cycle consists of 5 intravenous applications of immunoglobulins on 5 consecutive days in a dosage of 0.4 g per kg body weight per day. Subsequent cycles consist of 2 intravenous applications of immunoglobulins on 2 consecutive days in a dosage of 0.5 g per kg body weight per day.
89126323|NCT04871035||Immunoadsorption|
89126324|NCT04871035||Plasma Exchange|
89126325|NCT04857775|Experimental|Intervention group|A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups. Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal.
89126326|NCT04857060|No Intervention|Usual Care|Subjects in this arm do not meet with ACP Educator during their index hospitalization.
89126327|NCT04857060|Experimental|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
89126328|NCT04854161|Experimental|Compassion and Empathic Attunement to Affect|Empathic Attunement to Affect is based on Emotion-Focused Therapy. Compassion training program is based on Compassion Cultivation Training, CCT
89126329|NCT04854161|Active Comparator|Focusing and Empathic Attunement to Affect|Empathic Attunement to Affect is based on Emotion-Focused Therapy. Focusing training program is based on Focusing-Oriented Therapy
89126330|NCT04851886|Active Comparator|Individual robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will undergo 18 sessions of robot-assisted upper-limb rehabilitation. During the sessions, a therapist will administer one-on-one therapy (i.e. each study volunteer will work with a single therapist).
89126331|NCT04851886|Experimental|Group robot-assisted upper-limb rehabilitation|Participants randomized to this arm of the study will also undergo 18 sessions of robot-assisted upper-limb rehabilitation. However, a therapist will administer the intervention as group therapy with up to three subjects participating in the session at the same time. To facilitate the deliver of the therapeutic intervention, the robot will be equipped with a camera system (called PostureCheck) designed to track the quality of the exercises.
89126332|NCT04839354|Experimental|Arginine Hydrochloride|Arginine is a nutritional supplement in parenteral form
89126333|NCT04839354|Placebo Comparator|Placebo|Normal saline
89126334|NCT04839185|Other|Diagnostic: Ferumoxytol MRI|The participant will receive an infusion of an iron supplement, ferumoxytol, followed by a same day MRI scan and then a second MRI scan 3-5 days later.
89126335|NCT04838275|Experimental|Exercise Arm|antifibrotic therapy + mHealth monitoring + 12-wk mHealth home exercise prescription
89126336|NCT04838275|No Intervention|Non-Exercise Arm|antifibrotic therapy + mHealth monitoring
89126337|NCT04822636|Experimental|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
89233745|NCT00815165||Protocol 04-039 subjects|At least 50 and maximum of 100 healthy adolescent female subjects aged 12-17 years who were vaccinated in protocol 04-039 will be enrolled.
89233746|NCT00815165||Positive and Negative Controls|Approximately 100 screened subjects will be enrolled to serve as positive and negative controls.
89233747|NCT00815243|Experimental|Telemed|Group of trauma&orthopedic patients - for determination of clinical strategy and treatment plan telemedicine will be used
89126338|NCT04818047|Experimental|Experimental: VID-KIDS Intervention Program Group|Experimental: VID-KIDS Intervention Program Group RN review photos of infant engagement/ disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
89126339|NCT04809688|Experimental|Single arm|Single arm
89126340|NCT04806906|Experimental|CC-486|subjects will receive 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
89126341|NCT04804241|Experimental|10 mg daily Senicapoc|10 mg daily Senicapoc for 52 weeks
89126342|NCT04804241|Placebo Comparator|Placebo Group|Placebo daily for 52 weeks
89126343|NCT04776954|Active Comparator|Forced Air Warming System|Participants in this arm will receive warming using a forced air warming system.
89126344|NCT04776954|Active Comparator|Resistive Blanket Warming System|Participants in this arm will receive warming using a resistive blanket warming system.
89126345|NCT04752059|Experimental|T-DXd 5.4 mg|Single arm phase II trial
89126346|NCT04750473|Experimental|Diagnostic (Ga PSMA, fluciclovine F18, PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan over 30 minutes. On a separate day, patients receive fluciclovine F18 IV and undergo a PET/CT scan over 30 minutes.
89126347|NCT04745351|Experimental|Remdesivir (RDV)|Participants will receive continued Standard of Care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg from Day 2 up to Day 5.
89126348|NCT04745351|Placebo Comparator|Placebo|Participants will receive continued SOC therapy together with RDV matching placebo on Day 1 followed by RDV matching placebo from Day 2 up to Day 5.
89126349|NCT04741568|Experimental|Parental Psychoeducational Intervention|A brief (one-day or two half days) psychoeducation workshop will be provided alongside a website with downloadable content will be made available to review and refresh any skills and techniques. The psychoeducational intervention will be delivered by a research fellow and research assistant with a background in psychology and delivered in line with a protocol.
89126350|NCT04741568|No Intervention|Wait List Control|Parents randomised to the control arm will be put on the waiting list (wait-list controls) to receive the group intervention after the active treatment group have completed their final follow-up at 3 months.
89126351|NCT04710277|Experimental|Novel multimodal protocol group|They will receive scheduled topical ice therapy for 24 hours after surgery. It will be applied over abdominal incisions for 20 minutes every 2-3 hours. Acetaminophen and an NSAID will be scheduled for 96 hours. While inpatient, they will receive acetaminophen 975 mg every 8 hours and IV Toradol 15-30 mg every 6 hours with change to ibuprofen 800 mg every 8 hours when tolerating oral intake. They may take oxycodone 5 mg every 4-6 hours as needed (PRN) for breakthrough pain and pain score >6. They may use ice PRN after 24 hours. They will be prescribed acetaminophen 1000 mg every 8 hours and ibuprofen 800 mg every 8 hours for 96 hours postoperative. They may take them as needed after. If the participant used 0 narcotics in the first 24 hours, they will not be prescribed a narcotic. If up to 5 tablets were used, they will be prescribed 5 tablets of oxycodone 5 mg every 6 hours PRN. If more than 5 tablets were used, they will be prescribed 10 tablets of oxycodone 5 mg every 6 hours PRN.
89126352|NCT04710277|Active Comparator|Usual care protocol group|Participants randomly assigned to the usual care protocol will receive current standard of care: scheduled acetaminophen and an NSAID for 24 hours. They will take acetaminophen 975 mg every 8 hours. They will also receive IV toradol 15 to 30 mg every 6 hours then switch to ibuprofen 800 mg every 8 hours when tolerating oral intake. They can also take oxycodone 5 mg every 4 to 6 hours on an as needed (PRN) basis for breakthrough pain with a pain score >6. Per our current standard of care, usual care participants will be allowed to use either topical heat or ice on an as needed basis during their recovery. On discharge home, they will be prescribed acetaminophen 1000 mg every 8 hours PRN and ibuprofen 800 mg every 8 hours PRN. They will also be prescribed 15 tablets of oxycodone 5 mg every 6 hours PRN.
89126353|NCT04705623|Experimental|Intervention|The intervention group receives weekly 90 minute yoga classes over a course of 12 weeks. They are also asked to do two 45-minute yoga classes at home each week and document these in a Diary.
89126354|NCT04705623|No Intervention|Control|The control group receives an assessment of their biofunctional status at the beginning and the end of the study (same as the intervention group).
89126355|NCT04704869|Experimental|Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Cryoprecipitate will be given in addition to the standard of care massive transfusion protocol products, which include red blood cells, plasma, platelets and whole blood. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
89126356|NCT04704869|Active Comparator|Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Only standard of care massive transfusion protocol products will be given, including red blood cells, plasma, platelets, and whole blood.
89126357|NCT04687293|Experimental|HUBER|"HUBER is an isometric strengthening device. It consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed.~Intervention will consist of 2 sessions of HUBER per week. Each session lasts approximatively 30 minutes. The intervention is 8 weeks long."
89126358|NCT04687293|No Intervention|Control|The control group will not received any intervention except usual care.
89126359|NCT04682223|Experimental|Aphasia Remote Therapy (ART)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.~All treatment will be done remotely with a speech-language pathologist through an online platform using therapy applications. Participants will be provided with teletherapy kits (including an Internet hotspot if needed) to complete the therapy tasks."
89290163|NCT03116152|Active Comparator|paclitaxel/irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
89233748|NCT00815243|Active Comparator|InternalControl|Group of trauma&orthopedic patients from 3rd level trauma center - for determination of clinical strategy and treatment plan usual clinical approaches will be used
89126360|NCT04682223|Active Comparator|In-Clinic Therapy (I-CT)|"All participants in this group will receive 3 weeks of daily semantically-focused treatment (semantic feature analysis, semantic barrier task and verb network strengthening therapy) and 3 weeks of daily phonologically-focused treatment (phonological components analysis, phonological production task, phonological judgment task). Participants will be randomized to order of treatment.~All treatment will be done in person with a speech-language pathologist at the UofSC Aphasia Lab."
89126361|NCT04736849|Experimental|Percutaneous ES and DRS|Epidural Stimulation (ES) and Dorsal Root Stimulation (DRS) will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of ES and DRS will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
89126362|NCT04665089|Active Comparator|Erythromycin arm|The erythromycin arm (n=55) receives, in addition to the standard antimicrobial therapy, erythromycin 1 g three times per day intravenously: each gram is diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
89126363|NCT04665089|Placebo Comparator|Placebo arm|The placebo arm (n=55) receives, in addition to the standard antimicrobial therapy, isotonic saline, intravenously, 20 ml diluted in 250 ml of 5% glucose serum to be administered over 1 hour for 5 days.
89126364|NCT04652531|Experimental|Treatment|In the treatment arm, the lesion will be treated with EV for 3 weeks once a week
89126365|NCT04652531|Sham Comparator|Internal control|The contralateral ulcer will be treated with a standard dressing and an elastic-compression bandage for 3 weeks.
89126366|NCT04639024|Experimental|ADCT-301 Infusion|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
89126367|NCT04591002|Active Comparator|Osemertinib|
89126368|NCT04591002|No Intervention|Observation|
89126369|NCT04585945||Group 1 (Cases)|Patients that test positive for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
89126370|NCT04585945||Group 2 (Control)|Historic group of patients delivering prior to the COVID-19 pandemic.
89126371|NCT04566510|Experimental|Royal Guard|alpha-cypermethrin + pyriproxyfen (PPF)
89126372|NCT04566510|Active Comparator|PermaNet 3.0|deltamethrin + piperonyl butoxide (PBO)
89126373|NCT04535934||1 dose/week followed by 4 doses/week|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 1 dose/week followed by 4 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
89126374|NCT04535934||3 doses/week followed by 7 doses/week.|Directly observed dosing regimen with 2 mg adenine 5+ (five stable-labeled nitrogens) as follows: 3 doses/week followed by 7 doses/week. The duration of each dosing regimen will be approximately 12 weeks. A washout period of approximately 12 weeks will separates the dosing regimens.
89126375|NCT04526587||Basic science (medical chart review, biospecimen collection)|Patients electronic medical records are reviewed to capture clinical information, and patients undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples for diagnosis/treatment decision, biomarker assessments, and description of mechanisms of resistance/response related to ciclib-therapy.
89126376|NCT04523012||HIV patients|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
89126377|NCT04493333|Experimental|Vaginal DHEA|Vaginal insert with 6.5 mg vaginal DHEA self-administered once daily at bedtime for 12 weeks
89126378|NCT04493333|Active Comparator|Vaginal Polycarbophil Moisturizer|Prefilled vaginal applicator with 2.5 g of polycarbophil vaginal moisturizing gel, self-administered two times per week at night for 12 weeks
89126379|NCT04489472|Experimental|PCD Group|
89126380|NCT04489472|Placebo Comparator|Control Group|
89126381|NCT04452591|Experimental|Single Arm|"Patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease.~CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g. complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 49then every 24 weeks thereafter."
89126382|NCT04427501|Experimental|LY3819253|700 mg, 2800 mg, 7000 mg, LY3819253 administered intravenously (IV)
89126383|NCT04427501|Experimental|LY3819253 + LY3832479|350 mg, 700 mg, 2800 mg LY3819253 + 700 mg, 1400 mg, 2800 mg LY3832479 administered IV or subcutaneously (SQ)
89126384|NCT04427501|Experimental|LY3853113 Open Label Addenda Arm 23|Administered IV
89126385|NCT04427501|Placebo Comparator|Placebo|Placebo administered IV
89126386|NCT04403165|Experimental|Cognitively Normal (CN) Older Adults|
89126387|NCT04390347|Experimental|Intervention|The intervention product (Yakult) (supplied as fermented milk) and placebo will be delivered in sealed pots of 65 mL with date stamped expiry. Yakult contains Lactobacillus casei Shirota (a minimum of 6.5 × 109 live cells of Lactobacillus casei Shirota are contained in each pot).
89290164|NCT01123278|Experimental|Testosterone gel|Testosterone transdermal gel 50 mg/day
89126388|NCT04390347|Placebo Comparator|Placebo|The placebo will be indistinguishable (identical in taste and colour but will not contain Lactobacillus casei Shirota) to both participants and trial investigators. It will be stored and provided in exactly the same manner as the intervention product.
89126389|NCT05027789|Active Comparator|Self-Guided Group|Subjects in this group will be provided education on memory support strategies and healthy lifestyles. Participants will decide how they want to implement this information into their daily lives. The study will also provide information on various commercially available digital and other tools that might help participants implement healthy changes their lives. One in every three participants will be enrolled in this group (selected randomly).
89126390|NCT05027789|Active Comparator|Structured Group|Subjects in this group will will be provided with specific recommended behavior targets (e.g., like how much exercise you should engage in each week). Participants will also receive an iPad to use throughout the study and follow up period with the digital application installed. Subjects will be asked to use the digital application to record their activity and to receive reminders to complete this information. Two in every three participants will receive the iPad and digital application. Participants in this group will receive training on how to use the digital application. The researchers can install the digital application on the subjects' personal iPad or smartphone if they prefer.
89126391|NCT04368234||COVID-19 Patients|Any Duke patient that is being treated for COVID-19.
89126392|NCT04359069|Experimental|Urinary catheter removal on postoperative day 1|
89126393|NCT04359069|Active Comparator|Urinary catheter removal on postoperative day 3|
89126394|NCT04343573|Experimental|Proton CSI Followed by Standard of Care (NSCLC & Breast)|Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
89126395|NCT04343573|Experimental|Standard of Care|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
89126396|NCT04343573|Other|Proton CSI Followed by Standard of Care (Other Solid Tumors)|(Exploratory arm) Patients with solid tumor malignancies other than NSCLC or breast cancer will be enrolled to the exploratory proton CSI arm (Arm C) and will not undergo randomization. Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
89126397|NCT04337372|Experimental|Effects of shared book reading|There will be one arm since all participants will undergo the same intervention.
89126398|NCT04336553|Experimental|Intervention: Social prescribing in sweden (SPiS)|Patients (older adults experiencing loneliness) at a Health care clinic are invited to an optional additional internal referral for social prescribing (SPiS) within four working days. SPiS is a means of enabling the professionals to refer people to a range of local, non-clinical services. SPiS will involve a variety of activities, tailored to the patients needs and desires) which are typically provided by voluntary and community sector organisations.
89126399|NCT04336553|No Intervention|Control: Social prescribing in sweden (SPiS)|Patients (older adults experiencing loneliness) at a Health care clinic are invited to an optional additional internal referral for social prescribing (SPiS) within three months. SPiS is a means of enabling the professionals to refer people to a range of local, non-clinical services. SPiS will involve a variety of activities, tailored to the patients needs and desires) which are typically provided by voluntary and community sector organisations.
89126400|NCT04315571|Active Comparator|Group A|Routine Large Volume Paracentesis (LVP) with albumin infusion
89126401|NCT04315571|Active Comparator|Group B|Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX
89126402|NCT04289779|Experimental|Treatment Arm|Cabozantinib 40 mg orally daily x 9 weeks plus Atezolizumab 1200 mg every 3 weeks x 3 doses
89126403|NCT04262648|Experimental|Treatment|
89126404|NCT04262648|Placebo Comparator|Control|
89126405|NCT04241016|Active Comparator|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery. Postoperative treatment consists of daily nasal douching, daily nasal steroid sprays, pain medication when necessary and at least one postoperative control visit including endoscopy two weeks after the operation. Additionally medical treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
89126406|NCT04241016|No Intervention|Control|Conservative treatment including nasal corticosteroids, nasal douching and other allergy medication as necessary.
89126407|NCT04240691||60-Minutes-For-Health|60-Minutes-for Health: this is a psychological intervention which seeks to correct factors underlying decisions to delay or avoid HIV care and strengthen abilities to overcome HIV care utilization barriers. This is achieved through assistance identifying and reducing misinformation guiding HIV care attendance decisions; enhancing motivation to maintain HIV care via personal health goals; building skills for coping with negative feelings related to living with HIV; and increasing self-efficacy for navigating structural barriers and maintaining HIV care amidst competing priorities.
89126408|NCT04240691||Time-and-Attention Control Session|60 Minute diet & nutrition control session
89126409|NCT04226040||DOW and illness perception|Exploration of the association between DOW and illness perception
89126410|NCT04156802|Experimental|Real TBS to the mPFC|Two sessions of real Theta Burst Stimulation (TBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study
89126411|NCT04156802|Sham Comparator|Sham TBS to the mPFC|Two sessions of sham Theta Burst Stimulation (TBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study
89126412|NCT04156802|Experimental|Real TBS to the MC|Two sessions of real Theta Burst Stimulation (TBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study
89126413|NCT04156802|Sham Comparator|Sham TBS to the MC|Two sessions of sham Theta Burst Stimulation (TBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study
89126414|NCT04141878|Active Comparator|Aerobic Exercise Group|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise will vary, but will primarily focus on in-class walking tutorials. Participants will work with a Personal Trainer to create their own physical activity program that will fit their needs and schedule. The Personal Trainer will supervise the participants directly for the first 6 weeks. Once participants are consistently and safely meeting their goals, their Personal Trainer will allow unsupervised exercise sessions.
89126415|NCT04141878|Active Comparator|Diet Skills Group|Participants will attend weekly classes focused on incorporating heart healthy foods (e.g., fruits and vegetables) into their existing dietary plan. We will ask them to limit the number of calories they take in and will show them how to use portion control with the goal of losing body weight. Participants will also learn hands-on skills for preparing healthy meals at home in cooking classes led by professional chefs.
89126416|NCT04115085|Experimental|Hand therapy|9 weeks of standard hand therapy including two 20 min slots per week.
89126417|NCT04115085|Experimental|Therapeutic ultrasound|9 weeks of standard ultra sound therapy including two 10 min slots per week.
89126418|NCT04115085|Experimental|Combined hand therapy and therapeutic ultrasound|9 weeks of standard hand therapy plus therapeutic ultrasound including two 30 min slots per week.
89126419|NCT04115085|Sham Comparator|Sham ultrasound group|9 weeks of sham ultrasound therapy including two 10 min slots per week.
89126420|NCT04077567|Experimental|TS-152 30mg SC|TS-152 30mg subcutaneously (SC) every 4 weeks
89126421|NCT04077567|Experimental|TS-152 80mg SC|TS-152 80mg subcutaneously (SC) every 4 weeks
89126422|NCT04077021|Experimental|Part 1a: Dose Escalation QOD|CCW702 administered subcutaneously QOD, dose escalating cohorts.
89126423|NCT04077021|Experimental|Part 1b: Dose Escalation Q7D|CCW702 administered subcutaneously Q7D, dose escalating cohorts.
89126424|NCT04077021|Experimental|Part 2: Dose Expansion|CCW702 administered subcutaneously Q7D at RP2D.
89126425|NCT04055311|Active Comparator|Usual care enhanced|Bladder cancer patients & caregivers receive standard instructions about post-op care from nursing staff plus the NCI published Facing forward cancer survivorship manual.
89126426|NCT04055311|Experimental|Intervention|Bladder cancer patients & caregivers receive standard instructions about post-op care from nursing staff plus access to Internet based software program, specifically designed for this research study. Software program contains relevant bladder cancer care instructions through videos, text, and graphics.
89126427|NCT04049643|Active Comparator|Audiologist-Based|In this group, the audiologist-based fitting will be used to provide hearing aids.
88816405|NCT04187378|Experimental|Underbody Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown underbody blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
89126428|NCT04049643|Experimental|Service-Only|In this group, hearing aids that have minimum amplification will be fitted by audiologists.
89126429|NCT04049643|Experimental|Device-Only|In this group, hearing aids will be provided with minimum services from audiologists.
89126430|NCT04041583||Arm 1|Patients undergoing posterior cervical arthrodesis procedures for spondylosis supplemented with CIS involving three or more segmental levels in the subaxial cervicothoracic spine (between C2-upper thoracic)
89126431|NCT04030299|Experimental|OTC Group|In this group, the over-the-counter fitting will be used to provide hearing aids.
89126432|NCT04026867|Active Comparator|Clinician Referral Only|"The Clinician Referral arm will serve as an active control and baseline standard of care. All individuals who test positive for HCV antibodies or are identified with untreated, active HCV will be informed of their result and receive the following information from their clinical care teams in the ED: (a) explanation of process and rationale for follow-up RNA testing; (b) delivery of simple posttest counseling (e.g., risk for liver disease, risks of transmission); and (c) provision of a list of insurance enrollment resources, as needed, along with (d) a list of HCV treatment providers and their contact information as provided in aftercare instructions. For new HCV diagnoses, patients will be instructed to access their electronic patient portal (MyChart) for their RNA test results or to call a designated results line. Post-testing counseling messages and follow-up instructions will be included on the patient discharge papers."
89126433|NCT04026867|Experimental|Clinician Referral + Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS). Individuals randomized to this intervention will be contacted by a linkage navigator either during the ED visit (if during business hours) or the following business day (if during non-business hours). If the navigator does not contact the patient at the time of ED visit, they will offer to meet with the patient in person or over the phone. For all individuals in this arm, a structured linkage navigation process will include motivational interviewing and (a) reiteration of posttest counseling messages, (b) assessment of the patient's needs for medical insurance and substance abuse treatment, c) assistance scheduling and/or rescheduling appointments for HCV treatment, and d) follow-up phone call after the first HCV treatment appointment and thereafter as needed up to 6 months after ED visit.
89126434|NCT03989778|Experimental|Vitamin D supplement|The intervention group will receive VD Cholecalciferol (D2) 50,000 I.U once weekly for 12 weeks, followed by 50,000 I.U once every fortnight for 24 weeks with the Metformin treatment as prescribed by the physician whereas
89126435|NCT03989778|No Intervention|Control|control group will receive Metformin treatment during the study period.
89126436|NCT03964142|Experimental|Cardiac Rehabilitation|Patients enrolled in the integrated exercise-based cardiac rehabilitation program (centre-based or telematic)
89126437|NCT03964142|No Intervention|Conventional management|Patients with conventional management and physical activity recommendation
89126438|NCT03959527|Experimental|zoliflodacin|Participant in this arm will receive a single dose of zoliflodacin.
89126439|NCT03959527|Active Comparator|ceftriaxone and azithromycin combination|Participant in this arm will receive a single dose of comparators combination (ceftriaxone and azithromycin).
89126440|NCT03955172|Experimental|Everolimus|
89126441|NCT03952208|Experimental|Concussion Group|Subjects diagnosed with concussion defined as a clinician-diagnosed disease by the International Classification of Diseases (ICD)-10 due to a head injury with a Glasgow Coma Score ≥13 undergoing a planned surgery/anesthetic standard of care will undergo neurocognitive testing pre and post surgery/anesthetic.
89126442|NCT03952208|Experimental|Matched Subjects Group|Matched subjects without concussion undergoing a planned surgery/anesthetic standard of care, matching for procedural type, sex, age ± 2 years, and adherence to the exclusion criteria will undergo neurocognitive testing pre and post surgery/anesthetic.
89126443|NCT03947216|Experimental|PIMAVANSERIN|In this arm, each patient will take orally, once daily 2 tablets of active drug pimavanserin of 17mg each and this during the 8-weeks treatment period.
89126444|NCT03947216|Placebo Comparator|PLACEBO|In this arm, each patient will take orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) and this during the 8-weeks treatment period.
89126445|NCT03936335||Dupilumab cohort|"Exposed to dupilumab during the relevant exposure window:~First trimester~Pregnancy"
89126446|NCT03936335||Other systemic therapy or phototherapy cohort|"Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window:~First trimester~Pregnancy"
89126447|NCT03936335||Unexposed cohort|"Not exposed to systemic medications (including dupilumab) or phototherapy; and~Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window:~First trimester~Pregnancy"
89126448|NCT03889249|Active Comparator|Tenecteplase (tNK-TPA)|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization. Tenecteplase has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
89126449|NCT03889249|Active Comparator|Alteplase ( tPA)|The control group will receive standard of care dosing of intravenous alteplase (0.9 mg/kg body weight, 10% bolus and 90% infusion as per standard care, maximum dose 90 mg).
89126450|NCT03841201|Experimental|Treatment|"Lenvatinib peroral qd (8 mg for patients with body weight <60kg and 12 mg for patients with body weight ≥ 60kg)~Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles"
89126453|NCT03809169|Experimental|ROSE with guide sheath|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique and presence of ROSE
89126454|NCT03809169|Experimental|ROSE without guide sheath|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no guide sheath and the presence of ROSE.
89126455|NCT03809169|Experimental|Guide sheath without ROSE|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique but without ROSE.
89126456|NCT03809169|Experimental|No guide sheath without ROSE|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no the guide sheath an without the presence of ROSE.
89126457|NCT03799276|Experimental|Opticare study|"Phase I: Identification and Selection of study population The first step will include an active search by OPTICARE team for vulnerable and lost to follow up patients~Phase II: Implementation of the individualized follow-up program The patients who agree to participate to the program will be defined as the OPTICARE population."
89126458|NCT03779841|Experimental|AGN-151607 (250 U)|Injections of 50 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
89126459|NCT03779841|Experimental|AGN-151607 (125 U)|Injections of 25 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
89126460|NCT03779841|Placebo Comparator|Placebo|Injections of placebo will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
89126461|NCT03770273|Active Comparator|placebo|8 SC injections of placebo
89126462|NCT03770273|Active Comparator|sarilumab|8 SC injections of 200 mg/1.14 ml of sarilumab over 16 weeks
89126463|NCT03756454|Experimental|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
89126464|NCT03756454|Placebo Comparator|Normal Saline|Patients receiving normal saline as a placebo post-operatively.
89126465|NCT03733535|Experimental|Treatment|Benralizumab 30mg subcutaneous injection on study days 0, 28 and 56 and 1.0 L 129-Xenon/4-Helium mixture, twice per visit, on days 0, 14, 28 and 112.
89126466|NCT03728010||One-Lung Ventilarion|Thoracic surgery cases with one-lung ventilation strategy.
89126467|NCT03719092|Experimental|Prevention (vitamin A compound)|"Participants receive vitamin A compound PO or enterally once prior to stem cell transplant.~once over a given 24 hour period with or without food. We will re-dose at 2000 IU/kg (maximum 120,000 IU) if Week 2 Vitamin A levels remain within 10% of baseline Vitamin A."
89126468|NCT03661385|Active Comparator|Intervention arm|• Intervention arm will receive nitric oxide 20 parts per million (ppm) into the oxygenator of a cardio-pulmonary bypass circuit
89126469|NCT03661385|No Intervention|Control arm|Control arm will not receive nitric oxide, they will receive standard bypass as per local policy
89126470|NCT03638453|Experimental|PediCARE|"PediCARE Administered x6 mos~Resource Provision: Monthly Groceries (delivery via Instacart)~Resource Provision: Transport to/from home/hospital 8x per month (via RideHealth)"
89126471|NCT03638453|Active Comparator|Usual Care|The control group will receive usual supportive care
89126472|NCT03630055|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
89126473|NCT03630055|No Intervention|Standard of Care|Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
89126474|NCT03618667|Experimental|single group|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles, or till progression or uncontrolled toxicity.
89126475|NCT03617731|Active Comparator|IA|Patients in arm IA are treated with 3 cycles RVd (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
89233749|NCT00815243|Active Comparator|ExternalControl|Group of trauma&orthopedic patients from 1-2rd level trauma centers (in rural and small municipal hospitals) - for determination of clinical strategy and treatment plan personal arriving of the expert by the car (so-called Urgent Expert Care) will be used
89233750|NCT02551289||Patients|Patients newly diagnosed with Coeliac disease before starting treatment with a gluten free diet
89233751|NCT02551289||Healthy volunteers|Participants who do not meet criteria for a clinical diagnosis of Coeliac disease as determined by screening blood sample.
89233752|NCT00815399|Experimental|1|
89233753|NCT00815399|Active Comparator|2|
88821391|NCT04329312||PH due to combined emphysema and fibrosis (PH-LD-CPFE)|The patients with PH-LD-CPFE received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
88821392|NCT04329312||No PH|The patients without PH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
89126476|NCT03617731|Experimental|IB|Patients in arm IB are treated with 3 cycles RVd + Isatuximab (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32;dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Isatuximab (10 mg/kg i.v. C1: d 1, 8, 15, 22, 29; C2-3: d 1, 15, 29).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
89126477|NCT03617731|Active Comparator|IIA|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) repeated every 28d. Maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
89126478|NCT03617731|Experimental|IIB|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) + Isatuximab (10 mg/kg; C1: d1, 8, 15, 22; C2-C3: d1 + 15; C4-39:d1, repeated every 28d). Within the trial, maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
89126479|NCT03614819|Experimental|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
89126480|NCT03614819|Active Comparator|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
89126481|NCT03579563|Active Comparator|AUD (audiologist-based)|In this group, the audiologist-based fitting will be used to provide hearing aids.
89126482|NCT03579563|Experimental|OTC (over-the-counter)|In this group, the over-the-counter fitting will be used to provide hearing aids.
89126483|NCT03579563|Experimental|OTC-Plus|In this group, the hybrid fitting will be used to provide hearing aids.
89126484|NCT03578510|Active Comparator|SHD|Standard hemodialysis
89126485|NCT03578510|Experimental|HHD|Hemocontrol hemodialysis
89126486|NCT03532828|Experimental|Polysomnography alone|A polygraphy will be performed in 70 patient to search for obstructive sleep apnea
89126487|NCT03532828|Experimental|Polysomnography and postural assesment|A polygraphy and a postural assesment will be performed in 30 patients
89126488|NCT03503123||COPD patients with deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV with severe symptoms of deventilation dyspnoea (Borg Dyspnoea Scale ≥ 5)
89126489|NCT03503123||COPD patients without deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV without symptoms of deventilation dyspnoea, matched with the first cohort/group with regard to the degree of static lung hyperinflation and NIV settings.
89126490|NCT03493789|Experimental|Diagnostic (FDG-PET, SBRT)|Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction, prior to the second planned fraction, and prior to the fifth planned fraction.
89126491|NCT03479957|Experimental|REMOTE-CR|Remotely monitored and coached exercise training in real time using the REMOTE-CR system. The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link.
89126492|NCT03479957|Other|Usual care|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care).
89126493|NCT03439124|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
89126494|NCT03439124|Active Comparator|IV standard-of-care cephalosporin|"Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults.~Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa.~Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
89126495|NCT03429803|Experimental|DAY101 (formerly TAK-580, MLN2480) BSA </= 1.5m^2|"Phase I Part B BSA </= 1.5m^2~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1~Study treatment cycle lasts 28 days, oral, once a week"
89233754|NCT00644969|Placebo Comparator|Placebo Arm|Randomization 2:1 treatment to placebo
89126496|NCT03429803|Experimental|DAY101 (formerly TAK-580, MLN2480) BSA > 1.5m^2|"Phase I Part B BSA > 1.5m^2~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1~Study treatment cycle lasts 28 days, oral, once a week"
89126497|NCT03405025|Other|Safety and Feasibility|All patients will undergo endoscopic US guided radiofrequency ablation, to assess safety and feasibility.
89126498|NCT03393741||Taxane (nab-paclitaxel or paclitaxel)|"Up to 10 participants will be enrolled on the Taxane arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
89126499|NCT03393741||Eribulin|"Up to 5 participants will be enrolled on the Eribulin arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
89126500|NCT03393741||Vinorelbine|"Up to 5 participants will be enrolled on the Vinorelbine arm. TThe dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
89126501|NCT03393741||Ixabepilone|"Up to 5 participants will be enrolled on the Ixabepilone arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
89126502|NCT03393741||Control Arm|"Up to 10 participants will be enrolled on the control arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
89126503|NCT03304093|Experimental|Nivolumab|Nivolumab 3mg/kg every 2 weeks
89126504|NCT03289052|Experimental|Restylane Volyme|Single injection and optional touch up injection with Restylane Volyme in Midface
89126505|NCT03289052|No Intervention|No intervention arm|No treatment
89126506|NCT03263117|Active Comparator|Sedation|The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.
89126507|NCT03263117|Active Comparator|General Anesthesia|The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.
89126508|NCT03232918|No Intervention|Standard Dose Oxytocin|Patients randomized to the standard dose oxytocin will have their oxytocin infusion maintained at the standard of care protocol prior to placement of a combined spinal epidural for labor analgesia
89126509|NCT03232918|Experimental|Half Dose Oxytocin|Patients randomized to the half dose oxytocin will have their oxytocin infusion reduced by 50 % prior to placement of a combined spinal epidural for labor analgesia.
89126510|NCT03231358|Experimental|Intervention|"Participants randomized to the behavioral intervention called Our Family Our Future. These participants will receive an intervention to prevent sexually transmitted infections (STIs) including HIV, Chlamydia trachomatis and Neisseria gonorrhoeae; sexual risk behavior; and depression onset. This is a behavioral intervention involving adolescent-parent dyads, delivered in a group setting over 3-4 consecutive weeks."
89126511|NCT03231358|No Intervention|Control|The control arm will receive usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care).
89126512|NCT03221075||Invasive Aspergillosis|
89126513|NCT03212989|Experimental|VOR + HXTC arm|"This is an open label single arm study. All eligible participants receive the following interventions:~Step 2 - Single dose of Vorinostat (VOR) 400 mg PO~Step 4 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions~Step 5 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions"
89126514|NCT03203148||CABG Surgical Patients|Patients undergoing coronary bypass grafting with cardiopulmonary bypass
89233755|NCT00644969|Active Comparator|Treatment Arm|
88802286|NCT05483478|Experimental|mobile health combined Multi-course Program|The experimental group received the combination of mobile health and multi-course intervention. In the pre-test, the experimental group joined the LINE group by scanning the QR code. The LINE messages were nutrition and exercise content, as well as exercise videos. One message each for nutrition and exercise was sent every Monday, Wednesday, and Friday, for a total of 12 weeks. The multi-course includes exercise and nutrition, 1 time per week, 2 hours each time, a total of 12 times, and each unit is 50 minutes long. The three measurement time points of the tracking effect were: before intervention, after 4-times interventions, and after 12-times interventions. The following data were collected in the two groups: frailty assessment, grip strength, lower limb muscle strength, health literacy scale and nutrition knowledge scale.
89126515|NCT03200548|Experimental|Relaxing acupressure plus usual care|"There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily.The True Acupressure points were chosen based on a TCM theory for treating insomnia."
89126516|NCT03200548|Experimental|Stimulating acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. Acupoints were chosen by consensus of 4 acupressure practitioners and based on a previous study design in students with sleep disturbances as well as TCM theory for treating insomnia and fatigue.
89126517|NCT03200548|Sham Comparator|Sham acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. None of these points are on meridians nor are they on actual points. They were chosen to be in the same general body quadrant as the true points.
89126518|NCT03200548|Placebo Comparator|Usual care|Participants will be asked to continue following their healthcare providers' instruction for chronic SLE management. We anticipate that most women will be treated per the American College of Rheumatology clinical guidelines. Participants will be asked to continue any current treatment and not to start or stop treatments including acupuncture/acupressure over the course of the study. All treatments for pain will be recorded.
89126519|NCT03152383|Experimental|Autism Spectrum Disorder|Children diagnosed as having autism spectrum disorder
89126520|NCT03152383|Active Comparator|Typically developing|Children who are typically developing
89126521|NCT03152383|Active Comparator|Other Developmental Delay|Children diagnosed with a developmental delay other than autism spectrum disorder
89126522|NCT03137173|Experimental|ceftobiprole medocaril|Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
89126523|NCT03137173|Active Comparator|vancomycin+aztreonam|Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
89126524|NCT03126292|Experimental|Sit Down and Play|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visits.
89126525|NCT03126292|Active Comparator|Handout|Families in the control group will receive handouts regarding child safety
89126526|NCT03072147|Active Comparator|Group 1- Treatment|20 mcg dosage amounts of teriparatide, in the FDA approved form Forteo, manufactured by Lilly, LLC, are loaded into a 2.4 ml prefilled delivery device (multi injection pen) that administers 28 equal doses as subcutaneous injections in the thigh or abdominal wall. Subjects will inject themselves once a day for 24 weeks.
89126527|NCT03072147|Placebo Comparator|Group 2- Placebo|Saline placebo is packaged by the manufacturer (Lilly, LLC) in the same 2.4 ml injection pen that is used for teriparatide; it will provide 28 doses of placebo. Subjects will inject themselves once a day for 24 weeks.
89126528|NCT03063372|Experimental|Pomegranate Supplement|"Participants in this arm will take a capsule with 500 mg of Pomella pomegranate extract twice each day for 28 days."
89126529|NCT03063372|Placebo Comparator|Placebo|Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.
89126530|NCT03052374|No Intervention|Control Group|Mothers will receive standard care such as referral to psychotherapy (intervention mothers will have the same access) over the same length of time.
89126531|NCT03052374|Experimental|VID-KIDS Intervention Program Group|RN review photos of infant engagement/disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
89126532|NCT03027869|Active Comparator|Real Left DLPFC tDCS|Real tDCS on the left dorsolateral prefrontal cortex
89126533|NCT03027869|Sham Comparator|Sham tDCS|30sec ramp-up and 30sec ramp-down
89126534|NCT03027869|Active Comparator|Real Right DLPFC tDCS|Real tDCS on the right dorsolateral prefrontal cortex
89126535|NCT02841527|Active Comparator|Gastric Band|The procedure will involve an operation in which a gastric Band and port will be fitted using a laparoscopic technique.
89126536|NCT02841527|Active Comparator|Gastric Bypass|The procedure will involve a laparoscopic operation in which a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
89126537|NCT02841527|Active Comparator|Sleeve Gastrectomy|The procedure involves an operation which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach using a laparoscopic technique.
89126538|NCT02798120|Experimental|SB204 4%|All subjects received SB204 4% once daily (QD) in this open label study. Subjects assigned to SB204 4% QD in the parent study (NI-AC301/302) continued to receive SB204 for 40 more weeks. Subjects assigned to Vehicle Gel in the parent study (NI-AC301/302) received SB204 4% QD in this open label study.
89126539|NCT02723513|Experimental|Preterm Adults|All enrolled preterm adults will undergo non-contrast enhanced MRI (using ultra-short echo time methods), hyperpolarized noble gas MRI (using hyperpolarized xenon-129), x-ray computed tomography (CT), pulmonary function tests, and questionnaires in a single visit.
89290165|NCT01123278|Placebo Comparator|Placebo gel|Placebo gel
89233756|NCT00815477|Active Comparator|1|Waitlist control with generic Information about lifestyle and hypertension
89233757|NCT00815477|Experimental|2|Web-based intervention of lifestyle counseling messages based on the transtheoretical model of readiness for change.
89233758|NCT02551445|Experimental|Gradual exposure to food stimuli|The intervention entails 2 sessions of psychoeducation and a clinical assessment including a discussion on learned food-related fears, role of food-related fears in the maintenance of anorexia nervosa, anxiety and its time course, avoidance, exposure and habituation, irrational fears and safety behaviors; and 8 sessions of in vivo exposure to foods, starting from the least scary food of a hierarchy of threatening foods created by each patient. Each session will involve exposure to a new food item and patients will be encouraged to confront their fear by looking at and touching the chosen food item. They will also be encouraged to eat the food and reflect on the consequences of eating and assessing those relative to their fears (e.g. checking whether they have lost control or changed shape after eating).
89233759|NCT00815555||1|Women diagnosed with receptor positive breast cancer, treated with Tamoxifen
89233760|NCT04016909|Experimental|aerobic exercise plus calorie restriction|"The experimental intervention: both exercise and calorie restriction, as described below:~Exercise intervention. 6 months, 72 supervised aerobic exercise training sessions on cycle ergometers, including 3 sessions of training per week. A warm-up procedure consisting of 5 min of low-intensity stretching was completed by all women before the aerobic training. Subsequently, a 50 min aerobic training at an intensity between 60% and 70% of the maximum heart rate (HR) was performed. Thereafter, a cool-down consisting of 5 min of low-intensity stretching and breathing exercises was completed. HR was recorded continuously throughout the training sessions using an HR monitor (S625X, Polar Electro, Kempele, Finland).~Calorie restriction intervention. The CR intervention was designed to create a 12.5% energy deficit, with the goal of reducing body weight by 5%-10% over 6 months."
89233761|NCT04016909|No Intervention|Control|No intervention and participants were instructed to maintain their regular physical activity and diet regime for 6 months; they were also prohibited from participating in any weight-loss or exercise program.
89233762|NCT00812279|Experimental|1. SMAR|Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.
89233763|NCT00812279|Active Comparator|2 Conventional cigarette (CC)|Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.
89233764|NCT00812279|Active Comparator|3. smoking cessation (SC)|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
89233765|NCT00812357||1|Patients treated with Symbicort basic treatment
89233766|NCT00812357||2|Patients treated with Symbicort basic treatment + treatment of symptoms as needed
89233767|NCT04046081|Other|Dichloroacetate|Open label study
89233768|NCT00812435|Experimental|Eptifibatide|PCI with administration of eptifibatide
89233769|NCT00812747||1|
89233770|NCT00820547|Experimental|(FEC / Docetaxel) + Bevacizumab|Neoadjuvant treatment: 4 cycles FEC + Bevacizumab followed by 4 cycles Docetaxel + Bevacizumab Adjuvant: Bevacizumab for 1 year
89233771|NCT00815867|Experimental|A|Patient will receive Epoetin Beta
89233772|NCT00815867|No Intervention|B|
89233773|NCT00820625|Active Comparator|1|ablation: pulmonary vein isolation
89233774|NCT00820625|Active Comparator|2|ablation: pulmonary vein isolation with additional ablation of fragmented potentials
89233775|NCT02550509|Experimental|patients with hemiplegia after stroke|ultrasound echogenicity paraclinical assessment and elastography to patients with hemiplegia following stroke with an indication of injection of botulinum toxin into the triceps sural
89233776|NCT00815945|Experimental|PegLiposomal Doxorubicin + Carboplatin|Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)
89233777|NCT00820781|Active Comparator|Portacaval shunt|Undergo portacaval shunt surgery
89233778|NCT00820781|Active Comparator|Sclerotherapy|Undergo endoscopic sclerotherapy
89233779|NCT00644423|Active Comparator|1|Omega-3 Fatty Acid
89233780|NCT00644423|Placebo Comparator|2|Placebo
89233781|NCT00820859|Experimental|1|
89233782|NCT00820859|Active Comparator|2|
89233783|NCT00812825|Experimental|PF-04173127|
89233784|NCT00812825|Active Comparator|Prednisolone|
89233785|NCT00812825|Placebo Comparator|Placebo|
89233786|NCT00812825|Sham Comparator|Solution Placebo|
89233787|NCT00812825|Experimental|PF-04171327 Tablet|
89233788|NCT00628355|Experimental|lidocaine injection|"Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.~Patients received lidocaine injections once a week for 4 weeks"
89233789|NCT00628355|Experimental|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
89233790|NCT00627497|Experimental|DIAM Group1|
89233791|NCT00627497|Active Comparator|Single-Level Posterior Decompression|
89233792|NCT00627497|Experimental|DIAM Group2|
89233793|NCT00627497|Active Comparator|Posterolateral Interbody Fusion|
89233794|NCT00648167|Experimental|KRX-0502 (ferric citrate)|All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.
89233795|NCT00812903|No Intervention|Control|Control group
89233796|NCT00812903|Experimental|Exercise|Intervention group
89233797|NCT03691623|Experimental|EDP-938 Arm A|Subjects will take EDP-938 Dose 1 oral suspension for 5 days
89233798|NCT03691623|Experimental|EDP-938 Arm B|Subjects will take EDP-938 Dose 2 oral suspension for 5 days
88802287|NCT05483478|Active Comparator|Multi-course Program|The control group received multi-course includes exercise and nutrition, 1 time per week, 2 hours each time, a total of 12 times, and each unit is 50 minutes long. The three measurement time points of the tracking effect were: before intervention, after 4-times interventions, and after 12-times interventions. The following data were collected in the two groups: frailty assessment, grip strength, lower limb muscle strength, health literacy scale and nutrition knowledge scale.
88806117|NCT00243152|Active Comparator|Placebo to Lamotrigine Crossover|The placebo will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, the drug lamotrigine (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for drug will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
89126540|NCT02718690|Experimental|Transcutaneous nerve stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
89126541|NCT02718690|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
89126542|NCT02706054|Placebo Comparator|C-group|patients receiving an IM saline injection near the nerve root (periradicular)
89126543|NCT02706054|Experimental|M-group|patients receiving an IM Meloxicam injection near the nerve root (periradicular)
89126544|NCT02695875|Experimental|Aquatic therapy|Aquatic therapy is the experimental group. This therapy will take place in a warm pool which is located in Rialta's Sports Complex. Aquatic therapy session will be conducted by the main researcher with the help of an assistant. Because the number of patients (n=17), they will be subdivided into two subgroups of 8 and 9 people respectively in order to ensure the safety and care of patients. The intervention will last for one hour: Warming (15 minutes); exercises to train the static and dynamic balance (25 minutes); stretching (10 minutes); relaxation (10 minutes). Over 12 weeks of treatment, difficulty in performing exercises to train balance will increase progressively.
89126545|NCT02695875|Other|Land-based therapy|"The description is the same as aquatic therapy. The difference is land-based therapy sessions will be made at Faculty of Physiotherapy at University of A Coruña."
89126546|NCT02630641||Prostate cancer patients|
89126547|NCT02600117|Other|Tenofovir disoproxil fumarate|300 mg, orally, once a day for 3 years or when sAg+ve seroconverts to sAb+ve whichever comes earlier
89126548|NCT02599714|Experimental|Triplet Combination (Dose Finding)|Phase 1 triplet dose finding phase in 3-6 patients per cohort - approximately 30 patients depending on emerging data to determine the maximum tolerated dose (MTD) of the triplet.
89126549|NCT02599714|Experimental|Triplet Combination (Dose Expansion)|Additional patients will be enrolled at the dose determined in Part A.
89126550|NCT02421497||Normal Healthy Volunteer|
89126551|NCT02421497||Non-CKD Control|
89126552|NCT02421497||Chronic Kidney Disease (CKD)|
89126553|NCT02421497||Dialysis Patients|
89126554|NCT02421497||Renal Transplant Recipients|
89126555|NCT02337634|Placebo Comparator|Placebo|Matched dosage of milk thistle daily.
89126556|NCT02337634|Active Comparator|Milk Thistle|Capsule form, 150mg BID to 300mg BID
89126557|NCT02288195|Experimental|Chemotherapy|Patients receive neoadjuvant chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.Patients without disease progression undergo low-anterior resection (LAR) with total mesorectal excision (TME) and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days). Patients with disease progression undergo chemoradiation as in group chemoradiotherapy before proceeding to LAR with TME.
89126558|NCT02288195|Experimental|Chemoradiotherapy|Patients receive capecitabine 825 mg/m² twice daily concurrently with radiation therapy for 5 days per week. Patients also undergo intensity-modulated radiation therapy 5 days a week for approximately 5.5 weeks. Patients then undergo LAR with TME and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days) .
89126559|NCT02285127|Active Comparator|Short nail implant|used to treat pertrochanteric fractures
89126560|NCT02285127|Active Comparator|Long nail implant|used to treat pertrochanteric fractures
89126561|NCT02279329|Other|COPD and Bronchiectasis Patients|All enrolled COPD and Bronchiectasis patients will undergo Pulmonary Function Tests, Hyperpolarized Helium MRI, chest CT, 6-Minute Walk Test, and complete questionnaires at up to 8 visits over 2-3 years.
89126562|NCT02265874|Active Comparator|Treatment|Habitrol Nicotine patch - 7,14,21 mg patches Qd
89126563|NCT02265874|Placebo Comparator|Control|Placebo patch
89126564|NCT02263794|Experimental|Image guided bronchial thermoplasty|At pre-treatment Visit 3, imaging data will be acquired to generate a patient-specific bronchial thermoplasty treatment plan which will include 15-20 target airways, prioritized in order of importance and grouped by lobe, to be targeted during a single session BT treatment procedure. Airways demonstrating dynamic or static bronchoconstriction will be targeted for BT treatment based on their spacial proximity to ventilation defects.
89126565|NCT02263794|Active Comparator|Conventional bronchial thermoplasty|Patients in this group will undergo conventional 3 stage bronchial thermoplasty (during 3 separate bronchoscopies).
89126566|NCT02240251||Patients undergoing IVC filter removal using the excimer laser|Laser Assisted IVC Filter Removal
89126567|NCT02005861|Experimental|bone marrow cells transplantation|"surgical procedure :the day before the surgery: platelet gel production. The day of the surgery: bone marrow aspiration from the posterior iliac crest of the patient and concentration. After the bone marrow harvesting, ankle arthroscopy will be performed. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and implanted.~After that platelet gel will be loaded on the top of implant"
89126568|NCT01996436|Active Comparator|Nicardipine|Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty
89126569|NCT01996436|Active Comparator|Verapamil|Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty
89126570|NCT01996436|Active Comparator|Nicardipine + Verapamil + Nitroglycerin|Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty
89126571|NCT01892514|Experimental|Demineralized Bone Marrow (DBM)|core decompression of necrotic area and graft with a biological product based on Demineralized Bone Matrix (DBM), Platelet-Rich-Fibrin (PRF) and Concentrated Bone Marrow (CBM)
89126572|NCT01892514|Experimental|Lyophilized Bone Chips (LBC)|core decompression of the necrotic area and graft with a biological product based on homologous Lyophilized Bone Chips (LBC), Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
89126573|NCT01845337|Active Comparator|Capecitabine single agent|Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days
89126574|NCT01845337|Active Comparator|Capecitabine /Oxaliplatin|Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
89126575|NCT01845337|Active Comparator|Teysuno single agent|Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 40mg (BSA < 1.5 m2), 45 mg (BSA 1. 5 to < 1.7 m2), 55mg (BSA 1.7 - 1.9 m2),
89126576|NCT01845337|Active Comparator|Teysuno/ Oxaliplatin|Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA < 1.5 m2), 40mg (BSA 1.5 to < 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA >1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
89126577|NCT01801384|Experimental|Original contingent vouchers schedule|Women will receive an abstinence-contingent voucher-based incentives intervention (Contingency Management) for smoking cessation and relapse prevention.
89126578|NCT01801384|Experimental|Revised contingent vouchers schedule|Women receive abstinence-contingent voucher-based incentives (Contingency Management) intervention designed to further increase cessation and relapse prevention rates.
89126579|NCT01801384|Sham Comparator|Non-contingent vouchers schedule|This serves as a control condition wherein women earn incentives independent of smoking status.
89126580|NCT01635569|Active Comparator|OCD-affected subjects (Group 1)|OCD-affected subjects will participate in 12 sessions of group therapy (as per GF-CBT protocol).
89126581|NCT01635569|Active Comparator|OCD-affected subjects (Group 2)|Waitlist affected-controls awaiting a treatment spot.
89126582|NCT01575808|Experimental|GP1101|Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft
89126583|NCT01575808|No Intervention|Retrospective Surgical Bypass Outcomes|Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.
89126584|NCT01563341|Experimental|Deep Brain Stimulation|Parkinson's disease patients who would otherwise be undergoing subthalamic nucleus (STN) deep brain stimulation (DBS) will have dual hemispheric stimulation of the STN and globus pallidus interna (GPi).
89126585|NCT01546753|Experimental|Walnut Protein Powder|38 weeks on active walnut powder on blinded treatment phase
89126586|NCT01546753|Placebo Comparator|Oat Powder|38 weeks on placebo (oat) powder during blinded treatment phase
89126587|NCT01546753|Other|Open-label Walnut Protein Powder|Open-label treatment with walnut protein powder up to week 298 of total treatment
89126588|NCT01528982|No Intervention|Control|Psychoeducation
89126589|NCT01528982|Active Comparator|Mindfulness|Mindfulness activity and psychoeducation
89126590|NCT01528982|Active Comparator|Cognition|Cognitive training and psychoeducation
89126591|NCT01382082||subjects with breast cancer|
89126592|NCT01382082||subjects with lymphoma|
89126593|NCT01382082||subjects without cancer|
89126594|NCT01334788|Experimental|sleep deprivation|These are subjects who are randomized to undergo sleep deprivation.
89126595|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
89126596|NCT00836537|Experimental|1|
89126597|NCT00836537|Active Comparator|2|
89126598|NCT00832026||Sleep apnea|Patients with diagnosed obstructive sleep apnea
89126599|NCT00572169|Experimental|VDTPACE|Velcade, Dexamethasone, Thalidomide, Cisplatinin, Adriamycin, Cyclophosphamide and Etoposide
89126600|NCT02585284||vicenarian|20 to 29 years. Five males and five females
89126601|NCT02585284||tricenarian|30 to 39 years. Five males and five females
89126602|NCT02585284||quadragenarian|40 to 49 years. Five males and five females
89126603|NCT02585284||quinquagenarian|50 to 59 years. Five males and five females
89126604|NCT02585284||sexagenarian|60 to 69 years. Five males and five females
89126605|NCT02585284||septuagenarian|70 to 79 years. Five males and five females
89126606|NCT02585284||octogenarian|80 to 89 years. Five males and five females
89126607|NCT02585284||nonagenarian|90-99 years. Five males and five females
89126608|NCT00631280|Experimental|Choice|
89126609|NCT00631280|Active Comparator|Recommendation|
89126610|NCT02585206|No Intervention|Arm 1|"All 4 factors off - standard text message program~Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity OFF"
89126611|NCT02585206|Active Comparator|Arm 2|Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity ON
89126612|NCT02585206|Active Comparator|Arm 3|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity OFF
89126613|NCT02585206|Active Comparator|Arm 4|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity ON
89126614|NCT02585206|Active Comparator|Arm 5|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity OFF
89126615|NCT02585206|Active Comparator|Arm 6|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity ON
89126616|NCT02585206|Active Comparator|Arm 7|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity OFF
89126617|NCT02585206|Active Comparator|Arm 8|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity ON
89126618|NCT02585206|Active Comparator|Arm 9|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity OFF
89126619|NCT02585206|Active Comparator|Arm 10|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity ON
89126620|NCT02585206|Active Comparator|Arm 11|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity OFF
89126621|NCT02585206|Active Comparator|Arm 12|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity ON
89126622|NCT02585206|Active Comparator|Arm 13|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity OFF
89126623|NCT02585206|Active Comparator|Arm 14|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity ON
89126624|NCT02585206|Active Comparator|Arm 15|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity OFF
89126625|NCT02585206|Active Comparator|Arm 16|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity ON
89126626|NCT02585206|No Intervention|WEB|"Phase II arm.~Full access to standard BecomeAnEX.org web-based smoking cessation program."
89126627|NCT02585206|Active Comparator|WEB+OA_TXT|"Phase II arm.~Full access to standard BecomeAnEX.org web-based smoking cessation program PLUS optimal-adherence text message program from Phase I."
89126628|NCT04266626|Experimental|Group A kinesiotaping therapy|"Protocols mentioned in kinesiological taping i.e. 45 minutes will be pursued as with longer sessions children may tire out easily. Taping Technique for lip muscles would be used by cutting 2 I tapes according to the structure of lip muscles.The tape will be fixed in the center of the mouth on the upper lip, will be placed on an open mouth and a 10% tension will be given to the paper. The tape will then end at the corner of the upper lip. Kinesiotape wouldn't be placed on the lips. The second tape piece will be fixed to the center of the lower lip.The edges of the tape should overlap slightly.~The other piece of tape will be placed under chin (base of tongue) on sub mandibular triangle, inside the jaw line on the base of the tongue. A strip 1-1 ½ inch long will be cut, and then will further be cut in half such that the stretch is horizontal. It will be anchored in the middle on sub mandibular triangle. Paper off the tension to both sides."
89126629|NCT04266626|Active Comparator|Group B Oral Motor Manipulation therapy|"For the oral motor manipulation technique CP chair will be required to maintain the good sitting posture of children. Trunk will be in upright position with cut out lap board of the CP chair. Hips, knees and ankles would be flexed to 90 degrees. Shoulders and arms will be rested in symmetrical manner by keeping them rested in lap board and foot rest will be used to rest the feet tightly to control movement and maintain good posture. Each child would be taken for 12 weeks of therapy with three sessions per day of 15 minutes each. Oral motor manipulation like tapping protocols would be used for 45 minutes; slow, even rhythmic pressure will be applied around lip muscle and base of tongue muscle, keeping in view the comfort level of patient.~Training to do manipulation exercises will be given to the parents of children with CP at ."
89126630|NCT02585128|Other|Patients following TAVI|
89126631|NCT04266782|Experimental|Physical exercise program and Long-walking|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
89126632|NCT04266782|No Intervention|Usual care|The subjects will be followed according to current standard.
89126633|NCT04266782|Active Comparator|Control group-intervention|"A physical training will be started three months before the long-walking. The subjects will have to walk for at least 3 hours per week up to 6 hours per week during the training. THe long-distance capacity will be verified in 3 different one-day walking of 10, 15 and 18 Km before the long-walking performance.~The long-walking will be organized with the support of a physician, study nurse, physiotherapy with car support in case of need. The subject are request to complete the walk of 104 Km of Portuguese route of Santiago de Compostela walk."
89126634|NCT00941720|Experimental|Busulfan Treatment|
89126635|NCT02583568|Experimental|Part 1|In part 1 a dose escalation will be performed for the tracer bevacizumab-800CW in four different dose groups (4,5mg 10mg 25mg 50mg)
89126636|NCT02583568|Experimental|Part 2|In part 2, the two best performing dose groups of bevacizumab-800CW of part 1 will be expanded to a total of 10 patients per group.
89126637|NCT02583802|No Intervention|Control group|Control group received regular hemodialysis treatment, no given Ear pills and Shengmai capsule completed in the treatment of the first stage. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
89126638|NCT02583802|Experimental|Ear pills and Shengmai capsule|On regular hemodialysis based on given auricular Ear pills and Shengmai capsule
89126639|NCT02852564|Experimental|Enrolled Participants|Administration of a single, 50 mg oral dose of ethacrynic acid prior to bladder tumor removal surgery (Transurethral Resection of Bladder Tumor [TURBT])
89126640|NCT04481230|Experimental|99mTc-NTP 15-5 (level 1)|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg
89126641|NCT04481230|Experimental|99mTc-NTP 15-5 (level 2)|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg
89126642|NCT04481230|Experimental|99mTc-NTP 15-5 (level 3)|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
89126643|NCT02583412|Active Comparator|Group 1: Accelerated Schedule|
89126644|NCT02583412|Active Comparator|Group 2: Standard Schedule|
89126645|NCT05509816|Experimental|Midazolam + Imlunestrant|Midazolam administered orally alone on day 1 followed by imlunestrant administered orally alone on days 3 to 8. On day 9, midazolam is administered orally in combination with imlunestrant orally.
89126646|NCT02584972||children with Autism Spectrum Disorder|no intervention required
89126647|NCT02584972||heathy children|no intervention required
89233799|NCT03691623|Placebo Comparator|Placebo Arm C|Subjects will take matching placebo oral suspension for 5 days
89233800|NCT03691623|Experimental|EDP-938 Arm D|Subjects will take EDP-938 Dose 3 oral suspension for 5 days
89233801|NCT03691623|Experimental|EDP-938 Arm E|Subjects will take EDP-938 Dose 4 oral suspension for 5 days
89290166|NCT01215396|Placebo Comparator|Carbohydrate Placebo|
89126648|NCT04078750|Sham Comparator|Phase I. Control group|"The standard of care will be provided to the control group pre- and post-transplant. This does not involve any direct pre-transplant assessment of medication adherence or risk factors for non-adherence.~Tacrolimus capsules will be dispensed in Medication Event Monitoring System (MEMS) caps for 3 months post-transplant for the purpose of measuring adherence after transplantation.~Patients will be asked to complete Basel Assessment of Adherence to Immunosuppressive Medication instrument (BAASIS) questionnaire and Long-term Medication Behaviour Self-efficacy Scale at 3 months after transplantation."
89126649|NCT04078750|Experimental|Phase II. Intervention group|Patients will be given lactose containing white- and yellow-colored gelatin capsules stored in (MEMS®) bottles for a 1-month adherence trial. Yellow-colored gelatin capsules represent tacrolimus 0.5mg capsules while white-colored gelatin capsules represent tacrolimus 1mg capsules. MEMS® is designed to record the date/time of opening and closure of the drug vial. Patients will be asked to take a certain dose and expected to remove the correct number of white and yellow capsules from respective vial at the correct time each day. Phone calls will be made to patients to change the 'dose' at various times throughout the month to mimic the frequent need to make tacrolimus dosing changes early post-transplant.Pill count and MEMS record will be reviewed at the end of the 1-month trial period to assess adherence. Patients will also undergo health literacy, cognition testing, self-efficacy tests, with a customized post-transplant plan.
89126650|NCT02581852|Other|Single arm assessment|Cross sectional assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning of rheumatoid arthritis patients with different disease activity levels.
89126651|NCT02583334|Experimental|Verum Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the verum acupuncture group, participants will receive verum acupuncture (Device: 30# acupuncture needle) three times a week, for 4 weeks (12 treatment in total).
89126652|NCT02583334|Sham Comparator|Sham Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture (Device: Streitberger device) three times a week, for 4 weeks (12 treatment in total).
89126653|NCT04080310|Active Comparator|combination therapy group|The combination therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10 mg once daily.
89126654|NCT04080310|Other|intensive statin group|The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.
89126655|NCT02584894|Placebo Comparator|rTMS 1Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 1Hz on dorsolateral prefrontal cortex (1Hz rTMS is describe in the literature to have no effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter . Heart rate measure With electrocardiogram
89126656|NCT02584894|Experimental|rTMS 10Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 10Hz on dorsolateral prefrontal cortex (10Hz rTMS is describe in the literature to have effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter. Heart rate measure with electrocardiogram
89126657|NCT00933686|Active Comparator|Saizen®|
89126658|NCT00933686|Active Comparator|Placebo + Saizen®|
89126659|NCT04078048|Experimental|Vitamin C Group|Tablet Vitamin C 500 mg Once a day
89126660|NCT04078048|Experimental|Vitamin E Group|Tablet Vitamin E 600 I U Twice daily
89126661|NCT04078048|Placebo Comparator|Placebo Group|Capsule Paraffin oil 500 mg Once a day
89126662|NCT04079998|Experimental|Procellera® dressing|The Procellera® dressing will be applied to the wound site after standard of care cleaning and debridement. The dressing will be maintained according to the manufacturer's instructions for use.
89126663|NCT04079998|Active Comparator|Standard of Care|The Standard of care as prescribed will be followed for the dressing application for the wound site. Dressings will be applied to the wound site after standard of care cleaning and debridement.
89126664|NCT05379140|Experimental|The Therapeutic Chinese Massage Group|Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.
89126665|NCT05379140|Placebo Comparator|The Placebo Massage Group|The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
89126666|NCT04445896||Study Participants|Patients with a diagnosis of a life-limiting illness who have previosuly had a discussion with a healthcare professional about the care they would want at the end of life
89126667|NCT02729974|Experimental|ROTEM|Participants randomized to this arm will have rapid testing of hematocrit and clotting function every 30 minutes during the hysterectomy portion of their surgery for placenta accreta, with transfusion of blood products based on defined abnormalities in these tests.
89126668|NCT02729974|Active Comparator|Standard treatment|Participants randomized to this arm will have standard visual assessment of blood loss and standard laboratory studies to assess blood count and clotting function when indicated during the hysterectomy portion of their surgery for placenta accreta. Transfusion of blood products will be based on abnormalities of these test results.
89126669|NCT00937040|Experimental|001|OROS MPH Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
89126670|NCT00937040|Placebo Comparator|002|Placebo Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
89126671|NCT02583178|Experimental|Aegis Sierra Ligation System|The Aegis Sierra Ligation System is a series of devices designed for epicardial ligation of the Left Atrial Appendage through a minimally invasive transcatheter approach.
89126672|NCT00673387|Placebo Comparator|Placebo-P + Placebo-M|Placebo matched to pramlintide BID plus placebo matched to metreleptin BID
89126673|NCT00673387|Experimental|Pramlintide 360 mcg + Placebo-M|360 mcg pramlintide given twice per day (BID) plus Placebo matched to Metreleptin given BID
89126674|NCT00673387|Experimental|Placebo-P + Metreleptin 5.0 mg|Placebo matched to pramlintide BID plus metreleptin 5.0 mg BID
89126675|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 2.5 mg|Pramlintide 180 mcg BID plus Metreleptin 2.5 mg BID
89126676|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 5.0 mg|Pramlintide 180 mcg BID plus Metreleptin 5.0 mg BID
89126677|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 1.25 mg|Pramlintide 360 mcg BID plus Metreleptin 1.25 mg BID
89126678|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 2.5 mg|Pramlintide 360 mcg BID plus Metreleptin 2.5 mg BID
89126679|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 5.0 mg|Pramlintide 360 mcg BID plus Metreleptin 5.0 mg BID
89126680|NCT00607490|Experimental|Cognitive-behavioral Therapy|10 weekly individual 60-minute sessions
89126681|NCT00607490|Active Comparator|Supportive Psychotherapy|10 weekly individual 60-minute sessions
89126682|NCT02583100|Experimental|Intensive Feedback|Participants in this arm will receive intensive feedback on their complication rates, surgical technique, and peri-operative surgical management from peer surgeons participating in the study.
89126683|NCT02583100|Active Comparator|Routine Feedback|Participants in this arm will receive routine feedback on their complication rates.
89126684|NCT00933608|Experimental|memantine|after a period of gradual dose increase from 5 mg/day, participants will be asked to take memantine (20mg/day) for 16 weeks 10 mg in the morning, 10 mg at night
89126685|NCT00933608|Placebo Comparator|Placebo|dose increase to match active drug, after that 1 tablet in the morning, 1 tablet at night, to match active drug
89126686|NCT02582944|Experimental|Arm 1: Electromagnetic navigation|"The bronchoscope will be inserted transorally into the tracheobronchial tree and a standard airway inspection will be performed.~Following airway inspection, the bronchoscope will be removed and the tip tracked steerable catheter with optical system will be advanced transorally through the vocal cords and into the tracheobronchial tree.~Once the tip tracked catheter has been advanced to the peripheral pulmonary target lesion, the optical SpinView system will be removed from the tip tracked catheter and the 1.4mm radial endobronchial ultrasound mini-probe will be inserted through the tip-tracked catheter into the lung periphery to confirm the presence of a peripheral pulmonary lesion and accurate navigation.~Once target confirmation has been performed using radial probe endobronchial ultrasound, biopsy of the peripheral lesion will be performed using biopsy forceps, brushes and aspiration needles."
89126687|NCT02585050||patients alive discharged from hospital|patients alive discharged from hospital following CPR
89126688|NCT04264520|Experimental|PTSD Psychoeducation + Skills Intervention|
89126689|NCT05380310|Experimental|Active alerts|"SMART ANGEL Intra-hospital System with active alerts"
89126690|NCT05380310|Active Comparator|Inactive alerts|"SMART ANGEL Intra-hospital System with inactive alerts"
89126691|NCT00764569||Oral Tissue measurement|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
89126692|NCT02558023|Experimental|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
89126693|NCT02558023|Active Comparator|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
89126694|NCT00607568|Experimental|1|atomoxetine 40mg per day
89126695|NCT00607568|Placebo Comparator|2|second arm is placebo, sugar pill
89126696|NCT00606164|Placebo Comparator|Placebo|
89126697|NCT00606164|Experimental|10 ug/m2 Bryostatin|
89126698|NCT00606164|Experimental|15 ug/m2 Bryostatin|
89126699|NCT04266548|Experimental|super-selective hepatic artery ICG injection group|single arm for feasibility study of intra-hepatic artery base fluorescent segmental demarcation
89126700|NCT00604916|Experimental|E|received a 7 day standardized oral care protocol
89126701|NCT00604916|Placebo Comparator|C|received a 7 day mimic protocol
89126702|NCT04610710|Active Comparator|Operation|Operation for severe endometriosis
89126703|NCT04610710|Active Comparator|Fertility treatment|Fertility treatment for women with severe endometriosis.
89126704|NCT04323670|Other|Selectra 3D|Guiding catheter to position the brady lead into a untypical heart position
89126705|NCT00574951|Experimental|AMG 706|AMG 706 daily
89126706|NCT02584816|Experimental|Group 1 - BRV-PV Lot A|BRV-PV Lot A + DPT- HepB-Hib + OPV
89126707|NCT02584816|Experimental|Group 2 - BRV-PV Lot B|BRV-PV Lot B+ DPT- HepB-Hib + OPV
89126708|NCT02584816|Experimental|Group 3 - BRV-PV Lot C|BRV-PV Lot C + DPT- HepB-Hib + OPV
89126709|NCT02584816|Active Comparator|Group 4 - ROTARIX|ROTARIX + DPT-HepB-Hib + OPV
89126710|NCT02584738|Experimental|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4.~Intravenous methylprednisolone or oral prednisolone"
89126711|NCT02584738|Placebo Comparator|Nebulized isotonic saline|Nebulized salbutamol and ipratropium bromide with 2.5 ml of isotonic saline. Intravenous methylprednisolone or oral prednisolone
89126712|NCT00764647|Experimental|Single arm|Education program for family caregivers of frail elders.
89126713|NCT00765271|Active Comparator|Group 2|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Raltegravir 400 mg (2 x 200mg tablets) twice daily from days 2 to 15 Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 16 to day 29)
89126714|NCT00765271|Active Comparator|Group 1|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 2 to day 15) Raltegravir 400 mg (2 x 200mg tablets) twice daily from day 16 to 29
89126715|NCT04411186|Active Comparator|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Control for this study will be the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
89233802|NCT03691623|Placebo Comparator|Placebo Arm F|Subjects will take matching placebo oral suspension for 5 days
89233803|NCT00647699|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
89233804|NCT00647699|Sham Comparator|Control Group|riboflavin ophthalmic solution without UVA irradiation.
88806118|NCT01453075|Experimental|Arm 1: valacyclovir|Assigned patients will take 1.5 mg po valacyclovir twice daily
89126716|NCT04411186|Experimental|ERAS and 5 Lung Protective Interventions|"The standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height)~Positive end-expiratory pressure (PEEP) 7cm H2O5~Immediately post intubation recruitment breath (30cm water for 30 seconds)~Every 1 hour recruitment breath (30cm water for 30 seconds)~40% FIO2 initially - titrate up as necessary to maintain SPO2 >94%"
89126717|NCT02583022|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
89126718|NCT02583022|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
89126719|NCT02583022|Active Comparator|Elidel cream 1%|Elidel cream 1%, Twice daily for 4 weeks
89126720|NCT00765349||All patients undergoing major surgery|
89126721|NCT00764725|Active Comparator|A|MTX+SSZ+Plaquenil
89126722|NCT00764725|Active Comparator|B|MTX+Infliximab
89126723|NCT05297266|Experimental|Patients with replanted extremity monitored by tissue CO2|Patients with traumatic amputation of a limb who are undergoing replantation surgery and are monitored postoperatively with IscAlert biosensor measuring local tissue CO2 and temperature in the replanted extremity
89126724|NCT01557751|Other|Total knee arthroplasty subjects who are genotyped|All patients will have whole blood drawn for genotyping, and participate in the various assessments (psychosocial questionnaires, qualitative sensory testing, etc).
89126725|NCT00775099|Experimental|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
89126726|NCT00775099|Experimental|Diesel Exhaust Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 during intermittent exercise
89126727|NCT00775099|Experimental|Filtered Diesel Exposure|1 hour exposure to diesel exhaust with all particulates filtered out using teflon filter with intermittent exercise
89126728|NCT00775099|Experimental|PALAS Exposure|1 hour exposure to pure carbon particles produced by PALAS generator during intermittent exercise
89126729|NCT02582710|Experimental|VASCAZEN|Patients treated with Vascazen
89126730|NCT02582710|Placebo Comparator|Placebo|Patients treated with a placebo
89126731|NCT00936884|Experimental|Methylnaltrexone double-blind|Methylnaltrexone once every other day.
89126732|NCT00936884|Placebo Comparator|Placebo|Placebo once every other day.
89126733|NCT00936884|Other|Methylnaltrexone open-label|Subjects who completed the double-blind period had the option to receive methylnaltrexone once every other day during a 12-week, open-label extension period.
89126734|NCT04048135|Experimental|Dose 1|
89126735|NCT04048135|Experimental|Dose 2|
89126736|NCT04048135|Experimental|Dose 3|
89126737|NCT04048135|Experimental|Dose 4|
89126738|NCT04048135|Experimental|Dose 5|
89126739|NCT04048135|Experimental|Dose 6|
89126740|NCT04048135|Placebo Comparator|Placebo|
89126741|NCT04048135|Experimental|Dose 4 Open Label|
89126742|NCT04077892|Experimental|combination of budesonide and montelukast|receive treatment with either a combination of budesonide (Rhinorcort Astra Zeneca AB), 1 spray per nostril twice daily (total 256 μg/d) and 10mg oral montelukast tablet (Merck Sharp & Dohme Australia Pty Ltd) in the evening for 14 days (BD+MNT treatment group)
89126743|NCT04077892|Active Comparator|only intranasal budesonide|treatment with only intranasal budesonide 1 spray per nostril twice daily for 14 days (BD treatment group)
89126744|NCT02582788|Active Comparator|Bleach|Patients will use bleach added to their baths twice a week.
89126745|NCT02582788|Active Comparator|Vinegar|Patients will use vinegar (dilute acetic acid) added to their baths twice a week.
89126746|NCT00606242|Active Comparator|Low dose steroid|Fluticasone, 100 mcg per day
89126747|NCT00606242|Active Comparator|High dose steroid|Fluticasone, 1000 mcg per day
88806119|NCT01453075|Placebo Comparator|Arm 2: placebo|Assigned patients will receiving matching placebo twice daily
88806120|NCT01899092|Experimental|Escalating Dose of TT-034|The study contains one dose escalation arm with active drug.
89126748|NCT04048369|Experimental|Point-of-care testing arm|for patients randomized to the Point-of-care testing arm, nurse will perform influenza and RSV testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) in the ED, 24/24, 7/7.
89126749|NCT04048369|Active Comparator|Core Lab testing arm|for patients randomized to the Core lab testing arm, influenza/RSV PCR will be performed in the core virology laboratory using Simplexa Flu A/B and RSV direct (r) assay (Diasorin), during working hours (8 am-6pm Monday to Friday, 8 am-5pm the Saturday)
89126750|NCT04078438|Experimental|neurofeedback augmentation group|The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. The neurofeedback protocol was determined considering the patient's main symptoms. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.
89126751|NCT04078438|Active Comparator|medication-only (treatment as usual, TAU) group|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.
89126752|NCT04078438|No Intervention|healthy controls|The healthy controls provided blood samples using the same procedure at baseline only.
89126753|NCT00607646|Experimental|1|Hyperinsulinemic (high dose insulin) hypoglycemic clamp studies with oral administration of DHEA or placebo prior to each clamp x 2 on day 1. Day 2 hyperinsulinemic hypoglycemia. Participant randomized to either DHEA or placebo for baseline trial (arm 1) and 6 weeks treatment.
89126754|NCT00607646|Experimental|2|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
89233805|NCT00813059|Experimental|1|
89126755|NCT00607646|Experimental|Arm 3 (optional)|Individuals will be asked to return after at least 2 months and repeat the trial they did not complete (for example, placebo if they were in the DHEA trial before). Again Day 1 would consist of two hyperinsulinemic clamps with placebo or DHEA given orally. Day 2 hyperinsulinemic hypoglycemic clamp with oral administration of placebo or DHEA.
89126756|NCT00607646|Experimental|Arm 4|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
89126757|NCT00770263|Experimental|Dose Level 1A|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 10 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 10 mg IV on days 8, 15, and 22 during subsequent cycles."
89126758|NCT00770263|Experimental|Dose Level 1|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 15 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 15 mg IV on days 8, 15, and 22 during subsequent cycles."
89126759|NCT00770263|Experimental|Dose Level 2|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 20 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 20 mg IV on days 8, 15, and 22 during subsequent cycles."
89126760|NCT00770263|Experimental|Dose Level 3|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
89126761|NCT00770263|Experimental|Dose Expansion Phase|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
89126762|NCT00604994||Malignant|Patients with malignant gynaecological conditions including cancers of the cervix, uterus, ovary, vulva and vagina
89126763|NCT00604994||Benign|Patients without malignant gynaecological cancers
89126764|NCT02691026|Experimental|Pembrolizumab|200 mg pembrolizumab, i.v. infusion every 3 weeks for up to 10 cycles
89126765|NCT04267484||Older adults with mild cognitive impairment|"WP1, older adults with cognitive impairment will use a GPS tracker for 2 weeks, during which they are asked 1) to keep a daily diary about their activity (travel diary), 2) take the researcher on a walk that they often do (walking interview), and 3) participate in an in-depth interview after 2 weeks, in which their experience with the GPS ans the travel diary data are discussed.~WP2, older adults with mild cognitive impairment, caregivers, health professionals and technology developers will collaborate during group discussion meeting to co-design the e-decision support platform to be adapted.~WP3, older adults with mild cognitive impairment, caregivers and health professionals will then be asked to use the adapted e-decision support platform and fill a survey."
89126766|NCT04078360|Experimental|Mobile-based intervention (AMBIT)|This arm will receive a mobile based program delivered over messages/IVR calls.
89126767|NCT04078360|Active Comparator|Face-to-face counselling|This arm will receive a brief counselling session from a trained health worker.
89126768|NCT04078360|Active Comparator|Active control|This arm will receive an educational BI leaflet.
89126769|NCT00605228|Experimental|1|
89126770|NCT00605228|Active Comparator|2|
89126771|NCT00765505|Experimental|1|Exercise Group
89126772|NCT00765505|Experimental|Health Education Group|
89126773|NCT02584582|Experimental|Liraglutide + Liquid meal test|Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week)
89126774|NCT02584582|Experimental|Exenatide + Liquid meal test|Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)
89126775|NCT02584582|Other|Baseline + Liquid meal test|Baseline day with no additional medication
89126776|NCT05380232||Individuals with type 2 diabetes at the baseline examination|"UK Biobank: Prevalent type 2 diabetes is determined by the algorithm of Eastwood et al. (6) or from measured Hba1c ≥48 mmol/mol.~China Kadoorie Biobank: prevalent type 2 diabetes is based on self-reported current diabetes with a diagnosis age above 30 years, a random plasma blood glucose ≥11.1 mmol/L, or fasting plasma blood glucose ≥7.0 mmol/L."
89126777|NCT00765583|Experimental|restylane|Restylane arm with different re-treatment schedules
89126778|NCT04266002|Other|HIV-1 infected adult associated neurocognitiv|HIV-1 infected adult subjects with HIV-associated neurocognitive disorders despite effective antiretroviral therapy in plasma for more than one year, analyzing the evolution of cognitive disorders with Global Deficit Score and HAND classification, and markers of macrophagic inflammation in blood and cerebrospinal fluid, after a change in HIV treatment with an increased of the new scale CHARTER score ≥ 3 (total treatment score to be ≥ 9)
89126779|NCT00765739|Experimental|1|The group who will get neuromuscular electrical stimulation (NMES)
89126780|NCT00765739|Active Comparator|2|The group who will do the voluntary muscle contraction
89126781|NCT00765973|Experimental|A|Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
89126782|NCT00765973|Experimental|B|Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
89126783|NCT05378516||obstetric antiphospholipid syndrome|obstetric antiphospholipid syndrome 20 cases and normal pregnant women 20 cases
89126784|NCT04077814|Active Comparator|ShamtDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Sham Transcranial direct brain stimulation (tDCS)
89126785|NCT04077814|Experimental|tDCS+FDS|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Transcranial direct brain stimulation (tDCS)
89126786|NCT00775177|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
89126787|NCT00775177|Active Comparator|2|Adoxa ® 100mg tablets of Bradley Pharmaceuticals, Inc
89126788|NCT05378360|Placebo Comparator|Placebo of DWP708|EGF Cream Placebo evenly apply to skin lesion every 12 hr/day
89126789|NCT05378360|Experimental|DWP708 10 ug/g|EGF Cream 10 ug/g evenly apply to skin lesion every 12 hr/day
89126790|NCT05378360|Experimental|DWP708 20 ug/g|EGF Cream 20 ug/g evenly apply to skin lesion every 12 hr/day
89126791|NCT05378360|Experimental|DWP708 40 ug/g|EGF Cream 40 ug/g evenly apply to skin lesion every 12 hr/day
89126792|NCT00920530||Real time PCR monitoring|Women giving birth at the St Etienne Teaching Hospital
89126793|NCT00766129|Experimental|T|Implantation of Taxus stent into saphenous vein graft
89126794|NCT00766129|Experimental|C|Implantation of Luc-Chopin stent into saphenous vein graft
89126795|NCT00766207|Experimental|multi-faceted decision support|Multi-faceted decision support
89126796|NCT00766207|Active Comparator|control|stream-lined clinical alert
89126797|NCT04299022||Prospective Registry|Treatment for diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with Vivigen Cellular Bone Matrix
89126798|NCT04299022||Retrospective Data Collection|Treatment of diagnoses of long bone non-union involving the tibia or femur and other nonunion diagnosis (i.e. clavicle, humerus, and femur) with adjunct bone graft utilized in the acute, delayed, non-union and fusion settings.
89126799|NCT00770497|Experimental|Pioglitazone 15 mg to 30 mg QD|
89126800|NCT00770497|Active Comparator|Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD|
89126801|NCT00770497|Active Comparator|Ramipril 2.5 mg to 5 mg QD|
89126802|NCT05285852|Experimental|Dry Needling|For application of the Dry Needling the individual should be in the supine position. To facilitate the approach and adhesion of the Sternocleidomastoid Muscle, the person's neck is placed ipsilaterally in the slightly lateral flexed position. Consequently, the therapist identified the active Trigger Points in the Sternocleidomastoid Muscle and cleansed the surface using an antiseptic solution. Using the insertion pipe, the dry needle inserted into the muscle. For the separation of neurovascular structure from muscle belly the needle is carried out in an anterior-posterior direction. A compression of 90 secs with a cotton swab will be applied at the needling site immediately after removing the needle to reduce the intensity and duration of pain. The variables will then be measured immediately following the processing session. Six sessions of Dry Needling will be applied to each patient and there will be a gap of at least 48 hours between each session.
89126803|NCT05285852|Placebo Comparator|Placebo Dry Needling|Following identification of the trigger point in the muscle, the surface would be cleaned with an antiseptic solution. For placebo Dry Needling, which only causes a pricking sensation, a blunt needle will be applied to the trigger points without penetrating the skin after application of a certain pressure to the skin. The protocol will be applied six times, with a two-day pause between treatments. Like the intervention group, the variables will be measured immediately after the processing session.
89126804|NCT04048291|Experimental|Brisk walking and balance training|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~Participants practice own balance exercise and brisk walking 2-3 times/week (to aim at 150 min of moderate intensity of brisk walking per week at 40-60% of heart rate reserve)"
89126805|NCT04048291|Active Comparator|Upper limb exercise|"Week1-6: Supervised training in groups of 6-8 participant, once/week, 90 min/session~Week 7-26: Supervised training in groups of 6-8 participant, once/month, 90 min/session~Participants practice own upper limb exercise 2-3 times/week (to aim at 150 min of exercise per week)"
89126806|NCT02581696|Other|Single arm|This is a follow-up study of BR-LAF-CT-101, a phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers. Subjects judged to be appropriate to this study by screening.
89126807|NCT04265924|Active Comparator|>0.85 FIO2 group|This group receives FIO2 >0.85 during the surgery.
89126808|NCT04265924|Active Comparator|<0.7 FIO2 group|This group receives FIO2 <0.7 during the surgery.
89126809|NCT00607958|Experimental|1|dose reduction
89126810|NCT02582554|Experimental|Intervention|Intervention: NutriSTEP The intervention will be the administration of NutriSTEP, a nutrition risk screening questionnaire for preschoolers along with a nutrition education brochure called How to Build a Healthy Preschooler
89126811|NCT02582554|No Intervention|Control|Control: Wait-list control The wait-list control group will complete the NutriSTEP and receive the nutrition education information at the end of the 3 month study period
89126812|NCT00770575|Experimental|Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD|
89126813|NCT00770575|Active Comparator|Atorvastatin 20mg to 40 mg QD|
89126814|NCT00606788|Active Comparator|AW|Patients received computer-driven protocolized weaning (= Automated Weaning)
89126815|NCT00606788|Active Comparator|CW|Patients received physician-directed non-protocolized weaning (= Conventional Weaning)
89126816|NCT04108078|Experimental|Intervention|This arm consists of 1) MSM who receive the intervention (not wait listed) and healthcare facility staff who work at health facilities that have been chosen for the intervention.
89126817|NCT04108078|No Intervention|Wait listed|Participants in this arm (MSM and staff at health facilities that were wait listed) will complete assessments, but will receive the intervention after the experimental arm of the study.
89126818|NCT00770731|Experimental|Torisel + Hycamtin + Velcade|"Torisel starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle.~Hycamtin starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle.~Velcade starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle."
89126819|NCT00770731|Experimental|Expansion Group|"Torisel + Hycamtin + Velcade Expansion Group~Addition of 10 participants at highest tolerated dose level"
89126820|NCT05379764|Experimental|Embodiment group|This group this group will view the VR scenario being 'embodied' in the avatar who is experiencing the VR scenario. This implies first persons perspective, agency over the avatar, multi-sensorial integration and co-location.
89126821|NCT05379764|Sham Comparator|observation group|This group will view the VR scenario from a third persons perspective , as an observer.
89126822|NCT04287478|Experimental|Intravenous (IV)|Phage administered via the intravenous route.
89126823|NCT04287478|Experimental|Intravesical (IVS)|Phage administered via the intravesical route.
89126824|NCT04287478|Experimental|Subcohort A|Selected phage for E. coli administered via selected route based on previous Arms.
89126825|NCT04287478|Experimental|Subcohort B|Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.
89126826|NCT04287478|Experimental|Subcohort C|Selected phage for E. coli administered via selected route based on previous Arms.
89126827|NCT04287478|Experimental|Subcohort D|Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.
89126828|NCT04264598|Experimental|Experimental Adult Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
89126829|NCT04264598|Experimental|Experimental Children Group - Medium dosage|One intramuscular injection of the investigational vaccine (0.5 ml); Intervention: one-dose regimen of medium dosage investigational sIPV Intervention: Biological: one-dose regimen of medium dosage investigational sIPV
89126830|NCT04264598|Experimental|Experimental Infant Group - Medium dosage|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV Intervention: Biological: Three-dose regimen of medium dosage investigational sIPV
89126831|NCT04264598|Active Comparator|Control Infant Group - commercialized sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV Intervention: Biological: Three-dose regimen of commercialized sIPV
89126832|NCT04264598|Active Comparator|Control Infant Group - commercialized IPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV Intervention: Biological: Three-dose regimen of commercialized IPV
89126833|NCT00770887||Study participants|This study will enroll 50 English-speaking/literate women at least 18 years of age of any race who have sought contraception with DMPA at the Planned Parenthood of Southwest and Central Florida clinics in Tampa and Fort Myers. Patients who choose to begin DMPA or who have already been using DMPA will be approached regarding voluntary participation in the study. Because DMPA is contraindicated in pregnancy, women with a positive urine pregnancy will not be eligible. Should a woman become pregnant during the study, she will receive no further DMPA injections
89126834|NCT04076722|Experimental|Stress reactivity weight stigma|This study arm received a stress reactivity paradigm that involved weight stigma content in the form of an evaluated speech task.
89126835|NCT04076722|Active Comparator|Stress reactivity non-weight stigma.|This study arm received a stress reactivity paradigm that involved non-weight stigma content in the form of an evaluated speech task.
89126836|NCT04265690|Experimental|Teen and Tot Centering subjects|The cooking classes and text messages will supplement the subject's standard of care by incorporating text messages and a cooking class.
89126837|NCT00775255|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
89126838|NCT00775255|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
89126839|NCT02582398|Experimental|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
89126840|NCT02582398|Placebo Comparator|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
89126841|NCT00766285|Active Comparator|TIV|50 subjects to receive 45 mcg of TIV administered on Day 0 and Day 28.
89126842|NCT00766285|Experimental|rHAO|50 subjects to receive 405 mcg of rHAO administered on Day 0 and Day 28.
89126843|NCT05367700|Experimental|HS-10382 (Part 1: Dose escalation)|There are five escalation dose cohorts.
89126844|NCT05367700|Experimental|HS-10382 (Part 2: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
89126845|NCT00775333||1|Patients with diabetes and carpal tunnel syndrome
89126846|NCT00775333||2|Non-diabetic patients with carpal tunnel syndrome
89126847|NCT02581774||term isolated oligohydramnios|Labor Monitoring and normal delivery tracking
89126848|NCT02581774||prolonged pregnancies|Labor Monitoring and normal delivery tracking
89126849|NCT04265456|Experimental|1300 mg Acetaminophen and 100 mg IV Pregabalin|The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg based on Safety Monitoring Committee decision).
89126850|NCT04265456|No Intervention|Placebo|Saline solution
89126851|NCT04265456|Experimental|1300 mg Acetaminophen and 100 mg +/- 25 IV Pregabalin|Decisions to escalate or decrease the dose for Cohorts 2 through 6 will be dependent upon blinded review of emerging safety and tolerability data by the Safety Monitoring Committee (SMC). However, PK data is not part of the SMC review, but may be reviewed by a SMC designee at a later time.
89126852|NCT04379518|Experimental|Arm I (rintatolimod, recombinant interferon alfa-2b)|Patients receive rintatolimod IV over 2.5-3 hours and recombinant interferon alfa-2b IV over 20 minutes on day 1 and on day 3 (or 4) in the absence of disease progression or unacceptable toxicity.
89126853|NCT04379518|Active Comparator|Arm II/IV (standard of care)|Patients receive standard of care.
89126854|NCT04379518|Experimental|Arm III (rintatolimod)|Patients receive rintatolimod IV over 2.5-3 hours once.
89126855|NCT04264364||laparoscopic sleeve gastrectomy|Patients who underwent laparoscopic sleeve gastrectomy
89126856|NCT04264364||endoscopic sleeve gastroplasty|Patients who underwent endoscopic sleeve gastroplasty
89126857|NCT04378426|Experimental|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50%nitrous oxide and 50% oxygen plus intravenous saline
89126858|NCT04378426|Active Comparator|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
89126859|NCT04094506|Experimental|ASP1948 1200 mg|Participants received 1200 mg ASP1948 intravenously, on day 1 of cycle 1 and 2 followed by once every 2 weeks (Q2W) until discontinuation criteria or up to 2 years. Each cycle duration was 14 days.
89233806|NCT01323075||Renal insufficiency group|Patients in this group have renal insufficiency as defined by a creatinine clearance of < 30 ml/min without dialysis. These patients do not have diabetes.
89233807|NCT01323075||Diabetic group|These patients have diabetes, but not renal insufficiency.
89233808|NCT01323075||Non-exposed group|These patients have neither a neurological nor a metabolic disease and a creatine clearance of > 90 ml/min
89233809|NCT00467649|Experimental|Group A|
89233810|NCT00467649|Active Comparator|Group B|
89233811|NCT01023945|Experimental|ASP1941 high dose group|oral
89233812|NCT01023945|Experimental|ASP1941 low dose group|oral
89233813|NCT01023945|Placebo Comparator|Placebo group|oral
89233814|NCT00450333|Active Comparator|1|Erythropoietin(EPO)-naive BIW
89233815|NCT00450333|Active Comparator|2|EPO-naive QW
89233816|NCT00450333|Active Comparator|3|EPO QW
89233817|NCT00450333|Active Comparator|4|EPO Q2W
89233818|NCT00643565|Experimental|Bevacizumab + Chemotherapy|Participants received continuous IV infusion of bevacizumab (7.5 mg/kg every 3 weeks) on Day 1 of 3-week cycles followed by induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy) as per institutional practice for a total of 9 cycles during induction treatment phase. As per the investigator decision, local therapy (radiotherapy and /or surgery) was expected to start after 4 weeks of the last bevacizumab administration in the induction phase and resumed to bevacizumab in the maintenance phase at least 4 weeks after the last dose of local therapy. During maintenance treatment phase, participants received IV infusion of bevacizumab (5 mg/kg every 2 weeks) followed by vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Days 1 and 15 of 4-week cycles for a total of 12 cycles.
89233819|NCT00643565|Active Comparator|Chemotherapy|Participants received 9 cycles of induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy administered every 3 weeks as per institutional practice. As per the investigator evaluation, participants had option to undergo local therapy (radiotherapy and /or surgery) during last 3 cycles of IVA (i.e. from Cycle 6 to Cycle 9). During maintenance treatment phase, participants received vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Day 1 and 15 of 4-week cycles for a total of 12 cycles.
89233820|NCT00643487||1|observation of the behavior of the infrapatellar plica
89233821|NCT02551211|Experimental|Patients with resectable non-small cell lung cancer|
89233822|NCT00821405||peritoneal dialysis|peritoneal dialysis patient lasting for more than 3 months
89233823|NCT00450255|Experimental|Arm I|Patients receive Aflibercept IV at 4 mg/kg over 1 hour on day 1. Treatment repeats every 14 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
89233824|NCT00816335|Experimental|Arm 1|F-FDG-directed surgery for known or suspected malignancy using gamma detection probes.
89233825|NCT00450177|Experimental|Iron Group|Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
89233826|NCT00450177|Placebo Comparator|Placebo Group|Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
89233827|NCT00816569|Experimental|Keratoconus|One eye of Keratoconus patient
89233828|NCT00813137|Experimental|Folfox4 plus Endostar|
89233829|NCT00813215|Experimental|1|Relatives to patients with type 2 diabetes.
89233830|NCT00813215|Active Comparator|2|Controls with no family history of type 2 diabetes.
89233831|NCT01021917||Other Dieters (OD)|Those participating in weight loss programs other than Medifast Direct or Take Shape For Life.
89233832|NCT01021917||Take Shape For Life (TSFL)|Those using Medifast meal replacement products for weight loss while working closely with a Take Shape For Life certified Health Coach.
89233833|NCT01021917||Medifast Direct (MD)|Those using Medifast meal replacement products specifically for weight loss that were purchased directly from the company and individually monitored by the customer.
89233834|NCT01024023|Active Comparator|PPAM Aid|Suitable participants randomised to the treatment arm will receive the non articulated pneumatic early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
89233835|NCT01024023|Active Comparator|AMA Aid|Suitable participants randomised to the treatment arm will receive the articulated early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
89233836|NCT00816647|Active Comparator|1|Medial patellofemoral ligament reconstruction
89233837|NCT00816647|Active Comparator|2|Medial reefing
89233838|NCT01024179|Active Comparator|Group B: CTO|Chronic total occlusion
89233839|NCT01024179|Active Comparator|Group A : Non-CTO|"Non-chronic total occlusion :~Fibrous plaque+fibro-calcific plaque + Lipid plaque(<2 quadrants )~Lipid-rich plaque ( ≥2 quadrants )"
89233840|NCT00821483|Placebo Comparator|1: placebo|
89233841|NCT00821483|Active Comparator|2 Frovatriptan|
89233842|NCT01021995|Experimental|echinacea|
89233843|NCT01021995|Placebo Comparator|placebo|
89233844|NCT02551367|Experimental|letrozole|patients receive letrozole 2.5 mg twice daily from day 2 to day 6 of the cycle , for 3 consecutive cycles, hcg hormone10.000 iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound.
89233845|NCT02551367|Active Comparator|clomiphene citrate|patients will receive clomiphene citrate 50 mg twice daily from day 2 to day 6 of the cycle for 3 consecutive cycles , hcg 10.000 hormone iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound .
89233846|NCT00813371|Active Comparator|1|Airway Pressure Release Ventilation Arm
89233847|NCT00813371|Active Comparator|2|ARDSnet protocol
89233848|NCT03848949|Experimental|Orthotic Group|Subjects enrolled in the orthotic group receive the orthotic (Evenup) meant to increase the effective leg length of the uninjured limb.
89233849|NCT03848949|No Intervention|Control|Subjects enrolled in the control group receive the standard treatment associated with their injury (no orthotic)
89126860|NCT04094506|Experimental|ASP1948 2000 mg|Participants received 2000 mg ASP1948 intravenously, on day 1 of cycle 1 and 2 followed by once Q2W until discontinuation criteria or up to 2 years. Each cycle duration was 14 days.
89126861|NCT04094506|Experimental|ASP1948 3000 mg|Participants received 3000 mg ASP1948 intravenously, on day 1 of cycle 1 followed by once every 3 weeks until discontinuation criteria or up to 2 years. Each cycle duration was 21 days.
89126862|NCT00605618|Experimental|Single Arm|
89126863|NCT00608192|Active Comparator|Testing, Education, & Counseling (TEC)|HIV and hepatitis screening is done on-site, but vaccination and medical care will be provided by off-site referral. HIV and Hepatitis, Testing, Education, & Counseling (TEC) participants will receive standard HIV and hepatitis education & counseling. TEC participants will not receive case management services.
89126864|NCT00608192|Experimental|Hepatitis Care Coordination (HCC)|Participants will receive on-site HIV and viral hepatitis screening. Hepatitis A and B combination vaccination will be provided on-site. Participants will receive on-site theory-based HIV and hepatitis education, counseling, and 6 months of case management to promote adherence to HIV and HCV evaluation.
89126865|NCT02581462|Experimental|FLOT alone|Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
89126866|NCT02581462|Experimental|FLOT + Herceptin/Pertuzumab|Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab
89126867|NCT00668863|Experimental|1|
89126868|NCT00608348|Experimental|1|Hyperinsulinemic euglycemic or hypoglycemic clamp with Muscle and skin sympathetic nerve activity recording in arm and/or leg
89126869|NCT00608348|Experimental|2|Exercise with insulin or no insulin infused with muscle and skin sympathetic nerve activity measurements
89126870|NCT00766441|Active Comparator|1|Sitagliptin 100mg
89126871|NCT00766441|Active Comparator|2|Sulphonylurea
89126872|NCT00766519|Experimental|Optimization|volume optimization: continuous monitoring of the respiratory-induced arterial pulse pressure variation during surgery and systematic minimization to 10% or less by volume loading
89126873|NCT00766519|Active Comparator|control; standard volume administration|standard volume administration
89126874|NCT00771043|No Intervention|TYSABRI|
89126875|NCT00771043|No Intervention|AVONEX|
89126876|NCT00771121|Active Comparator|new emulsion|
89126877|NCT00771121|Placebo Comparator|new emulsion placebo|
89126878|NCT04267250|Experimental|Sequence 1|In sequence 1, period 1, participants will be dosed with a single administration of oral contraceptive (OC). Participants will continue directly into period 2 where they will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10.
89126879|NCT04267250|Experimental|Sequence 2|In sequence 2, period 1, participants will receive PF-06700841 PO for 13 days with a single dose of OC administered on the morning of day 10. After a wash-out period of at least 10 days, participants will continue into period 2 where they will receive an additional single dose of OC.
89126880|NCT00775489|Active Comparator|1|Steroid nasal spray (beclomethasone)
89126881|NCT00775489|Placebo Comparator|2|Normal saline nasal spray
89126882|NCT00771199|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl|
89126883|NCT04264130|Active Comparator|artemisinin-based combination therapies|subjects given Artemisinin-based combined therapies according to the study instruction
89126884|NCT04264130|Sham Comparator|non-artemisinin drugs|subjects given non artemisinin based combined therapies like describe in the study protocol
89126885|NCT00775567|Active Comparator|1|30g fructose dissolved in water twice a day
89126886|NCT00775567|No Intervention|No Intervention|
89126887|NCT04267016||All Subjects Enrolled|Renal transplant recipients who are undergoing routine management
89126888|NCT02557867|Experimental|Obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
89126889|NCT02557867|Experimental|Non-obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
89126890|NCT00605774|Experimental|1|Hyperinsulinemic euglycemic glucose clamps x 2 on Day 1 Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion on Day 2
89126891|NCT00605774|Experimental|2|Day 1 euglycemic exercise period x 2 Day 2 hyperinsulinemic euglycemic glucose clamp with epinephrine infusion
89126892|NCT04264286|Active Comparator|Esmolol group|Patients will receive intravenous esmolol after the end of the surgical procedure.
89126893|NCT04264286|Placebo Comparator|Placebo group|Patients will receive intravenous saline after the end of the surgical procedure.
89126894|NCT04356976|Experimental|Ventralex|Repair with Ventralex hernia patch in sublay position
89126895|NCT04356976|Active Comparator|Stratafix|Repair with Stratafix suture
89126896|NCT04077502|Active Comparator|stimulated group|The group stimulated by real coil of rTMS.
89126897|NCT04077502|Sham Comparator|controle group|The group stimulated by sham coil of rTMS.
89126898|NCT02582320||Study patients|Patients with Relapsed or refractory CLL or 17p deleted CLL fulfilling the eligibility criteria required by the Named Patient Program (NPP) who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014.
89126899|NCT02582086|Experimental|BOR15001L7 Cream|BOR15001L7 Cream with 5% 15019L0
89126900|NCT02582086|Placebo Comparator|Placebo Cream|Placebo Cream
89126901|NCT04078204|Experimental|Butylphthalide Soft Capsules|Two Butylphthalide soft capsules will be taken three times a day before meals.
89126902|NCT04078204|Placebo Comparator|Placebo Soft Capsules|Two placebo soft capsules will be taken three times a day before meals.
89126903|NCT04076488|Experimental|Dividat FIT: Computer based exercise|Tablet based interactive physical training.
89126904|NCT05325658||Oropharyngeal dysphagia|Patients with oropharyngeal dysphagia. Patients will be examined before and after combination therapy.
89126905|NCT00935012|Experimental|Open-Label|
89126906|NCT05373914|Experimental|Cudetaxestat (BLD-0409) 250mg once daily|250mg once daily (orally) with food
89126907|NCT05373914|Experimental|Cudetaxestat (BLD-0409) 500mg daily|500mg once daily (orally) with food
89126908|NCT05373914|Experimental|Cudetaxestat (BLD-0409) 500mg twice daily|500mg twice daily (orally) with food
89126909|NCT05373914|Placebo Comparator|Matching Placebo twice daily|Matching placebo twice daily (orally) with food
89126910|NCT00932360|Experimental|Active TENS Placebo TENS No TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor
89126911|NCT00932360|Experimental|Placebo TENS Active TENS No TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Participants wore a TENS unit that was turned off for blinding of the outcome assessor
89126912|NCT00932360|Experimental|No TENS Active TENS Placebo TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
89126913|NCT00932360|Experimental|Active TENS No TENS Placebo TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
89126914|NCT00932360|Experimental|Placebo TENS No TENS Active TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
89126915|NCT00932360|Experimental|No TENS Placebo TENS Active TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
89126916|NCT00668707|Experimental|Melatonin|To receive 20 mg of melatonin nightly for 1 year post-surgery
89126917|NCT00668707|Placebo Comparator|Placebo|To receive 20 mg placebo nightly for 1 year post-surgery
89126918|NCT05064514|Experimental|Transcatheter Tricuspid Valved Stent Graft intervention|Participants who have carcinoid heart disease with severe symptomatic tricuspid regurgitation and with a significant backflow in the caval and hepatic veins will be treated with the implantation of the Transcatheter Tricuspid Valved Stent Graft
89126919|NCT00766909|Experimental|CsA|Cyclosporine
89126920|NCT00766909|Experimental|Tac|Tacrolimus
89126921|NCT00766909|Placebo Comparator|Placebo|placebo/saline
89126922|NCT02581228||Training Set|The objective of the Training stage is to assess the predictive potential of ML-PrediCare for melanoma patients' response to Ipilimumab, Pembrolizumab and Nivolumab.
89126923|NCT02581228||Validation Set|The objective of the Validation stage is to test the predictive power of ML -PrediCare in an independent set of patients diagnosed with melanoma.
89126924|NCT00775801|Experimental|Treatment|FLD
89126925|NCT00775801|Active Comparator|Control|
89126926|NCT00767065|Active Comparator|Cardiac Computed Tomography (CCT)|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. CCT will be available Monday to Friday from 9am until 5pm. Patients will be entered into the study provided CCT can be undertaken within 24 hours of troponin result. Therefore, the only period during which a patient will be ineligible for inclusion will be between 5pm on a Friday and 9am the following Sunday. Studies will be reported at CWH by one of 2 experienced radiologists trained in CCT and results passed to the referring team on the same day.
89126927|NCT00767065|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will undergo further care as dictated by the responsible clinician. Except for CCT, all standard investigations will be available to the responsible clinician and may be used at their discretion. CCT does not form part of current in-patient management at our hospital.
89126928|NCT04229836|Experimental|Tildrakizumab|Participants will receive subcutaneous (SC) injection of tildrakizumab 100 milligrams (mg).
89126929|NCT00771355||1|Subjects with vitiligo.
89126930|NCT00771355||2|Subjects with melasma.
89126931|NCT00771355||3|Subjects with post-inflammatory hyper-pigmentation.
89126932|NCT00771355||4|Subjects with post-inflammatory hypo-pigmentation.
89126933|NCT00771433|Experimental|Group 1|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses.
89126934|NCT00771433|Experimental|Group 2|Patients receive G-CSF SC once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses. Patients may also receive secondary prophylaxis with G-CSF if they experience an episode of neutropenia.
89126935|NCT04053790|Placebo Comparator|placebo group|Patients in this group will receive placebo 1 tablet every 12 hours, during 4 weeks.
89126936|NCT04053790|Active Comparator|LB 10000|Patients in this group will receive placebo 1 tablet containing 5,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
89126937|NCT04053790|Active Comparator|LB 20000|Patients in this group will receive placebo 1 tablet containing 10,000 millions of lactobacillus LB, every 12 hours, during 4 weeks.
89126938|NCT00668395|Other|CYP2B6*1/*1 genotype|Efavirenz clearance in this genotype was compared with the other genotypes
89126939|NCT00668395|Other|CYP2B6*1/*6|Efavirenz clearance in this genotype was compared with the other genotypes
89126940|NCT00668395|Other|CYP2B6*6/*6|Efavirenz clearance in this genotype was compared with the other genotypes
89126941|NCT00668317|Other|omeprazole and ranitidine|20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte
89126942|NCT00775879|Experimental|A|2.5% target concentration
89126943|NCT00775879|Active Comparator|B|2.5% manually selected
89126944|NCT00767221|Experimental|A|The patient is his own control. Endpoint variables are measured before, during and after treatment.
89126945|NCT04024072|Experimental|Perrigo active|Test product
89126946|NCT04024072|Active Comparator|Reference active|Azopt ophthalmic suspension
89126947|NCT00771511|Experimental|1|Capsaicin cream applied to cervix after lidocaine gel
89126948|NCT00771511|Placebo Comparator|2|only lidocaine applied to the cervix
89126949|NCT04021576|Experimental|intervention|preventative training program
89126950|NCT04021576|No Intervention|control|no such training
89126951|NCT00775957||1|FLT-PET Scan
89126952|NCT00775957||2|FDG-PET Scan
89126953|NCT00776113|Active Comparator|2|Carvedilol 12.5 mg tablets
89126954|NCT00776113|Experimental|1|Carvedilol 12.5 mg tablets
89126955|NCT04076332|No Intervention|Controlled group|Standard oral explanation with booklet
89126956|NCT04076332|Experimental|Decision aid group|Shared decision making using decision aid
89126957|NCT04075786||Gynecologists|Gynecologists in active clinical practice and resident (in training) gynecologists.
89126958|NCT00670111|Experimental|RAP On then Off at 1 month visit|"Rate Adaptive Pacing (RAP) On for first cardiopulmonary exercise test (CPX) at one month.~Rate Adaptive Pacing (RAP) Off for second cardiopulmonary exercise test (CPX) at one month."
89126959|NCT00670111|Experimental|RAP Off then On at 1 month visit|"Rate Adaptive Pacing (RAP) Off for first cardiopulmonary exercise test (CPX) at one month.~Rate Adaptive Pacing (RAP) On for second cardiopulmonary exercise test (CPX) at one month."
89126960|NCT04077658|Experimental|HeartMath|
89126961|NCT04077658|Active Comparator|Waitlist Control|
89126962|NCT00771589|Experimental|Prosthesis|Motorized External Knee prosthesis for above knee amputees. Comprised of agonist and antagonist actuators to mimic behavior of knee joint during locomotion.
89126963|NCT05244148|Experimental|Group A|IP1 - Stérimar BLOCKED NOSE Baby nasal spray + standard of care
89126964|NCT05244148|Experimental|Group B|IP2 - Stérimar Stop & Protect Cold Baby + standard of care
89126965|NCT05244148|Other|Group C|Standard of Care alone
89126966|NCT00767377|Experimental|EOF5 Group|The regimen of 5-day Continuous infusion of FU combined with Epirubicin and Oxaliplatin will be used in the patients recruited in this trial.
89126967|NCT02580448|Experimental|Female Triple Negative Breast Cancer Patients|TNBC Patients - Enrollment is complete in this cohort
89126968|NCT02580448|Experimental|Female Estrogen Receptor (+) Breast Cancer Patients|Female ER(+) BC Patients - Enrollment is complete in this cohort
89126969|NCT02580448|Experimental|Male Breast Cancer Patients|Locally advanced or metastatic males with BC
89126970|NCT00776191|Active Comparator|Physioneal 35 vs. 40|Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.
89126971|NCT00776191|Active Comparator|Physioneal 40 vs. 35|Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks
89126972|NCT04008238|Experimental|Biomarker analysis|This study is a single arm study with biomarker analysis
89126973|NCT04077034|Experimental|Experimental group|Probiotic DE111®
89126974|NCT04077034|Placebo Comparator|Control group|Placebo
89126975|NCT04223674|Experimental|Serological screen and treat|Children who screened with sero test and microscopy. A 7-day high dose PQ will be provided for those with Pv seropositive regardless of their symptoms and symptomatic children with microscopic Pv/Po positive.
89126976|NCT04223674|No Intervention|Routine care|Children who screened with sero test and microscopy. A 7-day high dose PQ will be provided only for symptomatic children with microscopic Pv/Po positive.
88806121|NCT01891760|Experimental|Treatment|Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold
89126977|NCT02580682|Experimental|Sanfu herbal patch|one kind of acupoint application which used in hot dog days of summer,The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba asarum), Bai Jie Zi (Semen Sinapis Albae), and Rou Gui (Cortex Cinnamomi) at a ratio of 2:2:1:1:2:1.The bilateral Feishu (BL13), Pishu (BL20), Shenshu (BL23), Neiguan (PC6), and Guanyuan (CV4) acupoints were selected for treatment
89126978|NCT02580682|Experimental|Sanfu moxibustion|use moxibustion in hot dog days of summer,and adopting the indirect moxibustion box method at the bilateral BL13, BL20, and BL23 acupoints
89126979|NCT02580682|Experimental|Sanfu herbal patch and Sanfu moxibustion|use herbal patch and moxibustion together in hot dog days
89126980|NCT02580682|No Intervention|controlled|patients in this group will not accept herbal patch or moxibustion therapy in these 3 years. After the 3-year experimental period they will be offered corresponding treatments for free as well, so they are in our wait list.
89126981|NCT03776890|Experimental|DeStress for Health Program Participants|Rural residents 18 years and older of Granville and Vance counties (n=30) will be recruited to participate.
89126982|NCT00672139|Experimental|Methylnaltrexone bromide|"Methylnaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study.~Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information."
89126983|NCT00776269|Experimental|argon laser|
89126984|NCT02557789|Experimental|Treatment A|Lefamulin as a 600 mg IR tablet in the fasted state
89126985|NCT02557789|Experimental|Treatment B|Lefamulin as 600 mg API in capsule (three 200 mg capsules) in the fasted state
89126986|NCT02557789|Experimental|Treatment C|Lefamulin as 150 mg i.v. in 250 mL citrate buffered saline infused over 1 h
89126987|NCT02557789|Experimental|Treatment D|Lefamulin as a 600 mg IR tablet one hour after breakfast
89126988|NCT00771823|Active Comparator|2|
88806122|NCT01891760|Active Comparator|Reference Therapy|Profore - Four-layer compression bandaging therapy
89126989|NCT00771823|Active Comparator|1|"Maraviroc 300 mg twice daily for the first 14 days of the study.~Placebo twice daily for the last 14 days of the study"
89126990|NCT05224648|Active Comparator|TOF scan train of four ratio monitoring|recovery of train of four ratio after neostigmine administration
89126991|NCT05224648|Experimental|ITF device tetanus stimulation monitoring|recovery of tetanus 100 Hz and tetanus 50 Hz ratio after neostigmine administration
89126992|NCT05674084||Study group|Critically ill patients undergoing any vasopressor treatment. CRT will be measured over the course of hospitalization. Maximal number of CRT measurements from a single patient is limited to 5.
89126993|NCT04077112|Active Comparator|traditional PCIT|once a week parent training
89126994|NCT04077112|Experimental|intensive PCIT|every day for two weeks parent training
89126995|NCT02581150|Other|Outpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during an ambulatory hospitalisation, with the use of an arterial closure device (ACD).~The patients treated for PAD (Peripheral Arterial Disease) are informed and prepared in the morning of D0. The surgical endovascular procedure is performed at D0 before 1:00 p.m. The patients leave the hospital in the evening at D0 after a systematic visit."
89126996|NCT02581150|Other|Conventional inpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during a conventional hospitalisation, with or without ACD (ACD will be used at the discretion of the interventionalist).~The patients treated for PAD arrive at the hospital the day before surgery (D-1). The surgical endovascular procedure takes place the next day (D0). The day after (D1), the patients leave the hospital after a systematic visit."
89126997|NCT02581072|Experimental|SB204 4%|SB204 4% once
89126998|NCT02581072|Experimental|SB204 8% or 12 %|SB204 8 or 12 % (supratherapeutic) once
89126999|NCT02581072|No Intervention|Moxifloxacillin|Moxifloxacillin 400 mg orally
89127000|NCT02581072|Placebo Comparator|Vehicle Gel|Placebo
89127001|NCT03955900||Participants with Multiple Myeloma (MM)|Participants with MM will be observed in real-world clinical practice settings. The primary data source for this study will be the medical records of each participant.
89127002|NCT03955042|Experimental|Pemetrexed|Pemetrexed
89127003|NCT02580526|Active Comparator|V-E mask ventilation technique crossover C-E mask ventilation|
89127004|NCT02580526|Active Comparator|C-E mask ventilation technique crossover V-E mask ventilation|
89127005|NCT03717922|Experimental|Amygdala first, then Entorhinal Cortex|Low Intensity focused ultrasound pulsation (LIFUP) will be administered to the amygdala while participants are in the MRI scanner. Then, 2 weeks later, entorhinal cortex LIFUP will be administered.
89127006|NCT03717922|Experimental|Entorhinal Cortex first, then Amygdala|Low Intensity focused ultrasound pulsation (LIFUP) will be administered to the entorhinal cortex while participants are in the MRI scanner. Then, 2 weeks later, amygdala LIFUP will be administered.
89127007|NCT00570739|Placebo Comparator|Diabetic Participants: Metformin HCl+Placebo for Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
89127008|NCT00570739|Experimental|Diabetic participants: Metformin HCl + Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
89127009|NCT00570739|Placebo Comparator|Pre-diabetic Participants: Colesevelam Placebo|Participants will receive 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
89127010|NCT00570739|Experimental|Pre-diabetes Participants: Colesevelam|Participants will receive 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
89127011|NCT03689530|Experimental|Peer Support Arm.|Participants randomized to peer support will be matched with a peer supporter.
89127012|NCT03689530|Active Comparator|Enhanced Usual Care|Participants randomized to enhanced usual care will receive brief education and folder of information and resources.
89127013|NCT02580214|Experimental|Acerto|Preoperative immune nutrition for 5 days (Impact, Nestle) Preoperative fasting of 2h with a drink containing 12% maltodextrine No intravenous fluids postoperatively
89127014|NCT02580214|No Intervention|Control|No immune nutrition Preoperative fasting of 6-8 h Crystalloid intravenous fluids until PO day 1
89127015|NCT04076098|Experimental|Minocycline|Minocycline gel
89127016|NCT04076098|Placebo Comparator|Placebo|Similar gel without the active agent
89127017|NCT04076254|Experimental|albumin|albumin 5%
89127018|NCT04076254|Active Comparator|fluid|Ringer Lactate
89127019|NCT03938116|Experimental|Healing Hearts Together|
89127020|NCT03938116|No Intervention|Usual Care|
89127021|NCT00771979|Experimental|1|
89127022|NCT04048603||idiopathic REM sleep behavior disorder|Subjects with the diagnosis of idiopathic REM sleep behavior disorder
89127023|NCT04048603||Controls without iRBD|Healthy controls without the diagnosis of idiopathic REM sleep behavior disorder
89127024|NCT00767689|Experimental|vitamin B6|patient receiving xeloda and vitamin B6
89127025|NCT00767689|Placebo Comparator|2 placebo|patient receiving xeloda and placebo
89127026|NCT00772057|Active Comparator|Propranolol group|
89127027|NCT00772057|Placebo Comparator|Placebo group|
89127028|NCT00776347|Experimental|donepezil|
89127029|NCT00776425|Experimental|Epoetin Beta 150 IU/kg|Participants with solid and lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 150 IU per kg of body weight thrice weekly.
89127030|NCT00776425|Experimental|Epoetin Beta 30000 IU|Participants with lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 30000 IU once weekly.
89127031|NCT03913702|Active Comparator|Ketorolac|Assigned patients will receive a subacromial injection of ketorolac 60mg (2ml + 8ml lidocaine 1%)
89127032|NCT03913702|Active Comparator|Methylprednisolone|Assigned patients will receive a subacromial injection of methylprednisolone 80mg (1ml + 9ml lidocaine 1%)
89127033|NCT00776503|Experimental|B|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 1-(7 or 10 or 14)
89127034|NCT00776503|Experimental|A|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 15-(21 or 24 or 28)
89127035|NCT04075006|Experimental|Ketamine Group|adjunct low dose continuous infusion ketamine in addition to the standard of care. Ketamine will be given at a fixed infusion rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
89127036|NCT04075006|No Intervention|Control Group|Standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC sedation and analgesia protocol.
89127037|NCT00772213|Experimental|MIGTS treatment|controlled trial (quasi-randomized) versus controls (=conventional treatment not in the MIGTS)
89127038|NCT00772213|No Intervention|controls (=conventional treatment not in the MIGTS)|
89233850|NCT00813449|Experimental|A|Experimental group : Endostar combined with dacarbazine
89233851|NCT00813449|Placebo Comparator|2|Control group : Dacarbazine combined with placebo
89127039|NCT04188106|Experimental|Hydroxyzine and Varenicline|Participants enrolled in the study will take the FDA approved starter kit of varenicline for the first week of medication administration (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7). During the first week, participants will also receive hydroxyzine dosed in a similar manner, 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night. After the first week, participants will receive the FDA-approved dose of varenicline (1 mg twice daily) combined with hydroxyzine, 25 mg in the morning and 50 mg at nighttime. All medications will be dosed orally.
89127040|NCT00669955|Active Comparator|OAC 7 days|Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
89127041|NCT00669955|Experimental|OBMT 10 days|OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.
89127042|NCT04176874||Diastasis of the rectus abdominis muscles|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
89127043|NCT00772291|Placebo Comparator|placebo|
89127044|NCT00772291|Active Comparator|pregabalin|
89127045|NCT04048525|Experimental|CVVHD with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
89127046|NCT04048525|Active Comparator|CVVH with ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
89127047|NCT03595150|Active Comparator|Diclofenac|100 mg Diclofenac rectally prior to the ERCP
89127048|NCT03595150|No Intervention|No prophylaxis|No prophylaxis
89127049|NCT00776581||1|Records regarding combined spinal-epidural analgesia (CSEA) with patient-controlled analgesia (PCA) pump
89127050|NCT00776581||2|Records regarding combined spinal-epidural analgesia with intermittent bolus injection (IBI)
89127051|NCT00776581||3|Records regarding epidural analgesia (EA) with patient-controlled pump
89127052|NCT00776581||4|Records regarding epidural analgesia with intermittent bolus injection
89127053|NCT03565744|Experimental|Group 1 - B'N Fit POWER|Participants enrolling in B'N Fit POWER afterschool program will be assigned to Group 1.
89127054|NCT03565744|No Intervention|Group 2 - Standard of Care|All other PS/MS-95 participants who completed the screening (approximately 50) will be in comparison Group 2
89127055|NCT03565744|No Intervention|Group 3 - Standard of Care|Participants at an additional school site completing the screening (approximately 100) will be in an additional comparison Group 3.
89127056|NCT04047667||CBCT guided TBCB|Patients with ILD who met the following including criteria from September 2018 to July 2019 were suggested to receive TBCB under CBCT guidance: more than 18 years old, diffuse parenchymal lung diseases without a diagnosis after integration of clinical profile, laboratory tests and HRCT features, FVC more than 50%, DLCO more than 35%, patients without acute exacerbation within one month, patients without bleeding diathesis, anticoagulant therapy, using antiplatelet drugs, patients without pulmonary hypertension, respiratory failure, liver or kidney disfunction, or cardiac insufficiency, PLT more than 50 x 109/L. All included patients signed the informed consent.
89127057|NCT02580916|Experimental|Group 1 (Postal)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team and deemed 'low risk'; SCQOLIT questionnaires will be administered by post.
89127058|NCT02580916|Experimental|Group 2 (Clinic-based)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team, for whom all aspects of the study will be conducted in the Dermatology clinic. SCQOLIT questionnaires will be administered according to the protocol.
89127059|NCT02580916|No Intervention|Group 3 (Interviews)|A Qualitative Researcher (Co-Investigator) will undertake structured interviews with approximately 20 patients from both Group 1 and 2. Potential participants will be invited to volunteer their contact details at the time of consent to the Questionnaire study. This is optional; they may refuse to do so and still take part in the main questionnaire study. The patient will then be contacted by the Qualitative Researcher (Co-Investigator) at a later date and subsequently consented for the interview.
89233852|NCT00816725|Experimental|Self-help course and information|
88806123|NCT01791374|Experimental|Rilotumumab Monotherapy|Cohort 1A: Rilotumumab 10 mg/kg IV Q2W Cohort 1B: Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed): Rilotumumab 15 mg/kg IV Q2W
88821393|NCT04322643|Experimental|CPI therapy|Patients will be treated with CPI therapy for at least 24 weeks (+/- 4 weeks) as per standard of care (SOC), at which time those with a tumor burden reduction of 10% or greater will suspend CPI therapy.
89127060|NCT02580916|No Intervention|Group 4 (Clinician focus group)|We aim to discuss the project at the end of the study period in the same setting, to establish staff perspectives on the study, to establish usefulness of the SCQOLIT tool and to identify any barriers to implementation.
89127061|NCT02580760||Cosmetic silicone injection|People responding to inclusion criteria with a history of cosmetic silicone injection
89127062|NCT00768157|Experimental|antiviral group|Drug: antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC)
89127063|NCT00768157|Active Comparator|control group|Procedure/Surgery (radical resection of HBV-related HCC) without Drug of antiviral treatment - close observation without antiviral treatment
89127064|NCT04076878|Experimental|Intervention in a Mechanism and a Clinical substudy|"Mechanism substudy: 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo). Patients and datacollectors were blinded in terms of the randomised order of the treatment at each of the 3 trial sessions ( electrodes set to 1) 20 Hz, 2) 30 Hz, 3) 0 Hz (placebo).~Clinical substudy: Use of the fitted and individually set body suit, Mollii, in the home setting for 6 weeks"
88806124|NCT01791374|Experimental|Rilotumumab plus CX|Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W
89127065|NCT00671749|Experimental|Study Treatment|"adapalene gel, 0.3%~Other Names:~Differin® Gel, 0.3% Applied once daily at bedtime~clindamycin/benzoyl peroxide gel~Other Names:~Duac® Gel Applied once daily in the morning"
89127066|NCT04149106|Active Comparator|Standard|The Mali National Malaria Control program has initiated SMC for children less than 5 years since 2016 (countrywide) with SPAQ. This standard care will not change in this arm
89127067|NCT04149106|Active Comparator|SMC with SPAQ extended to older children|Within this arm, SMC with SPAQ will be extended to children 5-9 years old
89127068|NCT04149106|Active Comparator|SMC with DHAPQ|Children less than 10 years within this arm will received Dihydroartemisin piperaquin for SMC instead of SPAQ
89127069|NCT03889600|Experimental|REDD-CAT Recipient|The nurse care manager will incorporate the administration of the REDD-CAT to the patient as part of the standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
89127070|NCT00768235|Experimental|1: yoga group|Yoga group
89127071|NCT00768235|No Intervention|2: control group|
89127072|NCT00768391|Experimental|IMC-3G3|All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into.
89127073|NCT00669877|Experimental|Hyper-CVAD|Hyper-CVAD (odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses. Rituximab 375 mg/m2 days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses. Cyclophosphamide 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3. Doxorubicin 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses). Vincristine 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses). Dexamethasone 40 mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses). G-CSF 10 mg/kg/day (rounded) until neutrophil recovery 1 x 10^9/L or higher can be substituted or can be added to pegfilgrastim if neutrophils have not recovered to 1 x 10^9/L by day 21.
89127074|NCT04047901|No Intervention|control group|"A group of patients who will not be trained will be evaluated at baseline (pre) and after 16 weeks.~They are oriented to maintain lifestyle changes"
89127075|NCT04047901|Experimental|Training group|Patients will complete 16 weeks of training including 40 minutes of aerobic training, 15 minutes of resistive exercise and 5 minutes of relaxation.
89127076|NCT00922051|Experimental|Group 1|Application of Acu-TENS
89127077|NCT00922051|Placebo Comparator|Group 2|
89127078|NCT00772681|Experimental|1|
89127079|NCT02557633|Placebo Comparator|Placebo|2% w/v L-Tyrosine
89127080|NCT02557633|Experimental|Grass MATA MPL 10200 SU|Grass MATA MPL cumulative dose 10200 SU given as six injections of placebo, placebo, 600SU, 1600SU, 4000SU and 4000SU.
89127081|NCT02557633|Experimental|Grass MATA MPL 18200 SU|Grass MATA MPL cumulative dose 18200 SU given as six injections of 600SU, 1600SU, 4000SU, 4000SU, 4000SU and 4000SU.
89127082|NCT04143646|Active Comparator|Web-based prevention program|"Patients after myocardial infarction participate in a 12-months program with telemetric risk factor control, e-learning and E-Mail/App-contacts.~In a substudy patients are further randomly assigned to disclosure of genetic risk vs. no disclosure."
89127083|NCT04143646|No Intervention|Usual Care|Patients after myocardial infarction are treated following the standard of care (clinical practice as offered by general practitioners, cardiologists, etc.).
89127084|NCT00768547||By protocol|Where the test are predefined
89127085|NCT00768547||By degression|The group where the doctor decided which test are to be taken.
89127086|NCT00772759|Experimental|1|Dry powder for oral inhalation
89127087|NCT00772759|Placebo Comparator|2|Dry powder for oral inhalation
89127088|NCT00772837|Experimental|1.H.Pylori Eradication Group|The eradication group will receive triple therapy (omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BID and Amoxycillin 1g BID) for 1 week for the eradication of H. pylori
89127089|NCT00772837|Placebo Comparator|2.Control Placebo Group|The control group will receive omeprazole 20 mg BID for 1 week along with placebo antibiotics for 1 week
89127090|NCT03863704|Sham Comparator|nerve stimulation ear then leg|Subjects in this arm will be randomized to receive nerve stimulation with TENS of the ear followed by leg stimulation
89127091|NCT03863704|Sham Comparator|nerve stimulation leg then ear|Subjects in this arm will be randomized to receive leg nerve stimulation with TENS followed by ear nerve stimulation
89127092|NCT03863704|Other|Subjects receiving Infliximab|Subjects on Infliximab as part of their clinical care will not be randomized as the study treatment for these subjects will be the same. The sham arm is not included for patients on infliximab.
89127093|NCT00776971|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
89127094|NCT00776971|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
89127095|NCT00776971|Active Comparator|Semi-skimmed milk|202kJ/100mL
89127096|NCT00776971|Placebo Comparator|Water|0kJ/100mL
89127097|NCT02581540||Suspected Cardiac Chest Pain|This cohort is observed for the incidence of MACE (death, non-fatal myocardial infarction and emergency revascularisation)
89127098|NCT03850288||Anorexia Nervosa|"Patients with a diagnosis of anorexia nervosa (According to the DSM-V criteria). These patients are characterized by a restriction of food intake leading to weight loss or a failure to gain weight resulting in a significantly low body weight of what would be expected for someone's age, sex and height. Moreover, there is a fear of becoming fat or of gaining weight.Then, these patients have a distorted view of themselves and of their condition."
89233853|NCT00821717|Experimental|1:|
89233854|NCT00821717|Placebo Comparator|2|
89233855|NCT00822029|Experimental|1|FOSAMAX (oral bisphosphonate)
89233856|NCT00822029|Placebo Comparator|2|PLACEBO
89233857|NCT00816803|Experimental|BM transplant with physiotherapy|Autologous BM transplant
89233858|NCT00816803|Active Comparator|Physiotherapy only|conventional physical therapy for chronic spinal cord injury.
89233859|NCT00467259|Placebo Comparator|Placebo|28 cm² Placebo patch
89127099|NCT03850288||Bulimia Nervosa|"Patients with a diagnosis of bulimia nervosa. According to the DSM-V criteria, these patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time, an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode, recurrent inappropriate compensatory behaviour in order to prevent weight gain, such as self-induced vomiting, misuse of laxatives, diuretics, or other medications, fasting, or excessive exercise.~The binge eating and inappropriate compensatory behaviours both occur, on average, at least once a week for three months. Moreover, there is a self-evaluation influenced by body shape and weight."
89127100|NCT03850288||Binge Eating Disorder|Patients with a diagnosis of Binge Eating Disorder. These patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time (e.g. within any 2-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode. The binge eating episodes are associated with three or more of the following: eating much more rapidly than normal, eating until feeling uncomfortably full, eating large amounts of food when not feeling physically hungry, eating alone because of feeling embarrassed by how much one is eating, feeling disgusted with oneself, depressed or very guilty afterward,marked distress regarding binge eating is present. Moreover, binge eating occurs, on average, at least once a week for three months
89127101|NCT00772993||1|Primary open angle glaucoma
89127102|NCT00772993||2|Normal Control
89127103|NCT00772993||3|Myopia with no evidence of glaucoma
89127104|NCT00772993||4|Myopia with evidence og glaucoma
89127105|NCT00773071|Experimental|A|"Single photon emission computed tomography/computed tomography (SPECT/CT) guided lymphatic mapping and sentinel lymphadenectomy (LM/SL) vs. complete lymph node dissection (CLND)~All cervical cancer and vulvar cancer patients will undergo CLND according to the standard of care in gynecologic cancers as recommended by the International Federation of Gynecology and Obstetrics (FIGO).~Patients with FIGO IA2 and IB1 cervical cancers will be scheduled for radical hysterectomy and pelvic lymph node dissection.~Patients with FIGO IB and II vulvar cancers and those of patients with FIGO III with clinically negative regional lymph nodes will be scheduled for vulvectomy and inguinal lymph node dissection."
89127106|NCT03492346||LGMD2E Subject Population|"Individuals:~Confirmed LGMD2E diagnosis by genetic testing or~Suspected of having LGMD type 2E due to symptoms and a diagnosed family member or a member of a community with a large population of one of these two types"
89127107|NCT00773149|Experimental|1|all included patients
89127108|NCT00768781|Active Comparator|Mindfulness-Based Stress Reduction|
89127109|NCT00768781|Active Comparator|Mindfulness-Based Therapy for Insomnia|
89127110|NCT00768781|Other|Behavioral Therapy for Insomnia (Delayed treatment condition)|
89127111|NCT00777361|Experimental|AZD3480 iv|Single iv infusion AZD3480
89127112|NCT00777361|Experimental|Oral [14C] AZD3480|Single oral dose [14C]AZD3480
89127113|NCT02556853|Experimental|Ultrasound|Determination of correct placement of the double lumen tube by lung ultrasound.
89127114|NCT02556853|Active Comparator|Clinical|Determination of correct placement of the double lumen tube by clinical examination.
89127115|NCT00768859|Experimental|1|paclitaxel, trastuzumab and carboplatin
89127116|NCT00768937|Experimental|Treatment arm|all patients will be treated with sorafenib
89127117|NCT04047745|Active Comparator|liposomal bupivacaine|
89127118|NCT04047745|Active Comparator|ropivacaine|
89127119|NCT00773227|Experimental|1|All patients included
89127120|NCT00777439|Other|Domperidone|All eligible subjects will receive domperidone in an open label, single group assignment.
89127121|NCT00882999|Placebo Comparator|Placebo|Injection: Every 4 weeks in the placebo arm for 24 weeks (Weeks 0, 4, 8, 12, 16, and 20) for a total of 6 doses. Every 4 weeks in the LY2127399 arms [4 milligrams (mg) LY2127399 / 12 weeks and 120 mg LY2127399 / 12 weeks] for 24 weeks (except Week 0 and Week 12).
89127122|NCT00882999|Experimental|4 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
89127123|NCT00882999|Experimental|40 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
89127124|NCT00882999|Experimental|120 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
89127125|NCT00882999|Experimental|4 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
89127126|NCT00882999|Experimental|120 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
89127127|NCT00882999|Experimental|12 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
89127128|NCT00769093|Active Comparator|Group 1|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The first study group (n=6) will receive bevacizumab, the antiangiogenic agent for three weeks, then dexamethasone for three weeks.
89127129|NCT00769093|Active Comparator|Group 2|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The second study group (n=6) will receive dexamethasone for 3 weeks, then switch to bevacizumab, the antiangiogenic agent, for 3 weeks.
89127130|NCT00671437|Experimental|Arm 1|"Whole body FDG-PET/CT scan and CT scan of neck and chest (within 28 days of Day 1)~Cetuximab 400 mg/m2 intravenously (IV) over 2 hours on day 1 and 250 mg/m2 IV over 1 hour on days 8, 15, 22, 29, 36, 43, and 50.~Whole Body FDG-PET/CT scan and CT scan of neck and chest on Day 57 (prior to cetuximab infusion)~Cetuximab 250 mg/m2 IV over 1 hour on Day 57~Cetuximab 250 mg/m2 IV over 1 hour weekly until progressive disease"
89127131|NCT02556697|Experimental|patients with a suspicion of emphysema|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of emphysema
89127132|NCT02556697|Experimental|patients with a suspicion of scleroderma|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of sclerodermia
89127133|NCT04162353|Experimental|BCMA-CD19 cCAR|Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg
89127134|NCT00777517|Other|Reference|Commercial 10 mg Lipitor formulation tablet
89127135|NCT00777517|Other|Test|Atorvastatin pediatric formulation
89127136|NCT00769171|Active Comparator|Arm 2|
89127137|NCT00769171|Experimental|Arm 1|
89127138|NCT02579980|Experimental|DCE and DWI MRI group|Patients will undergo a baseline MR exam at enrollment within 4 weeks prior to scheduled surgery, which will include DW-MRI and DCE-MRI prior to surgery and tumor tissue collection.
89127139|NCT00777595|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
89127140|NCT00777595|Experimental|Treatment B|Single supratherapeutic dose of CHF 4226 pMDI
89127141|NCT00777595|Placebo Comparator|Treatment C|Single dose of placebo
89127142|NCT00777595|Active Comparator|Treatment D|Single dose of moxifloxacin
89127143|NCT02579746|Experimental|intervention|The intervention group received usual care plus the DASHNa-CC intervention.
89127144|NCT02579746|Active Comparator|control|The control group received usual care.
89127145|NCT02581618|Experimental|Study group|"Remote ischemic preconditioning arm~Blood pressure cuff will be inflated up to 200 mmHg in the non-dominant arm for 5 minutes before guiding catheter engagement."
89127146|NCT02581618|No Intervention|Control group|No intervention will be performed. Percutaneous coronary intervention will be performed without ischemic preconditioning.
89127147|NCT00769405|Experimental|Arm I|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery). Patients also undergo CHIP comprising oxaliplatin intraperitoneally during surgery and hyperthermia for 30 minutes.
89127148|NCT00769405|Experimental|Arm II|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery).
89127149|NCT00882921||Elaprase|Idursulfase 0.5 mg/kg Weekly
89127150|NCT02829502|Active Comparator|Byetta|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
89127151|NCT02829502|Placebo Comparator|Normosaline|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
89127152|NCT02635191|Experimental|Tailored Group|In tailored therapy, medications will be adjusted according to the antimicrobial susceptibility testing (including Clarithromycin sensitivity) and cytochrome P450 isoenzyme 2C19 genotype. 10 days regimen will be prescribed.
89127153|NCT02635191|Active Comparator|Standard group|In standard triple therapy, children will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) for 10 days.
89127154|NCT00773539|Active Comparator|1|
89127155|NCT00773539|Active Comparator|2|
89127156|NCT00773539|Active Comparator|3|
89127157|NCT00773617|Experimental|1|Integrative cognitive affective therapy (ICAT)
89127158|NCT00773617|Active Comparator|2|Cognitive behavioral therapy (CBT)
89127159|NCT02579824|Experimental|DS-3032b|"Dose Escalation Phase: DS-3032b administered once daily by mouth on Days 1 - 21 of a 28 day cycle. Starting dose level 90 mg/day.~Dose Expansion Phase: Starting dose level maximum tolerated dose from Dose Escalation Phase."
89127160|NCT02635113|Experimental|PD Shoe|40 subjects will wear the shoe in order to test abnormal gait patterns that increase likelihood of falls and the effectiveness of a gait synchronized vibration system to plantar surface to reduce fall risk.
89127161|NCT02557165||COPD patients|Patients with mild to moderate COPD having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery
89127162|NCT02557165||Patients with normal lung function|Patients with normal lung function having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery.
89127163|NCT05673850||NET|
89127164|NCT05673850||NCT|
89127165|NCT00656721|Experimental|Flutter Valve|This a crossover study, so all subjects performed both, control and experimental interventions. In Flutter Valve intervention the subjects remained comfortably seated, breathing through the device for 15 minutes, starting off from the total pulmonary capacity, and being free to cough. Thereafter, a 5-min session of cough ensued. In the control intervention the subjects followed the same sequence of the Flutter Valve intervention, but the metallic sphere and the cover of the device were removed. Since the patients were not acquainted with the valve, they did not know its proper assembly. As in the Flutter Valve intervention, during 15 minutes the patients could expectorate spontaneously and return to the device. A 5-min coughing session took place.
89127166|NCT02556619|No Intervention|Standard Therapy|Patients will undergo standard medical care for Hepatocellular Carcinoma diagnosis.Patients however will not be denied early palliative care if requested.
89127167|NCT02556619|Experimental|Early Palliative Care/Symptom Control|"Patients will undergo palliative care services at time of Hepatocellular Carcinoma diagnosis.~Palliative care and symptom control services are adapted from the National Consensus Project for Quality Palliative Care.~Early referral, patients meeting inclusion criteria will be enrolled and referred to palliative care within 3 weeks of the index consultation with Medical-Oncology, Surgical-Oncology or Gastroenterology.~Intervention will be:~Establish palliative care goals~Symptom Assessment and Control~End-of-Life Care"
89127168|NCT04162119|Experimental|multiple myeloma|This study is to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with Relapsed/Refractory Multiple Myeloma.
89127169|NCT02579902|Active Comparator|Vitamin D3|50000 IU vitamin D3 capsule, one capsule every 2 weeks for 6 months.
89127170|NCT02579902|Placebo Comparator|placebo|Placebo capsule, one capsule every 2 weeks for 6 months.
89127171|NCT02557087|Experimental|Hyoscine|Intravenous administration of Hyoscine N-butylbromide diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
89127172|NCT02557087|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
89127173|NCT02634879|No Intervention|Control|Control Group
89127174|NCT02634879|Active Comparator|Loss Aversion|Each physician in this arm will have access to funds prior to earning them.
89127175|NCT02634879|Active Comparator|Group Incentive|Each physician will receive 50% of their potential incentive based on group performance. Physicians will also receive information on the performance of physicians on key CI measures in their group.
89127176|NCT02579590||DEMPA group|This group are using DMPA (Depot Medroxyprogesterone Acetate 150 mg) injection every 3 month for 6-12 month
89127177|NCT02579590||Implanon group|"This group are using Implanon  (etonogestrel implant) 68 mg implant for 6-12 month"
89127178|NCT02579590||Cerazette group|This group are using Cerazette pills (75 micrograms desogestrel) one pill every day for 28 days without pill-free interval for 6-12 month.
89127179|NCT02579590||Normal healthy group|Those women not using any method of contraception
89127180|NCT02634957|Experimental|3 day absolute voice rest|participants would begin initiation of voice/speaking 3 days post phonomicrosurgery for benign vocal fold lesions
89127181|NCT02634957|Experimental|7 day absolute voice rest|participants would begin initiation of voice/speaking 7 days post phonomicrosurgery for benign vocal fold lesions
89127182|NCT03846544|No Intervention|control group|
89127183|NCT03846544|Experimental|double pick up group|
89127184|NCT02634723||Previously Untreated Patients (PUPs)|PUPs in China with Moderate to Severe Hemophilia A
89127185|NCT00769717|Experimental|Wellness-Centered|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
89127186|NCT00769717|Active Comparator|Weight-Centered|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
89127187|NCT04075942|Other|Atrophic Anterior Maxillary Ridges participants|Using customized Xenograft bone shell with equal mixture of autogenous and xenograft particulate bone as a graft with the modified cortical shell technique, with atrophic anterior maxilla with less than 5 mm Bucco-lingual
89127188|NCT02634567|No Intervention|Treatment as Usual|This group will not any training with the Cogmed training program.
89127189|NCT02634567|Experimental|Training Group|This group will receive intervention with the Cogmed training program and coach over a period of 5 weeks.
89127190|NCT03843424|Active Comparator|Enhanced Standard of Care (eSOC)|This group will receive the eSOC program. A minimum of 6 visits to the primary care provider (PCP) and includes assessment of weight status, patient/family motivation and readiness to change, promotion of healthy eating and activity habits, and use of health behavior change strategies.
89127191|NCT03843424|Active Comparator|Family-Based Behavioral Treatment (FBT + eSOC)|This group will receive eSOC plus the FBT program. Family-based behavioral treatment (FBT), an effective treatment that targets both child and parents meeting regularly with a health coach for healthy eating, activity, positive parenting strategies, and managing environmental cues.
89127192|NCT02634489|Active Comparator|Tamsulosin HCl and Solifenacin Succinate|Participants will receive daily doses of tamsulosin HCL and Solifenacin Succinate (3 dose strengths) as single tablets.
89127193|NCT02634489|Active Comparator|EC905 (tamsulosin HCI and solifenacin succinate)|Participants will receive a fixed combination tablet (3 dose strengths).
89127194|NCT02579512||Extra-corporeal ECG Signal Analysis|
89127195|NCT00582712|Experimental|Lithium Capsules|Lithium carbonate
89127196|NCT04161963||Phaco|tandard ultrasound phacoemulsification cataract surgery
89127197|NCT04161963||FLACS|femtolaser assisted cataract surgery
89127198|NCT04161963||phaco+MIGS|combined phacoemulsification cataract surgery plus micro invasive glaucoma surgery
89127199|NCT02754778|No Intervention|control group|no intervention, regular family life
89127200|NCT02754778|Active Comparator|intervention group|6 month of regular conditional workout 1-3 times a week
89127201|NCT02579668|Experimental|Language therapy in BSL|Working with Deaf practitioners to provide language activities in British Sign Language aimed at developing children's language skills.
89127202|NCT02578498|Placebo Comparator|High carbohydrate diet|high carbohydrate intake
89127203|NCT02578498|Active Comparator|Low carbohydrate diet|low carbohydrate intake
89127204|NCT00582790|Experimental|1|Interleukin-2 subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles in combination with Zoledronic acid IV on day 1 of every 4 week (28 days) cycle.
89127205|NCT00773929|Experimental|1|3-6 subjects each cohort. Escalate dose after safety evaluation of subjects in cohort
89127206|NCT00777907|Active Comparator|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. Stents are not allowed in this arm.
89127207|NCT00777907|Experimental|Pipeline|Placement of 1 or more Pipeline Embolization Device(s)(PED) into the parent artery at the target aneurysm.
89127208|NCT00774007|Placebo Comparator|Placebo|Placebo
89127209|NCT00774007|Active Comparator|Mesalazine|mesalazine 800 mg t.i.d.
89127210|NCT00774085||Patients with Schizophrenia|Patients with Schizophrenia are treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
89127211|NCT00769873|Active Comparator|Lovenox|Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days after laparoscopic splenectomy
89127212|NCT00769873|No Intervention|No Lovenox|Patients do NOT receive Lovenox post laparoscopic splenectomy
89127213|NCT00777985|Experimental|1|
89127214|NCT00777985|Active Comparator|2|
89127215|NCT00770107|Active Comparator|Thiamine|
89127216|NCT00770107|Placebo Comparator|Placebo|
89127217|NCT00774241|Experimental|1|
89127218|NCT00774319|Active Comparator|1|Induction Chemotherapy with TPF Then: cisplatin 100 mg/m2 on day 1, 22 and 43 combined with conventional radiotherapy
89127219|NCT00774319|Active Comparator|2|Induction chemotherapy with TPF Then cisplatin 40mg/m2 on day 1,8,15,22,29 and 35 combined with accelerated radiotherapy
89127220|NCT00881751|Experimental|Arm 1: bevacizumab and erlotinib|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28.
89127221|NCT00881751|Active Comparator|Arm 2: sorafenib tosylate|Patients receive oral sorafenib tosylate twice daily on days 1-28.
89127222|NCT00656955||Renal cancer patients|Renal cancer patients
89127223|NCT02634255|Active Comparator|Rocuronium elective surgery|patients undergoing inguinal herniorrhaphy
89127224|NCT02634255|Experimental|Rocuronium emergency surgery|patients undergoing appendectomy
89127225|NCT04161651|Experimental|single arm|
89127226|NCT02634021|Active Comparator|dexmedetomidine group|dexmedetomidine 1 mcg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
89127227|NCT02634021|Experimental|midazolam group|midazolam 0.1 mg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
89127228|NCT02634099|Other|hemoglobine monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
89127229|NCT04161729|Active Comparator|Magnesium sulfate|Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
89127230|NCT04161729|Placebo Comparator|Isotonic solution 0.9%|Isotonic solution 0.9% in the same volume as the study drug using identical pattern of administration.
89127231|NCT04161573||TBI group|15 people in this group. Each should be post TBI for 6 months.
89127232|NCT04161573||Control group to TBI|15 people in this group. Their gender and age accord with TBI group.
89127233|NCT04161573||Aging group 1- 20 to 39|Normal people whose age range from 20 to 39.
89127234|NCT04161573||Aging group 2- 40 to 59|Normal people whose age range from 40 to 59.
89127235|NCT04161573||Aging group 3- above 60|Normal people whose age are above 60.
89127236|NCT04161339|Experimental|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
89127237|NCT04161339|Placebo Comparator|Placebo|
89127238|NCT02633631||Women seeking family planning services|Women seeking family planning and gynecological services will be enrolled in our study.
89127239|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (over 2 days)|Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
89127240|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (over 2 days)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
89127241|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
89127242|NCT00934856|Experimental|MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 3.6 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 3.6 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
89127243|NCT00934856|Experimental|LABC: T-DM1 + Doc (Doublet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
89127244|NCT00934856|Experimental|LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg Iv infusion, docetaxel 60/75 mg/m^2 IV infusion, and pertuzumab 840 mg (for Cycle 1) or 420 mg (for remaining cycles) IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
89127245|NCT00934700|Experimental|Combination of hypothermia and xenon|Combination of hypothermia and inhaled xenon
89127246|NCT00934700|No Intervention|Hypothermia and standard intensive care|Hypothermia and standard intensive care
89127247|NCT00607100||1|Patients with Band atrophy of the optic nerve
89127248|NCT00607100||2|Normal Controls
89127249|NCT05369624|Experimental|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|Participants were given two hospital sessions: in the first session the physiotherapist explained the exercises to be performed at home and there was a reminder session at 4 weeks. Reminder call was carried out weekly for 8 weeks. The patients were advised to do the exercises at least 3 times a week. The number of times they performed physical activity and its duration were recorded in a questionnaire
89127250|NCT05369624|No Intervention|Control group|Participants received general written advice and recommendations for physical activity
89127251|NCT00930176|Experimental|Human Coagulation FACTOR X|
89127252|NCT04263116|Experimental|BAM group|Balloon assisted maturation
89127253|NCT04263116|Experimental|NO BAM|NO Balloon assisted maturation
89127254|NCT05171270||Psoriatic arthritis|Psoriatic arthritis Impact of Disease questionnaires (PsAID) used within routine clinic consultation.
89127255|NCT00669409|Experimental|10 mcg/kg|
89127256|NCT00669409|Experimental|100 mcg/kg|
89127257|NCT00669409|Experimental|200 mcg/kg|
89127258|NCT00669409|Experimental|25 mcg/kg|
89127259|NCT00669409|Experimental|50 mcg/kg|
89127260|NCT00669409|Placebo Comparator|Placebo|
89127261|NCT00778141|Experimental|1|metformin HC1 750 mg extended-release tablets
89127262|NCT00778141|Active Comparator|2|Glucophage® XR 750 mg tablets
89127263|NCT00778219||A|Patients needing intubation of single lumen tracheal tube and performed using laryngoscope
89127264|NCT00778219||B|Patients needing intubation of single lumen tracheal tube and performed using lightwand
89127265|NCT00778219||C|Patients needing intubation of double lumen endobronchial cath and performed using laryngoscope
89127266|NCT00774475|Placebo Comparator|1: standard therapy|clopidogrel 75 mg/day
89127267|NCT00774475|Active Comparator|2: doubled therapy|clopidogrel 150 mg/day
89127268|NCT00669331|Experimental|Mannitol|Inhaled mannitol 400mg
89127269|NCT00669331|Placebo Comparator|Control|Matched control - inhaled mannitol 50mg
89127270|NCT00932126|Experimental|1|
89127271|NCT00779077||cystic fibrosis|adults and children with cystic fibrosis
89127272|NCT00778297|Experimental|Group 1|
89127273|NCT00778297|Active Comparator|Group 2|
89127274|NCT05156216|Experimental|Experimental video|Knee OA educational video based on an empowerment discourse delivered online and embedded within the survey.
89127275|NCT05156216|Active Comparator|Control video|Knee OA educational video based on a disease and impairment discourse delivered online and embedded within the survey.
89127276|NCT00779233|Experimental|1|Zidovudine tablets 300 mg of Ranbaxy
89127277|NCT00779233|Active Comparator|2|RETROVIR ® 300 mg tablets (GlaxoSmithKline)
89127278|NCT04265300|No Intervention|Control|No intervention provided
89127279|NCT04265300|Experimental|Creative Roots|The intervention group will receive Creative Roots beverages and be instructed to have at least one drink (251mL) available at each meal (i.e. breakfast, lunch, and dinner) and drink as much as they would like throughout the day (i.e. ad libitum) of either Creative Roots or any other beverage they would normally consume. Subjects will be asked the keep their empty Creative Roots bottles to return them to the lab. Subjects will be instructed to refrigerate the beverages for better taste, and to refrigerate the beverages after opening.
89127280|NCT00607178|Experimental|Influenza vaccine|Enrolled patients who are randomly assigned to receive influenza vaccine
89127281|NCT00607178|Placebo Comparator|Placebo|Enrolled patients who are randomly assigned to receive placebo of influenza vaccine
89127282|NCT00778453|Experimental|Hospital-based mCIT|Hospital-based modified constraint-induced therapy(mCIT)
89127283|NCT00778453|Experimental|Hospital-based BIT|Hospital-based bilateral isokinematic training (BIT)
89127284|NCT00778453|Experimental|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
89127285|NCT00778453|Experimental|Home-based BAT|Home-based bilateral arm training(BAT)
89127286|NCT00778453|Experimental|Home-based TR|Home-based traditional rehabilitation (TR)
89127287|NCT00778453|Experimental|Home-based mCIT|Home-based modified constraint-induced therapy (mCIT)
89127288|NCT02556463|Experimental|Escalation MEDI9197|MEDI9197
89127289|NCT02556463|Experimental|Escalation MEDI9197 with durvalumab|MEDI9197 in combination with durvalumab
89127290|NCT02556463|Experimental|Escalation MEDI9197 durvalumab radiation|MEDI9197 in combination with durvalumab and palliative radiation
89127291|NCT02556463|Experimental|MEDI9197 with palliative radiation|MEDI9197 in combination with palliative radiation
89127292|NCT00779389|Experimental|Arm A|Erlotinib 150 mg
89127293|NCT00779389|Experimental|Arm B|Dasatinib + placebo
89127294|NCT00779389|Experimental|Arm C|Erlotinib (150 mg) plus Dasatinib (100 mg) for 14-21 days.
89127295|NCT00779389|Placebo Comparator|Arm D|Placebo for 14-21 days
89127296|NCT00778609|Experimental|Arm 1|
89127297|NCT00778609|Active Comparator|Arm 2|
89127298|NCT05357534|Experimental|"Type 1 diabetes group"|"type 1 diabetes group: patients with type 1 diabetes"
89127299|NCT05357534|Active Comparator|"healthy group"|"healthy group : subjects without type 1 diabetes"
89127300|NCT00774553|Experimental|1|AZD1656
89127301|NCT00774553|Placebo Comparator|2|Placebo
89127302|NCT00774631|Experimental|Hypothermia|mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming
89127303|NCT00774631|Active Comparator|No hypothermia|no hypothermia, according to local recommendations and guidelines of medical societies and literature
89127304|NCT00774709||1|
89127305|NCT00778765|Experimental|1|400 mg Gabapentin Capsules of Ranbaxy
89127306|NCT00778765|Active Comparator|2|Neurontin® 400 mg Gabapentin Capsules
89127307|NCT00774865||Surgical|Patients who have previously undergone robotic bypass surgery
89127308|NCT00774943|Active Comparator|AMG 557|
89127309|NCT00774943|Placebo Comparator|Placebo|
89127310|NCT02556151|Active Comparator|1 Hz|Six sessions of weekly therapy with 1 Hz magnetic stimulations of the lumbar and sacral regions.
89127311|NCT02556151|Active Comparator|5 Hz|Six sessions of weekly therapy with 5 Hz magnetic stimulations of the lumbar and sacral regions.
89127312|NCT02556151|Active Comparator|15 Hz|Six sessions of weekly therapy with 15 Hz magnetic stimulations of the lumbar and sacral regions.
89127313|NCT00779935|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
89127314|NCT00780013|Experimental|1|metformin hydrochloride (HCI) liquid 500 mg/5 mL of Ranbaxy
89127315|NCT00780013|Active Comparator|2|Glucophage® 1000 mg tablets
89127316|NCT00778843|Experimental|Viusid|
89127317|NCT00778843|Placebo Comparator|Placebo|Placebo three oral sachets daily during 24 weeks
89127318|NCT00780091||1|classical monitoring strategy
89127319|NCT00780091||2|optimized monitoring strategy
89127320|NCT00667225|Placebo Comparator|I|Subjects in this group will have topical application of cantharidin's vehicle at each visit.
89127321|NCT00667225|Experimental|II|Subjects in this group will have topical application of cantharidin at each visit.
89127322|NCT00784381||1|
89127323|NCT00784381||2|These units use the same electronic prescribing system, but had no counselling software
89127324|NCT00784537|Other|Arm A|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~PET-2 positive patients will be high-dose salvage treatment;~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to first arm:~No radiotherapy."
89127325|NCT00784537|Other|Arm B|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~PET-2 positive patients will be high-dose salvage treatment;~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to second arm:~Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease."
89127326|NCT00780169|Experimental|sorafenib +FOLFIRI|This is a Phase I safety study. There is only one arm of FOLFIRI administered every 14 days (2 week schedule) and sorafenib administered orally, twice daily continuously. First cycle sorafenib began at day +2 to FOLFIRI.
89127327|NCT00780247||Alaska residents|"50 healthy community dwelling males or females."
89127328|NCT00780247||Hawaiian residents|"50 healthy community dwelling males or females at each site"
89127329|NCT00789841||Patients with NET and diarrhea.|
89127330|NCT00780325|Experimental|1|CG100649, single oral dose of 2 mg
89127331|NCT00780325|Experimental|2|CG100649, single oral dose of 8 mg
89127332|NCT00780325|Active Comparator|3|Celecoxib, single oral dose of 200 mg
89127333|NCT00780325|Active Comparator|4|Naproxen, single oral dose of 500 mg
89127334|NCT00780325|Active Comparator|5|Acetazolamide, single oral dose of 250 mg
89127335|NCT00780325|Placebo Comparator|6|Placebo, single oral administration
89127336|NCT02556229|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
89127337|NCT00929864|Active Comparator|Abatacept|
89127338|NCT00929864|Active Comparator|Adalimumab|
89127339|NCT00597753|Experimental|Peginesatide|
89127340|NCT00597753|Active Comparator|Epoetin alfa|
89127341|NCT04262804|Experimental|Margetuximab & Chosen Chemotherapy|The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
89127342|NCT04262804|Active Comparator|Trastuzumab & Chosen Chemotherapy|The dosage and administering of Trastuzumab is 8 mg/kg loading dose then 6 mg/kg IV every 21 days. Investigators need to chose one of the 3 chemotherpies based on patient conditions.
89127343|NCT00665431|Experimental|Arm 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole bid
89127344|NCT00665431|Active Comparator|Arm 2 (Celebrex)|Celecoxib 200 mg
89127345|NCT00665431|Placebo Comparator|Arm 3 (Placebo)|sugar pill
89127346|NCT02633709|Placebo Comparator|Part 1: Single Ascending Dose: Placebo|Participants will receive a single dose of matching placebo orally on Day 1 of Part 1.
89127347|NCT02633709|Experimental|Part 1: Single Ascending Dose: Risdiplam|Participants will receive a single ascending dose (SAD) of Risdiplam orally on Day 1 of Part 1.
89127348|NCT02633709|Experimental|Part 2: Food Effect: Fasted-Fed|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fasted state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fed state on Day 1.
89127349|NCT02633709|Experimental|Part 2: Food Effect: Fed-Fasted|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fed state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fasted state on Day 1.
89127350|NCT02633709|Experimental|Part 3: Itraconazole Interaction|In Period 1 a single oral dose of Risdiplam will be administered. After a wash-out period in Period 2 participants will be administered oral doses of itraconazole twice daily from Day 1 to Day 8. On Day 4 participants will receive a single oral dose of Risdiplam in the fed state in combination with itraconazole.
89127351|NCT04265066||Measurement of sublingual microcirculation|
89127352|NCT04264988||Patients who had pelvic hemorrhage|Patients who had pelvic hemorrhage during complex abdomino-pelvic surgery
89127353|NCT00657033|Experimental|Arm 1|
89127354|NCT00657033|Experimental|Arm 2|
89127355|NCT00784615||1|Women with polycystic ovaries, oligo or anovulation and hyperandrogenism.
89127356|NCT00784615||2|Women with polycystic ovaries and oligo or anovulation without hyperandrogenism
89127357|NCT00784615||3|Women with normal ovaries, oligo or anovulation and hyperandrogenism
89127358|NCT00784615||4|Women with normal ovaries, oligo or anovulation and hyperandrogenism
89127359|NCT00784615||5|Women with out polycystic ovary syndrome
89127360|NCT04263740|Experimental|Kinesio Taping plus Traditional Physical Therapy|Kinesio Taping plus Traditional physical therapy
89127361|NCT04263740|Other|Traditional Physical Therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises.
89127362|NCT02633319|Experimental|Parenting Training|Skilful Parenting: 12-week group-based parent intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages.
89127363|NCT02633319|Experimental|Agricultural Training|Agrics: Initial 3-month agricultural training intervention with ongoing support afterwards.
89127364|NCT02633319|Experimental|Parenting and Agricultural Training|Village farmer groups receiving both Skilful Parenting and Agrics interventions.
89127365|NCT02633319|No Intervention|Control|6-month wait-list control group
89127366|NCT04262570|Experimental|SMA patients (therapy arm)|"Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~Magnetic Resonance Imaging (MRI) of lower leg~Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
89127367|NCT04262570|Active Comparator|SMA patients (control arm)|"Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 4 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~Magnetic Resonance Imaging (MRI) of lower leg~Physical assessment/milestones: expanded Hammersmith functional motor scale (HFMSE)/ Revised Upper Limb Module (RULM)/ 6-minute-walking-test (6-MWT)"
89127368|NCT04161261|Experimental|IntraOperative Group|The intra-operative group consists of patients who have met criteria for cochlear implants. We monitor the facial nerve EMG intraoperatively in all patients, and often get some facial nerve activation when we are testing the implant intraoperatively when we are looking to see if we are getting any hearing nerve responses from electrical stimulation of the implant. We will also measure the facial nerve responses for some other charge-balanced pulse shapes, which are asymmetric and in which either the positive or negative charge is expected to stimulate the nerve. We will only measure these for two electrodes, not for all 12-22 electrodes They will be then invited back post operatively for a second testing during a standard of care visit post switch on for other pulse shapes.
89127369|NCT04161261|Experimental|PostOperative Group|The post-operative group, are patients who are actually having facial nerve stimulation on one or more electrodes, and for whom these electrodes are turned down so much they can't hear very well, or are actually turned off because of the facial nerve stimulation. For these patients, we will slowly increase the current levels on the offending electrodes (maximum of two) until they get some facial nerve twitching, and then turn down the current until they do not have stimulation any more. We will do this for all pulse shapes and determine which shape produces the greatest loudness without stimulating the facial nerve. This will be the only testing session for the second group.
89127370|NCT00607334|Experimental|GP|Children with Developmental Language Impairments were enrolled in this group.
89127371|NCT00607334|Experimental|GC|Children with normal language development were enrolled in this group.
89127372|NCT00789919|No Intervention|1|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital for standard inpatient management of their disease.
89127373|NCT00789919|Experimental|2|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital and their infant is delivered as soon as possible after 34 weeks gestation. As there is no determined optimal time of delivery in these patients, delivery is the intervention.
89127374|NCT04161105|Experimental|Rectus femoris dry needling group|The rectus femoris dry needling group will have their strength assessed. They will then receive one treatment of dry needling to a trigger point in their rectus femoris muscle. They will have their strength re-assessed 24, 48 & 72 hours after dry needling.
89127375|NCT04161105|Experimental|Gluteus maximus dry needling group|The gluteus maximus dry needling group will have their strength assessed. They will then receive one treatment of dry needling to trigger points in their gluteus maximus muscle only. They will have their strength re-assessed 24, 48 & 72 hours after dry needling.
89127376|NCT04161105|No Intervention|Control|This group will receive no intervention. They will have their strength assessed at baseline and 24, 48 & 72 hour follow-up
89127377|NCT00934622|Experimental|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL)
89127378|NCT00657111|Experimental|A1|Subjects 01-08; 5 mg CS-8958
89127379|NCT00657111|Placebo Comparator|A2|Subjects 01-08; placebo
89127380|NCT00657111|Experimental|B1|Subjects 09-16; 10 mg CS-8958
89127381|NCT00657111|Placebo Comparator|B2|Subjects 09-16; placebo
89127382|NCT00657111|Experimental|C1|Subjects 17-24; 20 mg CS-8958
89127383|NCT00657111|Placebo Comparator|C2|Subjects 17-24; placebo
89127384|NCT00657111|Experimental|D1|Subjects 25-32; 40mg CS-8958
89127385|NCT00657111|Placebo Comparator|D2|Subjects 25-32; placebo
89127386|NCT04160871|Experimental|Family Connections|Experimental group
89127387|NCT04160871|Active Comparator|Treatment As Usual|Control group
89127388|NCT02633475||CONTROL: women no miscarriage|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than one successful pregnancy without miscarriage. Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
89127389|NCT02633475||CASE: patients with IRM|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than three consecutive miscarriages without clear cause (Idiopathic Recurrent Miscarriage, IRM). Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
89127390|NCT04032405|Active Comparator|CAF+CTG|the combined connective tissue graft (CTG) with coronally advanced flap (CAF)
89127391|NCT04032405|Experimental|CAF+CTG+i-prf|the combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
89127392|NCT04160637||Patients with post-thyroidectomy hypocalcemia|Patients with postoperative hypocalcemia defined as serum calcium levels < 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
89127393|NCT04160637||Patients without post-thyroidectomy hypocalcemia|Patients without postoperative hypocalcemia defined as serum calcium levels > 2.00 mmol/L regardless of clinical symptoms present. Patients may have low or normal PTH range (defined by the Department of Laboratory Diagnostics reference range from 1.6 to 6.9 pmol/L)
89127394|NCT04160949||Patients|Patients who have been diagnosed with Fatty Liver.
89127395|NCT04160403|Experimental|factors ( SES,age, sex,severity) and progress|the relation between progress in gross motor functions
89127396|NCT02633007|Experimental|CVT-301 then Placebo (AB)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
89127397|NCT02633007|Experimental|Placebo then CVT-301 (BA)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
89127398|NCT04160793|Other|Genital Nerve Stimulation|Stimulation of the DNP
89127399|NCT00881361|Other|Study cohort|Patients who plan to receive or have received neoadjuvant chemotherapy are eligible. Patients undergo examination for breast and axilla lymph adenopathy and then undergo ultrasound of the axillary nodes at baseline and after completion of neoadjuvant chemotherapy. Within 12 weeks of completing neoadjuvant chemotherapy, patients undergo a mastectomy or lumpectomy (per surgeon discretion) including both sentinel lymph node surgery and axillary lymph node dissection.
89127400|NCT01000727|Experimental|Darapladib 160 mg|Single daily oral tablet
89127401|NCT01000727|Placebo Comparator|Placebo|Single daily oral tablet
89127402|NCT04160247|Active Comparator|Angulated screw-retained crown|Restorations are connected to the implants by angulated screw channel system
89127403|NCT04160247|Placebo Comparator|Cemented crown|Restorations are cemented onto the implant abutment
89127404|NCT00657345||1|This is a tissue acquisition and collection protocol that will analyze potential cellular changes that occur after treatment with trastuzumab.
89127405|NCT04160559|Placebo Comparator|Control group|chemotherapy plus water
89127406|NCT04160559|Experimental|Test group|chemotherapy plus green tea
89127407|NCT04160481|Active Comparator|Tomato extract|
89127408|NCT04160481|Placebo Comparator|Placebo|
89127409|NCT00881205|Experimental|Rivastigmine|Rivastigmine patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
89127410|NCT00881205|Placebo Comparator|Placebo|Placebo patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
89127411|NCT00879879|Experimental|Losartan|50 mg tablets of losartan taken daily by mouth for 1 year
89127412|NCT04157283||Group 1|60 male patients
89127413|NCT04157283||Group 2|60 female patients
89127414|NCT00661999|Experimental|Arm I|Patients receive darbepoetin alfa subcutaneously and sodium ferric gluconate complex IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
89127415|NCT00661999|Experimental|Arm II|Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
89127416|NCT00661999|Experimental|Arm III|Patients receive darbepoetin alfa as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
89127417|NCT00661167|Experimental|1|ABI-007
89127418|NCT04156737|Experimental|Investigational Lens|TECNIS Symfony plus IOL Model ZHR00V
89127419|NCT04156737|Active Comparator|Control Lens|Trifocal Intraocular Lens
89127420|NCT00661245|Experimental|TOGA|The TOGA procedure is an incision-free treatment using a set of flexible staplers introduced into the mouth and esophagus to create a sleeve in the stomach (transoral formation of a gastric sleeve). The TOGA sleeve limits the amount of food that can be eaten and gives the patient a feeling of fullness after a small meal.
89127421|NCT00661245|Sham Comparator|Control|A gastric sleeve is not formed.
89127422|NCT04156815|Active Comparator|1,565nm NAFL only group|Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas. A facial sheet mask (skin repair dressing, Panion & BF Biotech Inc, Zhuhai, China) was used to clean the face after laser treatment, and the face was cooled by air cooler for 10 minutes. The patients received three treatment sessions with a 6-week interval between each session.
89127423|NCT04156815|Active Comparator|Oral isotretinoin only group|Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
89127424|NCT04156815|Active Comparator|Double therapy group|The patients first received 2-4 weeks of oral isotretinoin medication (1mg/kg/d), followed by 1565nm M22-ResurFx NAFL treatment. Subjects were then given isotretinoin with a dosage of 0.5 mg/kg/d for the next 12-14 weeks. Laser treatment parameters and procedures were as same as in the group one above.
89127425|NCT04156815|Experimental|Triple therapy group|The patients received the same treatments as the subjects in group (3) with additional PBT. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
89127426|NCT04156425|Experimental|escitalopram + golimumab|Patients will be treated with escitalopram from the minimum dosage and golimumab according to direction for use.
89127427|NCT04156425|Experimental|escitalopram + calcium tablet|Patients will be treated with escitalopram from the minimum dosage and calcium tablet according to direction for use.
89127428|NCT04156425|Active Comparator|escitalopram|Patients will be treated with escitalopram from the minimum dosage.
89127429|NCT02555059||BAYQ3939|Pediatrics patients treated with Ciproxan injection in daily clinical practice.
89127430|NCT00661323||1|Healthy volunteers will be recruited through the use of an approved study recruitment flyer.
89127431|NCT00661323||2|Chemotherapy patients will be approached at the time of their nuclear scan to rule out cardiac disease prior to chemotherapy. These patients will be referred to the study by their doctor for the assessment of heart function.
89127432|NCT04156503|Experimental|Test fat: Palm olein|One high fat muffin will be serves together with a glass of low fat milk shake.
89127433|NCT04156503|Experimental|Test fat: Lard|One high fat muffin will be serves together with a glass of low fat milk shake.
89127434|NCT00785083|Experimental|1|
89127435|NCT00785083|Placebo Comparator|2|
89127436|NCT02631681|Experimental|Men with prostate cancer on androgen deprivation therapy|Group based supervised combined aerobic and resistance training for 12 weeks.
89127437|NCT00780637|Experimental|Bradykinin|Patients receive 0, 10, 20, and 40 ng/min/100cc forearm volume of intrabrachial bradykinin, for 5 minutes at each dose. Forearm blood flow will be measured by strain gauge plethysmography, blood samples will be obtained to measure t-PA, PAI-1 at each dose. FMD and Radial artery tonometry will also be performed under resting conditions.
89127438|NCT00790153|Active Comparator|1|AZD1656
89127439|NCT00790153|Active Comparator|2|Insulin
89127440|NCT00911391|Active Comparator|Fluid restriction|Current best practice of intraoperative fluid restriction
89127441|NCT00911391|Experimental|Oesophageal Doppler|Oesophageal Doppler-guided fluid administration
89127442|NCT00785317|Experimental|Angemin|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP
89127443|NCT00785317|Active Comparator|Activelle|1 mg of oral E2 in continuous combination with 0.5 mg of NETA
89127444|NCT05017831|Active Comparator|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
89127445|NCT05017831|Experimental|FBT w/ Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of FBT over six months. The first 9 sessions of FBT will be preceded by adolescent-focused CRT.
89127446|NCT00661791|No Intervention|A|Control Group receives routine care.
89127447|NCT00661791|Experimental|B.|massage group, receives massage only.
89127448|NCT00661791|Experimental|C.|Massage and Exercise group, receives both massage and exercise.
89127449|NCT04156269|Experimental|BCMA-CD33 cCAR T cells|BCMA-CS1 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-BCMA and CS1 CARs
89127450|NCT00790231||men|observation of the urinary function with and without thoracic epidural anesthesia
89127451|NCT00790231||women|observation of the urinary function with and without thoracic epidural anesthesia
89127452|NCT00661869|Active Comparator|Wellness Group|
89127453|NCT05001217|Experimental|Chinese herbal medicine treatment plus conventional medication|"Participants will receive integrated medicine treatment combining Chinese herbal treatment, given in the form of granules, and conventional medication for 32 weeks. Patients will be differentiated into 4 subgroups based on their Chinese medicine pattern, and receive herbal treatment accordingly. An existing clinical pathway will guide the diagnosis and treatment of the Chinese medicine patterns. The four pattern subgroups are as follows:~1) the Phlegm-heat stirring Wind subgroup; 2) the Spleen-and Kidney-Yang subgroup; 3) the Internal Stirring of Yang and Wind subgroup; and 4) the Qi deficiency and stasis of Blood subgroup~To resemble actual clinical practice, minor adjustment of herbal treatment will be possible and also adhere to the mentioned clinical guideline. The dosage of each herbal drug will follow the instructions of China Pharmacopeia."
89127454|NCT05001217|Active Comparator|Conventional medication|Conventional medication for Parkinson's disease include levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
89127455|NCT02631603|Experimental|Placebo|Capsules of placebo will be taken for 3 months.
89127456|NCT02631603|Active Comparator|Prednisolone|"Oral prednisolone, anticipated dose:~first month after steroid pulse 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose.~Individual capsules will be prepared using rounded dose."
89127457|NCT00790309||Weight loss surgery|This group will be comprised of people having weight loss surgery: Roux-en Y gastric bypass, vertical sleeve gastrectomy, or adjustable gastric banding
89127458|NCT00790309||Abdominal surgery|This group will be comprised of people having abdominal surgeries such as nissen fundoplication or cholecystectomy.
89127459|NCT00790309||Lean|This group will be comprised of normal weight healthy volunteers.
89127460|NCT04156113|Experimental|Athletes Group|"The athletes group will be composed of healthy, non obese (body mass index < 30), male basketball, volleyball and handball players aged between 18 and 35 years who have been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
89127461|NCT04156113|Experimental|Sedentary Group|"The sedentary group will be composed of healthy, non obese (body mass index < 30), male aged between 18 and 35 years who have not been training regularly for at least 3 months. Participants must not be regular consumer of cigarettes, alcohol, drugs and antioxidant substances.~Intervention: Yo-Yo intermittent recovery test (level 1) is administered."
89127462|NCT00790387|Experimental|1 High dose tirofiban and enoxaparin|"Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg .~Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours."
89127463|NCT00790387|Active Comparator|2 tirofiban and unfractionated heparin|"Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours.~UFH heparin was administered as a bolus of 70 U/kg and additional heparin was given to maintain the activated clotting time (ACT) at 250"
89127464|NCT00661947||Public|General public. Those who are not currently taking any medication besides birth control pills.
89127465|NCT00662103|Active Comparator|progressive, aerobic exercise program|Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.
89127466|NCT00662103|Active Comparator|progressive, resistance exercise program|Patients undergo resistance exercise training 3 days a week for 18 months.
89127467|NCT00662103|Active Comparator|flexibility and relaxation training [control]|Patients perform a series of whole body flexibility (stretching) and relaxation (guided imagery, progressive neuromuscular relaxation, focused breathing) exercises 3 days a week for 18 months.
89127468|NCT00662181||H, NH|HIV positive patients with and without lipodystrophy
89127469|NCT04156035|Experimental|Lamotrigine + Ketamine|Pretreatment with lamotrigine will occur 2 hours before the ketamine infusion
89127470|NCT04156035|Experimental|Placebo + Ketamine|Pretreatment with placebo will occur 2 hours before the ketamine infusion
89127471|NCT04156035|Placebo Comparator|Placebo + Placebo|Pretreatment with placebo will occur 2 hours before the placebo infusion
89127472|NCT00662337|Experimental|1|Diphenydramine HCl
89127473|NCT00662415|Other|1|12 non-amputee control subjects will be scanned at 0, 2 and 4 weeks but will not recieve mirror therapy.
89127474|NCT00662415|Experimental|2|24 unilateral lower extremity amputee subjects will recieve daily mirror therapy for phantom limb pain and will be scanned at 0, 2, and 4 weeks.
89127475|NCT00665353|Experimental|PIO (step 1) then PIO+PEG-INF+RBV (step 2)|All participants in this study will receive pioglitazone therapy for 24 to 28 weeks. Participants will continue pioglitazone and add peginterferon and ribavirin to their treatment regimen for up to 48 additional weeks.
89127476|NCT00597207|Experimental|1|Mechanical CPR with AutoPulse
89127477|NCT00597207|Other|2|Manual CPR
89127478|NCT00662493|Experimental|1|Motor control retraining program
89127479|NCT00785395|Experimental|A|
89127480|NCT00662571||A|"Our hypothesis is that effective acamprosate response in alcohol dependent subjects may be influenced by genetically controlled variation in the functionality of the N-methyl-D-aspartate receptor (NMDA) and/or the type 5 metabotropic glutamate receptor (mGluR5). Hypothesis confirmation could lead to development of effective individualized treatment recommendations for alcohol dependent patients based on pharmacogenomically relevant genetic variations.~There will be no placebo drug given. Just measurement of genetic response."
89127481|NCT00780793|Active Comparator|1-M : Maintenance|Usual care
89127482|NCT00780793|Experimental|2 -S : Spacing of TNF-blocker injections|Spacing of TNF-blocker injections
89127483|NCT00662727|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
89127484|NCT00662727|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
89127485|NCT00661635|Active Comparator|Arm 1|
89127486|NCT00661635|Active Comparator|Arm 2|
89127487|NCT00661635|Placebo Comparator|Arm 3|
89127488|NCT00790465|Active Comparator|1|dark chocolate consumption during manometry and 2 weeks treatment with dark chocolate
89127489|NCT00790465|Other|2|placebo comparator: 7 grams of placebo-chocolate at day 1 during manometry, and than crossover to treatment with dark chocolate for 2 weeks.
89127490|NCT04155957|Active Comparator|Conventional Rehabilitation Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty and perform a daily 5-exercise plan autonomously.
89127491|NCT04155957|Experimental|ReHub Group|Participants follow the usual fast-track protocol used at Hospital Clínic de Barcelona for Total Knee Arthroplasty but use the telerehabilitation platform ReHub to do the exercises in their rehabilitation plan at home and to have their progress monitored.
89127492|NCT02555761||Lastacaft®|One drop of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) in each eye daily as prescribed as standard of care in clinical practice.
89127493|NCT04155879|No Intervention|Control Group|Cardioversion without treatment with Colchicine
89127494|NCT04155879|Active Comparator|Treatment group|This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months
89127495|NCT00662805||Salmeterol/Fluticasone propionate (50/500 μg)|Open label, 6 visits, single arm study
89127496|NCT02555137||outcome cohort study|'prediction score' and 'rule-out criteria'
89127497|NCT00662883|Experimental|A|"PMI-150 (intranasal ketamine HCl), day 1~mometasone furoate, days 2-15~PMI-150 (intranasal ketamine HCl), day 15"
89127498|NCT00662961|Experimental|1|Periosteum
89127499|NCT00662961|Experimental|2|Bone
89127500|NCT00785473|Active Comparator|1|cholecalciferol, calcium carbonate
89127501|NCT00785473|Placebo Comparator|2|capsules not containing cholecalciferol, otherwise identical to Active comparator; calcium carbonate
89127502|NCT02631291|Experimental|Lifestyle|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet.
89127503|NCT02631291|No Intervention|Usual Care|Participants randomized to this condition will receive the written education provided to all participants.
89127504|NCT02631291|Experimental|LIfestyle + coaching|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet; and behavioral self-monitoring + motivational interviewing lifestyle coaching.
89127505|NCT00785551|Experimental|1|quinine sulfate 648mg in subjects with normal renal function (CLcr > 80mL/min)
89127506|NCT00785551|Experimental|2|quinine sulfate 648mg in subjects with mildly impaired renal function (CLcr > 50 to 80 mL/min)
89127507|NCT00785551|Experimental|3|quinine sulfate 648mg in subjects with moderately impaired renal function (CLcr 30 to 50mL/min)
89127508|NCT04031937|Active Comparator|major depressive disorder|psychometric scales psychomotor assessment
89127509|NCT04031937|Active Comparator|Control|psychometric scales psychomotor assessment
89127510|NCT00780949|Experimental|1: Crohn's disease patient|intestinal biopsies
89127511|NCT02631369|Experimental|inter- & intrarater reliability study|pre-study: inter- and intrarater reliability study in 30 healthy subjects, interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
89127512|NCT02631369|Experimental|cyclotorsion in forth nerve palsy|measurement of cyclotorsion on SLO-fundusphoto in 20 patients forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
89127513|NCT02631369|Experimental|cyclotorsion in healthy subjects|measurement of cyclotorsion on SLO-fundusphoto in 30 healthy subjects to be compared to patients with forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
89127514|NCT00791011|Experimental|Cohort 4|AMG 655 (intermediate dose) with Vorinostat
89127515|NCT00791011|Experimental|Cohort 1|AMG 655 (low dose) with Bortezomib
89127516|NCT00791011|Experimental|Cohort 2|AMG 655 (low dose) with vorinostat
89127517|NCT00791011|Experimental|Cohort 5|AMG 655 (high dose) with Bortezomib
89127518|NCT00791011|Experimental|Cohort 6|AMG 655 (high dose) with Vorinostat
89127519|NCT00791011|Experimental|Cohort 7|Part 2 - Mantle Cell Lymphoma subjects only: AMG 655 at dose TBD with Bortezomib
89127520|NCT00791011|Experimental|Cohort 3|AMG 655 (intermediate dose) with Bortezomib
89127521|NCT00663273|Experimental|1|Lactic acid in small quantity during 21 days.
89127522|NCT00781027|Active Comparator|1|Torsional phacoemulsification
89127523|NCT00781027|Active Comparator|2|Longitudinal phacoemulsification
89127524|NCT02555917|Experimental|Remnant preserving|"Anterior cruciate ligament reconstruction:~anterior cruciate ligament remnant will be preserved in the operation"
89127525|NCT02555917|Active Comparator|Remnant resecting|"Anterior cruciate ligament reconstruction:~anterior cruciate ligament remnant will be removed in the operation"
89127526|NCT00781105|Experimental|1|
89127527|NCT00785863|Placebo Comparator|Placebo|
89127528|NCT00785863|Active Comparator|Remifentanil|
89127529|NCT00785863|Active Comparator|Ketorolac and remifentanil|
89127530|NCT00785863|Active Comparator|Parecoxib and remifentanil|
89127531|NCT00879645|Experimental|Sodium Sulfide - Mild Cohort|Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.
89127532|NCT00879645|Experimental|Sodium Sulfide - Healthy Cohort|Healthy subjects received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
89127533|NCT00879645|Experimental|Sodium Sulfide - Moderate Cohort|Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
89127534|NCT00879645|Experimental|Sodium Sulfide - Severe Cohort|Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
89127535|NCT00664105|Experimental|Therapeutic Intervention|
89127536|NCT04155645|Experimental|Cohort 1|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 1 injection (8 subjects) or matching placebo (3 subjects).
89127537|NCT04155645|Experimental|Cohort 2|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 2 injection (8 subjects) or matching placebo (3 subjects).
89127538|NCT04155645|Experimental|Cohort 3|On Days 1, 8, 29, and 57, randomized subjects will receive SC dose of AZD8233 dose 3 injection (8 subjects) or matching placebo (3 subjects).
89127539|NCT04155801|Experimental|Salix Probiotic Blend|Participants will receive a Salix Probiotic Blend capsule orally once a day for 30 days.
89127540|NCT00785941|Experimental|IMC-A12|"All patients will receive intravenous infusions of IMC-A12, with the dose depending on which cohort they are enrolled into a minimum of three patients will be enrolled in each Cohort. When all patients complete a cohort, dose escalation to the next Cohort will occur.~A treatment cycle will consist of IMC-A12 administered intravenously, once every other week for 4 weeks, for a total of 2 doses; followed by a 2-week observation period."
89127541|NCT00663585|Experimental|1|Structured Intervention Group
89127542|NCT00663585|Active Comparator|2.Comparison group|Unstructured comparison group
89127543|NCT00663663|Experimental|1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
89127544|NCT00663663|Experimental|2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
89127545|NCT04155255|No Intervention|Control|Age-matched overweight and obese students were selected from control schools. The students participated in their usual health and physical education classes plus any other curriculum activities provided by the school.
89127546|NCT04155255|Experimental|Intervention|Overweight and obese students were recruited from intervention schools. Students underwent MyBFF@school intervention programme that consisted of physical activity, nutrition and psychological modules for the duration of 6 months. MyBFF@school intervention programme were conducted by trained personnel that were stationed full-time at each intervention school.
89127547|NCT00781183|Experimental|pulmonary rehabilitation|patients that are enrolled in pulmonary rehabilitation
89127548|NCT00663741|Experimental|Arm 1|
89127549|NCT00663741|Experimental|Arm 2|
89127550|NCT00663741|Experimental|Arm 3|
89127551|NCT00661687|Active Comparator|Purevision Contact Lens #1|PureVision Soft Contact Lens Design (currently marketed)
89127552|NCT00661687|Experimental|PureVision Contact Lens #2|Redesign of the currently marketed PureVision soft contact lens.
89127553|NCT04155177||begining of curriculum|trainees in obstetrics and gynecology who have achieved less than 2 years of their hole curriculum
89127554|NCT04155177||mid curriculum|trainees in obstetrics and gynecology who have achieved at least 2 years and less than 4 years of their hole curriculum
89127555|NCT04155177||Advanced|trainees in obstetrics and gynecology who have achieved at least 4 years of their hole curriculm
89127556|NCT00791245||1|DeNovo NT
89127557|NCT00663897|Experimental|1|Treatment with lansoprazole (30 mg) once daily for 14 days
89127558|NCT00663897|Active Comparator|2|Treatment with mosapride (5 mg) thrice daily for 14 days
89127559|NCT00663975|Experimental|1|DCI-1020 Capsules contain an enteric-coated buffered microspheres of pancrelipase, encapsulated in clear capsules. Capsules are equivalent to 4,000 USP units of lipase
89127560|NCT00664053|Experimental|1|DHEA and Yoga
89127561|NCT00664053|Active Comparator|2|DHEA and exercise
89127562|NCT00664053|Active Comparator|3|Placebo and Yoga
89127563|NCT00664053|Placebo Comparator|4|Placebo and exercise
89127564|NCT00664131||1|
89127565|NCT04031859|Experimental|Group A|In this group a VTE risk stratification procedure will be used
89127566|NCT04031859|No Intervention|Group B|In this group a standard VTE risk stratification procedure will be used (Caprini VTE risk assessment tool)
89127567|NCT00664287|Experimental|Group 1|Patients will remain on existing lipid-modifying therapy throughout the study. Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
89127568|NCT00664287|Placebo Comparator|Group 2|Patients will remain on existing lipid-modifying therapy throughout the study. Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
89127569|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 1|Eligible subjects will receive GSK958108 with a starting dose of 1 milligram. The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
89127570|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 2|Eligible subjects will start dosing once the cohort 1 has completed the treatment phase and the initial dose will be the same as top dose in Cohort1.The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
89127571|NCT00664443||Dispatch-assisted CPR|Emergency ambulance dispatcher interaction to provide dispatch-assisted CPR instructions in order to determine bystander CPR rates and the impact of instructions on survival to hospital discharge
89127572|NCT00664599|Experimental|1|Rituximab
89127573|NCT00664599|Active Comparator|2|Cytotoxics combination
89127574|NCT02631135|Placebo Comparator|Group 1 (TIVA)|Only propofol (started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1)
89127575|NCT02631135|Active Comparator|Group 2 (TIVA+D)|Propofol started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1),and also dexmedetomidine infusion (started as 0.5 μg.kg-1 without making the loading dose and the dose change was not made during the operation)
89127576|NCT00664677|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off).
89127577|NCT00596817|Placebo Comparator|Placebo|
89127578|NCT00596817|Experimental|Vortioxetine: 5 or 10 mg|
89127579|NCT01000649|Experimental|FE 202158 1.25|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 1.25 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
89127580|NCT01000649|Experimental|FE 202158 2.5|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 2.5 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
89127581|NCT01000649|Experimental|FE 202158 3.75|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 3.75 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
89127582|NCT01000649|Placebo Comparator|PLCBO|Patients in the arm received an intravenous infusion for up to 7 days of placebo.
89127583|NCT00664833|Experimental|Arm 2|
89127584|NCT00664833|Other|Arm 4|
89127585|NCT00664833|Experimental|Arm 3|
89127586|NCT00664833|Experimental|Arm 1|
89127587|NCT00664911|Other|Chemotherapy|chemotherapy regimen
89127588|NCT02870777|Experimental|MRD-directed therapy|
89127589|NCT04352231|Experimental|High to Low Fiber Diet Intervention|Participants receive the high fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the low fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
89127590|NCT04352231|Experimental|Low to High Fiber Diet Intervention|Participants receive the low fiber diet intervention first, then undergo a washout period to reverse any changes from the diet before receiving the high fiber diet intervention. A second washout period will follow this diet so that we can track any reversal of diet-linked changes.
89127591|NCT00911469|Experimental|1|
89127592|NCT00911469|Placebo Comparator|2|
89127593|NCT00665379|Active Comparator|1|Regular compression therapy with non elastic trico bandaging
89127594|NCT00665379|Active Comparator|2|New two layer compression bandage coban 2
89127595|NCT00879411||arterial hypertension|
89127596|NCT00665535|Other|2. High Risk|High risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 10-12)
89127597|NCT00665535|Other|1. Moderate Risk|Moderate risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 13 and 14)
89127598|NCT01000493|Experimental|Orvepitant 60 mg|60 mg/day
89127599|NCT01000493|Placebo Comparator|Placebo|
89127600|NCT00671151|Active Comparator|1|Low-dose theophylline on top of standard therapy for COPD exacerbation
89127601|NCT00671151|No Intervention|2|Standard therapy for COPD exacerbation
89127602|NCT00671229||1|African American
89127603|NCT00671229||2|Caucasian
89127604|NCT04153461|Active Comparator|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
89127605|NCT04153461|Active Comparator|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
89127606|NCT00671307|Placebo Comparator|Placebo|Placebo
89127607|NCT00671307|Experimental|Low dose|3 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
89127608|NCT00671307|Experimental|Mid-dose|6 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
89127609|NCT00671307|Experimental|High dose|6 mg/kg of rhu-pGelsolin given a an IV infusion over 1 hour once a day for 3 days
89127610|NCT00666757|Experimental|duloxetine|study drug
89127611|NCT00666757|Active Comparator|citalopram|
89127612|NCT00666757|Active Comparator|fluoxetine|
89127613|NCT00666757|Active Comparator|paroxetine|
89127614|NCT00666757|Active Comparator|sertraline|
89127615|NCT01000337|Active Comparator|sevoflurane|Volatile anesthetic
89127616|NCT01000337|Active Comparator|Propofol|Intravenous anesthetic
89127617|NCT00671385||Women 21-50 years old|Women without a diagnosis of cancer or a history of cancer.
89127618|NCT02869763|Experimental|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
89127619|NCT02869763|Experimental|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
89127620|NCT02869763|Placebo Comparator|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
89127621|NCT00671463|Experimental|1|Pre-operative pancreatic duct stenting
89127622|NCT00671463|No Intervention|2|Control group, no endoscopy and no stent pre-operatively
89127623|NCT00911703||Acute heart failure|Subjects with an ED diagnosis of acute decompensated heart failure .
89127624|NCT02629653|Other|Single arm|The endovascular cooling system will be Zoll IVTM. This system consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585)
89127625|NCT00671697|Experimental|Dose Level 1 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
89127626|NCT00671697|Experimental|Dose Level 2 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
89127627|NCT00671697|Experimental|Dose Level 3 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
89127628|NCT00666679|Active Comparator|1|mometasone
89127629|NCT00666679|Placebo Comparator|2|montelukast followed by placebo; or placebo followed by montelukast.
89127630|NCT04031781|Active Comparator|Receiving repetitive transcranial magnetic stimulation (rTMS)|This group received 5 rTMS sessions, delivered over one week over the left dorsolateral prefrontal cortex (LDLPFC ) at 5-Hz frequency and 100% motor threshold intensity.
89127631|NCT04031781|Placebo Comparator|Group receiving placebo rTMS|This group received Placebo rTMS was given with the same stimulation frequency at a fixed intensity of 50% of the machine output
89127632|NCT00786097|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
89127633|NCT00786253|Experimental|Arm 1|
89127634|NCT00786253|Experimental|Arm 2|
89127635|NCT02556073|Active Comparator|Usual care|"Usual care means that intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed acts as asthma controller and patients will be scheduled to revisit clinics."
89127636|NCT02556073|Experimental|Usual care+Smartphone action|Intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed and Smartphone action, which provides the real-time health information of surroudings and actively remind the patients to use controller.
89127637|NCT00595413|Experimental|Atacicept 150 mg with loading dose|
89127638|NCT00595413|Experimental|Atacicept 150 mg without loading dose|
89127639|NCT00595413|Active Comparator|Adalimumab|
89127640|NCT00595413|Placebo Comparator|Placebo|
89127641|NCT00781261|Placebo Comparator|Control|Subjects in the control group will receive a placebo drug for a 1 year period
89127642|NCT00781261|Active Comparator|Zoledronic Acid|Subjects in this intervention group will be given 5mg Zoledronic acid as a single injection
89127643|NCT02629497|Experimental|Healthy subjects for Omega-6 protection|Platelets from healthy donors will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
89127644|NCT02629497|Experimental|T2DM patients for Omega-6 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
89127645|NCT02629497|Active Comparator|Healthy control for Omega-3 protection|Platelets from healthy donors will be assessed for regulation by Fish Oil (omega-3 fatty acid).
89127646|NCT02629497|Active Comparator|T2DM for Omega-3 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Fish Oil (omega-3 fatty acid).
89127647|NCT02554825|Experimental|Healthy Futures|
89127648|NCT02554825|Other|Control|
89127649|NCT00671775||Bariatric surgery patients|
89127650|NCT00671775||Weight loss programs|
89127651|NCT00786331|Active Comparator|A|Monochemotherapy
89127652|NCT00786331|Experimental|B|Combination chemotherapy
89127653|NCT01000025|Active Comparator|PF-00299804|Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89127654|NCT01000025|Placebo Comparator|Placebo|Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89127655|NCT00595335|Experimental|Rituximab|Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion.
89127656|NCT00595335|Placebo Comparator|Placebo|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
89127657|NCT00781417|Active Comparator|1|Cholecalciferol 50,000 IU once a week for 12 weeks then every other week for 40 weeks
89127658|NCT00781417|Placebo Comparator|Placebo|Placebo
89127659|NCT00781495||type 2 diabetes mellitus|
89127660|NCT00672087||A|Chronic prostatitis/chronic pelvic pain syndrome patients
89127661|NCT00672087||B|Painful bladder syndrome/interstitial cystitis patients
89127662|NCT00672087||C|Asymptomatic controls
89127663|NCT04279691||periodontitis and rheumatoid arthritis|group 1: patiernts with periodontitis and rheumatoid arthritis. only
89127664|NCT04279691||periodontitis|group 2: patiernts with periodontitis
89127665|NCT00672165|Experimental|1|This is a phase I, dose-escalation trial. The starting dose level will be 0.5 μCi/kg of 225Ac-HuM195. Three to six patients will be treated at each dose level, and dose escalation will proceed if less than 33% of patients in a cohort experience dose limiting toxicity. Six patients will be treated at the maximum tolerated dose
89127666|NCT00661609|Experimental|AZD4877|Single agent AZD4877
89127667|NCT04153071|Experimental|Unipolar microplasma RF treatment|Single cutaneous unipolar microplasma RF treatment, with variable treatment parameters
89127668|NCT00672399|Experimental|Sequence 1|Period 1 = placebo exenatide/placebo moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
89127669|NCT00672399|Experimental|Sequence 2|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
89127670|NCT00672399|Experimental|Sequence 3|Period 1 = placebo exenatide/moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/placebo moxifloxacin
89127671|NCT00672399|Experimental|Sequence 4|Period I = placebo exenatide/moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
89127672|NCT00672399|Experimental|Sequence 5|Period I = placebo exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/moxifloxacin
89127673|NCT00672399|Experimental|Sequence 6|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
89127674|NCT00661531|Experimental|Estrace & Anastrozole|Estrace 10 mg three times a day for 3 months. After 3 months of estrace, the estrace will be stopped and anastrazole 1 mg daily will be administered
89127675|NCT00998309||Azithromycin SR|Patients taking Azithromycin.
89127676|NCT00791791|Other|1|increasing remifentanil administration
89127677|NCT00791791|Other|2|decreasing remifentanil concentration
89127678|NCT02629185||normal weight|BMI 18.5 to 25.0 Healthy men and women ages 25-40 and 55-75
89127679|NCT02629185||overweight|BMI 25.0 to 30.0 Healthy men and women ages 25-40 and 55-75
89127680|NCT02629185||obese|BMI over 30.0 Healthy men and women ages 25-40 and 55-75
89127681|NCT00781573|Experimental|1|Clopidogrel (75 mg/day) is continued for another year at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
89127682|NCT00781573|No Intervention|2|Clopidogrel (75 mg/day) is stopped at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
89127683|NCT00672711||C|APS
89127684|NCT00672711||B|HPS
89127685|NCT00672711||A|LPS
89127686|NCT04293965|Experimental|Single Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in a single dose to assess the safety, tolerability, PK and PD profile of X842.
89127687|NCT04293965|Experimental|Multiple Ascending Dose Study|Healthy subjects will be screened and different doses of X842 will be administered in multiple doses to assess the safety, tolerability, PK and PD profile of X842. The dose ascending at this stage will be based on the results of the single dose tolerability study.
89127688|NCT04293965|Experimental|Food Effect Study|A randomized, open label, single-dose, self-controlled, double-cycle, two-way crossover clinical trial.
89127689|NCT00672789|Experimental|1|Blood Smear Education
89127690|NCT00672789|Active Comparator|2|Standard education
89127691|NCT00671541|Active Comparator|Merogel stent vs. Nasopore Stent|This study has two arms consiting of 50 subjects each (100 total) Arm 1 will recieve the standard stent (merogel)in their right sinus and a nasopore stent in their left sinus.
89127692|NCT00671541|Experimental|bacitracin vs. gentamicin treated stent|The second arm will consist of 50 new subjects. These 50 subjects will have a nasopore stent placed in the left sinus. The first 25 subjects will have nasopore stent placed postoperatively with a bacitracin soaked nasopore in right sinus the second 25 will have a gentamycin soaked nasopore stent in right sinus.
89127693|NCT00781729|Experimental|1|Yoga, one hour class, 3 times per week, for 24 weeks
89127694|NCT00781729|Placebo Comparator|2|Luncheon Seminar Series, once per month, for 24 weeks
89127695|NCT04152681|Experimental|Assigned Interventions|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
89127696|NCT00999713|Experimental|Calfactant|Endotracheal calfactant administration
89127697|NCT00999713|Placebo Comparator|Placebo (air)|Endotracheal air administration
89127698|NCT00781807|Experimental|1|The prospective intervention group with nutrition management, home-based bicycle ergometer training program and psychosocial support
89127699|NCT04053309||Males undergoing TESE or microTESE|All male patients undergoing surgical sperm extraction (TESE or microTESE) procedures as part of an IVF cycle at our center will be reviewed for inclusion and offered participation in the study. These men have been previously consented to the TESE or microTESE procedure at our center. The study will utilize the otherwise discarded round spermatids found in the TESE and microTESE surgical samples as the study samples being used for the ROSI procedure.
89127700|NCT00672867|Experimental|1|Clevudine
89127701|NCT00672867|Active Comparator|2|Adefovir
89127702|NCT00786721||Diffuse Optical Spectroscopy|muscle properties scanning
89127703|NCT00997373|Experimental|Letrozole|letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
89127704|NCT00997373|No Intervention|control|no treatemtn prior to hysterectomy
89127705|NCT04152759|Experimental|BAT2506 injection|50mg ；subcutaneous injection
89127706|NCT04152759|Active Comparator|Sinponi(EU-licensed)|50mg ；subcutaneous injection
89127707|NCT04047043||Taurine > 30 μmol/L|serum taurine level
89127708|NCT04047043||Taurine 30-20 μmol/L|serum taurine level
89127709|NCT04047043||Taurine < 20 μmol/L|serum taurine level
89127710|NCT00672945|Experimental|PRX-03140|
89127711|NCT00672945|Placebo Comparator|Placebo|
89127712|NCT02869607||Patients with breast cancer diagnosis|
89127713|NCT00786877|Experimental|Improved biomass cookstove with exterior ventilation|"In phase 1, installation of an improved cookstove with ventilation to exterior is the active arm.~In phase 2, this improved biomass cookstove is the control arm."
89127714|NCT00786877|No Intervention|Traditional cookstove|In phase 1, the control arm is the traditional standard open burning cookstove in house.
89127715|NCT00786877|Experimental|Phase 2 invervention arm (LPG stove)|In phase 2 of this project, households are individually randomized to either continuation of the improved biomass stove from phase 1, or a new LPG stove and gas for 12 months.
89127716|NCT04293731|Active Comparator|Symbiter-Smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
89127717|NCT04293731|Placebo Comparator|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day
89127718|NCT00673023|Experimental|1|
89127719|NCT00673023|Experimental|2|
89127720|NCT00673023|Experimental|3|
89127721|NCT02870231|Experimental|NNC9204-0530 / Placebo and Liraglutide 1.8|
89127722|NCT02870231|Active Comparator|NNC9204-0530 /Placebo and Liraglutide 3.0|
89127723|NCT02554747|Experimental|Navigated laser|Aflibercept, Navilas®
89127724|NCT02554747|Active Comparator|Conventional laser|Aflibercept, Pascal
89127725|NCT00911781||Infants with infantile hemangiomas|
89127726|NCT00663871|Active Comparator|Fish Oil|Participants will take fish oil supplements daily for 4 months.
89127727|NCT00663871|Placebo Comparator|Placebo|Participants will take soybean oil (placebo) supplements daily for 4 months.
89127728|NCT02869919||Patients with AKI|critically ill patients with acute kidney injury
89127729|NCT02869919||Patients without AKI|critically ill patients without acute kidney injury
89127730|NCT04152447|No Intervention|Standard of care|This arm describes the standard protocol used to aid in orthopedic recovery.
89127731|NCT04152447|Active Comparator|VR device|Patients randomly assigned to the experimental arm of the study were provided an Oculus Go™ device for the duration of their hospitalization. The device featured a headset with a 1280 x 1440, 60 Hz refresh rate LCD display, spatial audio (via built-in speakers; headphones were not provided or used to our knowledge, despite compatibility) and the ability to track 3 degrees of rotational freedom; it was compatible with glasses and included a soft, adjustable strap for optimal, user-based fit. A single controller, capable of recognizing hand motion, pointing, and clicking was also included.
89127732|NCT00628979|Other|1|CBT
89127733|NCT02629029|Other|Surgical - therapeutic free flap|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will be imaged using two systems: (i) pre-operative CTA with IV contrast; (ii) intra-operative fluorescence endoscopy with ICG.
89127734|NCT02870075|Active Comparator|Fed exercise|Fed prior to exercise
89127735|NCT02870075|Active Comparator|Fasted exercise|Fasted prior to exercise
89127736|NCT02629341|Active Comparator|Functional yogurt powder|This arm will receive one daily serving of the functional yogurt which is enriched in Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the Lactobacillus plantarum 3547 probiotic
89127737|NCT02629341|Placebo Comparator|Control yogurt powder|This arm will receive one daily serving of the control yogurt which consists of a regular yogurt not enriched
89127738|NCT02869997|Experimental|Single arm|arm wherein all patients Suppression Ratio evaluated by BIS will be collected
89127739|NCT00782041|Experimental|1|Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
89127740|NCT00673491|Experimental|1|Patients treated according to clinical pathways
89127741|NCT00673491|No Intervention|2|Patients treated according to usual care
89127742|NCT00787033|Experimental|1|Dose escalation study with Expansion Cohorts at RP2D and Schedule
89127743|NCT00792181|Experimental|1|Medical intervention - with benzodiazepines (Midazolam).
89127744|NCT00792181|Experimental|2|Course intervention - a professional development course for caregivers.
89127745|NCT00792181|Experimental|3|Combination of both medical interventions and a professional development course for caregivers.
89127746|NCT00792181|No Intervention|4|No intervention at all = a control group
89127747|NCT00673647|Experimental|1|Individual psychotherapy including cognitive behavioral components, motivational interviewing techniques and case management
89127748|NCT00673647|No Intervention|2|Delayed treatment control group
89127749|NCT00792337|Active Comparator|simvastatin|simvastatin in combination with budesonide
89127750|NCT00792337|Placebo Comparator|B1-6-12|Budesonide in combination with B1-6-12
89127751|NCT00673725|Experimental|1|
89127752|NCT00787111|Experimental|Fluoxetine ODT|Fluoxetine ODT ranging from 2mg to 54mg
89127753|NCT00673803|Other|A|cataract surgery, implantation of a Polylens Y10
89127754|NCT00673803|Other|B|cataract surgery, implantation of a Polylens Y30
89127755|NCT04152525|Experimental|experimental group|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
89127756|NCT04152525|No Intervention|control group|Routine care
89127757|NCT00782197|Experimental|1|PRGF
89127758|NCT00782197|Active Comparator|2|Hyaluronic Acid
89127759|NCT04152291|Experimental|E-EPA-diet group|All the study participants will receive the same treatment. 3.9g of E-EPA in capsules, which include 75µg of D3-vitamin, daily for 30 days.
89127760|NCT00792415||1|Limited continuous opioid exposure (at least 120 and less than 156 hours)
89127761|NCT00792415||2|Extended continuous opioid exposure (156 hours or more)
89127762|NCT02628717||SOF/SMV|SOF/SMV 400mg/150mg QD 12-24 weeks
89127763|NCT02628717||SOF/DCV|SOF/DCV 400mg/60mg QD 12-24 weeks
89127764|NCT02628717||SOF/LDV|SOF/LDV 400mg/90mg QD 12-24 weeks
89127765|NCT02628717||treatment duration|12 - 24 weeks
89127766|NCT00782353|Experimental|Cohort 1|Subjects randomized 8:2 (active:placebo) to receive ANA598 200 mg bid
89127767|NCT00782353|Experimental|Cohort 2|Subjects randomized 8:2 (active:placebo) to receive ANA598 400 mg bid
89127768|NCT00782353|Experimental|Cohort 3|Subjects randomized 8:2 (active:placebo) to receive ANA598 800 mg bid
89127769|NCT00996593|Experimental|open-label, single arm|
89233860|NCT00467259|Experimental|Testosterone|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
89233861|NCT00816881|Experimental|1|flutter mucus clearance device
89233862|NCT00816881|No Intervention|2|Observation
89233863|NCT01022151|Placebo Comparator|Placebo [group P]|
89127770|NCT00570661|Experimental|ITF2357|"ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength (dose strengths of 7.5, 10, 12.5, 15, 20 mg and 50 mg).~Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity"
89127771|NCT00787345|Other|Surgery residents|general surgery residents undergoing evaluation and training in MBP during CVC placement as per department policy are eligible for the study.
89127772|NCT02870153|Experimental|SOX(oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
89127773|NCT02870153|Active Comparator|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
89127774|NCT00934544|Experimental|Ruxolitinib|5 mg tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
89127775|NCT00934544|Active Comparator|Best Available Therapy (BAT)|"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.~Patients randomized to BAT were eligible to cross over to receive open-label ruxolitinib after a qualifying progression event, if they met the safety criteria. After the primary analysis in January 2011, patients randomized to receive BAT were allowed to cross over to receive ruxolitinib and move to the extension phase of the study without a qualifying progression event."
89127776|NCT02554669|No Intervention|Control|No physical activity
89127777|NCT02554669|Experimental|Postabsorptive physical activity|Physical activity performed before breakfast
89127778|NCT02554669|Experimental|Postprandial physical activity|Physical activity performed in the postprandial period after breakfast
89127779|NCT00787501|Active Comparator|SSRIs|Selective Serotonin Reuptake Inhibitors
89127780|NCT00787501|Active Comparator|CBT|Cognitive Behavior Therapy
89127781|NCT00792493|Experimental|ORM-12741|
89127782|NCT00792493|Placebo Comparator|Placebo|
89127783|NCT00792649||1|screening colonoscopy with HD+ endoscopes
89127784|NCT00792649||2|screening colonoscopy with standardvideoendoscopes
89127785|NCT05325320|Experimental|Stigma Reduction Intervention|Participants randomized to the experimental condition will receive the SMI/SIA Stigma Reduction Intervention.
89127786|NCT05325320|Other|Disaster Preparedness Course|Participants randomized to the control condition will receive a Disaster Preparedness Course, addressing the basics of natural disaster preparedness.
89127787|NCT00787579|Active Comparator|Bifocal spectacles|
89127788|NCT00787579|Active Comparator|Prismatic bifocals|
89127789|NCT00787579|No Intervention|Single vision spectacles|
89127790|NCT04264832||observation group|Participants were eligible if they met the Rotterdam diagnostic criteria of polycystic ovary syndrome (PCOS) and meet the inclusion and exclusion criteria , and all study participants received questionnaires and underwent the physical, transvaginal ultrasound and body composition examination. Blood samples were collected for analysis of metabolic markers, metabonomics and hormones.
89127791|NCT04264832||control group|The control group participants are normal women and had no history of any type of diabetes, cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization), stage 2 hypertension , malignant disease or severe renal or hepatic disease. They accepted the same examinations as the observation group.
89127792|NCT00787657||Arm 1|
89127793|NCT04263662||Pre-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours prior to implementation of an analgesia-sedation algorithm.
89127794|NCT04263662||Post-algorithm|Patients admitted to the pediatric ICU who are intubated for greater than 24 hours after implementation of an analgesia-sedation algorithm.
89127795|NCT00999167|Experimental|HPN-100|
89127796|NCT00999167|Placebo Comparator|Placebo|
89127797|NCT04251338||delayed visual maturation|children with delayed visual maturation
89127798|NCT00787735|Experimental|Integrated Care|Integrated Substance Abuse and Psychiatric Care (ISAP). Subjects received both their substance abuse and psychiatric care within the ATS clinic. Counseling compliance will be measured over time.
89127799|NCT00787735|Active Comparator|Parallel Care|Parallel Substance Abuse and Psychiatric Care (PSAP). Subjects received their substance abuse treatment at the ATS clinic. Their psychiatric care was received at Community Psychiatry. Counseling compliance will be measured over time.
89127800|NCT04264754||Cases Group|Subjects who have already been diagnosed with liver cancer, however did not yet undergo any surgery, ablation, embolization or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
89127801|NCT04264754||Control Group|"Cancer free subjects with high risk to development HCC. High risk subjects include the following:~Subjects with HCV (hepatitis C virus) and cirrhosis~Subjects with HBV (hepatitis B virus) and cirrhosis~Non-cirrhotic chronic HBV subjects at intermediate or high risk of HCC, according to EASL (European Association for the Study of the Liver) Clinical Practice Guidelines for the management of hepatocellular carcinoma~Subjects with NAFLD (Non-Alcoholic Fatty Liver Disease) with cirrhosis~Cirrhotic patients due to any other reasons, including alcohol disease"
89127802|NCT00782587|Experimental|Arm 1|Single arm, open label, single dose, intravesical instillation of Chemophase (combination of rHuPH20 and mitomycin) for appropriate superficial bladder cancer patients within 6 hours of TURBT.
89127803|NCT04293497|Experimental|Pancreatic Cancer|This arm includes patients with pancreatic cancer. Cytology specimens will be obtained with endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer. Cytology staining will be performed in the cytology specimens.
89127804|NCT04264676|Active Comparator|Metronidazole|supplement of metronidazole 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6(6 treatments totally),and every 6 weeks for CapeOX (4 treatments totally).
89127805|NCT04264676|Placebo Comparator|Placebo|supplement of identical-appearing placebo 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6 (6 treatments totally),and every 6 weeks for CapeOX 4 treatments totally).
89127806|NCT02869373|Experimental|Exercise|spinal stabilization exercise program was applied
89127807|NCT02869373|No Intervention|Control|
89127808|NCT00608660|Experimental|A|staging acupuncture for treating Bell's Palsy
89127809|NCT00608660|Experimental|B|staging acupuncture and moxibustion for treating Bell's Palsy
89127810|NCT00608660|Experimental|C|staging electroacupuncture for treating Bell's Palsy
89127811|NCT00608660|Experimental|D|staging acupuncture along Yangming musculature for treating Bell's Palsy
89127812|NCT00608660|Experimental|E|non-staging acupuncture for treating Bell's Palsy
89127813|NCT00782665|Active Comparator|Group 1|Patients who have labored and subsequently delivered by cesarean section
89127814|NCT00782665|Placebo Comparator|2|Patients who electively select cesarean section
89127815|NCT00607412|Experimental|1|Present focused, integrated psychotherapy for PTSD and substance use disorders
89127816|NCT00607412|Active Comparator|2|Supportive therapy using 12-step model
89127817|NCT00609440|Other|A|A single case study, of a patient that was submitted to a physiotherapeutic treatment.
89127818|NCT00570505|Experimental|LapBand|All subjects who receive the LAP-BAND System.
89127819|NCT05136482|No Intervention|Control|Participants will wear the cryocompression device for 30 mins without any cold or pressure being applied to the lower limb by the cuff.
89127820|NCT05136482|Experimental|Condition A|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 6℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
89127821|NCT05136482|Experimental|Condition B|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 8℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
89127822|NCT05136482|Experimental|Condition C|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 10℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
89127823|NCT05136482|Experimental|Condition D|Participants will wear the cryocompression device for 30 minutes while ice-water at a temperature of 12℃ and a pressure of 25 mmHg is applied to the lower limb by the cuff.
89127824|NCT02869529||Chronic lymphatic leukemia diagnosis|
89127825|NCT02555995|Experimental|All study participants|Patient's eyes are OCT-scanned with standard device and investigational device.
89127826|NCT00782743||1|patients with required new anticoagulation with phenprocoumon 1/2 of them with a GFR< 60 ml/min and >15 ml/min
89127827|NCT00782743||2|patients with required therapy with ASS, 1/2 of them with a GFR <60 ml/min and >15 ml/min
89127828|NCT00931892|Experimental|Low gluten group|Subjects will eat 3g of gluten per day
89127829|NCT00931892|Experimental|High gluten group|Subjects will eat 10g of gluten per day
89127830|NCT00666211|Active Comparator|Standard of Care|Standard pain control drugs.
89127831|NCT00666211|Experimental|Opioid Titration|Pain will be Monitored and Medication Titrated
89127832|NCT05331326|Experimental|HER2 Positive|Drug: RC48-ADC 2.0 mg/kg (HER2 Positive) 32 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
89127833|NCT05331326|Experimental|HER2 Low Expression|Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression) 32 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
89127834|NCT00782899||1|Schizophrenic patients with a acute episode treated in outpatients clinics
89127835|NCT00878709|Experimental|Neratinib|240 mg orally daily for one year
89127836|NCT00878709|Placebo Comparator|Placebo|orally daily for one year
89127837|NCT00927758|Active Comparator|Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
89127838|NCT00927758|Active Comparator|Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
89127839|NCT00927758|Active Comparator|Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
89127840|NCT00927758|Active Comparator|Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
89127841|NCT00927758|Active Comparator|Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
89233864|NCT01022151|Active Comparator|Aminophylline 2 mg/Kg [group A2]|
89233865|NCT01022151|Active Comparator|Aminophylline 3 mg/Kg [group A3]|
89233866|NCT01022151|Active Comparator|Aminophylline 4mg/Kg [group A4]|
89127842|NCT00927758|Active Comparator|Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
89127843|NCT00782977|Sham Comparator|1|Nasal cannulae with no oxygen flow
89127844|NCT00782977|Active Comparator|2|Nasal cannulae with oxygen flow at 5 L/minute
89127845|NCT00782977|Active Comparator|3|Nasal cannulae with oxygen flow at 10 L/minute
89127846|NCT05034302||Recordings|Selection criteria include individuals between the ages of 18-85 years, no major chronic illness that impair mobility and able to complete activities of daily living without assistance. We will recruit approximately equal number of men and women and 30% of the sample will be racial or ethnic minorities.
89127847|NCT00783055|Experimental|Treatment|12 weeks of individually tailored intervention programmes based on participants individual wishes for daily activities e.g.ADL, mobility, social, mental or creative that they want to improve, conserve - and/or to revive.
89127848|NCT00783445|Experimental|1|Exercise in a community setting while supervised by a coach
89127849|NCT00783445|Active Comparator|2|Self-exercise plan based on an individualized prescription after an initial fitness evaluation
89127850|NCT00783523|Active Comparator|Doxycycline|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
89127851|NCT00783523|Placebo Comparator|Placebo|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
89127852|NCT00927368|Active Comparator|Ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
89127853|NCT00927368|Active Comparator|Ultrasound guidance needle stimulation|For the ultrasound guidance and needle stimulation arm, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation
89127854|NCT00927368|Active Comparator|Ultrasound guidance+catheter stimulation|For the ultrasound guidance and catheter stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
89127855|NCT00783601|Experimental|1|Treatment Sequence 1: MK0524 + placebo, MK0524 + montelukast, placebo, placebo, placebo + montelukast
89127856|NCT00783601|Experimental|2|Treatment sequence 2: Placebo, montelukast, placebo, MK0524, MK0524 + montelukast
89127857|NCT00783679|Other|1|Twenty adult spontaneously breathing patients without intubation and mechanical ventilation recruited from the cardiac catheterization laboratory. All will be post-heart-transplant patients coming for yearly evaluation.
89127858|NCT04259840||Peri-implantitis|Patients who underwent resective surgical treatment for peri-implantitis at the University of Michigan Graduate Periodontics clinic from January 1, 1990 through July 1, 2018
89127859|NCT00783757|Experimental|Optical Imaging|Tomographic Optical Imaging Arm
89127860|NCT05331092|Experimental|Cryotherapy|20 minutes of cryotherapy on the dominant ankle with ice bags
89127861|NCT05331092|No Intervention|Control|20 minutes of rest
89127862|NCT04261868|Experimental|Virtual Reality|Dichoptic playing games with fine stimulation will present to the amblyopic eye.
89127863|NCT04261868|Active Comparator|Patching|Non- amblyopic eye will be recommended to patch.
89127864|NCT00787813|Active Comparator|1|N-Acetyl Cysteine
89127865|NCT00787813|Placebo Comparator|2|placebo
89127866|NCT04261634|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
89127867|NCT04261634|Active Comparator|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
89127868|NCT00787969|Experimental|Treatment (rituximab, cladribine, temsirolimus)|Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89127869|NCT00609596|Other|Arm 1|
89127870|NCT05007470|Experimental|Probiotic|VSL#3
89127871|NCT05007470|Placebo Comparator|Pacebo|
89127872|NCT00608816|Experimental|1|Hyperinsulinemic euglycemic glucose clamp study on day 1 Hyperinsulinemic euglycemic clamp study on day 2 with epinephrine infusion
89127873|NCT00608816|Experimental|2|Hyperinsulinemic hypoglycemic glucose clamp x 2 on day 1 Hyperinsulinemic euglycemic clamp with epinephrine infusion on Day 2
89127874|NCT02535273|Experimental|Low-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery"
89127875|NCT02535273|Experimental|Moderate-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery"
89127876|NCT02535273|Experimental|High-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery"
89127877|NCT02535273|Placebo Comparator|normal saline Control group|Intravenous injection normal saline equal quantity，completed within 10 minutes. Local anesthesia: lidocaine Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
89127878|NCT05006066||Healthy volunteers - Pain-Free|"Each participant will be stimulated with 4 temporal summation stimulation conditions:~continuous thermal (1 stimulation of two minutes)~repetitive thermal (30 stimulations of 1 second)~continuous mechanical (1 stimulation of two minutes)~repetitive mechanical (30 stimulation of 1 second)"
89127879|NCT00788047|Other|Regimen A (Reference)|
89127880|NCT00788047|Experimental|Regimen B (Test)|
89127881|NCT04152369|Active Comparator|24 hour prophylaxis|In this group patients received a AMP for the day of the procedure
89127882|NCT04152369|Active Comparator|72 hour prophylaxis|In this group patients received a AMP one day prior, on the day of the procedure and the following day.
89127883|NCT00788203||5-keys program|Counseling re family feeding behaviors.
89127884|NCT00788203||Lifestyle counseling|Counseling re healthy eating for child and family
89127885|NCT00674037|Experimental|inclusion with financial motivation|75 euros for each patient included
89127886|NCT00674037|No Intervention|no incentive|no incentive
89127887|NCT05331014|Experimental|JW0101+C2101|LivaloVA
89127888|NCT05331014|Active Comparator|JW0101+C2102|LivaloV
89127889|NCT05331014|Active Comparator|C2101|VA
89127890|NCT00788281|Experimental|A|laparoscopic surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
89127891|NCT00788281|Active Comparator|B|open surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
89127892|NCT04259684|Experimental|gNO Group|Participants in the treatment group will receive gNO added to the oxygenator gas flow at 20 ppm throughout the duration of cardiopulmonary bypass.
89127893|NCT04259684|No Intervention|Control Group|Participants in the control group will receive standard conduction of cardiopulmonary bypass.
89127894|NCT00788515|Experimental|1|
89127895|NCT00788515|Active Comparator|2|
89127896|NCT04259606|Active Comparator|Cassia Cinnamon|Cassia cinnamon, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
89127897|NCT04259606|Placebo Comparator|Calcined Magnesia|Placebo consists in calcined magnesia, capsule of 1 gram each, taken every 8 hours before meals for 90 days.
89127898|NCT00788749|Placebo Comparator|Placebo|Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
89127899|NCT00788749|Experimental|Prednisolone|25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months
89127900|NCT00609752|Active Comparator|1|
89127901|NCT00609752|Active Comparator|2|
89233867|NCT01022151|Active Comparator|Aminophylline 5 mg/Kg [group A5]|
89127902|NCT00662857|Experimental|1: TI Inhalation Powder A|Technosphere® Insulin Inhalation Powder, two 15 U cartridges
89127903|NCT00662857|Experimental|2: TI Inhalation Powder B|Technosphere® Insulin Inhalation Powder, one 30 U cartridge
89127904|NCT00662857|Experimental|3: RAA Population|Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro
89127905|NCT04261400|Experimental|MAMAACT|Post graduate training of midwives in intercultural communication and health education materials for the pregnant women.
89127906|NCT04261400|No Intervention|Control|Care as usual
89127907|NCT00788905|Experimental|A|"Subject will continue conventional hemodialysis therapy for one week (no intervention phase) and then swtich to the Allient system for two weeks (active comparator phase)."
89127908|NCT00878553|Placebo Comparator|Placebo|Two placebo tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
89127909|NCT00878553|Experimental|10 mg SKP-1041|One 10 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
89127910|NCT00878553|Experimental|15 mg SKP-1041|One 15 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
89127911|NCT00878553|Experimental|20 mg SKP-1041|Two 10 mg SKP-1041 controlled release zaleplon tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
89127912|NCT05220020|Experimental|Experimental group|Synchronous treatment group: the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.
89127913|NCT05220020|Active Comparator|Control group|Sequential treatment group: patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
89127914|NCT00996437|Placebo Comparator|Saline Injection|Saline injection at baseline, 4 and 8 weeks
89127915|NCT00996437|Active Comparator|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
89127916|NCT00789139|Other|AF monitoring by ICM|Only one arm
89127917|NCT04985396|Experimental|Platelet Rich Plasma (PRP) group|The PRP will be prepared based on the Sengodan et al, 2020 study.
89127918|NCT04985396|Active Comparator|Steroid group|"Steroid group will be treated with steroid injection. In this group, 2ml of Inj. Depo-Medrol 80 mg (Methylprednisolone) along with 1 ml lignocaine (0.25%) will be loaded in 5cc syringe and then the cocktail will be injected into medial calcaneal tuberosity at the most tender point using an aseptic technique as mentioned by Nishanth et.at,2018.~After the procedure, participants will be advised not to involve in any kind of rigorous activity with the affected foot for at least two days and then gradually return to their regular activities. All patients will be counseled to follow up in the next visit at 3 months and 6 months. The end-line information will be again recorded at 3 months and 6 months."
89127919|NCT00789217|Active Comparator|In-house penicillin testing preparation|In-house penicillin testing prepared from alkali-treated penicillin G
89127920|NCT00789217|Active Comparator|Commercial penicillin test kit|Commercial penicillin test kit order from Diater company
89127921|NCT00789217|Active Comparator|Penicillin G Sodium|Penicillin G Sodium from routine clinical use
89127922|NCT00783991||IVR-PC|This group will have instruments administered through interactive voice response (IVR) and personal computer (PC).
89127923|NCT00783991||PP-PC|This group will have instruments administered through paper and pencil (PP) and PC.
89127924|NCT00783991||PDA-PC|This group will have instruments administered by personal digital assistant (PDA) and PC.
89127925|NCT00783991||PC-PC|This group will have all instruments administered through PC.
89127926|NCT00609830|Experimental|Tailored Materials|
89127927|NCT00609830|Experimental|Physician Feedback|
89127928|NCT00609830|Active Comparator|Generic Materials|
89127929|NCT00609830|Placebo Comparator|Placebo Comparator|Participants receive no information
89127930|NCT00674193||Observational (pharmacological study)|Patients undergo blood and urine collection prior to, periodically during, and after treatment with dactinomycin and vincristine for pharmacokinetic, pharmacodynamic, and pharmacogenetic analysis. Samples are analyzed using a liquid chromatography-tandem mass spectrometry assay. Genomic DNA extracted from peripheral blood mononuclear cells is isolated and analyzed by polymerase chain reaction and genotyping assays for genetic variation in genes relevant to the pharmacology of dactinomycin and vincristine.
89127931|NCT04968379|Experimental|Ferric Carboxymaltose|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 5.0 mg/kg dose of FCM
89127932|NCT04968379|Experimental|Injectafer|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 7.5 mg/kg dose dose of FCM.
89127933|NCT04263506|Experimental|Vignette with supervisor's opinion|Participants in this arm will receive vignettes with an additional sentence describing supervisor's opinion (i.e. supervisor does not oppose to detrimental research practice)
89127934|NCT04263506|Active Comparator|Vignette without supervisor's opinion|Participants in this arm will receive vignettes without an additional sentence describing supervisor's opinion.
89127935|NCT00784069|Experimental|1|Lactic Acid (Dermacyd Breeze)
89127936|NCT00674271||Diabetics|100 patients with newly diagnosed (<5 years since diagnosis) type 2 diabetes referred from general practitioners to Medical Department M, Aarhus University Hospital, Denmark.
89127937|NCT00674271||Controls|100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects matched for age and gender
89127938|NCT02628951|Experimental|Ramucirumab + Paclitaxel|"Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.~Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason."
89127939|NCT00662311|Experimental|Treatment (vorinostat with paclitaxel and radiotherapy)|Patients receive vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.
89127940|NCT00929708|Experimental|1|AZD3199 low dose
89127941|NCT00929708|Experimental|2|AZD3199 intermediate dose
89127942|NCT00929708|Experimental|3|AZD3199 high dose
89127943|NCT00929708|Active Comparator|4|Formoterol 2x4.5 microgram bid
89127944|NCT00929708|Placebo Comparator|5|Placebo
89127945|NCT00674427|Experimental|CR|Subjects who are in CR ater 6-12 weeks after aDLI
89127946|NCT00674427|Experimental|Not in CR|Subjects not in CR after 6-12 weeks after aDLI
89127947|NCT00789295|Active Comparator|Mediterranean diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%)
89127948|NCT00789295|Active Comparator|Low-Carbohydrates diet|Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)
89127949|NCT00674505|Other|Treatment, Open label, Single Group Assignment|
89127950|NCT02628795|Experimental|PRT + FM|Progressive resistance training + functional mobility training 3 d/wk x 16 wk
89127951|NCT02628795|Active Comparator|Usual Care|Post-surgical usual care including physical therapy
89127952|NCT04261322|Experimental|rabies patient 1|not received immunoglobulins and symptomatic
89127953|NCT04261322|Experimental|rabies patient 2|received immunoglobulins and symptomatic
89127954|NCT04261322|Experimental|rabies patient 3|not received immunoglobulins and not yet symptomatic
89127955|NCT04261322|Experimental|rabies patient 4|received immunoglobulins and not symptomatic
89127956|NCT00792883||patients ARDS|142 Patients in respiratory failure with a diagnosis of ARDS hospitalized at the ICU.
89127957|NCT00792883||Patients non ARDS|432 patients in respiratory failure from other causes (ARDS being formally excluded), hospitalized at the same ICU.
89127958|NCT00792883||Healthy controls|626 healthy patients undergoing elective surgery at the Pediatric Surgery Department or recruited from the pediatric ambulatory.
89127959|NCT00674895|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
89127960|NCT00609908|Active Comparator|A1|Acute Burn Wounds: Wound debridement and split skin grafting
89127961|NCT00609908|Experimental|A2|Acute Burn Wounds: excision of the burn wound and primary closure, using a skin stretching device
89127962|NCT00609908|Active Comparator|B1|Scar reconstruction: serial excision
89127963|NCT00609908|Experimental|B2|Scar reconstruction: primary closure, using skin stretching device
89127964|NCT00789451|Sham Comparator|1|no ischaemia - only sham. Blood pressure cuff inflation up till 10 mmHg on the upper arm for 20 mins.
89127965|NCT00789451|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated around the upper arm for 20 minutes to induce ischaemia.
89127966|NCT00996281|Experimental|Azilsartan Medoxomil and Chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks.~For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg."
89233868|NCT01022151|Active Comparator|Doxapram 1 mg/kg [group D]|
89233869|NCT01022229|Experimental|Compound Natural Health Product|15 study participants who will receive the compound natural health product.
89233870|NCT01022229|Placebo Comparator|Placebo|15 participants will receive placebo natural health product.
89127967|NCT00996281|Active Comparator|Olmesartan Medoxomil and Hydrochlorothiazide QD|"Participants in the United States:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg.~Participants in Europe:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg."
89127968|NCT04259528|Experimental|Patients with esophageal stricture following surgical repair|Patients with esophageal atresia following surgical repair who developed an esophageal stricture
89127969|NCT04046653|Experimental|Study arm 1|Allin capsules (x2) and Sulforaphane capsules (x2) once daily for 4 weeks
89127970|NCT04046653|Experimental|Study arm 2|Allin capsules (x2) and placebo capsules (x2) once daily for 4 weeks
89127971|NCT04046653|Experimental|Study arm 3|Sulforaphane capsules (x2) and placebo capsules (x2) once daily for 4 weeks
89127972|NCT04046653|Placebo Comparator|Study arm 4|Placebo capsules (x4) once daily for 4 weeks
89127973|NCT00675129|Experimental|1|Dialectical behavioral therapy
89127974|NCT00675129|Active Comparator|2|Enhanced Usual Care (standard care plus monitoring and patient safety protocol implemented)
89127975|NCT04259294|Experimental|Telerehabilitation group via mobile apps|The experimental group will receive home-based treatment program through mobile apps
89127976|NCT04259294|Active Comparator|Control group via paper and pencil instructions|The control group will receive treatment via written home program sheets
89127977|NCT04293887|Experimental|Standard therapy + interferon therapy|Standard treatment + recombinant human interferon α1β 10ug Bid was administered by nebulization for 10 days.
89127978|NCT04293887|No Intervention|Standard therapy + blank therapy|Standard therapy
89127979|NCT04259216|Experimental|IMPACT Intervention|"Remote brief video session, introducing basic principles of cognitive behavioral theory and the structure of the mobile application message portion of the intervention.~Eight-weeks longitudinal tailored Cognitive Behavioral Therapy (CBT)-based messaging program"
89127980|NCT04259216|Active Comparator|Control Enhanced Online Resources (EOR)|1. We will provide a link to an online resource packet with information on bullying and mental health resources.
89127981|NCT00675207|Active Comparator|1|Brimonidine purite 0.15%
89127982|NCT00675207|Active Comparator|2|Dorzolamide 2%
89127983|NCT00675207|Active Comparator|3|Brinzolamide 1%
89127984|NCT00795223|Active Comparator|1|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
89127985|NCT00795223|Active Comparator|2|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
89127986|NCT00795223|Active Comparator|3|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
89127987|NCT00795223|Active Comparator|4|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
89127988|NCT00675285|Active Comparator|1|
89127989|NCT00675285|Placebo Comparator|2|
89127990|NCT04258982||AECOPD group|The study incruit AECOPD patients with type II respiratory failure who need the NIV treatment.
89127991|NCT00792961|Experimental|Endomicroscopy|Endomicroscopy is performed in addition to the patient's indicated robot-assisted prostate surgery
89127992|NCT00675363|Active Comparator|PS|Nurse-directed protocols for administering sedation and/or analgesia by continuous infusion.
89127993|NCT00675363|Active Comparator|PS + DI|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
89127994|NCT05211908|Experimental|D-SE|Absence of dentinal sclerosis and self-etching adhesive protocol
89127995|NCT05211908|Active Comparator|D-SELETIVE|Absence of dentinal sclerosis and selective enamel etching adhesive protocol
89127996|NCT05211908|Experimental|SD-SE|Sclerotic dentin and self-etching adhesive protocol
89127997|NCT05211908|Experimental|SD-SELETIVE|Sclerotic dentin and selective enamel etching adhesive protocol
89127998|NCT00795379|Experimental|IE|Participants will complete an at home four-week, intervention targeting their negative cognitions triggered by physical sensations. The goal of IE is to purposefully induce bodily sensations related to autonomic arousal so that participants can learn that those sensations are not harmful. IE and Cognitive restructuring have been found to be superior to progressive muscle relaxation as a way to avoid aversive autonomic sensations.
89127999|NCT00795379|No Intervention|2|waitlist control
89128000|NCT00996203|Experimental|1|
89128001|NCT04258748|Experimental|Motivational Interviewing (MI)|
89128002|NCT04258748|Experimental|Gaming and MI|
89128003|NCT04258748|Active Comparator|Conventional dental health education|
89128004|NCT00675519|Experimental|BI|
89128005|NCT00789763|Experimental|Sorafenib + gemcitabine + radiotherapy|
89128006|NCT05211752||Healthy young athletes (Eye-Tracker®T2 + e-VOG)|Subjects who first perform standard video-oculography assessment, followed by e-VOG digital assessment.
89128007|NCT05211752||Healthy young athletes (e-VOG + Eye-Tracker®T2)|Subjects who first perform e-VOG digital assessment, followed by the standard video-oculography assessment.
89128008|NCT00675675|Active Comparator|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training (HRT) plus functional assessment/intervention designed to identify and ameliorate environmental triggers for and consequences to tics that might serve to maintain and/or generalize these symptoms
89128009|NCT00675675|Other|Minimal Contact Waitlist|Bimonthly phone check-in to assess illness severity and maximize subject retention
89128010|NCT00793117|Experimental|1|poly vinil chloride packing
89128011|NCT00609050|Active Comparator|1|Self-Regulated Exercise with Telephone Reinforcement
89128012|NCT00609050|Active Comparator|2|Attention Control
89128013|NCT02873741||Validation Study|Participants will undergo a perianal and digital anorectal exam, a high resolution anoscopy, and cervical and anal swabs to determine the best method to identify women at high risk for anal cancer.
89128014|NCT04258670||Cross-reactive loiasis|This cohort will prospectively enroll 50 adults (age 18+) with cross-reactive antigenemia based on a positive filariasis test strip (FTS) and L. loa Mf counts >20,000 Mf/mL.
89128015|NCT04258670||non-cross-reactive loiasis|This cohort will prospectively enroll 10 adults (age 18+) with a negative filariasis test strip (FTS) and L. loa Mf counts >20,000 Mf/mL.
89128016|NCT02554357|Experimental|Exparel block in arthroscopic surgery|Evaluation of Exparel block in arthroscopic shoulder surgery.
89128017|NCT02554357|Experimental|Bupivacaine block in shoulder surgery|Evaluation of Bupivacaine block in shoulder surgery.
89128018|NCT00877929|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination
89128019|NCT00877929|Active Comparator|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
89128020|NCT00795457|Experimental|1|Patients must have undergone surgery or biopsy alone ≤16 weeks prior to study entry (no postoperative radiation or chemotherapy).
89128021|NCT00795457|Experimental|2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥6 months prior to enrollment, and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression.
89128022|NCT00931268|Other|Macrolane VRF 30|Open label, baseline-controlled, one treatment session with injection of Macrolane VRF30 to each buttock, not exceeding 400 ml per subject.
89128023|NCT00793195|Active Comparator|1) Intralipid|Fat Emulsions for Intravenous Nutrition
89128024|NCT00793195|Experimental|2) SMOFlipid|Fat Emulsions for Intravenous Nutrition
89128025|NCT00996125|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
89128026|NCT00996125|Experimental|Placebo Group|Subjects received 3 doses of placebo. Placebo vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
89128027|NCT00793273||A|
89128028|NCT04301141|Experimental|Virtual Reality Assisted Cognitive Behavioural Therapy|Between 8 to 20 individual in-person sessions of VR-assisted CBT will be delivered on a weekly basis by NHS therapists who are trained in delivering CBT to this patient group.
89128029|NCT04045951|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
89128030|NCT04045951|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
89128031|NCT05330624|Experimental|the D0- M1-M6 regimen|Adults receive three doses of 1.0 ml plague vaccine at day 0, month 1, and month 6 (referred as the D0-M1-M6 regimen).
89128032|NCT05330624|Experimental|the D0- M2-M6 regimen|Adults receive three doses of 1.0 ml plague vaccine at day 0, month 2, and month 6 (referred as the D0-M2-M6 regimen).
89128033|NCT02628639|Experimental|electroencephalography recording|Cerebral measurements from high-density electroencephalography after the presentation of personalized stimulations
89128034|NCT00610064|Other|A|Baseline neuroimaging
89128035|NCT00610064|Other|B|Neuroimaging during sacral neuromodulation
89128036|NCT04292951|Experimental|GDT group|Intraoperative fluid and inotropic/vasoactive drugs management based on information from FloTrac/EV1000
89128037|NCT04292951|Active Comparator|Control group|Intraoperative fluid and inotropic/vasoactive drugs management based on CVP, blood pressure, heart rate, and clinical signs at the discretion of attending anesthesiologists
89128038|NCT00795613|Experimental|PET pos|Patients With Interim Pet Positive Proceed To Escalated Beacopp Regimen
89128039|NCT00795613|Other|PET negative|Patients With Interim-Pet Negative Continue The Conventional ABVD Regimen
89128040|NCT00675753||Preterm group|Preterm (36 6/7 weeks gestation or earlier) mothers and their newborns.
89128041|NCT00675753||Term group|Term (> 37 weeks gestation) mothers and their newborns.
89128042|NCT04293263|Experimental|MCI patients hospitalised in the research departments|each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.
89128043|NCT04293263|Active Comparator|MCI patients hospitalized in the research departments|each of the elderly in the control group will Listen to random music twice a week for about 40 minutes each time, on personal headphones.
89128044|NCT00675831|Experimental|CD25+ Treg depleted DLI dose schema|"Patients will receive a defined dose of CD25+ Treg depleted DLI. 5 patients will be enrolled, initially at dose level B, and subsequent cohorts will be dose adjusted per the CD3+ dose escalation/de-escalation schema:~Dose level -C: 3x10^7 (CD3+Dose (#cells/kg*))~Dose level -B: 1x10^7 (CD3+Dose (#cells/kg*))~Dose level -A: 1x10^6 (CD3+Dose (#cells/kg*)) *Recipient's body weight in Kg"
89128045|NCT04263428|Experimental|Irregular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights, including an adaptation night and a baseline night of 7.5 h time in bed (0:00-7:30). Afterwards, they are instructed to sleep in bed on a schedule alternated between 6 h, i.e. 1:30-7:30, and 9 h, i.e. 22:30-7:30).
89128046|NCT04263428|No Intervention|Regular sleep|Participants sleep in lab while being monitored with polysomnography for 8 consecutive nights of 7.5 h time in bed (0:00-7:30).
89128047|NCT00800761|Active Comparator|Deferoxamine alone|comparison of deferoxamine subcutaneous 40mg/kg/die alone versus combined therapy deferoxamine-deferiprone
89128048|NCT00800761|Active Comparator|Deferoxamine plus Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
89128049|NCT04220645|Active Comparator|Standard of care|Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.
89128050|NCT04220645|Experimental|Opportunistic treatment|Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards
89128051|NCT05206136||Neck Pain Group|Patients with neck pain
89128052|NCT05206136||Low Back Pain Group|Patients with low back pain
89128053|NCT05206136||Healthy Individuals|Patients with no pain in neck or low back region
89128054|NCT05003102|Experimental|Dexmedetomidine cycling then Standard Pediatric Intensive Care Unit (PICU) sedation protocol|One the first night, participants receive a dexmedetomidine bolus of 0.5 mcg/kg which is then titrated at an increased drip rate of 0.3 mcg/kg/hr until a.) a targeted Richmond Agitation-Sedation Scale (RASS) state that is one level deeper than what was targeted during the day is achieved or b.) infusion is at max drip rate (dexmedetomidine 2 mcg/kg/hr). On the second night, participants receive the standard PICU Sedation Protocol of fentanyl infusion at 1 mcg/kg/hr and dexmedetomidine infusion at 0.3 mcg/kg/hr with no modifications made until goal RASS reached or at max infusion drips achieved (fentanyl 5 mcg/kg/hr and dexmedetomidine 2 mcg/kg/hr).
89128055|NCT05003102|Active Comparator|Standard Pediatric Intensive Care Unit (PICU) sedation protocol then Dexmedetomidine cycling|On the first night, participants will receive the standard PICU Sedation Protocol of fentanyl infusion at 1 mcg/kg/hr and dexmedetomidine infusion at 0.3 mcg/kg/hr with no modifications made until goal RASS reached or at max infusion drips achieved (fentanyl 5 mcg/kg/hr and dexmedetomidine 2 mcg/kg/hr). On the second night, participants receive a dexmedetomidine bolus of 0.5 mcg/kg which is then titrated at an increased drip rate of 0.3 mcg/kg/hr until a.) a targeted Richmond Agitation-Sedation Scale (RASS) state that is one level deeper than what was targeted during the day is achieved or b.) infusion is at max drip rate (dexmedetomidine 2 mcg/kg/hr).
89128056|NCT00676377|Experimental|1|Neostigmine
89128057|NCT00676377|Placebo Comparator|2|Placebo
89128058|NCT00795691|Experimental|Low-carbohydrate diet|The low-carbohydrate diet was based on the Atkins weight loss diet. The daily intake goals were to restrict intake of carbohydrate to 20-25 grams for the first 2-week phase. If body weight decreased, the daily goal for carbohydrate was increased by 5 grams. If body weight increased, the daily goal for carbohydrate intake was decreased by 5 grams. The minimum goal for carbohydrate intake was 20 grams per day and the maximum goal was 50 grams per day.
89128059|NCT00795691|Active Comparator|Low-fat diet|The low-fat diet was based on the algorithm used to restrict fat and calorie intake in the Diabetes Prevention Program. The daily goals for fat intake was based on an algorithm to reduce total calorie intake to achieve a one pound weight loss per week with 25% of calories from fat.
89128060|NCT00676533|Experimental|Arm 1|
89128061|NCT04261244|Experimental|Experimental Arm|preoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
89128062|NCT04261244|Active Comparator|Standard treatment|standard treatment (postoperative radiotherapy) in breast cancer after neoadjuvant chemotherapy
89128063|NCT04211363|Experimental|Rofumilast Cream 0.3%|Participants receive roflumilast cream 0.3% once daily for 8 weeks.
89128064|NCT04211363|Placebo Comparator|Vehicle cream|Participants receive vehicle cream once daily for 8 weeks.
89128065|NCT00676767|Experimental|1|
89128066|NCT00676767|Active Comparator|2|
89128067|NCT00676767|Placebo Comparator|3|
89128068|NCT04263272|Experimental|Upper Body Exercise|Seated upper body circuit training program for 16-weeks. Frequency - 1 to 3 one-hour sessions per week.
89128069|NCT00676845|Placebo Comparator|1|A 3-week placebo run-in period.
89128070|NCT00676845|Experimental|2|Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period
89128071|NCT00676845|Experimental|3|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.
89128072|NCT00676845|Experimental|4|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.
89128073|NCT04946708|Experimental|Small group zoom meeting|Group one: will be asked to follow the exercise program with a small group of peers (2 groups/6 participants each) in a zoom meeting 3 times a week/45 min each (including 5 min before and 10 min after the meeting for free talk-chat between the participants e.g. questions, perceptions, etc.).
89128074|NCT04946708|Experimental|YouTube pre-recorded video|Group two: will be asked to follow the exercise program 3 times a week/30 min each while watching a pre-recorded YouTube video.
89128075|NCT04152057|Experimental|Pyrotinib Combined With Albumin Paclitaxel and Trastuzumab|"Preoperative~-Drug: Pyrotinib Maleate Tablets combined with Albumin Paclitaxel and Trastuzumab.~Surgery:Subjects should be evaluated by tumor-enhanced MRI combined with mammary gland ultrasound during the preoperative neoadjuvant administration, and evaluated every 2 cycles. The subjects who were evaluated for CR and PR for the first time should be confirmed after at least 4 weeks. The confirmed tumor assessment cannot change the previously fixed examination time point.~Postoperative~Drug: Epirubicin hydrochloride combined with Cyclophosphamide~At the same time, according to the recommendation of the clinician, choose whether to accept the same anti-HER2 treatment plan before surgery. For patients with tumors positive for estrogen receptor (ER) and/or progesterone receptor (PR), endocrine therapy should be given at the end of adjuvant chemotherapy, and if there is clinical indication at the end of adjuvant chemotherapy, radiotherapy should be given."
89128076|NCT00610142|Active Comparator|1|
89128077|NCT00610142|Active Comparator|2|
89128078|NCT04151823|Experimental|Postbiotic &vitamin D3, lifestyle intervention.|Postbiotics will be given at the dose of 80 mg/day (2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN; immunofos from Lactobacillus paracasei CNCM I-5220). 2 mL of product will give 1600 UI/die of VIT D3. Healthy living habits will be encouraged at t0, t1 and t2 visit.
89128079|NCT00995345|Experimental|Dose 1: KRP-104 40 mg|Tablet, once-daily for 24 weeks
89128080|NCT00995345|Experimental|Dose 2: KRP-104 80 mg|Tablet, once-daily for 24 weeks
89128081|NCT00995345|Experimental|Dose 3: KRP-104 100 mg|Tablet, once-daily for 24 weeks
89128082|NCT00995345|Experimental|Dose 4: KRP-104 20/120mg|Tablet, once-daily for 24 weeks (dose switch from 20 to 120 mg at week 12)
89128083|NCT00995345|Placebo Comparator|Placebo|Tablet, once-daily for 24 weeks
89128084|NCT05199038|Experimental|2 Days of octreotide infusion|
89128085|NCT05199038|Active Comparator|5 Days of octreotide infusion|
89128086|NCT04262960|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
89128087|NCT04262960|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
89128088|NCT00660907|Experimental|1|dapagliflozin plus metformin
89128089|NCT00660907|Active Comparator|2|glipizide plus metformin
89233871|NCT01027455|Placebo Comparator|Dry Cold|Dry (0% relative humidity) and cold (20 degrees Celsius - Room Temperature) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
89128090|NCT04992572|Active Comparator|General anesthesia|"Patients under this group will be undergoing lumbar decompression surgery with general anesthesia:~General Anesthesia: Medically induced unconsciousness that suppresses reflexes and requires intubation (a tube inserted through the mouth and into the airway) to assist in breathing."
89128091|NCT04992572|Active Comparator|Monitored Anesthetic Care (MAC)/Local|"Patients under this group wil be undergoing limbar decompression surgery with Monitored Anesthetic care, (MAC)/Local.~Local + MAC: Local anesthetic (lidocaine) injected into the site of the incision/dissection with additional IV medication (Propofol) to achieve a state in which the patient is generally aware, but relaxed."
89128092|NCT00677157||screening|participants evaluated for possible inclusion in a natural history or intervention protocol
89128093|NCT05083052|Placebo Comparator|PLACEBO|Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Água deionizada q.s.p - 100mL.
89128094|NCT05083052|Experimental|PROPOLIS 10%|Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Própolis a 10%, Água deionizada q.s.p - 100mL.
89128095|NCT05083052|Experimental|PROPOLIS 15%|Carbonato de cálcio: 40,0%, Glicerina: 20,0%, Lauril Sulfato de sódio: 1,2%, Carboximetilcelulose: 2,0%, Goma xantana: 1,0%, Metilparabeno (nipagim): 0,15%, EDTA: 0,5%, Sacarina: 0,1%, Flavorizante: 0,75%, Própolis a 15%, Água deionizada q.s.p - 100mL.
89128096|NCT04031703|Experimental|6 cycles of PC adjuvant chemotherapy|6 cycles of PC (Paclitaxel 80 mg/m2 ivgtt d1,8,15+ Carboplatin Auc = 2 ivgtt d1,8,15, 28 days per cycle).
89128097|NCT04031703|Active Comparator|3 cycles of FEC followed by 3 cycles of Docetaxel|3 cycles of FEC (epirubicin100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
89128098|NCT05081258|Active Comparator|NAM treatment|Study Group: newborns with UCLP will be treated with a palate plate with nasal stent (Nasoalveolar Molding = NAM)
89128099|NCT05081258|Sham Comparator|pAM treatment|Control Group: newborns with UCLP will be treated with a palate plate without nasal stent (passive Alveolar Molding = pAM)
89128100|NCT00795847|Experimental|1. Preminent|Patients with blood pressure self-measurement-proven morning hypertension are treated with Preminent 1T qd for 3 months.
89128101|NCT00795847|Active Comparator|2. High-dose losartan|Patients with blood pressure self-measurement-proven morning hypertension are treated with losartan 100 mg qd for 3 months.
89128102|NCT00877773|Experimental|Temsirolimus|Temsirolimus 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
89128103|NCT00610220|Active Comparator|1|
89128104|NCT00610220|Experimental|2|
89128105|NCT00659815|Active Comparator|ReNu in Currently Marketed Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
89128106|NCT00659815|Experimental|ReNu in Clear Resin Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.
89128107|NCT00994643|Experimental|Treatment (Interleukin Therapy, Monoclonal Antibody)|Patients receive interleukin-2 SC twice weekly and rituximab IV once weekly in weeks 5-8 and 25-28. Courses repeat every 4 weeks for up to 7 months in the absence of disease progression or unacceptable toxicity.
89128108|NCT00912171|Active Comparator|Nasal steroid|
89128109|NCT00912171|Active Comparator|Anti-leukotrienes|
89128110|NCT00912171|Active Comparator|Nasal steroid + anti-leukotrienes|
89128111|NCT00800995|Sham Comparator|Control|
89128112|NCT00800995|Experimental|SOD|
89128113|NCT04293575||In list group|patients on active heart transplantation (HTx) list with a low likelihood to receive a donation shortly (e.g. for body weight or blood group)
89128114|NCT04293575||"Bridge to decision BTD group"|patients suitable for HTx, but that were still waiting for clinical decision
89128115|NCT04293575||"(Bridge to candidacy BTC group)"|patients who could not be yet in list for HTx because of concomitant, potentially reversible, contraindications such as severe pulmonary hypertension, elevated pulmonary-vascular-resistance, unsatisfactory response to vasodilator challenge or other causes resulting in a prohibitive peri-procedural risk (as pre-transplant body mass index [BMI] >35 kg/m2, severe renal dysfunction with creatinine clearance <30 mL/min) and other reasons (current alcohol, tobacco or drug abuse, poor social support, non-residents)
89128116|NCT02628327||Glaucoma subjects|Survey given to all glaucoma subjects agreening to study.
89128117|NCT00677391|Active Comparator|1|
89128118|NCT00677391|Placebo Comparator|2|
89128119|NCT00629057|Experimental|1|Lowest dose level
89128120|NCT00629057|Experimental|2|Middle level dose
89128121|NCT00629057|Experimental|3|Highest dose level
89128122|NCT00660829|Placebo Comparator|1|Placebo
89128123|NCT00660829|Active Comparator|2|0.15% Azelastine Hydrochloride
89128124|NCT00677469|Experimental|I|Cholestyramine 2g BID, Methimazole 10mg TID, and Propranolol 20mg BID
89128125|NCT00677469|Experimental|II|Cholestyramine 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
89128126|NCT00677469|Placebo Comparator|III|Placebo powder 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
89128127|NCT00629135|Experimental|1|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 1: Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily.
89128128|NCT00629135|Active Comparator|2|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 2: Piperacillin / Tazobactam 4,5 g administered intravenously three times daily
89128129|NCT00795925|Experimental|propiverine hydrochloride|
89128130|NCT00677547||1|Kidney transplant recipients
89128131|NCT00677547||2|Healthy volunteers
89128132|NCT00801073|Experimental|Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
89128133|NCT00677625||Liver Disease (LD)|These child subjects have some form of liver disease (including those who need a liver transplant) or have already had a liver transplant.
89128134|NCT02873663|Experimental|heavy drinkers|Plasma and head hair collection
89128135|NCT02873663|Experimental|teetotalers|Plasma and head hair collection
89128136|NCT00801151|Experimental|Vorinostat, vinorelbine|Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
89128137|NCT00793507|Experimental|1: Intervention Group|All participants in the intervention group will be receiving standard preventive dental care received by children in their dental providers' office. These intervention children will receive dental scaling, cleaning and fluoride varnish at visits every three to six months. All participants in the intervention group will receive active reminder/recall from the hygienist, encouraging the participants to return every three to six months for the oral exam, cleaning, scaling and fluoride application.
89128138|NCT00793507|Active Comparator|2: Control Group|The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist.
89128139|NCT00877383|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89128140|NCT00877383|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89128141|NCT00796159||Olmesartan medoxomil + HCTZ|
89128142|NCT00993473|Experimental|Lantus (insulin glargine)|Lantus given as basal insulin once a day in the morning by subcutaneous injection
89128143|NCT00993473|Active Comparator|NPH insulin|Neutral Protamine Hagedorn (NPH) human insulin given as basal insulin either once or twice per day generally in the morning and /or at bedtime by subcutaneous injection
89128144|NCT00660595|Experimental|1|Oral
89128145|NCT00660595|Active Comparator|2|Oral
89128146|NCT00929240|Active Comparator|Avastin (bevacizumab)|
89128147|NCT00929240|Experimental|Avastin (bevacizumab) + Xeloda (capecitabine)|
89128148|NCT00796237|Experimental|WBV|In their regular physiotherapy sessions, the subjects in the experimental group will receive whole body vibration therapy for a duration of 4 weeks during their stay in the Tung Wah Hospital.
89128149|NCT00796237|Active Comparator|CON|The subjects in this group will not receive whole body vibration therapy.
89128150|NCT04292249||Elective on-pump cardiac surgery patients|Adult patients (≥18 years) undergoing elective on-pump cardiac surgery (isolated coronary artery bypass graft (CABG), single and multiple valvular procedures, combined CABG and valvular surgery, and others).
89128151|NCT00801307|Experimental|1|He/O2 78:22
89128152|NCT00801307|Experimental|2|He/O2 65:35
89128153|NCT00801307|Active Comparator|3|Medical Air
89128154|NCT02869139|Experimental|Package of mentholated measures|Package of mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
89128155|NCT02869139|Active Comparator|Package of non-mentholated measures|Package of non-mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
89128156|NCT00677703|No Intervention|Standard Care|Participants will receive standard care without daily reminders.
89128157|NCT00677703|Experimental|Text Messages|Participants will receive a daily text message reminder for 6 months
89128158|NCT00793663|Experimental|1|The effect of xenon as an anaesthetic on the depth of hypnosis.
89128159|NCT00793663|Active Comparator|2|The effect of sevoflurane as an anesthetic on the depth of hypnosis
89128160|NCT00793663|Experimental|3|Dexamethasone as prevention of postoperative nausea and vomiting after xenon or sevoflurane anesthesia
89128161|NCT00793663|Placebo Comparator|4|
89128162|NCT00793663|Experimental|5|Ondansetron, to determine the onset-time of ondansetron when used as rescue medication for postoperative nausea and vomiting
89128163|NCT00793663|Placebo Comparator|6|
89128164|NCT00610298|Experimental|I|Subjects who receive whole body vibration
89128165|NCT00610298|No Intervention|N|Subjects do not receive whole body vibration intervention
89128166|NCT02628561|Active Comparator|Active tdcs/M1|Anodal tDCS on primary motor cortex and CIMT (constraint induced movement therapy)
89128167|NCT02628561|Experimental|Active tdcs/Premotor|Anodal tDCS on premotor cortex and CIMT (constraint induced movement therapy)
89128168|NCT02628561|Sham Comparator|Sham tdcs|Sham tDCS and CIMT (constraint induced movement therapy)
89128169|NCT04258202|Experimental|positive end expiratory pressure group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. PEEP increased in a stepwise manner from 5 to 20 cmH2O, until plateau pressure 30 cmH2, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with positive end expiratory pressure (PEEP) 5cmH2O.
89128170|NCT04258202|Experimental|tidal volume group|Alveolar recruitment maneuver is performed after intubation, pneumoperitoneum, closure of abdominal fascia. Tidal volume increased in steps of 4mL/kg of ideal body weight until plateau pressure 30 cmH2O, then 10 breaths. After recruitment, ventilation sets at tidal volume 7 mL/kg with PEEP 5 cmH2O.
89128171|NCT04151745|Other|study group|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
89128172|NCT02553811|Experimental|intervention|accuracy diagnostic in carpal tunnel syndrome = evaluation and comparison ultrasonography X electromyography
89128173|NCT00677781||F64|We investigate a cohort of 20 consecutive patients undergoing hepatic or pancreatic surgery (Pilot study)
88802288|NCT01890694|Placebo Comparator|Placebo|"Subjects will receive placebo once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
89128174|NCT02554045|Active Comparator|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
89128175|NCT02554045|Placebo Comparator|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
89128176|NCT00677859|Experimental|Single dose Arm|There will be six cohorts of three patients each. Three escalating doses of MultiStem will be evaluated.
89128177|NCT00677859|Experimental|Repeat Dose Arm|There will be six cohorts of three patients each. Four dosing regimens will be evaluated,varying doses at three times weekly or five times weekly.
89128178|NCT00993317|Placebo Comparator|Placebo of CDP870+MTX|
89128179|NCT00993317|Experimental|CDP870 200mg+MTX|
89128180|NCT04258124|Experimental|Experimental group|"Each session will last 10 minutes, taking place 3 days a week, over a period of 6 weeks. The intervention will take place at the beginning of the training session. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.~Exercise 1. In quadruped position, keeping the back flat, making an isometric contraction of the transverse muscle, and raising one arm and one leg contralaterally.~Exercise 2. Training of the deep cervical flexor muscles, supine. Players will move their heads slowly towards craniocervical flexion.~Exercise 3. In standing position, an ocular-cervical coordination exercise by means of a cranio-cervical flexion, adding a rotation, guided by an eye feedback provided by the physiotherapist by means of a laser projected on a wall."
89128181|NCT04258124|No Intervention|Control group|Athletes in the control group will be asked to follow their usual warm-up routine.
89128182|NCT02628483|Experimental|Ultimate Omega|5 capsules of Ultimate Omega fish oil daily in the morning with food
89128183|NCT02628483|Active Comparator|Meg-3|5 capsules of Meg-3 fish oil daily in the morning with food
89128184|NCT04045873|Experimental|ECMO plus IABP|
89128185|NCT04045873|Experimental|IABP|
89128186|NCT05330156|Active Comparator|Transurethral resection of the prostate group (TURP).|the 1st group of patients will undergone Transurethral resection of the prostate for treatment of BPH
89128187|NCT05330156|Active Comparator|transurethral enucleation of prostate group (TUEP)|the 2nd group of patients will undergone Transurethral enucleation of the prostate for treatment of BPH
89128188|NCT02628249|Experimental|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid made after egg protein.
89128189|NCT02628249|Experimental|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid made after egg protein.
89128190|NCT02628249|Experimental|Base + BCAA|Base protein intake + Branched chain amino acids
89128191|NCT02628249|Experimental|Base + EAA|Base protein intake + essential amino acids.
89128192|NCT02628249|Experimental|Base + NEAA|Base protein intake + non essential amino acids
89128193|NCT01030133|Active Comparator|Real TMS|Participants in the real Transcranial Magnetic Stimulation (TMS) group will receive real stimulation across all interventions; the operator role Real TMS and receiver role Real TMS. rTMS will be used to stimulate the left prefrontal cortex using two Neuronetics TMS machines with figure-8, iron core coils at 10Hz and at 110% of resting motor threshold [5 second trains following each trial (25 trials per visit)].
89128194|NCT01030133|Sham Comparator|Sham TMS|Participants in the sham Transcranial Magnetic Stimulation (TMS) group will receive sham stimulation across all interventions; the operator role Sham TMS and receiver role Sham TMS. Sham Stimulation involves 5 second trains of 10Hz rTMS in pairs alternating between real TMS and eSham TMS (randomly ordered). All sham treatment will be delivered with a specially designed, manufacture-provided sham TMS coil that looks and sounds identical to a real TMS coil but no magnetic current is transferred to the participant.
89128195|NCT01030133|Other|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
89128196|NCT00677937|Experimental|1|Intervention to include education and ongoing support
89128197|NCT00677937|No Intervention|2|Control to receive standard care
89128198|NCT04291781|Experimental|RC18 160mg|RC18 160mg SC once weekly ,and total of 24 doses
89128199|NCT04291781|Experimental|RC18 240mg|RC18 240mg SC once weekly ,and total of 24 doses
89128200|NCT04291781|Placebo Comparator|Placebo|Placebo SC once weekly ,and total of 24 doses
89128201|NCT04257968|Experimental|Diagnostic intervention|Complete diagnostic intervention
89128202|NCT00877071|Experimental|LC Drug Eluting Bead, Regional Chemoembolization|Use of LC Drug-Eluting Beads for chemoembolization will provide a method for downstaging patients with hepatocellular carcinoma which is not amenable to surgical resection or local ablative therapy to liver transplant eligibility
89128203|NCT04292795|Experimental|Group A|Intervention: Shortwave Diathermy Frequency: 27.12 MHz Time Duration: 10min Duration of Treatment: 4 weeks. Sessions per Week: 2 sessions per week
89128204|NCT04292795|Experimental|Group B|Intervention: Therapeutic Ultrasound Frequency: 1-3MHz Intensity: 0.2-1W/cm2 Time Duration: 10mins Duration of Treatment: 4 weeks Sessions per Week: 2 sessions per week
89128205|NCT00678093|Experimental|SNAG|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
89128206|NCT02868905|Other|Control group|Control group
89128207|NCT02868905|Other|Obese group|Obese group
89128208|NCT02868905|Other|Non-obese AD group|Non-obese AD groups
89128209|NCT02868905|Other|Obese AD group|Obese AD group
89128210|NCT02628171|Other|Control|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of cashew nuts (control).
89128211|NCT02628171|Active Comparator|Cashew|Participants will receive a controlled diet, typical of an American diet, with 42 g/day of cashew nuts (base diet with cashew nuts).
89128212|NCT00610376|Experimental|1A|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home intervention component.
89128213|NCT00610376|Active Comparator|2|This group did not receive any special treatment during the study, but did receive the intervention at the close of the study
89128214|NCT00610376|Experimental|1B|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home control component.
89128215|NCT02868827|Experimental|Cholecalciferol|This group of patients will receive single high dose of vitamin D (Cholecalciferol) dissolved in 45 ml of fresh milk (Nestle)
89128216|NCT02868827|Placebo Comparator|Placebo|This group of patients will receive placebo - 45 ml of fresh milk (Nestle) so that the amount, color, smell, taste etc will be the same as that of experimental drug)
89128217|NCT02628015||preschool children preterm|born 2010 or 2011 Birthweight <1500g
89128218|NCT02628015||preschool children full-term|born 2010 or 2011 born after 38 weeks
89128219|NCT02628015||school children preterm|same children from the preschool group will be tested 2 years later again
89128220|NCT02628015||school children full-term|same children from the preschool group will be tested 2 years later again
89128221|NCT02628015||youths preterm|born 2001 or 2002 Birthweight <1500g
89128222|NCT02628015||youths full-term|born 2001 or 2002 born after 38 weeks
89128223|NCT02628015||adults preterm|Birthweight <1500g
89128224|NCT02628015||adults full-term|born after 38 weeks
89128225|NCT02627937||pediatric sleep apnea|The children were confirmed to have OSAHS by comprehensive polysomnography (PSG).
89128226|NCT02869061|Experimental|ADRC injection|Subjects will be undergone liposuction under local anesthesia. Adipose-derived regenerative cells (ADRC) will be isolated from lipoaspirate by enzymatic digestion. Transurethral bladder neck resection followed by the injection of ADRC suspension will be performed. This is a single arm study with no control. All patients receive cell therapy.
89128227|NCT04151589|Experimental|Interventional Site|"The process below will be allocated in Interventional Sites:~At each interventional sites, implementing full assessment of current emergency work flow of acute ischemic stroke patients who eligible for endovascular treatment. All interventional sites would undergo assessment in order to form a baseline.~Drafting intervention approaches based on the assessment results of all interventional sites. These approaches are executable, reproducible, and measurable.~Emergency work flow management APP would be installed on smartphones of designated personnel at each interventional sites.~Both intervention approaches and APP would be incorporated with original work flow at each interventional site.~Training sessions would be held in interventional sites or online every 3 month once the patient enrolment begin.~Outcome data would be analysed and dispatched every 3 month for each interventional sites."
89128228|NCT04151589|No Intervention|Control Site|The control site would not undergo any emergency work flow modification for acute ischemic stroke patients who eligible for endovascular treatment.
89128229|NCT02867657|Experimental|Mindfulness in nature|A five day mindfulness retreat in nature
89128230|NCT02867657|Active Comparator|Mindfulness indoor|A five day mindfulness retreat indoor
89128231|NCT02867657|No Intervention|Wait list control|A wait list control group, that 6 months later is offered a two-day mindfulness retreat in nature
89128232|NCT02627859|Experimental|Durolane SJ|Durolane SJ intra-articular injection; device
89128233|NCT02867579|Other|women with denial pregnancy|women with denial pregnancy
89128234|NCT02867579|Other|women without denial pregnancy|women without denial pregnancy
89128235|NCT02868593|Experimental|Patient with clinical meningitis or meningo-encephalitis|
89128236|NCT00678405|Active Comparator|WLm / WLnm|Best supportive care
89128237|NCT00678405|Experimental|FTm / FTnm|Breathlessness Intervention Service
89128238|NCT00987389|Experimental|Plasma Exchange with Standard Glucocorticoids|Participants in this arm undergo plasma exchange and take a standard glucocorticoid dose.
89128239|NCT00987389|Active Comparator|No Plasma Exchange with Standard Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a standard glucocorticoid dose.
89128240|NCT00987389|Experimental|Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm undergo plasma exchange and take a reduced glucocorticoid dose.
89128241|NCT00987389|Active Comparator|No Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a reduced glucocorticoid dose.
89128242|NCT00929162|Experimental|ZD4054 + paclitaxel + carboplatin|ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
89128243|NCT00929162|Placebo Comparator|Placebo + paclitaxel + carboplatin|Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
89128244|NCT02627781||suspected appendicitis|This group includes all patients with suspected appendicitis, who are admitted to our University Hospital.
89128245|NCT02627625|Experimental|test product A|tiotropium
89128246|NCT02627625|Experimental|test product B|tiotropium
89128247|NCT02627625|Experimental|test product C|tiotropium
89128248|NCT02627625|Active Comparator|Commercial product D|tiotropium
89128249|NCT02627625|Active Comparator|commercial product E|tiotropium
89128250|NCT00678483|Experimental|1|10 mg
89128251|NCT00678483|Experimental|2|20 mg
89128252|NCT04292015|Experimental|Standard then Intervention|Infant will undergo standard method of examination with binocular indirect opthalmoscope (BIO) followed by retinal imaging with Optos ultra-wide field retinal imaging device.
89128253|NCT04292015|Experimental|Intervention then Standard|Infant will undergo retinal imaging with Optos ultra-wide field retinal imaging device followed by standard method of examination with binocular indirect opthalmoscope (BIO).
89233872|NCT01027455|Experimental|Humidification|Humidified (98% relative humidity) and warm (37 degrees Celsius) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
89128254|NCT04151355|Experimental|Atorvastatin group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) in addittion to atorvastatin (20 mg once daily) in addittion to atorvastatin (20 mg once daily)
89128255|NCT04151355|No Intervention|Control group|50 colorectal cancer patients receiving FOLFOX 6: (Oxaliplatin 85mg/m2 IV over 2 hrs + leucovorin 400mg/m2 IV over 2 hrs, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks) or FOLFIRI 6:( Irinotecan 180mg/m2 IV + leucovorin 400mg/m2 IV, followed by 5-FU 400mg/m2 IV bolus, followed by 5-FU 1,200mg/m2 /day IV x 2 days (total 2,400mg/m2 ) as a 46-48 hr continuous infusion. Repeat every 2 weeks)
89128256|NCT04291625|Other|congenital ptosis|children who had congenital ptosis with levator function of 4mm or better, underwent levator muscle resection guided by intraoperative lagophthalmos formula.
89128257|NCT00678717|Active Comparator|Healthy|Healthy volunteers
89128258|NCT00678717|Experimental|Chronic Visceral Pain|Chronic Visceral Pain patients. Participants will be tested before and after implantation of a Spinal Cord Stimulator (implantation of the Spinal Cord Stimulator is done as usual care and is not a study procedure)
89128259|NCT00609284|Experimental|1|Radiotherapy 70Gy, Erbitux, Carboplatin-5FU
89128260|NCT00609284|Active Comparator|2|Radiotherapy 70Gy, Erbitux
89128261|NCT00678873|Experimental|Surgical group|Patients with ultrasound proven symptomatic cholelithiasis (gallstones).
89128262|NCT04257890|Experimental|CBT intervention group|In addition to the information about IGD of the control group, the intervention group will receive eight weekly group-based 90-minute CBT sessions.
89128263|NCT04257890|Active Comparator|Wait-list control group|Members will receive printed education material about IGD but not CBT during the treatment period.
89128264|NCT04151511|Other|Continuous Thoracic Epidural|Continuous Thoracic Epidural Analgesia for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
89128265|NCT04151511|Experimental|Continuous Erector Spinae Plane Block|Continuous Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Adult Living Donar Open Hepatectomies
89128266|NCT00992459|Experimental|Buphenyl (NaPBA) /HPN 100 Placebo|Subjects in Arm A were randomly assigned to receive NaPBA + HPN 100 placebo for 2 weeks and then crossed over to receive HPN 100 + NaPBA Placebo for 2 weeks.
89128267|NCT00992459|Experimental|HPN-100/NaPBA Placebo|Subjects in Arm B were randomly assigned to receive HPN-100 + NaPBA placebo for 2 weeks and then crossed over to receive NaPBA + HPN 100 placebo for 2 weeks.
89128268|NCT00930722||quinapril|quinapril
89128269|NCT00679107|Experimental|1|autogenous bone graft with the addition of OP-1 Putty
89128270|NCT00679107|Active Comparator|2|autogenous bone graft alone
89128271|NCT00679185|Experimental|Experimental-EW|four emotion focused writing assignments
89128272|NCT00679185|Active Comparator|control group|non-emotional writing control
89128273|NCT04990622|Experimental|Dietary flavonoid group|"Participants will be encouraged to consume 2 x flavonoid-rich food items per day from the following list of flavonoid-rich foods across 2 weeks, above what they already consume each day, typically.~Berry fruits (~120g) e.g. blueberries, raspberries, strawberries, blackberries, blackcurrants, mixed berries~2 large squares of dark chocolate (at least 70% cocoa)~4-5 cups of tea (black or green) or coffee (normal or decaf varieties)~1 large glass of red wine* (250ml)~1 portion of leafy green vegetables such as spinach or cabbage (~70g)~1 glass (250ml) of fresh orange or grapefruit juice (not from concentrate)"
89128274|NCT04990622|No Intervention|Control group|Participants will be given no instructions regarding adding food items to their diet. They will be encouraged to continue their diet as normal for 2 weeks.
89128275|NCT00912249|Experimental|Horticultural Therapy|
89128276|NCT00610610|Experimental|A|Paroxetine - Controlled Release
89128277|NCT00610610|Placebo Comparator|B|Same colour, shape placebo
89128278|NCT00912327||Stage 1|
89128279|NCT00912327||Stage 2|
89128280|NCT04257812||Ceftolozane-Tazobactam cohort|Patients older than 18 years old that are hospitalised in the Virgen Macarena University Hospital that are being treated with Ceftolozane-Tazobactam in empiric or targeted treatment.
89128281|NCT00992225|Experimental|LY573636-sodium|
89128282|NCT00679419||Group 0 (Controllgroup)|eGFR >= 90 ml/min/1.73m^2 and no proteinuria
89128283|NCT00679419||Group 1|eGFR >= 90 ml/min/1.73m^2 and proteinuria
89128284|NCT00679419||Group 2|eGFR 60 - 89 ml/min/1.73m^2
89128285|NCT00679419||Group 3|eGFR 30 - 59 ml/min/1.73m^2
89128286|NCT00679419||Group 4|eGFR 15 - 29 ml/min/1.73m^2
89128287|NCT00679419||Group 5|eGFR < 15 ml/min/1.73m^2 or requiring dialysis
89128288|NCT04257734||optic neuritis|Aquaporin 4 antibody seropositive optic neuritis patients, Myelin oligodendrocyte glycoprotein antibody seropositive optic neuritis patients, and double antibodies seronegative optic neuritis patients
89128289|NCT02868749|Experimental|Hyaluronic Acid filler 1 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 1, 3 weeks to 4 months before the surgery~Injection Session 2 of Hyaluronic Acid filler 1, 5 to 9 days before the surgery"
89128290|NCT02868749|Active Comparator|Hyaluronic Acid filler 2 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 2, 3 weeks to 4 months before the surgery~Injection Session 2 of Hyaluronic Acid filler 2, 5 to 9 days before the surgery"
89128291|NCT00659581||Patients with hypertension|
89128292|NCT02627547|Experimental|Experimental tests|2 sets of experimental tests; once, during a period of normal training and repeated following one week of de-training
89128293|NCT00679497|Experimental|1|MVA HIV-B
89128294|NCT00679497|Placebo Comparator|2|Placebo
89128295|NCT00796393|Experimental|2|Subject with active product, not vaccinated against influenza.
89128296|NCT00796393|Placebo Comparator|3|Subject with placebo, vaccinated against influenza.
89128297|NCT00796393|Placebo Comparator|4|Subject with placebo, not vaccinated against influenza.
89128298|NCT00796393|Experimental|1|Subject with active product, vaccinated against influenza
89128299|NCT00679575||1|Cases : Patients with a first myocardial infarction
89128300|NCT00679575||2|Referents : Patients recruited by a GP during a routine consultation
89128301|NCT00793741||1|Type 1 Diabetes Hypoglycemia unawareness Islet transplant candidate
89128302|NCT00793741||2|Healthy control subjects
89128303|NCT00991289|Experimental|NTZ/PEG/RBV|Participants received nitazoxanide (NTZ) alone for 4 weeks followed by 48 weeks of NTZ with pegylated interferon (PEG) and ribavirin (RBV). Participants who did not achieve early virologic response (EVR) at Week 16 or had detectable hepatitis C virus (HCV) viral load at Week 28 discontinued treatment.
89128304|NCT00801463|Experimental|Large pred|Prednisone 60mg/d*8 wks
89128305|NCT00801463|Experimental|small pred|Pred 30mg/d*8wks
89128306|NCT04150809||Patients|Patients who have been diagnosed with ALS.
89128307|NCT04046029|Experimental|Bivalirudin|
89128308|NCT04046029|Active Comparator|Heparin|
89128309|NCT00679653|Active Comparator|1|verapamil/trandolapril
89128310|NCT00679653|Active Comparator|2|metoprolol/HCT
89128311|NCT00679653|Active Comparator|3|felodipine/ramipril
89128312|NCT00801541||AMD|Patients with wet AMD in one eye and dry AMD in the other eye (study eye).
89128313|NCT02868983|Experimental|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
89128314|NCT02868983|No Intervention|Co-Location|A Behavioral Health Clinician (BHC) such as a psychologist or counselor is housed in or near the primary care practice.
89128315|NCT00793897|Experimental|Sequential allocation of patients in two dosing schedules|
89128316|NCT00679887|Experimental|A|Ischemic compression on trigger points located around the shoulder. Active comparator. Ischemic compression, 5 weeks
89128317|NCT00793975|Experimental|IMC-1121B|"All patients will receive intravenous infusions of IMC-1121B with the dose depending on which cohort they are enrolled into. A minimum of three patients will be enrolled in each cohort.~A completed patient will be either a patient who completes the 4-week treatment cycle and 2-week observation period (for a total of 6 weeks), or a patient who discontinues therapy for an IMC-1121B-related toxicity. Toxicity data for each cohort will be reviewed prior to dose escalation.~When all patients complete a cohort, dose escalation to the next cohort will occur."
89128318|NCT00679965|Experimental|Group 1|AN2690 Solution, 2.5%
89128319|NCT00679965|Experimental|Group 2|AN2690 Solution: 5%
89128320|NCT00679965|Experimental|Group 3|AN2690 Solution, 7.5%
89128321|NCT00679965|Placebo Comparator|Group 4|AN2690 Solution Vehicle
89128322|NCT00801619||Intervention|Receive decision support when reviewing bilirubin results in the clinical information systems/electronic health record
89128323|NCT00801619||Control|No decision support
89128324|NCT00680199||1|Primary Insomnia
89128325|NCT00680199||2|Good Sleepers
89128326|NCT00930644|Experimental|teduglutide|0.05 mg/kg/day
89128327|NCT05251051|Active Comparator|Intervention Group|"At NICU discharge, infants will be referred to Illinois Early Intervention. A coordinator (the navigator) will assist families in engaging with Early Intervention and completing all enrollment requirements.~At NICU discharge, infants will be provided with standard home pediatric therapy services weekly for up to 14 weeks. These will be initiated within 2 weeks of discharge."
89128328|NCT05251051|Other|Control Group|At NICU discharge, infants will be referred to Illinois Early Intervention. A coordinator (the navigator) will assist families in engaging with Early Intervention and completing all enrollment requirements. If transitional services were recommended by the NICU providers, the navigator will help families identify these services and obtain the necessary referrals.
89128329|NCT02627469|No Intervention|Control|Common oral hygiene help administered by nursing staff
89128330|NCT02627469|Experimental|Intervention|Extended professional oral hygiene care Electric toothbrush (Oral-B Professional Care 7000) 1100 ppm sodium fluoride dentifrice (Zendium Classic, Opus Health Care AB/Zendium)
89128331|NCT00796783||1|Patients with presumed Cushing's disease who have failed pituitary surgery and/or radiation and require medical treatment for recurrent or persistent Cushing's syndrome.
89128332|NCT00680277|Experimental|1|
89128333|NCT00680277|Experimental|2|
89128334|NCT00794053|Experimental|study group|The members in this group will undergo intervention by having surgery and lymph node detection by dye staining
89128335|NCT00680355|Other|Golden rice meal with 10g fat|10 g corn oil in the Golden Rice meal
89128336|NCT00680355|Other|Golden Rice with 0g fat|0g corn oil eating with the Golden Rice meal
89128337|NCT00680355|Other|Golden Rice meal with 5 g fat|5 g corn oil in the Golden Rice meal
89128338|NCT00801697|Experimental|1A|rAD5-naive participants will receive rAd35 intramuscularly at study entry and rAd5 intramuscularly at Month 6
89128339|NCT00801697|Placebo Comparator|1B|Participants will receive rAd35 placebo intramuscularly at study entry and rAd5 placebo intramuscularly at Month 6
89128340|NCT00801697|Experimental|2A|rAD5-naive participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd5 intramuscularly at Month 6
89128341|NCT00801697|Placebo Comparator|2B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd5 placebo intramuscularly at Month 6
89128342|NCT00801697|Experimental|3A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
89128343|NCT00801697|Placebo Comparator|3B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
89128344|NCT00801697|Experimental|4A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
89128345|NCT00801697|Placebo Comparator|4B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
89128346|NCT02626299|Placebo Comparator|200 mg/day DHA|Participants will receive 2 placebo pills/day that do not contain DHA. Like the experimental group, they will be given a supplement of Docosahexaenoic acid - 200mg/day , a common amount in prenatal vitamins.
89233873|NCT01565967||Autotransfusion|All patients undergoing surgery which requires routine use of an autotransfusion system
89128347|NCT02626299|Experimental|1000 mg/day DHA|The intervention includes Docosahexaenoic acid - 800mg/day per day provided in two 400 mg capsules. The intervention group as well as the active comparator group will be given 1-200 mg/capsule per day of DHA that is a common amount in prenatal vitamins.
89128348|NCT00684489|Active Comparator|A; B|
89128349|NCT00684489|Active Comparator|2|Arm A is assignment to a clinical hypertension specialist Arm B is assigned renin-guided therapeutics
89128350|NCT00684489|Active Comparator|A is clinical hypertension specialist|Arm A is assigned to a clinical hypertension specialist
89128351|NCT00684489|Active Comparator|Arm B is renin-guided therapeutics|This group will be assigned to renin-guided therapeutics
89128352|NCT00684801||Usual care (control group)|Patients undergo usual care as determined by core cancer team.
89128353|NCT00684801||DMP (experimental group)|Patients undergo a systematic approach regarding specific domains related to their disease focusing on supportive care and symptom management determined by a multidisciplinary team of providers to help patients and caregivers manage.
89128354|NCT00990821|Experimental|Part I, Panel A|100 mg MK-0517 (nonpolysorbate 80 formulation [non-PS80]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant
89128355|NCT00990821|Experimental|Part I, Panel B|100 mg MK-0517 (PS80 formulation [PS80]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant
89128356|NCT00990821|Experimental|Part I, Panel C|40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant
89128357|NCT00990821|Experimental|Part II|2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam
89128358|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 1|125 mg aprepitant → 90 mg MK-0517 (PS80)
89128359|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 2|40 mg MK-0517 (non-PS80) → 125 mg aprepitant
89128360|NCT00990821|Experimental|Part III, Panel 2|40 mg MK-0517 (non-PS80)
89128361|NCT00990821|Experimental|Part IV|40 mg MK-0517 (non-PS80 formulation)
89128362|NCT00990821|Experimental|Part V, Treatment Sequence 1|125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)
89128363|NCT00990821|Experimental|Part V, Treatment Sequence 2|100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant
89128364|NCT00990821|Experimental|Part V, Treatment Sequence 3|115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)
89128365|NCT00990821|Experimental|Part V, Treatment Sequence 4|125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)
89128366|NCT00990821|Experimental|Part V, Treatment Sequence 5|100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)
89128367|NCT00990821|Experimental|Part V, Treatment Sequence 6|115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant
89128368|NCT00801853|Experimental|Aerovant 1|Aerovant 1mg bid
89128369|NCT00801853|Experimental|Aerovant 2|Aerovant 3mg bid
89128370|NCT00801853|Experimental|Aerovant 3|Aerovant 10mg bid
89128371|NCT00801853|Placebo Comparator|Placebo Control|Placebo Control
89128372|NCT00990665|Experimental|CRT-D and LV lead|
89128373|NCT00658567|Experimental|2|pimavanserin tartrate (ACP-103) 20 mg, tablet, once daily by mouth, 6 weeks
89128374|NCT00658567|Placebo Comparator|Placebo|Placebo tablet, once daily by mouth, 6 weeks
89128375|NCT00658567|Experimental|1|pimavanserin tartrate (ACP-103) 10 mg, tablet, once daily by mouth, 6 weeks
89128376|NCT00875433|Experimental|Monotherapy|BIBW 2992 high dose, once daily, continuous, monotherapy
89128377|NCT04292093|Experimental|Home rehabilitation training|Home rehabilitation training
89128378|NCT04292093|Active Comparator|Home control activity|Home control activity
89128379|NCT04291235|Active Comparator|Airway Management Pathway|An airway management pathway consisting of daily assessments and removal of the breathing tube as soon as patients can breathe on their own and appear able to protect their airway
89128380|NCT04291235|Active Comparator|Usual Care|The usual clinical practice is often to keep the patient on artificial respiration for longer in the hope that the patient will wake up before removing the tube, or performing a tracheostomy if the patient doesn't wake up
89128381|NCT00684957|Active Comparator|1|Subject taking growth hormone
89128382|NCT00684957|Active Comparator|2|Subject taking recombinant human IGF-1
89128383|NCT02868515|Experimental|Oatmeal containing beta-glucan|43 g cereal containing 3g fiber per serving
89128384|NCT00685191|Experimental|1|HIV-1-infected subjects initiating raltegravir-including salvage therapy
89128385|NCT02626143|Experimental|Investigational nutrient-rich whey protein formula|
89128386|NCT02626143|Active Comparator|Cow's milk based formula|
89128387|NCT02626143|No Intervention|Breast milk|
89128388|NCT00685269|Active Comparator|A|eszopiclone 3 mg QD
89128389|NCT00685269|Placebo Comparator|B|placebo tablet
89128390|NCT00794209|Experimental|1|
89128391|NCT00985985|Experimental|2mg nicotine lozenge|2 mg nicotine lozenge
89128392|NCT00985985|Placebo Comparator|2 mg placebo|2 mg placebo
89128393|NCT00985985|Experimental|4 mg nicotine lozenge|4 mg nicotine lozenge
89128394|NCT00985985|Placebo Comparator|4 mg placebo|4 mg placebo
89128395|NCT00685347|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
89128396|NCT00685347|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
89128397|NCT00796939|Active Comparator|Green Light Mask|
89128398|NCT00796939|Placebo Comparator|Red light mask|
89128399|NCT00685425|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
89128400|NCT00685425|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
89128401|NCT04290455|Experimental|treatment arm|using the microblepharoexfoliative procedure
89128402|NCT04290455|Active Comparator|control arm|using eyelid wipe (Optase)
89128403|NCT00794287||1|Hymenoptera allergic patients before allergen specific immunotherapy
89128404|NCT00794287||2|Hymenoptera allergic patients after allergen specific immunotherapy
89128405|NCT00802009|Experimental|1|Dexamethasone 8mg added to routine local anesthetic during brachial plexus blockade.
89128406|NCT00802009|Active Comparator|2|Routine anesthetic solution (30 cc 1.5% mepivicaine) used during brachial plexus blockade.
89128407|NCT02868437|Active Comparator|Group 1|The patients who are having curettage for retained product after second trimester abortion will also receive an intervention of intrauterine self-cross-linked hyaluronic acid gel after the procedure
89128408|NCT02868437|No Intervention|Group 2|The patients who are having curettage for retained product after second trimester abortion will receive no intervention
89128409|NCT00685581|Experimental|A|Arms A: the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
89128410|NCT00685581|Experimental|B|Arms B: the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed.
89128411|NCT00685581|Experimental|C|Arms C: the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed.
89128412|NCT00802087|Experimental|Egalet® hydrocodone treatment A|Single Dose administration
89128413|NCT00802087|Experimental|Egalet® hydrocodone Treatment B|Single Dose Administration
89128414|NCT00802087|Experimental|Egalet® hydrocodone Treatment C|Single Dose Administration
89128415|NCT00802087|Experimental|Egalet® hydrocodone Treatment D|Single Dose Administration
89128416|NCT00802087|Active Comparator|Active Comparator|Single Dose Administration
89128417|NCT04291157|Experimental|Proactive CVD prevention|Proactive invitation to total CVD risk estimation incorporating the PRS and provision of guideline based preventive interventions.
89128418|NCT04291157|Active Comparator|Usual care|Usual GP care (opportunistic CVD risk estimation and prevention upon usual GP contacts).
89128419|NCT04139811|Other|non-ILM peeling group|vitrectomy without ILM peeling is done to all cases
89128420|NCT04139811|Other|ILM peeling group|vitrectomy with ILM peeling is done to all cases
89128421|NCT00923936|Active Comparator|KS;classic/HIV+not improved on antiviral|Kaposi's Sarcoma (KS) in patients who are Human immunodeficiency virus (HIV) Negative, HIV infected with stable disease for one year despite antiretroviral therapy or progressive disease despite 4 months of antiretroviral therapy.
89128422|NCT00923936|Active Comparator|All other advanced HIV-asociated KS|All other patients with advanced acquired immune deficiency syndrome (AIDS)-associated KS
89128423|NCT00797017||001|
89128424|NCT00797017||002|
89128425|NCT00797017||003|
89128426|NCT00797017||004|
89128427|NCT00797017||005|
89128428|NCT00797017||006|
89128429|NCT00797017||007|
89128430|NCT02626221||Single|Single Cohort Study
89128431|NCT02868359||Pregabalin / Other analgesics|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
89128432|NCT02868359||Other analgesics|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
89128433|NCT05330000|Active Comparator|Voriconazole (R)|
89128434|NCT05330000|Experimental|Voriconazole (T)|
89128435|NCT00794443|Experimental|1. Monthly - Dose 1|Monthly intermittent administration, dose 1
89128436|NCT00794443|Experimental|2. Monthly - Dose 2|Monthly intermittent administration, dose 2
89128437|NCT00794443|Active Comparator|3. Daily|Daily administration
89128438|NCT04139889||normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
89128439|NCT04139889||non-malignant lesions|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of non-malignant lesions after intravenous injecting 10% fluorescein.
89128440|NCT04139889||malignant lesions|pCLE images of malignant lesions were associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
89128441|NCT00924950|Active Comparator|Taclonex Ointment/Hydrogel Patch Applied Topically Once Daily|Taclonex ointment once daily used to treat one psoriatic plaque, along with the Hydrogel Patch used once daily.
89128442|NCT00924950|Active Comparator|Taclonex Ointment Topically Once Daily|
89128443|NCT00685737|Active Comparator|1|1-MNA-Low Dose
89128444|NCT00685737|Active Comparator|2|1-MNA-High Dose
89128445|NCT00685737|Placebo Comparator|3|Placebo
89128446|NCT04291547|Experimental|Computerised Behavioural Activation Programme|All recruited young people will be given the BALM (Behavioural Activation for Low Mood) programme to work through
89128447|NCT00797251||Right posterior section group|Patients with tumors in the right posterior section of the liver (segments 6-7)
89128448|NCT02868203|Active Comparator|OCT at 3 months|OCT at 3 months and 12 OCT at 3 months
89128449|NCT02868203|Active Comparator|OCT at 6months|OCT at 6 months and 12 OCT at 3 months
89128450|NCT00685815|Experimental|24 participants|Intravenous Iron (FCM)
89128451|NCT00685815|Placebo Comparator|12 participants|Placebo
89128452|NCT00802165|Experimental|Electroacupuncture Treatment Group|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
89128453|NCT00802165|Sham Comparator|Sham Treatment Group|Sham electroacupuncture treatment gives comparison to the experimental group
89128454|NCT04881188||Patients with chronic low back pain|Patients suffering from chronic low back pain (duration longer than 3 months) undergoing a multimodal pain therapy
89128455|NCT02553889|Experimental|PK Cohort|A 4-week screening period followed by a 4-week treatment period followed by a 6-week post-treatment evaluation period. Treatment period includes 1 dose of 300 mg ISIS 416858 on Day 1 and again on Day 29. Both doses of Study Drug will be administered subcutaneously (SC).
89128456|NCT02553889|Placebo Comparator|Cohort A|"Patients in Cohort A will be randomized to receive either 200 mg ISIS 416858 or placebo. A 2:1 ratio will be used.~For Cohort A, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort A will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
89128457|NCT02553889|Placebo Comparator|Cohort B|"Patients in Cohort B will be randomized to receive either 300 mg ISIS 416858 or placebo. A 2:1 ratio will be used.~For Cohort B, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort B will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
89128458|NCT00685893|No Intervention|Control Arm|6 Community hospital ICUs receiving delayed intervention activities after the completion of the randomized trial
89128459|NCT00685893|Experimental|Intervention Arm|6 community hospital ICUs receiving 5-component intervention.
89128460|NCT04880174|Other|General arm|All patients follow this arm. Patients will undergo 3 blood sample testings at 3 different time points and have to fill in a questionnaire at 3 different time points
89128461|NCT04274621||Patients, family members of patient, medical staff|
89128462|NCT02867501||Aneurysmatic disease|Patients with dilatative arteriopathy (DA) the aortic diameter must be > 3 cm or the popliteal artery diameter > 1.5 cm
89128463|NCT02867501||Peripheral arterial occlusive disease|Patients with arterial occlusive disease (PAOD) defined with an Ankle brachial index (ABI) < 0.9 and positive criteria in the Edinburgh questionnaire.
89128464|NCT02867501||Healthy|Control group of age matched persons without PAOD (ABI > 0.9) and without DA.
89128465|NCT04256564|Experimental|Oblique visualization linear probe|A linear ultrasound probe will be utilized to place the central catheter into the jugular vein
89128466|NCT04256564|Experimental|Y-shape visualization micro-convex probe|A micro-convex endocavity ultrasound probe will be utilized to place the central catheter into the brachiocephalic vein
89128467|NCT02626065|Experimental|Nivolumab, patients with BRAF mutation|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.~Blood sampling at different time"
89128468|NCT02626065|Experimental|Nivolumab, patients with BRAF wild type|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.~Blood sampling at different time"
89128469|NCT00794755|Active Comparator|Vitamin K|
89128470|NCT00794755|Placebo Comparator|Placebo|
89128471|NCT00685971|Experimental|Vitamin D|vitamin
89128472|NCT00685971|Placebo Comparator|Placebo|
89128473|NCT00686049||Study Group|Participants will complete two audio computer assisted self interviews on laptop computers. This study will also involve the abstraction of participants' viral load and CD4 counts from their medical charts.
89128474|NCT00988637|Other|1) Vectical™ Ointment and Clobex® Spray|Vectical™ Ointment weekdays & Clobex® Spray weekends regimen
89128475|NCT00988637|Other|2) Clobex® Spray and Vectical™ Ointment|Clobex® Spray morning and Vectical™ Ointment evening regimen
89128476|NCT00802321|Experimental|dutasteride|
89128477|NCT00686283|Other|Exercise prescription|Each adolescents with type 1 or type 2 diabetes received individual fitness testing and a personalized exercise program prescription developed by an exercise physiologist. Pretest and posttest measures of glucose control and cardiorespiratory fitness, heart rate variability, metabolic control, lipid profile, body composition, and inflammatory markers, as well as psychological outcomes (i.e., diabetes quality of life) were completed.
89128478|NCT00802399|Other|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
89128479|NCT04162925|Experimental|Cancer screening cohort|"All women in this study to be evaluated for cancer screening utilization rates (breast, colon and oral cancers) and cancer screening perspectives of these hospitalized women.~The intervention will be a cancer screening education."
89128480|NCT00802477|Experimental|1|Application of Autologous Blood Products to surgical site during mastectomy.
89128481|NCT00802477|Active Comparator|2|Standard Modified Radical Mastectomy
89128482|NCT00686439|Experimental|adalimumab|
89128483|NCT00797329||observation|adult men with alcohol and polydrug use according to DSM-IV criteria, hospitalized in maximum security department between 2002 - 2008
89128484|NCT04031235|Experimental|Safe Sleep Education|Mothers in the intervention group will receive education on American Academy of Pediatrics safe sleep recommendations using a specially-designed children's book (Sleep Baby, Safe and Snug). In addition, they will receive information on the importance of reading with their infant using a brochure created by the AAP.
89128485|NCT04031235|Active Comparator|Infant Reading Education|Mothers in the control group will receive education on American Academy of Pediatrics recommendations on reading and talking to infants using a specially-designed children's book (Read Baby, Every Day). In addition, they will receive information on safe sleep using a brochure created by the AAP.
89128486|NCT02625987|Experimental|Continuous intradermic stitch|Closure was did with a continuous intradermic stitch.
89128487|NCT02625987|Sham Comparator|Separated stitches|Like comparator was used a closure with separated stitches.
89128488|NCT00797485|Active Comparator|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89128489|NCT00797485|Experimental|Arm II|Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89128490|NCT00686673|Experimental|A|Providing Videotape-based material & tailored workbook to make informed choice of disclosing terminal illness to patients
89128491|NCT00686673|Other|B|"Attention control arm:~Providing videotape-based material & non-tailored workbook about pain control"
89128492|NCT00686751|Experimental|A|"There is only one arm in this study. Each subject will be studied through 3 phases lasting a total of 4 weeks:~Phase 1: administration of study medication at the end of hemodialysis treatment.~Phase 2: no administration of study medication. Phase 3: administration of study medication at the beginning of hemodialysis."
89128493|NCT00797641||1|Patients admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
89128494|NCT00686985|Experimental|A|
89128495|NCT00802555|Experimental|ARQ 197|
89128496|NCT00687141|Experimental|1|
89128497|NCT00687141|Placebo Comparator|2|
89128498|NCT00687375|Other|1|Laparoscopic Inguinal Hernia Repair- Transabdominal preperitoneal (TAPP) approach
89128499|NCT00687375|Other|2|Laparoscopic Inguinal Hernia Repair- Totally extra peritoneal (TEP) Approach
89128500|NCT05192083|Experimental|Intervention group|The intervention group will receive a smartphone-based self-management support programme, including a 30-min face-to-face or online session at baseline, 3 phone calls (week 2, week 4 and week 6) and 2-month mobile messages in addition to usual care.
89128501|NCT00610766||1|
89128502|NCT02866955|Other|GROUP E (Estramustine)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by estramustine
89128503|NCT02866955|Other|GROUP T (Tamoxifen)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by tamoxifen
89128504|NCT00794911|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
89128505|NCT00794911|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
89128506|NCT00794911|No Intervention|Standard Care|
89128507|NCT02625753|Active Comparator|Codeine plus paracetamol|Codeine plus paracetamol every 6 hours for 72 hours after photorefractive keratectomy.
89128508|NCT02625753|Placebo Comparator|placebo|Placebo every 6 hours for 72 hours after photorefractive keratectomy.
89128509|NCT04907006|Experimental|Group-1|"The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water.~The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine.~After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration."
89128510|NCT04907006|Experimental|Group-2|"The subjects in both groups will be fasting overnight for at least 10 hours before administration. In Group-1 on D1, subjects will be orally administered with one SY-004 capsule(80mg ) on an empty stomach with 240ml warm water; In Group-2, subjects will have high-fat breakfast 30 minutes before administration ,then take one SY-004 capsule(80mg) orally with 240ml warm water.~The subjects in both groups will be fasted within 4 hours after taking the medicine, and drinking water is forbidden within 1 hour before and after taking the medicine.~After the cleaning period (D9-D16), the subjects will exchang the way of taking medicine and enter the second cycle of drug administration."
89128511|NCT04139421|Active Comparator|Urban Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in urban green space.
89128512|NCT04139421|Experimental|Rural Green Space group|This group of participants would experience a 3-hour Shinrin-Yoku session in rural green space.
89128513|NCT04257656|Experimental|Remdesivir group|active remdesivir
89128514|NCT04257656|Placebo Comparator|Control group|Placebos matched remdesivir
89128515|NCT04139031||Fluid loading group|Mechanically ventilated patients with low tidal volume in the intensive care unit whom clinician decided to provide fluid for correction of hypovolemia
89128516|NCT04895150||Patients|"Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation (Moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance(Biodex Balance System® and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)) will be evaluated."
89128517|NCT04895150||Healthy controls;|"Upper extremity exercise capacity (6 minutes Pegboard and Ring Test), muscle oxygenation (Moxy monitor), functional exercise capacity(6 minutes walk test), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), respiratory muscle endurance (incremental threshold loading test), peripheral muscle strength (dynamometer), balance(Biodex Balance System® and Y balance test), physical activity level (multi-sensor activity monitor) and quality of life (Quality of Life scale for Primary Ciliary Dyskinesia (QOL-PCD scale version 4.3)) will be evaluated."
89128518|NCT00687921||A|patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy.
89128519|NCT05329844|Experimental|Vildagliptin 50 mg Tablet|1 tablet of Vildagliptin 50 mg as single-dose administration
89128520|NCT05329844|Active Comparator|Galvus 50 mg Tablet|1 tablet of Galvus 50 mg (each tablet contains 50 mg Vildagliptin) as single-dose administration
89128521|NCT00687999|Other|1|
89128522|NCT00688077|Experimental|1|
89128523|NCT00688077|Placebo Comparator|2|NaCl 0,9% 2 ml, single subcutaneous injection
89128524|NCT00688233|Experimental|F-seifi|
89128525|NCT00923156|Experimental|Aliskiren|In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (Period 2), patients received aliskiren (150 mg once daily) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site and matching placebo of ramipril capsules.
89128526|NCT00923156|Experimental|Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (Period 2), patients received ramipril 10 mg capsule o.d and matching placebo of aliskiren tablet."
89128527|NCT00923156|Experimental|Aliskiren plus Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (period 2), patients received ramipril (10 mg once daily capsule) and aliskiren (150 mg once daily tablet) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site"
89128528|NCT00688311|Experimental|Synbiotic|Ingestion of synbiotic dietary supplement
89128529|NCT00688311|Placebo Comparator|Placebo|Ingestion of the Placebo
89128530|NCT00688389||healthy|
89128531|NCT00688389||DF|
89128532|NCT00688389||DHF|
89128533|NCT04257266|Experimental|Cryo Cooling Pack|Cryo cooling pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
89128534|NCT04257266|Active Comparator|Commerical Ice Pack|The commercial ice pack will be placed on subjects for 30 mins after exercise-induced hyperthermia is achieved.
89128535|NCT02625831||SLE patients|"165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without.~Biological analysis were performed."
89128536|NCT02625831||healthy patients|48 healthy patients. Biological analysis were performed.
89128537|NCT04203602|Experimental|Telepresence round|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
89128538|NCT04203602|Active Comparator|conventional round|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
89128539|NCT00688779|Experimental|1|
89128540|NCT00688779|Placebo Comparator|2|
89128541|NCT04203992|Experimental|Videogame|Educational videogame, five 60-minute sessions over one month
89128542|NCT04203992|Active Comparator|Booklet|Educational booklet, one session
89128543|NCT00688857|Experimental|A|Diazoxide choline controlled-release coated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 9 through 16).
89128544|NCT00688857|Experimental|B|Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release coated tablets administered orally once daily (Days 9 through 16)
89128545|NCT00689013|No Intervention|1|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the first month of observation. These patients have not been exposed to pharmacist-driven interventions utilized in this study. This group serves as the control group.
89128546|NCT00689013|Experimental|2|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the second month of observation. These patients may or may not have been exposed to pharmacist-driven interventions utilized in this study. This group serves as the study/intervention group.
89128547|NCT04203758|Experimental|Wholegrain rye products with a high content of dietary fiber|Cereal products based on wholegrain rye
89128548|NCT04203758|Active Comparator|Refined wheat products with a low content of dietary fiber|Cereal products based on refined wheat
89128549|NCT04256798|Experimental|Mouthwash and liberal oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 80-100% FiO2 during surgery.
89128550|NCT04256798|Active Comparator|No mouthwash and liberal oxygen during surgery|No pre-surgical mouthwash in combination with 80-100% FiO2 during surgery.
89128551|NCT04256798|Experimental|Mouthwash and restrictive oxygen during surgery|Pre-surgical mouthwash with 0.2% chlorhexidine gluconate in combination with 21-30% FiO2 during surgery.
89128552|NCT04256798|Active Comparator|No mouthwash and restrictive oxygen during surgery|No pre-surgical mouthwash in combination with 21-30% FiO2 during surgery.
89128553|NCT00687843|Active Comparator|1|The TS-1 group
89128554|NCT00687843|Experimental|2|The TS-1+PSK Group
89128555|NCT04139187|Experimental|Experimental|Individuals randomized to experimental group.
89128556|NCT04139187|No Intervention|No Intervention Control|Individuals without quadriceps dominance randomized to no intervention group.
89128557|NCT00689169|Experimental|Experimental|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
89128558|NCT00610844|Experimental|1|pulmonary radiofrequency ablation
89128559|NCT00610922|No Intervention|1|
89128560|NCT00610922|Experimental|2|
89128561|NCT04203914|Experimental|Intervention|Empagliflozin 25mg daily add-on therapy
89128562|NCT04260308||residents|"Voluntary residents~Can use mobile phone or computer"
89128563|NCT04260308||medical staff|"Voluntary residents~Can use mobile phone or computer"
89128564|NCT00874731|Experimental|Pt 1. Placebo/Ridaforolimus 100 mg; Pt 2. Ridaforolimus 40 mg|[Pt 1, Day 1]: Participants received a single dose of placebo (10 oral tablets) on Day 1 of Part 1. [Pt 1, Day 2]: Following completion of Part 1 / Day 1, participants received a single dose of ridaforolimus 100 mg (10 x 10 mg oral tablets) on Day 2 of Part 1. Following completion of Part 1 / Day 2, participants entered a washout period of ≥5 days before the first dose Part 2. [Pt 2]: Following completion of Part 1, participants received ridaforolimus 40 mg (4 x 10 mg oral tablets) given once daily (QD) for 5 consecutive days followed by 2 days off-drug.
89128565|NCT02625519|Experimental|Urinary follicle-stimulating hormone|Controled Ovarian stimulation with urinary follicle-stimulating hormone
89128566|NCT02625519|Experimental|Recombinant follicle-stimulating hormone|Ovarian stimulation with recombinant follicle-stimulating hormone
89128567|NCT00912483|Experimental|Test|Heparin Sodium 5.000UI/0.25mL
89128568|NCT00912483|Active Comparator|Ative comparator|Heparin Sodium 5.000USP/mL
89128569|NCT00689247|Experimental|A|AZD1305 given as oral solution
89128570|NCT00689247|Experimental|B|AZD1305 given as iv infusion
89128571|NCT00689403|Experimental|Part A: 2x2 crossover|4 different AZD1305 ER formulations
89128572|NCT00689403|Experimental|Part B: 3x3 crossover|2 different AZD1305 ER formulations and a reference formulation
89128573|NCT00924638|Active Comparator|Continuous Monitoring|Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
89128574|NCT00924638|No Intervention|Control Arm|Follow-up at the same frequency, but with no Insertable Cardiac Monitor
89128575|NCT00874497|Experimental|1 Tetomilast|
89128576|NCT00874497|Placebo Comparator|2 Placebo|
89128577|NCT00924560|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).
89128578|NCT00924560|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received a 28-day regimen consisting of 21 consecutive days of active combination tablets containing 100 μg LNG/20 μg EE followed by 7 days of placebo tablets for a total of 52 weeks (13 consecutive 28-day cycles).
89128579|NCT00924560|No Intervention|Untreated Control|Participants received no oral contraceptives during the study.
89128580|NCT00689559|Experimental|1|AZD3480 + Aripiprazole
89128581|NCT00689559|Experimental|2|Placebo + Aripiprazole
89128582|NCT00689637|Experimental|1|AZD3480 + warfarin
89128583|NCT00689637|Experimental|2|Placebo+ warfarin
89128584|NCT00689715|Experimental|EP|Single treatment arm
89128585|NCT04048473||MUH (Mansoura University Hospital)|enrolled 127 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5). Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
89128586|NCT04048473||Ocmu (Oncology center Mansoura University)|enrolled132 patients in outpatient pain clinic The health service quality was assessed using Patient Satisfaction Questionnaire Short Form (PSQ-18) (ranging from strongly agree = 1, agree = 2, uncertain = 3, disagree = 4 and strongly disagree = 5).Also the treatment satisfaction using The Pain Treatment Satisfaction Scale (PTSS) was evaluated (ranging from 0 = dissatisfied to 100 = satisfied)
89128587|NCT00689949|Other|folic acid|
89128588|NCT04256642|Active Comparator|Intrathecal morphine|
89128589|NCT04256642|Experimental|Erector Spinae Plane Block|
89128590|NCT04031157|Experimental|PGT arm|Predictix Antidepressant-guided treatment condition
89128591|NCT04031157|No Intervention|soc arm|Standard of Care condition
89128592|NCT04260386||Staff receiving the MOMS training|Delegates taking part in the routine Multidisciplinary Obstetric and Midwifery Simulation (MOMS) training course at the Chelsea and Westminster Hospital.
89128593|NCT00690027|Active Comparator|A|"Objective: See Brief Summary, page 2. Eligibility: Patients who require > 2 units blood transfusion for bleeding esophageal varices due to cirrhosis.~Randomization: By the blind card method to emergency portacaval shunt (EPCS) or emergency endoscopic sclerotherapy (EST) followed by long-term repetitive EST.~Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 8hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months, or rebleeding after varices were obliterated.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong. Data Collection on line, analysis by biostatistician Florin Vaida, PhD External Advisory, Data Monitoring and Safety Committee by 3 senior academicians."
89128594|NCT00690027|Active Comparator|B|Emergency endoscopic sclerotherapy
89128595|NCT00690105|Experimental|A|
89128596|NCT00690105|Active Comparator|B|
89128597|NCT00923078|Experimental|Auditory-Visual Train Order|4 weeks (20 sessions) of auditory cognitive training (Brain Fitness) followed by 4 weeks (20 sessions) of visual cognitive training (Insight)
89128598|NCT00923078|Experimental|Visual-Auditory Train Order|4 weeks (20 sessions) of visual cognitive training (Insight) followed by 4 weeks (20 sessions) of auditory cognitive training (Brain Fitness)
89128599|NCT04139265||Hospitalized patients aged 65 and over|- Patients aged 65 and over hospitalized in the department of Internal Medicine and Geriatry
89128600|NCT04260152|Active Comparator|Control: CAF + CTG|Following root preparation and conditioning, the CTG is obtained from the palate according to the randomization scheme and shaped to the recipient site and may be sutured to the papilla region and the coronally advanced flap (CAF) is sutured into place.
89128601|NCT04260152|Experimental|Test: CAF + Geistlich Fibro-Gide® (test)|Following root preparation and conditioning, Geistlich Fibro-Gide® is cut to size and shaped to the recipient and may be sutured and the coronally advanced flap (CAF) is sutured into place.
89128602|NCT04136613|Experimental|Post placental intra uterine device insertion|There was immediate post-partum insertion of CuT 380 A intrauterine device after delivery of placenta during cesarean delivery. To overcome the considerable expulsion rate in the previous studies, we stabilize the IUD in place at the fundus be an absorbable suture; vicryl 0 that was introduced through the fundus, held the needle with sponge holder that was introduce up the fundus and taken out the vicryl through the lower uterine inscion, cutting the needle, hold the vicryl around the the T arm of the IUD and withdrawn back to be placed inside the fundus. Before closing the uterine incision, the threads were placed in the lower uterine segment, then the uterine incision was then closed routinely.
89128603|NCT00978731|Experimental|Dasatinib|
89128604|NCT04136535|Experimental|Pemetrexed and Carboplatin with Anlotinib|Pemetrexed and Carboplatin with Anlotinib
89128605|NCT04136535|Active Comparator|Pemetrexed and Carboplatin without Anlotinib|Pemetrexed and Carboplatin without Anlotinib
89128606|NCT00694629|Active Comparator|1|rifampin, isoniazid, pyrazinamide, ethambutol
89128607|NCT00694629|Experimental|2|rifapentine 10 mg/kg, isoniazid, pyrazinamide, ethambutol
89128608|NCT00694629|Experimental|3|rifapentine 15 mg/kg, isoniazid, pyrazinamide, ethambutol
89128609|NCT00694629|Experimental|4|rifapentine 20 mg/kg, isoniazid, pyrazinamide, ethambutol
89128610|NCT00912639|Experimental|Genexol-PM|"All the patients are recurrent breast cancer after taxane treatment. Patients with a measurable lesion (at least 1 measurable lesion)~Spiral CT : lesion ≥ 10mm (unidimension)~X-ray, MRI, ultrasound : lesion ≥ 20 mm (unidimension)"
89128611|NCT02866409|Experimental|Bupivacaine,dexmedetomidine scalp block|Bupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept < 2 mg /kg for scalp block
89128612|NCT02866409|Active Comparator|bupivacaine dexmedetomidine infiltration|The incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
89128613|NCT02866409|Active Comparator|bupivacaine infiltration|The incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
89128614|NCT04136925||"runner participating of the Grand Raid"|
89128615|NCT02867969|Other|Motor training|The motor training comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
89128616|NCT00694785|Experimental|Group NT3|Patients will receive a total dose of approximately 1.7 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL
89128617|NCT00694785|Experimental|Group T3|Patients will receive a total dose of approximately 1.4 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
89128618|NCT00694785|Experimental|Group NT6|Patients will receive a total dose of approximately 3.9 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL.
89128619|NCT00694785|Experimental|Group T6|Patients will receive a total dose of approximately 3.1 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
89128620|NCT05834010|Experimental|FMT|rectal or oral route FMT
89128621|NCT05833997|Experimental|Holmium Laser En-bloc Resection of Bladder Tumors (HoLERBT) arm|Patients randomized to HoLERBT group will have their tumor resected using the Megapulse 70w (Richard Wolf).
89128622|NCT05833997|Active Comparator|Control arm|Patients randomized to control arm will undergo a monopolar transurethral resection of bladder tumor.
89128623|NCT05833984|Experimental|Dose Escalation Part|Mutiple dose level cohorts in the dose escalation part
89128624|NCT05833984|Experimental|Head and neck squamous cell carcinoma, nasopharyngeal carcinoma|Dose expansion cohort with IMM01 plus Tislelizumab
89128625|NCT05833984|Experimental|Ovarian carcinoma|Dose expansion cohort with IMM01 plus Tislelizumab
89128626|NCT05833984|Experimental|Non small cell lung carcinoma, small cell lung carcinoma|Dose expansion cohort with IMM01 plus Tislelizumab
89128627|NCT05833984|Experimental|Hepatocellular carcinoma|Dose expansion cohort with IMM01 plus Tislelizumab
89128628|NCT05833984|Experimental|Other solid tumors|Dose expansion cohort with IMM01 plus Tislelizumab
89128629|NCT05833984|Experimental|Classic hodgkin lymphoma|Dose expansion cohort with IMM01 plus Tislelizumab
89128630|NCT05833971|Experimental|Experimental: cadonilimab (AK104) + chemotherapy|Drug: Cadonilimab+ chemotherapy，10mg/kg IV every 3 weeks (Q3W)，Other Name: AK104； Cisplatin，60-75mg/m2 IV every 3 weeks (Q3W)，Other Name: DDP；Albumin Paclitaxel，260mg/m2 IV every 3 weeks D1, 8(Q3W)，Other Name: Nab-PTX
89128631|NCT05833919|Experimental|ARM A|Second line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days followed by third line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days.
89128632|NCT05833919|Experimental|ARM B|Second line Capecitabine 1250 mg/m2 orally twice per day on days 1 to 14 every 21 days; followed by third line Eribulin 1.23 mg/m2 i.v. on day 1, 8 every 21 days.
89128633|NCT05833893|Experimental|Treatment group|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
89128634|NCT05833841|Experimental|Evaluation of swallowing function|Measurement of swallowing function using Surface Electromyography and video flouroscopy
89128635|NCT05833815|Experimental|Additional Everolimus|Everolimus 10 mg. PO/day in addition to standard of care
89128636|NCT05833815|Other|Control|Standard of care alone i.e Capecitabine and Oxaliplatin or Gemcitabine and oxaliplatin
89128637|NCT05833802||the virtual cohort|the virtual cohort that enroll in silico clinical trial (ISCT), and will be treated by virtual anti-cancer drug.
89128638|NCT05833802||the real cohort|the real cohort that enroll in real word study, and will be treated by anti-cancer drug.
89128639|NCT05833750|Active Comparator|reflexology|Patients in the reflexology group were applied twice a week for eight weeks.
89128640|NCT05833750|No Intervention|Control group|No intervention was made
89128641|NCT05833698||Patients with failure of conservative treatment|
89128642|NCT05833698||Patients without failure of conservative treatment|
89128643|NCT05833672|Experimental|Locally Advanced Colon Cancers|Cycle 1 to Cycle 2 CapeOX + Terelizumab therapy(Day 1 through Day 21)
89128644|NCT05833659||The prepectoral breast reconstruction|The patients received prepectoral breast reconstruction after single-port insufflation endoscopic nipple-sparing mastectomy
89128645|NCT05833659||The subpectoral breast reconstruction|The patients received subpectoral breast reconstruction after single-port insufflation endoscopic nipple-sparing mastectomy
89128646|NCT05833620||Symptomatic patients|Adult patients (≥ 18 years old) with hereditary angioedema with C1INH deficiency (HAE-C1INH) from different regions of Spain will be included. Patients included in the study will be divided into two groups: a) symptomatic, which will be those who present symptoms compatible with HAE-C1INH and who have a confirmed diagnosis
89128647|NCT05833620||Asymptomatic patients|Asymptomatic patients, which will be those with a C1INH deficiency and who have not developed symptoms of HAE. Asymptomatic patients must be at least 22 years old and meet the same criteria than those symptomatic, except for the presence of symptoms consistent with HAE-C1INH
89233874|NCT01566045|Active Comparator|Core Needle TRUS biopsy (Transrectal ultrasound)|Patient receiving core needle TRUS biopsy (Standard of care biopsy)
89233875|NCT01566045|Experimental|Core Needle MRI/US fusion guided biopsy|Patients receiving Standard of Care core needle TRUS biopsy will then receive the MRI / Ultrasound fusion core needle guided biopsy
89128648|NCT05833607||ALL PATIENTS|"All patients are monitored with the transcranial Doppler helmet and the 2Hz probe in one of the middle cerebral hemispheres and the Brain 4 care on the other side.~Necessary monitoring: arterial line, electrocardiographic monitor, pulse oximetry, temperature. ETCO2 monitoring whenever possible.~Step 1: Test arterial line circuit, ensure proper temperature, arterial blood gases Step 2: Record data with the patient's baseline pressure (data from the monitor, transcranial doppler and brain4care), for 5 min Step 3: Vasopressor titrant for 3 MAP targets (65, 75 and 85 mmHg) , record data with the patient's baseline pressure (data from the monitor, transcranial doppler and brain4care), each target record for 3 minutes Step 4: Arterial blood gases, gradually restore PAM to baseline value"
89128649|NCT05833581|Experimental|Single Intervention Study Arm|All participants with HF will be evaluated by their HF providers who will use the NYHA Classification Guide to assist with assignment of HF class. The participant will then complete a 6-minute walk test. Subsequently participating providers will utilize the guide to assess and assign the class of their HF patients in practice.
89128650|NCT05833568|Active Comparator|10-Hz tACS Stimulation Group|tACS stimulation will be delivered over to parieto-occipital sites using only 2-minute ramp up and down and a continuous 20-minute 10 Hz sinusoidal current administered. The stimulation electrode montage will be identical for both conditions.
89128651|NCT05833568|Sham Comparator|Sham Stimulation Group|Sham stimulation will be delivered over to parieto-occipital sites using only 2-minute ramp up and down, without any sinusoidal current administered for 20 minutes. The stimulation electrode montage will be identical for both conditions.
89128652|NCT05833555|Active Comparator|Education and Resources|Education and Resources (E&R) involves online training through the E-Hub on delivery of basic MH task-shifting skills, such as screening, psychoeducation, and referral to MH care. A community directory along with training on community resources will be made available to all participants. Specifically, we will recommend that those identified to have common MH problems (PHQ-4 > 3) are offered a single two-hour zoom-based group psychoeducation session about depression and anxiety, COVID-19 impact on MH, wellness and self-care skills, and directory of Harlem-based MH services and other community resources. Participants exhibiting higher level needs are referred to MH specialists.
89128653|NCT05833555|Experimental|Multisector Collaborative Care|Multisector Collaborative Care (MCC) Model will consist of all resources offered in E&R and additional trainings on skills related to working in a multisectoral team, care navigation, syndemic risks and coordination of services related to MH, social services, and health care.
89128654|NCT05833555|Experimental|Multisector Collaborative Care and Technology|MCC sites will be randomized to receive an additional technology-based implementation tool to evaluate impact on implementation and consumer outcomes.
89128655|NCT05833542|Experimental|Health education materials only|"Participants will receive informational materials on their HIV treatment options and related support-service options. These will include a brief Frequently Asked Questions document with answers and a video comparing long-acting injectable with daily oral antiretroviral therapy, and explaining considerations for patients who may be interested in long-acting injectable treatment options. Both components are designed for patient self-guided use, but can also be presented or discussed in a session with medical case management program staff."
89128656|NCT05833542|Experimental|Health education materials and shared patient-provider decision tool|Prior to or during a medical case management visit, participants will receive informational materials (described above) on their HIV treatment options and related support-service options. During their medical case management visit, the participant and their medical case management provider will review a shared decision tool to facilitate patient-provider agreement on an HIV treatment plan.
89128657|NCT05833477|Experimental|Treatment group|Recombinant human erythropoietin treatment three times per week for three weeks
89128658|NCT05833451|Experimental|Reiki|The participants in the Reiki group (n=32) were given Reiki remotely for 60 minutes by two certified practitioners who completed the second level Reiki training with a Master degree Reiki instructor according to the Usui method.
89128659|NCT05833451|No Intervention|Control|No intervention was made in the control group (n=32).
89128660|NCT05833425||Scoliosis group|In this study, an evaluation form including demographic and clinical characteristics, respiratory muscle strength measurement, quadriceps muscle strength measurement with electronic hand dynamometer, hand grip strength with dynamometer and postural stability assessment with Biodex Balance System® will be applied to all scoliosis adolescent.
89128661|NCT05833425||Healthy group|In this study, an evaluation form including demographic and clinical characteristics, respiratory muscle strength measurement, quadriceps muscle strength measurement with electronic hand dynamometer, hand grip strength with dynamometer and postural stability assessment with Biodex Balance System® will be applied to all healthy adolescent.
89128662|NCT05833399||Addicted patients on treatment with psychiatric medications.|Addicted patients receiving treatment with either quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine or risperidone as oral dosage forms of usual prescribed doses for psychiatric disorders.
89128663|NCT05833399||Healthy non-addicted controls.|Individuals who have never been addicted to any substance of use and did not receive any treatment with psychiatric medications.
89128664|NCT05833295|Experimental|Walking on flat ground|Patients will walk for 20 minutes at a 0% slope.
89128665|NCT05833295|Experimental|-%7.5 Downhill walking|They will walk downhill for 20 minutes at a -(negative)7.5% gradient.
89128666|NCT05833295|Experimental|-%15 Downhill walking|They will walk downhill for 20 minutes at a -(negative)15% gradient.
89128667|NCT05833165||Feasibility of a supportive approach|Evaluating a feasibility of an approach
89128668|NCT05833152||<5°|
89128669|NCT05833152||5-10°|
89128670|NCT05833152||10-15°|
89128671|NCT05833152||≥15°|
89128672|NCT05833009|Experimental|Acupuncture Group|They receive actual acupuncture on purpose acupoints.
89128673|NCT05833009|Sham Comparator|Sham Group|They receive actual acupuncture on points but not an acupoint around the purpose acupoints.
89128674|NCT05833009|Sham Comparator|non-Acupuncture Group|They receive fake acupuncture (no needle) on purpose acupoints.
89128675|NCT05832996|Experimental|Cooled artificial tear group|Stored at 4 degree Celsius
89128676|NCT05832996|Active Comparator|Room temperature artificial tear group|Stored at 25 degree Celsius
88802289|NCT01890694|Experimental|Tolvaptan|"Subjects will receive Tolvaptan once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
88802290|NCT01883908|Experimental|Acupuncture with Seirin® needles|Participants will be randomized to receive acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
88802291|NCT01883908|Active Comparator|Usual medical care|Participants will be randomized to receive usual medical care for 8 weeks coinciding with their chemoradiation treatments. Patients will receive usual medical care such as viscous Lidocaine for relief of pain.
88802292|NCT03466866|Experimental|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
88802293|NCT03466866|Active Comparator|Intensive Diabetes Education|In-home diabetes education
88802294|NCT05474898|Experimental|Group (A)|
88802295|NCT05474898|Experimental|Group (B)|
88802296|NCT05474898|Other|Group (c)|
88802297|NCT04787536||Study cohort|Patients aged 65 years or greater; scheduled to perform noncardiac elective surgery expected to require at least an overnight stay in hospital after surgery; surgery deferred, with a known or probable surgery date in ≥6 weeks
88802298|NCT05483244||discontinuous weaning group|Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via taken directly to the heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator.
89128677|NCT05832970|Experimental|Hand cooling|Records will be taken for Baseline electromyography, Heart rate, H-reflex, and T-reflex measurements before, during, and at 0, 3, 6, 9, 12, and 15. minutes before applying 2-4 degrees Celsius cold to the back of the hand in this group.
89128678|NCT05832853|Experimental|Wu Qin Xi exercise|The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group.
89128679|NCT05832853|Experimental|Wu Qin Xi, resistance training and endurance training|The trial was divided into three cycles, each lasting eight weeks. Participants performed a hybrid program of Wu Qin Xi exercise, resistance training and endurance training of varying duration and intensity in each cycle. Each session lasted one hour, three times a week for 24 weeks.
89128680|NCT05832853|Experimental|Resistance training and endurance training|The trial was divided into three cycles, each lasting eight weeks. Participants performed a hybrid program of resistance training and endurance training of varying duration and intensity in each cycle. Each session lasted one hour, three times a week for 24 weeks.
89128681|NCT05832775|Experimental|MRx0029 Treatment Sequence 1|Patients will receive MRx0029 in the first treatment period and then placebo in the second treatment period
89128682|NCT05832775|Experimental|MRx0029 Treatment Sequence 2|Patients will receive placebo in the first treatment period and then MRx0029 in the second treatment period
89128683|NCT05832775|Experimental|MRx0005 Treatment Sequence 1|Patients will receive MRx0005 in the first treatment period and then placebo in the second treatment period
89128684|NCT05832775|Experimental|MRx0005 Treatment Sequence 2|Patients will receive placebo in the first treatment period and then MRx0005 in the second treatment period
89128685|NCT05832762|Experimental|Endovascular treatment + best medical treatment|Endovascular treatment associated with the best medical treatment.
89128686|NCT05832762|Active Comparator|best medical treatment|Best medical treatment alone
89128687|NCT05832749||Study Product: Ophtesis Bio 3%|Subjects to receive Ophtesis Bio 3% in one eye
89128688|NCT05832749||Control Product: Healon Endocoat 3%|Subjects to receive Healon Endocoat 3% in one eye
89128689|NCT05832710||Sedentary|It will be obtained by open call for both students and administrative staff at the CES University (Medellín) and Universidad Santo Tomás (Bogotá).
89128690|NCT05832710||Physically active|A sample of physical education majors and personal trainers who reside and work in Medellín and Bogotá will be invited to participate (Universidad Santo Tomás and Smart Fit).
89128691|NCT05832710||Professional Athletes|A sample of elite and sub-elite athletes with >2 years at the competitive level will be invited to participate (ARTHROS Physiotherapy and Exercise Center, INDEPORTES Antioquia, and Universidad Santo Tomás).
89128692|NCT05832697|Active Comparator|Treatment A|P1: DWJ1439(ursodeoxycholic acid) 100mg, P2: DWC202108(usrodeoxycholic acid) 250mg, P3: DWJ1464(ursodeoxycholic acid) 100mg
89128693|NCT05832697|Active Comparator|Treatment B|P1: DWC202108(usrodeoxycholic acid) 250mg, P2: DWJ1439(ursodeoxycholic acid) 100mg, P3: DWC202109(ursodeoxycholic acid) 250mg
89128694|NCT05832697|Active Comparator|Treatment C|P1: DWJ1464(ursodeoxycholic acid) 100mg, P2: DWC202109(ursodeoxycholic acid) 250mg, P3: DWJ1439(ursodeoxycholic acid) 100mg
89128695|NCT05832697|Active Comparator|Treatment D|P1: DWC202109(ursodeoxycholic acid) 250mg, P2: DWJ1464(ursodeoxycholic acid) 100mg, P3: DWC202108(usrodeoxycholic acid) 250mg
89128696|NCT05832684|Experimental|Experimental|Dose escalation and expansion of ZVS101e. All patients enrolled in the study will receive a single subretinal injection of ZVS101e in one eye.
89128697|NCT05832671|Active Comparator|US guided erector spinae muscle block|patients will receive US-guided erector spinae muscle block with a total volume of 0.4 mg/kg of 0.25% bupivacaine.
89128698|NCT05832671|Active Comparator|ultrasound-guided caudal block|patients will receive an ultrasound-guided caudal block with 2.5 mg/kg of 0.25% bupivacaine to be injected over one minute period while observing an ultrasound longitudinal image.
89128699|NCT05832619|Other|Waiting list group|This group will include 40 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist. After 6 weeks, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
89128700|NCT05832619|Sham Comparator|SIA+SSRIs group|This group will include 40 patients with MDD who will be treated with sham intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
89128701|NCT05832619|Experimental|AIA+SSRIs group|This group will include 40 patients with MDD who will be treated with active intradermal acupuncture combined with SSRIs. Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
89128702|NCT05832593||Group 1|
89128703|NCT05832593||Group 2|
89128704|NCT05832580|Experimental|Etidronate|Daily dosis of 20mg/kg of etidronate in a cyclical regimen of 2 weeks on and 10 weeks off, for a total of 24 months.
89128705|NCT05832580|Placebo Comparator|Placebo|Daily dosis of placebo in a cyclical regimen of 2 weeks on and 10 weeks off, for a total of 24 months.
89128706|NCT05832528|Experimental|FD patient|Low-FODMAP diet in patients with FD for 6 weeks.
89128707|NCT05832515|Experimental|AHSCT: FluCy200|"AHSCT with reduced intensity condition regimen (RIC):~cyclophosphamide intravenously at a dose of 50 mg/kg/day from -5 to day -2 inclusive; fludarabine intravenously at a dose of 30 mg/m2 from -5 to day -2 inclusive. Immunotherapy: ATG - ATGAM intravenously 20 mg/kg from -3 to -1 or Thymoglobulin 2.5 mg/kg from -3 to -1 day.~Also, within the framework of immunotherapy, instead of ATG, it is allowed to use anti-B-cell therapy - Rituximab 500 mg / m2 per day +12 AHSCT."
89128708|NCT05832476||Matured|It is defined as the target HDAVF can be used
89128709|NCT05832476||Non-matured|RC-AVF underwent additional intervention after 90 days of observation
89128710|NCT05832463|Experimental|Experimental arm|"In cohort 1, participants will receive either a 250 mg mulberry leaf extract CBS dose (1 supplement capsule t.i.d. + 1 placebo capsule to preserve blinding) or a 500 mg mulberry leaf extract CBS dose (2 supplements t.i.d.) in the experimental arm and will cross over to or from the placebo arm.~In cohort 2, participants will receive a 500 mg mulberry leaf extract CBS dose (2 supplement capsules t.i.d.) in the experimental arm and will cross over to or from the placebo arm."
89128711|NCT05832463|Placebo Comparator|Placebo arm|In Cohorts 1 and 2, participants will receive 2 placebo capsules in the placebo arm and will cross over to or from the experimental arm.
89128712|NCT05832385||radiation dose≤50Gy|rectal cancer with IMRT radiation dose≤50Gy
89128713|NCT05832385||radiation dose>50Gy|anal cancer with IMRT radiation dose>50Gy
89128714|NCT05832372||Normal colonoscopy group|Individuals with normal colonoscopy examination
89128715|NCT05832372||Colorectal polyps group|Individuals with colorectal polyps diagnosed by colonoscopy
89128716|NCT05832346|Experimental|Laughter yoga programme|The intervention group will receive a 4-week laughter yoga programme (8 sessions). This group also receives routine care provided by the special school as usual.
89128717|NCT05832346|No Intervention|Routine care|The control group receives routine care provided by the special school as usual.
89128718|NCT05832320|Experimental|Oral etoposide with dual induction of ATRA and RIF|RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
89128719|NCT05832320|Active Comparator|Daunorubicin with dual induction of ATRA and RIF|RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
89128720|NCT05832294|Sham Comparator|Sham Stimulation|15 Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of sham rTMS
89128721|NCT05832294|Active Comparator|Active Stimulation|15 Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of active rTMS
89128722|NCT05832242||Simple Diverticulitis|Computed tomograpy scan showing isolated inflammation
89128723|NCT05832242||Complicated Diverticulitis|Computed tomograpy scan evidence of diverticulitis with either an associated abscess, fistula, obstruction, bleeding, phlegmon or perforation.
89128724|NCT05832216|Experimental|Daratumumab|
89128725|NCT05832203|Experimental|Intervention|90 overweight/obese adults will be given counseling on planetary health diet, calorie restriction diet, and healthy lifestyle materials through a mobile app within 6 months
89128726|NCT05832203|Placebo Comparator|Control|90 overweight/obese adults will be given counseling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through a mobile app within 6 months
89128727|NCT05832099||Radiation|Conformal focal-brain irradiation using modern radiotherapeutic techniques (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
89128728|NCT05832073|Experimental|Experimental group|Natural full human monoclonal antibody CBB 1 injection：Each dose (2.5ml) contained 0.5 mg / natural monoclonal antibody ml CBB 1 Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection Character: colorless to pale green and yellow liquid Specification: 1.25 mg (2.5 ml) / bottle Mode of administration: intramuscular injection of the vastus lateralis muscle. Usage and dosage: The injection dose was calculated according to the group and body weight of the volunteer. On day 0, unilateral or bilateral extrafemoral muscle group injections were selected by dose, with no more than 5 mL at each site, and at least 2.5 cm apart.
89128729|NCT05832073|Active Comparator|Positive control group|"Rabies Human Immunoglobulin (HRIG) Active ingredient: Rabid human immunoglobulin Specification: 200 IU / 2 ml / bottle Administration mode: intramuscular injection of the vastus lateral muscle group.~Usage and dosage: the injection dose was calculated according to the body weight of the volunteer. On day 0, unilateral or bilateral extrafemoral muscle group injections were selected by dose, with no more than 5 mL at each site and at least 2.5 cm apart"
89128730|NCT05832073|Placebo Comparator|Placebo group|Healthy people in placebo group will receive a dose of placebo
89128731|NCT05832034|Experimental|Add-on IVIg|Patients in the intervention arm will be treated with Nanogam® in a dosage of 2 g/kg over 2-5 days, with a maximum of 80 g/day and a total of 180 gram at baseline and after 4 and 8 weeks. Nanogam® contains 100 mg/mL normal human immunoglobulin with a purity of at least 95% IgG and a maximum of 12 microgram/mL IgA, in a solution of water for injections and glucose. The first 30 grams are administered in hospital.
89128732|NCT05832034|Placebo Comparator|Placebo|Patients in the control arm will be treated with placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks. The first 30 grams are administered at the neurology ward, after 4 and 8 weeks infusions will be administered at home
89128733|NCT05831852||one group|
89128734|NCT05830539|Experimental|Triple Negative Breast Cancer(TNBC)|"Group 1: IN10018 in combination with PLD in Subjects with previously-treated locally advanced or metastatic TNBC.~Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated locally advanced or metastatic TNBC."
89128735|NCT05830539|Experimental|Head and Neck Squamous Cell Cancer(R/M-HNSCC)|"Group 1: IN10018 in combination with PLD in Subjects with previously-treated R/M-HNSCC.~Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated R/M-HNSCC."
89128736|NCT05830539|Experimental|Platinum-resistant Ovarian Cancer|Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with platinum-resistant ovarian cancer.
89128737|NCT05830539|Experimental|Platinum-sensitive Ovarian Cancer(PSOC)|Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with Platinum-sensitive recurrent ovarian cancer.
89128738|NCT05830539|Experimental|Small Cell Lung Cancer(SCLC)|Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with previously-treated locally advanced or metastatic SCLC.
89128739|NCT05830539|Experimental|Other solid tumor|"Group 1: IN10018 in combination with PLD in Subjects with other previously-treated locally advanced or metastatic solid tumors.~Group 2: IN10018 in combination with PLD and anti-PD-1 monoclonal antibody in Subjects with other previously-treated locally advanced or metastatic solid tumors."
89128740|NCT05828940|Placebo Comparator|placebo|microcellulose
89128741|NCT05828940|Experimental|losartan|50mg losartan (Cozaar)
89128742|NCT05828329|Experimental|Experimental group 1|The program with virtual reality will consist of a 30-minutes guided visualization session through virtual reality glasses. Students will visualize a 360º video that simulates the entire experience of an exam, from first person perspective.
89128743|NCT05828329|Active Comparator|Experimental group 2|The 4-weeks program will consist of a 30-minutes traditional guided visualization session, by listening only the part of the audio used for EG1.
89128744|NCT05828329|No Intervention|Control group|This group will not receive any intervention, as the most used strategy to cope with exams among students.
89128745|NCT05828134|No Intervention|Usual care group|The control group only performed routine data collection and gave them dietary suggestion.
89128746|NCT05828134|Experimental|Protein-enriched soup group|Protein-enriched soup /day for use as a supplement with meals and strength training /week
89128747|NCT05825521|Experimental|Patients with hydrocephalus|Age > 55, Ventricular dilation: Evans Index > 0.3; Patients with cognitive impairment, and gait disturbances and/or urinary incontinence or a combination of these three symptoms; Absence of other neurological diseases that could cause ventriculomegaly, information and non-opposition.
89128748|NCT05825521|Active Comparator|Controls|Age ≥ 55; No ventricular dilation: Evans Index < 0.3; Individuals who have no neurological or psychiatric disease; No neurological deficit. No history of neurosurgery or head trauma; signed informed consent; affiliation to a social security scheme.
89128749|NCT05825326||Patients diagnosed with Philadelphia-negative Myeloproliferative Neoplasms|
89128750|NCT05818423|Experimental|Brain Health Academy|Participant in this arm will watch expert videos on a wide range of brain health topics and will complete quizzes for 2.5 hours a week for 12 weeks (30 hours total)
89128751|NCT05818423|Experimental|Brain Health Together|Participants in this arm will participate in online, live-streaming Moving Together classes (1 hour a week) and group brain health classes (1 hour a week) and will work 1-on-1 with a brain health coach to set personalized risk reduction goals (0.5 hours a week) for 12 weeks (30 hours total)
89128752|NCT05818423|Experimental|Maintain Brain Health Together|Participants in this arm will participate in the full Brain Health Together program for 12 weeks (30 hours) followed by weekly group classes and six 1-on-1 coaching sessions for another 12 weeks (additional 15 hours; 45 hours total)
89128753|NCT05817929|Experimental|cardiac surgery|
89128754|NCT05805020|Experimental|Cellvizio|Cellvizio is a confocal laser endomicroscopy providing the possibility of obtaining in vivo high-magnification images of the gut epithelium. This allows real-time examination of the gastrointestinal mucosa at the cellular and subcellular level
89128755|NCT05800028||AD group|30 individuals aged between 50 and 85 years with probable Alzheimer's disease dementia with amnestic presentation and documented decline following the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
89128756|NCT05800028||SPPA group|16 individuals aged between 50 and 85 years with the semantic variant of primary progressive aphasia following the classification of primary progressive aphasia and its variants.
89128757|NCT05800028||HC group|46 individuals without cognitive complain.
89128758|NCT05800028||Partners|92 individuals without cognitive complaints. Each of these individuals will partner with one of the members of the experimental groups to carry out learning in social contexts.
89128759|NCT05796401|Active Comparator|Treatment as usual (TAU)|
89128760|NCT05796401|Experimental|TAU + cognitive training|
89128761|NCT05796401|Experimental|TAU + personalized neuroprotective strategies|
89128762|NCT05796401|Experimental|TAU + personalized neuroprotective strategies + cognitive training|
89128763|NCT05792813|Experimental|Experimental group|LGYY+ WZYZ mimetic
89233876|NCT01566123|Experimental|A|Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma
89233877|NCT00449865|Placebo Comparator|Placebo|
89128764|NCT05792813|Active Comparator|Control group|WZYZ + LGYY mimetic
89128765|NCT05771402|Experimental|Group 1|NAs combined with anti-PD-1 antibody and Peg-IFNα
89128766|NCT05771402|Active Comparator|Group 2|NAs combined with Peg-IFNα
89128767|NCT05769816|Experimental|Group 1|NAs combined with anti-PD-1 antibody, followed by NAs monotherapy
89128768|NCT05769816|Active Comparator|Group 2|NAs
89128769|NCT05745142||metastatic Renal Cell Carcinoma patients|metastatic Renal Cell Carcinoma patients with clear cell histology.
89233878|NCT00449865|Active Comparator|creatine|
89128770|NCT05737069|Experimental|Ibuprofen arginine granules 400 mg|Participants will be randomly assigned as per cross-over design to receive one sachet of Ibuprofen arginine granules 400 mg (test product) on day 1 of period 1 and will receive one sachet of Ibuprofen arginine granules 400 mg (Spedifen) (reference product) on day 1 of period 2 with at least 2 days washout period. Participants will be instructed to consume the product orally by dissolving it in 240 mL of warm water.
89128771|NCT05737069|Active Comparator|Ibuprofen arginine granules 400 mg (Spedifen)|Participants will be randomly assigned as per cross-over design to receive one sachet of Ibuprofen arginine granules 400 mg (Spedifen) (reference product) on day 1 of period 1 and will receive one sachet of Ibuprofen arginine granules 400 mg (test product) on day 1 of period 2 with at least 2 days washout period. Participants will be instructed to consume the product orally by dissolving it in 240 mL of warm water.
89128772|NCT05732311|Experimental|active treatment|600 pulses of iTBS per day with 120% resting motor threshold applied five days in one week; tapering interval over 8 months (three treatments with breaks of three weeks; two treatments with breaks of five weeks; one last treatment after eight weeks)
89128773|NCT05732311|Active Comparator|active treatment 2|600 pulses of iTBS per day with 120% resting motor threshold applied five sessions in one day (three treatments with breaks of three weeks; two treatments with breaks of five weeks; one last treatment after eight weeks)
89128774|NCT05732103|Experimental|Dose Escalation Cohort|Drug: CTX-712 administered at 20 mg, 40 mg, 80 mg, 100 mg, 140 mg weekly
89128775|NCT05732103|Experimental|Dose Expansion Cohort|Drug: CTX-712 administered at a dose to be determined from the data of dose escalation cohort
89128776|NCT05732103|Experimental|Phase 2|CTX-712 administered at the recommended dose by the expansion cohort
89128777|NCT05723432|Experimental|KD6001+Toripalimab|KD6001 combined with toripalimab in patients with advanced melanoma
89128778|NCT05723328|Experimental|Treatment Group|The intervention consists of a sequence of five music therapy song-writing and recording groups, one per day. Internalized stigma will be assessed within 3 days of admission (pretest/baseline), at ten days (posttest), and at 3 weeks from baseline (follow-up), using the Internalized Stigma of Mental Illness Inventory.
89128779|NCT05723328|No Intervention|Control Group|Access to standard of care services that include several groups per day focused on topics of coping skills, mindfulness, journaling, creative arts, wellness recovery, recreation, and at least one music therapy group.
89128780|NCT05722964|Experimental|SHR-1906，-Dose A|
89128781|NCT05722964|Experimental|SHR-1906，- Dose B|
89128782|NCT05722964|Placebo Comparator|Placebo|
89128783|NCT05716165|Experimental|self-comparison|"Volunteers will be asked to wear a knee brace on each limb during one of the training sessions. At the end of this training session, a questionnaire will be given to the volunteer to evaluate knee stability, range of motion, confidence when walking, and fear of falling.~The volunteers will then have to participate in 2 test sessions: one with and one without knee braces.~The patient will perform tests (Unipodal balance on flat ground, 30s chair stand test, 2,5m up and go test, 6 min-walk) with and without the proprioceptive knee brace in a randomized order.~At the end of the tests with and without knee brace, a questionnaire will be given to the volunteer to evaluate the stability of the knee, the range of motion, the confidence when walking, the fear of falling, as well as a satisfaction questionnaire about the device.~There is also a satisfaction questionnaire regarding the proprioceptive knee brace to be completed at the end of the study."
89128784|NCT05709483|Experimental|Women with prior history of preeclampsia who received aspirin in subsequent gestation|Single-dose of enteric-coated 81 mg aspirin
89128785|NCT05709483|No Intervention|Healthy volunteers|In this group, no aspirin will be given, as blood draw will not be performed at all among the healthy volunteers. The group of healthy volunteers will serve only for the SNP assay development.
89128786|NCT05709197|Experimental|Braun anastomosis|Open pancreatoduodenectomy with Braun enteroenterostomy
89128787|NCT05709197|Other|Standard Child reconstruction|Open pancreatoduodenectomy only
89128788|NCT05706441||ultrasound|Pulmonary and diaphragm ultrasound was evaluated within one hour before withdrawal
89128789|NCT05697198||Cohort lung cancer|
89128790|NCT05697198||Gyn malignancies|
89128791|NCT05697198||Gastrointestinal malignancies Cohort|
89128792|NCT05697198||Melanoma Cohort|
89128793|NCT05697198||Breast cancer Cohort|
89128794|NCT05697198||Head and neck cancer Cohort|
89128795|NCT05697198||Sarcoma and soft tissue cancer cohort|
89128796|NCT05697198||Prostate cancer|
89128797|NCT05683119|Experimental|EUM Group|"Participants must: have menstrual cycle lengths ≥ 21 days and ≤ 35 days resulting in 9 or more consecutive periods per year; provide evidence of a luteinising hormone (LH) surge; demonstrate the required hormonal profile as defined below; and have not used any type of hormonal contraceptives (HC) for a minimum of 3 months, but ideally 6 months, prior to enrolment.~Phase 1- Indicated by the onset of bleeding until day 5 Oestrogen and progesterone levels are low~Phase 2- Oestrogen higher than during phase 1 and 3 Progesterone higher than during phase 1, but lower than 6.36 nmol·L-1 Must be followed by a positive luteinising hormone surge~Phase 3- +7 days after ovulation has been confirmed Oestrogen higher than phase 1, but lower than phase 2 Progesterone >16 nmol·L-1"
89128798|NCT05683119|Experimental|OCP Group|"Participants must: have been taking their OCP ≥ 3 months prior to recruitment; be taking a combined, monophasic, second generation OCP; and demonstrate the correct hormonal profile as defined below.~Pill-taking phase- Indicated by the 21 consecutive pill-taking days Oestrogen and progesterone levels are low; ≤ phase 1 of the menstrual cycle~Pill-free phase- Indicated by the 7 consecutive pill-free days Oestrogen and progesterone levels may begin to rise in comparison with the pill-taking phase"
89128799|NCT05672134|Experimental|Experimental arm|Patients will receive 13 weeks of experimental treatment, followed by a 7 week wash-out period, continuing with 13 weeks of placebo as per crossover design.
89128800|NCT05672134|Placebo Comparator|Placebo arm|Patients will receive 13 weeks of placebo treatment, followed by a 7 week wash-out period, continuing with 13 weeks of experimental treatment as per crossover design.
89128801|NCT05664100|Experimental|FX-345 Cohort 1|Patients in the first cohort receiving FX-345 intratympanic injection
89128802|NCT05664100|Placebo Comparator|Placebo Cohort 1|Patients in the first cohort receiving placebo intratympanic injection
89128803|NCT05664100|Experimental|FX-345 Cohort 2|Patients in the second cohort receiving FX-345 intratympanic injection
89128804|NCT05664100|Placebo Comparator|Placebo Cohort 2|Patients in the second cohort receiving placebo intratympanic injection
89128805|NCT05640583|Experimental|IBD|10 patients diagnosed with colonic IBD (5 diagnosed with Ulcerative Colitis and 5 diagnosed with Crohn's Disease) scheduled for a surveillance colonoscopy
89128806|NCT05640583|Active Comparator|Control|10 patients scheduled for a routine screening colonoscopy who do not have a history of IBD symptoms or IBD diagnosis
89128807|NCT05635799|Experimental|Subjects with lower limb amputations|
89128808|NCT05635799|Active Comparator|Healthy volunteers|
89128809|NCT05631470||Enrolled|Participants with ICAS will be scheduled for both MR screening and pressure-wire-based FFR measurement.
89128810|NCT05627492|Experimental|Youth with and/or at familial risk for bipolar disorder|120 youth aged 14 to 26 with bipolar disorder (type I, type II, not otherwise specified/NOS) OR at high-risk for bipolar disorder (parent or sibling with bipolar disorder type I or II via KSADS-PL or SCID-5-RV) will be enrolled in the dialectical behavioral therapy booster session intervention.
89128811|NCT05623943||ICAS patients planning for endovascular treatment|Patients received pressure-wire-based intravascular pressure measurement and ASL measurement before and after operation.
89128812|NCT05623267|Experimental|Experimental arm|Intravenous infusion (IV) of Sugemalimab 1200 mg at least 60 minutes on Day 1 of each treatment cycle, every 3 weeks (21 days), for 1 year or until disease progression or intolerable toxicity.
89128813|NCT05623267|Placebo Comparator|Control arm|Intravenous infusion (IV) of placebo at least 60 minutes on Day 1 of each treatment cycle, every 3 weeks (21 days), for 1 year or until disease progression or intolerable toxicity.
89128814|NCT05622864|Experimental|PartA|
89128815|NCT05622864|Experimental|PartB|
89128816|NCT05617092|Experimental|Intervention group|intervention group will receive a physiotherapy individualized treatment
89128817|NCT05617092|No Intervention|Control Group|No intervention in women with injury in the levator ani
89128818|NCT05617092|No Intervention|Healthy controls|A group of women without injury that will be invited to filling in the questionnaires that will be carried out in the study three, six months and one year postpartum.
89128819|NCT05608057|Experimental|Vitamin C mesotherapy|
89128820|NCT05608057|Active Comparator|Diode laser|
89128821|NCT05602402|Active Comparator|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule beforebreakfast (preferably with milk/butter/ghee)
89128822|NCT05602402|Placebo Comparator|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
89128823|NCT05594693||Patients Referred by the Pain Service or Palliative Care Service|"Any CHCO patient referred for integrative interventions by the Pain Service or the Palliative Care Service.~Patients at CHCO include premature infants through young adults. Any of these patients could benefit from integrative treatments. The treatments will only be offered after medical team approval and parental consent. All treatments will be provided by credentialed and licensed providers and will follow CHCO approved policies and procedures."
89128824|NCT05594615|Experimental|EDP-235, midazolam, rosuvastatin and caffeine|Subjects will receive EDP-235, midazolam, rosuvastatin and caffeine throughout the treatment period on respective dosing days
89128825|NCT05594602|Experimental|EDP-235 and Itraconazole interaction (Part 1)|Subjects will receive EDP-235 and Itraconazole on respective dosing days
89128826|NCT05594602|Experimental|EDP-235 and Carbamazepine interaction (Part 2)|Subjects will receive EDP-235 and Carbamazepine on respective dosing days
89128827|NCT05594602|Experimental|EDP and Quinidine interaction (Part 3)|Subjects will receive EDP-235 and Quinidine on respective dosing days
89128828|NCT05594056|Experimental|Preeclampsia|Patients with severe preeclampsia and gestational age between 34-40 weeks.
89128829|NCT05594056|Active Comparator|Control|Patients with normal gestations between 34-40 weeks.
89128830|NCT05589844|Experimental|Treatment (CMV-alphaDC1)|Patients undergo standard of care allogeneic hematopoietic stem cell transplant on day 0 and receive CMV-alphaDC1 vaccine intradermally on days 28, 42, 56, and 70.
89128831|NCT05584280||Promus stent on shelf|Control
89128832|NCT05584280||Orsiro stent on shelf|Treatment
89128833|NCT05566951|Experimental|Experimental group|-The experimental group that applied the technology-based psychosocial program
89128834|NCT05566951|Other|Control group|Control group receiving standard care
89128835|NCT05541393|Experimental|COVID-19 Education Group|Participants randomized to the intervention will be engaged over a three-week period in discussions by their health ministries; any identified concerns or barriers around the initial vaccination series and/or booster vaccinations will be addressed and the importance of continued COVID-19 testing will be emphasized. Evidence-based vaccine strategies that focus on positive framing will be employed
89128836|NCT05541393|No Intervention|Delayed Control Group|Participants in the delayed intervention control group will not receive any outreach during the three-week control period. Subsequent to completing the follow-up questionnaire, they will then be invited to join the intervention for the next three weeks. A follow-up questionnaire will be administered following their intervention period to be used in later analyses.
89128837|NCT05525377|Experimental|Intervention|Subjects in the intervention group receive access to an online training and educational phenotype-specific programme on how to support their relative with non-memory-led dementia. The online course consists on 6 modules to complete in 7 weeks. A course facilitator is available throughout the duration of the intervention to support participants.
89128838|NCT05525377|No Intervention|Treatment as usual (TAU)|"The treatment as usual group does not receive access to the educational programme."
89128839|NCT05519540|Experimental|Group 1: Japanese: Xevinapant (Debio 1143)|
89128840|NCT05519540|Experimental|Group 2: Non-Japanese East Asian: Xevinapant (Debio 1143)|
89128841|NCT05506124|Experimental|group 1|Propose a novel airbag-type stretchable electrode array (ASEA) device for training of the female pelvic floor muscle (PFM) for the treatment of UI
89128842|NCT05506124|Active Comparator|group 2|Propose a two-channel hard electrode device for training of the female pelvic floor muscle (PFM) for the treatment of UI
89128843|NCT05494632|Experimental|Single arm|CI speech processor programming
89128844|NCT05485519|Experimental|Dexmedetomidine (D)|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
89128845|NCT05485519|Active Comparator|Midazolam (M)|1 mcg/kg/minute. Up to a maximum of 5 mcg/kg/minute.
89128846|NCT05462262|Experimental|intensive lipid-lowering group|Goal for LDL-C <1.8 mmol/L or ≥50% reduction from baseline.
89128847|NCT05462262|Active Comparator|moderate-intensity lipid-lowering group|Goal for LDL-C <2.6 mmol/L or 30%-50% reduction from baseline.
89128848|NCT05461950||Self-breathing infants|Vigorous infants with spontaneous onset of respiration within one minute after delivery by cesarean section, receiving extra-uterine placental transfusion and physiology-based cord clamping
89128849|NCT05461950||Infants with respiratory support|Infants with no or poor spontaneous onset of respiration after delivery by cesarean section, receiving extra-uterine placental transfusion, intact-cord stabilisation (any respiratory support) and physiology-based cord clamping after transfer to resuscitation table
89128850|NCT05461950||Historical control group|Infants delivered by cesarean section in a time period when delayed cord clamping after 1-3 minutes was default procedure. Less-than-vigorous infants needing respiratory support or full resuscitation had their umbilical cords cut early (within 30 seconds)
89128851|NCT05429788|Experimental|Low dose RLS103|3 mg CBD inhaled dry powder
89128852|NCT05429788|Experimental|High dose RLS103|6 mg CBD inhaled dry powder
89128853|NCT05429788|Experimental|placebo|placebo inhaled dry powder
89128854|NCT05392556|Experimental|Probiotic|Bifidobacterium longum R0175; Lactobacillus helveticus R0052 (Cerebiome; Lallemand Health Solutions)
89128855|NCT05392556|Experimental|Prebiotic|Bimuno-galactooligosaccharide (Bimuno-GOS; Clasado Biosciences)
89128856|NCT05392556|Placebo Comparator|Placebo|Maltodextrin placebo
89128857|NCT05381610|Experimental|Neurogenic Bowel|This is a US-Only, early feasibility, Investigational Device Exemption - Non-Significant Risk (IDE-NSR), single-center, open label study evaluating the effects of Peristeen, compared to a LVE administered into the rectum. The subjects to be analysed will be subjects with : Neurogenic Bowel Dysfunction (NBD). The NBD cohort will be broken down into two phases: LVE and Peristeen. See Statistical section 10 for more infor-mation on cohort and sub-group analyses.
89128858|NCT05366296|Active Comparator|: A Lyophilized COVID-19 mRNA Vaccine(RH109)|Participants received A Lyophilized COVID-19 mRNA Vaccine 0.5ml reconstituted by sterile water, 1 shots at Day0, intramuscular injection
89128859|NCT05366296|Placebo Comparator|Placebo control|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 1 shots at Day0, intramuscular injection
89128860|NCT05363839|Experimental|SAD Cohorts 1 to 3 - Participants Receiving ACH-000029|Each SAD cohort participant will be randomized to receive 10mg for cohort 1; up to 30mg and up to 60mg for cohorts 2 and 3 respectively dependent on dose review committee.
89128861|NCT05363839|Placebo Comparator|SAD Cohorts 1 to 3 - Participants Receiving Placebo|Each SAD cohort participant will be randomized to receive placebo on a ratio of 3:1 (active: placebo).
89128862|NCT05359627|Experimental|Arm 1|normal renal function group
89128863|NCT05359627|Experimental|Arm 2|mild renal insufficiency group
89128864|NCT05359627|Experimental|Arm 3|long-term IHD group
89128865|NCT05357625|Experimental|Treatment group|Clients in the treatment group received the usual floating support service as described for the control group together with feedback. The support workers received feedback from the clients through the ORS and SRS scales of the feedback tool (Bargmann and Robinson 2011). The support worker evaluated the progress of the outcome for the client and the alliance between the support worker and the client from session to session.
89128866|NCT05357625|No Intervention|Control group|Clients in the control group received the usual floating support service without Feedback. Therefore, there was no systematic feedback between clients and support workers in the control group. The service was provided in the clients' homes, and there was no fixed limit of sessions for the support. The support covered any problem, including setting up tenancies, working with clients around practical things, so they could live independently, making sure that clients received all relevant benefits and helping clients with access to physical and mental health services. Some support workers saw their clients on a weekly basis, but there was a large variation in the frequency of meetings. Furthermore, the duration of the support service varied, from a few weeks to several years.
89128867|NCT05316584|Experimental|Remote Monitoring|At the time of a medication dose, participants scan the smart label by tapping it with their mobile device. Participants receive a notification on their device indicating that their medication adherence was updated. Each day a medication is due, patients receive a morning reminder through SMS message notifying them on their medications schedule. If patients fail to scan the label at a given time (as expected by their specific medication regimen), they will receive an end of day text message. Participants will also complete a patient reported outcome (PRO) 2 assessment at baseline, and then monthly for the entire 12 months of the study through an HTML link sent to patients by SMS message. If nonadherence is present and/or moderate to severe symptoms, an alert will be triggered to the research team. The research team can send the PRO2 survey to patients at any given time, at their discretion, if patients are experiencing a flare or at the time of a change in medication dose.
89128868|NCT05316584|No Intervention|Control|The standard of care for participants in this study is modeled after the standard of care at all five study sites. Standard of care is based on current evidence-based guidelines including a comprehensive assessment, a guideline-concordant therapy plan, scheduled and as needed clinic visits, scheduled and as needed telephone calls, and administration of educational fact sheets about disease-specific topics when appropriate. Personnel used to provide standard of care at each site will vary and may include nurse coordinators, advanced practice providers, social workers, psychologists, dieticians, pharmacists, and other ancillary staff.
89128869|NCT05298774|Experimental|Postoperative recovery with G-tech WPS|
89128870|NCT05264337||Radical Cystectomy|Patients undergoing radical cystectomy with pelvic lymph node dissection for urinary bladder cancer
89128871|NCT05264337||Radical Prostatectomy|Patients undergoing radical prostatectomy with pelvic lymph node dissection for prostate cancer
89128872|NCT05264337||Retroperitoneal|Patients undergoing retroperitoneal lymph node dissection for testicular cancer
89128873|NCT05264337||Other|Patients undergoing other urologic surgery with lymph node dissection of inguinal, iliacal or retroperitoneal lymph nodes
89128874|NCT05262374||Laparoscopic Arm|This cohort of participants will have their procedure completed by a human surgeon
89128875|NCT05262374||Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
89233879|NCT00449787|Active Comparator|Sumatriptan|Sumatriptan 100 mg tablet
88802299|NCT05483244||continuous weaning group|In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support.
88802300|NCT05477940|Experimental|Absorbable zinc alloy drug eluting stent system|"Balloon pre dilation is required.~Inject nitroglycerin, perform angiography after stent implantation, and record the specification and model of the instrument.~After stent expansion, it should reach 100% - 110% of the vessel diameter, and the visual residual stenosis should be less than 20%."
88802301|NCT03428958|Experimental|NUC-3373 + leucovorin (LV) every other week|Arm 1a: NUC-3373 administered IV followed by a 2-week washout period. The next dose of NUC-3373 administered in combination with LV at 400 mg/m2. All subsequent doses of NUC-3373 administered in combination with LV every 2 weeks in 28-day cycles.
89128876|NCT05259163|Experimental|LFR-260|The LFR-260 is a portable digital refractor which allows for determination of refractive error as well as for fully remote refractions during eye exams.
89128877|NCT05259163|Active Comparator|Traditional phoropter|The traditional phoropter is intended to be used for distance vision testing in any environment. The traditional phoropter is an application-controlled instrument providing the same subjective refraction capabilities for distance vision testing as the standard of care eye examination including sphere, cylinder, and axis.
89128878|NCT05246293|Experimental|Tofacitinib Arm|Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.
89128879|NCT05246267||Study group|Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.
89128880|NCT05243147|Experimental|nasal stents|using nasal stents after septoplasty
89128881|NCT05243147|Other|merocel|using merocel as nasal packing after septoplasty
89128882|NCT05229224|Experimental|Osteo-Fluidic-Sensitive method|
89128883|NCT05229224|Placebo Comparator|Placebo method|
89128884|NCT05212610|Experimental|Pfizer-BioNTech mRNA COVID-19 vaccine or Moderna mRNA COVID-19 vaccine|Subject will receive an initial or additional dose of either the Pfizer-BioNTech (Comirnaty) mRNA COVID-19 vaccine or the Moderna (Spikevax) mRNA COVID-19 vaccine
89128885|NCT05207501|Active Comparator|Moderate-intensity intermittent training (MIIT)|The MIIT will be conducted on a cycle ergometer (Lode Ex. calibur Sport Ergometer, Lode B.V., the Netherlands) in normoxia (FiO2 = ~ 21%). The participants will perform the MIIT starting with the ergometer resistance set to obtain the %HRmax set (~75-80%) during 5 minutes and will rest 5 minutes after each interval of exercise. The HRmax will be considered as 200 - age.
89128886|NCT05207501|Experimental|MIIT during intermittent hypoxic exposure (IHYP + MIIT)|A normobaric hypoxic chamber (ATS Altitude Training, Sydney, Australia) will be used for this protocol. The chamber (2.4 m x 5 m x 2.5 m) allows, via a filter and compressor system, to extract oxygen molecules and to reduce the fraction of inspired oxygen (FiO2) with no modification of the barometric pressure.
89128887|NCT05207501|Experimental|MIIT during intermittent blood flow restriction (IBFR + MIIT)|The IBFR + MIIT protocol will be performed while cycling in normoxia (FiO2 = ~ 21%). Elastic, pneumatic cuffs (BStrong, Park City, Utah, USA) will be administered as high as possible at the inguinal crease of the upper thigh and will be inflated during the cycling to the set pressure of 400 mmHg (except for the first training session, it will be of 250 mmHg to minimize soreness and to accustom patients to vascular occlusion training). The cuffs will be deflated at interval rest.
89128888|NCT05207501|Experimental|Moderate-intensity eccentric cycling (MIEC)|The MIEC will be conducted on a cycle ergometer (Excalibur, Lode, Groningen, The Nederlands) in normoxia (FiO2 = ~ 21%). The participants will be instructed to resist against the pedal movement (cadence set at 15 revolutions/min) to produce the required torque (set to obtain the 75-80%HRmax) indicated by visual feedback for 5 minutes and will rest 5 minutes after each interval of exercise. The HRmax will be considered as 200 - age. The HR responses will be monitored (Polar Electro Oy, Kempele, Finland).
89128889|NCT05207280|Experimental|Noradrenaline plus Terlipressin|Patients enrolled in this arm, will receive noradrenaline with dose equal to or greater than 0.2 μg / Kg / min for at least 3 hours. Solution for infusion (Intravenous). And: Terlipressin with dose 1 mg every 6 hours diluted in a 50 mL serum to pass in 15-30 minutesin injectable solution. Intravenous (diluted in a 50 mL serum to pass in 15-30 minutes)
89128890|NCT05207280|Placebo Comparator|Noradrenaline plus placebo|Patients enrolled in this arm, will receive noradrenaline with dose equal to or greater than 0.2 μg / Kg / min for at least 3 hours in solution for infusion (Intravenous), and placebo with solution in vial with the same external appearance as terlipressin. 1 mg every 6 hours, diluted in a 50 mL serum to pass in 15-30 minutes in injectable solution Route of administration: Intravenous, diluted in a 50 mL serum to pass in 15-30 minutes
89128891|NCT05203835|Experimental|Placebo and acebilustat|Participants will take acebilustat and placebo over a period of 9 months.
89128892|NCT05196854|Other|Group 1: Standard Blood Pressure measurement at home|Standard home blood pressure measurement at home
89128893|NCT05196854|Experimental|Group 2. Hypnosis script prior to Home Blood Pressure measurement|Participant listens to a pre-recorded hypnosis script (approx 5 mins long) prior to standard home blood pressure measurement.
89233880|NCT00449787|Active Comparator|Naproxen|Naproxen 500 mg tablet
88802302|NCT03428958|Experimental|NUC-3373 every other week|Arm 1b: LV 400 mg/m2 administered IV over 2 hours prior to NUC-3373 infusion followed by a 2-week washout period. Then, NUC-3373 administered IV every 2 weeks without LV in 28-day cycles.
88802303|NCT03428958|Experimental|NUC-3373 + leucovorin (LV) weekly|Arm 1c: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV weekly on Days 1, 8, 15 and 22 of 28-day cycles.
88802304|NCT03428958|Experimental|NUC-3373 + leucovorin (LV); combination chemotherapy ineligible|Arm 1d: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV on Days 1, 8, 15 and 22 of 28-day cycles.
88802305|NCT03428958|Experimental|NUC-3373 + oxaliplatin weekly|Arm 2a: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
88802306|NCT03428958|Experimental|NUC-3373 + irinotecan weekly|Arm 2b: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
89128894|NCT05177679|Experimental|Active Supplement|The active supplementation group participants will be asked to consume a daily carotenoid supplement for 9 months.
88802307|NCT03428958|Experimental|NUC-3373 + oxaliplatin (NUFOX) expansion|Arm 2c: At the completion of Arm 2a, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
88802308|NCT03428958|Experimental|NUC-3373 + irinotecan (NUFIRI) expansion|Arm 2d: At the completion of Arm 2b, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
88802309|NCT03428958|Experimental|NUFOX + bevacizumab weekly|Arm 3a: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2a will be combined with bevacizumab. NUC-3373+LV will be administered weekly, oxaliplatin and bevacizumab will be administered every other week.
88802310|NCT03428958|Experimental|NUFOX + bevacizumab every other week|Arm 3b: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2a will be combined with bevacizumab. NUC-3373+LV+oxaliplatin+bevacizumab will be administered every other week.
88802311|NCT03428958|Experimental|NUFIRI + bevacizumab weekly|Arm 3c: NUC-3373, LV and irinotecan at dose levels used in Arm 2b will be combined with bevacizumab. NUC-3373+LV will be administered weekly, irinotecan and bevacizumab will be administered every other week.
89128895|NCT05177679|Placebo Comparator|Placebo Control|The placebo control group participants will be asked to consume a placebo supplement for 9 months.
89128896|NCT05153252|Experimental|Morning Exercise (AM)|Participants in this group will be prescribed morning aerobic exercise.
89128897|NCT05153252|Experimental|Evening Exercise (PM)|Participants in this group will be prescribed evening aerobic exercise.
89128898|NCT05134857|Experimental|ZON+ST|Zonisamide (ZON) plus standard treatment (ST)
89128899|NCT05134857|Placebo Comparator|PLO+ST|Placebo (PLO) plus standard treatment (ST)
89128900|NCT05116254|Other|AZD1390|"the experimental oral drug AZD1390 (starting dose once daily 20 mg) will be combined with radiotherapy. Drug will be taken at same day as radiotherapy for 5 weeks at weekdays.~When starting dose of 10 mg is proven safe the next cohort will be 40 and thereafter 80 mg"
89128901|NCT05114590|Experimental|Soliqua 100/33|Soliqua 100/33 (Insulin glargine 100 Units/ml /lixisenatide 33 μg/mL) once daily for 16 weeks.
89128902|NCT05109325|No Intervention|Enhanced usual care + assessment|Daily assessments (without delivery of intervention components) will be conducted with EUC participants and they will receive a brochure with violence, substance use, and mental health resources.
89128903|NCT05109325|Experimental|IntERact|Participants will receive three remotely delivered behavioral therapy sessions (combining motivational interviewing, cognitive behavioral skills training, and care management), with an smartphone APP supporting the therapy and delivering therapeutic content in-between therapy sessions.
89128904|NCT05108935|Experimental|Medication and telemedicine follow up|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
89128905|NCT05104307||Cardiac Performance System (NSR)|Subjects will wear Cardiac Performance System (CPS) non-invasive device during their standard echocardiogram
89128906|NCT05101668|Experimental|Intracranial Thrombosis Aspiration Catheter|Intracranial Thrombosis Aspiration Catheter, product of Sinomed Neurovita Technology Inc.
89128907|NCT05070130||dPR and FFR|Subjects with aortic stenosis who are considered for TAVR will undergo a physiological assessment and prediction of ischemic coronary lesions pre- and post-TAVR by using Opsens non-hyperemic dPR and/or Opsens FFR
89128908|NCT05056870|Experimental|Test/Control|Eligible subjects will be randomized to the sequence, Test/Control
89128909|NCT05056870|Experimental|Control/Test|Eligible subjects will be randomized to the sequence, Control/Test
89128910|NCT05055401||Anesthesiology providers|Group will contain anesthesiologists, CRNA and AAs. The type of healthcare professional participating will be recorded along with the years of experience the participant has. Each participants experience will be categorized into three ranges, 0-3 years, 3-10 years, and 10+ years of experience. For further clarification and analysis, the healthcare professional's normal practice setting will also be recorded including inpatient, outpatient, or hybrid (inpatient and outpatient) settings. All providers will be analyzed together.
88802312|NCT03428958|Experimental|NUFIRI + bevacizumab every other week|Arm 3d: NUC-3373, LV and irinotecan at dose levels used in Arm 2b will be combined with bevacizumab. NUC-3373+LV+irinotecan+bevacizumab will be administered every other week.
88802313|NCT03428958|Experimental|NUC-3373 + LV + bevacizumab; maintenance patients|Arm 3e: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with bevacizumab (administered every other week).
88802314|NCT03428958|Experimental|NUFOX + cetuximab|Arm 3f: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2a may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or every other week, oxaliplatin will be administered every other week and cetuximab will be administered weekly.
89128911|NCT05051527||Legalon®|Legalon® 140 mg
89128912|NCT05037266|Experimental|55 - 64 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1 and boost vaccine at Day 57
89128913|NCT05037266|Experimental|At least 65 years old (50 volunteers)|1 injection of vaccine Janssen (Ad26.COV2-S) at Day 1 and boost vaccine at Day 57
89128914|NCT05030987|Experimental|RDN|Renal Denervation
89128915|NCT05030987|Sham Comparator|Sham|Sham Procedure
89128916|NCT05006092|Experimental|surveillance endoscopy with CADe support|Endoscopy perfomed with CADe support.
89128917|NCT05006092|No Intervention|conventional surveillance endoscopy|Endoscopy perfomed without CADe support.
89128918|NCT04992845|Experimental|Intervention|Vertebral Body Tethering surgery
89128919|NCT04987255|Active Comparator|Free visit|Free visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
89128920|NCT04987255|Experimental|Guided visit|Guided visit of the museum during 75 minutes for individuals in sedentary condition (healthy)
89128921|NCT04987255|Other|Guided visit for individuals after stroke|This arm is specific for individuals with motor disability after stroke (non randomized condition)
89128922|NCT04980677|Other|Children|Tangiball (Autism, Neurotypical group) - 20 minute play sessions with digital toy
89128923|NCT04965753|Experimental|FHD-609|Up to approximately 104 patients will be enrolled in dose escalation and expansion.
89128924|NCT04939753||Sevoflurane group|Patients that received sevoflurane while in ICU care.
89128925|NCT05471401|Experimental|Occlusion balloon catheter|-Each participant will have an embolectomy balloon that is FDA approved for peripheral and neurovasculature temporary occlusion placed by nose or mouth. Anatomical position of balloon will be verified by on-board MR or CT imaging in to assess feasibility of using a duodenal balloon in this population. Participants who are imaged on the MR treatment machine will also be imaged with 4 or 8 frame per second sagittal imaging to assess real-time stomach and balloon respiratory motion. Participants imaged on CT based imaging (i.e. Ethos/Halcyon ring gantry system) will have CBCTs acquired at timed intervals (approximately 5-10 minutes between scans). After imaging, the balloon will be deflated and removed at that time.
89128926|NCT04924036|Other|Glycopyrronium Cloths then Placebo|Participants that are randomized to Glycopyrronium cloths for 4 weeks, then 2 week wash out, then cross over to placebo cloths for 4 weeks.
88806125|NCT03783416|Experimental|Ixazomib (NINLARO®)|Treatment will follow a 28-day cycle. Participants will take one Ixazomib (NINLARO) capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free week, in sequence, for the duration of the trial.
89128927|NCT04924036|Other|Placebo then Glycopyrronium Cloths|Participants that are randomized to placebo cloths for 4 weeks, then 2 week wash out, then cross over to Glycopyrronium cloths for 4 weeks.
89128928|NCT04917744||Ancillary-correlative (blood collection, chart review)|Patients undergo collection of blood samples prior to drug initiation, weekly thereafter for the first month of therapy, monthly for the first month, and at disease progression or after cessation of treatment to monitor for toxicity. Blood samples are analyzed. Patients' medical charts are also reviewed to determine outcomes after PARP inhibition.
89128929|NCT04914923|Experimental|Cognitive Behaviour Therapy|This study arm will receive 12 weeks of cognitive behaviour therapy as an intervention.
89128930|NCT04914923|Experimental|Mindfulness-based Cognitive Therapy|This study arm will receive 12 weeks of a mindfulness-based cognitive therapy intervention, along with open mindfulness sessions via an EEG headset.
89128931|NCT04914923|No Intervention|Waitlist|This study arm will not receive an intervention for 12 weeks.
89128932|NCT04902885|Active Comparator|Trilaciclib, carboplatin, etoposide|Trilaciclib plus Carboplatin combined with Etoposide (first line ES-SCLC patients)
89128933|NCT04902885|Placebo Comparator|Placebo, carboplatin, etoposide|Placebo plus Carboplatin combined with Etoposide (first line ES-SCLC patients)
89128934|NCT04902885|Active Comparator|Trilaciclib, Topotecan|plus Topotecan (second/third line ES-SCLC patients)
89128935|NCT04902885|Placebo Comparator|Placebo, Topotecan|Placebo plus Topotecan (second/third line ES-SCLC patients)
89128936|NCT04868058|Experimental|1 AF SAPB|Atrial fibrillation. Serratus anterior plane block
89128937|NCT04868058|Experimental|2 AF ESPB|Atrial fibrillation. Erector spinae plane block
89128938|NCT04868058|Experimental|3 VT SAPB|Ventricular Tachycardia.Serratus anterior plane block
89128939|NCT04868058|Experimental|4 VT ESPB|Ventricular Tachycardia. Erector spinae plane block
89128940|NCT04868058|Experimental|5 ISNT SAPB|Inappropriate Sinus node tachycardia. Serratus anterior plane block
89128941|NCT04868058|Experimental|6 ISNT ESPB|Inappropriate Sinus node tachycardia. Erector spinae plane block
89128942|NCT05192434|Experimental|Expressive Writing + Contingency Management|A total of 180 WWID will be randomly assigned to the EW+CM (expressive writing + contingency management) intervention arm. To begin each session, participants will complete a brief battery of psychological measures. Then, in a private setting, they will be asked to write for 20 minutes about a major trauma that occurred three or more months in the past. WWID who prefer not to write (e.g., have lower literacy) will be provided the opportunity to talk aloud about the traumatic experience while being audio recorded, which yields comparable effects to writing. Next, women will respond to a prompt that encourages cognitive processing of the trauma for ten additional minutes. To complete the session, participants will answer the same brief battery of psychological measures for the purposes of identifying acute distress. Those exhibiting clinically elevated distress symptoms will engage in a brief de-escalation and evaluation session with study staff who will be trained.
89128943|NCT05192434|Placebo Comparator|Neutral Writing + Contingency Management|A total of 180 WWID will be randomly assigned to the attention-control arm which includes neutral writing + CM. Women in this group will complete the same pre/post psychological measures as the intervention group for the purposes of time matching. During the writing session, they will be asked to describe their schedule from the preceding day as if they were reporting facts, without discussing personal thoughts and feelings (e.g., describe what you did from the time you got up until the time you went to bed). Those with lower literacy can opt to talk aloud while being audio recorded. This is the same attention-control used our previous work which balances contact time and study incentives.
89128944|NCT04844060||Patients with cognitive impairment|All patients with cognitive disorders observed at the memory center of Strasbourg and in whom a lumbar puncture is performed as part of the patient's diagnosis.
89128945|NCT04781465|Experimental|Immersive Virtual Reality|"The patients are divided into groups of 3. Each group of patients will attend 2 days of care per week (for 4 weeks) Group N ° 1: Monday and Thursday. Group N ° 2: Tuesday and Friday.~At each visit, the patient will participate in:~[a Kinesitherapy treatment and a Virtual Immersion treatment] + [a Balneotherapy treatment or an Adapted Physical Activity treatment). Each treatment lasts 1 hour 10 minutes.~Each patient will therefore come to the center 8 times over 1 month, or 4 hours 40 minutes a week, not counting virtual reality.~If the groups are not full or according to the advice of the healthcare team, only one group will be selected (always 3 patients) and will attend 3 days per week."
89128946|NCT04708769|Experimental|Smartphone App Participants (APP)|Smartphone application, diet and activity goals, online lessons, brief remote sessions with a Health Promotionist
89128947|NCT04708769|Experimental|Diabetes Prevention Program Participants (DPP)|Participant program manual, diet and activity logs, hour long remote sessions with a Health Promotionist
89128948|NCT04703439|Experimental|Experimental group|This group consisted of 116 participants who received a medication-taking reminder every morning at a random time between 7-8 am on WeChat app. Also, participants received a piece of educational material every five days at a random time between 8 am and 9 am regarding improving medication adherence and preventing coronary heart disease.
89233881|NCT01566201|Active Comparator|anakinra|
89233882|NCT01566201|Placebo Comparator|placebo|
89233883|NCT01566279|Other|everolimus|All patients in first part will receive everolimus 10mg q.d.
89128949|NCT04703439|Placebo Comparator|Control group|This group consisted of 114 participants who only received a piece of educational material every five days at a random time between 8 am and 9 am. The educational materials sent to this group were general medical information, which were not specifically about improving medication adherence or preventing coronary heart disease.
89128950|NCT04695210|Experimental|Virtual Peer-to-Peer Support|"Those participants randomised to the intervention arm will have access to a 12-week virtual peer-to-peer support programme which entails:~weekly audio, video, or text private messaging with a peer supporter;~synchronous weekly discussion forum attended by peer supporters and family caregiver participants moderated by the research team. These forums will discuss specific topics (e.g. caregiver self-care, the emotional impact of caregiving). Ask the expert forums will be moderated by clinical experts every 6 weeks (meaning all participants will have access to 2 ask the expert sessions);~asynchronous discussion forums in which participants can post questions; and~access to informational resources."
89128951|NCT04695210|No Intervention|Control|Those participants randomised to the control arm will receive usual care which comprises self-directed access to the MND Association Visitors programme and MND Association educational resources via their website.
89128952|NCT04676906|Experimental|Study compound 1|Up to 6 volunteers will receive one dose of study compound 1
89128953|NCT04676906|Experimental|Study compound 2|Up to 6 volunteers will receive one dose of study compound 2
89128954|NCT04676906|Experimental|Study compound 3|Up to 6 volunteers will receive one dose of study compound 3
89128955|NCT04652596|Active Comparator|Fresh Connect Produce Prescription Program|Investigators will partner with a community organization, About Fresh, that administers a produce prescription program (PPR) and operates mobile fresh foods markets. Participants randomized to this comparator will receive a stipend to Fresh Connect PPR to purchase fresh food items available at mobile markets and at independent farmers markets throughout Boston.
89128956|NCT04652596|Active Comparator|Grocery store gift cards|Participants randomized to this comparator will receive grocery gift cards redeemable at conventional grocery stores.
89128957|NCT04624139|Experimental|Intervention, group 1|Combined intervention of stress reducing I-CBT and physiotherapy.
89128958|NCT04624139|Active Comparator|Active control group, group 2|Physiotherapy only
89128959|NCT04614363|Experimental|68 Ga PSMA|Comparison between the results of 68 Ga-PSMA PET/CT to conventional imaging (bone scan, CT) in men with high risk prostate cancer.
89128960|NCT04555967||Transcatheter aortic valve implantation|
89128961|NCT04553237||Patients over 90 years old|
89128962|NCT04553237||Patients between 70 and 89 years of age.|
89128963|NCT04544904|No Intervention|Usual Care|Patients will receive the usual care.
89128964|NCT04544904|Experimental|PAARx|Patients will be prescribed technology-based physical activity programming.
89128965|NCT04544904|Experimental|PAARx and JM|Patients will be prescribed technology-based physical activity programming and be referred to a web-based resource for evidence-based joint management.
89128966|NCT04539002|Experimental|MS: Cycle|Twenty-two participants in the clinical trial arm will be randomized to MS:Cycle: an aerobic exercise intervention on a stationary ergometer. Participants will exercise thrice weekly for 30 minutes with graded supervision for 24 weeks.
89128967|NCT04539002|Active Comparator|MS: Take Control|Twenty-two participants in the clinical trial arm will be randomized to MS: Take Control (MSTC): a monthly, hour-long MS education control group led by a trained facilitator.
89128968|NCT04525274|Placebo Comparator|control group|patient will receive 40 ml bupivacaine 0.25% + 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
89128969|NCT04525274|Active Comparator|dexmedetomidine group|patient will receive 40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
89128970|NCT04525274|Active Comparator|ketamine group|patient will receive 40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline with a total volume of 45 ml to be installed intraperitoneally.
89128971|NCT04513483|Experimental|CPAP treatment for 12 months|CPAP treatment for 12 months
89128972|NCT04513483|Placebo Comparator|Placebo|observation
89128973|NCT04501445|Experimental|Rounding Summary|Surrogates who were assigned to the intervention group received a written rounding summary every day or every other day that the patient is in the ICU.
89128974|NCT04501445|No Intervention|Usual Care|
89128975|NCT04493606|Experimental|Intervention Patients|SCI patients receiving the physical activity coaching (Objective 1)
89128976|NCT04493606|Experimental|Intervention- Interventionists|Interventionists receiving physical activity coaching training (Objective 2)
89128977|NCT04491071||Volunteers|volunteers over 18 years of age
89128978|NCT04488822|Experimental|Pexidartinib|
89128979|NCT04488484|Other|Arm|"Serology test results~The Paris Saint- Joseph Hospital Group staff was submitted to a 2 times serology test: the 1st took place between April, 20th to May, 12th and the second, between May, 26th to June, 12th. The employees presenting positive antibodies titers to SARS-CoV-2 will be contacted and asked for a 12 month follow-up study organized by the Occupational Health Team and the team of COVID-19 Serology referents appointed to carry out and coordinate the procedure. Each enrolled member will receive a letter with containing an information letter describing the study with a written consent form and a questionnaire enabling the data to be collected individually on the COVID-19 infection."
89128980|NCT04472611|Experimental|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
89128981|NCT04472611|No Intervention|Standard of care (SOC)|Patients will undergo standard of care treatment during hospitalization determined by the primary care team during hospitalization
89128982|NCT04450550|Active Comparator|Active|
89128983|NCT04450550|Sham Comparator|Sham|
89128984|NCT04442074||Stroke Patients|These patients were hospitalized in the neurology / neurovascular department of the Paris Saint-Joseph Hospital Group, for the management of a transient ischemic infarction or accident for which the diagnosis of ipsilateral carotid diaphragm was accepted, between April 2017 and April 2020.
88802315|NCT03428958|Experimental|NUFIRI + cetuximab|Arm 3g: NUC-3373, LV and irinotecan at dose levels used in Arm 2b may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or every other week, irinotecan will be administered every other week and cetuximab will be administered weekly.
89128985|NCT04437446|Experimental|Case Group|"The Case group corresponds to patients with glaucoma following the clinical criteria for glaucoma:~papilla excavation> 5/10 with altered ISNT rule, or neuro-retinal rhyme characteristic of glaucoma, or fiber alterations characteristic of glaucoma.~OCT with typical alterations (loss of the layer of nerve fibers or loss of these ganglion cells), loss of fibers typical of glaucoma.~Humphrey 24: 2 visual fields produced, reliable and typical of glaucoma.~The assignment to the Cas group will be carried out by an ophthalmologist specializing in glaucoma according to the following criteria:~- The intraocular pressure must be increased before the start of treatment (21 mmHg or more), except in cases of normal pressure glaucoma.~The additional examination corresponds to an OCTA alone leading to an extension of the duration of the consultation by 5 minutes."
89128986|NCT04437446|Experimental|Control Groupe|"The Control group corresponds to patients with no glaucoma, no suspicion or history of glaucoma, ocular hypertension, or alterations detected during the ophthalmological consultation.~Witnesses will be matched to cases by age (+/- 5 years) and gender.~For patients in this group, the additional examinations correspond to a visual field, an OCT and an OCTA leading to an extension of the duration of the consultation by 35 minutes."
89128987|NCT04428489||Idiopathic cytopenia of undetermined significance (ICUS)|
89128988|NCT04428489||Clonal cytopenia of unknown significance (CCUS)|
89128989|NCT04396626||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A
89128990|NCT04391790|Active Comparator|Control|Study subject will cohere to current national guidlines with a cystectomy and standard urinary conduit ad modum Bricker
89128991|NCT04391790|Experimental|Intervention|Subject in the interventional arm, will be treated with a cystectomy and modified retrosigmoid conduit
89128992|NCT04373811||Principal cohort|"Quality of life, autonomy and survival will be assessed at one year on 50 patients.~Safety of early mobilization in post-ICU setting and Medical Reasearch Council (MRC) sum score will be assessed during hospitalization."
89128993|NCT04373811||Lung cohort|Lung Ultrasound will be carried out on the first 38 patients of the principal cohort.
89128994|NCT04373811||Muscle cohort|Muscle Ultrasound will be carried out on the first 27 patients of the principal cohort.
89128995|NCT04316663|Experimental|Well-Being and Sleep Hygiene|Participants in the experimental group will receive an intervention focused on both principles of psychological well-being and sleep hygiene education.
89128996|NCT04316663|Active Comparator|Sleep Hygiene (Control)|Participants in the control group will receive sleep hygiene education alone.
89128997|NCT04254939|Experimental|CS3007(BLU-285)|
89128998|NCT04242186|Experimental|Nursing home residents and staff|Nursing home residents at high risk for injurious falls, as well as nursing home staff at participating facilities
89128999|NCT04218448|No Intervention|Somatosensory evoked potentials without hypnorelaxation|"As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination.~Somatosensory evoked potentials are carried out according to the usual management."
89129000|NCT04218448|Experimental|Somatosensory evoked potentials with hypnorelaxation|As part of this research, the patient must complete a pain scale and a Spielberger Stay-A anxiety self-assessment questionnaire before the PES examination. Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes. The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of suggestions and metaphors. The protocol is adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. The investigator, thanks to hypnosis, allows the development of a creative imagination which allows a modification of the relation to space and time.
89129001|NCT04217499||Patients with pelvic ring fractures|This retrospective study will be carried out on the data of patients who have received treatment or followed for a pelvic ring fracture, in the Orthopedic Surgery department of the Paris Saint-Joseph Hospital Group between January 2015 and September 2019.
89129002|NCT04213261|Experimental|FCX-007 COL7A1 Genetically-Corrected Autologous Fibroblasts|Intra-subject randomized (paired wounds in each subject receive experimental treatment, FCX-007, or remain untreated). Up to three target wound pairs will be identified for each subject. Following pairing, target wounds will be randomly assigned as the treatment wound (FCX-007 is administered) or control wound. Subjects will receive intradermal injections of FCX-007 in each specified treatment wound in two or more treatment sessions. The first treatment session occurs at Day 1 and the second at Week 12/Month 3. Additional treatment sessions may occur at Week 24/Month 6 and Week 36/Month 9 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated.
89129003|NCT04183894|Experimental|Personalized Intervention Based on Network|Participants will receive personalized interventions based on their personalized network.
89129004|NCT04171440|Experimental|Minimally Invasive Pancreaticoduodenectomy|Patients that undergo pancreaticoduodenectomy through small incisions with state-of-the-art robotic-assisted technology.
89129005|NCT04125563|Placebo Comparator|Placebo capsules|Soft gel capsules with placebo: Sorbitol and colorant.
89129006|NCT04125563|Active Comparator|Active substance - oral capsaicin in soft gel capsules|"This is a phase 2 clinical study in humans for therapeutic use of Capsicum oleoresin - (capsaicin) in CIC. The study has a randomised, double-blind and cross-over design. During 4 weeks the participants take either active capsules (Capsicum oleoresin), or matching placebo capsules. This period follows by 2 weeks of wash out and then another 4 weeks with active capsules or placebo in accordance with the trial profile below."
89129007|NCT04113161|Active Comparator|Standard Care|Standard care will consist of 1) community-based screening and referral and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
89129008|NCT04113161|Experimental|Child Behavioral Health Navigators (cbhN)|CbhNs will engage in a series of face to face and phone contacts with families to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
89129009|NCT04078295|Experimental|Phase 1b: E7389-LF + Nivolumab|Participants will receive specified doses of E7389-LF (intravenous) and nivolumab (intravenous) on specified days.
89129010|NCT04078295|Experimental|Phase 2, Cohort-1: E7389-LF + Nivolumab|Participants with gastric cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
89129011|NCT04078295|Experimental|Phase 2, Cohort-2: E7389-LF + Nivolumab|Participants with esophageal cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
89129012|NCT04078295|Experimental|Phase 2, Cohort-3: E7389-LF + Nivolumab|Participants with small cell lung cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.
89129013|NCT04072367|Other|Active Treatment Group|NeVa Stent Retrievers
89129014|NCT04072367|Other|Control Device|Solitare Stent Retrievers
89129015|NCT04038021|Experimental|PEth-based CM|PEth-based CM participants will receive gift cards (starting at $30) each time they submit a blood spot sample (via finger prick ) with a negative alcohol result. They will receive an additional $5 (building on the previous amount) for each additional negative alcohol result in a row. There is a cap at $100 for each negative result.
89129016|NCT04038021|Active Comparator|Non-contingent Control|Non-contingent control participants will receive gift cards each visit if they provide a pinprick blood sample regardless of whether the results are positive or negative for alcohol. Their level of reinforcement (amount in gift cards) will be equal to the average weekly CM earnings from the previous month.
89129017|NCT04020471||Experimental|All subjects who have completed their standard of care total knee arthroplasty will undergo pharmacogenomics testing and will complete a daily pain and medication diary for 30 days post discharge from the hospital. Subjects will be offered a consultation visit with a member of the Pharmacogenomics Team to discuss results.
89129018|NCT03992703||Standard strategy|This group has been treated with antibiotic susceptibility testing on a conventional Mueller-Hinton medium with reading after 24 hours of incubation (Period 1: from July 1, 2015 to December 31, 2016)
89129019|NCT03992703||Rapid strategy|This group has been treated with antibiotic susceptibility testing on a rapid Mueller-Hinton medium after 8 hours of incubation (period 2: January 1, 2017 to June 30, 2018)
89129020|NCT03980899||Patients with PPI|
89129021|NCT03974828|No Intervention|Non-Contact|Participants in the non-contact group will be monitored by anesthesia control tower clinicians who will utilize AlertWatch and integrating machine-learning forecasting algorithms for adverse outcomes predictions, but who will not contact the postoperative provider unless it is clinically necessary for patient safety purposes.
89129022|NCT03974828|Experimental|Brief contact|PACU and ward providers caring for participants in the brief contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a brief summary of the patient's forecast risk of major adverse events.
89129023|NCT03974828|Experimental|Full contact|PACU and ward providers caring for participants in the full contact group will be notified by Anesthesia Control Tower clinicians before arrival if the patient's forecast for mortality is in the top 15% of historical PACU patients. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.
89129024|NCT03973580|Active Comparator|Attentional Bias Modification (ABM) group|Participants in this arm will participate in a six-session ABM task, one session per week.
89129025|NCT03973580|Placebo Comparator|Control group|Participants in this arm will participate in a six-session control task, one session per week.
89129026|NCT03954509||semi-structured interview|"Screening and inclusion of patients hospitalized or seen in day hospital to conduct semi-structured interviews according to the interview grid. This interview schedule was established after review of the literature and identification of primary and secondary objectives.~Identification of key ideas through content analysis of the interviews conducted and based of the anchored theory.~This step is performed until the results are saturated (approximately 15 patients). The principle of saturation is based on the fact that from a threshold, the diversity of the elements collected decreases. Much more than an end signal, this principle is a methodological guarantee since it allows the possibility of comparing divergent or contradictory data and thus validating the data."
89129027|NCT03954509||questionnaires|"From the previous results: elaboration of a written questionnaire built according to the results obtained thanks to the previous interviews. In order to apply the simple correspondence factor analysis method, this questionnaire will be constructed on a Likert scale. The objective is twofold:~to reduce the observer's bias by considering both the literature reviews but also the points of view of patients to develop the questionnaire;~reach a larger patient population (more than 100 patients) compared to the previous qualitative analysis (15 patients planned), in order to generalize the results. This methodology combines both qualitative and quantitative study to minimize bias induced by both types of study.~Dissemination of the questionnaire and filling by the patient independently. The health professional who submitted the questionnaire will remain available to answer any questions the patient may have."
89129028|NCT03953677|Experimental|Dexmedetomidine|
89129029|NCT03953677|Placebo Comparator|Placebo|
89129030|NCT03925480|Experimental|Azithromycin|A single 2g dose of Azithromycin
89129031|NCT03925480|Placebo Comparator|Placebo|Matching Placebo
89129032|NCT03905226||Heart Failure|Patients whom initiated a hospital pathway for heart failure management within the Paris Saint Joseph Hospital Group (GHPSJ) between January 1, 2015 and December 31, 2018.
89129033|NCT03891160|Experimental|Group A - 3D models|Group A will receive 3-D printed models will be used for pre-VAD planning. For patients in Group A, the surgeon will complete a questionnaire 1) after reviewing 2D imaging data and 2) after reviewing a patient specific 3D model. The investigators primary outcome measure will be an improvement in the clarity of cannula and VAD site demonstration. The investigators hypothesize that the 3D models will more clearly demonstrate the sites of cannula and VAD placement as compared to 2D imaging.
89129034|NCT03891160|No Intervention|Group B - Control|Group B will be the controls and will not receive a 3D model.
89129035|NCT03889561|Experimental|Improved Water Access, Promotion, and SSB taxes|Intervention parks will receive installation of water stations, multicultural water promotion campaign, and SSB taxes
89129036|NCT03889561|No Intervention|Control|SSB taxes
89129037|NCT03878069||ERT with ADA|Patients with diagnosis of ADA-SCID treated with ERT with Revcovi or transitioning to Revcovi from Adagen
89129038|NCT03876873|Experimental|Group A|Head Rotation During Face Mask Ventilation. Step 1: Neutral Position (1 minute), Step 2: Head Rotation (1 minute), Step 3: Neutral Position (1 minute)
89129039|NCT03876873|Experimental|Group B|Head Rotation During Face Mask Ventilation. Step 1: Head Rotation (1 Minute), Step 2: Neutral Position (1 minute), Step 3, Head Rotation (1 Minute)
89129040|NCT03875885|Other|CONNECT Intervention Group - Group A|A web-based intervention (CONNECT) to empower and connect caregivers of newly diagnosed cancer patients to supportive care resources A randomized pilot study will be conducted to assess feasibility and acceptability and obtain data on caregiver and patient outcomes. CONNECT e-tool, re-education and optional referral (2 weeks post CONNECT e-tool). Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
89129041|NCT03875885|Other|CONNECT Comparison Group - Group B|Baseline, one month post randomization data collection, three months post randomization data collection, quantitative and qualitative measures.
89129042|NCT03867214|Experimental|Experimental|"Receiving TXA, Study group~Tranexamic acid, Study group tranexamic acid 1g,~intravenous injection, pre-operationally"
89129043|NCT03867214|Placebo Comparator|Placebo Comparator|"Normal saline, Control group~Not receiving tranexamic acid, Control group Normal~saline 100mL, intravenous injection, pre-operationally"
89129044|NCT03815266|Experimental|Patient with first ischemic or hemorrhagic stroke|"Patient with first ischemic or hemorrhagic stroke will be included. They will have the following program Computerized Mirror Therapy (CMT) associated at transcranial Direct Current Stimulation (tDCS). This program will consist of 5 sessions per week for 4 weeks (20 minutes).~In more, they will have the following tests: Tolerance Assessment Questionnaire, Ashworth's scale, Frenchay arm test, Abilhand questionnaire, Fugl-Meyer test, and Goal Attainment Scaling (GAS)."
89129045|NCT03736941|Experimental|Patients with venous leg|"After inclusion, the medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. Follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.~During the various visits, clinical data will be collected in the patient's medical file as well as the answers to the questionnaires."
89129046|NCT03736668|Experimental|Patients with Type 2 diabetes|"One year after patient's inclusion, during the additional cardiology consultation, an echocardiography will be performed by the investigator to evaluate any changes.~Two years after the patient's inclusion, an investigator will contact by phone the general practitioner, cardiologist and / or diabetologist treating the patient to find out if any cardiovascular events occurred."
89129047|NCT03733600||Glaucoma|All patients followed for either early or moderate forms of primary or secondary open-angle glaucoma who had undergone surgery for Xen alone or in combination with cataract surgery for phacoemulisation of the lens.
89129048|NCT03642808|Experimental|rehabilitation program|"Duration of 8 weeks for a cycle of rehabilitation at the rate of two half-days per week~Two interventions per half-day: 30 minutes of education and 1h30 of rehabilitation: physiotherapist, psychomotricity, adapted physical activity"
89129049|NCT03642782|Experimental|early age of glaucoma or with important risk factors|All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.
89129050|NCT03623139|Active Comparator|Standard nutritional education|Control group
89129051|NCT03623139|Experimental|BCC|Education and training i basic carbohydrate counting (BCC) plus standard nutritional education
89129052|NCT03582956|Other|Adolescent Overweight|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
89129053|NCT03582956|Other|Adolescent Typical|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
89129054|NCT03582956|Other|Young Adult|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement
89129055|NCT03564132|Experimental|Yigansan|2.5g of Yigansan granules by mouth, three times a day for 4 weeks
89129056|NCT03564132|Placebo Comparator|Placebo|2.5g of Placebo(contained one-tenth Yigansan) granules by mouth, three times a day for 4 weeks
89129057|NCT03563339|Experimental|P-POD|All participants will complete the prevention for postpartum onset distress (P-POD)
89129058|NCT03550066|Experimental|Values affirmation|In the values affirmation condition, the health outreach message contained a prompt asking participants to reflect on important personal values.
89129059|NCT03550066|Active Comparator|No affirmation|"In the no affirmation condition, the health outreach message appeared alone, with no values affirmation."
88802316|NCT01869478|Active Comparator|Intravenous Thrombolysis|0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.
89129060|NCT03549091|Experimental|Transthoracic echocardiography and MRI|The TransThoracic Echocardiography imaging data are collected exactly as for a standard examination. However, an additional measurement of the flow at the level of the left subclavian artery is performed, resulting in a 10-minute increase in the examination time. A Cardiovascular Magnetic Resonance Imaging 4D Flow is programmed within a maximum of 10 (no change in treatment that could skew the comparison). The usual procedure for MRI is not modified. The examination allows the acquisition of conventional 2D sequences of flow measurements, regurgitant volume and regurgitation fraction obtained at the level of the descending aorta and the sino-tubular junction of the ascending aorta. An additional 4D sequence is acquired increasing the examination time by 10 minutes.
89129061|NCT03533855|Experimental|"CS plus FRFSE"|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
89129062|NCT03341052|Active Comparator|Obese Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
89129063|NCT03341052|Active Comparator|Normal Weight Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
89129064|NCT03295994|Active Comparator|Operative|surgery + post-operative physical therapy
89129065|NCT03295994|Active Comparator|Non-Operative|non-operative physical therapy
89129066|NCT03243097|Experimental|Study Subjects|All subjects enrolled in the study are required to complete Phase I before entering Phase II, and Phase II before entering Phase III.
89129067|NCT03222752|Active Comparator|Treatment Group|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
89129068|NCT03222752|Sham Comparator|Sham Treatment Group|Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
89129069|NCT03200353|Experimental|Active|Each patient included receive the experimental device system NATROX during 3 to 4 weeks
89129070|NCT03183128|Experimental|SER-109|Received oral dose of SER-109
89129071|NCT03183128|Placebo Comparator|Placebo|Received matching placebo
89129072|NCT03149484||Pediatric Group|Children with unilateral conductive hearing loss who are treated with bone conductive devices
89129073|NCT03149484||Parent/Guardian Group|The parent or guardian of a child with unilateral conductive hearing loss who are treated with bone conductive devices
89129074|NCT03127423|Experimental|Hybrid ablation group|Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
89129075|NCT03127423|Active Comparator|Thoracoscopic surgical ablation group|Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
89129076|NCT03118375||Cohort|Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.
89129077|NCT03097796|Experimental|PUL-042|PUL-042 Inhalation Solution
89129078|NCT03084627|No Intervention|Generic dietary advice for pregnancy|
89129079|NCT03084627|Experimental|Generic dietary advice for pregnancy + Tailored dietary advice|
89129080|NCT03067051|Experimental|PDT and verteporfin dose finding|"Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study.~The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer.~The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI).~The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer ."
89129081|NCT03013998|Experimental|BAML-16-001-S1 (Closed)|This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
89129082|NCT03013998|Experimental|BAML-16-001-S2 (Closed)|"This is an open-label Phase 1b/2 clinical study of BI 836858 given in combination with azacitidine, followed by BI 836858 plus azacitidine maintenance, in newly diagnosed acute myeloid leukemia. The target population is assigned by the Beat AML Master Protocol (the umbrella study). Eligible patients will have previously untreated acute myeloid leukemia, age greater than or equal to 60, with any 1 of the following: mutated TET2, IDH1, IDH2, or WT1, or marker negative as defined by the overall Beat AML umbrella protocol."
89129083|NCT03013998|Experimental|BAML-16-001-S3 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of IDH2-mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH2 inhibitor AG-221 for IDH2 R140 and R172-mutant patients. The dosing will be based on phase 1 experience of AG-221, which has established 100 mg daily as a safe and tolerated dose, with preliminary suggestion of efficacy. These will be administered continuously in 28 day cycles. Hydroxyurea will be allowed for the purposes of cytoreduction.
88802317|NCT01869478|Active Comparator|Endovascular Arterial Reperfusion|Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.
89129084|NCT03013998|Experimental|BAML-16-001-S4 (Closed)|This is a 2 cohort phase 1b/2 clinical trial to assess the feasibility and efficacy of entospletinib (ENTO) stepwise approach to the treatment of patients with balanced translocations of MLL identified cytogenetically (Cohort 1) and patients with MLL-partial tandem duplications identified molecularly (Cohort 2). All enrolled participants will be initiated on monotherapy with ENTO 400 mg PO BID. This dose will be administered continuously in 28 day cycles.
89129085|NCT03013998|Experimental|BAML-16-001-S5 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of patients with TP53 mutations (identified molecularly) with/without complex karyotype (Cohort A) or complex karyotype (3 or greater metaphase abnormalities without TP53) (Cohort B). All enrolled participants will be initiated on entospletinib 400 mg orally twice daily. This dose will be administered continuously in 28 day cycles.
89129086|NCT03013998|Experimental|BAML-16-001-S6 (Closed)|The study is an open-label phase 2 study of entospletinib in younger and older AML patients with NPM1+/FLT3ITD-AML. It includes patients age ≥18 years who are able and willing to receive 7 + 3 intensive chemotherapy. Entospletinib is administered daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2).
89129087|NCT03013998|Experimental|BAML-16-001-S9 (Closed)|This is an open-label phase 2 clinical trial of a stepwise approach to the treatment of patients with TP53 mutation AML. On day 1, all enrolled participants will be initiated on therapy with pevonedistat (20 mg/m2) day 1, 3 and 5 together with azacitidine (75 mg/m2 days 1-7 or day 1-5 then day 8, 9) every 28 days. During cycle 1, patients with rapidly progressive disease or severe organ dysfunction, not correctable by hydroxyurea cytoreduction will not be eligible to continue. Those patients who achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 4 will continue on pevonedistat and azacitidine until disease progression, unacceptable toxicity, or 12 cycles of therapy. After 12 months of combined therapy, pevonedistat will be continued until progression of disease, unacceptable toxicity, or up to 2 years of total therapy.
89129088|NCT03013998|Experimental|BAML-16-001-S16 (Closed)|This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.
89129089|NCT03013998|Experimental|BAML-16-001-S8|This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequency. Initially, the combination of gilteritinib and decitabine was tested (Group 1); however, subsequently the combination of decitabine and venetoclax was shown to be a highly effective therapy for older AML patients, so the triple combination of gilteritinib in combination with decitabine and venetoclax (Group 2) is now being evaluated in this study.
89129090|NCT03013998|Experimental|BAML-16-001-S10 (Closed)|This is a phase 1b/2 clinical trial to assess the safety and efficacy of the combination of AZD5153 and venetoclax. In a phase 1b component, safety and tolerability of the combination will be assessed in relapsed/refractory AML patients ≥ 18 years of age. Following determination of the recommended Phase 2 dose (RP2D), newly diagnosed, marker negative patients age ≥ 60 will be enrolled in the phase 2 component; these patients will be treated at the previously identified RP2D for the combination. The RP2D will be the highest dose level with ≤ 1 out of 6 patients with dose limiting toxicity and defined as the maximum tolerated dose.
89129091|NCT03013998|Experimental|BAML-16-001-S14 (Closed)|The study is an open-label Phase 1b/2 clinical study of TP-0903 given in addition to decitabine in patients ≥ 60 years with newly diagnosed, previously untreated AML with TP53 mutations and/or complex karyotype. The Phase 1b portion of this study will use a standard 3 + 3 design with dose escalation based upon dose limiting toxicities. The maximum tolerated dose will be defined as the highest dose where at most 1 patient in 6 experiences dose-limiting toxicity, and this is generally the recommended Phase 2 dose (RP2D). Once the RP2D is determined from Phase 1b, patients will be enrolled at this dose level to initiate the Phase 2 portion of the study.
89129092|NCT03013998|Experimental|BAML-16-001-S18 (Closed)|This is an open-label Phase 1b clinical study of AZD5991 + azacitidine in patients aged ≥60 years with newly diagnosed, previously untreated, hypermethylated and marker-negative AML. The phase 1b1 study will adopt a standard 3+3 design with dose escalation based upon dose limiting toxicities. The recommended Phase 2 dose (RP2D) is defined in this study as the highest dose level where less than 2 dose limiting toxicities (DLT) are observed out of 6 patients. Once the RP2D is defined, patients will be enrolled into 2 separate cohorts (hypermethylation and marker negative group) for the phase 1b2 expansion. These 2 groups will both be treated at the RP2D determined from phase 1b1.
89129093|NCT03013998|Experimental|BAML-16-001-S17|This is an open-label Phase 1b dose escalation and expansion clinical trial to determine the safety and recommended dose of SNDX-5613 combined with azacitidine and venetoclax in newly diagnosed, untreated AML patients age ≥ 60 years who are not candidates or do not wish to pursue intensive induction therapy and who have NPM1 mutated or MLL-rearranged disease. After determination of the recommended dose of SNDX-5613, the study will have an expansion cohort to be treated at the recommended dose in combination with azacitidine and venetoclax in the same patient population.
89129094|NCT03013998|Active Comparator|BAML-16-001-S12 (Arm A)|This is an open label phase 2 randomized study in which eligible AML patients will be randomly assigned (1:1) to receive either the FDA label-approved regimen of 28-day Venetoclax + Azacitidine (Arm A) or the 14-day regimen of Venetoclax + Azacitidine (Arm B). Newly diagnosed acute myeloid leukemia (AML) patients ≥ 60 years will be enrolled.
89129095|NCT03013998|Experimental|BAML-16-001-S12 (Arm B)|This is an open label phase 2 randomized study in which eligible AML patients will be randomly assigned (1:1) to receive either the FDA label-approved regimen of 28-day Venetoclax + Azacitidine (Arm A) or the 14-day regimen of Venetoclax + Azacitidine (Arm B). Newly diagnosed acute myeloid leukemia (AML) patients ≥ 60 years will be enrolled.
89129096|NCT03006328|Experimental|Participants with Obesity + GEM|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity. Will be assigned to GEM Tool and a health coach.
89129097|NCT03006328|Active Comparator|Participants with Obesity + Enhanced Usual Care|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity. Will receive receive non-tailored weight management handouts by health coaches.
89129098|NCT02901067|Experimental|Experimental|Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
89129099|NCT02901067|Placebo Comparator|Control|Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
89129100|NCT02889926|Experimental|a swab according to the method of Levine|
89129101|NCT02889926|Experimental|Bacteriological referred to biopsy|
89129102|NCT02859896|Experimental|Hectorol|Hectorol (Doxercalciferol) will be administered orally two to three times weekly dependent on patient age. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
89129103|NCT02859896|Active Comparator|Rocaltrol|Rocaltrol (Calcitriol) will be administered orally seven days/week. A dose titration scheme is used to individualize the dose to the patient's iPTH management.
89129104|NCT02845479|Experimental|Integrative Care Intervention|Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
89129105|NCT02830958|Experimental|Kinesiotaping Group|applied next to the lymphatic system from the validated methods Kinesiotaping®.
89129106|NCT02830958|Placebo Comparator|Ordinary tape Group|Installation of an ordinary tape (not having the characteristics of Curetape®).
89129107|NCT02775630|Experimental|Examination under hypnosis in addition to local anesthesia|Patients will have hypnosis add-on local anesthesia
89129108|NCT02775630|No Intervention|Examination under local anesthesia|Patients will receive a local anesthesia only without hypnosis
89129109|NCT02750358|Experimental|Enzalutamide|160mg orally as daily continuous dosing for 52 weeks. Patients will be seen for protocol visits every 4 weeks (+/- 2 week window) for the first 12 weeks followed by every 12 weeks (+/- 2 week window) to complete 52 weeks. An assessment will also be performed at 52 weeks (+ 4 week window).
89129110|NCT02718170|Experimental|Buried Intramedullary K-wire Fixation|Patients randomized to buried intramedullary k-wire fixation will undergo a standardized antegrade open reduction and fixation procedure with an intramedullary k-wire.
89129111|NCT02718170|Active Comparator|Plate and Screw Fixation|Patients randomized to Plate and Screw Fixation will undergo a standardized open reduction and internal fixation with plate and screws. Brand of plate will be left to the operating surgeon's discretion.
89129112|NCT02711670|Experimental|thiazide|Stone formers History of calcium containing kidney stones, hypercalciuria on previous urine tests, no kidney disease, not pregnant/lactating
89129113|NCT02649270|Experimental|Group1|10 Psoriasis patients,T1h 0.2mg/kg,only single dose administration at week 1.
89129114|NCT02649270|Experimental|Group2|10 Psoriasis patients,T1h 0.4mg/kg ,first administration at week 1 and continous administration from fifth week for 9 weeks.
89129115|NCT02649270|Experimental|Group3|10 Psoriasis patients,T1h 0.8mg/kg,first administration at week 1 and continous administration from fifth week for 9 weeks.
89129116|NCT02649270|Experimental|Group4|"10 Psoriasis patients,T1h 1.6mg/kg,first administration at week 1 and biweekly from fifth week for 9 weeks.~."
89129117|NCT02581527|Active Comparator|Rifampicin 150mg (Control)|2 months daily 4FDC - Rifampicin 150mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 4 months daily 2FDC - Rifampicin 150mg and Isoniazid 75mg (continuous phase)
89129118|NCT02581527|Experimental|Rifampicin 1200mg (Regimen 1)|2 months daily 4FDC - high dose Rifampicin 1200mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1200mg and Isoniazid 75mg (continuous phase)
89129119|NCT02581527|Experimental|Rifampicin 1800mg (Regimen 2)|2 months daily 4FDC - high dose Rifampicin 1800mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1800mg and Isoniazid 75mg (continuous phase)
89129120|NCT02471040|Experimental|Type 1 diabetic subjects|Subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
89129121|NCT02471040|Active Comparator|Healthy Subjects|Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
89129122|NCT02471040|Active Comparator|Healthy Subjects CONTROL|Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will undergo an NMR test to characterize brain metabolism under hypoglycemia.
89129123|NCT02466074|Experimental|Acetazolamide|Acetazolamide in oral daily divided dose administered for 6 consecutive months
89129124|NCT02466074|Placebo Comparator|Placebo|Placebo in oral daily divided dose administered for 6 consecutive months
89129125|NCT02438969||AUD/ELS-|Treatment seeking or non-treatment seeking individuals with AUD without ELS exposure
89129126|NCT02438969||AUD/ELS+|Treatment-seeking or non-treatment seeking individuals with AUD and early life stress (ELS) exposure
89129127|NCT02438969||non-AUD/ELS-|non-AUD controls without ELS exposure
89129128|NCT02438969||non-AUD/ELS+|Non-AUD controls with ELS exposure
89129129|NCT02393794|Experimental|Romidepsin (8mg/m2) + Cisplatin (75mg/m2)|Romidepsin 8mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
88802318|NCT01844206|Active Comparator|Epidural Morphine|Group receiving 3mg epidural morphine, 24 hours after the initial dose
88802319|NCT01844206|Placebo Comparator|Epidural Saline|Group receiving epidural saline 6ml, 24 hours after receiving epidural morphine 3mg.
88802320|NCT03626454|Active Comparator|group B|'Norepinephrine bolus' of 6 µg plus Normal Saline 0.9% Infusion Solution
89129130|NCT02393794|Experimental|Romidepsin (10mg/m2) + Cisplatin (75mg/m2)|Romidepsin 10mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
89129131|NCT02393794|Experimental|Romidepsin (12mg/m2) + Cisplatin (75mg/m2)|Romidepsin 12mg/m2 IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
89129132|NCT02393794|Experimental|Romidepsin Dose Expansion|Romidepsin maximum tolerated dose (MTD) from Phase I IV on days 2 & 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle Nivolumab 360mg on day 1 of each 21 day cycle
89129133|NCT02308488|Experimental|Radiation Therapy|
89129134|NCT02159950|Experimental|Arm I (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
89129135|NCT02159950|Experimental|Arm II (tasquinimod, sipuleucel-T)|Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
89129136|NCT02152137|Experimental|efatutazone dihydrochloride, paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 and efatutazone dihydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89129137|NCT02098538|Experimental|patients with adenoid cystic carcinoma|This is a single-arm phase II study of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) treated with regorafenib.
89129138|NCT02007512|Experimental|Enzalutamide & exemestane|Enzalutamide 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) once daily after food.
89129139|NCT02007512|Active Comparator|Placebo & exemestane|Placebo and exemestane 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet without placebo after unblinding) once daily after food.
89129140|NCT01971489|Experimental|Treatment (buparlisib, gemcitabine hydrochloride, cisplatin)|Patients receive buparlisib PO QD on days 1-21, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89129141|NCT01942135|Experimental|Arm A|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
89129142|NCT01942135|Active Comparator|Arm B|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
89129143|NCT01838174|Experimental|Acthar Gel (ACTH)|15 days of intramuscular (IM) or sub-cutaneous corticotropin (SQ) Acthar (ACTH).
89129144|NCT01838174|Active Comparator|IV methylprednisolone (steroids)|3 days of IV methylprednisolone (steroids) followed by 11 days of oral prednisone
89129145|NCT01782157||Prompt intervention|The prompt intervention group will receive context-aware text, audio, and video prompts to initiate specified activities of daily living.
89129146|NCT01782157||No prompt intervention|The no prompt intervention will not receive any prompts to initiate activities of daily living.
89129147|NCT01753414|Other|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
89129148|NCT01753414|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
89129149|NCT01743131|Placebo Comparator|Standard GVHD Prophylxis + Placebo|"Standard GVHD prophylaxis and placebo.~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
89129150|NCT01743131|Experimental|Standard GVHD Prophylxis + Abatacept|"Standard GVHD prophylaxis and abatacept (investigational product).~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
89129151|NCT01685814|Active Comparator|single stem cell transplant, 3-year lenalidomide maintenance|Arm A
89129152|NCT01685814|Experimental|tandem autologous transplant, lenalidomide maintenance|Arm B
89129153|NCT01685814|Active Comparator|allogeneic stem cell transplant, lenalidomide maintenance|Arm C
89129154|NCT01685814|Experimental|tandem autologous transplant|Arm D
89129155|NCT01603849|Experimental|A Prophylactic Cranial Irradiation|Patients will received PCI 25 Gy in 10 fractions WBRT 4 weeks after initial treatment in the absence of disease progression.
89129156|NCT01603849|No Intervention|B Observation Group|Patients in this arm will be observed (not receiving WBRT)
88802321|NCT03626454|Active Comparator|group I|'Norepinephrine infusion' 6 µg/kg/h plus 'Normal Saline Flush, 0.9% Injectable Solution
88806126|NCT03783416|Placebo Comparator|Placebo|Treatment will follow a 28-day cycle. Participants will take one placebo capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free, in sequence, for the duration of the trial.
89129157|NCT01495533|Active Comparator|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
89129158|NCT01495533|Active Comparator|drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
89129159|NCT01363596||Natural Procreative Technology (NPT)|Patients who are treated or who consider being treated with Natural Procreative Technology (NPT) for infertility or history of spontaneous abortion.
89129160|NCT01260090|Experimental|Vagus Nerve Stimulation|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
89129161|NCT01260090|Sham Comparator|No Stimulation|
89129162|NCT01147016|Experimental|HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy|"HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month~Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care."
89129163|NCT01140204|Placebo Comparator|Placebo control|Contrast medium without Paclitaxel
89129164|NCT01140204|Active Comparator|Iopromide Paclitaxel 0.85 mg|Iopromide Paclitaxel 0.85 mg
89129165|NCT01140204|Active Comparator|Iopromide Paclitaxel 4.27 mg|Iopromide Paclitaxel 4.27 mg
89129166|NCT01140204|Active Comparator|Iopromide Paclitaxel 8.54 mg|Iopromide Paclitaxel 8.54 mg
89129167|NCT01140204|Active Comparator|Iopromide Paclitaxel 17.08 mg|Iopromide Paclitaxel 17.08 mg
89129168|NCT01124890|Placebo Comparator|Conservative|no transfer for early percutaneous coronary intervention after thrombolysis
89129169|NCT01124890|Active Comparator|early PCI|transfer for early percutaneous coronary intervention after thrombolysis
89129170|NCT01118130||Case|MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
89129171|NCT01118130||Control|MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy
89129172|NCT00756509|Experimental|nilotinib|nilotinib
89129173|NCT00634998|Placebo Comparator|2|1000mg Placebo capsules orally twice daily for 90 days
89129174|NCT00634998|Experimental|1|1000mg Vitamin C capsules orally twice daily for 90 days
89129175|NCT00200200|Active Comparator|1|Bevacizumab in addition to HAI plus systemic chemotherapy
89129176|NCT00200200|Experimental|2|HAI plus systemic chemotherapy alone
89129177|NCT00106587|Active Comparator|Uncoated Angioplasty|PTCA of ISR
89129178|NCT00106587|Experimental|DCB Angioplasty|DCB PTCA of ISR
89129179|NCT02866331|Experimental|CB + G-CSF|
89129180|NCT02866331|Placebo Comparator|CB + placebo|
89129181|NCT02866331|Experimental|G-CSF|
89129182|NCT02866331|Placebo Comparator|Placebo|
89129183|NCT00694863|Experimental|1|In this open-label study all patients included are treated in the experimental group.
89129184|NCT02868047||Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination with suspected chronic pancreatitis
89129185|NCT02868047||NOT Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination without suspected chronic pancreatitis.
89129186|NCT04136301|Experimental|Informative video arm|"Nuliparus women admitted to an induction will be exposed to informative video with data regarding labor and possible obstetric emergencies such as cesarean delivery.~All patients will answer the State-Trait Anxiety Inventory (STAI) before and after intervention"
89129187|NCT04136301|No Intervention|control arm|no intervention. All patients will answer the State-Trait Anxiety Inventory (STAI) before and after delivery.
89129188|NCT04290143|Active Comparator|Colored healing water|Colored medical water in a bath tub. A single 20 minutes-long treatment will be performed.
89129189|NCT04290143|Placebo Comparator|Placebo - Colored tap water|Colored tap water. The temperature and the pH of the tap water will be adjusted to the temperature pH of the healing water. A single 20 minutes-long treatment will be performed.
89129190|NCT00694941|Experimental|E|ONO-2506PO in the presence of Riluzole
89129191|NCT02867891||Chemotherapy alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
89129192|NCT02867891||Chemotherapy/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
89129193|NCT02867891||Sorafenib alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
89129194|NCT02867891||Sorafenib/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
89129195|NCT00629213|Active Comparator|1|
89129196|NCT00629213|Placebo Comparator|2|
89129197|NCT00978341|Experimental|Pregabalin|
89129198|NCT00978341|Other|Placebo|
89129199|NCT00695331|Experimental|1|Titrated Oral Misoprostol Solution
89129200|NCT00695331|Active Comparator|2|Intravenous Oxytocin
89129201|NCT00695487|Experimental|1|Receives 0.125mg/kg THC before emergence
89129202|NCT00695487|Placebo Comparator|2|Receives NaCl before emergence
89129203|NCT00695643|Experimental|A|
89129204|NCT00695643|Placebo Comparator|B|
89129205|NCT02624349|Active Comparator|Transplant|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
89129206|NCT02624349|Active Comparator|Control|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
89129207|NCT00695799||1|Anesthesia Providers at UMDNJ
89129208|NCT00695877|Experimental|1|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
89129209|NCT00695877|Experimental|2|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^10 virus particles (VP) given at Days 0, 28, and 168
89129210|NCT00695877|Experimental|3|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^11 virus particles (VP) given at Days 0, 28, and 168
89129211|NCT00695877|Experimental|4|1 injection of rAd5.ENVA.48 HIV-1 vaccine or placebo at a dose determined by the safety data from Arms 1, 2 and 3 given at Day 0.
89129212|NCT00978029|Placebo Comparator|Placebo|Matching placebo tablet sublingual, once daily
89129213|NCT00978029|Experimental|SCH 39641 6 Amb a 1-U|6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily
89129214|NCT00978029|Experimental|SCH 39641 12 Amb a 1-U|12 Amb a 1-U in an AIT, sublingual, once daily
89233884|NCT00449163|Experimental|Combination Chemotherapy and Bevacizumab|"Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:~Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;~Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;~Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;~Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29."
88802322|NCT05477706|Experimental|Personalized Support for Progress (PSP)|PSP includes an initial 60-minute video or phone appointment and then follow-up tailored to the Veteran's preferences. The Peer Specialist guides the Veteran through a card-sorting task to prioritize concerns and then create a personalized care plan. The Peer then provides up to six months of outreach and support to implement the care plan. At the end of the six months, the Veteran and peer review the plan, determine next steps and consider other supports and resources to sustain progress made.
88802323|NCT05477706|Active Comparator|Tailored Referral (TR)|The Tailored Referral (TR) comparator will be comprised of written or emailed information describing resources and contact information for VHA and local social and mental health resources. Examples include information about the appropriate office/person to reach within the local VA or area, help scheduling an appointment, or information for a same-day Primary Care - Mental Health Integration (PCMHI) assessment.
88802324|NCT01834144|Active Comparator|Moderate intensity exercise|150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)
88802325|NCT01834144|Active Comparator|Moderate + Vigorous Intensity Exercise|150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)
88802326|NCT01814722||Raltegravir + 2 NRTIs|Raltegravir is an integrase inhibitor. Two Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
88802327|NCT01814722||NNRTI + 2 NRTIs|Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine; and two NRTIs.
88802328|NCT01814722||PI + 2 NRTIs|Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir, atazanavir and darunavir; and two NRTIs.
88802329|NCT01830790|Active Comparator|Healthy Controls|Healthy individuals >65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
88802330|NCT01830790|Experimental|AMD patients|Age-related macular degeneration (AMD) patients >65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
88802331|NCT01662102|Experimental|Zevalin Regimen Consolidation (Group A)|"90Y-Ibritumomab tiuxetan administered 8 to 12 weeks after the last chemotherapy infusion. Each participant randomized to this treatment group was to receive a therapeutic dose of 14.8 MBq/kg (0.4 mCi/kg of total body weight) of 90Y ibritumomab tiuxetan (maximum 1,184 MBq or 32 mCi). Participants with a pre-treatment platelet count between 100 and 149 x10^9/L were to receive 0.3 mCi/Kg 90Y-ibritumomab tiuxetan. (Body weight ≤80 kg: 14.8 MBq [0.4 mCi] yttrium-90/kg and Body weight >80 kg: 1,184 MBq [32 mCi] maximum dose).~The 90Y ibritumomab tiuxetan regimen is as follows: Day 1 rituximab (250 mg/m^2); Day 7,8, or 9 rituximab (250 mg/m^2) followed by 90Y ibritumomab tiuxetan within 4 hours of the end of the rituximab infusion. (Maximum duration of study was up to approximately 2.7 months)."
88802332|NCT01662102|Active Comparator|Rituximab Maintenance (Group B)|Participants were to receive 375 mg/m^2 of rituximab, administered by intravenous (I.V.) infusion every 8 weeks, starting 8 to 12 weeks after the last R-chemotherapy cycle. (Maximum duration of study was up to approximately 2.7 months).
88802333|NCT04692766|Experimental|RPH-104 80 mg|subjects will receive RPH-104 at a dose of 80 mg subcutaneously once every 2 weeks
88802334|NCT04692766|Placebo Comparator|Placebo|subjects will receive placebo subcutaneously once every 2 weeks
88802335|NCT05292976|Placebo Comparator|Zero dose:|
88802336|NCT05292976|Active Comparator|Reference 0.09 mg|
88802337|NCT05292976|Active Comparator|Reference 0.18 mg|
88802338|NCT05292976|Experimental|Test 0.09 mg|
88802339|NCT05292976|Experimental|Test 0.18 mg|
88802340|NCT01808950|Experimental|0.06% Resiquimod Gel - A|"60 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
88802341|NCT01808950|Experimental|0.06% Resiquimod Gel - B|"100 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
88802342|NCT01808950|Experimental|0.06% Resiquimod Gel - C|"100 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation~The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed"
88802343|NCT01808794|Active Comparator|Mucograft|Placement of randomized membrane on half of subjects Mucograft
88802344|NCT01808794|Active Comparator|Dynamatrix|Placement of randomized membrane on half of subjects Dynamatrix Membrane Placement
89233885|NCT01026987|Experimental|Related Donors: G-CSF & AMD3100|G-CSF 10 ug/kg SC daily for 5 days. AMD3100 320 mcg/kg IV over 30 min on Day 5. Leukapheresis on Day 5.
88802345|NCT00850720||Cardiac Surgery|Infants with congenital defects.
88802346|NCT04706338|Experimental|TMS treatment|Patients with TMS treatment
88802347|NCT04512742|Other|Leishmania infected-Phlebotomus duboscqi human challenge|There is no clear indication in the medical literature to determine which of the major sand fly vectors of Leishmania major - Phlebotomus papatasi or Phlebotomus duboscqi, will be most effective at transmitting infection to a human host. Both species have a similar mode of feeding and can support L. major development. In our previous study, FLYBITE, no significant difference in biting rates on humans was observed. Based on pre-clinical data , Phlebotomus duboscqi was determined to be the lead candidate for use in this study. If all the 6 participants have developed lesions within the 6-month follow up after Leishmania challenge, the challenge phase of the study is completed. If only 5 participants have developed lesions, then a further 6 participants will undergo Leishmania challenge by P. duboscqi. If only 4 or less subjects in the first cohort develop lesions, then the investigators will switch vector to P. papatasi and a further 6 subjects will undergo Leishmania challenge.
88802348|NCT00843310|Experimental|ReMeDex|"Treatment phase (28 days/cycle x 6 cycles):~Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.~Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):~lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles."
89233886|NCT01026987|Other|Recipient|Stem Cell Infusion on Day 0
89233887|NCT00448539|Experimental|Rufinamide (Rufinamide During Core Study)|
89233888|NCT00448539|Experimental|Rufinamide (Placebo During Core Study)|
89129215|NCT02624193|Experimental|MBSR Program|"MBSR Program:~The MBSR intervention is a nine-week program designed to cultivate mindfulness, a focused non-judgmental awareness of the present moment. It consists of eight 2-hour weekly sessions and one 3-hour retreat and the content includes three main components: 1) material related to mindfulness, meditation, yoga, and the mind-body connection; 2) experiential practice of mindful meditation (sitting, lying down, walking), gentle mindful yoga, and body scan during group meetings and encouragement of home practice; and 3) group discussion focused on problem-solving related to barriers to effective practice. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
89129216|NCT02624193|Placebo Comparator|HT Program|"Healthy Topics Program:~The health education program Healthy Topics (HT) will serve as an attention control group. The HT program is focused on providing age-appropriate health information and education. There is minimal content overlap in the MBSR and HT programs regarding self-care and healthy eating; however, the style, structure, and content of the MBSR and HT programs are distinct. HT participants will receive no training in MBSR or meditation. Topics covered include physical activity, nutrition, managing weight, building health, personal care, understanding adolescence, tobacco, alcohol, and other drugs. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
89129217|NCT02624037|Experimental|Individualized Dosage Precision IFX Dashboard|A clinician will select a dose and dosing frequency that is populated by a pharmacokinetic dashboard system that monitors and aims to dose patients to maintain a target trough infliximab concentration. Dosage and dosing frequency may vary from each patient.
89129218|NCT02623881|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
89129219|NCT02623881|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
89129220|NCT04135833|Experimental|Itraconazole and BPI-7711|BPI-7711 alone followed by BPI-7711 +Itraconazole, followed by Itraconazole alone.
89129221|NCT04135833|Experimental|Rifampicin and BPI-7711|BPI-7711 alone followed by BPI-7711 +Rifampicin, followed by Rifampicin alone.
89129222|NCT00696033|Experimental|1|Oral Lorazepam
89129223|NCT00696033|Experimental|2|Oral Diazepam
89129224|NCT00696033|Placebo Comparator|3|Oral placebo
89129225|NCT02623647|Other|A single-arm, nonrandomized|stereotactic body radiotherapy SBRT, 40 Gy for 3 fractions
89129226|NCT00871377|Placebo Comparator|Placebo|Corn Oil Placebo (n-6 fatty acids)
89129227|NCT00871377|Experimental|High Dose Fish Oil|2160 mg of EPA + DHA
89129228|NCT00871377|Experimental|Low Dose Fish Oil|1060 mg of EPA + DHA
89129229|NCT02623569|Experimental|Ivabradine|Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR（heard rate）>60times/min or negative ETT and HR（heard rate）>80times/min of subjects.
89129230|NCT02623569|Active Comparator|Atenolol|Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR（heard rate）>60times/min or negative ETT and HR （heard rate）>80times/min of subjects.
89129231|NCT02623413||Sites implementing contact precautions|"Centers isolating for VRE may only participate if complying with the following standards:~Contact precautions triggered by the initial detection of VRE~Patients discharged as a VRE-carrier must be placed in contact isolation upon readmission~Termination of contact precautions after at least two consecutive VRE-negative consecutive fecal screening cultures~Resumption of contact isolation on first subsequent VRE-positive culture~Contact precautions must encompass the following measures:~Patients: Placement in single rooms. Cohorting is only permitted, in case of unavailability of single rooms~Staff and visitors: Wearing of gloves and gowns when entering the room.~Patients: Wearing of gloves and gowns when leaving the room."
89129232|NCT02623413||Sites not implementing contact precautions|Only VRE colonized or infected patients with urinary or fecal incontinence or diarrhea (defined as > 3 loose bowel movements/day), must be isolated in single rooms at any time during the study.
89129233|NCT02623491|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive 0.75 milligrams (mg) of JNJ-55375515 (starting dose) or Placebo on Day 1. Dose of the study medication will be escalated sequentially up to a maximum of 200 mg.
89129234|NCT02623491|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-55375515 (at doses determined based on the data from the SAD part) or Placebo from Day 1 to 10.
89129235|NCT00977561|Experimental|Arm A|Figitumumab (CP-751,871) Plus Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
89129236|NCT00977561|Active Comparator|Arm B|Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
89129237|NCT05298735||Healthy volunteers|Healthy volunteers with no known significant medical conditions
89129238|NCT05298735||Patients with type 1 diabetes|Patients with a diagnosis of type 1 diabetes (with or without detectable C-peptide)
89129239|NCT04291313|Placebo Comparator|Current recommended dose of vitamin D|Women in this study arm receive 10 µg of vitamin D3 per day, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
89129240|NCT04291313|Experimental|Higher dose of vitamin D|Women in this arm receive 90µg of vitamin D3 per day: 10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3.
89129241|NCT02866253|Experimental|DHEA Group|DHEA 25mg t.i.d. for more than 12weeks
89129242|NCT02866253|No Intervention|Control Group|patients without any DHEA
89129243|NCT04080479|Experimental|Bolus enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding. The study subjects will undergo the following interventions:~Quadriceps Muscle Layer Fitness measurement~Muscle Strength measurement~Acute Physiology and Chronic Health Evaluation~Sequential Organ Failure Assessment~Nutritional Risk Screening~Energy and Protein Intake"
89129244|NCT04080479|Experimental|Continuous enteral feeding|"The patients randomized into this study arm will receive bolus enteral feeding.~The study subjects will undergo the following interventions:~Quadriceps Muscle Layer Fitness measurement~Muscle Strength measurement~Acute Physiology and Chronic Health Evaluation~Sequential Organ Failure Assessment~Nutritional Risk Screening~Energy and Protein Intake"
89129245|NCT04074629|Experimental|Skin related VOCs collected by Polydimethylsiloxane patch|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\or GC-MS analysis"
89129246|NCT02867423|Other|A - CK boost radiation|CK boost radiation
89129247|NCT00629291||1|Sickle cell anemia patients
89129248|NCT00629291||2|Sickle cell β thalassemia
89129249|NCT04120727||Patient|patients with predominant osteoarthritis of the knees
89129250|NCT04120727||Health professionals|health professionals with a link to osteoarthritis (physical and rehabilitation doctor, Rheumatologist, Physiotherapist, family doctor, pharmacist, Adapted physical activity teacher)
89129251|NCT04290767|Other|Sonovue|ICU patients with acute shock status (septic or non-septic) who are eligible for enhanced-contrast brain ultrasound with sulphur hexafluoride microbubbles contrast (Sonovue, BRACCO, Milan, Italy) examination.
89129252|NCT02865941|Experimental|5 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed five times per week, of native breast milk batches which had been prepared for 24 hours feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
89233889|NCT01024257|Experimental|conjunctival autograft plus beta-irradiation|
88802349|NCT04706572|Experimental|Patients with Golden Rhythm|Administration of an external auditory cue based on Golden Rhythm
88802350|NCT04706572|Placebo Comparator|Patients with Metronome|Administration of an external auditory cue based on metronome binary rhythm
89129253|NCT02865941|Experimental|1 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed once per week of native breast milk batches which had been prepared for 24 hours feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
89129254|NCT02865785|Active Comparator|Study Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20% (100 mL of intralipid 20% diluted in 250 mL sterile i.v. saline administered i.v. over two hours), once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
89129255|NCT02865785|Placebo Comparator|Placebo Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
89129256|NCT00594165|Experimental|Rotigotine|Rotigotine
89129257|NCT00975923|Experimental|Collaborative Group|Quality Improvement Virtual Learning Collaborative with Interactive Teleconferences and Tool Kit
89129258|NCT00975923|Active Comparator|Tool Kit Group|Tool Kit of Evidence-Based Guidelines, Education Seminars, and Aide for Quality Improvement Methods
89129259|NCT00928070|Experimental|Fesoterodine|
89129260|NCT00928070|Placebo Comparator|Placebo|
89129261|NCT04135755||vertebral compression fracture|No drugs intervention
89129262|NCT04135755||older adult without spinal deformity|No drugs intervention
89129263|NCT04135755||young adults|No drugs intervention
89129264|NCT00696345||1|Colorectal cancer patients, Stages I-IV
89129265|NCT00696345||2|Non colorectal cancer patients, verified by colonoscopy
89129266|NCT04289909|Other|MS patients|RRMS Patients with optic neuritis, RRMS patients without optic neuritis or Progressive MS patients
89129267|NCT04289909|Other|Control group|Healthy volunteers
89129268|NCT04135599|Active Comparator|real tDCS|Participants received 1.5mA tDCS for 20 minutes in 10 consecutive days.
89129269|NCT04135599|Sham Comparator|sham tDCS|Participants received sham tDCS for 20 minutes in 10 consecutive days.
89129270|NCT00629369|Experimental|A|subjects with Occlusion Support Device with active pushing in the second stage of labor
89129271|NCT00629369|No Intervention|2|Subjects without Occlusal Support Device with active pushing in the second stage of labor
89129272|NCT04290221|Experimental|Percutaneous electrolysis in the lumbar nerv|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3, L4 and L5, bilaterally (one times per week / 3 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
89129273|NCT04290221|Active Comparator|Electrical dry needling in trigger points|It consists in apply the electrical dry needling on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 6 weeks).
89129274|NCT04135287|Experimental|Arm 1|Treatment with GLP-1 RA
89129275|NCT04001621|Experimental|Pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
89129276|NCT02623179|Active Comparator|A-Culture and Sensitivity group|Diagnosis by Culture and Sensitivity group-Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
89129277|NCT02623179|Active Comparator|B-Diagnosis by Molecular Testing|Diagnosis by Molecular Testing-Treatment based on the results of the PathoGenius molecular testing - Even Numbers on randomization table
89129278|NCT02623101|Active Comparator|Standard of care procedure|"Clinical suspected basal cell carcinomas, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most clinical suspicious part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. Hematoxylin/eosin stained sections of the punch biopsies will be evaluated by an experienced pathologist. Subjects will receive surgical excision according to subtype.~When there is any doubt by reflectance confocal microscopic diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma."
89233890|NCT01024257|Active Comparator|conjunctival autograft|
89233891|NCT00457665|Active Comparator|Nelfinavir (Viracept)|
89233892|NCT00457665|Active Comparator|Efavirenz (Sustiva)|
89233893|NCT00447603|Active Comparator|Losartan 50 mg|Losartan 50 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
89233894|NCT00447603|Active Comparator|Losartan 100 mg|Losartan 100 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
89233895|NCT00447603|Experimental|Losartan 50 mg/HCTZ 12.5 mg|Losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg once daily for 4 weeks
89233896|NCT00447603|Experimental|Losartan 100 mg/HCTZ 12.5 mg|Losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg once daily for 4 weeks
89290167|NCT01215396|Active Comparator|Single Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 0.96 g of amino acids."
89290168|NCT01215396|Active Comparator|Double Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 1.92 g of amino acids."
89290169|NCT01218282|Experimental|Home Exercise Training Group A1|Patients assigned to this arm maintain the prescribed walking speed during the training with a metronome
89290170|NCT01218282|Experimental|Home Exercise Training Group A2|Patients assigned to this arm cover a fixed distance in a given period of time.
89290171|NCT01218282|No Intervention|Control|
89290172|NCT00226499|Experimental|MMRV Group|Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
89290173|NCT00226499|Experimental|OKAH Group|Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.
89290174|NCT00226499|Active Comparator|MMR Group|Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
89290175|NCT01219920|Active Comparator|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
89290176|NCT01219920|Experimental|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
88802351|NCT00809458|Experimental|Arm 1 (Vitamin E)|Vitamin E
88802352|NCT00809458|Placebo Comparator|Arm 2|Placebo (same vehicle as used for vitamin E)
88802353|NCT05482932||Patients with IBD|150 patients with IBD; either Ulcerative Colitis (N=75) or Crohns disease (N=75)
88802354|NCT05482932||Healthy volunteers without IBD|150 healthy volunteers (without IBD)
88802355|NCT04706182|Experimental|Combined PRF and PSG|
88802356|NCT04706182|Experimental|Only PRF|
88802357|NCT04706182|Experimental|Only PSG|
88802358|NCT04706182|No Intervention|Control (no treatment)|
89290177|NCT01400776|Experimental|WC3011 Estradiol Vaginal Cream (2 Times/Week)|WC3011 estradiol vaginal cream applied daily for 2 weeks, followed by dosing 2 times a week for 10 weeks.
89290178|NCT01400776|Placebo Comparator|Vehicle (2 Times/Week)|Vehicle applied daily for 2 weeks, followed by dosing 2 times a week for 10 weeks.
89290179|NCT01400776|Experimental|WC3011 Estradiol Vaginal Cream (3 Times/Week)|WC3011 estradiol vaginal cream applied daily for 2 weeks, followed by dosing 3 times a week for 10 weeks.
89290180|NCT01400776|Placebo Comparator|Vehicle (3 Times/Week)|Vehicle applied daily for 2 weeks, followed by dosing 3 times a week for 10 weeks.
89290181|NCT01219998||NGAL Kinetics in neonates|to describe postoperative kinetics of urinary NGAL in neonates and to identify the threshold for accurate prediction of severe AKI requiring RRT in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass
89290182|NCT01220076|Experimental|Tamoxifene|
89290183|NCT01220154|Experimental|Carboplatin Paclitaxel & Bevacizumab|Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab
89290184|NCT01182766|Experimental|topiramate|topiramate with brief behavioral enhancement therapy
89290185|NCT01182766|Placebo Comparator|Placebo|Placebo with brief behavioral enhancement therapy
88802359|NCT00422968|Active Comparator|coronary artery bypass graft|coronary artery bypass graft
88802360|NCT00422968|Experimental|percutaneous coronary intervention|Using silorimus eluting stent
88802361|NCT01697332|Experimental|Subjects with and without COPD|All subjects will inhale hyperpolarized 129Xe gas and then have a MRI scan performed to measure lung function.
88802362|NCT01701622|Experimental|Allopurinol, febuxostat|Patients currently treated with allopurinol will be switched to febuxostat, and the blood pressure differences between the two arms will be compared.
88802363|NCT01668940|Experimental|Lillipops Iced Soothies (4 flavours)|"Initially, women will be given 1 multiflavour box of Lillipop samples minus the ginger flavour (4 flavours). Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
88806127|NCT00248534|Experimental|IV Rituximab|"IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.~Induction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide [TMZ] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression"
89129279|NCT02623101|Experimental|Reflectance confocal microscopy (RCM)|The Vivascope 1500 and Vivascope 3000 (handheld divice) will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed on clinical suspected basal cell carcinomas, of all subtypes. When there are signs of a basal cell carcinoma imaged by RCM, subjects will receive surgical excision according to subtype. When there is any doubt by RCM diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma.
89129280|NCT00924404|Experimental|Xylitol|isotonic xylitol for sinus rinse
89129281|NCT00924404|Active Comparator|Saline|saline for sinus rinse
89129282|NCT00976937|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide along with sitagliptin placebo: lixisenatide 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24 along with placebo matching to sitagliptin 100 milligram (mg) capsule orally QD up to Week 24.
89129283|NCT00976937|Active Comparator|Sitagliptin|Sitagliptin along with 2-step initiation regimen of volume matching lixisenatide placebo: sitagliptin 100 mg capsule orally QD up to Week 24 along with volume matching lixisenatide placebo 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
89129284|NCT02623023|Experimental|Combigan group|Combigan will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
89129285|NCT02623023|Placebo Comparator|Refresh tears|Refresh tears will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
89129286|NCT02622945|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
89129287|NCT02622945|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
89129288|NCT04256330||Lean and metabolically healthy|
89129289|NCT04256330||Lean and metabolically unhealthy|
89129290|NCT04256330||Overweight and metabolically healthy|
89129291|NCT04256330||Overweight and metabolically unhealthy|
89129292|NCT04256330||Obese and metabolically healthy|
89129293|NCT04256330||Obese and metabolically unhealthy|
89129294|NCT02622867|Experimental|Lactobacillus plantarum 3547|1 capsule/daily during 12 weeks with Lactobacillus plantarum 3547 (10x109 cfu/d). The capsule contains 77 mg probiotic Lp3547 and 390 mg maltodextrin
89129295|NCT02622867|Placebo Comparator|Maltodextrin|1 daily capsule of maltodextrin (425 mg) during 12 weeks
89129296|NCT04256252|Experimental|Rituximab|Intravenous rituximab was administered at a fixed dose of 100 mg once weekly for 3 weeks, followed by maintenance treatment with 100 mg rituximab every 6 months.
89129297|NCT04256096|Experimental|thrombectomy|mechanical thrombectomy with stent-retriever and/or thromboaspiration
89129298|NCT04256096|Active Comparator|Clinical treatment|Best Medical treatment
89129299|NCT02622633|Experimental|Stimulation|One week after implantation of the device, participants randomized in this arm will receive continuous magnetic stimulation of high frequency (50Hz) with epidural electrode for 12 weeks. And then, the epidural electrode will be turned off for more 12 weeks in a crossover fashion.
89129300|NCT02622633|Sham Comparator|Sham Stimulation|One week after implantation of the device, participants randomized in this arm will receive sham stimulation for 12 weeks and then continuous magnetic stimulation with epidural electrode of high frequency (50Hz) stimulation for more 12 weeks.
89129301|NCT02865239|Placebo Comparator|Supine position|3.0 tesla MRI in supine position
89129302|NCT02865239|Active Comparator|Prone position|3.0 tesla MRI in prone position
89129303|NCT02622555||Mirabegron treatment|Women with overactive bladder syndrome eligible for Mirabegron treatment
89129304|NCT02866019|Experimental|CLS2702C/CLS2702D|
89129305|NCT05329454|Experimental|Treatment ABC|Receive the investigational product and active comparator in a sequence of treatment A, treatment B and treatment C.
89129306|NCT05329454|Experimental|Treatment ACB|Receive the investigational product and active comparator in a sequence of treatment A, treatment C and treatment B.
89129307|NCT05329454|Experimental|Treatment BAC|Receive the investigational product and active comparator in a sequence of treatment B, treatment A and treatment C.
89129308|NCT05329454|Experimental|Treatment BCA|Receive the investigational product and active comparator in a sequence of treatment B, treatment C and treatment A.
89129309|NCT05329454|Experimental|Treatment CAB|Receive the investigational product and active comparator in a sequence of treatment C, treatment A and treatment B.
89129310|NCT05329454|Experimental|Treatment CBA|Receive the investigational product and active comparator in a sequence of treatment C, treatment B and treatment A.
89129311|NCT02622789||Controls|Age-matched Healthy Controls
89129312|NCT02622789||General Exercises|Low Back Pain Participants Receiving General Exercises
89129313|NCT02622789||Pilates Exercises|Low Back Pain Participants Receiving Pilates Exercises
89129314|NCT02865863|Experimental|Eurycomalongifoliawater extract (Physta®) +Multivitamin|
89129315|NCT02865863|Placebo Comparator|Placebo|
89129316|NCT05331560|Experimental|Treatment Group|A 2-week intervention TPS intervention will result in a significant improvement in the Montreal Cognitive Assessment (HK-MoCA; Hong Kong Chinese version), which will be maintained for 12 weeks.
89129317|NCT02622711|Experimental|DI Dietary Intervention|Individualized dietary counselling to reduce body weight
89129318|NCT02622711|Experimental|PAI Physical Activity Intervention|Individualized physical activity counseling to reduce body weight
89129319|NCT02622711|Experimental|PADI Physical Activity+Diet Intervention|Individualized dietary and physical activity counseling to reduce body weight
89129320|NCT02622711|Experimental|LII Less Intensive Intervention|Materials and guidelines available to general public
89129321|NCT00629447|Experimental|1|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
89129322|NCT04289831|Active Comparator|Direct Surgery (DS) group|patients subjected to direct surgery (DS) within 1 week after randomization
89233897|NCT00447057|Experimental|Pemetrexed (Nonsquamous)|Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
89233898|NCT00447057|Experimental|Pemetrexed + Erlotinib (Nonsquamous)|Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
89233899|NCT00447057|Experimental|Pemetrexed (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
89233900|NCT00447057|Experimental|Pemetrexed + Erlotinib (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
89233901|NCT01027533||Restor +3|patients will be implanted bilaterally with Restor + 3
89233902|NCT01027533||restor +4|Patients will be implanted bilaterally with Restor +4
88802364|NCT01668940|Experimental|Lillipop Iced Soothies (Ginger flavour)|Initially, women will be given 1 Ginger flavor box of Lillipop samples. Each box contains 24 freezies (20 mL each). Each 20ml contains 80mg of dried ginger root. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 a day and to not have any other popsicles, freezies or other ginger products throughout the duration of the study (7 days). Due ginger's antiemetic property, a maximum daily dose is up to 1000mg/day of dried ginger root powder in pregnancy.They can request an additional box of freezies at each follow-up, as needed.All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol.
88802365|NCT01668940|Active Comparator|Mr. Freeze Freezies (4 flavours)|"Initially, women will be given 1 multiflavour box of Mr. Freeze samples. Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
88802366|NCT01668940|No Intervention|Natural Course Group|"Women will not receive any freezies and will be asked to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days).~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
88802367|NCT01675960|Experimental|Gabapentin, then placebo|Participants first receive gabapentin 3 times per day, with varying dosing based on the protocol. After 34-38 days, a washout period of 3 days occurs, before then receiving the placebo dose for 32 days.
88802368|NCT01675960|Experimental|Placebo, then Gabapentin|Participants first receive placebo 3 times per day. After 34-38 days, a washout period of 3 days occurs, before then receiving Gabapentin, with varying dosing based on the protocol, for 32 days.
88802369|NCT04053868|Experimental|Electronic Cigarette|The participants will participate in a standardized vaping session using a JUUL E-cigarette device with a JUUL e-liquid pod.
88802370|NCT04053868|Experimental|Tobacco Cigarette|The participants will participate in a standardized smoking session using commercial tobacco cigarettes.
88802371|NCT03999970|Active Comparator|Phlebotomus papatasi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus papatasi fed on blood twice in the laboratory prior to human exposure.
88802372|NCT03999970|Active Comparator|Phlebotomus duboscqi sand fly bite|Volunteers aged between 18-65 years will receive a bite or bites by sand flies using a watch-like biting chamber placed on the arm. The investigators will initially evaluate the use of biting chambers containing up to 5 sand flies maintained on the arm for 30 minutes, and evaluate the sand fly species Phlebotomus duboscqi fed on blood twice in the laboratory prior to human exposure.
88802373|NCT00787618|Active Comparator|50 mg Proellex Mild impairment|50 mg Proellex single dose Female subjects with mild renal impairment function.
88802374|NCT00787618|Active Comparator|50 mg Proellex Moderate|50 mg Proellex, Female subjects with moderate renal impairment function.
88802375|NCT00787618|Active Comparator|50 mg Proellex, Normal|50 mg Proellex, Female subjects with normal renal function.
88802376|NCT00749476|Experimental|1|
88802377|NCT01607320|Experimental|Raloxifene|3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
88802378|NCT01607320|Active Comparator|Clomiphene|3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7
88802379|NCT01606150|Active Comparator|Subcutaneous Lidocaine|0.1 ml/kg of 1% Lidocaine
88802380|NCT01606150|Active Comparator|Topical Lidocaine|LMX-4, 1 gram placed over lumbar puncture needle insertion site 30 minutes prior to the procedure
88802381|NCT00747916|Experimental|CryoSpray Ablation (TM) System|subjects will receive cryotherapy using the CryoSpray Ablation (TM) System DOSE: up to 3 cycles of 10-40 second sprays
88802382|NCT04706494|Experimental|AlphaWave® LTheanine|
88802383|NCT04706494|Placebo Comparator|Placebo|
88802384|NCT00739024|Active Comparator|Active Treatment|Ramelteon once daily (double-blind assignment)
89233903|NCT01027611|Experimental|proparacaine HCL 0.5%|
89233904|NCT01027611|Experimental|proparacaine + lidocaine|
89233905|NCT01027611|Experimental|lidocaine gel|
89233906|NCT01024413|Experimental|erlotinib|erlotinib 150 mg oral till disease progression
89233907|NCT01024413|Active Comparator|gefitinib|gefitinib 250mg oral till disease progression.
89233908|NCT03577587|Experimental|Verum|Silitidil for 21 days
89233909|NCT03577587|Placebo Comparator|Placebo|Placebo for 21 days
89233910|NCT03577587|No Intervention|Reference group|Non-randomized healthy volunteering mothers after term birth receiving no intervention
89233911|NCT00446511|Experimental|CKD patients: Valsartan+enalapril|
89233912|NCT00446511|Active Comparator|CKD patients: Enalapril|
89233913|NCT00446511|Experimental|Non-CKD patients: Valsartan|
89233914|NCT00446511|Active Comparator|Non-CKD patients: Enalapril|
89233915|NCT01024491|Experimental|paroxetine 15mg|Active treatment with daily dose of paroxetine 15mg.
89129323|NCT04289831|Active Comparator|Preoperative Biliary Drainage (PBD) group|patients managed by Preoperative Biliary Drainage followed by surgery after 4-6 weeks.
89129324|NCT02622477||Participants with idiopathic pulmonary fibrosis|Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.
89129325|NCT04290065|Experimental|Experimental group|The intervention will take place over a period of 4 weeks, with 2 weekly sessions, with an estimated execution time of 1.50 to 3 minutes each. A manual therapy technique of inhibition of the suboccipital musculature and an axial traction of the upper hemiarchy will be performed
89129326|NCT04290065|No Intervention|Control group|Athletes included in the control group will not perform any intervention, continuing with their usual routine.
89129327|NCT02622243|Experimental|tiotropium|2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge
89129328|NCT02622243|Experimental|glycopyrronium|1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge
89129329|NCT04255940||After outbreak|
89129330|NCT04255940||Past 3 months|
89129331|NCT04255940||Last year|
89129332|NCT04289675||Interferon-Beta|Patients with first treatment : interferon beta (1a subcutaneous 22 or 44 µg thrice a week OR 1a intramuscular 30 µg once a week OR 1b subcutaneous 250 µg every other day OR 1a PEGylated subcutaneous 125 µg every two weeks)
89129333|NCT04289675||Dimethyl fumarate|Patients with first treatment : dimethyl fumarate (oral, 240 mg twice a day)
89129334|NCT04289675||Teriflunomide|Patients with first treatment : teriflunomide (oral, 14 mg once a day)
89129335|NCT02622165|Experimental|The REWARD serious game intervention|A mobile 4-week serious game intervention will be administered.
89129336|NCT02622165|No Intervention|Control group|School curriculum as usual
89129337|NCT02865317||Study group|Patients with obstetrical brachial plexus injury involving upper trunk (C5-6)
89129338|NCT02622399|Experimental|Project NOW|Participants in the intervention arm receive access to free mobile communications and a web-based informational platform supported by txtwire.
89129339|NCT02622399|No Intervention|Control|Participants in the control arm do not receive access to the txtwire platform.
89129340|NCT00976703|Active Comparator|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
89129341|NCT00976703|Active Comparator|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
89129342|NCT04245800||Observational|All participants will be part of the prospective observational cohort. If participants develop flu-like symptoms, they will be prompted to complete the flu@home self-test kit. Analysis will be conducted for various subgroups (e.g. age, vaccination status)
89129343|NCT02622087|Experimental|Hormonal contraceptive|Women who receive one-session-treatment while they are on the hormonal contraceptive pill
89129344|NCT02622087|Experimental|Naturally cycling- high estradiol|Naturally cycling women who receive one-session-treatment during a period of high estradiol
89129345|NCT02622087|Experimental|Naturally cycling-low estradiol|Naturally cycling women who receive one-session-treatment during a period of low estradiol
89129346|NCT00696579|Active Comparator|A|Group A received BCG instillation 14 days after II look-TURB:6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
89129347|NCT00696579|Experimental|2|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
89129348|NCT02866097|Experimental|Intervention|mHealth inventory management and referrals via text messaging plus supportive supervision of CHWs via an mHealth strategy
89129349|NCT02866097|Placebo Comparator|Control|ICCM current standard of care with CHWs operating under standard conditions without enhanced inventory management or supportive supervision by mHealth
89129350|NCT04929938|Experimental|Inmediate UP plus Treatment As Usual|Treatment As Usual Plus Inmediate Virtual group Therapy applying the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. The treatment consists in 15 weekly sessions of 120 minutes that combines cognitive-behavioural techniques to improve emotional self-regulation skills.
89129351|NCT04929938|Active Comparator|Waiting list plus Treatment As Usual|A waiting list for treatment with delayed UP after 7 months while receiving the treatment as usual (WL + TAU).
89129352|NCT02622009||COPD I|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE I
89129353|NCT02622009||COPD II|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE II
89129354|NCT02622009||COPD III|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE III
89129355|NCT02622009||NONSMOKERS|BRONCHOSCOPIC PROCEDURE IN NONSMOKERS
89129356|NCT02622009||CURRENT OR EXSMOKERS|BRONCHOSCOPIC PROCEDURE IN CURRENT OR EXSMOKERS
89129357|NCT02865629|Experimental|N-acetyl cysteine|Following the screening and review of all laboratory studies, patients will be scheduled to receive N-acetylcysteine.
89129358|NCT04253210|Experimental|Sexualized images / High photo modification|
89129359|NCT04253210|Experimental|Sexualized images / Low photo modification|
89129360|NCT04253210|Experimental|Nonsexualized images / High photo modification|
89129361|NCT04253210|Experimental|Nonsexualized images / Low photo modification|
89129362|NCT04253210|Experimental|Control images|
89233916|NCT01024491|Experimental|paroxetine 20 mg|Active treatment daily dose of paroxetine 20 mg
89233917|NCT01024491|Experimental|placebo|placebo
88802385|NCT00739024|Placebo Comparator|Placebo|Placebo tablet, once daily (double-blind assignment)
89233918|NCT00446199|Experimental|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
89233919|NCT00446199|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
89233920|NCT00446199|Experimental|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
89233921|NCT00446199|Placebo Comparator|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
89233922|NCT01027689|Active Comparator|Alprazolam commercial immediate release oral tablet|
89233923|NCT01027689|Experimental|Alprazolam test sublingual tablet|
89233924|NCT01024647|Active Comparator|Loss of Reponse Reinduction Responders|Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks
89233925|NCT01024647|Active Comparator|Response loss Reinduction Non-Responders|Response Loss Reinduction Non-Responders:certolizumab pegol(Cimzia) 400 mg every 2 weeks
89233926|NCT01024647|Active Comparator|Responders|Responders: certolizumab pegol(Cimzia) 400 mg every 4 weeks
89233927|NCT01024647|Active Comparator|Non-Responders|Non-Responders: certolizumab pegol (Cimzia) 400 mg every 2 weeks
89233928|NCT01027767||Surgery/Radiation Arm|Patients that have had surgery along with radiation therapy
89233929|NCT01027767||Surgery Arm|Patients that have had surgery of a benign lesion.
89233930|NCT01027923|Experimental|Dose Level 1|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 320 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
89233931|NCT01027923|Experimental|Dose Level 2|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 420 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
89233932|NCT01027923|Experimental|Dose Level 3|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 560 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
89233933|NCT01565733||NovoMix® 30 users|
89233934|NCT01565811||Hepatic pedicle lymph node Involvement|Intervention Type: perihepatic lymphadenectomy(surgical procedure)
89233935|NCT01027065|Experimental|Tritherapy: CYT107+ vaccine+ antiviral|
89233936|NCT01027065|Experimental|Bitherapy: CYT107 + antiviral|
89233937|NCT00456495|Experimental|Subconjunctival ranibizumab|Patients will receive subconjunctival ranibizumab every 2-4 weeks.
89233938|NCT00445341|Experimental|Flavopiridol in lymphoma patients|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
89233939|NCT03846453|Experimental|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25% ophthalmic solution as topical ophthalmic drops, twice daily (BID) for up to 8 weeks. Exposures to the controlled adverse environment (CAE®) were conducted at Day 1, Day 15, Day 29 and Day 57
89233940|NCT03846453|Placebo Comparator|Placebo|Participants self-administered HL036 placebo (vehicle solution) as topical ophthalmic drops, BID for up to 8 weeks. Exposures to the CAE® were conducted at Day 1, Day 15, Day 29 and Day 57.
89233941|NCT00444951|Experimental|Menactra® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
89233942|NCT00444951|Experimental|Mencevax® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.
89233943|NCT00444951|Experimental|Control group|Participants have not previously received any meningococcal vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
89233944|NCT00444795||1|patients diagnosed as GIST after disease progression on or intolerance to imatinib mesylate
89233945|NCT00444795||2|patients diagnosed as advanced RCC
89233946|NCT00444795||3|patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
89233947|NCT03846219|Experimental|IMU-838 (30 mg/day)|"IMU-838 tablet containing 15 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 30 mg consists of 2 tablets IMU-838.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838 (up to 9.5 years for the main trial)."
89233948|NCT03846219|Experimental|IMU-838 (45 mg/day)|"Tablet containing 22.5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 45 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838."
89233949|NCT03846219|Placebo Comparator|Placebo|"Tablet containing no active ingredient. The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Once-daily oral dose consists of 2 active compound-free tablets.~Duration: until the end of the main treatment period (24 weeks). The placebo is not applicable in the optional extended treatment period, in which participants who were receiving placebo in the main treatment period were re-randomized to IMU-838 for the extended treatment period."
89233950|NCT03846219|Experimental|IMU-838 (10 mg/day) - Cohort 2|"Cohort 2 sub-trial: additional sub-trial with a small double-blind, placebo-controlled, randomized, parallel-group assessment of a low IMU-838 dose (i.e. 10 mg/day) to provide additional data for pharmacodynamic modelling.~Tablet containing 5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 10 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks). In the optional extended treatment period, patients were randomized to receive either 30 mg/day or 45 mg/day IMU-838 (up to 8.5 years for the cohort 2 sub-trial)."
88802386|NCT01602016|No Intervention|Phase I|Baseline Visit Phase 1: The screening portion of the CELF will be administered to the child to screen for language impairment. If a child is determined to be pre-verbal they will automatically qualify,If there is no language impairment, the subject will not be eligible. If language impairment is confirmed, the participant will immediately go on to the baseline visit of Phase 2.
89129363|NCT00696735|Active Comparator|1|standard chemotherapy arm, the CHVP (cyclophosphamide, low-dose doxorubicin, teniposide, and prednisone) regimen consisted of cyclophosphamide (600 mg/m2), doxorubicin (25 mg/m2), and teniposide (60 mg/m2), all administered intravenously on day 1, and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
89129364|NCT00696735|Experimental|2|VCAP (cyclophosphamide, high-dose doxorubicin, prednisone, and vincristine) regimen as a first-line therapy combining vindesine (3 mg/m2) on day 1, cyclophosphamide (1500 mg/m2) on day 2, doxorubicin (80 mg/m2) on day 2, and prednisolone (50 mg/m2) on days 1 to 5, every 3 weeks.19,31,32 Patients in CR, VGPR, or PR after the second or third VCAP cycle continued on to stem-cell harvesting and received, before transplantation, one course of IMVP16 (ifosfamide, methotrexate, and VP-16), which combined ifosfamide (1.5 g/m2) and VP16 (100 mg/m2) on days 1 through 3, and methotrexate (30 mg/m2) on days 1 and 10. Patients with less than PR after the VCAP cycles received, as salvage therapy, 2 to 3 courses of DHAP (dexamethasone, high-dose cytarabine, and cisplatin) combining cisplatine (100 mg/m2) on day 1, cytarabine (4 g/m2) on day 2, and dexamethasone (40 mg/m2) on days 1 through 4. If at least a PR was obtained after DHAP, stem cells were harvested or patients were considered as failures
89129365|NCT02867345||Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
89129366|NCT02867345||Comparable group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 wild-type T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
89129367|NCT04260230|Experimental|Lifetemp/Lifetouch sensors|Participants will be asked to wear the sensors for six weeks. Data will be collected from the devices but will only be reviewed retrospectively and will not be used to alter participants care in any way.
89129368|NCT02621853|Other|MRI+RAMAN|Patients will undergo an MRI for assessment of the fat content of the liver. Then during surgery, their livers will be illuminated (for a few seconds) by Raman spectroscope (the device in question) to see if MRI findings correlate well with Raman spectroscopy findings.
89129369|NCT02867189|Experimental|atlas of micro-instrument|anterior chamber cell counts and visual and intraocular pressures on postoperative days 1,3,7,14 by atlas of micro-instrument training method.
89129370|NCT02867189|No Intervention|traditional training|anterior chamber cell counts and visual and intraocular pressures on postoperative days1,3,7,14 by traditional training method.
89129371|NCT02621775|Experimental|Computer-based stress management program|Immediate e-learning condition with minimal contact (n =40),
89129372|NCT02621775|Experimental|Stress management in face-to-face|Immediate treatment in face - to- face (n = 40)
89129373|NCT02621775|Other|Waiting list|Waiting list (n=40)
89129374|NCT04259918|Experimental|Control|no applying alveolar recuritment maneuver
88806128|NCT00248612|Experimental|Venlafaxine & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
89129375|NCT04259918|Active Comparator|Low ARM|Applying 30 cmH2O of alveolar recruitment maneuver 5 times every 5sec
89129376|NCT04259918|Active Comparator|High ARM|Applying 60 cmH2O of alveolar recruitment maneuver 5 times every 5sec
89129377|NCT02867111|Other|ICSI Control|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with no intervention of the Sperm Selection Assay
89129378|NCT02867111|Placebo Comparator|ICSI + SSA placebo|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with control solution (culture medium)
89129379|NCT02867111|Experimental|ICSI + SSA Attractant substance|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with attractant solution (attractant diluted in culture medium at 10 pM)
89129380|NCT04253366|Other|Single arm|All patients perform standard breast screening and also MammoWave exam.
89129381|NCT04134975|Experimental|Scanner Group|lumbar spine surgical procedure with guided pedicle screw placement coupled with intraoperative scanning (BODYTOM, Samsung).
89129382|NCT04134975|Active Comparator|fluoroscopy group|lumbar spinal surgery with pedicle screw placement guided by fluoroscopy, a fluoroscopic control being performed with each set screw.
89129383|NCT04290533|Experimental|Active HD-tDCS|
89129384|NCT04290533|Sham Comparator|Sham HD-tDCS|
89129385|NCT04135053|Experimental|Challenge|Challenge participants will inoculated intranasallly with reconstituted lyophilised Neisseria lactamica (lyoNlac). The initial dose will be 10^5 colony-forming units (CFU) and will be escalated or de-escalated by 1/2 - 1 log depending upon the proportion of volunteers colonies with viable N. lactamica.
89129386|NCT04252976|Experimental|Mantra Meditation|8 weeks of mantra meditation with weekly group sessions.
89129387|NCT04252976|Experimental|Mantra Meditation plus Ethical Practice|8 weeks of mantra meditation plus ethical practice with weekly group sessions.
89129388|NCT04252976|Experimental|Mantra Meditation plus Yoga Exercises|8 weeks of mantra meditation plus Yoga Exercises with weekly group sessions.
89129389|NCT04252976|Experimental|Mantra Meditation plus Yoga Exercises plus Ethical Practice|8 weeks of mantra meditation plus Yoga Exercises plus ethical practice with weekly group sessions.
89129390|NCT02621697|Experimental|Cognitive motor training|Evaluate the effectiveness of a 12-week training based on dual-task (motor and cognitive) in institutionalized elderly.
89129391|NCT02621697|Active Comparator|Control Group|kinesiotherapeutic conventional treatment
89129392|NCT02621541|Experimental|Preoperative diagnosis|Preoperative diagnosis
89129393|NCT04862624|Experimental|Story-based media|Participants will receive a link to our story-based media with Latina characters.
89129394|NCT04862624|Active Comparator|Attention control media|Participants will receive a link to non-story based media that is informational and does not involve story characters.
89129395|NCT05329298|Experimental|Phase I|"Patients will receive a single dose on Day 1, then after an 7-day wash-out period, repeated dosing, once daily will be initiated(Ia).~Patients receive BPI-361175 PO. Cycles repeat every 28 days(Ib)."
89129396|NCT05329298|Experimental|Phase II|Patients receive BPI-361175 based on RP2D.
89129397|NCT02621385|Experimental|Tradipitant|One dose of midazolam followed by tradipitant dosing for days 3-16. Midazolam is also given on day 16
89129398|NCT00696813||paliperidone ER|Newly switched to or started on Paliperidone ER, not longer than 2 weeks ago
89129399|NCT00696813||Any other oral antipsychotic|Newly switched to or started on any other oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago
89129400|NCT04135131|Experimental|PILATES MAT EXERCISE EFFECT ON LOW BACK PAIN|Patients were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. The evaluations were made at the beginning and end of the treatment. Outcome parameters were VAS, Oswestry Disability Index, Qubec Disability Scale, Short Form-36, Beck Depression Questionnaire, sit and reach, Modified Schöber and sit up tests. Multifidus and abdominal muscle thickness were measured by ultrasound image
89129401|NCT04135131|Placebo Comparator|HOME EXERCISE|The exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises. Patients were asked to perform three sets of exercises (10 repetitions) for three times a week for 8 weeks. Exercise training was provided by a physiotherapist. Patients were also provided an illustrated exercise brochure along with an exercise diary to record the number of days on which exercise was performed. They were followed up by phone calls every 2 weeks
89129402|NCT00922766||1.0|
89129403|NCT04134897|Experimental|Neoadjuvant chemotherapy|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery within 2 weeks. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 8-10 weeks. After surgery patients receive 4 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
89129404|NCT04134897|Active Comparator|Neoadjuvant radiotherapy|Patients will receive 5x5 Gy radiotherapy and then surgery following 6-8 weeks. After surgery patients receive 8 cycles of adjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks).
89129405|NCT02621307|Experimental|Salba|50g glucose 25g ground Salba (Salba Corporation Ltd, Buenos Aires, Argentina) 200ml water
89129406|NCT02621307|Experimental|Flax|50g glucose 31g ground Flax (Bob's Red Mill Natural Raw Whole Flaxseed) 200ml water
89129407|NCT02621307|Placebo Comparator|Control|50g glucose 200ml water
89129408|NCT04255472|Experimental|WHO caregiver skills training program|Strategies to support children's communication skills by learning to engage in play activities and daily home routines activities with their caregivers.
89129409|NCT04255472|Experimental|Treatment as usual (TAU)|TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets.
89129410|NCT02620995|Experimental|hypertensive patients|Hypertensive patients will receive a single oral dose of sildenafil citrate (100 mg) - acute protocol - and a chronic 30-day treatment with sildenafil citrate (50 mg twice daily) - chronic protocol. Penile and systemic microvascular function will be evaluated before and one hour after acute sildenafil administration and in the end of each treatment period.
89129411|NCT02620995|Sham Comparator|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
89129412|NCT05313074|Placebo Comparator|Healthy volunteers|Healthcare workers at National Cancer Institute
89129413|NCT05313074|Active Comparator|Cancer patients|"Cancer patients were divided into 3 groups based on treatment status including~active cancer on treatment~Planned to start treatment~Post-treatment (<6 months)"
89129414|NCT04135209||Healthy controls|Healthy individuals of age-matched
89129415|NCT04135209||Myopic patients|Patients with myopia who meet the inclusion criteria
89129416|NCT04252898|Experimental|Intervention arm|In this arm (site n°1), participants will purchase their products in the restaurant first in a control phase and then in an interventional phase with the Nutri-Score affixed on food products.
89129417|NCT04252898|No Intervention|Control arm|In this arm (site n°2), participants will purchase their products in the restaurant during the whole study without any label affixed on food products.
89129418|NCT02620839|Experimental|Cohort 1A|Alpelisib: 200 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
89129419|NCT02620839|Experimental|Cohort 2A|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
89129420|NCT02620839|Experimental|Cohort 2B|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
89129421|NCT02620839|Experimental|Cohort 3A|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
89129422|NCT02620839|Experimental|Cohort 3B|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
89129423|NCT02620839|Experimental|Cohort 4A|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
89129424|NCT02620839|Experimental|Cohort 4B|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
89129425|NCT02620605|Active Comparator|Late administration of Cabirgoline 0.5 mg|Cabergoline 0.5mg (Dostinex®, Pfizer Australia Pty Ltd ) administrated once daily started on day of HCG triggering and continued for 8 days.
89129426|NCT02620605|Experimental|Early administration of Cabirgoline 0.5mg|Cabergoline 0.5mg(Dostinex®, Pfizer Australia Pty Ltd ) once daily stared once patients fulfilling the inclusion criteria at any day of cycle and continued for 8 days post HCG trigger.
89129427|NCT00696891|Experimental|Group A|
89129428|NCT00696891|Active Comparator|Group B|
89129429|NCT00917852|Experimental|GORE Conformable TAG® Thoracic Endoprosthesis|
89129430|NCT02620449|Experimental|single arm study|
89129431|NCT00976391|Active Comparator|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
89129432|NCT00976391|Active Comparator|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
89129433|NCT02620371|Placebo Comparator|(bupivacaine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine)
89129434|NCT02620371|Active Comparator|(bupivacaine, ketamine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine plus ketamine 1 mg/kg) .
89129435|NCT04252664|Experimental|Remdesivir group|active remdesivir
89129436|NCT04252664|Placebo Comparator|Control group|Placebos matched remdesivir
89129437|NCT00696969|Active Comparator|1|
89129438|NCT00696969|Experimental|2|
89129439|NCT00696969|Experimental|3|
89129440|NCT00696969|Experimental|4|
89129441|NCT04203680|Sham Comparator|HTK group|Patients received 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
89129442|NCT04203680|Active Comparator|blood cardioplegia group|patients received one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
89129443|NCT02620137|Experimental|Multicentrum® 3 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 3 months
89129444|NCT02620137|Active Comparator|Multicentrum® 12 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 12 months
89129445|NCT04255862|Experimental|Test 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with bimekizumab-safety syringe-2 mL presentation (test 1).
89129446|NCT04255862|Other|Reference 1|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-safety syringe-1 mL presentation (reference 1).
89129447|NCT04255862|Experimental|Test 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-2 mL presentation (test 2).
89129448|NCT04255862|Other|Reference 2|Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-1 mL (reference 2).
89129449|NCT02620215|Experimental|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
89129450|NCT02620215|Active Comparator|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
89129451|NCT04252820|No Intervention|Control|No prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer and zero-heat-flux temperature sensor will be used to measure the temperature throughout the perioperative period.
89129452|NCT04252820|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
89129453|NCT04252820|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
89129454|NCT04252820|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
89129455|NCT02620059|Experimental|Lifestyle Intervention|"Behavioral: Lifestyle Intervention These women will receive the Healthy Lifestyle Intervention. This intervention will have been delivered during 12 weeks, which will be Distance learning program (multimedia or internet). During the intervention (12 weeks) and follow up period, women will receive not only motivational messages through the Short Message System (SMS) but also a pedometer to record their steps.The intervention will focus on women increasing physical activity (walking) to 10'000 steps per day and receiving healthy eating guidelines.~This intervention curriculum will cover topics related to healthy eating, physical activity, and stress management during postpartum. General information about postpartum period will also be provided."
89129456|NCT02620059|No Intervention|Control|These women will receive general information via pamphlet about postpartum period and tips for stress management.
89129457|NCT04821908||Group 1|population included in the VIRASTHMA COVID G4 study
89129458|NCT04821908||Group 2|"population included in the previous studies VIRASTHMA, CHAMPIASTHMA (IRDCB No.: 2019-A03310-57), COBRAPED (NCT02114034), VIRASTHMA 2 (IRDCB No.: 2014 A01687 40, NCT: 03960359), INCOVPED (pediatric emergencies, NCT04336761)."
88806129|NCT00248612|Active Comparator|Placebo & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants.For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
89129459|NCT04252352|Active Comparator|Ablative fractional CO2 laser resurfacing|One fractional CO2 laser treatment are performed of acne scars on one side of the face
88805897|NCT05004467|Experimental|Mobilization with movement technique|"The therapist applies supported pressure on right and left side and articular planes. Meanwhile, the patient executes active movements and the therapist is trying to find the specifies cervical joint to get partial or total painful relief or movements with restrictions.~If the therapist couldn´t relief or remove pain or restriction with the pressure permorfem, he will readjust pressure and slide in differents planes of motion. It is necessary achieve that aim.~After that, the patient stay in sit down raised position on a stool, with his back in contact with the wall.~Hip, knee and ankle of the patient suppor a certain position: 90º of flexion which will be checked with a conventional goniometer. His hands are on the thighs. The treatment lasts 5 minutes."
89129460|NCT04252352|Active Comparator|Radio-frequency microneedling|One radio-frequency microneedling treatment are performed of acne scars on one side of the face
89129461|NCT02620293|Experimental|Eczema Emollient|Eczema Repair Emollient
89129462|NCT04288973||Typical development children|Control sample
89129463|NCT04288973||Children with developmental disability|Clinical sample
89129464|NCT04252508|Experimental|With animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
89129465|NCT04252508|No Intervention|Standard route|"The information about the surgery will be given by the surgeon during the consultation.~Those about anaesthesia will be delivered by anaesthesiologist during the anaesthetic consultation."
89129466|NCT02619981|Active Comparator|Father present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Father present
89129467|NCT02619981|Active Comparator|Mother Present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Mother present
89129468|NCT02619981|Active Comparator|Both parents present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , both parents present
89129469|NCT03872297|Placebo Comparator|Placebo supplement|Consumption of a non active food complement during 3 months.
89129470|NCT03872297|Active Comparator|Naticol supplement|Consumption of the active food complement during 3 months containing Naticol.
89129471|NCT04252430|Active Comparator|Patients with renal impaired function|6 patients with mild renal impaired function, 6 patients with moderate renal impaired function and 6 patients with severe ranal impaired function
89129472|NCT04252430|Active Comparator|Healthy subjects|Healthy volunteers will be matched with impaired renal function patients
89129473|NCT02864225|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
89129474|NCT00697047|No Intervention|1- Usual Care|Usual Care (UC) includes an annual birthday letter with information on overdue screening tests including CRC screening.
89129475|NCT00697047|Experimental|2 - Automated Mailing|Usual care plus automated mailing. Mailing 1 is a pamphlet about screening choices and number to call for colonoscopy. Mailing 2 is a FIT kit if not requesting colonoscopy. Mailing 3 is a Reminder letter.
89129476|NCT00697047|Experimental|3 - Automated Mailing Plus Assisted|Usual care, automated mailing plus, if screening is still not completed, phone assistance by a medical assistant (MA) who asks about patients screening intent, and provides brief assistance to complete this (e.g. sends another fecal test, assists with provider order for a colonoscopy).
89129477|NCT00697047|Experimental|4 - Auto Plus Assisted Plus Navigation|Usual care, automated mailing, phone assistance by a medical assistant, plus navigation by a registered nurse (RN) if still not screened. Navigators are trained to use motivational interviewing techniques. They assess CRC and procedure risk, facilitate screening choice, address barriers, and provide follow-up until screening is completed.
89129478|NCT04252196|Experimental|Device Usability Study|Usability evaluators of medical device (Healthy volunteers).
89129479|NCT04287881|Other|Adult patients who have epileptic seizures|Patients with adult-onset epileptic seizures and diagnosed ischemic stroke.
89129480|NCT04255706|Other|Biometric measurement repeatability|Biometric measurements will be performed in all patients
89129481|NCT04204889|Experimental|Oxaloacetate|3+3 dose escalating trial starting with 500mg twice daily orally and ending with 2500mg twice daily.
89129482|NCT02619903|No Intervention|COPD Control|Subjects with COPD recieve no treatment. When exiting the trial after 12 months, they do however receive the intervention.
89129483|NCT02619903|Active Comparator|COPD Test|Subjects with COPD that do get the additional dental cleaning, as well as dental examination.
89129484|NCT04287725|Experimental|exercise + active Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.~Photobiomodulation therapy: will be performed using the active super pulsed laser (904nm)."
89129485|NCT04287725|Placebo Comparator|exercise + placebo Photobiomodulation therapy (PBMT)|"Exercise protocol: The program will consist of individual sessions of progressive and submaximal exercises with aerobic training on a treadmill and spine strengthening exercise.~Photobiomodulation therapy: will be performed using the placebo super pulsed laser (904nm)."
89129486|NCT02619669|Experimental|TAK-228 followed by TAK-228 plus Letrozole|"Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.~The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects."
89129487|NCT02866799|Experimental|Multi-PAP intervention|Complex intervention with general practitioners and patients
89129488|NCT02866799|Active Comparator|Usual care|Patients will receive the usual clinical care
89129489|NCT02619825|Other|"Group 1 healthy volunteers"|Echography and Elastography To determine physiological standards across age classes of myocardial stiffness estimated by Elastography in ultrafast (estimated right ventricular stiffness [VD] and left ventricular [LV]). This will be done in groups of children without heart condition, age group (10 children per group, four age groups [0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years]).
89129490|NCT02619825|Other|Group 2 Patients CMH primitive|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Hypertrophic Cardiomyopathy (HCM) non obstructive primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
89129491|NCT02619825|Other|Group 3 Patients primitive CMD:|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Dilated Cardiomyopathy primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
89129492|NCT03965117|Experimental|norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect.
89129493|NCT00917462|Experimental|Sorafenib|Sorafenib for patients with metastatic or recurrent esophageal and gastroesophageal junction cancer.
89129494|NCT02619513|No Intervention|General anesthesia group(Group GA)|Group GA received general anesthesia only and intravenous analgesia pump.
89129495|NCT02619513|Experimental|TEB group(Group GE)|Group GE received continuous thoracic epidural block(TEB) combined with general anesthesia and postoperative continuous thoracic epidural analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
89129496|NCT02619513|Experimental|PVB without DEX group (Group GT)|Group GT received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block(PVB) combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
89129497|NCT02619513|Experimental|PVB with DEX group(Group GTD)|Group GTD received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia,but with dexmedetomidine 0.5μg/kg added to ropivacaine in PVB as an adjuvant.
89129498|NCT02619747|Active Comparator|Compound Sodium Alginate Oral Suspension sachet|Single dose of contents of two 10 ml sachets of Compound Sodium Alginate Oral Suspension
89129499|NCT02619747|Placebo Comparator|Matched placebo|Single dose of contents of two 10 ml sachets of matched placebo
89129500|NCT02866877||Subarachnoid Hemorrhage|
89129501|NCT00697125|Active Comparator|Group A|
89129502|NCT00697125|Experimental|Group B|
89129503|NCT00697125|Experimental|Group C|
89129504|NCT04287491|Experimental|Virtual Reality Group|This group will receive the virtual reality intervention during out-patient bedside procedures.
89129505|NCT04134273|Experimental|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
89129506|NCT04134273|Active Comparator|Clindamycin Phosphate Topical Gel 1%|Clindamycin Phosphate Topical Gel 1%, applied to the face twice a day for 84 days.
89129507|NCT04134273|Placebo Comparator|Vehicle of the test product|Placebo (vehicle of the test product), applied to the face twice a day for 84 days.
89129508|NCT05326659|Experimental|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
89129509|NCT05326659|Placebo Comparator|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
89129510|NCT04134117|Experimental|Tisagenlecleucel|"Study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits.~- Tisagenlecleucel will be administered intravenously as a one-time rapid infusion predetermined dose following lymphodepleting chemotherapy."
89129511|NCT03853187|Experimental|Durvalumab (MEDI4736) neo-adjuvant|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC. Patients are amendable to adjuvant chemo and/or radiation treatment, per standard-of-care. Additionally, patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and ex vivo In-111-oxine or in vivo [89Zr]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
89129512|NCT02619357|Experimental|Cohort 1|10 subjects diagnosed with COPD (GOLD stages 2 and 3). Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
89129513|NCT02619357|Experimental|Cohort 2|10 subjects diagnosed with asthma. Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
89129514|NCT00697281|Experimental|1|Dose level 1
89129515|NCT00697281|Experimental|2|Dose level 2
89129516|NCT00697281|Experimental|3|Dose level 3
89129517|NCT00697281|Experimental|4|Dose level 4
89129518|NCT00697281|Experimental|5|Dose level 5
89129519|NCT00979901|Experimental|1|montelukast
89129520|NCT00979901|Experimental|2|loratadine
89129521|NCT00979901|Placebo Comparator|3|placebo
89129522|NCT00979901|Experimental|4|montelukast/loratadine
89129523|NCT02619201|Experimental|ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
89129524|NCT02619201|Active Comparator|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
89129525|NCT04134741|Experimental|Kinetic Control Group|"The players participated in the classic training and for 4 weeks (3 times a week) underwent the Kinetic Control neuromuscular training with assistance of a physical therapist.~The duration of one training was 20-30 minutes."
89129526|NCT04134741|No Intervention|Traditional Training Group|Players participated in the classic training.
89129527|NCT00975611|Active Comparator|Amantadine 100mg BID|Subjects take amantadine 100mg tablets twice per day (BID)
89233951|NCT00455325|Placebo Comparator|First Intervention (3 weeks)|Cohort 1: Chloroquine placebo one tablet daily for 3 weeks, followed by 5-7 week rest period.
88802387|NCT01602016|Other|Phase II: 12 week Folinic Acid or Placebo intervention|The child will be consented for Phase 2 (the RCT) and undergo a blood draw (up to 20mL) for metabolic and autoantibody testing. the child will undergo language and behavioral assessment while the parent will be interviewed for the Vineland and other questionnaires (ASQ, RBS-R, SRS, and ABC). Demographic information including; age, race, gender, and ethnicity will be collected. The research pharmacist will randomize the participant to either Intervention A or B (only the research pharmacist will know which intervention has the folinic acid). The research pharmacist will distribute the drug or placebo to the parent and instruct the parent of the proper administration of the intervention. This will be considered the 12 week randomly controlled clinical trial that is investigating the safety and efficacy of folinic acis interventions in ASD and will last for approximately 12 weeks. At the end of 12 weeks, the same assessments that were conducted at baseline will be readministered
88802388|NCT01602016|Experimental|Phase III: Open Label Extension of Folinic Acid|If consent for Phase 3 is signed by parents with children who qualify for Phase 3, the research pharmacist will provide a 12 week supply of folinic acid to the parent. This arm will be offered to all clients that completed phase 2 of the trial. After consenting and 12 weeks of folinic acid dosing, the client will come back and complete the same protocol and be tested on the same measures used in phase II of the study. This will be a rolling stopping point so that new therapies can be started, if the parent/caregiver is so inclined
88802389|NCT01591954|Experimental|Video Augmentation|Qualitative assessment of the value of video-based navigation system
88802390|NCT00731770|Placebo Comparator|Placebo, then Advair 250- matched|1 puff bid Placebo for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Advair 250- matched 1 puff bid for two weeks.
88802391|NCT00731770|Active Comparator|Advair 250, then Placebo- matched|1 puff bid Advair 250 for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Placebo- matched 1 puff bid for two weeks.
88802392|NCT01589926|Experimental|Bi-level Positive Airway Pressure Device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
88802393|NCT01589926|Sham Comparator|Sham CPAP|Physiologic continuous positive airway pressure (CPAP) initiated for at least 16 hours per day for a minimum of 48hrs.
88802394|NCT01590394|Experimental|Pancreatic Cancer Patients|A large plastic biliary stent was placed in the bile duct.
88802395|NCT00719914|Active Comparator|1|Intracoronary injection of eptifibatide
88802396|NCT00719914|Placebo Comparator|2|Intra-coronary injection of normal saline.
88802397|NCT01566370|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind
88802398|NCT01566370|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group
88802399|NCT01558492|Experimental|All subjects|Carboplatin and Paclitaxel
88802400|NCT03579472|Experimental|Treatment (bintrafusp alfa, eribulin mesylate)|Patients receive bintrafusp alfa IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
88802401|NCT03371212|Active Comparator|Conventional Cohort|Patients in this group will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
88802402|NCT03371212|Experimental|Modular Dual Mobility Cohort|Patients in this group will receive a Taperloc femoral stem, inner ceramic femoral head (28mm), mobile polyethylene bearing, cobalt alloy liner, and G7 acetabular shell.
88802403|NCT05482620|Experimental|Study Group|Study group following Nordic walking program and educational sessions and usual care (medical visits, medication, etc).
88802404|NCT05482620|Active Comparator|Control Group|Group that will only receive educational sessions and usual care (medical visits, medication, etc).
89129528|NCT00975611|Active Comparator|Amantadine, 200mg BID|Subjects take amantadine 200mg tablets twice per day (BID)
89129529|NCT00975611|Placebo Comparator|Amantadine, placebo BID|Subjects take placebo tablets twice per day (BID)
89129530|NCT02619279|Experimental|Immediate treatment|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
89129531|NCT02619279|No Intervention|Delayed treatment|Participants' mothers will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
89129532|NCT05298189|Experimental|Audio-visual Group|
89129533|NCT05298189|Experimental|Auditory-only Group|This group will recover in the relaxation room with only auditory stimuli.
89129534|NCT05298189|Experimental|Visual-only group|
89129535|NCT05298189|No Intervention|Control Group|
89129536|NCT04287335||High risk CRC screening group|Prospective enrollment of subjects with pre-defined high risk factors for developing colorectal cancer
89129537|NCT04287335||CRC group|Retrospective enrollment of subjects with confirmed colorectal cancer
89129538|NCT04134039|Experimental|Polyurethane (PU) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
89129539|NCT04134039|Experimental|Natural Rubber Latex (NRL) condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. After use of at least 5 condoms, couples will return to the clinic site for collection of their next set of condoms. Each couple will test a maximum of 14 condoms during their participation in the investigation.
89129540|NCT02865161||NISELAT|Amtolmetin guacil should be taken in fasting conditions. The recommended dose is 600 mg b.i.d. Maximum daily dose - 1800 mg
89129541|NCT02619123|Active Comparator|invitation to mammography screening|44-45 years old women in this arm are invited to attend for a mammography screening every 1 year. After the age of 50, all women will continue to be screened in the usual service screening programme.
88802405|NCT05286190|Active Comparator|Transversus Abdominis Plane Block|US-guided Transversus Abdominis Plane Block was applied with 0.5 ml/kg of %25 Bupivacaine at each side before the surgical incision
88802406|NCT05286190|Active Comparator|Caudal Epidural Block|US-guided Caudal Block was applied with 0.7ml/kg of %25 Bupivacaine before the surgical incision
88802407|NCT05477316|Experimental|Treatment|Intensity-modulated Radiation Therapy (IMRT)/VMAT with integrated boost to the cerebellum and metastases and Stereotactic Radiosurgery (SRS) to the cerebral metastases as a novel treatment combination for brain metastases
88802408|NCT01551082||Outpatient chest tubes|All patients, mixed gender, race, and age, who underwent thoracic resection by one surgeon over the past seven years and discharged home with air leak present and chest tube to portable drainage device.
88802409|NCT05473260|Active Comparator|HOSPI Group|Patients with mild acute pancreatitis randomized to in-hospital care.
88802410|NCT05473260|Experimental|HOME Group|Patients with mild acute pancreatitis randomized to early discharge and outpatient clinic follow-up.
88802411|NCT00691444|Experimental|1|Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
88802412|NCT00691444|Experimental|2|Subjects will be given up to 10 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
88802413|NCT00691444|Experimental|3|Subjects will be given up to 20 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
88802414|NCT00693628|Active Comparator|Shrinker|Patients receive 20-30 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
88802415|NCT00693628|No Intervention|No Shrinker|Control group - participants will not receive an intervention (compression shrinker).
88802416|NCT00693628|Active Comparator|Shrinker 2|Patients receive 30-40 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
88802417|NCT05482464|Other|Casein glycomacropeptide (CGMP)|"The subjects will receive a daily oral intake of CGMP-protein-shake for 3 weeks with a 1 week wash-in and a 3 week wash-out.~Intervention: Dietary Supplement: Casein glycomacropeptide (CGMP)"
88802418|NCT00689884|Experimental|Group A|All eligible patients will receive chemotherapy and one dose of Pegfilgrastim
88802419|NCT05472870|Experimental|rTMS Group|Participants will receive continuous theta burst stimulation (cTBS) for a 5-day period (5 sessions), at an intensity that is 80% of the resting motor threshold (RMT) . cTBS repeats ten times a day with about 50 min interval . If feasible for the participant, all stimulation sessions will be held at the same time of the day. Treatment will be applied in left primary motor cortext (M1).
88802420|NCT01530880|Experimental|Intravenous Ibuprofen|Patients assigned to the ibuprofen treatment group will receive a 400 mg IV ibuprofen bolus over 30 minutes followed by an infusion of ibuprofen at 85 mg/hr.
88802421|NCT01530880|Other|Standard of Care|Patients assigned to the standard of care group will be given 650 mg of oral acetaminophen and continue to receive 650 mg of oral acetaminophen every 6 hours as needed to maintain temperature < 38.3 C (100.9 F).
88802422|NCT05482230|No Intervention|DLT in supine position|The double-lumen bronchial group was inserted in supine position
88802423|NCT05482230|Experimental|DLT in lateral position|The double-lumen bronchial group was inserted in lateral position
88802424|NCT05482230|No Intervention|BB in supine position|The bronchial blocker group was inserted in supine position
88802425|NCT05482230|Experimental|BB in lateral position|The bronchial blocker group was inserted in lateral position
88802426|NCT05482074|Experimental|OLAPARIB|"The research study procedures include screening for eligibility, study treatment including evaluations, surveys, optional biopsies, and follow up visits~Olaparib- Each study treatment cycle lasts 28 days . This will continue for as long as the study treatment is providing clinical benefit"
88802427|NCT03228472|Experimental|real stimulation|Cranial - electrical or magnetic stimulation. Stimulation will be different according to clinical conditions, as specified elsewhere.
88802428|NCT03228472|Placebo Comparator|sham stimulation|"Patients will be treated as in the Real stimulation arm, but no electrical or magnetic stimulation will be induced."
88802429|NCT05476848|Experimental|Covid-19 (+) Patients|Oral Examination, Radiography, oral (salivary) swap sample collection will be performed.
88802430|NCT05476848|Active Comparator|Healthy Individuals|Oral Examination, Radiography, oral (salivary) swap sample collection will be performed.
88802431|NCT03195790|Active Comparator|Medical center treatment arm|Family-based pediatric obesity treatment delivered at an urban medical center.
88802432|NCT03195790|Experimental|Home treatment arm|Family-based pediatric obesity treatment delivered in the family's home.
89129542|NCT02619123|Experimental|invitation to tailored screening|44-45 years old women in this arm with a dense breast (3-4 categories in BI-RADS) at the baseline mammography are invited again after 1 year, while the lower-density group in the intervention arm are invited after 2 years. After the age of 50, all women will continue to be screened in the usual service screening programme.
89129543|NCT04289129|Experimental|men|
89129544|NCT04289129|Experimental|women|
89129545|NCT02865005|Active Comparator|Dapsone 5.0% Gel (Allergan)|Dapsone 5.0% Gel applied twice daily for 84 days
89129546|NCT02865005|Experimental|Dapsone 5.0% Gel (SEEGPharm)|Dapsone 5.0% Gel applied twice daily for 84 days
89129547|NCT02865005|Placebo Comparator|Placebo|Vehicle of Experimental Gel applied twice daily for 84 days
89129548|NCT02618811||Group 1|not sarcopenic
89129549|NCT02618811||Group 2|sarcopenic
89129550|NCT02618811||Group 3|not myosteatotic
89129551|NCT02618811||Group 4|myosteatotic
89129552|NCT02619045|Other|Solid tumors|Patients with solid tumor starting a intra venous chemotherapy with 21 days cycles.
89129553|NCT03835403|No Intervention|Usual Care (control arm)|These cardiac arrests will receive standard EMS response.
89129554|NCT03835403|Experimental|HeartRunner Activation|For these cardiac arrests, HeartRunners will be activated in addition to standard EMS response.
89129555|NCT02618889|Active Comparator|CBT plus botox|Participants will be randomized to receive BoNT (onabotulinumtoxinA). Patients will undergo study assessments four weeks later. We will inject a total of 250 units of onabotulinumtoxinA, as the average optimal dose in cervical dystonia,11 using a 100:1 dilution with normal saline. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
89129556|NCT02618889|Placebo Comparator|CBT plus placebo|Participants will be randomized to receive normal saline (placebo). We will inject a total of 250 units of normal saline, as this is the average optimal dose of onabotulinumtoxinA in cervical dystonia. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
89129557|NCT04287257|Active Comparator|Standard treatment + Active FHP|The PEMF device - FHP (supplied by commercial support) will be placed under the cast in the ER after diagnosing the fracture and will be applied for 24 hours a day continuously for 30-40 days.
89129558|NCT04287257|Sham Comparator|Standard treatment + Sham FHP|Half of the PEMF devices will be not activated at random before the application to the patients. Two types of activators will be provided by the company: active and sham. Sham activated devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the device's functionality. The patients will not be able to determine whether the device is working or not. At study completion, device serial numbers will be used to determine which patients received a working device. The company supplying the PEMF-devices will have no knowledge of patient outcome.
89129559|NCT02618421||Participants Aged 40 Years or Over|Cross-section of general population of males and females in China, Taiwan, and South Korea
89129560|NCT02862977|Experimental|EMS association|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h.
89129561|NCT02862977|Active Comparator|Miosan Caf®|The patient will take 2 tablets (combination of Cyclobenzaprine and caffeine), oral, per day, each 12h.
89129562|NCT02618655||Fever，none definite diagnosis|Those who have fever，but the doctor can not make definite diagnoses with the diagnostic methods available.
89129563|NCT02864927|Experimental|Menactra Group 1|Participants aged 9 to 23 months will receive 2 doses of Menactra
89129564|NCT02864927|Experimental|Menactra Group 2|Participants aged 2 to 55 years will receive 1 dose of Menactra
89129565|NCT00697359|Experimental|1|There is only one group in this cohort study.
89129566|NCT02618499|Active Comparator|oxytocin inmediately at birth|Intervention: Timing of administration of postpartum Oxytocin. 10 international Units (IU) immediately at birth will be given intravenously (IV) to the mother.
89129567|NCT02618499|Experimental|oxytocin at 3 minutes|Intervention: Timing of administration of postpartum Oxytocin. 10 IU IV at 3 minutes immediately after the cord is clamped
89129568|NCT04133961|Experimental|Group A (Phenylephrine)|Phenylephrine infusion started immediately after administration of spinal block
89129569|NCT04133961|Placebo Comparator|Group B (Saline)|Normal saline infusion started immediately after administration of spinal block
89129570|NCT02618265|Experimental|Mobile terminal|Stroke received mobile terminal management for secondary prevention administration, as the same time platelet reactivity modified drug selection was performed. Mobile application management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
89129571|NCT02618265|Active Comparator|traditional management|Stroke received traditional management for secondary prevention administration
89129572|NCT02618265|Active Comparator|website platform management|Stroke received website platform management for secondary prevention administration. Website platform management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
89129573|NCT02618733|Experimental|Ticagrelor|Ticagrelor 90mg, twice a day
89129574|NCT02618733|Active Comparator|Clopidogrel|Clopidogrel 75mg, once a day
89129575|NCT04134195|Experimental|Real transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of real transcranial direct current stimulation over two distinct brain areas.
89129576|NCT04134195|Experimental|Sham transcranial direct current stimulation|Healthy adults and healthy seniors will undergo application of sham transcranial direct current stimulation over two distinct brain areas.
89129577|NCT02617953|Experimental|Active rTMS(A)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
89129578|NCT02617953|Experimental|Active rTMS(B)|Temporal low frequency repetitive transcranial magnetic stimulation
89129579|NCT02617953|Sham Comparator|Sham condition(C)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
89129580|NCT02618109|Other|Relapse Group|"Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.~Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis."
89129581|NCT02618109|Other|Control Group|"Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.~Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.~These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients."
89129582|NCT00970307|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of GSK2202083A vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. GSK2202083A and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
89233952|NCT00455325|Active Comparator|Second Intervention (3 weeks)|Cohort 2: 80mg chloroquine or placebo tablet once daily for Weeks 3, followed by 5-7 week rest period.
89233953|NCT00455325|Active Comparator|Third Intervention (3 weeks)|Cohort 3: 80mg chloroquine tablet daily: for 3 weeks, followed by 5-7 week rest period.
89233954|NCT00455325|Active Comparator|Fourth Intervention (3 weeks)|Cohort 4: 250mg chloroquine tablet daily: for 3 weeks, followed by 5-7 week rest period.
89233955|NCT01028079|Active Comparator|Arm 2|
89233956|NCT01028079|Placebo Comparator|Arm 3|
89233957|NCT01028079|Experimental|Arm 1|
89233958|NCT01028157|Placebo Comparator|General Health Control|
89233959|NCT01028157|Experimental|HIV Risk Reduction & Relapse Prevention|
89233960|NCT01024725||Not (yet) vaccinated persons|The participants do not want to take the vaccine (available only in the national vaccination campaign) or have not received it yet
89233961|NCT01024725||Vaccinated persons|The participants have taken the vaccine according to the national vaccination campaign
89233962|NCT01323231|Experimental|Communities in Schools Services|Communities in Schools services include case management, mental health services, mentorship services, after school programs, and academic assistance.
89233963|NCT00443781|Other|PD and F.A.D. diagnostic testing|
89233964|NCT01024881|Active Comparator|group 1|neutral shoulder position during infraclavicular subclavian catheterization
89233965|NCT01024881|Experimental|group 2|lowered shoulder position during infraclavicular subclavian catheterization
89233966|NCT00443703|Experimental|1|Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir )
89233967|NCT00443703|Active Comparator|2|Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)
88802433|NCT03584022|Experimental|Biopsy + Nerve Repair|Subjects will undergo standard sural nerve biopsy plus repair of the 6 cm nerve defect using a synthetic polymer (PCLF) nerve tube.
88802434|NCT03584022|Sham Comparator|Biopsy Only|Subjects will undergo the same standard sural nerve biopsy procedure as the Experimental Group, but will not include the nerve repair.
88802435|NCT01532362|Experimental|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
88802436|NCT01532362|Other|No drug intervention|
88802437|NCT00678574|Experimental|Premenstrual Dysphoric Disorder (PMDD) group|PMDD group received fluoxetine 20 mg daily by mouth for 2-3 months
88802438|NCT00678574|No Intervention|Healthy controls|
88802439|NCT05481918|Active Comparator|Standardized therapy|"The standardized outpatient rehabilitation program after ACL reconstruction contains 16 physiotherapeutic visits (groups+ individual), exclusively a stationary supervision.~Therapies: stationary: 1x individual (30 min); from 2nd to 6th week: 2x individual (30 min), 5x group (30 min), 4x group (30min); From 6th week: 5x group (30 min)"
88805898|NCT05004467|Sham Comparator|Placebo technique|Placebo manual technique is performed similar to experimental group technique but no slides are performed. The therapist simply embraces cervical region with boths hands, avoiding any pressure or any painfully caoture.
89233968|NCT01028235||Obstructive Dysphagia|Patients who complained of dysphagia, which had an obstructive etiology for their symptoms at the time of endoscopy (ring, mass, stricture, etc)
89233969|NCT01028235||Non-obstructive Dysphagia|Patients whose endoscopy was normal and without any obvious etiology for their symptoms noted.
89233970|NCT00381706|Experimental|Arm A (ECF + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab IV on days 1, 8 and 15. Patients receive epirubicin 50 mg/m^2 IV after cetuximab on day 1 followed by cisplatin 60 mg/m^2 IV over 60 minutes. On days 1-21, patients receive 5-fluorouracil 200 mg/m^2/day continuous IV infusion. Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
89233971|NCT00381706|Experimental|Arm B (IC + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1, 8 and 15. Patients receive cisplatin 30 mg/m^2 IV over 30 minutes on days 1 and 8 after cetuximab. Patients also receive irinotecan 65 mg/m^2 IV over 90 minutes on days 1 and 8 after receiving cisplatin.Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
89233972|NCT00381706|Experimental|ARM C (FOLFOX + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1 and 8. On Day 1, patients also receive oxaliplatin 85 mg/m^2 IV over 120 minutes and leucovorin 400 mg/m^2 IV over 120 minutes either concurrently with oxaliplatin via a separate infusion line or post oxaliplatin administration. Following leucovorin, patients will receive 5-fluorouracil 400 mg/m^2 IV bolus injection, then 5-fluorouracil 2400 mg/m^2 IV infusion over 46-48 hours. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
89233973|NCT01045642|Active Comparator|Prilosec 20 mg Tablets|
89233974|NCT01045642|Experimental|Omeprazole Magnesium DR 20 mg Capsules|
89233975|NCT00535236|Experimental|Autologous HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233976|NCT00535236|Placebo Comparator|Autologous HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233977|NCT00535236|Experimental|Allogeneic HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233978|NCT00535236|Placebo Comparator|Allogeneic HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233979|NCT00535236|Experimental|STM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233980|NCT00535236|Placebo Comparator|STM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233981|NCT00535236|Experimental|HM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233982|NCT00535236|Placebo Comparator|HM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233983|NCT00535236|Experimental|HIV-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233984|NCT00535236|Placebo Comparator|HIV-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
89233985|NCT05357430|Experimental|group D1(obese patient)|Administration of 0.3μg/kg of remifentanil in advance, then corresponding dose of remimazolam, according to the experimental results of the previous patient.
89233986|NCT05357430|Experimental|group D2(non-obese patient)|Administration of 0.3μg/kg of remifentanil in advance, then corresponding dose of remimazolam, according to the experimental results of the previous patient.
89233987|NCT05357430|Experimental|group R|Administration of 0.3μg/kg of remifentanil in advance, then the calculated dose of remimazolam, according to calculated results from group D1 and D2
89233988|NCT05357430|Experimental|group C|Administration of 0.3μg/kg of remifentanil in advance, then 1.5-2mg/kg propofol.
89233989|NCT00370552|Experimental|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|
89233990|NCT00370552|Experimental|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|
89233991|NCT00370552|Active Comparator|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|
89233992|NCT00537030|Experimental|Treatment (chemotherapy)|Patients receive 6 doses of Erwinia asparaginase IM on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase remaining on the original treatment protocol. All other chemotherapy continues according to the original treatment protocol.
88802440|NCT05481918|Experimental|Home-based therapy|The home-based program consists of five outpatient physiotherapeutic units (each 60 minutes) at the department of physical medicine and rehabilitation of the UHK. The timing of the physiotherapeutic supervisions was defined based on pre-existing studies, concerning home based therapy after ACL reconstruction. The five physiotherapeutic sessions will be executed by a physiotherapist in first, third, seventh, ninth and eleventh postsurgical week. In addition to a general information sheet, the patients of this group will receive phase-adapted training documents (with photographs) at each physiotherapeutic appointment.
88802441|NCT02551692|Placebo Comparator|NRT|
89233993|NCT01047904|Experimental|Iontophoresis-treated|Healthy volunteers will evaluate reliability and performance of Iontophoresis System in delivery of local anesthesia to the TM.
89233994|NCT00381238|Experimental|rosiglitazone|Extended Release Tablets
89233995|NCT04639596|Experimental|MBTS|It will consist of four hours of sailing and mindfulness training at the Jordanelle Reservoir. Boats and skippers will be provided by Park City Sailing Association, a non-profit community organization.
89233996|NCT04639596|Experimental|SRT|SRT will occur on four separate occasions during the summer of 2019. SRT will consist of 4 hours of bowling at a community bowling alley.
89233997|NCT05355714|Experimental|Sofwave|
89233998|NCT05355714|Other|Ultherapy|
89233999|NCT05260476||Reablement group|"The home reablement program will be implemented by a physical therapist according to Long-term Care Reablement Operational Guidelines announced by the Ministry of Health and Welfare of Taiwanese government"
89234000|NCT05260476||Non-reablement group|This group will only receive general home care service without the reablement program.
89234001|NCT04928820|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.
89234002|NCT03896022|Active Comparator|Auriculotherapy - Acupressure with Gold Beads|A designated trained auriculotherapy provider will place gold beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
89234003|NCT03896022|Active Comparator|Auriculotherapy - Acupuncture with Pyonex Needles|A designated trained auriculotherapy provider will place 1.2mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
89234004|NCT03896022|Sham Comparator|Placebo Group|A designated trained auriculotherapy provider will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
89234005|NCT04430946|Experimental|Lean patients with type 1 diabetes|Test meal consumed within 10 minutes
89234006|NCT04430946|Experimental|Obese patients with type 1 diabetes|Test meal consumed within 10 minutes
88802442|NCT02551692|Placebo Comparator|VAR|
88802443|NCT02551692|Placebo Comparator|PLAC|
88802444|NCT00247000|Active Comparator|1|Home teleheatlh for heart failure management
88802445|NCT00247000|Active Comparator|2|Usual care for the management of Heart Failure
88802446|NCT00547456|Other|Decrease in oxygen level when sleeping|Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
88802447|NCT05481840|Experimental|Intervention group|Receiving smart continence care by the use of continence material with sensor, in which their care professionals receive a notification when change is needed.
88802448|NCT05481840|No Intervention|Waiting list group|Will continue regular continence care as received by their care professionals. After data collection is finalized, they will receive smart continence care.
88802449|NCT00542542|Active Comparator|Paravertebral Block + General Anesthesia|Group 1: Paravertebral Block + General Anesthesia (Ropivacaine)
88802450|NCT00542542|Active Comparator|General Anesthesia Alone|Group 2: General Anesthesia Alone (Propofol, Midazolam, Fentanyl)
88805899|NCT00294632|Experimental|Lenalidomide + Rituximab|Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks
89234007|NCT04430946|Active Comparator|Lean healthy control subjects|Test meal consumed within 10 minutes
89234008|NCT04430946|Active Comparator|Obese healthy control subjects|Test meal consumed within 10 minutes
89234009|NCT03831880|Other|Daily to Weekly|Genotropin to somatrogon
89234010|NCT03831880|Other|Weekly to Daily|somatrogon to Genotropin
89234011|NCT00924456|Experimental|Transcendental Meditation program|a natural effortless mental technique practiced sitting quietly 20 minutes twice a day
89234012|NCT00924456|Placebo Comparator|Wait list control|student subjects on wait list control
89234013|NCT04429152|Experimental|Doravirine|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
89234014|NCT04257552|Active Comparator|Attention Control Group|If randomized to the attention control arm participants will receive discharge instruction from the postpartum nurses per usual care. Study investigators will ask them to provide us with an SMS number. This will enable collection of self-reported breast feeding duration as well as texts on general infant care. The infant care texts are educational in nature and no data will be collected. Participants will receive a total of two texts on general infant care in the first month postpartum. This increased attention to the control arm mirrors the attention received by the Healthy Beyond Pregnancy arms and seeks to isolate the effect of the intervention from a general increased level of contact with providers.
89234015|NCT04257552|Active Comparator|Pre-Scheduled Postpartum Visit:|If randomized the usual care with pre-scheduled visit arm, participants will schedule their postpartum visit with the study coordinator and receive discharge information per usual care.
89234016|NCT04257552|Experimental|Healthy Beyond Pregnancy|Healthy Beyond Pregnancy is a web platform with an electronic survey that assesses a participant's self-identified postpartum concerns. Participants are then presented with 3 educational videos that reflect their self-identified needs from the survey. The Healthy Beyond Pregnancy generates an individualized passport for postpartum care. This passport for care lists the women's self-identified postpartum needs as well as issues that should be prioritized based on her health history. The individualized passport for postpartum care will be printed out and given to participants. After the participant schedules her postpartum visit, she will receive a printout that includes the date and time of her appointment, a copy of the commitment statement.
89234017|NCT04001400|Experimental|High-dose rabeprazole|Rabeprazole 20mg twice daily by mouth before breakfast and dinner for 8 weeks
89234018|NCT04001400|Active Comparator|Standard-dose rabeprazole|Rabeprazole 20mg once daily by mouth before breakfast for 8 weeks
89234019|NCT04219566|Active Comparator|Active VeNS|The VeSTAL device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
89234020|NCT04219566|Sham Comparator|Sham VeNS|The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. However, it does not deliver vestibular stimulation to users. device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day in the period immediately prior to sleep onset.
89234021|NCT00380692|Experimental|Atomoxetine|atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks
88802451|NCT00545506|Active Comparator|conventional bandage|conventional bandage on sternal wound after skin closure after cardiac surgery. conventional gauze covered with elastic adhesive (Medipore™ Dress-it) The designated bandage will be positioned in the operating room by the surgeons after the skin will be closed. The conventional elastic bandage consists of several layers of gauze covered with a special adhesive bandage
88802452|NCT00545506|Active Comparator|warming bandage|The Warm-Up bandage consists of an adhesive shell and a foam frame that supports a clear window about one cm above the surface of the wound. A battery-powered heating card can then be inserted into the window to provide gentle warming of the wound. The surface temperature of heating card is fixed at 38°C, and heat is usually provided for two hours at a time. That is, the experimental bandage will be continuously applied to the wound and heated to 38°C using a two-hour on/off cycle.
88802453|NCT03333486|Experimental|Treatment (fludarabine, cyclophosphamide, TBI, PBSCT)|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.
88802454|NCT02703844|Active Comparator|Active|Participants will be receiving an active Caloric Vestibular Stimulation treatment for a duration of 8 weeks, 7 days a week, twice daily for 19 minutes.
88802455|NCT02703844|Sham Comparator|Placebo|"Participants will be receiving a Sham Caloric Vestibular Stimulation treatment for a duration of 8 weeks in the same manner as the active arm: 7 days a week, twice daily for 19 minutes.~Individuals allocated to this arm will be later crossed over, in unblinded fashion, to the active arm if the treatment shows evidence of efficacy and safety."
88802456|NCT03546660|Experimental|SECM capsule imaging|Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system
88802457|NCT02598778|Active Comparator|Chlorhexidine gluconate (0.12%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
88802458|NCT02598778|Active Comparator|Sodium Fluoride (0.05%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
88802459|NCT02598778|Placebo Comparator|Paraffin wax chewing gum (sugar-free)|A food product. Minimum of 2 minutes of chew time prior to salivary sample being obtained.
88802460|NCT02598778|Placebo Comparator|Deionized water|Water that has had the majority of its ions removed.
88802461|NCT05481606||Type I|1) the gestational sac is partially implanted in the uterine scar, partially or mostly located in the uterine cavity, and a few may even reach the uterine cavity at the bottom of the palace; 2) the gestational sac is significantly deformed, and elongated, and its the lower end presented a acute Angle; 3) The myometrium between the gestational sac and the bladder became thinner, with a thickness of >3 mm; 4) Doppler flow image: trophoblast blood flow signal can be seen in the scar (low resistance blood flow)
88805900|NCT01898624||Betanis group|mirabegron treated group
89234022|NCT00380692|Placebo Comparator|Placebo|"placebo every day (QD), by mouth (PO) for 8 weeks~Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks"
89234023|NCT05355636|Experimental|experiment group|patient receiving counseling
89234024|NCT05355636|No Intervention|control group|patient without counseling
89234025|NCT04285866||Durvalumab Group|Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.
89234026|NCT01047982|Active Comparator|myo-inositol|
89234027|NCT01047982|Placebo Comparator|placebo|acid folic 400 mcg twice per day
89234028|NCT05355558|Experimental|[18F]FLT-PET/MRI body scan|
89234029|NCT00536874|Experimental|Gemcitabine And Oxaliplatin|A Phase II Study of Neoadjuvant Gemcitabine And Oxaliplatin In Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
89234030|NCT04275102|Experimental|Three times weekly symptom screening|Three times weekly symptom reporting by guardians and children using the SPARK platform for 8 weeks
89234031|NCT00991848|Experimental|Lidocaine|Patients received 240 mg lidocaine diluted in 125 mL 0.9% saline. The solutions were infused over a period of 1 h, once a week, for 4 weeks (T1, T2, T3 and T4).
89234032|NCT05281068|Experimental|Iguratimod and Danazol|Iguratimod is given at a dose of 25 mg bid. Danazol is given at 200mg bid for 12 weeks.
89234033|NCT05281068|Active Comparator|Danazol|Danazol is given at 200mg bid for 12 weeks.
89234034|NCT05276700||case with hcv|
89234035|NCT05276700||control without hcv|
89234036|NCT00380068|Experimental|Ambrisentan|
89234037|NCT00991926||orlistat plus normo-caloric diet|10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
89234038|NCT00991926||normo-caloric diet|10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days
89234039|NCT04230954|Experimental|Cabozantinib (XL 184) Plus Pembrolizumab|A Phase II Study of Cabozantinib (XL 184)Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
89234040|NCT05265702|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
89234041|NCT04127838|Experimental|Low Vision Occupational Therapy|The anticipated low vision occupational therapy intervention strategy includes training participants to compensate for their vision more effectively for increased participation in ADLs and IADLs.
89234042|NCT04081974||Minimally invasive cardiac surgery|All consecutive patients presenting for minimally invasive cardiac surgery will be screened for participation to the study.
89234043|NCT03981432|Experimental|Constitutional leanness|Constitutional leanness
89234044|NCT03981432|Experimental|Normal weight|Normal weight women
89234045|NCT03981432|Experimental|Anorexia nevrosa|women presenting Anorexia nevrosa
89234046|NCT00536484|Experimental|Fesoterodine (Double-Blind)|
89234047|NCT00536484|Placebo Comparator|Placebo (Double-Blind)|
89234048|NCT00370396|Experimental|Synflorix-Synflorix Group|This group consisted of subjects previously vaccinated with the Synflorix™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
89234049|NCT00370396|Active Comparator|Prevenar-Prevenar Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Prevenar™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Prevenar™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
89234050|NCT00370396|Experimental|Prevenar-Synflorix Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
89234051|NCT00992004|Experimental|Arantal®|Highly bioavailable turmeric extract (food supplement)
89234052|NCT00992004|Placebo Comparator|Placebo|Same capsule without the active ingredients (only excipients)
89234053|NCT00992082|Active Comparator|Group LIA|Local Infiltration Analgesia
88805901|NCT01140191|Experimental|WR 279,396|All subjects in this one-arm study will receive topical WR 279,396
89234054|NCT00992082|Active Comparator|Group M|Intrathecal morphine
89234055|NCT00455013|Experimental|belatacept, mycophenolate mofetil (MMF)|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months; MMF 1g twice daily(bis in die, BID)
89290186|NCT03932994|Experimental|ACT on Health Intervention|Those assigned to ACT on Health will use the program over the next 8 weeks, completing weekly modules and coaching calls.
88805902|NCT04752176||Tinnitus group|At least 20 patients suffering from tinnitus will be enrolled in the study.
88805903|NCT04752176||Hyperacusis group|At least 20 patients suffering from hyperacusis will be enrolled in the study.
88805904|NCT01140815|Active Comparator|Total|The Smith and Nephew Total Knee System
89129583|NCT00970307|Active Comparator|INFANRIX HEXA + MENJUGATE GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 3 and 4 months of age, 2 doses of Menjugate® vaccine at 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Menjugate® vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
89129584|NCT00970307|Active Comparator|INFANRIX HEXA + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
89129585|NCT02617875|Active Comparator|Conventional EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a conventional EMS physician, if this is the result of the randomization software.
89129586|NCT02617875|Other|Tele-EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a tele-EMS physician, if this is the result of the randomization software.
89129587|NCT00917384|Experimental|ramucirumab|Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
89129588|NCT00917384|Placebo Comparator|Placebo|Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
89129589|NCT04133571|No Intervention|Control group|Control group: using normal saline for bladder irrigation
89129590|NCT04133571|Experimental|Study group|Study group: using 0.05% Lidocaine normal saline solution for bladder irrigation
89129591|NCT03749837|Experimental|C- MAC VS|Intubation with C- MAC VS
89129592|NCT03749837|Active Comparator|Video Endoscope|Intubation with standard fiberoptic scope
89129593|NCT02617641|Experimental|TAVIEenM@RCHE intervention|The experimental group will receive a web-based tailored nursing intervention. Between 3 and 4 sessions of 15 to 25 minutes each are completed within 4 weeks. A booster session is delivered at 8 weeks post randomization.
89129594|NCT02617641|Active Comparator|Publicly available websites|The control group will receive hyperlinks to four publicly available websites and one online booklet on the topic of walking.
89129595|NCT02862899|Experimental|Heating cable|
89129596|NCT04287023|Experimental|Group Physical therapy|1 physical therapists and groups of 10 patients during the sessions
89129597|NCT04287023|Active Comparator|Individual physical therapy|1 physical therapist and 1 patient during the sessions
89129598|NCT02617719||Primary care|Staff, patients aged 75 years and older and their carers associated with a single, participating United Kingdom primary care practice.
89129599|NCT00629681|Experimental|1|
89129600|NCT05308394||Control group|The control group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2), body fat percent < 25% (male) or < 35% (female), and up to 1 other risk factor among the following: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
89129601|NCT05308394||Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent > 25% (male) or > 35% (female).
89129602|NCT05308394||Metabolically Healthy Obesity|Metabolically healthy obesity will be defined as having an obese BMI (> 30 kg/m2), body fat percent < 25% (male) or < 35% (female), and up to 1 other risk factor among the following: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
89129603|NCT05308394||Metabolic Syndrome|Metabolic syndrome will be defined using the international Diabetes Federation criteria of an obese BMI ( > 30 kg/m2) and 2 or more of the following risk factors: blood pressure > 130/85 mmHg, fasting glucose >100 mg/dL, fasting triglycerides >150 mg/dL, and HDL < 40 (male) or < 50 (female).
89129604|NCT04289207|Experimental|Romiplostim and danazol|Treatment group (romiplostim and danazol)
89129605|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
89129606|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group.
89129607|NCT04252118|Experimental|MSCs Treatment Group|Conventional treatment plus MSCs Participants will receive conventional treatment plus 3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
88805905|NCT01140815|Experimental|Deuce|The Journey Deuce Bicompartmental Knee System
89129608|NCT04252118|No Intervention|Conventional Control Group|Without MSCs Therapy but conventional treatment should be received.
89129609|NCT02863835|Experimental|Intervention 1|"A 1:1 randomisation will be performed to decide the order of the administration of salbutamol and CPAP. All participants will receive both interventions in a cross-over fashion. Salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure.~Each participant will then have continuous assessment of the following whilst self venting:~Spirometry - FEV1, FVC, MVV~Muscle strength measurements: MIP, MEP, SNIP~Borg scale, mMRC, Visual Analogue Scale for breathlessness~Electrical impedance tomography~EMGpara~Transcutaneous measurement of CO2 and 02 level~End-tidal CO2 monitoring~Pneumotachography"
88802462|NCT05481606||Type II|1) The gestating sac is partially implanted in the scar of the uterus, partially or mostly located in the uterine cavity, and a few may even reach the uterine cavity at the bottom of the uterus; 2)the gestational sac is significantly deformed, and elongated, and its the lower end presented a acute Angle; 3) The myometrium between the stretch and the bladder becomes thinner (3 mm in thickness); 4) color Doppler flow image: trophoblast blood flow signal (low resistance blood flow) can be seen in the scar.
89129610|NCT00697437|Experimental|docetaxel only|
89129611|NCT00697437|Experimental|docetaxel with ketoconazole|
89129612|NCT04252274|Experimental|Darunavir, Cobicistat and conventional treatments|After randomization, subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments.
89129613|NCT04252274|No Intervention|Conventional treatments|After randomization, subjects take conventional treatments without darunavir and cobicistat.
89129614|NCT04133727|Experimental|Intervention|Intervention group will wear a simulation suit in which will mimic the physical limitations experienced by older adults. In addition, they will participate in a polypharmacy workshop which allows them to communicate with older adults
89129615|NCT04133727|Active Comparator|Control|This group will participate in a polypharmacy workshop which allows them to communicate with older adults
89129616|NCT04133649|Experimental|subjects treated with LGT|Subjects will be treated with a single IV dose of LGT (AAV-hTERT)
89129617|NCT05251844|Experimental|Email warning|"some individuals that accessed patients' data without authorization were randomly selected to receive an email warning. A sample email:~Dear Colleague,~The {Organization} proactive electronic record monitoring system has flagged you as having accessed the electronic patient record of {Patient_Name} on {Case_Event_Date}. A clear work-related purpose has not been identified for this access, and there are no approvals in place by the {Organization} Privacy Office to allow access to this record for personal purposes in accordance with A065. {Organization} takes the privacy of patient information very seriously. The {Organization} Privacy Office is now investigating this access as a potential privacy breach.~This potential noncompliance needs to be resolved immediately. To help determine whether a privacy breach has occurred, please respond to this email with answers to the following questions no later than 5 days from the date of this email...omitted due to length"
89129618|NCT05251844|No Intervention|No eamil warning|individuals that were flagged as accessing patients' data without authorization on the same day as the experimental group were used as the control group
89129619|NCT02617173|Experimental|Transcutaneous electrical nerve stimulation|Low current electrical stimulator
89129620|NCT05296226|Experimental|dry needling group|dry needling is probably the most popular, trigger-point dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Goniometry will be used to assess range ofmotion. Ischemic compression is one of the least invasive trigger point therapies.
89129621|NCT05296226|Experimental|ischemic compression group|compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points. Pressure is sustained for 10 to 20 second
89129622|NCT00698373||1|PET study
89129623|NCT04255316|Experimental|Modified eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a modified eversion carotid endarterectomy
89129624|NCT04255316|Active Comparator|Standard eversion|Patients with extensive atherosclerotic lesion of the carotid bifurcation (more 25mm in internal carotid artery) undergo a standard eversion carotid endarterectomy
89129625|NCT04130607|Experimental|Analytical|Students will receive brief instruction in probability, sensitivity, specificity, and likelihood ratios, with distributions and calculations. Pretest and posttest probabilities will be computed for two cases for each of the three conditions listed above.
89129626|NCT04130607|Active Comparator|Experiential|"Students will receive a brief instruction conceptually discussing sensitivity and specificity (e.g. a sensitive test will be positive at even low levels of disease. However, this can lead to a number of false positive errors, when the test is positive even when there is no disease. As a result, it is most useful for ruling out a diagnosis). They will then work through a total of 30 cases, 10 for each condition, in blocked sequence. For each brief written case they will be asked for a probability of diagnosis after the clinical information is presented. The test result will then be given and they will be asked for a post-test probability. Their estimate will be compared to the computed value based on published estimates of sensitivity and specificity and feedback provided."
89129627|NCT04130607|Placebo Comparator|No Explicit Instruction or Examples|Students will receive 3 passages from a clinical text related to each of the 3 conditions in the study and asked to study them for 15 min each.
89129628|NCT04130373||Women receiving autologous fat grafting|Women who received breast reconstruction and autologous fat grafting.
89129629|NCT04130373||Control|Women who received breast reconstruction only.
89129630|NCT04130451|Active Comparator|Pre pleurodesis Procedure Fever Pulse rate Respiratory rate Pa|Pre pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procedure 24 hours before 16 hours before 8 hours before
89129631|NCT04130451|Active Comparator|After Pleurodesis procedure Fever Pulse rate Respiratory rate|Post pleurodesis Fever Pulse rate Respiratory rate Pain thresholds total leukocytes procdure 24 hours before 16 hours before 8 hours before
89129632|NCT04130295|Experimental|Wearable intensive nerve stimulation|The device will be worn on the upper calf with each session of stimulation lasting 60 minutes after which the device will turn off for 60 minutes before turning back on. Participants will be instructed to wear the device for 5 hours a day in order to receive three one our sessions of stimulation.
89129633|NCT04031079|Experimental|Wearable tech with feedback|This group will be wearing an activity measurement device (wristband) and receive feedback about their activity level through a mobile application while taking part in a traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program).
89129634|NCT04031079|Active Comparator|Wearable tech without feedback|This group will be wearing the same the activity measurement device as the intervention group, but they will not receive any feedback about their activity level. They will not have access to the mobile application. They will take part in the same rehabilitation program as the intervention group.
89129635|NCT00864513|Experimental|chemotherapy|pemetrexed
89129636|NCT04130139||residents|obstetrics and gynecology residents from France with or without previous experience in oocyte pick up
89129637|NCT02614443|Experimental|Depression Condition|Participants in this group will be offered the Space from Depression programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
89129638|NCT02614443|Experimental|Anxiety Condition|Participants in this group will be offered the Space from Anxiety programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
89129639|NCT02614443|Experimental|Stress Condition|Participants in this group will be offered the Space from Stress programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
89129640|NCT02614365|Experimental|Aerobic Exercise|6-month 3-time/week aerobic exercise, and a 12-month passive follow-up.
89129641|NCT02614365|Active Comparator|Stretch Exercise|6-month 3-time/week stretch exercise, and a 12-month passive follow-up.
89129642|NCT04130217|No Intervention|Control group|patients will be intraoperatively mechanically ventilated without PEEP nor RM.
89129643|NCT04130217|Experimental|PEEP Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
89129644|NCT04130217|Experimental|PEEP and RM Group|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
89129645|NCT04130061|Experimental|Randomized|
89129646|NCT04130061|No Intervention|Control|
89129647|NCT04128891|Experimental|Sacubitril/Valsartan|30 participants to be administered Sacubitril/Valsartan (Entresto) tablets, minimum dose of 49/51mg or maximum dose of 97/103 mg twice daily for the duration of the study (two years).
89129648|NCT04128891|Active Comparator|Valsartan|30 participants to be administered Valsartan tablets, minimum dose 80 mg or maximum dose of 160 mg twice daily for the duration of the study (two years).
89129649|NCT00698529|No Intervention|No POL Training|Participating NGOs and their staff will receive no specialized training.
89129650|NCT00698529|Experimental|Face-to-Face|Participating NGOs and their staff will receive training through face-to-face seminars held at the NGOs and through post-seminar consultation telephone calls.
89129651|NCT00698529|Experimental|Distance Learning|Participating NGOs and their staff will receive training through Web-based seminars and through post-seminar consultation telephone calls.
89129652|NCT04127955|Experimental|Intervention|"Quasi-experimental design with one-group, pre-post test~A nurse-led Theory of Planned Behavior based Physical Activity intervention consists of five component. These are a health education, a group walking, an individually tailored counseling session grounded on motivational interview technique, having the individuals keep track their physical activity levels with a pedometer, and use of physical activity pamphlet and posters as a reminder was planned. This intervention will be completed in eight weeks."
89129653|NCT02613975|Experimental|on positional device|patients who could not tolerate cpap will be provided with positional device for treatment of OSA which will vibrate when patients lie in prone position
89129654|NCT02613975|Experimental|patients on dental device|patients on dental devices but not optimally treated for OSA will be provided positional device for optimization of treatment for OSA, which will vibrate when patients lie in prone position
89129655|NCT04126785|Placebo Comparator|Control without exercise in heated water-based|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the xiphoid process level for 30 min.
89129656|NCT04126785|Experimental|High Intensity Interval Exercise in Heated Water|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
89129657|NCT04126785|Experimental|Continuous Moderate Exercise in Heated Water|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light) level of RPE.
89129658|NCT00917150|Experimental|OPC-6535 12.5mg|
89129659|NCT00917150|Experimental|OPC-6535 25mg|
89129660|NCT00917150|Experimental|OPC-6535 50mg|
89129661|NCT00917150|Placebo Comparator|placebo|
89129662|NCT04251962|Experimental|Bupivacaine|Epidural solution containing 0.1% bupivaacaine in normal saline
89129663|NCT04251962|Experimental|Bupivacaine + Fentanyl|Epidural solution containing 0.1% bupivacaine and 3 mcg/ml of fentanyl in normal saline
89129664|NCT04251650||low severity|patient with periodontitis stage I and II
89129665|NCT04251650||high severity|patient with periodontitis stage III and IV
89129666|NCT04251728|Experimental|Exercise plus AMPS group (AMPS-G)|Physical exercise and automated mechanical peripheral stimulation (AMPS) with intensity at the pain threshold, performed two times a week for 12 weeks.
89129667|NCT04251728|Sham Comparator|Exercise plus SHAM group (Exercise-G)|Physical exercise and simulated automated mechanical peripheral stimulation (AMPS) with intensity at the sensory threshold performed two times a week for 12 weeks.
89129668|NCT04255238|Experimental|Gemigliptin 50 mg and Dapagliflozin 10 mg|"Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin 10 mg per day~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
89129669|NCT04255238|Active Comparator|Gemigliptin 50 mg and Dapagliflozin placebo|"Subject shoud took 1 tablet of Gemigliptin 50 mg and 1 tablet of Dapagliflozin placebo per day~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
89129670|NCT04255238|Active Comparator|Gemigliptin placebo and Dapagliflozin 10mg|"Subject shoud took 1 tablet of Gemigliptin placebo and 1 tablet of Dapagliflozin 10 mg per day~Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day"
89129671|NCT04251572|Experimental|HCV reinfection after DAA therapy in PWID|Hepatitis C virus reinfection after directly acting antiviral treatment in persons who inject drugs. DAA therapy is an inclusion criteria, not an intervention.
89129672|NCT04251494||Phenylketonuria (PKU) participants|"During their outpatient clinic appointment, participants will:~Undergo routine height and weight measurements and blood tests. A full patient history will be taken, including a record of cardiovascular disease within the family. Blood samples will be collected, including phenylalanine, lipids, vitamin B12 and related biomarkers.~Complete a 14-item diet history questionnaire, and fill in a 3 day diet diary before they arrive at their outpatient clinic appointment, which will be collected after the participant signs the informed written consent form.~Undergo assessment of carotid Intima-media thickness (CIMT), pulse wave velocity (PWV), ankle brachial pressure index (ABPI) and systolic and diastolic blood pressure."
89129673|NCT04251494||Age and gender matched reference controls|Only Phenylketonuria (PKU) patients will be studied. Controls are generated from the literature. Reference CIMT values exist for a healthy population based on age and gender (Engelen et al., 2013), eliminating the need to assess age- and gender-matched controls. The study would otherwise require performing blood tests and vascular assessments on healthy individuals, generating a risk of harm and a possible incidental finding. It would be inconvenient for controls because they would need to travel to hospital and undergo invasive venepuncture.
89129674|NCT05286164|Experimental|Eltrombopag|Patients with bone marrow aplasia for more than 30 days after CART treatment
89129675|NCT04251104|Experimental|Level of personal relevance of images|This is an exploratory randomized controlled study to compare the effectiveness of three types of autobiographical stimuli, classified according to their level of personal relevance (high, medium and low), in the induction of positive emotions resulting from the retrieval of specific positive autobiographical memories. To this end, the investigators will use three types of images, classified according to their personal relevance: a) personal autobiographical photographs (high personal relevance); b) images of locations related to the participants' lives (medium personal relevance); and c) images from the Internation Affective Picture System (IAPS; low personal relevance).
89129676|NCT04251104|Other|Age (young and older adults comparison)|To analyse any age-related differences in the effectiveness of the use of the three types of images to regulate emotion, the investigators will compare the efficacy of the three categories of pictures (high, medium and low relevance) in inducing positive mood states in a group of young adults (age range: 18-35 years) and a group of older adults (65 years or over).
89129677|NCT04255004|Active Comparator|A-PBMNC therapy|Patients in A-PBMNC therapy are treated with wound bed multiple perilesional and intramuscular injections of PBMNC cells suspension (0.2-0.3cc in boluses). This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
89129678|NCT04255004|No Intervention|No A-PBMNC therapy|Patients in No A-PBMNC therapy receive only supportive treatment including wound care and pain killer drug.
89129679|NCT00631436||1|If the individuals who meet the blast exposure criteria have a PCL score above 50 and meet the Hoge et al PCL criteria, thus indicating likely PTSD, they will be invited to participate as members of the Blast Exposed + PTSD group.
89129680|NCT00631436||2|Other individuals meeting the blast exposure criteria will be invited to participate in the as members of the Blast Exposed + No PTSD group if they have PCL scores below 30.
89129681|NCT00631436||3|Individuals reporting that they were not exposed to explosive blast will be recruited to participate. Those not exposed to blast but with PCL scores over 50 and meeting the Hoge et al PCL criteria will be invited to participate as members of the No Blast + PTSD group.
89129682|NCT00631436||4|Individuals not exposed to blast with PCL scores below 30 will be invited to participate as members of the No Blast + No PTSD group.
89129683|NCT05251766|Active Comparator|Arm1: epirubicin + cyclophosphamide followed by docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 4 cycles, Follow Docetaxel :75 mg/m2, D1, q3W, 4 cycles
89129684|NCT05251766|Experimental|Arm2: epirubicin + cyclophosphamide followed by nab-paclitaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 4 cycles, Follow Nab-paclitaxel :260 mg/m2, d1, q3W; 4 cycles
89129685|NCT05251766|Experimental|Arm3: nab-paclitaxel combined with epirubicin + cyclophosphamide|Nab-paclitaxel :260 mg/m2, D1, q3W; Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; 6 cycles
89129686|NCT04254848|Experimental|completely edentulous patients with maxillary tori|20 completely edentulous patients with maxillary tori will be recruited for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
89129687|NCT04254848|Active Comparator|completely edentulous patients without maxillary tori|20 completely edentulous patients without maxillary tori will serve as control group for the study. The oral stereognosis will be evaluated by oral stereognostic test which employs manipulation and identification 6 different test pieces when placed in the patients mouth.
89129688|NCT05253170|Experimental|Hypofractionation|"For the cumulative total dose of 39-45.9 Gy to the chest wall, a daily dose of 2.5-3.0 Gy is administered 13-17 fractions.~Should be started within 3 months of completion of mastectomy or chemotherapy.~Clinical target volume (CTV) may include regional lymph nodes.~If a tissue expander or implant is present at the time of radiotherapy planning, CTV contouring should be performed according to the ESTRO ACROP implant-based target delineation guidelines."
89129689|NCT05253170|Active Comparator|Conventional Fractionation|"For the cumulative total dose of 45-50.4 Gy to the chest wall, a daily dose of 1.8-2.0 Gy is administered 23-28 fractions.~Should be started within 3 months of completion of mastectomy or chemotherapy.~Clinical target volume (CTV) may include regional lymph nodes.~If a tissue expander or implant is present at the time of radiotherapy planning, CTV contouring should be performed according to the ESTRO ACROP implant-based target delineation guidelines."
89129690|NCT04719338|Experimental|participants|"Immediately after confirmation of 24 weeks SVR after the end of treatment, we will collect samples of peripheral blood from each patient into EDTA tube and test for HCV RNA in peripheral blood mononuclear cells (PBMCs) .~All patients included in this study will be subjected to full history taking and thorough clinical examination. The initial pre treatment data of the patients will be revised including body mass index (BMI), pre treatment status (naïve,experienced), pretreatment viral load by sensitive real-time HCV PCR technique, liver function tests, complete blood count, prothrombin time, international normalized ratio , Child-Pugh score, MELD score and FIB-4 score ."
89129691|NCT04254380|Experimental|Experimental: Gan & Lee Insulin Lispro Injection|Gan & Lee Insulin Lispro Injection for subcutaneous injection, 100 U/mL, in a disposable multidose pen injector with a pre-filled 3-mL type I glass cartridge. Subjects randomized to the Gan & Lee Insulin Lispro Injection group will participate in the study for 26 weeks.
89129692|NCT04254380|Active Comparator|Active Comparator: Humalog|EU-authorized Humalog KwikPen® - insulin lispro injection, solution for subcutaneous injection, 100 U/mL (pre-filled). Subjects randomized to the Humalog group will participate in the study for 26 weeks.
89129693|NCT00631514|No Intervention|1|Hypertensive persons taking either lisinopril/hydrochlorothiazide fixed combination or amlodipine all the time.
89129694|NCT00631514|Experimental|2|Intervention: NSAID. Hypertensives with osteoarthritis taking already amlodipine (5-10 mg o.d. per os) were randomized to the following drug interventions: to take either acetaminophen (1000 mg t.i.d. per os), piroxicam (10-20 mg o.d. per os) or ibuprofen (400-600 mg t.i.d. per os) for 1 month
89129695|NCT00631514|Experimental|3|Hypertensives with osteoarthritis taking already lisinopril/hydrochlorothiazide (20/12.5 mg o.d. per os), were sequentially randomized to the following drug interventions: acetaminophen (1000 mg t.i.d.), ibuprofen (400-600 mg t.i.d.) or piroxicam (10-20 mg o.d.), for 1 month each
89129696|NCT05253014|Active Comparator|lidocaine group|
89129697|NCT05253014|Active Comparator|bupivacaine group|
89129698|NCT05253014|Active Comparator|conservative group|
89129699|NCT05252780|Experimental|Intervention group|My Body, My Rhythm, My Voice
89129700|NCT05252780|No Intervention|Control group|No intervention
89129701|NCT04254458||PACG group|Cases who had first acute attack of primary angle closure glaucoma
89129702|NCT04254614|Experimental|Personalised mobile application for IBD patients|This is a cohort study with a 1 arm intervention group, without a control group. Patients included in this study will be invited to use a mobile application. The content and functionalities of this application are described in the intervention section.
89129703|NCT00659425|Experimental|5 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
89129704|NCT00659425|Experimental|10 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
89129705|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
89129706|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
89129707|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
89129708|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
89129709|NCT00659425|Experimental|40 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
89129710|NCT00659425|Experimental|32 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
89129711|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
89129712|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
89129713|NCT00794989|Experimental|Arm 1: Intervention|Patients ingest ground flaxseed daily, with already prepared foods, for 6 months.
89129714|NCT00794989|Other|Arm 2: Observational|Patients do not receive ground flaxseed.
89129715|NCT00795067||Carotid atherosclerosis group|Patients who undergo carotid ultrasound examination for carotid atherosclerosis screening
89129716|NCT00805753|Active Comparator|Arm 1 ACTH 40 units|Receive ACTH at the dose of 40 units sub-cutaneously for up to 12 weeks. If at day 91 no response has been shown, you will have the option to increase the dose of ACTH to 80 units for up to an additional 120 days.
89129717|NCT00805753|Active Comparator|Arm 2 ACTH 80 units|Receive ACTH at the dose of 80 units sub-cutaneously for up to 12 weeks.
89129718|NCT00797875|Experimental|1|PNF stretching x 5 repetitions for 3 days
89129719|NCT00797875|Active Comparator|2|passive stretching
89129720|NCT00805831|Experimental|A|Aortic anastomosis surgery will be conducted using HDH device.
89129721|NCT05179915|Experimental|Experimental Group|The experimental group will be administered 15-minute therapeutic touch in the latent phase and after it finishes, the participating pregnant woman will be asked to rest for 30 minutes.
89129722|NCT05179915|Placebo Comparator|Placebo Group|After the mimic (sham) therapeutic touch finishes, the pregnant woman will be asked to rest for 30 minutes.
89129723|NCT00656851|Active Comparator|Pioglitazone|Pioglitazone (Actos, 30mg/day for 16 weeks)
89129724|NCT00656851|Active Comparator|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
89129725|NCT00803257|Experimental|1|Lumbrical splint and lumbrical stretches
89129726|NCT00803257|Active Comparator|2|Lumbrical Splint and regular exercises
89129727|NCT00803257|Active Comparator|3|Regular splint and lumbrical exercises
89129728|NCT00803257|Active Comparator|4|Regular splint and regular exercises
89129729|NCT00803335|Active Comparator|Premarin cream 0.5gm|Application of 0.5gm of vaginal estrogen cream nightly until surgery.
89129730|NCT00803335|Active Comparator|Premarin cream 1.0gm|Application of 1.0gm of vaginal estrogen cream nightly until surgery.
89129731|NCT00803335|No Intervention|No intervention|Women in this arm will not apply any cream or moisturizers to the vagina until surgery, ie no intervention.
89129732|NCT00797953|Experimental|Low dose|2 capsules of T89 with 1 placebo capsule each time, twice daily. The daily dose is 250 mg.
89129733|NCT00797953|Experimental|High dose|3 capsules of T89 each time, twice daily. The daily dose is 375 mg
89129734|NCT00797953|Placebo Comparator|Placebo|3 placebo capsules (PC) each time, twice per day. The daily dose is 0 mg.
89129735|NCT00798031|Other|1|a minimum of two dental implants, but up to 3 dental implants, will be placed in each of 20 subjects. All surgical procedures will be performed as outpatient procedures at the College of Dentistry and implant placement will follow a one-stage procedure under local anesthesia. Placement of the 2-3 dental implants is the only intervention.
89129736|NCT00798109|Experimental|Motivational Therapy|Four motivational interview for cannabis abuse in schizophrenia population during one month
89129737|NCT00798109|Other|Usual Care|Usual care with intensive psychotherapy
89129738|NCT00656617|Experimental|Idarubicin + Ara-C + Vorinostat|Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
89129739|NCT00798187||Homogeneous Support Group|
89129740|NCT00798187||Heterogeneous Support Group One|
89129741|NCT00798187||Heterogeneous Support Group Two|
89129742|NCT00805909|Experimental|NI-0401|5 daily infusions of escalating doses of NI-0401
89129743|NCT00798343|Active Comparator|Seasonal vaccine|Seasonal influenza vaccination
89129744|NCT00798343|Experimental|Pandemic vaccine|MF59-adjuvanted H5N1 monovalent vaccine
89129745|NCT00803491|Experimental|Problem based learning program|PBL intervention - a self-promoting PBL program for patients with rheumatic diseases.
89129746|NCT00803491|Active Comparator|Control group|Traditional rheumatological care.
89129747|NCT02553187|Experimental|Treatment group|Kanglaite Injection plus standard therapy.
89129748|NCT02553187|No Intervention|Control group|Blank control and standard therapy.
89129749|NCT00803725|Active Comparator|1|Mepivicaine for spinal anesthesia
89129750|NCT00803725|Experimental|2|Mepivacaine with Fentanyl for spinal anesthesia
89129751|NCT00803803|Experimental|Pilocarpine Concentration|Varying concentration 0.5 to 8% - 22 patients were examined regarding: visual acuity, iris color, pupil size, chamber angle, C/D ratio, visual field (VF), coefficient of aqueous outflow and Goldmann tonometry. After a one month washout period, pilocarpine was used 4 times daily, in concentrations from 0.5 to 8%. The amount of IOP change was compared with various clinical findings
89129752|NCT00803803|Experimental|Pilocarpine Frequency|Varying frequency, once to four times daily - 15 patients were included in a crossover study: IOP was checked daily for 3 days and for 9 hours on fourth day. Pilocarpine was started on day 5 once daily OD and BID OS; on day 9 once daily OD and QID OS; on day 12 QID OD and once daily OS; on day 16 once daily OD and QID OS; and on day 19 QID OD and once daily OS. No medications were used on days 23-25. IOP was measured on days 4, 8, 11, 15, 18, 22 and 25.
89129753|NCT04775329|No Intervention|Control arm|Standard of care
89129754|NCT04775329|Active Comparator|Treatment arm|
89129755|NCT00803881||CF patients of all age groups|Longitudinal prospective assessment of upper and lower airway colonization in all patients attended in the Jena University CF centre
89129756|NCT00798421||Heathcare worker|health care worker exposed to patient with influenza
89129757|NCT00798499||1|Laboratory variables
89129758|NCT00659269|Active Comparator|Multivitamin (MV)|1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)
89129759|NCT00659269|Experimental|Multivitamin + Vitamin B12 + Vitamin B6|"1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts).~The patient will also take the following, starting on the first day of chemotherapy:~pyridoxine 50 mg three times per day, orally and continue for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)~Vitamin B12 one mg injected intramuscularly, every 3 or 4 weeks, depending on the timing of the chemotherapy for 4 doses."
89129760|NCT00806143|Active Comparator|1|patients will undergo sequential bilateral rTMS treatment
89129761|NCT00806143|Active Comparator|2|patients will undergo unilateral low frequency right sided DLPFC rTMS
89129762|NCT00922129|Experimental|Conversion to sirolimus|
89129763|NCT00922129|Active Comparator|Calcineurim inhibitor reduction|
89129764|NCT00798733||Non-Operative|Surgeon treated the patient non-operatively
89129765|NCT00798733||Operative|Surgeon treated the patient operatively
89129766|NCT02553655|Active Comparator|4x 5min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 5 minutes following by 5 minutes of rest. This will be repeated for 4 times.
89129767|NCT02553655|Active Comparator|3x 10min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
89129768|NCT02553655|Sham Comparator|3x 10min Sham Preconditioning|Either the right or left leg of the participant(s) will be squeezed without causing ischemia for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
89129769|NCT00804037|Active Comparator|Ethanol|
89129770|NCT00804037|Active Comparator|Ethanolamine Oleate|
89129771|NCT00806299|Experimental|1|Drug (including placebo)
89129772|NCT00806299|Experimental|2|Drug (including placebo)
89129773|NCT00806299|Experimental|3|Drug (including placebo)
89129774|NCT02553577||Conventional cigarettes -only|Women who are pregnant and use conventional tobacco products -only
89129775|NCT02553577||Electronic Cigarette (ecig) (ENDS) -ONLY|Women who are pregnant and use electronic cigarettes (ecigs) -only
89129776|NCT02553577||Conventional + ecig use (DUAL)|Women who are pregnant and use conventional + ecigs (dual)
89129777|NCT00804115|No Intervention|1|Latanoprost in combination with Pilocarpine
89129778|NCT00804115|No Intervention|2|Timolol or Cosopt
89129779|NCT00798811|Other|KSPNO-S-081|Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor
89129780|NCT00798811|Other|KSPNO-S-082|High-dose Chemotherapy and Autologous Stem Cell Rescue in Infants and Young Children with Newly Diagnosed High-risk Brain Tumor To Avoid or Reduce Craniospinal Radiation
89129781|NCT00798811|Other|KSPNO-S-083|High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Recurrent Brain Tumor or Non-germinomatous Germ Cell Tumor with Inadequate Response to Conventional Treatment
89129782|NCT02554123|Experimental|Vitamin E ointment|Vitamin E ointment application. Every 12 hours during 7 days.
89129783|NCT02554123|Placebo Comparator|Vaseline ointment|Vaseline ointment application. Every 12 hours during 7 days.
89129784|NCT00799045|Experimental|Aspirin + clopidogrel|Aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
89129785|NCT00799045|Active Comparator|Aspirin|Aspirin (80 mg/day) for 3 months following ASD closure.
89129786|NCT00658333|Experimental|Enteric-coated Mycophenolate Acid|Equimolar dose of enteric-coated mycophenolate acid with mycophenolate mofetil placebo. 1000 mg mycophenolate mofetil = 720 mg enteric-coated mycophenolate acid (MPA equivalent dose). The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
89129787|NCT00658333|Active Comparator|Mycophenolate Mofetil|Mycophenolate mofetil therapy with placebo enteric-coated mycophenolate acid. The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
89129788|NCT00804271|Other|Memantine|
89129789|NCT00806533||HES 130 / 0.42|paediatric patients aged up to 12 years requiring non-emergency volume replacement therapy with HES 130/0.42
89129790|NCT00804505|Experimental|1|Test arm daily wear hybrid contact lens.
89129791|NCT00804505|Other|2|Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
89129792|NCT00799201|Experimental|Control|Sennosides liquid 5mL (8.8mg) every 6 hours plus docusate sodium liquid 10mL (100mg) every 12 hours
89129793|NCT00799279|Experimental|Follow-up Counseling Arm|smoking cessation training for providers,practice tools for providers, patient quit plan, and follow-up telephone counselling for smokers
89129794|NCT00799279|Active Comparator|Practice Support Arm|smoking cessation training for providers,practice tools for providers, patient quit plan for smokers.
89129795|NCT02554201|Experimental|Electrical pudendal nerve stimulation|Electrical pudendal nerve stimulation At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of four weeks
89129796|NCT02554201|Active Comparator|Transvaginal electrical stimulation|At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 30 min three times a week for a total of four weeks.
89129797|NCT00806611|Experimental|50% Ethanol|Operating surgeon injects 20 ml of 50% ethanol on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
89129798|NCT00806611|Placebo Comparator|Placebo|Operating surgeon injects 20 ml of saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
89129799|NCT00806689||Cardiac surgery patients|Patients in atrial fibrillation being scheduled for cardiac surgery and concomitant ablation procedure
89129800|NCT00799513|Experimental|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
89129801|NCT00570037|Active Comparator|Immunization Program|Intervention Hospital - Standing postpartum vaccine orders, influenza vaccine clinic on postpartum ward for household contacts, mailed vaccine reminders
89129802|NCT00570037|No Intervention|No Immunization Program|Comparison Hospital - Receipt of vaccine through routine clinical care
89129803|NCT00804661||1|Children and adults with cystic fibrosis
89129804|NCT00804739|Experimental|MITT|Mothers will be assigned to the Mother-Infant Treatment Team (MITT)and will receive either psychotherapy or sertraline or both as well as outreach.
89129805|NCT00804817|Active Comparator|Care as usual|Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
89129806|NCT00804817|Experimental|SCION-HSCT program|"Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
89129807|NCT00799669||MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
89129808|NCT00799669||MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
89129809|NCT00799747|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
89129810|NCT00799747|Placebo Comparator|2|Placebo
89129811|NCT00863655|Experimental|Everolimus + Exemestane|Everolimus 10 mg daily in combination with exemestane 25 mg daily
89129812|NCT00863655|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
89129813|NCT00806845||HIV infected individuals, HIV controllers|CD4+ T cell count > 350/µl, HIV load < 1000 copies/ml
89129814|NCT00806845||HIV infected individuals, early progressors|CD4+ T cell count > 350/µl, HIV load > 1000 copies/ml
89129815|NCT00806845||HIV infected individuals, late progressors|CD4+ T cell count < 200/µl
89129816|NCT00806845||HIV infected individuals, late progressors with therapy|CD4+ T cell count < 200/µl, under ART
89129817|NCT00806845||Healthy individuals|Uninfected
89129818|NCT00806923|Experimental|1|
89129819|NCT00806923|Experimental|2|
89129820|NCT00806923|Placebo Comparator|3|
89129821|NCT00698607|Experimental|E6|Everolimus-eluting stent 6-month clopidogrel therapy
89129822|NCT00698607|Active Comparator|S6|Sirolimus-eluting stent 6-month clopidogrel therapy
88805906|NCT01141049|Active Comparator|Gabapentin|Gabapentin will be titrated over a 7-day period to the dose target or the maximum tolerated dose. The maximum dose will be 1200mg TID. Participants must be able to tolerate and comply with at least 400 mg daily.
89129823|NCT00698607|Experimental|E12|Everolimus-eluting stent 12-month clopidogrel therapy
89129824|NCT00698607|Active Comparator|S12|Sirolimus-eluting stent 12-month clopidogrel therapy
89129825|NCT04123041|Experimental|Virginia Tobacco|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Virginia Tobacco ENDS, JUUL 3% Virginia Tobacco ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
89129826|NCT04123041|Experimental|Mint|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mint ENDS, JUUL 3% Mint ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
89129827|NCT04123041|Experimental|Menthol|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Menthol ENDS, JUUL 3% Menthol ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
89129828|NCT04123041|Experimental|Mango|Subjects will use 5 products according to a randomized crossover assignment: JUUL 5% Mango ENDS, JUUL 3% Mango ENDS, Subject's UB combustible cigarette, Comparator e-cigarette, Nicorette White Ice Mint 4 mg nicotine polacrilex gum.
89129829|NCT04122495|Experimental|Probiotic|Bifidobacterium lactis M8 at 10 log CFU/day for 4 weeks
89129830|NCT04122495|Placebo Comparator|Placebo|Intervention consists of daily administration of 1g of maltodextrin, administered daily for 4-weeks
89129831|NCT00698763|Experimental|A|Levosimendan
89129832|NCT00698763|Placebo Comparator|B|Placebo
89129833|NCT00658723|Experimental|1|
89129834|NCT00658723|Active Comparator|2|SURGICEL™ Absorbable Hemostat
89129835|NCT00800059|Experimental|Treatment|Treatment with TMI and autologous Stem Cell transplant
89129836|NCT00804895|Experimental|1|subcutaneous injection of Cortivazol ALTIM, 3,375mg
89129837|NCT00804895|Placebo Comparator|2|PROAMP, subcutaneous serum physiological saline
89129838|NCT00805051||Severe aortic stenosis|Patients undergoing aortic valve replacement because of severe aortic stenosis
89129839|NCT00800137|Active Comparator|Bridging anti-coagulation|Low Molecular Weight Heparin or IV unfractionated Heparin
89129840|NCT00800137|Experimental|Continued oral anti-coagulation|Coumadin
89129841|NCT00807079|Experimental|single arm|
89129842|NCT00800293||Cohort Group 1|Subject Numbers 1 to 29
89129843|NCT00800293||Cohort Group 2|Subject Numbers 20 to 59
89129844|NCT00800293||Cohort Group 3|Subject Numbers 60 to 89
89129845|NCT00800293||Cohort Group 4|Subject Numbers 90 to 116
89129846|NCT00800371||JIA|Patients with JIA
89129847|NCT00593385|Other|iCAST covered stent|This is a one arm trial. All subjects received the iCAST covered stent.
89129848|NCT00658021|Placebo Comparator|Placebo|Subcutaneous injection, twice a day
89129849|NCT00658021|Experimental|Exenatide 5 µg|Subcutaneous injection, twice a day
89129850|NCT00658021|Experimental|Exenatide 10 µg|Subcutaneous injection, twice a day
89129851|NCT00698919||Development cohort|A first group of one hundred patients with SIRS will be included to evaluate the accuracy of this new test.
89129852|NCT00698919||Validation Cohort|Depending on the result of the previous (development) cohort we will more accurately evaluate the need of number of patients with SIRS to include in the second cohort of patients.
89129853|NCT04121637|Experimental|Aerobic exercise+Frenkel coordination Study group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set. Following this, an aerobic exercise of 30 minutes will be performed on the bicycle ergometer with electronic brake. Subjects will be advised not to do any exercise two days before or on that day and to eat only a light meal at least two hours before the test. The intensity of the exercise will be adjusted based on maximum oxygen consumption (VO2 max) specific to each individual.
89129854|NCT04121637|Active Comparator|Frenkel coordination exercise group - Control group|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. There will be a 1 minute break between each exercise set.
89129855|NCT00920816|Experimental|A|
89129856|NCT00920816|Active Comparator|B|
89129857|NCT04254224||Diverticulitis Hinchey I-IV|Patients with complicated diverticulitis (Hinchey I-IV) treated conservatively (iv antibiotics with or without percutaneous, transrectal or transvaginal drainage) or surgically.
89129858|NCT04254146|Experimental|Study group|Aerobic exercise will be performed for a single session
89129859|NCT04254146|Active Comparator|Control group|Aerobic exercise will be performed to healthy population for a single session
88805907|NCT01141049|Placebo Comparator|Placebo|Placebo capsules will be administered TID.
89129860|NCT05251688|Other|participants|The participants were encountered two times (before and after the application of cryoanalgesia).
89129861|NCT04253990|Experimental|Precut-EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
89129862|NCT04253990|Active Comparator|Conventional EMR|"For treating of 10~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~Conventional EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current"
89129863|NCT00631592|Other|GSK1349572|GSK1349572
89129864|NCT05251610|Active Comparator|PROPRANOLOL GROUP|Participants will receive 20mg of oral propranolol 10 minutes prior to initiation of augmentation or induction of labor with oxytocin
89129865|NCT05251610|Placebo Comparator|OXYTOCIN ONLY GROUP|Participants had outright augmentation or induction of labor with oxytocin only
89129866|NCT00657709|Experimental|rMenB Lot1|Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
89129867|NCT00657709|Experimental|rMenB Lot2|Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
89129868|NCT00657709|Experimental|rMenB Lot3|Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
89129869|NCT00657709|Active Comparator|Routine|Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
89129870|NCT00657709|Active Comparator|MenC + Routine|Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.
89129871|NCT00915356|Experimental|1|AZD1305 iv infusion
89129872|NCT00915356|Placebo Comparator|2|Placebo iv infusion
89129873|NCT05218070|Experimental|Low Dose Vaccine|35 mcg dose for both vaccinations at day 0 and day 14 (low dose, 15 subjects)
89129874|NCT05218070|Experimental|High Dose Vaccine|70 mcg dose for both vaccinations at day 0 and day 14 (high dose, 15 subjects)
89129875|NCT05218070|Placebo Comparator|Placebo|Placebo for both injections at day 0 and day 14 (Placebo, 15 subjects)
89129876|NCT00657553|Active Comparator|Bortezomib/Treatment Arm|Bortezomib Maintenance Year 1 - bortezomib days 1, 4, 8, 11 every 28 days Year 2 - bortezomib days 1, 4, 8, 11 every 2 months Year 3 - bortezomib days 1, 4, 8, 11 every 3 months
89129877|NCT00657553|No Intervention|Observation Arm (watchful waiting)|monitor myeloma parameters every 3-6 months
89129878|NCT04254068|Experimental|Parent based prevention|Parent-Based Prevention (PBP; Sadeh-Sharvit & Lock, 2018) is a manualized preventive intervention, focused on increasing parental awareness and competence to facilitate healthy eating habits, body image, and self-regulation in children whose parent has an eating disorder history. PBP is comprised of three phases that focus on unique goals. The strategies in each session include psycho-education, behavioral experiment planning, and skill practicing to augment parents' insight into how the context of the parental cognitions and behaviors may impact child outcomes, with the goal of creating a longstanding effect.
89129879|NCT04254068|No Intervention|Usual care|Families randomized to usual care will be permitted to utilize any medical, psychological, or nutritional services they desire for the waitlist period of 16 weeks.
89129880|NCT00807157|Placebo Comparator|2|Every morning subjects will consume a stick of placebo during 30 days
89129881|NCT00807157|Experimental|1|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
89129882|NCT04253912|Experimental|VBP-245|Topical 2% Povidone-Iodine Gel
89129883|NCT04253912|Placebo Comparator|Control|Placebo Gel (no Povidone-Iodine)
89129884|NCT02552797|Experimental|Using Power Up|Participants will use 'Power Up' to help them make shared decisions about their treatment or care
89129885|NCT02552797|No Intervention|Not using Power Up|Participants will continue treatment as usual
89129886|NCT04253600|Other|MRI Acquisition|This does not refer to any group intervention. At-risk and control children will take part in a natural-sleep MRI protocol.
89129887|NCT00800527|Active Comparator|1|Gabapentin
89129888|NCT00800527|Active Comparator|2|Diclofenac
89129889|NCT00862719|Experimental|Sitagliptin once per day|600 mg sitagliptin once per day orally starting on Day -1 for a total of 4 doses
89129890|NCT00862719|Experimental|Sitagliptin twice per day|600 mg sitagliptin twice per day orally starting on Day -1 for a total of 8 doses
89129891|NCT00862719|Experimental|Sitagliptin three times per day|600 mg sitagliptin three times per day orally starting on Day -1 for a total of 12 doses
89129892|NCT04120779|Experimental|The EMPOWER-SUSTAIN e-Health Intervention|The EMPOWER-SUSTAIN intervention is a multifaceted chronic disease management strategies based on the Chronic Care Model (CCM) and persuasive technology (PT) theory. It consists of training physicians and patients to use the EMPOWER-SUSTAIN web-based self-management intervention mobile apps, strengthening patient-physician relationship and reinforcing the use of relevant clinical practice guidelines for management and prescribing.
89129893|NCT04120779|No Intervention|Control|The control group will continue to receive usual care at the university primary care clinic. They will be given the EMPOWER-SUSTAIN Global CV Risks Self-Management Booklet©, as this is considered as usual care at the university primary care clinic. The EMPOWER-SUSTAIN web-based self-management tool will be made available to the control group at the end of the study. During the course of the study, there will be no limit to the number of clinic visits that a patient is allowed to make in either the intervention or control groups.
88802463|NCT05481606||Type III|1) The gestating sac is completely implanted in the muscle layer of the scar of the uterus and protrudes outward toward the bladder; 2) Uterine cavity and cervical canal emptiness; 3) The myometrium between the gestational sac and the bladder was significantly thinner or absent, with a thickness of 3 mm; 4) color Doppler flow image: trophoblast blood flow signal (low resistance blood flow) can be seen in the scar. Among them, there is a special ultrasonic manifestation of cesarean scar pregnancy in type III, namely mass type, whose sonographic characteristics
89129894|NCT00862641|Placebo Comparator|Placebo - Asthma|Matching intravenous (IV) bolus injection, subjects with Asthma
89129895|NCT00862641|Experimental|Regadenoson - Asthma|0.4mg / 5mL intravenous bolus injection, subjects with Asthma
89129896|NCT00862641|Placebo Comparator|Placebo - COPD|Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
89129897|NCT00862641|Experimental|Regadenoson - COPD|0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
89129898|NCT04120857|No Intervention|Educational Control Group|Education provided for optional use
89129899|NCT04120857|Experimental|Gentle Stretching and Education|Gentle Stretching for 60 minutes twice weekly
89129900|NCT04119921|Active Comparator|usage of topical ketorolac in group1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
89129901|NCT04119921|Active Comparator|usage of artificial tear in group 2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
89129902|NCT04119921|Active Comparator|usage of artificial tear in group 1|usage of topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval
89129903|NCT04119921|Active Comparator|usage of topical ketorolac in group2|usage of artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval
89129904|NCT02613663|Experimental|immediate implants with nanobone graft|Nano-hydroxyapatite bone graft fill the gap between immediate implant and labial bone wall.
88802464|NCT05470296|Other|Move & Eat 2 Live|12, 1-hour sessions with an education and motivational component and focused on nutrition, physical activity and healthy weight.
89129905|NCT02613663|Active Comparator|immediate implants with autogenous bone graft|Autogenous graft fill the gap between immediate implant and labial bone wall.
89129906|NCT00861471|Experimental|Docetaxel +Gleevec|
89129907|NCT00699231|Active Comparator|Group A1|Non-responders to vaccination after at least 7 previous injections
89129908|NCT00699231|Experimental|Group A2|Non-responders to vaccination after at least 7 previous injections
89129909|NCT00699231|Active Comparator|Group B1|Vaccine-responders requiring a booster dose
89129910|NCT00699231|Experimental|Group B2|Vaccine-responders requiring a booster dose
89129911|NCT00699231|Active Comparator|Group C1|Volunteers participating in the hospital's vaccination program
89129912|NCT00699231|Experimental|Group C2|Volunteers participating in the hospital's vaccination program
89129913|NCT00699231|Active Comparator|Group D1|Unvaccinated haemodialysis patients
89129914|NCT00699231|Experimental|Group D2|Unvaccinated haemodialysis patients
89129915|NCT00699309||Taperloc® Microplasty™ Hip System|
89129916|NCT02613585|Experimental|Permethrin Impregnated Clothing|Uniforms and work clothing (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin by Insect Shield.
89129917|NCT02613585|No Intervention|Untreated Clothing|Uniforms and work clothing sent to Insect Shield, washed and refolded (no permethrin applied).
89129918|NCT04119297|Active Comparator|Control|Routine care (Irregular cold application or gauze bandages wetted with isotonic solution or once daily heparinoid cream application) of the clinic was applied.
89129919|NCT04119297|Experimental|Cold application|Cold application was applied for three days after craniotomy.
89129920|NCT04119297|Experimental|Heparinoid group|Heparinoid cream was applied for three days after craniotomy
89129921|NCT00860067|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson (BD) Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
89129922|NCT00860067|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attentuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])a B strain of the Yamagata lineage.
89129923|NCT00860067|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria(trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004])a B strain of the Victoria lineage.
89129924|NCT00699387|Experimental|Benznidazole|Treatment of pediatric Chagas disease with benznidazole
89129925|NCT04030923|Active Comparator|Real rTMS|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses on the left DLPFC for 10 consecutive sessions totally over period of 10 days.
89129926|NCT04030923|Sham Comparator|sham rTMS|Sham rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses with coil perpendicular on scalp over the occipital cortex for 10 consecutive sessions totally over period of 10 days.
88802465|NCT00642382|Active Comparator|Active|Agilus (Hyaluronic Acid)
88802466|NCT00642382|Placebo Comparator|Control|Normal Saline
88802467|NCT02203006|Other|OVIHD|Cohort and a blood sample collection will be done with data and blood of HIV infected patients
88802468|NCT05481372|Experimental|Standard radiotherapy with research image acquisition|Radiotherapy delivered as per standard of care Additional trans-perineal ultrasound (TPUS) imaging at three timepoints (1 x pre-treatment and 2 x treatment). Additional magnetic resonance imaging (MRI) pre-treatment.
88802469|NCT05476380|Experimental|CCNT-ESCC|"This study is a single-arm, open-label, exploratory clinical study, the main purpose of which is to evaluate the efficacy and safety of neoadjuvant treatment of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma.~After screening, subjects who meet the requirements for entry and exclusion signed the informed consent, received neoadjuvant treatment of carrelizumab combined with combined with chemotherapy.The patient will receive three cycles of treatment of camrelizumab(200 mg, IV., d1, q3w), paclitaxel(175 mg/m2,continuous IV., d1, 24h q3w), cisplatin(75 mg/m2, iv., d1,q3w).Patients who are assessed as being able to undergo surgical resection receive elective resection surgery,and the maintenance treatment of postoperative patients implements individualized treatment."
89129927|NCT00699465|Active Comparator|1|Early enoxaparin
89129928|NCT00699465|Placebo Comparator|2|Late enoxaparin
89129929|NCT00858117|Experimental|Alemtuzumab and Rituximab|Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.
89129930|NCT04119141|Active Comparator|Standard Arm|the first acquisition will be carried out without a tin filter in supine position and the second with tin filter in procubitus.
89129931|NCT04119141|Experimental|Tin filter Arm|the first acquisition will be carried out with tin filter in supine position and the second without tin filter in procubitus.
89129932|NCT04030689||Axis 2|Each patient diagnosed HIV positive following VihTest test will be invited to participate to ALSO-Parcours; This program aimed to decribe the link to care for this population and to make a descriptive analysis of this HIV+ patients.
89129933|NCT00700947|Experimental|1|Patients who are asymptomatic with normal left ventricular systolic function and who agree to be treated medically for severe primary mitral regurgitation with Beta-blocker therapy. Patients may entered into the Arm 2 (surgical treatment) later on when they develop symptoms or enlarged left ventricle or left ventricular dysfunction or wishes to have surgical treatment of severe primary mitral regurgitation.
89129934|NCT00700947|No Intervention|2|Patients will be surgically treated for severe primary mitral regurgitation as a routine clinical care if they want to be treated surgically or develop symptoms or significant adverse left ventricular remodeling or left ventricular dysfunction.
89129935|NCT00700947|No Intervention|3|Health Control includes the subjects with no remarkable past medical history and not currently taking any medications. Normal subjects will be used for comparison with patients with severe primary mitral regurgitation in term of clinical, echocardiographic and neuro-hormonal findings.
89129936|NCT04116333|Experimental|ML + ETI|Intubation with using endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
89129937|NCT04116333|Active Comparator|ML|Intubation with using the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
89129938|NCT04116177|Active Comparator|Standard Stimulation|Standard stimulation using contact 3-6 to achieve best therapeutic stimulation
89129939|NCT04116177|Experimental|Flexible stimulation|Flexible stimulation using all available stimulation strategies provided by the VerciseTM system including stimulation of contacts 1-8 and variable pulse width and frequency.
89129940|NCT00652951|Active Comparator|Synflorix + Infanrix hexa Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with Infanrix hexaTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (Infanrix hexaTM) thigh or deltoid.
89129941|NCT00652951|Experimental|Synflorix + Pediacel Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with PediacelTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (PediacelTM) thigh or deltoid.thigh or deltoid.
89129942|NCT00652951|Active Comparator|Prevenar + Pediacel Group|Subjects received 3 doses of PrevenarTM co-administered with PediacelTM vaccine at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (PrevenarTM) or left (PediacelTM) thigh or deltoid.
89129943|NCT00848211|Placebo Comparator|Placebo|
89129944|NCT00848211|Experimental|TUTI-16 0.03 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
89129945|NCT00848211|Experimental|TUTI-16 0.1 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
89129946|NCT00848211|Experimental|TUTI-16 0.6 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
89129947|NCT04116255|Experimental|exercises group|exercises group apply regular therapeutic home exercises programme
89129948|NCT04116255|Experimental|splint group|splint group use mandibular oral occlusal splint
89129949|NCT00809419|Experimental|A|NeoVista Ophthalmic System procedure + Lucentis
89129950|NCT00805519|Active Comparator|Glucosamine and chondroitin sulfate|in this group patients will receive Glucosamine and chondroitin sulfate oral dietary supplementation
89129951|NCT00805519|Experimental|P :glucosa, chondroitin, Prednis|in this group patients will receive glucosamine and chondroitin sulfate plus Prednisolone oral administration
89129952|NCT00805519|Experimental|Glucosa, Chondroitin, Chloroquine|in this group pateints will orally receive Glucosamine and Chondroitin sulfate plus Chloroquine.
89129953|NCT00805519|Experimental|Glucosa, Chondro, Prednis,Chloroq|in this group patients will receive Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine
89129954|NCT00592683|Active Comparator|Aripiprazole plus Fish Oil|Subjects administered aripiprazole and randomized to receive fish oil
89129955|NCT00592683|Placebo Comparator|Aripiprazole plus Placebo|Subjects administered aripiprazole and randomized to receive placebo
89129956|NCT00805597|Experimental|radiotherapy|radiotherapy of 50Gy/25/f/5w to the ipsilateral chest wall and supraclavicular region
89129957|NCT00805597|Active Comparator|no radiotherapy|no radiotherapy
89129958|NCT02613039|Other|female outpatient subjects|Patients requiring combined Oral Contraceptives therapy.
89129959|NCT00807313||At best response|Patients with oligometastatic colorectal cancer, who presents at best response under chemotherapy, will receive stereotactic body radiotherapy on their residual disease
89129960|NCT00807313||No indication for chemotherapy|Patients with oligometastatic colorectal cancer, who are progressive under chemotherapy or who are no candidates for (further) chemotherapy, will receive stereotactic body radiotherapy on the sites of disease.
89129961|NCT02612961|Experimental|Saline Instillation|3mL normal saline from pink sodium chloride bullet instilled into tracheostomy immediately prior to suctioning.
89129962|NCT02612961|Sham Comparator|Placebo|Pretend to instill 3mL of normal saline using empty pink sodium chloride bullet immediately prior to suctioning.
89129963|NCT00813475|Experimental|tight control|
89129964|NCT00813475|Experimental|standard control|basal bolus insulin regimen
89129965|NCT04115943|Experimental|Experimental Group|The experimental group (EG) will be submitted to a clinical method considered the gold standard for the treatment of neck pain together with a tongue muscle release protocol.
89129966|NCT04115943|Active Comparator|Control Group|The control group (CG) will only receive the gold standard method for the treatment of neck pain.
89129967|NCT00701025||1|35 asthmatic participants with EIB
89129968|NCT00701025||2|35 without EIB
89129969|NCT04016857|Experimental|RIPC Group|Remote ischemic preconditioning
89129970|NCT04016857|Sham Comparator|Control Group|Sham remote ischemic preconditioning
89129971|NCT00847665|Active Comparator|Turning every 4 hours|The four-hours repositioning group patients were turned every four hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
89129972|NCT00847665|Experimental|Turning every 2 hours|The two-hours repositioning group patients, were turned every two hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
89129973|NCT00809653|Experimental|Visit 1|2 hour walk in city centre location in Beijing China
89129974|NCT00809653|Experimental|Visit 2|2 hour walk in city centre location in Beijing China
89129975|NCT00701259|Experimental|1|15 mg lansoprazole
89129976|NCT00701259|Experimental|2|30 mg lansoprazole
89129977|NCT00701259|Placebo Comparator|3|placebo
89129978|NCT00807391|Other|TBCA/TBNA|Under fluoroscopy first transbronchial forceps biopsy is performed, afterwards in random order transbronchial catheter aspiration(TBCA) and transbronchial needle aspiration (TBNA).
89129979|NCT00701337|Experimental|1 Oral|oestradiol by oral administration - Estrofem 2 mg
89129980|NCT00701337|Experimental|2 patch|oestradiol par patch - Estrapatch 60microg/24h
89129981|NCT00916370|Experimental|Core size registry (CSR)|Core size indicates the range of diameters of the stents used.
89129982|NCT00916370|Experimental|Long lesion registry (LLR)|Use of long lesion stents.
89129983|NCT04116021|Active Comparator|PECS block|Ultrasound-guided pectoral nerve block with bupivacaine 0.5 % 30 mL before surgical incision
89129984|NCT04116021|Active Comparator|Wound infiltration|Wound infiltration with bupivacaine 0.5 % 30 mL at the end of surgery
89129985|NCT00847197|Experimental|1|MK1903
89129986|NCT00847197|Placebo Comparator|2|Placebo to MK1903
89129987|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 1|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651); and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
89129988|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 2|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
89129989|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 3|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
89129990|NCT00654901|Active Comparator|Infanrix Hexa™|Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), (Infanrix Hexa™) plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 (NCT00404651) and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
89129991|NCT00813553|Placebo Comparator|beta-alanine 0|
89129992|NCT00813553|Experimental|beta-alanine 1|
89129993|NCT00813553|Experimental|beta-alanine 2|
89129994|NCT04253678||Study group|"Study participants will be started on a flexible-dose of vortioxetine (5-20 mg) followed by a baseline assessment of primary outcomes using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Perceived Deficit Questionnaire - 5 items (PDQ-5), and secondary outcomes using the EORTC Quality of life Questionnaire (QLQ-C30) and Clinical Global Impression (CGI). The assessment timelines will be at week 2, week 4, week 8, and week 12.~Side effects, if any, will be recorded using the Antidepressant Side-effect Checklist (ASEC)."
89129995|NCT02551939|Experimental|fat graft|Autologous Fat Grafting
89129996|NCT00813631|Experimental|silver-releasing dressings|Silver, in its common ionic (active) form (Ag+), is particularly attractive as an antibacterial agent because it can be readily incorporated into dressing materials. Silver-dressing are wound products designed to control infection and provide a wound environment conducive to management exudates, pain, and malodour.
89129997|NCT00809731||Observational Group|All commercially available 2nd-generation antipsychotic with an indication of treating schizophrenia will be prescribed by the physician according to normal practices
89129998|NCT00807469||1|20 healthy individuals not susceptible for COPD (age 18-40 years, >0>10 packyears, FEV1/VC >70%, FEV1 >85% predicted)
89129999|NCT00807469||2|20 healthy individuals susceptible for COPD (age 18-40 years >20 packyears, FEV1/VC >70%, FEV1 >85% predicted) and high prevalence of COPD in smoking family members older than 45 years
89130000|NCT00807469||3|20 healthy individuals very susceptible for COPD (age 18-40 years, > 0 > 10 packyears, FEV1/VC >70%, FEV1 >85% predicted), and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
89130001|NCT00807469||4|30 healthy individuals not susceptible for COPD (age 40-75 years, >20 packyears, FEV1/VC >70%, FEV1 >85% predicted)
89130002|NCT00807469||5|30 COPD patients with GOLD stage II (age 40-75 years, >10 packyears, FEV1/VC <_70%, FEV1 50-80% predicted)
89130003|NCT00846807||Patients 75 years or younger|
89130004|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir|Daclatasvir 60mg tablet and Sofosbuvir 400mg tablet oral dosing once daily for 8 weeks
89130005|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir + Ribavirin|Daclatasvir 60mg tablet + Sofosbuvir 400mg tablet+ Ribavirin 1000-1200mg tablet(weight based dosing) oral dosing split into am and pm once daily for 8 weeks
89130006|NCT00701571|Experimental|1|3 cohorts: 18-21 years, 40-60 years, and older than 60 years
89130007|NCT00701649|Experimental|1|
89130008|NCT00701649|Placebo Comparator|2|
89130009|NCT05297955||The number of CTC in HCC patient great than or equal to two|According to the cutoff of CTC, the number of CTC in HCC patient great than or equal to two
89130010|NCT05297955||The number of CTC in HCC patient less than two|According to the cutoff of CTC,the number of CTC in HCC patient less than two
88802470|NCT00637312|Experimental|Advent™ Cervical Disc|Cervical artificial disc replacement: Advent™ Cervical Disc
88802471|NCT00637312|Active Comparator|Standard care - Control|Anterior cervical discectomy and fusion (ACDF) with Hallmark™ Anterior Cervical Plate System
89130011|NCT00846495|Active Comparator|topiramate|Subjects randomized to Group A at Visit 2 were provided with topiramate, titrated over 4 weeks to a maximum dose of 100 mg daily. One dosage adjustment was allowed with a minimum dose of 50 mg daily.
89130012|NCT00846495|Active Comparator|frovatriptan|Subjects randomized to Group B at Visit 2 were provided with frovatriptan 5 mg to treat during prodrome at the point they were confident a disabling migraine would occur (before the onset of headache).
89130013|NCT02612805|Experimental|Aerobic training group|This group perform aerobic hydrogymnastics.
89130014|NCT02612805|Active Comparator|Combined training group|This group perform combined hydrogymnastics.
89130015|NCT02612805|Placebo Comparator|Training placebo|This group perform stretching and relaxation in aquatic environment.
89130016|NCT00654745|Experimental|aml + olm + hctz|amlodipine; and olmesartan medoxomil, if required; and hydrochlorothiazide, if required.
89130017|NCT00813787||A. glioma|A. glioma population
89130018|NCT00813787||B. Normal brain|B. Normal brain
89130019|NCT00809887|Placebo Comparator|1|ALT with placebo with systemic Micafungin therapy
89130020|NCT00809887|Experimental|2|ALT with Micafungin and heparin with systemic Micafungin therapy
89130021|NCT00807547|Active Comparator|Allergy vaccination|Allergy vaccination by 6 subcutaneous injections to 10,000 SQ-U with 1-3 days intervals, continuation by 2 injections with 10,000 SQ-U with 2-4 weeks intervals
89130022|NCT00807547|Placebo Comparator|Subcutaneous injections|Placebo injections
89130023|NCT00846027|Experimental|Bevacizumab + paclitaxel + gemcitabine|Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
89130024|NCT00807625|Active Comparator|IUCD|Assigned to use a copper intrauterine device
89130025|NCT00807625|Active Comparator|DMPA|Assigned to use Depo Provera
89130026|NCT00807703|Experimental|1|Select Stim: see summary
89130027|NCT02551549|Experimental|CD101 IV|multiple ascending dose intravenous infusion
89130028|NCT02551549|Placebo Comparator|Placebo|normal saline
89130029|NCT00646399|Placebo Comparator|Placebo|Phosphate Buffered Saline
89130030|NCT00646399|Experimental|Pagibaximab 50 mg/mL|Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.
89130031|NCT00807781|Experimental|Mammaglobin-A DNA vaccine|"Patients will receive vaccine day 1 (week 1), week 4 (day 29 +/- 7), week 8 (day 57 +/- 7) with at least 21 days between injection days.~All injections will be given intramuscularly using a jet delivery device.~Patients will be administered the vaccine in lateral shoulder and buttocks positions that will be rotated with each administration in the above order."
89130032|NCT00810121|Experimental|1|Ketoprofen 100 mg b.i.d. for 5 days
89130033|NCT00810121|Experimental|2|Ketoprofen 150 mg b.i.d. for 5 days
89130034|NCT02552875|Active Comparator|Tetanic Stimulation|50 Hz tetanic stimulation for 5 seconds before TOF-twitch stabilization at the one arm
89130035|NCT02552875|Active Comparator|Staircase Stimulation|TOF-twitch stabilisation without 50 Hz tetanic stimulation at the contralateral arm
89130036|NCT00652327|Experimental|Ezetimibe + Statin|
88802472|NCT05476302||Cognitive digital treatment|Cognitive digital treatment in patients with Parkinson's disease
89130037|NCT00652327|Active Comparator|Double Statin|
89130038|NCT00814021|Experimental|sunitinib,|
89130039|NCT02551627|Experimental|Test Product|MMN fortified beverage powder [27 gram (g)] made up in 150 milliliter (mL) of water, will be administered orally as a single serve, twice daily for 18 weeks.
89130040|NCT02551627|Active Comparator|Control|Isocaloric beverage powder without micronutrient fortification (27 g), made up in 150 mL of water will be administered orally as a single serve, twice daily for 18 weeks.
89130041|NCT00814099|Active Comparator|1|Participants will receive care at a pediatric ICU that is continuing the usual approach to sedation management.
89130042|NCT00814099|Experimental|2|Participants will receive care at a pediatric ICU that is implementing the team approach to sedation management.
89130043|NCT00808093|Other|fixed sequence|fixed sequence (14 days fasted followed by 14 days either high fat or standard meal
89130044|NCT00645853|Experimental|1|
89130045|NCT00645853|Active Comparator|2|
89130046|NCT02551783|Experimental|Urethroplasty with buccal mucosa graft|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the dorsal wall of the urethra.
89130047|NCT02551783|Active Comparator|Ventral Buccal|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
89130048|NCT00652093|Experimental|Opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
89130049|NCT00652093|Experimental|Opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
89130050|NCT00652093|Experimental|Placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
88802473|NCT00634972|Experimental|1|
88802474|NCT00634972|Placebo Comparator|2|
88802475|NCT02553330|Experimental|Ruxolitinib Phosphate Cream|"Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks;~Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks."
89130051|NCT00652093|Experimental|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
89130052|NCT00652093|Experimental|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
89130053|NCT00652093|Experimental|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
89130054|NCT00651937|Active Comparator|Standard Dose|Melphalan + Stem Cell Infusion (Standard Dose): Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 cluster of differentiation 34 (CD34)/kg on Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
89130055|NCT00651937|Active Comparator|High Dose|Melphalan + Stem Cell Infusion (High Dose): High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
89130056|NCT00654355|Experimental|Active Drug|tacrolimus ointment
89130057|NCT00651313|Active Comparator|Active|Lidocaine 10% (150mg) vaginal gel
89130058|NCT00651313|Placebo Comparator|Placebo|Placebo vaginal gel
89130059|NCT02551705|Experimental|functional Imaging mutation carrier|Premanifest mutation carrier, behavioral and neural emotional memory processing
89130060|NCT02551705|Active Comparator|functional Imaging non-carrier|non-carrier family member, behavioral and neural emotional memory processing
89130061|NCT00808171|Experimental|EMLA and Livopan|Administered EMLA and Livopan
89130062|NCT00808171|Experimental|EMLA and gas placebo|Administered EMLA and oxygen
89130063|NCT00808171|Experimental|Livopan and placebo cream|Administered Livopan and placebo cream
89130064|NCT00814411|Experimental|Group Counseling|Group family planning counseling
89130065|NCT00814411|Active Comparator|Individual Counseling|Individual family planning counseling with gynecological patients who have unmet need
89130066|NCT04703257|Placebo Comparator|Control group|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
89130067|NCT04703257|Active Comparator|Intervention group|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
89130068|NCT00808327|Active Comparator|1|Bupivacaine alone
89130069|NCT00808327|Active Comparator|2|Bupivacaine plus Fentanyl
89130070|NCT00814567|Active Comparator|Arm I (control)|Patients undergo standard whole breast radiotherapy once daily on days 1-5 for 3 weeks.
89130071|NCT00814567|Experimental|Arm II|Patients undergo reduced whole breast radiotherapy and standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
89130072|NCT00814567|Experimental|Arm III|Patients undergo standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
89130073|NCT00814645|Active Comparator|Dose level 1|a single dose (5 mg sodium nitrite)of AIR001 Inhalation Solution administered by inhalation following nebulization
89130074|NCT00814645|Active Comparator|Dose level 2|a single dose(15 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
89130075|NCT00814645|Active Comparator|Dose level 3|a single dose(45 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
89130076|NCT00814645|Active Comparator|Dose level 4|a single dose(113 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
89130077|NCT00814645|Placebo Comparator|Expansion arm|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
89130078|NCT00814723|Active Comparator|Fluvastatin|Fluvastatin 80 mg MR
89130079|NCT00814723|Active Comparator|Fluvastatin + Ezetimibe|Fluvastatin MR 80 mg plus Ezetimibe 10 mg
89130080|NCT00810433|Experimental|Arm 1|
89130081|NCT00969761|Experimental|A. BI 6727-cisplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to cisplatin
89130082|NCT00969761|Experimental|B. BI 6727-carboplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to carboplatin
89130083|NCT00845871|Experimental|Deferasirox|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
89130084|NCT02864849|Experimental|TNT|"Patients with MRI defined high-risk rectal cancer will receive chemotherapy before and after chemoradiation, and will not receive adjuvant treatment. This arm is called total neoadjuvant treatment (TNT). The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX (Capecitabine+Oxaliplatin) over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.~Finally, patients will receive TME (Total mesorectal excision) following TNT if no metastasis occurs."
89130085|NCT00915278|Experimental|PF-04605412|
89130086|NCT00701961|Experimental|1|Pregnat women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
89130087|NCT00701961|Active Comparator|2|Non-pregnant women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
89130088|NCT04286711|Experimental|Albumin-paclitaxel Combined With Apatinib and Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day; Repeat the therapeutic schedule every 3 weeks
89130089|NCT04115709|Experimental|Intervention: Device attached with advice activated|Beacon Caresystem device will be attached to the patients and its ventilator advice will be activated.
89130090|NCT04115709|Active Comparator|Control: standard care with device attached without advice|Beacon Caresystem device will be attached to the patients however the ventilator advice will be deactivated.
89130091|NCT02863913|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
89130092|NCT02863913|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
89130093|NCT02612571||Wind instrument players|A wind instrument is defined as any instrument that contains a resonator, in which a column of air is set into resonation by the player blowing into a mouthpiece at one end of the resonator.
89130094|NCT02612571||Non-wind instrument players|A non-wind instrument is defined as any instrument that does not contain a resonator.
89130095|NCT02612649||Ramosetron group|Female patients with diarrhea-predominant irritable bowel syndrome
89130096|NCT02612415|Experimental|High flow nasal cannula (HFNC)|Heated humidified high flow nasal cannula therapy delivered at 2 L/kg/min gas flow rate (for children older than 10 kg in weight, an additional 0.5 L/kg/min per kilogram over 10 kg). Any approved device can be used to deliver HFNC
89130097|NCT02612415|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure delivered using any interface (hood, mask or prongs)
89130098|NCT00702039||1|Those patients receiving intravitreal injections who will be listening to classical music during injection.
89130099|NCT00702039||2|Those patients receiving intravitreal injections who will not be listening to any music during injection.
89130100|NCT05237102|Experimental|The patients did not respond to CSF tap test|Participants assigned to the experimental group did not respond to the CSF tap test and did not show improvement in general symptoms of hydrocephalus and disturbance of consciousness, but there may be changes in eeg and imaging parameters (it is unknown whether such changes are related to surgical outcome).
89130101|NCT05237102|Other|The patients did respond to CSF tap test|The improvement of symptoms in these participants after the CSF tap test predicts a favorable prognosis for CSF shunt.
89130102|NCT00844857|Experimental|Olanzapine/Fluoxetine Combination|
89130103|NCT00844857|Placebo Comparator|Placebo|
89130104|NCT05158088|Active Comparator|Borescope group|Using an Endotracheal tube mounted over Borescope with the aid of conventional laryngoscope for intubation
89130105|NCT05158088|Active Comparator|Videolaryngoscope group|Using videolaryngoscope for intubation
89130106|NCT04712240|Other|Respiration rate monitor (concurrently measured with standard of care capnography)|Single group study whereupon participants will be fitted with portable respiration rate monitor around their chest for duration of surgery. Respiration rates acquired by the respiration rate monitor will be compared to capnography, which is standard of care and applied to all surgical cases
89130107|NCT00702117|Active Comparator|A|IV flecainide in atrial fibrillation
89130108|NCT00702117|Experimental|B|IV ajmaline in atrial fibrillation
89130109|NCT00702117|Active Comparator|c|iv procainamide in ventricular tachycardia
89130110|NCT00702117|Experimental|d|iv ajmaline in ventricular tachycardia
89130111|NCT00702117|Active Comparator|e|iv flecainide in diagnosis of Brugada Sd
89130112|NCT00702117|Experimental|f|iv ajmaline in diagnosis of Brugada Sd
89130113|NCT00702429|Experimental|1|Patients achieve of parodontopathies
89130114|NCT00702429|Placebo Comparator|2|Patients without parodontales diseases
89130115|NCT00913107|Experimental|Lamictal®|"Lamictal® was used as the active medication in this study."
89130116|NCT00913107|Active Comparator|Tegretol®|"Tegretol® was employed as the control for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®."
89130117|NCT00569803|Active Comparator|Belatacept 50 mg Subcutaneous Injection|Belatacept 50 mg subcutaneous (SC) injection
89130118|NCT00569803|Active Comparator|Belatacept 100 mg Subcutaneous Injection|Belatacept 100 mg SC injection
89130119|NCT00569803|Active Comparator|Belatacept 125 mg Subcutaneous Injection|Belatacept 125 mg SC injection
89130120|NCT00569803|Active Comparator|Belatacept 150 mg Subcutaneous Injections|2 SC injections of 75 mg Belatacept
89130121|NCT00569803|Active Comparator|Belatacept 200 mg Subcutaneous Injections|2 SC injections of 100 mg Belatacept
89130122|NCT00569803|Active Comparator|Belatacept 250 mg Subcutaneous Injections|2 SC injections of 125 mg Belatacept
89130123|NCT00569803|Active Comparator|Belatacept 125 mg Intravenous Infusion|125 mg Belatacept intravenous (IV) injection
89130124|NCT00569803|Placebo Comparator|Placebo|SC injection of placebo solution
89130125|NCT04043949||Normal|healthy subjects
89130126|NCT04043949||Dry eye group|patients with dry eye
89130127|NCT04043949||Dry eye after treatment|patients with dry eye after treatment
89130128|NCT00920426|Experimental|GSK1265744 30 mg|GSK1265744 30 mg
89130129|NCT00920426|Experimental|Placebo|Placebo to match GSK1265744
89130130|NCT00920426|Experimental|GSK1265744 5 mg|GSK1265744 5 mg
89130131|NCT04046185|Experimental|pd-1 inhibitor and progesterone|Toripalimab. 240mg intravenous injection, every 3 weeks, 4 times. Megestrol Acetate Tablets, 160mg, po, once a day.
89130132|NCT04046185|Active Comparator|progesterone|Megestrol Acetate Tablets, 160mg, po, once a day.
89130133|NCT00810589|Experimental|1|
89130134|NCT00810589|Active Comparator|2|
89130135|NCT00810667|Experimental|Lu AE58054|
89130136|NCT00810667|Placebo Comparator|Placebo|
89130137|NCT00810745|Experimental|rectal resection|
89130138|NCT04253132|Active Comparator|50 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
89130139|NCT04253132|Active Comparator|300 mg daily oral dose|300 mg daily, oral dose of tolfenamic acid
89130140|NCT04253132|Active Comparator|600 mg daily oral dose|50 mg daily, oral dose of tolfenamic acid
89130141|NCT04253132|Placebo Comparator|Placebo control - 50 mg daily oral dose|50 mg daily oral placebo control
89130142|NCT04253132|Placebo Comparator|Placebo control - 300 mg daily oral dose|300 mg daily oral placebo control
89130143|NCT04253132|Placebo Comparator|Placebo control - 600 mg daily oral dose|600 mg daily oral placebo control
89130144|NCT00814957|Experimental|Open-label|D3 receptor antagonist
89130145|NCT05136404|Experimental|Selpercatinib (Formulation 1)|Selpercatinib (formulation 1) given orally on days 1, 8 or 15.
89130146|NCT05136404|Experimental|Selpercatinib (Formulation 2)|Selpercatinib (formulation 2) given orally on days 1, 8 or 15.
89130147|NCT05136404|Experimental|Selpercatinib (Formulation 3)|Selpercatinib (formulation 3) given orally on days 1, 8 or 15.
89130148|NCT05054816|Experimental|Investigational adaptive directional microphone strategy|Receiver-in-canal hearing aid with an investigational adaptive directional microphone strategy.
89130149|NCT05054816|Active Comparator|Comparator omnidirectional microphone strategy|Receiver-in-canal hearing aid with a comparator omnidirectional microphone strategy.
89130150|NCT05054816|Active Comparator|Comparator fixed directional microphone strategy|Receiver-in-canal hearing aid with a comparator fixed directional microphone strategy.
89130151|NCT00644995|Active Comparator|Usual Care Control|Participants will receive usual care which includes advice to stop smoking and referral to standard care treatment available through participants' health insurance and health plan.
89130152|NCT00644995|Experimental|Step Up Intervention|Participants will receive the Step Up Wellness Program. The intervention is detailed below.
89130153|NCT04045327|Active Comparator|Normal Saline|Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.
89130154|NCT04045327|Experimental|PMZ-2010 (centhaquine)|Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.
89130155|NCT00815113||1|First degree relative of gastric cancer patient
89130156|NCT00815113||2|Consecutive gastro-esophageal reflux patients
89130157|NCT00914966|Experimental|CINRYZE|"There were 3 potential dose escalation steps:~Step 1: 1500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks~Step 2: 2000 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks~Step 3: 2500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks"
89130158|NCT02551471||French patients|
89130159|NCT02551471||Australians patients|
89130160|NCT00815269|Active Comparator|1|Halothane anesthesia: induction and maintenance with different doses
89130161|NCT00815269|Experimental|2|Isoflurane anesthesia: induction and maintenance with different doses
89130162|NCT00815269|Experimental|3|Sevoflurane anesthesia: induction and maintenance with different doses
89130163|NCT00815269|Experimental|4|Desflurane anesthesia: induction and maintenance with different doses
89130164|NCT00815269|Experimental|5|Enflurane anesthesia: induction and maintenance with different doses
89130165|NCT00914810|Experimental|Vitamin D|Cholecalciferol (2000 I.U. daily)
89130166|NCT00914810|Placebo Comparator|Placebo|Placebo capsule (sugar pill daily)
89130167|NCT00810823||1:Gastric bypass/diabetes|Patients undergoing gastric bypass surgery, and who are diagnosed with type 2 diabetes.
89130168|NCT00810823||2:Gastric bypass/not Diabetic|Patients undergoing gastric bypass surgery, not diagnosed with diabetes.
89130169|NCT00922285|Experimental|Art Therapy|
89130170|NCT00808561|Active Comparator|1 Alternative Fistula|
89130171|NCT00808561|Active Comparator|2 Forearm AV Graft|
89130172|NCT00815425||African Americans with RA|1063 participants with RA
88802476|NCT02553330|Placebo Comparator|Placebo Cream|Part B: Double-blind treatment is 24 weeks (and/or treatment with Ruxolitinib Phosphate Cream if eligible) and follow-up is an additional 12 weeks.
89130173|NCT00815425||African-Americans without RA|550 participants without RA
89130174|NCT00808717|Experimental|High dose Atorvastatin 80 mg|Administered Atorvastatin 80 mg before intervention
89130175|NCT00808717|Active Comparator|Control|Administered Atorvastatin 10 mg before intervention
89130176|NCT00644917|Experimental|A|Drug
89130177|NCT00644917|Placebo Comparator|B|Placebo comparator
89130178|NCT00644917|No Intervention|C|Subjects serve as own controls.
89130179|NCT00914732|Experimental|Group B, liquid, subcutaneous|Group B: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) liquid formulation by the subcutaneous route on Day 0 and 28.
89130180|NCT00914732|Experimental|Group C, liquid, intradermal|Group C: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (2x10^7 TCID50/0.1mL per dose) liquid formulation by the intradermal route on Day 0 and 28.
89130181|NCT00914732|Experimental|Group A, lyophilized, subcutaneous|Group A: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) lyophilized formulation by the subcutaneous route on Day 0 and 28.
89130182|NCT00844545|Experimental|Eculizumab|
89130183|NCT00815503|Active Comparator|Ropivacaine|
89130184|NCT00815503|Placebo Comparator|Saline|
89130185|NCT02552407||Manual Aspiration Thrombectomy with PCI|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to Manual Aspiration Thrombectomy followed by percutaneous coronary intervention (PCI).
89130186|NCT02552407||PCI Alone|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to percutaneous coronary intervention (PCI) alone without manual aspiration thrombectomy.
89130187|NCT04708262|Experimental|Cognitive Analytic Therapy for Containing Self-Harm in Young People|Brief one-to-one psychological therapy using Cognitive Analytic Therapy principles, designed for young people who self-harm
89130188|NCT00651157|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus (Reolysin®) IV administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89130189|NCT02691182|Experimental|Open-label treatment with SPN-810|Subjects aged 6-12 years will be treated with SPN-810 starting day 1 of Visit 1 of the study. The subjects will be given a choice of extending their participation in the study every 6-month period for up to 36 months. The clinician will be able to adjust the dose of SPN-810 throughout the study based on subject's response and tolerability.
89130190|NCT00843843|Active Comparator|9 hour sleep, then 3 hour nap and 6 hour sleep|
89130191|NCT00843843|Active Comparator|3 hour nap and 6 hour sleep, then 9 hour sleep|
89130192|NCT00650845|Experimental|Dotarem®-enhanced MRI|Patients undergoing Dotarem®-enhanced MRI for diagnostic purposes
89130193|NCT00650845|Other|Non-enhanced MRI|Patients undergoing non-enhanced MRI for diagnostic purposes
89130194|NCT00842985|Other|drug condition|Participants received each drug condition in sequential order across 4 test days. Not all participants received the interventions in the same order.
89130195|NCT04017091|Experimental|VR Group|ABI Patients Twenty-one patients with ABI participated in this pilot study (Figure 1): 9 diagnosed with stroke (43%), 6 with TBI (29%), 2 with anoxic injury (10%), 3 with brain tumor (14%), and 1 with amyloid angiopathy (5%).
89130196|NCT04017091|No Intervention|Control Group (Standard Care)|The 12 Controls were age- and gender-matched (and etiology when possible) patients who had previously received traditional neurorehabilitation and completed the same measures as the VR group prior to onset of the study, but they did not receive VR treatment.
89130197|NCT00808795|Experimental|N-acetylcysteine|
89130198|NCT00808795|Placebo Comparator|Placebo|
89130199|NCT00815581|Other|photorefraction|
89130200|NCT00808873|Experimental|1|brief education and 6 follow-up visits
89130201|NCT00808873|No Intervention|2|treatment-as-usual
89130202|NCT00811213|Experimental|1|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
89130203|NCT00811213|Active Comparator|2|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
89130204|NCT00808951|Experimental|Artemether -lumefantrine|Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
89130205|NCT00808951|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
89130206|NCT00815737|Experimental|A|
89130207|NCT00815737|Placebo Comparator|B|
89130208|NCT04045483|Experimental|VR based cognitive training|Participants perform the VR based cognitive training under the supervision of a research nurse or psychologist for 30 min per session, twice per week, over the 6-week intervention period.
89130209|NCT04045483|No Intervention|Usual care|Participants take some medication for risk factors and cognitive impairment and receive health advice as a usual care.
89130210|NCT02551393|Experimental|Intervention Group|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home Blood pressure monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
89130211|NCT02551393|No Intervention|Control Group|Usual Care of hypertension in primary care clinic
89130212|NCT00842829|Experimental|FBT 100 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 100 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
89130213|NCT00842829|Active Comparator|FBT 200 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 200 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
89130214|NCT04045249|No Intervention|1st Group|Children were treated as per standard CMAM protocols; provided RUTF until MUAC reaches 11.5 cm
89130215|NCT04045249|Experimental|2nd Group (1st Intervention group)|Children were initially provided RUTF until MUAC reach 11 cm then 50 % calories were provided from RUTF and 50% calories from home based food
89130216|NCT04045249|Experimental|3rd Group (2nd Intervention)|Children were initially provided RUTF until MUAC reach 11 cm then 100 % calories provided from home based food
89130217|NCT04045093|Experimental|Dabigatran etexilate|Subjects randomized into this group will be prescribed with either Dabigatran 150mg or Dabigatran 110mg (twice daily) according to creatinine clearance level, twice daily) for stroke prevention.
89130218|NCT04045093|Active Comparator|Warfarin|Subjects randomized into this group will be prescribed with Warfarin with dosage adjustment according to INR level (targeting to INR 2-3) for stroke prevention.
89130219|NCT00811291|Placebo Comparator|1|
89130220|NCT00811291|Active Comparator|2|folic acid and B-vitamin supplement
89130221|NCT00811369|Experimental|1|Fulvestrant + ZACTIMA Group
89130222|NCT00811369|Placebo Comparator|2|Fulvestrant + Placebo Group
89130223|NCT00653263||Methamphetamine dependent|Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
89130224|NCT00842361|Active Comparator|Mix30|
89130225|NCT00842361|Experimental|SIAC|
89130226|NCT00811447|Experimental|1|Administration of docetaxel 60 mg/m² on Day 1, Cisplatin 60 mg/m² after the end of the docetaxel infusion and 5-fluorouracil (5-FU) 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
89130227|NCT00811447|Active Comparator|2|Cisplatin 75 mg/m² on Day 1, 5-FU 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
89130228|NCT02552251|Experimental|A: hydrocortisone|hydrocortisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
89130229|NCT02552251|Experimental|B :dexamethasone (DECTANCYL)|dexamethasone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
89130230|NCT02552251|Experimental|C : prednisone (CORTANCYL)|prednisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
89130231|NCT00809107|Experimental|1|HCG GROUP
89130232|NCT00809107|No Intervention|2|LH pick
89130233|NCT02612181|Experimental|Dexmedetomidine group|Dexmedetomidine group: Dexmedetomidine infusion for dexmedetomidine group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Dexmedetomidine doses 0-0.7 mcg/kg/h
89130234|NCT02612181|Placebo Comparator|Control group|Control group: Placebo infusion for control group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Control drug doses 0-0.7 mcg/kg/h
89130235|NCT02612259|Experimental|TRYPTOPHAN|"tryptophan 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.~Total treatment duration for each patient is 6 months."
89130236|NCT02612259|Placebo Comparator|PLACEBO|"lactose capsules 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.~Total treatment duration for each patient is 6 months."
89130237|NCT00841035|Experimental|Eroltinib added to standard of care|150 mg of erlotinib for 7 days prior to surgery,then in the adjuvant stage the subject will receive 100mg of erlotinib and gemcitabine 1000mg/2 for 6 cycles
89130238|NCT00703131||1|Anal Fistula Plug
89130239|NCT02612103||Active Crohns disease|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index > 4.
89130240|NCT02612103||Crohns disease in remission|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index ≤ 4.
89130241|NCT02612103||Active ulcerative colitis|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index > 3.
89130242|NCT02612103||Ulcerative colitis in remission|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index ≤ 3.
89130243|NCT02612103||Irritable bowel syndrome|Verified irritable bowel syndrome according to standard criteria.
89130244|NCT02612103||Healthy controls|No known chronic diseases which needs continuously medication.
89130245|NCT00703209|Active Comparator|1|Patients who are randomized to receive surgical care, will receive the nerve decompression, along with similar incisions on the opposite leg, but no decompression on that leg. This will serve as the patient's control leg, and also blind them to the treatment leg.
89130246|NCT00703209|No Intervention|2|Subjects who are not randomized to receive the surgical procedure will be followed up with the same clinic visits as the patients who are receiving the surgical procedure.
89130247|NCT00642811|Experimental|1|Aspirin + Ticagrelor
89130248|NCT00642811|Active Comparator|2|Aspirin + Clopidogrel
89130249|NCT00838929|Experimental|Vorinostat (200 mg) and radiation|Cohort 1: Patients receive 200 mg of Vorinostat and radiation
89130250|NCT00838929|Experimental|Vorinostat (300 mg) and radiation|Cohort 2: Patients receive 300 mg of vorinostat and radiation
89130251|NCT00838929|Experimental|Vorinostat (400 mg) and radiation|Cohort 3: Patients receive 400 mg of vorinostat and radiation
89130252|NCT02612025|Experimental|Exercise group|Exercise training during intensive medical treatment
89130253|NCT02612025|No Intervention|Control group|Usual Care
89130254|NCT00811603|Active Comparator|1|Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
89130255|NCT00811603|Experimental|2|Patients who receive antibiotic prophylaxis prior to skin incision
89130256|NCT00811681|Experimental|Pioglitazone|pioglitazone
89130257|NCT00811681|Placebo Comparator|Control|placebo
88802477|NCT00529282|Experimental|001|Ceftobiprole Medocaril 500 mg every 8 hours 120-minute infusion [250 mL]
89130258|NCT00815893|Experimental|1 dex group|received dexmedetomidine (1.0 mcg/kg) infusion
89130259|NCT00815893|Placebo Comparator|2 control group|received 0.9% saline
89130260|NCT00815893|Active Comparator|3 Propofol group|received 1% propofol using effect-site TCI(Base Primea, Fresenius, France)
89130261|NCT00815971||NSCLC|Patients with non-small cell lung cancer carcinoma treated with erlotinib
89130262|NCT00816049|Active Comparator|6MPfixed|Fixed dose 6-mercaptopurine days 30-85
89130263|NCT00816049|Experimental|6MPindividualized|Individualized dose increments of 6-mercaptopurine days 30-85
89130264|NCT02550925|Experimental|Acceptance and Commitment Therapy Group|
89130265|NCT02550925|Active Comparator|Usual Care|
89130266|NCT04648891|Other|Control|Patients will receive laryngeal injection of Botox via a transcricothyroid approach without additional anesthesia
89130267|NCT04648891|Experimental|Lidocaine|Patients will receive laryngeal injection of Botox via a transcricothyroid approach following subcutaneous injection of 0.5cc 2% lidocaine in 1:100,000 epinephrine (done approximately 2 minutes before Botox injection)
89130268|NCT04648891|Experimental|Vibrating Wand|Patients will receive laryngeal injection of Botox via a transcricothyroid approach while a vibrating instrument is held adjacent to cricothyroid space
89130269|NCT04045015|Active Comparator|glycyrrhizic acid 1.5 mg/kg body weight|Liqourice corresponding to 1.5 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
89130270|NCT04045015|Active Comparator|glycyrrhizic acid 3.0 mg/kg body weight|Liqourice corresponding to 3.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
89130271|NCT04045015|Active Comparator|glycyrrhizic acid 6.0 mg/kg body weight|Liqourice corresponding to 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
89130272|NCT00811837|Experimental|Remifentail|Remifentanil Infusion
89130273|NCT00811837|Active Comparator|Midazolam|Active Placebo
89130274|NCT00817609|Experimental|A|
89130275|NCT00817609|Placebo Comparator|B|
89130276|NCT00811915|Experimental|Sirolimus|"Group A : Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14.~Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
89130277|NCT00811915|Active Comparator|B|Tacrolimus (Advagraf) dose to obtain a trough level between 4 and 10 ng/ml
89130278|NCT00816127|Experimental|1|DDAVP
89130279|NCT00816127|Active Comparator|2|Standard Treatment
89130280|NCT00916058|Experimental|Dose Level 1|Dose Level 1; Bendamustine 30 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
89130281|NCT00916058|Experimental|Dose Level 2|Dose Level 2; Bendamustine 60 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
89130282|NCT00916058|Experimental|Dose Level 3|Dose Level 3; Bendamustine 90 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
89130283|NCT00916058|Experimental|Dose Level 4|Dose Level 4; Bendamustine 120 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
89130284|NCT00916058|Experimental|Dose Level 5|Dose Level 5; Bendamustine 150 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
89130285|NCT00916058|Experimental|Dose Level 6|Dose Level 6; Bendamustine 225 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
89130286|NCT00916058|Experimental|Phase 2|Bendamustine 225 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
89130287|NCT05228678||Dyspnea group|"Patients with prior diagnosis of COVID-19 and present with persistent dyspnea after 12 weeks of occurrence of symptoms every patient in this group will undergo Cardiopulmonary exercise test (CPET) protocol: -~As regard CPET protocol we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.~The following parameters observed:~Metabolic response~Oxygen consumption VO2 (ml/ min):~P ETO2: Is the end-tidal O2 tension as measured from the exhaled air.~P ETCO2: Is the end-tidal CO2 tension as measured from the exhaled air. Normally decreased during exercise.~Anaerobic Threshold (AT): Is defined as the VO2 (in L/min) at which there is substantial transition to anaerobic metabolism to produce extra energy~Ventilatory response~Minute ventilation :~Breathing reserve(BR): Breathing reserve = measured/predicted minute ventilation maximum~Tidal volume (VT):~Respiratory frequency (RF)"
89130288|NCT05228678||Control group|"Patients with prior diagnosis of COVID-19, fully recovered, without persistent dyspnea every patient in this group will undergo Cardiopulmonary exercise test (CPET) protocol: -~As regard CPET protocol we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.~The following parameters observed:~Metabolic response~Oxygen consumption VO2 (ml/ min):~P ETO2: Is the end-tidal O2 tension as measured from the exhaled air.~P ETCO2: Is the end-tidal CO2 tension as measured from the exhaled air. Normally decreased during exercise.~Anaerobic Threshold (AT): Is defined as the VO2 (in L/min) at which there is substantial transition to anaerobic metabolism to produce extra energy~Ventilatory response~Minute ventilation :~Breathing reserve(BR): Breathing reserve = measured/predicted minute ventilation maximum~Tidal volume (VT):~Respiratory frequency (RF)"
89130289|NCT04253288|Other|Patients with severe radiation toxicity|Patients who received radiotherapy and developed abnormal radiation-induced toxicity
89130290|NCT04559906|Experimental|Group A|Spray and Stretch technique Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
89130291|NCT04559906|Active Comparator|Group B|Sustain pressure release Conventional treatment Hot pack (10-15 min) Stretching (3 sets of 10 repetitions with 10 seconds hold) AROM exercises (3 sets of 10 repetition)
89130292|NCT04633694|Experimental|Insect protein|The participants are are given insect protein
89130293|NCT04633694|Experimental|Pea protein|The participants are are given pea protein
89130294|NCT04633694|Experimental|Whey protein|The participants are are given whey protein
89130295|NCT04624334||Children with motility disorder|
89130296|NCT04624334||Healthy children|
89130297|NCT04624334||Adults with motility disorder|
89130298|NCT04624334||Healthy adults|
89130299|NCT00631904||Single Observation|Patients with permanent pacemakers undergoing medically indicated MRI scanning.
89130300|NCT04619498|Experimental|PediAppRREST app|The teams assigned to the PediAppRREST arm will manage the simulated scenario of pediatric cardiac arrest using the new PediAppRREST tablet app as a cognitive aid.
89130301|NCT04619498|Active Comparator|CtrlPALS+|The teams assigned to the CtrlPALS+ arm will manage the simulated scenario of pediatric cardiac arrest using the American Heart Association Pediatric Advanced Life Support (AHA-PALS) pocket reference card.
89130302|NCT04619498|No Intervention|CtrlPALS-|The teams assigned to the CtrlPALS- arm will manage the simulated scenario of pediatric cardiac arrest using no PALS-related cognitive aids.
89130303|NCT04422314||Cohort 1|Lyme disease testing cohort
89130304|NCT04422314||Cohort 2|Endemic, asymptomatic controls
89130305|NCT04422314||Cohort 3|Non-endemic, asymptomatic controls
89130306|NCT04422314||Cohort 4|Potential cross-reactive disease states
88802478|NCT00529282|Active Comparator|002|Cefepime with or without vancomycin 2 g every 8 hrs-30 min infusion vancomycin 1 000mg every 12 hrs-60 min infusion
89130307|NCT04422314||Cohort 5|Lyme disease testing cohort
89130308|NCT04606940||IO-KIN|Patients with a histological or cytological confirmed recurrent, metastatic or advanced HNSCC of the oral cavity, oropharynx, hypopharynx, larynx or unknown origin (but being treated as HNSCC). Patients who are going to receive at least one dose of anti-PD1 antibody (nivolumab or pembrolizumab).
89130309|NCT04599920|Active Comparator|Red meat supplementation providing 25% of protein intake|A diet supplemented with 760 g of cooked and boneless red meat per week, corresponding the average consumption of red meat in Finnish men.
89130310|NCT04599920|Experimental|Red meat mostly replaced with legume-based foods|A diet supplemented with legume-based foods providing 20% of protein intake and with 200 g per week of red meat providing 5% of protein intake.
89130311|NCT04443842|Experimental|Intervention|Participants will receive the usual standard care (same as control group), loss-framed financial incentive, social incentives and weekly feedback on performance for 6 months.
89130312|NCT04443842|No Intervention|Control|Participants will receive standard care including patient screening and education on diet, physical activity, and smoking conducted by a multi-disciplinary team. Participants in the control group will neither be told their baseline step count nor receive any feedback messages.
89130313|NCT00912782|Placebo Comparator|Placebo|Placebo one time per week for 3 weeks
89130314|NCT00912782|Experimental|Cholecalciferol|Vitamin D 200,000 IU per week for 3 weeks
89130315|NCT00632060|No Intervention|1|Standard Care Control Group - Participants randomized to the standard care group will continue their use of non-prescription or prescription medication and reduced duty loads, as prescribed by the credentialed medical provider.
89130316|NCT00632060|Experimental|2|Manual / Manipulative Therapy Group: Participants randomized to the M/MT group will receive a course of M/MT along with standard care. The patient will see the chiropractor twice a week for the entire course of the study, regardless of manipulation or not.
89130317|NCT04205396|Experimental|Written emotional disclosure|
89130318|NCT04205396|Experimental|Resilience training|
89130319|NCT04205396|Other|Control arm|
89130320|NCT04730804|Experimental|Cohort 1: ALXN1830 Single Dose 1/Placebo|Participants will receive a single SC dose of ALXN1830 or placebo.
89130321|NCT04730804|Experimental|Cohort 2: ALXN1830 Single Dose 2/Placebo|Participants will receive a single SC dose of ALXN1830 or placebo.
89130322|NCT04730804|Experimental|Cohort 3: ALXN1830 Multiple Dose 1/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
89130323|NCT04730804|Experimental|Cohort 4: ALXN1830 Multiple Dose 2/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
89130324|NCT04730804|Experimental|Cohort 5: ALXN1830 Multiple Dose 3/Placebo|Participants will receive multiple SC doses of ALXN1830 or placebo.
89130325|NCT04730804|Experimental|Cohort 6: ALXN1830 /Placebo in Japanese Population|Japanese participants will receive multiple SC doses of ALXN1830 (HTD) or placebo.
89130326|NCT04202978|Experimental|Camrelizumab+ Apatinib +XELOX +RFA|Camrelizumab combined with Apatinib 、XELOX 、RFA in the treatment of liver metastases of colorectal cancer
89130327|NCT04233944||Pregnant women and their infants|Mothers and their infants were followed throughout the first two years of the infant's life. Data were collected at enrollment, birth, 3, 6, 9,12, 18 and 24 months from the date of delivery.
89130328|NCT04186442|Experimental|Botulinum toxin type A (Botulax®)|
89130329|NCT04186442|Active Comparator|Botulinum toxin type A (Botox®)|
89130330|NCT00631982|Experimental|Group I|patients with PCO undergoing in vitro maturation and subsequently IVF and embryo transfer
89130331|NCT04203368|Active Comparator|adenosine group|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil
89130332|NCT04203368|Sham Comparator|verapamil group|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
89130333|NCT03444038|Experimental|Valbenazine|Valbenazine administered once daily for up to 24 weeks
89130334|NCT00911534|Experimental|1|
89130335|NCT00911534|Placebo Comparator|2|
89130336|NCT04319042|Active Comparator|Immediate Loading|Group A. The implant receives an artificial tooth the same day as it is placed.
89234056|NCT00455013|Experimental|belatacept, sirolimus|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months;sirolimus 5 mg/day on Day 1 (day of transplant)and continued through Day 2, dosing to be adjusted to keep pre-dose C0 levels at 7-12 ng/mL for first 6 months, followed by 5 - 10 ng/mL until 12 months.
89234057|NCT00455013|Other|tacrolimus, MMF|(IMPs as comparator regimen)thymoglobulin 1.5mg/kg for 4 days; oral tacrolimus 0.1 mg/kg/day in 2 divided doses with initial targeted trough level of 8-12 ng/mL for Days 1 - 30 with dose reduction to achieve 12 hour trough target of 5-10 ng/mL for 12 months; MMF (mycophenolate mofetil) 1g BID.
89234058|NCT00363298|Experimental|d-amphetamine|dextro-amphetamine capsules, 15 mg per capsule, in Bottles A and B, dose: one from Bottle A each morning and 1 from Bottle B each morning
89130337|NCT04319042|Active Comparator|Early Loading|Group B. The implant receives an artificial tooth 4 weeks after placement.
89130338|NCT04571840|Active Comparator|mpMRI|Multiparametric MRI
89130339|NCT04571840|Experimental|bpMRI|Biparametric MRI
89130340|NCT04302974||Sub-study 1: Trajectory study|All HA primary care patients aged 18 years or above with doctor-documented HT and/or DM receiving care in HA General Out-patient Clinics or Family Medicine Clinics (FMC) identified from the HA CMS database between 2006 and 2019, to explore the trajectory patterns for clinical, treatment and complication profiles and investigate the impact of multi-morbidity, continuity-of-care, different service delivery models and management strategies (including investigation frequency and specific drug regimens) on outcomes and health service utilization.
89130341|NCT04302974||Sub-study 2: RAMP-DM|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who attended the first RAMP-DM assessment between August 2009 to September 2010
88802479|NCT00623974|Experimental|Calcium + Calcitriol|1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
89130342|NCT04302974||Sub-study 2: usual care only|A cohort of patients with i) diagnosis of DM without any known complications on or before September 2010 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2009 and 2019, who have never attended any RAMP-DM assessment between August, 2009 to December, 2019
89130343|NCT04302974||Sub-study 3: RAMP-HT|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who attended the first RAMP-HT assessment between October 2011 to March 2013
89130344|NCT04302974||Sub-study 3: usual care only|A cohort of patients with i) diagnosis of HT without DM and any known complications on or before March 2013 and ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2011 and 2021, who have never attended any RAMP-HT assessment between October 2011 to December 2021
89130345|NCT04302974||Sub-study 4: PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have received the first PSCC call between September, 2012 to August, 2016 after the first RAMP-DM assessment
89130346|NCT04302974||Sub-study 4: without PSCC|A cohort of patients with i) diagnosis of DM without any known complications on or before August 2016, ii) Documented management in the HA General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) identified from the HA CMS database between 2012 and 2021 iii) attended the first RAMP-DM assessment between September, 2012 to August, 2016, who have never received any PSCC services between September 2012 to December 2021
89130347|NCT00911300|Active Comparator|Arm 1: fondaparinux|
89130348|NCT00911300|Active Comparator|Arm 2: unfractionated heparin + Vitamin-K-Antagonist|
89130349|NCT00632294||Retrieved Allograft|Patients that require the retrieval of a bone allograft (transplant).
89130350|NCT04239404||PMI|
89130351|NCT04239404||non-PMI|
89130352|NCT04202822|Other|Biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) at T0 and T24
89130353|NCT04565366||Spinal Cord Injury|Individuals recently admitted to hospital and diagnosed with acute, traumatic spinal cord injury.
89130354|NCT04565366||Trauma Control|Individuals recently admitted to hospital and diagnosed with an acute, traumatic injury that is not spinal cord injury.
89130355|NCT04565366||Healthy Control|Generally healthy individuals not recently diagnosed with an acute, traumatic injury (including spinal cord injury).
89130356|NCT00911144|Experimental|Synflorix Group|Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
89130357|NCT00911144|Active Comparator|Prevenar Group|Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
88802480|NCT00623974|Experimental|Teriparatide 20 mcg|Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
89130358|NCT04561622||Bipolar patients|Bipolar patients (type I,II, NOS) of the bipolar disorder expert center of CHU Grenoble Alpes.
89130359|NCT04561622||Healthy controls|Volunteers without any psychiatric disease matching inclusion criteria
89130360|NCT04395248|Active Comparator|Risk factors of difficult intubation|Appearance anpalpationpalpationpalpationd ultrasound features for predicting difficult laryngoscopy intubation
89130361|NCT04395248|Active Comparator|Radial artery cannulation using ultrasound or blind palpation|In the ultrasound group, a linear vascular probe in the frequencies 5 to 13 MHz (GE 12L-RS, GE Healthcare, Chicago, IL, USA) of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image.
89130362|NCT04395248|Active Comparator|Preoxygenation using high-flow nasal cannula or facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher & Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs.
89130363|NCT04395248|Active Comparator|Type of volatile anesthetics and M-Entropy guidance|Patients will be randomized by a computer-generated list into one of the four groups, desflurane with usual care (N=20), desflurane with M-Entropy guidance (N=20), sevoflurane with usual care (N=20), and sevoflurane with M-Entropy guidance (N=20).
89130364|NCT04247048|Experimental|Control group|Patients with no major LDL cholesterol abnormalities (patients eligible for LDL-apheresis, eg LDL-C> 200 mg / dL for secondary prevention and 300 mg / LDL-C) dl in primary prevention)) and a level of Lp (a) <50 mg / dl
88802481|NCT00623974|Experimental|Teriparatide 40 mcg|Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
88802482|NCT00623974|Experimental|Teriparatide 60 mcg|Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
88802483|NCT02550288|Active Comparator|Ezetimibe 10 mg|1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.
88802484|NCT02550288|Active Comparator|Atorvastatin 10 mg|1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.
88802485|NCT02550288|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.
89130365|NCT04247048|Experimental|High-dose group|Patients with no major LDL-cholesterol abnormalities (LDL-apheresis eligible patients, eg LDL-C> 200 mg / dL for secondary prevention and 300 mg / dl in primary prevention)) and a level of Lp (a)> 80 mg / dl
89130366|NCT04276298|Active Comparator|Metronidazole|Group A receiving 10% metronidazole cream
89130367|NCT04276298|Active Comparator|Metronidazole + Diltiazem|Metronidazole 10% + Diltiazem 2%
89130368|NCT04276298|Active Comparator|Metronidazole + Lignocaine|Metronidazole 10% + Lignocaine 4%
89130369|NCT04276298|Active Comparator|Metronidazole + Diltiazem + Lignocaine|Metronidazole 10% + Diltiazem 2% + Lignocaine 4%
89130370|NCT04273880|Experimental|10 mg Psychostimulant|Drug: Methylphenidate (MPH) Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 10mg of MPH an hour and a half before the testing session is set to begin, to account for the time taken for the effects of the drug to start.
89130371|NCT04273880|Placebo Comparator|90 mg Vitamin C|Placebo: Vitamin C Participants will be tested twice, approximately one month apart. In one of the sessions, they will be given 90mg of Vitamin an hour and a half before the testing session is set to begin, to follow the exact protocol that is used for MPH.
89130372|NCT03316742|Experimental|Intervention 1|Participants randomized to intervention 1 will complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant will attend twelve one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
88802486|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks
88802487|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks
89130373|NCT03316742|Experimental|Intervention 2|Participants randomized to intervention 2 will complete baseline and endline outcomes and participate in version 2 of a weight loss program. Each participant will attend 12 one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
89130374|NCT04099628|Experimental|Diagnostic tests|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
89130375|NCT00910988|Active Comparator|olanzapine|olanzapine injection in healthy control
89130376|NCT00910988|Active Comparator|ziprasidone|ziprasidone injection in healthy control
89130377|NCT00910988|Placebo Comparator|saline|saline injection in healthy control
89130378|NCT00644059|Experimental|TIV-adj|Adjuvanted trivalent inactivated subunit influenza vaccine
89130379|NCT00644059|Active Comparator|Flu-control|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
89130380|NCT00644059|Sham Comparator|Non-flu Control|Novartis meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
89130381|NCT00817687|Experimental|1|
89130382|NCT00817687|No Intervention|2|
89130383|NCT00811993|Experimental|1|
89130384|NCT00811993|Experimental|10|
89130385|NCT00811993|Experimental|11|
89130386|NCT00811993|Experimental|12|
89130387|NCT00811993|Experimental|13|
89130388|NCT00811993|Experimental|2|
89130389|NCT00811993|Experimental|3|
89130390|NCT00811993|Experimental|4|
89130391|NCT00811993|Experimental|5|
89130392|NCT00811993|Experimental|6|
88802488|NCT01954576|Experimental|NovoTTF therapy|Patients undergo NovoTFF therapy at least 18 hours daily for 6 months (bevacizumab-naive) or 4 months (bevacizumab-refractory). Treatment may continue for up to 2 years in patients experiencing CR, PR, or SD.
89130393|NCT00811993|Experimental|7|
89130394|NCT00811993|Experimental|8|
89130395|NCT00811993|Experimental|9|
89130396|NCT00817765|Active Comparator|Posaconazole alone|400mg posaconazole BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
89130397|NCT00817765|Active Comparator|Fosamprenavir ritonavir|Fosamprenavir 700mg / ritonavir 100mg BID for 10 days
89130398|NCT00817765|Experimental|Fosamprenavir posaconazole|Fosamprenavir 700mg / posaconazole 400mg BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
89130399|NCT02552329|No Intervention|Control group|Since no medication or other treatments are currently approved by Food and Drug Administration (FDA) for treatment of MCI, participants in the usual care group will not receive any form of treatment. They will receive an educational material about cognitive impairment. They will also be asked to maintain their daily routine.
89130400|NCT02552329|Experimental|Tai Chi exercise group|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down.
89130401|NCT00816205|Experimental|Single Arm|This is an open label, dose-finding study. After detrminig baseline resting anal pressure with a manometric test, coated Suppositories will be administered intra rectally. Subjects will take rectally a total of 3 Coated Suppositories per study.
89130402|NCT00817921||1|former premature children treated by ibuprofen
89130403|NCT00817921||2|former premature children not treated by ibuprofen
89130404|NCT00817921||3|former term children (control)
89130405|NCT00910910|Experimental|1 - Lenalidomide|1 - Lenalidomide
89130406|NCT00910910|Active Comparator|2- Chlorambucil|2- Chlorambucil
89130407|NCT04267172|Experimental|Surgical Residents with additional simulation training|Surgeon participant Group 1a: Interventional group ('StR's'): Trauma & Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving additional simulation training.
89130408|NCT04267172|Active Comparator|Surgical Residents with routine training|Surgeon participant Group 1b: control group (StR's): Trauma & Orthopaedic Specialty Registrars (Surgical Residents) on Arthroplasty clinical placements (n=6-8) receiving routine and normal training.
89130409|NCT04267172|Active Comparator|Orthopaedic Surgeon 'Experts & Fellows'|Consultant Orthopaedic Surgeons (n=5), and nationally appointed Arthroplasty Fellows (n=8). Surgeon participants within this group will not undergo any interventions.
89130410|NCT04384562|Experimental|Dopamine reuptake inhibitor|Participants in the dopamine reuptake inhibitor group will be asked to take one pill containing 20 mg methylphenidate 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
89130411|NCT04384562|Experimental|Noradrenaline reuptake inhibitor|Participants in the noradrenaline reuptake inhibitor group will be asked to take one pill containing 4 mg reboxetine 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
89130412|NCT04384562|Experimental|Cholinergic receptor agonist|Participants in the cholinergic receptor agonist group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a gum with 2 mg of nicotine.
89130413|NCT04384562|Placebo Comparator|Placebo|Participants in the placebo group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
89130414|NCT04519892|Experimental|Receiving PDRC and coach guidance|Intervention group: Receiving PDRC + coach guidance.
89130415|NCT04519892|Active Comparator|Receiving PDRC without coach guidance|Control group: Receiving PDRC only.
89130416|NCT04243304|Experimental|PD patients|At baseline and 2-year follow-up
89130417|NCT04243304|Active Comparator|Healthy controls|At baseline and 2-year follow-up
89130418|NCT04238390|Experimental|Ceftolozane-tazobactam|Participants will receive ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins
89130419|NCT04238390|Active Comparator|Meropenem|Participants will receive meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins.
89130420|NCT04236830|Experimental|Silver diamine fluoride/ potassium iodide group|Riva Star Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia
89130421|NCT04236830|Experimental|Silver diamine fluoride group|Advantage arrest TM, Elevate Oral Care, USA
89130422|NCT04236830|Active Comparator|Resin modified glass ionomer cement group|Riva light cure, SDI, Bayswater, Australia
89130423|NCT04203212||Endometriosis Group|20 premenopausal women with surgically verified endometriosis who will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration.
89130424|NCT04203212||Control Group|20 age- and BMI-matched premenopausal, health women who will receive no treatment and be monitored for 6 months.
89130425|NCT04187066||Obese|severe obesity
89130426|NCT04187066||Control|Control group with normal weight
89130427|NCT04789538||Monofocal IOL|
89130428|NCT04235348||BELIEVE|Consists of subjects referred to a colonoscopy between June 1, 2017, and December 1, 2019, in the hospital of Southern Denmark
89130429|NCT04484168|Active Comparator|Terminal Interruption of the Reflux Source (TIRS|These patients will have foam sclerotherapy of the veins in the immediate vicinity of their venous ulcer and thereafter be managed in compression bandaging and followed up fro 6 months or until the ulcer has healed
89130430|NCT04484168|Active Comparator|Axial Ablation|These patients will undergo endovenous ablation of the great or small saphenous veins, or other large superficial veins exhibiting significant reflux
89130431|NCT00637910|Experimental|Erlotinib Arm|
89130432|NCT00637910|Active Comparator|Docetaxel Arm|
89130433|NCT03408236|Experimental|Botulax|Single dose
89130434|NCT03408236|Active Comparator|Botox|Single dose
89130435|NCT04155320|Active Comparator|Group A|Subjects are encouraged to disclose their HIV status to their partner(s) with or without a counselor present (Options 1 & 2).
89130436|NCT04155320|Experimental|Group B|Subjects may choose to notify their partners themselves, with or without a counselor present (Options 1 & 2), or choose to have one or more partners notified anonymously by project staff (Option 3).
89130437|NCT04202744||Water Polo Group|"Participants were active water polo players who train regularly with ages in between 10-30 years.~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
89130438|NCT04202744||Non-Water Polo Group|"Participants who do not engage in overhead sports with ages in between 10-30 years.~Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated."
89130439|NCT04202510|Active Comparator|iStent|iStent Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
89130440|NCT04202510|Active Comparator|iStent Inject|iStent Inject Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
89130441|NCT04202510|Active Comparator|Hydrus|Hydrus Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
89130442|NCT04202666|No Intervention|not convex skin barrier|no intervention
89130443|NCT04202666|Experimental|convex skin barrier|intervention
89130444|NCT04473014||Positive Mood|This group will be exposed to a positive mood induction prior to heat pain.
89130445|NCT04473014||Negative Mood|This group will be exposed to a negative mood induction prior to heat pain.
89130446|NCT04473014||Neutral Mood|This group will be exposed to a neutral mood induction prior to heat pain.
89130447|NCT04031690||patient-caregiver dyads|
89130448|NCT04354220||no shunt, no lung injury|ventilated newborns / infants / children with healthy lungs and without or corrected congenital heart disease and no intra-/extra-cardiac shunt
89130449|NCT04354220||mild lung injury|ventilated newborns / infants / children with mild lung injury (OI between 4 and 8)
89130450|NCT04354220||moderate-severe lung injury|ventilated newborns / infants / children with moderate or severe lung injury (OI above 8)
89130451|NCT04354220||shunt lesion|ventilated newborns / infants / children with cyanotic heart diseases and therefore existing intra-cardiac or extra- cardiac right-left shunt lesions
89130452|NCT04449536|Experimental|Mesna|Administration of a single oral dose of 400 mg, 800 mg, 1200 mg or 1600 mg
89130453|NCT03960554|Active Comparator|Active drug|Denosumab 60 mg subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
89130454|NCT03960554|Placebo Comparator|Placebo|Placebo subcutaneous injection every 6 months for 12 months (i.e., 2 injections)
89130455|NCT00911768|Experimental|Korean Red Ginseng group|The brand name of experimental drug is 'Capsule of Korean Red Ginseng Powder'. It consists of the powder of steamed root of Panax ginseng made by Korean Ginseng Corp.
89130456|NCT00911768|Placebo Comparator|Corn-starch powder with ginseng flavor|The placebo of this study is corn-starch powder with Korean Red Ginseng flavor. It has the same shape, color and flavor like experimental drug.
89130457|NCT04131374|Experimental|Virtual Reality Intervention|Virtual Reality Intervention: Each Person Living with Dementia-caregiver dyad will receive 10 weekly sessions of tailored reminiscence therapy delivered via virtual reality. Each session will last for a period of 15-30 minutes.
89130458|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis
89130459|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis
89130460|NCT02377622|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis
89130461|NCT02377622|Active Comparator|FX CorDiax 800 dialyzer|FX CorDiax 800 dialyzer in high volume hemodiafiltration
89130462|NCT03038984|Experimental|Every 3 months|screening every 3rd month: (home monitoring: FC and DA)
89130463|NCT03038984|Active Comparator|On demand|screening On demand: (home monitoring: FC and DA)
89130464|NCT03753932|Experimental|Intervention|Dentures (fixed oral prosthesis) compared with standard treatment (removable oral prosthesis).
89130465|NCT04084106|Experimental|phenoximethylpenicillin|phenoximethylpenicillin, tablet, 1 g 3 times daily for 5 days.
89130466|NCT04084106|Active Comparator|amoxicillin|amoxicillin, tablet, 500 mg 3 times daily for 5 days.
89130467|NCT04084106|Active Comparator|amoxicillin-clavulanic acid|amoxicillin-clavulanic acid tablet, 500/125 mg 3 times daily for 5 days.
89130468|NCT04084106|No Intervention|No intervention|No intervention
89130469|NCT03750110|Active Comparator|Usual Care|Smoking Cessation NICE PH48 Guidelines
89130470|NCT03750110|Active Comparator|Intervention|Smoking Cessation NICE PH48 Guidelines plus personalised feedback from Lung Scan
89130471|NCT05580302||Laryngeal Dystonia|"The study will be performed on 10-15 (maximal 20) subjects with diagnosed laryngeal dystonia who meet the exclusion/ inclusion criteria.~Inclusion criteria: adults (18-65 years old) who have confirmed diagnosis of laryngeal dystonia, no implanted metals in body (e.g. pacemaker, metal prosthesis in skull and oral cavity).~Exclusion criteria: pregnancy, other neurological disorders, psychiatric disorders, epilepsy or history of previous epilepsy attack, using of brain affecting pharmaceuticals, traumatic, tumor, infectious, metabolic brain lesions, heart conditions (15 ).~The composition of the group is represented is both gender, various age gap, and different height.~Before the beginning of testing, all subjects with a confirmed diagnosis of laryngeal dystonia will be once again evaluated by a specialist otorhinolaryngologist at the University Hospital of Split. Medical documentation of the examination will be available for further analysis."
89130472|NCT05580302||Healthy subjects|"The study will be performed on 20 healthy volunteering subjects who meet the exclusion/ inclusion criteria.~Inclusion criteria: healthy adults (18-65 years old), no implanted metals in body (e.g. pacemaker, metal prosthesis in the skull and oral cavity) Exclusion criteria: pregnancy, neurological disorders, psychiatric disorders, epilepsy or history of previous epilepsy attack, using of the brain affecting pharmaceuticals, traumatic, tumor, infectious, metabolic brain lesions, heart conditions.~The composition of the group is represented is both gender, various age gap, and different height."
89130473|NCT02973542|Experimental|ethosuximide|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
89130474|NCT02973542|Placebo Comparator|placebo|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
89130475|NCT02973386|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
89130476|NCT02973386|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
89130477|NCT00632450||1|
89130478|NCT05576714||encephalopathy/encephalitis|Children will be classified as the following four diagnoses: 1. Encephalopathy (MERS, ANEC, ASED); 2. Acute encephalitis; 3. ADEM; 4. Fulminant cerebral edema. The classification will be adjudicated and discussed by neurology and critical care experts on the NTUH and CGMH study team (W.T.L, J.J.L, and K.L.L.)
89130479|NCT05576714||MIS-C|The following 6 criteria for MIS-C have to be met: age 0 to 19 years, fever for ≥3 days, clinical signs of multisystem involvement (at least 2 systems), elevated markers of inflammation (e.g., CRP, procalcitonin or ferritin), evidence of SARS-CoV-2 infection and no other obvious microbial cause of inflammation.
89130480|NCT05576714||control group|Age and gender matched healthy control children or mild COVID-19 cases without MIS-C will be also included for further comparison
89130481|NCT00632528|Experimental|1|Administration of MEOPA gaz during postoperative physical therapy
89130482|NCT00632528|Placebo Comparator|2|Administration of medical air during postoperative physical therapy
89130483|NCT04019132||Older adults|Older adults aged >65 years
89130484|NCT04019132||Young group|Younger adults between the age of 20 and 40 years
89130485|NCT04019132||Middle-aged group 1|Adults between the age of 40 and 55 years
89130486|NCT04019132||Middle-aged group 2|Adults between the age of 55 and 65 years
88802489|NCT00610558|Experimental|Arm 1: Juvenile Myoclonic Epilepsy|Juvenile Myoclonic Epilepsy group of subjects will participate for imaging assessment
89130487|NCT00632372||HeartPOD™ System with Cardiac Resynchronization Therapy|All patients will receive both a HeartPod device and a CRT-D device.
89130488|NCT04230200||Healthy cohort|People who received routine physical examination including blood test, and after 3 year follow-up, have not been diagnosed as any kind of malignant tumor.
89130489|NCT04230200||Malignancy Cohort|People who were diagnosed as one of the following malignant disease: breast cancer, lung cancer, gastric cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and cervical cancer
89130490|NCT00909428|Experimental|Solifenacin Succinate|The intervention for this study is 10mg daily solifenacin. Patients with overactive bladder syndrome will take this study drug for 30 days.
89130491|NCT03718130|Experimental|Group 1: 0.6 mg HTNV - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
89130492|NCT03718130|Experimental|Group 2: 3.0 mg HTNV - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
89130493|NCT03718130|Experimental|Group 3: 0.6 mg PUUV - Intradermal (ID)|0.1 mL 6.0 mg/mL PUUV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
89130494|NCT03718130|Experimental|Group 4: 3.0 mg PUUV - Intramuscular (IM)|0.5 mL 6.0 mg/mL PUUV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
89130495|NCT03718130|Experimental|Group 5: 1.2 mg HTNV/PUUV (0.6 mg each) - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 6.0 mg/mL PUUV DNA (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
89130496|NCT03718130|Experimental|Group 6: 6.0 mg HTNV/PUUV (3.0 mg each) - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 6.0 mg/mL PUUV DNA (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
89130497|NCT04756856|Experimental|Muscle-target oral nutritional supplementation|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D
89130498|NCT02801084|Experimental|Float|One arm only: restricted environmental stimulation
89130499|NCT00908960|Experimental|High TFMP: Enoxaparin|Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).Only patients with high TFMP status at baseline were randomized to treatment or observation.
89130500|NCT00908960|No Intervention|High TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.
89130501|NCT00908960|No Intervention|Low TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.
89130502|NCT03933020|Experimental|Exercise Group|
89130503|NCT03933020|Active Comparator|Control Group|
89130504|NCT03682796|Experimental|Escalation|Estimated to be <31 subjects across multiple centers
89130505|NCT03682796|Experimental|Expansion|Estimated to be <121 subjects across multiple centers
89130506|NCT03680066|Experimental|Foods with traces|Oral food challenge with foods with traces
89130507|NCT03449732|Experimental|PDR measurement group A|Two measurements of PDR perioperatively before and after opioid administration in toddlers (28 days until 23 months)
89130508|NCT03449732|Experimental|PDR measurement group B|Two measurements of PDR perioperatively before and after opioid administration in children (2 until 11 years)
89130509|NCT03449732|Experimental|PDR measurement group C|Two measurements of PDR perioperatively before and after opioid administration in adolescents (12 until 18 years)
89130510|NCT05332106|Experimental|Estradiol Valerate and Dienogest Test Product.|Participants will receive one tablet of the test formulation containing Estradiol Valerate and Dienogest 2 mg/ 2 mg.The tablet will be taken with water and in a fasting condition.
89130511|NCT05332106|Active Comparator|Estradiol Valerate and Dienogest Referent Product|Participants will receive one tablet of the marketed reference containing Estradiol Valerate and Dienogest 2 mg/ 2 mg. The tablet will be taken with water and in a fasting condition.
89130512|NCT05333198|Other|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
89234059|NCT00363298|Sham Comparator|Sham comparison|caffeine in capsules identical to those containing d-amphetamine, with 200 mg of caffeine in Bottle A capsules, and 100 mg of caffeine in Bottle B capsules, dose was 1 capsule from Bottle A and 1 capsule from Bottle B each morning
89234060|NCT05261412|Active Comparator|Standard Consent (Control)|Standard consent (written patient information leaflet (PIL) + verbal discussion with the responsible surgeon) for EVTA followed by signing of consent.
89234061|NCT05261412|Experimental|Digital health education tool (dHET)|dHET for EVTA + verbal discussion with the responsible surgeon followed by signing of consent.
88802490|NCT00610558|Experimental|Arm 2: Frontal Lobe Epilepsy|Frontal Lobe Epilepsy group of subjects will participate for imaging assessment
89130513|NCT05333198|Active Comparator|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
89130514|NCT05332028|Experimental|Group 1: Patients undergoing paravertebral block|After cleaning the area with antiseptic solution, the sterilized linear USG probe (Esaote MyLab30®, CA631 high-frequency probe, United Kingdom) was covered. The flat probe was placed between two transverse processes on the paramedian plane; transverse processes, superior costotransverse ligament and pleura were consecutively visualized. The linear ultrasound probe was fixed to the T3-T4 vertebra level. The skin and subcutaneous tissue were anaesthetized with 2% lidocaine, then 22 gauge 100 mm needle (Stimuplex ®; B Braun, Melsungen, Germany) was led in a cranial-cephalic direction to the paravertebral gap. Trapezius, rhomboid, erector spinae muscles were crossed by seeing the tip of the needle. Transverse processes were reached and the intercostal muscles were passed. When the needle reached the paravertebral level, a 20 mL of 0.25% bupivacaine was applied as a single administration.
89130515|NCT05332028|Active Comparator|Group 2: Patients undergoing Mid-Point Transverse Process Pleura (MTP) block|After cleaning the area with antiseptic solution, the sterilized linear USG probe (Esaote MyLab30®, CA631 high-frequency probe, United Kingdom) was covered. The flat probe was placed between two transverse processes on the paramedian plane; transverse processes, superior costotransverse ligament and pleura were consecutively visualized. The linear ultrasound probe was fixed to the T3-T4 vertebra level. The skin and subcutaneous tissue were anaesthetized with 2% lidocaine, then 22 gauge 100 mm needle (Stimuplex ®; B Braun, Melsungen, Germany) was led in a cranial-cephalic direction to the paravertebral gap. Trapezius, rhomboid, erector spinae muscles were crossed by seeing the tip of the needle. Transverse processes were reached and the intercostal muscles were passed. When the needle reached the midpoint level between the transverse process and pleura, a 20 mL of 0.25% bupivacaine was applied as a single administration.
89130516|NCT00650767|Experimental|ARRY-438162 (Schedule 1)|
89130517|NCT00650767|Experimental|ARRY-438162 (Schedule 2)|
89130518|NCT00650767|Experimental|ARRY-438162 (Schedule 3)|
89130519|NCT00650767|Placebo Comparator|Placebo|
89130520|NCT02552095|Other|Triathlon PKR|Patient who receives the Triathlon.
89130521|NCT02552173||stem anteversion|intraoperative surgeon's estimation and postopertive CT sacn were taken to measure stem anteversion
89130522|NCT00818077||Metformin, Type 2 Diabetes|
89130523|NCT00812227|Experimental|Psychodynamic psychotherapy|
89130524|NCT00816517|Experimental|botulinum toxin|injection of botulinum toxin type A
89130525|NCT00973349|Experimental|3.75_(50)MF59|50% of MF59 with 3.75 µg A/H1N1 antigen
89130526|NCT00973349|Experimental|7.5 w/o MF59|0% of MF59 with 7.5 µg A/H1N1 antigen
89130527|NCT00973349|Experimental|7.5_(50)MF59|50% of MF59 with 7.5 µg A/H1N1 antigen
89130528|NCT00973349|Experimental|7.5_(100)MF59|100% of MF59 with 7.5 µg A/H1N1 antigen
89130529|NCT00973349|Experimental|15 w/o MF59|0% of MF59 with 15 µg A/H1N1 antigen
89130530|NCT00973349|Experimental|15_(50)MF59|50% of MF59 with 15 µg A/H1N1 antigen
89130531|NCT00973349|Experimental|15_(100)MF59|100% of MF59 with 15 µg A/H1N1 antigen
89130532|NCT00973349|Experimental|30 w/o MF59|0% of MF59 with 30 µg A/H1N1 antigen
89130533|NCT00629603|Experimental|cytokine polymorphisms, HCV infection|Relate the fibrosis cytokine gene polymorphisms with disease severity of HCV-related chronic liver disease
89130534|NCT04288739||Acute Myeloid Leukemia (AML) group|"patients who are diagnosed as Acute Myeloid Leukemia (AML) based on peripheral blood, bone marrow, immunophenotyping and who fulfill the WHO 2016 criteria.~Complete blood count (CBC), bone marrow aspirate, flow cytometric immunophenotyping, cytogenetic analysis and fluorescence in situ hybridization (FISH) for XIST gene will be performed for all AML patients in the study."
89130535|NCT04286945|Other|SENSORY EXOTROPIA PATIENTS WITH LARGE ANGLES .|Patients with monocular low vision or loss of vision due to congenital or acquired cause with exodeviation of the poorly seeing eye ≥ 50PD, were included in the study.
89130536|NCT00643201|Active Comparator|Apixaban|apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
89130537|NCT00643201|Experimental|Enoxaparin + Warfarin|Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
89130538|NCT00643123|Experimental|Allopurinol|Subjects will be randomized to allopurinol at a fixed dose of 300 mg/day for the first week and then 600mg/day while continuing their current medications during the 7-week study. A battery of assessments will be administered at baseline and weeks 1, 2, 4, 6 after baseline. At each assessment, subjects will also be asked about side effects including potential side effects of allopurinol. Side effects will be assessed by the Treatment Emergent Side Effects Scale. Serum levels of lithium, valproic acid, carbamazepine, atypical antipsychotics or atypical antipsychotic metabolite, uric acid blood levels will be drawn at screen and at week 6 after baseline. Subjects taking only lithium, valproic acid, and/or carbamazepine will also have their serum levels drawn at week 2.
89130539|NCT00643123|Placebo Comparator|Placebo|Subjects will be randomized to placebo and will follow the same protocol as the allopurinol group.
89130540|NCT00816673|Placebo Comparator|placebo|
89130541|NCT00816673|Experimental|Circadin|
89130542|NCT00818155|Experimental|desvenlafaxine succinate SR|desvenlafaxine succinate SR
89130543|NCT00818155|Placebo Comparator|Placebo|
89130544|NCT00968981|Experimental|A|
89130545|NCT00968981|Experimental|B|
89130546|NCT00968981|Experimental|C|
89130547|NCT04288817|Active Comparator|Cryotherapy and intralesional tuberculin PPD|Efficacy of cryotherapy combined with intralesional tuberculin purified protein in treatment of multiple common warts
89130548|NCT04288817|Active Comparator|Intralesional tuberculin PPD|Efficacy of Intralesional tuberculin purified protein deravative monotherapy in the treatment of multiple common warts
89130549|NCT02863133|Experimental|Easyx Liquid Embolic|embolization of intracranial malformations and fistulas and brain tumours with Easyx Liquid Embolic
89130550|NCT00641719|Experimental|Duloxetine 40 mg|Duloxetine 40 milligrams (mg) once daily (QD), orally (PO), 1 year
89130551|NCT00641719|Experimental|Duloxetine 60 mg|Duloxetine 60 mg QD, PO, 1 year
89130552|NCT02863367|Experimental|Treatment group|Apatinib：500 mg，po，qd, d1-14, every 3 week Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
89130553|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 alone|
89130554|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|
89130555|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|
89130556|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|
89130557|NCT00648895|Active Comparator|1|Nebivolol
89130558|NCT00648895|Active Comparator|2|Metoprolol ER (TM)
89130559|NCT00812539|Experimental|"Diabetes Connected Health Tool Deluxe"|Subjects enrolled into the intervention arm will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal, where they can view their glucose readings and detailed graphical representation of their blood glucose levels over time, read educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to these subjects' information on the web portal).
89130560|NCT00812539|Active Comparator|"Diabetes Connected Health Tool Basic"|Control group will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal. where they can view their glucose readings in tabular form. Their physicians will not have access to this information.
89130561|NCT00818233||Observation|Variability will be assessed between each examiner.
89130562|NCT00812617|Experimental|Mineral water 1|
89130563|NCT00812617|Experimental|Mineral water 2|
89130564|NCT00975221|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally BID and were eligible for a dose titration once every 3 weeks during the 12-week dose-titration phase based on corrected total serum calcium concentration and safety assessments. Participants continued to receive cinacalcet for another 16 weeks during the efficacy assessment phase and then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
89130565|NCT00975221|Placebo Comparator|Placebo|Participants received placebo orally twice a day (BID) for 12 weeks during the dose titration phase and for another 16 weeks during the efficacy assessment phase. Participants then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
89130566|NCT02864693|Active Comparator|Configuration A (Kinnex)|
89130567|NCT02864693|Active Comparator|Configuration B (Pacifica LP)|
89130568|NCT04204421|Experimental|Experience Sampling Method (ESM)|Both patients with functional dyspepsia and healthy controls will be asked to fill out ESM questionnaires during 1 week. Moreover, at the end of this week, usual questionnaires for complaints assessment will be filled out.
89130569|NCT02863679|Experimental|Tetracaine hydrochloride gel group|Patients in getracaine hydrochloride gel group were covered with a gauze with tetracaine hydrochloride gel on the cervix after hysteroscopic insertion of utrauterine balloon stent.
89130570|NCT02863679|Placebo Comparator|Control group|Patients in control group were covered with a gauze with saline on the cervix after hysteroscopic insertion of utrauterine balloon stent.
89130571|NCT00972179|Experimental|Tezepelumab|Tezepelumab will be administered subcutaneously (SC) at doses from 35 mg once every 28 days (Q28D) (cohort 1) up to 210 mg once every 7 days (Q7D) (cohort 5) and an intravenous (IV) dose cohort of 700 mg Q28D (cohort 6).
89130572|NCT00972179|Placebo Comparator|Placebo|Two participants in each cohort (cohorts 1 to 6) will receive matching placebo administered subcutaneously (cohorts 1-5) or intravenously (cohort 6), matching the treatment regiment of tezepelumab.
89130573|NCT02864771||1|Derivation cohort (n=474); may be analyzed separately or combined with cohort #2 to enhance statistical power
89130574|NCT02864771||2|Validation cohort (patient #475 and after); may be combined with cohort #1 to enhance statistical power
89130575|NCT04288505|Experimental|single arm|
89130576|NCT00906698|Experimental|BIBW 2992 and vinorelbine i.v|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine i.v.
89130577|NCT00906698|Experimental|BIBW 2992 and vinorelbine per os|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine per os.
89130578|NCT00972023|Experimental|DHEA, surgical resection|Day-14 (approx. 2 wks prior to surgery): begin a 2 week course of DHEA; Day-7 (approx. 1 wk after starting treatment): answer question about pill diary; Day 0 (approx. 2 wks after starting treatment, within 48 hours prior to surgery;
89130579|NCT00971945|Experimental|Paclitaxel|
89130580|NCT03672500|Active Comparator|Bupivacaine arm|The edges of the 2PT/Epi will be infiltrated with 10ml of Bupivacaine 0.5%+Epinephrine 50mcg prior to suture placement.
89130581|NCT03672500|Sham Comparator|Control arm|Sham injection will be done using a syringe filled with 10ml of NaCl 0.9%, but the fluid will not be injected to the edges of the laceration but discarded. The sham injection will last no less than 10 seconds.
89130582|NCT00971867|Experimental|Paclitaxel|
89130583|NCT04744376||Major GIS Surgery|"The cohort includes all the patients who undergone major gastrointestinal (GIS) surgery.~Major GIS surgery includes:~Gastric surgery~Duodenal surgery~Pancreatic surgery~Hepatobiliary surgery~Colonic surgery~Rectal surgery"
89130584|NCT04202432||Coronary Artery Bypass Surgery patients|Patients undergoing coronary artery bypass surgery (on-pump / off-pump) measured perioperatively and postoperatively.
89130585|NCT03336164|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage sold in the same campus university restaurant after the control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
89130586|NCT05331872|Experimental|human umbilical cord-derived mesenchymal stem cell transplantation for patients with liver cirrhosis|"Umbilical cords from healthy donor are processed with 24 hours after vaginal delivery.~The cords are delivered in a sterilized jar the laboratory to process. After washing in PBS to remove any contaminating blood, the cord is cut into small pieces. The pieces are minced and digested by enzyme. The UC-MSCs is cultured and expanded using commercially available serum-free and xeno-free medium at 37°C in a humidified atmosphere with 5% CO2. The UC-MSCs is suspended in 15 ml of saline buffer"
89130587|NCT00971321|Experimental|GSK 2340272A F1 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 1 (F1) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (<) 12 months at study entry.
89130588|NCT00971321|Experimental|GSK 2340272A F2 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 2 (F2) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (<) 12 months at study entry.
89130589|NCT03200054|No Intervention|Clinic-based Care|Clinic-based care is the current standard of care and is defined as referral of women on antiretroviral therapy (ART) to general primary care adult ART services.
89130590|NCT03200054|Experimental|Adherence Club Care|Adherence club care involves referral of women on ART to community-based ART services in the form of adherence clubs, which are led by community health workers and supported by ART clinic nurses.
89130591|NCT00648739|Experimental|Samalizumab|All doses of samalizumab were individualized based on the participant's body surface area in mg/m^2 based on screening height and weight. Participants were assigned to a dose cohort, ranging from 50 to 600 mg/m^2, and received a single IV dose of samalizumab. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose. If no participants enrolled into a cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. If any 1 of the initial 3 participants in the cohort experienced a DLT, the cohort was expanded to at least 6 participants. Then, if less than one third of participants within the cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. Dose cohorts were enrolled sequentially.
89130592|NCT00812695|No Intervention|1|
89130593|NCT00812695|Active Comparator|2|CPAP
89130594|NCT00812773|Experimental|3 day repeat dose|
89130595|NCT02552017|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
89130596|NCT02552017|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
89130597|NCT00816985|Experimental|Liposuction + Questionnaires|Liposuction, followed by Quality of Life Questionnaires and extended follow-up period.
89130598|NCT00817141||Without urinary catheter|
89130599|NCT00818311|Other|5|
89130600|NCT00818467|Experimental|Tanning spray|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a group of normal subjects with skin types I and II while using multiple applications of 3% DHA for five weeks.
89130601|NCT00818467|Active Comparator|UVB|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a control group of normal subjects with skin types I and II who are not using 3% DHA applications.
89130602|NCT00648037|Experimental|Rituximab|Patients following a T cell depleted HLA-mis-matched related or unrelated hematopoietic stem cell transplant (HSCT) will be treated with monthly Rituximab.
89130603|NCT00813007||Questionnaire|Radical trachelectomy outcomes for cervical cancer
89130604|NCT00817297|Other|V60 Mask, Then Conventional Mask|Experimental V60 Mask Ventilator for treating adult patients with COPD, then Comparator Conventional Mask Ventilator for treating adult patients with COPD
89130605|NCT00817297|Other|Conventional Mask, Then V60 Mask|Comparator Conventional Mask noninvasive Ventilator for treating adult patients with COPD, then Experimental V60 Mask noninvasive Ventilator for treating adult patients with COPD.
89130606|NCT00817375|Experimental|SSRI treated group|SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline
89130607|NCT00817375|Active Comparator|non-SSRI treated group|non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
89130608|NCT00818545|Placebo Comparator|2|
89130609|NCT00818545|Experimental|hydroxypropyltetrahydropyrantriol|
89130610|NCT00818701|Placebo Comparator|1: low dose BNP alone|low dose BNP with placebo
89130611|NCT00818701|Active Comparator|2: low dose BNP + PDEVI|low dose BNpo + PDEVI
89130612|NCT00817453||1|Clinically diagnosed Early iPD
89130613|NCT00817453||2|Age/gender matched controls without neurodegenerative diagnosis
89130614|NCT00817453||atypical or late Parkinsonian Syndromes|Includes subjects facing or having undergone DBS, diagnoses of MSA, PSP or other atypical syndromes.
89130615|NCT00813085|Other|Electronic disease management decision support|An electronic Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS).
89130616|NCT00813085|No Intervention|2|Usual care by Family Physician
89130617|NCT00813241|Active Comparator|A|A single dose of 200 mg celecoxib capsule administered as 1 x 200 mg celecoxib capsule, (Reference Formulation)
89130618|NCT00813241|Experimental|B|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet formulation containing granule type A1
89130619|NCT00813241|Experimental|C|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type B2
89130620|NCT00813241|Experimental|D|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type C1
89130621|NCT00818857|Active Comparator|1|Early intervention.
89130622|NCT00818857|Active Comparator|2|Delayed intervention
89130623|NCT00813397|Experimental|Sepraspray|Receive Sepraspray
89130624|NCT00813397|No Intervention|Control|No Treatment, No Placebo
89130625|NCT00627523|Experimental|Active|The active treatment arm
89130626|NCT00627523|Experimental|Control|Control
89130627|NCT00640393|Active Comparator|Part 1 - Etanercept|All participants received etanercept 50 mg twice a week for 12 weeks.
89234062|NCT05254548|Experimental|ACT-539313 with or without a standard combination (probe substrate)|Treatment arm has 4 in-house treatment periods. In Treatment Period 1, participants will receive a single oral dose of the standardized combination (probe substrate: containing flurbiprofen [50 mg], midazolam [2 mg] and omeprazole 20 [mg]) on Day 1. Participants will be discharged from the study site on Day 2 and will be re-admitted on Day 7. In Treatment Period 2 (morning of Day 8) a first oral dose of 100 mg ACT-539313 will be administered. One hour later a single oral dose of the probe substrate will be administered. In the evening of Day 8, a second oral dose of 100 mg ACT-539313 will be administered. During Treatment Period 3 (morning of Day 9, ending on the evening of Day 14) oral doses of 100 mg ACT-539313 will be administered in the morning and evening. In Treatment Period 4 (Day 15), a single oral dose of 100 mg ACT-539313 together with the probe substrate will be administered. The participants will receive the last dose of ACT-539313 in the evening of Day 15.
89234063|NCT00363142|Active Comparator|FPV/r200|Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
89234064|NCT00363142|Experimental|FPV/r100|Fosamprenavir/ritonavir 1400/100mg QD
89234065|NCT05246982|Experimental|Arm A|HER2 negative and PD-L1 CPS≥5, as first-line therapy
89234066|NCT05246982|Experimental|Arm B|As third-line or above therapy
89234067|NCT01027221|No Intervention|0|primarily resectable pancreatic cancer patients
89234068|NCT01027221|Active Comparator|0,5 Gy|neoadjuvant Radiation of 0,5 Gy two days before resection
89234069|NCT01027221|Active Comparator|2 Gy|neoadjuvant Radiation of 2 Gy 2 days before resection
89234070|NCT01027221|Active Comparator|5 Gy|neoadjuvant Radiation of 5 Gy 2 days before resection
89234071|NCT04002492|Experimental|Addition of bodyweight training|All participants in this study fall into this non randomized single group. These participants will complete a total of 12 bodyweight training sessions over a six to eight week time period. Participants will attend one session per week at Holy Name Medical Center's Physical Therapy Center and will train for one session at their home or chosen location with the aid of a video guide.
89234072|NCT00454857||Patients with ITP|Participants with ITP and currently treated for ITP were followed prospectively for a period of 12 months.
89234073|NCT05243004|Experimental|Phone Nurse Consultation|Patients will benefit, in addition to the usual care, including a reminder by the secretary of the PORU the day before the operation, a phone call from nurse no later than 72 hours before surgery to explain and remind them of the instructions for preoperative preparation and answer any questions they may have.
89234074|NCT05243004|No Intervention|Standard care|Patients in this group will follow the usual preparation schedule including a reminder by the secretary of the PORU the day before the operation.
89234075|NCT02534818|Experimental|Group 1|lower fluorescein sodium dosage 0.02ml/kg for gastric intestinal metapalsia
89234076|NCT02534818|Active Comparator|Group 2|conventional fluorescein sodium dosage 0.1ml/kg for gastric intestinal metapalsia
89234077|NCT04002024|Active Comparator|Placebo and Treatment Arm A|The patients in treatment arm A group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the right side of their face and placebo which is moisturizer without those active ingredients on the left side of their face.
89234078|NCT04002024|Active Comparator|Treatment and Placebo Arm B|The patients in treatment arm B group will be received moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid on the left side of their face and placebo which is moisturizer without those active ingredients on the right side of their face.
89234079|NCT01027299|Active Comparator|Standard pacing|Standard pacing settings prescribed by the cardiac surgeon or intensivist after revascularisation.
89234080|NCT01027299|Active Comparator|BiVentricular pacing (BiV).|The group of patients receiving biventricular pacing after cardiac surgery.
89234081|NCT05355324||anemia|patients with anemia
89234082|NCT05355324||non-anemia|patients without anemia
89234083|NCT01028313|Experimental|1|Systemic Therapy
89234084|NCT04001712|Experimental|early caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate upon start of the respiratory support Caffeine citrate was given at a loading dose of 10 mg/kg and with a daily maintenance dose of 5 mg/kg until the patient was off respiratory support
89234085|NCT04001712|Active Comparator|late caffeine citrate group|preterm neonates who require respiratory support either nasal canula, continuous positive airway pressure (CPAP) or mechanical ventilation.were given caffeine citrate 6 hours before weaning of respiratory support
89234086|NCT05355246|Experimental|assisted sit-up exercises Group|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and a maximum of 10 repetitions, two times a day and two days a week.
89234087|NCT05355246|Active Comparator|swiss ball pikes exercises Group|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend their hips and try to pull their feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups.
89234088|NCT01028469|Experimental|Artelon MTP Spacer|Metatarsophalageal hemi-implant
89234089|NCT01027377|Experimental|A|Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
89234090|NCT01027377|Experimental|B|Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments
89234091|NCT00992160|Experimental|Active|Vestipitant 15mg once daily
89234092|NCT00992160|Placebo Comparator|Placebo|Placebo
89234093|NCT00379912|Experimental|Investigational Arm A|Azacitidine + Erythropoietin
89234094|NCT00379912|Experimental|Investigational Arm B|Azacitidine
89234095|NCT05239650|Experimental|A：1L treatment|HLX07 * 1000 mg+HLX10* 200mg +mFOLFOX6, IV, Q2W
89130628|NCT00640393|Active Comparator|Part 2 - Etanercept and nbUVB|Participants who did not reach a 90 percent reduction in psoriasis area and severity index (PASI-90) after 12 weeks and were randomized to the narrow band ultra violet B (nbUVB) group. They received nbUVB treatments three times a week and 50 mg Etanercept once per week.
89130629|NCT00640393|Active Comparator|Part 2 - Etanercept|Participants who did not reach PASI-90 after 12 weeks and were randomized to the Etanercept group. They received 50 mg Etanercept once per a week.
89130630|NCT00821353|Active Comparator|RFCA|
89130631|NCT00821353|Active Comparator|Drug|
89130632|NCT02550535|Experimental|Gene-modified WT1 TCR-transduced T cells|A single dose of bulk WT1 TCR-transduced T cells (≤ 2 x 107/kg) will be intravenously (i.v.) administered following protocol-specified lymphodepletive conditioning regimen. Additionally, daily IL-2 subcutaneous injections (1x106 units/m2 subcutaneously (s.c.)) will be administered for 5 days concomitantly to each subject, following infusion of the ATIMP.
89130633|NCT00907478|Experimental|Romiplostim|"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years.~The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L."
89130634|NCT05315024|Experimental|Repeat 0.5ml IM Quadrivalent IIV (IIV-IM)|Repeat 0.5ml IM Quadrivalent IIV (IIV-IM) (15micrograms haemagglutinin per vaccine strain)
89130635|NCT05315024|Experimental|0.1ml ID Quadrivalent IIV (IIV-ID)|0.1ml ID Quadrivalent IIV (IIV-ID) (3micrograms haemagglutinin per vaccine strain)
89130636|NCT05315024|Experimental|0.1ml ID Quadrivalent IIV|0.1ml ID Quadrivalent IIV (3micrograms haemagglutinin antigen per vaccine strain) + 5% imiquimod cream (IIV-Q-ID)
89130637|NCT00627445|Experimental|BIAsp 50-50-30|Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin
89130638|NCT00627445|Active Comparator|BIAsp 30-30|Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin
89130639|NCT00905840|Active Comparator|Titanium Zircon implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
89130640|NCT00905840|Placebo Comparator|Titanium Grade IV implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
89130641|NCT00821665|Experimental|Sucrose|Sucrose
89130642|NCT00821665|Placebo Comparator|Water|Water
89130643|NCT02030990|Experimental|Mitomycin-C; 3 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 3 week fluorometholone 1% topical steroid taper.
89130644|NCT02030990|Experimental|Mitomycin-C; 1 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 1 week of fluorometholone 1% topical steroid.
89130645|NCT02030990|Active Comparator|No mitomycin-C; 8 week FML steroid taper|No mitomycin-C will be administered during the procedure. Instead a sham application of salt solution will be given for 15 seconds. The patient will take 8 weeks of topical fluorometholone 1% topical steroid drop taper.
89130646|NCT00821743|Other|1|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
89130647|NCT05332964||stroke (right)|stroke patient with lesions at right hemisphere
89130648|NCT05332964||stroke (left)|stroke patient with lesions at left hemisphere
89130649|NCT05332964||control|age-matched group for the stroke patients
89130652|NCT00822055|Active Comparator|1|brimonidine/timolol Fixed-combination monotherapy
89130653|NCT00822055|Active Comparator|2|dorzolamide/timolol fixed-combination monotherapy
89130654|NCT00822055|Active Comparator|3|prostaglandin analogue + brimonidine/timolol fixed combination
89130655|NCT00822055|Active Comparator|4|prostaglandin analogue + dorzolamide/timolol fixed combination
89130656|NCT00822133|Active Comparator|lodocaine|lidocaine 5% cream will be put on the skin
89130657|NCT00822133|Experimental|ketamine|ketamine 5% will be put on the skin
89234096|NCT05239650|Experimental|B：≥2L treatment|HLX07 *1000 mg monotherapy,IV, Q2W
89130658|NCT00822133|Placebo Comparator|placebo|non-active cream will be put on the skin
89130659|NCT00822211|Experimental|Vildagliptin Dose 1|
89130660|NCT00822211|Experimental|Vildagliptin Dose 2|
89130661|NCT00822211|Placebo Comparator|Placebo|
89130662|NCT00822367|Experimental|Nutritional suplements|
89130663|NCT05295602||Group|A CT scan of both legs will be made in patient scheduled for a primary knee arthroplasty. No other additional intervention will be made apart from those already routinely used for the operation.
89130664|NCT01977560|Other|Standard Care|Participants randomized to this arm will receive dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines.
89130665|NCT01977560|Experimental|Intensive Lifestyle intervention|Participants randomized to this arm will be participate in weekly dietary and behavioral education session in addition to four 60-min supervised exercise training sessions per week for 8 months. All dietary and- behavioral education and exercise training sessions will be conducted at the worksite.
89130666|NCT00626821|Experimental|1|
89130667|NCT00826033||Therapy monitoring|
89130668|NCT05332886|Experimental|MetaHealth Group|It is intervention group that aims to provide youth with healthy lifestyle behaviors by using metaverse technology.
89130669|NCT05332886|Active Comparator|MobileHealth Group|It is comparator group that aims to provide youth with healthy lifestyle behaviors by using mobile application materials with digital health education will be given to the MobileHealth Group.
89130670|NCT03842930|Other|Platinum-fibered Microcoils (FPC)|Embolization using platinum fibred Coils (Cook Incorporated, Bloomington, IN, USA)
89130671|NCT03842930|Other|MVP® Vascular Plug|Embolization using MVP®-Plug (Medtronic Inc., Minneapolis, MI, USA).
89130672|NCT04018417|Experimental|Amphotericin B|The eye bank will add amphotericin B 0.255 μg/mL to the Optisol-GS donor cornea storage solution.
89130673|NCT04018417|No Intervention|Control|The donor cornea will be stored in Optisol-GS per the eye bank's standard procedure.
89130674|NCT03808220||post-surgical patients|post-surgical patients > 18 years
89130675|NCT03808220||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
89130676|NCT00826345|Experimental|Acupuncture/Moxibustion|Diagnostic Acupuncturists assessments will inform acupuncture/moxibustion treatment prescriptions for persons with HIV/AIDS experiencing distal peripheral neuropathy. This protocol is tailored specifically for the subject's unique diagnosis according to the symptoms being reported at each diagnostic acupuncture (DA) session.
89130677|NCT00826345|Placebo Comparator|Placebo Acupuncture / Moxibustion|Sham/placebo Arm: Points will be administered away from the classic/traditional true point location.
89130678|NCT01791920|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
89130679|NCT01791920|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A
89130680|NCT00826501|Active Comparator|1|Endoscopic cyst-gastrostomy with a neurolytic block along with oral/transdermal analgesic therapy
89130681|NCT00826501|Active Comparator|2|Surgical cyst-gastrostomy with neurolytic block and pain managed by only oral/transdermal analgesic
89130682|NCT00826579|Experimental|Colon cancer|Colon cancer patients of all stages
89130683|NCT03014024|Experimental|Low-Level Laser therapy|After inclusion in the study, patients will be treated with LLLT. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated from dorsal side of the wrist on the fracture area, and distal ulna area from the palmar side. Total 20 second on each side (3 points), with 3,6 J/cm2. the light from the laser is not visible to the eye, and will not give any perceptible stimulus. The x-ray will be used to find the fracture line.
89130684|NCT03014024|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, patients will be treated with placebo LLLT. This placebo laser is identical in appearance to the other super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated on the same areas, and have the same procedure and time. Since the light from the laser is invisible neither the participant nor the therapist will know whether the laser is a placebo.
89130685|NCT00826657|Placebo Comparator|placebo|Receive placebo (sugar pill) during the intervention. Received a 1000 mg vitamin B12 injection at the end of the study.
89130686|NCT00826657|Active Comparator|Vitamin B12|Received 500 micrograms vitamin B12 per day during the study Received a 1000 mg vitamin B12 injection at the start of the study
89130687|NCT03597776|Experimental|Lidocaine Group|Bolus of intravenous lidocaine of 2mg/kg over 5 mins will be given before skin incision.
89130688|NCT03597776|Placebo Comparator|Placebo Group|Normal Saline of 2mg/kg over 5 mins will be given as bolus before skin incision
89130689|NCT00625183|Experimental|Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy|Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends
89130690|NCT00826735|Experimental|Guided imagery|The experimental group received a relaxation focused guided imagery intervention to use through the remainder of pregnancy plus a physiologic guided imagery intervention during the third stage of labor. These interventions were scripted and prerecorded on CDs.
89130691|NCT03569072|Experimental|Dose escalated functionally adapted radiation therapy|This is a single arm study
89130692|NCT00826813|Experimental|stenting|The conventional esophageal stent or 125I radiation stent is placed in the patients with dysphagia who are enrolled to the study.
89130693|NCT02549443|Active Comparator|Insulin|hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
89130694|NCT02549443|Active Comparator|Insulin and amino acids|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.~Amino Acids (AA) in amounts to preserve normal AA"
89234097|NCT00379834|Active Comparator|Cosopt|Cosopt twice daily in both eyes
89130695|NCT02549443|Active Comparator|Insulin and hyperaminoacidemia|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.~AA in amounts to increase AA plasma concentrations to supra-normal levels (hyperaminoacidemia)"
89130696|NCT00904982|Other|1 Usual Care Group/Control|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant and can confirm when medication is taken correctly.
89130697|NCT00904982|Experimental|2Med-eMonitor/Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled.
89130698|NCT00904982|Experimental|3 Incentive Group/Lottery|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant. This group will also be entered into a daily lottery in which he/she can win money. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
89130699|NCT00904982|Experimental|4 Combined Group/Lottery and Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled. Participants in this group will also be entered into a daily lottery. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin medication as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
89130700|NCT00826969|Active Comparator|1|Ciclesonide 320µg
89130701|NCT00826969|Placebo Comparator|2|Placebo
89130702|NCT00822601|Experimental|1|
89130703|NCT00822601|Placebo Comparator|2|
89130704|NCT04044547|Experimental|LY03003|
89130705|NCT04044547|Placebo Comparator|Placebo|
89130706|NCT05332652|Experimental|Anodal tDCS stimulation to the ipsilesional M1|"Participant will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
89130707|NCT05332652|Experimental|Anodal tDCS to the contralesional premotor cortex|Participant will receive 1mA anodal tDCS to the contralesional premotor cortex. Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training.
89130708|NCT05332652|Sham Comparator|Sham tDCS|"Participant will receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.~Cathode will be used as reference electrode and placed over the supraorbital area contralateral to the anode. tDCS stimulation will be conducted daily for 20 sessions in consecutive days in the 4th month after stroke, with each session lasting for 20 minutes and combined with online occupational therapy training."
89130709|NCT05332652|No Intervention|Control group|Subjects who fulfill the inclusion criteria of Study 2 but refuse tDCS stimulation.
89130710|NCT05064787|Other|Single Arm Cohort Receiving Digital Health Coaching|All study participants will be enrolled in a 6-month digital health coaching program.
89130711|NCT00827047|Active Comparator|Total Hemihepatic Vascular Exclusion|Patients with HCC received Total Hemihepatic Vascular Exclusion in hepatectomy.
89130712|NCT00827047|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy.
89130713|NCT00827047|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
89130714|NCT05332184||Patients prior to aortic valve surgery|
89130715|NCT02880722||IBS patients|IBS according to Rome IV criteria.
89130716|NCT02880722||Healthy control group|Healthy volunteers without abdominal complaints fulfilling Rome IV criteria for IBS.
89130717|NCT02768948|Experimental|telmisartan|treatment with telmisartan at doses of 80 mg / day for 6 months
89130718|NCT02768948|Experimental|losartan|Losartan at a dose of 100 mg / d for 6 months.
89130719|NCT02761382|Experimental|Mindfulness-based treatment|"The mindfulness-based psychological treatment consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Mindfulness-based stress reduction (MBSR), Mindfulness-based cognitive therapy (MBCT) and Acceptance and commitment therapy (ACT). The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:~mindfulness-training (including meditation and yoga),~therapy based on ACT, and~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
89130720|NCT02761382|Experimental|Non-specific treatment|"The non-specific general psychological treatment is matched the mindfulness-based psychological treatment and consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Client-centered therapy. The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:~relaxation and physical training,~therapy based on the non-specific factors of psychological treatment which emphasize a focus on the relation and alliance between the therapist and the client and the therapist being a warm empathic, non-directive and unconditionally accepting support, and~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
89130721|NCT02761382|No Intervention|Waiting list control|Participants in this arm will be on the waiting list to participate in one of the two experimental treatments after a period of six months. Participants will receive medical treatment as usual in this period.
89130722|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 1.0 mg|Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.
89130723|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 2.5 mg|Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.
89130724|NCT00904748|Experimental|Test 1|
89130725|NCT00904748|Experimental|Test 2|
89130726|NCT00904748|Active Comparator|Reference|
89130727|NCT03864055||Pediatric Otogenic CSVT|Children with Otogenic Cerebral Sinus Vein Thrombosis (CSVT)
89130728|NCT02721758|Experimental|Brief Motivational Intervention|Single, 60-minute, manualized behavioural intervention designed to support cardiac rehabilitation enrollment, informed by principles of motivational interviewing
89130729|NCT02721758|No Intervention|Usual Care|Standard encouragement to enroll in cardiac rehabilitation, and meeting with a researcher to complete study questionnaires
89130730|NCT00574405|Active Comparator|1|MDI = 3-4+ insulin injections/day, using split-mix NPH insulin + regular insulin or Lantus + Novolog® (or Humalog®).
89130731|NCT00574405|Experimental|2|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
89130732|NCT00818935|Experimental|Low-Intermediate-Glycemic Index diets|
89130733|NCT00818935|Active Comparator|High GI diet|
89130734|NCT00971243|Experimental|MP-513 Lowest Dose and Metformin|
89130735|NCT00971243|Experimental|MP-513 Low Dose and Metformin|
89130736|NCT00971243|Experimental|MP-513 Medium Dose and Metformin|
89130737|NCT00971243|Experimental|MP-513 High Dose and Metformin|
89130738|NCT00971243|Placebo Comparator|Placebo and Metformin|
89130739|NCT04017169||No reflow phenomenon|"Those that during procedure experience no reflow phenomenon~To define no reflow requires:~• Angiographic evidence of reopening of occluded coronary artery and successful stent placement with no evidence of flow-limiting residual stenosis (<50%), dissection, vessel spasm, or thrombus burden~and~Angiographic documentation of a TIMI flow grade ≤II, or~A TIMI flow grade III with a myocardial perfusion grade 0 or I, at least 10 min after the end of PCI procedure."
89130740|NCT04017169||No NRP|Normal angiographic coronary flow/blush post patent culprit vessel.
89130741|NCT00822835|Active Comparator|ILV-095|6 SC single dose injections
89130742|NCT00822835|Placebo Comparator|Placebo|Placebo
89130743|NCT00822913|Experimental|Botulinum A toxin|Botulinum A toxin intravesical injection
89130744|NCT00827203|Experimental|Cohort|
89130745|NCT04400383|Experimental|AB011 Injection|AB011 Injection treatment. This phase 1 trial will include two stages, a single treatment stage and a Combo treatment stage.
89130746|NCT04381429|Active Comparator|Group 1: A-F-A-F|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.~All patients will test both insulin treatments (A and F) in alternating periods.~The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid).~Each treatment period will last 3 months."
89130747|NCT04381429|Active Comparator|Groupe 2: F-A-F-A|"The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study.~All patients will test both insulin treatments (A and F) in alternating periods.~The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP)."
89130748|NCT00568555|Experimental|Low Dose Naltrexone first|LDN first, then placebo.
89130749|NCT00568555|Placebo Comparator|Placebo - sugar pill first|Placebo first, then LDN.
89130750|NCT00819325|Experimental|Intensive glycemic control|Included routine use of pioglitazone (30 mg/d) for 6 months in addition to titration of their other oral hypoglycemic agents in order to get the HbA1c<6%.
89130751|NCT00819325|Active Comparator|conservative glycemic control|Included titration of oral hypoglycemic agents to get HbA1c<7% without the use of a thiazolidinedione.
89130752|NCT00904670|Experimental|Active|
89130753|NCT00904670|Placebo Comparator|Comparator|
89130754|NCT00827281|Experimental|1|DCS-augmented CBT for smoking cessation
89130755|NCT00827281|Placebo Comparator|2|Placebo-augmented CBT for smoking cessation
89130756|NCT00827437|Other|1|
89130757|NCT00827515|Experimental|One|
89130758|NCT00827515|Experimental|Two|
89130759|NCT00827515|Experimental|Three|
89130760|NCT00827515|Experimental|Four|
89130761|NCT02708654|Experimental|Intervention|Participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.(5) Research coordinators to remotely monitor weight gain thresholds and add alert into the participant's electronic health record for verified weight gain
89130762|NCT02708654|No Intervention|Control|Participants will receive usual care.
89130763|NCT00822991|Active Comparator|Group of CE-US|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
88802491|NCT00610558|Experimental|Arm 3: Normal Controls|Normal Controls, eligible subjects don't have Juvenile Myoclonic Epilepsy or Frontal Lobe Epilepsy will be placed in this group
88802492|NCT00380146|Experimental|SP plus artesunate|SP (Fansidar®, Roche South Africa) at a dose of 25/1.25mg/kg of sulfadoxine/pyrimethamine respectively on day 0 only, and artesunate (Arsumax®, Sanofi-Aventis, South Africa) at a dose of 4mg/kg on days 0, 1, and 2
88802493|NCT05476146|Experimental|Rerouting of track of high anal fistula|
88802494|NCT03985176||Aneurysmal SAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
88802495|NCT00379366|Active Comparator|1|14 Gy ionizing radiations
88802496|NCT00379366|No Intervention|2|
88802497|NCT00500890|Experimental|Carboplatin + Etoposide + Vincristine|Carboplatin 350 mg/m^2 by vein, Over 2 Hours x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
89130764|NCT00822991|Active Comparator|Group of B-mode US|screening by conventional B-mode US every 3-5 months
89130765|NCT05213156|Active Comparator|Patients without Dry Eye Disease|Control Group
89130766|NCT05213156|Experimental|Patients with Dry Eye Disease, except the severe Dry Eye Disease|non severe Dry Eye Disease
89130767|NCT05213156|Experimental|Patients with severe Dry Eye Disease|severe Dry Eye Disease
89234098|NCT04001322|Experimental|14 Intervention LGAs|Various target beneficiaries will receive broadcast, targeted and individualized SMS messages on immunization.
89234099|NCT04001322|Other|7 Control LGAs|This arm will not receive any SMS messages on immunization
88802498|NCT00500890|Experimental|Cyclophosphamide + Etoposide + Vincristine|Cyclophosphamide 1 g/m^2 by vein, Over 1 Hour x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
89130768|NCT00823147|Experimental|Pain Catastrophizing Induction Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress.~Subsequent blood draws occur per protocol time points:~25 minutes following IV placement (BASELINE)~15 minutes post catastrophizing induction (stress experiment)~90 minutes (1.5 hours) post-induction~150 minutes (2.5 hours) post-induction~210 minutes (3.5 hours) post-induction~270 minutes (4.5 hours) post-induction"
89130769|NCT00823147|No Intervention|Control Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them.~Blood draws and saliva samples gathered per protocol time points:~25 minutes following IV placement (BASELINE- T1)~25 minutes following baseline T2~115 minutes (1 hour 55 min) post baseline T3~175 minutes (2 hours 55 min) post baseline T4~235 minutes (3 hours 55 min) post baseline T5~295 minutes (4 hours 55 min) post baseline T6"
89130770|NCT00823225|Other|A: Standard therapy|
89130771|NCT00823225|Experimental|B: Urokinase|
89130772|NCT00823381|Experimental|Resveratrol|
89130773|NCT00823381|Placebo Comparator|Placebo|
89130774|NCT00823381|Active Comparator|Calorie Restriction|
89130775|NCT02850380|Other|spatial orientation in weightlessness|"subjects will be asked to flip a series of switches into the off position. On Earth, the off position corresponds to down in all three reference frames: the visual allocentric, the non-visual allocentric as well as the egocentric frames. We expect that flip direction will be dominated by visual allocentric cues when those are available, will be delayed and more variable when confirmatory gravitational cues are absent, and will be biased towards the egocentric reference when tactile cues are added"
89130776|NCT02850224|Experimental|Motivational interviewing to elicit PCO in pediatrics|"Providers will be randomized into a patient-centered outcomes (PCO) education course or standard of care. The PCO education course will educate and test providers on patient-centered outcomes of interest and appropriate methods to deliver PCO care.~Providers randomized into the intervention arm will be required to take a brief, one-hour, webinar describing the background, problem, results from focus groups we conducted, and a training program on motivational interviewing. After completing the course, providers will be required to complete an evaluation."
89130777|NCT02850224|No Intervention|No Intervention|Standard care
89130778|NCT00638443|Other|Pregabalin then Diphenhydramine|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days; no drug for 7 days; diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
89130779|NCT00638443|Other|Diphenhydramine then Pregabalin|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days; no drug for 7 days; pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
89130780|NCT00632684|Active Comparator|1|Participants in Phase 1 will undergo four interviews, including a single treatment planning session.
88802499|NCT04270578||Women with GDM|
89130781|NCT00632684|Experimental|2|Participants in Phase 2 will receive the adaptive treatment model.
89130782|NCT05184218|Experimental|Sentinel|In the Sentinel Cohort, healthy volunteers will be randomized to receive intranasal and intraoral administration of 1 mg of IGM 6268 or placebo once per day for 5 days.
89130783|NCT05184218|Experimental|Cohort 1|In Cohort 1, healthy volunteers will be randomized to receive intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo once per day for 5 days.
89130784|NCT05184218|Experimental|Cohort 2|In Cohort 2, healthy volunteers will be randomized to receive intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once per day for 5 days.
89130785|NCT05184218|Experimental|Cohort 3|In Cohort 3, healthy volunteers will be randomized to receive intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo twice per day for 5 days.
89130786|NCT05184218|Experimental|Cohort 4|In Cohort 4, mild-moderate Covid patients will be randomized to receive intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once per day for 5 days.
89130787|NCT05184218|Experimental|Cohort 5|In Cohort 5, mild-moderate Covid patients will be randomized to receive one intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo twice per day for 5 days.
89130788|NCT05184218|Experimental|Ph1b Expansion|In the Ph1b expansion cohort, mild-moderate Covid patients will be randomized to receive one intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once or twice per day for 5 days. This cohort may be opened per Sponsor's discretion based on initial safety and activity.
88802500|NCT04270578||Women without GDM|
88802501|NCT05469672|Active Comparator|low-level laser therapy|LLLT will be performed 3 times a week for a period of 3 weeks
88802502|NCT05469672|Active Comparator|high-intensity laser therapy|HILT will be performed 3 times a week for a period of 3 weeks
88802503|NCT05480748||Group 1: 19>BMI<25 AND BMI>40|51 patients with BMI>40 kg/m2 (morbidly obesity) and 51 patients with 19<BMI<25 kg/m2 (normal BMI), 18-75 aged, American Society of Anesthesiologists (ASA) physical status I-III scheduled for an elective surgical procedure requiring general anesthesia with endotracheal intubation.
88802504|NCT05480748||Normal body mass index and morbidly obese groups|51 patients with BMI>40 kg/m2 (morbidly obesity) and 51 patients with 19<BMI<25 kg/m2 (normal BMI), 18-75 aged, American Society of Anesthesiologists (ASA) physical status I-III scheduled for an elective surgical procedure requiring general anesthesia with endotracheal intubation.
88802505|NCT00379522|Active Comparator|Vasopressin|Vasopressin, 10 I.U./4 ml, Solution for Injection
88802506|NCT00379522|Placebo Comparator|Saline|Saline placebo 4 ml, Solution for Injection
89130789|NCT00636181|Active Comparator|Auto Aflex|auto adjusting positive pressure therapy with AFLEX
89130790|NCT00636181|Active Comparator|Auto CPAP|auto adjusting positive pressure therapy
89130791|NCT00636181|Active Comparator|CPAP|continuous positive airway pressure
89130792|NCT00968669|Experimental|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
89130793|NCT00968669|Experimental|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
89130794|NCT00968669|Experimental|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
89130795|NCT00968669|Experimental|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
89130796|NCT00568399|Experimental|Active Treatment|This is the only arm and involves active treatment with sodium thiosulfate in those subjects with high coronary artery calcium scores.
89130797|NCT00827593|Active Comparator|Standard behavioral weight loss|University-based behavioral weight loss treatment
89130798|NCT00827593|Active Comparator|Weight Watchers|Weight Watchers program
89130799|NCT00827593|Active Comparator|Combined Treatment|University-based behavioral weight loss treatment followed by Weight Watchers
89130800|NCT00975143|Experimental|CIP-Isotretinoin|
89130801|NCT00975143|Active Comparator|Isotretinoin|
89130802|NCT04288349|Active Comparator|epinephrine + ropivacaine +saline|1% epinephrine solution + 30 ml of 1% ropivacaine solution diluted with 20 ml of 0.9% saline for achievement a 0.75% anesthetic solution in a ratio of 1: 200 000
89130803|NCT04288349|Placebo Comparator|epinephrine + saline|1% epinephrine solution + 50 ml of 0.9% saline in a ratio of 1: 200 000.
89130804|NCT03667313|Experimental|sirolimus-eluting balloon (SEB)|treatment of bare-metal (BMS) or drug-eluting in-stent restenosis (DES-ISR) with SEB
89130805|NCT03667313|Active Comparator|paclitaxel-eluting balloon (PEB)|treatment of BMS- or DES-ISR with PEB
89130806|NCT04286477||15 conventional hemodialysis patients|15 patients undergoing hemodialysis with high-flux dialyzer
89130807|NCT04286477||15 patients undergoing online-hemodiafiltration|15 patients undergoing conventional hemodialysis with high-flux dialyzer will be allocated to online-hemodiafiltration with the same dialyzer
89130808|NCT04286477||15 patients undergoing expanded hemodialysis with MCO dialyzer|15 hemodialysis patients undergoing hemodialysis with a high-flux dialyzer will be allocated to HDx with an MCO dialyzers (THERANOVA dialyzer, Baxter International Inc. (NYSE: BAX))
89130809|NCT04286477||15 patients undergoing peritoneal dialysis|15 patients undergoing peritoneal dialysis
89130810|NCT03796091|Active Comparator|Educational Brochure|Participants will read an educational brochure from the National Eating Disorder Association and will receive referral resources.
89130811|NCT03796091|Active Comparator|Body Project Traditional|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project group therapy program (Stice & Shaw, 2001).
89130812|NCT03796091|Active Comparator|Body Project Expanded|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project Expanded group therapy program (Green et al., 2017).
89130813|NCT00629759|Experimental|1|1e8 pfu (plaque forming units)total dose each treatment day
89130814|NCT00629759|Experimental|2|3e8 pfu (plaque forming units) total dose each treatment day
89130815|NCT00629759|Experimental|3|1e9 pfu (plaque forming units) total dose each treatment day
89130816|NCT00629759|Experimental|4|3e9 pfu (plaque forming units) total dose each treatment day
89130817|NCT00974675|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
89130818|NCT00974675|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
89130819|NCT00974675|Experimental|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
89130820|NCT00974675|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
89130823|NCT00634933|Experimental|Arm 1|Consists of Arms 1a and 1b
89130824|NCT00634933|Experimental|Arm 2|Consists of Arms 2a and 2b
89130825|NCT00634933|Placebo Comparator|Arm 3|Consists of Arms 3a and 3b.
89130826|NCT00967499|Active Comparator|1|
89130827|NCT00967499|Active Comparator|2|
89130828|NCT04286399|Other|Intensive Treatment Group|High dose of RAASi and beta-blockers (unless contraindicated) as well as preferential use of SGLT2i as per local drug label guidelines on top of standard therapy.
89130829|NCT04286399|No Intervention|Control Group|Standard therapy where the use of SGLT2i at randomization is not encouraged but RAASi and beta-blockers (except for maximal dosage) are allowed. Prescription or up-titration of the study drugs listed under Intensive Treatment is not encouraged. If investigators/treating physicians feel that further prescription or up-titration is required, a thorough justification is mandatory. Unless there is clinically irrefutable reason, every attempt should be made to use other blood pressure lowering drugs than RAASi or beta-blockers, as well as glucose lowering drugs than SGLT2i, in the control group.
89130830|NCT00629837|Experimental|Arm 1|
89130831|NCT00629837|Experimental|Arm 2|
89130832|NCT00629837|Active Comparator|Arm 3|
89130833|NCT00629837|Active Comparator|Arm 4|
89130834|NCT00827671|Other|Pre-operative chemotherapy|
89130835|NCT03909971|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
89130836|NCT03473483|Experimental|SREC only or cigarette only use|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; pharmacokinetic (PK) blood draws; ad libitum use of product; cardiovascular (CV) monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
89130837|NCT03473483|Experimental|Alternate product from Arm 1|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
89130838|NCT03473483|Experimental|Standardized Dual Use|Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes ad libitum SREC use and less than usual amount of cigarette use; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
89130839|NCT00819481||3DKnee|Post Market Study
89130840|NCT02550145|Experimental|Exendin(9-39)|IV infusion of Exendin (9-39).
89130841|NCT02550145|Placebo Comparator|Placebo|IV infusion of normal saline
89130842|NCT00823693|Active Comparator|Bimosiamose Cream|
89130843|NCT00823693|Placebo Comparator|Placebo Cream|
89130844|NCT03643133|Active Comparator|Control arm|"Post-operative chemotherapy alone (EI or M-API regimen depending on patient age) :~M-API regimen (≤25 years) :~Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2~EI regimen (26-50 years) :~Etoposide 75 mg/m²/d, Day 1-4 Ifosfamide 3 g/m²/d, Day 1-4"
89130845|NCT03643133|Experimental|Experimental arm|Post-operative chemotherapy (EI or M-API regimen) combined with Mifamurtide 2 mg/m² twice weekly post-randomisation for 12 weeks then weekly for 24 weeks
89130846|NCT00967343|Experimental|ATIR|
89130847|NCT00973973|Experimental|Elagolix 150 mg|Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.
89130848|NCT00973973|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.
89130849|NCT00633139|Experimental|Cohort 1|Cohort 1: 50 U/kg Recombinant human Arylsulfatase A (rhASA)
89130850|NCT00633139|Experimental|Cohort 2|Cohort 2: 100 U/kg Recombinant human Arylsulfatase A (rhASA)
89130851|NCT00633139|Experimental|Cohort 3|Cohort 3: 200 U/kg Recombinant human Arylsulfatase A (rhASA)
89130852|NCT04044235|Experimental|PrEP Cohort|AGYW HIV-negative and established to be at high risk will be consented to enroll in the PrEP study. AGYW will be followed every 3 months for 12 months to determine incidence, assess factors and costs of delivering PrEP to AGYW.
89130853|NCT04044235|No Intervention|HIV Incidence|HIV Incidence Cohort: In the second component, AGYW who refuse PrEP will be consented to enroll in an HIV incidence cohort study and will be followed every 3 months for 12 months to determine HIV incidence.
89130854|NCT00827905||Hospitalized|Patients admitted to the hospital
89130855|NCT02549521|Active Comparator|Oral magnesium substitution|Daily 240 mg Magnesium Nycomed Pharma. Intervention day 0 - day 28.
89130856|NCT02549521|Placebo Comparator|Magnesium + or Magnesium -|Placebo tablets without magnesium.
89130857|NCT00823771||Reviewed by radiation oncologist|
89130858|NCT00823771||Reviewed by general practitioner|
89130859|NCT02864615|Experimental|Stereotactic Body Radiation Therapy|Patients with stable disease on targeted or IO therapy will receive SBRT on first metastasis of clear cell renal cell carcinoma. Second metastasis will be as a control. In case of safety and 50% reduction in size of first metastasis, up to 10 metastasis will be treated with SBRT.
89130860|NCT00823849|Experimental|1|
89130861|NCT00823849|Experimental|2|
89130862|NCT00823849|Experimental|3|
89130863|NCT00823849|No Intervention|4|Control Group
89130864|NCT02864459|Experimental|Muscular ultrasound|
89130865|NCT04284683|Experimental|Normal and overweight participants|"Healthy males and female, age 6 to 30. BMI range for participants age 6 to 18 is between 5th percentile to 85th percentile, overweight BMI between the 85 and 95th percentile, and obese, above the 95th percentile.~BMI range for participants age 18 to 30 is between 18.5 to 24.9 for normal weight, 25-30 for overweight and above 30 for obese."
89130866|NCT02550067|Active Comparator|Depot medroxyprogesterone acetate (DMPA)|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
89130867|NCT02550067|Active Comparator|Levonorgestrel implant (LNG)|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
89130868|NCT02550067|Active Comparator|Copper T380a IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
89130869|NCT03873935||Control|Healthy subjects
89130870|NCT03873935||Periodontitis|Patients with periodontal disease
89130871|NCT03873935||Cardiovascular|Patients with cardiovascular disease
89130872|NCT03873935||Periodontitis+Cardiovascular|People with both cardiovascular and periodontitis
89130873|NCT00823927||1|Alveolar macrophage proteomes from HIV-seropositive smokers with emphysema
89130874|NCT00823927||2|Alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.
89130875|NCT02862509|Experimental|Budesonide nasal instillation|budesonide(0.5mg/2ml) 1 respule plus normal saline solution 120ml instilled in vertex to floor position daily
89130876|NCT02862509|Placebo Comparator|Normal saline nasal instillation|Normal saline solution instilled in vertex to floor position daily
89130877|NCT02550379|Placebo Comparator|Placebo|The placebo protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point at baseline. A test phase is then administered which is identical to the baseline phase to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
89234100|NCT00992316||Pf-04531083|To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects
89130878|NCT02550379|Experimental|Intervention|The ER training protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point however this balance point is adjusted by 2 points on the 15 face continuum to train the participant to rate more faces as 'happy'. A test phase, identical to the baseline phase, is then administered to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
89130879|NCT04285775||Insertion of Dialysis Catheter|Hospital inpatients planned for dialysis catheter insertion, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
89130880|NCT04285775||Removal of Dialysis Catheter|Hospital inpatients planned for dialysis catheter removal, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
89130881|NCT02864537|No Intervention|Conventional treatment|Conventional anticoagulation treatment Before enrolment
89130882|NCT02864537|Experimental|Self-management|Trained to monitor INR and dose warfarin
89130883|NCT04285619|Experimental|Experimental group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
89130884|NCT04285619|Active Comparator|Control group|Each session will last 10 minutes and a weekly intervention will take place over 3 weeks. The intervention by flossing will be carried out following the application protocol described by the manufacturer for the application of flossing on the ankle. Before the intervention, participants will perform a standard warm-up: 10 minutes of exercise bike at a moderate intensity
89130885|NCT00965081|Experimental|Duloxetine|
89130886|NCT00965081|Placebo Comparator|Placebo|
89130887|NCT00961649|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
89130888|NCT00961649|Active Comparator|Brinz|Brinzolamide ophthalmic suspension, 1% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
89130889|NCT00961649|Active Comparator|Brim|Brimonidine tartrate ophthalmic solution, 0.2% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
89130890|NCT00961649|Active Comparator|Brinz+Brim|Brinzolamide ophthalmic suspension, 1% and brimonidine tartrate ophthalmic solution, 0.2%: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
89130891|NCT04284917|Experimental|Receive Carglumic Acid|Experimental Case_ Carglumic Acid
89130892|NCT02861261|Experimental|Group A|
89130893|NCT02861261|Experimental|Group B|
89130894|NCT02861261|Experimental|Group C|
89130895|NCT02861261|Placebo Comparator|Group D|
89130896|NCT02862197||study group|hemodialysis treated patients as described in the inclusion of the study
89130897|NCT04283435|Placebo Comparator|estradiol valerate + placebo|preparation of the endometrium with Estradiol valerate 2mg/day (every 8 hours)(white tablets of cycloprogenova) .from the first day of the cycle till 12th day and we add placebo from the first day of the cycle till the day of start progesterone (we stop 3 days before embryo transfer).
89130898|NCT04283435|Experimental|estradiol valerate + Sildenafil citrate|We add Sildenfil citrate 50 mg daily from the first day of the period till the day of starting the progesterone. and stop 3 days before the embryo transfer.
89130899|NCT00632125|Experimental|HX575 epoetin alfa i.v.|This post-authorization safety study was designed as a multi-center, multinational, prospective, single-arm clinical study with a 6-month HX575 (recombinant human) erythropoietin alfa treatment period. It was planned to include approximately 1,500 patients.
89130900|NCT00819559|Active Comparator|Open PCRT group|Patients who underwent preoperative chemoradiotherapy and open resection
89130901|NCT00819559|Experimental|Open no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and open resection
89130902|NCT00819559|Active Comparator|LAP PCRT group|Patients who underwent preoperative chemoradiotherapy and laparoscopic resection
89130903|NCT00819559|Experimental|LAP no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and laparoscopic resection
89130904|NCT00903968|Experimental|Phase I Dose Level 1|Phase I Dose Level 1 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
89130905|NCT00903968|Experimental|Phase I Dose Level 2|Phase I Dose Level 2 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
89130906|NCT00903968|Experimental|Phase I Dose Level 3|Phase I Dose Level 3 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
89130907|NCT00903968|Experimental|Phase I Dose Level 4|Phase I Dose Level 4 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
89130908|NCT00903968|Experimental|Phase I Dose Level 5|Phase I Dose Level 5 patients received plerixafor 320ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
89130909|NCT00903968|Experimental|Phase I Dose Level 5B|Phase I Dose Level 5B patients received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
89130910|NCT00903968|Experimental|Phase I Dose Level 6|Phase I Dose Level 6 patients received plerixafor 400ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
89130911|NCT00903968|Experimental|All Phase I Participants|All Phase I participants received plerixafor by injection and bortezomib intravenously according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
89130912|NCT00903968|Experimental|All Phase II Participants|All Phase I participants received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13, bortezomib 1.3 mg/m2 intravenously or subcutaneously days 3, 6, 10, and 13, and dexamethasone 40mg orally days 3, 6, 10, and 13 of each 21 day cycle during induction. In maintenance, participants received plerixafor, bortezomib, and dexamethasone days 1, 8, 15, and 22 of each 35 day cycle. Participants were treated until disease progression or unacceptable toxicity.
89130913|NCT00632606|Active Comparator|Arm 1|magnesium sulfate 2 grams intravenously w/ acetaminophen 1 gram orally
89130914|NCT00632606|Active Comparator|Arm 2|metoclopramide 10 mg intravenously w/ 1 gram acetominophen orally
89130915|NCT02602574||ERCP- induced acute pancreatitis|"All patients with indication for ERCP will be prepared for ERCP. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample.~Upon clinical and laboratory confirmation of acute pancreatitis according to ESGE guidelines for post-ERCP pancreatitis, will be further monitored during hospitalization for evaluation of the severity of the disease."
89130916|NCT02602574||non -ERCP acute pancreatitis|"All patients with acute pancreatitis according to Atlanta criteria admitted through Emergency Department will be taken 30 ml of heparinized peripheral venous blood and urine sample upon 24 hours after the clinical symptoms have started. 10 mL of collected blood samples will be examined in the Department of Laboratory Medicine. Other 20 mL of blood samples will be sent to Department of Physiology and Immunology, School of Medicine where immunologic analysis will be performed.~This group of patients will be further monitored during hospitalization for evaluation of the severity of the disease. Severity of the disease will be assessed according to the Atlanta criteria."
89130917|NCT02602574||Control group|"Control group will consist of patients who underwent ERCP but didn't develop acute pancreatitis. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample."
89130918|NCT02572934||Chemotherapy group (CT-group)|Patients treated with chemotherapy >20 years ago
89130919|NCT02572934||Radiotherapy group (RT-group)|Patients treated with radiotherapy >20 years ago
89130920|NCT02572934||Surgery-only group (SU-group)|Patients treated with only orchidectomy >20 years ago
89130921|NCT02572934||Control-group|Healthy controls
89130922|NCT02849834|Active Comparator|healthy volunteers|
89130923|NCT02849834|Experimental|Patients with resistant pain|
89130924|NCT02849756||older in intensive care unit|older (age superior at 85 years) hospitalized in intensive care unit. A follow-up until 6 months after hospitalization will determine the evolution of the quality of life and others secondary outcomes.
89130925|NCT00903344|Experimental|Vitamin D|4000IU Vitamin D3 in tablet taken daily with multivitamin
89130926|NCT00903344|Active Comparator|Multivitamin|Multivitamin with 400IU vitamin D tablet
89130927|NCT02847416|Experimental|Inspiratory group|the subjects will be instructed to inspire as deeply as possible with steady flow rate for 3 seconds with end-inspiratory pause for 2-3 seconds through the inspiratory circuit and follow by passive exhalation
89130928|NCT02847416|Experimental|expiratory group|the subjects will be instructed to inspire as deeply as possible through the nose with end-inspiratory pause for 2-3 seconds and partially forced exhalation with reach to 1/3 of expiratory reserve volume (ERV) for at least 3 seconds through expiratory circuit
89130929|NCT02849444||Moderate kidney failure|30 ≤ CrCl < 50 mL/min/1.73 m2
89130930|NCT02849444||Severe kidney failure|CrCl < 30 mL/min/1.73 m2
89130931|NCT02385812|Experimental|High lung cancer risk|Individuals with lung cancer risk >= 1.5% over 6 years
89130932|NCT02385812|Experimental|Low lung cancer risk|Individuals with lung cancer risk <1.5% over 6 years
89130933|NCT02383160|Active Comparator|Active LIPUS Unit|Low-intensity pulsed ultrasound treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
89130934|NCT02383160|Sham Comparator|Sham LIPUS Unit|Sham device treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
89130935|NCT04466072||High Ventricular Arrhythmia burden group|"Inclusion criteria for all groups:~age >18 years-old~competent and willing to provide consent~presence of implantable cardioverter-defibrillator~diagnosis of cardiomyopathy~left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment~Inclusion criteria for high ventricular arrhythmia burden group:~• at least one episode of sustained VT/VF or VT/VF requiring ICD therapies within the preceding 3 months as assessed on device interrogation at the time of study enrollment~Both groups will have stool sample collected for microbial analysis. This is anticipated twice for the high ventricular arrhythmia (VA) burden group. Once at the time of diagnosis of VA and later after the clinically indicated treatment for the VA."
89130936|NCT04466072||Control group|"Inclusion criteria for all groups:~age >18 years-old~competent and willing to provide consent~presence of implantable cardioverter-defibrillator~diagnosis of cardiomyopathy~left ventricular ejection fraction of 35% or less as assessed by echocardiogram within 1 year prior to enrollment~Inclusion criteria for control group:~• no VT/VF on device interrogation for a period of at least 3 months preceding study enrollment~Both groups will have stool sample collected for microbial analysis. This is anticipated only once for the control group."
89130937|NCT02847338|Experimental|Mono-therapy group|"The monotherapy group will be treated with the following treatments:~A) 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B) 1 to 2 weeks of Lisinopril 10mg followed by 6 to 7 weeks of Lisinopril 20mg C) Approximately 8 weeks of 25mg Chlortalidone~Participants will be randomly allocated to one of six possible sequences of treatments of the three-treatment-three period Williams design: ABC, ACB, BAC, BCA, CAB, and CBA."
89130938|NCT02847338|Experimental|Dual-therapy arm|"The dual-therapy group will be treated with the following treatments:~A) Approximately 8 weeks of Amlodipine 5mg and Lisinopril 20mg B) Approximately 8 weeks of Amlodipine 5mg and Chlortalidone 25mg C) Approximately 8 weeks of Lisinopril 20mg and Chlortalidone 25mg D) Approximately 8 weeks of Amiloride 10mg and Chlortalidone 25mg~Participants will be randomly allocated to one of four possible sequences of treatments of the four-treatment four-period Williams design: ABDC, BCAD, CDBA, and DACB."
89130939|NCT02847104||dynamic insulin protocol|patients received intravenous insulin infusion according to a dynamic insulin protocol
89130940|NCT02847104||static insulin protocol|patients received intravenous insulin infusion according to a static insulin protocol
89130941|NCT02849522||PAE patients|Men who have undergone PAE and are in the UK ROPE Register
89130942|NCT02849522||Comparator treatment patients|Men who have undergone TURP, Open Prostatectomy or laser ablation/enuclation of the prostate, and are on the UK ROPE Register.
89130943|NCT02849366|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89130944|NCT02849366|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89130945|NCT02849288|Experimental|Intervention|Use of the Investigational Bigfoot Type 1 Diabetes Management System (T1DMS)
89130946|NCT02846948|No Intervention|Non-echo group|Patients get the standard monitoring and treatment based on Good medical practice. Extended monitoring by focused echocardiography is not applied for this group.
89130947|NCT02846948|Experimental|Focussed echocardiography group|The extended cardiac monitoring by focused assessed transthoracic echocardiography is applied.
89130948|NCT02848976||IA group|EDSS (Expanded Disability Status Scale) below 6 with RE
89130949|NCT02848976||IB group|EDSS (Expanded Disability Status Scale) below 6 with no RE
89130950|NCT02848976||IIA group|EDSS (Expanded Disability Status Scale) betwin 6 and 8 with RE
89130951|NCT02848976||IIB group|EDSS (Expanded Disability Status Scale) below 6 with RE
89130952|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
89130953|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
89130954|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
89130955|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
89130956|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
89130957|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
89130958|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
89130959|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
89130960|NCT02849054|Experimental|4, 5, 6ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 5ml/kg, 6ml/kg. Measurement of PTPdi
89130961|NCT02849054|Experimental|4, 6, 5ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 6ml/kg, 5ml/kg. Measurement of PTPdi
89130962|NCT02849054|Experimental|5, 4, 6ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 4ml/kg, 6ml/kg. Measurement of PTPdi
89130963|NCT02849054|Experimental|5, 6, 4ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 6ml/kg,4ml/kg. Measurement of PTPdi
89130964|NCT02849054|Experimental|6, 5, 4ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 5ml/kg, 4ml/kg. Measurement of PTPdi
89130965|NCT02849054|Experimental|6, 4, 5ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 4ml/kg, 5ml/kg. Measurement of PTPdi
89130966|NCT02849210|Experimental|Allergovac depot|Allergovac depot with Olea europaea pollen extract
89130967|NCT02849132|Experimental|Treatment group|entecavir oral，0.5mg daily for 8 years
89130968|NCT02846870|Active Comparator|Standard Education|Patients receive standard-of-care prostate cancer radiation oncology consultation.
89130969|NCT02846870|Experimental|Visually Enhanced Education|Patients receive a visually enhanced prostate cancer educational Powerpoint presentation including prostate anatomy, pathologic results, surgical options, radiation therapy, and prognosis with pictographs during radiation oncology consultation.
89130970|NCT05116826|Experimental|Healthy Control Match (Normal hepatic function)|NTZ 500 mg twice a day for 7 days
89130971|NCT05116826|Experimental|Moderate Child-Pugh B (Moderate hepatic impairment)|NTZ 500 mg twice a day for 7 days
89130972|NCT05116826|Experimental|Severe Child-Pugh C (Severe hepatic impairment)|NTZ 500 mg twice a day for 7 days
89130973|NCT04268264|Experimental|Treatment arm|Will receive trial intervention, Incremental haemodialysis (n=20)
89130974|NCT04268264|Other|Control arm|Historical controls. Matched controls from database of historical patients receiving conventional, three times weekly haemodialysis treatment (n=40)
89130975|NCT04862078|Experimental|Shared decision making group|The Study arm - shared decision making when deciding surveillance strategy
89130976|NCT04862078|Other|Usual surveillance group|The control arm - surveillance with usual care
89130977|NCT02848898|Experimental|Equistasi Group|arm treated with application of devices
89130978|NCT02848898|Placebo Comparator|Placebo Group|arm treated with application of inactivated devices
89130979|NCT02848742|Experimental|Treatment with cryotherapy device|To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.
89130980|NCT04202198|Experimental|pinhole surgical technique with Platelet Rich Fibrin|minimally invasive tunneling procedure followed by coronal advancement with placement of Platelet Rich Fibrin membrane
89130981|NCT04202198|Active Comparator|pinhole surgical technique only|coronal advancement following minimally invasive tunneling procedure
89130982|NCT02848508|Experimental|moderate impairment, CKD stage 3a|(12 subjects): GFR 59-45 (moderate impairment, CKD stage 3a) Metformin : 1500mg/day
89130983|NCT02848508|Experimental|moderate impairment, CKD stage 3a)|(12subjects): GFR 44-30 (moderate impairment, CKD stage 3b) Metformin : 1000mg/day
89130984|NCT02848508|Experimental|severe impairment|(12 subjects): GFR 29-15 (severe impairment, CKD stage 4) Metformin : 500mg/day
89130985|NCT00903032|Experimental|Arm 1|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
89130986|NCT00903032|Active Comparator|Arm 2|Patients will receive usual care following ACS hospital discharge
89130987|NCT02113592|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
89130988|NCT02113592|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
89130989|NCT00902564|Experimental|Escitalopram|
89130990|NCT05055362|Experimental|Honey Spice Group|The dietary intervention will be a 10-day feasibility trial, using a honey, spice infused baked good. The participants will receive the baked good on day 1 and will be asked to consume a 50-gram baked good daily for 10 days with or without their meals. The honey, spice infused baked good will contain 15g honey and 3g of spice blend (turmeric and cinnamon). A saliva sample will be taken at the start of the intervention (day 1) before consumption of the baked good and after the intervention ends (day 10), 2 hours after consuming the final baked good. Additionally, participants will provide a urine sample to determine microalbuminuria level, complete a spice-consumption survey and a semi-quantitative food frequency questionnaire (day 1). At day 10, participants will indicate if their spice consumption and dietary intake has changed over the past 10 days. Each day, they will tick off the amount of baked good consumed (100%, 75%, 50%, 25%, 0%).
89130991|NCT00626197|Experimental|OCR 400 mg + SOC|Participants received Ocrelizumab 400 mg i.v. infusion on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
89130992|NCT00626197|Experimental|OCR 1000 mg + SOC|Participants received Ocrelizumab 1000 mg i.v. infusion on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
89130993|NCT00626197|Placebo Comparator|Placebo + SOC|Participants received placebo i.v. infusion on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks plus SOC regimen.
89130994|NCT05054894|Experimental|Experimental Group (Plasmapheresis for Age-Related Frailty)|Participants will receive plasmapheresis once a month for six months. All participants will be in this arm.
89130995|NCT01967030||Women with recent GDM pregnancy|The study cohort includes women who had gestational diabetes mellitus (GDM) in their index pregnancy for study enrollment. There are two pre-defined groups: 1) women who breastfeed intensively during the first 4 months postpartum, and 2) women who mostly fed formula during the first 4 months postpartum. The study enrolled women into these pre-defined groups, but some women transitioned into mixed feeding groups after enrollment.
89130996|NCT01940822|Experimental|Energy drink first, then placebo drink|Participants will receive an energy drink at the first study visit, and a placebo drink at the second study visit.
89130997|NCT01940822|Experimental|Placebo drink first, then energy drink|Participants will receive a placebo drink at the first study visit and an Energy Drink at the second study visit.
89130998|NCT00819715||1|Small for gestational age preterm infants
89130999|NCT00819715||2|Appropriate for gestational preterm infants
89131000|NCT02848430|Experimental|Humulus lupulus|Spent hop extract; 2 gelatin capsules (59.5 mg extract) per day for 14 days
89131001|NCT00824083||1|sarcoma survivors
89131002|NCT00824083||2|healthy subjects
89131003|NCT00828217|Experimental|with APA|Children have adapted physical activity during their hospitalization
88802507|NCT00437398|Experimental|Islet Transplant|Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.
89131004|NCT00828217|No Intervention|without APA|Children don't have adapted physical activity during their hospitalization
89131005|NCT02848352|Experimental|Positive placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
89131006|NCT02848352|Experimental|Negative placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it sensitizes for experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
89131007|NCT02848352|Placebo Comparator|Placebo control group|Participants receive a nasal spray that is a placebo and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
89131008|NCT02848352|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
89131009|NCT00626275|Experimental|ADL5859 -- 200 mg (Part A)|ADL5859: 200 milligrams (mg), capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
89131010|NCT00626275|Active Comparator|Naproxen -- 500 mg (Part A)|Naproxen: 500 mg, capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
89131011|NCT00626275|Placebo Comparator|Placebo (Part A)|Matching placebo, capsules, administered orally, as a single dose during 1 of 3 Treatment Periods in Part A of the study
89131012|NCT00626275|Experimental|ADL5859 - 100 mg (Part B)|ADL5859: 100 mg, capsules, administered orally, twice daily (BID) for 2 weeks during Part B of the study
89131013|NCT00626275|Placebo Comparator|Placebo (Part B)|Matching placebo, capsules, administered orally, BID for 2 weeks during Part B of the study
89131014|NCT00819871||PLI|patients with postoperative lung injury
89131015|NCT00819871||without PLI|patients without postoperative lung injury
89131016|NCT00819871||PLI/PKI|patients with at least one organ injury of lung or kidney after surgery
89131017|NCT00819871||without PLI/PKI|patients without lung or kidney injury after surgery
89131018|NCT02848118|Experimental|A nasal-oral cannula of capnography|Start bronchoscopy when the nasal-oral capnography shows hypoventilation during bronchoscopic sedation.
89131019|NCT02848118|Active Comparator|Sedation scale|Start bronchoscopy when Observer Assessment of Alertness and Sedation scale (OAAS)=3~2 during bronchoscopic sedation.
89131020|NCT00623935|Experimental|Fludarabine plus Busulfan (CR)|Patients in CR will receive a reduced intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu2).
89131021|NCT00623935|Experimental|Fludarabine plus Busulfan (PR)|Patients in PR will receive a full intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu4).
89131022|NCT03782246|No Intervention|Usual Care|No intervention, participant will continue their usual care for pain and MS. We will collect information about what treatments are used by the usual care participants. They will be offered the opportunity to participate in one of the two active study treatments (MBCT or CBT) after completion of the 6-month followup.
89131023|NCT03782246|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Participants will attend eight, 2-hour group treatment MBCT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. MBCT integrates mindfulness meditation practices within a CBT-oriented framework to address not only unhelpful pain cognitions and behaviors but also attentional control, decoupling of attention from emotion, mindful cognitions, and meditative behavior.
89131024|NCT03782246|Experimental|Cognitive Behavioral Therapy (CBT)|Participants will attend eight, 2-hour group treatment CBT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. CBT focuses on increasing adaptive pain coping strategies and reducing unhelpful thoughts and behaviors related to pain. Strategies include relaxation techniques, goal-setting, activity pacing, and changing unhelpful thinking patterns.
89131025|NCT04202042|Experimental|Psychological first aid|PFA responders are trained to deliver 8 core actions in the aftermath of traumatic event (: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services (within the first 24 hours)
89131026|NCT04202042|Active Comparator|Usual organisational intervention|One phone call by workplace psychologist (within the first 48 hours) and reference to employee aid program
89131027|NCT04043845|Experimental|LY3214996+Ibrutinib|"LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle~Ibrutinib will be administered by mouth once daily continuously throughout each treatment cycle."
89131028|NCT00828373|Placebo Comparator|Placebo|
89131029|NCT00828373|Active Comparator|Lidocaine|
89131030|NCT03573518|Experimental|BTX 1503 5% BID|BTX 1503 5% CBD (w/w) solution twice daily
89131031|NCT03573518|Experimental|BTX 1503 5% QD|BTX 1503 5% CBD (w/w) solution once daily
89131032|NCT03573518|Experimental|BTX 1503 2.5% QD|BTX 1503 2.5% CBD (w/w) solution once daily
89131033|NCT03573518|Placebo Comparator|Vehicle BID|Vehicle twice daily
89131034|NCT03573518|Placebo Comparator|Vehicle QD|Vehicle once daily
89131035|NCT02550301||Mean Platelet Volume|4 blood samples (1 pre procedure before clopidogrel loading) and 3 after Percutaneous Coronary Intervention will be drawn to assess the MPV
89131036|NCT00819949|Experimental|Arm 1|Potential eligible subjects for the trial will be individuals between ages 18-85, with a confirmed diagnosis of PD that experience freezing.
89131037|NCT00824239|Active Comparator|1. Intermittent sedation|
89131038|NCT00824239|Active Comparator|2. Daily interruption of sedation|
89131039|NCT04777760||one dose of surfactant|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
89131040|NCT04777760||two and more doses of surfactant|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
89131041|NCT02548975||Delirium|Patients diagnosed with delirium at any time postoperatively with the CAM-ICU.
89131042|NCT02548975||No delirium|Patients not diagnosed with delirium postoperatively.
89131043|NCT02847962|No Intervention|Control (No FBF)|FBF provided after the intervention period
89131044|NCT02847962|Active Comparator|Corn Soy Blend Plus (CSB+)|Consumed Corn Soy Blend Plus (CSB+)
89131045|NCT02847962|Experimental|Corn Soy Blend 14 (CSB14)|Consumed Corn Soy Blend 14 (CSB14)
89131046|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 1|Consumed White Sorghum Cowpea Blend Variety 1
89131047|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 2|Consumed White Sorghum Cowpea Blend Variety 2
89131048|NCT02847962|Experimental|Red Sorghum Cowpea Blend|Consumed Red Sorghum Cowpea Blend
89131049|NCT02847962|Experimental|White Sorghum Soy Blend|Consumed White Sorghum Soy Blend
89131050|NCT04044703|Experimental|Model-based vancomycin dosing|Participants will receive model-based intermittent intravenous vancomycin dosing as calculated by the dosing calculator available on a web application. Participants will then have routine therapeutic drug monitoring and linear dose adjustments.
89131051|NCT00824317|Placebo Comparator|1|Placebo
89131052|NCT00824317|Experimental|2|methylphenidate
89131053|NCT02847806|Experimental|Estradiol|dosage used in the study: 1 patch / 3-4 days dosed at 25, 37.5 or 50 mg / 24h titration according to the plasma level, with the objective of a physiological level of estradiol (25-40 pg / ml ) - During 4 weeks
89131054|NCT02847806|Experimental|Testosterone|dosage used : from 25 to 75 mg / day of testosterone (ie 2.5 to 7.5 g / day transdermal gel) according to the plasma level, with the goal of a physiological level of testosterone (5-8 ng / ml) - During 4 weeks
89131055|NCT02847806|Experimental|Testosterone + Estradiol|Testosterone + Estradiol During 4 weeks
89131056|NCT00820105|Experimental|ADX10059 25 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
89131057|NCT00820105|Experimental|ADX10059 50 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
89131058|NCT00820105|Experimental|ADX10059 100 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
89131059|NCT00820105|Placebo Comparator|ADX10059 Matching Placebo|Weeks 1-2: once daily Weeks 3-12: twice daily
89131060|NCT02847572|Other|Surgery Patient|All patients to be implanted bilaterally with a Tecnis Extended Range Lens in the Dominant eye and a Low Add Multifocal in the non dominant
89131061|NCT01780220|Experimental|abiraterone|Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy
89131062|NCT00824395||1|Individuals with diabetes
89131063|NCT00824395||2|Individuals without diabetes
89131064|NCT01632098||extremely obese|BMI ≥35kg/m2
89131065|NCT01632098||obese|BMI 30-34.9kg/m2
89131066|NCT02549053|Experimental|Barrett esophagus patients|esophagus biopsies (pathologic and healthy zones)
89131067|NCT02549053|Sham Comparator|control patients|esophagus biopsies (healthy zones)
89131068|NCT01461278|Experimental|Cataract surgery plus iStent supra|
89131069|NCT01461278|Active Comparator|Cataract surgery|
89131070|NCT02846402|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
89131071|NCT02846402|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
89131072|NCT02846402|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
89131073|NCT00824551|Experimental|Hyperbaric Oxygen Therapy|2 HBOT treatments
89131074|NCT00824551|Active Comparator|2|Standard care and treatment
89131075|NCT00632762|Active Comparator|1|Amantadine MANTADIX
89131076|NCT00632762|Placebo Comparator|2|placebo
89131077|NCT00820183|Experimental|quality improvement plan|It will be the group of primary health care teams who will undertake the quality improvement plan for hypertensive patients
89131078|NCT00820183|No Intervention|non intervention|It will be the group of primary health care teams that will not undertake the quality improvement plan for hypertension control
89131079|NCT02846480|Experimental|surgical treatment+behavior therapy+physical therapy|Including POP surgical treatment, and pre- post physical therapy to aim the posture, PFM awareness and the strengthening. They will be also informed and instructed on hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
89131080|NCT02846480|Experimental|surgical treatment+behavior therapy|Including POP surgical treatment, and information and instruction about hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
89131081|NCT00824629|Experimental|1|Afterloading embryo transfer procedure
89131082|NCT00824629|Active Comparator|2|Direct embryo transfer procedure
89131083|NCT00828607||liver mass|The group will comprise any patients with an unknown liver mass at the time of diagnostic imaging.
89131084|NCT01351766|Experimental|Behavioral Activation for Smoking|"Eight 60-minute group sessions over an eight-week period. Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue after treatment sessions have ended.~Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level."
89131085|NCT02548897|Experimental|Freezing of gait in PD|All participants will undergo an deep brain stimulation (DBS) for the FOG, and an electroencephalography (EEG) to better understand the neurophysiological underpinnings of the symptom. In addition, review changes in scalp recorded EEG and gait parameters during natural FoG episodes while participants are ambulatory in an advanced gait laboratory setting using a wireless EEG amplifier with active electrodes.
89131086|NCT01179932||Anesthesia Record|The nursing and anesthesia records will be examined for accuracy and completeness
89131087|NCT04044391||Intention to Treat: Cardiac Catheterization|All patients meeting inclusion criteria and scheduled to undergo cardiac catheterization will undergo a CardioFlux magnetocardiogram (MCG) to determine presence of patterns which indicate myocardial ischemia.
89131088|NCT04044391||Post Percutaneous Coronary Intervention|All patients found to have significant coronary artery obstruction seen via angiography +/- fractional flow reserve (FFR) or instant wave-free ratio (iFR) and who receive a catheter based intervention will have a post-procedure CardioFlux MCG scan. Follow up over the next 30 and 180 days will be performed to determine if a persistent pattern suggesting residual ischemia will correlate with an increased incidence of major cardiac adverse events (MACE).
89131089|NCT02845934|Experimental|Mucormycosis|blood sample
89131090|NCT00820261||Diarrhea|children and infants (less than 5 years of age) presenting with severe diarrhea will be enrolled
89131091|NCT02844608|Other|Quality of Life|Administration of Quality of Life questionnaires
89131092|NCT00820339|Active Comparator|Selective Hepatic Vascular Exclusion|Patients with HCC received Selective Hepatic Vascular Exclusion in hepatectomy.
88805908|NCT01141595|Experimental|Kuvan®|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
89131093|NCT00820339|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
89131094|NCT02844686|Experimental|Cardiac Dynamic SPECT|
89131095|NCT00828685|Active Comparator|Operative (CRPP)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized.
89131096|NCT00828685|Active Comparator|Operative (ORIF)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized
89131097|NCT00629707|Active Comparator|1|Slower infusion rate: Patients in this arm will receive an initial intravenous fluid bolus of 10cc/Kg followed by rehydration calculated to replace a deficit of 7.5% of body weight over 48 hours.
89131098|NCT00629707|Active Comparator|2|More rapid infusion: Patients in this arm will receive an initial bolus of 20 cc/Kg of intravenous fluids followed by replacement of an estimated deficit of 10% of body weight over 36 hours plus replacement of 1/2 of urine output volume.
89131099|NCT02846090|Experimental|D50 Dexmedetomidine 50 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
89131100|NCT02846090|Experimental|D25 Dexmedetomidine 25 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine + 4.5 ml of 2% lidocaine +0.5ml of 25 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
89131101|NCT02846090|Placebo Comparator|control|peribulbar block was given using 10 ml of a mixture of local anesthetics without Dexmedetomidine. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml with 150 IU hyaluronidase.
89131102|NCT04323098|Experimental|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg with prophylactic corticosteroids
89131103|NCT00828763|Experimental|1|[14C]-GSK1349572 administered as a single oral dose
89131104|NCT00824707|Experimental|anti-virus therapy|100 HCC patients will be allocated to receive anti-virus therapy.
89131105|NCT00824707|Active Comparator|conventional therapy|100 patients will undergo conventional therapy
89131106|NCT00824785|Active Comparator|Arm A EOX|EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)
89131107|NCT00824785|Active Comparator|Arm B EOX + panitumumab.|EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days
89131108|NCT02550457|No Intervention|Control group|It will not apply any tape.
89131109|NCT02550457|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
89131110|NCT02550457|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
89131111|NCT02550457|Placebo Comparator|Placebo group|Apply Micropore tape in the erector spine muscles.
89131112|NCT00902330|Experimental|Arm I (cranial microcurrent electrical stimulation [CES])|Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
89131113|NCT00902330|Sham Comparator|Arm II (sham CES)|Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
89131114|NCT04016701|Experimental|VR Intervention|Eight weeks of training with Floreo's VR Joint Attention Module with two sessions per week
89131115|NCT04016701|Active Comparator|Treatment as Usual|Regularly scheduled therapy
89131116|NCT00824863|Experimental|one arm|All 10 patients receive ketoconazole 2% foam in the uncontrolled study.
89131117|NCT02844530|Experimental|RIT|The experimental treatment will consist on 2 injections of 370 MBq/m2 of 90Y-epratuzumab tetraxetan fractionated RIT at day 1 and day 8. The first infusion of 90Y-epratuzumab tetraxetan will be co-injected for the six first patients in Nantes with 111In-epratuzumab tetraxetan for dosimetry purpose.
89131118|NCT02844530|Active Comparator|chemotherapy/ immunotherapy|"chemotherapy/ immunotherapy regimen will be assigned per investigator's choice to one of the following chemotherapy/ immunotherapy regimens:~FLAG +- anthracycline based regimen For subject's >60 years : idarubicin 5 mg/m2 day 1,3, fludarabine 20 mg/m2 days 1-5, cytarabine 1 g/m2 days 1-5.~Clofarabine or clofarabine based regimens. Clofarabine use as a single agent should follow the recommended prescribing information. Clofarabine combination based regimens should use >=20mg/m2/day for up to 5 days.~Hyper-C-VAd regimen: hyperfractionated cyclophosphamide 300 mg/m2 intravenously(i.v.) every 12 hours for 6 doses Days 1 to 3 + vincristine 2 mg i.v.Days 4 and 11; doxorubicin 50 mg/m2 i.v. over 24 hours via central venous catheter Day 4; and dexa-methasone 40 mg daily Days 1 to 4 and 11 to 14.~Blinatumomab (Blincyto®) : 28-day continuous infusion (9µg/d for days 1-7; 28µg/d thereafter, followed by 2 weeks of rest for up to 2 cycles."
89131119|NCT00820417|Experimental|a|Dose-escalation
89131120|NCT00820417|Experimental|B|Maximum tolerated dose (MTD)
89131121|NCT00820495|Experimental|Web + Phone|Highly interactive tailored Web-based smokeless tobacco cessation program plus phone counseling
89131122|NCT00820495|Experimental|Web Only|Highly interactive tailored Web-based smokeless tobacco cessation program
89131123|NCT00820495|Experimental|Phone Only|Phone counseling intervention for smokeless tobacco cessation
89131124|NCT00820495|Experimental|Control|Usual care (initial call plus self-help materials)
89131125|NCT00828997|Other|Prevenar vaccine|all participants are immunized with a dose of pneumococcal conjugate vaccine
89131126|NCT03454334|Active Comparator|AMO Tecnis Symfony|"Multifocal with extended range of vision, Diffractive, No Preloaded, Aspheric, +3.25 D near add and +2.17 D intermediate 6.0mm Hydrophilic~-0.20~Has nine diffractive steps, The proprietary achromatic technology corrects chromatic aberration. This creates improved contrast sensitivity."
89131127|NCT03454334|Active Comparator|AcrySof ReSTOR (Alcon Laboratories)|"Multifocal ,Diffractive, +3.00D and for Near, Aspheric, Has 9 steps (rings), Light: 41% for far; 41% for near: 18% reflected (lost).~6.0mm Silicone~-0.10 Bifocal ,One piece,Blue filter ,Central diffractive region of 3.6_mm for near and distance vision ,Apodised ,peripheral refractive region is dedicated to distance vision"
89131128|NCT03454334|Active Comparator|AT Lisa tri (CarlZeiss Meditec AG)|Trifocal, diffractive, +3.33 D near add and +1.66 D intermediate add at the IOL plane, aspheric (aberration correcting) Optic Diameter 6.0 mm Total Diameter 11.0 mm Haptic Angulation 0° Lens Design Single-piece, MICS Incision Size 1.8 mm Company Labeled A-Constant1 118.6 Diopter Range 0.0 to +32.0 D, 0.5 D increments ACD 5.32
89131129|NCT03454334|Active Comparator|PanOptix(Alcon Laboratories)|"Trifocal,Difractive,+3.25D Near,+2.17 D intermediate 6.0mm hydrophobic~-0.27 One piece ,aspheric , Focal 4.5 mm (15 diffractive zones)"
89131130|NCT00829075|Experimental|I|only r-FSH TREATMENT
89131131|NCT00829075|Experimental|II|only HP-hMG TREATMENT
89131132|NCT00829075|Experimental|III|r-FSH plus HP-hMG TREATMENT
89131133|NCT04849676|Experimental|Upper limb subacute spinal cord injury (sUL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Grip strength - measure of hand and forearm muscle strength using dynamometer~Instrumented Pendulum test - oscillations when forearm is dropped from a resting position~Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
89131134|NCT04849676|Experimental|Upper limb chronic spinal cord injury (sUL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Grip strength - measure of hand and forearm muscle strength using dynamometer~Instrumented Pendulum test - oscillations when forearm is dropped from a resting position~Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
89131135|NCT04849676|Experimental|Lower limb subacute spinal cord injury (sLL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position~10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
89131136|NCT04849676|Experimental|Lower limb chronic spinal cord injury (cLL)|"Intervention: neurofeedback. Participants will receive visual feedback on a screen.~Diagnostic Tests:~Modified Ashworth Scale grading muscle resistance to movement (all limbs tested)~Perceived Spasticity level questionnaire on impact of spasticity~Spinal Cord Independence Measure questionnaire on level of independence of patients~Diary of spastic episodes~Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position~10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device~EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria)~Brief Visual Analog Scale self-assessment of performance and mental strategies~Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)"
89131137|NCT02550223|Experimental|Oblique|Ultrasound guided radial artery catheterization using oblique view obtained by tilting the US probe 30-45 degrees over the course of the artery
89131138|NCT02550223|Active Comparator|Transverse group|Ultrasound guided radial artery catheterization using transverse view
89131139|NCT02550223|Active Comparator|Longitudinal group|Ultrasound guided radial artery catheterization using longitudinal view
89131140|NCT02844140|Experimental|Scans|Patients included in the trial will receive DE-CT in stead of SE-CT's.
89131141|NCT02548741|Active Comparator|Treatment (Metformin)|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the active comparator (metformin).
89131142|NCT02548741|Placebo Comparator|Placebo|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the placebo comparator.
89131143|NCT02548741|Other|Non-diabetic|Forty matched non-diabetic patients with HbA1C ≤ 5.6%. They will not receive either treatment (metformin) or placebo.
89131144|NCT02844374|Other|Partial Epilepsy Drug Resistant|Patients with partial Epilepsy Drug Resistant , justifying a SEEG exploration.
89131145|NCT02845856|Experimental|Cetuximab and NK immunotherapy|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89131146|NCT02845856|Active Comparator|Cetuximab|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89131147|NCT00825019|Experimental|1|
89131148|NCT00825019|Placebo Comparator|2|
89131149|NCT00825019|Active Comparator|3|paroxetine
89131150|NCT05337956|Active Comparator|ESPB catheter group|Patient in this group will receive ESP block
89131151|NCT05337956|No Intervention|Control group|Patient in this group will not receive any block
89131152|NCT02844218||Intensive chemotherapy group|Group 1: Patients' age ≥ 70 years treated from 1985 to 1999 with intensive induction chemotherapy.
89131153|NCT02844218||Lower intensity treatment group|Group 2: patients treated from 2000 to 2006 with intensive chemotherapy plus improved supportive care and a follow-up protocol systematically performed at the university hospital.
89131154|NCT02844218||personalized treatment group|"Group 3: patients who had received, starting in 2007, more personalized treatment with either intensive chemotherapy or lower-intensity therapy determined by the clinical judgment of the treating physician."
89131155|NCT02550691|Experimental|Subject carrying 3 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
89131156|NCT02550691|Other|Subject carrying 2 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
89131157|NCT02550691|Other|Subject carrying 3 copies of the SMN2 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
89131158|NCT02844452|Experimental|Verum Acupuncture 1|The participants with atopic dermatitis in the acupuncture group 1 will attend twelve acupuncture sessions over 4 weeks: 3 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
89131159|NCT02844452|Experimental|Verum Acupuncture 2|The participants with atopic dermatitis in the acupuncture group 2 will attend eight acupuncture sessions over 4 weeks: 2 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
89131160|NCT02844452|Sham Comparator|Sham Acupuncture|The participants in the sham acupuncture group will visit eight acupuncture sessions over 4 weeks. The acupuncture treatment will be conducted on six control points. The acupressure will be applied with ring-sham press tack needles on three control points. Unlike the acupuncture group 2, partially-individualized manual acupuncture according to the patient's symptoms will not be given but the questions about symptoms will be questioned to patients.
89131161|NCT02844452|No Intervention|Healthy Control|The participants will go through the screening test. The included subjects will complete questionnaires and their blood sample will be obtained.
89131162|NCT05337878|Placebo Comparator|SAD: Placebo|Single dose of Pelacarsen-matching placebo administered by SC injection on Day 1 of single-dose treatment period.
89131163|NCT05337878|Experimental|SAD: Pelacarsen 20 milligrams (mg)|Single dose of Pelacarsen, 20 mg, administered by SC injection on Day 1 of single-dose treatment period.
89131164|NCT05337878|Experimental|SAD: Pelacarsen 40 mg|Single dose of Pelacarsen, 40 mg, administered by SC injection on Day 1 of single-dose treatment period.
89131165|NCT05337878|Experimental|SAD: Pelacarsen 80 mg|Single dose of Pelacarsen, 80 mg, administered by SC injection on Day 1 of single-dose treatment period.
89131166|NCT05337878|Placebo Comparator|MD: Placebo|Multiple doses of Pelacarsen-matching placebo administered by SC injection every 4 weeks, on Days 1, 29, 57 and 85 of multiple-dose treatment period.
89131167|NCT05337878|Experimental|MD: Pelacarsen 80 mg|Multiple doses of Pelacarsen, 80 mg, administered by SC injection every 4 weeks, on Days 1, 29, 57 and 85 of multiple-dose treatment period.
89131168|NCT00929006|Experimental|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
89131169|NCT00929006|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
89131170|NCT00877214|Experimental|Rituximab|Follicular Lymphomas: Rituximab 375 mg/m² for additional 2 years after 2 years of standard maintainance All other lymphomas: Rituximab 375 mg/m² for 2 years as maintainance. From 2014 only Morbus Waldenstroem: Rituximab 1.400 mg absolute s. c. injection
89131171|NCT00877214|Active Comparator|Standard|Rituximab / Observation
89131172|NCT02845622|Experimental|30g peeled hazelnuts cream|Every person in this group will receive a 30 g peeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
89131173|NCT02845622|Experimental|30g unpeeled hazelnuts cream|Every person in this group will receive a 30 g unpeeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
89131174|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts|Every person in this group will receive a snack with 30 g peeled hazelnuts as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
89131175|NCT02845622|Experimental|snack w/ 2.5g cocoa powder|Every person in this group will receive a snack with 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
89131176|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts+2.5g cocoa|Every person in this group will receive a snack with 30 g peeled hazelnuts and 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
89131177|NCT02845622|Placebo Comparator|empty snack|Every person in this group will receive an empty snack as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
89131178|NCT00304148||CRIC Cohort|
89131179|NCT00304148||CRIC Subcohort|
89131180|NCT04887350|Experimental|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership is a phone administered talk therapy.
89131181|NCT04887350|Active Comparator|Problem Solving Therapy (PST)|Problem Solving Therapy is a phone administered talk therapy.
89131182|NCT04887350|Other|Wait List Control (WLC)|Participants in the WLC will continue with their regular treatments for the 12 week study period but not receive any study related intervention during this 12 weeks. Following completion of all study assessments WLC participants will self-select either SSIPP or PST. Participants in WLC will not complete study assessments after week 12.
89131183|NCT00187226|Other|Stratum 1|Ependymoma, craniopharyngioma, low-grade glioma
89131184|NCT00187226|Other|Stratum 2|High-grade glioma
89131185|NCT05242796|Experimental|12 sessions of magnet|
89131186|NCT05242796|Experimental|24 sessions of magnet|
89131187|NCT05242796|Placebo Comparator|Placebo magnet intervention|
89131188|NCT05242718|Active Comparator|N-Acetyl-L-cysteine (NAC)|600 mg 1 capsule twice daily for 14 days
89131189|NCT05242718|Active Comparator|Echinacea purpurea|252 mg 1 capsule twice daily for 14 days
89131190|NCT05242718|Active Comparator|Curcumin|60 mg 3 capsules once daily for 14 days
89131191|NCT05242718|Active Comparator|Palmitoylethanolamide|400 mg 3 capsules once daily for 14 days
89131192|NCT04202120|Experimental|Age-related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with age-related primes.
89131193|NCT04202120|Active Comparator|Non-age related priming|Participants received a review of the profile of their social participation. They also received psycho-education about memory components. They were give given memory tests with NON age-related primes.
89131194|NCT02846012|No Intervention|CSCM Control|Control medium
89131195|NCT02846012|Experimental|CSCM2|New Formulation medium
89131196|NCT05242328|Active Comparator|post-operative VAS score of Ultrasound-guided erector spinae plane block|
89131197|NCT05242328|Active Comparator|post-operative VAS score of surgical thoracoscopic intercostal nerve block|
89131198|NCT00045968|Active Comparator|treatment cohort|
89131199|NCT00045968|Placebo Comparator|Placebo Chohort|Autologous PBMC
89131200|NCT02845778|Experimental|melatonin niosomes oral gel 2.5 mg|apply onto oral mucosa as single use
89131201|NCT02845778|Experimental|melatonin niosomes oral gel 5 mg|apply onto oral mucosa as single use
89131202|NCT02845778|Experimental|melatonin niosomes oral gel 10 mg|apply onto oral mucosa as single use
89131203|NCT05242016|Experimental|structured individual reminiscence|Sessions, in chronological order; Starting with birth, it is planned to progress through life years by focusing on important events. In the sessions, considering the age and individual characteristics of the patients, the house and region where they were born and raised, childhood and school memories, childhood and school friends, youth years and friends, business life, if any, marriage process, birth of the first child, happy memories about children, successful events, old holidays It is talked about subjects such as unforgettable people or events, happy places to visit, old meals, old items, old songs. In each session, different sensory stimuli (visual, auditory, tactile, smelling, tasting) are used according to the subject.
89131204|NCT05242016|Placebo Comparator|unstructured social interview|Unstructured social interviews are conducted on topics such as current events not related to recollection, information specific to the individual patient wants to share, illness/diseases, hobbies, and activities.
89131205|NCT05242016|No Intervention|Control|There is no intervention other than standard nursing care.
89131206|NCT05241938|Experimental|Pattern Selective Laser Trabeculoplasty|PSLT will be performed using the Pascal Streamline 577 laser (Topcon Inc., Tokyo, Japan). The laser spot is directed at the anterior chamber angle encompassing the pigmented and non-pigmented trabecular meshwork. Laser power is titrated by placing a laser mark in the lower quadrant with an exposure duration of 10 milliseconds (ms). The initial energy of 500 megawatts (mW) is selected and the power is reduced or increased until a slight whitening of the trabecular meshwork is minimally noticed. This power is then maintained and the pulse duration is automatically reduced to 5ms to produce invisible injury. The treatment is administered in 32 steps, each pattern consists of 36 stitches: 3 rows of 13 stitches each (total of 1152), with zero space between adjacent stitches.
89131207|NCT05241938|Active Comparator|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops (latanoprost, bimatoprost or travoprost) will be prescribed
89131208|NCT02845544|Experimental|Experimental group - Pilates|A Pilates-based exercises program of 6 weeks' duration
89131209|NCT02845544|No Intervention|Control group - no exercises|
89131210|NCT05241782|Experimental|Experimental group|Experimental group will receive acupressure treatment by the second week, trice daily, 3~5minutes each session for a course of four weeks.
89131211|NCT05241782|No Intervention|Control group|Experimental group will receive routine care for a course of four weeks.
89131212|NCT05337332|Experimental|Central serous chorioretinopathy group|Cases with central serous chorioretinopathy (CSR) that will be injected with suprachoroidal triamcinolone acetonide.
89131213|NCT05337332|Experimental|Irvine-Gass Syndrome group|Cases with cystoid macular edema due to irvine-gass syndrome that will be injected with suprachoroidal triamcinolone acetonide
89131214|NCT02850302|Other|FDG PET + exome analysis before treatment and after|Participants will performed one PET with FDG an tumor exome analysis before treatment is started.After 6 cycles of chemotherapy a second PET with FDG and a second tumor exome analysis will be performed
89131215|NCT02845232||Intensive chemotherapy|First group: 68 patients receiving a combination of intermediate-dose cytarabine and an anthracycline. One patient with acute promyelocytic leukaemia (APL) also received all-trans retinoic acid (ATRA).
89131216|NCT02845232||Lower-intensity treatments|The second study group comprised 70 patients who were treated on frontline by lower-intensity treatments [LD-AraC(39 patients), azacitidine (16 patients), decitabine (11 patients),tipifarnib (3 patients), or ATRA (1 patient)]. Patients received LD-AraC 20 mg once or twice daily (according to physician'schoice) by subcutaneous injection for 10 consecutive days. Azacitidine was given at the dose of 75 mg/m2/day for 7 consecutive days by sc injection. Decitabine was administered by intravenous route once daily at 20 mg/m2 for 5 consecutive days. Tipifarnib was given at 600 mg administered orally twice daily for 21 consecutive days in 4-week cycles. ATRA was given at 45 mg/m2until CR achievement followed by maintenance combining 6-mercaptopurine with methotrexate.
89131217|NCT02845232||Best Supportive Care|The last study group comprises 76 patients: 31 patients received supportive care, while 36 patients also received hydroxyurea and 9 patients received 6-mercaptopurine.
89131218|NCT02850458||implant retained-overdentures with the attachment of bar|patients treated with implant-retained overdentures,and the attachment is bar
89131219|NCT02850458||implant retained-overdentures with the attachment of magnet|patients treated with implant-retained overdentures,and the attachment is magnet
89131220|NCT04793204|Experimental|fezolinetant|A single oral dose of fezolinetant will be administered with water under fasting conditions on day 1 (low dose), day 4 (medium dose) and day 7 (high dose). From day 10 to day 15, the medium dose of fezolinetant will be administered with water after breakfast once daily. On day 16, the medium dose of fezolinetant will be administered with water under fasting conditions.
89131221|NCT00901394|Experimental|Treatment 1|B12-Folic acid, nitrous oxide
89131222|NCT00901394|Active Comparator|Treatment 2|Nitrous oxide (NO) and placebo
89131223|NCT00901394|Placebo Comparator|Control group|oxygen nitrogen
89131224|NCT05241704|Experimental|Endovenous ablation of superficial venous reflux + Fat grafting|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice) + Fat grafting
89131225|NCT05241704|Active Comparator|Endovenous ablation of superficial venous reflux only|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
89131226|NCT05241626||group 1|70 eyes of 35 patients of thyroid inactive disease
89131227|NCT05241626||Group 2|70 eyes of 35 patients of thyroid active disease
89131228|NCT05241626||Group 3|Healthy controls
89131229|NCT05337254|Experimental|STS101 5.2 mg|STS101 (dihydroergotamine nasal powder), 5.2 mg
89131230|NCT05337254|Experimental|STS101 7.0 mg|STS101 (dihydroergotamine nasal powder), 7.0 mg
89131231|NCT05337254|Experimental|STS101 8.6 mg|STS101 (dihydroergotamine nasal powder), 8.6 mg
89131232|NCT05337254|Active Comparator|DHE intramuscular injection|Dihydroergotamine mesylate
89131233|NCT05337254|Active Comparator|DHE nasal spray|Dihydroergotamine mesylate
89131234|NCT00896532|Placebo Comparator|Placebo|"Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously (SC) for up to 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
89131235|NCT00896532|Active Comparator|Alendronate|"Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. At month 36 participants ended study participation."
89131236|NCT00896532|Active Comparator|Teriparatide|Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
89131237|NCT00896532|Experimental|Romosozumab 70 mg QM|"Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
89131238|NCT00896532|Experimental|Romosozumab 140 mg Q3M|"Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
89131239|NCT00896532|Experimental|Romosozumab 140 mg QM|"Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
89131240|NCT00896532|Experimental|Romosozumab 210 mg Q3M|"Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
89131241|NCT00896532|Experimental|Romosozumab 210 mg QM|"Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
89131242|NCT00574873|Experimental|1|Bosutinib
89131243|NCT00574873|Active Comparator|2|Imatinib
89131244|NCT02843334||Population of adult patients undergoing chronic renal dialysis|Population of adult patients undergoing chronic renal dialysis for end stage kidney disease in 5 French areas (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department of Gard)
89131245|NCT02840604||patient with all types of solid malignant tumors not treatable|In the treatment or assessment of metastatic solid tumor malignancies not curable it can be offered to patients to establish the profile of their tumor by next generation sequencing (NGS). This technique permits the sequencing of millions of fragments in parallel in a short time and allows to identify rapidly somatic or constitutional mutations known or yet unknown. The establishment of the genetic profile of the tumor coupled to the available clinical data can help clinicians to predict patient outcome in terms of survival or progression to disease, but may also provide key clues to adapt the management and patient treatment.
89131246|NCT05335746||Vitiligo patients on therapy|Patients diagnosed as vitiligo and on systemic and local therapy.
89131247|NCT05335746||Control group|Normal subjects recruited from ophthalmology clinic and visit the clinic for regular check-up.
89131248|NCT02843490|Experimental|Ranibizumab treatment of nAMD patients|nAMD patients will be treated with Ranibizumab (0.5 mg injection) 3 times within three months followed by individual therapy interval based on the clinical progress (PRN) up to 7 times. Analysis of specific biomarker.
89131249|NCT02843490|No Intervention|healthy subjects|Analysis of specific biomarker.
89131250|NCT00902174|Experimental|imatinib mesylate|Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted.
89131251|NCT00902174|Placebo Comparator|Placebo|Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.
89131252|NCT01397916||CLL-patients|
89131253|NCT01397916||Controls|
88802508|NCT03496896|Experimental|"TARGET intervention"|The intervention group will receive a standardized transition care intervention by a trained nurse composed of a pre-discharge component and 2 post-discharge follow-up phone calls 3 days and 14 days after discharge.
89131254|NCT04201808|Experimental|Single Arm Intervention Group|All approximately 100 patients experienced previous suboptimal response to other direct acting antivirals. Patients must have received nucleos(t)ide therapy consisting of LAM/LdT/ADV and its combinations with other second-line antivirals for 24 weeks, or with the first-line antiviral ETV or any antiviral combinations containing ETV for 48 weeks with medication adherence. All patients in this study are in the same arm.
89131255|NCT04201886|Other|RA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
89131256|NCT04201886|Other|OA patients|A. Full history taking B. Physical examination C. Laboratory investigation: • Serum Calprotectin (CLP)
89131257|NCT02845388|Active Comparator|estradiol valerate|estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
89131258|NCT02845388|Active Comparator|Sildenafil citrate and estradiol valerate|Sildenafil citrate 25 mg every 6 hours orally in combination with estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
89131259|NCT02843412||group 1|choose one tumor tissue paraffin blocks
89131260|NCT02843412||group 2|choose two tumor tissue paraffin blocks
89131261|NCT04357184|Experimental|BFRT with 4 exercises and low resistance loads|Blood flow resistance training will be performed with a standard blood pressure cuff that is placed and inflated by a clinician. The patient will perform 4 exercises with low resistance loads that will produce a muscle burn to enhance promotion of strength. Training will be supervised in the clinic. The cuff is deflated between exercises.
89131262|NCT02840760|Active Comparator|tardive dyskinesia group|tardive dyskinesia group will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 30 stimuli each (i.e., 1800 stimuli) and an intertrain interval of 12 sec in primary motor cortex（M1）.
89131263|NCT02840760|No Intervention|Healthy control group|
89131264|NCT02845466|Experimental|Becaplermin/Promagran Dressing|Topical Becaplermin with a protease inhibitor wound dressing.
89131265|NCT02845466|Active Comparator|Becaplermin/Placebo Dressing|Topical Becaplermin with a placebo wound dressing.
89131266|NCT00623623|Experimental|Tenecteplase|Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention
89131267|NCT00623623|Other|primary PCI|Standard primary PCI
89131268|NCT04281134|Experimental|Summit RC+S DBS Implant for OCD|all subjects will receive surgical implantation of DBS system
89131269|NCT04281134|Experimental|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline"
89131270|NCT02845310|Experimental|Restricted fluid therapy group|Patients will receive restricted fluid management guided by concomitant SVV monitoring. GDT protocol
89131271|NCT02845310|Placebo Comparator|Control group|Patients will receive standard fluid management.
89131272|NCT02845154|Active Comparator|Control (bolus purge)|The portal vein clamp will be totally released after end of portal vein anastomosis and all graft and portal blood contents are allowed free and complete access to the systemic circulation via the inferior vena cave
89131273|NCT02845154|Experimental|Intermittent Purge|The portal clamp will be released in situ for 5 seconds to allow purge of the graft and portal contents into the systemic circulation, followed by 30 seconds of portal clamping again. This will be followed by another two cycles of 5 seconds declamping and 30 seconds clamping , then, the portal clamp will be completely released.
89131274|NCT02845076|Active Comparator|Decrease in duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered. When a patient reaches without the presence of any reinstitution criteria, the duration of NIV use as 4 hours per 16 hours during daytime, it will be liberated definitively from NIV.
89131275|NCT02845076|Active Comparator|Decrease in pressure and duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. The level of pressure support will be decreased by 2-4 cmH2O per 4 hours during daytime in patients with good tolerance, with no change at night time. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered, based on the vitals and ABGs recorded at 8 pm (see above), with gradual decrease of at least 2 hrs/night. When a patient reaches without the presence of any reinstitution criteria, the level of PS of 8 cmH20, it will be liberated definitively from NIV.
89131276|NCT02845076|Active Comparator|Abrupt discontinuation of NIV|Patients will be disconnected from NIV and oxygenated with a nasal cannula. Oxygen flow will be limited to a maximum of 5L/min.
89131277|NCT00896454|Experimental|denosumab|Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
89131278|NCT04224584|Active Comparator|Duloxetine|Duloxetine is a serotonin-norepinephrine reuptake inhibitor. Duloxetine will be administrated as follows: 20 mg/daily duloxetinefor 1 week, 40 mg/daily duloxetine for 1 week, 60 mg/daily duloxetine for 10 weeks, 40 mg/daily duloxetine for 1 week, 20 mg/daily duloxetine for 1 week.
89131279|NCT04224584|Placebo Comparator|Placebo|Placebo will be administrated for 14 weeks.
89290187|NCT03932994|No Intervention|Waitlist|Those assigned to the waitlist will simply wait 8 weeks. A second online assessment will be completed 8 weeks after baseline in both conditions (for a between condition comparison). After the second assessment, waitlist participants will gain access to ACT on Health.
89290188|NCT01220232|Active Comparator|Abacavir/Lamivudine|
88802509|NCT03496896|No Intervention|Control|The group control will receive usual care without additional intervention.
89131280|NCT04168892||Female age ≤ 35 years: 150 IU of HMG|For controlling the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age ≤ 35 years, COS will be carried out by daily injections of 150 IU of Human Menopausal Gonadotropins (HMG) and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the Gonadotropin-releasing Hormone (GnRH) antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary human Chorionic Gonadotropin (hCG) 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
89131281|NCT04168892||Female age >35 years: 225 IU of HMG|In order to control the effect of the starting dose on the number of retrieved oocytes, the patients will be divided in two groups based on their age. For the patients with an age >35 years, the controlled ovarian stimulation will be carried out by daily injections of 225 IU of HMG and will be started on the 3rd day of the cycle. The starting dose will be maintained for the first 5 days and followed by individual dose-adjustments according to the patient's follicular response. The pituitary suppression will be obtained by the administration of the GnRH antagonist ganirelix (0.25 mg per day), starting from the 6th day of the ovarian stimulation until the day of the induction of the final oocyte maturation. Highly purified urinary hCG 10.000 IU will be used to induce final oocyte maturation. In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (buserelin acetate), 0.5 mg subcutaneously.
89131282|NCT02789670||MS patients|MS patient group is composed by 20 Individuals with inflammatory brain lesions seen in MRI (Radiologically Isolated syndrome) 20 patients with only one clinically isolated syndrome (CIS) 20 patients with relapsed remittent Multiple sclerosis (RRMS) 20 patients with primary progressive Multiple Sclerosis (PPMS)
89131283|NCT02789670||Control group patients|"Control patient cohort is composed by 20 patients suffering from inflammatory neurological disease other than MS Devic syndrome, Neurosarcoidosis, Neurobehcet... (autoimmune disease control group with neurological disease) 20 patients with systemic sclerosis (autoimmune disease control group) without neurological disease)~40 healthy subjects"
89131284|NCT05336942||MCI-HI group|Mild cognitive impairment and hearing impairment group
89131285|NCT05336942||MCI-nHI group|Mild cognitive impairment and no hearing impairment group
89131286|NCT05336942||Control group|Control group
89131287|NCT00820651|Placebo Comparator|Placebo|
89131288|NCT00820651|Experimental|Diamel|
89131289|NCT02993198|Experimental|Prophylactic Carvedilol|Carvedilol 3.125 mg by mouth every 12 hours, titrated to a max dose of 25 mg by mouth every 12 hours, depending on blood pressure and heart rate, until completion of study.
89131290|NCT02993198|No Intervention|No Therapy|Standard of care monitoring without prophylactic treatment.
89131291|NCT02843256||Patients receiving intravenous nutrition|Patients will blow into a bag that will capture 500 mL of their exhaled air daily for 7 days or the length of the parenteral nutrition, whichever is shorter. The Isomark Canary will analyze the air to generate a breath delta value.
89131292|NCT01012596||Creighton Model|New and return users of the Creighton Model FertilityCare System, a method of Natural Family Planning.
89131293|NCT00629239|Experimental|1|AZD4818
89131294|NCT00629239|Placebo Comparator|2|Placebo
89131295|NCT03797378|Experimental|eM2M|Participants in the eM2M arm will participate in an intervention that involves three 60-minute M2M sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. At the beginning and end of each session, vital signs (heart rate, blood pressure and peripheral capillary oxygen saturation) are obtained from participants. Participants rate perceived exertion, pain, and fatigue level on a log. Participants set weekly exercise goals and expectations at first session of each week. Participants also record daily activities using a provided log.
89131296|NCT03797378|No Intervention|Waitlist Control|Participants in the waitlist control arm are instructed to maintain their usual activities during the 12-week intervention period and are asked to record their activities on a provided log.
89131297|NCT02842944|Experimental|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
89131298|NCT02842944|Active Comparator|Routine care|"Connect and start Beacon with advice disabled~Standardized routine care"
89131299|NCT00625807|Active Comparator|Program A - Relaxation Response (RR)|One of the 2 stress reduction courses
89131300|NCT00625807|Active Comparator|Program B - Mindfullness-based stress reduction (MBSR)|One of the 2 stress reduction courses
89131301|NCT02907242|No Intervention|Concealment|Cerebroplacental ratio measurement at 37 weeks of pregnancy only taken into account if estimated fetal weight <p10
89131302|NCT02907242|Other|Revealment|Cerebroplacental ratio measurement at 37weeks and labor induction in case of cerebroplacental ratio <p5
89131303|NCT04251000|Experimental|Joovv Pilot Experimenta Arm|Individuals will receive 90 day access to the Joovv infrared mini light device.
89131304|NCT02520908||HSCT|Patients with an available sibling or 10/10 HLA-matched unrelated donor who undergo reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation (HSCT), will be included in the study. The reduced-intensity conditioning usually includes Fludarabine 90 mg/m2 IV and Melphalan 140 mg/m2 IV. As usual care, patients will receive peripheral blood stem cells from their sibling donor if available, otherwise from their 10/10 HLA-matched unrelated donor
89131305|NCT02520908||Standard care|Patients with no available sibling or 10/10 HLA-matched unrelated donor who therefore do not receive allogeneic HSCT but receive best standard of care treatment, will be included in the study, as the control group
89131306|NCT00829153|Experimental|U clip|Anastomosis with U clips
89131307|NCT00829153|Active Comparator|2|Prolene anastomosis
89131308|NCT02843022|Active Comparator|Usual care|Participant will receive the usual care provided by the nursing staff at Catholic Medical Center. A lactation consultant or childbirth educator attempts to call each patient within 2-3 weeks prior to discharge. Only one call is made, and a message left if the patient would like to call back.
89131309|NCT02843022|Experimental|Message Only|Participant will receive the usual care, and in addition, will receive four standardized electronic messages weekly for six months postpartum. These will be one-way messages without the option to respond.
88802510|NCT00593320|Active Comparator|1|Low-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 14 Gy
88802511|NCT00593320|Active Comparator|2|High-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 18Gy
88802512|NCT00421954|Experimental|Ziprasidone|
88802513|NCT00392860|Experimental|PalmRim Experimental|Participants will have PalmRim installed on their wheelchair.
88802514|NCT00392860|Experimental|Natural-Fix Experiment|Participants will have a Natural-Fit installed on their wheelchair.
88802515|NCT00392860|Placebo Comparator|Handrim Control|Participants in this arm had a new standard handrim installed on their wheelchair as a control.
88802516|NCT01662336||Lopinavir/Ritonavir + KASA|Patients were treated according to the standard of care provided by their respective study sites. Treatments with LPV/r and participation in the KASA program were according to the decision of the treating physician and the participant, and were not affected in any way by their decision to participate in the study.
88802517|NCT00387244|Experimental|Precision for Spinal Cord Stimulation|Single arm Precision for Spinal Cord Stimulation
88802518|NCT05476068||Epidemic area (Nanchang, Nanchang university)|
88802519|NCT05476068||Non-epidemic area (Kaifeng, Henan university)|
88802520|NCT05480436|Experimental|Experimental Group|"Total of 400 participants received one dose of BBIBP-Corv and IIV4 on Day 0, and received one dose of BBIBP-Corv and PPV23 on Day 28. Blood sampling was performed on Day 0, Day 28 and Day 56 for humoral immunity assessment.~30 of the 400 participants were selected to collect three blood samples on Day 0, Day 42 and Day 56 for cellular immune assessment."
88802521|NCT05480436|Active Comparator|Control Group 1|"Total of 400 participants received two doses of BBIBP-Corv on Day 0 and Day 28. Blood sampling was performed on Day 0, Day 28 and Day 56 for humoral immunity assessment.~30 of the 400 participants were selected to collect three blood samples on Day 0, Day 42 and Day 56 for cellular immune assessment."
88802522|NCT05480436|Active Comparator|Control Group 2|Total of 400 participants received one dose IIV4 on Day 0 and received one dose PPV23 on Day 28. Blood sampling was performed on Day 0, Day 28 and Day 56 for humoral immunity assessment.
89131310|NCT02843022|Experimental|Message and Nurse|"Participant will receive the usual care as well as the four standardized electronic messages/week for 6 months. Two of these weekly messages will be two-way, providing the option for the participant to respond yes to an offer to have a nurse call them. A nurse phone call if requested will be provided with a week."
89131311|NCT04024280|Experimental|Intervention arm|Patients will perform a supervised physical exercise program specifically developed for breast cancer patients, based on the guidelines of the American College of Sports Medicine. The physical exercise program comprises 3 weekly sessions of 60 minutes each. Each session will involve an initial warm-up with light mobility exercises, followed by resistance and aerobic training and ending with a return to calm phase of light stretching exercises.
88802523|NCT00572260|Experimental|A|Daptomycin as a single preoperative dose within 30 minutes prior to surgery Dosage: if creatinine clearance ≥ 30 ml/min: 6 mg/kg IV
88802524|NCT00000784||A|Consenting patients newly enrolled in either CPCRA 007 or CPCRA 006
88802525|NCT02549352|Experimental|LEO 43204 gel|Treatment once daily for 3 days
88802526|NCT02549352|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
88802527|NCT05480358|Experimental|ProlonADTM|The ProlonADTM diet, which will be taken by the patient once a month for 5 days, is a low-calorie and low-protein diet, and provides all the micronutrients necessary to avoid malnutrition. The diet will be performed in twelve consecutive months. The components of the diet will be approximately 30% calorie restricted and 50% protein restricted but supplemented with 50% of the RDA in vitamins and minerals and also supplemented with both nonessential and essential amino acids identified in animal studies to be effective. Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43%carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
88802528|NCT05480358|Placebo Comparator|Placebo diet|One meal which substitute or lunch or dinner for 5 days, without calories restriction.
88802529|NCT00271102|Active Comparator|Anterior colporrhaphy|Anterior vaginal wall colporrhaphy (repair) for cystocele (dropped bladder)
88802530|NCT00271102|Active Comparator|Paravaginal defect repair|Abdominal paravaginal defect repair cystocele (dropped bladder)
88802531|NCT02389946|Experimental|Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
88802532|NCT02389946|Active Comparator|Xience everolimus coronary stent system|Intervention with a Xience DES.
88802533|NCT00268450|Experimental|study intervention|Neo-adjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy. Patients without residual disease will enter follow up after surgery. Patients with residual disease will receive adjuvant therapy with bevacizumab and ciaplatin.
88802534|NCT02661932|Experimental|Letrozole associated COS|"Breast cancer patients undergo fertility preservation with letrozole associated COS for oocyte collection.~Letrozole is administered orally (5mg/day) during the entire stimulation protocol until ovulation triggering."
88802535|NCT00423124|Experimental|A|
88802536|NCT02809586|Active Comparator|SMI + Incentives|A Social Media + Incentives (SMI + I) condition
88802537|NCT02809586|Active Comparator|SMI|A Social Media Intervention (SMI) condition
88802538|NCT02809586|No Intervention|Control|An Attention-Control E-News (CONTROL) condition
88802539|NCT00177970|Active Comparator|IVIG|
88802540|NCT00177970|Placebo Comparator|Placebo|
88802541|NCT01892618|Active Comparator|Pneumovax|Pneumovax, 1x 0.5 ml injection
88802542|NCT01892618|Experimental|Prevenar 13|Prevenar 13, 1x 0.5 ml injection
88802543|NCT00088972|Experimental|Arm I - Celecoxib|Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
88802544|NCT00088972|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
88802545|NCT01892696|Other|mechanically ventilated patients|"patients admitted to a 18-bed medical surgical intensive care unit of the military hospital of Tunisia and were mechanically ventilated fully adapted to their ventilator and in sinus rhythm.~intervention:varying inspiratory flow waveforms"
88802546|NCT00089128|Experimental|Gemcitabine and Irnotecan|
88802547|NCT01892852|Experimental|Acupuncture|Acupuncture treatment
89131312|NCT04024280|No Intervention|Control arm|Patients should maintain the usual physical activity
89131313|NCT00629083|Experimental|1|Bulkamid Hydrogel injection
89131314|NCT00629083|Active Comparator|2|Contigen injection
89131315|NCT02640690|Experimental|Trauma Center Trauma-Sensitive Yoga (TCTSY)|10-weekly 1-hour TCTSY Sessions
89131316|NCT02640690|Active Comparator|Cognitive Processing Therapy (CPT)|12-weekly 1.5 hour CPT Sessions
89131317|NCT02840058|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting anti PD1/PDL1 treatment), and then 1 month, 3 months and 12 months after initiation of anti-PD1/PDL1 treatment.~Peripheral blood mononuclear cells (PBMC) and plasma will be collected.~Available tumor tissues will be collected."
89131318|NCT04841564|Active Comparator|ultrasound group|serratus anterior plane block will be done through ultrasound guidance
89131319|NCT04841564|Experimental|Open group|serratus anterior plane block will be done after mastectomy through the open wound
89131320|NCT02842710|Experimental|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
89131321|NCT00829231|Experimental|Arm 1|
89131322|NCT00829231|Experimental|Arm 2|
89131323|NCT00829231|Experimental|Arm 3|
89131324|NCT00901628|Experimental|Periarticular Injection group|Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime
89131325|NCT00901628|No Intervention|No Injection group|usual postoperative care without periarticular injection
89131326|NCT00623545|Experimental|Exenatide|Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.
89131327|NCT02840214|Active Comparator|tDCS rescue group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp half-way through the 3-hour fatigue task.
89131328|NCT02840214|Placebo Comparator|Sham Treatment Group|Subjects assigned to this arm will initially receive current of the same intensity for a period of 30 seconds and then gradually turned off.
89131329|NCT02840214|Active Comparator|tDCS prevent group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp at the beginning of the task.
89131330|NCT00825097|Experimental|Neurotomy Group|8 patients undergoing a selective tibial neurotomy under general anesthesia
89131331|NCT00825097|Active Comparator|BTX Group|8 patients undergoing a botulinum toxin injection in the calf muscles under EMG-control
89131332|NCT02844764|Experimental|StroMed + Platelet Rich plasma [PRP]|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product by direct injection to affected joints.
89131333|NCT00820729||1|Patients with interstitial pulmonary disease
89131334|NCT02839668|Experimental|Sevoflurane|The patients enrolled in this arm will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
89131335|NCT02839668|Active Comparator|Sevoflurane+Lidocaine|The patients enrolled in this group will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
89131336|NCT02839668|Experimental|TIVA-TCI|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine. The bispectral index- BIS will be monitored throughout the anesthesia.
89131337|NCT02839668|Active Comparator|TIVA-TCI+lidocaine|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia.
89131338|NCT04701788|Experimental|Study group|The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years.
89131339|NCT04701788|Placebo Comparator|Control group|The control group had never been vaccinated with any pneumococcal vaccine.
89131340|NCT00628927||METH and/or cocaine dependent group|The METH and/or cocaine dependent group were also enrolled in CTN0031 (NCT00573183) and seeking treatment. This group will be analyzed based on whether or not they completed treatment as defined by the study.
89290189|NCT01220232|Experimental|Lersivirine + Abacavir/Lamivudine|
88802548|NCT01892852|No Intervention|Control|No other active treatment or sham acupuncture for this symptoms
88802549|NCT02375126||Ages 18-35, no antidepressant use|Ages 18-35, up to 15 males and 15 females, no antidepressant use
88802550|NCT02375126||Ages 36-55, no antidepressant use|Ages 36-55, up to 15 males and 15 females, no antidepressant use
89131341|NCT00628927||Non METH and/or cocaine dependent group|The Non METH and/or cocaine dependent group participants are normal controls recruited from the community.
89131342|NCT04700618|Experimental|Study group|The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years.
89131343|NCT04700618|Placebo Comparator|Control group|The control group had never been vaccinated with any pneumococcal vaccine.
89131344|NCT02842632|Other|A virtual teaching|Group A will be introduced to the virtual TEE online (http://pie.med.utoronto.ca/TEE/)
89131345|NCT02842632|Other|B simulator|Group B will be introduced to the simulator (CAE Vimedix Simulator)
89131346|NCT02842632|Other|C hands on OR|group C will be introduced to the TEE training in the operation room.
89131347|NCT04698122||type 1 diabetes|Patients with type 1 diabetes
89131348|NCT04698122||type 2 diabetes|Patients with type 2 diabetes
89131349|NCT04698122||Healthy volunteers|Healthy volunteers
89131350|NCT04250844||Botulinum|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy with intrapyloric botulinum injections and if clinically applicable endoscopic functional luminal imaging probe (EndoFLIP). The dosage will be determined by the patient's physician.
89131351|NCT04250844||Control|We will follow for symptom improvement over time patients with nausea, vomiting, feeding intolerance, or other signs of gastric dysfunction who were determined by their gastroenterologist to require upper endoscopy without intrapyloric botulinum injections.
89131352|NCT00820807|Experimental|1|3g/day
89131353|NCT00820807|Experimental|2|6g/day
89131354|NCT00820807|Placebo Comparator|Placebo beverage|0g/day
89131355|NCT04688918|Active Comparator|Group A (Retrolamianar block(RLB))|Ultrasound-guided RLB with injection of 0.4ml/kglocal anesthestic (bupivacaine) 0.25%will be performed under strict aseptic precautions with ultrasound guidance with patient in the prone position.
89131356|NCT04688918|Active Comparator|Paravertebral group|Ultrasound-guided paravertebral injection of 0.4ml/kg saline 0.9% will be performed under strict aseptic precautions under ultrasound guidance with patient in the prone position.
89131357|NCT02839590||HiFu (ultrasound)|Manufacturer Name Eyehope Principle intended use Surgical treatment of uncontrolled glaucoma and OHT The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study.
89131358|NCT02839590||Baerveldt implant|"Manufacturer Name Abbott Medical Optics Inc., Abbott Laboratories Inc., Abbott Park, Illinois, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
89131359|NCT02839590||Ahmed Implant|"Manufacturer Name New World Medical, Inc., 10763 Edison Court, Rancho Cucamonga, CA 91730, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
89131360|NCT02839590||STARflo|"Manufacturer Name iSTAR Medical SA, Parc Créalys, Rue Phocas Lejeune, Bâtiment Regain 25/3, 5032 Isnes, Belgium.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
89131361|NCT02839590||Hydrus Microstent implant|"Manufacturer Name Ivantis, Inc., 38 Discovery, Suite 150, Irvine, CA 92618, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
89131362|NCT02839590||iStent implant|"Manufacturer Name Glaukos Corporation, 26051 Merit Circle, Suite 103, Laguna Hills, CA 92653, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
89131363|NCT02839590||Kahook Dual Blade|Manufacturer: New World Medical. Inc. Single use, ophthalmic blade Utilizes ab interno approach through a clear cornea micro incision Dual blades positioned for precise parallel incisions of the trabecular meshwork with minimal residual leaflets Maintains natural physiologic outflow pathways
89131364|NCT00829465|Active Comparator|control|
89131365|NCT00829465|Experimental|therapy|
89290190|NCT05174494|Active Comparator|Full mouth non surgical periodontal treatment|Each selected subject underwent to full mouth SRP.
88802551|NCT02375126||Ages 18-55, with antidepressant use|Ages 18-55, up to 10 males and 10 females, taking antidepressants
88802552|NCT00014560|Experimental|Single arm|Antibody
88802553|NCT02367092|Experimental|Exercise Program|The exercise intervention consists of a 30 minute exercise session led by an instructor through a DVD or a video available on the internet.
88802554|NCT02367092|No Intervention|Standard of care|Standard of care which consists of encouragement to exercise by the subject's transplant clinician.
88802555|NCT00020722|Experimental|therapeutic autologous lymphocytes|
88802556|NCT02650700|Experimental|spleen radiation plus spleen radiotherapy|Chemotherapy plus spleen radiotherapy Chemotherapy plus spleen radiotherapy are performed, simultaneously, to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). The intervention is spleen radiotherapy.
88802557|NCT02650700|Other|chemotherapy|Chemotherapy is performed to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). When severe CIT (≧grade III) occurs, the subjects should receive chemotherapy plus spleen radiotherapy. The intervention is spleen radiotherapy.
88802558|NCT04051996|Experimental|DAC5|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
89131366|NCT05336708|Experimental|Acupressure group|The acupressure (experimental) group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
89131367|NCT05336708|Sham Comparator|Sham Acupressure Group|The sham acupressure group will apply acupressure to themselves three times a week for a total of 12 sessions for four weeks.
89131368|NCT02839356|Experimental|Drug: epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
89131369|NCT02839356|Placebo Comparator|Drug: normal saline|20-mL irrigation with physiological saline over the entire papilla
89131370|NCT00829543|Experimental|sacroiliac injection|an open label study designed to evaluate the efficacy and safety of guide-free sacroiliac injection in refractory sacroiliac pain due to spondyloarthropathies
89131371|NCT02840526|Experimental|PVB group|Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
89131372|NCT02840526|Other|GEN group|Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
89131373|NCT02840370|Experimental|transcranial direct current stimulation|tDCS
89131374|NCT02840370|Sham Comparator|Sham tDCS|S-tDCS
89131375|NCT00820885|Other|cohort A|20 mg dose 20 mg/ML concentration and placebo
89131376|NCT00820885|Other|Cohort AR|20 mg in 50 mg/ml concentration and placebo
89131377|NCT00820885|Other|Cohort C|25 mg in 50mg/ml concentration and placebo
89131378|NCT00820885|Other|Cohort D|15 mg in 50mg/ml concentration and placebo
89131379|NCT00820885|Other|Cohort E|10 mg in 50mg/ml concentration and placebo
89131380|NCT00820885|Other|Cohort F|30mg in 50mg/ml concentration and placebo
89131381|NCT00820885|Other|Cohort H|50mg in 50mg/ml concentration and placebo
89131382|NCT00820885|Other|cohort I|80mg in 50mg/ml concentration and placebo
89131383|NCT00633048|Experimental|NSA-789|active drug
89131384|NCT00633048|Placebo Comparator|placebo|placebo
89131385|NCT02844842||1 day initiation schedule|The initiation Schedule consists in administering 0.2 mL and 0.3 mL with 30 minutes of interval in the same day. Thus, the patient will reach the maintenance dose of 0.5 mL in one day.
89131386|NCT02844842||Rapid initiation schedule|The patient will receive 3 increasing doses (0.1 mL + 0.3mL + 0.5 mL) weekly doses till the maintenance dose (0.5 mL) is reached.
89131387|NCT02840292||Cases|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal hemoglobin < 11gm/dl
89131388|NCT02840292||Controls|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal haemoglobin ≥ 11gm/dl
89131389|NCT00825331||1|patients for elective catheterization without special risks
89131390|NCT00825331||2|patients for elective catheterization with special risks
89131391|NCT00825331||3|patients for PCI without GP IIb/IIIa
88802559|NCT04051996|Experimental|DAC10|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
89131392|NCT00825331||4|Patients for PCI with GPIIb/IIIa and emergencies
89131393|NCT04533464|Experimental|MultiStem|
89131394|NCT04533464|Placebo Comparator|Placebo|
89131395|NCT02839434||Treated with oral anticoagulants|Ex vivo study using blood samples from patients treated with oral anticoagulant (direct oral anticoagulants or AVK) at curative dose, taken in the usual cardiac monitoring.
89131396|NCT00820963|Experimental|Arm I|Patients undergo standard radiotherapy 5 days a week for 6 weeks.
89131397|NCT00820963|Experimental|Arm II|Patients undergo hypofractionated radiotherapy 5 days a week for 2 weeks.
89131398|NCT00820963|Experimental|Arm III|Patients receive oral temozolomide on days 1-5. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89131399|NCT02834676||Chemonucleolysis by Gelified Ethanol|Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy and ozone-oxygen therapy. Written informed consent was obtained from all participants.
89131400|NCT00632840|Placebo Comparator|P|placebo group
89131401|NCT00632840|Active Comparator|Feno|Fenofibrate
89131402|NCT00632840|Active Comparator|ATV|Atorvastatin
89131403|NCT02834598|Experimental|Rocking movement|Participant is lying in a hammock with a rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
89131404|NCT02834598|Active Comparator|Lying position|Participant is lying in a hammock with no rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
89131405|NCT02834598|Active Comparator|Seated position|Participant is sitting on a chair. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
89131406|NCT03854695||Cohort 1|Cohort 1: clinically uninfected (1A and 1C) ulcers.
89131407|NCT03854695||Cohort 2|Cohort 2: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) with no recent antibiotic therapy (within 28 days)
89131408|NCT03854695||Cohort 3|Cohort 3: clinically infected (redness, edema, induration, heat, exudate, tenderness/pain (1B and 1D)) on antibiotic therapy
89131409|NCT00829699|Experimental|1|Euinsulinemic (low insulin infusion) Euglycemic (normal blood glucose levels) glucose clamp with lipid (fat) infusion
89131410|NCT00829699|Experimental|2|Euinsulinemic Hyperglycemic (high glucose levels) glucose clamp with lipid infusion
89131411|NCT00829699|Experimental|3|Hyperinsulinemic (High dose insulin) euglycemic glucose clamp with lipid infusion
89131412|NCT00829699|Experimental|4|Hyperinsulinemic hyperglycemic (high glucose level) glucose clamp with lipid infusion
89131413|NCT05334030|Experimental|Stroke|
89131414|NCT05334030|Experimental|Healthy|
89131415|NCT00821197|Active Comparator|long-limb bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
89131416|NCT00821197|Active Comparator|Distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
89131417|NCT00829855||1|Patients with hypertensive (systolic blood pressure ≥160 mmHg) acute pulmonary edema, evaluated within 120 minutes after admittance.
89131418|NCT00829855||2|The same patients from group 1 followed-up at 48 to 96 hours.
89131419|NCT05318586|Experimental|Individualized rTMS based on fNIRS|Low-frequency rTMS will be given to the most active brain regions assessed by fNIRS.
89131420|NCT05318586|Active Comparator|Traditional rTMS strategy|The control group will always be given low-frequency rTMS to contralesional M1
89131421|NCT00825487|Experimental|ARQ 621 treatment|
89131422|NCT00821275|Active Comparator|pregnancy expectation|The patients who desire for future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
89131423|NCT00821275|Active Comparator|No pregnancy expectation|The patients who don't desire for reserving uterus and/ or future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
89131424|NCT00830011|Active Comparator|standard care|Medical care including medication for neuropathic pain
89131425|NCT00830011|Active Comparator|CBT|
89131426|NCT02834832||Control|The patients will be given removable dentures with no coatings. These dentures are part of the standard of care to treat their edentulism.
89131427|NCT02834832||PECVD Coatings|The patients will be given removable partial dentures with PECVD coatings on both the tissue surface of the dentures and the acrylic denture teeth.
89131428|NCT00623467|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.
89131429|NCT02834754|Experimental|Vedolizumab|Vedolizumab infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
89131430|NCT02834754|Placebo Comparator|placebo|Placebo infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
89131431|NCT05310942||A|The fluid management of patients in this group will be assessed by IVC collapsibility index (IVC CI) calculated by ultrasound through maximum IVC diameter - minimum IVC diameter divided by maximum diameter then multiplied by 100. If it is less than 50% means that the patient is volume non- depleted while if it is more than 50% means the reverse.
89131432|NCT05310942||B|All patients in this group with sepsis will be evaluated by the electrical cardiometry monitor.
89131433|NCT02839512|Experimental|Jejunal to Ileal Diversion|All subjects who receive jejunal to ileal diversion endoscopic procedure
89131434|NCT02839122|Experimental|Dutasteride, Tadalafil|
89131435|NCT02839122|Experimental|Tadalafil, Dutasteride|
89131436|NCT02838810|Experimental|Experimental|CHB patients with low level HBsAg.Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1000 IU/mL and Hepatitis B virus DNA <100 IU/mL, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The longest course of treatment is 96 weeks. After treatment, patients will be followed up for 24 weeks. During the 96 weeks course of treatment, HBsAg level will be monitored. When HBsAg level is less than 0.05 IU/mL, peginterferon treatment will be stopped and patients will receive 24 weeks follow up.
89131437|NCT02838810|Other|Control|Patients do not need to change their NAs treatment.
89131438|NCT02838888||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
89131439|NCT00633282|Experimental|Lifestyle intervention|Life style intervention including aerobic exercise and reducing energy intake(-500kcal) without drug
89131440|NCT00633282|Experimental|Life style intervention, pioglitazone|Life style intervention with pioglitazone 15mg qd for 16 weeks
89131441|NCT00633282|Experimental|Life style intervention, berberine|Life style intervention with berberine 0.5g tid for 16 weeks
89131442|NCT00830089|Experimental|TAP block|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
89131443|NCT00830089|No Intervention|Standard care|No TAP block is given. Care is otherwise identical to arm 1
89131444|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 1|1 can per day for 5 days prior to surgery
89131445|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 2|2 cans per day for 5 days prior to surgery
89131446|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 3|3 cans per day for 5 days prior to surgery
89131447|NCT02838966|Active Comparator|Nestle Boost High Protein Drink - Control Arm|4 cans per day for 5 days prior to surgery
89131448|NCT00830245|Experimental|Erlotinib|Erlotinib 150mg/day (if no negative conversion --> increment to 250mg/day)
89131449|NCT02837874|Active Comparator|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
89131450|NCT02837874|Experimental|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
89131451|NCT02549911|Experimental|HIPEC,Chemotherapy AND surgery|"surgical exploration,if PCI<20,then we perform this study~HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~chemotherapy(3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
89131452|NCT02838030|Experimental|acetylsalicylic acid and L-arginine|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
89131453|NCT02838030|Placebo Comparator|acetylsalicylic acid and placebo|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and placebo 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
89131454|NCT00825643||Insulin detemir|
89131455|NCT04250298|Other|Iron deficient blood donors|Daily intake of 30 mg of sucrosomal iron during 90-120 days (male and female whole blood donors)
89131456|NCT04044079|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
89131457|NCT04044079|Active Comparator|misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
89131458|NCT04044079|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
89131459|NCT02837484|Other|NuTech Affinity™ Membrane|Sharp dissection of the defect will be performed being careful not to violate the subchondral bone sparing the calcified cartilage layer. After hemostasis is reached, the defect will be treated with an Affinity™ patch stabilized with fibrin glue.
89131460|NCT00830323|Experimental|1|
89131461|NCT00830323|Experimental|Arm 2|
89131462|NCT00830323|Active Comparator|Arm 3|
89131463|NCT05333562|Other|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
89131464|NCT05333562|Active Comparator|Motor control exercise with neural mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
89131465|NCT00830401|No Intervention|1|One or more of the predefined minor intra-uterine abnormalities have been detected, but not treated during hysteroscopy.
89131466|NCT00830401|Active Comparator|2|One or more of the predefined minor intra-uterine abnormalities have been detected and treated during hysteroscopy.
88802560|NCT02385292|Experimental|Intranasal then Extranasal Application|Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
89131467|NCT04249908|Active Comparator|Healthy Subjects|
89131468|NCT04249908|Experimental|Mild Renal Impairment (RI)|
89131469|NCT04249908|Experimental|Moderate RI|
89131470|NCT04249908|Experimental|Severe RI|
89131471|NCT00830713|Experimental|MKTP treatment|subject will undergo MKTP
89131472|NCT02837796|Active Comparator|inside-outside group|inside-out transobturator tape approach
89131473|NCT02837796|Active Comparator|outside-inside group|outside-in transobturator tape approach
89131474|NCT00825721|Active Comparator|1.3% (low dose)|
89131475|NCT00825721|Active Comparator|2% (medium dose)|
89131476|NCT00825721|Active Comparator|2.6% (high dose)|
89131477|NCT00825721|Placebo Comparator|Placebo|
89131478|NCT02837640|Experimental|Treatment|"This is a single armed study. All patients included will receive treatment. Control will happen with data from the same patients before they received treatment.~patients will receive sinemet 200/50 1/2 tablet (levodopa-carbidopa 100/25) b.i.d for two days and then will be increased to t.i.d. for 6 months."
89131479|NCT02548663|Experimental|active; sport therapy|active exercise carefully calibrated on residual capacities.
89131480|NCT02548663|Experimental|passive; osteopathic treatment|manipulative treatment according to osteopathic principles.
89131481|NCT02837718|Other|Bupivacaine 0,5% Single arm study|Bupivacaine 0,5% Single arm study
89131482|NCT00825799||Major Depressive Disorder|Adults with major depressive disorder who are experiencing a current depressive episode.
88802561|NCT02385292|Active Comparator|Extranasal then Intranasal Application|Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
88802562|NCT02640638|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care
88802563|NCT02640638|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care
88802564|NCT01893086|Active Comparator|LH alone|LH, laparoscopic hysterectomy
88802565|NCT01893086|Experimental|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
89131483|NCT00825799||Healthy controls|Individuals without any Axis I psychiatric diagnosis who are matched to depressed subjects by age and sex.
89131484|NCT04249752||Group 1 with GBS patients|GBS patients
89131485|NCT04249752||Group 2 with CIDP patients|with CIDP patients
89131486|NCT02834442|Experimental|Single ascending dose, MT-7117 or Placebo|
89131487|NCT02834442|Experimental|Multiple ascending dose, MT-7117 or Placebo|
89131488|NCT02834520||oral lichen planus|30 patients suffering from reticular, erosive and atrophic oral lichen planus
89131489|NCT02834520||control subjects|30 individuals age, gender and periodontal status matched with oral lichen planus patients and not suffering from any oral mucosal lesions or periodontal disease.
89131490|NCT02834208|Experimental|Schizophrenia subjects|35 patients suffering from schizophrenia
88802566|NCT02126878|Active Comparator|Kenalog 20mg|20mg/ 2ml and local anesthetic
88802567|NCT02126878|Active Comparator|Kenalog 40mg|40mg/ 2ml with local anesthetic
89131491|NCT02834208|Other|Healthy siblings|35 healthy siblings of the patients suffering from schizophrenia
89131492|NCT02834208|Other|Healthy controls|"35 healthy controls patients"
89131493|NCT02834286|Experimental|Rituximab, eltrombopag and dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21 Eltrombopag 50 mg PO days 1-28 Dexamethasone 40 mg IV/PO days 1-4
89131494|NCT02837562||Interventional Cardiology/Cath Lab Staff|"This is considered to be the case or group under study. These are Interventional Cardiology/ Cardiac Cath lab staff that are exposed to radiation as a result of their role as Cardiac Cath lab staff.~Intervention: Slit lamp eye examination"
89131495|NCT02837562||Non-Interventional Cardiology/ Controls|"This is considered to be the control or comparison group. These are non-interventional cardiology/ non-cardiac cath lab staff that are not exposed to radiation as they do no operate/ work in the Cardiac Cath Lab.~Intervention: Slit lamp eye examination"
89131496|NCT02834130|Other|children from 2 to 10 years with haemophilia or allied HBD, wh|
89131497|NCT04248270|Other|The relationship between image and AD disease|To evaluate the relationship between F-18-PMPBB3 PET image uptake pattern and AD disease classifications.
88802568|NCT02126878|Active Comparator|Kenalog 80mg|80mg/ 2ml and local anesthetic
89131498|NCT02837016|Experimental|Experimental 1|Wearable biofeedback device + Relaxation Training
89131499|NCT02837016|Active Comparator|Experimental 2|Relaxation Training only
89131500|NCT02833896||endometrial cancer|
89131501|NCT02833896||Control|
89131502|NCT02833818|Experimental|CAKE-intervention|Increased nutrition and dietary consultations. Growth rate followed by clinical nutritionists that supply high protein and energy if growth rate deviates from 17g/kg/day
89131503|NCT02833818|Active Comparator|CAKE-control|nutrition according to established procedures in the neonatal intensive care unit (NICU)
89131504|NCT02837172||Parkinson's disease from UAB|MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, Diffusion Weighted Imaging (DWI), and neurological examination.
89131505|NCT02837172||Parkinson's disease from PPMI dataset|Obtain retrospective and prospective de-identified data from the The Parkinson's Progression Markers Initiative (PPMI) dataset on Parkinson's disease (PD) subjects that have the following characteristics: within 2 years of diagnosis, positive DaTscan, and not (at study entry) on any PD related medication.
89131506|NCT02837172||Controls from PPMI dataset|Obtain retrospective and prospective de-identified DTI imaging and data from the PPMI dataset
89131507|NCT04250532||Lifeguard|Lifeguards who work on the Atlantic coast of Gironde France.
89131508|NCT02839044|Experimental|Vitamin K|One group receives tablets of 360 microgram menaquinone-7 daily
89131509|NCT02839044|Placebo Comparator|Placebo|One group receives placebo tablets daily
89131510|NCT02833740|Other|Click-MUAC & regular MUAC tape screening|"Each child will have nutritional status classified 11 times:~3 times with each of the 3 Click-MUAC prototypes by the mother/caregiver~1 time with a regular MUAC tape by the mother/caregiver~3 times with each of the 3 Click-MUAC prototypes by the case-finding/programme staff~1 time with a regular MUAC tape by the case-finding/programme staff~3 times with a regular MUAC tape by the data collection team (gold standard)"
89131511|NCT02833662|Other|Patients suspected to present a Sleep Apnea Syndrom|"Record nocturnal respiratory and cardiac parameters before and after surgery :~Severity of sleep respiratory disorders and relationship with cardiac rhythm abnormalities will be assessed in patients suspected to present Sleep Apnea, before and after surgery under general anesthesia."
89131512|NCT05285592|Experimental|Fecal Transplantation|"Donors will be supplied clean, sealable containers for collection and transport of stool. Containers will be labeled with the name, UHID and date/time of stool collection.~Collected stool will be immediately transferred to the laboratory facility for processing and used within 6 hours collection~Stool sample from Healthy donor will be processed~Patient preparation~Patient was kept NPO for 4 hours prior to stool instillation~Iv antibiotics were continued as per treating doctor in the event of sepsis~The patient was allowed to consume the prescribed diet 2 hours after the procedure instillation~Methods of FMT infusion.~Seven doses (30gm one dose) of FMT will be given via jejunal port of NJ/NG tube"
89131513|NCT05285592|Active Comparator|Standard Medical Treatment|Standard Medical Treatment
89131514|NCT04249440||PST|patient accepts preoperative systemic treatment as upfront strategy
89131515|NCT04249440||upfront surgery|patient accepts upfront surgery and run postoperative systemic treatment
89131516|NCT04249518|No Intervention|nurse instruction of CPAP|Normal extradition. 45 minutes face to face with a nurse.
89131517|NCT04249518|Experimental|Video extradition|Access to 7 min video - explaining how to start CPAP and how to adjust the mask.
89131518|NCT04249206|Experimental|Hydraulic Sealer Group|"The single-cone obturation technique is based on a master cone of gutta-percha in conjunction with a hydraulic sealer.~Hydraulic endodontic cements exhibit excellent hydraulic properties, biocompatibility and bioactivity."
89131519|NCT04249206|Active Comparator|Zinc oxide-eugenol Sealer Group|The continuous wave of condensation of gutta-percha and a zinc oxide-eugenol (ZOE) sealer is a gold standard in endodontic obturation.
88802569|NCT02634008|Experimental|Cohort 1|Paritaprevir/ritonavir/ombitasvir (75mg/50mg/12.5mg) and dasabuvir (250mg) with or without ribavirin (1000-1200mg) daily taken orally for 8 weeks.
88802570|NCT02634008|Experimental|Cohort 2|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 6 weeks
88802571|NCT02634008|Experimental|Cohort 3|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 4 weeks
88802572|NCT02802254|Experimental|Pedometer+physical-activity-feedback|At cardiac consultation patients receive a patient-targeted individual physical-activity-feedback.
89131520|NCT02833506|Active Comparator|Cohort I (NY-ESO-1 protein with MIS416)|Patients receive NY-ESO-1 protein with MIS416 vaccine SC on days 1, 15, 29, 57, 85, and 113 in the absence of disease progression or toxicity.
89131521|NCT02833506|Experimental|Cohort II (NY-ESO-1 protein with MIS416, sirolimus)|Patients receive NY-ESO-1 protein with MIS416 vaccine as in Cohort I. Patients also receive sirolimus PO daily for 2 weeks followed by 2 weeks off starting on days 1, 29, 57, and 85.
89131522|NCT02838108||patients with COPD|
89131523|NCT02838498|Experimental|Intensive EMS training group|"Device: ERCP mechanical simulator training EMS group was coached (by JWL) on how to use the EMS, and then practiced with supervision by a senior surgeon biliary endoscopist (WBM). Trainees practiced for a total of 20 hours performing basic maneuvers including scope insertion 2 hours, scope positioning 6 hours, selective guide wire cannulation of common bile duct (CBD) stricture or pancreatic duct (PD) 10 hours and placement of a biliary stent 2 hours.~All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over."
89131524|NCT02838498|No Intervention|Routine ERCP training group|Other: Routine ERCP training group All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over.
89290191|NCT05174494|Placebo Comparator|Control|Each selected subject underwent full mouth traditional oral hygiene.
89131525|NCT02833272|Experimental|EMPOWER Educational Brochure|This is the only arm of the study. All participants will undergo the intervention, which is an educational brochure (EMPOWER educational brochure) to explain the possible harms of benzodiazepine and non-benzodiazepine sedative drugs.
89131526|NCT02838576|Experimental|Conjugated Equine Estrogen|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive 0,625 mg/day conjugated equine estrogen (CEE) for 12 weeks. These 1 active pill containing conjugated equine estrogen, 0,625 mg will be provided by a laboratory with no trademark identification.~The bottles will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.~During the intervening period, use of conjugated equine estrogen, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug."
89131527|NCT02838576|Placebo Comparator|Placebo|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive placebo pills, identical in size, shape and color to the active drug, via oral administration, for 12 weeks.~The bottles, without trademark identification, will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.~During the intervening period, use of placebo, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug and placebo."
89131528|NCT02836860|Other|Healthy Controls|Effects of tactile stimulation on lumbar multifidus activation in healthy adults without LBP.
89131529|NCT02836860|Other|Low Back Pain|Effects of tactile stimulation on lumbar multifidus activation in adults with LBP.
89131530|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 1)|Neratinib 120 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131531|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 2)|Neratinib 120 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131532|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 3)|Neratinib 120 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131533|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 4)|Neratinib 120 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131534|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 5)|Neratinib 160 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131535|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 6)|Neratinib 160 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131536|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 7)|Neratinib 160 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131537|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 8)|Neratinib 160 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131538|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 9)|Neratinib 200 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131539|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 10)|Neratinib 200 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131540|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 11)|Neratinib 200 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131541|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 12)|Neratinib 240 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
89131542|NCT02836626|Experimental|Deep Fascial Mobilization|
89131543|NCT02836626|Experimental|Superficial Fascial Mobilization|
89131544|NCT02836548|Experimental|vorinostat|Vorinostat 360 mg once daily
89131545|NCT04249128|Experimental|Veg Collagen & Keratin Free (Hair Skin Nails)|Participants will receive a free 3 month supply of Collagen & Keratin for Hair, Skin & Nail Health
89131546|NCT04249128|Experimental|Veg Collagen Extended with Powder Free (Hair Skin Nails)|Participants will receive a free 3- month supply of Collagen & Keratin for Hair, Skin & Nail Health extended with a pro-berry powder
89131547|NCT04249128|Experimental|Veg Collagen & Keratin $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen & Keratin for Hair, Skin & Nail Health
89131548|NCT04249128|Experimental|Veg Collagen Extended with Powder $$$ (Hair Skin Nails)|Participants will receive a paid 3-month supply of Collagen & Keratin extended with pro-berry powder for Hair, Skin & Nail Health
89131549|NCT04249128|Experimental|Ceramides and Astaxanthin Free (Skin)|Participants will receive a free 3-month supply of ceramides and Astaxanthin for Hair, Skin & Nail Health
89131550|NCT04249128|Experimental|Ceramides and Astaxanthin Extended with Powder Free (Skin)|Participants will receive a free 3-month supply of Ceramides and Astaxanthin for Hair, Skin & Nail Health
89131551|NCT04249128|Experimental|Ceramides and Astaxanthin $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin & Nail Health
89131552|NCT04249128|Experimental|Ceramides and Astaxanthin Extended with Powder $$$ (Skin)|Participants will receive a paid 3-month supply of Ceramides and Astaxanthin extended with pro-berry powder for Hair, Skin & Nail Health
89131553|NCT02836938||Severe|Severe chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3
89131554|NCT02836938||Mild|Mild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2
89131555|NCT02836938||Control|Bronchiolitis obliterans syndrome (BOS), stage 0
89131556|NCT05333484|Experimental|Pilates Intervention Group|12-week programed Pilates intervention
89131557|NCT05333484|No Intervention|Control Group|maintenance of normal lifestyle in control group
89131558|NCT04030767|Experimental|lip repositioning technique with Botox injection.|"Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity (Binder et al., 1998).~Therefore, the technique is a useful adjunct in the esthetic improvement of the smile and provides better results when combined with resective gingival surgery(Pedron & Mangano, 2018)."
89131559|NCT04030767|Active Comparator|lip repositioning technique.|Lip repositioning aims to limit the retraction of elevator smile muscles. Lip repositioning results in a shallow vestibuler restricting of the muscle pull; Thereby limiting the gingival display during smiling.(Makkiah, 2017) It is a less invasive, viable substitute for patients, has fewer post-operative complications and provides a faster recovery compared to orthognathic surgery(Grover, Gupta, & Luthra, 2014).
89131560|NCT02836704|Active Comparator|Standard initial dose of insulin glargine|Dose 1 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
89131561|NCT02836704|Experimental|Higher initial dose of insulin glargine|Dose 2 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
89131562|NCT02611947||Healthy Volunteers|"Inclusion criteria:~Aged 18 or more.~Never smoked.~No respiratory infection in the 4 weeks before the begin of the study.~No history of pulmonary resection.~No active malignancy or malignancy of any organ system within the past 5 years."
89131563|NCT04478604||pregnant women|last trimester pregnant women and gave birth in the same hospital
89131564|NCT02833584|Experimental|Paracetamol|Eligible patients will be randomised to receive Paracetamol prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
89131565|NCT02833584|Placebo Comparator|Placebo|Eligible patients will be randomised to receive Placebo prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
89131566|NCT00837759|Other|T1D group|This study was terminated prior to full subject accrual because of changes to study personnel. The original study design was changed from a double-blind, placebo-controlled study to an open-label pilot study in order to collect safety data on enrolled subjects prior to study termination.
89131567|NCT02832960|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
89131568|NCT02832960|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
89131569|NCT00703287|Sham Comparator|A2|Generic physiotherapy
89131570|NCT00703287|Experimental|A1|Specialized Physiotherapy
89131571|NCT02836782||Naive patients|Patients who begin their first antiretroviral regimen. Blood sample withdrawal
89131572|NCT02836782||Experienced patients|"Patients with a history of antiretroviral treatment, switching to a new regimen.~Blood sample withdrawal"
89131573|NCT02836314|Experimental|PRF and ABBM|Intervention: Anorganic Bovine Bone Mineral and Platelet Rich fibrin is applied to the periodontal intrabony defects
89131574|NCT02836314|Active Comparator|Anorganic Bovine Bone Mineral|Intervention: Anorganic Bovine Bone Mineral is applied to the periodontal intrabony defects
89131575|NCT05333718||Newly diagnosed T2DM|"To assess and characterize the relevant subgroups (clusters) of type 2 diabetes at diagnosis in our population.~This objective will be addressed using the 6 main variables that have been used so far in previous studies in other populations to develop disease groupings, that is, age, GAD antibodies, body mass index, glycosylated hemoglobin (HbA1c), and estimates of the evaluation of the homeostatic model 2 of β-cell function and insulin resistance."
89131576|NCT00703365|Experimental|1|Sorafenib
89131577|NCT00891774|Experimental|Device|Treatment with EVOLENCE®
89131578|NCT00703521|Placebo Comparator|1,2,3,4,5|"Rabies vaccine 1.0 mL IM on day 0, 7, 28,and 1 year~Rabies vaccine 0.5 mL IM on day 0, 7, 28,and 1 year~Rabies vaccine 0.1 mL Intradermal on day 0, 7, 28,and 1 year~Rabies vaccine 0.1 mL Intradermal on day 0, 28,and 1 year~Japanese encephalitis vaccine 0.25 mL subcutaneous"
89131579|NCT05878899|Experimental|Enoxaparin|Enoxaparin 20-60mg o.d., according to bodyweight, for 10 days postpartum.
89131580|NCT05878899|No Intervention|No treatment|No treatment.
89131581|NCT05878886|Experimental|Treatment group|Treatment group received 50 g mangrove sword bean food bar during 15 days.
89131582|NCT05878886|Placebo Comparator|Control group|Control group received 50 g sword bean food bar during 15 days.
89131583|NCT05878847|Experimental|Q-actin|Q-actin gummies (2 x 10mg) daily for 12 weeks
89131584|NCT05878847|Placebo Comparator|Placebo|Placebo gummies (2 x 10mg) daily for 12 weeks
88802573|NCT02802254|Active Comparator|Pedometer-only|Patients use a Pedometer in order to measure their daily step number
89131585|NCT05878808||Cases with ocd|
89131586|NCT05878808||Cases without ocd|
89131587|NCT05878782|Experimental|Occupational therapy intervention associated with MCRO assesment.|the experimental care of this group will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
89131588|NCT05878782|Experimental|MCRO assessment without intervention|This experimental group will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
89131589|NCT05878782|No Intervention|Usual care|this group will have the usual cancer management care combining specific treatments and supportive care.
89131590|NCT05878678|Active Comparator|Fixed positions of arm up|Patients will receive particle radiotherapy in arm up position. Radiation: adjuvant hypofractionated intensity-modulated proton radiotherapy; For patients received modified radical mastectomy, Clinical Target Volume (CTV) 1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy; For patients received lumpectomy, CTV1: whole breast ± regional lymph drainage area, 40.05 Gy (RBE) in 15 fractions with proton radiotherapy; CTVtb: tumor bed SIB（simultaneous integrated boost） to 48 Gy (RBE) in 15 fractions with proton radiotherapy.
89131591|NCT05878678|Experimental|Fixed positions of arm down|Patients will receive particle radiotherapy in arm down position. Radiation: adjuvant hypofractionated intensity-modulated proton radiotherapy; For patients received modified radical mastectomy, CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy; For patients received lumpectomy, CTV1: whole breast ± regional lymph drainage area, 40.05 Gy (RBE) in 15 fractions with proton radiotherapy; CTVtb: tumor bed SIB to 48 Gy (RBE) in 15 fractions with proton radiotherapy.
89131592|NCT05878613|Experimental|treadmill training with KT group (TTKT group)|Participants will undergo treadmill training with kinesiotape applied on their trunk muscles/
89131593|NCT05878613|Active Comparator|treadmill training without KT group (TT group)|Participants will undergo treadmill training.
89131594|NCT05878574||LMWH group|Continuous use of low molecular weight heparin for more than 3 months during pregnancy preparation and during pregnancy with a history of more than 2 consecutive miscarriages before 28 weeks of gestation
89131595|NCT05878574||control group|No use of low molecular weight heparin during pregnancy preparation and throughout pregnancy and history of more than 2 consecutive miscarriages before 28 weeks of gestation
89131596|NCT05878561|Experimental|Fimasartan + Indapamide|Treatment Period I, II
89131597|NCT05878561|Active Comparator|Fimasartan + Indapamide placebo|Treatment Period I, II
89131598|NCT05878470|Experimental|Brief video intervention|Brief (119 seconds) social contact-based video
89131599|NCT05878470|No Intervention|Non-intervention control|Non-intervention control
89131600|NCT05878444|Experimental|Normal weight|People with BMI between 20-25 will be enrolled in this group. They will take the probiotic capsule daily during 15 days. Dosis will be 10^9-10.
89131601|NCT05878444|Experimental|Overweight/Obese|People with BMI >25 will be enrolled in this group. They will take the probiotic capsule daily during 15 days. Dosis will be 10^9-10.
89131602|NCT05878431|Experimental|Experimental groups|"patients in the experimental group during the pre-test phase; Patient Information Form, Herth Hope Scale, Four-Question Neuropathic Pain Questionnaire (DN4Q), The Effect of Neuropathic Pain on Quality of Life Questionnaire (NePIQOL) and Visual Analog Scale (VAS) were administered by face-to-face interview technique. Then to the patients in the experimental group; A total of 12 sessions of foot reflexology, two sessions per week, were applied for 6 weeks. patients in the experimental group during the pos-test phase; Herth Hope Scale, Four-Question Neuropathic Pain Questionnaire (DN4Q), The Effect of Neuropathic Pain on Quality of Life Questionnaire (NePIQOL) and Visual Analog Scale (VAS) were administered by face-to-face interview technique"
89131603|NCT05878431|No Intervention|Control groups|"patients in the control group at the pre-test stage; Patient Information Form, Herth Hope Scale, Four-Question Neuropathic Pain Questionnaire (DN4Q), The Effect of Neuropathic Pain on Quality of Life Questionnaire (NePIQOL) and Visual Analog Scale (VAS) were applied. with face-to-face interview technique. patients in the control group during the pos-test phase; Herth Hope Scale, Four-Question Neuropathic Pain Questionnaire (DN4Q), The Effect of Neuropathic Pain on Quality of Life Questionnaire (NePIQOL) and Visual Analog Scale (VAS) were administered by face-to-face interview technique"
89131604|NCT05878392|Experimental|group 1|immediate implant placement and the buccal jumping gap was packed using PRF
89131605|NCT05878392|Experimental|group 2|immediate implant placement and the buccal jumping gap was packed using xenograft
89131606|NCT05878392|Experimental|group 3|immediate implant placement and the buccal jumping gap was packed using alloplast
89131607|NCT05878379|Experimental|Dietary Iron Program|The dietary iron program was administered from weeks 2 to 15 in between pre-test and post-test measurements
89131608|NCT05878366|Active Comparator|Arm 1|SMC in children under the age of 5 years, implemented by the MoH without directly observed treatment for the full course of SMC
89131609|NCT05878366|Experimental|Arm 2|SMC in children under the age of 5 years, with directly observed treatment for the full course of SMC
89131610|NCT05878366|Experimental|Arm 3|SMC in children under the age of 10 years, with directly observed treatment for the full course of SMC
89131611|NCT05878340|Experimental|Miffy intervention|story of miffy, rewards based on colour they ate
89131612|NCT05878340|Active Comparator|Reward intervetion|no story, rewards not assigned to colours
89131613|NCT05878340|No Intervention|Control|no story, no rewards
89131614|NCT05878327||Thrombophilia screening|Patients with livedoid vasculopathy. Investigated by thrombophilia screening
89131615|NCT05878314||Group A: Tamoxifen|Patients with early HR+/HER2- Breast cancer receiving Tamoxifen
89131616|NCT05878314||Group B: Aromatase Inhibitor (+GnRH if premenopausal)|Patients with early HR+/HER2- Breast cancer receiving Aromatase Inhibitor (+GnRH if premenopausal)
89131617|NCT05878314||Group C: Control group|no preoperative endocrine treatment
89131618|NCT05878262|Experimental|pre-emptive analgesia group|For the pre-emptive analgesia group children, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg.
89131619|NCT05878262|No Intervention|control group|No medicine was taken for the control group.
89131620|NCT05878197|Experimental|Experimental group 1 - Straw Phonation|Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): straw phonation and vocal hygiene recommendations
89131621|NCT05878197|Experimental|Experimental group 2 - Resonant Voice Therapy|Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): resonant voice therapy and vocal hygiene recommendations
89131622|NCT05878197|Sham Comparator|Control group|Short-term intensive voice therapy program of one week (3 hours a day for 4 consecutive days): vocal hygiene recommendations
89131623|NCT05878158|Active Comparator|simvastatin|Drug The drug powder will be mixed with distilled water to form a paste applied in the pup chamber of immature permanent molars over the pulp stump
89131624|NCT05878158|Experimental|Mineral Trioxide Aggregate|Dental material It is a regenrative endodontic material prepared as apoweder that mixed with distilled water to form a paste applied in the pup chamber of immature permanent molars over the pulp stump
89131625|NCT05878145|Experimental|Intervention group|A 20-session structured rehabilitation exercise program in those with spinal cord injuries
89131626|NCT05878145|No Intervention|Control group|No exercise intervention in those with spinal cord injuries
89131627|NCT05878132|Experimental|Wearable device group|Participants in the experimental group will be instructed to wear the wristwatch device five days per week for a minimum of 3 hours per day and engage in telerehabilitation, 1hour per day for 5 times per week over 4 weeks. Weekly, there will be a 30-minute therapy consultation.
89131628|NCT05878132|Active Comparator|Conventional therapy group|The participants in the conventional group will receive similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They are instructed to perform the exercises 1hour per day, 5times per week over 4 weeks. Weekly, there will be a 30-minute therapy consultation.
89131629|NCT05878054|Other|Control period 2 months|2 months control period, followed by 12 months intervention, followed by 8 months observation
89131630|NCT05878054|Other|Control period 4 months|4 months control period, followed by 12 months intervention, followed by 6 months observation
89131631|NCT05878054|Other|Control period 6 months|6 months control period, followed by 12 months intervention, followed by 4 months observation
89131632|NCT05878054|Other|Control period 8 months|8 months control period, followed by 12 months intervention, followed by 2 months observation
89131633|NCT05878028|Experimental|L-TIL plus Tislelizumab and Docetaxel|Tislelizumab, 200mg, ivgtt, d1, Q3W for one year L-TIL cells, （3-10）x10^9/m2, ivgtt, d14, Q3W for 4 or 6 cycles Docetacel, 75mg/m2, ivgtt, d1, Q3W for 4 cycles
89131634|NCT05878002|Other|Patients affected by acute ischemic stroke treated with mechanical thrombectomy|
89131635|NCT05877989|Active Comparator|Standard care|Patients will receive usual care in Intensive Care Unit (prescription of a standard nutrition formula (at approximately 20 -25 kcal/ kg/day and protein intake 1.2 g/kg/day) once patients are hemodynamically stable.
89131636|NCT05877989|Active Comparator|Protein and exercise group|patients will receive the amino acid intervention that is provided in addition to 'usual care' enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day. The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient). The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
89131637|NCT05877950|Experimental|Smartphone-based speech therapy with usual stroke care|"Smartphone-based speech therapy: Participants will be instructed to use smartphone-based speech therapy (application), including oro-motor exercises, phonation, articulation, resonance, syllable repetition, and reading exercises.~Usual stroke care: Participants will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines."
89131638|NCT05877950|Active Comparator|Home-based speech therapy with usual stroke care|"Home-based speech therapy: Participants will receive treatment such as oro-motor exercises and reading tasks from a workbook.~Usual stroke care: Participants will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines."
89131639|NCT05877937|Experimental|Interventions group|The intervention group watched a comedy movie during routine IV biologic treatment in the chemotherapy day unit.
89131640|NCT05877937|No Intervention|Control group|The control group received only routine IV biologic treatment as a usual care.
89131641|NCT05877911|Experimental|HIPEC with sodium thiosulfate and hydration|"Sodium sulfate 9 g/m^2 combined with 0.9% natrium chloride 150 ml were instilled in 20 min as the time when HIPEC with cisplatin was beginning. After that, sodium sulfate 12 g/m^2 combined with 0.9% natrium chloride 1000 ml was pumped for 6 h .~hydration: On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters."
89131642|NCT05877911|Active Comparator|HIPEC with hydration only|hydration:On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.
89131643|NCT05877872|Experimental|Reduced-target resection group|Patients receive surgery according to pSTV-post-IC and adjuvant immunotherapy.
89131644|NCT05877872|Active Comparator|Full-target resection group|Patients receive surgery according to pSTV-pre-IC and adjuvant immunotherapy.
89131645|NCT05877794|Experimental|wing group|
89131646|NCT05877781|Active Comparator|PEA + participant ON-PPI|Patiënts that on baseline take daily PPI treatment are randomized in the ON-PPI PEA arm or ON-PPI placebo arm
89131647|NCT05877781|Placebo Comparator|Placebo + Participant ON-PPI|Patiënts that on baseline take daily PPI treatment are randomized in the ON-PPI PEA arm or ON-PPI placebo arm
89131648|NCT05877781|Active Comparator|PEA + participant OFF-PPI|Patiënts that do not take PPI at baseline are randomized in the OFF-PPI PEA arm or OFF-PPI placebo arm
89131649|NCT05877781|Placebo Comparator|Placebo + participant OFF-PPI|Patiënts that do not take PPI at baseline are randomized in the OFF-PPI PEA arm or OFF-PPI placebo arm
89131650|NCT05877768||Coronary Artery Disease|Patients with suspected coronary artery disease and those with known coronary artery disease and the suspicion of progressive disease who undergo clinically indicated Coronary Computed Tomography Angiography on the Photon-Counting Detector CT will be enrolled after written consent. All data from the CT scan and potential additional investigations (e.g. invasive coronary angiographies) will be collected. There will be no additional investigations for the purpose of the study. After 1, 2 and 5 years, participants will be asked to answer a health questionaire.
89131651|NCT05877755|Other|Cardiac MRI acquisition|200 patients with a clinical indication for cardiac magnetic resonance imaging
89131652|NCT05877742|Experimental|AA group|AA for drug abusers.
89131653|NCT05877742|Placebo Comparator|Control group|Routine seminar for drug abusers.
89131654|NCT05877690|Experimental|Group M|
89131655|NCT05877690|Experimental|Group p|
89131656|NCT05878509||patients with traumatic hand-forearm injuries|The patients between the ages of 18-65 who were referred to the hand rehabilitation unit due to traumatic hand and forearm injuries, those who did not have any neurological, orthopedic, rheumatological disease or surgery history in the relevant extremity and those who did not have communication problems were eligible to participate in the study.
89131657|NCT05877638|Experimental|SynePure with Catasyn|SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel
89131658|NCT05877638|Active Comparator|Silvadene|Routine care wound rinse and Silvadene cream
89131659|NCT05877521|Placebo Comparator|Wait List Control (WLC) Usual Care Procedure|Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
89131660|NCT05877521|Experimental|16-hour MORE treatments|Patients in the 16-hour MORE format will receive one 2hrs treatment a week for 8 consecutive weeks (as per study schema: from week 1 to week 8).
89131661|NCT05877521|Experimental|8-hour MORE treatments|Patients in the 8-hour MORE format will receive one 2hrs treatment a week for 4 consecutive weeks (as per study schema: from week 1 to week 4).
89131662|NCT05877521|Experimental|2-hour MORE treatments|Patients in the 2-hour MORE format will receive one 2hrs treatment (as per study schema: in week 1).
89131663|NCT05877495|Experimental|Nutrition Education Group|"The experimental group which is given the nutrition education about food security, safety and prevention food waste.~First of all, a data collection form will be applied to the participants. This form contains food insecurity experience scale, food consumption frequency form, determination of waste level form, safety knowledge, attitudes and behaviors. The they will receive a 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. After this education participants will be answered the same questions again."
89131664|NCT05877495|No Intervention|Control Group|"The control group will be asked the same data collection form with no intervention.~After the post-tests the control group will be given the same education."
89131665|NCT05877482|Experimental|Experimental Group|Short foot exercises with internal shoe modification (a medial longitudinal arch support) will be performed daily for six weeks.
89131666|NCT05877482|No Intervention|Control Group|Only internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe.
89131667|NCT05877417|No Intervention|Control|"If you are in the control group, there will be no supplement or exercise procedures.~You will be asked to come in to the lab for 5 visits"
89131668|NCT05877417|Experimental|Creatine and Blood Flow Restriction Exercise|"Of the other four groups, regardless of randomization, all 4 groups will be supplementing the same for the loading phase and throughout the study. Since this study is blinded, the research personnel will not know which supplement you are given and will therefore ensure everyone is following the same procedures.~Loading here means to consume more than the daily amount of supplement. This visit will have participants consume 5g twice in one day and twice more at home. This is a normal practice and standard use of the supplement.~If you are not in the control group, you will further be randomized into one of four possible supplementation groups. These groups will be double blinded and randomized into either placebo or creatine supplementation. Creatine monohydrate powder (Muscle Feast, Creapure®) will be used for the active supplement group. Dextrose powder (sugar) will be used for the placebo group.~The supplement and placebo are flavorless and odorless powder."
89131669|NCT05877417|Active Comparator|Creatine and No-BFR with Training|"Of the other four groups, regardless of randomization, all 4 groups will be supplementing the same for the loading phase and throughout the study. Since this study is blinded, the research personnel will not know which supplement you are given and will therefore ensure everyone is following the same procedures.~Loading here means to consume more than the daily amount of supplement. This visit will have participants consume 5g twice in one day and twice more at home. This is a normal practice and standard use of the supplement.~If you are not in the control group, you will further be randomized into one of four possible supplementation groups. These groups will be double blinded and randomized into either placebo or creatine supplementation. Creatine monohydrate powder (Muscle Feast, Creapure®) will be used for the active supplement group. Dextrose powder (sugar) will be used for the placebo group.~The supplement and placebo are flavorless and odorless powder."
89131670|NCT05877417|Placebo Comparator|Placebo and Blood Flow Restriction Exercise|"Of the other four groups, regardless of randomization, all 4 groups will be supplementing the same for the loading phase and throughout the study. Since this study is blinded, the research personnel will not know which supplement you are given and will therefore ensure everyone is following the same procedures.~Loading here means to consume more than the daily amount of supplement. This visit will have participants consume 5g twice in one day and twice more at home. This is a normal practice and standard use of the supplement.~If you are not in the control group, you will further be randomized into one of four possible supplementation groups. These groups will be double blinded and randomized into either placebo or creatine supplementation. Creatine monohydrate powder (Muscle Feast, Creapure®) will be used for the active supplement group. Dextrose powder (sugar) will be used for the placebo group.~The supplement and placebo are flavorless and odorless powder."
89290192|NCT01125852|Active Comparator|Intervention group|Patients in this group are treated with usual therapeutic endoscopy including endoscopic combination therapy and 72 hours intravenous proton pump inhibitor. Within 24 hours from the therapeutic endoscopy they receive supplementary angiographic embolization.
89131671|NCT05877417|Sham Comparator|Placebo and No-BFR with Training|"Of the other four groups, regardless of randomization, all 4 groups will be supplementing the same for the loading phase and throughout the study. Since this study is blinded, the research personnel will not know which supplement you are given and will therefore ensure everyone is following the same procedures.~Loading here means to consume more than the daily amount of supplement. This visit will have participants consume 5g twice in one day and twice more at home. This is a normal practice and standard use of the supplement.~If you are not in the control group, you will further be randomized into one of four possible supplementation groups. These groups will be double blinded and randomized into either placebo or creatine supplementation. Creatine monohydrate powder (Muscle Feast, Creapure®) will be used for the active supplement group. Dextrose powder (sugar) will be used for the placebo group.~The supplement and placebo are flavorless and odorless powder."
89131672|NCT05877378|Experimental|Intervention|The intervention group measurements will be carried out every 7 days, since the PICO system lasts from 7 to 14 days, except when the ulcer presents infection, which will be cured every 2-3 days.
89131673|NCT05877378|No Intervention|Control|The control group measurements will be carried out every 7 days, except when the ulcer is infected, when the cure will be carried out every 2-3 days. This group (GC) will be treated mainly with betadine and sugar, or other treatments such as alginate patches, corticosteroids, Aquacel, Celestoderm or Mepitel.
89131674|NCT05877365|No Intervention|Diet Only|Following the same diet as the Purification group
89131675|NCT05877365|Experimental|Purification|Following a diet along with whole food based supplementation
89131676|NCT05877352|Active Comparator|No IOERT|Extended margin surgery
89131677|NCT05877352|Experimental|Low Dose IOERT|Extended margin surgery and IOERT at standard dose (10 Gy)
89131678|NCT05877352|Experimental|High Dose IOERT|Extended margin surgery and IOERT at higher dose (15 Gy)
89131679|NCT05877235|Experimental|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
89131680|NCT05877235|Experimental|Atorvastatin|Atorvastatin, 80mg daily for 60 days.
89131681|NCT05877235|Placebo Comparator|Control|Starch, 1000mg daily for 60 days.
89131682|NCT05877170|Experimental|PEA|PEA-containing nutraceutical agent in oral formulation
89131683|NCT05877170|Placebo Comparator|Placebo|Patients treated with a placebo
89131684|NCT05877144|Experimental|ARM I (LiSWT)|Patients undergo nerve-sparing radical prostatectomy per standard of care. Patients then receive LiSWT treatment weekly for 6 weeks, then have a 6 week break, followed by 6 more weekly treatments. Patients also undergo DDUS at baseline and during follow up.
89131685|NCT05877144|Sham Comparator|ARM II (sham LiSWT)|Patients undergo nerve-sparing radical prostatectomy per standard of care. Patients then receive sham LiSWT treatment weekly for 6 weeks, then have a 6 week break, followed by 6 more weekly treatments. Patients also undergo DDUS at baseline and during follow up.
89131686|NCT05877131|Active Comparator|Levobupivacaina|Levobupivacaine 0.125% , dosage 10 ml frequency 1 one dosis duration 1 hour
89131687|NCT05877131|Active Comparator|Ropivacaina|Ropivacaine 2 % , dosage 10 ml frequency 1 one dosis duration 1 hour
89131688|NCT05877092|Active Comparator|acrylic resin denture base|complete overdenture constructed from heat cured acrylic resin for Group I
89131689|NCT05877092|Active Comparator|thermoplastic denture|complete thermoplastic denture was constructed for Group II
89131690|NCT05877079|Experimental|Menthol group|Hand and foot wraps with 8% w/w menthol lotion (20 grams each) will be delivered to each subject to wear for 5 min 5 days per week. The total duration is 4 weeks.
89131691|NCT05877079|Placebo Comparator|Non-Menthol group|Hand and foot wraps containing the lotion (20 grams each) without menthol will be delivered to each subject to wear for 5 min 5 days per week. The total duration is 4 weeks.
89131692|NCT05877053|Experimental|CK-4021586 for SAD Cohort|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-4021586
89131693|NCT05877053|Placebo Comparator|Placebo for SAD Cohort|Subjects will be assigned to one of approximately 8 planned cohorts and receive single doses of placebo
89131694|NCT05877053|Experimental|CK-4021586 for MAD Cohort|Subjects will be assigned to one of 4 planned dose cohorts and receive multiple doses of CK-4021586
89131695|NCT05877053|Placebo Comparator|Placebo for MAD Cohort|Subjects will be assigned to one of approximately 4 planned cohorts and receive multiple of placebo
89131696|NCT05877053|Experimental|Food Effect|Healthy subjects will be administered CK-4021586 with and without food in a cross-over fashion
89131697|NCT05877040|Experimental|Treated|
89131698|NCT05877001|Experimental|HAIC combined with Tislelizumab and Regorafenib|HAIC combined with Tislelizumab and Regorafenib until progression or death.
89131699|NCT05876975|Active Comparator|procedure: laparoscopic pectopexy|MRI evaluation will be conducted on eleven participants who underwent laparoscopic pectopexy surgery after one month.
89131700|NCT05876975|No Intervention|Nulliparous women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI
89131701|NCT05876936|Other|contact lens sensor Triggerfish® in patients selected for deep sclerectomy with collagen implant|The contact lens sensor (CLS) SENSIMED Triggerfish® in will be placed on the study eye as selected for deep sclerectomy with collagen implant (DSCI)
89131702|NCT05876897||Diagnostic Ultrasound|
89131703|NCT05876845|Experimental|Intervention Group|
89131704|NCT05876832|Experimental|XY0206|XY0206 will be administered orally once a day in continuous 28-day cycles.
89131705|NCT05876832|Active Comparator|Salvage chemotherapy|Participants will receive salvage chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) injection for 10 days. Participants on azacitidine will receive 75 mg/m^2 daily by SC or IV injection for 7 days.Participants on fludarabine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (FLAG) will receive 30 mg/m^2 of fludarabine daily by IV for 5 days (day 2 to 6), 1~2 g/m2 of cytarabine daily by IV for 5 days (day 2 to 6), and 300 μg/m^2 of G-CSF daily by SC or IV for 5 days (days 1 to 5). After completion of chemotherapy, G-CSF will be administered continually until absolute neutrophil count(ANC)>0.5 x 10^9 / L. Participants on mitoxantrone, etoposide, cytarabine(MEC) will receive 8 mg/m^2 of mitoxantrone daily by IV for 3 days (day 1 to 3), 100 mg/m2 of etoposide daily by IV for 7 days (day 1 to 7), and 100 mg/m^2 of cytarabine daily by IV for 7 days (days 1 to 7)
89131708|NCT05873855|Experimental|Intervention|From baseline to 6 months, participants randomized to the intervention arm will have access to the P3 web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessments that will occur at 3 months and 6 months.
89131709|NCT05873855|Experimental|Waitlist Control|"From baseline to 3-months, participants in the waitlist control condition will have access to the P3 web app for post-baseline assessment of 3 months and the resources section.~From 3 months to 6 months, participants randomized to the waitlist control arm will then have access to the P3 web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessment that will occur at 6 months."
89131710|NCT05873829|Experimental|Intervention Group|Hand-foot exercises were applied to the intervention group.
89131711|NCT05873829|No Intervention|Control Group|No intervention other than standard care was applied to the control group.
89131712|NCT05873777|Experimental|68Ga-FAPI-LM3|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAPI-LM3, and undergo PET/CT imaging within the specified time.
88802574|NCT04745858|Experimental|Bowen's Technique|Sequence of short gentle moves are applied over Hamstrings.Skin slack is taken to lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are be given for 4 weeks. The treatment time for each session is 20 minutes.
89131713|NCT05872802|Active Comparator|proprioceptive neuromuscular facilitation group.|Proprioception protocol for ankle dorsiflexion.
89131714|NCT05872802|Experimental|Eccentric exercises and electrical stimulation group.|Eccentric exercises and strengthening currents for ankle dorsiflexion.
89131715|NCT05869968||Individuals with Chronic Spinal Cord Injury who receive either Flu or COVID-19 vaccine|18-89 years old with traumatic SCI, AIS grade A-D, Neurological injury level of C1-T10 who are choosing to receive a vaccine against the flu or COVID-19 and demonstrate capacity to provide informed consent.
89131716|NCT05869968||Uninjured Controls who receive the Flu vaccine or COVID-19 vaccine|18-89 years old without traumatic Spinal Cord Injury (SCI) who are choosing to receive a vaccine against either the Flu or COVID-19 and demonstrate the capacity to provide informed consent.
89131717|NCT05859958||ABO + Group|All patient with blood type that does not include Rhesus Factor and COVID-19 Diagnosis
89131718|NCT05859958||ABO - Group|All patient with blood type that does not include Rhesus Factor and COVID-19 Diagnosis
89131719|NCT05859737|Experimental|Disaster Preparedness Education Program (SIMAH)|
89131720|NCT05859737|Active Comparator|Disaster and Emergency Management Presidency (AFAD) Education Program|
89131721|NCT05850585|Experimental|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
89131722|NCT05850585|Placebo Comparator|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
89131723|NCT05849623|Active Comparator|Endoscopic Mucosal Resection (EMR)|Patients will have an electrosurgical grounding pad attached, and an Erbe VIO electrosurgical unit will be adjusted to the endoscopist's preferred EndoCut Q and Coagulation settings. The polyp will be injected submucosally with a saline and methylene blue solution, with or without epinephrine at endoscopist's discretion. Using a 15mm snare connected to the electrosurgical unit, the resection will be performed, with the initial cut including a margin of normal mucosa and subsequent cuts to ensure no residual polyp tissue remains. In case of intraprocedural bleeding, snare tip soft coagulation (STSC) or coagulation forceps may be used. The resection site will be examined and any remaining polypoid tissue will be resected. Endoclips may be used to close the defect if there is significant intraprocedural bleeding. The polyp will be retrieved (en bloc or piecemeal) using suction into a trap or RothNet.
89131724|NCT05849623|Active Comparator|Cold Endoscopic Mucosal Resection (C-EMR)|The polyp will be positioned at the 6 o'clock position and injected submucosally with saline and methylene blue, with or without epinephrine. The size of the ensnared polyp will be limited to 10-15mm to make sure that the snare will cut through the tissue. If the snare encounters difficulty in cutting through, it will be loosened to release deeper tissue before being closed again. The base and margins of the resected polyp will be inspected for residual polyp, which will be resected using the same technique if found. The polyp will be retrieved (en bloc or piecemeal) using suction into a trap or RothNet.
89290193|NCT01125852|Active Comparator|Control group|Patients in this arm receive standard treatment including therapeutic endoscopy with endoscopic combination therapy followed by 72 hours intravenous proton pump inhibitor.
89290194|NCT03972293|Experimental|Within-participant Micro-randomization|"Each week in the study, with probability .25 for each, a participant is randomized to receive either a week of mood notifications, activity notifications, sleep notifications, or no notifications.~If the participant is assigned to receive mood, activity, or sleep notifications on a given week, then, for every day of that week the participant is randomized to: send notification on that day (with probability .5), or to not send a notification on that day (with probability .5)."
89290195|NCT03972293|Experimental|No intervention|Participants in this arm will not receive any notifications for the entire duration of the trial. Primary and secondary outcomes will still be collected on participants in arm 2 through the study app and Fitbit.
88802575|NCT04745858|Active Comparator|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
88802576|NCT02630498|Experimental|study (first group)|The first group will include those who receive a single shot brachial plexus block with or without general anesthesia.
88802577|NCT02630498|No Intervention|Controlled (second group)|The second group will be the control group and include those patients who receive general anesthesia only, without any block whether due to the preference of patient or the surgeon.
89131725|NCT05849623|Active Comparator|Underwater Endoscopic Mucosal Resection (U-EMR)|In the Underwater EMR arm, the patient will be connected to an electrosurgical grounding pad, and an Erbe VIO electrosurgical unit with EndoCut Q and Coagulation settings will be adjusted to the endoscopist's preference. Water, instead of carbon dioxide, will be used to fill the colon. Submucosal injection will not be performed.The patient will be positioned for optimal polyp exposure, and a 15mm snare will be used. The snare will be opened and positioned with a margin of normal mucosa and used to cut the polyp, en bloc if possible. Piecemeal resection should ensure no residual polyp tissue remains. Snare tip soft coagulation or coagulation forceps may be used for intraprocedural bleeding. The base and margins of the resected polyp will be inspected for residual polyp and resected if necessary. Closure of the defect with endoclips may be considered if there is significant bleeding. The polyp will be retrieved (en bloc or piecemeal) using suction into a trap or RothNet.
89131726|NCT05832918|Experimental|core stability exercises with cognitive tasks group|"This research will use core stability exercises to strengthen local muscles (transversus abdominis and multifidus) based on the training program provided by Shamsi et al., which is modified from the exercise program of Koumantakis et al.. Participants will be treated for six weeks, three sessions a week, and 16 sessions.~We will also combine stabilization exercises with cognitive tasks."
89131727|NCT05832918|Active Comparator|general exercises with cognitive tasks group|"This research will use general exercises to strengthen global muscles (abdominal flexor muscles and back extensor muscles) based on the training program provided by Shamsi et al.(110), which is modified by Koumantakis et al.. Participants will be treated for six weeks, three sessions a week, and 16 sessions.~We will also combine general exercises with cognitive tasks."
89131728|NCT05831670|Experimental|KSP-0243|Under double-blinding, KSP 0243 tablets will be orally administered.
89131729|NCT05831670|Placebo Comparator|Placebo|Under double-blinding, placebo tablets will be orally administered.
89131730|NCT05819125||Conventional prophylaxis|Hospitalized obese participants with an acute medical condition or undergoing surgery, receiving conventional (i.e., 40 mg once daily for 7 days) enoxaparin VTE prophylaxis
89131731|NCT05819125||High dose prophylaxis|Hospitalized obese participants with an acute medical condition or undergoing surgery, receiving high dose enoxaparin for the conventional VTE prophylaxis duration
89131732|NCT05819125||Extended duration prophylaxis|Hospitalized obese participants with an acute medical condition or undergoing surgery, receiving the conventional enoxaparin dose for an extended VTE prophylaxis duration
89131733|NCT05819125||High dose and extended duration prophylaxis|Hospitalized obese participants with an acute medical condition or undergoing surgery, receiving high dose enoxaparin for an extended VTE prophylaxis duration
89131734|NCT05819112||Conventional prophylaxis|Participants hospitalized for acute medical illness receiving conventional (i.e., once daily for 7 days) enoxaparin VTE prophylaxis
89131735|NCT05819112||Extended prophylaxis|Participants hospitalized for acute medical illness receiving extended duration (i.e., once daily for 14, 21 or 28 days) enoxaparin VTE prophylaxis
89131736|NCT05790707|Experimental|Atrial fibrillation + antiarrhythmic drugs|"The ablation can be done with different sources of energy (radiofrequency, cryoballoon or pulsed field ablation). Different sets of lesions can be performed but the cornerstone is pulmonary vein isolation which will be mandatory.~Antiarrhythmic drugs management will be at the operator discretion. Some operators may stop antiarrhythmic drugs after atrial fibrillation ablation."
89131737|NCT05790707|Active Comparator|Antiarrhythmic drugs alone|"Antiarrhythmic drugs available available are amiodarone, flecainide, propafenone, sotalol.~If not previously started, patients randomized to antiarrhythmic drugs arm should start antiarrhythmic drugs therapy within 1 week of randomization.~Apart from these recommendations, antiarrhythmic drugs management will be at the operator discretion."
89131738|NCT05790460|Experimental|Telehealth|Patients in the intervention arm will be scheduled for an enhanced synchronous telehealth visit with a trained lung cancer nurse navigator prior to tissue biopsy. The enhanced synchronous telehealth visit will ideally occur between the initial clinical appointment and diagnostic biopsy (typically a period between two and seven days). In addition to the activities conducted as part of usual care, the nurse navigator will: 1) provide more detailed and individualized education on lung cancer and the rationale for comprehensive molecular testing, including plasma-based tests; and 2) if the patient agrees to testing, pend a default order for plasma-based molecular testing (if not already ordered) for the clinician to sign and arrange for phlebotomy to be performed at the time of the patient's tissue biopsy.
89131739|NCT05790460|No Intervention|Usual Care|Patients in the usual care arm will receive a telephone call from a trained lung cancer nurse navigator after biopsy, as is typical at Penn Medicine, to 1) review the roles of clinicians on the medical oncology care team; 2) provide brief education on lung cancer; and 3) review the patient's diagnostic history and coordinate collection or completion of imaging required for guideline-recommended cancer staging. At the initial in-person oncology visit, the oncologist may choose to order plasma-based testing if appropriate (and if not already ordered or pending).
89131740|NCT05789420|Active Comparator|Product Sequence 1|"After at least 23 hours of abstinence from any Tobacco or Nicotine Product (TNP) on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects will smoke a single CIG or perform a single use of a THS either with a regular or a menthol stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
89131741|NCT05789420|Active Comparator|Product Sequence 2|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects will smoke a single CIG or perform a single use of a THS either with a regular or a menthol stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
89131742|NCT05789420|Active Comparator|Product Sequence 3|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects will smoke a single CIG or perform a single use of a THS either with a regular or a menthol stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
89290196|NCT01220310|Experimental|Intervention|Online diabetes workshop observation and learning sessions
89131743|NCT05789420|Active Comparator|Product Sequence 4|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects will smoke a single CIG or perform a single use of a THS either with a regular or a menthol stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
89131744|NCT05789420|Active Comparator|Product Sequence 5|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects will smoke a single CIG or perform a single use of a THS either with a regular or a menthol stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
89131745|NCT05789420|Active Comparator|Product Sequence 6|"After at least 23 hours of abstinence from any TNP on Day 1, and after at least 23 hrs of former IP use on Day 2 and Day 3 (nicotine wash-out), subjects will smoke a single CIG or perform a single use of a THS either with a regular or a menthol stick, according to randomized product use sequence.~The list of possible sequences are:~P1R; P1M; CIG / P1R; CIG; P1M / P1M; P1R; CIG / P1M; CIG; P1R / CIG; P1R; P1M / CIG; P1M; P1R"
89131746|NCT05754788||Favorable-prognosis pancreatic adenocarcinoma|Patients experiencing favorable prognosis (defined as RFS≥60 months) following resection for pancreatic adenocarcinoma
89131747|NCT05754788||Unfavorable-prognosis pancreatic adenocarcinoma|Patients experiencing unfavorable prognosis (defined as RFS<12 months) following resection for pancreatic adenocarcinoma
89131748|NCT05737121|Experimental|VNX001|VNX001 (lidocaine HCl [200 mg] and heparin sodium [50,000 USPU] in alkalinized buffer), administered as a single dose via intravesical instillation; n=45 (anticipated)
89131749|NCT05737121|Placebo Comparator|Placebo|Alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)
89131750|NCT05737121|Experimental|Lidocaine|Lidocaine HCl (200 mg) in alkalinized buffer, administered as a single dose via intravesical instillation; n=45 (anticipated)
89131751|NCT05737121|Experimental|Heparin|Heparin sodium (50,000 USPU) in alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)
89131752|NCT05725044|Experimental|Ginsengberry concentrate|This group takes Ginsengberry concentrate for 8 weeks.
89131753|NCT05725044|Placebo Comparator|Placebo|This group takes placebo for 8 weeks.
89131754|NCT05703256|Experimental|Amygdala real-time fMRI neurofeedback|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
89131755|NCT05703256|Sham Comparator|Sham feedback|Yoked sham - participants will see the amygdala activity of another subject who completed the intervention. Two sessions will be performed one week apart.
89131756|NCT05702983|Experimental|STSA-1002 subcutaneous injection: dose 1 (First cohort)|
89131757|NCT05702983|Experimental|STSA-1002 subcutaneous injection: dose 2 (Second cohort)|
89131758|NCT05695599|Experimental|Whole body vibration|Participants will undergo a whole body vibration training
89131759|NCT05695599|No Intervention|Control Group|Participants will not perform an intervention
89131760|NCT05694494|Experimental|iLiFE|receiving Lifestyle-integrated Functional Exercise training and home safety assessment
89131761|NCT05694494|Placebo Comparator|attention control|upper limb exercise training
89131762|NCT05689541|Other|Single group|
89131763|NCT05688917|Experimental|green been extract treated group|Participants included in the study were maintained on a balanced diet and supplemented with Green Coffee Bean (Coffea Arabica) extract capsules (800 mg/capsule
89131764|NCT05688917|Placebo Comparator|Placebo group|Participants included in the study were maintained on a balanced diet and supplemented with placebo capsules.
89131765|NCT05674110|Experimental|Education and Support|online education and support meetings
89131766|NCT05663658|Active Comparator|Control group|The patients in Control Group will be received patient controlled analgesia with morphine for postoperative analgesia
89131767|NCT05663658|Active Comparator|External oblique intercostal plane block group|The patients in external oblique intercostal plane block group will be received EOI plane block and patient controlled analgesia with morphine for postoperative analgesia
89131768|NCT05660135||patients with hypertension and dislipidemia|received olomax tablet as treatment.
89131769|NCT05647798|Active Comparator|Usual care glycemic management arm|Blood glucose will be checked every 2 hours during labor and glucose target will be 75-110 mg/dl
89131770|NCT05647798|Active Comparator|More liberalized glycemic management arm|Blood glucose will be checked every 4 hours during labor and glucose target will be 70-126 mg/dl
89131771|NCT05644834|Experimental|Mobile Medical Unit|Participants utilizing the mobile medical unit will be offered an appointment with a university system healthcare provider to receive blood pressure check, blood glucose check, HIV testing and/or Pre-exposure Prophylaxis (PrEP) consultation.
88802578|NCT02344472|Experimental|Chemotherapy with docetaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus docetaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
89131772|NCT05639673||NOPHO ALL2008|Children and adolescents treated according to the NOPHO ALL2008 protocol
89131773|NCT05639673||Australia|
89131774|NCT05639673||Poland|
89131775|NCT05639673||Dutch Childhood Oncology Group|
89131776|NCT05639673||St. Jude|
89131777|NCT05625659|Other|DBT and CESM Diagnostic Imaging in Women with Dense Breasts|Interventional Diagnostic
89131778|NCT05619523|Experimental|Intervention: DIY Tool Classrooms|Developing Inclusive Youth (DIY) classrooms complete a pretest and posttest survey in addition to completing 8 scenarios using the DIY online tool and a class discussion for each scenario.
89131779|NCT05619523|No Intervention|Control: Business As Usual Classrooms|"The control group follows a Business-As-Usual plan (no alternative program is implemented for the control group.) They complete a pretest and posttest in the same weeks as the experimental group."
89131780|NCT05611632|Experimental|Interventional|Blood collection and multi-cancer early detection testing with return of positive test results.
89131781|NCT05611632|No Intervention|Control|Blood collection only.
89131782|NCT05606263|Experimental|Caldonirimab and nimotuzumab|Caldonirimab combined with nimotuzumab therapy
89131783|NCT05606172|Experimental|PCIP for youth aged 6 to 11|This arm will receive the adapted PCIP intervention lasting from 1-4 weeks, and will complete baseline, post treatment, 1-month, and 3-month follow up assessments.
89131784|NCT05606172|Active Comparator|Waitlist Treatment as Usual|Receive standard care treatment and will complete baseline, post treatment, 1-month, and 3-month follow up assessments, and are offered PCIP treatment after conclusion of the study.
89131785|NCT05599451|Active Comparator|THS Blade device|Subjects randomized to this arm will participate in 5 days of ad libitum use, in confinement, of the THS Blade device (using regular THS blade tobacco sticks) between 06:30 AM and 11:00 PM.
89131786|NCT05599451|Active Comparator|THS Induction Mono device|Subjects randomized to this arm will participate in 5 days of ad libitum use, in confinement, of the THS Induction Mono device (using regular THS induction tobacco sticks) between 06:30 AM and 11:00 PM.
89131787|NCT05599451|Active Comparator|THS Induction Mid device|Subjects randomized to this arm will participate in 5 days of ad libitum use, in confinement, of the THS Induction Mid device (using regular THS induction tobacco sticks) between 06:30 AM and 11:00 PM.
89131788|NCT05599451|Active Comparator|Cigarette|"Subjects randomized to this arm will participate in 5 days of ad libitum use, in confinement, of the subject's preferred brand of regular (non-mentholated) cigarette between 06:30 AM and 11:00 PM.~(Every subject will bring a sufficient number of unopened, single-brand packs of CIG for the entire confinement period.)"
89131789|NCT05597722|Active Comparator|Digital cognitive behavioral intervention- RxWell|"The mobile app provides users with brief skill building techniques such as relaxation, behavioral activation and exposure, distress tolerance, cognitive reframing, and mindfulness meditation, for anxiety and depression. The content of RxWell was developed based on standard CBT techniques for treating anxiety disorders and depression. The user will have the option to select either the depression or anxiety program, and the coach will have the ability to personalize the program so that the individual can utilize the proper CBT techniques that fits with their presentation.~The health coach communicates with RxWell users via asynchronous, secure within app messaging. They reinforce CBT principles, guide users through goal setting, and help users work through challenges and recognize successes. The coaches will also receive individualized cognitive rehabilitation tips from the speech therapist after their appointment with the participant."
89131790|NCT05597722|Active Comparator|Stimulant Medication|The other intervention is a stimulant medication known to reduce cognitive impairment in other chronic medical conditions, such as Inflammatory Bowel Disease. The Long-COVID psychiatrist will order the medication and the participant will be scheduled for a 6-week research tele visit with the psychiatrist to monitor for any medication side effects. Amphetamine-dextroamphetamine drug dose will be 10mg daily for 12 weeks, and no dose changes will be made. Amphetamine-dextroamphetamine is a Schedule II controlled substance that has a risk for abuse, tolerance, and psychological dependence, which can be associated with severe social disability.
89131791|NCT05555667|Experimental|Remimazolam besylate|Remimazolam besylate at an initial infusion rate of 0.15 mg/kg/h and adjusted (maximum of 0.3 mg/kg/h) to maintain a RASS score between - 3 and 0
89131792|NCT05555667|Active Comparator|Propofol|Propofol intravenously at an initial infusion rate of 2.0 mg/kg/h and adjusted (maximum of 4.0 mg/kg/h) to maintain a RASS score between - 3 and 0
89131793|NCT05547438|Experimental|Treatment Arm 1|0.8, 4, 8, or 16 mg/mL NTS-104 solution for IV infusion
89131794|NCT05547438|Placebo Comparator|Treatment Arm 2|Single administration of placebo at the same volume and duration
89131795|NCT05534568|Experimental|Treatment Group|The treatment group consists of women who have used alcohol, opioids, or other drugs during pregnancy and their children. Mothers who are randomly assigned to the treatment group will receive PCAP services through the work of highly trained, closely supervised case managers.
89131796|NCT05534568|No Intervention|Control Group|The control group consists of women who have used alcohol, opioids, or other drugs during pregnancy and their children. Women in the control group will be provided with a service resource list and receive services as usual, but they will not be enrolled in PCAP.
89131797|NCT05533658|Experimental|VisionPure Dietary Supplement|One dose (2 softgel capsules) will be consumed once daily for 60 days. A single dose contains: 976mg fish oil (120mg eicosapentaenoic acid, 610 mg docosahexaenoic acid), 20mg lutein, 4mg zeaxanthin isomers, 25mcg vitamin D3.
89131798|NCT05533658|Placebo Comparator|Placebo|One dose (2 softgel capsules) will be consumed once daily for 60 days. A single dose contains: 727mg organic sunflower oil, 15mg organic lemon essential oil, 1.5mg vitamin E T-70, 0.7mg natural fish flavor.
89131799|NCT05483036||Persons with Parkinson's disease (PwPD)|
89131800|NCT05481450|Experimental|Dietary supplement|Consume one capsule every morning after the breakfast at the same time every day for 56 days
89131801|NCT05481450|Placebo Comparator|Placebo|Consume one capsule every morning after the breakfast at the same time every day for 56 days
89131802|NCT05463484|Experimental|Test product|Toothpaste including an olive product, betaine and xylitol.
89131803|NCT05463484|Placebo Comparator|Placebo product|Toothpaste with the same composition as the test product but without olive product, betaine and xylitol.
89131804|NCT05463484|Active Comparator|Control product|Toothpaste marketed for gingivitis with zinc mineral with antimicrobial activity.
89131805|NCT05451888|Experimental|Celestial Floatation Pool|
89131806|NCT05451888|Experimental|Dead Sea Salt Pool|
89131807|NCT05451888|Active Comparator|Balneotherapy Control Pool|
89131808|NCT05740280|Experimental|iCP-NI|"Part A will comprise a single dose, sequential group design. Part A: 40 subjects will be studied in 5 groups (Groups A1 to A5). In each of Groups A1 to A5, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part A: Five proposed dose levels per protocol.~Part B will comprise a multiple dose, sequential group design. Part B: 24 subjects will be studied in 3 groups (Groups B1 to B3). In each of Groups B1 to B3, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part B: Proposed dose levels to be determined following review of available data from Part A."
89290197|NCT01373944||Stress Only SPECT MPI with Anger Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the traditional Anger camera
89290198|NCT01373944||Stress Only SPECT MPI with SD Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the Spectrum Dynamics camera system.
89290199|NCT01126008|Experimental|weekly docetaxel and cisplatin|
88802579|NCT02344472|Experimental|Chemotherapy with paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus paclitaxel.Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
89131809|NCT05740280|Placebo Comparator|Placebo|"Part A will comprise a single dose, sequential group design. Part A: 40 subjects will be studied in 5 groups (Groups A1 to A5). In each of Groups A1 to A5, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part A: Five proposed dose levels per protocol.~Part B will comprise a multiple dose, sequential group design. Part B: 24 subjects will be studied in 3 groups (Groups B1 to B3). In each of Groups B1 to B3, 6 subjects will receive iCP-NI and 2 subjects will receive placebo.~Part B: Proposed dose levels to be determined following review of available data from Part A."
89131810|NCT05421754|Experimental|ANNE Sleep|After consent, subjects will wear the ANNE Sleep system with HST for 1 night and 3 nights with ANNE sleep system alone.
89131811|NCT05411887||Experimental/ Olostar Tablet|Eligible Subjects who received Olostar Tablet treatment for 24 weeks. Dosage: 10/5mg, 10/10mg, 20/5mg, 20/10mg, 20/20mg, 40/10mg, 40/20mg
89131812|NCT05411822|Experimental|Lighting Intervention Blue|Blue light (λmax = 451 nm) on and off axis
89131813|NCT05411822|Experimental|Lighting Intervention Green|Green light (λmax = 522 nm) on and off axis
89131814|NCT05409911|Experimental|S-217622: Group A|Participants with mild hepatic impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
89131815|NCT05409911|Experimental|S-217622: Group B|Participants with moderate hepatic impairment will receive a single dose of S-217622 on Day 1, in a fasted state.
89131816|NCT05409911|Experimental|S-217622: Group C|Participants with normal hepatic function will receive a single dose of S-217622 on Day 1, in a fasted state.
89131817|NCT05398081|Experimental|Cefuroxime|Cefuroxime (Zinnat®) will be used as prophylactic antibiotic in this arm
89131818|NCT05398081|Active Comparator|Ceftriaxone|Ceftriaxone (Rocephin®) will be used as prophylactic antibiotic in this arm
89131819|NCT05364008|Experimental|Green tea extract containing 45% epigallocatechin gallate (EGCG)|Low caffeine green tea extract (1650mg in 6 capsules) taken orally on a daily basis (QD) along with Clomiphene citrate-intrauterine insemination (CC_IUI) cycle, up to 4 cycles if no pregnancy is achieved, participant will stop green tea if she becomes pregnant
89131820|NCT05364008|Placebo Comparator|Placebo|Placebo (1650mg in 6 capsules) matched (smell, taste, color, texture) capsules taken orally on a daily basis (QD) along with Clomiphene citrate-intrauterine insemination (CC_IUI) cycle, up to 4 cycles if no pregnancy is achieved, participant will stop placebo if she becomes pregnant
89131821|NCT05343390|Experimental|Enhanced implementation strategy|digitally guided training and continuous quality improvement
89131822|NCT05343390|Active Comparator|Standard implementation strategy|standard training and clinical support
89131823|NCT05323045|Experimental|BYON3521|c-MET targeting Antibody-Drug Conjugate
89131824|NCT05307770|Experimental|Immediate Release Melatonin, Then Extended Release Melatonin|Subjects will receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks.
89131825|NCT05307770|Experimental|Extended Release Melatonin, Then Immediate Release Melatonin|Subjects will receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks.
89131826|NCT05307458||Buprenorphine Microdosing|Participants transitioning to buprenorphine from methadone using a microdosing protocol.
89131827|NCT05275634|Experimental|Standard treatment and interferential current with carrier frequency 2 KHz|Standard treatment and interferential current with carrier frequency 2 KHz will be received three times a week for four weeks.
89131828|NCT05275634|Experimental|Standard treatment and interferential current with carrier frequency 4 KHz|Standard treatment and interferential current with carrier frequency 4 KHz will be received three times a week for four weeks.
89131829|NCT05275634|Experimental|Standard treatment and interferential current with carrier frequency 8 KHz|Standard treatment and interferential current with carrier frequency 8 KHz will be received three times a week for four weeks.
89131830|NCT05275634|Placebo Comparator|Standard treatment and placebo interferential current|Standard treatment and placebo interferential current will be received three times a week for four weeks.
89131831|NCT05247645||Rare diseases with predominantly skeletal involvement|The group comprises all patients affected rare diseases with predominantly skeletal involvement
89131832|NCT05235204|Experimental|Foley catheter removal day 2 or 3 post-operative procedure|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
89131833|NCT05202210||patients with Noonan syndrome|extra sample of blood and urine will be collected and stored for research utilisation
89131834|NCT05154526|Experimental|Exercise Group|Exercise Program only
89131835|NCT05154526|Active Comparator|Manual Therapy Group|Manual Therapy only
89131836|NCT05154526|Active Comparator|Manual Therapy and Exercise Group|Manual Therapy + exercise program
89131837|NCT05123053|Experimental|Treatment Arm|subjects will be given active drug and titrated up in 10mg increments (with max single dose being 30mg) until a change or drug side effect is noticed.
89131838|NCT05117619|Experimental|HOME for Us|The HOME intervention is the delivery of an in-home, family inclusive, rehabilitation intervention in eight sessions. Six of the sessions will occur in the home, and two will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
89131839|NCT05117619|Active Comparator|Attention Control|The Attention-control condition is the delivery of educational materials over 8 contacts. Three of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
89131840|NCT05104125|Experimental|Experimental group 1|ASC40 25mg for 12 weeks
89131841|NCT05104125|Experimental|Experimental group 2|ASC40 50mg for 12 weeks
89131842|NCT05104125|Experimental|Experimental group 3|ASC40 75mg for 12 weeks
89131843|NCT05104125|Placebo Comparator|Placebo group|Placebo for 12 weeks
89131844|NCT05102084|Experimental|Experimental group|Patients listening to music during CPAP application
89131845|NCT05102084|No Intervention|Control group|Patients not listening to music during CPAP application
89131846|NCT05100368||Patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
89131847|NCT05098405|Experimental|Dose-escalation Cohorts (q3w)|"The starting dose is 0.03 mg/kg every 3 weeks (q3w) and up to 6 dose levels are planned.~Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first."
89131848|NCT05098405|Experimental|Dose-escalation Cohorts (q1w)|"The starting dose is 0,5 mg/kg every week (q1w) and up to 3 dose levels are planned.~Study treatment will be administered as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first."
89131849|NCT05060744|Active Comparator|Intervention (Antacid)|"An Antacid, a CE marked medical device under normal conditions of use.~Sodium alginate (reduces reflux) (250 mg/tablet) Calcium carbonate (reduces acidity) (80 mg/tablet) Magnesium carbonate (reduces acidity) (144 mg/tablet) Hyaluronic acid (mucosal protector) (6.15 mg/tablet) Aloe vera extract without anthraquinones (mucosal protector) (40 mg/tablet)~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
89131850|NCT05060744|Placebo Comparator|Control|"The control will consist of a placebo based on excipients without active ingredients that will be formulated so that the tablet has the same appearance as the test product, with three different colour layers.~Patients should take 2 tablets of treatment at the time they develop reflux or hyperacidity. The maximum dose will be 6 tablets per day."
89131851|NCT05057117|Active Comparator|Botulinum toxin A|One treatment with standard dosage (50-100 units) of botulinum toxin A in one axilla
89131852|NCT05057117|Active Comparator|Microwave thermolysis|One standard treatment (energy level 5) with microwave thermolysis in one axilla
89131853|NCT05051358||Subjects undergoing Therapeutic Endoscopic Ultrasound|"Procedures that will be captured include:~EUS- ERCP, Endoscopic Hepatology - EUS, EUS-Coils placement, EUS Glue injection, EUS-Fiducial placement, EUS-Neurolysis, EUS-Stent placement, EUS-alcohol injection, EUS-guided Ablation, EUS-guided anastomosis, EUS Guided ERCP for gallbladder, pancreatic duct or biliary duct drainage, EUS guided - Hemostasis, EUS guided- Therapy for cancer or premalignant lesion (Injection, neurolysis, fiducial, aspiration, RFA ), EUS - Fluid Collection, abscess or cavity drainage, EUS - Guided Ductal Drainage, EUS - Guided Anastomosis"
89131854|NCT05047939|Experimental|remimazolam group|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil 0.2mg, is administered at the end of surgery. In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
89131855|NCT05047939|Active Comparator|propofol group|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
89131856|NCT05041608||Subjects undergoing Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
89131857|NCT05037578|Experimental|Project Grace|This intervention will be delivered through church-based multilevel activities by trained church leaders using religiously/ culturally-tailored study materials (sermon guides, responsive readings, educational games, brochures, educational/testimonial videos) packaged in a culturally-tailored. Intervention churches will receive the Project Grace Tool Kit and intervention implementation directions to seek cognitive screening. These churches will hold a Project Grace Kickoff event, where a sermon, and other tool kit materials will be distributed. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities over 4 months. Delivery of intervention components will coincide with existing, multilevel activities that occur in churches through: a) church-wide services, b) outreach ministry groups; and c) individual level activities (e.g., text/voice/email health promotion messages from church) over 4 months.
89131858|NCT05037578|Active Comparator|Standard Control|Standard information churches will receive standard dementia education information. These churches will receive: a) non-tailored project materials collected from mental health organizations and b) standard community-based mental health screening events) coordinated by their Community Health Liaisons. These churches will receive all Project Grace Tool Kit materials and implementation training after the completion of assessments.
89131859|NCT05021211||Low Egg Consumers|Participants who consume fewer than 1 whole egg per week
89131860|NCT05021211||Moderate Egg Consumers|Participants who consume 5-9 whole eggs per week
89131861|NCT05021211||High Egg Consumers|Participants who consumes great than or equal to 14 whole eggs per week
89131862|NCT04996394||NMBAs|
89131863|NCT04994795||Pembrolizumab monotherapy|
89131864|NCT04994795||Chemotherapy and pembrolizumab combination therapy|
89131865|NCT04994795||Chemotherapy doublet|
89131866|NCT04926285|Experimental|Cohort 1|Omacetaxine 0.625 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
89131867|NCT04926285|Experimental|Cohort 2|Omacetaxine 1.25 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
89131868|NCT04926285|Experimental|Cohort 3|Omacetaxine 2.0 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
89131869|NCT04926285|Experimental|Cohort 4|Omacetaxine 2.5 mg/m2 SQ injection q12h days 1-7 with Venetoclax 400 mg orally daily on days 4-28 Cycles are 28 days
89290200|NCT01073345||Major hepatic resection|Patients undergoing resection of > 2 liver segments
89131870|NCT04899284|Experimental|Infants eligible for Early Intensive Bimanual Stimulation|Infants between 3 and 12 months of age at the time of inclusion, with unilateral brain injury and clinical signs of underuse of one of the two upper limbs
89131871|NCT04895033|Experimental|Responsibility vs No Responsibility|Within-subjects experimental manipulation of responsibility vs. no-responsibility condition
89131872|NCT04856566|Experimental|Low Dose THC + 0.05 BAC Alc|Participants will receive low dose of THC along with alcohol leading to a BAC of 0.05.
89131873|NCT04856566|Experimental|High Dose THC + 0.05 BAC Alc|Participants will receive high dose of THC along with alcohol leading to a BAC of 0.05.
89131874|NCT04856566|Experimental|Placebo Drug + 0.05 BAC Alc|Participants will receive placebo drug with no THC along with alcohol leading to a BAC of 0.05.
89131875|NCT04856566|Experimental|Placebo Drug + 0.08 BAC Alc|Participants will receive placebo drug with no THC along with alcohol leading to a BAC of 0.08.
89131876|NCT04854122|Experimental|Combined exercise intervention Down syndrome|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week.In the exercise sessions, the participant will work with the trainer on their strength, balance and aerobic endurance. Each session consists of 10 min of strength exercises (Foundational Exercise), 10 min of Hip Strengthening, 10 min of Vestibular and Balance Exercise, and 20 min of Aerobic Exercise, and starts with a warming up and ends with stretching/cooling down. Each new exercise will be introduced in easy steps and practiced until the participant is comfortable executing it.
89131877|NCT04854122|Sham Comparator|Usual care Down Syndrome|The control condition consists of usual activities.
89131878|NCT04854122|No Intervention|Reference group without Down syndrome|This reference group of age- and sex-matched inactive individuals without Down syndrome will undergo the same baseline testing as the other groups but without intervention or post-intervention measures.
89131879|NCT04849273|Experimental|TPX-0131|The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.
89131880|NCT04837742|Experimental|ESPB group|ESPB injection at T10 region with levobupivacaine 100mg (20 ml)+ Omnipaque10 ml
89131881|NCT04837742|Sham Comparator|Control group|ESPB injection at T10 region with 0.9% normal saline 20ml + Omnipaque10ml
89131882|NCT04798482|Experimental|Dexmedetomidine|This is a single arm, open label, interventional study examining the effects of dexmedetomidine on anal manometry. All subjects will be administered dexmedetomidine following their baseline manometry measurements. Following dexmedetomidine administration, anal manometry measurements will be observed for 15 minutes.
89131883|NCT04774250|Experimental|Zonisamide|For subjects randomized to zonisamide, the package will contain one zonisamide capsule (100 mg PO).
89131884|NCT04774250|Placebo Comparator|Placebo|For the subjects randomized to placebo, the package will contain one placebo capsule that looks, smells, and taste the same as zonisamide capsule.
89131885|NCT04746976||Diroximel Fumarate|Participants with RMS who are receiving diroximel fumarate orally in routine clinical practice will be enrolled.
89131886|NCT04736056|Experimental|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|"Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills (MBTI+)~The MBTI+ intervention will train participants in mindfulness-based sleep strategies and behavioral symptom management techniques. The MBTI+ intervention will consist of 6 weekly sessions that will last between 60 and 75 minutes."
89131890|NCT04703192|Experimental|Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma|Participants who will receive 200 mg/day valemetostat tosylate and had an eligible peripheral T-cell lymphoma subtype that was confirmed by independent hematopathology central review.
89131891|NCT04703192|Experimental|Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma|Participants who will receive 200 mg/day valemetostat tosylate and had an eligible adult T-cell leukemia/lymphoma subtype that was confirmed by the local pathologist/investigators and by documented positive anti-human T-cell leukemia virus type 1 (HTLV-1) antibody.
89131892|NCT04669457|Experimental|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
89131893|NCT04669457|Active Comparator|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
89290201|NCT01073345||Minor hepatic resection|Patients undergoing resection of </= 2 liver segments
89290202|NCT01073345||Control group|Patients undergoing exploratory laparotomy for hepatobiliary disease without resection (e.g. due to inoperable disease)
89290203|NCT01361074|Experimental|In Vivo Exposure|
89290204|NCT01361074|Experimental|Augmented Reality Exposure|
89290205|NCT01220388|Experimental|L-lysine|11 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
89290206|NCT01220388|Placebo Comparator|placebo|11 days treatment with study drug, order of periods (L-lysine or placebo) being sorted out.
89290207|NCT03974009|Experimental|Calcaneal taping and Conventional therapy|Calcaneal Taping Technique along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
89290208|NCT03974009|Active Comparator|Sham taping and Conventional therapy|Sham taping along with Conventional therapy will given to the patients for 3 days/week for 4 weeks.
89290209|NCT03938194|Experimental|Aquablation|Surgery of benign prostatic hyperplasia by waterjet ablation
89290210|NCT01073423|Experimental|Yoga|
89290211|NCT01073423|Active Comparator|Music Therapy|
89290212|NCT01123434||1|Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
89290213|NCT01123590||Thymoma|Patients with thymoma
89290214|NCT01123590||Control|Normal controls
89290215|NCT01123668||ADHD and non-ADHD Smokers|Those that are defined as regular smokers (10 cigarettes/day or Carbon Monoxide reading of 10 ppm). The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
89131894|NCT04647851|Experimental|Remote exercise intervention Down syndrome|Intervention: The program we will be using is specifically developed for individuals with Down syndrome based on the Mann Method PT Principles. The MMPT Principles TM focus on a progressive program of therapeutic activity (cardiovascular activity), therapeutic exercise (foundational strengthening and hip strengthening activities), and neuromuscular rehabilitation (visual/vestibular and balance activities) to address the unique needs of individuals with Down syndrome. This program has been developed and successfully implemented in Down syndrome activity centers across the country. This program will be offered through Zoom. Intensity will be submaximal for both data collection and during the exercise sessions, and recorded with Polar heart rate monitors.
89131895|NCT04647474||Radical Prostatectomy|Participants undergoing any curative surgical treatment option for prostate cancer irregardless of approach (open, laparoscopic or robotic)
89131896|NCT04647474||Active Surveillance|Participants undergoing active surveillance as the management option for prostate cancer as defined by regular surveillance attendance at the primary treating site.
89131897|NCT04647474||Hormone Monotherapy|Participants undergoing medical hormone therapy (Antiandrogens and Gonadotropin-releasing hormone (GnRH) agonists or antagonists) or surgical castration (e.g. orchidectomy) options as the primary treatment for prostate cancer.
89131898|NCT04647474||Radical Radiotherapy|Participants undergoing primary radiotherapy treatment for prostate cancer irregardless of delivery methods (e.g. External beam radiation therapy or brachytherapy).
89131899|NCT04644276|Active Comparator|Mask with Mask Adhesive/Arm 1|Patients will be randomized to AF531 if they receive mask adhesive with mask on the first study night then the mask without mask adhesive(Performatrak) on the second study night.
89131900|NCT04644276|Placebo Comparator|Mask without Mask Adhesive/Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then they will receive the mask with the mask adhesive on the second study night.
89131901|NCT04633980|Experimental|Experimental group|
89131902|NCT04566432||Immune checkpoint inhibitors|
89131903|NCT04566432||Targeted therapy|Targeting ALK, ROS1, MET ex14 skipping
89131904|NCT04537715|Experimental|Part 1: Tazemetostat and Itraconazole Drug Interaction Cycle 1|"Participants in Part 1 of the study will receive a single oral, 400 mg dose of tazemetostat on Day 1, 15, and Day 36.~The study participants will receive tazemetostat (oral 400 mg) tablets to be taken twice daily on Days 3 - 14 and Days 21 - 35. In addition, the participants will receive oral 200 mg itraconazole once daily on Days 18 - 38.~Study participants may continue tazemetostat from Day 40+ at the recommended therapeutic dose (oral 800 mg twice daily) in 28-day cycles."
89131905|NCT04537715|Experimental|Part 2:Tazemetostat and Rifampin Drug Interaction Cycle 1|"Participants in Part 2 of the study will receive a single oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 36.~The study participants will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily on Days 3 - 14 and Days 17 - 23. In addition, the participants will receive oral 200 mg rifampin once daily on Days 17 - 25.~Study participants may continue tazemetostat from Day 27+ at the recommended therapeutic dose (oral 800 mg twice daily) in 28-day cycles."
89131906|NCT04532528||Patients receiving standard of care (SOC)|(without advanced educational Intervention)
89131907|NCT04532528||Patients receiving SOC with advanced educational intervention|
89131908|NCT04489992||Standard radiology studies with AI|"The experiment is conducted on 10 types of studies with AI:~Chest CT/ LDCT with different pathologies;~Abdominal CT with different pathologies;~Head CT with different pathologies;~MSS XR with different fractures~Spine XR with different pathologies;~MMG;~Brain MRI with different pathologies;~Cervical spine MRI, Lumbosacral spine MR and Thoracic spine MRI with spine pathologies~Knee joint MRI~Lesser pelvis MRI."
89131909|NCT04489992||Standard radiology studies without AI|"The experiment is conducted on 10 types of studies without AI:~Chest CT/ LDCT with different pathologies;~Abdominal CT with different pathologies;~Head CT with different pathologies;~MSS XR with different fractures~Spine XR with different pathologies;~MMG;~Brain MRI with different pathologies;~Cervical spine MRI, Lumbosacral spine MR and Thoracic spine MRI with spine pathologies~Knee joint MRI~Lesser pelvis MRI."
89131910|NCT04463225|Other|Intervention condition|Participants assigned to the intervention condition will be invited to engage with an internet-based intervention three times during the course of the study.
89131911|NCT04463225|No Intervention|Control|The control group will not be offered the internet-based intervention.
89131912|NCT04427241|Experimental|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
89131913|NCT04427241|Placebo Comparator|Control|100 ml normal saline, days 4-17, once/day, IV
89131914|NCT04410731|Experimental|BM-MSC injections for low back pain|Single bilateral intra-articular injections of allogeneic BM-MSCs for lumbar facet joint arthropathy
89131915|NCT04385498|Experimental|BREATHE Intervention|Five session program, with additional sessions provided based on the individual's learning style and needs. Sessions are designed to be 20 to 30 minutes long, to accommodate the needs of the primary health care centers. Sessions will ideally be conducted once per week, but may be conducted as infrequently as once per month.
89131916|NCT04385498|Active Comparator|Waitlist Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm. At the End of the trial participants will be able to receive the BREATHE Ethiopia PTSD treatment
89131917|NCT04380116|Experimental|Sb+Aware|Patients will access to the Soberlink device and receive treatment with Aware Recovery Care
89131918|NCT04380116|No Intervention|Aware|Patients will only have access to Aware Recovery Care
89131919|NCT04335643|Experimental|TEACH|Participants will undergo CBT and continue medical TAU.
89131920|NCT04335643|No Intervention|Control|Participants will only continue medical TAU.
89131921|NCT04315701|Experimental|Treatment (cemiplimab, surgical resection)|Patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles (or up to 4 cycles for patients whose disease is unresectable after 3 cycles) in the absence of disease progression or unacceptable toxicity. Within 6 weeks of last dose of therapy, patients with potentially resectable tumors undergo surgical resection.
89131922|NCT04240093|Experimental|Experimental|Experimental: Behavioral Activation (8 sessions) + Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
89131923|NCT04240093|Active Comparator|Standard of Care|Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
89131924|NCT04180696|Experimental|AdaptivCRT ON (aCRT ON, treatment group)|"AdaptivCRT programmed to Adaptive Bi-V and LV The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise."
89131925|NCT04180696|Active Comparator|AdaptivCRT OFF (aCRT OFF, control group)|"AdaptivCRT programmed to Nonadaptive CRT (standard CRT). Control group subjects will be optimized per physician's discretion. The method of AV and VV optimization in the control group will be collected."
89131926|NCT04133285||Multiple Osteochondromas patients|Patients affected by Multiple Osteochondromas. The Registry will include also data on foetuses (prenatal).
89131927|NCT04133272||Ehlers-Danlos Syndrome patients|The group comprises all patients affected by Ehlers-Danlos Syndrome, including prenatal and fetal diagnosis of Ehlers-Danlos Syndrome
89131928|NCT04115774||Osteogenesis Imperfecta patients|The group comprises all patients affected by Osteogenesis Imperfecta, including prenatal and fetal diagnosis of Osteogenesis Imperfecta
89131929|NCT04093557|Active Comparator|Orton Score Cohort - High|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they score highly, they will receive an extended GoLytely bowel prep."
89131930|NCT04093557|Placebo Comparator|Prospective Orton Score Cohort - Low|"Patients will be scored using the Orton Score, a novel clinical prediction tool to determine which patients are at risk for poor bowel preps and may benefit from an extended prep. If they do not score highly, they will receive a standard GoLytely (or Suprep) bowel prep."
89131931|NCT04093557|Other|Retrospective Cohort (before Orton Score)|
89131932|NCT04025359|Active Comparator|Dronabinol 2.5mg|Dronabinol 2.5mg
89131933|NCT04025359|Active Comparator|Dronabinol 5mg|Dronabinol 5mg
89131934|NCT04025359|Placebo Comparator|Placebo|Placebo
89131935|NCT04005716|Experimental|tislelizumab plus etoposide and platinum|
89131936|NCT04005716|Active Comparator|Placebo plus etoposide and platinum|
89131937|NCT03972280|Experimental|Dose Level 1 (HS)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
89131938|NCT03972280|Experimental|Dose Level 1 (PPP)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
89131939|NCT03972280|Experimental|Dose Level 1 (Total)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
89131940|NCT03972280|Experimental|Dose Level 2 (HS)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
89131941|NCT03972280|Experimental|Dose Level 2 (PPP)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
89131942|NCT03972280|Experimental|Dose Level 2 (Total)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
89131943|NCT03969134|Active Comparator|Vaccine arm|ChAd63 KH 7.5x1010 vp, single dose, by IM injection
89131944|NCT03969134|Placebo Comparator|Placebo|Normal Saline, single dose, by IM injection
89131945|NCT03900286|Experimental|Single Arm Study|Total Diet Replacement for 12 weeks, food reintroduction 6 weeks
89131946|NCT03898843|Experimental|Animal assisted therapy group|Patients included in this arm will have animal assisted therapy session in a specific room outside of the ICU. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires
89131947|NCT03898843|Active Comparator|Control Group|"Patients included in this arm will have a sham session : they will leave their hospital bedroom, to go in the AAT session room. There, no specific activity is planned. After 20 minutes, the patient will go back to his room. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires"
89131948|NCT03837704|Active Comparator|IQOS Arm|Patients diagnosed with AAA, switching from cigarette smoking to IQOS use
89131949|NCT03837704|Active Comparator|CC Arm|Patients diagnosed with AAA, continuing to smoke cigarettes
89131950|NCT03837704|Active Comparator|Smoking Cessation Arm|Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)
89131951|NCT03813108|Experimental|1: NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes under mefloquine prophylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
89131952|NCT03813108|Experimental|2: Low dose NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 5 NF135.C10 infected Anopheles mosquitoes under mefloquine prophylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
89131953|NCT03813108|Experimental|3: NF135 CPS-immunization (A/L) challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemether/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes.
89131954|NCT03813108|Experimental|4: NF135 CPS-immunization (A/L) challenged by NF54|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemether/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
89131955|NCT03813108|Other|5: Control group challenged by NF135.C10 Cohort A|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
89131956|NCT03813108|Other|6: Control group challenged by NF54 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
89131957|NCT03813108|Other|7: Control group challenged by NF135 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
89131958|NCT03797807|Experimental|MINST|Minimally invasive non surgical treatment
89131959|NCT03797807|Active Comparator|MIST|Minimally invasive surgical treatment
89131960|NCT03797807|Active Comparator|GTI + MINST|Minimally invasive non surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
89131961|NCT03797807|Active Comparator|GTI + MIST|Minimally invasive surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
89131962|NCT03733626|Active Comparator|ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle Screw System|20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system
89131963|NCT03733626|Placebo Comparator|Local Bone Autograft with DePuy Synthes Spinal Pedicle Screw System|20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system.
89131964|NCT03694652|Experimental|PACE+DApp|Participants in this group will receive combined intervention and a mobile phone app.
89131965|NCT03694652|Active Comparator|PACE+Dface-to-face|Participants in this group will receive combined intervention and in person/phone communication.
89131966|NCT03664362|Experimental|The BSHAPE Intervention|Participants in the BSHAPE intervention attend a 9 sessions program post-assessments which is a combination of individualized and group-based sessions.
89131967|NCT03664362|No Intervention|Usual care or no treatment control|Participants in the control arm either are receiving no services or are engaged in usual care provided by community-based/health care organizations
89131968|NCT03621748|Active Comparator|Non-Awake Cohort|Cohort undergoing craniotomy utilizing general anesthesia protocol
89131969|NCT03621748|Experimental|Awake Cohort|Cohort undergoing craniotomy utilizing awake anesthesia protocol
89131970|NCT03552796|Experimental|sEphB4-HSA|Cohorts of at least 3 participants each will be treated with escalating doses of sEphB4-HAS at 25mg, 50 mg, 75mg, 100 mg, and 125 mg administered intravesically over 2 hours once a week for 6 consecutive weeks to determine the maximum tolerated dose (MTD) and recommended phase II dosing (RP2D). Cycle repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
89131971|NCT03454997|Active Comparator|Standard Implementation Intervention|The standard version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings.
89131972|NCT03454997|Active Comparator|Enhanced Implementation Intervention|The enhanced version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings. The enhanced version will also include performance coaching.
89131973|NCT03431493|Experimental|Behavioral Activation - Rehabilitation|Behavioral Activation - Rehabilitation
89131974|NCT03431493|No Intervention|Usual Care Control|Usual Care Control
89131975|NCT03423459||CT Cohort|"Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification.~Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification.~Determine how the Evolut PRO conforms to LVOT calcification.~Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO.~Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification.~Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR."
89131976|NCT03423459||Non-CT Cohort|"Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System.~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL.~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation."
89131977|NCT03417154|Experimental|Arm 1: Nivolumab every 2 weeks and Cyclophosphamide daily|
89131978|NCT03417154|Experimental|Arm 2: Nivolumab every 2 weeks and Cyclophosphamide every 7 days|
89131979|NCT03331796|Experimental|Active rTMS (Bilateral DLPFC)|One-third of participants will receive active rTMS to the right and left dorsolateral prefrontal cortex (DLPFC).
89131980|NCT03331796|Experimental|Active rTMS (Bilateral LPC)|One-third of participants will receive active rTMS to the right and left lateral parietal cortex (LPC).
89131981|NCT03331796|Placebo Comparator|Placebo rTMS (Inactive)|One-third of participants will receive placebo/inactive rTMS, either to the DLPFC or the LPC. Those receiving placebo rTMS will serve as the control group.
89131982|NCT03288844||HOLOCORE Patients|Patients who completed the main HOLOCORE clinical trial will undergo to Ophthalmologic examinations, Digital pictures collection and QoL questionnaires (NEI VFQ 25 and EQ-5D-3L/Y) will be performed/administered at each study visit
89131983|NCT03221036|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 during induction phase.
89131984|NCT03221036|Placebo Comparator|Induction Phase: Placebo|Matching placebo IV infusion at Weeks 0, 2, and 6 during induction phase.
89131985|NCT03221036|Experimental|Maintenance Phase: Vedolizumab 300 mg|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive vedolizumab 300 mg IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who did not achieve clinical response at Week 10 will receive vedolizumab 300 mg IV infusion every 4 weeks from Week 14 up to Week 58.
89131986|NCT03221036|Placebo Comparator|Maintenance Phase: Placebo|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive placebo, IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who received matching placebo in the induction phase and achieved clinical response at Week 10 will continue to receive placebo at Week 14, 22, 30, 38, 46, and 54.
89131987|NCT03189576|Other|CRC patients after primary surgery|sequential blood draw taken to monitor residual disease
89131988|NCT03142009|Experimental|Program group|Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
89131989|NCT03142009|No Intervention|Comparison group|Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.
89131990|NCT03075670|Experimental|N9-GP|
89131991|NCT03075670|Active Comparator|ALPROLIX®|
89131992|NCT03032783|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT)|Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.
89131993|NCT03002272||TAVR|This observational study will enroll subjects that underwent TAVR more than 3 years ago.
89131994|NCT03002272||SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
89131995|NCT02823730||Synergy Stent Cohort|Retrospective registry of 500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
89131996|NCT02823730||Xience V Cohort|500 patients that are propensity matched to the 500 patients that underwent PCI with a Synergy stent, eligible for similar time points of follow-up following the PCI.
89131997|NCT02778165|No Intervention|Usual Care|Patients receiving usual care are typically referred to CR at the time of discharge from the acute care center via paper or electronic systematic referral (completed by a physician or nurse practitioner). Additionally, a conversation with the patient regarding CR by a healthcare provider may occur, however this communication is not always a consistent occurrence. Once referred, patients will await contact from a CR program in their region/area and if actual program enrollment occurs, this usually happens between 8 to 10 weeks post discharge.
89131998|NCT02778165|Experimental|MyCaRe Android Application|The MyCaRe mobile application (education and symptom monitoring which includes pain, mood scales, wound monitoring) and Fitbit accelerometer (steps walked, distance) will be provided to patients receiving intervention group allocation for the initial 6 to 8 weeks recovery post cardiac surgery. The patients will be provided a temporary loan mobile device loaded with MyCaRe and Fitbit Inspire 2 before leaving hospital. They will be asked to input data (pain, mood, wounds, activity, blood sugar, blood pressure) daily if possible in first 2 weeks and once weekly thereafter until 6 to 8 weeks or until entry to a cardiac rehabilitation program.
89131999|NCT02740985|Experimental|Arm A|AZD4635 monotherapy as nanoparticle suspension 125 mg BID
89132000|NCT02740985|Experimental|Arm B|AZD4635 monotherapy as nanoparticle suspension 75 mg QD
89132001|NCT02740985|Experimental|Arm C|AZD4635 monotherapy as nanoparticle suspension 100 mg QD
89132002|NCT02740985|Experimental|Arm D|AZD4635 as nanoparticle suspension 75 mg QD plus durvalumab
89132003|NCT02740985|Experimental|Arm E|AZD4635 as nanoparticle suspension 100 mg QD plus durvalumab
89132004|NCT02740985|Experimental|Arm EA|AZD4635 as nanoparticle suspension plus enzalutamide
89132005|NCT02740985|Experimental|Arm AA|AZD4635 as nanoparticle suspension plus abiraterone acetate
89132006|NCT02740985|Experimental|Arm F|AZD4635 as nanoparticle suspension plus durvaluamb in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
89132007|NCT02740985|Experimental|Arm G|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with non-small cell lung cancer. Patients will be allocated randomly (1:1) between Arms F and G.
89132008|NCT02740985|Experimental|Arm H|AZD4635 monotherapy as nanoparticle suspension in patients post immunotherapy with other solid tumours.
89132009|NCT02740985|Experimental|Arm I|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
89132010|NCT02740985|Experimental|Arm J|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with metastatic castration resistant prostate cancer. Patients will be allocated randomly (1:1) between Arms I and J.
89132011|NCT02740985|Experimental|Arm K|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with colorectal carcinoma.
89132012|NCT02740985|Experimental|Arm KD|AZD4635 as nanoparticle suspension plus durvalumab in immunotherapy-naïve patients with colorectal carcinoma.
89132013|NCT02740985|Experimental|Arm L|AZD4635 monotherapy as nanoparticle suspension in immunotherapy naïve patients with other solid tumours.
89132014|NCT02740985|Experimental|Arm CA|AZD4635 capsule formulation monotherapy 75 mg, 150 mg, and 200 mg QD. A lower dose of 125 mg or 100 mg may be given. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CA. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycle 1 and Cycle 2 will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
89132015|NCT02740985|Experimental|Arm CB|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus durvalumab and oleclumab. The pharmacokinetics of AZD4635 capsule formulation will be characterized on Cycle 1, 2, and 4 (Day 1) in Arm CB. Steady-state pharmacokinetics will be assessed on Cycle 2 Day 15. Cycle 1 will be administered in a 3-week cycle to assess the safety and dose-limiting toxicity (DLT). PKs will also be collected on Day 1 of Cycles 3 and 5.
89132016|NCT02740985|Experimental|Arm CC|AZD4635 capsule formulation 50 mg QD or 75 mg QD plus docetaxel. The pharmacokinetics of the single dose AZD4635 capsule formulation will be characterized on Cycle 1 Day 1 in Arm CC. Steady-state pharmacokinetics will be assessed on Cycle 1 Day 15. Cycles will be administered in 3-week cycles to assess the safety and dose-limiting toxicity (DLT). After Cycle 1, PKs will be collected on Day 1 of every even numbered cycle (Cycles 2, 4, and 6).
89132017|NCT02660268|Experimental|Clinical pathway|Patients in the experimental group will be followed according to the clinical pathway
89132018|NCT02660268|No Intervention|Control|Patients in the control group will receive standard care
89132019|NCT02628899|Other|Prospective TAVR Arm|200 patients prospectively undergoing transfemoral TAVR
89132020|NCT02628899|Other|Historical SAVR Controls|Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
89132021|NCT02628899|Other|Low-Risk TAVR with Bicuspid Aortic Valve|The third arm of the trial will comprise a registry of TAVR in up to 100 low-risk patients with bicuspid aortic valve. The results from the registry arm will be analyzed independently.
89132022|NCT02571790|Experimental|Relaxation optimized virtual reality|six relaxation sessions with virtual reality
89132023|NCT02571790|Experimental|Classical relaxation (without Virtual Reality).|six relaxation sessions without virtual reality
89132024|NCT02515110|Experimental|Treatment (EBRT)|"External Beam Radiation Therapy (EBRT). Within 10 weeks after the last breast cancer surgery or the last dose of adjuvant chemotherapy, patients undergo hypofractionated RNI five days a week over 3-4 weeks.~The two subgroups are Cohort (A) sentinel lymph node (SLN) and Cohort (B) axillary lymph node (ALN) dissection. They are categorized depending on type of axillary surgery and treatment group. The type of axillary surgery is Sentinel lymph node (SLN) biopsy only vs axillary dissection with or without previous SLN biopsy. The treatment groups are lumpectomy vs mastectomy vs mastectomy/reconstruction."
89132025|NCT02484677|Experimental|Head and neck cancer patient|Association of Docetaxel, Cisplatin, 5-Fluorouracile for pharmacokinetic evaluation
89132026|NCT02480699|Experimental|Hemodialysed patients|
89132027|NCT02476097|Placebo Comparator|Sudden discontinuation|placebo for 7 days
89132028|NCT02476097|Active Comparator|Progressive discontinuation|Esomeprazole: Nexium® 20mg, Astra Zeneca , for 7 days
89132029|NCT02434809|Experimental|Patients with lung cancer|Physician evaluation of patient setup accuracy will be performed using all available images and adjustments will be made as per standard practice. In addition, a respiration motion-corrected CBCT (daily for SBRT, weekly for standard fractionation) will be used to confirm the accuracy of Calypso-based setup. Patients will return for follow up at 3,6, 9, 12, 15, 18, 21 and 24 months (+/- 4 weeks) following completion of radiation therapy. The following assessments will be performed at these visits: history and physical exam, diagnostic CT chest, and toxicity assessment.
89132030|NCT02335996|Active Comparator|patients with active hypercortisolism|
89132031|NCT02335996|Active Comparator|Patients in remission of their hypercortisolism after surgery|
89132032|NCT02316951||single-arm study group|Study participants will be adult patients recovering from orthopedic surgery. The study group will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room.
89132036|NCT03946358|Experimental|Atezolizumab and UCPVax|"Induction phase:~Atezolizumab 1200 mg intravenous (IV) every 3 weeks since day 1~UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase:~UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)~Atezolizumab 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
89132037|NCT02106507|Experimental|Progressive Metastatic Castration-Resistant Prostate Cancer|This is a single-institution Phase 1b dose-escalation study in which eligible patients with progressive mCRPC will receive oral doses of apalutamide in combination with everolimus.
89132038|NCT02085668|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
89132039|NCT02085668|No Intervention|Control Group|Maintenance of heart failure medications with option for cross-over renal denervation treatment after 6-months
89132040|NCT01964261|Experimental|Neural Prosthetic System 2|The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
89132041|NCT01596621|Experimental|Bendamustine|Participants will receive bendamustine hydrochloride administered at 120 milligrams (mg)/square meter (m^2) intravenously (IV) as a 60-minute infusion, and not more than 120 minutes, on Days 1 and 2 in each 21-day treatment cycle for 6 planned cycles and up to 8 total cycles.
89132042|NCT01337245|Experimental|Antivenom|For comparison with historical mortality rate, all patients prospectively enrolled will receive antivenom (Snake [Micrurus] North American immune F(ab')2 Equine) for treatment of coral snake bite.
89132043|NCT01264315|Other|Lenalidomide in maintenance|
89132044|NCT01108627|Active Comparator|corticosteroid + long acting beta agonist; steroids|
89132045|NCT01108627|Placebo Comparator|placebo + corticosteroid + long acting beta agonist; steroids|
89132046|NCT00890149|Experimental|Ondansetron|Ondansetron + BASICS Plus
89132047|NCT00890149|Placebo Comparator|Placebo|Placebo + BASICS Plus
89132048|NCT00813982|Experimental|Experimental Lotrafilcon A Contact Lens|Lotrafilcon A experimental contact lens randomly assigned to one eye
89132049|NCT00813982|Active Comparator|Commercial Lotrafilcon A Contact Lens|Lotrafilcon A commercial contact lens randomly assigned to one eye
89132050|NCT00566098|Experimental|ASCT+MILs|Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.
89132051|NCT00248287|Active Comparator|Arm 1|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle (Arm 1, ICb)
89132052|NCT00248287|Experimental|Arm 2|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2 Week 1 and then 250 mg/m2 weekly thereafter, (Arm 2, ICb+Erbitux)
89132053|NCT04250220|Experimental|intervention group|e-health-based strategy
89132054|NCT04250220|No Intervention|control group|symptom based AF-screening
89132055|NCT00703599|Experimental|1|This is the only arm and that is the treatment group.
89132056|NCT04249284|Experimental|Treatment A : BMS-986165|
89132057|NCT04249284|Experimental|Treatment B: BMS-986165 prototype 1|
89132058|NCT04249284|Experimental|Treatment C: BMS-986165 prototype 2|
89132059|NCT04249284|Experimental|Treatment D: BMS-986165 prototype 2|
89132060|NCT04474938|Experimental|Dara-BD|Daratumumab combined with bortezomib and dexamethasone
89132061|NCT00837213|Active Comparator|BPO with clindamycin foam|Benzoyl peroxide (BPO) wash with clindamycin foam
89132062|NCT00837213|Active Comparator|BPO + clindamycin foam + doxycycline|Benzoyl peroxide (BPO) wash with clindamycin foam and doxycycline capsules
89132063|NCT04249050|Experimental|Intervention group|The intervention group is receiving a nutritional drink containing potential immune stimulating ingredients (fish oil, arginine, nucleotides)
89132064|NCT04249050|No Intervention|Control group|The Control group is receiving the hospital´s Standard Of Care.
89132065|NCT05602155||Group 1|weight bearing situation: patients with partial weight bearing after treatment
89132066|NCT05602155||Group 2|weight bearing: patients with full weight bearing after treatment
89132067|NCT02833038|Experimental|Magnesium group|Intravenous administration of Magnesium Sulfate
89132068|NCT02833038|Placebo Comparator|Control group|Intravenous administration of normal saline
89132069|NCT00703755|Experimental|1|
89132070|NCT00703755|Experimental|2|
89132071|NCT00703755|Experimental|3|
89132072|NCT00703755|Experimental|4|
89132073|NCT00703755|Experimental|5|
89132074|NCT00703755|Experimental|6|
89132075|NCT00703755|Placebo Comparator|7|
89132076|NCT02836158|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
89132077|NCT05600205|Experimental|GOAL!|Combined Support for the Ambulatory Lifestyle Intervention
89132078|NCT05600205|No Intervention|Control group|Care and counseling as usual (matched for gender, age and diagnosis)
89132079|NCT04201314|Placebo Comparator|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
89132080|NCT04201314|Experimental|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
89132081|NCT00703833|Experimental|1|Drug
89132082|NCT00703833|Placebo Comparator|2|Placebo
89132083|NCT05599893|Experimental|Tele - physical therapy group|Participants in the tele-physical therapy group underwent tele-physical therapy sessions which includes an internet-based video conference under the supervision of physical therapists. Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm-up, 60 minutes of training and 10 minutes of a cool-down phase. The participants in the tele physical therapy group received training four times a week, for 8 weeks, each session lasted for 60 minutes.
89132084|NCT05599893|Active Comparator|Control intervention group|During the first visit, participants in the control intervention group (CIG) received patient education for 10 minutes from physical therapists and also received a pamphlet containing these instructions in written form. They were informed to do their normal daily activities, avoid sedentary lifestyle, perform regular physical activities such as household activities, maintain balance diet and have 6-8 hours of sleep per day.
89132085|NCT02838342|Experimental|Metronomic cyclophosphamide and interferon-alpha|
89132086|NCT05333640||AVFs treated with Sirolimus Drug Coated Balloon|Dysfunctional matured AVF that have underwent thrombolysis or balloon angioplasty with SDCB within 6 months witll be considered for the registry.
89132087|NCT05333640||AVFs treated with Paclitaxel Drug Coated Balloon|Dysfunctional matured AVF that have underwent thrombolysis or balloon angioplasty with PDCB within 6 months witll be considered for the registry.
89132088|NCT02838264|Experimental|Cohort 1|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
89132089|NCT02838264|Experimental|Cohort 2|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
89132090|NCT02838264|Experimental|Cohort 3|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
89132091|NCT02838264|Experimental|Cohort 4|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive the highest safe dose (mg) of PF-06463922 as a single-dose Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
89132092|NCT00902486|Experimental|INCB028050 4 mg QD|INCB028050 4mg Once daily (QD)
89132093|NCT00902486|Experimental|INCB028050 7 mg QD|INCB028050 7mg QD
89132094|NCT00902486|Experimental|INCB028050 10 mg QD|INCB028050 10mg QD
89132095|NCT00902486|Placebo Comparator|Placebo|Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.
89132096|NCT00633438|Placebo Comparator|B|
89132097|NCT00633438|Experimental|A|
89132098|NCT00836745||1|Non Interventional
88802580|NCT02344472|Experimental|Chemotherapy with vinorelbine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus vinorelbine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
89132099|NCT02833116|Experimental|Group Betamethasone|One ampule containing 12 mg of betamethasone in a syringe of 10 ml
89132100|NCT02833116|Active Comparator|Group Dexamethasone|One ampule containing 4 mg of dexamethasone in a syringe os 10 ml
89132101|NCT02838654||cervical epidural injection group|cervical epidural injection group
89132102|NCT00703989|Experimental|I|Patients with Type 1 diabetes
89132103|NCT00703989|No Intervention|II|Age-matched male subjects without Type 1 diabetes
89132104|NCT02838186|Active Comparator|right colon in retroflexion|"polyp/adenoma detection~feasibility"
89132105|NCT02838186|Active Comparator|right colon in forward view|polyp/adenoma detection
89132106|NCT02835924|Active Comparator|Arm A|160 mg/day 3w on/1w off
89132107|NCT02835924|Experimental|Arm B|120 mg/day 3w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
89132108|NCT02835924|Experimental|Arm C|160 mg/day 1w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
89132109|NCT00891618|Experimental|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
89132110|NCT05335460|Experimental|Envafolimab combined with XELOX regimen|Envafolimab:300mg,sc,d1,Q3W XELOX( Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w)
89132111|NCT03816878|Experimental|Cohort 1: pLAIV Recipients|Participants who have received the pandemic live attenuated influenza vaccines (pLAIVs) H2N2, H6N1, or H9N2 during a previous CIR study will receive a single dose of 0.5 mL H5N1 pISV vaccine at Day 0.
89132112|NCT03816878|Experimental|Cohort 2: pLAIV Naive|Participants who have never previously received a pLAIV will receive one dose of 0.5 mL H5N1 pISV vaccine at Day 0.
89132113|NCT02836002|Experimental|Group 1 - SP low/SP high|"Group 1 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).~Group 1 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
88802581|NCT02344472|Experimental|Chemotherapy with capecitabine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus capecitabine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
88802582|NCT02344472|Experimental|endocrine therapy with exemestane|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus exemestane.
88802583|NCT02344472|Experimental|endocrine therapy with fulvestrant|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus fulvestrant.
88802584|NCT02344472|Experimental|endocrine therapy with anastrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus anastrozole.
88802585|NCT02344472|Experimental|endocrine therapy with letrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus letrozole.
88802586|NCT02344472|Experimental|Chemotherapy with nab-Paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus nab-Paclitaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
88802587|NCT02344472|Experimental|Chemotherapy with eribulin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus eribulin. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
88802588|NCT02344472|Experimental|endocrine therapy with leuprorelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus leuprorelin.
88802589|NCT02344472|Experimental|endocrine therapy with goserelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus goserelin.
88802590|NCT02376946|Active Comparator|Actipatch|The study group will be comprised of subjects that will receive PEMF ActiPatchTM treatment for postoperative management of pain and edema.
88802591|NCT02376946|Placebo Comparator|Placebo|The control group will be comprised of the subjects that will receive a placebo patch as treatment for postoperative management of pain and edema.
89132114|NCT02836002|Experimental|Group 2 - SP low/Pip high|"Group 2 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).~Group 2 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
89132115|NCT02836002|Experimental|Group 3 - Pip low/Pip high|"Group 3 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).~Group 3 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
89132116|NCT02836002|Experimental|Group 4 - Pip low/SP high|"Group 4 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).~Group 4 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
89132117|NCT00836589||Data Collection Group|
89132118|NCT03711812|Active Comparator|Serratus Anterior Plane Catheter|
89132119|NCT03711812|Placebo Comparator|Thoracic Epidural|
89132120|NCT02835768|Experimental|Intervention|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Participants will be given an additional leaflet about the domestic safety website with address link and brief introductory information.
89132121|NCT02835768|No Intervention|Control|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Only this booklet serves as the anticipatory guidance to mothers about domestic safety.
89132122|NCT02835456|Active Comparator|Group A: Sharklet Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
89132123|NCT02835456|Active Comparator|Group B: Silicone Foley Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
89132124|NCT02842658|Active Comparator|A high-intensity interval exercise group|Supervised exercise training with be carried out at the Mayo Clinic Cardiac rehabilitation center on cycle ergometers using EKG telemetry. Treatment will begin one week prior to chemotherapy and is tailored around 8 weeks.
89132125|NCT02842658|Other|An attention-control group|Patients will receive counseling regarding physical activity during chemotherapy. Patients will receive a weekly phone call to maintain physical activity during chemotherapy and compliance will be verified using physical activity diaries and pedometers.
89132126|NCT05325060|Experimental|Electromagentically navigated Total knee arthroplasty|"Patients underwent total knee arthroplasty using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA). The system employs small reference frames attached to the femur and tibia which are incorporated within the primary surgical incision. A standard process of joint registration maps the surface anatomy of the joint. Alignment targets were similar in both groups with a neutral Hip-Knee-Ankle-Axis and the aim to implant both femur and tibial components perpendicular to this in the coronal plane.~All patients received a cemented posterior stabilized NexGen LPS Flex TKA (Zimmer, Warsaw, Indiana, USA)."
89132127|NCT05325060|Active Comparator|Conventional mechanically alligned Total knee arthroplasty|"Participants randomized to the conventional group received a TKA implanted using standard instrumentation.~All patients received a cemented posterior stabilized NexGen LPS Flex TKA (Zimmer, Warsaw, Indiana, USA).~Alignment targets were similar in both groups with a neutral Hip-Knee-Ankle-Axis and the aim to implant both femur and tibial components perpendicular to this in the coronal plane."
89132128|NCT02297516|Experimental|Azzalure/Dysport as single treatment|Azzalure/Dysport as single treatment at initial treatment
89132129|NCT02297516|Experimental|Filler as single treatment|Filler as single treatment at initial treatment
89132130|NCT00830479|Active Comparator|Open Surgery|
89132131|NCT00830479|Active Comparator|Endoscopic Surgery|
89132132|NCT02842580|Active Comparator|Standard arm (escalation strategy - arm A)|LV5FU2 (5 FLUOROURACYL)+avastin. After progression: FOLFIRI + avastin. after the 2nd progression:FOLFOX4 (eloxatine)+ avastin.
89132133|NCT02842580|Experimental|Experimental arm (de-escalation strategy -arm B)|(4 cycles of FOLFOXIRI (campto) + avastin and 4 cycles of FOLFIRI + avastin) is followed by maintenance with capecitabine
89132134|NCT00836277|Experimental|Irinotecan plus panitumumab|"Irinotecan 100 mg/m2 IV Day 1 and Day 8~+ Panitumumab 9mg/kg IV Day 1 Cycle = 21 days"
89132135|NCT00831025|Experimental|1|Depigmented and polymerized allergen extract of Olea europaea pollen for subcutaneous injection.
89132136|NCT00831025|Placebo Comparator|2|Placebo for subcutaneous injection.
89132137|NCT00843427|Experimental|Aphasia - CIAT|Patients with aphasia >1 year after left MCA stroke who will be randomized to receive CIAT
89132138|NCT00843427|No Intervention|Aphasia - observation|Patients with aphasia >1 year after left MCA stroke who will be randomized to no intervention (observation)
89132139|NCT02842502|Experimental|Skin graft pellet|This group concerns patients who are recruited for skin graft procedure leading to the collection of supernumerary biopsies.
89132140|NCT00835731|Experimental|1|400mcg buccal misoprostol
89132141|NCT00835731|Experimental|2|Dilapan-S, control: vitamin B-12 administered sublingually
89132142|NCT00843505|Experimental|1|Participants will take part in a telemedicine smoking cessation program.
89132143|NCT00843505|Active Comparator|2|Participants will take part in a telephone quitline smoking cessation program.
89132144|NCT03721406|Other|Ropivacaine|"25 ml single dose of 0.5% ropivacaine~continuous infusion of ropivacaine 0.2% with a constant infusion rate of 14 ml/h"
89132145|NCT00751166|Experimental|1|Desloratadine
89132146|NCT00751166|Active Comparator|2|Cetirizine
89132147|NCT00751166|Placebo Comparator|3|placebo
89132148|NCT00835341||p16-methylated|patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.
89132149|NCT00835341||p16-unmethylated|patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.
89132150|NCT03685448|Experimental|Experimental: Cabozantonib|Cabozantinib 60 mg/day for up to 12 cycles (one cycle is 28 days), taken orally
89132151|NCT00837343|Experimental|Quetiapine Fumarate arm|Quetiapine Fumarate arm
89132152|NCT00732368|Experimental|Mometasone Nasal Spray|Open-label. Two sprays per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
89132153|NCT00704067|Experimental|1|Supported employment for 12 months plus cognitive training for the first 12 weeks
89132154|NCT00704067|Active Comparator|2|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks
89132155|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
89132156|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Low residue|
89132157|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
89132158|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Low residue|
89132159|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Clear liquid|
89132160|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Low residue|
89132161|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
89132162|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Low residue|
89132163|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
89132164|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Low residue|
89132165|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Clear liquid|
89132166|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Low residue|
89132167|NCT00704145|Experimental|A|Device, paclitaxel drug-eluting stent
89132168|NCT00704223||A|
89132169|NCT00704301|Experimental|1|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Rivastigmine: two times 1,5 mg a day; The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
89132170|NCT00704301|Placebo Comparator|2|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Placebo: 2 times a day
89132171|NCT00837421||sepsis|sepsis survivors
89132172|NCT03618446||Survivors|Patients whose pelvic fracture and survived till time of discharge from the hospital.
89132173|NCT03618446||Non-Survivors|Patients whose pelvic fracture and died while in hospital.
89132174|NCT00837499||Mexican Women from Mexico|
89132175|NCT00837499||Mexican-American Women in U.S.|
89132176|NCT00837499||African-American Women in U.S.|
89132177|NCT00704457||A|One arm study. Urine collection.
89132178|NCT00831103|Experimental|EPB-348 1000 mg|EPB-348 1000 mg dosed once daily for seven days
89132179|NCT00831103|Experimental|EPB-348 2000 mg|EPB-348 2000 mg dosed once daily for seven days
89132180|NCT00831103|Experimental|EPB-348 3000 mg|EPB-348 3000 mg dosed once daily for seven days
89132181|NCT00831103|Active Comparator|Valacyclovir|Valacyclovir 1000 mg dosed three times daily for seven days
89132182|NCT00704444||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
89132183|NCT00704444||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
89132184|NCT02611791|Experimental|Radiofrequency|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genitalia.
89132185|NCT02611791|Sham Comparator|Radiofrenquency Off|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genital which was turned off, but a water-soluble gel was used
89132186|NCT05335382|Experimental|Implementing PCBH directly|PCCs randomized to this arm will immediately start the implementation of PCBH.
89132187|NCT05335382|Active Comparator|Delayed implementation of PCBH|PCCs randomized to this arm will have a delayed start of their PCBH implementation, waiting between 5-9 months. During this time, the same patient-level and organizational-level data will be collected from these centers while they continue to use traditional primary care / Care As Usual (CAU) .
89132188|NCT00704691|Experimental|Lenalidomide|
89132189|NCT02842190|Active Comparator|NIPPV|NIPPV after ekstubation
89132190|NCT02842190|No Intervention|BIPAP|BIPAP after ekstubation
89132191|NCT00574249|Active Comparator|adalimumab + placebo|adalimumab + placebo (vehicle ointment)
89132192|NCT00574249|Active Comparator|adalimumab + calcipotriol/betamethasone|adalimumab + calcipotriol/betamethasone ointment
89132193|NCT00891228|Placebo Comparator|Testosterone Gel 10 g and Nestorone® 0 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
89132194|NCT00891228|Experimental|Testosterone Gel 10 g and Nestorone® 8 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.
89132195|NCT00891228|Experimental|Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
89132196|NCT00896168|Experimental|Infliximab + Methotrexate (Moderate RA)|Participants with moderate RA (score greater than 3.2, but less than 5.1 on the disease activity score [DAS] 28) received infliximab 3 milligram per kilogram (mg/kg) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) at Week 0, 2, 6, 14 and 22 along with oral MTX IN a stable dose of 7.5 to 20 mg per week (equal to the dose used before participation in the study) for 22 weeks.
89132197|NCT00896168|Experimental|Infliximab + Methotrexate (Severe RA)|Participants with severe RA (score greater than 5.1 on the DAS 28) received infliximab 3 mg/kg intravenous infusion at Week 0, 2, 6, 14 and 22 along with oral MTX in a stable dose of 7.5 to 20 mg per week (mg/week) equal to the dose used before participation in the study) for 22 weeks.
89132198|NCT00833703|Placebo Comparator|Placebo|0.2 mL/kg/day matching placebo solution once daily.
89132199|NCT00833703|Experimental|Clopidogrel 0.2 mg/kg/day|0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.
89132200|NCT02842034|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 120% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 50 stimuli each (i.e., 3000 stimuli) and an intertrain interval of 10 sec. Treatment will be applied in sequential order to the dorsomedial prefrontal cortices (DMPFC).
89132201|NCT02842034|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the same site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
89132202|NCT00833547|Experimental|Eszopiclone|3mg of eszopiclone on two consecutive nights
89132203|NCT00833547|Placebo Comparator|placebo|placebo capsule that looks identical to eszopiclone capsule on two consecutive nights
89132204|NCT00833469|Experimental|Escitalopram|Flexible dose escitalopram 10mg
89132205|NCT02831478|Experimental|BAY987517|2/3 of subjects testing the test article
89132206|NCT02831478|Active Comparator|Sunscreen Lotion|1/3 of subjects testing the marketed control
89132207|NCT00837655|Experimental|1|Sevelamer intervention
89132208|NCT00837655|Active Comparator|2|Calcium carbonate
89132209|NCT02842268|Experimental|BAY987517|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams.Subject should sweat profusely.
89132210|NCT00843583||resistant hypertension subjects|subjects with resistant hypertension
89132211|NCT02611869|Experimental|Cryoballoon|
89132212|NCT02611869|Active Comparator|RF ablation|
89132213|NCT02841956|Experimental|Electronic Screen + Education (Phase 1)|Electronic screening of participants and targeted education of providers according to standard EDAPT model.
89132214|NCT02841956|Active Comparator|Targeted Provider Education (Phase 1)|Targeted education of providers according to standard EDAPT model.
89132215|NCT02841956|Experimental|Community Mobile Engagement (Phase 2)|Clinical intake interviews take place via videoconference at a location in the community convenient for the participant.
89132216|NCT02841956|Active Comparator|Clinic based Engagement (Phase 2)|Clinical intake interviews take place at the EDAPT clinic.
89132217|NCT00843661|Experimental|Ezetimibe and fenofibrate|
88802592|NCT02338232|Experimental|160 mg Telmisartan|60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days
89132218|NCT00843661|Active Comparator|Pravastatin|
89132219|NCT00832377|Experimental|Timolol/Dorzolamide|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
89132220|NCT00843739|Experimental|EMST|Four week device driven strength training program
89132221|NCT00843739|Sham Comparator|sham|Four week sham device driven training program
89132222|NCT00843739|No Intervention|Control|Four weeks of no intervention
89132223|NCT00705315|Experimental|1|Bevacizumab->Epirubicin->Docetaxel
89132224|NCT00837733|Experimental|Biopsy catheter|Biopsy catheter (Pipelle de Cornier, Prodimed, Neuilly-en-Thelle, France
89132225|NCT00892008||Open-Label|This study was open-label with only one treatment group. Pregabalin was prescribed in accordance with usual clinical practice.
89132226|NCT04247490||Pediatric AIH|Patients diagnosed with hepatitis type 1 and type 2 formulated between the ages of 0 and 18.
89132227|NCT04201236|Experimental|Oropharyngeal exercises|Oropharyngeal exercises include soft palate, tongue and facial muscle exercises as well as stomatognathic function exercises. Training sessions were held once a day, 5 days a week for 12 weeks under the supervision of a mirror.
89132228|NCT04201236|Experimental|Inspiratory muscle training|The inspiratory muscle training group was administered for 12 weeks starting from 30% of maximal oral pressure, 7 days a week, 15 minutes twice a day. Patients came to the control once a week, mouth pressures were measured and training pressure was adjusted in 30% of the new value.
89132229|NCT04201236|No Intervention|Control|This group was only monitorized without any rehabilitation intervention.
89132230|NCT00623233|Experimental|Gemcitabine + Bevacizumab|"Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.~Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
89132231|NCT02835612|Experimental|Early stimulation|skin-to skin care by mother (kangaroo care) plus massage therapy by mothers.
89132232|NCT02835612|Active Comparator|Conventional care|skin-to skin care by mother (kangaroo care).
89132233|NCT00837889||decompensated heart failure patients|
89132234|NCT00837889||chronic heart failure patients|
89132235|NCT00837889||healthy controls|
89132236|NCT00831259||1|Incidence of silent stroke in patients with PFO
89132237|NCT00831259||2|Incidence of silent stroke in patients without PFO
89132238|NCT02832882|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.
89132239|NCT02832882|Active Comparator|Conventional tumor puncture RFA arm|Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.
89132240|NCT02546557||OPTICABG|Patients undergoing a coronary artery bypass graft surgery for the repair of a multi-vessel disease or left main-coronary disease.
89132241|NCT00843973||iliac crest bone graft|Bone graft harvested via iliac crest bone graft procedure
89132242|NCT00843973||Reamer Irrigator Aspirator|Bone graft harvested via the Reamer Irrigator Aspirator (RIA) Procedure
89132243|NCT02832804|Experimental|anodal stimulation|10 person The patients treated by anodal stimulation (2mA) for 20 minutes
89132244|NCT02832804|Active Comparator|cathodal stimulation|10 person The patients treated by cathodal stimulation (1-2mA) for 20 minutes
89132245|NCT02832804|Sham Comparator|sham stimulation|10 person The patients treated by anodal stimulation (1-2mA) for 15 seconds
89132246|NCT02841488|Active Comparator|Continuous nerve block|Continuous peripheral sciatic nerve block through popliteal perineural catheter with ropivacaine
89132247|NCT02841488|Active Comparator|Systemic analgesia|Intravenous fentanyl patient controlled analgesia device
89132248|NCT02832726|Active Comparator|cyano-hydroxo B12|Absorption of 3 doses of 9 ug cyano-B12 and 9 ug hydroxo-B12 for two days (the CobaSorb test). No drugs given.
89132249|NCT02832726|Active Comparator|Cyano-B12 doses|Absorption of 3 doses of 3 ug, 6 ug, and 9 ug cyano-B12 for two days (the CobaSorb test). No drugs given.
89132250|NCT00831337|Experimental|Liver cirrhosis compensated|VSL3 supplemented twice daily for 28 days
89132251|NCT00831337|Experimental|Liver cirrhosis decompensated|VSL3 supplemented twice daily for 28 days
89132252|NCT00831337|Experimental|Control group|VSL3 supplemented twice daily for 28 days
89132253|NCT04201158||Obese Group (Girl)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria.Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
88802593|NCT01780636|Experimental|Botulinum toxin (Botox) injection|All patients will be given the active Botox injection and thus this study will remain open-label and non-randomized as this is a pilot study to determine initial efficacy.
89132254|NCT04201158||Obese Group (Boy)|Diagnosed with the obesity according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Diagnosed with a neurological disease or another clinical diagnosis that may affect the cognitive state, musculoskeletal and neurological disease, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease, which may affect the performance of exercise and using the drug that affects appetite and weight are the exclusion criteria.
89132255|NCT04201158||Control Group (Girl)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
89132256|NCT04201158||Control Group (Boy)|Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
89132257|NCT00838045|Experimental|Akreos TL intraocular lens|Bausch & Lomb Akreos TL intraocular lens
89132258|NCT02548754|Experimental|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
89132259|NCT02548754|Sham Comparator|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
89132260|NCT02831322|Experimental|radial artery occlusion|Radial artery occlusion was the absence of a flow signal by Doppler ultrasound examination.
89132261|NCT02831322|Other|radial artery normal|Radial artery normal was blood flow signal by Doppler ultrasound
89132262|NCT02547259|Experimental|schizophrenic pain words test|schizophrenic will have memory test with pain words on computer
89132263|NCT02547259|Experimental|schizophrenic negative words test|schizophrenic will have memory test with negative words on computer
89132264|NCT02547259|Other|Healthy volunteer pain words test|Healthy volunteer will have memory test with pain words on computer
89132265|NCT02547259|Other|Healthy volunteer negative words test|Healthy volunteer will have memory test with negative words on computer
89132266|NCT02831244|Other|Agili-CTM|Intervention
89132267|NCT02548039||Asian Normogonadotrophic Anovulatory Women|Asian women with normal gonadotropin levels but do not ovulate.
89132268|NCT02499302|Experimental|Mental training|"The intervention consists of one introductory session (patients and their parents/next-of-kin), followed by 9 individual therapy sessions (one each week) of 1.5 hours duration and related home-work, combining elements from cognitive behavioural therapy and music therapy: Important elements of the mental training program are:~Psychoeducation: Theories of CFS/ME pathophysiology and treatment rationale~Relaxation: Bodily stress reduction, mindfulness~Visualization: Contact with positive emotions, techniques of worrying reduction~Experiences: Behavioral 'experiments' (individually adjusted), 'trick into action'~Cognitive challenges: Challenging thoughts about disease process, stimulus and outcome expectancies, prognosis"
89132269|NCT02499302|No Intervention|Routine follow-up|Routine follow-up by the general practitioner, which is normal approach to chronic fatigue following acute EBV infection.
89132270|NCT02831400|Experimental|IFABP assessment (1 study group)|30 elderly volunteers
89132271|NCT00202904|Experimental|Arm 1|
89132272|NCT00202904|Active Comparator|Arm 2|
89132273|NCT04248660||Uterine artery doppler measurements|"Uterine artery doppler measurements will be made in the same patients at 11-14 weeks and 20-22 weeks of pregnancy.~Doppler results will be classified according to pregnancy results and primary results will be doppler findings."
89132274|NCT00844129||Neurofibromatosis Type 1|Children with Neurofibromatosis Type 1
89132275|NCT02690870|Experimental|tamoxifen|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from D3 for 5 days.All patients will check serum E2 and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle. The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG administration. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
89132276|NCT02690870|Active Comparator|clomiphene|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in clomiphene group will take 100 mg of CC oral tablets daily from D3 for 5 days.All patients will have sexual hormone determination and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle.The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG injection. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
89132277|NCT02835378||Bilateral upper limb amputation|Bilateral upper limb amputees, with amputation from the short transverse hand (hand completely non-functional) to complete arm, whatever their age
89132278|NCT00844207|Experimental|Treatment A|Two of the fixed combination tablets each containing 250 mg of azithromycin and 155 mg of chloroquine base.
89132279|NCT00844207|Active Comparator|Treatment B|A single tablet containing 500 mg of azithromycin and a single tablet containing 300 mg of chloroquine base.
89290216|NCT03131596|Experimental|IUB dilatation therapy|The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
88802594|NCT02973490|Experimental|Transanal Tube Drainage|patients with transanal tube drainage after ESD
89132280|NCT02835300|Experimental|CampAir Intervention|Adolescents assigned to receive ASMA 2.0 will receive all seven modules over the two month trial, completing one module per week. Adolescents will be assigned one module per week, but will have free access to all completed modules for the duration of the two-month trial. Each module is expected to take between 30-40 minutes to complete, although adolescents will be able to engage with the software for as long as desired.
89132281|NCT02835300|Active Comparator|Information and Referral Control|Adolescents assigned to the information-and-referral control condition will be provided access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will receive access to CampAir.
89132282|NCT02841722|Other|Biological samples|Only one arm in this pilot study. All patient will have a follow up and treatment as per standard care for this pathology. Specifically for the study all patients will have 8 additional blood samples to be drawn during the first 2 cycles of treatment (1 cycles is 21 days).
89132283|NCT02548117|Active Comparator|Finasteride|ARM 1 subjects will receive finasteride 5 mg orally daily.
89132284|NCT02548117|No Intervention|No Treatment|The ARM 2 (control group) will not receive any study treatment.
89132285|NCT05263518|Experimental|AcrySof IQ toric IOL|patients who had cataract surgery with AcrySof IQ toric IOL implantation. The patients diagnosed age related cataract The patients' ages are over 50.
89132286|NCT05263518|Experimental|TECNIS toric IOL|patients who had cataract surgery with TECNIS toric IOL implantation. The patients are diagnosed age related cataract. The patients' ages are over 50.
89132287|NCT02841566||Problem glambers|The group of problem gamblers will consist of patients already included in the cohort EVALADD [favorable opinion of GNEDS 06/09/2012; CNIL authorization No. 912631 of 10.09.2013], and the data will be extracted directly from the database EVALADD
89132288|NCT02841566||Non-problem gamblers|The subjects of this group will be matched on sex, age and education level with the group problem gamblers. They will be recruited over the Internet and using the volunteer base [normal declaration with the CNIL: No. 1761543 of 21/05/2014].
89132289|NCT02546947|No Intervention|Appropriate clinical group|group of patients with clinical dose adjustment
89132290|NCT02546947|Active Comparator|TOF adapted group|group with an objective of less than 2 responses to TOF stimulation monitored
89132291|NCT02841878|Other|analysis on colorectal biopsy|"Proteases activity (cystein and serin proteases)~Proteases inhibitors genes expression (Serpins A1 / E1)~Colonic biopsies permeabilityTight junctions genes expression~Cytokines genes expression (TNFalpha, interleukines)~Cellularity on histologic sections"
89132292|NCT02834988||SLND Patients|Patients scheduled to have their sentinel lymph nodes removed, as part of standard of care.
89132293|NCT02841800|Experimental|Intra-luminal radiofrequency ablation|Intra-luminal radiofrequency ablation Admission for endoscopic retrograde cholangiopancreatography (ERCP) and stent placement after radiofrequency ablation. ERCP should be performed for 2 times with an interval of two months.
89132294|NCT02832336|Experimental|Caffeine|"Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.~Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants."
89132295|NCT02832336|Placebo Comparator|Fiber|Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)
89132296|NCT03369236|Active Comparator|Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period)|"Danicopan was administered at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then dosage was to be increased to 200 mg TID for the remainder of the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID."
88802595|NCT02973490|No Intervention|Without Transanal Tube Drainage|patients without transanal tube drainage after ESD
89132297|NCT03369236|Placebo Comparator|Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period)|"Placebo was administered TID during the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID."
88802596|NCT01893164|Experimental|moderate cubital tunnel syndrome|Sensory,Intermittent paresthesias; vibratory perception normal or decreasedMotor,Measurable weakness in pinch or grip strengthTests,Elbow flexion test or Tinel's sign is positive; finger crossing may be abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
88806130|NCT00248612|Active Comparator|Venlafaxine & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
89132298|NCT02841410|Other|Healthy Volunteer|
89132299|NCT00621751|Experimental|Carbamazepine|Carbamazepine 800 mg daily
89132300|NCT00621751|Placebo Comparator|Placebo|Placebo
89132301|NCT02690792|Placebo Comparator|NAFLD/NASH - Placebo|"In NAFLD/NASH Group: Identically appearing Placebo capsules given as double-blinded, randomized intervention as a comparator to Vitamin E intervention.~Dosage: Placebo capsules. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
89132302|NCT02690792|Active Comparator|NAFLD/NASH - Vitamin E|"In NAFLD/NASH Group: Vitamin E capsules given as double-blinded, randomized intervention as a comparator to Placebo capsules intervention.~Dosage: Vitamin E 200 IU/capsule. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
89132303|NCT05335304|Active Comparator|intervention group 1|Kinesio taping and standard treatment program
89132304|NCT05335304|Active Comparator|intervention group 2|Rigid taping and standard treatment program
89132305|NCT05335304|Active Comparator|intervention group 3|Thoracic Mobilization and standard treatment program
89132306|NCT05335304|Active Comparator|intervention group 4|Core Stabilization and standard treatment program
89132307|NCT05335304|Other|Control group|No intervention, only standard treatment program
89132308|NCT00831649|Experimental|natalizumab|
89132309|NCT02841332|Experimental|Patients with glioblastoma|"Patient with histologically proved glioblastoma diagnostic will receive the following interventions :~Cerebral magnetic resonance imagery~Tomography emission positron with F-MISO~Bevacizumab administration~Clinical examination"
89132310|NCT00838357|Experimental|Plerixafor|Plerixafor added to a G-CSF Mobilisation regimen
89132311|NCT00156104|Experimental|1|Asenapine 5 mg BID
89132312|NCT00156104|Experimental|2|Asenapine 10 mg BID
89132313|NCT00156104|Active Comparator|3|Haloperidol 4m mg BID
89132314|NCT00156104|Placebo Comparator|4|placebo
89132315|NCT02841020|No Intervention|Control SOC|Standard of care is followed
89132316|NCT02841020|Experimental|Experimental additional biopsy|Additional biopsy
89132317|NCT05334602|Experimental|study group|Dermal fat graft is added over the grafted bone in the alveolar cleft to protect the bone from resorption
89132318|NCT05334602|No Intervention|control group|Conventional procedure of alveolar cleft grafting
89132319|NCT00844363|Other|NB-UVB|Regular, monitored NB-UVB treatment. Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
89132320|NCT00254462|Experimental|atomoxetine and parent training|atomoxetine capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
89132321|NCT00254462|Placebo Comparator|placebo and parent training|matching placebo capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
89132322|NCT00831727|Experimental|Expressive Writing|
89132323|NCT00831727|Placebo Comparator|Control|
89132324|NCT00891930|Experimental|Panitumumab|Participants received panitumumab (6 mg/kg starting dose) with irinotecan (starting dose of 180 mg/m²) every 2 weeks (Q2W) during Part 1. Upon radiographically confirmed disease progression, participants proceeded to Part 2 of the study and received treatment with panitumumab (6 mg/kg starting dose) and ganitumab (12 mg/kg starting dose) Q2W.
89132325|NCT04248426|Experimental|ATI-2173|
89132326|NCT04248426|Placebo Comparator|ATI-2173 Placebo|
89132327|NCT02835066||Ancillary-Correlative (HRQOL, fitness and psychosocial health)|Patients scheduled for surgery, radiation therapy, or chemotherapy complete the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-core 30 (C30) and QLQ-Lung Cancer 13 (LC13) in addition to psychosocial health and smoking status questions from baseline up to 2 weeks prior to the start of treatment, 5-6 weeks after treatment begins, and 5-6 months from the start of treatment. During the same time points, patients also undergo function/fitness assessments including standard health measurements, short physical performance battery (SPPB), 6 minute walk test (6MWT), and a grip strength test.
89132328|NCT02831166|Active Comparator|Transradial approach|Transradial approach primary percutaneous coronary intervention using the TR Band device to obtain hemostasis (n=125).
89132329|NCT02831166|Active Comparator|Transfemoral approach|Transfemoral approach primary percutaneous coronary intervention using a vascular closure device to obtain hemostasis (n=125).
89132330|NCT04392726||patients with suspected DPLD|
89132331|NCT04392726||patients with known DPLD|
89132332|NCT04392024|Other|Triumf|Subjects who have cataract surgery with Triumf IOL
89132333|NCT04247568|Experimental|Hypnosis|
89132334|NCT04247568|Placebo Comparator|Control|
89132335|NCT02832414|No Intervention|Regular program|
89132336|NCT02832414|Active Comparator|Intensive weight loss program|
89132337|NCT02842112||CD34+ CD38-|A first cell population, which expressed the CD34 antigen and lacked CD38 (CD34+ CD38-), and often contained very few events requiring to be tightly clustered in a forward light scatter /side light scatter (FSC/ SSC) and CD45/SSC plot;
89132338|NCT02842112||CD34+ CD38low|A second population characterized by expression of the CD34 antigen and by a low density of CD38 antigen (CD34+ CD38low)
89132339|NCT02842112||CD34+ CD38+|A third population characterized by a large density of CD38 and CD34 antigens (CD34+ CD38+). Antigens were expressed as percent positively stained cells as well as intensity of the fluorescence signal quantified as mean fluorescence intensity (MFI) from CD34+ gated cells and from CD45low/SSC total immature cells
89132340|NCT02832258||Children with urinary tract infection due to E-ESBL|In this prospective observational study between March 2013 and March 2017, children (0 to 18 years) with E-ESBL UTI (febrile UTI or cystitis) were enrolled in 24 pediatric departments in France. Clinical and biological characteristics, risk factors of infection of E-ESBL, first and second lines of antibiotic therapies were analyzed. We used the Kaplan-Meier method to estimate the time to apyrexia and length of hospital stay, and Log-rank test to assess equality of survivor functions. We also analyzed the resistance patterns and molecular characterization of ESBL types in the isolates.
89132341|NCT02831088|Experimental|Neu2000KWL High-dose group|
89132342|NCT02831088|Experimental|Neu2000KWL Low-dose group|
89132343|NCT02831088|Placebo Comparator|Placebo|
89132344|NCT02835144|Experimental|TIQAAM_therapy|Individuals in this group will receive units from the TIQAAM treatment program
89132345|NCT02835144|Active Comparator|active_control|Individuals in this group will receive units of psychoeducation
89132346|NCT02841098|Experimental|Carotid endarterectomy combined with optimal medical therapy|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
89132347|NCT02841098|Active Comparator|Optimal medical therapy (OMT)|Optimal medical therapy (OMT)
89132348|NCT05334446|Experimental|The Effect ''of Follow-up with the Mobile Application'' in Patients with Hypertension|Intervention Group:mobile application for 4 weeks; This is the training group in which individual motivational messages will be sent to the mobile phones every week for compliance with the diet, exercise and drug therapy of the patients, and the weekly average of blood pressure follow-ups is monitored over the system.
89132349|NCT05334446|No Intervention|The Effect ''of Follow-up with the Mobile Application'' in Hypertension control group|It is the control group whose routine outpatient follow-up will continue and no training is given
89132350|NCT02841176|Experimental|Experimental|Thermography and Golimumab (solution for subcutaneous injection, 50 or 100 mg, monthly)
89132351|NCT01615874|Experimental|MF/F MDI 50/10 mcg BID|
89132352|NCT01615874|Experimental|MF/F MDI 100/10 mcg BID|
89132353|NCT01615874|Experimental|MF/F MDI 200/10 mcg BID|
89132354|NCT01615874|Active Comparator|BDP HFA 160 mcg BID|
88802597|NCT01893164|Experimental|severe cubital tunnel syndrome|Sensory,Persistent paresthesias; vibratory perception decreased; abnormal two-point discrimination(static >6 mm, moving >4 mm)Motor,Measurable weakness in pinch and grip plus muscle atrophyTests,Positive elbow flexion test or positive Tinel's sign may be present; finger crossing usually abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
88802598|NCT00000874||1|Participants who are failing a regimen of ZDV, 3TC, and IDV
88802599|NCT00000874||2|Participants who are failing a regimen of ZDV, 3TC, and SRQ
88802600|NCT00000874||3|Participants who are failing a regimen of ZDV, 3TC, and RTV
89132355|NCT01615874|Active Comparator|Montelukast 5 mg QD (4 mg QD for 5-year-olds)|
89132356|NCT00891462|Experimental|1|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
89132357|NCT00891462|Experimental|2|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
89132358|NCT00891462|Placebo Comparator|3|Inhaled placebo for 12 weeks
89132359|NCT02834910||Case group|patients with Extended-Spectrum Beta-lactamase producing Enterobacteriaceae carrying a qnr gene isolate
89132360|NCT02834910||control-group|patients with Enterobacteriaceae isolate without qnr gene
89132361|NCT02830854|Experimental|Molecular Hydrogen|Molecular hydrogen: 20 min per day of 3% H2 during 4 weeks
89132362|NCT02832024|Active Comparator|Intervention: Stents|Stents group
89132363|NCT02832024|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
89132364|NCT02832024|Active Comparator|Intervention: Balloon|Balloon group
89132365|NCT04247022|Experimental|female subjects, 18-59 y, healthy|74 female subjects, 18 to 59 years of age, healthy with complaints of vaginal dryness that will receive the heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days.
89132366|NCT02831010||encephalopathy of prematurity|infants with encephalopathy of prematurity showed on MRI at term-equivalent age
89132367|NCT02831010||no encephalopathy of prematurity|infants with no encephalopathy of prematurity showed on MRI at term-equivalent age
89132368|NCT04245774|Experimental|Group L (Hyperbaric Levobupivacaine)|"7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.~In order to obtain hyperbaric levobupivacaine, 1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) was added to 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water."
89132369|NCT04245774|Active Comparator|Group B (Hyperbaric Bupivacaine)|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (Marcaine® Spinal Heavy, 0.5%, 4 mL ampoule, AstraZeneca/England, Eczacıbaşı/Turkey, dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.
89132370|NCT04245696|Experimental|Single Group|Single Arm: All subjects will undergo treatment for skin laxity in the submentum with a Dermal and SubQ handpiece
89132371|NCT02832102||Retrospective cohort|"A total of 1000 SCCHN patients will be enrolled in a retrospective observational study treated in the period 2008-2014.~Standard treatment of SCCHN patients The patients will be managed as foreseen by best clinical practice and international guidelines for SCCHN."
89132372|NCT02832102||Prospective cohort|"A total of 450 SCCHN patients will be enrolled in a study. Each participating Center will select consecutive patients according to the selection criteria (inclusion/exclusion criteria) for one year and will be followed up for two years or more.~Standard treatment of SCCHN patients: patients will be administered current best clinical practice treatments."
88802601|NCT00000874||4|Participants who are failing a regimen of d4T, 3TC, and IDV
89132373|NCT02832180|Experimental|Daily single dose of OC containing EE and NET|Daily single dose of OC Containing EE and NET alone.
89132374|NCT02832180|Experimental|Daily single dose of OC in combination with BMS-986142|Daily single dose of OC containing EE and NET in combination with BMS-986142.
89132375|NCT02831868|Experimental|EXP|Implantation of a HAVAI device to correct HVA without osteotomy
89132376|NCT02831946|Experimental|MODIFIED VICRYL PLUS|The intra-cuticular layer will closed with with VICRYL PLUS suture
89132377|NCT02831946|Experimental|DERMABOND GLUE|The intra-cuticular layer will closed with with DERMABOND GLUE
89132378|NCT00900146|Experimental|Canakinumab 5 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 5 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
89132379|NCT00900146|Experimental|Canakinumab 15 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 15 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
89132380|NCT00900146|Experimental|Canakinumab 50 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 50 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
89132381|NCT00900146|Experimental|Canakinumab 150 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 150 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
89132382|NCT00900146|Placebo Comparator|Placebo + Metformin|In 4 month dose finding period as well as during intermediate period, patients received one injection of canakinumab matching placebo monthly and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations).
89132383|NCT04247724|Experimental|Active group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~*1 group of men playing recreational handball"
89132384|NCT04247724|Experimental|Active group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~*1 group of women playing recreational handball"
89132385|NCT04247724|Experimental|Inactive group of men|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~*1 group of men continuing their normal lifestyle patterns"
89132386|NCT04247724|Experimental|Inactive group of women|"4 groups are randomized for 12 weeks of intervention; 2 groups are active, 2 groups are inactive:~*1 group of women continuing their normal lifestyle patterns"
89132387|NCT02828748|Experimental|active UC|patients with clinically active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
89132388|NCT02828748|Experimental|remission UC|patients with clinically non active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
89132389|NCT02828748|Experimental|active CD|patients with clinically active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
89132390|NCT02828748|Experimental|remission CD|patients with clinically non active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
89132391|NCT02831790|Experimental|Educational Intervention|Participants in the intervention group will have access to the 3 teaching videos, ~3:30-5:00 minutes in duration each, beginning several weeks prior to the preadmission clinic (as soon as written consent is obtained).
89132392|NCT02831790|No Intervention|Usual Care|Participants in the usual care will not be offered an intervention and will not be made aware of the existence of the teaching videos.
89132393|NCT02828670||patient|
89132394|NCT02828670||control|
89132395|NCT03621644|Experimental|Ablative MRIdian SMART|Radiation: Stereotactic MRI-guided On-table Adaptive Radiation Therapy 50 Gy in 5 fractions
89132396|NCT04245462||Participants|Older aged (>60 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco, Mexico).
89132397|NCT02828826|Experimental|telephone coaching|"Patients randomized to the experimental group will benefit from the telephone coaching , with 5 phone calls programmed by the physiotherapist according to the most convenient times for the patient, due to appointments per month.~The telephone coaching conducted by the physiotherapist with patients is to assess the number of exercises performed, the number of falls may have occurred, assess the fear of falling and overall assessment of the patient's general condition and a self-assessment of their physical ability (one leg balance, fear of falling, FTSST). With this information, the therapist may encourage patients to practice more diligently exercises can even strengthen the practice of some based on its evaluation.~Data from the telephone coaching will be recorded in the eCRF."
89132398|NCT02828826|No Intervention|Without telephone coaching|
89132399|NCT02830932|Experimental|VXA-RSV-f Tablets (high dose)|Singe dose of orally administered VXA-RSV-f Tablets (high dose). VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
89132400|NCT02830932|Experimental|VXA-RSV-f Tablets (low dose)|Singe dose of VXA-RSV-f Tablets (low dose).VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
89132401|NCT02830932|Placebo Comparator|VXA Placebo Tablets|Singe dose of matching placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
89132402|NCT00895310|Experimental|Ketoconazole and Hydrocortisone|Ketoconazole 200mg PO TID + Hydrocortisone 20mg PO Qam, 10mg PO Qpm
89132403|NCT02830386||LVIS stents group|The patients with ruptured intracranial saccular aneurysm wil be treated with a LVIS stent without coils.
89132404|NCT02840864|Experimental|Arm 1|Sonographically assisted breast surgery
89132405|NCT02840864|Active Comparator|Arm 2|Conventional breast surgery
89132406|NCT02831712|Other|Iron supplement|Ferrous Fumarate tablet 200 mg
89132407|NCT00895154|Active Comparator|General Tutoring Group|Participants will receive general tutoring in the subject of his/her choice.
89132408|NCT00895154|Experimental|Tutoring + Memory Training Group|Participants will receive tutoring and memory training.
89132409|NCT01769924||Live kidney donors|Nephrectomy
89132410|NCT01769924||Healthy controls|Who also meet criteria to donate a kidney
89132411|NCT02843984|No Intervention|A - untreated|The patients will be not treated with vaginal lactoferrin
89132412|NCT02843984|Active Comparator|B - 4 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
89132413|NCT02843984|Active Comparator|C - 12 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 12 hours prior to mid-trimester genetic amniocentesis.
89132414|NCT02840552|Experimental|FCH-PET/CT|18F-Fluoromethylcholine (18F-FCH) PET/CT
89132415|NCT02828280||NuMask|Pt's randomized to Numask first will be ventilated for 10 breaths with the NuMask device first, followed by 10 breaths with the traditional face mask
89132416|NCT02828280||Traditional mask|patients randomized to traditional mask first will receive 10 breaths by traditional mask, followed by 10 breaths with NuMask
89132417|NCT02840708|Active Comparator|125mcg|SK-1401 125mcg single inhalation
89132418|NCT02840708|Active Comparator|250mcg|SK-1401 250mcg single inhalation
89132419|NCT02840708|Active Comparator|500mcg|SK-1401 500mcg single inhalation
89132420|NCT02840786|Active Comparator|Intervention: Stents|Stents group
89132421|NCT02840786|Active Comparator|Intervention: Atherectomy|directional atherectomy group
89132422|NCT04245072|Active Comparator|Ranibizumab|Arm 1
89132423|NCT04245072|Active Comparator|Aflibercept|Arm 2
89132424|NCT01030484||NAFLD|adult patients with non-alcoholic fatty liver disease (NAFLD).
89132425|NCT00817076|Experimental|1|
89132426|NCT02844062|Experimental|anti-EGFRvIII CAR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti-EGFRvIII CAR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg
89132427|NCT02828046|Placebo Comparator|Placebo|Placebo
89132428|NCT02828046|Experimental|M281|M281
89132429|NCT02830230|Experimental|Intervention group/Case|"women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.~women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.A cervico-vaginal swab shall be taken for Lab diagnosis of RTIs along with HPVDNA test on day 1.Women shall be treated with Tab Azithromycin 1gm and Tab Cefixime 400mg stat along with barrier contraception advised.The women will be followed up after 7-14 days .A repeat cervicovaginal swab and HPVDNA shall be repeated."
89132430|NCT02830230|No Intervention|Control group|Women without signs and symptoms of cervicitis or cervico-vaginitis.No intervention will be done in this group
89132431|NCT02840396|Experimental|rTMS|
89132432|NCT02840396|Sham Comparator|Sham rTMS|
89132433|NCT00888654|Experimental|B-Dim, Radical Prosatectomy|"B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)~Radical Prostatectomy"
89132434|NCT03238430|Experimental|Ropivacaine infiltration|Continuous infiltration of local anesthetics + PCA morphine.
89132435|NCT03238430|Experimental|intrathecal morphine|Rachianalgesia + PCA morphine
89132436|NCT03238430|Active Comparator|morphine PCA|PCA morphine alone
89132437|NCT04246866|Experimental|Dose 1|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the lowest dose of GEM103
89132438|NCT04246866|Experimental|Dose 2|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the medium dose of GEM103
89132439|NCT04246866|Experimental|Dose 3|A single dose of GEM103 will be administered via intravitreal injection. This arm will be a higher dose of GEM103
89132440|NCT04246866|Experimental|Dose 4|A single dose of GEM103 will be administered via intravitreal injection. This arm will be the highest (extension) dose of GEM103
89132441|NCT02843906|Active Comparator|BD/CD +|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
89132442|NCT02843906|Active Comparator|BD/CD -|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
89132443|NCT02843906|Active Comparator|a-MCI|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
89132444|NCT02829840|Experimental|Cohort #1|"Cohort #1: Participants with no previous leukemia therapy (including no previous FLT3 inhibitor therapy) for either: a) front-line treatment of elderly (age 65 and greater) FLT3-mutated AML patients, or b) patients unable or unwilling to receive standard intensive therapy.~Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
89132445|NCT02829840|Experimental|Cohort #2|"Cohort #2: Participants with relapsed/refractory FLT3-mutated AML that have not received prior FLT3 inhibitor therapy.~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
89132446|NCT02829840|Experimental|Cohort #3|"Cohort #3: Participants with relapsed/refractory FLT3-mutated AML, that have received previous FLT3 inhibitor therapy (including, but not limited to, quizartinib, crenolanib, sorafenib, other FLT3 inhibitors).~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant will continue on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
89290217|NCT03131596|No Intervention|control group|Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
89290218|NCT01218360||Participants|All participants enrolled
89290219|NCT03816202||Sundt Carotid Shunt|Subject has undergone a endarterectomy procedure with the use of the Sundt Carotid Shunt.
88806131|NCT00248612|Placebo Comparator|Placebo & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
89132447|NCT02844296|Experimental|exercise group|"A free handgrip (strength 15 kg) will be given to the subject and some short-bout exercise will be introduced to the subjects for reliving the cravings for smoking through a short video. After the video, the counselor will install a smartphone application which is about exercise in the subject's mobile phone to set up exercise reminder schedule for 4 weeks. 20-30 reminders on exercise and quitting tips via the App for 4 weeks. Subjects will be requested o record a daily diary on smoking.~A leaflet with exercise instruction and motivation messages based on the Health Action Process Approach (HAPA) will be given to the participant. 2-month, 6 -month and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
89132448|NCT02844296|Experimental|diet group|"Subjects will view a short video on healthy diet only. After the video, the counselor will also install another smartphone application which is about healthy diet in the subject's mobile phone to set up healthy die reminder schedule for 4 weeks.~A leaflet on healthy diet will be given to the subjects, and 20-30 reminders on healthy diet and quitting tips via the App for 4 weeks.2-,6- and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
89132449|NCT00633516||Medical tool|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
89132450|NCT04246632|Experimental|Open label|Single arm study, all subjects receive device
89132451|NCT02827890|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Januvia Tab. 100mg)*1T/day for 5 days, QD, PO.~Period 2: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.~Each treatment period was separated by a washout period of at least 10 dyas."
89132452|NCT02827890|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.~Period 2: Treatment A(Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO.~Each treatment period was separated by a washout period of at least 10 dyas."
89132453|NCT04250792|Experimental|single arm|Low dose naltrexone was prescribed to the patients affected with psoriasis.
89132454|NCT04244994|Other|Intervention and Control|Self-taken penile meatal swabs versus first-catch urine for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
89132455|NCT02840318|Experimental|Compassion Intervention|Coordinated by the ICL who co-ordinates key activities at each site to address the two core components of the Intervention. Component 1 activities include: (a) person-centred assessment of residents, focussing on their physical, psychological, emotional and social needs, (b) meetings of the core care team (General practitioner, care home nurse and/or manager and ICL) and (c) meetings of the wider multidisciplinary care teams (including care home staff, ICL, and external healthcare professionals such as geriatrician, palliative care, mental health etc). Activities to facilitate component 2 include: (d) staff training sessions, education and support for staff and family carers. Training sessions are run by the ICL and logistics of training is planned at core meetings.
89132456|NCT02827968|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1, 2.5, 5 and 10 mg/kg weekly.
89132457|NCT02840162|Active Comparator|Celecoxib|Treated patients will receive 4 weeks of celecoxib at 400 mg twice daily by mouth
89132458|NCT02840162|Placebo Comparator|Placebo|Control patients will receive a suitable placebo for 4 weeks, twice daily by mouth
89132459|NCT02827812|Experimental|Participants Telemedicine Care (PTE)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).~B. Physical Intervention at home for 60 minutes 3 days/week for three months~C. Home-Based telemedicine program:"
89132460|NCT02827812|Active Comparator|Participants Usual Care (PUC)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).~B. Physical Intervention at home for 60 minutes 3 days/week for three months"
89132461|NCT04244526||Group1|Group 1:pregnant women with cystitis
89132462|NCT04244526||Group2|Group 2: pregnant women with Pyelonephritis
89132463|NCT04244526||Group3|Group 3: pregnant women with asymptomatic bacteriuria
89132464|NCT02827656|Experimental|Decapeptyl support|S.C single luteal Decapeptyl 0.1 mg on days 3, 6,9 post ovulation triggering
89132465|NCT02827656|Active Comparator|hCG luteal support|S.C single luteal S.C recombinant hCG 50 micrograms on days 3 ovulation triggering
89132466|NCT02829450||PD|"Patients with CHF and chronic renal disease which started the treatment with peritoneal ultrafiltration.~The patients will be follow up every 3 months for assesment of symptoms, QOL questionary, routine blood and urine tests and also for assesment of residual renal function and peritoneal membrane function: monitoring of clinical symptoms of fluid overload, hospital admissions, UF rate, peritoneal membrane damage parameters (cell-free DNA in peritoneal effluent, peritoneal equilibration test) and residual renal function markers (eGFR creatinine or cystatin C based , KT/V, urinary markers) at the start of the treatment, each 3 months during the treatment and at each change of prescription. Complications of all kinds will be recorded."
89132467|NCT02829450||Control|Patients with CHF and chronic renal disease which preferred to continue their regular treatment or choose other then peritoneal ultrafiltration type of renal replacement therapy (data from medical records): clinical symptoms of fluid overload, hospital admissions, urine volume,residual renal function markers (eGFR creatinine)
89132468|NCT02826954||COPD patients|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
88806132|NCT03774992|Experimental|Orthokeratology|Subjects randomized to OKL in the CONTROL-study
89132469|NCT02826954||Healthy subjects|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
89132470|NCT02829762|Experimental|Interventional arm PS-DR|The interventional arm (PS-DR) will include the implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance (in connection with a call center 24h/24).
89132471|NCT02829762|No Intervention|Reference Arm|In the reference arm, patients will have a conventional oncological care, social support measures will be left to the discretion of the clinician and the paramedical team.
89132472|NCT04246398|Experimental|Fecal microbiota transplant (FMT)|"10 capsules per dose for 6 consecutive weeks, twice a week, for a total of 120 capsules.~Each inoculum will be prepared from the feces of 1 donor and a dose of 10 capsules contains sieved, concentrated material derived from a mean of 10 grams of fecal matter. Donors are healthy, nonpregnant adults aged 18 to 50 years, taking no medications, and with a normal body mass index (18.5-25 [calculated as weight in kilograms divided by height in meters squared])."
89132473|NCT04246398|Placebo Comparator|placebo|Placebo capsules will consist of a combination of saline/glycerol (same vehicle as FMT capsules). The inner capsules is dark (green colored), so the general appearance of the capsules is the same to the people who do not prepare them.
89132474|NCT02827578|Experimental|Tamsulosin + Solifenacin|Tamsulosin and Solifenacin
89132475|NCT02827578|Active Comparator|Tamsulosin + Solifenacin Placebo|Tamsulosin and Solifenacin placebo
89132476|NCT04323930|Experimental|eyeWatch|
89132477|NCT04323930|Experimental|Trabeculectomy|
89132478|NCT04244838|Experimental|MP-TKA group|20 patients candidates for cemented TKA with MP design for tri-compartment gonarthrosis will be recruited on indications of the surgeon and according to normal clinical practice at the Orthopedic and Traumatological Clinic 2nd of the Rizzoli Orthopedic Institute.
89132479|NCT02827734||interstitial lung disease|patients with known or suspected ILD such as idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, sarcoidosis, granulomatosis with polyangiitis
89132480|NCT02827734||pulmonary healthy controls|patients without known or suspected pulmonary disease
89132481|NCT02827110|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope
89132482|NCT02827110|Experimental|fiberoptic bronchoscope with pentax-AWS|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope with pentax-AWS
89132483|NCT02829372|Experimental|GBR 1302|Dose escalation
89132484|NCT00899678|Active Comparator|Maintenance High-Dose|Maintenance High-Dose group: 400 mg Certolizumab Pegol for subjects ≥ 40 kg or 200 mg Certolizumab Pegol for subjects 20 to < 40 kg
89132485|NCT00899678|Active Comparator|Maintenance Low-Dose|Maintenance Low-Dose group: 200 mg Certolizumab Pegol for subjects ≥ 40 kg or 100 mg Certolizumab Pegol for subjects 20 to < 40 kg
89132486|NCT00887484|Experimental|Clindoxyl Gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
89132487|NCT00887484|Active Comparator|Epiduo gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
89132488|NCT00794378|Experimental|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
89132489|NCT00789152|Experimental|desloratadine followed by levocetirizine|Subjects in this arm received desloratadine 5 mg daily for 8 days, followed by 10 day washout period, then followed by levocetirizine 5 mg daily for 8 days
89132490|NCT00789152|Experimental|levocetirizine followed by desloratadine|Subjects in this arm received levocetirizine 5 mg daily for 8 days, followed by 10 day washout period, then followed by desloratadine 5 mg daily for 8 days
89132491|NCT00886938|Experimental|rTMS to DLPF, pilot study|rTMS to the dorsolateral prefrontal cortex for patients with tinnitus
89132492|NCT00783458|Active Comparator|Nasonex Followed by Flonase|
89132493|NCT00783458|Active Comparator|Flonase Followed by Nasonex|
89132494|NCT02690636|Active Comparator|Conventional|The patients will receive adjuvant radiotherapy conventionally fractionated 5000 cgy fractionated by 200cgy daily fractions, five fractions per week over 5 weeks with an additional 200cgy daily for five days as boost for patients with breast conservative surgery.
89132495|NCT02690636|Experimental|Hypofractionated|The patients will receive adjuvant radiotherapy hypofractionated 266cgy daily fractions, five fractions per week for total 16 fractions and an additional five daily fractions will be added as boost for patients with breast conservative surgery.
89132496|NCT00620659|Experimental|1|Arm 1: Treatment period 1: MK0249; Treatment period 2: Placebo; Treatment period 3: modafinil
89132497|NCT00620659|Experimental|2|Arm 2: Treatment period 1: Placebo; Treatment period 2: modafinil; Treatment period 3: MK0249
89132498|NCT00620659|Experimental|3|Arm 3: Treatment period 1: modafinil; Treatment period 2: MK0249; Treatment period 3: Placebo
89132499|NCT00620659|Experimental|4|Arm 4: Treatment period 1: MK0249; Treatment period 2: modafinil; Treatment period 3: Placebo
89132500|NCT00620659|Experimental|5|Arm 5: Treatment period 1: Placebo; Treatment period 2: MK0249; Treatment period 3: modafinil
89132501|NCT00620659|Experimental|6|Arm 6: Treatment period 1: modafinil; Treatment period 2: Placebo; Treatment period 3: MK0249
89132502|NCT05188638|Experimental|Single dose of up to 5 mL nebulised SIS @ 25 ppm/placebo|
89132503|NCT05188638|Experimental|Single dose of up to 5 mL nebulised SIS @ 50 ppm/placebo|
89132504|NCT05188638|Experimental|Single dose of up to 5 mL nebulised SIS @ 100 ppm/placebo|
89132505|NCT05188638|Experimental|OD dosing of up to 5 mL nebulised SIS @ x ppm/placebo for 5 days|The dose to be administered in the multiple dose groups will depend on the results obtained in the single dose groups and will be decided by the SMC. The dose tested in the first multiple dose group will be the second highest well-tolerated single dose or lower.
89132506|NCT05188638|Experimental|OD dosing of up to 5 mL nebulised SIS @ y ppm/placebo for 5 days|
89132507|NCT05188638|Experimental|BID dosing of up to 5 mL nebulised SIS @ y ppm/placebo, for 4 days + morning dose on Day 5|
89132508|NCT05188638|Experimental|QID dosing of up to 5 mL nebulised SIS @ y ppm/placebo for 4 days + morning dose on Day 5|
89132509|NCT00632996|Experimental|1|
89132510|NCT04245930|Active Comparator|Bovine Pericardial Patch|Immediate implant breast reconstruction using bovine pericardial patch. n=88
89132511|NCT04245930|Experimental|TiLOOP® Bra Mesh|Immediate implant breast reconstruction using TiLOOP® Bra Mesh. n=88
89132512|NCT04245852|Experimental|Experimental group|Experimental group will receive standard physical therapy care in addition to being provided a strength education video.
89132513|NCT04245852|Active Comparator|Control Group|The control group will receive standard physical therapy care at the University of Illinois at Chicago Faculty Practice.
89132514|NCT02547415||patients with questionnaires and psychological testing|children and adolescents with chronic pain without proven medical cause, type painful somatic complaints
89132515|NCT05182398||Multiple sclerosis patient|First day, first evaluator will perform all tests, and second day, second evaluator will perform Modified Four Square Step Test.
89132516|NCT02843750|Experimental|Inspiratory Muscle Training-Rehabilitation|Patients will start the IMT-R, following their consent and within 2 weeks of their scheduled surgery: 10 sessions lasting about 90 minutes. Participants who completed their initial IMT greater than 2 weeks prior to surgery will have an additional visit prior to surgery. Participants will receive a Participant Manual demonstrating and explaining the rehabilitation process. Participants will also receive a log for recording their efforts and notes. A DVD of the rehabilitation is available to the participant. Participants will complete questionnaires at baseline and 3 months.
89132517|NCT02829060|Active Comparator|1a: Indwelling drains (48 hr)|"This group has indwelling urinary tubes/drains and a negative urine culture~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
89132518|NCT02829060|Active Comparator|1b: Indwelling drains (7d)|"This group has indwelling urinary tubes/drains and a negative urine culture~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
89132519|NCT02829060|Active Comparator|2a: +UCx with Oral Options (48hr)|"This group has a positive pre-operative urine culture with oral antibiotic options~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
89132520|NCT02829060|Active Comparator|2b: +UCx with Oral Options (7d)|"This group has a positive pre-operative urine culture with oral antibiotic options~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
89132521|NCT02829060|Active Comparator|3a: +UCx No Oral options (48hr)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities~48 hour course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)~Gentamicin (80 mg) preferred if sensitive~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
89132522|NCT02829060|Active Comparator|3b: +UCx No Oral options (7d)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities~7 day course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)~Gentamicin (80 mg) preferred if sensitive~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
89132523|NCT00783146|Experimental|1|desloratadine
89132524|NCT00783146|Active Comparator|2|fexofenadine
89132525|NCT00783146|Placebo Comparator|3|placebo
89132526|NCT00844675|Experimental|rabeprazole|rabeprazole
89132527|NCT00844675|Experimental|placebo|placebo
89132528|NCT02837900|Placebo Comparator|Previous LT TX knee and right placebo|Previous left treated knee will have placebo treatment in this protocol.
89132529|NCT02837900|Placebo Comparator|Previous RT TX knee and left placebo|Previous right treated knee will have placebo treatment in this protocol.
89132530|NCT02837900|Active Comparator|Both TX with Active|Both knees with receive Active
88806133|NCT03774992|Experimental|Cross over|Subjects randomized to SVS in the CONTROL-study
89132531|NCT02826096|Experimental|biofeedback group|biofeedback therapy
89132532|NCT02826096|No Intervention|medication group|only medication treament
89132533|NCT00831883|Experimental|Partner Specific IMB|partner-specific HIV risk reduction intervention
89132534|NCT00831883|Placebo Comparator|HLS|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
89132535|NCT02840006|Active Comparator|General anesthesia only|Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1
89132536|NCT02840006|Active Comparator|General anesthesia associated spinal anesthesia|spinal anesthesia using bupivacaine 0,5% hyperbaric 20 mg, morphine 200 mcg, set trendeleburg for 10 minutes, sensitive test in T1. Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1.
89132537|NCT02826252||Ventavis|The study will be conducted in patients who are enrolled in the German Ventavis patient support program Ventaplus.
89132538|NCT02547961|Experimental|HER2-CAR-T|In interventional studies, participants are assigned to accept HER-2-targeting CAR T Cells infusion so that researchers can evaluate the effects and safety of the CAR-T cell.
89132539|NCT02547961|No Intervention|No Intervention|
89132540|NCT02839928|Experimental|Treatment|The experimental arm consists of children given intranasal Ketamine 1 mg/kg, once
89132541|NCT00838747||Gynaecological Cancer|Gynaecological Cancer
89132542|NCT05018520|Experimental|4RCHOP+4R|Four Courses of R-CHOP Plus Four Courses of Rituximab
89132543|NCT05018520|Experimental|6RCHOP+2R|Six Courses of R-CHOP Plus Two Courses of Rituximab
89132544|NCT02840084|Experimental|Treatment Patients|In stage I, 10 women aged 22 years or older who have received silicone or saline breast implants for subglandular or submuscular breast augmentation, and who subsequently developed Baker Grade III capsular contracture, will be invited to participate. In Stage II, the study group will be expanded to include an additional 50 patients who have received saline or silicone gel implants, placed in either the subglandular or submuscular position, with Grade III capsular contracture of the breast. The intervention will be treatment with the Aspen(TM) Ultrasound System.
89132545|NCT00838825|No Intervention|traditional|The traditional arm is composed of primary care physicians who continue the health care delivery model existing for the 5 years prior to the study. The traditional includes the physician, a pool of resources including random assignment of diabetic educators and includes the entire panel of patients assigned to the PCP.
89132546|NCT00838825|Experimental|care management|The care management group is composed of primary care physicians who have been assigned a specific physician extender, the care manager, and an additional medical assistant and form a care manager team working together with registry support, team meetings and instruction in self-management and includes the entire panel of patients assigned to the PCP.
89132547|NCT04321746|Active Comparator|Ketamine|
89132548|NCT04321746|Placebo Comparator|Control|
89132549|NCT02994680|Experimental|Intervention arm|"Will receive:~Three-burner LPG stove (at enrollment)~Delivery of LPG tanks (beginning at enrollment for one year)~The study will be conducted over three years, with staggered enrollment over one year, one year of observations during the intervention period, and one year of follow-up observations after the intervention period for each participant.~Participants in the intervention arm will receive an LPG stove upon enrollment and the research team will deliver fuel twice monthly to their homes during the first year. Participants in the intervention arm will not receive fuel during the second year, but researchers will encourage these participants to continue using LPG fuel for cooking."
89132550|NCT02994680|Active Comparator|Control arm|"Will receive:~Three-burner LPG stove (one year after enrollment)~Vouchers for LPG tanks (one year after enrollment)~Participants in the control arm but will not receive an LPG stove or fuel during the first year. Instead, participants will receive an LPG stove at the end of the first year and vouchers to obtain free fuel at distribution centers during the course of the second year."
89132551|NCT04043767||Pediatric patients aged between 1-8 years|Pediatric patients aged between 1-8 years who scheduled for general anesthesia in elective surgery. Additional physical examinations which were including thyromental distances, hyomental distances and neck circumferences, was performed at one day prior surgery. Intubation was done by general anesthesiologist in order to grade the laryngoscopic view.
89132552|NCT04243824|Experimental|All participants|All enrolled study participants will receive Ga-68MAA and PET/MRI scan.
89132553|NCT02839694|Experimental|Dose escalation cohort|dose escalation cohort
89132554|NCT02839694|Experimental|Expansion cohort|expansion cohort at MTD
89132555|NCT02839694|Active Comparator|expansion cohort with celecoxib|expansion cohort at MTD with celecoxib
89132556|NCT00831961||1|Patients randomized to gatifloxacin (Zymar)
89132557|NCT00831961||2|Patients randomized to moxifloxacin (Vigamox)
89132558|NCT00831961||3|Patients randomized to ofloxacin (Ocuflox)
89132559|NCT00831961||4|Patients randomized to azithromycin (AzaSite)
89132560|NCT00894686|Experimental|All subjects|Assessment of seropersistence of TBE antibodies at yearly intervals from approximately 3 years (38 months) to 10 years (118 months) after the first booster vaccination (in Study 700401), as well as antibody response to a second booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL, depending on the subject´s age. Timing of the second booster vaccination will depend on the level of serum TBE antibodies detected at the defined assessment time points. Subjects who are not protected against TBE for an entire further season (NT titer <= 20 and/or ELISA value <=126 VIE U/mL) will be invited to receive the second booster vaccination at either the 40, 48, 60, 72, 84, 96, 108, or 120-month time point.
89132561|NCT04243434|Experimental|Cohort A|Marqibo formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1, and VSLI-RTU formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
89132562|NCT04243434|Experimental|Cohort B|VSLI-RTU formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1 and Marqibo formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.
89132563|NCT00832039|Active Comparator|SelPCT|Patient receives sodium-selenite; causal therapy is guided by a PCT based algorithm.
89132564|NCT00832039|Active Comparator|SelKon|Patient receives sodium-selenite; causal therapy is not guided by a PCT based algorithm.
89132565|NCT00832039|Placebo Comparator|PlacPCT|Patient receives placebo; causal therapy is guided by a PCT based algorithm.
89132566|NCT00832039|Placebo Comparator|PlacKon|Patient receives placebo; causal therapy is not guided by a PCT based algorithm.
89132567|NCT02826564|Experimental|Sequential|Stereotactic body radiotherapy prior to pembrolizumab treatment
89132568|NCT02826564|Experimental|Concurrent|Stereotactic body radiotherapy concurrent with pembrolizumab treatment
89132569|NCT05333588|Experimental|Tumor infiltrating lymphocyte|1x10^9-5x10^10 of autologous TILs will be adoptive transfer to patients.
89132570|NCT02826642|Experimental|Arm 1: Medically fit for induction|IDH305 + Standard of care for patients that are medically fit for induction.
89132571|NCT02826642|Experimental|Arm 2 Medically unfit for induction|IDH305 + Standard of care for patients that are medically unfit for induction.
89132572|NCT02546479||Patientis|patients diagnosed with scoliosis and other spinal deformities
89132573|NCT00832195|Experimental|1|Footwear with motion controlling elements built into construction in order to reduce pronation of the foot and ankle during running.
89132574|NCT00832195|Active Comparator|2|Footwear with standard neutral stabilization elements for the foot and ankle during running.
89132575|NCT00885846|Active Comparator|Qigong Therapy|
89132576|NCT00885846|Active Comparator|PRT|
89132577|NCT00885846|No Intervention|Control|
89132578|NCT02843828|Experimental|Samsung Hip Assist v1|gait rehabilitation with Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
89132579|NCT02843828|Active Comparator|Conventional gait training|gait rehabilitation without Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
89132580|NCT00839059|Experimental|Lenalidomide|
89132581|NCT02839538|Active Comparator|local Infiltration|"Induction of General Anesthesia with Propofol(2mg/Kg) and Atracurium(0,5mg/Kg) . Pulmonary ventilation with laryngeal mask and Propofol infusion ( 100mcg/Kg/min.) After , Infiltration of 0.75% ropivacaine (10 ml) each side block injection of local anesthetic at perianal.~If necessary, fentanyl endovenous injection (50 mcg)."
89132582|NCT02839538|Other|Subarachnoidal block|"Sedation with midazolam 2 mg. After , Spinal block with 10 mg of hyperbaric 0.5% bupivacaine. Injection of anesthetic at subarachnoidal space with Quincke needle 27G.~If pain, local infiltration with lidocaine 1% (5 ml) in wound."
89132583|NCT02826018|Active Comparator|ALN-HBV|
89132584|NCT02826018|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
89132585|NCT02826174|Experimental|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
89132586|NCT02826174|Active Comparator|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
89132587|NCT02826174|Other|Anti-Rejection Agents|Anti-Rejection Agents for both groups
89132588|NCT02826174|Other|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
89132589|NCT02839460||subjects with sarcopenia|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
89132590|NCT02839460||healthy, physically-active controls|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
89132591|NCT00621517|Experimental|1|Participants will receive 150MG Bupropion nightly.
89132592|NCT00621517|Placebo Comparator|2|Participants will receive matching placebo capsule nightly.
89132593|NCT02827266|Experimental|Epoetin beta|Participants will receive epoetin beta over an 8-week correction phase and a 4-week extension or continuation phase, for a total exposure of up to 12 weeks.
89132594|NCT02839226|Active Comparator|AR/101|AR/101 will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 28 days, or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
89132595|NCT02839226|Placebo Comparator|Placebo|placebo will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 14 days or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
89132596|NCT00845221|Experimental|Imatinib|
89132597|NCT02950844|Experimental|STAR mapping guided ablation|Patients will undergo PVI guided ablation in addition to STAR mapping guided ablation. The impact on electrophysiological endpoints including cycle length prolongation and AF termination will be assessed.
89132598|NCT00832351|Experimental|1|Early mobilisation within 24 hours after admittance to hospital
89132599|NCT00832351|No Intervention|2|Mobilisation after 24 but within 48 hours from admittance to hospital
89132600|NCT02838056|Experimental|epidural injection|epidural injection of 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
89132601|NCT04243200||Analyses of repeat ambulance calls and costs|For our analyses of repeat ambulance calls and costs we will use routine anonymised data from routine call-and-dispatch and clinical records data from EMAS for 12 months before the intervention was first introduced (September 2017) to at least 6 months after the final step of the introduction in April 2019, i.e. October 2019. This is likely to involve the analysis of an estimated 11916 cases so that we can implement a stepped wedge (non-randomised control)design .
89132602|NCT04243200||Survey of patients receiving intervention|We will survey about 447 patients who received the intervention in order to obtain data from a sample of n=96
89132603|NCT04243200||Survey of ambulance staff|We will send out surveys/questionnaires to all front-line ambulance staff (n=approximately 600)
89132604|NCT04243200||Qualitative interviews of staff|We will sample 10-15 staff for qualitative interviews.
89132605|NCT04243200||Qualitative interviews of patients|We will sample 10-15 patients for qualitative interviews
89132606|NCT02546401|Experimental|Group 1|"Patients will perform their bolus for 2 weeks before meals (BE) and for 2 weeks after meals (AF).~Intervention: drug (insulin Aspart)"
89132607|NCT02546401|Experimental|Group 2|"Patients will perform their bolus for 2 weeks after meals (AF) and for 2 weeks before meals (BE).~Intervention: drug (insulin Aspart)"
89132608|NCT02843516||patients with stroke|patients with stroke
89132609|NCT02843516||patients without stroke|patients without stroke
89132610|NCT02547181|Experimental|Splint|Patients will be provided instructed to use a tensor bandage as well as specific behaviours to prevent movement of the injured part of the hand.
89132611|NCT02547181|Experimental|Behavioral Modification|Patients are given a removable plaster/fiberglass splint with a tensor bandage underneath
89132612|NCT02826876|Placebo Comparator|Ropivacaine|Topical use of Ropivacaine
89132613|NCT02826876|Placebo Comparator|Placebo|Topical use of placebo
89132614|NCT02839304|Experimental|Catheter Ablation Treatment|Cryoablation System: Atrial Fibrillation Ablation
89132615|NCT04043533|Experimental|Exercises Group|
89132616|NCT04043533|No Intervention|Control Group|
89132617|NCT04244448|Other|BIKTARVY® ADMINISTRATION DISSOLVED IN WATER|BIKTARVY® route in healthy volunteers: dissolved in water in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of dissolved in water versus crushed and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
89132618|NCT04244448|Other|BIKTARVY® ADMINISTRATION CRUSHED|BIKTARVY® route in healthy volunteers: crushed in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of crushed versus dissolved in water and solid form of BIKTARVY® in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
89132619|NCT04244448|Other|BIKTARVY® ADMINISTRATION SOLID|BIKTARVY® route in healthy volunteers: solid tablet in Pharmacokinetics study protocol Compare the pharmacokinetic (PK) of solid form of BIKTARVY® versus dissolved in water and crushed in the same healthy volunteer, to determine if there is a PK equivalence between these three modes of administration of BIKTARVY®.
89132620|NCT02843594|Active Comparator|LEEP Intervention C1|Cataract surgery with micro-interventional LEEP technology lens fragmentation (non-randomized cohort 1)
89132621|NCT02843594|Active Comparator|LEEP Intervention C2|Cataract surgery with micro-interventional LEEP technology lens fragmentation (randomized cohort 2)
89132622|NCT02843594|Placebo Comparator|Control Phaco C2|Cataract surgery with conventional phaco-assisted lens fragmentation (randomized cohort 2)
89132623|NCT02843672|Active Comparator|TWO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.~Triple´s Weil osteotomy is performed."
89132624|NCT02843672|Active Comparator|DMMO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.~Distal metatarsal minimally invasive osteotomy is performed."
89132625|NCT04242966|Active Comparator|Usual Care|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
89132626|NCT04242966|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
89132627|NCT00832663|Experimental|NSAID|receive NSAID
89132628|NCT00832663|Placebo Comparator|Placebo|receive placebo
89132629|NCT05333900|Active Comparator|Plant-based then animal based|plant based: diet low in sulfur-containing amino acids (Low-S diet), emphasizing plant-based foods and fat sources animal based: A diet high in sulfur-containing amino acids (High-S diet), emphasizing animal protein and fat sources
89132630|NCT05333900|Active Comparator|Animal-based then plant based|plant based: diet low in sulfur-containing amino acids (Low-S diet), emphasizing plant-based foods and fat sources animal based: A diet high in sulfur-containing amino acids (High-S diet), emphasizing animal protein and fat sources
89132631|NCT04250324|Experimental|BZ019|The subjects are enrolled into 2 dose-escalation cohorts, include 3x10^6/kg、6x10^6/kg, and dose-expansion cohorts, maybe 8x10^6/kg、10x10^6/kg.
89132632|NCT00839293|Experimental|A|ABT -335 capsules 135mg
89132633|NCT00839293|Experimental|B|ABT-335 capsules 45mg
89132634|NCT04201730|Experimental|ERAS|Perioperative intervention with individual Enhanced Recovery After Surgery （ERAS）
89132635|NCT00845377|Experimental|Counseling|
89132636|NCT04582214|Experimental|OLE Therapy with The MetaNeb® System|Subjects in the active treatment group will receive OLE therapy with The MetaNeb® System following the labeled instructions for the device.
89132637|NCT04582214|No Intervention|Control Group|The airway clearance regimen for subjects in the control group will be collected from the medical record.This information will be retrospectively collected from patients treated with standard care with no OLE therapy. Subjects in the control group will be identified from the population of patients previously admitted to the two study sites with COVID-19 infection who required invasive mechanical ventilation but were not treated with OLE therapy.
89132638|NCT02826720||HP+|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
89132639|NCT02826720||HP-|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
89132640|NCT02826720||NP+|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
89132641|NCT02826720||NP-|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
89132642|NCT00839371|Active Comparator|Midazolam|i.v. midazolam titration until adequate depth of sedation
89132643|NCT00839371|Active Comparator|Propofol|i.v. propofol titration until adequate depth of sedation
89132644|NCT02837822|Active Comparator|Stimulation Off|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn Off during the experiment."
89132645|NCT02837822|Active Comparator|Stimulation On|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn On during the experiment."
89132646|NCT02826408|Active Comparator|Active group|Will receive Rabeprazole sodium (Proton pump inhibitor 20 mg once daily)
89132647|NCT02826408|Placebo Comparator|Placebo group|Will receive Folic acid 5 mg once daily
89132648|NCT00845455||1. Harm Avoidance|Personality type
89132649|NCT00845455||2. Reward Dependence|Personality type
89132650|NCT00845455||3. Novelty Seeking|Personality type
89132651|NCT00633230|Active Comparator|1|standardized herbal formula, Sho-saiko-to (SST): 3 capsules containing 700 mg of the SST herbal extract/capsule and 28 mg of the excipients, magnesium stearate and silicon dioxide/capsule 2 x day
89132652|NCT00633230|Placebo Comparator|2|placebo capsules that look and smell identical to the active Sho-saiko-to (SST) capsules
89132653|NCT04242888|Experimental|Rotator Cuff Facilitation|The function of Rotator cuff muscles is passively augmented in one of the 5 trials
89132654|NCT04242888|Experimental|Serratus Anterior Stretch|Seratus anterior muscles is stretched through a novel technique
89132655|NCT04242888|Experimental|Posterior Capsular Stertch|Posterior capsule is stretched through a novel maneuver
89132656|NCT04242888|Experimental|Acromioclavicular Joint Mobilization|Acromio clavicular joint is mobilized posterio-anterior
89132657|NCT04242888|Experimental|Pragmatic Interventions|"The pragmatic interventions is a set of interventions which include~Rotator cuff facilitation~Posterior capsular stretch~Serratus anterior muscle stretch~Acromioclaicualr joint mobilization~Thoracic spine manipulation and~Stretch to the subclavious muscles"
89132658|NCT04250870|Active Comparator|Nursing Home Residents|Nursing home residents (n=59) were evaluated in five different nursing homes.
89132659|NCT04250870|Active Comparator|Community-Dwelling Elderly|The community-dwelling elderly people (n=59) were selected from two different municipalities of the city.
89132660|NCT02839382|Active Comparator|Coaching|External facilitation by a practice coach for 15 months
89132661|NCT02839382|Active Comparator|Educational Outreach|Academic detailing phone calls to support implementation of a cardiovascular risk calculator/estimator in each clinic
89132662|NCT02839382|Active Comparator|Site Visit|"Site visits made by practices to 'exemplar practices to learn innovative approaches to quality improvement"
89132663|NCT02839382|Active Comparator|Educational Outreach and Site Visit|In this arm of the study, practices will be offered both educational outreach and an opportunity for a site visit
89132664|NCT00573937|Active Comparator|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
89132665|NCT00573937|Active Comparator|Morphine|Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.
89132666|NCT02825862|No Intervention|Replication group|Replication group - this group will complete the entire questionnaire, in order to replicate the findings of O'Carroll et al (2011)
89132667|NCT02825862|Active Comparator|Omit affective attitudes|Omitting affective attitudes The intervention is the omission of all questions on affective attitudes. This group will complete a similar questionnaire to the replication group, with the same number of questionnaire items, but affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
89132668|NCT02825862|Active Comparator|Omit negatively-worded items|Omitting negatively-worded affective attitudes. This intervention is the omission of a subset of negatively-worded affective attitudinal items. This group will complete a similar questionnaire to the replication group, with the same number of items, but all negatively-worded affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
89132669|NCT00839449|Experimental|A|Patients in the group A are orally administered eicosapentaenoic acid ethyl ester.
89132670|NCT00839449|No Intervention|B|Patients in the group B (control) are not administered eicosapentaenoic acid ethyl ester.
89132671|NCT04958538|Experimental|MTX and corticosteroid|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
89132672|NCT02825472|Active Comparator|Exercise training program|Six-months sports participation, three times per week for 30 minutes in the target heart rate zone
89132673|NCT02825472|No Intervention|No exercise training program|no exercise training program, usual care
89132674|NCT02548195|Experimental|GEMOX|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2; every three weeks for 6-8 cycles in total.
89132675|NCT02548195|Active Comparator|Capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
89132676|NCT02546089|Active Comparator|intervention group|"local anaesthetic - lidocaine 1%, dry needling, autologous blood injection,~+ structured rehab programme"
89132677|NCT02546089|Placebo Comparator|control group|"local anaesthetic - lidocaine 1%, dry needling,~+ structured rehab programme"
89132678|NCT04244292|Other|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
89132679|NCT00573859|Experimental|ADHD medication versus placebo|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication (e.g., Dextroamphetamine; Amphetamine mixed salts; Atomoxetine; O-Methylphenidate; Lisdexamfetamine). For the placebo condition, a placebo pill was administered.
89132680|NCT04243980||Group 1|Patients after total hip arthroplasty with short femoral stem
89132681|NCT04244214||More Stamina users|This group of patients will use the app for 60 days and all information about utilization will be recorded
89132682|NCT00832897|Sham Comparator|Eyedrop|
89132683|NCT00832897|Active Comparator|Crosslinking|The patients will be submitted to corneal collagen crosslinking, by use riboflavin eyedrop with UVA light.
89132684|NCT04043065|Experimental|LEAP-2|Liver-enriched antimicrobial peptide 2
89132685|NCT04043065|Placebo Comparator|Placebo|Saline
89132686|NCT00839605||Dexmedetomidine|Those requiring thoracic surgery and receiving dex
89132687|NCT00839605||placebo|Group having thoracic surgery and not receiving dex drug
89132688|NCT05660304|Experimental|ccPAS group|Patients under this group will receive ccPAS followed by speech-language therapy.
89132689|NCT05660304|Sham Comparator|Sham ccPAS group|Patients under this group will receive sham ccPAS followed by speech-language therapy.
89132690|NCT04043611|Active Comparator|Conservative physical therapy management|Tens and hot pack , Soft tissue mobilization , Maitland's Lumbar segmental mobilization, Traction, Neurodynamics, Active Stretching, McKenzie Prone Extension Exercises
89132691|NCT04043611|Experimental|ELDOA|Conservative physical therapy management + ELDOA positions
89132692|NCT04242732|Experimental|MPFL reconstructed|20 patients with previous recurrent patella dislocation who underwent MPFL reconstruction surgery with fascia lata allograft between 2012 and 2013
89132693|NCT00839683|Active Comparator|simvastatin|
89132694|NCT00839683|Active Comparator|Dapagliflozin + simvastatin|
89132695|NCT00839683|Active Comparator|Dapagliflozin|
89132696|NCT00839683|Active Comparator|valsartan|
89132697|NCT00839683|Active Comparator|Dapagliflozin + valsartan|
89132698|NCT04242420|Other|Connexin genotype|Genotyping
89132699|NCT00833131|Experimental|1|25 Gy in 5 fractions of 5 Gy over 5 days. One week interval. Consolidating chemotherapy of 3 courses of FOLFOX4. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of fluorouracil.
89132700|NCT00833131|Active Comparator|2|Conventionally fractionated chemoradiation with 50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of radiation.
89132701|NCT02826330||case Crohn disease|60 cases with Crohn's Disease
89132702|NCT02826330||first relative healthy|2 healthy relatives per CD case (total 120)
89132703|NCT02826330||controls|60 controls matched on gender and age with CD cases
89132704|NCT00839761|Experimental|iron fortified rice group|
89132705|NCT00839761|Placebo Comparator|iron drop group|
89132706|NCT02825706|Experimental|Experimental group|The patients in experimental group received 60-minute educational sessions every two weeks about the pathophysiology of hemophilia, clinical manifestations, postural advice and prevention advice to avoid recurrent bleeding. Likewise, doubts on the clinical progress of hemophilic arthropathy, functional limitations and management of joint pain were resolved. In parallel with the educational sessions, patients followed a 15-week home exercise program performed once a day, 6 days a week. The program included muscle stretching exercises; isometric exercises; proprioceptive exercises on one leg with visual support; and a 20-minute walk. Low-intensity exercises with 20-25 repetitions were included.
89132707|NCT02825706|No Intervention|Control group|The patients in the control group did not receive any educational sessions and did no exercise at all at home.
89132708|NCT00839839|Experimental|Oocyte Vitrification|
89132709|NCT02825394||apixaban initiation|N=20
89132710|NCT02825394||apixaban on-treatment|N=20
89132711|NCT02825394||dabigatran initiation|N=20
89132712|NCT02825394||dabigatran on-treatment|N=20
89132713|NCT02825394||rivaroxaban initiation|N=20
89132714|NCT02825394||rivaroxaban on-treatment|N=20
89132715|NCT02825394||edoxaban initiation|N=20
89132716|NCT02825394||edoxaban on-treatment|N=20
89132717|NCT00845689|Placebo Comparator|1|liver resection with Pringle + placebo
89132718|NCT00845689|Active Comparator|2|liver resection with Pringle + adenosine preconditiong
89132719|NCT00845689|Active Comparator|3|liver resection with Pringle + adenosine pre- and postconditioning
89132720|NCT00845767|Experimental|Diesel Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 with intermittent exercise
89132721|NCT00845767|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
89132722|NCT05660694|Experimental|Group 1: Triamcinolone|Injection steroid Triamcinolone 400mg with lidocaine 1:1 was given twice a week for 4 weeks in bi-lateral buccal mucosa in multiple sites
89132723|NCT05660694|Experimental|Group 2: Pentoxifylline with Vitamin E|Pentoxifylline 40mg twice a day along with vitamin E supplement one tablet per day for 4 weeks
89132724|NCT00833209|Experimental|1|Patients with Medication Overuse Headache (MOH)
89132725|NCT00833209|Sham Comparator|2|controls suffering from migraine
89132726|NCT00833209|Sham Comparator|3|controls without any neurological disease
89132727|NCT00848029|Experimental|1|
89132728|NCT04241952|Experimental|Exercise group|Usual care and bedcycling.
89132729|NCT04241952|No Intervention|Control group|Usual care
89132730|NCT00839995||Patients undergoing multi-level spine surgery|
89132731|NCT02824614|No Intervention|Control|20 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups.
89132732|NCT02824614|Active Comparator|E967-Xylitol|20 obese, non-diabetic candidates will receive a daily dose of 24g of xylitol.
89132733|NCT02824614|Active Comparator|E968-Erythritol|20 obese, non-diabetic candidates will receive a daily dose of 36g of erythritol.
89132734|NCT00840151|No Intervention|Treatment Group A|Individuals randomized to Treatment Group A will receive standard treatment for study weeks 1-6.
89132735|NCT00840151|Experimental|Treatment Group B|Individuals randomized to Treatment Group B will receive contingency management plus standard treatment for study weeks 1-6.
89132736|NCT00840151|No Intervention|Aftercare Group A|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group A will receive standard treatment for study weeks 7-12.
89132737|NCT00840151|Experimental|Aftercare Group B|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.
89132738|NCT00840229|Experimental|1 capsular & intra-articular|corticosteroid injection (Triamcinolone) in capsule/rotator interval and intra-articular
89132739|NCT00840229|Active Comparator|2 intra-articular|corticosteroid injection (Triamcinolone) intra-articular placebo injection (Lidocaine) in capsule
89132740|NCT00840229|Placebo Comparator|3 placebo|placebo injections (Lidocaine) in capsule and intra-articular
89132741|NCT02825628|Experimental|Osteodex 3.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
89132742|NCT02825628|Experimental|Osteodex 6.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
89132743|NCT02825628|Experimental|Osteodex 9.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
89132744|NCT00831441|Active Comparator|Apixaban|
89132745|NCT00831441|Placebo Comparator|Placebo|
89132746|NCT00833599||1: NIRFLI with ICG|1) Persons affected with lymphatic or lympho-vascular disorders, 2) Family members (affected or unaffected) of persons affected with lymphatic or lympho-vascular disorders and 3) Health, normal persons (Controls) that participate at one of the clinical sites in both the lymphatic function imaging with indocyanine green and the Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) system, as well, as the genetic analysis portion of the study.
89132747|NCT00833599||2: Genetic Analysis Only|Family members of an affected subject from Group 1. Subjects in Group 2 can be either affected or unaffected and will provide a blood or saliva sample for the genetic analysis portion of the study, but will not undergo lymphatic function imaging with ICG and the NIRFLI system. Group 2 individuals are not required to travel to one of the clinical sites in order to participate in the study.
89132748|NCT04242108||Angle closure group|
89132749|NCT04242108||Open angle group|
89132750|NCT04242108||Peripheral synechia (PAS) group|
89132751|NCT04242108||Non-peripheral synechia (PAS) group|
89132752|NCT00840385|Experimental|A|
89132753|NCT00840541||DR|Type-2 diabetic subjects diagnosed with diabetic retinopathy (DR).
89132754|NCT02546245|Experimental|Heroes of Knowledge Game|
89132755|NCT02546245|Active Comparator|Attention/Time Control Games|
89132756|NCT02824848|Active Comparator|Passive Stretching|Passive Stretching intervention components include static passive stretching, active assistive range of motion, assisted stretching of the involved cervical musculature, and associated strengthening activities aimed to elicit head righting in developmentally appropriate positions and during developmentally appropriate movement transitions. Intervention is progressed by increasing head tilt angles, duration of head righting, and frequency and number of repetitions.
89132757|NCT02824848|Active Comparator|Perception-Action Approach|P-A Approach intervention components include environmental set-up for activity and participation in play, and manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions. Both components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing environmental supports provided to the infant's body parts, and by removing the therapist's hands from the infant's body to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
89132758|NCT00848263|Active Comparator|DVR|Volar plate
89132759|NCT00848263|Active Comparator|DNP|Dorsal nail plate
89132760|NCT02824458|Experimental|Gefitinib + Apatinib|"(Part A) Phase I, Open-label, Dose-escalation Study Escalating doses(500mg, 750mg, or 250mg) of Apatinib in combination with 250mg Gefitinib daily orally. Participants may continue to receive treatment until progress or intolerable.~(Part B)Multicenter, Randomized, Double-Blind Study Apatinib (dose determined from Part A of study) in combination with 250mg Gefitinib."
89132761|NCT02824458|Placebo Comparator|Gefitinib + Placebo|"(Part A) Not Applicable~(Part B) Placebo in combination with 250mg Gefitinib. Participants may continue to receive treatment until progress or intolerable."
89132762|NCT02827188|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
89132763|NCT02827188|No Intervention|Control-waitlist group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
89132764|NCT00848341||Control|
89132765|NCT00840697|Active Comparator|Work related rehabilitation|"work related rehabilitation and exercises~The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.~Exercises comprises of treatment in groups. The treatment includes exercises, both strength and fitness, in addition to cognitive intervention of how to manage pain and work."
89132766|NCT00840697|Active Comparator|Brief intervention|1 consultation at the physiotherapist, which give advise and a summary talk with the physician
89132767|NCT00840697|Active Comparator|Multidisciplinary exercise group|10 days of exercise and cognitive treatment group
89132768|NCT02824146|No Intervention|Control group|Patients received standard protective mechanical ventilation during all surgery, with tidal volumen 6 ml/kg and positive end-expiratory pressure (PEEP) level of 5 (centimeter of water) cmH2O.
89132769|NCT02824146|Experimental|Recruitment maneuver group|"Patient received a lung recruitment maneuver after pneumoperitoneum insufflation.~The recruitment maneuver consists in 10 breaths at 30/15 cmH2O of plateau pressure and PEEP, respectively. Then, the ventilatory settings back to protective ventilation but adding 8 cmH2O of PEEP to keep the lungs open."
89132770|NCT00834145|Experimental|1|Patients will receive a NormaTec pump and perform active pumping twice daily during hospitalization and thereafter once daily in addition to routine medical therapy.
89132771|NCT00834145|No Intervention|2|Routine medical treatment
89132772|NCT04241484|Experimental|Piezowave|"Initiation of Piezowave MyACT treatment to include parameters from the user manual~Set for frequency of five pulses per second~Delivery of 500 to 1000 pulses over multiple injured area sites, not to exceed 4000 pulses per session~Intensity ranging from 0.1 to 18 millijoule per square millimeter. This intensity if energy flux as the rate of transfer of the energy through the surface of the tissue is applied.~Focal transducer~Head size will be variable based on depth of tissue treated. The user manual will be consulted for depth of penetration recommendations"
89132773|NCT00840775|Other|Presillion™ Stent System|
89132774|NCT02825238|No Intervention|Control|Control group, did not undergo intervention.
89132775|NCT02825238|Experimental|Exercise group|Experimental, exercise group, underwent intervention
89132776|NCT00840931|Experimental|Immunotherapy|Participants will take two 5 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Participants will receive 4 treatment cycles with 28 days in each cycle. Those participants showing a clinical response after 4 cycles of treatment may continue to receive lenalidomide as a single agent for additional cycles at the treating Physicians discretion. During each 28 day cycle participants will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
89132777|NCT00848419|Active Comparator|Methadone|Epidural methadone bolus 4mg
89132778|NCT00848419|Active Comparator|Morphine|Epidural morphine 4mg bolus
89132779|NCT00848419|Active Comparator|Fentanyl|Epidural fentanyl 200 microgram bolus
89132780|NCT00848419|Placebo Comparator|Saline|Epidural saline bolus
89290220|NCT03934476|Experimental|Ketogenic diet|"Ketogenic diet:~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.~fat type intake recommendation:~natural fats~trans-FA reduction"
89132781|NCT05659992|Experimental|treatment group|Experimental: Venetoclax combined CACAG regimen for newly diagnosed AML. All recipients in this arm received azacytidine, cytarabine.aclamycin, chidamide,venetoclax and granulocyte colony-stimulating factor.Azacytidine was uesd as 75 mg/m2/day from day-1 to day-7.Cytarabine was uesd as 75 mg/m2 bid from day-1 to day-5. Aclamycin was uesd as 10 mg/m2/day on day1,3,5). Chidamide was uesd as 30 mg/day on days 0,3. Venetoclax was uesd as 100 mg on day 1, 200 mg on day 2, 400mg from day-3 to day-14.Granulocyte colony-stimulating factor was uesd as 5ug/kg/day from day 0 until agranulocytosis recovery.
89132782|NCT00848575||Group 1 - Device|The principal Investigator and sub-investigators of this study will identify potential participants that attend the gynecologic oncology or gynecology clinics of UAMS. These subjects will have been scheduled for diagnostic or therapeutic laparoscopy. Based on the Inclusion Criteria and Exclusion Criteria of this study, women who are eligible for the study will be approached to participate.
89132783|NCT04242576|Experimental|Action Observation|Subjects will watch 30-second videos, with a one-minute break between videos. The videos show the actions that subjects should imagine while watching the video.
89132784|NCT04242576|Experimental|Right/Left Judgment Task|"The laterality will be trained with the Recognize® application. Once the subjects have been trained, they are instructed to solve the different sections of the application, starting with the simplest tasks until reaching the most difficult ones.~These tasks would consist of indicating left or right, among the different images that appear on the iPad screen, indicating if the image's neck is rotated to the left or right. Being every level more complicated, so that people of different skin tones, with clothes or in a work environment are added."
89132785|NCT04242576|Active Comparator|Exercise|The subjects perform the exercises provided by the researchers. Which consist of neck exercises in all ranges of movement (inclinations and rotations to both sides), apart from flexion and extension.
89132786|NCT00834223|Other|Aquashunt|Open label, all subjects receive device.
89132787|NCT04042909|Experimental|Counter Attitudinal Advocacy|Participants in this arm will articulate ways to avoid alcohol-related consequences using self-generated protective strategies and publicly state those strategies.
89132788|NCT04042909|Active Comparator|Personalized Normative Feedback|Participants in this arm will view personalized normative feedback regarding their 1) own drinking quantity and frequency of drinking, 2) perceptions of typical drinking by same-sex students' on campus (i.e., perceived descriptive norms), and 3) actual drinking rates by same-sex students' on campus (i.e., actual descriptive norms).
89132789|NCT04042909|No Intervention|Assessment-only Control|Participants in this arm will not receive any intervention.
89132790|NCT00834301|Experimental|Treatment Arm|
89132791|NCT04242030|Other|COPD group|"Participants in the COPD group will receive examination of laser doppler flowmetry(LDF).~The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian."
89132792|NCT04242030|Other|Healthy control group|Participants in the healthy control group will receive examination of laser doppler flowmetry(LDF). The LDF probes will be left at 4 measuring acupoints, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
89132793|NCT04242030|Experimental|Healthy intervention group|Participants in the healthy intervention group will receive intervention of moxibustion in the Heart and Lung meridians.
89132794|NCT00834379|Experimental|Pravastatin|Pravastatin 40 mg Tablet (test) dosed in first period followed by Pravachol® 40 mg Tablet (reference) dosed in second period
89132795|NCT00834379|Active Comparator|Pravachol®|Pravachol® 40 mg Tablet (reference) dosed in first period followed by Pravastatin 40 mg Tablet (test) dosed in second period
89132796|NCT02825316|Experimental|Group A|Patients with active Crohn's disease that will be allocated to the Mediterranean diet group.
89132797|NCT02825316|Experimental|Group B|Patients with active Crohn's disease that will be allocated to the low residue diet group.
89132798|NCT02825004|Experimental|Psychological Intervention|All the professionals workers involved in the experimental group will attend three intensive psychological meetings about emotional exhaustion, depersonalisation, low personal accomplishment and how to improve coping skills.
89132799|NCT02825004|No Intervention|Control Group|There is not any intervention.
89132800|NCT00834457|Active Comparator|2A|co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg po(Trizivir)one tablet twice daily(BID)for 96 weeks
89132801|NCT00834457|Active Comparator|2B|co-formulated abacavir 600mg/3TC 300mg orally (as Kivexa) one tablet daily plus fixed dose lopinavir 133.3mg/ritonavir 33.3mg orally (as Aluvia) four tablets daily for 96 weeks
89132802|NCT04241406|Experimental|transcutaneous spinal cord stimulation|"Transcutaneous application of electrical (biphasic current, 1ms, 30Hz) stimulation over the back for a 10 minutes session.The intensity of the current will increase until motor reflex threshold. If it will not possible, intensity will be increase until participants report a strong but comfortable sensation.~Transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
89132803|NCT04241406|Experimental|sham stimulation|"Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequently.~Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)."
89132804|NCT02611635||VKA treatment of AF / Cohort 1|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
89132805|NCT02611635||NOAC treatment of AF / Cohort 2|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
89132806|NCT05659758|Other|control|patients will be preoxygenated in supine position
89132807|NCT05659758|Experimental|20 degree|patients will be preoxygenated in 20 degrees head up position
89132808|NCT05659758|Experimental|30 degree|patients will be preoxygenated in 30 degrees head up position
89132809|NCT02824926|Experimental|Dapaconazole|(cream; 2%; topical)
89132810|NCT02824926|Active Comparator|Ketoconazole|(cream; 2%; topical)
89234101|NCT00379210|Experimental|1|"Meditation training group-- received Mindfulness Based Stress Management from the Penn Program for Stress Management.~The meditation practice initially emphasized attention to a single focus. For most concentrative exercises, this focus was the breath. The sensations of breathing were to be examined closely, and when attention wandered it was to be redirected back to the breath. In other exercises, the focus of attention was to be directed to sensations within specific body parts (body scan exercise) and sensations of walking (walking meditation). During the 5th week of classes, the mindfulness training was expanded to include some explicit training in receptive attention."
89234102|NCT00379210|Active Comparator|2|"Nutrition education group~An active comparison condition involving nutrition education was offered. This course matched the mindfulness course in all dimensions including course duration, homework, psychosocial support, and teacher expertise. The course was taught by a nurse who had expertise in nutrition and offered a program described in the book, Nutrition for Life by Lisa Hark."
89234103|NCT00992472|Experimental|Prochlorperazine suppositories, 25mg|
89234104|NCT00992472|Active Comparator|Compazine® suppositories, 25mg|
89234105|NCT03453840|Active Comparator|HIV-infected 3-day AL|Standard 3-day twice daily (BID) regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-infected and stabilized on EFV-based ART.
89234106|NCT03453840|Experimental|HIV-infected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-infected and stabilized on EFV-based ART.
88802602|NCT05586464|Experimental|Traditional Chinese Medicine group|"Patients in the case group will take Ban xia xie xin Decoction and bismuth quadruplicate for 14 days. H. pylori was rechecked one month after drug withdrawal, and H. pylori clearance rate and adverse reactions were observed in the reorganized patients.~Ban xia xie xin Decoction includes 10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube. One dose in the morning and one dose in the evening, and take after meals.~Bismuth quadruplicate includes esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid)."
88802603|NCT05586464|Active Comparator|Bismuth quadruplicate group|"Patients in the control group will take bismuth quadruplicate for 14 days. H. pylori was rechecked one month after drug withdrawal, and H. pylori clearance rate and adverse reactions were observed in the reorganized patients.~Bismuth quadruplicate includes esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid)."
88802604|NCT01561378|Experimental|Insulin|Aspart Insulin 40 IU intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
88802605|NCT01561378|Placebo Comparator|Normal saline|Normal saline (0.9% sodium chloride solution) intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
88802606|NCT02628548|Experimental|Cognitive training program 1|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
88802607|NCT02628548|Experimental|Cognitive training program 2|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
88802608|NCT03236662|Experimental|Treatment|(-)-epicatechin 50mg twice per day (100mg per day total dose)
88802609|NCT04017754||Study sample|"In total, 267 women with unexplained recurrent pregnancy loss was included.~Only patients with a history of 3 or more consecutive spontaneous pregnancy losses are included. Both biochemical and clinical losses documented in hospital records are accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social reasons are not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (<22 and >35 days interval), and/or no MBL measurement."
88802610|NCT04017754||Reference Group|The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information. After informed approval, all controls had an extra blood sample taken, which was analysed for p-MBL.
88802611|NCT01893242|Experimental|Aleglitazar Arm|
88802612|NCT01893242|Placebo Comparator|Placebo Arm|
88802613|NCT04757792||No NSAID|included patients who did not receive NSAID prior to having COVID-19 disease
88802614|NCT04757792||Apsirin|included patients who received acetylsalicylic acid (ASA) prior to having COVID-19 disease
88802615|NCT04757792||Celecoxib|included patients who received celecoxib (CEL) prior to having COVID-19 disease
88802616|NCT04757792||Miscellaneous|included patients who received miscellaneous NSAID other than ASA or CEL prior to having COVID-19 disease
88802617|NCT02307500|Experimental|Regorafenib|Regorafenib 160 mg (40 mg tablets), po, every day for 3 weeks of every 4 week cycle
88802618|NCT02589938|Active Comparator|Standard Oral Hygiene|All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
88802619|NCT02589938|Experimental|Standard Oral Hygiene + True Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.~The True acupuncture points will be at 3 sites on each ear, a site on the chin, on each forearm, a site on each hand, a site on each leg, and one placebo needle for a total of 14 sites. All sites will be applied for 20 minutes."
89234107|NCT03453840|Active Comparator|HIV-uninfected 3-day AL|Standard 3-day BID regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-uninfected.
89132811|NCT00705471||Infliximab|Because of the difficulty of finding subjects with exactly the same disease severity, information will be recorded for the time period for up to three years before and for one year after their initial infliximab infusion for comparison of health care costs and utilization prior to infliximab and post infliximab use.
89132812|NCT00705549|Experimental|1|Gemzar/Cisplatin
89132813|NCT00705549|Experimental|2|Taxotere/Cisplatin
89132814|NCT00705549|Experimental|3|Cisplatin/Navelbine metronomic
89132815|NCT00705549|Experimental|4|Taxotere/Gemzar
89132816|NCT00705549|Experimental|5|Gemzar
89132817|NCT00705549|Experimental|6|Taxotere
89132818|NCT00705549|Experimental|7|Navelbine metronomic
89132819|NCT00705549|Experimental|8|Alimta/Cisplatin
89132820|NCT00705549|Experimental|9|Alimta/Gemzar
89132821|NCT00705549|Experimental|10|Taxotere
89132822|NCT00705549|Experimental|11|Alimta
89132823|NCT00705627|Experimental|B|Drug: cisplatin. Patients in the control arm received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
89132824|NCT00705705|Experimental|1|Participating social networks will receive standard HIV risk-reduction counseling and network leadership training on HIV prevention.
89132825|NCT00705705|Active Comparator|2|Participating social networks will receive standard HIV risk-reduction counseling.
89132826|NCT02824770|Active Comparator|Usual Care|After a major abdominal surgery, the control group will receive the usual postoperative care including continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) in the surgical intensive care unit.
89132827|NCT02824770|Experimental|Dimming of lights and decreasing noise|After a major abdominal surgery, the patients in the experimental group will be screened in the side-rooms where normally the patients who either have infections or are at risk of infection, are nursed and will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) as in the control group. The study intervention will include dimming of lights and decreasing noise. The lights will be dimmed to 40 lux. The doors of the side-rooms will be closed decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m.
89132828|NCT02824536|Experimental|Group 1|Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
89132829|NCT02824536|Experimental|Group 2|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
89132830|NCT02824536|Experimental|Group 3|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
89132831|NCT00831129|Active Comparator|Simvastatin + Placebo Rosiglitazone|Subjects will receive 40 mg Simvastatin + 1 tab Placebo Rosiglitazone daily
89132832|NCT00831129|Active Comparator|Simvastatin + rosiglitazone|Subjects will receive 40 mg Simvastatin + 4 mg Rosiglitazone once daily
89132833|NCT00637962|Experimental|Active product|CN54gp140 + gel
89132834|NCT00637962|Placebo Comparator|Gel alone|Gel alone
89132835|NCT02824380|Experimental|Sequence A|Period 1: DA-4001 H(High dose) Period 2: DA-4001 L(Low dose)
89132836|NCT02824380|Experimental|Sequence B|Period 1: DA-4001 L(Low dose) Period 2: DA-4001 H(High dose)
89132837|NCT00705861|Placebo Comparator|1|
89132838|NCT00705861|Experimental|2|
89132839|NCT00913341|Experimental|1|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
89132840|NCT00913341|Active Comparator|2|Alprazolam Tablets, 1 mg (The Upjohn Company)
89132841|NCT00620113|Placebo Comparator|Placebo|After an observation period of ~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
89132842|NCT00620113|Experimental|Odanacatib 10 mg|After an observation period of ~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
89132843|NCT00620113|Experimental|Odanacatib 25 mg|After an observation period of ~5 weeks, participants receive 25 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
89132844|NCT00620113|Placebo Comparator|Odanacatib 50 mg|After an observation period of ~5 weeks, participants receive 50 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
89132845|NCT00830115||Pantoprazole|All patients enrolled
89132846|NCT00633672|Experimental|1|20mg Oral tablet daily
89132847|NCT00633672|Experimental|2|40mg oral tablet daily
89132848|NCT00633672|Active Comparator|3|150mg oral twice daily
89132849|NCT02547103|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate-soaked cloths, clean topical area around catheter exit site with CHG 2% soaked cloths
89132850|NCT02547103|Active Comparator|Normal saline (usual care)|Normal saline, clean topical area around catheter exit site
89132851|NCT02547103|Active Comparator|Mupirocin ointment|Mupirocin ointment 2%, clean topical area around catheter exit site with Mupirocin ointment
89132852|NCT05659524|Active Comparator|Nasal saline irrigation|Patients randomized to standard postoperative nasal care with twice a day saline sinonasal irrigations
89132853|NCT05659524|No Intervention|No Intervention|Patients randomized to not performing saline sinonasal irrigations.
89132854|NCT02822664|Other|Pedophiles patients|Adults diagnosed with pedophilia
89132855|NCT02822664|Other|Healthy subjects|Healhy subjects (not diagnosed with pedophilia)
89132856|NCT00841165|Experimental|1|Participants in this arm are treated with Continuous Positive Airway Pressure at 5cm H2O and 100% oxygen
89132857|NCT00841165|Active Comparator|2|Participants in this arm receive standard of care therapy- oxygen via a non-rebreather mask
89132858|NCT02823756|Experimental|Physical Therapy|Treatment arm: manipulation, exercise, and education
89132859|NCT00841243|Active Comparator|nutritional advise/support|Nutritional advise and support
89132860|NCT00841243|No Intervention|control|Control
89132861|NCT02822586|Experimental|Cohort A (Stage IB and Stage IIA to IIIB [if N0-1])|"(Eligible patients with Stage IB, IIA, IIB, and IIIA [if N0-1])~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week."
88802620|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.~The Sham acupuncture points will be given according to the same schedule as the active acupuncture points, except the Sham needles will be placed below, above or between true active points."
88806134|NCT03951584||ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study cohort. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset, to evaluate the damage and prognosis of vestibular function.
89132862|NCT02822586|Experimental|Cohort B(Stage IIA to IIIB; IVA;transformed CTCL)|"(Eligible patients with Stage IIA, IIB, IIIA [if N2-3]; IIIB; Stage IVA; and transformed CTCL)~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week.~Continuation of brentuximab every 3 weeks until disease progression or unacceptable toxicity or for up to 2 years as a study participant, (whichever occurs first)."
89132863|NCT00834691||1|Patients with anemia and systolic heart failure
89132864|NCT00834691||2|Patients with systolic heart failure but without anemia
89132865|NCT00834691||3|Patients with at least moderate chronic renal failure, with or without anemia and without systolic heart failure.
89132866|NCT04239768|Experimental|MonoDermà HA gel combined to a low level laser|"Monodermà HA Bio-revitalizing gel is a sterile, biodegradable, isotonic intradermal filler produced by Innate S.r.l. (Italy) and distributed by Giuliani S.p.A. (Italy) in non-pyrogenic pre-filled syringe of 2 ml containing 2% (20mg/ml) of medium chain (1.0-1.5 x 106 Dalton) hyaluronic acid (HA), obtained from bacterial fermentation, in a physiologic buffer (see Appendix 1) and used as a filler for the correction of deep skin sagging and roughness."
89132867|NCT02822274|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89132868|NCT00841399|Experimental|E75 + GM-CSF vaccine|The dose escalation scheme is for three patients to receive each of the doses, 100, 500, and 1,000 mcg of peptide + 250 mcg GM-CSF each month for 6 months until the maximum tolerated dose is determined. Patients who receive the vaccine are HLA-A2+ and/or HLA-A3+. Responses to the vaccine are measured via immunologic assays.
89132869|NCT00841399|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients do not receive the E37 + GM-CSF vaccine, but are instead enrolled to the control arm for observation.
89132870|NCT02822118|Experimental|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe for 8 weeks.
89132871|NCT02822118|Placebo Comparator|Placebo|Patients in this group were administered the placebo for 8 weeks.
89132872|NCT00848809||1|Slow-low efficiency daily dialysis group
89132873|NCT00848809||2|Intermittent Hemodialysis group
89132874|NCT04240938|Other|Lacrimal sac mucocele|Adult patients with lacrimal sac mucocele
89132875|NCT00848887|Experimental|1|
89132876|NCT04240782|Experimental|Education with Produce Allocations|Participants will attend nutrition education and hands-on cooking classes with weekly produce allocations from a local farm.
89132877|NCT04240782|Experimental|Education only|Participants will attend nutrition education and hands-on cooking classes (with produce coupons provided after intervention).
89132878|NCT04240782|No Intervention|Control group|Participants will receive a delayed intervention once the study period is over.
89132879|NCT00834847|Experimental|Pravastatin fast|Test product under fasting conditions dosed in first period followed by either test or reference product dosed under fed conditions in second and third periods
89132880|NCT00834847|Experimental|Pravastatin|Test product under fed conditions dosed in first period followed by either test product dosed under fasting conditions or reference product dosed under fed conditions in second and third periods
89132881|NCT00834847|Active Comparator|Pravachol®|Reference product under fed conditions dosed in first period followed by test product dosed under either fed or fasted conditions in second and third periods
89132882|NCT02823132||patients who develop a fungal infection|
89132883|NCT02823132||patients without fungal infection|
89132884|NCT00841477|No Intervention|A1|standard behavioral intervention, standard HB vaccine schedule (0,1,6month)
89132885|NCT00841477|Active Comparator|A2|standard behavioral intervention, accelerated HB vaccine schedule (0,1,2month)
89132886|NCT00841477|Active Comparator|B1|enhanced behavioral intervention, standard vaccine schedule
89132887|NCT00841477|Active Comparator|B2|enhanced behavioral intervention, accelerated vaccine schedule (0,1,2MONTH)
89132888|NCT00830037|Experimental|IV Iron|
89132889|NCT00830037|Active Comparator|Oral Iron|
89132890|NCT00834925|No Intervention|standard dose diltiazem|
89132891|NCT00834925|Experimental|low dose diltiazem|
89132892|NCT00835315||3|patients with psoriasis , patients with atopic dermatitis and healthy patients.
89132893|NCT05659680|Experimental|Leadless Conduction System Pacing|Participants receive leadless conduction system pacing using the WiSE-CRT device.
89132894|NCT02611557|Other|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
89132895|NCT00841633|No Intervention|1|No induced hypertension (reference group)
89132896|NCT00841633|Experimental|2|Induced hypertension with a MAP of 30 mmHg above the average MAP on the previous day; during 24-36 hours, until a perfusion CT scan has been performed
89132897|NCT02823678||Pancreatectomy|Patients scheduled to undergo a pancreatectomy
89132898|NCT02823912|Experimental|Capsaicin|75 mg capsaicin every 12 hours for 90 days
89132899|NCT02823912|Placebo Comparator|Control|75 mg magnesia calcinada every 12 hours for 90 days
89132900|NCT00841711|Other|Behavioral counseling|
89132901|NCT02823288|Experimental|Sonke CHANGE intervention condition|This arm (n=9 clusters) will receive the Sonke CHANGE intervention for 12 months.
89132902|NCT02823288|No Intervention|Control condition|In this arm (n=9 clusters), no activities will take place during the trial period outside of data collection.
89132903|NCT04240860|Experimental|platelet rich plasma preparation|"About 15 ml of autologous blood from the patient was collected slowly in 20 ml syringe containing 1.5 ml anticoagulant citrate dextrose solution A (ACDA) under complete aseptic precautions.~2- Blood was mixed by swinging the syringe slowly. 3- By using 18G needle, the gathered blood was transfused into tube maintaining a slope of 45°.~4- The centrifugation step was then done by using non digital angle type centrifuge :the tube was put with water tube on the opposite side to achieve centrifuge balance.~5- The centrifugation occurred in one step by power 3600 RPM for 6 minutes. 6- The buffy coat was elevated up to the buffy coat line (Figure 1). 7- the buffy coat (2-3 ml PRP) was extracted from slim neck by tornado technique so that sunk platelets can be floated and drawn easily.~8- the remaining platelet poor plasma(PPP) was drawn using 5 cc syringe. then inserted by ovum pick up needle into subendometrium"
89132904|NCT04240860|Active Comparator|endometrial scratch|using scissor of hysteroscopr 3 snips was done in the fundus
89132905|NCT00841867||1|Subjects 18-80 years of age who have previously undergone partial pancreatectomy due to a benign lesion
89132906|NCT00841867||2|Healthy control subjects, 18-80 years of age, who have not had partial pancreatectomy.
89132907|NCT00829413|Other|Patients who received SonoVue|"Patients with at least one target lesions requiring work-up for characterization to undergo~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~SonoVue-enhanced ultrasound of the target lesion (CE-US):procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~Truth standard~2.4 mL of sulfur hexafluoride microbubbles (SonoVue®) will be administered as a bolus injection in a peripheral vein."
89132908|NCT00841945|Active Comparator|1|"Chemotherapy + Radiotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone~Radiotherapy 40 gray on initial nodes"
89132909|NCT00841945|Experimental|2|"Chemotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone"
89132910|NCT02823054|No Intervention|Standard group|bi lung ventilation usual practice
89132911|NCT02823054|Experimental|EZ-Blocker group|one lung ventilation 'EZ-Blocker'
89132912|NCT04239612|Other|Physical exercise|Specified circular training, 60 minutes, 1-3 times/week
89132913|NCT04239690|Experimental|Micromethods for blood sample analysis|Blood gases are analysed using 0.045 ml whole blood Levels of C-reactive protein (CRP) are analysed using 0.010 ml whole blood
89132914|NCT04239690|No Intervention|Standard clinical methods for blood sample analysis|Blood gases are analysed using 0.3 ml whole blood Levels of CRP are analysed using 0.5 ml whole blood
89132915|NCT00849043||Provent|Provent Professional Sleep Apnea Therapy device
89132916|NCT02822196|Experimental|Serratus Anterior Muscle Plane Block|The US probe will be placed in the mid-axillary line at the level of the 5th intercostal space. The latissimus dorsi, teres major and serratus muscles will be identified. Using in-plane approach, the block needle (22 G, 50 mm) will be inserted until the tip is visualized between the serratus anterior muscle and the intercostal muscles. As an extra reference point thoracodorsal artery will be used which aids in the identification of the plane superficial to the serratus muscle. After negative aspiration of blood, local anesthetic (20 ml of 0.25 % bupivacaine) will be injected and visualized in real-time.
89132917|NCT02822196|Active Comparator|Thoracic Paravertebral Block|The spinous processes of T1- T5 will be identified and at parasagittal plan at 2.5 cm, skin wheel will be raised using 1% lidocaine. A 20-gauge, bevel needle will be advanced until the transverse process is located. The depth from skin to transverse process will be marked/identified by needle marking. The needle will be withdrawn 1-2 cm and angled down.The needle will be re-advanced 1cm past the initial marking. After negative aspiration, 4-5 ml of 0.25% bupivacaine will be slowly injected. The same procedure will be repeated at each level from T2 to T6 ensuring total dose of bupivacaine does not exceed the maximum dose recommended.
89132918|NCT00849199||High risk of breast or ovarian cancer|
89132919|NCT00706017||A|
89132920|NCT04240236|Experimental|Group S|Group S received scalp block with 20 ml of 0.5% bupivacaine
89132921|NCT04240236|Placebo Comparator|Group C|Group C will not have any intervention
89132922|NCT02820636|Experimental|InVita|Participants receive the Socio-Cognitive Behavior Therapy (S-CBT) treatment.
89132923|NCT02820636|Active Comparator|Treatment as Usual|Intensive outpatient therapy of standard care for adolescents and their parents
89132924|NCT00849355|Experimental|unique|RCOMP-14 with Rituximab
89132925|NCT02822976||Critically Ill Patient HbA1c<6.5|Patients admitted to an intensive care unit with a HbA1c <6.5.
89132926|NCT02822976||Critically Ill Patient HbA1c≥6.5|Patients admitted to an intensive care unit with a HbA1c ≥6.5.
89132927|NCT00835393|Experimental|1|
89132928|NCT00835393|Active Comparator|2|
89132929|NCT02690610|Experimental|Patients with mediastinal lesions|EBUS TBNA of mediastinal lesions or lymph nodes
89132930|NCT00591591|Experimental|OSA|Persons with suspected obstructive sleep apnea (OSA) undergoning overnight sleep evaluation
89132931|NCT00591591|No Intervention|Controls|Healthy controls
89132932|NCT00849433||1|30 patients with asthma
89132933|NCT00849433||2|30 patients with COPD
89132934|NCT04240548|Experimental|Arm: A|regional nodal irradiation including axillary and supraclavicular lymph node groups along with chest wall or whole breast irradiation
89132935|NCT04240548|No Intervention|Arm: B|chest wall or whole breast only irradiation
89132936|NCT00706173|Experimental|Hydrocortisone|
89132937|NCT00706173|Placebo Comparator|Placebo|
89132938|NCT02822742|Other|DE-117 ophthalmic solution and Latanoprost|DE-117 is Experimental. Latanoprost is Active Comparator.
89132939|NCT00835471|Experimental|1|Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)
89132940|NCT00835471|Active Comparator|2|Erlotinib
89132941|NCT02822898|Active Comparator|Isotonic Maintenance Fluid|Isotonic Maintenance Fluid
89132942|NCT02822898|Active Comparator|Hypotonic Maintenance Fluid|Hypotonic Maintenance Fluid
89132943|NCT00828945||Hyperlipidemic Patients|
89132944|NCT00849511|Active Comparator|Placebo first|Placebo 8 weeks, 6 weeks washout, extended-release melatonin 2 mg vesper for 8 weeks
89132945|NCT00849511|Active Comparator|Melatonin first|Extended-release melatonin 2 mg vesper for 8 weeks, 6 weeks washout, placebo 8 weeks
89132946|NCT02822040||Experimental group|All patients who have initial and final records qualify in the experimental group.
89132947|NCT00849589|No Intervention|1|Treatment as Usual (TAU)
89132948|NCT00849589|Experimental|2|Computerized Screening and Brief Physician Advice (SBA)
89132949|NCT00849589|Experimental|3|Computerized screening and brief physician advice with technological extenders (SBA/TE)
89132950|NCT00706251||Primary|All the patients in our medical center who underwent nasolacrimal intubation, due to mild epiphora, during the years 2000-2007.
89132951|NCT02546791||Chronic myeloid leukemia patients treated with Dasatinib|patients with a diagnosis of chronic myeloid leukemia treated with Dasatinib for at least 45 days
89132952|NCT00842101||pressure monitor|Tibial Fracture
89132953|NCT00966875|Experimental|3 mg LY2439821 (bDMARD-naive population)|3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)]
89132954|NCT00966875|Experimental|10 mg LY2439821 (bDMARD-naive population)|10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
89234108|NCT03453840|Experimental|HIV-uninfected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-uninfected.
89132955|NCT00966875|Experimental|30 mg LY2439821 (bDMARD-naive population)|30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
89132956|NCT00966875|Experimental|80 mg LY2439821 (bDMARD-naive population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
89132957|NCT00966875|Experimental|180 mg LY2439821 (bDMARD-naive population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
89132958|NCT00966875|Experimental|80 mg LY2439821 (TNFa-IR population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)]
89132959|NCT00966875|Experimental|180 mg LY2439821 (TNFa-IR population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
89132960|NCT00966875|Placebo Comparator|Placebo (bDMARD-naive population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
89132961|NCT00966875|Placebo Comparator|Placebo (TNFa-IR population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
89132962|NCT04201080|Experimental|Part A: TRV250 for SC injection|2 SC injections of (10 mg/ml per injection)
89132963|NCT04201080|Placebo Comparator|Part A: Placebo for SC injection|2 SC injections (identical to the TRV250)
89132964|NCT04201080|Experimental|Part B: TRV250 dose 1 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
89132965|NCT04201080|Experimental|Part B: TRV250 dose 2 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
89132966|NCT04201080|Experimental|Part B: TRV250 dose 3 for SC injection|1 of 3 doses of TRV250 (using 2 identical syringes)
89132967|NCT04201080|Placebo Comparator|Part B: Placebo for SC injection|Placebo (using syringes identical to the TRV250 arms)
89132968|NCT00842179||Manual Closure|Patients who received vascular closure with manual compression after percutaneous coronary intervention (PCI)
89132969|NCT00842179||Perclose Device|Patients who received vascular closure with the Perclose VCD after percutaneous coronary intervention (PCI)
89132970|NCT02820792|Active Comparator|LMA ProtectorTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
89132971|NCT02820792|Active Comparator|Ambu AuraGainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
89132972|NCT00849745|Experimental|Systemic Lupus Erythematosus|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~Satisfy the American College of Rheumatology (ACR) criteria for the diagnosis of SLE~Have Lupus nephritis, refractory and severe seizures or encephalopathy, severe pulmonary involvement, transfusion-dependent cytopenias, catastrophic antiphospholipid syndrome or vasculitis and/or immune complex deposition causing end-organ signs or symptoms.~Have received a trial of corticosteroids equivalent to prednisone greater than or equal to 0.5 mg/kg/d for at least one month~Have received a trial of IV cyclophosphamide pulse greater than 500 mg/square meter at least once within the previous 6 months, unless contraindicated because of severe cytopenias or intolerance."
89132973|NCT00849745|Experimental|Systemic Sclerosis|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~Have diagnosis of SSc as defined by American College of Rheumatology and at high-risk for fatal outcome.~Have (1) both a and b below and (2) at least one of c, d, or e.~Diffuse cutaneous scleroderma with skin score of >= 16~Duration of systemic sclerosis <= 3 years from the onset of first non-Raynaud's symptom.~Presence of interstitial or pulmonary vascular lung involvement (FVC or DLCO <70% of predicted) especially with evidence of alveolitis (abnormal bronchoalveolar lavage or high-resolution chest CT scan).~Presence of myocardial disease~History or presence of proteinuria > 500 mg/24 hrs or serum creatinine > the upper limit of normal."
89132974|NCT02821884|Experimental|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes.
89132975|NCT02821884|Active Comparator|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation.
89132976|NCT02821884|Sham Comparator|Combination of sham tDCS and sham NMES|"Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Shame tDCS is started in a ramp-like fashion but fade out slowly after 30 seconds.~Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation."
89132977|NCT00835627|Active Comparator|sertraline|flexible dose sertraline
89132978|NCT00835627|Active Comparator|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual, 1 hour therapy sessions
89132979|NCT00835627|Active Comparator|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12 individual, 1 hour therapy sessions
89132980|NCT00835627|Active Comparator|Standard care|community care / treatment as usual: routine follow up with existing providers
89132981|NCT05659446|Active Comparator|endoscopic group|Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical & mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
89132982|NCT05659446|No Intervention|surgical group|Patients involved in surgical group were subjected to either redo of resection anastomosis manually or by circular stapler or primary repair of the defect with ileostomy. This was done under general anesthesia after colonic preparation.
89132983|NCT00849823|Active Comparator|Male Sexual Health Program|
89132984|NCT00849823|Experimental|Focus on the Future Program|
89132985|NCT02822820|Active Comparator|Advanced bipolar (Ligasure-Covidien)|Devices with advanced bipolar energy (Ligasure-Covidien) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
89132986|NCT02822820|Active Comparator|Conventional bipolar (RoBi forceps-Karl Storz)|Devices with conventional bipolar energy (RoBi rotating bipolar forceps-Karl Storz) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
89132987|NCT04820556||Arterial hypertension|
89132988|NCT04820556||Atherosclerosis occlusive disease|
89132989|NCT04820556||Heart failure with preserved ejection fraction|
89132990|NCT04820556||Heart failure with reduced ejection fraction|
89132991|NCT04820556||Diabetes mellitus, type 2|
89132992|NCT04820556||Chronic obstructive pulmonary disease and asthma|
89132993|NCT04820556||Nonalcoholic fatty liver disease|
89132994|NCT04820556||Control group|
89132995|NCT00849979|Other|Questionnaire|
89132996|NCT00849979|Other|Questionnaire + Interview|
89132997|NCT02546869|Experimental|Lebrikizumab|Participants will receive lebrikizumab SC using prefilled syringes (PFS), q4w up to Week 12.
89132998|NCT02820480||Patients/health professionals|Stroke AND cerebral palsy PATIENTS: greater than 18 years of age, who are more than 3 months post stroke, as well as health professionals who have considerable experience in stroke rehabilitation will be asked to evaluate the design of the Rehab in a Crate system. The aim is to survey stroke survivors and healthcare professionals on the design, ease of use, utility, and various features of, both existing and those yet-to-be-developed.
89132999|NCT02822430||Patients|"Patients with psychiatric disorders will be assessed using five evaluation of pain scales :~Visual analogic scale pain~Pain behaviour scale~Short-FormHealth Survey (SF-36)~Global Clinical Impression (GCI) for severity and improvement~Mini International Neuropsychiatric Interview (MINI)"
89133000|NCT02546635|Experimental|Potential food effect|
89133001|NCT02546635|Experimental|Multi-dosing|
89133002|NCT00842413||1|The study compares brain-damaged patients with healthy ones on two psychophysical tasks.
89133003|NCT00842413||2|The study does not intervene on the brain-damaged patients, it merely compares their behaviour with that of healthy patients on a range of psychophysical tasks.
89133004|NCT02821494|Experimental|Hespecta|Four dose groups of Hespecta
89133005|NCT00842491|Experimental|endostar+chemotherapy|
89133006|NCT02821728|Experimental|Normal diet|No dietary intervention
89133007|NCT02821728|Experimental|Dietary intervention|3 portions of broccoli soup per week
89133008|NCT02548273||Diabetics|diabetics with cataract who opted for phacoemulsification surgery
89133009|NCT02548273||controls|non-diabetics with cataract who opted for phacoemulsification surgery (subjects without corneal opacity, PXF ,high myopia, uveitis)
89133010|NCT00828711|Experimental|MVI 100|MVI 100 mcg vaginal insert
89133011|NCT00828711|Experimental|MVI 150|MVI 150 mcg vaginal insert
89133012|NCT00828711|Experimental|MVI 200|MVI 200 mcg vaginal insert
89133013|NCT00842569||Normal weighted|BMI<25
89133014|NCT00842569||Obese|BMI>30
89133015|NCT05659212|Active Comparator|Group D|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
89133016|NCT05659212|Active Comparator|Group M|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
89133017|NCT05659212|Placebo Comparator|Group L|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
89133018|NCT00835783||FUO|Patients with fever of unknown origin undergoing FDG-PET/CT as part of work-up.
89133019|NCT00835783||BUO|Patients with bacteremia of unknown origin undergoing FDG-PET/CT as part of work-up.
89133020|NCT00835783||VGI|Patients with vascular graft infections undergoing FDG-PET/CT as part of work-up.
89133021|NCT00966719|Active Comparator|Lactation Consultant|"In hospital meeting with lactation consultant~1 to 3 follow up visits at weekly intervals with lactation consultant"
89133022|NCT00966719|No Intervention|current treatment for jaundice|Babies will receive current standard of care for jaundice (IV fluids and phototherapy)
89133023|NCT02821650|Experimental|Intervention|Intervention arm will be administered with improved cook stoves (TEJ- Traditional stove to Efficient stove in Jhuggi).
89133024|NCT02821650|No Intervention|control|control arm will continue using traditional cook stoves (chulha) or a combination of the traditional stove and the kerosene/diesel stove.
89133025|NCT00835939|Active Comparator|25% Dextrose and 1% Lidocaine|
89133026|NCT00835939|Placebo Comparator|Lidocaine|
89133027|NCT04708704|Experimental|Erythrosine, prepared in drinking water|One point-of-use technology in development that has demonstrated potential for inactivating viruses in drinking water is the application of an edible photosensitizing dye to the water for disinfection. When exposed to sunlight, the photosensitizing dye produces singlet oxygen, a reactive oxygen species capable of inactivating a wide range of viruses. Erythrosine, an FDA-approved dye, has proven its ability to disinfect drinking water, achieving 4-log inactivation of bacteriophage MS2 in under 10 minutes of sunlight exposure. Furthermore, the dye photobleaches upon exposure to light, and the accompanying distinct color change (e.g., red to transparent) occurs at a rate comparable to the disinfection, providing a safety indication that disinfection has completed, a much-needed function lacking in other point-of-use technologies.
89133028|NCT00842803|No Intervention|Control Group|Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative
89133029|NCT00842803|Experimental|Albumin group|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
89133030|NCT04759170|Other|Mother Recorded Receptive Music Therapy Intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
89133031|NCT04759170|Other|Fother Recorded Receptive Music Therapy Intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
89133032|NCT04759170|Other|Music therapist Recorded Receptive Music therapy intervention|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
89133033|NCT04759170|Other|No singing|The effects of recorded receptive music therapy on oral nutrition and the well-being of the Italian premature baby
89133034|NCT00842881|No Intervention|a|healingstone
89133035|NCT00842881|No Intervention|b|stone powder
89133036|NCT05164289||Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
89133037|NCT05164289||EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
89133038|NCT00818649|Experimental|Velcade + Vorinostat|This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
89133039|NCT00850213||Endeavor Resolute Stent|Patients implanted with the Medtronic Endeavor Resolute stent
88806135|NCT00249470|Experimental|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
89133040|NCT02863211||Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease|One-thousand women 55 years of age or older will be recruited to be screened through the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol. This involves the cardiovascular assessment of resting blood pressure, blood pressure response to 3-min of moderate intensity exercise and large and small arterial elasticity. The participants will be classified into risk categories based on these measures. The incidence of the following adverse cardiovascular outcomes will be assessed in the five-year period after screening in both groups: Ischemic heart disease, acute myocardial infarction, stroke, percutaneous coronary intervention, coronary bypass surgery, congestive heart failure, and hypertension.
89133041|NCT04808544|Placebo Comparator|Placebo group|Patients assigned to placebo group will receive a single intramuscular injection of 2 ml solvent containing benzyl benzoate and sesame oil into the gluteus muscles under ultrasound-guidance.
89133042|NCT04808544|Active Comparator|Naldebain group|Patients assigned to Naldebain group will receive a single intramuscular injection of dinalbuphine sebacate (150 mg in 2 ml solvent containing benzyl benzoate and sesame oil) into the gluteus muscles under ultrasound-guidance.
89133043|NCT00850291||1|Electrosurgical vessel sealing device
89133044|NCT00850291||2|traditional surgical methods:stitches and ligations
89133045|NCT02822352|No Intervention|High Definition White Light|Surveillance colonoscopy using High Definition White Light alone
89133046|NCT02822352|Active Comparator|High Definition Virtualchromoendoscopy|High Definition Virtualchromoendoscopy
89133047|NCT02861105|Active Comparator|LMWH supplementation|40 mg of enoxaparin injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
89133048|NCT02861105|Placebo Comparator|0.9% saline solution|0.9% saline injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
89133049|NCT00842959|Other|ZO|XL Stabi ZO or Invent ZO
89133050|NCT04283357|Active Comparator|Exercise Group|One group only treated with short foot exercises.
88805909|NCT01141907|Experimental|Heart Failure Self Care Support|The goal of the Heart Failure Self Care Support Intervention (Navigator Program), delivered by a nurse and community health navigator team over 3 months post discharge from the index hospitalization, was to improve care transitions by providing patients with tools and support that promote knowledge and skills for HF self care as they transition from hospital to home. The multifaceted Navigator Intervention included the following intervention components: HF home automated telemonitoring support, medication and symptom self management, patient-centered record, HF care follow up, and activation of key supporter.
89133051|NCT04283357|Active Comparator|Virtual Reality Group|The second group treated with virtual reality
89133052|NCT02820558|Experimental|Substance P - 1nmol/kg|Substance P 1nmol/kg intra-celiac artery, single treatment
89133053|NCT02820558|Experimental|Substance P - 5nmol/kg|Substance P 5nmol/kg intra-celiac artery, single treatment
89133054|NCT02820558|Experimental|Substance P - 15nmol/kg|Substance P 15nmol/kg intra-celiac artery, single treatment
89133055|NCT02820558|Experimental|Substance P - 45nmol/kg|Substance P 45nmol/kg intra-celiac artery, single treatment
89133056|NCT04043299|Experimental|Intervention|This arm will receive 100% oxygen at a rate of 10L/min for 15 minutes
89133057|NCT04043299|Active Comparator|Control|This arm will receive medical air (21% oxygen) at a rate of 10 L/min for 15 minutes
89133058|NCT02820246||hospitalised patients|all patients present in a hospital ward during the morning shift
89133059|NCT00961571|Experimental|sunitinib and cepecitabine|Administration of sunitinib and capecitabine
89133060|NCT02818608|Active Comparator|Functional electrical stimulation (FES)|Chronic stroke patients submitted to functional electrical stimulation (FES).
89133061|NCT02818608|Experimental|Combination of transcranial direct current stimulation and FES|Chronic stroke patients submitted to transcranial direct current stimulation (tDCS) and functional and to functional electrical stimulation (FES).
89133062|NCT04284995|Experimental|Cohort 1|Cohort 1: 0.075 mg/kg RUC-4. 8 STEMI Patients will be enrolled.
89133063|NCT04284995|Experimental|Cohort 2|Cohort 2: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
89133064|NCT04284995|Experimental|Cohort 3|Cohort 3: Dose of RUC-4 selected by Safety Review Committee (SRC) after completion of Cohort 2 and review of data. 8 STEMI Patients will be enrolled.
89133065|NCT02820948|Experimental|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
89133066|NCT02820948|No Intervention|No Vitamin E ointment application|No vitamin E ointment was performed.
89133067|NCT04239378|Experimental|Test group -Autogenous dentin matrix and collagen membrane|Test group - After atraumatic tooth extraction , socket will be augmented with autogenous dentin matrix and covered with collagen membrane and sutures are placed.
89133068|NCT04239378|Active Comparator|Control group-bovine derived xenograft and collagen membrane|control group- After atraumatic tooth extraction, socket will be augmented with bovine derived xenograft and covered with collagen membrane and sutures are placed.
89133069|NCT04283279|Experimental|Virtual reality exercise|20 participants will be randomised to this arm
89133070|NCT04283279|Experimental|Vestibular rehabilitation exercise|20 participants will be randomised to this arm
89133071|NCT04283279|Other|Control|20 participants will be randomised to this arm
89133072|NCT02818686|Experimental|TD-1473 low dose|10 subjects will be randomized to receive low-dose TD-1473 orally daily for 28 days
89133073|NCT02818686|Experimental|TD-1473 mid dose|10 subjects will be randomized to receive mid-dose TD-1473 orally daily for 28 days
89133074|NCT02818686|Experimental|TD-1473 high dose|10 subjects will be randomized to receive high-dose TD-1473 orally daily for 28 days
89133075|NCT02818686|Placebo Comparator|Placebo|10 subjects will be randomized to receive placebo orally daily for 28 days
89133076|NCT02860949|Experimental|LAI with PCI|Local anesthetic infiltration with posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area, Lateral gutter area and Posterior capsular area)
89133077|NCT02860949|Active Comparator|LAI without PCI|Local anesthetic infiltration without posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area and Lateral gutter area)
89133078|NCT02690376|Other|Magnetic Assisted Capsule Endoscopy|There is only one arm and its does not reach criteria for other options
89133079|NCT04200612|Experimental|Intervention Group|Participants in the intervention group will go through the 5-week EAP program consisting of the clinical processing following some activities found in EAP manuals.
89133080|NCT04200612|Active Comparator|Active-control group|Participants in the active-control group will undergo a 5-week program that only involves interactions with horses without any clinical input (i.e. commonly coined as animal-assisted activities).
89133081|NCT04200612|Placebo Comparator|Placebo-control group|Participants in the placebo-control group will undergo a 5-week movie screening of 1 hour each session that is related to horses.
89133082|NCT00964223|Experimental|Duac gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
89133083|NCT00964223|Active Comparator|Epiduo gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
89133084|NCT00620815|Experimental|T/P-A|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22
89133085|NCT00620815|Experimental|A/P-T|One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22.
89133086|NCT00620815|Active Comparator|A/S-A|One dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22.
89133087|NCT00620815|Experimental|T/P-A (V2 blood draw)|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by a blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
89234109|NCT05356650|Experimental|Mulligan Mobilization|Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
89133088|NCT00620815|Experimental|A/P-T (V2 blood draw)|One dose of the Aflunov(A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by additional blood draw at visit 2 (V2) prior to the Tetravalent influenza vaccination (T) on day 22.
89133089|NCT00620815|Active Comparator|A/S-A (V2 blood draw)|One dose of Aflunov (A)and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed by an additional blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
89133090|NCT02820090||Success with SBT|The patient have a success in SBT.
89133091|NCT02820090||Success with mechanical ventilation|Weaning from mechanical ventilation is successful
89133092|NCT02820090||failure with SBT|The patient have a failure in SBT.
89133093|NCT02820090||failure with mechanical ventilation|Weaning from mechanical ventilation is failed
89133094|NCT02818764||Delirium|"Subjects undergoing elective total joint arthroplasty determined to have delirium by post operative 3D-CAM.~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.~CSF collected for biomarkers. Blood colelcted for biomarkers."
89133095|NCT02818764||Non-delirium|"Subjects undergoing elective total joint arthroplasty determined not to have delirium by post oeprative 3D-CAM.~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.~CSF collected for biomarkers. Blood colelcted for biomarkers."
89133096|NCT00843271||MESA Lung|MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.
89133097|NCT00850369|Experimental|1|All subjects wil receive monthly RBC transfusions for 6 months
89133098|NCT02861963|Experimental|Right ventricle outflow tract reconstruction|RVOT reconstruction used femoral allogenic vein valve conduit through ventricular fibrillation and without VSD closure
88802621|NCT02292368|Experimental|Acupuncture - One Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
89133099|NCT02861963|Active Comparator|Systemic-to-pulmonary artery shunts|systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt)
89133100|NCT05658744|Experimental|Video group|Insulin administration video was shown to 52 patients with diabetes using insulin. The video was sent to the patients' mobile phones
89133101|NCT05658744|Experimental|Brochure group|Insulin administration leaflet was given to 42 patients with diabetes using insulin. Patients read the brochure aloud
89133102|NCT00850447|Experimental|Cognitive Remediation Therapy|
89133103|NCT00850447|Placebo Comparator|Videogames|
89133104|NCT05658900|Experimental|Enucleation with albumin PRF|
89133105|NCT05658900|Active Comparator|Enucleation without albumin PRF|
89133106|NCT00850681|Experimental|1|PEP005 (ingenol mebutate) Gel
89133107|NCT04283591|Experimental|Experimental Intervention|Acupuncture Treatment Group: will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week. They also will continue to receive the conventional rehabilitation programme.
89133108|NCT04283591|Other|No Intervention|Control Group: will be included in the conventional rehabilitation programme and no interventional procedures will be made.
89133109|NCT04238988|Experimental|Carboplatin-Paclitaxel-Pembrolizumab|"Patients will be treated with 3 cycles of neoadjuvant Carboplatin-Paclitaxel chemotherapy (Carboplatin AUC 5 d1 q 21+ Paclitaxel 175 mg/mq d1 q 21)+ Pembrolizumab (200 mg flat dose every 3 weeks).~After 3 cycles of neo-adjuvant platinum-based chemotherapy patients non progressing will undergo radical surgery.~After surgery, patients presenting with high risk factors will receive 3 cycles of adjuvant Carboplatin-Paclitaxel chemotherapy + Pembrolizumab in combination and maintenance with Pembrolizumab 200 mg every 3 weeks until progression or unacceptable toxicity or patient consent withdrawal for up to 35 cycles."
89133110|NCT00836173|Experimental|RICE followed by GARD|"RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, for 3 cycles.~GaRD treatment: After RICE treatment, gallium nitrate will be given continuously over a 7 day period. In addition rituximab will be given on day 1 of each cycle. Dexamethasone will be given for the first 4 days of each cycle. The length of each cycle is 21 days."
89133111|NCT02862041|Active Comparator|Group Echogenic|Ultrasound guided infraclavicular brachial plexus block with Pajunk sonoplex echogenic needle
89133112|NCT02862041|Placebo Comparator|Group Nonechogenic|Non echogenic needle group, ultrasound guided infraclavicular brachial plexus block with Stimuplex Braun non echogenic needle
89133113|NCT00836251||H218O and 2H2O|schizophrenia
89133114|NCT04284215|Experimental|Albumin paclitaxel|"Albumin paclitaxel 40mg/m2/week was injected into normal saline at the same time as radiotherapy, once a week. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and 2 days. (Because toxicity and heart problems can replace DDP)] Repeat every cycle (21-28 days/cycle, minimum 2 cycles).~Three-dimensional radiotherapy:~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: > 60 Gy"
89234110|NCT05356650|Experimental|PNF Technique|Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.
89234111|NCT00378898|Active Comparator|EGD with proximal BRAVO capsule|Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
89133115|NCT04284215|Active Comparator|Paclitaxel|"Paclitaxel 175 mg/m2 was injected into saline solution on the first day. Cisplatin 75 mg/m2 was given intravenously for 2-3 days , carboplatin 300 mg/m2 and on the second day. (Because toxicity and heart problems can replace DDP)]Repeated every cycle (21-28 days/cycle, minimum 2 cycles).~Three-dimensional radiotherapy:~intensity-modulated radiotherapy (IMRT) or rotational intensity-modulated radiation therapy (VMAT) segmented dose: primary focus and mediastinal metastatic lymph nodes; segmented mode: continuous accelerated hypersegmentation; Dose: DTGTV: > 60 Gy"
89133116|NCT02816970|Experimental|A Test|Test drug (Gliptus) 1 tablet contains 50 mg vildagliptin
89133117|NCT02816970|Active Comparator|B Reference|Reference drug (Galvus) 1 tablet contains 50 mg vildagliptin
89133118|NCT04283123|Experimental|Treatment|Participants assigned to this group will receive an automated bidet (TOTO Washlet S300e with remote control) and an occupational therapy intervention over 3-4 in-home visits.
89133119|NCT04283123|Active Comparator|Waitlist Control|Caregivers will wait for 30 days and then will be offered the intervention.
89133120|NCT04239066|Experimental|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
89133121|NCT04239066|Experimental|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
89133122|NCT04284137|Experimental|Modified FE-SaLiR|FE-SaLiR is based on modified Ba Duan Jin and Wu Qin Xi exercises that include low to moderate intensity age-tailored activities targeting different parts of the body, integrating breathing and mindfulness. A trained Community Health Worker will serve as the class instructor.
89133123|NCT04284137|Experimental|Unmodified Chinese Medicine Exercise|The Ba Duan Jin and Wu Qin Xi low- to moderate- intensity exercises published by the General Administration of Sport of China. A trained Community Health Worker will serve as the class instructor.
89133124|NCT04284137|Active Comparator|Active Control|The active control program is a health education program for attention control. The participants will learn knowledge and skills about healthy aging and nutrition in a group with hands-on activities.
89133125|NCT02817282|Other|Hand hygiene implementation strategy|The implementation strategy will be tested in a stepped wedge cluster randomized trial which is based on a random sequential roll-out of the CHANGE implementation strategy to all participating NHs (n=20) for comparison. All groups (hence all NHs) start with the control situation (no CHANGE implementation activities) at the beginning of the study. At each time point, a new group of five NHs crosses over from the control situation to the implementation situation. Each group will start the implementation phase of 4 months at a different time point, directly after one of the measurements periods (Point of Time (PT) 0, PT1, PT2, PT3, PT4, PT5). The time point a group crosses over is randomized (over the groups).
89133126|NCT03372941|Active Comparator|Alternative treatment strategy|Patient will receive a single dose of dalbavancin administered in the BJH ED or ED observation unit for ABSSSI followed by discharge w/ close Infectious Disease outpatient clinic follow-up.
89133127|NCT03372941|No Intervention|Usual care|"Patients will receive usual care (i.e., hospital admission for intravenous antibiotics - typically, vancomycin) - antibiotic and doses to be determined at the discretion of the treating clinician (both in the BJH ED and on the BJH inpatient ward)."
89133128|NCT02819934|Experimental|Arm1|experimental group
89133129|NCT00630227|Experimental|Single|all patients are treated with the experimental therapy
89133130|NCT04238832|Active Comparator|Free Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and free base nicotine e-liquid to sample for one week.
89133131|NCT04238832|Active Comparator|Salt Base Nicotine|Participants assigned to this group will try both a free base nicotine and a salt base nicotine, and then take home an e-cigarette and salt base nicotine e-liquid to sample for one week.
89133132|NCT02818530|Experimental|IOP by tomoneter and ultrasound|Intraocular pressure will be measured by electronic tomometer (tonopen) at different point of time after induction of anaesthesia in patients undergoing robotic assisted surgery under steep Trendelenberg position. Anterior chamber depth will be measured by ultrasound at the same time intervals.
89133133|NCT04622904|Active Comparator|lidocaine-magnesium group|combination of lidocaine and magnesium infusions
89133134|NCT04622904|Active Comparator|lidocaine-ketamine group|combination of lidocaine and ketamine infusions
89133135|NCT04622904|Active Comparator|lidocaine group|lidocaine infusion alone
89133136|NCT02816892||Rupture group|Rupture was defined by direct visualisation of the discontinuity of the aortic wall by computed tomography, sonography, intraoperative findings or at autopsy with detection of blood in the pleural, pericardial or abdominal cavity.
89133137|NCT02816892||Covert rupture group|Covert rupture was defined as an intramural haematoma without detection of free blood in the body cavities.
89133138|NCT02816892||Acute dissection group|Acute dissection was defined when blood separating the layers of the aortic media was newly diagnosed.
89133139|NCT02816892||Chronic dissection group|Chronic dissection was defined as the absence of any visible propagation of a known dissection compared to preexisting examinations.
89133140|NCT02816892||Ectatic aneurysm group|Ectatic aneurysm was defined as a permanent localised dilatation of the aorta with a diameter of at least 50% greater than normal
89133141|NCT02817048|Active Comparator|Tubeless|Interventions: VATS without chest tube placement
89133142|NCT02817048|Active Comparator|Chest tube|VATS with chest tube placement
89133143|NCT02817204|Experimental|Aerobic Exercise group|Cardio Pulmonary Exercise Test(CPET) Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
89133144|NCT02817204|Other|Health Education Group|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol Cardio Pulmonary Exercise Test(CPET) No Cycle ergometer exercise
89133145|NCT02819622||Control group|control (no disease)
89133146|NCT02819622||central serous retinopathy group|Central serous retinopathy (with CSCR disease) by exam and OCT
89133147|NCT04239300|Experimental|Main group|The participant in main group have water labour
89133148|NCT04239300|No Intervention|Control group|The participant in control group will not have water labour
89133149|NCT00634062|Active Comparator|1|
89133150|NCT00634062|Placebo Comparator|2|
89133151|NCT00634140|Experimental|1|ezetimibe
89133152|NCT00634140|Placebo Comparator|2|placebo for 4-6 weeks
88802622|NCT02292368|Experimental|Acupuncture - Different Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
88802623|NCT02286674|Experimental|Tablet for watching movie|The study group will receive standard of care in addition to a tablet to watch movies and/or TV
88802624|NCT02286674|No Intervention|Standard of care - no tablet|The control group will receive standard of care only.
88802625|NCT01893398|Experimental|rehabilitation (MST) program|The Multidimensional Stimulation group therapy (MST) involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
88802626|NCT01893398|No Intervention|Usual care program|Usual care PWA program
89133153|NCT02819544|Active Comparator|Ropivacaine|Ropivacaine 7.5 mg/mL administration
89133154|NCT02819544|Placebo Comparator|Sodium chloride|NaCl 0.9% administration
89133155|NCT02816814|Active Comparator|Love Diet|Overweight females (BMI > 25) in menopause
89133156|NCT02816814|Experimental|LωVE diet|Overweight females (BMI > 25) in menopause
89133157|NCT02819388|Experimental|Intervention|Contraceptive counseling
89133158|NCT02819388|No Intervention|Control|Control group without counseling
89133159|NCT04189692||Patients with Inflammatory Bowel Disease and fatigue|Patients with Inflammatory Bowel Disease and fatigue that participated in the two studies (1,2).
89133160|NCT05658588|Experimental|Hemoperfusion and CKRT in pediatric septic shock|Hemoperfusion with Cytosorb in combination with CKRT
89133161|NCT02818296|Experimental|Active IU CBM-I|This paradigm was designed to train individuals to endorse benign interpretations of ambiguous information and reject negative/threatening interpretations of ambiguous information. Participant's baseline interpretation bias was measured at baseline. Participants then underwent two training phases in which their responses were either reinforced (i.e., they were told they were correct) or punished (i.e., they were told that they were incorrect). Interpretation bias was measured again at post-training.
89133162|NCT02818296|Sham Comparator|Control CBM-I|This paradigm was identical to the active condition except that the word/sentence pairings used were not relevant to IU and/or anxiety.
89133163|NCT02818374|Experimental|Disabled People with behavioral trouble|
89133164|NCT02819466||volunteers|Healthy volunteers over the age of 18 years employed by Amiens University Hospital 3D echography
89133165|NCT00633906|Experimental|1|HORIZONS HIV Intervention. Two-session, group-based interactive intervention.
89133166|NCT00633906|Active Comparator|2|Enhanced standard-of-care session. One hour, video-based and brief discussion.
89133167|NCT02819076||Painless Children|30 children
89133168|NCT02819076||Painful Children|70 children
89133169|NCT02818140|Active Comparator|Ropivacaine TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml of ropivacaine 0.75%
88802627|NCT05586854|Experimental|end-stage renal disease patients with heparin-induced thrombocytopenia|The research procedure consists of dialysing patients on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol. This protocol of decrease is done over a period of about 6 months divided into 4 periods.
89133170|NCT02818140|Placebo Comparator|Placebo TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml saline 0.9%
89133171|NCT02818452|Experimental|Oatmeal containing beta-glucan|27 g oatmeal
89133172|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 1|27.72g oatmeal
89133173|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 2|28.43g oatmeal
89133174|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 3|29.86g oatmeal
89133175|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 4|32.72g oatmeal
89133176|NCT02818452|Placebo Comparator|Hot Cereal - Cream of Rice|20g oatmeal
89133177|NCT04238208|Active Comparator|Group LL|Group LL patients received the 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm containing 700 mg of Lidocaine for 60 minutes
89133178|NCT04238208|Placebo Comparator|Group LP|Group LP received an identical placebo patch
89133179|NCT04238208|Experimental|Group LC|Group LC received the 8% Capsaicin patch [8% w/w] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK).
89133180|NCT04238286|Experimental|Dry needling group|Patients treated with dry needling
89133181|NCT04238286|Sham Comparator|Sham group|Patients treated with a simulated dry needling
89133182|NCT04238286|No Intervention|Control|Patients never treated
89133183|NCT02816502|Experimental|Stress Management Skill Building Program A|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
89133184|NCT02816502|Active Comparator|Stress Management Skill Building Program B|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
89133185|NCT02816112|Active Comparator|Ciprofloxacin|Oral tablet taken twice a day at home starting 5 days after chemotherapy for 14 days for every cycle of TC
89133186|NCT02816112|Active Comparator|G-CSF|Daily injection at home for the number of days as chosen by the treating physician
89133187|NCT04238130||Perioperative ctDNA Dynamic Monitoring Group|Samples were obtained at multiple pre-specified time points including before surgery (plasma samples)，during surgery after tumor resection (tumor samples) and after surgery(plasma samples were obtained every 6 months from ctDNA positive patients at baseline in the following 2 years)
89234112|NCT00378898|Sham Comparator|EGD with sham BRAVO capsule placement|Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
89133188|NCT02818062||Endophthalmitis|The diagnosis of endophthalmitis was made on the basis of clinical features including pain, decreased visual acuity (VA), diffuse bulbar conjunctival hyperaemia, chemosis, inflammation of the anterior segment and posterior segment inflammation (all patients had vitreous infiltration diagnosed by biomicroscopy or ophthalmic ultrasound).
89133189|NCT02818062||Cataract (Control)|Controls were patients who underwent cataract surgery.
89133190|NCT02815722|Active Comparator|SP2086 and Simvastatin|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from A stage to B stage.
89133191|NCT02815722|Active Comparator|Simvastatin and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from B stage to A stage.
89133192|NCT04238442|Experimental|BP oscillometric measurement|Oscillometric BP measurement
89133193|NCT00634218|Active Comparator|1|Mail-based Self Help (MSH) treatment. Participants will receive the self-help manual developed specifically for LGBT smokers.
89133194|NCT00634218|Active Comparator|2|Mail-based Self Help plus an Internet-based Smoking Treatment (IST). In the IST condition, participants will receive the manual plus access to an Internet-based intervention that includes social support.
89133195|NCT00634218|Active Comparator|3|Mail-based Self-Help plus Telephone Counseling (TC). In the TC condition, participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions.
89133196|NCT00634218|Active Comparator|4|Mail-based Self-Help plus an Internet-based Intervention plus Telephone Counseling. Participants will receive a self-help manual, have access to an internet-based smoking treatment and participante in 6 telephone counseling sessions.
89133197|NCT04237818|Placebo Comparator|Placebo drink|
89133198|NCT04237818|Experimental|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|
89133199|NCT04237740|Experimental|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight < 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
89133200|NCT00634296|Active Comparator|G2|Inspiratory muscle training added by aerobic training to aerobic training alone
89133201|NCT02816034|Experimental|Experimental Explicit|Cannabis user performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
88802628|NCT05586386|Experimental|Cherry group|Obese adults were asked to consume 200 mL of DSC juice supplemented with 3g of DSC powder twice / day for 30 days.
88802629|NCT05586386|Experimental|Placebo group|Obese adults were asked to consume 200 mL of placebo juice supplemented twice / day for 30 days.
89133202|NCT02816034|Active Comparator|Control Explicit|Healthy subject performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
89133203|NCT02816034|Experimental|Experimental Implicit|Cannabis user performs visuo-motor rotation tasks without being informed of the explicit strategy
89133204|NCT02816034|Active Comparator|Control Implicit|Healthy subject performs visuo-motor rotation tasks without being informed of the explicit strategy
89133205|NCT02817984|Experimental|Treatment Group|Participants (n=10) will be enrolled and assigned chronologically to one of five excision time points: Weeks 2 (n=10), 4 (n=2), 6 (n=2), 8 (n=2), and 12 (n=2) post-injection. Implants will be injected on Day 0. All participants will be administered up to five (5) 2 milliliter (mL) subcutaneous injections of acellular adipose tissue (AAT) via sterile injection into the area identified for planned excision. Total injected AAT volume per patient will not exceed 10 mL.
89133206|NCT02817750|Experimental|zolpidem hemitartarate (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
89133207|NCT02817750|Experimental|zolpidem hemitartarate (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
89133208|NCT02817672|Active Comparator|PRIME 1.0|8 weeks use of PRIME 1.0 (current version). Mobile application designed to improve psychosocial functioning and motivational deficits.
89133209|NCT02817672|Experimental|PRIME 2.0|8 weeks use of PRIME 2.0 (version with the NLP-powered dashboard). Mobile application designed to improve psychosocial functioning and motivational deficits.
89133210|NCT02815410|Other|Levetiracetam|Newly diagnosed histologically proven supratentorial glioblastoma patients received levetiracetam during and after their CCRT
89133211|NCT02817438|Experimental|Online Intervention|Participants randomized to the online intervention arm will be given access to the Good Days Ahead program for 12 weeks.
89133212|NCT02817438|No Intervention|Waitlist|Participants randomized to the waitlist arm will wait for 12 weeks without doing an online intervention.
89133213|NCT02814630|Other|Open-label Xolair|"The patients will receive one subcutaneous injection of omalizumab at a dose of 300 mg on Days 1, 30, and 60.~There is no control drug."
89133214|NCT04295382|Experimental|Software Application|
89133215|NCT02816268|Other|Conventional Pulmonary vein isolation|Conventional pulmonary vein isolation was gained by using an irrigated tip ablation catheter
89133216|NCT02816268|Other|Contact force pulmonary vein isolation|Contact force was meassured by using the SMART-Touch ablation catheter (Biosense-Webster®)
89133217|NCT00619957|Placebo Comparator|1|Placebo tablet once a week for 2 years followed by once a week Risedronate for 2 years
89133218|NCT00619957|Experimental|Risedronate|35 mg risedronate tablet once a week for 2 years followed by open label 35 mg risedronate once a week for 2 years
89133219|NCT02815956|Experimental|percutaneous tibial nerve stimulation (ST)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.~The protocol of stimulation is the same, that the one performed for fecal incontinence."
89133220|NCT02815956|Placebo Comparator|placebo (P)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.~The device delivers ineffective impulses."
89133221|NCT02815878|Experimental|Group 1: Intervention with Disability|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
89133222|NCT02815878|Active Comparator|Group 2: Intervention without Disability|Participants without a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
89133223|NCT02815878|No Intervention|Group 3: No intervention|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older complete pre and post outcome assessments.
89133224|NCT02815800|Experimental|ETHNODYNE VISIO|Administration 2 times a day of a dietary supplement, as add on therapy, in patients with Parkinson s disease
89133225|NCT00851149||1/10|Abdominal aortic surgery patients
89133226|NCT00851149||2/10|Total hip replacement patients
89133227|NCT00961415|Experimental|Part 1|
89133228|NCT00961415|Experimental|Part 2A|
89133229|NCT00961415|Active Comparator|Part 2B|
89133230|NCT00836329|Experimental|Intensive Glucose Management|Participants will receive intensive glucose management.
89133231|NCT00836329|Active Comparator|Traditional Glucose Management|Participants will receive a traditional method of glucose management.
89133232|NCT04237662|Experimental|Test Group|"Root Instrumentation + Enamel Matrix Derivative Application~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
89133233|NCT04237662|Active Comparator|Control Group|"Root Instrumentation~Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one- stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour."
89133234|NCT02815488|Experimental|CHF6297 Active|
89133235|NCT02815488|Placebo Comparator|Placebo|
89133236|NCT00851227|Experimental|1. Mildly Hepatic Impaired Subjects|
89133237|NCT00851227|Experimental|2. Moderately Hepatic Impaired Subjects|
89133238|NCT00851227|Experimental|3. Subjects with Normal Hepatic Function|
89133239|NCT00850837|Experimental|1|Participants will apply Acidform lubricant twice daily for 14 consecutive days between menses
89133240|NCT00850837|Placebo Comparator|2|Participants will apply HEC gel twice daily for 14 consecutive days between menses
89133241|NCT00850915|Other|1|in this arm contacts of enrolled TB-HIV index cases were actively approached and screened for TB and offered HIV testing by CHW at their homes
89133242|NCT00850915|Other|2|no interventation was done in this group, they received the regulare care and follow up following NTP guidelines
89133243|NCT02811276|No Intervention|Control Group|Those assigned to the Control Group will receive a eucaloric diet (a diet designed to meet the person's energy needs and maintain body weight) composed of 55% of carbohydrate, 15% of protein, and 30% of lipid.
89133244|NCT02811276|Experimental|High-Protein Diet Group|Those assigned to the High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®).
89133245|NCT02814240|Experimental|Pituitary gland failure|
89133246|NCT00851305|Experimental|1 confocal laser endomicroscopy|Targeted biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by confocal laser endomicroscopy.
89133247|NCT00851305|Active Comparator|2 Conventional endoscopy|Routine biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by conventional endoscopy.
89133248|NCT00963599|Experimental|1|montelukast/loratadine
89133249|NCT00963599|Experimental|2|loratadine
89133250|NCT00963599|Experimental|3|montelukast
89133251|NCT00963599|Placebo Comparator|4|placebo
89133252|NCT00851383|Experimental|Group A|Ad35-GRIN/ENV: 2x10^9 vp
89133253|NCT00851383|Experimental|Group B|Ad35-GRIN/ENV: 2x10^10 vp
89133254|NCT00851383|Experimental|Group C|Ad35-GRIN/ENV: 2x10^11 vp
89133255|NCT00851383|Experimental|Group D|Ad35-GRIN at 1x10^10 vp
89133256|NCT02814006|Experimental|every other day|participants will visualize educational video with timed intercourse as recommended by NICE and ASRM
89133257|NCT02814006|Experimental|fertile window|participants will visualize educational video with timed intercourse as recommended by well-know evidence of better conception rates when using this strategy
89133258|NCT02814006|No Intervention|CG|participants will respond to questionnaire with no knowledge of intervention
89133259|NCT04285385|Experimental|Aromatherapy|0.10 ml of lavender essential oil 30 minutes prior surgery
89133260|NCT04285385|Sham Comparator|Sham Aromatherapy|0.10 ml mineral oil 30 minutes prior surgery
89133261|NCT04016467|Experimental|Thoracic Manipulation (ThM)|Will undergo spinal manipulation between pain assessment pre and post.
89133262|NCT04016467|Sham Comparator|Sham thoracic treatment (ThS)|Sham manipulation between pain assessment pre and post
89133263|NCT02811120||single arm|single venepuncture
89133264|NCT04264169||• Study group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will be complicated by placenta accreta spectrum
89133265|NCT04264169||• Control group|100 patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one cesarean delivery and the current pregnancy will not be complicated by placenta accreta spectrum
89133266|NCT00836797||1 Case with scaffold|This group of patients will be having a placement of PLGA bioscaffold in the alveolar socket after teeth extraction
89133267|NCT00836797||2 Control without scaffold|The Alveolar socket will be left to heal and no treatment/scaffold placement will be done
89234113|NCT01045720|Placebo Comparator|Placebo Comparator|
89133268|NCT02862821|Experimental|validation of EEfRT task|20 healthy volunteers will be recruted to validate motivation EEfRT task which is adaptated to HR-EEG
89133269|NCT02862821|Experimental|biomarkers identification|20 addict online poker gamblers and 20 non-addict online poker gamblers will be recruted : After standardized questionnaires to define the socio-demographic data, the diagnosis of gambling addiction (Diagnostic and Statistical Manual of Mental Disorder 5th edition DSM-5), screening for comorbidities addictive, the level of anxiety and impulsivity, brain acvtivity will be registred (by randomisation between the 2 tasks) with HR-EEG: during the performance of a task of motivation evaluation laboratory (EEfRT) adaptated for high-resolution electroencephalography AND during a laboratory task that assesses decision making in conditions of uncertainty (IGT) with its version for high-resolution electroencephalography has already been validated in a previous study (Giustiniani et al., 2015).
89133270|NCT02862821|Experimental|biomarkers validation|13 online poker gamblers will be recruted, independently of their dependance profile and they will realize the same task that in precedent arm (quaestionnaires and 2 tasks adaptated to HR-EEG).
89133271|NCT04205136|Experimental|Spironolactone|Dose of 25 mg daily that may be titrated up to 50 mg daily, if tolerated and will receive treatment as usual for obstructive sleep apnea.
89133272|NCT04205136|Placebo Comparator|Placebo|Placebo and will receive treatment as usual for obstructive sleep apnea.
89133273|NCT00851539|No Intervention|Control|Participants received counseling from a live counselor.
89133274|NCT00851539|Experimental|Video|Behavioral Intervention Video
89133275|NCT02815332|Placebo Comparator|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
89133276|NCT02815332|Experimental|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
89133277|NCT02815332|Experimental|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
89133278|NCT00923923|Experimental|levels of stress|
89133279|NCT02811042|Active Comparator|Oropharyngeal leak pressure|Ambu AuraOnce
89133280|NCT02811042|Experimental|Fiberoptic position|Ambu AuraGain
89133281|NCT02811354|Experimental|AZD9291|Patient will be treated with AZD9291 at a starting dose of 80mg once a day until the patient completes the study, withdraws from the study or closure of the study. A cycle of treatment is defined as 28 days of once daily AZD9291 treatment. Patients may continue to receive AZD9291 until objective disease progression (determined by RECIST 1.1) or if the subject is no longer receiving clinical benefit in the Investigator's opinion.
89133282|NCT04285398|Other|Study Group 1|Four years follow up of patients with ophthalmic examination.
89133283|NCT04285398|Other|Study Group 2|Four years follow-up of patients with ophthalmic examination and mobility testing.
89133284|NCT02813772|Experimental|group 1|Patients with infantile colics who will receive the milk formula NAN Sensitive, Nestlè
89133285|NCT02813772|Active Comparator|group 2|Patients with infantile colics who will receive the milk formula NAN Optipro, Nestlè
89133286|NCT02814942||Heart Failure receiving CRT|Heart failure patients with QRS > 120ms receiving CRT
89133287|NCT02810808|Experimental|Ranibizumab 0.5 mg 1+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization in the 11 month treatment period Intervention: Drug: Ranibizumab
89133288|NCT02810808|Active Comparator|Ranibizumab 0.5 mg 3+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization after three Monthly intravitreal injections of the same dose.
89133289|NCT00619801|Placebo Comparator|Placebo|
89133290|NCT00619801|Experimental|Levocetirizine|
89133291|NCT02815020|Other|Boot Camp Translation|"Boot Camp Translation is rolled out in a stepped wedge design across participating PBRNs to assist practices with SMS implementation. The Boot Camp Translation intervention initiates practices to review and begin uptake and implementation of tools from the AHRQ Self-Management Support tool library."
89133292|NCT04237506|Experimental|Intervention group|All participants in this group will take the one-hour ballet dance class twice per week for six weeks
89133293|NCT02545777|Active Comparator|treatment group|Take oral medicine of tonifying spleen and descending turbid, one bag each time, two times a day, continuous treatment for 10 days.The onset of the joints afford steeping washing and wet wrapping medicine of descending turbid and clearing heat, once per day, continuous treatment for 10 days.
89133294|NCT02545777|Active Comparator|Control group|Take diclofenac sodium enteric-coated, 50 mg, three times a day, continuous treatment for 10 days.
89133295|NCT00851617|Experimental|IMT Group|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
89133296|NCT00851617|No Intervention|Control Group|Patients were evaluated until weaning without interventions
89133297|NCT02810886|Experimental|Single, arm exploratory|Patients will undergo a 68Ga-PSMA PET/CT within 1 month after routine imaging diagnostic work-up.
89133298|NCT00851695||Asthma|All 1024 participants of the Childhood Asthma Management Program, who provided blood samples.
89133299|NCT00851695||Asthma in Hispanics|All 616 subjects in the Genetic Epidemiology of Asthma in Costa Rica who have serum.
89133300|NCT00851695||Lung function and lung function decline|626 subjects from the Normative Aging Study who have serum and lung function.
89133301|NCT00634374|No Intervention|1|Oral Syringe
89133302|NCT00634374|Active Comparator|2|Rx medibottle
89133303|NCT00962741|Experimental|1|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
89133304|NCT00851773|Experimental|A|
89133305|NCT00851773|Experimental|B|
89133306|NCT00851773|Experimental|C|
89133307|NCT00851773|Experimental|D|
89133308|NCT00851773|Experimental|E|
89133309|NCT00851773|Placebo Comparator|F1|
89133310|NCT00851773|Placebo Comparator|F2|
89133311|NCT00851773|Placebo Comparator|F3|
89133312|NCT00851773|Placebo Comparator|F4|
89133313|NCT00851773|Placebo Comparator|F5|
89133314|NCT04376112|Active Comparator|Standard of Care|
89133315|NCT04376112|Experimental|Pharmacist Intervention|
89234114|NCT01045720|Experimental|ChinesMed|
89234115|NCT00992550|Experimental|Hookah visit, then cigarette visit|4-day inpatient stays for profile of biomarker excretion
89234116|NCT00992550|Experimental|Cigarette visit, then Hookah visit|4-day inpatient stay for profile of biomarker excretion
89133316|NCT02813304|Experimental|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction (see Table 1). In a sitting position (with folded towel between body and arm), participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand (the uninvolved side) will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force; practice during the meeting with the treating physiotherapist using EMG recording) over five seconds.
89133317|NCT02813304|Active Comparator|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap and a towel cloth. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
89133318|NCT00851929|Experimental|sarcoidosis associated pulmonary hypertension|sarcoidosis associated pulmonary hypertension
89133319|NCT02813460|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliters (mL) of each 6 ALS-008176 formulations A B F C E D on day 1.
89133320|NCT02813460|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations B C A D F E on day 1.
89133321|NCT02813460|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations C D B E A F on day 1.
89133322|NCT02813460|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations D E C F B A on day 1.
89133323|NCT02813460|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations E F D A C B on day 1.
89133324|NCT02813460|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations F A E B D C on day 1.
89133325|NCT02813460|Experimental|Session 2: Sequence 1|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G1 G2 H3 G3 H2 H1).
89133326|NCT02813460|Experimental|Session 2: Sequence 2|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G2 G3 G1 H1 H3 H2).
89133327|NCT02813460|Experimental|Session 2: Sequence 3|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G3 H1 G2 H2 G1 H3).
89133328|NCT02813460|Experimental|Session 2: Sequence 4|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H1 H2 G3 H3 G2 G1).
89133329|NCT02813460|Experimental|Session 2: Sequence 5|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H2 H3 H1 G1 G3 G2).
89133330|NCT02813460|Experimental|Session 2: Sequence 6|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H3 G1 H2 G2 H1 G3).
89133331|NCT02813538||IGC and thromboelastometry|Patients that have hyper, normo o hypcoagulability measured by tromboelastometry and anticoagulant proteins levels early after major liver resection and clinical evolution and patients with liver funcion impairment or without it, measured by indocyanine green clearance early after surgery and clinical evolution
89133332|NCT02813382||B-group|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
89133333|NCT02813382||C-group|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
89133334|NCT02813382||P-group|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
89133335|NCT00619645|Other|RIST for Heme malignancies|Busulfan 3.3 mg/kg over 3 hours on day -6 and day -5 Fludarabine 30 mg/m2 IV over 30 minutes on day -6 to day -2 followed by Transplant followed by Immunosuppressive/GVHD therapy
89133336|NCT02810730|Other|Single arm|Pancreatic MRI in the 6 months following the first consultation
89133337|NCT02861027|Active Comparator|PPTHA|Control Group performs the PPTHA.
89133338|NCT02861027|Experimental|FES and PPTHA|The Intervention Group performs the PPTHA associated with FES.
89133339|NCT00852007|Experimental|DC-Tn-MUC|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1. 1.2 x 10e7 dendritic cells per dose. 5 administrations (doses)may be given in total.
89133340|NCT02810574|Active Comparator|Active noninvasive brain stimulation and cognitive training|In active condition, subject will receive stimulation during all the 30-minute stimulation period combined with cognitive training.
89133341|NCT02810574|Sham Comparator|Sham noninvasive brain stimulation|In sham condition, subject will receive stimulation only during the first 30 seconds of the 30-minute stimulation period combined with cognitive training.
89133342|NCT02545699|Experimental|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
89133343|NCT02545699|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
89133344|NCT02810262||First bone metastasis of adenocarcinoma lung cancer|Patients entering the group have a suspected first bone metastasis of adenocarcinoma lung cancer and should undergo bone biopsy to histologically prove the diagnosis.
89133345|NCT00852085|Experimental|Group MI|Four group counseling sessions and a directed observational visit to the emergency department of a busy urban hospital
89133346|NCT00852085|Active Comparator|Enhanced community service|
89133347|NCT02545855|Experimental|Arm A (myAIRVO2® + HOT, HOT)|Subjects will receive the myAIRVO2® therapy plus HOT for week 1-6 and HOT only for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
89133348|NCT02545855|Experimental|Arm B (HOT, myAIRVO2® + HOT)|Subjects will receive HOT only for week 1-6 and the myAIRVO2® therapy plus HOT for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
89133349|NCT00852163|Experimental|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
89133350|NCT00851071|Active Comparator|Cognitive Behavioral Therapy|Three individual 45 minute cognitive behavioral therapy sessions over a 3 month period
89133351|NCT00851071|No Intervention|Usual Care Arm|The Usual Care Arm will be the control arm. These patients will not be scheduled with any CBT sessions.
89133352|NCT04237038|Experimental|laparoscopic Nissen fundoplication short gastric vessel divi|Randomized clinical trial conducted in forty patients submitted to short gastric vessel division (SGVD) forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life.
89133353|NCT00855517|Experimental|Punctal Plug|
89133354|NCT02690220|Other|surgical mesh implantation|Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally. Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.
89133355|NCT00855673|Experimental|Active|Active group receiving intermittent compression
89133356|NCT00855673|Active Comparator|Control|Standard Medical Treatment
89133357|NCT02814864|Experimental|Mesenchymal Stromal Cell (MSC)|Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)
89133358|NCT00855829|Active Comparator|Miniature Actilady device active|one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
89133359|NCT00855829|Sham Comparator|Miniature Actilady device not active|Sham Comparator: one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
89133360|NCT02810496|Experimental|patient|
89133361|NCT00855907||cases|IBD patients above the age of 18 years old, suffering from the disease for at least one year.
89133362|NCT00855985|Active Comparator|1|Pancreaticojejunostomy for reconstruction after pancreaticoduodenectomy
89133363|NCT00855985|Active Comparator|2|Pancreaticogastrostomy for reconstruction after pancreaticoduodenectomy
89133364|NCT02815176||Central serous chorioretinopathy|De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
89133365|NCT02815176||Polypoidal choroidal vasculopathy|De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
89133366|NCT02815176||Epiretinal membrane|Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
89133367|NCT02809794|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
89133368|NCT02814474|Placebo Comparator|SALINE|Infusion of saline (0.9 %)
89133369|NCT02814474|Experimental|KETONE|Infusion of Na-3-Hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
89133370|NCT02812836|Other|Manometry|All patients will be investigated by anorectal manometry and after the procedure with balloon expulsion test as previously described.
89133371|NCT02544919|No Intervention|Control group|No Intervention group: Patients do not receive any lipid emulsion of any type during the study period
89133372|NCT02544919|Active Comparator|SMOF Group|Intervention Group: Patients receive 1 gm.kg.day-1 SMOFlipid for 48 hours before the operation and 5 days post-operatively.
89133373|NCT02812914|Experimental|Phase 1|In Phase I, 25 pregnant women will receive a low-cost gas stove and will be taught by peer educators in group classes how to safely use gas stoves and how to reduce exposure to air pollution.
89133374|NCT02812914|Experimental|Phase 2|In Phase 2, the investigators will assess a more resource-intensive behavioral intervention approach with a different group of 25 women who will follow the same study procedures described in Phase I.
89133375|NCT00818259|Experimental|Part IA-fosaprepitant 115 mg/aprepitant|Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
89133376|NCT00818259|Experimental|Part IB-fosaprepitant 150 mg|Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
89133377|NCT00818259|Experimental|Part IIA-aprepitant 80 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to <12 years of age - 47 mg/m^2; 4 months to <6 months of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
89133378|NCT00818259|Experimental|Part IIB-aprepitant 125 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to <12 years of age - 74 mg/m^2; 6 months to <2 years of age - 1.3 mg/kg; 4 months to <6 months of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; birth to <1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
89133379|NCT00818259|Active Comparator|Part III-ondansetron|Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to <12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.
89133380|NCT00818259|Experimental|Part IV-aprepitant regimen|Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; Birth to <1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; Birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.
89133381|NCT00818259|Experimental|Part V-fosaprepitant regimen|Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to <12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
89234117|NCT05354700|Experimental|HLX07+HLX10+Chemotherapy|HLX07+HLX 10+Chemotherapy (Carboplatin-Etoposide)
89234118|NCT03339258|Experimental|Doxazosin Mesylate, Extended Release|Subjects will undergo a 4-week titration phase during which doxazosin may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study medication for a 4-week stable dose phase.
89234119|NCT03339258|Placebo Comparator|Placebo|Subjects will undergo a 4-week titration phase during which the placebo may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study placebo for a 4-week stable dose phase.
89234120|NCT04002570||GROUP I/GROUP I bis|20 breast cancer patients who performed radiotherapy treatment
89234121|NCT04002570||GROUP II|maximum 10 patients who performed radiotherapy and chemotherapy and/or immunotherapy and/or neo-adjuvant hormone therapy or/and adjuvant immunotherapy/hormone therapy.
89234122|NCT04002570||CONTROLS GROUP|healthy women with +/- 5 years compared to breast cancer patients age
89234123|NCT00992628|Active Comparator|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
89234124|NCT00992628|Active Comparator|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
89234125|NCT00378508|Experimental|1|The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2 over a 14 day treatment period.
89234126|NCT00378508|Placebo Comparator|2|Normal saline infusion
89234127|NCT02534740|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
89234128|NCT02534740|Experimental|48.8 mg tafamidis soft gel capsule formulation 1|
89234129|NCT02534740|Experimental|48.8 mg tafamidis soft get capsule formulation 2|
89234130|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 1|
89234131|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 2|
89234132|NCT01580956|Other|VARIABLE-PSV ventilatory mode|
89234133|NCT01580956|Other|STANDARD-PSV ventilatory mode|
89234134|NCT00454779|Experimental|Arm 1|Panitumumab + Docetaxel + Cisplatin
89234135|NCT00454779|Other|Arm 2|control
89234136|NCT00992862|Experimental|Moexipril HCl 15mg Tablets|
89234137|NCT00992862|Active Comparator|Univasc® 15mg Tablets|
89234138|NCT00992940|Experimental|Patient-Controlled Sedation/Analgesia|Patient controls the amount of sedation and analgesia delivered, according to their own requirements.
89234139|NCT00992940|Active Comparator|Anesthetist-Controlled Sedation/Analgesia|Patient sedation and analgesia requirements are delivered by the anesthetist.
89234140|NCT02416206|Experimental|BeEAM|Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma
89234141|NCT00993096|Experimental|IDegAsp low|
89234142|NCT00993096|Experimental|IDegAsp middle|
89234143|NCT00993096|Experimental|IDegAsp high|
89234144|NCT00993096|Experimental|BIAsp 30 low|
89234145|NCT00993096|Experimental|BIAsp 30 middle|
89234146|NCT00993096|Experimental|BIAsp 30 high|
89234147|NCT00439569|Experimental|Single Arm|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) calculation and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
89234148|NCT00443079|Experimental|Siliphos/Placebo|Received study medication first followed by placebo
89234149|NCT00443079|Experimental|Placebo/Siliphos|Received placebo first followed by study medicaiton
89234150|NCT01033929|Experimental|0.01µg C-Tb|12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
89234151|NCT01033929|Experimental|0.1µg C.Tb|12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
89234152|NCT02188836|Experimental|Electromagnetic device|The electromagnetic stimulation was performed by using a device capable of generating an electromagnetic field around the fracture site. This was applied once a day, one hour for 8 weeks.
89234153|NCT02188836|Placebo Comparator|Placebo device|A device with the same characteristics to the real device, except for the generation of the electromagnetic stimulation. It generates sham stimulation.
89234154|NCT00993174|Experimental|Topical anesthesia|Patients undergo strabismus surgery for esotropia using topical anesthesia (instillation of drops plus gel)
89234155|NCT00993174|Active Comparator|Sub-Tenon's anesthesia|Patients undergo surgery for strabismus (esotropia) using sub-Tenon's administration of anesthetic (xylocaine)
89234156|NCT02088372||Vanguard with E1 PS Bearing|"E1™ Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty.~Vanguard Total Knee System™ The Vanguard™ Knee System was designed to incorporate features from prior designs, including: ACG, Maxim, & Ascent."
89234157|NCT05348616||pre Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2013-2020 winter epidemic"
89234158|NCT05348616||Per-Covid-19 cohort|"Children hospitalized in the Pediatric Department of the  Hôpital Femme Mère Enfant , Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, 2023-2024 and 2024-2025 epidemics. The need for continuation of the study will be reassessed after each season."
89234159|NCT00993330||1|20 healthy subjects between 18 and 40 years
89234160|NCT00993330||2|20 healthy subjects between 41 and 50 years
89234161|NCT00993330||3|20 healthy subjects between 51 and 60 years
89234162|NCT00993330||4|20 healthy subjects between 61 and 70 years
89234163|NCT00993330||5|20 healthy subjects between 71 and 80 years
89234164|NCT00993330||6|20 healthy subjects between 81 and 90 years
89234165|NCT02553915|Placebo Comparator|Placebo|Soybean oil placebo capsules, 4 capsules daily for 12 weeks
89234166|NCT02553915|Experimental|EPA 1 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
89133382|NCT02810028|Experimental|ACT + Standard Medical Care (SMC)|This consists of 4 self-guided psycho-education modules supported by weekly telephone contact with a health professional trained in Acceptance and Commitment Therapy (ACT). Standard medical care will be provided as usual.
89133383|NCT02810028|No Intervention|Standard Medical Care (SMC)|All participants will receive SMC. As such, they will receive all the treatment and support they would otherwise receive outside of a research trial including a personalised assessment from the physiotherapist.
89133384|NCT02809950|Experimental|oral carbohydrate beverage group|
89133385|NCT02809950|Placebo Comparator|control group|
89133386|NCT02809872||Study Group|Study Group with Pleural effusion for any cause and receiving chest CT scan and thoracic Ultrasounds.
89133387|NCT00913575|Experimental|preoperative neuromuscular training|preoperative neuromuscular training
89133388|NCT00913575|Placebo Comparator|education|knee school
89133389|NCT02809638||DVT of the lower limbs|patients with first suspected episode of unprovoked DVT of the lower limbs and patients with episode of unprovoked DVT of the lower limbs at third month of follow-up
89133390|NCT04162548||cardio-relay|"Cardio-relay is a novel collaboration model between hospital-based specialists and primary care, to provide high-quality care to frail patients, relieving their burden to attend multiple hospital specialist visits.~Using telemedicine, it is possible to make measurements where the patient is (at the family clinic at the patient's home). Data are available for all the involved. That is, primary the patient, the relatives and caregivers that the patient wishes help from and health professionals from the family clinics and the hospital. Thereby, the hospital-based specialist supports the family clinic with expert knowledge, the need for attending the hospital facilities reduced to focus on what is strictly needed as specialized provider. Ultimately, the patient can be reached for high-quality care, relieving the patient's burden to attend multiple hospital specialist visits."
89133391|NCT05578482|Active Comparator|Dicillin & Elocon|20 of the participating patients are randomized to the active arm where systemic dicloxacillin and elocon creme (mometasone furoate 0.1%) is received.
89133392|NCT05578482|Placebo Comparator|Placebo & Elocon|20 of the participating patients are randomized to the placebo arm where placebo and elocon creme (mometasone furoate 0.1%) is received.
88802630|NCT02279654||Lenalidomide Population|Patients with transfusion-dependent, low- or intermediate (int)-1risk MDS and isolated del (5q) who receive at least 1 dose of lenalidomide after 15th June 2007 and have been followed up for on the registry for 3 years or until death/consent withdrawal
89133393|NCT04237428|Experimental|hCD19 CAR-T cells Infusion|
89133394|NCT02809560|Experimental|Asthmatic children|Induced sputum method using hypertonic serum
89133395|NCT02809560|Sham Comparator|Control children|Induced sputum method using hypertonic serum
89133396|NCT00619099|Experimental|1|
89133397|NCT00619099|Experimental|2|
89133398|NCT02812992|Active Comparator|GO-GO arm|Nab-paclitaxel 125 mg/m^2 i.v. over 30 minutes followed by gemcitabine infusion 1000 mg/m^2 on days D1, D8, D15 of a 28-day cycle.
89133399|NCT02812992|Active Comparator|SLOW-GO arm|Gemcitabine 1000 mg/m^2 i.v. on days D1, D8, D15 of a 28-day cycle.
89133400|NCT02812992|Active Comparator|FRAIL arm|Best supportive care as determined by the investigator.
89133401|NCT04018573|Active Comparator|Parent Support Film|Parents will watch Lead with Love, a 35-minute documentary style film designed to provide support, information, and behavioral guidance to parents with a lesbian, gay, or bisexual child. One month later, parents will look over material that reviews the major points of the film. All of this material is presented online via our webapp.
89133402|NCT04018573|Experimental|Parent Support Film + PATHS Sexual Communication Toolkit|Parents in this arm will have the option of watching Lead with Love, and then will engage with our parent toolkit, designed to increase the frequency and quality of parent-child communication about HIV and condoms. One month later, parents will engage with booster content, customized to address their self-reported barriers to communicating with their sons. All of this material is presented online via our webapp.
89133403|NCT02812446||IAI patients group|patients with Staphylococcus aureus of implant-associated infections
89133404|NCT02812446||control group|patients with Staphylococcus aureus nasal carriage
89133405|NCT00856141|Experimental|1. High fluidic parameters|Bottle height varied from 90-110cms, fixed aspiration flow rate 40cc/min, vacuum upto 650mmHg depending on the grade of cataract
89133406|NCT00856141|Active Comparator|2. Low fluidic parameters|Bottle height varied from 70-90cms, fixed aspiration flow rate of 25cc/min, vacuum upto 400mmHg, depending on the grade of cataract
89133407|NCT02812758||patients|All sedated, intubated, mechanically ventilated adult patients admitted for elective cardiac surgery, monitored for sedation depth (with the BIS) and for preload dependence indices (SVV, PPV and PVI) transthoracic echocardiography
89133408|NCT00856219|Active Comparator|Enteral Continuous|Continuous tube feeding for 72 hours.
89133409|NCT00856219|Active Comparator|Enteral Intermittent|Intermittent tube feedings for 72 hours
89133410|NCT00856219|Active Comparator|Parenteral|Parenteral continuously for 72 hours
89133411|NCT02812602|Experimental|Lidocaine patch|The patients was randomly assigned to experimental group or placebo group. In this arm, lidocaine patches will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
89133412|NCT02812602|Placebo Comparator|Placebo|The patients was randomly assigned to experimental group or placebo group. In this arm, a placebo patch will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
89234167|NCT02553915|Experimental|EPA 2 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
89133413|NCT00852319|Experimental|Central Mississippi group|Participants from central Mississippi are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
89133414|NCT00852319|Experimental|Mississippi Delta group|Participants from 18 counties of the Mississippi delta are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
89133415|NCT02809170|Active Comparator|Arginine|Endothelial function will be assessed before and after arginine supplementation
89133416|NCT02809170|Active Comparator|Citrulline|Endothelial function will be assessed before and after citrulline supplementation
89133417|NCT00837109|Experimental|1|Imagery Rescripting Nightmare Treatment
89133418|NCT00837109|Active Comparator|2|Treatment-as-usual in the Trauma Recovery Program
89133419|NCT02809326|Experimental|17 week Trauma Management Therapy (TMT)|TMTconsists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions (14 sessions) are followed by Social and Emotional Regulation (SER) sessions conducted in small groups. Individual exposure therapy includes virtual reality to assist in augmenting exposure therapy. Group therapy includes anger management, social skills training, problem solving and behavioral activation for depression. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
89133420|NCT02809326|Experimental|3 week Trauma Management Therapy (TMT)|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
89133421|NCT02809326|Active Comparator|17 week Exposure Therapy Control Arm|The Control Arm of the study contains 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
89133422|NCT03848377||Automated EMG/SSEP monitored|"In this study, all patients will be monitored for SSEP and EMG. For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored.~As this is an observational study, no intervention is planned."
89133423|NCT02809248|Active Comparator|coated stent|the patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
89133424|NCT02809248|Active Comparator|uncoated stent|the patient get a uncoated coronary stent implantation (BMS - bare metal stent)
89133425|NCT00837187|Active Comparator|Intravenous dexmedetomidine|Dexmedetomidine is administered intravenously
89133426|NCT00837187|Experimental|Intranasal administration|Dexmedetomidine is administered intranasally
89133427|NCT02809482|Other|Eucaloric Feeding|
89133428|NCT02809482|Other|Overfeeding|
89133429|NCT00962585|Placebo Comparator|Placebo|Placebo
89133430|NCT00962585|Experimental|S-equol 10 mg BID|S-equol 20 mg total daily dose
89133431|NCT00962585|Experimental|S-equol 50 mg BID|S-equol 100 mg total daily dose
89133432|NCT00962585|Experimental|S-equol 150 mg BID|S-equol 300 mg total daily dose
89133433|NCT00856453|Experimental|Yoga classes plus home yoga practic|
89133434|NCT00856453|Experimental|home yoga practice alone|
89133435|NCT04236960|Experimental|18~55 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
89133436|NCT04236960|Experimental|2~17 yrs|1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.
89133437|NCT04236960|Experimental|7~23 mos|2 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between the first and second dose.
89133438|NCT04236960|Experimental|3 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between every two doses.
89133439|NCT04236960|Experimental|2 mos|3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. Two-month interval between every two doses.
89133440|NCT00856531||1|
89133441|NCT00856531||2|
89133442|NCT00856531||3|
89133443|NCT00856531||4|
89133444|NCT00856531||5|
89133445|NCT00856531||6|
89133446|NCT00856531||7|
89133447|NCT00856531||8|
89133448|NCT00856531||9|
89133449|NCT00856531||10|
89133450|NCT00856531||11|
89133451|NCT00856531||12|
89133452|NCT00856531||13|
89133453|NCT00856531||14|
89133454|NCT00856531||15|
89133455|NCT00621985|Experimental|Experimental|Experimental therapy with nocturnal dexamethasone.
89133456|NCT02812368|Experimental|Clonidine|Taken once a day at bedtime; with the dose titrated from 0.05mg to 0.20mg over the course of 6 weeks
89133457|NCT02812368|Placebo Comparator|Placebo (for clonidine)|Taken once a day at bedtime
89133458|NCT02545621||ARDS Group (acute respiratory distress syndrome)|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
89133459|NCT02545621||control group|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
89133460|NCT02547805|Placebo Comparator|Placebo|Five (5) capsules of placebo by mouth (PO) three times per day (TID) with meals
89133461|NCT02547805|Experimental|ALLN-177|Five (5) capsules of ALLN-177 (1,500 units per capsule) PO TID with meals
89133462|NCT02814552|Other|High Blood Pressure Consented|Participants will have the following performed: medical history and blood pressure levels will be collected, and blood samples. Then using the HTN PRA App recommendation regarding standard of care medication dosing will be adjusted for optimal blood pressure control.
89133463|NCT02814552|No Intervention|De-identified historical data|De-identified historical data will be collect based on age (no dates), blood pressure of treated (noted with medications), blood pressure of non-treated (noted without medications), and list of medications. The data will be compared to the High Blood Pressure Consented group to determine the effect of using the HTN PRA App.
89133464|NCT02544841|Experimental|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is the treatment condition. SSI is an in-person, individual-level, clinic-based intervention that aims to reduce risky sexual behaviors among sexually active adolescent females.
89133465|NCT02544841|Active Comparator|Female Sexual Health|Female Sexual Health is the control counterfactual condition. It is an individual-level, information-only sex education program that aims to increase participants' knowledge on various topics related to STIs.
89133466|NCT02861729|Experimental|Suprinity|Vita Suprinity® (VITA Zahnfabrik H. Rauter GmbH & Co.KG- Germany) Zirconia reinforced lithium silicate PCRs
89133467|NCT02861729|Active Comparator|e.max|IPS-e.max® CAD (Ivoclar Vivadent AG, Schaan - Liechtenstein) lithium disilicate PCRs
89133468|NCT02814318||IV Vancomycin|GBS positive laboring women who are allergic to penicillin and clindamycin and are treated using IV vancomycin.
89133469|NCT02814318||IV Penicillin|GBS positive laboring women who are not allergic to penicillin and are treated using IV penicillin.
89133470|NCT02808000|Active Comparator|Group 1 (also called Group A )|Group 1/A will use standard catheter during the first ~6 months (observational period 1). Then the patients in this group will switch to the noble metal alloy urinary catheter (BIP Foley catheter of latex or silicone produced by Bactiguard AB) and be observed for another ~6 months (the second observational period).
89133471|NCT02808000|Experimental|Group 2 (also called Group B)|Group 2/B will use the BIP Foley (latex or silicone) during the first ~6 months (observational period 1). Then the patients in this group will switch to the standard catheter and be observed for another ~6 months (the second observational period).
89133472|NCT03312257|Experimental|Multifocal D +2.50 add & 0.01% atropine|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power; the 0.01% atropine is a low-dose atropine."
89133473|NCT02812134||anorexic|
89133474|NCT00856687|Experimental|PF-03893787|
89133475|NCT00856687|Placebo Comparator|Placebo|
89133476|NCT00856687|Active Comparator|Montelukast|
89133477|NCT02862665|Experimental|IV iron|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
89133478|NCT02862665|Placebo Comparator|Control|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
89133479|NCT02807922|Active Comparator|Zopiclone|Zopiclone six nights
89133480|NCT02807922|Placebo Comparator|Placebo|Placebo six nights
89133481|NCT04285073|Experimental|Paclitaxel-eluting graft|Single-arm
89133482|NCT00861445|Experimental|1|
89133483|NCT00861445|Placebo Comparator|2|
89133484|NCT04284059|Active Comparator|vitamin AD group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin A 6000 IU/day and vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks.
89133485|NCT04284059|Experimental|vitamin D group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive vitamin D 2100 IU/day supplementation in addition to methylphenidate for 8 weeks. After the study, vitamin D group will be administrated with vitamin A on the basis of serum retinol concentration after the study.
89133486|NCT04284059|Placebo Comparator|placebo group|The patients aged 6-12 with a diagnose of ADHD of this group is deficient or insufficient in vitamin A and vitamin D. They will receive placebo once a day in addition to methylphenidate for 8 weeks. After the study, the placebo group will be prescribed with vitamin A and vitamin D supplementation on the grounds of retinol and 25 (OH)D concentration.
89133487|NCT00856765|Experimental|1|Drug eluting balloon followed immediately by implantation of bare metal stent
89133488|NCT00856765|Active Comparator|2|Drug eluting stent
89133489|NCT00856765|Active Comparator|3|Bare metal stent
89133490|NCT03242447|Experimental|e-Practice Self-Regulation (e-PS-R)|e-Practice Self-Regulation (e-PSR) is the treatment condition. e-PS-R is a 'blended learning' intervention, combining online and face-to-face instruction. e-PS-R aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
89133491|NCT03242447|Active Comparator|Video Health Group|The Video Health Group is the control counterfactual condition. Youth assigned to the control group will view a video on a non-sexual health topic (the hazards of smoking).The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes. The informational video uses both narration and interviews to educate viewers on the dangers that cigarettes pose.
89133492|NCT00861523|Active Comparator|1. thiamine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive thiamine IV
89133493|NCT00861523|Active Comparator|2. promethazine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive promethazine IV
89133494|NCT02811978|Experimental|Group 1 : Intravenous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib intravenously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
89133495|NCT02811978|Experimental|Group 2 : Subcutaneous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib subcutaneously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
89133496|NCT00630149|Experimental|1|
89133497|NCT02812056|Experimental|Alisertib + TAK-228|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase:~Alisertib and TAK-228 taken at the maximum tolerated dose from Dose Escalation Phase."
89133498|NCT04283825|Experimental|Humanistic care|In addition to routine therapy, the combinations of different psychological and physical rehabilitation activities will be applied to the patients.
89133499|NCT04283825|No Intervention|Non-humanistic care|Patients only receive routine therapy.
89133500|NCT04042207|Active Comparator|Reference treatment (Open-Loop)|Sensor-augmented pump therapy (SAP) namely the Low Glucose Predictive Suspend system or LGPS and a blinded glucose sensor (Dexcom G6) followed by a 48-week extension period in closed-loop condition
89133501|NCT04042207|Experimental|DBLHU system (Closed-Loop)|DBLHU software (a Model Predictive Control [MPC]-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleido insulin pump followed by a 48-week extension period in closed-loop condition
89133502|NCT04204577|No Intervention|Thermal ablation|Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.
89133503|NCT04204577|Experimental|Thermal ablation combined with apatinib|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take about half an hour after a meal (the daily dose should be as much as possible), and take it with warm water. Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib."
89133504|NCT04204577|Experimental|Ablation combined with apatinib and PD-1 antibody SHR-1210|"Taking standard thermal ablation treatment. Its specific number and time interval depend on the patient's own condition and disease.~Oral apatinib mesylate tablets, 250 mg, orally once a day. Take it with warm water about half an hour after a meal (the daily dose should be as much as possible). Apatinib was discontinued 7 days before each thermal ablation treatment, and after the thermal ablation treatment, the patient's aminotransferase returned to normal and continued to take apatinib.~SHR-1210, 200mg, intravenous infusion for 30 minutes (including the time of the tube,the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks; the first dose with the apatite Simultaneous administration of PD, PD-1 injection is not affected by thermal ablation."
89133505|NCT02809092|Experimental|NK Cells + Chemotherapy Starting|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total. The first group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This will continue for up to 6 dose levels or until the highest tolerable dose of NK cells is found. One (1) to 10 participants will be treated in each dose level.~NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
89133506|NCT04041193|Experimental|SIDERA^B|Behavioral: telerehabilitation activities Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) 5 sessions/week of an individualized telerehabilitation program at home. The sessions will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by the therapist weekly. Each patient's performed session will be reviewed by the therapist.
89133507|NCT04041193|Active Comparator|usual care|Behavioral: paper and pencil activities as usual rehabilitation at home Participants will receive 3months (Chronic Heart Failure) or 4 months (Chronic Obstructive Pulmonary Disease and Parkinson Disease) of a usual rehabilitation program.
89133508|NCT02862587|Experimental|Precision Cells|"precision cells combined with Chemotherapy treatment:~Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood. precision cells：once per 3 weeks with a total of three periods."
89133509|NCT02862587|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
89133510|NCT00852787|Experimental|Low|0.1mg/kg
89133511|NCT00852787|Experimental|Medium|0.4mg/kg
89133512|NCT00852787|Experimental|High|1.6 mg/kg
89133513|NCT00852787|Placebo Comparator|Placebo|
89133514|NCT00634452|Experimental|MDX-1401|MDX-1401 iv at various doses
89133515|NCT02545465||BAY63-2521|Patients who have been switched from a Pulmonary Hypertension treatment to Adempas
89133516|NCT02808936|Experimental|RIPC group|remote ischemic conditioning group with three cycles of ischemia (5 min) / reperfusion (5 min) of upper or lower limb available with automated RIPC machine using blood pressure cuff
89133517|NCT02808936|Sham Comparator|Control group|No remote ischemic conditioning, but blood pressure cuff applied to the upper or lower limb available
89133518|NCT04041271||Nonspecific chronic neck pain (NCNP) group|Subjects with nonspecific chronic neck pain will be included to perform clinical test and assess their jaw kinematics and muscle activation.
89133519|NCT04041271||Control group|Healthy control subjects will be included to compare the differences in jaw kinematics, muscle activation and clinical tests between healthy subjects and subjects with nonspecific chronic neck pain. Subjects in this group will received the same assessment as the NCNP group.
89133520|NCT00961259|Experimental|Fenofibric Acid 35 mg (1 x 35 mg tab)|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
89133521|NCT00961259|Experimental|Fenofibric Acid 105 mg (3 x 35 mg tab)|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
89133522|NCT00961259|Experimental|Fenofibric Acid 105 mg (1 x 105 mg tab)|1 x 105 mg tablet administered after an overnight fast of at least 10 hours
89133523|NCT00852865|Experimental|1|24 healthy volunteers consuming L.farciminis during three weeks
89133524|NCT00852865|Placebo Comparator|2|24 healthy volunteers consuming placebo during three weeks
89133525|NCT02807688|Experimental|Intervention|"Health Promotion Intervention package including elements of psychoeducation on healthy lifestyles and practical sessions of physical activity, with the use of motivational techniques."
89133526|NCT02807688|No Intervention|Control|Control subjects receive treatment as usual at the Community Mental Health Services of the Department of Mental Health.
89133527|NCT00861679|Other|HSCT from matched family or unrelated donors(MD)|HSCT from matched family or unrelated donors(MD) to matched related donors.
89133528|NCT04111926|Experimental|Intervention group|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
89133529|NCT04111926|Placebo Comparator|Control group|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
89133530|NCT04041349|No Intervention|The standard treatment group|The standard treatment group is treated with conventional drugs and cholinesterase inhibitors
89133531|NCT04041349|Experimental|mouse nerve growth factor (mNGF)group|Conventional drugs and cholinesterase inhibitors + mouse nerve growth factor (mNGF) of 20 μg (9000 U)/day for 14 consecutive days by intramuscular injection.
89133532|NCT00961181|Experimental|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
89133533|NCT02807610|Experimental|IV Propofol and IV Etomidate lipuro|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group P Patients received IV Propofol 2mg kg-1 slowly over 60 seconds till Entropy of 40 as a comparator agent in patients undergoing Medical termination of pregnancy(MTP) and Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP
89133534|NCT02807610|Active Comparator|IV Etomidate Lipuro and Placebo|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP and placebo group received normal saline
89133535|NCT00861835|Experimental|ROSE for TBNA|
89133536|NCT00861835|No Intervention|NR|no on-site cytopathology assessment (NR)
89133537|NCT04041661|Experimental|Active tDCS plus gait training group|Participants in Active tDCS plus gait training group will execute Active tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
89133538|NCT04041661|Sham Comparator|Sham tDCS plus gait training group|Participants in Sham tDCS plus gait training group will executeSham tDCS on left dorsolateral prefrontal cortex which combined with treadmill, 12 times per week, least 4 weeks.
89133539|NCT00857077|Placebo Comparator|1 Placebo|
89133540|NCT00857077|Active Comparator|2 Sulfadoxine-pyrimethamine (SP)|
89133541|NCT00629993|Experimental|Multi-component Academic Detailing|"Multi-component, academic detailing regarding ACS guidelines on cervical cancer screening approaches.~Includes an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients."
89133542|NCT02808624|Experimental|Treatment group|this arm will receive L-CARNOSINE PO (each patient will receive 1 tablet daily and each tablet contains 500 mg thus a total of 500 mg per day) together with their chemotherapy wich is oxaliplatin.
89133543|NCT02808624|No Intervention|Control group|This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.
89133544|NCT00857155|No Intervention|Aspirin only|Continue aspirin until surgery
89133545|NCT00857155|Other|Clopidogrel and Aspirin|
89133546|NCT02808546||Case Group|All the patients who were diagnosed as gallbladder stone disease with definite clinical symptoms and underwent cholecystectomy in Cheju Halla General Hospital, Jeju, Korea during 2009-2013
89133547|NCT02808546||Control Group|Control group was determined as 1:1 age-sex matched subjects selected from the participants without GBS among Health Promotion Center in the same institute and periods.
89133548|NCT02544685|Active Comparator|Synbiotics group|"Interventions: administration of Probio-Fix Inum + Beneo Synergy 1~Start of prophylaxis: 5 days before or 2 days after starting chemotherapy~Prophylaxis duration: 3 months"
89133549|NCT02544685|Placebo Comparator|Placebo group|"Interventions: administration of placebo~Start: 5 days before or 2 days after starting chemotherapy~Duration: 3 months"
89133550|NCT02808468|Active Comparator|Brief Cognitive Intervention|One in person session (90 minutes) of trauma focused cognitive therapy followed by 4 weekly coaching calls (20 minutes each) with the same study therapist
89133551|NCT02808468|No Intervention|Assessment Only|Assessment session followed by weekly completion of assessment measures
89133552|NCT04281563|Experimental|the MCT oil massage|The neonates received massage with MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
89133553|NCT04281563|Placebo Comparator|massage alone|The neonates received massage without MCT oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation, which were given three times a day for 7 consecutive days.
89133554|NCT04281563|No Intervention|no massage groups|no intervention
89133555|NCT02811588||Phase1:Screening phase: normocapnic group|Normocapnic COPD patients
89133556|NCT02811588||Phase1;Screening phase: hypercapnic group|Hypercapnic COPD patients
89133557|NCT02811588||Phase1:Treatment phase: control group|Hypercapnic COPD patients in whom NIV is not indicated or who have contraindication(s) for, or refuse, NIV treatment.
89133558|NCT02811588||Phase1:Treatment phase: non-invasive ventilation group|Hypercapnic COPD patients in whom NIV is indicated and who accept NIV treatment.
89133559|NCT00857467|Experimental|1 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 1g rectal suppository
89133560|NCT00857467|Experimental|2 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository.
89133561|NCT00817635|Experimental|LCI699 0.25 mg BID|Following a 2-week placebo run-in period, participants received LCI699 0.25 mg, capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
89133562|NCT00817635|Experimental|LCI699 1 mg QD|Following a 2-week placebo run-in period, participants received LCI699 1 mg, capsules, orally, once daily (QD), with or without food for up to 8 weeks.
89133563|NCT00817635|Experimental|LCI699 0.5 mg followed by LCI699 1 mg BID|Following a 2-week placebo run-in period, participants received LCI699 0.5 mg, capsules, orally, BID, with or without food for up to 4 weeks, followed by LCI699 1 mg, capsules, orally, BID with or without food for up to 4 weeks.
89133564|NCT00817635|Active Comparator|Eplerenone 50 mg BID|Following a 2-week placebo run-in period, participants received eplerenone 50 mg, capsules, orally, BID, with or without food for up to 8 weeks.
89133565|NCT00817635|Placebo Comparator|Placebo|For a 2-week placebo run-in period, followed by 8 weeks of the treatment period, participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food.
89133566|NCT02861339|Experimental|Keratoconus and IBD|Opthalmologic measure with DM OPD scan III (Nidek)
89133567|NCT00853177|Experimental|nitrous oxide|"N2O of 50% and 50% O2~MEOPA"
89133568|NCT00853177|Active Comparator|lidocaine|Injection solution 1%
89133569|NCT02861495|Experimental|humeral nail|Surgical fixation with a humeral compression/distraction nail.
89133570|NCT00924079|Experimental|nalbuphine|
89133571|NCT00853255|Experimental|1|Participants will receive 0.5 mL of vaccine intranasally via an Accuspray device (0.25 mL in each nostril)
89133572|NCT02807532||atrial fibrillation group|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
89133573|NCT02807532||non-atrial fibrillation group|Patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
89133574|NCT00861991|Experimental|Perspective taking intervention|Students were given an instruction to take the perspectives of their standardized patients
89133575|NCT00861991|Active Comparator|Control|Students given standard instructions
89133576|NCT00817479|Active Comparator|Dexamethasone|20 mg of dexamethasone
89133577|NCT00817479|Placebo Comparator|Placebo [Saline]|Saline
89133578|NCT02811822|Experimental|Dose 1|
89133579|NCT02811822|Experimental|Dose 2|
89133580|NCT02811822|Experimental|Dose 3|
89133581|NCT02811822|Experimental|Dose 4|
89133582|NCT04030533|Experimental|Cohort 1: Guselkumab (SC): Dose 1|Participants will receive a single subcutaneous (SC) injection of guselkumab (dose 1), administered on Day 1.
89133583|NCT04030533|Experimental|Cohort 2: Guselkumab (SC): Dose 2|Participants will receive a single SC injection of guselkumab (dose 2), administered on Day 1.
89133584|NCT04030533|Experimental|Cohort 3: Guselkumab (IV): Dose 1|Participants will receive a single intravenous (IV) infusion of guselkumab (dose 1), administered on Day 1.
89133585|NCT04030533|Experimental|Cohort 4: Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2), administered on Day 1.
89133586|NCT04030533|Experimental|Cohort 5: Ustekinumab (IV): 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 milligrams per milliliter (mg/mL) solution on Day 1.
89133587|NCT02807298|Active Comparator|2% Lignocaine (lidocaine)|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine (adrenaline)
89133588|NCT02807298|Experimental|4% Articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine (adrenaline)
89133589|NCT04041427|Experimental|Fasting|Albendazole 400mg will be ingested by study participants with an 8-hour fasting diet.
89133590|NCT04041427|Experimental|High fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with high fat content (40 grams of fat).
89133591|NCT04041427|Experimental|Moderate fat content diet|Albendazole 400mg will be ingested by study participants 15 to 30 minutes after a meal with moderate fat content (15 grams of fat).
89133592|NCT00961961|Other|Lithium plus Fluoxetine Phase I|All participants were started in this arm. Those who met criteria for entry into Phase II were then randomized to one of the two Phase II arms.
89133593|NCT00961961|Other|Lithium plus Placebo Phase I|No participants began their participation on Lithium plus Placebo.
89133594|NCT00961961|Experimental|Lithium plus Fluoxetine Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to continue on both compounds.
89133595|NCT00961961|Placebo Comparator|Lithium plus Placebo Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to switch from Fluoxetine to placebo.
89133596|NCT02811666|Experimental|Patients operated for liver or pancreas cancer|
89133597|NCT02610933|No Intervention|Vitamin K antagonist|Vitamin K antagonist treatment targeting an international normalized ratio of 2 to 3 for 18 months
89133598|NCT02610933|Active Comparator|rivaroxaban|Rivaroxaban 10 mg tablet by mouth once daily for 18 months
89133599|NCT02610933|Active Comparator|rivaroxaban and vitamin K2|Rivaroxaban 10 mg tablet by mouth once daily and MK-7 2000 microgram tablet by mouth thrice weekly for 18 months
89133600|NCT02807220|Experimental|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
89133601|NCT04042441||Ryzodeg® as per local practice|Real-world population of patients with Diabetes Mellitus, Type 2 (T2DM), who have been initiated or switched to Ryzodeg® from previous antihyperglycaemic treatment according to local clinical practice.
89133602|NCT02859935|No Intervention|Control group|The control group will receive standard care - 3 monthly STI screening, motivational interviewing and counselling. Both groups will get questionnaires on mental health problems: ADHD, depression, anxiety disorder, alexithymia and sex and drug addiction.
89133603|NCT02859935|Other|Intervention group|The intervention group will receive -besides standard care- additional questionnaires depending on their baseline questionnaires and in case of an indication for mental health problems, feedback and referral to relevant mental health and addiction care will be provided.
89133604|NCT00817089|Placebo Comparator|Group 1 Asn40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
89133605|NCT00817089|Active Comparator|Group 2 Asn40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
89133606|NCT00817089|Placebo Comparator|Group 3 Asp40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
89133607|NCT00817089|Active Comparator|Group 4 Asp40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
89133608|NCT02807064|Active Comparator|Bifidobacteria mixture 0.5 ml|Bifidobacteria 0.5 ml per os all days for 2 months
89133609|NCT02807064|Placebo Comparator|placebo|Placebo 0.5 ml per os all days for 2 months
89133610|NCT04282577||patients with chron's disease|
89133611|NCT04282577||patients with ulcerative cholitis|
89133612|NCT00853801|Experimental|Provider/Patient Intervention Arm|Lifestyle modification education and counseling for intervention patients. Diagnosis and treatment education and feedback on performance for providers of intervention patients.
89133613|NCT00853801|No Intervention|Provider/Patient Control Arm|Pts will be informed that they have MetSyn and asked to speak with their PCP with any questions.
89133614|NCT04282499|Experimental|combined exercise|combined exercise (aerobic+resistance training)
89133615|NCT04282499|Active Comparator|aerobic exercise|aerobic exercise only
89133616|NCT02804958||STEMI treated with primary PCI|Patients diagnosed with acute ST-segment elevation myocardial infarction and treated with primary percutaneous coronary intervention were consecutively registered.
89133617|NCT00857701|No Intervention|1|Patient will receive post-surgical standard of care treatment with standard Physical therapy and NSAIDs.
89133618|NCT00857701|Experimental|2|Patients will be treated with the Standard of Care physical therapy and NSAIDs as well as a Knee Extension Dynasplint that includes tension chambers.
89133619|NCT00857779|Active Comparator|subcutaneous immunotherapy|subcutaneous immunotherapy using a slow updosing schedule
89133620|NCT00857779|Active Comparator|subcutaneous injections|subcutaneous immunotherapy using a fast updosing schedule
89133621|NCT02860793|Experimental|AML patients at diagnosis|
89133622|NCT00857935|Experimental|1|NatrOVA Creme Rinse - 1%
88802631|NCT02279654||Background Population|All MDS patients who have been diagnosed on 15th June 2007 or later, have never been exposed to lenalidomide and have been followed up on the registry for 3 years or until death/consent withdrawal
89133623|NCT00857935|Active Comparator|2|NIX Creme Rinse
89133624|NCT02808234|Other|Nucel treatment group|One or two level lumbar interbody fusion surgery with Nucel
89133625|NCT04282655|Active Comparator|Control|Standard method of warming breast milk in a hot water bath prior to feeding.
89133626|NCT04282655|Experimental|Treatment Guardian Milk Warmer (Medela TM)|External continuous milk warmer that heats milk within the tubing just posterior to the feeding tube to provide milk at body temperature for feeding infusion.
89133627|NCT00853879|Active Comparator|Arm 1. B6, B12, folate|Triple therapy with folate. Intervention #1.
89133628|NCT00853879|Active Comparator|Arm 2. B6, B12, L-methylfolate|Triple therapy with L-methylfolate. Intervention #2
89133629|NCT00853879|Placebo Comparator|Arm 3. B6, B12, Placebo|Triple therapy with placebo. Intervention #3.
89133630|NCT00634530|Other|I, Intervention|
89133631|NCT05271279|Experimental|OVV-01 Injection+IBR900 Cell Injection|OVV-01 injection combined with IBR900 cell injection, 2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10^9 cells per cycle.
88802632|NCT02278718|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.
88802633|NCT02278718|Active Comparator|Standard of Care|Non surgical and Surgical Debridement
88802634|NCT02779478||Positive NTM Culture|Subjects that meet inclusion criteria and have culture positivity for NTM: at least two separate expectorated induced sputum samples or from one bronchoalveolar lavage (BAL) or lung biopsy
89133632|NCT00862147|Experimental|ICDP|International Child Development Program
89133633|NCT00862147|Active Comparator|Treatment as usual|Treatment as usual
89133634|NCT05758311||Multi-center study|The study population will be inhabitants of both sexes with different levels of physical activity who reside in the metropolitan area of cities in Colombia, Mexico, Costa Rica, and Spain. The population sample will be obtained through an internal call to students and administrative personnel of universities and Smart Fit sites with an inter-institutional collaboration agreement with Dynamical Business & Science Society (DBSS International). The first study will be carried out in Colombia.
89133635|NCT04282265|Placebo Comparator|Placebo|
89133636|NCT04282265|Experimental|Red Spinach Extract|
89133637|NCT02611011||Women|Women seeking health services will perform the Congo Red Dot test (GV-005) individually by following the the test instructions
89133638|NCT03911076|Experimental|PVX-2|Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein
89133639|NCT03911076|Placebo Comparator|Placebo|Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)
89133640|NCT02860559|Experimental|TBX-1400 treatment|Single intravenous infusion of TBX-1400
89133641|NCT00815919|Experimental|Velcade (bortezomib)|
89133642|NCT03903744|Experimental|Treatment arm|Patients treated with cardioneuroablation.
89133643|NCT03903744|Active Comparator|Control arm|Patients treated with standard non-pharmacological methods.
89133644|NCT02808078|Experimental|Augmented reality training|Gait training with augmented reality
89133645|NCT02808078|Active Comparator|Standard training|Gait training without augmented reality
89133646|NCT02545153|Active Comparator|Fibrin sealant|Tisseel, Baxter (Aprotinin and Fibrinogen)
89133647|NCT02545153|Placebo Comparator|Control|Suturing the incision without fibrin glue
89133648|NCT02800746|Experimental|Experimental group|Ferric carboxymaltose
89133649|NCT02800746|Placebo Comparator|Control Group|Placebo
89133650|NCT00913653|Experimental|Stable heart failure patients|
89133651|NCT04042129||1|gynecologic operations with urologic complications
89133652|NCT02804880|Experimental|Group A|HAR + AWARD + Referral Card + A4 leaflet
89133653|NCT02804880|Experimental|Group B|LTM + AWARD + Referral Card + A4 leaflet
89133654|NCT02804880|Active Comparator|Group C|Brief advice + 12-page booklet
89133655|NCT05758155|Experimental|mental health literacy training supported by creative drama|nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
89133656|NCT05758155|Experimental|mental health literacy training supported by classroom instruction|nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
89133657|NCT00854035|Experimental|E|
89133658|NCT00854035|Placebo Comparator|P|
89133659|NCT00957905|Experimental|Part A (alvocidib and oxaliplatin)|Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89133660|NCT00957905|Experimental|Part B (alvocidib and FOLFOX)|Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
89133661|NCT02804724||Newly diagnosed individuals with HIV|Individuals newly diagnosed with HIV in Grampian between January 2009 and December 2014
89133662|NCT04042597|Experimental|Arm A: anlotinib arm|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
89133663|NCT04042597|Active Comparator|Arm B: imatinib arm|Imatinib was given at dose of 400 mg twice daily continuously
89133664|NCT02804568|Experimental|Group 1|Olanzapine/samidorphan 10 mg/10 mg
89133665|NCT02804568|Experimental|Group 2|Olanzapine/samidorphan 20 mg/10 mg
89133666|NCT00862225|Placebo Comparator|1|
89133667|NCT00862225|Active Comparator|2|
89133668|NCT00862225|Experimental|3|
89133669|NCT02804646|Experimental|endostar and chemotherapy group|recombinant human endostatin(endostar) injection was continuous intravenous transfusion for 7 days,with the dose of 15mg/m2 per one day,every 21 days of a cycle,combined with pemetrexed plus cisplatin or carboplatin.
89133670|NCT02804646|Active Comparator|chemotherapy group|pemetrexed injection was intravenous with the dose of 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin,without recombinant human endostatin.
89133671|NCT00862303|Placebo Comparator|IL-2/IFN-α|
89133672|NCT00862303|Experimental|DC-CIK|
89133673|NCT02768831|Experimental|Cuffed ETT|
89133674|NCT00854191|Experimental|1|4 half-day of simulator ERCP practice and usual training
89133675|NCT00854191|Active Comparator|2|Usual training
89133676|NCT02807142|Experimental|NC 1 cell therapy|All patients will be treated with the same treatment: NC1 cell therapy
89133677|NCT02858297|Experimental|Glucosamine/Corticosteroid 4|Topical steroid (triamcinolone acetonide 0.1 %) four times per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
89133678|NCT02858297|Experimental|Glucosamine/Corticosteroid 2|Topical steroid (triamcinolone acetonide 0.1 %) twice per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
89133679|NCT02858297|Active Comparator|Corticosteroid|Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks
89133680|NCT04236648|Other|Minimally-invasive non-surgical therapy (MINST)|Study treatment
89133681|NCT04200846|Experimental|Exercise intervention|Private supervised strength training exercise (e.g., body weight or dumbbell exercises) will occur in the Cancer Center Exercise Medicine Unit or the Hershey Center for Applied Research (HCAR) two days a week. In addition, subjects will be instructed to exercise on their own, at home, three days a week doing 30 minutes of moderate intensity aerobic exercise (e.g., walking at 45-55% maximum heart rate determined by the formula max heart rate = 220bpm - 0.64*age in years).
89133682|NCT04200846|No Intervention|Control|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional and to maintain their current exercise level. Weekly phone calls will be performed to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for interim history and physical to confirm self-reports. Subjects will also be given a FitBit ChargeHR3 and downloaded data review will be performed monthly at the in-person visits.
89133683|NCT02804490|Placebo Comparator|White maize|Conventional maize flour
89133684|NCT02804490|Experimental|Biofortified maize|Provitamin A carotenoid biofortified maize flour
88802635|NCT02779478||Negative NTM Culture|Subjects that meet inclusion criteria and have less than two separate expectorated induced sputum samples culture negative or culture negative bronchoalveolar lavage (BAL) or lung biopsy.
88802636|NCT04757948|Experimental|Acupuncture|Sterile needles are inserted into acupuncture points P-6 and St-36 bilaterally and retained for a total of 20 minutes. Halfway through the treatment, the needles are manipulated in order to re-create the acupuncture sensation. The needles are removed after 20 minutes of treatment prior to the second gag measurement.
89133685|NCT02804490|Active Comparator|Fortified maize|Retinyl palmitate fortified maize flour
89133686|NCT00960323|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
89133687|NCT00960323|Experimental|Colchicine with Atorvastatin|Colchicine pharmacokinetics in the presence of atorvastatin at steady state.
89133688|NCT00617929|Experimental|Conditioning for Graft Failure|Primary or secondary graft failure after hematopoietic stem cell transplantation defined as a > 50% loss of previously best donor chimerism or less than 25% donor chimerism beyond day +42 with pancytopenia and no evidence of relapse. Patients with any diagnosis, type of donor, hematopoietic cell graft or conditioning regimen should be considered for this study. Patients receive anti-thymocyte globulin, rituximab, and clofarabine.
89133689|NCT02804412|Active Comparator|Control group|Patients received a standard, house-typical aphasia therapy in single and group therapy sessions
89133690|NCT02804412|Experimental|CIAT-group|Patients received constraint-induced aphasia therapy.
89133691|NCT02804412|Active Comparator|communication treatment group (CTG)|Patients received aphasia group therapy without constraints
89133692|NCT00862381|Experimental|1|Hydrocortisone
89133693|NCT00862381|Placebo Comparator|2|Placebo
89234168|NCT02553915|Experimental|EPA 4 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
89133694|NCT02800668||DJBL implant-group|"T2DM Patients implanted with a DJBL (Duodenal jejunal Bypass liner, EndoBarrier, GI Dynamics) due to medical reasons.~The subjects were regular in-patients of the Diabetes Center at the Heart and Diabetes Center NRW, Germany and gave informed consent for related procedures and data handling. The subjects had BMI ≥35 kg/m2, T2DM, and a history of frustrated weight loss attempts. Exclusion criteria: history of gastric surgery, gastric or duodenal ulcers, thyroid disorders, gastrointestinal disorders with intestinal resorption dysfunction, therapy with oral anticoagulants, use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs, drug abuse (incl. alcohol), symptomatic cardiovascular disease, renal insufficiency (GFR <50 ml/min), pregnancy or breast feeding."
89133695|NCT00858481|Placebo Comparator|1|Vehicle control
89133696|NCT00858481|Active Comparator|2|0.5% Spinosad creme rinse
89133697|NCT00858481|Active Comparator|3|1.0% Spinosad Creme Rinse
89133698|NCT00858481|Active Comparator|4|2.0% Spinosad Creme Rinse
89133699|NCT05494008|Experimental|Korean herbal medicine treatment|"The Korean herbal medicine treatment group received Korean herbal medicine treatment for 28 days. A trained doctor of Korean medicine with at least 3 years of clinical experience prescribed Korean herbal medicine.~The Korean herbal medicine treatment group were also treated with other Korean medical treatment for twice a week for 4 weeks: acupuncture, pharmacoacupuncture, cupping, and chuna."
89133700|NCT05494008|Active Comparator|Non-Korean herbal medicine treatment|The control group received Korean medical treatment for twice a week for 4 weeks: acupuncture, pharmacoacupuncture, cupping and chuna. (except Korean herbal medicine)
89133701|NCT00858559|Experimental|1|Home Monitoring
89133702|NCT00858559|Active Comparator|2|Home Monitoring not used
89133703|NCT02800590|Experimental|ABP-700 30 μg/kg/min|Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
89133704|NCT02800590|Experimental|ABP-700 40 μg/kg/min|Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
89133705|NCT02800590|Experimental|ABP-700 45 μg/kg/min|Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
89133706|NCT00815295|Experimental|Cetuximab + sorafenib|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib will be given at 200mg/m2 twice daily.
89133707|NCT04235790|No Intervention|Medical Student or Resident|Subjects will perform simulated central venous catheters (CVC) insertions.
89133708|NCT04235790|Other|Novice and Expert IBP Teachers|Expert teachers will be identified based on years as faculty, number of supervised procedures, prior teacher awards, and participation in IBP teaching at international conferences. Novice teachers will include those that have performed less than 50 CVCs. Teachers will supervise 3 simulated central venous catheters (CVC) insertions with increased complexity while wearing an eye tracking device.
89133709|NCT00630383|Experimental|1|Patients will receive 25 live hookworm larvae.
89133710|NCT00630383|Placebo Comparator|2|Patients will receive 0.01 % histamine solution.
89133711|NCT04042519||Healthy control|age - and sex-matched healthy individuals without lung disease
89133712|NCT04042519||Patients with mild and moderate COPD|Grading according to the GOLD guide standards
89133713|NCT04042519||Patients with severe and very severe COPD|Grading according to the GOLD guide standards
89133714|NCT04042519||The severe and very severe COPD group baseline|Severe and very severe COPD patients were in the baseline time group
89133715|NCT04042519||The severe and very severe COPD group six months|Patients with severe and very severe COPD were six months from baseline.
89133716|NCT04042519||The severe and very severe COPD group one year|Patients with severe and very severe COPD were one year from baseline.
89133717|NCT02806830|Experimental|Optive after the second anti-VEGF injection|Naive patients requiring intravitreal injection. Patients will be enrolled in this study within the 2 first intravitreal injections to assess quality of life and ocular discomfort without wetting agent (ie after the first injection) and with wetting agent (ie after the second injection)
89133718|NCT03203135|Experimental|Intervention Group|
89133719|NCT03203135|No Intervention|Control Group|
89133720|NCT02610699|Active Comparator|Smartphone otoscope/Conventional otoscope|Participating clinicians will use a smartphone otoscope for one month followed by a conventional otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
89133721|NCT02610699|Active Comparator|Conventional otoscope/Smartphone otoscope|Participating clinicians will use a conventional otoscope for one month followed by a smartphone otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
89133722|NCT02806752|Experimental|Ranibizumab + Triamcinolone Acetonide|intravitreal injection: Ranibizumab 0.5mg + Triamcinolone Acetonide 2mg
89133723|NCT02806752|Active Comparator|Ranibizumab|intravitreal injection: Ranibizumab 0.5mg
89133724|NCT00854425|Experimental|L-asp|
89133725|NCT00814983|Experimental|Naive T-cell Depleted Stem Cell Transplant|Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.
89133726|NCT00814983|Active Comparator|Stem Cell Transplant No Manipulation|Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation
89133727|NCT02544529|Experimental|Echothiophate Iodide|Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
89133728|NCT02544529|Placebo Comparator|Carboxymethylcellulose Sodium (0.5%)|Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
89234169|NCT04001868|Experimental|Experimental Group|Application of the sub occipital inhibition technique.
89133729|NCT02858063||Pending chemotherapy +/- trastuzumab|In the 1st group (chemotherapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
89133730|NCT02858063||pending trastazumab +/- hormone therapy|In the 2nd group (trastazumab), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
89133731|NCT02858063||pending hormone therapy alone|In the third group (hormone therapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
89133732|NCT02858063||pending afercare period|In the last group (aftercare), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
89133733|NCT02806596|Other|sevoflurane|"induction of anesthesia using sevoflurane administered with facial mask at inspired concentration of 6% (in a mixture of oxygen and nitrous oxyde)~intervention : titration of inspired sevoflurane concentration until targeted bispectral index"
89133734|NCT02610621|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and chemotherapy.
89133735|NCT00854503|Active Comparator|Simvastatin|Simvastatin 20 mg/day
88802637|NCT04757948|Experimental|TENS|Gel pads are affixed to the acupuncture points P-6 and St-36, bilaterally. The amplitude of the TENS device will be gradually increased up to a maximum setting of 8/10, with the subject asked to notify the examiner as soon as any sensation is noticed. Once a gentle buzzing sensation is noticed, the amplitude will be reduced slightly for comfort and then the device will remain for the duration of 20 minutes. The pads are then removed prior to the second gag reflex measurement.
89133736|NCT00854503|Active Comparator|Rosuvastatin|Rosuvastatin 20 mg/day
89133737|NCT00854659|Active Comparator|1|ABT-102 Tablets, 4 mg BID
89133738|NCT00854659|Active Comparator|2|ABT-102 Tablets BID, escalating dose
89133739|NCT00854659|Active Comparator|3|ABT-102 Tablets BID, escalating dose
89133740|NCT00854659|Placebo Comparator|4|Placebo Tablets, BID
89133741|NCT02610543|Experimental|UCB5857|UCB5857 once daily for 12 weeks
89133742|NCT02610543|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
89133743|NCT00854737|Active Comparator|1|Omega-3 fatty acid and cytidine supplementation
89133744|NCT00854737|Active Comparator|2|omega-3 fatty acid supplementation
89133745|NCT00854737|Placebo Comparator|placebo|placeno or sugar pill
89133746|NCT02800044|Experimental|Wearing glucose sensor|The study team will measure glucose readings from the non-invasive sensor and from a glucometer at the following time points: fasting, 1.5 to 2 hours after a meal, and before and after 15-30 minutes of pedaling on a stationary bicycle at 80% maximum heart rate..
89133747|NCT05223153||Amblyopic eye group|
89133748|NCT05223153||Sound eye group|
89133749|NCT00858715|Active Comparator|1|75 mg clopidogrel + 100 mg aspirin
89133750|NCT00858715|Active Comparator|2|150 mg clopidogrel + 100 mg aspirin
89133751|NCT02806284|Active Comparator|Neurotrauma|Patients with basilar skull fracture with or without known cerebrospinal fluid leakage were enrolled in the neurotrauma (NT) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from trauma.
89133752|NCT02806284|Active Comparator|Neurosurgery|Patients scheduled for elective, transsphenoidal pituitary gland surgery were assigned to the neurosurgery (NS) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from surgery.
89133753|NCT02806284|Active Comparator|Control|All control patients had undergone neurotrauma with or without basilar skull fracture, or had neurosurgery, at least three weeks earlier. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b. They were vaccinated at least three weeks after trauma or surgery. The vaccines were administered by subcutaneous injections.
89133754|NCT02544997|Experimental|Poziotinib|12mg P.O. for 2wks q21days
89133755|NCT00960869|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)
89133756|NCT00960869|Active Comparator|EC-Aspirin 325 mg|EC-Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)
89133757|NCT02799888|Experimental|Maraviroc + standard GVHD prophylaxis|Maraviroc administration (in addition to the standard prophylaxis therapy of cyclosporine/tacrolimus and methotrexate) will start on day -2 and will end on day +30 after stem cell transplant, making the total number of days of drug administration 33 days. Maraviroc will be administered 300mg twice daily orally.
89133758|NCT00618787|Active Comparator|Arm 1|
89133759|NCT00618787|Active Comparator|Arm 2|
89133760|NCT02860715|Experimental|Cohort 1|GX-I7 SC 20㎍/㎏ (8 subjects) / Placebo (2 subjects)
89133761|NCT02860715|Experimental|Cohort 2|GX-I7 SC 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
89133762|NCT02860715|Experimental|Cohort 3|GX-I7 IM 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
89133763|NCT02800200|Experimental|Platelet rich plasma|The ultrasoud-guided injection with Platelet rich plasma (3cc) was perfomed in both groups.
89133764|NCT02800200|Experimental|Active shock wave|One-session active shock wave 2 weeks later after PRP injection was performed in intervention group.
89133765|NCT02800200|Placebo Comparator|Sham shock wave|One-session sham shock wave 2 weeks later after PRP injection was performed in control group.
89234170|NCT04001868|Placebo Comparator|Placebo Group|Hand contact in the sub occipital region without executing any technique.
89234171|NCT01034007|Experimental|Tissue Engineered Vascular Grafts|
89234172|NCT01031199|Experimental|Arm 1|
89234173|NCT01031199|Experimental|Arm 2|
89234174|NCT03994107|Experimental|PLD/albumin-bound paclitaxel/Trastuzumab|"First phase~PLD: Level 1：30mg/m2； Level 2：35mg/m2； Level 3：40mg/m2； IV, d1, q21d×6.~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.~Trastuzumab：8mg/kg IV for the first infusion , Subsequent infusions 6mg/kg. d1, q21d×6.~Second phase~PLD: maximum tolerated dose (MTD). IV, d1, q21d×6.~albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.~Trastuzumab：8mg/kg IV for the first infusion ,Subsequent infusions 6mg/kg. d1, q21d×6."
89234175|NCT03119766|Experimental|Kolofort|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
89234176|NCT03119766|Placebo Comparator|Placebo|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
89234177|NCT03474393|No Intervention|Normal diabetes care|Continue with their normal diabetes care. Come in for control visits
89234178|NCT03474393|Experimental|Systematic intensive therapy|Intensive Internet and telephone contact for 4 months and Control visits
89234179|NCT03469713|Experimental|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
89234180|NCT00993486|Experimental|L1 (dose 1.0x10E4 T-cells/kg)|
89234181|NCT00993486|Experimental|L2 (dose 5.0x10E4 T-cells/kg)|
89234182|NCT00993486|Experimental|L3 (dose 1.3x10E5 T-cells/kg)|
89234183|NCT00993486|Experimental|L4 (dose 3.2x10E5 T-cells/kg)|
89234184|NCT00993486|Experimental|L5 (dose 7.9x10E5 T-cells/kg)|
89234185|NCT00993486|Experimental|L6 (dose 2.0x10E6 T-cells/kg)|
89234186|NCT00993486|Experimental|L7 (dose 5.0x10E6 T-cells/kg)|
89234187|NCT00993642|Experimental|All Participants|
89234188|NCT01564446|Experimental|secure message regarding post-discharge medication|Participants will be sent a secure message to confirm compliance with post-discharge medication.
89234189|NCT01028547|Active Comparator|dexamethasone 8mg|
89234190|NCT01028547|Placebo Comparator|normal saline|
89234191|NCT04001790|Experimental|Project Search + ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center where they rotate through three 10-12 week internships within the business learning marketable skills, social communication, and adaptive behavior in the business setting. In order to meet the unique needs of youth with ASD, Wehman, et al. (2014) enhanced the Project SEARCH model by adding autism supports to the original model. Those added supports were: 1) on-site, intensive, systematic instruction using the principles of applied behavior analysis, 2) on-site support and consultation from a behavior/autism specialist, and 3) intensive staff training in ASD and the Project SEARCH Model.
89234192|NCT04001790|No Intervention|Business as Usual|Business as Usual means these youth remain in their high school programs as determined on their individualized education plans
89234193|NCT01031355|Experimental|Arm 1|
89234194|NCT01031355|Active Comparator|Arm 2|
89234195|NCT01031355|Active Comparator|Arm 3|
89234196|NCT00993720|Experimental|type 1 DM with betacell function: Liraglutide|
89234197|NCT00993720|Experimental|type 1 DM without betacell function: Liraglutide|
89234198|NCT00993720|No Intervention|type 1 DM without betacell function: Insulin|
89234199|NCT03006666|Active Comparator|Control Group (Data Only)|The teams randomly allocated to the Control Group will not have access to CHWs.
89234200|NCT03006666|Experimental|Intervention Group: (CHW Health Coaching Integrated into Team)|Teams randomly allocated to the Intervention Group will also receive regular panel data on their pre-DM patients and will have a CHW join the team, attend team meetings, and provide an outreach intervention to all prediabetic patients in the panel, as described below. CHWs and the researchers will provide regular updates to the team on these activities.
89234201|NCT00427011|Experimental|1|
89234202|NCT03891264|Experimental|CBD Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 4-week trial of a liquid formulation of CBD.
89234203|NCT00439179|Experimental|Cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
89234204|NCT00439179|Experimental|Cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
89234205|NCT00439179|Experimental|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
89234206|NCT00439179|Experimental|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
89234207|NCT00438633||Early Therapy|Subjects who begin therapy immediately after diagnosis of injury.
89234208|NCT00438633||Late Therapy|Subjects who delay therapy for 3 weeks after diagnosis of injury.
89234209|NCT03449589||Smokers|RA patients currently smoking
89234210|NCT03449589||Former smokers|RA patients who previously smoked
89234211|NCT03449589||Non smokers|Non smoking RA patients
89234212|NCT01034241|Experimental|Control|Diet consists of 15% dairy protein and low Glycemic Index (GI < 40), 55 En% carbohydrates and 30 En% fat
89234213|NCT01034241|Experimental|High dairy protein|Diet consists of 25% dairy protein and low GI (GI < 40), 45 En% carbohydrates and 30 En% fat
89234214|NCT01034241|Experimental|vegetable protein|Diet consists of 15 En% vegetable protein and low GI (GI < 40), 55 En% carbohydrates and 30 En% fat
89234215|NCT01034241|Experimental|High GI|Diet consists of 15 En% dairy protein and high GI(GI > 60, 55 En% carbohydrates and 30 En% fat
89234216|NCT01031511|Experimental|Treatment Group - CBT|
89234217|NCT01031511|No Intervention|Control Group|
89234218|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 1|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Wash-out up to 8 weeks~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
89234219|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 2|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
89234220|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 3|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
89234221|NCT00438399|Active Comparator|Corticosteroid 1-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
89234222|NCT00438399|Active Comparator|Corticosteroid 2-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
89234223|NCT00438399|Active Comparator|Corticosteroid 3-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
89234224|NCT00426231|Experimental|Patient Navigator intervention|Patient Navigator intervention
89234225|NCT00426231|Active Comparator|Information control|Information control
89234226|NCT03386409|No Intervention|Baseline|Participants receive the standard of care recommendations for safe firearm storage device usage.
89234227|NCT03386409|Experimental|Free Device|Participants receive the standard of care recommendations for safe firearm storage device usage In addition, the study intervention is provision of a free safe firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
89234228|NCT03386409|Experimental|Low Cost Device|Participants receive the standard of care recommendations for safe firearm storage device usage. In addition, the study intervention is the provision of a low cost ($5) firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
89234229|NCT00425607|Experimental|Lonafarnib|All subjects initiated oral Lonafarnib twice daily at a dose of 115mg/m2 and escalated to 150 mg/m2. Two subjects de-escalated to 115mg/m2 following toxicity.
89234230|NCT00437073|Experimental|lapatinib plus capecitabine|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
89234231|NCT00437073|Experimental|lapatinib + topotecan|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
89234232|NCT00425373|Experimental|Valsartan + amlodipine 40/2.5 mg|
89234233|NCT00425373|Experimental|Valsartan + amlodipine 40/5 mg|
89234234|NCT00425373|Experimental|Valsartan + amlodipine 80/2.5 mg|
89234235|NCT00425373|Experimental|Valsartan + amlodipine 80/5 mg|
89234236|NCT00425373|Active Comparator|Valsartan 40 mg|
89234237|NCT00425373|Active Comparator|Valsartan 80 mg|
89234238|NCT00425373|Active Comparator|Amlodipine 2.5 mg|
89234239|NCT00425373|Active Comparator|Amlodipine 5 mg|
89234240|NCT00425373|Placebo Comparator|Placebo|
89234241|NCT03742479|Experimental|Hyaluronic Acid Microinjection|
89234242|NCT03894540|Experimental|IPN60090|"Part 1: Dose escalation of IPN60090, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose administered up to Maximum Tolerated Dose (MTD) over a 21-day cycle"
89234243|NCT03894540|Experimental|IPN60090 in combination with pembrolizumab|"Part 1: Dose escalation of IPN60090 in combination with pembrolizumab, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose, starting with pharmacologically active dose identified in 1dose escalation of IPN60090 as a single agent, over a 21-day cycle in combination with 200 mg pembrolizumab given every 21 days (Day 1 of every cycle) as IV infusion"
89234244|NCT03894540|Experimental|IPN60090 in combination with paclitaxel|"Part 1: Dose escalation of IPN60090 in combination with paclitaxel, Part 2: Dose expansion~IPN60090 given as a BID oral dose, starting with pharmacologically active dose identified in dose escalation of IPN60090 as a single agent over a 21-day cycle in combination with 175 mg/m2 or 135 mg/m2 paclitaxel given every 21 days (Day 1 of every cycle) as IV infusion"
89133766|NCT00813813|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
89133767|NCT00858949||Post surgery monitored group|Outpatients undergoing elective surgery with anesthesia that is expected to last one hour and to require significant postoperative opioids
89133768|NCT02803866||Parents of preterm newborns (25-32 weeks of gestation)|Parents (mother or mother+father) of preterm newborns admitted at the Gregorio Marañón Hospital from birth, recruited during the first 10 days of preterm newborn hospitalization and receiving the training program CAP-PREM
89133769|NCT02857985|Experimental|Patient with Myocardial Infarction|
89133770|NCT00913731||psychotic patients|psychotic patients, acute ward, symptom rating scale.
89133771|NCT00859105|Experimental|Imiquimod 5%|Manufactured by Apotex
89133772|NCT00859105|Active Comparator|Adara 5 % Cream US|Manufactured by 3M, US.
89133773|NCT00859105|Active Comparator|Adara 5% Cream Canada|Manufactured by 3M, Canada
89133774|NCT00859105|Placebo Comparator|Vehicle|Manufactured by Apotex
89133775|NCT02610387|Active Comparator|Arm 1:tDCS|Transcranial direct current stimulation (tDCS) Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days
89133776|NCT02610387|Sham Comparator|Arm 2: Sham tDCS|Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days
89133777|NCT02804334||Healthy Volunteers|Participants with no current or lifetime psychiatric disorders
89133778|NCT02804334||Untreated Bipolar Disorder|Participants who meet criteria for current bipolar disorder but who are not currently taking any psychotropic medications
89133779|NCT00859183|Active Comparator|1|cumulative loading dose of 8 mg of sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
89133780|NCT00859183|Active Comparator|2|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
89133781|NCT00859183|Placebo Comparator|3|oral placebo
89133782|NCT05757765|Experimental|deprescribing pharmacotherapy approach (DPA)|A new way of medication review in patients with sarcopenia. This method is based on previous scientific research and is aimed at minimizing pharmacotherapy. The aim is to combat symptoms and complaints and to stop (preventive) medication as much as possible
89133783|NCT05757765|Active Comparator|STOPP-START deprescribing approach (SSA)|The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
89133784|NCT02803944||Cystic fibrosis patients taking azithromycin|Cystic fibrosis patients taking azithromycin continuously for two years.
89133785|NCT00859261|Experimental|Breast imaging using Ultrasound and Photoacoustic|Evaluating 3D ultrasound for breast abnormalities/masses/cysts. This includes ultrasound imaging and possibly photoacoustic imaging.
89133786|NCT05297721||Nurse|Nurses who (1) were employed as a nurse for at least 1 year, (2) cared for patients aged 65 and over and (3) agreed to participate in the study were included in the study.
89133787|NCT02803710||Case group|patients with decreased susceptibility to carbapenems Enterobacteriaceae isolate
89133788|NCT02803710||Control-group|patients with Enterobacteriaceae isolate without decreased susceptibility to carbapenems
89133789|NCT05980312|Active Comparator|Immobilized|Patients in the control group will be immobilized for 2 weeks and resume unrestricted motion once the splint is taken off.
89133790|NCT05980312|Experimental|Early Range of Motion|Patients in the experimental group will start early motion immediately after surgery.
89133791|NCT05980260|Other|Sequence 1|This sequence will assign eligible participants to scheduled opioid taper approach for 5 months followed by a 2-week washout period followed by symptom-based dosing approach for 5 months.
89133792|NCT05980260|Other|Sequence 2|This sequence will assign eligible participants to symptom-based dosing approach for 5 months followed by a 2-week washout period followed by scheduled opioid taper approach for 5 months.
89133793|NCT05980221|Other|Pancreatic cancer (main cohort)|investigation of PEI and the metabolome of patients with pancreatic cancer in the fed and fasted state
89133794|NCT05980221|Other|Sub-study cohorts: Chronic pancreatitis, cystic fibrosis, NET patients on SSAs|investigation of PEI and the metabolome of patients with other causes of PEI in the fed and fasted state
89133795|NCT05980221|Other|Dosing arm|Investigation metabolome of patients pre and post initiation of PERT as part of their PEI care
89133796|NCT05980156|Experimental|Intermittent Preventive Treatment with dihydroartemisinin-piperaquine (IPT-DP)|All students are treated at each intervention. Treatment will be with DP (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
89133797|NCT05980156|Experimental|Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus chloroquine (IPT-SPCQ)|All students are treated at each intervention. Treatment will be with SP + CQ (females less than 10 years old and all males) or chloroquine (females 10 years old or older).
89133798|NCT05980156|No Intervention|Control|Students will not receive preventive treatment.
89133800|NCT05980130|Experimental|RFCBT|This is a single subject design study. Thus, all participants receive Rumination-Focused Cognitive Behavior Therapy
89133801|NCT05980078|Experimental|Interactive consent|They were randomized to complete an interactive consent
89133802|NCT05980078|Active Comparator|Standard written consent|They were randomized to complete a standard written consent
89133803|NCT05980052|Experimental|Static weekly physical activity goal of 150 minutes/week|Participants will receive a physical activity action planning intervention and assigned a static weekly physical activity goal of 150 minutes/week of moderate-intensity activity; action planning sessions will focus on the participant achieving this weekly goal.
89133804|NCT05980052|Experimental|Incremental weekly physical activity goal increase|Participants will receive a physical activity action planning intervention and assigned a weekly physical activity goal that is 20% greater than the level of moderate-intensity physical activity performed the previous week; action planning sessions will focus on the participant achieving their assigned goal.
89133805|NCT05980052|Experimental|Self-selected weekly physical activity goal|Participants will receive a physical activity action planning intervention and will self-select their own moderate-intensity physical activity goal each week; action planning sessions will focus on helping participants achieve their self-selected goal.
89133806|NCT05980052|Experimental|No stated weekly physical activity goal (comparison group)|Participants will receive a physical activity action planning intervention that does not include explicitly stated physical activity goals to achieve.
89133807|NCT05980026|Active Comparator|oral omega-3 fatty acids supplementation|Intervention group included pediatric patients with diabetic nephropathy receiving oral omega-3 fatty acids supplementation on a daily basis.
89133808|NCT05980026|Placebo Comparator|Placebo comparator|Placebo group or control patients received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
89133809|NCT05979987|Experimental|Control Reminder|Eligible, randomized participants will receive a generic text message reminding them to close their outstanding health gap.
89133810|NCT05979987|Experimental|Anecdote-based Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.
89133811|NCT05979987|Experimental|Anecdote-based Reminder without link|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.
89133812|NCT05979987|Experimental|Research-based Reminder|Eligible, randomized participants will receive a text message reminding them to close their outstanding health gap. This message will mention that research has shown promptly closing health gaps saves lives. The message will contain a link to an official website that supports the statement.
89133813|NCT05979961|Experimental|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
89133814|NCT05979961|Active Comparator|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
89133815|NCT05979909|Experimental|Intravesical mitomycin C (MMC)|
89133816|NCT05979909|No Intervention|No intervention|
89133817|NCT05979896|Experimental|Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ)|Children aged 3-59 months will receive directly observed therapy of standard aged based dosing of Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ) over 3 days.
89133818|NCT05979766|Active Comparator|Manual lymphatic drainage vs marian clark drainage|Effect of Marian Clark drainage and manual lymphatic drainage in women suffering from pelvic congestion syndrome
89133819|NCT05979766|Active Comparator|Manual lymphatic drainage versus marian clark drainage|Effect of Marian Clark drainage and manual lymphatic drainage in women suffering from pelvic congestion syndrome
89133820|NCT05979753|Active Comparator|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS|The aim of this is study is to assess the effect of High Intensity Interval Training on Sprinter's speed and explosive strength.
89133821|NCT05979753|Active Comparator|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH|The aim of this is study is to assess the effect of High Intensity Interval Training on Sprinter's speed and explosive strength.
89133822|NCT05979714|Experimental|Cheeky Study Intervention|
89133823|NCT05979662|Experimental|Group one|Patients will undergo endoscopic frontal sinus surgery grade 6(Draf III).
89133824|NCT05979662|Active Comparator|Group two|Patients will undergo endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
89133825|NCT05979636|Experimental|Test group|
89133826|NCT05979636|Active Comparator|Control group|
89133827|NCT05979623||ZS-IB-NSCLC|A total of 971 NSCLC patients with pathological stage IB resected by surgery (R0) from January 2016 to December 2020 at Zhongshan Hospital of Fudan University
89133828|NCT05979558|Experimental|Ropivacaine with dexmedetomidine|
89133829|NCT05979558|Placebo Comparator|Ropivacaine with Normal Saline|
89133830|NCT05979480||Growth Hormone Treatment Continuation Group|Adult patients with GHD who have been on GH treatment for at least 5 years and will be continuing their treatment whilst on the study.
89133831|NCT05979480||Growth Hormone Treatment Discontinuation Group|Adult patients with GHD who have been on GH treatment for at least 5 years and will be discontinuing their treatment whilst on the study for 2 years.
89133832|NCT05979402|Experimental|Training group|Face-to-face pressure ulcer training will be given to the relatives of the patients in the training group in the determined common time period. The presentation and pressure ulcer content prepared during the trainings will be conveyed by the researcher in two 30-minute sessions using lectures, example events and question-answer techniques.
89133833|NCT05979402|Active Comparator|Control group|Participants in the control group will not be interfered with by the researcher during the research. They will receive routine in-clinic training given by nurses.
89133834|NCT05979324|Experimental|ABAStroke Digital Therapeutics|50 patients using ABAStroke with standard treatment after a stroke.
89133835|NCT05979324|No Intervention|Control group|50 people using standard treatment after a stroke.
89133836|NCT05979298|Active Comparator|Gemcitabin|Gemcitabine 1000 mg/m2 days 1,8 every 3 weeks
89133837|NCT05979298|Experimental|Gemcitabine+Elenagen|GEM was supplemented with ELENAGEN (2.5 mg i.m. weekly)
89133838|NCT05979285|Experimental|N1-Headache App|All participants used the N1-HEadache App, a digital migraine diary that allows identification of triggers/protectors for migraine (as well as monitoring of medication use)
89133839|NCT05979259|Experimental|Experimental (Foodbot Factory) Group|
89133840|NCT05979259|Active Comparator|Control Group|
89133841|NCT05979246|Experimental|Diabetic patients|undergo implant installation
89133842|NCT05979220|Experimental|Dalpiciclib combined with Letrozole|"Dalpiciclib combined with Letrozole,28 days as one cycle.~Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Letrozole: 2.5mg, p.o., once a day, continuous administration."
89133843|NCT05979194|Other|Labor care guide|In this study, we shall determine the effectiveness and other implementation outcomes of the new LCG using Proctor implementation outcome framework among HCPs delivering women across Mbarara District and Mbarara City and evaluate the diagnostic accuracy of the new WHO LCG versus the partogram in detecting prolonged labour and reducing rates of obstructed labour among women delivering in Mbarara district. We shall use local contextualized data from qualitative one-on-one key informant interviews in objective 1 from HCPs and Ministry of Health official involved in labour monitoring and implementation. The WHO labour care guide shall be refined and a Ugandan Ministry of Health prototype designed. An appropriated training and implementation strategy informed by the HCPs themselves shall be used to deliver the content to HCPs in all pilot sites.
89133844|NCT05979181||No extrauterine disease group|Women having placenta previa percreta with no extrauterine disease (FIGO grade 3a)
89133845|NCT05979181||Extrauterine disease group|Women having placenta previa percreta with extrauterine disease (FIGO grades 3b and 3c)
89133846|NCT05979142||program (pre-exposure)|During the pre-exposure period, usual care was provided by two public hospitals, several Ministry of Health clinics, private clinics and pharmacies, and Siempre Salud.
89133847|NCT05979142||program (post-exposure)|The program had components of four Chronic Care Model (CCM) elements (delivery system design, self-management, decision support, and community resources), community health workers (CHWs), and no out-of-pocket costs for visits and medications.
89133851|NCT05979116|Experimental|study group|this study group will receive abdominal myofascial release
89133852|NCT05979103|Experimental|Reggae Music|Group 1 (Reggae): Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks.
89133853|NCT05979103|Active Comparator|Nature Sounds|Group 2 (Nature): Participants in this group will listen to nature sounds over the 4 weeks and will not be told any stereotypes.
89133854|NCT05979103|No Intervention|Waitlist Group|Music Waitlist Group: Participants in this group will serve as a control and will not receive any intervention until the study is completed. They will complete a baseline survey and a follow-up survey at four weeks. Some recordings will be sent to this group after the study is completed, without tracking their usage.
89133855|NCT05979090|Experimental|Mastery Learning Group|
89133856|NCT05979090|No Intervention|Standard of Care Group|
89133857|NCT05979012|Active Comparator|Jazz Only|Jazz Group 1: Participants in this group will watch an introduction to jazz appreciation video prior to the 4-week intervention.
89133858|NCT05979012|Experimental|MIndfullness and Jazz|Jazz Group 2 (Mindful Jazz) Group: Participants in this group will watch an introduction to jazz appreciation and mindfulness training video, including the use of jazz for pain tolerance prior to the 4-week intervention.
89133859|NCT05979012|No Intervention|Waitlist|Music Waitlist Group: Participants in this group will serve as a control and will not receive any intervention until the study is completed. They will complete a baseline survey and a follow-up survey at four weeks. Some videos will be sent to this group after the study is completed, without tracking their usage.
89133860|NCT05978999||Subject use both BPM1 Arm Automatic Electronic BPM and mercury sphygmomanometers|
89133861|NCT05978960|Experimental|Resistance training with high quality low-carbohydrate nutrition regimen|The regimen will consist of an intense resistance training program with linear progression and the goal of increase strength, mobility, muscle mass, and functional capacity. The nutrition program will avoid calorie counting, and instead focus on quality, while maximizing protein and limiting carbohydrates.
89133862|NCT05978934|Active Comparator|L1 then L2 followed by L3 lighting condition|Participants will first experience a static lighting condition (L1) then a dynamic lighting condition (L2). After, participants will experience another dynamic lighting condition (L3) with increased morning brightness compared to L2.
89133863|NCT05978934|Active Comparator|L2 then L1 followed by L3 lighting condition|Participants will first experience a dynamic lighting condition (L2) then a static lighting condition (L1). After, participants will experience another dynamic lighting condition (L3) with increased morning brightness compared to L2.
89133864|NCT05978882|Experimental|Laparoscopic sentinel navigation surgery|compare the detection rate of sentinel lymph nodes to that of previous study (SENORITA1 trial)
89133865|NCT05978869|Experimental|physical fitness training|The training group received physical fitness training for 12 weeks
89133866|NCT05978869|No Intervention|No training group|The no training group did not receive any training program
89133867|NCT05978856||A|real photoes (after treatment)
89133868|NCT05978856||B|simulated photoes
89133869|NCT05978830|Experimental|Group 1|The group of subjects underwent active Transcranial ultrasound stimulation for 2 weeks
89133870|NCT05978830|Sham Comparator|Group 2|The group of subjects underwent sham Transcranial ultrasound stimulation for 2 weeks
89133871|NCT05978765|Experimental|Inclinometer|Inclinometer : An inclinometer is a sensor used to measure the magnitude of the inclination angle or deformation of any structure
89133872|NCT05978765|Experimental|Back Pain Functional Scale|a subjective scale used to measure the patient's physical function after low back pain
89133873|NCT05978765|Experimental|Functional Mobility Scale|has been constructed to classify functional mobility
89133874|NCT05978765|Experimental|Numeric Pain Rating Scale|"A pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning no pain and 10 meaning the worst pain imaginable"
89133875|NCT05978726||ticagrelor maintenance treatment group|Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and ticagrelor 90mg twice daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.
89133876|NCT05978726||clopidogrel maintenance treatment group|Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and clopidogrel 75mg once daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.
89133877|NCT05978700|Experimental|Video-game group|Received the video-game intervention
89133878|NCT05978700|Active Comparator|Conventional therapy group|Received the conventional therapy intervention
89133879|NCT05978674|Experimental|Experimental Group: rocking bed group|Preterms in the intervention group will lie in a rocking bed for a consecutive two-hour period without treatment and invasive procedures. During 30 minutes of this period, the rocking bed will be in the rocking mode and will stop at the end of 30 minutes.
89133880|NCT05978674|No Intervention|Control Group|Newborns in the control group will be followed in a fixed bed (open bed or incubator).
89133881|NCT05978635|Placebo Comparator|Group A|"Anesthesia provider asks the patient to take 4 deep breaths by intermittently stating take as deep a breath as you can. This is the standard of care technique for preoxygenation before induction of general anesthesia with the end point being 80% expired oxygen. The breath volumes in milliliters are recorded but not stated to the patient."
89133882|NCT05978635|Experimental|Group B|"Anesthesia provider asks the patient to take 4 deep breaths but provides coaching by informing the patient of the numeric volume (milliliters) to reach for every breath. Each tidal volume breath is measured using the anesthesia ventilator and the provider encourages the patient to achieve a higher tidal volume than previously achieved. For example, if the initial tidal volume achieved by the patient is 500 milliliter, the provider states, that was a 500 milliliter breath, now try to achieve a 1000mL breath. The numeric goal should continue to increase above the patient's actual tidal volume. The breath volumes are recorded."
89133883|NCT05978609|Experimental|Candonilimab in combination with cisplatin and gemcitabine|"This study is a single-arm study to evaluate the safety and efficacy of candonilimab combined with cisplatin and gemcitabine in advanced biliary tract tumors~Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；~Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；~gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；"
89133884|NCT05978544|Experimental|Itolizumab Dose Level 1|Itolizumab of 50 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
89133885|NCT05978544|Experimental|Itolizumab Dose Level 2|Itolizumab of 100 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
89133886|NCT05978544|Experimental|Itolizumab Dose Level 3|Itolizumab of 150 mg administered by intravenous infusion for once, investigator discretion to continue with the same dose every 3 days up to 7 days.
89133887|NCT05978505|Experimental|Reboxetine|7-day course of 4mg reboxetine, taken nightly before bed time. Reboxetine will be taken for 7-nights post-surgery.
89133888|NCT05978505|Placebo Comparator|Placebo|Placebo sugar pill in the form of one capsule, taken before bedtime. Dosage is taken for 7 nights post-surgery.
89133889|NCT05978479|Experimental|Teach-Back Method|The intervention group will be trained using the Teach Back Method in 3 sessions on every other day that will last 45-60 minutes. Training topics are hemodialysis treatment, end stage renal failure, fluid and diet restrictions and their importance, medication adherence and its importance and lifestyle rules. At the same time, patients will take education booklets.
89133890|NCT05978479|No Intervention|Control group|No intervention will be given to the patients in the control group.
89133891|NCT05978453||Subject use both BP7 Wrist Automatic Electronic BPM and mercury sphygmomanometers|
89133892|NCT05978440|Active Comparator|Scanning without rubber dam|After the onlay preparation, standard digital impression will be recorded for the working quadrant using the IOS without applying the rubber dam. Then the opposing quadrant will be scanned in addition to interocclusal bite registration.
89133893|NCT05978440|Experimental|Scanning under rubber dam with cut technique|"In this group a pre-operative scan will be already taken before the preparation for the working arch, opposing arch and the interocclusal bite registration. Then using the Cut feature in the software of the IOS to cut the area of the working tooth. After the preparation, rubber dam will be applied on the working quadrant and then rescan the prepared tooth."
89133894|NCT05978440|Experimental|Scanning under rubber dam with new lock technique|"After the onlay preparation, the rubber dam will be applied to the working quadrant. Digital impression will be taken using the IOS. After that using the lock feature in the software of the scanner, all the preparation area and margins will be locked. Rubber dam will be removed, and scanning will be completed for the whole quadrant and opposing arch in addition to interocclusal bite registration."
89133895|NCT05978427|Active Comparator|interscalene block group|participants undergoing shoulder surgeries will receive ultrasound guided interscalene block
89133896|NCT05978427|Active Comparator|superior trunk block group|participants undergoing shoulder surgeries will receive ultrasound guided superior trunk block
89133897|NCT05978401|Experimental|Phase I Dose-Escalation Stage：GLS-012+GLS-010|Participants will be treated with escalating doses of GLS-010 + GLS-012 to determine the MTD
89133898|NCT05978401|Experimental|Phase I Expansion Stage：GLS-012+GLS-010|Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of GLS-012+GLS-010 in Advanced Non-Small Cell Lung Cancer.
89133899|NCT05978401|Experimental|GLS-012+GLS-010+pemetrexed + carboplatin|Participants will be enrolled in the expansion stage to better characterize the safety, PK variability, and preliminary efficacy of GLS-012+GLS-010+pemetrexed+carboplatin in Advanced Non-Small Cell Lung Cancer.
89133900|NCT05978401|Experimental|GLS-012+GLS-010+paclitaxel+carboplatin|Participants will be enrolled in the expansion stage to better characterize the safety, PK variability, and preliminary efficacy of GLS-012+GLS-010+paclitaxel+carboplatin in Advanced Non-Small Cell Lung Cancer.
89133901|NCT05978349|Experimental|experimental group|Select adjuvant chemotherapy scheme according to 3D drug sensitivity test results of micro tumor (PTC) in vitro
89133902|NCT05978349|No Intervention|control group|Formulate adjuvant chemotherapy strategy based on clinical experience
89133903|NCT05978310||Group P|Patients operated in the prone position
89133904|NCT05978310||Group S|Patients operated in the supine position
89133905|NCT05978310||Group L|Patients operated in the lateral position
89133906|NCT05978193|Experimental|Arm A|PD-1 inhibitor + Paclitaxel + Cisplatin/Carboplatin+ Low-dose radiotherapy (LDRT) + Conventionally fractionated radiotherapy (CFRT)
89133907|NCT05978193|Active Comparator|Arm B|PD-1 inhibitor + Paclitaxel + Cisplatin/Carboplatin
89133908|NCT05978167|Experimental|Methylphenidate then Placebo|20 mg of methylphenidate then matching placebo pill.
89133909|NCT05978167|Placebo Comparator|Placebo then Methylphenidate|Matching placebo pill then 20 mg of methylphenidate.
89133910|NCT05978115|Experimental|short implant supported removable partial overdenture|
89133911|NCT05978115|Experimental|short Implant supported fixed partial denture|
89133912|NCT05978115|Experimental|Ridge Augmentation and implant supported fixed partial denture|
89133913|NCT05978076||Every children with elevated serum lipase|Every children with elevated serum lipase after trauma during those years will be included.
89133914|NCT05978050|Experimental|nimotuzumab|Participants received nimotuzumab injection 600 mg for the first time, followed by 400 mg once a week until disease progression or inability to tolerate or withdrawal from the trial; At the same time, in combination with paclitaxel 80 mg/m2, it was administered on days 1, 8 and 15 of each treatment cycle (4 weeks) until the disease progressed or could not be tolerated or withdrew from the trial.
89133915|NCT05978050|Placebo Comparator|placebo|Participants received placebo 600 mg for the first time, followed by 400 mg once a week until disease progression or inability to tolerate or withdrawal from the trial; At the same time, in combination with paclitaxel 80 mg/m2, it was administered on days 1, 8 and 15 of each treatment cycle (4 weeks) until the disease progressed or could not be tolerated or withdrew from the trial.
89133916|NCT05977985|Experimental|Dextrose 5%|Rotator interval hydro-dissection with dextrose 5% solution
89133917|NCT05977985|Active Comparator|Corticosteroid|Rotator interval hydro-dissection with corticosteroid solution
89133918|NCT05977881|Other|SCOPE Cohort|A cohort of PWUD (N=600) living in Baltimore. We will follow-up with participants every 6 months (for 18 months) in five recruitment zones throughout Baltimore (n=120/zone). The five recruitment zones will overlap the intervention sites. There will be 4 study visits (baseline, 6 months, 12 months, 18 months) total for participants.
89133919|NCT05977868|Experimental|Group 1 (Experimental)|COpAT (oral antimicrobial therapy) on hospital discharge
89133920|NCT05977868|Active Comparator|Group 2 (Control)|Standard of care (IV antimicrobial therapy) on hospital discharge
89133921|NCT05977855|Experimental|Diary|
89133922|NCT05977855|No Intervention|Standard Care|
89133923|NCT05977504|Experimental|Multi-Psychological Empowerment Courses|9 times online course and 3-days workshop for 6 months .
89133924|NCT05977504|No Intervention|Control group|Participants in control group will receive usual course.
89133925|NCT05976412|Experimental|RNI group|
89133926|NCT05976412|Placebo Comparator|non-RNI group|
89133927|NCT05975281||Hand osteoarthritis|Those diagnosed with hand osteoarthritis according to the American College of Rheumatology (ACR) criteria
89133928|NCT05975281||Rheumatoid arthritis|Those diagnosed with rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria
89133929|NCT05975203|No Intervention|Standard care|After delivery the infant will be separated from the mother and placed on a primary care unit in another room to monitor the cardiopulmonary adaption for at least 20 minutes.
89133930|NCT05975203|Experimental|skin-to-skin contact|After delivery the infant will be put skin-to-skin on the mother's breast in comfort position for 60 minutes. The cardiopulmonary adaption will be monitored and supervised by the attending neonatologist and nurse.
89133931|NCT05975177|Experimental|Sterify Gel + SRP|Scaling and root planing in the assigned site, followed by intra-pocket administration of Sterify Gel, applied to the bottom of the pocket until the gel emerges or becomes visible at the gingival margin
89133932|NCT05975177|Active Comparator|SRP only|Scaling and root planing in the assigned site.
89133933|NCT05974241|Experimental|Pharmacological treatment|During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate entered the second step with aripiprazole. After 4 weeks of treatment, those had suboptimal response to aripiprazole entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
89133934|NCT05970809|Experimental|Device A|Device configuration A has metal and novel microneedles and lasers.
89133935|NCT05970809|Experimental|Device B|Device configuration B has novel microneedles and lasers.
89133936|NCT05969587|Experimental|patients treated with 5% cysteamine cream|
89133937|NCT05969587|Active Comparator|patients treated with a combination of 4% hydroquinone cream and 0.06% betamethasone valerate|
89133938|NCT05969418||Patients with neovascular macular degeneration|
89133939|NCT05969418||healty patients matched age and sex without any ocular disease|
89133940|NCT05969275|Experimental|Umbilical Cord Mesenchymal Stromal Cells (UC-MSCs)|Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
89133941|NCT05969275|Placebo Comparator|Placebo|Intravenous infusion of placebo, with excipients
89133942|NCT05967039||Control|This is a control group of individuals who were diagnosed with post-COVID-19 syndrome but did not underwent Physiotherapy.
89133943|NCT05967039||Intervention|This is an intervention group of individuals who were diagnosed with post-COVID-19 syndrome and underwent Physiotherapy
89133944|NCT05956093|Experimental|high-grade epithelial ovarian cancers.|individuals who have been diagnosed or are suspected to have high-grade serous ovarian cancers (HGSOC). They must have had a CT scan of their abdomen and pelvis within 6 weeks before enrolling in the study and be at clinical stage III or IV.
89133945|NCT05955612|Experimental|Daily measurement of serum procalcitonin concentrations|
89133946|NCT05955612|No Intervention|Standard of practice (routine clinical care)|
89133947|NCT05934656||People with cystic fibrosis|People with confirmed diagnosis aged over six year old
89133948|NCT05900973|Experimental|NUBEQA® (darolutamide) administered to participants|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
89133949|NCT05884203|Experimental|Caregiver socket|Participants will wear a prosthetic socket whose shape was captured by a study helper using digital methods (i.e., a 3D scanner).
89133950|NCT05884203|Experimental|Prosthetist socket|Participants will wear a prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods.
89133951|NCT05880329||Care home residents|100 care home residents will be recruited and followed up for 6 months.
89133952|NCT05875779|Experimental|Peer-led vaccine education intervention|Parents randomized to peer-led vaccine education intervention.
89133953|NCT05875779|No Intervention|Usual Care|Parents randomized to usual care.
89133954|NCT05874726||Bariatric Surgery Patients|Subjects who have had bariatric surgery for obesity - primary and revision. Bariatric surgical procedures include laparoscopic adjustable gastric banding (LAGB), laparoscopic sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), bilio-pancreatic diversion (BPD) with or without duodenal switch (BPD-DS).
89133955|NCT05874726||Endoscopic Metabolic and Bariatric Therapies|Subjects who have had endoscopic bariatric therapies for obesity - primary and revision. Bariatric endoscopic procedures include ablation techniques, intragastric balloons, submucosal tunneling procedures (PSAM, GEM, G-POEM), tissue plication platforms (POSE, ROSE), endoluminal sleeves and endoscopic suturing devices (ESG).
89133956|NCT05874726||Medical Management|Subjects who follow lifestyle modification and/or anti-obesity medications for treatment of obesity with no previous surgical intervention for obesity. Medical therapies include weight loss diets or anti-obesity medications.
89133957|NCT05868928||Brain metastases patients who received stereotactic radiosurgery|Patients with brain metastases who received stereotactic radiosurgery
89133958|NCT05858528||Observational|No intervention in this study
89133959|NCT05857787|Active Comparator|With nerve track function(group A)|trained in the live demo method with nerve track function
89133960|NCT05857787|Active Comparator|Without nerve track function(group B)|trained in the existing live demo method without nerve track function
89133961|NCT05836740|Active Comparator|Minocycline treatment group|Minocycline Hydrochloride Capsules (50 mg per capsule) The first dose should be given immediately after randomization (within 30 minutes); 200mg (4 capsules) for the first dose; Subsequently, 100mg (2 capsules) will be administered once every 12 hours, a total of 9 times (lasting 4.5 days; the subject with dysphagia will be administrated through a nasal feeding tube)
89133962|NCT05836740|Placebo Comparator|Minocycline placebo-control group|Placebo of Minocycline Hydrochloride capsules (50mg per capsule, containing 0 mg of Minocycline) The method of administration was the same as that of treatment group.
89133963|NCT05827822|Experimental|Punch-in Intervention Group|4 weeks of alcohol-related daily tracking + brief assessment and intervention
89133964|NCT05827822|No Intervention|Control Group|waiting list group
89133965|NCT05825430|Experimental|Control group|Patients will not receive any block
89133966|NCT05825430|Experimental|Direct pecs block group|Pec I block will be given with 10 ml bupivacaine 0.25% which injected between two pectoral muscles and pecs II block will be given with 20 ml bupivacaine 0.25%.which given between pectoralis minor muscle and serratus muscle. Patients will receive direct pecs block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.
89133967|NCT05825430|Experimental|Ultrasound guided pecs|Pec I block will be given with 10 ml bupivacaine 0.25% which injected between two pectoral muscles and pecs II block will be given with 20 ml bupivacaine 0.25%.which given between pectoralis minor muscle and serratus muscle. Patients will receive ultrasound guided pecs block done after induction and before skin incision.
89133968|NCT05804214||Infants who started feeding with the product at ≤ 4 months of age|Infants who started feeding with the product at ≤ 4 months of age, either supplemental to breastfeeding or as sole source of feeding
89133969|NCT05788042|Active Comparator|Active transcranial Direct Current Stimulation (tDCS)|It will be given continuously for 30 minutes at 2 mA, twice daily (separated by >=2 hours) over the first 4 weeks, and daily over the second 4 weeks of the 8 week acute treatment period (84 sessions total).
89133970|NCT05788042|Sham Comparator|Sham transcranial Direct Current Stimulation (tDCS)|It will involve an initial ramping up to 0.5 mA and then a ramp down to 0 mA for the remainder of each treatment. The same number of sessions as active tDCS will be administered.
89133971|NCT05788042|Active Comparator|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS twice per day (separated by ≥ 2 hours) over the first 4 weeks. Two sessions per day (separated by ≥ 2 hours), given on 2 days each week for the following 4 weeks. The total number of rTMS sessions over the 8 week acute treatment period will be 56.
89133972|NCT05788042|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS twice per day (separated by ≥ 2 hours) over the first 4 weeks. Two sessions per day (separated by ≥ 2 hours), given on 2 days each week for the following 4 weeks. The same number of sessions as active rTMS will be administered.
89133973|NCT05786079|Experimental|Footstrike modification|
89133974|NCT05786079|Active Comparator|Control|
89133975|NCT05782270|Other|DAPT|Comparison group: dual antiplatelet only
89133976|NCT05782270|Experimental|DAPT+warfarin|Intervention group: dual antiplatelet combined with warfarin
89133977|NCT05781360|Experimental|Experimental: PART ONE- Dose escalation|The purpose of the Dose Escalation Phase (Part one) is to characterize the safety and tolerability of SIM0237 and determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose(s) (RD) based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period.
89133978|NCT05781360|Experimental|Experimental: PART TWO- Dose expansion|Patients will be administered a recommended dose of SIM0237 established from the Dose Escalation Phase of the study.
89133979|NCT05780710|Other|Meds2023 Cohort|"Study participants are asked to wear the Aktiia bracelet continuously every day for 13 weeks in total and initialize their Aktiia bracelet with the Aktiia cuff at different timepoints.~In parallel, study participants are asked to take 3 successive Blood Pressure lowering drugs during 2 weeks per treatment. Treatment periods are followed by 2 weeks of washout (no treatment)."
89133980|NCT05776680|Experimental|Psychological Support Course|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
89133981|NCT05776680|No Intervention|Control group|Participants in control group will receive usual course.
89133982|NCT05764954|Experimental|NovoTTF-200T System Tumor-Treating Fields (TTFields)|Following pathological confirmation on of lung ADC, patients will proceed with TTFields treatment. The NovoTTF-200T System is an investigational medical device delivering 150 kHz TTFields to the patient's chest. The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
89133983|NCT05756634|Experimental|CCAPB (intervention)|Intervention participants will receive an intervention focused on health care navigation and motivational enhancement.
89133984|NCT05756634|Placebo Comparator|Usual Care|Usual care participants will not receive the intervention.
89133985|NCT05754528|Active Comparator|Standard daily dosing of endocrine therapy|Standard daily dosing of endocrine therapy
89133986|NCT05754528|Experimental|Endocrine therapy dose-frequency escalation|Endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.
89133987|NCT05751811|Experimental|Virtual reality group|Participants under Virtual reality group will wear a virtual reality headset with immersive video content during the whole hysteroscopy.
89133988|NCT05751811|Experimental|Music therapy group|Participants under Music therapy group will wear a headphone playing music during the whole hysteroscopy.
89133989|NCT05751811|No Intervention|Control group|Participants under Control group will proceed with hysteroscopy as usual practise.
89133990|NCT05750329|Experimental|Surgical group|All patients underwent left hepatectomy combined with orthotopic S2-3 liver segment transplantation, and then underwent autologous right hepatectomy after the graft had grown sufficiently large.
89133991|NCT05718154||Assault-Induced Trauma Patients in Suez Canal University Hospital-Trauma Unit|"Total coverage of all patients fulfilled the inclusion criteria~From April 2023 to September 2023 in Suez Canal University Hospital, Emergency Department."
89133992|NCT05718154||Assault-Induced Trauma Patients in Assiut University Hospital-Trauma Unit|"Total coverage of all patients fulfilled the inclusion criteria~From October 2023 to March 2024 in Assiut University Hospital, Trauma Unit."
89133993|NCT05716061|Experimental|median approach|Sacral ESPB performed from the median sacral crest of 2.level of sacrum.
89133994|NCT05716061|Active Comparator|intermediate approach|Sacral ESPB performed bilateral and between the median and intermediate sacral crest of 2.level of sacrum.
89133995|NCT05708599|Experimental|Patients with early-stage and advanced-stage disease per indication|Indications: Pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and non-small cell lung cancer (NSCLC)
89133996|NCT05688618|Active Comparator|Experimental group|
89133997|NCT05688618|Placebo Comparator|Control group|
89133998|NCT05684120|Experimental|Treatment Group|Individuals in this arm will take part in the Mood Lifters program immediately after recruitment.
89133999|NCT05684120|No Intervention|Waitlist Control Group|Individuals in this arm will be invited to take part in the Mood Lifters program after they complete post-treatment surveys as part of the control group.
89134000|NCT05682118|Experimental|tested using the roadmap system|tested using the roadmap system
89134001|NCT05682118|Active Comparator|tested without using the roadmap system|tested without using the roadmap system.
89134002|NCT05678699|Other|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment) Only|The investigators will employ a quasi-experimental study design to test two hypotheses: H1: SMM rates among Black people will decline after the interventions (equity payment and obstetric bundled payment), relative to people of other race groups within Pennsylvania (PA); and H2: Racial inequities in SMM will decline among those exposed to the interventions in PA, relative to those in similar states. The investigators will collect qualitative data to assess the effects of the Medicaid healthcare interventions on beneficiaries' experiences.
89134003|NCT05678699|Other|Doula Only|The investigators will test two hypotheses: H1: SMM rates among Black people will decline more after the addition of doula care in PA, relative to healthcare quality interventions alone. H2: Racial inequities in SMM will decline more among those exposed to both healthcare quality and doula care interventions in PA, relative to states implementing doula care only. The investigators will collect qualitative data to assess the effects of the Medicaid healthcare and service interventions on beneficiaries' experiences.
89134004|NCT05678699|Other|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment) + Doula|
89134005|NCT05678699|No Intervention|Standard Care|
89134006|NCT05668481|Active Comparator|Constructive memory support|Participants will watch videos of a sleep expert delivering treatment components from the Transdiagnostic Sleep and Circadian Intervention (TranS-C). After each video, a team member will deliver constructive memory supports.
89134007|NCT05668481|Active Comparator|Non-constructive memory support|Participants will watch videos of a sleep expert delivering treatment components from the Transdiagnostic Sleep and Circadian Intervention (TranS-C). After each video, a team member will deliver non-constructive memory supports.
89134008|NCT05625256||Accuracy of Continuous Noninvasive Blood Pressure at Various Stages of Anesthesia|To compare noninvasive continuous arterial pressures obtained from the SentiCor-300 with direct intra-arterial blood pressure measurements at various stages of anesthesia (such as induction, laryngoscopy, maintenance, emergence, and recovery) and after emergence in various positions.
89134009|NCT05621447|Experimental|TAS-303, [14C]TAS-303|
89134010|NCT05602519|Active Comparator|Group fentanyl|Patients will receive 50 ug of fentanyl 20 min before the end of surgery.
89134011|NCT05602519|Active Comparator|Group oxycodone|Patients will receive 4 mg of oxycodone 20 min before the end of surgery.
89134012|NCT05587816|Experimental|Experimental|"Training and use of the PortionSize app by children and parents or caregivers~Using the PortionSize app at the clinic of Pennington Biomedical Research Center and at home (free-living condition)~Rating the satisfaction of using the PortionSize app"
89134013|NCT05527639|Other|intervention group during study|all participants completed a 12 week strength training program consisting of warm up exercises, dead-lifts and squats. They had all completed a program of Kegel exercise prior.
89134014|NCT05527639|Other|control group during study|all participants completed a 12 week strength training program consisting of warm up exercises, dead-lifts and squats
89134015|NCT05513183||Arm I (Severe neutropnia group),|After CRS followed by HIPEC using MMC of 35mg/m2, patients who had absolute neutrophil count (ANC) < 1000/mm3 during the postoperative period are assigned as experimental group (Arm I, severe neutropnia group).
89134016|NCT05513183||Arm II (No severe neutropenia group)|After CRS followed by HIPEC using MMC of 35mg/m2, patients who had ANC ≥ 1000/mm3 during the postoperative period are assigned as the control group (Arm II: no severe neutropenia group).
89134017|NCT05487885|Experimental|TMS and PAT|All open label with no randomization to placebo
89134018|NCT05487885|Experimental|TMS and PAT, then Ketamine|All open label with no randomization to placebo
89134019|NCT05485779|Experimental|Part A (SAD): Group A1|Single dose of AQ280, 3 mg or placebo
89134020|NCT05485779|Experimental|Part A (SAD): Group A2|Single dose of AQ280, dose to be determined (TBD) or placebo
89134021|NCT05485779|Experimental|Part A (SAD): Group A3|Single dose of AQ280, dose TBD or placebo
89134022|NCT05485779|Experimental|Part A (SAD): Group A4|Single dose of AQ280, dose TBD or placebo
89134023|NCT05485779|Experimental|Part A (SAD): Group A5|Single dose of AQ280, dose TBD or placebo
89134024|NCT05485779|Experimental|Part B (MAD): Group B1|AQ280 dose TBD or placebo, once daily (QD) for seven days
89134025|NCT05485779|Experimental|Part B (MAD): Group B2|AQ280 dose TBD or placebo, once daily (QD) for seven days
89134026|NCT05485779|Experimental|Part B (MAD): Group B3|AQ280 dose TBD or placebo, once daily (QD) for seven days
89134027|NCT05482958||Control: Participants without T2DM|"Participants without T2DM will be recruited and consented through the Courtois Cardiovascular Signature Biorepository protocol, HbA1c % will be measured at baseline from the stored bio-samples collected as a part of the biorepository program. A wearable will be worn for the duration of the clinic appointment.~The participant will then wear the HOP watch for the designated period of time."
89134028|NCT05482958||Case: Patients with T2DM|"Participants with T2DM, their baseline history of T2DM will be determined from chart review and patient history. In patients with T2DM, for the HbA1c % both at baseline and follow-up, the investigators will measure this value as a part of routine standard of care in the DECIDE-CV clinic.~A subset of 20 participants will be given a Polar H10 chest-strap to be worn during the clinic.~Participants will be given a HOP watch to wear in the clinical environment and will be discharged from the clinic to wear the watch for the designated period.~Participants will subsequently wear the watch again, in 3-6 months for the designated period of time."
89134029|NCT05482360|Experimental|PrEP Optimization Strategies|Up to 12 facilities will be assigned one of three intervention groups (4 facilities per group). The strategies have no yet been identified but will be through other activities in the PrEPARE study.
89134030|NCT05482360|No Intervention|Comparator|Up to 4 facilities will be assigned to the comparator group.
89134031|NCT05467813|Experimental|clinic-setting MT preceding AR-first group|In the experimental group, the participants will receive clinic-based rehabilitation first. After a 3-week washout period, the participants will receive home-based rehabilitation.
89134032|NCT05467813|Active Comparator|home-based MT preceding AR-first group|The comparison group will receive home-based rehabilitation first. After a 3-week washout period, the participants will receive clinic-based rehabilitation.
89134033|NCT05467813|Active Comparator|clinic-setting MT preceding conventional therapy group|The control group will receive clinic-based rehabilitation first. After a 3-week washout period, the participants will receive clinic-based rehabilitation.
89134034|NCT05445609|Experimental|Treatment ((vidutolimod, nivolumab)|Patients receive vidutolimod SC on days 1 and 7 of cycle 1, IT on day 14 of cycle 1 and days 1 and 14 of cycle 2, and then SC on day 1 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 14 of cycle 2 and on day 1 of subsequent cycles. Cycles of nivolumab repeat every 4 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Cycles of vidutolimod repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
89134035|NCT05442060|Active Comparator|Erlotinib|Erlotinib (150 mg daily)
89134036|NCT05442060|Experimental|Erlotinib + OBI-833/OBI-821|Erlotinib (150 mg daily) + 30 μg OBI-833/100 μg OBI-821
89134037|NCT05431751|Experimental|Experimental Group A|Crossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where they will consume the active intervention. Following the second clinic day, the participant will consume active intervention for 7 days. The participant will then undergo a washout period of 7 days.
89134038|NCT05429541||Otitis Media (OM) Case Group|"Case definition:~Acute otitis media (AOM)~AOM will be diagnosed by pneumatic otoscopy by validated otoscopists, when children with acute onset of otalgia had tympanic membranes (TMs) that were:~bulging or full; and~a cloudy or purulent effusion was observed, or the TM was completely opacified; and~TM mobility was reduced or absent~Otitis media with effusion (OME)~Collection of fluid within the middle ear without signs of acute inflammation, fever or otorrhea. Otoscopic findings include:~dull tympanic membrane (TM)~retraction of TM~fluid level or air bubble~TM colour change~restricted TM mobility with pneumatic otoscopy~Chronic suppurative otitis media (CSOM)~Otoscopic findings:~Perforated TM~Mucopurulent discharge"
89134039|NCT05422105||Suspected Prostate Cancer|
89134040|NCT05421273|Experimental|Active recharge burst stimulation|
89134041|NCT05421273|Experimental|Passive recharge burst stimulation|
89134042|NCT05417009|Active Comparator|Stimulation|Electrodes attached bliaterally to tragus nerve region of outer ear, with appropriate device settings to deliver current.
89134043|NCT05417009|Sham Comparator|Electrode attachment only.|Electrodes attached bliaterally to tragus nerve region of outer ear, with device switched off [blinded to operator].
89134044|NCT05406388|Active Comparator|Erector Spinae Plane Block|Erector Spinae Plane Block for Postoperative Analgesia
89134045|NCT05406388|Active Comparator|Control group|No regional anesthesia technique will be applied to the control group.
89134046|NCT05403502|Experimental|t:slim X2 insulin pump with Control-IQ technology utilizing insulin Lyumjev®|Current Control-IQ technology users with type 1 diabetes, age 6-80, will use the t:slim X2 insulin pump with Control-IQ technology 1.5 and Lyumjev insulin for 3-months of outpatient use.
89134047|NCT05402033||Survey / Interview Group|"All patients (or parent / caregiver, if relevant) who provide informed consent will be asked to complete baseline assessments utilizing validated questionnaires administered through the phone or video call. The clinical research coordinator will input responses into REDCap. Alternatively, patients may request assessments be sent through secure email.~Baseline assessment consisting of sociodemographic items and study eligibility questions (call #1)~In addition, each patient will complete the Comprehensive Score for financial Toxicity Patient Reported Outcome Measure (COST PROM) and Short Assessment of Health Literacy (SAHL) survey measures."
89134048|NCT05399550|Experimental|Balovaptan|Balovaptan will be administered as IV infusion once a day over 3 days
89134049|NCT05399550|Placebo Comparator|Placebo|Placebo will be administered as IV infusion once a day over 3 days
89134050|NCT05371249|Experimental|Vonoprazan-based triple therapy group|Including patients receiving vonoprazan-based triple therapy (vonoprazan 20mg + amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days)
89134051|NCT05371249|Active Comparator|Extended sequential therapy group|Including patients receiving extended sequential therapy (lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days)
89134052|NCT05351047|Experimental|Cohort 1|Once weekly dosing for 4 weeks (Dosing Days 1, 8, 15 and 22) OR Once weekly dosing for 6 weeks (Dosing Days 1, 8, 15, 22, 29 and 36) randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 1 (6 subjects) or matching placebo (2 subjects).
89134053|NCT05351047|Experimental|Cohort 2|Once weekly for 6 weeks dosing on Days 1, 8, 15, 22, 29 and 36 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 2 (6 subjects) or matching placebo (2 subjects).
89134054|NCT05351047|Experimental|Cohort 3|Three times weekly for 6 weeks dosing each week on Days 1, 3, and 5 randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 3 (6 subjects) or matching placebo (2 subjects).
89134055|NCT05351047|Experimental|Cohort 4 (optional)|Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 4 (6 subjects) or matching placebo (2 subjects).
89134056|NCT05351047|Experimental|Cohort 5 (optional)|Between one to seven doses each week for 6 weeks randomized subjects will receive a subcutaneous (SC) injection of AZD2373 dose 5 (6 subjects) or matching placebo (2 subjects).
89134057|NCT05331508|Experimental|Treatment group|Prior to commencement of the study, providers responsible for FP and ANC service provision will participate in a 3-day competency-based skills-building training activity on Caring for women subjected to violence: A WHO curriculum for training health-care providers and the ARCHES intervention. Following the training, providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
89134058|NCT05331508|No Intervention|Control group|FP clients and ANC clients will receive standard care. For FP services, this includes standard contraceptive care provided by personnel who have completed training on contraceptive service delivery by the Nigerian Federal Ministry of Health and partners. For ANC services, the standard is a minimum of 8 visits with health personnel trained on ANC care during pregnancy. This includes identification of women and girls at increased risk of developing complications during labor and childbirth; prevention, detection, and management of pregnancy-related and concurrent conditions; health education and promotion; promotion of the use of skilled attendance at birth and healthy behaviors such as breastfeeding, early postnatal care, and planning for optimal pregnancy spacing, routine examinations, detection of complications, prevention of malaria in pregnancy and other infections; provision of holistic care to ensure normal progression of the baby and good health of the mother.
89134059|NCT05325333|Experimental|Retrieval practice during word learning: expanding schedule|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) . Four nouns will be learned in an expanding spaced retrieval practice condition; four will be learned in a standard spaced retrieval practice condition. In the standard spaced retrieval practice condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase from 0 to 3 words. In the expanding spaced retrieval practice condition, the number of other words intervening between hearing the target and an attempt to retrieve it will increase gradually from 0 to 1 to 3 words."
89134060|NCT05320055||IPOM|receiving laparoscopic intraperitoneal onlay mesh repair
89134061|NCT05320055||rTARUP|recieving robotic assited retromuscular repair
89134062|NCT05317312|Experimental|MR-107A-02 1.25 mg twice in a 24 hour period|Oral tablet, one day of dosing
89134063|NCT05317312|Experimental|MR-107A-02 5 mg twice in a 24 hour period|Oral tablet, one day of dosing
89134064|NCT05317312|Experimental|MR-107A-02 15 mg twice in a 24 hour period|Oral tablet, one day of dosing
89134065|NCT05317312|Placebo Comparator|Placebo twice in a 24 hour period|Oral tablet, one day of dosing
89134066|NCT05307666|Experimental|Medication minimization|"Patients have a dedicated medication minimization visit with their usual primary care provider to which they bring all of their medications (a so-called brown bag medication review)."
89134067|NCT05307666|No Intervention|Usual Care|Patients will continue to receive care as appropriate but no dedicated visit to review and minimize medications will be organized as a result of the study. Medications are free to be minimized during the normal course of care should the need arise.
89134068|NCT05295277||Standard of care genetic testing group|Individuals with genomic test results from a standard of care (SOC) test (such as CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS, etc.) will be enrolled in the study to compare the SOC result to results from optical genome mapping.
89134069|NCT05293236|Placebo Comparator|Placebo|Nine COVID-19 patients (three from each treatment-group) treated with saline intravenous infusion
89134070|NCT05293236|Experimental|Dose 1|Seven COVID-19 patients treated with ApTOLL (0.05mg/kg) intravenous infusion
89134071|NCT05293236|Experimental|Dose 2|Seven COVID-19 patients treated with ApTOLL (0.1mg/kg) intravenous infusion
89134072|NCT05293236|Experimental|Dose 3|Seven COVID-19 patients treated with ApTOLL (0.2mg/kg) intravenous infusion
89134073|NCT05284032|Experimental|Isatuximab (Sarclisa)|4 weekly doses of isatuximab
89234245|NCT03894540|Experimental|IPN60090 food effect|"Part 1: Food Effect of IPN60090~IPN60090 given as a single oral dose as a single agent at the recommended dose (RD) under fasting and fed conditions followed by IPN60090 given as a BID oral dose administered at the RD over a 21-day cycle."
89234246|NCT00993876|Experimental|Selective serotonin reuptake inhibitor (SSRI)|citalopram
89234247|NCT00993876|Experimental|Serotonin-norepinephrine reuptake inhibitor (SNRI)|reboxetine
89134074|NCT05270395|Experimental|mPal intervention|Participants in this group will receive the mPal intervention. mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider. mPal's provider content (not randomized) will include education. System-level modifications will also be made to the electronic health record to facilitate palliative care discussions and referrals.
89134075|NCT05270395|No Intervention|Standard of care|Participants in this group will receive standard of care (applies to patients only).
89134076|NCT05260463|Experimental|Silver-coated Implant|The summary description and intended purpose of the investigational device (LOQTEQ® antibacterial silver-coated system) is the same as that of the comparator device (LOQTEQ® 3.5 System (uncoated) system). The investigational device differs from the comparator device in that its surface which has been modified by the addition of an antibacterial coating.
89134077|NCT05260463|Active Comparator|Uncoated Implant|The summary description and intended purpose of the investigational device (LOQTEQ® antibacterial silver-coated system) is the same as that of the comparator device (LOQTEQ® 3.5 System (uncoated) system) and differes only in the lack of the antibacterial coating.
89134078|NCT05256017|Active Comparator|Acoziborole|Single dose administration of 3 tablets of 320 mg
89134079|NCT05256017|Placebo Comparator|Placebo|Single dose administration of 3 tablets of 320 mg
89134080|NCT05239468|Active Comparator|Double Blind (DB) Phase Treatment A: BZF 100 milligrams (mg) Immediate Release (IR) tablet|Each Participant will take one OCA placebo tablet, one BZF 100 mg IR tablet and one BZF placebo tablet daily.
89134081|NCT05239468|Active Comparator|Double Blind (DB) Phase Treatment B: BZF 400 mg IR tablet|Each Participant will take one OCA placebo tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
89134082|NCT05239468|Experimental|Double Blind (DB) Phase Treatment C: OCA 5 mg + BZF 100 mg IR|Each participant will take one OCA 5 mg tablet, one BZF 100 mg IR tablet and one BZF placebo tablet, daily.
89134083|NCT05239468|Experimental|Double Blind (DB) Phase Treatment D: OCA 5 mg + BZF 400 mg IR|Each participant will take one OCA 5 mg tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
89134084|NCT05239468|Experimental|Long Term Safety Extension (LTSE) Phase Treatment D of the DB phase: OCA 5 mg + BZF 400 mg IR|Each participant will take one OCA 5 mg tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
89134085|NCT05217992||Carriers or potential carriers of hemophilia A and B|All obligate and potential carriers among families of patient with hemophilia followed at the hemophilia treatment center of the Cliniques universitaires Saint-Luc, Brussels. Belgium
89134086|NCT05207527|Experimental|Cardiovascular exercise|Cycloergometer
89134087|NCT05207527|Experimental|Muscle strength|Strength exercises will be performed during the hemodialysis session.
89134088|NCT05207527|Experimental|Mixed|Both aerobic and muscular strength exercises will be performed.
89134089|NCT05207527|No Intervention|Control|Conventional treatment or dyalisis usual care
89134090|NCT05514236|Experimental|Virtual reality group|"Participants assigned to the Visual reality group will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
89134091|NCT05514236|Experimental|Music group|"Participants in the music group will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the sound according to her comfort."
89134092|NCT05514236|No Intervention|Control group|While participants in the control group will not be given any Virtual reality or music device.
89134093|NCT05201534|Experimental|Integrative Symbolic Non-Symbolic (iSNS) Training|Integrative symbolic non-symbolic (iSNS) training: Over a period of 6 weeks, participants will complete activities that progressively strengthen the mapping of symbolic numerical representations to non-symbolic numerical quantities and enhance fluency in symbolic numerical skills.
89134094|NCT05201534|Active Comparator|Active Comparator: Active Control Intervention (Working Memory Training)|Active control intervention: Over a period of 6 weeks, participants will complete activities that enhance short-term storage and maintenance of visuospatial or verbal information.
89134095|NCT05200546||"group before"|1st period of 6 months during which only the current detection technique will be used.
89134096|NCT05200546||"group after"|- 2nd period of 6 months after implementation of the PCR solution (CPO and VRE) of the BD company in parallel with the usual screening technique
89134097|NCT05169320||Case group|Patients with symptomatic persistent AF episodes after previous failure of ≥2 pulmonary vein isolation procedures
89134098|NCT05169190|Active Comparator|SGB|SGB, the experimental procedure, is the injection of 7 cc of 0.5% ropivacaine plus 0.5 cc contrast anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle
89134099|NCT05169190|Sham Comparator|Sham|Sham, the placebo control group, is the injection of 7 cc of normal saline plus 0.5 cc contrast anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle
89134100|NCT05169190|No Intervention|Wait-List Control (WLC)|WLC, a control for time, expectancy and safety, is all study procedures without going to the procedure room for injection
89134101|NCT05168657|Active Comparator|EN-IP-UC|Random-order cross-over participants on USUAL CARE managed by ENDOCRINOLOGY with IN-PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
89134102|NCT05168657|Experimental|EN-TH-UC|Random-order cross-over participants on USUAL CARE managed by ENDOCRINOLOGY with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
89134103|NCT05168657|Experimental|EN-IP-BP|Random-order cross-over participants on BIONIC PANCREAS managed by ENDOCRINOLOGY with IN PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
89134104|NCT05168657|Experimental|EN-TH-BP|Random-order cross-over participants on BIONIC PANCREAS managed by ENDOCRINOLOGY with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
89134105|NCT05168657|Active Comparator|PC-IP-UC|Random-order cross-over participants on USUAL CARE intervention managed by PRIMARY CARE with IN-PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
89134106|NCT05168657|Experimental|PC-TH-UC|Random-order cross-over participants on USUAL CARE managed by PRIMARY CARE with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
89134107|NCT05168657|Experimental|PC-IP-BP|Random-order cross-over participants on BIONIC PANCREAS managed by PRIMARY CARE with IN PERSON visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
89134108|NCT05168657|Experimental|PC-TH-BP|Random-order cross-over participants on BIONIC PANCREAS managed by PRIMARY CARE with TELEHEALTH visits. Participants will be randomly assigned to initiate trial participation with either Bionic Pancreas intervention or Usual Care intervention, followed by the other intervention. Each intervention will consist of 14 days.
89134109|NCT05166564|Experimental|PROMED (Experimental Intervention 1)|A Protein Enriched Mediterranean Diet (PROMED) intervention. Participants will receive individually tailored resources to encourage adoption of a protein-enriched Mediterranean diet pattern.
89134110|NCT05166564|Experimental|PROMED-EX (Experimental Intervention 2)|A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention. Participants will receive the same PROMED diet resources (Experimental Intervention 1) and an individually tailored exercise intervention.
89134111|NCT05166564|No Intervention|Control group|'Standard Care' - consisting of a general diet information sheet.
89134112|NCT05148039|Active Comparator|Community cohort|Participants from the Ehlers Danlos UK society community who low diet quality
89134113|NCT05148039|Active Comparator|Clinic cohort|Participants from a Tertiary Neurogastroenterology clinic who have low die quality
89134114|NCT05135910|Experimental|HSG|Hallux terbinafine subungual gel
89134115|NCT05117008|Experimental|belantamab mafodotin|Belantamab mafodotin is an intravenous drug.
89134116|NCT05105789|Experimental|BinaxNOW Test + Lollipop PCR|"If a symptomatic participant's initial at-school BinaxNOW test was positive, then their study participation is complete after providing the lollipop swab for PCR testing.~If a symptomatic participant's initial at-school BinaxNOW test was negative, then they will be asked to complete an at-home BinaxNOW test approximately 24 hours later.~For the at-home BinaxNOW testing, the participant will schedule a follow-up virtual visit with the study coordinator. If they are unable to complete a virtual visit, they will schedule an in-person home visit. They will also be sent home with a BinaxNOW testing kit."
89134117|NCT05077956||Recently Diagnosed Multiple Sclerosis|Recently diagnosed MS, who have had a clinical attack within the last 6 months, have not received steroids in the last 30 days, and have not started on a disease modifying therapy (DMT).
89134118|NCT05077956||Clinically Stable Relapsing Multiple Sclerosis|Clinically stable relapsing MS, who are receiving a FDA-approved MS DMT and have had no evidence of a clinical relapse for at least the past 12 weeks or gadolinium enhancing lesions on MRI in the prior 4 weeks.
89134119|NCT05077956||Relapsing Multiple Sclerosis on Disease Modifying Therapy|Relapsing MS on a FDA-approved DMT with evidence of recent breakthrough disease, with a documented clinical relapse and/or gadolinium-enhancing lesion(s) on brain or spinal cord MRI taken within the 4 weeks.
89134120|NCT05077956||Healthy Volunteers|Patients without evidence of inflammatory systemic or CNS disease, who require CSF removal for some other cause, such as for idiopathic intracranial hypertension or communicating hydrocephalus.
89134121|NCT05074121|Experimental|NAC|Group receiving intervention/study drug NAC
89134122|NCT05074121|Placebo Comparator|Placebo|Group receiving placebo
89134123|NCT05053308|Active Comparator|IV PCA (proportional dosage)|Breakthrough pain control by bolus based IV patient-controlled anagesia Fentanyl bolus = MME * 15%
89134124|NCT05053308|Experimental|SL-FTN (equivalent dose for PCA bolus)|Breakthrough pain control by sublingual fentanyl Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
89134125|NCT05025462|Experimental|SPF|Salmon peptide fraction supplement: powder mixed in water
89134126|NCT05025462|Active Comparator|Comparator|Casein peptide fraction supplement: powder mixed in water
89134127|NCT05025332|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
89134128|NCT05012397|Experimental|Milademetan (RAIN-32)|260 mg once dailly orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
89134129|NCT05011851|Experimental|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
89134130|NCT05005117|Experimental|Laparoscopic operation|Laparoscopic emergency colon resection
89134131|NCT05005117|Active Comparator|Open operation|Open emergency colon resection
89234248|NCT00993876|Active Comparator|IPT|interpersonal psychotherapy
89134132|NCT04971057|No Intervention|Control Group|The control group received routine care
89134133|NCT04971057|Experimental|Multimedia information Group|The experimental group received a multimedia information
89134134|NCT04969991|Experimental|Varespladib: 250 mg QD + Placebo + placebo|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon and 1 placebo tablet in the evening.
89134135|NCT04969991|Experimental|Varespladib: 250 mg BID + placebo|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning and in the evening. In order to maintain the blind, they will also take 1 placebo tablet in the afternoon.
89234249|NCT04002336|Active Comparator|Traditional Voice Therapy|Standard of care (traditional) voice therapy.
89234250|NCT04002336|Experimental|App Group|Voice therapy using a smartphone app.
89134136|NCT04969991|Experimental|Varespladib: 250 mg TID|For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, in the afternoon, and in the evening.
89134137|NCT04969991|Placebo Comparator|Placebo|For 7 days, and in addition to institutional standard of care, participants will take 1 placebo tablet in the morning, in the afternoon, and in the evening.
89134138|NCT04969991|Experimental|Varespladib: 250mg BID (Part 2 of trial)|Dose chosen for Part 2 was twice a day dosing. For 7 days, and in addition to institutional standard of care, participants will take 250 mg varespladib in the morning, and in the evening.
89134139|NCT04969991|Placebo Comparator|Placebo (Part 2 of trial)|For 7 days, and in addition to institutional standard of care, participants will take 1 placebo tablet in the morning, and in the afternoon.
89134140|NCT04964778|Experimental|Arm1: SKED© only first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 1 will be in the following order: SKED© only; SKED©+OSS-II©; SKED©+Vacuum mattress; SKED©+foam padding
88802638|NCT04757948|Placebo Comparator|Sham-TENS|For the sham-TENS group, the protocol is identical to the TENS group, however the electrical wires have been severed and re-attached in the control unit. As such, the unit will flash a light but there will be no current delivered. The subject is told that no sensation is required. The amplitude will be turned up to a maximum setting of 8/10 and left there for 20 minutes, then the device turned off and pads removed.
89134141|NCT04964778|Experimental|Arm 2: SKED©+Vacuum mattress first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 2 will be in the following order: SKED©+Vacuum mattress; SKED©+OSS-II©; SKED©+foam padding, SKED© only
89134142|NCT04964778|Experimental|Arm 3: SKED©+OSS-II© first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 3 will be in the following order: SKED©+OSS-II©;SKED©+Vacuum mattress; SKED© only; SKED©+foam padding
89134143|NCT04964778|Experimental|Arm 4: SKED©+foam padding first|Each participant will be packaged using a SKED© system with no assumed spinal injury. Each arm will consist of the same interventions in a specified, but unique order. Arm 4 will be in the following order: SKED©+foam padding, SKED©+Vacuum mattress; SKED© only; SKED©+OSS-II
89134144|NCT04960618|Experimental|Participants with confirmed mycosis fungoides/Sezary syndrome|Participants will have confirmed mycosis fungoides/Sezary syndrome, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher.
89134145|NCT04954664|Experimental|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
89134146|NCT04954664|Active Comparator|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
89134147|NCT04948307|Other|SL BUP/NAL SOC background therapy|standard of care. Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.
89134148|NCT04948307|Experimental|SL BUP/NAL + OXD01|standard of care + OXD01 (digital therapy). Subjects in both groups will receive the assigned treatment for 24 weeks. Subjects in both groups may also be encouraged to participate in behavioral health therapies in accordance with the Investigator's standard of practice.
89134149|NCT04936607|Experimental|Personnalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; >18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio <2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
89134150|NCT04936607|Active Comparator|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
89134151|NCT04900792|Experimental|Cohort 1 (starting)|"Radiation Phase~Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.~Ferumoxytol: 512 g administered intravenously (IV) the day before radiation and then during weeks 5 to 6 of radiation therapy.~Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks)~Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first).~Adjuvant Phase~Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles~Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle~Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of chemotherapy."
89134152|NCT04900792|Experimental|Cohort 2|"Radiation Phase~Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.~Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, about 1 week after dose 1, during weeks 5 to 6 of radiation therapy, and then a week after that (for a total of 4 ferumoxytol infusions).~Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks)~Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first).~Adjuvant Phase~Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles~Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle~Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of"
89234251|NCT05088018|Experimental|Active Cannabigerol|25 mg daily swallowable Cannabigerol tablets for 2 weeks, immediately followed by 50 mg daily swallowable Cannabigerol tablets for 2 weeks
89234252|NCT05088018|Placebo Comparator|Placebo|25 mg daily swallowable placebo tablets for 2 weeks, immediately followed by 50 mg daily swallowable placebo tablets for 2 weeks
88802639|NCT01893476|No Intervention|control|In this arm, practitioners will provide usual care for COPD patients.
89134153|NCT04890223|Experimental|Intervention group|The participants in the intervention group will be asked to identify an unfavourable behaviour that they wish to change when filling out the baseline questionnaire. The research nurse will conduct the individual face-to-face brief MI interviews for this purpose, which will last for approximately five to ten minutes. After the face-to-face brief MI interviews, the participants in the intervention group will receive brief MI messages individually by means of mobile instant messaging for six months from the baseline. After six months, the brief MI messages will cease to be delivered to the participants in the intervention group, with whom the research team will then maintain only minimal contact until the 12-month follow-up.
89134154|NCT04890223|Placebo Comparator|Control group|Participants in the control group will be asked to identify an unfavourable behaviour that they want to change at the baseline but, rather than brief MI interviews delivered face-to-face, received generic health advice consultations on the selected unfavourable behaviour that lasted approximately five to ten minutes. Each participant will receive a self-help smoking cessation booklet titled Be Smart, Quit Smoking! published by the Hong Kong Council on Smoking and Health with information about the negative health consequences of smoking, reasons to quit, strategies for quitting, and smoking cessation services available in Hong Kong along with a public quitline number (specifically, 1833183). Those who express the intention to quit at follow-ups will receive usual smoking cessation support.
89134155|NCT04875754|Experimental|Group 1: ICM-203 (Low dose) vs Placebo|8 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e12 vg (n=6) or placebo (n=2) into the target knee at Day 1
89134156|NCT04875754|Experimental|Group 2: ICM-203 (Medium dose) vs Placebo|4 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 2x10e13 vg (n=3) or placebo (n=1) into the target knee at Day 1
89134157|NCT04875754|Experimental|Group 3: ICM-203 (High dose) vs Placebo (Optional)|4 subjects will be randomized to receive a single intra-articular injection of ICM-203 at 6x10e13 vg (n=3) or placebo (n=1) into the target knee at Day 1
89134158|NCT04869670|Experimental|G-POEM|
89134159|NCT04869670|Sham Comparator|Sham procedure|
89134160|NCT04864405|Active Comparator|Morning administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient wake up time
89134161|NCT04864405|Active Comparator|Evening administration of endocrine therapy|Administration of endocrine therapy defined as, within one hour of the patient bed time
89134162|NCT04853888|Other|Intervention group|"A quasi-experimental design was selected to more closely approximate service delivery models in agencies that do not typically employ control groups.~Given promising findings (from seven ATTACH™ pilot studies), a randomized controlled trial design, even employing wait-list controls was deemed unacceptable and even unethical by patients, health care professionals and health system administrators in engagement activities surrounding the preparation of this proposal."
89134163|NCT04782245|Experimental|Treatment group Daplagliflozin|
89134164|NCT04782245|Placebo Comparator|Control group|
89134165|NCT04775108|Experimental|Implanted patients|Implantation of Epygon mitral valve prosthesis
89134166|NCT04751201|Experimental|Receiving mindfulness open and circular program|
89134167|NCT04750707|Other|single arm|Single arm, open label of hydroxyurea starting at 20mg/kg and increased to 30mg/kg depending on clinical need and according to standard guidelines
89134168|NCT04748809|Active Comparator|Arm_1|Anti-inflammatory diet 1
89134169|NCT04748809|Experimental|Arm_2|Anti-Inflammatory diet 2
89134170|NCT04743921|Experimental|Reparel Sleeve Group|Patients receiving reparel knee sleeve for treatment of knee osteoarthritis.
89134171|NCT04731337|Active Comparator|Patient's normal canine occlusal relationship|The distance between the gingival zenith from the upper to the lower deciduous canines was determined by the digital calliper in millimetres (Shenzhen Jiabaili Electronic Commerce Co., Ltd) (fig1,2,3) at the right and left sides and a digital camera photographed the reading (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
89134172|NCT04731337|Sham Comparator|Canine occlusal relationship after full mouth rehabilitation|The distance between the gingival zenith from the upper to the lower deciduous canines was determined by the digital calliper in millimetres (Shenzhen Jiabaili Electronic Commerce Co., Ltd) (fig1,2,3) at the right and left sides and a digital camera photographed the reading (iPhone 11 dual 12 MP Ultra-Wide and wide camera, Apple Inc.).
89134173|NCT04714905||Pregnant Cohort|Pregnant (up to and including 15 weeks), 18+ years of age.
89134174|NCT04714905||Pre-pregnancy Cohort|Anticipating to be pregnant, 18-40 years of age.
89134175|NCT04644315|Experimental|ALK-positive Solid Tumors|Participants with locally advanced or metastatic ALK-positive tumors will receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
89134176|NCT04642898|Experimental|Standard Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
89134177|NCT04642898|Experimental|Standard Group, Full Intervention|Participants in this group will receive 12 sessions of treatment in accordance with the standard, published Unified Protocol (UP) manual.
89134178|NCT04642898|Experimental|Capitalization Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
89134179|NCT04642898|Experimental|Capitalization Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that capitalize on patient strengths.
89134180|NCT04642898|Experimental|Compensation Group, Brief Intervention|Participants in this group will receive 6 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
89134181|NCT04642898|Experimental|Compensation Group, Full Intervention|Participants in this group will receive 12 sessions of treatment organized to prioritize skills that compensate for patient weaknesses.
89134182|NCT04629859|Experimental|study arm|dento skeletal class III patients will undergo a mandibular setback surgery and maxillary advancement
89134183|NCT04629859|Experimental|controlled arm|dento skeletal class III patients will undergo a mandibular setback surgery
89134184|NCT04608877|Placebo Comparator|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
89134185|NCT04608877|Experimental|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
89134186|NCT04597827||Semantic dementia|Diagnosis of semantic dementia (revised criteria Moreaud et al., 2008; based on Neary et al., 1998)
89134187|NCT04597827||Alzheimer's disease|NIAAA 2011 criteria
89134188|NCT04597827||Control|MMSE above 27, no neurological or psychiatric disorder
89134189|NCT04596098||Group A|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient not previously followed in Grenoble University Hospital for a chronic disease.
89134190|NCT04596098||Group B|Patient hospitalized in Grenoble University Hospital for CoViD19. Patient followed in Grenoble University Hospital for a chronic disease.
89134191|NCT04594694|Active Comparator|Treatment A: BZF 200 milligrams (mg) Immediate release (IR)|Participants will receive Bezafibrate (BZF) 200 mg IR + OCA Placebo + BZF 400 mg Placebo
89134192|NCT04594694|Active Comparator|Treatment B: BZF 400 mg SR|Participants will receive BZF 400 mg SR + OCA Placebo + BZF 200 mg Placebo
89134193|NCT04594694|Experimental|Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR|Participants will receive OCA 5 mg to 10 mg + BZF 200 mg IR + BZF 400 mg Placebo
89134194|NCT04594694|Experimental|Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR|Participants will receive OCA 5 mg to 10 mg + BZF 400 mg SR + BZF 200 mg Placebo
89134195|NCT04594694|Experimental|Long-term safety extension (LTSE) phase: OCA + BZF|Participants will continue the original treatment assignment allocated during the DB Period. The OCA and BZF dose may be optimized based on safety and efficacy during the DB period.
89134196|NCT04586504|Experimental|0.2 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.2 mg/kg.
89134197|NCT04586504|Experimental|0.3 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.3 mg/kg.
89134198|NCT04586504|Experimental|0.4 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.4 mg/kg.
89134199|NCT04586504|Experimental|0.5 mg/kg|Children in a single urban pediatric emergency department (ED) randomized to receive IN midazolam at 0.5 mg/kg.
89134200|NCT04579900|Experimental|Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
89134201|NCT04579900|Active Comparator|Non Type 2 Diabetes patients|Upper gut biopsies and lower gut samples
89134202|NCT04571255|Experimental|Intervention group|Participants in the intervention group will receive a minimum of 3 and a maximum of 6 music therapy sessions (i.e. Music-Assisted Relaxation) during a two weeks time frame.
89134203|NCT04571255|No Intervention|Control Group|Treatment as usual.
89134204|NCT04557891|Experimental|Low Intensity Focused Ultrasound|"Device: Low Intensity Focused Ultrasound Device~Low Intensity Focused Ultrasound Pulsation (LIFUP) of amygdala (a key area for anxiety) will be performed during two sessions. The proposed experiment will involve behavioral (e.g. HAM-A) and paramedical (i.e., MRI/fMRI) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session). The device does not produce a sound when operating and as such, the active group will well blinded."
89134205|NCT04557891|Sham Comparator|Sham|Sham Treatment consists of placing the device but not turning it on. The device does not produce a sound when operating and as such, the sham group will well blinded.
89134206|NCT04544995|Experimental|Part 1A: Dose Escalation|Participants with body weight of ≥ 20 kilogram (kg) and who can swallow niraparib tablets will receive niraparib tablets and dostarlimab.
89134207|NCT04544995|Experimental|Part 1B: Dose Escalation|Participants who are not able to swallow niraparib tablets or who have a body weight of <20 kg will receive niraparib age-appropriate oral liquid formulation (AAOLF) (once available) and dostarlimab.
89134208|NCT04544995|Experimental|Part 2A: Cohort Expansion for Osteosarcoma|Participants with osteosarcoma who are not able to swallow niraparib tablets or have a body weight of < 20 kg, will receive the RP2D of niraparib AAOLF (when available) and dostarlimab. Participants with osteosarcoma who are able to swallow niraparib tablets and have a body weight ≥20 kg will receive the RP2D of niraparib tablets and dostarlimab.
89134209|NCT04544995|Experimental|Part 2B: Cohort Expansion for Neuroblastoma|"Participants with neuroblastoma who are not able to swallow niraparib tablets or who have a body weight of <20 kg will receive the RP2D of niraparib AAOLF (when available) and dostarlimab.~Participants with neuroblastoma who are able to swallow niraparib tablets and have a body weight of ≥ 20 kg, will receive the RP2D of niraparib tablets and dostarlimab, when available."
89234253|NCT00535626|Other|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell used in revision total hip replacement
89134210|NCT04527302|Active Comparator|active tDCS+exposure based CBT|The exposure and response prevention (ERP) treatment concurrently with an anode transcranial direct current stimulation over the mPFC will be applied 8 times (tDCS+ERP, 8sessions) in the whole treatment.
89134211|NCT04527302|Sham Comparator|sham tDCS +exposure based CBT|the exposure and response prevention (ERP) treatment concurrently with an sham transcranial direct current stimulation over the mPFC will be applied 8 times (sham tDCS+ERP, 8 sessions) in the whole treatment.
89134212|NCT04522843||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
89134213|NCT04522843||Colitis|Patients with active colitis
89134214|NCT04522843||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
89134215|NCT04510324|Active Comparator|Red meat patties|Participants will be randomized to group 1: Red meat, ''Costco Kirkland Signature 1/4 lb Ground Beef Patties'' (Beef burger). Participants will be given two patties per day.
89134216|NCT04510324|Experimental|Plant-based patties|"Participants will be randomized to group 2: plant-based burger which contains no animal products. The Plant-based burger selected is ''Beyond Burger (https://www.beyondmeat.com/products/the-beyond-burger/ ). Participants will be given two patties per day."
89134217|NCT04508985|Experimental|Intervention|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
89134218|NCT04508985|Other|Continuation of standard of care|No intervention, Continuation RAAS inhibitor [continued standard of care].
89134219|NCT04487847|Experimental|PIRADS 1-2|25 patients with PIRADS 1-2 (probably benign) on mpMRI
89134220|NCT04487847|Experimental|PIRADS 3|25 patients with PIRADS 3 (equivocal scan) on mpMRI
89134221|NCT04487847|Experimental|PIRADS 4-5|25 patients with PIRADS 4-5 (probably malignant) on mpMRI
89234254|NCT00994032|Active Comparator|vertebroplasty|
89134222|NCT04479306|Experimental|Arm A (osimertinib, alisertib)|Patients receive osimertinib PO QD on days 1-28 and alisertib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm B.
89134223|NCT04479306|Experimental|Arm B (osimertinib, sapanisertib)|Patients receive osimertinib PO QD on days 1-28 and sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease may crossover to Arm A.
89134224|NCT04449952|Experimental|AFEO-Containing Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive AFEO-containing mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 milliliter (mL) of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
89134225|NCT04449952|Experimental|Listerine Cool Mint Mouth Rinse (Marketed product)|Participants with Diabetes (Type 1 and 2) will be randomized to receive Listerine cool mint mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
89134226|NCT04449952|Experimental|5 Percent (%) Hydroalcohol Mouth Rinse|Participants with Diabetes (Type 1 and 2) will be randomized to receive 5% Hydroalcohol mouth rinse with a marketed fluoride-containing dentifrice, floss (if flossing is part of their normal oral care routine), a marketed soft bristled toothbrush and a timer (if needed). They will brush for at least one minute using full ribbon of a marketed toothpaste on the provided toothbrush. After brushing, rinse for 30 seconds with 20 mL of the assigned mouth rinse twice daily (morning and evening) for 12 consecutive Weeks.
89134227|NCT04419389|Experimental|Safety Lead-In Cohort 1|APR-246 + Acalabrutinib in Subjects with R/R CLL.
89134228|NCT04419389|Experimental|Safety Lead-In Cohort 2|APR-246 + Venetoclax + Rituximab in Subjects with R/R CLL.
89134229|NCT04419389|Experimental|Expansion Cohorts|APR-246 + (Acalabrutinib, OR, (Ven+R)) in Subjects with R/R TP53-mutant CLL, and/or MCL, and/or RT
89134230|NCT04419389|Experimental|Safety Lead-In Cohort 3|APR-246 + Venetoclax + Rituximab in Subjects with RT
89134231|NCT04410991|Experimental|SAR442168|Dose 1 of oral SAR442168 daily + placebo to match the teriflunomide tablet once daily
89134232|NCT04410991|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
89134233|NCT04410978|Experimental|SAR442168|Dose 1 of oral SAR442168 + placebo to match the teriflunomide tablet once daily
89134234|NCT04410978|Active Comparator|Teriflunomide|Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
89134235|NCT04410523|Experimental|CSJ117 0.5mg|CSJ117 0.5 mg inhaled once daily
89134236|NCT04410523|Experimental|CSJ117 1mg|CSJ117 1 mg inhaled once daily
89134237|NCT04410523|Experimental|CSJ117 2mg|CSJ117 2 mg inhaled once daily
89134238|NCT04410523|Experimental|CSJ117 4mg|CSJ117 4 mg inhaled once daily
89134239|NCT04410523|Experimental|CSJ117 8mg|CSJ117 8 mg inhaled once daily
89134240|NCT04410523|Placebo Comparator|Placebo|Placebo inhaled once daily
89134241|NCT04394559|No Intervention|Usual care|inpatient pharmacists as available; standard discharge orders; standard follow up visit.
89134242|NCT04394559|Experimental|Intervention|Discharge counseling; discharge opioid order set; post-discharge pain management follow up; patient pain management app.
89134243|NCT04390568|Experimental|Spesolimap (BI 655130) - 450 milligram (mg) - intravenous (IV)|A single dose of 450 mg Spesolimap was administered as solution for infusion intravenously over 90 minutes (mins) after an overnight fast.
89134244|NCT04390568|Experimental|Spesolimap - 900 mg - IV|A single dose of 900 mg Spesolimap was administered as solution for infusion intravenously over 90 mins after an overnight fast.
89134245|NCT04390568|Experimental|Spesolimap - 1200 mg - IV|A single dose of 1200 mg Spesolimap was administered as solution for infusion intravenously over 90 mins after an overnight fast.
89134246|NCT04390568|Experimental|Spesolimap - 300 mg - subcutaneous (SC)|A single dose of 300 mg Spesolimap was administered as solution for injection subcutaneously in the abdominal region within 60 seconds (s) after an overnight fast.
89134247|NCT04390568|Experimental|Spesolimap - 600 mg - SC|A single dose of 600 mg Spesolimap was administered as solution for injection subcutaneously in the abdominal region within 60 s after an overnight fast.
89134248|NCT04375072|Experimental|active tDCS paired with active MBM,|
89134249|NCT04375072|Active Comparator|sham tDCS paired with active MBM|
89134250|NCT04375072|Active Comparator|active tDCS paired with sham MBM|
89134251|NCT04375072|Sham Comparator|sham tDCS paired with sham MBM|
89134252|NCT04373707|Active Comparator|Low Prophylactic Dose of Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
89134253|NCT04373707|Experimental|Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
89134254|NCT04300075||CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
89134255|NCT04214496||Postoperative Delirium Risk Patients|Preoperative cognitive function testing- EEG monitorization during surgery - Postoperative function testing
89134256|NCT04211259|Experimental|Cohort I (loratadine)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive loratadine PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
89134257|NCT04211259|Placebo Comparator|Cohort II (placebo)|Beginning 5 days before the first dose of standard of care filgrastim, patients receive placebo PO QD. Treatment continues until 5 days after completion of stem cell mobilization in the absence of disease progression or unacceptable toxicity.
89134258|NCT04190225|Experimental|Multi-technology physical activity intervention|Digital/social media
89134259|NCT04190225|No Intervention|Control|Control group receives a Fitbit but none of the intervention components.
89234255|NCT00994032|Active Comparator|Medical Treatment|
89134260|NCT04156906|Experimental|D+ RH genotype matched Red Blood Cell Transfusion|Investigators will provide one red cell unit of D+ RH genotype matched RBCs at the first transfusion study visit. The remainder of units will be provided per clinical standard of care, i.e. D-, CEK-matched, and negative for all other antigens the patient is alloimmunized against. If laboratory monitoring shows no reappearance of anti-D and no signs of increased red cell hemolysis, the patient will receive one unit of D+ RH genotype matched RBCs at the 2nd transfusion study visit, and if tolerated, D+ red cell exposures will increase by one unit per study visit until all units required are D+.
89134261|NCT04156893|Experimental|RH genotype matched red cell transfusions|Subjects will receive RH genotyped matched red cell units for transfusion in addition to standard serologic C, E, and K antigen matching and being hemoglobin S negative, which is our institutional standard of care for patients with Sickle Cell Disease.
89134262|NCT04140149||Participants|Adults who have made a suicide attempt in the past 3 months who have been referred to, and enrolled in, the Living with Hope class.
89134263|NCT04133012|Other|Single Arm|Single arm composed by 34 HIV-1 infected male subjects
89134264|NCT04131166|Other|Metabolically healthy lean|Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
89134265|NCT04131166|Experimental|Metabolically healthy obese - Mediterranean diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the Mediterranean diet group.
89134266|NCT04131166|Experimental|Metabolically healthy obese - Low-carbohydrate ketogenic diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-carbohydrate ketogenic diet group.
89134267|NCT04131166|Experimental|Metabolically normal obese - Low-fat diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-fat diet group.
89134268|NCT04131166|Experimental|Metabolically unhealthy obese - Mediterranean diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the Mediterranean diet group.
89134269|NCT04131166|Experimental|Metabolically unhealthy obese - Low-carbohydrate ketogenic diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-carbohydrate, ketogenic diet group.
89134270|NCT04131166|Experimental|Metabolically unhealthy obese - Low-fat diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-fat diet group.
89134271|NCT04116320|Experimental|Cohort 1, primary regimen (Regimen 1a)|FUSA therapy and standard of care PD-1 blockade. FUSA therapy will be administered on day 8.
89134272|NCT04116320|Experimental|Cohort 1, secondary regimen (Regimen 2a)|FUSA therapy, standard of care PD-1 blockade, and intratumoral poly-ICLC will be administered on day 8.
89134273|NCT04116320|Experimental|Cohort 2, primary regimen (Regimen 1b)|FUSA therapy will be administered on day 1.
89134274|NCT04116320|Experimental|Cohort 2, secondary regimen (Regimen 2b)|FUSA therapy and intratumoral poly-ICLC will be administered on day 1.
89134275|NCT04086030|Sham Comparator|Sham Postoperative Rehabilitation|Patients in this group will complete the standardized postoperative rehabilitation program with sham BFR, which is pressure of 20 mmHG. Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set. The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
89134276|NCT04086030|Experimental|BFR Postoperative Rehabilitation|Assigned intervention of BFR where exercises are performed with BFR at 80% limb occlusion pressure (LOP). Patients in this group will undergo blood flow restriction (BFR) training during their postoperative rehabilitation program (use an inflatable cuff that prevents blood flow from flowing out of the leg while patients perform physical therapy exercises). Exercises will be performed for 4 sets of 30/15/15/15 repetitions with a 30 second rest period between each set.16 The tourniquet cuff will remain inflated for all sets and rest periods for the selected exercise. A cadence of 2-second concentric and 2- second eccentric contractions (4 second time under tension) will be maintained for each BFR repetition. Upon completion of the exercise, the tourniquet cuff will be deflated, and a 1 minute minimum rest period will occur before moving on to another BFR exercise.
89134277|NCT04060784|Experimental|Immediate implant placement and provisionalization|On the control group, Implant will be placed immediately after tooth extraction. The gap between the implant and buccal bone will be filled with bone graft. Temporary crown will be attached to implant fixture.
89134278|NCT04060784|Experimental|Socket shield technique|On the test group, Implant will be placed immediately after tooth extraction. A piece of root shield will be retained intentionally at facial side. Temporary crown will attached to implant fixture.
89134279|NCT04022772|Experimental|GROUP I (PACK Health program)|Patients participate in PACK Health program consisting of weekly contact with an assigned health coach via text message, phone call, and email for 3 months. After 3 months, patients continue to be contacted by the health coach at least once monthly for an additional 3 months.
89134280|NCT04022772|Active Comparator|GROUP II (standard of care)|Patients receive standard of care support services over 6 months.
89134281|NCT04008498|Experimental|AEEG monitoring|"Babies whose families consent to involvement will have their head cleaned, EEG leads attached, the monitor set up, and observations.~Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, the investigators will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby.~Before being discharged home, the babies will have additional follow-up. They will receive magnetic resonance imaging (MRI) of the brain on a 1.5T scanner at the University of Sheffield. They will also have a standardised examination of their neurological system performed by a physiotherapist (The Hammersmith Neonatal Neurological Examination)."
89134282|NCT04008355|Experimental|60mg/day/84 days|Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.
89134283|NCT04008355|Experimental|80mg/day/10 days followed by 50mg/day/74 days|Patients randomized in this arm will receive 80 mg of study investigational drug AZP2006 once daily during 10 days followed by 50 mg of study investigational drug AZP2006 once daily during the next 74 days.
89134284|NCT04008355|Placebo Comparator|Placebo/84 days|Patients randomized in this arm will receive placebo solution once daily during 84 days.
89134285|NCT03986931|Experimental|Pharmacist-Bidirectional Texting Group|Patients enrolled in the Pharmacist-Bidirectional Texting Group will return 7 morning and 7 evening blood pressure measurements via text message. The report will be shared with a pharmacist who will monitor them for 12 months. The pharmacist will have access to their entire medical record and will provide support and education via text messaging, email, or phone calls, whichever is preferred by the patient. The pharmacist will develop a care plan and make recommendations to the physician through the electronic medical record to quickly adjust therapy to improve control. They will also recommend laboratory testing if indicated. They will have contact with the patient every 2-3 weeks while blood pressure is uncontrolled, and at least every 2 months when it is controlled. The pharmacist will track all recommendations made to physicians and whether or not they were implemented, modified, or rejected.
89134286|NCT03986931|Active Comparator|Control Group|Patients randomized to the control group will also return 7 morning and 7 evening blood pressure measurements. The report will be shared with a pharmacist who will call the patient to discuss the measurements and possibly recommend follow up with a physician, but no other pharmacist intervention or monitoring will occur during the 12 months.
89134287|NCT03955991|Experimental|R-CBSM|10 weeks of group intervention convene by a broadband connection for approximately 75-90 minutes. Intervention given prior to Influenza Vaccine.
89134288|NCT03955991|Active Comparator|Wait List Condition (WLC)|Persons assigned to this group will receive R-CBSM approximately 28 days after receiving the Influenza Vaccine.
89134289|NCT03953768|Experimental|Patients undergoing device implantation|Patients undergoing device implantation with vagal nerve stimulator (VNS) for epilepsy
89134290|NCT03934905|Active Comparator|sulforaphane|Processed SFN-rich extract will be purchased in form of caplets from Nutramax Laboratories, Inc. 2208 Lakeside Blvd Edgewood, MD 21040. Caplets containing SFN-rich broccoli sprout extracts from Nutramax Labs will be dispensed to participants in sealed bottles with instructions to keep them in a household freezer. Size of the caplet will be about 2 cm in length. Dosing will be based on weight and will be dosed daily for 12 weeks.
89134291|NCT03934905|Placebo Comparator|Placebo|Placebo caplets will comprise of microcrystalline cellulose from Nutramax Labs and will be dispensed to participants in sealed bottles with instructions to keep them in a household freezer. Placebo pills will be identical in appearance to the sulforaphane pills and will be dosed in a similar manner (identical number of pills based on weight, daily dosing and for 12 weeks)
89134292|NCT03916263|Experimental|Traditional Treatment|Participant receives recommendations for caloric intake, exercise and prescription for metformin if indicated
89134293|NCT03916263|Other|One-On-One Low Starch Dietary Instruction|Participant receives One-On-One Low Starch Dietary Instruction from Study Collaborator
89134294|NCT03916263|Other|Low Starch Dietary Instruction by Video|Participant receives Low Starch Dietary Instruction by Video Link
89134295|NCT03901196||Interstitial Lung Disease|Ex : sarcoidosis, IPF
89134296|NCT03889418|Active Comparator|Electronic medical recorded clinical decision support|Usual care only
89134297|NCT03889418|Active Comparator|stepped opioid collaborative care model|Usual care AND collaborative care with behavioral health integration
89134298|NCT03870243|Active Comparator|Bubble CPAP|6 hospitals will be selected randomly for this arm
89134299|NCT03870243|Active Comparator|Low flow oxygen|6 hospitals will be selected for low flow oxygen therapy
89134300|NCT03802019|Experimental|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will complete a 30-day experimental period when they will continue to receive their own preferred brand of cigarettes (i.e., control group).
89134301|NCT03802019|Experimental|LNC Cigarettes + Gray Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in standard investigational packaging (gray).
89134302|NCT03802019|Experimental|LNC Cigarettes + Red Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in red packaging.
89134303|NCT03802019|Experimental|LNC Cigarettes + Blue Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in blue packaging.
89134304|NCT03802019|Experimental|LNC Cigarettes + Plain Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in plain packaging.
89134305|NCT03788694|Experimental|Intranasal Ketamine|Subjects will receive study medication, intranasal ketamine.
89134306|NCT03749109|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.
89134307|NCT03749109|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
89134308|NCT03745521||X-linked Hypophosphatemia (XLH)|Hypophosphatemic Rickets/osteomalacia
89134309|NCT03599297|Experimental|Bilateral synchronous simultaneous stone surgery|Patients who will be operated for kidney stones at both their kidneys in a single surgery session will be included in the study. Patients will undergo percutaneous nephrolithotomy for one side and flexible ureteroscopy for the other side.
89134310|NCT03555188|Experimental|Ondansetron|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
89134311|NCT03555188|Placebo Comparator|Placebo|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
89134312|NCT03547115|Experimental|voruciclib monotherapy and voruciclib in combination with venetoclax|"voruciclib monotherapy - Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level and disease type (AML or B-cell malignancies)~voruciclib and venetoclax - Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level for AML subjects"
89134313|NCT03543267|Experimental|epileptic Patients|
89134314|NCT03540706|Experimental|Care with C-reactive protein assay in micro method|During a visit to the general practitioner for a clinical suspicion of respiratory infection, the doctor will practice a C-reactive protein assay in micro method. He will prescribe antibiotics according to the result of the dosage
89134315|NCT03540706|No Intervention|Care without C-reactive protein assay in micro method|Simple management of a patient coming for a suspicion of respiratory infection without dosage of the C-reactive protein in micro method
89134316|NCT03517371|Experimental|mHealth delivered exercise program|"Participants in the mHealth delivered exercise program have up to 10 in-person visits with a physical therapist over 12 months. The mHealth exercise program, consisting of walking, strengthening and stretching exercises, is prescribed and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week. The exercise program is video-recorded and accessed on a smartphone or computer tablet via an application (app). Cognitive-behavioral elements are integrated emphasizing participant engagement in managing their health condition. Components of the mHealth program include goal setting, action planning, automated rewards, self-monitoring of progress and a remote connection to a physical therapist through a messaging feature."
89134317|NCT03517371|Active Comparator|Exercise only|Participants in the control group have up to 10 in-person visits with a physical therapist over 12-months - equivalent to the dose provided to the mHealth condition. Participants are instructed by the physical therapist to engage in walking and perform the same progressive resistance and stretching exercises (tailored to their needs and provided in written format) at the same frequency (5x/week) as participants in the mHealth condition. Participants in the control condition are instructed to gradually progress their exercise program and to increase the amount of walking over a 1-year period. No cognitive-behavioral approaches or mHealth technology will be provided.
89134318|NCT03499509|Experimental|Low Glycemic Diet|
89134319|NCT03499509|Placebo Comparator|High Glycemic Diet|
89134320|NCT03497689|Experimental|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Subjects began Remodulin at 2 ng/kg/min subcutaneously (SC) or intravenously (IV) and were optimized to their maximum tolerated dose (MTD) of Remodulin. Subjects were then transitioned to Orenitram XR tablets (oral) based upon their Remodulin dose. Subjects were optimized on Orenitram therapy to a MTD. There were no maximum Remodulin or Orenitram doses specified during the study.
89134321|NCT03492437|Experimental|Dabigatran Etexilate|
89134322|NCT03492437|Experimental|Tepotinib + Dabigatran|
89134323|NCT03484182|Active Comparator|Standard Home Exercise Program|
89134324|NCT03484182|Experimental|Web-based Home Exercise Program|
89134325|NCT03466294|Experimental|Azacitidine and Venetoclax|On day 1 of cycle 1, Azacitidine 75 mg/m2 will be given by injection or infusion, and will continue for 7 days. Azacitidine doses will be given in subsequent cycles for patients who do not achieve response. Venetoclax will be administered orally once daily on days 2 through 28 in cycle 1. Beginning with cycle 2, and each subsequent cycle, venetoclax will be administered Days 1 through 28.
89134326|NCT03363867|Experimental|Atezolizumab, Bevacizumab and Cobimetinib (ABC)|
89134327|NCT03344198|Experimental|Firefighter (Veteran) Group|Firefighters with >10yrs experience. Circuit Training exercise & Modified Mediterranean diet
89134328|NCT03344198|Experimental|Firefighter (Novice) Group|Firefighters with <10yrs experience. Circuit Training exercise & Modified Mediterranean diet
89134329|NCT03344198|Experimental|Control Non-Firefighter Group|Non-Firefighter adults. Circuit Training exercise & Modified Mediterranean diet
89134330|NCT03310125|Experimental|Colchicine|Participants received over-encapsulated colchicine 0.5 mg tablet orally twice daily for 10 days.
89134331|NCT03310125|Placebo Comparator|Placebo|Participants received matching placebo capsules orally twice daily for 10 days.
89134332|NCT03277495|Active Comparator|Usual SREC pods Flavor|The liquid in the e-cigarette refills contains nicotine and comes in the following flavors: tobacco, menthol, blueberry, and watermelon. The participant will receive SREC pods in their usual flavor.
89134333|NCT03277495|Active Comparator|Choice of SREC pods Flavors|The liquid in the e-cigarette refills contains nicotine and comes in the following flavors: tobacco, menthol, blueberry, and watermelon. The participant will receive SREC pods in their choice of flavor.
89134334|NCT03193853|Experimental|Tak + cisplatin and nab paclitaxel|Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion.
89134335|NCT03191084|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
89134336|NCT03191084|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
89134337|NCT03092843||No functional capacity testing|6 minute walk Quality of life Questionaire
89134338|NCT03092843||Functional Capacity Testing|6 minute walk Quality of Life Questionnaire Metabolic stress test
89134339|NCT03055819|Experimental|ZiftLift Tissue Anchor|Use of ZiftLift Tissue Anchors for Brow Lift
89134340|NCT03005366|Active Comparator|Flecainide|Conventional cardioversion group using intravenous flecainide.
89134341|NCT03005366|Active Comparator|Vernakalant|Atria-preferential and atrial-specific blockade group using intravenous vernakalant.
89134342|NCT02851121|Other|Healthy volunteers|
89134343|NCT02791646|Experimental|PCST-Full|PCST-full will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
89134344|NCT02791646|Experimental|PCST-Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
89134345|NCT02756637||Prognostic|Patients with NLR who completed curative therapy (surgery with or without chemo)
89134346|NCT02756637||Predictive|Patients with NLR who were assigned to a trial arm (chemo or no chemo)
89134347|NCT02738866|Experimental|Palbociclib and Fulvestrant|Participants will receive fulvestrant with palbociclib until disease progression or unacceptable toxicity.
89134348|NCT02613754|Experimental|Contingency Management|Contingency Management (CM+): This procedure is designed to reinforce treatment attendance, non-gambling behaviour, and study completion. Participants will earn points that will be recorded on vouchers that could be subsequently redeemed for gift cards at a variety of local businesses. Submission of evidence of gambling behaviour or non-attendance re-sets the point value for future vouchers to the starting level. This intervention is in addition to Treatment as Usual.
89134349|NCT02613754|Active Comparator|Treatment as Usual|Treatment as Usual (TAU): This is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling.
89134350|NCT02576912|Experimental|Active Delta-9-THC and Placebo Pregnenolone|
89134351|NCT02576912|Experimental|Active Delta-9-THC and Active Pregnenolone|
89134352|NCT02576912|Experimental|Placebo Delta-9-THC and Active Pregnenolone|
89134353|NCT02576912|Placebo Comparator|Placebo Delta-9-THC and Placebo Pregnenolone|
89134354|NCT02497521||ADPKD|Patients with diagnosis of ADPKD, who are either evaluated for tolvaptan treatment indication, planned for tolvaptan treatment, or are already treated with tolvaptan
89134355|NCT02353546|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
89134356|NCT02353546|No Intervention|Usual Care|
89134357|NCT02326129||Obese with Type 2 Diabetes|Obese adolescents with Type 2 Diabetes
89134358|NCT02326129||Obese without Type 2 Diabetes|Obese adolescents without Type 2 Diabetes
89134359|NCT02326129||Normal weight|Normal weight adolescents
89134360|NCT02310698||Breast Cancer Screening Patients|"Women presenting for screening full field digital mammography (FFDM) and WBUS on the same day or within 30 days of one another.~o These women will be offered CEDM instead of the FFDM.~Women that are scheduled for CEDM alone.~o These women will be offered WBUS in addition to the CEDM.~Women scheduled for both CEDM and WBUS on the same day or within 30 days of one another."
89134361|NCT02266017|Experimental|Mobile Pain Coping Skills Training|Coping Skills Training for pain will be delivered to participants using video-conferencing via a tablet computer.
89134362|NCT02266017|Active Comparator|In person Pain Coping Skills Training|Participants will be provided with an in-person pain coping skills training intervention
89134363|NCT02232152|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid, fluorouracil)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 and fluorouracil IV over 46 hours on days 2-4. Courses repeat every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
89134364|NCT02102113|Other|No Family History of Psychosis (FHN)|Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
89134365|NCT02102113|Experimental|Family History of Psychosis (FHP)|Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
89134366|NCT02073981||Parkinson Disease|
89134367|NCT02070705|Experimental|Arm I (High-risk for familial/hereditary pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
89134368|NCT02070705|Experimental|Arm II (IPMN)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
89134369|NCT02070705|Experimental|Arm III (Pancreatic cancer)|Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection. Patients currently undergoing neoadjuvant therapy or who have already completed neoadjuvant therapy that were unable to undergo imaging at baseline and are now proceeding to resection will have one DCE MRI scan prior to surgical resection.
89134370|NCT02070705|Active Comparator|Arm IV (Healthy volunteers)|Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
89134371|NCT02041195|Active Comparator|Setmelanotide Once Daily|Once daily in the morning, equivalent placebo in evening.
89134372|NCT02041195|Active Comparator|Setmelanotide Split Dose|Split dose, one half in the morning and one half in the evening.
89134373|NCT02041195|Placebo Comparator|Placebo|Placebo in the morning, placebo in the evening.
89134374|NCT01984671|Experimental|Mobile Pain Coping Skills Training|Pain coping skills training
89134375|NCT01984671|No Intervention|Standard Care Control|
89134376|NCT01980355|Experimental|Tranexamic Acid|1000mg tranexamic acid; given over 15 minutes into the vein once prior to surgery.
89134377|NCT01980355|Placebo Comparator|Placebo|Placebo given over 15 minutes into the vein once prior to surgery.
89134378|NCT01899508|Experimental|Pain Coping Training with 3D viewer|All participants will receive a 1 and a half hour pain coping training while using the virtual reality viewer. We are testing the feasability of using the 3D viewer in collaboration with Pain Coping training to see if people who suffer from Osteoarthritis of the knee experience some pain relief.
89134379|NCT01771718||Human skin|Multiphoton microscopy imaging to collect information about changes in skin cells and fibrilar structure.
89134380|NCT01758432|Experimental|Module 1 (90 mg bolus)|90 mg PRT064445 given as a single IV
89134381|NCT01758432|Experimental|Module 1 (210 mg bolus)|210 mg PRT064445 given as a single IV bolus
89134382|NCT01758432|Experimental|Module 1 (420 mg bolus)|420 mg PRT064445 given as a single IV bolus
89134383|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min|600 mg PRT064445 given as follows: 420 mg IV over ~14 minutes (~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes)
89134384|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg bolus) 30mg/min|600 mg PRT064445 given as follows: up to 420 mg IV over ~14 minutes (~30 mg/min), followed by a second bolus of 180 mg IV over ~6 minutes (~30 mg/min), 45 minutes after completion of the bolus
89134385|NCT01758432|Experimental|Module 1 (420 mg bolus + 480 mg infusion) 4mg/min|900 mg PRT064445 given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes
89134386|NCT01758432|Placebo Comparator|Module 1 Placebo|Placebo administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.
89134387|NCT01604317|Active Comparator|Resuscitation-torso plastic bag|Resuscitation with plastic bag covering torso and lower extremities for first hour to assist with temperature regulation.
89134388|NCT01604317|Active Comparator|Resuscitation-partial-head plastic bag|Resuscitation with plastic bag covering torso, upper and lower extremities, and a portion of the head for first hour after birth to assist with temperature regulation.
89134389|NCT01583218|Experimental|Betrixaban|Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
89134390|NCT01583218|Active Comparator|Enoxaparin|Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days
89134391|NCT01044160||Oncology Group|The study will recruit from outpatient clinics with procedures designed to obtain a representative sample of research participants, in terms of diagnosis and time since diagnosis.
89134392|NCT01044160||Control Group|The study will first identify a large cohort of children who are willing to participate, and then call them back individually as they are found to match participants in the cancer group.
89134393|NCT00994864|Other|adjuvant FOLFOX (1 pre-operative cycle)|One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
89134394|NCT00742859|Experimental|Arm 1: Betrixaban|Betrixaban, 40 mg, orally, once daily for at least 3 months.
89134395|NCT00742859|Experimental|Arm 2: Betrixaban|Betrixaban, 60 mg, orally, once daily for at least 3 months
89134396|NCT00742859|Experimental|Arm 3: Betrixaban|Betrixaban, 80 mg, orally, once daily for at least 3 months
89134397|NCT00742859|Active Comparator|Arm 4: Warfarin|Warfarin will be prescribed by investigators according to the standard of care.
89134398|NCT00667342|Experimental|Localized Resectable Disease (Stratum A)|Participants with localized resectable disease receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin, and doxorubicin, or methotrexate. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, or methotrexate.
89134399|NCT00667342|Experimental|Metastatic Disease (Stratum B)|Participants with metastatic disease (Stratum B) receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
89134400|NCT00667342|Experimental|Unresectable Disease (Stratum C)|Participants with unresectable disease (Stratum C) receive treatment identical to Stratum B: Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
89134401|NCT00375609|Experimental|Betrixaban 15 mg|Betrixaban 15 mg oral twice daily for 10 to 14 days
89134402|NCT00375609|Experimental|Betrixaban 40 mg|Betrixaban 40 mg oral twice daily for 10 to 14 days
89134403|NCT00375609|Experimental|Enoxaparin|Enoxaparin 30 mg administered subcutaneously every 12 hours for 10 to 14 days
89134404|NCT04042675||parkinson group|parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage.
89134405|NCT04042675||Control group|healthy individuals between the ages of 40-75 and without any neurological disorders.
89134406|NCT02803554|Experimental|Young donor plasma|An infusion of plasma derived from donors aged 25 years or younger
89134407|NCT00960011|Experimental|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
89134408|NCT00960011|Active Comparator|POLYPROPYLENE|Use of Polypropylene mesh for open inguinal hernia repair
89134409|NCT02545231|Active Comparator|Low dose 1mg pitavastatin|pitavastatin 1mg which is considered low dose statin will be administered for 36 months
89134410|NCT02545231|Active Comparator|High dose 4mg pitavastatin|pitavastatin 4mg which is considered high dose statin will be administered for 36 months
89134411|NCT02610309|Experimental|Family-Based Crisis Intervention|The Family-Based Crisis Intervention (FBCI) is a single-session intervention that takes place in the Emergency Department. Adolescents randomized to the experimental condition received a standard psychiatric evaluation followed by the experimental intervention. FBCI was administered by licensed psychiatric social workers who were trained in the intervention. The research clinician provided FBCI to the suicidal adolescent and his/her parent(s)/guardian(s) in a 60-90 minute session in which she helped the adolescent and family develop a joint crisis narrative of the problem and taught them cognitive-behavioral skill-building, therapeutic readiness, psycho-education about depression, and safety planning.
89134412|NCT02610309|No Intervention|Treatment As Usual|Treatment as usual included an emergency psychiatry evaluation (standard care).
89134413|NCT02803632|Experimental|suicide attempt|questionnaires actigraphic recording
89134414|NCT00854815|Active Comparator|Irrigation|Irrigation of the area with at least 500ml normal saline using the power suction/irrigator
89134415|NCT00854815|Active Comparator|No Irrigation|Only suction with the power suction/irrigator without saline attached
89134416|NCT02803788|Active Comparator|Group O|this group will receive inj. ondansetron 4mg iv stat and inj. dexamethasone 8mg iv stat just before extubation.
89134417|NCT02803788|Experimental|Group R|this group will receive inj. ramosetron 0.3mg iv stat just before extubation.
89134418|NCT04281953||People with ototoxicity|People living with and beyond who experience ototoxicity as a result of chemotherapy
89134419|NCT04041505|Active Comparator|Breastfeeding|Infant consumes mother's milk directly from the breast.
89134420|NCT04041505|Experimental|Bottle-feeding|Infant consumes mother's expressed milk from a bottle.
89134421|NCT05757375|Experimental|Volleyball players with Chronic Ankle Instability|Before the taping application, the application area of all athletes will be shaved. It will be cleaned with an alcohol wipe before the application so that situations such as sweat or moisture do not reduce the effect of the banding. For taping, while the athlete lies in a supine position on a portable stretcher, the leg weight will be taken by placing the athlete's foot on the abdomen with slight knee and hip flexion. The rigid tape will be measured and cut obliquely starting approximately 2 cm anterior to the fibula and approximately 1 cm anterior to the lateral malleolus and ending in the middle of the anterior tibia region. To increase the strength of the banding, another band will be added to it. In the application, only banding will be preferred and mobilization will not be done.
89134422|NCT05757375|Experimental|Volleybal players without Chronic Ankle Instability|Before the taping application, the application area of all athletes will be shaved. It will be cleaned with an alcohol wipe before the application so that situations such as sweat or moisture do not reduce the effect of the banding. For taping, while the athlete lies in a supine position on a portable stretcher, the leg weight will be taken by placing the athlete's foot on the abdomen with slight knee and hip flexion. The rigid tape will be measured and cut obliquely starting approximately 2 cm anterior to the fibula and approximately 1 cm anterior to the lateral malleolus and ending in the middle of the anterior tibia region. To increase the strength of the banding, another band will be added to it. In the application, only banding will be preferred and mobilization will not be done.
89134423|NCT02859701|Experimental|AK002|AK002 will be administered as an intravenous (IV) infusion in 8 cohorts of single escalating doses and two cohorts with multiple doses
89134424|NCT02859701|Placebo Comparator|Placebo|Placebo administered as anl IV infusion
89134425|NCT02610153||Cohort 1|Adult patients, diagnosed with no-valvular atrial fibrillation and who have recently initiated or are going to initiate VKA treatment, that attend the Cardiology Units
89134426|NCT02799966|Other|Early Treatment Group|Initiate treatment with MyndMove device on or after 10 days to 6 months (182 days) post spinal cord injury
89134427|NCT02799966|Other|Late Treatment Group|Initiate treatment with MyndMove device on or after 6 months plus one day (183 days+) post spinal cord injury
89134428|NCT04281641|Experimental|TCHP|"Neoadjuvant Therapy (Cycles 1-7):~Cycle 1: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) Cycle 2-7: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) + followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~Adjuvant Therapy:patients would complete 1 year of PH-based regimen in the adjuvant setting.~Patients are assessed by [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 68Ga-Affibody HER-2 Imaging PET. Besides, the changes of biomarkers would be examined by gene sequencing and organoid drug sensitivity test."
89134429|NCT00862693|Experimental|1 calcitriol|calcitriol 0.5ug/BIW for 12 months
89134430|NCT00862693|No Intervention|2|no intervention
89134431|NCT02799576|Experimental|Curved needle|This will utilize the curved block needle of performance of regional block
89134432|NCT02799576|No Intervention|Traditional needle|This will utilize the traditional block needle of performance of regional block
89134433|NCT02859311|Experimental|Withdrawal of therapy|Gradual, supervised withdrawal of medical therapy over 4-16 weeks
89134434|NCT02859311|No Intervention|Control|Continuation of usually prescribed pharmacological therapy
89134435|NCT00859417|Active Comparator|1|Traditional surgical method without prosthesis
89134436|NCT00859417|Experimental|2|Surgical method with Perigee prosthesis
89134437|NCT00854971|No Intervention|control|Oxaliplatin infusion (85mg/m2) on days 1 and 15 (every 2 weeks) 5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16 LV infusions (200 mg/m2) on days 1, 2, 15 and 16
88802640|NCT01893476|Other|adherence to guideline|Implementation educational programme: guideline adherences. The results of this trial will be directly applicable to primary care settings. Should the interventions delivered at the level of the GP practice be found to be effective in improving patients' quality of life then the findings would have a wider application.
88802641|NCT02773706|Experimental|Usual Subspecialty Care|"Once a subject is screened positive for anxiety or depression, the subspecialty provider is informed of the positive screen, and left to manage or refer the condition as per usual care by that provider.~Intervention: Depression / anxiety screen + clinician informed."
89134438|NCT00854971|Active Comparator|Active|FOLFOX-4 regimen + Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times
89134439|NCT02799498|Active Comparator|A-etanercept (ENBREL®) by auto-injector|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
89134440|NCT02799498|Other|B-etanercept (ENBREL®) by Manual injection|Single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
89134441|NCT02799420|Experimental|pCLE group|The intervention group
89134442|NCT02799420|Active Comparator|WLE group|The control group
89134443|NCT00617851|Experimental|Influenza virus vaccine (lot A)|Lot A of the investigational influenza virus vaccine
88802642|NCT02773706|Active Comparator|Integrated Psychology Care|"Once a subject is screened positive for anxiety or depression, an automated psychology referral occurs, in addition to any intervention determined by the subspecialty provider.~Intervention: Depression / anxiety screen + clinician informed + automated psychologist visit."
88802643|NCT02274896|Experimental|PD catheter group|All patients will receive the Bayston PD catheter
88802644|NCT02272556|Active Comparator|Subjects with Type 2 Diabetes|Type 2 DM subjects with HbA1C > 7.5% treated with metformin, sulfonylurea, insulin or combination
88802645|NCT02272556|Active Comparator|Non-Diabetic Obese|Age-matched, non-diabetic obese (BMI > 30 kg/m^3) individuals
89134444|NCT00617851|Experimental|Influenza virus vaccine (lot B)|Lot B of the investigational influenza virus vaccine
89134445|NCT00617851|Experimental|Influenza virus vaccine (lot C)|Lot C of the investigational influenza virus vaccine
89134446|NCT00617851|Experimental|Influenza virus vaccine (pooled)|Pooled data of all three lots (Lot A, B and C) of the investigational influenza virus vaccine
89134447|NCT00617851|Active Comparator|Comparator influenza vaccine|A US licensed influenza virus vaccine
89134448|NCT02544295|Experimental|Clinical interview-Virtual reality task:1|Healthy controls will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
89134449|NCT02544295|Experimental|Clinical interview-Virtual reality task:2|Patients will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
89134450|NCT00913809|Experimental|1|Desipramine HCL 100 mg Tablets Cord Laboratories
89134451|NCT00913809|Active Comparator|2|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
89134452|NCT02806362|Experimental|Ombitasvir/paritaprevir/ritonavir (12 weeks)|Ombitasvir/paritaprevir/ritonavir (25/50/100mg once daily) for 12 weeks
89134453|NCT00855049|Experimental|1|Intranasal acetaminophen administration
89134454|NCT00855049|Active Comparator|2|Oral acetaminophen administration
89134455|NCT02799030|Placebo Comparator|BF-200 ALA 0%|Topical application of matched placebo gel without containing 5-ALA. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
89134456|NCT02799030|Experimental|BF-200 ALA 1%|Topical application of BF-200 ALA gel containing 0.78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
89134457|NCT02799030|Experimental|BF-200 ALA 3%|Topical application of BF-200 ALA gel containing 3.8 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
89134458|NCT02799030|Experimental|BF-200 ALA 10%|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
89134459|NCT02799108|Experimental|patients|children with drug-resistant partial epilepsy, in whom preoperative assessment is indicated
89134460|NCT00812955|Experimental|A - ABT-143 capsules 5/135 mg|ABT-143 capsules 5/135 mg - ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
89134461|NCT00812955|Experimental|B - ABT-143 capsules 10/135 mg|ABT-143 capsules 10/135 mg - ABT-143 (rosuvastatin 10 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
89134462|NCT00812955|Experimental|C - ABT-143 capsules 20/135 mg|ABT-143 capsules 20/135 mg - ABT-143 (rosuvastatin 20 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
89134463|NCT00812955|Active Comparator|D - Simvastatin capsules 40 mg|Simvastatin capsules 40 mg daily for 8 weeks
89134464|NCT04235478|Experimental|Cervical interlaminar epidural steroid injecion|Floroscopy-guided cervical interlaminar epidural steroid injecion will be applied to the patients with cervical radiculopathy related neck and arm pain
89134465|NCT00619489|Experimental|Vedolizumab 2 mg/kg|Participants received vedolizumab, 2 mg/kg, intravenously (IV), on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
89134466|NCT00619489|Experimental|Vedolizumab 6 mg/kg|Participants received vedolizumab, 6 mg/kg, IV, on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
89134467|NCT02806206|Experimental|Drug: Prucalopride|A single 2 mg dose of prucalopride before ingesting the capsule endoscopy pill.
89134468|NCT02806206|Placebo Comparator|Drug: Placebo|A placebo pill just before ingesting the capsule endoscopy pill.
89134469|NCT00855127||Liver transplant recipients|
89134470|NCT04042363|Experimental|Active Transorbital electrical stimulation|Transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks
89134471|NCT04042363|Sham Comparator|Sham Transorbital stimulation|Sham stimulation - 10 sessions during 2 consecutive weeks
89134472|NCT02803476||Cases|Polycystic ovary syndrome (PCOS) female patients. 20-35 years of age.
89134473|NCT02803476||Controls|Non-PCOs female subjects. 20-35 years of age.
89134474|NCT00855205|Experimental|Treatment|Treatment with rituximab
89134475|NCT02803320|Experimental|SPF 50 Y65 110|All subjects received baseline skin evaluation and 1 day of sun exposure.
89134476|NCT00859729|Experimental|Cohort I|50 µg DNA/dose, 3 patients
89134477|NCT00859729|Experimental|Cohort II|150 µg DNA/dose, 3 patients
89134478|NCT00859729|Experimental|Cohort III|400 µg DNA/dose, 3 patients
89134479|NCT00859729|Experimental|Cohort IV|1000 µg DNA/dose, 3 patients
89134480|NCT00859729|Experimental|Cohort V|Optimal dose to be determined, 6 patients
89134481|NCT02806674|Experimental|Successful treatment|
89134482|NCT02806674|Experimental|Refractory infection of H.pylori|
89134483|NCT00859807|Experimental|Sequence 1 (19 subjects)|"Period 1: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment.~Period 2: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis); reference treatment)."
89134484|NCT00859807|Experimental|Sequence 2 (19 subjects)|Period 1: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis Period 2: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment
89134485|NCT04065126|Experimental|Physical activity Intervention|This arm receives ten two-hour group sessions with physical activity and psycho-educational components, held by a physiotherapist over a period of ten weeks.
89134486|NCT04065126|Active Comparator|Brief Psycho-education|This arm receives two brief lectures of psycho-education held by a physiotherapist.
89134487|NCT00859885||1|Patients who receive antithrombotic treatment only
89134488|NCT00859885||2|Patients who undergo percutaneous device closure
89134489|NCT02803398|Experimental|Patient at risk of venous thrombosis|
89134490|NCT02798874|Experimental|Ticagrelor Group|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
89134491|NCT02798874|Active Comparator|Clopidogrel Group|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
89134492|NCT00860041||Group I|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
89134493|NCT00860041||Group II|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
89134494|NCT00860041||Group III|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
89134495|NCT00860041||Group IV|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
89134496|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence AB (fasted followed by fed)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive a single tablet of cabotegravir 30 mg,(micronized 500 mg core weight) orally under fasted condition with at least 10 hours of prior fast. In Period 2, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
89134497|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence BA (fed followed by fasted)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. In Period 2, eligible subjects will receive a single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally under fasted condition with at least 10 hours of prior fast. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
89134498|NCT02806518||Women scheduled for DIEP|Women scheduled for DIEP breast reconstruction after mastectomy due to breast cancer are examined with DIRT, hand-held Doppler and CTA
89134499|NCT00959699|Placebo Comparator|PegIFN-2b + RBV|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600-1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by placebo to boceprevir plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up (Control Arm). Participants who do not achieve HCV-RNA <9.3 IU/mL by Treatment Week 24 (TW24) are eligible to cross-over and receive boceprevir along with the PegIFN-2b and RBV for up to 44 weeks.
89134500|NCT00959699|Active Comparator|PegIFN-2b + RBV + Boceprevir|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600- 1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by boceprevir (800 mg, orally, 3 times per day) plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up.
89134501|NCT02798796|Experimental|MRI Group|MRI Group - all patients will be submitted to clinical examination, mammography and / or ultrasound, and breast MRI
89134502|NCT02798796|No Intervention|Control Group|Control group - all patients will be submitted to clinical examination, mammography and / or ultrasound of the breasts.
89134503|NCT02803008|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89134504|NCT02806128|Experimental|Treatment group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .~Patients need to complete laboratory tests within a specified time."
89134505|NCT02806128|Experimental|Control group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) Once times a day, 14 days .~Patients need to complete laboratory tests within a specified time."
89134506|NCT04280861|Experimental|Intervention Group|The intervention group will participate in multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
89134507|NCT04280861|No Intervention|Control Group|Usual clinical care,
89134508|NCT02859545|Experimental|Validation Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to validate which is provided by the research assistant.
89134509|NCT02859545|Placebo Comparator|Education Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to ask questions about treatments, which is provided by the research assistant.
89134510|NCT02798718|Active Comparator|lactose digesters|Participants in arm 1 are grouped as lactose digesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is less than 20 ppm.
89134511|NCT02798718|Active Comparator|lactose maldigesters|Participants in arm 2 are also grouped as lactose maldigesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is not less than 20 ppm.
89134512|NCT02857907||ATG group|Patients who received T cell depleting ATG therapy (blood sample one year after transplantation)
89134513|NCT02857907||anti-CD25 group|Patients who received nondepleting anti-CD25 (blood sample one year after transplantation)
89134514|NCT04236570|Other|Pain tests with the standardized protocol|This arm will consisted of pain tests using the standardized protocol (thermode(hot plate) and cold water bath)). The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the standardized protocol, the TS will consisted of a noxius heat stimulus generated by a thermode (hot plate), applied for two minutes on the non-dominant anterior forearm. The CS will consisted of a cold pressor test (CT), wherein participants immersed their dominant forearm in a cold water bath for two minutes.
89134515|NCT04236570|Other|Pain tests with the TENS protocol|This arm will consisted of pain tests using the TENS protocol. The investigators will used the modified CPM testing procedure consisting of stimulus test (TS) administered before and after a conditioning stimulus (CS). For the TENS protocol, the TS will consisted of a noxius electrical stimulus generated by TENS, applied for 5 seconds on the non-dominant knee at a frequency of 1 Hz and 5 Hz. The CS will consisted of a noxius electrical stimulus generated by TENS' applied for 120 seconds on the non dominant knee and ankle at a frequency of 2 Hz
89134516|NCT02798640|Active Comparator|Active|Subject wearing Celliant garment
89134517|NCT02798640|Placebo Comparator|Control|Subject wearing non-celliant control garment
89134518|NCT02798562|Experimental|Native and dynamic contrast-enhanced CT|Patients will undergo a native high-resolution and a dynamic contrast-enhanced CT, both sides respectively.
89134519|NCT00617773|Experimental|hu3S193|
89134520|NCT00956813|Experimental|Arm I|Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
89134521|NCT00956813|Placebo Comparator|Arm II|Patients receive oral placebo bar once daily.
89134522|NCT00860119|Experimental|Sublingual tablet|Test treatment
89134523|NCT00860119|Experimental|Oral tablet|Reference treatment
89134524|NCT02802930|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products (SPF 50 Y65 110,SPF 50 Y51 002, and SPF 15 V27 l 04 compared to that of a negative control [0.9% NaCl]) were tested simultaneously on each subject.
89134525|NCT00855283|Experimental|Arm 1|SCI
89134526|NCT04236024|Experimental|Experimental group|The students in this group will learn medication knowledge by using board game.
89134527|NCT04236024|Active Comparator|Comparison group|The students in this group will learn medication knowledge through tradition lecture.
89134528|NCT00862927||Cue reactivity in virtual reality|Breath Scan + Saliva Sample + Questionnaires + View Virtual Reality Scenes
89134529|NCT02805738|Experimental|Experimental Group|once a time per a day, CKD-390 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
89134530|NCT02805738|Active Comparator|Active comparator Group|once a time per a day, Viread 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
89134531|NCT02857673|Experimental|Intervention Group|The intervention group will receive Child Abuse Prevention Problem Solving (CAPPS), a one-on-one, workbook-based intervention of six sessions, each lasting approximately 30-60 minutes. CAPPS is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. Sessions will be delivered at the medical home by bachelor level providers, whose availability and level of training mimic those of existing medical home care coordinators.
89134532|NCT02857673|Active Comparator|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers. The study team member will not be trained in CAPPS and will adhere to a case management model consistent with resources available in the medical home, checking in with control families and offering to help identify existing clinic and community resources as needed.
89134533|NCT00855361|Experimental|Rabeprazole sodium|
89134534|NCT02798406|Experimental|DNX-2401 + pembrolizumab|Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.
89134535|NCT02857751||Surf therapy cohort 1|The first cohort of participants to enroll in the study (i.e., participants in the first 6-week program)
89134536|NCT02857751||Surf therapy cohort 2|The second cohort of participants to enroll in the study (i.e., participants in the second 6-week program)
89134537|NCT02857751||Surf therapy cohort 3|The third cohort of participants to enroll in the study (i.e., participants in the third 6-week program)
88802646|NCT02272556|Active Comparator|Lean, healthy control subjects|Age-matched, lean, healthy control subjects (BMI < 25 kkg/m^3)
89134538|NCT02857751||Surf therapy cohort 4|The fourth cohort of participants to enroll in the study (i.e., participants in the fourth 6-week program)
89134539|NCT02857751||Surf therapy cohort 5|The fifth cohort of participants to enroll in the study (i.e., participants in the fifth 6-week program)
89134540|NCT03843619||Non-E-referral|Patients who are referred in the traditional manner between two separate organizations.
89134541|NCT03843619||E-referral|Patients who are referred in an automated manner between two separate organizations.
89134542|NCT02798484|Experimental|Breast cancer|Patients diagnosed with breast cancer and placed under neo-adjuvant treatment (hormonotherapy, chemotherapy) within the CHU Brugmann hospital.
89134543|NCT04040725|Experimental|Rogaratinib|"Rogaratinib is administered orally twice daily~Rogaratinib is held for 72 hours before cystoscopy/TURBT and if no complications are seen, treatment is resumed 24 hours after the TURBT"
88802647|NCT02582918|No Intervention|Group 1: Usual Care|Usual care with opportunistic visit-based HCC surveillance.
88802648|NCT02582918|Experimental|Group 2: Patient Education and Patient Navigation Services|Mailed HCC surveillance outreach with patient education and patient navigation services.
89134544|NCT00955955|Experimental|6(S)-5-MTHF(Deplin)|"Participants will receive 15 mg/day of Deplin, a medical food, for 8 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
89134545|NCT00955955|Experimental|Placebo/Deplin|"Participants will receive placebo for the first 4 weeks, and then 15 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
89234256|NCT05252286|Experimental|video watching|In the video-watching group, a patient will follow the exercise instructions from watching the video. The exercise content in video are set during the patient conducting the rehabilitation program. Then, the therapist will select 3 to 5 groups of movements pattern needed to be enhanced catching from the video for the patient to practice when returning the bedside after the rehabilitation programs.
89134546|NCT00955955|Experimental|Placebo/Placebo|"Participants will receive placebo for both phases of the study.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
89134547|NCT02798328||Reference Range|Healthy Subjects
89134548|NCT02798328||DOAC Pivotal|DOAC Eligible Subjects
89134549|NCT05550636|Experimental|BI 1015550 + midazolam treatment arm|test and reference treatment arm
89134550|NCT00860197|No Intervention|Control|No coffee
89134551|NCT00860197|Experimental|Group 1|Fully torrefied coffee
89134552|NCT00860197|Experimental|Group 2|Partially torrefied coffee
89134553|NCT02857829|Placebo Comparator|Placebo|
89134554|NCT02857829|Active Comparator|Caffeine-alone|The effects of the combination will be compared to both placebo and caffeine-alone, to test the hypothesis that the blend of ingredients will enhance cognitive measures greater than the most commonly used cognitive enhancer, caffeine.
89134555|NCT02857829|Experimental|CAF+|
89134556|NCT02805894|Experimental|NBTXR3 activated by IMRT only|"Part I Dose Escalation~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:~- EBRT delivered as 45 Gy in 25 fractions of 1.8 Gy each; to the prostate and seminal vesicles, followed by 34.2 Gy in 19 fractions to the prostate and proximal seminal vesicles , over 9-10 weeks, utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT A)"
89134557|NCT02805894|Experimental|NBTXR3 activated by Brachytherapy & IMRT|"Part I Dose Escalation~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:~- Brachytherapy Boost and EBRT delivered as a single fraction of 15 Gy in one day to the prostate by High Dose Rate Brachytherapy followed by EBRT (initiated within 2-4 weeks after completion of Brachytherapy), delivered as 45 Gy in 25 fractions of 1.8 Gy to the prostate and seminal vesicles utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT B)"
89134558|NCT00860275|Active Comparator|BMS-708163 / Ketoconazole|
89134559|NCT00860275|Active Comparator|BMS-708163 / Fluconazole|
89134560|NCT02798250|Active Comparator|Dual-hormone CL with overestimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
89134561|NCT02798250|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 35g of carbohydrates.
89134562|NCT00865111|Experimental|A|Bupropion 150 mg Extended-Released Tablet, single dose
89134563|NCT00865111|Active Comparator|B|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
89134564|NCT00863005|Experimental|1. K201|
89134565|NCT00863005|Active Comparator|2.|
89134566|NCT00860353|Experimental|1|
89134567|NCT00860353|Placebo Comparator|2|
89134568|NCT02805816||Study group|Children with suspicion of CD based on positive serology (TG2 >2 times upper limit of normal) and classical clinical manifestations or belonging to high risk groups, who underwent gastroscopy with intestinal biopsies.
89134569|NCT02805816||Control group|Children without suspicion of CD who underwent gastroscopy and duodenal biopsies for other reasons (abdominal pain, failure to thrive, vomiting, eg)
89134570|NCT00863083|Active Comparator|1|Multifamily group weight management intervention plus rewards for program attendance
89134571|NCT00863083|Active Comparator|2|Multifamily group weight management intervention plus rewards for attendance and goal attainment
89134572|NCT04018339|Experimental|RTA 402 5mg or 10mg oral administration|
89134573|NCT04018339|Placebo Comparator|Placebo|
89134574|NCT02802696|Experimental|Furosemide|Diuretic
89134575|NCT02802696|Placebo Comparator|Placebo|Normal saline
89134576|NCT00860431|No Intervention|1|Standard-of-care (conservative treatment)
89134577|NCT00860431|Experimental|2|AST-120 6g/day (3 times a day)
89134578|NCT02802774|Active Comparator|Plaster Splint|
89134579|NCT02802774|Active Comparator|Velcro Brace|
89134580|NCT02802774|Active Comparator|Soft Dressing|
89134581|NCT04041739||diabetic foot osteomyelitis|"Patients will be subjected to:~1-History taking including duration of diabetes and ulcer . 2 Clinical examination of ulcer , including diagnosis of osteomyelitis 3- Venous blood will be withdrawn to do the following laboratory tests :~HbA1c~erythrocyte sedimentation rate(ESR)~C reactive protein(CRP)~Complete blood culture~Serum urea and creatinine 4-culture and sensitivity test 5-Bone fragments and tissue biopsy from infected ulcers 6-Fundus examination"
89134582|NCT02802462|Experimental|High intensity-interval (HIT)|
89134583|NCT02802462|Experimental|moderate intensity-continuous (MCT)|
89134584|NCT02802462|No Intervention|control (CTL)|
89134585|NCT00865267|Experimental|A|Ultravate® 0.05% ointment, single exposure
89134586|NCT02798094||Depressed Participants|No intervention
89134587|NCT02798094||Healthy Control Participants|No intervention
89134588|NCT02798172|Experimental|Alogliptin+metformin|Alogliptin (alogliptin benzoate) is the most recent DPP-4 inhibitor; it entered the market in 2006. It is a potent and highly selective DPP-4 inhibitor with oral antidiabetic activity; Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
89134589|NCT02798172|Experimental|metformin|Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
89134590|NCT00865423|Experimental|A|Gabapentin 800 mg Tablets, single dose
89134591|NCT00865423|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
89134592|NCT02798016|Experimental|Platelet-Rich Plasma alone|The scars will be injected with Platelet-Rich Plasma alone.
89134593|NCT02798016|Active Comparator|Platelet-Rich Plasma with micro-needling|The scars will be dealt with using micro-needling as well as injecting Platelet-Rich Plasma
89134594|NCT00955721|Experimental|Phase 1: GEMOX + Sorafenib|"Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib.~Gemcitabine: 1000 or 750 mg/m2, IV, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~Oxaliplatin: 100 or 75 mg/m2, IV, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~Sorafenib: 200 mg, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
89134595|NCT00955721|Experimental|Phase 2 - RPTD GEMOX + Sorafenib|"Recommended Phase Two Dose (RPTD) of Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib:~Gemcitabine: Recommended Phase II Dose determined from Phase I, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~Oxaliplatin: Recommended Phase II Dose determined from Phase I, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~Sorafenib: Recommended Phase II Dose determined from Phase I, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
89134596|NCT02802540|Experimental|Nabilone|Patients start receiving a dose of 0.5 mg daily oral nabilone the first 2 weeks and then 1 mg to complete 8 weeks.
89134597|NCT02802540|Placebo Comparator|placebo|Patients start receiving a dose of 0.5 mg daily oral placebo the first 2 weeks and then 1 mg to complete 8 weeks.
89134598|NCT00865501|Experimental|1|spironolactone
89134599|NCT00865501|Placebo Comparator|2|placebo
89134600|NCT04277351|Experimental|tACS in individuals with and without dyslexia|Each participant in both the group of normo-readers and individuals with dyslexia receive all tACS stimulation conditions (fixed frequencies and sham) over different experimental days.
89134601|NCT02797704|Experimental|SC Aflibercept|The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization
89134602|NCT00865579|Experimental|1|All subjects to receive first 50mg/d Safinamide with an increase of target dose of 100mg/d after 14 days of taper period until end of treatment visit. In case of any intolerance the daily dose of 100mg might be decreased to 50mg/d. Patients permanently discontinuing treatment will enter a 7day taper phase before treatment discontinuation at a dose of 50mg/day. Subjects already taking 50mg/d may stop Safinamide immediately.
89134603|NCT02860325|Experimental|NIV-NAVA|Patients allocated to non-invasive NAVA
89134604|NCT02860325|Active Comparator|Conventional|Patients allocated to nasal CPAP or non-synchronized nasal IPPV
89134605|NCT02805582|Active Comparator|Anterior musculus serratus block|"Proximal nerve block above the second intercostal space between Musculus serratus anterior and Musculus pectoralis minor.~Intervention: 10ml ropivacain 0.5%"
89134606|NCT02805582|Active Comparator|Subpectoral block|"Distal nerve block under the Musculus pectoralis major at the medial border of the axillary triangle.~Intervention: 10ml ropivacain 0.5%"
89134607|NCT00860509|Placebo Comparator|Low Phytosterol Diet|Diet with 100 mg of daily phytosterols
89134608|NCT00860509|Active Comparator|High Phytosterol Diet|Diet with 600 mg of daily phytosterols
89134609|NCT04281095|Experimental|Botulinum toxin type A(ATGC-110)|
89134610|NCT04281095|Active Comparator|Botulinum toxin type A|
89134611|NCT02797938|Experimental|Taper guard tube|Taper guard tube was intubated in 26 patients
89134612|NCT02797938|Active Comparator|Cylindrical tube|Cylindrical tube was intubated in 26 patients
89134613|NCT02860403|Experimental|C6-C7 patients|C6-C7 patients able to recover tenodesis grasp.
89134614|NCT02860403|Experimental|C5-C6 patients|C5-C6 patients for whom surgery for rehabilitation of an upper limb is indicated with a upper limit of one year after trauma, and after complete clinical and functional evaluation
89134615|NCT02860403|No Intervention|Control group|a control group (n=6) matched on age and sex to C6-C7 without medical history or neurological disorder
89134616|NCT02802306|Experimental|Tack Implant|Implantation of a Tack implant using the Intact Vascular Tack Endovascular System for the repair of post DCB-angioplasty dissections.
89134617|NCT00863161|Experimental|1|AZD3355 65 + 65 mg capsule
89134618|NCT04281407|Experimental|Probiotics treatment on midazolam and acetaminophen metabolism|"Experimental:~Day 1: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV) Days 1-28: Visbiome (2 capsules) administered BID Day 11: midazolam (2 mg oral) + acetaminophen (500 mg oral) + midazolam (1 mg IV)"
89134619|NCT00860665||1|Observational study on consecutive persons over the age of 55 years presenting for screening colonoscopy
89134620|NCT02802150|Active Comparator|Zanthoxylum schinifolium seed Oil|Zanthoxylum schinifolium seed Oil 100% (4g/day)
89134621|NCT02802150|Placebo Comparator|soy bean oil|soy bean oil 99.9%, edible dyes 0.01% (4g/day)
89134622|NCT02857595|Active Comparator|Online Weight Loss Program|
89134623|NCT02857595|Experimental|Online Weight Loss Program + Nomogram|
89134624|NCT02857595|Experimental|Online Weight Loss Program + Nomogram + Bite Counter|
89134625|NCT00863239|Experimental|1|Locteron™ (controlled-release interferon alpha 2b) 320 µg as biweekly subcutaneous injection
89134626|NCT00863239|Experimental|2|Locteron™ (controlled-release interferon alpha 2b) 480 µg as biweekly subcutaneous injection
89134627|NCT00863239|Experimental|3|Locteron™ (controlled-release interferon alpha 2b) 640 µg as biweekly subcutaneous injection
89134628|NCT00863239|Active Comparator|4|PEG-Intron™ (12 kDalton pegylated interferon alpha 2b) 1.5 µg/kg body weight weekly subcutaneous injection
89134629|NCT02805270|Experimental|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
89134630|NCT02805270|No Intervention|usual care|Usual care provided by ward pharmacist, nurses and doctors in the ward
89134631|NCT04262297||Prosthesis users|Prosthesis users with transtibial amputation
89134632|NCT04262297||Able-bodied Controls|Prosthesis users' age-, sex- and dominancy-matched healthy controls
89134633|NCT02802072|Experimental|Enterprise stent implantation group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive Enterprise stent implantation in combination with antiplatelet medication for carotid artery stenosis.
89134634|NCT02802072|Experimental|Only aspirin medication group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive only antiplatelet medication for carotid artery stenosis.
89134635|NCT00865657|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
89134636|NCT00865657|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
89134637|NCT02801994|Experimental|Ventilator settings, PAV|"A first 30-minutes recording in PSV will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously. Patients will be subsequently switched to PAV.~The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min."
89134638|NCT00863395|Experimental|Skin Biopsy|
89134639|NCT02939183|Experimental|Part 1 Arm 1|Oprozomib (Immediate Release) plus dexamethasone
89134640|NCT02939183|Experimental|Part 1 Arm 2|Oprozomib (Gastro-retentive) plus dexamethasone
89134641|NCT02939183|Experimental|Part 2 Arm 1|Oprozomib (Immediate release) plus pomalidomide and dexamethasone
89134642|NCT02939183|Experimental|Part 2 Arm 2|Oprozomib (Gastro-retentive) plus pomalidomide and dexamethasone
89134643|NCT02801916|Other|Study subjects|Each healthy subject will receive each of the interventions in randomized order.
89134644|NCT00865813|Experimental|Punch Biopsy|
89134645|NCT02801760||Subjects Currently or Previously Enrolled in ATN 110/ATN 113|Younger and older YMSM and transgender women who have sex with men, ages 15 through 22 years, inclusive, at the time of consent into the ATN 110 or ATN 113 study.
89134646|NCT02801760||Sub-Sample of Subjects to Complete Qualitative Interview|A sub-sample of subjects who completed the web-based survey and indicated willingness to complete the qualitative interview.
89134647|NCT00860821|Experimental|1|AZD8309
89134648|NCT00860821|Placebo Comparator|2|Placebo
89134649|NCT02801838|Experimental|Ventilator settings, morphine titration|First, ventilator settings optimization and when the clinician judges necessary (remains discomfortable), opioid titration with a maximum of 10mg of morphine
89134650|NCT00863473|No Intervention|Conservative /Physiotherapy|Active training protocol with instructed physiotherapy and self excercises
89134651|NCT00863473|Active Comparator|Surgery with LCP T plate|Surgical treatment with interlocking plate
89134652|NCT04276025||German cohort Bayreuth|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
89134653|NCT04276025||German cohort Hof|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
89134654|NCT04276025||Chinese cohort Beijing|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
89134655|NCT02797860||transabdominal cervicoisthmic cerclage|Second Stage of Labor pregnant women who are scheduled for transabdominal cervicoisthmic cerclage due to incompetent internal os of cervix
89134656|NCT02797860||control|women of childbearing age between 20 and 45
89134657|NCT00860899|Active Comparator|clonidine|Clonidine is an alpha2-adrenergic agonist with sedative, analgesic and hemodynamic properties. It inhibits transmission of nociceptive stimuli in the dorsal horn of the spinal cord, acting on the inhibitory descending pathways.
89134658|NCT00860899|Active Comparator|levobupivacaine|Levobupivacaine is long-acting local anesthetic, S-enantiomer of bupivacaine, with identical anesthetic potency.
89134659|NCT02797626|Other|Primary RPNLD|
89134660|NCT00863629|No Intervention|1|25 normoglycemic patients as control group
89134661|NCT00863629|Active Comparator|2|20 hyperglycemic patients (glucose >140 mg/dl) randomized to conventional glycemic control by insulin (CGC group; glucose goal 180-200 mg/dl)
89134662|NCT00863629|Experimental|3|20 hyperglycemic patients (glucose >140 mg/dl) were randomized to intensive glycemic control by insunin (IGC group; glucose goal 80-140 mg/dl)
89134663|NCT02859857|Experimental|Rising dose; safety and tolerance|Sequential cohorts of patients with advanced solid tumors and recurrent high-grade gliomas will be be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL is reached.
89134664|NCT02859857|Experimental|Solid tumor patients|Cohort of patients with advanced solid tumors administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
89134665|NCT02859857|Experimental|Glioblastoma Multiforme patients|Cohort of patients with recurrent high-grade gliomas administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
89134666|NCT02859857|Experimental|Gastrointestinal tumor patients|Cohort of patients with Gastrointestinal tumors as defined in the protocol and administered BXQ-350 at the 2.4 mg/kg dose level.
89134667|NCT02859857|Experimental|Ependymoma tumor patients|Cohort of patients with ependymoma administered BXQ-350 at the 2.4 mg/kg dose level.
89134668|NCT02859857|Experimental|Solid tumor patients other than HGG|Cohort of patients with advanced solid tumors other than HGG administered BXQ-350 at the 2.4 mg/kg dose level.
89134669|NCT02805348||Chronic kidney disease|Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time.
89134670|NCT00860977|Placebo Comparator|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
89134671|NCT00860977|Experimental|Valacyclovir|oral valacyclovir 500mg twice daily
89134672|NCT02805192|Other|one Arm: size measurement by Smart phone App|
89134673|NCT00865891|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
89134674|NCT00865891|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
89134675|NCT02797392|Experimental|Lifestyle intervention|All included citizens receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is collated with existing Electronic Patient Record (EPR) data and the citizen's risk of lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All citizens receive an electronic health profile and targeted advice. Citizens at increased risk of disease are offered a preventive program at the GP including an initial health examination and subsequent lifestyle counselling. Citizens with risk behavior are offered lifestyle counselling in the municipality and community health services, if necessary. Citizens diagnosed with a lifestyle related disease are already being treated by the GP, and therefore, like citizens with a healthy lifestyle, they are not offered any further services.
89134676|NCT02797236|Experimental|vaccine dose 1|SF2a-TT15 vaccine, 2 μg
89134677|NCT02797236|Experimental|vaccine dose 1+ adjuvant|SF2a-TT15 vaccine, 2 μg + alum
89134678|NCT02797236|Experimental|vaccine dose 2|SF2a-TT15 vaccine, 10 μg
89134679|NCT02797236|Experimental|vaccine dose 2 + adjuvant|SF2a-TT15 vaccine, 10 μg + alum
89134680|NCT02797236|Placebo Comparator|Placebo|Tris buffer
89134681|NCT02797236|Placebo Comparator|Placebo + adjuvant|Tris buffer + Alum
89134682|NCT00863785|Experimental|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
89134683|NCT02801526|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
89134684|NCT02801526|Experimental|CKD-330|CKD-330 16/5mg - A, PO, 1days or 22days
89134685|NCT05227495|Experimental|VR group|
89134686|NCT05227495|Active Comparator|control group|
89134687|NCT02805426|Experimental|Tranexamic acid|1950 mg oral tranexamic acid + 800 mcg sublingual misoprostol
89134688|NCT02805426|Placebo Comparator|Placebo|oral placebo + 800 mcg sublingual misoprostol
89134689|NCT00866203|Experimental|HDS|modified high dose sequential therapy
89134690|NCT00866203|Active Comparator|ProMECE/CytaBOM|four additional courses of standard ProMECE/CytaBOM
89134691|NCT02805036||30 cmH20 for 30 seconds|"plateau pressure is hold on at 30 cmH20 pour 30 seconds. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.~echocardiography - arterial oximetry"
89134692|NCT02805036||10 cmH20 above|"plateau pressure is hold on at 10 cmH20 above. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.~echocardiography - arterial oximetry"
89134693|NCT00861055||Infants|Infants less than 7 days of age with clinical signs of sepsis
89134694|NCT00861055||Mothers|Mothers following antenatal care at SMRU antenatal clinic, Maela camp who are 28 - 30 weeks gestation
89134695|NCT04235946|Experimental|accompanied and adapted water polo program|"16 and 20 aqua polo sessions (adapted water polo) over a period of 20 weeks, at the rate of one session per week at the Cercle des Nageurs de Marseille (CNM). They will be divided into 3 cycles imitating the preparation of the season of a high-level athlete: a first cycle intended for physical preparation, a second cycle intended for practical learning (technique and tactics) and the third cycle for preparation of a mini tournament.~Each session will be organized as follows: 1 hour of training in the water followed by 30 min of debriefing as a team or individually with the coach. The announced duration of the session will be 2 hours, transport and changing rooms included."
89134696|NCT02801682||Healthy Controls|
89134697|NCT02801682||Invasive Candidiasis|
89134698|NCT02801682||Bacterial Sepsis (Bacteremia)|
89134699|NCT02801682||ICU patients without infectious disease|
89134700|NCT02805114||Asthma and COPD patients|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken from the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions"
89134701|NCT00573469|Active Comparator|1|D9421-C 9 mg
89134702|NCT00573469|Active Comparator|2|D9421-C 15 mg
89134703|NCT00573469|Placebo Comparator|3|Placebo
89134704|NCT02796066|Placebo Comparator|Vehicle|Vehicle gel
89134705|NCT02796066|Experimental|Low Dose Active|Low Dose of TSN2898
89134706|NCT02796066|Experimental|Mid Dose Active|Mid Dose of TSN2898
89134707|NCT02796066|Experimental|High Dose Active|High Dose of TSN2898
89134708|NCT02801292|Other|administering of ketamine|adjuvant to standard of care
89134709|NCT02544061|Experimental|NM-IL-12 plus Standard of Care (SOC)|"Single 12 µg unit subcutaneous dose of NM-IL-12 plus SOC.~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
89134710|NCT02544061|Placebo Comparator|Placebo plus SOC|"Single subcutaneous dose of placebo plus SOC~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
89134711|NCT02801058|No Intervention|Control|Simple observation
89134712|NCT02801058|Sham Comparator|Shame|Light touch manipulative simulation
89134713|NCT02801058|Experimental|Treatment|Osteopathic manipulative techniques on the abdominal diaphragm
89134714|NCT02690142|Experimental|ABY-035 i.v.|Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.
89134715|NCT02690142|Experimental|ABY-035 s.c.|Part B: Bioavailability study where 6 subjects will receive ABY-035 as a single subcutaneous injection.
89134716|NCT02690142|Experimental|ABY-035 i.v. in psoriasis patients|Part C: Up to 12 psoriasis patients will receive ABY-035 as a single intravenous injection.
89134717|NCT02690142|Experimental|ABY-035 s.c. in psoriasis patients|Part D: Up to 18 patients will receive 3 or 7 biweekly doses of ABY-035 as s.c. injections
89134718|NCT00863863|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
89134719|NCT00863863|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
89134720|NCT03853044|Experimental|Chidamide plus CHOP|Participants received six 21-day cycles of chidamide, combined with six cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (21-day cycles).
89134721|NCT00870337|Experimental|Single arm|
89134722|NCT02797158|Experimental|Interventional Arm|
89134723|NCT00866437|Experimental|Healthy Control group|
89134724|NCT00866437|Experimental|PMS|
89134725|NCT02797002||Chronic non specific neck pain|Experiencing neck pain for at least 3 months in the last year
89134726|NCT02797002||Without neck pain (asymptomatic)|No history of neck pain
89134727|NCT00863941|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
89134728|NCT00863941|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
89134729|NCT02795910|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions
89134730|NCT02795910|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will receive no outreach education training.
89134731|NCT00870415|Experimental|Surgerie|
89134732|NCT00812565|Placebo Comparator|Placebo every 2 weeks|Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).
89134733|NCT00812565|Experimental|0.1 g/kg octagam 10% every 2 weeks|Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).
89134734|NCT00812565|Experimental|0.25 g/kg octagam 10% every 2 weeks|Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
89134735|NCT00812565|Experimental|0.4 g/kg octagam 10% every 2 weeks|Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
89134736|NCT00812565|Placebo Comparator|Placebo every 4 weeks|Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).
89134737|NCT00812565|Experimental|0.2 g/kg octagam 10% every 4 weeks|Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).
89134738|NCT00812565|Experimental|0.5 g/kg octagam 10% every 4 weeks|Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
89134739|NCT00812565|Experimental|0.8 g/kg octagam 10% every 4 weeks|Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
89134740|NCT02801214||Recreational Cannabis Use|ages 18-40
89134741|NCT02801214||Healthy control subjects|socio-demographically matched
89134742|NCT00866515|Experimental|Active|Ketoconazole 400mg OD days 1-6
89134743|NCT00866515|Placebo Comparator|Placebo|Placebo OD for 1 to 6 days
89134744|NCT02795754|Experimental|GSK2838232 PIB (50 mg+100 mg+200 mg)+Placebo|During Part 1A, subjects will receive QD single dose of either GSK2838232 50 mg, 100 mg or 200 mg or placebo in each of the four visits (one treatment per visit).Subjects will also receive RTV along with all the doses and QD RTV for 48hours (2 doses) before all doses of GSK2838232 and placebo.
89134745|NCT02795754|Experimental|GSK2838232 PIB+IR1+IR2|During Part 1B, subjects will receive either GSK2838232 PIB, GSK2838232 IR1 or IR2 in each of the three visits (one treatment per visit) after at least 10 hours fasting and IR1 or IR2 after fat meal at visit 4.
89134746|NCT02795754|Experimental|GSK2838232 PIB (20mg/50 mg/100 mg/200 mg)/Placebo|During Part 2, subjects will receive repeated QD doses of either GSK2838232 (20 mg, 50 mg, 100 mg or 200 mg) or placebo for 11 days. Subjects will also receive RTV along with all the doses of GSK2838232 and placebo.
89134747|NCT00864019|Experimental|A|Sertraline HCl 100 mg tablets, single dose
89134748|NCT00864019|Active Comparator|B|Zoloft® 100 mg tablets, single dose
89134749|NCT02800980||Drainage and sclerotherapy.|Patients with symptomatic lymphocele who are managed with percutaneous drainage and sclerotherapy.
89134750|NCT02800980||Drainage alone.|Patients with symptomatic lymphocele who are managed with percutaneous drainage alone.
89134751|NCT00812487|Experimental|Intravenous insulin|
89134752|NCT00812487|Active Comparator|Subcutaneous Insulin|4 injections of insulin/day
89134753|NCT04235868|Active Comparator|control group|
89134754|NCT04235868|Experimental|experimental group|
89134755|NCT02800902|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
89134756|NCT02800902|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
89134757|NCT02800902|Active Comparator|group 3|SRP followed by 1.2% Atorvastatin (ATV) gel
89134758|NCT05756595|Experimental|35kDa hyaluronan fragment HA35 injection|100 mg Hyaluronan is locally injected at the pain point or where the nerve trunk is innervated by the pain point.
89134759|NCT02796768||Participants|"Study participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans:~BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2.~FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2,~1 2D US scanning session of right and left hip by Specialist 1,~1 2D US scanning session of right and left hip by Specialist 2."
89134760|NCT02796690||Group Methicillin susceptible Staphylococcus aureus (MSSA)|
89134761|NCT02796690||Group methicillin resistant Staphylococcus aureus (MRSA)|
89134762|NCT02796846||CPAP prescription group|Patients with a CPAP prescription (both compliant and noncompliant)
89134763|NCT02796846||Without a CPAP prescription|Patients without a CPAP prescription to satisfy our primary goals/objectives.
89134764|NCT00617461|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, 4 weeks treatment in either the first or second treatment period
89134765|NCT00617461|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, 4 weeks treatment in either the first or second treatment period
89134766|NCT02795130|Experimental|8-0 polyglactin 910|
89134767|NCT02795130|Experimental|6-0 plain gut suture|
89134768|NCT00812331|Experimental|Genotype 2|Participants with chronic genotype 2 hepatitis C virus (HCV) infection
89134769|NCT00812331|Experimental|Genotype 3|Participants with chronic genotype 3 HCV infection
89134770|NCT00812331|Experimental|Genotype 4|Participants with chronic genotype 4 HCV infection
89134771|NCT00812331|Experimental|Genotype 5|Participants with chronic genotype 5 HCV infection
89134772|NCT00812331|Experimental|Genotype 6|Participants with chronic genotype 6 HCV infection
89134773|NCT04233996|Experimental|Extended infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in half time of the dosing interval
89134774|NCT04233996|Active Comparator|Intermittent infusion|Piperacillin-tazobactam, cefepime or meropenem will be administered in 30 minutes
89134775|NCT03802812|No Intervention|Conventional arm|"Perform bronchial washing using conventional methods.~CT-guided thick bronchoscope"
89134776|NCT03802812|Active Comparator|Investigational arm|"Perform bronchial washing using investigational methods.~virtual bronchoscopic navigation (VBN)-guided thin bronchoscope (4.0mm of outer diameter)"
89134777|NCT00870493|Experimental|I|each subject will receive oral aliskiren 300 mg/day for 16 weeks, followed by a washout period of 4 weeks, then crossed over to placebo for another 16 weeks
89134778|NCT00870493|Active Comparator|II|each subject will receive placebo for 16 weeks, followed by a washout period of 4 weeks, then crossed over to oral aliskiren 300 mg/day for another 16 weeks
89134779|NCT02795208|No Intervention|Control group|Patients received standard protective ventilation along the protocol.
89134780|NCT02795208|Experimental|Recruitment maneuver group|Patient received a lung recruitment maneuver after cardiopulmonary bypass. The recruitment maneuver consists in 10 breaths at 40/20 cmH2O of plateau pressure and PEEP, respectively. Then, the .ventilatory settings back to protective ventilation but adding 10 cmH2O of PEEP to keep the lungs open.
89134781|NCT00864331|Active Comparator|Radiotherapy|For patients in Group A (Stage IIIA or IIIB), EBRT 39 Gy in 13 daily fractions over, with no chemotherapy.
89134782|NCT00864331|Experimental|Chemotherapy and radiotherapy|For patients in Group A (either stage IIIA or IIIB) receive a course of up to 3 cycles of chemotherapy followed by EBRT of 10 Gy in a single fraction or 16 Gy in 2 fractions 1 week apart.
89134783|NCT00864331|Active Comparator|Chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive up to 3 cycles of chemotherapy, and no radiotherapy.
89134784|NCT00864331|Experimental|Palliative radiotherapy and chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive EBRT of 10 Gy in a single fraction or 16 Gy in two fractions 1 week apart, followed by up to 3 cycles of chemotherapy.
89134785|NCT00812253|Experimental|Intravenous Insulin|
89134786|NCT00812253|Active Comparator|Subcutaneous Insulin|Basal bolus insulin (4 injections per day)
89134787|NCT02790294|Experimental|Postoperative Magnetic Resonance Imaging|Three MRIs will be performed. One at baseline, one within 72 hours postoperative, and one 2-3 weeks postoperative.
89134788|NCT00870571|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
89134789|NCT00870571|Active Comparator|B|NorvasC® 10 mg Tablets, single dose
89134790|NCT02796612|Active Comparator|No intervention|Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.
89134791|NCT02796612|Experimental|Intervention group|"Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.~Additionally, delivery of a take-home brochure to the patients during the first visit is planned. The biopsy is explained to the patient and performed by a psychological trained physician. Patient care by a psychologically trained physician is performed in the sense that patients are informed about their biopsy result by a specifically trained physician."
89134792|NCT05756439||Control|Participants having dental surgery
89134793|NCT05756439||Intravenous sedation|Participants having dental surgery
89134794|NCT00616759|Active Comparator|1|ECT as usual
89134795|NCT00616759|Experimental|2|ECT-induced seizures terminated with propofol
89134796|NCT02795364|Active Comparator|Structural Image Guidance|In this arm, the patients will receive maximum resection of the tumor with the MRI T1W-enhanced image guidance, in addition to the standard therapy
89134797|NCT02795364|Experimental|Metabolic Image Guidance|In this arm, the patients will receive quantitative resection of the tumor with both the MRI T1W-enhanced and the MRS Cho-to-NAA index (CNI) image guidance, in addition to the standard therapy.
89134798|NCT00870649|Experimental|Bilhvax vaccine (Sh28GST)|Arm 1 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of candidate vaccine at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
89134799|NCT00870649|Placebo Comparator|Placebo|Arm 2 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of placebo at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
89134800|NCT02796456||Normal weight women|BMI between 18.5 and 25 kg/m2 and without gestational diabetes
89134801|NCT02796456||Obese women without gestational diabetes|BMI more than 30 kg/m2 and without gestational diabetes
89134802|NCT02796456||Obese women with gestational diabetes|BMI more than 30 kg/m2 and with gestational diabetes
89134803|NCT00812097|Other|Primary Augmentation|The Primary Augmentation cohort will include patients who wish general breast enlargement receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
89134804|NCT00812097|Other|Primary Reconstruction|The Primary Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
89134805|NCT00812097|Other|Revision Augmentation|The Revision Augmentation cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast augmentation surgery.
89134806|NCT00812097|Other|Revision Reconstruction|The Revision Reconstruction cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast reconstruction surgery.
89134807|NCT02790216||Brachytherapy|men eligible for monotherapy seed implant brachytherapy
88802649|NCT02268656|Other|concentration of propofol in male|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in male
89134808|NCT05227183|Experimental|Patients with suicidal recurrence during VigilanS monitoring (Reattempters)|Patients with at least a past experience of suicidal attempt (SA), included after their last SA in the 6 months VigilanS monitoring protocol and who have presented a recurrence of SA during this monitoring
89134809|NCT05227183|Experimental|Patients without suicidal recurrence during VigilanS monitoring (No reattempters)|Patients with at least a past experience of suicidal attempt (SA), included after their last SA in the 6 months VigilanS monitoring protocol and who have not presented a recurrence of SA during this monitoring
89134810|NCT00866593|Experimental|1|Generic Escitalopram Oxalate Tablets
89134811|NCT00866593|Active Comparator|2|Innovator Escitalopram(Lexapro®)
89134812|NCT02795286|Experimental|ASIST A|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic
89134813|NCT02795286|Experimental|ASIST B|Artis Haemodialysis Machine w/ ASIST Software - Isotonic
89134814|NCT02795286|Active Comparator|Conventional HD|Artis Haemodialysis Machine w/o ASIST Software
89134815|NCT00866671||Nelarabine|nelarabine 650mg/m2 IV daily for 5 days. repeat every 21 days.
89134816|NCT04030611||control group|Participants in the type 2 DM group were diagnosed with DM based on criteria recommended by the American Diabetes Association and required to have a fasting plasma glucose of ≥7mmol/L or an HbA1c of ≥6.5%, as measured on 2 separate occasions.
89134817|NCT04030611||diabetic retinopahty group|Participants in th ediabetic retinopahty group group were diagnosed according to the International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales.
89134818|NCT02794818||Participating Patients|Participating patients will receive a prescription for weekly CSA produce boxes with nutritional education
89134819|NCT02794818||Participating Providers|Participating providers will be surveyed at the end of the pilot to evaluate their perceived program efficacy, the benefit of the program to their patients, and elicit program feedback.
89134820|NCT02796378|Active Comparator|Training+Simvastatin+Q10-placebo|Training+Simvastatin+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day and Q10-placebo.
89134821|NCT02796378|Placebo Comparator|Training+Simvastatin-placebo+Q10-placebo|Training+Simvastatin-placebo+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week, Simvastatin-placebo and Q10-placebo.
89134822|NCT02796378|Active Comparator|Training+Simvastatin+Q10|Training+Simvastatin+Q10. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day in combination with 400 mg of oral supplementation with Q10.
89134823|NCT00864409|Active Comparator|Hip 1|high volume local anesthetic infiltration
89134824|NCT00864409|Placebo Comparator|Hip 2|
89134825|NCT00864487|Experimental|1|Neratinib alone
89134826|NCT00864487|Experimental|2|Neratinib plus rifampin
89134827|NCT04235166||Patient cohort|Different risk score was used to assess the prognosis of acute upper gastrointestinal bleeding in cirrhosis.
89134828|NCT00870805|Experimental|bilateral-ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 3-4 times seizure threshold.
89134829|NCT00870805|Active Comparator|bilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a bilateral placement at 1.5 times seizure threshold.
89134830|NCT00870805|Experimental|right-unilateral ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a right unilateral placement at 8 times seizure threshold.
89134831|NCT00870805|Active Comparator|right-unilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a right unilateral placement at 5 times seizure threshold.
89134832|NCT05226013|Experimental|PEGylated Urate Oxidase for Injection|PEGylated Urate Oxidase for Injection，specification:5mg，Single dose ascending.Healthy subjects were divided into three dose groups (0.5mg, 1mg, 2mg), and hyperuricemia patients were divided into four dose groups (2mg, 4mg, 8mg, 12 mg), with increasing dose design.Each group will receive the experimental drug in 6 subjects.
89134833|NCT05226013|Placebo Comparator|Placebo|Placebo , specification: 5mg,Single dose. Groups received the placebo in 2 patients per group.
89134834|NCT00870961|Experimental|Arm I|Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
89134835|NCT00870961|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
89134836|NCT02796222||Hemophilia A patients on rFVIIIFc|Patients with hemophilia A who switch from on-demand or prophylactic treatment with rFVIII to rFVIIIFc
89134837|NCT02796222||Hemophilia A patients on rFVIII|Patients with hemophilia A who remain on on-demand or prophylactic treatment with rFVIII
89134838|NCT02796222||Hemophilia B patients on rFIXFc|Patients with hemophilia B who switch from on-demand or prophylactic treatment with rFIX to rFIXFc
89134839|NCT02796222||Hemophilia A patients on rFIX|Patients with hemophilia B who remain on on-demand or prophylactic treatment with rFIX
89134840|NCT00811941|Placebo Comparator|Placebo|
89134841|NCT00811941|Experimental|Nalmefene|
89134842|NCT04235088|Experimental|Somatosensory intensive intervention|
89134843|NCT00864565|Experimental|A|Fentanyl 25 μg/h transdermal system, single application
89134844|NCT00864565|Active Comparator|B|Duragesic 25 μg/h transdermal system single application
88802650|NCT02268656|Other|concentration of propofol in female|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in female
89134845|NCT02789904||Chest pain patients in DEM|Recruitment done at SGH DEM. Blood taking will be done at 0, 1 and 2 hr.
89134846|NCT00864643|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin QD|
89134847|NCT00864643|Active Comparator|Atorvastatin QD|
89134848|NCT00871039|Experimental|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
89134849|NCT00871039|Experimental|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
89134850|NCT04233684|Experimental|Study|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H&E stain and Giemsa stain~All tissues will be sent to immunohistochemistry as a gold standard"
89134851|NCT02794740|Experimental|X0002 First Dose|Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind.
89134852|NCT02794740|Experimental|X0002 Second Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
89134853|NCT02794740|Placebo Comparator|Placebo Second Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
89134854|NCT02794740|Experimental|X0002 Third Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
89134855|NCT02794740|Placebo Comparator|Placebo Third Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
89134856|NCT02794740|Experimental|X0002 Fourth Dose|8 Subjects,Single Dose,Once,Double-Blind.
89134857|NCT02794740|Placebo Comparator|Placebo Fourth Dose|2 Subjects,Single Dose,Once,Double-Blind.
89134858|NCT02543827|Experimental|MV140 I|The subjects will receive daily dose of MV140 during 6 months
89134859|NCT02543827|Experimental|MV140 II|The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
89134860|NCT02543827|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 6 month
89134861|NCT05756283|Experimental|Multimodal Prehabilitation|Participants in the intervention group will undergo, in addition to the standard of care, 6+/-1 weeks of a personalized multimodal prehabilitation program. The interventions included will be patient-centered, aiming to optimize patients' preoperative health status while enhancing their empowerment and engagement.
89134862|NCT05756283|No Intervention|Control group (standard of care)|Participants in the control group will receive the standard of care. This will include comorbidity optimization, anemia correction and smoking cessation advice if deemed appropriate.
89134863|NCT03834714|Active Comparator|Noise Stimulus and Infrared Light|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive infrared light therapy for 2 out of the 4 visits and sham infrared light therapy for the other 2 visits.
89134864|NCT03834714|Sham Comparator|Noise Stimulus and Sham|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive sham infrared light therapy for 2 out of the 4 visits and infrared light therapy for the other 2 visits.
89134865|NCT05756205|Experimental|Virtual Reality|The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation.
89134866|NCT05756205|No Intervention|Routine care|The control group will receive the usual follow-up pregnancy monitoring, without the e-health intervention.
89134867|NCT02794662|Experimental|Oxygen Environment|Blended oxygen delivered by servo-controlled incubator
89134868|NCT02794662|Active Comparator|Nasal cannula oxygen|Blended oxygen delivered by nasal cannula
89134869|NCT00864799|Active Comparator|Vaginal misoprostol|"Women allocated to the vaginal misoprostol management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 4 hours by 400 mcg vaginal misoprostol, the latter repeated every 4 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
89134870|NCT00864799|Active Comparator|Oral misoprostol|"Women allocated to the standard management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg misoprostol orally, the latter repeated every 3-hours to a maximum of 4 oral doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
89134871|NCT00864799|Active Comparator|Sublingual misoprostol|"Women allocated to the sublingual misoprostol protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg sublingual misoprostol, the latter repeated every 3 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
89134872|NCT04234776|Experimental|Rapid-acting antidepressant|Subjects eligible to participate in the study will receive IM ketamine and will use 2 placebo tablets as randomized.
89134873|NCT04234776|Active Comparator|Comparator|Subjects eligible to participate in the study will receive IM saline and will use escitalopram 15 mg and aripiprazole 5 mg as randomized
89134874|NCT00867295|Placebo Comparator|placebo|no antibiotic is used
89134875|NCT00867295|Active Comparator|drug|cefazolin Sodium 1g i.v. before the operation
89134876|NCT00867373|Experimental|Education Intervention|"The intervention used in the randomized controlled trial consists of 1) measuring the parents' height and weight and 2) providing the parents with feedback on their calculated BMI on an educational handout (included in Appendix V). The purpose of the handout is to convey the following 5 messages:~Definition of BMI~How BMI is calculated~What the parent's BMI is based on the measurements taken~What weight category the parent is in (underweight, normal weight, overweight, or obese)~Children with overweight or obese parents are at higher risk of becoming overweight themselves.~The Research Assistant will verbally review the educational handout with the parent. The handout will be available in both English and Spanish."
89134877|NCT00867373|No Intervention|Control Group|Parents assigned to the control group will proceed to their child's well child visit after their baseline data are collected.
89134878|NCT03831516||Non Invasive Electroanatomical Mapping|Patients will undergo non invasive electroanatomical mapping (CardioInsight by Medtronic) prior and during an invasive electrophysiology study and ablation of ventricular Arrhythmias.
89134879|NCT05227807|Active Comparator|Control group|the control group received routine care.
89134880|NCT05227807|Experimental|Intervention group|Intervention develop from the theoretical framework of social cognition theory
89134881|NCT02794506|Experimental|Propolis|400 mg oral proplois (capsule) was given to participants once daily for 6 months after performing scaling and root planing.
89134882|NCT02794506|Placebo Comparator|Placebo|Placebo capsule was given to participants once daily for 6 months after performing scaling and root planing.
89134883|NCT04040491|Experimental|Newly diagnosed PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
89134884|NCT04040491|Other|Relapse/refractory PTCL|PD-1 Antibody: 200mg, d1, Chidamide: 30mg, twice a week, Lenalidomide: 10mg, d1-10 gemcitabine:600mg/m2, d1 and 21 days made one treatment cycle.
89134885|NCT02794584|Active Comparator|Off-pump hybrid closure|Hybrid closure is that a periventricular technique uses an occluding device to closure ventricular septal defects of patients through the delivery system by transthoracic minimally invasive small incision without cardiopulmonary bypass.
89134886|NCT02794584|Placebo Comparator|Control|Control group: Conventional closure of ventricular septal defects was aided with cardiopulmonary bypass.
89134887|NCT05227651|Experimental|AK104|Patients will be treated with 1-2 cycles of neoadjuvant AK104. 4-6 weeks after the first cycle of neoadjuvant treatment, patients will undergo radical surgery.
89134888|NCT02794272|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
89134889|NCT02794272|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
89134890|NCT02794272|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
89134891|NCT00811473|Experimental|Quetiapine XR|
89134892|NCT00811473|Placebo Comparator|Placebo|
89134893|NCT02788500||Swedish para-athletes|The total population of athletes in the Swedish Paralympic program, which covers candidates for the Paralympic Summer or Winter Games, will be invited by mail to participate in the study and report their incidence of sports-related injuries and illnesses
89134894|NCT00864955|Experimental|phototype 2|Volunteers with cutaneous phototype 2
89134895|NCT00864955|Experimental|phototype 4|Volunteers with cutaneous phototype 4
89134896|NCT02789748|Experimental|Treatment ON|Kinesthetic stimulation administered during one night
89134897|NCT02789748|No Intervention|Treatment OFF|NO kinesthetic stimulation administered during one night
89134898|NCT00871507|Experimental|001|
89134899|NCT00871507|Experimental|002|
89134900|NCT00871507|Placebo Comparator|003|
89134901|NCT00871507|Active Comparator|004|
89134902|NCT02789826|Experimental|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic Gastrectomy' group will undergo laparoscopic gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
89134903|NCT02789826|Active Comparator|Open gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive gastrectomy via laparotomy. This group is considered the control group
89134904|NCT02793960|Experimental|Topical BPM31510 3.0% Cream|Patients/ caregiver will apply topical BPM31510 3.0% cream from every other day to twice per week to wounded skin, and every day to a section of intact skin for up to 12 weeks.The area to be covered may not exceed 10% BSA inclusive of intact skin area, and other lesions.
89134905|NCT00865033|Experimental|1|Metformin HCL Tablets, 1000 mg
89134906|NCT00865033|Active Comparator|2|Glucophage 1000 mg Tablets
89134907|NCT04234932|Experimental|Netarsudil alone|Topical application of netarsudil 0.02%
89134908|NCT04234932|Active Comparator|Netarsudil plus latanoprost|Topical application of netarsudil 0.02% with latanoprost 0.005%
89134909|NCT00871663|Experimental|Advanced solid tumors|Participants with advanced solid tumors treated with SCH 727965 in dose-escalation cohorts
89134910|NCT00871663|Experimental|Non-Hodgkin's lymphoma and multiple myeloma|Participants with non-Hodgkin's lymphoma or multiple myeloma treated with SCH 727965
89134911|NCT00871663|Experimental|B cell chronic lymphocytic leukemia|Participants with B-cell chronic lymphocytic leukemia treated with SCH 727965 in dose-escalation cohorts
89134912|NCT00867607|Experimental|MRX-6 (2%)|
89134913|NCT00867607|Experimental|MRX-6 (1%)|
89134914|NCT00867607|Experimental|MRX-6 (0.2%)|
89134915|NCT00867607|Active Comparator|Steroid|
89134916|NCT02794350||Cohort|
89134917|NCT00876109|Experimental|Group A: GDC-0941 QD Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally QD at a starting dose of 15 milligrams (mg).
89134918|NCT00876109|Experimental|Group B: GDC-0941 BID Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally BID at a starting dose determined from Group A assessments.
89134919|NCT00876109|Experimental|Group C: GDC-0941 QD or BID Expansion|Participants will receive GDC-0941 for up to 1 year, administered orally QD or BID. The dose/regimen will be determined on the basis of data from Groups A and B.
89134920|NCT04234074|Other|Breathing test or sleep study|infants undertaking cardiorespiratory polysomnography
89134921|NCT04040803|Experimental|10 Hz tACS|"Stimulation will be applied at 10 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~10 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
89134922|NCT04040803|Experimental|20 Hz tACS|"Stimulation will be applied at 20 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~20 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
89134923|NCT04040803|Experimental|70Hz tACS|"Stimulation will be applied at 70 Hz tACS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~70 Hz tACS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
89134924|NCT04040803|Experimental|0.1-640Hz tRNS|"Stimulation will be applied at 0.1-640Hz tRNS with an intensity of 1.5 mA (peak to peak), a fade in/out of 10 s and a duration of 10min.~0.1-640Hz tRNS will be performed over the pharyngeal cortex region and contralateral supraorbital region."
89134925|NCT04040803|Sham Comparator|Sham|"Stimulation will be performed only for 10 s before the fade out, with 20 Hz tACS and an intensity of 1.5 mA (peak to peak).~Sham condition will be applied over pseudo-stimulation of pharyngeal cortex region and contralateral supraorbital region."
89134926|NCT02794194|No Intervention|Control group|No intervention
89134927|NCT02794194|Experimental|Vibration group|Proprioceptive training on a whole body vibration platform. Participants in the Vibration group trained with a BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
89134928|NCT02794194|Experimental|Non-vibration group|Proprioceptive training with the BOSU® on the floor. Participants in the Non-Vibration group trained with a BOSU® on the floor.
89134929|NCT02789592|Experimental|Group 1|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
89134930|NCT02789592|Experimental|Group 2|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
89134931|NCT02789592|Experimental|Group 3|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
89134932|NCT02789592|Experimental|Group 4|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
89134933|NCT02789592|Experimental|Group 5|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
89134934|NCT02789592|Experimental|Group 6|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
89134935|NCT00867685|Experimental|Treatment A|Single oral dose of 40 mg AZD2624 liquid suspension in a fasted state.
89134936|NCT00867685|Experimental|Treatment B|Single oral dose of 40 mg (2x20mg tablets)AZD2624 in a fasted state.
89134937|NCT00867685|Experimental|Treatment C|Single oral dose of 40 mg (2x20mg tablets) in a fed state.
89134938|NCT00871897||Cardiac Rehabilitation|People with heart failure who elect to participate in cardiac rehabilitation.
89134939|NCT00871897||No Cardiac Rehabiliation|People with heart failure who elect NOT to participate in cardiac rehabilitation.
89134940|NCT02794038|Active Comparator|Soberlink Cellular Device|BAC reading with Soberlink Cellular Device
89134941|NCT02794038|Active Comparator|BACtrack S80 Pro|BAC reading with BACtrack S80 Pro
89134942|NCT00876421|Placebo Comparator|P|
89134943|NCT00876421|Active Comparator|A|
89134944|NCT00876421|Experimental|E1|
89134945|NCT00876421|Experimental|E2|
89134946|NCT00876421|Experimental|E3|
89134947|NCT02794116|Active Comparator|Control group: Sound teeth|"20 first permanent molars sound, that not affected by MIH will be included.~The teeth were treated with conventional sealants to prevent caries lesion"
89134948|NCT02794116|Experimental|Test: Hypomineralized teeth|"20 first permanent molars affected by MIH will be included.~The MIH teeth were treated with a resin sealants."
89134949|NCT04235010|Experimental|Manual toothbrush|Patients used manual orthodontic toothbrush (Oral B Ortho, Procter & Gamble, USA) for four months
89134950|NCT04235010|Experimental|Genius toothbrush|Patients used genius orthodontic toothbrush (Oral B Genius 8900, Procter & Gamble, USA) for four months
89134951|NCT00872053|Experimental|Arm 1|Focused Ankle Training
89134952|NCT00872053|Experimental|Arm 2|Combination Therapy
89134953|NCT04233450||Patient group|
89134954|NCT00872131||Generalized social anxiety disorder participants|Participants with generalized social anxiety disorder will undergo MRI scanning and sertraline treatment.
89134955|NCT00872131||Healthy control participants|Healthy control participants will undergo MRI scanning.
89134956|NCT04233294|Experimental|chidamide in combination with camrelizumab plus decitabine|chidamide 10mg/day, days 1-4, 20mg/day, day 8, 11, 15, 18; camrelizumab 200mg d6; decitabine 10 mg/day, days 1-5, every 3 weeks
89134957|NCT00872209|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
89134958|NCT00872209|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
89134959|NCT02788110|Other|NIV NAVA then NIPPV|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIV NAVA then NIPPV.
89134960|NCT02788110|Other|NIPPV then NIV NAVA|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIPPV then NIV NAVA.
89134961|NCT00872287|Active Comparator|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
89134962|NCT00872287|Active Comparator|SILS|Single transumbilical incision laparoscopic cholecystectomy
89134963|NCT02787876|Experimental|Chemotherapy induced neutropenia|Pegteograstim 100 ug/kg (maximum 6 mg) on day 7 of the chemotherapy cycle
89134964|NCT00872365|Other|1|Regular aerobic physical exercise + placebo
89134965|NCT00872365|Other|2|Activities of daily living + Micronutrients
89134966|NCT00872365|Other|3|Regular aerobic exercise + micronutrients
89134967|NCT00872365|Placebo Comparator|4|Activities of daily living + placebo
89134968|NCT04040647||colorectal surgery|50 consecutive patients scheduled to colorectal surgery in an enhanced recovery programme
89134969|NCT04040647||bariatric surgery|50 consecutive patients scheduled to bariatric surgery (gastric by-pass, sleeve gastrectomy) in an enhanced recovery programme
89134970|NCT02787954||Transcatheter Chemoembolization or TACE|A technique called transcatheter chemoembolization (TACE) is used for some patients with liver cancer that cannot be treated surgically. The procedure is a way of delivering cancer treatment directly to a tumor through minimally-invasive means.
89134971|NCT02787954||Yittrium 90 or Y-90|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue.
89134972|NCT02787954||Microwave Ablation or MWA|Microwave ablation (MWA), destroys liver tumors using heat generated by microwave energy. A CT scan or ultrasonic guidance is used to pinpoint the exact location of the tumor. A thin antenna, which emits microwaves, is then inserted into the tumor. The probe produces intense heat that ablates (destroys) tumor tissue, often within 10 minutes.
89134973|NCT02787954||electroporation|Irreversible electroporation (IRE) is a nonthermal method of destroying the cell. A cell is subjected to a powerful electrical field using high-voltage direct current (up to 3 kV); this creates multiple holes in the cell membrane and irreversibly damages the cell's homeostasis mechanism, leading to instant cell death.
89134974|NCT02793804|No Intervention|Control|All HIV testing and counselling services will be conducted as currently.
89134975|NCT02793804|Experimental|HIV Self-Testing|Community-based distribution agents (CBDA), including Voluntary Male Medical Circumcision (VMMC) mobilisers, will deliver OraQuick® HIV Self-Tests (Orasure Technologies, Thailand). The kits will also be available at the health facility.
89134976|NCT02788032|Other|EnergieShake Intervention|Single arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.
89134977|NCT02789514||children|Investigators give observation to the patients who need esophagogastroduodenoscopic procedures.
89134978|NCT02789436|Experimental|L. reuteri Prodentis® lozenges|"15 subjects~Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). Probiotic lozenges are used twice daily for 28 days."
89134979|NCT02789436|Placebo Comparator|Placebo lozenges|"15 subjects~Placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.Placebo lozenges are taken twice daily for 28 days."
89134980|NCT02789280|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
89134981|NCT02789280|Active Comparator|Wait List|Participants will be asked to wait for a week until they receive the behavioral activation condition
89134982|NCT02793648|Experimental|Treatment|Ascorbic acid 200mg twice a day for twelve weeks Alpha tocopherol 200mg twice a day for twelve weeks
89134983|NCT02793648|Placebo Comparator|Placebo|colloidal Silica 200mg twice a day for twelve weeks
89134984|NCT02789358|Active Comparator|Control Arm|"Conventional protocol for cryoablation:~At least 2 applications of 180s each"
89134985|NCT02789358|Experimental|Study Arm|"Experimental protocol for cryoablation:~Time to effect + 1 minute and a bonus application of 120s"
89134986|NCT03847506|Experimental|EZE/ROS+CAN/AML|Ezetimibe/Rosuvastatin 10 mg/10 mg and Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
89134987|NCT03847506|Active Comparator|CAN/AML|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
89134988|NCT03847506|Active Comparator|EZE/ROS+CAN|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg, once a day for 6 weeks
89134989|NCT02689908|Other|The patients underwent thorax CT|The patients refered to radiology service underwent thorax computed tomography without contrast material for the evaluation of various complaints such as dyspnea, hemoptysis and pulmonary infections.
89134990|NCT05361954|Experimental|STI-1386|A dose-escalation standard 3+3 design will be utilized and a total of 3 dosing cohorts are planned, receiving up to 4 mL of 1 x 10^6 / 1 mL, 1 x 10^7 / 1 mL, or 1 x 10^8 / 1 mL.
89134991|NCT04232904|Active Comparator|TAP Block Group|this is study group.
89134992|NCT04232904|No Intervention|Control Group|This patients are control group. TAP block will be not perform
89134993|NCT02793414||Malaria patients|
89134994|NCT02793414||Febrile controls|
89134995|NCT02788266|Active Comparator|connective tissue graft+composite resin|connective tissue graft plus composite resin
89134996|NCT02788266|Active Comparator|connective tissue graft+ glass ionomer|connective tissue graft plus resin modified glass ionomer cement
89134997|NCT02788266|Active Comparator|connective tissue graft+giomer|connective tissue graft plus giomer
89134998|NCT04234620||Toripalimab injection|Use of Toripalimab injection in the real world
89134999|NCT03618420|Other|Clinical Investigation|All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.
89135000|NCT04234308|Experimental|Polyglycolic Acid Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
89135001|NCT04234308|Experimental|Chromic Gut Absorbable suture|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
89135002|NCT04234308|Experimental|ePTFE Non absorbable suture|Periodontal and periimplant flaps closed with at least one suture with ePTFE Non absorbable suture, synthetic, 4-0. (TAGUM®)
89135003|NCT04234308|Experimental|Nylon Non absorbable sutures|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
89135004|NCT00617305|Experimental|Ambrisentan|Patients were assigned ambrisentan at open-label enrollment or randomization, and received at least one dose of ambrisentan plus an approved phosphodiesterase type-5 (PDE-5) inhibitor (PDE-5i; sildenafil or tadalafil).
89135005|NCT00617305|Active Comparator|Placebo|Patients were assigned placebo at randomization and received at least one dose of placebo plus an approved PDE-5i (sildenafil or tadalafil).
89135006|NCT02793102|Experimental|Olfactory workshop + Somesthesia workshop|Olfactory workshop, Twenty odorants. Somesthesia workshop, time for moving the body, Talk Time
89135007|NCT02793102|Experimental|Auditory workshop + Somesthesia workshop|Auditory workshop, Twenty extracts of music tracks. Somesthesia workshop, time for moving the body, Talk Time
89135008|NCT04232748||stage IV colorectal cancer|stage IV colorectal cancer on first line systemic treatment are observed for the trend of weight change and treatment outcomes
89135009|NCT02793024|Experimental|Arm 1 - Intervention|Counties will be randomized to receive the intervention or act as a delayed control. Students in the intervention arm will receive the 12-week intervention to improve shopping choices.
89135010|NCT02793024|No Intervention|Arm 2 - Intervention|Control adolescents will not receive the intervention and will receive routine information normally distributed through schools.
89135011|NCT02792868||patient|patient with cardiovascular risk (moderate)
89135012|NCT03608202|Experimental|POCUS protocol group|"POCUS protocol group~It will be submitted to an ultrasound protocol which consists in performing the following ultrasound studies in each patient:~Measurement of the diameter of the optic nerve. Neck. Pulmonary ultrasound (LUS score). Echocardiogram (function and volemia). Abdomen. Femoral vascular package. Eco-guided interventionism. Central venous accesses (controlling positioning with saline injection under ultrasound), arterial, pleural or abdominal drainage and percutaneous tracheotomy will be performed under ultrasound."
89135013|NCT03608202|Active Comparator|Control group|The usual handling will be followed. The studies will only be performed if the medical team-treating team considers it, requesting a radiologist specialist the same, as is done routinely.
89135014|NCT02792712|Experimental|STEMI_MRI_Ticagrelor|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Ticagrelor Arm
89135015|NCT02792712|Active Comparator|STEMI_MRI_Clopidogrel|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Clopidogrel Arm
89135016|NCT00870883|Experimental|N-acetylcysteine plus deferoxamine|
89135017|NCT02787720|Experimental|Family centered empowerment model|The Family-Centered Empowerment Model (FCEM)
89135018|NCT02787720|Experimental|Continuous care model|The Continuous Care Model
89135019|NCT00867763|Experimental|IVM|Early egg retrieval, in vitro maturation, then IVF
89135020|NCT00867763|Active Comparator|Mild IVF|Mild gonadotropin and conventional IVF
89135021|NCT02789202|Experimental|Silver Diamine Fluoride|Control treatment
89135022|NCT02789202|Active Comparator|Fluoride Varnish|Test treatment
89135023|NCT00811395|Placebo Comparator|Placebo + IFN-β|Placebo (for teriflunomide) once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
89135024|NCT00811395|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
89135025|NCT00811395|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
89135026|NCT00811395|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
89135027|NCT00811395|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
89135028|NCT00811395|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
89135029|NCT00867841||Pneumonia|Children diagnosed with community-acquired pneumonia by the emergency department physician
89135030|NCT02792946|Experimental|Sulfolase CR (200mg, QD)|for 7 days with or without meal
89135031|NCT02792946|Active Comparator|Sulfolase Capsule (100mg, BID)|for 7 days with or without meal
89135032|NCT00876499||Questionnaire|
89135033|NCT00872443||FOP|Patients who already have an occlusion of POF secondary to a cryptogenic CVA and younger than 55 years old and without characterized thromboembolic events.
89135034|NCT05083065||Women who underwent Covid-19 vaccination|This group includes women who underwent both the first or complete cycle of Covid-19 vaccination, regardless of the vaccine used.
89135035|NCT00876577||Group 1|
89135036|NCT02787798|Experimental|Entresto|"Stop of all angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor during 2 days.~valsartan/sacubitril 100 mg tablets (51 and 49 mg) during 2 to 4 weeks twice a day.~valsartan/sacubitril 200 mg tablets (103 and 97 mg) during 2 to 4 weeks twice a day.~Microneurography recording of sympathetic activity in muscle destiny (MSNA)"
89135037|NCT02787798|Placebo Comparator|Control|"Hearth failure treatment as usual (angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor)~Microneurography recording of sympathetic activity in muscle destiny (MSNA) will be done"
89135038|NCT00867919|Experimental|1|Participants will receive a cognitive behavioral family therapy for adolescent depression to be developed in this study.
89135039|NCT00867919|Active Comparator|2|Participants will receive treatment as usual 1 year prior to the experimental treatment group.
89135040|NCT02792556||patient having a drug abortion|Urine pregnancy test for adult women having a drug abortion until 8 weeks of amenorrhea, presenting to the control visit between the 14th and 21th day after drug intake.
89135041|NCT02609997|Experimental|Single-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a single-piece IOL
89135042|NCT02609997|Experimental|Three-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a three-piece IOL
89135043|NCT00876655|Experimental|free acid|TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700)
89135044|NCT00876655|Experimental|di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
89135045|NCT00867997|Active Comparator|Dentifrice|Chemoactive (remineralizing, neuroactive) dentifrice treatment
89135046|NCT00867997|Active Comparator|Sealant|DBA/sealant application
89135047|NCT00867997|Active Comparator|Resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
89135048|NCT05755659|Experimental|Tumor chemotherapy patients|To evaluate the safety of Fosaprepitant Dimeglumine for injection in the prevention of nausea and vomiting caused by tumor chemotherapy drugs
89135049|NCT02788968|Other|Adolescents|MRI 11-15 years
89135050|NCT02788968|Experimental|Young adults|MRI 19-25 years
89135051|NCT00913887|Experimental|1|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
89135052|NCT00913887|Experimental|2|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
89135053|NCT00913887|Active Comparator|3|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
89135054|NCT00872677||Dietitian-led counseling and Weight Watchers|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
89135055|NCT00872677||Dietitian & Weight Watchers + Spirituality Counseling|Dietitian wkly for the 1st-3 months, every other week for the next 3 months and monthly thereafter; Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
89135056|NCT02789124|Experimental|Carotid Artery Flow Time|Patients with radial aline and flotrac vigileo will have carotid dopper measured for carotid flow time and a passive leg raise
89135057|NCT05181865|Experimental|Phase 1 - Cohort 1|
89135058|NCT05181865|Experimental|Phase 1 - Cohort 2|
89135059|NCT05181865|Experimental|Phase 1 - Cohort 3|
89135060|NCT05181865|Experimental|Phase 1 - Cohort 4|
89135061|NCT05181865|Experimental|Phase 1 - Cohort 5|
89135062|NCT05181865|Experimental|Phase 2a - Group 1|
89135063|NCT05181865|Experimental|Phase 2a - Group 2|
89135064|NCT05181865|Experimental|Phase 2a - Group 3|
89135065|NCT02788890|Active Comparator|Control Group (T0)|The supragingival scaling without LA
89135066|NCT02788890|Experimental|Test Group 1 (T1)|The simple restoration under LA
89135067|NCT02788890|Experimental|Test Group 2 (T2)|The simple exodontia under LA
89135068|NCT00872755|Active Comparator|Nissen|Laparoscopic Nissen Fundoplication
89135069|NCT00872755|Active Comparator|Gastropexy|Procedure/Surgery Laparoscopic Nissen Fundoplication combined with posterior gastropexy
89135070|NCT02792400|Placebo Comparator|A1: GRA-placebo + MEAL + DPP4-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + linagliptin placebo
89135071|NCT02792400|Placebo Comparator|A2: GRA-active + MEAL + DPP4-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + linagliptin placebo
89135072|NCT02792400|Active Comparator|A3: GRA-placebo + MEAL + DPP4-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
89135073|NCT02792400|Active Comparator|A4: GRA-active + MEAL + DPP4-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
89135074|NCT02792400|Placebo Comparator|B1: GRA-placebo + MEAL + SGLT2-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
89135075|NCT02792400|Placebo Comparator|B2: GRA-active + MEAL + SGLT2-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
89135076|NCT02792400|Active Comparator|B3: GRA-placebo + MEAL + SGLT2-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
89135077|NCT02792400|Active Comparator|B4: GRA-active + MEAL + SGLT2-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
89135078|NCT04040023|Other|I Group: PBMi|Non-drug intervention First part of PBM program (PBMi) Training part for medical care staff to improve transfusion practices
89135079|NCT04040023|Experimental|C Group: PBMc|"Patient Blood Management: full program~PBMi intervention and Drug intervention (systematic correction of pre- and postoperative iron and vitamin deficiencies, and erythropoietin preoperative treatment for anemic patient)"
89135080|NCT05755581|Active Comparator|Neoadjuvant chemotherapy group|Patients in this arm will receive neoadjuvant chemotherapy as usual
89135081|NCT05755581|Active Comparator|Neoadjuvant endocrine therapy group|Patients in this group will receive neoadjuvant endocrine therapy
89135082|NCT00868075|Experimental|Chest Physiotherapy|Twice daily chest physiotherapy
89135083|NCT00868075|Experimental|Chest Physiotherapy + Exercise Program|Chest Physiotherapy + Exercise Program
89135084|NCT02792010|Experimental|T1rho MRI|Patients included had hip cartilage MRI with acquisition of T1rho MRI sequence.
89135085|NCT05017155|Active Comparator|Lamotrigine|When on the lamotrigine treatment arm, the participant will commence at lamotrigine 25mg (milligram) daily for two weeks; then increase to 25mg twice daily for two weeks; then increase to 50mg daily for one week; then increase to 100mg in the morning, 50mg at midday and 50mg at night for one week; then increase to 100mg in the morning, 50mg at midday and 100mg at night for two weeks.
89135086|NCT05017155|Active Comparator|Mexiletine|When on the mexiletine treatment arm, the participant will commence at mexiletine 100mg daily for two weeks; then increase to 200mg daily for two weeks; then increase to 200mg twice daily for one week; then increase to 200mg three times a day for one week; then remain on 200mg three times a day for two weeks.
89135087|NCT00868153||Group 1|
89135088|NCT02791932|Experimental|Exercise|The intervention will last 8-10 months depending on when during pregnancy the participant is randomized. The intervention will consist of three components (i.e., telephone, print materials, and exercise log/goal setting) designed to increase exercise. Social Cognitive Theory (SCT) and Self-Determination Theory will guide the exercise intervention. The counseling sessions will be a collaboration between the counselor and participants on how to best integrate exercise into the participant's daily routine. Participants will receive 15 intervention phone calls lasting approximately 15-20 minutes each. There will be a one-month intensive phase (weekly contacts), followed by bi-weekly contacts for two months, and then monthly until delivery. Beginning at 6 weeks postpartum, bi-weekly contacts will resume through 3 months postpartum.
89135089|NCT02791932|No Intervention|Usual Care|Participants in the usual care condition will follow their usual standard of care as suggested by their healthcare provider. Participants will complete the same assessments and incentives as the active interventions but will not receive the exercise counseling sessions. Following completion of the nine-month follow-up, the usual care arm can choose to receive a six-month version of the exercise intervention.
89135090|NCT04232592|Experimental|Stem cell preparation solution injection group|The solution of stem cells preparation will be injected.
89135091|NCT04232592|Experimental|Injected stem cell group|The stem cells will injected.
89135092|NCT00868387|Experimental|energy-restricted, CHO-restricted diet|Interventions: carbohydrate restriction of diet: 40% Frequency: daily Duration: 12 months
89135093|NCT00868387|Active Comparator|energy-restricted, CHO-rich diet|Comparator: carbohydrate content of diet: > 55% Frequency: daily Duration: 12 months
89135094|NCT04234230||VAD Patients|Patients with implanted ventricular assist device in the outpatient setting
89135095|NCT00872911|Experimental|Nutritional supplement|
89135096|NCT00872911|Experimental|Placebo + Exercise|
89135097|NCT00872911|Experimental|Nutritional Supplement + Exercise|
89135098|NCT00872911|No Intervention|Placebo|
89135099|NCT02791620|Experimental|A nanofractional radiofrequency device|
89135100|NCT00873067|Active Comparator|ACVP plus roof line|Standard procedure for atrial fibrillation ablation, including pulmonary vein isolation plus roof line ablation. All ablation lines will be tested.
89135101|NCT00873067|Active Comparator|Additional CFAEs ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
89135102|NCT00876811|Experimental|one-cup|
89135103|NCT00876811|Experimental|two-cups|
89135104|NCT00876811|Experimental|four-cups|
89135105|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~collection of patient's radiographic and clinical parameters"
89135106|NCT02788734||INC Contact Registry|INC Contact Registry will complete the online questionnaires
89135107|NCT00873145||1|Patients with major bone defects around the elbow.
89135108|NCT03550404||Navigators|"AIE Navigators will use the Seasons of Care app in the context of their everyday outreach work with AIEs over two four-month intervention periods (P1 and P2). Their goal will be to facilitate health literacy to shift attitudes, beliefs, and behaviors to create a Culture of Coverage for AIEs at individual, organizational/community, and policy levels. Separated by distance, the AIE Navigators will receive coaching as necessary, using virtual meeting space, to help refine their implementation skills from a member of the research team with experience in AIE health outreach."
89135109|NCT03550404||American Indian Elders (AIEs)|Elders will be exposed to the Seasons of Care app when they reach out to navigators for assistance navigating the healthcare system.
89135110|NCT03550404||Healthcare providers/staff|This cohort will be exposed to the Seasons of Care app via navigators and their patients.
89135111|NCT00868465|Active Comparator|1|Artemether-lumefantrine; currently the first line treatment in Tanzania
89135112|NCT00868465|Experimental|2|Dihydroartemisinin-piperaquine, alternative ACT
89135113|NCT00638040||1|The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses. To achieve this goal, we will perform gene expression analysis of the tumor samples collected from an IRB-approved study (IRB #: 4516-05-2R2) International Phase III Study of Chemoradiotherapy versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer directed by Dr. Mark Dewhirst. We will correlate the gene expression signatures of different microenvironmental stresses with the measured physiological parameters to understand their role in tumor progression, treatment response and clinical outcomes.
89135114|NCT00868543|Active Comparator|Long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with long (150 cm) alimentary Roux limb
89135115|NCT00868543|Active Comparator|Very long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with very long (250 cm) alimentary Roux limb
89135116|NCT02689986|Experimental|Treatment arm|Bendamustine, Rituximab
89135117|NCT00876967|Experimental|1|metallic single use blade
89135118|NCT00876967|Experimental|2|plastic single use blade
89135119|NCT00876967|Active Comparator|3|metallic reusable blade
89135120|NCT02788812|Active Comparator|Open modified Lichtenstein repair|
89135121|NCT02788812|Active Comparator|Laparoscopic TAPP inguinal hernia repair|
89135122|NCT02791464|No Intervention|wait list control|Waitlist control subjects interested in learning the TM program will be asked to wait for 4 months before learning if they were randomly assigned to this comparison group. Controls will receive usual medical care during 4 month intervention period.
89135123|NCT02791464|Experimental|Transcendental Meditation|The TM technique is a simple, effortless, mental technique to reducing stress which allows the mind to experience finer levels of the thinking process to achieve a state of restful alertness. The Transcendental Meditation program will be taught as a standard seven-step program over five consecutive days.
89135124|NCT00868621||1|Control
89135125|NCT00868621||2|Overactive Bladder Patients
89135126|NCT00868621||3|Urinary Tract Infection
89135127|NCT00955409|Experimental|ACC-001(3µg) + QS21|ACC-001(3µg) + QS21
89135128|NCT00955409|Experimental|ACC-001(10µg) + QS21|ACC-001(10µg) + QS21
89135129|NCT00955409|Experimental|ACC-001(30µg) + QS21|ACC-001(30µg) + QS21
89135130|NCT00877123|Experimental|Vitamin D|Intervention arm: Oral vitamin D 100,000 IU once a month for three consecutive months.
89135131|NCT00877123|Placebo Comparator|Placebo|
89135132|NCT00868777|Experimental|Sinus grafting using allogenic bone|
89135133|NCT00873223|Experimental|A|
89135134|NCT00873301|Experimental|vulvodynia|
89135135|NCT00873379|Active Comparator|melatonin|.5 mg (one half of a 1 mg tablet of GNC rapid dissolving Melatonin, natural product number (NPN) 80001380)
89135136|NCT00873379|Placebo Comparator|placebo|half a white placebo tablet
89135137|NCT03489174|Experimental|Monthly Pregnancy Screening|Patients at the Hamilton Clinic present to the clinic most often on a weekly basis to provide a urine sample for urine drug screening and to meet with their MRP. This same urine sample will be tested for pregnancy in the intervention group once per month. Resulting positive test results will be reported to the patient through their attending physician on the day of testing.
89135138|NCT03489174|Active Comparator|Usual Care|Participants in the control group will not receive study-initiated urine pregnancy testing but will receive usual care, which may include pregnancy testing based on patient request or clinical judgement.
89135139|NCT02787486||Aneuploidy Arm|Includes pregnant women at high risk for fetal chromosome aneuploidy for serum screening
89135140|NCT02787486||TORCH Arm|Infectious disease arm: Toxoplasmosis, other viruses, rubella, cytomegalovirus, and herpes simplex virus (TORCH). Includes pregnant women at low-risk for fetal aneuploidy that may be at increased risk for fetal infection for serum screening
89135141|NCT00868855|Experimental|1|Bradykinin
89135142|NCT02791386||Chinese Patients With CHB and Drug Resistance to NA Therapy|
89135143|NCT00615901|Experimental|1|This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A safety analysis will then be performed.
89135144|NCT03436290|Experimental|Palliative Care Intervention|
89135145|NCT03436290|No Intervention|Standard of Care|
89135146|NCT02791074||Control|"Healthy Volunteers will undergo the following studying procedures:~Echocardiography Arterial tonometry"
89135147|NCT02791074||Heart Failure Patients|"Patients will undergo the following studying procedures:~NTproBNP Echocardiography Arterial tonometry"
89135148|NCT00868933|Active Comparator|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
89135149|NCT00868933|Placebo Comparator|Simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
89135150|NCT02788422|Experimental|Video|Video discharge instructions developed using Easy Sketch Pro3TM software (Easy Sketch Pro, United Kingdom). It was created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
89135151|NCT02788422|Active Comparator|Standard of care|This is a one-page paper handout created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
89135152|NCT00869011|Experimental|1|Exercise
89135153|NCT00869011|No Intervention|2|No structured exercise program
89135154|NCT02790918||Diagnosed Pulmonary Hypertension|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
89135155|NCT02790918||Healthy Volunteer|Healthy Volunteer will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
89135156|NCT00616603|Other|Group A|This is the control arm and subjects in Group A will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV of normal saline.
89135157|NCT00616603|Experimental|Group B|Subjects in Group B will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 8mg Dexamethasone + 2ml IV of normal saline.
89135158|NCT00616603|Active Comparator|Group C|Subjects in Group C will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV (8mg)of Dexamethasone.
89135159|NCT02787330|Active Comparator|Control Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
89135160|NCT02787330|Experimental|Experimental Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program which focuses on education, therapeutic problem solving, and social support. Each intervention session is structured by theme relevant to the cancer experience and themes are addressed through fun activities, games, arts, and crafts.To maximize the therapeutic effect of the intervention fun work (homework) will be assigned after each session. Training for the EG facilitators requires reading and studying the manual to become fully familiarized with the intervention approaches, observing group sessions through a one-way mirror prior to participation as a group facilitator, and participating as a group facilitator assistant for the intervention program.
89135161|NCT00873535|Active Comparator|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
89135162|NCT00873535|Placebo Comparator|Placebo|This group (N=40) will receive placebo in the same dosing regimen as for Varenicline. The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
89135163|NCT02787174|No Intervention|Control|Participants will receive routine clinical treatment care.
89135164|NCT02787174|Experimental|Intervention|Participants will receive interactive tailored asthma medication adherence education on an iPad.
89135165|NCT02790996|Experimental|Vancomycin - Optimised Regimen|"A single loading dose of 25 mg/kg followed by a maintenance dose of:~Postmenstrual age ≤ 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly"
89135166|NCT02790996|Active Comparator|Vancomycin - Standard Regimen|Postmenstrual age < 29 weeks - 15 mg/kg given 24 hourly; Postmenstrual age 29 - 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly
89135167|NCT00573313|Experimental|S-adenosylmethionine (SAMe)|Alcoholic liver disease patients receiving S-adenosylmethionine (SAMe)at 400 mg capsule three times daily for 24 weeks
89135168|NCT00573313|Placebo Comparator|Sugar pill|ALD subjects receiving Placebo three times daily for 24 weeks.
89135169|NCT02790840|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (15mg and 30 mg) administered twice daily for 15 days + Omeprazole oral capsules (20 mg or 40 mg) administered once or twice daily for 10 days
89135170|NCT05225779|Active Comparator|sevoflurane|General Anesthesia procedure with sevoflurane
88805910|NCT01141907|Active Comparator|Usual Heart Failure Care|Usual care for HF patients included the following: 1) Referral to HF clinic if the patient has no usual source of HF outpatient care, 2) HF patient education by HF care coordinator (advanced practice nurse), and 3) HF self care guide. All participants were treated by their usual source of HF care in the usual manner.
89135171|NCT05225779|Active Comparator|desflurane|General Anesthesia procedure with desflurane
89135172|NCT02790762|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
89135173|NCT00877357|Experimental|Shan 5 Lot No 1|
89135174|NCT00877357|Experimental|Shan 5 Lot No 2|
89135175|NCT00877357|Experimental|Shan 5 Lot No 3|
89135176|NCT04232826|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
89135177|NCT00873613|No Intervention|Direct ophthalmoscopy|
89135178|NCT00873613|Experimental|Non-dilated retinal photography|
89135179|NCT02790684|Experimental|DS-8500a|
89135180|NCT02786862|Experimental|Ventilation|Measurements were made for conventional and independent at 1:1 proportion ventilation in supine position; then independent ventilation was discontinued and patient was moved to right or left decubitus position due to left or right lung surgery. Then were made measurements for conventional anaesthetic practices and followed independent at 1:1, 2:1, 3:1, 5:1 proportions ventilation routines. Constantly were monitored expired volume, peak respiratory pressure, dynamic compliance separately for each lung. Measurements covered also hemodynamic (MAP, HR) and oxygenation (SpO2). These attributes were documented at each point of the study. Subsequently, the control system was disconnected and performed typical anaesthetic procedures for thoracic surgery with a one-lung ventilation procedure.
89135181|NCT00877435|Experimental|1|Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
89135182|NCT00877435|Active Comparator|2|Cognitive behavioral therapy (CBT)
89135183|NCT02790372|No Intervention|Control nursing homes|Nursing homes carries out usual care
89135184|NCT02790372|Active Comparator|Intervention nursing homes|Nursing homes that carries out regularly case conferencing
89135185|NCT00869245|Experimental|1|Cardiac MRI Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
89135186|NCT00869245|Experimental|2|Conventional care cardiac testing. Patients will be transferred to the observation unit and undergo cardiac testing as determined by their treating physician.
89135187|NCT02352389||Influenza|"Children and young adults identified as having influenza infections by the St. Jude Children's Research Hospital diagnostic microbiology will be approached to participate in the study. Biological samples will be collected on Day 0 within 72 hours of the diagnosis of influenza, and at 7, 14, 21, and 28 days later.~Interventions: Symptom checklist, Blood sample, Nasal swab, Oropharyngeal swab, Stool sample."
89135188|NCT02787252|Experimental|HF DRG|HF DRG Implants
89135189|NCT04204109|Experimental|Interprofessional case-based learning|The experimental intervention will be the interprofessional group receiving case-based learning about gastro-intestinal toxicities and side effects of children and adolescents with cancer.
89135190|NCT04204109|Active Comparator|Monoprofessional case-based learning|The control group is the monoprofessional group that will receive the same case-based learning as the intervention group.
89135191|NCT00877513|Experimental|Smokers|Cigarette smokers wishing to quit
89135192|NCT02786784|Other|healthy control|patients with patellofemoral pain
89135193|NCT05001399|Experimental|Holographic Memory Resolution® (HMR) Intervention|Intervention will be comprised of 4 sessions lasting approximately 90 minutes at one of two sites, Billings Clinic in Billings, Montana or Healing Dimensions AAC in Tucson, Arizona. The 4 sessions will be completed in approximately 9 weeks.
89135194|NCT02790450|Experimental|Benzbromarone|1x200mg Benzbromarone
89135195|NCT00873691||1|ICD shocks programmed to Tuned Waveform
89135196|NCT00873691||2|ICD shocks programmed to 50% Tilt waveform
89135197|NCT02790528|Experimental|Atorvastatin|20mg QD
89135198|NCT02790528|Placebo Comparator|Placebo|
89135199|NCT04039711|Other|Genital infections|Women with vaginal/cervical sampling indications
89135200|NCT00953615|Experimental|Thalidomide|Participants will be treated with Thalidomide, starting at a dose of 100 mg per day, increasing the dose by 100 mg every 14 days to a maximum of 400 mg per day.
89135201|NCT02787096|Experimental|laxIRM|Patients will have dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
89135202|NCT00873769|Experimental|Healthy smokers|Healthy smokers, male and female
89135203|NCT00873769|Experimental|Healthy nonsmokers|Healthy nonsmokers, Healthy smokers, male and female
89135204|NCT02785614|Experimental|II-1|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:~R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days. Wash-out period is 14 days."
89135205|NCT02785614|Experimental|II-2|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:~T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days. Wash-out period is 14 days."
89135206|NCT02859155|Other|Multiviceral resection colorectal cancer|Multiviceral resection surgery of 2 or more intrabdominal organs en bloc with colorectal cancer
89135207|NCT00810615|Sham Comparator|Sham treatment|Subject will breathe air at less than 1.3 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at less that 1.3 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
89135208|NCT00810615|Experimental|Hyperbaric oxygen 2.4 ATA|Subject will breathe 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
89135209|NCT02787018|Placebo Comparator|Block with Ropivacaine and Normal saline|Patients will receive brachial plexus block with 20 ml 0.5% ropivacaine with 1ml normal saline: Total volume 21 ml
89135210|NCT02787018|Active Comparator|Block with Ropivacaine and Dexamethasone|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 4mg (1ml) dexamethasone: Total volume 21 ml
89135211|NCT02787018|Experimental|Block with Ropivacaine and Dexmedetomidine|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 50mcg (1ml) dexmedetomidine: Total volume 21 ml
89135212|NCT02858999|Experimental|treatment|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles PAD-VCD
89135213|NCT00873925|Experimental|Autologous UCB Plus Vit D Omega 3 FA|A single autologous (self) intravenous umbilical cord blood infusion followed by 1 year of daily Vitamin D and Omega 3 Fatty Acid supplementation give as liquid drops and gel capsules that can be swallowed or added to food
89135214|NCT00873925|No Intervention|Control|Subjects randomized to be controls will continue to use intensive insulin therapy in order to compare c-peptide production at 1 year in those receiving combination therapy vs those who do not
89135215|NCT02859233|No Intervention|Control group|Routine advices about the interest of increase fluid after lumbar puncture to prevent PDPH will be transmitted: 2 liters will be provided to be drunk in 2 hours.
89135216|NCT02859233|Experimental|Interventional group|Lack of hyperhydration : no particular advices will be transmitted about the interest of oral hyperhydration. 500 milliliters will be provided in case of thirst, according to patient's convenience.
89135217|NCT04040257|No Intervention|Individual Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
89135218|NCT04040257|Experimental|Group Performance|Each participant will first take the exam as an individual. After a delay of 3-6 months, participants will then be randomized to take the exam again either as an individual again (control group) or as a team (exposure group).
89135219|NCT05755503||IS modeling and validation group|Uremia patients receiving hemodialysis.This group was used to establish the IS three-compartment model and verify the accuracy and predictive value of the model
89135220|NCT03412266|Other|RIC regimen|"Low- and intermediate MDS patients without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
89135221|NCT00869479||1|subjects with a histologically-proven diagnosis of NSF
89135222|NCT00869479||2|subjects with other fibrosing skin diseases
89135223|NCT00869479||3|subjects with non-fibrosing skin diseases
89135224|NCT00869479||4|subjects without skin diseases
89135225|NCT00877591|Experimental|1|Buprenorphine + Fosamprenavir/Ritonavir
89135226|NCT00877591|Active Comparator|2|Control Fosamprenavir/Ritonavir
89135227|NCT00877591|Experimental|3|Buprenorphine + Darunavir/Ritonavir
89135228|NCT00877591|Active Comparator|4|Control Darunavir/Ritonavir
89135229|NCT00877591|Experimental|5|Buprenorphine + Rifampin
89135230|NCT00877591|Experimental|6|Buprenorphine + Rifabutin
89135231|NCT05755425||CPAP|When a patient needs FiO2 >50% to keep SpO2 >93%, or SpO2 >95% in case of persistent respiratory distress defined as RR>35/min, full face CPAP will be applied
89135232|NCT05755425||HFNO|When a patient needs FiO2 >50% to keep SpO2 >93%, or SpO2 >95% in case of persistent respiratory distress defined as RR>35/min, HFNO will be applied
89135233|NCT02785536|Active Comparator|Standard Treatment|The standard treatment was a well-established, manual-driven, multicomponent CBT for tobacco dependence that has been delivered in multiple modalities (i.e., group, individual, and telephone), used in numerous studies, and considered intensive, comprehensive, and consistent with the Public Health Service Clinical Practice Guideline.
89135234|NCT02785536|Experimental|RITCh Treatment|The RITCh treatment is an adaptation of the standard treatment which proactively addresses the needs and experiences of a diverse group of lower SES smokers as well as ensures that the treatment is culturally congruent and experientially resonant for African Americans while maintaining the same amount of treatment contact (i.e., six one-hour sessions).
89135235|NCT04200222||Preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
89135236|NCT04200222||Control|Pregnant women with uncomplicated pregnancies were randomly selected to serve as controls. Healthy subjects who had a normal pregnancy and outcomes without any fetal-neonatal complications were accepted into the control group.
89135237|NCT00874003|Experimental|mirtazapine, tablet, 30 mg|n=29
89135238|NCT00874003|Placebo Comparator|sugar pill|n=30
88805911|NCT01142297|Other|dental implant|standard SLA surface and chemically modified surface
89135239|NCT04232046|Experimental|Intervention|Trigger point massage
89135240|NCT04232046|Active Comparator|Control|Treatment with standard drug Nortriptyline
89135241|NCT04915365|Experimental|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
89135242|NCT04915365|Placebo Comparator|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
89135243|NCT00877669|Active Comparator|Transurethral resection of the prostate|TURP group
89135244|NCT00877669|Experimental|Holmium Laser Enucleation of Prostate|HoLEP group
89135245|NCT02785146|Experimental|mFOLFOX6 + Huaier Granule|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ). Huaier Granule will be administrated from the first cycle of chemotherapy until 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
89135246|NCT02785146|Active Comparator|mFOLFOX6|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ).
89135247|NCT00869635|Experimental|1|"Treatment by combination of photodynamic therapy and S-1~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment"
89135248|NCT00869635|Active Comparator|2|"Treatment by photodynamic therapy only~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~Other managements except systemic chemotherapy were added freely."
89135249|NCT00869635|Other|3|Treatment by photodynamic therapy only or combined chemotherapy with photodynamic therapy: Open label
89135250|NCT00913965|Experimental|1|Atenolol Tablets 100 mg (Cord Laboratories)
89135251|NCT00913965|Active Comparator|2|Atenolol Tablets 100 mg (Stuart Pharmaceutical)
89135252|NCT02785380|Experimental|laparoscopic surgery(LS)|For LS,the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg.Intra-operative ultrasonography was performed routinely. Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. The Pringle maneuver was not used. Wedge resection, segmentectomy or subsegmentectomy was performed. The surgeon aimed to achieve a 1.0-cm safety margin during the liver resection.
89135253|NCT02785380|Active Comparator|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA).
89135254|NCT00877747||PET2 negative|Patients with negative early interim PET after 2 courses of ABVD who continued therapy with ABVD
89135255|NCT00877747||PET2 positive|Patients with positive early interim PET after 2 courses of ABVD who changed their therapy to BEACOPP
89135256|NCT02609451|Experimental|2 weeks|Ileostomy closure after 2 weeks
89135257|NCT02609451|Experimental|12 weeks|Ileostomy closure after 12 weeks
89135258|NCT03166332|Active Comparator|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and mixed nuts.
89135259|NCT03166332|Active Comparator|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
89135260|NCT03166332|No Intervention|No intervention|No intervention strategy
89135261|NCT05226481||TF-CBT|Trauma-focused cognitive-behavioral therapy (TF-CBT), an evidence-based method for the treatment of posttraumatic stress among youth, was provided to children and adolescents referred to CAMHS.
89135262|NCT02609529|Experimental|SBI|Entergam 10 g/day PO
89135263|NCT02609529|Placebo Comparator|Placebo|Placebo 10 g/day PO
89135264|NCT02689752|Experimental|fruquintinib|fruquintinib suspension, 5 mg （100 mCi）oral taken once
88805912|NCT03011723|Experimental|Music therapy|10 weekly sessions of in-home music therapy for PWDs and a caregiver, including weekly practicing of the interventions with the caregiver between the sessions. The treatment is administered individually.
88805913|NCT01143701|Experimental|ADHD Collaborative Intervention|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the American Academy of Pediatrics consensus recommendation for evidence-based ADHD care.
88805914|NCT01143701|No Intervention|Typical ADHD care|Physicians in this group will provide typical ADHD care.
89135265|NCT05753865|Experimental|SYHX2011|Patients will be administrated with SYHX2011 once every 3 weeks.
89135266|NCT05753865|Active Comparator|Paclitaxel for injection (albumin-bound)|Patients will be administrated with paclitaxel for injection (albumin-bound) once every 3 weeks.
89135267|NCT00869869|Experimental|melatonin|melatonin
89135268|NCT00869869|Placebo Comparator|placebo|placebo
89135269|NCT02785302||Adolescents and Young Adults:|Behaviorally-infected, HIV-positive, adolescents and young adults enrolled in ATN 125, aged 18 through 24, inclusive who are transition eligible. All subjects with available endpoint data will be included in the analysis.
89135270|NCT02785302||AMTU and Adult Clinic Staff|Clinical staff at the Adolescent Medical Trials Units (AMTUs) and at adult clinics where the AMTUs refer their transitioning patients will be recruited to complete quantitative surveys and semi-structured interviews.
89135271|NCT04213755||patients with risks of intraoperative massive bleeding|patients with risks of intraoperative massive bleeding
89135272|NCT05753709|Active Comparator|EE|End-to-end anastomosis, done in a conventionally described hand-sewn technique using sutures
89135273|NCT05753709|Active Comparator|SSSA|Stapled side-to-side anastomosis of the stoma using a linear cutter stapling device
89135274|NCT05753709|Active Comparator|HSSA|Hand-sewn anastomosis of the stoma using suturing of bowel loops placed in a side to side orientation
89135275|NCT00874393|Active Comparator|Dopamine and hydrocortisone|Dopamine AND hydrocortisone
89135276|NCT00874393|Active Comparator|Dopamine and placebo|Dopamine AND normal saline placebo
89135277|NCT00874393|Active Comparator|Placebo and hydrocortisone|Dextrose (D5W) placebo AND hydrocortisone
89135278|NCT00874393|Placebo Comparator|Placebo and Placebo|Dextrose (D5W) placebo AND normal saline placebo
89135279|NCT02786706||Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
89135280|NCT05753631||SRP+i-PRF (test)|Injectable platelet-rich fibrin (i-PRF) application into the selected deep periodontal pocket after scaling and root planning (SRP) procedure.
89135281|NCT05753631||SRP (Control)|No agent was applied to the periodontal pocket after scaling and root planning.
89135282|NCT04199364|Experimental|Low FiO2 threshold|A fraction of inspired oxygen (FiO2) of 25% to have an oxygen saturation (SpO2) of 90-92%.
89135283|NCT04199364|Experimental|Medium FiO2 threshold|A fraction of inspired oxygen (FiO2) of 35% to have an oxygen saturation (SpO2) of 90-92%.
89135284|NCT00874471||sarcoidosis|
89135285|NCT00874471||ankylosing spondylitis|
89135286|NCT00874471||Behcet's disease|
89135287|NCT00874471||toxoplasmosis|
89135288|NCT00874471||herpetic acute retinal necrosis|
89135289|NCT00874471||idiopathic uveitis|
89135290|NCT00874471||ankylosing spondylitis (no uveitis)|
89135291|NCT00874471||sarcoidosis (no uveitis)|
89135292|NCT00874471||Behcet's disease (no uveitis)|
89135293|NCT00874471||normal control|
89135294|NCT04231890|Experimental|IPI group|IPI monitoring
89135295|NCT04231890|No Intervention|Control group|Standard monitoring
89135296|NCT00870025|Active Comparator|hCG|200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH
89135297|NCT00870025|Placebo Comparator|placebo|similar injection at same time points with similar diluent but no hCG
89135298|NCT04198974|Experimental|PreVenture Training (PTtT)|Schools randomized to this arm will identify 4 staff members to participate in a 2-day training workshop + 3 hours of supervised practice and will be provided with access to screening and PreVenture intervention materials through the local trainer. Local trainers will deliver 2-day workshops and then supervise school staff in the delivery of two 90-minute group sessions (for at least one personality profile).
89135299|NCT04198974|Experimental|PreVenture Training + Implementation Facilitation (PTtT+IF)|Schools randomized this arm will receive the standard PreVenture TtT protocol plus an additional Implementation Facilitation package that will contain 3 new components designed to increase the likelihood that schools will continue to implement the program with high quality and satisfaction: 1) Youth Engagement, 2) ongoing coaching and supervision for Facilitators, and 3) access to easy-to-use performance metrics.
89135300|NCT04198974|No Intervention|Control (TAU)|For schools randomized to this arm, students will have usual access to drug and alcohol prevention through the standard curriculum and mental health care provided through student counseling at the participating schools. The schools will be incentivized to participate in the study with the promise of free PreVenture training and materials in subsequent years of the trial. Information on other drug prevention efforts implemented at the school will be collected, but the randomized design should control for any potential differences between intervention conditions on this random factor.
89135301|NCT00877981|Active Comparator|Videoassited surgery|"In patients randomized to a video-assisted approach, the surgeon has the option to choose either the lateral- (VAPLA) or medial (MIVAP) techniques, both initiated with a 15 mm transverse skin incision. The lateral approach is performed as described by Henry.~The medial approach is performed using the gasless procedure developed by Miccoli."
89135302|NCT00877981|Active Comparator|Open surgery|Open surgery, a 15 mm transverse skin incision is made close to the site of the parathyroid adenoma indicated by sestamibi scintigraphy.
89135303|NCT02786472|Active Comparator|Haven|"Online Bystander Training or Haven provides students with definitions and statistics associated with sexual assault and relationship violence, bystander skills and strategies, and campus policies and resources. The trainings are personalized and reflective and incorporate the student's unique perspectives and experiences. This 45-minute training is mandatory and students are asked to complete a follow-up survey 45-days after the training. Because this training is mandatory for all incoming students, all students are expected to have exposure to this training."
89135304|NCT02786472|Active Comparator|AlcoholEdu|Online Substance Abuse Training or AlcoholEdu provides confidential substance abuse education course which uses a science-based approach to educate students about alcohol and its effects. Whether the student drinks or not, the course will help them make informed decisions about alcohol and better deal with drinking behavior that may occur around them. AlcoholEdu is used by more than 500 colleges nationwide through EVERFi.
89135305|NCT02786472|Experimental|ConnectEd|In-person Combination Training provides Green Dot Intensive Bystander Training AND Substance Abuse Prevention cross-programming to develop ConnectED. The intentional coordination between substance abuse and violence prevention programming would include in-depth information related to interpersonal violence and substance use/abuse, activities to help participants explore their connection to these issues; information and activities related to the culture of violence, drinking and drug use and how everyone has a role in impacting that culture; information about bystander behaviors and barriers to taking action when they encounter problem situations; participant self-evaluation of their own attitudes, beliefs and biases around these issues; and, in-depth skill building activities to prepare participants to safely intervene in problem situations.
89135306|NCT02786472|Experimental|GreenDot|"In-person Bystander Training provides Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions. While a Popular Opinion Leader strategy has been used in prior training, for this trial all incoming students randomized to this condition will be offered intensive bystander training.~NOTE: Green Dot Speeches will be supplemental to Intensive Green Dot Bystander training. These speeches will continue to occur as usual. As the aim of this study is to compare bystander intensive training, we will not attempt to limit participation to Green Dot Speeches."
89135307|NCT00870181|Experimental|ADV-TK/GCV|ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
89135308|NCT00870181|Active Comparator|Control group|Patients received surgery or systemic chemotherapy or palliative care.
89135309|NCT00874627|Experimental|Experimental|Administration of Milk
89135310|NCT00874627|Placebo Comparator|Placebo|meals without milk
89135311|NCT02786550|Experimental|Botulinum Toxin|"Immediately after lower blepharoplasty surgery 3 injections of 2.5U of botulinum toxin over lateral part of orbicularis oculi muscle.~Intervention: Botulinum toxin injection"
89135312|NCT02786550|Placebo Comparator|Normal saline|"Immediately after lower blepharoplasty surgery 3 injections of same amount of normal saline over lateral part of orbicularis oculi muscle.~Intervention: Normal saline injection"
89135313|NCT00878059||Proxies|A family member-caregiver (the medical decision-maker) for someone with Alzheimer's Disease. Must be the person who would be able to make decisions for someone with Alzheimer's disease about being in medical research.
89135314|NCT05139511|Experimental|Study group|IPL + laser refractive surgery
89135315|NCT05139511|Placebo Comparator|Control group|Laser refractive surgery without IPL
89135316|NCT03838471||Central sensitization symptoms|This group will contain persons with a clinically relevant degree of symptoms of CS (CSI score ≥40).
89135317|NCT03838471||No Central sensitization symptoms|This group will contain persons with a lower degree of symptoms of CS (CSI score < 40).
89135318|NCT02784054|Experimental|Intracranial NGGCT|"Six cycles of chemotherapy with carboplatin, etoposide, bleomycin (CEB) and cyclophosphamide, etoposide, bleomycin (CyEB) regimen.~Peripheral blood stem cell collection during the first cycle of chemotherapy.~Surgery, if there is residual tumor after chemotherapy.~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation (auto-SCT)~1st HDCT: Carboplatin, thiotepa, etoposide~2nd HDCT: Cyclophosphamide, melphalan~Reduced dose of radiotherapy"
89135319|NCT00874861|Experimental|Vaccine + Poly-ICLC|Peptide Vaccine + Poly-ICLC
89135320|NCT00878137||APLA|Patients with antiphospholipid antibody syndrome.
89135321|NCT00878137||Control|Patients on warfarin therapy but without antiphosphilipid antibody syndrome.
89135322|NCT02176278|No Intervention|Usual Care Group|"Usual care (UC) group:~After undergoing a comprehensive assessment, all patients will receive UC in accordance to the practice of the health institution and return at 12 months for a repeat comprehensive assessment."
88802651|NCT02554890|Experimental|sacubitril/valsartan (LCZ696)|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."
88802652|NCT02554890|Active Comparator|Enalapril|"Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"
89135323|NCT02176278|Experimental|Empowered Care Group|"Empowered care (EC) group:~After undergoing a comprehensive assessment, all patients will be given a JADE comprehensive assessment report which is a personalize risk report with treatment targets and decision support with explanation from the doctor and nurse. In addition to receiving UC in accordance to the practice of the health institution, the nurse will provide telephone reminder to patient 3-monthly to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns. All patients will return at 12 month for a repeat comprehensive assessment."
89135324|NCT02176278|Experimental|Team-based, Empowered Care Group|"Team-based, empowered care (TEC) group:~After undergoing a comprehensive assessment, patients randomized to the TEC group will be given a JADE comprehensive assessment report which is a personalized risk report for patient empowerment. They will receive telephone reminders and doctor-nurse follow up at least 3 monthly to achieve multiple targets recommended. The patients will also be given JADE reports 3-monthly and return at 12 month for a repeat comprehensive assessment."
89135325|NCT04038853|Experimental|Vitamin D|Intervention drug, containing 1,25-dihydroxy-vitamin D, comes in original packages as vials containing a total amount of 10 ml of clear solution. 5 drops accounting for 1000 IU of 1,25-dihydroxy-vitamin D will be administered orally on a daily basis.
89135326|NCT04038853|Placebo Comparator|Placebo|A placebo identical to the study intervention drug in all its characteristics (package, visual characteristics of the fluid, smell, and taste) will be administered in the same manner.
89135327|NCT00878293|Experimental|A|Dose 1, 40 µg
89135328|NCT00878293|Experimental|B|Dose 2, 120 µg
89135329|NCT00878293|Experimental|C|Dose 3
89135330|NCT00878293|Experimental|D|Dose 4
89135331|NCT00878293|Experimental|E|Dose 5
89135332|NCT00878293|Experimental|F|Dose 6
89135333|NCT00878293|Experimental|G|Dose 7
89135334|NCT00878293|Active Comparator|H|Morphin
89135335|NCT00878293|Placebo Comparator|I|Placebo
89135336|NCT02066220|Experimental|PNET 5 MB-LR (low-risk)|Radiotherapy and reduced-intensity maintenance chemotherapy. Total treatment duration is 39 weeks.
89135337|NCT02066220|Experimental|PNET 5 MB-SR (standard-risk)|"Radiotherapy with carboplatin or radiotherapy without carboplatin and maintenance chemotherapy.~Total treatment duration is 48 weeks."
89135338|NCT02066220|Experimental|PNET 5 MB WNT-HR|"Radiotherapy adapted to age and metastatic Status and maintenance chemotherapy adapted to age.~Total treatment duration is 39 to 48 weeks."
89135339|NCT02066220|Experimental|PNET 5 MB SHH-TP53|"Reduced chemotherapy with Doxorubicin, VCR, HD-MTX, Carboplatin, and MTX intraventricularly Stratification of radiotherapy according to~presence of metastasis~germline mutation in TP53 (including mosaicism) Maintenance chemotherapy with VBL Total treatment duration is 1 year"
89135340|NCT00573391|Experimental|VTD = Velcade, Thal, and Dex|VTD = Velcade, Thalidomide, and Dexamethasone
89135341|NCT00573391|Experimental|VMD = velcade, melphalan, and dex|VMD = velcade, melphalan, and dexamethasone
89135342|NCT00590967|Experimental|Treatment Group 1|"Pelvic Lymph Nodes Only Positive on FDG PET.~IMRT External Beam radiation to the para-aortic region (45 Gy)~Pelvis intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin 40 mg/m^2"
89135343|NCT00590967|Experimental|Treatment Group 2|"Para-Aortic Lymph Nodes Positive on FDG PET~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)~IMRT external beam pelvic radiation therapy as appropriate for stage~Intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m^2)"
89135344|NCT02783976||Sovaldi-based regimens|Adult patients with chronic HCV infection living in Mexico who take Sovaldi as part of routine clinical care at a participating clinical site.
89135345|NCT00878371|Other|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
89135346|NCT05753553||Heart Failure with preserved Ejection Fraction (HFpEF)|After signing informed consent, clinical and echocardiographic data will be collected. Thereafter, they will be followed up for major clinical events (cardiovascular death, HF requiring hospitalization, myocardial infarction, and atrial fibrillation) for a period of 12 months.
89135347|NCT00875095||IUI patients|Patients undergoing routine semen analysis as part of their infertility treatment pertaining to success or failure with intrauterine insemination, based upon their sperm DNA integrity
89135348|NCT00875095||IVF patients|Couples undergoing routine screening prior to IVF retrievals to assess their reproductive treatment outcomes as compared to the sperm DNA integrity
89135349|NCT05753475||hypotension|
89135350|NCT05753475||normotension|
89135351|NCT04230720|Experimental|Artificial Tears|One eye of each participant is randomized to receive Systane Complete artificial tears 4 times a day for 14 days
89135352|NCT04230720|No Intervention|No Artificial Tears|One eye of each participant is randomized to receive no artificial tears for 14 days
89135353|NCT00923299|Other|cetuximab, trastuzumab|
89135354|NCT02783742|Experimental|Intervention|Providers in this arm will receive a communication coaching intervention immediately post-randomization.
89135355|NCT02783742|Other|Waitlist Control|Providers assigned to this arm will be offered the option of receiving the communication coaching intervention after follow up data collection is complete.
89135356|NCT04030065|Experimental|Experimental Arm - omega 3 fatty acid|
89135357|NCT04030065|No Intervention|Control Arm - No intervention|
89135358|NCT02689830|Experimental|Bead Block microspheres|Prostate embolization
89135359|NCT05753397|Experimental|Single injection|1x21ml Ropivacaine (7.5mg/ml) at ITTC T4. Including two sham injections at ITTC T2 and ITTC T6
89135360|NCT05753397|Experimental|Multiple injection|3x7ml Ropivacaine (7.5mg/ml) at ITTC T2, T4 and T6.
89135361|NCT04230798|No Intervention|Control|This group did not perform any specific exercise program nor injury prevention program. They continued their normal training routine
89135362|NCT04230798|Experimental|Prevention program|This group performed two sessions per week of the injury prevention program. The program included strength training, plyometrics and core stability training.
89135363|NCT00875173|Experimental|Selenium|Sodium selenite 100 micrograms in capsugel by mouth diary for 365 consecutive days
89135364|NCT00875173|Active Comparator|Placebo|Capsugel for placebo (selenium 100 micrograms capsugel) by mouth diary for 365 consecutive days
89135365|NCT04039477|Experimental|Arm A - KZR-616 30mg|KZR-616 30mg Subcutaneous (SC) injection weekly for 13 weeks
89135366|NCT04039477|Experimental|Arm B - KZR-616 45mg|KZR-616 30 mg SC injection weekly for 1 dose then 45mg weekly for 12 weeks.
89135367|NCT04029831|Experimental|K61|Patients in K61 group received propofol and ketamine in a ratio of 6:1. The 6:1 ketofol mixture was made by mixing 30 mL of 1% propofol (10 mg/mL) and 1 mL of ketamine (50 mg/ml), then 19 mL of 0.9% NaCl was added until the volume of the mixture was 50 mL. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
89135368|NCT04029831|Experimental|K41|Patients in K41 group received propofol and ketamine in a ratio of 4:1. The 4:1 ketofol mixture was made by combining 20 mL of 1% propofol (10 mg/mL) and 1 mL ketamine (50 mg/ml). Afterward, 29 mL of 0.9% NaCl was added until the volume of mixture was 50 mL. Mixtures were mixed in a 50 mL syringe and were given to patients through a syringe pump (B Braun).
89135369|NCT00875251||term infants body composition|Term infants from 2 days of life to 7 days of life without IUGR
89135370|NCT00875251||preterm infants body composition|very low birth weight infants before discharge
89135371|NCT04230642|Experimental|Robotic device|Needle placement to the tumor, one time, the day of the ablation procedure
89135372|NCT04029675|Experimental|Study Group ( High dose vitamin C group )|They will receive 1.5 gm intravenous (IV) Vitamin C in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes every 6 hours daily for 4 days or until ICU discharge.
89135373|NCT04029675|Active Comparator|Control Group (Daily requirements vitamin C Group )|They will receive standard daily requirements of Vitamin C intravenously which is 75-90 mg in 100 ml dextrose 5% (D5W) administered as an infusion over 30 to 60 minutes daily for 4 days or until ICU discharge
89135374|NCT00878449|Experimental|ABT-263 + etoposide/cisplatin|
89135375|NCT02783352|Experimental|treatment group|arthroscopic rotator cuff repair + injection of autologous micro-fragmented adipose tissue (10 mL)
89135376|NCT02783352|Other|control group|arthroscopic rotator cuff repair only
89135377|NCT06167759|Experimental|Opioid Use Agreement|Patients in this group will be administered a safe opioid use agreement by the research coordinator. This agreement is in addition to any routine education and counseling provided by the surgical team.
89135378|NCT06167759|No Intervention|Standard of Care|Patients in this group will receive standard care which includes safe opioid education from the surgical care team.
89135379|NCT06167707|Experimental|Treatment Sequence 1|Period 1: SC Period 2: IV
89135380|NCT06167707|Experimental|Treatment Sequence 2|Period 1: IV Period 2: SC
89135381|NCT06167642||People with RMS due to commence or already receiving ofatumumab therapy|75 people with RMS due to commence or already receiving ofatumumab therapy within 60 days of baseline.
89135382|NCT06167616||LADA|Classification of LADA based on age ≥35 years at diagnosis, GADA positivity (≥10 U/ml) and C-peptide concentrations of ≥0.2 nmol/L (IMMULITE) or ≥0.3 nmol/L (Cobas).
89135383|NCT06167616||Type 2 diabetes|≥35 years, GADA negative and C-peptide concentrations of &gt;0.60 (IMMULITE)/&gt;0.72 (Cobas) nmol/L.
89135384|NCT06167616||Controls|≥35 years, free of diabetes
89135385|NCT06167590|Other|Anxious-depressive disorder|
89135386|NCT06167590|Other|Healthy controls|
89135387|NCT06167564|Active Comparator|Routine allergy tests|Routine allergy tests (prick tests, specific IgE detection) will be done to establish the sensibilization of the patient.
89135388|NCT06167564|Experimental|Newly developed microarray-based diagnostic test system|Newly developed microarray-based diagnostic test system will be used to establish the sensibilization of the patient.
89135389|NCT06167538||SABI patients with a tracheal tube treated with the new decannulation procedure.|All adult SABI patients ≥ 18 years with a tracheal tube at admission to the Department of Brain Injury from September 2021 to October 2022 and treated with the new decannulation procedure.
89135390|NCT06167538||SABI patients in whom decannulation was attempted before implementation of the new procedure.|Patients with SABI and a tracheal tube in whom decannulation was attempted between July 2019 until December 2020 will serve as a historical control group.
89135391|NCT06167473|Experimental|low-dose stem cell group (1×10^6cells/kg per infusion)|Peripheral intravenous infusion of low-dose stem cells
89135392|NCT06167473|Experimental|medium-high-dose stem cell group (3×10^6cells/kg per infusion)|Peripheral intravenous infusion of medium-high-dose stem cells
89135393|NCT06167447||multiple sclerosis group|Demographic data of all participants were recorded. Tampa Scale of Kinesiophobia (TSK), Beck Depression Inventory (BDI), Quality of Life Scale Short Form-36 (SF-36), International Physical Activity Questionnaire Short Form (IPAQ-SF), Functional Ambulation Classification (FAS), Functional Independence Measure (FIM), Expanded Disability Status Scale (EDSS) were implemented.
89135394|NCT06167447||control group|Demographic data of all participants were recorded. Tampa Scale of Kinesiophobia (TSK), Beck Depression Inventory (BDI), Quality of Life Scale Short Form-36 (SF-36), International Physical Activity Questionnaire Short Form (IPAQ-SF), Functional Ambulation Classification (FAS)
89135395|NCT06167421|Experimental|Kimura group|Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique.
89135396|NCT06167421|Active Comparator|Warshaw group|Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique.
89135397|NCT06167408||Pemphigus patients in the First Affiliated Hospital of Chongqing Medical University|
89135398|NCT06167382|Experimental|Healthy Female and Male Adults|Demographic Survey Form,the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+),Digital Dynamometer Measurement,ROM Measurements, Muscle Strength Tests, Grip Strength Measurement, Hand Skill and Function Tests, Arm Ergometer,Modified Borg Scale, Pulseoximeter will be applied to the participants.
89135399|NCT06167356||Patients with non-muscle invasive bladder cancer|Patients with non-muscle invasive bladder cancer who underwent one of the following endoscopic resection surgeries : TURBK, MAPPING, TURBK SECOND LOOK, BLADDER BIOPSIES
89135400|NCT06167291|Experimental|Arm 1- Ipsilateral|Participants with ipsilateral-only drainage (Arm 1- Ipsilateral) will be randomized to assign definitive ipsilateral RT (without concurrent chemotherapy) -vs- ipsilateral surgery (TORS/ND).
89135401|NCT06167278|Experimental|Shell tray group|
89135402|NCT06167278|Experimental|Bar tray group|
89135403|NCT06167213|Experimental|TMVR in failing mitral surgical bioprosthetic valve|Transcatheter Mitral Valve Replacement (TMVR) in subjects with a failing mitral surgical bioprosthetic valve.
89135404|NCT06167213|Experimental|TMVR in failing native mitral valve with an annuloplasty ring|Transcatheter Mitral Valve Replacement (TMVR) in subjects with a failing native mitral valve with an annuloplasty ring.
89135405|NCT06167187|Active Comparator|Study group (IAN block group)|patients will receive bilateral inferior alveolar nerve block. 23 patients
89135406|NCT06167187|Active Comparator|control group|"patients will not receive the block and will receive intravenous multimodal analgesia according to standard protocol.~23 patients"
89135407|NCT06167174||MMF treatment|Patients that have been diagnosed as III/IV ± V LN and treated with MMF 2g/d in combination with glucocorticoid.
89135408|NCT06167174||CYC treatment|Patients that have been diagnosed as III/IV ± V LN and treated with CYC 0.5g IV per two weeks in combination with glucocorticoid.
89135409|NCT06167148|Experimental|940nm wavelength Diode laser|
89135410|NCT06167148|Active Comparator|980nm wavelength Diode laser|
89135411|NCT06167122||Craniofacial fibrous dysplasia|Fibro-osseous lesions within the affected bones based on image, and surgical intervention based on 4 different anatomical zones.
89135412|NCT06167109|Experimental|Optimized CTV|The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
89135413|NCT06167109|No Intervention|Conventional CTV|The CTV1 was defined as GTVnx + 5 mm + entire nasopharynx mucosa .The CTV2 was defined as GTV1+ 5 mm + corresponding anatomical structures.
89135414|NCT06167044|Active Comparator|thoracic mobilization group|which will include 17 patients who will receive thoracic manual mobilization exercises in addition to selected physical therapy .The treatment will conducted for 45 minutes, 3 sessions per week for 6 weeks.
89135415|NCT06167044|No Intervention|control group|which will include 17 patients who will receive selected physical therapy.The treatment will conducted for 45 minutes, 3 sessions per week for 6 weeks.
89135416|NCT06167031|Experimental|Chatbot-facilitated Group|
89135417|NCT06167031|Active Comparator|Controlled Group|
89135418|NCT06167018||Nurse-delivered, gut-directed hypnotherapy|Adult patients suffering from irritable bowel syndrome (IBS), with symptoms refractory to standard treatment. Patients referred to a tertiary care center were included.
89135419|NCT06167005||One anastomosis gastric bypass|
89135420|NCT06167005||Roux en y gastric bypass|
89135421|NCT06167005||Sleeve gastrectomy|
89135422|NCT06167005||Adjustable gastric band|
89135423|NCT06166979|Active Comparator|Study Group A: Probiotic Micrococcus luteus Q24 serum (high dose)|Group A: Probiotic Micrococcus luteus Q24 serum (dose: 1e8 colony forming units per application)
89135424|NCT06166979|Active Comparator|Study Group B: Probiotic Micrococcus luteus Q24 serum (low dose)|Group : Probiotic Micrococcus luteus Q24 serum (dose: 1e6 colony forming units per application)
89135425|NCT06166953|Experimental|mobile application|The mobile application will be downloaded on smart phones of participants. This group will be able to look up information related to surgical period when needed.
89135426|NCT06166953|No Intervention|Control|The control group will receive routine care. This group will wear smart band for pulse rate, sleep, blood pressure, and SpO2 record for data collection times.
89135427|NCT06166940||Conventional Management|
89135430|NCT06166823|Experimental|EMR Alert|
89135431|NCT06166823|No Intervention|Usual Care|
89135432|NCT06166797||No NAFLD|individuals with <5 percent hepatic fat fraction on magnetic resonance spectroscopy
89135433|NCT06166797||Simple Steatosis|individuals with at least 10% fat fraction on magnetic resonance spectroscopy without any history of nonalcoholic steatohepatitis or evidence of fibrosis
89135434|NCT06166797||Nonalcoholic Steatohepatitis|individuals with biopsy confirmed nonalcoholic steatohepatitis and stage 2 or 3 fibrosis
89135435|NCT06166784||Mectascrew B|
89135436|NCT06166771|Experimental|Woman who developed PPH after vaginal birth and first line therapies have been attempted and faile|Group which Alma treatment was applied
89135437|NCT06166680||Healthy children|Healthy children between the ages of 4 to 17 will undergo tongue motor functions assessment and their parents will fulfill the Pediatric Sleep Questionnaire
89135438|NCT06166667|Experimental|experimental group|Fecal Microbiota Transplant
89135439|NCT06166641||Intraoperative acquired pressure injury|Intraoperative acquired pressure injury are wounds that develop during a surgical procedure or while a patient is in the operating room. These ulcers are caused by prolonged pressure on a specific area of the body, which reduces blood flow and leads to tissue damage.
89135440|NCT06166615|Active Comparator|Pyllium group|"Take 2 sachets (12 g) orally once daily. Increase or decrease the dose as needed to treat your symptoms, with a maximum daily dose of 18 grams (6 grams in the morning and 12 grams in the evening). Do not chew this medication and take it with 1 to 2 cups of water.~Take it for 1 month"
89135441|NCT06166615|Experimental|Ramosetron group|"Men: 5 μg orally once daily. Increase or decrease the dose as needed based on symptoms, with a minimum daily dose of 2.5 μg and a maximum daily dose of 10 μg.~Women: 2.5 μg orally once daily. Women: 2.5 μg orally once daily, titrated up or down as needed, with a maximum daily dose of 5 μg.~Take it for 1 month"
89135442|NCT06166589|Experimental|Zimberelimab in combination with SIROX chemotherapy|
89135443|NCT06166563|Active Comparator|AF-FM|Patients with Fibromyalgia
89135444|NCT06166563|Active Comparator|AF-IBS|Patients with irritable bowel syndrome
89135445|NCT06166563|Active Comparator|AF-FM-IBS|Patients with fibromyalgia and irritable bowel syndrome
89135446|NCT06166524|Active Comparator|Early invasive strategy|Patients will undergo early catheter ablation for atrial fibrillation using pulsed-field ablation energy
89135447|NCT06166524|Placebo Comparator|Conservative arm|Patients will undergo cardioversion with antiarrhythmic drug treatment. In patients with atrial fibrillation reoccurrence, an optimalization of bradycardia medication will be done using smart watches heart rate monitoring
89135448|NCT06166511|Experimental|Group undergo laparoscopic liver resection|Any patient from 18 to 65 and has localized liver pathology and underwent laparoscopic non anatomical resection of this pathology
89135449|NCT06166472|Experimental|AK132|Each subject will receive a single dose of AK132 every 2-week cycle (Q2W).
89135450|NCT06166459|Experimental|Yao technique|The following 2 treatment strategies are available. (1) DCB combined with provisional DES implantation 1-2 mm distally to the lesion ostium whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the lesion ostium followed by DCB (DES+DCB strategy).
89135451|NCT06166433|Experimental|Intervention|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period
89135452|NCT06166433|No Intervention|Control|Assessment-only control
89135453|NCT06166329|Experimental|chair lift test|
89135454|NCT06166303||Previous Cesarean Section|Subjects with one or more previous cesarean sections
89135455|NCT06166303||No Cesarean|Subjects scheduled for an elective or urgent cesarean, but no history of previous cesarean section
89135456|NCT06166264|Experimental|Progressive resistance training|
89135457|NCT06166264|Experimental|Control group|
89135458|NCT06166212||Cases with high myopic astigmatism|Cases having myopic astigmatism more than 1.5 diopter
89135459|NCT06166212||Cases with not high astigmatism|Cases having astigmatism less than 1.5 diopter
89135460|NCT06166199|Experimental|High-intensity interval training (HIIT) combined with resistance training|"Patients with SLE will undergo supervised HIIT on an ergometercycle 4 x 4 minutes interval (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the supervised training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week."
89135461|NCT06166199|No Intervention|Control group|Both the control group and the HIIT combined with resistance training group receive standard care.
89135462|NCT06166186|Active Comparator|Music Group|Music will be delivered via headphones intraoperatively. Blood samples will be collected as per the protocol.
89135463|NCT06166186|Active Comparator|Control Group|Headphones will be applied but no music will be played intraoperatively. Blood samples will be collected as per the protocol.
89135464|NCT06166173||Breast tumor|Female patients with breast tumors and/or axillary lymph node metastases who had markers placed before neoadjuvant chemotherapy (NACT), and patients undergoing preoperative marker localization after NACT
89135465|NCT06166160|Experimental|SDR FLOW + bulk fill flowable|in class II cavities of primary molars
89135466|NCT06166160|Active Comparator|high-viscosity glass ionomer cement (EQUIA Forte)|in class II cavities of primary molars
89135467|NCT06166147||Cancer arm|Participants with new diagnosis of pancreatic cancer, from whom a peripheral blood sample will be collected.
89135468|NCT06166147||Benign disease arm|Participants with benign pancreatic diseases, from whom a peripheral blood sample will be collected.
89135469|NCT06166121|Experimental|ShenJu|On the basis of standardized drug treatment for Hyperlipidemia combined with carotid atherosclerosis, participants who met the inclusion criteria were randomly given ShenJu intervention on the day of inclusion, taking it twice a day for 90 days.
89135470|NCT06166121|Placebo Comparator|placebo|On the basis of standardized drug treatment for Hyperlipidemia combined with carotid atherosclerosis, participants who met the inclusion criteria were randomly given placebo granules on the day of inclusion, which were taken twice a day for 90 days (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
88802653|NCT02257112|Experimental|Multistage low-energy stimulation|Multistage low-energy electrical pulses as described in Janardhan AH et al. JACC 2014 Jan7-14:63(1):40-8 will be delivered to a patient in atrial fibrillation. The responses to these stimuli will be recorded.
88802654|NCT02249390||Anyone|Any individual may complete this survey
88802655|NCT04491552||Patients monitored with TruGraf and TRAC testing|Subjects will have TruGraf and TRAC testing at study enrollment (Baseline) and thereafter every 3 months. In addition subjects will have TRAC testing at any time there is a suspicion of acute rejection.
88802656|NCT03252600|Experimental|Arm I (lenalidomide, dexamethasone, elotuzumab)|"Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on days 1, 8, 15, and 22 of courses 1 and 2 and days 1 and 15 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
88802657|NCT03252600|Experimental|Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)|"Patients receive lenalidomide, dexamethasone, and elotuzumab as in Arm I. Patients also receive cyclophosphamide IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
88802658|NCT02086682||General Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.
88802659|NCT02086682||Critical Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.
88802660|NCT02749526|Experimental|Endostar combined with MPFC|"Chemotherapy regimens (er degree + mPFC) :~Endostar:~degrees 30 mg civ24h d0-6;~Liposo:~135 mg/m2 D1; cisplatin: D1-3, 25 mg/m2~Gimeracil and Oteracil Potassium (Tegafur):~(40 mg bid Tegafur), D1-14. A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
88802661|NCT04423770||U.S. dentists|Dentists in the United States
88802662|NCT05475912|Experimental|group A, Conventional Pysical Therapy treatment|group A will be given, Electrotherapy Modalities treatment:Hot pack - 20 min,Transcutaneous Electrical Nerve Stimulator - 30 min and will perfome Active Exercises including;Knee to chest exercise,Hamstring stretch, Pelvic bridging,Pelvic tilt, Lumbar rotation stretch exercise.(1set with10 reps of each excercise) Home exercise plan & precautions; Perform above mentioned active exercises, 3 sessions per day (1sets x 10 reps) will also be given to Group A.
88802663|NCT05475912|Experimental|Group B, Talocrural joint manipulation and Conventional Physical Therapy treatment|group Bwill be given, Talocrural Joint Manipulation with Electrotherapy Modalities treatment:Hot pack - 20 min,Transcutaneous Electrical Nerve Stimulator - 30 min and will perfome Active Exercises including;Knee to chest exercise,Hamstring stretch, Pelvic bridging,Pelvic tilt, Lumbar rotation stretch exercise.(1set with10 reps of each excercise) Home exercise plan & precautions; Perform above mentioned active exercises, 3 sessions per day (1sets x 10 reps) will also be given to Group B.
88802664|NCT00000928|Experimental|A|All study participants
88802665|NCT02552316|Other|NB-UVB Phototherapy|NB-UVB phototherapy is a therapy which uses ultraviolet B (UVB) light directed at the skin. This type of light therapy is given through the use of phototherapy booths which contain fluorescent tubes that emit UVB light. Booths used for phototherapy look similar to commercial tanning booths. NB-UVB phototherapy affects psoriasis by causing changes to the cells of the skin and producing a local effect by reducing the number of certain types of skin cells which have an impact on psoriasis formation.
88802666|NCT04423692||pregnant women with abnormal labs|Mothers who have abnormal labs during pregnancy with abnormal coagulation profile
88802667|NCT05480280|Experimental|mFOLFOX6 + dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days. mFOLFOX6 will be administered every 2 weeks.
88802668|NCT04757324|Experimental|education arm|Breastfeeding training was given to the training arm
88802669|NCT04757324|No Intervention|control arm|Breastfeeding training not given to control arm
88802670|NCT02208830|Experimental|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
88802671|NCT02208830|Experimental|pulmonary rehabilitation|Duration of 8 week, twice weekly exercise program with: lower limb strength training and aerobic training per 30 minutes.
89135471|NCT06166108|Active Comparator|"Group M bupivacaine +normal saline +MgSO4"|will receive 25 ml volume on each side (20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 250 mg of MgSO4)
89135472|NCT06166108|Active Comparator|"Group D bupivacaine +normal saline +dexamethasone"|will receive 25ml volume on each side (20 ml of 0.25% bupivacaine plus 5 ml of normal saline containing 8 mg of dexamethasone)
89135473|NCT06166095|Experimental|high-dose moderate to vigorous physical activity (MVPA)|"Participants will be asked to perform a high-dose (HD) (i.e., 300 minutes of moderate to vigorous physical activity (MVPA) per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max.~Participants will be asked to track their activity using Fitbit."
89135474|NCT06166095|Experimental|moderate-dose moderate to vigorous physical activity (MVPA)|"Participants will be asked to perform a moderate-dose (MD) (i.e., 150 minutes of moderate to vigorous physical activity (MVPA) per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max.~Participants will be asked to track their activity using Fitbit."
89234257|NCT05252286|Active Comparator|paper sheet|For the paper sheet group, the therapist will prepare the exercise leaflet, suitable for the patients, in advance, and select three to five groups of movement exercises on the leaflet that his/her therapist deem the patients needed to be enhanced. When the patients ends his/her rehabilitation program, they can practice following the instructions on the leaflet for them-self in bedside.
88802672|NCT05480202|Experimental|Thoracic block technique and designed chest physical therapy program|Manual compression on healthy lung for 20 seconds and rest for 20 seconds, total time 20 minutes and percussion,vibration , postural drainage one session time for 35 minutes every day for ten days
88802673|NCT05480202|Active Comparator|Designed chest physical therapy program|Percussion, vibration and postural drainage for 30 minutes every day for ten days
88802674|NCT02543346|Other|cetirizine hydrochloride|
88802675|NCT02543346|Placebo Comparator|placebo|
88802676|NCT04390100|Active Comparator|PRF|PRF membrane is placed in the area where the free gingival graft was taken from the palate
88802677|NCT04390100|Active Comparator|hyaluronic acid|hyaluronic acid gel is placed in the area where the free gingival graft was taken from the palate and the patient is instructed to place the gel 3 times per day
88802678|NCT04390100|Active Comparator|Gel foam|Gel foam is placed in the area where the free gingival graft was taken from the palate
88802679|NCT04818814|Experimental|Mindfulness Meditation (MM) App|Participants randomized to the MM condition will be asked to download and use the free Mindfulness Coach app (available for iOS and Android platforms) developed by the Veteran Affairs National Center for PTSD. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes. Participants will attend a live videochat orientation to the study with the research coordinator (RC) to receive assistance in downloading and using the app. Participants will be asked to listen to at least one, and ideally two, audio-guided meditation exercises using the app daily for six weeks. The RC will ask participants to complete weekly logs of their MM app use via a Qualtrics survey sent via email.
88802680|NCT04818814|Active Comparator|Engagement and Distraction (ED) App|Participants randomized to the Engagement and Distraction condition will be asked to download and use the free TED Talk app (available for iOS and Android platforms). The app offers many videos of engaging and distracting presentations about technology, entertainment, and design. The research coordinator will work with the participant to create a customized list of Ted Talk videos, each lasting 6-12 minutes, based on participants' personal interests. Participants will be asked to listen to or watch at least one, and ideally two, presentations using the app daily for six weeks. The research coordinator will ask participants to complete weekly logs of their TED Talk app use via a Qualtrics survey sent via email.
88802681|NCT02549196|Experimental|Cohort 1|Donepezil 20mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
88802682|NCT02549196|Experimental|Cohort 2|Donepezil 20mg/day upward dose titration of 20mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
88802683|NCT02549196|Experimental|Cohort 1b|Donepezil 10mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
88802684|NCT02549196|Experimental|Cohort 3c|Donepezil 10mg/day upward dose titration of 5mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 40mg/day with solifenacin 15mg/day.
88802685|NCT02904954|Experimental|Arm 1 (Durvalumab monotherapy)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
88802686|NCT02904954|Experimental|Arm 2 (Durvalumab plus SBRT)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
88802687|NCT00000250|Active Comparator|Lukewarm water|Subjects will immerse forearm in lukewarm water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
88802688|NCT00000250|Active Comparator|Ice cold water|Subjects will immerse forearm in ice cold water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
88802689|NCT03244020|Experimental|LMWH for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
88802690|NCT03244020|Experimental|ASA for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to aspirin 325 mg po daily for VTE prophylaxis
88802691|NCT03244020|Experimental|LMWH for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
88802692|NCT03244020|Experimental|ASA for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to aspirin 325 mg po daily for VTE prophylaxis
88802693|NCT03244020|Experimental|LMWH for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
88802694|NCT03244020|Experimental|ASA for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to aspirin 325 mg po daily for VTE prophylaxis
88802695|NCT00000262|Placebo Comparator|Placebo +/- 30% Nitrous oxide|
88802696|NCT00000262|Active Comparator|Sevoflurane 0.2% +/- 30% Nitrous oxide|
89234258|NCT05252286|Placebo Comparator|oral health education group|In the oral health education group, the program is similar to the paper sheet group without providing any exercise paper sheet the patient but oral education.
89234259|NCT00995280|Active Comparator|1|Single lumen needle use in oocyte retrieval
89234260|NCT00995280|Active Comparator|2|Double lumen needle with follicle flushing during oocyte retrieval
88802697|NCT00000262|Active Comparator|Sevoflurane 0.4% +/- 30% Nitrous oxide|
89234261|NCT00994266|Experimental|A|Diamel
89234262|NCT00994266|Placebo Comparator|B|Placebo
88802698|NCT01188499|Experimental|Carboplatin/Paclitaxel + Birinapant|Carboplatin (AUC 6/Paclitaxel (175 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
88802699|NCT01188499|Experimental|Irinotecan + Birinapant|Irinotecan (350 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
88802700|NCT01188499|Experimental|Docetaxel + Birinapant|Docetaxel (75 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
88802701|NCT01188499|Experimental|Gemcitabine + Birinapant|Gemcitabine (1000 mg/m2/IV) once weekly (7 days +/- 2 days) for 3 consecutive weeks followed by 1 week off + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 week off for each cycle (4 weeks per cycle).
88802702|NCT01188499|Experimental|Liposomal Doxorubicin + Birinapant|Liposomal doxorubicin (40 mg/m2/IV) every 4 weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 weeks off for each cycle (4 weeks per cycle).
88802703|NCT02830152|Experimental|Left Atrial Appendage Occlusion (LAAO)|The intervention is implantation of Amplatzer Amulet LAAO device within two months after randomization. Device implantation comprises a catheterization procedure using venous access and a transseptal puncture to obtain access to the left atrium (LA). Procedural imaging guidance is left to the physician's discretion and may include several techniques such as angiography/fluoroscopy, transesophageal echocardiography (TEE) and/or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes ASA therapy for at least 6 months, which may be combined with clopidogrel for the first 45 days after implantation.
88802704|NCT02830152|Active Comparator|Medical Therapy|The optimal medical therapy of stroke prevention in non-valvular atrial fibrillation (NVAF) after intracerebral hemorrhage (ICH) is not known. Therefore, it will be left to the discretion of the treating physician to decide if, when, and which pharmacological therapy will be prescribed. Available options include anticoagulation with oral anticoagulation (OAC) or novel oral anticoagulants (NOAC), antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
88802705|NCT00982865|Experimental|MSC1936369B Regimen 1|Subjects will be administered MSC1936369B (pimasertib) capsules 1 to 120 milligram (mg) orally, once daily (QD) on Days 1 to 5, 8 to 12, 15 to 19 of each 21-day treatment cycle until progressive disease (PD) or intolerable toxicity or investigator/subject decision.
88802706|NCT00982865|Experimental|MSC1936369B Regimen 2|"MSC1936369B Regimen 2 (Without Food Effect): Subjects will be administered MSC1936369B capsules 1 to 255 mg orally QD on Days 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.~MSC1936369B Regimen 2 (With Food Effect): : Subjects will be administered MSC1936369B capsules 90 or 150 mg orally QD on Day 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. Subjects in the Regimen 2 FE cohort were assigned in a 1:1 ratio to either the fed/fasted sequence or fasted/fed sequence for Day 1 of Cycle 1 and Day 1 of Cycle 2."
88802707|NCT00982865|Experimental|MSC1936369B Regimen 3 once daily|Subjects will be administered MSC1936369B capsules 60 to 90 mg orally QD in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
88802708|NCT00982865|Experimental|MSC1936369B Regimen 3 twice daily (BID)|Subjects will be administered MSC1936369B capsules 45 to 75 mg orally BID in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
88802709|NCT05475756|Experimental|Experimental Group|Material：Small intestinal submucosa Specifications：A、B、C、D、E Dosage: investigator selects the specification and quantity(dosage) according to the postoperative uterine cavity volume Frequency：one time after the operation Duration：Single-use
88802710|NCT05475756|Active Comparator|Control Group|Material: auto-crosslinked HA gel Specifications: 1 ml, 1.25 ml, 1.5 ml, 1.75 ml, 2 ml, 2.25 ml, 2.5 ml, 2.75 ml, 3 ml, 3.25 ml, 3.75 ml, 4 ml, 4.25 ml, 4.5 ml, 5 ml, 6 ml, 8ml Dosage: investigator selects the specification and quantity(dosage) according to the postoperative uterine cavity volume Frequency：one time after the operation Duration：Single-use
88802711|NCT02522468|Experimental|Radioactive Seed Localization|Radioactive Seeds
88802712|NCT02522468|Active Comparator|Wire Localization|Wire
88802713|NCT00380536|Experimental|1|Participants will participate in peer-led medical illness self-management group sessions.
88802714|NCT00380536|No Intervention|2|Participants will receive treatment as usual.
88802715|NCT01226719|Experimental|FOLFOXIRI+panitumumab regimen|"All patients will receive the FOLFOXIRI/panitumumab regimen, with drugs administered in the following order:~Panitumumab~Oxaliplatin~Irinotecan~Leucovorin~5-Fluorouracil"
88802716|NCT02518256|Other|(Suspected) Ovarian Epithelial Cancer|Lavage of the Cavum uteri and proximal fallopian tubes
88802717|NCT02194868||donors of hematopoietic stem|Adult and minor donors of hematopoietic stem
88802718|NCT02194868||patients requiring allogeneic hema|Adult and minor patients (recipients) requiring allogeneic hema
88802719|NCT04331470|Experimental|Levamisole Pill + Budesonide+Formoterol inhaler+Standard care|This group will take Levamisole + Budesonide/Formoterol along side with standard treatment regime.
88802720|NCT04331470|Active Comparator|Standard care|This group will take standard treatment regime introduced by Ministry of health.
88802721|NCT00983489|Active Comparator|counselling|counselling: Breast feeding counselling will be done to mothers
88802722|NCT00983489|Active Comparator|Video demonstration|Video demonstration to mothers on the advantages of exclusive breast feeding
88802723|NCT00983489|No Intervention|Standard Care|Standard care includes the routine care provided to the neonates as per hospital protocol
88802724|NCT02743832|Experimental|High-level tumor budding group with CLND|Resection for primary lesion and cervical lymph node dissection (CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
88802725|NCT02743832|Experimental|High-level tumor budding group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
88802726|NCT02743832|Experimental|Low-level tumor budding group with CLND|Resection for primary lesion and cervical lymph node dissection (CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
88802727|NCT02743832|Experimental|Low-level tumor budding group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
88802728|NCT02179736|Experimental|Active treatment|
88802729|NCT01147627|Active Comparator|Exenatide|
88802730|NCT01147627|Active Comparator|Premixed insulin analog|
88802731|NCT01147627|Active Comparator|pioglitazone|
88802732|NCT02511626||Case group|Women with a surgically confirmed diagnosis of endometriosis
88802733|NCT02511626||Control group 1|Women without any evidence of endometriosis (= no clinical symptom and/or no surgical evidence of endometriosis)
88802734|NCT02511626||Control group 2|Women without endometriosis (surgically confirmed) but chronic abdominal/pelvic pain due to other reasons (e.g. Crohn's disease, colitis etc)
88802735|NCT02548962|Experimental|Phase 1: Dose Finding|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
88802736|NCT02548962|Experimental|Phase 2: Treatment Arm A|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
88802737|NCT02548962|Experimental|Phase 2: Treatment Arm B|Placebo PO+ Pomalidomide PO+ Dexamethasone PO
88802738|NCT02743598|Experimental|Liraglutide|
88802739|NCT00983801|Experimental|Ixabepilone|
88802740|NCT01188577|Experimental|Epinephrine Inhalation Aerosol, HFA|Experimental treatment of 10 inhalations of 125 mcg epinephrine base propelled by HFA 134a
88802741|NCT01188577|Active Comparator|Epinephrine Inhalation Aerosol, CFC|Epinephrine Inhalation Aerosol, CFC propelled, 220 mcg/inhalation , 10 inhalations
88802742|NCT03948672|Active Comparator|Control-then-Intervention|In each intensive care unit assigned to the Control-then-Intervention arm, all participants who regularly access the ICUs will wear the wristband while at work for 5 months. The functionality of the wristband will not be disclosed to the healthcare providers. Handwashing compliance data will be automatically collected, but data will not be shared with the healthcare providers or hospital management teams. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from the sensor system. Then, all healthcare providers will be educated on the functionalities of the CleanHands system with real time reminders now turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection reduction. This phase will last for 5 months.
88802743|NCT03948672|Active Comparator|Intervention-then-Control|In each intensive care unit assigned to the Intervention-then-Control arm, all participants who regularly access to the ICUs will be educated on the functionalities of the CleanHands system with real time reminders turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection control. This phase will last for 5 months. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from sensor system installation and implementation. Then, the real-time reminder functionality of the wristband will be turned off and no more education will be provided. Handwashing compliance data will be automatically collected but will not be shared with the healthcare providers. This process will last for 5 months.
88802744|NCT02507336|Experimental|Group A - CR+Thalidomide|Patients who achieved complete response (CR) in 20030165 and continue to receive maintenance Thalidomide. Patients in Group A will receive daily oral thalidomide (THALOMID®) as per standard of care and THALOMID® REMS™ guidelines. Patients will continue with thalidomide (THALOMID®) as per standard of care guidelines, until progression of disease, discontinuation due to toxicity, death or study withdrawal. Patients will receive annual clinical/laboratory evaluations.
88802745|NCT02507336|No Intervention|Group B - CR+No Thalidomide|Patients who achieved complete response (CR) in 20030165, but are not receiving maintenance Thalidomide. Patients will receive annual clinical/laboratory evaluations.
88802746|NCT02507336|No Intervention|Group C - PD or Expired|All other patients enrolled in 20030165 who expired or experienced disease progression (PD). Patients will be followed annually for survival.
88802747|NCT02734550|Active Comparator|Control|Diagnosis of invasive candida infection according to standard of care.
88802748|NCT02734550|Experimental|(1,3)-β-D-glucan guidance|Treatment according to BDG-result
88802749|NCT00984815|Experimental|HZT-501|Open-label treatment with HZT-501
88802750|NCT00000304|Experimental|1|15/30 mg d-amphetamine
88802751|NCT00000304|Experimental|2|30/60 mg d-amphetamine
88802752|NCT00000304|Experimental|3|placebo
88802753|NCT02548650|Experimental|Patients with diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
88802754|NCT02548650|Active Comparator|Patients without diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
89234263|NCT05302674|Experimental|Hot Dry|The participant will complete four hours of work at a 45:15 work rest cycle in a 98°F (36.7°C) and 20% relative humidity environment.
88802756|NCT05394077|Experimental|Active Release Technique|Using Active Release Technique
88802757|NCT05394077|Experimental|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
88802758|NCT00001978||Study Cohort|Selected patients with proteinuria
88802759|NCT01227655|Experimental|BIA 9-1067 25 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).
88802760|NCT01227655|Experimental|BIA 9-1067 50 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).
88802761|NCT01227655|Placebo Comparator|Placebo|PLC, Placebo
88802762|NCT05459532|Experimental|Monulpiravir|Eligible participants will be randomised in a 1:1 manner to receive either molnupiravir 800 mg orally approximately 12-hourly for five days or a placebo for the equivalent amount of time.
88802763|NCT05459532|Placebo Comparator|Placebo|Eligible participants will be randomised in a 1:1 manner to receive either molnupiravir 800 mg orally approximately 12-hourly for five days or a placebo for the equivalent amount of time.
89234264|NCT01646814|Experimental|PL2200|Investigational product, PL2200
89234265|NCT01646814|Active Comparator|Aspirin tablets|Active comparator, 325 mg aspirin tablets
88802764|NCT02506556|Experimental|experimental|BYL719 350 mg orally daily until progression, undue adverse events or withdrawal of consent.
89135475|NCT06166095|Experimental|walking attention control|"Participants will be provided sleep education material and will be asked to perform 15 minutes of leisure walking three times per week. This exercise intensity does not meet the recommended volume of exercise necessary for health benefits.~Instructing participants to walk will reduce the likelihood that participants will undertake a more vigorous exercise routine.~Participants will be asked to track their sleep each night using Fitbit."
88802765|NCT01189123|Active Comparator|Standard dose influenza vaccine|Fluzone (Sanofi Pasteur)
88802766|NCT01189123|Active Comparator|High Dose Vaccine|High Dose Fluzone by sanofi pasteur
88802767|NCT04423224|Active Comparator|Control group|Control group Management of the hemodynamic status in the control group will be performed in the discretion of the attending anesthesiologist, with the aim of keeping mean arterial pressure (MAP) > 65mmHg. The type and amount of delivered fluids, and vasoactive or inotropic drugs will be recorded.
89135476|NCT06166043|Experimental|NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION IN|An online training consisting of 10 sessions in total for 5 weeks will be given to the patients in order to improve their fatigue management skills. In addition to this training, they will receive a nurse support program.
89135477|NCT06166030|Experimental|Effects of ImmuneRecov on Lung Function and Immune Response|Effects of 30 days supplementation with ImmuneRecov on Lung Function and Immune Response of post-COVID-19 patients.
89135478|NCT06166030|Experimental|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength
89135479|NCT06166004|Experimental|BalanceTrainer|"Balance Trainer Exercises (30 min) Person-Specific Rehabilitation Program~Stretching and Strengthening Exercises~Mat Activities~Joint Range of Motion Exercises~Static and Dynamic Balance Exercises~Walking Exercises"
89135480|NCT06166004|Other|Control Group|"Person-Specific Rehabilitation Program~Stretching and Strengthening Exercises~Mat Activities~Joint Range of Motion Exercises~Static and Dynamic Balance Exercises~Walking Exercises"
89135481|NCT06165965|Experimental|Treatment(Experimental): JLP-2008|- Group I(Peroid I-Comparator[JT-001,JT-002], Peroid II-JLP-2008), Group II(Period I-JLP-2008, Period II-Comparator[JT-001,JT-002])
89135482|NCT06165965|Active Comparator|Control(Active Comparator): JC-013|- Group I(Peroid I-Comparator[JT-001,JT-002], Peroid II-JLP-2008), Group II(Period I-JLP-2008, Period II-Comparator[JT-001,JT-002])
89135483|NCT06165939|Experimental|Intra-articular corticosteroid injection and hydrodilation with 15% hypertonic dextrose|The patient receives ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine). Subsequent assessments occur at the second and fourth weeks, followed by a second round of ultrasound-guided shoulder joint injection with 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml Normal saline, totaling 20 ml). The entire treatment comprises two sessions.
89135484|NCT06165939|Placebo Comparator|Intra-articular corticosteroid injection and hydrodilation with Normal saline|The patient receives ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine). Subsequent assessments occur at the second and fourth weeks, followed by a second round of ultrasound-guided shoulder joint injection with 15% hypertonic dextrose ( 2 ml 2% Xylocaine + 18 ml Normal saline, totaling 20 ml). The entire treatment comprises two sessions.
89135485|NCT06165926|Experimental|15% hypertonic dextrose and physical therapy|The patient receives a single ultrasound-guided injection of 15% hypertonic dextrose into the shoulder joint (3 ml of 50% Dextrose + 1 ml of 2% xylocaine + 6 ml of normal saline). Subsequent evaluations occur at the second and fourth weeks, followed by a second round of ultrasound-guided shoulder joint injection treatment, totally two sessions. Simultaneously, the patient undergoes an 8-week physical therapy program, attending sessions twice a week. Each session, lasting approximately 30 minutes, includes joint activities, stretching, and muscle-strengthening exercises under the guidance and supervision of a physical therapist.
89135486|NCT06165926|Placebo Comparator|normal saline and physical therapy|The patient undergoes a single ultrasound-guided normal saline injection for shoulder joint distension (1 ml of 2% xylocaine + 9 ml of normal saline). Subsequent assessments occur at the second and fourth weeks, followed by a second round of ultrasound-guided shoulder joint injection treatment, totally two sessions. Simultaneously, the patient is undergoing an 8-week physical therapy program, with sessions held twice a week. Each session, lasting approximately 30 minutes, includes joint activities, stretching, and muscle-strengthening exercises under the guidance and supervision of a physical therapist.
89135487|NCT06165913|Experimental|Group (1): Early implant placement(type II) group.|Patients will be scheduled for tooth extraction then performing implant placement between 4-8 weeks later after soft tissue healing.
89135488|NCT06165913|Experimental|Group (2): Early implant placement (type III) group.|Patients will be scheduled for tooth extraction and performing implant placement between 12-16 weeks with partial bone healing.
89135489|NCT06165874|Experimental|non-small cell lung cancer|Patients were recruited in the Department of Thoracic Surgery
89135490|NCT06165861|Experimental|Experimental (with VR-G)|The patients in this procedure watched video with using VR-G for approximately 6 minutes at the surgical clinic before going surgery.
89135491|NCT06165861|No Intervention|Standard (No VR-G)|The patients took the standart protocol of the surgical clinic and didn't watch video with using VR-G
88805915|NCT03012503|Placebo Comparator|Control|Five minutes before cervical manipulation, controls received a placebo gel applied to their neck.
88805916|NCT03012503|Experimental|Treatment|Five minutes before cervical manipulation the treatment group received a menthol containing gel (Biofreeze®) applied to their neck.
88805917|NCT01167569|Active Comparator|A-Ascorbic Acid (Vitamin C)|Ascorbic Acid (Vitamin C) 10mg/kg x 2 in the operating room followed by Ascorbic Acid (Vitamin C) 5mg/kg every 4 hours x 48 hours.
88805918|NCT01167569|Placebo Comparator|B-5% Dextrose Water or Normal Saline|5% Dextrose Water or Normal Saline (placebo) x 2 in the operating room followed by 5 % Dextrose Water or NS (placebo) every 4 hours X 48 hours.
88805919|NCT00296192|Placebo Comparator|Placebo 1|Placebo nasal spray 1 - 4 puffs
88805920|NCT00296192|Experimental|Rotigotine 1|Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)
88805921|NCT00296192|Experimental|Rotigotine 2|Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)
88802768|NCT04423224|Active Comparator|GDFM|Goal-directed fluid management group (GDFM). . Baseline SV will be measured after the patients will be turned to left/right position & before implementation of regional anesthesia. Fluid challenges of 250 ml will be repeated until SV fails to increase by 10%. At this point, preload is considered optimized and SV optimum is defined. SV trigger is defined as SV opt - 10%. N/S 250ml boluses will be administered when SV is below SV trigger. Inotropic drugs will be administered (dobutamine infusion at 0.2-10mcg/kg/min) if CO is below 3.5 L/min and vasopressors (phenylephrine bolus doses of 50-100mcg) if SV and CO are within the target range but MAP is below 65mmHg. Patients will be reassessed during the intraoperative period every 10 minutes . Except from the fluid boluses, all patients will be administered Ringer's lactate solution at an infusion rate of 2ml/kg/h.
88802769|NCT01026623|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60-70 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88802770|NCT05433870||PRES group|patients in PE or E with PRES
89135492|NCT06165848||General anesthesia|After preoxygenation, anesthesia induction was performed with 2 mg/kg IV propofol and 1 mcg/kg IV fentanyl in the general anesthesia group. Anesthesia was maintained with a mixture of 0.3-0.5 mcg/kg/min remifentanil, 2% sevoflurane, 50% air, 50% oxygen. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by a psychiatrist.
89135493|NCT06165848||Sedation anesthesia|In the sedation group, 1 mcg/kg IV fentanyl and 1 mg/kg IV ketamine were administered at induction, and 30-50 mg IV propofol was added if necessary to maintain anesthesia. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by a psychiatrist.
89135494|NCT06165835|No Intervention|Experimental|Patients who have recovered from COVID-19
89135495|NCT06165835|Experimental|Three months after recovering from COVID-19|Patients who have from COVID-19 in three months
89135496|NCT06165835|Experimental|Six months after recovering from COVID-19|Patients who have from COVID-19 in three to six months
89135497|NCT06165835|Experimental|Nine months after recovering from COVID-19|Patients who have from COVID-19 in six to nine months
88802771|NCT05433870||NON-PRES group|patients in PE or E without PRES
88802772|NCT02725424|Active Comparator|Her2 Positive with SOX|Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA <1.25m2) ,100mg/day (BSA ≥1.25m2, <1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
88802773|NCT02725424|Experimental|Her2 Positive with SOXT|Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA <1.25m2) ,100mg/day (BSA ≥1.25m2, <1.5 m2), 120mg/day (BSA ≥1.5m2), trastuzumab 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1, every 3 weeks.
88802774|NCT02725424|Active Comparator|Her2 Negative with SOX|Oxaliplatin 130 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA <1.25m2) ,100mg/day (BSA ≥1.25m2, <1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
88802775|NCT02725424|Experimental|Her2 Negative with DOS|Docetaxel 60 mg/m2, ivgtt, d1; Oxaliplatin 100 mg/m2, ivgtt, d1; S-1 twice a day depending on body surface areas (BSA) po d1-14, 80mg/day (BSA <1.25m2) , 100mg/day (BSA ≥1.25m2, <1.5 m2), 120mg/day (BSA ≥1.5m2), every 3 weeks.
88802776|NCT01189279|Experimental|Part 1: bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
88802777|NCT01189279|Experimental|Part 1: bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
88802778|NCT01189279|Experimental|Part 2: bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
88802779|NCT03010189|Experimental|Patient|Cluster headache patients are examined with light reflex pupillometry, two weeks actigraphy and heart-rate variability monitoring both in headache phase and remission phase.
88802780|NCT03010189|Active Comparator|Controls|Healthy controls undergo the same examinations once: light reflex pupillometry, actigraphy and heart-rate variability monitoring.
88802781|NCT01228435|Experimental|ALK-inhibitor naive|No prior exposure to ALK-inhibitor
88802782|NCT01228435|Experimental|ALK-inhibitor pre-treated|Prior exposure to ALK inhibitor
88802783|NCT02535000|Experimental|Group C (control)|subjects who will receive one capsule of placebo before the surgery and being repeated the next day
89135498|NCT06165835|Experimental|Twelve months after recovering from COVID-19|Patients who have from COVID-19 in nine to twelve months
89135499|NCT06165822|Experimental|Itraconazole drug-durg interaction (DDI)|Itraconazole capsules, 0.2g once daily from Day 3 to Day 10 TQB3909 tablets, single oral dose on Day 1 and Day 8.
89135500|NCT06165822|Experimental|Rifampicin DDI|Rifampicin capsule, 0.6g once daily from Day 3 to Day 11. TQB3909 tablets, single oral dose on Day 1 and Day 10.
88802784|NCT02535000|Active Comparator|Group D (duloxetine)|subjects who will receive one capsule of duloxetine 60 mg before the surgery and being repeated the next day
88802785|NCT01228903|Placebo Comparator|Control|Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
88802786|NCT01228903|Active Comparator|Allopurinol|Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
88802787|NCT05440552|Placebo Comparator|Risk score1|
88802788|NCT05440552|Active Comparator|Risk score2|
88802789|NCT01189747|Experimental|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1.
88802790|NCT01189747|Placebo Comparator|placebo (normal saline)|normal saline injected into bilateral Crow's Feet Line areas on Day 1.
88802791|NCT03009955||Group P|patients who received primary caesarean section
89135501|NCT06165536|Other|Voice therapy|Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
88802792|NCT03009955||Group R|patients who received repeated caesarean section
88802793|NCT01149733|Experimental|Tamsulosin|0.4 mg Capsule
89135502|NCT06163703|Experimental|Intervention|Participants in the intervention arm will receive a 12-session parent-based prevention program based on Family Life Skills Triple P.
89135503|NCT06163703|No Intervention|Waitlist Control|Participants in the waitlist control arm will not receive any intervention during the clinical trial. They will be placed on a waitlist and then offered the intervention once post assessments are complete.
88802794|NCT01149733|Active Comparator|Flomax®|0.4 mg Capsule
88802795|NCT01893866|Experimental|A|
88802796|NCT01893866|Experimental|B|
88802797|NCT02150642||Neurological Injury|
88802798|NCT02150642||No Neurological Injury|
89135504|NCT06162364|Experimental|VR group|In this group, students were taught surgical hand washing and sterile dressing skills through theoretical training, demonstration, and VR glasses. Later, a theoretical knowledge assessment test was administered, and they were subjected to a skill evaluation exam in the laboratory.
88802799|NCT01190527|Other|FDG-PET|All subjects will have the same course of treatment, the study treatment.
88802800|NCT04352023|Experimental|A (IV-PCA group)|IV-PCA drug: Fentanyl 3000 mcg and Oxycodone 100 mg were mixed Normal saline 200 ml
88802801|NCT04352023|Experimental|B (PCEA group)|"PCEA drug: Morphine 5 mg and Ropivacaine 750 mg were mixed Normal saline 400 ml~loading of preadministered Morphine 1 mg and Ropivacaine 11.25 mg"
88802802|NCT01229527|Experimental|Remifentanil RS1|
88802803|NCT01229527|Experimental|Remifentanil RS2|
88802804|NCT01229527|Active Comparator|Meperidine|
88802805|NCT02723162|Experimental|VRN+ NAC|Titrated VRN up to 1mg BID with NAC at 1200mg BID for 28 days
88802806|NCT02723162|Active Comparator|NAC+ PBO|1200mg BID for 28 days plus VRN placebo for 28 days
88802807|NCT02723162|Active Comparator|VRN+ PBO|Titrated VRN up to 1mg BID with NAC placebo for 28 days
88802808|NCT02723162|Placebo Comparator|PBO+PBO|Double placebo taken for 28 days
88802809|NCT04757558|Active Comparator|C-MAC-VS group|C-MAC-VS will be used to facilitate intubation
88802810|NCT04757558|Placebo Comparator|control group|direct laryngoscopy using Macintosh laryngoscope will be done for DLT insertion.
88802811|NCT02721680|Experimental|Healthy Subjects- Awareness Training Group 1|Subjects in this arm will undergo an internal awareness training program.
88802812|NCT02721680|Experimental|Healthy Subjects - Awareness Training Group 2|Subjects in this arm will undergo an external awareness training program.
88802813|NCT02143388|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
88802814|NCT02143388|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
88802815|NCT04757480|Experimental|Thoracolumbar Interfascial Plane Block (TLIP)|
88802816|NCT04757480|Experimental|Bilateral Erector Spinae plane Block (ESB)|
88802817|NCT01191541|Active Comparator|DNR+Ara-c(Ara-C group)|patients in this group were treated with DNR+Ara-C in consolidation
88802818|NCT01191541|Experimental|DNR(No Ara-C group)|patients in this group were treated with DNR alone in consolidation
88802819|NCT02141906|Experimental|Oncozene-DEB-TACE|"Screening Visit (procedures should be done within 28 days of treatment day):~Study visit assessments will be performed prior to Oncozene-DEB-TACE delivery (except pharmacokinetic blood draw).~Labs may be done within 3 days of the procedure. All visits can be completed +/- 10 days of planned visit day~Follow up after completion of treatment every 4-6 weeks:"
88802820|NCT02193542||Pregnant patient|Pregnant woman presenting for vaginal or cesarean delivery
89135505|NCT06162364|No Intervention|theoretical training group|In this group, students were taught surgical hand washing and sterile dressing skills through theoretical training and demonstration. Later, a theoretical knowledge assessment test was administered, and they were subjected to a skill evaluation exam in the laboratory.
89234266|NCT00994344|Experimental|Darunavir/ritonavir|to switch from the triple therapy based regimens to Darunavir/ritonavir
88802821|NCT01150903||PDE5 inhibitor prescription|
88802822|NCT01150903||Age-matched Control|
88802823|NCT01894334|No Intervention|Control group|no intervention
88802824|NCT01894334|Experimental|Tranexamic acid group|tranexamic acid ，intravenous 30mg/kg/d，Preoperative
88802825|NCT01894334|Experimental|Edaravone group|edaravone, iv, 1mg/kg/d,Preoperative
88802826|NCT01894334|Experimental|Ulinastatin group|Ulinastatin ,iv，20,000 U /kg/d，Preoperative
88802827|NCT01150981|Experimental|Rosiglitazone|One 8mg capsule daily for 6 weeks.
88802828|NCT01150981|Placebo Comparator|Placebo|One capsule daily for 6 weeks.
88802829|NCT01230931|Experimental|Vitagel and Standard of Care|This group of patients will receive the vitagel topical surgical hemostat spray intra-operatively, along with all the other standards of care.
88802830|NCT01230931|Active Comparator|Standard of Care|This group of patients will receive the standard of care for hemostasis in acetabular surgery (electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing). They will not receive the vitagel product.
88802831|NCT00000400|Experimental|PTH|Human parathyroid hormone [hPTH-(1-34)]
88802832|NCT00000400|Active Comparator|ALN|Alendronate
88802833|NCT00000400|Experimental|PTH+ALN|Human parathyroid hormone [hPTH-(1-34)] plus alendronate
88802834|NCT02477774|Experimental|Arista|Arista to ALT donor site
88802835|NCT02477774|No Intervention|Control|No Arista to ALT donor site
88802836|NCT01195597|Experimental|E-Cigarette 7.2 mg nicotine|Well characterized group of 40 regular smokers not intending to quit experimenting the E-Cigarette with 7.2 mg nicotine cartridges.
88802837|NCT00000412|Active Comparator|Group A|Group A active alendronate (10 mg/day) and placebo calcitriol.
88802838|NCT00000412|Placebo Comparator|Group B|We will give Group B placebo alendronate and active calcitriol (0.25 micrograms BID).
88802839|NCT04390256|Active Comparator|Egg shell powder nanoparticles|
88802840|NCT04390256|Experimental|Clove water extract|
88802841|NCT04390256|Experimental|Carbopol|
88802842|NCT04390256|Experimental|Carboxymethyle cellulose|
89135506|NCT06162364|Experimental|video training group|In this group, students were taught surgical hand washing and sterile dressing skills through theoretical training, demonstration, and two-dimensional video. Later, a theoretical knowledge assessment test was administered, and they were subjected to a skill evaluation exam in the laboratory.
89135507|NCT06160453|Experimental|Stroke with upper limb monoparesis or hemiparesis|Patients from Greece, 18 y.o. or older, suffering from chronic stroke and motor disability
89135508|NCT06160453|Experimental|Stroke with monoplegia or hemiplegia|Patients from Greece, 18 y.o. or older, suffering from chronic stroke and motor disability
89135509|NCT06160453|Active Comparator|Healthy Participants|Healthy participants, age and sex matched to the participants in the other arms
89135510|NCT06160050|Experimental|BPC|
89135511|NCT06160050|No Intervention|Treatment as usual|
89135512|NCT06159634|Experimental|ESD with traction device|ESD of target lesion will be performed with the assistance of a traction device.
89135513|NCT06159634|Active Comparator|Control arm|ESD of target lesion will be performed without the use of a traction device
89135514|NCT06159179|Other|undiagnosed transudative and exudative pleural effusion|Subjects with undiagnosed transudative and exudative pleural effusion will undergo medical thoracoscopy as per studies protocols.
89135515|NCT06159010||Acute kidney injury|
89135516|NCT06159010||Patients with non-acute kidney injury|
89135517|NCT06157931|Experimental|Resilient Student Training intervention (ReST)|Each participant will receive 3 intervention sessions over a 6-week period (1 individual 60-minute session and two 90-minute group-based sessions) delivered by the same interventionist. The specific skills, intervention protocol and intervention manual will be developed in the Phase 1. The skills and exercises will aim to address pertinent areas of needs relating to self-concept, emotional awareness, and maintaining relationships. The individual session will be conducted based on self-assessment results, identifying presenting concerns and goal planning. Group sessions will be gamified to enhance engagement and reward progress. The first group session will build on the individual session's content in a group setting, with the aim to learn from peers. The second group session aims to reinforce the principles and skills learned in the individual session and group session 1 and plan for the future.
89135518|NCT06157931|No Intervention|Waitlist Control|The waitlist control group will not receive any additional support or interventions whilst waiting to receive the ReST intervention. These participants will be asked to report any psychological interventions or psychotropic medications that they have accessed outside of the trial whilst they are on the waiting list. Wait list control participants will be offered the ReST intervention following their 6-week follow-up assessment.
89135519|NCT06157567|Experimental|Treatment Group|Study subjects may be treated with any of the Profound Matrix applicators: Sublime, Sublative RF and/or Matrix Pro. Treatments may include combination of applicators or additional commercial devices per PI discretion.
89135520|NCT06157541|Experimental|Part 1|"Patients with recurrent disease. Interventions:~allogeneic CMV-specific T cells (cell suspension for infusion), dose cohorts: 2 × 10^7 cells, 4 × 10^7 cells, 8 × 10^7 cells; 4 infusions; administered weekly~pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks"
89135521|NCT06157541|Experimental|Part 2 Group A|"Patients with recurrent disease. Interventions:~allogeneic CMV-specific T cells (cell suspension for infusion), maximum-tolerated dose identified in phase I; 4 infusions; administered weekly~pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks"
89135522|NCT06157541|Experimental|Part 2 Group B|"Patients with newly diagnosed disease. Interventions:~allogeneic CMV-specific T cells (cell suspension for infusion), maximum-tolerated dose identified in phase I; 4 infusions; administered weekly~pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks"
89135523|NCT06155747||People infected with related NTM isolates identified as having membership in a related cluster|Characterize the source(s) of acquisition and/or direct or indirect patient-to-patient transmission of NTM within a healthcare setting among participants with highly related isolates.
89135524|NCT06155708|Experimental|Ketone|- Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.
89135525|NCT06155708|Placebo Comparator|Placebo|100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
89135526|NCT06154005|Experimental|Low Dose OsteoAdapt SP (0.8 mg/cc AMP2/OsteoAdapt SP)|"Participants will receive a Transforaminal Lumbar Interbody Fusion with OsteoAdapt SP Low Dose (0.8mg/cc AMP2/OsteoAdapt SP) inside the interbody fusion cage with the availability of having local autograft placed anterior/lateral to the cage within the disc space."
89135527|NCT06154005|Experimental|High Dose OsteoAdapt SP (2.0 mg/cc AMP2/OsteoAdapt SP)|"Participants will receive a Transforaminal Lumbar Interbody Fusion with OsteoAdapt SP Low Dose (2.0 mg/cc AMP2/OsteoAdapt SP) inside the interbody fusion cage with the availability of having local autograft placed anterior/lateral to the cage within the disc space."
89135528|NCT06154005|Active Comparator|Control (Standard of Care - Autograft/Mineralized Allograft)|Patients will follow standard of care Transforaminal Lumbar Interbody Fusion in which local autograft will be placed inside the interbody fusion cage with the availability of mineralized, frozen, banked, allograft to be placed anterior/lateral to the cage.
89135529|NCT06153381|Experimental|Chatbot care|
89135530|NCT06153381|Active Comparator|Standard care|
89135531|NCT06151483|Active Comparator|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89135532|NCT06151483|Experimental|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89135533|NCT06147011|Experimental|3D medical education model group|Received a regular learning plus 3D printing model
88805922|NCT00296192|Experimental|Rotigotine 3|Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)
88805923|NCT00296192|Experimental|Rotigotine 4|Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)
89135534|NCT06144684|Placebo Comparator|Placebo|placebo solution
89135535|NCT06144684|Active Comparator|GUB014295|GUB014295 solution 5 mg/mL
89135536|NCT06144398|Experimental|Single Use Bronchoscope|
89135537|NCT06144398|Active Comparator|Standard Bronchoscope|
89135539|NCT06136923|Experimental|Multiple Sclerosis with Mobility Limitations Study App A|Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis with mobility limitations.
89135540|NCT06136923|Other|Multiple Sclerosis with Mobility Limitations Study App B|Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis with mobility limitations.
89135541|NCT06136923|Experimental|Multiple Sclerosis without Mobility Limitations Study App A|Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis without mobility limitations.
89135542|NCT06136923|Other|Multiple Sclerosis without Mobility Limitations Study App B|Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis without mobility limitations.
89135543|NCT06136923|Experimental|Oncology Breast Cancer Study App A|Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for breast cancer.
89135544|NCT06136923|Other|Oncology Breast Cancer Study App B|Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for breast cancer.
89135545|NCT06136923|Experimental|Oncology Lung Cancer Study App A|Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for lung cancer.
89135546|NCT06136923|Other|Oncology Lung Cancer Study App B|Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for lung cancer.
89135547|NCT06127420||All patients|All patients referred to angiography and undergo assessment with coronary pressure sensor
89135548|NCT06124118|Experimental|Device Duration Level 1|Participants in Device Duration Level 1 will receive Tumor Treatment Fields (TTF) therapy during standard of care consolidation durvalumab.
89135549|NCT06124118|Experimental|Device Duration Level 2|Participants in in Device Duration Level 2 will begin TTF therapy during SOC durvalumab and SOC Concurrent chemoradiation following Device Duration Level 1.
89135550|NCT06123572|Placebo Comparator|Placebo|Mode of Usage: Twice a day on clean skin Route of Administration: Topical application.
89135551|NCT06123572|Experimental|Anti-Ageing and Skin Brightening Gel|Mode of Usage: Twice a day on clean skin Route of Administration: Topical application.
89135552|NCT06123143|Experimental|Standardized NIS Wean|A standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean). All infants in the treatment group will remain on NIS until either 32 or 34 weeks CGA, depending on their gestational age at birth. Infants born at 27 6/7 weeks or less will continue on NIS until at least 34 weeks if they are in the treatment group, whereas infants born between 28 0/7 and 29 6/7 weeks will stay on NIS until at least 32 weeks if they are in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RNs) and respiratory therapists (RTs), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices.
89135553|NCT06123143|No Intervention|Control|Babies in the control group (non-standardized wean) will be weaned based on unit specific practices.
89135554|NCT06113146|Experimental|ultra-processed slow eating rate diet then the ultra-processed fast eating rate diet|Participants assigned to this arm will receive an ultra-processed slow eating rate diet for two weeks, followed by a two week washout period and a two week ultra-processed fast eating rate diet.
89135555|NCT06113146|Experimental|ultra-processed fast eating rate diet then the ultra-processed slow eating rate diet|Participants assigned to this arm will receive an ultra-processed fast eating rate diet for two weeks, followed by a two week washout period and a two week ultra-processed slow eating rate diet.
89135556|NCT06105580|Experimental|Conduction system pacing|"Pacing the His-Purkinje system.~Crossover to biventricular pacing allowed in case of failed conduction system pacing: failed His bundle pacing and failed Left bundle branch pacing (high thresholds (>3.5V / 1ms); no left bundle branch pacing criteria; no left bundle branch correction).~Electrocardiographic optimization allowed in order to obtain the narrowest QRS."
89135557|NCT06105580|Active Comparator|Biventricular pacing|"Pacing from the right ventricular and coronary sinus lead. Electrocardiographic optimization with fusion-optimized intervals (FOI).~Crossover from biventricular pacing to conduction system pacing will be allowed in the following situations: coronary sinus cannot be cannulated; no lateral or posterolateral branches; or phrenic stimulation."
89135558|NCT06101589|Experimental|experimental arm in which we will give the active Vitamin D to participants|the intervention will be the Vitamin D in its active form 200,00 IU 25(OH)D3.route of administration is oral.
89135559|NCT06101589|Placebo Comparator|placebo arm in which we will give the placebo|olive oil will be the placebo medicine. the placebo medicine have similar taste and quantity. the route of administration is oral.
89135560|NCT06098573|Experimental|Program 1: High Alert|High Alert
89135561|NCT06098573|Active Comparator|Program 2: Information condition|Active Control- Information condition
89135562|NCT06098573|Placebo Comparator|No contact|Passive control- No contact
89135563|NCT06098443|Experimental|Acupressure|The acupressure points will be determined, patients are informed that they will feel soft vibrations and pain during acupressure application. Patients are advised that it is sufficient for them to feel the vibrations of the acupressure device slightly. It be felt first symmetrically right knee, right leg, left knee, left leg Patients will receive acupressure 24 sessions three times a week for eight weeks. After application the patient will be asked about the severity of pain half an hour after administration (Çevik & Taşcı, 2020).
89135564|NCT06098443|Active Comparator|Transcutaneous electrical nerve stimulation|"• Placement electrodes applied on the painful area lower leg.~Settings:~Intensity up to patient tolerance.~Duration 30min."
89135565|NCT06096207|Experimental|Discontinuation Phase Group 1|Patients will be randomized into two groups for crossover treatment analysis of different parameter settings for six weeks.
89135566|NCT06096207|Experimental|Discontinuation Phase Group 2|Patients will be randomized into two groups for crossover treatment analysis of different parameter settings for six weeks.
89135567|NCT06095050|Experimental|Embolization|"Angiography will be performed to identify hyperemic neovasculature arising from one or more of branch shoulder arteries. After localizing the abnormal neovessels a microcatheter will be inserted coaxially and selectively placed in the targeted artery(ies). The abnormal vessels will be embolized with Lipiodol emulsion (Guerbet, Villepinte, France) The embolic agent will be used under an investigational device exemption from the FDA. The embolic will be injected in small volume increments until blood flow stagnates in the target artery(ies).~Angiography and embolization will be repeated until the hyperemia is markedly reduced as demonstrated on digital subtraction angiography.~Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12."
89135568|NCT06095050|Active Comparator|Physical Therapy|Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
89135569|NCT06094205|Experimental|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
89135570|NCT06091306||Participants in a multifamily therapy group for adolescents, their parents and siblings|"The study is therefore being proposed to all the families who have taken part in the multifamily therapy for anorexia nervosa, i.e. the adolescents being followed, their parents and siblings.~The investigators propose to use a qualitative methodology aimed at collecting the experiences of patients suffering from anorexia nervosa, their parents and their siblings, using alternately, depending on the group, data collection by focus group or by individual semi-structured interview according to a semi-structured interview guide specifically designed by the research team. The data was collected 4 to 6 months after the tenth and final session of the multi-family group."
89135571|NCT06087133|Experimental|Routine Care + StEP:Prenatal|Participants will receive routine care and up to 8 StEP:Prenatal sessions. Routine care will follow through the post-partum period.
89135572|NCT06087133|Active Comparator|Routine Care|Participants will receive routine care during pregnancy and the post-partum period.
89135573|NCT06080477|Experimental|Adapted ENHANCE Intervention|Nurse-delivered community-based treatment model for people living with psychosis in the community, coordinated with the usual outpatient care
89135574|NCT06080477|Active Comparator|Enhanced usual care|Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
89135575|NCT06076694|Experimental|Group A|TNP-2198 capsules 400 mg + rabeprazole sodium enteric-coated tablets 20 mg + amoxicillin capsules 1 g; Twice daily (BID) for 14 days
89135576|NCT06076694|Experimental|Group B|TNP-2198 capsules 600 mg + rabeprazole sodium enteric-coated tablets 20 mg + amoxicillin capsules 1 g; BID for 14 days
89135577|NCT06076694|Experimental|Group C|TNP-2198 capsule 600 mg + rabeprazole sodium enteric-coated tablets 20 mg; Three times daily (TID) for 14 days
89135578|NCT06076694|Experimental|Group D|TNP-2198 capsules 600 mg + rabeprazole sodium enteric-coated tablets 20 mg + amoxicillin capsules 1g; TID for 7 days
89135579|NCT06076694|Active Comparator|Control group|Rabeprazole sodium enteric-coated tablets 20 mg + amoxicillin capsules 1 g
89135580|NCT06073951|Experimental|Arm I (Mates in Motion)|Dyads participate in the Mates in Motion program consisting of weekly sessions to train couples in the use of communal coping strategies to support one another in achieving PA goals and skill building focus on instruction and practice in effective communication, with emphases on adaptive speaking, responsive listening, and joint decision-making and problem-solving around PA over 8 weeks. Patient-partner dyads receive weekly step-count goals, complete walk-tests and questionnaires and wear an Actigraph device and Fitbit on study.
89135581|NCT06073951|Active Comparator|Arm II (usual care)|Patient-partner dyads wear an Actigraph device, compete walk-tests and questionnaires on study. Dyads receive usual care on study. Dyads receive a Fitbit at the end of the study.
89135582|NCT06073223|Experimental|CQUPLE Intervention|"A novel intervention called CQUPLE (pronounced couple), which includes two interventions delivered together: (1) a Chart of side-by-side, evidence-based information comparing all three treatment options for low-risk thyroid cancer, including expected outcomes and (2) a Question Prompt List that contains key questions to consider asking the surgeon."
89135583|NCT06073223|Active Comparator|Usual Care Control|The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.
89135584|NCT06072300|Experimental|Intervention|The placement of physical activity calorie equivalent labelling on beverage vending machines
89135585|NCT06072300|No Intervention|Comparator|No physical activity calorie equivalent labelling on beverage vending machines
89135586|NCT06056674|Experimental|U-PEACE Group|Participants in this group will receive the U-PEACE intervention (study participation to last approximately 13 weeks).
89135587|NCT06056674|Active Comparator|Services As Usual (SAU) Group|Participants in this group will receive service as usual (study participation to last approximately 13 weeks).
89234267|NCT00994344|Active Comparator|Lopinavir/ritonavir|to switch from the triple therapy based regimens to Lopinavir/ritonavir
89135588|NCT06053047|Experimental|Use of Bluedrop Monitoring Service|"The BMS is made up of the Delta Foot Scanner (DFS) device, its accompanying Sentinel Review Interface (SRI) software and a Bluedrop virtual monitoring service.~The DFS is intended to be used for 30 seconds, once per day, by a person in their home. It is important that while using the device that the participant continues with their routine foot care as recommended by their doctor."
89135589|NCT06053047|No Intervention|Standard of care|Participants continue with routine foot care as recommended by their doctor
89135590|NCT06049537||Young children|"Children aged 1-5 years old attending school or day care. Follow-up for 28 days using minimally-invasive nasosorption sampling and questionnaires relating to symptoms.~No intervention administered"
89135591|NCT06049537||Parents|"Parents of enrolled children, if it is a one-child family. Follow-up for 28 days using minimally-invasive saliva sampling.~No intervention administered"
89135592|NCT06029036|Experimental|Darolutamide + ADT|Duration of treatment: 28-day cycle of darolutamide treatment and 6 cycles of neoadjuvant therapy.
89135593|NCT06027619|Experimental|Regimen A|Apply topical aminolevulinic acid gel and incubate for 10 minutes prior to red light source
89135594|NCT06027619|Experimental|Regimen B|Apply topical aminolevulinic acid gel and incubate for 20 minutes prior to red light source
89135595|NCT06027619|Experimental|Regimen C|Apply topical aminolevulinic acid gel and incubate for 60 minutes prior to red light source
89135599|NCT06017999|Experimental|high dose|XG005 1250 mg Q12 hours
89135600|NCT06017999|Experimental|low dose|XG005 750 mg Q12 hours
89135601|NCT06017999|Placebo Comparator|placebo|placebo Q12 hours
89135602|NCT06011057||threatened miscarriage Group|"This group will include 50 pregnant women presenting with vaginal bleeding and/or abdominal cramps concerning for possible miscarriage in the first trimester. Inclusion criteria will be gestational age between 6-14 weeks by last menstrual period and/or ultrasound dating, and clinical signs/symptoms suggestive of threatened miscarriage including:~Vaginal bleeding Abdominal cramps/pain Closed cervical os on exam Women with confirmed fetal demise on ultrasound will be excluded. Participants in this group will undergo blood testing to measure C reactive protein (CRP) level and fetal ultrasound to assess parameters like crown-rump length, heartbeat, yolk sac size, and embryonic motion. This group will provide data to assess C reactive protein (CRP) and ultrasound findings in women with threatened first trimester miscarriage."
89135603|NCT06011057||Control Group|"The control group will include 50 low-risk pregnant women matched to the threatened miscarriage group based on gestational age. Inclusion criteria are normal pregnancy dating, no vaginal bleeding/cramping, normal prior ultrasounds, and no history of pregnancy complications. Controls will undergo the same CRP blood testing and fetal ultrasounds as the threatened miscarriage group. This will provide comparative normal pregnancy CRP and ultrasound data. Matching controls on demographics and gestation will allow analysis of differences in CRP and ultrasound parameters between groups to determine predictors of pregnancy viability.~Copy Retry"
89135604|NCT06010784|Experimental|Intervention: After-school program + family support|
89135605|NCT06010784|Active Comparator|Control: After-school program only|
89135606|NCT06006390|Experimental|Intravenous of CD70-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89135607|NCT06006390|Experimental|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89135608|NCT06002139|Experimental|Immersive Virtual Reality Therapy|Conventional orthopedic rehabilitation supplemented by VR therapy
89135609|NCT06002139|Active Comparator|Conventional rehabilitation|Conventional orthopedic rehabilitation
89135610|NCT06000787|Other|Diffuse Midline Glioma|Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B
89135611|NCT06000787|Other|Neuroblastoma|Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B
89135612|NCT05996172|Active Comparator|CAMS Single Session Consultation (SSC)|CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients. The foundational brief intervention that all participants will receive includes 1 90-minute session of CAMS assessment and planning interview with follow-up care navigation.
89135613|NCT05996172|Active Comparator|CAMS SSC + Driver-Focused Skills Training|Specific skills are taught to youth based on CAMS drivers/case conceptualization of suicidality. Based on our pilot work, the common components of treatment include explicit coaching in skills informed by evidence-based treatments like Dialectical Behavior Therapy (DBT), Cognitive Behavioral Therapy (CBT), and Behavioral Activation (BA). Skills are drawn from the following 3 domains: emotion regulation and crisis survival skills (e.g., paced breathing, use of temperature and exercise to alter mood, Hope Box), behavioral activation strategies (e.g., goal-directed behavior, scheduling of activities, problem-solving) and communication skills (communication around suicidality, validation of self and others, making clear requests/DEAR MAN). Youth assigned to the Ongoing CAMS Intervention condition will receive three, 50-minute sessions that include the interim SSF and driver focused treatment encompassing skills instruction, in-session practice, and assigned homework.
89135614|NCT05996172|Active Comparator|CAMS SSC + Caregiver Skills Building|Caregivers will receive 3, 30-minute modules across 3 sessions that provide explicit coaching in several skills. Module content will include 1) psychoeducation on suicidality and the escalation cycle and creation of a communication plan related to responding to youth suicidality (i.e., Crisis Escalation and Communication Plan); 2) positive communication and relationship building strategies including reflective listening, validation, and how to implement regular teen-directed one-on-one time; and 3) setting up behavioral expectations, house rules, and using positive reinforcement based contingency management in the home (i.e., targeted praise, using rewards to promote more effective behaviors). All modules will include didactic skill building, role-play of skill use with the therapist, and a check-in with the youth and youth therapist to collaboratively problem-solve barriers to use of skills.
88802843|NCT03110562|Active Comparator|selinexor+bortezomib+dexamethasone (SVd)|Selinexor will be given on Days 1, 8, 15, 22, and 29 of each 35-day cycle. Bortezomib will be given Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
89135615|NCT05996172|Active Comparator|CAMS SSC + Lethal Means Safety|The CAMS Therapeutic Assessment incorporates low levels of lethal means restriction (see above). Experimental Intervention Component 4 will provide a high level of lethal means restriction that includes the evaluation of the need for a lock box, the provision of a lock box if needed, structured process for evaluating home safety in each room of the house, specific directives to accomplish, follow up with the clinician, and problem-solving barriers to lethal means restriction over two, 30-minute modules delivered across 2 sessions.
89135616|NCT05996172|Active Comparator|CAMS SSC + Driver Focused Skills Training + Caregiver training|This arm includes CAMS SSC, 3 sessions of youth facing driver focused skills, and 3 sessions of caregiver skills training.
89135617|NCT05996172|Active Comparator|CAMS SSC + Driver Focused Skills Training + Lethal Means Safety|This arm includes the CAMS single session intervention, 3 sessions of skills training for the youth, and lethal means safety for caregiver.
89135618|NCT05996172|Active Comparator|CAMS SSC + Caregiver Skills Training + Lethal Mean Safety|The arm includes the CAMS single session intervention, 3 sessions caregiver skills training and lethal means safety.
89135619|NCT05996172|Active Comparator|CAMS SSC + Driver Focused Skills Training + Caregiver Skills + Lethal Means Safety|This arm includes the single session intervention, youth skills training, caregiver skills training and lethal means safety.
89135620|NCT05995067||control group|-healthy groups/without the condition
89135621|NCT05995067||study group|-diseased group-/with the condition (periodontitis)
89135622|NCT05993689|Experimental|BUNDLE Intervention|Proposed components of the intervention will include: 1) attendance at two visits in the 2nd trimester and two visits in the 3rd trimester by a doula; 2) exchange of contact information between the clinic and the doula; 3) exchange of social needs and social-structural risk factors complicating patient's prenatal care from doula and exchange of clinical risk factors complicating prenatal care from obstetric provider; 4) communication between the doula and provider; 5) educating the obstetric team on benefits of doula support; 6) preparing labor and delivery team for presence of doula during labor ; and 7) enhancing doula support postpartum for cardiovascular risk reduction.
89135623|NCT05993689|Active Comparator|Usual Care|Standard of care for pregnancy and pregnancy-related issues will be provided by the obstetric provider as per routine.
89135624|NCT05992402|Experimental|Intervention|Participants in this arm will receive 2 one-on-one virtual education sessions as well as 4 virtual group education sessions prior to their epilepsy surgery.
89135625|NCT05992402|No Intervention|Treatment-as-Usual|Participants in this arm will not receive the education sessions and will receive standard epilepsy care prior to their surgery.
89135626|NCT05981755|Experimental|Breathing tasks and Brain mapping with stimulation|
89135627|NCT05979610|Experimental|Reiki Therapy|Participants randomized to Arm 1 will receive a session of Reiki therapy during the standard wait time between the placement of the brachytherapy device and their first brachytherapy treatment.
89135628|NCT05979610|No Intervention|Standard of Care|Participants randomized to the standard of care control arm will be asked to remain in a clinic room during the standard waiting period between the placement of the brachytherapy device and the start of brachytherapy treatment. Participants may participate in any activity other than Reiki therapy during this time. Participants may be accompanied by a family member or friend.
89135629|NCT05975606|Experimental|Treatment group|Participants of this group will receive active rTMS along with real FES cycling.
89135630|NCT05975606|Sham Comparator|Control group|Participants of this group will receive sham rTMS along with real FES cycling.
89135631|NCT05975008|Experimental|RECLAIM intervention|Eight sessions of a brief mindfulness-based intervention that meets weekly in a virtual setting.
89135632|NCT05975008|No Intervention|Psychoeducation materials only|We will use a psychoeducation-only control group. They will only receive psychoeducational materials (e.g., suggested readings, podcasts, blogs). These are the same materials that the intervention arm participants will receive.
89135633|NCT05970640|Experimental|BI 3006337 dose group 1 or placebo|
89135634|NCT05970640|Experimental|BI 3006337 dose group 2 or placebo|
89135635|NCT05970640|Experimental|BI 3006337 dose group 3 or placebo|
89135636|NCT05970640|Experimental|BI 3006337 dose group 4|
89135637|NCT05970341|Experimental|Arm 1: Intervention + usual care|"Welcome package~Welcome information: telephone call~Produce delivered at their choice of time and location + Recipes customized to produce~E-gift cards to a grocery store of choice~Personalized practical, emotional & educational support through a dedicated health partner"
89135638|NCT05970341|Other|Arm 2: Educational materials + usual care|"Welcome package~Welcome information: SMS/Text"
89135639|NCT05969730|Experimental|A|Baricitinib 4-mg daily plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream
89135640|NCT05969730|Experimental|B|Azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream
89135641|NCT05967390||Neurocognitive disorder (NCD)|The NCD patients are defined with a chronological age over 60 years and a Montreal Cognitive Assessment (MoCA) total score between 22 and 26.
89135642|NCT05954936||Blunt injury|Patients with non-penetrating injuries from falls, car accidents, or other mechanisms. Injuries that were caused by impact with a blunt object where there is no penetration of the skin.
89135643|NCT05954936||Penetrating injury|Penetrating wounds by guns, knives, and other penetrating injuries. Wounds that were caused by objects penetrating the skin.
89135644|NCT05953532|Other|All Participants|All participants will perform the same study activities
89135645|NCT05950802|No Intervention|Cyclophosphamide and fludarabine, standard dose|Fludarabine 30mg/m2 Cyclophosphamide 500mg/m2 Days -4, -3, -2
89135646|NCT05950802|Experimental|Cyclophosphamide and fludarabine, standard dose with radiation|Fludarabine 30mg/m2 Cyclophosphamide 500mg/m2 Days -6, -5, -4, and 2 Gy in 2 Fractions Days -3, -2
89135647|NCT05950802|Experimental|Cyclophosphamide (intermediate dose) and fludarabine|Fludarabine 30mg/m2 Cyclophosphamide 750mg/m2 Days -4, -3, -2
89135648|NCT05950802|Experimental|Cyclophosphamide (intermediate dose) and fludarabine with radiation|Fludarabine 30mg/m2 Cyclophosphamide 750mg/m2 Days -6, -5, -4, and 2 Gy in 2 Fractions Days -3, -2
89135649|NCT05948839|Experimental|active rTMS treatment|3 sessions of active rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse.
89135650|NCT05948839|Sham Comparator|sham control|3 sessions of sham rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse.
88802844|NCT03110562|Active Comparator|bortezomib+dexamethasone (Vd)|Bortezomib will be given Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, bortezomib will be given on Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, dexamethasone will be given on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
88802845|NCT00380770|Experimental|HAART alone|Arm 1. HAART These patients will be given one tablet twice daily of Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
88802846|NCT00380770|Active Comparator|Combination HAART and chemotherapy|Arm 2. CTX PLUS HAART. HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
88802847|NCT01231399|Experimental|Arm I|Patients receive fluorouracil IV continuously over 46 hours, leucovorin calcium IV over 2 hours, and oxaliplatin IV over 2 hours on day 1. Patients also receive oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88802848|NCT05432154|Experimental|Treatment arm|Patients apply 7-0940 at least 2 times daily for 3 months.
88802849|NCT01231633|Experimental|Group 1|Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
89135651|NCT05946304|Experimental|Standard care + moderate-intensity continuous exercise training (MICT)|Supervised virtual MICT exercise sessions for 12 weeks (2x/wk) using the platform Zoom Care.
89135652|NCT05946304|Experimental|Standard care + high-intensity interval training (HIIT)|Supervised virtual HIIT exercise sessions for 12 weeks (2x/wk) using the platform Zoom Care.
89135653|NCT05928689|Experimental|Memory Reminder followed by Propranolol Hydrochloride|This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a propranolol hydrochloride tablet.
89135654|NCT05928689|Placebo Comparator|Memory reminder followed by Placebo|This arm aims to have 30 participants with a pharmacological manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger followed by ingestion of a placebo tablet.
89135655|NCT05928689|Experimental|No memory reminder followed by Propranolol Hydrochloride|This arm aims to have 30 participants with a pharmacological manipulation. They will not receive a reminder to reactivate their memory of a misophonia sound and only receive a propranolol hydrochloride tablet.
89135656|NCT05928689|Experimental|Memory reminder followed by counterconditioning|This arm aims to have 30 participants with a behavioral manipulation. They will receive a reminder to reactivate their memory of a misophonia trigger and then will undergo counterconditioning.
89135657|NCT05928689|Experimental|No memory reminder followed by counterconditioning|This arm aims to have 30 participants with a behavioral manipulation. They will not receive a reminder to reactivate their memory of a misophonia trigger and then undergo counterconditioning.
89135658|NCT05924698|Active Comparator|Control group|This arm only received the Neuromuscular and Muscular Electrical Stimulation (NMES) intervention.
89135659|NCT05924698|Experimental|Experimental group|This arm received the intervention with NMES and Blood flow restriction (BFR).
89135660|NCT05916534|Experimental|WeCAB Intervention|
89135661|NCT05916534|No Intervention|Usual Care|
89135662|NCT05904912|Active Comparator|Group PENG = PENG block|PENG block will be performed
89135663|NCT05904912|Other|Group C = Control group|Local infiltration will be applied.
89135664|NCT05903950|Active Comparator|Active mode|In home use of portable air cleaners with a High Efficiency Particulate Air (HEPA) filter for 4 weeks.
89135665|NCT05903950|Sham Comparator|Sham mode|In home use of portable air cleaners without a High Efficiency Particulate Air (HEPA) filter for 4 weeks.
88802850|NCT01231633|Active Comparator|Group 2|Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
88802851|NCT02247037||Triple Negative Breast Cancers|All women eligible for this protocol will fall into this group. These women will have histologically confirmed triple negative breast cancer and be eligible for neoadjuvant chemotherapy or have evidence of metastatic disease.
88802852|NCT00000448|Placebo Comparator|Placebo|Subjects were given an inert placebo for 2 days, followed by daily doses of matching placebo for a total of 12 weeks.
89135666|NCT05903651||Single Group Assignment|The subjects will undergo a single retinal imaging session with the Optina MHRC device, on one or both eyes.
89135667|NCT05901896||study group|The study group consists of five volunteers who originally lived in a plain area. They will be living in a high-altitude region for one year.
89135668|NCT05901896||control group|Five healthy residents living on the high-altitude region , matched 1:1 by age, gender, and race, will serve as control group.
89135669|NCT05882604|Experimental|Intra-articular injection with MESNA solution|1 ml of MESNA will be injected intra-articular
89135670|NCT05882604|Active Comparator|Arthrocentesis with ringer solution|ringer solution will be used for arthrocentesis
89135671|NCT05878067|Experimental|ABBV-444|Participants will administer 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.
89135672|NCT05868161||Retrospective|All subjects in whom the Pounce Thrombectomy System was attempted will be included.
89135673|NCT05867433|Experimental|STHS Intervention|Participants in this group (10 schools) will participate in the STHS program.
89135674|NCT05867433|Other|Usual Care|Participants in this group (10 schools) will continue with usual care, as they will not be asked to add or remove any of their current, physical activity, healthy eating, or positive youth development programming.
89135675|NCT05864391|Other|Cohort 1|Dose A cohort: 20 participants; n=15 on AZD7503 dose A, n=5 on Placebo
89135676|NCT05864391|Other|Cohort 2|Dose B cohort: 20 participants; n=15 on AZD7503 dose B, n=5 on Placebo.
89135677|NCT05864391|Other|Cohort 3|Dose C cohort: 20 participants n=15 on AZD7503 dose C, n=5 on Placebo.
89234268|NCT00994500|Experimental|Treatment (vorinostat, bortezomib)|Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89135678|NCT05863598|Experimental|Enhancing protective factors|Participants will learn to improve their body image through body appreciation tasks, body image flexibility and focus on body functionality appreciation. They also learn to focus on important life values, be more accepting of themselves, and learn to eat regularly and with attention to bodily needs and signals. This is don in interactive ways, and by using a cognitive dissonance frame.
89135679|NCT05863598|Placebo Comparator|Expressive writing|Participants will be instructed to write about any thoughts, feelings, images, memories, interceptions, ideas or emotions related to their body for the same during as the active intervention (i.e., 40 minutes/week across four consecutive weeks).
89135680|NCT05860452|Active Comparator|ropivacaine|Participants in this group will receive TAP block with 0,75%, bilaterally.
89135681|NCT05860452|Placebo Comparator|normal saline|Participants in this group will receive TAP block with normal saline, bilaterally.
89135682|NCT05832047|Experimental|Plasma solution|
89135683|NCT05832047|Active Comparator|Lactated Ringer's solution|
89135684|NCT05830097|Experimental|Ia stage - CBP-1019 Dose escalation/ Ib、II stage - CBP-1019 monotherapy|"Ia:Patients will receive CBP-1019 IV infusion every 2 weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.~Ib:Patients will receive CBP-1019 RP2D IV infusion every two weeks until disease Patients will receive CBP-1019 RP2D IV infusion every two weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue."
89135685|NCT05826457||RBD Group|Clinical observation involving annual visits to a study site for up to 5 years.
89135686|NCT05826457||Control Group|Clinical observation involving annual visits to a study site for up to 5 years.
88802853|NCT00000448|Experimental|Naltrexone|Subjects were prescribed 25 mg naltrexone for 2 days, followed by daily doses of 50 mg of naltrexone for a total of 12 weeks.
89135687|NCT05823922|Active Comparator|Clinician-delivered Cognitive Behavioral Therapy only|Participants receive treatment with a licensed clinician for 6 weeks.
89135688|NCT05823922|Experimental|Clinician-delivered CBT + Supplemental app|Mobile application at least two times per week for six weeks, for at least 20 minutes on each of the two days in addition to the clinician-delivered CBT
89135689|NCT05820152|Experimental|NFS-02 Injection|"Potential doses at the dose-finding stage:~5.0×107 vg, 0.05 mL/eye/dose (low dose) 1.5×108 vg, 0.05 mL/eye/dose (starting dose) 5.0×108 vg, 0.05 mL/eye/dose (intermediate dose) 1.5×109 vg, 0.05 mL/eye/dose (high dose)"
89135690|NCT05808738|Active Comparator|therapeutic game group|therapeutic play will be played 10 minutes before the hydrotherapy treatment.
89135691|NCT05808738|No Intervention|control group|No intervention was given to the children prior to hydrotherapy treatment.
89135692|NCT05800249|Experimental|Dose Escalation|"A total of 9 dose groups are expected to be evaluated in Phase Ia: 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg, 6 mg/kg, and 10 mg/kg. One subject will be enrolled in the starting dose group of 0.03 mg/kg (if any ≥ Grade 2 dose-related adverse event is observed in this group during the DLT observation period, the group will be changed to the 3 + 3 method), and 3 or 6 subjects will be enrolled in each of other dose groups. The first 2 subjects in the same dose group shall receive the first dose at an interval of at least 48 hours to avoid acute hypersensitivity reactions, and the specific interval shall be determined by the investigator based on the safety assessment of subjects in the previous dose group. Ultimately, the sponsor and the investigator will determine whether an increase in dose group or in a specific fixed dose is required according to the actual situation of the trial."
89135693|NCT05789147|Active Comparator|active tVNS|Patients randomized to active treatment will be instructed to receive the stimulation at the tragus
89135694|NCT05789147|Placebo Comparator|sham tVNS|Patients randomized to active treatment will be instructed to receive the stimulation at the ear lobe
88802854|NCT01234207|Active Comparator|Randomized Order of Interventions 1|Randomized to first wear standard, non-free-form, non-customized PAL spectacles, then second, crossover to wear individually customized free-form surfaced PAL spectacles
88802855|NCT01234207|Active Comparator|Randomized Order of Interventions 2|Randomized to first wear individually customized free-form surfaced PAL spectacles, then second, crossover to wear standard, non-free-form, non-customized PAL spectacles
88802856|NCT01234831|Other|Active Screening|Patients randomized to active screening will have two nasal swabs collected daily for 3 days, for both nucleic acid amplification and culture (CHROMagar)assays.
89135695|NCT05786027|Experimental|Peer Driven Intervention (PDI)|Participants from two experimental (E) prisons that are HIV-negative will be assigned to this arm. Participants will receive 12 weeks of PDI and weekly opioid urine tests. Prior to intervention participants will receive training by a Health Educator (HE) in Health Advocate (HA) and Peer roles.
89135696|NCT05786027|No Intervention|Treatment As Usual (TAU)|Participants from two control (C) prisons that are HIV-negative will be assigned to this arm. Participants will receive treatment as usual (which includes universal access to SSP, MMT, and Atlantis program for individuals with opioid dependence) and weekly urine opioid tests for 12 weeks.
89135697|NCT05782855|Sham Comparator|Control group|Participants in the control group will receive usual individualized training with a physiotherapist and passive sham training of lower extremities with the rehabilitation robot twice a day until day of discharge. The physiotherapist will be blinded to allocation. Sham training consists of 3 sets of 8 passive repetitions with each leg twice a day.
89135698|NCT05782855|Active Comparator|Intervention group|The intervention group will receive usual individualized training with a physiotherapist and active strength training of lower extremities by the robot twice a day until day of discharge. The physiotherapist will be blinded to allocation. Training will focus on the muscle groups in the lower extremities, which are used to get up from a chair and walk around (thigh- and calf muscles). Active training consists of 3 sets of maximum repetitions with a minimum of 65% (65-80%) intensity of 1 RM with each leg twice a day.
89135699|NCT05773014|Active Comparator|Speculum Exams|If a patient requires cervical evaluation after PPROM, their cervix will be evaluated with a sterile speculum exam. A sterile speculum with lubricating jelly will be inserted into the patient's vagina to visualize the cervix and visually estimate cervical dilation and effacement.
89135700|NCT05773014|Active Comparator|Digital Exams|If a patient requires cervical evaluation after PPROM, their cervix will be evaluated with a digital exam. The provider will wear sterile gloves with lubricating jelly and will palpate the cervix to assess cervical dilation, effacement, and station.
89135701|NCT05771948|Placebo Comparator|Group 1 (Control)|1 IA injection of 4 ml Normal Saline solution.
89135702|NCT05771948|Experimental|Group 2 (Study)|1 IA injection of 4 ml AqueousJoint low conc (15mM)
89135703|NCT05771948|Experimental|Group 3 (Study)|1 IA injection of 4 ml AqueousJoint high conc (30mM)
89135704|NCT05762107|Experimental|ZT-01 7 mg|Participants receive placebo and ZT-01 7 mg each by subcutaneous injection daily for 28 days, randomized to order
89135705|NCT05762107|Experimental|ZT-01 15 mg|Participants receive placebo and ZT-01 15 mg by subcutaneous injection daily for 28 days, randomized to order
89135706|NCT05762107|Experimental|ZT-01 22 mg|Participants receive placebo and ZT-01 22 mg by subcutaneous injection daily for 28 days, randomized to order
89135707|NCT05760690|Experimental|Retro-Auricular Single-Site Endoscopic Thyroidectomy group|Patients in the retro-auricular single-site endoscopic thyroidectomy (RASSET) group will receive endoscopic thyroid lobectomy and central lymph node dissection.
89135708|NCT05760690|Active Comparator|Transoral Endoscopic Thyroidectomy Vestibular Approach group|Patients in the Transoral Endoscopic Thyroidectomy Vestibular Approach group will receive endoscopic thyroid lobectomy and central lymph node dissection.
89135709|NCT05760690|Active Comparator|Transareola Endoscopic Thyroidectomy group|Patients in the Transareola Endoscopic Thyroidectomy group will receive endoscopic thyroid lobectomy and central lymph node dissection.
89135711|NCT05737628|Experimental|BYON4228 + Rituximab|"BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.~Rituximab IV infusion (375 mg/m2) starts after first BYON4228 cycle. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles."
89135712|NCT05728801||Superagers|SuperAgers are determined by the scores of global cognitive function. This ensured that the participants are divided by a measure relevant to the current study without directly biasing the results toward the domain of interest.
89135713|NCT05728801||Normal ageing elderly|The cases with the scores of cognitive performance within 1.5 standard deviation (SD) of age and education matched normative values derived from our cohort study, of which presented with HK MoCA score greater than 26 and CDR score equal to 0
89135714|NCT05728801||Neurocognitive disorders patients|NCD patients are deﬁned as: evidence of modest decline in one or more cognitive domains, which is set as ≥ 1.5 SD below the age- and education-adjusted normative scores; no interference with independence in everyday activities; and no comorbid major psychiatric disorders.
89135715|NCT05725564|Experimental|FAST-BCT|FAST exercise intervention without behavior change techniques applied. Daily exercise intervention including functional resistance training and personalized coaching.
89135716|NCT05725564|Experimental|FAST+BCT|FAST exercise intervention with behavior change techniques applied. Daily exercise intervention including functional resistance training and personalized coaching with added reminders, education, goal setting, self monitoring, and feedback to encourage adherence and effort.
89135717|NCT05725564|Active Comparator|BT-BCT|Band Together exercise intervention without behavior change techniques applied. 3 times weekly group exercise intervention held over Zoom featuring strength and balance exercises for 45 minutes.
89135718|NCT05725564|Active Comparator|BT+BCT|Band Together exercise intervention with behavior change techniques applied. 3 times weekly group exercise intervention held over Zoom featuring strength and balance exercises for 45 minutes with added reminders, education, goal setting, self monitoring, and feedback to encourage adherence and effort.
89135719|NCT05715359||Reconstruction of jaws.|Patients treated with free tissue transfer reconstruction of the jaws.
89135720|NCT05711784|Experimental|Phaseolean (White Kidney Bean Standardized Extract)1500 mg Capsules|Phaseolus Vulgaris L. is rich in alpha-amylase and alpha-glucosidase inhibitor. It has been used for calories absorption through preventing or delaying the digestion of complex carbohydrate.
89135721|NCT05711784|Experimental|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|Phaseolus Vulgaris L. is rich in alpha-amylase and alpha-glucosidase inhibitor. It has been used for calories absorption through preventing or delaying the digestion of complex carbohydrate.
89135722|NCT05711784|Placebo Comparator|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
89135723|NCT05705505|Experimental|Escalating daily doses of narazaciclib in combination with letrozole (2.5mg day)|"Phase 1: Initiating at 160mg per day of narazaciclib, patients will receive escalating doses of narazaciclib (oral tablets/once daily) in combination with 2.5mg of letrozole (oral tablet/once daily).~Phase 2: All patients will receive the recommended phase 2 dose (RP2D) of the combination of narazaciclib (oral tablets) and letrozole (oral tablet/QD)"
89135724|NCT05699759|Experimental|Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema
89135725|NCT05699460||Early Parkinson's disease|
89135726|NCT05699460||Possible or Probable MSA-P|
89135727|NCT05684614||Healthy individuals|Adult individuals recruited from the community through announcements at the university and social media
89135728|NCT05681650|Experimental|HypoSti.CAR-HER2 T cells|Enrolled participants will be given a preconditioning regimen consisted of albumin-bound paclitaxel, cyclophosphamide and/or fludarabine before the infusion of HypoSti.CAR-HER2 T cells. Fludarabine will be administered only before the first dose infusion, and will not be administered before the secondary or multiple doses of HypoSti.CAR-HER2 T cell infusion.
89135729|NCT05674916|Experimental|Point-of-care ultrasound-driven diagnostic pathway|The intervention is focused lung and cardiac ultrasound performed as an extension to physical examinations plus diagnostic decision recommendations based on those test results (a point-of-care ultrasound-driven diagnostic pathway). Final decision on next-line imaging and further diagnostic testing should incorporate history and other physical examinations and will remain upon the treating physicians' discretion.
89135730|NCT05674916|No Intervention|Standard diagnostic pathway|Standard diagnostic pathway will include, but not be limited to, blood samples, blood gases, electrocardiogram, and chest x-ray. Focused lung and cardiac ultrasound cannot be performed while the patients stay in the emergency department.
89135731|NCT05672459|Experimental|Dose Escalation (Part 1) and Expansion (Part 2 )|Participants will receive IVS 3001 at the selected dose Participants will receive IVS 3001 at the recommended phase 2 dose
89135732|NCT05670119|Active Comparator|Intervention Group|Nurses in the intervention group will be given face-to-face training on evidence-based catheter-related infection control measures. The content of the training program will also be given to the participants as written material (brochure). The training will take an average of 30 minutes. After the data collection forms are applied to the participants in the intervention group (pre-test), evidence-based training on catheter-related infection control measures will be conducted. The forms will be applied again immediately after the training (post-test) to measure the knowledge level of nurses and three months after the training (post-test) to measure the level of attitude.
89135733|NCT05670119|No Intervention|Control Group|Routine in-service training practices will be given to the control group. Data collection forms will be applied to the participants in the control group at the same time as the intervention group.
89135734|NCT05664828|Experimental|Single dose (i.v.) SN132D|SN132D is a nanoparticle solution at 20 µmol Mn/kg dosage, administrated via intravenous infusion.
89135735|NCT05647044|Active Comparator|active iTBS|Subjects receiving active iTBS treatment
89135736|NCT05647044|Placebo Comparator|placebo iTBS|Subjects receiving placebo (sham) iTBS treatment
89135737|NCT05641766|Experimental|THC|Participants will receive THC into a rapidly flowing IV infusion.
89135738|NCT05641766|Other|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
89135739|NCT05641688|Experimental|PI-2620 PET Scan|
89135740|NCT05630768|Experimental|Actonel®|Risedronate Sodium 35mg
89135741|NCT05623787|Experimental|DWI-High Risk|Patients to undergo DWI-MRI (patients included in the study).
89135742|NCT05622682||Children, adolescents, and young adults who recently completed ALL treatment|This cohort of participants who recently completed leukemia therapy will be assessed for infection incidence during the year following treatment and give blood samples to be measured for antibodies to vaccine-preventable diseases. A small subset will also have their blood samples tested for B and T cell recovery.
89135743|NCT05619900||Mucopolysaccharidosis I|Prenatally or postnatally diagnosed individuals
89135744|NCT05619900||Mucopolysaccharidosis II|Prenatally or postnatally diagnosed individuals
89135745|NCT05619900||Mucopolysaccharidosis IV A|Prenatally or postnatally diagnosed individuals
89135746|NCT05619900||Mucopolysaccharidosis VI|Prenatally or postnatally diagnosed individuals
89135747|NCT05619900||Mucopolysaccharidosis VII|Prenatally or postnatally diagnosed individuals
89135748|NCT05619900||Infantile-Onset Pompe Disease|Prenatally or postnatally diagnosed individuals
89135749|NCT05619900||Neuronopathic Gaucher|Prenatally or postnatally diagnosed individuals
89135750|NCT05619900||Wolman Disease|Prenatally or postnatally diagnosed individuals
89135751|NCT05618574|Active Comparator|Beet-It nitrate beverage|Participant will receive 210 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14. All participants will undergo physical therapy 2-3 times per week based on tolerance for activity and recovery needed after each session. Physical therapy will be standardized to include strength, balance, inspiratory muscle training, and aerobic training.
89135752|NCT05618574|Placebo Comparator|Nitrate-depleted placebo.|Participants will receive 210 ml of nitrate-depleted placebo for 14 days. All participants will undergo physical therapy 2-3 times per week based on tolerance for activity and recovery needed after each session. Physical therapy will be standardized to include strength, balance, inspiratory muscle training, and aerobic training.
89135753|NCT05613660|Experimental|VEGCOL™️ (Veg Collagen Peptide)|"Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water~VEGCOL helps in providing the necessary nutrition needed for the body to produce collagen. Vegan collagen gives a lighter feel on consumption compared to any other collagen and increases the elasticity of the skin and makes skin supple. VEGCOL has more amino acids than animal derived Collagen which makes it very ideal to consume not only in Vegetarian populated countries like in India but around the world. Pepsin, a digestive enzyme, is added to help structure the building blocks into collagen molecules with the exact structure of human collagen."
89135754|NCT05613660|Experimental|PROCOL (Bovine Collagen Peptide)|"Bovine collagen is a naturally occurring protein present in the connective tissue, bones, cartilage, and hides of cows.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
89135755|NCT05613660|Experimental|"AQUACOL (Fish | Marine Collagen Peptide)"|"Marine Collagen is made from Fish Skin which delays the signs of aging such as wrinkles, Joint issues and weakness.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
89135756|NCT05613660|Experimental|CALCOL (Chicken Collagen Peptide)|"Chicken collagen is used to treat joint pain associated with many types of arthritis and surgery, as well as back pain, neck pain, and pain following injury. Chicken collagen works by causing participants' body to produce substances that fight inflammation and pain. It also contains chondroitin and glucosamine, two compounds that help rebuild cartilage. That's why chicken collagen can provide some amazing benefits for participants' gut, immune system, skin, and more.~Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water."
89135757|NCT05610969|Active Comparator|Music group|self-selected music
89135758|NCT05610969|Active Comparator|Midazolam group|IV midazolam (1mg to 2mg max)
89135759|NCT05605509|Active Comparator|RP-6306 + Gemcitabine|
89135760|NCT05605509|Active Comparator|RP-6306 + FOLFIRI|
89135761|NCT05605509|Active Comparator|RP-6306 + Trastuzumab|
89135762|NCT05601544|Experimental|Sphere TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere TEST/CONTROL sequence.
89135763|NCT05601544|Experimental|Sphere CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere CONTROL/TEST sequence.
89135764|NCT05601544|Experimental|Multifocal TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal TEST/CONTROL sequence.
89135765|NCT05601544|Experimental|Multifocal CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal CONTROL/TEST sequence.
89135766|NCT05601544|Experimental|Toric TEST/CONTROL|Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric TEST/CONTROL sequence.
89135767|NCT05601544|Experimental|Toric CONTROL/TEST|Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric CONTROL/TEST sequence.
89135768|NCT05597865|Other|Control Arm|Control arm will received Alcohol and Drug Use Risk Reduction Sessions
89135769|NCT05597865|Experimental|Intervention|Participants in the intervention arm will receive four (4) Financial Literacy (FL) training sessions and receive a Youth Development Savings account (YDA) at a financial institution accredited by the Bank of Uganda for long-term savings. Each YDA account will be opened in the name of the participant. Savings will be matched at a 1:1 rate with money from the program.
89135770|NCT05597267|Experimental|Treatment with the MIRIA Laser|3-4 experimental treatments at 4-6 week intervals
89135771|NCT05592093|Experimental|KRGO group|Korean red ginseng capsule (KRGO)marketed product in Korea donated by The Korean Society of Ginseng.
89135772|NCT05592093|Placebo Comparator|placebo group|Same smell, color and shape as Korean red ginseng capsule (KRGO)without herbs in capsules.
89135773|NCT05579132|Experimental|CN201|"By study design, planned target CN201 dose levels in adults are 600μg, 1200 μg, 2500 μg , 5000 μg, 10000μg, and 20000μg. Planned target CN201 dose levels in pediatric subjects are 5000μg and 10000μg. Consider enrollment of pediatric subjects only if safety data are available for the corresponding target dose group in adults which demonstrates safety.~Subjects will receive CN201 by intravenous infusion (IV), once per week, four weeks per treatment cycle."
89135774|NCT05578716|Experimental|Study formula 1|Formula-fed intervention group randomised to one of two study formulae
89135775|NCT05578716|Experimental|Study formula 2|Formula-fed intervention group randomised to one of two study formulae
89135776|NCT05578716|No Intervention|Standard formula|Formula-fed control group randomised to standard formula
89135777|NCT05578716|No Intervention|Breast feeding|Reference group with exclusively breast-fed infants
89135778|NCT05575349|Experimental|Mandala coloring group|Mandala painting will be applied to climacteric women with anxiety.
89135779|NCT05575349|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practice on their own to reduce anxiety symptoms
89135780|NCT05574426|Experimental|Cardiovascular Movement Breaks|Participants will perform 3-4 exercise snacks (30-60s bursts of exercise) on at least 3 days of the week. The exercises prescribed in this arm will be designed to increase heart rate.
89135781|NCT05574426|Active Comparator|Mobility Movement Breaks|Participants will perform 3-4 mobility snacks (30-60s of mobility exercises or stretching) on at least 3 days of the week. The exercises prescribed in this arm are not designed to increase heart rate.
89135782|NCT05572177|Experimental|Asthma SMART|Subjects randomized to the intervention arm will be provided with the app to download to their personal iPhone or Android smartphone. Subjects will be asked to use the app every day for 6 months.
89135783|NCT05572177|No Intervention|Standard of care|Subjects randomized to the standard-of-care arm will continue to receive regular care for their condition.
89135784|NCT05571397|Experimental|Dexcom CGM|Dexcom G6
89135785|NCT05571397|No Intervention|Historical Controls|Matched historical controls
89135786|NCT05570851|Active Comparator|Control|Usual Care
89135787|NCT05570851|Experimental|Intervention|Text Message Based Program
89135788|NCT05568225|Experimental|Etavopivat 400 mg QD daily|Non-transfusion dependent (NTD), Low transfusion burden (LTB) , and High transfusion burden (HTB) patients
89135789|NCT05564026||Ancillary-Correlative|Children and adolescents with a germ cell tumor, previously enrolled on APEC14B1 or AEPI10N1 who allow access to medical records (including audiograms), grant permission to: evaluate of all of their DNA, place their genetic and health information in scientific databanks, and collect a blood sample at a routine clinic/home visit, as well as complete a questionnaire about your health and quality of life since treatment.
89135790|NCT05554497|Experimental|Mindfulness training|8 week virtual mindfulness-based stress reduction curriculum. Weekly 2.5 hour sessions over zoom.
89135791|NCT05546099|Experimental|Self-management|Patients monitor their home BP and self manage their BP medications based on a predesigned titration protocol and under the guidance of the clinical pharmacist.
88802857|NCT01234831|Other|Passive Screening|Patients randomized to passive screening will not actively be identified for testing but may be tested using culture-based algorithm by care team.
89135792|NCT05546099|Active Comparator|Self-monitoring|Patients monitor their home BP and contact their provider if the BP is above the goal.
89135793|NCT05545215||Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
89135794|NCT05536895|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
89135795|NCT05536895|Active Comparator|MD-CT|An evaluation with conventional, standard of care, multi-detector CT (MD-CT)
89135796|NCT05531201|Experimental|Interventional|Trainig of GP and physiotherapist at collaborative coordinated care pathway
89135797|NCT05531201|No Intervention|Control|without modification of the usual follow-up
89135798|NCT05506254||Patients who have previously received hLB-001|
89135799|NCT05497427||Normative|BrainCheck assessment values from participants that have indications of healthy cognition at the time of testing ( a SLUMS result considered 'normal', more than 4 hours of sleep the night before, not having consumed alcohol or drugs within the last 6 hours, or not have participated in high capacity and strenuous physical activity within the last hour.)
89135800|NCT05497427||Test-Retest|Comparing BrainCheck assessment values between an initial visit test and a follow-up visit test 7-14 days later within subjects.
89135801|NCT05497427||Per Protocol|BrainCheck assessment values from participants that completed all procedures with no protocol deviations
89135802|NCT05490381|Experimental|Treatment (PVA, EOV, tumor vessel embolization)|Patients receive iodixanol via injection and undergo diagnostic cerebral angiogram over 30 minutes. If the tumor blood supply is suitable, patients undergo tumor vessel embolization with PVA suspended in EOV and delivered via a catheter. Patients also undergo head and neck CT scans immediately after completion of tumor vessel embolization, and again between 2-3 months later.
89135803|NCT05488080|Experimental|Department-level audit and feedback and electronic health record-embedded clinical decision support|Clinicians will receive monthly pooled, department-level 'Equity Report Cards' that will provide aggregate information on clinical data stratified by patient race/ethnicity. Subsequently, for all visits that may be related to appendicitis or long bone fracture, clinicians will then receive real-time, electronic health record-embedded clinical decision support regarding pain management.
89135804|NCT05487924|Experimental|SVV-GDHT|SVV ≤12% and CI of at least 2.5 L•min-1•m-2 were required. 500 mL of crystalloids was infused during induction, followed by a 2 ml•kg-1•h-1continuous infusion. If SVV was higher than 12% for over 5 minutes, a 250 mL bolus of crystalloid was given. Another 250 ml bolus of colloid was administrated if SVV was still higher than 12% or SVV decreased over 10%. If CI value was below 2.5 L•min-1•m-2, inotropes were applied to reach this minimum CI, serving as a safety parameter to prevent patients from low cardiac output. If SVV and CI were within the target range but MAP was below 65 mmHg, norepinephrine was started. After the initial assessment, patients were reassessed every 5 minutes intraoperatively to maintain values according to the study algorithm
89135805|NCT05487924|Experimental|O2ER-GDHT|the goal of O2ER is assessed every one hour to keep O2ER<27% which calculated by the following equation:(SaO2 - SvO2)/SaO2, when O2ER is greated than 27%, CVP lower than 10mmHg, 250ml colloid is given, otherwise, inotropes is given as CVP≥10mmHg.
89135806|NCT05487924|Active Comparator|conventional care|MAP was kept between 65 and 90 mmHg, CVP between 8 and 12 mmHg and urinary output more than 0.5 ml•kg-1•h-1. 500 ml of crystalloids was infused during induction, followed by a continuous infusion of crystalloids (4 ml•kg-1•h-1). If the MAP decreased below 65 mmHg, or if the CVP decreased below 8 mmHg, a 250 mL bolus of colloid was given after waiting 5 minutes if any one of the criteria was met. If the MAP decreased below 65 mmHg and remained unresponsive to fluids, norepinephrine or inotropes was given to maintain the MAP above 65 mmHg.
89135807|NCT05481736|Experimental|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
89135808|NCT05481736|Active Comparator|1 mg COMP360 Psilocybin|1 mg COMP360 Psilocybin
89135809|NCT05481489|Experimental|PRO-230|Healthy volunteers will apply one drop of PRO-230 ophthalmic solution (atropine sulphate) on both eyes, QD (one time per day) for 14 days.
89135810|NCT05479890|No Intervention|Treatment as Usual (TAU)|TAU will receive no training during the intervention period.
89135811|NCT05479890|Experimental|ClientBot (CB)|CB trainees will engage in 5 weekly practice sessions with ClientBot
89135812|NCT05474742|Experimental|Intervention group|Use of the Nori Health app during the study period, standard care
89135813|NCT05474742|No Intervention|Control group|No use of the Nori Health app during the study period, standard care
89135814|NCT05473663|Active Comparator|Radiofrequency Ablation|Patient undergoing genicular nerve radiofrequency ablation.
89135815|NCT05473663|Sham Comparator|Sham|Patient undergoing sham.
89135816|NCT05471856|Experimental|BI 1703880 (Cycle 1) then BI 1703880 + ezabenlimab (Cycle 2 onwards)|
89135817|NCT05471830||Patient survey|Survey-eligible patients with Commercial or Medicare Advantage health insurance who are current/past users of sMRA therapies and diagnosed with chronic kidney disease (CKD), type 2 diabetes (T2D) or heart failure (HF).
89135818|NCT05470868|Experimental|PRO-185|Healthy volunteers will apply one drop of PRO-185 ophthalmic solution (naphazoline / hypromellose) on both eyes, QID (four times per day) for 8 days.
89135819|NCT05465941|Experimental|Treatment (pegylated SN-38 conjugate PLX038)|Patients receive PLX038 IV over 1 hour on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, biopsy, as well as blood and stool sample collection during screening and on the trial.
89135820|NCT05460611|Experimental|Androgenetic Alopecia|The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject to target androgenetic alopecia.
89135821|NCT05460611|Experimental|Scarring Alopecia|The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject to target scarring alopecia.
89135822|NCT05454293|Experimental|OTAAT|This group will receive the One Talk at a Time curriculum.
89135823|NCT05454293|Active Comparator|Parent-Child Communication|This group will receive a curriculum focused on tips and strategies for navigating difficult topics with one's children such as current events and dating.
89135824|NCT05451628|Active Comparator|Default CI fitting|Programming of cochlear implant speech processor according to standard clinical care
89135825|NCT05451628|Active Comparator|Anatomy-based CI fitting|Programming of cochlear implant speech processor with anatomy-based fitting
89135826|NCT05451303||Oral Squamous Cell Carcinoma (OSCC)|OSCC case cohort will consist of patients with Oral Squamous Cell Carcinoma (all stages, locations), recruited from secondary care.
89135827|NCT05451303||OroPharyngeal Cancer (OPC)|OPC case cohort will consist of patients with OroPharyngeal cancer (all stages, locations), recruited from secondary care.
89135828|NCT05451303||Oral Potentially Malignant Disease (OPMD)|"OPMD cohort will consist of patients with both potential malignancies or benign conditions including, but not limited to:~Dysplasia~Hyperplasia~Leukoplakia~Erythroplasia~Lichenoid lesions~Actinic Keratosis~Lichenoid reaction~Aphthous ulcer/ Canker Sores~Gingival enlargement (side effect)~Lichen planus~Keratosis~Inflammatory reaction~Cheek bites"
89135829|NCT05451303||Cancer-free|Cancer free control cohort will be matched with cases. Participants will be recruited following clinical adjudication with self-reported confirmation of no cancer and from primary care facilities.
89135830|NCT05440864|Experimental|Tremelimumab in combination with Durvalumab preoperatively, followed by adjuvant Durvalumab|Patients will receive 1 dose Tremelimumab (300 mg) with Durvalumab (1500mg) at cycle 1 (4W) and 1 further cycle of Durvalumab (1500mg) pre surgical resection. Post-surgical resection patients will begin adjuvant Durvalumab (1500mg Q4W) to complete 13 cycles of treatment (or 11 post operatively) in total.
89135831|NCT05421624|Experimental|Amped-PD|6-week community-based, self-directed walking program that uses a novel digital therapeutic that delivers music-adaptive rhythmic auditory stimulation.
89135832|NCT05421624|Active Comparator|Active-Control|6-week community-based, self-directed walking program without using a novel digital therapeutic or any form of rhythmic auditory stimulation.
89135833|NCT05417724|Other|Battlefield Acupuncture|All subjects will receive BFA treatment weekly for 12 weeks.
89135834|NCT05405491|Experimental|PCR group|
89135835|NCT05405491|Sham Comparator|Control group|
89135836|NCT05401630|Experimental|Symptomatic women with no obstructive CAD who have CMD|Symptomatic women with chest pain and no obstructive CAD who have an abnormal myocardial flow reserve (MFR < 2.5)
89135837|NCT05401630|Experimental|Symptomatic women with chronic obstructive CAD (oCAD)|This group will serve as one comparison group since these women represent the prevailing paradigm of ischemia from obstructive stenosis while sharing common cardiovascular risk factors with the CMD group.
89135838|NCT05401630|Active Comparator|Asymptomatic control women with no prior history of CAD or angina|Asymptomatic control women with no prior history of CAD or angina, who are age-matched to the CMD women; not on any cardiac medications, who will also have to pass a maximal Bruce protocol exercise treadmill test.
89135839|NCT05397691|Experimental|Intervention refinement arm|20 parent-youth [12-18 years old] dyads will be randomized to this arm and receive the Modified Family Talk intervention.
89135840|NCT05397691|Experimental|Parameter estimation arm|20 parent-youth dyads randomized to this control-like arm will receive current best practice care in the patient-centered medical home
89135841|NCT05394662|Experimental|Transcervical Gynecological Procedure + Juveena Hydrogel|Transcervical Gynecological Procedure + Juveena Hydrogel
89135842|NCT05394662|No Intervention|Transcervical Gynecological Procedure alone (standard of care)|Transcervical Gynecological Procedure alone (standard of care)
89135843|NCT05393609||Sigmoidectomy|Patients with diverticular disease undergoing elective resection of the sigmoid colon
89135844|NCT05393609||Conservative|Patients with diverticular disease not referred to surgery, but conservative treatment
89135845|NCT05391321|Experimental|administration of quality of sexual life questionnaires|
89135846|NCT05384405|Active Comparator|active stimulation|Active Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
89135847|NCT05384405|Sham Comparator|Sham stimulation|Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
89135848|NCT05383560|Experimental|mRNA-1273.214 + mRNA-1273.214|Fourth & Fifth doses of an investigational mRNA vaccine, 56 days apart N ≈ 60 Under protocol versions 1.01-1.06
89135849|NCT05383560|Experimental|mRNA-1273.214 + Placebo|Fourth dose of an investigational mRNA vaccine followed by a fifth dose of placebo, 56 days apart N ≈ 60 Under protocol versions 1.01-1.06
89135850|NCT05383560|Active Comparator|mRNA-1273 + Placebo|Fourth dose of the commercial mRNA vaccine, followed by a fifth dose of placebo, 56 days apart N ≈ 30 Under protocol versions 1.01-1.06
89135851|NCT05383560|Experimental|mRNA-1273.214|A booster dose of an investigational mRNA vaccine at Visit 1 (Day 1). N ≈ 30 Under protocol versions 1.07
89135852|NCT05383560|Active Comparator|mRNA-1273.222|A booster dose of the commercial mRNA vaccine at Visit 1 (Day 1). N ≈ 30 Under protocol versions 1.07
89135853|NCT05378789|Experimental|20-min nap|"ICU nurses can take a 20-minute nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
89135854|NCT05374473|Experimental|Intervention|Intervention-tailored program with information regarding modifiable lifestyle related risk factors implicated in disease progression.
89135855|NCT05374473|Other|Standard-care|containing general health information sourced from standard MS websites.
89135856|NCT05369598|Active Comparator|ABF fitting followed by standard fitting|
88802858|NCT02546856|Active Comparator|Heart Failure (HF) cardiologist up-titration|Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.
89135857|NCT05369598|Active Comparator|Standard fitting followed by ABF fitting|
89135858|NCT05360277|Experimental|Tislelizumab + Capecitabine|"Tislelizumab 200mg every 3 weeks, or 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
89135859|NCT05360277|Active Comparator|Best supportive care|Best supportive care was the standard care in this setting.
89135860|NCT05354856|Experimental|ICG patient|All patients included in the study will be injected with ICG (0.2 mg/kg bodyweight) to assess gastric perfusion.
89135861|NCT05335122|Experimental|OTX-TIC Low Dose|Travoprost Intracameral Implant low dose
89135862|NCT05335122|Experimental|OTX-TIC High Dose|Travoprost Intracameral Implant high dose
89135863|NCT05335122|Active Comparator|Durysta|Bimatoprost Intracameral Implant 10 µg
89135864|NCT05332704|Experimental|Part A, Active|
89135865|NCT05332704|Placebo Comparator|Part A, Placebo|
89135866|NCT05332704|Experimental|Part B, Active|
89135867|NCT05332704|Placebo Comparator|Part B, Placebo|
89135868|NCT05332704|Experimental|Part C, Active|
89135869|NCT05332704|Placebo Comparator|Part C, Placebo|
89135870|NCT05313152|Experimental|TAVO103A Low Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
89135871|NCT05313152|Experimental|TAVO10A Medium Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
89135872|NCT05313152|Experimental|TAVO103A High Dose|TAVO103A: TAVO103A single ascending dose IV infusion.
89135873|NCT05313152|Placebo Comparator|Placebo|Placebo single ascending dose IV infusion.
89135874|NCT05306067||Children at low transmission health facilities|
89135875|NCT05306067||Children at medium-to-high transmission health facilities|
89135876|NCT05306067||Pregnant women at low transmission ANC|
89135877|NCT05306067||Pregnant women at medium-to-high transmission transmission ANC|
89135878|NCT05305313|Active Comparator|Total Body Weight group|Anesthesia will be induced with Propofol administered by CLADS which will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on total body weight (TBW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
89135879|NCT05305313|Active Comparator|Adjusted Body Weight group|Anesthesia will be induced with Propofol administered by CLADS which will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
89135880|NCT05298046|Experimental|TAVO101: Low dose|TAVO101: TAVO101 single ascending dose IV infusion.
89135881|NCT05298046|Experimental|TAVO101: Medium dose|TAVO101: TAVO101 single ascending dose IV infusion.
89135882|NCT05298046|Experimental|TAVO101: High dose|TAVO101: TAVO101 single ascending dose IV infusion.
89135883|NCT05298046|Placebo Comparator|Placebo|Placebo single ascending dose IV infusion.
89135884|NCT05280145|Experimental|Patients benefitting ultrasound examination|This is the only arm of the study. Patients with an indicative clinical picture that leads the clinician to resort to the use of an ultrasound to potentially support the diagnosis will be examined to verify the presence of pleural effusion or intra-abdominal effusion, or to identify basilic vein. The patients will be assessed first with the echOpen device and second witn an ultrasound routinely used in the department. In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating.
89135885|NCT05269173|Active Comparator|Active group(low dose group)|Take 5 tablets each time (including 3 tablets of study drug and 2 tablets of placebo), 3 times a day, a total of 2.7g per day. Take it with warm water half an hour before meals.
89135886|NCT05269173|Active Comparator|Active group(high dose group)|Take 5 tablets of the study drug each time, 3 times a day, a total of 2.7g per day. Take it with warm water half an hour before meals.
89135887|NCT05269173|Placebo Comparator|Control group|Take 5 tablets of the control drug (placebo) each time, 3 times a day, 2.7g a day. Take it with warm water half an hour before meals.
88802859|NCT02546856|Experimental|HF nurse up-titration|Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.
88802860|NCT03011515||LRTI patients|Patients with suspicion of LRTI, excluding episodes of COPD exacerbations
89135888|NCT05268809|Experimental|Ketogenic Diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies. Metabolic Meals will be delivered to KETO subjects' homes via courier, consisting of 3 meals a day plus snacks, targeting 70% fat, 20% protein, 10% carbohydrates.
89135889|NCT05268809|No Intervention|Diet as usual|The Diet As Usual (DAU) participants will be asked to maintain their current dietary habits and will be discouraged from starting new diets during the 4-week study.
89135890|NCT05267639|No Intervention|Comparator Baseline|The subject will wear their usual Microprocessor Knee (MPK) for 3 months, as well as in the lab to complete outcome measures.
89135891|NCT05267639|Experimental|Power Knee|The subject will wear the Ossur PK in place of their usual MPK for 3 months, as well as in the lab to complete outcome measures.
89135892|NCT05261399|Active Comparator|Chemotherapy|Pemetrexed (500 mg/m2) with either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles (Q3W) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) Q3W
88802861|NCT03011515||Non-infectious patients|Afebrile patients with no apparent infectious disease
88802862|NCT03011515||LRTI patients with COPD|Patients with suspicion of LRTI in a sub-group of patients with COPD
88802863|NCT03011437||cases|Patients who undergo esophagogastroduodenoscopy during 01/12/2016 and 31/12/2016 in the First People's Hospital of Kashgar Region.
89135893|NCT05261399|Experimental|Savolitinib + Osimertinib|300 mg savolitinib BID plus 80 mg osimertinib QD
89135894|NCT05254509|Active Comparator|Occupational Therapy (OT)|Subjects in this treatment group will receive outpatient occupational therapy geared towards people with chronic pain conditions. After obtaining consent, an occupational therapist will meet with the participant to begin their occupational therapy sessions targeted for those who have chronic pain. Additionally, subjects will complete online surveys administered by the therapist before and after each therapy session. There is a total of six 1-hour visits during the 3-month study duration involving occupational therapy. They will also receive online surveys every two weeks and will be asked to complete them at home.
89135895|NCT05254509|Experimental|Occupational Therapy + Virtual Reality (OT+VR)|Subjects in this treatment group will receive outpatient occupational therapy intervention geared towards people with chronic pain conditions followed by active, immersive virtual reality sessions. Participants in this treatment group will have 10-30minutes of usual care while receiving 10-30 minutes of virtual reality (e.g. exercises, games, and activities in the virtual world) during each study visit. Subjects will complete online surveys before and after each virtual reality session, along with debriefing from a therapist after each VR session to review what happened and why. Debriefing will include questions to obtain thoughts and narrative information about the participant's experience, as well as overall take-aways from the session. The therapist and subject will also watch a video recording of the subject's VR experience as a method to provide them feedback on their performance. Subjects will receive online surveys every two weeks and will be asked to complete them at home.
89135896|NCT05247463||Women invited to Breast Cancer Screening in England|Women invited to Breast Cancer Screening in England up to 31st March 2018
89135897|NCT05247463||Women attending Breast Cancer Screening in England|Women attending mammography screening to examine the effect of screening test threshold on outcomes, up to 31st March 2018
89135898|NCT05247424|Experimental|Early unfractionated heparin|Administration of UFH at a dose of 100 IU/kg body weight at first medical contact. Addition of UFH before coronary intervention according to ACT measurement after coronary angiography before coronary intervention.
88802864|NCT01151371|Experimental|narafilcon B daily disposable 4 weeks|narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks
88802865|NCT01151371|Active Comparator|nelfilcon A daily disponsable 1 week|nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week
88802866|NCT01151371|Active Comparator|lotrafilcon B daily wear, monthly replacement, 4-weeks|lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks
89135899|NCT05247424|No Intervention|Control - Unfractionated heparin for coronary intervention only|Control arm with administration of UFH at a dose of 100 IU/kg body weight after coronary angiography before coronary intervention.
89135900|NCT05230784|Experimental|HEPA Air Purifier|Air purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period.
89135901|NCT05230784|Placebo Comparator|EGAPA Air Purifier|Air purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period.
89135902|NCT05226637|Sham Comparator|Control group|"In addition to standard of care, with BoNTA injections, the randomly selected control group will be treated with a sham head to the flexor muscles of the upper extremity. The sham component made by the manufacturers is designed such that the internal pneumatic projectile is physically blocked from providing high energy impact with the contact surface, however the handset looks and sounds identical. In doing so, the sham head still actuates and makes the same sounds but produces no shockwave~ESWT will be apply on every candidate over the anterior region of the upper extremity injected with the BoNTA."
89135903|NCT05226637|Experimental|Experimental group with ESWT|"The randomly selected Study group will be comprised of patients who will receive the appropriate treatment with BoNTA in addition to actual ESWT (extra-corporeal shock wave therapy.~ESWT is an existing technology that uses a device that generates high intensity shockwaves. These shock waves are generated outside of the body (extra corporeal) but penetrate through the skin surface to underlying structures and tissue. ESWT has been historically used safely and for many years to treat common musculoskeletal (MSK) conditions.~For the purpose of the study these variables are standardized. We will treated with the Storz Duolith SD1 and we will use the D15 head 3000 number of shocks, 2.5 bar, 15 Hz over the same area of upper extremity described for the control group."
89135904|NCT05214365|Active Comparator|Conventional stimulation|An electrode (in the apical or septal portion) will be implanted at the discretion of the implanter physician. Parameters of (sensing, impedance and threshold) will be measured as is usually done in our center.
89135905|NCT05214365|Active Comparator|Physiological stimulation|Pacing the his-purkinje system.
89135906|NCT05214131|Experimental|gogoband alarm|patients will be assigned to the novel bedwetting alarm
89135907|NCT05214131|Active Comparator|standard nocturnal enuresis alarm (SNEA) group|this is the standard bedwetting alarm that is presently available through out the world
89135908|NCT05211180|Active Comparator|Vida Sana|Vida Sana is a cultural-adaption of Group Lifestyle Balance, a 12-month intervention that targets at least 5% weight loss and at least150 minutes per week of moderate-to-vigorous physical activity. Health coaches will facilitate 12 weekly 1-hour group education sessions, followed by nine 30-45 minute individual monthly phone sessions. Health coaches will also conduct two home visits (at baseline and 12-weeks post-enrollment). The health coach will review participant's fitbit health tracking data with them and give personalized feedback.
89135909|NCT05211180|Experimental|Vida Sana y Completa|Vida Sana y Completa is an obesity intervention with integrated treatment for food insecurity. This arm includes all the activities described for the active comparator arm (Vida Sana) as well as a weekly food box delivery for the first 12 weeks of the intervention. The food box will contain approximately 40 pounds of food including proteins and dairy, whole grains, and produce. Just like the Vida Sana active comparator arm, the Vida Sana y Completa group will include health coaches who will facilitate 12 weekly 1-hour group education sessions, followed by nine 30-45 minute individual monthly phone sessions. Health coaches will also conduct two home visits (at baseline and 12-weeks post-enrollment). The health coach will review participant's fitbit health tracking data with them and give personalized feedback.
89135910|NCT05199233|Experimental|Muse S™ Headband system for post-Covid Syndrome|Subjects will utilize the Muse S™ Headband system at least 4 times per week for a minimum of 10 minutes each time over a period of 3 months (12 weeks).
89135911|NCT05195411||Nephroblastoma with vena cava thrombosis|Children with nephroblastoma with vena cava thrombosis +/- atrial extension, cared between 1999 and 2019 in Parisian hospitals: Necker and Bicêtre.
89135912|NCT05184764|Experimental|AP-SA02|Anti-staphylococcal bacteriophage
89135913|NCT05184764|Placebo Comparator|Placebo|Inactive isotonic solution
89135914|NCT05183490|Experimental|Group A: Allogenic Stem Cell Transplant Recipient (SCT)|"Dose levels selected for Group A are based on previous experience with VST cells in HCT recipients and are lower than in Group B (SOT recipients), as donor-derived R-MVST cells are more likely to persist in recipients of HCT from the same donors. Thus, there is theoretically a higher risk for development of GVHD in this subset of patients. Each group will undergo independent dose escalation.~Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion."
89135915|NCT05183490|Experimental|Group B: Solid organ transplant recipients (SOT)|"In SOT recipients, the study will use higher doses of R-MVST cells, as the infused anti-viral T cells are less likely to persist long-term and cause GVHD, based on the safety profile of PyVST cells used for therapy of PML in non-HCT subjects.~Subjects will receive a single dose of R-MVST Cells, and followed for toxicity and GVHD for 28 days days after infusion. Up to two additional doses may be administered, minimum of 28 days apart if cohort safety is established and reinfusion criteria are met. A new 28-day safety-monitoring period will ensue for each additional infusion. Subjects will be followed for possible virological and clinical responses for up to 1 year after the initial R-MVST infusion."
89135916|NCT05180071|Experimental|TEMA elbow arthroplasty|
89135917|NCT05179447|Experimental|Molecular profile based treatment|Determination of the integrated genomic-pathologic profile to determine adjuvant treatment: observation for POLE-mutated profile; vaginal brachytherapy for intermediate profile; chemo-radiotherapy for p53-abnormal profile.
89135918|NCT05179447|Active Comparator|Radiotherapy|Adjuvant vaginal brachytherapy for intermediate risk (stage I A with G3 or stage I B with G1-2) and external beam pelvic radiotherapy for high-intermediate risk (stage I B with G3, or stage II) (standard treatment)
89135919|NCT05176197|Experimental|Almond Group|Participants will consume almonds every day for 16 weeks, but will not be allowed to consume any other nuts or nut products.
89135920|NCT05176197|Experimental|Control Group|Participants will consume pretzels every day for 16 weeks, but will not be allowed to consume any other nuts or nut products.
89135921|NCT05173675|Experimental|Program arm|"Usual Care+~Phase 1 (6 months, months 1-6), Program. Includes empathetic communications (phone & letter), health-promoting incentives, educational materials.~Phase 2 (6 months, months 7-12) No Program. During this follow-up period they will receive monthly SMS texts with customized messages encouraging health promoting behaviors."
89135922|NCT05173675|Other|Control arm|"Usual Care+~Phase 1 (6 months, months 1-6), No Program.~Phase 2 (6 months, months 7-12) Material components of program including health-promoting incentives and educational materials."
89135923|NCT05169957|Experimental|Ipilimumab + Nivolumab + Stereotactic Body Radiation Therapy (SBRT)|Liver SBRT following the second cycle of ipilimumab + nivolumab, which will then be continued up to 4 total cycles prior to subsequent maintenance nivolumab for duration of clinical benefit and tolerance (standard of care systemic therapy)
89135924|NCT05168020|Experimental|Safety Behavior Fading|"Participants will be asked to identify their five most common SBs from the SAFE. Participants will then be shown a sample checklist with instructions to fill it out. For the next 14 days, participants will receive the following text message Please remember to avoid using SBs you selected. As you drop them, you'll be able to go into social situations with greater confidence! with a link for their daily checklist to complete. Participants will be asked to rate how often they engaged in each SB over the past 24 hours"
89135925|NCT05168020|Active Comparator|Unhealthy Behavior Fading|"Participants will be asked to pick five unhealthy behaviors they engage in most often to decrease. Participants will then be shown the same sample checklist as the Safety Behavior Fading Group. For the next 14 days participants will receive the following text message Please try to remember to decrease your unhealthy behaviors. As you decrease them you will feel better, and you'll be able to go into social situations with greater confidence! with a link for their daily checklist to complete. Participants will be asked to rate how often they engaged in each Unhealthy Behavior over the past 24 hours."
89135926|NCT05162768|Experimental|Elamipretide|0.75 mL of 80mg/mL solution of elamipretide for a single daily SC dose of 60mg elamipretide
89135927|NCT05162768|Placebo Comparator|Placebo|0.75 mL of 80mg/mL solution of matching placebo for a single daily SC dose of 60mg
89135928|NCT05161832|Experimental|nocebo|Ultrasound with fake results of rotator cuff injury.
89135929|NCT05161832|Active Comparator|placebo|Ultrasound with fake results of the healthy rotator cuff.
89135930|NCT05155683|Active Comparator|Photobiomodulation|PBM with infrared LED application + sham ultrasound + muscle electrostimulation
89135931|NCT05155683|Active Comparator|low frequency ultrasound|LED sham PBM + LOFU + muscle electrostimulation
89135932|NCT05155683|Active Comparator|Combined treatment (PBM + LOFU)|Combined treatment (PBM + LOFU) + muscle electrostimulation
89135933|NCT05155683|Sham Comparator|Sham Treatment|Sham combined treatment + muscle electrostimulation
89135934|NCT05154305|Experimental|Children 6 months post acute treatment|children and adolescents between 6 months and 8 years post acute cancer treatment
89135935|NCT05137847||Remitoro|Participants with recurrent or refractory peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) will be administered with Remitoro 9 microgram per kilogram (mcg/kg), intravenous (IV) infusion, over 1 hour once daily for 5 consecutive days followed by 16 days withdrawal period in a 21 day cycle (up to maximum of 8 cycles). The dosage will be adjusted depending on the condition of the participant. All the participants will be observed for up to 24 weeks prospectively.
89135936|NCT05136898|Experimental|UGN-102|Patients will receive 6 once-weekly intravesical instillations of UGN-102. Treatment Visit 1 will occur at the investigative site and instillation will be performed by a qualified physician. Treatment Visits 2 to 6 will occur at the patient's home and instillation will be performed by a properly trained and qualified home health professional.
89135937|NCT05132166|Active Comparator|BAT|anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
89135938|NCT05132166|Experimental|DSC|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
89135939|NCT05122728||Concussed Cohort|Active duty Service Members and physically active civilians who have self-reported as asymptomatic post-concussion.
89135940|NCT05122728||Non-Concussed Cohort|Gender, age, occupation, and physical activity matched active duty Service Members and physically active civilians who have not sustained a concussion.
89135941|NCT05117918|Placebo Comparator|Traditional In-Person Clinic Visit Arm|Patients will receive overactive bladder (OAB) treatment as described in the Society for Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction (SUFU) OAB clinical care pathway. These patients will have all visits in-person
89135942|NCT05117918|Experimental|Telemedicine Arm|Patients will receive OAB treatment as described in the SUFU OAB clinical care pathway but all visits will be performed via telemedicine
89135943|NCT05103683|Experimental|Monotherapy Dose Finding - Part 1|TORL-1-23
89135944|NCT05103683|Experimental|Expansion as Monotherapy - Part 2|TORL-1-23
89135945|NCT05102162|Active Comparator|Continuous Antibiotic Dose Over 24 hours Arm|Subjects will be receiving a continuous dose of antibiotic prescribed by their doctor for the duration they choose.
89135946|NCT05102162|Active Comparator|Intermittent Antibiotic Dose Over 30 minutes|Subjects will be receiving an intermittent dose of antibiotic prescribed by their doctor for the duration they choose.
89135947|NCT05098080|Active Comparator|Hutrukin|At least six healthy subjects in each of the three dose cohorts (1000 mg, 3000 mg, and 5000 mg), will be administered Hutrukin.
89135948|NCT05098080|Placebo Comparator|Placebo|At least two healthy subjects in each of the three dose cohorts (1000 mg, 3000 mg, and 5000 mg), will be administered placebo.
89135949|NCT05058404|Experimental|Standard arm (A)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).~Patients randomized to Arm A will receive an induction immunochemotherapy at full doses (standard schedule).~After cycle 4, patients will be assessed for response and will complete their planned therapy if at least a stable disease is confirmed.~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
89135950|NCT05058404|Experimental|Experimental arm (B)|"Patients will start immunochemotherapy with one of the approved regimens (R-CHOP, R-Bendamustine, G-CHOP, G-Bendamustine, G-CVP).~Patients randomized to Arm B will start their induction treatment with 4 cycles of the immunochemotherapy standard dose chosen by the physician: after cycle 4, patients will be assessed for response and will proceed with subsequent treatment based on the quality of their response. Specifically:~Patients achieving a CR will receive a shortened treatment: in detail, they won't receive any further chemotherapy but will complete induction with 4 additional cycles of only the Monoclonal Antibody (MoAb) given during the first four cycles;~In case if response less than CR, (PR,SD), patients will complete treatment as planned for patients in Arm A.~At the end of induction responding patients (CR, PR) will be addressed to a standard anti-CD20 maintenance (1 dose every 8 weeks for two years) with the same Monoclonal Antibody (MoAb) given during induction."
88802867|NCT03011359|Experimental|1) Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
89135951|NCT05052905|Experimental|Study|Exercises
89135952|NCT05020535|Experimental|Experimental|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
89135953|NCT05020535|Placebo Comparator|Control|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
89135954|NCT05018377|Active Comparator|Raj'z catheter|
89135955|NCT05018377|Active Comparator|NAVI catheter|
89135956|NCT05016661|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
89135957|NCT05016661|Experimental|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles
89135958|NCT05000762||Patients with diabetes mellitus|Patients with type 2 diabetes mellitus
89135959|NCT04995198|Other|Participants with at least one germline pathogenic/likely pathogenic variant|
89135960|NCT04995198|Other|Participants with at least one variant of uncertain significance|
89135961|NCT04989725|Active Comparator|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
89135962|NCT04989725|Experimental|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
89135963|NCT04987489|Experimental|Etavopivat 400 mg daily - SCD with transfusions|Patients with sickle cell disease on chronic red blood cell transfusions
89135964|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia with transfusions|Patients with thalassemia on chronic red blood cell transfusions
89135965|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia|Patients with thalassemia not on chronic red blood cell transfusions
89135966|NCT04983849|Active Comparator|hydrogel metronidazole 25%|metronidazole hydrogel in adjunct to non surgical periodontal therapy
89135967|NCT04983849|Active Comparator|scaling and root planing|the only use of scaling and root planing
89135968|NCT04974398|Experimental|Group A|Group A (study group): Penpulimab plus cisplatin and gemcitabine
89135969|NCT04974398|Placebo Comparator|Group B|Group B (control group): Placebo plus cisplatin and gemcitabine
89135970|NCT04972955||Pregnant women diagnosed with gestational diabetes|Pregnant individuals who have been diagnosed with gestational diabetes during the current pregnancy
89135971|NCT04972682|Experimental|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|This arm includes patients with endometrioid adenocarcinoma of the endometrium of low- and intermediate-risk who will undergo a laparoscopic total hysterectomy and bilateral salpingo-oophorectomy with sentinel lymph node biopsy (SLNB) performed with near-infrared-guided surgery using indocyanine green (ICG).
89135972|NCT04972604||Duchenne and Becker muscular dystrophy|Individuals with Duchenne muscular dystrophy and Becker muscular dystrophy
89135973|NCT04972604||Carriers|Carriers of Duchenne muscular dystrophy and Becker muscular dystrophy
89135974|NCT04958889||HIV+ adults with recent COVID-19 diagnosis|"Required study visits:~Baseline questionnaire at enrollment or month 1.~Follow up questionnaire at month 1 and month 4~Height, weight, vital signs, and blood sampling at month 1 and month 4~Optional study visits:~• Follow up questionnaire at month 2, month 6, and month 12"
88802868|NCT03011359|Active Comparator|2) Optimizing B.I PCA mode|Optimizing Basal Infusion (New) PCA mode(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
89135975|NCT04958889||HIV- adults with recent COVID-19 diagnosis|"Required study visits:~Baseline questionnaire at enrollment or month 1.~Follow up questionnaire at month 1 and month 4~Height, weight, vital signs, and blood sampling at month 1 and month 4~Optional study visits:~• Follow up questionnaire at month 2, month 6, and month 12"
89135976|NCT04958889||HIV+ adults with no history of COVID-19|"Required study visits:~Baseline questionnaire at enrollment.~Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.~Height, weight, vital signs, and blood sampling at enrollment.~Optional study visits:~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
89135977|NCT04958889||HIV- adults with no history of COVID-19|"Required study visits:~Baseline questionnaire at enrollment.~Follow up questionnaire at enrollment and approximately 3 months after first follow up questionnaire.~Optional study visits:~• Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire."
89135978|NCT04956809|Active Comparator|Dapagliflozin 10mg|Active arm will be 6 weeks in duration, separated by a 2-week wash-out period.
88802869|NCT04713436||Triple antibiotic paste(TAP)|ciprofloxacin, metronidazole and minocycline
88802870|NCT04713436||Doble antibiotic paste(DAP)|ciprofloxacin and metronidazole
88802871|NCT04713436||Modified triple antibiotic paste(mTAP)|ciprofloxacin, metronidazole and cefaclor
89135979|NCT04956809|Placebo Comparator|Placebo|Placebo arm will be 6 weeks in duration, separated by a 2-week wash-out period.
89135980|NCT04949464|Experimental|Prevention (smoking cessation, nicotine replacement, LDCT)|Patients use the smartphone application, Positively Smoke Free - Mobile, for 42 days. Patients also receive nicotine replacement therapy for 12 weeks. Within 60 days of study registration, patients undergo LDCT.
89135981|NCT04946942|Experimental|Caregiver Checklist (CHEC)|CHEC is composed of two elements: 1) a checklist to identify the needs and concerns of unpaid/family caregivers who accompany older adults (aged 65+) to their primary care visits and 2) Tip Sheet for clinicians.
89135982|NCT04946942|Active Comparator|Usual care|Attendance at primary care appointments as usual.
89135983|NCT04925921|Experimental|Treatment|Treatment with the SR-1 Laser
89135984|NCT04915729|Experimental|tenecteplase|Treatment Group
89135985|NCT04915729|Active Comparator|alteplase|Active control group
89135986|NCT04914611||HBsAg Positive|Patients with chronic hepatitis B infection as defined by HBV surface antigen positive
89135987|NCT04911426|Experimental|Treatment plus telehealth|Individuals will receive telehealth support services, including seven brief motivational interviewing sessions, delivered by a licensed substance use counselor via live interactive video calls during the 12-week intervention.
89135988|NCT04901702|Active Comparator|(Arm A) ONI plus TAL|The phase I/II study will evaluate a treatment regimen; nanoliposomal irinotecan (nal-IRN, Onivyde) plus talazoparib (TAL)
89135989|NCT04901702|Active Comparator|(Arm B) ONI plus TMZ|The phase I/II study will evaluate a treatment regimen; Onivyde (ONI) plus temozolomide (TMZ)
89135990|NCT04901234|Active Comparator|Standard radiotherapy|Radiotherapy as planned at baseline, with replanning allowed only if significant weight loss or change in anatomy due to unforeseen circumstances (eg that would affect dosimetry and treatment delivery of baseline treatment plan). No adaptation to shrinking tumour is allowed.
89135991|NCT04901234|Experimental|Adaptive radiotherapy|Systematic radiation treatment plan adaptation according to the shrinking tumour on mid-treatment MRI.
89135992|NCT04899349|Experimental|Alpelisib + Fulvestrant + Dapagliflozin + Metformin XR|Alpelisib 300mg administered orally once daily starting at Cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants also received a combination treatment of dapagliflozin+metformin XR (as a single tablet or as two separate tablets, at the discretion of the investigator) at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily which could be titrated to a maximum dose of 10 mg dapagliflozin + 2000 mg metformin XR once daily.
89135993|NCT04899349|Active Comparator|Alpelisib + Fulvestrant + Metformin XR|Alpelisib 300mg administered orally once daily starting at cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants also received metformin XR 500mg orally once daily which could be titrated to a maximum dose of 2000 mg once daily.
89135994|NCT04891107|Experimental|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|
89135995|NCT04882527|Experimental|anodal stimulation of the rIFL|Anodal stimulation over the right inferior frontal lobe
89135996|NCT04882527|Experimental|cathodal stimulation of the rIFL|Cathodal stimulation over the right inferior frontal lobe
89135997|NCT04882527|Experimental|anodal stimulation of the lIFL|Anodal stimulation over the left inferior frontal lobe
89135998|NCT04882527|Experimental|cathodal stimulation of the lIFL|Cathodal stimulation over the left inferior frontal lobe
89135999|NCT04882527|Experimental|anodal stimulation of the rSPL|Anodal stimulation over the right superior parietal lobe
89136000|NCT04882527|Experimental|cathodal stimulation of the rSPL|Cathodal stimulation over the right superior parietal lobe
89136001|NCT04882527|Sham Comparator|sham stimulation|Sham stimulation over either of the three real stimulation areas
89136002|NCT04881617|Experimental|Lexical Retrieval Treatment|
89136003|NCT04881617|Experimental|Script Training|
89136004|NCT04871451|Experimental|ABP-450 - Between Low Dose and High Dose|ABP-450 Between Low Dose and High Dose - Intramuscular injections into affected neck muscles with investigator's determined dose within the range of low dose and high dose - 4 injection cycles at 3-month intervals.
89136005|NCT04866472|Other|Video Laryngoscope and GlideRite Ridgid Stylet|
89136006|NCT04866472|Experimental|Video Laryngoscope and TCI Articulating Introducer|
89136007|NCT04860960|Experimental|Experimental|Intravenous administration of 2000 mg/kg hydroxypropyl betacyclodextrin (Trappsol Cyclo) (based on body weight) diluted with 0.5N saline over at least 6.5 hours every 2 weeks
89136008|NCT04860960|Placebo Comparator|Placebo comparator|Intravenous administration of 0.5N saline over at least 6.5 hours every 2 weeks
88802872|NCT01151449|Experimental|Treatment (gamma-secretase/Notch signalling pathway inhibitor)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88802873|NCT02122952|Experimental|Cohort 1|6.7 X 10^13 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=3)
89136009|NCT04860960|Experimental|Open Label sub-study for Infants up to age 3|Up to 12 patients age 0 - 3 yrs in countries following EMA guidance may be enrolled in this open label sub-study. All patients will receive 2000 mg/kg hydroxypropyl betacyclodextrin (Trappsol Cyclo) diluted with 0.5N saline at the clinician's discretion over 6.5 hours every 2 weeks. Outcome measures are safety, clinician and caregiver impressions.
89136010|NCT04859764|Experimental|Reparel Sleeve Group|Reparel sleeve and corticosteroid injection
89136011|NCT04859764|Placebo Comparator|Placebo Sleeve Group|Placebo sleeve and corticosteroid injection
89136012|NCT04857502|Experimental|Diagnostic (99mTc-PSMA-I&S, SPECT/CT)|The first 5 patients receive an initial dose of undergo 99mTc-PSMA-I&S IV followed by 5 SPECT/CT scans at 3-5, 5-20, 17-21, 25-29, and 40-46 hours later. These 5 patients then receive a second dose of 99mTc-PSMA-I&S IV and then undergo standard of care surgery. All subsequent patients receive one dose of 99mTc-PSMA-I&S IV before standard of care surgery.
89136013|NCT04855422||Stable SPK recipients without rejection and/or BKV viremia|All SPK transplant recipients are monitored for routine labs twice a week first month, weekly at 2nd and 3rd month, every 2 weeks between 3-6 months, once a month between 6-12 months and then once every 2 months.
89136014|NCT04855422||Acute T-Cell Mediated Rejection (TCMR )|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
89136015|NCT04855422||Antibody Medicated Rejection (ABMR)|Kidney and pancreas transplant biopsies will be solely for clinically indicated for increased creatinine, amylase, lipase, blood sugar levels of more than 20% of the baseline, increased spot urine protein/creatinine ratio more than 1 gram/day, and development of donor-specific anti-HLA antibodies.
89136016|NCT04855422||BKV viremia|All patients will be monitored for BKV viremia monthly after transplantation up to 6 months and at 9, 12 and 24 months. Luminex SAB will be monitored at 1, 3, 12 and 24 months. Spot urine protein and creatinine and HbA1c will be monitored every 3 months after transplantation
89136017|NCT04855422||Follow-up of subjects with acute TCMR, ABMR and BKV viremia after treatment|BKV viremia, Luminex SAB, spot urine protein and creatinine is studied at the time clinically indicated biopsy and/o worsening kidney function and proteinuria.
89136018|NCT04848220|Experimental|Stage A (Dose Cohort 1) and Stage B (Dose Group 1)|
89136019|NCT04848220|Experimental|Stage A (Dose Cohort 2) and Stage B (Dose Group 2)|
89136020|NCT04848220|Placebo Comparator|Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)|
89136021|NCT04847479|Experimental|Self-Test kit distribution|Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to their close contacts.
89136022|NCT04847479|Active Comparator|Test referral distribution|Participants in the test referral arm receive text messages providing testing information to send to their close contacts.
89136023|NCT04843904|Experimental|Venetoclax|"Participants will be separated into two cohorts: Cohort A: Patients at low risk for TLS. Cohort B: Patients with both median and high risk for TLS.~Five (5) participants from cohort A will be initially enrolled, if these first 5 participants tolerate the accelerated ramp-up, cohorts A and B will enroll simultaneously.~All participants will be hospitalized and receive venetoclax daily with accelerated dose increases over 5 days to reach full dose. After reaching full dose, participants will be discharged and continue daily venetoclax at home.~Per doctor assessment, some participants may also receive rituximab or obinutuzumab as part of the treatment regimen with venetoclax.~Rituximab: Given every 28 days starting on the second study cycle and continuing for up to 6 cycles as per standard of care.~Obinutuzumab: Days 1, 2, 8, and 15 of cycle 1 and once every 28 days there after for up to 6 cycles as per standard of care."
89136024|NCT04814433|Experimental|Topical lidocaine and bupivacaine alone|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine
89136025|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin
89136026|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin and tranexamic acid|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid
89136027|NCT04814433|Experimental|Topical lidocaine and bupivacaine with thrombin and aminocaproic acid;|In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid
89136028|NCT04803084||Advanced Pathology|Breast magnetic resonance imaging (MRI) as a preliminary predictive biomarker for breast cancer treatment response.
89136029|NCT04797221||Veteran study group|The investigators will recruit approximately 20 Veterans who were identified as having elevated suicide risk while being treated in a VA Emergency Department.
89136030|NCT04788628|Experimental|Epilepsy inpatients|Epilepsy inpatients with implanted hippocampal electrodes and continuous scalp EEG monitoring
89136031|NCT04780932|Placebo Comparator|Control Arm|Oral Standard-of care riociguat from Day 1 to Week 42 (+/- 1 week). Posology 1mg tid - 2,5 mg tid. Oral Placebo 10 mg/day from Day 8 (+/- 3 days) to Week 42 (+/- 1 week). At week 16, subjects who are still symptomatic (WHO functional II to IV) and have PVR ≥ 240 dyn.sec.cm-5 will be offered additional treatment by BPA.
89136032|NCT04780932|Experimental|Experimental Arm|Oral Standard-of care riociguat from Day 1 to Week 42 (+/- 1 week). Posology 1mg tid - 2,5 mg tid. Oral Macitentan 10 mg/day from Day 8 (+/- 3 days) to Week 42 (+/- 1 week). At week 16, subjects who are still symptomatic (WHO functional II to IV) and have PVR ≥ 240 dyn.sec.cm-5 will be offered additional treatment by BPA.
89136033|NCT04767880|Experimental|Whey|Whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients). The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast in the women's own environment.
89136034|NCT04767880|Placebo Comparator|Placebo|The placebo will be ingested 30 min. prior to an OGTT (3 hours). The placebo will also be ingested 30 min prior to breakfast in the women's own environment.
89136035|NCT04752293||Hypertension Cohort|Participants with newly diagnosed primary hypertension
89136036|NCT04752293||Control Cohort|Healthy participants with normal blood pressure
89136037|NCT04745390|Active Comparator|Standard Dose Radiation|Patients in the standard arm will receive a standard dose of 2000cGy in 5 fractions using simple CT planning. IMRT is allowed. Treatment will be every second day excluding weekends and holidays.
89136038|NCT04745390|Experimental|Personalized Dose Selection Radiation|Patients in the experimental arm will receive individually selected prescription dose guided by radiobiological parameters described below, preferably delivered in 5 fractions every other day, excluding weekends and holidays. Volumetric-modulated arc therapy (VMAT) is the preferred planning technique. Typical planning uses 2 arcs, <=10MV and FFF mode where possible as almost all liver treatments are gated). In the event of multiple lesions, multiple isocentres are allowed. Often lateral isocentre shifts are significant and therefore arc ranges should be chosen to minimize collision risk. Treatment will be every second day excluding weekends and holidays.
89136039|NCT04743973|Experimental|Practicing Physicians|Practicing physicians at Mayo Clinic caring for patients during the COVID 19 pandemic will receive the Muse S™ Headband system, and will be asked to utilize it at least 4 times per week for a minimum of 10 minutes each time over a period of 3 months (12 weeks).
89136040|NCT04743804|Experimental|Ravulizumab|
89136041|NCT04743804|Placebo Comparator|Placebo|
89136042|NCT04741542|Experimental|Group A|Study subjects will receive a 14mg/kg starting dose of SP-420 three times a week
89136043|NCT04741542|Experimental|Group B|Study subjects will receive a 28mg/kg starting dose of SP-420 three times a week
89136044|NCT04741542|Experimental|Group C|Study subjects will receive a 42mg/kg starting dose of SP-420 three times a week
89136045|NCT04741542|Experimental|Group D|Study subjects will receive a 56mg/kg starting dose of SP-420 three times a week
89136046|NCT04739813|Experimental|Arm 1: Dose Escalation|Venetoclax (PO) 800mg at escalating doses (2 dose levels) on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at escalating doses (2 dose levels) on day 2 of each 21-day cycle (maximum 6 cycles) to determine MTD of polatuzumab and venetoclax
89136047|NCT04739813|Experimental|Arm 2: Dose Expansion|Venetoclax (PO) at the MTD days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at the MTD of each 21-day cycle (maximum 6 cycles)
89136048|NCT04730882||Healthy Control|Healthy subjects 18-35 years of age
89136049|NCT04730882||Type 1 Diabetes|People with type 1 diabetes (18-35 yrs) who have type 1 diabetes based on WHO diagnostic criteria for > 1 year
89136050|NCT04728217|Experimental|Patients receiving Efmoroctocog alfa|For long term prophylaxis, the recommended starting dose is 50 IU of factor VIII per kg body weight at intervals of 3 to 5 days. The dose may be adjusted based on patient response in the range of 25 to 65 IU/kg. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.
89136051|NCT04727008|Experimental|CXCR4 modified anti-BCMA CAR T cell therapy|CAR T cell therapy
89136052|NCT04725123|Experimental|Clostridioides difficile infection|Stool of patients with Clostridioides difficile infection that will be subject to microbiome analysis. Comparisons will be done between patients with favorable and unfavorable outcome
89136053|NCT04724044|Placebo Comparator|Placebo|These patients will be treated with 1 placebo tablet every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.
89136054|NCT04724044|Active Comparator|Clarithromycin|These patients will be treated with 1 tablet of 500 mg of clarithromycin every 12 hours and intravenously with ceftriaxone or one β-lactam/β-lactamase combination as part of standard of care therapy indicated by the summary of product characteristics and according to bibliographic references. The total duration of treatment will be seven days.The dose regimen of ceftriaxone will be 2g once daily. The β-lactam/β-lactamase combination can be either amoxycilln/clavulanate or ampicillin/sulbactam or piperacillin/tazobactam. These may be administered three or four times daily and the dose is adjusted according to renal clearance. In case urinary antigen for Legionella spp is positive and/or Mycoplasma pneumoniae spp is isolated in sputum culture and/or in BioFire Respiratory FilmArray, patients will receive intravenously 400mg of moxifloxacin instead of ceftriaxone as part of standard of care therapy according to bibliographic references.
89136055|NCT04722263|Experimental|Radiotherapy for patients with nonresectable keloids|Patients will be seen by a treating radiation oncologist and treatment with the assigned dose schedule will be planned using either EBRT with electrons or high dose-rate radiotherapy (HDR) brachytherapy as deemed appropriate by the treating radiation oncologist. The treatment dose of 15 Gy in 3 fractions will be prescribed to the 90% isodose line.
89136056|NCT04717817|Experimental|Group 1: experimental|Daily inspiratory muscle training (IMT) using an IMT Threshold device (Philips) prior to surgery
89136057|NCT04717817|Active Comparator|Group 2: comparator|Standard physiotherapy prior to surgery
89136058|NCT04714840|Other|Personalized exercise group (INTGroup)|Participants in this group have individually tailored exercise program with supervision, 20 weeks,clinic 3 times during the course of this study: at baseline (this appointment), at 4 months and 10 months from now for follow-up.
89136059|NCT04714840|Other|Generalized exercise group, Attention Control (AC Group)|Study participants in this group receive generalized exercise recommendations, 20 weeks,clinic 3 times during the course of this study: at baseline (this appointment), at 4 months and 10 months from now for follow-up.
89136060|NCT04707794||Elderly|Patients > 65 years age undergoing non-cardiac surgery will be administered general anesthesia maintained with sevoflurane or desflurane titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
89136061|NCT04704336|No Intervention|Self-directed without Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and provided standard of care.
89136062|NCT04704336|Experimental|With Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and will receive the task-shifting strategy for HTN control (TASSH) protocol.
89136063|NCT04702789|Experimental|Arm 1; Dorzolamide-timolol-brimonidine and latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
89136064|NCT04702789|Experimental|Arm 2; Dorzolamide-timolol and latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®|Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days).
89136065|NCT04702711||Patients with symptoms of generalized anxiety in primary health care|Patients (18 years or older) with symptoms of generalized anxiety at a primary health care center.
88802874|NCT02122952|Experimental|Cohort 2|2.0 X 10^14 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=12)
88802875|NCT01151761|Experimental|SBRT, Chemo and Liver Transplantation|The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU
88802876|NCT01196377|Active Comparator|Nebulized albuterol 10mg/hr continuous|Active control arm, 10mg/hr continuous.
88802877|NCT01196377|Experimental|10mg/hr pulsed|Experimental 10mg/hr pulsed albuterol regimen.
88802878|NCT01196377|Experimental|25mg/hr continuous|Experimental 25mg/hr continuous albuterol.
88802879|NCT01196377|Experimental|25mg/hr pulsed|Experimental 25mg/hr pulsed albuterol
88802880|NCT01152307|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
88802881|NCT01152307|No Intervention|Control|Group not receiving the decision aid (DVD/booklet)
88802882|NCT01235377|Active Comparator|Favor Chlorthalidone|Providers randomized to Favor Chlorthalidone will have agreed to prescribe chlorthalidone for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
88802883|NCT01235377|Active Comparator|Favor Hydrochlorothiazide|Providers randomized to Favor Hydrochlorothiazide will have agreed to prescribe hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
88802884|NCT01196533|Experimental|Non Invasive Monitoring|Intervention: Device: Non invasive peripheral blood monitoring
88802885|NCT02700308|Active Comparator|Conventional vertebroplasty|Conventional vertebroplasty (device's trade at the discretion of the investigator)
88802886|NCT02700308|Experimental|Kyphoplasty|Vertebroplasty with balloon placement and inflation prior to cement injection (device's trade at the discretion of the investigator)
88802887|NCT01196923|Experimental|HeartLight Ablation|
88802888|NCT00381160|Experimental|1|Provision of non-caloric beverages to home
88802889|NCT00381160|No Intervention|2|
88802890|NCT00985517|Experimental|Phase 1: Cohort 1|CERE-120 9.4 x 10^11 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
88802891|NCT00985517|Experimental|Phase 1: Cohort 2|CERE-120 2.4 x 10^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
88802892|NCT00985517|Experimental|Phase 2: CERE-120|CERE-120 2.4 x 10^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
88802893|NCT00985517|Sham Comparator|Phase 2: Sham Surgery|Neurosurgical procedure that mimics the procedure for CERE-120 delivery. No injections were administered during sham surgery.
88802894|NCT02451176|Active Comparator|Active Comparator: Davol Bard ®Soft Mesh|Device: Davol Bard ®Soft Mesh Synthetic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: synthetic mesh SoftMesh™ (CR Bard)
88802895|NCT02451176|Active Comparator|Active Comparator: LifeCell Strattice®|Device: LifeCell Strattice® Reconstructive Tissue Matrix Biologic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: Biologic mesh Strattice
88802896|NCT02696616|Experimental|BI 655088|
88802897|NCT02696616|Placebo Comparator|Placebo|
89136066|NCT04702711||Health care professionals|Health care professionals working with patients with symptoms of generalized anxiety in a primary health care center.
88802898|NCT02688140|Experimental|Arm A|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1 and 3, oral tretinoin twice daily on day 1-28 (max. up to day 60) and arsenic trioxide i.v. over 2 hours on day 5-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide i.v. over 2 hours on days 1-5 in week 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses."
88802899|NCT02688140|Active Comparator|Arm B (standard chemotherapy)|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1,3,5 and 7, oral tretinoin twice daily on day 1-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation I:~IDA 5 mg/m2 i.v. day 1-4 Ara-C 1000 mg/m2/3h i.v. day 1-4 ATRA 45 mg/m2 p.o. day 1-15~Consolidation II:~MTZ 10 mg/m2 i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15~Consolidation III:~IDA 12 mg/m2 i.v. day 1 Ara-C 150 mg/m2 every 8h i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15~Maintenance (duration 7 cycles = 2 years; one cycle lasts 106 days):~6-MP 50 mg/m2 p.o. Cycle 1-7: day 1-91 (followed by 15 days of ATRA on days 92-106)~MTX 15mg/m2 i.m./p.o. Cycle 1-7: once weekly for 91 days (followed by 15 days of ATRA on days 92-106)~ATRA 45 mg/m2 p.o. Cycle 1-6: day 92-106 Cycle 7: without ATRA Administration~(treatment break of 6-MP and MTX during ATRA administration)"
88802900|NCT04423536||tested group|
88802901|NCT04423536||controlled group|
88802902|NCT01027559|Active Comparator|Depressed Group: CBT|Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
88802903|NCT01027559|No Intervention|Healthy Control Group|Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.
88802904|NCT01027559|Active Comparator|Depressed Group: SRT|Depressed participants randomized to receive the antidepressant sertraline (SRT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
88802905|NCT05466084|Experimental|tissue glue|mesh fixed using tissue glue
88802906|NCT05466084|Experimental|metallic tackers|mesh fixed using metallic tackers
89136067|NCT04672044|Active Comparator|active rTMS+Exercise|active rTMS
89136068|NCT04672044|Sham Comparator|sham rTMS+Exercise|sham rTMS
89136069|NCT04668599||Patient with chronic lung or cardiac diseases|"This study will focus on patients with obstructive or restrictive lung diseases eligible for pulmonary rehabilitation.~Patient with cardiac disease such as heart failure, coronary artery disease or cardiomyopathies who are eligible for cardiac rehabilitation will also be included."
89136070|NCT04662905|Experimental|ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
89136071|NCT04659161|Experimental|KarXT|
89136072|NCT04659161|Placebo Comparator|Placebo|
89136073|NCT04642820|Experimental|Placebo Then Methamphetamine|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
89136074|NCT04642820|Experimental|MethamphetamineThen Placebo|Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
89136075|NCT04640766|Experimental|Participants with ADHD|
89136076|NCT04627727|Experimental|low FODMAP diet|
89136077|NCT04608656|Experimental|Intervention arm 1: Livestock feed only|Households in villages assigned to intervention arm 1 will receive a pre-defined amount of feed to maintain two tropical livestock units for a total of 60 days during the dry season (when animals would be moved away in search of pastures).
89136078|NCT04608656|Experimental|Intervention arm 2: 1. Provision of Livestock feeds, 2. Nutrition counselling|Households recruited into intervention arm two will receive livestock feeds similar to intervention arm 1 and will be enrolled in a nutritional education and counselling program through Infant and Young Child Nutrition (IYCF) feeding program and household food utilization. The IYCF program through the Baby Friendly Community Initiative (BFCI) will include the promotion of exclusive breastfeeding in the first six months, continued breastfeeding up to the age of two years, adequate complementary feeding, hygiene promotion and the uptake of child health services including immunization, treatment of illness, moderate and severe acute malnutrition and micro-nutrient supplementation.
89136079|NCT04608656|No Intervention|Control arm|The households recruited under this arm will receive none of the two study interventions. These households will receive identical assessment and data collection like other study households in the study. Their access to support through other interventions will be monitored. Households within the control arm will receive nutritional counselling and education given outside of the project. This is mainly at health facilities when mothers present for antenatal care or visit health facilities seeking healthcare. On some occasions in places where community health volunteers are present, nutritional counselling and education may be provided at the community level. The study instruments have been designed to collect information at the household level if such nutritional counselling and education has been provided.
89136080|NCT04605055|Experimental|Low Oxalate Diet Followed by High Oxalate Diet|Subjects will consume a low oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a high oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
89136081|NCT04605055|Experimental|High Oxalate Diet Followed by Low Oxalate Diet|Subjects will consume a high oxalate diet for four days, with blood collections on Days 1 and 4 and 24-hour urine collections on Days 3 and 4. A ten day wash out period will follow, during which participants will consume their normal diet. After the wash out period, subjects will consume a low oxalate diet for four days, with blood and 24-hour urine collections occurring again as described previously.
89136082|NCT04575337||AD group|Dementia is diagnosed according to the 2011 NIA-AA criteria.
89136083|NCT04575337||MCI group|aMCI diagnosed according to the criteria of 2004 Peterson.
89136084|NCT04575337||pre-MCI group|β-Amyloid positive or APOE ε4 carrier or complains of cognitive impairment; not up to MCI or cognitive impairment.
89136085|NCT04575337||Other neurodegenerative diseases|Frontotemporal Dementia; or Parkinson's disease
89136086|NCT04575337||Cognitive normal group|Individuals are with normal cognitive function and ≥ 60 years old.
89136087|NCT04526808|Experimental|FODMAP diet|
89136088|NCT04521699|Experimental|CalmioGo + Standard of care|Use of CalmiGO stress management device once daily + standard of care during the 12 weeks of Cardiac rehabilitation
89136089|NCT04521699|No Intervention|Standard of Care|Stand of care alone with 12 weeks of Cardiac rehabilitation
89136090|NCT04497116|Experimental|RP-3500 (camonsertib) alone|"Phase 1:~Multiple doses of RP-3500 (camonsertib) for oral administration alone"
89136091|NCT04497116|Experimental|Expansion cohorts with RP-3500 (camonsertib)|"Phase 2:~Expansion cohorts with RP-3500 (camonsertib)"
89136092|NCT04497116|Experimental|RP-3500 (camonsertib) with Talazoparib or Gemcitabine|"Phase 1:~Multiple doses of RP-3500 (camonsertib) for oral administration in combination with talazoparib or gemcitabine"
88802907|NCT00985829|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
88802908|NCT01661790|Experimental|Bevacizumab & Cisplatin|Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
88802909|NCT01661790|Active Comparator|Cisplatin|Cisplatin 30mg by intrapleural given every two weeks
89136093|NCT04495855||Visanne treatment|Patients from post-menarche to menopause with clinically or surgically diagnosed endometriosis, who have been prescribed Visanne
89136094|NCT04478422|Experimental|Muscle strengthening with vascular occlusion|Quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, with partial occlusion to blood flow. The occlusion equipment will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017).
89136095|NCT04478422|Active Comparator|Conventional muscle strengthening|Conventional quadriceps strengthening exercises will be performed in isometric, concentric and eccentric phases, without occlusion to blood flow.
89136096|NCT04474132|Other|single group|binary: positive or negative result
89136097|NCT04472897|Experimental|Part A: Participants receiving GSK2556286|Participants will be randomized to receive GSK2556286 in any of the 11 cohorts. In each dosing cohort, 6 participants will receive a single dose of GSK2556286. Following initial dosing of cohorts in the fasted state, one cohort will investigate the effect of food administration (high fat meal) on safety, tolerability and PK data of GSK2556286. One cohort may also investigate the effects of a moderate fat meal.
89136098|NCT04472897|Placebo Comparator|Part A: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 11 cohorts. In each dosing cohort, 2 participants will receive a single dose of matching placebo.
89136099|NCT04472897|Experimental|Part B: Participants receiving GSK2556286|"Participants will be randomized to receive GSK2556286 in any of the 4 cohorts. In each dosing cohort, 6 participants will receive repeat doses of GSK2556286 under either fasting or fed conditions, dependent on the results from Part A.~Appropriate doses and dose regimens for Part B will be selected by the Dose Escalation Committee based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B."
89136100|NCT04472897|Placebo Comparator|Part B: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 4 cohorts. In each dosing cohort, 2 participants will receive repeat doses of matching placebo under either fasting or fed conditions, dependent on the results from Part A.
89136101|NCT04471727|Experimental|HPN328 monotherapy dose escalation|HPN328 will be administered as a single agent once weekly via IV infusion during each 21 day cycle.
89136102|NCT04471727|Experimental|HPN328 monotherapy dose escalation with extended dosing intervals|HPN328 will be administered as a single agent, via IV infusion either once every 2 weeks (28-day cycle), or once every 3 weeks (21-day cycle).
89136103|NCT04471727|Experimental|HPN328 dose escalation in combination with atezolizumab|SCLC patients will be treated with a combination regimen of HPN328 and atezolizumab. HPN328 will be administered once every 2 weeks via IV infusion during each 28-day cycle. Atezolizumab will be administered once every 4 weeks via IV infusion on Day 1 of each 28-day cycle.
89136104|NCT04463979||Cerebellar Tumors|Thirty-three adult (≥18 years of age) patients with primary cerebellar tumors or metastatic tumors located in the cerebellum who will undergo surgery for tumor resection.
89136105|NCT04463979||Brain Tumors|Thirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison.
89136106|NCT04459468||HCC for Lipiodol TACE, denovo ablation, or Y90 radioembolization|These patients will receive standard of care Lipiodol TACE, denovo ablation, or Y90 radioembolization treatment. No research intervention is planned.
89136107|NCT04459468||Healthy controls|Healthy controls from public database
89136108|NCT04459468||HCC patients|HCC patients will be used for biomarker validation.
89136109|NCT04452396|Experimental|patients|patients undergoing CGM monitoring
89136110|NCT04448639||STEMI|Patients with ST-elevation myocardial Infarction (STEMI) (TS) who undergo urgent coronary angiography within 12 hours of symptom onset.
89136111|NCT04448639||TS|Patients with Takotsubo Syndrome (TS) who undergo urgent coronary angiography within 12 hours ofsymptom onset.
89136112|NCT04435756||Observational (blood collection)|Patients undergo collection of blood every 3-6 months for up to 3 years.
89136113|NCT04432285||Deep Brain Stimulation (GPi-DBS)|Patients with cervical dystonia (CD) who were operated at Oslo University Hospital between June 2004 and December 2017 with a DBS-device targeting the GPi bilaterally, and who have been treated with chronic GPi-DBS for a minimum of 3 years.
89136114|NCT04432285||Botulinum toxin treatment|CD patients who for a minimum of 3 years have received treatment with botulinum neurotoxin (BoNT) injections at regular intervals (minimum 12 injection cycles) and still are receiving them (Age- and gender matched to the GPi-DBS group)
89136115|NCT04430738|Experimental|Cohort 1A|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
89136116|NCT04430738|Experimental|Cohort 1B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
89136117|NCT04430738|Experimental|Cohort 1C|Tucatinib + trastuzumab + CAPOX given in 21-day cycles
89136118|NCT04430738|Experimental|Cohort 1D|Tucatinib + trastuzumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles and trastuzumab given every 21 days
89136119|NCT04430738|Experimental|Cohort 1E|Tucatinib + trastuzumab + pembrolizumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles, trastuzumab given in 21-day cycles, and pembrolizumab given in 42-day cycles
89136120|NCT04430738|Experimental|Cohort 1F|Tucatinib + trastuzumab + pembrolizumab + CAPOX. Tucatinib, trastuzumab, and CAPOX given in 21-day cycles and pembrolizumab given in 42-day cycles.
89136121|NCT04430738|Experimental|Cohort 1G|Tucatinib + trastuzumab + pembrolizumab. Tucatinib and trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
89136122|NCT04430738|Experimental|Cohort 2A|Tucatinib + trastuzumab + pembrolizumab + (FOLFOX or CAPOX). Either (1) tucatinib and FOLFOX given in 14-day cycles or (2) tucatinib and CAPOX given in 21-day cycles. Trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
89136123|NCT04430738|Experimental|Cohort 2B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles.
89136124|NCT04414774|Experimental|using app first|The experimental group will immediately start using the GGSI app, for a period of 15 days (T1). After 15 days (T2) the experimental group ceases its use of the app. The end of this period is marked T3. The research team will contact the experimental group on T1, T2 and T3 in order to fill out questionnaires regarding suicide ideation and related risk factors.
89136125|NCT04414774|Active Comparator|waiting list|During the first 15 days, the control group is inactive (T1). After 15 days (T2) the control group will start using GGSI app for additional 15 days (T3). Participants will fill questionnaires about suicide ideation and related risk factors three time during the study on: T1, T2 and T3.
89136126|NCT04407741|Experimental|SHR2554+ SHR1701|Drug: SHR2554 recommended dose from phase Ⅰstudy, PO, twice a day, every 3 weeks SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
89136127|NCT04407741|Experimental|SHR1701|Drug: SHR1701 30mg/kg IV over 30 minutes on day 1, every 3 weeks
89136128|NCT04405401|Active Comparator|Standard of care|Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
89136129|NCT04405401|Experimental|Experimental SABR arm|Definitive SABR to oligoprogressive lesions + continue current systemic therapy
89136130|NCT04401319|Sham Comparator|Sham Stimulation Group for Crossover Study (DLPFC + AG)|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) and on the angular cortex (AG) using a sham coil in the crossover study.
89136131|NCT04401319|Active Comparator|DLPFC Stimulation Group for Crossover Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the crossover study.
89136132|NCT04401319|Active Comparator|AG Stimulation Group for Crossover Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the crossover study.
89136133|NCT04401319|Sham Comparator|Sham Stimulation Group for Parallel Study (DLPFC + AG)|Sham stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or on the angular cortex (AG) using a sham coil in the parallel study.
89136134|NCT04401319|Active Comparator|DLPFC Stimulation Group for Parallel Study|Real stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil in the parallel study.
89136135|NCT04401319|Active Comparator|AG Stimulation Group for Parallel Study|Real stimulation will be delivered on the left angular cortex (AG) using a real coil in the parallel study.
89136136|NCT04398433|Experimental|INO-3107|Participants will be administered one INO-3107 intramuscular (IM) injection followed by electroporation (EP) using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9.
89136137|NCT04367766|Active Comparator|Immediate Implant Placement|prosthetically driven immediate implant placement (TLC implant, Straumann) with bone substitute (BioOss Collagen, Geistlich) filling the gap between the buccal socket wall and the implant surface and a collagen matrix (Fibrogide, Geistlich) positioning at the vestibular aspect to increase soft tissue volume, with immediate (non occlusal loading) prosthetic provisionalization.
89136138|NCT04367766|Active Comparator|Alveolar Ridge Preservation (ARP) + Delayed Implant Placement:|ARP performed with bone substitute (BioOss Collagen, Geistlich) and a collagen matrix placed to seal the socket entrance (Mucograft Seal, Geistlich). After 4 months of healing a prosthetically driven implant (TLC implant, Straumann) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm
89136139|NCT04367766|Active Comparator|Spontaneous Healing + Delayed Implant Placement|extraction socket will be left to heal spontaneously. After 4 months of healing a prosthetically driven implant (TLC implant, Straumann) will be placed with adjunctive GBR procedure with bone substitute (BioOss Collagen, Geistlich) and a collagen membrane (BioGide, Geistlich) if buccal bone will be < 2 mm, and soft tissue augmentation with a collagen matrix (Fibrogide, Geistlich) if soft tissue thickness will be < 2mm .
89136140|NCT04316559|Placebo Comparator|Placebo|Placebo capsule
89136141|NCT04316559|Experimental|TRV734|TRV734 at different doses vs. oxycodone for withdrawal suppression
89136142|NCT04301518|Experimental|PTB Prevention|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the PTB Prevention arm will receive the PreTRM® test results. If high risk, women will be consented to take part in the intervention. Those not higher risk will continue on with standard of care.
89136143|NCT04301518|No Intervention|Control|Approximately 6500 women will be screened, consented, and have the PreTRM® test sample collected. Randomization will occur 1:1 at each site. Those randomized to the Control arm will not receive the PreTRM® test results. Control arm subjects will continue on with standard of care.
89136144|NCT04267861||1|Medical records of subjects enrolled on NCI protocols 15-C-0179 and 18-C-0056
89136145|NCT04264702||Prospective arm|Patients who have undergone surgery for stage I to IV colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
89136146|NCT04264702||Control Arm|The control arm will consist of matched Stage I to Stage IV CRC cases using the following criteria: sex, age of diagnosis and ECOG performance prior to ACT, and a minimum of 3 evaluations per year. The patient cases would have a minimum of 2 years follow-up data and received treatment no more than 3 years prior to study start date.
89136147|NCT04258475|Experimental|Raltegravir-Calcium PK measure|"Period 1: Raltegravir 1200 mg alone; Period 2: Calcium carbonate antacid 500 mg and 1200 mg of raltegravir given concomitantly; Period 3: two tablets of calcium carbonate antacid 500 mg and 1200 mg of raltegravir given concomitantly.~Patients will have a total of 8 visits during the study. Day 1 visit: Raltegravir 1200 mg oral daily until day 7. Day 7 visit: Timed serial phlebotomy before dosing t(0) and 0.5, 1, 1.5, 2, 3, 4, 6 hours after observed dosing.~Day 8 visit: 24 h PK sampling followed by Raltegravir 1200 mg + Calcium carbonate 500 mg oral daily until day 14.~Day 14 visit: Timed serial phlebotomy before dosing t(0) and 0.5, 1, 1.5, 2, 3, 4, 6 hours after observed dosing.~Day 15 visit: 24 h PK Sampling followed by Raltegravir 1200 mg + Calcium carbonate 1000 mg oral daily until day 21.~Day 21 visit: Timed serial phlebotomy before dosing t(0) and 0.5, 1, 1.5, 2, 3, 4, 6 hours after observed dosing.~Day 22 visit: 24 h PK Sampling. Day 51 visit: Final safety visit."
89136148|NCT04254588||Phase I: Adult patients with abdominal pain|Adult patients with abdominal pain presenting to the MGH ED between February and March 2020.
89136149|NCT04254588||Phase II: Adult patients with abdominal pain|Adult patients with abdominal pain presenting to the MGH ED between July and December 2021.
89136150|NCT04212442|Experimental|Immediate Intervention|Upon enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
89136151|NCT04212442|Experimental|Wait-list Control|Two months after study enrollment, participants receive the adapted telephone-based intervention, the Independent Living Program for Affordable Housing, for two consecutive months.
89136152|NCT04191655|Experimental|High Definition White Light Colonoscopy|
89136153|NCT04191655|Active Comparator|Dye Spraying Chromo-colonoscopy|
89136154|NCT04188418|Experimental|Group I (shuttle walk test, FBT)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive FBT sublingually daily on days 6-19.
88802910|NCT00985907|Experimental|Doxil® + Melphalan + Velcade (DMV)|
89136155|NCT04188418|Experimental|Group II (shuttle walk test, morphine)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive morphine PO daily on days 6-19.
89136156|NCT04188418|Active Comparator|Group III (shuttle walk test, placebo)|Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive placebo (sublingually or PO) daily on days 6-19.
89136157|NCT04178174|Experimental|SABR boost and de-escalated chemoradiation|SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2.
89136158|NCT04178174|Active Comparator|Standard chemoradiation|The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2.
89136159|NCT04172012|Active Comparator|Probiotic|Study subjects receive probiotic mixture for 4 weeks
89136160|NCT04172012|Placebo Comparator|Placebo|Study subjects receive placebo mixture for 4 weeks
89136161|NCT04166721|Experimental|DKN-01 and atezolizumab|"DKN-01 is an intravenous medication which will be given at a variable dose during the Phase IIA safety run in phase of the trial (150mg, 300mg or 600mg IV q14d).~During the Phase IIB efficacy phase of the trial patients will be treated with DKN-01 at the safe and tolerated combination dose identified during the Phase IIA safety run in phase.~Atezolizumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 840mg on the first day of a two week cycle. (Day 1 q 14d) from cycle 2 onwards.~In the first cycle of treatment, patients will be treated with only DKN-01, and following this they will be treated with both DKN-01 and atezolizumab"
89136162|NCT04166331|Placebo Comparator|Control|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
89136163|NCT04166331|Experimental|Experimental|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min
89136164|NCT04164069|Experimental|Prevention (dasatinib, mFOLFOX, bevacizumab)|Patients receive oxaliplatin IV over 2 hours, leucovorin IV over 2 hours, fluorouracil slow IV push over 2-4 minutes followed by continuous infusion over 46 hours on days 1 and 15. Patients also receive dasatinib PO QD on days 14, 15, and 28 of cycle 1 and day 1 of cycle 2. Patients may receive bevacizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to cycle 3 day 1 in the absence of disease progression or unacceptable toxicity.
89136165|NCT04120246|Experimental|Treatment (alpha-TEA, trastuzumab)|Patients receive one of 4 doses of alpha-TEA PO on days 1-14 of each cycle. Patients also receive trastuzumab on day 1 of cycle 1 and then every 3 weeks per standard of care. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89136166|NCT04118972|Experimental|Functionality Mirror Exposure & Journal|"A text-based functionality gratitude journaling prompt three times weekly paired with three weeks of weekly functionality-based guided mirror exposure sessions in the lab (the IM FAB program)"
89136167|NCT04118972|Active Comparator|Pure Mirror Exposure & Gratitude Journal|Thrice weekly generic (non body-focused) gratitude text prompts and pure mirror exposure in the lab. Participants are not given instructions on how to examine body parts, only instructed to examine the same specific body parts as the Functionality group to control specifically for impacts of the body functionality focus.
89136168|NCT04118972|No Intervention|Assessment only control|Assessments at Week 1, Week 3, and 1- and 4-month follow-ups, identical to those received by participants in the active condition
89136169|NCT04118166|Experimental|Ipilimumab/nivolumab + cryotherapy|1 mg/kg with nivolumab 3 mg/kg every 3 weeks x 4 doses. (One cycle of treatment is 3 weeks). Cryotherapy (cryoablation) will be performed between investigational agent treatment Cycles 1 and 2
89136170|NCT04103749|Experimental|Exalt DScope 02|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
89136171|NCT04091464|Experimental|TRAIN-BW|1x/week for 8 weeks + home exercise program
89136172|NCT04091464|Active Comparator|TRAIN-FW|1x/week for 8 weeks + home exercise program
89136173|NCT04085250|Experimental|Nivolumab Consolidation|Patients in experimental group will receive Nivolumab consolidation (360 mg) via iv infusion Q3W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
89136174|NCT04085250|Active Comparator|Observation|Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
89136175|NCT04072315|Experimental|PLN-74809 Dose Level 1 (60 mg)|PLN-74809 Dose Level 1 (60mg)
89136176|NCT04072315|Experimental|PLN-74809 Dose Level 2 (80 mg)|PLN-74809 Dose Level 2 (80 mg)
89136177|NCT04072315|Experimental|PLN-74809 Dose Level 3 (120 mg)|PLN-74809 Dose Level 3 (120 mg)
89136178|NCT04072315|Experimental|PLN-74809 Dose Level 4 (240 mg)|PLN-74809 Dose Level 4 (240 mg)
89136179|NCT04072315|Experimental|PLN-74809 Dose Level 4 (320 mg)|PLN-74809 Dose Level 4 (320 mg)
89136180|NCT04065776|Experimental|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
89136181|NCT04063332||GROUP A|Absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
89136182|NCT04063332||GROUP B|Control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
89136183|NCT04063332||GROUP C|Patients with sepsis as defined by the Sepsis-3 classification criteria3
88802911|NCT00986453|Experimental|PlasmaBlade arm|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
89136184|NCT04060056|Other|Standardized breakfast|Egg (50g), whole-wheat bread (35g), celery (30g), and dried bean curd (10g)
89136185|NCT04060056|Other|Standardized snack|Tomato (50g) and skim milk (200g)
89136186|NCT04060056|Other|Standardized lunch|Rice (40g), oats (40g), shrimp (70g), lettuce (80g), lean pork (30g), carrot (10g), soaked auricularia auricula (20g), broccoli (80g), cucumber (10g), tomato egg drop soup (200g), salt (3g), and oil (8g)
89136187|NCT04043598|Active Comparator|high sodium infusion fluid|Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
89136188|NCT04043598|Active Comparator|low sodium infusion fluid|Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
89136189|NCT04043091|Experimental|percutaneous coronary intervention|stable obstructive coronary artery disease (coronary artery stenosis >70%) - percutaneous coronary intervention performed in all diseased segments until 300 mL of contrast reached; preferably with drug eluting stents; along with standard medical therapy
89136190|NCT04043091|No Intervention|standard of care|stable obstructive coronary artery disease (coronary artery stenosis >70%) - no intervention (revascularization), just standard medical therapy
89136191|NCT04039672|Experimental|Biopsy|Skin biopsy before BRAFi/MEKi treatment
89136192|NCT04034251|Experimental|Paclitaxel Intraperitoneal 20mg & Intravenous 80mg Every 3Weeks & Capecitabine 825mg/m^2 Twice Daily|Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine
89136193|NCT04034251|Experimental|Paclitaxel Intraperitoneal 60mg & Intravenous 80mg Every 3Weeks &Capecitabine 825mg/m^2 Twice Daily|Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine
89136194|NCT04034251|Experimental|Paclitaxel Intraperitoneal & Intravenous Every 3 Weeks & Capecitabine Twice Daily|Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine
89136195|NCT04022239|Experimental|Schedule I (non-lymphoma)|Patients receive fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo TBI on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal.
89136196|NCT04022239|Experimental|Schedule II (lymphoid malignancies)|Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8.
89136197|NCT03954990|Placebo Comparator|Control Arm|Placebo tablets oral, 4 tablets once.
89136198|NCT03954990|Active Comparator|Treatment Arm|Will receive 4 tablets (2g) of metronidazole oral once.
89136199|NCT03937011||Stratafix Arm|The single study arm would comprise of two different specialties in Robotic surgical procedures: Bariatric Sleeve gastrectomy (Staple line reinforcement) and Hysterectomy (Vaginal cuff closure).
89136200|NCT03882073|Experimental|Intervention group|Modified amputation procedure
89136201|NCT03882073|Active Comparator|Control group|Standard amputation procedure
89136202|NCT03879512|Experimental|Active vaccination arm|All patients receive depletion of regulatory T cells, reoperation, followed by a personalized cancer vaccine and double checkpoint blockade.
89136203|NCT03878342|Active Comparator|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
89136204|NCT03878342|Experimental|No Radiotherapy|No Irradiation- Active surveillance
89136205|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
89136206|NCT03877276|Experimental|5d Diet+Spinach Smoothie+Breakfast|5 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
89136207|NCT03877276|Experimental|3d Diet+Kale Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On the final day, participants will return to the study site and drink a prepared kale smoothie and be provided a breakfast meal.
89136208|NCT03877276|Experimental|3d Diet+V Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie with varying amounts of spinach and be provided a breakfast meal.
89136209|NCT03877276|Experimental|3d Diet+Blended Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended smoothie and be provided a breakfast meal.
89136210|NCT03877276|Experimental|3d Diet+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and be provided a breakfast meal.
89136211|NCT03877276|Experimental|3d Diet+Sodium Oxalate Drink+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared sodium oxalate drink and be provided a breakfast meal.
89136212|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast w/ 24 Hr Urine|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a blended spinach smoothie and be provided a breakfast meal.
89136213|NCT03873389||Ocrelizumab|All participants enrolled in the study. All participants will be receiving the treatment of interest (Ocrelizumab)
89136214|NCT03861494|Other|Enhanced Stroke Education|This group of participants will receive enhanced education provided by the Stroke Coordinator at the time of discharge. The enhanced education session will last 30 minutes with the participant.
89136215|NCT03861494|Other|Usual Stroke Education|This group of participants will receive the usual stroke education provided by the usual Neuroscience Registered Nurse throughout the hospitalization and at the time of discharge.
89136216|NCT03860857|Experimental|Age 60-65 ApoE e4+|Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136217|NCT03860857|Experimental|Age 66-70 ApoE e4-|Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136218|NCT03860857|Experimental|Age 66-70 ApoE e4+|Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136219|NCT03860857|Experimental|Age 71-75 ApoE e4-|Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136220|NCT03860857|Experimental|Age 71-75 ApoE e4+|Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136221|NCT03860857|Experimental|Age 76-80 ApoE e4-|Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136222|NCT03860857|Experimental|Age 76-80 ApoE e4+|Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136223|NCT03860857|Experimental|Age 81+ ApoE e4-|Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136224|NCT03860857|Experimental|Age 81+ ApoE e4+|Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
89136225|NCT03847428|Experimental|Arm A|Durvalumab 1120 mg (Q3W) + bevacizumab 15 mg/kg (Q3W)
89136226|NCT03847428|Experimental|Arm B|Durvalumab 1120 mg (Q3W) + bevacizumab placebo (Q3W)
89136227|NCT03847428|Placebo Comparator|Arm C|Durvalumab placebo (Q3W) + bevacizumab placebo (Q3W)
89136228|NCT03845504|Experimental|Open Label|Open-label rTMS sessions will occur within ~2 days after the baseline session with daily sessions delivered to left DLPFC over 2-6 weeks.
89136229|NCT03844672|Experimental|Low Concentration / Low Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a low power for three weeks.
89136230|NCT03844672|Experimental|Low Concentration / High Power|Participant will receive an e-liquid with a low nicotine concentration and an e-cigarette with a high power for three weeks.
89136231|NCT03844672|Experimental|High Concentration / Low Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a low power for three weeks.
89136232|NCT03844672|Experimental|High Concentration / High Power|Participant will receive an e-liquid with a high nicotine concentration and an e-cigarette with a high power for three weeks.
89136233|NCT03840421|Experimental|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
89136234|NCT03840421|Active Comparator|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
89136235|NCT03840226|Active Comparator|Magnesium|oral magnesium oxide tablets [Magnox 520 TM (magnesium oxide monohydrate, 520 mg/day of elemental magnesium), Naveh Pharma, Israel]
89136236|NCT03840226|Placebo Comparator|Placebo|Placebo tablets
89136237|NCT03822351|Experimental|Control Arm (Durvalumab monotherapy)|durvalumab IV
89136238|NCT03822351|Experimental|Arm A (durvalumab + oleclumab):|durvalumab IV and oleclumab IV
89136239|NCT03822351|Experimental|Arm B (durvalumab + monalizumab)|durvalumab IV and monalizumab IV
89136240|NCT03819712|Experimental|No recurrent UTI|Healthy female volunteer aged 18 to 28 years reporting a single cystitis since the age of 14 years
89136241|NCT03819712|Experimental|Recurrent UTI|
89136242|NCT03810794|Experimental|Acupuncture Treatment Group|Participants in this group will be given acupuncture treatment in combination with donepezil for 12 weeks.
89136243|NCT03810794|Active Comparator|Donepezil Group|Participants in this group will be given only donepezil for 12 weeks.
89136244|NCT03804905|Experimental|No-cost Medications|Eligible patients of physicians allocated to the no-cost medications arm will receive free medications through Trillium Health Partners outpatient pharmacy.
89136245|NCT03804905|No Intervention|Usual care|Eligible patients of physicians allocated to the usual care arm will continue to access their medications through self-pay or other mechanisms.
89136246|NCT03784911||During Cancer Treatment Group|Participants' body composition will be estimated using a SOZO device at 5 different time points across their cancer treatment. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, cancer distress assessment, ECOG performance status, hand grip strength test, and 24-hour food recall. DEXA scans will be performed before treatment and after completion of treatment.
89136247|NCT03783429|Active Comparator|Intervention group|The intervention group will receive low-dose digoxin
89136248|NCT03783429|Placebo Comparator|Placebo group|The placebo group will receive a matching placebo
89136249|NCT03778294|Experimental|Treatment (18F-DOPA, PET/MRI, PET/CT, temozolomide)|Patients receive 18F-DOPA IV and undergo PET/MRI or PET/CT imaging scan. Patients then receive proton beam radiotherapy over 5 or 10 consecutive days excluding weekend and standard of care temozolomide on days 1-7 or 1-14. Beginning cycles 2, patients receive standard of care temozolomide on days 1-5. Cycles with temozolomide repeat every 28 days for up to 7 cycles in the in the absence of disease progression or unacceptable toxicity.
89136250|NCT03759431|Experimental|Vocal-cord Radiotherapy|
89136251|NCT03759431|Active Comparator|Complete Larynx Radiotherapy|
89136252|NCT03752619|Experimental|Contraction Producing Peripheral Nerve Stimulation|This group will receive: 1) muscle contraction producing peripheral nerve stimulation treatment (which will produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
89136253|NCT03752619|Active Comparator|Non Contracting Producing Peripheral Nerve Stimulation|This group will receive: 1) non contraction producing peripheral nerve stimulation treatment (which will not produce muscle contraction) for three weeks (6 hours daily); and, 2) physical therapy.
89136254|NCT03749421||Prosigna Assay|"Biopsy specimen will be subject to molecular profiling via the Prosigna PAM-50 assay~The results of Prosigna assay will be provided to the study team in a standardized report.~This report will include the patient's intrinsic subtype, ROR score, and general risk (high, intermediate, low)."
89136255|NCT03734601|Experimental|TBI+TLI|TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)
89136256|NCT03731000|Experimental|PHIL® device|Using device
89136257|NCT03697031||REKOVELLE®|Follitropin Delta
89136258|NCT03690401||Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed before treatment and after completion of treatment. Moving On assessments will be performed at first and last study visits.
89136259|NCT03690401||Non-Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed at first and last study visits.
89136260|NCT03687086|Experimental|Program A|cognitive behavioral therapy type A plus medications in packaging type A
89136261|NCT03687086|Active Comparator|Program B|cognitive behavioral therapy type B plus medications in packaging type B
89136262|NCT03683940|Other|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening.
89136263|NCT03662542|Experimental|Combination Therapy|Participants will receive guselkumab Dose 1 as intravenous (IV) infusion and Dose 2 as subcutaneous (SC) injection; and golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
89136264|NCT03662542|Experimental|Monotherapy: Guselkumab|Participants will receive guselkumab Dose 1 as IV infusion, Dose 2 as SC injection and placebo to maintain the blind.
89136265|NCT03662542|Active Comparator|Monotherapy: Golimumab|Participants will receive golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
89136266|NCT03660670|Experimental|Interventional Arm|Application of the ONCORAL program of multidisciplinary ONCOlogic interventions between town and hospital (doctor-pharmacist-nurse) for ambulatory patients under oRAL anticancer drugs
89136267|NCT03660670|Sham Comparator|Standard of care|Patients in the control group will receive regular follow-up from their oncologist, but no more that the standard care.
89136268|NCT03660553|Active Comparator|Multiple Subcutaneous Injection (MSI)|MSI group will receive four insulin injections per day that will include a long acting and a short acting insulin. Short acting insulin will be either insulin aspart or insulin lispro.
89136269|NCT03660553|Experimental|Basal Insulin (BI)|BI group will receive only one injection of insulin glargine in the morning.
89136270|NCT03655574|Experimental|Motivational + Family Check-up (MET+FCU)|"The MET individual session covers three constructs; 1) intentions to use marijuana; 2) normative beliefs about peer substance use; and 3) attitudes towards peer substance use. These same three constructs are also addressed with respect to truancy. In addition, motivation to abstain from substance use is discussed.~The FCU session with teens and parents/caregivers begins by collecting self-report measures and conducting a videotaped Family Assessment Task (FAsTask) to assess parent-teen interactions. The FAsTask is the basis of FCU feedback. There are four specific phases of the feedback session: 1) Self-assessment, 2) Support and clarification, 3) Feedback, and, 4) Action plan."
89136271|NCT03655574|Placebo Comparator|Psychoeducation|An interventionist will review a set of educational materials with the parents regarding teen marijuana use, effects of marijuana on the brain, body and behavior, risks associated with marijuana use, how to tell if a teen is engaging in marijuana use or truancy, and parenting skills. A comparable set of materials will be reviewed with the adolescent.
89136272|NCT03654989|Experimental|Treprostinil iontophoresis|"Gel of treprostinil 1 mg/mL (target concentration)~Part 1: 1 administration/day, on separate days, with 72h between two doses. Ascending doses are 0.025 mg/mL, 0.05mg/mL, 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.7 mg/mL, and 1 mg/mL. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~Part 2: 1 administration/day at the maximum tolerated dose (MTD) for 10 days; dressing will be changed by a trained nurse every 2 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
89136273|NCT03654989|Placebo Comparator|Remodulin® Placebo iontophoresis|Placebo will be made from the placebo of Remodulin® incorporated into hydrogel (Suprasorb® G). The route and frequency of administration will be the same as for the investigational drug (topical administration by iontophoresis).
89136274|NCT03654989|No Intervention|Standard care|subjects randomized to the standard of care group (no iontophoresis) will only undergo standard blood test at visit 0 or 1, unless tests <1 month before inclusion are available This group is not double blind Standard care consists on debridement and dressings
89136275|NCT03638375|Experimental|Treatment with nivolumab plus TIL|"In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
88802912|NCT00986453|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
89136276|NCT03638375|Experimental|Treatment with Nivolumab plus TIL and IFN-alpha|"In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.~IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
89136277|NCT03635333|Experimental|Low nicotine, tobacco|6 mg nicotine combined with tobacco flavored e-juice
89136278|NCT03635333|Experimental|Low nicotine, menthol|6 mg nicotine combined with menthol flavored e-juice
89136279|NCT03635333|Experimental|Low nicotine, strawberry|6 mg nicotine combined with strawberry flavored e-juice
89136280|NCT03635333|Experimental|High nicotine, tobacco|18 mg nicotine combined with tobacco flavored e-juice
89136281|NCT03635333|Experimental|High nicotine, menthol|18 mg nicotine combined with menthol flavored e-juice
89136282|NCT03635333|Experimental|Hign Nicotine, strawberry|18 mg nicotine combined with strawberry flavored e-juice
89136283|NCT03617666|Experimental|Avelumab|Patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles
89136284|NCT03582748||New surgical subjects|This group will be consist of 150 consecutively consented subjects who are scheduled to have sleeve gastrectomy at the Hartford Hospital Surgical Weight Loss Center.
89136285|NCT03582748||Carry over surgical subjects|This group will include 45 subjects who participated in the pilot study and who will be contacted and consented into the present study.
89136286|NCT03582748||Non-surgical subjects|This group will include 15 non-surgical patients who will be group-matched to Group A on pertinent characteristics. These patients will be non-surgical in that they will have been evaluated for bariatric surgery by the SWLC but deemed ineligible for any of a number of reasons.
89136287|NCT03581500|Experimental|Diagnostic (hyperpolarized carbon C 13 pyruvate MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and undergo MRSI over 2-3 minutes at 6 and 8 weeks.
89136288|NCT03571945|Active Comparator|BIS Guided Group|GA will be monitored and controlled with Bi-spectral index (BIS) monitoring.The anaesthesiologist will be blinded to ETAG and MAC readings.
89136289|NCT03571945|Active Comparator|ETAG Guided Group|GA will be monitored and controlled with end-tidal anaesthesia gas (ETAG) monitoring.The anaesthesiologist will be blinded to the BIS readings.
89136290|NCT03555591||Trelagliptin 100 mg|Trelagliptin 100 mg tablet, orally, once weekly for up to 36 months. Participants received interventions as part of routine medical care.
89136291|NCT03552692|Experimental|ARM1 - Venetoclax (ABT-199)|"Venetoclax (ABT-199) will be administered orally at the dose of 800 mg once daily.~Response evaluation will be performed initially after 3 cycles from the beginning of treatment with ABT-199 and then every 3 cycles during the first 12 cycles, every 4 cycles from cycle 13 to 24; for those patients still on therapy after 24 cycles, the response evaluation, after this time, will be performed every 6 cycles."
89136292|NCT03541902|Experimental|Group 1 (cabozantinib)|Participants receive cabozantinib PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89136293|NCT03541902|Experimental|Group 2 (sunitinib malate)|Participants receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89136294|NCT03525691|Experimental|Minimal distension|Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
89136295|NCT03525691|Experimental|Maximal recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
89136296|NCT03525691|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)
89136297|NCT03525392|Experimental|177Lu-3BP-227|"Screening: 177Lu-IPN01087 - 25 µg 3BP-227 (IPN01087) per 1 GBq of 177Lu. 1 GBq in a total volume of 10 mL.~Treatment phase: 177Lu-IPN01087 - 2.5 to 7.5 GBq escalation dose of 177Lu-3BP-227 (IPN01087) in a total volume of 20 mL for each cycle of administration (2 cycles plus 4 optional additional)."
89136298|NCT03522142|Experimental|INCB081776|Single-agent INCB081776.
89136299|NCT03522142|Experimental|INCB081776 + INCMGA00012|INCB081776 in combination with INCMGA00012.
89136300|NCT03510091|Experimental|Video-Assisted Counseling|Patients receiving video-assisted counseling
89136301|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength light therapy
89136302|NCT03496662|Experimental|Part A - Experimental Dose Level 0|"BMS-813160 300 mg twice per day~Nivolumab 30-minute intravenous (IV) infusion at a flat dose of 480 mg on Day 1 of each 28-day cycle~Gemcitabine 30-minute IV infusion 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Nab-paclitaxel 30-40-minute IV infusion 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Post-treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cyclesore cycles"
89136303|NCT03496662|Active Comparator|Part A - Control (chemotherapy only)|"Gemcitabine 30-minute IV infusion 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle Nab-paclitaxel 30-40-minute IV infusion 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Post treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
89136304|NCT03496662|Experimental|Part B - Dose expansion|"BMS-813160 300 mg twice per day~Nivolumab 30-minute IV infusion at a flat dose of 480 mg on Day 1 of each 28-day cycle~Gemcitabine 30-minute IV infusion 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Nab-paclitaxel 30-40-minute IV infusion 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle~Post-treatment biopsy at the end of cycle 2~Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles"
89136305|NCT03480698||Cerebrolysin and standard stroke care|
89136306|NCT03480698||Standard stroke care|
89136307|NCT03472885|Experimental|Group 1: 100 mg Danicopan TID + Eculizumab|Starting dose of 100 mg danicopan TID in combination with eculizumab.
89136308|NCT03472885|Experimental|Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab|Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.
89136309|NCT03472885|Experimental|Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab|Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.
89136310|NCT03472885|Experimental|Group 4: Optimal Dose of Danicopan TID + Eculizumab|Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.
89136311|NCT03450005||emerging Candida isolates|Web-based registry of invasive infections by Candida species
89136312|NCT03440385|Experimental|Administration of oral Ozanimod|
89136313|NCT03440385|Placebo Comparator|Administration of Placebo|
89136314|NCT03437486||Familial Pulmonary Fibrosis|Subjects asked to participate in this study will be unaffected family members of patients previously diagnosed with familial interstitial pneumonia (FIP) which is the familial form of idiopathic pulmonary fibrosis (IPF).
89136315|NCT03425266|Experimental|Interactive decision support tool|Online interactive multimedia decision support tool that the patient interacts with before seeing their provider that helps them learn more about chronic pain, identify treatment goals and preferences, and communicate more effectively with their provider. The tool takes between 20-45 minutes to use. It generates and transmits a preference summary for the patient and a summary of relevant shared decision making elements and medical history elements intended for sharing with providers if the patient chooses.
89136316|NCT03425266|No Intervention|Control|Our control arm is a leading consumer-facing website designed for people with chronic pain (the ACPA). Subjects randomly assigned to this arm will be directed to the page focusing on communication tools, which also includes links to other parts of the website. The specific page is: https://theacpa.org/Communication-Tools
89136317|NCT03424525|Experimental|Biodistribution|The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
89136318|NCT03424525|Experimental|Dynamic|The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
89136319|NCT03424330|Experimental|Arm1 - ReX first|Subjects begin with the ReX-C Intervention stage followed by Standard of Care stage.
89136320|NCT03424330|Experimental|Arm 2- Standard of Care first|Subjects start with Standard of Care stage followed by ReX-C Intervention.
89136321|NCT03404388|Experimental|Experimental|Balance Training
89136322|NCT03374319|Experimental|Intervention group|Modified amputation procedure
89136323|NCT03338192||African American/Black QST|This group will consist of a full range of socioeconomic status in African American/Black individuals with chronic low back pain.
89136324|NCT03338192||Caucasian/White QST|This group will consist of a full range of socioeconomic status in Caucasian/White individuals with chronic low back pain.
89136325|NCT03289299|Experimental|Arm A|Non-high dose treatment in 3 phases Induction 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Consolidation 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Maintenance 12 cycles: lenalidomide, daratumumab
89136326|NCT03286166||Study arm|"20 subjects will undergo one session of PRP in which 60 cc of blood is drawn and centrifuged into 3 months of autologous serum tears.~• Subjects will utilize autologous tears twice daily in the study eye."
89136327|NCT03286166||Control Arm|Subjects in the control arm will receive study vehicle to be used twice daily in the left eye.
89136328|NCT03246126|Experimental|Primary Arm: Treatment with Valiant Thoracoabdominal Stent Graft System|The implantation of the Valiant Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance.
89136329|NCT03246126|Experimental|Expanded Use Arm: Treatment with Valiant Thoracoabdominal Stent Graft System|The implantation of the Valiant Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance.
89136330|NCT03240627|Experimental|LH-8 cutaneous solution|LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp:
89136331|NCT03240627|Placebo Comparator|Placebo cutaneous solution|Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp:
89136332|NCT03217110|Experimental|patient active rTMS|Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.
89136333|NCT03217110|Sham Comparator|patient sham rTMS|Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.
89136334|NCT03217110|Active Comparator|Control active rTMS|
89136335|NCT03217110|Sham Comparator|Control sham rTMS|
89136336|NCT03213990|Other|Continuous Infusion|The prescribed Beta-lactam is administered by a continuous infusion.
89136337|NCT03213990|Other|Intermittent infusion|the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes
89136338|NCT03169881|Experimental|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC)
89136339|NCT03169881|Placebo Comparator|Placebo|Equal volume normal saline for IV administration, or sham dosing
89136340|NCT03167437|Experimental|1|participants will receive Vorinostat 100mg PO BID for 12 weeks
89136341|NCT03167437|Experimental|2|participants will receive Vorinostat 100mg PO BID for 6months
89136342|NCT03167437|Active Comparator|3|participants will receive ustekinumab (weight base induction dose followed by 90mg SC every 8 weeks for 24 months)
89136343|NCT03160859|Other|Control Method|One arm of the study will include unsedated colonoscopy with water exchange (WE) as the control method. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
88802913|NCT02085980|Experimental|Laser Treatment|Laser Treatment
89136344|NCT03160859|Other|Study Method|The other arm will include unsedated colonoscopy with water exchange (WE) and the addition of a simple commercially available accessory to the colonoscopy device: a cap (Disposable Distal Attachment, Olympus Medical Systems Corp., Tokyo, Japan) fitted to the colonoscope per manufacturer instruction. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
89136345|NCT03121261|Experimental|0.5% levobupivacaine with 0.015% clonidine|0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block
89136346|NCT03121261|Active Comparator|0.5% levobupivacaine with 0.9% saline|0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block
89136347|NCT03117049|Experimental|ONO-4538 group|"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
89136348|NCT03117049|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
89136349|NCT03113617|Experimental|Diagnostic (68Ga-RM2 PET/CT)|Patients receive 68Ga-RM2 IV. Within 45-60 minutes, patients undergo a PET/CT scan. Patients may undergo a second PET/CT scan immediately after the first scan for attenuation correction. Patients may undergo also a repeat 68Ga-RM2 PET/CT scan after the completion of their treatment to evaluate response to therapy, if requested by the treating physician.
89136350|NCT03080896|Active Comparator|control group videolaryngoscope/preformed stylet|The control group will intubate using the video-laryngoscope / pre formed stylet. Will convert to using video-laryngoscope and fiber-optic bronchoscope (aScope III) if failure to intubate occurs
89136351|NCT03080896|Experimental|Interventional Group videolaryngoscope/fibeoptic bronch|The interventional group will Intubate using the video-laryngoscope and the fiber-optic bronchoscope (aScope III)
89136352|NCT03073512|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 32 weeks gestation.
89136353|NCT03069183|Active Comparator|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
89136354|NCT03069183|Placebo Comparator|Normal Saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
89136355|NCT03057717|Other|Ultrasound|All participants in the study will have fetal thymus size measured using ultrasound.
89136356|NCT03047395|Experimental|Risankizumab|Participants will receive risankizumab administered by subcutaneous injection.
89136357|NCT03044483||18-34 year olds|Healthy adults aged 18-34 years old
89136358|NCT03044483||35-54 year olds|Healthy adults aged 35-54 years old
89136359|NCT03044483||55 and over year olds|Healthy adults aged 55 years old and over
89136360|NCT03027102|Experimental|Patient Arm|Patients will receive DNT cells from healthy donors.
89136361|NCT03027102|No Intervention|Donor Arm|Healthy volunteer donors will donate blood.
89136362|NCT02972801||Testicular tissue biopsy|Testicular biopsy
89136363|NCT02970214||Heart Failure|Patients with chronic heart failure and with/without reduced left ventricular ejection fraction (EF) at baseline (HFrEF, HFmrEF, HFpEF)
89136364|NCT02970214||Cardiometabolic risk|Patients with cardiovascular diseases and metabolic risk factors at baseline
89136365|NCT02927028|Other|Chewing group|50 individuals, both male and female, between the ages of 18 and 60 years old, with a BMI between 18-35 kg/m2 from any ethnic/racial background will be recruited. Participants must have natural dentition and rate the hedonic value of all study foods between 3 and 7 on a 9-point category scale.
89136366|NCT02917096|Experimental|Treatment (ruxolitinib phosphate, chemotherapy,allogeneic HCT)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5, melphalan IV over 20 minutes on day -4, and ruxolitinib phosphate PO BID on days -3 to 30 with a taper for 2-3 weeks in the absence of disease progression or unacceptable toxicity. Patients being treated with ruxolitinib phosphate prior to allogeneic HCT as standard therapy may continue receiving ruxolitinib phosphate.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously beginning on day -3 and convert to PO daily when the patient is able to tolerate and absorb oral medications. Patients also receive sirolimus PO daily beginning on day -3. Treatment continues in the absence of GVHD.~STEM CELL TRANSPLANT: Patients undergo allogeneic HCT on day 0."
89136367|NCT02888353|Experimental|Device: MRI no pre-screen|"Clinically Indicated MRI will be done in patients with cardiac devices (pacemakers and defibrillators).~Patients will not be pre-screened prior to hospital visit."
89136368|NCT02875353|Other|Standard endoscopy (not experimental)|For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted. Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies. This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
89136369|NCT02875353|Experimental|Doppler treatment (experimental)|A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (< 4 mm deep) for arterial blood flow. If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow. This will be confirmed by rechecking with Doppler probe after endoscopic treatment. Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
89136370|NCT02837510|Other|Standard smoking cessation counseling|Participants will receive a standard treatment program consisting of smoking cessation counseling.
89136371|NCT02821013|Active Comparator|Arm 1: Intermittent PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
89136372|NCT02821013|Active Comparator|Arm 2: Continuous PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
89136373|NCT02771093|Experimental|Trelagliptin 100 mg group|Trelagliptin 100 mg once weekly taken orally before breakfast
89136374|NCT02771093|Experimental|Alogliptin 25 mg group|Alogliptin 25 mg once daily taken orally before breakfast
89136375|NCT02716038|Experimental|MPDL3280A, Carboplatin, Nab-paclitaxel|"Subjects with advanced or recurrent cancers receiving:~MPDL3280A every 21 days for up to 84 days~Carboplatin every 21 days for up to 84 days~Nab-paclitaxel every 7 days for up to 84 days"
89136376|NCT02702869||uCL(A)|Children with unilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
89136377|NCT02702869||uCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, or Veau-III).
89136378|NCT02702869||bCL(A)|Children with bilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
89136379|NCT02702869||bCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
89136380|NCT02702869||CP|Children with cleft secondary palate only, but intact lip and alveolus. Subgroup analysis by severity (submucous, Veau-I, or Veau-II).
89136381|NCT02632422|Experimental|Non-ambulatory - dAIH|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
89136382|NCT02632422|Sham Comparator|Non-ambulatory - dSHAM|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
89136383|NCT02632422|Experimental|Ambulatory - dAIH+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
89136384|NCT02632422|Sham Comparator|Ambulatory - dSHAM+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
89136385|NCT02632422|Other|Ambulatory-Walk|Ambulatory subjects will be randomly assigned to 10 sessions of walking practice only for 5 consecutive sessions/week x 2 weeks.
89136386|NCT02512068|Experimental|Trelagliptin 25 mg|Trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period I + II)
89136387|NCT02512068|Experimental|Placebo and Trelagliptin 25 mg|Placebo tablet, orally, once weekly before breakfast for up to Week 12 (Period I), followed by trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period II)
89136388|NCT02494258|Experimental|Oral Azacitidine (CC-486)|This study is an open-label, single-arm study and is divided into the screening period, treatment period and follow-up period. It is intended to evaluate the long-term safety of CC-486 and is to be taken at the same dose, schedule and frequency used from the last dose of CC-486 given in the parent study.
89136389|NCT02479698|Experimental|Treatment (BK-specific cytotoxic T lymphocytes)|Patients receive allogeneic BK-specific cytotoxic T-lymphocytes IV over 30 minutes. Patients achieving partial response, stable disease, or progressive disease are eligible for 19 additional infusions of CTL occurring at least 2 weeks after the previous CTL infusion if they meet the eligibility criteria for subsequent therapy.
89136390|NCT02469129|Experimental|Dosimetry Studies Arm|Twelve participants with cancer and eight healthy volunteers will be recruited first to undergo whole-body PET/CT imaging to determine the whole body dosimetry of [18F]FluorThanatrace.
89136391|NCT02469129|Experimental|Kinetic Studies Arm|An additional 30 participants with cancer will undergo a 1-hour dynamic scan upon injection of [18F]FluorThanatrace to determine the kinetics of the tracer in tumors to correlate with tissue-based markers of PARP activity and to obtain metabolite information to help determine the best quantification approach for the PET images. When possible these subjects will also undergo 18F-FDG imaging for comparison to tumor metabolism
89136392|NCT02439749|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
89136393|NCT02439749|Sham Comparator|Sham Procedure|Renal angiography
89136394|NCT02434705||Antigen (wheat base soy sauce) spray|"Ten patients with active and ten with inactive eosinophilic esophagitis (defined by consensus guidelines) undergoing clinically indicated endoscopy and esophageal biopsies will participate in this study.~During the endoscopy two biopsies will be taken from the esophageal body, 10 cm above the gastroesophageal junction.~After biopsies are taken, approximately 10 cc of wheat based soy sauce (antigen spray) will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction."
89136395|NCT02410304|Other|Arm C (Clinical)|No drug and no placebo were used in this arm. Patients were followed only by clinical évaluation.
89136396|NCT02410304|Other|Arm B (Clinical + Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Clinical evaluation in combination with ultrasound (in B mode).
89136397|NCT02410304|Other|Arm D (Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach in D mode.
88802914|NCT03016247|Active Comparator|Enhanced Usual Care|Group will receive a single visit with a Nutritionist for dietary and physical activity counseling
88802915|NCT03016247|Experimental|TRUST intervention|Group will receive parent-adolescent trust-building and weight self-management training.
89136398|NCT02382549|Experimental|6MHP and MEKi and BRAFi|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 36, 57, 78. All peptide vaccines are administered intradermally and subcutaneously.~A selective BRAF inhibitor and a selective MEK inhibitor will be administered in accordance with the prescribing information."
89136399|NCT02324569|Experimental|Treatment Group I|One tablet of SYR-472 100 mg orally once weekly before breakfast
89136400|NCT02324569|Experimental|Treatment Group II|One tablet of SYR-472 100 mg orally or one placebo tablet orally once weekly before breakfast
89136401|NCT02312622|Experimental|Cohort A - Pegylated Irinotecan to treat NSCLC|Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
89136402|NCT02312622|Experimental|Cohort B - Pegylated Irinotecan to treat SCLC|Patients with small cell lung carinoma (SCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
89136403|NCT02312622|Experimental|Cohort C - Pegylated Irinotecan to treat mBC|Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
89136404|NCT02297698|Experimental|Trastuzumab + NeuVax|Patients randomized to this arm will receive vaccinations of nelipepimut-S (1000 μg) and GM-CSF (250 μg) (NeuVax vaccine) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumbab to overlap with the PVS. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
89136405|NCT02297698|Active Comparator|Trastuzumab + GM-CSF|Patients randomized to this arm will receive inoculations of GM-CSF (250 μg) administered in an identical manner to those receiving nelipepimut-S/GM-CSF (NeuVax). Patients will be blinded as to whether they are receiving nelipepimut-S/GM-CSF or GM-CSF alone. Upon completion of the primary vaccination series (PVS), booster inoculations (same dose and route) will be administered every six months x 4. The first booster inoculation will occur 6 months ± 2 weeks after the completion of the PVS, with subsequent boosters timed every six months + 2 weeks. Boosters will therefore occur at the following time points after completion of the PVS: 6 months ± 2 weeks, 12 months ± 2 weeks, 18 months ± 2 weeks and 24 months ± 2 weeks.
89136406|NCT02296450||Quality of Life (QoL) Assessment|Patients involved in this study will have a wide range of dermatologic conditions for which they will be assessed and managed by the treating physician. An appropriate QoL instrument will be administered at the initial visit, and if applicable, at subsequent follow-up visit(s). Treatment of the dermatologic condition will be at physician's discretion based on the patient's presenting symptoms and is not an intervention itself within this study.
89136407|NCT02279004||Newly Diagnosed Patients|Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.
89136408|NCT02279004||Acquired Resistance Patients|NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.
89136409|NCT02279004||Known Genotype Patients|NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.
89136410|NCT02279004||Advanced NSCLC|Advanced NSCLC patients with a biopsy planned for tissue genotyping.
89136411|NCT02259712|Active Comparator|Pelvic-perineal physiotherapy|"The treatment duration is 2 days per week during 8 weks (two months). The aproximate duration of the season is 45 minutes. The protocol consists in:~Anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity).~Hygienic and behavioral advises preventing pelvic floor dysfunctions.~Awareness of the pelvic floor muscles.~Strengthening the pelvic floor muscles and the entire abdominal pelvic cavity. Use of electrostimulation and biofeedback in different positions if deemed necessary.~Treatment the abdominal-pelvic cavity pain if it requires."
89136412|NCT02259712|Experimental|Hyporessive and Pelvic-perineal PT|The treatment duration is 2 days per week, 8 weeks (two months). The session is about 45 minutes. All women are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle. The participants are also treated by doing Hypopressive exercises and by specific physiotherapy for the strengthening the pelvic floor muscles.
89136413|NCT02259712|Experimental|Hypopressive exercises|The treatment is done 2 times per week for 8 weeks (2 months). The session duration is about 45 minutes. All participants are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity). The participants are also treated by doing Hypopressive exercises in standing, sitting, and supine fours.
89136414|NCT02200367|Experimental|e-mental health collaborative programme|It is a complex intervention to support primary care providers of rural primary care service to manage depressed patients. Primary care providers at the intervention sites were supported by psychiatrist using an electronic platform.Patients were monitored through a call center.
89136415|NCT02200367|Other|Usual Care|Patients in this arm received all the interventions that are guaranteed for the persons with depression in Chile: treatment in the primary clinics with the primary care team and referral to the regional specialized psychiatric service
89136416|NCT02133521|Placebo Comparator|Placebo|Placebo 3 x 1 tablet, given everyday for 28 days of study period
88802916|NCT02546544|Other|Linsitinib|Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
89136417|NCT02133521|Experimental|DLBS1033|DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period
89136418|NCT02130492|Experimental|FDG arm|Patients will receive increasing doses of FDG.
89136419|NCT02068794|Experimental|Treatment (MV-NIS infected mesenchymal stem cells)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89136420|NCT02060890||Group A|Patients will undergo collection of tumor at the time of tumor resection and after confirmation of tumor progression and will have blood samples drawn pre-surgery and during standard of care follow-up visits. Patients will then be provided with a specialized tumor board recommendations for personalized treatment options for up to 4 medications based on the specimen analysis results within 35 days of surgery. Patients may then elect to initiate recommended therapy within 42 days of surgery.
89136421|NCT02051712|No Intervention|Usual care|Usual car accruing to guidelines
89136422|NCT02051712|Experimental|Individualized training|Individualized exercise training program in addition to usual care
89136423|NCT02051712|Experimental|Individualized training plus adherence measures|Individualized exercise training plus measures to increase adherence
89136424|NCT02038075|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|In addition to TAU, participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
89136425|NCT02038075|Active Comparator|Treatment As Usual (TAU)|Participants in TAU receive usual care from military clinicians as well as non-military clinicians from the local community, as determined by participants' primary mental health care provider. All mental health, substance abuse, and medical treatment are provided within the military health care system at no cost to participants.
89136426|NCT02010658|No Intervention|Memory|
89136427|NCT02010658|Experimental|Cognitive Aid|
89136428|NCT02007044|Experimental|Arm I (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89136429|NCT02007044|Experimental|Arm II (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm I beginning on day 1 or 2. Patients also receive rituximab IV over 3-8 hours on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-6. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89136430|NCT01996046||Bone mets|Patients will undergo an [18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
89136431|NCT01982890||Normal human controls|"Observational study. Subjects are screened for the absence of severe illnesses and followed prospectively with sequential blood draws, noting the occurence of acute and chronic severe illnesses.~Subjects are matched by age groups and sex with patients of the prospective cohort EUPA including patients with recent-onset inflammatory polyarthritis."
89136432|NCT01886404||Efavirenz Group|Participants will be taking efavirenz as part of their antiretroviral regimen.
89136433|NCT01864746|Experimental|Palbociclib|Palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
89136434|NCT01864746|Placebo Comparator|Placebo|Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a28-day cycle for thirteen cycles
89136435|NCT01729091|Experimental|Treatment (chemotherapy, UCB-derived NK cells, transplant)|Patients receive elotuzumab IV over 2-5 hours on day -15 and -8, lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.
89136436|NCT01618123||All CPU subjects|All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
89136437|NCT01550133|Experimental|Not Learned: Non-nutritive bev to Nutritive bev|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid and act as a control for the learned effects.
89136438|NCT01550133|Experimental|Not Learned: Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid and act as a control for the learned effects.
89136439|NCT01550133|Experimental|Not Learned: Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage and act as a control for the learned effects.
89136440|NCT01550133|Experimental|Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
89136441|NCT01550133|Experimental|Learned: Non-Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of non-nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage to determine if cephalic phase response changes with learning.
89136442|NCT01550133|Experimental|Learned: Nutritive solid to Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid to determine if cephalic phase response changes with learning.
89136443|NCT01550133|Experimental|Learned: Nutritive beverage to Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive beverage to determine if cephalic phase response changes with learning.
89136444|NCT01550133|Experimental|Not Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
89136445|NCT01475500||Screening|These high-risk subjects will undergo screening for lung cancer. All subjects will undergo all listed interventions
89136446|NCT01473992|Active Comparator|Prosthetic knee 1 (Otto Bock C-Leg)|This arm included unilateral transfemoral amputees who were assessed while using their preferred knee at study start(C-Leg). The Otto Bock C-Leg is a microprocessor knee using 2 sensors (1 for kinetics and 1 for kinematics).
89136447|NCT01473992|Active Comparator|Prosthetic knee 2 (Otto Bock Genium)|This arm included unilateral transfemoral amputees who were assessed while using the experimental/study knee, the Genium. The Otto Bock Genium is a microprocessor knee using multiple sensors that hypothetically increase mobility functions (e.g. walking backwards, intuitive stance)
89136448|NCT01473992|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
89136449|NCT01421524|Experimental|CC-122 MM-2|A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
89136450|NCT01421524|Experimental|CC-122- DLBCL-2|A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week [5/7 days] and/or 21 continuous days out of 28 days per cycle [21/28 days]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
89136451|NCT01421524|Experimental|CC-122- GBM-2|A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.
89136452|NCT01421524|Experimental|Primary Central Nervous System Lymphoma (PCNSL)|During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
89136453|NCT01299168||Kidney Transplant Biopsies for Cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).
89136454|NCT01258296|Active Comparator|Active fentanyl patch|25 mcg/hr fentanyl patch
89136455|NCT01258296|Placebo Comparator|Placebo patch|Inactive patch that resembles treatment patch but contains no drug
89136456|NCT01248624|Active Comparator|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
89136457|NCT01248624|Placebo Comparator|Conventional Cancer Care|This control arm receives standard cancer care.
89136458|NCT01120353||Cancer survivors|Survivors of cancer, diagnosed under 21 years of age, between 1970 and 1999 This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
89136459|NCT01120353||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine consistency of findings between data sources.
89136460|NCT01042015|Active Comparator|Concurrent controls|These subjects would undergo standard resuscitative efforts.
89136461|NCT01042015|Experimental|Emergency preservation and resuscitation|These subjects would undergo the complete EPR protocol, including rapid induction of hypothermia, resuscitative surgery, and resuscitation with cardiopulmonary bypass.
89136462|NCT00832429|Experimental|Diagnostic (SLN localization and biopsy)|Patients receive technetium Tc 99m sulfur colloid ID and then undergo lymph node mapping and SLN biopsy.
89136463|NCT00587717|Active Comparator|1|Two 80 mg pills simvastatin taken 24 hours prior to surgery
89136464|NCT00587717|Placebo Comparator|2|Two 80 mg pills placebo are taken 24 hours prior to surgery
89136465|NCT00512239||EUPA cohort|Consecutive adult patients presenting to receive rheumatological care at the Sherbrooke University Hospital Centre (CHUS) with an immune-mediated inflammatory arthritis affecting at least 3 joints for a duration of more than 4 and less than 52 weeks.
89136466|NCT00375830|Experimental|Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Preliminary pilot assessment to confirm feasibility & improved diagnostic accuracy of the combined 18F-NaF CT & 18F-FDG PET scan procedures, as compared to the regular medical care procedure, 99mTc MDP bone scans.
89136467|NCT00375830|Experimental|Cohort 2 WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Assessment to define the accuracy of the combined 18F-NaF CT & 18F-FDG PET/CT scan procedures compared to 99mTc MDP bone scan.
89136468|NCT00375830|Experimental|Cohort 3 Combined 18F-NaF / 18F-FDG PET/WB-MRI scan|Assessment to define the utility of 18F-NaF & 18F-FDG as the radiolabels in a single combined PET / WB-MRI procedure.
89136469|NCT00878527|Experimental|Treatment with the pump|Treatment with the CircuLite Synergy Pocket Circulatory Assist Device
89136470|NCT05753163|Experimental|treatment|
88802917|NCT02075996||Pomalidomide following lenalidomide|75 patients with pomalidomide directly following lenalidomide treatment
88802918|NCT02075996||Pomalidomide following other therapy|75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.
88802919|NCT01027793|Active Comparator|Tretinoin|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
88802920|NCT01027793|Active Comparator|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.
88802921|NCT04389554||Control Group|Healthy pregnant women
88802922|NCT04389554||Study Group|Pregnant women with COVID-19
89136471|NCT04039555|Active Comparator|Active Arm - CO2 intimate|Patients will receive 2 sessions of CO2 laser treatment, spaced 4 to 6 weeks apart
89136472|NCT04039555|Active Comparator|Active Arm - Erbium-yag|Patients will receive 2 sessions of Erbium-Yag laser treatment, spaced 4 to 6 weeks apart
89136473|NCT04039555|Sham Comparator|Sham Arm|Patients will receive 2 sessions of Erbium-Yag laser or CO2 laser treatment with non-therapeutic energy, spaced between 4 and 6 weeks apart
89136474|NCT02786628||Solid tumor malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
89136475|NCT02786628||Hematologic malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
89136476|NCT02786628||Hematopoietic cell transplantation|15 patients. Will participate in physical performance testing and patient-generated health data.
89136477|NCT00878683|Experimental|1|Device and standard catheter
89136478|NCT00878683|No Intervention|2|Standard catheter
88802923|NCT05427552|Experimental|Prefrontal hemodynamic response to 50% rMT iTBS|Participants will receive 50% rMT iTBS over left DLPFC in this arm. The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
88802924|NCT05427552|Experimental|Prefrontal hemodynamic response to 70% rMT iTBS|Participants will receive 70% rMT iTBS over left DLPFC in this arm. The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
88802925|NCT05427552|Experimental|Prefrontal hemodynamic response to 90% rMT iTBS|Participants will receive 90% rMT iTBS over left DLPFC in this arm. The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
88802926|NCT02444390|Other|Exemestane+everolimus|Exemestane+everolimus are administered as per their approved indication
88802927|NCT01029587|Experimental|Eculizumab|Patients will receive eculizumab in conjunction with systemic anticoagulation before and after kidney transplant operation
89136479|NCT02786238|Active Comparator|Standard Behavioral Treatment (SBT)|For the Standard Behavioral Treatment (SBT) condition, participants will participate in the standard behavioral weight loss programming, which utilizes strategies from existing obesity treatments (e.g., the Diabetes Prevention Program). These features include the following: 1) nutritional education, 2) diet and physical activity, 3) expectations for daily self-monitoring of calorie intake and activity, 4) stimulus control, behavior shaping, behavior analysis, and relapse prevention strategies, and 5) social support.
89136480|NCT02786238|Experimental|Acceptance-Based Treatment (ABT)|"The Acceptance-Based Treatment (ABT) group will receive most features listed in the SBT arm as well as unique ABT training designed to help individuals increase awareness of their cognitive and affective experiences, and the following exercises: 1) identifying weight-related goals from personal life values (e.g., health) and connecting these values to day-to-day eating, 2) increasing awareness of moment-by-moment behavior choices, 3) tolerating aversive internal states that include eating-related states as well as affective states such as stress, sadness, and anxiety (i.e., urge-surfing). These strategies that have been empirically tested and found to be effective in the NIH-funded Mind Your Health RCT (R21DK080430)."
89136481|NCT00875719|Active Comparator|continuous v intermittent Oxygen therapy|intermittent oxygen compared to constant flow oxygen as regards walking distance
88802928|NCT02444078|Experimental|Exercise|Exercise sessions will be done in groups of three-to-eight persons; whilst being a group-based exercise program, participants will be guided and the exercises will be adapted in an individual basis, which may increase adherence and compliance rates.
88802929|NCT02444078|Active Comparator|Social activity|Participants in this group will participate in group-based activities such as music (percussion instruments), arts and board games; no intervention on physical activity will be provided to these participants.
88802930|NCT05427396|Other|JS004 200 mg in combination with Toripalimab Injection 240 mg was administered every 3 weeks|
88802931|NCT05440630|Experimental|Probiotic|Participants in this arm will receive a daily dose of 1x10^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
88802932|NCT05440630|Experimental|Postbiotic|Participants in this arm will receive a daily dose of 1x10^10 Colony Forming Unit (CFU) of a single strain probiotic (Heat treated bacteria) for 16 weeks.
88802933|NCT05440630|Placebo Comparator|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
88802934|NCT01893944|Experimental|Virtual Reality|- Participate in this group 20 women to be treated by means of games Xbox 360 ®, attributed to this, custom applications using virtual and augmented reality to be developed.
88802935|NCT01893944|Experimental|Vibration therapy|- participate in this group 20 women who will undergo 15 minutes of continuous vibration by vibration of the upper mantle, with a frequency of 40 Hz, 3 function and intensity tolerable, keeping the limb supported and raised to 120 °.
88802936|NCT01893944|Active Comparator|control group|- participate in this group 20 women who are treated with conventional cinesioterapia through muscle stretching exercises, dissociation girdle, active and active-assisted exercises for groups flexors, extensors, abductors and adductors of the upper limbs, which will be three series 10 repetitions for each exercise.
88802937|NCT00988013|Experimental|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day (total of 3Gy).
88802938|NCT00988013|Experimental|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days (for a total of 6Gy).
88802939|NCT00988013|Experimental|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days (for a total of 9Gy).
88802940|NCT00988013|Experimental|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days (for a total of 12Gy).
88802941|NCT01894412|Experimental|HD 203|prefilled syringe
89136482|NCT04231812|Other|open lable|Prospective, open-label
89136483|NCT00875875|Active Comparator|1|This is the approved treatment regimen for travelers' diarrhea (600 mg)
89136484|NCT00875875|Active Comparator|2|This is the same dose as the standard dose, given once daily (200 mg)
89136485|NCT00875953|Active Comparator|Standard dissection|standard neck dissection technique: scalpel and cautery.
89136486|NCT00875953|Experimental|Harmonic Scalpel|Harmonic scalpel used in neck dissection.
89136487|NCT01716312|Placebo Comparator|1|Subjects who were randomized to the placebo arm originally will receive 600 mg omalizumab by subcutaneous injection
89136488|NCT01716312|Active Comparator|2|Subjects in the omalizumab arm will receive 300 mg omalizumab by subcutaneous injection in a doubleblinded fashion
89136489|NCT00880243|Experimental|EMA+GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.~GM-CSF (LeucomaxR): 5 µg/kg/jour IV over 6 hours from day 1 to day 10."
88802942|NCT01894412|Active Comparator|Enbrel|prefilled syringe
89136490|NCT00880243|Active Comparator|EMA without GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10."
89136491|NCT00880243|Experimental|HD AraC+ GM-CSF|"AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5~GM-CSF :5 µg/kg/d IV (6 hours) from day1 to day 5"
89136492|NCT00880243|Active Comparator|HD-AraC without GM-CSF|- AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5
89136493|NCT02783586|Experimental|Quadratus Lumborum Block type II|Unilateral ultrasound guidance QLB on the operated side after induction of general anaesthesia - 20 ml of 0,25%bupivacaine with adrenaline injected with ultraplex needle
89136494|NCT02783586|Active Comparator|Transversus Abdominalis Plane Block|Unilateral ultrasound guidance TAPB on the operated side after induction of general anaesthesia - 20 ml of 0,25% bupivacaine with adrenaline injected with ultraplex needle
89136495|NCT00590577|Experimental|001|Paliperidone palmitate 25 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8 36 64
89136496|NCT00590577|Experimental|002|Paliperidone palmitate 100 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8 36 64
89136497|NCT00590577|Experimental|003|Paliperidone palmitate 150 mg eq. Paliperidone palmitate 150 mg eq. i.m. Days 1 8 36 64
89136498|NCT00590577|Placebo Comparator|004|Placebo Placebo i.m. Days 1 8 36 64
89136499|NCT00880321|Experimental|Part 1|Part 1 will identify the recommended Part 2 dose using a dose-escalation procedure. Escalation may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached. Subjects may dose up to three times a day.
89136500|NCT00880321|Experimental|Part 2|Part 2 will explore further the safety, tolerability, and clinical activity of GSK2118436 in subjects with BRAF mutation-positive tumors using the recommended part 2 dose identified during Part 1. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
89136501|NCT02784990||Patient|
89136502|NCT02877498|Experimental|Adaptive support ventilation|adaptive support ventilation mode during invasive mechanical ventilation
89136503|NCT02877498|Active Comparator|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
89136504|NCT02608671|No Intervention|Continuous skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
89136505|NCT02608671|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
89136506|NCT00614575||BI-Sifrol® Tablets (Pramipexole)|BI-Sifrol® Tablets, pramipexole dose: 0.125 mg, 0.5 mg, No reference therapy
89136507|NCT02786316|Experimental|intervention group|Hit program for the rehabilitation of persons with nonspecific chronic low backpain
89136508|NCT02786316|Active Comparator|Control group|a conventional rehabilitation program for persons with nonspecific chronic low backpain
89136509|NCT02608437|Experimental|SGI-110 and Ipilimumab|SGI-110 in combination with Ipilimumab
89136510|NCT02786160|Active Comparator|HMO1|Daily bolus of HMO1
89136511|NCT02786160|Active Comparator|HMO2|Daily bolus of HMO2
89136512|NCT02786160|Placebo Comparator|Dextropur|Daily bolus of Dextropur
89136513|NCT04230330|Experimental|Nivolumab|After 4 doses of nivolumab, if the patient has complete responses (CR) or good partial response (PR), the patient will continue on nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment. During PET4-directed treatment with single agent nivolumab, if patient has PD, they will proceed to the Nivo+GDP/L-aspa arm.
89136514|NCT04230330|Experimental|Nivolumab + GDP/ L-asparaginase|After 4 doses of nivolumab, if the patient has PR, stable disease (SD), or progressive disease (PD), the patient will switch to nivolumab-GDP/L-aspa treatment. After 6 cycles of treatment, if CR is achieved, the patient will continue on single agent nivolumab until disease progression, unacceptable toxicities, or discontinuation of treatment.
89136515|NCT02785068|Experimental|Phase 1b/2a|"Phase 1b: Safety Evaluation - MM-151 (weekly dosing) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400mg/m2 every two weeks.~Phase 2a: Expansion - MM-151 (Maximum Tolerated Dose or Recommended Phase 2 Dose) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400 mg/m2."
89136516|NCT05752929|Active Comparator|Umpierrez|The Umpierrez sensitive correction scheme correction
89136517|NCT05752929|Experimental|Davidson|Davidson correction factor
88805924|NCT04312139||Fast progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated fast progression from moderate to severe aortic valve stenosis: echocardiographic dVmax>0.25 m/sec/year (difference in transaortic Vmax).
89136518|NCT02782962||Cohort|Patients with acute vertigo/unsteadiness
89136519|NCT02783118|Experimental|Healthy sample, active intervention|Healthy participants will be testing a depression prevention app employing a self administered online CBT intervention, for 4 weeks.
89234269|NCT01416636|Active Comparator|Treprostinil sodium low dose - Arm I|"Arm I (low dose):~Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
89234270|NCT01416636|Experimental|Treprostinil sodium high dose - Arm II|"Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
89234271|NCT00995358|Experimental|vaccination|
89234272|NCT00994578|No Intervention|Internet Only|Patients assigned to the internet only group will enter the initial CHESS portal which will take them to a window displaying a standard web search engine and common cancer information sites. We will monitor their internet usage via logins to the CHESS portal.
88802943|NCT02440646||CCTA group|All stable chest pain comers admitted to the chest-pain outpatient or inpatient cardiac center with the chronic coronary syndrome who underwent functional tests (CMR and/ or SPECT, and Echo are mandatory) and coronary computed tomography angiography (CCTA) without further immediate quantitative coronary angiography (QCA), applicable intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (PCI).
88802944|NCT02440646||CCTA + Invasive group|All stable chest pain comers admitted to the chest-pain outpatient or inpatient cardiac center with the chronic coronary syndrome who underwent functional tests (CMR, and/ or SPECT, and Echo are mandatory) and coronary computed tomography angiography (CCTA) with further quantitative coronary angiography (QCA), applicable intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) with or without implantation of a stent.
88802945|NCT02003690|Experimental|Dialectical Behavior Therapy + Pharmacotherapy|Dialectical Behavior Therapy + Pharmacotherapy
88802946|NCT02003690|Active Comparator|Standard of Care Psychotherapy + Pharmacotherapy|Standard of Care Psychotherapy + Pharmacotherapy
88802947|NCT00988325|Experimental|Oseltamivir 3 mg|infants 3 to <12 months
88802948|NCT00988325|Experimental|Oseltamivir 2.5 mg|infants 1 to <3 months of age
88802949|NCT00988325|Experimental|Oseltamivir 2 mg|infants 0 to 30 days (post natal) of age
88802950|NCT02435264|Experimental|Healthier Dining Program Intervention|Food centers that receive the Healthier Dining Program (HDP)
88802951|NCT02435264|No Intervention|Control centers|Food centers that do not receive the Healthier Dining Program (HDP)
88802952|NCT05752630||Healthy control|Healthy controls who engage in sedentary behaviour for more than 9 hours per day. Strata will be used to ensure equal distribution of active and inactive participants (< and > 150min/MVPA/week)
88802953|NCT05752630||Persons with MS|Persons suffering from MS who engage in sedentary behaviour for more than 9 hours per day. Strata will be used to ensure equal distribution of active and inactive participants (< and > 150min/MVPA/week)
88802954|NCT00381316|Active Comparator|1|Thallous Chloride T1-201
88802955|NCT00381316|Active Comparator|2|Technetium Tc99m Tetrofosmin injections
88802956|NCT02161133|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
88802957|NCT02161133|Active Comparator|Health Education|Health education provides didactic information about Gulf War Illness
88802958|NCT01894490||Jejunostomy|Patients who received a jejunostomy
88802959|NCT01894490||Nasojejunal catheter|Patients who received a nasojejunal catheter
88802960|NCT03830177|Experimental|Adults|All adults in the study will receive the treatment for dry scalp.
88802961|NCT03830177|Experimental|Children|All children in the study will receive the treatment for dry scalp.
88802962|NCT01030289|Active Comparator|real tDCS First Visit|On the First Visit, A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
88802963|NCT01030289|Sham Comparator|sham tDCS First Visit|On the First Visit, For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
88802964|NCT01030289|Active Comparator|real tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
88802965|NCT01030289|Sham Comparator|sham tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
88802966|NCT04756934|Experimental|Ia: LP002 dose escalation-1mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 1mg/kg, Q3W for up to 1 year.
88802967|NCT04756934|Experimental|Ia: LP002 dose escalation-3mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 3mg/kg, Q3W for up to 1 year.
88802968|NCT04756934|Experimental|Ia: LP002 dose escalation-5mg/kg|3-6 participants will receive HX008 of 200mg, Q3W plus LP002 of 5mg/kg, Q3W for up to 1 year.
88802969|NCT04756934|Experimental|Ib: Expansion|Approximately 30 participants will receive HX008 of 200mg, Q3W plus LP002 of the recommended dose, Q3W for up to 1 year.
88802970|NCT04756934|Experimental|Ib: Control|Approximately 15 participants will receive LP002 of recommended dose, Q3W for up to 1 year.
88802971|NCT01236391|Experimental|Participants received PCI-32765 560 mg daily|Participants were enrolled and received 560 mg/day dose, stratified into 2 groups based on prior bortezomib exposure.
89136520|NCT02783118|No Intervention|Healthy sample, delayed intervention|Healthy participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
89136521|NCT02783118|Experimental|Mild depression, active intervention|Mildly depressed participants will be testing a depression prevention app, employing a self administered online CBT intervention, for 4 weeks.
89136522|NCT02783118|No Intervention|Mild depression, delayed intervention|Mildly depressed participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
89136523|NCT04039321|Active Comparator|ESPB group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
89136524|NCT04039321|Sham Comparator|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
89136525|NCT00878761|Experimental|STX-100 (0.03mg/kg)|8 patients (6 active and 2 placebo)
89136526|NCT00878761|Experimental|STX-100 (0.1mg/kg)|8 patients (6 active and 2 placebo)
89136527|NCT00878761|Experimental|STX-100 (0.3mg/kg)|16 patients (12 active and 4 placebo)
89136528|NCT00878761|Experimental|STX-100 (1mg/kg)|16 patients (12 active and 4 placebo)
89136529|NCT05295888|Experimental|Experimental Arm|130Hz TI stimulation (total 2700 sec): ramp-up (30-60 sec) => stimulation (130Hz, 2mA per electrode pair, 4mA total, 2580-2640 sec) => ramp-down (30-60sec)
89136530|NCT05295888|Sham Comparator|Sham Arm|Sham stimulation (total 2700 sec): ramp-up (30-60 sec) => ramp-down (30-60 sec) => stimulation (130Hz, 0mA, 2520-2610 sec) => ramp-down (30-60 sec)
89136531|NCT00880477|Experimental|Group A|
89136532|NCT00880477|Experimental|Group B|
88802972|NCT02167217|Experimental|Oral Prednisolone|Oral Prednisolone 5mg/kg/ day on two consecutive days, Friday and Saturday with breakfast
89136533|NCT00882739|Other|no pre-treatment|No pre-treatment at first medical contact - Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
89136534|NCT00882739|Experimental|600 mg loading dose|600 mg clopidogrel loading dose at first medical contact
89136535|NCT00882739|Experimental|900 mg loading dose|900 mg clopidogrel loading dose at first medical contact
89136536|NCT00878839|Other|Toric|AcrySof Toric IOL to assess corneal aberration
89136537|NCT02783040|Experimental|single dose cocktail (Midazolam, Warfarin, Omeprazole)|
89136538|NCT02783040|Experimental|single dose Midazolam|
89136539|NCT02783040|Experimental|single dose Digoxin|
89136540|NCT02783040|Experimental|multiple dose BI 425809|
89136541|NCT00882817|Active Comparator|1|Pulmonary Rehabilitation
89136542|NCT00882817|No Intervention|2|
88802973|NCT01152697|Experimental|Patient Noncompliance|There was only one arm for this study.
88802974|NCT04637230||Sinus Rhythm|Subjects/patients in normal sinus rhythm
88802975|NCT04637230||Atrial Fibrillation|Patients with atrial fibrillation
89136543|NCT04038775|Experimental|Volunteering|"The experimental arm will receive a volunteer prescription from their provider and assistance from a study team member to find a volunteer job."
89136544|NCT04038775|No Intervention|Control|The control arm will not be recommended to volunteer or assisted in finding a volunteer activity. They will answer the same survey questions as the intervention subjects.
89136545|NCT02786082|Experimental|Group I|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group I, half are male and half are female, will take Azilsartan tablet 20mg orally on fasting.~For Pharmacokinetics Studies of Azilsartan with Multiple-dose oral administration, 12 subjects in group I will take 20mg Azilsartan orally once daily for 7 day (day 3~day 9) after completing the last time blood sample collection (in day 2, 48h) of the first time administration (day 1)"
89136546|NCT02786082|Experimental|Group II|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group II, half are male and half are female, will take Azilsartan tablet 40mg orally on fasting.~For The effects of diet for pharmacokinetic study: The 12 healthy subjects, in group II (in single-dose administration study), after 7-day washout period after the first administration (at day 1, 40mg) will receive Azilsartan tablet 40mg after high-fat diet at day 8"
89136547|NCT04728919||COVID-19 positive cases|Subjects with acute respiratory infection and positive COVID-19 test, who are well enough to be treated at home.
89136548|NCT04728919||COVID-19 negative controls|Subjects with acute respiratory infection and negative COVID-19 test, who are well enough to be treated at home.
89136549|NCT05275686|Placebo Comparator|Arm 1 (Placebo)|Arm 1 (placebo) will get placebo spray per day.
89136550|NCT05275686|Active Comparator|Arm 2 (EDS-FLU)|Arm 2 (EDS-FLU) will get 744 mcg of fluticasone propionate per day.
89136551|NCT01503606|Active Comparator|one-week treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization for one week
89136552|NCT01503606|Active Comparator|until-delivery treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization until delivery
89136553|NCT05082727|Experimental|KOVIR (TD0068)|Standard dose, 5 capsules/time x 3 times/day x 14 days
89136554|NCT05082727|Placebo Comparator|Placebo|Placebo, 5 capsules/time x 3 times/day x 14 days
89136555|NCT02784522|Experimental|locking compression plate group|In the experimental group, patients will undergo closed reduction via a lateral approach to the shoulder followed by locking compression plate fixation using a minimally invasive technique.The locking compression plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
89136556|NCT02784522|Active Comparator|conventional locking plate group|Patients in the control group will be subjected to closed reduction via a lateral approach to the shoulder followed by conventional steel plate fixation using a minimally invasive technique. The conventional locking plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
89136557|NCT05062993|Experimental|study group|Patients with chronic radicular pain will be included in this study. Ultrasound guided caudal epidural pulse radiofrequency technique will be applied to the study group.
89136558|NCT00882973|Experimental|Cohort 1|Genexol-PM 220 mg/m2 + Gemcitabine 1,250 mg/m2
89136559|NCT00882973|Experimental|Cohort 2|Genexol-PM 260 mg/m2 + Gemcitabine 1,250 mg/m2
89136560|NCT00882973|Experimental|Cohort 3|Genexol-PM 300 mg/m2 + Gemcitabine 1,250 mg/m2
89136561|NCT00805935|Experimental|Menotropin/Progesterone vaginal insert|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 100 mg starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
89136562|NCT00805935|Experimental|Menotropin/Progesterone in oil|"Menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
89136563|NCT00805935|Active Comparator|Follitropin beta/Progesterone vaginal insert|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
89136564|NCT00805935|Active Comparator|Follitropin beta/Progesterone in oil|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
89136565|NCT04230096|Experimental|applied group|low level laser therapy applied in one group
89136566|NCT04230096|No Intervention|controlled group|other group will be controlled in which low level laser will not be applied
89136567|NCT00880711||1|Patient with advanced BC, already receiving Faslodex therapy
89136568|NCT05265390|Experimental|intervention group|Anxiety level of the group watching the informational video
89136569|NCT05265390|No Intervention|control group|Anxiety level of control group adolescents
89136570|NCT00880789|Experimental|Dose Level One: 5x10^6/m2|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
89136571|NCT00878917|Experimental|Dorzolamide|
89136572|NCT03969927|Experimental|Low-Fidelity PDS Training|Individuals with stroke, PD, or MS
89136573|NCT03969927|Active Comparator|High Fidelity Fixed-Base Simulator Training|Individuals with stroke, PD, or MS
89136574|NCT05752851||T2DM group|Collect stool and blood samples，No drugs use.
89136575|NCT05752851||Control group|Collect stool and blood samples，No drugs use.
89136576|NCT00805545|Experimental|A|Group of patients that will receive antibiotics 30-60 minutes prior to incision
89136577|NCT00805545|Active Comparator|B|Group of patients that will receive antibiotics immediately after clamping the umbilical cord
89136578|NCT02845440|Active Comparator|Treatment as Usual (TAU) - Cohort 1|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention.Cohort 1 (AD-eligible) comprised participants seen in primary care clinics serving ≥3 enrolled participants.
89136579|NCT02845440|Experimental|AD + CHW - Cohort 1|"Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. The aim of AD is to help clinicians understand and adopt targeted evidence-based practices.~Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers."
89136580|NCT02845440|Experimental|AD - Cohort 1|Participant in this arm will have Academic Detailing offered to their primary care clinical staff as described above. Participants who are randomized to this condition will not be offered Community Health Worker support.
89136581|NCT02845440|Experimental|CHW - Cohort 2|Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers.
89136582|NCT02845440|Active Comparator|Treatment as Usual (TAU) - Cohort 2|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention. Cohort 2 (AD-ineligible) comprised participants whose primary care clinic served ≤2 enrolled participants
89136583|NCT00590031|Experimental|1|External Beam Radiation Therapy, Cisplatin, Irinotecan
89136584|NCT02421276|Other|Persons without Down syndrome|White blood cell analysis from persons without Down syndrome assessed by absence of trisomy 21.
89136585|NCT02421276|Other|Persons with Down syndrome|White blood cell analysis from persons with Down syndrome assessed by presence of trisomy 21.
89136586|NCT04232514|Experimental|Part A|Subjects will receive HEC74647 on Day 1~7 and Day13~19, co-administration with HEC110114 on Day13~19.
89136587|NCT04232514|Experimental|Part B|Subjects will receive HEC110114 on Day 1~7 and Day13~19, co-administration with HEC74647 on Day13~19.
88802976|NCT04637230||Atrial Premature Complexes|Patients with atrial premature complexes in between sinus beats
88802977|NCT04637230||Ventricular Premature Complexes|Patients with ventricular premature complexes in between sinus beats
88802978|NCT04637230||Ventricular Tachycardia, Nonsustained|Patients with episodes of nonsustained ventricular tachycardia in between sinus beats
88802979|NCT01197547|Other|Genesys HTA|Genesys HTA Endometrial Ablation
89136588|NCT02785692||Combined Radiation/ Surgery|All patients treated with combined radiotherapy and surgery at Balgrist University Hospital and University Hospital Zurich
89136589|NCT04232436||Planned vaginal delivery|Planned vaginal delivery
88802982|NCT03011281||RA patients who start Tofacitinib|Korean RA patients who start Tofacitinib with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate or biologics.
88802983|NCT00990509|Experimental|Albumin|
88802984|NCT00990509|Placebo Comparator|Placebo|
88802985|NCT01238341||Pancreatobiliary disease|Patients who have altered gastric anatomy who need an ERCP with an overtube for evaluation of pancreatobiliary disease.
88802986|NCT04756622|Experimental|N acetyl cysteine|NAC dissolved in water at a dose of 600 mg three times per day from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
88802987|NCT04756622|No Intervention|Control|No intervention
88802988|NCT00992927|Experimental|CPIHD|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
88802989|NCT00992927|Active Comparator|CRIHD|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
88802990|NCT04756466|Placebo Comparator|Control group|Control group that will receive a daily placebo capsule consisting of maltodextrin during 3 months
88802991|NCT04756466|Experimental|Probiotic group|Experimental group that will receive one capsule with the probiotic strain per day (3x10 9 CFU / day) during 3 months
88802992|NCT01198327|Experimental|Ranibizumab as needed|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart; with optional peripheral laser to areas of non-perfusion.
88802993|NCT04694950||Group feasibility|Adults undergoing elective urologic laparoscopic robotic surgery.
88802994|NCT02405234|Experimental|Carbon Modular Radial Head|PyroCarbon Modular Radial Head replacement
88802995|NCT02405234|Active Comparator|Metal Radial Head|Metal Radial Head replacement
88802996|NCT00994175|Experimental|Pioglitazone, Then Placebo|Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the placebo phase for 16 weeks in the second treatment phase to receive the placebo.
89136590|NCT04232436||Planned cesarean delivery|Planned cesarean delivery
89136591|NCT02783196|Experimental|Liraglutide (LIR)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with Liraglutide ( IR) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with placebo (PLA)
89136592|NCT02783196|Placebo Comparator|Placebo (PLA)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with placebo ( PLA) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with Liraglutide ( LIR)
89136593|NCT02782884||Outpatient general surgery operation|Patients undergoing outpatient general surgical operations They will be given a specified number of narcotic pills based on our retrospective analysis of patient post-operative opioid use
89136594|NCT02782884||Inpatient general surgical patients|Inpatients who are being discharged They will be given a specified number of narcotic pills based on the number of pills they took in the 24 hrs prior to discharge
89136595|NCT00634608|No Intervention|Survey|Control group participants are sent a survey within one week of clinic visit
89136596|NCT00634608|Experimental|Health Information Prescription|Health Information Prescription is emailed to participants within 24 hours of clinic visit.
89136597|NCT02784678|Experimental|closed reduction group|Patients will be assigned to C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws (experimental group).
89136598|NCT02784678|Experimental|open reduction group|Patients will be assigned to open reduction (palmar and dorsal incisions) and internal fixation with titanium plate (control group).
89136599|NCT02782650||Survey and interviews|"* part one * (quantitative)~Survey on:~A) prenatal counseling at the limits of viability, both current and preferred, within three domains of interest:~organization of prenatal counseling~content of prenatal counseling~decision-making in prenatal counseling~B) treatment options at the limits of viability against the background of the Dutch guideline~* part two * (qualitative)~Focus groups interviews (qualitative) to in-depth explore preferences in prenatal counseling~insight in the specific preferred content of prenatal counseling.~study influencing factors on preferences in the domains of organization and decision-making."
89136600|NCT04231656|Experimental|Sequence A before sequence B|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence A of positioning (before the procedure), and sequence B after the procedure.
89136601|NCT04231656|Experimental|Sequence B before sequence A|Patients eligible for intermediate risk surgery requiring the placement of an invasive continuous blood pressure measurement device and stroke volume monitoring for fluid management. Sequence B of positioning before the procedure, and sequence A after the procedure.
89136602|NCT04230174|Experimental|Multiple sclerosis patients|Multiple sclerosis patients will be evaluated with 11C-PBR28 MR-PET at baseline before and at 12 month follow up after Ocrelizumab therapy.
89136603|NCT04231422||Treatment Group|Monthly intracavernosal platelet-rich plasma injection + daily physical manipulation.
89136604|NCT02782572|Experimental|Exercise with Non-invasive ventilation|Patients with acute haert failure who performed aerobic exercise with non-invasive ventilation. This group also received conventional medical treatment.
89136605|NCT02782572|Sham Comparator|Exercise|Patients with acute haert failure who performed aerobic exercise with placebo of non-invasive ventilation. This group also received conventional medical treatment.
89136606|NCT02782572|Other|Control|Patients who receiveid only conventional medical treatment and not performed exercise during protocol.
89136607|NCT02782494||Dialysis group|Patient receiving long term dialysis
89136608|NCT02784132|Other|Study Arm A|Right eye examined first with video diversion then left eye examined without video diversion
89136609|NCT02784132|Other|Study Arm B|Right eye examined first without video diversion then left eye examined with video diversion
89136610|NCT02784132|Other|Study Arm C|Left eye examined first with video diversion then right eye examined without video diversion
89136611|NCT02784132|Other|Study Arm D|Left eye examined first without video diversion then right eye examined with video diversion
89136612|NCT02782260|Experimental|Active|"Dipyridamole eye drops 8.48 mg in 100ml~1 drop three times a day for 1 year"
89136613|NCT02782260|Placebo Comparator|Placebo|"Fluorescein in Active Vehicle~1 drop three times a day for 1 year"
89136614|NCT02782416|No Intervention|Waiting for renal transplant_no screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination but no LTBI check
89136615|NCT02782416|Placebo Comparator|Not waiting for renal transplant|Dialysis patients who are not waiting for renal transplant
89136616|NCT02782416|Other|Status post renal transplant|patients who have received renal transplant
89136617|NCT02782416|Experimental|Waiting for renal transplant_ screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination in addition to LTBI check
89136618|NCT05342610|Experimental|Experimental (distant reiki) group|Reiki (complementary and integrative medicine method) was applied individually to the experimental group for 30 minutes three times a week for four weeks. Data collection forms was applied 3 times in total, before the intervention, in the fourth and the eighth week.
89136619|NCT05342610|No Intervention|Control group|No intervention was made to women in the control group. However, data collection forms was applied 3 times in total, before the intervention, in the fourth and the eighth week.
89136620|NCT04229784|Experimental|RF ARM|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
89136621|NCT04229862|Experimental|Evaluation with 14 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 14 cm high pillow.
89136622|NCT04229862|Active Comparator|Evaluation with 7 cm high pillow|When inserting laryngeal mask airway, head elevation is performed using a 7 cm high pillow.
89136623|NCT04230018||primary and metastasis lesion|tissue of colorectal cancer primary lesion and tissue of colorectal cancer metastasis were obtained
89136624|NCT02782728|Active Comparator|TIPS-Basic|Providers receive tailored scripts based on the patient's responses to the questions administered via tablet.
89136625|NCT02782728|Experimental|TIPS-Plus|Patients receive tailored messages in addition to the scripts given to providers.
89136626|NCT05031936|Active Comparator|Touhy needle group|cervical medial branch block using touhy needle
89136627|NCT05031936|Placebo Comparator|Quincke needle group|cervical medial branch block using quincke needle
89136628|NCT03577704|Experimental|HLX07+Gemcitabine+Cisplatin arm|"HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
89136629|NCT03577704|Experimental|HLX07+Paclitaxel+Carboplatin arm|"HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
89136630|NCT03577704|Experimental|HLX07+mFOLFOX6 arm|"HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
89136631|NCT05341206|Experimental|Treatment group|The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
89136632|NCT05341206|Sham Comparator|Control group|The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
89136633|NCT04229706|Experimental|High dose group|xiangjurupining capsule ,8 capsules，tid
89136634|NCT04229706|Experimental|Lower dose group|xiangjurupining capsule, 4 capsules,tid, xiangjurupining capsule placebo ,4 capsules，tid，po
88805925|NCT04312139||Slow progressors of Aortic Valve Stenosis|50 patients that retrospectively demonstrated slow progression from moderate to severe aortic valve stenosis: echocardiographic dVmax<0.15 m/sec/year (difference in transaortic Vmax).
89136635|NCT04229706|Placebo Comparator|Placebo group|xiangjurupining capsule placebo ,8 capsules，tid，po
89136636|NCT05341050||patients with Ph+ CML-CP|
89136637|NCT02780076|Experimental|Functional training group|Participation in a functional training program in addition to usual care. The functional training program is initiated by the nurses and consists of walking, sit-to-stands, balance training, weight transfer training, knee squats. The program is performed 4 times a day for 3 weeks while at short-term stays.
89136638|NCT02780076|No Intervention|Control group|Usual care only. No participation in the functional training program while at short-term stays.
89136639|NCT05333172|Active Comparator|balance exercise group|The balance program was performed on soft and hard surface. Firstly the participants started the exercises on hard ground while standing. Postural balance program consisted of static and dynamic functional balance exercises (hıp flexion, hıp abduciton, semitandem stance, one leg stance, toe tips lifting). Afterwards exercises were performed on soft surface. Three sets of eight to ten repetitions of each exercise in a slow, controlled manner were performed. This section was completed 30 minitues.
89136640|NCT05333172|Experimental|Dual task exercises|"Dual task exercises are in two forms as motor dual task and cognitive dual task. In this study we used cognitive secondary task exercises. In addition to the exercises applied by the balance exercise group, a cognitive task was added. Participants in this group tried to count 4, 5 and 7 back from 100 while practicing balance exercises.~The balance program was performed on soft and hard surface. Firstly the participants started the exercises on hard ground while standing. Postural balance program consisted of static and dynamic functional balance exercises (hıp flexion, hıp abduciton, semitandem stance, one leg stance, toe tips lifting). Afterwards exercises were performed on soft surface. Three sets of eight to ten repetitions of each exercise in a slow, controlled manner were performed. This section was completed 30 minitues."
89136641|NCT04228770|Experimental|Warfarin patients|Patients on high risk medication - warfarin
89136642|NCT04228770|Experimental|Parkinson's patients|Patients with high risk disease - parkinson's
89136643|NCT00615199|Experimental|1mg BD|
88802997|NCT00994175|Experimental|Placebo, Then Pioglitazone|Placebo was administered for 16 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the Pioglitazone treatment group. Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the treatment phase, followed by 45 mg daily for an additional 14 weeks.
89136644|NCT00615199|Experimental|5mg BD|
89136645|NCT00615199|Experimental|15mg BD|
88802998|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (three)|Treatment with three initial sessions
88802999|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (two)|Treatment with two initial sessions
89136646|NCT00615199|Placebo Comparator|Placebo BID|
89136647|NCT02780232|Experimental|Internet-based program|"Adolescents in the intervention will receive a tailored online program during 3 months.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links."
89136648|NCT02780232|No Intervention|Treatment as usual|-Waiting list control group.
89136649|NCT02780154|Experimental|1600 7G8 PfSPZ|N= 7-9 participants will receive 1600 7G8 PfSPZ DVI in a volume of 500mcL
89136650|NCT02780154|Experimental|3200 7G8 PfSPZ|N= 9 participants will receive 3200 7G8 PfSPZ DVI in a volume of 500mcL
89136651|NCT02780154|Experimental|3200 NF54 PfSPZ|N= 5-6 participants will receive 3200 NF54 PfSPZ DVI in a volume of 500mcL
89136652|NCT02780154|Experimental|4800 7G8 PfSPZ|N= 2-3 participants will receive 4800 7G8 PfSPZ DVI in a volume of 500mcL
89136653|NCT02780154|Experimental|800 7G8 PfSPZ|N= 7-9 participants will receive 800 7G8 PfSPZ DVI in a volume of 500mcL
89136654|NCT02782026|Experimental|idiopathic PAH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
89136655|NCT02782026|Experimental|heritable PAH with BMPR2 mutation|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
89136656|NCT02782026|Experimental|chronic thromboembolic PH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
89136657|NCT02782026|Experimental|Controls|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
89136658|NCT05328024||Recurrent and/or metastatic head and neck carcinoma|Patients with indication of anti-PD1 immunotherapy according to recommendations
89136659|NCT00879073|Experimental|A - Cohort 1 Treatment|Cohort 1: Bendamustine 60 mg/m² x 4 weeks
89136660|NCT00879073|Experimental|B - Cohort 2 Treatment|Cohort 2: Bendamustine 80 mg/m² x 4 weeks
89136661|NCT00879073|Experimental|C - Cohort 3 Treatment|Cohort 3: Bendamustine 100 mg/m² x 4 weeks
89136662|NCT05342142|Active Comparator|Exercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
89136663|NCT05342142|No Intervention|Control|No intervention will be made
89136664|NCT00880867|Experimental|Poly-ICLC|Poly-ICLC plus low dose local radiation.
89136665|NCT04229550|No Intervention|Control subjects|1 week of normal daily life and only by the National Health Board recommendated alcohol consumption.
89136666|NCT04229550|Experimental|Festival subjects|1 week's participation in Roskilde Festival 2016
89136667|NCT00880945||36-40 patients|patients with small peripheral lesions who need bronchoscopy for diagnostic purposes
89136668|NCT05340660|Experimental|ALS Patient|
89136669|NCT00883285||1|conventional aortic valve replacement
89136670|NCT00883285||2|transfemoral aortic valve replacement
89136671|NCT00883285||3|transapical aortic valve replacement
89136672|NCT02780934|Active Comparator|Pressure Dressing|Participants randomized to this group will receive the standard post-operative dressing following their Mohs procedure: a pressure dressing consisting of high absorbency gauze and retention tape.
89136673|NCT02780934|Experimental|Simple Adhesive Dressing|Participants randomized to this group will receive the experimental post-operative dressing following their Mohs procedure: a simple adhesive dressing consisting of a non-adherent pad and transparent dressing.
89136674|NCT04228926|Experimental|0.002% ZKY001 eye drops|Experimental group A: 35 subjects .0.002% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
89136675|NCT04228926|Experimental|0.004% ZKY001 eye drops|Experimental group B: 35 subjects .0.004% ZKY001 eye drops . 4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
89136676|NCT04228926|Placebo Comparator|The placebo|Placebo group C: ZKY001 simulated eye drops .4 times a day,1 drop every time, continuously administered for 14±2 days ZKY001 simulated eye drops will be directly dripped into the test eye (the surgical eye was taken as the test eye).
89136677|NCT02781948||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
89136678|NCT02781948||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus
89136679|NCT00883363|Experimental|Precondition|Induction of precondition at start of operation on a arm
89136680|NCT00883363|No Intervention|Control|No precondition
89136681|NCT05324670|Experimental|Experimental condition|Didactic intervention based on religious teachings and cultural milieu, the experimental group will receive 12 sessions for three months, 4 sessions per month including focused group discussion.
89136682|NCT05324670|Other|Control condition|They will have sessions like the experimental group but the control group will get the knowledge in the form of written material without any explanation (Information Leaflet).
89136683|NCT04377061||NCWS retrospective and prospective patients|"The clinical charts of NCWS patients, diagnosed by DBPC gluten/wheat challenge, between January 2001 and December 2019, attending the Department of Internal Medicine at the University Hospital of Palermo, the Department of Internal Medicine of the Hospital of Sciacca, and the Department of Medical and Surgical Sciences of the University of Bologna, will be reviewed retrospectively. The investigators prospectively will also survey patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS by DBPC gluten/wheat challenge. The patients will be recruited between January 2019 and January 2022 at the same centers, and at the Internal Medicine Division of the Cervello-Villa Sofia Hospital of Palermo, Palermo."
89136684|NCT04377061||CD retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of a control group of CD patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of CD patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
89136685|NCT04377061||IBS retrospective and prospective control patients|To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of another control group of IBS patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of IBS patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.
89136686|NCT02782182|Experimental|FOLFIRINOX+surgery|4 cycles of pre-operative FOLFIRINOX, followed by surgery, followed by 2 more cycles of FOLFIRINOX
89136687|NCT02780778|Experimental|Treatment group|Apatinib：500 mg，po，qd； Docetaxel：60mg/m²，vein input 1hour，every 3w
89136688|NCT04327219|Experimental|CDED diet|The CDED will be divided into 3 stages: 0-6 weeks- induction phase (phase 1), weeks 7-12 step-down phase (phase 2), week 13 -24 maintenance phase (phase 3). During these weeks the diet is structured and contains a list of allowed/disallowed foods, and mandatory foods with specific daily/weekly amounts. Patients will be asked to progress with the diet if they respond to the diet clinically. Patients who do not improve, but show a clinicaly significant trend in symptoms, may be asked to prolong a dietary phase until reaching clinical reaction.
89136689|NCT04327219|No Intervention|standard diet|The control standard diet will be personally tailored for nutritional needs according to patient's daily recommended intake (DRI) for calories and protein intake (25kcal/kg and 0.8-1gr/kg per day respectivlly), and will follow the clinical guidelines for dietary therapy of patients with IBD.
89136690|NCT04229082||lean|BMI between 18-25
89136691|NCT04229082||obese|BMI between 27.5-35
89136692|NCT00881101|Experimental|1|Liposomal paclitaxel
89136693|NCT02781012||Healthy|Healthy volunteers without any known pancreatic disease
89136694|NCT02781012||Healthy At-Risk|Healthy volunteers with no known benign or malignant pancreatic disease, AND with one first-degree relative with pancreatic cancer, OR two second-degree relatives with pancreatic cancer. These subjects also include those who have undergone surgery for suspected pancreatic cancer, and who are found to have a non-pancreatic cancer pathology upon final local site or central pathology review.
89136695|NCT02781012||Pancreatitis|Subjects diagnosed with acute or chronic pancreatitis
89136696|NCT02781012||Early Stage/Borderline/Locally Advanced|Subjects diagnosed with early stage pancreatic cancer who undergo surgery as standard of care therapy with or without preoperative (neoadjuvant) chemotherapy and/or radiation therapy; subjects diagnosed with borderline pancreatic cancer, or subjects diagnosed with locally advanced pancreatic cancer.
89136697|NCT02781012||Metastatic|Subjects diagnosed with metastatic pancreatic cancer and treated with any standard of care therapy/therapies.
89136698|NCT00879151|Experimental|Psychotherapy|Patients are randomized to one of three different types of psychotherapy: Cognitive-Behavioral Therapy for adolescents, Family-Based Therapy for Bulimia Nervosa, and Supportive Psychotherapy. All treatments consist of 18 sessions over a period of approximately 6 months.
89136699|NCT02779998|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute in order to maintain peripheral oxygen saturation (SpO2) above 94% during electrophysiology procedure under light sedation.
89136700|NCT02779998|Experimental|non invasive ventilation|non invasive ventilation (NIV) which associated positive end expiratory pressure (PEEP: 5 to 10 cmH2O) and pressure support ventilation (PSV: 5 to 15 cmH2O, to achieve total Pressure bellow 20cmH2O) will be delivered during electrophysiology procedure under light sedation. The patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
89136701|NCT00883441|Experimental|VM|implementation of new vector control tools (insecticide treated curtains and jar covers) through the existing routine vector control programme
89136702|NCT00883441|Experimental|PM|implementation of new vector control tools (insecticide treated covers and curtains) through partnerships
89136703|NCT05168748|Experimental|IMJ995 in ALL|Dose escalation and expansion of IMJ995 single agent in ALL
89136704|NCT04039009||Infertility patients|Infertility patients will be examined according to the pelvic organ prolapse quantification classification system during hysteroscopy.
89136705|NCT02779764|Experimental|ASP1517 Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
89136706|NCT00883519|Active Comparator|IPT-A|
89136707|NCT00883519|Active Comparator|IPT-AP|
88803000|NCT01239355|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88803001|NCT02168153|Active Comparator|Chiropractic Manipulative Therapy|Participants will complete questionnaires and biomechanical assessments, and additionally receive CMT treatment.
89136708|NCT02781714|Experimental|Two-way SMS|Pre-programmed SMS messages by partner track will be delivered twice weekly to participants in participants' preferred languages from enrollment to 6 months postpartum. They will include a question soliciting a response from the participant(s). Interactive SMS communication will be responded to and managed by the study nurse at each site. Content themes will include: general support/encouragement, postpartum visit reminders, postpartum pregnancy risk and benefits of birth spacing, postpartum contraceptive options and side effects, family planning misconceptions, and couple communication.
89136709|NCT02781714|No Intervention|Control|The control arm will receive standard education and counseling provided in antenatal care and in postnatal care.
89136710|NCT04205383||pregnancy|pregnant women with normal pregnancy
89136711|NCT04205383||pregnancy with complications|pregnant women with placental-mediated complications of pregnancy type complications
89136712|NCT04205383||healthy volunteer|healthy, non-pregnant women volunteers
89136713|NCT02781636|Experimental|Chronic Tibial Implant Arm|StimGuard Protect System (Chronic Tibial Nerve Stimulation) Implant Procedure. Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
89136714|NCT00883831|Experimental|Individualized manual acupuncture|
89136715|NCT00883909||observational|A follow-up study in adult male subjects who have received investigational
89136716|NCT04229160|Experimental|patient with persistent atrial fibrillation|persistent atrial fibrillation is defined as lasting longer than 6 months documented by a 24h holter monitoring
89136717|NCT04229238||Home-dwelling older adults|Older adults (70 +) receiving regular health care from the home nursing service. Setting is two rural municipalities in southern Norway.
89136718|NCT05341830|Experimental|Recovery Housing|Individuals in this arm will have access to a placement in recovery housing and the associated services. Recovery housing organizations provide individuals recovering from substance use disorders with housing and a variety of services, including transportation, rental assistance, life skills, family services, and educational and employment opportunities.
89136719|NCT05341830|No Intervention|No Recovery Housing|Individuals in this arm will not receive a placement in recovery housing. When possible, they will be informed about other available services in their community.
89136720|NCT00634686|Experimental|1|
89136721|NCT00634686|Placebo Comparator|2|
89136722|NCT05341674||Model of the stump scanned with a 3d scanner|For the artificial intelligence-based software planned to be created, the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner. The scanned patterns were saved as point clouds
89136723|NCT05341674||Socket matched to stump|The socket parts of the prostheses used by the same patients (with other group) were also scanned with the same scanner device and recorded.
89136724|NCT05340192|Other|Healthy Volunteer|Octreotide, 100 mcg (1 ml) s.c.
89136725|NCT00883987||Back Pain|"Patients with chronic mechanical low back pain (Chronic low back pain is defined as having pain between the lower ribs and gluteal folds, with minimal radiation to the thigh and never below the knee, present for a minimum of seven weeks)"
89136726|NCT05340114|Experimental|Subjects examined by the operations with CEREBO®|CEREBO® - A portable non-invasive device to detect intracranial haemorrhage Frequency - The operator will scan at least 10 patients Duration - 40 seconds per subject No adverse effect or contraindications
89136727|NCT02780544|Experimental|skin-to-skin contact + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in skin-to-skin position with a parent (intervention group) and one in the incubator (standard care). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination.
89136728|NCT02780544|Active Comparator|incubator + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in the incubator (standard care) and one in skin-to-skin position with a parent (intervention group). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination
88803002|NCT02168153|Placebo Comparator|Wait-List Control Group|Participants will complete questionnaires and biomechanical assessments
88803003|NCT04389476||Medical staff in high contact with patients|
89136729|NCT05341596||Reintubation after planned extubation|Reintubation after planned extubation(RAP) was defined as repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room.
89136730|NCT05341596||matched group|Patients without RAP during the PACU stay were designated as the matched group
89136731|NCT04038463|Experimental|Early Follicular Phase (EFP)|The group will engage in the Resistance Training intervention on the fourth day of their menstrual cycle, which will correlate with the middle of the early follicular phase (EFP).
89136732|NCT04038463|Experimental|Late Follicular Phase (LFP)|The group will engage in the Resistance Training intervention on the eleventh day of their menstrual cycle, which will correlate with the middle of the late follicular phase (LFP).
89136733|NCT04038463|Experimental|Early Luteal Phase (ELP)|The group will engage in the Resistance Training intervention on the eighteenth of their menstrual cycle, which will correlate with the middle of the early luteal phase (ELP).
88803004|NCT04389476||Other personnel in low contact with patients|
88803005|NCT04389476||Patients|
89136734|NCT04038463|Experimental|Late Luteal Phase (LLP)|The group will engage in the Resistance Training intervention on the twenty-fifth day of their menstrual cycle, which will correlate with the middle of the late luteal phase (LLP).
89136735|NCT04468243|Experimental|Nurse-led|Nurse-led (group A). Patients randomized to group A will be taken to an available consultation room within the clinic and provided brief diabetes education which includes understanding what it means to have diabetes, healthy eating, and physical activity. Patients will also receive instructions on how to use a glucometer and how to take Metformin.
89234273|NCT00994578|Experimental|CHESS|Participants in the CHESS arm will be given access to the University of Wisconsin CHESS website, modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support. The participant's usage of the site will be monitored.
88803006|NCT04389476||Community residents|
88803007|NCT03011203|Experimental|Ketone-ester drink|Oral intake - physical exercise
88803008|NCT03011203|Active Comparator|Carbohydrate drink|Oral intake - physical exercise
89136736|NCT04468243|No Intervention|Usual Care|Usual Care (Control; group B). Patients randomized to usual care will be informed of their HbA1c value, will continue to receive usual cancer care, and will be encouraged to follow-up with their PCP for T2D management. The RA will ensure that oncology visit clinic notes and the results of the HbA1c testing are relayed to the patient's PCP office. Patients who do not have a PCP identified will be referred to an appropriate provider.
88803009|NCT02402192|Active Comparator|Corifollitropin alfa|Under current practice, 67 participants will be stimulated with a single injection of 100 mg, sc of Corifollitropin alpha (Elonva®). From day 6 stimulation and even prior to induction of ovulation day, 0.25 mg / day was administered sc ganirelix (Orgalutran®). From day 8 stimulation and depending on the ovarian response, you can add recombinant FSH (Puregon) up to 150 IU by Puregon Pen® device. In the presence of 3 or more follicles ≥17 mm, ovulation is induced with a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) if there is no risk of OHSS, and 36 hours later he held the follicular puncture oocyte retrieval.
89136737|NCT00881179|Experimental|1|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
89136738|NCT00881179|Active Comparator|2|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)
89136739|NCT04228614||Retrospective cohort|Whole exome sequencing of 2500 retrospective tissue sample.
89136740|NCT04228614||Prospective cohort|Whole exome sequencing of 500 prospectively collected tissue samples. Panel sequencing of 451 genes of prospectively collected blood samples.
89136741|NCT02781246|Active Comparator|saline (Group A)|perineural ropivacaine
89136742|NCT02781246|Active Comparator|0.5 mcg/kg dexmedetomidine (Group B)|(perineural ropivacaine plus 0.5 mcg/kg dexmedetomidine),
89136743|NCT02781246|Active Comparator|1 mcg/kg dexmedetomidine (Group C)|(perineural ropivacaine plus 1 mcg/kg dexmedetomidine)
89136744|NCT02781246|Active Comparator|1.5 mcg/kg dexmedetomidine (Group D)|(perineural ropivacaine plus 1.5mcg/kg dexmedetomidine)
89136745|NCT02781246|Active Comparator|2 mcg/kg dexmedetomidine (Group E)|(perineural ropivacaine plus 2 mcg/kg dexmedetomidine)
89136746|NCT00613951|Experimental|SIAC 30 (B)|
89136747|NCT00613951|Experimental|SIAC 45 (B)|
89136748|NCT00613951|Active Comparator|BIAsp 30|
89136749|NCT05321238|Experimental|High agency and immediate threat|Participants were asked to make decisions within the interactive digital narrative and were presented with acute alcohol poisoning of the main character in the story.
89136750|NCT05321238|Experimental|High agency and distant threat|Participants were asked to make decisions within the interactive digital narrative and were presented with multiple organ failure after years of alcohol consumption of the main character in the story.
89136751|NCT05321238|Experimental|Low agency and immediate threat|Participants were presented with a fixed (passive) narrative without decisions and were presented with acute alcohol poisoning of the main character in the story.
89136752|NCT05321238|Experimental|Low agency and distant threat|Participants were presented with a fixed (passive) narrative without decisions and were presented with multiple organ failure after years of alcohol consumption of the main character in the story.
89136753|NCT00881257|Experimental|1|GRST Peripheral Catheter System
89136754|NCT02781402|Experimental|4 weeks of Aerobic Training for normal BMI group|4 weeks of aerobic training on treadmill 3 times per week.
89136755|NCT02781402|Experimental|4 weeks of Aerobic Training for overweight BMI group|4 weeks of aerobic training on treadmill 3 times per week.
89136756|NCT00881413|Experimental|Esomeprazole|High-dose esomeprazole
89136757|NCT00881413|Active Comparator|Pantoprazole|High-dose pantoprazole
89136758|NCT04229394|Experimental|2ccPA|"Only day 1 Intra-articular injection can be given under direct ultrasound guidance; the only one strength for 2ccPA injection vial is 2,400 μg (1.2 mL per vial).~IP name: 2-carba-cyclic phosphatidic acid (2ccPA)"
89136759|NCT04229394|Placebo Comparator|Placebo|Only day 1 Intra-articular injection can be given under direct ultrasound guidance; placebo
89136760|NCT00881491|Experimental|Group A|Group A - Double antibiotic paste: intracanal medicament consisting of ciprofloxacin and metronidazole
89136761|NCT00881491|Experimental|Group B|Group B - Triple Antibiotic Paste: intracanal medicament consisting of ciprofloxacin, metronidazole, minocycline
89136762|NCT00881491|Active Comparator|Group C|Group C - Mineral trioxide aggregate: used as an apical barrier
89136763|NCT00805467|Experimental|1|R935788 50 mg tablet, orally, twice-a-day
89136764|NCT00805467|Experimental|2|R935788 100 mg tablet, orally, twice-a-day
89136765|NCT00805467|Experimental|3|R935788 100 mg tablet, orally, once-a-day
89136766|NCT00805467|Experimental|4|R935788 150 mg tablet, orally, once-a-day
89136767|NCT02608281|Other|CEDEM|diagnostic contrast enhanced Dual Energy mammograms after Iodine based contrast media administration compared to CE MRI
89136768|NCT00958841|Experimental|pasireotide LAR 60mg|Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.
89136769|NCT02937116|Experimental|Phase 1a|"Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.~Drug: IBI308"
89136770|NCT02937116|Experimental|Phase 1b Cohort A|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
89136771|NCT02937116|Experimental|Phase 1b Cohort B|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
89136772|NCT02937116|Experimental|Phase 1b Cohort C|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
89136773|NCT02937116|Experimental|Phase 1b Cohort D|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308/Cisplatinum/Pemetrexed"
89136774|NCT02937116|Experimental|Phase 1b Cohort E|"Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\gemcitabine\cisplatin"
89136775|NCT02937116|Experimental|Phase 1b Cohort F|"Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\oxaliplatin\capecitabine"
89136776|NCT02937116|Experimental|Phase 1b Cohort G|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\etoposide\cisplatin"
89136777|NCT02937116|Experimental|Phase 1b Cohort H|"Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\irinotecan\5-FU"
89136778|NCT02781168|Experimental|Use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
89136779|NCT02781168|Active Comparator|No use of earmuffs|No use of earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
89136780|NCT00613327|Experimental|Oxybutynin Chloride OROS|
89136781|NCT02780466||Patients with septic shock|
89136782|NCT04273997|Active Comparator|Metronidazole Ointment|"Treatment Group A: Metronidazole 10% w/w ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.~One dose contains approximately 70 mg metronidazole in a formulation of white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound"
88805926|NCT04312139||Prospective Moderate Aortic Valve Stenosis|100 consecutive prospectively enrolled patients with moderate aortic valve stenosis. Plus 20 patients accounting for 20% drop-out rate, total prospective cohort = 120 patients.
88805927|NCT04312139||Negative calcium score group|50 patients at intermediate to high risk for Cardiovascular Disease (CVD) and negative aortic valve and coronary calcium score at CT scan, prospectively followed-up. Plus 10 patients accounting for 20% drop-out rate, total control cohort = 60 patients.
89136783|NCT04273997|Placebo Comparator|Placebo Ointment|"Treatment Group B: Placebo ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.~One dose of placebo ointment contains titanium dioxide and white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound."
89136784|NCT05339802|Experimental|Cohort 1|9MW1411 injection , single administration, intravenous infusion, infusion time 2H (120 ± 15min);
89136785|NCT05339802|Experimental|Cohort 2|9MW1411 injection , single administration, intravenous infusion, infusion time 2H (120 ± 15min);
89136786|NCT05339802|Placebo Comparator|Placebo|9MW1411 injection placebo, single administration, intravenous infusion, infusion time: 2h (120 ± 15min)
89136787|NCT04649203|Experimental|Group 1|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 10 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 75 days
89136788|NCT04649203|Placebo Comparator|Group 2|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 10 days + Placebo, 2 tablets 2 times a day, for 75 days
89136789|NCT00634764||Pregnant|Pregnant women who present to MUSC's Cannon Place or Prenatal Wellness Center
89136790|NCT00881725|Experimental|Metformin|500mg t.i.d. for 4-12 weeks prior to Radical Prostatectomy
89136791|NCT04250090||Long-term type ureteral stent set|Patients with Long-term type ureteral stent set due to ureteral stricture.
89136792|NCT02837588|Active Comparator|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
89136793|NCT02837588|No Intervention|CONTROL|No intervention with radiofrequency treatment, only evaluation to usual drug treatment
89136794|NCT04250012|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 10-week internet-based acceptance and commitment therapy intervention with three remote meetings with a psychologist"
89136795|NCT04250012|Active Comparator|Psychoeducation|"Group Psychoeducation will receive a self-help booklet and a link to mobile wellness training program"
89136796|NCT02779842|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89136797|NCT00954941|Experimental|Group 1: Ondansetron|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
89136798|NCT00954941|Active Comparator|Group 2: Ondansetron + Aprepitant|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy. Aprepitant 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
89136799|NCT02837666|Active Comparator|Exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group with exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
89136800|NCT02837666|Active Comparator|No exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group without exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
89136801|NCT05339646|Experimental|SSD8432 dose 1~7|Dose level 1 ~7 of SSD8432
89136802|NCT05339646|Experimental|SSD8432 dose 8~9|Dose level 8 ~9 of SSD8432
89136803|NCT05339646|Experimental|SSD8432 dose 10~12|Dose level 10 ~12 of SSD8432
89136804|NCT05339646|Experimental|SSD8432 dose 13|Dose level 13 of SSD8432
89136805|NCT05339646|Experimental|SSD8432 dose 14|Dose level 14 of SSD8432
89136806|NCT00630695|Experimental|1|Lanreotide LP 90
88805928|NCT04161950||Tested device model (EG-UR5-S50 )|Tested device model: The EG-UR5 echoendoscope manufactured by SonoSscope Medical Crop. That used with the HD-500 image processor, HDL-500X light source and S50 ultrasonic processor.
89136807|NCT00630695|Placebo Comparator|2|
89136808|NCT02843438|Other|Subjects suspected of toxoplasmosis chorioretinitis infection|Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
89136809|NCT00954707|Placebo Comparator|12m DAPT Group|
89136810|NCT00954707|Active Comparator|30m DAPT Group|
89136811|NCT05334992|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) combines the ideas of cognitive therapy with meditative practices and attitudes based on the cultivation of mindfulness. The heart of this work lies in becoming acquainted with the modes of mind that often characterize mood disorders while simultaneously learning to develop a new relationship to them.
89136812|NCT05334992|Experimental|Behavior Activation|BA Increase reinforcing behaviors in order to influence emotions and cognitions.
89136813|NCT05304702||NEGBAL|"Negative Fluid Balance (NEGBAL) Approach:~COVID-19 patients with tomographic detection of pulmonary edema (dilated superior vena cava, large pulmonary arteries, diffuse interstitial infiltrates with Kerley lines, and dilated right ventricle or dilated cardiac axis) treated with NEGBAL approach. This consisted of oral hydric restriction and use of diuretics (20 mg of furosemide, intravenous bolus, followed by furosemide in endovenous continuous infusion, starting at 60 mg/day).~The objective of this approach was to achieve negative fluid balance, between 600 to 1400 mL/day adjusted to body surface area, with a final target of 8-10% of body weight in up to 8 days. The furosemide dose was titrated considering heart rate and blood pressure, target fluid balance, hematocrit, and serum creatinine."
89136814|NCT05304702||NO-NEGBAL|"Treatment for COVID-19 pneumonia in this series were based on standard recommendations.~All patients in this group received dexamethasone 6 mg/day and thromboembolic prevention with enoxaparin 40 mg/day.~Participants in the NO-NEGBAL group, did not received a NEGBAL approach as treatment."
89136815|NCT02857517|Experimental|intravitreal 0.05ml conbercept for ICNV|0.05ml conbercept ,1 injection with PRN
89136816|NCT00589797|Experimental|Investigational|Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
89136817|NCT00589797|Active Comparator|Control|Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
89136818|NCT00630851|Experimental|1|
89136819|NCT00630851|Placebo Comparator|2|
89136820|NCT00613171|Experimental|ST1571|Participants received ST1571 100 mg tablets, orally, once daily. Initiated at an oral dose of 200 mg/day for 4 weeks then titrated up to 400 mg/day for 2 weeks followed by 600 mg/day until Week 24, if well tolerated.
89136821|NCT05156892|Experimental|Dose-escalation/ expansion|SUBA-itraconazole (oral 150mg twice daily) and escalating dose of Tamoxifen (oral once daily) then expansion cohort
89136822|NCT03894345|Experimental|Open-label treatment with Prazosin|"Week 1 Day 1-3: 0.5 mg at bedtime Day 4-7: 1.0 mg at bedtime Week 2 Day 8-10: 2.0 mg at bedtime Day 11-14: 4.0 mg at bedtime Week 3 2 mg in the morning, 4 mg at bedtime Week 4 4 mg in the morning, 4 mg at bedtime Week 5 4 mg in the morning, 6 mg at bedtime Week 6 4 mg in the morning, 8 mg at bedtime~Dosage of Prazosin will be titrated at the discretion of the study physician."
89136823|NCT00881803||Group 1|Ascorbic Acid Supplementation Only
89136824|NCT00881803||Group 2|Iron Supplementation Only
89136825|NCT00881803||Group 3|Concurrent Ascorbic Acid & Iron Supplementation
89136826|NCT02859077|Experimental|EGFR-TKI and Chemotherapy|NSCLC patients
89136827|NCT00896480|Experimental|GSK2132231A Group|Subjects, male or female, 18 years of age or older, received up to 24 doses of GSK2132231A intramuscularly in 4 cycles. In Cycle 1 (ending Week 13) 6 doses were administered at 2-week intervals; in Cycle 2 (ending Week 32) 6 doses at 3-week intervals; in Cycle 3 (ending Week 54) 4 doses at 6-week intervals and in Cycle 4 4 doses at 12-week intervals, starting 12 weeks after end of Cycle 3, followed by, after an interruption of treatment of 6 months, 4 doses at 24-week intervals.
89136828|NCT00881881||1|Patients with early RA
89136829|NCT05752695||ACL injured athletes|Athletes with defined ACL injury.
89136830|NCT05149794|Experimental|Calisthenic Exercises|The participants of this group perform calisthenic exercises.
89136831|NCT05149794|No Intervention|Conventional Training|The participants of this group perform activities of daily routines like playing cricket, taking swings etc
89136832|NCT00879307|Experimental|1|Use of quetiapine
89136833|NCT02857127|Experimental|Intervention Group|A group of people who participated in the walking program during a six month period. This group also received an educational material and attended meetings for behavioral change strategies.
89136834|NCT02857127|No Intervention|Control Group|A group of people who did not receive the educational material and did not participated in any of the activities offered by the research team, such as walking classes and meetings for behavioral change.
89136835|NCT00879385|Experimental|All patients|All participants enrolled.
89136836|NCT00914121|Experimental|1|SKI-606 alone
89136837|NCT00914121|Placebo Comparator|2|Placebo
89136838|NCT00914121|Active Comparator|3|Moxifloxacin
89136839|NCT00914121|Experimental|4|SKI-606 plus ketoconazole
89136840|NCT00914121|Placebo Comparator|5|Placebo plus ketoconazole
89136841|NCT00953225|Experimental|Vitamin D3|4,000 IU vitamin D3 daily for one year
89136842|NCT00953225|Placebo Comparator|Placebo|Placebo daily for one year
89136843|NCT00879463|Active Comparator|GROUP A|Brain tissue oxygen saturation monitoring
89136844|NCT00879463|Active Comparator|GROUP B|CONTROL GROUP
89136845|NCT04249934|Experimental|Caffeinated Coffee|
89136846|NCT04249934|Active Comparator|Decaffeinated Coffee|
89136847|NCT03819231|Experimental|Mindfulness and intranasal oxytocin|Given oxytocin through intranasal administration and self-directed mindfulness training.
89136848|NCT03819231|Active Comparator|Mindfulness and placebo|Given sterile saline through intranasal adminstration and self-directed mindfulness training.
89136849|NCT03819231|Sham Comparator|Sham mindfulness and placebo|Given sterile saline through intranasal adminstration and sham self-directed mindfulness training.
89136850|NCT02843048|Experimental|Exercise training|Exercise training plus standard medical follow-up care
89136851|NCT02843048|Active Comparator|Standard medical care|Standard medical follow-up care only
89136852|NCT02854943||Critically ill patients|Male and female critically ill patients admitted to the Charité - University Medicine Berlin during 2000 and 2018.
89136853|NCT02779920|Experimental|Per oral pylorotomy|Patients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
89136854|NCT00613015|Experimental|Modafinil/Stress|Participants received placebo for 2 days. modafinil on the third day and participated in the TRIER social stress task on the third day.
89136855|NCT00613015|Experimental|Modafinil/no stress|Participants received placebo for 2 days. modafinil on the third day and did not participate in the TRIER social stress task on the third day.
89136856|NCT00613015|Experimental|Guanfacine/stress|Participants received guanfacine for 3 days and participated in the TRIER social stress task on the third day.
89136857|NCT00613015|Experimental|Guanfacine/no stress|Participants received guanfacine for 3 days and did not participate in the TRIER social stress task on the third day.
89136858|NCT00613015|Placebo Comparator|Placebo/Stress|Participants received placebo for 3 days and participated in the TRIER social stress task on the third day.
89136859|NCT00613015|Placebo Comparator|Placebo/no stress|Participants received placebo for 3 days and did not participate in the TRIER social stress task on the third day.
89136860|NCT04249856||Women examined by colposcopy|Women referred to colposcopy at our facilities who met inclusion criteria
89136861|NCT02858765|Experimental|white polychromatic light A|
89136862|NCT02858765|Experimental|white polychromatic light B|
89136863|NCT02858765|Experimental|white polychromatic light C|
89136864|NCT02858765|Experimental|white polychromatic light D|
89136865|NCT03811899|Experimental|18F-DCFPyL PET/CT imaging|We will use technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
89136866|NCT02779608|Experimental|intraperitoneal docetaxel and oral S-1|"Docetaxel is diluted in 1litre normal saline and administered intraperitoneal（IP）at a dose of 60 mg/m2 over 1 hour on day 1. S-1 was administered orally twice daily at a dose of 40mg/m2 per day for 14 consecutive days, followed by 7 days of rest.~Intervention: Drug: Intraperitoneal docetaxel Intervention：Drug：Oral S-1"
89136867|NCT04250480|Experimental|Beta-alanine|4 g by mouth, 3 times per day with regular meals for 14 days.
89136868|NCT04250480|Placebo Comparator|Placebo|4 g by mouth, 3 times per day with regular meals for 14 days.
89136869|NCT05750589|Experimental|IRX-101|Subjects randomized to IRX-101 will receive the investigational product, IRX-101.
89136870|NCT05750589|Active Comparator|5% Povidone-iodine|Subjects randomized to this arm will receive the standard of care, Providone-iodine, at a concentration of 5%.
89136871|NCT02543671|Active Comparator|vitamin D3 enriched cheese|vitamin D3 enriched, reduced-fat yellow cheese
89136872|NCT02543671|Placebo Comparator|plain cheese|plain (non-fortified) reduced-fat yellow cheese
89136873|NCT02838992|Experimental|ATG, Cy and cord blood transfusion group|"ATG 3mg/kg/d for 5 days Cy 50mg/kg/d for 2 days CSA Started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml One unit of cord blood having no more than 3 HLA-A,B and DRB1 mismatches is transfused 24h after last dose of ATG administration.~Intervention:~Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus Cyclophosphamide plus CSA Biological: Cord blood transfusion"
89136874|NCT02838992|Active Comparator|ATG and CSA group|ATG 3mg/kg/d for 5 days CSA started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml Intervention: Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus CSA
89136875|NCT00879541|Other|PK Biostate® [SP]|"Part 1: PK subjects are randomized to receive Biostate® [SP] either on Day 1 or Day 8.~Part 3: All PK subjects receive Biostate® [SP] on Day 180."
89136876|NCT00879541|Other|PK Biostate® [RP]|Part 1: PK subjects are randomized to receive Biostate® [RP] either on Day 1 or Day 8.
89136877|NCT00879541|Experimental|Efficacy|Part 2: This arm includes all subjects during the efficacy component of the study.
89136878|NCT02838914|Experimental|patients with AF|Before radiofrequency ablation (RFCA)
89136879|NCT02838914|Experimental|Assigned Comparisons|After radiofrequency ablation (RFCA)
89136880|NCT02514798|Experimental|High-flow humidified nasal oxygen delivery system|We will describe effects of varying settings of high-flow nasal oxygen (10-30-45-60 L/min) on respiratory rate, tidal volume, and diaphragmatic work of breathing in patients with severe COPD. We will also describe changes in gas exchange and effects on the subjects' comfort and dyspnea. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system.
89136881|NCT02514798|Active Comparator|CPAP (Positive Control)|"We want to describe the breathing responses to varying setting of CPAP in the subject population. We plan to use the CPAP response as a positive control, to determine if our population responds as described by CPAP studies in the literature. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system."
89136882|NCT04029285|Other|Traditional Gym Based exercise - Control|Twice weekly sessions of TGB exercise for six weeks.
89136883|NCT04029285|Experimental|Exergaming|Twice weekly sessions of exergames for six weeks.
89136884|NCT00633308|Experimental|A|Long hemodialysis
89136885|NCT00884299|No Intervention|1|Free diet
89136886|NCT00884299|Experimental|Diet rich in antioxidants|Diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients in this arm will be seen regularly in the outpatient clinic where there will be informed for the potential beneficial effects of fruits and vegetables in health status by two members of the study team (attending physician and specialist nurse). At baseline and at each visit it is clearly explained to them that the dietary goal is to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the 3-year study period.
89136887|NCT02507856||investigational group|early/late dabigatran
89136888|NCT02507856||control group|vitamin k antagonist (vka)
89136889|NCT00914355|Experimental|SBRT for Hepatocellular Carcinoma|
89136890|NCT04205318||study|obese (BMI ≥25.00 kg/m2, n=200)
89136891|NCT04205318||control|non-obese (BMI= 18.50-24.99 kg/m2, n=200)
89136892|NCT02543593|Experimental|Intervention|Participants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
89136893|NCT02543593|Sham Comparator|Placebo|Participants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
89136894|NCT02843126|Experimental|Trastuzumab and NK immunotherapy|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89136895|NCT02843126|Active Comparator|Trastuzumab|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89136896|NCT02606721||Challenge Subjects|Male or female subjects aged 5 - 35 with suspected food allergy and an upcoming scheduled clinical food challenge
89136897|NCT04201652|Active Comparator|Superficial|Intervention: Superficial local anesthetic infiltration.
89136898|NCT04201652|Active Comparator|Deep|Intervention: Superficial and deep local anesthetic infiltration.
89136899|NCT05338476|Experimental|Midazolam|Midazolam administered orally.
89136900|NCT05338476|Experimental|Selpercatinib and Midazolam|Selpercatinib and midazolam administered orally.
88803010|NCT02402192|Active Comparator|recombinant FSH|Under current practice, 67 participants will be stimulated with a daily dose of recombinant FSH. Administration of recombinant FSH (Puregon) starts at an initial dose of 150-225 IU / day by the Puregon Pen® device. From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of recombinant FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg or Decapeptyl hCG 6500u (Ovitrelle) is given if there is no risk of OHSS, and 36 hours then held follicular puncture for recovering oocytes.
89136901|NCT00885469||1|Patients with known Barrett's Esophagus or chronic GERD
89136902|NCT02838758|Experimental|Cryoablation|Ultrasound guided perineural cryoablation. The mechanism of therapeutic cryoablation involves using short and repeated cycles of freezing and thawing to cause axonal degeneration and disrupt neuronal activity without damage to epineurium and perineurium.
89136903|NCT02838758|Active Comparator|Lidocaine|Ultrasound guided perineural lidocaine injection. Under ultrasound guidance, roughly 3cc of 2% lidocaine will be injected near the neuroma.
89136904|NCT02838758|Placebo Comparator|Saline|Ultrasound guided perineural normal saline injection. Under ultrasound guidance, roughly 3cc of normal saline will be injected near the neuroma.
89136905|NCT04228224|Experimental|Robot-assisted Rehabilitation|Participants will receive Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain). Patients will perform lower limb exercises assisted by the device. Training involve 24 sessions, 2 sessions per week for 12 weeks, each lasting about 1 hour.
89136906|NCT04228224|Active Comparator|Conventional Gait Rehabilitation|Participants in this group will perform conventional gait rehabilitation on a rehabilitation institution with assistance of a physical therapist. Training involve 24 sessions, 2 sessions per week, each session lasting about 1 hour.
89136907|NCT00803595|Experimental|CS-8958 Low Dose|CS-8958 powder to be inhaled - low-dose arm
89136908|NCT00803595|Experimental|CS-8958 High Dose|CS-8958 powder to be inhaled - high-dose arm
89136909|NCT00803595|Active Comparator|Oseltamivir phosphate|oseltamivir phosphate oral capsules
89136910|NCT02779374|Experimental|Autologous bone marrow transplantation|autologous bone marrow will be given by intravenous infusion. the intervention will be preceded by a period of 6 months of follow up the a period of 12 months follow up
89136911|NCT02543359|Experimental|Clinicians and Supervisors|After randomization clinicians and supervisors from community behavioral health agencies receive training in one of three PCIT training models: Train the Trainer (TTT), Learning Collaborative (LC) or Web-Supported Self Study (SS).
89136912|NCT02543359|Experimental|Administrators|After randomization administrators from participating community behavioral health agencies receive one of three treatments for PCIT (1/3 Learning Collaborative, 1/3 other treatment - none, and 1/3 other treatment - none).
89136913|NCT02543359|Experimental|Parent-Child Dyads|Parent-child dyads receive Parent-Child Interaction Therapy (PCIT) treatment from trained clinicians/supervisors.
89136914|NCT02606487||CF pulmonary exacerbation group|Patients with cystic fibrosis admitted for inpatient treatment of a pulmonary exacerbation
89136915|NCT02779686||ARMD Free|Patient free of ARMD on clinical examination
89136916|NCT02779686||ARMD Positive|Patients with evidence of ARMD on clinical examination
89234274|NCT00994578|Experimental|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each visit, and access to the patient's audio-recorded conversations for review. The participant's usage of the site will be monitored.
89234275|NCT00994578|Experimental|CHESS/COPE|Participants in the CHESS+COPE arm will receive training in, and access to, both components on the CHESS website, with the accompanying levels of support. The participant's usage of the site will be monitored.
88803011|NCT02402192|Active Comparator|HP- hMG|Under current practice, 67 participants will be stimulated with HP-hMG, following the same pattern described for the group of recombinant FSH. In this case, the initial dose is 225-300 IU / day of HP-hMG (Menopur®). From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of HP-hMG according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) is given if there is no risk of OHSS and 36 hours then held the follicular puncture for oocyte retrieval .
88803012|NCT02168309|Other|Labetalol|Labetalol 200mg PO BID starting dose
88803013|NCT02168309|Other|Nifedipine|Nifedpine XL starting at dose 30mg PO daily
88803014|NCT01894724|Experimental|NeuroSave Device|Targeted Hypothermia with NeuroSave Device
88803015|NCT01895582||Active TB-infected patients|TB-infected patients with bacteriological and histological evidences
88803016|NCT01895582||Non active TB-infected patients (already met TB)|some of elders have already met M tuberculosis before active antibiotherapy exists
88803017|NCT01895582||Non active TB-infected patients (other diagnosis)|same symptoms than two others groups but an other diagnosis
88803018|NCT01199965|Other|IV DHE then MAP0004|Smokers and non-smokers received Intravenous Dihydroergotamine Mesylate (IV DHE) at Visit 2 followed by MAP0004 7-11 days later at Visit 3.
88803019|NCT01199965|Other|MAP0004 then IV DHE|Smokers and non-smokers received MAP0004 at Visit 2 followed by Intravenous Dihydroergotamine Mesylate (IV DHE) 7-11 days later at Visit 3.
88803020|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
88803021|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
88803022|NCT00995501|Active Comparator|Intensive Glucose Control, placebo, Light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
88803023|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
88803024|NCT00995501|Active Comparator|Intensive Glucose Control, Placebo, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
88803025|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
88803026|NCT00995501|Active Comparator|Conventional Glucose Control, Placebo, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
88803027|NCT00995501|Placebo Comparator|Conventional Glucose Control, Placebo, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
89234276|NCT00995514||Clopidogrel|Patients receiving clopidogrel 75 mg/day as prescribed by their physician, and are extensive metabolizers by CYP2C19 genotype
89234277|NCT00995514||Prasugrel|Patients receiving prasugrel 5 or 10 mg/day as prescribed by their physician
88803030|NCT03011047|Experimental|endoscopic trans-antral approach|The maxillary sinus and prolapsed orbital contents will be visualized employing a 30-degree endoscope for the repair of orbital blow out fracture (sinus scope 4 mm, 30 degrees short one 17 cm).
88803031|NCT03011047|Active Comparator|trans-orbital surgical approach|trans-orbital surgical approach through the lower eyelid Sub-ciliary incision ( through the lower eyelid) The skin incision is made just below the eyelashes.
88803032|NCT01942694|Placebo Comparator|Placebo|One pill daily
88803033|NCT01942694|Active Comparator|Vitamin D (Cholecalciferol)|One vitamin D pill daily
88803034|NCT01153711|Experimental|BI 1744 10 mcg|solution for oral inhalation
88803035|NCT01153711|Experimental|Ketoconazole 400 mg|tablet
88803036|NCT02168855|Active Comparator|Active nicotine gum|
88803037|NCT02168855|Placebo Comparator|Inactive gum|
89234278|NCT00995592|Experimental|Mentor mothers|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
89234279|NCT00995592|No Intervention|Control|Control cases were visited and their infants were weighed 4 times over one year period. After one year, mothers were provided Philani nutrition intervention program.
89136917|NCT02843204|Experimental|Pembrolizumab and NK immunotherapy|In this group, the patients will receive regular Pembrolizumab first to control tumor burden; then NK immunotherapy will be given. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89136918|NCT02843204|Active Comparator|Pembrolizumab|In this group, the patients will receive regular Pembrolizumab to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89136919|NCT00885547|Experimental|immunosuppressor|
89136920|NCT00953927|Experimental|Investigational Vaccine|MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
89136921|NCT00953927|Placebo Comparator|Control Group|Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.
89136922|NCT02606565|Experimental|Intervention arm: 4% chlorhexidine|Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
89136923|NCT02606565|No Intervention|Control arm: Dry cord care|Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
89136924|NCT04227990|Active Comparator|TAC + Pegfilgrastim (6 mg)|
89136925|NCT04227990|Experimental|TAC + Plinabulin 10 mg/m^2|
89136926|NCT04227990|Experimental|TAC + Plinabulin 20 mg/m^2|
89136927|NCT04227990|Experimental|TAC + Plinabulin 30 mg/m^2|
89136928|NCT04227990|Experimental|TAC + Pegfilgrastim (1.5 mg) + Plinabulin (20 mg/m^2)|
89136929|NCT04227990|Experimental|TAC + Pegfilgrastim (3 mg) + Plinabulin (20 mg/m^2)|
89136930|NCT04227990|Experimental|TAC + Pegfilgrastim (6 mg) + Plinabulin (20 mg/m^2)|
89136931|NCT04581746|Other|experimental arm|questionnaire and follow-up visit
89136932|NCT02606409|Active Comparator|Dexmedetomidine|Dexmedetomidine intravenous sedation at 0.2-0.7 µg/kg/h for >24h.
89136933|NCT02606409|Active Comparator|Propofol|Propofol sedation at 10-70µg/kg/h for >24h.
89136934|NCT00611767|Active Comparator|Family History Negative for Alcoholism|Family History Negative for Alcoholism subjects will receive 2 interventions
89136935|NCT00611767|Placebo Comparator|Family History Positive for Alcoholism|Family History Positive for Alcoholism subjects will receive 2 interventions
89136936|NCT02857439|Other|MD as first examiner|Patients will be examined according to a standardized physical examination item list
89136937|NCT02857439|Other|Triage nurse as first examiner|Patients will be examined according to a standardized physical examination item list
89136938|NCT05266326|Other|Test group|conventional Western medical treatment + bloodletting puncture
89136939|NCT05266326|Other|Control group|conventional Western medical treatment.
89136940|NCT02838446|Experimental|Cognitive Therapy|Graded motor imagery program was applied in only intervention group for 8 weeks.
89136941|NCT02838446|Active Comparator|Control|Rehabilitation program applied in both groups for 8 weeks. Frequency of the treatment was 2 days in per week and its duration was approximately one hour in one session.
89136942|NCT04967508|Experimental|SB17 (Proposed Ustekinumab Biosimilar)|
89136943|NCT04967508|Active Comparator|Stelara® (Ustekinumab)|
89136944|NCT00803361|Experimental|Duloxetine|
89136945|NCT00803361|Placebo Comparator|Placebo|
89136946|NCT02504840||healthy volunteers|healthy volunteers
89136947|NCT02504840||patient controls|Participants with diseases that share features with MS.
89136948|NCT02504840||patients with suspected or confirmed multiple sclerosis|Participants with definite, probable, or possible MS.
89136949|NCT02837198|Experimental|Uric acid-overproduction Type|FYU-981
89136950|NCT02837198|Experimental|Uric acid- underexcretion Type|FYU-981
89136951|NCT02837198|Experimental|Uric acid-overproduction Type (combination)|FYU-981 , Topiroxostat
89136952|NCT02837198|Experimental|Uric acid- underexcretion Type2|FYU-981
89136953|NCT00611533|Active Comparator|Atomoxetine|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
89136954|NCT00611533|Placebo Comparator|Placebo|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
89136955|NCT04038307|Placebo Comparator|control|will receive 100 ml of saline
89136956|NCT04038307|Experimental|paracetamol group|will receive 1gm paracetamol (100ml)
89136957|NCT05703243||Active|Newly diagnosed cancer patients.
89136958|NCT05703243||Control|Historically diagnosed cancer patients.
89136959|NCT02420990|Active Comparator|Behavioral Only- Treatment|All participants will receive behavioral interventions (CASH-AA): family psycho-education in ADHD symptoms, executive functioning, and developmental impacts; family-based motivation and ADHD accommodation interventions; and academic training focused on home environment support and organizational skills.
89234280|NCT00999024||Healthy subjects|20 healthy subjects will be included
89136960|NCT02420990|Experimental|Integrated Treatment|Half of the participants will also receive medication decision-making interventions (MIP): ADHD medication psychoeducation, family decision-making interventions, and (for those who elect to start medication) coordinated medication management.
89136961|NCT02543125|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O,R:30 per minute .
89136962|NCT02543125|Active Comparator|NHFOV|NHFOV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,MAP：6-14 cm H2O,Hertz(HZ):5-10 to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O.
89136963|NCT00884533|Experimental|Group 1|Group 1 - placebo on Day -1, rosi XR 8mg from Days 1-20, rosi XR 20mg on Day 21
89136964|NCT00884533|Placebo Comparator|Group 3|Placebo on Day -1, Days 1-20 and Day 21
89136965|NCT00884533|Active Comparator|Group 2|Placebo for Day -1, placebo on Days 1-20 and moxifloxacin active comparator 400 mg on Day 21
89136966|NCT02842814|Experimental|Full withdrawal|Intervention: 'Drug free'.
89136967|NCT02842814|Experimental|GC withdrawal|Intervention: 'HCQ' .
89136968|NCT02842814|Experimental|No withdrawal|Intervention: 'GC+HCQ' .
89136969|NCT02543047|Active Comparator|Right Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the right region of the heart
89136970|NCT02543047|Active Comparator|Left Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the left region of the heart
89136971|NCT02838602|Experimental|Carbon ions therapy|Radical and exclusive carbon ions radiotherapy
89136972|NCT02838602|Active Comparator|Conventional radiotherapy|Radical radiotherapy by Xrays and / or protons
89136973|NCT00882271|Experimental|1|Traditional Chinese Acupuncture
89136974|NCT00882271|Placebo Comparator|2|Placebo Acupuncture
89136975|NCT02778360|Experimental|Neurofeedback NFT|"Neurofeedback Training based on real time electroencephalography (EEG) signal. The patient is trained to modulate his brain activity thanks to a tablet installed with serious game.~Initiation/Discovery period during 21 days: initiation and discovery sessions Treatment period during 9 weeks: 36 training sessions at home"
89136976|NCT02778360|Active Comparator|Methylphenidate MPH|"Methylphenidate long acting preparation.~Open titration protocol during 21 days: 10 mg/day as a start until optimal dose is reached (maximum dose: 60 mg/day).~Treatment period during 9 weeks: optimal dose with MPH LA 10 and 30 mg (dose range: 10 mg/day to 60 mg/day)."
89136977|NCT00953147|Experimental|Ciclesonide HFA 80 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 40 mcg canister, to be administered as 1 puff in each nostril (80 mcg per day).
89136978|NCT00953147|Experimental|Ciclesonide HFA 160 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 80 mcg canister, to be administered as 1 puff in each nostril (160 mcg per day).
89136979|NCT00953147|Placebo Comparator|Placebo once daily|The placebo HFA nasal aerosol is identical to active drug, but does not contain ciclesonide.
89136980|NCT02842892|Other|Squat Jump|
89136981|NCT02842892|Other|Drop Jump|
89136982|NCT02842892|Other|Countermovement Jump|
89136983|NCT05333744|Experimental|Prednisone plus rhTPO|Prednisone 20mg per day, 2 weeks and rhTPO 300U/kg per day, 2 weeks
89136984|NCT05333744|Active Comparator|Prednisone|Prednisone 20mg per day, 2 weeks
89136985|NCT04228458|Experimental|Thermal Imaging|Thermal Imaging acquisition
89136986|NCT04250246|Experimental|Ipilimuamb plus nivoluamb plus guadecitabine|ipilimumab plus nivolumab combined with guadecitabine
89136987|NCT04250246|Active Comparator|Ipilimumab plus nivolumab|Ipilimumab plus nivolumab
89136988|NCT02779296|Experimental|2-Octyl Cyanoacrylate Glue|At the surgical site, a thin layer of cyanoacrylate glue will be applied over the sutures at the time of closure.
89136989|NCT02779296|No Intervention|No Glue|No cyanoacrylate glue will be applied.
89136990|NCT04273529|Placebo Comparator|Control group|placebo
89136991|NCT04273529|Experimental|Thalidomide group|thalidomide
89136992|NCT05333666||Age over 20 years and under non-vitamin K antagonist oral anticoagulant therapy|
89136993|NCT02838290|Experimental|Induction|
89136994|NCT02838290|Other|Control group|
89136995|NCT02776176|Experimental|ERAS group|Patients receive the Enhanced Recovery After Surgery program during the peri-operative period.
89136996|NCT02776176|Other|Traditional group|Patients receive the Traditional program during the peri-operative period.
89136997|NCT02858843|Experimental|Lumacaftor-ivacaftor|Subjects will be monitored for glycemic changes before and after starting lumacaftor-ivacaftor.
89136998|NCT00803205|Experimental|Ataluren|Participants will receive ataluren 3 times per day (TID): 10 milligrams (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
89136999|NCT00803205|Placebo Comparator|Placebo|Participants will receive placebo TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
89137000|NCT02836964|Active Comparator|Loading of Dental Implants after 4 weeks|"A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar. for this group.~After 4 weeks definitive crown will be placed."
89137001|NCT02836964|Active Comparator|Loading of Dental Implants after 3 months|A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar for this group. After 3 months definitive crown will be placed
89137002|NCT02779530|Experimental|Diclofenac|
89137003|NCT02779530|Placebo Comparator|Placebo|
89137004|NCT02836730||Lumbar disc herniation|Patients with surgery for lumbar disc herniation;
89137005|NCT02836730||Spinal stenosis|Patients with surgery for lumbar spinal stenosis
89137006|NCT02836730||No surgery|Patients with no surgery for lumbar disc herniation; patients with no surgery for lumbar spinal stenosis;
89137007|NCT00952523|Experimental|Tretinoin & Adapalene-Benzoyl Peroxide|Tretinoin and Adapalene-Benzoyl Peroxide facial gels applied once daily in a split face model
89137008|NCT02836808|No Intervention|Control|Patients attended with the standard model of care for diabetes, as out-patients in the Internal Medicine area
89137009|NCT02836808|Experimental|CAIPaDi|Patients attended in the Center of Comprehensive Care for the Patient with Diabetes, where they receive attention from 9 specialists in 1 day
89137010|NCT02779218|Experimental|Sequence 1|"The patients will receive in order :~Paired Associative Stimulation~Paired Associative Stimulation + Motor Imagery exercises~Placebo Paired Associative Stimulation + Motor Imagery exercises"
89137011|NCT02779218|Experimental|Sequence 2|"The patients will receive in order :~Paired Associative Stimulation + Motor Imagery exercises~Placebo Paired Associative Stimulation + Motor Imagery exercises~Paired Associative Stimulation"
89137012|NCT02779218|Experimental|Sequence 3|"The patients will receive in order :~Placebo Paired Associative Stimulation + Motor Imagery exercises~Paired Associative Stimulation~Paired Associative Stimulation + Motor Imagery exercises"
89137013|NCT04249154|Other|Post-op IMRT & hormonal therapy|The protocol is designed to recruit patients who have undergone prostatectomy and high risk features of the disease were found post-operatively or for patients that, after prostatectomy, a PSA rise has been documented will be enrolled in the Phase II trial. Patients will receive Eligard injection 8-12 weeks before starting radiation. The second injection is given 12 weeks after the first one concomitant with radiation therapy.
89137014|NCT02779140|Experimental|0.033 mg/kg NTM-1632|N=6 administered 0.033 mg/kg NTM-1632 IV, N=2 administered placebo IV
89137015|NCT02779140|Experimental|0.165 mg/kg NTM-1632|N=6 administered 0.165 mg/kg NTM-1632 IV, N=2 administered placebo IV
89137016|NCT02779140|Experimental|0.33 mg/kg NTM-1632|N=6 administered 0.33 mg/kg NTM-1632 IV, N=2 administered placebo IV
89137017|NCT00914433|Experimental|TPI 1100|Drug to be given by inhalation.
89137018|NCT04228146|Experimental|CBT-I condition|Participants in the CBT-I condition start the 6-week CBT-I immediately after randomization, complete the post-intervention assessment right after they finish the treatment, and complete the follow-up assessment six weeks after the post-intervention assessment.
89137019|NCT04228146|Other|Waitlist control condition|Participants in the waitlist control group complete the post-intervention assessment six weeks after the baseline assessment, start CBT-I (equivalent to that of the CBT-I group) immediately after completing the post-intervention assessment, and complete the follow-up assessment right after they finish the 6-week CBT-I.
89137020|NCT02857361|Experimental|Treatment A: Simultaneous Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered simultaneously at T=0 minute.
89137021|NCT02857361|Experimental|Treatment B: Sequential Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered sequentially, one 25 mg wafer at T=0 minute and one 25 mg wafer at T=3 minutes.
89137022|NCT02836886||Sézary syndrome|Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
89137023|NCT02606175|Other|Admitted for renal transplantation|"Patients who are hospitalised on the abdominal transplantation surgery ward at the University Hospitals of Leuven (UZLeuven) and undergo a kidney transplantation during this hospitalisation.~Intervention: taking questionnaires and tests at predefined timepoints:~at discharge: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire~1 month after kidney transplantation: BAASIS, medication knowledge test~3 months after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test~1 year after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire~2 years after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire"
89137024|NCT02778282|No Intervention|Standard Care|Standard Care through office-based opioid treatment with buprenorphine/naloxone and weekly urine toxicology screening
89137025|NCT02778282|Experimental|Standard Care + MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents Standard Care plus MySafeRx™.
89137026|NCT02857205|Other|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
89137027|NCT05333510||TEG group|Thromboelastography guided blood product administration in patients of liver cirrhosis with non variceal bleed
89137028|NCT05333510||ROTEM group|Throboelastometry guided blood product administration in patients of liver cirrhosis with non variceal bleed
89137029|NCT02778126|Experimental|[¹⁴C]Prexasertib|170 milligrams (mg) of prexasertib containing approximately 50 μCi [¹⁴C] prexasertib radiotracer administered intravenously (IV) as a 1 hour continuous IV infusion.
89137030|NCT02778126|Experimental|Prexasertib|"105 milligrams per square meter (mg/m²) of prexasertib administered IV as a 1 hour continuous IV infusion once every 14 days (14 day cycles). Treatment may continue until discontinuation criteria are met.~Treatment for this arm was administered after ¹⁴C administration (¹⁴C was administered during first phase of the study)"
89137031|NCT02606331|Experimental|Piezosurgery|In one half of the dental arch, piezosurgery will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
89137032|NCT02606331|Experimental|ER:YAG Laser|In one half of the dental arch, ER:YAG laser irradiation will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
89137033|NCT02834702|Experimental|Sinew acupuncture|Sinew acupuncture
89137034|NCT02834702|Sham Comparator|Sham acupuncture|Sham acupuncture
89137035|NCT05052060|Experimental|Group A|19 patients will be treated with pelvic tilt exercises
89137036|NCT05052060|Active Comparator|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
88803038|NCT01938326|Active Comparator|Multi-port laparoscopic distal gastrectomy|Laparoscopic distal gastrectomy using the conventional 5-port access
89137037|NCT05689281|Experimental|PrEP peer navigation|Culturally informed health care empowerment and PrEP peer navigation and support through social determinant of health stressors
89137038|NCT02778048||fecal incontinence patients (m/f)|patients suffering from fecal incontinence (m/f) are going to be assessed via MRI, US, FLIP, and HRAM
88803039|NCT01938326|Active Comparator|Single incision distal gastrectomy|Pure single incision distal gastrectomy using one transumbilical incision
88803040|NCT05751850|Experimental|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|
88803041|NCT05751850|Active Comparator|nab-paclitaxel; gemcitabine|
88803042|NCT02168933|Experimental|active excimer laser|308 nm excimer laser treatment: treatment with the laser by a dose protocol with increasing output.
88803043|NCT02168933|Sham Comparator|Sham excimer laser|Sham 308 nm excimer laser treatment: laser dose was administered with a cap that blocks all active UV passing through the device, therefore is a placebo, but because the procedure is the same, maintains a blind.
88803044|NCT01239511|Placebo Comparator|Placebo group|placebo capsule 2# t.i.d./day
88803045|NCT01239511|Experimental|Treatment Group A|150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
88803046|NCT01239511|Experimental|Treatment Group B|300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
88803047|NCT01239511|Experimental|Treatment Group C|450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
88803048|NCT03009877|Active Comparator|Preoxygenation with face mask|Standard preoxygenation with a mask will be performed for five minutes. Once preoxygenation is complete, patients will be induced with standard induction medications including lidocaine, midazolam, fentanyl and propofol. Once the patient is apneic, one breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. The 5.5mm flexible intubation scope will be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope. Once the flexible intubation scope is in the trachea, the endotracheal tube (7.0 mm unless otherwise specified) will be advanced. Ventilation will not begin until the primary or secondary endpoints are reached.
88803049|NCT03009877|Experimental|Preoxygenation via hi flow nasal cannula|The high flow nasal cannula (Optiflow) will be applied as soon as the patient is in the operating room. The patient will be preoxygenated with high flow nasal cannula at 50 L/min for 5 minutes. After induction, general anesthesia will be maintained with a propofol infusion. One breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. Upon apnea, the Optiflow™ flow will be increased to 70 L/min and jaw thrust will be performed until the patient is adequately relaxed. The video laryngoscope (C-MAC) will then be introduced into the oropharynx and the flexible intubation scope advanced into the trachea with the assistance of the C-MAC. Once the flexible intubation scope is in the trachea, the endotracheal tube will be advanced.
88803050|NCT01241539|Experimental|Dabigatran etexilate 110 mg|Capsule, oral
88803051|NCT01241539|Experimental|Dabigatran etexilate 75 mg|Capsule, oral
88803052|NCT01241539|Experimental|Dabigatran etexilate 150 mg|Capsule, oral
88803053|NCT01242241|Other|Non-obese|Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile
88803054|NCT01242241|Active Comparator|Obese children|Obese children are categorized as those with a body mass index >95th percentile
88803055|NCT04962113|Experimental|Tunnel group Tube bath during the phototherapy|
88803056|NCT04962113|No Intervention|Tunnel group rutin care|
88803057|NCT04962113|Experimental|LED group Tube bath during the phototherapy|
88803058|NCT04962113|No Intervention|LED group rutine care|
88803059|NCT02393690|Experimental|Arm I (selumetinib, iodine I-131)|Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.
88803060|NCT02393690|Active Comparator|Arm II (placebo, iodine I-131)|Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.
88803061|NCT05751616|Active Comparator|Conventional sintering|
88803062|NCT05751616|Experimental|Speed sintering|
88803063|NCT02189161|Experimental|Radiofrequency Ablation|circumferential radiofrequency ablation (RFA) to the anal canal
88803064|NCT05593367||VD-， VD deficiency group|The IBS-D patients whose serum 25(OH)D level was<20ng/ml
88803065|NCT05593367||VD+， VD normal group|The IBS-D patients whose serum 25(OH)D level was ≥20ng/ml
88803066|NCT02246959|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive electronic pill bottles for their statin medication but are not enrolled in the sweepstakes.
88803067|NCT02246959|Experimental|Process Arm|Arm 2 will be a Process incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
88803068|NCT02246959|Experimental|Outcome Arm|Arm 3 will be an Outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group may receive incentives if they lower their LDL.
88803069|NCT02246959|Experimental|Process Plus Outcome Arm|Arm 4 will be a process plus outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication and receive additional incentives for lowering their LDL cholesterol.
88803070|NCT05751538||Train dataset|This group is dedicated to developing an automated algorithm.
88803071|NCT05751538||Test dataset|This group is dedicated to testing the performance of an automated algorithm.
88803072|NCT05751538||Clinical Validation|This group is dedicated to assessing the clinical validity of the measurement in an independent validation cohort.
88803073|NCT05593211|Experimental|Patients undergoing a scheduled, elective, solid organ biopsy procedures on the liver or kidneys|
88803074|NCT01499342||Rutherford category 2 - 5|
88803075|NCT01200433|Active Comparator|propofol|Subjects will be sedated with propofol.
88803076|NCT01200433|Active Comparator|dexmedetomidine|Subjects will be sedated with dexmedetomidine.
88803077|NCT02973022||Community CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group in the community will be exposed to the modified CC&S educational sessions in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational sessions. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
89137039|NCT02834858|Experimental|Umbilical Cord Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells Infusion.
89137040|NCT02834858|Placebo Comparator|saline|saline injection
89137041|NCT02232737|Experimental|0.8 mg nicotine|0.8 mg nicotine cigarettes
89137042|NCT02232737|Experimental|0.12 mg nicotine|0.12 mg nicotine cigarettes
89137043|NCT02232737|Experimental|0.03 mg nicotine|0.03 mg nicotine cigarettes
89137044|NCT04226196|Experimental|Axis 0|IOL Implantation at the 0 +/- 10 degrees axis
89137045|NCT04226196|Experimental|Axis 45|IOL Implantation at the 45 +/- 10 degrees axis
89137046|NCT04226196|Experimental|Axis 90|IOL Implantation at the 90 +/- 10 degrees axis
89137047|NCT04226196|Experimental|Axis 135|IOL Implantation at the 135 +/- 10 degrees axis
89137048|NCT04272359||Group 1|SGLT2 inibitori +/- Metformin
89137049|NCT04272359||Group 2|DPP4 inibitori +/- Metformin
89137050|NCT04272359||Group 3|GLP1-RA + Long-Acting Insulin +/- Metformin
89137051|NCT04272359||Group 4|SGLT2 inibitori + DPP4 inibitori +/- Metformin
89137052|NCT02834468|Experimental|Treatment group|DEX Combined With RTX, CSA and IVIG All patients are assigned to receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
89137053|NCT02777814|Experimental|Prophylactic Entecavir|Entecavir is prophylactically used from the time of chemotherapy initiation at the dose of 0.5 mg p.o daily
89137054|NCT02777814|Active Comparator|Preemptive Entecavir|Entecavir is preemptively used from the time that hepatitis B virus DNA copies are more than 100 IU/ml at the dose of 0.5 mg p.o daily
89137055|NCT00914511|Experimental|Healthy young males|Healthy young males age 18-45, inclusive
89137056|NCT00914511|Experimental|Elderly males|Elderly males 65 years of age and older
89137057|NCT02778906|Active Comparator|Abatacept|Abatacept 125 mg s.c. weekly
89137058|NCT02778906|Placebo Comparator|Placebo|Placebo (NaCl 0,9%) s.c. weekly
89137059|NCT00630929|Active Comparator|A|
89137060|NCT00630929|Placebo Comparator|C|
89137061|NCT00630929|Experimental|B|
89137062|NCT02838212||Drug-related deaths|fatal adverse drug reactions
89137063|NCT02838212||non drug-related deaths|deaths for other causes different as drugs
89137064|NCT02779452||GDM newborns|Newborns from gestational diabetes mellitus pregnancy
89137065|NCT02779452||No GDM newborns|Newborn from a normal pregnancy
89137066|NCT05212116|Experimental|SDI-118 low dose|SDI-118 (low dose) orally once daily (QD) for 17±1 day.
89137067|NCT05212116|Experimental|SDI-118 high dose|SDI-118 (high dose) orally once daily (QD) for 17±1 day.
89137068|NCT05212116|Placebo Comparator|Placebo|Placebo orally once daily (QD) for 17±1 day.
89137069|NCT00952367||Per-protocol population|In all, 3641 participants were enrolled; however, 38 were excluded because of violation of inclusion/exclusion criteria and 3 participants were excluded for unavailability of nasopharyngeal swab sample. The record presents demographic and result data for 3600 participants in the per-protocol population. These participants completed collection of the nasopharyngeal swab sample, the Epidemiology questionnaire, and 24 hours safety observation.
89137070|NCT02834546||Patients with HCC treated with sorafenib|
89137071|NCT04114032||High-risk elective surgical patients|"The patient population to be studied are elective patients for non-cardiac surgery.~Age ≥ 45 years of age.~Undergoing intermediate or major non-cardiac surgery requiring an overnight stay in hospital.~With at least one of the following criteria:~History of ischaemic heart disease or peripheral vascular disease (coronary equivalent)~History of stroke or transient ischaemic attack~History of congestive cardiac failure~Diabetes currently on an oral hypoglycaemic agent or insulin~Serum creatinine >175 µmol/L (>2.0mg/dl)"
89137072|NCT02834312|Experimental|2.5 mg estetrol|
89137073|NCT02834312|Experimental|5 mg estetrol|
89137074|NCT02834312|Experimental|10 mg estetrol|
89137075|NCT02834312|Experimental|15 mg estetrol|
89137076|NCT02834312|Placebo Comparator|placebo|
89137077|NCT04227834|Active Comparator|Single education|Single health hygiene education
89137078|NCT04227834|Experimental|Repeated education|Four-monthly health hygiene education
89137079|NCT02831738|Experimental|Active Treatment|Polydextrose 12 g
89137080|NCT02831738|Placebo Comparator|Control Treatment|No polydextrose
89137081|NCT02857049|Experimental|Geriatric patients administered with ONS|Oral nutritional supplements (ONS) degustation
89137082|NCT02831582|Active Comparator|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid supplementation PO QD for 6 months.
89137083|NCT02831582|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
89137084|NCT02776332|Active Comparator|3 day group|Manual expression for 3 days after delivery Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
89137085|NCT02776332|Active Comparator|7 day group|The 7 day group will manually express for 7 days after delivery. Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery follow up phone call at 5 days to encourage continued manual expression
89137086|NCT00948857|Experimental|DHEA active treatment|Dehydroepiandrosterone 25 mg tid po
89137087|NCT00948857|Placebo Comparator|DHEA Placebo|Blinded placebo
89137088|NCT04227912|Active Comparator|Group TAP|Ultrasound-guided TAP Block
89137089|NCT04227912|Active Comparator|Group Local|Ultrasound-guided Local Infiltration
89137090|NCT04227912|Active Comparator|Group Dexketoprofen|Intravenous Dexketoprofen
89137091|NCT02831504||Myotonic Dystrophy type 1 (DM1) patients|Natural History Study
89137092|NCT04270253|Experimental|End-range mobilization|End-range mobilization applied 6 times for 2*2 min in end-range of flexion and extension end-range of the tibiofemoral and patellofemoral joint beside the same conservative therapy, as used for the Control
89137093|NCT04270253|Active Comparator|Control|Conservative therapy including aquatic exercises (5-times), land-based exercises (3-times), balneotherapy (5-times) and TENS therapy (3-times)
88803078|NCT02973022||Community Control Group|Once participants are randomized, they will be given survey 1. The control group in the community will be exposed to a nutrition education program in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational session. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
88803079|NCT02973022||ACEC CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group at ACEC (Adams-Columbia Electric Company) will be exposed to the modified CC&S educational sessions in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. The researchers anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
88803080|NCT02973022||ACEC Control Group|Once participants are randomized, they will be given survey 1. The control group at ACEC will be exposed to a nutrition education program in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. We anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
88803081|NCT04755686|Experimental|Fast-tracking at geriatric medicine ward|Fast-tracking hip fracture patients at geriatric medicine ward. The goal is to optimize the medical care of older hip fracture patients at a geriatric ward and to shorten the time to operation.
88803082|NCT04755686|No Intervention|Regular admission|Regular admission and care of hip fracture patients at the emergency room prior to surgery.
88803083|NCT01894880|Active Comparator|early SSC|Early SSC: bonding straight after birth
88803084|NCT01894880|Other|late SSC|late SSC: bonding after termination of operation
88803085|NCT01243333|Experimental|Diagnostic (multi-tracer PET scans)|Patients undergo Positron Emission Tomography (PET) scans with [F-18]fluorodeoxyglucose and [F-18]fluorothymidine at baseline and within 7 days of completion of 1 or 2 (if the course is less than 3 weeks) therapeutic agent courses.
88803086|NCT05593133|Experimental|Pnf exercises|warm up, rhythmic stabilization, hold relax, contract relax and light exercises performed on three muscle groups
88803087|NCT05593133|Experimental|Gait training exercises|exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking.
88803088|NCT01924052|Active Comparator|Migraine patients with high genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
88803089|NCT01924052|Active Comparator|Migraine patients with low genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
88803090|NCT01243567|Active Comparator|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
88803091|NCT01243567|Active Comparator|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
88803092|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
88803093|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
88803094|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
88803095|NCT01001195|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
88803096|NCT02185729|Active Comparator|Healthy Volunteer|Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat)
88803097|NCT01001975|Experimental|SPF Testing|Following Food and Drug Administration (FDA) guidelines for SPF testing, exposure control and product-protected site erythema responses are scored after 16 to 24 hours post-exposure to full spectrum light (Ultraviolet B radiation [UVB] and UVA).
88803098|NCT01001975|Experimental|UVA Protection Testing|Determination of Ultraviolet A Protection Factor (PFA). Following FDA guidelines, test sites exposed to UVA are scored for pigmentation responses 2 to 4 hours post-exposure.
88803099|NCT01201057|Experimental|0.5% SPL7013 Gel|
88803100|NCT01201057|Experimental|1.0% SPL7013 Gel|
88803101|NCT01201057|Experimental|3.0% SPL7013 Gel|
88803102|NCT01201057|Placebo Comparator|Placebo Gel|
89137094|NCT02776254|Experimental|START|The START model aims to deliver a higher intensity of treatment services by offering same-day CD4 testing and results, streamlined adherence counseling, and quicker initiation of life-long ART to patients enrolling in HIV care and treatment services.
88803103|NCT01444040|Active Comparator|iStent inject|Implantation of two iStent inject devices
88803104|NCT01444040|Active Comparator|Drug|Travoprost drops
88803105|NCT05751382|Experimental|Group A - Restoration with Surefil one hybrid composite|Restoration will be performed with Surefil one hybrid composite applied according to manufacturer's instruction and cured for 20 secunds with a LED lamp (Smartlamp Pro).
89234281|NCT00999024||COPD Patients|20 Patients with Grade IV COPD will be included
89137095|NCT02776254|Experimental|FAST Track|In the FAST-TRACK model a pharmacy technician will dispense drugs) and lay health care workers will provide brief symptom screening to identify patients in need of higher-level care. If there is no need of higher-level care, then the clinic visit is over.
89137096|NCT02776254|Experimental|CAG (intervention)|CAG intervention, consists of facilitated groups of six people based on geographic proximity of home address and patient preference. This group of six people, will meet monthly at a designated place in the community to provide support and receive medications. Each month one of the members will rotate visiting the clinic for their routine medical visit and will pick up medications for the entire CAG and bring them back to the community. This rotation schedule will recur every six months. Lay health care workers will provide brief symptom screening to identify patients in the group that need of higher-level care.
89137097|NCT02776254|Active Comparator|CAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
89137098|NCT02776254|Experimental|UAG (intervention)|Urban sites will be eligible for the UAG model in which patients will be joined into a UAG group consisting of 30 people. Each UAG group will meet every two to three months at a designated site (either at the clinic facility or another site in the community). Patients will receive (a) group adherence counseling led by a lay HCW (b) two to three month supply of ART medications via a pharmacy tech (c) attendance record and symptom assessment. As in the CAG model, patients may be referred up-referred for care based on acute illness or patient preference. Patients will continue to visit the facility for a routine medical visit with a professional HCW every six months.
89137099|NCT02776254|Active Comparator|UAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
89137100|NCT02834156|Other|LP in a seated position then LP in a lying position|Patients will have first a lumbar puncture (LP) in a seated position then a LP in a lying position
89137101|NCT02834156|Other|LP in a lying position then LP in a seated position|Patients will have first a lumbar puncture (LP) in a lying position then a LP in a seated position
89137102|NCT02854787|Active Comparator|Phenylephrine|A bolus of 100 mcg
89137103|NCT02854787|Active Comparator|Norepinephrine|A bolus of 0,2 mcg/kg
89137104|NCT02834234||Peritoneal mesothelioma specimens|"The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group.~The CGH arrays will be realized on frozen samples (for the comparative genomic analysis)."
89137105|NCT02776020||Propofol sedated patients|Women undergoing a short trans vaginal ovum retrieval (TVOR) will be sedated with propofol , and monitored non-invasively for changes in blood propofol concentration levels. Propofol dosages will be adapted according to patients vital signs and their reaction to noxious stimuli exerted during the trans vaginal ovum retrieval (TVOR) procedure, irrespective to the proposed study in which these participants undergo.Those changes of administered propofol dosages will be observed by the anesthetic drug monitor (ADM). Propfol is administered by the anesthesiologist in a routine manner and according to anesthesiologist discretion .
89137106|NCT02831426|Active Comparator|ADM two-stage reconstruction|Two-stage with Acellular Dermal Matrix (CELLIS® Breast). Tissue Expander A, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by ADM
89137107|NCT02831426|Experimental|TCPM two-stage reconstruction|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra). Tissue Expander B, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by TCPM
89137108|NCT02778828|Experimental|Patients with Multi-Resistant Tb|
89137109|NCT02831270||Control Group|Patients undergoing cardiac surgery supposed not to get acute normovolemic hemodilution (ANH) before CPB
89137110|NCT02831270||Active Comparator: Acute normovolemic hemodilution group|Patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
89137111|NCT02831192|Experimental|MST（microtransplantation）|
89137112|NCT02778984|Active Comparator|standard face masks|The standard mask is used in usual care
89137113|NCT02778984|Experimental|QuadraLite face masks|This study will compare tightness of 2 face masks during preoxygenation and after induction of anesthesia with propofol, sufentanil and rocuronium. During preoxygenation, a 10 l.min-1 fresh gas flow and 8 cm H2O PEEP will be applied. After induction of anesthesia, patients will receive pressure-controlled ventilation (fresh gaz flow 3 L.min-1, pressure set to obtain a 7 ml.kg-1 ideal body weight, 10 cpm, peep 5 cm H2O).
89137114|NCT02831114|Experimental|Intervention|The nine participants in the intervention arm will receive 18 acupuncture treatments over the course of 12 weeks (2 treatments per week for 6 weeks and 1 treatment per week for 6 weeks). They will undergo assessments at baseline, 6 weeks, and 12 weeks through the use of questionnaires and blood tests. The participants will also be allowed to continue their conventional therapy for TIPN.
89137115|NCT02831114|No Intervention|Control|The nine participants in this arm will undergo the same assessments as the intervention arm at baseline, 6 weeks, and 12 weeks. They will not receive any acupuncture treatments during this time, but will be allowed to continue their conventional therapy. The control arm will be offered the same 18 acupuncture treatments after a wait of at least 12 weeks.
89137116|NCT02777736|Experimental|Arm A - Methotrexate i.v.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive 2 cycles of methotrexate 3g/m2 i.v. after the 3rd and 6th cycle of systemic chemotherapy (R CHOP or DA EPOCH R).
89137117|NCT02777736|Active Comparator|Arm B - Methotrexate i.t.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive intrathecal methotrexate 12mg in each cycle of systemic chemotherapy (6x).
89137118|NCT02777736|No Intervention|Arm C - no Methotrexate|Patients with 0-1 risk factor for CNS relapse will not receive CNS prophylaxis.
89137119|NCT04247360|Other|cuff pressure with 20cmH2O|continuous monitoring and maintaining cuff pressure with 20 cmH2O during surgery
89137120|NCT04247360|Other|cuff pressure with 30cmH2O|continuous monitoring and maintaining cuff pressure with 30 cmH2O during surgery
89137121|NCT05026086|Experimental|biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
89137122|NCT05026086|Active Comparator|isometric exercises|10 patients will be treated with isometric exercises without pressure biofeedback.
89137123|NCT02775942|Experimental|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
89137124|NCT02775942|Experimental|IPOVAC 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
88803106|NCT05751382|Active Comparator|Group B - Restoration with Venus Pearl composite|After the application of the adhesive system (iBond universal), the Venus Pearl composite will be layered on the cavity and cured for 20 seconds with a LED lamp Smartlamp Pro).
88803107|NCT01002287|Experimental|SprayShield Adhesion Barrier|SprayShield Adhesion Barrier
88803108|NCT01002287|Sham Comparator|Control|Good Surgical Technique Alone
88803109|NCT04294862|Experimental|TNP-2092 300mg IV|TNP-2092 for injection 100mg/vial, 300mg, BID, 1 dose
88803110|NCT04769791|Experimental|cuff inflation by the residual volume|LMA will be inserted with the initial inflating volume correspondent to residual volume group ( RV group): volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 ml syringe without plunger is connected to the laryngeal cuff for 5 minutes.
88803111|NCT04769791|Experimental|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group):
88803112|NCT04769791|Experimental|unchanged cuff inflation volume|LMA will be inserted with the initial inflating volume correspondent to unchanged volume group (NV group): LMA is unpacked and used without inflating or deflating the cuff.
88803113|NCT01437176|Experimental|Unstable intertrochanteric fracture fixed with novel nail|AO/OTA A2 fracture fixed with novel nail
88803114|NCT01437176|Experimental|unstable intertrochanteric fracture fixed with PFNA|AO/OTA A2 fracture fixed with PFNA
88803115|NCT05751304|Active Comparator|Group D|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg dexametomidine.
88803116|NCT05751304|Active Comparator|Group K|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
88803117|NCT01202071|Experimental|Rabeprazole sodium Tablets, 5 mg|
88803118|NCT01202071|Experimental|Rabeprazole sodium Tablets, 10 mg|
88803119|NCT01202071|Experimental|Rabeprazole sodium Tablets, 20 mg|
88803120|NCT01202071|Experimental|Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets)|
88803121|NCT05592821||Test Group: soft tissue level implants|In this study, it was planned to use 20 implants of the same brand, with a single implant in the bilateral posterior regions in 10 patients. While the bone level implant is placed on one side of the patients, the tissue level implant will be used on the other side. The study will be designed as split-mouth. The type of implant to be placed in the regions will be decided according to the amount of keratinized gingival level above the alveolar crest level. Soft tissue level implants are in this group
88803122|NCT05592821||Control Group: bone level implants|In this study, it was planned to use 20 implants of the same brand, with a single implant in the bilateral posterior regions in 10 patients. While the bone level implant is placed on one side of the patients, the tissue level implant will be used on the other side. The study will be designed as split-mouth. The type of implant to be placed in the regions will be decided according to the amount of keratinized gingival level above the alveolar crest level. Bone level implants are in this group
88803123|NCT01422746|Experimental|metformin|12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
88803124|NCT01002755|Experimental|Treatment (lenalidomide, ofatumumab)|Participants receive ofatumumab IV over 4 hours on days 1, 8, 15, and 22 of course 1, day 1 of courses 2-6, and day 1 of every even course beginning course 8. Beginning day 9 of course 1, participants also receive lenalidomide PO daily. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
88803125|NCT04331314|Experimental|SYMBIOS®|Sinus augmentation with SYMBIOS® Biphasic Bone Graft Material
89137125|NCT02775942|Experimental|IPOVAC 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
89137126|NCT02775942|Active Comparator|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
89137127|NCT02836340|Experimental|2-Iminobiotin|Increasing dosage of study drug
89137128|NCT02775786|No Intervention|Healthy Volunteers|Normal volunteers with no pancreas mass or risk factors for pancreas cancer will be recruited for MRI protocol optimization and nothing more. No intravenous contrast will be given. They will be asked to lie in the scanner for up to 1 hour and non-contrast imaging will be performed.
89234282|NCT00994656||posterior spinal fusion subject|Subject will have a history of either idiopathic or neuromuscular scoliosis who is now scheduled to have a posterior spinal fusion.
88803126|NCT04331314|Active Comparator|Algipore®|Sinus augmentation with Algipore® Bone Substitution Material
88803127|NCT01887860|Experimental|Cetaphil Daily Facial Moisturizer SPF50|All subjects receive Cetaphil Daily Facial Moisturizer SPF 50
88803128|NCT01003067|No Intervention|No Mesh|
88803129|NCT01003067|Experimental|Mesh Implementation|
88803130|NCT01885130|Experimental|Cetaphil Daily Advance Ultra Hydrating Lotion|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
88803131|NCT01003301|Experimental|Omalizumab|Active treatment: Experimental This arm will receive treatment with omalizumab at the dose FDA-approved for the treatment of allergic asthma.
88803132|NCT01003301|Placebo Comparator|Placebo|This arm will receive treatment with a placebo injections based on the FDA-approved dosing schedule approved for omalizumab for the treatment of allergic asthma.In general injection number and frequency are determined by a subject's weight and IgE level.
88803133|NCT01421810|Experimental|dexamethasone, rhCG (Ovidrel)|rhCG (Ovidrel) administered 25 mcg IV; dexamethasone administered 1 mg PO
88803134|NCT01243957|Experimental|LY2216684 + fluoxetine|"LY2216684: 18 milligrams (mg) oral (po) once daily (QD) on Days 1, 2, and 3 and Days 25-27~Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)"
88803135|NCT01895816|Experimental|fertility coated tablet|700 mg fertility coated tablet containing 8 herbal powders by mouth every 12 hours for 180 days
88803136|NCT02979847|Experimental|Treated|hybrid approach (epicardial and subsequent endocardial mappings and ablations)
88803137|NCT02979847|Active Comparator|Control|conventional endocardial approach
88803138|NCT01884740|Experimental|SIACI of Erbitux and Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Erbitux (200 mg/m^2) and Bevacizumab (15 mg/kg)
88803139|NCT01003769|Experimental|Treatment (lenalidomide in combination with AT-101)|Patients receive lenalidomide PO QD on days 1-21. Beginning in course 2, patients also receive AT-101 PO BID on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.
88803140|NCT01244503|Experimental|Sodium Octanoate Breath Test|Only subjects with metabolic syndrome and suspected non alcoholic fatty liver disease will undergo breath test. They must not have any other liver disease.
88803141|NCT01004393|Experimental|Methylnaltrexone bromide|A single dose of methylnaltrexone will be administered subcutaneously to eligible subjects based on weight at the study entry. Since we will include subjects at all stages of cancer management, administering this study drug is considered experimental. We will use the dose approved by FDA, i.e., 0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg.
88803142|NCT01245439|Experimental|1|
88803143|NCT01876628|Placebo Comparator|Flucloxacillin and Placebo oral capsule|Intravenous or oral Flucloxacillin with a Placebo oral capsule
88803144|NCT01876628|Active Comparator|Flucloxacillin and Clindamycin|Intravenous or oral Flucloxacillin with Clindamycin oral capsule
88803145|NCT01004705|Experimental|Fixed Dose Combination Pill|Once daily oral dose of combination of acetylsalicylic acid, simvastatin, and ramipril (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 or 10 mg ramipril)
88803146|NCT01004705|Active Comparator|Simvastatin|Once daily oral dose of Simvastatin 40 mg
88803147|NCT01417286|Experimental|Radiation Therapy|Patients undergo hypofractionated accelerated radiation therapy over 11 weekdays (for 15 elapsed days) within 21-63 days after last surgery or last course of chemotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
88803148|NCT01417208||SNaP® Wound Care System|
88803149|NCT00505310|Experimental|Emotional Expression Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
88803150|NCT00505310|Experimental|Neutral Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
88803151|NCT01004939||fondaparinux prescribed subjects|fondaparinux prescribed subjets
88803152|NCT05750836|Experimental|Specific nursing support|The caregivers benefit from specific nursing support.
88803153|NCT05750836|Active Comparator|No specific nursing support|Caregivers do not receive any specific support from the nurses.
88803154|NCT04389710|Experimental|Intervention Group|Participants included in the experimental group will receive 200-600 milliliters of convalescent plasma, administered at a rate of 100-250 mL/hr
88803155|NCT04239248|Experimental|ACTIVE-RCT-I Tasty&Healthy intervention group|Patients with mild-moderately symptomatic disease, will follow the Tasty&Healthy dietary approach.
88803156|NCT04239248|Active Comparator|ACTIVE-RCT-I Control group|Patients with mild-moderately symptomatic disease, will receive EEN with Modulen formula only.
88803157|NCT04239248|Experimental|MH-RCT-II Tasty&Healthy intervention group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will follow the Tasty&Healthy dietary approach.
88803158|NCT04239248|No Intervention|MH-RCT-II Control group|Patients with laboratory evidence of mucosal inflammation but who are asymptomatic or have only minimal symptoms not requiring immediate treatment modification, will continue their habitual diet.
88803159|NCT03015389||Barrett's associated esophageal dysplasia|
88803160|NCT01245595|Active Comparator|Aminophylline|Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
88803161|NCT01245595|Placebo Comparator|Placebo|Normal Saline Placebo
88803162|NCT01864772|Experimental|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
88803163|NCT03010891|Active Comparator|control condition|Preterm infants in the control condition will receive only usual NICU care, plus positioning and gentle touch during intrusive procedures.
88803164|NCT03010891|Experimental|experimental condition|The bundle of supportive interventions will be designed to alleviate preterm infants' stress/pain from birth to discharge from the hospital NICU.
88803165|NCT00002494|Experimental|Combination therapy|Patients receive combination therapy as described in the study description. All patients must complete at least the first 3 courses of chemotherapy. Courses 2 and 3 each repeat 3 times in the absence of disease progression or unacceptable toxicity. On days 134-139, patients who have had prior bone marrow involvement receive cranial radiation therapy. Patients who achieve less than a complete response and who have an HLA-matched sibling should undergo allogeneic bone marrow transplant on protocol CLB-9113. Patients are followed monthly for 6 months, every 2 months for 18 months, every 6 months for 2 years, and thereafter for survival.
88803166|NCT02164721|Other|CRT-D (Defibrillator)|Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
88803167|NCT01895894|Experimental|Mycophenolate mofetil|
88803168|NCT01895894|No Intervention|Control|
88805929|NCT04161950||Compared device model (GF-UE260-ME2)|Compared device model: The GF-UE260 echoendoscope manufactured by Olympus and its compatible light source, image processor and ME2 ultrasonic processor.
88803169|NCT02165111|Experimental|Onabotulinumtoxin A|"One hand of each patient will be randomly selected for injection of Botulinum Toxin A (Onabotulinumtoxin A, 20 units/mL).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (10 units each=0.5mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (5 units each= 0.25mL each). Total treatment dose of Botulinum Toxin A will not exceed 50 units per hand."
88803170|NCT02165111|Placebo Comparator|Placebo|"One hand of each patient will be randomly selected for injection of sterile saline solution (placebo).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (0.5 mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (0.25 mL each)."
88803171|NCT04043975||Cohort 1|Participants with advanced or metastatic renal cell carcinoma (aRCC) receiving the combination of nivolumab plus ipilimumab as the first line of systemic therapy
88803172|NCT05750602|Experimental|LIMICOL|"LIMICOL : red yeast rice (with monacolin K, 2 mg), artichoke leaf extract, policosanols, French maritime Pine bark extract, Garlic extract, vitamins E, B2 and B3.~1 tablet during the 3 principal meals for 12 weeks."
88803173|NCT05750602|Placebo Comparator|PLACEBO|"dicalcium phosphate, calcium citrate, vegetable magnesium stearate, microcrystalline cellulose, Maltodextrin, Tricalcium phosphate, Beet powder, Yellow coloring shellac, Brown coloring shellac.~1 tablet during the 3 principal meals for 12 weeks."
88803174|NCT04755374||Group 1|Discharged from palliative care unit in equal or less than 21 days
88803175|NCT04755374||Group 2: Prolonged discharged in longer than 21 days|Discharged from palliative care unit in longer than 21 days
88803176|NCT04389788|Active Comparator|Rt Eye|The right eye of the patients received carboxy therapy for 6 sessions every 2 weeks. The used device is locally manufactured by a national company for esthetic and dermatological devices. Carbon dioxide gas was subcutaneously injected at the lateral one-third of each eye lid (5 cc gas in each puff according to standardized flowmetry) using insulin syringe. Compression of the injected area will be avoided to prevent rapid leakage of the gas.
88803177|NCT04389788|Active Comparator|Lt Eye|The left eye of the same patients received microneedling with topical glutathione for 6 sessions every 2 weeks. Microneedling was done with Derma pen which is automatic and rechargeable device (vibrating frequency : 6500-10000 r/m , vibration speed level 5 , model :Ultima A6 , company : Dr ,pen and country : Korea). Needle length is adjustable from 0.25 mm to 0,5 mm.Needles number : 36 .Then, Patient was subjected to topical glutathione about 0.25 ml (vial : 600mg/5ml).
88803178|NCT03998657|Experimental|Exablate Treated Arm|Treatment with Exablate Prostate 2100 Type-3 System
88803179|NCT05750524|Experimental|reflexology|In the reflexology group, reflexology hand massage applied between two suctioning period
88803180|NCT05750524|Placebo Comparator|classical massage|In the classical massage group, classical hand massage applied between two suctioning period
88803181|NCT02246387||Manchester Operation|Manchester Operation: Native tissue repair
88803182|NCT05750446|Other|Riociguat / Placebo|Riociguat or Placebo as oral capsule in randomized order
88803183|NCT05750446|Other|Placebo / Riociguat|Riociguat or Placebo as oral capsule in randomized order
88803184|NCT04756310|Placebo Comparator|Control|"Patients receiving Theavit food supplement considered as a placebo treatment for AMD condition.~Two capsules/day before breakfast each day for 2 years"
88803185|NCT04756310|Experimental|Retilut|Patients receiving Retilut food supplement. Two capsules/day before breakfast each day for 2 years
88803186|NCT05750290|Experimental|CKD-702 in combination with irinotecan|
88803187|NCT03845621|Active Comparator|CM-OA-OA-CM Sequence|Use of a conventional custom-made mouthguard (CM) while playing water polo for first and fourth weeks and the occlusal-adjusted custom-made mouthguard (OA) for the second and third weeks.
88803188|NCT03845621|Active Comparator|OA-CM-CM-OA Sequence|Use of an occlusal-adjusted custom-made mouthguard (OA) for the first and fourth weeks and a conventional custom-made mouthguard (CM) while playing water polo for the second and third weeks.
88803189|NCT03015467|Active Comparator|treatment for part 1|Fecal Microbiota Transplantation (FMT) and traditional treatments according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 1.
88803190|NCT03015467|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline (NS) according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 2.
88803191|NCT04755296|Experimental|Low level laser therapy and aerobic exercises group|They received low level laser therapy and aerobic exercises using a treadmill, 3 sessions per week for 12 weeks.In addition to traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
88803192|NCT04755296|Active Comparator|Control group (aerobic exercises group)|They received aerobic exercises 3 times weekly for 12 weeks.In addition to the same traditional physical therapy program.
88803193|NCT01840046|Experimental|Interleukin 2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit (MIU) / day D1 to D5, S3, S6 and S9: 3 mille-International unit /Jour D1 to D5."
88803194|NCT00437216||1|Monotherapy - Subjects who are not currently being treated with anti-psoriatic medication and start using Clobex®
88803195|NCT00437216||2|Add-on therapy - Subjects who are taking some form of anti-psoriatic medication and add Clobex® treatment
88803196|NCT00002524|Experimental|Regimen A|Regimen A: 5-Drug Combination Chemotherapy followed by Radiotherapy.
88803197|NCT00002524|Experimental|Regimen B|Regimen B: 4-Drug Combination Chemotherapy alternating with 3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy
88803198|NCT00002524|Experimental|Regimen C|Regimen C: 2-Drug Combination Chemotherapy with Drug Modulation followed, as indicated, by Radiotherapy.
88803199|NCT03736811|Active Comparator|Absorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyglactin 910 [Vicryl] or polydioxanone [PDS II] sutures.
89137129|NCT02775786|Experimental|Pancreatic Mass or Risk Factors Group|Participants with pancreatic adenocarcinoma who are planning to undergo surgical resection. Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis .
89137130|NCT04196244|Experimental|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
89137131|NCT04196244|Active Comparator|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
89137132|NCT02836184|Active Comparator|control group|Group treated with calcium carbonate for 6 weeks first,then switch to nicotinic acids treatment after 2 week of wash-out.
89137133|NCT02836184|Experimental|nicotinic acids group|Group treated with nicotinic acids for 6 weeks first,then switch to calcium carbonate treatment after 2 week of wash-out.
89137134|NCT02834078|Experimental|BGG|Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
89137135|NCT02834078|Placebo Comparator|Placebo|Matching placebo capsules [for BGG tablet] composed of micro crystalline cellulose and added colors and odors. Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
89137136|NCT02777658||Primary Study Cohort|Patients with prior confirmed EGFR mutation-positive locally advanced or advanced NSCLC (Non-Small Cell Lung Cancer) who have progressed on or after EGFR-TKI (Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor) therapy
89137137|NCT02777658||Secondary Study Cohort|Patients diagnosed with de-novo (wild-type) EGFR T790M mutation-positive (alone or in combination with other mutations) locally advanced or advanced NSCLC
89137138|NCT05299268|Experimental|Pain (hypertonic saline)|Injection (1 ml) of painful hypertonic saline (5.8%) prior to performance of the 1x3 min Seated Isometric Knee Extension
88803200|NCT03736811|Experimental|Nonabsorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyester [Ethibond Excel] or polypropylene [Prolene] sutures.
89137139|NCT05299268|Placebo Comparator|No pain (isotonic saline)|Injection (1 ml) of non-painful isotonic saline (0.9%) prior to performance of the 1x3 min Seated Isometric Knee Extension
89137140|NCT02775708|Experimental|capsule endoscopy|open label arm ; up to 100 subjects indicated for capsule endoscopy (CE) procedure will undergo the CE procedure with the Pillcam endoscopy system
89137141|NCT02831036|Experimental|trial group|subjects in trial group will be following the experimental protocol (VO2max tests and spatial orientation tests) while performing a training program during the trial (3 months).
89137142|NCT02831036|Other|control group|following the experimental protocol (VO2max tests and spatial orientation tests)without performing additional exercise.
89137143|NCT04193124||Prolonged vasospasm|Adult patients with a diagnosis of subarcnoid hemorrhage CT scan or presence of blood in the cerebrospinal fluid were incorporated. Patients with vasospasm were followed daily with transcranial doppler. Prolonged vasospasm was defined for patients who persisted with vasospasm after day 21 of cerebral bleeding.
89137144|NCT02830802|Experimental|Group A|Active Agent
89137145|NCT02830802|Placebo Comparator|Group B|Placebo
89137146|NCT02775474|Experimental|Methadone|Methadone used as anesthesia opioid: induction with 0,15 mg / kg intravenous methadone. Boluses of 0,05 mg / kg intravenous methadone as needed intraoperatively
89137147|NCT02775474|Active Comparator|Fentanyl|Fentanyl used as anesthesia opioid: induction with 6 mcg / kg intravenous fentanyl. Boluses of 2 mug / kg intravenous fentanyl as needed intraoperatively
89137148|NCT04248374|No Intervention|Fatty Acid Taste|Fatty acid taste without sour adaptation
89137149|NCT04248374|Experimental|Fatty Acid Taste after sour adaptation|Fatty Acid Taste after sour adaptation
89137150|NCT05158686||Paclitaxel-coated balloon angioplasty|Patients with previous failed recanalization of a CTO treated with paclitaxel coated balloon immediately proximal to the CTO during the index procedure
89137151|NCT05158686||Non-coated balloon angioplasty|Patients with previous failed recanalization of a CTO treated with non-coated balloon immediately proximal to the CTO during the index procedure
89137152|NCT02835794|Experimental|Arm 1|Omacetaxine - escalating doses subcutaneous twice daily on Days 1-5 and 8-12 Azacitidine 50 mg/m2 subcutaneous/intravenous daily on Days 8-12 G-CSF 5mcg/kg subcutaneous daily on Days 15-19 and 22-26
89137153|NCT02775396|Experimental|Adult computer user|Wearing each of the two spectacle lens designs for one month in random sequence
89137154|NCT02834000|No Intervention|Standard Care|We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. The control group will compose of patients supervised in a standard way.
89137155|NCT02834000|Experimental|LiDCO rapid™ CNAP monitoring|Young, healthy adult patients (ASA I and II) undergoing elective orthopaedic surgery under general anaesthesia will be included in to this study. We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. We will use in the LiDCO rapid™ CNAP monitoring group, the continuous real time haemodynamic monitoring through non-invasive arterial pressure waveform. The monitor LiDCO rapid™ CNAP permits, through analysis the arterial blood pressure trace, to acquire information about CO, SVR, HR variability, SV and BIS.
89137156|NCT02836028|Experimental|talazoparib|Cohorts 1A (PARP inhibitor naïve), 2A (PARP inhibitor sensitive), and 3A (PARP inhibitor refractory)
89137157|NCT02836028|Active Comparator|talazoparib + temozolomide|Cohorts 1B (PARP inhibitor naïve), 2B (PARP inhibitor sensitive), and 3B (PARP inhibitor refractory)
89137158|NCT02778672||Infants with potential pneumonia|
89137159|NCT01778946|Experimental|Nicotine|"Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)~All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).~Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.~All participants will apply a new patch daily for a total of 28 days (1 month)"
88803201|NCT01155193||Palivizumab|Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season.
88803202|NCT01823432||BAV Cohort|Patients with bicuspid or unicuspid aortic valves, regardless of surgical status.
89137160|NCT04247204|Experimental|Platelet-rich plasma (PRP) intrauterine infusion|
89137161|NCT05224544|Experimental|Test Catheter|Healthy volunteers to test the investigational intermittent catheter.
89137162|NCT05224544|Active Comparator|Comparator Catheter|Healthy volunteers to test the comparator.
89137163|NCT04227210|Experimental|RSV Vaccine: Dosage Group #1|Participants in this group will receive a single dose of the RSV vaccine at dosage #1
89137164|NCT04227210|Experimental|RSV Vaccine: Dosage Group #2|Participants in this group will receive a single dose of the RSV vaccine at dosage #2
89137165|NCT02833766|Experimental|anti-EGFR-IL-dox|Metastatic, non resectable, EGFR positive TNBC patients treated in first-line
89137166|NCT04974840|Experimental|Treadmill training combined with thera-band|Participants will receive walking training on treadmill with thera-band at the waist. The direction of the thera-band resistance will be straight backward, backward-toward-right, and backward-toward-left. For each direction, the level of resistance and treadmill speed will be adjusted to allow the participants to perceive a 10-minute training to be 'slightly difficult'.
89137167|NCT04974840|Active Comparator|Treadmill training alone|Participants will receive treadmill walking training at a speed that will be adjusted to allow the participants to perceive a 10-minute training to be 'slightly difficult'. For each session, there will be three 10-min treadmill walking bouts.
89137168|NCT02830568||couples kidney living donor - receiver|"Three groups for each technique of taking of kidney :~open donor nephrectomy~standard and hand-assisted laparoscopic donor nephrectomy~laparoscopic robotic-assisted nephrectomy"
89137169|NCT04813380|Active Comparator|Oraltek Sublingual immunotherapy group|one drops under tongue for ten days then three Drops for another ten days then five drops for another ten days for three successive months then five drops every two days per week for two months then five drops one day per week for one months
89137170|NCT04813380|Placebo Comparator|Placebo|one drops under the tongue then three drops then five drops for three successive months then five drops every two days per week for two months then five drops one day per week for one months
89137171|NCT02835872|Placebo Comparator|Cellulose control|3 g Insoluble Fiber (Cellulose)/d contained within drinks and crackers
89137172|NCT02835872|Active Comparator|Soluble fiber treatment|3 g soluble dietary fiber test ingredient contained within drinks and crackers
89137173|NCT04951362|Active Comparator|intranasal Ivermectin group|49 pateints with anosmia received ivermectin nanosuspension nasal spray
89137174|NCT04951362|Placebo Comparator|saline nasal spray|47 pateints with anosmia received saline nasal spray
89137175|NCT02830412|Experimental|PONV Reminder|After patient has non-cardiac surgery, the subject will have Post-Operative Nausea and Vomiting Reminder display
89137176|NCT02830412|No Intervention|No PONV Reminder|After patient has non-cardiac surgery, the subject will not have Post-Operative Nausea and Vomiting Reminder display
89137177|NCT02833610|Experimental|Denosumab Injection|Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles. Denosumab Q4W is administered by subcutaneous injection.
89137178|NCT04225728|Active Comparator|Iron sucrose IV arm|Perfusion of diluted iron sucrose i.v. in two weeks. Half of the total dose at Day 0 and the other half at Day 14
89137179|NCT04225728|Active Comparator|Ferric polymaltose hydroxide complex IM arm|Injection in two series, begin at Day 0 and the second at Day 14. In each series, we administered 300 mg of iron IM until reach half of the dose
89137180|NCT04225728|Placebo Comparator|Placebo arm|100 ml i.v. of normal saline administered at Day 0 and at day 14.
89137181|NCT02830646|Other|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC
89137182|NCT02775552|Experimental|A&T intervention areas|
89137183|NCT02775552|Active Comparator|Comparison areas|(Receive standard government services)
88803203|NCT01352078||Non Healing Ulcer|
88803204|NCT01352078||Hidradenitis suppurativa|
88803205|NCT03678467|Experimental|EB-CMF Implant|Subject receiving EB-CMF implant
88803206|NCT01349894||SNaP® Wound Care System|
89137184|NCT02833454|Active Comparator|direct insertion single bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using single bundle technique.
89137185|NCT02833454|Experimental|anatomical double bundle ACLR|Patients with ACL rupture undergo double bundle anterior cruciate ligament reconstruction.
89137186|NCT02833454|Experimental|anatomical single bundle ACLR|Patients with ACL rupture undergo single bundle anterior cruciate ligament reconstruction.
89137187|NCT02833454|Active Comparator|direct insertion double bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using double bundle technique.
89137188|NCT04247984|Experimental|mXELIRI+ Bevacizumab|
89137189|NCT04247984|Active Comparator|FOLFIRI + Bevacizumab|
89137190|NCT05146362|Experimental|RETAIN Programming|The experimental group receives the full set of RETAIN intervention activities.
89137191|NCT05146362|No Intervention|Control|This arm receives information about American Job Center services and assistance with opening a JobLink account if an individual doesn't have one. Medical providers at all practices will receive training on how to identify early and then manage the risk of work disability to help prevent long-term unemployment
89137192|NCT00948389|Active Comparator|Dasatinib|
89137193|NCT00948389|Active Comparator|Lomustine|
89137194|NCT02777112|Placebo Comparator|Control|This group will receive generic information about depression and serve as control
89137195|NCT02777112|Experimental|e-mental health program|This group will receive the developed e-mental health program
89137196|NCT02777112|Experimental|e-mental health program and job coaching|This group will receive the developed e-mental health program plus interactive job coaching through telephone.
89137197|NCT02775318|Other|Stellate Ganglion Block|After diagnosis of vasospasm patients were administered ultrasound guided Stellate Ganglion block using 10 cc of 0.5% Inj Bupivacaine on the same side of vasospasm or the side contralateral to the focal neurological deficit.Patients were then assessed using transcranial Doppler and digital subtraction angiography after 30 minutes
89137198|NCT02854709|No Intervention|Control|Continue with habitual sleep duration
89137199|NCT02854709|Experimental|Intervention|Sleep extension
89137200|NCT04246736|Experimental|Intervention group|"The intervention group received a Recovery programme including three group sessions."
89137201|NCT04246736|No Intervention|Control group|The control group was on a waiting list to receive the intervention after the last follow-up measure (six months after the intervention group's last group session).
89137202|NCT00948155|Experimental|Varenicline before placebo|"Drug (Varenicline (Chantix)): Placebo~Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21."
89137203|NCT00948155|Experimental|Placebo then Varenicline|"Placebo: Drug Varenicline (Chantix)~Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.~Intervention 'Drug (Varenicline (Chantix)): Placebo'"
89137204|NCT02775084|Experimental|Healthy Fish Oil|8 grams fish oil
89137205|NCT02775084|Placebo Comparator|Olive Oil|8 grams olive oil
89137206|NCT02777034|Experimental|Enhanced Recovery|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（<2000ml/d）."
89137207|NCT02777034|Other|Unenhanced Recovery|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（>2000ml/d）."
89137208|NCT02854553|Experimental|TAP|Transversus abdominis plane block
89137209|NCT02854553|Experimental|TAP and rectus sheath block|Transversus abdominis plane block with rectus sheath block
89137210|NCT02854553|No Intervention|control|no truncal blocks, conventional analgesia
89137211|NCT02776956|Experimental|atorvastatin group|atrial fibrillation in atorvastatin group will orally receive atorvastatin before and after operation.
89137212|NCT02776956|Other|non-atorvastatin group|atrial fibrillation in non-atorvastatin group will not receive atorvastatin before and after operation..
89137213|NCT04226430||Before cytosorb|Arterial blood samples were taken from patients before the Cytosorb therapy course.
89137214|NCT04226430||after cytosorb|Arterial blood samples were taken from patients immediately after the Cytosorb therapy course.
89137215|NCT04910178|Experimental|Empa group|patients will be given Empagliflozin 25 mg once daily
89137216|NCT04910178|Experimental|PTX group|patients will be given PTX 400 mg twice daily or 3 times daily
89137217|NCT04910178|Experimental|UDCA group|patients will be given UDCA 500 mg twice daily
89137218|NCT04910178|Placebo Comparator|Placebo|patients will be given a placebo
89137219|NCT02856737|Experimental|Earplugs and eye masks (to be used concurrently)|Group will include patients consented to the use of earplugs and eye masks. Patients will participate in the intervention nightly
89137220|NCT04888026|Experimental|Automated QST procedure|The QST robot will autonomously perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. All verbal information is giving through the computer
89137221|NCT04888026|Active Comparator|Manual QST procedure|The research assistant will perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. All tests are performed manually without using the robot.
89137222|NCT04888026|Active Comparator|Semi-automated QST procedure|The QST robot will with guidance from the research assistant perform i) pressure pain thresholds at the tibialis anterior, ii) the cold-pressor test, and iii) repeat the pressure pain threshold. However and in contrast to the first arm, all verbal information and procedure guiding is given by a research assistant.
89137223|NCT02778594|Placebo Comparator|Placebo|Placebo (4 tablets) Simultaneously with the placebo dose, subjects were administered 1 capsule of Madopar® HBS 125
89137224|NCT02778594|Experimental|Nebicapone 50 mg|Nebicapone 50 mg (1 tablet of 50 mg plus 3 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
89137225|NCT02778594|Experimental|Nebicapone 100 mg|Nebicapone 100 mg (2 tablets of 50 mg plus 2 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
89137226|NCT02778594|Experimental|Nebicapone 200 mg|Nebicapone 200 mg (4 tablets of 50 mg). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
89137227|NCT02775006|Active Comparator|Docetaxel|Docetaxel 75mg/m2 every 21 days until disease progression or toxicity related
89137228|NCT02775006|Active Comparator|Docetaxel plus erlotinib|Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days, until disease progression, or toxicity related.
89137229|NCT00958217|Experimental|Cognitive Processing Therapy-Modified|12 individually delivered sessions of Cognitive Processing Therapy-Modified (CPT-M) provided once weekly following initial group delivery of 12 sessions of Integrated Cognitive Behavioral Therapy
89137230|NCT00958217|Active Comparator|Integrated Cognitive Behavioral Therapy|12 individually delivered sessions of Integrated Cognitive Behavioral Therapy (ICBT) once weekly following initial group delivery of 12 sessions of ICBT
89137231|NCT00958217|No Intervention|Integrated Cognitive Behavioral Group Therapy|All participants were enrolled in an initial group-delivered Integrated Cognitive Therapy Group, consisting of 12 sessions over approximately 12 weeks prior to randomization to one of the study individually delivered interventions (CPT-M or ICBT). Individuals who were no longer participating in the study at the end of group sessions were not randomized.
89234283|NCT00999180|Active Comparator|Btx-A and Kinesiotherapy|The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport). During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
89137232|NCT02778516|Active Comparator|Sodium Restriction 1500mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
89137233|NCT02778516|Active Comparator|Sodium Restriction 2400mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
89137234|NCT02778516|No Intervention|Control Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
89137235|NCT04851834|Experimental|NTX-301 Monotherapy Dose Escalation|NTX-301 monotherapy dose escalation in patients with advanced solid tumours
89137236|NCT04851834|Experimental|NTX-301 platinum-based doublet therapy Dose Escalation|NTX-301 combined with platinum-based chemotherapy in platinum-resistant advanced ovarian & bladder cancer
89137237|NCT04851834|Experimental|NTX-301 platinum-based doublet therapy Dose Expansion|NTX-301 combined with platinum-based chemotherapy in platinum-resistant advanced ovarian & bladder cancer
89137238|NCT04851834|Experimental|NTX-301 Temozolomide doublet therapy Dose Escalation|NTX-301 combined with Temozolomide (TMZ) as adjuvant (maintenance) treatment in IDH1 mutated high-grade glioma
89137239|NCT04851834|Experimental|NTX-301 Temozolomide doublet therapy Dose Expansion|NTX-301 combined with Temozolomide (TMZ) as adjuvant (maintenance) treatment in IDH1 mutated high-grade glioma
89137240|NCT02776800|Experimental|Allevyn Life|Foam Dressing
89137241|NCT02776800|Other|Foam Dressing|Standard Care - Foam Dressing
89137242|NCT02776878|Experimental|Dasatinib|Dasatinib is given orally 50 mg 2 times a day for the first week, if subject is tolerate, then increased to 70 mg 2 times a day. Dasatinib will be continued until unacceptable toxicity and progression.
89137243|NCT02772900|Active Comparator|Beetroot gel (dietary nitrate)|Beetroot-based nutritional gel containing approximately 10.0 mmol of nitrate per dose
89137244|NCT02772900|Active Comparator|Placebo gel (nitrate-depleted)|Nutritional gel nitrate-depleted
89137245|NCT02772822|Experimental|Experimental|SCT400 plus CHOP, six cycles SCT400: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
89137246|NCT02772822|Active Comparator|Active Comparator|Rituximab plus CHOP, six cycles Rituximab: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
88803207|NCT01203319|Experimental|60mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
88803208|NCT01203319|Experimental|30mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
88803209|NCT01203319|Placebo Comparator|10mcg/1.0ml recombinant hepatitis B vaccine|300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
89137247|NCT04869540|Active Comparator|Usual care|Families randomized to this arm will receive the usual care by providers trained in the 'Got Transition' toolkit and that have access to web-based transition resources.
89137248|NCT04869540|Experimental|Usual care + PSE|Families randomized to this arm will receive the usual care by providers trained in the 'Got Transition' toolkit and that have access to web-based transition resources and will also receive a family-based problem solving eduction (PSE) intervention.
89137249|NCT00635076|Placebo Comparator|Placebo group|
89137250|NCT00635076|Active Comparator|Alprazolam XR group|
89137251|NCT02774928||Chronic Obstructive Pulmonary Disease|Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality throughout the world.COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.Spirometry is required to make a clinical diagnosis of COPD; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD .
89137252|NCT02774928||Interstitial lung diseases|Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
89137253|NCT02774928||Obstructive sleep apnea (OSA)|"Obstructive sleep apnea (OSA) is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep.~These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.~OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome-also referred to as obstructive sleep apnea-hypopnea syndrome."
89137254|NCT00891020|Experimental|Tocilizumab 8 mg/kg Monotherapy|Participants received Tocilizumab 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
89137255|NCT00891020|Experimental|Tocilizumab 4 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 4 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants not achieving a 20% improvement from baseline in tender and swollen joint counts at Week 8 were to have their dosage increased to 8 mg/kg, per protocol. Beginning at Week 12 dosage increase to 8 mg/kg was at the discretion of the investigator. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
89137256|NCT00891020|Experimental|Tocilizumab 8 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
89137257|NCT02776566|Active Comparator|Anticoagulation Clinic|"Usual care through pharmacist managed anticoagulation clinic~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
89137258|NCT02776566|Experimental|Patient Self-Monitoring|"In home self-monitoring and pharmacist guided education~Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages."
89137259|NCT02772744||Group 1: Easy to treat group|"Treatment naïve~Total serum bilirubin ≤ 1.2 mg/dl~Serum albumin ≥ 3.5 g/dl~International normalized ratio ≤ 1.2~Platelet count ≥ 150000 mm3~This group will be receiving Sofosbuvir + daclatasvir for 12 weeks."
89137260|NCT02772744||Group 2: Difficult to treat group|"Peg interferon treatment experienced.~Total serum bilirubin ≥ 1.2 mg/dl~Serum albumin ≤ 3.5 g/dl~International normalized ratio ≥ 1.2~Platelet count ≤ 150000 mm3~This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 12 weeks."
89137261|NCT02772744||Group 3: Sofosbuvir resistant cases|This is the group of patients who failed in previous Sofosbuvir treatment regiment. This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 24 weeks.
89137262|NCT02774382|Active Comparator|Vancomycin|"Oral vancomycin according to number of recurrences (Danish guidelines):~First recurrence: Capsule vancomycin 125 mg x 4 p.o. times daily for 14 days~≥2 recurrences:~capsule vancomycin 125 mg x 4 times daily p.o. for 14 days followed by~capsule vancomycin 125 mg x 2 times daily p.o. for 7 days followed by~capsule vancomycin 125 mg x 1 times daily p.o. for 7 days followed by~capsule vancomycin 125 mg x 1 p.o. every second day for 7 days followed by~capsule vancomycin 125 mg x 1 p.o. every third day for 14 days"
89137263|NCT02774382|Experimental|Vancomycin + fecal microbiota transplantation|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Fecal Microbiota Transplantation with 200 ml fecal suspension administrated with a rectal catheter.
89137264|NCT02774382|Experimental|Vancomycin + rectal bacteriotherapy|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Rectal bacteriotherapy with 200 ml suspension of a fixed mixture of bacterial strains administrated with a rectal catheter.
89137265|NCT02774460|Active Comparator|Zestril® (Lisinopril)|Inhibition of angiotensin converting enzyme (ACE inhibitor). Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
89137266|NCT02774460|Active Comparator|Atacand® (Candesartan)|Angiotensin receptor blocker. Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
89137267|NCT02774460|Active Comparator|Norvasc® (Amlodipine)|Calcium channel blocker. Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
89137268|NCT02774460|Active Comparator|Hydrochlorothiazide® (Hydrochlorothiazide)|Diuretic agent. Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
89137269|NCT02774460|Active Comparator|Repeated treatment X|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.~The repeated arms will be given with the same duration and dosing as the other arms."
89137270|NCT02774460|Active Comparator|Repeated treatment Y|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.~The repeated arms will be given with the same duration and dosing as the other arms."
89137271|NCT02774460|Placebo Comparator|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
89137272|NCT02772354|Experimental|Ablation|Standard radiosurgery ablation of premature ventricular complexes using navigation system.
89137273|NCT02772354|Active Comparator|Control|Antiarrhythmic therapy of premature ventricular complexes according to the guidlines
89234284|NCT00999180|Placebo Comparator|Saline and Kinesiotherapy|The control group will have the syringe filled with saline.During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
89137274|NCT02830178||Any Paracetamol|Participants with age 18 and over who received a first prescription of single-ingredient paracetamol or ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
89137275|NCT02830178||Ibuprofen|Participants with age 18 and over who received a first prescription of single-ingredient ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
89137276|NCT00611455|Experimental|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
89137277|NCT00611455|Placebo Comparator|1000 ml Saline|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
89137278|NCT04429724|Experimental|health workers at hospital|Three blood samples will be taken at day 1, month 3 and month 6. A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
89137279|NCT02772510|Experimental|Smart glove system with functional electrical stimulation|game-based virtual reality rehabilitation combined with functional electrical stimulation for upper extremity
89137280|NCT02772510|Active Comparator|Functional electrical stimulation|functional electrical stimulation on upper extremity
89137281|NCT04246580||Indocyanine green|Women with endometrial and cervical cancer undergoing indocyanine green-guided systematic pelvic lymphadenectomy by laparoscopy or robotic surgery
89137282|NCT04246580||Control|Women with endometrial and cervical cancer undergoing systematic pelvic lymphadenectomy by laparoscopy or robotic surgery without the use of indocyanine green tracer injection.
89137283|NCT02830022|Experimental|Patients|Children from 8 to 18 years with autism without without intellectual disabilities (IQ > 70), verbals and responding to classification CIM 10-DSM IV.
89137284|NCT02830022|Experimental|Healthy volunteers|Paired for age, gender, IQ and and the practice of a physical activity strictly within the school context.
89137285|NCT02776410|Experimental|Intervention group|Group receiving tailored messages promoting sustainable and healthy eating through an mobile-application together with six principles of sustainable healthy eating that will be included in the mobile application,
89137286|NCT02776410|No Intervention|Control group|Group who will not download the mobile application
89137287|NCT02835482|Experimental|Patient with glaucoma|Patient eligible for bilateral cataract surgery, with glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with phacoemulsification for the other eye.
89137288|NCT02835482|Other|Patient without glaucoma|Patient eligible for bilateral cataract surgery, without glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with the phacoemulsification for the other eye.
89137289|NCT02774304|Active Comparator|arterial line|invasive haemodynamic monitoring
89137290|NCT02774304|Experimental|Cheetah®|non-invasive cardiac output
89137291|NCT02835560|Experimental|Experimental|Ilaprazole-based quadruple therapy for 14 days: Ilaprazole 5mg bid
89137292|NCT02835560|Active Comparator|Active Comparator|"Esoprazole~Esoprazole-based quadruple therapy for 14 days: Esoprazole 20mg bid"
89137293|NCT02774070|Other|Symptomatic atlantoaxial joint affection|Undergo plain X-ray and magnetic resonance imaging
89137294|NCT02774070|Other|Asymptomatic atlantoaxial joint aff.|Undergo plain X-ray and magnetic resonance imaging
89137295|NCT02833532|Experimental|Volus|Maxium: 22ml
89137296|NCT02833532|Active Comparator|Powerfill|Maxium: 22ml
89137297|NCT02767752|Experimental|T-ChOS + Gemcitabine + Capecitabine|"T-ChOS: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
89137298|NCT02767752|Placebo Comparator|Placebo + Gemcitabine + Capecitabine|"Placebo: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
89137299|NCT02835404|Experimental|Concurrent radiochemotherapy Group|Concurrent radiochemotherapy with Nedaplatin Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f with 8mv-X rays (SSD) 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations; Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
89137300|NCT02835404|Active Comparator|Radiotherapy Group|patients received Radiotherapy only Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X Linear Accelerator SSD 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations.
89137301|NCT02767908|No Intervention|Usual Care|Participants in the usual care group will be offered and, if accepted, provided with smoking cessation support that meets the recommendations of NICE PH48 guidance including pharmacotherapy and behavioural support before leaving hospital, referral to NHS SSS for continued care after discharge, and ascertainment of smoking status at 4 weeks; participants will also be asked to consent to smoking status ascertainment at three months. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation. All will be asked at four weeks and 3 months to list the cessation support, in terms of pharmacotherapy and behavioural support from local or other services, delivered since the last contact.
88803210|NCT05521217||Children with Spinal Muscular Atrophy|The patients were included if they were between 0 to 4 yeats, with a diagnosis of Spinal Muscular Atrophy.
88803211|NCT05521217||Healthy children|The healthy age-matched control group was included.
88803212|NCT05696314|Experimental|Outpatient Oropharynx Ultrasound|Transoral and/or Transcervical ultrasound of the oropharynx
88803213|NCT01204255|Experimental|Arm I|Patients apply lorazepam, diphenhydramine hydrochloride, and haloperidol gel topically over 2 minutes.
88803214|NCT01333826|Experimental|Unconditional cash transfers|Monthly cash transfers given to households with school aged girls with no strings attached. Transfer amounts randomized within this arm.
88803215|NCT01333826|Experimental|Conditional Cash Transfer|Monthly cash transfers given to households with school aged girls conditional on regular school attendance (80%). Transfer amounts randomized within this arm.
88803216|NCT01333826|No Intervention|Control Group|No cash transfer program implemented in this group.
88803217|NCT02246465|Experimental|RXI-109|RXI-109 dosed at the site of the revised hypertrophic scar
88803218|NCT01156597|Active Comparator|Pioglitazone Group|This is a baseline versus treatment study comparing subjects on pioglitazone to a matched group of subjects treated with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level
88803219|NCT01156597|No Intervention|Comparator Group|This group of subjects will be maintained on standard treatment with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level as group treated with pioglitazone.
88803220|NCT03015623|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
88803221|NCT03015623|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
88803222|NCT03015623|Sham Comparator|Control|Sham device containing no MSCs
88803223|NCT01331408|Experimental|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks
88803224|NCT01156987|Experimental|Healthy Volunteers|Five healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.
88803225|NCT01156987|Experimental|Breast Cancer Patients|40 breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.
88803226|NCT03015311|Experimental|Intensive BP control|SBP within 110 - <130 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 110 - <130 mm Hg.
88803227|NCT03015311|Active Comparator|Standard BP control|SBP within 130 - <150 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 130 - <150 mm Hg.
88803228|NCT03011125|Placebo Comparator|placebo|
88803229|NCT03011125|Experimental|Dexlansoprazole Injection|
88803230|NCT05749978|Experimental|Trendelenburg position|
88803231|NCT05749978|No Intervention|Procumbent|
88803232|NCT03015545|Active Comparator|Control|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval, but no vibration will be given.
88803233|NCT03015545|Active Comparator|High intensity whole body vibration|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval. The whole body vibration platform will be set with frequency at 30Hz and amplitude at 1.5mm.
88803234|NCT05749900|Experimental|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin
88803235|NCT03541577||Participants|Subjects who meet the inclusion criteria and do not meet the exclusion criteria and undergo FFR measurement with the TruePhysioTM Microcatheter and the Pressure Wire
88803236|NCT02973178|Other|Usability|Evaluate and validate the user-interface of the Scanadu Urine Device by the intended users for human factors and user interface of the Scanadu Urine Device.
88803237|NCT02973178|Active Comparator|Method Comparison|"Evaluate and validate the clinical performance of the Scanadu Urine Device in the hands of intended users as compared to:~The visual read of chemical test strips performed by lab technicians utilizing the Siemens Multistix® 10SG technology (K905396),~Scanadu Urine Device tests performed by lab technicians."
88803238|NCT02973178|Other|Reproducibility|Evaluate the reproducibility in the hands of the lay-users after repeated testing of samples with known test levels.
88803239|NCT05749666|Experimental|Tofacitinib group|Tofacitinib 5mg BID taken orally for 24 weeks and placebo of prednisolone taken daily according to preset tapering protocol during same period
88803240|NCT05749666|Active Comparator|Prednisolone group|Prednisolone taken daily according to preset tapering protocol and placebo of tofacitinib 5mg BID taken orally for 24 weeks
88803241|NCT03295799|Experimental|Patient Self-Management|Patients will go through a preparatory phase (creation of warfarin dosing chart, process for documentation and retrieval of labs), a practical training phase (formulate warfarin management plan with support) and then perform patient-self management of their own warfarin.
88803242|NCT03295799|No Intervention|Anticoagulation Clinic Care|Patients will not have their care altered, and will continue to be managed by our Anticoagulation Clinic.
88803243|NCT05449535|Experimental|JYB1904/JYB1904 Placebo|single-dose; subcutaneous injection in the deltoid region of the upper arm.
88803244|NCT05449535|Active Comparator|Omalizumab|single-dose; subcutaneous injection in the deltoid region of the upper arm.
88803245|NCT05749510||NCRT+TME|Neoadjuvant chemoradiotherapy (NCRT) and total mesorectal excision (TME) Interventions
88803246|NCT04222985|Experimental|Part A - Group 1|HSV 2 formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803247|NCT04222985|Experimental|Part A - Group 2|HSV 2 formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803248|NCT04222985|Experimental|Part A - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803249|NCT04222985|Experimental|Part A - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
89137302|NCT02767908|Active Comparator|Intervention|A home visit will be carried out as soon as practicable after discharge and typically within 48 hours, to deliver a multi-component intervention. Intervention components all have an existing evidence base proving or suggesting potential efficacy for smoking cessation and/or relapse prevention, though their feasibility and importance when delivered as a combined package have not been tested.
89137303|NCT00952289|Experimental|Ruxolitinib|Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count > 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
89137304|NCT00952289|Placebo Comparator|Placebo|Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.
89137305|NCT00885781|Experimental|SMOFlipid|
89137306|NCT00885781|Active Comparator|Lipovenoes MCT|
89137307|NCT02830100|Other|Healthy volunteers|
89137308|NCT00882427|Experimental|eMPC|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
89137309|NCT02767674|Experimental|R-GemOx|Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)
89137310|NCT02767674|Active Comparator|R-miniCHOP|Rituximab, 375 mg/m2 IV d0 Cyclophosphamide 400 mg/m2 IV d1 Epirubicin 35 mg/m2 IV d1 vindesine 2 mg IVP d1 Prednisone 40mg/m2 PO d1-5(every 21 days a cycle)
89137311|NCT02829788||Digestive peritoneal carcinomatosis staging|All patients underwent laparoscopic followed by laparotomic surgical staging.
89137312|NCT02542891|Experimental|Blended CBT|"Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with smart phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 16 sessions (8 online and 8 face-to-face), once a week. The online platform is called Moodbuster.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
89137313|NCT02542891|Active Comparator|Treament as Usual (TAU)|"In order to increase the comparability between the two arms, we defined TAU as a traditional face to face CBT of 16 sessions. These sessions will be administered over a course of 16 weeks.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
89137314|NCT02833688|Experimental|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
89137315|NCT02833688|Placebo Comparator|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
89137316|NCT02767440|Experimental|Families on Track Intervention|This is a pre-post study. Enrolled parents will receive the Families on Track intervention plus usual care at the Healthy Lifestyles clinic at Duke University.
89137317|NCT00885859||1|responders: patients who have a pain reduction of 30% or more after two weeks TENS-treatment
89137318|NCT00885859||2|non-responders: patient who have a pain reduction smaller than 15% after two weeks TENS-treatment
89137319|NCT04721262||Patients prescribed Ferumoxytol for iron deficiency anemia|Patients with iron deficiency anemia are commonly prescribed Ferumoxytol periodically as part of their standard clinical care. Multiple studies have characterized the efficacy and safety of Ferumoxytol in the treatment of iron deficiency anemia. Patients prescribed Ferumoxytol for iron-deficiency anemia typically include otherwise healthy women with heavy menstrual periods, patients with inflammatory bowel disease, and patients with chronic kidney disease. Such patients make ideal candidates for characterizing the effects of Ferumoxytol on novel imaging devices by obviating a medically unnecessary injection of the contrast agent.
89137320|NCT00885937|Experimental|Arm 1|
89137321|NCT00885937|Active Comparator|Arm 2|
89137322|NCT00885937|Placebo Comparator|Arm 3|
89137323|NCT02771964||All patients|All patients receive both types of quality of life assessment, thus serving as their own controls.
89137324|NCT02854397||patients with hereditary angioedema|A blood sample will be performed in crisis and 7 days after the crisis.
89137325|NCT02854397||patients with angioedema resulting of mast cell activation|A blood sample will be performed in crisis and 7 days after the crisis.
89137326|NCT02854397||healthy patients, without angioedema|A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.
89137327|NCT02772042|Experimental|Intervention Group|Investigators will performed traction manipulation of those articulations of upper cervical spine with indication for this treatment. Before manipulation soft tissue techniques will be applied in order to prepare the joint. After manipulation the patient rest in supine position. The intervention will have a duration of 10 minutes.
89137328|NCT02772042|Other|Control Group|The patient of the control group maintain the supine position for 10 minutes.
89137329|NCT00612313|Active Comparator|Continued medication alone|Participants will receive antidepressant treatment with fluoxetine for 30 weeks
89137330|NCT00612313|Experimental|Continued medication plus CBT|Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment
89137331|NCT00890552|Experimental|Lenalidomide+Melphalan+Dexamethasone|Patients received lenalidomide 10 mg/day orally on days 1-21, melphalan 0.18 mg/kg orally on days 1-4, and dexamethasone 40 mg orally once weekly of a 28-day cycle (MDR treatment).
89137332|NCT02772198|Experimental|Single Arm|All patients will be treated on this single arm
89137333|NCT02856503|Experimental|Phase 1 - Group A - VD 3 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 3 weeks.
89137334|NCT02856503|Active Comparator|Phase 1 - Group B - VD 4 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 4 weeks
89137335|NCT02856503|Active Comparator|Phase 1 - Group C - VD 5 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 5 weeks.
89137336|NCT02856503|Experimental|Phase 2 - VD|Weekly oral dose of 50,000 IU Vitamin D3 (VD) therapy for the duration selected from the phase I part of the study.
89137337|NCT02542735||Spanish di@bet.es cohort|Representative of Spanish population
89137338|NCT02829632|Experimental|Experimental: Group Sessions|Participants will be asked to attend 3 group meetings over a 12 week period. Groups will meet for approximately 1 hour on weeks 2, 4 and 8. At each of the group meetings, the participant will be weighed and a group leader will present information on topics related to eating and exercise.
89137339|NCT02829632|Experimental|Active Comparator: Self-Monitoring|Active Comparator: Self-monitoring Participants will record diet, activity and weight as described above in the participant's smartphone app to assist the participant in losing weight.
89137340|NCT02829632|Experimental|Experimental: Feedback|"Participants will be sent via the participant's smartphone between~1 and 4 feedback messages a day about whether the participant has been self monitoring, or the amount of calories, fat or sugar the participant has consumed."
88803250|NCT04222985|Experimental|Part A - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2.
88803251|NCT04222985|Placebo Comparator|Part A - Group 6|Sodium chloride 0.9% (in both arms) at Month 0 and Month 2
88803252|NCT04222985|Experimental|Part B (Stage 1) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803253|NCT04222985|Experimental|Part B (Stage 1) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803254|NCT04222985|Experimental|Part B (Stage 1) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803255|NCT04222985|Experimental|Part B (Stage 1) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
88803256|NCT04222985|Experimental|Part B (Stage 1) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
88803257|NCT04222985|Placebo Comparator|Part B (Stage 1) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
88803258|NCT04222985|Experimental|Part B (Stage 1) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803259|NCT04222985|Experimental|Part B (Stage 2) - Group 1|HSV 2 Formulation 1 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803260|NCT04222985|Experimental|Part B (Stage 2) - Group 2|HSV 2 Formulation 2 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803261|NCT04222985|Experimental|Part B (Stage 2) - Group 3|HSV 2 Formulation 3 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803262|NCT04222985|Experimental|Part B (Stage 2) - Group 4|HSV 2 Formulation 4 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0, then HSV 2 Formulation 3 administered with concomitantly with 0.9% sodium chloride in the opposite arm at Month 2
88803263|NCT04222985|Experimental|Part B (Stage 2) - Group 5|HSV 2 Formulation 5 administered in one arm and Formulation 3 in the opposite arm, at Month 0 and Month 2
88803264|NCT04222985|Placebo Comparator|Part B (Stage 2) - Group 6|Sodium Chloride 0.9% (in both arms) at Month 0 and Month 2
89137341|NCT02542579||Subjects for pyrosequencing analysis|Dyspeptic subjects who visited for evaluation and agreed on 16S rRNA pyrosequencing analysis
89137342|NCT02834936|Experimental|pyrotinib treatment|
89137343|NCT04280237||Cefazolin in liver transplantation|Patient undergoing liver transplant surgery and receiving antibiotic prophylaxis with Cefazolin
89137344|NCT02833376|Experimental|Alcohol group|Patients allocated to this group will receive skin antisepsis with alcohol 70% prior spinal anesthesia
89137345|NCT02833376|Experimental|Chlorhexidine group|Patients allocated to this group will receive skin antisepsis with alcoholic solution of chlorhexidine 0.5% prior spinal anesthesia
89137346|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50, 200, 400, 600)|Subjects will receive IM oxytocin, IH placebo/IH oxytocin at doses of 50, 200, 400, 600 mcg.
89137347|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50)|Subjects will receive IM oxytocin and IH placebo and/or IH oxytocin at 50 mcg.
89137348|NCT02772120|Active Comparator|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
89137349|NCT02772120|Active Comparator|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
88803265|NCT04222985|Experimental|Part B (Stage 2) - Group 7|HSV 2 Formulation 6 administered concomitantly with 0.9% sodium chloride in the opposite arm at Month 0 and Month 2
88803266|NCT05749354|Experimental|liver meridian group|Four acupoints; LR3 Taichong, LR5 Ligou, LR8 Ququan, and LR12 Jiman. Based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be in a supine position. Taichong will be punctured at a 25-mm depth using a 0.35×25-mm filiform needle, Ligou will be punctured at a 15-20-mm depth with a 0.35×25-mm filiform needle, Ququan at a 20-25-mm depth with a 0.30×40-mm filiform needle, and an acute pulse of 15-20 mm. Each acupoint will be subject to a small amount of uniform lifting and twisting to the degree of local acid distension. An auxiliary needle (0.16×13 mm) will be inserted approximately 5 mm into the needle, 2 mm proximal to the heart of each acupoint along the meridian. The negative electrode will be connected to the main point, and the positive electrode will be connected to the auxiliary needle, and connect the electroacupuncture instrument. The needles will be retained for 30 min respectively, once every other day, 24 treatments.
89137350|NCT02856347|Other|PET 18-FDOPA|"18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm).~PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min).~Other series of images will be done 50 min after tracer injection. Images will be interpreted."
89137351|NCT04248608|Experimental|erector spinae block|Ultrasound guided erector spinae block with will be done after induction of intravenous anesthesia. After identification of trapezius, rhomboid major, and erector spinae muscles. The needle will be inserted in a cephalad-to-caudal direction until the tip contact transverse process and the needle tip is visualized in the plane deep to the erector spinae muscle. The needle tip position is confirmed by visualizing linear spread of test dose between the muscles after injection. A total dose of 25 mL of 0.25% bupivacaine will be injected.
89137352|NCT04248608|Experimental|serratus anterior block|Ultrasound guided serratus anterior block will be done after induction of intravenous anesthesia. The serratus anterior, latissimus dorsi, and the intercostal muscles will be identified in the fourth and fifth intercostal level, an 18 G Tuohy needle will be advanced in the plane between the serratus anterior muscle and the intercostal muscles. A total dose of bupivacaine 25ml in a concentration of 0.25% will be administered under the serratus muscle after a test dose using an in-plane technique.
89137353|NCT04248608|Active Comparator|intravenous morphine|intravenous morphine will be administrated in a dose of 0.1 mg per kg after induction of general anesthesia
89137354|NCT04783194|Active Comparator|Dexamethasone + bupivacaine in bilateral TiPVB in lumbar spine surgery|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia
89137355|NCT04783194|Active Comparator|Bupivacaine in bilateral TiPVB in lumbar spine surgery|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery for postoperative analgesia
89137356|NCT02854241|Experimental|LC group|LC group under surveillance of biannual ultrasonography and annual noncontrast liver MRI. Six month after the last MRI, contrast enhanced liver CT is performed to investigate presence of HCC.
89137357|NCT02835248||Primary|Older adult study participants will be recruited from the cohort of participants in the STRIDE Study at the Boston trial site (http://www.stride-study.org/).
89137358|NCT04225104|Experimental|Yogic breathing intervention|Participants assigned to this group will complete a 20-minute yogic breathing video at least 5 days per week for 4 weeks. All sessions except the initial yogic breathing session will be completed at home. Participants will complete the first session at Texas State under the supervision of the investigative team for familiarization.
89137359|NCT04225104|No Intervention|Control|Participants in the control group will be asked to maintain their current daily activities and will be given access to the yogic breathing video once all follow-up testing has been completed at the end of week 4.
89137360|NCT02835170|Experimental|Autologous immunoglobulin|Intramuscular injection of autologous immunoglobulin (IgG)
89137361|NCT02835170|Placebo Comparator|Placebo|Intramuscular injection of normal saline
89137362|NCT02542345|Experimental|magnetic resonance imaging|
89137363|NCT02835014||Adolescents with T1DM|Adolescents with type I Diabetes Mellitus diagnosed for at least one year will be screened for mental health symptoms with the PHQ9, SCARED and UCLA PTSD. Self-efficacy regarding self-care and diabetes management will be assessed by using the SEDM. Parenting styles will be assessed by administering the Parenting Styles and Dimensions Questionnaire (PSDQ).
89137364|NCT00946985|Experimental|001|paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years
89137365|NCT00946985|Active Comparator|002|oral risperidone 2 4 6 or 8 mg tabs once daily for two years
89137366|NCT02767206||portal hypertension|Patients with cirrhosis or non-cirrhotic portal hypertension.
89137367|NCT02829710||group 1 : pre implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between January 2013 and December 2013.~Prior to implementation of the protocol, analgesia and sedation were managed by the attending physician's order."
89137368|NCT02829710||group 2 : post implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between May 2014 and March 2015.~Nurses managed analgesia and sedation following an algorithm, including COMFORT-B scale."
89137369|NCT00611923|Placebo Comparator|B|Participants will take placebo flutamide
89137370|NCT00611923|Experimental|A|Participants will take flutamide
89137371|NCT04246502|Experimental|A|
89137372|NCT04246502|Active Comparator|B|
89137373|NCT02767362|Experimental|Single Arm|Patients will undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgery. At the time of hysterectomy and surgical staging, women will undergo repeat endometrial biopsy in the operating room under general anesthesia.
89137374|NCT04246658|Experimental|Treatment group|gait training on platform swing walkway for 30 minute.
89137375|NCT04246658|Experimental|control group|conventional physical therapy program
89137376|NCT02854319|Experimental|LOTUS Edge Valve System|Transcatheter aortic valve implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
89137377|NCT02773992||The IoT group|
89137378|NCT02773992||The routine management group|
89137379|NCT02771886|Active Comparator|2-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 2nd week in the study. The duration of the study will be 6 weeks."
89137380|NCT02771886|Active Comparator|4-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 4th week in the study. The duration of the study will be 6 weeks."
89137381|NCT04246190|Experimental|Group 1|"Period 1: CKD-501 and D759~Period 2: CKD-396"
89137382|NCT04246190|Experimental|Group 2|"Period 1: CKD-396~Period 2: CKD-501 and D759"
89137383|NCT00609973|Active Comparator|A|Ciprofloxacin 500 mg bid
89137384|NCT00609973|Placebo Comparator|B|Placebo bid
89137385|NCT02767284|Experimental|UCST-V1|The UCST-V1 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
89137386|NCT02767284|Experimental|UCST-V2|The UCST-V2 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
88803267|NCT05749354|Active Comparator|stomach meridian group|Four acupoints have been selected for the gastric meridian group, including ST42 Chongyang, ST40 Fenglong, ST36 Zusanli, and ST31 Biguan. The acupoint locations are based on the national standard of the People's Republic of China in 2006 (GB/T 12346-2006). The patient will be supine during the procedure, and the needles will be routinely sterilized. Straight needling will be performed in the hip region using a 0.30×50-mm-filiform needle, a 0.30×50-mm filiform needle in Zusanli, and a 0.30×40-mm filiform needle in Fenglong. A 0.35×25-mm filiform needle will be used to stimulate Chongyang for 10-15 mm, and each acupoint will be gently and evenly lifted, inserted, and twisted to local acid distension. Electroacupuncture will be applied in the same manner as for the liver meridian group. The needles will be retained for 30 min respectively, once every other day, then thrice weekly for a total of 24 treatments in the three groups.
88803268|NCT05749354|Placebo Comparator|non-acupoint group|Four points: (1) On the lateral thigh, between the vastus lateralis and biceps femoris, the midpoint of the popliteal stria, and the highest point of the greater trochanter. (2) On the lateral side of the calf, beside the level of Zusanli, and at the lateral edge of the tibia. (3) On the fibular side of the calf, the midpoint of the stomach meridian, and the bile meridian, 3 cm above the tip of the lateral malleolus and in front of the hanging bell. (4) On the lateral side of the calcaneus, and the servant enters the midpoint of the line connecting the posterior edge of the calcaneus at the same level. The 0.30×25-mm filiform needles are inserted straight for 3-5 mm at the points, the needles can stand without Deqi. The auxiliary needle will be inserted and electroacupuncture will be connected (same as in the other group). The internal wire of the electroacupuncture instrument will be interrupted, no current passed through. The treatment time is the same as the other two groups.
88803269|NCT05749276|Experimental|Darzalex|"DARZALEX®~Dose level 1 : 1800 mg Day 1 Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days) Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
88803270|NCT05749042|Experimental|Sintilimab+Cisplatin+Radiotherapy|
88803271|NCT05749042|Active Comparator|Cisplatin+Radiotherapy|
88803272|NCT03015077|Active Comparator|Glutamine|"intake of 5g glutamine and 10g maltodextrin. Oral glutamine is a food additive issued by food and drug government in Taiwan with number 009929.L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin.~The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy."
88803273|NCT03015077|Placebo Comparator|placebo|intake of 15g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
88803274|NCT05659420|Experimental|High intensity interval training|
88803275|NCT05659420|Active Comparator|Moderate intensity continous training|
88803276|NCT05659420|Placebo Comparator|Control|
88803277|NCT02940509|Active Comparator|Ketamine plus Magnesium sulfate|Ketamine 0.5mg/kg IV dose with 2g magnesium IV dose
88803278|NCT02940509|Placebo Comparator|Placebo|Normal Saline (NaCl 0.9%)
88803279|NCT05748964||Transperitoneal approach laparoscopic pyeloplasty. (TALP)|Transperitoneal approach laparoscopic pyeloplasty. (TALP)
88803280|NCT05748964||Retroperitoneal Approach laparoscopic pyeloplasty. (RALP)|Retroperitoneal Approach laparoscopic pyeloplasty. (RALP)
88803281|NCT02786615|Experimental|Peer Unity|Subjects assigned to this arm would receive a 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
88803282|NCT02786615|No Intervention|Pre-implementation|Subjects assigned to this arm would not receive the group-delivered intervention.
88803283|NCT05652088|Experimental|Patients with HIV Therapy|Subjects receiving therapies with the potential for HIV cure
88803284|NCT05748886||Period 1|00:00 30th Jan 2023 - 23:59 26th Feb 2023 (+ 30 Day Follow-up)
88803285|NCT05748886||Period 2|00:00 27th Feb 2023 - 23:59 26th Mar 2023 (+ 30 Day Follow-up)
88803286|NCT05748886||Period 3|00:00 27th Mar 2023 - 23:59 23th Apr 2023 (+ 30 Day Follow-up)
88803287|NCT05748886||Period 4|00:00 24th April 2023 - 23:59 21st May 2023 (+ 30 Day Follow-up)
88803288|NCT02246075|Experimental|EVP-6124, low dose|Low dose, Tablet, Once Daily, Day 1 through Day 168
88803289|NCT02246075|Experimental|EVP-6124, high dose|High dose, Tablet, Once Daily, Day 1 through Day 168
89137387|NCT02767284|Experimental|UCST-V3|The UCST-V3 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
89137388|NCT02767284|Experimental|Quick-CSF|The Quick-CSF test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
89137389|NCT02767284|Active Comparator|Pelli-Robson|The Pelli-Robson contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
88803290|NCT02246075|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 168
88803291|NCT02246153|Experimental|Laparoscopic gastrectomy|Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
88803292|NCT02246153|Active Comparator|Open gastrectomy|Open distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
88803293|NCT05650294|Active Comparator|Active group|This group will receive a single dose of the PL+ omega 3 fatty acids capsules first, then receive a single dose of the standard FO EE omega 3 fatty acids capsules. Wash-out period is 2 weeks between treatments.
88803294|NCT05650294|Placebo Comparator|Placebo group|This group will receive a single dose of the standard FO EE omega 3 fatty acids capsules first, then receive a single dose of the PL+ omega 3 fatty acids capsules. Wash-out period is 2 weeks between treatments.
88803295|NCT03014999|Experimental|High frequency rTMS|Volunteers will be submitted to high frequency of repetitive transcranial magnetic stimulation (10Hz)
88803296|NCT03014999|Experimental|Low frequency rTMS|Volunteers will be submitted to low frequency of repetitive transcranial magnetic stimulation (1Hz)
88803297|NCT03014999|Sham Comparator|Sham rTMS|Volunteers will be submitted to sham session of repetitive transcranial magnetic stimulation
88805930|NCT00297596|Experimental|Intervention|Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days.
89137390|NCT02767284|Active Comparator|Optec 6500|The Optec 6500 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
89137391|NCT04246424|Active Comparator|Fitbit + Coaching|Fitbit + coaching will receive both the fitbit and coaching interventions.
89137392|NCT04246424|Active Comparator|Coaching|Coaching group will receive weekly remote coaching lessons by phone email or text for 1-6 weeks. They will also receive a weekly email lesson for 1-6 weeks on things such as basics of sleep, enhancing sleep environment and managing stress.
89137393|NCT04246424|Active Comparator|Fitbit|Fitbit group will receive a Fitbit and are asked to monitor their sleep over the smartphone application for 1-6 weeks.
89137394|NCT04246424|No Intervention|Self-management|Self-management participants will be given some information of improving sleep but asked to keep their same schedule. Once their participation concludes, they will be given the opportunity to receive a fitbit and coaching if they so choose.
89137395|NCT02773914|Experimental|CGA intervention|The CGA intervention will include multidisciplinary teams consisting of physician, nurse (RN), physiotherapist (PT), occupational therapist (OT) and social worker (SW). The team will work according to CGA, and have the primary and continuing responsibility for planning of hospital care and discharge. CGA will include assessment of socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, as well as treatment and planning for discharge and follow-up.
89137396|NCT02773914|No Intervention|Control group|The control group receives usual hospital care, that is care given at an ordinary medical hospital ward, without the specialized multi-disciplinary team approach and CGA.
89137397|NCT02829398|Experimental|Patients with subarachnoid hemorrhage|Patients with subarachnoid hemorrhage will have CerebroSpinal fluid and plasma sample.
89137398|NCT02829398|Active Comparator|Control subjects|healthy controls from a previous study with a CerebroSpinal fluid and plasma sample
89137399|NCT02829554||Respondents|US residents recruited to an on-line questionnaire through Amazon mTurk.
89137400|NCT00888667||ICD patient with frequent PVCs|
89137401|NCT02771808||diabetic patients|obtain biomarker samples from diabetic patients and examine for 1-1 & 1-2 & 2-2 haptoglobin genotype
89137402|NCT04246268|Experimental|Treatment Group|"Device: INVOcell Intravaginal Culture System~Intervention: During an IVF/IVC cycle, participants will retain the INVOcell Culture Device with the Retention Device in the vaginal cavity for 5-days vaginal incubation."
89137403|NCT00888745|Experimental|1|
89137404|NCT00888745|Placebo Comparator|2|
89137405|NCT02833298|Experimental|Automated reminders|Patient will be contacted for automated reminders within one month before the six-month interval indicating they are due for HCC screening.
89137406|NCT02833298|Experimental|Patient navigation|The patient navigator will coordinate with the provider and subject to schedule the appropriate office visit and imaging for HCC screening as needed within one month before the test is due.
89137407|NCT00884689||1|Asthma patient with specific treatment
89137408|NCT00884689||2|Asthma patient on different specific treatment compared to the other group
89137409|NCT02771652|Active Comparator|e-training intervention|Resistance and endurance training
89137410|NCT02771652|Other|Control|no exercise
89137411|NCT02696694||P25-P75|serum progesterone between 25 and 75 percentile
89137412|NCT02696694||<P25 ó >P75|serum progesterone <25 or >75 percentile
89137413|NCT05323682|Experimental|Experimental|Individualized physical exercise program
89137414|NCT05323682|Active Comparator|Control|No individualized physical exercise program
89137415|NCT00886093|Experimental|Sequence 1|
89137416|NCT00886093|Experimental|Sequence 2|
89137417|NCT02773680|Experimental|Study cohort 1|"electrical impedance tomography"
89137418|NCT04038073||ADHD|Attention Deficit/Hyperactivity Disorder
89137419|NCT05323526||Study Group|100 patients who will undergo cataract surgery
89137420|NCT04739592|Experimental|alendronate sodium vitamin D3 tablets|participants will receive alendronate sodium vitamin D3 tablets once per week for one year.
89137421|NCT04739592|Placebo Comparator|placebo|participants will receive a placebo tablet once per week for one year.
89137422|NCT00633386|Experimental|A|
89137423|NCT00633386|Placebo Comparator|B|
89137424|NCT02771418|Sham Comparator|TIVA with propofol|Induction and maintenance of general anesthesia using TIVA with propofol
89137425|NCT02771418|Active Comparator|VIMA with sevoflurane|Induction and maintenance of general anesthesia using VIMA with sevoflurane
89137426|NCT02542423|Other|patients undergoing cardiac surgery|
89137427|NCT02833220||Healthy volunteers|"Healthy adults between the ages of 18-65 are eligible.~Participants will receive non-invasive brain stimulation by way of single-pulse transcranial magnetic stimulation to the motor cortex"
89137428|NCT02766972|Experimental|RVP|
89137429|NCT02541721|Experimental|LabiaStick#01|Each participant will have an at least 2-week baseline period followed by a 4-week treatment period with LabiaStick#01.
89137430|NCT04246034|Experimental|Cases|As described by Saaristo et al. in 2012, the surgical technique starts with wide axillary scar removal, followed by elevation of contralateral dual flap which includes DIEP/MS-TRAM with attached groin lymph nodes and fat, then the anastomosis is preferably done to internal mammary vessels.
89137431|NCT04245878||intensive care unit inpatient|Inpatient intubated resuscitation patient with a scheduled extubation
89137432|NCT00888901|Experimental|1|Patients on eltrombopag
89137433|NCT00888901|Active Comparator|2|Patients on corticosteroids
89137434|NCT00888901|No Intervention|3|Untreated patients
89137435|NCT02766816|Experimental|Part 1 Study - BBio bOPV|
89137436|NCT02766816|Active Comparator|Part 1 Study - Licensed bOPV|
89137437|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 1|
89137438|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 2|
89137439|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 3|
89137440|NCT02766816|Active Comparator|Part 2 Study - Licensed bOPV|
89137441|NCT02829476|Experimental|patients with AIS|Patients will have 'Osteoblast sample'
89137442|NCT02829476|Experimental|control patients|
89137443|NCT00803049|Experimental|Placebo/Teriflunomide 7 mg|Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.
89137444|NCT00803049|Experimental|Teriflunomide 7 mg/7 mg|Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.
89137445|NCT00803049|Experimental|Placebo/Teriflunomide 14 mg|Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
89137446|NCT00803049|Experimental|Teriflunomide 14 mg/14 mg|Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
89137447|NCT02767050||GROUP 1: CONTROL GROUPS|Patients with no habit history of tobacco are included in group 1.
89137448|NCT02767050||GROUP 2: SMOKING TOBACCO|Patients with a history of tobacco consumption in the form of smoking.
89137449|NCT02767050||GROUP 3: SMOKELESS TOBACCO|Patients with a history of tobacco consumption in the form of chewing.
89137450|NCT00890084||Group1|
89137451|NCT00884845|Experimental|Arm 1|Administration of i.v. infusions of PM02734 (on Days 1, 8 and 15) every three weeks and a daily oral dose of erlotinib
89137452|NCT02773602|Experimental|Dexamethasone|Dexamethasone has been used for adult epidurals and nerve blocks and in spine surgeries. It prolongs the duration of pain relief and causes less sedation. It is commonly administered to children during surgery to help decrease nausea and vomiting after surgery. It is also much cheaper than clonidine The patient will receive Ropivacaine plus 200 μgm/kg of dexamethasone in 1 ml saline
89137453|NCT02773602|Active Comparator|Clonidine|"Clonidine has been added to caudal analgesia for infants and children for many years. It increases the duration of pain relief of ropivicaine by itself, however, it may lead to prolonged sedation following the surgical procedure (an undesired effect) and it is expensive.~The patient will receive Ropivacaine plus 2 μg/kg of clonidine in 1 ml saline."
89137454|NCT02773602|Placebo Comparator|Normal Saline|The patient only will receive Ropivacaine
89137455|NCT00886171|Experimental|Social Skills Training|
89137456|NCT00886171|Experimental|Physical Activity Training|
89137457|NCT05198726|Active Comparator|Active tACS plus active SoP|Active alpha range tACS plus Speed of Processing Training
89137458|NCT05198726|Active Comparator|Active tACS plus sham SoP|Active alpha range tACS plus sham Speed of Processing Training
89137459|NCT05198726|Active Comparator|Sham tACS plus active SoP|Sham alpha range tACS plus Speed of Processing Training
89137460|NCT02770950|Active Comparator|High dose group|"High dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 24h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 24h per day."
89137461|NCT02770950|Active Comparator|Low dose group|"Low dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 12h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 12h per day."
89137462|NCT02770950|Active Comparator|Controlled group|Indometacin Cataplasms will be used topically on the knee for 24h per day
89137463|NCT00885001|Experimental|Short Arc Banding Group|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
89137464|NCT02468895||Idiopathic Inflammatory Myopathy|PM, DM, sIBM, necrotizing myopathy, anti-synthetase syndrome, suspected myopathy
89137465|NCT02828930|Experimental|Idasanutlin|On Day 1, 300 milligram (mg) idasanutlin tablet orally and 100 mg [14C]-radiolabeled idasanutlin capsule orally (2, 50 mg capsules containing approximately 100 microcurie of radioactivity). After 5 hours and 45 minutes of the oral dose, 100 microgram (mcg) of [13C]-radiolabeled idasanutlin will be administered over a 15-minute intravenous (IV) infusion. On Day 11, idasanutlin matching placebo aqueous dispersion orally and approximately after 1 hour, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. On Day 19, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days, and no treatment during 23 days of 28-day cycle, until the development of progressive disease, unacceptable toxicity, consent withdrawal or any other criteria for removal.
89137466|NCT02766738|No Intervention|Control|All participants assigned to the control group will be given the option to engage in other activities that were offered by the facility during the 24-week intervention period. However, no specific resistance exercises were offered in these activities.
89137467|NCT02766738|Experimental|GrACE program|Participants in the exercise group will perform twice weekly training for 24 weeks. In brief, the program will include weight-bearing exercises and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. The following-weight bearing and resistance exercises: chair stands, chair dips, calf raises and hip flexor/abdominal lifts, trunk twists, and bicep curl and shoulder press. In total the sessions will be 45 minutes twice weekly.
89137468|NCT02766738|Experimental|GrACE + gait program|GrACE program as mentioned above plus focus on gait specific training will be one-hour training sessions for 24 weeks. Gait exercises will be a combination of exercises: heel and toe raises, stepping in different directions, single leg stand¬ing, step-ups, and task-specific balance work (e.g. reaching outward from the base of support while standing, sitting, and standing and turning). Gait exercises will be upgraded by: 1) reducing hand support and/or 2) narrowing the base of support, and/or 3) introducing a cognitive challenge (e.g. counting backwards while performing exercise) or perform¬ing exercise with the eyes closed.
89137469|NCT02352207||identification of a pulmonary malformation in the fetus|pregnant women referred to a prenatal Center, because of the identification of a pulmonary malformation in the fetus
89137470|NCT00889057|Experimental|sorafenib|
89137471|NCT02773290|Experimental|Romiplostim|Weekly Subcutaneous (SC) administration
89137472|NCT02832986||Patients in frailty consultation|Patients consulting in frailty consultation, at this occasion they will complete a medical questionary for the collection of study data
89137473|NCT02541799|Experimental|Telemedicine|Participants allocated to this arm will be approached the using a telemedicine medium to discuss study participation. The consent form will be administered while the investigator is on a telemedicine link.
89234285|NCT03889704|Experimental|Neuromuscular electrical stimulation|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. It will be applied for 20 minutes per session. For each patient, there will be 2 sessions per week, spaced 3 to 4 days apart. Each patient will participate in 16 sessions over the 8 weeks of the study. There will be 6 patients total.
89234286|NCT00999258|Active Comparator|sirolimus|the subjects will undergo conversion from tacrolimus to sirolimus OR they will continue to receive tacrolimus.
89234287|NCT00999258|No Intervention|tacrolimus|
89234288|NCT00994734|No Intervention|clinic administration of mifepristone|
89234289|NCT00994734|Experimental|home administration of mifepristone|
89234290|NCT00995826|Placebo Comparator|placebo|
88803298|NCT05647252|Experimental|Decolonization|"This study will be performed with an existing set manufactured by Schülke & Mayr GmbH. The distribution of octenisan® wash lotion and octenisan® nasal gel in the form of a set (octenisan® set) largely streamlines and facilitates the application and compliance.~The duration of pre-surgical decolonization is planned to be five days. However, when this pre-surgical time period is too short, the decolonization may also start at least 3 days before surgery and be contin-ued up to 2 days post-surgery.~During the post-surgery application, the patient will be washed with water and Octenisan® set by their treating nurses. The patient will also return the empty/used set and answer to a short questionnaire during their hospital stay. The study team will recuperate the questionnaire during hospitalization."
88803299|NCT05647252|No Intervention|Non-Decolonization|No Decolonization preoperatively
88803300|NCT02170649|Experimental|Single Group|the volunteers received a single 800 mg BIA 2-093 following either a standard high fat content breakfast or 10 hours of fasting. Fed and fasting periods were separated by a washout period
88803301|NCT05288699|Experimental|Aliento|Participants complete the brief (~30 minute) intervention at baseline and will have access to intervention material for up to 1-month after the baseline appointment via the mobile health application.
88803302|NCT05646160|Experimental|chronic migraine (CM)|CM is diagnosed after a patient has experienced a tension or migraine headache for at least 15 days in a month for at least 3 months, when not less than 8 days is characterized by the symptoms typical of migraine diagnosis.
88803303|NCT05646160|Experimental|episodic migraine with aura (EMa)|EMa, known as classical migraine, is characterized by an attack of pain lasting several or tens of minutes, during which the appearance of unilateral visual and sensory symptoms from the central nervous system, usually associated with pain and migraine symptoms.
88803304|NCT05646160|Experimental|episodic migraine without aura (EMb)|EMb is diagnosed after at least 5 attacks per month, characterized by a one-sided, pulsating headache of moderate or severe intensity, which increases with physical activity, sometimes with vomiting, and sensitivity to light and sound. This episode of migraine must last from 4 to 72 hours.
88803305|NCT02316470|Active Comparator|VLA84 75 mcg (microgram) w/o Alum|VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
88803306|NCT02316470|Active Comparator|VLA84 200 mcg w/o Alum|VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
88803307|NCT02316470|Active Comparator|VLA84 200 mcg with Alum|VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
88803308|NCT02316470|Placebo Comparator|Placebo|Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
88803309|NCT03014921|Placebo Comparator|placebo injection group|saline solution injection as placebo
88803310|NCT03014921|Active Comparator|iron injection group|iron injection
88803311|NCT04094207|Placebo Comparator|Control group|Equivalent Placebo will be given
88803312|NCT04094207|Experimental|Pentoxifylline group|Pentoxifylline will be given orally at 800 mg a day for 8 weeks
88803313|NCT02144831|Active Comparator|anti-thrombotic treatment|10 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
88803314|NCT02144831|Active Comparator|anti-thrombotic|30 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
88803315|NCT05232461|Active Comparator|PrimeC ER Fasted|Single dose PrimeC-ER (748 mg), administered following an overnight fast of at least 10 hours.
89234291|NCT00995826|Experimental|CS-8958 DPI|
89234292|NCT00994812|Experimental|Metformin|
89234293|NCT03887442|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
88803316|NCT05232461|Active Comparator|PrimeC ER Meal|Single dose PrimeC-ER (748 mg), administered at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours.
88803317|NCT05232461|Active Comparator|Marketed ciprofloxacin and celecoxib|Single dose of 750 mg of ciprofloxacin 200 mg of celecoxib, co-administered following an overnight fast of at least 10 hours.
88803318|NCT01804790|Active Comparator|Arm A : Radiotherapy + capecitabine|Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session ; 25 fractions) + capecitabine 800 mg/m² twice daily 5 days/7, excluding weekends), then 6-8 weeks after chemoradiation, surgery with total mesorectal excision (TME), followed by adjuvant chemotherapy for 6 months, either mFolfox6 or capecitabine, depending on the center's choice.
88805931|NCT01144637|Experimental|Group 1|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
88805932|NCT01144637|Experimental|Group 2|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
88805933|NCT01144637|Experimental|Group 3|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
88805934|NCT01144637|Placebo Comparator|Group 4|Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
89234294|NCT03887442|Experimental|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
89234295|NCT00996060|Experimental|Hydralazine and Valproic Acid|Starting dose of Hydralazine is 25 mg orally daily, days 1-28. (See Intervention for Dose Escalation Schema) Valproic acid 250 mg orally three times per day for days -14 through -8, then 500 mg orally three times per day daily for days -7 through 28, with the dose titrated to keep the serum level between 0.4 and 0.7 mM.
88803319|NCT01804790|Experimental|Arm B : Chemotherapy then radiochemotherapy|"Drug: Chemotherapy mFolfirinox~Investigational arm: Neoadjuvant CT mFolfirinox, 6 cycles (ca. 3 months; each cycle = 2 weeks):~oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-fluorouracil (5-FU): 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles).~Then followed by 5 weeks of chemoradiotherapy 50 Gy (2 Gy/session, 5 sessions per week) + capecitabine 800 mg/m² twice daily 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, followed by 3 months of adjuvant chemotherapy, either mFolfox6 or capecitabine depending on the center's choice."
88803320|NCT05745922|No Intervention|Control|Resting in seated position
88803321|NCT05745922|Experimental|Moderate intensity exercise|Moderate intensity endurance exercise, treadmill walking/running at 70% of heart rate maximum for 40 minutes
88803322|NCT05745922|Experimental|High intensity exercise|High intensity interval training: treadmill walking/running. 10 minutes warm-up at 70% of heart rate maximum, followed by four 4-minutes bouts at 90-95% of heart rate maximum, separated by 3-minutes active recovery (at 70% of heart rate maximum)
88803323|NCT01317134|Active Comparator|Therapy-naive|"This group consists of patients with a newly diagnosed PH (Class I or IV). First blood sampling takes place before initiation of PH therapy (0 months), the following measurements will be performed after 3, 6, 9 and 12 months under specific therapy.~Initiation of standard therapy is performed directly after baseline visit / study inclusion. No special study medication will be used.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood Test"
88803324|NCT01317134|Active Comparator|Under therapy|"This group consists of patients under ERA monotherapy at timepoint of inclusion. Observation period is one year to detect intraindividual changes in endothelial dysfunction measured by L-arginine/NO-metabolites after 0, 3, 6, 9 and 12 months under investigation.~Specific PAH therapy has been started prior to the study for medical reasons and will be continued throughout.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood"
89137474|NCT02541799|Active Comparator|Standard Care|Participants allocated to this arm will be approached in standard fashion where the investigator approaches the patient face to face. The consent form will be administered while the investigator is in the participant's room.
89137475|NCT02771106||vision dysfunction|This group are subjects with mild TBI who have been diagnosed with profound oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist. These subjects will undergo neuro vision rehabilitation.
89137476|NCT02771106||control|This group are subjects with mild TBI who have no oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist
89137477|NCT02829008|Experimental|low-dose-bevacizumab/Pemetrexed|Low-dose-bevacizumab is given at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and every three weeks are a treatment cycle .Pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too. The pretreatment of pemetrexed should be conducted within the study.
89137478|NCT02829008|Active Comparator|Treatment of physician' choice|Treatment of physician's choice can be any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. It can be drugs like taxanes,capecitabine, gemcitabine, cisplatin, everolimus or even nutrient solution,et al.
89137479|NCT04828590||Patients with suspected CAD containing at least one 30%-90% coronary CTA stenosis|Patients' datasets with suspected CAD containing at least one 30%-90% coronary CTA stenosis; and ICA-FFR was measured on vessels with diameters greater than 2 mm will be analyzed. Diagnostic performance based on CT-derived FFR using DVFFR software will be compared with the diagnostic performance from ICA-FFR measurements.
89137480|NCT00889213|Experimental|Patch and glue arm|Randomized patients to the patch and glue arm will undergo placement of a falciform ligament tissue patch and fibrin glue to the resection margin of the remnant pancreas following distal pancreatectomy
89137481|NCT00889213|Active Comparator|stapled /sutured pancreatic closure|
89137482|NCT05272748|Experimental|Conventional Exercise|Conventional exercises used in the treatment of knee and hip osteoarthritis will be performed by the telerehabilitation method for 8 weeks. Patients will be contacted via laptop, ipad and phones with cameras, microphones and internet connection. Exercise by telerehabilitation will be implemented with a live connection for the first 4 weeks. In the second 4 week periods, exercise videos will be given to the patients and it will be checked by phone. Strengthening and flexibility exercises will be done to the conventional exercise group. Hip and knee isometric and isotonic exercises, terminal knee extension, mini squat, lunge, range of motion exercises for lower extremities, hamstring, quadriceps, gastrocnemius stretching exercises will be performed by the patients. Exercises will be applied 3 times a week.
89234296|NCT00996138|Other|Arm 1|Dose ranging
88803325|NCT01317134|Active Comparator|Healthy controls|This group consists of healthy individuals. Sex and age matching is intended. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood
88803326|NCT01315340|Experimental|Glaucoma Patients|
88803327|NCT01315340|Active Comparator|Control subjects|
88803328|NCT01313702|Experimental|polipillV1|poli pill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
88803329|NCT01313702|Experimental|polipillV2|Polipill versão2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
88803330|NCT01313702|Active Comparator|usual care|
88803331|NCT04983446|Experimental|Foralumab Arm + Standard of Care|Subjects in this arm would receive, intranasal foralumab 100 µg (50 µg in 0.1 ml solution into each nostril).
88803332|NCT04983446|Active Comparator|Placebo Arm + Standard of Care|Subjects in this arm would receive, placebo (0.1 ml vehicle solution into each nostril).
88803333|NCT00365690|Active Comparator|1|Participants will receive individual therapy upon request
88803334|NCT00365690|Active Comparator|2|Participants will receive telephone-administered supportive-expressive group therapy
88803335|NCT00365690|Experimental|3|Participants will receive telephone-administered coping improvement group therapy
88803336|NCT04331392|Experimental|Spatial navigation intervention|
88803337|NCT04331392|Active Comparator|Educational Videos|
88803338|NCT00301184|Experimental|1A|One 0.3 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^7 TCID50 MVA or placebo at Months 4 and 6
89137483|NCT05272748|Experimental|Conventional Exercise + Core Stabilization Exercise|Conventional exercises and core stabilization exercises will be performed with the telerehabilitation method for 8 weeks. Patients will be contacted via laptop, ipad and phones with cameras, microphones and internet connection. Exercise by telerehabilitation will be implemented with a live connection for the first 4 weeks. In the second 4 week periods, exercise videos will be given to the patients and it will be checked by phone. In addition to the exercises in the conventional exercise group, patients will perform bridging, lateral bridging, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, clam exercise. Exercises will be applied 3 times a week.
89137484|NCT02046135|Experimental|Sodium bicarbonate|At the start of the surgery, the patient will receive NaHCO3 as a continuous infusion of D5% 1/3NS + 100 meq/L NaHCO3 + 20 meq/L KCl at maintenance IVF (solution contains ~154 meq of sodium which is equivalent to normal saline). The NaHCO3 infusion will continue for the first 24 hours after the discontinuation of CPB. After 24 hours of receiving the NaHCO3 infusion, the IVF administered to the patient will be the standard solutions used in the PICU at CCMC.
89137485|NCT02046135|Active Comparator|Sodium Chloride|At the start of surgery, patients in the control arm will receive D5% Normal Saline + 20 meq/L KCl at maintenance IVF. After 24 hours, standard IVF, not containing NaHCO3 or Na acetate will be administered for the duration of the PICU stay as required, determined by the clinicians primarily caring for the patient postoperatively.
89137486|NCT00886327||Postoperative patients|Patients with CD who recently underwent bowel resection
89137487|NCT04245488|Other|taste testing|Participants will first taste 5 sour solution containing acetic acid for sour compounds, sucrose esters, and xanthan gum to help them stay dissolved). Then rate them for their taste intensities. Next, participants will taste 5 butyric acid solutions, 5 hexenoic acid solutions, 5 caprylic acid solutions, 5 lauric acid solutions, 5 palmitic acid solutions, 5 oleic acid solutions, and 5 linoleic acid solutions (all will also contain the sucrose esters and xanthan gums.) and rate them for their taste intensities. This should take no longer than 1 hour. Participants will spit all samples into a cup after tasting them. They will not swallow any samples.
89137488|NCT00382200|Experimental|Decitabine and All-Trans Retonoic Acid (Tretinoin)|Decitabine and All-Trans Retonoic Acid (Tretinoin)
89137489|NCT04245566|Experimental|Prostatic Artery Embolization (PAE)|PAE will be performed as an inpatient or outpatient procedure by interventional radiologists who are familiar with the procedure and according to established techniques. A unilateral femoral sheath is placed in the right common femoral artery under local anaesthesia. The prostatic arterial supply is identified by selective internal iliac arteriography. Prostatic arteries are selectively catheterised and embolised by use of 250-600 μm microspheres . PAE is performed bilaterally if possible and considered successful in the absence of the normal blush of the prostate and stasis of flow in the prostate arteries on angiography after embolisation.
89137490|NCT04245566|Placebo Comparator|Pharmocotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations. Thus, patients with a prostate size smaller than 40mL will be treated with 0.4 mg tamsulosin once daily, while patients with larger prostates will be treated with 0.4 mg tamsulosin plus 0.5 mg dutasteride once daily during the complete study follow-up.
89137491|NCT00802893|Experimental|Experimental Drug|
89137492|NCT00802893|Placebo Comparator|Placebo Comparator|
89137493|NCT02696928|Other|Artemeter-Lumefantrine (combination therapy)|"33 patients~(standard of care)"
89137494|NCT02696928|Active Comparator|Artemeter-Lumefantrine and Primaquine (combination therapy)|33 patients
89137495|NCT02696928|Experimental|Artemeter-Lumefantrine and MB (combination therapy)|33 patients
89137496|NCT00885157|Experimental|Group A|Will receive fractional doses of IPV Intradermally
89137497|NCT00885157|Active Comparator|Group B|Will receive full doses of IPV Intramuscularly
89137498|NCT02606097|Experimental|regorafenib|regorafenib 160 mg daily, 3 weeks on/1 week off
89137499|NCT00886405|Experimental|Nytroglicerin|
89137500|NCT02773134|Active Comparator|Brace Group|Patients in the brace group will be fitted by an orthotist postoperatively and will be instructed to wear a rigid molded Lumbosacral Orthosis (LSO) full time for 8 weeks except during hygiene and wound care followed by daytime wear for another 4 weeks. All patients will start wearing the brace 48 hours after the surgery following removal of the wound drain. All braces will be molded and fitted by the same experienced orthotist affiliated with the hospital. Self-compliance to brace wear will be noted every day for 3 months by each patient on a specific form.
89137501|NCT02773134|Experimental|Control Group|No brace prescription postoperatively. Patients in this group will be observed and results will be compared to the brace group.
89137502|NCT02828852|Experimental|Pregnancy|Blood sample
89137503|NCT02828852|Experimental|No pregnancy|Blood sample
89137504|NCT02766426|Other|Lifestyle change intervention|Overweight/obese pregnant women enrolled in a healthy lifestyle change programm
89137505|NCT00885235||A|Subjects that are indicated for colonoscopy who are suspected or known to suffer from large bowel diseases.
89137506|NCT02829086|Experimental|Group I|Participants in Group I will receive the following interventions: Intro to Relationship Enhancement (8 hours), Family Stress and Conflict Management (8 hours), and case management
89137507|NCT02829086|Experimental|Group II|Participants in Group II will receive the following interventions: Intro to Relationship Enhancement (8 hours), RE & Financial Management (8 hours), and case management
89137508|NCT02829086|No Intervention|Group III|Participants in Group III will receive the the standard care of all participants, case management ONLY
89137509|NCT02766660|Other|Thyroid ophthalmopathy|Thyroid associated ophthalmopathy patients were measured by optical coherence tomography.
89137510|NCT02766660|Other|Control|Control group was consisted by age and sex- macthed healthy people adn they were measured by optical coherence tomography.
89137511|NCT00889369|Experimental|A|Use of duloxetine, flexible dose (60-120mg/day) for 8 weeks, following a 2-week placebo lead-in phase
89137512|NCT02766192|Experimental|TIMBER-Ketamine arm|This arm received TIMBER psychotherapy and ketamine infusion.
89137513|NCT02766192|Placebo Comparator|TIMBER-placebo arm|This arm received TIMBER psychotherapy and placebo (normal saline) infusion.
89137514|NCT04248062||IEM experts|Heterogeneous group of health professionals (physicians, psychologists, nutritionists) working in the field of Inborn Errors of Metabolism (IEM)
89137515|NCT04248062||Paediatric IEM patients|IEM patients between 10 and 18 years
89137516|NCT04248062||Parents of paediatric IEM patients and patient representatives|"Parents of IEM patients (between 0 and 18 years)~Patient representatives"
89137517|NCT05278897|Experimental|Soft Tissue Adapted Biocompatible Hyaluronic Acid|Soft Tissue Adapted Biocompatible Hyaluronic Acid is a clear solution of sterile 1% sodium hyaluronate (10 mg/mL) contained in a 1.2 mL pre-filled syringe. Patients will receive two injections, spaced 2 to 3 days apart (for ankle sprains) or 7 days apart (for elbow injections).
89137518|NCT04243928|Active Comparator|control group|15 diplegic children received regular exercise program including balance exercise
89137519|NCT04243928|Experimental|study group|15 diplegic children recieved regular exercise program plus putting kinesiotape
89137520|NCT02542033|Active Comparator|verum|500mL treated apple juice with low sugar content given on one experimental day
89137521|NCT02542033|Placebo Comparator|control|500mL un-treated apple juice with normal sugar content given on one experimental day
89137522|NCT02770560||Chronic hemodialysis patients with a tunneled cuffed catheter|In case of thrombotic dysfunction of the dialysis catheter : administration of Urokinase (100 000 units in total) as locking solution in the dead space of the catheter lumen, interdialytic (between two dialysis sessions) or intradialytic (during the dialysis in case of complete obstruction of the dialysis catheter)
89137523|NCT02541487||Nutritional/Physical Activity (NuPA) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
89137524|NCT02541487||Physical Activity only (PAo) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the exercise only arm that achieve pregnancy.
89137525|NCT02541487||Infertile, non-lifestyle intervention controls|Obese women (60) with unexplained infertility who meet the inclusion/exclusion criteria for FIT-PLESE but decline participation in the trial and who elect to undergo CC-IUI treatment and achieve pregnancy without prior diet and exercise interventions.
89137526|NCT02773056|Active Comparator|Socket 1 (Ischial Ramus Containment)|This arm included unilateral transfemoral amputees who were assessed while using the Ischial Ramus Containment socket.
89137527|NCT02773056|Active Comparator|Socket 2 (Dynamic Socket IRC)|This arm included unilateral transfemoral amputees who were assessed while using the Dynamic Socket Ischial Ramus Containment socket.
89137528|NCT02773056|Active Comparator|Socket 3 (Sub-Ischial Interface)|This arm included unilateral transfemoral amputees who were assessed while using the Sub-Ischial Interface socket.
89137529|NCT04245410||Patients surgically treated of pancreatic metastases from RCC|Patients surgically treated of pancreatic metastases from renal cell carcinoma. Pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy are included.
89137530|NCT00889525|Experimental|Cabergoline|
89137531|NCT02770872||Obese, normal|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2. Observation of SAA on apoB containing lipoproteins
89137532|NCT02770872||Obese, MetS|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2, blood pressure above 135/80, HDL less than 40 mg/dl, triglycerides greater the 150 mg/dl and fasting blood glucose greater than 100 mg/dl but less than 126 mg/dl. Observation of SAA on apoB containing lipoproteins
89137533|NCT02770872||Obese, diabetic|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2 and physician diagnosed diabetes mellitis. Observation of SAA on apoB containing lipoproteins
89137534|NCT02833142|Experimental|BIIB033-A|Staggered single dosing schema
89137535|NCT02833142|Experimental|BIIB033-B|Staggered single dosing schema
89137536|NCT00885313|Experimental|DHA250|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
89137537|NCT00885313|Experimental|DHA500|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
89137538|NCT00885313|Placebo Comparator|PLA|placebo and lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
89137539|NCT05149196|Experimental|Targeted blood pressure management|"During anesthesia, mean blood pressure is maintained ≥85 mmHg or above baseline by combining fluid challenge and norepinephrine infusion;~For patients admitted to intensive care unit after surgery, mean blood pressure is maintained ≥85 mmHg or above baseline by combining fluid challenge and norepinephrine infusion;~In the general ward, systolic blood pressure is maintained ≥110 mmHg or within 10% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or norepinephrine infusion."
89137540|NCT05149196|Active Comparator|Routine care|"During anesthesia, mean blood pressure is maintained ≥65 mmHg or within 20% of baseline according to routine practice;~For patients admitted to intensive care unit, mean blood pressure is maintained ≥65 mmHg or within 20% of baseline according to routine practice;~In the general ward, management is performed according to routine practice."
89137541|NCT02762760|Experimental|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
89137542|NCT02762760|Experimental|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
89137543|NCT00886561|Experimental|HIV risk reduction intervention|Behavioral intervention designed to reduce HIV risk behaviors and enhance enhance HIV-preventive behaviors among female sex workers (FSWs) in Armenia
89137544|NCT00886561|Active Comparator|Wait list control|Will receive behavioral intervention after completion of study upon request.
89137545|NCT02770794|Experimental|All patients|Discontinue infliximab; Receive infliximab when relapse
89137546|NCT04245332|Experimental|Fish Oil|This group will receive fish oil (4g/d).
89137547|NCT04245332|Placebo Comparator|Placebo|This group will receive coconut oil (4g/d) as an iso-energetic, iso-lipidic placebo comparator to the fish oil arm.
89137548|NCT04036513|Experimental|MINST|"Usage of magnification loupes, specific thin and delicate tips together with piezoelectric device and specifically designed Hu-Friedy mini five, micro mini five, and after five Gracey curettes under local anaesthesia."
89137549|NCT04036513|Active Comparator|Conventional SRP|Conventional non-surgical mechanical treatment using piezoelectric device (PiezoLED, Kavo) and standard Gracey curettes under local anaesthesia.
89137550|NCT04224246|Experimental|One arm with Gamma-OH® treatment|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours between 10 p.m. to 4 a.m.
89137551|NCT00892567|Experimental|9 Peptide Vaccine|
89234297|NCT00996138|Other|Arm 2|Dose ranging
89137552|NCT02766270|Experimental|Chemoradiotherapy with Temozolomide|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy) and receive temozolomide PO QD (75 mg/m2/day, 7 days/week) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5 (150-200 mg/m2). Treatment with temozolomide repeats every 28 days for up to 12 courses
89137553|NCT02766270|Active Comparator|Radiotherapy alone|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy)
89137554|NCT04300010|Active Comparator|Blue Light Therapy|FDA cleared blue light product, Omniluxblue (Globalmed Technologies, Glen Elen, CA), which emits a 415 nm blue light irradiance of 40mW/cm2. Following the application of blue light protective eyewear, the blue light therapy device will be centered over the deltopectoral interval according to device standardized use instructions and a 23-minute treatment will be administered to dry skin. As was done in the topical BPO group, following treatment, a skin swab culture of the treatment shoulder will be taken, then both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder. Participants and research personnel conducting the blue light treatments will be wearing medical grade blue light protective glasses for safety.
89137555|NCT04300010|Active Comparator|5% Topical Benzoyl Peroxide Gel|A pea-sized amount, ~0.5 grams, will be applied to a 10cm strip over the deltopectoral interval beginning the morning 48 hours prior to schedule research visit to obtain cultures. The benzoyl peroxide will be applied on dry skin after a shower. The gel will be applied once in the morning and once in the evening for two consecutive days as well as the morning of the scheduled research visit. Following treatment, a skin swab culture of the treatment shoulder will be taken, both the treatment shoulder and control shoulder will be sterilely prepped with 2% chlorhexidine gluconate solution with 70% isopropyl alcohol and allowed to dry for 3 minutes. Following chlorhexidine preparation, a single set of cultures will be obtained from each shoulder.
89137556|NCT04300010|Active Comparator|Light and Gel|Prior to treatment, a skin swab culture will be taken, 5% topical benzoyl peroxide treatment will be performed on dry skin immediately after a shower as described in the above paragraph. Again, five total treatments will be performed prior to research visit. On the day of the research visit, the blue light therapy protocol described above will be performed exactly the same followed by culture obtainment.
89137557|NCT02766348|Experimental|DC-CTL|After accepting chemotherapy of gGemcitabine and Cisplatin according to National comprehensive Cancer Network(NCCN) guidelines, patients will receive 3 cycles of DC-CTL treatment
89137558|NCT02766348|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
89137559|NCT02762916|Experimental|1- Telemedicine arm|"The intervention arm (IA), telehealth control, were followed up by himself helped by CONTECI program. They have to use every three months and if somethings was wrong the patient have to send mail to the doctor.~The intervention consisted to use the CONTECI program (included test) for the following of the patients."
89137560|NCT02762916|No Intervention|2- Control arm|The Control Arm (CA) were followed up as usual every 6 months in outpatient vascular visits in the clinical hospital. If some patient have a complications or and emergency they have to do usual protocol, go to primary care or emergency.
89137561|NCT02833064||Acute Liver Failure|"biological sampling~MRI scanning for patients with paracetamol induced acute liver failure"
89137562|NCT02833064||Acute Liver Injury|- biological sampling
89137563|NCT02833064||Acute on Chronic Hepatic Injury|- biological sampling
89137564|NCT02833064||Stable Cirrhotics|- biological sampling
89137565|NCT02833064||Non-cirrhotic liver disease|- biological sampling
89137566|NCT04223700|Experimental|Group 1|Ultrasound scanning of the rhomboid muscle
89137567|NCT02828306||Patients with skull defects|Patients with skull defects after craniotomy for example tumor resection, head trauma, stroke which need a Patient Specific Implant.
89137568|NCT00608569|Experimental|mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.
89137569|NCT00608569|Active Comparator|non-mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.
89137570|NCT02832830|Experimental|A|intensity modulated radiotherapy (IMRT) 10 x 3 Gy
89137571|NCT02832830|Active Comparator|B|fractionated conventional external beam RT 10×3 Gy
89137572|NCT04699422|Active Comparator|Experimental group|Patients in the experimental group will receive the serratus anterior plane block combined with postoperative PCIA with Piritramide.
89137573|NCT04699422|Sham Comparator|Control group|Patients in the control group will receive postoperative PCIA with Piritramide.
89137574|NCT02828384|Active Comparator|low fodmap diet|Subjects receive formalized teaching in low fodmap diet by a dietician
89137575|NCT02828384|Active Comparator|psyllium|subjects receive 7.1 g of psyllium daily
89137576|NCT02770482|Experimental|AD Patients|
89137577|NCT04245098|Experimental|Amyloid|Biopsy
89137578|NCT02771184|Other|Lung-Healthy|Subjects with no diagnosed lung disease. The intervention is the recording of lung sounds with the Lung Sound Recording System.
89137579|NCT02771184|Other|Pneumothorax|Subjects with pneumothorax. The intervention is the recording of lung sounds with the Lung Sound Recording System.
89137580|NCT02771184|Other|Pulmonary Fibrosis|Subjects with pulmonary fibrosis. The intervention is the recording of lung sounds with the Lung Sound Recording System.
89137581|NCT02828696|Other|No prep|"No prep treatment of worn dentition with CAD-CAM composite (PICN)"
89137582|NCT00889837|Experimental|Inhaled Loxapine|Staccato Loxapine, 10 mg doses x 2, 10 hours apart
89137583|NCT00889837|Placebo Comparator|Inhaled Placebo|Staccato Placebo,inhalations x 2, 10 hours apart
89137584|NCT02828540|Experimental|HT047 High-dose group|three times a day dosing schedule 3 tablets per dose
88803339|NCT00301184|Experimental|1B|One 3.0 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^8 TCID50MVA or placebo administered at Months 4 and 6
88803340|NCT00301184|Experimental|2A|One MTD (determined in Part 1) of DNA HIV vaccine or placebo administered at study entry. One dose of placebo or MTD of MVA at Months 2 and 6
88803341|NCT00301184|Experimental|2B|One dose of placebo or MTD of MVA administered at study entry and Months 2 and 6
89137585|NCT02828540|Experimental|HT047 Low-dose group|three times a day dosing schedule 3 tablets per dose
89137586|NCT02828540|Placebo Comparator|Placebo|three times a day dosing schedule 3 tablets per dose
89137587|NCT02770404|Experimental|Nafithromycin|"Subjects in Cohorts 1 through 5 receive active treatments. Subjects in Cohort 6 will receive an IV dose of nafithromycin and a single oral dose of nafithromycin in each crossover period.~Subjects in each of Cohorts 1, 2, and 3 will receive a single dose of 100, 200, or 400 mg, respectively, of nafithromycin on Day 1"
89137588|NCT02770404|Placebo Comparator|Placebo|Subjects in Cohorts 1 through 5 will be randomly assigned in an 8:2 allocation to receive active or placebo treatments.
89137589|NCT02762682||CASES OF ITS AND PRE ITS|"Either sex, age less than 3 years~Clinical diagnosis of Infantile Tremor Syndrome as evidenced by the following features:~[Developmental delay or regression WITH history of exclusive or predominant breast feeding WITH two or more of the following; skin pigmentation, hair depigmentation, tremors] ITS:1 and 2 plus tremors PreITS:1 and 2 without tremors"
89137590|NCT02762682||HEALTHY CONTROLS|Developmentally normal child not suffering from any acute or chronic neurological illness
89137591|NCT04243694|Experimental|Intervention group|mindfulness intervention administered
89137592|NCT04243694|No Intervention|Control group|no intervention administered
89137593|NCT00886873|Experimental|Group 1|Oral administration of mifepristone 5 mg daily for six months.
89137594|NCT00886873|Experimental|Group 2|Oral administration of mifepristone 10 mg daily for six months.
89137595|NCT02766114|Experimental|Issa1|After local anesthesia, through transverse approach on the middle of dorsal wrist crease the incision is made for 1.5 cm length, then the subcutaneous fat is dissected, soon we see the the palmaris longus tendon or its connection with the carpal ligament , take the ulnar side of the palmaris longus tendon and cut the carpal ligament axillary by scalpel, not going deep with the scalpel to avoid medial nerve injury, soon we see the nerve, we use the scissors to cut the proximal part then the distal part of the carpal ligament by enclosing it between the blades of the scissors, now the full released carpal tunnel most be observed, and one stitch is enough, in this operation most be an assistant exist.
89137596|NCT04243850|Experimental|Empagliflozin|Empagliflozine 7 days
89137597|NCT04243850|Placebo Comparator|Placebo|Placebo 7 days
89137598|NCT00892801|Experimental|Treatment|RAD001 + radiation therapy
89137599|NCT04222842|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25mg BID/50mg QD/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
89137600|NCT02541253|Experimental|GC3110A|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
89137601|NCT02541253|Active Comparator|GCFLU Pre-filled Syringe inj.|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
89137602|NCT04245020|Active Comparator|Text Message|Patients will be followed up with a series of text messages at 6-8 weeks
89137603|NCT04245020|Active Comparator|Telephone|Patients will be followed with a telephone conversation at 6-8 weeks
89137604|NCT04245020|Active Comparator|In person|Patients will be followed in person in the Outpatient department at 6-8 weeks
89137605|NCT00890071||Acute circulatory failure|Patients for whom the decision to give fluids was taken because the presence of one or more clinical signs of acute circulatory failure.
89137606|NCT02832908|Other|Patients + parents|Patients with severe head trauma
89137607|NCT02762292|Experimental|Patients|
89137608|NCT00633542|Experimental|TD|thalidomide-dexamethasone
89137609|NCT00633542|Active Comparator|ID|Interferon-dexamethasone
89137610|NCT02765958||Healthy|subjects without heart disease or arrhythmia, no evidence of obstructive sleep apnea
89137611|NCT02765958||OSA|obstructive sleep apnea
89137612|NCT02828150|Experimental|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements
88803342|NCT05374694||Group 1|Macrovasculature + (FFR ≤ 0.80) / Microvasculature + (IMR ≥25)
88803343|NCT05374694||Group 2|Macrovasculature + (FFR ≤ 0.80) / Microvasculature - (IMR <25)
88803344|NCT05374694||Group 3|Macrovasculature - (FFR>0.80) / Microvasculature + (IMR ≥25)
88803345|NCT05374694||Group 4|Macrovasculature - (FFR>0.80) / Microvasculature - (IMR <25)
88803346|NCT05374694||Group 5|"Microvascular spasm (<90% diameter contraction, Chest pain, ECG changes) or Macrovascular spasm (>90% diameter contraction, Chest pain, ECG changes)~*Only patients in groups 3 and 4 will undergo the acetylcholine test."
88803347|NCT04868708|Experimental|AK104+Paclitaxel+Cisplatin/Carboplatin|"AK104 intravenously(IV) every 3 weeks (Q3W)~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)~Cisplatin 50mg/m2 or Carboplatin AUC5 IV every 3 weeks (Q3W)"
88803348|NCT04868708|Experimental|AK104+Bevacizumab+Paclitaxel+Cisplatin/Carboplatin|"AK104 every 3 weeks (Q3W)~Bevacizumab 15mg/kg IV every 3 weeks (Q3W)~Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)~Cisplatin 50mg/m2 or Carboplatin AUC5 IV every 3 weeks (Q3W)"
88803349|NCT04868708|Experimental|AK104|AK104 IV every 2 weeks (Q2W)
88803350|NCT05604274||Healthy controls|
88803351|NCT05604274||Patients with cirrhosis on lactulose|
88803352|NCT05604274||Patients with cirrhosis on rifaximin|
89137613|NCT02766036|Active Comparator|Propolis|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses.
89137614|NCT02766036|Placebo Comparator|Placebo|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis-placebo in the form of tablets split in two daily doses.
89137615|NCT00610675|Experimental|Esmirtazapine|One tablet of Esmirtazapine, 4.5 mg orally, daily for up to 52 weeks
89137616|NCT02832752|Active Comparator|ECPR Region|The ECPR region has incorporated ECPR therapy into the out-of-hospital cardiac arrest algorithm. Within the ECPR Protocol, full standard advanced cardiac life support treatments will continue up until the time of ECMO initiation. The anticipated enrolment in this group is 70 patients. All eligible patients in the region will be enrolled, regardless of whether the ECPR protocol is activated or whether the patient is actually treated with ECPR.
89137617|NCT02832752|No Intervention|Control Region|"The control region will continue usual care as per current protocols which include standard advanced cardiac life support. Patients will be enrolled in the control region group at the same juncture of study eligibility. The anticipated enrolment in this group is 350 patients.~Within BCEHS practice, transport to hospital without prior return of spontaneous circulation is rare. Termination of resuscitation must be approved by an on-call physician and cannot occur prior to 30 minutes of resuscitation efforts."
89137618|NCT02770092|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
89137619|NCT02770092|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
89137620|NCT02770092|Experimental|Congestive Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
89137621|NCT04245254|Experimental|Intervention Arm|Single arm study. Receives collagen protein powder.
89137622|NCT00886951|Experimental|Access I123MNI388/I123MNI390 and brain imaging|
89137623|NCT02828228|Experimental|Vitamin D 1200 IU|Supplementation with vitamin D (1200 IU) once a day for 26 weeks
89137624|NCT02828228|Placebo Comparator|Placebo|Placebo once a day for 26 weeks
89137625|NCT00892879|Experimental|1|Single port laparoscopic device
89137626|NCT00892879|Active Comparator|2|Four-port laparoscopic device
89137627|NCT00890227|Active Comparator|Traditional technique|All level open instrumented posterior spinal fusions
89137628|NCT00890227|Active Comparator|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
89137629|NCT02828072|Experimental|Sky|Sky treatment foe 15 days
89137630|NCT02828072|Sham Comparator|control|standard medical therapy
89137631|NCT02769936|Placebo Comparator|Healthy Adult - Placebo|Single dose placebo pill in healthy adults
89137632|NCT02769936|Experimental|Healthy Adult - D-cycloserine|Single 100 mg dose D-cycloserine pill in healthy adults
89137633|NCT02769936|Placebo Comparator|Schizophrenia - Placebo|Single dose placebo pill in schizophrenia patients
89137634|NCT02769936|Experimental|Schizophrenia - D-cycloserine|Single 100 mg dose D-cycloserine pill in schizophrenia patients
89137635|NCT00887029|Active Comparator|DuoTrav|
89137636|NCT00887029|Active Comparator|Xalacom|
89137637|NCT00635310|Active Comparator|HD patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with hemodialysis (HD), pretreated with DDAVP 0.3 ug/kg body weight infusion 30-60 minutes before percutaneous liver biopsies (PLBs)
89137638|NCT00635310|Active Comparator|Ordinary patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with normal renal function (NRF) receiving percutaneous liver biopsies (PLBs)
89137639|NCT05278429|Active Comparator|Myosuit arm|Patients perform exercise training with the Myosuit
89137640|NCT05278429|Other|Control arm|Patients perform exercise training without the Myosuit
89137641|NCT02762448||Daclatasvir + Asunaprevir|Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks .
89137642|NCT02765724|Experimental|Group 1|Patients with mild hepatic impairment
89137643|NCT02765724|Experimental|Group 2|Patients with moderate hepatic impairment
89137644|NCT02765724|Experimental|Group 3|Patients with severe hepatic impairment
89137645|NCT02765724|Experimental|Group 4|Healthy subjects
89137646|NCT04223544||GPs Healthcare Workers|
89137647|NCT04223544||Hospital Healthcare Workers|
89137648|NCT00888134|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89137649|NCT00573157|Experimental|Atacicept Plus Mycophenolate mofetil Plus Corticosteroids|
89137650|NCT00573157|Placebo Comparator|Placebo Plus Mycophenolate mofetil Plus Corticosteroids|
89137651|NCT02832518||patients under hemodialysis|
89137652|NCT04627662|Other|Care Partners|Based on previous work, we will recruit up to 75 Care Partners and their 75 care recipients with dementia. This allows for 20% attrition. We will recruit participants from Alzheimer's Disease Research Centers (ADRCs) and other national locations.
89137653|NCT04224714|Experimental|Coronary heart disease patient|Quantitative coronary angiography (QCA) showed that there was a critical lesion in the proximal or middle segment of the coronary artery (diameter stenosis rate was 50% - 70%), and the diameter of the artery was more than 2.5mm
89137654|NCT00890383|No Intervention|Crystalloid only|patients will receive crystalloid fluids only for volume therapy of severe trauma
89137655|NCT00890383|Active Comparator|Colloid + Crystalloid arm|Goal directed volume therapy for severe trauma resuscitation
89137656|NCT02762058|Experimental|Experimental Group|Patients receiving Virtual Reality Mirror Therapy
89137657|NCT02762058|Experimental|Control Group|Patients receiving Traditional Mirror Therapy
89137658|NCT00887107|Experimental|sorafenib|30 patients with non-radioiodine avid differentiated thyroid carcinoma
89137659|NCT02769468|Active Comparator|The Back|The probe is placed lateral from the spine, 1 cm above the intergluteal cleft, and in side position to the flank between the hips and the ribs.
89137660|NCT02769468|Active Comparator|Chest|The probe is placed on the chest, 1 cm above the left nipple.
89137661|NCT02769468|Active Comparator|Left Axilla|The probe is placed deep in the left axilla
89137662|NCT00887185|Active Comparator|1 - Traditional training|Temporal bone dissection training in cadaveric laboratory. Subjects are provided 2 cadaveric temporal bones and asked to spend 2 weeks practicing the surgical technique of complete mastoidectomy with facial recess approach.
89137663|NCT00887185|Experimental|2 Simulator training|Subjects perform temporal bone surgical dissection training on a simulator.
89137664|NCT00802737|Experimental|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
89137665|NCT02769390|No Intervention|Bupivacaine 0,166%|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% for hypospadia surgery
89137666|NCT02769390|Active Comparator|Clonidine 1 mcg/Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 1 mcg/ Kg of clonidine for hypospadia surgery
89137667|NCT02769390|Active Comparator|Clonidine 2 mcg/ Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 2 mcg/ Kg of clonidine for hypospadia surgery
89137668|NCT02769390|Active Comparator|Clonidine 3 mcg/Kg|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 3 mcg/ Kg of clonidine for hypospadia surgery
89137669|NCT00890461||Defibrillator|The subject population will be obtained by approaching the Principal and Co- Investigators' patients who have been referred for ICD implantation or who already have an ICD. This population ranges in age from 18 years on, and includes both males and females. A maximum of 50 subjects will be enrolled in this study.
89137670|NCT02765568|Experimental|Moderate Intensity Continuous Exercise|Moderate Intensity Continuous Exercise Training
89137671|NCT02765568|Experimental|Nordic Walking|Nordic Walking
89137672|NCT02765568|Experimental|High Intensity Interval Training|High Intensity Interval Training
89137673|NCT04036591||Children under 24 months with ARIS|
89137674|NCT02762214|Active Comparator|With Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer using uterine manipulator.
89137675|NCT02762214|Experimental|Without Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer without support of uterine manipulator.
89137676|NCT02762136|Placebo Comparator|placebo|Participants will orally take the placebo granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
89137677|NCT02762136|Active Comparator|Xiang-sha-liu-jun granules|Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
89137678|NCT00588861|Active Comparator|Answer® hip stem with Simplex Cement|Femoral stem replacement with Answer® hip stem & Simplex Bone Cement
89137679|NCT00588861|Active Comparator|Answer® hip stem with Palacos Cement|Femoral stem replacement with Answer® hip stem & Palacos Bone Cement
89137680|NCT00890539|Experimental|Quadrupling|methacholine challenge using quadrupling concentrations
89137681|NCT00890539|Active Comparator|doubling|doubling concentrations of methacholine
89137682|NCT02765412||standard implementation|Webinar, Promotion, Tool Access, academic detailing + Audit and Feedback
89137683|NCT02765412||intensive implementation|Webinar, Promotion, and Tool Access, academic detailing + Audit and Feedback + LEAP
89137684|NCT00887263|Experimental|A|
89137685|NCT00887263|Placebo Comparator|B|
89137686|NCT02765334|Experimental|nBETTER and Conventional Therapy|Intervention: nBetter therapy
89137687|NCT00893191||Sildenafil|Treated with 50 mg of Sildenafil at night
89137688|NCT00893191||Placebo|Treated with placebo at night
89137689|NCT02769234||Alzheimer's disease|Subjects with a diagnosis of Alzheimer's disease that successfully performed an ERP/EEG test with the COGNISION(TM) System prior to enrollment for the current study are eligible to participate.
89137690|NCT00914667|Experimental|Warfarin Alone|Reference treatment
88805935|NCT00298610|Experimental|Artesunate and Malarone|Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
89137691|NCT00914667|Experimental|Warfarin Concomitantly With Fesoterodine|Test treatment
89137692|NCT00887978|Placebo Comparator|Placebo|Identical placebo tablets to UT-15C, doses were titrated in the same manner
89137693|NCT00887978|Experimental|UT-15C SR|Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.
89137694|NCT02761824|Experimental|Camp Discovery|One week activity based camp.
89137695|NCT00608023|Experimental|Tesamorelin 12 months (T-T)|Tesamorelin 2 mg/day for 12 months
89137696|NCT00608023|Experimental|Tesamorelin-Placebo (T-P)|Tesamorelin 2 mg/day for 6 months - Placebo for 6 months
89137697|NCT00608023|Experimental|Placebo-Tesamorelin (P-T)|Placebo 6 months - Tesamorelin 2 mg/day for 6 months
89137698|NCT02761902||Preschool group|3-6 years old
89137699|NCT02761902||school age group|7-12 years old
89137700|NCT02761902||Adolescence group|13-15 years old
89137701|NCT00802659|Experimental|Group -1|1000 cGY radiation
89137702|NCT00802659|Experimental|Group 1|1200 cGY radiation
89137703|NCT00802659|Experimental|Group 2|1400 cGY radiation
89137704|NCT00802659|Experimental|Group 3|1600 cGY radiation
89137705|NCT02768844|Experimental|SVS vs Control|Prospective, within-subject design. Compare effects of mattress SVS (ON) and Control (SVS OFF) on physiology in opioid-exposed newborns. SVS is alternated in intervals between continuous stimulation (ON) and no stimulation (OFF/Control) throughout inter-feed intervals. The order of the ON-OFF cycles is randomized across subjects and counterbalanced between feeding periods within subjects.
89137706|NCT04012203||Healthy subjects|Participants free from any pain specific to the upper limb during the past 3 months, chronic pain or other disease.
89137707|NCT02765178||Patients with Tourette Syndrome|The primary caregiver will be asked to fill the Children's motivation Scale. Other measures will be collected including a clinician filled Yale Global Tic Severity Scale (YGTSS) - severity score, Center for Epidemiological Studies Depression Scale for Children (CES-DC) and Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL). Demographic data will also be collected for each study patient. Demographic data will also be collected for each study patient.
89137708|NCT02765178||Patients with Diabetes type 1|The primary caregiver will be asked to fill the Children's motivation Scale. Demographic data will also be collected for each study patient.
89137709|NCT00887419|Experimental|Coping Skills Training|Coping Skills Training in pain management
89137710|NCT00887419|Active Comparator|Education|Chronic Pain Education
89137711|NCT00887419|No Intervention|Usual Care|Patients receive no study intervention, continue with usual medical care.
89137712|NCT02765022|Experimental|Clip|Clip closure of mucosal defects after endoscopic mucosal resection.
89137713|NCT02765022|Active Comparator|No clip|No clip closure of mucosal defects after endoscopic mucosal resection. Observation.
89137714|NCT00607789|Experimental|Duloxetine Group|Start with 30 mg duloxetine hydrochloride capsule/day to be increased up to 120 mg per day.
89137715|NCT00607789|Placebo Comparator|Placebo Group|Sugar pill with matching dosage as Duloxetine
89137716|NCT02761512|Experimental|CJ-12420 50 mg QD|CJ-12420 50 mg, tablet, once daily, oral administration for up to 8 weeks
89137717|NCT02761512|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
89137718|NCT02761512|Active Comparator|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, once daily, oral administration for up to 8 weeks
89137719|NCT00893269|Experimental|Active Medication|Participants receive active hypnotic medication prior to sleep
89137720|NCT00893269|Placebo Comparator|Placebo|Participants receive placebo prior to sleep
89137721|NCT02764944|Experimental|Intervention|simple non-exposure EFTR group (single arm study)
89137722|NCT02605707|Experimental|Intravenous stem cell transplantation|Intravenous transplantation of autologous endothelial progenitor cells plus conventional treatment include rehabilitation
89137723|NCT02605707|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
89137724|NCT00893347|Active Comparator|I|Treatment as usual
89137725|NCT00893347|Experimental|II|Treatment as usual + cognitive-behavioural therapy
89137726|NCT02761434|Active Comparator|Dehydration|Infusion of 3% sodium chloride for osmotic stimulation of vasopressin
89137727|NCT02761434|Placebo Comparator|Euhydration|Infusion of 0.9% sodium chloride that will induce similar expansion of plasma volume without any significant change in osmolality and vasopressin
89137728|NCT04115475|Active Comparator|Healthy Volunteers (HV)|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
89137729|NCT04115475|Experimental|Spinal Muscular Atrophy (SMA) patients|"Multispectral Optoacoustic Tomography (MSOT) and B-Mode Ultrasound of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: forearm flexors;~physical assessment/milestones: Hammersmith Infant Neurological Examination (HINE)/ expanded Hammersmith functional motor scale (HFMSE)/ The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP Intend)/ Upper Limb Module (ULM)"
89137730|NCT00890851|Other|Procedure TUNA|
89137731|NCT02768922|Experimental|Aphasia telerehabilitation|Speech and language therapy is given by telemedicine to improve expressive language function. The therapy will include knowledge based tasks of aphasia rehabilitation including training of language forms and overall functional communication. A special emphasis will be put on naming training. The telerehabilitation will be given in a addition to standard face-to-face aphasia rehabilitation
89137732|NCT02768922|Active Comparator|Control|Control Group receives standard face-to-face aphasia rehabilitation
89137733|NCT04115397|Experimental|Bisphophonate|Zolendronic acid, one infusion iv
89137734|NCT04115397|Placebo Comparator|Placebo|Placebo, one infusion iv
89137735|NCT00891007|Experimental|Group 1|
89137736|NCT00891007|Experimental|Group 2|
89137737|NCT00891007|Active Comparator|Group 3|
89137738|NCT00887497|Experimental|Catheterization|Patients receive angioembolization prior to surgery
89137739|NCT00887822|Experimental|Bevacizumab, Capecitabine and Cisplatin|Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
89137740|NCT00887822|Placebo Comparator|Placebo, Capecitabine and Cisplatin|Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m^2 orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
89137741|NCT02542111|Experimental|V-GDP|Bortezomib 1.6 mg/m2/d iv d1 and d8 Gemcitabine 1000mg/m2/d iv d1 and d8 Dexamethasone 40mg/d iv d1-4 cisplatin 25 mg/m2 iv d2-4 Frequency every 28 days Total cycles 4
89137742|NCT02768688|Experimental|Brain connectivity and physiology|Dexmedetomidine anesthesia on glymphatic flow in human subjects as visualized by diffusion tensor MRI.
89137743|NCT00891163|Experimental|Synera|
89137744|NCT00891163|Placebo Comparator|Placebo|
89137745|NCT02827994|Experimental|Education and exercise|The intervention included neurophysiology of pain education and exercises.
89137746|NCT02827994|No Intervention|No intervention|This group received no intervention as participants were students that were not seeking treatment for their pain.
89137747|NCT02764866|Experimental|Sleep testing|Enrolled patients with lung cáncer will undergo home sleep testing during their initial oncologic evaluation, prior to treatment.
89137748|NCT02541331|Experimental|ISMIGEN|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
89137749|NCT02541331|Placebo Comparator|PLACEBO|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
89137750|NCT02828462||Experimental|Patients using the device
89137751|NCT02828462||Control|Patients not using the device
89137752|NCT00635388|Sham Comparator|1|
89137753|NCT00635388|Experimental|2|
89137754|NCT00635388|Experimental|3|
89137755|NCT02827916|Experimental|All patients|Measure of painful neuropathy for al patients with thermotest and sudoscan Devices and Neuropathic Pain Symptom Inventory.
89137756|NCT05662059|Experimental|Treatment|Two therapy sessions (active stimulation) per day for 12 weeks with Treatment device
89137757|NCT05662059|Sham Comparator|Sham|Two therapy sessions per day for 12 weeks with Sham device (no active stimulation)
89137758|NCT02761590|Experimental|Circuit training protocol|"The CT protocol will be held in three sessions per week for 14 weeks. The volume of work is defined by the training section of time and intensity of effort by the heart rate response to exercise.~The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. that concludes in favor of the organization of training adapted to the reality of the public to be trained."
89137759|NCT02761590|Active Comparator|Strength training protocol|"The strength training protocol was performed in three sessions per week for 14 weeks and divided into three levels.~The initial load set for each exercise was based on the one repetition maximum test (1 RM). Strengthening exercises were performed in two sets of 15 repetitions, using 25% 1RM for hip adductors and abductors, and 50% 1RM for the quadriceps and hamstrings, using ankle weights. Exercises for the trunk were performed in 3 10-second series, increasing the duration when participants were able."
89137760|NCT02761590|No Intervention|Educational Protocol|In order to provide care, social interaction, and health education, an educational protocol was conducted. This protocol consisted in interactive presentations of 60 minutes, twice a month for 14 weeks, totaling 7 meetings. The topics addressed pathophysiology of osteoarthritis, and American College of Rheumatology (ACR) recommendations on nutrition, posture, and lifestyle.
89137761|NCT04223388|Experimental|Probiotic|
89137762|NCT04223388|Placebo Comparator|Placebo|
89137763|NCT00951665|Experimental|Phase lb Regimen 1|Participants received trastuzumab emtansine (T-DM1) every three weeks (Q3W) + paclitaxel weekly (QW) intravenously.
89137764|NCT00951665|Experimental|Phase Ib Regimen 2|Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.
89137765|NCT00951665|Experimental|Phase Ib Regimen 3|Participants received T-DM1 QW + paclitaxel QW intravenously.
89137766|NCT00951665|Experimental|Phase Ib Regimen 4|Participants received T-DM1 QW + paclitaxel QW + pertuzumab Q3W intravenously.
89137767|NCT00951665|Experimental|Phase IIa Group A|Participants received maximum tolerated dose (MTD) from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW intravenously.
89137768|NCT00951665|Experimental|Phase IIa Group B|Participants received MTD from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW + pertuzumab Q3W intravenously.
89137769|NCT00887731||Part 1 group|Observational study with a convenience sample of ten (10) patients. PART 1 will end when at least 3 of 4 consecutive patients achieve the goal of less than six (6) operator required interruptions per hour for oxygen saturation deviations from study guidelines, or at ten (10) patients.
89137770|NCT00887731||Part 2 group|(After successful completion of PART 1) Within patient cross-over study with a randomized cross-over sequence. Sequential data analysis methods will be used to help minimize the patient sample size which will be no more than twenty (20) patients plus up to a maximum of seven (7) who might be eligible from PART 1.
89137771|NCT00887731||Part 3 Group|(After successful completion of PART 2) Within patient cross-over study with a randomized cross-over sequence. Studies will last 4 to 12 hours divided in two (2) equal time blocks with one cross-over to either automatic or manual control modes.
89137772|NCT02764632|Active Comparator|Didgital group|After induction of anesthesia, and after ensuring muscle relaxation, NGT will be inserted through the selected nostril and advanced for 12 cm then the NGT was advanced according to study group advancing. In control group; NGT was inserted with patient head flexed. In D group, after feeling the NGT in pharynx, with the head in neutral position,the index finger was used to support the NGT with slight direction towards the left side. This will prevent tube kinking at this point in front of the resistance offered by the inflated tube cuff or arytenoids cartilage. Also, this digital support reinforces the tube at the area weakened by its openings
89137773|NCT02764632|No Intervention|Control group|
89137774|NCT02769078||Patients who received dabigatran|Patients who received dabigatran
89137775|NCT02769078||Patients who received rivaroxaban|Patients who received rivaroxaban
89137776|NCT02769078||Patients who received apixaban|Patients who received apixaban
89137777|NCT02769078||Patients who received warfarin|Patients who received warfarin
89137778|NCT04036201|Experimental|Group 1(22-24 mm)|Group 1 (patients with axial length between 22 and 24 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyalurindase 150 IU (1 ml) to a total volume of 7 ml.
89137779|NCT04036201|Experimental|Group 2(24.1-26 mm)|Group 2 (patients with axial length between 24.1 and 26 mm): received a mixture of bupivacaine 0.5% (3ml) + lidocaine 2% (3ml) + hyaluronidase 150 IU (1 ml) to a total volume of 7 m
89137780|NCT04114773|Experimental|SCARF|"The participants will take part in a rehabilitation intervention focused on the physical, mental, and social consequences of cardiac arrest with an overarching theme of managing fatigue. This will consist of:~a 5-day residential rehabilitation stay~followed by a 12 week home-based programme including one telephone call by a member of the clinical rehabilitation team,~after the 12 week home intervention there will be a further 2-day rehabilitation stay."
89137781|NCT00891241|Experimental|Cohort 1|Healthy Population
89137782|NCT00891241|Experimental|Cohort 2|Heart Failure Subjects with a documented ejection fraction of 35% or less, and a diagnosis of NYHA Class II-III heart failure, history of ventricular arrhythmia and ICD placement
89137783|NCT02856191|Other|Septic shock|
89137784|NCT04037449|Experimental|TAP block|Transversus Abdominis Plane (TAP) block technique will be carried out by a restricted group of anaesthesiologists. Standard monitoring will be applied to all patients, which will include pulse oximetry, electrocardiogram and non-invasive monitoring of blood pressure.
89137785|NCT04037449|Active Comparator|Conventional analgesia|Patients be given conventional endovenous analgesia, and morphine 2 mg / ev every 15 minutes until the level of pain measured by a Visual Analogue Scale (VAS) ≤ 3
89137786|NCT00801099|Experimental|Abx|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
89137787|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression Before Polypectomy|A biopsy will taken in infertility patients with endometrial polyp before polypectomy
89137788|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression After Polypectomy|A biopsy will taken in infertility patients with endometrial polyp 1-3 months after polypectomy
89137789|NCT04017715|Experimental|warm up|warm up exercises
89137790|NCT04017715|Experimental|cool down|cool down exercises
89137791|NCT04017715|Active Comparator|control|Following conventional protocol
89137792|NCT02768610|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine is administered before endotracheal intubation for 10 minutes
89137793|NCT02768610|Placebo Comparator|Normal Saline|
89137794|NCT02605629|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
89137795|NCT02605629|Placebo Comparator|Placebo|Patients will self-administer the study placebo twice per day (morning, evening) for 6 months, for the efficacy assessment
89137796|NCT02764710|Experimental|Short treatment|Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.
89137797|NCT02764710|Active Comparator|Long treatment|Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7.
89137798|NCT00887744|Other|Aperius Treatment Arm|Single Arm
89137799|NCT00887887||liver surgery|patients with benign or malignant hepatobiliary disease requiring partial hepatic resection
89137800|NCT02764554||Lenvatinib 4 milligram (mg) and 10 mg capsule|Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.
89137801|NCT02541019|Experimental|Palonosetron|Palonosetron (iv) one minute before anesthesic induction.
89137802|NCT02541019|Experimental|Ondansetron|ondansetron (iv) one minute before anesthesic induction and ondansetron regular three times a day for two days after the surgery.
89137803|NCT02832440|Other|Intradialytic exercise|Exercise during hemodialysis
89137804|NCT02832440|Other|Home-based exercise|Exercise at home
89137805|NCT05297253||telescopic overdenture group|patients receiving implant retained telescopic overdentures
89137806|NCT05297253||fixed group|patients receiving fixed implant prostheses
89137807|NCT04676880|Experimental|Intervention arm - Left atrial appendage occlusion (with Watchman FLX or Amplatzer Amulet device)|Patients randomized to the intervention arm will receive left atrial appendage occlusion. In order to prevent device-related thrombus, they will use dual antiplatelet therapy (acetylsalicylzuur + clopidogrel) for three months and single antiplatelet therapy (acetylsalicylzuur) until at least 12 months after the procedure.
89137808|NCT04676880|No Intervention|Control arm - no or usual care|The patients in the control arm will stay on optimal treatment as decided by the referring physician (antiplatelet therapy or nothing).
89137809|NCT02832362|Experimental|Carbomer 980|Participants will be administered test product (nasal spray) containing 0.5% carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
89137810|NCT02832362|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
89137811|NCT00893581|Active Comparator|1--Quetiapine & Placebo|Quetiapine & Placebo in the place of Lithium
89137812|NCT00893581|Active Comparator|2-- Lithium & Placebo|Lithium & Placebo in the place of Quetiapine
89137813|NCT00893581|Placebo Comparator|Placebo|Sugar Pill (Placebo) given to mimic drug
89137814|NCT04114305||Intervention|HIV-infected pregnant women enrolled in ECD program implemented by m2m program; women followed during pregnancy and 18 months post-partum with their infants.
89137815|NCT04114305||Control|HIV-infected pregnant women receiving routine care in clinics without ECD program; women followed during pregnancy and 18 months post-partum with their infants.
89137816|NCT00951509||Condition 1 (PC Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
89137817|NCT00951509||Condition 2 (PC Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
89137818|NCT00951509||Condition 3 (VR Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
89137819|NCT00951509||Condition 4 (VR Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
89137820|NCT00951509||Condntion 5 (Real-world driving)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
89137821|NCT04224168|Experimental|Green Beans|Green beans will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from green beans will be given. This equates to 3x 4 ounce jars of green beans per day.
89137822|NCT04224168|Experimental|Liquid Pectin|Liquid pectin will be provided in the daily diets of the patients enrolled for 3 months via gtube or oral means. Only up to 6g of fiber total from liquid pectin will be given. This equates to 6 teaspoons or 30mL of liquid pectin per day.
89137823|NCT04114461|Experimental|HL-TOF tab. 5mg|Tofacitinib freebase
89137824|NCT04114461|Active Comparator|Xeljanz tab. 5mg|Tofacitinib citrate (5mg as tofacitinib)
89137825|NCT04111146||1|Liver transplant patients with severe vitamin D deficiency (<10ng/ml)
89137826|NCT04111146||2|Liver transplant patients with vitamin D insufficiency (10-20ng/ml)
89137827|NCT04111146||3|Liver transplant patients with normal vitamin D status (>20ng/ml)
89137828|NCT02768454||inpatient under broad-spectrum antibiotics|medical review
89137829|NCT04222452||Hypophosphatasia patients (HPP)|Patients with known hypophosphatasia (HPP) as diagnosed using genetic testing.
89137830|NCT04222452||Controls|Healthy individuals (controls) matched to the cases by gender and age.
89137831|NCT02854085|Experimental|Art Therapy|Art Therapy, 24 sessions
89137832|NCT02854085|Experimental|Music Reminiscence Activity|Music Reminiscence Activity, 24 sessions
89137833|NCT02854085|No Intervention|Control|Participants will not participate in either of the interventions and will continue life as usual.
89137834|NCT02768376|Active Comparator|General anesthesia group|General anesthesia group: Standard anesthetic technique will be applied.Anesthesia will be induced by propofol 1% (1-2 mg/kg), Fentanyl 1-2 mic/kg, and Atracurium 0.5 mg/kg then according to train of four response. Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
89137835|NCT02768376|Experimental|Spinal anesthesia group|While in sitting position; intrathecal injection using 25 G spinal needle using 3 mls of Bupivacaine 0.5% with 20 mic Fentanyl, at L 2-3 level the patient head will be lowered till sensory blockade of T6 obtained at least.
89137836|NCT00610441|Experimental|MK-8777 FD→PBO|Participants receive a fixed dose (FD) of MK-8777 100 mg twice each day (BID) for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of placebo (PBO) BID for 3 weeks (Treatment Period 2).
89137837|NCT00610441|Experimental|PBO→MK-8777 FD|Participants receive a fixed dose of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of MK-8777 100 mg BID for 3 weeks (Treatment Period 2).
89137838|NCT00610441|Experimental|MK-8777 RD→PBO|Participants receive rising doses (RD) of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of placebo BID for 3 weeks (Treatment Period 2).
89137839|NCT00610441|Placebo Comparator|PBO→MK-8777 RD|Participants receive rising doses of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 2).
89137840|NCT04732806|No Intervention|Treatment as usual|
89137841|NCT04732806|Experimental|Intervention|Six months of ad lib Mightier play in home
89137842|NCT02855723|Active Comparator|GS strategy|sentinel node biopsy
89137843|NCT02855723|Other|Classic strategy|systematic lymphadenectomy
89137844|NCT02854163|Experimental|Secukinumab|"Secukinumab will be given to all 20 patients registered (Secukinumab group). All doses will be given subcutaneously using the following schedule: 4 weekly injections of 150 or 300 mg subcutaneous injections depending the severity of skin involvement, followed by 11 monthly subcutaneous injections of 150mg.~Patients will continue to use their normal DMARDs treatment."
89137845|NCT02696460|Active Comparator|N2O/O2 analgesia|Wound debridement under analgesia with N2O/O2 premix.
89137846|NCT02696460|Active Comparator|Lidocaine/Prilocaine analgesia|Wound debridement under analgesia with eutectic mixture of 5% lidocaine/prilocaine.
89137847|NCT02858453|Experimental|AQX-1125 100 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
89137848|NCT02858453|Experimental|AQX-1125 200 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
89137849|NCT02858453|Placebo Comparator|Placebo|2 placebo tablets, by mouth, once per day for 12 weeks; followed by randomization to 100 mg or 200 mg AQX-1125 for a 52-week Extension Period
89137850|NCT02696538|Experimental|Experimental|All participants included in this group and will complete all three outcomes assessment
89137851|NCT00888043|Other|I|CNTO 95 and avastin
89137852|NCT02761356||Tc99-MAA and SPECT-CT|26 of the patients were examined with Tc99-MAA and SPECT-C
89137853|NCT02761356||Tc99-MAA , SPECT-CT and PET-CT|24 patients were examined with Tc99-MAA , SPECT-CT and PET-CT.
89137854|NCT02696304|Other|TBI for childhood leukemia|Patients with a metabolic syndrom who received TBI.
89137855|NCT02696304|Other|No TBI for childhood leukemia|Patients with a metabolic syndrom without previousTBI
89137856|NCT02855801|Experimental|constant exercise without cryotherapy|constant exercise without cryotherapy
89137857|NCT02855801|Experimental|constant exercise with cryotherapy|constant exercise with cryotherapy
89137858|NCT02855801|Experimental|intermittent exercise, no cryotherapy|intermittent exercise without cryotherapy
89137859|NCT02855801|Experimental|intermittent exercise and cryotherapy|intermittent exercise with cryotherapy
89137860|NCT02768220|Active Comparator|Linagliptin|Eligible patients were randomized to receive linagliptin 5mg daily for 30 days.
89137861|NCT02768220|Experimental|Empagliflozin|Eligible patients were randomized empagliflozin 25mg daily for 30 days.
89137862|NCT02853851||France|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
89137863|NCT02853851||Italy|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
89137864|NCT02853851||spain|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
89137865|NCT02853851||montreal|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
89137866|NCT02760888|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
89137867|NCT02760888|Active Comparator|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
89137868|NCT02760888|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure
89137869|NCT00799617|Active Comparator|AndroGel® (testosterone gel)|The initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day. Participants will apply AndroGel once daily to the shoulders, abdomen or upper arms. The serum testosterone concentration will be measured monthly for the first three months, then at months 6, 9 and 12. If the testosterone concentration is not between 500 and 800 ng/dL at any time point, the dose will be either increased by increments of 1.25-2.5 g/day, up to a maximum of 15 g/day or decreased by increments of 1.25-3.75 ng/day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
89137870|NCT00799617|Placebo Comparator|Placebo gel|Placebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
89137871|NCT02760732|Experimental|drug eluting balloon group|patients with unstable angina were randomised to drug eluting balloon group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon(Flextome Cutting Balloon, Boston Scientific Corporation, US) pre-dilation first and then drug eluting balloon(Sequent please; B. Braun, Melsungen, Germany) .
89137872|NCT02760732|Experimental|drug eluting stent group|patients with unstable angina were randomised to this group for drug eluting stent (YINYI® Polymer-free Drug-coated (Paclitaxel) Coronary Stent System, Liaoning Biomedical Materials R&D Center Co., Ltd. China) implantation.
89137873|NCT02855879||CAD patients|
89137874|NCT02855957|Other|Blood sample|A blood collection is carry out in the three populations of patients during the day of their enrolment.
89137875|NCT02768142|Experimental|Natural cesarean delivery|Placing the neonate on maternal chest immediately after the extraction from the uterus, and permitting breastfeeding during surgery.
89137876|NCT02768142|Active Comparator|Standard cesarean delivery|Presentation of the neonate to the mother during the operation.
89137877|NCT00607087|Experimental|sequence 1|sequence 1: insulin glulisine / insulin aspart / insulin lispro.
89137878|NCT00607087|Experimental|Sequence 2|Sequence 2: insulin aspart / insulin lispro / insulin glulisine
89137879|NCT00607087|Experimental|Sequence 3|Sequence 3: insulin lispro / insulin glulisine / insulin aspart
89137880|NCT02854007||Coronary stenosis treated with Absorb|Patients with ischemic heart disease who have undergone percutaneous coronary revascularization with Absorb according to standard clinical practice. One thousand revascularized patients will be recruited at 40 siteS.
89137881|NCT02764242|Other|insect sting allergy|"Skin prick tests to local and imported insect sting allergen with different concentration are performed.~sIgE Measurement (to insect and the recombinant venom)"
89137882|NCT02760966|Experimental|Alcohol 70º|Umbilical cord care will be carried out using alcohol 70º at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
89137883|NCT02760966|Active Comparator|Soap|Umbilical cord care will be carried out using soap at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
89137884|NCT05653635|Experimental|Simultaneous-integrated boost with Intensity-modulated radiation therapy (IMRT)|"Planning Target Volume (PTV) 37,5 Gray (Gy): 37,5 Gy in 6 fractions of 6,25 Gy at the rate of one fraction each 2 days~Prescription isodose line (PIL) at 80%, corresponding to 30 Gy as total dose, or 5 Gy per fraction~PTV SIB 45 Gy: 45,0 Gy in 6 fractions of 7,50 Gy at the rate of one fraction each 2 days~PIL at 80% corresponding to 36 Gy as total dose, or 6 Gy per fraction"
89137885|NCT05653635|No Intervention|Standard IMRT|"PTV 37,5 Gy: 37,5 Gy in 6 fractions of 6,25 Gy at the rate of one fraction each 2 days~PIL at 80%, corresponding to 30 Gy as total dose, or 5 Gy per fraction~No SIB"
89137886|NCT02763930|Experimental|CONTROL (dairy-free)|6 weeks experimental diet with all meals and foods provided to participants. The diet contain 32% of fat, 11% of saturated fat (SFA), 13% of mono-unsaturated fat (MUFA), 8% of polyunsaturated fat (PUFA) and 15% of proteins.
89137887|NCT02763930|Experimental|MILK (low fat dairy)|6 weeks experimental diet with all meals and foods provided to participants including 3 servings/day of milk (1% fat) per 2500 kcal. The diet contain 32% of fat, 11% of SFA, 13% of MUFA, 8% of PUFA and 15% of proteins.
89137888|NCT02763930|Experimental|GABA-rich cheese (high-fat dairy )|6 weeks experimental diet with all meals and foods provided to participants including 50g/day of GABA-rich cheddar cheese (approximately 32% fat). The diet contain 32% of fat, 13% of SFA, 13% of MUFA, 6% of PUFA and 15% of proteins.
89137889|NCT00610363|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 16.
89137890|NCT00610363|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 16.
89137891|NCT00887588|Experimental|LCZ696|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.
89137892|NCT00887588|Active Comparator|Valsartan|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.
89137893|NCT04659096|Experimental|ION537|Multiple ascending doses of ION537 will be administered by intravenous (IV) injection on Days 1, 4, 8, 11, 15, and 22 in Cycle 1 and weekly dosing in each subsequent cycle until disease progression.
89137894|NCT00945893|Experimental|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414 - Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 fluorescent focus units (FFU) of live, attenuated influenza virus reassortant A/California/7/2009 strain that was propagated in chicken eggs. H1N1 monovalent influenza vaccine (MEDI3414) contained no preservatives and no adjuvants.
89137895|NCT00945893|Placebo Comparator|Placebo|Placebo -Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
89137896|NCT00799383|Experimental|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
89137897|NCT00799383|Placebo Comparator|Placebo|Placebo
89137898|NCT02763852|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Madopar 125. BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
89137899|NCT02763852|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
89137900|NCT02763852|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
89137901|NCT02763852|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
89137902|NCT02763852|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
89137903|NCT00893659|Experimental|wheat bread with beta-glucan supplementation|
89137904|NCT00893659|Placebo Comparator|wheat bread without beta-glucan|
89137905|NCT02768064|Experimental|Flexible screwed electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a flexible screwed electrode.
89137906|NCT02768064|Active Comparator|Stiff standard electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a stiff standard temporary electrode
89137907|NCT04114149|Active Comparator|TENS (transcutaneous electrical nerve stimulation)|High frequency, high intensity TENS treatment. Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
89137908|NCT04114149|Active Comparator|Conventional treatment with iv opioid|Patients who report postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 during the time spent in post-anesthesia care unit.
89137909|NCT04114149|No Intervention|Control|Patients who report postoperative pain intensity according to NRS (numeric rating scale) < 3 during the time spent in post-anesthesia care unit.
89137910|NCT00891397|Experimental|1|Pregabalin group is made up of 20 patients. Patients will receive 150mg/day in two divided does. The patients will be assessed weekly and the dose can be increased to 300mg/day, if the patient does not report any decrease in pain. The following week the dose may be increased to 600mg/day if once again the patient reports no decrease in pain. This is also the maximum permissible does that will be given to the patient. If patient reports any side effects then the dose can be decreased once. The time period of 2 to 5 weeks will be the dose adjustment period. After which the drug maintenance period extends from week 5 to 12. All doses will be given in two divided doses/day.
89137911|NCT00891397|Placebo Comparator|2|Ten patients will be be in the placebo group.
89137912|NCT02767596|Experimental|Lixisenatide|S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks
89137913|NCT04113837|Experimental|verum|"The food range is comprised of:~sausages (1100 g per week / exchange of saturated fatty acids by long-chain unsaturated omega-3 fatty acids from fish oil (Maris Oil ED0222N rich in docosahexaenoic acid (DHA)), partially exchange of fat by plant protein (sesame)), eggs (3 eggs per week / 2 µg vitamin D per egg), 100 g mushrooms per day (5 µg Vitamin D/d), one bread per week (5 µg Vitamin D/d), bread rolls (16 g dietary fibers/d), 100 ml ice cream per week (exchange of sugar by xylitol), 3x 70 g pasta per week (3 x 10 g dietary fibers per week)"
89137914|NCT04113837|Active Comparator|control|In the placebo period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), eggs, mushrooms, bread, bread rolls, ice cream and pasta) with traditional nutrient profile.
89137915|NCT01691729|Other|Ostomy 1|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy AccessoryProduct/Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2
89137916|NCT01691729|Other|Ostomy 2|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1
89137917|NCT01691729|Other|Ostomy 3|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product
89137918|NCT01691729|Other|Ostomy 4|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product
89137919|NCT01691729|Other|Ostomy 5|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2
89137920|NCT01691729|Other|Ostomy 6|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #1
89137921|NCT02826902|Active Comparator|TIVA group|
89137922|NCT02826902|Active Comparator|Inhalation anesthesia group|
89137923|NCT00610207|Experimental|AFP|Anal fistula plug placement performed during surgical procedure
89137924|NCT00798759|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
89137925|NCT00798759|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
89137926|NCT02853773|Experimental|Artificial sweetener|Effects of co-ingestion of artificially sweetened beverage on the response to a test meal
89137927|NCT02853773|Active Comparator|Sugar|Effects of co-ingestion of sugar-sweetened beverage on the response to a test meal
89137928|NCT02853773|Active Comparator|Water|Effects of co-ingestion of water on the response to a test meal
89137929|NCT00891475|Experimental|Arm 1|38 patients
89137930|NCT00891475|Experimental|Arm 2|38 patients
89137931|NCT00891475|Experimental|Arm 3|38 patients
89137932|NCT00887432|Experimental|Arm I (cholecalciferol and placebo)|Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.
89137933|NCT00887432|Experimental|Arm II (placebo and cholecalciferol)|Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.
89137934|NCT02855645|Experimental|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
89137935|NCT02855645|Placebo Comparator|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
89137936|NCT04222686|Active Comparator|Perindopril Arm|10 mg Perindopril tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
89137937|NCT04222686|Active Comparator|Losartan Arm|100 mg Losartan tablet per day at 8am (+/- 1 hour) was add to the usual treatment for each patient. Patients are followed-up for a period of 08 weeks.
89137938|NCT04113915||Group 1|Group of ITP patients received triple therapy
89137939|NCT04113915||Group 2|Group of ITP patients received steroids
89137940|NCT04113915||Group 3|Normal control group
89137941|NCT00893815||1|HIV-Positive and Early HIV infection
89137942|NCT00893815||2|HIV-Positive and Late HIV-infection
89137943|NCT00893815||3|HIV-negative
89137944|NCT02758470|Experimental|Acetazolamide|Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.
89137945|NCT02758470|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.
89137946|NCT02758470|Placebo Comparator|Placebo|Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.
89137947|NCT05652231||School children (control group)|parented school children (control group)
89137948|NCT05652231||Non-Governmental orphanage children (exposed group 1)|
89137949|NCT05652231||Governmental orphanage children (exposed group 2)|
89137950|NCT00893893||1|Lean premenopausal women
89137951|NCT00893893||2|Visceral obese premenopausal women
89137952|NCT02758314||Cases / NSCLC patients|"Evaluation of PD-1/PDL-1 expression.~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 150 NSCLC, free treatment by flow cytometry.~Evaluate the expression of PD-1 / PD-L1 in tumor tissue obtained by biopsy of patients with NSCLC by immunohistochemistry.~The patients for the enrollment have to be diagnosed with advanced Non-Small Cell Lung Adenocarcinoma (clinical stages IIIA, IIIB and IV), treated at the Instituto Nacional de Cancerología (INCan) who had not received radiotherapy and / or chemotherapy prior to obtaining samples to analyze. ECOG performance status 0-2 and present evidence of measurable disease."
89137953|NCT02758314||Control / Healthy subjects|"Evaluation of PD-1/PDL-1 expression.~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 50 samples, by flow cytometry.~Healthy subjects blood cells will be obtained from the blood bank at the Instituto Nacional de Cancerología (INCan)"
89137954|NCT04036825|Experimental|Liquid Nutritional Supplement from Hospital Product|This group received liquid nutritional supplement from hospital product. The product is in a form of low lactose milk ready to drink with volume 200 ml and will be given 2 times daily for 14 days. This product is consist of 1.017 kcal/ml, 10 vitamin and 9 mineral
89137955|NCT04036825|Placebo Comparator|Placebo|This group received standard liquid nutritional supplement as a placebo. Placebo will be given 2 times daily for 14 days
89137956|NCT02763696||normal women|Composition of Viginal flora of Child-Bearing women in normal woman
89137957|NCT02763696||vaginitis women|Women of childbearing age with vaginitis
89137958|NCT00891553||Ronacaleret|Subjects receiving ronacaleret (200mg,300mg or 400mg) in study CR9108963 will be enrolled into this study.
89137959|NCT00891553||Placebo|Subjects receiving placebo in study CR9108963 will be enrolled into this study.
89137960|NCT00891631|Experimental|iSBIRT|Participants will complete the iSBIRT system.
89137961|NCT00891631|Experimental|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system and technological extenders
89137962|NCT00891631|No Intervention|TAU|Participants will receive Treatment as Usual from their primary care provider.
89137963|NCT02541877|Experimental|Down sizing valve in type-0 BAS|Down Sizing Transcatheter Self-expandable Valve in Type-0 BAS
89137964|NCT02541877|Active Comparator|Standard sizing valve in type-0 BAS|Standard Sizing Transcatheter Self-expandable Valve in Type-0 BAS
89137965|NCT02541877|Active Comparator|Standard sizing valve in TAS|Standard Sizing Transcatheter Self-expandable Valve in TAS
89137966|NCT04223076|Experimental|Chlorhexidine 0.2% mouthwash control|Chlorhexidine 0.2%, Corsodyl Intervention rinsing 60 sec twice daily
89137967|NCT04223076|Experimental|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System|Chlorhexidine 0.2%, Curasept Intervention rinsing 60 sec twice daily
89137968|NCT00951275|Experimental|1|
89137969|NCT00888199|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
89137970|NCT00888199|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
89137971|NCT02764008|Active Comparator|Low thoracic paravertebral block|T8-T9 Ultrasound guided paravertebral block with 20 ml %0,25 bupivacaine
89137972|NCT02764008|Active Comparator|Peritubal infiltration|Peritubal infiltration with 20 ml %0,25 bupivacaine
89137973|NCT02764008|No Intervention|Control Group|No drug
89137974|NCT00891709|Experimental|1|LEO 29102 2.5 mg/g cream
89137975|NCT00891709|Placebo Comparator|2|LEO 29102 cream vehicle
89137976|NCT04222530|Experimental|Linear EUS|patients underwent linear endoscopic ultrasonography followed by magnifying narrowband endoscopy
89137977|NCT04222530|Experimental|ME-NBI|patients underwent magnifying narrowband endoscopy followed by linear endoscopic ultrasonography
89137978|NCT00798603|Experimental|pemetrexed + carboplatin + bevacizumab|Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease or partial or complete response after 6 courses may continue to receive pemetrexed disodium and bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
89137979|NCT04036981||Brachialis|Targeted muscle for BoNT A injection
89137980|NCT04036981||Biceps|Targeted muscle for BoNT A injection
89137981|NCT04036981||Brachialis plus Brachioradialis|Targeted muscles for BoNT A injection
89234298|NCT00995046|Active Comparator|usual prophylaxis regimen|All patients will receive their usual prophylaxis regimen during the first 6 months
89234299|NCT00995046|Experimental|individually tailored prophylaxis regimen|All patients will receive an individually tailored prophylaxis regimen in accordance with TGT results during the second 6 month-period.
89137982|NCT02763618|Active Comparator|Group A: Theta/beta ratio Neurofeedback|"In this condition, participants will receive three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions.~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
89137983|NCT02763618|Active Comparator|Group B: Theta/beta ratio Neurofeedback|"In this condition, participants will receive nine baseline sessions and continue with eight theta/beta ratio Neurofeedback sessions.~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
89137984|NCT02763618|Placebo Comparator|Group C: Placebo Neurofeedback training|Three baseline sessions and continue with 14 placebo training sessions. The placebo training will be a previously recorded Neurofeedback session of a participant in group A (receiving 14 real Neurofeedback sessions). Before the participants in group C (placebo trainings) start, they will be matched to a participant in group A, and receive the exact same (prerecorded) feedback per session of their matched participant. In this way, participants in the placebo training are then made to think that the video and EEG feedback is their own, however they are actually not able to influence the continuation of the video.
89137985|NCT02758392|Experimental|Dose 1: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.
89137986|NCT02758392|Experimental|Dose 2: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.
89137987|NCT02758392|Experimental|Dose 3: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.
89137988|NCT02758392|Experimental|Dose 4: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.
89137989|NCT02758392|Experimental|Dose 5: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.
89137990|NCT02758392|Experimental|Dose 6: JNJ-61178104 OR Placebo SC|Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.
89137991|NCT00887354|Experimental|Teriparatide|"20 micrograms (mcg) a day by subcutaneous injection throughout study.~Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only."
89137992|NCT00887354|Active Comparator|Risedronate|"35 milligrams (mg) risedronate sodium orally once weekly throughout study.~Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only."
89137993|NCT00891865||Pediatric lung transplantation|
89137994|NCT00951041|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
89137995|NCT00951041|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
89137996|NCT02760576|Experimental|BAY 987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89137997|NCT00894049|Experimental|Flu-Bu-ATG|Fludarabine (30mg/m²/5 days) Oral Busulfan (8 mg/kg over 2 days) Thymoglobuline (2.5 mg/m²/1day).
89137998|NCT00894049|Experimental|Fluda-TBI|Fludarabine (25mg/m²/ 3 days) 2 Gy TBI
89137999|NCT02763540|Other|Lung cryobiopsy|
89138000|NCT02541097|Active Comparator|Language therapy-Individual treatment|Participants will receive intervention for naming impairment based on either phonological or semantic cues.
89138001|NCT02541097|Active Comparator|Language therapy-Group treatment|Following the individual therapy, participants will be randomly assigned to either verbal or non-verbal group
89138002|NCT02832596|No Intervention|Control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
89138003|NCT02832596|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
89138004|NCT02832206||hybrid ablation|60 patients with stand-alone, persistent or long-standing persistent atrial fibrillation
89138005|NCT00891943|Other|Structured lifestyle support|Intervention group-structured lifestyle support.
89138006|NCT00891943|No Intervention|Usual care for weight management|"This is the control group, and they will receive usual care for weight management at their GP practice."
89138007|NCT02758158|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of thyroid and adjacent lymph nodes. Imaging time: Approximately 30 minutes
89138008|NCT00610129|Experimental|1|MK-0646
89138009|NCT02760420|Experimental|Placebo|250 mg of placebo (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
89138010|NCT02760420|Active Comparator|3 Days|250 mg amoxicillin (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
89138011|NCT04612530|Active Comparator|Arm A: Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will start with the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
89138012|NCT04612530|Experimental|Arm B: IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will first receive (an incomplete) IRE of the primary pancreatic tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
89234300|NCT00995124|Experimental|NeutraLice Lotion|Single application of head lice product.
89138013|NCT04612530|Experimental|Arm C: CpG + IRE + Nivolumab|4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), a toll-like receptor ligand (CpG) will be administered into the primary pancreatic tumor. A week later, the patient will receive (an incomplete) IRE of the primary tumor. 2 weeks thereafter, they will start the Nivolumab scheme. The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg. This treatment will continue until disease progression.
89138014|NCT02763774|Experimental|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
89138015|NCT02763774|Experimental|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
89138016|NCT02763774|Experimental|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
89138017|NCT00945815|Experimental|treatment|AraC 1 g/m2/d IV Days 1-5 clofarabine 40 mg/m2/d IV Days 2-6 epratuzumab 360 mg/m2/d IV Days 7, 14, 21, 28 acetaminophen 650 mg/d PO Days 7, 14, 21, 28 diphenhydramine 50 mg/d IV Days 7, 14, 21, 28 IT methotrexate 12 mg IT at least 1 wk apart during induction All give 1 cycle
89138018|NCT02758002|Experimental|Firm ablation for transitional AF rotors|All subjects will undergo this ablation, in addition to their standard PVI and Firm ablation for sustained AF rotors.
89138019|NCT00606307|Experimental|ITF2357|Initial dose of 50 mg b.i.d. that was subsequently escalated to 50 mg t.i.d in case of lack of significant toxicity.
89138020|NCT00892021|Experimental|NSA-789|Active study drug
89138021|NCT00892021|Placebo Comparator|Placebo|Inactive study drug
89138022|NCT00798369|Experimental|Canakinumab 10 mg|Canakinumab 10 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
89138023|NCT00798369|Experimental|Canakinumab 25 mg|Canakinumab 25 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
89138024|NCT00798369|Experimental|Canakinumab 50 mg|Canakinumab 50 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
89138025|NCT00798369|Experimental|Canakinumab 90 mg|Canakinumab 90 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
89138026|NCT00798369|Experimental|Canakinumab 150 mg|Canakinumab 150 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
89138027|NCT00798369|Active Comparator|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg intramuscularly (i.m) once. The i.m. injection was recommended to be administered deeply into the gluteal muscle. Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
89138028|NCT00950963|Experimental|Phone Counseling|The telephone outreach intervention was considered an adjunct to usual care. The study nurse focused on optimizing lipids utilizing published guidelines through phone contact.
89138029|NCT00950963|Active Comparator|Standard Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
89138030|NCT04221360|Experimental|Group 1|"Period 1: D390~Period 2: CKD-375"
89138031|NCT04221360|Experimental|Group 2|"Period 1: CKD-375~Period 2: D390"
89138032|NCT02757612|Active Comparator|Interventional|"Device Laser diode parameters: spot size of 0.04 mm2, average power (output) of 40 mW and 0.4 J per irradiation point, energy density of 10 J cm2, irradiation time of 10 seconds per point~1 session per week during 4 session"
89138033|NCT02757612|Sham Comparator|Comparator|"laser probe inactive for similar duration as for the laser diode group; only a beep sound was produced by the laser machine~1 session per week during 4 session"
89138034|NCT00608959|Experimental|omiganan 1% gel|Omiganan has a rapid bactericidal and fungicidal effect which is under development for the prevention of infections arising from short-term central venous catheters, as well as for the prevention of surgical wound infections in contaminated wounds.
89138035|NCT00608959|Active Comparator|chlorhexidine 2%|
89138036|NCT02763306|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
89138037|NCT00945659|Active Comparator|Standard Care|"Standard Care constitutes intensified diabetes management, an enrollment criterion for the study, consisting of either continuous subcutaneous insulin infusion (insulin pump) or multiple daily injections using a basal-bolus approach. All patients must be using carbohydrate counting and have prescribed correction factors for targeted insulin bolus dose adjustments."
89138038|NCT00945659|Active Comparator|Continuous Glucose Sensor|Patients will have the same diabetes management regimen as those in the Standard Care group. In addition they will be given a continuous glucose sensor, receive expert instruction in its use, and be guided by a physician and diabetes educator in achieving glycemic benefits through retrospective and real-time interpretation of CGS results and by learning to respond judiciously to the various CGS alarms.
89138039|NCT00945659|Experimental|CGS + Behavior Therapy|Patients in the use group will receive the same medical management as the Continuous Glucose Sensor group above. In addition, they will have 6 scheduled encounters with a behavior therapist that are designed to reduce or eliminate typical behavioral and/or psychological barriers to optimal use of CGS as part of diabetes care.
89138040|NCT02541175||All study participants|In order to cover a wide variety of common arrhythmias but keeping the number of subjects needed low (pilot study), the subjects are pre-selected according to following 4 categories: 1) 4 patients with intermitting or persisting atrial fibrillation. 2) 4 patients with atrial flutter 3) 6 patients with frequent atrial or ventricular extra-systoles. 4) 6 cardiac healthy subjects.
89138041|NCT04222296|Other|Cochlear Implant and Hearing Aid|Comparing performance of conventional hearing aid fitting to Phonak's Bimodal Fitting formula using the Phonak Naida Link hearing aid. All patients are tested in a bimodal (hearing aid plus cochlear implant) setup. Initial tests are completed with the Advanced Bionics Naida Q70 or Q90 sound processor and the patient's own hearing aid. In this arm, a patient's own hearing aid is replaced with the Phonak Naida Link hearing aid to test if there is a benefit.
89138042|NCT04222296|Other|Cochlear Implant alone|To determine if the addition of a contralateral routing of signal (CROS) microphone on the un-implanted ear improves performance. Baseline tests are completed with Advanced Bionics Naida Q70 or Q90 sound processors. Patients are then given the Phonak Naida Link CROS aid to test if there is a benefit.
89138043|NCT04222296|Other|Hearing Aid and Hearing Aid|Comparing performance of conventional hearing aid fitting to a modified signal processing strategy more aligned with how a cochlear implant manages sound. All patients are tested initially with their own hearing aids to obtain a baseline measurement. Patients are then fitted with a modified Phonak hearing aid to determine if performance improves.
89138044|NCT04113369|Sham Comparator|TENS group|30 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training program, patients will receive 30 minutes of conventional antalgic TENS (100 Hz) program as controls with electrostimulation device to the non-paretic wrist flexors.
89138045|NCT04113369|Active Comparator|EMS group|0 sessions (5 sessions/week, 6 weeks) of training including 40 minutes of lower limb training including a mixture of lower limb gait training, balance training and aerobic training and a combination of task-oriented treatment, fine motor skill training, range of motion exercises stretch exercises and strength training (75% repetition maximum (RM), 6 repetitions) for 20 minutes. After that training, the patients will receive 20 minutes of electrical stimulation to their non-paretic forearm upon wrist flexors by an intermittent maximum strength program (6 seconds of contraction, 10 seconds of rest) along with 5 minutes of pre and post warm-up with the same device.
89138046|NCT03517813||Cohort 1|"Asymptomatic women at increased risk of breast cancer referred clinically for high risk screening breast MRI or women with newly diagnosed primary unilateral breast cancer referred for evaluation of extent of disease (EOD) in the index breast and screening of the contralateral breast.~All women enrolled on study will complete a clinical breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
89138047|NCT03517813||Cohort 2|"Women receiving MRI for any indication and for whom percutaneous biopsy with ultrasound or MRI guidance has been recommended.~All women enrolled on study will complete a standard breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
89138048|NCT02760342|Experimental|ASP015K and Metformin|Subjects will receive a single oral dose of metformin on Days 1 and 10, a single dose of ASP015K on Day 3 and multiple doses of ASP015K once daily Day 5 to Day 11. Subjects will receive a single dose of metformin and ASP015K concurrently on Day 10.
89138049|NCT00894205|Experimental|strengthening exercise|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises."
89138050|NCT04221282||Epileptic elderly patients|Elderly patients with partial-onset seizures
89138051|NCT00894283|Active Comparator|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
89138052|NCT00894283|Active Comparator|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
89138053|NCT04113291|Experimental|DASH diet group|Participants randomized to receive the DASH diet will be prescribed an isocaloric DASH diet using meals (lunch, dinner, snacks) prepared by a Clinical Research Metabolic Kitchen under the direction of a registered dietician. Participants will prepare their own breakfast from a menu. The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
89138054|NCT04113291|Active Comparator|Attention Control Group|Participants randomized to attention control will continue their usual diet, but they will be instructed to limit their sodium intake to 2300 mg/day. They will be requested and voluntarily agree to not make additional diet or exercise changes during the 12-week study.
89138055|NCT02760186|Experimental|Altitude Exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
89138056|NCT01138709|Experimental|Convexity/Vitala|For all enrolled Subjects, STAGE 1 (Days 1 - 14 equals Convex Product Wear Period followed by, for those who successfully complete Stage I, weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 15 to 21), followed by 8 hours of daily wear time per week (Day 22 to 28), followed by 12 hours of daily wear time (Days 29 to 43).
89138057|NCT00895609|Experimental|Sugammadex|Sugammadex in doses: 0 (placebo), 0.0625, 0.125, 0.25, 0.5 and 1 mg/kg
89138058|NCT00895609|Active Comparator|Neostigmine|Neostigmine in doses: 0 (placebo), 5, 8, 15, 25, 40 mg/kg
89138059|NCT02757690|Active Comparator|2-dimenasional distal pancreatectomy|device: 2 dimensional laparoscopy of Olympus
89138060|NCT02757690|Experimental|3-dimenasional distal pancreatectomy|device : 3 dimensional laparoscopy of Olympus
89138061|NCT04269317|Experimental|Tixel C|Tixel Treatment, between 3-5 treatment session according to investigator's review of subject response follow by 3 Follow up sessions, 1,3 and 6 month after last treatment visit. Subject would be questioned about pain levvel, subjective dountime assessment and subjective response assessment. Images would be taken before treatment visit and in Follow-Up.
89138062|NCT04113681|Experimental|Geniculate Artery Embolization Arm|Single-arm prospective study of geniculate artery embolization for symptomatic knee osteoarthritis
89138063|NCT00894439|Experimental|1|
89138064|NCT04113213|No Intervention|Control|Standard care during consultations.
89138065|NCT04113213|Experimental|Intervention|Standard care during consultations with the addition of a physical lifestyle prescription.
89138066|NCT04035889|Experimental|Group 1|Participants assigned to Group 1 will take 2 weeks of melatonin followed by 2 weeks of placebo
89138067|NCT04035889|Experimental|Group 2|Participants assigned to Group 2 will take 2 weeks of placebo followed by 2 weeks of melatonin.
89138068|NCT00895687|Experimental|Erlotinib + Bortezomib|Up to 4 dose levels of study drug combination tested with 3-6 participants enrolled at each dose level. Erlotinib beginning dose of 150 mg taken by mouth daily for 21-day cycle. Bortezomib beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
89138069|NCT02758080|Experimental|Matched|A molecular profile is identified using next generation sequencing. A participant in this arm is assigned to early clinical trial studying targeted agent, which is anticipated to have the best response rate.
89138070|NCT02758080|Other|Not matched|A participants in this arm is assigned to a clinical trial at physician's choice.
89138071|NCT00894595|Experimental|Intervention group|The clubs in the intervention group are instructed to perform a warm-up program at two training sessions per week throughout the entire 2009 competitive season.
89138072|NCT00894595|Active Comparator|Control group|The clubs in the control group are instructed to train and play as usual throughout the 2009 season
89138073|NCT02757924|Experimental|Infant formula supplemented with prebiotics|infant formula powder, feed ad libitum
89138074|NCT02762838|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
89138075|NCT02762838|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
89138076|NCT02752854||Group A|Pain threshold measurement in high altitude
89138077|NCT02752854||Group B|Pain threshold measurement in low altitude
89138078|NCT00941603|Experimental|SCH 900271 15 mg|Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
89138079|NCT00941603|Experimental|SCH 900271 10 mg|Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
89138080|NCT00941603|Experimental|SCH 900271 5 mg|Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
89138081|NCT00941603|Experimental|SCH 900271 2.5 mg|Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
89138082|NCT00941603|Experimental|SCH 900271 1 mg|Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
89138083|NCT00941603|Placebo Comparator|Placebo|Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks
89138084|NCT02753166|Experimental|Dexamethasone|
89138085|NCT02753166|No Intervention|Control|
89138086|NCT04112901||People with trans-femoral amputation or knee dis-articulation|include individuals with unilateral transfemoral amputation or knee disarticulation, with ≤ K2 mobility grade OR SIGAM grade D or below; i.e. able to walk ≤ 50 meters on level ground, who have been users of either microprocessor-controlled knee or non-microprocessor-controlled knee joint for at least 6 months prior to the recruitment date.
89138087|NCT02605161||Parkinson's disease group|"patients diagnosed with Parkinson's disease by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus~to undergo pre-operative MRI with contrast"
89138088|NCT02605161||Control group|"patients diagnosed with either essential tremor or cervical dystonia by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus~to undergo pre-operative MRI with contrast"
89138089|NCT04222140|Experimental|ERIPTO Protocol|Protocol arm actively being studied
89138090|NCT04222140|Active Comparator|BMAC only|bone marrow aspirate concentrate only arm
89138091|NCT02605083|Experimental|eFT508|Escalation cohort
89138092|NCT02605005||GA|general anesthesia
89138093|NCT02605005||ISB|interscalene block
89138094|NCT02752698|Experimental|Micro Hand S robotic group|Micro Hand S robotic surgery group
89138095|NCT02752698|Other|laparoscopic surgery|laparoscopic surgery group
89138096|NCT02752698|Other|da Vinci robotic group|da Vinci robotic robotic group
89138097|NCT04113135|Experimental|Journaling, meditations, education, yoga intervention Arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post testing will take approximately 45 minutes to one hour. Session 1 for all participants will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The intervention sessions (2-6) for the experimental group participants consist will include a group discussion of the objectives for the week, 20-30 minutes of education and journaling (Attachment B), 45-60 minutes of PA consisting of various yoga poses followed by SMART goal setting and guided relaxation..
89234301|NCT00995124|Experimental|NeutraLice Advance|single application of head lice product
89234302|NCT00995124|Active Comparator|Moov Head Lice Solution|Single application for head lice with 10 min application time.
89138098|NCT04113135|Active Comparator|Journaling, meditation, education arm|Participants will be required to attend 1x/wk for 7 total sessions. The pre/post-testing will take approximately 45 minutes to one hour. Session 1 for all participants (control and experimental) will be comprised of an initial screening with a health history questionnaire regarding information about comorbidities, medications, and type of Multiple Sclerosis (MS) diagnosis, and completion of all outcome measurement tests as listed above. Following session one, subjects will be assigned to the control or experimental group utilizing the robust randomization application (RRApp) and the block randomization technique to ensure an equal number of subjects in each group.39 The control group will participate in a 45-60 minute session for weeks 2-6 consisting of goal setting to facilitate behavior change, education on MS, and meditation. Session 7 will conclude the study with reassessment of all outcome measurements as listed above.
89138099|NCT02753088|Experimental|BCD-063 (glatiramer acetate)|Subcutaneous injection of glatiramer acetate BCD-063 subcutaneously every day
89138100|NCT02753088|Active Comparator|Copaxone-Teva (glatiramer acetate)|Subcutaneous injection of glatiramer acetate Copaxone-Teva subcutaneously every day
89138101|NCT02753088|Placebo Comparator|Placebo|Subcutaneous injection of mannitol 40 mg, water for injections till 1 ml, every day
89138102|NCT04112979|Experimental|Auditory stimulation 1 (Music)|45 deciBel Sensation Level (dB SL), normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
89138103|NCT04112979|Experimental|Auditory stimulation 2 (Mother's lap)|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
89138104|NCT04112979|Experimental|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 deciBel (dB)
89138105|NCT04112979|No Intervention|No stimulation|Current standard of care
89138106|NCT02605239|Experimental|bleaching teeth|Group of patients will be bleaching with 10% peroxide carbamide , and them will be assessed the impact on dental confidence , impact psychosocial and esthetic perception
89138107|NCT00914901|Other|Healthy|10 healthy men
89138108|NCT00914901|Other|Asthmatics|10 male asthmatic subjects
89138109|NCT00914901|Other|Elite athletes with asthma|10 male elite athletes with asthma
89138110|NCT04112745|Experimental|Experimental group|
89138111|NCT04112745|Placebo Comparator|Control group|
89138112|NCT02759874|Experimental|Experimental|Intervention is pregnant women enrolled and using specialized breathalyzer device w face recognition technology linked to a cellphone
89138113|NCT02759874|No Intervention|Control Group|No intervention. No breathalyzer given. Access granted by participant to IHE to collect data from Alberta Health Services (medical records)
89138114|NCT04530318|Experimental|TolDec|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
89138115|NCT04530318|Placebo Comparator|Placebo|Placebo of dendritic cells
89138116|NCT00797823|Placebo Comparator|Insulin + Placebo|Glycemic control of subject participants was managed by the closed-loop system which delivered insulin and normal saline (instead of glucagon) as a placebo, based upon algorithm calculations.
89138117|NCT00797823|Active Comparator|Insulin + Glucagon|Glycemic control of subject participants was managed by the system which delivered insulin and glucagon based upon algorithm calculations.
89138118|NCT00797823|Experimental|Pilot Study|Pilot studies designed to assess safety of the system. Includes 6 participants undergoing 7 studies.
89138119|NCT02757378|Experimental|Neuroplasticity Education Group|Patients who receive manual physical therapy treatment with a neuroplasticity explanation of the basis for the technique
89138120|NCT02757378|Active Comparator|Biomechanical Education Group|Patients who receive manual physical therapy treatment with a traditional, biomechanical explanation of the basis for the technique
89138121|NCT02760108||Index case|Patients with a family history of Parkinson's/parkinsonism, and/or early onset Parkinson's/parkinsonism. The first individual member from a family who is recruited to the study.
89138122|NCT02760108||Affected relatives|Patients with Parkinson's/parkinsonism who are first or second degree relatives of an Index Case.
89138123|NCT02760108||Unaffected relatives|Participants who do not have Parkinson's/parkinsonism and are first or second degree relatives of an Index Case.
89138124|NCT02757456|Other|Aerobic Exercise program|Intervention of aerobic exercise
89138125|NCT02757456|Other|Control|no aerobic exercise program
89138126|NCT00797667|Experimental|Telcagepant 140 mg|Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
89138127|NCT00797667|Experimental|Telcagepant 280 mg|Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks
89138128|NCT00797667|Placebo Comparator|Placebo|Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
89138129|NCT02757144|Experimental|Cohort 1: DWP14012 Amg|DWP14012 Amg, tablets, orally, single dose administration
89138130|NCT02757144|Experimental|Cohort 2: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single dose administration
89138131|NCT02757144|Experimental|Cohort 3: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single dose administration
89138132|NCT02757144|Experimental|Cohort 4: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, single dose administration
89138133|NCT02757144|Experimental|Cohort 5: DWP14012 Emg|DWP14012 Emg, tablets, orally, single dose administration
89138134|NCT02757144|Experimental|Cohort 6: DWP14012 Fmg|DWP14012 Emg, tablets, orally, single dose administration
89138135|NCT02757144|Placebo Comparator|Cohort 1-6: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration
89138136|NCT02757144|Active Comparator|Cohort 1-6: Esomeprazole|Nexium® tablets, orally, single dose administration
89138137|NCT02757144|Experimental|Cohort 7: DWP14012 Amg|DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)
89138138|NCT02757144|Experimental|Cohort 8: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)
89138139|NCT02757144|Experimental|Cohort 9: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)
89138140|NCT02757144|Placebo Comparator|Cohort 7-10: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)
89138141|NCT02757144|Active Comparator|Cohort 7-10: Esomeprazole|Nexium®, orally, repeated dose administration(for 7days)
89138142|NCT02757144|Experimental|Cohort 9: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)
89138143|NCT00950807|Placebo Comparator|Placebo|Placebo
89138144|NCT00950807|Active Comparator|Tiotropium|Tiotropium
89138145|NCT00950807|Experimental|Arm 1|GSK573719 1000mcg once daily
89138146|NCT00950807|Experimental|Arm 2|GSK573719 500mcg once daily
89138147|NCT00950807|Experimental|Arm 3|GSK573719 250mcg once daily
89138148|NCT00950807|Experimental|Arm 4|GSK573719 125mcg once daily
89138149|NCT00950807|Experimental|Arm 5|GSK573719 62.5 mcg once daily
89138150|NCT00950807|Experimental|Arm 6|GSK573719 250mcg twice daily
89138151|NCT00950807|Experimental|Arm 7|GSK573719 125mcg twice daily
89138152|NCT00950807|Experimental|Arm 8|GSK573719 62.5mcg twice daily
89138153|NCT00797511|Experimental|Study Group|Participants will receive one dose of Tetanus, diphtheria (reduced antigen content), pertussis (acellular components) vaccine (TdcP-IPV, ADACEL Polio) on Day 0
89138154|NCT02752620|Experimental|Osteopathic Manipulative Treatment|"We selected two types of osteopathic techniques for this study:~Technical articulation: rhythmic technique with low speed in which the goal is the full gain range of motion.~Myofascial techniques (Neuromuscular): techniques involving lateral stretching, linear, deep pressures and pulls of the origins and insertions aiming at a myofascial relaxation.~Sacroiliac articulatory technique; Dorsal articulatory technique; Lumbar paraspinal muscles stretching technique; Lumbar myofascial technique (inhibitory)."
89138155|NCT02752620|Active Comparator|Exercise Therapy|"2 types of therapeutic exercises techniques were used:~Stabilization exercises~Stretches~Stabilization exercises:~Bridge on the ball 10 - 15 sec Side plank 10 - 15 sec Front board 10 - 15 sec active mobilization lumbopelvic 3 x 6 rep Squats with the ball on the wall 3 x 8 rep~Static-passive stretch (2 x 30 sec):~Paraspinal; Abdominals; Quadratus lumborum; Hip extenders; Hip flexors; Hip abductors; Hip adductors."
89138156|NCT00608881|Active Comparator|A - coenzyme Q10 2400 mg/day|Randomized to active treatment (coenzyme Q10 2400 mg/day)
89138157|NCT00608881|Placebo Comparator|B - Placebo|Randomized to placebo
89138158|NCT02752386|Experimental|Biofeedback Training 1|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide pain relief when relaxation is achieved.
89138159|NCT02752386|Active Comparator|Biofeedback Training 2|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide a painful context in which to practice relaxing.
89138160|NCT02752386|Active Comparator|Biofeedback Training 3|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback.
89138161|NCT00914979|Experimental|1|Single Arm - Interventional
89138162|NCT02759796|Placebo Comparator|Clinical assessment of flap perfusion|Tailoring the flap according to clinical assessment of flap perfusion
89138163|NCT02759796|Experimental|Angiography assessment of flap perfusion|Tailoring the flap according to ICG Angiography assessment of flap perfusion
89138164|NCT02852759|Experimental|intervention group|Add Selective Cold and Electroacupuncture treatment to the existing treatment for patients with insulin resistance.
89138165|NCT02852759|No Intervention|Intensive Care group|continue the existing management of insulin resistance in these patients. They will receive the same follow up, examinations etc as intervention group.
89138166|NCT05608395|Experimental|11C-Methionine PET/CT Arm|"The cohort consists of patients:~diagnosed with GB~with confirmed REP~indicated for adjuvant chemoradiotherapy~will undergo the 11C-MET PET/CT"
89138167|NCT05608395|No Intervention|Arm A-historical|"The cohort consists of a historical group of patients collected in the period 2014-2018:~with diagnosed GB~with confirmed REP~were indicated for adjuvant chemoradiotherapy"
89138168|NCT02759718|Experimental|pancreatic neuroendocrine tumor|chromogranin A
89138169|NCT04221906|Experimental|BOS-475 0.5%|Daily application of BOS-475 0.5%
89138170|NCT04221906|Experimental|BOS-475 1%|Daily application of BOS-475 1%
89138171|NCT04221906|Experimental|BOS-475 2%|Daily application of BOS-475 2%
89138172|NCT04221906|Placebo Comparator|Active ingredient-free vehicle cream|Daily application of vehicle cream
89138173|NCT04221906|Active Comparator|Daivonex cream|Daily application of Daivonex cream (calcipotriol 0.005%)
89138174|NCT04221906|Active Comparator|Betnesol-V cream (betamethasone 0.1%)|Daily application of Betnesol-V cream (betamethasone 0.1%)
89138175|NCT00945191|Experimental|CS-1008 with paclitaxel and carboplatin|CS-1008 will be administered with paclitaxel and carboplatin.
89138176|NCT04108923|Active Comparator|Ligasure ( group A)|
89138177|NCT04108923|Active Comparator|Conventional vessel ligation (group B)|
89138178|NCT01082393|Active Comparator|topical tacrolimus|
89138179|NCT01082393|Active Comparator|topical pimecrolimus|
89138180|NCT01082393|Active Comparator|local steroids|
89138181|NCT01082393|Placebo Comparator|cold cream|
89138182|NCT02757066|Experimental|NPC-15 Granules Lower Dose|NPC-15 Granules Lower Dose group which is administered 1mg melatonin
89138183|NCT02757066|Experimental|NPC-15 Granules Higher Dose|NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
89138184|NCT02757066|Placebo Comparator|NPC-15 Placebo Granule|NPC-15 Placebo Granules group which is administered placebo melatonin
89138185|NCT00894673|Experimental|1|Heparin sodium Hipolabor
89138186|NCT00894673|Active Comparator|2|Heparim Sodium APP 5.000 USP
89138187|NCT04222218|Active Comparator|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
89138188|NCT04222218|Sham Comparator|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
89138189|NCT04220736||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
89138190|NCT04220736||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
89138191|NCT02540551|Experimental|Sentinel node procedure.|Intervention: injection of blue dye and radioactive tracer (99mTc-nanocolloid or Nanocoll) in remains of the ovarian ligaments.
89138192|NCT02855333||Merendino Group (MER)|Patients who underwent merendino procedure for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
89138193|NCT02855333||Control Group (CON)|Patients who underwent alternative surgery for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
89138194|NCT02759406|Experimental|Mach-5 Grooved|grooved
89138195|NCT02759406|Experimental|Mach 5 Bare Metal|bare metal
89138196|NCT00606931|Experimental|one arm|
89138197|NCT00892411||All study participants|Patients With Acute Low Back Pain
89138198|NCT04220580|Other|Cold Pressor Test|The participants are instructed to keep the non-dominant hand submerged in ice-water for as long as possible with a maximum of 10 minutes.
89138199|NCT02752308|Active Comparator|General anesthesia + caudal block|Patients who receive general anesthesia plus caudal epidural block and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
89138200|NCT02752308|Active Comparator|General anesthesia only|Patients who receive only general anesthesia and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
89138201|NCT00895999|Experimental|1|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to 8 individual sessions of IPT adapted for depression and pain.
89138202|NCT00895999|Other|2|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to Enhanced Support and Connection to Counseling (ESCC).
89138203|NCT02752464|Experimental|Feedback report plus peer counseling|Feedback report plus peer counseling Participants receive 12 sessions of behavioral counseling and a brief printed feedback report
89138204|NCT02752464|Active Comparator|Feedback report|Feedback report Participants receive a brief printed feedback report
89138205|NCT00894751|Active Comparator|dexmedetomidine|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
89138206|NCT00894751|Active Comparator|propofol|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
89138207|NCT02752230|Active Comparator|Exparel (Bupivicaine Liposome)|Patient will have Exparel (Bupivicaine Liposome) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
89138208|NCT02752230|Active Comparator|Marcaine (Bupivicaine)|Patient will have Marcaine (Bupivicaine) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
89138209|NCT00896077|Active Comparator|Subcutaneous|Subcutaneous administration of LSF
89138210|NCT00896077|Active Comparator|IV|IV administration arm
89138211|NCT00792909|Experimental|Synflorix™ Group 1|Subjects previously vaccinated with the Synflorix™ vaccine according to a 2+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
89138212|NCT00792909|Experimental|Synflorix™ Group 2|Subjects previously vaccinated with the Synflorix™ vaccine according to a 3+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
89138213|NCT00792909|Active Comparator|Unprimed Group|Age-matched subjects not previously vaccinated with any pneumococcal vaccine receiving two doses of Synflorix™ at 36-46 and 38-48 months of age. Age-matching was ensured by the enrolment of subjects 36-46 months of age.
89138214|NCT02752152|Experimental|Computer-assisted counseling|Computer-assisted informational/educational interactive session followed by an interactive face-to-face session to discuss personal issues with a counselor as needed
89138215|NCT02752152|Experimental|On-demand counseling|The counselor asks whether the participant has any questions
89138216|NCT02752152|Active Comparator|Standard counseling|Interactive face-to-face counseling session
89138217|NCT02752152|Experimental|Appointment + reminder|Make appointment and send SMS reminder
89138218|NCT02752152|Experimental|Reminder only|Send SMS reminder only
89138219|NCT02752152|Active Comparator|No appointment and no reminder|No appointment and no SMS reminder sent
89138220|NCT00896155|Experimental|Concurrent Tamoxifen and Radiotherapy|ARM 1 will receive Tamoxifen given concurrently with radiotherapy. Tamoxifen will continue for a period of 5 years.
89138221|NCT00896155|Active Comparator|Sequential radiotherapy and tamoxifen|ARM-2 shall receive radiotherapy followed by tamoxifen sequentially. Again tamoxifen will continue for a period of 5 years.
89138222|NCT00896311|Active Comparator|1|Treatment solution consisted of 100 micrograms/mL of nitroglycerin. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
89138223|NCT00896311|Placebo Comparator|2|Placebo solution was saline. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
89138224|NCT02751996|Active Comparator|Part A Cohort 1: 25mg SB 9200|Part A Cohort 1: 25mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138225|NCT02751996|Placebo Comparator|Part A Cohort 1: 25mg Placebo|Part A Cohort 1: 25mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138226|NCT02751996|Active Comparator|Part A Cohort 2: 50mg SB 9200|Part A Cohort 2: 50mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138227|NCT02751996|Placebo Comparator|Part A Cohort 2: 50mg Placebo|Part A Cohort 2: 50mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138228|NCT02751996|Active Comparator|Part A Cohort 3: 100mg SB 9200|Part A Cohort 3: 100mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
88803353|NCT05473936|No Intervention|Control Arm - Standard Treatment (Group 1)|"The standard care for the control arm will be: the LACDHS Vaccine Hesitancy Outreach Group calling patients once every month to remind patients of the need to be vaccinated and tested if needed. During the duration of the six weeks, the study participants will be exposed to the call from the LACDHS Vaccine Hesitancy Outreach Group.~Participants will receive two phone calls six-weeks apart, where they will complete a pre-survey in the first phone call, and 2 surveys (post-survey and CDE survey) in the second phone call. The survey will measure their trust in medical institutions, rate their self-efficacy, and intention, knowledge, and perceptions on COVID-19 testing and vaccination."
89138229|NCT02751996|Placebo Comparator|Part A Cohort 3: 100mg Placebo|Part A Cohort 3: 100mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138230|NCT02751996|Active Comparator|Part A Cohort 4: 200mg SB 9200|Part A Cohort 4: 200mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138231|NCT02751996|Placebo Comparator|Part A Cohort 4: 200mg Placebo|Part A Cohort 4: 200mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138232|NCT02751996|Active Comparator|Part B: SB 9200 with tenofovir|Part B: SB 9200 selected dose from Part A administered in combination with tenofovir 300 mg qd. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138233|NCT02751996|Active Comparator|Part B: Tenofovir 300 mg|Part B: Tenofovir 300 mg qd monotherapy. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
89138234|NCT00944645|Active Comparator|A|MK0524A Source 1 (Phase III manufacturing site)
89138235|NCT00944645|Active Comparator|B|MK0524A Source 2 (commercial manufacturing site)
89138236|NCT00900991|Experimental|10 ug|10 microgram per dose
89138237|NCT00900991|Experimental|15 ug|15 microgram per dose
89138238|NCT00635622|Experimental|1|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
89138239|NCT00635622|Placebo Comparator|2|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
89138240|NCT04018027|Active Comparator|Difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablet administered twice daily
89138241|NCT04018027|Active Comparator|Difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablet administered twice daily
89138242|NCT04018027|Active Comparator|Difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg tablet administered twice daily
89138243|NCT04018027|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
89138244|NCT02853617|Experimental|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
89138245|NCT02853617|Experimental|AV0328 - Cohort 2|Cohorts 2 will receive 30 µg to be given as an IM injection
89138246|NCT02853617|Experimental|AV0328 - Cohort 3|Cohorts 3 will receive 75 µg to be given as an IM injection
89138247|NCT02853617|Experimental|AV0328 - Cohort 4|Cohorts 4 will receive 150 µg to be given as an IM injection
89138248|NCT00915291|No Intervention|Usual education|"Participants randomized into the no intervention arm were not exposed to the web-based educational modules"
89138249|NCT00915291|Experimental|Web-based educational modules|Participants randomized into the intervention arm were exposed to the web-based educational modules
89138250|NCT02855255|Active Comparator|NHS smoking cessation|NHS 1-1 smoking cessation programme. One thirty minute session followed by up to five shorter sessions (approx.10/15minutes) comprising Cognitive Behavioural Therapy/Motivational Interviewing to assist with smoking cessation.
89138251|NCT02855255|Active Comparator|Allen Carr's Easyway smoking cessation|Group smoking cessation programme. One 5/6 hour group session (plus one or two 3 hour booster sessions over the following 3 months for those who require them) comprising of Allen Carr's Easyway method being delivered in a spoken form.
89138252|NCT02751918|Experimental|Anetumab ravtansine|Anetumab ravtansine in combination with pegylated liposomal doxorubicin in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.
89138253|NCT00901069|Other|Azacitidine|
89138254|NCT02604147|Sham Comparator|Simulated inspiratory muscle training|Inspiratory muscle training with load of 15% of maximal inspiratory pressure.
89138255|NCT02604147|Experimental|Inspiratory muscle training group|Inspiratory muscle training with initial load of 50% of maximal inspiratory pressure.
89138256|NCT02853539|Experimental|Denosumab|One per 6 months subcutaneous injection of Denosumab (2 doses in total)
89138257|NCT02853539|No Intervention|No Denosumab|No intervention, just observation of HPN patients
89138258|NCT02751840|Experimental|Caffeine|Caffeine capsule (200 mg) is taken prior to RMR measurement
89138259|NCT02751840|Placebo Comparator|Placebo|Placebo (starch) capsule is taken prior to RMR measurement
89138260|NCT02751840|Experimental|Coffee|Black coffee (9 grams) is consumed prior to RMR measurement
89138261|NCT02751840|Placebo Comparator|Decaffeinated|Decaffeinated Black coffee (9 grams) is consumed prior to RMR measurement
89138262|NCT00894829|Experimental|1|Heparin sodium - Eurofarma
89138263|NCT00894829|Active Comparator|2|Heparin APP
89138264|NCT04108845|Experimental|experimental group|Received Vaccine: 15-valent pneumococcal Conjugate Vaccine, 0.5 ml/dose
89138265|NCT04109157|Other|Study population|Women who had fulfilled the standardization of terminology of lower urinary function from ICS were diagnosed as urodynamic stress incontinence (USI) after urodynamic study (UDS) and enrolled for analysis in this study.
89138266|NCT04269941||prognostic factors of gastrointestinal stromal tumors|for the patient diagnosed with gastic GIST , they underwent subtotal or total gastrectomy.
89138267|NCT02756988|Experimental|Coppertone (BAY987704)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89138268|NCT02855099|Active Comparator|CR group|patients will be referred to our rehabilitation centre at the following week after the procedure, and assigned to a personalized rehabilitation program for duration of 3 month.
89138269|NCT02855099|No Intervention|conservative group|No intervention
89138270|NCT00606229|Experimental|1|
89138271|NCT02756754|Experimental|Radiofrequency ablation|"Radiofrequency ablation (RFA) is a minimally invasive technique for eliminating both primary tumors and metastases.~The needles that will be used are monopolar RFA, the LeVeen™ Needle Electrode Family with a generator RF 3000 by Boston Scientific. The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored."
89138272|NCT04108533|Experimental|Text-Based Support|"Text-Based Support - Women randomized to this arm will receive text-based support via the Way to Health platform as described below.~Supportive texts - Encouraging text messages with prompts to ask questions will be sent twice weekly during the first four weeks postpartum and once weekly thereafter for the remaining two weeks of the program~Inquiry texts - Questions regarding infant feeding with prompts to answer will be sent three times weekly during the first two weeks postpartum and twice weekly thereafter for the remaining 4 weeks of the program.~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.~Women in this group will also have the option to send a text with a question or concern at any time during the study. Weekdays from 8am to 5 pm these will be fielded by a trained obstetrician. If a text is received after-hours or on the weekend, women will be instructed to reach out to their primary OBGYN provider."
89138273|NCT04108533|No Intervention|Usual Care|"Usual care - Women randomized to this arm will receive usual postpartum care with the following exceptions:~Inquiry texts- Questions regarding infant feeding with prompts to answer will be sent once weekly for all 6 weeks of the program.~PHQ2 text - Women will be sent the PHQ2 at 2 weeks and 6 weeks postpartum to assess mood symptoms.~Women in this group will be directed to their physician with any questions or concerns during the study period."
89138274|NCT02756598|Active Comparator|Sufentanil I|"Randomized arm moderate sufentanil I: bolus 1 microgram/kg propofol I: infusion 0.03 mg/kg/min"
89138275|NCT02756598|Active Comparator|Sufentanil II|"Randomized arm low sufentanil II bolus 0.5 microgram/kg propofol II: infusion 0.06 mg/kg/min"
89138276|NCT00896545|Experimental|5-keys feeding program|Counseling in small groups aimed at enhancing children's self control over eating
89138277|NCT00896545|Active Comparator|Healthy lifestyle counseling|Counseling in small groups aimed at achieving healthy eating patterns aimed at both the family and young children
89138278|NCT04108611|Experimental|systemic lupus in activity|Sixty systemic lupus patients in activity will receive conventional therapy (47 patient as cases 1) and immunadsortion (13 patients as cases 2) will be provided to the non responders
89138279|NCT04108611|Other|Control group 30 subjects|controls 1 (20 healthy volunteers, controls 2 (10 patients with glomerular diseases other than lupus) will do routine laboratory investigations
89138280|NCT02756676|Experimental|Rehabilitative treatment (MIRT)|Rehabilitative treatment MIRT consist in daily sessions of: motor treatment, occupational therapy and language speech therapy
89138281|NCT05278273|Experimental|At home cognitive training|We recruited 20 adults (10 female, mean age = 68.3 years, SD = 6.75) as the at-home training group. We assessed cognitive health status for participants using a self-report questionnaire and the Mini-Mental State Examination (MMSE), and all participants were deemed cognitively healthy (MMSE > 26). At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility.
89138282|NCT00950651|Experimental|1 Tramadol HCl Contramid® Once A Day|
89138283|NCT00950651|Active Comparator|2 Tramadol HCl Twice a day (SR)|
89138284|NCT02756520||Chronic kidney disease (pre-dialysis)|Observational study: supplemented protein-restricted diet
89138285|NCT00901147|Experimental|panobinostat and bortezomib|Oral Panobinostat and intravenous bortezomib
89138286|NCT02756442|Experimental|pregnant women with gestational diabetes|
89138287|NCT02756442|Active Comparator|pregnant women without gestational diabetes|
89138288|NCT02756286||ADHD: Adults with ADHD|NAT electroencephalography (EEG) test
89138289|NCT02756286||Controls: Healthy adults without ADHD|NAT electroencephalography (EEG) test
89138290|NCT04108689|Experimental|I-ACT|I-ACT is short for Internet-Acceptance and Commitment Training
89138291|NCT04268537|Experimental|PD-1 group|Anti-PD-1 antibody, 200mg, IV, one time
89138292|NCT04268537|Experimental|thymosin group|Thymosin, 1.6 mg sc qd, last for 5 days
89138293|NCT04268537|Placebo Comparator|control group|stand treatment
88806136|NCT00249470|Other|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
89138294|NCT02756130|Experimental|Treatment (birinapant, carboplatin)|Patients receive birinapant IV over 30 minutes on days 1 and 8, and carboplatin IV over 30 minutes to 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89138295|NCT00605293|Experimental|C.E.R.A|Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
89138296|NCT00605293|Active Comparator|Epoetin Alfa|Participants received IV injection of 6000 International Units (IU) of epoetin alfa every 3 weeks (q3wk) during the Stability Verification Period (SVP; Week -4 to -1), and 7443 IU of epoetin alfa q3wk during Dose Titration Period (DTP; Week 0 to 15), 7363 IU of epoetin alfa q3wk during Efficacy Evaluation Period (EEP; Week 16 to 23) up to 23 weeks.
89138297|NCT02855177|Placebo Comparator|Placebo|Placebo will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
89138298|NCT02855177|Experimental|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
89138299|NCT00635466|Experimental|Lap, 1|Patients undergoing laparoscopic surgery for rectal carcinoma
89138300|NCT04107987|Active Comparator|Reglicemi|Reglicemi is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
89138301|NCT04107987|Placebo Comparator|Placebo|Placebo
89138302|NCT04017637|No Intervention|Usual Care (UC)|Those randomized to the UC group will complete baseline and post-intervention assessments only. No intervention will be administered.
89138303|NCT04017637|Experimental|Resistance Training Intervention (RT)|Those randomized to the RT group will complete baseline and post-intervention assessments at weeks 0 and 12. For the intervention, they will complete resistance training for approximately 12 minutes 2x per week for 12 weeks.
89138304|NCT02852603||thoracic aortic aneurysm and dissection|Patients with thoracic aortic aneurysm and/or dissection are recruited in the study.
89138305|NCT04221126|Experimental|TMFI +cream|TMFI + ALA cream
89138306|NCT04221126|Experimental|TMFI + gel|TMFI + ALA gel
89138307|NCT04221126|Active Comparator|ALA creAM|ALA cream
89138308|NCT04221126|Active Comparator|ALA GEL|ALA gel
89138309|NCT04221126|No Intervention|Control|Untreated control with no intervention
89138310|NCT04035655|Experimental|Clinical and electrophysiological evaluation of tDCS session|"In this prospective case-control study, the investigator's main goal was to evaluate the impact of a single standard-care tDCS session on brain activity (EEG).~The effect of a single 20 minutes 2 mA tDCS session with the anode placed over the left dorsolateral prefrontal cortex and the cathode over the right supraorbital cortex administered as routine care were evaluated by combined behavioral and electrophysiological assessments immediately before and after the stimulation.~The study consisted of the following interventions, administered immediately before and after the stimulation session:~detailed behavioral assessment by the Coma Recovery Scale-Revised (CRS-R)~5 minutes resting state high-density EEG recordings and 6 minutes auditory oddball paradigm immediately.~Additionally, clinical anatomical MRI (T1) acquired as routine care were used to model the estimated tDCS-induced electric fields in the entire head of patients, based on available T1-weighted MRI."
89138311|NCT02756052|Sham Comparator|Medical Student - Sham tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
89138312|NCT02756052|Sham Comparator|General Surgery Resident - Sham tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
89138313|NCT02756052|Experimental|Medical Student - Anodal tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
89138314|NCT02756052|Experimental|General Surgery Resident - Anodal tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
89138315|NCT04035733|Experimental|Open-label single arm study|
89138316|NCT02855021|Other|Parkinson disease|Patients with a Parkinson disease with clinical diagnosis made for at least 5 years
89138317|NCT02755740|Other|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
89138318|NCT02759250|Experimental|adjuvant monotherapy|ARGX-110 5mg/kg once every three weeks for a maximum of 18 cycles
89138319|NCT02759250|Experimental|metastatic/recurrent monotherapy|ARGX-110 5mg/kg once every three weeks until disease progression
89138320|NCT02759250|Experimental|metastatic/recurrent combination therapy|ARGX-110 5mg/kg once every three weeks plus chemotherapy until disease progression. The choice of the chemotherapy agents is limited to: cisplatin, carboplatin, 5-fluorouracil, gemcitabine and paclitaxel.
88806137|NCT05266820|Experimental|TAS-102+Thalidomide|Thalidomide 100mg PO BID+TAS-102 35mg/m2, po, bid, d1-5, d8-12, q4wks
88806138|NCT05266820|Active Comparator|TAS-102|TAS-102 35mg/m2, po, bid, d1-5, d8-12, q4wks
88806139|NCT05266742|Experimental|END|Use of web based education
89234303|NCT04001010|Experimental|inhaled THC/CBD (PPP011)|PPP011 (synthetic THC/CBD) inhalation with mighty medic device
89138321|NCT00896701||Patient samples from C9621, C9720 and C19808|This is a CALGB Leukemia Tissue Bank project that makes use of tissue from patients who have previously provided their consent. Diagnostic and follow-up samples from acute myeloid leukemia (AML) patients treated on CALGB protocols 9621, 9720 and 19808, and who have been registered on the mandatory companion Leukemia Tissue Bank Protocol CALGB 9665 will be used.
89138322|NCT04268225|Experimental|Ultrasound Guided Dynamic Needle Tip Positioning Technique|In this arm the US transducer, protected with a sterile cover and sterile gel will be placed in the short axis above the distal end of the selected vein, moving the probe to place the vein in the center of the ultrasound screen under the middle mark of the image. The catheter needle will be inserted close to the transducer. The needle tip will be visualized as a white dot on the ultrasound screen. Then, the transducer will be shifted slightly proximally until the white dot disappears from the screen. The needle and the transducer will be moved alternately toward the patient several times to visualize the needle tip in real time. After penetrating the anterior wall of the vein, these steps will be repeated a few more times with a smaller insertion angle to visualize the white dot in the vein. Finally, the outer catheter will be fully advanced and the needle core will be extracted.
89138323|NCT04268225|Active Comparator|Traditional insertion group|For traditional insertion technique insertion attempt will be blind or tactile. Otherwise, the same protocol and measurements as elaborated for the US guided group will be applied.
89138324|NCT04220346|Experimental|Tablet group|The Tablet group played the game with Tablet during the whole circumcision.
89138325|NCT04220346|No Intervention|Control group|The control group did not play game with Tablet during the procedure.
89138326|NCT02540863|Experimental|myofascial release protocol and Rocabado exercise therapy|"Myofascial Release Protocol:~Suboccipital release.~Compression - decompression of temporomandibular joint.~Horizontal release of temporomandibular joint.~Deep fascia release in temporal region.~Masseter deep fascia release.~Pterygoiddeep fascia release.~Intraoral pterygoid deep fascia release."
89138327|NCT02540863|Active Comparator|exercise therapy|Rocabado´s 6 x 6 exercises program utilizes six exercises six times by day. The patient is in supine position with a loop of 6 cm in the cervical area, and the therapist sits at the head of the bed.
89138328|NCT02759172|Experimental|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
89138329|NCT02759172|No Intervention|Standard Care|Standard Care for pretrial jail detainees is assessment of risk and stabilization to the extent possible during their jail detention. No post-release community follow-up is typically provided. This study will augment standard care with regular assessment and emergency referral post-release, as well as provision of a list of community resources.
89138330|NCT02751606|Experimental|Breast and rectal cancer|Subjects will receive intravenous dose of ferumoxtran-10. 24-36 hours later a 7 Tesla MRI scan will be performed, to detect lymph node metastases. In rectal cancer patients the mesorectum will be imaged and for breast cancer patients this will be performed in the ipsilateral axilla. Subjects will also undergo a 3 Tesla MRI scan as a comparison to the 7 Tesla MRI scan.
89138331|NCT00631085|Other|1|
89138332|NCT00572533|Active Comparator|Control|ESA Dose Adjustment per standard Anemia Management Protocol
89138333|NCT00572533|Experimental|Treatment|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"
89138334|NCT02759328|Experimental|Xbox Kinect™ training group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program plus 60 minutes/day, 5 days/week, 4 weeks (20 sessions) Xbox Kinect™ upper extremity training. Two games both of which require using upper extremities, were chosen and each game was played for 30 minutes per session.
89138335|NCT02759328|Active Comparator|Conventional rehabilitation group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program only. The treatment protocol was individualized according to the goals which were determined depending on each patient's needs and functional level.
89138336|NCT04107909|Other|3 ports|3port operation
89138337|NCT04107909|Other|4 port|4 port operation
89138338|NCT04107753|Experimental|Intervention: Brief counseling based on the 5As model|The intervention group received a brief counseling based on the 5As model. It mainly consists of the following steps: ask, advice, asses, assist, arrange. It is performed by the nurse who take clinical care of the patient. The patients receive an information card about the Smoke cessation center's (CTT) and the patients who agree are contacted by the CTT's staff.
89138339|NCT04107753|No Intervention|Control group|"No other intervention than the usual care (range between the not mentioning the subject at all, to a general advice to quit without bringing any evidence or any structured counseling)."
89138340|NCT00894907|Experimental|PiCCO-group|Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids according to PiCCO-parameter-guided algorithm
88806140|NCT05266742|No Intervention|END free|patient witout of web based education
89138341|NCT00894907|Other|2|Control: Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.
89138342|NCT04269863|Experimental|Control Group|This group of 75 patients is the control group that will be receiving the standard lowest dosage of 81mg aspirin.
89138343|NCT04269863|Experimental|Treatment Group|This group of 75 participants is the treatment group that will be receiving personalized aspirin dosage between 81mg-325mg (within standard clinical recommendations), which will be determined based on platelet analysis via PFA-200.
89138344|NCT00901381|Experimental|G-CSF|
89138345|NCT00901381|No Intervention|Control|
88821395|NCT04282304|Other|Usual Care|The patients in this arm will have usual care during preoperative period, bariatric surgery and follow-up.
89138346|NCT02751528|Experimental|ETBX-021|Ad5 [E1-, E2b-]-HER2/neu Vaccine, Suspension for Injection
89138347|NCT02755428|Experimental|retinal pigment epithelium transplantation|Subretinal transplantation of human embryonic stem cell derived retinal pigment epitheliums.
89138348|NCT00949715|Active Comparator|RV Mid-Septal Pacing|Pacing lead located in the right ventricle at the middle of the muscle separating the right and left sides of the heart
89138349|NCT00949715|Active Comparator|RV Apical Pacing|Pacing lead located at the bottom of the right ventricle of the heart, in the right ventricular apex
89138350|NCT02539927||Controlled|
89138351|NCT02539927||Not controlled|
89138352|NCT02539927||Control status yet to be clarified|
89138353|NCT02758938|Experimental|Patient Subjects|Patients that are part of the UW LUTD Program (n=30) will undergo 3 weekly biofeedback sessions each lasting 1 hour. All interactive biofeedback sessions will be conducted by American Family Children's Hospital nurses that are experienced in standard biofeedback techniques. After the patient has completed all of the biofeedback sessions, he/she will complete a feedback form about their satisfaction with the device.
89138354|NCT02758938|Experimental|Biofeedback Nurse Subjects|"The nurses (n=3) involved in the biofeedback portion of the UW LUTD Program will undergo a Nurse Training Session where they will be asked to think aloud while completing an outlined scenario. Their feedback will be used to update the software to make it more user friendly. After the session, they will be asked to complete the System Usability Scale (SUS). Additionally, after guiding patients through biofeedback sessions using the new software, they will be asked to complete the Nurse Feedback Form."
89138355|NCT02758938|Experimental|Biofeedback Physician Subject|The physician (n=1) that oversees the UW LUTD Program will assess data from each patients session. Based on the information he gathers from the session, he will complete a feedback form. Each patient's EMG activity will be stored by the video game which will allow the physician to review the patient's performance. Specifically, the physician will look for the minimum relaxation and the maximum contraction levels of the patient throughout play as well as muscular isolation.
89138356|NCT02758938|Experimental|Focus Group Subjects|A Focus Group session will involve the physician involved in this study, an advisor on the project and staff involved in the project as well as three random individuals outside of the project (n=7). These individuals will provide feedback on the software that will be used to improve the software.
89138357|NCT00901537|Experimental|Azacitidine and Cisplatin|Every 4 weeks, azacitidine is given daily as subcutaneous injection for 5 days from day 1 to day 5, and cisplatin is given as intravenous injection on day 8. The dose of azacitidine will be dose escalated among each group of 3-6 patients, and the dose of cisplatin is fixed.
89138358|NCT02853227||BCS|Photographs og consecutive group of 346 patients operated with breast conserving surgery were used to investigate cosmetic outcomes.
89138359|NCT02853227||DIEP|Photographs og consecutive group of 30 patients operated with DIEP-flap were used to assess cosmetic results
89138360|NCT02751372|Experimental|BAY 987517|All subjects are patched .
89138361|NCT00894985|Experimental|1|Heparin 5.000UI
89138362|NCT00894985|Active Comparator|2|Heparin 5.000USP - APP
89138363|NCT00791661|Experimental|Panel A: MK-1006 15/30/45|Participants received a single rising dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
89138364|NCT00791661|Experimental|Panel B: MK-1006 60/80/60 fed|Participants received a single rising dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
89138365|NCT00791661|Experimental|Panel C: MK-1006 100/140/170|Participants received a single rising dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
89138366|NCT04585152|Experimental|Rituximab biosimilar|"Drug Name: Rituximab biosimilar monoclonal anti-CD20 antibody Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities (of note CD20 is mostly represented on B cells but also in Th17 cells) How: RTX IV: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~Where: in Hospital When and how much: once; diluted in 1000 ml of normal saline."
89138367|NCT04585152|Active Comparator|Mycophenolate mofetil|"Drug Name: Mycophenolate Mofetil (MMF)~Why: selective and reversible inhibition of inosine monophosphate dehydrogenase with inhibition that particularly affects lymphocytes since they rely almost exclusively de novo purine synthesis Procedures: MMF 1,200 mg/m2 orally divided in 2 daily doses"
89138368|NCT00943787|Other|SMBG followed by clamp|One month of self-monitored blood glucose (SMBG) field data was used to calculate measures of glucose variability and risk of hypoglycemia, while the hyperinsulinemic, euglycemic and hypoglycemic clamp procedure was used to evaluate insulin sensitivity and epinephrine response during induced hypoglycemia.
89138369|NCT00895063|Experimental|Vocal Exercise|Subject will speak continually for one hour following injection of botulinum toxin.
89138370|NCT00895063|Placebo Comparator|Silence|Subject will remain silent for one hour following injection of botulinum toxin.
89138371|NCT02751294|Experimental|TQ Control+ TQ SIL|Subjects received TQ Control product (2 tablets) and 30 mg TQ SIL solution orally with water after a meal.
89138372|NCT02751294|Experimental|TQ X + TQ SIL|Subjects received 2 tablets of Tafenoquine dissolution profile X and 30 mg TQ SIL solution orally with water after a meal.
89138373|NCT00895141|Experimental|Low saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 8%E saturated fat
89138374|NCT00895141|Experimental|High saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
89234304|NCT04001010|Placebo Comparator|Placebo|Placebo inhalation with mighty medic device
89138375|NCT04220502|Experimental|Magic Shave Powder Gold|This group will receive magic shaving powder gold and instructions on how to apply it. They will keep a log for their facial hair removal
89138376|NCT04220502|Other|Traditional Methods|This group will continue using traditional razors with the standard of care directions to shave. They will keep a log of their facial hair removal
89138377|NCT04107597|Experimental|Core stabilization exercises|Patients with CLBP who practice core stabilization exercises
89138378|NCT04107597|Experimental|Core stabilization exercises and paced breathing training|Patients with CLBP who practice core stabilization exercises combined with paced breathing training
89138379|NCT04107597|Experimental|Myofascial trigger point release|Patients with CLBP who receive myofascial trigger point release therapy
89138380|NCT04107597|Experimental|Myofascial trigger point release and paced breathing training|Patients with CLBP who receive myofascial trigger point release therapy combined with paced breathing training
89138381|NCT00901615|Experimental|Lenalidomide and R-CHOP|Escalating Lenalidomide dose from 2.5 to 25 mg Lenalidomide and R-CHOP
89138382|NCT00949325|Experimental|temsirolimus plus liposomal doxorubicin|Single arm study: Dose escalation of temsirolimus plus constant dose of liposomal doxorubicin.
89138383|NCT02755662|Active Comparator|Narval O.R.M CC™|First mandibular retention device : Narval O.R.M CC™
89138384|NCT02755662|Active Comparator|Narval O.R.M™ trad|Second mandibular retention device : Narval O.R.M TRAD™
89138385|NCT04107441|Experimental|Part 1 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg, 10 mg, 20 mg or 40 mg AX-8 twice daily (8 hours apart, i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of treatment periods 1, 2, 3 or 4, respectively.
89138386|NCT04107441|Experimental|Part 2 arm|Ten healthy participants will receive one orally disintegrating tablet (ODT) with 5 mg AX-8 and one ODT with 40 mg AX-8 8 hours later (i.e. at 0 hour and +8 hours), during the treatment day (Day 1) of the treatment period.
89138387|NCT02539615|Experimental|ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection|Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
89138388|NCT00897169|Experimental|A|
89138389|NCT00897169|Experimental|B|
89138390|NCT02853071|Experimental|Estramustine|560 mg per day
89138391|NCT02853071|Active Comparator|Standard practice center|"Standard treatment center choice.~Excepted: anthracyclines, taxanes, capecitabine and eribulin"
89138392|NCT02755506|Experimental|patients with thoracic lesions|Patients with thoracic lesions is going to undergo endobronchial ultrasound elastography followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
89138393|NCT02603913||Normal pregnancy|Normal uncomplicated pregnancy
89138394|NCT02603913||Pre-eclampsia|"Hypertension (>140 mmHg systolic or >90 mmHg diastolic) developing after 20 weeks gestation and the coexistence of one or more of the following new onset conditions:~Proteinuria (>300 mg/day)~Other maternal organ dysfunction~renal insufficiency (creatinine >90 μmol/L)~liver involvement (elevated transaminases - and/or severe right upper quadrant or epigastric pain)~neurological complications (eclampsia, altered mental status, blindness, stroke, hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia, persistent visual scotomata)~hematological complications (thrombocytopenia, disseminated intravascular coagulation, hemolysis)~Uteroplacental dysfunction"
89138395|NCT02603913||Pregnancy induced hypertension|New onset of hypertension (>140 mmHg systolic or >90 mmHg diastolic) after 20 weeks gestation, without proteinuria, in a previously normotensive woman.
89138396|NCT02603913||Preterm birth|Babies born alive before 37 weeks of pregnancy are completed.
89138397|NCT02603913||Intra-uterine growth restriction|Moderate IUGR is an estimated fetal weight and / or abdominal circumference < 10th percentile for its gestational age Severe IUGR is an EFW (estimated fetal weight) and/ or AC (abdominal circumference) < 5th percentile for its gestational age
89138398|NCT02852915|Experimental|Laparoscopic surgery for T4 colon cancers|Laparoscopic surgery for T4 colon cancers
89138399|NCT02852915|No Intervention|Conventional open surgery for T4 colon cancers|Conventional open surgery for T4 colon cancers
89138400|NCT02603757|Active Comparator|Group A|Standard-dose of 2,000 IU Vitamin D3, daily
89138401|NCT02603757|Experimental|Group B|Higher-dose of 50,000 IU of Vitamin D3, weekly
89138402|NCT02758782|Active Comparator|Golimumab monotherapy|Treatment with 50 mg Golimumab subcutaneous once monthly
89138403|NCT02758782|Active Comparator|Golimumab combined with Celecoxib|Treatment with Golimumab 50 mg subcutaneous once monthly in combination with Celecoxib 400 mg orally every day
89138404|NCT02852369|Experimental|Task Oriented Training|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
89138405|NCT00895219|Active Comparator|1|Breathing re-training
89138406|NCT00895219|Active Comparator|2|Breathing re-training and musculoskeletal physiotherapy techniques
89138407|NCT04221672|Experimental|Terlipressin plus standard care|Immediately after hepatectomy, 1 mg terlipressin was given intravenously after hemostasis was achieved. After surgery, participants were routinely managed, and terlipressin were administrated at a dosage of 2 mg per day for 4 days.
89138408|NCT04221672|Other|Standard care|Participants were not administrated with terlipressin during surgery and were routinely managed after surgery.
89138409|NCT02854865||Echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
89138410|NCT02604069|Experimental|Continuous Glucose Monitor|Application of CGM for 6 days following free flap reconstruction in conjunction with clinical monitoring
89138411|NCT02695914||Control group|Conventional treatment methods will be given to cases in control group.
89138412|NCT02695914||Experiment group|On the base of control group, Compound Qingre Granule will be added to in experiment group.
89138413|NCT00943319|Experimental|Busulfan and fludarabine|Intravenous busulfan (Busulfan®) in combination with fludarabine
89138414|NCT02540785|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
89138415|NCT02540785|Experimental|small-incision lenticule extraction|The patients in this group chose to receive the small-incision lenticule extraction surgery.
89138416|NCT04243278|Experimental|PO LD-ASA|Study participants who are assigned to the oral aspirin arm of the study will receive 81mg oral aspirin. Over-encapsulated 81mg aspirin tablets will be used. Study participants in this arm will take 81mg aspirin daily for 6 months.
89138417|NCT04243278|Placebo Comparator|PO Placebo|A standard placebo pill, the same size, shape and color of the oral aspirin will be used. The placebo pills will be over-encapsulated in the same manner as the aspirin tablets. The placebo will be administered to the participants randomized to placebo group in the same manner the oral aspirin would be administered - they will take the pill daily for 6 months.
89138418|NCT02854475|Experimental|Proband group|Raman spectroscopy and venous blood collection
89138419|NCT00915447||Cat Allergic Rhinitis|Individuals with cat allergic rhinitis, yet without routine cat exposure
89138420|NCT05381831|Experimental|NatestoTM|Participants in this group will receive Natesto for a 26 consecutive weeks treatment course
89138421|NCT00897325||Ancillary-Correlative (Collecting and banking ALL specimens)|Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment.
89138422|NCT02758548|Other|Capillary Blood Sampling|Capillary blood sampling, collected as two fingerprick samples with POCT device and two venous samples
89138423|NCT04107363|Experimental|Experimental group:|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes.~After the oropharyngeal aspiration was completed, the patient's position was changed."
89138424|NCT04107363|Other|Control group|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
89138425|NCT04268927|Experimental|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
89138426|NCT04268927|Active Comparator|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
89138427|NCT00790647|Experimental|Stem Cell Transplant with Bortezomib and Melphalan|Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
89138428|NCT00323141|Active Comparator|Ventralex|
89138429|NCT00323141|Active Comparator|Leight Weight Vypro II prothesis|
89138430|NCT02755194||Breastfeeding women on the study medications|The study population consists of lactating/breastfeeding women over the age of 18, who are able to communicate in English and are taking one or more of the study drugs (Infliximab, Adalimumab, Golimumab, Certolizumab, Etanercept, Methotrexate, Ezetimibe, Bupropion, Citalopram, Venlafaxine)
89138431|NCT02540473|Experimental|Group therapy|12 week manualized group therapy (one hour per week)
89138432|NCT02540473|Other|Control Group|Participants get one hour of time away from patient care/duties to do as they wish.
89138433|NCT02754882|Active Comparator|Bevacizumab (Avastin)|Avastin® + Carboplatin/Paclitaxel
89138434|NCT02754882|Experimental|SB8 (A proposed bevacizumab biosimilar)|SB8 + Carboplatin/Paclitaxel
89138435|NCT02852135|Experimental|LMA Proseal group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Prosealgroup,LMA Proseal was inserted into each patient after anesthesia induction.
89138436|NCT02852135|Experimental|LMA Supreme group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Supreme group,LMA Supreme was inserted into each patient after anesthesia induction.
89138437|NCT00790569|Experimental|Arm I|Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
89138438|NCT00790569|Placebo Comparator|Arm II|Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
89138439|NCT00790569|Active Comparator|Arm III|Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
89138440|NCT00902005||Rheumatic patients|"Three groups:~RA patients: 30 starting on Methotrexate, 30 starting on combination of Methotrexate and TNFalpha inhibitor.~PSA patients: 20 starting on Methotrexate, 20 starting on combination of Methotrexate and TNFalpha inhibitor.~AS patients: 20 starting on TNFalpha inhibitor"
89138441|NCT00939029|Active Comparator|Active|2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
89138442|NCT00939029|Placebo Comparator|placebo|2 patches (containing non active ingredients) per day for 8 weeks
89138443|NCT00895375||Psoriasis patients|40 subjects (male or female) age 18 or older with psoriasis covering >10% BSA and without a diagnosis of depression.
89138444|NCT00895375||Patients without psoriasis|40 subjects without psoriasis matched for age, sex and BMI, as a control population.
89138445|NCT02603601|Active Comparator|Standard lifestyle intervention|The standard lifestyle intervention is a 1-hour individual nutritional counseling session with a registered dietician at BIDMC.
89138446|NCT02603601|Experimental|Mind-body lifestyle intervention|The mind-body lifestyle intervention is a 10-week mindfulness-based intervention that integrates mindfulness with traditional behavioral strategies to improve long-term weight maintenance.
89138447|NCT02754804||PAD patients|Patients with grade 1 claudication Measurement of biomechanic parameters while walking on treadmill
89138448|NCT04106895||Fibryga|
89138449|NCT02758704|Experimental|High-Stress (HS)|In the HS environment, the resident will be exposed to various stressors. There will be the presence of audio alarms as well as the presence of a senior physician who will be supervising the performance of the resident. In addition, the mannequin will be slightly unstable which will be reflected in its oxygen saturation dropping throughout the first 30 seconds the procedure.
89138450|NCT02758704|Active Comparator|Low-Stress (LS)|In the LS environment, there will be absence of audio (alarms), physical (third-party supervisor, nurse and respiratory therapist) and situational (unstable infant) stressors.
89138451|NCT00902083|Experimental|surgery plus p53 gene|using p53 gene therapy before surgery
89138452|NCT00902083|Active Comparator|surgery alone|Surgery without pre-p53 gene therapy
89138453|NCT00902083|Experimental|p53 plus chemotherapy|p53 gene therapy with concurrent chemotherapy
89138454|NCT00902083|Experimental|p53 gene therapy alone|Intra-tumor injectio of rAd-p53 gene with no concurrent treatment
89138455|NCT02852291|Experimental|Parents Make the Difference|Parents Make the Difference (Caregivers attend 10 group parent training sessions)
89138456|NCT02852291|Experimental|Parents Make the Difference Plus|Parents Make the Difference Plus (Caregivers attend 10 group parent training sessions and receive 3 home visits)
89138457|NCT02852291|No Intervention|Waitlist Control|No parenting intervention until the end of the study period
89138458|NCT02603523|Experimental|Senior Dance|The intervention group will attend a single educational class on fall risk factors and prevention, and will participate in a 12-week, twice-weekly group-based program of Senior Dance. Each dance class will last for an hour, and the number of participants per class will range from 10 to 15. Senior Dance-certified instructors will lead the classes. The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups.
89138459|NCT02603523|No Intervention|Control group|Participants in the control group will attend the same educational class on fall risk factors and prevention that intervention group participants will receive, and will be instructed not to take part in any regular exercise programs such as supervised group exercise, Tai Chi, Yoga, or any dance activity during the study period. At the end of the study, they will be offered Senior Dance classes, twice a week, during 12 weeks.
89138460|NCT00635544|Experimental|1|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
89138461|NCT00635544|Active Comparator|2|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
89138462|NCT04107207|Active Comparator|Kombucha Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
89138463|NCT04107207|Placebo Comparator|Placebo Intervention|Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.
89138464|NCT02754960|Active Comparator|Thalidomide group|Patients were randomly assigned to the thalidomide group and received 100 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
89138465|NCT02754960|Placebo Comparator|Placebo group|Patients were randomly assigned to the placebo group and received 100 mg of thalidomide placebo (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
89138466|NCT00902317|Active Comparator|Boston Scientific|The PolarCath peripheral balloon catheter (CryoVascular Systems, Inc., Los Gatos, CA) is a novel angioplasty system that simultaneously dilates and cools the plaque and vessel wall in the area of treatment. Cooling is achieved by inflating the balloon with nitrous oxide rather than the usual saline/contrast mixture.
89138467|NCT00902317|Active Comparator|Spectranetics|The excimer laser has unique properties that make it ideally suited to debulk atheromatous and thrombotic arterial blockages. LASER is an acronym for Light Amplification by Stimulated Emission of Radiation. However, there are many types of lasers, each distinguished by the wavelength of the emitted light, the effective power of the light beam, and whether the light is pulsed (like a flashbulb) or continuous (like a light bulb). The effectiveness of a given laser for intraarterial applications depends on how the light interacts with tissue inside an artery.
89138468|NCT00902317|Active Comparator|Fox Hollow|"The SilverHawk peripheral catheter system and cutter driver (FoxHollow Technologies, Redwood City, CA) are designed for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries. The catheter consists of a flexible shaft designed to track over a 0.014 guidewire. At the distal end of the catheter is a small cutting assembly comprised of a rotating inner blade contained within a tubular housing. The proximal end of the catheter contains a connector and Positioning Lever designed to fit into a small, disposable, battery-driven Cutter Driver which powers the device."
89138469|NCT00902317|Active Comparator|WL Gore|Viabahn Endoprosthesis (W.L. Gore & Associates, Flagstaff, AZ) is a flexible self-expanding endoluminal device consisting of expanded polytetrafluoroethylene (ePTFE) lining with an external Nitinol (NiTi=Nickel:Titanium) support extending along its entire length. The device is compressed and attached to a catheter delivery system. The Gore Viabahn Endoprosthesis is available in a wide range of diameters and lengths.
89234305|NCT00999570||Patients operated by AR trained surgeons|patients who had their total knee replacements performed by surgeons who have completed a fellowship training in adult reconstruction surgery
89138470|NCT00902317|Placebo Comparator|Control Group, Guidant|Balloon angioplasty is a treatment that uses a catheter with a tiny balloon mounted on the end. The balloon is positioned through the narrowing/blockage in your leg artery, and then it is inflated to push the narrowing apart and restore a channel for blood flow. The balloon is then deflated and removed from your body. A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface. The FDA has approved the use of certain stents for the treatment of narrowing in the leg arteries. Stents have been widely used in various parts of the body, including blocked blood vessels in the arms, legs, heart (coronary arteries), and kidneys (renal arteries).
89138471|NCT00587847|Other|Campath maintenance treatment|Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.
89138472|NCT00604331|Active Comparator|A|Pyruvate
89138473|NCT00638196|Experimental|1|placebo/active crossover
89138474|NCT02540239|Placebo Comparator|2L PEG|only used 2L PEG
89138475|NCT02540239|Experimental|Simethione+2L PEG|used 2L PEG+Simethione
89138476|NCT02852993||Transfused patients|A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period.
89138477|NCT02755038||premenopausal and postmenopausal women|One group will include 20 premenopausal women under the age 40 years old, with regular menstruation cycles and without any illness or medication including birth control pills or steroidal ointments, and without known diagnosis of polycystic ovaries or fertility disorder. The second group will include 20 postmenopausal women over the age of 60, with no menstruation at least for the last five years, and without hormone therapy or treatment of any Steroidal therapy for the last year.
89138478|NCT02540395|Active Comparator|Group A: Standard of care|"Standard of care immunosuppressive regimen based on TAC (Prograf) (achieving 4-8ng/ml trough levels), MMF (Cellcept, Myfortic, Myfenax)(1gr bid) and steroids (6-methyl prednisolone, Urbason, Methypred) (according to KDIGO guidelines).~All patients in group A recieve the tripple-drug IS as suggested by guidelines. In case of rejection the patients are treated with high dosage of Methypred and/or Thymoglobuline"
89138479|NCT02540395|Experimental|"Group B: Low Immunosuppression regimen"|"(based on TAC monotherapy (Prograf) to achieve 8-10 ng/ml trough levels during the first 4 weeks after transplantation and 6-8 ng/ml thereafter, MMF (Cellcept, Myfortic, Myfenax) (1g bid) during the first 7 days post-transplant and stopped thereafter) and steroids (6-methyl prednisolone; Urbason, Methypred) (tapering until discontinuation on month 2 post-transplant).~In contrast to Group A the patients are treated with a two drug IS combination consisting of Prograf and Methypred. In case of rejection the patients are treated with hifg dosage of Methypred and/or Thymoglobuline."
89138480|NCT04547166|Experimental|Serplulima +Bevacizumab+XELOX|Serplulimab (HLX10) in Combination With Bevacizumab and chemotherapy (XELOX)
89138481|NCT04547166|Placebo Comparator|placebo + Bevacizumab+XELOX|placebo in combination with Bevacizumab and chemotherapy (XELOX)
89138482|NCT00602693|Experimental|UCB post-transplant Treg Cell Infusion|Includes patients with high risk malignancy receiving allopurinol, fludarabine phosphate, cyclophosphamide, sirolimus, total body irradiation, double umbilical cord blood transplantation and Treg infusion cells after transplant. Patients will receive differing dose levels as they are entered and assigned to determine the maximum tolerated dose.
89138483|NCT00902395|Active Comparator|Midazolam|Oral midazolam
89138484|NCT00902395|Experimental|Midazolam/ketamine|Combined midazolam and ketamine
89138485|NCT00902395|Other|Protective stabilization|No drug or placebo administered
89138486|NCT04213404|Experimental|Ribociclib-spartalizumab|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
89138487|NCT00604409|Experimental|Treatment (SIRT and capecitabine)|Patients receive capecitabine PO twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients undergo SIRT on day 2 and may undergo a second course of SIRT on day 58.
89138488|NCT00905905|Experimental|Ezetimibe-Simvastatin 10/40 mg|
89138489|NCT00905905|Active Comparator|Simvastatin 40 mg|
89138490|NCT00784563|Active Comparator|Continuous training|Aerobic walking using continuous heart rate training.
89138491|NCT00784563|Active Comparator|Interval training|Aerobic walking using interval heart rate training
89138492|NCT04269083|Experimental|experimental arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
89138493|NCT04269083|Active Comparator|control arm|fresh specimens from the tumour and normal mucosa will be collected endoscopically at diagnosis and placed immediately into RNALater to isolate RNA. The mRNA expression of BIRC3 will be quantified using a SYBR green-based real-time PCR analysis; the BIRC3 median expression in normal mucosa samples will be used as calibrator. Patients with a tumor expression level of BIRC3 lower than the established cutoff will receive a standard carboplatin/paclitaxel regimen with concurrent radiotherapy followed by surgery. Patients with an expression of BIRC3 higher or equal than the cutoff (chemoradiation resistant patients) will undergo upfront surgery.
89138494|NCT00897637||Observational|Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers.
89138495|NCT00902473|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
89138496|NCT00902473|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
89138497|NCT04104633|Other|Patients with breast or colorectal cancer|10 patients with invasive breast carcinoma, not otherwise specified (NOS) (Stade I to III) and 10 patients with invasive colorectal adenocarcinoma (Stade I to III)
89138498|NCT02540317|Experimental|Active treatment, Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy. Participants will be stratified based on diagnosis, i.e. adjustment disorder and burnout.
89138499|NCT02540317|No Intervention|Waiting list control|The control condition is a waiting list. Participants in this arm receive no active treatment. After 12 weeks on waiting list, participants are crossed over to treatment.
89138500|NCT05429034|Experimental|MIST-paradigm|Patients assigned to the MIST paradigm arm are exposed to psychosocial stress.
89138501|NCT05429034|Sham Comparator|Sham-paradigm|Patients assigned to the sham paradigm are not exposed to psychosocial stress.
89138502|NCT04104789|Experimental|Kovanaze Nasal Spray (General Practice)|Adults who require restorations in the maxillary teeth that would need local anesthesia
89138503|NCT04104789|Active Comparator|Articaine Injections (General Practice|Adults who require restorations in the maxillary teeth that would need local anesthesia
89138504|NCT00938717|Placebo Comparator|Placebo|
89138505|NCT00938717|Experimental|290 μg Linaclotide|
89138506|NCT00905983|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
89138507|NCT04220268||Participants|All the patients with proved malignant ground glass nodule will be enrolled.
89138508|NCT00897793||patients with epithelial cancers|Patients with head and neck cancer, and lung, breast, colorectal, and prostate cancers who are to undergo radiation therapy
89138509|NCT02602587|Experimental|blood samples and bone marrow samples|The patients included in this study will be processed according to the standard treatment in force for their disease. This study does not in any way interfere with this treatment regimen, and is only based on additional samples of blood and bone marrow in acts planned in the prognostic or follow-up protocols. Treatment shall start within the 15 days following inclusion and first sampling.
88821396|NCT04282304|Experimental|UGECAM|During the preoperative period, the patients in this arm will have usual care and a 4 weeks intensive, comprehensive behavioral lifestyle intervention. They will then have usual bariatric surgery and follow-up.
89138510|NCT05428878||Pregnant|pregnant women
89138511|NCT05428878||Non-pregnant|non-pregnant women
89138512|NCT04104399|Experimental|XC101-D13H|single dose
89138513|NCT04104399|Placebo Comparator|Placebo|single dose
89138514|NCT00906061|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
89138515|NCT04104087|Experimental|deepithelializ free gingival graft|performing tunneling technique with deepithelialized free gingival graft in treating RT2 gingival recession
89138516|NCT04104087|Active Comparator|subepithelial connective tissue graft|performing tunneling technique with sub epithelial connective tissue graft in treating RT2 gingival recession
89138517|NCT02754648|Active Comparator|Group A; laparoscopic ovarian endometrial aspiration|Laparoscopic ovarian endometrial aspiration will be done for thirty patients with ovarian endometriotic cyst. .
89138518|NCT02754648|Active Comparator|group B; laparoscopic ovarian endometrial stripping|Laparoscopic ovarian endometrial stripping will be done for thirty patients with ovarian endometriotic cyst.
89138519|NCT02754648|Active Comparator|Group c laparoscopic ovarian endometrial de-roofing|Laparoscopic ovarian endometrial de-roofing and bed cauterization will be done for thirty patients with ovarian endometriotic cyst.
89138520|NCT00902551||1|Subjects underwent cervical sample DNA image cytometry
89138521|NCT00902551||2|Subjects underwent cervical sample conventional cytology
89138522|NCT02602509|Experimental|Celecoxib plus rifampicin group|Visit 1: Celecoxib 400mg Visit 2: Rifampicin 10mg/kg Visit 3: Celecoxib 400mg PLUS rifampicin 10mg/kg
89138523|NCT02602509|Experimental|Celecoxib plus pyrazinamide group|Visit 1: Celecoxib 400mg Visit 2: Pyrazinamide 25mg/kg Visit 3: Celecoxib 400mg PLUS pyrazinamide 25mg/kg
89138524|NCT02852837|Experimental|Part 1: Dose Escalation Part|Participants will receive single dose of daratumumab from Week 1 till Week 3 (Period 1 - single dosing period) followed by 6 weekly doses of daratumumab until Week 9 (Period 2 - weekly dosing period) and every 2 weeks for 8 infusions and then once every 4 weeks from Week 26 until disease progression, intolerability, or other reasons for treatment discontinuation (Period 3 - less intense dosing period). A dose of 8 milligram per kilogram (mg/kg) will be chosen as the starting dose and will be escalated to 16 mg/kg if the 8 mg/kg is determined safe and tolerated by study evaluation team (SET).
89138525|NCT02852837|Experimental|Part 2: Pharmacokinetic (PK) Expansion Part|Participants will receive daratumumab at 16 mg/kg in 3 periods as given in the Part 1.
89138526|NCT02852837|Experimental|Part 3: Safety Expansion Part|Participants will receive daratumumab 16 mg/kg every week for 8 weeks followed by every 2 weeks for an additional 16 weeks, and then every 4 weeks thereafter. Participants will be treated with daratumumab until disease progression, intolerability, or any other reasons for treatment discontinuation.
89138527|NCT02754414|Experimental|Healthy Volunteers|Autologous, cold stored, PAS/plasma suspended platelets stored for various periods (3 to 20 days).
89138528|NCT02539381|Other|Gold Standard Assessments|"Formal perimetry (Goldman or Octopus visual field)~Albert's visual inattention test~Star cancellation visual inattention test~line bisection test~These are performed as part of the routine assessment in the visual stroke orthoptic clinic and neuro-ophthalmology clinics.~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
89138529|NCT02539381|Other|Usual Clinical Screening Practice|"Visual field assessment to confrontation~Visual inattention assessment to bilateral stimuli~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
89138530|NCT02539381|Other|Stroke Vision App|"Digital tumbling E visual accuity assessment~Digital visual field assessment~Digital line crossing assessment~Digital shape cancellation assessment~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
89138531|NCT04219098|Experimental|Treatment|Butterfly IQ utilized to inject 10cc prior to surgery the remainder after incision
89138532|NCT04219098|Active Comparator|Control|Entire injection will be given after initial incision is made.
89138533|NCT04104009|Experimental|Interventional group|"In the exam group there will be group training for four meetings of one hour each.~After completing the training program with the test group, a break of 5 weeks will follow, during which a new test and control group will be formed. The procedure will be carried out until the estimated sample size (99 subjects per group) is met."
89138534|NCT04104009|Active Comparator|Control group|In the control group there will not be any group training.
89138535|NCT04103853|Experimental|Proxalutamide|"Stage one - Dose climbing:~Each dose cohort will assess toxicity within the 35 days following the first dose of GT0918.~Stage two- the expansion cohort :~30 patients will be enrolled to the 200mg cohort . 15 patients will be enrolled to the 300mg cohort."
89138536|NCT00902629|Experimental|Intervention|Intervention group contains the patients randomized for early treatment of their epiretinal fibrosis.
89138537|NCT00902629|No Intervention|Control|Control contains patients not randomized for early surgery.
89138538|NCT04221048||PREG-GUCH|Pregnant women with congenital heart diseases
89138539|NCT00587223|Experimental|1|Apligraf (a living bilayered cell therapy product)
89138540|NCT00587223|Active Comparator|2|Dressing regimen comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer.
89138541|NCT00902707|Experimental|Mucinex 1200mg|Pill
89138542|NCT00902707|Placebo Comparator|Placebo|Pill
89138543|NCT04478994|Active Comparator|TEPEZZA 20mg/kg|Approximately 15 participants will receive 8 infusions of TEPEZZA q3W for a total of 21 weeks. TEPEZZA 10mg/kg will be administered on Day 1 and TEPEZZA 20mg/kg will be administered q3W for the remaining 7 infusions.
89138544|NCT04478994|Placebo Comparator|Placebo|Approximately 10 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
89138545|NCT00906139|Active Comparator|Propofol|To receive propofol (0.5 mg/kg up to 400 mg) and fentanyl (0.05 mg);
89138546|NCT00906139|Active Comparator|Midazolam|To receive midazolam (0.1 mg/kg) and fentanyl (0.05 mg).
89138547|NCT02538835|Experimental|Metacognitive Therapy|
89138548|NCT02538835|Active Comparator|Mindfulness based cognitive therapy|
89138549|NCT02538835|Placebo Comparator|Support groups|
89138550|NCT05428410||IL-4R responders|IL-4R was injected subcutaneously. Base line and treatment end point nasal polyp score were compared and NPS >1.
89138551|NCT05428410||IL-4R nonresponders|IL-4R was injected subcutaneously. Base line and treatment end point nasal polyp score were compared and NPS ≤1.
89138552|NCT05428410||Controls|Placebo was injected subcutaneously.
89138553|NCT00938639|Experimental|CSL425 (15 mcg)|15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
89138554|NCT00938639|Experimental|CSL425 (30 mcg)|30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
89138555|NCT00906217||elderly patients|patients older than 70 years with normal renal function
89138556|NCT05428254|Active Comparator|Exercise and Manual therapy|"Group I will be treated with stretching exercises (EX), manual therapy (EX group) and serves as a control group.~Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session. Mobilization of the facet joint of the cervical vertebrae is performed after neck exercises."
89138557|NCT05428254|Active Comparator|Exercise and radiofrequency therapy|"Group II will be treated with capacitive and resistive radiofrequency therapy plus EX without manual therapy (CRRT+ EX group).~In addition to neck stretching exercises, they will receive 20 minutes of CRRT. Both the capacitive and resistive electrodes. CRRT is applied by the INDIBA radiofrequency therapy. INDIBA radiofrequency therapy has a long wavelength diathermy with frequency of 488 KHz range. The integration of two operational modes capacitive electrode (CAP) and (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. Capacitive electrodes will be applied for five minutes. Then the resistive electrodes will be applied for 10 minutes and finally the capacitive will be applied again for another five minutes."
89138558|NCT05428254|Active Comparator|Exercise, Manual and Radiofrequency therapy|Patients in this group will receive the same program of exercises as in group one. in addition, patients will receive the CRRT as in group two and the mobilization of the facet joints of the cervical vertebrae is applied while applied the CRRT by a trained physiotherapist. The same protocol of mobilization is applied for group one and three.
89138559|NCT00906295|Active Comparator|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
89138560|NCT00906295|Experimental|Allowed drop in hemoglobin to 5.6-6.5 mmol/L|Transfusion with red blood cells to level between 5.6-6.5 mmol/L
89138561|NCT04219488|Experimental|Neuromobilization group|The neuromobilization group received a supervised home program plus radial nerve mobilization. Radial nerve mobilization exercises were performed by the physiotherapist for 3 days a week for 3 weeks. The patients in the neuromobilization group also performed self-neuromobilization exercises at home for 6 weeks. Supervised home program including patient education and eccentric exercises was administered three times daily for 6 weeks.
89138562|NCT04219488|Active Comparator|Control group|The control group received a supervised home program. Supervised home program including patient education and eccentric exercises was administered 3 times a day for 6 weeks.
89138563|NCT02538601|Experimental|CBT-A|An 8-session, CBT-based group smoking cessation program (CBT-A) enhanced with transdiagnostic skills for the management of anxiety and fear-based avoidance behaviors.
89138564|NCT02538601|Active Comparator|CBT-S|An 8-session, CBT-based, traditional group CBT based smoking cessation program.
89138565|NCT00135161|Experimental|Intensity modulated radiation therapy (IMRT).|
89138566|NCT00902785||no drug|no drug
89138567|NCT02754336|Active Comparator|Cogmed Robomemo, working memory training|Robomemo working memory training, 25 sessions with 8 verbal and non-verbal tasks per session.
89138568|NCT02754336|Active Comparator|Othmer, neurofeedback|Othmer method neurofeedback, 25 sessions a 30 minutes.
89138569|NCT05381519|Experimental|DXP604|1800mg，IVgtt
89138570|NCT05381519|Placebo Comparator|placebo|IVgtt
89138571|NCT02754102|Experimental|Sunscreen Spray-Liquid|All subjects are patched with the same product
89138572|NCT00902863|Experimental|YOGA patients|Patients assessed for chronic pain at our Pain Management Centre
89138573|NCT00134303|Experimental|NASH|
89138574|NCT00902941|Experimental|Rasagiline|
89138575|NCT00902941|Placebo Comparator|Placebo|
89138576|NCT02754258|Placebo Comparator|Placebo|60 day oral administration of sugar placebo twice per day before lunch and supper.
89138577|NCT02754258|Experimental|Methylphenidate (MPH)|60 day oral administration of active study drug (methylphenidate) twice per day before lunch and supper.
89138578|NCT04267991||Tacrolimus|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
89138579|NCT04267991||Phototherapeutic Keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
89138580|NCT04267991||Control|patients received only artificial tears eyedrop
89138581|NCT02539069|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect through arthroscopy
89138582|NCT02754024||Total shoulder arthroplasty (TSA)|Replacement of humeral head and glenoid
89138583|NCT02754024||Hemi shoulder arthroplasty (HSA)|Replacement of humeral head only
89138584|NCT02852681|Other|15 mg E4/3 mg DRSP without food|Treatment A (Reference): a single 15 mg E4/3 mg DRSP tablet without food (fasted).
89138585|NCT02852681|Other|15 mg E4l/3 mg DRSP with food|Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed)
89138586|NCT02753868|Experimental|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
89138587|NCT02753868|Experimental|Hemodialysis with Exercise (1-st hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 1-st hour into treatment
89138588|NCT02753868|Experimental|Hemodialysis with Exercise (3-rd hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 3-rd hour into treatment
89138589|NCT00903019|Experimental|1|Participants will receive problem-solving therapy (PST) delivered via teleconferencing (tele-PST).
89138590|NCT00903019|Active Comparator|2|Participants will receive problem-solving therapy (PST) delivered in-person.
89138591|NCT00903019|Placebo Comparator|3|Participants will receive monitoring phone calls.
89138592|NCT02754180|Active Comparator|chemotherapy|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles.
89138593|NCT02754180|Experimental|chemotherapy with chemoradiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
89138594|NCT00906451|No Intervention|No lipid-lowering|No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
89138595|NCT00906451|Experimental|Simvastatin 20 mg|Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
89138596|NCT00906451|Experimental|Simvastatin 40 mg|Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
89138597|NCT00906451|Experimental|Simvastatin 80 mg|Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment
89138598|NCT02753634|Experimental|Square-stepping exercise Intervention|Participant attend sessions 2 times per week for 24-weeks at a community location. An instructor demonstrated increasingly difficulty walking or stepping patterns across a gridded mat and participants are asked to try and remember and repeat the patterns. Social engagement is encouraged.
89138599|NCT02753634|No Intervention|Usual care wait-list control group|This group will be invited to participate in square-stepping exercise after final assessments are completed.
89138600|NCT00906529|Active Comparator|Conservative Blood Glucose Control|Goal Pre-prandial blood glucose <180 mg/dl.
89138601|NCT00906529|Active Comparator|Aggressive Blood Glucose Control|Pre-prandial goal blood glucose <110 mg/dl
89138602|NCT02851589|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
89138603|NCT02851667|Experimental|Training group|Resident training programs such as talks, day camp and thematic activities were delivered in training group.
89138604|NCT02753478|Experimental|intracoronary hypothermia group|Patients who will receive intracoronary hypothermia before and during percutaneous coronary intervention
89138605|NCT00783705|Experimental|Arm I (inositol)|Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
89138606|NCT00783705|Experimental|Arm II (placebo)|Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
89138607|NCT04268459|Active Comparator|Regular exchange|Patients will be appointed each 3 months for regular exchange of voice prosthesis.
89138608|NCT04268459|Active Comparator|Leakage exchange|Patients will have voice prosthesis exchange when leakage occurs.
89138609|NCT00906607||Group I|10-18 years
89138610|NCT00906607||Group II|20-35 years
89138611|NCT00906607||Group III|45-60 years
89138612|NCT00906607||Group IV|65-75 years
89138613|NCT05136222|Experimental|Intervention|"This trial of PSG-assisted commencement of non-invasive ventilation (NIV) in motor neurone disease (MND) follows the methodology of our previous single-site study (Hannan et al 2019 ERJ), with the addition of an open label cohort that extends until (the earlier of) 12 months or death.~After empirical NIV set-up and an acclimatisation period (3 weeks), participants will undergo single night in-laboratory polysomnography (PSG). The PSG will be performed and supervised by a sleep scientist. In the intervention group, the intervention PSG results will be used to adjust/titrate NIV settings to optimize ventilation and improve synchrony between the patient and the NIV device. Participants will be asked to continue to use NIV as prescribed for the subsequent 7 week intervention period."
89138614|NCT05136222|Placebo Comparator|Control|"The participants allocated to the control group will also be asked to attend a single night in-laboratory PSG. The NIV settings will not be adjusted throughout the PSG (sham PSG). Participants in the control group will retain their original settings after the sham PSG, and will be asked to continue to use NIV in this manner for the subsequent 7 week intervention period."
89138615|NCT04034953|Other|Colorectal Cancer Screening|"Potential screening participants will firstly be briefed about the CRC screening pilot program launched by the Department of Health (DH).~This project will offer screening referrals to the government pilot program or FIT screening tests for a total of 10,000 consecutive visitors."
89138616|NCT04034953|Other|Prostate Cancer Screening|A blood test for Prostate Specific Antigen (PSA) will then be performed. Subsequently, for subjects with serum PSA 4-10 ng/ml, additional blood tests for Prostate Health Index (PHI) will be performed for the further assessment of risk of prostate cancer. Subjects with serum PSA > 10 ng/ml; or PHI ≥ 35 will be referred for Trans-rectal Ultrasound-guided Prostatic Biopsy (TRUS+PB). Subjects with serum PSA < 4 ng/ml or with PHI level < 35 will be invited to repeat the prostate screening tests every 2-years. We aim to screen not more than 5,000 subjects. For all patients recruited for prostate cancer screening, the study team will continue follow the subjects, by phone or mail or other means, for the long term clinical outcome for up to 10 years.
89138617|NCT04034953|Other|Breast Cancer Screening|Up to 5,000 eligible female subjects will receive a mammography on a 2-yearly basis. Individuals with abnormal findings on mammography will be referred for subsequent follow-up by the Jockey Club Breast Health Centre (BHC) run by the Hong Kong Breast Cancer Foundation (HKBCF).
89138618|NCT04268381||Healthy (n=23)|
89138619|NCT04268381||Gingivitis (n=20)|
89138620|NCT04268381||Periodontitis (n=40)|
89138621|NCT02755350|Experimental|Truvada|Daily oral PrEP (Truvada) is provided to a cohort of 2100 participants who will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period. In between some visits, they will return to the pharmacy for a refill of PrEP, counselling on adherence and medication of side effects.
89138622|NCT04103541|Experimental|IP-Colombia|
89138623|NCT04103541|No Intervention|Waitlist control|
89138624|NCT04034875|Experimental|Patients with acquired brain injury|
89138625|NCT00604487|Active Comparator|1|Insertion of the Atad double balloon ripener device (100 ml NS in each balloon).
89138626|NCT00604487|Active Comparator|2|Insertion of the double balloon instillation device (100 ml NS in each balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
89138627|NCT00604487|Active Comparator|3|Insertion of the folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
89138628|NCT04219410||Cases|Patients who underwent minimally invasive esophagectomy with this novel procedure at Kaiser Permanente, Northern California, Oakland Medical Center
89138629|NCT04103697|Experimental|4xCapOx|Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery. The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
89138630|NCT04103697|Active Comparator|Surgery|Patients will receive standard surgery for rectal cancer with partial or total mesorectal excision (based on exact tumor location and surgeons discretion). The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage
89138631|NCT02852525|Other|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction. Photographs will be taken and digitally stored. Biopsies (which are part of the routine diagnosis and surveillance of Barrett's) will be targeted based on the microscopic images. The histologic findings on the biopsy specimens will be compared to the microscopic images to determine the accuracy of the probe-based microscopy in predicting pathology.
89138632|NCT04321668|Other|Injection of SYNVISC-ONE|Patients suffering from symptomatic knee osteoarthritis (OA), receiving intra-articular (IA) injection of SYNVISC-ONE® (Hylan G-F 20; 10 mL single-injection viscosupplement)
89138633|NCT04103463|Experimental|Interactive stepping exercise group|
89138634|NCT04103463|Active Comparator|Home exercise group|
89138635|NCT02851745|Experimental|Linagliptin|Linagliptin 5 mg daily for 48 weeks
89138636|NCT02851745|Placebo Comparator|Placebo|Placebo 5 mg daily for 48 weeks
89138637|NCT02602197|Active Comparator|Paracetamol|1 gr paracetamol received intravenously bolus 15 minutes after anesthetic induction and at the postoperative 6 th,12 th, 18 th and 24 th hours
89138638|NCT02602197|Active Comparator|Dexketoprofen|50 mg dexketoprofen received intravenous bolus 15 minutes after anesthetic induction and at the postoperative 8 th,16 th and 24 th hours.
89138639|NCT04035343|Active Comparator|Conventional face down positioning|Patients in third arm will be treated with the current standard of care, that is, they will be kept supine in the ophthalmic surgery chair after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will transition to face down positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
89138640|NCT04035343|Experimental|Supine positioning|Patients in the second arm will be kept supine after the completion of their surgery. They will then be taken to the recovery area where, once transferred to the care of the postoperative care unit staff, they will maintain supine positioning. They will maintain this positioning until their first day postoperative visit after which they will position according to the retinal breaks found during surgery.
89138641|NCT02753712|Active Comparator|fluticasone/vilanterol DPI (Relvar Ellipta DPI)|Inhalation powder. 92/22µg, I inhalation od
89138642|NCT02753712|Experimental|Fluticasone/formoterol BAI|Pressurised suspension for inhalation 125/5µg, 2 inhalations bid
89138643|NCT00898885||Bone Marrow Transplantation|
89138644|NCT00938327||Rotarix Group|Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.
89138645|NCT04220892|Experimental|Pembrolizumab plus Pemetrexed|Pembrolizumab plus Pemetrexed
89138646|NCT04220892|Experimental|Pembrolizumab plus Abemaciclib|Pembrolizumab plus Abemaciclib
89138647|NCT02696148|Experimental|Liraglutide|
89138648|NCT02696148|Placebo Comparator|Placebo|
89138649|NCT00887198|Placebo Comparator|Placebo + prednisone|Placebo plus prednisone
89138650|NCT00887198|Experimental|Abiraterone + prednisone|Abiraterone acetate plus prednisone
89138651|NCT05402904|Active Comparator|patients with chronic low back pain|50 Patients will be recruited from neuropsychiatric outpatient clinic at Sohag University Hospital complaining of CLBP for more than 12 Weeks. Patients who are suspected of suffering from any autoimmune, rheumatological, or neurological disorders that could explain the pain that they experienced will be excluded from the study. Patients who are suffering from any disease that could affect the results and interpretation of the parameters of the H-reflex, F-wave or SSEP, including polyneuropathy and radiculopathy. Structural Spinal cause of pain will be excluded by relative investigations. Routine nerve conduction studies on both lower limbs as well as H-reflex, F-wave and SSEP will be performed on both patients and controls.Arabic versions of the Beck depression inventory and Taylor's Manifest Anxiety Scale will be used to measure depression and anxiety in both patients and healthy controls.
89138652|NCT05402904|Active Comparator|healthy controls|"50 Healthy volunteers will be included in the control group of the study. Routine nerve conduction studies on both lower limbs as well as H-reflex, F-wave and SSEP will be performed on both patients and controls.~Arabic versions of the Beck depression inventory and Taylor's Manifest Anxiety Scale (TMAS) will be used to measure depression and anxiety in both patients and healthy controls."
89138653|NCT00903643||Healthy subjects|
89138654|NCT00903643||PBS subjects|
89138655|NCT05399706||Men|Male participants
89138656|NCT05399706||Women|Female Participants
89138657|NCT04219644|Other|Breathing test or sleep study|To evaluate the usability of the device in non-clinical and clinical settings
89138658|NCT02826668|No Intervention|Control|Baseline ultrasound only, with no markings placed. No ultrasound prior to epidural placement.
89138659|NCT02826668|Experimental|Ultrasound|Baseline and pre-puncture ultrasound with markings placed.
89138660|NCT02826590|Experimental|Neck passive mobilizations|Neck passive mobilizations
89138661|NCT02826590|Placebo Comparator|Manual contact|Manual contact
89138662|NCT05110794|Experimental|LY3502970 (Fed)|LY3502970 administered orally to participants who are in a fed state.
89138663|NCT05110794|Experimental|LY3502970 (Fasted)|LY3502970 administered orally to participants who are in a fasted state.
89138664|NCT02832128|Experimental|AUT00063 - Placebo|AUT00063 (800 mg/day) for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with placebo
89138665|NCT02832128|Experimental|Placebo - AUT00063|Placebo for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with AUT00063 (800 mg/day)
89138666|NCT04243460|Experimental|CTG connective tissue graft augmentation|CTG connective tissue graft (CTG) was used for soft tissue augmentation. I
89138667|NCT04243460|Active Comparator|XCM Xenogeneic collagen matrix (XCM)graft augmentation|Xenogeneic collagen matrix (XCM) was used for soft tissue augmentation.
89138668|NCT00633620|Experimental|colonoscopy|Non-NBI HDTV colonoscopy
89138669|NCT02753322|Experimental|Dual-task training group|"Subjects in this group will have 30 minutes of dual-task training with simultaneously performing balance and walking exercise and attention demanding tasks, and 30 minutes of stretching exercises.~The training program will last for 8 weeks with frequency of 2 sessions a week."
89138670|NCT02753322|Active Comparator|Single-task training group|"Subjects in this group will have single-task training with 30 minutes of balance and walking exercise and 30 minutes of attention demanding task performed separately.~The training program will last for 8 weeks with frequency of 2 sessions a week."
89138671|NCT02753322|Active Comparator|Limbs exercise group|"Subjects in this group will have stretching and strengthening exercise for 60 minutes.~The training program will last for 8 weeks with frequency of 2 sessions a week."
89138672|NCT02831894|Sham Comparator|0% Hypnotic Medication Taper|In this condition patients will be maintained on their baseline hypnotic medication dosage throughout a 20-week double-blinded tapering period.
89138673|NCT02831894|Active Comparator|25% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 25% every 2 weeks throughout a 20-week double-blinded tapering period.
89138674|NCT02831894|Active Comparator|10% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 10% every 2 weeks throughout a 20-week double-blinded tapering period.
89138675|NCT00782067|Experimental|Midostaurin (PKC412)|Midostaurin was administered at a dose of 100 mg twice daily (bid) in continuous cycles of 28 days until disease progression, intolerable toxicity or withdrawal due to any cause, whichever occurred first.
89138676|NCT02753244|Experimental|Intendu FBT inpatient|Other: Motion Based Cognitive Video Games Software
89138677|NCT02753244|Active Comparator|iPad games|Other: iPad apps
89138678|NCT02753244|Experimental|Intendu FBT community|Other: Motion Based Cognitive Video Games Software
89138679|NCT05521269|Experimental|ANX1502 SAD|Participants will be administrated a single oral dose of ANX1502 at various ascending dose levels or matching placebo.
89138680|NCT05521269|Experimental|ANX1502 with Food|Participants will be administrated a single oral dose of ANX1502 or matching placebo with food.
89138681|NCT05521269|Experimental|ANX1502 MAD|Participants will be administrated multiple oral doses of ANX1502 at various ascending dose levels or matching placebo for 14 days.
89138682|NCT02752932|Other|HNSCC -PDX development|Participants with HNSCC who will undergo curative surgery will be included in this group. This involves PDX development only, no drug testing will be done on the PDX.
89234306|NCT00999570||Patients operated by non-AR surgeons|patients who had their total knee replacements performed by orthopaedic surgeons who did not complete an adult reconstruction fellowship training
89234307|NCT01003860||0.5% Ropivicaine (150 mg)|
89234308|NCT01003860||0.75% Ropivicaine (225 mg)|
89234309|NCT04000542|Experimental|Eligible Participants|Eligible Participants that consent will receive the pharmacist intervention.
89234310|NCT00999648|Experimental|Manual therapy|Myofascial trigger point pressure release
89234311|NCT00999648|Placebo Comparator|Control|Placebo myofascial trigger point pressure release
89234312|NCT04000698|Experimental|intervention/treatment|"Preparative chemotherapy before allogeneic HSCT~Fludarabin~Cytarabine~Venetoclax~Daratumomab~Vecanoid~treosulfan~fludarabine~thiophosphomide~Venetoclax~Plerixafor~abatacept~tocilizumab~rituximab~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
89234313|NCT00996294|Experimental|surgery|patients will be submitted to biliopancreatic diversion or gastric bypass
89234314|NCT01004016|Placebo Comparator|Placebo|
89234315|NCT01004016|Experimental|KPS-0373|
89234316|NCT04000932|Experimental|Platelet rich plasma (PRP) -T lab PRP kit|A single 1ml PRP extract injection will be will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel. performed once into the carpal tunnel in the wrist . PRP will be obtained by centrifugation of autologous anticoagulated whole blood.
89234317|NCT04000932|Active Comparator|Diprospan ®, Schering Plough|A single steroid injection (1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be injected into the carpal tunnel of the wrist in which a diagnosis of carpel tunnel syndrome has been established. A 23 gauge needle will used to perform the injection through the distal wrist creased into the carpal tunnel.
89234318|NCT01004094|Experimental|simple goal setting|This group will only set a goal.
89234319|NCT01004094|Experimental|goal setting plus action intentions|This group will set goals and form action intentions (plans) to facilitate goal attainment.
89234320|NCT01004094|Experimental|goal setting plus coping intentions|This group will set goals and form coping intentions (plans) to facilitate goal attainment.
89234321|NCT01004094|Experimental|goal setting plus action intentions plus coping intentions|This group will set goals, form action intentions (plans), and form coping intentions (plans) to facilitate goal attainment.
89234322|NCT00999882|Experimental|AZD8055|Dose escalation
89234323|NCT00996528|Experimental|Philani Intervention Program|
89234324|NCT00996528|No Intervention|Standard Care|No intervention during study. Referral to clinic-based health care that is delivered by the province. Offered intervention at end of study, i.e. after 18 months.
89234325|NCT05170230|Active Comparator|intracapsular myomectomy Terlipressin injection|intracapsular myomectomy Terlipressin injection in women undergoing laparoscopic myomectomy procedure
89234326|NCT05170230|Active Comparator|intracapsular myomectomy Carbetocin injection|intracapsular myomectomy Carbetocin injection in women undergoing laparoscopic myomectomy procedure
89234327|NCT05170230|Placebo Comparator|intramyometrial saline|intracapsular myomectomy saline injection in women undergoing laparoscopic myomectomy procedure
89234328|NCT00999960|Active Comparator|1: without simulator|without simulator
89234329|NCT00999960|Experimental|2: with simulator|with simulator
89234330|NCT01004328|Experimental|Intervention Group 1|All participants
89234331|NCT01000116|Active Comparator|Fibrin glue|
89234332|NCT01000116|Active Comparator|Tacks|
89234333|NCT00996684|Experimental|microplasmin, intravitreal injection|Subjects will receive one intravitreal injection of microplasmin on Day 0.
89234334|NCT00996684|Placebo Comparator|Placebo|Subjects will receive one intravitreal injection of the placebo on Day 0.
89234335|NCT00996762|Experimental|Part 1-3|2-period crossover, Period 1 (D1-7) will receive either the commercial formulation or the alternative formulation. Period 2 (D1-7) will receive the formulation not received in Period 1. There will be 3 parts with 3 different alternative formulations. Subjects will only participate in one part.
89234336|NCT05162196|Experimental|SBRT combined with Niraparib and Toripalimab|"Induction therapy (cyc1: D1-D28): Niraparib 200mg QD + SBRT 8Gy✖️3 QD, D4-D6 + Toripalimab 240mg iv drip D7~Maintenance (cyc2+): Niraparib 200mg QD, D1-D21 + Toripalimab 240mg iv drip D1, until disease progression or intolerable toxicity"
89234337|NCT04000464|Experimental|Single Arm|24 Week Lifestyle Modification intervention
89234338|NCT01000194|Experimental|High polyunsaturated fat meal|A high fat milkshake containing 55g of fat, mainly PUFA
89234339|NCT01000194|Experimental|High monounsaturated fat meal|A high fat milkshake containing 55g of fat, mainly MUFA
89234340|NCT01000194|Experimental|High saturated fat meal|A high fat milkshake containing 55g of fat, mainly SFA
88805936|NCT04236947|Experimental|SCPP-YA group|SCPP-YA adapted to Chile consist of ten sessions promoting self-regulation strategies, prosocial, and problem-solving skills. It also includes a module (6 sessions) specially designed for substance use prevention, developing social competence, and assertiveness to deal with peer pressure. These 16 sessions will be implemented during an academic year (2020), and complemented with three booster sessions the following year (2021).
88805937|NCT04236947|No Intervention|Control Group|The control schools will continue providing their traditional preventive actions.
89234341|NCT01004484|Active Comparator|Yogurt with probiotics and inulin|A probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving).
89234342|NCT01004484|Placebo Comparator|Placebo|Acidified dairy snack without yogurt cultures, probiotic or inulin.
89234343|NCT00997074|Experimental|ibuprofen|the group will receive 2 tablets of ibuprofen 400 mg at the time of misoprostol administration. The information about the effect of the analgesics on the pain, and on the course of medical abortion, will be prospectively gathered from questionnaires completed by the study participants
89234344|NCT00997074|No Intervention|placebo|this group will receive 2 placebo tablets together with the misoprostol
89234345|NCT00997308|Experimental|AZD1446 Low|Low dose of AZD1446
89234346|NCT00997308|Experimental|AZD1446 High|High dose of AZD1446
89234347|NCT00997308|Placebo Comparator|Placebo|
89234348|NCT01000584|Other|1|Group A: One dose of the licensed H1N1 vaccine and one dose of the seasonal influenza vaccine given concurrently
89234349|NCT01000584|Other|2|Group B: One dose of seasonal influenza vaccine given 3 weeks after administration of one dose of the licensed H1N1 vaccine
89234350|NCT01000740|Experimental|1|Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment
89234351|NCT01000740|No Intervention|2|Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP
89234352|NCT01000740|No Intervention|3|Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being
89234353|NCT05249712|Experimental|ADT with Darolutamide|"Pathological response rate after radical prostatectomy with dalotamide combined with androgen deprivation therapy (ADT) in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer.~Duration of treatment: 28-day cycle of darotamide treatment and 6 cycles of neoadjuvant therapy. ADT treatment continued during neoadjuvant therapy and was discontinued after surgery.~Adjusted dosing: When the serum testosterone concentration cannot be maintained at <50 ng/dL, the dose and type of ADT can be adjusted. Investigators can adjust the dose of darostatide according to the situation."
89234354|NCT01005030||PostCEPT Subjects|Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study
89234355|NCT01005030||Control Subjects|Non-blood relatives of PostCEPT Subjects matched for age and other demographics
89234356|NCT01000896|Experimental|AZD0530 + carboplatin and paclitaxel|AZD0530 in combination with carboplatin and paclitaxel
89234357|NCT00425061|Experimental|1|
89234358|NCT00425061|Experimental|2|
89234359|NCT00425061|Placebo Comparator|3|
89234360|NCT04000308|Experimental|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
89234361|NCT04000308|Active Comparator|Wound Infiltration|Patricipants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
89234362|NCT01005186|Experimental|Active|Active
89234363|NCT01005186|Experimental|Active 2|Active
89234364|NCT00997542|Active Comparator|Allopurinol|
89234365|NCT00997542|Placebo Comparator|Placebo|
89234366|NCT01001130||fluticasone furoate group|Korean patients administered fluticasone furoate according to the Prescription information
89234367|NCT01005264|Active Comparator|non-removable fiberglass|Softcast3M®, 3M Health Care, St. Paul, MN (USA) were used for construction of the pressure-relief apparatus
89234368|NCT01005264|Active Comparator|Stabil-D®|Composed of a specifically designed rigid, boat shaped, and fully rocker bottom sole
89234369|NCT00424827|Experimental|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
89234370|NCT01001286|Active Comparator|Youth Club|The intervention will be compared to a waitlist comparison group. The group will enter NFE after the four-month posttest. During the four months, the youth will be offered a biweekly recreational youth club. The club will be led by Jordanian university student volunteers out of community-based organizations. Club activities will take place approximately every two weeks, including games, sports, arts and crafts, cultural activities, and trips. The Club will not include any significant education components or youth empowerment methodology--the hypothesized active ingredients of QS NFE.
89234371|NCT01001286|Experimental|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
89234372|NCT01028625|Active Comparator|Cognitive Behavior Therapy|
89234373|NCT01028625|Other|Usual Care|Participants who are randomly assigned to usual care will receive whatever treatment (if any) for depression their own physician may prescribe. In most cases, treatment (if any is provided) is likely to consist of a serotonin reuptake inhibitor (SSRI) antidepressant such as sertraline or citalopram.
89234374|NCT01001364|Experimental|Formoterol/Budesonide|
89234375|NCT01001364|Active Comparator|Foraseq|
89234376|NCT03994185|Experimental|Group Treated with stent graft|This is a single arm study. All subjects will be treated with the WRAPSODY stent graft.
89234377|NCT03885726|Active Comparator|Treatment as Usual|
89234378|NCT03885726|Experimental|High Velocity Nasal Insufflation|
89234379|NCT03995277|Other|Healthy cohort - high dose|Apparently healthy subjects, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
89234380|NCT03995277|Other|Hypothyroid cohort|Subjects under thyroid medication, who take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).
89234381|NCT03995277|Other|Healthy cohort - low dose|Apparently healthy subjects, who take 50 µg/d of biotin at the same time each morning for 20 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), after 20 days of biotin supplementation (day 20), and 10 days after participants stopped taking biotin (day 30).
89234382|NCT01034319|Experimental|Diabetes Genetic Counseling|Subjects will have been genotyped and will received genetic counseling based on their results
89234383|NCT01034319|Placebo Comparator|No Genotyping or Counseling|Patients will not be genotyped and will therefore not receive genetic counseling
89234384|NCT00997776|Experimental|Exercise|High intensity lower extremity exercise
89234385|NCT00997776|Sham Comparator|Attention control|lower extremity TENS
89234386|NCT01034475|Experimental|CPI-613|CPI-240 mg/m2
89234387|NCT00997854|Active Comparator|Group 1 Bolus Feeds|This group will receive feeds administered by bolus method over no more than 30 minutes per feed.
89234388|NCT00997854|Experimental|Group 2- Slow Infusion Feeds|This group will receive feeds administered by slow infusion over pump for 2 hours.
88805938|NCT00299000|Other|Naglazyme, 1.0 mg/kg|Dose comparison
89138683|NCT02752932|Other|RMHNSCC -PDX drug testing|Participants with RMHNSCC who are under palliative treatment will be included in this group. Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX. Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists. Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.
89138684|NCT00886340|Active Comparator|Enhanced standard care|
89138685|NCT00886340|Experimental|Lifestyle counseling|
89138686|NCT02753010||Acute hip fracture|Women preoperatively with acute hip fracture with gastric emptying of carbohydrate-rich beverage
89138687|NCT02753010||Elective hip replacement|Women on waiting list for elective hip replacement with gastric emptying of carbohydrate-rich beverage
89138688|NCT02753010||Healthy volunteers|Healthy female volunteers with gastric emptying of carbohydrate-rich beverage
89138689|NCT02826746|Experimental|Magnesium group|intravenous administration of Magnesium Sulfate
89138690|NCT02826746|Placebo Comparator|Control group|intravenous administration of normal saline
89138691|NCT02750904|Experimental|Experimental therapy|
89138692|NCT02750904|Active Comparator|Control Therapy|
89138693|NCT02831972|Experimental|Period 1|A single oral dose of AG-120 will be administered at Hour 0 followed by PK sampling for 504 hours (21 days).
89138694|NCT02831972|Experimental|Period 2|In Period 2, multiple oral doses of itraconazole will be administered once daily (QD) for 18 consecutive days (Days -4 to 14) with a single oral dose of AG-120 coadministered at Hour 0 on Day 1. PK sampling for AG-120 will be taken for 504 hours (21 days) following AG-120 dosing on Day 1. PK sampling will also be collected for itraconazole and its metabolite, hydroxy-itraconazole, from Day -2 up to Day 13.
89138695|NCT02827760|Placebo Comparator|Maltodextrin DE19|Placebo
89138696|NCT02827760|Active Comparator|Prebiotic Synergy1|Effective prebiotic
89138697|NCT02695758|Active Comparator|interscalene brachial plexus block|Direct interscalene nerve block injection via brachial plexus
89138698|NCT02695758|Active Comparator|Bupivacaine extended-release liposome injection|Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
89138699|NCT04200950|Experimental|Intervention|Previse alert arm
89138700|NCT04200950|No Intervention|Control|No alert
89138701|NCT00605215|Placebo Comparator|Placebo|Participants will receive 1 capsule of placebo matching to laquinimod orally once daily for 24 months.
89138702|NCT00605215|Experimental|Laquinimod|Participants will receive 1 capsule of laquinimod 0.6 mg orally once daily for 24 months.
89138703|NCT00605215|Active Comparator|Avonex®|Participants will receive an injection of Avonex® 30 micrograms (mcg) given intramuscularly (IM) once weekly for 24 months.
89138704|NCT02827682|Experimental|study group|Using Angel-6000D Multiparameter Anesthesia Monitor to maintain the Hemodynamic stability during surgery. Keep IoC1 40 to 60 while IoC2 30-50.Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when IoC1<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when IoC2>50 but was decreased by 1 ng/ml per adjustment when IoC2<30, with the maintenance value between 30 and 50.
89138705|NCT02827682|Placebo Comparator|control group|Using BIS VISTA Monitor to maintain the Hemodynamic stability during surgery. Keep BIS 40 to 60.The doses of propofol and remifentanil were adjusted by the anesthetists according to BIS. Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when BIS<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when BIS>60 but was decreased by 1 ng/ml per adjustment when BIS<40, with the maintenance value between 40 and 60.
89138706|NCT04877262|Experimental|early time-restricted eating (eTRE)|Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 6-h window in the morning hours (e.g., 8:00 AM - 2:00 PM)
89138707|NCT04877262|Experimental|control eating schedule (CON)|Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 12-h window in the morning hours (e.g., 8:00 AM - 8:00 PM)
89138708|NCT04244474|Experimental|vitamin D3 supplementation|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) . Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
88805939|NCT00299000|Other|Naglazyme, 2.0 mg/kg|Dose Comparison
88805940|NCT01144949|Active Comparator|silodsosin|
88805941|NCT01144949|Placebo Comparator|placebo|
88805942|NCT00215930|Experimental|Double Agent Chemotherapy|Molecular Analysis-Directed Chemotherapy Assignment based on gene expression of ERCC1 and RRM1.
89138709|NCT04244474|Placebo Comparator|Placebo|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.
89138710|NCT05271474|Experimental|Intervention Arm|Participants will be assigned to use Sibel sensor and download the ANNE ONE platform to their mobile devices. The Sibel sensors are to be worn on the sternum and index finger and can be attached using provided replaceable gel adhesive. The Sibel sensors will transmit data to the ANNE ONE platform. The ANNE ONE platform will send automated alerts to the CRC via email when a patient is flagged as uncontrolled, which will occur when a patient's vitals reach or pass one of the safety thresholds.
89138711|NCT05271474|No Intervention|Control Arm|These patients will be followed by the Clinical Research Coordinator for CAT scores, emergency department visits and hospitalizations.
89138712|NCT05660876|Other|Fistulotomy|Standard fistulotomy was done in this arm
89138713|NCT05660876|Other|Fistulotomy with marsupialization|This arm consists of fistulotomy in which marsupialization was done
89138714|NCT04243382|Experimental|group 1|Autologous umbilical cord blood transfusion Single dose of an Autologous umbilical cord blood transfusion
89138715|NCT04243382|Experimental|group 2|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml,
89138716|NCT04218942|Experimental|Prospective non randomised feasibility study|
89138717|NCT00903799|Other|1|"Gastric electrical stimulation using Enterra Therapy. Device activated during 4 months then device in 'OFF' position the 4 following months.~After the cross-over period, device activated until the end of the trial"
89138718|NCT00903799|Other|2|"Gastric electrical stimulation using Enterra Therapy. Device in 'OFF' position during 4 months then device activated the 4 following months.~After the cross-over period, device activated until the end of the trial"
89138719|NCT00636012|Experimental|1|verum acupuncture
89138720|NCT00636012|Sham Comparator|2|sham acupuncture
89138721|NCT02826200|Experimental|Group 1 (SOC+OAT)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving single antiplatelet therapy plus oral anticoagulant therapy.
89138722|NCT02826200|Active Comparator|Group 2 (SOC)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving standard of care therapy.
89138723|NCT02750982|Experimental|Laughter therapy|effects of Laughter therapy (LT) on mood, self-efficacy and other wellness measures in people with neurological conditions.
89138724|NCT04754802|Experimental|PH94B|3.2 micrograms PH94B intranasal spray (100 microliters to each nostril) one time
89138725|NCT04754802|Experimental|Placebo|Placebo intranasal spray (100 microliters to each nostril) one time
89138726|NCT04244708|Experimental|Radiotherapy plus temozolomide|Undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day), followed by six cycles of adjuvant temozolomide.
89138727|NCT04244708|Placebo Comparator|Radiotherapy plus placebo|Radiotherapy treatment alone undergoing fractionated radiotherapy, total 54 Gy, 2GyX27, received placebo.
89138728|NCT02750748|Experimental|4mg Intranasal Naltrexone|Administer one 0.1 mL spray of a 40 mg/mL solution in one nostril
89138729|NCT02750748|Experimental|4mg Intranasal Naltrexone with Intravail|Administer 0.1 mL spray of a 40 mg/mL solution with 0.25% Intravail in one nostril
89138730|NCT02750748|Experimental|2mg Intramuscular Naltrexone|Administer 2 mg formulation intramuscularly
89138731|NCT02750748|Experimental|50mg Naltrexone|Administer 50mg formulation orally
89138732|NCT00604279|Experimental|Paliperidone palmitate|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
89138733|NCT00604279|Active Comparator|Risperidone long acting injection (LAI)|Risperidone LAI intramuscular at a dose of 25 milligram (mg) on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
89138734|NCT02826122|Active Comparator|FitBit APP|FitBit Zip APP registers and give feed-back on number of steps per day, distance and calories burned.
89138735|NCT02826122|Experimental|Pai APP|Mio Pai APP registers duration and intensity of the Activity and give feed back as activity Points.
89138736|NCT02827292|Experimental|Laparoscopic Surgery without music|Intervention: Headphones without music (Silent). A headphone will be applied peroperatively but no music will be played. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
89138737|NCT02827292|Experimental|Laparoscopic Surgery with music|Intervention: peroperative music via head phones. A headphone will be applied peroperatively and music will be played for the entire duration of the surgical procedure. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
89138738|NCT00906685|Active Comparator|Intravitreal bevacizumab|
89138739|NCT00906685|Sham Comparator|Sham injection|
89138740|NCT00938015||PsA Patients (New)|New patients
89138741|NCT00938015||PsA Patients|CU patients
89138742|NCT04244318|Experimental|Video Feedback ODISEA 2.0.|Once a week, the 5 session intervention of Video-feedback ODISEA 2.0 will be done with the family. In the first session, a play interaction between the child and the caregiver will be recorded for 10 minutes. The second session will be done between the therapist and caregivers, where they will watch different selected parts of the video, and will provide feedback through a mentalization constructed framework. Then, in the third session another play interaction video will be recorded, that will be discussed on the fourth session with the caregiver. Finally, in the fifth session a final interaction video will be recorded.
89138743|NCT04244318|No Intervention|Control Group.|Patients in control group will be placed as a non intervention group. After collecting the post-test data, they will be offered the same intervention than the experimental group.
89138744|NCT04679532|Other|Validation. Gx sweat collection patch|Left ventral forearm placement using Epicore Biosystems Gx patch
89138745|NCT04679532|Other|Validation. Reference sweat collection patch|Right ventral forearm placement using a well-established methodology as published in peer-reviewed journals
89138746|NCT02826278||Healthy female newborns|Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances
89138747|NCT00906763|Active Comparator|Dark Chocolate (85% cocoa)|Oral Intake of dark chocolate (85% cocoa) over 15 minutes.
89138748|NCT00906763|Active Comparator|White chocolate (0% cocoa)|Oral intake of 200 grams of white chocolate (0% cocoa) over 15 Minutes.
89138749|NCT02746926|Experimental|4x20 mg tafamidis meglumine soft gel capsule|
89138750|NCT02746926|Experimental|48.8 mgA tafamidis free acid capsule|
89138751|NCT02746926|Experimental|61 mgA tafamidis free acid capsule|
89138752|NCT04266743|Experimental|Hemiparetic patient|patients who had a stroke at least 6 months before inclusion
89138753|NCT05660720|Experimental|Orelabrutinib tablet 150 mg (study drug) and placebo 250 mg (orelabrutinib tablet simulator)|The subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.
89138754|NCT05660720|Experimental|Orelabrutinib 400 mg (study drug)|The subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.
89138755|NCT05660720|Placebo Comparator|Placebo 400mg (orelabrutinib tablet simulator)|The subjects will be dosed once on Day1 or Day6 or Day11 or Day16according to randomization.
89138756|NCT05660720|Active Comparator|Moxifloxacin hydrochloride 400 mg|he subjects will be dosed once on Day1 or Day6 or Day11 or Day16 according to randomization.
89138757|NCT05277883||Group|All patients scheduled for a total knee arthroplasty without any previous lower limb deformities or previous hip/knee surgery will be enrolled. A long leg standing x-ray and a CT scan of the lower limb will be obtained for every patient.
89138758|NCT02695212|Experimental|Apremilast ( open label)|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
89138759|NCT00903955||Chronic Obstructive Pulmonary Disease|Subjects diagnosed with COPD are classified according to standards set forth by the Global Initiative on Obstructive Lung Disease. This study recruits subjects in each of three GOLD categories.
89138760|NCT05381207|Active Comparator|Montelukast|Montelukast, 10 mg, oraly Local corticosteriod nasal spary
89138761|NCT05381207|No Intervention|No drug|No drug taking , only local corticosteriod nasal spray
89138762|NCT02824640|Active Comparator|Patient Navigation|"The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.~Health Promotion Sessions: PNs will deliver 4 standardized health promotion sessions to all patients either individually or within a group.~Optional Weekly Support Groups: Subjects randomized to the PN arm will be offered weekly support groups led by Peers."
89138763|NCT02824640|Active Comparator|modified Directly Observed Therapy|"OAT clinic setting: Observation of HCV medications will be linked to methadone visits among patients receiving methadone. Patients will be receiving methadone as part of routine clinical care for opioid addiction and not as an intervention related to this study. The schedule of five days per week will be considered modified DOT (mDOT). Subjects will initiate HCV treatment on Mondays if feasible. Take home medications will be packed in a weekly electronic blister pack.~Community health clinic setting: This intervention is considered modified DOT (mDOT) since between 3-5 weekly doses will be directly observed. A minimum of one dose will be observed in person by clinic/study staff. For the remaining observed doses, the research staff and provider will present the participant with a menu of options and determine what will work best for that participant."
89138764|NCT02750670|Experimental|GD2P|Obinutuzumab 1000mg by IV for 1.5-6.5 hours with Gemcitabine 1000mg/m^2 by IV for 30 minutes with dexamethasone 40mg by mouth daily and Cisplatin 75mg/m^2 by IV for 1 hour all for a duration of 3 cycles
89138765|NCT00605891|Experimental|A|carmoterol (CHF 4226) 1.0 μg once a day, in the morning
89138766|NCT00605891|Experimental|B|carmoterol (CHF 4226) 2.0 μg once a day, in the morning
89138767|NCT00605891|Experimental|C|carmoterol (CHF 4226) 4.0 μg once a day, in the morning
89138768|NCT00605891|Placebo Comparator|D|Placebo once a day, in the morning
89138769|NCT00605891|Active Comparator|E|Salmeterol 50 μg BID, in the morning and in the evening
89138770|NCT05007704||Anesthesiologists for preliminary survey|Anesthesiologists who have completed their training within the last three years to identify preliminary competencies for Delphi round one survey.
89138771|NCT05007704||Global Experts in Anesthesiology and Critical Care Medicine|Anesthesiologist (a medical graduate who has completed a nationally recognized Anesthesiology training programme) involved in the management of critically ill patients in ICU and have more than ten years of experience in teaching and training in Critical Care. They will be involved in the Delphi process to generate expert consensus on the additional competencies (mandatory desirable and optional) required for Anesthesiologists to practice Critical Care in the Intensive Care Unit (ICU).
89138772|NCT02695602|Experimental|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|Turbinoplasty using microdebrider turbinate blade (2.9mm inferior turbinate blade, Medtronic, 5000 Hz)
89138773|NCT02695602|Experimental|Submucous Resection (SMR)|Turbinoplasty using non-powered instruments
89138774|NCT05122208||Famotidine Group|Patients who were administered Famotidine 160 mg/day PO or nasogastric.
89138775|NCT05122208||Control Group|Patients who were not administered Famotidine
89138776|NCT02825888||Non-obese|Body Mass index less than 30 kg/m2
89138777|NCT02825888||Obese|Body Mass index more than 30 kg/m2
89138778|NCT00631241|Experimental|Intraoperative Lymphatic Mapping|Single Photon Emission Computed Tomography - First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients. Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
89138779|NCT00781911|Experimental|Carcinoid tumor|Participants with carcinoid tumor will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
88805943|NCT01145183|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
89234389|NCT04000386|Experimental|zinc oxide nanoparticles coated socks|62 patients with zinc oxide nanoparticles coated socks
89234390|NCT04000386|Placebo Comparator|placebo|62 patients with placebo socks
89234391|NCT00998088|Experimental|Erythropoietin|
89234392|NCT00998088|No Intervention|Control arm|
89138780|NCT00781911|Experimental|Islet cell carcinoma|Participants with islet cell carcinoma will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
89138781|NCT00605917||Sertraline hydrochloride.|The patients of Panic disorder taking Sertraline hydrochloride.
89138782|NCT04242056|Other|Using image to diagnosis Multiple sclerosis (MS)|In current study, we will enroll 38 patients with MS and evaluate their clinical severity; measure the WM lesion and disease activity by magnetic resonance imaging (MRI); myelination state and amyloid deposition by amyloid PET scan; tau deposition by state of-art tau PET scan
89138783|NCT04919096|Experimental|SCB-420|Subjects randomized to SCB-420 will receive SCB-420 2mg (0.05 mL) via intravitreal injection in the study eye every 4 weeks for the first 3 months.
89138784|NCT04919096|Active Comparator|Aflibercept|Subjects randomized into Aflibercept (Eylea) group will receive Aflibercept (Eylea) 2 mg (0.05 mL) via intravitreal injection in the study eye every 4 weeks for the first 3 months.
89138785|NCT04585386|Experimental|ATLAS|"Medical device named ATLAS which is an active corset (rigid lumbar restraint) and connected."
89138786|NCT04585386|Active Comparator|Standard lumbar support belt|Standard lumbar support belt : LombaSkin® or Lombogib®
89138787|NCT02690285|Other|Part 1: glutathione transferase zeta 1 (GSTZ1) haplotyping|The participants will have blood collection and cheek cell collection after signing the informed consent, to determine GSTZ1 haplotype.
89138788|NCT02690285|Experimental|Part 2: Dichloroacetate (DCA) Kinetics|Eight study participants will be administered oral Dichloroacetate (DCA) 25 mg/kg daily for 5 days. On the fifth day frequent blood samples will be obtain over the following 24 hours. Study participants will complete a DCA kinetic study on day 5, at the Clinical Research Clinic (CRC).
89138789|NCT02746848|Experimental|Patients with cornea injury|Patients with cornea injury who received healing Amniotic Membrane Extract Eye Drop.
89138790|NCT05381051||original cohort|In the original cohort, 314 patients had catheter implantation between 1st Jan, 2005 to 31st Dec 2009. 269 patients started PD and followed up in our center. 26 patients were excluded due to missing baseline peritoneal membrane function data. 243 patients (n=243, age 53.2±16.3 year) entered the analysis.
89138791|NCT05381051||validation cohort|The validation cohort started PD from 2015 to 2018. It was originally designed for a 12 month observational study around fluid balance. 187 patients were in the validation cohort (age 53.0±15.9 year).
89138792|NCT02824484|Experimental|Guided Written Disclosure Protocol|GWDP consists of three 20-minutes writing sessions. Participants write every two weeks at home following the specific instructions for each session.
89138793|NCT02824484|Placebo Comparator|Control|Control condition consists of three 20-minutes writing sessions. Participants write every two weeks at home following the instructions. Their task is constructed to be emotionally neutral.
89138794|NCT00781599|Active Comparator|1|Chantix for 3 months and Standard Counseling
89138795|NCT00781599|Experimental|2|Chantix for 3 months and Adherence Counseling
89138796|NCT04266899|Experimental|FDS+Treadmill gait training|Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Treadmill gait training during two weeks.
89138797|NCT02826044|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
89138798|NCT02826044|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
89138799|NCT02826044|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
89138800|NCT00899041|Active Comparator|Standard knee prosthesis|'standard' knee prosthesis (Sigma FB, J&J, UK).
89138801|NCT00899041|Active Comparator|High flexion knee prosthesis|'high flexion' knee prosthesis (Sigma RP-F, J&J, UK).
89138802|NCT04468074|Experimental|Therapy Group|"Therapy Group participants start the treatment period with three 1 ½ hour introductory sessions:~An education session on the science behind chronic pain and a basic overview of the VR therapy.~A session to customize the VR experience to match the participant's own pain experience.~A training session on the use of the VR hardware and software.~Upon completion, participants begin using the VR therapy app at home once a day, 5 times a week (minimum), for a total of 8 weeks. The VR app contains different training exercises. A workbook provides a schedule and background on each of the training sessions.~Therapy Group participants may continue their other pain treatment regimes, and are asked to notify the research team of any changes."
89138803|NCT04468074|No Intervention|Standard of Care (SOC) Group|The SOC Group (no-intervention) completes a daily pain survey. SOC Group participants are asked to maintain their pain treatment regimes, and are asked to notify the research team of any changes.
89138804|NCT04266587|Experimental|Healthy volunteers|blood sampling is done on healthy volunteers
89138805|NCT00605839|Experimental|Glucopak Care|Glucopak cell phone and intensive monitoring. This group will be given the experimental device, and placed in close communication with the clinic.
89138806|NCT00605839|Active Comparator|Cell Phone Care|Cell phone only, without the Glucopak. Participants will be given cell phones and encouraged to communicate more closely with the clinic, but will not use the Glucopak.
89138807|NCT00605839|Placebo Comparator|Usual Care|Usual care, without cell phone or glucopak
89138808|NCT02746614|Active Comparator|Psychomotor Therapy & Adaptive Behavior|After the initial assessment of adaptive behavior, i.e.., set of skills that each individual with intellectual disability should train to cope with environmental demands, a Psychomotor Intervention Program was designed specifically. The program integrated individual and group sessions during 3 months, and the main goals of the program were related to independent functioning, motor development, economic and professional activities, academic and verbal skills.
89234393|NCT00998088|Experimental|cell saver|
89234394|NCT00998088|Experimental|drain|
89138809|NCT02746614|Active Comparator|Psychomotor Therapy & Motor Proficiency|Motor Proficiency After the initial assessment, a Psychomotor Intervention Program was designed specifically for participants with IDD. This program integrated individual and group sessions during 3 months, and the main goals of the program were related to motor coordination (balance, manual dexterity and coordination, global and fine praxis).
89138810|NCT00906841|Experimental|90Y-DOTA-hLL2|Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
89138811|NCT00605969|Active Comparator|FAI patients|This group consists of participants diagnosed with femoroacetabular impingement that are undergoing surgical correction.
89138812|NCT00605969|Placebo Comparator|Control|This group consists of healthy control participants with no hip problems.
89138813|NCT02746770|Experimental|Cawthorne and Cooksey exercises group|Intervention: Participants allocated in both control and experimental groups were receiving treatment for their specific vestibular disorders. Patients assigned to the experimental group also performed the Cawthorne and Cooksey exercises for vestibular rehabilitation during a six week of treatment period.
89138814|NCT02746770|No Intervention|control group|intervention: The control group will not perform the active exercise that will be applied to intervention group.
89138815|NCT02539147||patients with severe sepsis|blood samples from patients with severe sepsis
89138816|NCT02746692|Experimental|Intervention|
88805944|NCT01145183|Placebo Comparator|Placebo|Matched placebo daily dosing.
88805945|NCT04183673|Experimental|Laser-cryo-usual care|Sessions 5 days a week for 3 weeks. Each session includes laser therapy+ cryo-thermal followed by standard rehabilitation program
89138817|NCT02746692|Active Comparator|Comparison|
89138818|NCT00603005|Experimental|1|
89138819|NCT00603005|Experimental|2|
89138820|NCT00603005|Experimental|3|
89138821|NCT00603005|Experimental|4|
89138822|NCT02750436|Experimental|Ultrasound guided|Ultrasound guided sacral lateral branch block
89138823|NCT02750436|Active Comparator|Fluoroscopy guided|Fluoroscopically guided sacral lateral branch block
89138824|NCT00904111|Experimental|Lidocaine 5% Patch|Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)
89138825|NCT00904111|Placebo Comparator|Placebo Topical Patch|Matching placebo patch, 2 patches applied directly to the most painful area of the low back once daily (q24h)
89138826|NCT05380895||SVT group|Varicose vein patients complicated with superficial thrombophlebitis
89138827|NCT05380895||Non-SVT group|Patients had varicose vein only
89138828|NCT02750280|Experimental|Urinary Bladder matrix (UBM)|UBM covered with silicone foam dressing plus total contact cast
89138829|NCT02750280|Active Comparator|Standard Care|Silicone foam dressing plus total contact cast
88805946|NCT04183673|Active Comparator|usual care|Sessions 5 days a week for 3 weeks. Each session includes only standard rehabilitation program
89138830|NCT00781365|No Intervention|Control|Patients in the control group will receive usual care from their primary care physicians at HealthPartners Medical Group clinics.
89138831|NCT00781365|Experimental|Telemonitors and pharmacy management|The telemonitoring intervention (TI) patients will receive a home blood pressure telemonitor and will work with a clinical pharmacist case manager to control elevated blood pressure. Patients will use their home telemonitors to read and send their blood pressures to their Pharmacist case manager, who will use phone meetings with the patient to make medication adjustments.
89138832|NCT03912636|Active Comparator|Diaphragmatic breathing in healthy volunteers in study1|Healthy volunteers will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
89138833|NCT03912636|Active Comparator|Diaphragmatic breathing in rumination patients in study1|Rumination patients will perform diaphragmatic breathing, and the investigators will investigate changes of cardiac vagal tone.
89138834|NCT03912636|Active Comparator|Deep slow breathing in healthy volunteers in study1|Healthy volunteers will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
89138835|NCT03912636|Active Comparator|Deep slow breathing in rumination patients in study1|Rumination patients will perform deep slow breathing, and the investigators will investigate changes of cardiac vagal tone.
89138836|NCT03912636|Placebo Comparator|Normal breathing in healthy volunteers in study1|healthy volunteers will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
89138837|NCT03912636|Placebo Comparator|Normal breathing in rumination patients in study1|rumination patients will perform normal breathing, and the investigators will investigate changes of cardiac vagal tone.
89138838|NCT03912636|Active Comparator|Diaphragmatic breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
89138839|NCT03912636|Active Comparator|Deep slow breathing in study 2; cross over test|Rumination patients will perform diaphragmatic breathing in randomized cross-over test. The investigators will compare the effects on rumination.
89138840|NCT03240211|Experimental|Arm A: Pembrolizumab plus Pralatrexate|Subjects will receive pembrolizumab 200 mg IV day 1 with pralatrexate 30 mg/m2 IV day 1, 8, and 15.
89138841|NCT03240211|Experimental|Arm B: Pembrolizumab plus Pralatrexate plus Decitabine|Subjects will receive pembrolizumab 200 mg IV day 8 with pralatrexate 20 mg/m2 IV day 1, 8, and 15 and decitabine 10 mg/m2 from day 1 to 5 ( or day 1 to 3, depending on dose level).
89138842|NCT03240211|Experimental|Arm C: Pembrolizumab plus Decitabine|Subjects will receive pembrolizumab 200 mg IV and decitabine 20 mg/m2 from day 1 to 5 (or day 1 to 3, depending on dose level).
89138843|NCT04103229|Experimental|10 ml sterile distilled water|The indwelling urinary catheterization was inflated with 10 ml sterile distilled water (SDW) of the balloon.
89138844|NCT04103229|Experimental|15 ml sterile distilled water|The indwelling urinary catheterization was inflated with 15 ml sterile distilled water (SDW) of the balloon.
89138845|NCT04103229|Experimental|10 ml 0.9% sodium chloride (NaCL)|The indwelling urinary catheterization was inflated with 10 ml 0.9% sodium chloride (NaCL) of the balloon.
89138846|NCT04103229|Experimental|15 ml 0.9% sodium chloride (NaCL)|The IUC was inflated with 15 ml 0.9% sodium chloride (NaCL) of the balloon.
89234395|NCT00998088|Experimental|Erythropoietin and cell saver|
89234396|NCT00998088|Experimental|Erythropoietin and drain|
89138847|NCT00603083|Active Comparator|A|This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.
89138848|NCT00603083|Placebo Comparator|B|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.
89138849|NCT02827058|Experimental|G25 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 25 gauge pencil point needle
89138850|NCT02827058|Active Comparator|G27 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 27 gauge pencil point needle
89138851|NCT00906919|Active Comparator|Regular diabetes patient education|Regular professionally-led diabetes patient education
89138852|NCT00906919|Experimental|Augmented Diabetes Patient Education|Regular professionally-led diabetes patient education augmented by participation in the Stanford Chronic Disease Self-Management Program
89138853|NCT05379257|Experimental|Random dose|Random dosage and timing of furosemide
89138854|NCT02695836|Active Comparator|Standard feedback|Facilities in this arm will receive an initial face-to-face dissemination workshop that includes feedback of research data on modifiable aspects of their microsystem context but no goal setting.
89138855|NCT02695836|Experimental|Basic assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive a face-to-face goal setting workshop focused on modifiable areas of their microsystem context and two virtual support workshops at six month intervals.
89138856|NCT02695836|Experimental|Enhanced assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive an additional face-to-face goal setting workshop focused on modifiable areas of their microsystem context, two additional face-to-face support workshops at six month intervals plus on-demand email and telephone support.
89138857|NCT04241900|Experimental|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
89138858|NCT04241744|Active Comparator|vancomycin oral solution|vancomycin oral solution will be administered to consented patients >65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
89138859|NCT04241744|Placebo Comparator|placebo oral solution|placebo oral solution will be administered to consented patients >65 years of age receiving IV antimicrobial(s) for a bacterial infection twice daily while hospitalized.
89138860|NCT02746536|Experimental|Slow chest compression|Patients will receive the slow chest compression for one minute, immediately after 6MST.
89138861|NCT02746536|Placebo Comparator|No slow chest compression|Immediately after 6MST, the patient will not receive the SCC and will remain seated at rest for one minute, without any intervention.
89138862|NCT04218630|Experimental|Reformer pilates group|All participants were informed about the reformer machine and the treatment program by the physiotherapist in reformer pilates group. Reformer pilates exercises were applied in the form of general muscle strengthening and flexibility exercises under the supervision of physiotherapist. Exercises were performed in 2 times a week for 6 weeks. The duration of one session was 60 minutes.
89138863|NCT04218630|Active Comparator|Home mat pilates group|In home mat pilates group, clinical pilates exercises were applied as a home program. Brochures and exercise follow-up forms, which illustrated and written all the exercises in this program, which consisted of clinical pilates-based general muscle strength and flexibility exercises, were given to all participants in this group. Exercises were performed in 2 times a week for 6 weeks at home. Participants marked the follow-up form when they performed exercises. Attendance of participants to exercise was checked by phone calls.
89138864|NCT00780975|Experimental|Arm 1|Aplidin (Plitidepsin)
89138865|NCT02824250|Experimental|MBSR + Usual Care|8-week standard Mindfulness-Based Stress Reduction (MBSR) course + standard of care
89138866|NCT02824250|No Intervention|Usual Care|Standard of care
89138867|NCT04204031|Other|Presentation of the adherence record|"Following a first observation period of 15 days, participants whose actual time of use will be less than prescribed will be offered an intervention which will consist of a presentation of the adherence record. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.~Only participants with an actual time of use less than prescribed will be offered this intervention and will continue the monitoring over a period of 15 additional days."
89138868|NCT04217460|Active Comparator|Intervention for fluency difficulty (controls)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for controls.
89138869|NCT04217460|Experimental|Intervention for fluency difficulty (experimental)|Behavioural intervention (children practice speaking specially constructed non-word materials). Intervention is the same for both arms, here this is for experimental group
89138870|NCT00899587|Experimental|Oxygen|
89138871|NCT00899587|Experimental|Enalapril|
89138872|NCT00899587|Placebo Comparator|Control|
89138873|NCT04268069|Placebo Comparator|Placebo Ophthalmic Solution (vehicle)|vehicle
89138874|NCT04268069|Active Comparator|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution
89138875|NCT02538913|Experimental|Exercise training|Patients randomized to the exercise training group will be individually instructed in correct pelvic floor muscle contractions and intensive pelvic floor muscle training to perform daily. In addition they will be encouraged to exercise regularly ≥3 days/week. The exercise program will be individualized and consisting of both aerobic and strength exercise training.
89138876|NCT02538913|Active Comparator|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
88805947|NCT00230126|Active Comparator|A erlotinib 150 mg|erlotinib 150 mg/day cycles 1 - 3
88805948|NCT00230126|Experimental|B erlotinib modified according to weight|erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
89138877|NCT04218474|Other|patient lost sensation ant half of lower lip|patient with injured inferior alveolar nerve at one side
89138878|NCT02824406||Patients|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
89138879|NCT02824406||Controls|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
89138880|NCT04267679|Experimental|Cannabidiol|Participants will take 25 mg full-spectrum CBD soft gel capsules (2 to 4 per day) for 12 weeks.
89138881|NCT04251312|Experimental|Preoperative dental hygiene education|Patients who are scheduled for elective esophageal or lung resections who consent to participate will undergo oral hygiene education and be given an oral hygiene packet. An oral hygiene assessment using the Plaque Assessment tool will be conducted in the clinic. A Dysphagia Screening Tool questionnaire will also be administered. Patients who screen positive for dysphagia will be referred to Speech Pathology for evaluation but for the study purposes, the only data collected from the evaluation will be whether or not the participant received this intervention. A repeat dental exam will occur on the day of surgery. Patients will be followed for 30 days post operatively.
89138882|NCT04951388|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89138883|NCT04951388|Placebo Comparator|MVC-COV1901(Saline)|Saline/0.5 mL
89138884|NCT04205526|Experimental|Active rTMS|Sub-acute stroke patients will be randomized to receive actual rTMS treatment. 1Hz rTMS will be applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
89138885|NCT04205526|Sham Comparator|Sham control|Sub-acute stroke patients randomized to receive sham rTMS. For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
89138886|NCT04035265|Active Comparator|pain+ / synovitis +|SLE patients with inflammatory pain and synovitis determined by the practitioner during physical examination of radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP. Defining synovitis as pain and inflammation and/or deformity (present or existing over the past year) included in the clinical history
89138887|NCT04035265|Active Comparator|pain + / synovitis -|SLE patients with inflammatory pain without determined synovitis. Current (or over the past year) pain in radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP, with no synovitis
89138888|NCT04035265|Active Comparator|pain - / synovitis -|SLE patients without inflammatory pain with normal physical examination currently or over the past year
89138889|NCT04035265|Placebo Comparator|healthy|control patients (healthy participants: no pain, no SLE, no family affected by systemic inflammatory disease, a blood test with no elevation APR or autoimmunity +)
89138890|NCT04242914|Experimental|Research: Ketamine + Midazolam|Research group will receive ketamine and midazolam.
89138891|NCT04242914|Experimental|Control: Midazolam|Control group will receive midazolam.
89138892|NCT00780273|Experimental|Ankylos dental implants.|"3 Ankylos dental implants placed in platform switch configuration on one side of the mandible in support of a fixed restoration.~A total number of 19 subjects participated in this randomized, split mouth, masked, prospective, open, comparison, monocenter study. Participants were subjects with an edentulous mandible who recieved 3 implants on each side which were splinted for the delivery of a fixed prosthesis."
89138893|NCT00780273|Active Comparator|3i Prevail dental implants.|"Three 3i Prevail dental implants placed on the opposite side of the mandible from the Ankylos implants in support of fixed dental restoration.~After a baseline phase of 1 month the mandible sides of subjects were randomly assigned to one of the 2 parallel treatment groups: one side received ANKYLOS plus implants. The contralateral sde recieved Certain PREVAIL Implants. Abutments were installed and loaded immediately by a fixed temporary bridge. After 3 months the final prosthesis was incorporated."
89138894|NCT00904501|Placebo Comparator|A|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL). A placebo cell-product (30 mL saline with 4 ml peripheral blood) is implanted and the BM-MNC are cryo-conserved. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted. After 6 months, it is possible to use previously cryo-conserved BM-MNC.
89138895|NCT00904501|Experimental|B|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL) . The BM-MNC are implanted on the same day. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted
89138896|NCT02827136|Experimental|Patch group|Lidocaine patch and Hypafix
89138897|NCT02827136|Placebo Comparator|Control group|Just Hypafix
89138898|NCT04102995|Experimental|Sepranolone (UC1010) low dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
89138899|NCT04102995|Experimental|Sepranolone (UC1010) high dose|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
89138900|NCT04102995|Placebo Comparator|Placebo|Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine
89138901|NCT02825498|Experimental|Operator guided by contact force|Operator has full access to contact force parameters including force time integral (FTI).
89138902|NCT02825498|No Intervention|Operator blinded to contact force|Operator is blinded to contact force with ablation guided by standard markers of effective ablation.
89138903|NCT04102683|Experimental|Intervention Group|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
89138904|NCT04102683|No Intervention|Control Group|
89234397|NCT03994341||NEC Group|Infrared images of the abdomen, timed at handling. A FLIR Thermovision a320M thermal IR camera bound with an Microsoft Kinect RGB-D sensor system connected to a laptop will be used. Both imaging technologies are non-invasive and represent no risk to the subject. The thermal images record the temperature distribution, the Kinect sensor will acquire color image and depth image that will be used to segment the subject from the background bedding surface. All three sets of images will be collected in synchronization. Thermography requires period of slight cooling of the skin surface to stabilize the body surface temperature. The room temperature will be maintained slightly below thermoneutrality. Thermographic camera will be positioned about 60-70 cm above the baby.
89234398|NCT03994341||Normal Group|Same procedure for both experimental and active comparator.
89234399|NCT00377962|Experimental|Everolimus + CNI reduction|Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level < 75 ng/mL or a tacrolimus trough level < 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.
89234400|NCT00377962|Active Comparator|Control|CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.
89234401|NCT00424749|Experimental|Rituximab|375 mg/m^2/week for 4 weeks
89234402|NCT01031745|Experimental|Contingency|
89234403|NCT01031745|Active Comparator|Control|
89234404|NCT01048294|Active Comparator|Standard Light Treatment|30 min of Standard bright light treatment (color 5000K)
89234405|NCT01048294|Experimental|Blue enriched Light treatment 20 min|20 minutes of Blue enriched light treatment (color 17000K)
89234406|NCT01048294|Experimental|Blue enriched light treatment 30 min|30 minutes of Blue enriched light treatment (color 17000K)
89234407|NCT03246022||Group l|SBP index was less than 30% of AHI
89234408|NCT03246022||Group 2|SBP index was less than 60% but more than 30%
89234409|NCT00424593|Experimental|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
89234410|NCT00424593|Placebo Comparator|Placebo|every day (QD), by mouth (PO), 13 weeks
89234411|NCT01031823|Experimental|Social Skills Training|All participants will take part in this arm of the study.
89234412|NCT00369382|Active Comparator|1|Group 1: Continuation of CNI regimen
89234413|NCT00369382|Experimental|2|Group 2: (CNI-Free) Conversion to SRL-based regimen
89234414|NCT01324648|Experimental|TG + GP TAU|
89234415|NCT01324648|Experimental|UG + GP TAU|
89234416|NCT01324648|Active Comparator|GP TAU|
89234417|NCT00424515|Experimental|Treatment Arm|Imatinib
89234418|NCT01581112|Experimental|Heavy armpit odour|Subjects with heavy armpit odour.
89234419|NCT01581112|Experimental|Heavy foot odour|Subjects with heavy foot odour.
89234420|NCT01028703||Donors|"110 will be cases that undergo uninephrectomy"
89234421|NCT01028703||Controls|"110 controls"
89234422|NCT03994263|Experimental|iTind arm|ITind device implant
89234423|NCT00377260|Experimental|Amoxicillin-clavulanate|Reconstituted amoxicillin-clavulanate at 90/6.4 mg/kg/day in 2 divided doses for 10 days.
88805949|NCT01169519|Active Comparator|Sildenafil|Pharmacokinetic and hemodynamic evaluation following sildenafil administration
88805950|NCT02103608|Experimental|Percentage of hair reduction|This is an open label, prospective study to evaluate safety and efficiency of Silk'n Glide on the face. During the study, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment .
89234424|NCT00377260|Placebo Comparator|Placebo|Reconstituted placebo in 2 divided doses for 10 days.
89234425|NCT00441441|Experimental|Fluticasone propionate/salmeterol 100/50 HFA|Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily
89234426|NCT00441441|Experimental|Fluticasone propionate 100mcg HFA|Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily
89234427|NCT01048372||Early HIV infection|HIV infected adults with early evidence of suppressed cell-mediated immunity but whose disease has not progressed far enough to indicate antiretroviral therapy.
89234428|NCT01048372||Control|Healthy adults without HIV infection.
89234429|NCT00436917|Experimental|zoledronic acid|4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.
89234430|NCT00436605|Experimental|Treatment (kinase inhibitor therapy)|Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89234431|NCT01034787|Experimental|Open Label CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of every 90-day cycle for up to 4 cycles or until disease progression or intolerance of toxicity.
89234432|NCT02910999||NSCLC patients with squamous tumor histology|
89234433|NCT02910999||NSCLC patients with non-squamous tumor histology|
89234434|NCT01323543|Experimental|Elaspine™|Impantation of Elaspine™ device
89234435|NCT01028781|Other|Thalidomide|Thalidomide was administered and pain reports were recorded over the course of 6 months.
89234436|NCT01031901|Placebo Comparator|TSC Placebo Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas
89234437|NCT01031901|Experimental|TSC 1% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas
89234438|NCT01031901|Experimental|TSC 5% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas
89234439|NCT01031901|Placebo Comparator|NF1 Placebo Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas
89234440|NCT01031901|Experimental|NF1 1% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas
89234441|NCT01031901|Experimental|NF1 5% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas
89234442|NCT00368992|Experimental|Treatment (cetuximab, paclitaxel, bevacizumab)|"INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
89234443|NCT00376246|Other|Group 1|1st group will receive Ezetimibe for 2 weeks followed by washout (no medication) period for 4 weeks and followed by placebo for 2 weeks.
89234444|NCT00376246|Other|Group 2|2nd group will receive Ezetimibe and placebo in reverse order with interspaced 4-week washout period.
89234445|NCT00368836|Experimental|BreathScreen PE + D-dimer|CO2/O2 ratio will be measured using the Breath Screen PE device. D-dimer levels will also be collected.
89234446|NCT03992716|Experimental|SmofKabiven® extra Nitrogen|Parenteral nutrition with SmofKabiven® extra Nitrogen in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
89234447|NCT03992716|Active Comparator|Olimel N9E|Parenteral nutrition with Olimel N9E in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.
89234448|NCT01050010|Other|Dedicated extremity MRI|Structural deterioration radiographic assessed by dedicated extremity MRI
89234449|NCT01050088|Experimental|Sucrose|5cc sucrose solution
89234450|NCT01050088|Placebo Comparator|Saline|5cc saline p/o
89234451|NCT00376168|Experimental|prGCD 30 Units/kg|
89234452|NCT00376168|Experimental|prGCD 60 Units/kg|
89234453|NCT00375934|Experimental|1|
89234454|NCT00375934|Placebo Comparator|2|
89234455|NCT01052584|Experimental|Chloroquine-P. vivax|P. vivax randomized to receive chloroquine 3-day regimen
89234456|NCT01052584|Experimental|Artemether-Lumefantrine: P. vivax|
89234457|NCT01052584|Experimental|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
88805951|NCT04071977|Active Comparator|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
88805952|NCT04071977|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 28 patients with proliferative diabetic retinopathy (PDR) who will undergo vitrectomy.
89234458|NCT01050166||Labeled islets|Type 1 diabetic recipients after islet transplantation with islets labeled by iron contrast agent
89234459|NCT01050244|Experimental|Soy Protein|30g of soy protein from whole soybean soymilk powder given daily for 3 weeks
89234460|NCT01050244|Placebo Comparator|Milk Protein|30g of milk protein from whole milk powder given daily for 3 weeks
89234461|NCT02534506|Experimental|Urelumab (+ Nivolumab) intravenous (IV) infusion|
89234462|NCT01050322|Active Comparator|Capecitabine Lapatinib|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
89234463|NCT01050322|Experimental|Vinorelbine Lapatinib|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
89234464|NCT01050322|Experimental|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
89234465|NCT01048450|Experimental|Treatment|Those who were diagnosed with hallux limitus/rigidus (end stage degeneration at the 1st metatarsal phalangeal joint)
89234466|NCT01048528|Experimental|Stress Management|Stress Management and Relaxation Training workshops
89234467|NCT01048528|No Intervention|Wait-list|Wait-list comparison group
89234468|NCT03990844|Placebo Comparator|0% Okra seed noodle|In this arm, subjects will consume noodles made with 0% okra seed. This serves as a control arm for the study.
89234469|NCT03990844|Experimental|10% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
89234470|NCT03990844|Experimental|20% Okra seed noodle|In this arm, subjects will consume noodles made with 10% okra seed.
89234471|NCT02534662|Experimental|Treatment Arm|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
89234472|NCT00642941|Experimental|Cohort 1: Ewings Sarcoma Primary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.
89234473|NCT00642941|Experimental|Cohort 2: Ewings Sarcoma Secondary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.
89138905|NCT02602275|Experimental|Neurexan®|0.6 mg / tablet, 3 tablets, 40-60 minutes before the second MRI Intervention: Drug: Neurexan®
89138906|NCT02602275|Placebo Comparator|Placebo|3 tablets, 40-60 minutes before the second MRI
89138907|NCT00904579||1|Cancer patients who have had organ transplants identified through the transplant and cancer registries.
89138908|NCT04241042||Down syndrome volunteers|Males and females from 16 to 35 years
89138909|NCT04241042||Healthy volunteers|Males and females from 18 to 35 years
89138910|NCT02602041||Patients with breast cancer and partners|We will invite 10 women with early stage breast cancer (BC) and their partners for a semi-structured interview.
89138911|NCT02602041||Patients with testicular cancer and partners|We will invite 10 men with disseminated testicular cancer (TC) and their partners for a semi-structured interview.
88805953|NCT02101190|Experimental|Group 1 - Hepatic impaired subjects|Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
89138912|NCT04034641|Experimental|probiotics plus standard therapy|
89138913|NCT04034641|Placebo Comparator|placebo plus standard therapy|
89138914|NCT04163406|Active Comparator|ferrous fumarate|Maize-based porridge fortified with iron (5mg) as ferrous fumarate
89138915|NCT04163406|Active Comparator|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) as ferrous fumarate + GOS (3g)
89138916|NCT04163406|Active Comparator|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) as ferrous fumarate + HMOs (2'-FL (2g) + LNnT (1g))
89138917|NCT04102605|Experimental|Nunap Vision|Nunap Vision , 5 days a week for 12 weeks
89138918|NCT04102605|Sham Comparator|Nunap Vision-C|Nunap Vision-C, 5 days a week for 12 weeks
89138919|NCT04218552|Experimental|Experimental 1|AD-209 High
89138920|NCT04218552|Experimental|Experimental 2|AD-209 Middle
89138921|NCT04218552|Experimental|Experimental 3|AD-209 Low
89138922|NCT04218552|Active Comparator|Active Comparator 1|Amlodipine Low
89138923|NCT04218552|Active Comparator|Active Comparator 2|Amlodipine High
89138924|NCT04218552|Active Comparator|Active Comparator 3|Telmisartan
89138925|NCT04218552|Placebo Comparator|Placebo comparator|Placebo
89138926|NCT04102761|Placebo Comparator|Trigger Point Needling|The first group will receive a deep trigger point injection of saline into deep tissue.
89138927|NCT04102761|Active Comparator|Platelet Rich Plasma Injection|The Platelet Rich Plasma group will receive an injection of approximately 1-2 mL of Platelet Rich Plasma into the painful disc/discs.
89138928|NCT04102761|Active Comparator|Bone Marrow Aspirate Injection|The third group will receive an injection of approximately 1-2 mL of Bone Marrow Concentrate into the painful disc/discs.
89138929|NCT05107154|Experimental|Dialectical Behavioural Therapy|Participants randomized to the Dialectical Behavioural Therapy (DBT) skills training intervention will receive a 90-minute DBT skills training session every week for 16 weeks total. The sessions will be facilitated by a health practitioner supervised by a clinical health psychologist with expertise in program development and DBT-adaptations for a variety of populations. Sessions for Pilot 1 will be delivered via Zoom HealthCare and in person if allowable. In-person sessions would be delivered at the Children's Hospital Research Institute of Manitoba. Pilot 2 will be adapted to address any additional needs uncovered through he qualitative assessment of Pilot 1. Traditional medicine components will be developed within the first 2 years of the grant by Indigenous researchers, patient and parent advisors, elders, and community advisory groups. These elements will be offered as an encouraged, yet optional component (additional modules) within the 16-week DBT intervention in Pilot 2.
89138930|NCT05107154|No Intervention|Control|Participants randomized to the control arm will receive standard medical care and clinical follow-up. Controls will be offered DBT after completion of Pilot 1 and 2. Participation will be optional.
89138931|NCT00907075|Active Comparator|NES With Energy Restriction|
89138932|NCT00907075|Active Comparator|NES Without Energy Restriction|
89138933|NCT04034407|Experimental|Damage control surgery|In the damage control surgery (DCS) group the surgeon was asked to perform rapid source control by stapling the perforated segment leaving blind ends or suturing the perforation site if possible, doing a thorough lavage of the abdominal cavity and placing an intra-abdominal negative pressure system avoiding the retraction of the abdominal wall with dynamic sutures as published. The second-look operation was scheduled for a time 24-48 hours after primary surgery that would be during regular working hours with a colorectal surgeon on hand to make the decision for either anastomosis or ostomy.
89138934|NCT04034407|Active Comparator|Control group|In the conventional treatment group (Group C), the decision to reconstruct the colon or perform a Hartmann procedure was made by the surgeon during the emergency operation. After performing the anastomosis or the Hartmann procedure, patients with advanced peritonitis received an intraabdominal negative pressure system at the discretion of the operating surgeon.
89138935|NCT02746146|Experimental|Chronic dialysis patients|"The study population consists of patients over 70 (≥) and under 85 years (<) of age with stage 5 chronic renal disease and initiating a first session of chronic dialysis in the Languedoc-Roussillon and Midi-Pyrénées regions. Eligible patients must have a 3 year prognostic mortality score less than (<) 7 points (Dusseux et al. 2015).~Intervention: Systematic use of a prognostic score"
89138936|NCT04242836||Control group|"70 patients with normal vision (NVG) with adequate literacy of written Greek language~30 patients with low vision (LVG) with adequate literacy of written Greek language~These patients are tested on the printed Greek MNREAD"
89138937|NCT04242836||Study group|The same patients as those in the control group (NVG, LVG) are tested on the digital version of the Greek MNREAD (DeDART)
89138938|NCT00904735|Experimental|Arm I|Patients receive oral hydroxyurea twice daily and oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
89138939|NCT00904735|Experimental|Arm II|Patients receive oral hydroxyurea twice daily in the absence of disease progression or unacceptable toxicity.
89138940|NCT02823626||Intervention|Spironolactone and patiromer
89138941|NCT04887038|Active Comparator|Drug :SRT-015|Experimental, Single and Multiple Oral escalating dose and Food Effect Cohort
89138942|NCT04887038|Placebo Comparator|Matching Placebo for SRT-015|
89138943|NCT02750046|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
89138944|NCT02750046|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
89138945|NCT00904891|Experimental|1|Participants will receive a cognitive-behavioral group intervention.
89138946|NCT00904891|Active Comparator|2|Participants will receive cognitive-behavioral bibliotherapy.
89138947|NCT00904891|No Intervention|3|Participants will only complete study assessments.
89138948|NCT02746224|Other|group 1A|the surgical technique initially dissects the inferior mesenteric vein (IMV).
89138949|NCT02746224|Other|group 1B|the surgical technique initially dissects the inferior mesenteric artery (IMA).
89138950|NCT02746224|Other|group 2A|the patients will have a latero-terminal colorectal anastomosis
89138951|NCT02746224|Other|group 2B|the patients will have a termino-terminal colorectal anastomosis.
89138952|NCT02824172|Experimental|Cast immobilization|36 patients in the experimental cast immobilization
89138953|NCT02824172|Active Comparator|complete sport rest|36 patients in the complete sport rest group
89138954|NCT04136496|Active Comparator|Ink placed before chemotherapy (Study A)|In Study A, 0.5 mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy
89138955|NCT04136496|Active Comparator|Ink placed after chemotherapy (Study B)|In Study B, 0.5 mL of Black Eye Ink will be placed before neoadjuvant therapy
89138956|NCT00779259|Active Comparator|Theophylline alone|baseline theophylline pharmacokinetics
89138957|NCT00779259|Active Comparator|Quinine alone|baseline quinine pharmacokinetics at steady state
89138958|NCT00779259|Experimental|Theophylline with steady state quinine|Theophylline pharmacokinetics in the presence of steady state quinine and quinine pharmacokinetics in the presence of theophylline.
89138959|NCT02824016|Active Comparator|with supraclavicular irradiation|Patients received supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
89138960|NCT02824016|Active Comparator|without supraclavicular irradiation|Patients did not receive supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
89138961|NCT05629884|Experimental|Experimental arm|This group will perform the rehabilitation from home or from the gym following online instructions in the COPERIA platform.
89138962|NCT05629884|No Intervention|Control arm|This control arm will train at the rehabilitation service or at home following the instructions provided by the rehabilitation service.
89138963|NCT04196192||Group 1|All infants aged 0-90 days (inclusive) undergoing routine assessments for fever without source.
89138964|NCT02746302|Experimental|HS-20004|One dose of HS-20004(0.02,0.04,0.05,0.06,0.08,0.1mg) Injected s.c. (under the skin) once for one subject.
89138965|NCT02746302|Placebo Comparator|Placebo|Placebo Injected s.c. (under the skin) once for one subject.
89138966|NCT00779025|Active Comparator|MINE Alone|Female Personal Lubricant (PD-F-5254)
89138967|NCT00779025|Experimental|YOURS and MINE|Male Personal Lubricant (10855-096) used in conjunction with Female Personal Lubricant (PD-F-5254)
89138968|NCT02746380|Experimental|LBAL|Adalimumab
89138969|NCT02746380|Active Comparator|Humira®|Adalimumab
89138970|NCT04241354|Active Comparator|Intra-articular LP-PRP Injection|A single injection of leukocyte poor platelet rich plasma (LP-PRP) will be administered to the intra-articular space under ultrasound guidance at the treatment visit.
89138971|NCT04241354|Experimental|Intra- and extra- articular LP-PRP Injection|A single injection of LP-PRP will be administered to the intra- articular space and the extra- articular structures under ultrasound guidance at the first visit.
89138972|NCT04102917||QFR group|915 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, acute myocardial infarction with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
89138973|NCT02745990|Experimental|EPO group|In EPO group, The recombinant human erythropoietin (rhEPO) will be given by 500 U/kg/dose intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
89138974|NCT02745990|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
89138975|NCT02538289|Other|Patients admitted before talks|Patients admitted to Cardiology or Respiratory Medicine Departments before the interventional teaching talks.
89138976|NCT02538289|Other|Patients admitted after talks|Patients admitted to Cardiology or Respiratory Medicine Departments after the interventional teaching talks.
89138977|NCT02823782|Experimental|Laminar HP|Structural and functional MRI markers
89138978|NCT02823782|Experimental|Complex HP|Structural and functional MRI markers
89138979|NCT02823782|Experimental|ADHD|Structural and functional MRI markers
89138980|NCT02823782|Other|Control|Structural and functional MRI markers
89138981|NCT00915915|Experimental|Arm 1|
89138982|NCT00915915|Experimental|Arm 2|
89138983|NCT05659862|Experimental|Digitally assisted behavioral physical activity intervention+Education|"An activity diary and a pedometer will be given to write down the number of steps per day.~After one week, the patient will be asked to send the activity diary as a photo via WhatsApp.~Afterwards, a 20-minute phone call will be made to provide patient education.~After the patient education, the patient will be consulted about the average number of steps he wants to take at the end of the intervention, and the daily average number of steps will be determined for the first week of the intervention, taking into account the patient's number of steps in the last week and the goal of the number of steps she wants to reach.~The person will be added to the WhatsApp patient support group. Patients will receive messages from this group by the researcher twice a week.~The target for the number of steps will be renewed every next week and an average of 20 minutes of phone calls including motivational interviews will be held in the light of Social Cognitive Theory."
89234474|NCT00642941|Experimental|Cohort 3: Ewings Sarcoma Expanded Cohort|Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.
89138984|NCT05659862|Active Comparator|Education|"An activity diary and a pedometer will be given to write down the number of steps per day.~After one week, the patient will be asked to send the activity diary as a photo via WhatsApp.~Afterwards, a 20-minute phone call will be made to provide patient education.~A reminder call will be made to the patient in the 4th week after the training and any questions will be answered.~Individuals in the patient education group will be asked to record their steps for one week with a pedometer in the 8th week after the training."
89138985|NCT02538367|Experimental|YH12852 IR 0.05mg|Once daily
89138986|NCT02538367|Experimental|YH12852 IR 0.1mg|Once daily
89138987|NCT02538367|Experimental|YH12852 IR 0.3mg|Once daily
89138988|NCT02538367|Experimental|YH12852 IR 0.5mg|Once daily
89138989|NCT02538367|Experimental|YH12852 IR 1mg|Once daily
89138990|NCT02538367|Experimental|YH12852 IR 2mg|Once daily
89138991|NCT02538367|Experimental|YH12852 IR 3mg|Once daily
89138992|NCT02538367|Experimental|YH12852 DR1 0.5mg|Once daily
89138993|NCT02538367|Experimental|YH12852 DR1 1mg|Once daily
89138994|NCT02538367|Experimental|YH12852 DR1 2mg|Once daily
89138995|NCT02538367|Experimental|YH12852 DR1 4mg|Once daily
89138996|NCT02538367|Experimental|YH12852 DR2 8mg|Once daily
89138997|NCT02538367|Active Comparator|Prucalopride 2mg|Once daily
89138998|NCT02538367|Placebo Comparator|Placebo|Once daily
89138999|NCT02750124|Active Comparator|HPV self sampling test sent|A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.
89139000|NCT02750124|Active Comparator|HPV self sampling test ordered|An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.
89139001|NCT02750124|Active Comparator|Nurse navigator contact|An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured
89139002|NCT02750124|Placebo Comparator|Control|The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.
89139003|NCT04241432|Active Comparator|Platform type 1|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
89139004|NCT04241432|Active Comparator|Platform type 2|12 pre-pubertal boys, aged 9-12 years who have previously sustained at least one fracture.
89139005|NCT00900445||Basic science (pharmacokinetics)|Patients receive anticancer therapy as prescribed by their treating clinicians. Patients receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.
89139006|NCT04217538||EBH|
89139007|NCT04240964||Dd group|Patients with diabetic foot osteomyelitis
89139008|NCT04240964||ND group|Foot osteomyelitis without diabetes
89139009|NCT02825810|Experimental|Cervical motor control group|
89139010|NCT02825810|No Intervention|Control group|
89139011|NCT00936065|Active Comparator|Group A|
89139012|NCT00936065|Experimental|Group B|
89139013|NCT00936065|Active Comparator|Group C|
89139014|NCT00916071||Eating Disorders|Study subjects will be individuals with a history of eating disorder(s) diagnosis
89139015|NCT04241276|Active Comparator|Gemcitabine + nab-paclitaxel|Patients will receive Gemcitabine and nab-Paclitaxel in 28 day cycles until disease progression.
89139016|NCT04241276|Experimental|Gemcitabine + nab-paclitaxel + ATRA|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
89139017|NCT04023513|Experimental|Strength Training and Protein high|6 weeks of high protein intake (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
89139018|NCT04023513|Experimental|Strength Training and Protein low|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
89139019|NCT04023513|Other|Control|No Intervention.
89139020|NCT00905047|Other|XELODA|
89139021|NCT00905047|Other|UFT|
89139022|NCT04023357|Experimental|PEEK|"PEEKs (polyetheretherketones) are presented as alternative materials to metal and glass ceramics,1 Their elastic modulus comparable to those of cortical bone and dentin so the polymer could exhibit good stress distribution. Also they have high fracture resistance, and low abrasion to the antagonist enamel.~Yet clinical studies are needed to evaluate their clinical performance."
89139023|NCT04023357|Active Comparator|Emax|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for Endocrowns
89139024|NCT02540005||Aneurysmatic subarachnoid haemorrhage|Acute subarachnoid haemorrhage (confirmed by computed tomography, CT, or cerebrospinal fluid erythrocyte count over 1000 x 106/l) AND confirmed origin either with computed angiography (CTA) or digital subtraction angiography (DSA)
89139025|NCT02540005||Control patients|Elective craniotomy due to non-ruptured intracranial aneurysm
89139026|NCT04023201||Parkinson's disease patients|Parkinson's disease patients with or without nocturnal symptoms
89139027|NCT04102449|Other|Treatment with Apremilast|"Single group:~Apremilast will be prescribed according to the patient information leaflet, i.e.:~Dosage form: Oral pill Dosage and Frequency: First 6 days titration phase, followed by 30mg twice daily (in case of kidney problems 30mg once daily in the morning). Treatment duration at the discretion of the treating physician."
89139028|NCT00905203|Experimental|1|moderate exercise training (three times/ week including one home-based training and two supervised training)
89139029|NCT00905203|Experimental|2|intensive exercise training (four times/ week including one home-based training and three supervised training)
89139030|NCT00900523||Known or suspected ovarian cancer|Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
89139031|NCT02825108|Experimental|experimental group|The patients who receive 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
89139032|NCT02825108|Placebo Comparator|placebo group|The patients who receive only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
89139033|NCT02825108|Other|control group|The patients for whom the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups
89139034|NCT00905281|Experimental|Action Group|
89139035|NCT00905281|Other|Standard care|
89139036|NCT02822534|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
89139037|NCT02822534|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
89139038|NCT02822534|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
89139039|NCT02822300|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89139040|NCT02823548|Experimental|Droglican|Patients take one sacchet of Droglican (Chondroitin Sulfate 1,500mg + Glucosamine Hydrochloride 1,200mg) Once a day during 6 months.
89139041|NCT02823548|Placebo Comparator|Placebo|Patients take one sacchet of Placebo once a day during 6 months.
89139042|NCT04441788|Placebo Comparator|Placebo|Single-dose of placebo was administered by oral inhalation via nebulizer, once every week for up to 13 weeks.
89139043|NCT04441788|Experimental|ION-827359 37.5 milligrams (mg)|Single-dose of ION-827359 37.5 mg was administered by oral inhalation via nebulizer, once every week for up to 13 weeks.
89139044|NCT04441788|Experimental|ION-827359 75 mg|Single-dose of ION-827359 75 mg was administered by oral inhalation via nebulizer, once every week for up to 13 weeks.
89139045|NCT02823236|Active Comparator|Intralesional Triamcinolone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months.
89139046|NCT02823236|Experimental|Topical Pirfenidone|Dosage commensurate with scar surface to be treated. After washing and drying the affected area, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
89139047|NCT02823236|Experimental|Triamcinolone + Pirfenidone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months. Simultaneously, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
89139048|NCT00633698|Active Comparator|1|Nicotinic acid (niacin)
89139049|NCT00633698|Placebo Comparator|2|Placebo
89139050|NCT03931512|Experimental|transcranial direct current stimulation|"20 minutes of transcranial direct current stimulation~1 mA on bi-hemispheric colocation with cathode on the left M1 and anode on the right M1"
89139051|NCT03931512|Sham Comparator|sham transcrial direct current stimulation|20 minutes positioning the electrodes on the scalp. Whith an initial increasing of the current intensity by 10 seconds, until 1mA and a ramp down from 20 seconds to reach zero.
89139052|NCT02825342|No Intervention|GERD with PPI's therapy|Patients will abnormal distal acid esophageal exposure will receive PPI twice daily for 8 weeks .
89139053|NCT02825342|Active Comparator|PPI's and SSRI's therapy|Patients with positive symptom index for chest pain will receive citalopram 20 mg once daily and PPI once daily for 8 weeks.
89139054|NCT02825342|Active Comparator|SSRI's therapy|Patients with a negative symptom index for chest pain will receive citalopram 20mg once daily for 8 weeks
89139055|NCT02749812|Experimental|Constant Continuous Positive Airway Pressure|
89139056|NCT02749812|Experimental|automatic Continuous Positive Airway Pressure|
89139057|NCT02823158|Experimental|GPi DBS and best medical treatment|
89139058|NCT02823158|Active Comparator|Best medical treatment|
89139059|NCT02749890|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
89139060|NCT02749890|Active Comparator|lixisenatide|"Lixisenatide (AVE0010) is injected subcutaneously (under the skin) once daily. It will be initiated with Dose 1 for 1 week and then continue with Dose 2 for 1 week followed by the maintenance dose of Dose 3 up to the end of treatment period.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
89139061|NCT04242758|Experimental|Dapaglifozin|People undergoing SGLT2i (Dapaglifozin) therapy
89139062|NCT04242758|Experimental|Hydrochlorothiazide|People undergoing thiazide (Hydrochlorothiazide) therapy
89139063|NCT02745912|Experimental|Metformin + Naltrexone/Bupropion|Metformin (850 mg, immediate release tablet, orally, once on Day 1 and Day 14) naltrexone/bupropion (8/90 mg/mg, extended-release tablets, orally, twice daily from Day 3 through Day 5 and 16/180 mg/mg, twice daily from Day 6 through Day 15.
89139064|NCT02746068|Experimental|AXS-02|Administered orally in the morning for 6 weeks
89139065|NCT02746068|Placebo Comparator|Placebo|Administered orally in the morning for 6 weeks
89139066|NCT02825186|Experimental|Loteprendol|Topical Loteprendol used after strabismus surgery
89139067|NCT02825186|Experimental|Dexamethasone|Topical Dexamethasone used after strabismus surgery
89139068|NCT00604825|Placebo Comparator|Placebo|Placebo
89139069|NCT00604825|Active Comparator|GSK232802|GSK232802
89139070|NCT00604825|Experimental|PREMARIN|PREMARIN
89139071|NCT04239560|Experimental|Boron-based Gel|During each radiation therapy session, 15 minutes before radiotherapy, 3% sodium pentahydrate panteurate will be used.
89139072|NCT04239560|Placebo Comparator|Radiation Traumatic Dermatitis Treated with Placebo|During each radiotherapy session, 15 minutes before radiotherapy, the gel will be free of any chemical treatments
89139073|NCT05380817|Other|BAWSI Group|By partnering with a community sports club (BAWSI), will the partnership recruitment model be effective in enrolling minority children.
89139074|NCT05380817|Other|YMCA of Silicon Valley Group|By partnering with a community organization (YMCA of Silicon Valley), will the partnership recruitment model be effective in enrolling minority children.
89139075|NCT04218162|Experimental|Lasmiditan 50mg|
89139076|NCT04218162|Experimental|Lasmiditan 100mg|
89139077|NCT04218162|Placebo Comparator|Placebo|
89139078|NCT02690324|Experimental|Major depressive disorder|DSM-5 major depressive disorder HAMD-17 > 16
89139079|NCT02690324|Active Comparator|panic disorder|DSM-5 panic disorder PDSS>7
89139080|NCT02690324|Active Comparator|normal control|age >20, healthy adults HAMD-17<17 PDSS<7
89139081|NCT00604799|Active Comparator|Test (Enrollment Completed)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair whom are low to moderate risk (0, 1, & 2) per the modified SVS/AAVS criteria who meet inclusion/exclusion criteria. The aneurysm must be at least 20 mm distal to the left common carotid artery & 20 mm proximal to the origin of the celiac artery.
89139082|NCT00604799|Other|Registry (Enrollment Completed)|Surgical candidates of low to moderate risk (SVS 0, 1, 2) that meet the Registry Inclusion/Exclusion criteria.
89139083|NCT00604799|Other|High Risk (Enrollment Completed)|"Patients that meet one or more of the following:~High Risk (SVS 3)~Non-surgical candidates not associated with SVS scoring~Traumatic thoracic injuries"
89139084|NCT00604799|Other|Talent Captivia (Recruiting)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair who meet inclusion/exclusion criteria.
89139085|NCT02821988|Experimental|Nonstress test|"Subjects will undergo weekly nonstress tests beginning at 32 weeks until delivery in addition to monitoring fetal kick counts.~A nonstress test is a test in which an external fetal monitor is placed on the mother to defect the fetal heart rate for 20 to 40 minutes. A test is considered reactive if there are more than 2 accelerations in fetal heart rate defined as an increase of at least 15 beats per minute lasting at least 15 seconds in a 20 minute period."
89139086|NCT02821988|Experimental|Biophysical profile|Subjects will undergo weekly biophysical profile testing beginning at 32 weeks until delivery in addition to monitoring fetal kick counts. A Biophysical profile is a test using real time ultrasonography to determine the presence of absence of certain components of fetal well being. There components include: an episode of fetal breathing lasting at least 30 seconds, 3 or more discrete body movements, 1 or more episodes of extension of a fetal extremity with return to flexion, and determination of amniotic fluid volume to detect a maximum vertical pocket of >2cm. The duration of this test is no more than 30 minutes.
89139087|NCT02821988|No Intervention|Kick counts only|Subjects will monitor fetal kick counts only.
89139088|NCT03886350||Patients with cystic fibrosis|Patients with CF whom follow-up is undertaken at University Hospital of Tours, France
89139089|NCT05659706||"Arm 1: intervention group, named Group 3+"|attend at least three workshops per week
89139090|NCT05659706||"Arm 2: control group, named Group 0-1"|not participate in the activities program or will attend a maximum of one workshop per week.
89139091|NCT03842124|Active Comparator|Intervention|Use of bidirectional rail (superior and inferior approaches) and force sensing using a force gauge to optimize Force application to less than 8 lbs during the extraction procedure.
89139092|NCT03842124|No Intervention|Control|Conventional lead extraction procedures using a superior approach is performed by experienced operators. Although force information is available the operators are blinded to the information. Inferior rail is left to the discretion of the operator.
89139093|NCT00606125|Experimental|Arm 1|
89139094|NCT04242212||Clinic-based|Women who get misoprostol from a clinic-based provider
89139095|NCT04242212||PMV-based|Women who get misoprostol from a patent medicine vendor
89139096|NCT02851433|Experimental|Sevoflurane Group|
89139097|NCT02851433|Active Comparator|Propofol Group|
89139098|NCT05629806|Active Comparator|Metformin plus pioglitazone|
89139099|NCT05629806|Active Comparator|Acarbose|
89139100|NCT04239482|Experimental|L-arginine + Nitrate/Nitrite|Subjects will receive 1 L-arginine tablet per day and drink 35 mL of beetroot juice for 8 weeks.
89139101|NCT04239482|Placebo Comparator|Placebo|Subjects will receive 1 cellulose tablet per day and drink 35 mL of nitrate/nitrite depleted beetroot juice for 8 weeks.
89139102|NCT05277649|Experimental|Experimental Group|Performance of a warm-up and cool-down exercise programme for the cervical and mandibular region before and after instrumental practice.
89139103|NCT05277649|No Intervention|Control Group|"Participants in the control group will not make any changes in their instrumental practice habit.~At the end of the study, participants in the control group will be asked to perform the exercises tested in the experimental group."
89139104|NCT02745834|Experimental|Chronic Ankle Instability|Soldiers who suffer from chronic ankle instability who had a first major ankle sprain one year or more ago, and did not sustained any major ankle sprain in the last two months, will go through Gait analysis intervention.
89139105|NCT02745834|Experimental|Healthy controls|Healthy soldiers who are not suffering from chronic ankle instability, will go through Gait analysis intervention.
89139106|NCT04242290||Cervicogenic headache|The group with cervicogenic headaches
89139107|NCT04242290||Neck pain|The group with isolated neck pain
89139108|NCT02745756|Experimental|Combined Cell Therapy|Hematopoietic progenitor cell (HPC) transplant (HPCT) with autologous tumor cell lysate and keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.
89139109|NCT04242368|Active Comparator|Isotonic rinse, then hypertonic rinse|Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses isotonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete hypertonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.
89139110|NCT04242368|Experimental|Hypertonic rinse, then isotonic rinse|"Participants will start with a one week washout period without rinses. Then they will complete twice daily sinus rinses of hypertonic saline for two weeks. Next they will have a one week washout period without rinses. Then they will cross-over and complete isotonic saline sinus rinses for two weeks. Participants will maintain fluticasone treatment throughout the study.~Fluticasone propionate nasal spray - two sprays to each nare twice a day used for the entire study duration"
89139111|NCT02745600|Other|Software assisted RFA treatment|Non-controlled, prospective, multicenter study arm, to evaluate RFA therapy simulation software.
89139112|NCT04217226||study group|adult patients (18-59 years), ASA I-II-III, scheduled for elective surgeries under general anaesthesia.
89139113|NCT04034563|Other|Risk of advanced neoplasia at 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy at 3-years
89139114|NCT04034563|Other|Risk of advanced neoplasia beyond 3-year|Risk of metachronous advanced neoplasia in those patients who done surveillance colonoscopy beyond 3-years
89139115|NCT00937391|Experimental|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
89139116|NCT04240652||Subjects with fundus photography|Subjects diagnosed with diabetes or not who have fundus images from MMCs and other medical institutes.
89139117|NCT04217148|Experimental|ATRA and HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and ATRA 10mg bid po, 12 consecutive weeks
89139118|NCT04217148|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
89139119|NCT00905671|Experimental|LCP+ Bifurcation Lesion|Bifurcating lesions that are positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
89139120|NCT00905671|Experimental|LCP- Bifurcation Lesion|Bifurcating lesions that are not positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
89139121|NCT04191720|No Intervention|Control group|The control group, or usual care group, will receive occupational therapy standard of care. Occupational therapy standard of care provide training, education, and therapeutic activities including relaxation strategies. These coping mechanisms are aimed at reducing the impact of anxiety on a patient's performance and participation in necessary and meaningful activities of daily living, refeeding and medical stabilization. Specifically, these interventions will include diaphragmatic and yogic breathing exercises, mindfulness-based cognitive therapy (MBCT) education and exercises, therapeutic restorative yoga activities, occupational therapy group participation, aromatherapy, identifying and promoting engagement in meaningful leisure activities, client-centered sensory diets to provide patients with consistent preferred sensory experiences, and individualized checklists and schedules to grade the self-initiation of effective coping strategies.
89139122|NCT04191720|Experimental|Weighted blanket group|In the weighted blanket intervention group, patients will receive usual occupational therapy care in addition to a weighted blanket. The patient will be given an appropriately weighted blanket, within 1 lb +/- of 10% of body weight as measured on day of admission. Further, the occupational therapy will provide education to the patient on the use of the weighted blanket. Patients will be free to use the weighted blanket at their discretion, however, during meals, over the shoulders or head, and during ambulation, weighted blanket use will not be permitted.
89139123|NCT04216836|Experimental|High magnesium diet (SUP condition)|Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
89139124|NCT04216836|Experimental|Low magnesium diet (CON condition)|Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
89139125|NCT00937157|Other|1|Patients diagnosed with multiple sclerosis who have the presence of at least 1 or more Gd enhancing lesions and/or acute relapse.
89139126|NCT00907309|No Intervention|Treatment as usual|Participants will receive treatment as usual from their provider.
89139127|NCT00907309|Experimental|iMET|Participants will receive the iMET intervention.
89139128|NCT00907309|Experimental|iMET/TE|Participants will receive the iMET intervention and Technological Extenders (TEs).
89139129|NCT05659472|Experimental|Intervention group = Combination mindfulness spiritual-based cognitive therapy plus hypnosis|Given to the intervention group with a frequency of once a week for eight weeks. Each session for 120 minutes or 2 hours with a set of MSBCT intervention packages resulting from modified mindfulness-based cognitive therapy with using the mindfulness concept of Kabat Zinn and the five-step model of mindfulness developed by Vidyamala Burch.
89139130|NCT05659472|Experimental|Control group = Mindfulness-based cognitive therapy|Given to the control group with a frequency of once a week for eight weeks. Each session is 90 minutes or 1.5 hours with a set of MBCT intervention packages developed by Teasdale, 2014
89139131|NCT04034173|Other|RAS mutations frequency <= 7%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~5-FU 400 mg/m² BSA, bolus, D1~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
89139132|NCT04034173|Other|RAS mutation frequency >7% to <=14%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~5-FU 400 mg/m² BSA, bolus, D1~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
89234475|NCT00642941|Experimental|Cohort 4: Osteosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.
89139133|NCT04034173|Other|RAS mutation frequency >14% to <=20%|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.~Followed by FOLFIRI regimen~Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1~Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1~5-FU 400 mg/m² BSA, bolus, D1~5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2~q day 14"
89139134|NCT00606203|Experimental|A|The aims of this study are to investigate the prophylactic effect of milnacipran in post stroke depression.
89139135|NCT00606203|Placebo Comparator|B|Placebo
89139136|NCT02749734|Experimental|hESC-RPE|Subretinal transplantation of Human embryo stem cell derived retinal pigment epitheliums
89139137|NCT00604877|Experimental|1|
89139138|NCT00604877|Active Comparator|2|
89139139|NCT02539849|Other|adalimumab + FOS|Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)
89139140|NCT02749578|Other|Treatment|Atorvastatin followed by MGL-3196 daily followed by separate co-administration of atorvastatin
89139141|NCT02825030|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89139142|NCT00927199|Experimental|High-Oleic Canola Oil|
89139143|NCT00927199|Experimental|High-Oleic Canola/Flaxseed Oil Blend|
89139144|NCT00927199|Active Comparator|Western Diet|
89139145|NCT05378867|Experimental|TRS003.|"Lead in Treatment Period~Will consist of 6 cycles of Bevacizumab® + mFOLFOX6~Each cycle length is 14 days~After completion of the Lead-in Period, patients who have not progressed or experienced intolerable side effects and remain on study will be randomized 1:1 to either the Non-Switch or Switch Arm of the study.~Switch Arm~TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period (to occur during Cycle 14, adequate for washout of preceding Bevacizumab®)."
89139146|NCT05378867|Active Comparator|China-approved Bevacizumab|"Lead in Treatment Period~Will consist of 6 cycles of Bevacizumab® + mFOLFOX6~Each cycle length is 14 days After completion of the Lead-in Period, patients who have not progressed or experienced intolerable side effects and remain on study will be randomized 1:1 to either the Non-Switch or Switch Arm of the study.~Non-Switch Arm:~Bevacizumab®, 5 mg/kg administered IV every 14 days~mFOLFOX6 administered as described above every 14 days"
89139147|NCT02749656|Experimental|0.25% Desoximetasone cream (Topoxy®)|"0.25% Desoximetasone cream (Topoxy®): apply on scalp psoriasis lesion twice a day for 8 weeks.~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
88805954|NCT02101190|Experimental|Group 2 - Healthy subjects|Group 2 - healthy subjects treated with BIA 9-1067
89139148|NCT02749656|Active Comparator|0.25% Desoximetasone cream (Topicorte®)|"0.25% Desoximetasone cream (Topicorte®): apply on scalp psoriasis lesion twice a day for 8 weeks.~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
89139149|NCT02749656|Placebo Comparator|Placebo|Placebo: apply on scalp psoriasis lesion twice a day for 8 weeks. (Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)
89139150|NCT02822066|Experimental|IRE for refractory neoplasms in liver and pancreas|To evaluate the safety and efficacy of irreversible electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients. Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.
89139151|NCT00603317|Experimental|1|Order 1 : Firstly Amoxicillin-Acid clavulanic, and Secondly Placebo
89139152|NCT00603317|Experimental|2|Order 2 : Firstly Placebo, and Secondly Amoxicillin-Acid clavulanic
89139153|NCT00907465||Calibration study|These individuals were used to develop cut points for sedentary behavior using accelerometers and a metabolic chamber.
89139154|NCT02745522|Experimental|Oxytocin|Oxytocin nasal spray
89139155|NCT02745522|Placebo Comparator|Placebo|Placebo nasal spray
89139156|NCT00603395|Other|ReCap|ReCap Total Hip Resurfacing System
89139157|NCT00908401|Active Comparator|sucrose|This group will receive oral sucrose for procedural pain
89139158|NCT00908401|Experimental|breastmilk|this group will receive breastmilk as analgesic product to avoid procedural pain
89139159|NCT04218318|Active Comparator|Low-threshold group|Neonates in the low-threshold group phototherapy will be stopped if TSB reached ˃100 µmol/L below the AAP phototherapy threshold.
89139160|NCT04218318|Active Comparator|High-threshold group|Neonates in high-threshold group phototherapy will be ceased if TSB level is 50-100 µmol/L below the appropriate AAP phototherapy threshold.
89139161|NCT02823314|Experimental|Intervention group|One piece of a special hypoallergenic adhesive tape, called Cure Tape®, they will have a size of 12-20 cm and will be attached in the front and back torso area on the T7- T8 dermatomes.
89139162|NCT02823314|Placebo Comparator|Placebo group|Two piece of a special hypoallergenic adhesive tape, called Cure Tape®, have a size of 2.5 cm x 2 cm and they will have to be placed near the greater trochanter area.
89139163|NCT05380271|Experimental|sequential DEB-BACE and Arotinib and Tirelizumab|"First treatment. Only infusion chemotherapy (THP + Nedaplatin + Letitrexed), THP 20 ~ 30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~Second treatment. After infusion chemotherapy, Callispheres microspheres is used for embolization: Callispheres microspheres (300-500 μ m) 1tube was loaded and adsorbed THP (40 ~ 600mg/m2) End point of embolization: stagnation of blood flow in tumor feeding artery.~The third treatment. Arotinib, 8-12mg, oral (stop oral for 1W every 3W).Tirelizumab, 200mg, intravenous drip (every 3W)."
88805955|NCT01170533|Active Comparator|Omeprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
89139164|NCT05380271|Active Comparator|DEB-BACE alone|"First treatment. Only infusion chemotherapy (THP + Nedaplatin + Letitrexed), THP 20 ~ 30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~Second treatment. After infusion chemotherapy, Callispheres microspheres is used for embolization: Callispheres microspheres (300-500 μ m) 1tube was loaded and adsorbed THP (40 ~ 600mg/m2) End point of embolization: stagnation of blood flow in tumor feeding artery."
89139165|NCT00927277|Placebo Comparator|placebo laser|inactive light on the laser device.
89139166|NCT00927277|Active Comparator|Erchonia (R) LipoLASER PL|The Erchonia(R) LipoLASER PL is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
89139167|NCT02745678|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation.
89139168|NCT02824718|Experimental|rh PTH(1-34)|40 µg/day rhPTH(1-34) (teriparatide or FORSTEO® 20 µg twice daily) over 7 to 8 weeks (52±3 days).
89139169|NCT02824718|Active Comparator|Thiazide + potassium sparing diuretic|hydrochlorothiazide 25 mg/day (ESIDREX®) + amiloride 5 mg/day (MODAMIDE®) + 0.5 µg/day alfacalcidol (ALFACALCIDOL®) over 7 to 8 weeks (52±3 days).
89139170|NCT00908479|Experimental|LE|Leg Exercise group
89139171|NCT00908479|Experimental|LM|Leg Management (Control group)
89139172|NCT05378711|Experimental|Fluoxetine|Children will receive an introductory dose and therapeutic dose of fluoxetine at various time points in the study. Onset of fluoxetine is determined by assignment to a pre-determined randomized treatment schedule.
89139173|NCT00777153|Experimental|Cediranib 30mg|Cediranib 30mg
89139174|NCT00777153|Other|Cediranib 20mg + lomustine|Cediranib 20mg + lomustine
89139175|NCT00777153|Active Comparator|Lomustine and Placebo Cediranib|Lomustine and Placebo Cediranib
89139176|NCT04240730||extremely obese patients with early-stage endometrial cancer|
89139177|NCT00907543|Other|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy treatment
89139178|NCT00907543|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy treatment
89139179|NCT00606359|Experimental|Study Group 1|
89139180|NCT00606359|Active Comparator|Study Group 2|
89139181|NCT02821520|Experimental|Initial PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~PDT: PDT with verteporfin is administered at baseline and then PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
89139182|NCT02821520|Active Comparator|Delayed PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~PDT:PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
89139183|NCT00604955|Experimental|A|Paromomycin IM Injection (approved product in India)
89139184|NCT02824796|Experimental|Schema Parent Behavioral Training|An enhanced protocol which combines a Schema Focused Therapy (SFT) and Behavioral Parent Training (PBT)
89139185|NCT02824796|Active Comparator|Parent Behavioral Training|Usually medication & The usual PBT treatment
89139186|NCT04266509|Experimental|Rifampin and PF-06651600 DDI|In Period 1, participants will receive a single oral 50 mg dose of PF-06651600. In Period 2, participants will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, in the morning of Day 8 participants will be administered with rifampin 600 mg 2 hour prior to administration of a single 50 mg oral dose of PF-06651600.
89139187|NCT00567541|Active Comparator|Active BBPM stimulation|Therapeutic Stimulation is applied via the Battery Powered Microneuromodulator (BBPM) which is programmed to deliver set stimulation parameters with approximate frequency of 30 Hz, current 5mA for 200 microseconds for the first 12 weeks of the study. The BBPM is implanted near the axillary nerve within the quadrilateral space.
89139188|NCT00567541|Placebo Comparator|Sham BBPM stimulation|The Battery Powered Microneuromodulator is implanted near the axillary nerve within the quadrilateral space. The BBPM is programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, the device will be reprogrammed to deliver therapeutic stimulation over a 12 week period.
89139189|NCT02749500|Active Comparator|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
89139190|NCT02749500|Experimental|OT + Device-assisted therapy|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy. The m2 BAT will enable repeated movement of the affected body part without the help of a therapist, providing the opportunity to maintain range-of motion in the affected limb to limit spasticity, contracture and the ensuing deformity, a major goal of rehabilitation therapy and produces movement in the affected limb from activating the patient's own brain, rather than from being acted on by an external powered source such as a robot.
89139191|NCT02824874|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO~Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO~Each treatment period was separated by a washout period of at least 10 dyas."
89139192|NCT02824874|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO~Period 2: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO~Each treatment period was separated by a washout period of at least 10 dyas."
89139193|NCT04102215|Experimental|ARCI25|Robot assited Cochlear implant surgery.
89139194|NCT04204265|Other|Monovisc|
89139195|NCT03972150|Experimental|Part I: BI 836880 alone|Part I followed by Part II
89139196|NCT03972150|Experimental|Part II: BI 836880 and BI 754091|
89139197|NCT00908557|Experimental|1|Patients receiving an information and consent form that has been modified using the LISYCOM methods.
89139198|NCT00908557|Active Comparator|2|Patients receiving a standard information and consent form.
89139199|NCT02820662|Experimental|RETCAM|
89139200|NCT04267913|Experimental|Arm A (docetaxel, dexamethasone, sapanisertib)|Patients receive docetaxel IV and dexamethasone IV over 30 minutes on days 1 and 8 and sapanisertib PO QD on days 2-4, 9-11, and 16-18. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. If docetaxel is discontinued, patients receive sapanisertib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89139201|NCT04267913|Active Comparator|Arm B (standard of care treatment)|Patients receive standard of care treatment comprising either docetaxel IV and dexamethasone IV over 30 minutes on day 1 or docetaxel IV, dexamethasone IV over 30 minutes, and ramucirumab IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89139202|NCT04216758|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
89139203|NCT04216758|Experimental|tegafur + gemcitabine|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; tegafur: Body surface area < 1.25 m^2, 60 mg/d; Body surface area ≥ 1.25 m^2 to < 1.5 m^2, 80 mg/d; Body surface area ≥ 1.5 m^2, 100 mg/d; Oral (po), Bid, D1-21
89139204|NCT00776997|Other|Magnetic Sphincter Augmentation|Single-arm study: all subjects were treated with magnetic sphincter augmentation. A subject's baseline measurements prior to sphincter augmentation were compared to post-sphincter augmentation measurements. Subjects served as their own control.
89139205|NCT02821598|Experimental|Upper limb pattern|Upper Limb pattern with flexion - abduction - external rotation
89139206|NCT02821598|Experimental|Lower limb pattern 1|Lower Limb pattern with flexion - adduction - external rotation with knee flexion;
89139207|NCT02821598|Experimental|Lower limb pattern 2|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion;
89139208|NCT02821598|Experimental|Lifting to the right|
89139209|NCT02821598|Active Comparator|Sit to Stand|Sit to Stand task
89139210|NCT00927433|No Intervention|Standard care|Patients received standard education about fatigue by clinicians.
89139211|NCT00927433|Experimental|Education arm|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions.
89139212|NCT02749266|Experimental|Chiropractic Activator Adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
89139213|NCT02749266|Sham Comparator|Chiropractic sham adjustment|Participant will receive a sham (simulated) chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
89139214|NCT00908635||survivor|survivors of patients
89139215|NCT00908635||fatalities|non-survivors of patients
89139216|NCT04200794|Experimental|musical instrumental training|Bi-weekly musical string instrument training in a group setting, over 24 months, provided by professional string instrument teachers
89139217|NCT04200794|Active Comparator|sensitization to music|Bi-weekly sensitization to music in a group setting, over 24 months, involving listening, playing small percussive instruments and choir singing, provided by professional school music teachers
89139218|NCT04216914|Experimental|Use of hand outline for bone age xray|Where children and young people are having left hand X-rays for clinical purposes the radiographer will place a template under their hand. The plate is designed not to show up on the X-ray and to not interfere with the X-ray itself. They will be asked to match their hand to the hand outline on the template.
89139219|NCT00606437|Experimental|I|Total Body Irradiation (TBI)/Flu Conditioning followed by combined UCB
89139220|NCT02821442|Experimental|Acupuncture|Acupuncture will consist of acupuncture points ST36, LR3, LI4 bilaterally x 30 minutes, once a week over 6 weeks. ST36 will have EA with 2Hz at the maximum tolerated intensity (ES-130 Portable Japanese Electro-Acupuncture Device, UPC Medical Supplies Inc. South El Monte, CA, USA).
89139221|NCT02821442|Sham Comparator|Sham Acupuncture|Sham acupuncture (Streitberger Placebo Needles, Asiamed) uses the same points and treatment parameters but the placebo needle does not penetrate the skin and the current for EA is not turned on.
89139222|NCT02749344|Experimental|FET after endometrial preparation|Natural cycle/progesterone fortified endometrial preparation before embryo transfer
89139223|NCT02538211|Placebo Comparator|Control|"Control group - subjects will receive no antibiotics~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
89139224|NCT02538211|Active Comparator|Broad-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~Ciprofloxacin 500mg 2dd1~Vancomycin 250mg 3dd2~Metronidazole 500mg 3dd1~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
89139225|NCT02538211|Active Comparator|Narrow-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~• Vancomycine 250mg 3dd2~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
89139226|NCT02745366|Experimental|BFPSC+|The combination of BFPSC+FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure.
89139227|NCT02745366|Active Comparator|BFPSC-|The combination of FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure
89139228|NCT04267835||MICS (Minimal invasive coronary surgery)|Patients undergoing MIDCAB surgery.
89139229|NCT04267835||OPCABG (thoracotomy off-pump CABG)|Patients undergoing thoracotomy OPCABG surgery
89139230|NCT02821676|Experimental|PEC1/SPB Block|
89139231|NCT02821676|Active Comparator|Intercostal Block|
89139232|NCT00907933|Experimental|Part 1 - Arm 1|HVTs
89139233|NCT00907933|Placebo Comparator|Part 2 - Arm 3|HVTs
89139234|NCT00907933|Experimental|Part 1 - Arm 2|HVTs
89139235|NCT00907933|Experimental|Part 1 - Arm 3|HVTs
89139236|NCT00907933|Experimental|Part 1 - Arm 4|HVTs
89139237|NCT00907933|Experimental|Part 1 - Arm 5|HVTs
89139238|NCT00907933|Placebo Comparator|Part 1 - Arm 6|HVTs
89139239|NCT00907933|Experimental|Part 2 - Arm 1|HVTs
89139240|NCT00907933|Experimental|Part 2 - Arm 2|HVTs
89139241|NCT02851199|Active Comparator|study group 1|1. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the prone position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. Finally the participants will performed additional 3 minutes of hyperventilation in the sitting position
89139242|NCT02851199|Active Comparator|study group 2|2. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the sitting position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. . Finally the participants will performed additional 3 minutes of hyperventilation in the
89139243|NCT00908089|Active Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 35 mg/kg/week)+ Prednisolon 7.5 mg/day + infliximab 3 mg/kg at weeks 4, 6, 10, 18, 26
89139244|NCT00908089|Placebo Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 25 mg/kg/week)+ Prednisolon 7.5 mg/day + placebo at weeks 4, 6, 10, 18, 26
89139245|NCT02745444|Other|low-calorie formula diet|Donor taking low-calorie formula diet, 50% of basal energy rate, individually calculated with Mifflin-St. Jeor formula.
89139246|NCT02745444|No Intervention|no diet|Donor ingesting food as usual.
89139247|NCT02745444|Other|protein-restricted diet|Donor taking protein-restricted diet according to diet plans of clinical dietetics of University Hospital of Cologne, with unchanged calorie supply, individually calculated with Mifflin-St. Jeor formula.
89139248|NCT02745444|No Intervention|Normal protein supply|Donor taking same dishes as protein-restricted diet group but with customary protein levels, with unchanged calorie supply.
89139249|NCT04758416||Metastatic breast cancer patients|50 metastatic breast cancer patients
89139250|NCT04218396|Experimental|Standard Treatment, Then Virtual Reality + Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment only. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment AND virtual reality
89139251|NCT04218396|Experimental|Virtual Reality + Standard Treatment, Then Standard Treatment|Participants will have an initial painful bedside procedure (eg: bedside wound care or dressing change) under standard treatment AND virtual reality. After a washout period, they then will have a repeat procedure (eg: similar bedside wound care or dressing change) under standard treatment only.
89139252|NCT02538445|Experimental|Patients group 1|Memorization of the verbs by miming the action
89139253|NCT02538445|Experimental|Patients group 2|Memorization of the verbs by imagining the action
89139254|NCT02538445|Experimental|Patients group 3|Memorization of the action verbs by means of another word
89139255|NCT02538445|Experimental|Patients group 4|Simple memorization of the verbs
89139256|NCT02538445|Active Comparator|Healthy volonteers group 1|Memorization of the verbs by miming the action
89139257|NCT02538445|Active Comparator|Healthy volonteers group 2|Memorization of the verbs by imagining the action
89139258|NCT02538445|Active Comparator|Healthy volonteers group 3|Memorization of the action verbs by means of another word
89139259|NCT02538445|Active Comparator|Healthy volonteers group 4|Simple memorization of the verbs
89139260|NCT02820974||Healthy control|Healthy women of child bearing age (25-39) with regular cycles.
89139261|NCT02820974||Perimenopause|Women at the age of 40-54 with irregular cycles filling in th criteria of perimenopause.
89139262|NCT02820974||Menopause|Women at the age of over 55 without normal cycles filling in th criteria of menopause.
89139263|NCT03553446|Experimental|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
89139264|NCT04266119|Experimental|Intervention|"The HOPE intervention can be accessed through web. It consists of two sessions per week, with a total of four sessions. In this study, participants will be sent weekly weblinks for access to each session. Each session take about ten minutes to complete. Each session consist of pre-post multiple-choice and/or open-end question, video(s) and mental health information. The first session is about depression. The second session is about positive psychology and consists of relevant exercises such as gratitude, affect-based and strength-based exercises. The third session describes anxiety disorder. The last session describes relaxation techniques and self-management of unhelpful thoughts.~Each session consists of quizzes, video(s), and graphical / written information"
89139265|NCT04266119|Active Comparator|Control|The group will receive a control website intervention that consists of several graphical inspirational quotes. Examples of the quotes are, 'Today is full of possible' and 'You can do anything'.
89139266|NCT02821130||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis
89139267|NCT00908167|Other|Research Participants|Participants treated with sorafenib, cytarabine and clofarabine.
89139268|NCT02749188|Other|bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes.
89139269|NCT04267757|Experimental|group 1|RVF with Martius flap
89139270|NCT04267757|Experimental|group 2|RVF without Martius flap
89139271|NCT02821052||insulin degludec/insulin aspart|
89139272|NCT00908245|Experimental|Preconditioning|Surgery with ischemic preconditioning
89139273|NCT00908245|Active Comparator|Control|Surgery without preconditioning ischemia
89139274|NCT05659628|Experimental|CAR-T combined with anti-PD1 treatment group|CD19-7×19 CAR-T combined with Tislelizumab
89139275|NCT03481686|Experimental|Patients with injections of ESA|Patients with injections of ESA
89139276|NCT00606515|Experimental|A|Liposomal paclitaxel
89139277|NCT00606515|Active Comparator|B|Paclitaxel
89139278|NCT00908323||A|Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205
89139279|NCT00908323||B|Participants receiving the placebos of the JS7 DNA and MVA/HIV62 vaccines in HVTN 205
89139280|NCT04240418||Lyon University Hospital employees|
89139281|NCT02749032|Active Comparator|Vildagliptin - stratum diet/exercise|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.~Mixed meal test were performed in the morning after an overnight fast."
89139282|NCT02749032|Active Comparator|Vildagliptin - stratum metformin|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.~Mixed meal test were performed in the morning after an overnight fast."
89139283|NCT02749032|Active Comparator|Sitagliptin - stratum diet/exercise|"The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
89139284|NCT02749032|Active Comparator|Sitagliptin - stratum metformin|"In patients treated with metformin, sitagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening.~Mixed meal test were performed in the morning after an overnight fast."
89139285|NCT02749032|Placebo Comparator|Placebo - stratum diet/exercise|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
89139286|NCT02749032|Placebo Comparator|Placebo - stratum metformin|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
89139287|NCT02820740|Other|NeuroBlate LITT Treatment|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.
89139288|NCT00908713|Experimental|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
89139289|NCT00908713|Placebo Comparator|Placebo|
89139290|NCT02749110|Experimental|Self-sampling for HPV test|Invitation to participate to the screening process by means of the usual care (pap-test) or the provision of a vaginal self-sampling brush (Evalyn Brush°). Self-collected samples are mailed to a central lab for HPV testing.
89139291|NCT02749110|No Intervention|Usual care (Pap test)|Intervention: invitation to participate to the screening process by means of the usual care (pap-test).
89139292|NCT02820896|Placebo Comparator|Multiple Dose Placebo IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of matching placebo IV QW, a total of 4 doses.
89139293|NCT02820896|Experimental|Multiple Dose RO7105705 IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of RO7105705 IV QW, a total of 4 doses.
89139294|NCT02820896|Experimental|Single Dose RO7105705 SC|Healthy participants will receive a single dose of RO7105705 SC on Day 1.
89139295|NCT02820896|Placebo Comparator|Single dose Placebo IV|Healthy participants will receive a single dose of placebo IV on Day 1.
89139296|NCT02820896|Experimental|Single dose RO7105705 IV|Healthy participants will receive a single dose of RO7105705 IV on Day 1.
89139297|NCT00940823|Active Comparator|Ahmed FP7 Valve|Ahmed valve glaucoma drainage device implant for treatment of refractory glaucoma.
89139298|NCT00940823|Active Comparator|Baerveldt-350 Tube|Baerveldt tube glaucoma drainage device implant for treatment of refractory glaucoma.
89139299|NCT02820428|Other|Healthy participants|Submission of the scale 'Evaluation of behaviour in Parkinson's Disease' to healthy subjects
89139300|NCT02745288|Experimental|Nerve block|This arm will receive inferior alveolar nerve block
89139301|NCT02745288|No Intervention|control|Control arm will not receive inferior alveolar block
89139302|NCT05277415|Active Comparator|Ghrelin infusion|Ghrelin infusion 30 pmol/kg/min, 0.50 ml/min during 120 minutes
89139303|NCT05277415|Placebo Comparator|Placebo|Saline 0.50 ml/min during 120 minutes
89139304|NCT02820584|Experimental|GSC-loaded autologous dendritic cells|DC-GSC immunotherapy. Six vaccinations are envisaged. The first three vaccinations will be performed every two weeks; subsequent three vaccinations every month. The first vaccination will be performed using 20 million DC, the second and third with 10 million DC; and from the 4th vaccine 5 million DC
89139305|NCT00909025|Experimental|Claudiximab|
89139306|NCT02745132|Other|Cognitive evaluation in HCV patients|"Neuropsychological evaluation and Brain MRI~Intervention: The only intervention to be carried out along the study will consist of complete neuro-psychological tests and MRI studies performed at different times.~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied: A neuro-psychological battery of tests and brain MRI studies will be performed at different times before and after the end of the treatment. The participation in the study will not influence neither the indication to treat nor the treatment used.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
89139307|NCT02818712||Patients with IPF|
89139308|NCT00909103||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histological confirmation
89139309|NCT00909103||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
89139310|NCT02744820|Placebo Comparator|Cohort 1 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
89139311|NCT02744820|Placebo Comparator|Cohort 2 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
89139312|NCT02744820|Placebo Comparator|Cohort 3 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
89139313|NCT02744820|Placebo Comparator|Cohort 4 (Part 2)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
89139314|NCT04267523|Experimental|Web-based parenting intervention|Families randomized to this intervention group will receive a self-administered web-based parenting intervention. Parents have access to a weekly 6-modules parenting intervention.
89139315|NCT04267523|Active Comparator|Face-to-face parenting intervention|Families randomized to this intervention group will receive a face-to-face group parenting intervention. Groups will meet weekly for 120 minutes for 4 weeks.
89139316|NCT05658770|Experimental|Five sessions/week|Perform five exercise sessions per week. The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1 (NCT05612698).
89139317|NCT05658770|Experimental|Three sessions/week|Perform three exercise sessions per week. The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1 (NCT05612698).
89139318|NCT05658770|Experimental|Two sessions/week|Perform two exercise sessions per week. The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1 (NCT05612698).
89139319|NCT02538133|Experimental|99mTc-Exametazime (HMPAO)-labeled leucocytes|
89139320|NCT02818634|Active Comparator|Muscle-sparing|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were passed with blunt dissection. Muscle fibers were dissected parallel to their positioning.
89139321|NCT02818634|Active Comparator|Muscle-cutting|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were cut with Monopolar electrocautery at (25 watts).
89139322|NCT02818790|No Intervention|Group 1. Control|
89139323|NCT02818790|Experimental|Group 2. Intervention 1|
89139324|NCT02818790|Experimental|Group 2. Intervention 2|
89139325|NCT02748954|Experimental|Thoughts.|"Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week"
89139326|NCT02748954|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
89139327|NCT02748954|Experimental|Assertiveness|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict
89139328|NCT02748954|Experimental|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
89139329|NCT02748954|Active Comparator|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
89139330|NCT00909259|Experimental|Phrenic Stimulation|
89139331|NCT04240496|Other|Schizophrenic patients|"Determination of trough plasma concentration of clozapine (C0)~Genotyping of CYP1A2 & CYP2C19 Drug: Leponex (Clozapine) : was started at a dose of 25 mg/j, the dose was gradually increased and was administered in one, two or three divided doses."
89139332|NCT00603551||Chemotherapy|Postmenopausal women who have been diagnosed with a breast or gynecological cancer and who have undergone chemotherapy as a result of that diagnosis
89139333|NCT02537977|Experimental|CAR-T cells|Autologous 2nd generation CD19-directed CAR-T cells
89139334|NCT04815044||Women from the PED-t study|Women who participated in the PED-t study in 2016-2018 who report previous (or in future time) pregnancy.
89139335|NCT04265807|Active Comparator|Intervention Group|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on an upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
89139336|NCT04265807|Sham Comparator|Control Group|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
89139337|NCT00909337|Other|Bosentan|"In this study, all participants have normal pulmonary arterial pressure at rest and elevated pulmonary arterial pressure during exercise. First, they were followed up for a year and were controlled after 1 year without specific therapy for pulmonary hypertension. Then Bosentan was introduced. A second control showing the effects of the therapy was done after 6 months. The changes in the therapy period can be compared with the changes in the follow up period."
89139338|NCT02822456|Experimental|Individual 3D-printed guided tube|IOE tube feeding using individual 3D-printed guided tube and nelaton tube whenever they eat
89139339|NCT02822456|Active Comparator|traditional IOE tube|classic IOE tube feeding using nelaton tube only whenever they eat
89139340|NCT02822456|Active Comparator|nasogastric tube|nasogastric tube feeding using levin tube always
89139341|NCT02748876|Experimental|His-Ventricular (HV)-optimised|His-Ventricular (HV) optimised atrioventricular delay
89139342|NCT02748876|No Intervention|Non-optimised|Standard atrioventricular delay
89139343|NCT00909493|Experimental|Access to Pain Specialist|Network
88805956|NCT01170533|Active Comparator|Pantoprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
89139344|NCT04267445||Embolization patients|"Single center, open label, pilot study. Eligible patients will undergo transarterial embolization of the prostatic vasculature. Each patient will undergo a single embolization procedure.~After completion of treatment in the first 2 patients and a review of follow-up assessments after 7 days, subsequent patients will be enrolled if no safety concerns have arisen in the first 2 patients.~Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.~Magnetic resonance imaging (MRI) and CEUS is used to assess changes in prostate volume and in central gland enhancement characteristics using 3D volume assessment software."
89139345|NCT02822690||University Medical Center Groningen|all patients that died on one of the wards with the exception of children; on several wards the Hospice care will be introduced as an intervention
89139346|NCT02822690||Martini Ziekenhuis|all patients that died on one of the wards with the exception of children
89139347|NCT02822690||Ommelander ZorgGroep|all patients that died on one of the wards with the exception of children
89139348|NCT02538055|Placebo Comparator|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
89139349|NCT02538055|Experimental|Living Healthy Program|Participants in this arm worked with a Community Health Worker (CHW) who provided the Living Healthy Program. The Living Healthy Program was a cognitive-behavioral therapy based lifestyle modification program. Participants and CHW interacted by telephone 8 times over 3 months.
89139350|NCT02748720|Experimental|RFM Visible|Patients will be randomize in other Group 1, where these parameters (from the device Respiratory Function Monitor) of lung mechanics would be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). We adapt or change PIP using visible TVe.
89139351|NCT02748720|No Intervention|RFM No Visible|Patients will be randomize in a Group 2, where the parameters of TVe and respiratory flow would not be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). Always, in both groups, current recommendations ventilation measures included in cardiopulmonary resuscitation of newborns of the Spanish Society of Neonatology, based on international recommendations (1-3.5) apply. In turn, the results analyzed in two subgroups between 24 and 27 + 6 weeks gestational age and 28 to 32 + 6 weeks
89139352|NCT04200716|Active Comparator|Moderate intensity continuous training - session|The volunteers perform a 30-minute moderate-intensity exercise session on the exercise bike.
89139353|NCT04200716|Active Comparator|High intensity interval training - session|The volunteers perform a session of high intensity interval exercise on the exercise bike.
89139354|NCT02748642|Experimental|Part A Cohort A: BITS7201A Dose Level 1 Subcutaneous (SC)|Healthy participants will receive a single SC dose of BITS7201A dose Level 1 on Day 1.
89139355|NCT02748642|Experimental|Part A Cohort B: BITS7201A Dose Level 2 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 2 on Day 1.
89139356|NCT02748642|Experimental|Part A Cohort C: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 on Day 1.
89139357|NCT02748642|Experimental|Part A Cohort D: BITS7201A Dose Level 4 Intravenous (IV)|Healthy participants will receive a single IV dose of BITS7201A dose Level 4 on Day 1.
89139358|NCT02748642|Experimental|Part A Cohort E: BITS7201A Dose Level 6 IV|Healthy participants will receive a single IV dose of BITS7201A dose Level 6 on Day 1.
89139359|NCT02748642|Placebo Comparator|Part A: Placebo|Healthy participants will receive a single SC or IV dose of placebo matched to BITS7201A on Day 1.
89139360|NCT02748642|Experimental|Part B Cohort F: BITS7201A Dose Level 3 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 3 every 4 weeks (Q4W) on Days 1, 29, and 57.
89139361|NCT02748642|Experimental|Part B Cohort G: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 Q4W on Days 1, 29, and 57.
89139362|NCT02748642|Experimental|Part B Cohort H: BITS7201A Dose Level 5 SC|Healthy participants will receive SC dose of BITS7201A dose Level 5 Q4W on Days 1, 29, and 57.
89139363|NCT02748642|Experimental|Part B Cohort I:BITS7201A Dose Level 5 SC (Mild Atopic Asthma)|Mild atopic asthma participants will receive SC dose of BITS7201 dose Level 5 Q4W on Days 1, 29, and 57.
89139364|NCT02748642|Placebo Comparator|Part B: Placebo|Healthy participants or mild atopic asthma participants will receive SC doses of placebo matched to BITS7201A Q4W on Days 1, 29, and 57.
89139365|NCT00909571|Experimental|1. FK506E high dose group|
89139366|NCT00909571|Experimental|2. FK506E low dose group|
89139367|NCT00606671||1|lean control women without PCOS
89139368|NCT00606671||2|lean women with PCOS
89139369|NCT00606671||3|Obese control women without PCOS
89139370|NCT00606671||4|Obese women with PCOS
89139371|NCT00606671||1xx - 04 LC|lean control women
89139372|NCT00606671||1xx-04 LP|lean women with PCOS
89139373|NCT00606671||1xx-04 OC|obese control women
89139374|NCT00606671||1xx-04 OP|obese women with PCOS
89139375|NCT05659550|Experimental|Fan-to-face|The participants will complete a 4-minute constant work rate treadmill test with a basic, portable fan placed in front of the face. The fan will be placed at a location to target the second and third branches of the trigeminal nerve and will be placed a distance chosen by the participant so that the airflow speed is comfortable.
89139376|NCT05659550|Sham Comparator|Fan-to-leg|The participants will complete a 4-minute constant work rate treadmill test with a basic, portable fan placed in front of the face. The fan will be placed at a location to target the second and third branches of the trigeminal nerve and will be placed a distance chosen by the participant so that the airflow speed is comfortable.
89234476|NCT00642941|Experimental|Cohort 5: Synovial Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.
89139377|NCT05659550|No Intervention|No fan|The participants will complete a 4-minute constant work rate treadmill test with no fan.
89139378|NCT02850731|Experimental|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
89139379|NCT02850731|No Intervention|supervision by a therapist|an adapted physical activity program under supervision of a therapist
89139380|NCT04216992||Three dimensional-rotational epidurography (3D-RE)|3D-RE is obtained on a commercial digital bi-plane angiography system. Reconstruction time was 30 seconds. Detailed information regarding technical performance and reconstruction procedure has been reported. Postprocessing techniques provided by the software included real-time 3D volume rendering and multiplanar reformatting. Real-time 3D volume rendering creates a 3D model of the examined object. The software allows emphasizing bony structures or soft tissue by changing intensity, brightness, and opacity of different X-ray structures. Additionally, rotation of the 3D object in all directions is possible, as is a virtual stereoscopic view provided by the software in combination with special glasses. The multiplanar reformatting modus generates virtual sections according to the three main axes and free defined axes. The section planes can be freely chosen, and curved sectioning is also possible.
89139381|NCT04015375|Experimental|Dapsone gel, 7.5% (Torrent Pharmaceuticals Ltd.)|Topical, once daily for 84 days
89139382|NCT04015375|Active Comparator|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical, once daily for 84 days
89139383|NCT04015375|Placebo Comparator|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical, once daily for 84 days
89139384|NCT02850887|Active Comparator|general endotracheal anesthesia|an inhalation anesthetic (substance that blocks pain) technique in which anesthetic and respiratory gases pass through a tube placed in the trachea (throat) via the mouth or nose
89139385|NCT02850887|Active Comparator|deep sedation without endotracheal intubation|local anesthesia together with sedation (drug that produces sleep) and analgesia (drug that treats pain) only.
89139386|NCT02744664|Experimental|Experimental|The subject receive Cryotherapy and than receive Icotinib 125mg, 3 times a day, orally administered until disease progression or intolerable toxicity reaction.
89139387|NCT00909805|Experimental|Cutaneous suture with glue|Inguinal surgical incision closing using Dermabond® glue instead of cutaneous suture with surjet
89139388|NCT00909805|Active Comparator|Conventional suture|Inguinal surgical incision closing with conventional cutaneous suture (surjet)
89139389|NCT00603629||I|People with acute asthma in the Emergency department or inpatient settings
89139390|NCT02744586|Experimental|Strengthening our Vows (SOV) Group|"Participants in the SOV arm will participate in the Together HIV Free and Protecting My Spouse plans."
89139391|NCT02744586|Placebo Comparator|Good Health Package Plus (GHPP) Group|Participants in the GHPP arm will receive education on the prevention of helminths, schistosomiasis, hypertension, diabetes, and diarrheal diseases through participatory and interactive group sessions.
89139392|NCT00931567|Active Comparator|Vaselitulle|after surgery, the loss of substance is treated using vaseline dressing
89139393|NCT00931567|Experimental|Autologous platelets gel|after surgery, the loss of substance is treated with Autologous platelets gel
89139394|NCT02820272|Experimental|NPWT with cold water|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change.
89139395|NCT02820272|Active Comparator|NPWT with normal saline room temp|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change.
89139396|NCT02820272|Placebo Comparator|NPWT without other intervention|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was no injection of any liquids into sponge before dressing change.
89139397|NCT03290508||Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
89139398|NCT03290508||No Prolaris Testing|Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing
89139399|NCT00931645|No Intervention|Complete responders|watch and wait policy
89139400|NCT00931645|Experimental|arm 2: complete responders patients|ABMT : TBI, 10 grays d-3-1 & cyclophosphamide 60 mg/sqm d-5-4
89139401|NCT00931645|Experimental|Non CR patients arm 3|Rescue chemotherapy and ABMT (see arm 2)
89139402|NCT00931645|Active Comparator|Non CR patients at random : arm 4|Rescue DHAP, F+C
89139403|NCT05658692|Experimental|protective ventilation|For ARDS patients with moderate to severe mechanical ventilation(MAQUET), give 6-8ml/kg (ideal body weight PBW), and control the plateau pressure to <30cmH2O; In patients with respiratory distress, the tidal volume can be increased to 7-8ml/kg (PBW), while the plateau pressure is <30cmH2O. Adjust breathing rate according to CO2 level, up to 35 breaths/min. PBW, male: 50+0.91 (height cm-152.4); female: 45.5+0.91 (height cm-152.4).
89139404|NCT05658692|Experimental|prone position ventilation (including awake state)|For patients with moderate to severe ARDS who have no contraindications to prone ventilation, protective lung ventilation is given and prone ventilation is performed; the duration is more than 12 hours/time.
89139405|NCT05658692|Experimental|glucocorticoid therapy|Glucocorticoids are used for ARDS patients, with small doses and short courses of treatment in the acute phase (within 14 days). There is no clear recommendation for patients with ARDS from other causes. At present, the main research methods are methylprednisolone program(Solu-Medrol®), dexamethasone program, and hydrocortisone program
89139406|NCT05658692|Experimental|restrictive fluid resuscitation|ARDS patients with circulatory or organ hypoperfusion problems should use as little fluid as possible to maintain treatment and circulation; other ARDS patients should focus on stabilizing circulation during the resuscitation phase, with controlled fluid replacement combined with early vasoactive drugs; ultrasound, Central venous pressure measurement, mixed central venous oxygen saturation, alveolar-arterial oxygen difference, blood lactate, etc. guide fluid resuscitation therapy; stop using vasoactive drugs for more than 12 hours, and use diuretics or diuretics combined with albumin to achieve fluid balance.
89139407|NCT05658692|Experimental|Immunomodulatory therapy|Thymosin Alpha（Thymalfasin for Injection） 1.6mg subcutaneously twice a week.
89139408|NCT05658692|Experimental|Muscle relaxant therapy|For patients with moderate to severe ARDS, if light sedation cannot achieve protective lung ventilation strategy and prone position ventilation, deep sedation combined with intermittent bolus injection of muscle relaxants（Vecuronium Bromide for Injection） is used; if protective lung ventilation strategy and prone position ventilation still cannot be achieved, deep sedation combined with continuous Inject muscle relaxants.
89139409|NCT05658692|Experimental|Integrated Chinese and Western Medicine Treatment|Mechanical ventilation + conventional western medicine + Dachengqi Decoction/Rhubarb-Salvia Injection/Tanreqing/Xuanbai Chengqi Decoction(Drugs determined by syndrome differentiation and treatment)
89139410|NCT05658692|Experimental|statin therapy|There are currently two options: 1) Simvastatin （Simvastatin Tablets）80 mg QD orally for up to 28 days in patients with acute lung injury. 2) Rosuvastatin （Rosuvastatin Calcium Tablets）40 mg for the first time, followed by 20 mg orally daily for 28 days, or 3 days after being transferred out of the ICU, or after the patient died.
89139411|NCT05658692|Experimental|anti-infective treatment|"Refer to the Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. recommendations."
89139412|NCT05658692|Experimental|Extracorporeal Membrane Oxygenation（ECMO）|ECMO (Medtronic) is chosen as rescue therapy for severe ARDS patients with refractory hypoxemia within 7 days of onset. (Oxygenation index < 50 mmHg for 3 hours, or oxygenation index < 80 mmHg for 6 hours, or arterial pH < 7.25, arterial partial pressure of carbon dioxide [Paco2] ≥ 60 mmHg > 6 hours, and respiratory rate increased to every minute 35 breaths, adjusting mechanical ventilation settings to maintain plateau pressure ≤32 cmH2O) despite ventilator optimization (defined as inspired oxygen concentration) ≥ 0.80, tidal volume 6 ml/kg (PBW), and positive end-expiratory pressure [PEEP] ≥ 10 cmH2O). V-V mode is preferred.
89139413|NCT05658692|Experimental|stem cell therapy|Previous clinical studies have found that stem cell therapy is safe, using a single injection of bone marrow stem cells at a dose of 1, 5, 10*106 cells/kg; START trial, ClinicalTrials.gov NCT02097641, for patients with moderate to severe ARDS, a single intravenous injection of bone marrow stem cells 10* 106 cells/kg intervention protocol.
89139414|NCT05658692|Experimental|Sedative analgesia/muscle relaxant therapy|For patients with moderate to severe ARDS, if light sedation cannot achieve protective lung ventilation strategy and prone position ventilation, deep sedation（Propofol Injectable Emulsion or Midazolam Injection） combined with intermittent bolus injection of muscle relaxants is used; if protective lung ventilation strategy and prone position ventilation still cannot be achieved, deep sedation combined with continuous Inject muscle relaxants（Vecuronium Bromide for Injection）.
89139415|NCT05658692|Experimental|inotropes therapy|"For unconventional medication, according toSurviving sepsis campaign: international guidelines for the management of sepsis and septic shock 2021."
89139416|NCT05658692|Experimental|Vasoactive drug therapy|"According toSurviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
89139417|NCT03638713|Experimental|colonoscopy first group|Patients received water-exchange colonoscopy first and followed by esophagogastroduodenoscopy
89139418|NCT03638713|Active Comparator|EGD first group|Patients received esophagogastroduodenoscopy first and followed by water-exchange colonoscopy
89139419|NCT02744508|Active Comparator|P group|Palonosetron group
89139420|NCT02744508|Experimental|PD group|Palonosetron and dexamethasone group
89139421|NCT00927511|Experimental|A - Dose Tritation|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity
89139422|NCT00927511|Active Comparator|B- Control|Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
89139423|NCT02748486|Experimental|Jumping To Conculsions|Metacognitive Training Jumping to conclusions module
89139424|NCT02748486|Experimental|Theory of Mind|Metacognitive Training To empathize... module
89139425|NCT02748486|Sham Comparator|Control|group discussion of current events
89139426|NCT04015063|Other|Primary Subjects|Women subjects 40-65 years of age that meet the specified inclusion/exclusion criteria taking P29429-01 as a skin care product per the protocol.
89139427|NCT03211338|Active Comparator|Preterm labor placentas and progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
89139428|NCT03211338|Active Comparator|Term labor placentas and progesterone|IMC cells taken from term labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
89139429|NCT03211338|Active Comparator|Preterm labor placentas without progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
89139430|NCT03211338|Active Comparator|Term labor placentas without progesterone|IMC cells taken from term labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
89139431|NCT03211338|Active Comparator|Term placentas from progesterone treated pregnancies|IMC cells taken from term labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
89139432|NCT03211338|Active Comparator|Preterm placentas from progesterone treated pregnancies|IMC cells taken from preterm labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
89139433|NCT03211338|Active Comparator|Term placentas not treated with progesterone in pregnancy|IMC cells taken from term placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
89139434|NCT03211338|Active Comparator|Preterm placentas not treated with progesterone in pregnancy|IMC cells taken from preterm placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
89139435|NCT03211338|Active Comparator|Term postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
89139436|NCT03211338|Active Comparator|Preterm postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
89139437|NCT03211338|Active Comparator|Term postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
89139438|NCT03211338|Active Comparator|Preterm postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
89139439|NCT00927667|Experimental|Arm 1|
89139440|NCT00927667|Experimental|Arm 2|
89139441|NCT00927667|Experimental|Arm 3|
89139442|NCT00927667|Experimental|Arm 4|
89139443|NCT00927667|Experimental|Arm 5|
89139444|NCT00936611|Experimental|LBH589|"30 mg three days a week (Mondays, Wednesdays and Fridays).~1 cycle was 28 days~Dose modifications for attributable toxicities allowed for reduction to:~25 mg, 20 mg three times a week every week~Or 20 mg three times a week every other week. No dose re-escalation was allowed.~The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose."
89139445|NCT00927745|Experimental|With AutoFlow|Assist-controlled ventilation with activation of AutoFlow mode
89139446|NCT00927745|Active Comparator|Without AutoFlow|Assist-controlled ventilation without activation of AutoFlow mode
89139447|NCT03123822|Experimental|Single vision glasses|Typical glasses prescribed for children to correct only distance refractive error and to be worn all waking hours.
89139448|NCT03123822|Experimental|Single vision glasses with anti-glare coating|Typical glasses prescribed for children to correct only distance prescription with anti-glare coating and to be worn all waking hours.
89139449|NCT03123822|Experimental|Eyezen|Commercially available, low-powered, progressive addition lenses glasses with anti-glare coating to be worn all waking hours
89139450|NCT04267289|Experimental|iCBT treatment group|Subjects were given license to use Beating the Blues, a commercially available iCBT program. Subjects were given 3 months to use the program.
89139451|NCT04265729|Other|single test product arm|use of Neocate Infant and Junior marketed products (product type depending on subject's age and condition)
89139452|NCT02748252||HIV patients|HIV patients admitted in Stroke units for the first occurence of acute stroke
89139453|NCT02748252||non HIV patients|non HIV patients admitted in Stroke units for the first occurence of acute stroke
89139454|NCT02920476|Experimental|Treatment arm|TAS-102
89139455|NCT02850653|Other|Endophthalmitis sufferers|Patients hospitalized for diagnostic and therapeutic evaluation of a post-operative acute endophthalmitis.
89139456|NCT02850653|Other|Healthy control patient|Patients hospitalized in the context of a scheduled surgery with sampling of aqueous humour.
89139457|NCT04217928|Active Comparator|Arthroscopic Debridement|Patients who are randomized into this arm will receive arthroscopic debridement
89139458|NCT04217928|Active Comparator|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Patients who are randomized into this arm will receive arthroscopic hemi-trapeziectomy with mini tightrope
89139459|NCT02744274|Experimental|Verum acupuncture|16 patients will be randomized to receive verum acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
89139460|NCT02744274|Placebo Comparator|Sham acupuncture|16 patients will be randomized to receive sham acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
89139461|NCT04203719|Experimental|Anlotinib and AK105 injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89139462|NCT02744196|Experimental|Acellbia + methotrexate|"106 patients of this group will receive methotrexate in combination with a drug Acellbia to be used at a dose of 600 mg as a slow intravenous infusion carried out on day 1 and day 15.~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the therapy with Acellbia is repeated by the same scheme - 2 infusion at a dose of 600 mg at intervals of 14 days."
89139463|NCT02744196|Placebo Comparator|Placebo + methotrexate|"53 patients of this group will receive methotrexate in combination with a placebo to be used as a slow intravenous infusion carried out on day 1 and day 15.~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the patient receives open therapy with Acellbia is initiated: 2 infusion at a dose of 600 mg at intervals of 14 days."
89139464|NCT02744118|Experimental|Marijuana Screening and Brief Counseling|The marijuana screening and brief counseling intervention will be developed based on a tested adolescent tobacco cessation intervention and the Public Health Service 5As model. The proposed intervention will be adapted using current literature, input from content experts, and qualitative data gathered using focus groups.
89139465|NCT02744118|Active Comparator|Healthy Internet Use Model|The media screening and brief counseling intervention is based on a media use screening and brief counseling intervention tested as the active comparator for a 5As tobacco cessation randomized control trial (NCT01312480) and the 2010 American Academy of Pediatrics policy statement on children and media.
89139466|NCT02743884|Experimental|Esophageal Cooling Device|Esophageal cooling
89139467|NCT02743884|Experimental|Esophageal Warming|Esophageal warming
89139468|NCT05379647|Experimental|QN-019a in Combination with Monoclonal Antibodies|QN-019a in Combination with Rituximab in adult subjects with r/r B-cell lymphoma.
89139469|NCT05379647|Experimental|QN-019a Monotherapy|QN-019a Monotherapy in adult subjects with r/r B-ALL
89139470|NCT02748330|Experimental|Ticagrelor|Oral ticagrelor 90 mg tablet, twice daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
89139471|NCT02748330|Active Comparator|Clopidogrel|Oral clopidogrel 75 mg tablet, once daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
89139472|NCT04265417||RARC group|Participants in this group underwent robotic assisted rectal cancer resection
89139473|NCT04265417||NOSE group|Participants in this group underwent robotic rectal cancer resection assisted rectal with natural orifice extraction
89139474|NCT00606827|Experimental|A|Bicarbonate
89139475|NCT00606827|Active Comparator|B|Saline
89139476|NCT05379569|Experimental|conditioning regimen with Malilane,cyclophosphamide and fludarabine|Malilane 3.2mg/kg/d *4d (-5,-4,-3,-2day) cyclophosphamide 25mg/kg/d*4d (-9-8,-7,-6 day) fludarabine 30mg/m2/d*4d (-9-8,-7,-6 day) Donor stem cells will be transfused at 0 days.
89139477|NCT05379569|Active Comparator|conditioning regimen with Malilane and cyclophosphamide|malilane 3.2mg/kg *4d (-5,-4,-3,-2day) cyclophosphamide 50mg/kg/d*2d (-2,-1day) Donor stem cells will be transfused at 0 days.
89139478|NCT02748174|Experimental|Episodic Migraine group|100 patients with chronic or episodic migraine
89139479|NCT02748174|Experimental|Chronic Migraine Group|100 patients with chronic or episodic migraine
89139480|NCT02748174|Experimental|Post concussive Headache Group|75 patients
89139481|NCT00603707||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
89139482|NCT00603707||Constipated|Adult subjects with functional constipation as define by Rome II criteria
89139483|NCT04217772|Experimental|Eyes post-lensectomy|Eyes of children after cataract surgery
89139484|NCT04217772|No Intervention|Healthy Eyes|Eyes of healthy volunteers
89139485|NCT02818556|Other|Restylane Right, Belotero Left|Patients will receive one treatment with Restylane® Silk (right side of the face) and one treatment of Belotero Balance® (left side)
89139486|NCT02818556|Other|Restylane Left, Belotero Right|Patients will receive one treatment with Restylane® Silk (left side of the face) and one treatment of Belotero Balance® (right side)
89139487|NCT04238936||study group ; Patients with gestational diabetes|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
89139488|NCT04238936||control group ; healthy pregnant women|Women who are healthy pregnant women, the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
89139489|NCT04627142|Experimental|Expansion dose 1|Part C: Combination therapy expansion part
89139490|NCT04627142|Experimental|Expansion dose 2|Part C: Combination therapy expansion part
89139491|NCT04238858|Active Comparator|Before application|Forty-nine eyes belonging to 37 patients before injection aPRP.
89139492|NCT04238858|No Intervention|After application|Forty-nine eyes belonging to 37 patients after injection aPRP.
89139493|NCT04238858|Sham Comparator|Sham application|11 patients before - after aPPP injection
89139494|NCT02818166|Experimental|Endoaortic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and endoaortic balloon clamp
89139495|NCT02818166|Active Comparator|Transthoracic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and transthoracic clamp.
89139496|NCT02818478|Other|RA; at home first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
89139497|NCT02818478|Other|RA; outpatient clinic first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
89139498|NCT02818478|Other|AxSpa; at home first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
89139499|NCT02818478|Other|AxSpa; outpatient clinic first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
89139500|NCT05658614|Active Comparator|Arm 1 (Group Vacc3)|Volunteers will receive three (3) intramuscular injections into the deltoid muscle of 0.5mL of of the Sm14+ GLA-SE vaccine on D0, W4 and W8. (D = Day; W = Week). (Vaccination schedule used in previous phases).
89139501|NCT05658614|Experimental|Arm 2 (Group Vacc2+1)|Volunteers will receive three (3) intramuscular injections of the Sm14+ GLA-SE vaccine into the deltoid muscle of 0.5mL of vaccine on D0, W4 and W20 (new vaccination schedule).
89139502|NCT02818322|Experimental|telemedical monitoring ( T)|Home care by a nurse trained in the management of diabetic foot lesions with transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion every week
89139503|NCT02818322|Active Comparator|classic monitoring|Home care by a nurse trained in the management of diabetic foot lesions without transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion
89139504|NCT04238312|Experimental|RESPeRATE™|RESPeRATE™: 2breathe Tech. Ltd., Eshtaol, Israel. The device includes a belt-type respiration sensor worn outside of the clothing that is placed around the torso. It is connected to a computerized box that generates musical patterns listened through an earbud. The device guides the user interactively to slow breathing with a relatively prolonged expiration.
89139505|NCT04238312|Active Comparator|Tell, Show and Do technique|
89139506|NCT02817386||POD and Non-POD;|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The assessment of post deliriu (POD) was performed once per day between 8:00 AM to 10:00 AM. Patient notes were not reviewed for episodes of delirium which could occur outside the time of assessment. The clinical research assistants who performed the delirium assessments in this study had good training and went through quality control procedures. We used state-of-the-art delirium detection methods, which tend to report a higher incidence of delirium. The interview included the Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS).
89139507|NCT02817308|Experimental|Patients|"Patients with a proven diagnosis of ductal adenocarcinoma of the pancreas with elevated levels of CA19-9 and possibly elevated CEA levels.~intervention: samples of blood, saliva and urine"
89139508|NCT02817308|Other|Control|"Patients or healthy volunteers with out a known evidence of malignancy with presumably normal levels of CA19-9 and CEA.~intervention: samples of blood, saliva and urine"
89139509|NCT00936221|Active Comparator|1|AZD6244 in combination with dacarbazine
89139510|NCT00936221|Placebo Comparator|2|Placebo in combination with dacarbazine
89139511|NCT00776919|Experimental|1|clindamycin / benzoyl peroxide gel
89139512|NCT00776919|Active Comparator|2|Clindamycin gel
89139513|NCT00776919|Active Comparator|3|BPO gel
89139514|NCT00776919|Placebo Comparator|4|vehicle gel
89139515|NCT00247728|No Intervention|Untreated Control|Untreated control arm
89139516|NCT00247728|Experimental|160 mg PI-88/Day|PI-88 160 mg/day SC injection
89139517|NCT00247728|Experimental|250 mg PI-88/Day|PI-88 250 mg/day SC injection
89139518|NCT02747940|Experimental|patients with chronic migraine|flunarizine for patients with chronic migraine
89139519|NCT02747940|Experimental|patients with fibromyalgia|pregabalin for patients with fibromyalgia
89139520|NCT02747940|Experimental|patients with chronic migraine and fibromyalgia|flunarizine and pregabalin for patients with chronic migraine and myalgia
89139521|NCT04238702|Experimental|Empagliflozin + Losartan|Empagliflozin + Losartan
89139522|NCT04238702|Experimental|Losartan + Placebo|Losartan + Placebo
89139523|NCT04238702|Experimental|Empagliflozin + Placebo|Losartan + Placebo
89139524|NCT04238702|Placebo Comparator|Placebo + Placebo|Placebo + Placebo
89139525|NCT00603785|Placebo Comparator|A|Subjects to receive placebo treatment for 6 months
89139526|NCT00603785|Experimental|B|Subjects to receive Xolair treatment for 6 months
89139527|NCT02743650|Experimental|Sodium Bicarbonate|"All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).~The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening."
89139528|NCT00633776|Experimental|1|Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 1; Formoterol 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 2
89139529|NCT00633776|Active Comparator|2|Formoterol fumarate 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 1; Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 2
89139530|NCT05382923|Experimental|Bright Light Alone|Bright light administered with Re-Timer glasses for 1 hour on 3 consecutive days. Following the 8 hour delay of the light/dark and sleep/wake cycle in the laboratory, the light will be administered, on average at 5:30-6:30 pm, 7:00-8:00 pm, and 9:30-10:30 pm, respectively on these three days.
89139531|NCT05382923|Experimental|Bright Light + Exercise + Melatonin|Bright light will be administered with Re-Timer glasses for 1 hour on 3 consecutive days. Following the 8 hour delay of the light/dark and sleep/wake cycle in the laboratory, the light will be administered, on average at 5:30-6:30 pm, 7:00-8:00 pm, and 9:30-10:30 pm, respectively on these three days. Exercise (1 hour at 65-75% heart rate reserve) will be administered on 3 consecutive, at 1:30-2:30 pm, 4:00-5:00 pm, and 6:30-7:30 pm on these days. Melatonin (0.5 mg) will be administered at 6 am, 8:30 am, and 11:00, on the 3 days.
89139532|NCT05382923|Placebo Comparator|Placebo Control|Dim red light will be administered with Re-Timer glasses for 1 hour on 3 consecutive days. Following the 8 hour delay of the light/dark and sleep/wake cycle in the laboratory, the light will be administered, on average at 5:30-6:30 pm, 7:00-8:00 pm, and 9:30-10:30 pm, respectively on these three days. Placebo tablets (0.5 mg) will be administered at 6 am, 8:30 am, and 11:00, on the 3 days.
89139533|NCT02743572|No Intervention|control group|preterm infants of this group with iron-free PN for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
89139534|NCT02743572|Experimental|iron sucrose-1|preterm infants of this group with iron supplementation of 100μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
89139535|NCT02743572|Experimental|iron sucrose-2|preterm infants of this group with iron supplementation of 200μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
89139536|NCT02743572|Experimental|iron sucrose-3|preterm infants of this group with iron supplementation of 300μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
89139537|NCT02743572|Experimental|iron sucrose-4|preterm infants of this group with iron supplementation of 400μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
89139538|NCT04238468|Experimental|Intradermal injection of stromal vascular fraction|Most lateral 5 cm of abdominal donor site will be injected with stromal vascular fraction just after the wound is closed.
89139539|NCT04238468|No Intervention|control|Most contralateral 5 cm of abdominal donor site will serve as control.
89139540|NCT02751216|Experimental|spinal cord stimulation|
89139541|NCT04238156|Experimental|Hypopressive abdominal exercises|"Hypopressive abdominal exercises will be performed in basic postures (standing, sitting and supine position). In each posture, three slow cost-diaphragmatic respiration will be performed followed by an expiratory apnea and a rib cage opening, during 2 to 10 seconds, and an exhalation of 10 to 30 seconds. Each exercise will be repeated three times.~There will be 3 stages of application throughout the 12 intervention sessions, supervised by a physical therapist:~First stage: To explain the concept of hypopressive respiration and how to perform it.~Second stage: To explain and apply the hypopressive abdominal exercises: 1. Axial auto-elongation (reducing curvatures in the sagittal plane); 2. Cervical auto-elongation (chin toward the neck); 3. Moving forward of gravity axis; 4. Activation of the shoulder girdle (shoulder joint decoaptation); 5. Slight knee flexion; 6. Dorsal ankle flexion.~Third stage: To review and update all the exercises, increasing their intensity."
89139542|NCT00775983|Active Comparator|laminaria|laminaria placed for cervical dilation; usual standard of care in study clinic
89139543|NCT00775983|Experimental|Dilapan-S|experimental treatment
89139544|NCT02820116|Experimental|Icotinib|Patients receive Icotinib PO TID for 8 weeks and then undergo thoracotomy.
89139545|NCT02747706|Experimental|Parent Mentoring|1-on-1, phone, SMS/text, and smartphone-based parent-to-parent mentoring.
89139546|NCT02747706|No Intervention|Usual Care|No intervention through study.
89139547|NCT02817152|Sham Comparator|Periodontal ultrasonic debridement|Periodontal pockets received ultrasonic periodontal debridement intervention.
89139548|NCT02817152|Active Comparator|Low-level laser therapy|Periodontal pockets received ultrasonic periodontal debridement plus low-level laser therapy intervention.
89139549|NCT02747784|Experimental|Study group experimental|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Divided Attention 2 (GEA2)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
89139550|NCT02747784|Active Comparator|Study group active comparator|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Working memory (WOME)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
89139551|NCT02747784|No Intervention|Control group|48 female control subjects aged 18 years or older (24 without surgery, 24 with urogynecological or breast cancer surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
89139552|NCT00939809|Experimental|Treatment (urokinase-derived peptide A6)|Patients receive A6 subcutaneously once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89139553|NCT05658926|Experimental|Intervention|Participants will learn a brief, mindfulness skill
89139554|NCT05658926|Placebo Comparator|Education|Participants will receive education about the effects of emotions on pain
89139555|NCT02818010||exposed = patient practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire)~A patient is defined as practicing physical activity (exposed) when he meets one of the conditions following:~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
89139556|NCT02818010||unexposed = patient not practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire(Global Physical Activity Questionnaire)~A patient is defined as unexposed if he does not fulfill any of these conditions :~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
89139557|NCT02747550|Experimental|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
89139558|NCT02747550|Active Comparator|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy.
89139559|NCT00606983|No Intervention|1|
89139560|NCT00606983|Experimental|2|oral administration of Tamsulosin
89139561|NCT02817932|Experimental|Group 1 (Korean, 375 mg)|Group 1 (Korean, 375 mg): Ranolazine PR 375 mg
89139562|NCT02817932|Experimental|Group 2 (Korean, 500 mg):|Group 2 (Korean, 500 mg): Ranolazine PR 500 mg
89139563|NCT02817932|Experimental|Group 3 (Korean, 750 mg):|Group 3 (Korean, 750 mg): Ranolazine PR 750 mg
89139564|NCT02817932|Experimental|Group 4 (Caucasian, 375mg)|Group 4 (Caucasian, 375mg) : Ranolazine PR 375 mg
89139565|NCT02817932|Experimental|Group 5 (Caucasian, 750mg)|Group 5 (Caucasian, 750mg) : Ranolazine PR 750 mg
89139566|NCT02818088|Experimental|Cognitive Training|Cognitive Training - n Back.
89139567|NCT04265495||DUAL TRIGGERING|PATIENTS WILL RECEIVE DUAL TRIGGERING
89139568|NCT04265495||URINARY HCG|PATIENTS WILL RECEIVE URINARY HCG
89139569|NCT04265495||RECOMBINANT HCG|PATIENTS WILL RECEIVE RECOMBINANT HCG
89139570|NCT02743260|Experimental|pitavastatin (OATP1B1)|2 mg pitavastatin single dose
89139571|NCT02743260|Experimental|metformin (MATE1, MATE2K, OCT1, OCT2)|500 mg metformin single dose
89139572|NCT02743260|Experimental|digoxin (intestinal & renal P-glycoprotein)|0.5 mg digoxin single dose
89139573|NCT02743260|Experimental|adefovir dipivoxil (OAT1)|10 mg adefovir dipivoxil single dose
89139574|NCT02743260|Experimental|sitagliptin (OAT3)|100 mg sitagliptin single dose
89139575|NCT02743260|Experimental|cocktail (all substances)|combination of all individual drugs at respective single doses
89139576|NCT00607061|Other|1|Full term newborn babies with gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile.
89139577|NCT00607061|Other|2|Low birth weight newborn babies (gestational age < 32 weeks of amenorrhea and/or weight of birth < 1500 g and/or weight of birth < third percentile for their gestational age.
89139578|NCT00607061|Other|3|Full term newborn babies (gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile).
89139579|NCT02817854||Patients with acute diverticulitis|Patients admitted in emergency setting for acute diverticulitis
89139580|NCT02819648|Experimental|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France); administered 30 minutes before endodontic treatment
89139581|NCT02819648|Placebo Comparator|Control|Milk tablet administered 30 minutes before endodontic treatment
89139582|NCT00934661|Experimental|Extended Release Epidural Morphine|Four mg (0.4 ml) of EREM will be delivered to the epidural space and flushed with 1 ml of saline
89139583|NCT00934661|Placebo Comparator|Placebo Group|The epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
89139584|NCT02743182|Active Comparator|Pegylated interferon alfa-2a|adding Pegylated interferon alfa-2a (180 microgs /week during 48 weeks) in HBeAg-negative patients receiving nucleos(t)ide analogues
89139585|NCT02743182|No Intervention|Control|HBeAg-negative patients receiving nucleos(t)ide analogues
89139586|NCT00775437|Experimental|Adalimumab|Adalimumab 24 mg/m^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.
89139587|NCT03924336|Experimental|Advanced- platelets rich fibrin plus with open flap debridement|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually. Then the defects will be thoroughly debrided using curettes and ultrasonic scalers. The clinical measurements will be then recorded. After debridement and intraoperative recordings, A-PRF+ of the required size will be filled into the intraosseous defect, the mucoperiosteal flaps will be repositioned and secured in place using 4-0 silk sutures
89139588|NCT03924336|Active Comparator|Open flap debridement (OFD)|Mucoperiosteal flaps will be elevated using an intrasulcular incision buccally and palatally or lingually. Then the defects will be thoroughly debrided using curettes and ultrasonic scalers. The clinical measurements will be then recorded. After debridement and intraoperative recordings, The interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
89139589|NCT04238078||Polycystic ovary syndrome|Women with PCOS diagnosed according to Rotterdam criteria
89139590|NCT04238078||Healthy control|Healthy women without any feature of ovulatory dysfunction or androgen excess
89139591|NCT02743416||ECG screening|Will be screened for AF using only one-stop protocol
89139592|NCT02743416||Control group|as per regular standard as of today
89139593|NCT04238000|Active Comparator|Real Stimulation|Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.
89139594|NCT04238000|Placebo Comparator|Sham Stimulation|The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)
89139595|NCT02747394|Experimental|Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of adaptive Cogmed
89139596|NCT02747394|Other|Non-Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of non-adaptive Cogmed
89139597|NCT02816918|Experimental|Extraluminal use of Univent Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
89139598|NCT02816918|Experimental|Innerluminal use of Univent Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
89139599|NCT05369507|No Intervention|Treatment as Usual|TAU group will receive standard care coordination efforts by health care team throughout course of HCV treatment
89139600|NCT05369507|Experimental|Virtual Care Coordination|Participants will download a mobile phone app (emocha) to facilitate care coordination throughout course of HCV treatment
89139601|NCT02742168|Experimental|Breast Cancer,99mTc-3PRGD2,SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of breast cancer
89139602|NCT04266821|Experimental|Experimental|Experimental-arm providers will complete two rounds of three simulated patient cases (CPVs) with two additions described in the next column:
89139603|NCT04266821|No Intervention|Control|These providers will complete two rounds of three simulated patient cases (CPVs) only.
89139604|NCT02695134|Other|Intervention Group|This group will receive 6 Healing Touch treatments over 3 weeks
89139605|NCT02695134|No Intervention|Control Group[|This group will continue with their usual medical treatments but receive NO Healing Touch
89139606|NCT02819414|Placebo Comparator|Control Group|Treatment with placebo at a volume of 2.25 cc/kg/dose x 4/day to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
89139607|NCT02819414|Active Comparator|Treatment Group|Treatment with paracetamol drops at 15 mg/kg/dose x 4/day. Drops will be diluted 1:15 in order to reduce osmolality. This will yield a dose of 2.25 ml/kg/dose, to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
89139608|NCT04265339|No Intervention|None smokers|50 participants who are non-smokers
89139609|NCT04265339|Experimental|Smoking Cessation|50 smokers who quit smoking
89139610|NCT04265339|No Intervention|Active smokers|50 smokers who continue smoking
89139611|NCT02816762|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
89139612|NCT02816762|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
89139613|NCT02743104|Active Comparator|Ketamine for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.~This study group will be exposed to ketamine as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
89139614|NCT02743104|Active Comparator|Propofol for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.~This study group will be exposed to propofol as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
89139615|NCT02816528||Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
89139616|NCT02816528||Nothing|Not Trained Physicians
89139617|NCT00775203|Experimental|Trazodone Contramid Once A Day (OAD)|
89139618|NCT00775203|Placebo Comparator|Placebo|
89139619|NCT02816684|Active Comparator|SET-C|Social Effectiveness Therapy for Children (SET-C; Beidel et al., 2000) includes social skills training, peer generalization experiences, and in vivo exposure.
89139620|NCT02816684|Experimental|Pegasys-VR|SET-C SST and individual exposure sessions are the same as the active comparator. Peer generalization sessions are replaced by a virtual environment, known as Pegasys School. children engage with artificially intelligent avatars throughout the school.
89139621|NCT02743026|Experimental|Intervention|participants will complete the FOXY intervention
89139622|NCT02817542||STEMI TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention with TA
89139623|NCT02817542||STEMI without TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention without TA
89139624|NCT00607217|Experimental|CAD-Exp|Enrolled coronary artery disease patients who are randomly assigned to receive influenza vaccine
89139625|NCT00607217|Placebo Comparator|CAD-Control|Enrolled coronary artery disease patients who are randomly assigned to receive placebo of influenza vaccine
89139626|NCT00607217|Experimental|Healthy-Control|Enrolled healthy subjects serve as control for CAD-Exp
89139627|NCT02742714|Experimental|PillCam SBC|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
89139628|NCT02601807|Active Comparator|Active|Subjects given active ActiPatch device before or after crossover (randomised)
89139629|NCT02601807|Placebo Comparator|Placebo|Subjects given placebo ActiPatch device before or after crossover (randomised)
89139630|NCT02817620|Experimental|Spirulysat®|Food supplement packaged in 10 ml vials called Spirulysat®. This product is a phycocyanin concentrated fresh spirulina water extract (Spirulina Platensis). 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
89139631|NCT02817620|Placebo Comparator|Placebo|Placebo with the same characteristics, appearance, packaging and composition as the active formula except for active ingredient (Spirulina) replaced by a classical blue food colorant used to colour desserts. 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
89139632|NCT02742792|Experimental|Resistance training|Resistance training, twice a week during 12 weeks.
89139633|NCT02742792|Other|Advice on lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
89139634|NCT05382767|Experimental|CKDB-501A|
89139635|NCT05382767|Active Comparator|Botox®|
89139636|NCT05650814|Experimental|ButterfLife|The patient will be recommended to take the measurement of five vital parameters once a day by ButterfLife device. Daily telemonitoring will be conducted in addition to standard home care.
89139637|NCT05650814|Other|Control|The patients will receive standard home care.
89139638|NCT00607529||1|Patients having a creatinine drawn
89139639|NCT05658848|Experimental|women cases|
89139640|NCT05658848|No Intervention|women control|
89139641|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 20|
89139642|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 30|
89139643|NCT02816216|Other|End User Iterative Testing - CampAir|To ensure the software and website function as intended, investigators will systematically test each of the seven CampAir modules with target end users. Participants will review one module per week for seven weeks. As part of each module, participants will also complete a daily asthma checklist. Following the review of each module, participants will be prompted to complete measures assessing technology acceptability and usability and product quality. Results will be used to modify and finalize the user interface and navigation to maximize usability.
89139644|NCT04238234||study group|Participants will be adult patients (above 18 years), ASA I-II-III, scheduled for elective surgeries under general anesthesia.
89139645|NCT04237766|Experimental|Experimental group|All patients included in the experimental group should be on prophylactic treatment with factor 8 (FVIII) or factor 9 (FIX) concentrates. Likewise, the factor should be administered on the same day that they receive each movement display therapy treatment sessions. Each session will last approximately 40 minutes, with 7 physiotherapy sessions a week taking place over a period of 4 weeks.
89234477|NCT00642941|Experimental|Cohort 6: Rhabdomyosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.
89234478|NCT00642941|Experimental|Cohort 7a: Alveolar Soft Part Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.
89234479|NCT00642941|Experimental|Cohort 7b: Desmoplastic Small Round Cell Tumors.|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.
89234480|NCT00642941|Experimental|Cohort 7c: Extraskeletal Myxoid Chondrosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.
89234481|NCT00642941|Experimental|Cohort 7d: Clear Cell Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
89234482|NCT00642941|Experimental|Cohort 7e: Myxoid Liposarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.
89234483|NCT00642941|Experimental|Cohort 8: Diagnosis Not Specified|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.
89234484|NCT00531960|Active Comparator|Bevacizumab, Chemotherapy|Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator.
89234485|NCT00531960|Experimental|Bevacizumab, Erlotinib|Participants received bevacizumab, 15 mg/kg, IV, on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received erlotinib, 150 mg, orally (PO), daily until disease progression, unacceptable toxicity, death, or withdrawal.
89234486|NCT01001676|Active Comparator|Conventional Balloon Angioplasty|
89234487|NCT01001676|Experimental|Drug Eluting Balloon Angioplasty|
89234488|NCT00816959|Active Comparator|Arm I: R-mabHDI and ABVD|
89234489|NCT00816959|Active Comparator|Arm II: ABVD|
89234490|NCT01001754|Experimental|PEG-rIL-29 at 120 µg|
89234491|NCT01001754|Experimental|PEG-rIL-29 at 180 µg|
89234492|NCT01001754|Active Comparator|Peginterferon alfa-2a at 180 µg|
89234493|NCT00825851|Active Comparator|continuous smoking|subjects smoke 20 cigarettes per day
89234494|NCT00825851|Active Comparator|smoking cessation and NRT|subjects quit smoking and use transdermal nicotine patch
89234495|NCT00825851|Placebo Comparator|smoking cessation and placebo patch|subjects quit smoking and use placebo patch
89234496|NCT00825851|No Intervention|never smokers|subjects being never smokers and who refrain from smoking
89234497|NCT00361504|Experimental|Tapentadol (CG5503)|Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
89234498|NCT00361504|Active Comparator|Oxycodone|Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.
89234499|NCT04446611|Experimental|Test at 1st ANC + Test-of-Cure (Treatment 1)|Single point-in-time diagnostic screening plus test-of-cure three weeks post-treatment
89234500|NCT04446611|Experimental|Test at 1st ANC + 30-34 gestation (Treatment 2)|Repeated diagnostic screening at first antenatal care and 30-34 weeks gestation
89234501|NCT04446611|No Intervention|Syndromic Management (Control)|Syndromic management (standard of care) at every antenatal care visit per South African National Guidelines.
89234502|NCT00826085|Experimental|Thermodox in combination with hyperthermia|Single arm study
89234503|NCT00361270|Experimental|Arm 1 Hyp-8|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist without audio recordings
89234504|NCT00361270|Experimental|Arm 2 Hyp-8 w recordings|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist with audio recordings
89234505|NCT00361270|Experimental|Arm 3 Hyp-2 w recordings|Single-site study at MEDVA-Houston Behavioral: 2 weeks 1-hour hypnosis with hypnotherapist with audio recordings
89234506|NCT00361270|Active Comparator|Arm 4 BIO|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour EMG biofeedback without audio recordings
89234507|NCT00826163|Active Comparator|stable COPD|Postbronchodilator FEV1> or = 50% predicted
89234508|NCT00826163|Sham Comparator|Asthma|Postbronchodilator FEV1 > or = 50% predicted
89234509|NCT00998166|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Chemotherapy infusion on Day 1 of a 3-week cycle
89139646|NCT04237766|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through mirror therapy and motion display. They will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with factor 8 (FVIII) or factor 9 (FIX) concentrates. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
89139647|NCT02747160|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a six-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
89139648|NCT04579406||non-diabetic group|The non-diabetic patients undergoing non-cardiac surgery.
89139649|NCT04579406||Diabetic group|The diabetic patients without peripheral neuropathy undergoing non-cardiac surgery.
89139650|NCT04579406||Diabetic neuropathic group|The diabetic patients with peripheral neuropathy undergoing non-cardiac surgery.
89139651|NCT04216368|Experimental|experimental group|
89139652|NCT04216368|Other|controlled group|
89139653|NCT02819492||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
89139654|NCT02741934||Preterm cohort|Among the infants who were born and admitted to Seoul National University Hospital from 2008 to 2009, the birth weight of the infants less than 1,500g or gestational age less than 32 weeks patients were enrolled.
89139655|NCT02741934||Term control cohort|The infants who were born from 2008 to 2009 with term gestational age will be enrolled.
89139656|NCT05648786|Experimental|Standard outpatient treatment plus Laddr®|"Laddr® is a smartphone application integrating science-based, therapeutic processes to address a wide range of behavioral problems in the context of a single mobile platform. Laddr includes tools for activating behavior change, solving problems and overcoming obstacles to effective behavior change; teaching skills and providing guidance on the execution of behavior change; and maintaining the end user's motivation to change. It enables longitudinal assessment of individuals' behavior and health status in naturalistic contexts, offers science-based self-regulation behavior change tools of relevance to an array of populations, and enables ongoing monitoring of health behavior. This study evaluates the effectiveness of new features to Laddr®. These new features are designed to be used with a support person, which could include a friend, family member, or acquaintance.~In addition to Laddr®, participants will receive standard outpatient substance use disorder treatment."
89139657|NCT05648786|Active Comparator|Standard outpatient treatment|The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
89139658|NCT02742870||Patients with MRI pelvic imaging|Women over 18 years old, having undergone a magnetic resonance imaging of the pelvis within the CHU Brugmann Hospital
89139659|NCT05648708|Active Comparator|Group AS|The investigators will perform an adductor canal block and sciatic nerve block on that patient group for postoperative analgesia
89139660|NCT05648708|Active Comparator|Group FS|The investigators will perform femoral and sciatic nerve blocks on that patient group for postoperative analgesia
89139661|NCT04190472||IOP VPH test|Immediately after the LEEP, a cervical sample is token for the IOP-HPV test
89139662|NCT02815748|Other|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
89139663|NCT02742948|Active Comparator|preoperative antibiotic group|200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision
89139664|NCT02742948|Active Comparator|early intraoperative antibiotic group|200 women will receive IV ceftriaxone (2g) immediately with skin incision
89139665|NCT02742948|Active Comparator|post cord clamping antibiotic group|200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping
89139666|NCT02816294|Experimental|Housing Prescription|Participants in the intervention group will be referred to the Care Coordinator at Project Hope, who will conduct case management with the family to stabilize their housing. The Care Coordinator will refer families all families to benefit maximization services and complete Problem Solving Education. The Care Coordinator will also refer families as necessary to Medical-Legal Partnership Boston for pro-bono legal services and/or the Boston Housing Authority for priority on a subsidized housing waitlist.
89139667|NCT02816294|No Intervention|Resource List|At present, for families facing housing insecurity, Children's HealthWatch offers paper resources with contact information for local social service agencies that may assist with housing stability.
89139668|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/4|
89139669|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/6|
89139670|NCT00636246|Active Comparator|sertraline-satellite|
89139671|NCT00636246|Active Comparator|sertraline-main|
89139672|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/2|
89139673|NCT00636246|Placebo Comparator|Placebo|
89139674|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-main|
89139675|NCT00636246|Active Comparator|[S,S]-reboxetine-main|
89139676|NCT02819570|Experimental|cefuroxime|I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg*2/d for 7 days
89139677|NCT02819570|Active Comparator|ampicillin|I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg*2/d for 7 days
89139678|NCT02747472|Placebo Comparator|Placebo|Infusion of saline
89139679|NCT02747472|Active Comparator|GIP(1-42)|Infusion of agonist, GIP(1-42)
89139680|NCT02747472|Experimental|GIP-A|Infusion of GIP-A alone
89139681|NCT02747472|Experimental|GIP-A + GIP(1-42)|Infusion of GIP-A and GIP(1-42)
89139682|NCT04239170|Experimental|Camrelizumab(SHR-1210) Combined With GEMOX|
89139683|NCT02741622|Experimental|Exercise|Acute High aerobic intensity training (HIT) and long slow distance training (LSD)
89139684|NCT04200638|Experimental|ProTaper Next group|Clean and shape the necrotic canals with ProTaper instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
89139685|NCT04200638|Experimental|WaveOne Gold group|Clean and shape the necrotic canals with Wave One Gold instruments. In case of pain or inflammation 800mg Ibuprofen 3 times a day
89139686|NCT02819336|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions within 21 days)~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)~20 minutes duration with middle frequency (30 Hz) of electrical stimulation~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
89139687|NCT02819336|Sham Comparator|Park sham (PS) group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions within 21 days)~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)~20 minutes duration with undelivered electrostimulation of middle frequency (30 Hz)~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
89139688|NCT02747082|Active Comparator|1% sodium hypochlorite (NaOCl)|"Retreatment of root-filled teeth with infection with 1% NaOCl as irrigation solution.~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
89139689|NCT02747082|Active Comparator|2% chlorhexidine gluconate (CHX)|"Retreatment of root-filled teeth with infection with 2% CHX as irrigation solution.~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
89139690|NCT00636324|Experimental|1|Nasal CPAP, level of 7 to 9 cmH2O
89139691|NCT00636324|Active Comparator|2|Nasal CPAP, level 4 to 6 cmH2O
89139692|NCT04480190|Experimental|Research Treatment|Gemcitabine/Cisplatin/ChemoRT
89139693|NCT02741778|Other|Minimally invasive group|"In this group, all manipulations are finished by laparoscopy and thoracoscopy.~Horizontal position, undergoing laparoscopy through 5-port method. The sequence: gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes ), gastric tube making, and jejunostomy.~Left lateral position, undergoing thoracoscopy through 3-port method. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection, gastro-esophageal anastomosis by using CEEA."
89139694|NCT02741778|Other|Open group|"Right lateral position, Traditional thoracotomy through the 7th intercostal incision. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection.~Then,oped the diaphragm,undergoing gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes), gastric tube making, gastro-esophageal anastomosis by using CEEA. Nasointestinal tube is placed for feeding."
89139695|NCT02819258|Other|Endodontic treatment for a tooth with a periapical pathology|
89139696|NCT02741856|Experimental|Arm 1 (carboplatin/paclitaxel+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (50Gy/25 fractions)"
89139697|NCT02741856|Experimental|Arm 2 (cisplatin/capecitabine+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14~Cycles 3 and 4 are given concomitantly with radiotherapy (50Gy/25 fractions). Capecitabine stops on last day of RT."
89139698|NCT02741856|Experimental|Arm 3 (carboplatin/paclitaxel+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (60Gy/25 fractions)"
89139699|NCT02741856|Experimental|Arm 4 (Cisplatin+Capecitabine+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14 Cycles 3 and 4 are given concomitantly with radiotherapy (60Gy/25 fractions). Capecitabine stops on last day of RT."
89139700|NCT04574102|Experimental|Study Eye|Omega Refractive capsule, model V, with an FDA approved intraocular lens.
89139701|NCT04574102|Active Comparator|Control Eye|FDA approved Intraocular Lens
89139702|NCT02741466|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
89139703|NCT04565834||Suicidal patients|Patients who have made at least one attempt to commit suicide.
89139704|NCT04565834||Control group|"This group will consist of two types of people:~75 healthy subjects (i.e. those who have no mental disorders and have never attempted to commit suicide) and~150 patients suffering from depression but have never attempted to commit suicide."
89139705|NCT02742636|Experimental|Group A (treatment group)|The patients in this group will have their catheter directly removed in the OR after LH.
89139706|NCT02742636|Active Comparator|Group B (control group)|The patients in the control group will have their catheter removed according to the regular protocol of the hospital (at least 6 hours in place).
89139707|NCT00633854||1|30 volunteer subjects who are age 60 and older
89139708|NCT02741232|Active Comparator|Pectoral nerve block|After induction of general anesthesia and under ultrasound visual guidance, pectoral block is performed with 30 mL total of local anesthetic (1% lidocaine + 1/400000 epinephrine). 10 mL of local anesthetic between pectoralis major muscle and pectoralis minor muscle and 20 mL between pectoralis minor muscle and serratus anterior muscle at the third rib.
89139709|NCT02741232|Sham Comparator|Sham block|No needle or injection will be used
89139710|NCT02816606||Standard Reconstruction Technique|ACL reconstruction using hamstring autograft Using 30-degree arthroscope Using rigid femoral tunnel reamer (Rigid Reamers)
89139711|NCT02816606||Alternative Reconstruction Group|ACL reconstruction using hamstring autograft Using 30-degree and 70-degree arthroscopes Using flexible femoral tunnel reamer (Flexible Reamers)
89139712|NCT02742558|Experimental|cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
89139713|NCT02742558|Active Comparator|shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
89139714|NCT02816450|Experimental|HIGH|Increase water intake to 2.5 liters per day for 4 days
89139715|NCT02816450|Experimental|LOW|Decrease water intake to 0.5 liter per day for 4 days
89139716|NCT02816840|Experimental|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
89139717|NCT02816840|Experimental|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
89139718|NCT02816840|No Intervention|Computed Tomography|Patients in this arm take radiotherapy positioning with CT.
89139719|NCT04291950||Control group|Hispanic and NHW women undergoing either a benign breast surgery or prophylactic mastectomy.
89139720|NCT04291950||Newly diagnosed TNBC|Hispanic and NHW with newly diagnosed TNBC. Patients with TNBC will be eligible regardless of whether their treatment plan is surgery first or chemotherapy first (neoadjuvant chemotherapy).
89139721|NCT04426058|Experimental|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
89139722|NCT04426058|Active Comparator|Fascia iliaca|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
89139723|NCT02737020|Experimental|Rhodiola|Rhodiola rosea 200mg up to four times a day for 28 days
89139724|NCT02737020|Placebo Comparator|Placebo|Placebo pill manufactured to mimic Rhodiola rosea 200mg, up to four times a day for 28 days
89139725|NCT05629104||Preserved heart function|The group will be defined as preserved left ventricular ejection fraction (LVEF) with and without hypertrophy and with and without reduced global longitudinal strain (GLS).
89139726|NCT05629104||Reduced heart function|The group will be defined as reduced LVEF
89139727|NCT04239014|Experimental|Arm 1 (ceralasertib+olaparib)|Participants received ceralasertib 160 mg QD PO on Days 1 to 7 plus olaparib 300 mg BD PO continuous (28 day cycle).
89139728|NCT04239014|Experimental|Arm 2 (olaparib monotherapy)|Olaparib 300 mg BD PO daily continuous.
89139729|NCT04239014|Experimental|Arm 3 (placebo)|Placebo to match olaparib BD PO daily continuous.
89139730|NCT00568321|Experimental|1|
89139731|NCT00568321|Active Comparator|2|
89139732|NCT00568321|Placebo Comparator|3|
89139733|NCT02742480||Dabigatran|300 patients treated with dabigatran under the habitual clinical practice.
89139734|NCT02742480||Acenocoumarol|200 patients treated with acenocoumarol under the habitual clinical practice.
89139735|NCT02740998||Depo Provera|Ten women ages 18-40 who elect to start a using Depo Provera for contraception.
89139736|NCT02740998||Mirena IUD|Ten women ages 18-40 who elect to start a using a Mirena IUD for contraception.
89139737|NCT02740998||Nexplanon|Ten women ages 18-40 who elect to start a using Nexplanon for contraception.
89139738|NCT02740998||Control: Tubal Sterilization|Five women ages 18-40 who elect to have a tubal sterilization.
89139739|NCT02816060|Experimental|neural tensionner exercise|This group will receive a specific tensionner nerve exercise to provide mechanical stress across the median nerve. This technique have two positions, start and end. It consists on going from one to the other position constantly, controlling the speed of the technique to be constant. In the start position, the subject will be supine lying on a couch with the following parameters: contralateral cervical side bending, shoulder depression, shoulder abduction and external rotation to 90°, elbow flexion to 90º, and forearm supination. In the final position, the therapist will perform full elbow extension while maintaining all the joints previously situated as described above until the patients feel tension, then return to the start position.
89139740|NCT02816060|Placebo Comparator|sham neural tensionner exercise|The control group will receive a sham technique (ST) with minimal mechanical stress across the median nerve. Patients will be placed in neutral cervical spine position with no shoulder depression, shoulder abduction and external rotation to 45°, 45° of elbow extension, and forearm pronation.. This technique will be passively repeated from elbow flexion to extension in the same way than the NTE group
89139741|NCT00774345|Experimental|Experimental: 1|Lenalidomide po qd on days 1-28 of a 28 day cycle
89139742|NCT00774345|Placebo Comparator|Placebo Comparator: 2|Placebo capsules given orally on days 1-28 of a 28 day cycle
89139743|NCT02742402|Experimental|Observation|Clinical follow-up for at least 6-8 hours, after follow-up repeated laboratory tests and repeated clinical examination is done. Adult Appendicitis Score is calculated after observation to determine further actions. Observation is continued in patients with decreasing score. Patients with the same or higher score undergo diagnostic imaging (score 11-15) or laparoscopy (score 16 or higher). Diagnostic imaging is abdominal ultrasound first and if the result is inconclusive or negative for appendicitis abdominal computed tomography is done. Laparoscopic appendectomy is done for those patients with appendicitis in diagnostic imaging.
89139744|NCT02742402|Active Comparator|Diagnostic imaging|Patients undergo abdominal ultrasound and if the result is inconclusive or negative for appendicitis patients will have abdominal computed tomography. Laparoscopic appendectomy is done for patients with appendicitis in diagnostic imaging.
89139745|NCT02816372|Experimental|Tidal volume 4 ml/kg Predicted Body Weight (PBW)|
89139746|NCT02819102|Experimental|Metabolic Probes and BCX7353|"Day 1: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, and 30 mg dextromethorphan orally.~Day 2: a single oral dose of 2 mg midazolam. Days 3 to 9: 350 mg BCX7353 once a day. Day 10: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, 30 mg dextromethorphan and 350 mg BCX7353, orally.~Day 11: a single oral dose of 2 mg of midazolam along with 350 mg BCX7353."
89139747|NCT02815358|Experimental|Segmental Stabilization Group|Patients receiving segmental stabilization exercises.
89139748|NCT02815358|Active Comparator|Control Group|Patients receiving home exercises.
89139749|NCT02736708||PSC|Male or female > 18 years of age Clinically Indicated for ERCP and/or cholangioscopy for dominant PSC stricture Inclusion of patients either previously stented or not
89139750|NCT02815436|Active Comparator|Telephone reminder|subjects in this arm will receive a telephone reminder
89139751|NCT02815436|Active Comparator|SMS reminder|Subjects in this arm will receive a SMS reminder
89139752|NCT02815436|No Intervention|No reminder|usual care, where no additional intervention will be offered
89139753|NCT02736552|Experimental|S-1 for 6 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 6 months after D2 resection
89139754|NCT02736552|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
89139755|NCT02815514||Aortic valve procedures|"percutaneous transfemoral aortic valve implantation~percutaneous transapical aortic valve implantation~percutaneous transaortic aortic valve implantation~aortic valve valvuloplasty~surgical aortic valve replacement~conservative treatment"
89139756|NCT02819180||Healthy adults group|Healthy men and women between 18 and 59 years of age.
89139757|NCT02819180||Elderly group|Elderly over 60 years old.
89139758|NCT02740842|Active Comparator|Non-intensive group|Essential Health Care (EHC) only This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
89139759|NCT02740842|Experimental|Intensive group|"Interpersonal behavioral change communication This arm will have a behavior change communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.~In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm."
89139760|NCT02736396||Healthy Controls|Medical History, Neuropsychological tests, clinical assessments, fMRI
89139761|NCT02736396||Cognitive impairment|Medical History, Neuropsychological tests, clinical assessments, fMRI
89139762|NCT04101981||healthy subjects|10 subjects
89139763|NCT04101981||oncological patients|10 subjects
89139764|NCT04661930|Experimental|Fenofibrate + Usual Care|Participants in this arm will receive the study drug, Fenofibrate, in combination with usual care.
89139765|NCT04661930|Placebo Comparator|Placebo + Usual Care|Participants in this arm will receive placebo treatment, in combination with usual care.
89139766|NCT04661930|No Intervention|Usual Care (Observetional)|Participants in this arm will receive the usual care and be compared by their medical records and laboratory results
89139767|NCT00916227|Experimental|ARRY-614|
89139768|NCT02814188|Experimental|Carbohydrate Beverage|
89139769|NCT02814188|Placebo Comparator|Placebo Beverage|
89139770|NCT04102137||3|Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines
89139771|NCT02815202|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89139772|NCT05326035|Experimental|Experimental： WJ05129 tablets|Twice daily (except for single dose), 12 hours apart, fixed time is recommended
89139773|NCT02814812|Experimental|pancreatic surgery|
89139774|NCT04324008|Experimental|Constic|Constic (DMG, Hamburg, Germany)
89139775|NCT04324008|Experimental|G-ænial Universal Flo|G-ænial Universal Flo (GC Corporation, Tokyo, Japan) in combination with G-Premio Bond (self-etch mode)
89139776|NCT04324008|Experimental|Tetric N-Flow (self-etch)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (self-etch mode)
89139777|NCT04324008|Experimental|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Ivoclar Vivadent, Schaan, Liechtenstein) in combination with Tetric N-Bond Universal (etch&rinse mode)
89139778|NCT02814266|Other|difficult intubation|Intubation difficulty score >5
89139779|NCT02814266|Other|Easy intubation|Intubation difficulty score >5
89139780|NCT04101825|Experimental|Auralya|Auralya® 25 (Cross-linked Hyaluronic Acid) Injection
89139781|NCT04314414|Experimental|Intervention group|Participants in the intervention group will receive a semi-scripted brief motivational interview from the peer recovery coach (PRC) in addition to the standard of care at Boston Medical Center (BMC) for HIV, HCV, and opioid use disorder.
89139782|NCT04014517|Active Comparator|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
89139783|NCT04014517|Experimental|Immunonutrition|Impact
89139784|NCT02601963|Experimental|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
89139785|NCT02601963|Experimental|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
89139786|NCT02601963|Placebo Comparator|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
89139787|NCT00927979|Experimental|Ropivacaine|
89139788|NCT00927979|Placebo Comparator|Water for injection|
89139789|NCT00931957|Active Comparator|Etanercept-MTX-Prednisolone|Methotrexate + Prednisolone + Etanercept
89139790|NCT00931957|Other|B, MTX-Prednisolone|Methotrexate + Prednisolone
89139791|NCT04014985|Other|Girls with RETT syndrome|100 girls over 18 years old with RETT syndrome
89234510|NCT03866135||patients with osteoporosis|Osteoporosis has been operationally defined on the basis of bone mineral density (BMD) assessment. According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviations or more below the average value for young healthy women (a T-score of <-2.5 SD)
89139792|NCT02731950|Active Comparator|A magnesium|"Consists of 20 patients:~Each receive bupivacaine 0.125% with 5% magnesium sulfate by infusion through a small diameter multi-hole soft catheter generally used for epidural analgesia positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 hours postoperative. A bolus of 5 ml of the study solution will be injected in the catheter after aspiration test before connection to infusion pump that delivers continuous infusion pump that delivers continuous infusion at a fixed rate of 5 ml/h.~postoperative : 25 µg fentanyl for breakthrough pain. placebo will be given in same intravenous instead of paracetamol and ketorolac of group B , to keep the investigator blinded"
89139793|NCT02731950|No Intervention|B control|"Consists of 20 patients:~saline as placebo infusion through a small diameter multi-hole soft catheter positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 Postoperative pain control will be managed with 1gm paracetamol /6 hr, Ketorolac 30 mg every 8-12 hour .25 µg fentanyl for breakthrough pain."
89139794|NCT00773253|Active Comparator|standard EMG-guided Botox injection|All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.
89139795|NCT00773253|Experimental|Multi-channel EMG-guided Botox injection|Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.
89139796|NCT00928213|Experimental|1|Control not treated, no placebo
89139797|NCT00928213|Experimental|2|Patient treated with low molecular weight heparin after repeated pregnancy loss
89139798|NCT00928213|Experimental|3|Patient super from first trimester bleeding treated with progesterone
89139799|NCT02731872|Experimental|High Flow humidification system|In addition to their usual oxygen apparatuses, the treatment group will have an Airvo humidifier system installed in the home. The supplied oxygen flow will be entrained along with room air through the Airvo humidification system. this combined respiratory gas will then be warmed and humidified and delivered to the patient via a nasal cannula. The total respiratory gas flow rate will be between 20-25 l/min, depending on participant´s preference. Then the oxygen fraction is adjusted until the subjects target oxygen saturation levels are achieved.
89139800|NCT02731872|No Intervention|Standard oxygen therapy|The control group will continue receiving the standard oxygen therapy prescribed by the department
89139801|NCT00924391|Active Comparator|dairy milk|Control phase with 1% milk.
89139802|NCT00924391|Experimental|phytosterol enhanced soy based beverage|Treatment phase where control-phase diets are provided with phytosterol enhanced soy based beverage.
89139803|NCT02731794|Experimental|LVA group|LVA group: left ventricular assist group.
89139804|NCT02731794|Active Comparator|BiVA group|BiVA group: Biventricular assist group.
89139805|NCT00928291|Experimental|Group 1 - PCT group|interventions on antibiotic therapy will be based on circulating PCT levels
89139806|NCT00928291|Active Comparator|Group 2 - Control group|antibiotic therapy will be guided by appropriate guidelines, and will be left at the discretion of caregivers.
89139807|NCT02736240|Active Comparator|Control Arm|7-valent pneumococcal conjugate vaccine
89139808|NCT02736240|Experimental|Test Arm|13-valent pneumococcal conjugate vaccine
89139809|NCT00924547|Experimental|Docosahexanoic Acid Supplement|In this arm, participants took two different doses of a DHA supplement. Each dose of the DHA supplement was taken for 4 weeks.
89139810|NCT00924547|Placebo Comparator|Placebo|In this arm, participants took a placebo pill that did not contain any DHA.
89139811|NCT02736162||Perampanel|Participants with a diagnosis of epilepsy who received perampanel as primary or secondary (conversion) monotherapy at any time between 1 Jan 2013 and 15 Oct 2015.
89139812|NCT03743467||Control group|Health subjects
89139813|NCT03743467||PD patients Hoehn Yahr 1|Patients with Hoehn Yahr stage 1
89139814|NCT03743467||PD patients Hoehn Yahr 2-3|Patients with Hoehn Yahr stage 2 and 3
89139815|NCT02736084|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events Using personal strengths Gratitude letter Enjoyable and meaningful activities Recalling past success Performing acts of kindness Repeating one of the previous exercises."
89139816|NCT03743545|Active Comparator|conventional drilling with irrigation|
89139817|NCT03743545|Experimental|low speed without irrigation|
89139818|NCT00932191|Active Comparator|Ultrasound phacoemulsification|Cataract nucleus is removed using standard amounts of ultrasound energy.
89139819|NCT00932191|Active Comparator|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
89139820|NCT00773175|Active Comparator|Subcutaneous|Isotonic fluid rehydration by SC administration with hylenex (150 Units in 1 mL)
89139821|NCT00773175|Active Comparator|Intravenous|Isotonic fluid rehydration by IV
89139822|NCT02741154|Experimental|aromataze group|patients will receive induction with HMG plus aromataze inhibitor plus GnRh antagonist plus HCG injection
89139823|NCT02741154|Active Comparator|classic group|same protocol for induction without aromataze inhibitor
89139824|NCT02735850|Experimental|Ablative SBRT to all (max 3) sites followed by L19-IL2|Ablative cohort
89139825|NCT02735850|Active Comparator|Ablative SBRT to all (max 3) sites|Ablative cohort
89139826|NCT02735850|Experimental|SBRT 1 site, L19-IL2 and then standard of care|Non-ablative cohort
89139827|NCT02735850|Active Comparator|Standard of care|Non-ablative cohort
89139828|NCT02601885|Experimental|Group 2|Participants will receive multiple doses of ABT-555 or placebo
89139829|NCT02601885|Experimental|Group 3|Participants will receive multiple doses of ABT-555 or placebo
89139830|NCT02601885|Experimental|Group 1|Participants will receive multiple doses of ABT-555 or placebo
89139831|NCT05467722|Experimental|CTP-543 Treatment - Mild Hepatic Impairment|
89139832|NCT05467722|Experimental|CTP-543 Treatment - Moderate Hepatic Impairment|
89234511|NCT03866135||patients without osteoporosis|Bone mineral densities of patients were based on the World Health Organization (WHO) classification of a T score between -1 and -2.5 for osteopenia
88803354|NCT05473936|Experimental|Intervention Arm - CHW-led curriculum (Group 2)|Participants assigned to the intervention group will complete the same activities as Group 1 and be asked to participate in the virtual intervention, consisting of six-weekly group classes via Zoom, and six-weekly personalized teleconsultations (via phone call or Zoom) at a suitable time for both participants and CHWs. Study participants will receive 6 linguistically and ethnically concordant weekly two-hour group classes and personalized teleconsultations led by CHWs. The total time commitment for Group 2 will be a maximum of 20 hours (6 two-hour group classes, + 6 one hour personal session, + 2 half hour phone calls), over the next 6 weeks.
89139833|NCT02740764|Experimental|Optimization of drug prescribing|The group with optimization program will have: (i) a medical history of the drug prescribing; (ii) analysis and pharmaceutical recommendations and (iii) preparation of a management plan. Notices will be sent only to referring physicians in this experimental group.
89139834|NCT02740764|No Intervention|No intervention|This group will receive the current management of patients in geriatric or memory consultation, during which the intervention of a clinician pharmacist is not provided. There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital, but the recommendations will not be transmitted to the referring physicians of patients.
89139835|NCT02731560|Other|Single Arm|Treatment with Rituximab in RA patients showing inadequate response to standard DMARDs
89139836|NCT02736006|Experimental|20 meters air dive|
89139837|NCT02740686||Frequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the frequent exacerbators group based on whether they have had 2 or more hospitalisations for exacerbations or have taken 2 or more courses on steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
89139838|NCT02740686||Infrequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the infrequent exacerbators group based on whether they have had no more than 1 hospitalisation for exacerbations or have not taken more than 1 course of steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
89139839|NCT02740686||Healthy smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and currently smoke.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. A resting blood sample will be taken from these patients and used to compare baseline measurements with the COPD groups.
89139840|NCT02740686||Healthy never smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and have never smoked.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. Resting blood samples will be taken from these patients and used to compare baseline measurements with the COPD groups.
89139841|NCT00566527|Experimental|Arm 1: ProQuad® at 9 and 12 months|Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 at 12 months of age.
89139842|NCT00566527|Experimental|Arm 2: ProQuad® at 11 and 14 months|Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 at 14 months of age.
89139843|NCT00566527|Active Comparator|Arm 3: ProQuad at 12 and 15 months|Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 at 15 months of age.
89139844|NCT02735772|Other|cystocele|"Arm: Patients with paravaginal defect cystocele~Intervention: transobturator approach for paravaginal repair"
89139845|NCT00924625|Experimental|Neuromuscular electrical stimulation|NMES will be used as in clinical practice based on an evidence-based approach. NMES will be applied at the participant's maximum tolerance. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions.
89139846|NCT00924625|Active Comparator|Volitional exercises|VE will be used as in clinical practice based on an evidence-based approach. VE program will be the one shown to positively affect muscle hypertrophy and will follow the resistance training principles. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions
89139847|NCT00773097|Experimental|MUC1 Poly-ICLC|
89139848|NCT02815826||Barefoot training|16 weeks of progressive barefoot running training
89139849|NCT02731482|Experimental|Training Group|Patients with bronchiectasis in home-based pulmonary rehabilitation
89139850|NCT02731482|Active Comparator|Control Group|Patients with bronchiectasis in usual care and recommendations for performing exercises
89139851|NCT00933335|Experimental|Single Arm|Patients will first receive an abbreviated course of three cycles of fludarabine (25 mg/m2 for 5 days every 5 weeks). Iodine I 131 tositumomab will be initiated 6 to 8 weeks after completion of fludarabine. Patients will undergo dosimetry studies to determine the appropriate patient-specific activity of iodine I 131 tositumomab required to deliver a fixed dose of 75 cGy. The dose will be attenuated to 65 cGy for patients with platelet counts between 100,000 and 150,000/micoliter.
89139852|NCT04015297|Experimental|control|healthy controls
89139853|NCT04015297|Experimental|patient|patients diagnosed with endometriosis
89139854|NCT02814110|Other|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor Muscle strength Muscular dystrophy
89139855|NCT02731404|Other|IPPV ventilation|standard intermittent positive pressure ventilation in patients undergoing laparoscopic cholecystectomy
89139856|NCT02731404|Other|HFJV ventilation|high frequency jet ventilation in patients undergoing laparoscopic cholecystectomy
89139857|NCT00932269||Seroimmunity 2007|Cord blood from 400 newborns, 1800 children (2 - 18 years) and 2400 adults (above 18 years), randomly selected and stratified in age groups, from which blood samples are taken.
89139858|NCT00932269||Sub Study|800 immigrated children (14 - 16 years) from which blood samples are taken.
89139859|NCT02731326|Experimental|iHEART|Participants will transmit daily ECGs using AliveCor for 6 months following cardioversion or ablation procedure to treat AF/AFL. Participants will also receive read-only behavioral altering messaging three times per week focusing on AF, cardiovascular risk factors, and healthy living.
89139860|NCT02731326|No Intervention|Usual Care|Participants will continue with usual care with their physician.
89139861|NCT02815904|Experimental|Yakson touch and Kinesthetic stimulation|"Yakson touch (YT) The therapist will relax arms and shoulder muscles for 1 minute and will do deep breathing to accumulate Ki energy on the palms. The Therapist will apply Yakson on the neonate.~Kinesthetic stimulation (KS) For giving kinesthetic stimulation the neonate will be placed in supine position. There will be six passive flexion and extension movements. Each of the movement will each last for approximately 10 seconds. The movements will be performed in the following order -right arm, left arm, right leg, left leg, both legs simultaneously"
89139862|NCT02815904|Active Comparator|Conventional Handling and KMC|"Conventional Handling (CH) The neonates in control group will receive developmental positioning(positioning of preterm infants for optimal physiological development) for 20 minutes per hour for 5 days.~Kangaroo mother care (KMC) Holding the neonate skin to skin by mother for one hour a day"
89139863|NCT04237610||Bipolar disorder type I|
89139864|NCT04237610||Bipolar disorder type II|
89139865|NCT04237610||healthy controls|
89139866|NCT04264481|Experimental|Adductor Canal Block|Adductor Canal Block (Saphaenous Nerve Block) done under Ultrasonographic guidance with 5cc of Bupivacaine, 5cc of lidocaine diluted with 10 cc of Normal Saline
89139867|NCT04264481|Active Comparator|Intra-articular Steroid and Lignocaine|Intra-articular knee joint injection of 40mg triamcinolone and 1-2cc of lidocaine
89139868|NCT00932347|Experimental|Mouthwash A|Mouthwash A: Camellia sinensis mouthwash
89139869|NCT00932347|Placebo Comparator|Mouthwash B|Mouthwash B: Placebo mouthwash
89139870|NCT02814032||PTC group 1|papillary thyroid carcinoma patients with cervical lymph node metastasis
89139871|NCT02814032||PTC group 2|papillary thyroid carcinoma patients without cervical lymph node metastasis
89139872|NCT02814032||Positive control group|benign disease
89139873|NCT02814032||Negative control group|histologically normal
89139874|NCT05382611||Patients Controls|Control group
89139875|NCT05382611||Patients with aneurysma|Patients with aneurysma
89139876|NCT02735538||osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
89139877|NCT02735538||osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
89139878|NCT00928603|Experimental|cryotherapy|Focal Cryotherapy of localized tumor of prostate after spatial definition by in-house extended perineal core biopsy using a template biopsy strategy under local or general anesthesia
89139879|NCT05303909|Experimental|Gentamicin|a single dose of IV gentamicin at a dose of 5 mg/kg (rounded up to the nearest 10mg) diluted in 100mls of 0.9% normal saline infused over 30 minutes via a peripheral vein
89139880|NCT05303909|Placebo Comparator|Placebo|100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein
89139881|NCT04306692|Experimental|Inositol group|Myo-inositol 4000 mg Dosing: 2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged) during 3 consecutive treatment cycles.
89139882|NCT04306692|Active Comparator|Clomiphene citrate group|Each tablet contains 50 mg of clomiphene citrate Dosing: 1 tablet per day, per os, from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days during 3 consecutive treatment cycles.
89139883|NCT00928681|Other|0.03 mg/kg or placebo iv|
89139884|NCT00928681|Other|0.1 mg/kg or placebo iv|
89139885|NCT00928681|Other|0.3 mg/kg or placebo iv|
89139886|NCT00928681|Experimental|1.0 mg/kg or placebo iv|
89139887|NCT00928681|Other|3.0 mg/kg or placebo sc|
89139888|NCT00928681|Other|10 mg/kg or placebo iv|
89139889|NCT00928681|Other|0.3 mg/kg or placebo sc|
89139890|NCT00928681|Other|0.1 mg/kg or placebo iv (multiple dose)|
89139891|NCT00928681|Other|0.3 mg/kg or placebo iv (multiple dose)|
89139892|NCT00928681|Other|3.0 mg/kg or placebo iv|
89139893|NCT00928681|Other|0.1 mg/kg or placebo sc|
89139894|NCT00928681|Other|0.3 mg/kg or placebo sc (multiple dose)|
89139895|NCT00772941||Varenicline|Patients taking Varenicline.
89139896|NCT00607295|Experimental|1|Clino-san 2ml vaginal application 3 times per week for 12 weeks
89139897|NCT00607295|Placebo Comparator|2|placebo 2ml vaginal application 3 times per week for 12 weeks
89139898|NCT02813798|Experimental|Mild Renal Impairment|A single dose of IV Rivipansel over 20 minutes
89139899|NCT02813798|Experimental|Moderate Renal Impairment|A single dose of IV Rivipansel over 20 minutes
89139900|NCT02813798|Experimental|Severe Renal Impairment|A single dose of IV Rivipansel over 20 minutes
89139901|NCT02813798|Experimental|Normal Renal Functions|A single dose of IV Rivipansel over 20 minutes
89139902|NCT02735694|Active Comparator|Cycloserine|Cycloserine, 250 mg capsules by mouth, one hour prior to initiation of sleep study, single dose
89139903|NCT02735694|Placebo Comparator|Placebo|Placebo, sugar capsule by mouth, one hour prior to initiation of sleep study, single dose
89139904|NCT00932503|No Intervention|PDS II|PDS II® loop suture was used for abdominal wall closure
89139905|NCT00932503|Active Comparator|Vicryl plus|"antiseptic coated Vicryl plus was used for abdominal wall closure"
89139906|NCT00607607|Experimental|A|Ovarian Cancer Patients
89139907|NCT00607607|Experimental|B|Endometrial Cancer Patients
89139908|NCT05592444|Experimental|Low concentration|"Patients receive a contrast medium with an iodine concentration of 140 mg/ml. The volume is 1 ml/kg which result in a dose of 140 mg/kg.~Maximal dose of contrast medium is 90 ml i.e. 12.6 g of iodine."
89139909|NCT05592444|Experimental|Low volume|"Patients receive a contrast medium with an iodine concentration 350 of mg/ml. The volume is 0.4 ml/kg which result in a dose of 140 mg/kg.~Maximal dose of contrast medium is 36 ml i.e. 12.6 g of iodine."
89139910|NCT05592444|Experimental|Saline Dilution|"Patients receive a contrast medium with an iodine concentration of 350 mg/ml. The contrast medium is diluted 1:1 with saline.~The injected volume is 0.8 ml/kg which result in a dose of 140 mg/kg. Maximal dose of contrast medium is 72 ml i.e. 12.6 g of iodine."
89139911|NCT00924859||1|Patients with clinical suspicion of CVT
89139912|NCT04237454|Experimental|Infrared Imaging undertaken|
89139913|NCT02735616||study|"15 CVA patients, 1-3 weeks after their first stroke. The patients will be hospitalized in the neurology department at the geriatric Beit-Rivka hospital at Petah-Tiva, Israel.~patients with pacemaker or those who use Beta-Blocker drugs, as well as patients with cerebellar injury, will be excluded from the research"
89139914|NCT02735616||control|15 patients from the orthopedic department at the same hospital, matching by age and gender to the study group.
89139915|NCT04101435|Experimental|Group A|Aged 3 to 8 years old vaccine naïve subject (without prior seasonal influenza vaccine exposure)
89139916|NCT04101435|Active Comparator|Group B|Aged 3 to 8 years old vaccine non-naïve subject (with prior seasonal influenza vaccine exposure)
89139917|NCT04101435|Experimental|Group C|Aged 9 to 17 years old subject
89139918|NCT02813720||Patients with peripheral PsA|
89139919|NCT02813720||Patients with psoriatic nail onycholysis|
89139920|NCT02813720||Patients with PsO only|
89139921|NCT02813720||Healthy match control subjects|
89139922|NCT02694900|Experimental|Resuscitation on the flor|2 min asynchronous cardiopulmonary resuscitation. The patient lies on the floor
89139923|NCT02694900|Experimental|Resuscitation on the stretcher|2 min asynchronous cardiopulmonary resuscitation. The patient lies on a stretcher
89139924|NCT00772707|Experimental|Opti-Free Replenish|Multi-purpose contact lens solution for cleaning and disinfecting study contact lenses used on a daily basis for 30 days.
89139925|NCT02735460|Experimental|Treatment arm|In this arm the Andago V2.0 is used.
89139926|NCT00924937|Active Comparator|Low Fat Diet|Dietary Intervention with a Low fat diet: <30% fat (12% monounsaturated fatty acids; 6-8%polyunsaturated fatty acids; <10% saturated fatty acids)
89139927|NCT00924937|Experimental|Mediterranean Diet|Dietary Intervention with a Mediterranean Diet: 35-38% fat (22% monounsaturated fatty acids; 6% polyunsaturated fatty acids; <10% saturated fatty acids).
89139928|NCT05382455||Delphi Panel|A team of experts in the use AI technology in medicine together with experts in PRISMA, STARD-AI, CONSORT-AI, SPIRIT-AI, TRIPOD-AI, PROBAST-AI, CLAIM-AI and DECIDE-AI will evaluate the PRISMA-AI extension reporting guidelines
89139929|NCT05325957||Norepinephrine variation|Patients with septic shock, cardiac output monitoring device with the PICCO2 system or swan ganz catheter and decision by the physician in charge to modify the norepinephrine dose.
89139930|NCT05325957||Fluid infusion|Patients with septic shock, cardiac output monitoring device with the PICCO2 system or swan ganz catheter and decision by the physician in charge to give fluid infusion
89139931|NCT02735304|Other|Innovation treatment 3M ESPE materials|"The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment during the Impression intervention.~Materials to be used all 3M ESPE - Astringent Retraction Paste, Imprint™ 4 Preliminary, Imprint™4 VPS, Imprint™ 4 Bite, Intra-oral syringes, Impression Tray,"
89139932|NCT02735304|Other|standard clinical practice treatment|"The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment during the Impression intervention~Materials as per the operating dentist's choice to be recorded on CRF"
89139933|NCT04264559|Other|Healthy control group|This group will include 40 healthy adults.
89139934|NCT04264559|Other|CSAP group|This study will include 40 patients with chronic stable angina pectoris (CSAP).
89139935|NCT04264559|Experimental|Healthy intervention group|This group will include 40 healthy adults. They will receive moxibustion intervention.
89139936|NCT03743389|Experimental|12G pigtail catheter|
89139937|NCT03743389|Active Comparator|16F chest tube|
89139938|NCT04101201|Other|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
89139939|NCT04101201|Placebo Comparator|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
89139940|NCT04237532|Experimental|Intranasal Dexmedetomidine|
89139941|NCT04237532|Experimental|Sublingual Dexmedetomidine|
89139942|NCT02731092|Experimental|Lactoferrin 100 mg/kg|100 mg/kg enteral administration daily for 30 days
89139943|NCT02731092|Experimental|Lactoferrin 200 mg/kg|200 mg/kg enteral administration daily for 30 days
89139944|NCT02731092|Experimental|Lactoferrin 300 mg/kg|300 mg/kg enteral administration daily for 30 days
89139945|NCT05382377|Experimental|KD-025 cell infusion|Each subject will receive KD-025 cell infusion
89139946|NCT02813876|Experimental|Enhanced recovery|Enhanced recovery protocol for nursing, diet and analgesic regimen
89139947|NCT02813876|No Intervention|Standard care|Standard care arm
89139948|NCT00928837|Active Comparator|flavocoxid 250 mg|Medical Food product
89139949|NCT00928837|Active Comparator|Naproxen|antiinflammatory
89139950|NCT00928837|Placebo Comparator|Placebo|Placebo
89139951|NCT00928837|Experimental|flavocoxid 500 mg|medical food product
89139952|NCT02811146|Experimental|Cardiopulmonary exercise testing|Assess whether people who wore noninvasive ventilation during aerobic exercise have greater functional capacity than those who did not wear.
89139953|NCT02811146|Experimental|ADL Glitre test|Check that people who wore noninvasive ventilation during aerobic exercise have greater submaximal functional capacity than those who did not wear. Compare a ventilatory metabolic response of the ADL Glitre test with an six-minute walk test. .
89139954|NCT02811146|Experimental|Minnesota Living with Heart Failure|Check if people undergoing heart rehabilitation has improved quality of life.
89139955|NCT02811146|Experimental|Bioimpedance balance|Check if people undergoing heart rehabilitation has improved the body composition.
89139956|NCT02811146|No Intervention|Six-minute walk test|Compare a ventilatory metabolic response of the six-minute walk test with an ADL Glitre test.
89139957|NCT02811146|Experimental|Metabolic ventilatory response|"To verify if non-invasive ventilation during aerobic exercise modifies the ventilatory metabolic response in patients with heart failure.~Check the metabolic ventilatory response during the Glittre ADL test and six-minute walk test."
89139958|NCT00772629|Experimental|Group 1|Subjects naïve to any meningococcal vaccination
89139959|NCT00772629|Experimental|Group 2|Subjects who previously received unconjugated polysaccharide vaccine (either bivalent A and C or tetravalent A, C, Y, and W 135)
89139960|NCT02730936|Experimental|Antimicrobial Hernia Repair Device|Antimicrobial hernia repair device for repair of ventral or incisional hernias in Class II and III surgical fields.
89139961|NCT00925093|Active Comparator|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
89139962|NCT00925093|Active Comparator|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
89139963|NCT00925093|Active Comparator|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
89139964|NCT02813330|Experimental|Sterile Water injection|Subcutenous injection at low back portion during labor pain
89139965|NCT02813330|Experimental|saline injection|Subcutenous injection at low back portion during labor pain
89139966|NCT02731170|Experimental|rehabilitation treatment (MIRT)|MIRT consists of a 4-week physical therapy. daily sessions are subdivided in: motor treatment (2 hour), occupational therapy (1 hour) and speech Therapy (1 hour)
89139967|NCT04101123||Children and adolescents with cancer|Children and adolescents between 10-18 years with newly diagnosed leukemia, brain tumors, and sarcomas
89139968|NCT01562977|Other|no arms|no arms were present for the study, only 2 different cohorts:MCL and LDCGB
89139969|NCT05638646|Other|Intervention group|Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
89139970|NCT05638646|Other|control group|Maintain current treatment
89139971|NCT00607685|Experimental|1|The participants will receive a subconjunctival injection of a mixture of 5FU with hyaluronic acid.
89139972|NCT00607685|Active Comparator|2|Participants will receive a subconjunctival injection of 5 Fluorouracil only.
89139973|NCT04101279|Experimental|Midurethral synthetic tape with tension control mechanism|
89139974|NCT04101279|Active Comparator|midurethral tension free tape|
89139975|NCT04265183|Experimental|patients treated with preformed metal crowns|All patients included received a preformed metal crown on their HSPM affected teeth.
89139976|NCT04237298|Active Comparator|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
89139977|NCT04237298|Experimental|Modified vacuum-formed retainer covering the palate|The modified vacuum-formed retainer is designed to cover the palate. It is cheaper, easier to fabricate and more esthetic. Patients will be instructed to wear the retainer 24 hours during the study period.
89139978|NCT02731014|Experimental|Dry Needling Group|Dry Needling, Manual Therapy, and Exercise.
89139979|NCT02731014|Sham Comparator|Sham Dry Needling Group|Sham Dry Needling, Manual Therapy, and Exercise.
89139980|NCT00925171|Experimental|Pulmonary Rehabilitation Group|Intervention with exercise management
89139981|NCT00925171|No Intervention|Control Group|"Patients will receive the standard advice to undertake strength and endurance exercises at home and invitation to attend the Norwich Breath Easy Group~Patients will be stratified according to whether the initial programme took place in the outpatient hospital or community setting"
89139982|NCT04265027|Experimental|Group 1 (50 mg Dose)|"Test IMP: 50 mg BIA 9 1067 and Reference IMP: 50 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
89139983|NCT04265027|Experimental|Group 2 (25 mg Dose)|"Test IMP: 25 mg BIA9 1067 and Reference IMP: 25 mg Ongentys. The IMPs were administered fasted (after an overnight fast of at least 8 h) with 240 mL water once daily on Days 1 and Days 3 to 12. Subjects remained fasted and sitting upright for at least 4 h after dose. No fluids (apart from water taken with dose) were allowed from 1 h prior to dosing until 1 h afterwards.~There were at least 14 days between the last dose of treatment period 1 and the first dose of treatment period 2."
89139984|NCT02814578|Experimental|Optical coherent tomography|Optical coherent tomography provides more detailed information about the morphology of scaffolds, microstructures and coronary vasculature based on tissue characteristics as compared to conventional IVUS. In spite of angiographic success in BVS placement, further scaffold optimization was required in over a quarter of cases based on OCT findings due to malapposition or scaffold under expansion.
89139985|NCT02814578|Active Comparator|IntraVascular UltraSound|Intravascular ultrasound guidance has been associated with improved event-free survival compared with angiographic guidance after DES placement.
89139986|NCT00636402|Experimental|1|Vessel Sealing System Tonsillectomy (VSST)
89139987|NCT00636402|Active Comparator|2|Cold Knife Tonsillectomy (CKT)
89139988|NCT00607763|Experimental|1. Micafungin|
89139989|NCT00928915|Experimental|Prothrombin complex concentrate (PCC)|intravenously, 30 IU/kg
89139990|NCT00928915|Experimental|Fresh frozen plasma (FFP)|intravenously, 20ml/kg
89139991|NCT02740296||Healthy controls|Healthy controls
89139992|NCT02740296||RRMS|Relapsing-Remitting Multiple Sclerosis
89139993|NCT02740296||RRMS+MDD|Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder
89139994|NCT02740296||MDD|Major Depressive Disorder
89139995|NCT02814500|Experimental|A group|Amlodipine and Rosuvastatin, DP-R212
89139996|NCT02814500|Experimental|B group|DP-R212, Amlodipine and Rosuvastatin
89139997|NCT00928993||Main group|pediatric patients receiving overnight sleep study
89139998|NCT00939341|Experimental|1|Symbicort Turbuhaler 160/4.5 µg delivered dose
89234512|NCT03990922|Experimental|CTPVB with ropivocaine|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
89234513|NCT03990922|Placebo Comparator|CTPVB with saline|Continuous Paravertebral block with saline and Patient-controlled analgesia with morphine
89234514|NCT01005342|Experimental|Mixture of fiber|Single intake of a mixture of spray-dried oat drink, rye bran and sugar beet fiber
89234515|NCT01005342|Experimental|Sugar beet fiber|Single intake of sugar beet fiber
89234516|NCT01005342|Experimental|Rye bran|Single intake of rye bran
89234517|NCT01005342|Experimental|Oat bran|Single intake of oat bran
89234518|NCT01005342|Experimental|Spray-dried oat drink|Single intake of spray-dried oat drink
89234519|NCT01005342|Placebo Comparator|Control|Single intake of a meal with no added fiber
89234520|NCT00822263|Placebo Comparator|2|control
89234521|NCT00822263|Experimental|1|Active medicine
89234522|NCT03992170|Experimental|Single Arm|"Patients will receive Daratumumab (16 mg/Kg day) every week for 8 weeks intravenous (8 infusions) and then every 2 weeks for 16 weeks intravenous (8 more infusions).~If MRD positive by NGF, the patients will receive Daratumumab every 4 weeks for 80 weeks intravenous; if MRD negative by NGF, the patients can stop the treatment."
89234523|NCT04044755|Experimental|Using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children. Meanwhile, myopia prediction algorithm will be used to predict SER at 3 years.
89234524|NCT04044755|No Intervention|Not using myopia prediction algorithm|After examination of visual acuity, eye refraction and biometrics, the examination results are shown to the children.
89234525|NCT05154474||Standard|Standard follow-up MNA, IPAQ, SARC-F and SarQOL questionnaire
89234526|NCT00817037|Experimental|Sitaxsentan|"Once daily oral sitaxsentan 100mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
89234527|NCT00817037|Placebo Comparator|Placebo|"Once daily oral placebo tablet given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
89234528|NCT00817037|Active Comparator|Nifedipine|"Open labeled active comparator~Once daily oral nifedipine 30mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
89234529|NCT00998244|Experimental|Very Low Carbohydrate Diet|Very Low Carbohydrate Diet
89234530|NCT00998244|Active Comparator|Low Fat Diet|Low Fat Diet
89234531|NCT00817115|No Intervention|1|Subjects undergoing routine cardiac catheterization or interventional procedures using the standard fluoroscopy system.
89234532|NCT00817115|Experimental|2|Subjects undergoing routine cardiac catheterization or interventional procedures using the region-of-interest fluoroscopy (x-ray fovea imaging) system.
89234533|NCT04044833||intervention|(n=63)
89234534|NCT04044833||control|(n=65)
89234535|NCT00367744|Active Comparator|Rosigitazone arm|Rosiglitazone active 4 mg BID
89234536|NCT00367744|Placebo Comparator|Placebo arm|Matching Placebo BID
89234537|NCT01002222|Experimental|MCS-2|
89234538|NCT00826319||Bioimpedance sub-study cohort|Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
89234539|NCT00826319||Ethnic enrichment cohort|Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
89234540|NCT00826319||Original CanPreddict cohort|The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
89234541|NCT01005498|Experimental|Low carbohydrate diet (F)|The group attended to low carbohydrate diet
89234542|NCT01005498|Active Comparator|Traditional diet (K)|The group attended to traditional diet
89234543|NCT01002378|Experimental|Arm 1|
89234544|NCT01002378|Experimental|Arm 2|
89234545|NCT01002378|Experimental|Arm 3|
89234546|NCT01052818||Stage IV NSCLC|Stage IV non small-cell lung cancer patients will be recruited for this protocol
89234547|NCT00822419|Active Comparator|lidocaine|Lidocaine 5% cream 5 gr will be double blindly put on the skin preoperatively
89234548|NCT00822419|Experimental|ketamine|ketamine cream 5% 5gr will be put on the skin preoperatively
89234549|NCT00822419|Sham Comparator|placebo|non-drug similar cream will be put on the skin preoperatively
89234550|NCT01050400||Observant|Individuals within this group will receive pharmacotherapy according to the established institutional guidelines.
89234551|NCT01050400||Prospective CYP2D6 genetic screening|Individuals within the prospective group will receive their CYP2D6 genotype results prior to pharmacotherapy and their analgesic regimen will be tailored to their genetic results.
89234552|NCT01006044|Experimental|Vaccination|Autologous Dendritic cells loaded with tumor lysate
88803355|NCT05554666|Experimental|ASKG315|Single or multiple ascending dose of ASKG315
88803356|NCT05553574|Experimental|Food response|
88803357|NCT05553574|Experimental|Food stop|
89234553|NCT00817193|Experimental|Physical Activity|Participants will begin to participate in walking sessions and strength building classes that will be offered at each location. Participants will be asked to attend a minimum of 1 strength class per week, with a target of doing 150 minutes of moderate exercise each week. The exercise classes will include stretching and counseling to help participants understand and address the barriers to becoming and staying involved in regular exercise.
89234554|NCT00817193|Active Comparator|Wellness|Participants will begin to participate in a wellness program that will meet at each site twice per month. The first meeting will involve a lecture or presentation on a wellness-related topic. The second meeting will follow-up on concepts that were introduced in the first meeting, and will also to provide participants an opportunity to share experiences. Participants will be asked to attend both wellness sessions each month for whole year that the program is running.
89234555|NCT02534428|Experimental|wool-first (wool-standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing (cotton)
89139999|NCT00925249||1|The study group will consist of RA patients of the Walter Reed Army Medical Center (WRAMC) rheumatology clinic being considered for treatment with anti-TNF alpha therapy. We will enter patients into the study over a projected course of 12-24 months or until we reach the statistical requirement of 60 subjects.
89140000|NCT00925249||2|The control group will consist of healthy subjects without known immune-dysregulation or history of treatment with biologic agents who present to the WRAMC Allergy- Immunology clinic for routine screening TST as a part of current WRAMC policy.
89140001|NCT02814344||pregnant women not in labour|"from 24 weeks of gestation until term, provided that they are not in labour~Electrohysterography"
89140002|NCT02814344||women in labour|Electrohysterography
89140003|NCT00925327|Experimental|Corneal collagen cross-linking with riboflavin and UVA light|
89140004|NCT02740062|Active Comparator|Active treatment|Active tDCS treatment
89140005|NCT02740062|Sham Comparator|Sham treatment|Sham tDCS treatment
89140006|NCT04237376||Treatment Arm A: CHB Mothers treated with TAF during Pregnancy|120 pregnant women with double positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10^6 IU/mL were recruited from all four treatment centers. Mothers were enrolled and observed from gestational week 24-28 until postpartum week 28, and treated with TAF (25mg oral daily) from gestational week 28 until delivery (if the liver function is significantly abnormal after delivery, that is, ALT ≥ 5 × Upper Limit of Normal (ULN), the oral antiviral drug can be continued according to the wishes of the pregnant woman and the test results). All babies were given 3 HBV vaccines (0, 1, 6) and 1 routine Hepatitis B immunoglobin (HBIG) after birth. All babies were followed up to 2 years. According to the mother's wishes, if the mother agrees to collect breast milk and determine TAF concentration, breast milk was collected every day, and continuously collected 5-7 days for TAF concentration measurement. The time of last TAF dose taken as well as the time between milk collection and delivery was recorded.
89140007|NCT04237376||Comparative Arm C: CHB Pregnant Mothers|This arm C consists of 360 cases of pregnant women with HBsAg and HBeAg double-positive, and HBV DNA level ≥ 2 × 10^6 IU/mL. The mothers in this historical cohort did not receive any antiviral treatment during their pregnancy. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
89140008|NCT04237376||Comparative Arm B: CHB Pregnant Mothers treated with TDF|This retrospective cohort arm B consists of 120 cases of pregnant women with double-positive HBsAg and HBeAg and HBV DNA levels ≥ 2 × 10^6 IU/mL. All cases of pregnant mothers in this arm were extracted from the four treatment centers involved in this study: Beijing You'an Hospital, Capital Medical University, Fourth Hospital Affiliated to Harbin Medical University, Third Hospital of Qinhuangdao, and Tongliao Infectious Disease Hospital. Pregnant mothers were treated with TDF (300mg oral daily) starting from gestational week 28 and discontinued the drug at delivery. All babies received 3 doses of HBV vaccine (0, 1, 6) and 1 dose of HBIG after birth.
89140009|NCT02811380|Experimental|BIP CVC|Bactiguard Infection Protection Central Venous Catheter
89140010|NCT02811380|Placebo Comparator|Uncoated standard CVC|Uncoated standard Central Venous Catheter
89140011|NCT04264793|Experimental|Intervention|Behavioral Lifestyle Intervention (3 health centers): In addition to usual care in the health center, the intervention included individual counseling and group education on nutrition and physical activity.
89140012|NCT04264793|Active Comparator|Control|Control (4 health centers): Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
89140013|NCT02735226||Acute Stroke patient|Patients who are presented to hospital within 7days from onset. The key measurement of clinical quality controlled in patients with acute stroke managment and inhouse stroke care were record automatically
89140014|NCT02811224||Ovarian Cancer|
89140015|NCT02811224||Benign Neoplasm|
89140016|NCT00607841|Experimental|Dose Escalation Cohort 1|Ispinesib given on days 1 and 15 of a 28 day cycle.
89140017|NCT00607841|Experimental|Dose Escalation Cohort 2|Ispinesib given on days 1 and 15 of a 28 day cycle.
89140018|NCT00607841|Experimental|Dose Escalation Cohort 3|Ispinesib given on days 1 and 15 of a 28 day cycle.
89140019|NCT04015687|Experimental|AG-881 (Group 1)|On Day 1 of Period 1, Group 1 participants will receive a single 50-milligram (mg) oral dose of lamotrigine at Hour 0. In Period 2, they will receive 50-mg oral doses of AG-881 once daily (QD) for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14.
89140020|NCT04015687|Experimental|AG-881 (Group 2)|Following a safety and tolerability review of the data from at least 7 days of AG-881 dosing of Group 1 participants in Period 2, Group 2 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1, and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15), with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
89140021|NCT04015687|Experimental|AG-881 (Group 3)|Following a safety and tolerability review of the data from Group 1 participants, and from at least 7 days of AG-881 dosing of Group 2 participants in Period 2, Group 3 participants will receive a single 50-mg oral dose of lamotrigine at Hour 0 in Period 1; and 50-mg oral doses of AG-881 QD for 15 consecutive days (Days 1 to 15) with a single 50-mg oral dose of lamotrigine coadministered at Hour 0 on Day 14 in Period 2.
89140022|NCT02811068||Venepuncture|Collection of single blood sample to assess antibody persistence over time
89140023|NCT04264715|Experimental|405nm light room|In this room, surgeries will be performed under ambient light including the wavelength 405nm
89140024|NCT04264715|No Intervention|Control room|In this room, surgeries will be performed under ambient light from regular phosphorescent light does not include 405nm frequencies
89140025|NCT02739906|Experimental|HinsBet®|
89140026|NCT02739906|Active Comparator|Humalog®|
89140027|NCT02739906|Active Comparator|Huminsulin® Normal|
89140028|NCT02810912||Supraglottic airway device-based anesthesia|Investigators planned to enroll 200 cases who will receive scheduled surgery under supraglottic airway device-based general anesthesia.
89140029|NCT00607451|Experimental|1|
88803358|NCT05553574|Experimental|Food response-inhibition|
89140030|NCT00607451|Experimental|2|
89140031|NCT00607451|Experimental|3|
89140032|NCT00607451|Experimental|4|
89140033|NCT00925405||Breast MRI Screening|
89140034|NCT02739672|Experimental|TAH tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide tablet
89140035|NCT02739672|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
89140036|NCT02810678|No Intervention|Control|No Intervention: Program runs as per usual. Minimal interference and visits from study staff. Main study outcomes evaluated in first and last 6 months of trial. Minimal visits to collect information on costing at control sites.
89140037|NCT02810678|Active Comparator|Intervention|Latent Tuberculosis Infection program evaluation & diagnosis: In intervention health facilities the current Latent Tuberculosis Infection program will be evaluated and gaps in the Latent Tuberculosis Infection cascade of care will be identified. Gaps in the current cascade will be quantified and solution proposed that are unique to the problems identified in each site. In phase 2 of the study low cost solutions will be implemented and the Latent Tuberculosis Infection program scaled up and improved. Study outcomes are evaluated in the first and last 6 months of trial. Costing evaluations are done throughout the trial.
89140038|NCT04263155|Experimental|Experimental: The Body Project for high school young women|The 4-hour Body Project workshop delivered by trained peer leaders
89140039|NCT04263155|No Intervention|Control|The business-as-usual comparison group does not participate in the Body Project but may engage in any other programs or services they normally would
88803359|NCT05449834|Experimental|Fibrinogen Concentrate (FC)|"Fibrinogen Replacement using 3g Fibrinogen Concentrate as per:~ROTEM FIBTEM A5 ≤ 10mm or TEG FF A10 ≤ 15mm or FibC ≤ 2g/L"
89140040|NCT00925483|Experimental|daily long|daily long (4 hours, 6 times weekly) dialysis for 6 months
89140041|NCT00925483|Experimental|daily short|daily short (2 hours 6 times weekly) dialysis for 6 months
89140042|NCT00925483|Experimental|alternate day conventional|alternate day conventional (4 hours, 3 times weekly) dialysis for 6 months
89140043|NCT00925483|Experimental|alternate day long|alternate day long (8 hours, 3 times weekly) dialysis for 6 months
89140044|NCT02810834|Experimental|Walking/Running Program|Walking/running/jogging program; school-based.
89140045|NCT02810834|Experimental|Classroom activity break program|Classroom physical activity break program; school-based.
89140046|NCT02810834|No Intervention|Control|Control/Delayed Intervention
89140047|NCT00932971|Placebo Comparator|PEG-IFN alfa-2a plus placebo|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally
89140048|NCT00932971|Active Comparator|PEG-IFN alfa-2a plus Tenofovir|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally
89140049|NCT05382143|Experimental|Intervention|All the participants in this pilot study will receive atosiban
89140050|NCT00933049|Active Comparator|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) + Amoxicillin placebo
89140051|NCT00933049|Active Comparator|Amoxicillin|Amoxicillin (25 mg/kg/dose) + Cotrimoxazole placebo
89140052|NCT02810756|Experimental|Treated patients|
89140053|NCT05381987|Experimental|Intervention (experimental) group|These will receive a total of 6 sessions with a week's interval of radial shockwaves that will be performed using a (Storz Medical) device with the following manufacturer's parameters: 0.57mJ/mm2 (intensity 1.5 bar) applied as low energy, pulses 2000, frequency 15 Hz. The D20 transmitter (Ø 20 mm) headpiece will be used. Total treatment time including standard PT stretches and exercises would be 30 minutes). The radial shockwave will be delivered by designated physiotherapist, who will evaluate the participants before the treatment. Before the treatment, the treating physical therapist would ensure aseptic techniques, they would ensure the participants skin is intact and clean coupling gel will be used during the treatment. Furthermore prior to treatment, the myofascial triggers would be specifically confirmed by twitching response induced by a localized probe using a digital algometer.
89140054|NCT05381987|Placebo Comparator|Control (placebo) group|These will receive an identical treatment regime except that they will receive a none-therapeutic level energy shock of 0.03 mJ/mm2, an ineffective (a non-therapeutic) level of radial shockwave therapy, and participants will be blinded to their treatment by only hearing the sound from the shockwave machine.
89140055|NCT00929227||1|Stress MRI perfusion, and cardiac CT will have observed sensitivity, specificity, and accuracyof at least 0.80 in predicting CAD in a patient population with prior equivocal stress testing.
89140056|NCT03418272||Ventilated Pediatric Intensive Care Unit patient Group|This will be a prospective descriptive case series where tracheal cultures and PCR results will be analyzed at initial intubation and again several days into the ICU stay.
89140057|NCT03418272||Intubated OR patient Control Group|For the healthy operating room children, also a case series where a single set of studies will be obtained. tracheal cultures and PCR results will be analyzed after intubation These two groups will be compared, non-randomized.
89140058|NCT05788445|Experimental|nrTMS treatment|using nrTMS coli to stimulate the contralateral Broca's area on the right hemisphere with high freqency stimulation.
89140059|NCT05788445|Sham Comparator|nrTMS sham|using nrTMS sham-coli to stimulate the contralateral Broca's area on the right hemisphere with high frequency stimulation.
89140060|NCT05788419||examination group|Group of active hockey players
89140061|NCT05788419||control group|Group of athletes, non hockey players
88803360|NCT05449834|Active Comparator|Cryoprecipitate (Cryo)|"Fibrinogen Replacement using 10 Units WB or 4U Apheresis Cryo (Australia) as per:~ROTEM FIBTEM A5 ≤ 10mm or TEG FF A10 ≤ 15mm or FibC ≤ 2g/L"
88803361|NCT05443750|Experimental|Motivational Behavioral Economic Intervention|Web-based alcohol risk reduction brief intervention
88803362|NCT05443750|Active Comparator|Health Education|Web-based health education material
89140062|NCT05788380|Other|The Scapular Muscles Endurance (SME|The Scapular Muscles Endurance (SME) test was used to assess the endurance of the Serratus Anterior muscles.
89140063|NCT05788380|Other|Vizual Analog Scale|The VAS for pain, measures pain severity in the affected shoulder from 0 to 10 points, with 0 points representing no pain at all and 10 points representing pain as bad as it can be
89234556|NCT02534428|Active Comparator|cotton-first (standard-wool)|standard (cotton) clothing to be work for 6 weeks followed by 6 weeks of superfine merino wool clothing
89234557|NCT01002534|No Intervention|baseline|visit 1
89140064|NCT05788354|Active Comparator|conventional method|IFirst, we Performed time out and verify that there were no contraindications to IUD placement:, Second, after package opening we Removed the IUD from the introducer and trimmed IUD threads to 12 cm, Third, we Grasped the IUD firmly along the stem of the device, Fourth we Stabilized the uterus using the non-dominant hand or with the aid of an assistant and advanced the IUD through the hysterotomy to the fundus, Fifth, we Removed hand and directed the IUD threads into the cervix and finally we Closed the uterine incision, took care not to incorporate the IUD strings.
89140065|NCT05788354|Experimental|new method|First we Performed time out and verified that there were no contraindications to IUD placement, Second, after package opening we Removed IUD from the introducer and trimmed the IUD threads to 12 cm and also trimmed the introducer to 12 cm, Third, we Loaded the IUD again inside the introducer (through the trimmed end) and kept the arms of the IUD unfolded, Forth, we removed the shoulders of the introducer, Fifth, we held the uterus and stabilized it by the non-dominant hand and guided the introducer containing the IUD strings first through the cervix then we advanced the introducer with the IUD arms unfolded to the fundus and kept the IUD their by pressing on the fundus, then we pushed the introducer gently through the cervix to the vagina, Finally, we Closed the uterine incision, took care not to incorporate the introducer or the threads and then we removed the introducer gently manually from the vagina after closure of the skin and ceiling of the wound.
89140066|NCT05788302|Experimental|Prolonged Exposure therapy for posttraumatic stress disorder|15 participants who meet study inclusion/exclusion criteria will be individually administered a full course of PE during 10, 60 minute-sessions, with independent multimodal assessment batteries administered at pre-treatment, mid-treatment (post session 5), post-treatment, and a 1-month follow-up.
89140067|NCT05788250|Experimental|Subacromial spacer implantation|
89140068|NCT05788250|Active Comparator|Rotator Cuff Repair|
89140069|NCT05788211||REFRACTORY CARDIOGENIC SHOCK|All patients with medical or postcardiotomy refractory cardiogenic shock requiring renal replacement therapy concomitant with venoarterial extracorporeal membrane oxygenation.
89140070|NCT05788159|Experimental|Lacosamide extended release tablets|Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃~25℃, short-term can be at 15C~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.
89140071|NCT05788159|Active Comparator|Lacosamide Tablets|Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH
89140072|NCT05788146|Experimental|Blended psychological intervention|
89140073|NCT05788133|Experimental|treatment|administration neuropsychological tests with pepper
89140074|NCT05788055||Acute Coronary Syndrome Patients|Stool Analysis will be done for all cases to detect H.pylori Antigen and results will be analysed into infected patients and non infected patients.
89140075|NCT05788055||Chronic Stable Angina Patients|Stool Analysis will be done for all cases to detect H.pylori Antigen and results will be analysed into infected patients and non infected patients.
89140076|NCT05788029|Experimental|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy
89140077|NCT05788029|Active Comparator|open pancreaticoduodenectomy|open pancreaticoduodenectomy
89140078|NCT05787925|Experimental|Topical corticosteroid and Vitamin E|
89140079|NCT05787925|Active Comparator|Topical corticosteroid|
89140080|NCT05787912|Experimental|Photobiomodulation|
89140081|NCT05787912|Experimental|Hyaluronic acid gel after photobiomodulation|
89140082|NCT05787808|Active Comparator|Treatment 1|1000 mg Calcium tablets + 20µg vitamin D and optimal efficacy dose of Jarlsberg cheese
89140083|NCT05787808|Active Comparator|Treatment 2|1000 mg Calcium tablets + 20µg vitamin D
89140084|NCT05787769|Active Comparator|P shot arm|Drug: Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
89140085|NCT05787769|Active Comparator|PDE5i arm|Drug: Tadalafil + placebo injection Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
89140086|NCT05787756||Parkinson disease|Participants with newly diagnosed Parkinson's disease
89140087|NCT05787756||Control Subjects|Control subjects - will be selected from household/spousal contacts of the participants with Parkinson's disease
89140088|NCT05787691|Experimental|Individualised Pain Management|"In the intervention group, patients will be followed by the team of the transitional pain service of the HUG, and depending on individual risk factors, contraindications and following discussion with the patient (shared decision-making) the bundle of individually targeted measures will be applied."
89140089|NCT05787691|No Intervention|Standard care|In the control group, no specific measures will be applied, and patients are followed by their surgeon and general practitioner. In addition, during the hospitalization the Acute Pain Team may be requested. In case of persistent pain, it may happen that the surgeon or the general practitioner refers a patient to a chronic pain specialist.
89140090|NCT05787626|Experimental|Interventional group|The intervention consists of the application of a myofascial technique in the diaphragmatic region, one hand of the therapist will be placed on the hemidiaphragm to be treated and the other hand on the same side but on the dorsal part of the patient on the costal edge of the last ribs.
89140091|NCT05787626|Sham Comparator|Control group|In the subjects of the control group, the hands will be placed in the same position but without any therapeutic intention, applying the minimum possible pressure.
89140092|NCT05787535|Experimental|HRYZ-T101 TCR-T cell therapy|Patients will undergo lymphocytapheresis, then treatment with TCR-T cell.
89140093|NCT05787522||control group|independent investigator contouring of thoracic organs at risk
89140094|NCT05787522||experimental group|software-assisted contouring of thoracic organs at risk
89140095|NCT05787522||golden standard group|contouring of thoracic organs at risk by a team of experts, in which contours by two experts separately will be arbitrated by the third expert as the golden standard
89234558|NCT01002534|Active Comparator|Vardenafil|nasal instillation of Vardenafil ( visit 2 or 3)
89140096|NCT05787509|Experimental|The Trial group|we will prolong the duration of vaginal progesterone treatment until 24 weeks of gestation.
89140097|NCT05787509|Experimental|The control group|we will use vaginal progesterone treatment until 12 weeks of gestation.
89140098|NCT05787470||Cis Man|Person assigned male at birth and whose gender identity is man.
89140099|NCT05787470||Cis Woman|Person assigned female at birth and whose gender identity is woman.
89140100|NCT05787470||Transgender Man|Person assigned female at birth and whose gender identity is man.
89140101|NCT05787470||Transgender Woman|Person assigned male at birth and whose gender identity is woman.
89140102|NCT05787470||Transgender Man plus Testosterone|Person assigned female at birth and whose gender identity is man and are currently on testosterone replacement.
89140103|NCT05787470||Transgender Woman plus Estrogen|Person assigned male at birth and whose gender identity is woman and are currently on estrogen replacement.
89140104|NCT05787457||Tamil natives with Diabetes Type 2|Thirty Tamil natives (15 men, 15 women), representing general Tamil diabetic cohort.
89140105|NCT05787457||Swiss natives with Diabetes Type 2_matched|Thirty Swiss natives (15 men, 15 women) matching the Tamil cohort.
89140106|NCT05787457||Swiss natives with Diabetes Type 2_not matched|Thirty Swiss natives (15 men, 15 women), who are not matched to the Tamil cohort, representing general Swiss diabetic cohort.
89140107|NCT05787431||Unvaccinated individuals|COVID-19 recovered individuals who are not been vaccinated with any dose of COVID-19 vaccines.
89140108|NCT05787431||Vaccinated individuals|COVID-19 recovered individuals who are vaccinated with one or more dose of COVID-19 vaccines, and stratified by sub-groups.
89140109|NCT05787340|Experimental|BETY exercise group|"intervention group Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model via telerehabilitation~Exercise dosage is 60 minute three days a week."
89140110|NCT05787301||Patients with hearing loss after infection|Patients with hearing loss after infection
89140111|NCT05787301||Patients with hearing loss before infection|Patients with hearing loss before infection
89140112|NCT05787301||Healthy control|Healthy subjects who have never been infected with COVID-19 or diagnosed with hearing loss.
89140113|NCT05787275|Active Comparator|Control|received, traditional medical treatment and no exercise
89140114|NCT05787275|Experimental|diaphragmatic positioning group|received diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
89140115|NCT05787275|Experimental|incentive spirometer group|received diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
89140116|NCT05787236||Secukinumab|Clinical psoriasis patients who received secukinumab treatment in Indonesia from 1 August 2017 to 31 October 2020.
89140117|NCT05787171|Experimental|PDS group|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS. This is the group which received 2-0 PDS suture to sew up the incision.
89140118|NCT05787171|Experimental|Vicryl group|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.This is the group which received 2-0 Vicryl suture to sew up the incision.
89140119|NCT05787171|Experimental|Ethibond group|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.This is the group which received 2-0 Ethibond suture to sew up the incision.
89140120|NCT05787158|Experimental|Group A|Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles.
89140121|NCT05787158|Active Comparator|Group B|Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes.
89140122|NCT05787145|Experimental|Let's Discuss Health Group|Patients in this group will be encouraged to prepare each of the four medical encounters targeted in the trajectory in radiation oncology using Let's Discuss Health website, which are the initial visit, the mid-treatment visit, the end-of-treatment visit and the 3-month post-treatment visit.
89140123|NCT05787145|No Intervention|Usual Care Group|Patients in this group will received the usual care in the radiation oncology care pathway.
89140124|NCT05787093||pediatric patients accessing for constipation with rectal diameter >3 cm|
89140125|NCT05787093||pediatric patients accessing for constipation with rectal diameter <3 cm|
89140126|NCT05787080|Experimental|Massage Group/experimental|Blood tests will be taken at the entrance of dialysis from all participants. Then, in the second hour of hemodialysis, low voltage vibrations will be applied to both calf muscles of the patients for 10 minutes, three times a week for one month.Vibration application will be made with this device 53 Hz head. The vibration application will be performed for 2.5 minutes, starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes. This cycle will be repeated twice. After the one-month application period is completed, blood tests will be taken from all participants at the entrance to hemodialysis.
89140127|NCT05787080|No Intervention|Control Group|No intervention will be made on the patients in the control group.
89234559|NCT01002534|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
89234560|NCT01324804||CABG - subjects|only one group
89234561|NCT00817271|Experimental|1|
89234562|NCT00817271|Experimental|2|
89140128|NCT05787067|Experimental|Intervention group|"The web-based Insulin Guide mobile application prepared by the researcher was installed on the phones of the intervention group participants. They were asked to use this application for three months, at least three hours a week. Participants were followed up through the application. Participants who did not use the application were informed by SMS or phone and asked to use the application. Participants who did not use the application were excluded from the study. At the end of three months, the participants in the intervention groups were invited to the Endocrinology and Metabolic Diseases Outpatient Clinic for a post-test. Both groups were asked to practice again on the insulin injection model. Whether the application was correct, incomplete, or incorrect was recorded on the observation form by the diabetes nurse."
89140129|NCT05787067|No Intervention|control group|Control group participants were invited to the Endocrinology and Metabolic Diseases Polyclinic for the pre-test. They were asked to administer insulin injections using an insulin injection model. Whether the application was correct, incomplete or incorrect was recorded in the observation form by the diabetes nurse. No intervention was made to the participants. At the end of three months, the participants in the control group were invited to the Endocrinology and Metabolic Diseases Polyclinic for the final test. And they were asked to repeat the insulin injection model. Whether the application was correct, incomplete or incorrect was recorded in the observation form by the diabetes nurse.
89140130|NCT05787015|Experimental|Vaccine Norms Feedback|The participants in the treatment condition will receive personalized normative feedback (PNF) that entails correcting normative misperceptions for US young adults' vaccine uptake rates and prevalence of vaccine hesitancies (e.g., fear of side effects). Participants will be shown discrepancies between their perceived estimate of young adults' vaccination rates and actual national estimates derived from the US Census Bureau's Household Pulse Survey to highlight, in most cases, that they underestimated the vaccination norms.
89140131|NCT05787015|Active Comparator|Alcohol Norms Feedback|Participants randomized to control will complete all measures at the same time as participants in the treatment condition, but will not receive any normative information regarding vaccines. Instead, to match for attention and provide potential benefit, those in the control condition will receive a standard dynamic norms feedback pertaining to alcohol use norms and behaviors.
89140132|NCT05787002|Experimental|Treatment sequence A-B|Participants will receive treatments in the following sequence, a single dose of rosuvastatin tablet alone (Treatment A) in period 1, and then a single dose of rosuvastatin tablet + Dose X AZD0780 tablet (Treatment B) in period 2.
89140133|NCT05787002|Experimental|Treatment sequence B-A|Participants will receive 1 treatment during each study period in the following sequence: a single dose of rosuvastatin tablet + AZD0780 tablet (Treatment B) in period 1 and then a single dose of rosuvastatin tablet alone (Treatment A) in period 2.
89140134|NCT05786989|Experimental|Treatment|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. R-GemOx will be given at standard dosing every 21 days
89140135|NCT05786976|Experimental|Lotion BNO 3732 for topical care|
89140136|NCT05786976|Active Comparator|Body Lotion Benchmark product for topical care|
89140137|NCT05786950|Experimental|bronchodilators|compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
89140138|NCT05786937|Placebo Comparator|Placebo|The participants will receive a placebo, which is the excipient solution of aDC1 cell suspension consisting of a commercial ringer´s lactate solution.
89140139|NCT05786937|Active Comparator|aDC1immunization|The participants will be immunized with aDC1 unpulsed with HIV peptides.
89140140|NCT05786937|Experimental|aDC1 immunization with analytical treatment interruption of ART|The participants will be immunized with aDC1 pulsed with HIV peptides.
89140141|NCT05786911||vaginal delivery under epidural|60 patients, having had a vaginal delivery under an epidural, will be recruited at the maternity ward
89140142|NCT05786898|Experimental|NEAR TSA|Neuropsychological and Educational Approach of Cognitive Remediation, adapted for autism (NEAR-TSA)
89140143|NCT05786885|Experimental|Intervention Group|Microneedling will be done with application of topical vitamin C paste for depigmentation
89140144|NCT05786885|Active Comparator|Control Group|Gingival depigmentation will be done by vitamin C injection only.
89140145|NCT05786859|Experimental|Rifaximin Treatment Group|
89140146|NCT05786859|Sham Comparator|Standard Treatment Group (control group)|
89140147|NCT05786807|Experimental|Tegoprazan 50mg|single group
89140148|NCT05786781|Experimental|Transarterial CT angiography|Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
89140149|NCT05786755||Healthy Control|Total number of 52 Healthy Control Included in the study
89140150|NCT05786755||Alcoholic Control|Total number of 46 Alcoholic Control Included in the study
89140151|NCT05786755||Only Cirrhosis|Total 10 patients with only cirrhosis (n= 10, age 66.66±13.51 years) are included in this study
89140152|NCT05786755||Cirrhosis+ HCC|Total 26 patients with Cirrhosis+ hepatocellular carcinoma (HCC) (n= 26, age 61.61±9.85 years) are included in this study
89140153|NCT05786755||Cirrhosis+ Varices|Total 7 patients with Cirrhosis+ Varices (n= 7, age 48.42±15.80 years) are included in this study
89140154|NCT05786755||Cirrhosis+ Ascites|Total number of 26 patients with Cirrhosis+ Ascites (n= 26, age 55.96±8.51years) are included in this study
89140155|NCT05786755||Cirrhosis+ 2 Complications|Total number of 44 patients with cirrhosis with 2 complications (n=44, age 57.84±9.18 years) are included in this study
89140156|NCT05786755||Cirrhosis+ 3 Complications|Total number of 29 patients with cirrhosis and 3 or more complication (n=29, aged 59.64±12.61 years) are included in this study
89140157|NCT05786729|Experimental|Intervention Aerobic Exercise (AER)|Consented participants will be randomly assigned to aerobic exercise regimen (AER) + Standard Rehabilitation(R+AER) or Standard Rehabilitation only (R) group. In order to determine the necessary time window for AER exercise treatment, TBI subjects will partake in supervised AER sessions for a period of 12 weeks. After a baseline evaluations follow-ups will take place at take place at weeks 4, 8 and 12. Thus each participants will be evaluated 4 times.
89234563|NCT01052896|Experimental|Gabapentin|Half of the 100 patients enrolled will be placed on Gabapentin therapy to determine if they have improved dyspepsia symptoms.
88803363|NCT05520892|Experimental|low-dose intravenous immunoglobulin|0.4g/kg.d, d1-5
88803364|NCT05520892|Active Comparator|high-dose intravenous immunoglobulin|1.0g/kg.d, d1-2
89140158|NCT05786729|Active Comparator|Rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 12 weeks. Activity levels will be monitored.
89140159|NCT05786729|No Intervention|Control (C)|Healthy volunteers' responsiveness to exercise will be compared to TBI responsiveness.
89140160|NCT05786638|Active Comparator|Sublingual immunotherapy|50 Bronchial asthma (BA) patients received Sublingual immunotherapy
89140161|NCT05786638|Active Comparator|Subcutaneous immunotherapy|50 BA patients received Subcutaneous immunotherapy
89140162|NCT05785975|Experimental|Certain ommunications(Nudge), community-outreach(landline call), and single FIT testing|The intervention is an integrated system made up of single FIT testing, community outreach (landline call), and specific messages (Nudge). In order to encourage people to attend the screening, a primary care physician will be used in addition to text messages that participants at the outreach get for information, education, and communication (IEC).
89140163|NCT05785975|No Intervention|Routine Care for colorectal cancer screening|The comparators will be individuals with an average risk of colorectal cancer of both genders attending the selected health centres / or recruited through a community outreach approach.
89140164|NCT05785884|Experimental|Non-Hispanic Black|Black adults ages 40-75 with knee OA.
89140165|NCT05785884|Experimental|Non-Hispanic White|White adults ages 40-75 with knee OA.
89140166|NCT05784779|Experimental|GH509|
89140167|NCT05784779|Placebo Comparator|Placebo|
89140168|NCT05784688|Experimental|TU2218 + Pembrolizumab Phase 1b|Escalating doses of TU2218 orally and Pembrolizumab intravenously administered daily for two weeks followed by one week to determine RP2DC.
89140169|NCT05784688|Experimental|TU2218 + Pembrolizumab in Biliary Tract Cancer (BTC) expansion cohort Phase 2a|A RP2DC of TU2218 + Pembrolizumab administered, orally BID, for 2 weeks followed by 1 week of rest in 3-week cycles for TU2218 and intravenous 200mg once every 3 weeks for Pembrolizumab to patients with BTC to see whether TU2218 has potential to reverse resistance to an anti-PD-(L)1 agent.
89140170|NCT05784688|Experimental|TU2218 + Pembrolizumab in Cervical Cancer (CC) expansion cohort Phase 2a|A RP2DC of TU2218 + Pembrolizumab administered, orally BID, for 2 weeks followed by 1 week of rest in 3-week cycles for TU2218 and intravenous 200mg once every 3 weeks for Pembrolizumab to patients with CC to see whether TU2218 has potential to reverse resistance to an anti-PD-(L)1 agent.
89140171|NCT05784688|Experimental|TU2218 + Pembrolizumab in Colorectal Cancer (CRC) expansion cohort Phase 2a|A RP2DC of TU2218 + Pembrolizumab administered, orally BID, for 2 weeks followed by 1 week of rest in 3-week cycles for TU2218 and intravenous 200mg once every 3 weeks for Pembrolizumab to patients with CRC to see whether TU2218 has potential to reverse resistance to an anti-PD-(L)1 agent.
89140172|NCT05783869||Patient with bronchiectasis and cardiovascular comorbidities|Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period.
89140173|NCT05783869||Patients with bronchiectasis and without cardiovascular comorbidities|Patients with Bronchiectasis had no comorbidities.
89140174|NCT05783011|Experimental|EA (electroacupuncture)|Individuals who underwent electroacupuncture before and after flap surgery
89140175|NCT05783011|Active Comparator|Control|Individuals who have undergone flap surgery only
89140176|NCT05781971|Experimental|high protein + early bedside rehabilitation|
89140177|NCT05781971|Active Comparator|high protein alone|
89140178|NCT05781971|Placebo Comparator|standard protein + early bedside|standard protein and rehabilitation
89140179|NCT05781971|Sham Comparator|standard protein|only standard protein
89140180|NCT05765838|Experimental|Sequence for upper airway specimen collection (NPS right - Nasal swab left - OPS)|"1 NPS right - Nasal swab left - OPS~NPS = nasopharyngeal swab OPS = oropharyngeal swab"
89140181|NCT05765838|Experimental|Sequence for upper airway specimen collection (NPS left - Nasal swab right - OPS)|2 NPS left - Nasal swab right - OPS
89140182|NCT05765838|Experimental|Sequence for upper airway specimen collection (Nasal swab right - NPS left - OPS)|3 Nasal swab right - NPS left - OPS
89140183|NCT05765838|Experimental|Sequence for upper airway specimen collection (Nasal swab left - NPS right - OPS)|4 Nasal swab left - NPS right - OPS
89140184|NCT05765838|Experimental|Sequence for upper airway specimen collection (NPS right - OPS - Nasal swab left)|5 NPS right - OPS - Nasal swab left
89140185|NCT05765838|Experimental|Sequence for upper airway specimen collection (NPS left - OPS - Nasal swab right)|6 NPS left - OPS - Nasal swab right
89140186|NCT05765838|Experimental|Sequence for upper airway specimen collection (Nasal swab right - OPS - NPS left)|7 Nasal swab right - OPS - NPS left
89140187|NCT05765838|Experimental|Sequence for upper airway specimen collection (Nasal swab left - OPS - NPS right)|8 Nasal swab left - OPS - NPS right
89140188|NCT05765838|Experimental|Sequence for upper airway specimen collection (OPS - NPS right - Nasal swab left)|9 OPS - NPS right - Nasal swab left
89140189|NCT05765838|Experimental|Sequence for upper airway specimen collection (OPS - NPS left - Nasal swab right)|10 OPS - NPS left - Nasal swab right
89140190|NCT05765838|Experimental|Sequence for upper airway specimen collection (OPS - Nasal swab left - NPS right)|11 OPS - Nasal swab left - NPS right
89140191|NCT05765838|Experimental|Sequence for upper airway specimen collection (OPS - Nasal swab right - NPS left)|12 OPS - Nasal swab right - NPS left
89140192|NCT05764044|Other|Control Arm (Standard of Care)|Patients will be followed with computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
89140193|NCT05764044|Experimental|Experimental Arm|Receive two cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days. After that, patients will be followed with conduction of computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
89140194|NCT05762991||Helicobacter pylori infection and premalignant gastric lesion|Application of artificial intelligence to analyze the correlation between endoscopic images and urea breath test results/histopathological results.
89140195|NCT05752032||ICM-203|Participants who previously received ICM-203 in ICM-203 clinical studies
89140196|NCT05752032||Placebo|Participants who previously received placebo in ICM-203 clinical studies
88803365|NCT04567498|Experimental|Presumptive TB patients (395 participants - adult and children)|The participants breathe normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full.
88803366|NCT04567498|Experimental|Residents of area with high risk of TB (1383 participants - adult and children)|The participants breathe normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full.
89140197|NCT05751551|Experimental|Intervention group|"The intervention group will conduct a motor-cognitive training program added to usual care. The intervention starts with a familiarization period in rehabilitation centers (face-to-face supervision) for 2 weeks before participants of the intervention group continue it at home (under remote supervision) for 10 weeks with 3 training sessions per week for about 20-30 minutes.~Besides, participants of the intervention group will participate in 3 assessment sessions: (1) T1 (baseline assessments), (2) T2 (pre-intervention, after familiarization period, before starting the home-based training), (3) T3 (post-intervention assessment)."
89140198|NCT05751551|No Intervention|Control group|The control group will continue with their usual care. Apart from that, they will only attend 3 assessment sessions: (1) T1 (baseline assessments), (2) T2 (pre-intervention, after familiarization period, before starting the home-based training), (3) T3 (post-intervention assessment).
89140199|NCT05746793||Subfertile polycystic ovarian syndrome (PCOS) patients undergoing ART treatment|Peripheral blood collection. MOCK frozen embryo preparative cycle. Endometrial pipelle biopsy. Collection of menstrual blood. Questionnaire. Nutritional/metabolic evaluation. Cardiac work-up. Preconceptional and prenatal ultrasound. Blood pressure measurements. Urine analysis.
89140200|NCT05746793||Oocyte acceptors|Peripheral blood collection. MOCK frozen embryo preparative cycle. Endometrial pipelle biopsy. Collection of menstrual blood. Questionnaire. Nutritional/metabolic evaluation. Cardiac work-up. Preconceptional and prenatal ultrasound. Blood pressure measurements. Urine analysis.
89140201|NCT05738174|Experimental|intermittent theta burst stimulation (iTBS)|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold
89140202|NCT05738174|Sham Comparator|sham treatment|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
89140203|NCT05735275|Experimental|SHR-A2102 Does Escalation and Expansion|
89140204|NCT05725980||Skeletal Class I patients|Patients from this group present 0° < ANB < 4° on the cephalometric tracing.
89140205|NCT05725980||Skeletal Class II patients|Patients from this group present ANB > 4° on the cephalometric tracing.
89140206|NCT05725980||Skeletal Class III patients|Patients from this group present ANB < 0° on the cephalometric tracing.
89140207|NCT05718635|Experimental|patients candidate for lateral arm flap|
89140208|NCT05718128|Experimental|Biopsy|patients
89140209|NCT05706844|Experimental|Spinal Anaesthesia (SA)|"Patients undergoing total hip, total knee or unicompartmental knee arthroplasty are anaesthetized using:~Plain or heavy Bupivacaine hydrochloride 10 mg (2 mL)"
89140210|NCT05706844|Experimental|General Anaesthesia (GA)|"Patients undergoing total hip, total knee or unicompartmental knee arthroplasty are anaesthetized using:~Propofol (induction: 1.0-2.0 mg/kg. infusion: 3-5 mg/kg/hour) + Remifentanil (induction: 3-5 mcg/kg, infusion: 0.5 mcg/kg/min)"
89140211|NCT05702827|Experimental|bupivacaine-meloxicam|All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure. 3-4 cc of bupivacaine-meloxicam will be infiltrated into each suprapubic abdominal incision in the study group
89140212|NCT05702827|No Intervention|Standard of Care|All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure.
89140213|NCT05702788|Experimental|Jaktinib 75mg BID|Jaktinib 75mg BID
89140214|NCT05702788|Experimental|Jaktinib 100mg BID|Jaktinib 100mg BID
89140215|NCT05702788|Placebo Comparator|Placebo|Placebo
89140216|NCT05700578|Experimental|Safety Behavior Elimination for Traumatic Stress (SBETS)|Web-Based Safety Behavior Elimination for Traumatic Stress Intervention. (1) 30-minute session focused on providing psychoeducation about the nature of posttraumatic stress disorder (PTSD), how trauma-related safety behavior use worsens PTSD, and strategies to reduce or eliminate safety behavior use
89140217|NCT05700578|Active Comparator|Modifiable Behavior Intervention (MoBI)|Web-Based Modifiable Behavior Intervention. (1) 30-minute session focused on providing psychoeducation about strategies to maintain one's physical and mental health, such as by exercising, maintaining a healthy diet, and managing stress.
89140218|NCT05687994|Experimental|Audiovisual Speech Entrainment Practice|Audiovisual Speech Entrainment includes repeated practice of speaking synchronously with a recorded model, which provides contextual, temporal, and audiovisual cues for speaking.
89140219|NCT05687994|Experimental|Auditory Speech Entrainment Practice|Auditory Speech Entrainment includes repeated practice of speaking synchronously with a recorded model, which provides contextual, temporal, and auditory cues for speaking.
89140220|NCT05680467|Experimental|"Soft Tissue Mobilization"|Participants allocated to this group will receive six sessions of soft tissue mobilization technique accord to Kaltenborn (2018) .
89140221|NCT05680467|Experimental|"Soft Tissue Mobilization and TECAR"|Participants allocated to this group will receive the same manual therapy protocol with Group 1 in combination with Capacitive and Resistive Electric Transfer Therapy (TECAR).
89140222|NCT05680467|Active Comparator|"Control"|Control Group
89140223|NCT05678231|No Intervention|Standard of Care|Patients will receive standard of care instructions rehabilitation instructions following total knee replacement.
89140224|NCT05678231|Experimental|Zero Degree Knee|Patients will receive the Zero Degree Knee device and instructions for use following total knee replacement.
89140225|NCT05673889|Experimental|Dabigatran etexilate with and without ARV-471|Dabigatran etexilate administered as a single dose in Period 1 and Period 2. ARV-471 administered as a single dose in Period 2.
89140226|NCT05673759||75 Mild AD|75 patients diagnosed with Mild Alzheimer's disease.
89140227|NCT05673759||75 MCI due to any etiology|75 patients diagnosed with Mild Cognitive Impairment due to any etiology.
89140228|NCT05673759||25 Healthy Older Adults|25 Healthy older adults age: 50-90 (control).
89140229|NCT05673759||25 Healthy Younger Adults|25 Healthy younger adults age: 20-50 (control).
89140230|NCT05671705||Stroke patients with sarcopenia|Group will be stratified according to gender
89140231|NCT05671705||Stroke patients without sarcopenia|Group will be stratified according to gender
89140232|NCT05667597|Experimental|Residents and staff from nursing homes from the previous PICOV-VAC study|
89140233|NCT05667597|Experimental|Healthy adults from the previous REDU-VAC study|
89140234|NCT05667597|Experimental|Kidney transplant and dialysis patients from the previous NEPHRO-VAC study|
89140235|NCT05667597|Experimental|Lung transplant patients from the previous LUNG-VAC study|
89140236|NCT05661175|Experimental|Experimental group(group 1)|Percutaneous nephrolithotripsy was performed using one - hand lithotripsy
89140237|NCT05661175|No Intervention|Control group(group 2)|Percutaneous nephrolithotripsy was performed using traditional techniques
89140238|NCT05654298|Experimental|Ubrogepant|
89140239|NCT05654298|Experimental|Sumatriptan|
89140240|NCT05651997|Experimental|Matrix-Assisted Autologous Chondrocytes Transplantation (MACT)|Matrix-Assisted Autologous Chondrocytes Transplantation (MACT, also called third generation of autologous chondrocyte implantation) is based on the use of type I/III collagen membrane as a three-dimensional structural support on which autologous articular chondrocytes are seeded and cultured to form cartilage prior to implantation.
89140241|NCT05651997|Active Comparator|The Augmented Microfracture Technique (AMT)|The Augmented Microfracture Technique (AMT, also called Autologous Matrix-Induced Chondrogenesis or AMIC) which is part of a therapeutic continuum, combines a microfracture treatment with the application of a type I/III collagen membrane. The principle is to cover the microfractured area with a resorbable membrane to stabilize the formed blood clot in order to increase the concentration of mesenchymal stem cells and promote their differentiation into a repaired tissue.
89140242|NCT05649293||major depressive disorder patients|patient diagnosed with major depression for first time
89140243|NCT05649293||depression free persons|healthy persons
89140244|NCT05620303|Experimental|Exercise group|
89140245|NCT05620303|No Intervention|Control group|
89140246|NCT05618613|Experimental|Elacestrant / Onapristone|Elacestrant and Onapristone combination
89140247|NCT05617963|Experimental|Durvalumab treatment|"Patients will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death or patient's decision for a maximum of 24 months. For patients receiving prophylactic cranial irradiation as per standard of care, the first dose of durvalumab may be delayed by up to 42 days from the end of the CRT. Radiological assessments will be planned every 12 weeks (± 7 days) of maintenance treatment.~The first dose of durvalumab should be administered within 3 days of inclusion."
89140248|NCT05617963|No Intervention|Surveillance|Surveillance as per standard of care. Patients will perform radiological assessment every 12 weeks (± 7 days) from randomization.
89140249|NCT05611151|Experimental|CADe Colonoscopy|CADe Colonoscopy: Patient undergoes WISE VISION® Endoscopy CADe colonoscopy
89140250|NCT05611151|Active Comparator|HDWL Colonoscopy|HDWL Colonoscopy: Patient undergoes HDWL colonoscopy without CADe
89140251|NCT05593354||MPTLT patients|All UK patients undergoing MPTLT
89140252|NCT05587036|Experimental|Rifaximin|Rifaximin oral tablets, 550 mg, twice daily, two-weeks
89140253|NCT05587036|Placebo Comparator|Placebo|Placebo oral tablets, twice daily, two-weeks
89140254|NCT05570097|No Intervention|"the before group"|Control group as a standard therapy in Poland (regional analgesia: intrapleural or bilateral erector spine plane block added to multimodal analgesia).
89140255|NCT05570097|Experimental|"the after group"|During modyfied Nuss thoracoscopy the intraoperative Cryolesia of at least 5 intercostal nerves added to regional analgesia: bilateral erector spine plane block and multimodal therapy.
89140256|NCT05565638|Experimental|PROLONGED FASTING INTERVENTION|The prolonged nightly fasting (PROFAST) intervention involves gradually working up to a 14-hour fast during the nighttime hours. Participants will be supported by means of calls with a health coach during the first 4 weeks of the study. Participants will also be asked to use a text messaging platform to record their first and last meal of the day, and will receive personalized feedback based on the meal times they record via the text messaging system. The text messaging system will be used throughout the duration of the study.
89140257|NCT05565638|Active Comparator|EDUCATION CONTROL|For participants randomized to the control group, an introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living during the 4 months of the study
89140258|NCT05558579|No Intervention|Patients Using Sling|Patients will continue using shoulder sling per standard of care
89140259|NCT05558579|Experimental|Patients Without Sling|Patients will not use shoulder sling postoperatively.
89140260|NCT05555212|Experimental|dose escalation (in China)|
89140261|NCT05548816||Subgroup (1) Male|Includes swimmers from 12 to less than 14 years.
89140262|NCT05548816||Subgroup (2) Male|Includes swimmers from 14 to less than 16 years.
89140263|NCT05548816||Subgroup (3): Male|Includes swimmers 16 to less than 18 years.
89140264|NCT05548816||Subgroup (4) Male|Includes swimmers from 18 to less than 20 years
89140265|NCT05548816||Subgroup (5) Male|(1st Team) includes swimmers from 20 - 25 years.
89140266|NCT05548816||Subgroup (1) Female|Includes swimmers from 12 to less than 14 years.
89140267|NCT05548816||Subgroup (2) Female|Includes swimmers from 14 to less than 16 years.
89140268|NCT05548816||Subgroup (3) Female|Includes swimmers 16 to less than 18 years.
89140269|NCT05548816||Subgroup (4) Female|Includes swimmers from 18 to less than 20 years.
89140270|NCT05548816||Subgroup (5) Female|(1st Team) includes swimmers from 20 - 25 years.
89140271|NCT05534490|Experimental|Massage group|The group will have a foot massage.
89140272|NCT05534490|No Intervention|Control group|The group will not have any intervention.
89140273|NCT05507099|Active Comparator|Knee arm randomized to Lipoaspirate Concentrate and Bone Marrow Aspirate|The Subjects will be randomized to one of the treatment groups separately for the knee and hip arms of the study. Group A will receive a single intra-articular injection with lipoaspirate concentrate to the knee and Group B will receive a single intra-articular injection with bone marrow aspirate concentrate.
88803367|NCT04436692|Other|Improve dietary pattern|Nudging approach to test this methodological approach in persons with intellectual disabilitites with goal to improve dietary pattern and loss of weight
89140274|NCT05507099|Active Comparator|Hip Arm randomized to Lipoaspirate Concentrate and Bone Marrow Aspirate|The subjects will be randomized to one of the treatment groups separately for the knee and hip arms of the study. Groups C will receive a single intra-articular injection with lipoaspirate concentrate to the hip and Group D will receive a single intra-articular injection with bone marrow aspirate.
89140275|NCT05506046|Experimental|Reduced Nicotine Messages|Participants will receive messages with information about reduced nicotine cigarettes.
89140276|NCT05506046|Experimental|Modified Risk Messages|Participants will receive messages with information about e-cigarettes.
89140277|NCT05506046|Experimental|Combined Message -- Reduced Nicotine + Modified Risk Exposure|Participants will receive messages about reduced nicotine cigarettes and about e-cigarettes.
89140278|NCT05506046|Other|Control|Participants will receive messages about bottled water which should have no impact on the outcomes of interest.
89140279|NCT05502003|Experimental|High Intensity Interval Training|With the arm ergometer given to the participants, a telerehabilitation-based upper extremity aerobic exercise program will be applied. Maximum Heart Rate (MHR) will be determined by the formula '220-age', and exercise intensity will be calculated, and exercise will begin with a 5 minute warm-up. Cycle will be created with 4 min MHR (80-95%) high intensity and 3 min MHR (70%) active recovery and exercise will be terminated with 5 min cool down. A total of 35 minutes of exercise program will be given.
89140280|NCT05502003|Active Comparator|Moderate Exercise Training|An upper extremity exercise program with telerehabilitation (Zoom/videoconference) will be applied to the moderate-intensity exercise group. Maximum heart rate (MHR) will be determined by the formula 220-Age. A total of 55 minutes of moderate exercise training will be given at 65-70% of MHR, with five minutes of warm-up and cool-down.
89140281|NCT05502003|No Intervention|Control|No aerobic exercise program will be applied to this group.
89140282|NCT05496842||Rehabilitation patients with post-COVID-19 Syndrome|This group includes rehabilitation patients with and without respiratory muscle training
89140283|NCT05487950|Experimental|experimental group|Patients in the Rivaroxaban group will receive Rivaroxaban at the dose of 15 mg once daily ((or 10 mg if renal insufficiency) during 2 years.
89140284|NCT05487950|No Intervention|group control|Patients in the control group will be followed according to the standard of care (SOC) chosen by the investigator during 2 years. Additions or changes to SOC are allowed during the patient participation in the study based on patient status and evolution (with the exception of the use of anticoagulant therapy).
89140285|NCT05464667|Experimental|Radiation Therapy (RT)|"Preoperative Dose-escalated RT (5 Cohorts):~The first 3 patients to consent to the study will be registered to Cohort 1; the second 3 patients to consent will be registered to Cohort 2; the next 3 patients to consent will be registered to Cohort 3. The remaining patients will be assigned 2 patients to each Cohort, starting with Cohort 4. From that point on, a statistical analysis will be done to calculate the dose for the next Cohort (5)."
89140286|NCT05452967|No Intervention|Conventional analgesia group Group C|this group will receive rescue analgesia as per need
89140287|NCT05452967|Experimental|Distraction group: Group CD|This group will be distracted with the help of mobile or tablet and then will assess that rescue analgesia will be needed in post anaesthesia care unit or not
89140288|NCT05452512|Sham Comparator|Self monitoring arm using smart clinical trial application|The subjects in this arm will take vitamin D for 3 months and keep track of drug administration using smart clinical trial application (self monitoring).
89140289|NCT05452512|Experimental|Active monitoring using smart watch coupled with self monitoring|The subjects in this arm will take vitamin D for 3 months and keep track of drug administration using smart watch and smart clinical trial application (self monitoring).
89140290|NCT05452499|Experimental|Intervention group|
88803368|NCT05432752|Experimental|Concussed Subjects|Subjects with known history of concussion will be evaluated using current clinical evaluation and also using the Concussion Pen.
89140291|NCT05443295|Experimental|Intervention Group|The intervention group will carry out the MoveUS Program.
89140292|NCT05443295|Active Comparator|Control Group|The control group will be subjected to the conventional guidelines in the approach to shoulder instability.
89140293|NCT05441917|Experimental|Sanae with LED|"Phototherapy is related to light emission as a form of treatment for tissue and skin conditions. Its action depends on the absorption of light by chromophores, organelles present in the dermis and epidermis that give rise to cellular responses according to the different chemical reactions caused by light. The term LED means light emitted by a diode, thus, when the diode is subjected to an electrical current, light emission occurs (photon). Its applicability occurs in various disorders such as acne, alopecia, localized adiposity, stretch marks, cellulite, pre and postoperative, dark circles, etc. And they can also enhance treatments by promoting drainage, hydration, whitening, and rejuvenation, among other benefits."
89234564|NCT01052896|Placebo Comparator|Placebo|Half of the 100 patients will be placed on placebo look-alike of the gabapentin.
89234565|NCT00822497|Experimental|1|Music-Based Imagery
89234566|NCT00822497|Experimental|2|Music Alternate Engagement
89234567|NCT00822497|No Intervention|Control|Debridement under standard care with no music therapy interventions
88803369|NCT05432752|Experimental|Non-Concussed Subjects|Subjects with no known history of concussion will be evaluated using current clinical evaluation for a concussion and also using the Concussion Pen.
88803370|NCT05235412||Chinese mothers with the intention to breastfeed, and their infants.|Observational study.
88803371|NCT05422378|Experimental|STP705, 120ug/mL, 0.5 cc|Volume of Injection 0.5cc
88803372|NCT05422378|Experimental|STP705, 120ug/mL, 1.0 cc|Volume of Injection 1.0cc
88803373|NCT05422378|Experimental|STP705, 240 ug/mL, 0.5 cc|Volume of Injection 0.5cc
89234568|NCT01002690|Experimental|Etoricoxib|10-13 days treatment with etoricoxib
88803374|NCT05422378|Experimental|STP705, 240ug/mL, 1.0 cc|Volume of Injection 1.0cc
88803375|NCT05422378|Experimental|STP705, 320ug/mL, 0.5 cc|Volume of Injection 0.5cc
88803376|NCT05422378|Experimental|STP705, 320ug/mL, 1.0 cc|Volume of Injection 1.0cc
88803377|NCT05422378|Placebo Comparator|Vehicle|1.0cc placebo
88803378|NCT05447572||FIT combingning FC with colonscopy|
89140294|NCT05441917|Placebo Comparator|Sanae with Radiofrecuency|"Radiofrequency (RF) is considered a non-invasive therapy that enables thermal modification in the connective tissue of the skin, through dermal heating and vasodilation. Upon reaching the tissue, the current encounters resistance, and heat is produced by converting it into thermal energy. In this way, the deep dermis undergoes controlled volumetric heating, while the epidermis is preserved through cooling systems.~Thermal damage triggers an inflammatory cascade and stimulates neocollagenesis, causing the dermis to thicken. Vasodilation, on the other hand, leads to hyperemia and lymphatic drainage in the fat tissue. The expected physiological effects are increased circulatory and nutrient supply, improving tissue hydration and oxygenation, greater metabolic and enzymatic activity, accelerating the elimination of catabolites, lipolysis, and the contraction of connective tissue."
89140295|NCT05432089|Experimental|Experimental Group|
89140296|NCT05432089|Placebo Comparator|Placebo Group|
89140297|NCT05427513|Placebo Comparator|placebo|will injection 10 ml of normal saline to ensure binding
89140298|NCT05427513|Active Comparator|tranexamic acid(TXA)|will inject tranexamic acid according to body weight
89140299|NCT05418179|Placebo Comparator|Placebo|Maltodextrin (1 capsule/day)
89140300|NCT05418179|Active Comparator|Probiotic|Probiotic (Bifidobacterium animalis subsp. Lactis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus rhamnosus) - 1 capsule/day
89140301|NCT05407532|Experimental|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
89140302|NCT05407532|Experimental|Group with oral management|The investigators taught and monitored patients or caregivers to oral health care plus oral exercises such as salivary glands massage methods after meals and before sleep.
89140303|NCT05407532|No Intervention|Group with standard of care|Only provided oral care education.
89140304|NCT05403723|Experimental|Single Treatment Arm|"Eligible patients will complete 2 cycles of study treatment with durvalumab, platinum (cisplatin or carboplatin per investigator choice), and etoposide. Patients will then undergo standard of care restaging imaging. Those patients who have a partial or complete response will continue with combination systemic therapy, without additional intervention.~In patients with less than a partial response (stable disease or progressive disease), SBRT will be given prior to cycle 3 of systemic therapy. The radiotherapy will be given in 5 fractions of 6 Gy to the primary tumor site. See study schema. Patients who undergo SBRT will resume systemic therapy within 2 weeks of completing SBRT and the interval between cycle 2 and cycle 3 should not exceed 6 weeks. Subsequent restaging imaging will continue as per standard of care. All patients will continue maintenance therapy with durvalumab until confirmed progressive disease."
89140305|NCT05391412|Experimental|Fibrinogen group|The fibrinogen concentrate (20-30mg/kg, max 2g) will be administered in 100ml (Aqua pro injection) intravenously to the patient.
89140306|NCT05391412|No Intervention|Control group|Patients in the control group will not receive any additional medication than standard of care.
89140307|NCT05390931|Experimental|Study group|Study group intervention consists of 6-session motivational interviews (6 times in total, once every month), a health education structured according to the health belief model, a training booklet on healthy lifestyle behavior changes at the end of the training, and 6-month follow-up.
89140308|NCT05390931|Other|Control group|Control group intervention consists of a health education structured according to the health belief model, a training booklet on healthy lifestyle behavior changes at the end of the training, and a 6-month follow-up.
89140309|NCT05390372|Experimental|humanmilk|For skin damage care of preterm newborns randomly assigned to the breast milk group, their own breast milk will be applied topically once every 60 minutes until complete healing. Skin damage in newborns will be evaluated by an independent nurse and specialist doctor for 60 minutes during the treatment, and the score will be given and recorded. A minimum decrease of 1 point in the skin condition assessment scale score will be considered to indicate 'improvement'. The decision that the skin integrity of the newborn is completely healed will be made by the neonatal doctor independent of the trial. Areas between 0-3 on the newborn skin condition assessment scale will be considered healed. Breastfeeding does not have any side effects in preterm newborns.
89140310|NCT05390372|Experimental|routine care group|cream applied as part of hospital routine practice
89140311|NCT05386095|Active Comparator|0.25%Bupivacaine group|"Axillary brachial plexus block will be done with patient in supine position under general anesthesia . A total volume of (0.5ml/kg) 0.25% bupivacaine + 1 µg/kg dexmedetomidine.this volume will be divided equally among the median,ulnar,radial and the musculocutaneous nerve.~The surgical procedure will be start after 15-20 min. At the end of surgery, residual neuromuscular block will be antagonized with IV neostigmine 0.05 mg/kg and atropine 0.02mg/kg. All patients will receive 15mg/kg paracetamol IV.~At recovery room motor power will be assisted using Modified Bromage scale , then each 30 min till full recover of motor power. post operative pain assessment will be done using (FLACC score) for Pain assessment.For patients with pain score more than 4\10 ,Pethidine I.V will be given as rescue analgesic (1 mg/kg) when needed and total rescue analgesia will be recorded."
89140312|NCT05386095|Experimental|0.19%Bupivacaine group|"Axillary brachial plexus block will be performed with the patient in supine position under general anesthesia .~A total volume of (0.5ml/kg) 0.19% bupivacaine + 1 µg/kg dexmedetomidine will be divided equally among the median,ulnar,radial and the musculocutaneous nerve.~The surgical procedure will be start after 15-20 min.At the end of surgery, residual neuromuscular block will be antagonized with IV neostigmine 0.05 mg/kg and atropine 0.02mg/kg. All patients will receive 15mg/kg paracetamol IV.~At recovery room motor power will be assessed using Modified Bromage scale , then each 30 min till full recover of motor power. post operative pain assessment will be done using (FLACC score) for Pain assessment,For patients with pain score more than 4\10 ,Pethidine I.V will be given as rescue analgesic (1 mg/kg) when needed and total rescue analgesia will be recorded.."
89140313|NCT05372666|Placebo Comparator|Control IG100|1 small bread loaf using T55 standard white flour for a final content of 50 g equivalent digestible carbohydrates
89140314|NCT05372666|Experimental|Reference WB|1 small bread loaf using T55 Qualista white flour for a final content of 50 g equivalent digestible carbohydrates
89140315|NCT05372666|Active Comparator|Reference HFB|1 small bread loaf using T55 standard white flour supplemented with 11 % standard wheat bran (6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
88803379|NCT05413408|Experimental|education and contact to change participants stigma towards schizophrenia|The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).
89140316|NCT05372666|Experimental|Qualista HFB 01|1 small bread loaf using T55 Qualista white flour supplemented with 13 % untreated Qualista wheat bran (6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
89140317|NCT05372666|Experimental|Qualista HFB 02|1 small bread loaf using T55 Qualista white flour supplemented with 13 % pretreated Qualista wheat bran (treatment A - 6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
89140318|NCT05372666|Experimental|Qualista HFB 03|1 small bread loaf using T55 Qualista white flour supplemented with 13 % pretreated Qualista wheat bran (treatment B - 6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
89140319|NCT05372666|Experimental|Qualista HFB 04|1 small bread loaf using T55 Qualista white flour supplemented with 13 % pretreated Qualista wheat bran (treatment C - 6% dietary fiber content) for a final content of 50 g equivalent digestible carbohydrates
89140320|NCT05360264|Experimental|Experimental group|"A fresh, mandatory, tumor biopsy will be performed at baseline to assess KRAS mutational status and functional dependency and determine the patient's eligibility for the trial. KRAS dependency will be assessed based on computational score and inferred by a transcriptional signature of tumor cells. Transcriptomic data will be generated by using RNAseq data. Sample RNA processing and generation of the gene expression profile will be guaranteed within a maximum of 10 working days from the biopsy.~Patients with high L-, S- or both L/S- scores of KRAS-dependency will receive DACOGEN.~DACOGEN will be administered i.v. over 1 hour, at the dose of 10 mg/m2/d, daily on days 1-5 and 8-12 of each 4-wk cycle.~Patients will continue to receive study treatment until objective radiological disease progression per modified RECIST 1.1, as assessed by the investigator, unacceptable toxicity, physician's decision, patient's refusal, or until they meet any other discontinuation criteria."
89140321|NCT05359094|Placebo Comparator|Placebo|Placebo
89140322|NCT05359094|Active Comparator|Probiotics|Probiotics
89140323|NCT05356923||Healthy volunteers|Age- and sex- matched to participants, those aged 50 or over without known heart disease. n=20
89140324|NCT05356923||Acute myocardial infarction - multi-timepoint imaging|Those aged 50 or over with recent myocardial infarction who will be imaged using PET/MR at 1,2,4, and 12 weeks post-MI. n=20
89140325|NCT05356923||Acute or chronic myocardial infarction - single timepoint imaging|Those aged 50 or over with recent (n=20) or prior established (>24 months, n=20) myocardial infarction who will be imaged at a single timepoint (1,2,4, or 12 weeks post-MI for acute, at the time of enrolement to the study for chronic).
89140326|NCT05355532||"CMVO+ (patients has presented CMVO in PCI)"|Patients with 1 type MI that has presented CMVO in emergency PCI.
89140327|NCT05355532||"CMVO- (patients hasn't presented CMVO in PCI)"|Patients with 1 type MI that hasn't presented CMVO in emergency PCI.
89140328|NCT05348018|Experimental|"test group"|"test group which accessed SGs during a four-week test period in addition to conventional lectures"
89140329|NCT05348018|No Intervention|"control group"|"control group which benefited solely from conventional lectures"
89140333|NCT05322434|Experimental|experimental group|Postpartum breastfeeding training, which is routinely done immediately after birth, and breastfeeding counseling will be provided in the 1st, 2nd, 4th and 6th months after birth.
89140334|NCT05322434|No Intervention|control group|Postpartum breastfeeding education will be given routinely immediately after birth.
89140335|NCT05321524|Experimental|SD (1.5mg adult-equivalent dose of OCA) + MD Low dose (1.5mg adult-equivalent dose of OCA)|"At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Enrollment in the Multiple Dose (MD) Phase will occur in a sequential fashion. At Day 28, the first 8 (±1) eligible subjects will be assigned to the Low Dose Cohort and will receive a 1.5 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 2 OCA tablet dose strength (0.1mg and 1.5mg) are available in the study and dose will be determined using weight based dosing chart."
89140336|NCT05321524|Experimental|SD (1.5mg adult-equivalent dose of OCA) + MD Medium dose (5mg adult-equivalent dose of OCA)|"At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Upon safety and tolerability assessment in the Low Dose Cohort, 8 (±1) eligible subjects will be assigned to the Medium Dose Cohort and will receive a 5 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 3 OCA tablet dose strength (0.1mg, 1.5mg and 5mg tablets) are available in the study and dose will be determined using weight based dosing chart."
89234569|NCT01048684|Active Comparator|20% Mannitol 0.7 g/kg (low-dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 0.7g/kg over 30 minutes after induction of general anesthesia.
89140337|NCT05321524|Experimental|SD (1.5mg adult-equivalent dose of OCA) + MD High dose (10mg adult-equivalent dose of OCA)|"At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Upon safety and tolerability assessment in the Medium Dose Cohort, 8 (±1) eligible subjects will be assigned to the High Dose Cohort and will receive a 10 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 3 OCA tablet dose strength (0.1mg, 1.5mg and 5mg tablets) are available in the study and dose will be determined using weight based dosing chart."
89140338|NCT05317845||Patients with Type 2 Diabetes (T2D)|Selected for inclusion in the study by their primary or secondary care physicians
89140339|NCT05280496|Experimental|Metformin|Participants will be given a daily prescription of metformin for 12 months postpartum. At 12 months and again at 15 months (3 months off the drug), HbA1c and weight will be assessed.
89140340|NCT05280457|Experimental|nivolumab-GX-188E-GX-I7|
89140341|NCT05274399||Hemodialysis Patients|Receiving hemodialysis treatment for at least three months
89140342|NCT05266235|Experimental|Withings WBS08 and 12-lead reference ECG|The electrodes of the 12-lead ECG will be set up on the participants, before they step on withings WBS08 to have ECGs simultaneously recorded by the study device and the control device
89140343|NCT05254353||Patients with EVD|
89140344|NCT05247268|Experimental|GnRHa+letrozole|Patients will be stratified into BMI≥28kg/m2 group and BMI<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI<28kg/m2 group will be randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group. Patients who will be assigned to GnRHa+letrozole group will receive triprorelin acetate (intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses) plus letrozole (2.5mg oral daily and no more than 24 weeks). Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
89140345|NCT05247268|Active Comparator|MA/MPA|Patients will be stratified into BMI≥28kg/m2 group and BMI<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI<28kg/m2 group were randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group.Patients assigned to MA/MPA group will receive MA/MPA (160 mg oral MA daily or 500 mg oral MPA daily).Then every 3 months, an hysteroscopy will be used to evaluate the endometrial condition, and the findings will be recorded.
89140346|NCT05229523||1/Children with diparetic and hemiparetic cerebral palsy|1/Children with diparetic and hemiparetic cerebral palsy aged 7-18 years with the Communication Function Classification System (CFCS) level ≤ 3 and Extended Gross Motor Function Classification System (GMFCS-E&R) level ≤ 2
89140347|NCT05222841|Experimental|Spermotrend|
89140348|NCT05217017|Experimental|Chronic pain|Fear-avoidance components scale
89140349|NCT05213039||1/Children with diparetic and hemiparetic cerebral palsy|1/Children with diparetic and hemiparetic cerebral palsy whose Gross Motor Function Classification System (GMFCS) Level ≤ 2 will be evaulated by two different observers.
89140350|NCT05211804||Treatment-naïve|15 patients not previously receiving anti-VEGF treatment for nAMD.
89140351|NCT05211804||Undergoing treatment|15 patients already undergoing treatment with anti-VEGF for nAMD.
89140352|NCT05210504|Experimental|Participants administered oral lysine|participants will be administered 5g oral lysine
89140353|NCT05197140|Active Comparator|4 ounce beef patty|Subjects consume one beef patty of 4 ounces of cooked meat.
89140354|NCT05197140|Experimental|4 ounce vegetarian burger|Subjects consume one patty of 4 ounces of cooked vegetarian product.
89140355|NCT05197140|Experimental|2x 4 ounce vegetarian burger|Subjects consume two patties of 4 ounces of cooked vegetarian product.
89140356|NCT05162729|Experimental|Working memory intervention group|Receive game-like working memory online training for 5 weeks, 3 times per week, each lasting for15 minutes.
89140357|NCT05162729|Active Comparator|Social emotional intervention group|Receive game-like social-emotional online training for 5 weeks, 3 times per week, each lasting for 15 minutes.
89140358|NCT05162729|No Intervention|Control group|Receive no training
89140359|NCT05156099||ScanNav Anatomy PNB unaided|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance without the device.
89140360|NCT05156099||ScanNav Anatomy PNB-aided|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance with the device.
89140361|NCT05151133|Experimental|Low dose UCMSCs|
89140362|NCT05151133|Experimental|Moderate dose UCMSCs|
89140363|NCT05151133|Experimental|High dose UCMSCs|
89140364|NCT05127460|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool.
89140365|NCT05127460|No Intervention|Control|Patients randomized to control will continue routine practice.
89140366|NCT05108779|Experimental|QLF32004|
89140367|NCT05107752|Experimental|Stellate ganglion block (SGB) treatment during cognitive processing therapy (CPT)|Participants will receive 12 sessions of cognitive processing therapy (CPT) for PTSD combined with SGB during the first week of CPT.
89140368|NCT05107752|Experimental|SGB three months after completing CPT|Participant will receive 12 sessions of cognitive processing therapy (CPT) for PTSD and will receive SGB three months after completing the CPT sessions.
89140369|NCT05102500||Retrospective Chart Review Patients|The PI will conduct a retrospective chart review of breast cancer, colorectal cancer, and pancreatic cancer patients to better understand the patient, disease, and treatment characteristics that play a role in second opinion retention rates.
89140370|NCT05102500||Semi-structure Interview Patients|The PI will conduct semi-structured interviews with breast cancer, colorectal cancer and pancreatic cancer patients to better understand the decision-making process that goes into continued care with their primary or second opinion physician.
89140371|NCT05084586|Active Comparator|Continuous Intravesical Infusion of Epirubicin|Patients who received continuous epirubicin infusion into the bladder in the early postoperative period.
89140372|NCT05084586|Sham Comparator|Single-Dose Instillation of Epirubicin|Patients who received single-dose epirubicin into the bladder in the early postoperative period.
89140373|NCT05080595|Experimental|Transportation assistance, reports unreliable transportation|Lyft rides provided to transplant-related appointments
89140374|NCT05080595|No Intervention|No transportation assistance, reports unreliable transportation|No intervention, standard-of-care
89140375|NCT05080595|No Intervention|Transportation assistance, control|No intervention, standard-of-care
89140376|NCT05077085|Experimental|Strategy A: initial SoC + bezlotoxumab. SoC + FMT rescue therapy.|initial bezlotoxumab in addition to 14 days SoC oral antibiotic treatment with vancomycin 125 mg QID. 14 days of vancomycin 125mg QID plus fecal microbiota in case of treatment failure.
89140377|NCT05077085|Active Comparator|Strategy B: initial SoC + FMT. Fidaxomicin rescue therapy.|fecal microbiota transplantation in addition to 14 days SoC oral antibiotic treatment with vancomycin 125 mg QID. 10 days of fidaxomicin 200 mg BID in case of treatment failure.
89140378|NCT05069428|Experimental|ramelteon|ramelteon 8 mg crushed tablet daily at 20:30
89140379|NCT05069428|Placebo Comparator|placebo|placebo powder equivalent grams at 20:30
89140380|NCT05040711|Experimental|mindfulness coach|"Mindfulness coach is an app that provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. . To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
89140381|NCT05040711|Active Comparator|control - web MD|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
89140382|NCT05033626|Other|Thyroidectomy|
89140383|NCT05033626|Experimental|Simultaneous thyroidectomy and hyoid suspension|
89140384|NCT05021601|Experimental|Bi-atrial ablation group|Participants in this group will receive mitral valve surgery concomitant with bi-atrial ablation procedure.
89140385|NCT05021601|Active Comparator|Left atrial ablation group|Participants in this group will receive mitral valve surgery concomitant with left atrial ablation procedure.
89140386|NCT05018312|Experimental|Modified Collaborative Assessment (MCA)|The patients allocated to this arm will receive assessment inspired by therapeutic/collaborative assessment, as a pre-treatment to the standard psychotherapeutic treatment they will receive in the clinic.
89140387|NCT05018312|Active Comparator|Assessment as usual (AAU)|The patients allocated to this arm will receive standard assessment offered in the clinic, before proceeding to the standard psychotherapeutic treatment they will receive in the clinic.
89140388|NCT05005026|Active Comparator|Virtual reality (VR) game 1|Participants will be asked to play a virtual reality game twice a day for 10 days.
89140389|NCT05005026|Active Comparator|Virtual reality (VR) game 2|Participants will be asked to play a virtual reality game twice a day for 10 days.
89140390|NCT04985838|Experimental|Online HEADS: UP|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered using a video communication platform e.g. Zoom. An informal introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course.
89140391|NCT04985838|No Intervention|Control|No intervention provided.
89140392|NCT04983342|Experimental|Apollo Armband|Armband that can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain.
89140393|NCT04937803|Experimental|Drug-coated balloon group|Patients assigned to drug-coated balloon group will receive angioplasty with drug-coated balloon for treatment of lesions.
89140394|NCT04937803|Active Comparator|Stent group|Patients assigned to drug-eluting stent group will receive a Zotarolimus -Eluting Coronary Stent treatment .
89140395|NCT04921163|Active Comparator|aluminium|4-day test periode with intake of aluminium pancakes
89140396|NCT04921163|Placebo Comparator|placebo|4-day test periode with aluminium-free pancakes
89140397|NCT04921163|Placebo Comparator|second placebo|Again a 4-day test periode with aluminium-free pancakes
89140398|NCT04918199||Paris Transplant Group cohort|400 (10%) of the patients were randomly selected from 4,000 consecutive patients over 18 years of age prospectively enrolled at the time of kidney transplantation from a living or deceased donor at Necker Hospital, Saint-Louis Hospital, Foch Hospital, and Toulouse Hospital between January 1, 2005, and January 1, 2014, in France.
89140399|NCT04917471|Active Comparator|Nitrate-rich beet root juice|Nitrate-rich Beet root juice 70 ml bid
89140400|NCT04917471|Placebo Comparator|Placebo|Nitrate-depleted beet root juice 70 ml bid
89140401|NCT04903873|Experimental|EU101: Dose Escalation Cohort|Participants with advanced solid tumors will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with escalating doses starting from 0.05 milligrams per kilogram (mg/kg) to 10 mg/kg until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
89140402|NCT04903873|Experimental|EU101: Dose Expansion Cohort 1|Participants with CRC will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with a determined recommended phase 2 dose until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
89140403|NCT04903873|Experimental|EU101: Dose Expansion Cohort 2|Participants with NSCLC will receive EU101 intravenously once every 3 weeks (3 weeks = 1 cycle) with a determined recommended phase 2 dose until disease progression, unacceptable toxicities or death, withdrawal of consent, end of study, or physician's decision, whichever occurs first.
89140404|NCT04898608|Experimental|Exercise group|The patients will participate in intradialytic exercise 3 times a week for 24 weeks.
89140405|NCT04898608|No Intervention|Control group|The patients will receive regular care and treatment in every dialysis sessions without any intradialytic exercise.
89140406|NCT04895995|Experimental|Digital Cognitive Behavior Therapy (dCBT) for Generalized Anxiety Disorder|
89140407|NCT04895995|No Intervention|Waitlist Control|
89140408|NCT04852861|Experimental|Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 20 mcg|In this arm participants will receive two doses of Comirnaty BNT162b2 mRNA 20 mcg.
89140409|NCT04852861|Active Comparator|Comirnaty®; Pfizer-BioNTech BNT162b2 mRNA 30 mcg|In this arm participants will receive two doses of Comirnaty BNT162b2 mRNA 30 mcg.
89140410|NCT04850911|Experimental|Ketamine|Participants in this arm will receive a single intravenous, antidepressant dose of ketamine hydrochloride (0.5mg/kg)
89140411|NCT04850911|Placebo Comparator|Placebo|Participants in this arm will receive a single intravenous injection of an inactive placebo (0.9% sodium chloride).
89140412|NCT04836533|Experimental|Computerized Cognitive Training|Those assigned to the computerized cognitive training arm prior to antidepressant trial enrollment will receive computerized cognitive training that includes games that scale in difficulty.
89140413|NCT04836533|Active Comparator|Solitaire Training|Those assigned to the solitaire training arm prior to antidepressant trial enrollment will receive computerized solitaire games.
89140414|NCT04836533|Experimental|Open-label antidepressant treatment|Those assigned to receive open-label antidepressant treatment will begin with 10 mg of escitalopram. If the participant cannot tolerate or has an adverse reaction to escitalopram, duloxetine will be offered instead.
89140415|NCT04836533|Placebo Comparator|Placebo-controlled antidepressant treatment|Those assigned to the placebo-controlled group will be told that they have a 50/50 chance of receiving either escitalopram or placebo.
89140416|NCT04831411|Active Comparator|Whole Body Vibration|The training program will last 2 days a week and 6 weeks in total. Each session includes a warm-up, progressive whole-body vibration training and a cooling exercise. On the remaining days of the week, all patients will apply the standard exercise program, which includes simple home exercises, at home.
89140417|NCT04831411|Active Comparator|Progressive Resistance Training|The training program will last 2 days a week and 6 weeks in total. Each session includes a warm-up, progressive resistance training and a cooling exercise. On the remaining days of the week, all patients will apply the standard exercise program, which includes simple home exercises, at home.
89140418|NCT04807127||ICI-pneumonitis|Cancer patients experiencing ICI-pneumonitis
89140419|NCT04807127||Radiotherapy induced pneumonitis|Cancer patients experiencing RT-pneumonitis
88803380|NCT05413408|Active Comparator|Participants reading a book about schizophrenia knowledge|The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks.
89140420|NCT04807127||TKI-induced pneumonitis|Cancer patients experiencing TKI-induced pneumonitis
89140421|NCT04807114||NSCLC st.IV (PD-L1 > 50%)|Anti-PD-1 monotherapy
89140422|NCT04807114||NSCLC st.IV (PD-L1 < 50%)|Combination anti-PD-1 + chemotherapy
89140423|NCT04806984||Call center phone call|Participants randomized to this arm will receive a phone call from the call center reminding them to schedule their appointments.
89140424|NCT04806984||No call center phone call|Participants randomized to this arm will not receive a phone call from the call center reminding them to schedule their appointments.
89140425|NCT04806984||MyChart message|Participants randomized to this arm will receive an automated MyChart message reminding them to schedule their appointments.
89140426|NCT04806984||No MyChart message|Participants randomized to this arm will not receive an automated MyChart message reminding them to schedule their appointments.
89140427|NCT04790396||Patient presenting at emergent department with cardiac arrest|
89140428|NCT04789850|Experimental|Itacitinib|200mg of oral Itacitinib everyday for 360 days.
89140429|NCT04789850|Placebo Comparator|Placebo|Oral placebo everyday for 360 days.
89140430|NCT04787107|Experimental|10 Minute Chair Massage|Chair massage for 10 minutes once a week for 5 weeks
89140431|NCT04787107|Experimental|10 Minute Scheduled Break|Scheduled 10-minute break once a week for 5 weeks
88803381|NCT04330924|Experimental|Virtual Reality|3D avatar in a virtual simulation environment
89140432|NCT04774185|Experimental|New hearing aid loudspeaker|The new hearing aid loudspeaker is a loudspeaker system with a modified acoustic coupling approach which will be fitted based on the participants' individual ear anatomy.
89140433|NCT04774185|Active Comparator|Standard hearing aid loudspeaker|The hearing aid loudspeaker is a loudspeaker system with the existing acoustic coupling approach which will be fitted based on the participants' individual ear anatomy.
89140434|NCT04761055|Experimental|Screening Visits for Breast Cancer|Consenting patients will receive their already scheduled standard CBE and mammogram and in addition will receive a breast exam utilizing the iBreast Exam (iBE).
89140435|NCT04728282|Experimental|RTSA with subscapularis repair|
89140436|NCT04728282|Active Comparator|RTSA without subscapularis repair|
89140437|NCT04661254|Other|Lymphapheresis|Blood is drawn from one of the patient's two arms and passes through a separation circuit. After removing the white blood cells, it is reinjected into the other arm.
89140438|NCT04649099|Experimental|Leaflex™ Performer|
88803382|NCT04330924|No Intervention|Live Simulation|Live-based simulation in a simulation ward
88803383|NCT00002548|Active Comparator|HDCTX and PBSC|"High dose chemotherapy with peripheral blood stem cells~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7"
89234570|NCT01048684|Experimental|20% Mannitol 1.4 g/kg (high dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 1.4 g/kg over 30 minutes after induction of general anesthesia.
89234571|NCT01002768|Experimental|IDeg|
89234572|NCT01002768|Experimental|IGlar|
89234573|NCT01048762|Active Comparator|supervised exercise training|Intervention: supervised exercise training and dyspnea counseling in groups for 10 weeks Instruction on home based exercise training
89140439|NCT04642404|Experimental|Epidiolex 10mg/kg single dose|After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
89140440|NCT04642404|Experimental|Epidiolex 20mg/kg single dose|The 20mg/kg dose is the maximum recommended daily dose from the manufacturer. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
89140441|NCT04642404|Placebo Comparator|Placebo group|Placebo drug will be a solution with the same taste, texture and color as the drug. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.
89140442|NCT04642352||SLN intervention group|Participants will undergo a superior laryngeal nerve (SLN) block
89140443|NCT04637282|Experimental|PLX-200|This is randomized, placebo-controlled comparator study of PLX-200 in patients with CLN3 disease.
89140444|NCT04637282|Placebo Comparator|Placebo|This is randomized comparator study of PLX-200 vs. placebo in a 2:1 ratio in patients with CLN3 disease.
89140445|NCT04611321|Experimental|Phase Ib/II|Patients with advanced CSCC. IBI318 administered intravenously every 2 weeks.
89140446|NCT04594408|No Intervention|No epinephrine or TXA|No intervention given.
89140447|NCT04594408|Active Comparator|Epinephrine in irrigation fluid|Epinephrine intervention used.
89140448|NCT04594408|Experimental|Intravenous TXA|Tranexamic acid intervention used.
89140449|NCT04594408|Experimental|Epinephrine and TXA|Epinephrine and tranexamic acid intervention used.
89140450|NCT04557215|Active Comparator|Standard dose for IBS-D|Rifaximin 550 mg
89140451|NCT04557215|Placebo Comparator|Traveler's diarrhea dose + placebo|Rifaximin 200 mg + placebo
89140452|NCT04557215|Experimental|Traveler's diarrhea dose + NAC|Rifaximin 200 mg plus N-acetylcysteine (NAC) 600 mg days
89140453|NCT04514549||Cohort 1|will enroll approximately 5 patients with pronounced respiratory dysfunction. Patients may be enrolled with tremors and or seizures. All patients will be observed via Emerald to capture sleep staging, movement and breathing for up to approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. MC10 nPoint data will be captured for at least two 24-hour periods in each of the 4 weeks to assess patch placements for breathing detection. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 1 progresses.Preliminary results from Cohort 1 will determine if Emerald will continue to be evaluated and will inform on MC10 nPoint optimizations for Cohort 2. If preliminary results indicate Emerald is not an effective device, then Emerald will be discontinued
89140454|NCT04514549||Cohort 2|will enroll approximately 15 patients. Patients with pronounced respiratory dysfunction, tremors, seizures, and/or other expanded features of Rett syndrome deemed appropriate may be enrolled. If Emerald is continued, all patients are observed via Emerald to capture sleep staging, movement and breathing up to for approximately 4 weeks. Caregivers will keep a daily questionnaire diary of the patient's anxiety, sleep and seizures. Ongoing assessment of MC10 nPoint data may lead to the use of more or less sensors, changes in duration of sensor data collection, or placement as Cohort 2 progresses.
89140455|NCT04481295|Active Comparator|High SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 94-96%, and a flow of 10 L/min).
89140456|NCT04481295|Active Comparator|Low SpO2 group|In this group, patients have undergone 4 weeks of pulmonary rehabilitation under the HFNC (FIO2 value that the minimum SpO2 value during pulmonary rehabilitation is 84-86%, and a flow of 10 L/min).
89140457|NCT04445545|Experimental|Experimental group 1 (HILT + stretching exercise)|The group will receive treatment of high-intensity laser therapy (HILT) with a total energy delivery of 1,060J divided into 3 phases will be achieved: phase 1, 500J; phase 2, 60J; phase 3, 500J. It will work with an average power of 3W and an energy density of 50J/cm2. At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
89140458|NCT04445545|Sham Comparator|Experimental group 2 (Sham HILT + stretching exercise)|The group will receive a sham treatment of high-intensity laser therapy (HILT). At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
89140459|NCT04445545|Active Comparator|Experimental group 3 (US + stretching exercise)|The group will receive treatment of therapeutic ultrasound. The US parameters will be programmed with a frequency of 1MHz, the intensity of 1.5 W/cm2, the Duty cycle of 100%, an ERA of 5cm2, and a time of 6 minutes. At the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series.
89234574|NCT01048762|Sham Comparator|one instruction on homebased exercises|One instruction on home based exercise training and dyspnea management
89140460|NCT04432636|Other|Prospective French population based cohort|"Data collection of environmental factors at the recruitment~Collection of maternal feces~Collection of infant feces:~A food questionnaire completed by the mother the week after delivery, a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year and a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years~A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day~The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up"
89140461|NCT04423627|Experimental|Clonidine|0.2 mg/day oral
89140462|NCT04423627|Active Comparator|Hydrochlorothiazide|37.5 mg/day oral
89140463|NCT04423627|Placebo Comparator|Placebo|Placebo
89140464|NCT04398654|No Intervention|Control Group|Monitoring and therapy adjustment within the scope of the basic care described in the clinical trial plan.
89140465|NCT04398654|Active Comparator|Intervention Group|As in control group. In addition, in the intervention arm the CardioMEMSTM HF sensor implanted.
89140466|NCT04391764|Experimental|Naltrexone|Naltrexone at a dose of 50 mg per day.
89140467|NCT04391764|Placebo Comparator|Placebo|Placebo tablets will be identical in size, colour, shape, and taste and will be given in a similar manner.
89140468|NCT04292470|Experimental|Amitriptyline|Amitriptyline 10 mg daily
89140469|NCT04276532|Experimental|Sentinel lymph node sampling|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN)
89140470|NCT04276532|Active Comparator|Pelvic lymphadenectomy|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
89140471|NCT04274764|Experimental|Personalized eHealth Education & Motivational Interviewing|Personalized eHealth Glaucoma Education & Motivational Interviewing
89140472|NCT04274764|No Intervention|Standard Education|Participant will receive standard glaucoma education.
89140473|NCT04250675|Sham Comparator|Sham|Participants will apply Intermittent Pneumatic Compression (IPC) using a customized version of the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The sham device applies a compression sequence of 30 mmHg to the foot, ankle and calf with inflatable cuffs.
89140474|NCT04250675|Active Comparator|Active Comparator - Intermittent Pneumatic Compression|Participants will apply Intermittent Pneumatic Compression (IPC) using the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The Arterial Assist Device® applies a compression sequence of 120 mmHg to the foot, ankle and calf with inflatable cuffs.
89140475|NCT04230473|Experimental|Single dose of CNCT19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.
89140478|NCT04217590|Experimental|Sodium Zirconium Cyclosilicate (SZC)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
89140479|NCT04217590|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
89140480|NCT04214730|Experimental|Combination of NK with chemotherapy group|Patients will receive NK treatments combined with Chemotherapy.
89140481|NCT04214730|Active Comparator|Chemotherapy group|Patients will only receive Chemotherapy.
89140482|NCT04214717|Experimental|Combination of DC-CIK with chemotherapy group|Patients will receive DC-CIK treatments combined with Chemotherapy .
89140483|NCT04214717|Active Comparator|Chemotherapy group|Patients will only receive Chemotherapy.
89140484|NCT04212728|Experimental|AMSCs plus PRP group|Three intra-articular injections in total and autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
89140485|NCT04212728|Active Comparator|PRP group|Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.
89140486|NCT04208334|Experimental|Curcumin|Curcumin 4000mg/day x 60 days
89140487|NCT04208334|Placebo Comparator|Placebo|Placebo x 60 days
89140488|NCT04205019|Experimental|Neuro-Cell group|Patient receives treatment once at start of study and followed up for safety.
89140489|NCT04193397|Experimental|Exercise training|Post-bariatric patients - Intervention group
89140490|NCT04193397|No Intervention|No intervention|Post-bariatric patients - Non-exercised control group
89140491|NCT04109131|Other|CNS metastases from solid tumours|"The study will be organised on three time-periods based on the time of the 1st CNS event:~Part A - Pre-diagnosis period: before diagnosis of the 1st CNS event Part B - At 1st CNS diagnosis period Part C - Post diagnosis period: after the 1st CNS event"
89140492|NCT04084470|Active Comparator|Bread types 1, 2 and 3|Daily consumption of 5 slices of allocated bread type for three intervention days (separated by a wash-out period of at least 7 days).
89140493|NCT04084470|Active Comparator|Bread types 4, 5 and 6|Daily consumption of 5 slices of allocated bread type for three intervention days (separated by a wash-out period of at least 7 days).
89140494|NCT04073797|Experimental|Stable CVD - treatment|Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to add on therapy with inclisiran + placebo tablet
89140495|NCT04073797|Active Comparator|Stable CVD - placebo control|Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to placebo injection + colchicine tablet
89140496|NCT04073797|Placebo Comparator|HeFH - treatment|Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to placebo injection + placebo tablet
89140497|NCT04070261||User|
89140498|NCT04058561|Experimental|6 weeks|6-week lengthening interval
89140499|NCT04058561|Active Comparator|16 weeks|16-week lengthening interval
89140500|NCT04053673|Experimental|RBN-2397|Dose Escalation: Multiple doses of RBN-2397 for oral administration Dose Expansion: Oral dose of RBN-2397 as determined during Dose Escalation
89140501|NCT04027309|Active Comparator|Arm A (Midostaurin)|Midostaurin (50 mg BID PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
89140502|NCT04027309|Experimental|Arm B (Gilteritinib)|Gilteritinib (120 mg QD PO) - Cycle 1 (day 8-21), Cycle 2 (day 8-21), Consolidation (only during chemo consolidation (day 8-21 - with max of 3 cycles), Maintenance (day 1-365)
89140503|NCT04003584||Minimally Invasive Cardiac Bypass patients|
89140504|NCT04003584||Traditional Sternotomy Cardiac Bypass patients|
89140505|NCT03988933|Experimental|Intervention Arm 1|Two months of daily self-administered rifampin at 20 mg/kg (maximum 1200 mg/day).
89140506|NCT03988933|Experimental|Intervention Arm 2|Two months of daily self-administered rifampin at 30 mg/Kg (maximum 1800 mg/day).
89140507|NCT03988933|Active Comparator|Control Arm|Four months of daily self-administered rifampin at a dose of 10mg per kg per day (maximum 600mg per day).
89140508|NCT03983694||BabyLux device|Cerebral haemodynamics of neonates undergoing erythrocyte transfusion according to the local clinical guidelines are monitored with BabyLux device before and after transfusion and with traditional NIRS during itself.
89140509|NCT03978468|Active Comparator|Usual Care Group|Children will receive usual care.
89140510|NCT03978468|Experimental|Interagency Collaboration (ICollab Group)|Subjects of this arm will receive ICollab intervention in addition to usual care which consists of communication with Home Health Nurse (HHN) , Collaborative meetings, and communication with Primary Care Physician (PCP)
89140511|NCT03963232|Placebo Comparator|Placebo|"Double-blind treatment phase: Participants received placebo once per month subcutaneously (SC) for 3 months.~Open-label treatment phase: After completion of double-blind phase, participants could enter open-label treatment phase where they received 240 milligram (mg) loading dose of galcanezumab SC (2 injections of 120 mg) in the first month followed by 120 mg per month for 2 months.~Follow-up phase: After completion or discontinuation from double-blind or open-label treatment phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
89140512|NCT03963232|Experimental|Galcanezumab 120 mg|"Double-blind treatment phase: Participants received 240 mg loading dose of galcanezumab SC (2 injections of 120 mg) in the first month followed by 120 mg per month for 2 months.~Open-label treatment phase: After completion of double-blind phase, participants could enter open-label treatment phase where they continued to receive 120 mg galcanezumab SC per month for 3 months.~Follow-up phase: After completion or discontinuation from double-blind or open-label treatment phases, participants entered follow-up phase where they were observed for 4 months. No treatments administered."
89140513|NCT03958565||Actionable driver oncogene|One group will have an actionable driver oncogene and initiate treatment in any line with a TKI as standard of care and concurrent to participation to this study; expected to have an objective response rate in ≥40% who have not previously seen anti-bone resorptive therapy.
89140514|NCT03958565||No Actionable Mutations|The other group will not have actionable mutations and initiate treatment with chemotherapy/immunotherapy along with new onset therapy with IV zoledronic acid 4mg Q4 weeks or subcutaneous denosumab 120 mg Q12 weeks for bone disease, which is standard of care and would be concurrent to participation in this study.
89140515|NCT03958552|No Intervention|Standard Care|Participants will receive the standard Medicare Skilled Nursing Facility care.
89140516|NCT03958552|Experimental|Palliative Care Consult|Participants will receive the standard Medicare Skilled Nursing Facility care plus a Palliative Care Consultation with a trained provider.
89140517|NCT03954392|Experimental|CBT+SCT|Cognitive behavioral therapy plus social cognitive skills training (SCT)
89140518|NCT03954392|Active Comparator|CBT-only|Cognitive behavioral therapy only (without SCT)
89140519|NCT03927391|Active Comparator|reference (normal) dose|Normal dose of enzalutamide (160mg once daily)
89140520|NCT03927391|Experimental|test (reduced) dose|Reduced dose of enzalutamide (120mg once daily)
89140521|NCT03913169|Other|Students in Interprofessional Education Curriculum|The interprofessional intervention for the students to be employed in this study will include five modalities in a scaffolded structure progressing from low- to high-fidelity experiences over a two-year period: (1) classroom didactic sessions; (2) simulation laboratory sessions; (3) standardized patient sessions; (4) community-based clinical case conferences; and, (5) community-based interprofessional rotations.
89140522|NCT03913169|Other|Patients Experience with Interprofessional Care|For patients and their families, those who receive care from an Interprofessional team will receive the usual health care they normally receive at the participating clinics. In many cases patients already receive this care, but are unaware of it. Most of what occurs in Interprofessional practice happens outside of the patient encounter. For patients the process is generally invisible, but its affects are felt in terms of better communications with the patient. In this study, patients will be informed as usual about the presence of students as learners and will have the opportunity to decline student involvement in their care. The only difference for the patients and their families will be a request to fill out a survey form on paper indicating their perception of the experience in terms of quality of care and its potential impact on their access to care.
89140523|NCT03913169|Other|Clinician (Preceptor) Interprofessional Education Curriculum|Clinicians will experience many of the same learning experiences as the students, but will differ in the level of education and its focus. Clinicians and faculty will be taught the concepts of Interprofessional education, the same as the students, but they will also be taught how to educate students using Interprofessional practices.
89140524|NCT03913169|Other|Faculty in Interprofessional Education Curriculum|Doctor of Osteopathic Medicine and Physician Assistant Faculty will be taught the concepts of Interprofessional education, the same as the students, but they will also be taught how to educate students using Interprofessional practices.
89140525|NCT03886831|Experimental|PRT543|PRT543 will be administered orally
89140526|NCT03871608||DTM Disorders|Patient with DTM Disorders with Examination of functional etiologies on DTM Disorders and Assessment of symptoms on DTM Disorders
89140527|NCT03856593|Experimental|Standard letter|Prescribers randomized to this arm will be sent the standard letter.
89140528|NCT03856593|Experimental|Comparator letter|Prescribers randomized to this arm will be sent the comparator letter.
89140529|NCT03845101|Experimental|CBT in virtuo|Receives CBT in group format with Virtual Reality Exposure Therapy
89140530|NCT03845101|Active Comparator|CBT in vivo|Active comparator, receives CBT in group format. Treatment as usual.
89140531|NCT03829631|Experimental|Intervention|Participants will be instructed to follow their current low back pain management program, in addition, they will be instructed to wear a lumbar brace (Horizon 627 Lumbar Brace) during the day for four weeks only when they are in pain in addition to their current management program.
89140532|NCT03829631|No Intervention|Control|Participants will be instructed to follow their current low back pain management program.
89140533|NCT03807167|Experimental|Patients|
89140534|NCT03807167|Active Comparator|healthy controls|
89140535|NCT03800940|Experimental|Fistulography and trans-drain occlusion|Fistulography is performed to assess the condition of the fistula, and trans-drain occlusion is performed by injecting glue (NBCA and Lipiodol) through the drain to occlude the tract.
89140536|NCT03800940|Sham Comparator|Fistulography|Fistulography is performed to assess the condition of the fistula, without trains-drain occlusion.
89140537|NCT03785925|Experimental|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Participants will receive bempegaldesleukin (NKTR-214) in combination with nivolumab.
89140538|NCT03768700||Cohort|Hospitalization in a Post-Resuscitation Rehabilitation Care Units (SRPR)
89140539|NCT03766347||Pediatric Neuromyelitis Optica|Participants under the age of 18 that are positive for Aquaporin-4 antibody.
89140540|NCT03764514||Spinal Cord Stimulator - Permanent Implantation|
89140541|NCT03763357|Experimental|Heat Therapy|Subject will dress in water-circulating trousers that are connected to a Heat Therapy (HT) pump. Warm water (42-43 degrees C) will be perfused through the pants for 90 minutes.
89140542|NCT03757845|No Intervention|Control diet|
89140543|NCT03757845|Experimental|Mediterranean diet|
89140544|NCT03750318|Experimental|Aingeal|All patients will wear the Aingeal device as part of the vital sign monitoring with opioid delivery system at ward setting.
89140545|NCT03748069||Influenza positive CAPIV|All consecutive patients older than 18 years, admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
89140546|NCT03748069||Influenza negative CAPIV|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza
89140547|NCT03734692|Experimental|cisplatin + rintatolimod + pembrolizumab|Intraperitoneal (IP) cisplatin 50mg/m^2 solution with IP rintatolimod 200 mg solution and IV pembrolizumab 200 mg solution.
89140548|NCT03717298|Experimental|Ocoxin-Viusid|It will be used at a rate of 60 ml daily (1 vial every 12 hours).
89140549|NCT03700476|Experimental|Sintilimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
89140550|NCT03700476|Active Comparator|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
89140551|NCT03676998|Other|Measurement of diaphragm function|Patients will be followed up from admission to weaning with twice a week a diaphragm function multimodal evaluation (ultrasound, phrenic nerves stimulation technique)
89140552|NCT03669627|Active Comparator|Group 1: aTIV primer, QIV booster|Two doses (0.25 mL) aTIV (FLUAD )received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2.
89140553|NCT03669627|Other|Group 2: QIV primer, QIV booster|"Standard of care control group:~Two doses (0.5 mL) QIV (Fluzone) received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2."
89140554|NCT03669627|Experimental|Group 3: aTIV primer, aTIV booster|"This arm is experimental in that some participants will be receiving the MF59-adjuvanted TIV (FLUAD) in year two of the study, after the age of two years, which is off label.~Two doses (0.25 mL) TIV (FLUAD) received one month apart in year 1. One dose (0.25 mL) TIV (FLUAD) received as booster in year 2."
89140555|NCT03573453|Experimental|Intermittent|enteral nutrition will be administered via enteral feeding pump as 30-60minutes lasting bolus 6 times per day volume of initial bolus will be 80ml. The volume of bolus will be increased gradually according to tolerance, till the estimated target rate will be reached
89140556|NCT03573453|Experimental|Continuous|enteral nutrition will be administered via enteral feeding pump for at least 16 hours par day initial rate will be 25ml/hour. The rate will be increased gradually according to tolerance, till the estimated target rate will be reached
89140557|NCT03466463|Experimental|GNT0003|2 doses of the IMP assessed in the dose escalation, open-label, phase 1/2 study
89140558|NCT03442816|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
89140559|NCT03427411|Experimental|1/Arm 1-M7824 1,200 mg intravenous (IV) once every 2 weeks|M7824 at a flat dose of 1,200 mg intravenous (IV) once every 2 weeks
89140560|NCT03420807|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
89234575|NCT01002846|Experimental|traditional acupuncture|Procedure : ST 36 and PC 6 are selected, subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth
89234576|NCT01002846|Sham Comparator|sham acupuncture|Procedure : Beside 1cm of ST 36 and PC 6 are selected( not meridian point), subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
88803384|NCT00002548|Experimental|HDCTX with PBSC and Autologous BMT|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Auto Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0"
88803385|NCT00002548|Experimental|HDCTX with PBSC and interferon|"High dose chemotherapy with peripheral blood stem cells and interferon~Experimental: HDCTX with PBSC and interferon High dose chemotherapy with peripheral blood stem cells and interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7~IFN: IFN 3 million units/m2 MWF SQ"
88803386|NCT00002548|Experimental|HDCTX with PBSC and transplant plus IFN|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~Experimental: HDCTX with PBSC and transplant plus IFN High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0~IFN: 3 million units/m2 MWF SQ"
88803387|NCT02087306|Experimental|Brincidofovir|"Subjects who weighed <50 kg received 2 mg/kg (not to exceed 100 mg) BCV twice weekly administered orally as the appropriate volume of 10-mg/mL liquid suspension.~Subjects who weighed ≥50 kg received 100 mg BCV twice weekly administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine)."
88803388|NCT05190172|Experimental|Radiation therapy with protons|Radiation therapy with protons at The Skandion Clinic, Uppsala, Sweden
88803389|NCT05190172|Active Comparator|Radiation therapy with photons|Radiation therapy with photons at an University Hospital nearby subject's home address
88803390|NCT00289094|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System
88803391|NCT00289094|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Retaining Knee System
88803392|NCT01293578|No Intervention|Usual Care|Clinicians will present diabetes medication options to patients, in their usual way.
88803393|NCT01293578|Experimental|Diabetes Medication Decision Aid|In the decision aid arm, clinicians will use the diabetes medication decision aid cards (if they choose) when discussing diabetes medication options with their patients.
88803394|NCT01284686|Active Comparator|dopamine|ON DOPA:The patient will take his usual treatment with dopamine
88803395|NCT01284686|Experimental|without dopa|OFF Dopa: The patient will be deprived of his treatment usual dopaminergique for at least 12 hours
88803396|NCT01800500|Experimental|Arm I (fixed rate ST product prices)|Participants purchase ST products using a fixed rate of product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks
88803397|NCT01800500|Experimental|Arm II (escalating ST product prices)|Participants purchase ST products using escalating product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks.
88803398|NCT04668742|Experimental|Arm 1: DYNAtraq - tracheostomy fixation device|Use of DYNatraq installed in chest with skin adhesive and fixed to tracheostomy tube
88803399|NCT04668742|No Intervention|Arm 2: Usual management of tracheostomy|No interventions will be used additional to usual management
88803400|NCT00199082|Experimental|Experimental|This is a single arm trial with complex chemotherapy (6 cycles) stratified by age, subtype (Burkitt-leukemia vs Burkitt-lymphoma) and initial involvement
88803401|NCT04755998|Experimental|Experimental Group|The Experimental Group watched cartoons with virtual reality glasses during vaccination applications.
88803402|NCT04755998|No Intervention|Control Group|Pre-test and post-tests were applied to the non-intervention group
88803403|NCT01797458|Experimental|Hall Technique|This technique uses preformed Stainless Steel Crowns (SSCs) to restore carious primary molars. Local anaesthesia, caries removal or tooth preparation are not required.
88803404|NCT01797458|Experimental|Non-Restorative Caries Treatment|This is a less operative approach, here carious lesions are opened removing the overhanging enamel and making the cavity accessible for biofilm removal. No carious dentine will be removed from the pulpal wall and no local anaesthesia will be placed. Fluoride varnish (Duraphat ®) will be applied to the cavity. Parents/children will be trained to clean the cavity by brushing using a buccolingual technique.
88803405|NCT01797458|Active Comparator|Conventional Restoration|This technique corresponds to the conventional way of treating cavitated carious lesions involving complete caries removal, use of local anaesthesia (when needed), and a compomer (Dyract ®) restoration. Cotton wool roll isolation and continuous aspiration will be used.
88803406|NCT00002602|Experimental|Group 1|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6] x 10) is ≤ 15. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
88803407|NCT00002602|Experimental|Group 2|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6]x10)>15. Any clinical T2c with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
88803408|NCT00002602|Experimental|Group 3|Clinical stage T3 with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
88803409|NCT00198068||Group 1: aPL+/SLE-|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units; no SLE
89234577|NCT00826397|Experimental|Acupuncture Arm|Patients in the treatment arm will receive acupuncture administered twice weekly for six weeks and will be allowed to take pain medication as necessary.
88803410|NCT00198068||Group 2: aPL+/SLE+|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.
89140561|NCT03416868|Experimental|Week 3 start|"For the first two weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In the following 3 weeks of voice therapy (weeks 3 through 5), patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
89140562|NCT03416868|Experimental|Week 4 start|"For the first three weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy weeks 4 and 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
89140563|NCT03416868|Experimental|Week 5 start|"For the first four weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy week 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
89140564|NCT03402269||Adolescents with displaced clavicle fractures|Adolescents (11 to 17 years old) with displaced clavicle fractures will be enrolled in this study.
89140565|NCT03335657|Experimental|CBPT Treatment|The CBPT intervention delivers a patient-oriented cognitive-behavioral self-management program to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy. The program consists of six weekly telephone sessions with a trained physical therapist. Sessions cover an introduction and rationale for treatment in addition to techniques such as deep breathing, graded activity plan and goal-setting, distraction techniques, automatic thoughts, coping self-statements, being present-minded, and relapse prevention and symptom management plans. At the end of the 6th week, patients will build individualized recovery plans with selected strategies and details on frequency of practice.
89140566|NCT03335657|Placebo Comparator|Education Treatment|The education program provides a postoperative recovery and is based on education that would typically be provided by a treating physician or a physical therapist in an outpatient setting. The education program is matched to the CBPT treatment in terms of session frequency and contact with the study therapist. The therapist will call weekly to check in with the patient and encourage him/her to read the manual. Manuals contain educational information on injury patterns and symptoms, stress and recovery, benefits of physical therapy, and importance of daily exercise, and ways to promote healing. Education on sleep hygiene, energy management, healthy eating, and preventing future injury are also provided.
89140567|NCT03330106|Experimental|Part A: Pevonedistat 25 mg/m^2 + Pevonedistat 50 mg/m^2|Pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
89140568|NCT03330106|Experimental|Part A: Pevonedistat 50 mg/m^2 + Pevonedistat 25 mg/m^2|Pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
89140569|NCT03330106|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 in combination with docetaxel 75 mg/m^2 or pevonedistat 20 mg/m^2 in combination with carboplatin plus paclitaxel 175 mg/m^2, infusion, intravenously, once on Day 1 in each 21-day treatment cycle followed by pevonedistat 25 mg/m^2 or 20 mg/m^2 infusion, intravenously, once on Days 3 and 5 in each 21-day treatment cycle for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped. The combination and dose of pevonedistat will be based on investigator discretion.
89140570|NCT03239145|Experimental|Pembrolizumab + Trebananib|Part 1 Standard 3+3 Dose Escalation
89140571|NCT03239145|Experimental|Pembrolizumab + Trebananib (Melanoma)|Part 2 Dose Expansion
89140572|NCT03239145|Experimental|Pembrolizumab + Trebananib (Ovarian)|Part 2 Dose Expansion
89140573|NCT03239145|Experimental|Pembrolizumab + Trebananib (Colorectal)|Part 2 Dose Expansion
89140574|NCT03239145|Experimental|Pembrolizumab + Trebananib (Renal Cell Carcinoma)|Part 2 Dose Expansion
89140575|NCT03213951||Prostate cancer|Gleason grade group 1-5 on prostate biopsy or prostate cancer recurrence.
89140576|NCT03200626||Cytokine alone or JIT plerixafor based mobilization|
89140577|NCT03200626||Routine plerixafor based mobilization|
89140578|NCT03200626||Chemomobilization|
89140579|NCT03192696|Experimental|Treatment Cohort|Atherectomy of in-stent restenosis
89140580|NCT03164564|Experimental|Arm A: CAB + Placebo TDF/FTC + CAB LA|During Step 1, participants will receive daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
88803411|NCT00198068||Group 3: aPL-/SLE+|No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.
88803412|NCT00198068||Group 4: aPL-/SLE-|Healthy controls: no antiphospholipid antibodies; no SLE
88803413|NCT01237418||Myocardial Infarction|Any patient over 18 years admitted for myocardial infarction (MI) of less than 48 hours, characterized by the typical rise and fall of troponin or CPKMb
88803414|NCT01895192|Other|Fertile men|Assessment of sperm morphology by high magnification with interference contrast microscopy.
88803415|NCT04160000|Active Comparator|Phase 1 Catheter Ablation|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They randomly assigned to catheter ablation as one arm. They will undergo a catheter ablation procedure within 14 days of randomization. This procedure will include isolation of all four pulmonary veins in the antrum using catheter delivered radiofrequency current, cryothermal or laser ablation energy with standard FDA approved ablation catheter systems used in atrial fibrillation ablation. Patients will be monitored for a minimum period of 9 months after the catheter ablation intervention.
88803416|NCT04160000|Active Comparator|Phase 1 Antiarrhythmic drug therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent. They will be randomly assigned to antiarrhythmic drug therapy for Rate or Rhythm control in this arm. They will undergo drug dose titration within 14 days of randomization. . Patients will be monitored for a minimum period of 9 months after the AAD therapy initiation
88803417|NCT04160000|Active Comparator|Phase 2 Guided Heart Failure Therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent and completion of Phase 1. They will be randomly assigned to insertion of an implantable hemodynamic monitor in this arm and heart failure therapy guided by wireless hemodynamic monitoring. Patients will be monitored for a minimum period of 9 months after the implantable hemodynamic monitor insertion on guided drug therapy
89140581|NCT03164564|Active Comparator|Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA|During Step 1, participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. In Step 2, participants will receive daily TDF/FTC and placebo for CAB LA injections at two times points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.
89140582|NCT03103841||Children and young people with epilepsy|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
89140583|NCT03103841||Healthy controls|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
89140584|NCT03070886|Active Comparator|Arm I (androgen deprivation therapy, EBRT)|Patients receive androgen deprivation therapy comprising leuprolide acetate, goserelin acetate, bicalutamide, flutamide, or nilutamide for 6 months. Beginning 8 weeks after the start of androgen deprivation therapy, patients receive EBRT for 7.5 weeks.
89140585|NCT03070886|Experimental|Arm II (androgen deprivation therapy, EBRT, docetaxel)|Patients receive androgen deprivation therapy and EBRT as in Arm I. Within 4-6 weeks after completion of radiation therapy, patients receive docetaxel IV on day 1 of every 21 days for 6 courses in the absence of disease progression or unexpected toxicity.
89140586|NCT03066271|Experimental|Exercise + usual care|"The supervised exercise training is carried out on a ergometer cycle as individual daily (mon-fri) training and each exercise training session consists of 20min.~The training comprised a warm-up phase followed by 3 exercise phases. Warm-up consisted of 5min light stationary cycling, adjusted to 50-60% of the patients peak power output determine at the incremental cycle test (iPPO). The first exercise phase comprised of 5min interval training consisting of 5x30 sec intervals at 80-95% of the patient's iPPO. Between each interval, there is a 30 sec pause. The 2nd exercise phase consisted of 5min continuous cycling at an intensity equaling 80% of the patient's iPPO. The 3rd exercise phase was similar to the first exercise phase. Intensities increased progressively from the first week to the last week (from 50%, 80% and 70% of iPPO according to the three different phases to 60%, 95% and 80 % of iPPO respectively."
89140587|NCT03066271|Experimental|Control - usual care|The patients randomized to the control group received no training but will be wearing the activity tracker during the intervention.
89140588|NCT03043378||Chronic Non-Malignant Pain - Cancer Patients|Chronic non-malignant pain among cancer patients undergoing a consultation at the outpatient Supportive Care Clinic at MD Anderson Cancer Center.
89140589|NCT03040895|Experimental|ICDP-intervention for caregivers|Group-based ICDP-intervention for caregivers through a sequence of eight meetings. The groups are led by facilitators trained in the ICDP.
89140590|NCT03040895|Other|Treatment as usual|Participants may use other health services (GP, other interventions) as usual through the data Collection period (6 months). Afther this period, they will have the opportunity to join an ICDP-Group if they still want.
89140591|NCT02996578|Active Comparator|Solid Matrix - Intervention|"Dietary Supplement: polyphenol rich chocolate bar~17.5g of commercially available dark chocolate will be consumed daily for 8 weeks"
89140592|NCT02996578|Active Comparator|Powder Matrix - Intervention|"Dietary Supplement: polyphenol rich cocoa powder~6g of commercially available cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
89140593|NCT02996578|Placebo Comparator|Solid Matrix Intervention - Placebo|"Dietary Supplement: low polyphenol chocolate~17.5g of commercially available, nutritionally similar, dark chocolate will be consumed daily for 8 weeks"
89140594|NCT02996578|Placebo Comparator|Powder Matrix - Placebo|"Dietary Supplement: nutritionally similar low polyphenol cocoa powder~6g of commercially available, nutritionally similar, cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
89140595|NCT02992821|Experimental|Bed-side pocket-size ultrasound|All participants will be examined bed-side by pocket size ultrasound for the assessment of the carotid arteries by junior doctors. All participants will then be examined by reference imaging in specific ultrasound laboratories with conventional high end equipment and new doppler techniques and when appropriate computer tomography or magnetic resonance imaging.
89140596|NCT02987257|Placebo Comparator|Harmonized supportive care|Harmonized supportive care with placebo cyclosporine days 0-14 and etanercept placebo days 0 and 3
89140597|NCT02987257|Active Comparator|Cyclosporine 5mg/kg bid days 0-14|Harmonized supportive care with placebo etanercept days 0 and 3
89140598|NCT02987257|Active Comparator|Etanercept 50mg sc day 0 and day 3|Harmonized supportive care with placebo cyclosporine days 0-14
89140599|NCT02888691|Experimental|Low Carbohydrate Diet|< 100 grams of carbohydrate per day
89140600|NCT02888691|Experimental|High Carbohydrate Diet|> 250 grams of carbohydrate per day
89140601|NCT02844647|Experimental|MRI w/ Hyperpolarized Pyruvate (13C)|"Hyperpolarization of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI."
89140602|NCT02821754|Experimental|1/A1-Durvalumab + Tremelimumab|Durvalumab + Tremelimumab
89140603|NCT02821754|Experimental|2/A2 - Durvalumab + Tremelimumab + Trans-arterial Catheter Chemoembolization (TACE)|Durvalumab + Tremelimumab + TACE
89140604|NCT02821754|Experimental|3/A3 - Durvalumab + Tremelimumab+ Radiofrequency Ablation (RFA)|Durvalumab + Tremelimumab+ RFA
89140605|NCT02821754|Experimental|4/A4 - Durvalumab + Tremelimumab+ Cryoablation|Durvalumab + Tremelimumab+ Cryoablation
89140606|NCT02815618||Infants delivered by elective caesarean|Infants to be measured immediately after birth and on their second day of life.
89140607|NCT02815618||Infants on mechanical ventilation|Infants to be measured while changing ventilator settings to normalize arterial pCO2.
89140608|NCT02815618||Infants on ventilatory support|Infants to be measured for 24 hours continuously to assess user-friendliness and loss of signal.
89140609|NCT02781883|Experimental|Untreated AML|BP1001 in combination with Ventoclax plus decitabine
89140610|NCT02781883|Experimental|Refractory/Relapsed AML|BP1001 in combination with Ventoclax plus decitabine
89140611|NCT02781883|Experimental|Refractory/Relapsed AML (ventoclax-intolerant or resistant)|BP1001 + decitabine combination in patients who are resistant or intolerant of venetoclax-based treatment, or considered not optimal candidates for a venetoclax-based therapy.
88803418|NCT04160000|Active Comparator|Phase 2 Empiric Heart Failure Therapy|Patients with atrial fibrillation and heart failure with preserved systolic function will be enrolled after informed consent and completion of Phase 1. They will be randomly assigned to heart failure management with empirical selection of heart failure therapy. Patients will be monitored for a minimum period of 9 months after the initiation of empirically selected heart failure drug therapy
89140612|NCT02708108|Experimental|Obesity Intervention|Personalized 28-day Dietary Intervention and Activity and Exercise Intervention with the goal to reduce fat gain and lean muscle loss while inducing an overall negative energy balance.
89140613|NCT02648009|Other|Healthy Volunteers|"Arm 1~Group 1A: control male volunteers between 19 and 50 years of age.~Group 1B: control female volunteers between 19 and 50 years of age.~Group 1C: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice~Group 1D: control male volunteers between 19 and 50 years of age.~Group 1E: control female volunteers between 19 and 50 years of age.~Group 1F: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice"
89140614|NCT02648009|Other|Hypertension Hypertrophy Volunteers|"Arm 2~Group 2A: patients aged 30 to 75 with hypertension and hypertrophy~Group 2B: patients aged 30 to 75 with non-obstructive hypertrophic cardiomyopathy (HCM).~Group 2C: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.~Group 2D: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents.~Group 2E: patients aged 30 to 75 with hypertrophy~Group 2F: patients aged 30 to 75 with hypertrophic cardiomyopathy (HCM).~Group 2G: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.~Group 2H: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents."
89140615|NCT02617589|Experimental|Nivolumab + Radiotherapy Arm|Nivolumab IV infusion + Radiotherapy dose as specified
89140616|NCT02617589|Active Comparator|Temozolomide + Radiotherapy Arm|Temozolomide + Radiotherapy dose as specified
89140617|NCT02587403|Active Comparator|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
89140618|NCT02587403|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
89140619|NCT02540707|Placebo Comparator|Solifenacin|Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks
89140620|NCT02540707|Experimental|Mirabegron|Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks
89140621|NCT02504346|Experimental|Treatment|Non-randomized trial, all patients receive therapy - singel-arm
89140622|NCT02471807|Experimental|Edwards FORMA Tricuspid Transcatheter Repair System|Edwards FORMA Tricuspid Transcatheter Repair System
89140623|NCT02446626|Active Comparator|1|Patients with Lyme disease, post treatment
89140624|NCT02446626|Active Comparator|2|Patients with post-Lyme disease complaints at least 12 months from initial treatment
89140625|NCT02446626|Active Comparator|3|Acute erythema migrans patients (possible positive control)
89140626|NCT02446626|Active Comparator|4|Lyme Arthritis patients (possible positive control)
89140627|NCT02446626|Active Comparator|5|Healthy Volunteers (negative control)
89140628|NCT02340169|Experimental|Topicort® Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25%, twice a day for 28 days
89140629|NCT02333357|Experimental|Toolkit|Counselors randomized to the toolkit (TK) condition will receive a one to three hour standardized toolkit orientation that will include a description of the overall goal of the toolkit curriculum comprised of five modules, the purpose of each individual element of the toolkit, and an introduction to the toolkit teaching aids such as counselor guides, posters, and patient materials (hand-outs, sampling menus, worksheets, etc). TK counselor participants then conduct group treatment sessions using the toolkit materials with their patient participants.
89140630|NCT02333357|Active Comparator|Treatment as Usual|Counselors assigned to the Treatment as Usual (TAU) attention control condition complete a training that reviews the same five 12-step topics that are included in the toolkit, but they do not receive any toolkit materials. TAU counselor participants then conduct group treatment sessions on the 12-step topics without using toolkit materials.
89140631|NCT02330042||Group A|"Patients with:~Type 1 or Type 2 diabetes mellitus~severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR)."
89140632|NCT02330042||Group B|"Patients with:~Type 1 or Type 2 diabetes mellitus~with or without mild to moderate NPDR"
89140633|NCT02330042||Group C (controls)|Patients without diabetes or evidence of any form of eye disease
89140634|NCT02315859||All patients|All patients
89140635|NCT02240745||All patients|Patients with a suspicion of coronary heart disease
89140636|NCT03481907|Other|Internalized Control|Subjects will receive 2 punch biopsy created wounds, one on each thigh, which will be addressed with primary closure with sutures or will be treated with Nuvagen collagen powder at time of wounding and daily thereafter. Suture(s) will be removed in 2 weeks. At week four, the wounded site will be biopsied again for tissue collection/evaluation, and treated with primary closure again. Suture(s) will be removed within to weeks. For those using collagen powder, the biopsy site will be biopsied again at week 4, and wound care will again be with NuvagenTM collagen powder until closure.
89140637|NCT02210403|Active Comparator|Upper limb motor function training + tDCS|Bi-hemispheric tDCS with motor function training
89140638|NCT02210403|Sham Comparator|upper limb motor function training + sham tDCS|sham tDCS with motor function training
89140639|NCT02152033|Experimental|Home-based Continuing Care|The components of Home-based Continuing Care (HCC) include brief parent training, brief Young Adult (YA) orientation and recovery planning, telephone-based continuing care (TCC) and home-based contingency management. Both parent and YA participants will attend sessions with a family specialist.
89140640|NCT02152033|Other|Services as Usual|YAs completing residential care usually are referred to continuing outpatient services and/or self-help groups.
89140641|NCT02148276||Research Participants|All participants will complete two measures of social harm at monthly research appointments for a three month period. The social harms assessments will be (1) the ACASI-SHQ that was developed in Phase 1 and (2) the HIV Vaccine Trials Network (HVTN) Social Impact Assessment.
89140642|NCT02148237|No Intervention|Treatment as Usual|Participants in Treatment as Usual (TAU) will receive standard breastfeeding (BF) services from the WIC program and participate in research assessments. Standard services include an on-site and home-visiting lactation consultant, occasional one-on-one peer counseling, and an enhanced food package for BF women.
89140643|NCT02148237|Experimental|Contingency Management|These participants will receive usual WIC care. The frequency, duration, content, and size of the meetings and participation requirements will be the same as for the TAU group, except that this group will also receive contingency management (CM). Members will demonstrate breastfeeding and receive cash incentives weekly if they breastfeed.
89140644|NCT01931631|Experimental|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
89140645|NCT01931631|Active Comparator|ADA diet|American Diabetes Association diet
89140646|NCT01919749|Other|treatment|recommended treatment
89140647|NCT01899326|Experimental|Treatment (desipramine, filgrastim)|Participants received desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection began on day 6.
89140648|NCT01831999|Experimental|RecoveryTrack - Extended Care (RT-E)|Counselors will conduct monitoring and feedback sessions using the RecoveryTrack-Extended Care (RT-E) web-based monitoring system for clients newly admitted to Intensive Outpatient (IOP) treatment. Counselors will be instructed to document their reminders, contact attempts, and scheduling of RT-E appointments within a Contact Log incorporated into RT-E. All RT-E sessions will be audio recorded.
89140649|NCT01831999|No Intervention|Treatment as Usual (TAU)|Counselors will conduct standard treatment during IOP/OP in this condition. Exceptions to this condition are that counselors will: audio record their first 3 biweekly and subsequent 7 monthly individual in-person sessions; document on a Contact Log outreach attempts; and complete a Counselor Activity Log for client participants. There are several steps that counselors typically take when a client misses a session. Clients are called to reschedule for the same week, if the client doesn't return for their next scheduled session, the counselor sends a letter asking the client to return, etc.
89140650|NCT01813864|Experimental|CASPAR Resource Guide|Treatment Enhanced/CASPAR-- All counselors in this study will receive a training and take part in the experimental arm of the study in Phase 2.
89140651|NCT01751672|Active Comparator|SBIRT|Screening, Brief Intervention, and Referral to Treatment
89140652|NCT01751672|Experimental|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment
89140653|NCT01591239|Experimental|Home-Based Intervention|Parents will receive a 1-session training on how to deliver a 3-session intervention across a 3-week period. The intervention program begins with a 3 and a half hour training session delivered by the staff Trainer to the participating parent. At the conclusion of training, the parent will be given the intervention manual and supplemental materials. The trainer will phone the parent shortly before session 1, in between each intervention session, and after the third intervention (four phone calls total) to review the objectives and tasks associated with that week's intervention session and to help prepare for the coming session. At the final phone call between the parent and trainer (after the third week), the trainer will deliver to the parent the follow-up resources.
89140654|NCT01591239|Active Comparator|Educational Group|Parents will receive a 2-hour, education-only psychoeducational curriculum (no parent-led intervention with their teen will occur.
89140655|NCT01523444|No Intervention|Treatment as Usual|
89140656|NCT01523444|Active Comparator|computer Screening & Brief Advice|All participants receiving care at the site assigned to the computer-facilitated screening and brief advice (cSBA) condition will receive the cSBA intervention as part of their care at that clinic.
89140657|NCT01523444|Experimental|computer Screening & Brief Advice Plus|All participants receiving care at the site assigned to the cSBA+ condition will receive the cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider as part of care at that clinic.
89140658|NCT01515605||Patients after kidney transplantation|Patients after kidney transplantation
89140659|NCT01515137|Experimental|Arm A erlotinib plus sulindac|erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A),
89140660|NCT01515137|Experimental|Arm B erlotinib|erlotinib (150 mg PO QD) (Arm B)
89140661|NCT01515137|Experimental|Arm C|placebo (for Erlotinib) QD (Arm C).
89140662|NCT01482637||CAS|There are no separate groups. All subjects are being asked to complete the CAS measure.
89140663|NCT01481428|Active Comparator|Attention Control|
89140664|NCT01481428|Experimental|Computer-facilitated HIV intervention|
88803419|NCT05120362|Experimental|Cream containing JAK Inhibitor|
88803420|NCT04330768|Experimental|PRF|
88803421|NCT04330768|Active Comparator|MTA|
89140665|NCT01465555|Experimental|Clinical Alert|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
89140666|NCT01465555|No Intervention|Treatment As Usual|Counselors in this condition will work with the original RecoveryTrack which has not been altered to provide automated Clinical Alerts for High Risk patients. Supervisors will receive no automated help in identifying these clients in the counselors' caseloads. The Clinical Alert feature will not be discussed in the training these counselors receive. Rather, the counselors will receive an attention-control training, a one-day training on assessment and treatment planning, with monthly tips and reminders for six months.
89140667|NCT01439113|No Intervention|Standard of care|In this arm, patients who have difficult IV access will undergo the standard of care. The options include a) repeated attempts by a primary nurse, b) new attempts by a second nurse, c) central line placement by a physician, d) intraosseous line placement by a physician, e) physician use of ultrasound for peripheral IV placement
89140668|NCT01439113|Experimental|Ultrasound-guided IV|In this arm, the emergency nurse will apply the ultrasound machine to locate and cannulate a patient's peripheral veins
88803422|NCT01896440|Active Comparator|Group A - standard ondansetron dose first|Group A will receive the standard dose of ondansetron (0.15 mg/kg) with the first cycle of chemotherapy and the high dose (0.3 mg/kg) with second cycle.
89140669|NCT01393509|Experimental|PU-H71|This Phase 1 trial will be an open-label, dose-escalation study of single-agent PU-H71 in patients with advanced solid malignancies and lymphoma.
89140670|NCT01366716|Experimental|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
89140671|NCT01366716|Experimental|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
89140672|NCT01366716|No Intervention|Non-CM Control|Participants in the non-CM control condition will provide urine specimens during the 12-week period as do the two experimental conditions, but will receive no contingent rewards other than praise from the RAs.
89140673|NCT01344382|Experimental|CRAFT|All parents will be scheduled for 12 individual Community Reinforcement and Family Training for parents (CRAFT-P) training sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
89140674|NCT01344382|Active Comparator|Al-Anon Facilitation|All parents will be scheduled for 12 individual Alanon/Naranon Facilitation Training (ANF) sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
89140675|NCT01126190|Active Comparator|Double-Blind Phase: Pegfilgrastim|Participants will receive pegfilgrastim 6 milligrams (mg), administered by subcutaneous (SC) injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/square meter (m^2) and docetaxel 75 mg/m^2 administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
89140676|NCT01126190|Experimental|Double-Blind Phase: Neugranin 40 mg|Participants will receive neugranin 40 mg, administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/m^2 and docetaxel 75 mg/m^2 administered sequentially by IV infusion on Day 1 of treatment for up to four 21-day cycles.
89140677|NCT01126190|Experimental|Open-Label Phase: Neugranin 40 mg|Participants will receive neugranin 40 mg, administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/m^2 and docetaxel 75 mg/m^2 administered sequentially by IV infusion on Day 1 of treatment for up to four 21-day cycles.
89140678|NCT00995384|Other|CT scan|CT Scan for endocarditis patients. All patients receive intervention.
89140679|NCT00921609||Acromegaly patients|All patients will undergo oral glucose tolerance test at postoperative day 1, 6 weeks, 3 months, and 1 year
89140680|NCT00842517|Experimental|Extended|36-week duration contingency management program
89140681|NCT00842517|Active Comparator|Standard|12-week duration contingency management program
89140682|NCT00842036|Active Comparator|ANft|12- step Al/Nar-Anon Facilitation
89140683|NCT00842036|Experimental|TEnT|Treatment Entry Training
89140684|NCT00842036|Experimental|CRAFT|Community Reinforcement and Family Training
89140687|NCT00472654|Placebo Comparator|WL|
89140688|NCT00472654|Experimental|WL + D|
89140689|NCT00472654|Placebo Comparator|WM|
89140690|NCT00472654|Active Comparator|WM + D|
89140691|NCT00413998|Experimental|CABG + Mitral valve repair|
89140692|NCT00413998|Active Comparator|CABG only|
89140693|NCT00323960|Active Comparator|Methylprednisolone pulse (MPDN)+PDN+CSA|MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A
89140694|NCT00323960|Active Comparator|MPDN+PDN+MTX|MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate
89140695|NCT00323960|Active Comparator|MPDN+PDN|MPDN= methylprednisolone PDN= prednisone or equivalent
89140696|NCT00323037|Active Comparator|1|
89140697|NCT00323037|Active Comparator|2|
89140698|NCT00128297|Active Comparator|Arm A: continuous administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 18 months
89140699|NCT00128297|Experimental|Arm B: alternate administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 6 months, followed by a 6 month rest, and a new 6 months treatment period.
89140700|NCT02813564|Experimental|Training group|This group of children will receive the software based intervention program (CAVINS) and will train at home during the training phase.
89140701|NCT02813564|No Intervention|Control group|This group of children will play video-games-as-usual and return in about 3 weeks for their next assessment appointment.
89140702|NCT02813564|Experimental|fMRI-training group|"This sub-group of children from the Training group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and train on CAVINS (the intervention) during the training phase."
89140703|NCT02813564|No Intervention|fMRI-Control group|"This sub-group of children from the Control group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and play video-games-as-usual until their next assessment appointment (after about 3 weeks)."
89140704|NCT00925561||No treatment|
89140705|NCT00939185||Azithromycin group|
89140706|NCT02808026|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 8 weeks
89140707|NCT00925639|Experimental|Isoflavone|Patients will receive daily doses of 150 mg of concentrated extract of soy per os
89140708|NCT00925639|Placebo Comparator|Control|Patients will receive daily placebo pills
89140709|NCT02730390||Probucol Tablets|Target is 3,000 patients in the Philippines diagnosed with hyperlipidemia (including familial hypercholesterolemia and xanthoma).
89140710|NCT02808104|Experimental|Mazindol Controlled Release|Mazindol controlled release taken once daily. Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose during the study is 3 mg taken once daily.
89140711|NCT02808104|Placebo Comparator|Placebo|Matching placebo
89140712|NCT05165771|Experimental|GS-5718 Dose A|Participants will receive GS-5718 Dose A once daily + placebo to match (PTM) GS-5718 Dose B once daily + PTM tofacitinib twice daily for up to 12 weeks.
89140713|NCT05165771|Experimental|GS-5718 Dose B|Participants will receive GS-5718 Dose B once daily + PTM GS-5718 Dose A once daily + PTM tofacitinib twice daily for up to 12 weeks.
89140714|NCT05165771|Active Comparator|Tofacitinib|Participants will receive tofacitinib 5 mg twice daily + PTM GS-5718 (Dose A + Dose B) once daily for up to 12 weeks.
89140715|NCT05165771|Placebo Comparator|Placebo|Participants will receive PTM GS-5718 (Dose A + Dose B) once daily + PTM tofacitinib twice daily for up to 12 weeks.
89140716|NCT00929461|Other|Omega-3 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
89140717|NCT00929461|Other|Omega 3 + Omega 6 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter.
89140718|NCT00925717||2500 patients|Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.
89140719|NCT02730624|Experimental|piperacillin/tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h
89140720|NCT02807870|Experimental|Methylphenidate-psychoeducational group|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments) and weekly psychoeducational groups for parents during 8 weeks.
89140721|NCT02807870|Experimental|Parental training-placebo pill|Weekly parental training conducted by behavioral psychologists and placebo pill during 8 weeks.
89140722|NCT02807870|Placebo Comparator|Psychoeducational group-placebo pill|Weekly psychoeducational groups for parents and placebo pill during 8 weeks.
89140723|NCT00925795|Active Comparator|Group A (1. EVOO; 2. ROO)|
89140724|NCT00925795|Active Comparator|Group B (1. ROO; 2. EVOO)|
89140725|NCT02739438||E Cigarette users|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months. Total pack years of smoking should be less than 20 for their smoking history, with normal lung function (FEV1 and FEV1/FVC) and no clinical symptoms of airway obstruction/inflammation (cough, dyspnea, sputum and wheeze).
88803423|NCT01896440|Active Comparator|Group B - high dose ondansetron first|Group B patients will receive the higher dose of ondansetron (0.3 mg/kg) with the first cycle of chemotherapy and the standard dose (0.15 mg/kg) with the second.
88803424|NCT00118586||Muscle tension dysphonia|Increased phonatory muscle tension in the paralaryngeal and suprahyoid muscles onpalpation
88803425|NCT00118586||Normal Volunteers|Normal vocal function refers to normal voice quality with a negative history of voice orlaryngeal disorders
89140726|NCT02739438||Cigarette smokers|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
89140727|NCT02739438||Control group|Subjects with no history of prior conventional cigarette (< 100 cigarettes lifetime) or electronic cigarette use.
89140728|NCT03372720|Experimental|Arm I (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy at 3 time points 30 days apart.
89140729|NCT03372720|Sham Comparator|Arm II (sham laser therapy)|Patients undergo sham laser therapy at 3 time points 30 days apart. Patients may then crossover to Arm I.
89140730|NCT02807792|Experimental|Perianal access device|
89140731|NCT00925873|Active Comparator|1|"Control arm without fludarabine~Induction course: Ara-C 100mg/m2 days 1-7, idarubicin 8mg/m2 days 1-5, GM-CSF (molgramostim, Novartis) 5 microg/kg days 1 to neutrophil recovery;~Consolidation course: Ara-C 1g/m2 q12h days 1-3, idarubicin 10mg/m2 days 2-3;~and 3 quarterly reinduction courses during maintenance including Ara-C 80mg/m2 days 1-5, CCNU 40mg and mitoguazone 350mg/m2 day 1, ± fludarabine days 1-2."
89140732|NCT00925873|Experimental|2|"Fludarabine arm~The same regimen with fludarabine 20 mg/m2/day IV for 30 minutes~induction course + fludarabine days 2-7;~consolidation course + fludarabine days 4-5;~during reinduction courses + fludarabine days 1-2."
89140733|NCT02735148|No Intervention|Conventional Training|Conventional training sessions generally consisted of exercises which aimed to improve range of motion, strength, and movement quality in upper and lower extremity as an in-patient rehabilitation protocol. Also developing static and dynamic postural control and increasing walking distance were the other aims of training. Duration of the Conventional Training is 45 minute per session, 3 days a week for 6 weeks.
89140734|NCT02735148|Experimental|Body Weight Supported Treadmill Training|"Body weight supported treadmill training (BWSTT) was composed of outpatients who were undertaken only BWST training with 45-minute sessions, 2 days a week during 6 weeks.~BWST Training~Locomat (Hocoma) was used in BWSTT group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait pattern."
89140735|NCT02735148|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-BWST training, 2 days a week during 6 weeks.
89140736|NCT00925951|Experimental|Wet Cupping|
89140737|NCT00925951|No Intervention|Waiting Control|They can't use any other specific treatment except exercises and behavior modification (we'll offer a brochure which includes exercise method and directions about behavior modifications).
89140738|NCT04237142|Experimental|Eligible patients who had consented to participate|Eligible patients who had consented to participate to the study, namely parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week with cervical dilation < 4cm and without known uterine malformation, fetal malformation, placenta previa or abundant metrorrhagia. Patients underwent vaginal swabbing and blood sample collection at the admission.
89140739|NCT02735070|Experimental|Corisitina D|The patient will use the medication 4 times a day - orally The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine. Coristina® d is indicated as an analgesic, antipyretic, antiallergic, and nasal congestion for the treatment of the symptoms of influenza and common cold.
89140740|NCT02735070|Active Comparator|Resfenol|The patient will use the medication 4x / day - orally Resfenol® drug acts against the symptoms of colds and flu, such as nasal congestion, runny nose, fever, headache, muscle pain and other symptoms. The capsules containing 400mg of paracetamol, 4 mg chlorpheniramine and 4mg phenylephrine.
89140741|NCT02813408||Participants with Prostate Cancer (abiraterone acetate)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive abiraterone acetate at the discretion of his treating physician.
89140742|NCT02813408||Participants with Prostate Cancer (enzalutamide)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive enzalutamide at the discretion of his treating physician.
89140743|NCT02813486|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
89140744|NCT02813486|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
89140745|NCT02734836|Experimental|Zilver PTX Stent|Diagnostic assessment of the lesion after implantation of drug eluting stent with Balloon Angioplasty and placement of the Zilver PTX Stent with Optical Coherence Tomography (OCT)
89140746|NCT02807714||No CAD|Patients scheduled for elective cardiac catheterization for evaluation of suspected CAD that are found to not have CAD
89140747|NCT02807714||Obstructive CAD (non-ACS) Group|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have obstructive CAD requiring intervention.
89140748|NCT02807714||Stable CAD, no intervention required|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have non-obstructive CAD not requiring intervention.
89140749|NCT02807714||Acute Coronary Syndrome (ACS)|Patients who undergo an emergent cardiac catheterization for evaluation of known or suspected STEMI, NSTEMI, Unstable Angina (UA).
89140750|NCT02734914|Experimental|SF-URS with automatic control of RPP|Participants in SF-URS with automatic control of renal pelvic pressure (RPP) group undergo ureteroscopy using the intelligent pressure control device (Medical irrigation and suctioning platform with pressure feedback function, and suctioning ureteral access sheath with function of pressure measuring).
89140751|NCT02734914|Active Comparator|conventional F-URS|Participants in conventional F-URS group undergo ureteroscopy using the classic flexible ureteroscope.
89140752|NCT02739516|Active Comparator|Control|In letrozole stimulated cycle: On the day of ovulation trigger the patient received standard dose of Human chorionic gonadotropin (10,000 IU).
89140753|NCT02739516|Experimental|Study|In letrozole stimulated cycle: On the day of ovulation trigger the patient received hCG 10000 IU plus FSH co-trigger (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once .
89140754|NCT04428853|Experimental|exercise|A schedule has designed by the researcher for group yoga therapy of the participant twice a week, each session lasting for 75- minutes for the duration of 8 weeks
89140755|NCT02807324||Controls|Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies)
89140756|NCT02807324||Early PE with IUGR|These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
89234578|NCT00826397|Sham Comparator|Control Arm|The control patients will receive a form of sham acupuncture, which will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks.
89234579|NCT00998478|Experimental|Activity prescription|
89140757|NCT02807324||Early PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
89140758|NCT02807324||Late PE with IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
89140759|NCT02807324||Late PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
89140760|NCT02807324||HELLP syndrome|Cases consist of women (18 years or older) with HELLP syndrome in the current pregnancy (defined as (1) the presence of microangiopathic hemolytic anemia with abnormal blood smear, low serum haptoglobin and elevated lactate dehydrogenase (LDH) levels, (2) aspartate transaminase (ASAT) above 70 IU/L and lactate dehydrogenase (LD) above 600 IU/L or bilirubin more than 1.2 mg/dL, (3) platelet count below 100 x 10^9 L-1 )
89140761|NCT00933283|Experimental|Telaprevir + Methadone|Patients will receive telaprevir 750 mg orally, every 8 hours from Day 1 to Day 7, along with methadone 30 to 130 mg, once daily.
89140762|NCT00634478|Experimental|1|preleminiscal radiation deep brain stimulation
89140763|NCT00634478|Active Comparator|2|VIM deep brain stimulation
89140764|NCT02807246|Active Comparator|Probiotic|Experimental: Breast milk+ Probiotics(Maflor®, Mamsel Pharmaceuticals, Turkey) The study group will be fed with probiotics at a dose of 1x109 CFU/day (Lactobacillus rhamnosus GG 109colony ). Probiotic is in a liquid drop form at a dose of 5 drops a day and is used orally for 10 days.
89140765|NCT02807246|Active Comparator|Saline|Active Comparator: Breast milk+five drops of saline The control group will be given Breast milk without the addition of probiotics
89140766|NCT02730156|Experimental|Altitude exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
89140767|NCT04186130||SB|Children over 3 years old and under 12 years old who have been diagnosed with spinal bifida with spinal MRI. They should not have known inflammatory bowel disease or cloacal anomaly
89140768|NCT04186130||Control|Children over 3 years old and under 12 years without known inflammatory bowel disease or cloacal anomaly
89140769|NCT02739126|Active Comparator|Thick USS (1.7mm) with use of additional aspiration needle|
89140770|NCT02739126|Active Comparator|Thin USS (1.4mm)|
89140771|NCT02813018|Experimental|preemptive group|Group who will be received ropivacaine bolus and continous infusion 5 minutes before skin incision.
89140772|NCT02813018|Placebo Comparator|saline group|Group who will be received saline bolus and continous infusion 5 minutes before skin incision
89140773|NCT02730078|Active Comparator|Attention-meetings (AG)|Attention-control
89140774|NCT02730078|Experimental|VEMOFIT (VG)|Personal value exploration, disease education, emotional skills and goal setting.
89140775|NCT02810210||Cohort 1|Monitoring of children born without congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
89140776|NCT02810210||Cohort 2|Monitoring of children born with congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
89140777|NCT02810210||Cohort 3|Monitoring of children born without congenital anomalies to mothers with no biologically confirmed ZIKV's infection during the pregnancy
89140778|NCT02730000|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
89140779|NCT02730000|Experimental|ART with Riva Self Cure|Occlusal-proximal restoration in primary molars using Riva Self Cure from SDI, encapsulated, pre-dosed and mechanized handling.
89140780|NCT02810288||Expert|Anaesthesiologist with large paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
89140781|NCT02810288||Non-experts|Anaesthesiologist with little paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
89140782|NCT02729688|Active Comparator|ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
89140783|NCT02729688|Active Comparator|customized pressure guide bandage|Bandaging was applied by spiral methods. Three customized pressure guide elastic bandage were applied by stretching until the elliptical shape marker in the bandage turned into circular shape with 50% overlapping from foot to just below knee level.
89140784|NCT02813174|Experimental|Automated online Compassionate Mind Training|
89140785|NCT02810366|Active Comparator|Physician Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the electronic Verbal Autopsy (eVA) instrument.~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a short checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness, followed by a free-text narrative.~Cause of death for these VAs will be assigned by trained physicians using the MDS physician coding system; this includes dual, independent coding of VA records, disagreements resolved by reconciliation, and remaining cases by adjudication by a third physician. The assignment of cause of deaths will be in line with the international classification of disease version 10 (ICD-10)."
89234580|NCT00998478|No Intervention|Normal Curriculum|Followed normal curriculum including physical education
89140786|NCT02810366|Experimental|Computer Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the Extended Symptom List (ESL) VA instrument.~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a long checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness. This VA instrument does not contain a free-text narrative.~The cause of death for these VAs will be independently assigned by five leading computer-coding VA algorithms. The assignment of cause of deaths will be in line with 17 broad cause of death categories."
89140787|NCT02810132|Active Comparator|Metformin|Drug: Metformin Target dose: 1000 mg x 2 (if eGFR 30-60 ml/min: 500 mg x 2) Other name: Glucophage XR 500
89140788|NCT02810132|Placebo Comparator|Placebo|Drug: Placebo
89140789|NCT02734992|Other|Acceptance and Commitment therapy + MTAU|"The Acceptance and Commitment therapy + MTAU (active treatment) consists of an unpublished manual developed for the purposes of the Algea project (Vasiliou & Karekla, 2015). The protocol specifies the following goals: (a) increase individuals' willingness to face uncomfortable internal experiences; b) promoting meaningful activities even in the present of head pain; (c) emphasizing acceptance as an alternative to avoidance in coping with headache; (d) clarifying individuals' values in important life domains; e) enhancing present moment-to-moment awareness.~Participants will be asked to remain stable on their pharmacotherapy during this study. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions.~Participants will complete questionnaires at pre-, post-treatment, and at 3-month follow-up. The WL group will enter treatment at the 3-month follow-up of the ACT-group."
89140790|NCT02734992|Other|MTAU/ Wait-list Control Gr|"The MTAU/ Wait-list Control Gr will follow their usual treatments, including any new treatments their GPs or Neurologists might prescribe (mostly prophylactic and abortive medication), during the study at the time. Following the completion of the active group follow up 3months, participants allocated to the control group will receive the active treatment. Participants will complete the same questionnaires at three different time points: pre-, post-treatment, and at 3-month follow-up.~Participants will be asked to remain stable on their pharmacotherapy during this study and inform the researchers of any changes. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions. Excluded participants will be referred to appropriate services."
89140791|NCT02807168|No Intervention|Usual care|Control Group
89140792|NCT02807168|Experimental|Usual care plus NT-proBNP|Experimental Group
89140793|NCT02734758||Atrial fibrillation stroke|
89140794|NCT02734758||Non-atrial fibrillation Stroke|
89140795|NCT02734680|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
89140796|NCT02734680|Experimental|Stereotactic Radiotherapy(SBRT) Group|Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
89140797|NCT02807012|Experimental|Nursing educational intervention|The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.
89140798|NCT02807012|No Intervention|Usual care|The family caregivers won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.
89140799|NCT02734524|Experimental|NK infusion+chemotherapy|Treatment includes four cycles. For each cycle: Taxol and carboplatin will be given at the first week. Lymphodepletion will be conducted at the second week. Autologous NK cells will be infused at the third week. Each cycle includes four weeks.
89140800|NCT02734524|Active Comparator|chemotherapy|Receive the same taxol and carboplatin in experimental arm without NK cell infusion.
89140801|NCT03977155|Experimental|High dose of BOS-589|Participants will receive a high dose of BOS-589 orally twice a day (BID).
89140802|NCT03977155|Experimental|Low dose of BOS-589|Participants will receive a low dose of BOS-589 orally BID.
89140803|NCT03977155|Placebo Comparator|Placebo|Participants will receive matching placebo orally BID.
89140804|NCT02807090|Experimental|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
89140805|NCT02807090|Experimental|Circular Dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
89140806|NCT04237272|Active Comparator|Pod System|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
89140807|NCT04237272|Active Comparator|Customizable Tank|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week sampling period.
89140808|NCT04237272|Active Comparator|Control|Participants assigned to this arm will not receive any e-cigarette
89140809|NCT00930059|Experimental|PF-04447943|
89140810|NCT00930059|Placebo Comparator|Placebo|
89140811|NCT04173962|Experimental|Ketamine group|One 0.5mg/kg intravenous dose of ketamine
89140812|NCT04173962|Active Comparator|Midazolam group|One 0.045mg/kg intravenous dose of midazolam
89140813|NCT02734446|Active Comparator|Reuterin D3 drops|Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) 5 drops/day for 3 months (Reuterin D3 drops)
89140814|NCT02734446|Placebo Comparator|Placebo|The patients will receive 5 drops/day of placebo for 3 months
89140815|NCT00772005|Active Comparator|150 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
89140816|NCT00772005|Active Comparator|200 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
89140817|NCT00772005|Active Comparator|250 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
89140818|NCT00772005|Placebo Comparator|Matching Placebo|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
89140819|NCT02806856|Active Comparator|Active tDCS|
89140820|NCT02806856|Sham Comparator|Sham|
89140821|NCT02813096|Experimental|folfox4 chemotherapy regimen|"details in the Intervention Description"
89140822|NCT02813096|Placebo Comparator|Placebo|"details in the Intervention Description"
89140823|NCT02734368||Healthy non-smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
89140824|NCT02734368||Asymptomatic smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
89140825|NCT02734368||COPD subjects|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
89140826|NCT04262999||drug sodium valproate|individuals on antiepileptic drug sodium valproate for at least 1 year at the time of participation of the study.
89140827|NCT04262999||drug levetiracetam|individuals on antiepileptic drug levetiracetam monotherapy for at least 1 year at the time of participation of the study.
89140828|NCT04262999||drug sodium valproate + levetiracetam|individuals on antiepileptic drug sodium valproate + levetiracetam combination therapy for at least 1 year at the time of participation of the study.
89140829|NCT04262999||control group|systemically healthy individuals
89140830|NCT02733978|Experimental|ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
89140831|NCT02733978|No Intervention|non-ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
89140832|NCT00939107|Experimental|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
89140833|NCT00939107|Active Comparator|Spinal manipulation|Spinal manipulation in combination with information of clinical findings and advice about back care
89140834|NCT00933361|Experimental|ghrelin|Ghrelin, a 28 amino acid peptide discovered in 1999, is predominantly secreted by gastric endocrine cells and is an endogenous ligand for the growth hormone secretagogue (GHS) receptor. When administered peripherally it stimulates growth hormone secretion, food intake, triggers a positive energy balance, produces weight gain through a central mechanism involving hypothalamic neuropeptides and has anti-inflammatory effects
89140835|NCT02729766|Active Comparator|Empagliflozin 25mg Tbl|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
89140836|NCT02729766|Placebo Comparator|Placebo P-Tablet|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
89140837|NCT02812940|Experimental|Everolimus as part of GvHD prophylaxis after allogeneic SCT|Everolimus from day +5 to day +100
89140838|NCT00929617|Experimental|1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
89140839|NCT00929617|Other|2. Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
89140840|NCT02729610|Active Comparator|DLT group|In this arm, patient will be intubated with a double lumen endotracheal tube
89140841|NCT02729610|Experimental|BB group|In this arm, patient will be intubated with an endobronchial blocker
89140842|NCT00604097|Experimental|1|Attachment-Based Family Therapy
89140843|NCT00604097|Active Comparator|2|Enhanced Usual Care
89140844|NCT02810054|Sham Comparator|Control Group (MIST without EMD)|Those participants who will receive the minimally invasive surgical techniques but without application Enamel Matrix Derivative (EMD) .
89140845|NCT02810054|Experimental|Test Group (MIST with EMD)|Those participant who will receive the minimally invasive surgical techniques with the application of Enamel Matrix Derivative (EMD) .
89140846|NCT00933439|Experimental|Duloxetine|
89140847|NCT00608075|Other|1|Manic Patients
89140848|NCT00608075|Other|2|Depressed Patients
89140849|NCT02809742||Epidural group|Epidural : automatic intermittent boluses ( 8-12 mL per hour) + patient controlled bolus (4 mL evrey 20 min) using ropivacaine
89140850|NCT00929851|Experimental|BDP/FF|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
89140851|NCT00929851|Active Comparator|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
89140852|NCT02729376|Experimental|Single dose of [14C]-galeterone|[14C]-galeterone will be supplied as 325 mg capsules (powder in capsule [PIC]). The treatment to be administered will be 2600 mg (~500 µCi) (8 x 325 mg capsules).
89140853|NCT00608153||1|Patient with essential hypertension under treatment with candesartan or candesartan HCT
89140854|NCT02806700|No Intervention|Twitter Diabetes Control|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys
89140855|NCT02806700|Experimental|Twitter Diabetes Intervention|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys. This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
89140856|NCT02739282|Active Comparator|Systematic therapeutic drug monitoring|"Systematic therapeutic drug monitoring performed at each clinic consultation and automatically transmitted to the clinician will be compared with clinically required therapeutic drug monitoring (rescue therapeutic drug monitoring, transmitted only in case of predefined inefficacy or tolerance problems, as defined in the combine endpoint below), to assess if systematic therapeutic drug monitoring can prevent a proportion of treatment failure or adverse events."
89140857|NCT02739282|No Intervention|"Rescue therapeutic drug monitoring"|"In the rescue therapeutic drug monitoring arm, communication of levels results will only be provided if a study endpoint (treatment failure or side effect as discussed below) is reached."
89140858|NCT00926341|No Intervention|Active control|1. Active Control: (n=20), intervention: no intervention
89140859|NCT00926341|Active Comparator|PIO arm|PIO arm (n=30), Pioglitazone 30 mg/day, given for 24 weeks.
89140860|NCT00926341|Active Comparator|Telmi arm|Telmia arm (n=30): Tab. Telmisartan 40 mg/day given for 2 weeks.
89140861|NCT05279105||Humanitarian workers|Staff working in humanitarian organisations will be recruited for interviews
89140862|NCT05279105||Internally displaced persons|Internally displaced persons living in conflict settings will be recruited for interviews
89140863|NCT02806778||Hypoxic brain injury|Consecutive out-of-hospital, post-cardiac arrest patients who remain comatose after successful resuscitation, admitted on ICU of University Hospital Ostrava. The patients will undergo BIS monitor-guided sedation and jugular bulb catheterisation.
89140864|NCT02729532||Xpert cohort|HIV-positive presumptive TB patients tested for TB using Xpert MTB/RIF assay (fluorescence microscopy and TB culture also done to serve as reference standard)
89140865|NCT02729532||Standard of Care cohort|HIV-positive presumptive TB patients tested for TB using standard of care testing (sputum smear microscopy plus clinical evaluation)
89140866|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
89140867|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
89140868|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
88803426|NCT00118586||Spasmodic dysphonia|A diagnosis of adductor or abductor SD will be based on voice testing and fiberoptic nasolaryngoscopy conducted during the initial interview
88803427|NCT00118586||Vocal Tremor|Vocal tremor during vocalization that primarily involves laryngeal structures
88803428|NCT01223066||Women treated with Macrolane in the breasts|
89140869|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
89140870|NCT00926419|Active Comparator|Varicella (full dose) - SC - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle-free Syringe Jet Injector
89140871|NCT00926419|Active Comparator|Varicella (full dose) - SC - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle Syringe
89140872|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
89140873|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
89140874|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle-free Syringe Jet Injector
89140875|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle Syringe
89140876|NCT02806622||Division II Collegiate Athletes|Student athletes (18-45) currently enrolled and participating on a sports team.
89140877|NCT04259879|Experimental|Fasting|The participants will follow a short-term fasting period for 36 hours
89140878|NCT02806466|Active Comparator|Asthmatic children|
89140879|NCT02806466|Sham Comparator|Non-asthmatic children|
89140880|NCT00929929|Experimental|L-Leucine|This arm receives a supplement of leucine along with a progressive resistance exercise program.
89234581|NCT01050478|Experimental|Paliperidone ER|Paliperidone ER: recommended dose: 6 mg/day. Can be 9 mg/day for patients with an acute exacerbation of schizophrenia. A benzodiazepine for sedation and/or rescue medication can be added with a maximum of 7.5 mg/day, at the investigators' discretion.
89234582|NCT00822575|Active Comparator|A|
89234583|NCT00822575|Sham Comparator|B|
89234584|NCT00826475|Experimental|Mindfulness|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
89234585|NCT00826475|Active Comparator|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
89234586|NCT00998556|Experimental|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks, thereafter the patients continue to be observed in the follow-up part of the study up to month 6. The study medication is taken on top of standard therapy for heart failure. Part of this therapy are ACE inhibitors. ACE inhibitors are potentially harmful for the baby when getting into the breast milk, as bromocriptine stops milk production, no additional drug is needed.
89234587|NCT00998556|No Intervention|Control Group|The control group will receive standard therapy for heart failure. Part of this therapy are ACE inhibitors. Since ACE inhibitors are potentially harmful for the baby when getting into the breast milk, it is necessary to stop lactation in the control group as well.To stop lactation, application of bromocriptine (2.5mg/day) for up to one week.
89234588|NCT01052974|Placebo Comparator|physiological serum|ropivacaïne controlled by placebo (physiological serum).
89234589|NCT01052974|Active Comparator|ropivacaine|ropivacaïne controlled by placebo (physiological serum).
89234590|NCT00817427|No Intervention|Baseline|CKD subjects and healthy, matched controls will have measures of cardiovascular function (BP, HR) measure of hormonal fluid balance (renin/aldosterone) measure and measures of glucose metabolism (response to glucose load and over 24 hr profile) with 3 days of habitual sleep time
89234591|NCT00817427|Experimental|CKD- Sleep extension|Measures as in baseline but with bed time increased by 2 hours
89234592|NCT00817427|Experimental|Controls short sleep|Measures as in baseline but with sleep disruption
89234593|NCT00998634|Experimental|LITHIUM CARBONATE 150 and/or 300 mg|
89234594|NCT00998634|Placebo Comparator|PLACEBO|
89234595|NCT04044989|Experimental|Root resorption (total)|The resorption cavities on the root surface were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
89234596|NCT04044989|Experimental|Root resorption (local)|The resorption cavities on the root surface (palatal, buccal, distal and mesial root surfaces) were determined and the volumes of the cavities were measured in CTAn software (micro-CT).
89234597|NCT00998712||1|Black women in the third trimester of a pregnancy complicated by gestational diabetes.
89234598|NCT00998712||2|Black women in the third trimester of a normal, uncomplicated pregnancy.
89234599|NCT00998712||3|White women in the third trimester of a pregnancy complicated by gestational diabetes.
89234600|NCT00998712||4|White women in the third trimester of a normal, uncomplicated pregnancy.
89234601|NCT01003002||PD Cohort|The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
89234602|NCT01008774|Experimental|A|
89234603|NCT01008774|Active Comparator|B|
89234604|NCT01008774|No Intervention|C|
89234605|NCT01006200||Structural /dynamic airway obstruction|Obstructive granulation tissue formation after SEMS implantation was defined as granulation tissue obstructing the lumen of the SEMS under bronchoscopic examination.
89234606|NCT01008930|Experimental|PEM Scan|HR PEM images (High Resolution PEMFlex Solo II scan images)
89234607|NCT01003158|Experimental|Monotherapy part|AZD8931 monotherapy
89234608|NCT01003158|Experimental|Combination part|AZD8931 plus paclitaxel
89234609|NCT01003236|Placebo Comparator|placebo|1 tablet 3 times daily
89234610|NCT01003236|Experimental|Milk Thistle extract|1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day
89234611|NCT03883386|Experimental|Loratadine first|Take treatment daily for 7 days.
89234612|NCT03883386|Placebo Comparator|Placebo first|Take placebo daily for 7 days.
89234613|NCT00530946|Active Comparator|CI-1038 2.5mg/5mg|
89234614|NCT00530946|Active Comparator|CI-1038 2.5mg/10mg|
89234615|NCT00530946|Active Comparator|CI-1038 5mg/5mg|
88803429|NCT01217216|Active Comparator|Group-based Intervention|We randomly assigned 30 individuals to a group-based intervention to promote weight loss through dietary restriction and physical activity.
88803430|NCT01217216|Active Comparator|Telephone-based Intervention|We randomly assigned 22 individuals to the telephone-based intervention to promote weight loss through dietary restriction and physical activity.
89234616|NCT00530946|Active Comparator|CI-1038 5mg/10mg|
88803431|NCT01195064||COPD+ OSAS- patients|Patients with chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
89234617|NCT00424047|Experimental|CC-5013 plus dexamethasone|Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
89234618|NCT00424047|Experimental|Dexamethasone plus placebo|Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
89140881|NCT00929929|Placebo Comparator|Maltodextrin|This arm receives a supplement of maltodextrin along with a progressive resistance exercise program.
88803432|NCT01195064||COPD- OSAS+ patients|Patients with obstructive sleep apnea syndrome (OSAS) and without chronic obstructive pulmonary disease (COPD), before planned cardiovascular surgery
89140882|NCT00608231|Experimental|PD-STN|Parkinson's Disease -- STN target
89140883|NCT00608231|Experimental|PD - GPi|Parkinson's Disease -- GPi target
89140884|NCT00608231|Experimental|ET - VIM|Essential Tremor -- VIM target
89140885|NCT00608231|Experimental|Dystonia - GPi|Dystonia -- GPi target
89140886|NCT00608231|Placebo Comparator|PD - STN Control|Parkinson's Disease -- STN target
89140887|NCT00608231|Placebo Comparator|PD - GPi Control|Parkinson's Disease -- GPi target
89140888|NCT00608231|Placebo Comparator|ET - VIM Control|Essential Tremor -- VIM target
89140889|NCT00608231|Placebo Comparator|Dystonia - GPi Control|Dystonia -- GPi target
89140890|NCT02729142|Experimental|Tibial cortical density evaluation|
89140891|NCT04015531|Active Comparator|Conventional radiotherapy|"50 Gy in 25 fractions to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla), followed by tumor bed boost of 10 Gy in 5 fractions in case of breast conserving surgery.~Total time: 5-6 weeks."
89140892|NCT04015531|Experimental|Hypofractionated radiotherapy|"40 Gy in 15 fractions (2.67 Gy each) to chest wall or whole breast and regional lymph regions (supraclavicular fossa with or without axilla).~Patients undergoing breast conserving surgery will receive concomitant boost with total dose of 48 Gy in 15 fractions (3.20 Gy each) to tumor bed.~Total time: 3 weeks."
89140893|NCT02729220|Other|Healthy controls|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
89140894|NCT02729220|Other|Smokers|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
89140895|NCT02729220|Other|COPD rapid decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
89140896|NCT02729220|Other|COPD slow decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
89140897|NCT00933595|Experimental|Smoking Cessation|The overall smoking cessation rate for the intervention is 18.8 at 3 months, 13.1 at 6 months and 10.0 at 12 months.
89140898|NCT04236674|No Intervention|No intervention|
89140899|NCT04236674|Experimental|Buzzy|Thermomechanical device for periprocedural analgesia
89140900|NCT04236674|Experimental|Music Selection|Patient specified music selection for procedural room
89140901|NCT04236674|Experimental|Buzzy and Music Selection|A combination of use of the Buzzy device and patient specified music selection
89140902|NCT02733744|Experimental|Fecal Microbiota Transplant|"Each participant will undergo allogeneic hematopoietic stem cell transplantation, according to institutional standards.~Participants will receive a single standard dose of oral Fecal Microbiota Transplantation (FMT), which is 15 capsules per day for two consecutive days, for a total of 30 capsules. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Capsules will be individually handed to participants by a research nurse or physician. Each capsule will be taken with a sip of water."
89140903|NCT00930085|Experimental|SELDI-TOF MS|The proteic profiling is performed by SELDI-TOF mass spectroscopy.
89140904|NCT02733666|Experimental|Absorbable screw group|One absorbable screw was used for fixation in the experimental group
89140905|NCT02733666|No Intervention|K-wires group|two 1.8-mm K-wires were used for the fixation in the control group. The K-wires were the most common used by the orthopaedic surgeon.
89140906|NCT00933673|Experimental|L-DICE|
89140907|NCT02812550|Other|full-spectrum colonoscopy|Colonoscopy is performed with a full-spectrum colonoscopy (330º angle of view)
89140908|NCT02812550|Other|standar forward-viewing colonoscopy|Colonoscopy is performed with standar forward-viewing colonoscopy (170º angle of view)
88803433|NCT01195064||COPD+ OSAS+ patients|Patients with chronic obstructive pulmonary disease (COPD) and with obstructive sleep apnea syndrome (OSAS), with planned cardiovascular surgery
88803434|NCT01195064||COPD- OSAS- patients|Patients without chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
89140909|NCT02739204|Experimental|Celecoxib|Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib
89140910|NCT00927485|Experimental|Curcumin|Curcumin
89140911|NCT00927485|Placebo Comparator|Placebo|Placebo (sugar pills)
89140912|NCT00926653||Depressed|Elderly participants with depression
89140913|NCT00926653||Control|Elderly participants who have never experienced depression
89140914|NCT04237064||Patients with carotid artery stenosis|In this study, patients in the age of > 18 year will be included that are scheduled for an endarterectomy procedure at CZE.
89140915|NCT02733822|Experimental|IMP: buccal naloxone (single dose)|0.8 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
89140916|NCT02733822|Experimental|IMP: buccal naloxone (double dose)|1.6 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
89140917|NCT02733822|Active Comparator|Intramuscular (IM) reference|0.8 mg IM injection of 1 mg/ml Naloxone Hydrochloride Injection
89140918|NCT02733822|Active Comparator|Intravenous (IV) reference|0.8 mg IV injection of 1 mg/ml Naloxone Hydrochloride Injection
89140919|NCT02805998|Experimental|Web-based CBT-I|Sleepio delivers CBT-I through 6 weekly web-sessions (www.sleepio.com). Treatment content is based on CBT for insomnia manuals (Espie et al., 2007, 2008) and includes a behavioral component (sleep restriction, stimulus control, and relaxation), a cognitive component (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, putting the day to rest) and an educational component (psycho-education, sleep hygiene).
89140920|NCT02805998|Other|Treatment as Usual|Our control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy. Use of non-study treatment will be tracked.
89140921|NCT00930241|Experimental|Advagraf|Advagraf® (one daily dose of Tacrolimus)
89140922|NCT00930241|Active Comparator|Prograf|Prograf® (two daily doses of Tacrolimus)
89140923|NCT02738970|Active Comparator|Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV.
89234619|NCT00530790|Experimental|ropinirole CR-RLS|"Subjects will orally take ropinirole CR-RLS tablet(s) once daily 1-2 hours before the onset of RLS symptoms at about the same time of the day. The time of taking ropinirole must be after 16:00.Adjustment of the Ropinirole CR-RLS tablets should be completed after the Week 1 visit up to the Week 10 visit. The dose will be increased at intervals of at least one week until sufficient efficacy is obtained (use much improved as a guide) without safety problem. Dose escalation will start at the initial dose 0.5 mg/day to 1 mg/day; after 1 mg/day, the dose will be increased by 1 mg/day to the maximum 6 mg/day."
89234620|NCT02869971|Experimental|Embolization|Prostatic Arteries Embolization
89234621|NCT02869971|Active Comparator|Combined Therapy|Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day
89234622|NCT01032057|Active Comparator|Gemcitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po) followed by gemcitabine 300mg/m2 weekly (IV) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
89234623|NCT01032057|Active Comparator|chemoradiotherpay with capecitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po), followed by capecitabine 830mg/m2 bd (po, Mon-Fri) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
89234624|NCT01006278||Surgical group with knee pain|patients 18 years of age or greater with a history of knee pain for more than three but less than six months who failed conservative management with the presence of mechanical symptoms including locking, catching, or giving way; positive physical exam findings including joint line tenderness, McMurray's exam, or Steinman's exam; and MRI of the knee positive for meniscus tear in a location correlating with physical examination. Exclusion criteria were as follows: the presence of high grade gonarthrosis including Kellgren-Lawrence grade IV; a history of prior knee surgery or trauma; ligamentous incompetence on examination or MRI; and diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases.
89234625|NCT01006278||Group 2|volunteer group
89234626|NCT01003314|Experimental|Group 1|
89234627|NCT01003314|Experimental|Group 2|
89234628|NCT01003392||Normal|Normal volunteers, with no diagnosed chronic disease.
89234629|NCT01003392||Coronary artery disease|Group of patients with diagnosed coronary artery disease.
88803435|NCT00086762|Experimental|MR Therapy|Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. A CD with the mindfulness relaxation technique recorded on it will be given to participant. Participant to listen to the recording for about 30 minutes before receiving chemotherapy and during the time they are receiving chemotherapy. In addition to the mindfulness relaxation technique, they will also receive general information about how to manage symptoms that develop due to the chemotherapy they are receiving.
88803436|NCT00086762|Experimental|Relaxing Music (RM) Therapy|Arm II: Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment.
89234630|NCT01003392||Diabetes|Diabetic patients.
89234631|NCT00530088|Experimental|Porfimer Sodium|Patients receive porfimer sodium subcutaneously followed by photodynamic therapy (PDT) comprising laser light delivered by a single or a diffuser (i.e., for broad areas of dysplasia) fiberoptic lens fiber.
89234632|NCT01009008|Experimental|Post-mastectomy|Post-mastectomy patients undergoing expander reconstruction
89234633|NCT01006434||Thrombolysis group (Pilot phase)|Patients receiving intravenous thrombolysis for acute ischemic stroke. Pilot phase (100 Patients).
89234634|NCT01006434||Thrombolysis group|Patients receiving intravenous thrombolysis for acute ischemic stroke.
89234635|NCT01009320||Pacemaker with magnets|Patients with pacemakers who will be tested for magnetic interference with a magnetic drape.
89234636|NCT01003470|Experimental|acupuncture|
89234637|NCT01003470|Active Comparator|rehabilitation|
89234638|NCT01003470|Active Comparator|acupuncture and rehabilitation|
89234639|NCT01003548|Active Comparator|Static culture|Embryos individually cultured in microdrops of 40 microliters of G-IVFplus series V
89234640|NCT01003548|Experimental|Smart plataform|Embryos culture in dynamics microfluidic culture system
89234641|NCT01006668|Experimental|Sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
88803437|NCT00086762|Active Comparator|Standard Symptom Management|Arm III: Participants receive standard symptom management education.
89234642|NCT01006668|Active Comparator|Propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary
88803438|NCT00002656|Experimental|Pyrazoloacridine|Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
88803439|NCT01750112|Experimental|Macrolane VRF20|All subjects will receive treatment with Macrolane VRF20 to correct pectus excvatum deformity.
88803440|NCT02973334|Experimental|Sugar|Effects of ingestion of sugar-sweetened beverages on acute stress response
88803441|NCT02973334|Experimental|Artificial sweetener|Effects of ingestion of artificially-sweetened beverages on acute stress response
89234643|NCT01003626|Experimental|IFP Measurement|Tumor interstitial fluid pressure (IFP) assessments
89234644|NCT01003704||General Anesthesia only|
89234645|NCT01003704||Peripheral nerve block|
89234646|NCT01003704||spinal|
89234647|NCT04000230|Experimental|TCIT|Teachers in the intervention group receive TCIT in the first half of the school year and booster coaching is provided throughout the second half of the school year as the Waitlist Control group is trained.
89234648|NCT04000230|Active Comparator|Waitlist Control|Waitlist Control teachers do not receive any intervention for the first half of the school year. They then receive the same TCIT training as the intervention group in the second half of the school year.
88803442|NCT02973334|Active Comparator|Water|Effects of ingestion of water on acute stress response
89234649|NCT00360568|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks).~Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances."
89234650|NCT00436215|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (sorafenib) + Bevacizumab
89234651|NCT03742674||Cohort patients post stroke|
89234652|NCT01006746||ICD patient and Home Monitoring|Patients primo implanted with ICD
89234653|NCT01028859|Experimental|CKD-516 inj|
89234654|NCT05734248|Experimental|Intervention group|"This test region (right or left cheek) will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFL) with a 100 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a operator- and subject- blinded fashion. A lidocaine and tetracaine mixture cream will be applied at each cheek at t1.Ten minutes after cream application (incubation time), the facial filler injections will be performed.~Interventions: AFL Device: AFL Drug: anesthetic mixture cream"
89234655|NCT05734248|Placebo Comparator|Control|"A pass with the same fractional carbon dioxide laser with a 100 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to the test region on the other to the intervention cheek (sham AFL) at t0 in a operator- and subject-blinded fashion.~A lidocaine and tetracaine mixture cream will be applied at each cheek at t1.Ten minutes after cream application (incubation time), the facial filler injections will be performed.~Interventions: sham AFL Device: sham AFL Drug: anesthetic mixture cream"
89234656|NCT05602974|Experimental|adjuvant stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy after hepatectomy with narrow margin
89234657|NCT05602974|Active Comparator|regular follow-up|regular follow-up after hepatectomy with narrow margin
89234658|NCT00441363|Active Comparator|Bromocriptine Mesylate|Bromocriptine mesylate 0.8 mg
89234659|NCT00441363|Placebo Comparator|Placebo|Bromocriptine mesylate 0.8 mg matching placebo
89234660|NCT01048840||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
89234661|NCT01048840||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
89234662|NCT05139186|Experimental|WL+AI|Colonoscopy in white light and artificial intelligence
89234663|NCT05139186|Experimental|WL|Colonoscopy in white light
89234664|NCT03992248|Experimental|Time Restricted Feeding|Participants are instructed to eat within a limited time frame during the day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
89234665|NCT03992248|Other|Control|Participants are instructed to spread their habitual food intake over at least 14hrs per day. They are also instructed to keep record of their eating and sleeping record with eat- and sleep diaries.
89234666|NCT05734170|Other|Cheerio breakfast|Patient consumes 1 serving of cheerios for breakfast every day for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
89234667|NCT05734170|Other|Instant Oatmeal Breakfast|Patient consumes 1 package instant oatmeal for breakfast each day for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
89234668|NCT05734170|Experimental|Chia Seeds and Instant Oatmeal breakfast.|Patient consumes 1 package instant oatmeal with 2 tbsp chia seeds everyday for breakfast for 1 month. Blood is drawn to assess lipid panels before diet and after 1 month of diet.
89234669|NCT01006824|Experimental|1|Capsule Endoscopy
89234670|NCT01006824|Active Comparator|2|Dedicated small bowel contrast radiography
89234671|NCT05734092|Active Comparator|Control group|The strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage
89234672|NCT05734092|Experimental|Low-Level Laser Therapy group|In the experimental group (LLLT), where a (Ga-Al-As) diode laser, will be used with 808 nm wavelength in continuous mode, 250 milli-Watt power output, 4 Joules/point energy density, 16 s per point. In addition to adjusting the force gauge every 4 weeks until the end of the intrusion stage and reaching normal coverage
89234673|NCT01006902||Individuals age 65 or older|Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.
89234674|NCT04000074|Experimental|Telephonic Services - Intervention|Persons in this group are linked with a telephonic case manager to help address their social needs.
89234675|NCT04000074|No Intervention|Telephonic Services - Control|Persons in this group are similar in risk to those in the 'Telephonic Services - Intervention' arm, but are not linked with a case manager.
89234676|NCT04000074|Experimental|In-Person Services - Intervention|Persons in this group are linked with an in-person case manager who makes home visits to help address their social needs.
89234677|NCT04000074|No Intervention|In-Person Services - Control|Persons in this group are similar in risk to those in the In-Person Services - Intervention' arm, but are not linked with a case manager.
89234678|NCT00530712|Experimental|PTA and Stenting with EverFlex device|Qualified subjects undergo treatment of atherosclerotic lesions in the native SFA/SFA/PPA with PTA and stenting using the PROTÉGÉ® EverFlex™ Self-Expanding Stent System
89234679|NCT01007058||Response Markers|Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon
89234680|NCT05733858|Experimental|tRNS with digital MT|
89234681|NCT05733858|Experimental|tDCS with digital MT|
89234682|NCT05733858|Sham Comparator|sham stimulation with digital MT|
89234683|NCT00626795|Experimental|1|
89234684|NCT00626795|Experimental|2|
89234685|NCT00626795|Active Comparator|3|
89234686|NCT01007214|Experimental|Prostate cancer|A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
89140924|NCT02738970|Experimental|Part 1-Cohort 2: Pertuzumab 400 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.
89140925|NCT02738970|Experimental|Part 1-Cohort 3: Pertuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC.
89140926|NCT02738970|Experimental|Part 1-Cohort 4: Pertuzumab 1200 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.
89140927|NCT02738970|Active Comparator|Part 1-Cohort 5: Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC.
89140928|NCT02738970|Experimental|Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC.
89140929|NCT02738970|Experimental|Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC.
89140930|NCT02738970|Experimental|Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient.
89140931|NCT02738970|Experimental|Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1.
89140932|NCT02738970|Experimental|Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.
89140933|NCT02738970|Experimental|Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1.
89140934|NCT02806076|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
89140935|NCT02806076|Active Comparator|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
89140936|NCT00926731|Experimental|1|AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.)
89140937|NCT02805686|Experimental|"En face OCT (C-scan)"|
89140938|NCT04259957||Clinician using Virtual Reality in Pain Management Program|Clinicians who have used immersive virtual reality as part of Pain Management program group.
89140939|NCT02729454|Active Comparator|Exclusively physical therapy|The patients will be submitted to 15 therapeutical sessions two times per week with length of 40 minutes for motor physiotherapy . Each session of the motor physiotherapy will be constituted of exercises that include stretching (emphasizing the front of the torso), reinforcement (with emphasis in inferior members extensores); active exercises as transference (for example, to put into motion it bed or uprising of a chair), to reach and to grasp and training of balance and march.
89140940|NCT02729454|Experimental|Mental Practice And Physical Therapy|In the group submitted to the mental Practice the sessions will be individualized and occur in tranquil room after physical therapy (Same performed with the control group). During the mental practice the patient will be guided to stand, where he will be requested initially to identify and to sequencer the necessary joints for the accomplishment of an only step, being they:flexion of the thigh and leg rights, extension of the right leg more dorsiflexed of the right foot; touch of the heel and discharge of weight of the right foot and inclined body to the front. The sessions occur two times per week during 15 minutes.
89140941|NCT00926809|Active Comparator|Eradication|Helicobacter pylori eradication
89140942|NCT00926809|Placebo Comparator|No eradication|No eradication for Helicobacter pylori
89140943|NCT02805920|Active Comparator|GROUP 1 : G20|Postoperative pain for ACLR : G20 : received ACB with 20 ml 0.25% Bupivacaine
89140944|NCT02805920|Active Comparator|GROUP 2 : G25|Postoperative pain for ACLR : G25: received ACB with 25 ml 0.25% Bupivacaine
89140945|NCT02805920|Active Comparator|GROUP 3 : G30|Postoperative pain for ACLR : G30 received ACB with 30 ml 0.25% Bupivacaine
89140946|NCT04262765|Experimental|Treatment A-B-C-ABC|"The demographic characteristics of the 18 male subjects were as follows:~Age: 18-49 years~Weight: 55-105 kg~Height: 163-188 cm~BMI 18.5-29.9 kg/m²"
89140947|NCT00933751||Patients before emergent major abdominal surgery|
89140948|NCT02738814|Experimental|PAED > 13|When severe emergence agitation(PAED is 14 or more) is occured, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
89140949|NCT02738814|No Intervention|PAED < 14|Caregivers must first try to reassure patients.
89140950|NCT05148455||pregnant women|
89140951|NCT05148455||non-pregnant women (control group)|
89140952|NCT00933829|Placebo Comparator|Non-absorbable arm|uses non-absorbable suture such as Prolene to repair lacerations
89140953|NCT00933829|Active Comparator|Absorbable Suture Arm|uses absorbable sutures to repair lacerations
89140954|NCT02805608|Experimental|uPAR PET/CT and FDG PET/MR|One injection of 68Ga-NOTA-AE105 followed by PET/CT and on a separate day one injection of 18F-FDG followed by PET/MRI. Both scans will be evaluated for possible regional lymph node metastases.
89140955|NCT02729064|Experimental|Intranasal 40|Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
89140956|NCT02729064|Experimental|Intranasal 80|Patients will receive 80 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
89140957|NCT02729064|Placebo Comparator|Placebo|Patients will receive intranasal normal saline via a metered nasal dispenser
89140958|NCT00609401|Experimental|1|Sorafenib 400 bid + IL-2 3 MU per 5 day/week for 2 weeks every 4
89140959|NCT00609401|Experimental|2|Sorafenib 400 mg bid
89234687|NCT00826553|Experimental|GABA agonist|
89234688|NCT00826553|Experimental|Alpha 2 agonist|
89140960|NCT00933907|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
89140961|NCT02805842|Active Comparator|Tacrolimus BID|20 patients receiving twice daily (BID) Tacrolimus
89140962|NCT02805842|Active Comparator|Advagraf QD|40 patients randomized to receive once daily (QD) Advagraf
88803443|NCT00381784|Experimental|Community PROMISE|Community PROMISE is a community level HIV/STD prevention program that relies on role model stories and peer advocates from the community. Sites will adapt PROMISE for local use remaining faithful to the core elements.
89140963|NCT05272553|Experimental|Narrative Exposure Therapy|This is a single case series design which focuses on assessing whether Narrative Exposure Therapy could reduce symptoms of traumatic stress in cancer survivors; no comparator will be included.
89140964|NCT03102996|Experimental|Verum|Patients will receive Nephrotrans.
89140965|NCT03102996|Placebo Comparator|Placebo|Patients will receive Placebo.
89140966|NCT00926965|Experimental|Olanzapine group|randomized to Olanzapine group with dose range of 2.5-30mg/day
89140967|NCT00926965|Experimental|Amisulpiride group|the subjects were randomized to the amisulpiride group with dose range of 100 to 800mg/day
89140968|NCT00926965|Active Comparator|FGA group|The subjects were randomized to maintain the conventional antipsychotics
89140969|NCT04260113|Experimental|Apatinib Arm|
89140970|NCT02738736|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
89140971|NCT02738736|No Intervention|Usual Care|Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
89140972|NCT00608387|Experimental|A|Participants will receive usual care from their healthcare providers and have access to a Web-based CVD risk-factor management program.
89140973|NCT00608387|No Intervention|B|Participants will receive usual care from their healthcare providers.
89140974|NCT02728986|Active Comparator|Compression1|Multilayer compression bandage (Profore)
89140975|NCT02728986|Experimental|Compression2|Coban2 compression system
89140976|NCT02809274||Patients with PV, not newly diagnosed|"Patients with clinically overt PV treated with watchful waiting (with or without aspirin), Phlebotomy (PHL), Hydrea or any other treatment.~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
89140977|NCT02809274||Newly diagnosed patients with PV|"Patients with clinically overt PV, newly diagnosed, before any treatment and before phlebotomy initiation.~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
89140978|NCT05249855|Other|Longitudinal Study|A longitudinal study of anxiety over the balneological treatment.
89140979|NCT02694510|Active Comparator|Light-protection|Light-protection of TPN solutions. TPN bags and infusion sets will be protected from light by aluminum foils throughout the study period.
89140980|NCT02694510|Active Comparator|Light-exposure|TPN bags and infusion sets will be exposed to light throughout the study period.
89140981|NCT02812472|Experimental|treadmill training with functional electrical stimulation|Subjects in the experimental group received additional treadmill training with functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
89234689|NCT00626639|Placebo Comparator|Placebo|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of matching placebo. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of matching placebo after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
89140982|NCT02812472|Active Comparator|treadmill training without functional electrical stimulation|Subjects in the control group received additional treadmill training without functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
89140983|NCT05628714||Control group|Patients who did not use the PDA
89140984|NCT05628714||PDA-group|Patients who did use the PDA
89140985|NCT00927251|Experimental|Model 4296 LV Lead|Non-randomized study
89140986|NCT02738658|Experimental|Bioresorbable vascular scaffold (BVS)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a bioresorbable vascular scaffold.
89140987|NCT02738658|Active Comparator|Everolimus-eluting stent (EES)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a Everolimus-eluting stent .
89140988|NCT04259567|Active Comparator|Filter|Patients with CytoSorb absorber
89140989|NCT04259567|No Intervention|Control|Patients without CytoSorb absorber
89140990|NCT02733510||subclinical rejection group|patients whose protocol biopsy outcome is subclinical rejection and treat with steroid pulse therapy (methylprednisolone)
89140991|NCT02733510||No rejection group|patients whose protocol biopsy outcome is normal
89140992|NCT02809508|Experimental|Oily fish|
89140993|NCT02809508|Experimental|Poultry (control)|
89140994|NCT00930397||Low risk women|Women without any personal risk.
89140995|NCT00930397||High risk women|Women at high risk for pre-eclampsia with personal of pre-eclampsia and/or IUGR in a previous pregnancy, diabetes, auto-immune syndrome such as lupus, hypertension, renal insufficiency and anti-phospholipid.
89140996|NCT00927043||1|
89140997|NCT02805764|Experimental|Homeoblock functional dental appliance|Removable functional dental appliance to be used at during sleep for one year.
89140998|NCT00927095|Active Comparator|Continuous OC (EE/DROS)|Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)
89140999|NCT00927095|Active Comparator|Intermittent OC (EE/DROS)|Interrupted (21 days active - 7 days placebo) oral DROS (20ug)/EE(3mg)
89141000|NCT00927095|Placebo Comparator|Placebo|Continuous daily oral placebo
89234690|NCT00626639|Experimental|Palifermin|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of palifermin at 120 μg/kg. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of palifermin at 120 μg/kg after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
89234691|NCT00626561|Experimental|Bevacizumab + Paclitaxel|Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.
89234692|NCT00822653|Experimental|Calf Muscle Pump Stimulation|Subjects serve as self-control. Six weeks of dialysis data without intervention will be compared to six weeks post intervention
89234693|NCT00822731|Experimental|Lymphoma|patients diagnosed as lymphoma
89234694|NCT00826631|Active Comparator|1|Fast food intake, doubling of caloric intake, in combination with sedentary behavior (no exercise)
89234695|NCT00826631|No Intervention|2|Control group, parallel
89234696|NCT03880266|Active Comparator|Group 1 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
89234697|NCT03880266|Placebo Comparator|Group 1 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
89234698|NCT03880266|Active Comparator|Group 2 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
89234699|NCT03880266|Placebo Comparator|Group 2 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
89234700|NCT03880266|Active Comparator|Group 3 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes
89234701|NCT03880266|Placebo Comparator|Group 3 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes
89234702|NCT03880266|Active Comparator|Group 4 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes
89234703|NCT03880266|Placebo Comparator|Group 4 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes
89234704|NCT00423891|Experimental|Arm 1: Entecavir|
89234705|NCT00830609|Active Comparator|A|Patients in this arm will receive standard of care (Peginterferon alfa 2A 180 mcg/weeks SC plus ribavirin 800 mg/day for 24 weeks).
89234706|NCT00830609|Experimental|B1|After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
89234707|NCT00830609|Experimental|B2|If RNA-HCV at week 4 remains positive after the induction phase, then peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day will be continued for 20 additional weeks (Arm B2). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
89234708|NCT00822809|Experimental|A|"Patients will receive premedication of 25 mg (i.v.) prednisolone 30 minutes prior start of infusion of catumaxomab.~Catumaxomab will be infused i.p. with 3 hour constant rate infusions via an indwelling catheter."
89234709|NCT00822809|Other|B|Catumaxomab will be administered in a dosage identical to Arm A but without the prednisolone premedication.
89234710|NCT00830687|Other|Targon FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
89234711|NCT01007370|Active Comparator|LMA-Fastrach|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients)~Tracheal intubation through the LMA-Fastrach~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
89234712|NCT01007370|Active Comparator|I-gel|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through I-gel using fibrescope (one out of ten patients)~Tracheal intubation through the I-gel~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
89234713|NCT00822887|Experimental|Vandetanib|Dose level 1:100 mg qd, 2:200 mg qd, 3:300 mg qd. Fractionated Stereotactic Radiotherapy: all patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
89234714|NCT02549651|Experimental|MEDI4736|
89234715|NCT02549651|Experimental|MEDI4736 and tremelimumab|
89234716|NCT02549651|Experimental|MEDI4736 and AZD9150|
89234717|NCT03999762|Active Comparator|Density gradient sample prep|Standard density gradient sample preparation
89234718|NCT03999762|Experimental|Automated sample prep|Automated experimental sample preparation
89234719|NCT03999372|Experimental|PICSI procedure|PICSI procedure: PICSI dishes are conventional plastic culture dishes pre-prepared with 3 microdots of powdered. The powdered HA is re-hydrated by adding 5 μL droplets of fresh culture medium to each of the three microdots. A 2 μL droplet with suspension of treated spermatozoa is then connected with a pipette tip to these culture medium droplets. The PICSI dish is incubated under oil; within 5 minutes the bound spermatozoa are attached by their head to the surface of the HA-microdots and are spinning around their head. An ICSI injecting pipette is used to pick the best motile HA-bound sperm up and inject them one by one into an oocyte. The ICSI injecting pipette can be previously loaded with viscous medium (PVP or Sperm Slow) to facilitate sperm micromanipulation.
89141001|NCT00933985|Experimental|Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)|"STRATUM 1 (dose-escalation): Patients receive obatoclax mesylate IV over 3 hours on days 1 and 8 and vincristine sulfate IV, doxorubicin hydrochloride IV, and dexrazoxane hydrochloride IV on day 8 of course 1 (28 days). Drugs are administered on day 1 of subsequent courses and repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~STRATUM 2: Patients receive obatoclax mesylate (at starting dose in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.~STRATUM 3: Patients receive obatoclax mesylate (at the MTD determined in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1."
89141002|NCT05377476|Experimental|Motor Imagery Group|Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation. Patients will be trained 3 days a week for 6 weeks.
89141003|NCT05377476|Experimental|Action Observation Group|Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation. Patients will be trained 3 days a week for 6 weeks.
89141004|NCT05377476|Other|Control Group|Individuals included in this group will receive only 40 minutes of standard rehabilitation. Patients will be trained 3 days a week for 6 weeks.
89141005|NCT02805296|Active Comparator|Double light|"High-intensity phototherapy with blue LED light from above combined with a fiber optic, blue LED blanket from below.~Intervention: Light irradiance: 66 µW/cm2/nm + 39 µW/cm2/nm"
89141006|NCT02805296|Active Comparator|Single light|High-intensity phototherapy with blue LED light from above. Intervention: Light irradiance: 66 µW/cm2/nm
89141007|NCT02738268|Sham Comparator|Control group|Control group: receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
89141008|NCT02738268|Experimental|Treatment Group|Treatment Group: receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
89141009|NCT05009303||Participants|Thirty healthy individuals and seventy patients suffering from chronic pain or disability in one or both of their lower extremities
89141010|NCT04236362|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89141011|NCT02812628|Active Comparator|Conventional LAPR|Patients undergoing conventional laparoscopic abdominoperineal resection (LAPR).
89141012|NCT02812628|Experimental|LAPR-TILT|Patients undergoing LAPR with transabdominal individualized levator transection (TILT).
89141013|NCT00934063||A|
89141014|NCT00934063||B|
89141015|NCT02738424||3T patients : Calculate the ADC scores|In this group all the patients perform a 3 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS (picture archiving and communication system) Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
89141016|NCT02738424||1.5T patients : Calculate the ADC scores|In this group all the patients perform a 1,5 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
89141017|NCT02812394|Experimental|CVT-301|"CVT-301 (Dose Level 1): two (low dose) levodopa fine particle dose (FPD) capsules administered to the lung via oral inhalation using the CVT 301 inhaler.~CVT-301 (Dose Level 2): two (high dose) levodopa FPD capsules administered to the lung via oral inhalation using the CVT 301 inhaler.~Sinemet® (carbidopa/levodopa)"
89141018|NCT05127941||Patient group|Patients under effective anticoagulation with rivaroxaban or apixaban and treated with andexanet alfa
89141019|NCT05623592|Experimental|Methotrexate|The patient will be treated for 12 months weekly with methotrexate. Methotrexate will be provided at a dose of 17.5mg as a pre-filled syringe for self-injection. A dose reduction to 15 mg/week in case of intolerance, elevated liver enzymes >3x upper limit of normal or to 10 mg/week if glomerular filtration rate <50/min will be possible. If glomerular filtration rate <30/min, termination of treatment.
89141020|NCT05623592|Placebo Comparator|Placebo|Patients receive sodium chloride as a placebo subcutaneously. It will be administered in the form of a pre-filled syringe for self-injection once a week for 12 months.
89141021|NCT02728518|Experimental|Nebulized Amikacin|patients in this arm will take amikacin nebulizer 400 mg twice daily in addition to standard beta lactam
89141022|NCT02728518|Active Comparator|Amikacin Intravenous|patients in this arm will take intravenous (IV) amikacin 20 mg/kg once daily in addition to standard beta lactam
89141023|NCT00927121|Active Comparator|Group 1 : G_1|G_1: stimulation for 4 - 6 hours a day, 4 tones per sequence
89141024|NCT00927121|Active Comparator|Group 2 :G_2|G_2: stimulation for 4 - 6 hours a day with 12-tone sequences
89141025|NCT00927121|Active Comparator|Group3 : G_3|G_3: stimulation for 4 - 6 hours a day, 4 tones per sequence with a signal controlled by EEG measurement
89141026|NCT00927121|Active Comparator|Group 4 : G_4|G_4: stimulation for 1 hour a day, 4 tones per sequence
89141027|NCT00927121|Placebo Comparator|Group5 : G_5|G_5: stimulation with placebo-tone
89141028|NCT00634400|Active Comparator|1|
89141029|NCT00634400|Placebo Comparator|2|
89141030|NCT04262375|Experimental|Durvalumab and Oleclumab|A single dose level for oleclumab and durvalumab will be used, comprising of Oleclumab 3000 mg IV Q2W for 4 doses, then Q4W AND Durvalumab 1500 mg IV Q4W
89141031|NCT02728674|Other|Man+Breathlessness|Person in the case is a male. Symptom in the case is breathlessness.
89141032|NCT02728674|Other|Man+Pain|Person in the case is a male. Symptom in the case is pain.
89141033|NCT02728674|Other|Woman+Breathlessness|Person in the case is a female. Symptom in the case is breathlessness.
89141034|NCT02728674|Other|Woman+Pain|Person in the case is a female.Symptom in the case is pain.
89141035|NCT00936637|Experimental|Extensively hydrolyzed infant formula|
89141036|NCT00930631|Other|Single Arm|Single arm PK study
89141037|NCT00636558|Experimental|CVA21|IV administration of CVA21 in a dose escalation manner
89141038|NCT00609479|Experimental|1|Internal fixation with Micronail. 41 patients.
89141039|NCT00609479|Experimental|2|External fixation with Hoffmann-II-non-bridging. 41 patients.
89141040|NCT02805218|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
89141041|NCT02733120|Experimental|Healthy matched controls|Study Day: The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
89141042|NCT02733120|Experimental|Adults with Autism Spectrum Disorder|The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
89141043|NCT04262063|Experimental|tell play do technique|Tell play do technique with a dental imitation toy and using euphemisms instead of demonstrating on a model or observing one. Tell play do technique provides a better explanatory concept of the dental procedure and can lead to more cooperation of the children patients which can influence the dental treatment in a good and positive way.
89141044|NCT04262063|Active Comparator|tell show do technique|Tell show do is the gold standard of the non-pharmacological behavior management techniques. It is based on the principle of learning theory and it is performed by the dentists themselves . It is the most important behavior modification technique practiced by dentists and it is commonly used for management of children anxiety in the first dental visit .
89141045|NCT02805452|Experimental|Succinate of Solifenacin|1 tablet of 5 mg of succinate of Solifenacin will be administered each day for 3 months.
89141046|NCT02805452|Placebo Comparator|Placebo of Succinate of Solifenacin|1 tablet of placebo of succinate of solifenacin will be administered each day for 3 months.
89141047|NCT00936949|Active Comparator|posterolateral approach|The posterolateral approach was described by many authors, but all share a common muscular interval in reference to the gluteus medius tendon. Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
89141048|NCT00936949|Active Comparator|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
89141049|NCT02733198|Experimental|Prognosis-guided|Duration of bed rest and duration of length of stay will be guided according to a predefined prognostic algorithm.
89141050|NCT02733198|No Intervention|Standard medical therapy|Duration of bed rest and duration of length of stay will be decided by the attending physician.
89141051|NCT04261985|Active Comparator|Mobile Phone Obesity Intervention|Caregiver-child dyads will be recruited from two early childhood education centers in East Los Angeles. Approximately 30 caregiver-child dyads will be randomized into the intervention arm. Every week for 4 weeks, caregivers will receive 4 interactive multi-media phone prompts to support the intervention's targeted topics. Each mobile phone prompt starts with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share their goal/s, perceived barriers, questions, tips and strategies that may be helpful to other participants. Each week, caregivers will also receive strategies, and individual and group feedback on changing unhealthy behaviors. The content shared by caregivers are summarized by a team research assistant and sent back to participants at the end of every week.
89141052|NCT04261985|No Intervention|Control|Caregiver-child dyads will be recruited from two early childhood education centers in East Los Angeles. Approximately 30 caregiver-child dyads will be randomized into the control (no intervention) arm. Every week for 4 weeks, these caregivers will receive 4 interactive multi-media phone prompts around managing common illness in young children (i.e. fever, vomiting, constipation, etc.) Each mobile phone prompt will start with a 140-character text with an embedded link. Clicking on the link navigates caregivers to a web-based application with interactive content that includes images, text, videos, and prompts. Each week, caregivers will share questions and strategies that may be helpful to other participants. Each week, caregivers will also receive tips and group feedback based on group questions. The content shared by caregivers will be summarized by a team research assistant and sent back to participants at the end of every week.
89141053|NCT02805374|Experimental|ASP1517 fasting then fed|Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.
89141054|NCT02805374|Experimental|ASP1517 fed then fasting|Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.
89141055|NCT00937027|Active Comparator|Aminopterin one 1.0 mg tablet|
89141056|NCT00937027|Active Comparator|Aminopterin 1 four 0.25 mg tablets|
89141057|NCT02738502|Experimental|Single Group|Intervention: Darunavir monotherapy darunavir/ritonavir 600 mg/100mg twice day in monotherapy.
89141058|NCT04261907|Experimental|ASC09/ritonavir group|ASC09/ritonavir (300mg/100mg tablet)+conventional standardized treatment
89141059|NCT04261907|Active Comparator|lopinavir/ritonavir group|Lopinavir/ritonavir tablet (200mg / 50mg tablet)+conventional standardized treatment
89141060|NCT02809352||women tested positive for hrHPV|All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
89141061|NCT00934219|Active Comparator|High dose Lovaza|Lovaza 4 g twice a day, if not effective then 4 g 3 times a day
89141062|NCT00934219|Active Comparator|Standard Dose|2 g twice a day
89141063|NCT04139876|Active Comparator|Minimal open hemorrhoidectomy|Patients randomized to Minimal open hemorrhoidectomy
89141064|NCT04139876|Active Comparator|LigaSure hemorrhoidectomy|Patients randomized to LigaSure hemorrhoidectomy
89141065|NCT00934297||Pilot group|Real-time US imaging with simultaneous display of dynamically corresponding MR images (from a previous MRI screening) will be used to re-locate the lesion previously reported as occult under a second-look ultrasound screening.
89141066|NCT02733276|Experimental|Electroacupuncture|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: 6 needles in each lower limb, 8 abdominal, 3 in upper extremity and 3 on the front
89141067|NCT02733276|Sham Comparator|Electroacupuncture sham|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: needles on each forearm on nonselective points
89141068|NCT02733276|No Intervention|Control|Initially no intervention. In a second period in this group we will perform EAP
89141069|NCT02808806|Active Comparator|real-time audio-visual feedback|real-time audio-visual feedback to caregivers (i.e. both in- and outside the hospital) bringing the patient to the location where IVT/IAT is administered . The real time audio-visual feedback consists in information on the actual TSD for a particular patient and whether or not this exceeds pre-set median time delay. The feedback is provided by handhelds in the ambulance and by pre-set monitors on different locations in the participating hospitals.
89141070|NCT02808806|No Intervention|regular care|no real-time audio-visual feedback
89141071|NCT00930709|Active Comparator|Active strength training and stretching|Active strength training and stretching
89141072|NCT00930709|Active Comparator|Botulinum toxin type A injections|Botulinum toxin type A injections
89141073|NCT02738346|Experimental|Arm A : Carboplatin-Etoposide|Intravenous administration of Carboplatin Auc 5 at Day 1 and Intravenous administration of 100 mg / m² / of Etoposide J Day 1 to Day 3 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
89141074|NCT02738346|Active Comparator|Arm B : Topotecan|Per os administration of 2.3 mg / m² of Topotecan Day 1 to Day 5 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
89141075|NCT05619068||Medical treatment group|Conservative medical treatment
89141076|NCT05619068||Surgical treatment group|Direct revascularization, indirect revascularization or combined revascularization
89141077|NCT00932165||Exemestane|Patients taking Exemestane Tablets.
89141078|NCT02611063|Experimental|fostamatinib|Subjects will receive fostamatinib 100 mg qd, 150 mg qd, or 100 mg bid with dosage determined by the modified continual reassessment method. The treatment period begins at baseline 90 days after transplant and continues for up to 1 year after transplant. In patients with steroid-refractory cGVHD who are also included on this study, these subjects also receive fostamatinib 100mg qd, 150mg qd, or 100mg bid dosage determined by the modified continual reassessment method.
89141079|NCT02690090||enoxaparin|enoxaparin prophylaxis as directed by treating Intensivist
89141080|NCT04261829||Autologous Fat Transfer|
89141081|NCT02804984||ICUS|idiopathic cytopenia of undetermined significance (ICUS)
89141082|NCT00937261|Experimental|Risperdal|Risperdal 2-8mg per day
89141083|NCT00937261|Experimental|Invega|Invega 6-12mg per day
89141084|NCT05906433|Experimental|Kenalog with 0ml bupivacaine|The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0ml of bupivacaine. The patients will be randomized into this group.
89141085|NCT05906433|Experimental|Kenalog with 4ml bupivacaine|The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,4ml of bupivacaine. The patients will be randomized into this group.
89141086|NCT05906433|Experimental|Kenalog with 0.25% bupivacaine|The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0.25% of bupivacaine. The patients will be randomized into this group.
89141087|NCT05906420||ASTRAL|
89141088|NCT05906381|Placebo Comparator|Control group|Subjects will take a capsule of containing microcrystalline cellulose per day for 35 days.
89141089|NCT05906381|Experimental|Treatment group|Subjects will take a capsule of containing Streptococcus thermophilus per day for 35 days.
89141090|NCT05906355|Experimental|Group A（wearable filtrating artificial Kidney+traditional hemodialysis）|Group A was isolated ultrafiltration with wearable filtrating artificial Kidney Device first, and then with traditional hemodialysis machine.
89141091|NCT05906355|Experimental|Group B（traditional hemodialysis+wearable filtrating artificial Kidney）|Group B was isolated ultrafiltration with traditional dialysis machine first, and then with wearable filtrating artificial Kidney Device.
89141092|NCT05906342|Experimental|20% fat meal|This meal will contain 15 kcal/kg of body weight and consist of 20% fat, 65% carbohydrates, and 15% protein.
89141093|NCT05906342|Experimental|40% fat meal|This meal will contain 15 kcal/kg of body weight and consist of 40% fat, 45% carbohydrates, and 15% protein.
89141094|NCT05906342|Experimental|60% fat meal|This meal will contain 15 kcal/kg of body weight and consist of 60% fat, 25% carbohydrates, and 15% protein.
89141095|NCT05906342|Experimental|80% fat meal|This meal will contain 15 kcal/kg of body weight and consist of 80% fat, 5% carbohydrates, and 15% protein.
89141096|NCT05906329|Other|Low-dose radiotherapy combined with conventional radiotherapy after immunotherapy resistance|By using enhanced CT to locate the chest, abdomen, and pelvis, the target area was delineated. The lesion was a visible lymph node with a short diameter of ≥ 1cm, and there was metastasis confirmed by two deputy chief physicians based on enhanced MR and PET/CT examination results. Select the primary lesion, the largest metastatic lesion, or the lesion causing symptoms, and perform routine segmentation (1.8-2Gy/f, 40Gy-60Gy). For the remaining lesions, at least one easily assessable and measurable lesion should be selected as the observation lesion. Unselected lesions (≤ 10) should be given 1.6Gy/f, 1f/w, 4-6 times in total. The immunotherapy plan is carried out according to the specific dose and interval of the original immune plan. Usually, immunotherapy is combined with radiotherapy at a frequency of once every 3 weeks until progression.
89141097|NCT05906290|Experimental|Multigenerational eHealth Intervention for Grandparents and Grandchildren Group|Participants in this group will have access to eHealth intervention for 2 weeks.
89141098|NCT05906264|No Intervention|Pulmonary rehabilitation, Control|"for COPD patients, who have been trained with the pulmonary rehabilitation program~Compliance will be checked by monitoring wearable device at one month~Pulmonary function and symptom improvement effect will be checked at 3 months"
89141099|NCT05906264|Active Comparator|Pulmonary rehabilitation, Intervention|Compared to Control group, Intervention group will be provided with additional tele-intervention every week to check the compliance and encourage of the rehabilitation
89141100|NCT05906225|Experimental|Electroencephalogram|Adjustment of concentration of sevoflurane according to EEG
89141101|NCT05906225|Active Comparator|Conventional|Adjustment of concentration of sevoflurane according to vital signs
89141102|NCT05906212|Experimental|Nonpenetrating deep sclerectomy&phacoemulsification&autotransplantation of anterior lens capsule|The intervention group will be undergoing non-penetrating deep sclerectomy and phacoemulsification with the use of an autotransplantation of the human anterior lens capsule as the spacer in the intrascleral lake.
89141103|NCT05906212|Active Comparator|Non-penetrating deep sclerectomy and phacoemulsification|The control group will be undergoing non-penetrating deep sclerectomy and phacoemulsification without any spacer.
89141104|NCT05906199|Experimental|Renexin CR 200/160mg|Single oral administration of Renexin CR 200/160mg, QD
89141105|NCT05906199|Active Comparator|Aspirin 100mg|Single oral administration of Aspirin 100mg, QD
89141106|NCT05906186||Pre-test|Standard care: all patients who are starting their first (neo adjuvant or adjuvant) treatment with chemotherapy visit the nurse practitioner. Site effects like constipation will be discussed and the prescription of laxatives is standard care. Participants will keep a stool pattern diary during two months using the Bristol Stool Scale (BSS). During follow up the occurrence of side effect, such as nausea, diarrhea and constipation is assessed.
89141107|NCT05906186||Post-test|After the first four months (pre-test phase) of the study, nurse practitioners are asked, as lifestyle advice, to eat two kiwis per day instead of two pieces of fruit. A similar group of patients undergoing their first (neo-adjuvant or adjuvant) chemotherapy treatment are approached with a request to participate in the study. Participants keep a diary of defecation patterns for two months using the Bristol Stool Scale (BSS). During follow-up, the occurrence of side effects such as nausea, diarrhea and constipation will be assessed.
89141108|NCT05906134|Active Comparator|local intercostal nerve block|Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
89141109|NCT05906134|Active Comparator|cryo-ablation plus intercostal nerve block|Patients receiving cryo-analgesia and intercostal blocks, the patient will receive cryo-ablation prior to the intercostal block. The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
89141110|NCT05906134|Active Comparator|serratus plane catheter plus intercostal nerve block|Patients receiving serratus plane catheter blocks and intercostal nerve blocks, a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on Post Operative Day (POD) #1, 2, 3, 4, and 5 by the pain service.
89141111|NCT05906069|Experimental|iCBT intervention|Participants will enroll in an internet-based cognitive behavioral program during 14 weeks. The program comprises 10 modules and three videoconferencing psychotherapy sessions.
89141112|NCT05906069|No Intervention|Wait list|Participants will be enrolled in the iCBT program after 14 weeks
89141113|NCT05906017|Active Comparator|Open repair|Open ventral hernia repair
89141114|NCT05906017|Experimental|Robotic-assisted repair|Robotic-assisted ventral hernia repair
89141115|NCT05905978|Experimental|CXL graft group|Corneal donors predisposed by CXL were used and the conventional DALK procedure was conducted in patients
89141116|NCT05905978|Active Comparator|Conventional graft group|Corneal donors stored in corneal storage media were used and the conventional DALK procedure was conducted in patients
89141117|NCT05905965|Experimental|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily
89141118|NCT05905965|Active Comparator|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily
89141119|NCT05905952||patient group|to twenty five patient of Haglund syndrome as (patient group) after being diagnosed and referred by orthopedic surgeon and twenty
89141120|NCT05905952||control group|twenty five Healthy volunteers as (control group) based on the following inclusion and exclusion criteria
89141121|NCT05905913|Experimental|Part A: Single Intravenous Ascending Dose of ANT3310|
89141122|NCT05905913|Placebo Comparator|Part A: Single Intravenous Dose of Matching placebo|
89141123|NCT05905913|Experimental|Part B: Multiple Intravenous Ascending Doses of ANT3310|
89141124|NCT05905913|Placebo Comparator|Part B: Multiple Intravenous Ascending Doses of Matching Placebo|
89141125|NCT05905913|Experimental|Part C: ANT3310 + Meropenem|Participants will receive a single intravenous dose of ANT3310 or Meropenem in one of the 2 treatment sequences followed by the repeat administrations of ANT3310 + Meropenem.
89141126|NCT05905913|Placebo Comparator|Part C: ANT3310 Placebo + Meropenem Placebo|Participants will receive a single dose of ANT3310-placebo or Meropenem-placebo in one of the 2 treatment sequences followed by repeat administrations of ANT3310-placebo + Meropenem-placebo
89141127|NCT05905900||Emergent IV Dye Preparation & Administration|The emergent IV dye drug trio is administered and followed immediately by Computed Tomography (CT) Angiography and/or CT Perfusion.
89141128|NCT05905874||AECOPD patients present with DVT and/or PTE|
89141129|NCT05905874||AECOPD patients absent with DVT and/or PTE|
89141130|NCT05905848|Experimental|RASI group|Administer RASI, with or without other antihypertensives except for CCB, and blood pressure should be controlled within the target range (140/90 mmHg). RASI intaking starts at least 5 days before stenting.
89141131|NCT05905848|Active Comparator|CCB group|Administer CCB, with or without other antihypertensives except for RASI, and blood pressure should be controlled within the target range (140/90 mmHg). CCB intaking starts at least 5 days before stenting.
89141132|NCT05905809|Experimental|Group I|"Patients wearing the UniRelieverTM offloading brace (THUASNE):~For intervention group I, in addition to the usual care described above for the control group, patients will wear the studied UniRelieverTM offloading brace."
89141133|NCT05905809|Experimental|Group II|"Patients wearing the Unloader One® X brace (Össur):~For intervention group II, in addition to the usual care described above for the control group, patients will wear the Unloader One® X brace by Össur"
89141134|NCT05905809|No Intervention|Group III|"Patients wearing no orthosis:~In the control group, usual care is defined by:~buffer heel and/or~insoles and/or~outer edge raisin and/or~walking stick and/or~physiotherapy and/ or~analgesics oral and local depending on the patient's needs."
89141135|NCT05905757|Experimental|Group T|"Group T (Adjuvant tramadol): Bilateral subcostal TAP block was performed using solutions prepared by adding 0.250% bupivacaine + 40 mL adjuvant 1.5mg/kg (maximum 100 mg) tramadol.~Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), HR, SpO2 values were recorded.~Demographic data of the patients [age, weight, height, body mass index (BMI), smoking use] and operation times were recorded.~All patients were administered 1000 mg parol IV as standard analgesic before extubation.~The patients were followed up for side effects (such as nausea-vomiting, chills, itching and desaturation) including drug allergies.The patients were evaluated at 0, 3 and 6 hours after the operation with a 0-10 verbal rating scale visual analog scale (VAS) and the data were recorded. In all groups, VAS˃ 4 value was evaluated in favor of analgesic need and 50 mg Dexketoprofen IV bolus was administered in accordance with conventional treatment."
89141136|NCT05905757|Experimental|Group D|"Group D (adjuvant dexmedetomidine): Bilateral subcostal TAP block was performed using solutions prepared by adding 0.250% bupivacaine + 0.5 mcg/kg and (maximum 50 mcg) dexmedetomidine.~All patients were administered 1000 mg parol IV as standard analgesic before extubation.~The patients were followed up for side effects (such as nausea-vomiting, chills, itching and desaturation) including drug allergies.~The patients were evaluated at 0, 3 and 6 hours after the operation with a 0-10 verbal rating scale visual analog scale (VAS) and the data were recorded. VAS 0-2: no pain, 3-4: mild pain, 5-6: moderate pain, 7-8: severe pain, 9-10: excruciating pain. Additional analgesic requirement in the postoperative period was calculated by measuring VAS>4 values. In all groups, VAS˃ 4 value was evaluated in favor of analgesic need and 50 mg Dexketoprofen IV bolus was administered in accordance with conventional treatment."
89141137|NCT05905744||patients with unexplained bile duct stenosis|Patients with unexplained bile duct stenosis undergo cholangioscopy examination and ERCP
89141138|NCT05905731|Experimental|HBV-TCR T cell infusion|Autologous HBV specific TCR redirected T cells
89141139|NCT05905692|Experimental|L carnitine group|patients will take L carnitine (20 mg/kg/day) 3 times per week (on the same days of the dialysis session, 30 minutes before the session)
89141140|NCT05905692|Placebo Comparator|Placebo group|patients will take placebo 3 times per week (on the same days of the dialysis session, 30 minutes before the session)
89141141|NCT05905666|Experimental|self-controlled design|The research period was divided into a control stage (first to fourth week: standard of care) and the experimental stage (fifth to eighth week: health education and counseling).
89141142|NCT05905653|Experimental|STN1012600 0.002%|
89141143|NCT05905614|Experimental|SPH4336 Tablets|SPH4336 Tablets
89141144|NCT05905588|Experimental|Hydrogen-rich water|Patients receive hydrogen-rich water.
89141145|NCT05905588|Placebo Comparator|Placebo|Patients receive placebo.
89141146|NCT05905497|Experimental|Bemnifosbuvir (BEM)|oral tablet
89141147|NCT05905484|Experimental|Bemnifosbuvir (BEM) therapeutic dose|oral tablets
89141148|NCT05905484|Experimental|Bemnifosbuvir (BEM) supratherapeutic dose|oral tablets
89141149|NCT05905484|Placebo Comparator|Placebo|oral tablets
89141150|NCT05905484|Active Comparator|Moxifloxacin|oral tablet
89141151|NCT05905445|Experimental|ozone gel with conventional scaling and root planning|administered ozone gel in the probing pocket depth after scaling and root planning by a disposable plastic syringe with a blunt tip until the access ozone became out of the pocket. this procedure is made at baseline and in the first month. instructed the patient not to eat or drink for at least 30 minutes
89141152|NCT05905445|No Intervention|only conventional scaling and root planning|only scaling and root planning without any intervention.
88803444|NCT00381784|Experimental|Mpowerment|MPowerment is a community level HIV/STD prevention program that relies on peer advocates from the community to lead outreach activities including discussion groups (Mgroups), venue-based outreach, social events and a publicity campaign. Sites will adapt MPowerment for local use remaining faithful to the core elements.
89141153|NCT05905406|Experimental|S60|The Hip will be positioned at 80°, and knee positioned 60°. The sessions will be initiated with heating and muscle enhancement. The following outcomes will be observed before and after the fatigue protocol: (1) CVIM; (2) voluntary activation level; (3) electromyographic activity; (4) muscular architecture; and (5) tendinous properties. During the fatigue protocol, except for item 1), will be evaluated: (1) fatigue by torque decay curve; (2) integral force-time; (3) muscular architecture; (4) tendinous properties; and tissue oxygen extraction.
89141154|NCT05905406|Experimental|S20|The Hip will be positioned at 80°, and knee positioned 20°. The sessions will be initiated with heating and muscle enhancement. The following outcomes will be observed before and after the fatigue protocol: (1) CVIM; (2) voluntary activation level; (3) electromyographic activity; (4) muscular architecture; and (5) tendinous properties. During the fatigue protocol, except for item 1), will be evaluated: (1) fatigue by torque decay curve; (2) integral force-time; (3) muscular architecture; (4) tendinous properties; and tissue oxygen extraction.
89141155|NCT05905406|Experimental|D60|The Hip will be positioned at 0°, and knee positioned 60°. The sessions will be initiated with heating and muscle enhancement. The following outcomes will be observed before and after the fatigue protocol: (1) CVIM; (2) voluntary activation level; (3) electromyographic activity; (4) muscular architecture; and (5) tendinous properties. During the fatigue protocol, except for item 1), will be evaluated: (1) fatigue by torque decay curve; (2) integral force-time; (3) muscular architecture; (4) tendinous properties; and tissue oxygen extraction.
89141156|NCT05905406|Experimental|D20|The Hip will be positioned at 0°, and knee positioned 20°. The sessions will be initiated with heating and muscle enhancement. The following outcomes will be observed before and after the fatigue protocol: (1) CVIM; (2) voluntary activation level; (3) electromyographic activity; (4) muscular architecture; and (5) tendinous properties. During the fatigue protocol, except for item 1), will be evaluated: (1) fatigue by torque decay curve; (2) integral force-time; (3) muscular architecture; (4) tendinous properties; and tissue oxygen extraction.
89141157|NCT05905393|Experimental|preoperative stimulation of the efferent loop with GABA before ileostomy closure surgery|Preoperative stimulation of the distal limb of the ileostomy loop with GABA was performed during the 5 days prior to surgery every day. During the process and after it, the patient himself registers the appearance of symptoms after each stimulation session: abdominal pain, emission of gas and stool. Sterile Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of a solution with 3000 mg of GABA diluted in 100 ml of 0.9% physiological saline. Each preparation was made under sterile conditions and maintaining the cold chain.
89141158|NCT05905393|Sham Comparator|control group was stimulated without giving any substance|"Control group was stimulated without giving any substance. During the process and after it, the patient himself registers the appearance of symptoms after each stimulation session: abdominal pain, emission of gas and stool.~After 5 stimulation sessions, reconstructive surgery was performed within the following 24 h."
89141159|NCT05905354|Experimental|lose dose,high dose|Four dose groups were set up: dose group 1, a single dose of 2mg, administered at week 0, 4 and 12, three times in total; Dose group 2, a single dose of 6mg, respectively at the 0, 4, 12 weeks, a total of 3 times; Dose group 3, a single dose of 2mg, was given at the 0, 2, 4, 12 weeks, a total of 4 times; Dose group 4, with a single dose of 6mg, was given 4 times at week 0, 2, 4 and 12, respectively. There were 3 subjects in each group. Climb from the low dose group to the high dose group.
89141160|NCT05905315|Active Comparator|Primary chemoradiation|Patients included in the standard treatment arm will receive a combination of weekly cisplatin combined with 30 fractions of external beam radiotherapy on the primary tumour with a total dose of 64.5 Gy. Cisplatin will be given for six weeks intravenously with a dose of 40 mg/m2, if possible on the first day of the week. On day 1 until day 5 the patient will receive external beam radiotherapy. This will be repeated for a six-week period.
89141161|NCT05905315|Experimental|NACT (3-weekly carboplatin and paclitaxel) followed by surgery|Patients included in the experimental arm will be treated with intravenous infusion of paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme with preferably 3 and a maximum of 4 courses, with evaluation after two courses of chemotherapy by physical examination. NACT will be subsequently followed by radical surgery in responding patients. A four to six weeks interval after the last course of chemotherapy needs to be respected before surgery, to allow sufficient physical recovery.
89141162|NCT05905211||Infected COVID-19|Balance, functional mobility, activities of daily living, quality of life, fear of COVID-19, depression evaluated
89141163|NCT05905211||Non-Infected COVID-19|Balance, functional mobility, activities of daily living, quality of life, fear of COVID-19, depression evaluated
89141164|NCT05905198|Experimental|HFS-VFS|This arm will experience HFS first during the crossover, and then VFS.
89141165|NCT05905198|Experimental|VFS-HFS|This arm will experience VFS first during the crossover, and then HFS.
89141166|NCT05905185|Experimental|Treatment|Sime Darby Bioganic Sdn. Bhd, Malaysia provided the TRF pills that were used in the study. The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol. During a period of six months, the patients were instructed to consume oral TRF (50 mg) daily
89141167|NCT05905185|Placebo Comparator|Placebo|During a period of six months, the patients were instructed to consume oral placebo (50 mg) pills daily.
89141168|NCT05905159|Experimental|ABM|"ABM training will consist of five sessions over five consecutive days during which patients performed a modified version of the visual dot-probe task. The whole ABM program will include a total of 1000 trials that will be distributed in 200 trials per session (twenty minutes per session).~Participants assigned to ABM training condition will be trained implicitly to attend away from pain-related stimuli (i.e., facial expressions). They will be presented with a modified dot-probe task with trials including targets that often replaced neutral faces. Thus, 80% of trials (i.e., 160 trials) included targets that replaced neutral cue faces (pain incongruent trials: target appeared in the opposite side of pain-related faces). The rest of trials (i.e., 40 trials) belonged to pain congruent trials (i.e., target will occur in the same location of the pain-related facial expression)."
89141169|NCT05905159|Placebo Comparator|Control|By contrast, patients assigned to control condition were exposed to a standard visual dot-probe task in which targets were equally likely to replace pain or neutral cues (i.e., facial expressions) during pain trials (i.e., 50% pain-incongruent trials and 50% pain-congruent tri-als). The whole Control program will include a total of 1000 trials that will be distributed in 200 trials per session (twenty minutes per session).
89141170|NCT05905146|Experimental|interventional group|benefiting from a multi-professional intervention around the strong opioid treatment with the aim of setting up a personalized pharmaceutical plan
89141171|NCT05905146|No Intervention|control group|routine management, including medication reconciliation at entry and exit and pharmaceutical analysis of prescriptions
89141172|NCT05905107|Experimental|Interventional Group A|These patients will be treated by nerve sequencing proximal to distal in 3 sets of 15 repetitions in one session on alternate days for 4 weeks. For this, participants will be given a comfortable supine lying position. ULTT method will be implemented to the ipsilateral upper limb given in the table below
89141173|NCT05905107|Active Comparator|Interventional Group B|These patients will be treated by nerve sequencing distal to proximal in 3 sets of 10 repetitions in one session for 4 weeks. For this, participants will be given a comfortable supine lying position. ULTT method will be implemented to the ipsilateral upper limb
89141174|NCT05905016||Esophageal POEM|Data will be collected for patients under going standard of care Esophageal POEM (E-POEM)
89141175|NCT05905016||Gastric POEM|Data will be collected for patients under going standard of care Gastric POEM (G-POEM)
89141176|NCT05905016||Zenker's POEM|Data will be collected for patients under going standard of care Zenker's diverticulum POEM (Z-POEM)
89141177|NCT05905003||CHR|Clinical High Risk (CHR) for psychosis subjects meeting diagnostic criteria for CHR on the Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS).
89141178|NCT05905003||HC|Healthy Control (HC) Subjects
89141179|NCT05904977||Type B resection|The patients reviced type B resection of the antierior leaf of vesicouterine ligament
89141180|NCT05904977||Type C resection|The patients reviced type C resection of the antierior leaf of vesicouterine ligament
89141181|NCT05904925|No Intervention|Usual care|Usual care group will perform the usual prenatal care indicated by the obstetrician and will receive an educational booklet.
89141182|NCT05904925|Active Comparator|Pilates|Pilates group will perform the usual prenatal care indicated by the obstetrician and will receive an educational booklet. Additionally, this group will receive an exercise program based on Pilates, twice a week, individually, throughout the gestational period.
89141183|NCT05904873|Experimental|The group who removed their hands from ice packs before 240 seconds|In our study, a cold pressor test was applied to the participants in order to measure the pain tolerance according to the time duration they could keep their hands on the ice pack before the operation. Participants were prepared for an ice test in another area other than the operation area. Participants were asked to place their hands on standardized ice packs and keep them on the ice pack for 240 seconds. It was also said that if they could not tolerate pain, they could remove their hands from the ice before 240 seconds. The participants were asked to express the pain as a number between 0 (no pain) and 10 (unbearable pain) according to the visual analog scale when they removed their hands from the ice pack. Participants were divided into two groups according to the time duration of ice test as less than 240 seconds and equal to seconds.
89141184|NCT05904873|Experimental|The group that can keep their hands on ice packs for 240 seconds|In our study, a cold pressor test was applied to the participants in order to measure the pain tolerance according to the time duration they could keep their hands on the ice pack before the operation. Participants were prepared for an ice test in another area other than the operation area. Participants were asked to place their hands on standardized ice packs and keep them on the ice pack for 240 seconds. It was also said that if they could not tolerate pain, they could remove their hands from the ice before 240 seconds. The participants were asked to express the pain as a number between 0 (no pain) and 10 (unbearable pain) according to the visual analog scale when they removed their hands from the ice pack. Participants were divided into two groups according to the time duration of ice test as less than 240 seconds and equal to 240 seconds.
89141185|NCT05904860|Other|Experimental Group|The experimental group will be receiving a 30-minute backward gait training using parallel bars, a mirror, and on a firm surface. Patients will receive training for 4 days per week with a total time period of 4 weeks. Balance, fall risk, and spatiotemporal gait parameters will be quantified and evaluated before the commencement of treatment, after 2 weeks, and at the end of the last session.
89141186|NCT05904860|Other|Control group|The control group will be receiving a 30-minute forward gait training using parallel bars, a mirror and on a firm surface. Patients will receive training for 4 days per week with a total time period of 4 weeks. Balance, fall risk, and spatiotemporal gait parameters will be quantified and evaluated before the commencement of treatment, after 2 weeks, and at the end of the last session.
89141187|NCT05904795|Active Comparator|PNF strengthening exercises|Pnf strengthening exercises along with isometrics and range of motion exercises
89141188|NCT05904795|Active Comparator|de-lorme and watkins progressive resistance exercises|progressive resistance exercises along with isometrics and range of motion exercises
89141189|NCT05904704|Experimental|Diagnostic (oxygen-enhanced MRI)|Patients receive supplemental oxygen while undergoing standard of care MRI.
89141190|NCT05904626|Active Comparator|ELGN-2112 Human insulin [rDNA]|
89141191|NCT05904626|Placebo Comparator|Placebo|
89141192|NCT05902715|Experimental|oral implant placement with socket shield technique|cohort of 20 patients in need of tooth replacement with oral implant
89141193|NCT05902624|Other|Group intralesional injection(0.3 ml)|Group 1: will include 22 patients with multiple plane or genital warts. They will be treated by intralesional injection of HBV vaccine at a dose of (0.3 ml) into the largest wart by an insulin syringe every 2-weeks until complete clearance or for a maximum of 5 sessions.
89141194|NCT05902624|Other|Group intralesional injection(0.5 ml)|Group 2: will include 22 patients with multiple plane or genital warts. They will be treated by intralesional injection of HBV vaccine at a dose of (0.5 ml) into the largest wart by an insulin syringe every 2-weeks until complete clearance or for a maximum of 5 sessions.
89141195|NCT05902624|Other|Group intramuscular injection|Group 3: will include 22 patients with multiple plane or genital warts. They will be treated by intramuscular injection of HBV vaccine at a dose of (0.5 ml)in patients who are 18 years or younger and (1ml)in patients older than 18 years in the deltoid muscle using a 25-gauge syringe every month until complete clearance or for a maximum of 3 months.
89141196|NCT05901506|Experimental|Motivational Interview|Participants will receive the nurse-led, motivational interview educational intervention in this group.
89141197|NCT05897229||PC - end-stage disease criteria and high risk of death from the disease prior to COVID-19|"Patients with severe forms of COVID-19 (RT-PCR+) admitted to a high-complexity hospital.~Of these, patients with end-stage disease criteria and high risk of death from the disease prior to COVID-19 were admitted, at clinical criteria, to palliative care unit.~If there are patients who received both types of treatment, this group will also be analyzed."
89141198|NCT05897229||ICU - end-stage disease criteria and high risk of death from the disease prior to COVID-19|"Patients with severe forms of COVID-19 (RT-PCR+) admitted to a high-complexity hospital.~Of these, patients with end-stage disease criteria and high risk of death from the disease prior to COVID-19 were admitted, at clinical criteria, to the ICU.~If there are patients who received both types of treatment, this group will also be analyzed."
89141199|NCT05897229||PC & ICU - end-stage disease criteria and high risk of death from the disease prior to COVID-19|"Patients with severe forms of COVID-19 (RT-PCR+) admitted to a high-complexity hospital.~Of these, patients with end-stage disease criteria and high risk of death from the disease prior to COVID-19 were admitted, at clinical criteria, to the ICU and palliative care unit.~If there are patients who received both types of treatment, this group will also be analyzed."
89141200|NCT05896618|Experimental|Group I|TPA group
89141201|NCT05896618|Experimental|Group II|Nance group
89141202|NCT05896046|Experimental|Phase I/ II: SHR1701|Phase I: 30-150 mg/kg, IV over 30 minutes, every 3 weeks. Phase II: recommended dose from phase I trial, IV over 30 minutes, every 3 weeks.
89141203|NCT05896046|Experimental|Phase II: SHR2554+ SHR170|SHR2554: 350mg/day, PO, twice a day, every 3 weeks. SHR1701: recommended dose from phase I trial, IV over 30 minutes, every 3 weeks.
89141204|NCT05892679|Experimental|Acupressure|"Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks."
89141205|NCT05892679|No Intervention|Control|No intervention will be made to the control group only the data will be collected at the same time as the study group.
89141206|NCT05888961|Active Comparator|Control subjects|
89141207|NCT05888961|Experimental|Subjects with an isolated cognitive complaint|
89141208|NCT05888961|Experimental|Subjects with minor neurocognitive disorders|
89141209|NCT05888961|Experimental|Subjects with major neurocognitive disorders of the mild Alzheimer's disease type|
89141210|NCT05888961|Experimental|Subjects with major neurocognitive disorders of the moderate Alzheimer's disease type|
89141211|NCT05887856|Active Comparator|Intervention Group|Volunteers in the Intervention group will receive specially designed educational program which will be aimed at reduction of pre-operative anxiety in breast cancer patients undergoing surgery as a part of their treatment.
89141212|NCT05887856|No Intervention|Non-Intervention Group|"Non-Intervention group will get the usual standard information as per existing protocols which includes~Explanation of surgical procedure by primary team.~Information about anesthesia on pre-operative anesthesia assessment.~Phone call from Primary team explaining surgery details one day prior to surgery in case of day case surgery.~Information about surgery on admission from floor resident in case of Pre-Op Admission.~Afore mentioned practices are standard at SKMCH and RC and will remain same for both intervention and non-intervention group."
89141213|NCT05887531|Experimental|Prehabilitation|
89141214|NCT05882279||Pharmacists in Hospitals Prescribing NINLARO|Pharmacists included in Nikkei Research Access Panel who are active in clinical practice, with valid contact and who have instructed the dosing of NINLARO IRD therapy to patients with rrMM will self-administer a web-based survey. The questionnaires in the survey will be provided in Japanese.
89141215|NCT05875987||Obstetric Patients|Obstetric patient population experiencing excessive bleeding around the time of delivery
89141216|NCT05874895|Experimental|Manual Lymphatic Drainage|In addition to usual care, daily manual lymphatic drainage will be performed for five consecutive days. After this period.
89141217|NCT05874895|Active Comparator|Usual Care|Usual care for patients with septic shock will be provided.
89141218|NCT05873660||People with established CVD|Adults diagnosed with established CVD, attending routine medical care or follow-up in a cardiology clinic.
89141219|NCT05872438|Other|Multisite sampling|Vaginal, Oral and anal sampling for all participants
89141220|NCT05846919|Active Comparator|Pediatric patients indicated for RSI and face-mask preoxygenation|face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
89141221|NCT05846919|Active Comparator|Pediatric patients indicated for RSI and HFNOC preoxygenation|HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
89141222|NCT05846919|Experimental|Pediatric patients indicated for RSI and HFNOC + face-mask preoxygenation|HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
89141223|NCT05843565|Experimental|Cobalt group: Cobalt blade then Miller blade|Patients enrolled in the study will receive sevoflurane 6% for induction of general anesthesia followed by rocuronium 0.6 mg/kg to facilitate tracheal intubation. In patients allocated to the Cobalt group, the POGO and C&L classification will be recorded using video laryngoscopy with a Cobalt blade followed by an assessment using the Miller blade. Intubation will then be attempted during the second assessment. Endotracheal tube size will be selected according to body weight and a guiding stylet will be used. If the first attempt at intubation fails, the subsequent attempts will be left at the discretion of the attending anesthesiologist.
89141224|NCT05843565|Placebo Comparator|Miller group: Miller blade then cobalt blade|Patients enrolled in the study will receive sevoflurane 6% for induction of general anesthesia followed by rocuronium 0.6 mg/kg to facilitate tracheal intubation. In patients allocated to the Miller group, the POGO and C&L classification will be recorded using video laryngoscopy with a Miller blade followed by an assessment using the Cobalt blade. Intubation will then be attempted during the second assessment. Endotracheal tube size will be selected according to body weight and a guiding stylet will be used. If the first attempt at intubation fails, the subsequent attempts will be left at the discretion of the attending anesthesiologist.
89141225|NCT05838703|Experimental|Tiotropium bromide (Spiriva Respimat)|Images obtained using 129XeMRI will be obtained after one-time use of Spiriva Respimat
89141226|NCT05838703|Active Comparator|Tiotropium bromide inhalation powder (Spiriva HandiHaler)|Images obtained using 129XeMRI will be obtained after one-time use of Spiriva HandiHaler
89141227|NCT05828901||Relapsing Remitting Multiple Sclerosis starting Ozanimod|
89141228|NCT05828901||Relapsing Remitting Multiple Sclerosis stopping Ozanimod|
89141229|NCT05819931|Experimental|Mechanical In-Exsufflator treatment|
89141230|NCT05814913|Experimental|CaCBT for psychosis|CaCBT is a culturally adapted psychosocial intervention for people with early psychosis that comprises of 12 sessions. These sessions are conducted individually on a weekly basis and last 45-60 minutes
89141231|NCT05814913|Experimental|CulFI Intervention|CulFI is a culturally adapted psychosocial intervention delivered over 10 sessions of 40-60 minutes, weekly for the first 8 weeks and fortnightly for the remaining 4 weeks. Sessions are delivered to patients and their carers, though patient participation in sessions is not necessary.
89141232|NCT05814913|No Intervention|Treatment as Usual (TAU)|TAU will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of TAU delivered to each participant over a period of 3 months.
89141233|NCT05814848|Experimental|single arm|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
89141234|NCT05814107|Experimental|CT-996|Capsule of CT-996 intervention
89141235|NCT05814107|Placebo Comparator|Placebo|Capsule of placebo matching CT-996 dose
89141236|NCT05807048|Experimental|Patients with STK11/LKB1-Mutated NSCLC|"Participants will receive daratumumab 1800mg and hyaluronidase 30,000 units (combined product DARZALEX Faspro) administered subcutaneously per the following dosing schedule:~Once per week for 8 administrations (Week 1-8)~Once every two weeks for 8 administrations (Week 9-16)~Once every 4 weeks until disease progression or unacceptable toxicity."
89141237|NCT05798286|Experimental|QUANTRA group|"Adult subjects (18 years-old or older) undergoing double-lung transplantation: transfusion algorithm based on whole blood viscoelastic test with Quantra® + standard coagulation test. These samples are collected at five standard surgical time points:~on arrival at the hospital on the day of surgery,~after first pulmonary artery clamping,~after first graft implantation,~after second graft implantation,~at end-surgery status."
89141238|NCT05798286|Active Comparator|Control group|"Adult subjects (18 years-old or older) undergoing double-lung transplantation: standard transfusion algorithm based on standard practice and coagulation test. These samples are collected at five standard surgical time points:~on arrival at the hospital on the day of surgery,~after first pulmonary artery clamping,~after first graft implantation,~after second graft implantation,~at end-surgery status."
89141239|NCT05790421|Experimental|Group A|Participants received foot muscle energy techniques and conventional physical therapy program for three sessions/week for 4 weeks, each lasting 30 min
89141240|NCT05790421|Experimental|Group B|Participants received conventional physical therapy program only for three sessions/week for 4 weeks, each lasting 30 min
89141241|NCT05789992|Active Comparator|Group 1 BIS under tetanic electrical stimulation|During tetanic electrical stimulation, and with propofol(random:3-5ug/ml) and remifentanil(random:0-3ng/ml), the response (body movement or hemodynamic change) was observed, and recorded it's BIS.
89141242|NCT05789992|Active Comparator|Group 2 eMAC under tetanic electrical stimulation|During tetanic electrical stimulation or intubation, and with propofol(random:3-5ug/ml) and remifentanil(random:0-3ng/ml), the response (body movement or hemodynamic change) was observed, and recorded it's eMAC.
89141243|NCT05789992|Active Comparator|Group 3 BIS under intubation|During intubation, and with propofol(random:3-5ug/ml) and remifentanil(random:3-5ng/ml), the response (body movement or hemodynamic change) was observed, and recorded it's BIS.
89141244|NCT05789992|Active Comparator|Group 4 eMAC under intubation|During intubation, and with propofol(random:3-5ug/ml) and remifentanil(random:3-5ng/ml), the response (body movement or hemodynamic change) was observed, and recorded it's eMAC.
89141245|NCT05788939|Experimental|intervention group|The sample of this cluster randomized controlled experimental study consisted of 2nd year university students (n=116) training in Faculty of Economics and Administrative Sciences (FEAS) and Hasan Ferdi Turgutlu Faculty of Technology (HFTFT) from the faculties of Manisa Celal Bayar University (MCBU) between February-Semptember 2019. Among the faculties in MCBU, simple random sampling was used to draw lots, with the first lot being assigned to FEAS as the intervention group (IG), and the second lot being assigned to HFTFT as the control group (CG) . Among seven departments in FEAS and four departments in the HFTFT, simple random sampling was used to draw lots again. The Department of Econometrics from the FEAS was assigned as the IG and Mechatronics Engineering from HFTFT was assigned as the CG. The planned visual education based Health Belief Model was given.
89141246|NCT05788939|No Intervention|Control group|No attempt was made by researcher during the study. Only data were collected. At the end of the study, the planned visual education based Health Belief Model was given and all students continued in the study were given key rings with pictures about sun protection designed by the researchers.
89141247|NCT05776719|Active Comparator|Health & Wellness|8 weeks, once weekly 90 minute sessions, groups of 8-10 subjects, gender stratified
89141248|NCT05776719|Experimental|Warrior Renew|8 weeks, once weekly 90 minute sessions, groups of 8-10 subjects, gender stratified
89141249|NCT05764993|Experimental|Group #1|SCIgR with Cuvitru 125 mg/kg/week + standard of care management
89141250|NCT05764993|Placebo Comparator|Group #2|Standard of care management = 20 patients
89141251|NCT05757986||Experimental group|
89141252|NCT05757986||Control group|
89141253|NCT05743738|Other|Presence of thrombosis|Doppler ultrasound D8, D15, D30, D45, D60 and D90
89141254|NCT05743738|No Intervention|Absence of thrombosis|
89141255|NCT05743192||Before group|Group of patients with a positive urine culture for Enterococcus faecalis before the procedure consisting of systematically performing an antibiotic susceptibility test.
89141256|NCT05743192||After group|Group of patients with a positive urine culture for Enterococcus faecalis after the procedure consisting of systematically performing an antibiotic susceptibility test.
89141257|NCT05718102|Active Comparator|Pharmacist led|Pharmacists will conduct population health management for patients with COPD
89141258|NCT05718102|Active Comparator|Pulmonologist led|Pulmonologists will conduct population health management for patients with COPD
89141259|NCT05712057|Experimental|Cognitive Restructuring + Repetitive Transcranial Magnetic Stimulation (rTMS)|Group 1 (G1)- 80 eligible participants will receive training in Cognitive Restructuring (CR). These participants will use CR while receiving rTMS over their individual dlPFC target and will partake in short term and long term follow up testing.
89141260|NCT05712057|Active Comparator|Cognitive Restructuring + scalp electrical stimulation|Group 2 (G2) - 80 eligible participants will receive training in CR. These participants will use CR while receiving scalp electrical stimulation over their individual dlPFC target and will partake in short term and long term follow up testing.
89141261|NCT05712057|Active Comparator|Emotional Awareness Training + Repetitive Transcranial Magnetic Stimulation (rTMS)|Group 3 (G3) - 80 eligible participants will receive emotional awareness training. These participants will receive rTMS over their individual dlPFC target and will partake in short term and long term follow up testing.
89141262|NCT05709834|Experimental|Autogenic training|It consists of patients who will receive autogenic training and conventional treatment with the frequency of 3 times per week for 4 weeks.
89141263|NCT05709834|Other|Control group|Its consists of patients who will receive conventional treatment with the frequency of 3 sessions per week
89141264|NCT05701501|Experimental|Vitamin B5 group|Based on the standard IBD treatment, Vitamin B5 (5mg/tablet) is given orally three times a day, four tablets each time, for 12 weeks.
89141265|NCT05701501|Placebo Comparator|Control group|Based on the standard IBD treatment, the same type of placebo tablets are given orally three times a day, four tablets each time, for 12 weeks.
89141266|NCT05700812|Experimental|IUD insertion study in three phases|"In phase one, the IUD will be placed in standard fashion with a uterine sound to obtain baseline data.~In phase two, the IUD will be placed without the use of a uterine sound and under abdominal ultrasound guidance.~In phase three, the IUD will be placed without the use of a uterine sound and without ultrasound guidance."
89141267|NCT05697536|Experimental|Pilates training|Group A will receive Pilates training. The treatment will be given with the frequency of 3 times per week for 8 weeks. Treatment sessions will be of 45 minutes with short resting intervals.
89141268|NCT05697536|Experimental|Aerobic exercise|Group B will receive aerobic exercise plan. The frequency of treatment will be as same as that of Pilates exercise program i.e. 3 times a week for 8 weeks. Treatment sessions will be of 45 minutes with short resting intervals.
89141269|NCT05681273|Experimental|Group A|D1: Oral single dose of Empagliflozin 10 mg; D5~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Empagliflozin 10 mg and Chiglitazar 48 mg.
89141270|NCT05681273|Experimental|Group B|D1: Oral single dose of Atorvastatin 20 mg; D5~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Atorvastatin 20 mg and Chiglitazar 48 mg.
89141271|NCT05681273|Experimental|Group C|D1: Oral single dose of Valsartan 160 mg; D5~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Valsartan 160 mg and Chiglitazar 48 mg.
89141272|NCT05667870||Newborns with CHD and their mothers|Consecutive newborns with CHD (n=100), who are diagnosed and born in the University Hospitals of Leuven and Ghent, are eligible for inclusion. Mothers (n=100) will be asked for participation in the study before delivery and written informed consent will be obtained. Umbilical cord blood of the ENVIRONAGE study (Hasselt University) will be used as a control group.
89141273|NCT05667870||(Young) adults with CHD - study 2|An age-stratified random sample of (young) adults with CHD, followed-up at the University Hospital of Leuven and the Ghent University Hospital will be included. Age strata for this study are: 18-24y; 25-34y; 35-44y; 45-54y; 55+. In total 500 patients will be included, 100 in each age stratum.
89141274|NCT05667870||(Young) adults with CHD - study 3|At the University Hospital of Leuven and Ghent University Hospital, patients with selected complex (Fontan operation; Systemic right ventricle), moderate (Tetralogy of Fallot; Coarctation of the aorta), and mild heart defects (isolated atrial septal defect; isolated ventricular septal defect) are eligible. For each type of heart defect 20 patients between the age of 30-50 years are enrolled. The overall sample will comprise 120 patients, who will be part of study 2 as well.
89141275|NCT05667870||Healthy controls|Data on healthy controls (n=500) will be retrieved from blood donors at the blood donation service of the Belgian Red Cross-Flanders. The healthy controls will be matched to the included adult patients (in study 2 and 3) based on sex and age.
89141276|NCT05666115|Experimental|Probiotic group|Participants in the probiotics group will receive probiotic supplementation for 12 weeks.
89141277|NCT05666115|Active Comparator|Exercise group|The control group will undergo a 12-week online-delivered Tabata program, as a form of high-intensity interval training.
89141278|NCT05656742|Experimental|Vitamin D|5,000 IU of oral vitamin D3 in white powder form, daily for 8 continuous weeks
89141279|NCT05653869|Experimental|APS03118 Dose Escalation|APS03118 administered orally
89141280|NCT05651568|Experimental|Periodized resistance training|It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.
89141281|NCT05651568|Experimental|High intensity interval training|It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30-35 minutes.
89141282|NCT05636462|Experimental|Global postural re-education|It consists of 27 patients who will receive conventional exercises and global postural re-education which will be divided in three components First in lying posture to stretch anterior muscles of neck for 15 min, second component in supine position and stretching posterior muscles for 15 min and final component is in standing position under a load of gravity for 5 min for 3 days a week .
89141283|NCT05636462|Active Comparator|Conventional Physical therapy|It consists of 27 patients who will receive conventional therapy including stretching and strengthening exercises of neck for 3 days a week.
89141284|NCT05633186|Experimental|Condition 1|Moodbuster Life + Mobile Application + Guidance by a coach + Motivational Content
89141285|NCT05633186|Experimental|Condition 2|Moodbuster Life + Mobile Application + Guidance by a coach
89141286|NCT05633186|Experimental|Condition 3|Moodbuster Life + Mobile Application + Motivational Content
89141287|NCT05633186|Experimental|Condition 4|Moodbuster Life + Mobile Application
89141288|NCT05633186|Experimental|Condition 5|Moodbuster Life + Guidance by a coach + Motivational Content
89141289|NCT05633186|Experimental|Condition 6|Moodbuster Life + Guidance by a coach
89141290|NCT05633186|Experimental|Condition 7|Moodbuster Life + Motivational Content
89141291|NCT05633186|Experimental|Condition 8|Moodbuster Life
89141292|NCT05628012|Experimental|Circadian Based Time Restricted Eating|Personalized restricted eating protocol approximately ~4h before DLMO or sleep onset.
89141293|NCT05628012|No Intervention|Control|Continue with normal dietary habits and behaviors.
89141294|NCT05625360|Experimental|Arm 1 - eHealth Mindful Movement and Breathing Group (eMMB)|Participants will be given access to 20-minute eMMB videos (either saved as a local files on an iPad or via links to watch on their own devices) with written instructions for eMMB and to watch a video at least once before surgery (videos have the same content, one is taught in a bed and one in a chair). The instructor will call participants before surgery to offer guidance upon request and meet with participants individually via a synchronous videoconference or telephone session, postoperative day 1 (the day after surgery), or as soon as feasible.
89141295|NCT05625360|Active Comparator|Arm 2 Life Impacts Reflection Group (LIR)|The format for interactions with an LIR interventionist, frequency of recommended home practice (brief diary entries), and home assessments will be matched to the eMMB group. LIR will not include active ingredients of eMMB.
89141296|NCT05616234|Experimental|Exercise trial|Participants will perform a bout of exercise. In addition, a baseline and post-exercise blood sample will be drawn.
89141297|NCT05598151|Experimental|HM97662|Tablet, oral administration, once daily (QD), continuous dosing
89141298|NCT05573048|Experimental|Trans-Perineal Grid for prostate interventions|Subjects will have the trans-perineal guide grid placed the prostate biopsy or ablation procedure.
89141299|NCT05557058|Experimental|Gore GDI High Device Arm|Implantation of the GORE GDI High Device Configuration
89141300|NCT05557058|Experimental|Gore GDI Low Device Arm|Implantation of the GORE GDI Low Device Configuration
89141301|NCT05552053|Active Comparator|Maternal Wellness Self Help (MWSH) Application|The Maternal Wellness Self Help (MWSH) app was created to help individuals to identify and manage perinatal depression and anxiety. The app is designed is to meet the emotional needs of those who are pregnant, want to become pregnant or have given birth. This psycho-educational app informs and normalizes the range of emotional responses throughout the reproductive journey. By learning about perinatal mental health, this app hopes to empower patients to understand and name their experiences.
89141302|NCT05552053|Experimental|MWSH plus Candlelit Care|Candlelit Care is a virtual perinatal mental health application that builds on cognitive behavioral therapy (CBT) to provide Black, Indigenous and POC women and birthing parents access to culturally affirming mental health support during pregnancy. Driven by an integrated care team, women have access to self-guided therapeutic tools, peer coaching and education about perinatal mood disorders as a primary resource. This convenient and trauma informed app allows parents to see if their mental health symptoms warrant further treatment in a secure setting. The app also provides education of role transitions, discussion of types of interpersonal conflicts common around childbirth (including racial discrimination) and techniques for resolving them, and role-playing with feedback from other parents during groups. The goals are to improve self-advocacy skills; patient communication with medical providers and provide a support network with other Black pregnant women.
89141303|NCT05538767|Experimental|Emodepside 30 mg|
89141304|NCT05538767|Active Comparator|Albendazole 400 mg|
89141305|NCT05529797|Experimental|Veovita-VR|Participants receive one VR session with positive emotional stimuli and positive behavioral activation.
89141306|NCT05529797|No Intervention|Care as Usual|Participants receive CAU.
89141307|NCT05524168|Experimental|SBRT+PD-1+Chemotherapy|Patients will receive SBRT first, then PD-1 antibody (Camrelizumab 200mg/Q3W) and chemotherapy (cisplatin 80mg/m2 on d1, gemcitabine 1000mg/m2, d1 and d8, Q3W, maximum 6 cycles), followed by Camrelizumab (200mg/Q3W) until progressive disease, intolerable toxicity, withdrawal of consent or a maximum of 1 year treatment.
89141308|NCT05522452|Experimental|Telerehabilitation group|"The telerehabilitation group will participate in the treatment in their homes. While the participants are performing the activities in their own homes, applications will be made via webcam-based software (Zoom) and synchronous access via video and audio from the physiotherapist's computer screen. The activities determined by the physiotherapist will be directed to the family, and the activities will be adapted and implemented according to the child's needs and functional level.~Physiotherapy program will include the following applications:~Tone regulation~Active stretching and strengthening exercises~Gross and fine motor activities to improve bilateral hand use~Daily living activities to improve upper extremity functional skills such as dressing, eating, and buttoning.~Arts and crafts activities"
89141309|NCT05522452|Active Comparator|Face to face group|"The face-to-face group will be treated in the clinic. To this group; The activities determined by the physiotherapist will be applied face to face.~Physiotherapy program will include the following applications:~Tone regulation~Active stretching and strengthening exercises~Gross and fine motor activities to improve bilateral hand use~Daily living activities to improve upper extremity functional skills such as dressing, eating, and buttoning.~Arts and crafts activities"
89141310|NCT05512182|Experimental|Chemotherapy|
89141311|NCT05496244||Epidemiological Section|Consecutive enrollment of patients with indications of interest
89141312|NCT05496244||Observational Section|Extended data collection on patients treated via conventional laparoscopy or robotic-assisted surgery
89141313|NCT05491525|Experimental|Cohort 1: Vibegron Adolescents (12 to < 18 years)|"Part A: Participants aged 12 to < 18 years will receive vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times.~Part B: Participants will receive a Data and Safety Monitoring Board (DSMB)-selected vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A."
89141314|NCT05491525|Experimental|Cohort 2: Vibegron Children (2 to < 12 years)|"Part A: Participants aged 2 to < 12 years will receive vibegron based on their weight, after DSMB review of Cohort 1, Part A data, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times.~Part B: Participants will receive a DSMB-selected vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A."
89141315|NCT05487911|Experimental|rTMS|20 sessions of rTMS
89141316|NCT05479851||UK National Health Service Patient Postal Survey Participants|Patients who have agreed to participate in the study after receiving a postal invitation
89141317|NCT05475392|Experimental|Stretching Exercise with PIR on neck pain and muscle spasm in breastfeeding women|Experimental Group (Group A) will receive stretching with Post Isometric Relaxation and conventional treatment. Treatment will be given for five days per week for total two weeks. Pain will be assessed through VAS scale and MJM scale will be used to assess spasm. Assessment was done 2 times pretreatment and post treatment.
89141318|NCT05475392|Active Comparator|Stretching Exercise without PIR on neck pain and muscle spasm in breastfeeding women|Active Compatitor (Group B) will receive only stretching and conventional treatment. Treatment will be given for five days per week for total two weeks. Pain will be assessed through VAS scale and MJM scale will be used to assess spasm. Assessment was done 2 times pretreatment and post treatment.
89141319|NCT05449496|No Intervention|Control|
89141320|NCT05449496|Experimental|Intervention|
89141321|NCT05440448|Experimental|Patch-free occlusion therapy|
89141322|NCT05440448|Active Comparator|Standard-of-care patching with an adhesive patch|
89141323|NCT05439200|Experimental|Asynchronous movies|Asynchronous 3D movies
89141324|NCT05439200|Active Comparator|Standard-of-care patching with an adhesive patch|Standard-of-care patching with an adhesive patch
89141325|NCT05431582|Experimental|Regimen A|ZN-c3 in combination with bevacizumab
89141326|NCT05431582|Experimental|Regimen B|ZN-c3 in combination with bevacizumab and pembrolizumab
89141327|NCT05430113|Experimental|Spinal Cord Stimulation|All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the epidural (T12-L2 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
89141328|NCT05426564||ECMO Patients|Patients undergoing an ECMO procedure
89141329|NCT05419687|Experimental|Arm 1 De-escalating violence training|The de-escalating violence training intervention will be introduced after a pre-interventional period of 3 months. A refreshment training will be introduced at month 11.
89141330|NCT05419687|Experimental|Arm 2 De-escalating violence training|The de-escalating violence training intervention will be introduced before the second observation period at month 11. A refreshment training will be introduced at month 18.
89141331|NCT05419687|Experimental|Arm 3 De-escalating violence training|The de-escalating violence training intervention will be introduced before the third observation period at month 18.
89141332|NCT05419687|Experimental|Arm 4 De-escalating violence training + Code of conduct|The de-escalating violence training intervention will be introduced after a pre-interventional period of 3 months. The code of conduct via a warning board will be introduced at month 11. A refreshment training will be introduced at month 18.
89141333|NCT05419687|Experimental|Arm 5 De-escalating violence training + Code of conduct|The de-escalating violence training intervention and the code of conduct via a warning board will be simultaneously introduced at month 11. A refreshment training will be introduced at month 18.
89141334|NCT05419687|Experimental|Arm 6 Code of conduct + De-escalating violence training|The code of conduct via a warning board will be introduced at month 11. The de-escalating violence training intervention will be introduced at month 18.
89141335|NCT05419687|Experimental|Arm 7 De-escalating violence training + Code of conduct|The de-escalating violence training intervention is introduced after a pre-interventional period of 3 months. The code of conduct via a warning board and a refreshment training will be simultaneously introduced at month 18.
89141336|NCT05419687|Experimental|Arm 8 De-escalating violence training + Code of conduct|The de-escalating violence training intervention will be introduced before the second observation period at month 11. The code of conduct via a warning board and a refreshment training will be simultaneously introduced at month 18.
89141337|NCT05419687|Experimental|Arm 9 De-escalating violence training + Code of conduct|The code of conduct via a warning board and the violence de-escalating training will be simultaneously introduced at month 18.
89141338|NCT05419687|Experimental|Arm 10 Code of conduct|The code of conduct via a warning board will be introduced at month 11.
89141339|NCT05419687|Experimental|Arm 11 Code of conduct|The code of conduct via a warning board will be introduced at month 18.
89141340|NCT05390801||Patients|Any patient ≥ 18 years old with congenital aniridia, able to respond independently to a questionnaire and patients under 18 years old with congenital aniridia, whose parents can respond for their child.
89141341|NCT05384756|Experimental|Treatment (TMLI, alemtuzumab)|Patients receive alemtuzumab IV over 4 hours QD on days -7 to -3. Patients undergo TMLI BID on day -2. Patients also undergo HCT on day 0 and receive sirolimus on day -1 and day 0.
89141342|NCT05373485|Experimental|Vaccine Group, low dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
89141343|NCT05373485|Experimental|Vaccine Group, low dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
89141344|NCT05373485|Experimental|Vaccine Group, high dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
89141345|NCT05373485|Experimental|Vaccine Group, high dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
89141346|NCT05373485|Placebo Comparator|Placebo Group, low dose, 18-59 year-old|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
89141347|NCT05373485|Placebo Comparator|Placebo Group, low dose, 60 year-old and above|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
89141348|NCT05373485|Placebo Comparator|Placebo Group, high dose, 18-59 year-old|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
89141349|NCT05373485|Placebo Comparator|Placebo Group, high dose, 60 year-old and above|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
89141350|NCT05373472|Experimental|Vaccine Group, low dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
89141351|NCT05373472|Experimental|Vaccine Group, low dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21
89141352|NCT05373472|Experimental|Vaccine Group, high dose, 18-59 year-old|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
89141353|NCT05373472|Experimental|Vaccine Group, high dose, 60 year-old and above|2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21
89141354|NCT05373472|Placebo Comparator|Placebo Group, low dose, 18-59 year-old|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
89141355|NCT05373472|Placebo Comparator|Placebo Group, low dose, 60 year-old and above|2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21
89141356|NCT05373472|Placebo Comparator|Placebo Group, high dose, 18-59 year-old|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
89141357|NCT05373472|Placebo Comparator|Placebo Group, high dose, 60 year-old and above|2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21
89141358|NCT05364866||Medical treatment group|Using class I or class III AAD to maintain sinus rhythm
89141359|NCT05364866||Cryoballoon ablation group|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
89141360|NCT05356702|Experimental|Brain Health Intervention|"Calculate eRADAR scores using EHR data to identify eligible individuals~Invite eligible individuals for brain health assessment visit~Enter results of brain health assessment visit into EHR~Provide summary of results and recommended next steps to the Primary Care Physician and participant"
89141361|NCT05356702|No Intervention|Usual care|Individuals who meet eligibility criteria will receive usual care.
89141362|NCT05344989|Active Comparator|APNmAb005 (5mg/kg) vs Placebo|Single Ascending Dose (SAD)
89141363|NCT05344989|Active Comparator|APNmAb005 (10 mg/kg) vs Placebo|Single Ascending Dose (SAD)
89141364|NCT05344989|Active Comparator|APNmAb005 (25 mg/kg) vs Placebo|Single Ascending Dose (SAD)
89141365|NCT05344989|Active Comparator|APNmAb005 (50 mg/kg) vs Placebo|Single Ascending Dose (SAD)
89141366|NCT05344989|Active Comparator|APNmAb005 (70 mg/kg) vs Placebo|Single Ascending Dose (SAD)
89141367|NCT05334368|Experimental|Depemokimab|All participants in this arm will receive depemokimab.
89141368|NCT05334368|Placebo Comparator|Placebo|All participants in this arm will receive placebo.
89141369|NCT05331378|Experimental|Test myopia control lenses|A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
89141370|NCT05331378|Other|Single vision lenses|A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
89141371|NCT05331027|Experimental|Desflurane Group|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
89141372|NCT05331027|Active Comparator|Sevoflurane Group|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
89141373|NCT05322005|Experimental|Arm A: augmentation to surgery|Patients will be surgically treated with partial meniscectomy combined with an intraarticular and intra-meniscal injection of polynucleotide gel, during an arthroscopic procedure. After 6 weeks the patients attend a second injection session, during an ambulatorial visit. At 8 weeks from the surgery the patients attend the third ambulatorial injection session
89141374|NCT05322005|Experimental|Arm B: conservative treatment|The patients are going to receive three injections session (polynucleotide gel) performed with a time interval of 2 weeks.
89141375|NCT05312125|Active Comparator|control group|Children in this group will take routine physiotherapy (stretching, strengthening) program during 6 weeks. 3 days/week.
89141376|NCT05312125|Active Comparator|intervention group|Children in this group will take routine physiotherapy (stretching, strengthening) program + backward downhill walking (10 minutes in a day) during 6 weeks. 3 days/week.
89141377|NCT05299242|Active Comparator|Arm A|Participants will receive 2 injections of adalimumab. First injection: 160mg in 3.2ml Second injection approximately 2-3 weeks later 80mg in 1.6ml
89141378|NCT05299242|Placebo Comparator|Arm B|Participants will receive 2 injections of placebo First injection: 3.2ml Second injection approximately 2-3 weeks later 1.6ml
89141379|NCT05292482|Experimental|pharmacopunture therapy|The physicians will choose the type and volume of pharmacopuncture according to participants' conditions and inject it at the proper acupoints they choose.
89141380|NCT05292482|Active Comparator|physical therapy|The physicians will choose the type and time of physical therapy according to participants' conditions.
89141381|NCT05282706|Experimental|Pain Symptoms Arm|Subjects who will receive physical or occupational therapy experiencing pain prior to therapy session.
89141382|NCT05282706|Experimental|Nausea Symptom Arm|Subjects who will receive physical or occupational therapy experiencing nausea prior to therapy session.
89141383|NCT05282706|Placebo Comparator|Placebo Group|Subjects who will receive physical or occupational therapy experiencing pain or nausea prior to therapy session.
89141384|NCT05282706|No Intervention|Standard of Care Group|Subjects who will receive physical or occupational therapy experiencing pain or nausea prior to therapy session that decline the option to use an aromatherapy patch.
89141385|NCT05282394|Experimental|Massage Intervention|Families will be instructed to provide parent-provided newborn abdominal massage three times per day through 5 days of life
89141386|NCT05282394|Other|Attention Control Intervention|Families will be provided with information about reading with baby.
89141387|NCT05267665|Experimental|BFI|Family members in this arm receive the 2-session BFI intervention.
89141388|NCT05267665|No Intervention|No BFI|Family members in this arm do not receive the BFI sessions
89141389|NCT05265312|Active Comparator|Intervention clinic|Patients with prediabetes seen for routine care at intervention clinic
89141390|NCT05265312|No Intervention|Control clinic|Patients with prediabetes seen for routine care at control clinic
89141391|NCT05250180|Experimental|Intervention|animal assisted therapy
89141392|NCT05250180|Active Comparator|Control|Treatment as usual
89141393|NCT05244733|Experimental|Social Engage (S-ENGAGE)|S-ENGAGE is a skills-based psychotherapy that focuses on helping patients engage in meaningful rewarding social activities. Subjects will receive 10 one-hour individual sessions of S-ENGAGE over 10 weeks.
89141394|NCT05244733|Placebo Comparator|The Healthy Lifestyles Education Program|The healthy lifestyles education program consists of a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources. Study staff meet with participants once, individually, for 1 hour to review each section and answer questions participants might have.
89141395|NCT05243511|Active Comparator|Digital Acceptance and Commitment Therapy (ACT) Arm|
89141396|NCT05243511|Active Comparator|Digital Symptom Tracker|
89141397|NCT05231213|Experimental|Active tDCS|Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
89141398|NCT05231213|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
89141399|NCT05222984|Experimental|Treatment (navitoclax, venetoclax, decitabine)|Patients receive venetoclax PO QD and navitoclax PO QD on days 1-35, and decitabine IV over 1 hour on days 8-12 of cycle 1. Starting on cycle 2, patients receive venetoclax PO QD and navitoclax PO QD on days 1-28, and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89141400|NCT05215886||Surgery|Patients scheduled for or have already completed Weight Loss Surgery at UC Davis Medical Center
89141401|NCT05211037|Experimental|Kidney function assessment|
89141402|NCT05198063|Experimental|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
89141403|NCT05197309|Active Comparator|Women with anorexia nervosa|adult women with anorexia nervosa who have been recently restored to normal weight
89141404|NCT05197309|Active Comparator|Women with no history of eating disorders|adult women with no history of eating disorders
89141405|NCT05193162||Pancreatic ductal adenocarcinoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
89141406|NCT05193162||Chronic pancreatitis|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
89141407|NCT05193162||Pancreatic serous cystadenoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
89141408|NCT05193162||Pancreatic mucinous cystadenoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
89141409|NCT05193162||Intraductal papillary mucinous tumor|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
89141410|NCT05193162||Pancreatic neuroendocrine tumor|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
89141411|NCT05193162||Pancreatic acinar cell carcinoma|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
89141412|NCT05193162||Solid pseudopapillary tumor of pancreas|According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
89141413|NCT05193162||Blank paraffin section|
89141414|NCT05180981|Experimental|Breath task|Participants will breathe in specific patterns.
89141415|NCT05180981|Experimental|Transcutaneous vagal nerve stimulation|Participants will receive transcutaneous vagal nerve stimulation in specific patterns.
89141416|NCT05177848|Experimental|Exclusive cigarette smokers|Exclusive cigarette smokers will be recruited and will be exposed to all of the conditions described in the intervention section.
89141417|NCT05177848|Experimental|Dual cigarette/ nicotine vaping product users|Dual cigarette and nicotine vaping product users will be recruited and will be exposed to all of the conditions described in the intervention section.
89141418|NCT05169008|Experimental|Vaccine Group|1000 participants，500 children aged 6-12 years and 500 adolescents aged 13-17 years, Ad5-nCoV or Ad5-nCoV-IH, ≥90 days after two doses of CoronaVac. Intramuscular injection or nebulized inhalation.
89141419|NCT05166135||Acute Myeloid Leukemia|Patients ≥18 years old at diagnosis, with de novo AML diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for AML within the study period.
89141420|NCT05166135||Relapsed/Refractory Acute Lymphoid Leukemia|Patients ≥18 years old at diagnosis, with R/R ALL diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for R/R ALL within the study period.
89141421|NCT05139342|Active Comparator|PD patients|patients diagnosed with PD will be allocated to this arm
89141422|NCT05139342|Active Comparator|MSA patients|patients diagnosed with MSAwill be allocated to this arm
89141423|NCT05139342|Active Comparator|4RT patients|patients diagnosed with 4RT will be allocated to this arm
89141424|NCT05128669|Experimental|CPIP+ECS|"CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy (PaCT), elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.~ECS (Enhanced Caregiving Support) is described in other arm."
89141425|NCT05128669|Active Comparator|ECS only|"Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS."
89141426|NCT05108246|Experimental|Dual-Task Training|
89141427|NCT05108246|No Intervention|Control|
89141428|NCT04975906||Participants|All inpatient admissions with serum lactate, ketones and/or salicylates performed, and with urea, electrolytes and creatinine at the same time. The patients will be grouped into patients with organic (gap) acidosis (elevated serum lactate, ketones and/or salicylates) and patients with no organic acidosis.
89141429|NCT04932278|Active Comparator|Usual Care Group|Participants in this group will receive routine care for the management and treatment of concussions
89141430|NCT04932278|Experimental|OMT Group|Participants who are randomized into the OMT group will receive OMT in addition to their usual care.
89141431|NCT04913753|Experimental|No systematic CBEU|Patients will not have bacterial culture performed before double J removal.
89141432|NCT04913753|Active Comparator|Systematic CBEU|Patients will have a systematic urine culture performed before double J removal.
89141433|NCT04902365|Active Comparator|Patients group 1|This group will regulate a brain region by real-time functional magnetic resonance imaging that is centrally involved in the visual snow syndrome
89141434|NCT04902365|Placebo Comparator|Patients group 2|This group will regulate a brain region by real-time functional magnetic resonance imaging that is not centrally involved in the visual snow syndrome
89141435|NCT04888494|Experimental|Hippocampus-stimulation|Active high-frequency rTMS (20 Hz pulse trains)
89141436|NCT04888494|Experimental|Sham-stimulation|Sham rTMS
89141437|NCT04880070|Experimental|Shockwave Device|The Shockwave device will be used on multiple areas of the body for the purpose of treating connective tissue.
89141438|NCT04869319||MyChart message|MyChart message subjects with high A1C blood tests to help manage their diabetes and prevent some of the complications caused by high sugars. The message recommends that they schedule a visit with their doctor who can recheck the blood test and help get their diabetes under control.
89141439|NCT04869319||No MyChart message|No message
89141440|NCT04868474|Active Comparator|Usual care training|A refresher training course will be the equivalent of 'enhanced' usual care. Enhanced because the course will likely augment short-term knowledge of smoking cessation treatments, and participation in the study could trigger more discussions about smoking cessation than routine practice. However, it will be impossible to have any blinding between groups without at least some training.
89141441|NCT04868474|Experimental|Intervention training|The training course and decision aid aim to make treatment of tobacco use the default choice
89141442|NCT04867681|Experimental|Administration of a short psycho-education programme|
89141443|NCT04867681|No Intervention|Control group|
89141444|NCT04807205|Experimental|Elite IQ Laser|The Elite IQ will be used on multiple areas of the body such as, but not limited to, the face, legs, and arms.
89141445|NCT04806100|Experimental|Compliant, NoCDO, Stiff|Participants will be tested while wearing a moderate stiffness device (Compliant), then while wearing no brace (NoCDO), then while wearing a stiff device (Stiff).
89141446|NCT04806100|Experimental|Compliant, Stiff, NoCDO|Participants will be tested while wearing a moderate stiffness device (Compliant), then while wearing a stiff device (Stiff), then while wearing no brace (NoCDO).
89141447|NCT04806100|Experimental|NoCDO, Compliant, Stiff|Participants will be tested while wearing no brace (NoCDO), then a moderate stiffness device (Compliant), then while wearing a stiff device (Stiff).
89141448|NCT04806100|Experimental|NoCDO, Stiff, Compliant|Participants will be tested while wearing no brace (NoCDO), then while wearing a stiff device (Stiff), then while wearing a moderate stiffness device (Compliant).
89141449|NCT04806100|Experimental|Stiff, Compliant, NoCDO|Participants will be tested while wearing a stiff device (Stiff), then while wearing a moderate stiffness device (Compliant), then while wearing no brace (NoCDO).
89141450|NCT04806100|Experimental|Stiff, NoCDO, Compliant|Participants will be tested while wearing a stiff device (Stiff), then while wearing no brace (NoCDO), then while wearing a moderate stiffness device (Compliant).
89141451|NCT04785794|Experimental|M2SR dose, 50-64 years of age|Intranasal M2SR vaccine followed by standard, licensed IIV
89141452|NCT04785794|Placebo Comparator|Placebo dose, 50-64 years of age|Intranasal physiological saline followed by standard, licensed IIV
89141453|NCT04785794|Experimental|M2SR dose, 65-85 years of age|Intranasal M2SR vaccine followed by licensed IIV recommended for people 65 years and older
89141454|NCT04785794|Placebo Comparator|Placebo dose, 65-85 years of age|Intranasal physiological saline followed by licensed IIV recommended for people 65 years and older
89141455|NCT04782895|Experimental|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) group|Subjects would receive 3 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .
89141456|NCT04782895|Active Comparator|Gardasil®9 group|Subjects would receive 3 doses of 270μg/0.5ml Gardasil®9 .
89141457|NCT04773782|Experimental|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
89141458|NCT04767789|Experimental|NZ-GHMH-01|Dietary supplement in shape of capsule to be taken once per day in the evening.
89141459|NCT04767789|Placebo Comparator|Placebo|The placebo is in shape of capsule to be taken once per day in the evening and in which only the active ingredients are not present.
89141460|NCT04757194|Experimental|Intervention|Calculation of risk assessment score by machine learning algorithm and display of risk assessment information to dispatch nurses. Staff encouraged but not required to comply with suggested ranking.
89141461|NCT04757194|No Intervention|Control|Ambulance dispatch per standard of care
89141462|NCT04730791||Chronic Pain Patients|Adult patients 18-65 years, with chronic pain lasting for 3 or more months, with a pain intensity of at least 3 on a 0-10 numerical pain rating scale on most days.
89141463|NCT04730791||Control Group|Free pain participants
89141464|NCT04727554|Experimental|Part 1a: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
89141465|NCT04727554|Experimental|Part 1b: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
89141466|NCT04727554|Experimental|Part 1c: Dose Exploration|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404.
89141467|NCT04727554|Experimental|Part 2: Dose Expansion|Participants will be administered with the MTD or RP2D of AMG 994 identified in the dose escalation part of the study, in combination with AMG 404.
89141468|NCT04707235||Sickle cell disease patients treated with Siklos|
89141469|NCT04706234||Multiple System Atrophy|Patients diagnosed will probable or possible MSA according to the 2nd criteria for the diagnosis of MSA (Gilman 2008) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
89141470|NCT04706234||progressive supranuclear palsy|Patients diagnosed will probable or possible Progressive Supranuclear Palsy or (PSP) related 4repeat tauopathies according to the Movement Disorders Society diagnostic criteria (Höglinger 2017) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
89141471|NCT04706234||Parkinson Disease|Patients diagnosed will Parkinson's disease according to the Movement Disorders Society diagnostic criteria (Postuma 2015) that received laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).
89141472|NCT04624568|Experimental|Papilocare group|"Papilocare® for 6 months according to the following schedule:~1 self-applying single dose per day for 21 days over 28 during the first month, then 1 day over 2 during the following 5 months, with a 7-day break during the menstrual period. (This break must be respected even in menopausal women or women undergoing artificial amenorrhea (amenorrhea induced by certain contraceptives: implant, hormonal IUD, micro-progestogen)."
89141473|NCT04624568|No Intervention|Control group|No treatment for 12 months. Smear and HPV test will be perform by all patients at 6 and 12 months
89141474|NCT04590872|Experimental|Autologous Tolerogenic Dendritic Cell with Proinsulin Peptide (PIpepTolDC)|After completion of leukapheresis, patients receive a prime dose of PIpepTolDC intradermally (ID) on Day 0, followed by a boost dose of PIpepTolDC ID on Day 28.
89141475|NCT04584099|Experimental|Biopsy Removed Post Tx|All subjects had one radiofrequency treatment before scheduled biopsy or abdominoplasty on tissue to be removed during abdominoplasty immediately post treatment, 10 days post treatment, 20 days post treatment, and/or 30 days post treatment.
89141476|NCT04579445||TAVI patients|Consecutive, severe aortic stenosis patients undergoing transcatheter aortic valve implantation (TAVI) (there will be a retrospective part: documentation of 30 patients who underwent transfemoral TAVI; and a prospective part enrolling 50 patients undergoing transfemoral TAVI)
89141479|NCT04549142||Pregnant women- high level pollution|Exposed to high levels of pollution (PM2.5)
89141480|NCT04549142||Pregnant women- low level pollution|Exposed to low levels of pollution (PM2.5)
89141481|NCT04549142||Non-pregnant women-high level pollution|Exposed to high levels of pollution (PM2.5)
89141482|NCT04549142||Non-pregnant women-low level pollution|exposed to low levels of pollution (PM2.5)
89141483|NCT04537156|Experimental|HPV vaccine (6,11,16,18,31,33,45,52,58 Types)|Participants in this arm would receive 270μg/0.5ml HPV vaccines (6,11,16,18,31,33,45,52,58 Types).
89141484|NCT04537156|Active Comparator|HPV vaccine (16,18 Types)|Participants in this arm would receive 60μg/0.5ml HPV vaccines (16,18 Types).
89141485|NCT04526990|Experimental|Experimental group|20000 participants, Ad5-nCoV , single dose, Intramuscular administration
89141486|NCT04526990|Placebo Comparator|Placebo group|20000 participants, placebo, single dose, Intramuscular administration
89141487|NCT04522102|Experimental|Intervention|Start antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation).
89141488|NCT04522102|No Intervention|Comparator|Avoid antiplatelet therapy.
89141489|NCT04512040|Experimental|Yoga Dyads AD patients and Caregivers|Initially Yoga will be delivered in 1-on-1 format between the yoga therapist and the AD/caregiver dyad. Five outpatient adults, with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver, will receive at-home teleyoga classes via video conferencing. Later, yoga will be delivered in a group format. Ten outpatient adults with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver will receive group at-home teleyoga classes via video conferencing.
89141490|NCT04465318|Experimental|E-cigarettes (EC)|EC + Counseling
89141491|NCT04465318|Active Comparator|Nicotine Replacement Therapy (NRT)|NRT + Counseling
89141492|NCT04464317||Patient who has had cardiovascular surgery|Undergone an elective, urgent, and/or emergent cardiovascular surgery via endovascular or open (sternotomy and/or extended thoracotomy) technique at the University of Florida Health.
89141493|NCT04462523|Experimental|Group 1 Pre-surgery Dextenza insert|Ten patients will receive the dexamethasone intracanalicular insert pre-operatively (1 week to 1 days prior to vitreo-retinal surgery). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
89141494|NCT04462523|Experimental|Group 2 Surgery Day Dextenza insert|Ten patients will receive dexamethasone intracanalicular insert on the day of surgery. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
89141495|NCT04462523|Experimental|Group 3 Post op Day 1 Dextenza insert|Ten patients will receive DEXTENZA insert Day 1 post-operatively. All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops
89141496|NCT04462523|Active Comparator|Group 4 Topical steroid|Ten patients will be prescribed standard of care ophthalmic drops, Prednisolone Acetate, and no dexamethasone insert (control group). All patients no matter what cohort will receive Gentamicin, antibiotic ophthalmic drops.
89141497|NCT04437108|Active Comparator|Li-SWT|Patients will be treated by 8 sessions of Li-SWT with one week interval. This group is subdivided into 3 subgroups according to the approach through which Li-SWT is applied; suprapubic, perineal and combined approaches
89141498|NCT04437108|Sham Comparator|Sham treatment|Patients will be treated by 8 sessions of sham treatment with one week interval, applied through suprapubic and perineal approaches.
89141499|NCT04437108|Active Comparator|antimuscarinics|Patients will be treated by solifenacin 10 mg once daily for 6 months.
89141500|NCT04420949|Experimental|Healthy|Healthy adults with visually-induced dizziness with undergo the testing and treatment.
89141501|NCT04420949|Experimental|Vestibular-impaired|Adults with unilateral or bilateral, peripheral vestibular loss who also have visually-induced dizziness with undergo the testing and treatment.
89141502|NCT04406792|Experimental|DPP+doula divas|Enrolled participants will have access to an online DPP with other Black post-partum mothers who have had GDM. The teams will be led by doula divas trained in aspects of motivational interviewing and trained on the Healthiby platform.
89141503|NCT04406792|Active Comparator|DPP only|Online DPP only support without doula as team lead. The participants will be in groups with a diverse group of patients that are non-mothers but who are at risk of type 2 diabetes.
89141504|NCT04396691||Instructors group|Group of flight instructors at the reactor school.
89141505|NCT04396691||Students group|Group of students at the reactor school.
89141506|NCT04396002||Primary Open-Angle Glaucoma|Patients diagnosed with primary open-angle glaucoma.
89141507|NCT04396002||Control|Participants with healthy eyes.
89141508|NCT04395079|Experimental|Arm I (durvalumab, brachytherapy)|Patients receive durvalumab IV on day 1. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
89141509|NCT04395079|Experimental|Arm II (tremelimumab, brachytherapy)|Patients receive tremelimumab IV on day 1. Treatment repeats every 28 days for 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo brachytherapy on day 8. Treatment repeats every 21 days for 3 fractions in the absence of disease progression or unacceptable toxicity.
89141510|NCT04391309|Experimental|anti-CD14 + SOC|"Anti-CD14: Anticipated 150 participants randomized to 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 intravenously.~Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness."
89141511|NCT04391309|Placebo Comparator|Placebo + SOC|"Anticipated 150 participants randomized to Placebo diluent on Days 1-4 intravenously.~Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness."
89141512|NCT04385745|Experimental|Elastic Stable Intramedullary Nailing|BIN (biodegradable intramedullary nailing) method will be compared with the ESIN (elastic stable intramedullary nailing)
89141513|NCT04385745|Experimental|Biodegradable intramedullary nailing|BIN method will be compared with the ESIN.
89141514|NCT04362592|Experimental|Percutaneous Technique|"The percutaneous technique uses endoscopic scopes through the maternal skin and uterus to perform the surgery. A variation of the percutaneous technique is the mini-laparotomy technique, which uses an endoscopic scope through an incision on the abdomen, smaller than a laparotomy (mini-laparotomy), and smaller endoscopic scopes through the maternal skin and uterus to perform the surgery."
89141515|NCT04362592|Experimental|Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique consists of performing a laparotomy (incision into the abdominal cavity), exteriorizing the uterus, and using endoscopic scopes through the uterus to perform the correction.
89141516|NCT04356690|Experimental|Cohort 1 - Etoposide|Participants that are on ventilation Etoposide 150 mg/m2 daily days 1 and 4
89141517|NCT04356690|No Intervention|Cohort 1 - Control|Standard of care therapy in participants that are on ventilation
89141518|NCT04352205|Experimental|Treatment (daratumumab-based treatment)|Patients receive daratumumab IV weekly of cycles 1-3 and on day 1 only of cycle 4, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV or PO on days 1-4 of cycle 1 and on day 1 of cycles 2-4 and PO on days 8 and 15 of all cycles. Beginning cycle 2, patients may also receive lenalidomide PO daily on days 1-14 or thalidomide PO QD on days 1-21. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89141519|NCT04339140|Experimental|Zafirlukast|Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.
89141520|NCT04337827|Experimental|Rituximab and Acalabrutinib|Participants will receive treatment of Rituximab weekly for 4 weeks, and Acalabrutinib twice daily for 4 weeks. Response assessment via diagnostic CT scans will dictate further treatment decisions.
89141521|NCT04251117|Experimental|GNOS-PV02 + INO-9012 + Pembrolizumab|"First line therapy with standard of care tyrosine kinase inhibitors (TKI) during which patient-specific GNOS-PV02 will be manufactured.~GNOS-PV02 + INO-9012 + Pembrolizumab will be administered upon disease progression or intolerance to TKI."
89141522|NCT04219774|Experimental|Endovascular arm|Subjects meet all inclusion criteria and were randomized to intervention
89141523|NCT04219774|Active Comparator|Medical arm|Subjects meet all inclusion criteria and were randomized to best medical management
89141524|NCT04219774|Active Comparator|Non-Randomized Arm|Subject meets all inclusion criteria EXCEPT abnormal CTP. Subjects are not randomized and are eligible for only best medical management
88805957|NCT01790906|Active Comparator|RSD+Conventional therapy|We will recruit 100 randomised CHF patients who meet the inclusion criteria.First undergo renal artery angiography procedure to confirm anatomy.If renal artery meet the inclusion criteria,give the renal sympathetic denervation.At the same time, we will use conventional therapy to protect cardiac function.then we will conduct a clinic follow-up and a telephone follow-up.
89141525|NCT04218838|Active Comparator|CornerLoc SI Joint Stabilization Group|Patient will receive the CornerLoc minimally invasive SI Joint Stabilization procedure. This procedure will be performed in an outpatient surgery center under local sedation or general anesthesia, and normally takes around 45 minutes. During the procedure, the physician will make two small incisions in the patient's lower back to access the SI joint, and place four small cadaveric bone grafts into the SI joint to help stabilize the SI joint.
89141526|NCT04218838|Active Comparator|SI Joint Steroid Injections Group|Patient will receive an injection of steroid medication directly into their SI joint. The area around the SI joint will be numbed with an injection of local anesthetic and then ultrasound guidance will be used to guide the needle of steroid medication directly into the SI joint. This procedure will be performed in the physician's office or an outpatient surgery center, and normally takes around 30 minutes.
89141527|NCT04202965|Experimental|PTG-300|PTG-300 Subcutaneous
89141528|NCT04195139|Experimental|Nivolumab and Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive Nivolumab with concurrent adjuvant temozolomide treatment
89141529|NCT04195139|Active Comparator|Temozolomide|After radiotherapy and 4 week break, participants who are assigned to this arm will receive the standard treatment of adjuvant temozolomide treatment
89141530|NCT04193891||Diet Group|Participants choosing to newly initiate the modified Atkins diet, a high fat low carb diet, for improved epilepsy control.
89141531|NCT04193891||Control Group|Participants not choosing to initiate dietary therapy for epilepsy. The participants in the control group will continue with the treatment regimen they have chosen together with their physician.
89141532|NCT04174352|Experimental|Tamoxifen Dose Levels|"Three participants will be enrolled to each dose level of oral tamoxifen (n = 12)~Dose Level 1 = 20 mg daily Dose Level 2 = 80 mg daily Dose Level 3 = 160 mg daily Dose Level 4 = 200 mg daily~Tamoxifen should be started within 14 days of the FES-PET/CT scan, at least 24 hours after FES injection. Participants will continue tamoxifen therapy until there is radiologic or clinical evidence of progressive disease or drug intolerance."
89141533|NCT04151498|Experimental|Intervention Group|This group will complete an HIV health reengagement intervention on a mobile van, in addition to a pre- and post-intervention qualitative interview.
89141534|NCT04151498|Other|Usual Care Reengagement Group|This group will complete a qualitative interview about barriers and facilitators to HIV care.
89141535|NCT04151498|No Intervention|Non-enrolling Group|This group will not be enrolled in the intervention, and will include de-identified data from clinic patients referred to bridge counselors during the study time period that do not participate in the intervention.
89141536|NCT04141150|Experimental|[18F]APN-1607|Subjects will undergo PET imaging using [18F]APN-1607.
89141537|NCT04136756|Experimental|Dose Escalation|"Evaluation of NKTR-255 as:~Monotherapy~In combination with daratumumab~In combination with rituximab~This phase will help to determine the RP2D of NKTR-255"
89141538|NCT04136756|Experimental|Dose Expansion Cohort A|Evaluation of RP2D of NKTR-255 as monotherapy in patients with NHL relapsed after CAR-T
89141539|NCT04136756|Experimental|Dose Expansion Cohort B|Evaluation of RP2D of NKTR-255 as monotherapy and in combination with SC daratumumab in patients with R/R MM
88805958|NCT01790906|Placebo Comparator|Conventional therapy|We also will recruit 100 randomised CHF patients who meet the inclusion criteria.there are no significant differences in age,gender,race,past medical history,personal history and so on between the two groups.In this group we will use therapy just like the RSD+Conventional therapy group.we will conduct a clinic and a telephone follow-up.
89141540|NCT04136756|Experimental|Dose Expansion Cohort C|Evaluation of RP2D of NKTR-255 as monotherapy and in combination with rituximab in patients with R/R iNHL
89141541|NCT04098419|Experimental|Williams Implementation|
89141542|NCT04098419|Experimental|Pittsburg Implementation|
89141543|NCT04092647|Experimental|ashwagandha|Ashwagandha
89141544|NCT04092647|Placebo Comparator|placebo|Placebo
89141545|NCT04084730|Experimental|Participants with Breast Cancer|Participants will have unicentric pathological stage I invasive ductal breast cancer or Grade 1 or 2 DCIS measuring <3cm in longest diameter on pathology and/or mammogram that is histologically confirmed at MSKCC.
89141546|NCT04078672|Experimental|AMD|NOTAL-OCT V3.0 scan
89141547|NCT04056624|Experimental|Low dose|1 x 6 ounces of carotenoid-containing juice (6 mg carotenoids/6 oz)
89141548|NCT04056624|Experimental|High dose|2 x 6 ounces of carotenoid-containing juice (12 mg carotenoids/12 oz)
89141549|NCT04056624|Placebo Comparator|Placebo|12 ounces of apple juice (negligible carotenoids 0.06 mg/12 oz)
89141551|NCT04015609|Experimental|Meaning Centered Psychotherapy for Latinos (MCP-L)|
89141552|NCT04015609|Active Comparator|Control|
89141553|NCT04013984|Experimental|Accupuncture|"Acupuncture twice a week during the preceding cycle and the ovarian stimulation by GnRH agonist stopped protocol."
89141554|NCT04013984|No Intervention|Non-accupuncture|"Ovarian stimulation by GnRH agonist stopped protocol without intervention."
89141555|NCT04007276|Experimental|Lumify Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
89141556|NCT04007276|Sham Comparator|Control Arm|In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
89141557|NCT03985098|Experimental|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
89141558|NCT03985098|No Intervention|Control|usual care
89141559|NCT03901833|Experimental|Telemedicine Support|Weekly telemedicine breastfeeding support visits for four weeks, delivered via telemedicine
89141560|NCT03901833|Placebo Comparator|Control|Standard of care
89141561|NCT03900715|Experimental|Luspatercept Administration|Luspatercept will be administered as a subcutaneous injection every 3 week (21 days; Q3W), at an initial dose level of 1.0 mg/kg. Doses may be titrated up starting at dosing visit Week 7 Day 1 (W7D1)
89141562|NCT03870763|Experimental|Dimethyl Fumarate 240 mg|Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).
89141563|NCT03870763|Experimental|Peginterferon Beta-1a 125 µg|Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).
89141564|NCT03870763|Placebo Comparator|Placebo|Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)
89141565|NCT03862911|Active Comparator|Standard of Care Treatment (Arm 1)|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
89141566|NCT03862911|Experimental|Stereotactic Arm (Arm 2)|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
89141567|NCT03853954|Experimental|Methoxyflurane|Dosage form: inhalation Dosage: 3 mL methoxyflurane per inhaler, to be self-administered Frequency: maximum one inhaler (3 mL) per patient Duration: <15 minutes
89141568|NCT03822572|Experimental|A - endurance exercise|All patients receive a pulse-controlled endurance exercise program based on the study results by O'Donovan. The individual pulse-controlled endurance exercise should be performed 3 times a week. On the basis of age, weight, sex and body fat the normal weight will be calculated. The kilocalories (kcal), which correspond to the metabolic equivalent task (MET) hour per week, will be calculated after age and gender adjustment of the normal weight. The endurance exercise will be increased gradually until reaching 18 MET-hours/wk during the year of endurance exercise. Patients in arm A can perform different types of endurance exercise (bicycling, cross walking, jogging, walking, nordic walking, cross country skiing)
89141569|NCT03822572|Other|B - control arm|Patients in this arm should maintain their habitual physical activity pattern as before the diagnoses of colorectal cancer.
89141570|NCT03806452|Experimental|Hydroxycarbamide|"Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
89141571|NCT03806452|Placebo Comparator|Placebo|"Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
89141572|NCT03731260|Experimental|(Part 1) Avapritinib Dose 1 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
89141573|NCT03731260|Experimental|(Part 1) Avapritinib Dose 2 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
89141574|NCT03731260|Experimental|(Part 1) Avapritinib Dose 3 + BSC|Avapritinib will be administered orally in continuous 28-day cycles
89141575|NCT03731260|Placebo Comparator|(Part 1) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
89141576|NCT03731260|Experimental|(Part 2) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
89141577|NCT03731260|Placebo Comparator|(Part 2) Placebo + BSC|Placebo will be administered orally in continuous 28-day cycles
89141578|NCT03731260|Experimental|(Part 3) Avapritinib RP2D + BSC|Avapritinib will be administered orally in continuous 28-day cycles
89141579|NCT03728556|Experimental|CS1001monoclonal antibody|
89141580|NCT03728556|Placebo Comparator|CS1001 Placebo|
89141581|NCT03715894||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 aortic transcatheter valve Implantation, who are with a high risk for PPI
89141582|NCT03694015|Active Comparator|SUPR (Arm 1)|"Planning according to local protocols. No more than 2 fields; no beam modifying devices, other than multileaf collimators (MLCs). Alternate weighting of beams allowed (ie. 1:2 AP:PA). Review of dosimetry not required, if performed as per institutional standard.~Minimum of kV image matching on unit daily."
89141583|NCT03694015|Active Comparator|VMAT rapid (Arm 2)|"Contouring: GTV based on available imaging (CT sim scan alone-no special imaging), expect to be between 1.5cm and 20cm clinically or from imaging. CTV-optional in all scenarios. If using CTV=GTV +0.5 to 0.7cm adjust to anatomy as follows:~If only bone involved: recommend not to expand past bone; but a 0.5-0.7cm CTV expansion outside of bone into muscle or soft tissue is allowed at RO discretion~If bone and soft tissue involved: 0.5 to 0.7cm CTV expansion is optional, allowed at RO discretion~If spinal metastases: CTV is optional. If used can include whole vertebral body at RO discretion PTV=CTV or GTV+(1 to 1.5)cm at RO discretion. PTV_eval=PTV cropped 0.5cm below skin. OARs: max 2 OARs permitted for VMAT arm. OAR constraints are at RO discretion. If lung/kidneys are within 5cm of PTV, absence of constraints for contours should be noted in treatment plans or dose constraint sheet prior to planning. PTV can be compromised for OAR at RO's discretion. Kidneys considered 1 organ"
89141584|NCT03682042|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
89141585|NCT03682042|No Intervention|Early Cord Clamping|The umbilical cord is clamped immediately after the delivery (within 60 seconds).
89141586|NCT03647501|Active Comparator|3D-printed titanium cage|Subjects enrolled in this arm will have the Nexxt Spine Nexxt MatrixxTM 3D-printed titanium cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
89141587|NCT03647501|Active Comparator|Poly-ether-ether-ketone (PEEK) cage|Subjects enrolled in this arm will have the HonourTM poly-ether-ether-ketone (PEEK) cage (interbody cage) implanted at each level of 1 or 2-level lumbar arthrodesis procedures. All constructs will be supplemented with a pedicle screw system (Depuy Synthes Expedium) cleared for lumbar spinal fusion.
89141588|NCT03634228|Experimental|Phase I (low dose cytarabine, MDM2 inhibitor DS-3032b)|Patients receive low dose cytarabine SC BID on days 1-10 and milademetan tosylate PO QD on days 8-14, 8-21, or 5-7 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88805959|NCT02186795||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.
89141589|NCT03634228|Experimental|Phase II (low dose cytarabine, MDM2 inhibitor DS-3032b)|Patients receive low dose cytarabine SC BID on days 1-10, milademetan tosylate PO QD on days 8-14, 8-21, or 5-7 and 15-17, and venetoclax PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89141590|NCT03617783|Active Comparator|Prebiotin|
89141591|NCT03617783|Placebo Comparator|Placebo|
89141592|NCT03612973|Active Comparator|non cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
89141593|NCT03612973|Active Comparator|cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~Fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
89141594|NCT03611972|Experimental|Sugar-sweetened beverage (SSB)|SSB provided at 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 2 weeks
89141595|NCT03603223|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
89141596|NCT03587142|Active Comparator|Buspirone|Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks
89141597|NCT03587142|Placebo Comparator|Placebo|Placebo capsule orally three times daily, 30 minutes before each meal, for 4-weeks; manufactured to look identical to buspirone capsule
89141598|NCT03576924|Active Comparator|MICT|Continuous exercise for 30 minutes per session at 60-70% of heart rate max for five times per week, consistent with physical activity guidelines that advocate 150 minutes per week of moderate activity.
89141599|NCT03576924|Active Comparator|HIIT|Five repeated vigorous intervals of 1-min duration at 80-90% of heart rate max interspersed with 1-min recovery periods; 3-min warm-up and 2-min cool-down, making the total session duration 15 minutes for five times/week, equated to match the guidelines of 75 min of vigorous exercise per week.
89141600|NCT03576924|Experimental|CHOICE|Participants will be introduced to HIIT and MICT during sessions 1 and 2 of the 4-week intervention in a counterbalanced randomized order, and will thereafter self-select one of the two exercise types for remaining sessions. Exercise will be matched to the parallel imposed conditions.
89141601|NCT03532139|Experimental|Enoxaparin|-Enoxaparin is administered subcutaneous daily
89141602|NCT03532139|Experimental|Enoxaparin + Rosuvastatin|"Enoxaparin is administered subcutaneous daily.~Rosuvastatin is administered daily orally starting on day 15"
89141603|NCT03532139|Experimental|Thromboprophylaxis|-Thromboprophylaxis is administered per clinician discretion
89141604|NCT03527277|Experimental|Naturally-sweetened orange juice|Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
89141605|NCT03527277|Active Comparator|Sugar-sweetened beverage|Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
89141606|NCT03524352|Experimental|fecal microbiota|
89141607|NCT03524352|Placebo Comparator|placebo|
89141608|NCT03509584|Experimental|part #1a|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
89141609|NCT03509584|Experimental|part #1b|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
89141610|NCT03509584|Experimental|part #2a|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
89141611|NCT03509584|Experimental|part #2b|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
89141612|NCT03494049|Active Comparator|Veil sparring HoLEP|"Early mucosal incision lateral to the Veru followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
89141613|NCT03494049|Active Comparator|Standard HoLEP|Standard HoLEP TECHNIQUE as described by Elhilali et al 2010
89141614|NCT03493854|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor [G-CSF] support as needed according to local guidelines) followed by paclitaxel Q1W for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
89141615|NCT03493854|Experimental|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
89141616|NCT03459456||OCD subjects|"Subjects meeting inclusion/exclusion criteria with OCD will be exposed to the following:~Provocation OC task (Provoc)~Trier Social Stress Test (TSST)~Exposure provocation task"
89141617|NCT03459456||Control subjects|"Subjects meeting inclusion/exclusion criteria without OCD (age and gender matched with OCD subjects) will be exposed to the following:~Provocation OC task (Provoc)~Trier Social Stress Test (TSST)~Exposure provocation task"
89141618|NCT03385577|Experimental|Yoga Intervention|"The intervention, Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer, is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment."
89141619|NCT03384277|Experimental|Steroid+Rituximab|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.
89141620|NCT03384277|Active Comparator|Steroid +Cyclophosphamide|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
89141621|NCT03382054||Older robust surgical patients|Male and female patients with age 65 years and above scheduled for surgery, which are robust according to Fried's Modified Frailty Score.
89141622|NCT03382054||Older pre-frail surgical patients|Male and female patients with age 65 years and above scheduled for surgery, which are pre-frail according to Fried's Modified Frailty Score.
89141623|NCT03382054||Older frail surgical patients|Male and female patients with age 65 years and above scheduled for surgery, which are frail according to Fried's Modified Frailty Score.
89141624|NCT03370367|Experimental|Arm A|13-cis retinoic acid will be dispensed in 3.75 mg and 5 mg gelatin capsules. Take 2 capsules once a day for up to 2 years.
89141625|NCT03370367|Placebo Comparator|Arm B|Take 2 placebo pills once a day for up to 2 years.
89141626|NCT03363243|Experimental|STOP Therapy Treatment group|Self-regulation Treatment for Opioid addiction and Pain (STOP) is a 12-week, rolling entry group therapy protocol that underwent initial development in a previous K23 study. Treatment consists of weekly 90-minute CBT+SR (Self Regulation) treatment with skill building exercises for co-morbid opioid addiction and pain. STOP will be provided in lieu of TAU (Treatment as Usual) group therapy.
89141627|NCT03363243|Active Comparator|Treatment as usual (TAU) group|Psychotherapy for Addiction in conjunction with medication assisted treatment. Standard community treatment for opioid addiction consists of 90-minute weekly rolling entry addiction treatment for 12 weeks to allow for the learning and rehearsal of skills designed to reduce relapse.
89141628|NCT03317457|Experimental|Durvalumab and Tremelimumab|"Cycles/courses 1-3:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks~Cycles/courses ≥4:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks"
89141629|NCT03317457|Active Comparator|Doxorubicin|Doxorubicin 75 mg/qm q3wks for 6 courses
89141630|NCT03313622||OCD group|"Day 1: Questionnaires/Assessments~Day 2: Tasks"
89141631|NCT03285750||Diabetic group|Patients with recently diagnosed type 2 diabetes
89141632|NCT03285750||Controls|Age- and BMI-matched normoglycemic subjects
89141633|NCT03267836|Experimental|Avelumab + Proton Therapy|"Avelumab will be started concurrently with proton therapy (up to 3 days before or after is permissible) and administered every 2 weeks for 3 months~Proton therapy 20 CGE (cobalt gray equivalent) will be given over 5 daily fractions of 4 CGE per day during weekdays~After 3 months of avelumab, patient will have a brain MRI evaluation, and radiological response will be assigned based on the iRANO criteria. Surgery will be performed as per routine clinical care~If the brain MRI after 3 months of avelumab shows complete response with no signs of residual tumor, no surgery will be indicated, and the patient may continue to take adjuvant avelumab for an additional 3 months.~After the patient has recovered from the surgery and if deemed medically eligible by the treating physician to receive additional immunotherapy, avelumab will be restarted and administered every 2 weeks for an additional 3 months"
89141634|NCT03197506|Experimental|Group 1 (pembrolizumab, surgery, temozolomide, radiation)|"NEOADJUVANT (CYCLE 1): Patients receive pembrolizumab IV over 30 minutes on day 1.~SURGERY (CYCLE 2): Patients undergo standard of care surgery within days 4-7.~CONCURRENT (CYCLE 3): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLE 4-8): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 1-5 every 28 days. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
89141635|NCT03197506|Experimental|Group 2 (pembrolizumab, temozolomide, radiation therapy )|"CONCURRENT (CYCLE 1): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLES 2-6): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 of cycles 2-5 and 1 and 22 of cycle 6 (up to a total of 17 doses). Patients also receive temozolomide PO daily on days 1-5, 29-33, and 57-61 of cycles 2 and 6, days 22-26 and 50-54 of cycle 3, days 15-19 and 43-47 of cycle 4, days 8-12 and 36-40 of cycle 5. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
89141636|NCT03188705|Experimental|Overall Cohort|Participants will receive clopidogrel treatment alone (300 mg loading dose followed by 75 mg/d for 6 days), followed by clopidogrel (75 mg) plus aspirin (324 mg) treatment on day 8.
89141637|NCT03032484|Experimental|Bevacizumab and TVB-2640|Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
89141638|NCT03032484|Experimental|Bevacizumab for Cycle 1, then Bevacizumab and TVB-2640|Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle, and then receive both Bevacizumab and TVB-2640 for the remainder of their participation in this study.
89141639|NCT03013946|Experimental|Arm A (Coaching)|Concomitant coaching (24 weeks) Pro-active TEAE (Treatment emergent adverse events) management Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
89141640|NCT03013946|No Intervention|Arm B (Control)|Re-activeTEAE management (SOC) Cancer therapy according to Standard of Care (SOC) QoL assessments/ primary endpoint FKSI-15
89141641|NCT03003546|Experimental|Treatment (AR160)|Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89141642|NCT02975349|Experimental|Placebo then Evobrutinib 25 mg QD|Participants who received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1 received Evobrutinib 25 milligram (mg) orally, once daily (QD) in blinded extension (BE) period from week 25 to week 48.
89141643|NCT02975349|Experimental|Evobrutinib 25 mg QD|Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
89141644|NCT02975349|Experimental|Evobrutinib 75 mg QD|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
89141645|NCT02975349|Experimental|Evobrutinib 75 mg BID|Participants received Evobrutinib 75 mg orally, twice daily (BID) up to Week 48 in active treatment period 1 and BE period.
89141646|NCT02975349|Active Comparator|Tecfidera|Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period.
89141647|NCT02975349|Placebo Comparator|Placebo|Participants received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1.
89141648|NCT03645681|Experimental|InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
89141649|NCT02955394|Placebo Comparator|Fulvestrant Without Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
89141650|NCT02955394|Experimental|Fulvestrant With Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC), plus160mg of Enzalutamide will be given daily.
89141651|NCT02882321|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759) Cohort 1|"IACS-010759 Starting dose: 0.5 mg~INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7."
89141652|NCT02882321|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759) Cohort 2|"IACS-010759 Starting dose: 1 mg~INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7."
89141653|NCT02882321|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759) Cohort 3|"IACS-010759 Starting dose: 2 mg~INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Treatment repeats every 21 days for subsequent courses for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of oxidative phosphorylation inhibitor IACS-010759 at the discretion of study doctor."
89141654|NCT02882321|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759) Cohort 4|"IACS-010759 Starting dose: 2.5 mg~INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Treatment repeats every 21 days for subsequent courses for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of oxidative phosphorylation inhibitor IACS-010759 at the discretion of study doctor."
89141655|NCT02768532|Experimental|Crohn's disease patients|The patients will receive vedolizumab in compliance with the marketing authorization regimen (300 mg at weeks 0, 2, 6 and then every 8 weeks) in Crohn's Disease patients in clinical failure or intolerant to anti-TNF (Tumor Necrosis Factor) drugs. In case of lack of clinical response at week 10 or loss of response in the follow-up, all patients will be optimized with vedolizumab 300 mg at week 10 (additional infusion) and every following 4 weeks in contrast with responder patients at week 10 who will not have vedolizumab infusion at this time-point but will receive the next vedolizumab infusion at week 14 and then every 8 weeks, as recommended.
89141656|NCT02765074|Experimental|Roactemra|subcutaneous tocilizumab
89141657|NCT02739776||A|Pt receiving standard Epidural block care for vaginal delivery
89141658|NCT02710851|Experimental|low dosage HPV Vaccine(1:1)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
89141659|NCT02710851|Experimental|low dosage HPV Vaccine(1:2)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
89141660|NCT02710851|Experimental|high dosage HPV Vaccine(1:1)|Participants in this arm would receive high dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
89141661|NCT02710851|Placebo Comparator|Hepatitis E vaccine,Hecolin®|Participants in this arm would receive Hepatitis E vaccine,Hecolin®
89141662|NCT02703207|Active Comparator|Positive airway pressure therapy|Control group patients will receive standard care with PAP- positive airway pressure.
89141663|NCT02703207|No Intervention|COPD|The COPD control group will be patients with moderate-to-severe COPD alone per the GOLD criteria.
89141664|NCT02703207|No Intervention|OSA and comorbid COPD|Eligible elderly (age >/=60yrs) Veterans with moderate to severe Overlap Syndrome.
89141665|NCT02675829|Experimental|Cohort 1: Lung cancers, HER2 mutant|
89141666|NCT02675829|Experimental|Cohort 2: Lung cancers, HER2 amplified|
89141667|NCT02675829|Experimental|Cohort 3: Colorectal cancers|
89141668|NCT02675829|Experimental|Cohort 4: Endometrial cancers|
89141669|NCT02675829|Experimental|Cohort 5: Salivary gland cancers|
89141670|NCT02675829|Experimental|Cohort 6: Other solid cancers|
89141671|NCT02645019||Cuffed ETT|Airway secured using a cuffed endotracheal tube.
89141672|NCT02645019||LMA 2|Airway secured using a size 2 laryngeal mask airway.
89141673|NCT02645019||LMA 2.5|Airway secured using a size 2.5 laryngeal mask airway.
89141674|NCT02645019||LMA 3|Airway secured using a size 3 laryngeal mask airway.
89141675|NCT02645019||LMA 4|Airway secured using a size 4 laryngeal mask airway.
89141676|NCT02609880|Experimental|Cognitive Behavioral Therapy|This group will receive Cognitive Behavioral Therapy to optimize sleep, pain, and mood in women with gynecologic cancers. The therapy will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
89141677|NCT02609880|Placebo Comparator|Psychoeducation|This group will receive Psychoeducation which is aimed at providing information, resources, and non-specific support related to adapting well to cancer. The education will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
89141678|NCT02554851|Placebo Comparator|placebo|This group will receive the standard medication and the placebo drug
89141679|NCT02554851|Experimental|recombinant human Epidermal Growth Fact|This group will receive the standard medication and the recombinant human Epidermal Growth Factor (HEBERPROT)
89141680|NCT02552628|Experimental|"Stimulation on"|"The deep brain stimulation is on"
89141681|NCT02552628|Sham Comparator|"Stimulation off"|"The deep brain stimulation is off"
89141682|NCT02530164|Active Comparator|real tDCS|
89141683|NCT02530164|Placebo Comparator|sham tDCS|
89141684|NCT02520141|Experimental|Treatment (ramucirumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89141685|NCT02513875|Experimental|vitamin D with diet and lifestyle|vitamin D supplementation along with diet and lifestyle modification was given
89141686|NCT02513875|Placebo Comparator|placebo with diet and lifestyle modification|placebo with diet and lifestyle modification was given
89141687|NCT02405351|Experimental|Training Group|Participants will be 10 individuals post stroke, living in the community. The intervention, adaptive working memory training, is a dual n-back working memory task. This training will take place once for 30 minutes per day, 5 days a week for 6 weeks, with one week dedicated for familiarizing participants to the program in the very beginning (i.e., Week 1).
89141688|NCT02365090|Active Comparator|patching (occlusion therapy)|2 hours per day patching of the sound eye (for strabismic, anisometropic, and combined mechanism amblyopia) or current patching regimen (deprivation amblyopia)
89141689|NCT02365090|Experimental|binocular games|1 hour per day (5 days per week) binocular game play
89141690|NCT02329847|Experimental|Cohort A1|Participants will receive ibrutinib 420 milligram (mg) capsule orally once daily and nivolumab intravenously as 3 milligram/kilogram (mg/kg) every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
89141691|NCT02329847|Experimental|Cohort A2|Participants will receive ibrutinib 560 mg capsule orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
89141692|NCT02329847|Experimental|Cohort B1|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
89141693|NCT02329847|Experimental|Cohort B2|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
89141694|NCT02329847|Experimental|Cohort B3|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
89141695|NCT02329847|Experimental|Cohort B4|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
89141696|NCT02314624|Experimental|WILLOW|Clinicians have access to WILLOW's dynamic progress monitoring, clinical decision support, rich visual displays of client outcomes, online training modules in ESTs, just-in-time training for guided real-time assistance in delivering ESTs, educational videos, and a client portal
89141697|NCT02314624|Active Comparator|Treatment-as-Usual|Usual care without access to WILLOW.
89141698|NCT02289781||Zirconia posterior crowns|Monolithic zirconia crowns which are polished and non-glazed
89141699|NCT02289781||Metal-Ceramic posterior crowns|Metal-supported glass-ceramic veneered crowns which are polished and non-glazed
89141700|NCT02287428|Experimental|Coh 1 (Original Cohort): Standard RT Followed by NeoVax|"After the screening procedures confirm participant eligible to participate in the research study (must be registered to within 6 weeks of resection):~~ 6 weeks of standard radiation therapy (RT) followed by an RT-recovery period.~During that time, participant NeoAntigen Vaccine-Preparation is created (process takes ~ 12 weeks)~After participant recovers from RT and vaccine is created, participant will re-screen to confirm participant is eligible to receive study vaccinations. Once registered, participant will proceed to receive study vaccinations:~- NeoAntigen Vaccine: NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases (~ 7 months total: 5 priming followed by 2 boost vaccine administrations)"
89141701|NCT02287428|Experimental|Coh 1a: Pembrolizumab w Std RT Followed by NeoVax + Pembro|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Starts within 2 weeks of start of RT, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
89141702|NCT02287428|Experimental|Coh 1b: Std RT Followed by NeoVax + Pembrolizumab|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
89141703|NCT02287428|Experimental|Coh 1c: Std RT (+ 1 dose Pembro) Followed by NeoVax & Pembo|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Single dose of pembrolizumab administered within 2 weeks of start of RT; re-starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years.~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
89141704|NCT02287428|Experimental|Coh 1d: Std RT+TMZ Followed by 6 Cyc TMZ + NeoVax + Pembro|"• RT: Standard RT (60Gy) + concurrent daily temozolomide (TMZ) over 6 weeks. Concurrent TMZ @ 75 mg/m2/day for 6 weeks.~Followed by:~6 cycles of Adjuvant temozolomide (TMZ): Starts 4-6 weeks after completion of RT. TMZ (150-200 mg/m2/day) on days 1-5 of each 28-day cycle for 6 cycles.~Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
89141705|NCT02255227|Active Comparator|1 dose Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
89141706|NCT02255227|Experimental|2 doses Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4
89141707|NCT02205294|No Intervention|Assessment Only|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
89141708|NCT02205294|Active Comparator|Assessment and Treatment|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas of tension will receive osteopathic treatment, using myofascial release techniques. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
89141709|NCT02192359|Experimental|Treatment (hCE1m6-NSCs and irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89141710|NCT02145143|Experimental|thyroid cancer patients|Patients will have lesional dosimetry with 124I PET/CT performed to quantify the baseline iodine avidity of index metastatic lesion(s). Patients will then receive vemurafenib (960 mg orally BID) for about 4 weeks, after which a second 124I PET/CT will be performed. For patients in whom the second 124I PET/CT demonstrates that > or = 2000 cGy can be achieved in at least one tumor with < 300 mCi of 131I, Thyrogen-stimulated standard dosimetry & therapeutic 131I will be performed/administered concurrently with vemurafenib. The drug will then be discontinued & tumor assessments will be conducted with serial radiologic scan(s) & thyroglobulins (scans will be performed at baseline, before 131I, 3-4 months following 131I, & 6 months after 131I). Patients whose tumors fail to demonstrate adequate iodine incorporation following vemurafenib to warrant 131I therapy, the study drug will be discontinued, a final tumor assessment will be performed, & the patient will be taken off the study.
89141711|NCT02122835|Other|heart failure|aerobic exercise training
89141712|NCT02122835|Other|heart failure plus type 2 diabetes|aerobic exercise training
89141713|NCT02122328|Active Comparator|Selective procedure|Selective laser photocoagulation of communicating vessels.
89141714|NCT02122328|Experimental|Sequential procedure|Sequential laser photocoagulation of communicating vessels
89141715|NCT02119468|Experimental|Treatment (3mg MLN9708)|Patients receive 3mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89141716|NCT02119468|Experimental|Treatment (4mg MLN9708)|Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89141717|NCT01976091|Experimental|Cohort 1A: SRP-9004 Low Dose (Single Limb Perfusion)|Non-ambulant participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to a single limb on Day 0.
89141718|NCT01976091|Experimental|Cohort 1B Low Dose (Bilateral Limb Perfusion)|Participants with LGMD2D will receive 1 low dose of SRP-9004 via ILI to both limbs on Day 0.
89141719|NCT01976091|Experimental|Cohort 2 High Dose (Bilateral Limb Perfusion)|Participants with LGMD2D will receive 1 high dose of SRP-9004 via ILI to both limbs on Day 0.
89141720|NCT01935921|Experimental|Treatment (cetuximab, IMRT, and ipilimumab)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Treatment with cetuximab repeats every 4 weeks for 2 courses. Beginning in week 2 of course 1, patients undergo concurrent IMRT 5 days per week for 7 weeks. Beginning in week 4 (day 1 of course 2) patients also receive ipilimumab IV over 90 minutes once every 21 days for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may undergo surgery after completion of therapy.
89141721|NCT01927731|Experimental|Arm I (cord blood transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.
89141722|NCT01927731|Experimental|Arm II (haploidentical donor stem cell transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.
89141723|NCT01729858||Metal-Ceramic|Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.
89141724|NCT01729858||Ceramic-Ceramic|Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.
89141725|NCT01725035||Fatty liver|
89141726|NCT01725035||Non Fatty liver|
89141727|NCT01670227|Experimental|PARENTCORPS|ParentCorps is a school-based, family-focused universal intervention designed to attenuate the multiple risks associated with urban poverty, on children's health and development
89141728|NCT01670227|Other|Control Condition|No intervention
89141729|NCT01552434|Experimental|Group I (temsirolimus, bevacizumab, cetuximab)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89141730|NCT01552434|Experimental|Group II (temsirolimus, bevacizumab, valproic acid)|Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89141731|NCT01552434|Experimental|Group III (temsirolimus, bevacizumab)|Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89141732|NCT01482455|Placebo Comparator|Clamp/Glycerol|"Glycerol infusion (glycerol in 0.9% saline provided by the pharmacy of the Vienna General Hospital, will be applied at a rate of 0.7 mg.kg-1.min-1) in order to match the lipid-induced rise in serum glycerol concentrations in the same experimental setting. 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
89141733|NCT01482455|Active Comparator|OGTT/Lipid|On study-day 1, four hours after start of a triglyceride/heparin infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
89141734|NCT01482455|Placebo Comparator|OGTT/Glycerol|On study-day 2, four hours after start of a glycerol infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
88805960|NCT02186795||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
89141735|NCT01482455|Active Comparator|Clamp/Lipid|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
89141736|NCT01419080||Peripheral Arterial Disease (PAD) patients|Patients with new onset or exacerbation of peripheral artery (PA) symptoms.
89141737|NCT01231100|Experimental|HCUE-guided care|Hand-carried ultrasound echocardiography
89141738|NCT01231100|No Intervention|Standard care|
89141739|NCT01230346|Experimental|Arm I|Patients receive a culturally-informed adapted motivational interviewing telephone call.
89141740|NCT01230346|Experimental|Arm II|Patients participate in a controlled condition comprising a health habits intervention group.
89141741|NCT01230346|Active Comparator|Arm III|Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
89141742|NCT01164228|Experimental|Arm A (Sunitinib + Gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 22, and 29 and oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
89141743|NCT01164228|Experimental|Arm B (Sunitinib)|Patients receive oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
89141744|NCT00554515|Experimental|HD IL2|Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.
89141745|NCT00160771||Joint Motion Analysis|Joint motion will be recorded for analysis.
89141746|NCT00049517|Experimental|Standard Daunorubicin Then Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
89141747|NCT00049517|Experimental|High-dose Daunorubicin Then Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
89141748|NCT00049517|Experimental|Standard Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
89141749|NCT00049517|Experimental|High-dose Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
89141750|NCT00049517|Active Comparator|Standard Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count > 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
88805961|NCT01147601|Active Comparator|Topical 0.5% Timolol|Half of the enrolled subjects (intervention group) will receive topical 0.5% Timolol.
88805962|NCT01147601|Placebo Comparator|Placebo|Aqueous placebo, 2-3 drops to cover the hemangioma, twice daily
89141751|NCT00049517|Experimental|High-dose Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.~Consolidation/Transplant:~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count > 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
89141752|NCT00028990|Active Comparator|Paclitaxel + Bevacizumab|
89141753|NCT00028990|Active Comparator|Paclitaxel|
89141754|NCT00002520|Experimental|Quit Smoking Intervention|Patients received advice and help to quit smoking. The intervention employed physician and patient resources that had already been developed and evaluated or pre-tested, including written materials, prescriptions for nicotine replacement, counseling, and follow-up contact.
89141755|NCT00002520|Active Comparator|Usual Care|"No special intervention after randomization. Usual care may or may not include advice or assistance to stop smoking. Physicians were reassured that usual care did not preclude quit smoking counseling."
89141756|NCT00609557|Experimental|A|All subjects receive placebo for the first two weeks and then duloxetine for the next 10 weeks, but they are blind to what they are receiving.
89141757|NCT02812082|Experimental|video web-based patient education application|This is a single-arm design. Development of the web-based application will occur over a 6 month period. Patient accrual will not occur until development of the program is complete. Controlled usability testing during the development/design process of the computer program will not be employed as we do not aim to assess the mechanics of patient use, but rather overall time spent interacting with the application in an uncontrolled environment. Following completion of the tool, patient accrual will occur over a six month time period in order to meet our target sample size of up to 50 participants. Participants will be directed to complete a pre-test questionnaire at the time of accrual and will have 3 months to use the program before being directed to complete the post-test questionnaire.
89141758|NCT04014673|Other|Patients with a PGRN gene mutation|Symptomatic patients with a PGRN gene mutation
89141759|NCT04014673|Other|Presymptomatic individuals|Asymptomatic 'At-risk' individuals with a PGRN gene mutation
89141760|NCT04014673|Other|healthy volunteers|'At-risk' individuals without a PGRN gene mutation
89141761|NCT02738190|Active Comparator|Albumin|5% Albumin to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and albumin to reach the standard volume administered to these patients (400 ml)
89141762|NCT02738190|Active Comparator|Fresh Frozen Plasma|Fresh Frozen Plasma to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and plasma to reach the standard volume administered to these patients (400 ml)
89141763|NCT02805140|Experimental|Virtual exercise and mobile apps|Participants randomized to the intervention arm will join a virtual group convenient for them. They will plan and participate in 8 weeks (every week day) of virtual exercise sessions. Sessions will all be under 30 minutes and include a brief check in amongst participants. The investigators will provide links to information on physical activity and links to online resources for being active.
89141764|NCT02805140|Active Comparator|Exercise resources and information|The investigators will provide links to information on physical activity and links to online resources for being active. Women will be invited to join the exercise groups at the end of the 8 weeks.
89141765|NCT05122481|Experimental|Care home residents|On the test days, the participant will be asked to provide a urine sample before taking the supplement, this sample will be used as a baseline and assessed for Vitamin C and creatinine/protein and specific gravity, with the same testing strips as mentioned above. Once collected, the participant will be provided with a drink containing an increasing daily dose of vitamin C (0 - 500 mg). A second urine sample will then be collected approx. 3 - 4 hours later to assess the extent of vitamin C excretion in urine with an increase in vitamin C supplement. Another urine test strip will also be used to determine creatinine concentrations, the presence of albumin/protein, and specific gravity (to determine urine concentration). Up to 3 days will be allowed between daily testing to allow for long weekends, absences, illness, etc. Therefore, the participants are expected to complete the study within 4 weeks.
89141766|NCT00937339|Active Comparator|Control|The control group will perform the same exercises on the vibration platform, as in the experimental group. However, the vibration device will be turned off during the exercises.
89141767|NCT00937339|Experimental|Whole body vibration|Subjects in the experimental group will undergo whole body vibration (1 session per day, 3 sessions per week) for 8 weeks. The vibration loading will be carried out using the Jet-Vibe System (Danil SMC Co., Ltd., Seoul, Korea). The vibration protocol used in this study will be 30Hz. While standing on the vibration platform, patients will be instructed to repeat the following set of light exercises: (1) light squatting,(2)deep squatting , (3) side-to-side weight-shift, (4) Forward and backward weight-shift, (5) forward lunge, (6) marching on the spot. The total duration of exposure of whole body vibration per session will be about 10 minutes.
89141768|NCT02805062||Pleural Effusion|Malignant pleural effusion patients requiring investigation with thoracoscopy.
89141769|NCT02733354||Control Group|Control Group:perform routine oral education.Both groups were asked to complete kidney disease knowledge questionnaire before education.
89141770|NCT02733354||Intervention Group|Intervention Group ：On the basis of Control Group, watching video demonstration of each type of dialysis. The videos were based on real cases, showing patients with peritoneal and hemodialysis life modes, lasting for 20 minutes respectively for each type of dialysis. Both groups were asked to complete kidney disease knowledge questionnaire before education.
89141771|NCT00937417|Experimental|Arm 1|vandetanib and docetaxel
89141772|NCT02728440||Hypogonadotropic hypogonadism patients|30 patients with idiopathic hypogonadotrophic hypogonadism
89141773|NCT00609713|Experimental|1|Comprehensive 12-month family-based obesity treatment with separate adolescents and parents group sessions
89141774|NCT00609713|Active Comparator|2|Individual 12-month nutrition education program
89141775|NCT00934453|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) capsules containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
89141776|NCT00934453|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
89141777|NCT05358912|Active Comparator|Control|"Patients who are diagnosed with septic shock and who have intra-abdominal pressure of less than 8 mmHg.~Target mean arterial pressure is 65 mmHg and above."
89141778|NCT05358912|Active Comparator|MAP Group|"Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg.~Target mean arterial pressure is 65 mmHg and above."
89141779|NCT05358912|Experimental|APP Group|"Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg.~Target abdominal perfusion pressure is 65 mmHg and above."
89141780|NCT02812316|Experimental|Scleral lenses|Subjects who meet all eligible requirements for entry into the study will be instructed to insert the Hi-Brite Large Diameter Rigid Gas Permeable contact lens in daily wear basis for clinical evaluation purposes.
89141781|NCT04261517|Experimental|Hydroxychloroquine and conventional treatments|After randomization, subjects take hydroxychloroquine 400mg per day for 5 days, also take conventional treatments.
89141782|NCT04261517|No Intervention|Conventional treatments|After randomization, subjects take conventional treatments without hydroxychloroquine.
89141783|NCT00930865|Active Comparator|Bumetanide|
89141784|NCT00930865|Active Comparator|Dapagliflozin|
89141785|NCT00930865|Active Comparator|Bumetanide + Dapagliflozin|
89141786|NCT02804906|Experimental|Home-Based Physical Therapy|
89141787|NCT02804906|Active Comparator|Control-30-minute counseling session|Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge.
89141788|NCT02812004|Experimental|Study Eye|Ultra Q Reflex YAG laser (Ellex)
89141789|NCT02812004|Sham Comparator|Contralateral Eye|Short light impulse is simulated
89141790|NCT04014439||Normal Diaphragm|Diaphragm thickness is 2 mm or more
89141791|NCT04014439||Thinning Diaphragm|Diaphragm thickness is less than 2 mm
89141792|NCT02737800|Active Comparator|1A endometrioma more than 5cm|Endometrioma aspiration GnRh agonist :Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
89141793|NCT02737800|Sham Comparator|1B endometrioma more than 5cm control|Endometrioma aspiration Standard long stimulation protocol & ICSI
89141794|NCT02737800|Active Comparator|2A endometrioma less than 5cm|Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
89141795|NCT02737800|Sham Comparator|2B endometrioma less than 5cm control|Standard long stimulation protocol & ICSI
89141796|NCT00934531|Experimental|Donepezil|participants with MCI receiving donepezil
89141797|NCT00934531|Placebo Comparator|Placebo|Participants with MCI receiving placebo
89141798|NCT04013828||Patients|Patients with recurrent high-grade glioma
89141799|NCT04013828||Relatives|Close relatives of patients with recurrent high-grade glioma
89141800|NCT00934609|Experimental|Training|12 weeks of endurance training on the cycle ergometer under supervision on a physician
89141801|NCT00934609|No Intervention|Control|Control condition
89141802|NCT00937573||Xience V|Percutaneous coronary intervention with Xience V stent placement
89141803|NCT00937573||Historical BMS|Percutaneous coronary intervention with bare metal stent placement prior to availability of Cypher, Taxus, or Xience V drug eluting stents at WFUBMC
89141804|NCT00937573||Historical DES|Percutaneous coronary intervention with drug eluting stent placement prior to availability of Xience V drug eluting stents at WFUBMC
89141805|NCT00937573||Contemporary BMS|Percutaneous coronary intervention with bare metal stent placement after Xience V drug eluting stents were available for use at WFUBMC
89141806|NCT00937573||Contemporary DES|Percutaneous coronary intervention with Cypher or Taxus drug eluting stent placement after Xience V drug eluting stents were available for use at WFUBMC
89141807|NCT02732886|Experimental|Betafoam®|Brand name: Betafoam® Generic term: Wound dressing with 3% povidone iodine
89141808|NCT02732886|Active Comparator|Medifoam®|Brand name: Medifoam® Generic term: Wound dressing
89141809|NCT05531006||pandemic time group|The surgeries performed during the COVID-19 pandemic and the anesthesia techniques applied for these surgeries
89141810|NCT05531006||normal time group|The surgeries performed during the non-pandemic period and the anesthesia techniques applied in these surgeries
89141811|NCT00937651|Placebo Comparator|Placebo|Placebo, 3 tablets
89141812|NCT00937651|Active Comparator|BR-A-657•K 20 mg group|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
89141813|NCT00937651|Active Comparator|BR-A-657•K 60 mg group|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
89141814|NCT00937651|Active Comparator|BR-A-657•K 180 mg group|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
89141815|NCT00931021|Active Comparator|Varenicline (Chantix)|
89141816|NCT00931021|Active Comparator|Nicotine Patch|
89141817|NCT02732808|Experimental|poor ovarian responder|The women with diagnose of poor ovarian responder after IVF/ICSI treatments underwent ovulation stimulation and egg collection in the same IVF/ ICSI cycle ( Shanghai protocol)
89141818|NCT02808884|Experimental|Circulating tumor DNA assay- First test - Negative result|Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
89141819|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Negative result|Participants whose sample provided a positive result after first test, will be contacted immediately by telephone by an oncologist co-investigator and concurrently sent a letter by mail informing them of the result and asking them to return for a second blood draw. We expect that this communication will happen with about a month of the original blood draw. The letter will include contact information for the study team and the oncologist co-investigators, in case the participant has any questions or concerns at this stage. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn at the blood collection visit, to allow repeat testing and confirmation that the mutation is present consistently. Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
89141820|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Positive result|Participants with positive results after first test will be contacted by an oncologist and sent a letter informing them of the result. They will be ask to return for a second blood draw. The letter will include contact info of the study team and the oncologist co-investigators. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn to allow repeat testing and confirmation that the mutation is consistently present. Participants whom additional blood sample yields a positive result for the same cancer mutations seen in the first blood draw, will be contacted by an oncologist to explain the results and next steps. This should happen within about a week of the second blood draw. Pending oncological evaluation of the participant and study results, a PET-CT scan with FDG agent, and possibly other tests will be requested. Unless exams suggest otherwise, the default follow-up will be a full body PET-CT.
89141821|NCT00931099||Low risk pregnant women|300 women in the third trimester of a singleton uncomplicated pregnancy, who attend a low risk obstetric surveillance
89141822|NCT00931099||High risk pregnant women|100 women hospitalized at the Antenatal department due to pregnancy related hypertensive disorder, IUGR, diabetes mellitus or premature labor
89141823|NCT00931099||Pregnant women in labor|200 women of a singleton uncomplicated full term pregnancy will be recruited during labor at the delivery room
89141824|NCT00931099||Newborns|400 newborns belong to women in first two groups
89141825|NCT00937729||enfuvirtide|all patients would received enfuvirtide and and optimised background
89141826|NCT02809040||Hypertensive Heart Disease|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
89141827|NCT02809040||Volunteer subjects|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
89141828|NCT02809040||Diagnosed Hypertension|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
89141829|NCT00926783|Active Comparator|(1) targeted CFAE ablation|
89141830|NCT00926783|Active Comparator|(2) generalized CFAE ablation|
89141831|NCT00937807|Active Comparator|sévoflurane|hypnotic use in standard general anesthesia
89141832|NCT00937807|Experimental|LENOXe™ (xénon 100 % v/v)|Safety of use in terms of hemodynamic stability to the LENOXe™ (xénon 100 % v/v) within the framework of the carotid surgery on the old person
89141833|NCT02811926||Ileostomy or colostomy|Patients with a ileostomy or colostomy in the Capital Region of Denmark
89141834|NCT02728128||Low cardiac output syndrome|Patients who experience low cardiac output syndrome
89141835|NCT02728128||No low cardiac output syndrome|Group that does not experience low cardiac output syndrome.
89141836|NCT00934687|Experimental|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
89141837|NCT00934687|Placebo Comparator|0.9% sodium chloride NaCl solution|0.9% NaCl solution will be injected like the experimental compound
89141838|NCT02808728|Active Comparator|Pain Cocktail with Ropivacaine|"patients given the standard intra-articular pain cocktail injection, consisting of ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.~given in one single dose"
89141839|NCT02808728|Experimental|Pain Cocktail with Exparel|"patients given a similar intra-articular injection consisting of bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel, 20cc of 1.3% Exparel, to total 100cc.~given in one single dose"
89141840|NCT02732730|Experimental|PrEP Acceptor|"For those women who choose to accept PrEP (Truvada), the following adherence support package will be provided:~Cognitive Behavioral Theory adherence support sessions~Two-way SMS communications~Optional monthly adherence support clubs Drug level counseling for those randomized to that extra intervention (1:1)"
89141841|NCT02732730|No Intervention|PrEP Decliner|Standard of care
89141842|NCT04996667|Active Comparator|Interventional Radiology Arm (Invasive Cohort)|"Interventional radiology (IR) will perform a right heart catheterization (RHC) as part of a planned IR procedure.~Bedside apical 4 chamber view (RV:LV ratio) will be recorded using an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform.~The Butterfly iQ+ (one possible ultrasound device which may be used) is a single-probe, whole-body ultrasound device.~After initial measurements, inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The same measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
89141843|NCT04996667|Active Comparator|Non-intervention Arm (Non-invasive Cohort)|Vitals including O2 amount and modality, blood pressure, pressor name, dose, and rate will be recorded. If the patient is intubated, the name, dose, and rate of sedation and analgesia will be recorded. If the patient is not intubated, name and dose amount of sedation will be recorded. Arterial blood gas will be obtained if an A-line is placed. Bedside apical 4 chamber view will be recorded (RV:LV ratio) with an ultrasound device, and noninvasive RV data will be obtained with Edwards ClearSight system and Edwards EV1000 clinical platform. This data will be obtained before, during iNO administration, and after iNO has been withheld for 2 minutes.
89141844|NCT00931177||Dehydrated children|children with dehydration
89141845|NCT02732496|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
89141846|NCT02732496|Placebo Comparator|Youth Appropriate Online Games|Engaging games not designed to improve cognition
89141847|NCT00937885|Experimental|Implementation of reminiscence|Individual and group reminiscence sessions held with residents, supplemented by reminiscence boxes, posters and exhibitions.
89141848|NCT00937885|No Intervention|Usual nursing care|
89234720|NCT03999372|Active Comparator|ICSI procedure|ICSI procedure: following sperm preparation as described before, samples were incubated until time of injection. Each oocyte was injected with a single morphologically abnormal and immobilized in polyvinyl Pyrolidone (PVP) spermatozoon. Individual sperm subjected to ICSI was examined and evaluated. The injection procedure was carried out in a sterilized dish using holding pipette and injection needle. Intra cytoplasmic sperm injection was performed according to the protocol of Van Steirteghem.
89234721|NCT00826709|Experimental|Arm 1|2 Nasal swabs
89234722|NCT00826709|Experimental|Arm 2|2 Nasopharyngeal swabs
89234723|NCT00826709|Experimental|Arm 3|Nasal wash or aspirate
89234724|NCT00822965||Patient Knowledge Assessments|Questionnaires + Phone Interview
89141849|NCT02732574|Experimental|OPEP Device Treatment|Patients randomized to OPEP will receive the device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The OPEP device group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The OPEP device will be set to the highest pressure setting unless deemed inappropriate by the PT, at which time the most appropriate pressure setting will be selected and then increased daily until the OPEP device is set to the highest pressure setting by POD #3 if able. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
89141850|NCT02732574|Sham Comparator|SHAM Device|Patients randomized to the sham treatment will receive the sham device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The sham group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The sham device is identical in exterior appearance to the OPEP device but does not contain the internal mechanism providing expiratory pressure. As such, the device will be set to the highest setting and will not need to be adjusted at all for patient tolerance. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
89141851|NCT02804516|Experimental|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
89141852|NCT02804516|Experimental|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
89141853|NCT00929669|Experimental|Pasireotide LAR|80 mg IM once monthly
89141854|NCT02737644||CHD birth cohort|Cases are identified as those whose newborns screened and confirmed with CHD during the follow-up and four age- and delivery-hospital matched controls are selected for each case from the rest of the cohort.
89141855|NCT02804360|Experimental|therapy|Dexamethasone injection
89141856|NCT02727738|Experimental|Methimazole plus selenium|Methimazole 5-30 mg daily for 90 days Selenium 80 bid for 90 days
89141857|NCT02727738|Active Comparator|Methimazole|Methimazole 5-30 mg daily for 90 days
89141858|NCT02804048|Experimental|Pelvic Floor Muscle Training|"superficial heat pelvic floor muscle intra vaginal manual therapy. PERFECT scale is applied in 5 sessions and based on the result of each assessment is performed the treatment plan with exercises of the pelvic floor muscles.~It is performed manual therapy in iliopsoas, diaphragm and piriformis. From the fourth session, initiate treatment with electromyographic biofeedback based on the result of PERFECT scale."
89141859|NCT02804048|Placebo Comparator|Low back|superficial heat low back Manual therapy in piriform, lumbar, iliopsoas and diaphragm.
89141860|NCT02737488|Experimental|TST|
89141861|NCT02737488|Active Comparator|TAU Group|
89141862|NCT05102513|Experimental|Unilateral Cleft Lip Repair with the New Hybrid Technique|
89141863|NCT05102513|Active Comparator|Unilateral Cleft Lip Repair with the Millard II Technique|
89141864|NCT04111952|Experimental|Additional laser treatment|Women receiving a single laser treatment.
89141865|NCT04111952|Sham Comparator|Sham laser treatment|Women receiving sham laser treatment.
89141866|NCT02727426|Experimental|low salt diet|All subjects will be instructed to maintain a low-sodium (LS) diet, with an intake of less than 2.3 g of salt per day (DASH eating plan; US Department of Health and Human Services, 2006) for 7 days (washout period).
89141867|NCT02727426|Experimental|high salt diet|After washout period, all subjects will be instructed to maintain a high-sodium (HS) diet, with an intake of 11.2 g of salt per day for 7 days.
89141868|NCT00610025|Active Comparator|1|10 patients with no previous abdominal surgeries, pre-insufflation of the abdomen using a veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
89141869|NCT00610025|Active Comparator|2|10 patients with history of previous abdominal surgeries, pre-insufflation of the abdomen using veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
89141870|NCT00610025|Active Comparator|3|10 patients with no previous history of abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
89141871|NCT00610025|Active Comparator|4|10 patients with history of previous abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
89141872|NCT00610025|Active Comparator|5|10 patients, all with no previous mid to upper abdominal surgeries, no Veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
89141873|NCT00610025|Active Comparator|6|10 patients, all with previous mid-to-upper abdominal surgeries, no Veress needle pre-insufflation, endoscopic take-down of intra-abdominal adhesions (if identified)
89141874|NCT02811770||children with HSN|
89141875|NCT02732418|Experimental|Depo-Provera CI 45 mg|a single subcutaneous (SC) injection of 45 mg/0.3 mL
89141876|NCT02732418|Experimental|Depo-Provera CI 75 mg|a single subcutaneous (SC) injection of 75 mg/0.5 mL
89141877|NCT02732418|Experimental|Depo-Provera CI 105 mg|a single subcutaneous (SC) injection of 105 mg/0.7 mL
89141878|NCT02732418|Active Comparator|Depo-subQ 104|a single subcutaneous (SC) injection of 104 mg/0.65 mL
89141879|NCT02811692||BAY86-5321|Anti-Vascular Endothelial Growth Factor (VEGF) - naive patients starting intravitreal Aflibercept injection treatment for Neovascular age-related macular degeneration (AMD), macular edema following Branch Retinal Vein Occlusion (BRVO), macular edema following central retinal vein occlusion (CRVO), and diabetic macular edema (DME)
89234725|NCT05733468|Experimental|Theracal LC Pulpotomy|36 children with the cariously exposed mature permanent molar teeth indicated for pulpotomy and fulfilling the inclusion criteria will be taken for the study and coronal pulpotomy will be done till the level of root canal orifice.
88805963|NCT03011645|Active Comparator|Ziprasidone|Ziprasidone 60 mg tablet by mouth, once a day for one day.
88805964|NCT03011645|Active Comparator|Lorcaserin|Lorcaserin 20 mg tablet by mouth, once a day for one day.
89141880|NCT02732340|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
88803445|NCT01743872|Experimental|iOCT|"Arterial access will performed by the operating surgeon. An aortic and infrainguinal angiogram using the standard method of intravenous iodinated contrast under digital subtraction fluoroscopy will be conducted in the usual manner according to the vascular surgeon. A 54 mm section of Superficial Femoral Artery will be chosen for study imaging. An intervention sheath or injection catheter will be placed just proximal to the area of interest. An 0.014 wire will be passed distal to the area of interest. The patient will then undergo OCT of this 54mm section with each of the three mediums below using a continuous flushing method through injection catheter. All OCT imaging will be collected at a rate of 25mm/sec. In the event of a subsequent procedure, OCT imaging will again be performed"
88805965|NCT03011645|Placebo Comparator|Placebo Oral Tablet|Sugar pill (in place of ziprasidone and lorcaserin) by mouth, once a day for one day.
88805966|NCT03012269|Experimental|Working Memory Training|The subjects of experimental group received a series of working memory training, 30 min for 5 days per week during 6 weeks.
89141881|NCT04259723|Experimental|Intervention|
89141882|NCT04259723|No Intervention|Control|
89141883|NCT02737410|Active Comparator|Treatment|Treatment group obtaining Gut-directed Hypnotherapy
89141884|NCT02737410|No Intervention|Control|Control group
89141885|NCT04004078||Group A|Non-gene directed group：Voriconazole was intravenously administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 4mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 400mg or 200mg（weight>40Kg or <40Kg）at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight>40Kg or <40Kg）. Voriconazole was sequential therapy administered 2 times at the loading dose of 6mg/Kg at 12h intervals , followed by maintenance dosing 200mg or 100mg（weight>40Kg or <40Kg）.
89141886|NCT04004078||Group B|Gene directed group（UMs and EMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with UMs，EMs.
89141887|NCT04004078||Group C|Gene directed group（IMs）：The dosage of the drug was the same as that of the non-gene-directed group for patients with IMs.
89141888|NCT04004078||Group D|Gene directed group（PMs）： Voriconazole was intravenously administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 3mg/Kg at 12h intervals . Voriconazole was oral administered 2 times at the loading dose of 200mg or 100mg（weight>40Kg or <40Kg）at 12h intervals , followed by maintenance dosing 100mg . Voriconazole was sequential therapy administered 2 times at the loading dose of 4mg/Kg at 12h intervals , followed by maintenance dosing 100mg.
89141889|NCT02732262|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
89141890|NCT02732262|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
89141891|NCT02732262|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
89141892|NCT00566995|Experimental|Vandetanib in Participants with Kidney Cancer|300 mg/day (starting dose) oral dose of vandetanib once a day for 28 days
89141893|NCT04097834||PrEP Prescription at Enrollment|
89141894|NCT04097834||No PrEP Prescription at Enrollment|
89141895|NCT00938119||Diabetes patients with PCI|this is single group
89141896|NCT00926393|Active Comparator|Quetiapine Immediate Release (IR)|Quetiapine 25, 100, 200 and 300 mg
89141897|NCT00926393|Active Comparator|Quetiapine Extended Release (XR)|Quetiapine 50, 200, 300
89141898|NCT02737254|Experimental|Oxytocin and Secure CBM training|
89141899|NCT02737254|Active Comparator|Placebo and Secure CBM training|
89141900|NCT02737254|Active Comparator|Oxytocin and Neutral CBM training|
89141901|NCT02737254|Placebo Comparator|Placebo and Neutral CBM training|
89141902|NCT00938197|Active Comparator|Part A|
89141903|NCT00938197|Active Comparator|Part B|
89141904|NCT00608621||1-physostigmine|"Physostigmine 4 mg in 50 ml NaCl 0.9% per 24 h as syringe pump continuously for 48 hours, plus physostigmine 2mg (in NaCl 0.9% 50 ml)at termination of sedation~PCA: Patient-controlled analgesia with piritramide 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
89141905|NCT00608621||2-placebo|"NaCl 0.9% 50 ml per 24 h continuously over 48 hours, plus 50 ml NaCl 0.9% at termination of sedation~PCA: Patient-controlled analgesia with piritramid 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
89234726|NCT05733468|Active Comparator|MTA Pulpotomy|36 children with the cariously exposed mature permanent molar teeth indicated for pulpotomy and fulfilling the inclusion criteria will be taken for the study and coronal pulpotomy will be done till the level of root canal orifice.
89141906|NCT02727504||Patient with aortic valve stenosis|"115 patients will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.~Then will be performed :~An electrocardiogram~2D and 3D echocardiography~Dobutamine stress echocardiography~Blood tests : blood electrolytes, creatinine, hemoglobin, N-terminal pro-brain natriuretic peptide (NT-ProBNP), C reactive protein (CRP), soluble suppression of tumorigenicity-2 (ST-2)~A cardiac MRI~A cardiac scanner~A 6-minutes walking test~An evolution of the Duke Activity Score"
89141907|NCT02811848||Barbers|Barbers that service African American clientele mainly will be recruited for this study; there is no intervention.
89141908|NCT00931333|Experimental|1|
89234727|NCT00830843|Active Comparator|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
89234728|NCT00830843|Experimental|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
89141909|NCT04259489|No Intervention|Traditional therapy group|All patients in the control group will receive routine diabetes management, including lifestyle education, health guidance, blood glucose monitoring and medicine adjustment and other treatments which conducted by the endocrinology medical team. After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
89141910|NCT04259489|Active Comparator|Shared Care group|The Patients download the Shared Care mobile application and connect with the smart-glucometer BG1 to upload blood glucose dairy in real time. With patient's informed consent, his or her data from each visit will be collected and recorded for analysis. After the patient returns home from the clinic, they can communicate through the APP with online diabetes educators. According to protocol, online diabetes educators answer patients' questions, give suggestions on patients' diet and summarize patients' issues to physicians, who provide high level supervision.
89141911|NCT02727348|Experimental|Sciatic block with or without femoral block|Sciatic block with or without femoral block performed on the patient with 3mg/kg of ropivacaine
89141912|NCT02727348|Active Comparator|Spinal anaesthesia|Spinal anaesthesia will be performed on the patient with heavy marcaine 0.5% up to 3mls
89141913|NCT04013815|Experimental|group E|patients receiving the ESP block
89141914|NCT04013815|Active Comparator|group I|patients receiving the intercostal nerve block
89141915|NCT00610103|Active Comparator|KW-6500|Drug: KW-6500 (apomorphine hydrochloride (USAN))
89141916|NCT00610103|Placebo Comparator|Placebo|Placebo
89141917|NCT02804204||Anti-TNF|
89141918|NCT04261283|Experimental|Circuit Training|Specific exercise are designed in circuit training
89141919|NCT04261283|Active Comparator|Control Group|Conventional treatment
89141920|NCT00938275|Experimental|0.5g SRT2104|"Cohort 1 (10 males) & Cohort 2 (10 females) must attend the clinic on 4 separate treatment visits during the study; each treatment visit will be one week apart. At each treatment visit, subjects will receive one of the following 4 treatments:~A) 0.5g SRT2104 administered as an oral suspension in the fasted state B) 0.5g SRT2104 administered as an oral suspension following consumption of a standard meal C) 0.5g SRT2104 administered as two 0.25g capsules in the fasted state D) 0.5g SRT2104 administered as two 0.25g capsules following consumption of a standard meal.~For treatments A and C, subjects will have fasted for at least 10 hours overnight. Water will be restricted from 1h prior to dosing until 1h post dose. A light lunch will be provided 4h post dose. For treatments B and D, subjects will receive SRT2104 within 30 min following the start of consumption of a standardized non high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat)."
89141921|NCT04263623|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
89141922|NCT04263623|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
89141923|NCT04263623|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
89141924|NCT02737176|Experimental|Tobacco cessation intervention|Tobacco cessation intervention is implemented for 12 weeks. The nicotine dependence status is evaluated by the FTND (Fagerstrom Test for Nicotine Dependence) test. The point 3 or more is regarded as a moderate or high tobacco dependence and determining a cessation intervention. During the tobacco cessation intervention for the subjects, attending doctors implement standard treatments for their oral diseases. Even if participants fail to abstain from smoking, the oral treatment is continued. In case of the use of the NRTs (nicotine patch and/or gum), the investigators supply it for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy.
89141925|NCT02737176|No Intervention|Non-tobacco cessation intervention|Those who do not intention to abstinence from smoking strongly and/or having less than 3 points in FTND test are allocated to non-tobacco cessation intervention group. The same treatment as the tobacco cessation intervention group is carried out for their oral diseases.
89141926|NCT04014127||Controls|25 controls with preserved renal function
89141927|NCT04014127||Kidney Donors|25 living kidney donors who have donated a kidney at least 12 months prior to enrollment in the study.
89141928|NCT04014127||Pre-dialysis|25 patients with pre-dialysis chronic kidney disease stage 5
89141929|NCT04014127||Peritoneal dialysis|25 patients with chronic kidney disease stage 5 undergoing peritoneal dialysis
89141930|NCT04260893|Experimental|Tixel Treatment|3 Tixel treatment sessions, 2 weeks apart follow by 3 Follow up sessions
89141931|NCT02803814|Experimental|Superior mesenteric artery approach|Initial approach of the superior mesenteric artery to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
89141932|NCT02803814|Active Comparator|Classic approach|Classic approach to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
89141933|NCT02727114||participants aged 8 weeks to 3 years|"Echographic measurement of skin thickness at the proximal forearm, the deltoid region and medial thigh (till age of 2 years) in participants aged 8 weeks to 3 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
89141934|NCT02727114||participants aged 3 to 6 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 3 to 6 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
89141935|NCT02727114||participants aged 6 to 12 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 6 to 12 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
88805967|NCT03012269|No Intervention|Non-Working Memory Training|The subjects of control group performed traditional cognitive rehabilitation without working memory training, 30 min for 5 days per week during 6 weeks.
88805968|NCT01149785|Experimental|1|There should be at least 14-day washout period between treatment A and B.
88805969|NCT02182115|Active Comparator|standard of care|Surgeon's routine for preoperative showering.
89141936|NCT02727114||participants aged 12 to 18 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 12 to 18 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
89141937|NCT04236752|Experimental|Single arm radiotherapy|HDR Brachytherapy Boost of 15Gy to the prostate followed by Stereotactic Ablative Body Radiation (SBRT) 25 Gy in 5 fractions, once weekly to prostate, SVs and pelvic lymph nodes + 6-18 months of ADT
89141938|NCT04260971|Experimental|Cyclical Stimulation|This group will undergo cyclical stimulation mode of stimulation
89141939|NCT04260971|Active Comparator|Continuous Stimulation|This group will undergo the standard continuous mode of stimulation
89141940|NCT00938353|Experimental|BDP UDV|
89141941|NCT00938353|Placebo Comparator|Placebo|
89141942|NCT03076476|Active Comparator|DES-std group|(DES: drug-eluting stent). Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
89141943|NCT03076476|Experimental|DES-slow group|"(DES: drug-eluting stent). Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
89141944|NCT03076476|Experimental|BVS group|(Bioresorbable Vascular Scaffold) Introduced after the interim analysis (phase 2) for comparison with DES-slow.
89141945|NCT04263701|Active Comparator|Conventional Physiotherapy Group|45 minutes, 2 days in a week for 8 weeks
89141946|NCT04263701|Experimental|Dual Task Training Group|45 minutes, 2 days in a week for 8 weeks
89141947|NCT02726958||group M|patients who died or suffered from stroke, acute coronary syndrome, heart failure, complete atrioventricular block or life-threatening ventricular arrhythmias within 30 days after the procedure
89141948|NCT02726958||group T|other patients
89141949|NCT00610181||Breast MRI|Magnetic resonance imaging (MRI) of breast for patients with invasive lobular carcinoma of the breast.
89141950|NCT02727036|Experimental|Pumpkin seed oil|Pumpkin seed oil (1g) capsules - 2 capsules per day for 12 weeks
89141951|NCT02727036|Active Comparator|Pumpkin seeds|Packet of pumpkin seeds (4.1 grams /~0.15ounces) - 1 pack per day for 12 weeks
89141952|NCT00935077|Experimental|24 Month PPCM BP|A 24 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
89141953|NCT00935077|Experimental|9 Month PPCM BP|A 9 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
89141954|NCT00935077|Sham Comparator|PPCM Asthma|A 9 month long physician/pharmacist collaborative intervention is implemented to manage asthma
89141955|NCT00935077|No Intervention|BP Control Arm|No PPCM intervention
89141956|NCT00610259|Experimental|1|brief behavioral therapy for insomnia (bBT-I) in addition to treatment as usual (TAU)
89141957|NCT00610259|Active Comparator|2|Treatment as usual (TAU)
89141958|NCT02737098|Active Comparator|Standard Implementation|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
89141959|NCT02737098|Active Comparator|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
89141960|NCT04259333|Experimental|Test Arm|celecoxib 200 mg tablet by mouth every 12 hours for 7 days postoperatively prn pain
89141961|NCT04259333|Active Comparator|Control Arm|codeine 30mg-acetaminophen 300mg-caffeine 15 mg tabelt by mouth every 4 hours for 7 days postoperatively prn pain
89141962|NCT02736942|Active Comparator|Laparoscopic|Laparoscopic TME
89141963|NCT02736942|Experimental|Transanal|TaTME
89141964|NCT02726724|Experimental|Condition B|An audience of 5 people with at least 2 neonatologists will be present with the operator during the intubation of the mannequin.
89141965|NCT02726724|Experimental|Condition A|Only the staff will be present with the operator during the intubation of the mannequin.
89141966|NCT00926237|Experimental|Sham followed by active 1Hz, then active 10Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 1Hz and then active rTMS at 10 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
89141967|NCT00926237|Experimental|Sham followed by active 10Hz and active 1Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 10 Hz and then active rTMS at 1 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
89141968|NCT02721576|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T>40Gy/20f,week 1->5"
89141969|NCT04259099||QUALITY OF LIFE QUESTIONNAIRES|The group is anticipated to consist of 150 female and male with osteoporosis, osteopenia or normal bone mineral density.
89141970|NCT02721420|Other|Drug + short message(SMS) reminder|dihydroartemesinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with SMS reminders prior to each treatment course
89141971|NCT02721420|Other|Drug + no short message(SMS) reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) without SMS reminders prior to each treatment course.
89141972|NCT02721420|Other|Drug+ Health worker reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with Health surveillance assistants reminders prior to each treatment course.
89141973|NCT02721420|Other|Drug at hospital + SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department without an SMS reminders prior to each treatment course.
89141974|NCT02721420|Other|Drug at Hospital+no SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department with a short message reminder prior to each treatment course
89141975|NCT05330819||Group and Interventions|Participants: Adult patients with stable coronary artery disease and previous history of myocardial infarction currently receiving aspirin monotherapy.
89141976|NCT05330819||Groups and interventions|Interventions: Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using Badimon perfusion chamber, SEM and TEG.
89141977|NCT02732964|No Intervention|Control|baseline hemodynamics and anxiety screen; no music
89141978|NCT02732964|Experimental|Pandora Music|A study investigator will create a station in the Pandora® music application based on the patient's preferred music genre or artist.
89141979|NCT02732964|Experimental|Mozart Music|A study investigator will turn on a playlist of pre-selected Mozart music.
89141980|NCT02726568|Experimental|Icotinib 375mg Tid|The human subject gets icotinib 375mg, Tid until intracranial PD or intolerable toxicity reaction.
89141981|NCT02726490|Active Comparator|Glyburide|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.~The dose of glyburide will be increased as needed to a maximum of 20mg /day.~Antenatal testing will be initiated at 28 weeks~Patients will receive monthly growth scans"
89141982|NCT02726490|Active Comparator|Glucovance|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.~Patients will receive monthly growth scans~Antenatal testing will be initiated at 28 weeks."
89141983|NCT02716350|Experimental|B-GOS|powder, 3.5g/day
89141984|NCT02716350|Placebo Comparator|Maltodextrin|powder, 3.5g/day
89141985|NCT02726802|Experimental|Physical Therapy route of entry|The subject will see a physical therapist as their initial encounter into the healthcare system
89141986|NCT02726802|Active Comparator|Primary Care Provider rout of entry|The subject will see a primary care provider as their initial encounter into the healthcare system
89141987|NCT02726646|Placebo Comparator|Debridement|mechanical debridement in one session and application of 1 mg placebo microspheres in two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
89141988|NCT02726646|Experimental|Debridement plus Doxycycline|mechanical debridement in one session associated with the application of 1 mg of microspheres loaded with doxycycline per periodontal pockts, two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
89141989|NCT02811458|Experimental|Transdiagnostic CBT|Group psychotherapy according to the Transdiagnostic Cognitive-Behavioral Therapy treatment protocol (Norton, 2012)
89141990|NCT02811458|No Intervention|Treatment-as-usual|Treatment-as-usual and a differed intervention (if desired by participants) after the 8-month follow up.
89141991|NCT02726256||Diabetes and Impaired glucose Tolerance (G-CREDIT)|Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
89141992|NCT02803892|Placebo Comparator|Group 1: Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received placebo x 2 placebo (Group 1) After 4 weeks of treatment, patients will discontinue relevant placebo treatment, but continue the second placebo for a further 8 weeks
89141993|NCT02803892|Experimental|Group 2: Rapamycin plus Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus placebo. After 4 weeks of treatment, patients will discontinue rapamycin, but continue the second placebo for a further 8 weeks
89141994|NCT02803892|Experimental|Group 3: Rapamycin plus Vildagliptin|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus vildagliptin. After 4 weeks of treatment, patients will discontinue rapamycin , but continue Vildagliptin o for a further 8 weeks
89141995|NCT04189380|Experimental|Cohort 1|liver transplanted patient
89141996|NCT02800382|Other|Lung Malignancy|"Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.~The samples (fine-needle aspiration biopsy and fine-needle aspiration cytology) were diagnosed by pathological examination."
89141997|NCT02800382|Other|Lung bening Diseases|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
89141998|NCT02721108|Experimental|Mindfulness: Group A|Using a 60-day mindfulness instruction meditation app: 60 days of 10 and 20 minute long app modules with a spoken guide to mindfulness meditation, to be used once a day, including modules on the basics of mindfulness and a module targeted to pain, which can re-revisited until the end of the study
89234729|NCT00823121|Active Comparator|frozen-embryo transfer|In this group all embryos are cryopreserved and two months later embryo transfer will perform.
89234730|NCT00823121|Active Comparator|fresh embryo transfer|In this arm fresh embryo transfers are performed on day 2 or 3.
88805970|NCT02182115|Experimental|antiseptic bundle|"Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.~Chlorhexidine gluconate soap applied for bathing daily.~Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.~Nasal mupirocin to applied inside nostrils twice daily."
88805971|NCT01151189|Placebo Comparator|Placebo|The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
89141999|NCT02721108|Active Comparator|Relaxation: Group B|Using comparison relaxation app with a series of non-meditative progressive muscle relaxation instructions: 60 days of 10 and 20 minute long app modules to be used once per day with spoken words and relaxing sounds, which can re-revisited until the end of the study
89142000|NCT02721108|No Intervention|Treatment as usual: Group C|No app: treatment as usual (watch and wait, medication and/or surgery) to investigate if any app intervention makes a difference to wellbeing and to ascertain dropout rates for the full-scale trial in patients who perceive that they are getting no intervention.
89142001|NCT02803658|Experimental|infertile couples|smoking behavior
89142002|NCT02803658|Active Comparator|Fertile couples|smoking behavior
89142003|NCT02721186|Experimental|MDA with DHAp and SLD Primaquine|MDA will be conducted at two time points with an approximate four-week interval. All consenting and eligible community members will be administered age-appropriate treatment dose of dihydroartemisinin-piperaquine (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and single low dose (0.25mg/kg) primaquine (Primaquine, Remedica Ltd., Cyprus) in house-to-house campaigns.
89142004|NCT02721186|No Intervention|Control|The control arm (no MDA) will have the standard care offered by the Ministry of Health and Social welfare which applies to both arms. This includes passive case detection of individuals seeking treatment at local health facilities, and universal coverage of long lasting insecticide treated bed nets and indoor residual spraying in the study areas.
89142005|NCT02803424|Experimental|Volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
88805972|NCT01151189|Experimental|MVA85A/AERAS-485|MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
89142006|NCT02803424|Active Comparator|Autoflow-volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, Autoflow-volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
89142007|NCT02726334|Experimental|Group/Stream 1 - Monotherapy|"Patient group: Patients who have failed at least two lines of chemotherapy for metastatic disease.~Treatment: BNC101 administered via intravenous infusion over 60 minutes weekly.~Patients with stable disease or a response at or after day 56 (2 cycles) will be allowed to continue to receive weekly doses of BNC101 until disease progression."
89142008|NCT02726334|Experimental|Group/Stream 2 - Combination Chemo|"Patient Group: Patients who have failed at least one line of chemotherapy for metastatic disease.~Treatment: BNC101 administered in combination with FOLFIRI~Participants will be treated until disease progression, intolerable toxicity, withdrawal of consent, or study termination by the Sponsor, whichever occurs first."
89142009|NCT02803736|Experimental|Real acupuncture group|Patients in the real acupuncture group will receive true acupuncture 3 times a week for 4 weeks (12 sessions). A standardized prescription of six acupuncture points is used unilaterally. Needles are inserted and manipulated manually until needling sensation (de qi) is obtained, and are retained for 20 minutes with manual manipulation at 10 minutes. Acupuncturists are trained to inquire about specific needle sensations when providing true acupuncture.
89142010|NCT02803736|Sham Comparator|Sham acupuncture group|Patients in the sham acupuncture group will receive sham acupuncture 3 times a week for 4 weeks (12 sessions).
89142011|NCT02716428|Experimental|Cohort 1|12 weeks of Faldaprevir plus TD-6450 plus Ribavirin
89142012|NCT02716428|Experimental|Cohort 2|12 weeks of Faldaprevir plus TD-6450
89142013|NCT02803346||septic shock patients|
89142014|NCT04921644||patient cohort|Newly diagnosed patients with colon, rectum, liver, pancreas or lung cancer, malignant melanoma, breast or other gynecological cancers, prostate, kidney, bladder or thyroid gland cancer, non-Hodgkin lymphoma or leukemia recruited approximately 6 months after diagnosis and followed up to 2 years post-diagnosis. No intervention.
89142015|NCT00931463|Active Comparator|Ritonavir-boosted lopinavir and 2N(t)RTI|This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.
89142016|NCT00931463|Experimental|Ritonavir-boosted lopinavir and raltegravir|This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.
89142017|NCT02694432|Active Comparator|GOALS|Participants will use for approximately four months an online platform, GOALS, consisting of weekly lessons designed to enhance blood pressure control. Recommended lifestyle changes for hypertension, including a low-sodium diet, physical activity, weight loss (if appropriate) and behavioral self-management skills will be offered. Attention to medication adherence and pharmacist support as well as that of a dedicated online health coach and ongoing collaboration with the primary care physician are also provided.
89142018|NCT02694432|Experimental|Minding GOALS|Participants in this arm will also use the GOALS standard tools for blood pressure control. To further maximize success, they will receive additional online behavioral training throughout the 4-month intervention that focuses on mind-body approaches. Weekly topics, for example, will include meditation lessons, mindfulness-based stress reduction and mindfulness-based eating awareness.
89142019|NCT03974594|Experimental|Trifluridine and Tipiracil Tablets|
89142020|NCT03974594|Active Comparator|TAS-102|
89142021|NCT02694276|Experimental|Internet-based cognitive behavior therapy|10 sessions of ICBT during 10 weeks.
89142022|NCT03964688|Experimental|Vitamin C|vitamin C intravenous during hospitalization, followed with vitamin C oral
89142023|NCT03964688|Experimental|Placebo|placebo intravenous during hospitalization, followed with placebo oral
89142024|NCT02726100|Experimental|Intervention arm|Participants in intervention communities will receive the SMARTHealth Diabetes intervention that connects community health service centers and family health providers for diabetes management. Medical staff and FHPs in the intervention communities will be provided with an initial training session on the installation and use of the platform.
89142025|NCT02726100|No Intervention|Control arm|"Control group doesn't use SMARTHealth Diabetes.The usual-care in our study will be conducted in a standard way which is defined in the Guidance of National Essential Public Health Service. All the relevant doctors in control group will be trained and required to record the activities defined in the guidance."
89142026|NCT00610337|Placebo Comparator|1|
89142027|NCT00610337|Experimental|2|1mg Cethrin®
89142028|NCT00610337|Experimental|3|3mg Cethrin®
89142029|NCT00610337|Experimental|4|6mg Cethrin®
89142030|NCT00610337|Experimental|5|12mg Cethrin®. Administration of this dose is dependent on data from lower doses.
89142031|NCT00610337|Experimental|6|18mg Cethrin®. Administration of this dose is dependent on data from lower doses.
89142032|NCT02803268|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.
89142033|NCT02803268|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.
89142034|NCT02803268|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.
89142035|NCT02721264|Experimental|Fecal Microbiota Transplantation (FMT)|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 5 month.
89142036|NCT02721264|Active Comparator|Standard Treatment Care|
89142037|NCT00929201|Active Comparator|Sita + Met then Sita/Met FDC|Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
89142038|NCT00929201|Active Comparator|Sita/Met FDC then Sita + Met|Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.
89142039|NCT02795702|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
89142040|NCT02795702|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
89142041|NCT02720796|Other|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
89142042|NCT02800772|Experimental|acetic acid|spray 50ml acetic acid to duodenal bulb
89142043|NCT02800772|Placebo Comparator|saline|spray 50ml saline to duodenal bulb
89142044|NCT04260815|Experimental|anodal tDCS on the left inferior frontal gyrus (IFG)|
89142045|NCT04260815|Experimental|anodal tDCS on the right IFG|
89142046|NCT04260815|Sham Comparator|sham tDCS|
89142047|NCT02773212|Experimental|d-Amphetamine and Contingency Management|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
89142048|NCT02773212|Active Comparator|d-Amphetamine alone|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.
89142049|NCT02773212|Active Comparator|Placebo and Contingency Management|Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
89142050|NCT05506280||Pregnant women|pregnant women infected by Covid-19
89142051|NCT05494268||Experimental ( Carb Group)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. The Carb Group will consume carbohdrate fluid and Non-carb Group will consume equal amount of water at night and two hours before the surgery.
89142052|NCT05494268||Standart Care (Non-carb Group)|Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. The Carb Group will consume carbohdrate fluid and Non-carb Group will consume equal amount of water at night and two hours before the surgery.
89142053|NCT04117373||Cohort 1|Patients from the existing Optum insurance claimed database with a confirmed diagnosis of melanoma, basal cell carcinoma, or squamous cell carcinoma who have undergone skin cancer excision surgery followed by interpolated flap repair between the years 2001-2006.
89142054|NCT02720640|Experimental|Implant 'on' vs implant 'off'|Intra-individual comparison of implant 'on' vs implant 'off'
89142055|NCT00610493|Experimental|Bevacizumab + Temsirolimus|Bevacizumab 5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle. Temsirolimus 5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle. First tumor biopsy during screening visit and Second at the end of Cycle 1. DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1.
89142056|NCT02716272|Experimental|MONOTHERAPY ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
89142057|NCT02716272|Experimental|COMBINATION ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
89142058|NCT05484518|Experimental|Method of Levels Therapy|Method of levels therapy, see intervention details. All participants will receive therapy and must attend a minimum of one session for their data to be included in the study.
89142059|NCT00926003|Experimental|Full Computerized Cognitive Training|Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. Each training game become more difficult as the child gains proficiency.
89142060|NCT00926003|No Intervention|Control|Passive Control with no intervention training (computer cognitive games) for 8 weeks.
89234731|NCT00423813|Placebo Comparator|1|
89234732|NCT00423813|Experimental|2|
89234733|NCT01007604|Active Comparator|Exercise and lifestyle counselling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
89234734|NCT01007604|Experimental|PCD with peristaltic pulse waveform|Daily use for two hours
89234735|NCT03687372|Experimental|A-101|topical solution
89234736|NCT03687372|Other|Vehicle|topical solution
89142061|NCT00926003|Active Comparator|Limited computerized cognitive training|"Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. In this arm, however, the training games do NOT become progressively more difficult as the child gains proficiency, but rotates randomly among simpler to moderate levels of difficulty for each game. The purpose to to give children int he limited CCRT arm comparable exposure to the cognitive games training as with the full CCRT arm, with the exception of the titrating nature of the game training."
89142062|NCT02720562||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
89142063|NCT02720562||TD group|Typically development controls without lifetime diagnosis with ADHD
89142064|NCT05505032|Experimental|Group F30|In these patients, the FiO2 value will be adjusted to 30% in the perioperative period.
89142065|NCT05505032|Experimental|Group F50|In these patients, the FiO2 value will be adjusted to 50% in the perioperative period.
89142066|NCT05505032|Experimental|Group F80|In these patients, the FiO2 value will be adjusted to 80% in the perioperative period.
89142067|NCT05330741|Experimental|Designed Physical Therapy Program|Designed Physical Therapy Program Down syndrome children will receive the designed physical therapy program for 1 hour. The duration of treatment will be 3 times/week for 12 weeks.
89142068|NCT05330741|Experimental|Whole-Body Vibration|Designed physical therapy program in addition to whole-body vibration. Down syndrome children will receive the designed physical therapy program for 1 hour in addition to whole-body vibration with an amplitude of 2 mm, vibration frequency ranged from 25 to 30 Hz and, vibration time ranged from 5 to10 minutes. The duration of treatment will be 3 times/week for 12 weeks.
89142069|NCT05330741|Experimental|Gravity Force Stimulation|Designed physical therapy program in addition to gravity force stimulation. Down syndrome children will receive the designed physical therapy program for 1 hour in addition to gravity force stimulation with 10 repetitions for each position. The duration of treatment will be 3 times/week for 12 weeks.
89142070|NCT02802800|Experimental|Water|Plyometric Training in water, twice per week for 6 weeks.
89142071|NCT02802800|Experimental|Land|Plyometric training on land, twice per week for 6 weeks.
89142072|NCT02720406|Active Comparator|Intravenous ketamine0.5mg/kg|intravenous ketamine 0.5 mg/kg given after induction of anesthesia and before surgery.
89142073|NCT02720406|Active Comparator|Nebulized ketamine 1mg/kg|nebulized ketamine group received 1mg/kg ketamine by nebulzation before induction of anesthesia.
89142074|NCT02720406|Active Comparator|Nebulized ketamine 2mg/kg|nebulized ketamine group received 2mg/kg ketamine by nebulzation before induction of anesthesia.
89142075|NCT02720406|Placebo Comparator|control group|control group received placebo nebulization
89142076|NCT05504876|Experimental|Midazolam Syrup HEC74647PA HEC110114|Subjects will receive 5mg Midazolam Syrup on Day 1,100 mg HEC74647PA and 600 mg HEC110114 on Day3~8, 5mg Midazolam Syrup co-administered with 100 mg HEC74647PA and 600 mg HEC110114 on Day9.
89142077|NCT02725632|No Intervention|Control|"An age-matched control group will be enrolled and consented. A Data Collection Sheet will be used to document data from the subject's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. Another blood drawn will be collected after one month. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
89142078|NCT02725632|Active Comparator|OSA|"Newly diagnosed OSA patients will be enrolled and consented. A Data Collection Sheet will be used to document data from the patient's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. The patients on CPAP treatment will be followed-up for 1 month. Another blood drawn will be collected after one month of CPAP treatment. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
89142079|NCT02802722|Active Comparator|Immediate supplementation|Dietary supplement: Vitamin D3 supplementation - oral capsules 6400 International Units once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
89142080|NCT02802722|Placebo Comparator|Delayed supplementation|Placebo: oral placebo capsules once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
89142081|NCT02725944||Patients with cryptogenic stroke and TIA|Implantation of ICRM in all participants.
89142082|NCT02802644|Experimental|DPP-4 Inhibitor|Any dose of Sitagliptin for 6 months with any other oral anti-diabetic medication
89142083|NCT02802644|Active Comparator|Non DPP-4 Inhibitor|Oral anti-diabetic medication except DPP-4 inhibitor
89142084|NCT02744976|Experimental|Prediabetes, metformin|Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations
89142085|NCT02744976|Active Comparator|Prediabetes, lifestyle|Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations
89142086|NCT00928889|Experimental|Nateglinide 120 mg|Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
89142087|NCT00928889|Active Comparator|Acarbose 50 mg|Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
89142088|NCT02803034|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89142089|NCT02725398|Experimental|Buscopan group|First to use standard white light to observe, to record spasm score, to observe the lesion.Buscopan (BSP, 20mg) is administered by endoscopic nurse, recorded blindly.
89142090|NCT02725398|Active Comparator|Scopolamine group|First to use standard white light to observe, to record spasm score, to observe the lesion.Scopolamine is administered by endoscopic nurse, recorded blindly.
89142091|NCT02725398|Placebo Comparator|physiological saline group|First to use standard white light to observe, to record spasm score, to observe the lesion. Physiological saline is administered by endoscopic nurse, recorded blindly.
89142092|NCT02802956|Experimental|intervention group|Daily Life Promotion Program
89142093|NCT02802956|Experimental|control group|general rehabilitation treatment
89142094|NCT04258865|Experimental|Sequence 1|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
89142095|NCT04258865|Experimental|Sequence 2|"Period 1: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
89142096|NCT04258865|Experimental|Sequence 3|"Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 3: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions"
89142097|NCT04258865|Experimental|Sequence 4|Period 1: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions Period 2: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions
89142098|NCT04258865|Experimental|Sequence 5|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions~Period 3: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions"
89142099|NCT04258865|Experimental|Sequence 6|"Period 1: CKD-348 formulation 2 - A single oral dose of 1 tablet under fasting conditions~Period 2: CKD-348 formulation 1 - A single oral dose of 1 tablet under fasting conditions~Period 3: CKD-828, D097, D337 - A single oral dose of 3 tablets under fasting conditions"
89142100|NCT02795624||Flight attendants|Flight attendants
89142101|NCT02795546|Experimental|Test group|400µg Alendronate sodium+ β-TCP + saline. 400µg alendronate sodium is combined with beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
89142102|NCT02795546|Active Comparator|Control group|β-TCP + saline Beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
89142103|NCT02720328|Other|DOAC-treated patients|Concerning patients taking DOACs, blood samples are drawn to evaluate DOAC plasma concentration. One EDTA tube is also drawn to extract DNA and determine the genetic profile of genes involved in the metabolism of DOACs. The aim will be to assess if genetic determinants can explain the observed interindividual variability in plasma concentrations.
89142104|NCT02795312|Experimental|Smoking Cessation Training Program|Participants will take part in a 9-week Smoking Cessation Program class curriculum consisting of weekly 2.5 hour classes and complete pre and post questionnaires
89142105|NCT05224115||[11C]CHDI-180R|Biodistribution and whole-body dosimetry for [11C]CHDI-00485180-R in 3 healthy volunteers.
89142106|NCT05224115||[11C]CHDI-626|Biodistribution and whole-body dosimetry for [11C]CHDI-00485626 in 3 healthy volunteers.
89142107|NCT03978091|Experimental|Arm 1|2.5g dose of ceftazidime-avibactam (AVYCAZ) administered intravenously as a 2-hour infusion, every 8 hours for 7 days. N=8
89142108|NCT03978091|Experimental|Arm 2|2.5g dose of AVYCAZ administered intravenously as a 2-hour infusion once, then 0.32g dose per hour daily as a continuous infusion (7.5 g/day) for 7 days. N=8
89142109|NCT03978091|Experimental|Arm 3|2g dose of aztreonam (ATM) administered intravenously as a 2-hour infusion, every 6 hours for 7 days. N=8
89142110|NCT03978091|Experimental|Arm 4|2g of ATM administered intravenously as a 2-hour infusion once, then 0.33g dose administered intravenously per hour, daily as a continuous infusion (8 g/day) for 7 days. N=8
89142111|NCT03978091|Experimental|Arm 5|2.5g dose of AVYCAZ administered intravenously as a 2-hour infusion, every 8 hours for 7 days, and a 1.5g dose of ATM administered intravenously as a 2-hour infusion, every 6 hours for 7 days. N=8
89142112|NCT03978091|Experimental|Arm 6|2.5 g dose of AVYCAZ administered intravenously as a 2-hour infusion every 8 hours for 7 days, and a 2g dose of ATM as a 2-hour infusion every 6 hours for 7 days. N=8
89142113|NCT02795468|Active Comparator|Palpation group|The operator will use the pulsation of the radial artery as a guide for the cannulation.
89142114|NCT02795468|Experimental|Ultrasound group|The ultrasound guided technique will be used to find a radial artery and insert a radial arterial catheter.
89142115|NCT01969812|Experimental|Evie Slow-Release Insemination Device|Preliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter.
89142116|NCT01969812|Active Comparator|Traditional Intrauterine Insemination|Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
89142117|NCT05219279||HIV+ participants|"HIV-infected between age of 20 and 65 years~Consistently have plasma HIV RNA levels <200 copies/mL for at least the last 12 months on a stable antiretroviral regimen with any changes made only for convenience, safety or simplicity."
89142118|NCT05219279||HIV- participants|25 age- and sex- matched HIV- subjects (healthy) will be recruited also at the UCLA Medical center who will undergo the neuroimaging examination.
89142119|NCT02800616|Experimental|Full intervention group|The full intervention ('The Healthy Primary School of the Future') is implemented in two schools involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years.
89234737|NCT00626405|Experimental|Arm I|Patients receive oral temozolomide on days 1-5 and bevacizumab IV over 30-90 minutes on days 1 and 15.
89234738|NCT00626405|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1.
89142120|NCT02800616|Experimental|Partial intervention group|The partial intervention ('The Physical Activity School') is implemented in two other schools: involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years. Hence, this intervention only differs from the full intervention on the absence of nutritional intervention. Instead, children bring their own food from home, as they normally do.
89142121|NCT02800616|No Intervention|Control group|Four primary schools will function as control schools. The control schools have a representative Dutch school environment in terms of lifestyle education, school hours and amount of Physical Education (PE) lessons.
89142122|NCT00610571|Experimental|Oral Topotecan and Temodar|Two separate strata to accrue independently. Stratum 1: Patients taking receiving Dilantin, Tegretol, Trileptal or Phenobarbital. Stratum 2: Patients on anti-convulsants other than Dilantin, Tegretol, Trileptal or Phenobarbital or patients not on any anti-convulsants
89142123|NCT02720250|Experimental|Omega-3|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
89142124|NCT02720250|Experimental|Regular|Intake of 3 regular chicken eggs per day for three weeks.
89142125|NCT02800460|Other|Deep brain stimulation with fMRI-3T|Patients will have a 3T-fMRI before their usual MRI-1,5T
89142126|NCT00608933|Active Comparator|Arm I (intervention)|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
89142127|NCT00608933|Other|Arm II (wait-list)|Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I (educational intervention) are made available to the wait-list health providers.
89142128|NCT02725320||Female Rotator Cuff Surgical Group|Females, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
89142129|NCT02725320||Male Rotator Cuff Surgical Group|Males, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
89142130|NCT02795390|Experimental|Chinese herbal medicine|MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. They are ShuDiHuang 15g and Danggui 10g for deficiency of blood, Maidong 15g and ShengDiHuang 10g for deficiency of Yin, and RouCongRong 15g and Niuxi 10g for deficiency of Yang.
89142131|NCT02795390|Placebo Comparator|Placebo|Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules.
89142132|NCT02725242|Experimental|Once-daily budesonide/formoterol (160/4.5 μg/d)|once-daily budesonide/formoterol (160/4.5 μg/d)
89142133|NCT02725242|Active Comparator|Twice-daily Budesonide (200μg)|twice-daily Budesonide (400μg/d)
89142134|NCT02802332|Active Comparator|Footlength Card|Pregnant women will receive a card that enables them to measure the length of their baby's foot. The card contains a phone number to pre-recorded message that provides basic information/advice regarding care of preterm and/or low birth weight babies
89142135|NCT02802332|No Intervention|No Footlength Card|Women in this group do receive any footlength card.
89142136|NCT00564733|Experimental|Chemotherapy|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients undergo FDG PET/CT (fludeoxyglucose F 18 positron emission tomography/computed tomography) scan between days 18-21. The FDG PET/CT is an imaging biomarker analysis. Patients that are responding to treatment receive paclitaxel IV and carboplatin IV on day 1. Treatment repeats every 3 weeks for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.Patients that are not responding to chemotherapy per FDG PET then receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Non-responding patients undergo an additional FDG PET/CT scan between days 18-21 of course 2.
89142137|NCT02802410|Experimental|IQ-Tape|IQ-application on leg muscles muscles
89142138|NCT02802410|Experimental|Kinesiotape|Kinesiotape application on leg muscles
89142139|NCT02802410|Experimental|No-Tape|No-Tape on leg muscles
89142140|NCT02725164|Placebo Comparator|Uncuffed tracheal tubes|After tracheal intubation with an uncuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
89142141|NCT02725164|Active Comparator|Cuffed tracheal tubes|After tracheal intubation with a cuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
89142142|NCT02800538|Experimental|Lauric acid|the nutrient that can be widely found in daily food.
89142143|NCT02800538|Experimental|Palmitic acid|the nutrient that can be widely found in daily food.
89142144|NCT02800538|Experimental|Capric acid|the nutrient that can be widely found in daily food.
89142145|NCT02800538|Placebo Comparator|Saline|physiological salt water
89142146|NCT00935155|Experimental|Acupuncture|Acupuncture in combination with exercise therapy
89142147|NCT00935155|Active Comparator|exercises|Coordination, mobilizing, endurance, strength
89142148|NCT00931385|Experimental|BI 1744 (Olodaterol) Low Dose|BI1744 Low Dose once daily
89142149|NCT00931385|Experimental|BI 1744 (Olodaterol) Med Dose|BI 1744 Med Dose once daily
89142150|NCT00931385|Placebo Comparator|Placebo|Placebo once daily
89142151|NCT00931385|Active Comparator|Foradil|Foradil 12 mcg twice daily
88805973|NCT01173029||Resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was not achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure >/=130 mmHg or mean 24hr diastolic pressure >/=80mmHg) by non-investigation specialized hypertensive unit care, in spite of appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
89142152|NCT02800226|Experimental|10Hz|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4-6 weeks
89142153|NCT02800226|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4-6 weeks
89142154|NCT02725086|Experimental|Part 1; Filgrastim 5 ㎍/kg|Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 5 ㎍/kg or Neupogen®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
89142155|NCT02725086|Experimental|Part 2; Filgrastim 10 ㎍/kg|Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
89142156|NCT00939289||Adults with T1DM|Adults (18+ years-old) diagnosed with type 1 diabetes mellitus; treated with multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy
89142157|NCT02724852|Active Comparator|HIV-infected adults|"Two-hundreds and forty-nine HIV-infected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologicals) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
89142158|NCT02724852|Experimental|HIV-uninfected adults|"Forty-six HIV-uninfected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologic) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
89142159|NCT00938665||Control Group|
89142160|NCT00938665||AD Group|
89142161|NCT02724618|Experimental|Curcumin plus RT|120mg/day nanocurcumin during RT course
89142162|NCT02724618|Placebo Comparator|Placebo plus RT|120mg/day placebo of nanocurcumin during RT course
89142163|NCT02801786|Placebo Comparator|Placebo|Five capsules containing placebo
89142164|NCT02801786|Experimental|Tamoxifen|Five capsules containing 20mg of tamoxifen.
89142165|NCT02801786|Experimental|Lidocaine|One sachet containing lidocaine gel at 4%
89142166|NCT02720172|Experimental|Early Home Exercise Program|The early home exercise program is an exercise-based self-management program for patients immediately after cervical spine surgery.
89142167|NCT02720172|Other|Usual Care|Usual postoperative care.
89142168|NCT04258553||Cervix cancer|Cervix cancer n=62
89142169|NCT04258553||Healthy controls|Healthy volunteers n=61
89142170|NCT03743233|Active Comparator|Hand file instrumentation|
89142171|NCT03743233|Active Comparator|Reciprocating instrumentation|
89142172|NCT02719782|Experimental|HBV/TCR T cell Infusion|"This is a single-arm study.~Patients will receive a total of 2 cycles, in which first 28-day treatment cycle consists of escalating doses of TCR-T on Day 1, Day 8, Day 15 and Day 22, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of second (final) cycle. A one month treatment break will be given between the cycles."
89142173|NCT02801864|Experimental|Combined real tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. The stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. For the experimental group, the stimulation will be ramped up for 45 seconds and stay there for 20 min. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
89142174|NCT02801864|Sham Comparator|Combined sham tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. For the sham group, the stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. The stimulation will be ramped up for 45 seconds and then ramp down after the initial 45 seconds. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
89142175|NCT00938743|Active Comparator|Atomoxetine|Treatment with a final dosis of 40-80mg atomoxetine daily
89142176|NCT00938743|No Intervention|Waiting list|
89142177|NCT02719392|Active Comparator|Minocycline|Patients in the minocycline group will take 1 minocycline (100mg) and 2 NAC placebo capsules in the morning and 1 minocycline (100mg) and 2 NAC placebo capsules in the evening for a total of 6 capsules per day over the course of the study.
89142178|NCT02719392|Active Comparator|N-acetylcysteine|Patients in the NAC group will take 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the morning and 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
88821397|NCT04280926||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
89142179|NCT02719392|Active Comparator|Minocycline + N-acetylcysteine|Patients in the minocycline NAC combination group will take 2 NAC (500mg) and 1 minocycline (100mg) capsule in the morning and 2 NAC (500mg) and 1 minocycline (100mg) capsule in the evening for a total of 6 capsules per day over the course of the study.
89142180|NCT02719392|Placebo Comparator|Placebo Control|Patients in the placebo control group will take 2 NAC placebo capsules and 1 minocycline placebo capsule in the morning and 2 NAC placebo capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
89142181|NCT02802098|Experimental|Bevacizumab + Durvalumab|Treatment with DURVALUMAB 10 mg/kg Q2W IV infusion plus Bevacizumab 10 mg/ Kg Q2W, IV infusion for a maximum duration of treatment of 12 months. Study treatment should be discontinued prior to 12 months if there is confirmed PD (unless the investigator considers the subject to continue to receive benefit from treatment), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or if other reasons to discontinue study treatment occur.
89142182|NCT00938821||Caudal Block|Review of charts of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B).
89142183|NCT02719704|Experimental|"MEXA-SE"|Intervention on physical fitness, eating habits and body image
89142184|NCT02719704|No Intervention|Control|School of the control group carried out one semester with the regular and traditional activities. The control school had three physical educations lessons per week, similar of experimental schools.
89142185|NCT02719704|Experimental|"Espelho, espelho meu"|School-based intervention on body image
89142186|NCT02719860|Experimental|Green tea|
89142187|NCT02719860|Experimental|Black tea|
89142188|NCT02719860|Placebo Comparator|Placebo tea|
89142189|NCT02795234|Other|Participants with Vitamin D deficiency|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
89142190|NCT02795234|Other|Participants with sufficient Vitamin D Level|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
89142191|NCT04013581|Experimental|TZD group|Pioglitazone added to Metformin, DPP-4 inhibitors, Sulfonylurea
89142192|NCT04013581|Active Comparator|SGLT-2 inhibitor group|Empagliflozin added to Metformin, DPP-4 inhibitors, Sulfonylurea
89142193|NCT02715960|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.
89142194|NCT02715648|No Intervention|No Phenazopyridine before cystoscopy|This group will not receive phenazopyridine prior to cystoscopy
89142195|NCT02715648|Experimental|Phenazopyridine before cystoscopy|This group will receive 200mg of phenazopyridine prior to cystoscopy
89142196|NCT00565747|Experimental|Test culture|Culture with GM-CSF
89142197|NCT00565747|Placebo Comparator|Control culture|Culture without GM-CSF
89142198|NCT02799836|Experimental|Light deprived study subjects|Study subjects who are blindfolded for 48 hours
89142199|NCT02794922|Experimental|Interventional|Name: Neurovit Forte tab Dosage: Each tablet contains Vitamin B1 242.5mg, Vitamin B6 250mg, Vitamin B12 1mg Frequency: One tab, once per day Duration: 6 weeks
89142200|NCT02794922|Placebo Comparator|Placebo|Capsule containing 250mg corn starch
89142201|NCT00935389|Experimental|immunosuppressor|TW 30mg,q.d.*3 months and reduced into 20mg b.i.d
89142202|NCT02715882|Experimental|1 injection of CBLB502 0.35 μg/kg|One subcutaneous injection of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 before tumor removal
89142203|NCT02715882|Experimental|1 injection of CBLB502 0.45 μg/kg|One subcutaneous injection of CBLB502 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 before tumor removal
89142204|NCT02715882|Experimental|2 injections of CBLB502 0.35 μg/kg|Two subcutaneous injections of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 and Day 4 before tumor removal
89142205|NCT02715882|Experimental|2 injections of CBLB502 0.45 μg/kg|Two subcutaneous injections of CBLB502 at 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 and Day 4 before tumor removal
89142206|NCT02801552|Experimental|Regenerative Endodontic Procedure + PRF|Visit 1: root canal dressing with triple antibiotic paste. Visit 2: a 5 ml sample of whole blood was drawn intravenously from the patient's forearm. The blood sample is centrifuged at 400 g for 10 min. The prepared PRF membrane is cut into segments, the fragments are placed into the canal space. The coronal is sealed mineral trioxide aggregate and composite resin.
89142207|NCT02801552|No Intervention|Regenerative Endodontic Procedure|Regenerative Endodontic Procedure Visit 1: root canal dressing with triple antibiotic paste. Visit 2: Blood clot formation is induced in the root canal after disinfection. No PRF was used in this group. Then the canal access is sealed with mineral trioxide aggregate and composite resin.
89142208|NCT00935467|Other|Saxagliptin|
89142209|NCT02719548|Experimental|Breastshield treatment group A|"Participants will be treated with the following three breast shields:~Soft edge oval - Hard oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
89142210|NCT02719548|Experimental|Breastshield treatment group B|"Participants will be treated with the following three breast shields:~Modified PF breast shield - Soft edge oval - Hard oval Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
89142211|NCT02719548|Experimental|Breastshield treatment group C|"Participants will be treated with the following three breast shields:~Hard oval - Soft edge oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
89142212|NCT00935545|Experimental|Open Label|
89142213|NCT02799992|Active Comparator|Half Dose Photodynamic Therapy|Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin
89142214|NCT02799992|Experimental|689 nm Laser Treatment|A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.
89142215|NCT02724306|Experimental|Active Lifestyle Programme|ALP will receive supervised exercise sessions twice per week for three months and once per week for the following three months. Participants will also take part in biweekly physical activity workshops for the period of the intervention. Each session consists of a warm-up (5-10min), aerobic (20-30min) and resistance exercises (15-20), and cool-down (5-10)stretches lasting in total 60min. The intensity of exercises will be at 65-85% of maximum heart rate as determined by maximal fitness test. Exercise will take place in small groups of two to five people. Behaviour change workshops to aid the uptake and maintenance of physical activity will be delivered every fortnight throughout the whole intervention period totalling 12 workshops. Workshops will also take place in small groups.
89142216|NCT02724306|No Intervention|Standard Care|The standard care group will not be offered the intervention until the end of the study at 12 months. Participants in this group will be encouraged to continue with their usual lifestyle.
89142217|NCT00935623|Experimental|Cohort 1|The first cohort will be challenged with 5 bites from P. vivax-infected mosquitoes each carrying at least a grade 2 sporozoite infection (>10 sporozoites in salivary gland).
89142218|NCT00935623|Experimental|Cohort 2|If the first cohort has less than 100% infectivity rate, the second cohort will be challenged with up to 10 grade 2 infective bites to ensure 100% infectivity rate.
89142219|NCT02715570|Experimental|Single dose - healthy volunteers|
89142220|NCT02715570|Experimental|Repeat dose - healthy volunteers|
89142221|NCT02715570|Experimental|Single dose - asthmatic patients|
89142222|NCT00935779||Gastric cancer|patients with operable local gastric adenocarcinoma were studied
89142223|NCT00935779||Control group|patients operated on for benign diseases served as controls, randomly selected among patients with chronic gastro-esophageal reflux disease who were considered good candidates for antireflux surgery and properly matched in sex and age to study group
89142224|NCT02801474|Experimental|direct reduction|Intervention: The posterior and lateral malleoli were accessed via a posterolateral approach with the patients in prone position. The fibular fracture was exposed and reduced anatomically in the first place. The posterior malleolus was then exposed between the fiexor halluces longus and peroneus longus interval. The posterior malleolar fragment was then reduced with reference to the typical metaphyseal-diaphyseal spike of the posterior malleolus. One-third tubular plate, reconstruction plate, or distal radius plate were applied spanning the fracture in a buttress mode. Cannulated screws could also be used.
88821398|NCT04272827|Active Comparator|Intervention group|In the intervention group, patients will receive liposuction treatment (number of surgeries at the discretion of the attending study physician: a maximum of 4 surgical procedures, with a minimum of 5 and a maximum of 7 weeks between each surgery) with concomitant complex decongestive therapy (CDT), if necessary, to maintain surgical outcomes as required by the patient.
89142225|NCT02801474|Experimental|indirect reduction|Intervention: After open reduction and internal fixation of lateral and medial malleolar fractures, the posterior malleolus was then reduced through ligamentotaxis with the ankle in dorsiflexion. One or two 4.0 mm cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
89142226|NCT00935935||HIV older than 50 years|
89142227|NCT01315392|Active Comparator|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for debridement and definitive closure.
89142228|NCT01315392|Active Comparator|immediate wound closure|traumatic and surgical wounds closed at initial surgical intervention
89142229|NCT00936013|Experimental|oseltamivir|single antiviral treatment
89142230|NCT00936013|Experimental|oseltimivir and chinese medicinal herbs|combination treatment
89142231|NCT02801318|Other|Polysomnography|
89142232|NCT02724384|Experimental|Group 1|Plasma treatment using Plasma delivery system A 3 treatments/week for 2 weeks, then monthly
89142233|NCT02724384|Experimental|Group 2|Plasma treatment using Plasma delivery system A 2 treatments/week for 2 weeks, then monthly
89142234|NCT02724384|Experimental|Group 3|Plasma treatment using Plasma delivery system B 3 treatments/week for 2 weeks, then monthly
89142235|NCT00939445|Active Comparator|Online HDF|Online HDF
89142236|NCT00939445|Active Comparator|Short Daily Hemodialysis|Short Daily Hemodialysis
89142237|NCT00936091|Placebo Comparator|placebo|125 schoolchildren were allocated randomly to receive placebo
89142238|NCT00936091|Active Comparator|vitamin A supplement|125 children received vitamin A supplements capsules (200 000 IU)
89142239|NCT02801630|Sham Comparator|Sham Crossover|"After the enrollment and lead in period, subjects will be given a sham device to sleep with every night for a month. They will be asked to fill out their pain and analgesic use logs, and undergo the bi weekly assessments. After a month they will be crossed over to an active Painshield SAW patch device and will continue to complete their pain and analgesic use logs as well as undergo biweekly assessments for months two and 3."
89142240|NCT02801630|Active Comparator|Active Device|After the enrollent and lead in period, subjects will be given an active PainSHield SAW Patch device to sleep with every night. They will be asked to fill out their pain and analgesic use logs, and undergo bi weekly assessments. They will continue to use the device while completing their logs and undergoing assessments for 3 months.
89142241|NCT02795000||Primary Ovarian insufficiency group|"amenorrhea one year or more than one year~amenorrhea more than 4 months and FSH≥40IU/L~≤42 years old and AMH≤0.071"
89142242|NCT02795000||The normal group|"normal regular menorrhea~≤42 years old~normal FSH and AMH level"
89142243|NCT00563797|Experimental|Mecamylamine|Mecamylamine is a noncompetitive, high-affinity nAChR antagonist with low selectivity for the alpha-7 receptor. Those receiving mecamylamine started at 2.5mg once daily (second dose was placebo). The dose was increased to 5.0 mg twice daily over 3 weeks.
89142244|NCT00563797|Placebo Comparator|Placebo|Placebo capsules were prepared by the pharmacy and were identical in size and color to the medication capsules.
89142245|NCT01192698|Experimental|IV interferon|IV interferon oral ribavirin
89142246|NCT01192698|No Intervention|Standard of care|standard of care
89142247|NCT00771927||Lacosamide|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with add-on Vimpat
89142248|NCT00771927||Other AED|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with other approved AED as add-on therapy
89142249|NCT02794688||Ductal lavage group|The patients will receive ductal lavage therapy every other day for two weeks, and will be followed up for one year.
89142250|NCT02719470|Experimental|normal cognition|Group 1: patients with normal cognitive profile, assessed with MMSE (27 ≤ correct score ≤ 30) undergoing MIRT
89142251|NCT02719470|Experimental|mildly impaired cognition|Group 3: patients with middle cognitive decline, assessed with MMSE (20 ≤ correct score < 27) undergoing MIRT
89142252|NCT02719470|Experimental|moderately-severely impaired cognition|Group 2: patients cognitive decline, assessed with MMSE (correct score < 20) undergoing MIRT
89142253|NCT02719470|Experimental|patients with normal executive functions|Group 4: patients with pathological executive functions, assessed with FAB (FAB ≥ 13.8) undergoing MIRT
89142254|NCT02719470|Experimental|pathological executive functions|Group 5: patients with pathological executive functions, assessed with FAB (FAB < 13.8) undergoing MIRT
89142255|NCT02801162|Active Comparator|Conventional ABG analyser|
89142256|NCT02801162|Experimental|Proxima 3® arterial blood gas|
89142257|NCT02715492|Active Comparator|Transarterial Chemoembolization|1st group: included 20 patients with HCC treated by TACE only.
89142258|NCT02715492|Experimental|TACE and LMWH|2nd group: included 20 patients with HCC treated by TACE and adjuvant dose of Low Molecular Weight Heparins (LMWH).
89142261|NCT05131230||CytoSorb group|
89142262|NCT02719236|Active Comparator|Direct anterior approach|Primary total hip arthroplasty using a direct anterior approach
89142263|NCT02719236|Active Comparator|Direct lateral approach|Primary total hip arthroplasty using a direct lateral approach
89142264|NCT00936169|Experimental|IVUS optimised stent implantation|
89142265|NCT00936169|Active Comparator|angiographically guided DES implantation|
89142266|NCT02724150|Active Comparator|Omeprazole High dose|Omeprazole 80 mg loading dose,then 8mg/h IV continuous infusion for 3 days
89142267|NCT02724150|Experimental|Omeprazole Low Dose|Omeprazole 80 mg loading dose IV then 40 mg two times per day IV for 3 days
89142268|NCT00939601|Active Comparator|Motivational Enhancement Therapy|MET will involve counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
89142269|NCT00939601|Active Comparator|Educational Counseling|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
89142270|NCT00939601|No Intervention|Standard Care|
89142271|NCT02800850|Experimental|Bright Light Group|Bright Light Exposure
89142272|NCT02800850|Placebo Comparator|Control Group|Placebo Light Exposure
89142273|NCT00771849|Experimental|Menactra® Vaccine Group|Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
89142274|NCT00771849|Active Comparator|Hiberix® Vaccine Group|Participants receiving Haemophilus Influenzae Type b (Hib) vaccine
89142275|NCT00936247|Experimental|1|HES 130/0.42 + Sterofundin ISO
89142276|NCT00936247|Active Comparator|2|Albumin + NaCl 0.9%
89142277|NCT00936403|Experimental|NNC126-0083|
89142278|NCT00936403|Active Comparator|Norditropin NordiFlex®|
89142279|NCT02601729||RT-CGM population|Prospective data collection during standardized clinical follow-up and from filled out questionnaires.
89142280|NCT02601729||Pump only population|Retrospective data collection on demographic and clinical characteristics.
89142281|NCT02794454|Active Comparator|HeezOn Ultra-1|HeezOn Ultra-1 includes ingredients like Shilajit, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
89142282|NCT02794454|Active Comparator|HeezOn Ultra-2|HeezOn Ultra-2 includes ingredients like Arjuna, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
89142283|NCT02794454|Placebo Comparator|Placebo|Placebo consists of Micro-crystalline Cellulose. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
88821399|NCT04272827|Other|Control group|"After randomisation, the control group will be treated for 12 months with complex decongestive therapy (CDT) alone.~After these 12 months, patients can opt for liposuction treatment if they continue to meet the inclusion and exclusion criteria."
89142284|NCT02715336|Experimental|Study group: High Responders|1000 units hCG
89142285|NCT02715336|No Intervention|Control group: High Responders|1000 units hCG
89142286|NCT02715336|Experimental|Study group: Normal Responders|5000 units hCG
89142287|NCT02715336|No Intervention|Control group: Normal Responders|5000 units hCG
89142288|NCT02715336|Experimental|Study group: Low Responders|10000 units hCG
89142289|NCT02715336|No Intervention|Control group: Low Responders|10000 units hCG
89142290|NCT02799680|Experimental|allogeneic CART-33|infusions of allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
89142291|NCT00936559|Experimental|1|Arm A
89142292|NCT00936559|Experimental|2|Arm B
89142293|NCT00936559|Experimental|3|Arm C
89142294|NCT02794610|Experimental|Topical tacrolimus|Ten patients will be include. Topical tacrolimus 0.05% will be instilled into the eyes of patients 15 minutes before cataract surgery. Aqueous samples will be collected at the time of cataract surgery and will be subjected to detection of presence and level of tacrolimus.
89142295|NCT00940225|Experimental|Arm 1|RDT Open-Label
89142296|NCT00940225|Experimental|Arm 2|RDT Randomized Blinded-XL184
89142297|NCT00940225|Placebo Comparator|Arm 3|RDT Randomized Blinded
89142298|NCT00940225|Experimental|Non-Randomized Expansion (NRE) Cohorts|Drug: XL184
89142299|NCT02801240|Experimental|Nutrition Support Product|Participants will be asked to take a nutrition support product twice per day for a period of 12 weeks.
89142300|NCT02799758|Experimental|NK-104-CR|NK-104-CR 8 mg tablet and Placebo (for Livalo® IR 4 mg tablet) orally once daily for 52 weeks.
89142301|NCT02799758|Active Comparator|Livalo® IR|Livalo® IR 4 mg tablet and Placebo (for NK-104-CR 8 mg tablet) orally once daily for 52 weeks.
89142302|NCT03259165|Experimental|Nitrate Intense Strategy|Patients randomized to the Nitrate intense strategy will be treated according to protocol with nitrates in combination with IV loop diuretics. This protocol only involves therapies used in everyday AHF clinical practice.
89142303|NCT03259165|Experimental|Diuretic Intense Strategy|Patients randomized to the Diuretic intense strategy will be treated according to protocol with IV loop diuretics in combination with nitrates. This protocol only involves therapies used in everyday AHF clinical practice.
89142304|NCT04013659|Experimental|G1 - Permanence of the Whitening Gel|Permanence of the Whitening Gel (Biological Product: 35% Hydrogen Peroxide) on the tooth enamel during the 15 minutes of dental-bleaching
89142305|NCT04013659|Experimental|G2 - Renewal of the Whitening Gel|3 Whitening Gel (Biological Product: 35% Hydrogen Peroxide) renewal every 5 minutes during the 15 minutes of dental-bleaching
89142306|NCT02799368|Experimental|CJ Plasma Solution A Injection|Before contrast media administration : CJ Plasma Solution A Injection (3mL/kg for 1 hour) After contrast media administration : CJ Plasma Solution A Injection (1.5 mL/kg/h for 4 hours)
89142307|NCT02799368|Active Comparator|CJ 0.9% Normal Saline Injection|Before contrast media administration : CJ 0.9% Normal Saline Injection (3mL/kg for 1 hour) After contrast media administration : CJ 0.9% Normal Saline Injection (1.5mL/kg/h for 4 hours)
89142308|NCT00938977|Active Comparator|CPAP|Response to treatment before/after treatment in patients with OSAS and SOH
89142309|NCT00938977|Active Comparator|Bilevel support ventilation|Before and after effect of Bilevel support ventilation in patients with SOH without OSA
89142310|NCT02790398|Experimental|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol.
89142311|NCT02790398|Active Comparator|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol that includes a component aimed at the regulation of PA.
89142312|NCT02790554|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
89142313|NCT02790554|Active Comparator|Hand-held Doppler|Intermittent fetal heart rate monitoring
89142314|NCT02790320||Patients with locally recurrent or metastatic breast cancer|Patients received 1.4 mg/m2 eribulin, administered intravenously on day 1 and 8 of each 21 day cycle until disease progression or unmanageable toxicity, per routine clinical practice.
89142315|NCT00939133|Active Comparator|Tretinoin microsphere 0.04% gel|
89142316|NCT00939133|Placebo Comparator|Vehicle gel|
89142317|NCT02790476|Experimental|Letter intervention|The intervention arm will involve letters sent to prescribers in San Diego County.
89142318|NCT02790476|No Intervention|Control|The control group will involve prescribers not receiving letters
89142319|NCT00939679|Experimental|Earlier gastric bypass surgery (7 weeks)|These patients will undergo gastric bypass surgery 7 weeks after starting a low calorie diet, and will continue the low calorie diet for 3 weeks following surgery.
89142320|NCT00939679|Active Comparator|Later gastric bypass surgery (10 weeks)|These patients will undergo gastric bypass surgery 10 weeks after starting a low calorie diet.
89142321|NCT02799446|Experimental|Reslizumab|Reslizumab will be administered intravenously every 4 weeks at a dose of 3mg/kg.
89142322|NCT02799446|Placebo Comparator|Placebo|Matching placebo.
89142323|NCT02794532|No Intervention|Pre oxygenation with 100% oxygen via tight fitting mask|Pre Oxygenation will be done using a tight mask
89142324|NCT02794532|Experimental|Pre oxygenation with 100% oxygen in high-flow nasal cannula|Pre Oxygenation will be done using high-flow nasal canula
89142325|NCT02794376|Experimental|Immediate Treatment Group|Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments.
89142326|NCT02794376|Other|Delayed Treatment Group|Waiting period plus Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments after the waiting period has finished.
89142327|NCT00564889|Experimental|CRD|"Lenalidomide 15mg daily (days 1-21)~Cyclophosphamide 300 mg/m^2 (days 1, 8, 15)~Dexamethasone 40 mg weekly"
89142328|NCT02790164|Experimental|Rocuronium|Patients will receive a bolus dose of 0.6 mg/kg, then a continuous I.V. infusion of 0.3-0.6 mg/kg/hr as per standard intensive care unit practice.
89142329|NCT02790164|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
89142330|NCT02790008||Aortic valve disease|Patients with aortic stenosis referred to surgery. Exclusion criteria are concomitant heart valve disease, congenital heart disease, hemodynamic instability, previous cardiac surgery, history of myocardial infarction and coronary artery disease.
89142331|NCT05417750|Experimental|Experimental: Cohort 1|dose escalation group: participants with advanced solid tumors using cryopreserved GC101 TIL
89142332|NCT05417750|Experimental|Experimental: Cohort 2|participants with advanced cervix tumors using cryopreserved GC101 TIL
89142333|NCT05417750|Experimental|Experimental: Cohort 3|participants with advanced malignant melanoma using cryopreserved GC101 TIL
89142334|NCT05417750|Experimental|Experimental: Cohort 4|participants with advanced HNSCC using cryopreserved GC101 TIL
89142335|NCT00939757|Experimental|1. mirabegron, lower dose|
89142336|NCT00939757|Experimental|2. mirabegron, higher dose|
89142337|NCT05415644|Experimental|Bioequivalence study part|
89142338|NCT05415644|Experimental|Food impact study part|
89142339|NCT02690012|Active Comparator|Drug Magnesium oxide|Participants will be given standard dose levels of Magnesium oxide according to the level of magnesium in blood.
89142340|NCT02690012|Active Comparator|Drug Magnesium citrate|Participants will be given standard dose levels of Magnesium citrate according to the level of magnesium in blood.
89142341|NCT00939913|Placebo Comparator|intravenous N-acetlycysteine|"intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)as compared to placebo~Acetadote provided by Cumberland Pharmaceuticals Inc."
88821400|NCT04270747|Experimental|ABP 938-Treatment Group A|Subjects will receive 2 mg (0.05 mL) of ABP 938 by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8) and every 8 weeks from week 16 until week 48.
89142342|NCT00939913|Placebo Comparator|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
89142343|NCT04234958|Experimental|Experimental|Participants received osteopathic treatment
89142344|NCT04234958|Sham Comparator|Sham|Participants received sham therapy
89142345|NCT04234958|No Intervention|Control|Participants received no intervention
89142346|NCT04013425|Experimental|Ice Cream Cone Technique|Atraumatic extraction followed by addition of barrier membrane and xenograft in the socket.
89142347|NCT04013425|No Intervention|Spontaneous Healing|Spontaneous Healing after Atraumatic Extraction
89142348|NCT02793986|Experimental|dexmedetomidine sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h.
89142349|NCT02793986|Experimental|propofol sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
89142350|NCT04013347||Early Surgery|Surgery after ≤ 42 days from the end of neoadjuvant radio-chemotherapy
89142351|NCT04013347||Late Surgery|Surgery after 43-56 days from the end of neoadjuvant radio-chemotherapy
89142352|NCT04013347||Very Late Surgery|Surgery after 57 or more days from the end of neoadjuvant radio-chemotherapy
89142353|NCT02794064|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of breast and adjacent lymph nodes. Imaging time: Approximately 30 minutes
89142354|NCT00940069|Experimental|TS high expression genotype|TS high expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
89142355|NCT00940069|Experimental|TS low expression genotype|TS low expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
89142356|NCT00940303|Experimental|1|
89142357|NCT02794220|Experimental|CN Electronic cigarette 10 mg|"10 mg strength~- Administration once every hour for a total of 4 hours."
89142358|NCT02794220|Experimental|CN Electronic cigarette 15 mg|"15 mg strength~- Administration once every hour for a total of 4 hours."
89142359|NCT02794220|Active Comparator|Nicorette Inhalator 15 mg|"15 mg strength~- Administration once every hour for a total of 4 hours."
89142360|NCT02794220|Active Comparator|Cigarette|"Subjects will all smoke the same brand.~- Administration once every hour for a total of 4 hours."
89142361|NCT00941083|Experimental|RAL QD 800 mg/24 hs|
89142362|NCT00941083|Active Comparator|RAL BID 400 mg/12 hs|
89142363|NCT00941083|Experimental|RAL BID to QD|
89142364|NCT02798900|Experimental|Functional task-training and Ultrasound|This group will receive 16 sessions of functional task-training program and therapeutic ultrasound will be applied prior to functional task-training.
89142365|NCT02798900|Active Comparator|Functional task-training|This group will receive 16 sessions of functional task-training program.
89142366|NCT04405999|Experimental|Bromhexine hydrochloride Group|medical personnel at risk for COVID-19 infection with oral administration of Bromhexine hydrochloride
89142367|NCT04405999|No Intervention|Control Group|medical personnel at risk for COVID-19 infection without oral administration of Bromhexine hydrochloride
89142368|NCT02794142|Experimental|HD patient|
89142369|NCT02794142|Other|Healthy volunteers|
89142370|NCT02794298|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
89142371|NCT02794298|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
89142372|NCT02794298|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
89142373|NCT02793908|Experimental|Pleyris|Subcutaneous progesterone will be administered 25 mg a day from the day following the ovulation for 14 days
89142374|NCT02793908|Active Comparator|Crinone8|Vaginal progesterone will be administered 90 mg a day from the day following the ovulation for 14 days
89142375|NCT02793830|Experimental|Mobile App Group|Participants in the experimental group will receive daily reminders and educational materials from mobile applications.
89142376|NCT02793830|Active Comparator|Control Group|The control group will receive the same educational materials, but no daily reminder.
89142377|NCT02789618|Active Comparator|A01|Toothpaste containing calcium silicate and Sodium Monofluorophosphate (1450ppm F) and a gel containing sodium fluoride (1450ppm F)
89142378|NCT02789618|Active Comparator|B99|Toothpaste containing Stannous Fluoride and a dentinal bonding agent
89142379|NCT02789618|Placebo Comparator|M89|Toothpaste containing sodium fluoride (1450ppm F)
89142380|NCT02718846|Experimental|Meniace and Isobide|co-administration Isobide solution and Meniace tablets
89142381|NCT02718846|Active Comparator|Meniace|single administration Meniace tablets
89142382|NCT00560833|Placebo Comparator|Placebo|Participants receive placebo, encapsulated tablets, orally (PO), once daily (QD) for up to 12 weeks
89142383|NCT00560833|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine 2.25 mg, encapsulated tablets, PO, QD for up to 12 weeks
89142384|NCT00560833|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg, encapsulated tablets, PO, QD for up to 12 weeks
89142385|NCT00560833|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine 9 mg, encapsulated tablets, PO, QD for up to 12 weeks
89142386|NCT00560833|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine 18 mg, encapsulated tablets, PO, QD for up to 12 weeks
89142387|NCT02789696|Other|Acromegaly|Diagnosis of acromegaly
89142388|NCT02715414|Active Comparator|Multiple Family Group (MFG)|A multiple family group (MFG) is a 12-week, family-centered, group delivered intervention consists of six to eight families (caregiver/child dyads). Groups meet for approximately two hours per week, and sessions focus on targeting family-level factors that are associated with child problem behaviors. Specifically, eight of the 12 sessions are devoted to establishing rules (family organization, consistent discipline), responsibilities (inter-connectedness, expectancies), relationships (family warmth, within family support), respectful communication (family communication and conflict). An additional four sessions are focused on factors that impact the ability of families to incorporate new behaviors (family stress and social support).
89142389|NCT02715414|Experimental|MFG + Clinic Implementation Team|This condition consists of service providers, directors, and clinic staff who will create site-specific plans to enhance uptake and implementation of MFG. CITs address potential barriers to implementation and adjust the format and structure of MFG as needed in order to be implemented as part of clinic care.
89142390|NCT02715414|No Intervention|Standard Care|Standard Care consists of services including outpatient individual and family therapy, which are offered as part of clinic care.
89142391|NCT04233710|Experimental|Robot + tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period, with 20 minutes of 1mA cathodal tDCS applied to the contralesional M1 area during first 20 minutes of robotic therapy. Robotic therapy will be conducted using the Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
89142392|NCT04233710|Sham Comparator|Robot + sham tDCS|10 sessions of 1.5 hrs of robotic therapy within a 3 week period with 20 minutes of SHAM tDCS applied during the first 20 minutes of the robotic therapy. As with experimental arm, electrode will be placed on contralesional M1. Current will ramp up and then immediately ramp down to simulate the cutaneous sensations felt with actual tDCS. Robotic therapy will be delivered with Kinarm Exoskeleton robot and use games to target unilateral and bilateral motor and sensory impairments.
89142393|NCT04013113|Active Comparator|Standard Medical Treatment|Group A will be given standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
89142394|NCT04013113|Experimental|Hemoadsorption plus standard medical therapy|
89142395|NCT04013113|Experimental|Plasma Exchange plus standard medical therapy|
89142396|NCT02718924||morbidly obese pregnant|Term pregnant women with BMI more than 40
89142397|NCT02718924||non obese pregnant|Term pregnant women with BMI less than 30
89142398|NCT00940147||1|patients with OAC, Score finding
89142399|NCT00940147||2|patients without OAC, Score finding
89142400|NCT02789852|Experimental|Orthosis Group|Will use the night orthosis for interphalangeal in the treatment of OA hand.
89142401|NCT02789852|No Intervention|Control Group|wait for treatment
89142402|NCT00941161|Experimental|combination|long acting Metformin/Glimepiride
89142403|NCT00941161|Active Comparator|metformin|metformin hydrocloride
89142404|NCT00941161|Active Comparator|glimepiride|glimepiride
89142405|NCT02798822|Active Comparator|RME on upper first permanent molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 35 ± 6 days for Gr6, and the average treatment time was 12 ± 1.3 months.
89142406|NCT02798822|Active Comparator|RME on upper second deciduous molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 41 ± 8 days, and the average treatment time was 12 ± 1.3 months.
89142407|NCT00944515|Active Comparator|azithromycin|azithrimycin 3 days/week
89142408|NCT00944515|Placebo Comparator|placebo|placebo 3 days/week
89142409|NCT00771654|Placebo Comparator|Placebo|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
89142410|NCT00771654|Experimental|Phentermine|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
89142411|NCT04234412|Experimental|Osteoarthritic knee patients|Osteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells.
89142412|NCT00941239|Experimental|metformin ER|Extended Release Metformin
89142413|NCT00941239|Active Comparator|metformin|Immediate release metformin
89142414|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation A Group|Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142415|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142416|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142417|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142418|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142419|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142420|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142421|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142422|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89142423|NCT02723604|Experimental|Experimental: Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
89142424|NCT02793596|Experimental|Obstetrical patients|Obstetrical patients requiring epidural analgesia for delivery
89142425|NCT04235426|Experimental|surgical group.|30 patients went to the surgical release of carpal tunnel.
89142426|NCT04235426|Experimental|medical group.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
89142427|NCT04235426|Experimental|injection group.|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
89142428|NCT02714946|Active Comparator|LA Arm|Percutaneous Laser Ablation
89142429|NCT02714946|Active Comparator|RFA Arm|Percutaneous Radiofrequency Ablation
89142430|NCT02793440|Active Comparator|cortivazol|anti-inflammatory therapy and epidural
89142431|NCT02793440|Experimental|Traction arm|Medical treatment associated with 5 lumbar traction sessions
89142432|NCT00560755|Experimental|ProQuad®|Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.
89142433|NCT05276934||Evolution of brain imaging in Non-traumatic Intracranial Hemorrhage|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome
89142434|NCT02789150|Experimental|MAP 65-70|Goal MAP of 65-70
88805974|NCT01173029||Pseudo-resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure <130 mmHg and mean 24hr diastolic pressure <80mmHg) by non-investigation specialized hypertensive unit care, with appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
88805975|NCT01174823|Experimental|Bepotastine Besilate Ophthalmic Solution|
89142435|NCT02789150|Active Comparator|MAP greater than or equal to 85|MAP greater than or equal to 85
89142436|NCT00770991|Experimental|Black Raspberry (BRB) Slurry plus BRB suppositories|20 grams BRB Slurry BID plus two, 730 mg BRB suppositories HS
89142437|NCT00770991|Experimental|Black Raspberry (BRB) Placebo Slurry plus BRB suppositories|20 grams BRB Placebo Slurry BID plus two, 730 mg BRB suppositories HS
89142438|NCT02723526||Single arm|
89142439|NCT02715024|Experimental|Tamsulosin alone|
89142440|NCT02715024|Experimental|Tamsulosin + solifenacin|
89142441|NCT02793752||Mitochondrial Activity of Cumulus Cells|One way that cumulus cells influence oocyte competence is via metabolism (Dumesic et al., 2015). Analysis of mitochondria respiration is an established methodology used for evaluation of cell metabolic homeostasis and for diagnosis of different pathologies.
89142442|NCT02793752||Competence to Blastocyst|The percentage of fertilized eggs that develop to the blastocyst stage.
89142443|NCT00941395|Experimental|Arm I (smoker, survey)|Participants who currently smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2. Participants also complete 3 internet surveys over 20 minutes.
89142444|NCT00941395|Experimental|Arm II (non-smoker, survey)|Participants who currently do not smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2.
89142445|NCT02798744|Experimental|Empagliflozin 25mg once daily|Empagliflozin (Jardiance™) 25mg once daily (orally)
89142446|NCT02798744|Experimental|Empagliflozin 25mg once daily + diet|Empagliflozin (Jardiance™) 25mg once daily (orally) + energy restriction diet
89142447|NCT02798744|Placebo Comparator|Placebo once daily|Placebo once daily (orally)
89142448|NCT02798744|Active Comparator|Placebo once daily + diet|Placebo once daily (orally) + energy restriction diet
89142449|NCT00925769|Experimental|1|
89142450|NCT00770913|Active Comparator|1|
89142451|NCT00770913|Experimental|2|
89142452|NCT00770913|Experimental|3|
89142453|NCT00562861|Active Comparator|citalopram + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to citalopram.
89142454|NCT00562861|Placebo Comparator|placebo + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to placebo
89142455|NCT02723448|Other|Single Arm Study|Aclarubicin (6 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days (Days 2-5) of each 28 day cycle to each participant [Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) patients]. There is no maximum number of cycles.
89142456|NCT02793362||Normal subjects without stroke|"subjects who can walk independent without any difficult~subjects without history of CNS or PNS lesion~Modified ranking scale (MRS) <=2~Functional ambulation category (FAC) >=2"
89142457|NCT02793362||Post stroke patients with sarcopenia(by sarcopenia index)|Existence of sarcopenia will be determined by DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
89142458|NCT02793362||Post stroke patients without sarcopenia(by sarcopenia index)|patients who do not satisfy the value of DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
89142459|NCT02793362||Post stroke patients with sarcopenia(by lean body mass)|Existence of sarcopenia will be determined by DEXA scan where appendicular lean mass less than <19.75 kg in men, and <15.02 kg in women are considered sarcopenia.
89142460|NCT02793362||Post stroke patients without sarcopenia(by lean body mass)|patienst who do not satisfy the value of DEXA scan where appendicular lean mass less than <19.75 kg in men, and <15.02 kg in women are considered sarcopenia.
89142461|NCT00944593|Experimental|300kcal liquid Nutrient|300kcal liquid nutrient delivered by NJ tube over 60 minutes before ingestion of a standard oral liquid nutrient test meal
89142462|NCT00944593|Placebo Comparator|Normal Saline|Normal Saline delivered via NJ tube over 60 minutes ahead of a standard liquid nutrient test meal
89142463|NCT02715180|Other|Chest computed tomography|Low dose chest computed tomography during expiration and inspiration
88805976|NCT01174823|Placebo Comparator|Placebo|
89142464|NCT02798510|Experimental|Arm 1|Patients in arm 1 will receive adjuvant chemotherapy followed by concurrent chemoradiotherapy. Patients will receive four cycles of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days followed by concurrent capecitabine (1,330mg/m2 per day) and radiotherapy (50.4Gy/28fx to regional lymphatics with or without tumor bed)
89142465|NCT02798510|Active Comparator|Arm 2|Patients in arm 2 will receive six cycles chemotherapy of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days
89142466|NCT05297175|Other|Single arm|Implantation of a medial meniscus prosthesis in the medial knee compartment of a post medial meniscectomy knee.
89142467|NCT02723214|Active Comparator|Frame-based stereotactic brain biopsy|Brain biopsy
89142468|NCT02723214|Active Comparator|Frameless fiducial-less brain biopsy|Brain biopsy
89142469|NCT00941551||Group A|receiving levothyroxine postoperatively
89142470|NCT00941551||Group B|not-receiving levothyroxine postoperatively
89142471|NCT00770679|Experimental|High-Dose Statin|80 mg atorvastatin daily for 3 weeks
89142472|NCT03914066|Experimental|Group treatment in primary care|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
89142473|NCT02718534|Experimental|ERTAS-1|first limb rehabilitation therapy took place within 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
89142474|NCT02718534|Active Comparator|ERTAS-2|first limb rehabilitation therapy took place after 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
89142475|NCT05330663|Experimental|Intervention group|Low protein diet with Fresubin® renal
89142476|NCT05330663|Other|Standard of care|Low protein diet with normal food
89142477|NCT03768284||Psoriasis patients|Patients (of any age) who developed psoriasis before 12 years of age and who have no family history of psoriasis in either parent.
89142478|NCT03768284||Parents of psoriasis patients|Parents of patients who developed psoriasis before 12 years of age
89142479|NCT03768284||Up to third-degree family members with or without psoriasis|Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.
89142480|NCT04260503||Biliary Atresia|Disease group
88805977|NCT03011489|Experimental|Vacuum formed aligners group|This group will receive Vacuum formed aligners in addition to taping for 3 Months with follow-up every 1-2 weeks
89142481|NCT04260503||Choledochal cyst|Disease control
89142482|NCT04260503||Neonatal hepatitis|Disease control
89142483|NCT04260503||Healthy baby|Healthy control
89142484|NCT03838640|Experimental|Study group|Consecutive eligible patients requiring endoscopic surgery for sinonasal pathology Transnasal localization of internal carotid artery with TEE ECHO device will be performed
89142485|NCT04042116|Experimental|Phase 1b: Dose Escalation|- Up to 50 patients with advanced solid tumor
89142486|NCT04042116|Experimental|Phase 1b: Food Effect Cohort|- Approximately 16 evaluable patients with an advanced, metastatic solid tumor will be enrolled
89142487|NCT04042116|Experimental|Phase 2: Expansion Cohort - Endometrial Cancer|"Recurrent endometrial carcinoma at least 1 prior platinum-based chemotherapy regimen~Up to 10 patients who have progressed on treatment with 1 prior PD-(L)1 inhibitor administered as monotherapy will be allowed to enroll"
89142488|NCT04042116|Experimental|Phase 2: Expansion Cohort - Ovarian Cancer|"Recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma~At least 2 prior chemotherapy regimens which at least 1 must have been platinum-doublet chemotherapy~Up to 10 subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma who have progressed within 6 months after completing first-line platinum-based chemotherapy will be allowed to enroll"
89142489|NCT04042116|Experimental|Phase 2: Expansion Cohort - Clear Cell Cancer|"Recurrent, metastatic clear cell carcinoma of ovarian, fallopian tube, primary peritoneal or endometrial origin~At least 1 prior platinum- and taxane-based chemotherapy regimen"
89142490|NCT04042116|Experimental|Phase 2: Expansion Cohort - Cervical Cancer|"Persistent or recurrent cervix cancer of squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma histology~At least 1 prior regimen of platinum-based chemotherapy, with or without bevacizumab, for metastatic disease"
89142491|NCT00941629|Active Comparator|Cognitive Processing Therapy FTF|Cognitive Processing Therapy delivered in traditional face-to-face sessions (FTF)
89142492|NCT00941629|Experimental|Cognitive Processing Therapy TMH|Cognitive Processing Therapy delivered over videoconferencing equipment to a distant location (or telemental health; TMH)
89142493|NCT02798432|Experimental|Hybrid NEXGEN LPS|Noncemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
89142494|NCT02798432|Sham Comparator|Cemented NEXGEN LPS|Cemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
89142495|NCT04260581|Experimental|PD patients who have taken amantadine|
89142496|NCT00770601|Experimental|Canakinumab|Participants received body-weight stratified dosage of canakinumab treatment at 300 milligrams (mg) (for participants weighing more than 40 kilograms (kg)) and at 2 mg/kg (for participants weight less than or equal to 40 kg) subcutaneously every 4-8 weeks as per investigator discretion for a treatment period of 6 months. The first 3 Neonatal-Onset Multisystem Inflammatory Disease (NOMID) participants enrolled received a dose of 150 mg (>40 kg) and 2 mg/kg for children <40 kg. Since this dose was insufficient to fully control the symptoms of the disease the 300 mg / 4mg/kg dose was introduced by Protocol Amendment 2.
88805978|NCT03011489|No Intervention|control group|This group will not receive any treatment
88805979|NCT03886649|Experimental|Copanlisib + Venetoclax|Phase Ib -> dose escalation with 2 expansion cohorts
88805980|NCT01151813|Active Comparator|Varenicline|Varenicline, oral administration for 1 week
89142497|NCT00941707|Experimental|JNJ-38518168|
89142498|NCT00941707|Placebo Comparator|Placebo|
89142499|NCT00609089|Experimental|I|Community Reinforcement and Family Training for Retention in Treatment and Recovery and Reduction of HIV Risk Behavior (CRAFT-T)
89142500|NCT00609089|Active Comparator|II|Treatment As Usual
89142501|NCT02718378|Placebo Comparator|No added active|placebo without estetrol
89142502|NCT02718378|Active Comparator|estetrol dose level 1|estetrol given in dose level 1
88805981|NCT01151813|Placebo Comparator|Placebo|Placebo, oral administration for 1 week
89142503|NCT02718378|Active Comparator|estetrol dose level 2|estetrol given in dose level 2
89142504|NCT02718378|Active Comparator|estetrol dose level 3|estetrol given in dose level 3
89142505|NCT00770367|Experimental|Pioglitazone then Placebo|18 volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take Pioglitazone for the first 12 week period of the study and then take the placebo for the final 12 weeks of the study.
89142506|NCT00770367|Experimental|Placebo then Pioglitazone|18 (other half of participants) volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take the placebo for the first 12 week period of the study and then take the Pioglitazone for the final 12 weeks of the study.
89142507|NCT00931307|Experimental|Lotrafilcon A|
89142508|NCT04012255|Experimental|DV3396|Participants will receive once-weekly doses of semaglutide administered with the DV3396 pen-injector (test drug product)
89142509|NCT04012255|Active Comparator|PDS290|Participants will receive once-weekly doses of semaglutide administered with the PDS290 pen-injector (comparator drug product)
89142510|NCT02789462||Patients undergoing laser-assisted PCI|Patients of VAMC centers who undergone laser-assisted percutaneous coronary interventions.
89142511|NCT02723370|Experimental|Initial Intervention|Staff will receive the intervention during the initial intervention period.
89142512|NCT02723370|Experimental|Delayed Intervention|Staff will receive the intervention during the replication study.
89142513|NCT04263545|Active Comparator|Intervention|
89142514|NCT04263545|Placebo Comparator|Standard Care|
89142515|NCT00941785|Experimental|DHA-PQ|Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October.
89142516|NCT00941785|Active Comparator|SP-AQ|Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine
89142517|NCT00610805|Experimental|1|Participants randomized to this arm (n=15) will be followed by Preventive Cardiology and will have appropriate goal oriented interventions on their risk factor levels for 2 years.
89142518|NCT00610805|Other|2|Participants randomized to this arm (n=15) will receive usual care. The PI will send a letter of all testing results to their primary care physician. No standard care will be withheld.
89142519|NCT02798198||Diabetes group|37 T2DM adults (diabetes group) without DKD
89142520|NCT02798198||Control group|33 healthy adults (control group)
89142521|NCT00944827|Experimental|GTE|The experimental group will receive 20 mg atorvastatin (Lipitor) daily and 600 mg. of pure catechin in capsules
89142522|NCT00944827|Placebo Comparator|CON|The control group will receive 20 mg atorvastatin (Lipitor) and Placebo in identical capsules containing 600 mg placebo for 12 weeks
89142523|NCT02723292|Experimental|Experimental group services|This study will replicate the evidence-based TOP™ in after-school sessions held during RC hours. The primary components of TOP™ include: Comprehensive age-appropriate sexuality education; 90-minute sessions, once a week after-school, during the school year for nine months, using the Changing Scenes© curriculum, and at least twenty hours of youth-led service learning, which involves youth in planning, implementing and reflecting on, community service and leadership.
89142524|NCT02723292|Active Comparator|Control group services|Youth in the control arm will receive a work readiness training curriculum focused on competencies to secure employment. This will include such topics as building customer service skills, clear and direct communication, and creating a work portfolio.
89142525|NCT02793518|Experimental|Bipolar Disorder patients|
89142526|NCT02793518|Experimental|Healthy Controls|
89142527|NCT00941941|Experimental|Non-mesh Hernia Repair|Reinforcement with a strip of external oblique aponeurosis
89142528|NCT00941941|Active Comparator|Mesh Hernia Repair|Polypropylene mesh placement
89142529|NCT02723136|Experimental|Smartphone application|Participants allocated to this arm will receive a smartphone application developed to assist and guide the study of internal medicine and its subspecialties. The application will provide feedback to participants regarding their overall performance in terms of correct answers and the overall time required to solve a clinical vignette.
89142530|NCT02723136|No Intervention|Usual care|Students allocated to this arm will not receive any further assistance in studying for this trial's tests.
89142531|NCT02793050||Trabectedin|Trabectedin give according the market authorization for advanced soft tissue sarcoma
89142532|NCT04263233||Other|This program, which is provided for all patients new to dialysis at the participating units, will be evaluated by assessing patient clinical outcomes and the results of surveys measuring patient-reported symptoms, quality of life, knowledge and activation. In addition, satisfaction with the program will be assessed.
89142533|NCT00944905|Experimental|MDX-1203|Accelerated titration design (ATD)of 6 dose levels. Subjects will be assigned to a dose level in the order they enter the study
89142534|NCT02722980|Placebo Comparator|Placebo|Capsules
89142535|NCT02722980|Active Comparator|Active|Capsules.
89142536|NCT00942019||obese smokers|BMI > 30 kg/m2 CO ≥ 15 ppm
89142537|NCT00942019||non-obese smokers|BMI < 25 kg/m2 CO ≥ 15 ppm
89142538|NCT00942019||obese non-smokers|BMI > 30 kg/m2 CO ≤ 6 ppm
89142539|NCT00942019||non-obese non-smokers|BMI < 25 kg/m2 CO ≤ 6 ppm
89142540|NCT02789306||Peri-implantitis|"Peri-implantitis' - Loss radiographic bone beyond the biological bone remodeling at baseline (after prosthesis delivery) from the implant neck~Early:> 4 mm probing depth; <25% radiographic bone loss~Moderate:> 6mm probing depth; <50% radiographic bone loss~Severa:> 8 mm probing depth; > 50% radiographic bone loss"
88805982|NCT01175369|No Intervention|Usual Care|Usual asthma care
88805983|NCT01175369|Experimental|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
88805984|NCT03835949|Experimental|TJ004309 plus Atezolizumab|TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.
89142541|NCT02789306||Healthy|No signs of inflammation and otherwise no bone loss beyond the biological bone remodeling
89142542|NCT00942097|Placebo Comparator|Nutritional plus Placebo (homeopathy)|Nutritional oriented diet for pregnancy period add homeopathic preparation from inert substance.
89142543|NCT00942097|Active Comparator|Nutr and Homeop Sulph Puls Lyc Lackt Con Sep Nuxv Calcc Phos|Nutrition oriented diet for pregnancy period add active homeopathic medication (Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos)
89142544|NCT04233320|Experimental|silicone cream containing Allium Cepa extract|Silicone cream containing Allium Cepa extract will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
89142545|NCT04233320|Active Comparator|commercial scar gel|Commercial scar gel will be applied on half of post-cesarean surgical scars 2 times per day for 3 months.
89142546|NCT00610961||Basiliximab (Simulect) Induction|Prospective group: patients are scheduled to receive a kidney transplant; and will receive Simulect®, Myfortic® and Prograf® with or without steroids according to routine care (Standard of Care).
89142547|NCT00610961||Thymoglobulin Induction|Retrospective (historical or control) group: patients have already received a kidney transplant and were treated with Thymoglobulin®, Myfortic®, and Prograf® with or without steroids. This treatment was Standard of Care at a time of transplant.
89142548|NCT02797886|Experimental|FES+VOL|Electrical stimulation (FES) in concert with volitional effort. The subject is visually cued to initiate the movement and when they begin the movement (as ascertained by EMG response), the stimulation is immediately applied until the completion of the trial.
89142549|NCT02797886|Active Comparator|FES|Electrical stimulation alone. The subject is asked to do nothing as electrical stimulation initiates and completes the movement for them.
89142550|NCT02797886|Active Comparator|VOL|Volitional effort alone. When cued, the subject initiates and completes the movement on their own until the completion of the trial. There is no electrical stimulation in this group.
89142551|NCT02789072|Other|Microgravity|effect of microgravity on central aortic blood pressure.
89142552|NCT02788760|Other|6 weeks|This group of patients will be treated for 6 weeks with a cervical collar (Miami J collar - Össur)
89142553|NCT02788760|Other|12 weeks|This group of patients will be treated for 12 weeks with a cervical collar ( (Miami J collar - Össur)
89142554|NCT00942253|Experimental|Dopamine Agonist Group|"Dialysis patients will receive dopamine agonist for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist and aerobic intradialytic exercise.~Patients will be given evening doses of dopamine agonists, 2 hours before bedtime. The dopamine agonists' dose will be 0.25 mg/dose and remain constant until the end of the study."
89142555|NCT00942253|Placebo Comparator|Placebo Group|"Dialysis patients will receive placebo for 24 weeks following a 24 weeks period of combined treatment with placebo and aerobic intradialytic exercise.~Patients will be given evening doses of placebo, 2 hours before bedtime."
89142556|NCT02792816||Kawthaung Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Kawthaung is one of the sentinel site and located at the Southern Myanmar.
89142557|NCT02792816||Myawaddy Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Myawaddy is one of the sentinel site and located at the northern part of the Southern Myanmar.
89142558|NCT02792816||Thanbyuzayat Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Thanbyuzayat is one of the sentinel site and located at the northern part of the Southern Myanmar.
89142559|NCT02792816||Shwegyin Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Shwegyin is one of the sentinel site and located at the southern part of the central Myanmar.
89142560|NCT02792816||Magway Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Magway is one of the sentinel site and located at the middle part of the central Myanmar.
89142561|NCT02792816||Rakhine Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Rakhine is one of the sentinel site and located at the western Myanmar.
89142562|NCT00930761|No Intervention|Control|
89142563|NCT00930761|Experimental|Music therapy|
89142564|NCT00940381|Experimental|Sirolimus + Cetuximab|Sirolimus beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle. Cetuximab Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
89142565|NCT00637988|Experimental|1|Nexium 40mg
89142566|NCT00637988|Experimental|2|Nexium 40mg + aspirin
89142567|NCT00637988|Experimental|3|Nexium 40mg + Rofecoxib 25 mg
89142568|NCT00637988|Active Comparator|4|Rofecoxib 25mg
89142569|NCT02792894|No Intervention|Enhanced Usual Care (EUC)|Enhanced Usual Care comprises of normal routine visits conducted by the local community health workers / Lady Health Workers (LHWs). Care is enhanced in 2 ways: (a) LHWs in the EUC arm will receive training in identifying children with developmental disorders and delays, as well as making referrals to their primary care physicians for treatment using the WHO mhGAP training program for developmental disorders and (b) The primary care physicians will receive the training in WHO mental health GAP(mhGAP) program developmental disorders module, by WHO Collaborating Center in Rawalpindi, Pakistan.
89142570|NCT02792894|Experimental|Family Networks program|Intervention is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO Parent Skills Training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
89142571|NCT00945217||Postmenopausal women|women with natural menopause
89142572|NCT04115150||self-gripping mesh|
89142573|NCT04115150||non-self-gripping mesh|
89142574|NCT02792972|Active Comparator|Acmella oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers 3 minutes before the venipuncture
89142575|NCT02792972|Placebo Comparator|alcohol 70%|70% alcohol were used in the volunteers 3 minutes before the venipuncture
89142576|NCT04258163||MCT Group|People who received chemotherapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
89142577|NCT04258163||MET Group|People who received endocrine therapy as a maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks. One patient only received one of the intervention drugs for maintenance therapy.
89142578|NCT04258163||Observation Group|People who didn't receive any maintenance therapy after first-line chemotherapy reaching a state of no progress for at least 4 weeks.
89142579|NCT00942487|Experimental|Nebivolol|
89142580|NCT00942487|Active Comparator|Metoprolol|
89142581|NCT02792738|Experimental|hypnosis, visual distraction|"This is a crossover study in which each subject will be exposed to a 5 min phase of hypnotic suggestion and visual distraction.~For hypnotic suggestion, subject will be invited to experience a pleasant memory . Indirect and permissive suggestion will be used.~For visual distraction, subject will be watching the movie la marche des empereurs"
89142582|NCT00611039|Experimental|1|Darunavir 900mg + ritonavir 100 mg once a day
89142583|NCT00611039|Active Comparator|2|Darunavir 600mg + ritonavir 100mg twice day
89142584|NCT00942565|Active Comparator|Tramadol/acetaminophen|The tramadol and acetaminophen combination was given to patients at the same day after surgery.
89142585|NCT00942565|Active Comparator|acetaminophen|Acetaminophen was used as active control.
89142586|NCT02792660|Experimental|Injeq IQ-Needle|Lumbar puncture is performed using Injeq IQ-Needle
89142587|NCT00942643|No Intervention|no treatment|being observed at 4 weeks and 12 weeks
89142588|NCT00942643|Active Comparator|CPAP treatment|a machine delivers positive airway pressure into the upper airway via nasal mask
89142589|NCT00945373|Experimental|Erythematotelangiectatic Rosacea|2.5% gel calcium dobesilate and pulsed dye laser
89142590|NCT02788994|Experimental|Endovis BA2 Nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~stable fracture synthesis for fast rehabilitation and early mobilization~an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)~This is a one off surgical fixation."
89142591|NCT02788994|Active Comparator|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
89142592|NCT00945451|Experimental|CyberKnife irradiation|
89142593|NCT02797730|Experimental|art-therapy sessions|Caregivers will receive 6 art-therapy sessions
89142594|NCT02797730|No Intervention|no art-therapy sessions|Caregivers will not receive 6 art-therapy sessions during the evaluation period
89142595|NCT02788916||Cohort 1|Assessment of tumor biopsies and histological preparations of participants diagnosed with peripheral T-cell lymphoma (PTCL) in the six years between 01 January 2008 and 31 December 2013 will be performed.
89142596|NCT04100655|Experimental|GM-CSF|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.~3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice."
89142597|NCT04100655|Experimental|Control|"Hysteroscopy will be arranged to confirm the uterine cavity is normal and there is no significant intrauterine adhesion.~After hysteroscopy examination, nothing was applied to the uterine cavity."
89142598|NCT00770289||Single group|
89142599|NCT02797652||Neoadjuvant chemotherapy|ctDNA of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
89142600|NCT02797652||Surgery|ctDNA of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
89142601|NCT02797496|Experimental|Asymmetric Motor Strengthening|
89142602|NCT02797496|Active Comparator|Conventional Therapy|
89142603|NCT02788448|Experimental|VIVASURE CLOSURE DEVICE|Large hole closure device
89142604|NCT04100889||Alzheimer's disease patients|Patients who have been diagnosed with Alzheimer's disease
89142605|NCT02792348||children with congenital urine flow impairment|this group contain children with an unilateral urinary tract dilatation diagnosed by prenatal ultrasonography
89142606|NCT02792348||control group|this group contains children, between 1 and 3 months of age, without nephrological or urological anomaly
89142607|NCT02792426|Active Comparator|Group 1 AB|Smoker subject's own brand of combustion cigarette
89142608|NCT02792426|Active Comparator|Group 1 BA|Smoker subject's own brand of combustion cigarette
89142609|NCT02792426|Active Comparator|Group 2|E-cigarette user's own brand of electronic nicotine delivery system (ENDS)
89142610|NCT02797418|Experimental|Cognitus and Me|Cognitus & Me is a cognitiv remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among children with intellectual disabilities.
89142611|NCT02797418|Active Comparator|control group|the control management that involves fine motor skills and research computer information,management control is usually done
89142612|NCT00770211|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
89142613|NCT00770211|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
89142614|NCT02792036|Experimental|Treatment|"Participants with retinoblastoma that is refractory or has relapsed inside the eye.~Interventions: Carboplatin, Maxitrol® , focal therapy, plaque radiotherapy."
89142615|NCT00942721|Experimental|Web-based CBT for PPD|Participants will receive Web-based CBT for PPD.
89142616|NCT00942799|Experimental|Study Drug: Genz-644282 (28-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
89142617|NCT00942799|Experimental|Study Drug: Genz-644282 (21-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
89142618|NCT02788682||Patients|WT+ Diplotype
89142619|NCT02788682||Controls|WT- Diplotype
89142620|NCT04100265|Experimental|Panel 1 - High risk for postoperative ileus|Intervention in patients at high risk to develop prolonged postoperative ileus. Monitoring postoperative gastric motility for 2 consecutive days in patients who require preventive placement of a nasogastric feeding tube due to a high risk to develop postoperative ileus. Allowing to explore associations between gastric motility and general clinical evolution.
89142621|NCT04100265|Experimental|Panel 2 - Postoperative ileus arm with investigational device|Intervention in a population of patients with clinical signs of postoperative ileus, requiring a nasogastric feeding tube for symptom relief. The investigational medical device will be applied. Allowing to explore the association of gastric motility and clinical signs of postoperative ileus in an enriched population with true postoperative ileus.
89142622|NCT04100265|No Intervention|Panel 3 - Postoperative ileus arm with standard of care|Standard of care control group of patients with clinical signs of postoperative ileus requiring a standard nasogastric feeding tube for symptom relief. Symptoms will be surveyed as control group to assess safety and tolerability of the investigational medical device.
89142623|NCT02788526|Experimental|Adjuvant TACE|Adjuvant TACE were performed 4-6 weeks after surgery
89142624|NCT02788526|Other|Follow-up|Routine follow-up were performed instead of adjuvant TACE
89142625|NCT02797340|Experimental|Interventional|All participants
89142626|NCT00928187|Active Comparator|Arm A|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
89142627|NCT00928187|Active Comparator|Arm B|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
89142628|NCT00928187|Active Comparator|Arm C|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
89142629|NCT05279911|No Intervention|Control|Implants were randomly inserted in 20 non-lased T2DM patients (Control)
89142630|NCT05279911|Experimental|Low level laser therapy|Implant were randomly inserted in 20 lased T2DM patients (Intervention)
89142631|NCT00942955||CLT|The patients whose blood are analyzed by conventional central laboratory.
89142632|NCT00942955||POCT|the patients group whose lab analyze by POCT device.
89142633|NCT04235270|Experimental|Group 1 (Bioequivalence Part)|Participants will receive Treatment A (single oral dose of an fixed dose combination [FDC] of macitentan/tadalafil [10 milligram [mg]/40 mg] in fasted conditions [test]) or Treatment B (single oral dose of a free combination of 10 mg macitentan and 40 mg tadalafil in fasted conditions [reference]) on Day 1 of Treatment Period 1 followed by Treatment B or Treatment A on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
89142634|NCT04235270|Experimental|Group 2 (Food-effect Part)|Participants will receive Treatment C (single oral dose of an FDC of macitentan/tadalafil [10 mg/40 mg] in fed conditions [test]) or Treatment D (single oral dose of an FDC of macitentan/tadalafil (10 mg/40 mg) in fasted conditions [reference]) on Day 1 of Treatment Period 1 followed by Treatment D or Treatment C on Day 1 of Treatment Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 10 days.
89142635|NCT00943033|Experimental|Mindfulness-Based Cognitive Therapy plus treatment as usual|
89142636|NCT00943033|No Intervention|MBCT Waitlist plus Treatment as Usual|
89142637|NCT00945607|Experimental|Guided Relaxation Training|"Eligible subjects who have been randomized to the intervention arm will be scheduled for GRT introduction and training with a research staff member. The GRT sessions will consist of six weekly on-site sessions in which the subject is provided instructions and then allowed to listen to the GRT CD. Subjects will be instructed to conduct independent GRT sessions at home, twice daily, at least four hours apart, for the duration of the study. Subjects will also be instructed that on the days of one-on-one sessions with a research staff member at TCCC, that they will only be required to perform the independent session once at home.~Subjects will be provided with a diary to record the date and time of each independent GRT session performed at home. Subjects will be instructed to bring their completed diary with them at each subsequent visit."
89142638|NCT00945607|No Intervention|Standard of Care(SOC)|Eligible subjects who are randomized to the SOC arm will not receive the GRT sessions. During the six week treatment phase, these subjects will only receive SOC provided to all subjects newly diagnosed with breast cancer at TCCC. This consists of an education session with the nurse or nurse practitioner. In addition, they will also be provided with supportive care and symptom management as needed. This arm will also be provided with a diary to record their stress level at least twice daily.
89142639|NCT04256525|Experimental|Aspirin 100mg|
89142640|NCT04256525|Experimental|rivaroxaban 10mg|
89142641|NCT04256525|Experimental|low molecule heparin|
89142642|NCT04256525|No Intervention|Reference|mechanical prophylaxis
89142643|NCT02791958|Experimental|CV Fixed Dose Combination Pill AAR|Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).
89142644|NCT02791958|Active Comparator|Atorvastatin|Atorvastatin 40 mg (Lipitor®).
89142645|NCT02791958|Active Comparator|Ramipril|Ramipril 10 mg (Altace®).
89142646|NCT00945685|Experimental|Endymion study group|
89142647|NCT00769119|Experimental|AZD9668 active treatment|
89142648|NCT00769119|Placebo Comparator|AZD9668 placebo treatment|
89142649|NCT00945841|Other|1|
89142650|NCT02797106||health care professionals|health care professionals potentially involved in assessment and/or treatment of drooling in children with Cerebral Palsy.
89142651|NCT04200014||Syncope and Implantable loop recorder|Patients implanted with a subcutaneous Loop Recorder after syncope in Nancy University Hospital
89142652|NCT02601651|Experimental|Lidocaine|Lignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
89142653|NCT02601651|Placebo Comparator|Normal saline|Normal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
89142654|NCT03865238|Experimental|EV71vac|
89142655|NCT03865238|Placebo Comparator|Placebo|
89142656|NCT00943267|Experimental|Activated protein C|
89142657|NCT00943267|Placebo Comparator|Saline|
89142658|NCT00945997|Active Comparator|A|
89142659|NCT00945997|Active Comparator|B|
89142660|NCT00927953|Experimental|MGAWN1|30 mg/kg single intravenous infusion of MGAWN1
89142661|NCT00927953|Placebo Comparator|Placebo - Normal Saline|single intravenous infusion of saline placebo
89142662|NCT00943345|Active Comparator|GS dual sugar permeability test|"Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
89142663|NCT00943345|Other|Multi sugar test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
89142664|NCT00943345|Other|Protein test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
89142665|NCT00943345|Other|PEG test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
89142666|NCT02797028|Placebo Comparator|Placebo capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. Control group taking placebo capsule
89142667|NCT02797028|Experimental|Anthocyanidins capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. The experimental group taking anthocyanins capsule.
89142668|NCT02797028|Experimental|Allopurinol|The experimental group taking allopurinol.
89142669|NCT00916461|Active Comparator|Minocycline|
89142670|NCT00916461|Placebo Comparator|Sugar Pill|
89142671|NCT04011943|Experimental|Participants with bowel diseases|Treatment by transplantation of fecal microbiota
89142672|NCT04011943|Experimental|autologous transplantation of fecal microbiota - healthy|Healthy volunteers will receive autologous transplantation of fecal microbiota (capsules)
89142673|NCT04011943|Experimental|Both autologous and heterologous transplantation - healthy|Healthy volunteers will receive both autologous and heterologous transplantation (capsules)
89142674|NCT04011943|Placebo Comparator|placebo capsules - healthy|Healthy volunteers will receive placebo capsules
89142675|NCT03664466|Experimental|Astaxanthin|Astaxanthin 12mg twice daily by mouth
89142676|NCT03664466|Placebo Comparator|Placebo|Placebo twice daily by mouth
89142677|NCT04260035|Active Comparator|Vasoactive Intestinal Polypeptide (VIP)|"Intravenous infusion of 8 pmol/Kg/min of Vasoactive Intestinal Polypeptide (VIP).~The infusion is administered at constant speed by an automatic pump, lasting 120 minutes."
89142678|NCT04260035|Placebo Comparator|Sterile, isotonic, non-active saline (Placebo)|Intravenous infusion of sterile, isotonic, non-active saline 9 mg/ml (placebo). The infusion is administered at constant speed by an automatic pump, lasting 120 minutes.
89142679|NCT04941209||Case|Inpatients/Outpatients with confirmed COVID-19 with and without pulmonary symptoms.
89142680|NCT04941209||Matched-Control|Outpatients without COVID-19 without known non-pulmonary diagnoses or symptoms.
89142681|NCT00768651|Experimental|One arm: Sitagliptin + Pantoprazole|"Intervention Details:~Sitagliptin 100 mg daily and Pantoprazole 40 mg bid for 6 months, followed by a three-month washout."
89142682|NCT00943501|Experimental|I.a|
89142683|NCT00943501|Placebo Comparator|I.b|
89142684|NCT00943501|Experimental|II.a|
89142685|NCT00943501|Placebo Comparator|II.b|
89142686|NCT04234256|Experimental|Static exercise|The experimental group doing static exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
89142687|NCT04234256|Experimental|Dynamic exercise|This group doing dynamic exercises, three times with five repetitions for a period of three months lasting 15 to 20 minutes at the end of the training.
89142688|NCT04234256|No Intervention|Control group|Control group doing not the stretching exercise
89142689|NCT04258241|Active Comparator|Local infiltration analgesia with local anesthetic (LIA+)|Local infiltration analgesia will be performed at the end of the surgery by injection of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
89142690|NCT04258241|Placebo Comparator|Local infiltration analgesia without local anesthetic (LIA-)|Local infiltration analgesia will be performed at the end of the surgery by injection of 0.3 mg of epinephrine and 120 ml of normal saline.
89142691|NCT04099953|Experimental|dialysis patients|Dialysis patients were evaluated by objective diagnostic tests.
89142692|NCT04099953|Experimental|Control group|Healthy individuals
89142693|NCT02791724|Experimental|Desiconnect|Desiconnect is an Internet-administered intervention developed for persons with epilepsy and elevated depression symptoms.
89142694|NCT02791724|Active Comparator|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Desiconnect three months post-baseline (i.e., wait list with respect to Desiconnect access).
89142695|NCT00946231||Heart Failure|Subjects admitted to the hospital with decompensated heart failure.
89142696|NCT02796794|Active Comparator|Genistein|Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
89142697|NCT02796794|Other|control|Control group are the patients receiving enteral nutrition
89142698|NCT04097691||on subcutaneous glucose|this group was on subcutaneous glucose 0.5 ml per site around subcutaneous nerves in the foot region both on palm and sole.which is repeated every 2 weeks for 2 months.
89142699|NCT04097691||control(not receiving treatment)|the second group is considered as control.received no treatment.
89142700|NCT00943813||Patients in clinic waiting room|When patients are approached in the clinic, they will be given the permission form and asked to participate in the assessment through allowing video-recording and completing the survey. Procedures will be similar to our current operations, with the RSA starting the video-recording equipment before the fellow enters the room and stopping it when the fellow leaves the room. One additional step will be added: When the RSA goes into the room to turn off and remove the video-recording equipment, she will also give the patient the survey, to complete. We expect this survey to take no longer than 5 minutes. In our experience, it is usually at least 10 minutes from when the fellow leaves the room until the attending comes back into the room. Thus, we believe there will be sufficient time for the patient to complete the survey.
89142701|NCT02791178||STEMI patients|"The patients presenting with a STEMI and undergoing PPCI will be screened and approached to participate in this study.~All patients to do Optical Coherence Tomography (OCT), Index of Microcirculatory Resistance (IMR) and Cardiac MRI."
89142702|NCT04097613|Experimental|Betadine Treatment|Study subjects will use betadine saline sinus rinse for period of 6 weeks.
89142703|NCT00946387|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
89142704|NCT00946387|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
89142705|NCT02788604|Experimental|Experimental Group|Participants in this arm will have a summary of their family's psychosocial risk factors provided to the treatment team. This will occur twice: once shortly after diagnosis (within 2-4 weeks) and once approximately 6 months following diagnosis.
89142706|NCT02788604|Active Comparator|Control Group|Participants in this arm will NOT have a summary of their family's psychosocial risk factors provided to the treatment team shortly after diagnosis. However, the risk factors will be distributed to the treatment team 6 months following diagnosis.
89142707|NCT00943891||Tumor biopsies|
89142708|NCT02601261||Patients with some access to internet during stay|
89142709|NCT02601261||Patients without access to internet during stay|
89142710|NCT00943969|Other|obemo|
89142711|NCT02788214||Advanced intestinal metaplasia|"H. pylori strains from patients with:~Complete-type intestinal metaplasia with extension to corpus, or~Incomplete-type intestinal metaplasia of any extent"
89142712|NCT02788214||Non-atrophic gastritis|H. pylori strains from patients with non-atrophic gastritis
89142713|NCT02788214||Gastric cancer|H. pylori strains from patients with gastric cancer
89142714|NCT00916695|Active Comparator|Complex PCI strategy for bifurcation coronary lesions|Stenting main vessel and T-stenting for the side branch
89142715|NCT00916695|Active Comparator|Simple PCI strategies for bifurcation coronary lesions|Stenting main vessel, with provisional stenting for the side branch.
89142716|NCT00946465|Experimental|1|Ramipril 10 Capsule (Sandoz)
89142717|NCT00946465|Active Comparator|2|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)
89142718|NCT04012021|Experimental|EX-VIVO SPECIMENS|"Three groups of ex-vivo surgical specimen:~Group A: native livers in transplant recipients Group B: liver grafts excluded for donation Group C: primary pancreatic cancer"
89142719|NCT00756717|Experimental|MK-0752|Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days
89142720|NCT06005753|Experimental|Group A|Surgical intervention group
89142721|NCT06005727|Active Comparator|Transanal ice pack applied to hemorrhoidectomy wound for 1 minute|Transanal ice pack is applied to hemorrhoidectomy wound for 1 minute. After the surgery, standard postoperative analgesia and medications will be prescribed.
89142722|NCT06005727|No Intervention|Standard postoperative care after hemorrhoidectomy|Standard postoperative analgesia and medications will be prescribed.
89142723|NCT06005714|Experimental|The effects of clarithromycin on pharmacokinetics of deuterium hydrobromide ramidvir tablets|
89142724|NCT06005714|Experimental|The effects of cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets|
89142725|NCT06005636||with post-stroke delirium|ischemic stroke patients with post-stroke delirium
89142726|NCT06005636||without post-stroke delirium|ischemic stroke patients without post-stroke delirium
89142727|NCT06005584|Active Comparator|High Frequency SCS|Participants will be randomly assigned to this arm for up to 6 weeks
89142728|NCT06005584|Active Comparator|Burst SCS|Participants will be randomly assigned to this arm for up to 6 weeks
89142729|NCT06005584|Sham Comparator|Sham SCS|Participants will be randomly assigned to this arm for up to 6 weeks
89142730|NCT06005519|Other|Type 2 diabetes|
89142731|NCT06005519|Other|healthy participants|
89142732|NCT06005506|Active Comparator|Probiotic + fiber|"These subjects will be given a passive symbiotic preparation again consisting of two sticks of 1500mg each to be taken once a day:~Purple Sachet - Prebiotic - Composed of 500mg acacia fiber (Fibregum®) with high prebiotic activity and 500mg mai starch. Excipients and flavorings.~White Sachet - Probiotic - 30 Billion bacterial strains Lactobacillus plantarum LP (PBS067- EU Collection DSM 24937), Lactobacillus acidophilus L."
89142733|NCT06005506|Experimental|Probiotic + Prebiotic|"These subjects will be given an active symbiotic preparation consisting of two differently colored sticks of 1500mg each to be taken once a day:~Purple Sachet - Active Prebiotic - 500 mg of Fibregum®, a slow-fermenting prebiotic fiber and 500 mg of standardized extract of pigmented Zea Mays L fruit, rich in anthocyanins and polyphenols. Excipients and flavorings.~White Sachet - Probiotic - 30 Billion Bacterial Strains Lactobacillus plantarum LP (PBS067- EU Collection DSM 24937), Lactobacillus acidophilus LA (PBS066 - EU Collection DSM 24936) and Bifidobacterium animalis subsp. lactis BL (BL050 - Eu Collection DSM 25566)."
89142734|NCT06005467|Experimental|V shaped plate|its a new plate that have been used in fixation of fractures in various areas of the mandible,V shaped plate was used in the treatment of three angle fracture cases which provided the advantage of including both lines of osteosynthesis which are the superior border and the lateral surface of the external oblique ridge using one plate.
89142735|NCT06005467|Active Comparator|champy technique|champy technique is one of the standard methods that are used in fixation of mandibular angle fractures by applying a mini-plate in the superior border of the external oblique ridge.
89142736|NCT06005402|Experimental|CSX-1004|Single doses of CSX-1004 Injection
89142737|NCT06005402|Placebo Comparator|Placebo|Sterile saline for injection
89142738|NCT06005389||50 patients with common or planter cutaneous warts|"Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. The therapeutic efficacy was evaluated by a decrease in the size (measured by a ruler) and the number of warts with photographic documentation at (the baseline, each visit, 2 weeks after the final session, and the 3 months follow-up period). The response of the treated wart was considered: complete; if there was a disappearance of the wart and appearance of normal skin markings, partial; if the warts had regressed in size or decreased in number and no response; if no decrease in wart size or number.~From each patient 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits."
88805985|NCT01176617|No Intervention|Conventional Monitoring Strategy|Subjects will be monitored for 12 months using the conventional strategy which includes wearing a monitor over 3 separate 30-day periods over the first year post-ablation and daily pulse checks.
89142739|NCT06005389||50 healthy age-and sex-matched control subjects.|From each control subject, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits.
89142740|NCT06005376|Active Comparator|No additive|This arm was served 2 reference wheat bread rolls (a 40 g) a day.
89142741|NCT06005376|Experimental|E304i/zinc additive|This arm was served 2 wheat bread rolls (a 40 g) a day containing a E304i/zinc additive.
89142742|NCT06005363|Experimental|BIS group|Use BIS monitoring to adjust intraoperative anesthetics.
89142743|NCT06005363|Experimental|DEX group|use BIS monitoring to adjust anesthetics and give dexmedetomidine infusion.
89142744|NCT06005363|No Intervention|Usual group|usual care with 1 MAC sevoflurane maintainance.
89142745|NCT06005337|Active Comparator|Group A - Sore Throat Swab, Cough and Cold, Asthma|"Group A will receive three of six blogshots (different to Group B) over a 4-week period (a different blogshot will be sent by email to them each week for three weeks, then in the final week they will receive the same three blogshots in one summary email to review). They will act as their own control group.~All participants from both groups will be asked to complete one baseline questionnaire at the start of the study and a follow-up questionnaire at week 5, month 3 and month 6 about different common acute childhood conditions, the blogshots and their content.~All participants can also participate in an optional semi-structured interview to give their thoughts on the blogshots and their experience in the study."
89142746|NCT06005337|Active Comparator|Group B - Ear Infection, Bronchiolitis, Antibiotics for Sore Throat|"Group B will receive three of six blogshots (different to Group A) over a 4-week period (a different blogshot will be sent by email to them each week for three weeks, then in the final week they will receive the same three blogshots in one summary email to review). They will act as their own control group.~All participants from both groups will be asked to complete one baseline questionnaire at the start of the study and a follow-up questionnaire at week 5, month 3 and month 6 about different common acute childhood conditions, the blogshots and their content.~All participants can also participate in an optional semi-structured interview to give their thoughts on the blogshots and their experience in the study."
89142747|NCT06005324|Other|Induction Treatment Arm|All participants will receive 3 cycles (9 weeks) of chemotherapy with paclitaxel, carboplatin, and cetuximab.
89142748|NCT06005324|Experimental|De-Escalation CRT Cohort|After completing induction chemotherapy, participants that have significant disease response by imaging will receive low dose radiation treatment with additional chemotherapy (CRT). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
89142749|NCT06005324|Active Comparator|Standard Treatment Cohort|After completing induction chemotherapy, participants that have limited disease response by imaging will receive standard dose radiation treatment with additional chemotherapy (CRT). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
89142750|NCT06005259|Experimental|Intervention|Participants will be administered 25 mg of spironolactone daily for 12 months, beginning 5 to 15 days prior to chemotherapy.
89142751|NCT06005259|Placebo Comparator|Control|Participants will be given placebo daily for 12 months, beginning 5 to 15 days prior to chemotherapy.
89142752|NCT06005233|Experimental|Application of Smartwatch|Application of smartwatch in addition to an implanted event recorder. Follow-up of 6 months
89142753|NCT06005207|Experimental|Vaginal progesterone supplementation|90 mg progesterone vaginal sustained-release gel is added daily to induce endometrial transformation and luteal support
89142754|NCT06005207|No Intervention|Regular progesterone|No additional vaginal progesterone gel, routine endometrial transformation and luteal support drugs
89142755|NCT06005168|No Intervention|Standard of Care|The patients assigned to this group have cefazolin dose assignments based on body weight, which is the standard of care.
89142756|NCT06005168|Active Comparator|Morphomic-based|The patients assigned to this group have cefazolin dose assignments based on body depth and kidney function.
89142757|NCT06005116|Experimental|Bladder Cancer Patients|
89142758|NCT06005103|Experimental|Active treatment with T-PEMF (Active)|The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.
89142759|NCT06005103|Sham Comparator|Inactive treatment with T-PEMF (sham)|Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.
89142760|NCT06004999|Experimental|Vibration group|An exercise program organized by the researchers on the vibration platform will be applied to the pre-frail participants in the vibration group. The exercises will be applied 5 days a week for 6 weeks.
89142761|NCT06004999|Active Comparator|Control group|An exercise program organized by the researchers (same exercise program as the vibration group) will be applied to the pre-frail participants in the control group on a flat surface. The exercises will be applied 5 days a week for 6 weeks.
89142762|NCT06004960|Experimental|[14C]CCX168|Participants will receive a single oral dose of [14C]CCX168 100 mg containing 400 μCi of [14C] on Day 1.
89234739|NCT05454306|Experimental|Anser Clavicle Pin|Patients treated with Anser Clavicle Pin in the setting of a displaced midshaft clavicle fracture
89142763|NCT06004947|Experimental|Cohort A|A single dose of 2 mg midazolam (a Cytochrome P450 [CYP]3A4 probe drug) and a single dose of 200 mg celecoxib (a CYP2C9 probe drug) will be given orally concurrently on Day 1 and Day 13. On Day 3 through Day 18, CCX168 will be given orally at 30 mg twice daily (b.i.d.), and a single dose of 30 mg CCX168 will be given in the morning on Day 19. On Day 16 through Day 19, a once daily (q.d.) dose of 200 mg itraconazole (a CYP3A4 inhibitor) will be given orally.
89142764|NCT06004947|Experimental|Cohort B|A single dose of 30 mg CCX168 will be given on Day 1 and Day 14, while rifampicin (a CYP3A4 inducer) will be given at 600 mg once daily from Day 4 through Day 17.
89142765|NCT06004934|Experimental|Group 1: Mild Hepatic Impairment|Participants with mild hepatic impairment (defined using Child-Pugh Classification of the Severity of Liver Disease [C-P] criteria [C-P Class A, score of 5 to 6 points]) will receive a single oral dose of 30 mg avacopan on Day 1 in the fasted state.
89142766|NCT06004934|Experimental|Group 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (defined using the C-P criteria [C-P Class B, score of 7 to 9 points]) will receive a single oral dose of 30 mg avacopan on Day 1 in the fasted state.
89142767|NCT06004934|Active Comparator|Group 3: Healthy Control Group|Participants with normal hepatic function (medically normal with no clinically significant illness or disease or abnormal physical examination findings, and with normal laboratory values at screening) will be demographically-matched to participants in Group 1 and Group 2, and will receive a single oral dose of 30 mg avacopan on Day 1 in the fasted state.
89142768|NCT06004882|Experimental|Group 1 (standard steroid injection)|Participants will receive 1 standard steroid injection.
89142769|NCT06004882|Experimental|Group 2 (PNS therapy plus 1 standard steroid injection).|Participants will receive PNS therapy plus 1 standard steroid injection.
89142770|NCT06004882|Experimental|Group 3 (PNS therapy plus 1 placebo injection)|Participants will receive PNS therapy plus 1 placebo injection.
89142771|NCT06004843|Experimental|Remimazolam|In this group, participants are sedated with remimazolam and remifentanil.
89142772|NCT06004843|Active Comparator|propofol|In this group, participants are sedated with propofol and remifentanil.
89142773|NCT06004817||Juvenile dermatomyositis|Dermatomyositis before 18 years-old
89142774|NCT06004817||Adult-onset dermatomyositis|Dermatomyositis from 18 years-old
89142775|NCT06004791|Placebo Comparator|Herombopag + CsA|Herombopag 10mg/ day, adjust the dose according to the blood image, the course of treatment is at least 3 months, CsA: 3-5 mg/kg/d, adjust the valley concentration 100-200ng/ml, at least 6 months, effective patients continue to use for 1 year, and then gradually reduce the dose.
89142776|NCT06004791|Experimental|rhTPO combined with Herombopag + CsA|Administer rhTPO (15000U, subcutaneously once daily for 7 days, once a month for 3 months),Herombopag 10mg/day, adjust dose according to blood picture for at least 3 months, CsA: 3-5 mg/kg/d, adjust trough concentration 100-200ng/ml for at least 6 months, continue for 1 year if effective, then gradually reduce dose
89142777|NCT06004778|Experimental|Motivational Support Program|Training booklet will be provided.A total of 5 sessions of sleep training will be given by dividing them into groups of 30 minutes, 3 days a week for 2 weeks.Individual motivational interviews will be held with students and reminder messages will be sent twice a week.
89142778|NCT06004778|Active Comparator|educational support|Training booklet will be provided. A total of 5 sessions of sleep training will be given by dividing them into groups of 30 minutes, 3 days a week for 2 weeks.
89142779|NCT06004765|Experimental|lenalidomide and sequential azacitidine|Lenalidomide (10mg/d *21 days, 28 days for 1 course), at least 2 courses. If effective, continue to use lenalidomide until ineffective or intolerant. Patients receive azacitidine (75mg/m2/d*5 days, 28 days for 1 course). Until progression or intolerance. At least 2 sessions of treatment are needed.
89142780|NCT06004765|Experimental|azacitidine|Azacitidine (75mg/m2/d*5 days, 28 days for 1 course) for at least 4 courses
89142781|NCT06004687|Active Comparator|By applying acetaminophen mannitol to patients with gastrointestinal tumors before surgery|Acetaminophen mannitol injection 50ml(500mg) intravenously pumped 30 minutes before surgery
89142782|NCT06004687|Placebo Comparator|By applying normal saline to patients with gastrointestinal tumors before surgery|Normal saline injection 50ml intravenously pumped 30 minutes before surgery
89142783|NCT06004648||Supraclavicular nerve block|"The high- frequency linear USG probe will be placed in the supraclavicular fossa pointing caudally, and the subclavian artery will be localized by moving it medially and laterally. A characteristic honeycomb plexus will be visualized in the lateral and superficial subclavian artery. Vascular structures will be detected using color Doppler, the first rib will be visualized as hyperechoic structure. After the pleura, which makes a~sliding movement through the patient&#39;s breathing is detected, a 22 gauge, 80 mm scale peripheral block needle will be directed from the lateral to the medial by an in-plane technique. After the sheath punctured, nerves will be determined with triceps, biceps, and wrist motor activity by using a nerve stimulator, and then 15 ml of 0.5% bupivacaine will be injected between the 1st rib and the lower trunk."
89142784|NCT06004648||Selective Trunk Block|Sequential ultrasound imaging technique (SUIT) will be used which is shown successfully in identifying individual elements of the brachial plexus. The neural complex of the upper trunk, middle trunk, and C8 ventral ramus, which are superficial to the T1 TP-1.rip complex will be defined. The first injections contains 8 ml and 7 ml 0.5% bupivacaine will be made as, close to the upper trunk(8ml) and middle trunk(7ml) in the interscalene groove. Then the needle will be completely withdrawn.The ultrasound probe will be placed caudally in the supraclavicular fossa. After providing the optimal view of the lower trunk in the corner pocket, 10 ml of 0.5% bupivacaine will be injected between the first rib and lower trunk.
89142785|NCT06004596|Other|Reference Range determination|13C-Spirulina Gastric Emptying Breath Test (GEBT) administered to healthy participants
89234740|NCT05733234|Experimental|Test|Laser-assisted surgical treatment of peri-implantitis
88805986|NCT01176617|Other|Reveal XT|Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.
88805987|NCT01177709|Experimental|Metformin|
88805988|NCT01179113|Placebo Comparator|Placebo|Placebo: Will receive a normal saline bolus during induction, and an infusion of normal saline intraoperatively
88805989|NCT01179113|Active Comparator|Esmolol|Will receive Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively
89142786|NCT06004596|Active Comparator|Biological Variability|13C-Spirulina GEBT administered a second time to subset of participants to determine pediatric biological variability.
89142787|NCT06004583||Acne group|Acne Vulgaris Diagnosed Patients
89142788|NCT06004583||Control group|Healthy participants
89142789|NCT06004518|Experimental|sexual counselling group|Women with MS who are given sexual counseling along with the training booklet will form the sexual counseling group.
89142790|NCT06004518|No Intervention|control group|Women with MS who are not given sexual counseling will form the control group.
89142791|NCT06004505|Other|Vestibular Rehabilitation Group|Vestibular rehabilitation program; Gaze consisted of stabilization, adaptation, neck and balance exercises.
89142792|NCT06004401|Experimental|Penicillin negative test group|（Vonopazan 20mg 2//day+Amoxicillin 1.0g 3/day）*14 days
89142793|NCT06004401|Active Comparator|Penicillin negative contral group|（Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day）*14 days
89142794|NCT06004401|Experimental|Penicillin positive test group|（Vonopazan 20mg 2/day+Minocycline 100mg 2/day）*14 days
89142795|NCT06004401|Active Comparator|Penicillin positive control group|（Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day）*14 days
89142796|NCT06004375|Experimental|intervention group|The intervention group was given a High-Calorie High-Protein + ONS diet containing 4.8 g arginine and 2 g glutamine, namely Neomune 2x 200 cc, purchased from Otsuka Pharmaceutical Co., Ltd
89142797|NCT06004375|Active Comparator|control group|the control was administered with a High-Calorie High-Protein diet + ONS hospital standard.
89142798|NCT06004323|Experimental|Digital health literacy intervention|The interventions will be developed based on the Best Practices for Digital Health Literacy, WHO health literacy toolkits and the findings of the interviews. The content to be covered in the intervention will include news about vaccines; alerts about COVID-19 preventive measures; guidelines on social distancing, COVID-19 screening test arrangements, vaccination and compulsory quarantines; COVID-19-related law enforcement; and self-monitoring of COVID-19 symptoms
89142799|NCT06004323|No Intervention|Control|No intervention will be provided to the control group
89142800|NCT06004297|Active Comparator|Group 1|Single bundle group
89142801|NCT06004297|Active Comparator|Group 2|Double bundle only group
89142802|NCT06004297|Experimental|Group 3|Double bundle with lateral release group
89142803|NCT06004258|Experimental|Intervention group (IG)|Welcoming the child and his or her guardians Invite them to participate, explain the study, and collect informed consent Recording of vaccinations in the medical record Safety check-list and identification Structural and environmental adaptation of the office Decorated nursing uniforms Use of distracting and rewarding elements according to age Preparation of vaccines out of sight of children Apply antalgic measures according to age and preferences. If the skin is dirty, clean it with physiological saline solution. Administer vaccines from least painful to most painful Only cover the puncture site if there is bleeding. Give post-vaccination recommendations Measure pain before, during and after vaccination with validated scales according to age
89142804|NCT06004258|No Intervention|Control group (CG)|"The right 5+2 might be identified (patient, vaccine, interval, dose, route of administration, anatomical site, record) might be identified In infants, a non-pressing but secure breastfeeding position is recommended >3 years old: they sit on the tutor's lap, encouraging their collaboration to hold the child without compressing ensuring to avoid movements, and try to distract them 6-12 years old: they sit in the chair with the tutor sitting next to him/her and they are vaccinated asking for the child's collaboration. If necessary, they might be held to avoid movements Vaccines will be administered following The 2021 Vaccination Protocol Tutors will receive recommendations on adverse effects Queries might be solved The atmosphere of the immunization clinic is similar to the rest of the clinics in the health centre (white walls and no child decoration) The uniform used by the nurses is white and the vaccination techniques are the same as those previously used in these centres"
89142805|NCT06004193||Regular Exercisers|The group of regular exercisers includes individuals who engage in at least 150 minutes of exercise per week according to World Health Organization criteria.
89142806|NCT06004193||Non-exercisers|The group of non-exercisers includes individuals who do not have a habit of engaging in regular exercise.
89142807|NCT06004089|Experimental|V NOTES Sacrocolpopexy arm|V-NOTES sacrocolpopexy was performed who met the eligibility criteria and gave written informed consent. Pelvic organ prolapse quantification (POP-Q) scores were evaluated before and 1 month after surgery. Quality of life was evaluated before and 1 month after surgery with the Turkish-validated Pelvic Floor Impact Questionnaire (PFIQ-7) and Pelvic Floor Distress Inventory (PFDI-20).
89142808|NCT06004076|Experimental|Release Group|Release of upper track of deep front fascial line
89142809|NCT06004076|Other|Corrective Group|Corrective exercises for upper crossed syndrome.
89142810|NCT06003998|Experimental|Intraperitoneal irinotecan 75 mg + mFOLFOX-4 and bevacizumab|Intraperitoneal irinotecan, 75 mg flat dose + systemic oxaliplatin, 5-Fluorouracil and bevacizumab (mFOLFOX+beva) (dose via standard of care)
89142811|NCT06003972|Active Comparator|Control|This arm serves as the control arm, patients allocated receive guideline directed medical therapy only
89142812|NCT06003972|Experimental|Copaxone arm|Patients receive guideline directed medical therapy with an add-on GA therapy for 14 days
89142813|NCT06003959|Experimental|Breastfeeding Support System|The intervention group was given breastfeeding support system care
89142814|NCT06003959|No Intervention|Control group|Routine nursing care was given to the pretrms in this groups without any breastfeeding support system care
89142815|NCT06003920|Experimental|Process Group|Medical students enrolled in the small process group, led by psychiatrist.
89142816|NCT06003920|No Intervention|Control Group|Medical students from the same cohorts, not enrolled in the small process group.
89234741|NCT05733234|Active Comparator|Control|Surgical treatment of peri-implantitis - No laser
89234742|NCT01007682|No Intervention|Screening for working memory capacity|
89234743|NCT01007682|Experimental|Distressing movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
89142817|NCT06003816|Experimental|Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI|The CHoBI7 program is first delivered during group sessions by a health promoter to those residing in a ring around a cholera patient. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A cholera prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After the group session, households receive weekly voice and text messages from the CHoBI7 mHealth program over 12 months on the recommended WASH behaviors.
89142818|NCT06003816|Active Comparator|Standard Message Arm|Standard message given in the Bangladesh to diarrhea patients at health facility discharge on use of oral rehydration solution
89142819|NCT06003725|Experimental|ADAP-ITT Phase 8|Phase 8 consists of piloting the culturally adapted CYT intervention with 30 Black JIY to examine feasibility and acceptability.
89142820|NCT06003660||Patients|Adult recipients of allo-HCST.
89142821|NCT06003660||Controls|Healthy adult subjects
89142822|NCT06003582|Experimental|Infant Parent Support|Families engage with the new therapeutic intervention, Infant Parent Support.
89142823|NCT06003582|No Intervention|Services As Usual|Families randomised to Services As Usual, engage with already existing services.
89142824|NCT06003517||Patients with perioperative safety events|Patients with perioperative safety events, including post extubation tracheal intubation, intraoperative cardiac arrest, allergic reactions.
89142825|NCT06003517||Patients without perioperative safety events|Patients without perioperative safety events, including post extubation tracheal intubation, intraoperative cardiac arrest, allergic reactions.
89142826|NCT06003491|Experimental|Intra-articular Group|Posterior intra-articular distraction and fusion
89142827|NCT06003491|No Intervention|Posterior Group|Posterior direct distraction and fusion
89142828|NCT06003478||Hypertrophic Obstructive Cardiomyopathy Patients|
89142829|NCT06003400|Experimental|Tri.O FITT|The study patients will undergo a screening period of upto 4 weeks, a traetment period of upto 12 weeks and a follow-up period of upto 12 additional weeks.
89142830|NCT06002230||Patients treated with individualized homeopathy|Patients suffering from symptoms of Long COVID-19 were treated with individualized homeopathy.
89142831|NCT06001281|Other|plasma collection|Plasma samples will be prospectively collected at relevant time points during patient treatment.
89142832|NCT06000826|Experimental|Neonatal|"A trained study nurse or clinician will transfer the enrolled participant to the study location and place the infant on the Celsi Warmer mattress.~A trained study nurse or clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual~A trained study nurse or clinician will wrap the baby according to the standard care at the hospital.~Study personnel may observe the participant during the intervention period and annotate timestamped events that might affect temperature measurement and/or thermoregulation support intervention.~Study personnel will perform routine abdominal skin assessments as often as every two hours and at least every 8 hours to observe for skin irritation or indentation.~Thermoregulation support intervention will be provided as long as the infant continues to meet criteria for continued care at clinician's discretion."
89142833|NCT06000306||ddPCR MRD positivity|
89142834|NCT06000306||ddPCR MRD negativity|
89142835|NCT06000280|Active Comparator|Study group|The Study group refers to patients who are using topical prostaglandins analogues
89142836|NCT06000280|Placebo Comparator|Control group|The Control group refers to patients who discontinued the use of topical prostaglandins analogues
89142837|NCT06000215||Uphold™ Lite Vaginal mesh - Boston Scientific (Anterior)|Patients previousely received the Uphold™ Lite for the surgical management of apical and/or anterior vaginal mesh prolapse.
89142838|NCT06000215||Pinnacle posterior Vaginal mesh - Boston Scientific|Patients previousely received the Pinnacle posterior Vaginal mesh for the surgical management of posterior and/or apical vaginal mesh prolapse.
89142839|NCT06000215||Artisyn® Y-Shaped Mesh (Robotic-assisted Sacral colpopexy)|Patients previousely received the Artisyn® Y-Shaped Mesh via robotic-assisted approach Patients previousely received th Artisyn® Y-Shaped Mesh via robotic-assisted approach for the surgical management of apical prolapse..
89142840|NCT06000215||Native tissue repair|Patients previousely received native tissue repair for the surgical management of prolapse.
89142841|NCT05999630|Experimental|Experimental Arm (Artificial Tears)|"Participants in this arm will receive artificial tears to be administered in the 4 days immediately following radioactive iodine therapy. The schedule of administration will be as follows:~Day 1 (day of radioactive iodine therapy): Every 15 minutes for 2 hours, then every 30 minutes for at least 4 hours or until bedtime at night Day 2: Once every 1 hour for 12 hours Day 3: Four times (approximately morning, lunch, dinner, and evening) Day 4: Two times (morning and evening)"
89142842|NCT05999630|No Intervention|No Intervention (No Artificial Tears)|Participants in this arm will not administer artificial tears in the 4 days immediately following radioactive iodine therapy.
89142843|NCT05999175|Other|Group 1 (20 subjects)|"using the delicate mint toothpaste Dentifricio gel tau-marin® Menta Delicata."
88816406|NCT04187378|Experimental|Surgical Access Blanket Group|Patients with hypothermia (<36C) will be warmed by air blown surgical access blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
89142844|NCT05999175|Other|Group 2 (12 subjects)|"using of the mint toothpaste Dentifricio gel tau-marin® Menta."
89142845|NCT05999175|Other|Group 3 (20 subjects)|"using the mint mouthwash Collutorio tau-marin® Menta."
89142846|NCT05999175|Other|Group 4 (20 subjects)|"using the delicate mint toothpaste Dentifricio gel tau-marin® Menta Delicata, mint mouthwash Collutorio tau-marin® Menta."
89142847|NCT05999175|Other|Group 5 (12 subjects)|continuing to use their routine oral hygiene products.
89142848|NCT05998291||Refractory dermatitis herpetiformis patients|Dermatitis herpetiformis rash not controlled by strict glute-free diet
89142849|NCT05998291||Dermatitis herpetiformis patients with good response to gluten-free diet|Dermatitis herpetiformis rash controlled by strict glute-free diet
89142850|NCT05997095|Active Comparator|30Hz (low-intensity)|"Volunteers receive 30 mins of neuromuscular electrical stimulation at 30Hz with a contraction pattern of 1 second on and 1 second off"
89142851|NCT05997095|Experimental|100Hz (higher-intensity)|"Volunteers receive 30 mins of neuromuscular electrical stimulation at 100Hz with a contraction pattern of 1 second on and 1 second off"
89142852|NCT05997095|Experimental|30Hz (low-intensity, 3:1)|"Volunteers receive 30 mins of neuromuscular electrical stimulation at 30Hz with a contraction pattern of 3 seconds on and 1 second off"
89142853|NCT05994781|No Intervention|No treatment|The control group is a non-treatment group, and for 3 months after the procedure, general moisturizers that have been used or will be used are available.
89142854|NCT05994781|Experimental|Treatment|In the case of the study group among the subjects of the clinical study, The experimental group apply an appropriate amount of EasyDew MD Regen Cream twice a day (morning and evening) and can be absorbed well.
89142855|NCT05989139|Experimental|NPPV|non-invasive positive-pressure ventilation arm
89142856|NCT05989139|Experimental|HFNC|High-flow nasal cannulae arm
89142857|NCT05989087||Early-onset Alzheimer's disease|Patients were recruited from the outpatient memory clinics of the Department of Neurology, Dokuz Eylül University Hospital. The patient group was diagnosed by an expert neurologist, according to the National Institute on Aging-Alzheimer's Association diagnostic criteria for Alzheimer's disease
89142858|NCT05989087||Healthy controls|Age-and gender-matched healthy volunteers were recruited via advertisements and word-of-mouth.
89142859|NCT05987670|Experimental|Intervention|"Receive 3-6 AI-stethoscopes (Eko DUO, Eko Health Inc, CA, USA) including artificial intelligence software for detection of:~Reduced left ventricular ejection fraction <40%~Atrial fibrillation~Cardiac murmurs"
89142860|NCT05987670|No Intervention|Control|Usual care
89142861|NCT05982977|Experimental|Acupuncture rehabilitation group|Acupuncture rehabilitation intervention was given on the basis of conventional rehabilitation therapy.Disinfected with 75% alcohol and applied the needles at a depth of 25-35mm. Acupuncture stimulation of Lianquan (CV23) and Fengchi (GB20). The needles were retained for 30 minutes/time, once a day, and 5 days/week for a total of 4 weeks.
89142862|NCT05982977|Active Comparator|Conventional rehabilitation group|This group participants would take swallowing training 30 minutes/time, once a day, 5 days/week, a total of 4 weeks of intervention. At the same time, stroke basic treatment, nutritional support and other symptomatic treatment
89142863|NCT05975957|Experimental|FBM|volunteers who will receive adjuvant photobiomodulation therapy (n=119)
89142864|NCT05975957|Placebo Comparator|Control|volunteers who will receive placebo treatment with inert light (n=119)
89142865|NCT05969769|Active Comparator|Experimental Group|Sustained Natural Apophyseal Glides will be performed with Muscle Energy Technique and Short Wave Diathermy as experimental group.
89142866|NCT05969769|Active Comparator|Control Group|Short wave diathermy will be given with Muscle Energy Techniques.
89142867|NCT05966922|Experimental|Electrical Stimulation|Electrical Stimulation and Sham will be delivered transcutaneously in random consecutive sessions
89142868|NCT05966831|Experimental|Metacognitive Self-Control Training (MCT) + Virtual Reality Job Interview Training (VR-JIT)|This group will receive the MCT intervention plus the VR-JIT intervention. We are anticipating 6-8 weeks, with 1-3 sessions per week for each intervention.
89142869|NCT05966831|Experimental|Virtual Reality Job Interview Training (VR-JIT)|This group will receive just the VR-JIT intervention. We are anticipating 6-8 weeks, with 1-3 sessions per week for this intervention.
89142870|NCT05959031|Experimental|active kTMP|Participants received 0.5 - 8 V/m of active stimulation.
89142871|NCT05959031|Sham Comparator|sham kTMP|Participants received 0.01 V/m of sham stimulation.
89142872|NCT05947864|Experimental|Allo-HSCT recipients|Adult recipients of allogenic hematopoietic stem cell transplantation, eligible for live-attenuated vaccines, i.e. who are more than 24 months after their HSCT, without GVHD and more than 3 months after cessation of any immunosuppressant treatment
89142873|NCT05947864|Placebo Comparator|Healthy volunteers (HV)|Healthy adults with a history of measles (=convalescents) or vaccinated with two doses of MMR in the past (=vaccinated)
89142874|NCT05946499||Group A|30 ICU-admitted SARS-CoV-2- infected individuals with ARDS or in need of oxygen supplementation
89142875|NCT05946499||Group B|30 ward-admitted SARS-CoV-2-infected individuals not suffering from ARDS and not in need of oxygen supplementation
89142876|NCT05946499||Group C|30 sex and age-matched normal individuals
89142877|NCT05933603|Experimental|Ato-oxy|0.5 mg/kg (max 40 mg) atomoxetine and 5 mg oxybutynin
89142878|NCT05925062|Experimental|QActual|QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
89142879|NCT05925062|No Intervention|Control Arm - Subjects not using App|No intervention
89142880|NCT05919290|Other|HNSCC patients|Up to 100 HNSCC patients receiving CT-based radiation therapy will receive up to weekly non-contrast MRI scans during treatment.
89142881|NCT05919290|Other|Healthy volunteers and HNSCC patients|"Cohort A - Up to 20 healthy volunteers will undergo non-contrast MRI at two time points.~Cohort B - Up to 53 patients planned to receive curative (chemo) radiotherapy for HNSCC will undergo two baseline MRI scans, one MRI in week 2 and week 4, and final MRI scan 6-8 weeks after completion of treatment."
89142882|NCT05919251|Active Comparator|Healthy Older Adults|This subset of subject's have a fair history with this methodology and are being used as the comparator. Age matched older adults
89142883|NCT05919251|Experimental|Subject's Post Stroke|Individuals post stroke have recently participated in this ongoing investigation in a live format but these subjects are now entered into a telehealth arm. In the future others will participate in the live format
89142884|NCT05917678|Other|Repositioning Therapy|Infants will be treated with at-home repositioning strategies for their deformational head shape. Physical therapy will be provided, if indicated, for treatment of torticollis. This is a standard treatment.
89142885|NCT05917678|Other|Repositioning Therapy + Cranial Remolding Orthoses|After attempting at 2-4 months of repositioning therapy, infants with residual cranial deformation may be treated with a custom made helmet (cranial remolding orthosis) which is adjusted every few weeks to direct skull growth. It is worn 23 hours per day. Physical therapy will be provided, if indicated, for treatment of torticollis. This is a standard treatment.
89142886|NCT05917678|No Intervention|Control|Healthy infants without deformational head shapes or need for physical therapy will be followed and measured. No intervention.
89142887|NCT05907551||Patients with Digestive System Cancer|
89142888|NCT05907551||Patients with Head and Neck Cancer|
89142889|NCT05907551||Patients with Breast Cancer|
89142890|NCT05907551||Patients with Nervous System Tumors|
89142891|NCT05907551||Patients with Urological Cancer|
89142892|NCT05907551||Patients with Lung Cancer|
89142893|NCT05907551||Patients with Gynecologic Cancer|
89142894|NCT05899179|Experimental|Left arm injection EC group|The Recombinant Mycobacterium tuberculosis fusion protein(EC) was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm.
89142895|NCT05899179|Active Comparator|Right arm injection EC group|The Recombinant Mycobacterium tuberculosis fusion protein(EC) was injected intradermally into the volar side of the right forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the left forearm.
89142896|NCT05896020|Experimental|Treatment group with SHR-A1811|
89142897|NCT05888233|Experimental|Allopurinol - African American Veterans|Subjects will receive Allopurinol (300mg/daily) for 4 weeks. If tolerated, dose will be increased to 600mg/daily for an additional 4 weeks. Subjects will take Allopurinol (300-600mg/daily) for 8 weeks total
89142898|NCT05887882|Experimental|Dose Level 2 (3x10^6/m^2) - Starting Dose|Enrolled patients must proceed to surgery for tumor resection and Ommaya placement into the resection cavity within 14 days of enrollment. Starting dose of 3x10^6/m^2 of TGFβi NK cells (first dose) may be administered at least 14 days after the Ommaya reservoir placement, and may not start until all acute surgical complications have resolved (maximum of 6 weeks after enrollment). TGFβi NK cell infusions through the Ommaya reservoir will occur once weekly for three weeks followed by one rest week. If patients have stable or improved disease, patients may continue to receive therapy for a total of 12 cycles.
89142899|NCT05887882|Experimental|Dose Level 3 (3x10^7/m^2)|If no safety or toxicity events are demonstrated by the starting dose cohort, enrolled patients in the next dosing cohort must proceed to surgery for tumor resection and Ommaya placement into the resection cavity within 14 days of enrollment. The dose of 3x10^7/m^2 of TGFβi NK cells (first dose) may be administered at least 14 days after the Ommaya reservoir placement, and may not start until all acute surgical complications have resolved (maximum of 6 weeks after enrollment). TGFβi NK cell infusions through the Ommaya reservoir will occur once weekly for three weeks followed by one rest week. If patients have stable or improved disease, patients may continue to receive therapy for a total of 12 cycles.
89142900|NCT05887882|Experimental|Dose Level 4 (3x10^8/m^2)|If no safety or toxicity events are demonstrated by the previous dose cohort, enrolled patients in the next dosing cohort must proceed to surgery for tumor resection and Ommaya placement into the resection cavity within 14 days of enrollment. The dose of 3x10^8/m^2 of TGFβi NK cells (first dose) may be administered at least 14 days after the Ommaya reservoir placement, and may not start until all acute surgical complications have resolved (maximum of 6 weeks after enrollment). TGFβi NK cell infusions through the Ommaya reservoir will occur once weekly for three weeks followed by one rest week. If patients have stable or improved disease, patients may continue to receive therapy for a total of 12 cycles.
89142901|NCT05885971|Other|Group of pregnant women with eating disorder|
89142902|NCT05885971|Other|Group of pregnant women with no eating disorder|
89142903|NCT05884177||Greenlanders|Subjects born in Greenland with parents born in Greenland
89142904|NCT05884177||non-Greenlanders|Subjects not born in Greenland with parents not born in Greenland
89142905|NCT05874219|Experimental|Local antibiotic spray|Local antibiotic spray (n=75) The intervention Sprayed 1 to 3 times /day for 45 day Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU Bivatracin Spray
89142906|NCT05874219|Active Comparator|Mupirocin 2% ointment|(The standard) 10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm mupirocin 2% ointment
89142907|NCT05870605||Database Survey|All prescriptions for Intuniv available in the database in Denmark, Germany, Norway, Spain, Sweden, and the United Kingdom will be analyzed.
89142908|NCT05870605||Physician Survey|The physicians will collect participant records of those who have been prescribed Intuniv® at least once during the study period of 4 years. This will be done in Belgium, Finland, Ireland, and the Netherlands.
89142909|NCT05865652|Experimental|Patient group|"Participants of this group are subjects with ultra high risk of psychotic transition.~At inclusion visit, subjects will have a psychiatric evaluation and a cerebral MRI examination with phosphorus 31 Magnetic Resonance Spectroscopy in order to investigate membrane phospholipid metabolism and cellular energy metabolism.~One and two years after the inclusion visit, subjects will have a psychiatric evaluation in order to objectivize if a psychotic transition has occured."
89142910|NCT05865652|Active Comparator|Control group|Participants of this group are healthy volunteers. Subjects will have one single visit with a psychiatric evaluation and a cerebral MRI examination with phosphorus 31 Magnetic Resonance Spectroscopy in order to investigate membrane phospholipid metabolism and cellular energy metabolism.
89142911|NCT05862194||Lazertinib|
89142912|NCT05862194||Platinum-based Chemotherapy|
89142913|NCT05844176||Symptomatic intracranial arterial stenosis|
89142914|NCT05844176||Asymptomatic intracranial arterial stenosis|
89234744|NCT00830921||1|"Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services.~Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept."
89234745|NCT00358150|Experimental|Eliglustat tartrate|
89234746|NCT00830999|Experimental|Positive energy balance|Comparison between isocaloric and hypercaloric diets with no exercise performed in any trials
89142915|NCT05843695|Experimental|iTCBT-I (Intensive Transdiagnostic Cognitive Behavioral Therapy-Individual)|"Patients in this arm will receive transdiagnostic CBT delivered in an intensive individual format over 2 weeks. Intensive Transdiagnostic Cognitive Behavior Therapy-Individual (iTCBT-I): Participants randomized to this condition will receive 12 hours of treatment in four 3 hour sessions, over a 2-week period. Treatment consists of psychoeducation, cognitive restructuring, and exposure exercises.~For treatment non-responders (i.e., BAI score decrease < 10), patients will receive 4 additional 90 minute sessions of individual therapy over a 2-week period (iTCBT-Enhanced). These sessions will identify areas where participants might benefit from more in-depth focus on specific concepts taught in the treatment."
89142916|NCT05843695|Active Comparator|iTCBT-G (Intensive Transdiagnostic Cognitive Behavioral Therapy-Group)|"Patients in this arm will receive transdiagnostic CBT delivered in an intensive group format over 2 weeks. Intensive Transdiagnostic Cognitive Behavior Therapy-Group (iTCBT-G): Participants randomized to this condition will receive 12 hours of treatment over a 2-day period (6 hrs each day). Treatment consists of psychoeducation, cognitive restructuring, and exposure exercises.~For treatment non-responders (i.e., BAI score decrease < 10), patients will receive 4 additional 90 minute sessions of individual therapy over a 2-week period (iTCBT-Enhanced). These sessions will identify areas where participants might benefit from more in-depth focus on specific concepts taught in the treatment."
89142917|NCT05843695|Active Comparator|Treatment as Usual (TAU)|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual, which may include other forms of psychotherapy and/or medication.
89142918|NCT05836298|Placebo Comparator|Periodontitis quadrant Scaling root planing (SRP)|Each selected subject underwent quadrant SRP
89142919|NCT05836298|Active Comparator|MINST treatment|Non surgical periodontal treatment performed with Minimally invasive non-surgical therapy (MINST) approach
89142920|NCT05829486||ketaprop|At the beginning of anesthesia, 0.25 mg/kg ketamine and 0.75 mg/kg propofol will be administered.
89142921|NCT05829486||remiprop|At the beginning of anesthesia, 1 mcg/kg of remifentanil and 0.75 mg/kg propofol will be administered.
89142922|NCT05825417|Active Comparator|Arm A (selexipag/riociguat)|Baseline - established PDE/ERA therapy Week 1 - initiate OPA (PDE/ERA/OPA therapy) Weeks 2-12 - uptitration of OPA to maximal therapy (PDE/ERA/OPA therapy) Weeks 13-14 - reduce OPA (PDE/ERA/OPA therapy) Week 15 - washout OPA (PDE/OPA therapy) Week 16 - washout PDE (ERA therapy) Week 17 - initiate sGCS (ERA/sGCS therapy) Weeks 18-27 - uptitration of sGCS to maximal therapy (ERA/sGCS therapy)
89142923|NCT05825417|Active Comparator|Arm B (riociguat/selexipag)|Baseline - established PDE/ERA therapy Week 1 - washout PDE (ERA therapy only) Week 2 - initiate sGCS (ERA/sGCS therapy) Weeks 3-12 - uptitration of sGCS to maximal therapy (ERA/sGCS therapy) Week 13 - reduce sGCS (ERA/sGCS therapy) Week 14 - reduce and washout sGCS (ERA therapy) Week 15 - initiate PDE (PDE/ERA therapy) Week 16 - initiate OPA (PDE/ERA/OPA therapy) Weeks 17-27 - uptitration of OPA to maximal therapy (PDE/ERA/OPA therapy)
89142924|NCT05806801|Experimental|Moderate Intensity Continuous Training (MICT) exercise group|45 minutes of continuous steady-state exercise at 70% maximal heart rate throughout the 10% weight loss phase of the study
89142925|NCT05806801|Experimental|No exercise (Control)|to remain sedentary (no planned physical exercise) throughout the duration of the 10% weight loss phase of the study
89142926|NCT05794815|Experimental|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
89142927|NCT05794815|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
89142928|NCT05790044|Active Comparator|Group Placebo|Children will receive intra-oral infra-orbital nerve block using bupivacaine 0.2% after induction of general anesthesia and before starting surgical procedure. Total volume of 1 ml each side.
89142929|NCT05790044|Active Comparator|Group Clonidine|Children will receive intra-oral infra-orbital nerve block using bupivacaine 0.2% and clonidine 1 ug/kg after induction of general anesthesia and before starting surgical procedure. Total volume of 1 ml each side.
89142930|NCT05784714|Experimental|Intervention|This arm will include daily diary assessment and GPS phone tracking, access to psychoeducational modules, skills practice, and tools to help with coping and stress reduction. Enhancements include geofencing alerts for risky environments; progress tracking and feedback reports; self-initiated tool engagement (e.g. push button to engage in coping exercise), robust JITAI programming that recommends skills for participants to use in the moment based on daily diary responses, positive mood building exercises, and support.
89142931|NCT05784714|No Intervention|GEMA|This arm will include daily diary and phone tracking. Participants in this arm will also respond to daily diary assessments twice daily but will not receive the psychoeducation interactive components such as tracking and feedback, alerts, or capacity to send alerts that connect them to tools. This arm will have access to resources.
89142932|NCT05783375|Other|ADUNU Participants|Individuals and healthcare providers residing and working in the involved Ugandan Districts.
89142933|NCT05783336|Experimental|SSCF+|Stepping Stones and Creating Futures Plus (SSCF+). Small group intervention, comprising approximately 15 sessions (each session ~3 hours), addressing gender, livelihoods, mental health.
88805990|NCT01152359|Experimental|Arm 1|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
89142934|NCT05783336|No Intervention|Control|No intervention control (wait-list)
89142935|NCT05776030|Experimental|Ergonomic Wheelchair Gear Testing|This study has two aims. The first aim will have participants use a single speed ergonomic wheelchair to test three different gear ratio set ups (3:2, 1:1, 2:3).
89142936|NCT05776030|Experimental|Multispeed Testing - Ergonomic Wheelchair|The second aim will have participants compared to the participant's standard wheelchair to a multi-speed (2 gear ratios) ergonomic wheelchair.
89142937|NCT05776030|Experimental|Multispeed Testing - Standard Wheelchair|The second aim will have participants compared to the participant's standard wheelchair to a multi-speed (2 gear ratios) ergonomic wheelchair.
89142938|NCT05773950|Placebo Comparator|Dual therapy group|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes.~The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
89142939|NCT05773950|Experimental|Triple therapy group|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants. In the case of the experimental group, 150 ml of normal saline mixed with 150 mg of fosaprepitant is administered over 30 minutes.~The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
89142940|NCT05769283|Active Comparator|Platelet Rich Plasma|Platelet Rich Plasma Injection
89142941|NCT05769283|Placebo Comparator|Saline|Placebo injection of saline
89142942|NCT05766553|Experimental|Interventional Group|"Patients in this arm will have 6 sessions of virtual reality in a pod (1 session per week).~Patients will then have a visit at day 90 and day 180."
89142943|NCT05766553|Active Comparator|Control group|"Patients in this arm will receive the gold standard of treatment for tobacco cessation (nicotine patches and chewing gum) from day 0 (inclusion visit) to day 90.~Patients will then have a visit at day 90 and day 180."
89142944|NCT05755360||Participants with T2D|Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician.
89142945|NCT05741632|Experimental|Moxifloxacin|Subjects will receive 0.1 cc undiluted non preserved intracameral Moxifloxacin during cataract surgery.
89142946|NCT05741632|Active Comparator|Levofloxacin|Subjects will receive 0.1 cc undiluted non preserved intracameral Levofloxacin during cataract surgery.
89142947|NCT05732987||Biobank- samples from NMID patients|600 samples from NMID patients from the Biobank Dermatology Unispital Basel (USB) (Biobank USB) and from the biobank of the Dermatology Department of the University Hospital Zürich (USZ) (Biobank USZ) will be included.
89142948|NCT05732987||Formalin-fixed and paraffin-embedded (FFPE) samples|About 50 of formalin-fixed and paraffin-embedded (FFPE) samples from the Dermatology USB collected before 2014 for RNA and protein expression analyses will be reused. The patients in questions are informed about the study and the coded use of their samples.
89142949|NCT05732987||Biobank- samples from controls|2'700 anonymized control genomes as well as 150 anonymized control samples for the proteomics approach can be used as control samples from the biobank of the Dermatology Department of the University Hospital Zürich (Biobank Dermatology USZ).
89142950|NCT05732987||Fresh skin samples from healthy donors|A maximum of 20 fresh skin samples from healthy donors are required per skin location. They will be requested from healthy volunteers after information about the study and receiving the informed consent.
89142951|NCT05728645|Experimental|colloid group|The participants in colloid group will received intravenous Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg before the Induction of general anesthesia.
89142952|NCT05728645|Active Comparator|crystalloid group|The participants in crystalloid group will received intravenous multiple electrolyte injection of 5ml/kg before the Induction of general anesthesia.
89142953|NCT05726890|Experimental|bedtime checking|"The intervention is based on the principles of graduated extinction, defined as an effective and recommended therapy in the treatment of bedtime problems and night-wakings by the AASM. The basic guidelines for this intervention are: (1) When the infant shows tired signs, he/she should be put to bed awake; (2) parents should minimize their involvement after putting the infant to bed; (3) if the child protests/cries, the parent should check the infant's crib every few minutes (e.g., 5 minutes), briefly comfort the infant without taking him/her out of the crib, and help the infant resume a sleeping position/find sleep aids (e.g., pacifier); (4) disengage and leave the crib until the next visit, (5) In order to increase consistency, the same parent should implement the intervention.~In the bedtime checking arm, parents will be instructed to implement the changes only at bedtime and will be asked to continue soothing their infant at night, as they normally do"
89142954|NCT05726890|Active Comparator|standard checking|"Same as for bedtime checking at bedtime, but in the standard checking arm, parents apply the intervention guidelines also when the infant wakes up during the night."
89142955|NCT05724719||Unprovoked First Seizure (UFS)|Participants will undergo cognitive screening assessment, MRI imaging and EEG (if not already done) within 2-4 weeks of the initial First seizure clinic visit. Seizure recurrence will be monitored by a diary provided to each participant with details of the research team to contact in the event of a seizure. A researcher via perform telephone reminders at 3, 6, 9 and 12 months following the seizure. The primary outcome will be seizure recurrence at 12 months.
89142956|NCT05724719||Healthy Controls|Healthy control participants will complete the same neuropsychological battery, MRI scans and EEG protocols to evaluate baseline level of impairment in a healthy population and for the group comparisons of UFS to healthy controls to establish the changes already present at initial presentation with UFS.
89142957|NCT05724472|Experimental|Study Group 1|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^6 pfu intramuscularly Day 1
89142958|NCT05724472|Experimental|Study Group 2|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^7 pfu intramuscularly Day 1
89142959|NCT05724472|Experimental|Study Group 3|rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^8 pfu intramuscularly Day 1
89142960|NCT05722743|Experimental|Harmony at HOME|Participants in this group will receive the Harmony at HOME intervention.
89142961|NCT05722743|Active Comparator|National Institute on Aging Program|Participants in this group will receive the National Institute on Aging education.
89142962|NCT05704062||Diagnostic (multi-parametric MRI)|Patients undergo an MRI exam that includes standard anatomic scans, DCE-MRI, and DW-MRI at baseline, after first treatment cycle, at mid-point of treatment course, and after completion of neoadjuvant chemotherapy.
89142963|NCT05688969|Active Comparator|Early Biopsy|"The investigators will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks (early) or 6-8 months (late) after starting therapy. This is not a clinical trial: the investigators will not be assigning volunteers to a specific osteoporosis therapy, though the investigators will randomize volunteers to either the early or late second biopsy."
89142964|NCT05688969|Active Comparator|Late Biopsy|"The investigators will perform paired iliac crest bone biopsies in postmenopausal women who meet standard romosozumab treatment indications and are being prescribed romosozumab by their treating physician. All study volunteers will have a bone biopsy procedure prior to starting therapy, and then an identical procedure at the contralateral side either 3-6 weeks (early) or 6-8 months (late) after starting therapy. This is not a clinical trial: the investigators will not be assigning volunteers to a specific osteoporosis therapy, though the investigators will randomize volunteers to either the early or late second biopsy."
89142965|NCT05685342|Experimental|Preemptive administration group|Preemptive administration group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 minutes at the end of induction of anesthesia.
89142966|NCT05685342|Active Comparator|Preventive administration group|The preventive administration group will receive intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) for 15 minutes when surgical site closure starts.
89142967|NCT05681312|Active Comparator|systemic proteolytic enzyme|Tibrolin combination of (Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg) one by one for five day
89142968|NCT05681312|Placebo Comparator|amoxicillin, metronidazol, doliprane|amoxicillin 500 mg one by three metronidazol 500 mg one by three doulprane 1000 mg one by one
89142969|NCT05663762||Pre-pandemic pregnancy and birth|Live hospital births that occurred Jan 1 - Mar 31 2019
89142970|NCT05663762||Pregnant and gave birth during the pandemic but before widespread COVID-19 vaccine availability|Live hospital births that occurred Jan 1 - Mar 31 2021
89142971|NCT05663762||Pregnant and gave birth during the pandemic and after widespread COVID-19 vaccine availability|Live hospital births that occurred Jan 1 - Mar 31 2022
89142972|NCT05651061|Experimental|Dose cohorts|Dose cohorts were designed to evaluate the safety, immunogenicity and PK/PD.
89142973|NCT05632185|No Intervention|Control group|standard regular treatment modalities
89142974|NCT05632185|Active Comparator|Equine assisted intervention|patients will receive weekly equine-assisted therapy sessions over a period of 8 weeks in addition to their standard regular therapy
89142975|NCT05627622|Experimental|Experimental group,|Receiving stone-prevention information on a monthly basis, using WhatsApp Messenger® application.
89142976|NCT05627622|No Intervention|control group|will not receive stone-prevention information
89142977|NCT05625503|Active Comparator|Verapamil|Intra-arterial Verapamil 5 mg (2mL) diluted with 8 mL of normal saline
89142978|NCT05625503|Placebo Comparator|Nicardipine|Intra-arterial Nicardipine 400 mcg undiluted (8mL)
89142979|NCT05611580|No Intervention|Control|The participant in the control group receive usual care.
89142980|NCT05611580|Experimental|Intervention|The participants in the intervention group received the chronic disease risk reduction intervention.
89142981|NCT05563519|Active Comparator|I-PRF + collagen|I-PRF will be applied with type 1 collagen to the extraction socket after the wisdom tooth operation.
89142982|NCT05563519|Active Comparator|L-PRF|Only L-PRF will be applied to the extraction socket after the wisdom tooth operation
89142983|NCT05557929||Hemodialysis patients|The present study will comparatively evaluate a series of parameters (measured with cardiopulmonary exercise testing, spirometry, heart ultrasound, lung ultrasound and bioelectrical impedance analysis) in end-stage kidney disease patients undergoing hemodialysis between the end of the long and the end of the short interdialytic interval. The primary aim of the study is the evaluation of cardiorespiratory fitness - cardiovascular reserve assessed with cardiopulmonary exercise testing at these time points.
89142984|NCT05557929||Controls without CKD|Controls without CKD will be evaluated with cardiopulmonary exercise testing, spirometry, heart ultrasound, lung ultrasound and bioelectrical impedance analysis at one time point (baseline visit)
89142985|NCT05537402|Experimental|Arm A: Atezolizumab and bevacizumab|"Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.~Atezolizumab will be administered first followed by bevacizumab, with a minimum of 5 minutes between dosing."
89142986|NCT05537402|Active Comparator|Arm B: Locoregional therapy with TACE or TARE|"Patients will undergo locoregional therapy with TACE or TARE per investigator preference.~TACE will be administered every 8 +/- 4 weeks; TARE will be administered every 12 +/- 4 weeks. Proportion of patients being treated with TARE will be capped at 50% of cohort at a protocol level. After 50% cap is reached, patients randomized to Arm B will be treated with TACE."
89142987|NCT05534204|Active Comparator|Silk suture|Silk suture is a multifilament suture, used for surgical sides closure.
89142988|NCT05534204|Active Comparator|Polyester suture|Polyester suture is a monofilament suture, used for surgical sides closure.
89142989|NCT05529290|Active Comparator|Dexketoprofen Trometamol + Thiocolchicoside|(25mg + 4mg, 2x1)
89142990|NCT05529290|Active Comparator|Dexketoprofen Trometamol + Paracetamol|(25mg + 300mg, 2x1)
89142991|NCT05529290|Active Comparator|Dexketoprofen Trometamol|(25mg, 2x1)
89142992|NCT05529290|Active Comparator|Paracetamol|(500 mg, 4x1)
89142993|NCT05523453|Active Comparator|Processing of Positive Memories Technique (PPMT)|Participants receive 5 60-minute Processing of Positive Memories Technique (PPMT) sessions for PTSD following the treatment procedures as outlined in PPMT therapy manual.
89142994|NCT05523453|Active Comparator|Supportive Counseling (SC)|Participants receive 5 60-minute supportive counseling (SC) sessions. SC includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
89234747|NCT00830999|Experimental|Energy balance with exercise|Comparison between an isocaloric diet without exercise and a hypercaloric diet with a sufficient amount of exercise performed to match the excess calories consumed resulting in both trials being in net energy balance.
89234748|NCT00830999|Experimental|Negative energy balance|Comparison between isocaloric and hypocaloric diets with no exercise performed in any trials
89142995|NCT05518487|Experimental|Kidney transplant recipients|This single-arm trial will administer a single dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine to kidney transplant recipients who demonstrate a persistently low (=< 2500 u/mL) anti-spike antibody response after completion of primary series and bivalent booster of either the Moderna COVID-19 Vaccine or the Pfizer-BioNTech Vaccine, as described in their respective Food and Drug Administration (FDA) Emergency Use Authorizations (EUAs)
89142996|NCT05517369|Experimental|Hybrid-ESD+|All participants receive resection of non-pedunculated colorectal polyp between 2 and 3 cm using the Hybrid-ESD+ method.
89142997|NCT05516342|Experimental|Experimental: Experimental, LEAD IT! Programming|Participants in the Experimental / LEAD IT! arm will take part in LEAD IT! programming for 18 weeks. The programming will occur twice per week, for a total of 36 sessions.
89142998|NCT05516342|No Intervention|No Intervention: Control, Standard Care / Programming|Participants in the Control arm will receive standard care / programming.
89142999|NCT05505669||Adults with type 1 diabetes|Adults with type 1 diabetes
89143000|NCT05505669||Adult healthy volunteers|Adult healthy volunteers
89143001|NCT05505669||Children with type 1 diabetes|Children with type 1 diabetes
89143002|NCT05505669||Adults with type 2 diabetes|Adults with type 2 diabetes
89143003|NCT05505669||Adults with high blood sugar|Adults with high blood sugar
89143004|NCT05505669||Those at risk of developing type 1 diabetes|Those at risk of developing type 1 diabetes
89143005|NCT05468918|Experimental|Participants tested with comparator devices first, then Audeo Lumity devices|All participants who completed speech in noise testing in the lab with the comparator devices first, and then the Audeo Lumity devices.
89143006|NCT05468918|Experimental|Participants who were tested with Audeo Lumity first, then comparator devices|All participants who completed speech in noise testing in the lab with the Audeo Lumity devices first, and then the comparator devices.
89143007|NCT05461391||Study Group|Participants who got COVID-19.
89143008|NCT05461391||Control Group|Healthy participants
89143009|NCT05456035|Experimental|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy with depressed adolescents using modules from the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, therapists will teach teens explicitly about theory of mind and social perspective taking during each session and will use examples from the teen's own life to help them learn the skills.
89143010|NCT05456035|Active Comparator|Cognitive behavioral therapy (CBT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. Therapists will conduct individual therapy sessions with depressed adolescents using modules from the Coping with Stress manual. Social cognitive training will not be provided to teens in this condition.
89143011|NCT05454722|Experimental|Adex Gel|Dry Skin Emollient with Nicotinamide
89143012|NCT05454631|Experimental|patient present at the respiratory SSR department of the Pitié-Salpêtrière hospital|All the participants will evaluate 5 different types of surgical mask, in random order.
89143013|NCT05436899|Experimental|Intensive training group|Participants in this group will undergo an intensive virtual training program twice a week
89143014|NCT05436899|Active Comparator|Non-Intensive training group|Participants in this group will undergo a non-intensive virtual training program once a week
89143015|NCT05435677|Experimental|Sequence 1|All participants will get each of the 3 medicines at 3 different timepoints IcoSema - insulin icodec - semaglutide, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
89143016|NCT05435677|Experimental|Sequence 2|All participants will get each of the 3 medicines at 3 different timepoints IcoSema- semaglutide . insulin icodec, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
89143017|NCT05435677|Experimental|Sequence 3|All participants will get each of the 3 medicines at 3 different timepoints insulin icodec- IcoSema- semaglutide, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
89143018|NCT05435677|Experimental|Sequence 4|All participants will get each of the 3 medicines at 3 different timepoints insulin icodec- semaglutide - IcoSema separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
89143019|NCT05435677|Experimental|Sequence 5|All participants will get each of the 3 medicines at 3 different timepoints semaglutide - IcoSema - insulin icodec, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
89143020|NCT05435677|Experimental|Sequence 6|All participants will get each of the 3 medicines at 3 different timepoints semaglutide - insulin icodec - IcoSema, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.
89143021|NCT05415917|Experimental|Group 1- Gemcitabine and Capecitabine Treatment|"Day 1, Day 8, Day 15 • Gemcitabine infused through a vein over 120 minutes~Day 1 - Day 21~• Capecitabine tablets will be taken two times a day; once in the morning and once in the evening. The tablets should not be crushed or split and should be taken with a full glass of water (8 ounces/240 milliliters) within 30 minutes after a meal."
89143022|NCT05415917|No Intervention|Group 2 - Observational|Usual therapy used to treat this type of cancer, chemotherapy plus radiation therapy. If cancer returns during observation, there will be offered standard of care therapy. Follow-up visits will be every three months.
89143023|NCT05408130|Experimental|Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|All patients randomized to the intervention arm will receive 5 cycles of ischemia/reperfusion in the non-paralyzed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.
88816407|NCT01189760|Experimental|onabotulinumtoxinA 44U|44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
89143024|NCT05408130|Sham Comparator|Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke.
89143025|NCT05407441|Experimental|Phase I a: DOSE ESCALATION (STRATUM A, ATRT and primary CNS malignant tumor, INI/SMARCA4-deficient)|"Part 1 will be two concurrent rolling six phase 1 studies starting at a different tazemetostat dose for each stratum), with one dose escalation and one dose de-escalation planned. All subjects will receive the same nivolumab and ipilimumab doses and dosing schedule"
89143026|NCT05407441|Experimental|Phase I b: DOSE ESCALATION (STRATUM B, NON-ATRT, NON-CNS)|"Part 1 will be two concurrent rolling six phase 1 studies starting at a different tazemetostat dose for each stratum), with one dose escalation and one dose de-escalation planned. All subjects will receive the same nivolumab and ipilimumab doses and dosing schedule"
89143027|NCT05407441|Experimental|EXP A1: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A1)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
89143028|NCT05407441|Experimental|EXP A2: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A2)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
89143029|NCT05407441|Experimental|EXP A3: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA A3)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
89143030|NCT05407441|Experimental|EXP B1: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B1)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
89143031|NCT05407441|Experimental|EXP B2: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B2)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
89143032|NCT05407441|Experimental|EXP B3: TAZEMETOSTAT + NIVOLUMAB + IPILIMUMAB DOSE EXPANSION (SUBSTRATA B3)|"Once the MTD or RP2D of the combination is determined for each stratum, the Part 2 portion will open for that stratum, with subjects from Part 1 who are treated at the RP2D to be counted towards the enrollment numbers for Part 2.~Part 2 will consist of 3 substrata per stratum based on their disease status"
89143033|NCT05397158|Experimental|Single administration of low dose polyethylene glycol group|The patients take 30ml lactulose in the morning 1 day before the examination, and eat without residue in lunch and dinner; Take 2L PEG in the morning of the examination day and fast at breakfast and lunch of the day.
89143034|NCT05397158|Active Comparator|control group|The patients in control group take 2L PEG the day before the examination, fast at dinner (patients without diabetes) and eat without residue (patients with diabetes). Patients take 2L PEG again in the morning of the examination day, and fasted at breakfast and lunch of the day.
89143035|NCT05367687|Experimental|Treatment group|Camrelizumab Plus Rivoceranib (Apatinib)
89143036|NCT05367687|Active Comparator|Control group|Camrelizumab
89143037|NCT05361174|Experimental|Cohort 1|Participants with unresectable or metastatic melanoma
89143038|NCT05361174|Experimental|Cohort 2|Participants with Stage III or IV non-small-cell lung cancer
89143039|NCT05353829|Active Comparator|Per oral|Drug:per oral Methotrexate Tablets dosage 5-30mg once weekly.
89143040|NCT05353829|Active Comparator|Subcutaneous|Drug: subcutaneous Methotrexate Injection dosage 5-30mg once weekly.
89143041|NCT05352568|Experimental|Cognitive Group|Computer Cognitive-Based Training
89143042|NCT05345509|Active Comparator|Aricept Tablet|Aricept Tablet, QD, PO
89143043|NCT05345509|Experimental|IVL3003 (A mg)|SC, Single Dose
89143044|NCT05345509|Experimental|IVL3003 (B mg)|SC, Single Dose
89143045|NCT05345509|Experimental|IVL3003 (C mg)|SC, Single Dose
89143046|NCT05307731|Experimental|Fingoland group|The patients of this group were treated with Fingolimod 0.5mg per day, in addition to guideline based treatment.
89143047|NCT05307731|Active Comparator|Control group|The patients of this group were treated with diabetes drugs based on guideline
89143048|NCT05299034||Stroke patients 6-24h receiving non-contrast CT + CTA|Stroke patients 6-24h undergoing non-contrast CT + CTA to decide stroke therapy
89143049|NCT05299034||Stroke patients 6-24h receiving multimodal imaging|Stroke patients 6-24h undergoing NCCT+CTA+CTP or MRI with DWI and PWI imaging to decide stroke therapy
89143050|NCT05287035|Active Comparator|Steroid injection|Dexamethasone will be injected 1 dose intraoperatively, 3 doses post-operatively every 8hrs
89143051|NCT05287035|Placebo Comparator|Saline solution|Saline will be injected 1 dose intraoperatively, 3 doses post-operatively every 8hrs
89143052|NCT05282069|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
89143053|NCT05282069|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
89143054|NCT05282069|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
89143055|NCT05282069|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
89143056|NCT05263479|Experimental|HS-20089 (Phase Ia：Dose escalation )|HS-20089 for IV infusion of various dose strengths administered in 21 day dosing cycles.
89143057|NCT05263479|Experimental|HS-20089 (Phase Ib: Dose expansion)|The recommended dose from the dose-escalation stage and other potential doses will be further explored.
89143058|NCT05251090|Experimental|Arm 1|Subjects(up to 12 years of age) received two treatments: 50 IU/kg ADVATE in the first period, followed by 50 IU/kg FRSW107 in the second period.
89143059|NCT05249920|Experimental|Edaravone Dexborneol group|Patients in this arm will be given Edaravone Dexborneol Concentrated Solution for injection twice a day for 10 to 14 days.
89143060|NCT05249920|Placebo Comparator|Edaravone Dexborneol Placebo group|Patients in this arm will be given a placebo of Edaravone Dexborneol for injection twice a day for 10 to 14 days.
88803446|NCT04747340|Experimental|Training for Awareness, Resilience and Action (TARA)|12 weekly online sessions, each 90 minutes, 6 participants/group. For participants <18 years at CAP, parents/legal guardians will participate in parts of the sessions. Manual-based: Session 1: Introducing group members; establishing guidelines; investigating attitudes and previous experiences, introducing contemplative practices. All sessions: participants sit on yoga mats. Facilitators open and briefly check-in. Participants are guided through a breathing practice, yoga-based movement (a flow of positions synchronized with the breath) and then a meditation focusing primarily on interoceptive and sensory awareness. After a short break, a psychoeducational presentation is held followed by group exercises and discussions. The sessions conclude with feedback and questions regarding the practice, followed by a description of the home practice for the coming week. Finally, participants gather their attention and have the opportunity to express their reflections and current state.
88803447|NCT04747340|Active Comparator|Standard Treatment|Standard treatment (ST) as given at each participating study site. ST is based on the health practitioners' knowledge, experience, current guidelines and both the practitioners' and participants' preferences. For young people with depression The Swedish National Board of Health and Welfare recommends social support and psychoeducation (as first priority), Selective Serotonin reuptake inhibitors (as second priority) and cognitive behavioral therapy (as second priority). These recommendations are generally followed and given as stand-alone treatment or in different combinations. In our study we have no control over which of these treatments are given in the ST-arm, nor the combination or timing of them. To obtain data on what treatment has been given in the ST-arm we will go through the individual medical records of all participants at the conclusion of data collection.
88803448|NCT05293210|Experimental|Experimental arm|A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.
88803449|NCT05293210|Active Comparator|Standard treatment regimen|Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily).
88803450|NCT01895348|Active Comparator|propofol only|
88803451|NCT01895348|Active Comparator|propofol-remifentanil|
88803452|NCT01895348|Active Comparator|dexmedetomidine-remifentanil|
88803453|NCT05292040|Experimental|LY3857210|Single doses of LY3857210 administered orally.
88803454|NCT04271852|Experimental|UUI patients|50 UUI patients will have biofeedback treatment once a week.
88803455|NCT04271852|No Intervention|Control|
88803456|NCT05278546|Experimental|Treatment Arm|
88803457|NCT04784078|Experimental|dTRA group|
88803458|NCT04784078|Active Comparator|cTRA group|
89143061|NCT05219955|Experimental|Active condition (SAMM Protocol)|The goal of the SAMM protocol is to increase morning activity engagement over a 6-week period. Participants in this condition will review their morning routine, and make a list of potential morning activities to add. They will choose one activity and develop a plan for doing it. Each day, participants are asked to track if they do the morning activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one.
89143062|NCT05219955|Active Comparator|Attention-matched supportive control condition|Participants in this condition will receive sessions in the same number and duration as the SAMM experimental condition. Therapists will create a comfortable environment by demonstrating interest, empathy, and acceptance without judgment. Caregivers will be encouraged to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials.
89143063|NCT05217667|Experimental|ARO-ANG3 Dose 1|ARO-ANG3 Dose Level 1 subcutaneous (SC)
89143064|NCT05217667|Experimental|ARO-ANG3 Dose 2|ARO-ANG3 Dose Level 2 SC
89143065|NCT05199090|Active Comparator|MBL949 Arm 1|One dose C followed by two doses E followed by five doses D of MBL949
89143066|NCT05199090|Active Comparator|MBL949 Arm 2|Two doses C followed by six doses D of MBL949
89143067|NCT05199090|Active Comparator|MBL949 Arm 3|One dose G followed by seven doses D of MBL949
89143068|NCT05199090|Active Comparator|MBL949 Arm 4|One dose A followed by seven doses B of MBL949
89143069|NCT05199090|Active Comparator|MBL949 Arm 5|One dose C followed by two doses E followed by five doses F of MBL949
89143070|NCT05199090|Placebo Comparator|Placebo|"MBL949 Arm 1, MBL949 Arm 2 and placebo to be enrolled in a 1:1:1 ratio~MBL949 Arm 3, MBL949 Arm 4 and placebo to be enrolled in a 1:1:1 ratio~If MBL949 Arm 1 is tolerated, MBL949 Arm 5 to be enrolled with a 2:1 ratio (MBL:placebo) within each stratum. MBL949 arm 5 will have 12 participants and 6 participants added to placebo arm"
89143071|NCT05193071|Experimental|double antiplatelet group|aspirin 100mg plus clopidogrel 300mg
89143072|NCT05193071|Placebo Comparator|control group|aspirin placebo plus clopidogrel placebo
89143073|NCT05174403||SPG5 patients|Adult SPG5 patients with diagnostic confirmed by the identification of two mutations in the CYP7B1 gene
89143074|NCT05162846|Active Comparator|Arm 1 - Usual care (UC)|Participants are provided with a link to the Michigan Department of Health and Human Services (MDHHS) informational website and are instructed to follow up with their oncology provider about genetic testing.
88803459|NCT04784000|Experimental|AT-527 550 mg + carbamezepine|
88803460|NCT04784000|Experimental|AT-527 1100 mg + carbamezepine|
88803461|NCT04783688|Experimental|Experimental Group|All subjects will snorkel using the same FFSMs.
88803462|NCT05261620|Experimental|SoC + WISE|Candidates for surgery and habitual consumers of alcohol-containing beverages (7-21 alcohol-containing beverages per week) with a body mass index between 18 and 30 kg/m2. Subjects assigned to the Experimental Arm will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men.
88803463|NCT05261620|No Intervention|SoC|Control Arm subjects adhere to diet free of any alcohol-containing beverages, as normally recommended by surgeons in their clinical practice
88803464|NCT01113476|Experimental|Nab-paclitaxel, Gemcitabine + Bevacizumab|Starting doses of Nab-paclitaxel 50 mg/m^2, Bevacizumab 5 mg/kg + fixed dose of Gemcitabine 1000 mg/m^2
89143075|NCT05162846|Experimental|Arm 2 - Virtual genetics navigator|Participants receive access to an online genetics tool, the virtual genetics navigator, to help learn why and how to seek out genetic testing for hereditary cancer syndromes.
89143076|NCT05162846|Experimental|Arm 3 - Motivational interviewing (MI)|Participants receive up to 2 phone calls from trained genetics health coaches who provide information about genetic testing and use motivational interviewing to encourage participants to seek out clinical genetic testing.
89143077|NCT05162105|Experimental|Evening shift followed by day shift (Quick Return)|Participants work a simulated evening shift, from 03:00PM to 11:00PM, followed by a simulated day shift, 07:00AM to 03:00PM, the following day.
89143078|NCT05162105|Active Comparator|Day shift followed by day shift|Participants work a simulated day shift, from 07:00AM to 03:00PM, followed by another simulated day shift, from 07:00AM to 03:00PM, the following day.
89143079|NCT05145010|Experimental|Arm 1: Rollover subjects|Children who have completed QED-sponsored interventional study with infigratinib
89143080|NCT05145010|Experimental|Arm 2: Treatment naïve subjects|Children naïve to infigratinib
89143081|NCT05122286|Experimental|Bailout angioplasty|If the patient is randomized into the bailout angioplasty arm, the choice of balloon dilation or stenting will be left to the discretion of the interventionalist.
89143082|NCT05122286|Active Comparator|Standard therapy|If the patient is randomized into the standard therapy arm, the interventionalist will decide whether to stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters.
89143083|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 1)|Dose level 1: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Carbohydrate High Calorie (HCHC)
89143084|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 2)|Dose level 2: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: HCHC
89143085|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 3)|Dose level 3: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: HCHC
88803465|NCT01718600||Neuroimaging Correlates|Carotid revascularization can significantly reduce the risk of stroke in patients with severe carotid stenosis; however, it has been associated with cognitive decline in 25% of the older adults who undergo the procedure. Neuroimaging techniques that characterize white matter integrity and regional hypoperfusion have the potential to provide sensitive brain structure indicators that may be associated with memory decline following revascularization procedures. In this proposal, we hope to determine the risk factors and cognitive effect of microembolization following carotid revascularization procedures.
88803466|NCT04839718||Control|Patients receiving referral to specialty mental healthcare
88803467|NCT04839718||ADAPT|ADAPT
89143086|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 4)|Dose level 4: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: Standard Diet (SD)
89143087|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 5)|Dose level 5: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
89143088|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 6)|Multiple dose administration of PF-07258669 and placebo over 14 days in Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
89143089|NCT05113940|Experimental|Midazolam with and without PF-07258669 (Cohort 8)|Drug-drug interaction assessment of pharmacokinetics interaction in PF-07258669 and midazolam Dietary allocation: SD
89143090|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 7)|Multiple dose administration of PF-07258669 and placebo over 14 days in older adult participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
89143091|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 9)|Dose level 6: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
89143092|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 10)|Dose level 7: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
89143093|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 11)|Dose level 8: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD
89143094|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 12)|Dose Level 9: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Fat High Calorie (HFHC)
89143095|NCT05113940|Experimental|PF-07258669 and Placebo (Cohort 13)|Dose Level 10: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Fat High Calorie (HFHC)
88803468|NCT04783766|Experimental|CK-3773274 for Single Ascending Dose (SAD) Cohorts|Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274
88803469|NCT04783766|Placebo Comparator|Placebo comparator for SAD Cohorts|Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator
88803470|NCT04783766|Experimental|CK-3773274 for Multiple Dose (MD) Cohort|Subjects will receive multiple doses of CK-3773274
88803471|NCT04783766|Placebo Comparator|Placebo comparator for MD Cohort|Subjects will receive multiple doses of placebo comparator
88803472|NCT04835194||Phenotype 1 (from LCA)|
88803473|NCT04835194||Phenotype 2 (from LCA)|
88803474|NCT04835194||Phenotype 3 (from LCA)|
88803475|NCT01107236|Experimental|IW-6118|
88803476|NCT01107236|Placebo Comparator|Placebo|
88803477|NCT01107236|Active Comparator|Naproxen Sodium|
89143096|NCT05082259|Experimental|Part A-Escalation|"Increasing doses of ASTX660 in combination with a fixed dose of pembrolizumab to establish the maximum tolerated dose (MTD) of ASTX660 and Pembrolizumab when given in combination in patients with advanced solid tumours.~escalating doses of ASTX660 will be investigated in combination with a fixed dose of Pembrolizumab (200mg). ASTX660 administration will follow a 7 day on / 14 day off pattern (ie dosing for 7 consecutive days leading up to administration of the immune check-point inhibitors). Therefore in Cycle 1, ASTX660 will be given alone from Day 1 to Day 7, followed by a 14 day break, then taken again in Cycle 2 . Each cycle will run for a period of 21 days, with ASTX660 taken always on Days 1 to 7 and Pembrolizumab given always on Day 8.~Up to 4 dose levels of ASTX660 will be explored."
89143097|NCT05082259|Experimental|Part B-Expansion|"Patients in Part B will be treated at the RP2D as determined by the SRC after the initial dose escalation (Part A) has been completed. The treatment schedule will be the same as that for Part A, i.e. each cycle will be 21 days-long. Pembrolizumab will always be administered on D8 of every cycle. ASTX660 will be taken daily on Days 1-7.~Part B will be split into 3 cohorts; Cohort B1, Cohort B2 and Cohort B3.~Cohort B1: Patients with Immune-checkpoint refractory tumours Cohort B2: Patients with PD-L1 positive Cervical Cancer Cohort B3: Patients with Triple Negative Breast Cancer"
89143098|NCT05076123|Experimental|Experimental group-1 (M-CIMT group)|participants in this group will be trained with Modified Constraint Induced Therapy (M-CIMT) in addition to conventional therapy. M-CIMT is shorter versions of CIMT. The original CIMT devotes six or more hours for therapy and constraining of the intact arm for 90% of waking hours per day and over a period of two weeks. Researchers have observed that such a schedule of CIMT is exhaustive and possibly resulting in non-compliance. Because of this reason,s Modified shorter versions of CIMT (mCIMT) have been designed by researchers. Duration of M-CIMT interventions varies from 2 to 10 weeks and the treatment time also varies from as short as 30 minutes to three hours per day in various studies. Nevertheless both CIMT and mCIMT have shown promising success. M-CIMT emphasizes massed practice with the affected upper limb.
89143099|NCT05076123|Experimental|Experimental group-2 (M-CIMT+TES group)|participants in this group will be trained with Modified Constraint Induced Therapy (M-CIMT) and threshold electrical stimulation (TES) in addition to conventional therapy. TES is based on low-intensity (<100 Hz) and long-duration current and is applied with superficial electrodes. TES provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction. TES can improve motor learning and motor performance by improving connections between sensory-motor cortical association regions in the brain.
89143100|NCT05076123|No Intervention|Control group|participants in this group will be trained with conventional therapy. Conventional therapy consists of strength training, stretching exercises and functional activity training.
89143101|NCT05073172|Experimental|Arm I (StrataXRT)|Patients apply StrataXRT topically to the affected area once or twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =< 1.
89143102|NCT05073172|Active Comparator|Arm II (standard of care)|Patients receive standard of care including calendula and/or Aquaphor applied 2-6 times daily plus hydrogel or Silvadene or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =< 1.
89143103|NCT05065372|Active Comparator|Metformin plus automated insulin delivery system|Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with metformin and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
89143104|NCT05065372|Placebo Comparator|Placebo plus automated insulin delivery system|Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with a placebo pill which is identical in appearance to the metformin pill and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
89143105|NCT05065372|Other|Multiple daily insulin injections plus continuous glucose monitor|Participants with type 1 diabetes using multiple daily injections plus a continuous glucose monitor will not be randomized to receive medication treatment but will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in additional to assessments of cardiovascular and endothelial function.
89143106|NCT05059899|Experimental|Exercise group|Home-based circuit and community walking exercise
89143107|NCT05059899|No Intervention|Usual care|Usual activity/healthcare
89143108|NCT05046483||Cohort with type 1 diabetes (T1D) and type 2 diabetes (T2D)|Prospectively followed cohort of people with new onset of ST-segment elevation myocardial infarction and diabetes mellitus (type 1 or type 2) according to the American Diabetes Association (ADA) and German Diabetes Society (DDG) criteria (HbA1c ≥6.5% or pathological oral glucose tolerance test (OGTT)), aged 18-80 years at inclusion into the study
89143109|NCT05046483||Cohort of normal glucose tolerant people (NGT)|Prospectively followed cohort of healthy people with new onset of ST-elevation myocardial infarction and normal glucose tolerance status (HbA1c <5.7% and normal OGTT), aged 18-80 years at inclusion into the study
89143110|NCT05046483||Cohort of people with impaired glucose metabolism (IGM)|Prospectively followed cohort of people with new onset of ST-elevation myocardial infarction and impaired glucose metabolism, usually called prediabetes including impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) and/or HbA1c 5.7-6.4%, aged 18-80 years at inclusion into the study
89143111|NCT05040308|Active Comparator|Participants in PrEP and MAT programs|Integrated PrEP and MAT program
89143112|NCT05040308|Active Comparator|Participants in PrEP and NSP programs|Integrated PrEP and NSP program
89143115|NCT05033782||MS patients|"This group includes patients living in Ile de France, followed in the neurology department of the Pitié Salpêtrière Hospital in Paris for relapsing-remitting MS.~Clinical examination will be performed to evaluate the disability (EDSS scale), as part of the care (systematic for all MS consultations)~- A paper questionnaire is given to the patient during the consultation. The patient will be contacted by telephone within 15 days after the consultation by a health care staff to collect the answers to the questionnaire."
89143116|NCT05014139|Experimental|Enfortumab vedotin: Dose escalation cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
89143117|NCT05014139|Experimental|Enfortumab vedotin: Dose expansion cohort|During the induction phase, participants will receive enfortumab vedotin once a week for 6 weeks. During the maintenance phase, participants will receive enfortumab vedotin once a month for 9 doses.
89143118|NCT04994782|No Intervention|Usual care recipients|Participant dyads in this group will receive usual care (standard clinical education materials)
89143119|NCT04994782|Experimental|Usual care plus GAME-EOL intervention|Participant dyads in this group will receive usual care (standard clinical education materials) plus the GAME-EOL intervention.
89143120|NCT04987762|Experimental|Adhansia XR|Adhansia XR capsules taken orally once daily in the morning
89143121|NCT04962672|Experimental|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide.
89143122|NCT04962672|Active Comparator|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group will received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide.
89143123|NCT04954248|Experimental|Covid-19 Negative/Uninfected Population|5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
89143124|NCT04954248|Experimental|Covid-19 Positive/Infected Population|5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
89143125|NCT04951206|Active Comparator|Clobetasol Group|Clobetasol propionate 0.05% ointment is the active treatment arm that will be use in women with lichen sclerosus in the study per standard clinical recommendations. Participants will be instructed to apply 0.25-0.5g of the ointment to the affected tissues nightly for 4 weeks starting after the initial FxCO2 laser treatment, then 2 times a week for the remainder of the study (until final study visit).
89143126|NCT04951206|Placebo Comparator|Placebo Group|Placebo ointment is the control treatment arm. Participants will be instructed to apply 0.25-0.5g of the ointment to the affected tissues nightly for 4 weeks starting after the initial FxCO2 laser treatment, then 2 times a week for the remainder of the study (until final study visit).
89143127|NCT04950920|Experimental|Y-2 sublingual test group|Y-2 sublingual tablets: Edaravone 30mg and d-borneol 6mg.
89143128|NCT04950920|Sham Comparator|placebo group|60 μg d-borneol
89143129|NCT04946656|Experimental|SPG block|The sphenopalatine ganglion will be blocked with bipuvacaine for this study
89143130|NCT04936126|Active Comparator|Quetiapine group|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment.
89143131|NCT04936126|Experimental|Amantadine group|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment
89143132|NCT04936126|Experimental|Pramipexole group|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment
89143133|NCT04932655|Other|Sequence A|This arm received Phase 2 tablet fasted (Period 1), Phase 3 tablet fasted (Period 2), Phase 3 tablet after a high-fat meal (Period 3), and Phase 3 tablet after a low-fat meal (Period 4).
89143134|NCT04932655|Other|Sequence B|This arm received Phase 3 tablet after a low-fat meal (Period 1), Phase 2 tablet fasted (Period 2), Phase 3 tablet fasted (Period 3), and Phase 3 tablet after a high-fat meal (Period 4).
89143135|NCT04932655|Other|Sequence C|This arm received Phase 3 tablet fasted (Period 1), Phase 3 tablet after a high-fat meal (Period 2), Phase 3 tablet after a low-fat meal (Period 3), and Phase 2 tablet fasted (Period 4).
89143136|NCT04932655|Other|Sequence D|This arm received Phase 3 tablet after a high-fat meal (Period 1), Phase 3 tablet after a low-fat meal (Period 2), Phase 2 tablet fasted (Period 3), and Phase 3 tablet fasted (Period 4).
89143137|NCT04927234|Experimental|Standard of care + geko™ Therapy|In addition to their standard of care, for patients randomised to the intervention arm, geko™ therapy will be applied immediately post-surgery on the operated leg and administered for 24 hours / day whilst the patient remains in hospital, after which geko™ therapy will then be applied for 12hrs / day until the patient returns for their first post-operative follow-up visit (Day 14 ± 2 days post-surgery)
89143138|NCT04927234|No Intervention|Standard of care|Patients will receive their standard of care as per hospital practice.
89143139|NCT04918472|Experimental|MCCE|Magnetically controlled capsule endoscopy will be performed before UGI endoscopy.
89143140|NCT04907240||Iliac|Subjects with de novo or restenotic lesions in the iliac arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
89143141|NCT04907240||Superficial Femoral Artery (SFA)|Subjects with de novo or restenotic lesions in the SFA and proximal popliteal arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
89143142|NCT04907240||Superficial Femoral Artery (SFA) In-Stent Restenosis (ISR)|Subjects with in-stent restenosis lesions in the SFA and proximal popliteal arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
89143143|NCT04907240||AV access|Subjects with stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access graft and in the venous outflow of dialysis access circuits, including the central veins treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
89143144|NCT04907240||Popliteal Artery Aneurysms|Subjects with popliteal artery aneurysms treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
89143145|NCT04907240||Trauma/Injury|Subjects with traumatic or iatrogenic vessel injuries in arteries that are located in the chest cavity, abdominal cavity, or pelvis (except for aorta, coronary, innominate, carotid, vertebral, and pulmonary arteries) treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
89143146|NCT04907240||Visceral Artery Aneurysms|Subjects with isolated visceral artery aneurysms treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
89143147|NCT04907240||Others|Subjects treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) but do not fit any of the cohorts listed above.
89143148|NCT04860973|Experimental|Weighted blankets|Provided with weighted blanket suitable for participant's weight
89143149|NCT04860973|No Intervention|Standard linen|Use of standard hospital linen
89143150|NCT04839042|Experimental|SC-Ad6-1 Low Dose Intramuscular|Low Dose SC-Ad6-1, I.M., single-dose (Day 1)
89143151|NCT04839042|Experimental|SC-Ad6-1 Medium Dose Intramuscular|Medium Dose SC-Ad6-1, I.M., single-dose (Day 1)
89143152|NCT04839042|Experimental|SC-Ad6-1 High Dose #1 Intramuscular|High Dose #1 SC-Ad6-1, I.M., single-dose (Day 1)
89143153|NCT04839042|Experimental|SC-Ad6-1 High Dose #2 Intramuscular|High Dose #2 SC-Ad6-1, I.M., single-dose (Day 1)
89143154|NCT04839042|Experimental|SC-Ad6-1 Multiple Dose Intramuscular|Multiple Dose SC-Ad6-1, I.M., multiple-dose (Day 1 and Day 22)
89143155|NCT04839042|Experimental|SC-Ad6-1 High Dose #3 Intramuscular Booster|High Dose #3 SC-Ad6-1, I.M., single-dose booster (Day 1)
89143156|NCT04839042|Experimental|SC-Ad6-1 Low Dose Intranasal|Low Dose SC-Ad6-1, I.N., single-dose (Day 1)
89143157|NCT04839042|Experimental|SC-Ad6-1 Medium Dose Intranasal|Medium Dose SC-Ad6-1, I.N., single-dose (Day 1)
89143158|NCT04839042|Experimental|SC-Ad6-1 High Dose #1 Intranasal|High Dose #1 SC-Ad6-1, I.N., single-dose (Day 1)
89143159|NCT04839042|Experimental|SC-Ad6-1 High Dose #2 Intranasal|High Dose #2 SC-Ad6-1, I.N., single-dose (Day 1)
89143160|NCT04839042|Experimental|SC-Ad6-1 Multiple Dose Intranasal|Multiple Dose SC-Ad6-1, I.N., multiple-dose (Day 1 and Day 22)
89143161|NCT04839042|Experimental|SC-Ad6-1 High Dose #3 Intranasal Booster|High Dose #3 SC-Ad6-1, I.N., single-dose booster (Day 1)
89143162|NCT04839042|Experimental|SC-Ad6-1 High Dose #4 Intranasal Booster|High Dose #4 SC-Ad6-1, I.N., single-dose booster (Day 1)
89143163|NCT04839042|Experimental|SC-Ad6-1 Low Dose Inhaled|Low Dose SC-Ad6-1, I.H., single-dose booster (Day 1)
89143164|NCT04839042|Experimental|SC-Ad6-1 Medium Dose Inhaled|Medium Dose SC-Ad6-1, I.H., single-dose booster (Day 1)
89143165|NCT04839042|Experimental|SC-Ad6-1 High Dose Inhaled|High Dose SC-Ad6-1, I.H., single-dose booster (Day 1)
89143166|NCT04824534||Healthy subjects|
89143167|NCT04824534||Healthy subjects matching baseline characteristics with patients|
89143168|NCT04824534||Patients with sarociliac joint dysfunction|
89143169|NCT04817332|Experimental|Brensocatib|Brensocatib oral tablet, 25mg once per day for 28 days
89143170|NCT04817332|Placebo Comparator|Placebo|Placebo oral tablet, 25mg once per day for 28 days
89143171|NCT04801784|Experimental|Fluid balance neutralization|Fluid balance neutralization using increased net ultrafiltration, aiming to neutralize the cumulative fluid input received over the first 72 hours of study participation.
89143172|NCT04801784|Active Comparator|Standard care|Active control group of positive fluid balance during the first 72 hours of study participation with zero or near-zero net ultrafiltration.
89143173|NCT04800016|Experimental|Vivity IOL|AcrySof IQ Vivity Extended Vision IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery
89143174|NCT04797637|Experimental|Treatment Group|Patients randomized to the treatment group will have the ABBy device applied by study personnel at the time of randomization, followed by a continuation of usual postoperative care.
89143175|NCT04797637|No Intervention|Standard of Care|The control group will have postoperative care per usual care
89143176|NCT04787666|Experimental|the first group: non-invasive mask ventilation|Dinamika of the indicator p/F Ratio
89143177|NCT04787666|Experimental|the second group:high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation)|Dinamika of the indicator p/F Ratio
89143178|NCT04787666|Experimental|the third group:non-invasive ventilation with a helmet|Dinamika of the indicator p/F Ratio
89143179|NCT04774276||Group with occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They will have the cardiac rehabilitation protocol (4 weeks) with occupational therapist as usual practice. The inclusion in this group will be prospective, from January 2021.
89143180|NCT04774276||Group without occupational therapist|Patient with Coronary Artery Disease (CAD) will be included. They have done the cardiac rehabilitation protocol (4 weeks) without occupational therapist until december 2020. The inclusion in this group will be retrospective,
89143181|NCT04736888|Sham Comparator|Conventional group|Conventional CPR training consists of a BLS video and a manikin equipped with a feedback device.
89143182|NCT04736888|Active Comparator|XR group|The XR group participants will be provided training via the XR BLS module and are allotted an additional 2 minutes that is needed to adapt to the XR equipment.
89143183|NCT04715373|Experimental|DR-LISA|"Experimental:~Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs. A trained physician will perform LISA using Hobart method. Infants requiring FiO2 >0.8 on CPAP 8 cm H2O to maintain SpO2 88-94% by 20 minutes of life will be intubated prior to transport. After admission to the NICU, CPAP will be titrated 5-8 cm H20."
89143184|NCT04715373|Active Comparator|NICU-LISA|Infants will be resuscitated per NRP guidelines. Infant with stable HR and respiratory effort will be changed to binasal prongs and transported to NICU on CPAP. After admission to NICU, CPAP will be escalated every 30 minutes up to a maximum level of 7 cm H2O at which point infant would qualify for LISA if the FiO2 requirement is ≥0.3. LISA will be performed using Hobart method. Infants requiring FiO2 >0.8 to maintain SpO2 88-94% by 20 minutes of life will be intubated in the DR.
89143185|NCT04673266|Experimental|romiplostim|Romiplostim will be administered from the beginning of the next chemotherapy cycle with a starting dose of 3 mcg/kg subcutaneously. Dose will be titrated based on nadir of the platelet counts during the prior cycle. The maximum dose of romiplostim will be 6 mcg/kg.
89143186|NCT04664946|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
89143187|NCT04618692|Active Comparator|Surgical Loupes|In this group , patients will undergo biliary reconstruction using surgical loupe
89143188|NCT04618692|Active Comparator|Microscope|In this group , patients will undergo biliary reconstruction using microscope
89143189|NCT04582409|Experimental|HSY244|HSY244 150 mg concentrate solution for injection via intravenous infusion
89143190|NCT04582409|Placebo Comparator|Placebo|Placebo concentrate solution for injection via intravenous infusion
89143191|NCT04574518|Experimental|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
89143192|NCT04574518|Other|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
89143193|NCT04541355|Experimental|Cisplatin, Radiotherapy, STS|Patients undergo standard of care radiation therapy daily in combination with cisplatin on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate over 1-2 hours on day 1. Treatment will continue on either a 1 week or 3 week cycle per physician discretion for up to 6-7 weeks in the absence of disease progression or unacceptable toxicity.
89143194|NCT04516915|Experimental|IMU-838 + Oseltamivir|Loading dose of IMU-838 followed by 22.5mg BID plus Oseltamivir (75mg BID) for 14 days
89143195|NCT04516915|Active Comparator|Oseltamivir|Oseltamivir (75mg BID) for 14 days
89143196|NCT04505826|Experimental|OP-1250 Phase I Part A (Dose Escalation) and Part B (Dose Expansion)|Phase I Part A will evaluate the safety and pharmacokinetics (PK)of a range of OP-1250 doses to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Phase I Part B will evaluate the safety and PK of OP-1250 to confirm the RP2D dose.
89143197|NCT04505826|Experimental|OP-1250 Phase II|"This portion of the study further explores the clinical activity, safety, and PK of OP-1250 monotherapy at the RP2D and will estimate preliminary anti-tumor efficacy in 3 cohorts.~Cohort A will enroll subjects with measurable disease without evidence of CNS metastases; Cohort B will enroll subjects with non-measurable (evaluable) disease without evidence of CNS metastases; and Cohort C will enroll subjects with evaluable disease (measurable and non-measurable) with CNS metastases."
89143198|NCT04496635|No Intervention|Baseline phase|Patients included in the VINCat program, and operated on colorectal surgery between 2007 and 2015 in Catalonia
89143199|NCT04496635|Experimental|Implementation phase|Patients included in the VINCat program, and operated on colorectal surgery between 2016 and 2018 in Catalonia
89143200|NCT04483466|Experimental|Treatment with methotrexate|100 participants will be treated with methotrexate
89143201|NCT04483466|Placebo Comparator|Placebo methotrexate|50 will receive placebo
89143202|NCT04448301|Experimental|PointCheck Cohort|
89143203|NCT04445701|Experimental|AO-176 Dose Escalation Monotherapy|The dose escalation monotherapy cohorts will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
89143204|NCT04445701|Experimental|AO-176 + DEX Expansion Cohort|Once the monotherapy RP2D has been established, an expansion cohort of AO-176 + dexamethasone will be enrolled.
89143205|NCT04445701|Experimental|AO-176 + DEX + BORT Dose Escalation|Following evaluation of AO-176 + dexamethasone, dose escalation cohorts of AO-176 + dexamethasone + bortezomib will be enrolled. Each dose escalation cohort will initially recruit 3 patients in a standard 3+3 design; cohorts will be expanded in the event of a DLT. The Phase 2 portion of the study will further evaluate the RP2D of AO-176 + DEX + BORT.
89143206|NCT04427202|Other|Referral to harm reduction services|Participants will be taken through the study survey and interview, blood and urine toxicology testing and given a referral to a harm reduction organization.
89143207|NCT04427163||Genomic, transcriptomic, proteomic, metabolomic profiles|Determination of genomic, transcriptomic, proteomic, metabolomic profiles in subjects.
89143208|NCT04403542|Experimental|LID018869 (OD) / Biofinity (OS)|Lehfilcon A contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 1 week of continuous wear
89143209|NCT04403542|Active Comparator|Biofinity (OD) / LID018869 (OS)|Comfilcon A contact lens worn in the right eye, with lehfilcon A contact lens worn in the left eye, as randomized, for approximately 1 week of continuous wear
89143210|NCT04381078|Experimental|Intervention|Standardised Verbal Instructions Standardised Written Instructions Audiovisual Guide
89143211|NCT04381078|No Intervention|Control|Standardised Verbal Instructions Standardised Written Instructions
89143212|NCT04376268|Active Comparator|Chlorhexidine gluconate|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects.
89143213|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
89143214|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
89143215|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
89143216|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
89143217|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
89143218|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
89143219|NCT04376268|Active Comparator|Boric acid mouthwash (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
89143220|NCT04365088|Experimental|Deflazacort|Deflazacort is a glucocorticoid used as an anti-inflammatory drug. We used deflazacort 30 mg tablet. Patient took a pill once preoperatively (1 hour ago) in third molar surgery.
89143221|NCT04365088|Placebo Comparator|Sugar pill|Placebo is an inert substance or treatment which is designed to have no therapeutic value. Patients took sugar pill for plasebo once one hour before operation.
89143222|NCT04364074|Experimental|GoodBelly Probiotic|Subjects randomized to this arm consume one serving of the Goodbelly lactobacillus plantarum 299v probiotic
89143223|NCT04364074|Placebo Comparator|Placebo|Subjects randomized to this arm consume one serving of the Goodbelly that does not contain lactobacillus plantarum 299v
89143224|NCT04360421|Experimental|Intraoperative liposomal bupivacaine field block|Patients will receive the maximum dosage of liposomal bupivacaine allowed for their body weight or the full vial, whichever is less. Injected once, along the incision before closure of the skin.
89143225|NCT04349579|Experimental|Rifamycine|Rifamycine is a broad spectrum semi-synthetic antibiotic that acts on gram-positive and gram-negative microorganisms. As a local application, it has areas of use in dentistry such as washing fistula mouths, maxillary sinus and abscess wounds and treating osteomyelitis.
88803478|NCT00002704|Experimental|Arm I|Single Agent Chemotherapy. TSPA or DTC101. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 2-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. ARA-C/ASP; plus TIT. 4-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. CTX/MP/MTX/VP-16; with CF; plus TIT. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 6-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. ARA-C/ASP/CTX/MP/MTX/VP-16; with CF; plus TIT. Radiotherapy plus 3-Drug Combination Chemotherapy. Craniospinal irradiation using x-rays with energies of 4-6 MV (electrons acceptable for spinal cord irradiation); plus ASP/DM/VCR. 2-Drug Combination Chemotherapy Alternating with 2-Drug Combination Chemotherapy. MP/MTX; alternating with CTX/VCR.
88803479|NCT04783922||Benign Hematoma|Patients (having novel image markers or clinical features) suggestive of a benign hematoma relatively , that is having relatively good prognostic outcome and less likely to expand.
88803480|NCT04783922||Malignant Hematoma|Patients (having novel image markers or clinical features) suggestive of a malignant hematoma relatively, that is more likely to expand and have poor prognostic outcome.
88803481|NCT01091480||Patients with HCM|Patients ≥ 15 years with HCM(sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
88803482|NCT00002716|Experimental|Arm I - laparotomy + conventional surgery + chemotherapy|"Patients undergo laparotomy for placement of a hepatic artery catheter and then subcutaneous placement of a hepatic artery infusion pump. Patients with unresected primary disease also undergo resection at the time of catheter and pump placement. Beginning within 1-2 weeks after surgery, patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
89143226|NCT04349579|Active Comparator|Saline|Saline, also known as saline solution, is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds. It is also used to dilute other drugs to be injected and to wash the operation site in dental surgery operations. It is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.
89143227|NCT04339023|Experimental|OLP-Group|patients will receive in addition to TAU, 2 open-label Placebo (OLP) injections (containing each 5 ml of NaCl 9%) per day for two consecutive days following minimally invasive TLIF
89143228|NCT04339023|Other|TAU-group|The treatment as usual (TAU) group will serve as control group and will control for the natural course of postoperative pain under usual medication intake, following minimally invasive TLIF
89143229|NCT04300296|Experimental|Cutaneous lichen planus secukinumab 300mg Q4W|Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in cutaneous lichen planus patients
89143230|NCT04300296|Placebo Comparator|Cutaneous lichen planus placebo|Placebo in 1ml PFS in cutaneous lichen patients
89143231|NCT04300296|Experimental|Mucosal lichen planus secukinumab 300 mg Q4W|Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in mucosal lichen planus patients.
89143232|NCT04300296|Placebo Comparator|Mucosal lichen planus placebo|Placebo 1 ml PFS in mucosal lichen planus patients
89143233|NCT04300296|Experimental|Lichen planopilaris secukinumab 300 mg Q4W|Secukinumab 300 mg every 4weeks provided in pre-filled syringe in lichen planopilaris patients.
89143234|NCT04300296|Placebo Comparator|Lichen planopilaris placebo|Placebo in 1ml PFS in lichen planopilaris patients
89143235|NCT04300296|Experimental|Cutaneous lichen planus placebo to secukinumab 300 mg Q2W|Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
89143236|NCT04300296|Experimental|Mucosal lichen planus placebo to secukinumab 300 mg Q2W|Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
89143237|NCT04300296|Experimental|Lichen planopilaris placebo to secukinumab 300 mg Q2W|Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
89143238|NCT04295681|Experimental|MMH-MAP|Oral administration. 2 tablets twice daily (approximately at the same time). The drug is taken outside a meal (between the meals or 15 min prior to meal or fluid intake). Tablets should be held in the mouth until completely dissolved. The overall duration of treatment is 90 months.
89143239|NCT04295681|Placebo Comparator|Placebo|Oral administration. For 90 days according to MMH-MAP dosing regimen.
88803483|NCT00002716|Experimental|Arm II - conventional surgery + chemotherapy|"Patients receive CF IV and fluorouracil IV on days 1-5. Patients with unresected primary disease undergo resection within 3-4 weeks before initiation of chemotherapy.~Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
89143240|NCT04277689|Experimental|Brain signal data collection|Collection of brain data during deep brain stimulation
89143241|NCT04266054|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care
89143242|NCT04266054|No Intervention|Control|The comparison group will receive usual clinical care.
89143243|NCT04257617|Experimental|Single arm, ZL-1201|Single arm, ZL-1201
89143244|NCT04236843|Active Comparator|Smal intestine once|90-g fecal transplant given into the small intestine once.
89143245|NCT04236843|Active Comparator|Small intestine twice|90-g fecal transplant given into the small intestine twice with 1 week interval.
89143246|NCT04236843|Active Comparator|Large intestine once|90-g fecal transplant given into the large intestine once.
89143247|NCT04221815|Active Comparator|IVUS guided PCI|Patients will receive a pre-PCI IVUS, IVUS guided stent sizing and optimization per study protocol, post-PCI IVUS
89143248|NCT04221815|Placebo Comparator|Angiographic-guided PCI|Patients will receive angiography guided PCI and angiographic optimization per local standard practice, as well as a post-PCI IVUS blinded to the investigator
89143249|NCT04166656|Other|Arm A : Trumenba®: Standard vaccination|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
89143250|NCT04166656|Other|Arm B:Bexsero®: standard vaccination regimen|Two doses of 0.5 ml each at one month intervals
89143251|NCT04166656|Other|Arm C : Bexsero® Innovative vaccine strategy|Two doses of 0.5 ml each at one month intervals, followed by a third dose given at 6 months after the second dose.
89143252|NCT04158713|Placebo Comparator|CTX-alone|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly placebo-DP, given as a fixed dose of 3 placebo-DP tablets daily for three days until delivery.
89143253|NCT04158713|Experimental|CTX-DP|Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly DP, given as a fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery.
89143254|NCT04144127|Experimental|Soccer Group|Participants in the soccer group will participate in soccer drills and other fitness routines (two 1-hour sessions per week). They will meet with the soccer coach after the soccer sessions to discuss the lifestyle education topics (Life's Simple 7 education topics). During the soccer sessions participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. All participants will receive a Garmin Vivofit wearable device to help monitor their PA goals and achievements.
89143255|NCT04118491|Sham Comparator|sham1st|40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.
89143256|NCT04118491|Active Comparator|sham second|"iii. We will divide the subjects into two groups of five. One group will receive 40 Hyperbaric Oxygen (HBO2) treatments (100% oxygen at twice normal air pressure (2 ATA)) followed by 40 sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday. The second block will be treated similarly except that they will receive sham treatments in the first block and oxygen treatments in the second block.~iv. Neurological and psychologic assessments will be done prior to starting treatments, after the first block of 40 and again after the second block of 40."
89143257|NCT04050696|Experimental|Treatment (with PT run-in)|Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period
89143258|NCT04047836|Other|Low Nicotine|Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.
88803484|NCT02533674|Experimental|gemcitabine plus PM060184|
89143259|NCT04047836|Other|Medium or High Nicotine|The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.
89143260|NCT04046978|Experimental|Group F|Mos3.1 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
89143261|NCT04046978|Experimental|Group G|Mos3.2 100 ug at Month 0 Mos3.1 100 ug at Month 2 Mos3.3 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
89143262|NCT04046978|Experimental|Group H|Mos3.3 100 ug at Month 0 Mos3.2 100 ug at Month 2 Mos3.1 100 ug at Month 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
89143263|NCT04046978|Experimental|Group I|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug at Months 0, 2 and 4 ConM SOSIP 50 ug and ConS UFO 50 ug at Month 6
89143264|NCT03994146|Experimental|Remifentanil tapering / Placebo abrupt cessation|Syringe one contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1 and Syringe two contains 40 ml NaCl 9 mg.ml-1 at an identical infusion rate. According to randomisation syringe one will then be tapered towards the end of surgery and syringe two abruptly stopped.
89143265|NCT03994146|Placebo Comparator|Placebo tapering / Remifentanil abrupt cessation.|Syringe one contains 40 ml NaCl 9 mg.ml-1 and Syringe two contains Remifentanil 2 mg in 40 ml NaCl 9 mg.ml-1 = 50 µg.ml-1 which will be infused at a rate of 0.9 µg.kg-1.min-1. According to randomization syringe one will be tapered towards the end of surgery and syringe two abruptly stopped.
89143266|NCT03989440|Experimental|AXER-204|Part 1 - Single ascending doses; Part 2 - Repeated dose
89143267|NCT03989440|Placebo Comparator|Placebo|Part 2 only - Repeated dose
89143268|NCT03983343|No Intervention|control group|Standard technique: Suturing the perineal skin with fast-absorbable running sutures (Vicryl Rapide 3-0).
89143269|NCT03983343|Active Comparator|intervention group|Closing the perineal skin using adhesive glue- exofin® (Octyl-2-cyanoacrylate)
89143270|NCT03962465|Experimental|3-drug re-induction regimen with inotuzumab|"One cycle of a 3-drug regimen comprised of standard doses of prednisone, vincristine, and daunorubicin with inotuzumab ozogamicin at a reduced dose.~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
89143271|NCT03962465|Experimental|4-drug re-induction regimen with inotuzumab|"One cycle of a 4-drug regimen comprised of standard doses of prednisone, vincristine, daunorubicin, and pegaspargase with inotuzumab ozogamicin at a reduced dose.~Intrathecal methotrexate (IT-methotrexate) and intrathecal cytarabine (IT-Ara-C) will be included for CNS prophylaxis.~IV inotuzumab ozogamicin will be given at a reduced dose (may vary from a total cycle dose of 0.4 mg/m^2 to 0.9 mg/m^2)"
89143272|NCT03952299|Active Comparator|Oral administration|"Oral oxybutynin (5mg) is administered in the preoperative area prior to surgery. The current regimen is to mix the oxybutynin with the standard preoperative Versed so children do not have to take two dosages.~Post-operatively oral oxybutynin (5mg) is administered every 8 hours in the hospital."
89143273|NCT03952299|Experimental|Transdermal administration|Guardian will be given the transdermal patch (3.9mg oxybutynin) at the preoperative appointment with instructions to apply the day prior to surgery. While in the hospital no oral oxybutynin will be prescribed.
89143274|NCT03945747||Control group|Individuals continue current treatment regimen with either standard insulin pump therapy or multiple daily insulin injections for the duration of the study.
89143275|NCT03945747||Hybrid closed-loop artificial pancreas system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a hybrid closed-loop system at the beginning of the study after initial labs and imaging studies are completed.
89143276|NCT03945747||Predictive low glucose suspend system group|Individuals transition from either standard insulin pump therapy or multiple daily injections to a predictive low glucose suspend system at the beginning of the study after initial labs and imaging studies are completed.
89143277|NCT04646941||T2DM with OSA|Type 2 diabetes patients with obstructive sleep apnea
89143278|NCT04646941||T2DM without OSA|Type 2 diabetes patients without obstructive sleep apnea
89143279|NCT03922581|Experimental|Mindfulness-Based Cognitive Therapy|Participants randomized to this study arm will receive Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks.
89143280|NCT03922581|No Intervention|Wait-list Control Group|Participants randomized to the wait-list control study arm will be administered the study assessments while not receiving active treatment. Participants will be given the opportunity to participate in the MBCT intervention following completion of the study assessments.
89143281|NCT03917251|Other|Right ventricular Pacemaker|Patients with right ventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
88803485|NCT04756544|Experimental|Depressive Disorders + probiotic|
89143282|NCT03917251|Other|Biventricular Pacemaker|Patients with Biventricular pacing and evidence of coronary ischemia who have evidence of coronary ischemia who are to undergo coronary angiogram.When an intermediate stenosis (40-80%) has been identified angiographically, this lesion will undergo further hemodynamic assessment, All data including resting flow, FFR, CFR, vital signs, arrhythmias and patient symptoms will be recorded twice: once when the pacemaker is programmed to pace, and once when the PPM is reprogrammed such that the pacemaker is no longer pacing.
89143283|NCT03908437|Experimental|Rapid initiation|Rapid initiation of buprenorphine/naloxone, counseling, peer support and case management
89143284|NCT03908437|Active Comparator|Treatment as usual|Seeking treatment from the BAC/CRC (treatment as usual)
89143285|NCT03907982|Experimental|DCCV + PVI|"DC cardioversion (DCCV) plus Pulmonary Vein Isolation (Cryoablation)~At end of pulmonary vein isolation, DCCV performed (if patient still in AF). An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure."
89143286|NCT03907982|Active Comparator|DC cardioversion (DCCV)|Acute treatment of heart rhythm by cardioversion. An implantable loop recorder will be inserted in the prepectoral area with local anaesthetic at the end of the procedure.
89143287|NCT03903185|Active Comparator|HCV-infected patients with hematological malignancy|HCV-infected patients with hematological malignancy on maintenance chemotherapy
89143288|NCT03903185|Active Comparator|Control HCV-infected patients|Control HCV-infected patients without haematological malignancy or co-morbidities.
89143289|NCT03886961|Experimental|Lung Transplant Patients|For the first four weeks, lung transplant patients will not wear the Reflux Band. Use of the Reflux Band will subsequently commence in the next four weeks.
89143290|NCT03873714|Experimental|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
89143291|NCT03846531|Active Comparator|Nano-Pulse Stimulation (NPS) Lesion|Three of four selected SK lesions receive Nano-Pulse Stimulation treatment.
89143292|NCT03846531|No Intervention|Non-Treated Lesion|One of four SK lesions is randomized to not receiving Nano-Pulse Stimulation treatment.
89234749|NCT00830999|Experimental|Negative energy balance with exercise|Comparison between consuming an isocaloric diet without exercise and consuming the same amount of calories as in the isocaloric trial but with exercise performed resulting in net negative energy balance in the exercise trial.
89234750|NCT00831077|Active Comparator|14C-ORM-14540|
89143293|NCT03835767|Experimental|Milk DBPCFC|There are two double blind placebo controlled food challenges. The first challenge is to baked milk. The following participants will undergo this DBPCFC: - All participants who eat baked milk less than once per month. - Participants who never eat baked milk or straight milk. On the first day of this challenge, participants will be randomized to either milk Baked milk or rice milk. Dry milk powder or corn starch. or placebo, and then will be challenged with the other food on the next day.
89143294|NCT03835767|Experimental|One-Step Open Feeding|Participants who are consuming baked milk, straight milk, and/or peanut products at least once per week will do a one-step oral food challenge.
89143295|NCT03835767|Experimental|Peanut DBPCFC|The DBPCFC for peanut allergy will be done with either peanut flour or a placebo (oat flour). The following participants will undergo this DBPCFC: - All participants who eat peanut less than once per month - Participants who never eat peanut On the first day of this challenge, participants will be randomized to either peanut or placebo, and then will be challenged with the other food on the next day.
89143296|NCT03835767|Experimental|Two-Step Open Feeding|Participants who consume baked milk, straight milk, and/or peanut products less than once per week but at least once per month will do a two step open oral food challenge.
89143297|NCT03834948|Experimental|AO-176 Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
89143298|NCT03834948|Experimental|AO-176 Dose Expansion|Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.
89143299|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
89143300|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + paclitaxel.
89143301|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and pembrolizumab in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
89143302|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + pembrolizumab.
89143303|NCT03829280|Experimental|Cognitive Adaptation Training|Psychosocial treatment using environmental supports such as signs, alarms, pill containers, checklists, technology and the organization of belongings established in a person's home or work environment to bypass the cognitive and motivational difficulties associated with schizophrenia, and support habits for functional behavior to promote recovery.
89143304|NCT03829280|Active Comparator|Community Treatment|Medication follow-up and case management as provided by the community mental health center according to usual care.
89143305|NCT03802253|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
89143306|NCT03802253|Active Comparator|RCD|Participants in this group will focus on standard care with daily reduced calorie diet (RCD)
89143307|NCT03792282|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
89143308|NCT03792282|Active Comparator|Usual care|Participants in this group will receive a general lifestyle counseling.
89143309|NCT03741777|Active Comparator|3 ml/kg of clear oral fluid|This group of patient will consume 3 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
88803486|NCT04756544|Placebo Comparator|Depressive Disorders + placebo|
89143310|NCT03741777|Active Comparator|5 ml/kg of clear oral fluid|This group of patient will consume 5 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
89143311|NCT03741777|Active Comparator|7 ml/kg of clear oral fluid|This group of patient will consume 7 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
89143312|NCT03741777|Active Comparator|10 ml/kg of clear oral fluid|This group of patient will consume 10 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
89143313|NCT03695276|Experimental|PuSHCon model|A health coach will contact patients with poorly controlled asthma or COPD. The health coach will gather information from the patient and medical record and review the case with a pulmonary specialist. The specialist will provide recommendations to the primary care clinician based on the case review; the specialist may request an in-person patient visit if needed. The health coach will follow up with the primary care clinician and will support implementation of recommendations that the the primary care clinician accepts,
89143314|NCT03695276|Active Comparator|Usual care|Patients with poorly controlled asthma or COPD will receive the standard of care, which usually means management within primary care. The study team will provide in-service sessions on COPD and asthma guidelines to primary care clinicians in both arms. As in standard practice, a primary care clinician may refer a patient for specialty consultation or diagnostic testing at any time.
89143315|NCT03695250|Experimental|Treatment (BMS-986205 and nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-14 and nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89143316|NCT03691532|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~60 min (duration of exercise performed in other arm). Following the intervention they are fed a liquid meal.
89143317|NCT03691532|Experimental|Arm cycle exercise (ACE)|Participants complete continuous arm cycle exercise (ACE) for ~60 min. Following the intervention they are fed a liquid meal.
89143318|NCT03663543|Active Comparator|Active Arm|Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).
89143319|NCT03663543|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.
89143320|NCT03603899|Experimental|Hp 129Xenon|Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
89143321|NCT03526354|Experimental|Experimental|Brexpiprazole 4mg daily for 12 weeks
89143322|NCT03526354|Active Comparator|Treatment as Usual|Stay on current antipsychotic medication for 12 weeks
89143323|NCT03448003|Experimental|Group I (IO prevention program)|Patients attend IO prevention program consisting of 1-2 physical activity, nutrition and diet, and mind-body practice sessions over 60 minutes weekly for 12 weeks. Patients also attend a behavioral counseling session once weekly for up to 26 weeks. Patients complete exercises over 30-60 minutes 3-5 times weekly for 12 weeks.
89143324|NCT03448003|Active Comparator|Group II (no intervention)|Patients receive no intervention. After 26 weeks, patients may crossover to Group I.
88803487|NCT04756544|Experimental|Depressive disorder + metabolic syndrome + probiotic|
88803488|NCT04756544|Placebo Comparator|Depressive disorder + metabolic syndrome + placebo|
88803489|NCT00002734|Experimental|Arm I|Patients receive interferon alfa subcutaneously on days 1, 3, 5, and 7; paclitaxel intraperitoneally (IP) on day 4 or topotecan IP on day 6; and 177Lu-CC49 IP on day 6. Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity. Once the MTD of paclitaxel is determined, the dose of 177Lu-CC49 is escalated. Once the MTD of 177Lu-CC49 is determined, 90Y-CC49 is substituted. The MTD of 90Y-CC49 is then determined when administered with paclitaxel. Topotecan is then substituted for paclitaxel (administered with the MTD of 177Lu-CC49 and interferon alfa only) and escalated until the MTD is determined.
88803490|NCT04783610|Experimental|Study subjects for vHIT- and VOG-measurements|Each study subject is his/hers own comparator at different phases of ethanol consumption.
88803491|NCT00002740|Experimental|Treatment - Carboplatin Chemotherapy|See detailed description.
88803492|NCT02540850||CRC group|stage 0-IV CRC subjects
88803493|NCT02540850||precancerous disease group|subjects with adenoma or polyps
88803494|NCT02540850||other disease group|subjects with other bowel diseases, other cancers, and subjects with no evidence of disease
88803495|NCT05073406|Experimental|Hypobaric normoxia|Altitude exposure in hypobaric normoxic condition
88803496|NCT05073406|Sham Comparator|Hypobaric hypoxia|Altitude exposure in hypobaric hypoxic condition
88803497|NCT01662024|Experimental|Endoscopic gastric restrictive procedure|Restrict gastric size by approximating tissue endolumenally via an incisionless/per-oral approach.
88803498|NCT01049945|Experimental|Arm I|Patients receive dexamethasone orally or IV on days 1, 8, 15, and 22; bendamustine hydrochloride IV over 30 minutes on days 1 and 2; and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88803499|NCT04500080|Experimental|PE intervention|Aerobic, resistance, and neuromotor exercise
88803500|NCT01050647|Active Comparator|17-hydroxyprogesterone caproate|Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
88803501|NCT01050647|Placebo Comparator|Castor oil injections|Weekly injections of Caster Oil (placebo)
88803502|NCT04457544||Retrospective patients|The investigators will review the hospital records at the investigational site for SCAD events having occurred over the last 5 years. All SCAD patients aged ≥18 years, not presenting atherosclerotic or iatrogenic coronary dissection will be informed about the SwissSCAD study by phone and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the retrospective arm.
88803503|NCT04457544||Prospective patients|Patients presenting at the hospital with newly diagnosed SCAD will be informed of the SwissSCAD study and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the prospective arm.
89143325|NCT03415412|Experimental|Group CU (Clearfil Universal)|Clearfil Univesal Bond (Kuraray Dental, New York, United States of America), adhesive system
89143326|NCT03415412|Experimental|Group IU (Ibond Universal)|IBond Universal (Heraeus Kulzer GmbH, Hanau, Germany), adhesive system
89143327|NCT03415412|Experimental|Group GP (G-Premio)|G-Premio Bond (GC Coorporation, Tokyo, Japan), adhesive system
89143328|NCT03402139||IUGR infants|Intrauterine growth restricted infants will be enrolled. There are no interventions.
89143329|NCT03402139||AGA infants|Appropriate for gestational age infants will be enrolled. There are no interventions.
89143330|NCT03376893||SCA with overt stroke|Participants have sickle cell disease and a history of overt stroke.
89143331|NCT03376893||SCA with silent stroke|Participants have sickle cell disease and a history of silent stroke.
89143332|NCT03376893||SCA with no stroke|Participants have sickle cell disease and no history of stroke.
89143333|NCT03344354|Active Comparator|Brand 1|sterile surgical gloves Two arms of Brand 1 were combined to allow comparison of the total of all comparator gloves.
89143334|NCT03344354|Active Comparator|Brand 2|sterile surgical gloves
89143335|NCT03344354|Active Comparator|Brand 3|sterile surgical gloves
89143336|NCT03344354|Active Comparator|Brand 4|sterile sergical gloves
89143337|NCT03329378|Active Comparator|ddACTHP|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Pegfilgrastim 6mg SC, day 2 of AC~Cycled every 14 days for 4 cycles, followed by, Paclitaxel 80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15 Trastuzumab 8 mg/kg IV day 1, followed by 6mg/kg Pertuzumab loading dose 840 mg IV followed by 420 mg IV every 3 weeks~Cycled every 21 days for 4 cycles, followed by, Trastuzumab 6mg/kg every 21 days to complete 1 year"
89143338|NCT03329378|Active Comparator|TCHP|TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim ) institutional practice is to titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
89143339|NCT03320408||Asymptomatic AAA|These patients will be included while their AAA is asymptomatic and while they are under surveillance by their vascular surgeon.
89143340|NCT03320408||Acute AAA|These are the patients that are included while they presented in the participating hospitals because either a symptomatic or ruptured AAA. For this group, a different recruitment procedure exists which has been approved by the appropriate medical ethical committee.
89143341|NCT03320408||Repaired AAA|These patients are included while they already had had AAA repair (both elective and emergency repair).
88803504|NCT05045326|Experimental|Experimental: Intervention Group|Participants in the intervention group will receive an intensive motivational intervention with individual and group treatment for smoking cessation. The treatment, provided by trained professionals, will include psychological, psycho-educational support and pharmacological treatment advice.
89143342|NCT03314129|Experimental|Contrast sensitivity|UltimEyes
88803505|NCT05045326|Placebo Comparator|Placebo Comparator: Brief Counselling|Participants in the placebo group will receive a brief intervention for smoking cessation.
88803506|NCT05167175|Experimental|Intervention/Treatment|Subjects will receive a regimen of Olaparib tablets 300 mg twice daily in combination with Abiraterone acetate 1000 mg plus Prednisone 5mg once daily until radiographic disease progression (assessed by the investigator according to RECIST1.1 and PCWG3) or intolerable adverse events (assessed by the investigator according to the actual clinical situation).
89143343|NCT03314129|Experimental|Perceptual organization|Contour Integration Training
89143344|NCT03314129|Experimental|Contrast sensitivity + Perceptual org.|UltimEyes + Contour Integration Training
89143345|NCT03314129|Active Comparator|Cognitive remediation|MyBrainSolutions
88803507|NCT00002590|Experimental|Regimen A|See detailed description.
88803508|NCT04782908|Experimental|Transcatheter tricuspid valve edge-to-edge repair|Patients will undergo transcatheter tricuspid valve edge-to-edge repair (TTVR) and hemodynamic characteristics will be analysed on a multimodal approach using cardiac magnetic resonance imaging and pressure volume loop analysis before and after TTVR.
88803509|NCT04352933|Active Comparator|Hydroxychloroquine - Daily dosing|"Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
88803510|NCT04352933|Active Comparator|Hydroxychloroquine - Weekly dosing|"Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
88803511|NCT04352933|Placebo Comparator|Placebo|"Placebo arm - 2 tablets twice daily for first 2 days (loading phase), followed by 1 tablet every day for 90 days plus 2 tablets every 7th day, for approximately 90 days.~Route: Oral. Pharmaceutical form: Tablet"
88803512|NCT05246696||Patient group|
88803513|NCT04783792|Experimental|ascorbic acid / phytochemical supplement|A mixture of active phenolic compounds with ascorbic acid
88803514|NCT04783792|Experimental|ascorbic acid|Ascorbic acid group
89143346|NCT03292302|Placebo Comparator|Placebo Comparator Arm|Placebo
89143347|NCT03292302|Active Comparator|Active treatment|ELX-02
89143348|NCT03289897|Experimental|Study Arm-LiverMultiScan|Patients will be scanned using the LiverMultiScan. Follow-up will be determined by the results of the scan.
89143349|NCT03289897|No Intervention|Control Arm|Standard of care as per guidelines of the local centre
89143350|NCT03274895|Experimental|PHMB 0.08% plus placebo|polihexanide (PHMB) 0.08% and placebo were administered in the affected eye until clinical resolution for a maximum of 12 months
89143351|NCT03274895|Active Comparator|PHMB 0.02% plus propamidine 0.1%|polihexanide (PHMB) 0.02% and propamidine 0.1% were administered in the affected eye until clinical resolution for a maximum of 12 months
89143352|NCT03244163|Experimental|LASER ARM|Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
89143353|NCT03244163|Active Comparator|CONVENTIONAL ARM|Stone removal by conventional techniques, for example BML, without laser lithotripsy
89143354|NCT03199352||RYGB: Hand-sewn|This group would receive a Roux-en-y gastric bypass with the anastomosis hand-sewn using a minimally-invasive robotic surgical approach
89143355|NCT03199352||RYGB: linear-staple|This group would receive a Roux-en-y gastric bypass with the anastomosis sewn with a linear stapler using a laparoscopic surgical approach
89143356|NCT03186560|Active Comparator|Group A: Arterial Leg Ulcer|Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
89143357|NCT03186560|Active Comparator|Group B: Mixed Leg Ulcer|only to be done once Arterial leg ulcers show change in flux ABPI of <0.8-0.6
89143358|NCT03186560|Active Comparator|Group C: Diabetic Foot Ulcer - neuropathic|On clinical inspection present as neuropathic
89143359|NCT03186560|Active Comparator|Group D: Diabetic Foot Ulcer - neuroischemic|On clinical inspection present as neuroischemic
89143360|NCT03162081||Users|"Elderly patients who use prescription benzodiazepines/Z-hypnotics or opiates~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
89143361|NCT03162081||Non-users|"Age and gender matched controls not using the above~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
88816408|NCT01189760|Other|onabotulinumtoxinA 24U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo (normal saline) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
89143362|NCT03162081||Screening group|"Patients over 65 admitted to hospital as in-patients~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Medication use, Comorbidity"
89143363|NCT03054831|Active Comparator|Age 2-5 years-Before GA|The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
89143364|NCT03054831|Active Comparator|Age 2-5 years-After GA|In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
89143365|NCT03054831|Active Comparator|Age 6-8 years-Before GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
89143366|NCT03054831|Active Comparator|Age 6-8 years-After GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
89143367|NCT03035201||Cocoa extract + multivitamin (MTV)|2 capsules containing 500 mg/d cocoa extract; daily MTV
89143368|NCT03035201||Cocoa extract + multivitamin placebo|2 capsules containing 500 mg/d cocoa extract; daily MTV placebo
89143369|NCT03035201||Cocoa extract placebo + multivitamin|Cocoa extract placebo (2 capsules/d); daily MTV
89143370|NCT03035201||Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo (2 capsules/d); daily MTV placebo
89143371|NCT03003065|Other|Foscan|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
89143372|NCT03002870|Other|Endometriosis|Patients whom pathology results post surgery document endometriosis
89143373|NCT02969915|Active Comparator|Integrated care centers|Participants in the active comparator arm have access to integrated care centers (ICCs)
89143374|NCT02969915|Experimental|ICC + incentives|Participants in the experimental arm have access to the ICC intervention and the incentive intervention
89143375|NCT02931240|Experimental|Treatment|Treatment with the Revivent TC System
89143376|NCT02931240|No Intervention|Control Pool|Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
89143377|NCT02906332|Experimental|Pembrolizumab + lenalidomide|"This is an open label study.~Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.~This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles."
89143378|NCT02872844|Experimental|Heat-stress|Each participant will undergo a 30-minute heat stress to one randomized ear. The participant will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes.
89143379|NCT02864732|Experimental|Stabilization exercises|The stabilization exercises program will consist of exercises for the lower back and abdomen. These exercises include various types of abdominal bracing and bridging and side bridging. The exercises will be performed in supine, sidelying, and quadruped. It involves activation of muscles, dissociation of lumbar spine movement from extremities movement and endurance.
89143380|NCT02864732|Experimental|Stabilization exercises plus electrical stimulation|The neuromuscular electrical stimulation is a hand-size unit that has four plastic adhesive electrical conductors known as electrodes. These electrodes are going to be placed on the skin covering the lower back muscles. They will deliver an electric current that will generate muscle contraction that resembles normal muscle contraction. This treatment will be given in addition to the stabilization exercise program.
89143381|NCT02823665|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
89143382|NCT02823665|Experimental|Atropine|to evaluate the effect of neural activation on insulin secretion and glucose metabolism
89143383|NCT02755597|Experimental|Venetoclax + Bortezomib and Dexamethasone|Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m^2 subcutaneously or IV on Days 1, 4, 8 & 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 & 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23
89143384|NCT02755597|Placebo Comparator|Placebo + Bortezomib and Dexamethasone|Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m^2 subcutaneously or IV on Days 1, 4, 8 & 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 & 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 & 23
89143385|NCT02723708|Experimental|Self activation of VTA bold signal|Participants meeting study inclusion will then be scheduled for 4 fMRI sessions to assess and manipulate the ability to self-stimulate VTA activation. Each session will contain the same tasks and instructions. The experimental imaging task sessions will be done 24-72 hours apart and will consist of two types of runs: Test Runs (one pre-test and post-test each) and three Training Runs. Participants will be instructed to achieve heightened state of motivation using personally relevant thoughts and imagery.
89143386|NCT02715284|Experimental|Part 1: Participants receiving dostarlimab|Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.
89143387|NCT02715284|Experimental|Part 2A: Participants receiving dostarlimab|In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days. Cohorts will enroll participants with advanced solid tumor using a modified 6+6 design and will follow a 6+6 design.
89234751|NCT00831077|Active Comparator|14C-ORM-12741|
89234752|NCT01007760|Placebo Comparator|Room air|
89234753|NCT01007760|Active Comparator|Low dose exposure second-hand smoke|
89234754|NCT01007760|Active Comparator|High dose exposure second-hand smoke|
88816409|NCT01189760|Placebo Comparator|placebo (normal saline)|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
88816410|NCT03010202|Experimental|Induction phase: Rituximab+Dexamethasone|Open-label, intravenous infusions of rituximab 1000 mg and oral dexamethasone 20 mg daily for 4 days given on day 1 and day 15.
88816411|NCT03010202|No Intervention|Induction phase: Rituximab|Open-label, intravenous infusions of rituximab 1000 mg given on day 1 and day 15.
88816412|NCT03010202|Experimental|Maintenance phase: Rituximab|Patients who respond to rituximab in the induction phase will be proceed into the maintenance phase and randomized to rituximab infusion of 500 mg in week 1 and week 24, or
88816413|NCT03010202|No Intervention|Maintenance phase: Placebo|Infusion of normal saline 0,9% in week 1 ande week 24 in second randomization.
88816414|NCT01191320|Placebo Comparator|Placebo|Placebo
88816415|NCT01191320|Experimental|Androxal 12.5 mg|12.5 mg/day
89143388|NCT02715284|Experimental|Part 2B: Cohort A1 dMMR/MSI-H endometrial cancer|Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >= IIIB) disease.
89143389|NCT02715284|Experimental|Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer|Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >=IIIB) disease.
89143390|NCT02715284|Experimental|Part 2B: Cohort E NSCLC|Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
89143391|NCT02715284|Experimental|Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers|Participants with recurrent or advanced dMMR/MSI-H solid tumors except endometrial cancers, and gastrointestinal cancers, who have received prior systemic therapy and, who have no alternative treatment options. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
89143392|NCT02715284|Experimental|Part 2B: Cohort G PROC without known BRCA|Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease receiving dostarlimab and who have also been previously treated with bevacizumab. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.
89143393|NCT02705300|Experimental|Chemotherapy plus tocotrienol|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.~Daily: Tocotrienol 300 mg x 3 daily"
89143394|NCT02705300|Placebo Comparator|Chemotherapy plus placebo|"Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.~Daily: Placebo x 3 daily"
89143395|NCT02598557|Experimental|Arm I: Exemestane 25 mg QD|Patients receive exemestane PO QD on days 1-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
89143396|NCT02598557|Experimental|Arm II: Exemestane 25 TIW (exemestane, placebo)|Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
89143397|NCT02598557|Experimental|Arm III: Exemestane 25 mg QW (exemestane, placebo)|Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
89143398|NCT02592330|Experimental|Cultivated Autologous Limbal Epithelial Cell (CALEC) graft|Participants will have a corneal biopsy in their non-diseased eye, which will provide cells for the creation of the CALEC graft. The CALEC will be made at the Good Manufacturing Practice (GMP) Laboratory, Dana Farber Cancer Institute and transported to Mass. Eye and Ear Infirmary for application to the participant's diseased eye during their standard corneal reconstruction procedure.
89143399|NCT02517892|Experimental|Patients with metastatic oncogen-driven cancer|
89143400|NCT02494973|Active Comparator|Adjuvant systemic chemotherapy with mFOLFOX6|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, every 14 days:~Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,~Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours."
89143401|NCT02494973|Experimental|Adjuvant HAI oxaliplatin and systemic LV5FU2|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, and performed every 14 days:~Oxaliplatin 85 mg/m² in 4-6 hours HAI day (D)1,~Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours. In both arms, continuation of targeted therapy (if any) used in the preoperative treatment is allowed."
89143402|NCT02340780|Experimental|Buparlisib|100mg daily orally every 28 days
89143403|NCT02317783|Experimental|All Participants|All enrolled subjects will complete three imaging sessions on separate days that consist of: 1) [18F]Flutemetamol-PET/CT, 2) FDG-PET/CT, and 3) MRI. The order of the performance of these studies will be based upon subject and radioisotope availability, but they will all be completed within 2 months of each other.
89143404|NCT02293122||Observational|Observational group exposure to three test devices and one comparative device. The test Konan Non-con Robo Pachy F&A Specular Microscope.
89143405|NCT02242110|Experimental|Nightmare Treatment|The nightmare treatment, Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder (ERRT-Bipolar Disorder), is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
89143406|NCT02236390|Active Comparator|Cognitive Processing Therapy-Cognitive|12 sessions of cognitive processing therapy-Cognitive
89143407|NCT02236390|Active Comparator|ERRT + CPT-C|5 sessions of Exposure, Relaxation, and Rescripting Therapy, followed by 12 sessions of Cognitive Processing Therapy- Cognitive
89143408|NCT02236390|Active Comparator|CPT-C + ERRT|12 sessions of Cognitive Processing Therapy - Cognitive, followed by 5 sessions of Exposure, Relaxation, and Rescripting Therapy
89143409|NCT02141919|Experimental|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Radiation Therapy (SABR)
89234755|NCT00823355|Experimental|BCX1777|
89234756|NCT03999450|Experimental|Behavioral intervention|Patients admitted to Strong Hospital with opioid use will be given 1 to 3 brief motivational interventions and computer based cognitive behavioral therapy
89234757|NCT01048996||Non ALI/ARDS|Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
88816416|NCT01191320|Experimental|Androxal 25 mg|25 mg/day
89143410|NCT02044497|Experimental|oral oxycodone|An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines at Boston Children's Hospital.
89143411|NCT02033993|Active Comparator|Arm 1|Nab-Paclitaxel - 260mg/m2: q21 days
89143412|NCT02033993|Active Comparator|Arm 2|Paclitaxel - 175mg/m2: q21 days
89143413|NCT01997879|Experimental|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
89143414|NCT01906385|Experimental|186Rhenium Liposome Treatment|"Arm~Phase I:~Experimental: Dose Escalation for Cohorts 1-8 Each participant will receive a single administration of 186RNL. At each dose level, a minimum of three to a maximum of six participants will be enrolled.~If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment.~The dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below:~COHORT ACTIVITY Cohort 1 (1.0 mCi) Cohort 2 (2.0 mCi) Cohort 3 (4.0 mCi) Cohort 4 (8.0 mCi) Cohort 5 (13.4 mCi) Cohort 6 (22.3 mCi) Cohort 7 (31.2 mCi) Cohort 8 (41.5 mCi)~Phase 2:~Single arm, prospective study utilizing a non-DLT dose obtained from the dose escalation portion of IND 116117, NIH-NCI Grant (22.3 mCi (total 186RNL activity) at a concentration of 2.5 mCi/mL and 8.8 mL total volume)."
89143415|NCT01889108|No Intervention|Control|Usual care
89143416|NCT01889108|Experimental|Intervention group|Intervention with SPEEDI
89143417|NCT01803451|Experimental|hyperglycemic clamp-Meal tolerance test|these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
89143418|NCT01803451|Experimental|Labeled meal tolerance test|The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
89143419|NCT01734122||Essential Tremor|Patients with severe, medication-refractory Essential Tremor
89143420|NCT01734122||Parkinsonian Tremor|Patients with severe, medication-refractory, tremor-dominant Parkinsons
89143421|NCT01621828|Other|video|video showing a patient's pathway into the operating room.
89143422|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
89143423|NCT01528462||Expedited Treatment of Sleep Disorders|Please see below.
89143424|NCT01481246||Normal Aging/Cognitive Decline|Health adults as well as adults with MCI and early stage AD are being recruited in the study
89143425|NCT01470417|Active Comparator|Chemotherapy|Individuals with low risk disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
89143426|NCT01470417|Active Comparator|Chemotherapy and ChemoRadiotherapy|Individuals with high-risk disease or borderline resectable disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
89143427|NCT01409772||Intestinal Rehab|Pediatric Patients Undergoing Intestinal Rehabilitation for short bowel syndrome
89143428|NCT01367873|Placebo Comparator|Placebo|Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.
89143429|NCT01367873|Experimental|VIA-3196|Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.
89143430|NCT01331083|Experimental|PX-866|
89143431|NCT01241708|Experimental|Tandem Transplantation with Melphalan and Bortezomib|Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma
89143432|NCT01208766|Active Comparator|R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)|All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
89143433|NCT01208766|Experimental|R1: 1 (2) cycle(s) HDM|All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
89143434|NCT01208766|No Intervention|R2: none|No consolidation, patients will continue to Lenalidomide maintenance.
89143435|NCT01208766|Experimental|R2: 2 cycles of VRD|In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
88816417|NCT01151852|Experimental|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
89143436|NCT00999336|Active Comparator|Group H|Healthy subjects matched to the renal impairment groups
89143437|NCT00999336|Experimental|Group A|Patients with mild renal impairment
89143438|NCT00999336|Experimental|Group B|Patients with moderate renal impairment
89143439|NCT00999336|Experimental|Group C|Patients with severe renal impairment
89143440|NCT00992901|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
89143441|NCT00992901|Experimental|atropine|To evaluate the effect of neural activation on insulin secretion and glucose metabolism
89143442|NCT00992901|Experimental|GLP-1 and GIP|to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
89143443|NCT00935103|Active Comparator|Psychoeducation|Psycheducation
89143444|NCT00935103|No Intervention|Control|The control group will not take any intervention
89143445|NCT00883272||Normal Controls|25 women with CADP-CT > 66 seconds were treated with Femarelle
89143446|NCT00883272||Thrombophilic|Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT < 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
89143447|NCT00820248|Active Comparator|Arm I|Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
89143448|NCT00820248|Experimental|Arm II|Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.
89143449|NCT00795340|Experimental|Arm I Cediranib|Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
89143450|NCT00795340|Placebo Comparator|Arm II Placebo|Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
89143451|NCT00668642|Experimental|A: Dutasteride During First Off-Cycle|Arm A patients received dutasteride (0.5 mg/day) during the first off-cycle and received placebo during the second off-cycle
89143452|NCT00668642|Placebo Comparator|B: Placebo During First Off-Cycle|Arm B patients received placebo during the first off-cycle and received dutasteride (0.5 mg/day) during the second off-cycle
89143453|NCT00489710|Experimental|Talabostat|Talabostat 600 mcg orally, daily x 14 days (21 day cycle); 2 cycles
89143454|NCT00488696|Experimental|Interventional|Endovascular Bifurcated Stent Graft: The investigational operation involves placing a stent-graft over the aortic aneurysm.
89143455|NCT00482677|Active Comparator|Temozolomide|Temozolomide and short course radiation
89143456|NCT00482677|Active Comparator|Radiation|Short course radiation alone
89143457|NCT00288119||Cases|Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
89143458|NCT00288119||EGD Screening|Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
89143459|NCT00288119||Colon Screening|Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
89143460|NCT00288119||Controls|Patients scheduled for EGD who do not meet criteria for screening
89143461|NCT00101101|Experimental|Vaccine and Conventional Therapy|"Patients were treated with 3-6 cycles of chemotherapy +/- rituximab, with type and duration at the discretion of the individual clinician.~Chemotherapy: 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.~Patients who achieve a partial or complete response after completion of chemotherapy proceed to autologous tumor cell-based vaccine therapy.~Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2.~Treatment continues in the absence of disease progression or unacceptable toxicity."
89143462|NCT04097457|Experimental|Parent mediated intervention (PMI) group|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. The protocol is administered to groups of 4 families.
89143463|NCT04097457|Experimental|Waitlist control|Families will be recruited and will fill out measure for 3 months prior to participation and will then join the active intervention
89143464|NCT04097457|Experimental|Individual|A short term parent training protocol based on behavioral principles, which is delivered by trained therapists. The protocol includes eleven core sessions, a home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered to parents in an outpatient and home settings. In this arm the protocol is administered individually to families.
89143465|NCT02788370|Sham Comparator|Sham-PEP breathing|Patients will perform a constant work load cycling test with sham-positive expiratory pressure breathing util symptom limit.
89143466|NCT02788370|Experimental|Conical-PEP breathing|Patients will perform a constant work load cycling test with positive expiratory pressure breathing using a conical positive expiratory pressure device until symptom limit.
89143467|NCT00946621|Experimental|1|Ramipril 10 mg Capsule (Sandoz)
89143468|NCT00946621|Active Comparator|2|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
89143469|NCT02600793|Experimental|Arm 1|Single dose IV ceftaroline will be administered
89143470|NCT04114214||patients with suspected infection or sepsis|All patients admitted with suspected infection or sepsis from January 2018 to February 2018 at Prince of Wales Hospital
89143471|NCT00940459|Experimental|Acuvue Oasys|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
89143472|NCT00940459|Experimental|Biofinity|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
89143473|NCT00940459|Experimental|Air Optix|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
89143474|NCT00940459|Experimental|PureVision|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
89143475|NCT00940459|Active Comparator|Acuvue 2|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
89143476|NCT04235894||Patients undergoing GI endoscopy at Osijek University Hospital|Observational study. A total of 130 consecutive patients undergoing gastrointestinal endoscopy were included. The anesthesia was provided with propofol, starting with 0,5 mg/kg, and titrated until a patient was unresponsive to painful stimuli and maintaining spontaneous breathing. The blood pressure, pulse and Bispectral index values were measured in 6 defined points. On the emergence from anesthesia, the patient's facial expression was rated numerically by the investigator.
89143477|NCT04096599|Experimental|Test group|
89143478|NCT04096599|Active Comparator|Control group|
89143479|NCT03648632|Experimental|Stereotactic Radiotherapy|50 Gy in 5 fractions within a total of 7 - 8 days
89143480|NCT03962101|Experimental|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
89234758|NCT01048996||ALI/ARDS|Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
89234759|NCT01049074|Experimental|Verus acupuncture|
89234760|NCT01049074|Sham Comparator|Sham acupuncture|
89143481|NCT00923351|Experimental|Arm A - Participants who did not receive rhIL-7|Six patients with Ewings sarcoma family or tumors (ESFT) participants will receive cytotoxic/lympholytic therapy with cyclophosphamide and fludarabine (if cluster of differentiation 4 (CD4) count > 200 cells/mcl). Participant will receive Tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccine followed by Infusion of 8H9/CD25 depleted autologous lymphocyte infusion on Day 1, followed by Tumor lysate/KLH pulsed dendritic cell vaccine on week 4, 6, 8, 10, and 12.
89143482|NCT00923351|Experimental|Arm B - Participants who received rhIL-7|"Eight patients with rhabdomyosarcoma, fifteen patients with Ewings sarcoma family or tumors (ESFT), two patients with desmoplastic small round cell tumor, and one patient with synovial cell sarcoma participants will receive CYT107 20 mcg/kg/dose subcutaneous (SQ) (approx. 48h prior to vaccine[Day 0]), Tumor lysate/KLH pulsed dendritic cell vaccine followed by Infuse 8H9/CD25 depleted autologous lymphocyte infusion on Day 2, followed by CYT107 20 mcg/kg/dose SQ on days 14, 28 and 42 (± 7 days), and Tumor lysate/KLH pulsed dendritic cell vaccine on Days 16, 30, 44, 56, and 70 (± 7 days).~Apheresis/flow cytometry/delayed type of hypersensitivity (DTH) responses for immune endpoint monitoring (skin tests) will be performed on Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (+/- 7 days) (Arm B); and radiographic studies for clinical restaging will be performed on Week 8 and 20 (Arm A) and Days 42 and 126 (+/- 7 days) (Arm B)."
89143483|NCT02788292|Experimental|Acetylcysteine (NAC)|NAC added to tumescent solution for liposuction and eventual fat grafting.
89143484|NCT02788292|No Intervention|Control|Just tumescent solution for liposuction and fat grafting.
89143485|NCT00755937||Subjects receiving Remicade|Crohn's disease subjects receiving Remicade® per Product Monograph.
89143486|NCT00944203|Experimental|Test Area|Test Area = Standard Treatment plus Ipomea pes-caprae oinment
89143487|NCT00944203|No Intervention|Control Area|Control = Standard Treatment
89143488|NCT05424302|Experimental|Virtual Reality Group|Patients have baseline data collected two weeks pre-intervention by assessing patient symptomatology using the dizziness handicap inventory, activities specific balance confidence questionnaires and a simulator sickness questionnaire remotely. Next, an interview will be conducted to collect information including age, sex, ethnicity, physical activity level and VR experience. Lastly, VR headset will be mailed to patients home address. A date for VR device tutorial will be discussed during this interview. Next patients will undergo 4 or 8 weeks of vestibular rehabilitation if diagnosed with unilateral or bilateral vestibular hypofunction respectively. This involves weekly 40-45 minute in-person sessions with a physiotherapist and three 20 minute sessions a day of at-home independent exercises. In addition, they will undergo an at home VR vestibular rehabilitation protocol that involves playing a video game projected on an android or apple device in a VR headset for 20 minutes daily.
89143489|NCT05424302|Active Comparator|Control Group|Patients have baseline data collected two weeks pre-intervention by assessing patient symptomatology using the dizziness handicap inventory, activities specific balance confidence questionnaires and a simulator sickness questionnaire remotely. Next, an interview will be conducted to collect information including age, sex, ethnicity, physical activity level and VR experience. Next patients will undergo 4 or 8 weeks of vestibular rehabilitation if diagnosed with unilateral or bilateral vestibular hypofunction respectively. This involves weekly 40-45 minute in-person sessions with a physiotherapist and three 20 minute sessions a day of at-home independent exercises. In addition, they will undergo an at-home regime that consists of auditory stimulation while wearing a VR headset for 20 minutes daily.
89143490|NCT00946699|Experimental|1|MEDI-551
89143491|NCT00946699|Experimental|2|MEDI-551
89143492|NCT00946699|Experimental|3|MEWDI-551
89143493|NCT00946699|Experimental|4|MEDI-551
89143494|NCT00946699|Experimental|5|MEDI-551
89143495|NCT00946699|Placebo Comparator|6|Placebo
89143496|NCT00944281|Experimental|LNS-Zn5|Daily intake of 20 g LNS containing 5 mg of zinc and a daily placebo supplement
89143497|NCT00944281|Experimental|LNS-Zn10|Daily intake of 20 g LNS containing 10 mg of zinc and a daily placebo supplement
88816418|NCT01151852|Placebo Comparator|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
88816419|NCT02586909|Experimental|RVT-101 35 mg tablets|once daily, oral tablets
88816420|NCT04073810||Myocardial infarction|Patients with recent MI
88816421|NCT03011606|Experimental|Robotic surgery|Single arm. All Registered patients will undergo robotic surgery
88816422|NCT03011138||V 1|Gait velocity will be set at 1.0km/h.
89143498|NCT00944281|Placebo Comparator|LNS-Zn0|Daily intake of 20 g LNS containing 0 mg of zinc and a daily placebo supplement
89143499|NCT00944281|Experimental|Suppl-Zn5|Daily intake of zinc supplement containing 5 mg of zinc and 20 g LNS containing 0 mg of zinc
89143500|NCT00944281|No Intervention|Delayed intervention group|Standard care from age 8 to 18 months. Daily consumption of LNS from age 18 to 28 months.
89143501|NCT04096911|Experimental|Sintilimab and HPV Vaccine|Sintilimab 200 mg intravenously every 3 weeks ，3 doses of quadrivalent HPV vaccine intramuscularly at day 1,60,180
89143502|NCT04253405|Active Comparator|High Flow Nasal Cannula (HFNC)|The HFNC (Airvo2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
89143503|NCT04253405|Active Comparator|Non-invasive positive pressure ventilation (NIPPV)|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or an invasive mechanical ventilator with NIPPV mode are accepted. The interface should be an oronasal or full face mask.
89143504|NCT04096677||hysteroscopy repair|patients with post cesarean scar defect
89143505|NCT04096677||transvaginal repair|patients with post cesarean scar defect
89143506|NCT00944359|Experimental|Daily preventive Zn; placebo treatment|7 mg zinc per day for 12 months and placebo supplement during diarrhea episode
89143507|NCT00944359|Experimental|Therapeutic Zn; daily placebo|20 mg of zinc for 10 days during episodes of diarrhea and daily placebo supplement
89143508|NCT00944359|Experimental|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, daily placebo during 80 days of 3 months period and placebo during diarrhea episode
89143509|NCT00944359|Active Comparator|Surveillance control group|Surveillance control group will be randomly assigned to intervention groups every 3 months
89143510|NCT00944359|No Intervention|Non-intervention|Standard care provided by health system
89143511|NCT02791412||unprotected left main|undergone percutaneous coronary intervention or coronary artery bypass graft
89143512|NCT04096287|Experimental|PNT001|Single escalating doses of intravenous PNT001 administered as a 30 minute infusion at doses of 33mg, 100mg, 300mg, 900mg, 2700mg, and as a 60 minute infusion at 4000 mg
89143513|NCT04096287|Placebo Comparator|Placebo|Single intravenous dose of vehicle administered as a 30 minute infusion up to 2700 mg and as a 60 minute infusion at 4000 mg
89143514|NCT00946777|Experimental|Systane® Ultra|
89143515|NCT02791256|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants will receive 360 microgram (mcg) of Peginterferon Alfa-2a subcutaneous (SC) once a week plus ribavirin (1000 - 1200 milligram per day [mg/day] orally as a split dose in the morning and the evening based on the participant's body weight) for 32 weeks.
89143516|NCT04096209|Experimental|Graft-less and grafting using xenograft and autograft|Extraction of badly decayed teeth with immediate implant placement using graft-less and grafting using autogenous bone and xenograft between the implant and labial socket bone
89143517|NCT04258007|Placebo Comparator|Reversal Neostigmine|Patients undergoing cardiac catheterization will receive a combination of 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
89143518|NCT04258007|Active Comparator|Reversal Sugammadex|Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
89143519|NCT00944437|Active Comparator|Helmet|Patients in this group will receive continuous positive airway pressure delivered through a helmet connected to a high-flow reservoir system.
89143520|NCT00944437|Experimental|Mask|Patients in this group will receive continuous positive-airway pressure delivered through a novel full-face mask connected to a high-flow system. Expiratory pressure will be maintained using an expiratory valve connected to a T-tube.
89143521|NCT02787824|Experimental|continuous iv administration of iron sucrose|Prior to the study, all our patients were receiving intravenous iron sucrose in an intermittent mode (every 1-4 weeks).Patients on this arm will receive the same previous dose of iron glucose but in a continuous mode (smaller doses of iron sucrose in every session).
89143522|NCT02787824|Active Comparator|intermittent iv administration of iron sucrose|Patients on this arm will continue to receive the same previous intermittent mode of iron sucrose.
88816423|NCT03011138||V 2|Gait velocity will be set at 1.5km/h.
88816424|NCT03011138||V 3|Gait velocity will be set at 2.0km/h.
88816425|NCT03011138||V 4|Gait velocity will be set at 2.5km/h.
88816426|NCT03011138||V 5|Gait velocity will be set at 3.0km/h.
89143523|NCT04096131||SURGERY|subjects with early DME undergoing cataract surgery
89143524|NCT04096131||OBSERVATION|subjects with early DME
89143525|NCT00946855||soccer players|players of the first two German soccer leagues
89143526|NCT02796872|Placebo Comparator|mother's breast milk.|mother's breast milk.
89143527|NCT02796872|Active Comparator|other GOS|Commercial infant formula containing 4% w/w FOS:GOS (1:3)
89143528|NCT02796872|Experimental|B-GOS 3%|Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
89143529|NCT02796872|Experimental|B-GOS 2%|Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
89143530|NCT04095819|Experimental|Middle Meningeal Artery Embolization|Middle Meningeal Artery Embolization
89143531|NCT04095819|Active Comparator|Traditional Surgery|Craniotomy/Burr hole
89143532|NCT00946933|Placebo Comparator|Placebo|0.025 g/kg/day of NaCl (sodium chloride)
89143533|NCT00946933|Active Comparator|High salt diet|0.2 g/kg/day of NH4Cl (ammonium chloride)
89143534|NCT04095897||conventional analgesic therapy|Patient underwent mastectomy with conventional analgesic therapy
89143535|NCT04095897||Pecs II block|Patient underwent mastectomy with conventional analgesic therapy with pre induction Pecs II block
89143536|NCT00947089|Experimental|group A-the treatment group|Group A-patients have their wound, the site of the previous stoma, wad with ORC
89143537|NCT00947089|Active Comparator|group B-the control group|control group-patients have their wound wad with iodoform gauze
89143538|NCT02787980|Other|Patients = premature newborns|"Patients will consist of all premature babies (<37 weeks of amenorrhea), managed in the first 24 hours of life at the Reims university hospital for whom parents accepted to participate in the research Additional taking blood"
89143539|NCT02787980|Other|"Controls = children born full term"|"For controls the participation to research would be proposed to parents of children born full term, just after each patient child included.~Additional taking blood"
89143540|NCT00950053|Active Comparator|Achilles decompression & debridement|
89143541|NCT00950053|Active Comparator|Achilles decompression,debride&FHLtransf|Achilles tendon decompression and debridement augmented with FHL transfer. The preferred skin incision will be followed by central-splitting Achilles debridement, resection of a Haglund's lesion if present and pathologic, followed by FHL harvest for patients in group 2. The fixation technique in group 2 will utilize an interference screw for the FHL. For all patients, the Achilles will be reattached with lateral and medial suture anchors (just distal to interference screw in FHL patients).
89143542|NCT02796950|Experimental|Acipimox|Administration of acipimox 250 mg p.o.
89143543|NCT02796950|No Intervention|Control|No intervention.
89143544|NCT00755079|Placebo Comparator|Arm 1|group of persons with spinal cord injury will receive blinded placebo capsule
89143545|NCT00755079|Experimental|Arm 2|group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
89143546|NCT00950131|Experimental|Directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009)and a directive warning (i.e., stating the issue and why it matters) for new drugs.~This directive warning mentions that serious drug side effects may emerge only after the drug is already on the market, and the reader should ask their doctor there is an available drug with a longer track record."
89143547|NCT00950131|Experimental|Non-directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009) and a non-directive warning (i.e., just stating the issue) for new drugs.~This non-directive warning mentions only that serious drug side effects may emerge only after the drug is already on the market."
89143548|NCT00950131|Experimental|No new drug warning|Survey contains information about when the drug was approved by the FDA (2009) only.
89234761|NCT01050556|Placebo Comparator|Placebo|Placebo daily
89143549|NCT02796638|Experimental|Minute Ventilation Adaptive Servo-Ventilation plus SOC|Patients in this arm will be instructed to use the adaptive servo-ventilation (ASV) device for up to five days of inpatient stay while in the hospital. Patients are encouraged to use the device during any and all hours of sleep, and as needed during waking hours. Apart from this treatment, no other interventions will be administered, and the patient's standard of care will not otherwise be altered for the purposes of the study.Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
89143550|NCT02796638|No Intervention|Standard of Care (SOC)|Patients in this arm will not have their standard of care as dictated by their provider altered in any way. Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
89143551|NCT05301127|Active Comparator|CSEGA group|Will be received combined spinal-epidural-general anesthesia.
89143552|NCT05301127|No Intervention|GA group|will be received general anesthesia only.
89143553|NCT04096053|Experimental|TEACHH|The training workshop is designed as a 3-hour session for care providers. The training will be delivered by trans women. During this training, we plan to have providers: 1) discuss human rights for trans women; 2) teach providers about common words with which to discuss gender identity and expression, and develop a basic understanding of trans healthcare, HIV prevention, and HIV treatment, and how these types of healthcare affect trans women living with and affected by HIV; 3) discuss what it means to be trans-affirming in their work and how they can make their organizations more trans- affirming; and 4) have participants complete a case study to apply what they have learned to practice. These case studies will address issues affecting trans women who are immigrants/newcomers, trans women who are living with HIV, and trans women who experience other vulnerabilities.
89143554|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l."
89143555|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp with Endolipide and heparin|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l but will be also infused with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids."
89143556|NCT00950209|Active Comparator|hyperglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose."
89143557|NCT04095585||Patients presenting with WBS and ASD|patients with WBS and ASD. The diagnosis of WBS was confirmed by fluorescent in situ hybridization. All patients met formal ASD criteria.
89143558|NCT00947245|Experimental|BMS-791325 - Part A, Dose 1|
89143559|NCT00947245|Experimental|BMS-791325 - Part A, Dose 2|
89143560|NCT00947245|Experimental|BMS-791325 - Part A, Dose 3|
89143561|NCT00947245|Experimental|BMS-791325 - Part B, Dose 1|
89143562|NCT00947245|Experimental|BMS-791325 - Part B, Dose 2|
89143563|NCT00947245|Experimental|BMS-791325 - Part B, Dose 3|
89143564|NCT02791100|No Intervention|No promotion of chicken eggs|The community receives no chickens and therefore has no additional eggs or egg shell powder for children
89143565|NCT02791100|Experimental|Promotion of Chicken eggs for children|The community receives chickens so that each study child receives 2 eggs a day and also receives some egg shell daily (1/4 bottle cap which provides 500 mg Ca). The community receives information on using the egg and eggshell, and has help in caring for the chickens.
89143566|NCT02600481|Experimental|low-pressure pneumoperitoneum group|Subjects assigned to the low-pressure pneumoperitoneum group will receive 7-10 mm Hg carbon dioxide pneumoperitoneum, and the expected duration is longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
89143567|NCT02600481|Active Comparator|standard-pressure pneumoperitoneum group|Subjects assigned to the standard-pressure pneumoperitoneum group will receive 12-16 mm Hg carbon dioxide pneumoperitoneum, which is expected lasted longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
89143568|NCT00947323|Placebo Comparator|placebo|
89143569|NCT00947323|Experimental|Simvastatin|Treatment arm.
89143570|NCT04236050|Experimental|rocuronium is administered via continuous infusion|"40 patients. General anesthesia is maintained with propofol and remifentanil, with standard anesthetic monitoring, bispectral index (BIS) and train-of-four(TOF). In experimental group, rocuronium was administered via continuous infusion so that theTOF ratio was 5%. Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
89143571|NCT04236050|Active Comparator|rocuronium is administered in bolus doses|"40 patients. General anesthesia was maintained with propofol and remifentanil, with standard anesthetic monitoring, BIS and TOF. In this group, rocuronium was administered in separate bolus doses with the TOF ratio of 5%.~Hand-grip muscle strength was measured with a dynamometer on three occasions: before general anesthesia, in the early post-anesthesia period in the operating room, and 24 hours after anesthesia.~The quality of patient recovery was assessed with a Qor-40 questionnaire before anesthesia, 24 hours after anesthesia, and 30 days after anesthesia and surgery"
89143572|NCT02790866|Experimental|LuCaS Decision Aid|Access to LuCaS, a web-based lung cancer screening decision aid
89143573|NCT02790866|Active Comparator|NCI Website|Access to NCI website on lung cancer screening
89143574|NCT02790632|Experimental|EG-1962 Group|"1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg~Up to 21 days of placebo capsules/tablets"
89143575|NCT02790632|Active Comparator|Enteral Nimodipine Group|"1 dose of intraventricular normal saline~Up to 21 days of oral nimodipine capsules/tablets"
89143576|NCT02787122|Active Comparator|CBT-E|"Emotion-focussed Cognitive behavior therapy:~Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy. Interventions are behavioral activation, training of emotion regulation strategies, improvement of self-esteem and relapse prevention."
89143577|NCT02787122|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait list are required to wait for half a year, while they receive standardized care (antipsychotic medication). After half a year, they receive CBT-E, as well.
89143578|NCT02689934|Experimental|Lactoflorene colesterolo|Red Yeast Rice titrated in 10 mg monacolin K per daily dose plus Bifidobacterium longum 50 mg, powder form, 1 packet per day
89143579|NCT02689934|Placebo Comparator|Placebo Lactoflorene colesterolo|placebo, powder form, 1 packet per day
89143580|NCT00925301|Experimental|Migalastat|Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
89143581|NCT00925301|Placebo Comparator|Placebo|Placebo capsule taken orally QOD for 6 months.
89143582|NCT03633110|Experimental|Part A|"Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy).~Part A will consist of approximately 9 participants."
89143583|NCT03633110|Experimental|Part B|"Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).~Part B will consist of up to 90 participants."
89143584|NCT04232930|Active Comparator|Music group|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
89143585|NCT04232930|No Intervention|Non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
89143586|NCT04955327|Experimental|A. Paniculata150 mg|Extract from Andrographis Paniculata
89143587|NCT04955327|Experimental|A. Chilensis 300 mg|Extract from A. Chilensis
89143588|NCT04955327|Experimental|A. Panicluata 150 mg + A. Chilensis 300 mg.|combination of extract of A. Paniculata and A. Chilensis
89143589|NCT04955327|Placebo Comparator|Microcrystalline Cellulose +/-450 mg|Comparator
89143590|NCT04966013|Active Comparator|RD-X19 Device, Dose A|RD-X19. Investigational device that uses safe electromagnetic energy to target the oropharynx.
89143591|NCT04966013|Active Comparator|RD-X19 Device, Dose B|RD-X19. Investigational device that uses safe electromagnetic energy to target the oropharynx.
89143592|NCT04966013|Sham Comparator|Sham Device|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
89143593|NCT02788136|Experimental|Klinefelter syndrome|13 men with diagnosis of Klinefelter syndrome were stimulated with human chorionic gonadotropin (hCG)
89143594|NCT02788136|Active Comparator|Control|12 healthy age-related men were stimulated with human chorionic gonadotropin (hCG)
89143595|NCT02788058|Experimental|EGFR-TKI|Patients take EGFR-TKI alone till tumor progression
89143596|NCT02788058|Active Comparator|EGFR-TKI+hypofractionated radiotherapy|After 3 mos TKI, patients with limited metastatic take EGFR-TKI concurrent with hypofractionated radiotherapy till tumor progression.
89143597|NCT02796404|Experimental|Homebased cardiac rehabilitation program|Homebased Cardiac rehabilitation program with monitoring vest and mixed surveillance.
89143598|NCT02796404|Other|Traditional cardiac rehabilitation|Multidisciplinary program in a cardiac rehabilitation gym. Routine clinical practice
89143599|NCT02796482|Other|EnergieShake 1.5 kcal Complete Intervention|Single am of intervention of ONS, EnergieShake 1.5 kcal Complete, in the open label study are to be given to participants for 8 days, i.e. two bottles twice daily.
89143600|NCT02796326|Experimental|Dilatation|Patients undergoing tracheal dilatation with the study device
89143601|NCT04200092|Experimental|Cohort 1|Single orally-inhaled dose
88816427|NCT03011138||V 6|Gait velocity will be set at 3.5km/h.
88816428|NCT03011138||V 7|Gait velocity will be set at 4.0km/h.
89143602|NCT04200092|Experimental|Cohort 2|Single orally-inhaled dose
89143603|NCT04200092|Experimental|Cohort 3|Single orally-inhaled dose
89143604|NCT04200092|Experimental|Sequence 1|Single orally-inhaled dose
89143605|NCT04200092|Active Comparator|Sequence 2|Single IV administered dose
89143606|NCT00754065|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 26 days, followed by one capsule placebo for 2 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
89143607|NCT00754065|Active Comparator|Ortho Tri-Cyclen Lo|Daily oral administration of one capsule Ortho Tri-Cyclen Lo [Ethinylestradiol (EE)/ Norgestimate (NGM)] for 21 days, followed by one capsule placebo for 7 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
89143608|NCT02787902|Experimental|Communication|Behavioral weight loss program with communication skills training
89143609|NCT02787902|Active Comparator|Standard|Standard behavioral weight loss program
89143610|NCT02795936|Active Comparator|Institutional based rehabilitation|Conduct cardiac rehabilitation exercise protocol within the hospital
89143611|NCT02795936|Active Comparator|Home based rehabilitation|Conduct cardiac rehabilitation exercise protocol at home
89143612|NCT02795936|Placebo Comparator|Observational arm|No prescribed exercises, followed up monthly
89143613|NCT02785640|Experimental|Prompt group|Following feedback on their baseline sitting behaviour and an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered via Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing
89143614|NCT02785640|No Intervention|Control group|The control group will receive the same education session as the prompt group, as well as feedback on their baseline sitting behaviour. However, the will not receive prompts on their PC.
88803515|NCT02981381|Experimental|Active sTMS (NEST-1)|"Subjects randomized to this group will receive 20 active synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 active sTMS sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place on the last day of active sTMS.~Participants that elect to participate in the open-label continuation phase, will receive an additional 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
88803516|NCT02981381|Sham Comparator|Sham sTMS (SHAM)|"Subjects randomized to this group will receive 20 sham synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 sham sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place immediately after the final sham session.~Participants that elect to participate in the open-label continuation phase, will receive 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
88803517|NCT01680302|Experimental|High intensity exercise|High intensity exercise(Borg 16) in intervals.
88803518|NCT01680302|Experimental|Moderate intensity exercise|Moderate intensity exercise 3 times a week.
88803519|NCT01680302|Experimental|Control group|Exercise on their own. Follow current guidelines.
88803520|NCT01676402|Experimental|Group 1: HA DNA + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV ID at Week 14±2 wks
88803521|NCT01676402|Experimental|Group 2: HA DNA + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV IM at Week 14±2 wks
88803522|NCT01676402|Experimental|Group 3: TIV ID + TIV ID|licensed 2012/13 TIV ID at Day 0 and licensed 2013/14 TIV ID at Week 44±2 weeks
88803523|NCT01676402|Experimental|Group 4: TIV IM + TIV IM|2012/13 licensed TIV IM at Day 0 and licensed 2013/14 TIV IM at Week 44±2 weeks
88803524|NCT01676402|Experimental|Group 5: (HA DNA and TIV ID) + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV ID at Day 0 followed by licensed 2013/14 TIV ID at Week 44±2 weeks
88803525|NCT01676402|Experimental|Group 6: (HA DNA and TIV IM) + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV IM at Day 0 followed by licensed 2013/14 TIV IM at Week 44±2 weeks
88803526|NCT01052207||Critically Ill Patients|Evaluation of Oxidative Stress, Glucocorticoid Receptor function, and Adrenal Insufficiency amongst critically ill pediatric patients. Serum, and when available endotracheal samples, will be obtained within 24 hours of admission and at 5 days provided patients are 1) still in the PICU and 2) blood draws and endotracheal aspirates are part of their standard of care. Endotracheal aspirates will be sent on day 14, 21, and 28 provided patients are intubated and require suctioning as part of their standard of care.
88803527|NCT01052207||Healthy Controls|Healthy controls will be evaluated and defined as those who do not have any chronic medical condition, are not on steroids (inhaled or oral), and have not received steroids or etomidate in the last month. Given the time and need for multiple lab draws low dose adrenocorticotropin (ACTH) testing will not be done in healthy patients, nor will tracheal aspirate samples be obtained.
88803528|NCT01670006|Experimental|Cochlear Implantation|Cochlear Nucleus Cochlear Implant System
88803529|NCT01052831|Active Comparator|Naltrexone|For the first four weeks of the study, participants were administered naltrexone at 50mg per day. Participants not in response at week 4 were increased to 100mg per day for the remaining four weeks of the study.
88803530|NCT01052831|Placebo Comparator|Placebo|Participants received the placebo treatment which looked identical to active study medication.
88803531|NCT01005368||Group 1|Blood and bone marrow is collected at baseline, 3 months after completion of induction therapy, 2 months after completion of consolidation therapy, 1 year after completion of study treatment, and at disease relapse. Samples are analyzed by FISH for interphase cytogenetics, PCR for IgV_H mutational status, flow cytometry for surface expression of CD38 cells, western blot to assess Mcl-1, Bcl-2, BAK-1, ATM, ZAP-70, and Bar expression, and sequencing for p53 and ATM function.
88803532|NCT04330300|Experimental|Alternative anti-hypertensive medication|Switch to an alternative BP medication (specifically a Calcium channel blocker [CCB] or Thiazide/Thiazide-like diuretic at an equipotent blood pressure lowering dose). The choice of either CCB or Thiazide/Thiazide-like anti-hypertensive provided as alternative therapy will be at the discretion of the patient's treating physician.
88803533|NCT04330300|Active Comparator|Continue ACEi/ARB antihypertensive|Continue with either the ACEi (Angiotensin Converting Enzyme Inhibitor) or the Angiotensin Receptor Blocker (ARB) that had already been prescribed for the treatment of hypertension.
88803534|NCT04352855||C/T|C/T cases: individuals fulfilling eligibility criteria and treated with ceftolozane-tazobactam
88803535|NCT04352855||C|C cases: individuals fulfilling eligibility criteria and treated with colomycine
88803536|NCT04782128|Experimental|intravitreal 1.0mg RC28-E injection Q8|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
88803537|NCT04782128|Experimental|Experimental: intravitreal 1.0mg RC28-E injection PRN|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
89143615|NCT02787746|Other|donepezil|This is a multi-center single-arm study, which assess the safety and efficacy of donepezil in mild to moderate Alzheimer's disease in China.
89234762|NCT01050556|Experimental|Folic Acid 400 ug|400 µg folic acid daily
89234763|NCT01050556|Experimental|Folic Acid 800 ug|800 µg folic acid daily
89234764|NCT01050556|Experimental|Creatine|creatine daily
89234765|NCT01050556|Experimental|Creatine + Folic Acid|creatine + folic acid daily
89234766|NCT05890014|Experimental|High flavonoid group|"Participants will be encouraged to consume 2 x flavonoid-rich food items per day from the following list of flavonoid-rich foods across 30-days, above what they already consume each day, typically.~Orange juice (190 mls) Grapefruit juice (169mls) Dark chocolate (64g) Spinach (109g) Blueberry (64g) Strawberry (157g) Blackberry (81g) Blackcurrant (61g) Cherries (182g) Plums (90g) Black grapes (142g) Oranges (247g) Black olives (89g) Red grapes (339g)"
89234767|NCT05890014|Experimental|Low flavonoid group|"Participants will be encouraged to consume 1 x flavonoid-rich food items per day from the following list of flavonoid-rich foods across 30-days, above what they already consume each day, typically.~Orange juice (190 mls) Grapefruit juice (169mls) Dark chocolate (64g) Spinach (109g) Blueberry (64g) Strawberry (157g) Blackberry (81g) Blackcurrant (61g) Cherries (182g) Plums (90g) Black grapes (142g) Oranges (247g) Black olives (89g) Red grapes (339g)"
89234768|NCT05890014|No Intervention|Control|Participants will be given no instructions regarding adding food items to their diet. They will be encouraged to continue their diet as normal for 30-days.
89234769|NCT05889923|Experimental|learning with the EDU|Students will perform 5 ultrasound-guided regional anesthesia procedures on a phantom using the EDU which shows the student how to hold the needle and probe to hit the target.
89234770|NCT05889910|Experimental|Intervention Group|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
89234771|NCT05889910|Active Comparator|Control Group|"The control group intervention will be the usual clinical practice offered by the patient's nurse in the Primary Care setting during the duration of the study.~The usual clinical practice is based on attention to the user's demands, as well as the performance of interventions that can influence falls and/or the fear of falling. These activities or interventions are based on the Services of the Standardized Service Portfolio of the Community of Madrid (Updated as of January 28, 2022) in which these patients are included due to age or as a consequence of their chronic pathology."
89234772|NCT05889884|Experimental|Fixed retainer group|test group who undergoes retention using extended maxillary fixed retainer
89234773|NCT05889871|Experimental|Standard endocrine therapy plus Apatinib|5 to 10 years of endocrine therapy (e.g., aromatase inhibitors, tamoxifen, LHRH agonists, etc.) and 2 years of CDK4/6 inhibitors, depending on clinical indications. plus Apatinib, 250mg orally once a day;
89234774|NCT05889871|Active Comparator|Standard endocrine therapy|5 to 10 years of endocrine therapy (e.g., aromatase inhibitors, tamoxifen, LHRH agonists, etc.) and 2 years of CDK4/6 inhibitors, depending on clinical indications.
89234776|NCT05889806||Healthy|Healthy subjects with no history of chronic disease
89234777|NCT05889806||Subjects with various conditions|Subjects that have been diagnosed with a condition of interest such as Diabetes, NASH, Breast Cancer, Endometriosis, or other designated condition.
89234778|NCT05889767|Active Comparator|Normal weight and low body fat percent|The low risk comparator group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2) and body fat percent < 25% (male) or < 35% (female).
89234779|NCT05889767|Experimental|Normal-weight obesity|Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent > 25% (male) or > 35% (female).
89234780|NCT05889767|Active Comparator|Overt obesity and high body fat percent|Overt obesity (BMI > 30 kg/m2) with high body fat percent (> 25% [male] or > 35% [female]) will be used as a high-risk comparator group.
89234781|NCT05889754||Hemophilia Group|The PedHAL questionnaire will be administered to children aged 4-17 years with a diagnosis of hemophilia twice, one week apart. For construct validity assessment, the questionnaire will be compared with the Hemophilia Functional Independence Score (HJHS).
89234782|NCT05889728|Experimental|68Ga Bombesin PET/CT (NeoB) imaging for staging breast cancer|All patients will undergo a single time point imaging at Day 0 with PET CT to be conducted 120 (+/- 30) minutes after intravenous administration with 68Ga NeoB (3.0MBq/kg or up to a maximum of 250 Mbq).
89234783|NCT05889598|Experimental|Ballistic resistance exercise training|This arm will perform the exercises in a hack squat machine using low loads and explosive high-velocity (as if trying to jump)
89234784|NCT05889598|Experimental|Conventional resistance exercise training|This arm will perform the exercises in a hack squat machine using high-load and low-velocity (conventional training)
89234785|NCT05889598|No Intervention|Control|Continue usual life
88803538|NCT04782128|Experimental|Experimental: intravitreal 2.0mg RC28-E injection Q8|Subjects received 2.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
88803539|NCT04782128|Experimental|Experimental: intravitreal 2.0mg RC28-E injection PRN|Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
88803540|NCT05100875|Experimental|Intervention SSERT|The SSERT intervention will take place over 10 weekly individual intervention sessions of 60 minutes. SSERT for trauma history in psychosis will draw inspiration from the Skills Training in Affective and Interpersonal Regulation intervention as well as other CBT and DBT-based interventions for emotion regulation and social skills functioning. Therapists will be provided with a semi-structured manual that can be implemented flexibly to consider participant needs.
88803541|NCT00995150|Experimental|LNG20|LNG20 levonorgestrel-releasing intrauterine system
88803542|NCT00995150|Active Comparator|Mirena|Levonorgestrel-releasing intrauterine system for contraception
88803543|NCT00382642|Experimental|Ondansetron|Arm 1 = Ondansetron 4 mcg/kg b.i.d.+ Cognitive behavioral therapy
88803544|NCT00382642|Placebo Comparator|Placebo|Arm 2 = Placebo + Cognitive behavioral therapy
89143616|NCT04200170|Experimental|Intervention Arm|Eligible participants had been scheduled for either weekly or biweekly sessions with their therapists. Participants in the intervention arm were asked to download the Rose application on to their personal mobile phones and were given their therapist's unique ID for verification in the app. During the first week of the study, participants were prompted to complete key surveys and assessments at predetermined time intervals. Participants seen weekly will use the app for a total of 5 weeks and receive weekly in-person therapy for a total of 4 weeks (one-week application only lead-in, four weeks application plus in-person psychotherapy). Participants seen biweekly will use the app for a total of 10 weeks and receive biweekly in-person therapy for a total of 8w weeks (two-week application only lead-in, eight weeks application plus in-person psychotherapy).
89143617|NCT04200170|No Intervention|Waitlist Control Arm|The participants in the waitlist control arm served as controls for the study. They completed the pre-pilot and post-pilot assessments only. The waitlist participants continued their standard care and were offered entrance to the intervention arm at the end of the study period or earlier if patients in the intervention arm dropped out mid-study. During their time on the waitlist, participants could reach out to study personnel if they needed assistance with their psychiatric care.
89143618|NCT03266900|Experimental|re-TURBT|Patients in this arm will receive a 2nd TURBT within 4-6 weeks of initial TURBT
89143619|NCT03266900|Active Comparator|6 BCG instillations|Patients in this arm will not receive a 2nd TURBT, but will receive 6 instillations of BCG.
89143620|NCT04095507|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
89143621|NCT03254654|Experimental|Vinorelbine Plus Apatinib|"Vinorelbine: 20 mg/m2, D6, D13, D20~Apatinib: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2."
88803545|NCT01054079|Experimental|Treatment (cinacalcet hydrochloride)|Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
89143622|NCT03254654|Active Comparator|Vinorelbine|Vinorelbine: 25 mg/m2, D1, D8, D15
89143623|NCT02785718|Experimental|Patients with FXI or FXII deficiency|12 patients with FXI deficiency and 6 patients with FXII deficiency
89143624|NCT04094805|Active Comparator|Rocaltrol Combining HD-DXM|Rocaltrol 0.25 μg once per day, 1 month; HD-DXM (orally at 40 mg daily for 4d )
89143625|NCT04094805|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
89143626|NCT02786966|Other|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
89143627|NCT04094727|Experimental|Presumptive treatment and enhanced vector control|"For all eligible HRPs in intervention areas, after obtaining informed consent, presumptive treatment for malaria will be carried out using artemether-lumefantrine (AL) at two time points.~Enhanced vector control activities will include: (1) a mop up indoor residual spraying (IRS) campaign and (2) distribution of long-lasting insecticide-treated nets (LLINs) and/or vector control packs with topical repellent.~The intervention arm will also receive the standard of care in Namibia."
88803546|NCT00991094||Observational (questionnaire)|Patients undergoing standard of care proton therapy are assessed for toxicities weekly during proton treatment, then from 1 to 3 times up to 90 days from the start of treatment and annually thereafter. Patients also complete questionnaires over 15-20 minutes at baseline, weekly during treatment, and every 2 weeks during follow up for up to 3 months.
89143628|NCT04094727|No Intervention|Standard of care|The control arm will receive the standard of care in Namibia: passive case detection through health facilities and health extension workers, routine indoor residual spraying (IRS), and reactive case detection (RACD) accompanied by reactive IRS.
89143629|NCT02787434|Experimental|PCSPrep decision aid|All participants recruited to the trial will receive the decision aid. This a one-group study with a quasi-experiemental pre/post evaluation design.
89143630|NCT04094571|Experimental|Healthy Individuals and those with Movement Disorders|Participants will perform the FES cycling protocol along with the FES angle protocol.
89143631|NCT02785796|Experimental|CV4|The practitioner will contact the participant's occiput (lateral to the external occipital protuberances, but medial to the occipital-mastoid suture) with his or her thenar eminences. When no cranial mobility will be found, operators will be free to use any kind of technique to enhance the cranial movement before CV4 procedure. Once the practitioner will detect the CRI, the practitioner will resist the flexion phase of the CRI and exaggerate the extension phase. This compressive pressure will be maintained until the CRI stopped, and the still-point is reached. The still-point will be held until the CRI return, at which point the compressive pressure will be slowly release
89143632|NCT02785796|Placebo Comparator|sham technique|"The operator will overlap the hands so that the thumbs formed a V. The operator's thenar eminences will contact the occiput very lightly well below the positioning used in the CV4 procedure but with no pressure on the occiput between the occipitomastoid sutures. Once placement will be achieved, the operator's hands will remain motionless for 10 min. Finally, the practitioner's hands will be gently removed and the participant's head will be placed on the table for both procedures"
89143633|NCT02785796|No Intervention|Control|The control group will not receive ant type of treatment: subject just stay quietly in supine position in ambulatory room for ten minutes
89143634|NCT02787512|Active Comparator|Plastic stent|10 Fr plastic stent (Percuflex Amsterdam® or C-flex pigtail® or Advanix® Biliary stent)
89143635|NCT02787512|Experimental|Uncovered metal stent|Uncovered metal stent (WallFlex® Biliary RX stent)
89143636|NCT02785484|Experimental|Label with constituent disclosure message|
89143637|NCT02785484|Other|Label with litter message|
89143638|NCT03487640||Transanal rectal mucosa resection|TARMR: Transanal resection of rectal mucosa for at least 5cm in length.
89143639|NCT03487640||Laparoscopic rectal suspension and colectomy|LARSC: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
89143640|NCT00638066|Experimental|1|
89143641|NCT00638066|Active Comparator|2|
89143642|NCT02786732|Experimental|210mg Brodalumab|Administered by subcutaneous injection until Week 12
89143643|NCT02786732|Experimental|140mg Brodalumab|Administered subcutaneous injection until Week 12
89143644|NCT02786732|Active Comparator|Ustekinumab|Administered subcutaneous injection until Week 52
89143645|NCT02786732|Placebo Comparator|Placebo|Administered subcutaneous injection until Week 12
89143646|NCT02785250|Experimental|Arm 1|DPX-Survivac, Cyclophosphamide, Epacadostat (Phase 1 and initially Phase 2)
89234786|NCT05889585||high-dose of chemotherapy with autologous transplant and relapse-free after a minimum of 3 years.|Men with a histologically-confirmed (or high level serum tumor marker-based) diagnosis of germ-cell tumor, treated for relapse with high-dose of chemotherapy (HDCT) with autologous transplant at Gustave Roussy and relapse-free after a minimum of 3 years.
89234787|NCT05889585||Treated by orchidectomy only and no evidence of relapse after a minimum of 3 years|Men with a histologically confirmed (or high level serum tumor marker-based) stage I germ cell tumor, treated by orchidectomy only and no evidence of relapse after a minimum of 3 years.
89234788|NCT05889585||Treated by first line cisplatin-based chemotherapy and relapse-free after a minimum of 3 years.|Men with a histologically confirmed (or high level serum tumor marker-based) germ cell tumor and good or intermediate prognosis metastatic disease according to the International Germ-Cell Cancer Collaborative Group (IGCCCG), treated by first line cisplatin-based chemotherapy (and surgery of residual masses if needed), with no evidence of relapse after a minimum of 3 years.
89234789|NCT05889455|Experimental|Sildenafil|
89234790|NCT05889455|Placebo Comparator|Placebo|
89234791|NCT05889442|Experimental|Levcromakalim|
88803547|NCT00969956||Group A|150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)
88803548|NCT00969956||Group B|150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)
88803549|NCT00969956||Group C|150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)
88803550|NCT00969956||Group D|50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)
88803551|NCT01054703|Experimental|Ethmoid Sinus Spacer placement|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
88803552|NCT02544750|Experimental|GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.
88803553|NCT01662050|Experimental|One arm for all patients.|Rituximab, Bendamustine, Cytarabine
88803554|NCT04330456|Experimental|SaE treatment|"This group will receive combined treatment of soft tissue sarcoma that include 3 steps:~step - preoperative stereotactic radiation therapy in hypofractionation mode (5 fractions 5 Gy each)~step - operation~step - postoperative conformal radiation therapy in normofractionation mode (25 fractions 2 Gy each)"
88803555|NCT02654028|Experimental|Autotransfusion group|These group of patients will receive autotransfusion before liver resection.
88803556|NCT02654028|Active Comparator|Control group|These group of patients will not receive autotransfusion before liver resection.
88803557|NCT02536092|Experimental|755nm and 1064nm Nd:YAG laser|755nm and 1064nm Nd:YAG laser
88803558|NCT04748848|Experimental|CC-90011 in combination with Venetoclax and Azacitidine in Dose Escalation|CC-90011 in combination with venetoclax and azacitidine in dose escalation
88803559|NCT04748848|Experimental|Venetoclax and Azacitidine|Venetoclax and Azacitidine control arm in dose expansion. The participants will be randomized to the treatment arm or control arm at a 2:1 ratio.
88803560|NCT04748848|Experimental|CC-90011 in combination with Venetoclax and Azacitidine in Dose Expansion|CC-90011 in combination with venetoclax and azacitidine in dose expansion
89234792|NCT05889442|Placebo Comparator|Placebo|
89234793|NCT05889429||brain ischemic stroke patients|"Participants who meet the inclusion criteria.~All participants will undergo four testing sessions spanning the acute and subacute post-stroke phases:~Session 1 (t1) - 2-14 days from stroke onset Session 2 (t2) - 4 weeks (± 7 days) after the stroke Session 3 (t3) - 8 weeks (± 7 days) after the stroke Session 4 (t4) - 12 weeks (± 7 days) after the stroke"
89234794|NCT05889429||Control group|"Participants with healthy age and gender-matched with no history of neurological impairments.~Each participant will visit the testing sites 4 times within one month between different sessions."
89234795|NCT05889390|Active Comparator|wTAX (+ carboplatin) +AC|"wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks~AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x~Breast cancer tumor removal surgery (if feasible)"
89234796|NCT05889390|Experimental|wTAX (+ carboplatin) +AC + mEHT|"wTAX + mWEHT~wTAX: Weekly paclitaxel (+ carboplatin in the case of triple-negative breast cancer) for 12 weeks~mEHT: Concomitant modulated electro-hyperthermia using the Oncotherm EHY-2030 device, 3 times per week, for 12 weeks~AC: Doxorubicin/Cyclophosphamide every three-weeks, 4x~Breast cancer tumor removal surgery (if feasible)"
88803561|NCT04782206|Active Comparator|group 1|superior hypogastric plexus block
88803562|NCT04782206|Active Comparator|group 2|pulsed radiofrequency at S3 nerve root + superior hypogastric plexus block
88803563|NCT02526342|Active Comparator|Negative Pressure Wound Therapy|Patients receive a Negative Pressure Wound Therapy-Dressing (V.A.C. Ultra (KCI®,San Antonio, Texas, USA) with a subatmospheric pressure of 125mmHg to cover the muscle flap for five days following surgery.
88803564|NCT02526342|No Intervention|Conventional Dressing|Patients receive a conventional dressing for the muscle flap including fatty gauze and cotton gauze.
88803565|NCT02171195|Experimental|Group 1 (20 mg)|
88803566|NCT02171195|Experimental|Group 2 (50 mg)|
88803567|NCT02171195|Experimental|Group 3 (100 mg)|
89234797|NCT05889377|Experimental|Bovine Bone|
88803568|NCT02171195|Experimental|Group 4 (200 mg)|
88803569|NCT02171195|Experimental|Group 5 (400 mg)|
88803570|NCT02171195|Experimental|Group 6 (600 mg)|
88803571|NCT02171195|Experimental|Group 7 (900 mg)|
88803572|NCT02171195|Experimental|Group 8 (1200 mg)|
88803573|NCT04739878|Experimental|Ultrasound Airway|Ultrasound Airway for subglottic secretion
88803574|NCT04782440|Experimental|Telerehabilitation|
88803575|NCT04782440|Active Comparator|Home exercise|
89234798|NCT05889377|Experimental|Platelet Rich Fibrin|
89234799|NCT05889377|Experimental|Bovine Bone + PRF|
89234800|NCT05889377|No Intervention|Control|
89234801|NCT05889364||Sample N1|"(n=140) with ratio normal: tuberculosis 50:50"
89234802|NCT05889364||Sample N2|"(n=150) with ratio normal: tuberculosis 95:5"
89234803|NCT05889351|Placebo Comparator|Placebo|Vehicle treatment
89143647|NCT02785250|Experimental|Arm 2|DPX-Survivac, Cyclophosphamide (in Phase 2 only)
89143648|NCT05319314|Experimental|GCC19CART|"Single infusion of GCC19CART at the dose assigned to an individual subject.~All subjects will receive the same investigational therapy with the dose administered dependent upon the dose level they are assigned to in a sequential manner.~Two dose level escalations are planned with one dose de-escalation listed if needed."
89143649|NCT02787356|Experimental|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic with trained skin graders and images of skin
89143650|NCT02787356|Experimental|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD with trained skin graders and images of skin
89143651|NCT02787278|Experimental|SP-8203 High dose group|SP-8203 160mg (80mg/dose twice a day for three days)
89143652|NCT02787278|Experimental|SP-8203 Low dose group|SP-8203 80mg (40mg/dose twice a day for three days)
89143653|NCT02787278|Placebo Comparator|Placebo group|Placebo group: twice a day for three days
89143654|NCT02786888||conventional needle|conventional needle used
89143655|NCT02786888||fenestrated needle|fenestrated needle used
89143656|NCT02785328|Experimental|obstructive sleep apnoea|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from obstructive sleep apnoea syndrome.
89143657|NCT02785328|Experimental|narcolepsy|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from narcolepsy.
89143658|NCT02785328|Experimental|BECTS (Benign epilepsy with centro-temporal spikes)|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from BECTS.
89143659|NCT02785328|Experimental|high intellectual potential|The objective of this task is to evaluate the sleep-dependent consolidation abilities in children with high intellectual potential.
89143660|NCT02785328|Experimental|healthy children|The objective of this task is to evaluate the sleep-dependent consolidation abilities in healthy children.
89143661|NCT02786420||Observational|Pregnant women
89143662|NCT03093818|Experimental|Pharmacogenomic testing arm|"4,050 patients will provide a DNA sample. A pharmacogenomic test is performed. Results of this test are incorporated in the (electronic) medical record and combined with a clinical decision support system. Physicians and pharmacists may choose to use these results to guide drug and dose selection as per the Dutch Pharmacogenomics Working Group guidelines. Patients will receive a Safety-Code card containing their personal pharmacogenomics results, which can be used by other physicians or pharmacists during subsequent prescriptions."
89143663|NCT03093818|No Intervention|Standard of care arm|"4,050 patients will provide a DNA sample. However, no pharmacogenomic test is performed until the study is completed. Physicians and pharmacists will prescribe and dispense drugs routinely, without using pharmacogenomic test results to guide drug and dose selection. Patients will receive a mock Safety-Code card, which does not contain personal pharmacogenomics results."
89143664|NCT03083678|Experimental|Afatinib|Afatinib active treatment.
89143665|NCT04231916|Experimental|Patients aged 5-18 years|"Patients with Osteogenesis Imperfecta (with known vertebral fractures)for phase one of the study.~Patients with Osteogenesis Imperfecta for phase 2 of the study In both groups patients will be aged 5 years and over"
89143666|NCT04232150|Experimental|Group C (control group)|control group will receive no sedation under spinal anesthesia.
89143667|NCT04232150|Experimental|Group O (single dose group)|patients will receive 0.025mg/kg midazolam sedation under spinal anesthesia.
89143668|NCT04232150|Experimental|Group M (double dose group)|patients will receive 0.025mg/kg midazolam sedation twice under spinal anesthesia.
89143669|NCT04197752||Obese patients|Body mass index > 30 kg/m2
89143670|NCT04197752||Non-obese patients|Body mass index < 30 kg/m2
89143671|NCT02786576||Participants receiving adalimumab|Hidradenitis Suppurativa (HS) participants receiving adalimumab
88803576|NCT04781738||patients with history of vascular ring who didn't have corrective surgery|patients with history of vascular ring who didn't have corrective surgery
89143672|NCT04230902|Experimental|Lipogems|The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo harvesting of their own adipose tissue for aMAT then this aMAT will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study.
89143673|NCT04230902|Active Comparator|Steroid|The cases assigned to this group will be injected intra-articularly in the knee with corticosteroids. No extra preparation of any type is necessary in this case. It will be administered once at the baseline visit of the study.
89143674|NCT02336750|Experimental|treatment group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3 Mirtazapine:15mg D2-4
88803577|NCT04781738||patients with history of vascular ring who underwent corrective surgery|patients with history of vascular ring who underwent corrective surgery
89143675|NCT02336750|Experimental|control group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3
89143676|NCT02784314|Experimental|Robotic-Assisted Radical Prostatectomy|Robotic-Assisted Radical Prostatectomy using da Vinci Surgical System
89143677|NCT02784314|Active Comparator|Laparoscopic Radical Prostatectomy|Standard laparoscopic Radical Prostatectomy
89143678|NCT02784392|Experimental|Active|Ulimorelin
89143679|NCT02784392|Active Comparator|Comparator|Metoclopramide
89143680|NCT02972996|Experimental|Blueberry|22 g freeze-dried blueberries
89143681|NCT02972996|Placebo Comparator|Placebo|22 g placebo
89143682|NCT00634556|Experimental|levodopa solution 2mg/ml for i.v. use|"levodopa solution in saline, given intravenously, dosed as per final protocol in Black et al 2003."
89143683|NCT00634556|Placebo Comparator|Placebo|normal saline i.v.
89143684|NCT02784080||HLA-alloantibodies exposure|Preformed, persistent, and de novo HLA-alloantibody exposure in the whole cohort.
89143685|NCT02784860|Active Comparator|Lidocaine|Lidocaine. Administration of lidocaine is started with 1.5 mg/kg bolus injection followed by a continuous infusion of 4mg/kg/h.
89143686|NCT02784860|Placebo Comparator|Placebo|Placebo Administration of normal saline: same volume of saline as lidocaine.
89143687|NCT02783924|Active Comparator|Cholecalciferol|Vitamin d (as a 20.000 IU capsule) will be given i a dose of 40.000 IU per week for two months
89143688|NCT02783924|Placebo Comparator|Placebo|two capsules (identical looking to the vitamin D capsules) will be given per week for two months
89143689|NCT05249348|Experimental|Part 1 Sequence A|Period 1 will be fed, then washout, then Period 2 will be fasted.
89143690|NCT05249348|Experimental|Part 1 Sequence B|Period 1 will be fasted, then washout, then Period 2 will be fed.
89143691|NCT05249348|Experimental|Part 2 Sequence C|Period 1 will be fed, then washout, then Period 2 will be fasted. A different dose of PC14586 will be tested.
89143692|NCT05249348|Experimental|Part 2 Sequence D|Period 1 will be fasted, then washout, then Period 2 will be fed. A different dose of PC14586 will be tested.
89143693|NCT05249348|Experimental|Part 2 Japanese Cohort|6 Japanese participants will be administered a single dose of PC14586.
89143694|NCT02783846|Placebo Comparator|Group control|24 eligible patients are received equal volumes of saline intravenously for 10 minutes
89143695|NCT02783846|Active Comparator|Group dexmedetomidine 0.5 µg/kg|24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes
89143696|NCT02783846|Active Comparator|Group dexmedetomidine 1.0 µg/kg|25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes
89143697|NCT02786342||Advanced HCC patients treated with sorafenib|
89143698|NCT02784938|Experimental|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
89143699|NCT02784938|No Intervention|Wait-list Control|Services as usual
89143700|NCT02864576|Experimental|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program, performed 3 days per week, lasting 40 minutes."
89143701|NCT02864576|Active Comparator|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Health Promotion:~12 weeks of health promotion sessions, performed 3 days per week, lasting 40 minutes each."
89143702|NCT04198142|Experimental|Imagery Rehearsal Therapy Intervention|This group receives one to two sessions of Imagery Rehearsal Therapy.
89143703|NCT04198142|Active Comparator|Treatment as Usual with dream diaries|This group receives the usual inpatient care without additional Imagery Rehearsal Therapy sessions, but also keeps dream diaries.
89143704|NCT01890590|Experimental|Cyberknife|You will receive a series of Cyberknife Radiosurgery treatments, with the amount of radiation dosing adjusted for the size of your tumor. The treatment will ideally take place over the course of 3-4 days, but not more than 14 days overall. (3 or 4 fractions of radiation therapy delivered by cyberknife)
89143705|NCT02783612|Experimental|glucose application|Regular high risk pregnancy clinic surveillance in addition to a Smart phone application for registering the Blood glucose levels and submitting via email every 3-5 days to the High risk Doctor involved in the trial.
89143706|NCT02783612|No Intervention|Regular monitoring|Regular high risk pregnancy clinic surveillance
88816429|NCT01191398|Placebo Comparator|Placebo and Ketamine|Normal Saline 0.9% will act as a placebo. Two ml of normal saline 0.9% will be administered intravenously 30 minutes prior to the administration of the ketamine.
88816430|NCT01191398|Active Comparator|Atropine and Ketamine|Atropine will be administered as a single dose of 0.01 mg/kg, with a minimum of dosage of 0.1 mg and a maximum dosage of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
89143707|NCT02783378|Other|Gaviscon syrup|"Gaviscon will be given to threat patients with reflux after first 24 hours of oesophagal pH-monitoring.~This is a syrup and will be given after every meal. dosage depends from age between 1ml and 5ml after every meal"
89143708|NCT02783456|Active Comparator|Noise and silence|Exposition of 80dB flight noise for 30 minutes and 30 minutes silence.
89143709|NCT02783456|Active Comparator|silence and noise|Exposition of 30 minutes silence.and 80dB flight noise for 30 minutes
89143710|NCT02783534|Experimental|Verum acupuncture|Participants will receive verum acupuncture plus usual care. Participants will receive acupuncture treatment start from the 5th or 7th day before the estimated first day of menstrual cycle, and for each cycle, participants will receive one session of treatment each day for 5 consecutive days, totally be treated with 15 sessions.Verum needles will be inserted into the skin and manipulated manually until deqi occurs. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and manipulates the needles to maintain the intensity of deqi. Participants will receive the same usual care as those in the usual care group.
89143711|NCT02783534|Sham Comparator|Sham acupuncture|Participants will receive sham acupuncture plus usual care. The Streitberger placebo needle will be placed at non-acupuncture points which are distant from the meridian parts and not located on the same neuromuscular segments as the prescribed points used in the VA group, so as to minimize any therapeutic and segmental effects. The same acupuncture schedule as that in the verum acupuncture group will be applied. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and pretends to manipulate the needles but deqi is not sought.Participants will receive the same usual care as those in the usual care group.
89143712|NCT02783534|Placebo Comparator|Usual care|Participants will not receive acupuncture treatment besides health education as a control group.
89143713|NCT01631084|Experimental|JADE|Patients randomized to the JADE group will be followed according to protocol-driven diabetes care based on their individual risk levels, using a web-based disease management program. In addition to their annual comprehensive assessments at baseline, year 1 and year 2, all subsequent follow-up visits will be documented and entered into the JADE portal, which will then issue reports to both patients and doctor to promote sharing of information and informed decisions.
89143714|NCT01631084|Active Comparator|DIAMOND|Patients will receive a comprehensive assessment at baseline, year 1 and year 2. In the interim between these time points patients will be managed according to 'usual care' procedures.
89143715|NCT02785094||A|Group of High Education level
89143716|NCT02785094||B|Group of Low/Non Education level
89143717|NCT02785094||C|Group has Accessibility to Social Media
89143718|NCT02785094||D|Group has not Accessibility to Social Media
89143719|NCT02785874|Experimental|Statin(Crestor) taken|Subjects take Statin(Crestor) 10mg per day for a- year
89143720|NCT02785874|No Intervention|non Statin(Crestor) taken|non Statin(Crestor) taken as a reference for experimental group.
89143721|NCT05338814|Experimental|conventional neck exercises & scapular corrective exercise|isometric & stretching exercises of neck plus scapular corrective exercise
89143722|NCT05338814|Active Comparator|conventional neck exercises|isometric & stretching exercises of neck
89143723|NCT05334524|Active Comparator|kinesiotaping with combined chain exercises|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises."
89143724|NCT05334524|Active Comparator|kinesiotaping|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension."
89143725|NCT04231994|Experimental|TPE|additive singular therapeutic plasma Exchange (TPE) using fresh frozen Plasma (FFP) as replacement fluid
89143726|NCT04231994|No Intervention|SMT|Standard medical Treatment (SMT) for septic shock following the present surviving sepsis guidelines
89143727|NCT02786030|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions.
89143728|NCT02786030|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will not receive outreach education training.
89143729|NCT04197206|Experimental|Costotransverse block|The Costotransverse block will be administrated to this group before induction of anesthesia. An intravenous patient-controlled analgesia device within morphine will be given to the patients postoperatively.
89143730|NCT04197206|No Intervention|Control Group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with morphine. No block will be performed.
89143731|NCT02863796|Experimental|Single arm|This prospective, multi-center, single arm study is designed to evaluate the safety and feasibility of the WhiteSwell System in the reduction of interstitial fluid overload in patients with acutely decompensated heart failure (ADHF)
89143732|NCT05237726|Active Comparator|Unfractionated Heparin (UFH) 5000 U q8 hours|Severely burn injuries (BSA≥20%) will receive Unfractionated Heparin (UFH) 5000 U q8 hours as pharmacological VTE prophylaxis
89143733|NCT05237726|Active Comparator|Enoxaparin 40 mg q24 hours|Severely burn injuries (BSA≥20%) will receive Enoxaparin 40 mg q24 hours as pharmacological VTE prophylaxis
89143734|NCT05237726|Active Comparator|Enoxaparin 30 mg q12 hours|Severely burn injuries (BSA≥20%) will receive Enoxaparin 30 mg q12 hours as pharmacological VTE prophylaxis
89234804|NCT05889351|Active Comparator|Cohort 1|For all subjects, the IMP was applied 4 times during an intensive dosing regimen for 4 ½-hours (on Day 1 at 0, 1 ½, 3 and 4 ½ - hours). For subjects in Cohort 1, this was followed by 4 additional applications: on Day 1 at 12 hours, on Day 2 at 24 and 36 hours, and on Day 3 at 48 hours.
89234805|NCT05889351|Active Comparator|Cohort 2|For all subjects, the IMP was applied 4 times during an intensive dosing regimen for 4 ½-hours (on Day 1 at 0, 1 ½, 3 and 4 ½ - hours). For subjects in Cohort 2 the IMP was likewise applied 4 times during the 4 ½-hour period (on Day 1 at 0, 1 ½, 3 and 4½ hours), but was followed by 2 applications: on Day 1 at 12 hours and on Day 2 at 36 hours.
89234806|NCT05889338|Active Comparator|Case: adults with severe psoriasis treated by adalimumab therapy.|
89234807|NCT05889338|Active Comparator|Control: adults with severe psoriasis treated by methotrexate therapy.|
89234808|NCT05889312||Non-small cell lung cancer|NSCLC
89234809|NCT05889312||Head and neck squamous cell cancer|HNSCC
88803578|NCT03015155|Experimental|Hypothermia|Infusion of Cold Saline into Local Infarction Myocardium. A standard working guide-wire, Runthrough NS (Terumo, Japan), is advanced into the distal part of the target coronary artery by using angiography. Compared to the standard PPCI after the balloon expansion, the aspirated catheter (Diver C.E. MAX, Italy) is firstly placed at the location of the distal occlusion lesion to achieve local myocardial hypothermia by infusing the cold saline (4℃, 2.5ml/min, 5min). Then we retract the aspirated catheter, following the balloon expansion and the drug eluting stent implanting. Subsequently, the infusion catheter is tautologically placed at the location of the opened occlusion, within the stent, to persistently perfuse the infarct myocardium with cold saline (4℃, 2.5ml/min, 15min).
88803579|NCT03015155|No Intervention|Standard treatment|We place a standard working guide-wire, Runthrough NS (Terumo Corporation, Japan), crossover the criminal lesion of to the distal of the target coronary artery after angiography. Then the pre-dilated balloon is placed at the occluded lesion site to expand the criminal vessel without hypothermia intervention. The operation will be completed when the flow of target coronary artery achieves TIMI class 3 after the drug eluting stent implanting.
88803580|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 50mg|
88803581|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 100mg|
88803582|NCT01620788|Active Comparator|Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg)|
88803583|NCT01620788|Active Comparator|Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg)|
88803584|NCT03014843|Active Comparator|Naloxone|Administration of a centrally acting µ-opioid receptor antagonist Naloxone (20µg/kg/h intravenous infusion after 0.4mg bolus) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
88803585|NCT03014843|Active Comparator|Methylnaltrexone bromide|Administration of a peripherally acting µ-opioid receptor antagonist Methylnaltrexone (12mg/0.6mL subcutaneous injection) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
88803586|NCT03014843|Placebo Comparator|Placebo|Administration of placebo injection (1mL 0.9% saline IV or 0.6 IM) as a control condition to compare to the administration of naloxone or methylnaltrexone bromide in the multimodal esophageal stimulation protocol.
88803587|NCT02540538|Active Comparator|HB vaccine naive - HBVaxPro|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.
88803588|NCT02540538|Experimental|HB vaccine naive - HBAI20|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.
88803589|NCT02540538|Experimental|Non-responders - HBAI20|"Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.~Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180."
88803590|NCT00923858||Control - participants from cycles 1 & 2|no intervention. Control group is composed of participants from Cohort I (recruited during our first grant cycle) and from Cohort II (recruited during our second grant cycle). Continued observation is planned for those controls, partial tears and full tears who enrolled in study at age 65 years or younger and have less than 11 years of follow up.
88803591|NCT00923858||Cuff Tear Cohort III|These participants are being recruited from our clinical population and have been scheduled to undergo a standard of care rotator cuff repair and post op therapy. One shoulder has been indicated for rotator cuff repair and the contralateral shoulder is asymptomatic. Both shoulders will be monitored.
88803592|NCT05081375|Active Comparator|Enoxaparin|Enoxaparin dose will not be held for surgical procedure.
88803593|NCT05081375|Placebo Comparator|Placebo dose given and Enoxaparin dose held|Enoxaparin dose will be held and replaced by placebo and not given prior to surgical procedure.
89234810|NCT05889299|Experimental|OMS906 study drug|OMS906 study drug repeat-dose 5 mg/kg SC administration at 4-week intervals
89234811|NCT05733156|Experimental|SBRT + LDRT|
89234812|NCT05889247|Experimental|ctDNA monitoring|Treatment monitoring by longitudinal circulating tumor DNA measurements and Quality of Life assessments
89234813|NCT05889247|No Intervention|CT scan monitoring|Treatment monitoring by longitudinal CT scans (standard) and Quality of Life Assessments
89234814|NCT05889208|Active Comparator|Prophylactic pacemaker implantation|Brady-pacemaker implantation prior the TAVI-procedure. Pacemaker modus is according to local conditions.
89234815|NCT05889208|No Intervention|Usual care|Pacemaker implantation after TAVI if atrioventricular block occurs.
89234816|NCT05889169||Stroke patients with immunosuppression|Patients with ischemic or hemorrhagic stroke with a neutrophil to lymphocyte ratio >= 5 at hospital admission
89234817|NCT05889169||Stroke patients without immunosuppression|Patients with ischemic or hemorrhagic stroke with a neutrophil to lymphocyte ratio < 5 at hospital admission
89234818|NCT05889130|Active Comparator|first two hours of exercise group|This is the group that will do resistance exercise in the first two hours of the hemodialysis session.
89234819|NCT05889130|Active Comparator|last two hours of exercise group|This is the group that will do resistance exercise in the last two hours of the hemodialysis session.
89290607|NCT03927534|No Intervention|Control|Treatment As Usual (TAU) in Primary Care (PC) is any kind of treatment administered by the GP to the patient with overweight and obesity. According to nutritional status, overweight or obesity, as well as the presence of co-morbidity, different actions can comprise the treatment offered at a PC level. For individuals presenting with overweight (BMI 25-29.9 kg/m2) but with no co-morbidities, PC teams organise care plans to enable them to achieve a normal BMI range (BMI 18.5-24.9 kg/m2). In case of suicide risk, severe social dysfunction or worsening of symptoms, it is recommended that patients are referred to mental health facilities.
88803594|NCT02201628|Experimental|Nasopharyngeal and oesophageal temperatures|An oesophageal and nasopharyngeal temperature probe will be placed and temperature will be measured at these site
88803595|NCT04980898|Experimental|Electrical stimulation wound management system|Two daily electrostimulation sessions using the WoundEL® device on wound two for 30 minutes at an adjustable intensity, between 5 and 42 milliampere and chosen by the patient.
88803596|NCT04980898|Active Comparator|Standard of care|Use of dressings appropriate to the stage of healing according to French recommendations for the management of leg ulcers.
88803597|NCT04755062|Experimental|Micronutrient-dense plant-rich Intervention|The intervention will consist of a 2-hour 'immersion' group session, followed by weekly 1-hour group sessions over the following 11 weeks. Groups of no more than 15 individuals will meet weekly for 12 weeks with a trained Lifestyle Coach. Group sessions, held at the Twin Arrows Casino, will provide participants with instructions, assistance with goal setting, support, encouragement, cooking demonstrations, Casino (workplace) dining tours, and will socially engage with other participants. Participants will be requested to follow the mNDPR nutrition protocol for the first 12 weeks. Each week the participants will use a simple tracking method to self-monitor their daily compliance with the nutrition protocol. Lifestyle Coaches will monitor adherence and verify attendance. Instructional materials discussed each week will provide resources and methods to overcome common barriers to dietary change including (i) meal prepping, (ii) social gatherings, and (iii) family resistance.
88803598|NCT04755062|Active Comparator|Wait-list Control|Participants in the wait-list control group will be requested to maintain their typical eating patterns during a 12-week waiting period, until they are scheduled to start the intervention 13-weeks later.
88803599|NCT01609400||Breast enhancement|
88803600|NCT03014531|Experimental|almond|In this group, participants were provided with 56 g of almonds per day either as preload before meals or snack between meals. A snack was defined as an eating event that occurred between participants' regular meals, specifically two hours before and after meals. All the participants in almond group were provided daily portions of packaged almonds.
88803601|NCT03014531|Other|high-carbohydrate control food item|In this group, participants were provided with high-carbohydrate control food item that had a similar number of calories as 56 g of almonds.
88803602|NCT01895504|Experimental|ColoAssist|Screening colonoscopy with a new colonoscope with gradual stiffness
88803603|NCT01895504|Active Comparator|MEI|Screening colonoscopy with colonoscopes compatible with and guided by MEI
88803604|NCT03852797|Active Comparator|Ketamine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
88803605|NCT03852797|Active Comparator|Ketamine + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
88803606|NCT03852797|Active Comparator|Propofol|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
88803607|NCT03852797|Active Comparator|Propofol + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
88803608|NCT03852797|Active Comparator|Etomidate|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
88803609|NCT03852797|Active Comparator|Etomidate + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
88803610|NCT00900224||Group 1|Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, CBL, and DNMT3A mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
88803611|NCT01055171|Active Comparator|Propranolol|Patients will receive Propranolol in this condition.
88803612|NCT01055171|Placebo Comparator|Placebo|Patient to receive placebo in this condition.
88803613|NCT04941053||group 1 chronic haemodialysis patients|seroprevalnce of COVID 19
88803614|NCT04941053||healthy control|seroprevalnce of COVID 19
88803615|NCT04714996|Experimental|ES-481|
88803616|NCT04714996|Placebo Comparator|Placebo|
88803617|NCT04714996|Other|Open-Label Extension Study|
88803618|NCT00888290|Active Comparator|Sodium Bicarbonate|Sequential design. Participants will be getting different doses of sodium bicarbonate during the study.
88803619|NCT00888290|Placebo Comparator|Placebos|Sequential design. Participants will be getting either placebo of different doses during the study.
88803620|NCT01057277|Experimental|RAD001(Afinitor)|Radiation 47 days Cisplatin day 1,8,15,22,29,36,43 RAD001 Day 1 according to assigned group to day 47
88803621|NCT04697056|Experimental|Imsidolimab|Participants received a starting dose of 400 milligrams (mg) of imsidolimab on Day 1 followed by 200 mg imsidolimab every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
88803622|NCT04697056|Placebo Comparator|Placebo|Participants received imsidolimab matching placebo on Day 1 and thereafter, every 4 weeks (Days 29, 57 and 85) by subcutaneous injection.
88803623|NCT00866840|Experimental|Riluzole|100 mg orally twice daily
88803624|NCT01057901|Experimental|Flibanserin 100 mg|Flibanserin 100 mg administered at bedtime
88803625|NCT01057901|Placebo Comparator|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
88803626|NCT04755608|Experimental|Low Intensity Blood Flow Restriction Group|
88803627|NCT04755608|Active Comparator|High Intensity Resistant Training Group|
88803628|NCT04686916|Experimental|IP2018_dose 1|IP2018_dose1
88803629|NCT04686916|Experimental|IP2018_dose 2|IP2018_dose2
88803630|NCT04686916|Placebo Comparator|Placebo|Placebo
88803631|NCT04349722|Active Comparator|Hyoscine|Participants receive intravenous bolus of 1ml (20 mg) Hyoscine
88803632|NCT04349722|Placebo Comparator|Placebo|Participants receive intravenous bolus of 1ml normal saline
88803633|NCT01058993|Experimental|AMD3100 or plerixafor|SINGLE arm study with increasing doses of Plerixafor
88803634|NCT04657276||Down Syndome|Infants with Down Syndrome
89290608|NCT01329276|Other|Symbicort® forte Turbohaler®|
89234820|NCT05889091|Experimental|Quality of life questionnaires|After the Fat Flap Reconstruction at 6 months post-operatively, all patients will be asked to complete the selected patient reported outcomes instruments and to complete clinical assessment with either the Head and Neck Surgery (HNS) or Plastic & Reconstructing Surgery (PLA) care team. Range of Motion (ROM) measurements using a goniometer will be completed by a member of the HNS clinical team. At 12 months post-operatively, all patients will be asked to complete the selected patient reported outcomes instruments and to complete clinical assessment. Patients will be asked to complete inter-incisor distance measurement and barium swallow assessment, done by a member of the SLP team. Range of Motion (ROM) measurements using a goniometer will be completed by a member of the HNS clinical team.
89234821|NCT05889078|Experimental|Nature condition|Participants will walk in a nature setting 3x per week for a period of 4 weeks.
89234822|NCT05889078|Experimental|Urban condition|Participants will walk in an urban setting 3x per week for a period of 4 weeks.
89234823|NCT05889065|Active Comparator|Conventional PT Group|"Conventional group will receive routine physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
89234824|NCT05889065|Experimental|Scapular PNF + Conventional PT Group|This group will receive scapular PNF techniques along with routine physical therapy (same as above). In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
89234825|NCT05889026|Active Comparator|Botulinum toxin treatment with extracorporeal shock wave therapy|"Nabota® (Daewoong Pharmaceutical Co. Ltd., Seoul, Korea) was used. It was diluted with 0.9% sodium chloride solution and injected into the bellies of the upper-extremity muscles.~ESWT was performed immediately after botulinum toxin injection and was performed once a day for 5 days. Three weeks and 3 months after ESWT, spasticity was evaluated."
88803635|NCT01059305|Experimental|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
88803636|NCT04650490|Experimental|Immediate SRS followed by IO|Participants will receive SRS followed by physician's choice of standard of care immunotherapy, given at the FDA-approved dose within 14 days of SRS.
88803637|NCT04650490|Experimental|Immediate IO followed by SRS|Participants will receive physician's choice of immunotherapy, given at the FDA-approved dose followed by SRS, if deemed appropriate, at the time of intracranial progression.
88803638|NCT04649788|Active Comparator|Ultrasound-guided axillary vein access|This group of patients will receive the cardiac implantable electronic device with ultrasound-guided axillary venous access.
88803639|NCT04649788|Active Comparator|Cephalic vein access|This group of patients will receive the cardiac implantable electronic device with cephalic venous access.
88803640|NCT04641832|Experimental|Chronic cannabis use and subconcussive head impacts|"Group: Chronic cannabis users Criteria: self-reported chronic THC use (average use once per week but not dependent). Urine cannabis test must show positive.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
88803641|NCT04641832|Active Comparator|Non-cannabis use and subconcussive head impacts|"Group: Non cannabis users Criteria: self-reported none THC use. Urine cannabis test must show negative.~Device: Soccer Heading Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 20 consecutive soccer headings, separated by one minute intervals."
88803642|NCT03014687|Placebo Comparator|Standard Nasal Care|One dose of preoperative intravenous (iv) antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Postoperative antibiotics: Study participants will receive one dose only of postoperative intravenous antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Placebo PO BID (twice daily) will commence on the morning of postoperative day 1 and continue for 7 days.
88803643|NCT03014687|Experimental|Standard Nasal Care + Oral Antibiotics|One dose of preoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg) will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Participants will receive 1 dose only of postoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Oral antibiotics will commence on the morning of postoperative day 1; this group will receive oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.
88803644|NCT04296292||AMBITION Trial Participants|Individuals who have been enrolled into the AMBITION trial
88803645|NCT04296292||The next-of-kin of AMBITION Trial Participants|Individuals who have provided consent for an AMBITION trial participant who had an abnormal mental status at baseline
89234826|NCT05889026|Sham Comparator|Botulinum toxin treatment only|Nabota® (Daewoong Pharmaceutical Co. Ltd., Seoul, Korea) was used. It was diluted with 0.9% sodium chloride solution and injected into the bellies of the upper-extremity muscles. Three weeks and 3 months after Botox treatment, spasticity was evaluated.
89234827|NCT05889000||main group|304 patients with verified CPVD
89234828|NCT05889000||comparison group|93 participants without signs of CPVD.
89234829|NCT05888909||Type 2 diabetic nephropathy|The cohort will be divided into 2 or 3 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
88803646|NCT04296292||AMBITION Researchers|Individuals working on the AMBITION trial
88803647|NCT04629274|Experimental|Test of Imotopes® candidates on blood cells of patients with stabilized NMO|To test in vitro the binding of different Imotopes® to class II HLA antigens on PBMC isolated from patients presenting a diagnosed and stabilized neuromyelitis optica spectrum disorders, as well as their ability to generate a cytolytic response directed against the immune cells involved in the maintenance and triggering of the disease (i.e. non-cytolytic T cells recognising the same epitopes and antigen presenting cells (APC) presenting the same epitopes).
89143735|NCT04138056|Experimental|RSV120_dTpa_RSV120(Pooled)|Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and either one dose of 300 μg or 500 μg dTpa (Boostrix) vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
88803648|NCT03824405|Active Comparator|BTX 1204|BTX 1204 twice daily
88803649|NCT03824405|Placebo Comparator|Vehicle|Vehicle twice daily
89143736|NCT04138056|Placebo Comparator|RSV120_Placebo_RSV120(Pooled)|Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
89143737|NCT04138056|Experimental|RSV60_dTpa_RSV120(Pooled)|Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
89143738|NCT04138056|Placebo Comparator|RSV60_Placebo_RSV120(Pooled)|Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
89143739|NCT04138056|Placebo Comparator|dTpa_Placebo_RSV120(Pooled)|Subjects received one dose of Placebo and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
89143740|NCT02782988||CMV symptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
89143741|NCT02782988||CMV asymptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
89143742|NCT02782988||Healthy controls|olfactory tests, otoacoustic emissions (OAE)
89143743|NCT02783144|Experimental|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, 4 mg of Dexamethasone are added to 20 ml of 0,375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
89143744|NCT02783144|Placebo Comparator|TAP Block and Saline|After general anesthesia and before the beginning of surgery, 2 ml of saline are added to 20 ml of 0.375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
89143745|NCT02783144|Active Comparator|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, 20 ml of 0,375% Levobupivacaine are used in Ultrasound-guided Tranversus Abdominis Plain Block. In this group 4 mg of dexamethasone are injected intravenously.
89143746|NCT04230044||Fycompa® (perampanel)|Fycompa® (perampanel) (oral tablets) treatment will be initiated at 2 milligram (mg) once daily according to the approved package insert, as an add-on drug in addition to other anti-epileptic drugs (AEDs) as prescribed by physician. The dose will be increased based on clinical response and tolerability (by increments of 2 mg/day to a maintenance dose of 4 to 12 mg/day) and participants will be enrolled and observed prospectively for up to 54 Weeks.
89143747|NCT05219240||Program participants|
89143748|NCT02723058|Experimental|ICMHM|ICMHM mothers receive services of a primary care clinician (PCP) and a care manager both trained in depression care management in a shelter-based primary care clinic.
89143749|NCT02723058|No Intervention|Treatment as Usual|Treatment as Usual mothers receive usual services of a PCP and case manager from a shelter-based primary care clinic. .
89143750|NCT02783222|Active Comparator|Arm B|Nab-paclitaxel 125 mg/mq weekly for 3 out of every 4 weeks
89143751|NCT02783222|Experimental|Arm A|Nab-paclitaxel 100 mg/mq weekly for 3 out of every 4 weeks
89143752|NCT02718456|No Intervention|Standard of care|Standard HIV counseling and referral to care
89143753|NCT02718456|Experimental|CD4 testing|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week.
88803650|NCT02246699|Experimental|KiOnutrime®-Cs|The product is presented as a capsule containing chitosan as ingredient supporting the activity.
88803651|NCT02246699|Placebo Comparator|Placebo|Placebo is presented as a capsule containing inactive ingredients.
89143754|NCT02718456|Experimental|CD4 testing plus peer counseling|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week. Additionally, a trained peer counselor provides supplemental counseling at the time of diagnosis and at the 1 week telephone follow-up.
89143755|NCT04231604|Experimental|A Lust for Life programme group|A Lust for Life programme will be delivered to adolescents by their school teachers in six weekly lessons. Well-being and resilience will be promoted in each lesson through classroom discussions, videos, classroom activities and homework assignments.
89143756|NCT04231604|Other|Waiting list control group|Participants will be placed on a twelve-week waiting list for the programme.
89143757|NCT02718222|Experimental|3-9 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 3 months.~Nepal and Sri Lanka: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 9 months."
89143758|NCT02718222|Experimental|9-15 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 9 months.~Nepal and Sri Lanka: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 15 months."
89143759|NCT02782910|Experimental|SBAA+|Upon exceeding pre defined SBAA-threshold limits during the randomisation phase the treating physician is alerted (+) to this signal and required to contact the patient so as to assess the current mental status and collaboratively discuss the potential need for medical/psychiatric treatment with the patient.
89143760|NCT02782910|No Intervention|SBAA|Continuous monitoring will occur analogous to SBAA+. Exceeding the pre defined SBAA-threshold will not result in any action taken.
89143761|NCT02689856|Placebo Comparator|Vehicle cream|Placebo control base cream
89143762|NCT02689856|Experimental|3% hydrocortisone|3% Hydrocortisone acetate cream
89143763|NCT02689856|Experimental|0.5% hydrocortisone|0.5% Hydrocortisone acetate cream
89143764|NCT02689856|Experimental|5% lidocaine|5% Lidocaine hydrochloride cream
89143765|NCT02689856|Experimental|1% lidocaine|1% Lidocaine hydrochloride cream
89143766|NCT02689856|Experimental|3% Hydro 5% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 3% and 5% cream
89143767|NCT02689856|Experimental|0.5% Hydro 1% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 0.5% and 1% cream
89143768|NCT02718144|Experimental|estetrol|3 + 3 design with inter-patient dose escalation
89143769|NCT02722902|Experimental|LIPID + Carnitor|"intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion~L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
89143770|NCT02722902|Placebo Comparator|LIPID + PLAC|"Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline)~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
89143771|NCT02722902|Placebo Comparator|PLAC|"Infusion of saline (no IntraLipid and no carnitor)~Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h."
89143772|NCT02722824|Placebo Comparator|Placebo|Wearable stimulators will be placed on the patients and controls without stimulation for 20 minutes
89143773|NCT02722824|Experimental|Active Stimulation|Instrinsic auricular muscles will be stimulated for 20 minutes
89143774|NCT02722824|Sham Comparator|Sham|An area out of the instrinsic auricular muscles region will be stimulated with the same parameters of the active group for 20 minutes
89143775|NCT02722824|No Intervention|Passive Control|Only the electrodes of the wearable stimulators will be inserted but there will not be electrostimulation for 20 minutes
89143776|NCT02784782|Experimental|Orthesis|Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol Intervention: After fitting the patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes.
89143777|NCT02784782|Active Comparator|No Orthesis|"Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol.~Control: The patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes."
89143778|NCT02722746|Placebo Comparator|Ropivacaine only Control group|The participants in this group will receive standard anesthesia, epidural analgesia with 0.2% ropivacaine with no epinephrine added during the procedure.
89143779|NCT02722746|Active Comparator|Ropivacaine + 2 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 2mcg/mL of epinephrine during the procedure.
89143780|NCT02722746|Active Comparator|Ropivacaine + 5 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 5mcg/mL of epinephrine during the procedure.
89143781|NCT02784626|Experimental|Dexmedetomidine|Patients who received dexmedetomidine during the operation
89143782|NCT02784626|Experimental|Propofol|Patients who received propofol during the operation
89143783|NCT02717988|Experimental|SKI-O-703 50 mg|SKI-O-703 capsule (2x25 mg)
89143784|NCT02717988|Experimental|SKI-O-703 100 mg|SKI-O-703 capsule (4x25 mg)
89143785|NCT02717988|Experimental|SKI-O-703 200 mg|SKI-O-703 capsule (1x200 mg)
89143786|NCT02717988|Experimental|SKI-O-703 400 mg|SKI-O-703 capsule (2x200 mg)
89143787|NCT02717988|Experimental|SKI-O-703 600 mg|SKI-O-703 capsule (3x200 mg)
89143788|NCT02717988|Experimental|SKI-O-703 800 mg|SKI-O-703 capsule (4x200 mg)
89143789|NCT02717988|Placebo Comparator|Placebo|Placebo capsule
89143790|NCT02782754|Experimental|Intracranial germinoma|"Four cycles of chemotherapy with carboplatin, etoposide, (+ bleomycin) and cyclophosphamide, etoposide, (+ bleomycin) regimen~Reduced dose of radiotherapy~Without seeding: 18 Gy to ventricle + 12.6 Gy to primary site~With seeding: craniospinal irradiation 18 Gy + 12.6 Gy to primary site"
89143791|NCT04799340|Experimental|holistic face training + repetition lag training|
89143792|NCT04799340|No Intervention|waitlist control|
89143793|NCT02717910|Experimental|Health game group|Participants in this arm will receive the health game intervention including both 20 minutes guided training session at school and 2 weeks free usage of the health game during free time.
89143794|NCT02717910|Sham Comparator|Web page group|Participants in this arm will receive the web page intervention including both 20 minutes guided training session at school and 2 weeks free usage of the web page during free time.
89143795|NCT02717910|No Intervention|Group with no intervention|The participants in this arm will receive no intervention.
89143796|NCT02694354|Experimental|BI 685509|
89143797|NCT02694354|Placebo Comparator|Placebo|matching placebo
89143798|NCT05341076|Experimental|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
89143799|NCT05341076|Active Comparator|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
89143800|NCT02722512|Experimental|Newly Diagnosed High Grade Glioma (HGG)|Heat Shock Protein Peptide Complex-96 (HSPPC-96) therapy will be given between 0-28 days after the completion of radiation therapy (XRT) AND no more than 60 days from completion of XRT. Vaccine will be given once weekly for 4 weeks. The 4 weeks (28 days) of vaccine administration will be followed by an observation visit. In patients with sufficient vaccine (on both Arms A and B), a maintenance therapy will be instituted. It will be administered at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be administered 7 days after completion of the observation visit.
89143801|NCT02722512|Experimental|Recurrent HGG and Ependymoma|On Arm B, Heat Shock Protein Peptide Complex-96 (HSPPC-96) will be given as soon as possible after tumor resection post-operative recovery and sufficient time for vaccine preparation (typically 0-28 days post-operatively) AND no more than 60 days post-operatively. Vaccine will be given once weekly for 4 weeks. These 4 weeks (28 days) of vaccines will be followed by an observation visit. In patients with sufficient vaccine, a maintenance therapy will be given. It will be given at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be given 7 days after completion of the observation visit.
89143802|NCT05133518|Active Comparator|MELT-300|Participants will receive a single dose of MELT-300 sublingual, rapidly dissolving tablet containing 3 mg of midazolam and 50 mg of ketamine.
89143803|NCT05133518|Active Comparator|Midazolam alone|Participants will receive a single dose of midazolam 3 mg sublingual tablet.
89143804|NCT05133518|Active Comparator|Ketamine alone|Participants will receive a single dose of ketamine 50 mg sublingual tablet.
89143805|NCT05133518|Placebo Comparator|Placebo|Participants will receive a single dose of a matching placebo sublingual tablet.
89143806|NCT02714712||HCV group (Peginterferon alfa-2a)|A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
89143807|NCT02714712||Control Group|There were 153 healthy controls negative for anti-HCV enrolled simultaneously from the database of Health Management Center.
89143808|NCT02722590||All Participants|Participants who are prescribed Fycompa (Perampanel) film-coated tablets and oral suspension per approved prescribing information in a normal clinical practice setting will be enrolled and observed prospectively for up to 24 Weeks.
89143809|NCT02784470|Experimental|gastrojejunostomy arm|
89143810|NCT02784470|Active Comparator|gastroduodenal stent placement|
89143811|NCT02717676|Experimental|Group A|Episiotomy
89143812|NCT02717676|No Intervention|Group B|no episiotomy
89143813|NCT02782520|Active Comparator|Ringer Lactate|Ringer Lactate group
89143814|NCT02782520|Experimental|Hypertonic saline|Hypertonic saline group
89143815|NCT02714166|Experimental|Sunscreen lotion Sun Protection Factor 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
89143816|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
89143817|NCT04094064|Experimental|CGM Use while on Hemodialysis Therapy|All subjects will use a CGM for 10 days. Subjects will continue their standard of care hemodialysis treatments during the study period.
89143818|NCT03251144|Experimental|Switch to E/C/FTC/TAF daily|"Intervention: Participants will be asked to switch antiretrovirals (ART) for a period up to 12 months and mitochondrial physiology will be assessed using a variety of assays. The new ART will be~If the participant is on an ART other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to E/C/FTC/ tenofovir alafenamide (TAF) 1 tablet once daily for a period of 12 months.~If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
89143819|NCT02717520|Experimental|All study participants|One permanent molar with an approximal and occlusal carious lesion restored with EQUIA Forte, and one permanent molar with an approximal and occlusal carious lesion restored with Tetric EvoCeram
89143820|NCT04231682|Experimental|Denosumab receiving group.|Patients in this arm will receive denosumab injection 60 mg subcutaneously every 6 months. (A total of 4 injections)
89143821|NCT04231682|Placebo Comparator|Placebo receiving group.|Patients in this arm will receive Placebo injection subcutaneously every 6 months. (A total of 4 injections)
89143822|NCT05224674|Active Comparator|Large-Focused Extracorporeal Shock Wave Therapy|
89143823|NCT05224674|Active Comparator|Controlled-Unfocused Extracorporeal Shock Wave Therapy|
89143824|NCT05224674|Sham Comparator|Sham Extracorporeal Shock Wave Therapy|
89143825|NCT05340842|Experimental|Simulation training experiment group|"In this training, the researcher firstly explained breastfeeding by wearing the Lactation Simulation Model on himself and showing it practically on himself.~Afterwards, the model was dressed on the pregnant woman and the pregnant woman was given one-on-one breastfeeding practice.~In this process, all questions of the pregnant woman were answered by the researcher."
89143826|NCT05340842|No Intervention|Control group|At this stage, the standard video screening prepared for breastfeeding education within the scope of the hospital protocol was shown to the pregnant woman by the researcher with a tablet.
89143827|NCT02722356|Experimental|Oxytocin|Oxytocin administered according to proposed protocol
89143828|NCT02722356|Active Comparator|Standard Practice|Oxytocin administered according to standard practice at facility
89143829|NCT00753675|Experimental|A|Vandetanib 300 mg as a once daily oral dose, from Day 1
89234830|NCT05888818|Experimental|cold application group|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
89143830|NCT00753675|Experimental|B|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)
89143831|NCT00753675|Placebo Comparator|C|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).
89143832|NCT04229186|Experimental|Patients with assumption of EVOO-C|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg EVOO-C
89143833|NCT04229186|Experimental|Patients with assumption of ROO|12 patients with Mild Cognitive Impairment or Mild Alzheimer's Disease will receive 10 mg ROO
89143834|NCT05131178|Placebo Comparator|Saline|ON-Q Pump® with continuous infusion of saline (270 mL of normal saline)
89143835|NCT05131178|Experimental|Bupivacaine|ON-Q Pump® with continuous infusion of bupivacaine (270 ml of 0.5 % bupivacaine)
89143836|NCT04094649|Sham Comparator|Sham vs Active Stimulation Positions|Adults with Diabetes Mellitus Type 2 (DMT2) will be recruited and randomized to active uVNS or sham across two sessions according to a 2x2 crossover design. Sham uVNS will be delivered with the same stimulation parameters as active uVNS, but will be targeted to the left sternocleidomastoid muscle ~2 cm away from the vagus nerve.
89143837|NCT04094649|Active Comparator|Active uVNS|Active stimulations will be targeted with the ultrasound beam of the DECIMA device .Active uVNS will be delivered to the left cervical vagus nerve following the OGTT through the 60-min time point.
89143838|NCT04197284|Active Comparator|Control group|In control group subjects will undergo individual kinesitherapy- isometric exercise for strengthening of the quadriceps muscle.
89143839|NCT04197284|Active Comparator|Biofeedback group|Biofeedback group will perform physical therapy using biofeedback device for better activation control of the quadriceps muscle with audio and visual signal. They will also perform isometric exercise.
89143840|NCT04197284|Active Comparator|Electrical stimulation|Electrical stimulation group will receive electrical stimulation of the quadriceps muscle and they will also perform isometric exercise.
89143841|NCT02546934|Experimental|ABX, cisplatin|AP (ABX and cisplatin combination)
89143842|NCT02546934|Active Comparator|Gemcitabine, Cisplatin|GP (Gemcitabine and Cisplatin combination)
89143843|NCT05123066|Experimental|Aquatic group|group I
89143844|NCT05123066|Experimental|Land Exersises group|group II
89143845|NCT02717598|Experimental|CSP|Cold snare polypectomy is an easy-to-apply technique and has been the most popular technique esprcially for small and diminutive polyps. Briefly, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp, until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
89143846|NCT02717598|Experimental|HSP|Hot snare polypectomy, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp,then use Electrocoagulation until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
89143847|NCT00586521|Experimental|rFVIII-FS (octocog-alfa), (Kogenate FS)|On-demand treatment was to follow the same treatment pattern the subject was using before entering the study. While on prophylactic treatment, all subjects were to be treated at a dose of 20-40 IU/kg, 3 times per week at a stable dose.
89143848|NCT02782286|Active Comparator|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
89143849|NCT02782286|Active Comparator|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
89143850|NCT04094493|Experimental|A1|vit D + no hypocalcemia
89143851|NCT04094493|Experimental|A2|Vit D + hypocalcemia
89143852|NCT04094493|No Intervention|B1|NO vit D + no hypocalcemia
89143853|NCT04094493|No Intervention|B2|NO vit D + hypocalcemia
89143854|NCT02694042|Experimental|Mission is Remission® Group|Participants in this group will be given access to the Mission is Remission® web-based teaching and support site. They will also be emailed a link to complete online questionnaires at set time points throughout the study.
89143855|NCT02694042|No Intervention|Control Group|Participants in this group will continue to receive standard care without access to the Mission is Remission® website. They will also be emailed a link to complete online questionnaires. At the end of the 6 month study period, participants in this group will be given access to the study website.
89143856|NCT02780960|Experimental|HPV self-testing|Patients will perform HPV self-testing at home, prior to their follow-up visit. At the colposcopy visit, the doctor or nurse will also perform HPV testing. This procedure will be repeated at 6 and 12 months following LEEP.
89143857|NCT02600247|Experimental|Duloxetine group|"Experimental: Duloxetine group~Phase I (preemptive): 1day before operation (30mg for 1 day)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon"
89143858|NCT02600247|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
89143859|NCT04229108|Other|Healthy volunteer|Will record traditional timed up and go followed by two digitised versions
89143860|NCT02694120||colonoscopy population|
89143861|NCT05453253|Experimental|interventional 6 months interval between OCV doses|This intervention arm will modify the recommended interval for administration of the second Euvichol-Plus®, which will be extended to 6 months.
89143862|NCT05453253|Experimental|interventional 12 months interval between OCV doses|This intervention arm will modify the recommended interval for administration of the second Euvichol-Plus®, which will be extended to 12 months.
89143863|NCT05453253|Active Comparator|control arm (standard 14-day interval)|Participants will receive the oral cholera vaccine, Euvichol-Plus®, according to the manufacturer instructions: 2 doses two weeks apart.
89143864|NCT04229498||Carbapenem resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
89143865|NCT04229498||Carbapenem hetero-resistant Klebsiella pneumoniae group|Participants having bloodstream infection caused by carbapenem-heteroresistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
89143866|NCT04005066||Cohort 1|"Currently using Elunate® or will use Elunate®(Fruquintinib) within a week;~Provision of informed consent by the patient."
89143867|NCT04229342|Active Comparator|Conventional|"In the conventional group, standard posterior myotomy will be performed and the sling or the oblique fibers will not be spared beyond the gastroesophageal junction."
89143868|NCT04229342|Experimental|Oblique or sling fiber sparing group|In the oblique or sling fiber group, only the circular muscle fibers will be severed selectively and the sling fibers will be spared
89143869|NCT02717052|Experimental|(S)-ketamine|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)~all patients and 10 HC (randomized, double blind)~Interventions:~Drug: (S)-ketamine (Main study) Other: Main study: PET1 Other: Main study: PET2"
89143870|NCT02717052|Placebo Comparator|Placebo|"0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)~10 HC (randomized, double blind)~Interventions:~Drug: Placebo Other: Main study: PET1 Other: Main study: PET2"
89143871|NCT02717052|Experimental|(S)-ketamine (Pilot Study II, 5 subj.)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight applied over the course of 130 minutes.~Pilot-study II is cross-over design!~Interventions:~Drug: (S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
89143872|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study II, 5 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied over the course of 130 minutes.~Pilot-study II is cross-over design!~Interventions:~Drug: (R,S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
89143873|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study I, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 5 minutes before PET measurement)~Interventions:~Drug: (R,S)-ketamine (Pilot I) Other: PILOT Study I: PET1 Other: PILOT Study I: PET2"
89143874|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study III, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50 Minutes~Interventions:~Drug: (R,S)-ketamine (Pilot III) Other: PILOT Study III: PET1 Other: PILOT Study III: PET2"
89143875|NCT04020861|Active Comparator|PBM + TENS|The patients will be submitted to the active PBM and active TENS
89143876|NCT04020861|Active Comparator|PBM|The patients will be submitted to the active PBMT and placebo TENS
89143877|NCT04020861|Active Comparator|TENS|The patients will be submitted to the placebo PBMT and active TENS
89143878|NCT04020861|Placebo Comparator|Placebo|The patients will be submitted to the placebo PBMT and placebo TENS.
89143879|NCT05342558|Active Comparator|Biomass Smoke COPD|"Fluticasone Furoate/Vilanterol 100/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks.~Umeclidinium/Vilanterol 62.5/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks."
89143880|NCT05342558|Active Comparator|Tobacco Smoke COPD|"Fluticasone Furoate/Vilanterol 100/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks.~Umeclidinium/Vilanterol 62.5/25 mcgs. Dry powder inhaler with 30 blisters. 1 inhalation a day for 24 weeks."
89143881|NCT00923273|Experimental|Treatment level 1 - 3mg load|Sirolimus 3mg load/1mg/day; Pemetrexed 375mg/m^2
89143882|NCT00923273|Experimental|Treatment level 2 - 6 mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
89143883|NCT00923273|Experimental|Treatment level 3 - 6mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
89143884|NCT00923273|Experimental|Treatment level 4 - 10 mg load|Sirolimus 10mg load/3mg/day; Pemetrexed 500mg/m^2
89143885|NCT00923273|Experimental|Treatment level 5 - 15 mg load|Sirolimus 15mg load/5mg/day; Pemetrexed 500mg/m^2
89143886|NCT02714478|Experimental|treatment|"3 Equistasi devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
89143887|NCT02714478|Placebo Comparator|controls|"3 placebo devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
89143888|NCT04019925|Other|ADM/MDM hip prosthesis|Type of prosthesis participant received.
89143889|NCT04231370|Experimental|treatment arm|Sintilimab, 200mg, iv day1 Lenalidomide, 25mg/d, oral, day 1-14 repeated every 3 weeks
89143890|NCT02717286|Sham Comparator|Control|"20 first permanent molars from children aged between 6 to 12 years old presenting MIH will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the European Academy of Pediatric Dentistry (EADP) criteria.~Intervention of Control: The restorative treatment using a total-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
89234831|NCT05888818|No Intervention|standard treatment|No application will be made and the presence of nausea, severity, vomiting and vital signs will be measured after 5 minutes.
89234832|NCT05888766||Episodic migraine patients|20 patients with episodic migraine (<15 attacks/month) will be recruited from a specialized headache Clinic (headache clinic of the Sapienza University of Rome, Latina).
89234833|NCT05888740|Experimental|TUS Therapy|These subjects will undergo treatments with the Vibrato Sleeve TUS device.
89290609|NCT01329276|Placebo Comparator|Placebo (lactose)|
89290610|NCT01224366|Experimental|Vildagliptin|
89143891|NCT02717286|Experimental|Test|"20 first permanent molars from children aged between 6 to 12 years old presenting Molar Incisor Hypomineralization will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the EAPD criteria.~Intervention of test: the restorative treatment using a self-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), air jet (5 s), adhesive application (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
89143892|NCT04094025|Experimental|dATS patch|dATS, placebo and saline will be administered simultaneously
89143893|NCT04231292|Experimental|Experimental Group A +Group a|Group A: 0.8μg/kg RD01, once every two weeks, Day 1~ 18th week;Group a: refers to the weekly dose at the end of the first stage , once every two weeks, 19th~46th week
89143894|NCT04231292|Experimental|Experimental Group B +Group b|Group B: 1.2μg/kg RD01, once every two weeks, Day 1~ 18th week; Group b: refers to the weekly dose at the end of the first stage , once every four weeks, 19th~46th week
89143895|NCT04231292|Experimental|Experimental Group C +Group c|Group C: 1.6μg/kg RD01, once every two weeks, Day 1~ 18th week; Group c: refers to the weekly dose at the end of the first stage , once every six weeks, 19th~46th week
89143896|NCT04231292|Experimental|Experimental Group D +Group d|Group D: 0.8μg/kg RD01, once every two weeks, Day 1~ 18th week; Group d: refers to the weekly dose at the end of the first stage , once every four weeks, 19th~46th week
89143897|NCT04231292|Active Comparator|Experimental Group E +Group e|Group E: 150IU/kg rHuEPO, once a weeks, subcutaneous administration, Day 1~ 18th week; Group e: refers to the weekly dose at the end of the first stage , once a weeks, intravenous administration, 19th~46th week
89143898|NCT04231292|Placebo Comparator|Experimental Group F +Group f|Group F: 8μl placebo, once every two weeks, for 6 weeks; 150 IU/kg rHuEPO, once week, subcutaneous injection, 7th ~ 18th week; Group f: refers to the weekly dose at the end of the first stage , once a weeks, subcutaneous administration, 19th~46th week
89143899|NCT04231292|Experimental|Experimental Group G|Group G: 1.6μg/kg RD01, once every four weeks, Day 1~ 28th week;
89143900|NCT02717208|Active Comparator|HL036 0.5mg/ml|Administration : 2 times per day for one day
89143901|NCT02717208|Active Comparator|HL036 5mg/ml|Administration : 2 times per day for one day
89143902|NCT02600169||Patients treated with pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. Patients will be included from all 14 WIN-O (Werkgroep Immunologie Nederland voor Oncologie) centers in the Netherlands. Patients are at least 18 years of age.
89143903|NCT04231136|Experimental|Tegoprazan 50 mg|Oral administration of Tegoprazan 50 mg tablet once a day
89143904|NCT04231136|Active Comparator|EAPA115|Oral administration of EAPA115 once a day
89143905|NCT04231136|Active Comparator|RAPA115|Oral administration of RAPA115 once a day
89143906|NCT02722122|Experimental|AIR DNase™ 2.5 mg|2.5 mg of AIR DNase™ administered once daily via inhalation for 28 days
89143907|NCT02786108|Experimental|left gastric artery embolization|Patients undergoing left gastric artery embolization
89143908|NCT02786108|Active Comparator|healthy diet and exercise|Patients undergoing healthy diet and exercise
89143909|NCT03981393||'Less severe hypoxaemia'|PaO2/FiO2 ratio > 68 mmHg (9.1kPa) at decision-to-cannulate
89143910|NCT03981393||'Very severe hypoxaemia'|PaO2/FiO2 ratio ≤ 68 mmHg (9.1kPa) at decision-to-cannulate
89143911|NCT05205408|Experimental|Oncolytic Virus Injection(RT-01)|Intratumoral administration of RT-01 as single agent for patients with advanced solid tumors. Dose cohorts: 1×10^8 TCID50/mL and 7×10^8 TCID50/ mL
89143912|NCT05340530|Experimental|The injectable TQD3606|received a single dose of 0.75g TQD3606 for injection
89143913|NCT05340530|Active Comparator|The injectable TQD3606+ meropenem|First, a single dose of 0.5g of meropenem for injection was administered for 0.5h intravenous infusion; after washout for at least 2 days, 0.75g of TQD3606 for injection was administered for 1h intravenous infusion; for at least 2 days of washout, 0.75g was administered A single dose of TQD3606 for injection was administered for 2 hours, and the elution time was at least 2 days. Finally, a single dose of 0.75 g of TQD3606 for injection was administered, and the duration of intravenous infusion was 3 hours.
89143914|NCT05340530|Active Comparator|The injectable TQD3606+ meropenem+ Avibactam Sodium|According to the random table, they were divided into two groups, A and B, Group A was given 1.0g meropenem for injection (Mepin) in the first cycle, and 0.5g avibactam sodium for injection in the second cycle. The third cycle was given 1.5g TQD3606 for injection; group B was given 0.5g avibactam sodium for injection in the first cycle, 1.0g meropenem (Mepin) for injection in the second cycle, and 1.5g for injection in the third cycle TQD3606.
89143915|NCT05340530|Experimental|The injectable TQD3606-1|First, 0.75g TQD3606 for injection was administered multiple times (Dosing every 8 hours, 3 consecutive doses), and at least 2 days were washed out after the last dose; then 1.125g TQD3606 for injection was administered multiple times (Dosing every 12 hours, 2 consecutive doses) times), wash out at least 2 days after the last administration; finally, a single administration of 2.25 g of TQD3606 for injection (Dosing every 12 hours, once administered). Intravenous infusion for 3 hours.
89143916|NCT05340530|Placebo Comparator|The injectable TQD3606/ Placebo|First, a single dose of 3.0g TQD3606 for injection/placebo was administered, intravenous infusion for 3hours, and washout for at least 3 days; then multiple doses of 3.0g TQD3606 for injection/placebo were administered (Dosing every 8 hours, 10 consecutive doses) , the intravenous infusion duration is 3hours.
89143917|NCT02600091|Experimental|MBCT Intervention|Participants in the Mindfulness-based Cognitive Therapy Intervention arm will receive an 8-week programme in mindfulness-based cognitive therapy
89143918|NCT02600091|No Intervention|Waiting List Control|The participants who are allocated to the waiting list control group will receive usual care. They will receive the MBCT intervention 3 months after the intervention group complete their MBCT programme.
89143919|NCT02714088|Experimental|Intervention|Participants will undertake a high-intensity interval training intervention, completing two exercise sessions per week for 12 weeks. The exercise sessions will consist of 4 sets of 4-6 repetitions of 60s (45s high-intensity exercise, followed by 15s rest), interspersed with 3 minutes rest. During each exercise repetition participants will be encouraged to reach >90% of their maximal heart rate.
89143920|NCT02714088|No Intervention|Control|Participants will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
89143921|NCT00634712|Active Comparator|1|
89143922|NCT00634712|Placebo Comparator|2|
89143923|NCT00636714|Experimental|Nurse-directed|Using nursing judgement to control blood glucose
89143924|NCT00636714|Active Comparator|Nomogram-directed|Blood glucose control directed by pre-approved paper nomogram
89143925|NCT00923195|Experimental|TBI 600cGy + PBL + HD IL-2+gp100:154-162|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
89143926|NCT00923195|Experimental|TBI 600cGy+PBL+HD IL-2+MART-1:26-35(27L)|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
89143927|NCT04093791|Experimental|"Collective Intervention G"|"HAPPY MAMA intervention will follow the following steps: listening and establishing relationship phases; analysis of the problems; definition of the problem and the goal of intervention.~The duration will be of 3.5 hours in one day and the intervention will happen in Sapienza University of Rome, in a group of 15 women.~This group fill in an on line questtionarie for four times, the first before the intervention."
89143928|NCT04093791|Experimental|"Individual Intervention I"|"The same intervention of G group (HAPPY MAMA), but at individual level and the intervention will happen at the participants' house.~This group fill in an on line questtionarie for four times, the first before the intervention."
89143929|NCT04093791|No Intervention|"Control group C"|The women from this group will not receive any intervention. This group fill in an on-line questtionarie for four times.
89143930|NCT05117996|Active Comparator|Standard small bowel preparation|2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
89143931|NCT05117996|Experimental|Simplified small bowel preparation|Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
89143932|NCT02713932||Transcatheter aortic valve implantation|
89143933|NCT02784236|Other|pre-post evaluation|All patients undergo the condition of telemedicine.
89143934|NCT00753519|Experimental|Real iTBS|iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes that standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals. The 2 sec trains were repeated 20 times every 10 sec. iTBS was applied to the primary motor and the dorsolateral prefrontal cortex bilaterally.
89143935|NCT00753519|Sham Comparator|Sham iTBS|The sham coil was placed in the same areas, and made a similar sound as the rTMS but was without a magnetic pulse.
89143936|NCT04256057|Other|magnesium sulphate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
89143937|NCT02721810|No Intervention|Control|Prompts standard to rounds or electronic medical records.
89143938|NCT02721810|Experimental|Prompting Intervention|Prompting consideration of 3-month functional outcome.
89143939|NCT02598765|Active Comparator|Standard Trabeculectomy|Patients in the Standard Trabeculectomy arm will undergo regular trabeculectomy
89143940|NCT02598765|Experimental|Microtrabeculectomy|Patients in the Microtrabeculectomy arm will undergo microtrabeculectomy
89143941|NCT04189302|Experimental|palatal connective tissue graft harvest with KPM blade|palatal connective tissue graft is harvested using single incision technique using KPM blade
89143942|NCT04189302|Active Comparator|palatal connective tissue graft harvest with 15C blade|palatal connective tissue graft is harvested using single incision technique using 15 C blade
89143943|NCT02780726|Experimental|ASP1517 Low Dose Group (ESA Untreated)|This group includes subjects who have not received Erythropoieses Stimulating Agents (ESAs). Study drug will be dosed three times weekly and dose adjustments will be made during the study.
89143944|NCT02780726|Experimental|ASP1517 High Dose Group (ESA Untreated)|This group includes subjects who have not received ESAs. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
89143945|NCT02780726|Experimental|ASP1517 ESAs Treated Group|This group includes subjects who have received ESAs. The treatment was converted from ESAs to study drug. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
89143946|NCT02598921|Other|Three dimensional ultrasound|Three dimensional ultrasound evaluated the uterine cavity for cavitary lesions
89143947|NCT02598921|Other|Office hysteroscopy|Office hystrescopy evaluated the uterine cavity for cavitary lesions
89143948|NCT02714010|Experimental|Arm 1|Patients take EGFR-TKI alone till tumor progression
89143949|NCT02714010|Active Comparator|Arm 2|Patients take EGFR-TKI concurrent with whole brain radiotherapy (WBRT) till tumor progression, WBRT started within the first week of taking TKI
89143950|NCT05340140||CBCT Images of Maxillary 1st molars|
89143951|NCT00917241|Experimental|MMI+IID group|MMI,methimazole；IID,intrathyroid injection of dexamethasone
89143952|NCT00917241|Active Comparator|MMI Group|MMI,methimazole
89143953|NCT00919061|Experimental|Gemcitabine and Cisplatin plus Sorafenib|This is a non-randomized, open label, single institution, phase II study of gemcitabine and cisplatin plus sorafenib for the treatment of patients with advanced or biliary tract carcinomas naïve to systemic therapy.
89143954|NCT02716662|Experimental|Open Label|Axona
89290611|NCT01224366|Placebo Comparator|Placebo|
89143955|NCT02598687|Other|treatment|treatment arm: TH-302 pre-treatment day 4 and weekly during treatment. 5 x carboplatin and paclitaxel, radiotherapy: 23 x 1.8Gy HX4 scans day 1 and day 8,surgery 6-10 weeks after chemo-radiotherapy
89143956|NCT04880447||COMIRNATY|COVID-19 mRNA vaccine
89143957|NCT04229810|Active Comparator|STD-02|Conventional standardized lung protective ventilation.
89143958|NCT04229810|Experimental|iOLA-iHFNC|Individualized ventilatory strategy that mantains an open lung condition.
89143959|NCT04090281|Other|Precision medicine implementation|Patients will receive a precision medicine approach, incorporating both CYP2C19 genotyping and platelet reactivity phenotyping, to guide dual antiplatelet therapy selection for patients with ACS, post PCI and followed over a 12 month period.
89143960|NCT02713620|Placebo Comparator|Healthy|"the Healthy group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
89143961|NCT02713620|Active Comparator|HIV-Group1|"the Standard doses group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
89143962|NCT02713620|Active Comparator|HIV-Group 2|"the Four doses group receiving four intramuscular doses of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
89143963|NCT02713620|Active Comparator|HIV-Group 3|"the Four double doses group receiving four intramuscular double doses (40 μg) of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
89143964|NCT02598609|Other|Cluster A|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster A. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 4 months. The intervention is implemented during 4 months. The length of the post interventional period is 12 months.
89143965|NCT02598609|Other|Cluster B|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster B. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 8 months. The intervention is implemented during 4 months. The length of the post interventional period is 8 months.
89143966|NCT02598609|Other|Cluster C|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster C. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 12 months. The intervention is implemented during 4 months. The length of the post interventional period is 4 months.
89143967|NCT04908605|Active Comparator|Mirtazapine group (Group I) (n=55)|
89143968|NCT04908605|Active Comparator|Melatonin group (Group II) (n=55)|
89143969|NCT04908605|Placebo Comparator|Placebo group (Group III) (n=55)|
89143970|NCT04229732|Experimental|ClearMate Intervention|Participants undergo passive isocapnic hyperventilation via the ClearMateTM device and have regular venous blood samples obtained to measure ethanol clearance kinetics.
89143971|NCT04229732|No Intervention|Supportive Management|Participants receive standard of care, supportive management, for alcohol intoxication, having regular venous blood samples obtained to measure ethanol clearance kinetics.
89143972|NCT02716740|Experimental|Leucine-enriched amino acid : 2.16g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
89143973|NCT02716740|Experimental|Leucine-enriched amino acid : 4g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).
89143974|NCT05330117|Experimental|Active TENS|In the active treatment group, the TENS unit will remain on up to 30 minutes (10 minutes pre-procedure, during the procedure and during the questionnaires).
89143975|NCT05330117|Sham Comparator|Control TENS|The sham stimulation group will undergo the same procedure; however, the TENS stimulation current will be reduced to a minimal detectable level and turned off after 20 seconds.
89143976|NCT02782208|Active Comparator|Acipimox/GH substitution|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Continue GH substitution as usually.
89143977|NCT02782208|Active Comparator|Acipimox/GH pause|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Pause GH substitution to days prior to the study day.
89143978|NCT02782208|Placebo Comparator|Placebo/GH substitution|Drug: Placebo tablets Continue GH substitution as usually.
89143979|NCT02782208|Placebo Comparator|Placebo/GH pause|Drug: Placebo tablets Pause GH substitution to days prior to the study day.
89143980|NCT02598453|Experimental|Ibandronate IV|Participants will receive ibandronate 3 mg IV once every 3 months
89143981|NCT02598453|Experimental|Ibandronate Oral|Participants will receive ibandronate 150 milligrams (mg) tablet once monthly
89143982|NCT00611286|Experimental|1|treatment with Aspirin and clopidogrel for 24 months after coronary intervention with stents. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent.
89143983|NCT00611286|Active Comparator|2|Treatment with aspirin and clopidogrel for minimum 1 or 6 month(s) after BMS or DES implantation, respectively. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent
89143984|NCT04257851|Active Comparator|Group T (n=30)|Theophylline group
89143985|NCT04257851|Active Comparator|Group S (n=30)|Sumatriptan group
88803652|NCT04199572|Experimental|Diclofenac and Oral Paracetamol|Diclofenac (75mg intramuscular), Placebo (100ml intravenous Normal Saline), Paracetamol (per oral 1gm)
89143986|NCT05342246|Experimental|conservative treatment|The patent canal is retreated, no attempt to deal with the separated instrument
89143987|NCT05342246|Active Comparator|traditional|All canals are retreated with attempts to retrieve the broken file
89143988|NCT04255979|Experimental|Cohort 1|Single dose of HY209 0.1 mg/kg or placebo.
89143989|NCT04255979|Experimental|Cohort 2|Single dose of HY209 0.2 mg/kg or placebo.
89143990|NCT04255979|Experimental|Cohort 3|Single dose of HY209 0.4 mg/kg or placebo.
89143991|NCT04255979|Experimental|Cohort 4|Single dose of HY209 0.8 mg/kg or placebo.
89143992|NCT04255979|Experimental|Cohort 5|Single dose of HY209 1.6 mg/kg or placebo.
89143993|NCT04255979|Experimental|Cohort 6|Single dose of HY209 3.2 mg/kg or placebo.
89143994|NCT00611364|Experimental|Study group|
89143995|NCT00611364|Active Comparator|Control group|
89143996|NCT02780102|Experimental|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR): 20 sixty-minute sessions of cognitive-motor rehabilitation
89143997|NCT02780102|Experimental|Ritalin|2 to 3 doses of 10 mg Ritalin tablets per day during 8 week.
89143998|NCT02780102|Active Comparator|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
89143999|NCT00747435|Experimental|Original Audiological Criteria|"Inclusion Criteria:~Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition."
89144000|NCT00747435|Experimental|Expanded Audiological Criteria|"Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition.~Study Arm 2 candidates are those who meet the inclusion criteria listed above with the exception that:~In the ear to be implanted, the pure-tone air conduction threshold(s) at 250, 500, and/or 750 Hz will be greater than or equal to 0 dB HL and less than 10 dB HL, and/or In the ear to be implanted, the pure-tone air conduction threshold(s) at 1000 and/or 1500 Hz will be greater than or equal to 0 dB HL and less than 60 dB HL and/or In their best-aided condition, they score 51-60% on monosyllabic word scores."
89144001|NCT04252781|Other|Exhaustive exploration|Exhaustive exploration of newly diagnosed COPD patients (pulmonary pathology and associated comorbidities)
89144002|NCT04197128|Active Comparator|Resorbable collagen membrane and bone graft|Subjects will receive bovine derived bone graft and resorbable collagen membrane for augmentation.
89144003|NCT04197128|Experimental|Ribose cross-linked collagen matrix|Subjects will receive ribose cross linked collagen matrix for augmentation
89144004|NCT02693886||A group|Experience of endoscopist: >2000 cases
89144005|NCT02693886||B group|Experience of endoscopist:between 1000 and 2000 cases
89144006|NCT02693886||C group|Experience of endoscopist:between 500 and 1000 cases
89144007|NCT02693886||D group|Experience of endoscopist:<500 cases
89144008|NCT02693964||Postmenopausal women with T1D|Postmenopausal between 45-70 years of age and having T1D for at least 10 years
89144009|NCT02693964||Postmenopausal women without diabetes|Postmenopausal between 45-70 years of age without diabetes
89144010|NCT04197050|Experimental|sacubitril/valsartan group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. sacubitril/valsartan will be given.
89144011|NCT04197050|No Intervention|control group|The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. Valsartan will be given.
89144012|NCT00917319|Experimental|Infection control measure|Bundling Infection Control Interventions
89144013|NCT02712918|Experimental|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression. The study utilized the revised version of the Brief Behavioral Activation Treatment for Depression (BATD) protocol from 2011. The treatment was added to treatment as usual. Up to 10 sessions were administered.
89144014|NCT02712918|Placebo Comparator|Standard care|Standard CARE (SC) at the inpatient unit. Mandatory: Therapeutic conversations with psychiatrist, psychologist or M.D, milieu therapy. Optional: Psychosomatic physiotherapy, therapeutic groups, psychopharmacological treatment.
89144015|NCT05342168|Experimental|Histology|Specimen samples from the tradition pinch esophageal biopsy and the supernatant sample obtained from the mesh sponge (Cytosponge TM) will each be fixed and stained. The eosinophil count per high power field for the mesh sponge sample and the traditional biopsy sample will be compared for each subject.
89144016|NCT02598375||Children with feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have the feeding intolerance at least for12 hours or more.
89144017|NCT02598375||Children without feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have not the feeding intolerance signs at least for 12 hours or less
89144018|NCT03976947||Before group|"The before group is the control group. We collect retrospective data in consecutive patients operated before the implementation of lung recruitment maneuvers protocol"
89144019|NCT03976947||After group|We collect data in consecutive patients operated after the implementation of lung recruitment maneuvers protocol. This lung recruitment maneuvers will be realised along the surgery, (After tracheal intubation, per-CPB, post-CPB). Each recruitment maneuver consisted of applying a continuous positive airway pressure of 30 cm of water for 30 seconds
89144020|NCT02781974|Experimental|Intervention|Intervention consists of strength and balance exercise in group sessions, twice a week for 12 weeks
89144021|NCT02781974|No Intervention|Control|"Participants allocated in the control group are instructed to live as usual"
89144022|NCT02712840|Experimental|Freeze-All Protocol|Participants freezing all good quality embryos, with subsequent frozen embryo transfer of best quality blastocyst.
89144023|NCT02712840|Active Comparator|Fresh Protocol|Participants receiving fresh embryo transfer of best quality blastocyst and freezing of all good quality supernumerary embryos.
89144024|NCT02781896|Active Comparator|Right ventricular pacing|Rapid pacing during TAVI is provided by a temporary pacing catheter placed in the right ventricle. An additional venous vascular access is required.
89144025|NCT02781896|Experimental|Left ventricular pacing|Rapid pacing during TAVI is provided by the valve delivery guidewire inserted into the left ventricle using two alligator clamps. One clamp is attached directly to the skin at the femoral entry site, the other is attached to the body of the valve delivery guidewire. No additional venous vascular access is required.
89144026|NCT04090047|Experimental|PF-06700841 and Itraconazole|This fixed sequence, 2-period arm will consist of two treatments. Participants will receive a single oral dose of 30 milligrams (mg) PF-06700841 on Day 1 in Period 1. On Days 1-7 in Period 2, Itraconazole 200mg will be administered once daily(QD). On Day 4 of Period 2, co-administration of Itraconazole 200 mg and 30 mg PF-06700841 tablets will occur.
89144027|NCT02708550|Experimental|Participatory Organizational Intervention|Participatory intervention (workshops) with workers, consultants and leaders. The workshops will find solutions for increased use of assistive devices
89144028|NCT02708550|No Intervention|Control|This group will go through the same baseline and follow-up tests as the intervention group, but will not receive any intervention.
89144029|NCT02782052|Experimental|Nebulized ipratropium bromide|Administration in a random order nebulized ipratropium bromide at V3 or V4 or V5
89144030|NCT02782052|Experimental|Nebulized combination ipratropium bromide with salbutamol|Administration in a random order combination Ipratropium bromide and Salbutamol at V3 or V4 or V5
89144031|NCT02782052|Placebo Comparator|Placebo|Administration in a random order placebo at V3 or V4 or V5
89144032|NCT00918749|Active Comparator|150 mg|150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
89144033|NCT00918749|Experimental|75 mg|75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
89144034|NCT00918749|Experimental|100 mg|100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
89144035|NCT02708628|Active Comparator|Patients using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin two times in a day.
89144036|NCT02708628|Active Comparator|Patients not using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will not use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin.
89144037|NCT05339906|Experimental|ZOV.ai digital therapy candidate|"The arm will use a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms.~The total length of the audio stimuli is 5 minutes."
89144038|NCT02713464|Active Comparator|maternal education|Phase IIa: Pregnant women attending antenatal clinics or postpartum in clinics or hospital who receive programmed maternal education about risks and care of newborn jaundice.
89144039|NCT02713464|No Intervention|Historic control|Phase I: (before-after design) Baseline prevalence of acute bilirubin encephalopathy before maternal education instituted.
89144040|NCT02713464|No Intervention|No intervention|Phase IIb: Opportunistic controls - infants of mothers who failed to receive education about risks and care of newborn jaundice.
89144041|NCT02780570|Active Comparator|GBS patients|Small Volume Plasma Exchange
89144042|NCT02780570|No Intervention|non-GBS|non-GBS patients with central venous catheter
89144043|NCT00746733|Experimental|Vyvanse (LDX)|
89144044|NCT00746733|Experimental|Adderall XR (AXR)|
89144045|NCT02713308||Group1-CRT|Patients with RV-to-LV delay≥80ms, CRT standard programming (single-point)
89144046|NCT02713308||Group2-MPP|Patients with RV-to-LV delay<80ms, CRT programming with MPP (multi-point)
89144047|NCT05098184|Experimental|Tumor Infiltrating Lymphocytes (TIL)|1x10^9-5x10^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced melanoma after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
89144048|NCT00634790|Active Comparator|alprazolam group|
89144049|NCT04831151|Active Comparator|Drospirenone group: 0,03 mg ethinylestradiol + 3 mg drospirenone|generic name:yasmin dosage form:oral dosage: 0,03 mg ethinylestradiol + 3 mg drospirenone frequency: once a day duration: 3 months
89144050|NCT04831151|Active Comparator|cyproterone acetate group: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate|generic name:diane 35 dosage form:oral dosage: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate frequency: once a day duration: 3 months
89144051|NCT00917397|Experimental|psychotherapy|Trauma-focused cognitive behavioral therapy
89144052|NCT00917397|Experimental|Drug|drug treatment and psychoeducation
89144053|NCT00917397|No Intervention|Waiting list|subjects randomized to waiting list
89144054|NCT00917397|Experimental|Combination|Both drug and psychotherapy
89144055|NCT02708472|Experimental|Open-label|"Subjects who qualify will receive daily active synchronized Transcranial Magnetic Stimulation (sTMS) treatments. Treatment will be initiated on Day 1 of the study. Subjects will come to the clinic for 5 daily treatment sessions for a total of 4 treatment weeks (20 treatment sessions). Treatment will be discontinued at the end of Week 4. Subjects will be clinically evaluated for safety and efficacy at the end of each of the four weekly treatment courses.~At the end of Week 4, subjects who have not met the endpoint of 50% reduction in Hamilton Anxiety Rating Scale (HAM-A) score will be eligible to be considered for 2 additional weeks of daily treatment in an extended phase (for a total of 30 treatment sessions)."
89144056|NCT02708160|Placebo Comparator|Fluoride Free toothpaste|Fluoride free (0%), silica based toothpaste
89144057|NCT02708160|Experimental|1.1% Fluoride toothpaste|Prevident 5000 Plus, silica based toothpaste
89144058|NCT02708160|Active Comparator|0.243% Fluoride Toothpaste|silica based fluoride toothpaste
89144059|NCT00634868|Sham Comparator|1|The device is emitting a sham light
89144060|NCT00634868|Experimental|2|The device is emitting curative light
89144061|NCT02708082||Glaucoma|Early, moderate or advanced glaucoma, glaucoma suspects or pre-perimetric glaucoma will perform OCT scanning and HFA perimetry
89144062|NCT03974763||Test Group|Patients with acute, unilateral, facial paralysis (Bell's Palsy)
89144063|NCT03974763||Control Group|A group of age- and sex-frequency matched 'normal' controls. Based on past research, gender and age are possible confounders of facial movement/function. Thus, the control group will be frequency-matched to the patient group on gender and age.
89234834|NCT05888714|Experimental|Experimental FES cycling|New medical device combining cycle ergometer use and neuromuscular electrical stimulation (FES cycling)
89144064|NCT02782130|Active Comparator|Intervention Group|Subjects randomized to the Epic Allies Intervention will download and install the intervention branch of the Epic Allies app and receive a tour of the app guided by site staff. During the 26-week intervention phase, intervention arm subjects will receive daily adherence reminders set up through Epic Allies with tailored feedback for encouragement and reinforcement. Intervention arm subjects will have 24-hour access to all features of Epic Allies and will receive supportive messages from other subjects on the intervention arm.
89144065|NCT02782130|Placebo Comparator|Control Group|Subjects randomized to the control arm will download and install the control branch of the Epic Allies app (phone-based notifications only) and be provided with instructions on using the app. During the 26-week intervention phase, the control arm subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
89144066|NCT03929016|Experimental|Active DNDI-0690 male 10mg fasting|Single dose 10mg male fasting
89144067|NCT03929016|Placebo Comparator|Placebo male fasting|Single dose placebo male fasting
89144068|NCT03929016|Experimental|Active DNDI-0690 male 30mg fasting|Single dose 30mg male fasting
89144069|NCT03929016|Experimental|Active DNDI-0690 male 150mg fasting|Single dose 150mg male fasting
89144070|NCT03929016|Experimental|Active DNDI-0690 male 400mg fasting|Single dose 400mg male fasting
89144071|NCT03929016|Experimental|Active DNDI-0690 male 1200mg fasting|Single dose 1200mg male fasting
89144072|NCT03929016|Experimental|Active DNDI-0690 male 3600mg fasting|Single dose 3600mg male fasting
89144073|NCT03929016|Placebo Comparator|Placebo male fed|Placebo male fed
89144074|NCT03929016|Experimental|Active DNDI-0690 400mg male fed|Single dose 400mg male fed
89144075|NCT03929016|Placebo Comparator|Placebo female fasting|Placebo female fasting
89144076|NCT03929016|Experimental|Active DNDI-0690 1200mg female fasting|Single dose 1200mg female fasting
89144077|NCT04257461|No Intervention|Group1 Arm A|Observation only
89144078|NCT04257461|Other|Group 1 Arm B|Mono- or bichemotherapy: fluoropyrimidine with or without Oxaliplatin (choice by physician/patient or by randomisation)
89144079|NCT04257461|Other|Group 2 Arm C|Monochemotherapy: fluoropyrimidine
89144080|NCT04257461|Other|Group 2 ARM D|Bichemotherapy: fluoropyrimidine with oxaliplatin
89144081|NCT05328830|Experimental|Instrument assisted soft tissue mobilization group|Instrument assisted soft tissue mobilization will be applied after 30 minutes of DOMS creation
89144082|NCT05328830|Experimental|Foam roller|Foam roller will be applied after 30 minutes of DOMS creation
89144083|NCT05328830|No Intervention|control group|no intervention
89144084|NCT02712528|Active Comparator|remifentanil-based|remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60
89144085|NCT02712528|Placebo Comparator|sevoflurane-sufentanil balanced|balanced sevoflurane (end-tidal 1.2-2.8 vol%) and sufentanil (0.015 mcg/kg/min) regimen
89144086|NCT04089657|Experimental|Apatinib+Sintilimab|Apatinib 500mg qd p.o and Sintilimab 200mg intravenously on day 1 every 3 weeks until disease progression or intolerable toxicity or patients withdrawal of consent
89144087|NCT04257539|Experimental|Intervention Group|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior. This will include an initial, in-person behavioral intervention with a health coach trained and a 4 week phone call. Participants will receive a wrist-worn activity prompter to aid in sedentary behavior reduction.
89144088|NCT04257539|No Intervention|Wait-list Control Group|Chronic low back pain participants in this group will not receive the intervention until completion of the study. Over the 8 week intervention period, participants will be asked to maintain currently levels of physical activity, sedentary behaviors, and treatment for low back pain.
89144089|NCT04257539|No Intervention|Pain-free Control Group|These subjects will be healthy, pain-free adults and receive no intervention. Over the 8 week intervention period, participants in this group will be asked to maintain currently levels of physical activity, sedentary behaviors, and medication regimen.
89144090|NCT05339750|Experimental|Allergy Skin Patch Testing|On day 1, subjects will have a allergy skin patch test applied and a routine skin examination. On day 3, the patch test will be removed and documentation of the test sites using iPhone app. On day 5, the final assessment for allergic contact dermatitis will be conducted by a medical professional.
89144091|NCT02713074|Active Comparator|Group A|povidone-iodine group
89144092|NCT02713074|Active Comparator|Group B|Normal saline group
89144093|NCT05089292|Experimental|Chinese Immigrants|NYC Chinese immigrants provided with narrative breast health education
89144094|NCT02712372|Experimental|Part 1, Dose Level 1|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
89144095|NCT02712372|Experimental|Part 1, Dose Level 2|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
89144096|NCT02712372|Experimental|Part 1, Dose Level 3|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
89144097|NCT02712372|Experimental|Part 1, Dose Level 4|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
89144098|NCT02712372|Experimental|Part 1, Dose Level 5|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
89144099|NCT02712372|Experimental|Part 1, Dose Level 6|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
89144100|NCT02712372|Experimental|Part 2, Dose Level 1|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
89144101|NCT02712372|Experimental|Part 2, Dose Level 2|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
89144102|NCT02712372|Experimental|Part 2, Dose Level 3|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
89144103|NCT02712372|Placebo Comparator|AZD4831 Placebo|"Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.~Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12"
89144104|NCT00637793|Placebo Comparator|1|Placebo capsules
89144105|NCT00637793|Experimental|2|2 capsules in the am of each treatment period
89144106|NCT00637793|Experimental|3|2 capsules in the am of each treatment period
89144107|NCT00637793|Experimental|4|2 capsules in am of each treatment period
89144108|NCT04228640|Experimental|Investigational Product|Ingredient: NMN Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
89144109|NCT04228640|Placebo Comparator|Placebo|Ingredient: Starch powder Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
89144110|NCT00745875|Experimental|1|ZD4054 + Pemetrexed
89144111|NCT00745875|Placebo Comparator|2|ZD4054 matched placebo + pemetrexed
89144112|NCT02712294|No Intervention|Control Group (GC)|The GC received standard ambulatory care, including routine exams and drug therapy. All patients were reassessed after the 2 month protocol.
89144113|NCT02712294|Experimental|NMES Group (GE)|Receiving the usual care and guidance on their illness, underwent 30 minute NMES sessions twice a week for two months using an electrostimulator. Specifically, 5 cm adhesive surface electrodes in four alternate channels on the Rectus Femoris (two channels the right and two on the left) were used to deliver two-phase symmetrical currents, with a rectangular pulse wave at a frequency of 35 Hz and pulse duration of 250 μ. The time of ascent and descent was one second, contraction time was four seconds and relaxation was eight seconds.
89144114|NCT04203563|Experimental|Group 1|Group 1 participants attend twice weekly progressive strength training classes with CPR certified and Strong People trained educators in fall 2019 for 12 weeks. Intervention Group.
89144115|NCT04203563|Other|Group 2|Group 2 participants receive twice weekly progressive strength training classes in January 2020 for 12 weeks. Delayed Intervention Group.
89144116|NCT02712216|Other|Trocar Insertion Sites|Insertion of a 21-gauge 3.5inch spinal needle perpendicular to the abdominal wall at each possible trocar site. The needle will be placed after the abdomen is insufflated under direct visualization with the laparoscopic camera. The needle will be inserted to the level of the peritoneum and a hemostat will be place on the needle at the level of the epidermis.
89144117|NCT00611520||1|Patients with COPD treated with budesonide/formoterol
89144118|NCT04196660|Experimental|The Dance Practitioner Spouse/Partner Group|The Dance Practitioner Spouse/Partner Group (DPSG)
89144119|NCT04196660|Experimental|The Dance Practitioner Midwife Group|The Dance Practitioner Midwife Group (DPMG) included 40 pregnant women and midwives who had received labor dance training
89144120|NCT04196660|No Intervention|The Control Group|The Control Group included 80 pregnant women who were subjected to routine treatment without dance
89144121|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 0.5 mg/kg|HAM8101 (Adrecizumab) : 0.5 mg/kg
89144122|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 2 mg/kg|HAM8101 (Adrecizumab) : 2 mg/kg
89144123|NCT04252937|Experimental|HAM8101 (Adrecizumab) : 8 mg/kg|HAM8101 (Adrecizumab) : 8 mg/kg
89144124|NCT02712450||Control group|"Patients included from January 2016 to August 2016~Before regulating doctors training course"
89144125|NCT02712450||Experimental group|"Patients included from January 2017 to August 2017~After regulating doctors training course"
89144126|NCT05339516||Healthy group|
89144127|NCT05339516||Women with low back pain|
89144128|NCT04089813||Metformin|Patients use metformin to control blood sugar
89144129|NCT04089813||Insulin|Patients use Insulin to control blood sugar
89144130|NCT02708316||schizophrenia group|schizophrenia patients in the group
88803653|NCT04199572|Experimental|Diclofenac and IV Paracetamol|Diclofenac (75mg intramuscular), Paracetamol (intravenous1gm in 100ml solution), Placebo (sugar tablets)
88803654|NCT04199572|Experimental|Diclofenac and Placebo|Diclofenac (75mg intramuscular),Placebo (100ml intravenous Normal Saline),Placebo (sugar tablets)
89144131|NCT02708316||control group|healthy population
89144132|NCT05071430|Active Comparator|Active Treatment (HB-01)|Approximately 40 patients will receive HB-01 active study drug.
89144133|NCT05071430|Placebo Comparator|Placebo Treatment|Approximately 40 patients will receive a matched placebo.
89144134|NCT02598141|Other|Per-op biopsy around material|"Patients included in this study require biopsies for suspicion of infected osteo-articular materials (implants, protheses, nails, screw, plates).~Interventions:~Biological sampling grinding~Biological sampling with standard procedures"
89144135|NCT04255667||Study group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing with hemostat at start of surgery
89144136|NCT04255667||Control group|Eyelid surgery involving eyelid margin is done after eyelid margin crushing without hemostat
89144137|NCT00611988|Experimental|1|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
89144138|NCT00611988|Active Comparator|2|Attention control group will receive routine follow-up phone calls
89144139|NCT04252469|Experimental|intervention|receiving oral care with 20mL of 0.12% CHX by medicine cup, gargling 30 seconds.
89144140|NCT04252469|No Intervention|Control|Standardized care
89144141|NCT02713152||Patients with OAG|Patients with a diagnosis of Open Angle Glaucoma
89144142|NCT02713152||Controls|Controls without a diagnosis of Open Angle Glaucoma
89144143|NCT05068388|Placebo Comparator|Placebo|oral capsule
89144144|NCT05068388|Experimental|1 mg (Z)-endoxifen|oral capsule
89144145|NCT05068388|Experimental|2 mg (Z)-endoxifen|oral capsule
89144146|NCT05320679||Study Group|Patients who have musculoskeletal pain
89144147|NCT02712060||EDS patients|Patients with the diagnosis of Ehlers-Danlos syndrome
89144148|NCT02712060||controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
89144149|NCT02780258|Experimental|Restylane Silk Treated Hand|The dorsal aspect of one hand will be injected with Restylane Silk.
89144150|NCT02780258|No Intervention|Control Hand|The dorsal aspect of the hand that is not treated will be used for baseline comparison.
89144151|NCT00611208|Experimental|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diptheria toxin)
89144152|NCT05339204|Experimental|allo-HSCT|Patients with AML in CR1, MRD-negative after first course recieve allo-HSCT
89144153|NCT05339204|Active Comparator|Chemo|Patients with AML in CR1, MRD-negative after first course continue chemotherapy
89144154|NCT00555217|Experimental|Combination of ARB and ACEI|Combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB)
89144155|NCT00555217|Active Comparator|Monotherapy ARB|Mono therapy arm. Standard treatment with angiotensin receptor blocker (ARB)
88816431|NCT01191398|Active Comparator|Glycopyrrolate and Ketamine|Glycopyrrolate will be administered as a single dose of 0.01 mg/kg, with no minimum dosage and a maximum dose of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
89144156|NCT02711904|Active Comparator|Extubation U|Remifentanil concentration between 2 - 3 ng/ml.
89144157|NCT02711904|Experimental|Extubation T|Remifentanil concentration between 3 - 4 ng/ml
89144158|NCT05326490|Experimental|Test arm|"Double-blinded treatment period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage~Open-label extended period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage"
89144159|NCT05326490|Placebo Comparator|Placebo arm|"Double-blinded treatment period:~PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;Basic treatment with stable dose of Glucophage~Open-label extended period:~PB201 100 mg, one tablet in the morning and one tablet in the evening;Basic treatment with stable dose of Glucophage"
89144160|NCT05339048||General group|18-80 years old adults from the Colombian Caribbean Coast.
89144161|NCT00745251|Experimental|VI-0521|15 mg Phentermine and 92 mg Topiramate
89144162|NCT00745251|Placebo Comparator|Placebo|
89144163|NCT04252157|Experimental|kinesiotaping|Kinesotape will be apply with suitable tension and necessery region.
89144164|NCT04252157|Placebo Comparator|plesebo taping|Tape will be appy with randomly region without tension.
89144165|NCT04252157|Other|control|Nothing will be applied
89144166|NCT02779868|Experimental|Omega-3|Group who will receive 2g eicosapentaenoic (4 capsules) acid per day during the chemoradiotherapy protocol.
89144167|NCT02779868|Placebo Comparator|Olive oil|Group who will receive olive oil per day (4 capsules) during the chemoradiotherapy protocol.
89144168|NCT00950287||cohort|One group of preterm infants
89144169|NCT02780336||Blepharospasm (BL)|Participants in this group should be diagnosed with blepharospasm, but may have dystonia in other body parts as well.
89144170|NCT02780336||Disease Control Group|Participants in this group should be diagnosed with a disorder affecting their eyes or face, such as hemifacial spasm, facial tics, or apraxia.
89144171|NCT02780336||Normal Control Group|Participants in this group should not have any neurologic problems or other disorders affecting patients eyes or face.
89144172|NCT04252079|Other|We compare different endovascular techniques as an alternative|We compare different endovascular techniques as an alternative to surgical reconstruction to repair JAAS regarding ; success rates, 30-day mortality, endoleak events secondary intervention rates
89144173|NCT00947401||elective post surgery patients|
89144174|NCT02711982|Active Comparator|Optic nerve decompression|Optic canal and optic nerve sheath decompression within 5 days from trauma occur.
89144175|NCT02711982|Active Comparator|methylprednisolone|a maximum daily dose of 1 g of methylprednisolone
89144176|NCT00745095|No Intervention|SCI MoviPrep® (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI, GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (without neostigmine plus glycopyrrolate [NG])
89144177|NCT00745095|No Intervention|SCI PIEE (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation [PIEE] (without neostigmine plus glycopyrrolate [NG])
89144178|NCT00745095|No Intervention|Control MoviPrep® only|(Control, glomerular filtration rate (GFR)>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid (MoviPrep®) only (no NG)
89144179|NCT00745095|No Intervention|Control PIEE only|(Control, glomerular filtration rate (GFR)>=50ml/min), pulsed irrigation enhanced evacuation (PIEE) only (no NG)
89144180|NCT00745095|Experimental|SCI MoviPrep® (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (with neostigmine plus glycopyrrolate [NG])
89144181|NCT00745095|Experimental|SCI PIEE (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (with neostigmine plus glycopyrrolate [NG])
89144182|NCT00950443|Experimental|1|Children with upper airway obstruction
89144183|NCT00950443|Active Comparator|2|Children without upper airway obstruction
89144184|NCT02711748|Experimental|Bradycardia|Treatment In case of bradycardia. The patient unconscious, breathing preserved in ECG - bradycardia 40 / min with pulse.
88816432|NCT05249595|Experimental|Group A - Particiapnts without neurological disorders|Individuals without neurological disorders will be recruited (Group A).
88816433|NCT05249595|Experimental|Group S - Participants with iSCI or transverse myelitis|Individuals with neurological disorders, like iSCI or transverse myelitis, will be recruited (Group S). These individuals usually have weakened ankle joint functionalities but can walk independently.
89144185|NCT02711748|Experimental|PEA|In case of bradycardia. The patient unconscious, not breathing, the ECG - bradycardia 30 / min - no pulse. Pulseless electrical activity
89144186|NCT02780180|Experimental|QGC001|QGC001 from 50mg to 500mg capsule twice daily, for 28 days, oral use
89144187|NCT02780180|Placebo Comparator|Placebo|Placebo, capsule twice daily, for 28 days, oral use
89144188|NCT00947479|Other|continuous positive airway pressure (CPAP)|CPAP will be applied in all patients
89144189|NCT02623010|Experimental|Single arm|Imbruvica (ibrutinib) will be given as maintenance treatment until relapse or toxicity to 30 elderly PCNSL patients after achieving response to first line treatment
89144190|NCT00950521|Active Comparator|PBSC Treatment|Patients in PBSC treatment will receive brain implant of autologous peripheral blood stem cell(CD34+) plus convention stroke treatment that include rehabilitation and antiplatelet medication
89144191|NCT00950521|Active Comparator|Control|Control group receive conventional stroke treatment that include rehabilitation and antiplatelet medication
89144192|NCT05181462|Experimental|Phase Ib: Single-arm (dose-escalation 3+3 design).|"Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8, every 3-week cycles.~Gemcitabine 1000 mg/m2 IV on days 1 and 8, every 3-week cycles.~Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8, every 3-week cycles."
89144193|NCT05181462|Experimental|Phase II: Randomized 1:1, non-comparative, open-label.Patients randomized to arm A|"Carboplatin AUC 2 mg/mL/min IV on days 1 and 8, every 3-week cycles.~Gemcitabine 1000 mg/m2 IV on days 1 and 8, every 3-week cycles.~Nadunolimab Recommended Phase II Dose (RP2D) mg/kg IV on days 1 and 8, every 3-week cycles"
89144194|NCT05181462|Active Comparator|Phase II: Randomized 1:1, non-comparative, open-label.Patients randomized to arm B|"Carboplatin AUC 2 mg/mL/min IV on days 1 and 8, every 3-week cycles.~Gemcitabine 1000 mg/m2 IV on days 1 and 8, every 3-week cycles."
89144195|NCT02781662|No Intervention|Control|No Intervention; Control Arm: Receives Written Medication Information
89144196|NCT02781662|Experimental|Intervention|Behavioral: Pharmacist Home-Visit
89144197|NCT00947635|Experimental|Islet transplant|People with Type 1 diabetes undergoing islet transplantation
89144198|NCT00947635|Experimental|Liver transplant|People with liver failure undergoing liver transplantation
89144199|NCT00947635|Experimental|Control|Healthy normal people which serve as control group
89144200|NCT00612612|Experimental|Treatment (obatoclax mesylate, fludarabine, rituximab)|"Patients receive obatoclax mesylate IV over 3 hours on days 1 and 3, fludarabine IV over 20-30 minutes on days 1-5, and rituximab IV over 4 hours on day 1 (days 1 and 3 of course 1 only). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo peripheral blood collection for correlative studies. Samples are analyzed for expression of pro- and anti-apoptotic Bcl-2 family members by western blot; apoptosis induction by measurement of lymphocyte count, Annexin V staining, and Caspase and PARP cleavage; activated Bax by immunoprecipitation; and Bax promoter polymorphism by PCR amplification and direct sequencing."
89144201|NCT02781740|Active Comparator|CPAP therapy|Continuation of the already established CPAP therapy.
89144202|NCT02781740|Sham Comparator|Sham CPAP therapy|Sham-CPAP is achieved by setting the CPAP machine to the lowest pressure, insertion of a flow-restricting connector at the machine outlet, and insertion of six extra holes in the collar of the main tubing at the end of the mask to allow air escape and to prevent rebreathing of CO2.
89144203|NCT05018156|Experimental|Default Genetics Referral Process|
89144204|NCT00744939||Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Participants received Magnevist in accordance with its labeling
89144205|NCT00940615|Experimental|1|participants in the aerobic exercise intervention
89144206|NCT00940615|Active Comparator|2|participants in the stretching/toning control condition
89144207|NCT00947713|Experimental|Low dose hCG group|
89144208|NCT00947713|Active Comparator|Clomiphen citrate plus HMG|
89144209|NCT05341934|Active Comparator|Conditionning|
89144210|NCT05341934|Placebo Comparator|Placebo|
89144211|NCT00940693|Active Comparator|duloxetine|
89144212|NCT00940693|Placebo Comparator|placebo|
89144213|NCT02598063|Active Comparator|ADV + Lamivudine|Participants will receive ADV and lamivudine tablets at a dose of 10 mg orally QD for first 12 weeks followed by ADV for 60 weeks.
89144214|NCT02598063|Experimental|Peginterferon alfa-2a + Lamivudine|Participants will receive peginterferon alfa-2a injection at a dose of 180 micrograms (mcg) once weekly (QW) and 100 milligrams (mg) lamivudine tablets orally once daily (QD) for first 12 weeks followed by peginterferon alfa-2a for 36 weeks.
89144215|NCT02707458|Experimental|Single arm|All subjects will receive probucol, starting with a fixed dose of 600 mg daily following the evening meal. The variable plasma concentrations achieved and the resulting modification in concentration of CSF apoE will suggest an ideal range of plasma concentrations for use of the drug as an inducer of increased availability of apoE in the CSF. The known dose-proportionality of the drug in plasma will then be used to estimate an ideal individualized dose for each participant. The effects of such individualized dosage will be tested over 1 year of follow-up observations, searching for treatment effects on CSF apoE and for evidence of other treatment effects, particularly including adverse effects.
89144216|NCT00950677|Active Comparator|exenatide|exenatide one dose
89144217|NCT00950677|Active Comparator|pramlintide|pramlintide one dose
89144218|NCT02689622|Experimental|Evaluation of disease prognostic factors|Research of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
89144219|NCT00917475||Preterm infants|birth weight<1500 grams and gestational age<30 weeks
89144220|NCT05174598|Experimental|Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Spray formulation applied topically, twice daily, for the duration of 8 weeks.
89144221|NCT05174598|Active Comparator|Calcipotriol Ointment 50 micrograms/g, Sandoz|Ointment applied topically, twice daily, for the duration of 8 weeks.
89144222|NCT05174598|Placebo Comparator|Placebo|Spray formulation applied topically, twice daily, for the duration of 8 weeks.
89144223|NCT04229420|Active Comparator|Rectus sheath block group (RSB)|After preparing the skin, a high frequency (5-10 MHz) ultrasound probe will be placed in a longitudinal orientation above the level of the umbilicus with the Patient in the supine position. After identifying the rectus abdominis muscle, A 22 G echogenic needle using the in plane technique will be inserted just below the costal margin then, a total of 20 ml of 0.25% bupivacaine will be injected into the plane between the rectus muscle and posterior rectus sheath. Negative aspiration will be confirmed every 5 ml. The block will then be repeated on the other side.
89234835|NCT05888714|Active Comparator|Comparator FES cycling|Existing medical device combining cycle ergometer use and neuromuscular electrical stimulation (FES cycling)
89234836|NCT05888714|Active Comparator|Conventional physical therapy|Conventional physical therapy.
89234837|NCT05888714|No Intervention|Operators|Operators will evaluate systems usability during interventions.
89144224|NCT04229420|Active Comparator|Erector spinae plane block group (ESPB)|After induction of anesthesia; the patient will be positioned on the lateral position. The skin will be prepared with povidone iodine, and a high frequency (5-10 MHz) ultrasound probewill be placed in a transverse orientation on the T9 spinous process which will be located by palpating and counting down from the C7 spinous process. The tip of the T9 transverse process will be identified and centred on the ultrasound screen, the probe will then be rotated into a longitudinal orientation to produce a parasagittal view. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is conﬁrmed by injecting 0.5-1 ml saline and seeing the ﬂuid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20 ml of 0.25% bupivacaine will then be injected into the ESP of both sides.
89144225|NCT02329808||Mycophenolic acid|Patients treated for their regular patient care with mycophenolic acid.
89144226|NCT02329808||Cyclosporin|Patients treated for their regular patient care with cyclosporin.
89144227|NCT02329808||Tacrolimus|Patients treated for their regular patient care with tacrolimus.
89144228|NCT02329808||Sirolimus|Patients treated for their regular patient care with sirolimus.
89144229|NCT02329808||Everolimus|Patients treated for their regular patient care with everolimus.
89144230|NCT02329808||Voriconazole|Patients treated for their regular patient care with voriconazole.
89144231|NCT02329808||Posaconazole|Patients treated for their regular patient care with posaconazole.
89144232|NCT02329808||Itraconazole+metabolite|Patients treated for their regular patient care with itraconazole.
89144233|NCT02329808||Fluconazole|Patients treated for their regular patient care with fluconazole.
89144234|NCT04344054|Experimental|Arm 1|RV3-BB/TV P2-VP8 boost
89144235|NCT04344054|Experimental|Arm 2|RV3-BB/TV P2-VP8 co-administered
89144236|NCT04344054|Experimental|Arm 3|RV3-BB primed TV P2-VP8
89144237|NCT04344054|Experimental|Arm 4|Rotarix®/TV P2-VP8 Boost
89144238|NCT04344054|Experimental|Arm 5|Rotarix®/TV P2-VP8 co-administered
89144239|NCT04344054|Experimental|Arm 6|TV P2-VP8 alone
89144240|NCT02707380|Active Comparator|Group 1 Resistance Training Group|Participants will perform 3 exercises, one of which will be a series of 7 muscle-strengthening exercises using body weight resistance and elastic resistance bands + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
89144241|NCT02707380|Active Comparator|Group 2 Standard of Care|Participants will perform 3 exercises that do not include the 7 muscle-strengthening exercises + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
89144242|NCT04978376|Experimental|Time restricted eating|ad-libitum eating between 12:00-20:00
89144243|NCT04978376|Experimental|TRE with endurance training|ad-libitum eating between 12:00-20:00 with 3-5 days of supervised endurance exercise per week
89144244|NCT04978376|Experimental|TRE with resistance training|ad-libitum eating between 12:00-20:00 with 3-5 days of supervised resistance training per week
89144245|NCT04978376|No Intervention|Control|no change in diet or physical activity
89144246|NCT02707536|No Intervention|No socket grafting|Extraction with normal socket healing
89144247|NCT02707536|Active Comparator|Socket grafting with platelet rich fibrin (PRF) alone|Extraction with socket grafting with platelet rich fibrin (PRF) alone.
89144248|NCT02707536|Active Comparator|Socket grafting with bone grafting alone|Extraction with socket grafting using bone graft (xenograft).
89144249|NCT02707536|Active Comparator|Socket grafting with PRF and bone grafting|Extraction with socket grafting using PRF combined with bone graft (xenograft).
89144250|NCT00951067|Active Comparator|Group A|Exercise, Elevation, and Garment Compression
89144251|NCT00951067|Active Comparator|Group B|Pneumatic Compression Device (B)
89144252|NCT00951067|Active Comparator|Group C|Pneumatic Compression Device (C)
89144253|NCT00951067|Active Comparator|Group D|Pneumatic Compression Device (D)
89144254|NCT00951067|Active Comparator|Group E|Pneumatic Compression Device (E)
89144255|NCT05016284|Experimental|JW-100|Subjects applying JW-100 cream twice daily at home (experimental group).
89144256|NCT05016284|Active Comparator|EUCRISA|Subjects applying EUCRISA® (Pfizer) product twice daily at home (comparator group).
89144257|NCT02707614||Robotic vs open prostastectomy|One group is operated by open prostatectomy the other by robotic assistance
89144258|NCT02779322|Active Comparator|Minigastric bypass|Intervention(s): The patient will have done a Laparoscopic one anastomosis gastric bypass (minigastric bypass) at the time of the surgical procedure.
89144259|NCT02779322|Active Comparator|Gastric bypass|The patient will have a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
89144260|NCT02711436|Active Comparator|Computed Tomography Scan|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with Computed Tomography scan.
89144261|NCT02711436|Active Comparator|Fast Magnetic Resonance Imaging|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with T1/T2-weighted MRI.
89144262|NCT05341856|Active Comparator|Uterine artery Doppler Changes After IMN In Patients with URPL|compare uterine artery blood flow before and after the administration of Isosorbide mononitrate as a nitric oxide donor during mid secretory phase of menstrual cycle for patients with unexplained recurrent pregnancy loss.
89144263|NCT05341856|Placebo Comparator|Uterine artery Doppler Changes After placebo In Patients with URPL|compare uterine artery blood flow before and after the administration of placebo during mid secretory phase of menstrual cycle for patients with unexplained recurrent pregnancy loss.
89144264|NCT05143710||PRES in PE or E|patients diagnosed with PRES in PE or E
89144265|NCT00947947|Experimental|intervention media condition|Received a stage tailored DVD-based intervention
89144266|NCT00947947|Placebo Comparator|standard of care|received only clinical standard of care
89144267|NCT03817866||BRAHMS CgA II KRYPTOR|Adult patients with well defined grade 1 and grade 2 GEP-NETs. Serial serum samples from all patients will be analyzed using the BRAHMS CgA II KRYPTOR Assay.
89144268|NCT02068976||Women with Primary Ovarian Insufficiency|
89144269|NCT00951223||Patients with Chronic Hepatitis C|HCV positive patients who have failed previous HCV therapy This observational prospective registry is designed to evaluate the safety, adherence, and efficacy of prescribed, patientadministered therapy with Infergen® (Interferon alfacon-1) and other prescribed therapies in patients chronically infected with HCV. The primary endpoint for efficacy will be the SVR rate at 24 weeks after therapy ends. Safety will be assessed by monitoring AEs, reduction/discontinuation of therapy because of AEs, routine laboratory results and by other means determined by the Investigator
89144270|NCT02711592|Other|Genetic Panel for Analgesics|Genetic testing for analgesics prior to surgery will be conducted. The subject will receive postoperative analgesia based on test results.
89144271|NCT00948103|Placebo Comparator|Oxygen|
89144272|NCT00948103|Active Comparator|Nitrous Oxide|
89144273|NCT02012114|No Intervention|Cysteamine Bitartrate|Single arm study. Subjects receive their current oral form of cysteamine bitartrate treatment : Cystagon® or RP103
89144274|NCT00951301|Active Comparator|mangosteen juice|subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient
89144275|NCT00951301|Placebo Comparator|placebo juice|subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient
89144276|NCT02579317|Experimental|Resonance Breathing|Breathing is paced to the cardiovascular resonance frequency where heart, respiratory, and brain signals become aligned. This can potentially positively impact cognitive-emotional functioning.
89144277|NCT02579317|Placebo Comparator|Non-Resonance Breathing|Breathing is paced at a non-resonance frequency. It does not align heart, respiratory, and brain signals, and thus does not impact cognitive-emotional functioning.
89144278|NCT02711046|Experimental|single stage nasolabial flap|single staged nasolabial flap as an interpositional material after surgical resection of fibrous band in oral submucous fibrosis
89144279|NCT00948181||Surgeon|To detect the degree of intraoperative stress, venous blod will be drawn from one surgeon during 8 pheochromocytoma resections.
89144280|NCT00948181||Anesthesiologist|To detect the degree of intraoperative stress, venous blood will be drawn from one anesthesiologist during 8 pheochromocytoma resections.
89144281|NCT00948181||Patients with pheochromocytoma|Venous blood will be drawn from 8 patients with pheochromocytoma during tumor resection.
89144282|NCT02707302|Experimental|Iodophor-impregnated adhesive drapes|"In the iodophor-impregnated adhesive drapes group, routine disinfection will be carried out and bacteria samples will be harvested 1 cm from the wound site using sterilized swabs prior to use of the surgical adhesive drapes, and again at the end of surgery before skin suturing, for preoperative bacterial culture. The packaging of the 3M™ iodophor-impregnated adhesive drapes will be opened and the aseptic adhesive drapes unfolded until the stop instruction. The adhesive drapes will then be pasted to the surgical wound and smoothed using an aseptic cloth, taking care to avoid air bubbles."
89144283|NCT02707302|Experimental|Iodophor-free adhesive drapes|Patients in the iodophor-free adhesive drapes group will undergo the same procedures, but with iodophor-free drapes.
89144284|NCT00948259|Experimental|NP031112|Patients will receive 400 mg of NP031112 for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this dose will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for dose escalation will remain on the tolerated dose for the remainder of the study.
89144285|NCT00948259|Placebo Comparator|Placebo|Patients will receive 400 mg for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for escalation will remain on the tolerated dose for the remainder of the study.
89144286|NCT02707068|Experimental|QOLITI|"Intervention group receives the QOLITI (Quality Of LIfe Tool for IBD) manual immediately to work with over the course of several weeks along with 3 x 30 minutes of telephone support by a trained healthcare professional. Telephone calls will occur at two, four and six weeks post-randomisation.~Participants will be invited to discuss their experiences after the end of the actual study. These interviews are no obligatory part of the QOLITI study."
89144287|NCT02707068|No Intervention|Waitlist Control group (WLC)|Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions.
89144288|NCT02779400|Experimental|Evaluation of the device perfomance|
89144289|NCT02781350|Placebo Comparator|High fat high carbohydrate (HFHC) meal|Subjects will consume a HFHC meal. HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
89144290|NCT02781350|Experimental|HFHC meal plus Fiber|HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). Subjects will also receive FiberOne Original cereal 14 grams (half cup) before and after the HFHC meal. 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
89144291|NCT05071560|Active Comparator|Face-to-Face Group|This arm will have a 3 day per week face-to-face participant-tailored combined exercise program, with 2 supervised sessions and 1 non supervised aerobic session, for 8 weeks
89144292|NCT05071560|Experimental|Home-Based Group|This arm will have a 3 day per week home-based participant-tailored combined exercise program, with 2 remotely supervised sessions (online) and 1 non supervised aerobic session, for 8 weeks
89144293|NCT05301205|Active Comparator|group I|will be received oral gabapentin capsule 1200 mg 2h pre-operatively.
89234838|NCT05888649||Cluster 1|Communities highly affected and impacted by EVD
89144294|NCT05301205|Active Comparator|group II|will be received oral gabapentin capsule 600 mg 2h pre-operatively.
88803655|NCT04177966|Experimental|women watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term The day before surgery the women will watch a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation
89144295|NCT05301205|No Intervention|Group III|will be received placebo capsules at 2 hours preoperatively.
89144296|NCT02707224|Experimental|Group A|combination dose of Candesartan cilexetil and Rosuvastatin and DP-R208 in order
89144297|NCT02707224|Experimental|Group B|DP-R208 and combination dose of Candesartan cilexetil and Rosuvastatin in order
89144298|NCT04996628|Experimental|Pancreatic Quantitative Sensory Testing (P-QST)|Definite Chronic Pancreatitis patients undergoing decompressive invasive treatments (endoscopic therapy or surgery) to relieve main pancreatic duct obstruction due to stones and/or stricture for management of pain will undergo P-QST prior to clinically-indicated invasive treatment.
89144299|NCT00744861|Active Comparator|Exogen 4000+|Low intensity pulsed ultrasound (LIPUS) delivered via Exogen 4000+ (single transducer) device for a treatment duration of 20 minutes per fusion site per day.
89144300|NCT00744861|Sham Comparator|Exogen 4000+ sham|Non-active sham device identical to Exogen 4000+ (single transducer); treatment duration of 20 minutes per fusion site per day
89144301|NCT00744861|Active Comparator|Exospine|Low intensity pulsed ultrasound delivered via Exospine device (dual transducers); treatment duration of 20 minutes per day
89144302|NCT00744861|Sham Comparator|Exospine sham|Non-active sham device identical to Exospine (dual transducers); treatment duration of 20 minutes per day
89144303|NCT00951691|Experimental|Enhanced acute medical rehabilitation|Participants will receive enhanced acute medical rehabilitation.
89144304|NCT00951691|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
89144305|NCT02706990|Other|Physica KR|Patients who have received a Physica KR total knee implant.
89144306|NCT02706990|Other|Physica PS|Patients who have received a Physica PS total knee implant.
89144307|NCT04229264|Active Comparator|Control group|Aspirin 100 mg (oral, once-daily) for 1 year plus Clopidogrel 75 mg (oral, once-daily) for 3 months.
89144308|NCT04229264|Experimental|Apixaban group|Apixaban 2.5 mg (oral, twice daily) for 1 year plus Aspirin 100 mg (oral, once-daily) for 1 year.
89144309|NCT02706912|Experimental|VOTA Group|All enrolled subjects are in this arm. After pre-assessment subjects have an 8-week waiting period, after which a mid-assessment takes place. Subject then participate in VOTA therapy for 8 weeks, followed by a post-assessment . The pre-/mid-assessment difference is used to control for spontaneous recovery. The mid-/post-assessment difference is used to ascertain efficacy.
89144310|NCT02597829|Other|Open Label Certolizumab Pegol|Active Treatment
89144311|NCT04012879|Experimental|study group|After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours
89144312|NCT02711202|Active Comparator|Sirolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at post-operative day (POD) 14, they were randomized to sirolimus monotherapy.
89144313|NCT02711202|Active Comparator|Tacrolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at POD 14, they were randomized to tacrolimus monotherapy.
89144314|NCT00948337|Experimental|Photonovella of Secondary Cancer Screening|
89144315|NCT00948337|Active Comparator|Photonovella of Dietary Suppelment of Cancer survivor|
89144316|NCT02597751|Experimental|Treatment Arm|Participants are randomized to treatment group. After the first MRI scan, participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a second MRI scan. Twelve weeks later, participants have a third, follow-up scan.
89144317|NCT02597751|No Intervention|Waitlist control|"Participants are randomized to the waitlist control group. After the first MRI scan, participants wait for 12 weeks and then have a 2nd MRI scan. Participants then have 10 treatment sessions with an occupational therapist and are assessed by an independent occupational therapist before and after treatment. Participants then have a third MRI scan to examine brain changes associated with intervention."
89144318|NCT04227938|Experimental|ALPN-101|All subjects will receive a single dose of ALPN-101. In Part A, ascending dose levels of ALPN-101 will be evaluated. In Part B, a single dose level of ALPN-101-as identified in Part A-will be evaluated.
89144319|NCT02711358|Experimental|indomethacin|indomethacin suppositories
89144320|NCT02711358|Placebo Comparator|placebo|placebo suppositories
89144321|NCT00948415|Experimental|SURI Enhanced|
89144322|NCT00948415|Active Comparator|SURI Standard|
89144323|NCT02597595|Experimental|patients|thirty children with beta thalassemia major, with age range from 4-18 years, will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
89144324|NCT02597595|No Intervention|controls|thirty healthy children of matched age and sex
89144325|NCT02779946||CHD-positive|positive tested for coronary artery disease
89144326|NCT02779946||CHD-negative|negative tested for coronary artery disease
89144327|NCT03969589|Experimental|Reproductive Life Planning-Mental Health Intervention|Reproductive Life Planning-Mental Health (RLP-MH) intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
88803656|NCT04177966|Placebo Comparator|women not watching the pre-prepared video before surgery|Women undergoing primary elective cesarean surgery at term Women will receive general information about the surgery as part of informed consent, without watching a pre- prepared film.
89234839|NCT05888649||Cluster 2|Communities not highly affected and impacted by EVD
89144328|NCT03969589|Other|Written materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
89144329|NCT02706600|Other|Written Self Management|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
89144330|NCT02706600|Active Comparator|Online Self Management|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary, pulmonary rehabilitation videos to promote and support exercises that can be done in the home.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
89144331|NCT02778854||cohort 1|Participants are recruited for diagnostic test
89144332|NCT02778854||cohort 2|participants are recruited for follow-up
89144333|NCT05031702|Active Comparator|Dietary supplement|Extract from Camellia Sinensis leaf
89144334|NCT05031702|Placebo Comparator|Placebo|Tablets of the same size as the active component
89144335|NCT04945928|Experimental|Surgery after conversion therapy|Participants with locally advanced or advanced NSCLC who received first-line treatment have been evaluated as resectable after multidisciplinary discussion involving the department of thoracic surgery, respiratory medicine, radiology and oncology.
89144336|NCT04011865|Active Comparator|Robotic-assisted surgery|
89144337|NCT04011865|Sham Comparator|Laparoscopic surgery|
89144338|NCT00744627|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
89144339|NCT00744627|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
89144340|NCT04942886|Experimental|Treatment group|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation. The intervention group visit clinic every month and examined liver function test, HBsAg/Ab. HBV DNA level is examined at every 3 months.
89144341|NCT04942886|No Intervention|delayed treatment group|The delayed treatment group visit clinic every month and examined liver function test, HBsAg/Ab. HBV DNA level is examined at every 3 months. If the patient in the delayed treatment group shows HBV reactivation (positive HBsAg or HBV DNA ≥10 IU/mL), entecavir treatment is started.
89144342|NCT02711124||Group with hemoglobin A1c < 7|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
89144343|NCT02711124||Group with hemoglobin A1c ≥ 7%|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
89144344|NCT00951847|Experimental|1|Oxcarbazepine oral suspension 300 mg/5 mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
89144345|NCT00951847|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5 mL of Novartis
89144346|NCT04227782||NAFLD|
89144347|NCT04227782||NASH|
89144348|NCT04227782||Cirrhosis|
89144349|NCT04227782||Healthy Volunteers|
89144350|NCT02711280|Experimental|Sevoflurane General anesthesia|Anesthesia was induced with 8% sevoflurane with 8L/min oxygen. Anesthesia was maintained with 1-3% sevoflurane in oxygen/air mixture.
89144351|NCT02711280|Experimental|Propofol General anesthesia|Anesthesia was induced with propofol 4mg/kg. Anesthesia was maintained with propofol 7-12mg/kg/h.
89144352|NCT03959137||Primary study group|Stage IV untreated NSCLC
89144353|NCT05341388||Patients with type 2 diabetes-SGLT2 inh|patients with type 2 diabetes who were recently prescribed an SGLT2 inhibitor
89144354|NCT05341388||Patients with type 2 diabetes-control|patients with type 2 diabetes who were recently prescribed a pre-defined antidiabetic medication other than SGLT2 inhibitors
89144355|NCT02706756|Experimental|Education, exercise and manual therapy|"One group will receive education and advice, manual therapy that is applied toward the impairments of the subject, a prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Subjects will be seen twice weekly for 4 to 6 weeks, depending on the progression.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
89144356|NCT02706756|Active Comparator|Education and exercise|"Group will receive a prescriptive intervention designed to strengthen the hip and surrounding regions as well as improve flexibility of the lower extremity. This group will not receive additional physiotherapy management but will be schedule bi-weekly to review the home exercises and to receive appropriate educational support.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
89144357|NCT02706756|Placebo Comparator|Supervised neglect|"Group will receive supervised neglect. We will monitor this group for changes or emergent situations but no formal care will be provided.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
89144358|NCT00951925||No Treatment|
89234840|NCT05888649||Cluster 3|Communities receptive to EVD vaccination
89234841|NCT05888649||Cluster 4|Communities resistance to EVD vaccination
89234842|NCT05888623||Computer Assisted Detection|Colonoscopies performed at a VA facility with computer assisted detection (CADe) artificial intelligence available.
89144359|NCT04089501||Inflammatory Bowel Disease (IBD)|Subjects will be asked to provide a stool sample (if no colonoscopy is to be performed) or if clinically indicated, a colonoscopy will be performed per standard medical routine. During colonoscopy, stool will be collected for analysis and 3 additional biopsies will be taken each from the ileum and colon for research purposes. Alternatively, subjects who are undergoing intestinal and/or colonic resection will provide stool prior to surgery and a portion of their pathology specimens will be used for research purposes following complete pathologic evaluation.
89144360|NCT04089501||Subjects not affected by IBD (Control Group)|Results of subjects with IBD will be compared to subjects in the control group.
89144361|NCT02781194|Experimental|forced-air warming blanket|Forced-air warming blanket via 3M™ Bair Hugger™.
89144362|NCT02781194|Experimental|warmed, humidified insufflation|Warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
89144363|NCT02781194|Experimental|forced-air warming blanket & warmed, humidified insufflation|Combination of forced-air warming blanket via 3M™ Bair Hugger™ and warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
89144364|NCT04011553|Experimental|Virtual group|This virtual realtiy was implemented with MarVAJED® (Marmara Visual Auditory Joint Education Device) system which was developed by Marmara University, Department of Physiotherapy and Rehabilitation, Istanbul,Turkey. MarVAJED® is a system that evaulates the range of motion of the joints, analyzes the sensation of joint position, provides biofeedback support to increase joint control and the same time allows exercises to be controlled. This device analyzes the joint motion with the help of small sensors (Figure 2). The obtained data transfers to your mobile phone, to the tablet or to your personal computer. It stores the data by downloading it to the central server via internet for storage.
89144365|NCT04011553|Active Comparator|Control group|Conventional physiotherapy consists of electrotherapy and exercise programs. Hotpack or coldpack, therapeutic ultrasound (US) and conventional TENS were applied as electrotherapy program.
89144366|NCT02706522|Experimental|Allocated to Carbohydrated group|"Patients was administered in hospital~Randomization~Patient was allocated to Carbohydrated group~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
89144367|NCT02706522|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital~Randomization~Patient was allocated to Placebo group~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
89144368|NCT02706210||vascular cognitive disorders pre-dementia (VCD-P)|
89144369|NCT02706210||amnestic mild cognitive impairment (aMCI)|
89144370|NCT00952003|Experimental|interventional arm|Oxaliplatin, Irinotecan and Bevacizumab for 3 cycles followed by Docetaxel and Bevacizumab for a further 3 cycles. Upon completion of the combination therapy cycles Bevacizumab will be continued until progression.
89144371|NCT02597517||Intervention group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and positive stool antigen test for H pylori in whom gastric body mucosal will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
89144372|NCT02597517||Control group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and negative stool antigen test for H pylori in whom gastric mucosal body will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
89144373|NCT00612144|Experimental|1|Amaryl M group
89144374|NCT00612144|Active Comparator|2|Metformin group
89144375|NCT04227548|Experimental|Healthy individuals|
89144376|NCT02706444|Active Comparator|Conventional Balloon Angioplasty|Conventional balloon angioplasty. After fistulogram, full expansion of conventional balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
89144377|NCT02706444|Active Comparator|Drug-Coated Balloon Angioplasty|Drug-coated balloon angioplasty. After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
89144378|NCT04228406|Experimental|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
89144379|NCT00562627|Experimental|LIA IV|Local infiltration analgesia with ropivacaine and adrenaline and intravenous ketorolac and morphine
89144380|NCT00562627|Experimental|LIA IA|Local infiltration analgesia with ropivacaine, adrenaline and ketorolac and morphine
89144381|NCT00562627|Active Comparator|EDA|standard continuous epidural analgesia
89144382|NCT04227626|Experimental|GlucoSTAT|Type 1 diabetes and Type 2 diabetes with a total daily dose (TDD) of insulin that is > 0.75 u/kg or ≥ 2 u/kg.
89144383|NCT02597283|Experimental|Biguard stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
89144384|NCT02597283|Active Comparator|Sirolimus-eluting stent system|PCI with regular sirolimus-eluting stent system
89144385|NCT00948571||head down, laparoscopic|20 patients with laparoscopic surgery (radical robotic prostatectomy) in head down position
89144386|NCT00948571||head down, open|"20 patients undergoing opensurgery (open radical prostatectomy) in head down position."
89144387|NCT00948571||horizontal, open|"20 patients undergoing open surgery in horizontal position (open hemicolectomy)"
89144388|NCT02779010|Experimental|Hand washing with soap|Hand washing with soap and health education every 2 weeks for 6 months
89144389|NCT02779010|No Intervention|Books and pens|Books and pens for every 2 months for 6 months
89144390|NCT00948649|Active Comparator|Varenicline|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
89234843|NCT05888623||Conventional Colonoscopy|Colonoscopies performed at a VA facility without CADe artificial intelligence available
89144391|NCT00948649|Placebo Comparator|Placebo|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
89144392|NCT04195490|Other|children with disorders of sex development|children with disorders of sex development needing feminizing genitoplasty
89144393|NCT00952159||Not Poor metabolizer|
89144394|NCT00952159||Poor metabolizer|
89144395|NCT05265234|Experimental|Dupixent|"Patients will receive initial dose of 600 mg (two 300 mg injections in different injection sites), followed by 300 mg given every other week for 16 weeks.~Patients will self-administer by subcutaneous injection at home, instructions will be provided at first visit."
89144396|NCT00948727|Experimental|Dose adjustment according CN activity|
89144397|NCT04195334|Experimental|IMN and union|putting an intramedullary nail in femoral shaft fractures and finding a relation between the nail diameter to femoral canal diameter and how this will affect healing or predict union
89144398|NCT05264766|Experimental|Cooling helmet on|Cooling helmet on means there was circulating cold water inside the helmet, put after induction during cardiopulmonary bypass on
89144399|NCT05264766|Active Comparator|Cooling helmet off|Cooling helmet on means there was no circulating cold water inside the helmet, put after induction during cardiopulmonary bypass on
89144400|NCT00952237|Experimental|IL-2 and GM-CSF for Mobilization|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
89144401|NCT02778776|Experimental|Agave inulin + Metfomin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
89144402|NCT02778776|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
89144403|NCT02778776|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
89144404|NCT02778776|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
89144405|NCT00948805|Experimental|GnRH agonist|3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation. 250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
89144406|NCT00948805|Active Comparator|Control|250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
89144407|NCT05264532|Experimental|Arm A (video via text message)|Participants receive a 2-minute information-graphic video via text message consisting of misconceptions and issues that may be paramount when discussing mutation status with relatives that they can share with family via text message, email, or social media.
89144408|NCT05264532|Active Comparator|Arm B (letter via standard U.S. mail)|Participants receive family letter via U.S. postal service mail consisting of misconceptions and issues that may be paramount when discussing mutation status with relatives.
89144409|NCT04194632|Experimental|Single Arm|All patients will undergo hemodynamic measurements at baseline, with the intervention, and post-intervention thus serving as their own control.
89144410|NCT00948883||Patient-Case|Transplanted patient with cancer
89144411|NCT00948883||Patient-Control|Transplanted patient without cancer
89144412|NCT02710812||Rectum sparing group|"Patients who have all of the following requirements:~Major or complete clinical response at restaging after 7-8 weeks from the end of neoadjuvant therapy, confirmed at second restaging (after 11-12 weeks from the end of neoadjuvant therapy);~Written informed consent (after 2nd restaging).~Note: They will be subject to wait-and-see approach only patients with cCR."
89144413|NCT04227236|Experimental|E-based virtual training|Participants in the e-based virtual training (up to 8 participants per session) will be placed at one of eight computers (with headphones), which we estimate will take less time (about 40 minutes), due to the individualized learning and 1:1 nature of the training instead of 1:15. Participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
89144414|NCT04227236|Active Comparator|In-person training|Participants in-person training will participate in a class with 15-20 participants like the usual MPC training environment. The training will last 1 hour. Like the e-based virtual training, participants will complete the condom-line up facilitator training module that corresponds to the Making Proud Choices curriculum.
89144415|NCT00949039|Experimental|Chemotherapy|Isolated pelvis perfusion
89144416|NCT00949039|Active Comparator|Control|Standard treatment
89144417|NCT02710656|Experimental|Drug Coated Balloon (DCB) - Legflow®|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.
89144418|NCT02710656|Active Comparator|Standard PTA - POBA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).
89144419|NCT00952471|No Intervention|Baseline Period|Patients in the baseline period were cared for using the standard historical electronic order set.
89144420|NCT00952471|Active Comparator|Post Intervention Period|Patients in the Post intervention period were cared for with evidence-bsed modified order set changes
89144421|NCT04227392|Experimental|Experimental|women who undergo radiofrequency therapy
89144422|NCT00952549|Experimental|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
89144423|NCT02710500|Experimental|Cohort 1 (Low Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 2 x 10^12 in one muscle.~Intervention Drug: rAAVrh.MHCK7.DYSF.DV"
89290612|NCT05415826|Active Comparator|PPV group|Eyes with proliferative diabetic retinopathy underwent PPV surgery with silicone oil filling.
89144424|NCT02710500|Experimental|Cohort 2 (High Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 6 x 10^12 vg in one muscle.~Intervention Drug: rAAVrh74.MHCK7.DYSF.DV"
89144425|NCT02781038|Experimental|Interventional|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will be given a teaching intervention and receive another attitude survey.
89144426|NCT02781038|Other|Control|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will receive another attitude survey.
89144427|NCT02710578|Active Comparator|Alcohol|Alcohol
89144428|NCT02710578|Placebo Comparator|Placebo|Tonic water
89144429|NCT00940849|Experimental|Dietary Supplement: Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
89144430|NCT02780882|Experimental|Pasireotide|Each patient will be treated with pasireotide at an initial dose of 600 μg twice daily for one month. The dose will be further increased to 900 μg twice daily for month 2 and 3. After month 3, patients who continue to meet the inclusion and exclusion criteria will be entered into an additional 3 months of treatment.
89144431|NCT02710266|Placebo Comparator|Placebo group|hepatectomy without Gabexate Mesilate
89144432|NCT02710266|Experimental|Preoperative Gabexate Mesilate group|Gabexate Mesilate administered from the preoperative day
89144433|NCT02710266|Experimental|Intraoperative Gabexate Mesilate group|Gabexate Mesilate administered from the operative day
89144434|NCT04229576|Active Comparator|Using TENS to relief pain during hystroscopy|device intensity (amplitude) will be individually adjusted to each participant's maximum sensory level (strongest reported tingling feeling without pain and with no muscle contractions, the TENS output intensity will be increased during the treatment every time the patient accommodated to the TENS stimulus.
89144435|NCT04229576|Placebo Comparator|Using placebo TENS (not active) during hystroscopy|participants will be connected to the TENS unit in exactly the same way as participants in the active TENS group with the unit emitting the active indicator light and sound but delivering no electrical stimulation.
89144436|NCT00612846|Experimental|A|
89144437|NCT00612846|Experimental|B|
89144438|NCT00562159|Placebo Comparator|Placebo|Matching Placebo
89144439|NCT00562159|Experimental|SCH 697243|
89144440|NCT02710344|No Intervention|Usual Care|Usual care at community mental health care provider
89144441|NCT02710344|Experimental|Telehealth|Usual care at community mental health care provider PLUS psychiatric telehealth program with remote monitoring.
89144442|NCT02778464||Group A: Female IBD and RA (non-pregnant)|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
89144443|NCT02778464||Group B: Female IBD|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
89144444|NCT02778464||Group C: Female - Healthy Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
89144445|NCT02778464||Group D: Female - RA Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
89144446|NCT02710110|Experimental|Active Respiratory Trainer|Participants enrolled in this arm will be given the PowerLung trainer. The adjustable spring allows for discrete and calibrated changes to the valve, which in turn blocks air until sufficient inspiratory or expiratory pressure is applied by an individual. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
89144447|NCT02710110|Sham Comparator|Sham Trainer|Participants enrolled in this arm will be given the PowerLung trainer; however, the adjustable spring allows for discrete and calibrated changes to the valve and these will not have any resistance. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
89144448|NCT05284292|Experimental|experimental arm|The Guardian platform consists of the robot Misty II, the Senior App and the Caregiver App will be tested by the elderly subjects together with their caregivers
89144449|NCT00949195||COPD patients|COPD patients with severe obstruction performed the tests.
89144450|NCT00949195||Healthy subjects|Age-matched healthy subjects performed the same test also.
89144451|NCT05264454|Placebo Comparator|0 L|This will be the arm where the baseline IVC assessment size is conducted at
89144452|NCT05264454|Active Comparator|30 L|The HFNC flow will be set at 30 L / min. The IVC size will then be assessed using a POCUS
89144453|NCT05264454|Active Comparator|60 L|The HFNC flow will be set at 60 L / min. The IVC size will then be assessed using a POCUS
89144454|NCT04936646|Experimental|Classic rTMS Stimulation using the B65 Coil|
89144455|NCT04936646|Experimental|Deeper rTMS Stimulation using the B70 Coil|
89144456|NCT04936646|Sham Comparator|control group with a sham stimulation using a sham coil|
89144457|NCT00952627|Experimental|Pycnogenol|200 mg/day
89144458|NCT00952627|Placebo Comparator|Control|placebo
89144459|NCT02710188|Experimental|HTL0009936 modified release (MR) Formulation|Intervention: 5 different modified release formulations of HTL0009936, as a single dose
89144460|NCT02710188|Active Comparator|HTL00009936 immediate release (IR) fasted|Intervention: 1 immediate release formulation of HTL0009936, as a single dose in the fasted state
89144461|NCT04011709|Other|Visit 1 and Visit 2, Test Arm 2A|Subjects who carried out 3 attempts at Visit 1, failed to achieve nebulization success and subsequently were included in Test Arm 2A for Visit 2
89144462|NCT04011709|Other|Visit 1 and Visit 2, Test Arm 2B|Subjects who carried out 3 attempts at Visit 1, achieved nebulization success and were subsequently included in Test Arm 2B for Visit 2
89144463|NCT02778620||Aortic Valve Replacement|Post Anaesthetic Care Unit (PACU) patients treated with aortic valve replacement (AVR) are highly eligible for this study.These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
89144464|NCT04862832|Experimental|CPT - LLM - MLM|On day 1: CPT On day 2: LLM On day 3: MLM
89144465|NCT04862832|Experimental|CPT - MLM - LLM|On day 1: CPT On day 2: MLM On day 3: LLM
89144466|NCT00952783||1|
89144467|NCT02779712|Active Comparator|Remote Ischaemic Conditioning|Remote ischaemic conditioning (RIC group): 4 cycles of intermittent limb ischaemia - alternating 5 minutes inflation (20mmHg above systolic BP) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
89144468|NCT02779712|Sham Comparator|Control|Control: 4 cycles of alternating 5 minutes inflation (up to 30 mmHg) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
89144469|NCT00611676|Experimental|A|All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
89144470|NCT00949273||cylindrical abdominoperineal resection|patients underwent cylindrical abdominoperineal resection for advanced very low rectal cancer
89144471|NCT00949273||abdominoperineal resection|patients underwent conventional abdominoperineal resection for advanced very low rectal cancer
89144472|NCT04848714|Experimental|Group A: ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab´)2]|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab´)2] lyophilized powder for solution 10 mL
89144473|NCT02710032|Experimental|Intervention|Social Network-Based Adherence Intervention
89144474|NCT02710032|No Intervention|Control|Control
89144475|NCT05300581|Other|Observational Arm|Patients with a history of injection opioid use will receive home OPAT while also receiving substance use disorder care including medications for opioid use disorder and multidisciplinary health coach and case management support.
89144476|NCT00952861|Active Comparator|Doxycycline|Doxycycline 200 mg QD in 5 days
89144477|NCT00952861|Placebo Comparator|Placebo|Matching placebo QD i 5 days
89144478|NCT04844346|Experimental|Plant stanol group|This arm receives 4g of plant stanols per day (delivered as plant stanol esters) by consuming mini drinks (100 mL each).
89144479|NCT04844346|Placebo Comparator|Placebo group|This arm receives mini drinks without added plant stanols (delivered as plant stanol esters).
89144480|NCT00949351|Placebo Comparator|Aliskiren|
89144481|NCT05140070|Experimental|Intervention|Mousse with prebiotic
89144482|NCT05140070|Active Comparator|Control|Mousse without prebiotic
89144483|NCT00953095|Experimental|Caregiver Mediated Model (CMM)|focuses on joint attention/engagement intervention using an established evidence based treatment (Kasari et al., 2006). It involves meeting the parent and child in their home for one hour, twice a week for 12 weeks. In this intervention, the parent-child pair meet with the interventionist (as opposed to the group training in the CEM condition). Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input and coaching from the interventionist) as they implement these techniques with their child.
89144484|NCT00953095|Experimental|Caregiver Education Model (CEM)|focuses on teaching parents information about autism, behavior modification, and community services using a manualized approach (Brereton & Tonge, 2005). Parents will receive information on child development each week, and will be able to ask questions and discuss the information vis-à-vis their own child. This intervention is manualized (Brereton & Tonge 2005). In the CEM condition, parents meet in a group (without their children) in a community-based setting to receive the intervention. Intervention sessions occur once a week for 2 hours.
89144485|NCT00949507||anaesthesia using propofol|the children are anaesthetized using intravenous anaesthesia with propofol and remifentanil; a binasal catheter is used for administration of oxygen during the anaesthesia
89144486|NCT00949507||anaesthesia using sevoflurane|the patients are anaesthetized using sevoflurane 1 MAC; a laryngeal mask is used
89144487|NCT04228562|No Intervention|Non-modifiable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
89144488|NCT04228562|Experimental|Non-modifiable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
89290613|NCT05415826|Experimental|PPV+implant group|Eyes with proliferative diabetic retinopathy underwent PPV surgery with silicone oil filling and slow-release dexamethasone implant.
89290614|NCT01227330|Experimental|Medication adherence intervention|Receives 12-week behavioral feedback intervention to improve adherence to statin medication
89144489|NCT04228562|Experimental|Non-modifiable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. Participant begins with 130 points (each worth HK$0.5) in each round. After the 10 rounds, the computer randomly selects 1 round and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. X is a modifiable cause, which means that it can be changed by taking some actions. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
89144490|NCT04228562|Experimental|Non-modifiable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
89144491|NCT04914806||Cases|Infants treated with iNO (from birth to 1-3 weeks of life) or sequential treatment with iNO and sildenafil (for 1 to 3 months).
89144492|NCT04914806||Controls|Infants matched to cases (gestational/postnatal age, gender, disease state) and no iNO treatment.
89144495|NCT05109416|Active Comparator|Group A|Children will receive bupivacaine 0.5% ( 1 mg / kg ) ,divided in each side , by infiltration through anterior and posterior approaches to block glossopharyngeal nerve
89144496|NCT05109416|Placebo Comparator|Group B|Children will receive sterile saline 0.9 , 5 cm in each side , by infiltration through anterior and posterior approaches
89144497|NCT05100290||HVS+|Subjects without documented respiratory or cardiac disease, with a spirometry and metacholine tests within expected values AND with complaints documented by a Nijmegen questionnaire score of ≥23/64 (suspected of idiopathic hyperventilation)
89144498|NCT05100290||HVS-|Healthy controls without documented respiratory or cardiac disease, with a spirometry and metacholine tests within expected values AND without complaints documented by a Nijmegen questionnaire score of <23/64
89144499|NCT04226924|Experimental|Trehalose|Trehalose 9% solution: The dose is 0.75 g/kg administered IV over 60 ± 5 minutes once weekly.
89144500|NCT04226924|Placebo Comparator|0.9% Normal Saline|Normal saline: weight-based volume administered IV over 60 ± 5 minutes once weekly.
89144501|NCT02778386|Experimental|Cohort 1|6 subjects, male & female will receive one dose each of 200 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
89144502|NCT02778386|Experimental|Cohort 2|6 subjects, male & female will receive one dose each of 400 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
89144503|NCT02778386|Experimental|Cohort 3|8 subjects, males and females, 6 subjects will receive one dose each 800 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
89144504|NCT02778386|Experimental|Cohort 4|8 subjects, males and females, 6 subjects will receive one dose each 1200 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
89144505|NCT02779088|Experimental|Early exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the AB arm receive exercise and nutrition intervention first, followed by the education course.
89144506|NCT02779088|Active Comparator|Delayed exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the BA arm receive the education course first, followed by exercise and nutrition.
89144507|NCT05264064||Infants aged 0-18 months|Healthy infants aged 0-18 months, divided into four age groups: 0-3 months, 4-7 months, 8-11 months, and older than 12 months
89144508|NCT02778542|Active Comparator|Electronic Pill Bottle|Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data. Participants will also receive a daily text message reminder to take your blood pressure medication.
89144509|NCT02778542|Active Comparator|Bidirectional Text Messaging|Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication. Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day.
89144510|NCT02778542|No Intervention|Usual Care|Participants in this arm do not receive a medication reminder system.
89144511|NCT00612300|Experimental|A-B|Gait training by an automatic gait trainer (Lokomat) for 3 weeks followed by 3 weeks of categorized gait training by a physical therapist
89144512|NCT00612300|Experimental|B-A|Categorized gait training by physical therapists for 3 weeks followed by 3 weeks of lokomat training
89144513|NCT02778308|Active Comparator|chemotherapy group|6 cycles of Gemcitabine + Cisplatin as per the following schedule Injection Gemcitabine 1 gm/kgm2 intravenous over 30 min Day1 and Day8 Injection Cisplatin 70 mg/m2 intravenous on Day1
89144514|NCT02778308|No Intervention|control group|follow up
89144515|NCT00612378|Experimental|1|
89144516|NCT02709876|Experimental|Stem Cells|Intravitreal Injection of bone marrow derived CD34+, CD133+, CD271+ stem cells.
89290615|NCT01227330|No Intervention|Control|No intervention
89144517|NCT02709798|Experimental|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection), ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
89144518|NCT02709798|Placebo Comparator|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
89144519|NCT02776202|Experimental|Reduced-intensity conditioning regimen|"The HSCT preparative regimen will consist of~Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~Fludarabine: 35 mg/m2/day IV on Days -8 through -4~Melphalan: 140 mg/m2 IV on Day -3~Rest on Day -2 and -1~Day 0 is the day of transplant~GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
89144520|NCT00921557|Experimental|1A: Alendronate/Alendronate|Participants received alendronate for 96 weeks and calcium carbonate/vitamin D for 144 weeks
89144521|NCT00921557|Experimental|1B: Alendronate/Placebo|Participants received alendronate for 48 weeks followed by placebo for 48 weeks and calcium carbonate/vitamin D for 144 weeks
89144522|NCT00921557|Experimental|2: Placebo/Alendronate|Participants received placebo for 48 weeks followed by alendronate for 48 weeks and calcium carbonate/vitamin D for 144 weeks
89144523|NCT04226378||Omnipod cohort|Adults with T1D who switch from MDI therapy to insulin pump therapy with Omnipod.
89144524|NCT04226378||MDI cohort|Adults with T1D who continue MDI therapy.
89144525|NCT04226066|Experimental|T601/T601+5-FC|Part 1: Dose-escalation study of T601 single-dose; Part 2: Dose-escalation study of T601 single-dose combined with 5-FC; Part 3: Dose-escalation study of T601 multiple-dose combined with 5-FC; Part 4: Extended study of T601 multiple-dose combined with 5-FC.
89144526|NCT00953251||patients with acute coronary syndrome|patients with acute coronary syndrome
89144527|NCT00953251||Non-STEMI and unstable angina|
89144528|NCT02709642|No Intervention|Control|Control Participants will complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight.
89144529|NCT02709642|Experimental|Deposit Contract|The deposit contract group will also complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight. In addition, the deposit contract group will be asked to make a deposit of at least $100 each 10-week period over the course of one year (50 weeks). Each week, they will recoup 1/10 of their 10-week deposit if they are within two pounds of their baseline weight or lower. If they are more than two pounds above their baseline weight, they will forfeit 1/10 of their 10-week deposit. The money they forfeited for that week will go into a collective pool to be divided up at the end of each 10-week period by all deposit contract participants who successfully maintained their weight loss at the end of the 10-week period.
89144530|NCT04252391|Active Comparator|Standard care|Standard care will consist of standard physical therapy care which may include the following: cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, dry needling with or without electrical trigger point dry needling, soft tissue release and prescribed therapeutic exercises .
89144531|NCT04252391|Active Comparator|standard care with perineural electrical dry needling.|This arm will consist of standard care with perineural electrical dry needling, using a high frequency stimulation placed near the nerve, differing from addressing muscular trigger points. For example, a dry needle placed in the semispinalis capitus muscle along the greater occipital nerve pathway, stimulated at 80 Hz.
89144532|NCT02776124|Experimental|ONS group|Individualized dietary counseling+ONS(Healing elements)during CRT Interventions: (Healing elements)
89144533|NCT02776124|No Intervention|control group|Individualized dietary counseling during CRT
89144534|NCT05263752||Undergone ERCP with NvisionVLE® Imaging Low Profile System|Undergone ERCP with NvisionVLE® Imaging Low Profile System at MDMC between 10/15/2017 and 10/15/2019
89144535|NCT02779634|Placebo Comparator|Placebo|Placebo three times daily
89144536|NCT02779634|Active Comparator|Active|Pills of 100 mg ubiquinol three times daily
89144537|NCT04255589|Experimental|Experimental Group|Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)
89144538|NCT04255589|Active Comparator|Active comparator Group|Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)
89144539|NCT05261256||Participants treated for pediatric cancer|This group includes children, adolescents and young adults treated for pediatric cancer who received anthracyclines and/or chest radiation during treatment.
89144540|NCT05261256||Healthy control subjects|This group includes healthy children, adolescents and young adults without a history of pediatric cancer as age-and gender-matched control subjects.
89144541|NCT02776280|Placebo Comparator|Negative control|Meal prepared with non-fluoridated water and salt
89144542|NCT02776280|Experimental|Fluoridated water|Meal prepared with fluoridated water
89144543|NCT02776280|Experimental|Fluoridated salt|Meal prepared with fluoridated salt
89144544|NCT04225910|Experimental|mCRPC for PSMA RLT|225Ac-PSMA 100KBq/kg, iv. Totally 2 doses, every 8 weeks.
89144545|NCT04252313|No Intervention|Group A|This arm represents the control group. They will be undergoing the circumcision without any music, with the established standard for analgesia [EMLA+Sucrose+Ring Block]
89144546|NCT04252313|Experimental|Group B: Music|"In addition to the standard analgesia as explained for group A, Music will be played from the Baby Go to Sleep playlist which includes nursery rhymes and lullabies metonymized to an actual human heartbeat (Houser, 1994). Music will start after the baby settles on the board and before the surgeon starts the procedure."
89144547|NCT02776358|Experimental|High Fidelity Simulation|Students will receive a 1 hour High fidelity simulation session
89144548|NCT02776358|Experimental|Video Case|Students will receive a 1 hour assisted Video Case learning session
89144549|NCT04252001|Experimental|Group YT|Group receives YESS! game and transition-toolkit
89144550|NCT04252001|Experimental|Group GT|Group receives control game and transition-toolkit
89144551|NCT04252001|Experimental|Group T|Group receives transition-toolkit
89144552|NCT04252001|No Intervention|Group O|Group receives usual transition care
89144553|NCT00744471|Experimental|Tanezumab 10 mg|Tanezumab 10 mg IV every 8 weeks
89144554|NCT00744471|Experimental|Tanezumab 5 mg|Tanezumab 5mg IV every 8 weeks
89144555|NCT00744471|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg IV every 8 weeks.
89144556|NCT00744471|Experimental|Placebo|Placebo
89144557|NCT02776436|Experimental|Breast cancer|"Dose of prophylactic dexamethasone will be reduced as follows:~STEP 1: 12 mg dexamethasone per day (8-4mg/day) for 3 days starting 1 day before administration. (n=6)~STEP 2: 8mg dexamethasone per day (8mg once a day) for 3 days starting 1 day before administration. (n=6)~STEP 3: day -1: 4 mg, day 0: 8 mg, day 1: 4 mg. (n=6)~STEP 4: day -1: 0 mg, day 0: 8 mg, day 1: 4 mg. (n=6)~STEP 5: day -1: 0 mg, day 0: 8 mg, day 1: 0 mg. (n=6)~STEP 6: day -1: 0 mg, day 0: 4 mg, day 1: 0 mg. (n=6)"
89144558|NCT02776436|Experimental|Prostate cancer|"Dose of prophylactic dexamethasone will be reduced as follows:~STEP 1: 2dd 8 mg at 12 and 1 hr before treatment (besides standard prednisone 5mg bid) (n=6)~STEP 2: 8mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)~STEP 3: 4mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)~STEP 4: 0mg dexamethasone (only standard prednisone 5mg bid). (n=6)"
89144559|NCT04251923|Experimental|vagianl prolapse surgery accompanied with TVT sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need. Patient who falls in Group will undergo mid urethral sling with tension free vaginal tape (TVT) using TVT mid urethral sling.
89144560|NCT04251923|No Intervention|vaginal prolapse surgery not accompanied with sling|patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need.
89144561|NCT02776046|Experimental|High FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively 3h with 0.8 FiO2 and individualized CPAP"
89144562|NCT02776046|Active Comparator|Conventional FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.3. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively 3h with 0.3 FiO2 and individualized CPAP"
89144563|NCT02775734|Active Comparator|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + LOD
89144564|NCT02775734|Active Comparator|NO N-acetyl-cysteine|Clomiphene citrate + LOD
89144565|NCT02778230|Experimental|Pea Fiber|Two fiber snacks fortified with 5 g/each of pea fiber (Best Pea Fiber 200) will be consumed each day for a period of two weeks.
89144566|NCT02778230|Other|Control|Two control snacks will be consumed each day for a period of two weeks.
89144567|NCT02772926|Placebo Comparator|Placebo|450 g per pill, 2 pills per day to get 900 mg per day
89144568|NCT02772926|Active Comparator|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 450 mg per pill, 2 pills per day to get 900 mg per day
89144569|NCT02709564|Placebo Comparator|Group A|400 mg placebo
89144570|NCT02709564|Active Comparator|Group B|400 microgram misoprostol
89144571|NCT02773082|Experimental|Reclaim™ DBS Therapy|Procedure: Reclaim™ DBS Therapy The DBS lead is stereotactically introduced into the target in the brain (AIC) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region. This is performed by a neurosurgeon skilled in this technique, as the same procedure is routinely performed in patients with other diseases (using other brain targets).
89144572|NCT00611832|Active Comparator|Standard|"Standard information-only version of the television series that includes only modeling and demonstration of the targeted parenting skills"
89144573|NCT00611832|Experimental|Enhanced|"Enhanced behavior activation version of the television series that includes all of the content of the standard information-only version, but is also designed to actively promote parental behavior change, through additional content elements addressing attributions, self-efficacy and expectancies, social support, and emotional reactivity."
89144574|NCT00611832|No Intervention|Control|Waitlist control
89144575|NCT02777996|Active Comparator|Screening arm|Low Dose Computed Tomography offered at baseline and for 3 repeated rounds
89144576|NCT02777996|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care (in Europe lung cancer screening is not raccomended), according with the GP.
89144577|NCT02777840|Active Comparator|Face mask group|Patients will be given oxygen via face mask as per routine practice, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
89144578|NCT02777840|Active Comparator|THRIVE group|Patients will be given oxygen via high flow oxygen in Optiflo, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
89144579|NCT04688814|Active Comparator|Morphine Group|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine. Intravenous morphine in a dose of 0.05 mg/kg will be given as a rescue analgesic when the VAS ≥4 postoperatively for 24 hours
89144580|NCT04688814|Experimental|SEQ group|Patients will receive ultrasound guided SEQ block preoperatively before the induction of general anaesthesia. Twenty five ml of 0.25 % bupivacaine will be given in the QL plane and 25 ml of the same concentration will be given in the erector spine plane
89144581|NCT02775890||Eating lead-shot wild game|Hunters that have eaten lead-shot in the past week will have blood lead levels measured.
89144582|NCT02775890||Not eating lead-shot wild game|Hunters that have not eaten lead-shot in the past week will have blood lead levels measured.
89144583|NCT02709252|Experimental|Cohort|Only one cohort is included with comparisons of two different hemodynamic parameters
89144584|NCT04826042|Active Comparator|contrast group|injection of contrast medium 6 cc during thoracic epidural catheterization
89144585|NCT04826042|Placebo Comparator|normal saline group|injection of normal saline 6 cc during thoracic epidural catheterization
89144586|NCT05260632||no intervention|
89144587|NCT05260632||2 groups|
89144588|NCT02772692|Experimental|Squatting pan|Defecation using a squatting pan
89144589|NCT02772692|No Intervention|Toilet|defecation using a standard-sized toilet
89144590|NCT00744237|Experimental|1|"Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration~Open-label amlodipine may be given"
89144591|NCT00744237|Active Comparator|2|"Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration~Open-label amlodipine may be given"
89144592|NCT00744237|Active Comparator|3|"HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration~Open-label amlodipine may be given"
89144593|NCT05260554||using fosfomycin|The patients in this group; have been prescribed fosfomycin for 7 days (3 doses, two days apart).
89144594|NCT05260554||using cranberry extract|The patients in this group; took 7 days (1 tablet each day) of cranberry tablets.
89144595|NCT04177316||hypermethylation|The hypermethylation group was defined as differential methylation status of tumor- normal ≥ 5%.
89144596|NCT04177316||hypomethylation/no change|The hypomethylation were defined as differential methylation status of tumor- normal <5%
89144597|NCT04089345|Experimental|Open label ustekinumab|All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48. All subjects will receive concomitant antibiotic treatment with ciprofloxacin or metronidazole from baseline through Week 4. Intravenous induction doses will be 260mg for patients <55kg, 390mg for patients between 55 and 85kg, and 520mg for patients with a body weight >85 kg.
89144598|NCT02772536|Other|Visual Stimulus Condition Set|"In this single arm study all participants are subject to a set of three visual stimulus conditions.~These are: Low ambient light; Self selected tinted light; White light"
89144599|NCT02693574|Active Comparator|Clarithromycin|Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days
89144600|NCT02693574|Experimental|Levofloxacin|Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days
89144601|NCT04920110||Phase 1: Qualitative Interviews|Approximately 20 parents/caregivers will discuss typical communication abilities of their loved one and complete the ORCA measure for determination of its content validity through a hybrid approach of concept elicitation and cognitive testing.
89144602|NCT04920110||Phase 2: Cross-Sectional Assessment of Psychometric Properties|Approximately 250 parents/caregivers will complete the ORCA measure and additional measures to determine its psychometric properties including reliability, floor/ceiling effects and construct validity.
89144603|NCT02597205|Experimental|Mobile app|Multi-faceted intervention for physicians and patients respectively: physician-facing app and patient-facing messages
89144604|NCT02709174||pregnant with pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
89144605|NCT02709174||pregnant without pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
89144606|NCT02709408||Carbapenem-resistant Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-resistant Enterobacteriaceae
89144607|NCT02709408||Carbapenem-resistant A. baumannii|Patients with bloodstream infections due to carbapenem-resistant Acinetobacter baumannii
89144608|NCT02709408||Susceptible Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-susceptible Enterobacteriaceae matched to carbapenem-resistant ones by centre, type of ward, infection type, acquisition and previous duration of hospitalisation.
89144609|NCT02709408||Admitted control patients|Patients without infection due to Enterobacteriaceae matched to carbapenem-resistant Enterobacteriaceae cases according to centre, ward and previous length of hospitalisation.
89144610|NCT00743145|Placebo Comparator|Placebo naltrexone + Inactive marijuana|Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
89144611|NCT00743145|Placebo Comparator|Placebo naltrexone + Active marijuana (5.5% THC)|Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
89144612|NCT00743145|Placebo Comparator|Placebo naltrexone + Active marijuana (6.2% THC)|Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
89144613|NCT00743145|Experimental|Naltrexone + Active marijuana (5.5% THC)|Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
89144614|NCT00743145|Experimental|Naltrexone + Active marijuana (6.2% THC)|Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
89144615|NCT00743145|Placebo Comparator|Naltrexone + Inactive marijuana|Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
89144616|NCT02772614|Experimental|Nebicapone (200 mg)|"Each subject was to receive one single dose of 2.5 MBq [14C]-labelled BIA 3-202 (200 mg) together with a total of 250 mL non-carbonated water.~The study drug was given after an overnight fast of at least 10 hours after the in-house stay. During waking hours on Day 1, subjects had to have a fluid intake of at least 150 mL per hour starting 1 hour before study drug administration."
88803657|NCT02169479|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
88803658|NCT02169479|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
88803659|NCT02169479|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
89144617|NCT00917631|Experimental|Co-bedding|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
89144618|NCT00917631|No Intervention|Standard care|For infants who are randomized to receive standard care, the twin pair will remain in separate incubators as per current NICU policy. The infant will be nested in boundaries consistent with neonatal care practices. The heelstick may occur at any time following randomization (within 10 days) to maintain consistency between groups.
89144619|NCT00611910|Experimental|DES|drug-eluting stents
89144620|NCT00611910|Active Comparator|BMS|bare metal stents
89144621|NCT04089189|Experimental|IMP4297|100 subjects to receive IM4297 orally.
89144622|NCT02775656||Prospective cohort|For a pregnancy to be enrolled in the prospective cohort, the pregnancy outcome cannot be known (ie, no prenatal diagnosis of a fetus with a congenital defect and the pregnancy is still ongoing at the time of consent).
89144623|NCT02775656||Retrospective cohort|For a pregnancy to be enrolled in the retrospective cohort, the pregnancy outcome must already be known (ie, a congenital defect has already been identified at the time of consent into the pregnancy follow-up study, or the pregnancy has been completed at the time of consent).
89144624|NCT05388903|Experimental|DS-2325a SC|Participants who will be randomized to receive DS-2325a as a fixed dose subcutaneous (SC) injection (starting dose 30 mg).
89144625|NCT05388903|Placebo Comparator|Placebo SC|Participants who will be randomized to receive placebo as a subcutaneous (SC) injection.
89144626|NCT05388903|Experimental|DS-2325a IV|Participants who will be randomized to receive DS-2325a as a fixed dose intravenous (IV) infusion (starting dose 100 mg).
89144627|NCT05388903|Placebo Comparator|Placebo IV|Participants who will be randomized to receive placebo as an intravenous infusion.
89144628|NCT00613158||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with significant subclinical atherosclerosis (SA) and a low Framingham risk score
89144629|NCT00613158||2|Participants from MESA with no SA and a low Framingham risk score
89144630|NCT00613158||3|Healthy participants from Northwestern University
89144631|NCT04089267|Experimental|experimental group 1|rhTPO injection7500 U ;one time a day; 14 times of administration
89144632|NCT04089267|Experimental|experimental group 2|rhTPO injection15000 U;one time a day;14 times of administration
89144633|NCT04089267|Experimental|experimental group 3|rhTPO injection15000 U;1 time every other day, 7 times;
89144634|NCT04089267|Experimental|experimental group 4|rhTPO injection30000 U；1 time every other day, 7 times;
89144635|NCT04788524|Experimental|Computer Task Manipulation|Participants will complete computer tasks while undergoing an fMRI brain scan
89144636|NCT02708784||Pompe disease|Patients will perform muscle strength measurement with dynamometer and MR-imaging. After 8 months the investigations will be repeated.
89144637|NCT02708784||Myotonic Dystrophy|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
89144638|NCT02708784||Healthy controls|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
89144639|NCT00635180|Experimental|1|1: Healthy subjects
89144640|NCT00920855|Experimental|Bendamustine and Bortezomib|Bendamustine in escalating doses of 50, 70 or 90 mg/m^2 as combination therapy with bortezomib at 1.0 mg/m^2/dose administered for up to eight 28 day cycles.
89144641|NCT04247256|Experimental|Treatment arm|SCO-101 in combination with FOLFIRI
89144642|NCT04088877|Experimental|Exercise and Art Sculpting Class|Participants will take part in a twelve week exercise program twice per week as well as an eight week art sculpting class once a week.
89144643|NCT02772458|Experimental|Crohn's Disease|Active Crohn's Disease
88803660|NCT02169479|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
89144644|NCT02772458|Experimental|Healthy|Healthy volunteers
89144645|NCT02596815|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 3 times a week during 6 continuous weeks.The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
89144646|NCT02596815|Active Comparator|Waiting list control group|Patients assigned to a 6 week waiting list to receive treatment
89144647|NCT02775422|Experimental|Pregnant women|Pregnant women
89144648|NCT04251767|Experimental|Observational group|5u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
89144649|NCT04251767|Placebo Comparator|Control group|5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.
89144650|NCT02693028|Active Comparator|probiotic lozenge|Two probiotic lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
89144651|NCT02693028|Active Comparator|Probiotic capsule|Two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
89290616|NCT01227330|Active Comparator|Attention-control|Receives visits on the same schedule as the intervention group, with health education that is unrelated to medications or cholesterol
89144652|NCT02693028|Active Comparator|Probiotic chewing gum|The probiotic chewing gum should be chewed on for about 10 minutes. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
89144653|NCT02693028|Placebo Comparator|Placebo lozenge|Two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
89144654|NCT02693028|Placebo Comparator|Placebo capsule|Two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
89144655|NCT04816019|Experimental|Group 1a: Low Dose|"A single, Covid-19 vaccine naive volunteer will receive a single dose of 5x10^9vp ChAdOx1 nCOV-19 IN.~Volunteers in Group 1a & b will be randomized to receive booster dose of 5 x 10^9vp ChAdOx1 IN or no booster"
89144656|NCT04816019|Experimental|Group 1b: Low dose|"5 Covid-19 vaccine naive volunteers will receive a single dose of 5x10^9vp ChAdOx1 nCOV-19 IN.~Volunteers in Group 1a & b will be randomized to receive booster dose of 5 x 10^9vp ChAdOx1 IN or no booster"
89144657|NCT04816019|Experimental|Group 2a: High Dose|"3 Covid-19 vaccine naivevolunteers will receive a single dose of 5x10^10vp ChAdOx1 nCOV-19 IN.~Volunteers in Group 2a & b will be randomized to receive booster dose of 5 x 10^10vp ChAdOx1 IN or no booster"
89144658|NCT04816019|Experimental|Group 2b: High Dose|"Up to 15 Covid-19 vaccine naive volunteers will receive a single dose of 5x10^10vp ChAdOx1 nCOV-19 IN.~Volunteers in Group 2a & b will be randomized to receive booster dose of 5 x 10^10vp ChAdOx1 IN or no booster"
89144659|NCT04816019|Experimental|Group 3: Intermediate Dose|"Up to 18 Covid-19 vaccine naive volunteers will receive a single dose of 2x10^10vp ChAdOx1 nCOV-19 IN.~Volunteers will be randomized to receive booster dose of 2 x 10^10vp ChAdOx1 IN or no booster"
89144660|NCT04816019|Experimental|Group 4: High Dose, vaccinated boost|6 volunteers, previously vaccinated with two doses of ChAdOx1 nCoV-19 IM will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 IN.
89144661|NCT04816019|Experimental|Group 5: High Dose, vaccinated boost|6 volunteers, previously vaccinated with two doses of BNT162b IM will receive a single dose of 5x10^10vp ChAdOx1 nCoV-19 IN.
89144662|NCT04251845|Active Comparator|Trial group|Intervention : Topical Melatonin(3%) at dosage of 15 mg once daily
89144663|NCT04251845|Placebo Comparator|Control Group|Intervention : Placebo once daily
89144664|NCT02775578|Experimental|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
89144665|NCT02775578|Experimental|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
89144666|NCT02775578|Experimental|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
89144667|NCT05207358|Experimental|RITUXILUP regimen|- 2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15. Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.
89144668|NCT05207358|Other|EUROLUPUS regimen (Standard therapy)|3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment. All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
89144669|NCT02596737|Other|workers|"Workers will fulfil a visual analog scale of Well-being regarding 3 main categories: Physically, Mentally, At Work."
89144670|NCT04251299|Experimental|Single Arm|All participants will receive the 10-month mentored, vegetable gardening intervention
89144671|NCT02772380|Experimental|VT/ VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and termination through use of a defibrillator, will be carried out as the intervention in all subjects undergoing study procedures.
89144672|NCT04186884||Observational (questionnaires)|Patients and caregivers visiting SCC for a consult or admitted to PCU complete questionnaires over 35 minutes.
89144673|NCT02596581|No Intervention|diabetics with periodontally healthy group|Control group
89144674|NCT02596581|No Intervention|systemically and periodontally healthy group|Control group
89144675|NCT02596581|Active Comparator|diabetics with chronic periodontitis group|non-surgical periodontal treatment was performed
89144676|NCT02596581|Active Comparator|chronic periodontitis group|non-surgical periodontal treatment was performed
89144677|NCT02777684||knee osteoarthritis|
89144678|NCT04257149|Experimental|Hemorrhagic stroke group (group A)|Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.
89144679|NCT04257149|Experimental|Ischemic stroke group (group B)|Patient group B is defined as patients that are diagnosed with ischemic stroke.
89144680|NCT04257149|Experimental|Stroke mimic group (group C)|Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.
89144681|NCT02596425|Experimental|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
89144682|NCT02596425|Experimental|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
89144683|NCT02596425|Experimental|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
89144684|NCT02772146|Experimental|Device: CLS UF|The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.
89144685|NCT04593810|Experimental|INTELLiVENT-ASV|Use of INTELLIVENT-ASV after intubation and during all mechanical ventilation in the ICU.
89144686|NCT04593810|Active Comparator|Conventional ventilation|Use of conventional ventilation after intubation and during all mechanical ventilation in the ICU.
89144687|NCT04255355|Active Comparator|Pelvic alignment and forceful expiration exercise|
89144688|NCT04255355|Experimental|Pelvic repositioning exercise|
89144689|NCT04255355|Experimental|Diaphragmatic breathing exercise|
89144690|NCT05387031||patients with symptomatic stricturing Crohn's disease|The decision to start ustekinumab was at the discretion of the treating physician. The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician.
89144691|NCT04251455||TMJ disease/disorder characterisation|Patients with the diagnosis disc displacement without reduction (DDwoR), or disc displacement with reduction (DDwR), or osteoarthritis (OA), or chronic inflammatory arthritis (CIA) were designated to TMJ surgery. According to the Swedish national guidelines on TMJ surgery DDwoR, OA, and CIA patients had arthroscopy and DDwR had discectomy.
89144692|NCT02596659|Experimental|The experimental group|Participants in the experimental group received radial extracorporeal shock wave therapy (rESWT) plus physical therapy for 3 weeks.
89144693|NCT02596659|Sham Comparator|The control group|Participants in the control group received sham shockwave therapy plus physical therapy for 3 weeks.
88803661|NCT04313530|Experimental|fatigue in MSA Arm one|This arm will receive a total 10 sessions of TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
89144694|NCT02777450||Block group|Lumbar facet block. Levobupivacaine 0,25% and corticosteroids
89144695|NCT04805411|Experimental|High-dose arm|600mg for 1st dose, and then 300 mg for 2-8nd doses, every 2 weeks, SC
89144696|NCT04805411|Experimental|low-dose arm|300mg for 1st dose, and then 150 mg for 2-8nd doses, every 2 weeks, SC
89144697|NCT04805411|Placebo Comparator|placebo|placebo for 1-8 doses, every 2 weeks, SC
89144698|NCT04570644|Other|Part A|"24 subjects randomized to receive treatment: (A-B) = Single 17.1 mg oral inhaled dose of ALZT-OP1a (cromolyn) via dry powder inhaler and a single oral 10 mg tablet of ALZT-OP1b (ibuprofen) on Day 1. On Day 2, subjects would receive two 17.1 mg doses of ALZT-OP1a via dry powder inhaler and two 10 mg tablets of ALZT-OP1b (ibuprofen), within two minutes of each other.~(B-A) = Two 17.1 mg doses of ALZT-OP1a (cromolyn) and two doses of 10 mg ALZT-OP1b (ibuprofen) on Day 1 and single 17.1 mg dose of ALZT-OP1a cromolyn 17.1 mg and a single 10 mg dose of ALZT-OP1b (ibuprofen) on Day 2.~All subjects will have plasma and CSF collected for PK analysis."
89144699|NCT04570644|Other|Part B|"PD - 32 subjects (AD only) will be enrolled in the PD portion of the study. Twenty-four (24) subjects will be assigned to Treatment Group 1 to receive a single (17.1 mg) inhaled dose of ALZT-OP1a (cromolyn) plus a single (10 mg) oral dose of ALZT-OP1b (ibuprofen) daily for 60 days.~All subjects will have plasma and CSF collected for PD biomarker analysis. Eight (8) A subjects will be assigned to Treatment Group 2 (Control Group) and will not be administered study drug."
89144700|NCT02596347||Beryllium Sensitization (BeS)|Blood draw
89144701|NCT02596347||Chronic Beryllium Disease(CBD)|blood draw BAL
89144702|NCT05016596|Placebo Comparator|placebo|Acacia gum
89144703|NCT05016596|Experimental|turmeric|Turmeric supplement
89144704|NCT05192070|Experimental|Percussive Massage Group|Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
89144705|NCT05192070|Experimental|Dynamic stretching group|Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
89144706|NCT05192070|Experimental|Static stretching group|Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
89144707|NCT04019847|Experimental|STAK Tool|The STAK Tool enables patients to apply a high intensity stretch to their knee independently. Patients are asked to do this for a maximum of 60 mins per day.
89144708|NCT04019847|Active Comparator|Standard treatment|Patients are treated as per their Clinician's prescription. Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain ROM and function.
89144709|NCT02775110|Active Comparator|Immediate Discontinuation Group|Patients will discontinue the natalizumab therapy at once and initiate another disease modifying therapy at 1 month following the last natalizumab infusion. The disease modifying therapy at 1 month following natalizumab discontinuation will be at the discretion of the neurologist and may differ among patients.
89144710|NCT02775110|Experimental|Taper-off Group|Patients will be administered two more natalizumab infusion, one at six weeks and the second at eight weeks (14 weeks from study entry), followed by six months natalizumab discontinuation. Another DMT will be initiated within two months after the last natalizumab infusion.
89144711|NCT02596113||No pathological findings|blood and biopsy samples from normal colon mucosa
89144712|NCT02596113||>1 cm adenomatous polys|blood and biopsy samples from the polyp
89144713|NCT02596113||Colorectal cancer|blood (plasma) and biopsy samples from colorectal cancer
89144714|NCT02775188|Experimental|Physical Therapy with InterACTION|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
89144715|NCT02775188|Other|Physical Therapy|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week
89144716|NCT04250909||Passeo 18 PTA|Previous treatment with uncoated Passeo 18 PTA balloon catheter
88803662|NCT04313530|Sham Comparator|fatigue in MSA Arm two|This arm will receive a total 10 sessions of sham-TMS stimulation in two weeks. Pre and post intervention scales will be performed on week one, week 2 and week 4.
88803663|NCT01059851|Experimental|Participants with Severe Renal Impairment (Part I)|"Participants with severe renal impairment will receive a~single dose of 20 mg open-label suvorexant during Part I of the~study."
88803664|NCT01059851|Experimental|Healthy Participants (Severe Impairment Controls) (Part I)|Healthy participants matched to participants with severe renal impairment will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
89144717|NCT04250909||Passeo-18 Lux DCB|Previous teatment with Passeo-18 Lux DCB
89144718|NCT02775266|Active Comparator|ALA + Scaling and Root planing|Systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months(group B)
89144719|NCT02775266|Placebo Comparator|Scaling and root planing only|Patients will receive scaling and root planning at baseline and 3 months(group A)
89144720|NCT04770311|No Intervention|Control|In a typical Healthy Lifestyless Nutrition visit, dietitians provide medical nutrition therapy to patients and their families. This includes addressing abnormal, nutrition-related lab values and providing targeted nutrition advice (foods to include, foods to limit) in order to resolve said labs. Motivational interviewing techniques will be used to help families identify barriers to Lifestyles change and provide strategies to help overcome these barriers. Families will receive compensation per each nutritional visit.
89144721|NCT04770311|Other|Intervention|Besides the usual standard of care during the nutrition visits, participants will have guidance on a microbiome-friendly diet and will receive groceries 1 time per week for 4 weeks.
89144722|NCT02692638|Experimental|Early laparoscopic enterolysis|Patient randomized to the early laparoscopy arm will undergo diagnostic laparoscopy within 24 hours of admission (depending on surgeon and operating room availability). Standard laparoscopy will be performed including supine positioning, sequential compression devices, and appropriate pre-incision antibiotics. Trocar placement will be at the surgeon's discretion and as appropriate for the patient's previous incisions. The necessity for conversion will be left to the discretion of the attending surgeon. Post operative management will conform to the standards of care. Nasogastric tubes will not be routinely placed.
89144723|NCT02692638|Active Comparator|trial of nonoperative management|Patients randomized to the trial of nonoperative management arm will undergo standard therapy including nil per os (NPO), nasogastric decompression only if actively vomiting, intravenous fluids while awaiting return of bowel function. Patients who do not achieve return of bowel function within 72 hours of admission will undergo attempted laparoscopic enterolysis with the understanding that conversion to open procedure may be necessary.
89144724|NCT04254887|Experimental|EPBD|Small incision of the duodenal nipple + EPBD
89144725|NCT04254887|Active Comparator|EST|Large incision of the duodenal nipple
89144726|NCT05342766||Group 1|Half of participants (healthy M and F, no children), randomly assigned. Group assignment will balance sex distribution. Nutrigenetic testing will be performed prior to intervention. Participants will work with a registered dietician, who will assess their current nutrient intakes and corresponding nutrient plasma values (T0). Target nutrient intakes will be determined based on nutrigenetic assessment. Participants undergo a nutrition intervention (first 3 months, Intervention 1), in which the difference between actual intakes and nutrigenetically-recommended intakes will be provided using supplements. At the end of Intervention 1 (T1), nutrient plasma values will be measured. After a wash-out period (3 months, no supplementation), nutrient plasma levels will be measured (T2), and a second intervention (3 months, Intervention 2) will consist of supplements administered according to EFSA recommended levels. At the end of Intervention 2, plasma nutrient levels will be measured (T3).
89144727|NCT05342766||Group 2|Half of participants (healthy M and F, no children), randomly assigned. Group assignment will balance sex distribution. Nutrigenetic testing will be performed prior to intervention. Participants will work with a registered dietician, who will assess their current nutrient intakes and corresponding nutrient plasma values (T0). Target nutrient intakes will be determined based on nutrigenetic assessment. Participants undergo a nutrition intervention (first 3 months, Intervention 1), in which the difference between actual intakes and EFSA-recommended intakes will be provided using supplements. At the end of Intervention 1 (T1), nutrient plasma values are measured. After a wash-out period (3 months, no supplementation), nutrient plasma levels will be measured (T2), and a second intervention (3 months, Intervention 2) will consist of supplements administered according to targets recommended by nutrigenetic testing. At the end of Intervention 2, plasma nutrient levels will be measured (T3).
89144728|NCT04747925|Active Comparator|mulligan two leg rotation , core muscle strengthening exercises|Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
89144729|NCT04747925|Experimental|Mulligan bent leg raise technique core muscle strengthning exercises.|Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
89144730|NCT05342688|Experimental|High contextual interference|The intervention will involve practicing three items from the Wolf motor function test in random order during three sessions. Each item will be repeated 30 times in total.
89144731|NCT05342688|Active Comparator|Low contextual interference|The intervention will involve practicing three items from the Wolf motor function test in blocked order during three sessions. Each item will be repeated 30 times in total.
89144732|NCT05329805|Experimental|interventional group|Job crafting intervention
89144733|NCT05329805|No Intervention|control group|Regarding the control group, the participants will receive a simple educational booklet with one-session
89144734|NCT05007236|Experimental|RP7214 + Standard of care (SOC)|
89144735|NCT05007236|Placebo Comparator|Placebo + Standard of care (SOC)|
89144736|NCT02772224|Experimental|Drug eluting balloon angioplasty|Paclitaxel coated balloon angioplasty
89144737|NCT02772224|Active Comparator|Conventional balloon angioplasty|Conventional balloon angioplasty
89144738|NCT02774876|Active Comparator|Carbohydrate meal|
88803665|NCT01059851|Experimental|Participants with Moderate Renal Impairment (Part II)|Participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
89144739|NCT02774876|Active Comparator|Carbohydrate + fat meal|
89144740|NCT02774876|Active Comparator|Carbohydrate + protein meal|
89144741|NCT02774876|Active Comparator|Carbohydrate + fat + protein meal|
89144742|NCT00614016|Experimental|single|8 subjects total (6 active and 2 placebo)
89144743|NCT04225364|Experimental|camrelizumab plus concurrent chemotherapy|Neoadjuvant immunotherapy, PD-1, plus concurrent chemotherapy（albumin-bound paclitaxel + Cisplatin） will be applied to patients with operable esophageal squamous cell carcinoma before surgery.
89144744|NCT04510350||MS CIS+|
89144745|NCT04510350||Healthy volunteers|
89144746|NCT00742209|Placebo Comparator|Placebo|PBO
89144747|NCT00742209|Active Comparator|GSK 1838262 1200 mg/day|600 or 1200 mg/day
89144748|NCT00742209|Active Comparator|GSK 1838262 1800 mg/day|600 or 1200 or 1800 mg/day
89144749|NCT00742209|Active Comparator|GSK 1838262 2400 mg/day|600 or 1200 or 1800 or 2400 mg/day
89144750|NCT00742209|Active Comparator|GSK 1838262 3000 mg/day|600 or 1200 or 1800 or 2400 or 3000 mg/day
89144751|NCT02774720|Experimental|Centre-based physical activity|People with Mild Cognitive Impairment (MCI) and early dementia will receive centre-based physical activity for one hour each week for three months, plus at-home prescribed exercise.
89144752|NCT02774720|Experimental|Home-based exercise|People with Mild Cognitive Impairment (MCI) and early dementia be prescribed at-home prescribed exercise and will received monthly support phone calls.
89144753|NCT02771834||Experimental|women with osteoporosis
89144754|NCT02771834||Control|women without osteoporosis
89144755|NCT02774564|Experimental|Nebicapone 50 mg|1 tablet of 50 mg plus 3 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
89144756|NCT02774564|Experimental|Nebicapone 100 mg|2 tablets of 50 mg plus 2 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
89144757|NCT02774564|Experimental|Nebicapone 200 mg|4 tablets of 50 mg concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
89144758|NCT02774564|Placebo Comparator|Placebo|4 tablets concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
89144759|NCT02777294|Experimental|Online intervention|Therapist-facilitated, cognitive behavioral therapy
89144760|NCT02777294|Active Comparator|Psycho-educational website|Self-help, psycho-educational website
89144761|NCT00613470|Experimental|Citalopram and escitalopram|"Citalopram tablet or solution starting at 20 mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.~Escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5."
89144762|NCT02771912|Experimental|Propofol|"Infusion containing Propofol lipuro® 2% at a concentration of 2 mg/ml (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Propofol lipuro® 2 %).~Self administration of propofol via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution (0.25 mg/kg propofol) with a programmed lock-out period of 3 minutes.~Maximal dose of propofol : 1,25 mg/kg corresponding to 5mg/kg/h."
89144763|NCT02771912|Placebo Comparator|Intralipid|"Infusion containing Intralipid® (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Intralipid® 20%) to obtain an identical aspect to that of propofol infusion.~Self administration via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution with a programmed lock-out period of 3 minutes."
89144764|NCT00741819|Experimental|Inhaled treprostinil|Solution for oral inhalation treprostinil (0.6 mg/mL). Inhaled via an ultrasonic nebulizer which provides a dose of 6mcg of treprostinil per breath. Doses are titrated up to 12 breaths four times daily.
89144765|NCT02774408|Other|CPAP|"Infants on CPAP will receive backup breafs whenever the SpO2 <88 % along with~automated FiO2 controller. In the control period they will receive automated FiO2~alone"
89144766|NCT02774408|Other|NIMV/NIPPV|"Infants on NIMV NIPPV will receive an increase in the backup rate to 2 times the rate~of the backup triggered by apnoe (apnoe time 5s), whenever the SpO2 under 88%~( max rate 100/min) in the reference period as compared to baseline (automated FiO2~- control + unchanged SIPPV settings)"
89144767|NCT04088721|Experimental|AD17002 20μg|Intranasal weekly dosing of AD17002 for three times
89144768|NCT04088721|Experimental|AD17002 40μg|Intranasal weekly dosing of AD17002 for three times
89144769|NCT04088721|Experimental|AD17002 60μg|Intranasal weekly dosing of AD17002 for three times
89144770|NCT04088721|Placebo Comparator|Placebo|Intranasal weekly dosing (placebo) for three times
89144771|NCT04457466||Healthy musicians|Men and women aged 18-60, who must be enrolled in a music conservatory performance program or be professionally active, and must speak and understand English.
89144772|NCT04457466||Healthy non-musicians|Men and women aged 18-60, must speak and understand English and not have any kind of musical training.
89144773|NCT04457466||Musicians with chronic pain|Men and women aged 18-60 with chronic and idiopathic musculoskeletal upper limb and/or neck pain lasting more than 6 months. They must be enrolled in a music conservatory performance program or be professionally active and must speak and understand English.
89144774|NCT04457466||Non-musicians with chronic pain|Men and women aged 18-60 with chronic and idiopathic musculoskeletal upper limb and/or neck pain lasting more than 6 months. They must not have any kind of musical training and must speak and understand English.
89144775|NCT00917709|Experimental|DLB with extrapyramidal syndrome|patients dementia with Lewy bodies with extrapyramidal syndrome
89144776|NCT00917709|Other|DLB without extrapyramidal syndrome|patients dementia with Lewy bodies without extrapyramidal syndrome
89144777|NCT00917709|Sham Comparator|healthy volunteers|healthy volunteers
89144778|NCT02774330||Minneapolis, Minnesota Customers|"Minneapolis, Minnesota has a policy in place whereby minimum quantities and varieties of healthy food are required for all licensed food stores. The policy is our intervention condition."
89144779|NCT02774330||St. Paul, Minnesota Customers|No policy exists in St. Paul, Minnesota. This is the control condition.
89144780|NCT05197335||Study Group|Age of 65 at the time of signing the informed consent.
89144781|NCT04225208|Experimental|[14C]-AZD4205|A single dose of [14C]-AZD4205
89144782|NCT02771444|Experimental|Tomo Assessment|Subjects will have a 4-view tomosynthesis examination with the study device.
89144783|NCT02678013|Experimental|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
89144784|NCT02678013|Active Comparator|RFA+CTL|RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.
89144785|NCT02774486|Experimental|IQP-AK-102|2 capsules to be taken 3 times daily orally, 30 min before each main meal (breakfast, lunch, dinner) with 250 mL of water
89144786|NCT02678169||Penumbra Aspiration System|Penumbra Aspiration System with the ADAPT technique
89144787|NCT04790318|Active Comparator|General Anesthesia +TiQLB|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume limited to 20 ml
89144788|NCT04790318|Active Comparator|General Anesthesia+ Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
89144789|NCT02677935|Experimental|Intervention|community support program
89144790|NCT02677857|Active Comparator|Lifestyle|Participants will be educated on the relationship between MVPA and improved health outcomes, including weight management, and cancer survivorship. The goal will be to increase MVPA to > 40 min/day 5 times/wk As participants will be overweight/obese, inactive, and coming into the program with different levels of baseline fitness and time since last cancer treatment, participants will shape their MVPA to meet the targeted goals. Initially, participants will be encouraged to complete MVPA > 10 min/day 5 times/wk, and then progressively increase MVPA by 5 min/day every week until reaching the intervention goal (week 7 of the 12 week intervention). Participants will be encouraged to do brisk walking and be allowed to accumulate time spent being physically active by engaging in multiple short bouts (i.e., > 10 min in length). Any MVPA in bouts of > 10 min in length will be counted towards the MVPA goal. Participants will self-monitor their MVPA using the Polar® Loop tracking system.
89144791|NCT02677857|Active Comparator|Lifestyle + SB|Participants will receive everything that is described in Lifestyle. Additionally, they will be educated on the relationship between SB and weight management, and cancer survivorship risk. The goal will be to reduce sedentary time by > 2 hrs/day or > 14 hrs/wk. Participants will shape towards the goal. Baseline measures will be used as the starting point from where to calculate the 2 hrs/day reduction, providing participants with a total SB goal per day. For example, if baseline measures indicate that a participant has a mean daily SB amount of 9.75 hrs, the participant's SB goal will be 7.75 hrs/day. To achieve that goal, participants will reduce SB by 20 minutes a day, starting week 2, with a decrease of an additional 20 minutes/day occurring weekly until the SB goal is achieved (week 7 of the 12 week intervention. Participants will self-monitor their SB using the Polar® Loop tracking system.
89144792|NCT02677857|No Intervention|Newsletter|Participants in this condition will receive standard care and every month they will receive a newsletter that provides information and tips about healthy eating and activity behaviors. This newsletter will include information on myPlate,28 activity guidelines,29 reading food labels, healthy recipes, and seasonal activity suggestions.
89144793|NCT04954742|Other|Riociguat|Riociguat (1 mg, 1.5 mg, 2 mg and 2.5 mg three times daily) starting at 1.0 mg three times daily at the beginning of the study. Dosage will be individually up-titrated up to a maximum dosage of 2.5 mg three times daily after 8 weeks. Study medication will be provided orally with or without food. Tablets should be taken three times daily approximately 6 to 8 hours apart.
89144794|NCT05662995|Experimental|Lung- and cardiac ultrasound, as well as optic nerve sheath diameter.|An ultrasound examination (approximately 25-30 minutes in duration) will be performed at the time of venous blood sampling on admission. The examination will consist of an assessment of systolic and diastolic function, lung ultrasound, and measurement of the optic nerve sheath diameter
89144795|NCT04193696|Experimental|radiotherapy plus PD-1|
89144796|NCT00642447|Experimental|1|
89144797|NCT02771678||Asthma|All participants will have an asthma-related crisis event due to an asthma exacerbation that resulted in A&E attendance and/or hospital admission.
89144798|NCT04181541|Active Comparator|Women receiving abortion care by physicians|Patients who receive second trimester medical abortion care from a physician.
89144799|NCT04181541|Experimental|Women receiving abortion care from midlevel providers|Patients who receive second trimester medical abortion care from a midlevel provider.
89144800|NCT04181697||PwH A|People with Haemophilia (PwH) A, moderate or severe.
89144801|NCT04181697||Controls|Demographically and seasonally matched non-haemophilia controls.
89144802|NCT02774252|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
88803666|NCT01059851|Experimental|Healthy Participants (Moderate Impairment Controls) (Part II)|Healthy participants matched to participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
88803667|NCT01059851|Experimental|Participants with Mild Renal Impairment (Part II)|Participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
88803668|NCT01059851|Experimental|Healthy Participants (Mild Impairment Controls) (Part II)|Healthy participants matched to participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
89144803|NCT02677467||Spontaneous epistaxis|A participant enroll if their age is over 18 with spontaneous epistaxis and their cause of visiting ER is spontaneous epistaxis. Exclusion criteria is that they needs immediately treatment for hypertensive urgency. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
89144804|NCT02677467||Bleeding of wound|A participant enroll if their age is over 18 with bleeding of wound and their cause of visiting ER is to bleed on wound. Exclusion criteria is that their wounds' condition is serious or their pain is much severe. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
89144805|NCT02774096|No Intervention|Control group（Ascending aorta）|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
89144806|NCT02774096|Experimental|Xenon Post-conditioning|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
89144807|NCT02677389|Experimental|Arm I (Enhanced SCP)|See Detailed Description
89144808|NCT02677389|Active Comparator|Arm II (SCP)|"Participants receive a standard SCP, comprised of a treatment and follow up recommendations, including basic physical activity guidance, copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on Healthy Habits at 1, 2, 4, and 8 weeks. Specific topics in emails include positive self-talk, daily relaxation breathing techniques, better sleep, and ways to find pleasure."
89144809|NCT02774174||METS Proximal Humeral system|Implanted with METS Proximal Humerus
89144810|NCT04181385|Experimental|Olanzapine|Olanzapine, 10mg, oral, single dose
89144811|NCT04181385|Experimental|Olanzapine plus bromocriptine|Olanzapine, 10mg, oral, single dose Bromocriptine, 5mg, oral, single dose
89144812|NCT04181385|Placebo Comparator|Placebo|Placebo, oral, single dose
89144813|NCT02774018|Experimental|12 institutionalized elderly people|Mindfulness-Based Stress Reduction program.
89144814|NCT00924443|Experimental|Clofarabine|Clofarabine 30 mg/m^2/day intravenously over 1 hour for 5 days every 28 to 42 days (one cycle), then 20mg/m^2/day intravenously over 1 hour for 5 days every 29 to 43 days for the second and subsequent cycles, up to a maximum of 3 cycles.
89144815|NCT02677155|Experimental|Intranodal immunotherapy and anti-PD1|"Induction phase: 3 cycles of sequential intranodal immunotherapy (SIIT), every second week:~Radiotherapy 8 Gy single dose day 2, Rituximab 5 mg intranodal day 1 and 3, Autologous dendritic cells 1x 10 e8 intranodal day 4 and 5, GM-CSF 50 ug subcutaneously day 4 and 5, Pembrolizumab 200 mg intravenous day 5,~Consolidation phase:~Pembrolizumab 200 mg intravenous every third week for 8 cycles"
89144816|NCT02773940|Experimental|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during the patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
89144817|NCT04256447||Sixty-eight children and adolescents with type 1 diabetes|Sixty-eight children and adolescents aged between 4 and 18 years with type 1 diabetes. Patients with celiac disease, thyroid disease, other autoimmune diseases, concurrent illness, patients with diabetic nephropathy, other renal disease and in therapy with natriuretic drugs were excluded.
89144818|NCT02771756|Experimental|test group|Zhen qishen capsule (2 capsules, Bid) and Oral Supplement of Yuyikang (50g, Bid), a total of 150 people, are used for 42 days continuously.
89144819|NCT02771756|Placebo Comparator|placebo group|Zhen qishen capsule placebo (2 capsules, Bid) and Oral Supplement of Yuyikang placebo (50g,Bid), a total of 150 people, are used for 42 days continuously.
89144820|NCT02677233||preeclamptic group|"Blood pressure: greater than or equal to 140 mmHg systolic or greater than or equal to 90 mmHg diastolic on two occasions at least 4 hours apart after 20 weeks of gestation (Roberts et al., 2013).~Proteinuria: protein/creatinine ratio greater than or equal to 0.3~In the absence of proteinuria, a new-onset hypertension with new onset of the following:~thrombocytopenia: platelet count less than 100.000/microliter~renal insufficiency: serum creatinine greater than 1.1 mg/dl~impaired liver function: elevated concentration of liver transaminases~pulmonary edema~cerebral or visual symptoms~Severe right upper quadrant or epigastric pain unresponsive to medication."
89144821|NCT02677233||non preeclamptic group|All are normotensive with blood pressure <140/90 with no proteinuria.
89144822|NCT04254965|Experimental|Group 1|Participants of integrated music therapy (integration of active and passive music therapy) includes instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process. The four stages of activities are warm-up, main activities, secondary activities, and the ending section.
89144823|NCT04254965|Active Comparator|Group 2|Participants of the music listening group will receive background music listening, music selection based on the musical preference and background of subjects, for relax or boost the spirit of the subjects.
89144824|NCT04254965|Sham Comparator|Group 3|Participants in the control group receive their regular occupational therapy during the experimental period.
89144825|NCT02537691|Other|Inhaled Corticosteroids (ICS) + Controller Medications|Participants with severe asthma Global Initiative for Asthma (GINA) step 4/5 as indicated by current treatment with daily ICS consisting of >/=500 mcg FP administered by DPI (or equivalent), and at least one of the following controller medications: LABAs, LTRAs, LAMAs, theophylline or oral corticosteroids.
89144826|NCT04836884|Experimental|Vascular anomaly/malformation biopsy|Subjects with a vascular anomaly will have a research percutaneous vascular anomaly/malformation biopsy completed at the time of the clinically indicated percutaneous sclerotherapy, embolization and/or ablation.
89144827|NCT04881383||Patients from Primary Care Clinics|Participating Chinese adults aged 18-84 from Primary Care clinics to validate the risk prediction function. Each subject will complete an assessment on the relevant risk factors and have a blood test on OGTT and HbA1c on recruitment and at 12 months.
89144828|NCT02773862|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an invasive monitoring device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 48 hours, continuously depending on the patient's clinical condition.
89144829|NCT04256135|Experimental|Experimental mobilization: Mulligan|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
89144830|NCT04256135|Active Comparator|Control mobilization: AP Maitland|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
89144831|NCT04225052|Other|Group1|16 subjects, Cross-over, Single dose of comparator on day1, Single dose of YHP1903 on day8
89144832|NCT04225052|Other|Group2|16 subjects, Cross-over, Single dose of YHP1903 on day1, Single dose of comparator on day8
89144833|NCT02777138||Young males aged 20-35 years old|"Maintaining a normal daily living lifestyle~Healthy~Reasonably active- PAL: 1.4-1.9~Non-obese- Fat mass index based on DEXA of 4-8kg/m2~Weight stable for more than 3 months (±3% body mass)~Non-smoker~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription~No medications that may influence lipid or carbohydrate metabolism or immune system function~No known negative reaction to lidocaine~No participation in heavy resistance training"
89144834|NCT02777138||Old males aged 65-85 years old|"Maintaining a normal daily living lifestyle~Healthy~Reasonably active- PAL: 1.4-1.9~Non-obese- Fat mass index based on DEXA of 4-8kg/m2~Weight stable for more than 3 months (±3% body mass)~Non-smoker~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription~No medications that may influence lipid or carbohydrate metabolism or immune system function~No known negative reaction to lidocaine~No participation in heavy resistance training"
89144835|NCT00642525|Experimental|A|A prospective, blinded, intraindividual controlled study is conducted with patients with transthoracic esophagectomy due to esophageal cancer. A radiographic contrast study is performed prior to endoscopy at the 5th to 7th postoperative day.
89144836|NCT04255121|Experimental|alkalinization of adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
89144837|NCT04255121|Active Comparator|adrenaline lidocaine solution arm|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using a adrenaline lidocaine solution
89144838|NCT05662839|Experimental|Research Arm|Each group will undergo the same study procedures; Dermoscope Cytological brushing Complete questionnaire on experience of the cytological brushing SoC treatment
89144839|NCT02777060|Experimental|Exergame|inertial sensor based system (wearable sensors, LEGSys, Biosensics LLC) will be used for balance training with computerized feedback. The balance training program is focused on lower extremities including ankle joint exercise and virtual obstacle crossing tasks.
89144840|NCT02777060|Active Comparator|Home based balance training|The control group will ask to perform a home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback. Exercises include postural balance tasks, such as backward and forward weight shifting, as well as dynamic balance exercises, such as marching in place (comparable to virtual obstacle crossing in experimental group).
89144841|NCT02773784||invasive breast cancer|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
89144842|NCT03521232|Experimental|150 mg/60 ml|Niclosamide enemas 150 mg/60 ml given twice daily for 6 weeks
89144843|NCT03521232|Experimental|450 mg/60 ml|Niclosamide enemas 450 mg/60 ml given twice daily for 6 weeks
89144844|NCT02677311|Other|Cases|Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
89144845|NCT02677311|Other|Controls|Participants who will receive chemoradiation therapies presumed to be low risk for gonadotoxicity as determined by the literature and the patient's oncolologist as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
89144846|NCT00924287|Experimental|Metastatic Cancer|Cancer that has invaded other parts of the body
89144847|NCT02696954|Experimental|Group A|
89144848|NCT02696954|Experimental|Group B|
89144849|NCT02773628|Placebo Comparator|control group|stable asthmatics receiving an Acar'up placebo system
89144850|NCT02773628|Active Comparator|treatment group|stable asthmatics receiving Acar'up system
89144851|NCT02677077||Czech Republic|Approximately 230 participants with RRMS receiving commercial natalizumab in Czech Republic
89144852|NCT02677077||Belgium|Approximately 70 participants with RRMS receiving commercial natalizumab in Belgium
89144853|NCT03523416|Experimental|Edwards Transcatheter Atrial Shunt System|
89144854|NCT00923975|Other|Intended Users of the Software|Young adults, parents/guardians of young people under age 18, and healthcare professionals who work with this population would be intended users of the data management program. The DIDGET World Reports software is used to upload blood glucose results from the DIDGET Blood Glucose Monitoring System so that intended users can identify patterns in their diabetes management.
89144855|NCT02771600|Experimental|Buzzy|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
89144856|NCT02771600|Active Comparator|Standard Care (Maxilene)|Maxilene topical anaesthetic cream will be applied 30 minutes before the needle-related procedure on the insertion site
89144857|NCT02676921||GROUP 1|Ten samples of sinus membrane where harvested from fifteen patients during a surgical nasal approach for treatment of chronic rhinosinusitis.
89144858|NCT04203407|Experimental|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
89144859|NCT04203407|Active Comparator|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
89144860|NCT02773394||Group 1|Brazilian participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype.
89144861|NCT04180839|Experimental|gaming-related retrieval-extinction|about 30 individuals with IGD will be randomly assigned to the R-E training group
89144862|NCT04180839|Other|nongaming-related retrieval-extinction|about another 30 individuals with IGD will be randomly assigned to the NR-E training group
89144863|NCT05249010||acupuncture and moxibustion group|The investigators intend to recruit 30 participants who receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
89144864|NCT02773316|Experimental|MR902 50/0.5 mg|MR902 50/0.5 mg PR tablets, single dose oral
89144865|NCT02773316|Experimental|MR902 200/2 mg|MR902 200/2 mg PR tablets, single dose oral
89144866|NCT02773316|Active Comparator|IR morphine sulphate 10 mg/5mL solution|IR morphine sulphate 10 mg/5mL solution, single dose oral
89144867|NCT00642681||1: TI Inhalation Powder|Technosphere® Insulin (TI) Inhalation Powder
89144868|NCT04188444||Agonist|Ovarian stimulation with agonist of GnRH
89144869|NCT04188444||Antagonist|Ovarian stimulation with antagonist of GnRH
89144870|NCT04853381|Experimental|1st Group: Traditional diet recommendations|Traditional diet recommendations will apply for 4 weeks.
89144871|NCT04853381|Experimental|2nd Group: Low FODMAP diet|Low FODMAP diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
89144872|NCT04853381|Experimental|3rd Group: Gluten-free diet|Gluten-free diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
89144873|NCT04853381|Experimental|4th Group: Low-FODMAP gluten-free diet|Low-FODMAP gluten-free diet recommendations will apply for 4 weeks. When individuals are first enrolled in the study, they will be trained by the dietician for one hour before the medical nutrition treatment they will apply for 4 weeks.
89144874|NCT02771288|Other|Kawasaki disease|
89144875|NCT04791449|Experimental|Treatment-as-usual plus medically-supervised exercise (TAU-EX)|This group attends normal wound care appointments as scheduled with the wound care provider, generally 2 - 3 times per week. Coincident with these appointments, ideally, they will also attend a medically-supervised exercise program supervised by the exercise physiologists of the Cardiac Rehabilitation facility. The exercise sessions will last no more than 1-hr per session. The maximum number of sessions possibly attended over the 12-wk intervention period is 36. In addition, participants in this group will maintain their activities of daily life unless contraindicated by the would care provider.
89144876|NCT04791449|No Intervention|Treat-as-usual (TAU)|This group attends normal wound care appointments as scheduled with the wound care provider, generally 2 - 3 times per week. In addition, participants in this group will maintain their activities of daily life unless contraindicated by the would care provider.
89144877|NCT02676687|Active Comparator|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
89144878|NCT02676687|Experimental|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
89144879|NCT02773550|Experimental|Velcadito|Bortezomib 1.3 mg/m2 days 1,4,8 and 11 first cycle, the 1.0 mg/m2 days 1 and 4. Melphalan 9 mg/m2 days 1 to 4 Prednisone 60 mg/m2 days 1 to 4 Cycles of 28 days
89144880|NCT04181073|Active Comparator|Jet Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Jet Nebuliser
89144881|NCT04181073|Experimental|Vibrating Mesh Nebuliser|Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Vibrating Mesh Nebuliser
89144882|NCT02770976|Experimental|NAVA|Seven increasing and decreasing NAVA levels (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0 and 0.5 cmH2O/uV) will applied to 20 preterm infants each for 10 minutes.
89144883|NCT04614935|No Intervention|Standard of Care|Pediatric patients with functional constipation who are treated with medications and/or behavioral therapies as they would be if they were not enrolled in the study. In addition to standard of care treatment, these families will fill out a brief quality of life survey.
89144884|NCT04614935|Experimental|Action Plan|Pediatric patients with functional constipation who are treated with standard of care medications and/or behavioral therapies and are also provided with a medication adherence log along with a constipation action plan. These families will also fill out a brief quality of life survey.
89144885|NCT04436016|Experimental|Ivabradine|"Ivabradine will be administered in an individualized regimen adapted to the subject's heart rate at each visit in a dosage ranging from 0-7.5mg twice daily (morning and evening) from the morning of surgery until post-operative day 2, as follows:~If heart rate is ≥101 bpm: capsule D (Ivabradine 7.5 mg);~If heart rate is 86-100 bpm: capsule C (Ivabradine 5 mg);~If HR is 71-85 bpm: capsule B (Ivabradine 2.5 mg);~If HR ≤ 70 bpm or the patient received rescue treatment for bradycardia (eg.atropine) after the previous dose: capsule A (placebo)."
88803669|NCT02169869|Experimental|Immediate postplacental IUD insertion|Women randomized to the immediate postplacental IUD group will receive their IUD within 60 minutes of placental delivery.
88803670|NCT02169869|Active Comparator|6 weeks postpartum IUD insertion|Subjects who are randomized for IUD insertion at their postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with their usual obstetrical care provider.
89144886|NCT04436016|Placebo Comparator|Placebo|"Placebo will be administered twice daily (morning and evening) from the morning of surgery until post-operative day 2, as follows:~If heart rate is ≥101 bpm: capsule D (Placebo)~If heart rate is 86-100 bpm: capsule C (Placebo)~If HR is 71-85 bpm: capsule B (Placebo)~If HR ≤ 70 bpm or the patient received rescue treatment for bradycardia (eg.atropine) after the previous dose: capsule A (Placebo)."
89234844|NCT05888584|Experimental|Intervention tool|A research recruitment tool will be available in paper and online formats and will include information on finding out about LC clinical trials, the role of research teams, embedding research into multidisciplinary team meetings and health needs assessments, communication pathways, signposting LCPs, practical considerations and reaching underrepresented groups. The tool will be used by lung cancer nurses in their daily practice as an aid to support their discussions with lung cancer patients about clinical trial opportunities. They will be asked to complete a survey at three time-points (baseline, three and six months) to measure their self-efficacy, knowledge, confidence and awareness in talking to lung cancer patients about clinical trials.
89234845|NCT05888584|No Intervention|Control|Lung cancer nurses will undertake usual care. They will be asked to complete a survey at three time-points (baseline, three and six months) to measure their self-efficacy, knowledge, confidence and awareness in talking to lung cancer patients about clinical trials.
89234846|NCT05888558||Ocular myasthenia gravis group|Ocular myasthenia gravis,age between 18-50 years old
89234847|NCT05888558||General myasthenia gravis group|General myasthenia gravis,age between 18-50 years old
89234848|NCT05888558||Healthy control group|people who are healthy without any systemic diseases，18-50 years old
89234849|NCT05888467|Other|Control group|non-supervised exercise group
89234850|NCT05888467|Active Comparator|Intervention: supervised non-infrared exercise group|supervised non-infrared exercise group
89234851|NCT05888467|Active Comparator|Intervention: supervised infrared exercise group|supervised infrared exercise group
89234852|NCT05888415||sophrology practitioners|Practice sophrology - no intervention
89234853|NCT05888415||non practitioners|Do not practice sophrology - no intervention
89234854|NCT05888376||Consecutive CKD including ESRD treatments|Consecutive retrospective treatments across all sites with a diagnosis of CKD, including ESRD
89234855|NCT05888376||Consecutive treatments with minimum hospital stay of 20 days|Consecutive retrospective treatments across all sites with a minimum hospital stay of days (excluding cases previously identified; may be acute or chronic disease)
89234856|NCT05888376||Consecutive acute/chronic kidney disease treatments|Consecutive retrospective treatments across all sites with acute or chronic disease (excluding cases previously identified)
89234857|NCT05888363||Rectal foreign body removed in emergency department|All patients where the removal of the rectal foreign body was successful in the emergency department
89234858|NCT05888363||Rectal foreign body removed in operating room|All patients where the removal of the rectal foreign body was not successful in the emergency department and required removal in the operating room
89234859|NCT05888298|Active Comparator|Proximal block|GON block is performed at C2 vertebra level
89234860|NCT05888298|Other|Distal block|GON block is performed at occipital protuberence
89234861|NCT05888285|Active Comparator|ESP Block|ESP block for back pain treatment is applied
89234862|NCT05888285|Active Comparator|ESP RFT|ESP block and pulsed radiofrequency for back pain treatment is applied
89234863|NCT05888272|Experimental|Experimental - Stress Managment|A locally adapted self-help guidebook originally developed by the World Health Organization (WHO), 'Doing what matters in times of stress' for managing disruptive emotions and psychological distress, will be delivered to women entrepreneurs at their residences, followed by 7 phone calls from a trained mental health helper to reinforce the materials over a 10-week period. The intervention is intended to help people manage their psychological distress associated with a range of adversities but is not intended for participants with severe mental health problems such as psychosis or imminent risk of suicide
89234864|NCT05888272|No Intervention|Waitlist Control|This group will receive the DWMTS handbook if the study documents a positive impact on the outcomes of interest.
89234865|NCT05888259|Experimental|foot insole, medication and wound care (study group)|"Pressure maps were recorded to calculate peak pressures and pressure-time integrals for (hindfoot, middle foot, hallux, medial forefoot, and lateral forefoot).~The measurements were uploaded to a server of software that uses technology to create a 3D model of the foot insole from multiple images taken by the user."
89234866|NCT05888259|Active Comparator|medication and wound care (control group)|participants will receive only medical treatments and wound care for the diabetic foot ulcer
89234867|NCT05888220|Experimental|warm salt water group|The patients were told how to prepare and apply the temperature and salt ratio of the water to be used in the hand and foot bath (280 grams of rock salt to 8 liters of water) with a demonstration method with video training. video tutorial tablet It was done in a quiet environment in the hospital, in a room with the patient and the researcher. The temperature of the water and the duration of application were determined based on research that previously examined the effectiveness of warm water and warm salt water baths in various patient groups. Bath hours were determined to be between 21:00 and 22:00 in order to prevent the patients from doing any activity after this application and to provide relaxation and rest after the bath. Starting 1 day after the training, each patient is at home for six weeks from 21:00 to He applied a warm salt water bath at 41°C for 20 minutes to his hands and feet three times a week between 21:00-22:00.
89234868|NCT05888220|Experimental|warm water group|The patients were told how to prepare and apply the temperature of the water to be used in the hand and foot bath with video training and demonstration method. The video training was carried out using a tablet in a quiet environment in the hospital in a room with the patient and the researcher. The temperature of the water and the duration of application were determined based on research that previously examined the effectiveness of warm water and warm salt water baths in various patient groups. Bath hours were determined to be between 21:00 and 22:00 in order to prevent the patients from doing any activity after this application and to provide relaxation and rest after the bath. Starting 1 day after the training, each patient applied a 20-minute warm water bath at 41°C every other day, three times a week between 21:00 and 22:00 at home for six weeks, on their hands and feet.
89144887|NCT02676531|Experimental|Walking Meditation|"Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking while listening to the sound Budd and Dha and squeeze rubber balls according to the sound in order to practice mindfulness while walking. In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set. In both phases of the training, the frequency of Walking Meditation training is three times a week."
89144888|NCT02676531|No Intervention|No Walking meditation|keep regular activities, sedentary life style.
89144889|NCT02773472|Experimental|Electroacupuncture Group|In addition to morphine, patients will receive 4 sessions of electroacupuncture after surgery over four days, with each session lasting 30 minutes.
89144890|NCT02773472|Other|Morphine Group|Neither electroacupuncture nor sham acupuncture will be given. Patient use morphine for analgesia.
89144891|NCT00637871|Experimental|1|
89144892|NCT00637871|Active Comparator|2|
89144893|NCT00635258||GnRH-ant|Patients were treated with a GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
89144894|NCT00635258||GnRH-a|GnRH long protocol using 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Furthermore, the triptorelin administration was maintained until the day of donor's hCG administration.
89144895|NCT00642837||001|
89144896|NCT00642837||002|
89144897|NCT00642837||003|
89144898|NCT00642837||004|
89144899|NCT00642837||005|
89144900|NCT00642837||006|
89144901|NCT00642837||007|
89144902|NCT00642837||008|
89144903|NCT00642837||009|
89144904|NCT02777216|Experimental|ConfidenHT system|ConfidenHT system
89144905|NCT05282849|Active Comparator|Group F: ultrasound guided fascia iliaca block group|
89144906|NCT05282849|Active Comparator|Group Q: ultrasound guided quadratus lumborum block group|
89144907|NCT00613548|Active Comparator|1|CABG Alone
89144908|NCT00613548|Active Comparator|2|CABG + Mitral repair
89144909|NCT04226534|Other|Maximal effort test|Physiological database
89144910|NCT02776748|Other|FTC-TDF|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) PrEP: 200mg FTC /300 mg TDF
89144911|NCT02676609|Active Comparator|Use of smart phone application (device glucal)|"Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio.~During the first month, then during the second month they'll use as usual their traintement and meal without the apllication"
89144912|NCT02676609|Active Comparator|Use of smart phone application (second month)|"During the first month they'll use as usual their traintement and meal without the apllication ,then during the second month they'll use the apllicatioin.~Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio."
89144913|NCT02771054|Experimental|TAF/emtricitabine (FTC)|All 20 patients will switch their nucleoside backbone, either ABC/3TC or TDF/FTC to TAF/FTC
89144914|NCT02676297|Experimental|Test product A|tiotropium
89144915|NCT02676297|Experimental|Test product B|tiotropium
89144916|NCT02676297|Active Comparator|reference product|tiotropium
89144917|NCT02776592|Experimental|Experimental|A cow's milk-based formula with added nutrients
89144918|NCT02776592|Active Comparator|Control|A cow's milk-based formula
89144919|NCT04180761|Experimental|HIPEC-Treatment|"Doxorubicin (15 mg/m²/body surface) Cisplatin (75 mg/m²/body surface) applied as hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy.~All drugs used are approved."
89144920|NCT02773160|Experimental|Sensor-based postural feedback|Subjects will receive visual feedback on a computer screen while practicing the motor control task. The feedback is based on information from from motion sensors that mointor the movements of the lumbar spine
89144921|NCT02773160|Experimental|Mirror Feedback|Subjects will receive feedback from a mirror while practicing the motor control task
89144922|NCT02773160|Active Comparator|control group|Subjects will receive no feedback while practicing the motor control task
89144923|NCT02676219|Experimental|RS01|oral care product containing containing sodium monofluorophosphate and sodium fluoride
89144924|NCT02676219|Placebo Comparator|Water|Water
89144925|NCT02696720|Experimental|Lidocaine|During a period of six weeks, a lidocaine patch will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
89144926|NCT02696720|Sham Comparator|Sham|During a period of six weeks, a visually identical patch (sham) will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
89144927|NCT04180683||Semi-structured interview group|Participants assigned to this group will be administered the GDS-30, GDS-15, GDS-10 nad GDS-5, and also the BDI-II and a semi-structured interview based on the DSM-5 criteria. The psychologists performing the assessment will answer a questionnaire about which GDS version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
89144928|NCT04180683||No semi-structured interview group|Participants assigned to this group will be administered the GDS-30 and the GDS-15, and also the BDI-II.
89144929|NCT04180293|Other|Military Veterans and their families|This group will participate in both the pilot psychoeducation program and its evaluation.
89144930|NCT02767622||Patient Group|Twenty right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation.
89144931|NCT02767622||Control Group|Twenty age-matched healthy persons. They were similar to the patient group in respect to the number of education years, sex, and handedness.
89144932|NCT02767544|Experimental|ropivacaine group|Vaginal wound local analgesia by 10ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
89144933|NCT02767544|No Intervention|Control group|Vaginal wound no local analgesia by 10 ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
89144934|NCT00643071|Experimental|1|
89144935|NCT03728634|Placebo Comparator|Multiple Dose Cohort: Placebo|Participants received ION-682884 matching placebo, subcutaneously (SC) once every 4 weeks [Q4W] (total of 4 doses) along with daily oral supplemental doses of the recommended daily allowance (RDA) of vitamin A during the 13-week Treatment Period.
89144936|NCT03728634|Experimental|Multiple Dose Cohort A: ION-682884 45 mg|Participants received ION-682884, 45 milligrams (mg), SC, Q4W (total of 4 doses) along with daily oral supplemental doses of the RDA of vitamin A during the 13-week Treatment Period.
89144937|NCT03728634|Experimental|Multiple Dose Cohort E: ION-682884 60 mg|Participants received ION-682884, 60 mg, SC, Q4W (total of 4 doses) along with daily oral supplemental doses of the RDA of vitamin A during the 13-week Treatment Period.
89144938|NCT03728634|Experimental|Multiple Dose Cohort B: ION-682884 90 mg|Participants received ION-682884, 90 mg, SC, Q4W (total of 4 doses) along with daily oral supplemental doses of the RDA of vitamin A during the 13-week Treatment Period.
89144939|NCT03728634|Placebo Comparator|Single Dose Cohort: Placebo|Participants received single dose of ION-682884 matching placebo, SC along with daily oral supplemental doses of the RDA of vitamin A on Day 1.
89144940|NCT03728634|Experimental|Single Dose Cohort C: ION-682884 120 mg|Participants received single dose of ION-682884, 120 mg, SC along with daily oral supplemental doses of the RDA of vitamin A on Day 1.
89144941|NCT02767466||G|"All participants were randomly exposed to two different treatments:~Conventional physical therapy (no specific device used)~Robotic assisted gait training (Lokomat, Hocoma AG, Switzerland)~We consider the study as observational, since the both interventions of the study (physical therapy, robotic assisted gait training) did not change in the patients' usual therapy plan, as they received both interventions daily.~We only added diagnostic interventions to assess the affective responses."
89144942|NCT02767310|Experimental|Test Product|Rosuvastatin 20 mg film-coated tablets
89144943|NCT02767310|Active Comparator|Reference product|Crestor 20 mg film-coated tablets
89144944|NCT04180605|Active Comparator|Standard of care treatment arm|"When patients are randomized to the standard treatment arm, patients will be treated according to the participating site's routine practice. As pre-procedural imaging, a cardiac CT-scan has to be performed; this can also be complemented with TEE at the discretion of the operator. The LAA closure procedure should be performed according to routine practice of the participating site - either in general or local anesthesia.~For those cases randomized to the standard treatment arm, the pre-procedural CT-scans will still be collected at completion of the study and FEops HEARTguideTM simulations will be generated, blinded for the procedural images and outcome. These simulations will be compared with the final device size and implant position and will be used for an additional comparative PREDICT-LAA sub-study."
89144945|NCT04180605|Experimental|Computational simulation arm|When patients are randomized to the computational simulation arm, the procedure will still be performed according to the participating site's routine practice - however, the procedure will only be performed after careful review of the FEops HEARTguideTM simulation results. The only prerequisite is that all patients randomized to this arm will have to undergo a pre-procedural cardiac CT-scan that will be uploaded into the FEops HEARTguideTM platform. Following this upload, a pre-procedural simulation plan will be provided to the operator, containing a set of optimal and suboptimal closure device sizes and implant positions. Software and technology upgrades of the FEops HEARTguideTM platform will be allowed during the course of the study.
89144946|NCT02771132|Experimental|Intervention|"12-hour intervention IMPower empowerment self defense course for girls and 12-hour Source of Strength for boys+ 2 refresher sessions (at 2 hrs. per session)"
89144947|NCT02771132|Other|Standard of Care|1-2 hour course based on Ministry of Education life skills course (no refresher sessions)
89144948|NCT04353414|Active Comparator|Pericapsular Injection (PCI) group|Subjects in PCI group will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
89144949|NCT04353414|Active Comparator|Transmuscular QL Block + Pericapsular Injection (PCI) group|Subjects in the TQLB group will receive the TQLB containing 30mL of 0.5% Bupivacaine Hydrochloride (HCL) plus PCI containing 20 mL of 0.25% of Bupivacaine Hydrochloride (HCL). For PCI, subjects will receive the injection through both hip portals administered by the surgeon. 10 mL of 0.25% Bupivacaine Hydrochloride (HCL) will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
89144950|NCT04226300|Experimental|Laparoscopic-Assisted|Surgeons will place TAP block laparoscopically using a camera prior to beginning a surgical procedure.
89144951|NCT04226300|Active Comparator|Ultrasound-Guided|Anesthesiologists will use ultrasound to place TAP block prior to beginning a surgical procedure.
89144952|NCT03492606||multiple sclerosis patients|
88803671|NCT01059929|Active Comparator|Dexmedetomidine|Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
88803672|NCT01059929|Active Comparator|Propofol|Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
88803673|NCT04353011||patient with chronic painful|
89144953|NCT02676453|Experimental|Intervention|Dental hygienist support
89144954|NCT02676453|No Intervention|control|Care as usal
89144955|NCT00643149|Experimental|1|
89144956|NCT00643149|Experimental|2|
89144957|NCT02770898|Experimental|Brief Intervention|The brief intervention is individual focus and consists of three main components, which include enhancing the individual personal attributes such as participant's knowledge, values, and behaviors related to physical exercise. Second, the intervention will promote changes in behavioral attributes by providing opportunities and experience in goal setting, skills development in physical exercise and self-monitoring. Finally, the brief intervention promotes family relations and well-being by encouraging individuals to share their knowledge and increase physical activities with other family members. The brief intervention will be delivered by the probation officer during regular monthly consultation.
89144958|NCT02770898|Experimental|Combined Intervention|Participants allocated to the combined intervention will receive the individual brief intervention and participate in a community group program. The components in the brief intervention will also be reinforced in the group program. The group nature is designed to create an environment that is supportive of physical exercise, through role models, peer support, and encourages families to exercise with probationers.
89144959|NCT02770898|No Intervention|Care-as-usual|Participants allocated to Care-as-usual arm will receive their usual services. Participants will be offered the combined interventions upon completion of 3-months follow up assessment.
89144960|NCT02770664|Experimental|LC28-0126 Dose A|
89144961|NCT02770664|Experimental|LC28-0126 Dose B|
89144962|NCT02770664|Experimental|LC28-0126 Dose C|
89144963|NCT02770664|Placebo Comparator|Placebo|
89144964|NCT04333680|Active Comparator|Phased Array|Operators who will be using a phased array-type transducer to perform the FAST exam on a healthy normal volunteer.
89144965|NCT04333680|Active Comparator|Curvilinear|Operators who will be using a curvilinear array-type transducer to perform the FAST exam on a healthy normal volunteer.
89144966|NCT00643227|Experimental|1|
89144967|NCT00643227|Experimental|2|
89144968|NCT00613392|Experimental|1|
89144969|NCT00613392|Placebo Comparator|2|
89144970|NCT02776514|Active Comparator|Triamcort (1 ml, 40 mg/ml)|30 patients receive intraarticular injection with steroids (and contrast media Iopamiro 200)
89144971|NCT02776514|Active Comparator|Platelet-rich-plasma (PRP 3 ml)|30 patients receive intraarticular injection with platelet-rich-plasma (PRP) (and contrast media Iopamiro 200)
89144972|NCT02776514|Active Comparator|Suplasyn1-shot (60 mg/ ml)|30 patients receive intraarticular injection with hyaluronic acid (and contrast media Iopamiro 200)
89144973|NCT02776514|Placebo Comparator|Placebo (Iopamiro 200)|30 patients receive intraarticular injection with contrast media only
89144974|NCT05018676|Experimental|ARX788|
89144975|NCT02537457|Experimental|BAY59-7939 Rivaroxaban granule|
89144976|NCT02537457|Active Comparator|BAY59-7939 Rivaroxaban tablet|
89144977|NCT02762864|Experimental|PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period. For patients in the PRU-target group with PRU ≥234 seconds, rescue medicine (ticagrelor) will be added to keep PRU<234 seconds.
89144978|NCT02762864|Active Comparator|non PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period, regardless the levels of PRU.
89144979|NCT05556915|Experimental|Ultrasound-guided AVF cannulation method|The AVF cannulation is carried out using ultrasoud guidance
89144980|NCT05556915|Other|Conventional AVF cannulation method|The AVF cannulation is carried out by palpation
89144981|NCT02767154|Active Comparator|PrimECC|1250 ml of a priming solution based on the colloid Dextran 40 to use for extracorporeal circulation.
89144982|NCT02767154|Active Comparator|Ringer-Acetate/Mannitol|1250 ml of a priming solution based on the crystalloid Ringer-Acetate (1000ml) and Mannitol (250ml).
89144983|NCT04178499||smokers|active smokers
89144984|NCT04178499||non-smokers|never smokers
89144985|NCT02767232|Active Comparator|Standard Anticoagulation Therapy|Anticoagulant therapy will be prescribed in accordance with 2012 ACCP Guidelines for children. Initial therapy generally will consist of low molecular weight heparin (LMWH) or unfractionated heparin (UFH), monitored to achieve and maintain a target anti-Xa activity of 0.5-1.0 IU/mL for LMWH and 0.35-0.7 IU/mL for UFH. Long-term therapy generally will consist of warfarin/coumadin, monitored to achieve and maintain a target INR of 2.0-3.0. The use of novel anticoagulants is permitted based on investigator preference.
89144986|NCT02767232|Experimental|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis (CDT) with intrathrombus delivery of Recombinant tissue plasminogen activator (rt-PA) (maximum allowable total dose 35 mg/24 hours) into the DVT over a period of up to 24 hours. CDT will be initiated within 72 hours of diagnosis. Two methods of initial rt-PA delivery will be used: 1.) AngioJet Thrombectomy System- maximum first-session rt-PA dose 25 mg; or 2.) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole catheter. Before and after CDT, patients will receive standard DVT therapy as in the standard anticoagulation group
89144987|NCT02673645|No Intervention|Control group|These youth will receive standard mathematics instruction and support, but not the intensive tutoring offered through the intervention.
88803674|NCT03579641||Implantable Cardiac device with HeartLogic feature|Patients with Heart Failure, implanted with Boston Scientific Implantable Cardioverter Defibrillator or Defibrillator with Cardiac Resynchronization device with HeartLogic feature
89144988|NCT02673645|Experimental|SAGA Innovations|These youth will receive the intensive mathematics tutoring by SAGA Innovations, with students randomized to tutors.
89144989|NCT02767076|Active Comparator|Conventional|conventional paramedian spinal anesthesia
89144990|NCT02767076|Experimental|Ultrasound|ultrasound guided paramedian spinal anesthesia
89144991|NCT04178733|Experimental|LY3493269 - Subcutaneous (SC)|LY3493269 administered SC.
89144992|NCT04178733|Placebo Comparator|Placebo - SC|Placebo administered SC.
89144993|NCT04178733|Experimental|LY3493269 - Intravenous (IV)|LY3493269 administered IV.
89144994|NCT02766764|Active Comparator|Study group|Women will receive oral DHEA 25 mg t.d.s daily for 12 weeks before ICSI in addition to daily GH injections from day 6 of hMG administration until the day of hCG administration.
89144995|NCT02766764|Placebo Comparator|Placebo group|Women will receive an oral placebo similar to DHEA t.d.s daily for 12 weeks before ICSI in addition to daily placebo injections similar to GH from day 6 of hMG administration until the day of hCG administration.
89144996|NCT04658654|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 24 weeks
89144997|NCT04658654|Experimental|Roflumilast 50ug|Roflumilast (50 microgram) oral capsule, once daily for 24 weeks
89144998|NCT04658654|Experimental|Roflumilast 100ug|Roflumilast (100 microgram) oral capsule, once daily for 24 weeks
89144999|NCT04178343|Experimental|Group A|Meningeal Metastases, with or without brain metastases
89145000|NCT02673801||Patient referred to orthopedic clinic|Orthopedic assessment in the outpatient clinic as well as a new algorithm (using patient-reported symptoms and radiographic evaluation) will be applied
89145001|NCT02766842|Active Comparator|EUS-FNB with ProCore needle|General anesthesia or conscious sedation will be started and an upper endoscopic ultrasound will be inserted into the participants mouth and advanced to the site of the lesion. The lesion will be punctured by the ProCore needle, then the stylet is completely removed, and negative suction pressure is applied using a 10 ml syringe for 30 seconds while the needle is stationary with the target. Then, the needle is moved back and forth several times within the target, utilizing the fanning technique. Finally, suction is released by closing the lock of the syringe and the needle is removed.
89145002|NCT02766842|Active Comparator|EUS-FNB with SharkCore needle|The procedure will be done in the same manner with same endoscopic technique and method of tissue procurement. The only difference will be using the SharkCore needle to acquire tissue.
89145003|NCT02673177|Experimental|Robot-assisted total mesorectal excision|Robot-assisted total mesorectal excision (RTME) for rectal cancer. Two different RTME procedures were chose to personalized patients. Generally, when the tumor located within 5-15cm from the anal verge, low anterior resection (LAR) was employed, and tumor located below 5cm, abdominoperineal resection (APR) was applied usually.
89145004|NCT02673177|Active Comparator|Laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer was performed. The Urinary, sexual function and sphincter- preservation outcomes were evaluated.
89145005|NCT00644241|Experimental|stem cell|
89145006|NCT02770508|Experimental|Darunavir/ritonavir plus lamivudine|Darunavir/ritonavir 800/100 mg, 1 coformulated tablet QD and lamivudine 300 mg, 1 tablet QD
89145007|NCT02770508|Active Comparator|Darunavir/ritonavir plus emtricitabine/tenofovir(FTC/TFD)|Darunavir/ritonavir 800/100 mg1 coformulated tablet QD (FDC) plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
89145008|NCT04178421|Experimental|Experimental Group|A computerized eye -tracking program training the eye gaze fixation with the target to improve impulse control and sustained attention of children with special needs
89145009|NCT04178421|Placebo Comparator|Control Group|Computerized program
89145010|NCT02762786|Experimental|Experimental|Participants in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation. The Music Children Foundation is a non-governmental organization established by a group of professional musicians with the objective of transforming children's lives and instils positive values in the entire community through music. It aims to provide free musical training to low-income children and children with chronic diseases, including those with Down's syndrome, mucopolysaccharidoses, skeletal dysplasia and visual impairment.
89145011|NCT02762786|No Intervention|Wait-list control group|Participants in the waitlist control group will receive the same training after the experimental group had completed the intervention.
89145012|NCT02537301||ERCP-chat group|All the doctors who finished their ERCP training in Xijing Hospital of Digestive Diseases and were invited to join in a chatting group in a mobile social app (Wechat).
89145013|NCT02762942|Active Comparator|Vaginal misoprostol alone|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol according to local protocols
89145014|NCT02762942|Experimental|Vaginal misoprostol + Foley catheter|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. At the same time a 16French Foley catheter will be inserted through the internal os with visualization of the cervix by sterile speculum examination. The catheter balloon will be inflated with 30 ml of sterile normal saline solution and then the catheter will be taped with gentle traction to the inner thigh of the patient until spontaneous expulsion. If this does not occur, the catheter will be deflated and removed after 12 hours. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol.
89145015|NCT02673099|Other|HDF online|All patients were started on HF (high-flux) hemodialysis. After 6 months they were then treated by HDF online.
89145016|NCT02770430|Active Comparator|conventional treatment|"After randomization, patients will be allocated to receive conventional treatment:~Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
89145017|NCT02770430|Experimental|mesenchymal stem cells|Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg
89145018|NCT05355987|Experimental|Early oncological supportive care|Evaluation of needs in oncological supportive care by a nursing coordinator from diagnosis and recommendation to plan appointments with different specialists in supportive care regarding to patient's needs
89145019|NCT05355987|Other|Delayed oncological supportive care|Evaluation of needs in oncological supportive care by a nursing coordinator at 6 months after diagnosis and recommendation to plan appointments with different specialists in supportive care regarding to patient's needs
89145020|NCT02673255|Experimental|Sanofi Pasteur (Tenivac)|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: Sanofi Pasteur (Tenivac), Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
89145021|NCT02673255|Experimental|MassBiologics|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: MassBiologics, Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
89145022|NCT02672787|Active Comparator|ED usual care plus education|ED usual care plus education
89145023|NCT02672787|Experimental|Intervention|Subjects will receive the ED-based behavioral intervention
89145024|NCT00918203|Active Comparator|Paclitaxel + Carboplatin|"(Initial 4-6 cycles) Paclitaxel 200 milligram/square meter (mg/m2) over 3 hrs (Day 1) Carboplatin Area Under Concentration (AUC)=6 (Day 1) of each 21-day cycle (Initial 4-6 cycles) Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants who experience progressive disease may cross over to olaratumab monotherapy."
89145025|NCT00918203|Experimental|Olaratumab + Paclitaxel + Carboplatin|"(Initial 4-6 cycles)~Olaratumab 15 milligrams/kilogram (mg/kg) over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit."
89145026|NCT02766452|Experimental|Pre-operative educational DVD preparation|"After their pre-assessment clinic (PAC) appointment, parents in the intervention group took the hospital's 20 minute surgical virtual tour in the hospital's family library. Parents in the intervention group also watched the 12 minute DVD entitled, You and Your Child in the RR. This pre-operative educational tool was developed and tested in a previous study (Chartrand 2014). It was designed to enable parents to gain knowledge about the equipment and procedures related to the RR, and about nurses' and parents' roles in supporting their child in the RR. The DVD also focused on potential reactions of children waking up after a general anesthesia and strategies parents can use to support their child in the RR. The DVD included images of RR equipment and positive nurse-family and parent-child interactions."
89145027|NCT02766452|Placebo Comparator|Standard pre-operative preparation|After their PAC appointment, parents in the control groups took the hospital's 20 minute surgical virtual tour in the hospital's family library.
89145028|NCT04754438|Experimental|e-CBT|12 weekly sessions of approximately 30 slides and interactive content, delivered through OPTT. The e-CBT module content mirrors in-person standard CBT content, including different weekly topics, general information, skill overviews, and homework. Participants are instructed to go through the content and complete homework at the end of the session which helps them practice skills they learned through that session. Homework is submitted through OPTT and reviewed by the therapist assigned to the participant, who will provide personalized feedback within three days of submission. Therapists have access to pre-designed session-specific feedback templates to use as a basic structure to write their feedback. By doing so, the time needed to respond to each patient is reduced and therefore the number of patients each therapist can handle increases.
89145029|NCT04754438|Experimental|Mental Health Coaching|"Weekly interactions with the therapist using general questions on the following topics:~Week 1 (Mood) Week 2 (Sleep) Week 3 (Activity) Week 4 (Hobbies) Week 5 (Friendship) Week 6 (New Events) Week 7 (Job/Study) Week 8 (Diet/Food) Week 9 (Books/Movies/Shows) Week 10 (Phone/Apps/Games) Week 11 (Habits) Week 12 (Accomplishments)"
89145030|NCT02672865|Experimental|HIPEC|The administration of hyperthermic intraperitoneal chemotherapy (HIPEC), using a warm solution of two chemotherapy medications (mitomycin and cisplatin) to bathe the internal surfaces of the abdomen in an attempt to kill any microscopic cancer cells that might be present on these surfaces.
89145031|NCT04224116|Experimental|Group TA|receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
89145032|NCT04224116|Placebo Comparator|Group SSI|Serum saline isotonic (SSI) group: placebo with isotonic saline serum.
89145033|NCT05252975|Active Comparator|Supine|Patients undergo supine setup and imaging for radiation planning
89145034|NCT05252975|Experimental|Prone|Patients undergo prone setup and imaging for radiation planning
89145035|NCT02672943|No Intervention|Normal|30 normal volunteers with age, sex and BMI-match as control group
89145036|NCT02672943|Active Comparator|treatment group|The Rehabilitation treatment group will receive rehabilitation training once per day, 3 days per week, for 12 weeks. The duration of each session is about 1 hour. Participants will first receive relaxation exercises, positioning and self-stretch exercises (emphasizing on spinal mobility and flexor muscle groups of limbs and trunk) for 15 minutes. Then they will have balance training for 20 minutes. The investigators will use goal-directed tasks, such as different types of ball games, for balance training. At the end, participants will receive walking exercise for 20 minutes, and cool down exercises for 5 minutes.
89145037|NCT02672943|Sham Comparator|non-treatment group|The group will not receive non-rehabilitation treatment, before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
89145038|NCT02696408|Experimental|Laser treatment|preventive treatment performed by nurses of mucositis by laser treating daily by scanning the entire oral cavity for 2 minutes with a power of 250 mW associated with mouthwashes several times a day (standard preventive treatment of mucositis)
89145039|NCT02696408|Placebo Comparator|laser-off|daily laser-off session performed by nurses associated with mouthwashes several times a day (standard preventive treatment of mucositis)
89145040|NCT05269901||Seizures group|20 newly diagnosed untreated school-aged children from Jan 20, 2021 to Jan 1, 2022 in affiliated Hospital of Jiangnan University, department of pediatrics.
89145041|NCT05269901||Healthy control group|20 age-matched healthy school-aged children from Jan 20, 2021 to Jan 1, 2022 in affiliated Hospital of Jiangnan University, department of pediatrics.
89145042|NCT02672709|Experimental|Anticoagulation|Apixaban will be prescribed at the dose of 2.5 mg twice per day for nine days.
89145043|NCT02770274|Experimental|Group Cilostazol|Patients receiving dual antiplatelet therapy with cilostazol 100mg twice daily and aspirin 100mg once daily for 12 months.
89145044|NCT02770274|Active Comparator|Group Aspirin|Patients receiving monotherapy with aspirin 100mg once daily for 12 months.
89145045|NCT00910221|Active Comparator|1|
89145046|NCT00910221|Placebo Comparator|2|
89145047|NCT00918281|Experimental|Fluciclatide Injection|Fluciclatide Injection
89145048|NCT02766530|Experimental|PETMR study|All the study participants will receive PET MR examinations before neoadjuvant chemotherapy and during neoadjuvant chemotherapy (during early cycle as well as during mid-cycle of chemotherapy treatment). There will be two groups of patients after completion of neoadjuvant chemotherapy, that is, responders versus non-responders. We will compare the PET MR imaging parameters before, during neoadjuvant chemotherapy between the two groups of patients.
89145049|NCT00644397||Blade Plate Group|95-degree Angled Blade Plate
89145050|NCT00644397||Locking Plate Group|4.5mm Condylar Locking Plate
89145051|NCT04657562||De novo renal/liver transplant recipients|The group of 40 consecutive adult (age > 18 years) male and female recipients of deceased kidney or liver transplant from the Regional Qualification Center (Warsaw, Poland).
89145052|NCT04657562||Random renal transplant recipients|The group of 300 random adult (age > 18 years) male and female recipients of deceased kidney attending the local outpatient clinic.
89145053|NCT04657562||Renal transplant recipients experiencing graft rejection|The group of 40 consecutive adult (age > 18 years) male and female recipients of deceased kidney experiencing acute rejection of the renal allograft.
89145054|NCT05252117|Experimental|Articaine 4%|With the patient in the lithotomy position, asepsis of the thighs, vulva and vagina will be performed with aqueous chlorhexidine; insertion of vaginal speculum; puncture in the uterine cervix, at the 12h point, injecting 1.8 ml of articaine. After a latency of five minutes, the procedure to insert the IUD will start with clamping the cervix at 12 hours with the Pozzi clamp, followed by rectification of the uterus and hysterometry with the hysterometer. After confirming the hysterometry, the IUD will be inserted with its own applicator and the excess wire will be cut.
89145055|NCT05252117|Experimental|Mepivacaíne 3%|With the patient in the lithotomy position, asepsis of the thighs, vulva and vagina will be performed with aqueous chlorhexidine; insertion of vaginal speculum; puncture in the uterine cervix, at the 12h point, injecting 1.8 ml of Mepivacaine. After a latency of five minutes, the procedure to insert the IUD will start with clamping the cervix at 12 hours with the Pozzi clamp, followed by rectification of the uterus and hysterometry with the hysterometer. After confirming the hysterometry, the IUD will be inserted with its own applicator and the excess wire will be cut.
89145056|NCT02672397|Experimental|Hispanic Intervention|Hispanic subjects that receive additional epidural education [44 patients]
89145057|NCT02672397|No Intervention|Hispanic Control|Hispanic subjects that receive standard of care [44 patients]
89145058|NCT02672397|Experimental|Non-Hispanic Intervention|Non-Hispanic subjects that receive additional epidural education [44 patients]
89145059|NCT02672397|No Intervention|Non-Hispanic Control|Non-Hispanic subjects that receive standard of care [44 patients].
89145060|NCT00631397||Premature Infants|Premature Infants weighing less than 1500 gms
89145061|NCT04178265|Experimental|Electroacupuncture group|"At the 4th week after surgery, electroacupuncture was performed, and the activity of wrist joint on the affected side was performed at same time, and at a frequency of three times per week for four weeks, for a total of twelve times.~Acupoint selection: needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints."
89145062|NCT04178265|No Intervention|Control group|At the 4th week after surgery, only the activity of wrist joint on the affected side was performed, and at a frequency of three times per week for four weeks, for a total of twelve times.
89145063|NCT04224350|Experimental|Once-Daily Tacrolimus|Experimental arm: TacroBell SR Cap.
89145064|NCT04224350|Active Comparator|Twice a Day Tacrolimus|Active Comparator arm: TacroBell Cap.
89145065|NCT02672631||Median Nerve injury hand|Participants will be randomly called; and that 10 participants which had unilateral median nerve transection totally and repaired primely in our clinic at 2014. In the sample, correlations between physical examination (Tinnel Test, motor strength assessment (Medical Research Council (MRC) Scale), static two-point discrimination test (S2PD), Semmes-Weinstein (SW) monofilament test, the Disability of the Arm, Shoulder and Hand (DASH) test), ENMG with the DTI results will be assessed.
89145066|NCT02672631||Healthy Hand|Control group will be taken from patients other hand which had not injured before. And we will compare with first group's results.
89145067|NCT02770716|Experimental|Terlipressin|Participants receive terlipressin intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
89145068|NCT02770716|Placebo Comparator|Placebo|Participants receive matching placebo intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
89145069|NCT04224896||NBI PATIENT|
89145070|NCT04224896||LUGOL PATIENT|
89145071|NCT02672319|Experimental|EUS-guided glue injection|Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
89145072|NCT02672319|No Intervention|Historical control|A historical control group of HCC patients with gastroesophageal variceal bleeding who underwent conventional cyanoacrylate injection by OGD for index variceal bleeding based on de-identified data from an existing prospective GI bleed database from 2009-2013 would also be included to allow a more meaningful interpretation of the rebleeding rate from gastroesophageal varices from this study.
89145073|NCT02766296|Experimental|Active Emotional Working Memory Training|Each participant will receive 15 sessions (each lasting 20 minutes) over a 5 week. This will be Internet-based cognitive training based on the adaptive dual n-back paradigm.
89145074|NCT02766296|Placebo Comparator|Control Working Memory Training|Participants in this condition will receive 15 sessions (each lasting 20 minutes) over a 5-week period. This will also be home-based training over the Internet. This training will be based on a fixed 1-back training program.
89145075|NCT04254029|Experimental|Non-randomized single-arm of MOROLSTEVER1|"Non-randomized single-arm clinical trial with a before and after design. The study population consisted on all type 2 diabetes mellitus (T2DM) patients with a target population of T2DM patients with HbA1c between 42 to 64mmol/mol (6-8%) with no change in anti-diabetic treatment during the last three months, previous the study.~The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days."
89145076|NCT02672241|Experimental|radio-chemotherapy plus nimotuzumab|Radiotherapy: The total radiation dose is 52.2Gy (1.8Gy fractions). Chemotherapy: Nimotuzumab, given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
89145077|NCT02766218||Behavioral: Lifestyle Intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
89145078|NCT02766218||No Intervention: Standard Care|
89145079|NCT02672007|Other|Included patients|All included patients will have respiratory rates measured by a research assistant using a criterion standard approach, by the SensiumVitals device and by the ward staff.
89145080|NCT02671929|Experimental|self-help program + feedback|Patients in this arm receive access to the internet-based self-help program and get feedback on their progress in the program.
89145081|NCT02671929|Active Comparator|self-help program|Patients in this arm receive access to the internet-based self-help program and don't get any therapeutic feedback
89145082|NCT03794310|Experimental|NPF-08 （1-day treatment）|
89145083|NCT03794310|Experimental|NPF-08 （2-day split dose）|
89145084|NCT03794310|Active Comparator|Moviprep（1-day treatment）|
89145085|NCT04177875|Experimental|Chemoradiation and pd-1|Subjects in Arm A receive 2 cycles of Docetaxel /Albumin-bound Paclitaxel + Cisplatin, for neoadjuvant therapy Neoadjuvant radiotherapy for 40Gy/20F
89145086|NCT02770118|Experimental|PSR-TSD|Partial sleep restriction (PSR) followed by total sleep deprivation (TSD). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
89145087|NCT02770118|Experimental|TSD-PSR|Total sleep deprivation (TSD) followed by partial sleep restriction (PSR). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
89145088|NCT00917579|Other|Reference|10 mg atorvastatin
89145089|NCT00917579|Experimental|Test|New 10 mg atorvastatin tablet
89145090|NCT03808740|Experimental|Roux-en-Y gastric bypass (RYGB)/Atomoxetine|Participants with standard of care RYGB will receive atomoxetine, 0.5 mg/kg/day for 3 days
89145091|NCT03808740|Experimental|Vertical sleeve gastrectomy (VSG) /Atomoxetine|Participants with standard of care VSG will receive atomoxetine 0.5 mg/kg/day for 3 days
89145092|NCT03808740|Placebo Comparator|Roux-en-Y gastric bypass (RYGB)/Placebo|Participants with standard of care RYGB will receive placebo 0.5 mg/kg/day for 3 days
89145093|NCT03808740|Placebo Comparator|Vertical sleeve gastrectomy (VSG)/ Placebo|Participants with standard of care VSG will receive placebo 0.5 mg/kg/day for 3 days
89145094|NCT04096521||East Jakarta Cohort Study|One group included in the study was originated from mothers who participated in the first data collection pregnancy. The follow-up study included mothers and their children born as the subject in the follow-up in the study. This study also includes peer of the subjects that lived in the same neighbourhood since the first cohort study and have children in the same age with cohort participant
89145095|NCT02762552|Experimental|Transcranial-holter monitoring|Transcranial doppler in patient with ischemic stroke
89145096|NCT04277286||Experimental group|Patients transferred to adult service according to the Transend transition program (between September 2016 and January 2018)
89145097|NCT04277286||Control group|Patients transferred to adult service without a transition program, in the same center, before the implementation of Transend (between January 2015 and September 2016)
89145098|NCT02766140|Experimental|SHR1020 plus Docetaxel|
89145099|NCT02766140|Placebo Comparator|Placebo plus Docetaxel|
89145100|NCT04177641||low grade squamous intraepithelial lesion(LGSIL)|low grade squamous intraepithelial lesion(LGSIL) n=100
89145101|NCT04177641||high grade squamous intraepithelial lesion(HGSIL)|high grade squamous intraepithelial lesion(HGSIL) n=100
89145102|NCT04177641||Healthy controls|Healthy volunteers n=100
89145103|NCT00614250|Experimental|Dose Level 1|
89145104|NCT00614250|Experimental|Dose Level 2|
89145105|NCT00614250|Experimental|Dose Level 3|
89145106|NCT00614250|Experimental|Dose Level 4|
89145107|NCT00614250|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
89145108|NCT04640948|Experimental|High flow nasal therapy (HFNT)|Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
89145109|NCT04640948|Active Comparator|Low flow oxygen (LFO)|Characterized by an elevated arterial CO2 (PaCO2) level of > 6kPa due to ventilatory failure. The ventilatory failure relates to the imbalance between the respiratory demand and the capacity of the respiratory system to match the demand.
89145110|NCT04177563|Experimental|a group of ten students with high physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
89145111|NCT04177563|Experimental|a group of eight students with moderate physical activity|"The participants of the study were subjected to 24 whole-body cryotherapy treatments (one treatment three times a week for two months). Before the procedure, they were informed about how to move and breathe in the cryochamber. Each entrance to the cryochamber was preceded by a 30-second adaptation period in the vestibule at a temperature of -60 ºC. Then the subjects entered the cryochamber for three minutes.~Blood was collected from each participant (with an empty stomach) at a laboratory located at the Academy of Physical Education in Krakow, where after a ten-minute rest in a sitting position at room temperature (about 19 °C), blood was collected from the vein in the crook of the elbow by a laboratory diagnostician in accordance with applicable standards. Blood was collected 13 times."
89145112|NCT04276974|Experimental|Organic first then non-organic|Organic diet then non-organic diet, each for 4 consecutive days
89145113|NCT04276974|Experimental|Non-organic first then organic|Non-organic diet then organic diet, each for 4 consecutive days
89145114|NCT00915551|Experimental|PEP005 (Ingenol Mebutate) gel|
89145115|NCT00915551|Placebo Comparator|Vehicle gel|
89145116|NCT02770196|Experimental|Group One (Two-year Intervention, 2016 Enrollment)|Group one intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2016 and 2017. During the 2016 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
89145117|NCT02770196|Experimental|Group Two (Delayed Two-year Intervention, 2016 Enrollment)|Group two intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2017 and 2018. During the 2017 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
89145118|NCT02770196|Experimental|Group Three (One-year Intervention, 2017 Enrollment)|Group three intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2017 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
89145119|NCT02770196|Experimental|Group Four (Delayed One-year Intervention, 2017 Enrollment)|Group four delayed intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2018 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
89145120|NCT04178109|Active Comparator|Group A|"Group A was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.~Group A was given the oral combination dexketoprofen/tramadole (25mg/75mg) 2h after surgery every 8h for 72h."
89145121|NCT04178109|Placebo Comparator|Group B|"Group B was under spinal anesthesia with a 25G cutting edge needle with levobupivacaine 10-15mg and fentanyl 10μg.~Periarticular injection was done by the surgeon with a dilition of 100ml N/S 0,9% with 300mg ropivacaine and 0,5mg epinephrine.~Group B received postoperative analgesia with intravenous tramadole 75mg and paracetamol 1g every 8h with the first dose beginning 2h after the end of the surgery. For 72h"
89145122|NCT04253795|Active Comparator|Laryngeal mask group (Group 1)|Laryngeal mask will be placed in the airway by the anesthesiologist. Lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing
89145123|NCT04253795|Active Comparator|Double lumen tube Group (Group 2)|After the correct position of double lumen tube will be determined, one lung ventilation will be started. Lung isolation will be achieved by deflation of the nondependent lung.
89145124|NCT00644475|Experimental|2|Imidapril
89145125|NCT00644475|Active Comparator|1|Candesartan
89145126|NCT03655704|Experimental|Apabetalone|100mg BID for 16 weeks.
89145127|NCT04177719|Experimental|Oxytocin|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
89145128|NCT04177719|Placebo Comparator|Placebo|Single-dose oxytocin or placebo will be given intranasally on separate scan days. The order of administration will be counterbalanced
89145129|NCT02762240|Active Comparator|DHQP 2016|This group consists of general practices allocated to undergo accreditation scheme in 2016.
89145130|NCT02762240|Placebo Comparator|DHQP 2018|This group consists of general practices allocated to undergo accreditation scheme in 2018.
89145131|NCT00644553|Active Comparator|A|
89145132|NCT00644553|Active Comparator|B|
89145133|NCT02762474|Experimental|nab-paclitaxel group|Weekly Regimens of paclitaxel Plus Cispaltin Combined With Concurrent IMRT
89145134|NCT00915473|Experimental|Active Injection|Subjects randomized to this arm will receive 2.5 mL 0.5% bupivicaine plus 0.5 mL 20 mg methylprednisolone injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
89145135|NCT00915473|Placebo Comparator|Placebo Injection|Subjects randomized to this arm will receive 2.75 mL normal saline plus 0.25 mL 1% lidocaine injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
89145136|NCT04691726|Active Comparator|Lidocaine infusion|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 2 mg/kg IBW i.v., continuous infusion of 1% lidocaine postoperatively rate 1 mg/kg IBW i.v. for 24 hours
89145137|NCT04691726|Placebo Comparator|Saline infusion|equal volumes of placebo - 0,9% saline i.v.
89145138|NCT00614328|Active Comparator|1|Naltrexone (50 mg once a day) + placebo baclofen + behavioral therapy (n=10)
89145139|NCT00614328|Active Comparator|2|Placebo naltrexone + baclofen (10 mg t.i.d) + behavior therapy (n=10)
89145140|NCT00614328|Active Comparator|3|Baclofen (10 mg t.i.d) + naltrexone (50 mg once per day) + behavior therapy (n=10)
89145141|NCT00614328|Placebo Comparator|4|Placebo baclofen + placebo naltrexone + behavior therapy
89145142|NCT04177173|Experimental|Simvastatin & Methotrexate|Methotrexate 10 mg once a week per oral for 6 months and Statins (Simvastatin) 20 mg once a day per oral
89145143|NCT04177173|Active Comparator|Methotrexate|Methotrexate 10 mg once a week for 6 months
89145144|NCT04224818|Experimental|Dual trigger|Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
89145145|NCT04224818|Active Comparator|hCG (standard)|HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
89145146|NCT02672085|Experimental|PRP infiltration|Supraspinatus interstitial lesion needling and infiltration with PRP
88803675|NCT04162522|Active Comparator|escitalopram (10-20 mg)|"Participants are given escitalopram for 8 weeks. At week 8, participants will be assessed and classified as responders or non-responders. Responders will continue on escitalopram until the study endpoint (16 weeks)."
89145147|NCT02672085|Active Comparator|Needling|Supraspinatus interstitial lesion needling and infiltration with NaCl
89145148|NCT02766062|Active Comparator|propofol group|Patients with metabolic syndrome were randomly assigned to receive propofol anesthesia
89145149|NCT02766062|Active Comparator|sevoflurane group|Patients with metabolic syndrome were randomly assigned to receive sevoflurane anesthesia
89145150|NCT03651804|Active Comparator|Control Group|"The control group will receive usual care for treatment of vertebral compression fractures, which will consist of but not limited to: physical therapy, opioids, NSAIDs, acetaminophen and bisphosphonates as indicated. They will have the option of crossing over (see Crossover Group) at twelve weeks."
89145151|NCT03651804|Active Comparator|Treatment Group|The treatment group will receive usual care for treatment and the treatment procedure comprised of the Medial Branch Block and Radiofrequency Ablation. In cases where a medial branch nerve block has confirmed there is pain relief, a radiofrequency ablation is considered. These patients will continue their usual care therapy as well.
89145152|NCT03651804|Active Comparator|Crossover Group|This group will comprise of patients within the control group who after 12 weeks of usual therapy will have the option of crossing over to the treatment group. Once crossed over, their treatment and course and measurements will be identical to that of the treatment group.
89145153|NCT02765750|Experimental|BIS 40-60|Patient with intraoperative Bispectral Index (BIS) 40-60.
89145154|NCT02765750|Experimental|BIS 20-40|Patient with intraoperative Bispectral Index (BIS) 20-40.
89145155|NCT02765750|Placebo Comparator|Placebo|Placebo group
89145156|NCT00917501|Placebo Comparator|Placebo|Placebo to the Omega-3 given in other group taken twice a day.
89145157|NCT00917501|Active Comparator|Omega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA & will be taken twice a day.
89145158|NCT02670681|Active Comparator|Aerobic Exercise Mild Intensity|The subjects engage in aerobic exercise training (8 weeks) of mild intensity (continuous). The intensity is controlled by a corresponding heart rate at anaerobic threshold.
89145159|NCT02670681|Active Comparator|Aerobic Exercise Moderate Intensity|The subjects engage in aerobic exercise training (8 weeks) of moderate intensity (continuous). The intensity is controlled by a corresponding heart rate between anaerobic threshold and respiratory compensation point.
89145160|NCT02670681|Active Comparator|Aerobic Exercise High Intensity|The subjects engage in aerobic exercise (8 weeks) of high intensity interval training. The intensity is controlled by a corresponding heart rate above respiratory compensation point.
89145161|NCT03580512||Group 1|- 800 existing clients who already received PrEP
89145162|NCT03580512||Group 2|"800 new clients who present for HIV testing and are HIV-negative. All will be offered PrEP~600 clients who will refuse PrEP~200 clients who will receive PrEP"
89145163|NCT03580512||Group 3|- 400 new clients who are HIV-positive or new clients who present for HIV testing and are HIV-positive
89145164|NCT02765828||Late-Onset Pompe Disease|
89145165|NCT02765828||Acquired/Hereditary Myopathy|
89145166|NCT02765828||Neuropathy|
89145167|NCT04176003||Patients with CPPD|
89145168|NCT04176003||Healthcare professionals working with CPPD patients|
89145169|NCT04176003||Stakeholders working on behalf of CPPD patients|
89145170|NCT04688762||Group without the e-consult tool|standard consultation
89145171|NCT04688762||Group with the e-consult tool|The e-consult tool is a digital application developed and designed by the Center François Baclesse, This tool is a consultation support to explain the surgical management of the patient.
89145172|NCT05188755|Active Comparator|Healthy controls|sex and age matched healthy controls
89145173|NCT05188755|Experimental|young adults recovered from lymphoma or Hodgkin's disease|young adults recovered from lymphoma or Hodgkin's disease
89145174|NCT04540952|Experimental|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
89145175|NCT04540952|Active Comparator|Control|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
89145176|NCT00917267|Experimental|1|
89145177|NCT00917267|Active Comparator|2|
89145178|NCT03606252|Other|pneumocystosis with favourable evolution|patients with a favourable pneumocystosis outcome
89145179|NCT03606252|Other|pneumocystosis with unfavourable outcome|patients with unfavourable pneumocystosis outcome
89145180|NCT03606252|Other|Pneumocystis colonization|subject colonized by Pneumocystis jirovecii
89145181|NCT02670759|Experimental|Paravertebral analgesia|A paravertebral nerve block will be performed under ultrasound guidance by the anaesthesiologist prior to the induction of general anesthesia. A catheter will be inserted and a continuous infusion of bupivacaine will be administered.
89145182|NCT02670759|Active Comparator|Intercostal analgesia|An intercostal nerve block using a single dose of bupivacaine will be performed by the surgeon at the end of surgery before skin closure.
89145183|NCT03300492|Experimental|NK-DLI|"Preemptive immunotherapy with ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses following haplo-HSCT."
89145184|NCT04521738|Experimental|SAR441255|Single dose, subcutaneous, escalating dose
89145185|NCT04521738|Placebo Comparator|Placebo|Single dose, subcutaneous, matched volume
89145186|NCT00644943|Active Comparator|1|
89145187|NCT00644943|Active Comparator|2|
89145188|NCT02692404||Hospital Birth|Healthy nulliparous participants, planning spontaneous vaginal or induced vaginal delivery, and planning delivery at a hospital woman-care birth center (Magee-Womens Hospital of UPMC) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to utilize labor epidural analgesia for pain control during labor.
89145189|NCT02692404||Midwife Center Birth|Healthy nulliparous participants, planning vaginal delivery under the primary care of a nurse midwife (The Midwife Center for Birth and Womens Health, or UPMC-Mercy) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to avoid labor epidural analgesia for pain control during labor.
89145190|NCT02769884|Experimental|MMPPC arm|Subjects in this arm will wear the experimental MMPPC algorithm artificial pancreas for 72 hours in a hotel/house setting. The study period will involve unannounced meals and exercise
89145191|NCT05213507|Experimental|Inhaled Amikacin plus Conventional Therapy|"0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time."
89145192|NCT05213507|Other|Conventional Therapy|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long-term oxygen therapy.
89145193|NCT02765984||normal placental site|women with normal implantation site at early trimester with normal placental site
89145194|NCT02765984||Low placental site|women with low implantation site at early trimester with low placental site
89145195|NCT00614796|Experimental|1|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
89145196|NCT00614796|No Intervention|2|daily physical activity is assessed at baseline, 3 months, 9 months and 15 months. No counseling.
89145197|NCT02670603|Experimental|Experimental arm|In experimental arm, each patient painted EVONAIL® solution on nails and periungual areas once a day till developing onycholysis grade 2 or more.
89145198|NCT02670603|Other|Control arm|"In control arm, each patient painted EVONAIL® solution on nails and periungual area twice a day after developing onycholysis grade 2.~This study design allowed cross-over. Therefore, this control arm would give EVONAIL® solution after developing onlycholysis grade 2 in spite of control arm."
89145199|NCT02761928||Epidural|Positive response (>50% pain relief) to any epidural (e.g. interlaminar/paramedian, transforaminal, caudal)
89145200|NCT02761928||Selective nerve root block|Positive response (>50% pain relief) to selective nerve root block
89145201|NCT02761928||Facet injection|Positive response (>50% pain relief) to intra-articular facet injection
89145202|NCT02761928||Medial branch block|Positive response (>50% pain relief) to median branch nerve block
89145203|NCT02761928||Medial branch RFA|Positive response (>50% pain relief) to median branch nerve radiofrequency ablation
89145204|NCT02761928||SIJ injection|Positive response (>50% pain relief) to sacroiliac joint injection
89145205|NCT02761928||Lateral branch block|Positive response (>50% pain relief) to lateral branch nerve block for SIJ
89145206|NCT02761928||Greater trochanter injection|Positive response (>50% pain relief) to greater trochanteric bursa injection
89145207|NCT02761928||Piriformis injection|Positive response (>50% pain relief) to piriformis injection
89145208|NCT02761928||Trigger point injection|Positive response (>50% pain relief) to trigger point injection
89145209|NCT04253639||Chronic pain patients|
89145210|NCT02670369|Experimental|Sitting time prompt|All participants will receive a prompting device (one-arm intervention).
89145211|NCT03385902|Experimental|optimal start dialysis group|The DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE reaching to 30-35, which defined as the optimal start time.
89145212|NCT03385902|Active Comparator|late start dialysis group|the DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE less than 30, which defined as late start time.
89145213|NCT04253873|Experimental|Apatinib mesylate + temozolomide|Apatinib mesylate tablets (0-14 days, 500 mg, qd), one week apart, then temozolomide (150mg/m2, 5 days);Every 28 days is a cycle, the drug until the disease progress, the toxicity of intolerable.
89145214|NCT05147727|Experimental|Fluconazole and Famitinib interaction|
89145215|NCT02769650|Experimental|Stress-MRI + Chronic total occlusion PCI|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Coronary angioplasty with stenting of RCA CTO
89145216|NCT02769650|Active Comparator|Stress-MRI + Optimal medicamentous treatment|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Optimal medicamentous treatment
89145217|NCT04444362|Experimental|Inspiratory Muscle Training|The Inspiratory Muscle Training group received respiratory muscle training, in addition to routine preparation, including laboratory and radiological examinations and preoperative education.
89145218|NCT04444362|No Intervention|Control|The control group received routine preparation, including laboratory and radiological examinations and preoperative education.
89145219|NCT04175535|Other|The experimental group|PPECD was performed in the experimental group
89145220|NCT04175535|Other|control group|ACDF was performed in the control group
89145221|NCT02765906|No Intervention|No intervention|No additional education
89145222|NCT02765906|Experimental|Graphic card|Education with graphic card
89145223|NCT02765906|Experimental|Video|Education with video
89145224|NCT02669979|Experimental|Intervention|"Intervention in the research groups is professional oral care with tooth brush, ordinary fluoridated tooth paste (1100-1450 ppm NaF), and repeated oral care instruction to participants and staff (contact person) , supra gingival depuration if necessary. The group receive treatment each month."
89145225|NCT02669979|No Intervention|Control|Care as usual. Common oral hygiene help administered by nursing staff.
89145226|NCT02765594|Experimental|valsartan only:control group|valsartan (160mg/d)
89145227|NCT02765594|Experimental|hydroxychloroquine with valsartan:study group|valsartan (160mg/d) and Hydroxychloroquine Sulfate ( 400mg/d, twice daily)
88803676|NCT04162522|Active Comparator|brexpiprazole (0.5-2 mg)|"At week 8, participants classified as non-responders will be given 8 weeks of brexpiprazole as add-on treatment to escitalopram."
89145228|NCT00920699|Experimental|600 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day of CoQ10 in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
89145229|NCT00920699|Experimental|1200 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
89145230|NCT00920699|Experimental|2400 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
89145231|NCT02670057|Experimental|Transnasal SPG block|
89145232|NCT02769728|Experimental|EndoBarrier|EndoBarrier will be implemented for 9 months.
89145233|NCT02670135|Placebo Comparator|triclosan free toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
89145234|NCT02670135|Active Comparator|Triclosan containing toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
89145235|NCT02769494|Experimental|Mesalazine Group|Mesalazine Sustained-Release Tablets and 0.02L glycerol mixed, 2.5% mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. Daily treatment time of the drug is 8 am,12 pm and 4 pm.
89145236|NCT02769494|Active Comparator|Riboflavin Sodium Phosphate Group|wipe the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. Daily treatment time of the drug is am,12 pm and 4 pm.
89145237|NCT04334772|Experimental|Muscle belly Microelectrolysis|"Group to receive direct current application percutaneously using an acupuncture needle with intensities in microamps (µA) at hamstring muscular belly. The acupuncture needle will correspond to the negative electrode or cathode.~The group will also receive a passive stretching exercise treatment by a physical therapist."
89145238|NCT04334772|Experimental|Tendon Microelectrolysis|"Group to receive direct current application percutaneously using an acupuncture needle with intensities in microamps (µA) at the hamstring tendon. The acupuncture needle will correspond to the negative electrode or cathode.~The group will also receive a passive stretching exercise treatment by a physical therapist."
89145239|NCT04334772|Active Comparator|Control|Group to receive treatment by assisted passive stretching performed by a physical therapist on tightness hamstrings.
89145240|NCT02669745||Women of Chinese Descent|Females of Chinese descent, aged 18 year to 70 year, diagnosed with Stage 1 or Stage 2 (excluding those involving more than 3 lymph nodes) breast cancer.
89145241|NCT02765516|Active Comparator|Plant sterols|
89145242|NCT02765516|Placebo Comparator|Placebo|
89145243|NCT00614562|Experimental|NAVA|
89145244|NCT02765438|Experimental|BOBO|"Playing with the BOBO system."
89145245|NCT02537145||Obese pregnant women|20 obese pregnant women (BMI ≥ 30)
89145246|NCT02537145||Lean pregnant women|20 lean pregnant women (BMI 18,5 - 25)
89145247|NCT02769572|Experimental|real moxibustion plus placebo gel|In subjects with osteoarthritis of the knee
89145248|NCT02769572|Active Comparator|diclofenac sodium gel plus sham moxibustion|In subjects with osteoarthritis of the knee
89145249|NCT02669823||Children <15y|no intervention
89145250|NCT02669823||Adults >=15y|no intervention
89145251|NCT02669589|Active Comparator|heparin anticoagulation|"Systemic anticoagulation of the continuous renal replacement therapy with heparin.~Dose will be titrated to maintain aPTT (activated partial thromboplastin time) between 45-60s)"
89145252|NCT02669589|Experimental|citrate anticoagulation|"Regional anticoagulation of the continuous renal replacement therapy with citrate.~Target posthemofilter ionized calcium level: 0.25-0.35 mmol/l"
89145253|NCT02765204|Experimental|DS-D-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
89145254|NCT02765204|Experimental|DS-DG-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
89145255|NCT02765204|Experimental|D-DG-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
89145256|NCT02765204|Experimental|D-DS-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
89145257|NCT02765204|Experimental|DG-D-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
89145258|NCT02765204|Experimental|DG-DS-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
89145259|NCT00910377|Experimental|visit with grandmother|Teenagers mothers and their grandmothers receive counseling sessions about breastfeeding and complementary feeding.
89145260|NCT00910377|Experimental|visit without grandmother|Teenagers mothers don´t live with their grandmothers and receive counseling sessions about breastfeeding and complementary feeding.
89145261|NCT00910377|No Intervention|no visit with grandmother|Teenagers mothers live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
89145262|NCT00910377|No Intervention|no visit without grandmother|Teenagers mothers don´t live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
89145263|NCT02765282|Experimental|DBS-Expert Programming First|These patients will be undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) first and then be programmed by a clinician within five days.
89145264|NCT02765282|Experimental|Traditional Programming First|These patients will be programmed by a clinician first and then undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) within five days.
89145265|NCT04175223|Experimental|probiotics|probiotic administration
89145266|NCT04175223|No Intervention|without probiotic|no change from the usual care
89145267|NCT03342456|Experimental|group 1|week1 to week2：Doxycycline Hyclate Enteric-Coated Capsules 0.1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily
89145268|NCT03342456|Active Comparator|group 2|"Amoxicillin Capsules 1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily.~week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily"
89145269|NCT02669199|Experimental|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
89145270|NCT04224662||Patients with Gout|Patients who have been diagnosed with Gout
89234869|NCT05888220|No Intervention|control group|No intervention was made for the patients. Visual Analog Scale, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, Pittsburgh Sleep Quality Index, Health Assessment Questionnaires were re-administered at the end of the sixth week in this group.
89145271|NCT05106413|Experimental|Speech Intelligibility with CROS device|"The focus of this study is on Speech Intelligibility (SI), evaluated by the Oldenburg Sentence test (OLSA), which measures a speech recognition threshold (SRT) in dB SNR (signal to noise ratio).~Therefore each participant will perform the tests with the experimental rechargeable CROS transmitter (CROS) in different interventions, like comparison to monaural fitting and unaided condition.~All participants will perform the same tests. The order of the intervention in the speech test is randomized, but will be performed in the same visit by each participant."
89145272|NCT02765048|Experimental|GAIN Program|Subjects randomly assigned to receive the GAIN Program intervention
89145273|NCT02765048|No Intervention|Usual Care|Subjects randomly assigned to receive community-based services as part of their usual care
89145274|NCT03462576|Experimental|Emricasan 25mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
88803677|NCT04896658|Experimental|Arm A|"Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.~Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 3 weeks cycles."
88803678|NCT04896658|Experimental|Arm B|"Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.~Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 6 weeks cycles."
88803679|NCT01062269|Active Comparator|Cholestyramine 4 grams|
88803680|NCT01062269|Active Comparator|Cholestyramine 12 grams|
88803681|NCT01062269|Placebo Comparator|Tang|
88803682|NCT04156828|Experimental|Treatment (copanlisib, R-GCD)|Patients receive copanlisib IV and gemcitabine IV on days 1 and 8, carboplatin IV and rituximab IV on day 1, and dexamethasone PO or IV 30-60 minutes prior to chemotherapy on day 1 and PO in AM or 30-60 minutes prior to chemotherapy on days 2-4. Patients also receive pegfilgrastim SC on day 8 or 9. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
89145275|NCT03462576|Experimental|Emricasan 5mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
89145276|NCT03462576|Placebo Comparator|Placebo|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
88803683|NCT01062893|Placebo Comparator|0 mls saline injected|NO SALINE INJECTED
88803684|NCT01062893|Active Comparator|15 mls saline|15ML SALINE ADMINISTERED EPIDURALLY
88803685|NCT01063049|Active Comparator|Nulytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
88803686|NCT01063049|Experimental|Gatorade/Miralax + Placebo|Gatorade 64 oz (1/2 gallon), Miralax 306 g and a placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and placebo at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
88803687|NCT01063049|Experimental|Gatorade/Miralax + Bisacodyl|Gatorade 64 oz (1/2 gallon), Miralax 306 g and Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and Bisacodyl 10 mg at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
88803688|NCT04104178|Active Comparator|Clindamycin|600 mg clindamycin, 3 times daily for 10 days, orally
88803689|NCT04104178|Placebo Comparator|Placebo|Arm consumes placebo capsules identical to clincamycin capsuls from the other arm,3 times daily for 10 days, orally
88803690|NCT03661138|Experimental|Arm A|Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).
88803691|NCT03661138|Experimental|Arm B|Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).
88803692|NCT03661138|Experimental|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
88803693|NCT03661138|Experimental|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
88803694|NCT04086160|Experimental|schizophrenia- tDCS|
88803695|NCT04086160|Sham Comparator|schizophrenia- sham|
88803696|NCT04086160|Experimental|at risk- tDCS|
88803697|NCT04086160|Sham Comparator|at risk- sham|
88803698|NCT04086160|Experimental|healthy controls for schizophrenia- tDCS|
88803699|NCT04086160|Sham Comparator|healthy controls for schizophrenia- sham|
88803700|NCT04086160|Experimental|healthy controls for at risk- tDCS|
88803701|NCT04086160|Sham Comparator|healthy controls for at risk- sham|
88803702|NCT04081792|Experimental|1. Trial (Amputation) Soft tissue - short antibiotic arm|The intervention group consists of 1 day of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.
88803703|NCT04081792|Active Comparator|1. Trial (Amputation) Soft tissue - long antibiotic arm|The control group consists of 4 days duration of postoperative antibiotic therapy for eventual residual soft tissue infection after amputation.
88803704|NCT04081792|Experimental|1. Trial (Amputation) Bone - short antibiotic arm|The intervention group consists of 1 week of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.
88803705|NCT04081792|Active Comparator|1. Trial (Amputation) Bone - long antibiotic arm|The intervention group consists of 3 weeks of postoperative antibiotic therapy for eventual residual bone infection / contamination in the proximal bone stump after amputation.
88803706|NCT04081792|Experimental|2.Trial (soft tissue infection) - short antibiotic arm|The intervention group consists of 10 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.
89145277|NCT02669277|No Intervention|group A|no platelet enhancing therapy
89145278|NCT02669277|Active Comparator|group B|Standard IVIG single dose 1.0 gm /kg/dose
89145279|NCT02669277|Experimental|group C|minipool IVIG product single dose 1.0 gm /kg/dose
89145280|NCT02769104|Experimental|AI+Chemo|aromatase inhibitors (Letrozole 2.5mg po. QD for 5 years) starts at the beginning of neoadjuvant treatment combined with chemotherapy (AC*4-T*4) in patients with postmenopausal hormone receptor-positive breast cancer
89145281|NCT02769104|Active Comparator|Chemo|chemotherapy (AC*4-T*4) as neoadjuvant treatment without aromatase inhibitors in patients with postmenopausal hormone receptor-positive breast cancer
89145282|NCT02545842|Experimental|Group 1|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
89145283|NCT02545842|Experimental|Group 2|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
89145284|NCT02545842|Experimental|Group 3|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
89145285|NCT00645255|Other|1|Single-blind Placebo Run-in with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
89145286|NCT00645255|Placebo Comparator|2|Double-blind Treatment with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
89145287|NCT00910455|Experimental|Active|Single oral dose of SRX246 capsule
89145288|NCT00910455|Placebo Comparator|Placebo|Single oral dose of placebo capsule
89145289|NCT05086679|Active Comparator|Compression stockings with 25-30 mm Hg pressure|Compression stockings with 25-30 mm Hg pressure, as long as they could (ideal would be the majority of the time they are upright)
89145290|NCT05086679|Sham Comparator|Compression stockings with up to 10 mm Hg pressure|Compression stockings with up to <=10 mm Hg pressure, as long as they could (ideal would be the majority of the time they are upright)
89145291|NCT04182048||All patients|
89145292|NCT04175379|Experimental|group 40|In group 40, target PaCO2 is 40 during surgery
89145293|NCT04175379|Experimental|group 50|In group 50, target PaCO2 is 50 during surgery
89145294|NCT04175379|Experimental|group 60|In group 60, target PaCO2 is 60 during surgery
89145295|NCT02764892|Experimental|V81444|Single oral dose of V81444
89145296|NCT02765126|Active Comparator|Group 1|Diphtheria-tetanus-acellular pertussis vaccine administered day 0, followed by seasonal influenza vaccination four weeks later. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week, 4 weeks, 4 weeks + 24 hours, 5 weeks, 8 weeks and 30 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
89145297|NCT02765126|Active Comparator|Group 2|Seasonal influenza vaccine administered on day 0, to be offered DTP vaccine at week 26. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
89145298|NCT02765126|Active Comparator|Group 3|Seasonal influenza vaccine and DTP vaccine administered together on day 0. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
89145299|NCT02668965|No Intervention|control|intrauterine infusion with standard embryo culture media 10 microliters before embryo transfer
89145300|NCT02668965|Experimental|intrauterine hCG|intrauterine infusion with hCG (500 IU) 10 microliters before embryo transfer
89145301|NCT02668809|Experimental|Experimental Group 1|consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence.
89145302|NCT02668809|Experimental|Experimental group 2|Consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence, varnish application
89145303|NCT02668809|Placebo Comparator|Control Group|Consent,clinical exam, microbiological sampling, questionnaires
89145304|NCT02764658|Experimental|Pulmonary recovery on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
89145305|NCT02764658|Other|Routine care on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
89145306|NCT02764658|Other|Routine care on the stable COPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in stabel COPD Patients
89145307|NCT00916721|Active Comparator|Propranolol|propranolol
89145308|NCT00916721|Placebo Comparator|Placebo|sugar pill
89145309|NCT04175457|Experimental|e-cigarette inhalation with nicotine|inhalation of e-cigarette vapor with nicotine for 30 minutes.
89145310|NCT04175457|Active Comparator|e-cigarette inhalation without nicotine|inhalation of e-cigarette vapor without nicotine for 30 minutes.
89145311|NCT02764814|Active Comparator|Treatment|subjects receiving cryopreserved amniotic membrane
89145312|NCT02764814|No Intervention|Control|no intervention
89145313|NCT05345340|Experimental|Telemedicine Group|Patients will receive an individualized intensive 5-day rehabilitation program (2 hours/day, five days/week, one week) by a qualified physiotherapist at the USD Parkinson's Disease and Movement Disorders Unit of Verona (Italy) followed by an individualized self-management program implemented with the Digital Telemedicine platform support ((PHOEMA G.P.I PLATFORM, GPI spa, Trento, Italy). Telemedicine will consist of 24 tele-sessions (1 h/day, one day/week, 24 weeks) and two self-management sessions (1 h/day, two days/week, 24 weeks). For each patient, the duration of the activity, number of steps taken, distance traveled (km), Kcal consumed, duration of inactivity, total hours of sleep, and number of training sessions performed will be monitored through Polar Vantage M devices.
89145314|NCT05345340|Active Comparator|Control Group|Patients will receive the same individualized intensive 5-day rehabilitation program (2 hours/day, 5 days/week, 1 week) of the Telemedicine Group by a qualified physiotherapist at the USD Parkinson's Disease and Movement Disorders Unit of Verona (Italy) followed by a home-based self-management plan (Treatment, as usual, 1 h/day, 3 days/week, 24 weeks) without any Digital Telemedicine platform support.
89145315|NCT05054075|Experimental|Vaccinated|Subjects that received a vaccine against COVID-19 lineage virus
89145316|NCT05054075|Experimental|Non-vaccinated|Subjects that did not receive a vaccine against COVID-19 lineage virus
89145317|NCT05054075|Experimental|Infected|Subjects that are infected with a COVID-19 lineage virus
89145318|NCT02668341||psoriasis patients in Denmark|non-interventional survey study in psoriasis patients in daily practice care
89145319|NCT02668341||psoriasis patients in Spain|non-interventional survey study in psoriasis patients in daily practice care
89145320|NCT02668341||psoriasis patients in Poland|non-interventional survey study in psoriasis patients in daily practice care
89145321|NCT02668341||psoriasis patients in Germany|non-interventional survey study in psoriasis patients in daily practice care
89145322|NCT02761772||PEP-A|See detailed description
89145323|NCT02761772||PEP-S|See detailed description
89145324|NCT00613782|Active Comparator|1|Reandron 100 treatment
89145325|NCT00613782|Placebo Comparator|2|Placebo
89145326|NCT02761616||eBC treated participants|Participants with metastatic disease after previously being treated for eBC were observed for 24 months.
89145327|NCT02668263|Active Comparator|Surgery and Drain|Group 1 will be allocated to receive a drain intra-operatively.
89145328|NCT02668263|Other|Surgery alone|Group 2 will not receive a drain and no further intervention.
89145329|NCT02668263|Experimental|Surgery and quilting sutures|Group 3 will not receive a drain but will receive quilting sutures
89145330|NCT04106388|Experimental|Virtual Behavioral Health Integration|All patients who meet eligibility criteria at sites where the virtual behavioral health program is offered will be considered exposed to the intervention.
89145331|NCT04106388|No Intervention|Usual Care - Behavioral Health|All patients who meet eligibility criteria at sites where the virtual behavioral health program is not offered will be considered exposed to usual care.
89145332|NCT02769260|No Intervention|No toothbrushing during experiment and Pyrosequencing|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope) and 16S DNA pyrosequencing.
89145333|NCT02769260|No Intervention|No toothbrushing during experiment|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
89145334|NCT02769260|Active Comparator|Toothbrushing during experiment|48hours-Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
89145335|NCT02420964|Other|Nurse instruction|Traditional injection teaching method. No video instruction
89145336|NCT02420964|Other|Video instruction|Video instruction that can be paused/repeated by subject
89145337|NCT02668419|Active Comparator|Usual Care|Patients in this group were subject to regular Physical Therapy Sessions in the hospital and each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise.
89145338|NCT02668419|Experimental|Neuromuscular Electrical Stimulator|Lower limb muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min. Heart rate, blood pressure, respiratory rate and pulse oximetry were monitored throughout the sessions, in all patients.
89145339|NCT02768714|Experimental|Eurofarma's pegfilgrastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Eurofarma's pegfilgrastim (subcutaneous injection)
89145340|NCT02768714|Active Comparator|Neulastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Neulastim (subcutaneous injection)
89145341|NCT00614640|Experimental|1|One 0.8 ml vaccine-containing patch and 1 placebo patch placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
89145342|NCT00614640|Experimental|2|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
89145343|NCT00614640|Experimental|3|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 7, 42, 49, 84, and 91
89145344|NCT02761460|Experimental|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy,
89145345|NCT00631865|Experimental|cell transplantation group|Epidermal Cell transplantation in patients with vitiligo
89145346|NCT02354274|Active Comparator|Standard: Homogeneous dose plan|Treatment will be given over 33 treatments. The dose is 66 Gy.
89145347|NCT02354274|Experimental|Escalation: Inhomogeneous dose plan|"Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.~Treatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration"
89145348|NCT02764736|Experimental|atorvastatin|Patients in this arm will receive 20mg atorvastatin PO daily for 12 weeks followed by 40mg atorvastatin PO daily for 12 weeks.
89145349|NCT04652999|Experimental|Muscle Relaxation with Guided Imagery|The participants in Experimental Group will receive four individual 45-minute sessions, every two weeks, of progressive muscle relaxation intervention with guided imagery focused on ulcer healing, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
89145350|NCT04652999|Placebo Comparator|Active Control Group|Participants in the Active Control Group will receive four individual 45-minute sessions of neutral guided imagery placebo, carried out by the Psychologist responsible for implementing the project, on the day of the Diabetic Foot appointments.
89145351|NCT04652999|No Intervention|Passive Control Group|The participants in the Passive Control Group will not receive any intervention nor placebo session.
89145352|NCT00646737|Experimental|1|Mycophenolate sodium
89145353|NCT04705376|Active Comparator|Breg Polarcare|Patients within the Breg Polarcare treatment arm will use the Breg Polarcare device for the first two days post-operatively following their arthroscopic rotator cuff repair. They will switch to the Thermazone device for post-operative days 3 and 4. They will continue to alternate every two days for 8 days total post-operatively.
89145354|NCT04705376|Experimental|Thermazone|Patients within the Thermazone treatment arm will use the Thermazone device for the first two days post-operatively following their arthroscopic rotator cuff repair. They will switch to the Breg Polarcare device for post-operative days 3 and 4. They will continue to alternate every two days for 8 days total post-operatively.
89145355|NCT00646815|Experimental|a|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in 12 adult patients, recently diagnosed with growth hormone deficiency
89145356|NCT00646815|No Intervention|Control|Intramyocellular, intrahepatic and intraabdominal lipid content, lean body mass and body fat percentage, are assessed in ten healthy controls matched on age, gender and BMI.
89145357|NCT02764502|Experimental|Pressure Gauge Manometer|Tuohy needle is introduced into intervertebral space at the level of L3-L4 up to the interspinous ligaments . The needle is advanced slowly using both hands while monitoring the manometer reading and is stopped when the pressure suddenly dropped ( the pressure usually drops by 5-10 mm Hg when the tip of the needle inters the epidural space ).
89145358|NCT04033185|Active Comparator|study group|virtual reality, robot-assisted gait training, conventional treatment
89145359|NCT04033185|Other|control group|conventional treatment
89145360|NCT02764346|Experimental|iCanCope app|iCanCope app
89145361|NCT02764346|Active Comparator|Attention control app|Control group: iCanCope attention control app
89145362|NCT00646893|No Intervention|1|Control: assisted hatching, without Preimplantation Genetic Diagnosis
89145363|NCT00646893|Experimental|2|Test: embryo biopsy with Preimplantation Genetic Diagnosis
89145364|NCT02769182|Experimental|Monitoring and training using the system|
89145365|NCT02769182|Active Comparator|Standard of care|
89145366|NCT00915005|Experimental|Group 1|"Group 1: Photon Therapy - 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
89145367|NCT00915005|Experimental|Group 2|"Group 2: Proton Therapy - 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
89145368|NCT00915005|Experimental|Group 3|"Group 3: Receives either photon or proton therapy, whichever participant's doctor decides is better, for for 6-7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
89145369|NCT00915005|Experimental|Group 4|"Photon Therapy - Highest practical dose (74 CGE, 66 CGE) radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
89145370|NCT00910533|Active Comparator|Early Lyme neuroborreliosis patients|
89145371|NCT00910533|No Intervention|control subjects|Control subjects without a history of Lyme borreliosis.
89145372|NCT02696642|Experimental|Control group|Anetumab ravtansine was given at 6.5 mg/kg body weight (BW) as a 1 hour intravenous (IV) infusion once every 3 weeks (Q3W) for subjects with adequate hepatic and renal function.
89145373|NCT02696642|Experimental|mild HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with mild hepatic impairment (HI).
89145374|NCT02696642|Experimental|moderate HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate hepatic impairment (HI).
89145375|NCT02696642|Experimental|moderate RI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate renal impairment (RI).
89145376|NCT00646971|Experimental|1|CPAP
89145377|NCT00646971|Sham Comparator|2|sham CPAP
89145378|NCT04439045|Experimental|VPM1002|A single dose of 0.1 mL of the reconstituted vaccine containing VPM1002 (Mycobacterium bovis rBCGΔureC::hly, live 2-8 × 105 CFU), administered via intradermal injection.
89145379|NCT04439045|Placebo Comparator|Placebo|A single dose of 0.1 mL of the 0.9% sodium chloride injection, administered via intradermal injection.
89145380|NCT00647049|Experimental|A|first diagnosis of PCNSL: combined chemotherapy with methotrexate
89145381|NCT00647049|Experimental|B|Patients with relapse or progressive disease of PCNSL after methotrexate containing chemotherapy
89145382|NCT02696330|Active Comparator|clopidogrel|50 patients undergoing ICSI
89145383|NCT02696330|Active Comparator|enoxaparin|50 patients undergoing ICSI
89145384|NCT02696330|Placebo Comparator|placebo|50 patients undergoing ICSI
89145385|NCT04857593|Experimental|Intervention|"M4M online is a 6-week intervention for mothers with PND. The original M4M programme would be delivered face-to-face in groups of 8-12 mothers in weekly sessions lasting one hour. However, due to the current situation with COVID-19, we will therefore modify the original face-to-face intervention for this online study, as follows:~Run groups of around 15-17 women to ensure that all participants can be visible on one screen during online delivery to create a stronger sense of community and connection~Offer 6 weeks of intervention, also building on the evidence from the face-to-face intervention that by 6 weeks there is already a significant improvement in depressive symptoms compared with control interventions24~Introduce a two-week lead-in period before the beginning of the six-session course, where mothers will be able to use WhatsApp and at least one (monitored) Zoom session to get to know each other."
89145386|NCT04172727|Active Comparator|ultrasound guided transversalis fascia plane block|20 mL of 0.25% bupivacaine
89145387|NCT04172727|Placebo Comparator|ultrasound guided sham block|20 mL of saline
89145388|NCT02761148||Control|
89145389|NCT02761148||White matter hyperintensity|
89145390|NCT04648319|Experimental|locally advanced, metastatic or recurrent cholangiocarcinoma|D1: Compound: BMS-936558 treatment d8: radiotherapy D 20: CT guided Biopsy D 28: BMS-936558 treatment monthly: BMS-936558 treatment CT CAP: after 4doses
89145391|NCT02761226|Experimental|Group A (Platform Matched Design)|10 Patients with missing tooth in upper posterior area will receive dental implant (implants with the same abutment diameter)
89145392|NCT02761226|Active Comparator|Group B (intervention - Platform Switching Design)|10 patients with missing tooth in upper posterior area will receive dental implant (implants with smaller diameter abutment)
89145393|NCT02764424||Preterm or term newborns|Preterm or term newborns, hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France), who have to acute painful stimuli related to their care will be included in the study. This painful stress is made in the patient's usual care and is not modified by the protocol. Their stress due to the painful stimuli will be measured with different scales (2 PIPP (Premature Infant Pain Profile) and DAN (Newborn Acute Pain)) and compared with the index obtained with the NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®).
89145394|NCT00647127|Active Comparator|Buprenorphine|
89145395|NCT00647127|Active Comparator|Fentanyl|
88803707|NCT04081792|Active Comparator|2. Trial (soft tissue infection) - long antibiotic arm|The control group consists of 20 days of post-debridement antibiotic therapy for non-amputated diabetic foot soft tissue infection.
89145396|NCT00647127|Placebo Comparator|Placebo|
89145397|NCT04172883|No Intervention|Control arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the standard device setting or MINERVA setting ( control arm)
89145398|NCT04172883|Active Comparator|Treatment arm|The devices on the study are all commercially available and enabled with reactive ATP( rATP)feature, for the study both arms will have rATP switched on with one arm on the reduced sequence programming ( treatment arm)
89145399|NCT02765360|Experimental|Treatment|Each patient will be assigned to Continuous Positive Airway Pressure (CPAP), Pressure Support Ventilation (PSV) and Pressure Control Ventilation (PCV) modes in a random order with a 10 minute washout period modes.
89145400|NCT04172493|Experimental|Diagnostic|Patients undergo standard of care white light endoscopy (WLE) and hyperspectral endoscopy (HySE) during routine colonoscopy procedure.
89145401|NCT00647205|Sham Comparator|1|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active TB with CD4 cell count > 350/mm3
89145402|NCT00647205|Sham Comparator|2|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active T with CD4 < 350/mm3)
89145403|NCT00647205|Sham Comparator|3|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 < 350/mm3)
89145404|NCT00647205|Sham Comparator|4|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 > 350/mm3)
89145405|NCT00647205|Sham Comparator|5|HIV infected patients with active TB
89145406|NCT00647205|Sham Comparator|6|HIV negative patients with active TB
89145407|NCT02768636|Experimental|Before and after omega-3 used|Before and after omega-3 used
89145408|NCT00647283|Experimental|1|Stable liver transplant recipients fulfilling inclusion criteria.
89145409|NCT02761304|Experimental|ultrasound results given to obstetrical practionnair|
89145410|NCT02761304|Other|ultrasound results shaded to obstetrical practionnair|
89145411|NCT00647361|Experimental|NAVA|
89145412|NCT04750070|Experimental|Dopamine arm|Children in the dopamine arm (Treatment plan A) will receive dopamine, 8 microgram/kg/min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
89145413|NCT04750070|Experimental|Adrenaline arm|Children in the adrenaline arm (Treatment plan B) will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
89145414|NCT04750070|Active Comparator|Blood transfusion arm|Children in the blood transfusion arm (Treatment plan C) will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
89145415|NCT04172415||Retrospective cohort|Patients that received procedural sedation in a community Emergency Department.
89145416|NCT04222400|Active Comparator|Transplantation|Frailty assessment before, after and 6 month after surgery
89145417|NCT04222400|Active Comparator|VAD Implantation|Frailty assessment before, after and 6 month after surgery
89145418|NCT04172337|No Intervention|No labeling Control|Arm 1 was the Control condition, which did not display FOP labels on any products.
89145419|NCT04172337|Experimental|HCS-only|Arm 2 (termed HCS-only) displayed the HCS on eligible products, crossed referenced via the Health Promotion Board's HCS database (https://www.hpb.gov.sg/food-beverage/healthier-choice-symbol). Out of the 4,177 products available on NUSMart, 311 (7·45%) carried the HCS. This was comprised of 150 foods and 161 beverages.
89145420|NCT04172337|Experimental|HCS+PAE|Arm 3 displayed the HCS on eligible products as in Arm 2 and the PAE label on all products (termed HCS+PAE). PAE was calculated as the minutes required to burn off the calories of a single serving for a 73 kg person jogging at 8 km per hour.
89145421|NCT02763722|Experimental|Emollient spray product|"Study design~A 3 visits are planned:~0 week (first visit) 2nd week (second visit) 4th week (third visit)~B. During each visit will be made:~The clinical examination (including an assessment of any adverse effects)~Evaluation of transepidermal water loss (TEWL) and capacitance of outer areas of the stratum corneum as an indirect assessment of skin hydration,~fill out questionnaires CDLQI (The Children's Dermatology Life Quality Index)~will assess VAS (visual analogue scale)~C. All patients will be instructed to use emollients spray the entire surface of the skin at least twice daily for four weeks."
89145422|NCT01143246|Experimental|Terlipressin|Participants receive terlipressin intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
89145423|NCT01143246|Placebo Comparator|Placebo|Participants receive matching placebo intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
89145424|NCT00647517|Experimental|ultracet|
89145425|NCT00647517|Placebo Comparator|placebo|
89145426|NCT04656392|Other|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
89145427|NCT00647595|Experimental|A|Women in this group will exercise 3x per week at a moderate/vigorous level for 45 min per session through their 36 week of pregnancy.
89145428|NCT00647595|No Intervention|B|Women in this group will continue their usual activities throughout their pregnancy.
89145429|NCT04654754|Experimental|high-flow high humidity oxygen device with tracheostomy adapter|This device provides high-flow gas to tracheostomy patients with heat and humidification. A special adapter is used to connect the tracheostomy tube and circuit.
89145430|NCT04654754|Active Comparator|large-volume nebulizer (cool aerosol) with trach collar|This device is the conventional device that is commonly utilized to provide humidification for spontaneous breathing patients with tracheostomy.
89145431|NCT04654754|Placebo Comparator|Venturi-adapter with trach collar|This device did not provide any humidification but only oxygen
89145432|NCT04654754|Experimental|large-volume nebulizer (cool aerosol) with T-piece and a filter|this device is added with a filter, in order to reduce aerosol particle concentrations in the surrounding environment
89145433|NCT04654754|Experimental|high-flow high humidity device with a scavenger or a surgical mask|this device is added with a scavenger or a surgical mask over the adapter, in order to reduce aerosol particle concentrations in the surrounding environment
89145434|NCT00647673|Experimental|1|Verapamil HCL Extended-Release Capsules 300 mg
89145435|NCT00647673|Active Comparator|2|Verelan® PM Extended-release Capsules 300 mg
89145436|NCT03100890|No Intervention|Control|Non-active comparator
89145437|NCT03100890|Active Comparator|Balance-Proprioception (Hospital)|Preoperative training (hospital)
89145438|NCT03100890|Experimental|Balance-Proprioception (Home)|Preoperative training (home)
89145439|NCT02664675||Periimplantitis|"patients formerly treated with a non surgical procedure without antibiotics with at least one functional dental implant with at least on pocket deeper than 5 mm with bleeding on probing and radiographical alveolar bone loss.~These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis."
89145440|NCT02664675||Periodontitis|patients formerly treated with a non surgical procedure without antibiotics for a generalized severe chronic periodontitis (in accord to Armitage 2009) and needing a resective surgical procedure (periodontal pockets deeper than 5 mm with bleeding on probing) These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis.
89145441|NCT02664675||Healthy patient|healthy patients needing crown lengthening allowing collection of gingival explants
89145442|NCT04062825||VIH positive patients without lymphoma|200 VIH positive patients without lymphoma
89145443|NCT04062825||VIH positive patients with lymphoma|20 VIH positive patients with lymphoma
89145444|NCT04062825||healthy volunteers|20 healthy volunteers
89145445|NCT02102022|Experimental|ADI-PEG 20 plus modified FOLFOX6|"Dose: 36 mg/m2 given weekly~Route of Administration: Intramuscular (IM)~In combination with modified FOLFOX6, every 2 weeks, intravenous (IV) / IV bolus"
89145446|NCT04223336|No Intervention|Control Group|When a participant in the control group is identified via a mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will not receive any computer alerts for physical activity and fruits/vegetable consumption. However, practitioners will still have access to the physical activity and diet data as part of the baseline assessment (Screening). Practitioners will also continue to have access to all the same resources as they currently do (treatment as usual).
89145447|NCT04223336|Experimental|Intervention Group|When a participant in the intervention group is identified via mandatory baseline questionnaire as having low levels of physical activity and/or low levels of fruits/vegetable consumption, the practitioner seeing this participant during their visit will receive computer alerts (screening), prompting to provide participant with a brief intervention (risk communication) and a self-monitoring resource for physical activity and/or fruits/vegetable consumption.
89145448|NCT04172181||UCBT-SCID-Case|SCID patients who underwent cord blood stem cell transplantation.The only curative therapy for SCID is allogeneic hematopoietic stem cell transplantation.
89145449|NCT05345028|Active Comparator|Boswellia Phytosome|
89145450|NCT05345028|Placebo Comparator|Placebo|
89145451|NCT00561925|Experimental|nevirapine XR|400 mg QD
89145452|NCT00561925|Active Comparator|nevirapine IR|200 mg BID
89145453|NCT02760992|Active Comparator|Oral Baclofen|Subject will start baclofen at a 5 mg oral dose every 8 hours. Oral baclofen will be increased incrementally and self-administered over 13 days to a maximum dose of 20 mg every 8 hours. Following IV administration, subjects will be changed back to oral baclofen at a 15 mg dose self-administered every 8 hours and tapered off of baclofen over 15 days.
89145454|NCT02760992|Experimental|IV Baclofen|Subjects will be crossed over to 16 mg intravenous baclofen infused over 120 or 150 minutes every 8 hours for 11 doses.
89145455|NCT04155060||DM group , non-DM group|Septic patients were divided into the DM group and non-DM group, based on their comorbidity
89145456|NCT04155060||high lactate group,low lactate group|high lactate group (lactate > 2 mmol/L) and low lactate group (lactate ≤ 2 mmol/L), according to the admission lactate level.
89145457|NCT02768480|Active Comparator|Primary Care|Patients will be followed by primary care team exclusively.
89145458|NCT02768480|Experimental|Phone Calls Support and Primary Care|Patients will be followed by primary care team and supported by periodic nurse phone calls.
89145459|NCT02761538|Experimental|AVIITAM Group|Utilization of the web platform Aviitam
89145460|NCT02761538|No Intervention|Control group|No utilization of web-platform Aviitam
89145461|NCT04171947|Experimental|Matuzalem|Tea extract vaginal ovule daily for 7 consecutive days
89145462|NCT04171947|Sham Comparator|Vehicle|Polyethylene glycol vaginal ovule daily for 7 consecutive days
89145463|NCT02995668|No Intervention|Control|Non-active comparator
89145464|NCT02995668|Active Comparator|Strength-Function|Active comparator
89145465|NCT02995668|Experimental|Balance-Proprioception|Experimental
89145466|NCT02696252||CGM Users|
89145467|NCT00647751|Experimental|1|Lamotrigine Tablets 25 mg
89145468|NCT00647751|Active Comparator|2|Lamictal® Tablets 25 mg
89145469|NCT05344794||CCS group|Patients with cerebral syndrome diagnosed by the Second Hospital of Shanxi Medical University
89145470|NCT05344794||Control group|Patients who have not had a cerebral syndrome in ischemic stroke
89145471|NCT02696018||Critically ill patients|Ultrasonography in critically ill patients in weaning from mechanical ventilation
89145472|NCT02536989|Experimental|1|receive high dose PPI treament with intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
89145473|NCT02536989|Active Comparator|2|receive usual dose PPI treatment with ntravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
89145474|NCT04073004|Experimental|Rapid Resolution Therapy|"RRT is a talk therapy that uses Neurolinguistic Programming Language and trance states to cause a shift in how the mind is processing incoming data.~The understanding is that the part of the mind that is causing the disturbing emotion, thought or sensation is causing them to cause the person to take an action to ensure the organisms survival. RRT therapists employ psycho-therapeutic techniques taht are designed to cause the mind to process information differently so that the disturbing content and distorted meaning shift."
89234870|NCT05888181|Experimental|Intervention group A (weekly RAID)|Access to the study app with weekly prompts to complete the patient-reported questionnaire Rheumatoid Arthritis Impact of Disease (RAID)
89234871|NCT05888181|Experimental|Intervention group B (monthly RAID)|Access to the study app with monthly prompts to complete the patient-reported questionnaire Rheumatoid Arthritis Impact of Disease (RAID)
89145475|NCT02763878|Experimental|uncut Roux-en-Y anastomosis|After distal gastrectomy, duodenal stump closure, side to side anastomosis was underwent on the remnant stomach and jejunum,which was 25cm from Treitz ligament. Then underwent side to side anastomosis between jejunum about 35cm distance from gastrojejunostomy and jejunum about 5cm from Triez ligament . close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis by using uncut Closure devices
89145476|NCT02763878|Sham Comparator|Billroth II anastomosis|After distal gastrectomy, duodenal stump closure, the investigators first underwent remnant stomach and upper jejunum side anastomosis. Then choose the jejunum about 25cm from Treitz ligament, premenstrual colon using a disposable cutting closure (or tubular stapling) in the rear wall of the stomach and jejunum anastomosis, common opening was closed with the (barbed wire) hand-stitched. After that, steps were same with the group A.
89145477|NCT00647829|Active Comparator|Arm 1|
89145478|NCT00647829|Active Comparator|Arm 2|
89145479|NCT00647829|Placebo Comparator|Arm 3|
89145480|NCT02517918|Experimental|Sirolimus combined with CP, MT and ZA|Drug : Metronomic Cyclophosphamide, Methotrexate, Sirolimus, Zoledronic acid Assessment of the maximum tolerated dose of sirolimus Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).
89145481|NCT04012489|Active Comparator|Breath Stacking|Breath stacking: patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
89145482|NCT04012489|Experimental|Air Stacking|Air stacking: the same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
89145483|NCT00647907|Experimental|A|
89145484|NCT02763800|Experimental|Group 1: BIA 3-202 50 mg/placebo|"Group 1: BIA 3-202 50 mg/placebo on Day 1; BIA 3-202 50 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 50 mg/placebo on Day 9.~50 mg BIA 3-202: 5 x 10 mg BIA 3-202 tablets"
89145485|NCT02763800|Experimental|Group 2: BIA 3-202 100 mg/placebo|"Group 2: BIA 3-202 100 mg/placebo on Day 1; BIA 3-202 100 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 100 mg/placebo on Day 9.~100 mg BIA 3-202: 1 x 100 mg BIA 3-202 tablet"
89145486|NCT02763800|Experimental|Group 3: BIA 3-202 200 mg/placebo|"Group 3: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
89145487|NCT02763800|Experimental|Group 4: BIA 3-202 200 mg/placebo|"Group 4: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo t.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
89145488|NCT00949585|Other|Dietary potassium intake: 100 mmol/day|Participants will be given one of two diets: one contains 100 mmol of potassium per day, and the other contains 40 mmol of potassium per day
89145489|NCT00949585|Other|Dietary potassium intake: 40 mmol/day|Diet containing 40 mmol/day of potassium
89145490|NCT04171791|Experimental|ABT-199 (Venetoclax)|Patients with Cutaneous T Cell Lymphoma (CTCL) will receive ABT-199 (Venetoclax).
89145491|NCT04222946|Experimental|Experimental:|bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point
89145492|NCT04003818|Experimental|Teicoplanin|teicoplanin, administered orally 100-200 mg, twice a day
89145493|NCT00949663|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
89145494|NCT00949663|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
89145495|NCT00949663|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
89145496|NCT02664519|Experimental|Exercise training followed by no exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
89145497|NCT02664519|Experimental|No exercise training followed by exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
89145498|NCT02664519|No Intervention|Normal Control|Control subjects without CKD will undergo baseline assessment as above.
89145499|NCT02763332|Experimental|Upper trunk group (UTG)|In the UTG, the bandage was applied over the superior fibbers of the trapezious and levator scapulae muscle using a strip in a 'Y' shape. The individuals were asked to remain in an upright sitting position and the base of the strip was attached to the skin beyond the acromion without any tension. Later, we placed the two straps of the bandage with a range of tension from 15 to 25%. The main goal of this shape is achieve muscular relaxation of the trapezius, scapula levator and supraspinatus.
89145500|NCT02763332|Active Comparator|Global trunk group (GTG)|In the GTG the bandage was applied parallel to the paravertebral muscles in a 'C' shape. The individuals were sit in the same position with the head in the neutral position. The strip was pasted with approximately 25% of tension all over the paravertebral musculature. The main goal was procuring a global mechanical correction of the superior part of the trunk.
88803708|NCT04081792|Experimental|2. Trial (osteomyelitis) - short antibiotic arm|The intervention group consists of 3 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.
89145501|NCT02033616|Experimental|AVOVA-1|Autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells. AVOVA-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
89145502|NCT02033616|Placebo Comparator|MC|Autologous monocytes will serve as the control arm. MC is admixed with GM-CSF as an adjuvant, prior to injection.
89145503|NCT00647985|Experimental|1|Fexofenadine Tablets 180 mg
89145504|NCT00647985|Active Comparator|2|Allegra® Tablets 180 mg
89145505|NCT02768402|Experimental|Treatment Arm|All eligible patients will be in the treatment arm for the 'Caisson TMVR System' (transcatheter mitral valve replacement) procedure. No control or comparator in this study.
89145506|NCT01844232|Experimental|Arbaclofen Extended Release (ER) Tablets|Arbaclofen Extended Release Tablets, 20 mg/day, 30 mg/day or 40 mg/day
89145507|NCT02664285|Other|closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section.
89145508|NCT02664285|Other|No closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will not sutured after cesarean section.
89145509|NCT02763410||control group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery, with no renal failure at the 48th hour after surgery, based on the RIFLE classification, and regardless of the transfusion received after the H6 assessment.
89145510|NCT02763410||Renal failure group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery and who developed renal failure before H48 with no new transfusion prior to diagnosis of kidney failure.
89145511|NCT02664051|Placebo Comparator|placebo|mannitol
89145512|NCT02664051|Active Comparator|disodium cromoglycate|disodium cromoglycate
89145513|NCT05344638|Experimental|AGS (Experimental)|AGS + Placebo of AGU
89145514|NCT05344638|Active Comparator|AGU (Active Comparator)|Placebo of AGS + AGU
89145515|NCT04223180||Stroke patients|Inpatients and outpatients admitted to the investigators' rehabilitation facility with an upper limb impairment due to neurologic or orthopedic disorders.
89145516|NCT00648063|Experimental|1|Letrozole Tablets 2.5 mg
89145517|NCT00648063|Active Comparator|2|Femara® Tablets 2.5 mg
89145518|NCT01129362||Group 1|Participants that only received Pentacel® vaccine.
89145519|NCT01129362||Group 2|Participants that only received a single brand of pertussis vaccine other than Pentacel® vaccine.
89145520|NCT01129362||Group 3|Participants that received more than one brand of Pertussis vaccine or one or more doses of an unknown brand.
89145521|NCT00953563|No Intervention|compression therapy|
89145522|NCT00953563|Active Comparator|Biologic with compression therapy|
89145523|NCT00648141|Experimental|A|
89145524|NCT00648141|Experimental|B|
89145525|NCT00648141|Active Comparator|C|
89145526|NCT03865602|Experimental|Sepsis Transition And Recovery (STAR)|Virtual sepsis navigation delivered across the peri-hospital discharge interval
89145527|NCT03865602|Active Comparator|Usual Care|Patients and their providers will have no access to the STAR program. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
89145528|NCT03743155|Experimental|treatment with mesenchymal stem cells|xerostomy using mesenchymal stem cells adult autologous bone marrow
89145529|NCT00949897|Active Comparator|Biofoam|
89145530|NCT00949897|Active Comparator|Iliac Crest Allograft with locked plate|
89145531|NCT02763488|Active Comparator|Standard physical therapy|These individuals will conduct physical therapy for 12 sessions as per the institutional standard physical therapy protocol
89145532|NCT02763488|Experimental|Blood flow restriction|These individuals will conduct physical therapy for 12 sessions with the addition of blood flow restriction interventions to their standard physical therapy
89145533|NCT02692326|Experimental|Intervention: Cyclic parenteral nutrition Cohort|All newborn who were included in the study to receive cyclic parenteral nutrition (within 24 hours). The parenteral nutrition was stopped for one hour the first day until 4 hours in preterm infants and 6 hours in term neonates.
89145534|NCT02692326|No Intervention|Control: Continuous parenteral nutrition|All newborn who were included in the study to receive continuous parenteral nutrition (24 hours). The parenteral nutrition was given by a central line in 24 hours with a basal flow
89145535|NCT02664129|Experimental|Experimental group with video|30 patients will watch the video of them in acute decompensation phase
89145536|NCT02664129|Sham Comparator|Control group without video|30 patients will not watch the video of them in acute decompensation phase, they pass a standard interview with psychometric scales
89145537|NCT00953641|Active Comparator|Pre-Menopausal 1|Pre-Menopausal group, receiving Misoprostol
89145538|NCT00953641|Placebo Comparator|Pre-Menopausal 2|Patients will insert a placebo vaginal suppository 12h or more prior to the endometrial biopsy
89145539|NCT00953641|Active Comparator|Post-Menopausal 1|Post-Menopausal patients will insert a Misoprostol vaginal suppository 12h or more prior to the endometrial biopsy
89145540|NCT00953641|Placebo Comparator|Post-Menopausal 2|Placebo vaginal suppository prior to the endometrial biopsy
89145541|NCT02763098|Experimental|Remi 0.1|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [(0.1), 0.2, 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
89145542|NCT02763098|Experimental|Remi 0.2|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, (0.2), 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-RoiFrance) for two minutes.
89145543|NCT02763098|Experimental|Remi 0.3|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, 0.2, (0.3) µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
89145544|NCT00648219|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
89145545|NCT00648219|Active Comparator|2|Benicar® Tablets 40 mg
89145546|NCT02763020|Placebo Comparator|Food bar without fruit|snack bar without fruit
88803709|NCT04081792|Active Comparator|2. Trial (osteomyelitis) - long antibiotic arm|The control group consists of 6 weeks of post-debridement antibiotic therapy for non-amputated diabetic foot osteomyelitis.
88803710|NCT04053088||SAVR patients|patients undergoing surgical aortic valve replacement (SAVR) by usage of the INSPIRIS RESILIA Aortic valve™
88803711|NCT04562038|Experimental|YC-PEM e-PRO|Participants are administered an electronic patient-reported outcome measure to obtain information about parent priorities, and they obtain a summary report of their responses to share with their early intervention team for discussion during the annual IFSP meeting.
88803712|NCT04562038|No Intervention|Family Assessment|Participants are scheduled to complete a semi-structured family interview to obtain information about parent priorities, for use during the annual IFSP meeting
88803713|NCT04038970|Experimental|KN019 5mg/kg|Intravenous (IV) solution, 5 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
89145547|NCT02763020|Experimental|Food bar with cranberry extract (0.5%)|Snack bar with cranberry extract (0.5% total weight)
89145548|NCT02763020|Experimental|Food bar with cranberry extract (1.0%)|Snack bar with cranberry extract (1.0% total weight)
88803714|NCT04038970|Experimental|KN019 10mg/kg|Intravenous (IV) solution, 10 mg/kg, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
88803715|NCT04038970|Placebo Comparator|Placebo|Intravenous (IV) solution, Day 1, Day 15, Day 29; every 28 days thereafter, 12 months
88803716|NCT05426538||Interview group|A selection of patients will be interviewed, mapping the craving for the next biologic administration. These interviews will be used to develop a questionnaire to quantify the craving for the next administration in the total population.
88803717|NCT05426538||Questionnaire group|The remaining patients will be asked to fill in a questionnaire, based on the interviews from Group 1.
88803718|NCT05426304|Experimental|Agomelatine|The Agomelatine group will be received agomelatine (25 mg/day) for 180 days.
88803719|NCT05426304|Placebo Comparator|Placebo|The Placebo group will be received placebo (25 mg/day) for 180 days.
88803720|NCT02991144|Experimental|Cohort 1: DTX301 2.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) 2.0 × 10^12 GC/kg will be administered as a single peripheral IV infusion. A reactive corticosteroid taper regimen will be administered to control transient vector-induced hepatic effects. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
88803721|NCT02991144|Experimental|Cohort 2: DTX301 6.0 × 10^12 GC/kg|DTX301 (scAAV8OTC) 6.0 × 10^12 GC/kg will be administered as a single peripheral IV infusion. A reactive corticosteroid taper regimen will be administered to control transient vector-induced hepatic effects. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
88803722|NCT02991144|Experimental|Cohort 3: DTX301 1.0 × 10^13 GC/kg|DTX301 (scAAV8OTC) 1.0 × 10^13 GC/kg will be administered as a single peripheral IV infusion. A reactive corticosteroid taper regimen will be administered to control transient vector-induced hepatic effects. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
88803723|NCT02991144|Experimental|Cohort 4: DTX301 1.0x10^13 GC/kg + Prophylactic Corticosteroids|A prophylactic corticosteroid taper regimen (oral prednisone [or prednisolone], 60 mg tapered over 9 weeks) will be administered before dosing with DTX301 (scAAV8OTC) to prevent or minimize transient vector-induced hepatic effects. DTX301 (scAAV8OTC) 1.0x10^13 GC/kg administered as a single peripheral IV infusion. Sodium acetate will be used as a tracer to measure the rate of ureagenesis.
88803724|NCT05426226|Active Comparator|laser group|"Laser group use specific wavelength to light the sleep acupoints during.~If the laser group take light acupuncture in the first month, and then become the sham group in the next month, vice versa."
88803725|NCT05426226|Sham Comparator|sham group|"sham group use the same divce and acupointsas the laser group, but the light is just a regular light.~If the laser group take light acupuncture in the first month, and then become the sham group in the next month, vice versa."
88803726|NCT03468166||Chronic stroke|The data for motor function and gait pattern analysis was obtained.
88803727|NCT04499092|Active Comparator|Multifunction treatment|Patients that will receive a simulataneous multifunction treatment
88803728|NCT04499092|Experimental|Sequential treatment|Patients will receive a sequential function by function treatment
88803729|NCT04781660|Experimental|Implantable Alginate Hydrogel|All patients will be treated with Implantable Alginate Hydrogel
88803730|NCT02973750||Pre-Surgery Chemotherapy Patients|All participants. Patients receiving chemotherapy with carboplatin and paclitaxel before their debulking surgery, who may have more chemotherapy after surgery. Sampling procedures will include: Baseline Biopsy; Tissue Collection; Blood Draws.
88803731|NCT02532972|Experimental|Cochlear Implant surgery|All subjects will be part of a single arm involving placement of the Med-El MAESTRO Cochlear Implant with Flex 28 electrode array
88803732|NCT05450406|Active Comparator|Intervention group|Participants in the intervention group will receive 12-week follow-up from the Healthy Life Center
88803733|NCT05450406|No Intervention|Control group|Participants in the intervention group will not receive follow-up from the Healthy Life Center
88803734|NCT03919396|Experimental|OrthoK (orthokeratology)|Group wearing Breath-O corrected orthokeratology lenses for 2 years
89145549|NCT02763020|Experimental|Food bar w/ dried black raspberry (10%)|Snack bar with freeze-dried black raspberry(10% total weight)
89145550|NCT02763020|Experimental|Food bar w/ dried black raspberry (20%)|Snack bar with freeze-dried black raspberry (20% total weight)
89145551|NCT02760758|Experimental|Cohort 1A HV|CDI-31244 20 mg active or placebo single dose (SD)
89145552|NCT02760758|Experimental|Cohort 2A HV|CDI-31244 50 mg active or placebo SD
89145553|NCT02760758|Experimental|Cohort 3A HV|CDI-31244 100 mg active or placebo SD
89145554|NCT02760758|Experimental|Cohort 4A HV|CDI-31244 200 mg active or placebo SD; food effect
89145555|NCT02760758|Experimental|Cohort 5A HV|CDI-31244 400 mg active or placebo SD
89145556|NCT02760758|Experimental|Cohort 6A HV|CDI-31244 200 mg active or placebo multiple dose (MD)
89145557|NCT02760758|Experimental|Cohort 7A HV|CDI-31244 200 mg active or placebo MD
88803735|NCT03919396|No Intervention|SV Lenses (Single vision)|Group wearing spectacle with single vision lenses for 2 years
88803736|NCT00382954|Experimental|Phase 1 escalation|
88803737|NCT03879070|Experimental|Intervention group|
88803738|NCT03879070|No Intervention|Control group|
88803739|NCT03268876||Epithelial ovarial cancer|Patients primary treated with primary surgery for advanced epithelial ovarian cancer (> stage IIa) at the participating institutions will be asked to participate.
88803740|NCT03234556|Active Comparator|Arm I (SR-Bx)|Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.
88803741|NCT03234556|Experimental|Arm II (MRI, MRUS-Bx, SR-Bx)|"Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.~If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.~If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx."
88803742|NCT04420078||CA BrS|Symptomatic BrS patients who underwent catheter ablation of the BrS/VF substrate
89145558|NCT02760758|Experimental|Cohort 8A HV|CDI-31244 400 mg active or placebo MD
89145559|NCT02760758|Experimental|Cohort 1B HCV genotype (GT) 1|CDI-31244 400 mg active or placebo MD
89145560|NCT02760758|Experimental|Cohort 2B HCV GT 1|CDI-31244 600 mg active or placebo MD
89145561|NCT02760758|Experimental|Cohort 3B HCV GT 1|CDI-31244 800 mg active or placebo MD
89145562|NCT00614718||1|Total number of patients receiving an ICD between 1993 and 2004 and not having re interventions due to malfunctioning leads.
89145563|NCT00614718||2|Patients with ICD lead failure receiving a new ICD lead
89145564|NCT00614718||3|Patients with ICD lead failure but intact shock-coil of the ICD lead receiving only an additional pace/sense lead.
89145565|NCT00648297|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
89145566|NCT00648297|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
89145567|NCT02760680|Placebo Comparator|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
89145568|NCT02760680|Active Comparator|Diagnostic Device (WatchPAT 200 (TM))|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
89145569|NCT00549445||Azithromycin-treated|Participants in the COPD Network Macrolide Study who received azithromycin for 1 year.
89145570|NCT00549445||Placebo-treated|Participants in the COPD Network Macrolide Study who received placebo for 1 year.
89145571|NCT05344014|Experimental|Photobiomodulation group|In the experimental group, before local infiltration anesthesia was administered, PBMT (a diode laser: 940 nm; continuous mode; 0.5W; 78 J/cm2) was applied perpendicular to the root surface at buccal and palatal area for 60 sec each).
89145572|NCT05344014|Placebo Comparator|Placebo Group|In the control group, the laser probe was directed to the mucosa for (buccal and palatal area), but not activated.
89145573|NCT02760914||Coronary heart disease|Patients with coronary heart disease undergoing planned coronary artery bypass surgery
89145574|NCT02660151|Experimental|Treatment A-B|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
89145575|NCT02660151|Experimental|Treatment B-A|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
89145576|NCT00956449|Experimental|1|
89145577|NCT02768012|Active Comparator|mindfulness-based cognitive therapy|The practice of mindfulness will be followed plus the basics of cognitive therapy given in small group format.
89145578|NCT02768012|No Intervention|waitlist|Women diagnosed with AISD randomised to wait list will receive no active treatment during the trial period.
89145579|NCT00649155|Experimental|1|Ciprofloxacin Extended-Release Tablets 500 mg
89145580|NCT00649155|Active Comparator|2|Cipro® XR Tablets 500 mg
89145581|NCT00956527|Experimental|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
89145582|NCT02758340|Experimental|M=misoprostol|Patients who would receive Only oral misoprostol{(50 micrograms) tab cytotec ¼ tablets (Searle)}. All patients in this group will be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes). If labor is not established within 4 hours of the administration of the fourth dose, induction will be considered to be failed
89145583|NCT02758340|Experimental|M+F=MISOPROSTOL+FOLEY'S BALLOON CATHETER|All patients in this group will be explained the technique of foley's catheter ballooning and informed consent will be taken. The cervix will be visualized with the help of Cusco's speculum. The balloon will be inflated with about 30 cc of sterile water. The catheter will be pulled down to bring the balloon into the cervical canal and will be tapped around the thigh. Patients will also be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes).
89145584|NCT00614952|Experimental|PR|
89145585|NCT00614952|Active Comparator|PSG|
89145586|NCT00956605|Experimental|EEG biofeedback intervention|
89145587|NCT00956605|Active Comparator|Non EEG biofeedback computerized attention training|
89145588|NCT00956605|No Intervention|waitlist control|
89145589|NCT02692092||Total Arthroplasty Patients|Any patient who has received a total hip or total knee arthroplasty at a healtheast acute care hospital.
89145590|NCT02768168|Experimental|Group D|40 patients receive dezocine 0.1 mg/Kg
89145591|NCT02768168|Placebo Comparator|Group C|40 patients receive matching placebo （normal saline）
89145592|NCT02660073|Experimental|NMES+FES group|NMES+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.
89145593|NCT02660073|Experimental|Control+FES group|Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
89145594|NCT00956683|Experimental|Ultrasound|Ultrasound guided infraclavicular block
89145595|NCT00956683|Active Comparator|Dual Endpoint Nerve Stimulator|Nerve stimulator guided dual endpoint infraclavicular block
89145596|NCT02758418|Experimental|Online Computerized Program group.|"Intervention group that uses TAO program."
89145597|NCT02758418|No Intervention|Waiting list control group.|Participants of this group are able to access the treatment program after 7 weeks of waiting period. After this waiting period of 7 weeks, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (Online Computerized Program group or Bibliotherapy group).
89145598|NCT00956917|Active Comparator|Akern EFG|
89145599|NCT00956917|Active Comparator|RJL device|
89145600|NCT02659683|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
89145601|NCT02659683|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
89145602|NCT05343780|Placebo Comparator|Placebo|Placebo (Rice bran) in 2 capsules size 1, administered PO TID on empty stomach with plenty of water.
89145603|NCT05343780|Experimental|Heptex-low dose|Low dose The contents of one capsule of Heptex is equally distributed and inserted into 2 capsules size 1, administered PO TID on empty stomach with plenty of water.
89145604|NCT05343780|Experimental|Heptex-high dose|High dose The contents of two capsule of Heptex is equally distributed and inserted into 2 capsules size 1, administered PO TID on empty stomach with plenty of water.
89145605|NCT02758262|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the duration of the experimental session.
89145606|NCT02758262|Placebo Comparator|Noninvasive brain stimulation: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of the experimental session.
89145607|NCT00957073|Experimental|Device|Rheos® system
89145608|NCT00957073|No Intervention|Medical Management|Medical Management Therapy
89145609|NCT02659839||Cancer patients admitted to the ICU|Patients with cancer admitted to the ICU. No intervention will be administered.
89145610|NCT02659761|Experimental|dolutegravir/abacavir/lamivudine|All study subjects will receive triumeq (600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine) single tablet that will be taken orally, once daily, during 96 weeks
89145611|NCT02768324||sepsis with diarrhea|
89145612|NCT02768324||sepsis without diarrhea|
89145613|NCT05343546|Active Comparator|Group 1: Early insertion|Early insertion will refer to Group 1 where a post abortion intrauterine device will be placed within seven days of giving medical management of first trimester incomplete abortion
89145614|NCT05343546|Active Comparator|Group 2: Standard insertion|Standard insertion will refer to Group 2 where a post abortion intrauterine device will be inserted in the recommended 2-4 weeks after medical management of first trimester incomplete abortion
89145615|NCT00953953||Acutely Decompensated Systolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
89145616|NCT00953953||Chronic HF Patients on Dialysis|Patients who have heart failure (defined as NYHA class II, III, or IV) and are on dialysis.
89145617|NCT00953953||Ambulary Chronic HF|Patients with diagnosis of chronic heart failure (NYHA class II and III) who are on optimal medical therapy.
89145618|NCT00953953||Acutely Decompensated Diastolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
89145619|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer|Pit and fissure sealing using conventional glass-ionomer cement
89145620|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement|Pit and fissure sealing using conventional glass-ionomer cement
89145621|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer -|Restoration using conventional glass-ionomer cement
89145622|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement -|Restoration using conventional glass-ionomer cement
88803743|NCT01246063|Experimental|Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)|Dose Level 0: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (27 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
89145623|NCT02758106|Active Comparator|HFCW oscillation|"HFCWO was performed using a Vest Airway Clearance System Model 105 (Hill-Rom, St. Paul, Minnesota). HFCWO was applied to each subject at a frequency of 10-12 Hz and a pulse pressure setting of 1-2 selected for 15 minutes. The patients receiving HFCWO were placed in a semi-upright sitting position. Following HFCWO, suction was performed immediately via an endotracheal tube.~Changes to the initial ventilator settings during HFCWO were recorded before and at 5, 10 and 15 minutes. The variables included peak airway pressure, positive-end expiratory pressure, respiratory rate, fraction of inspired oxygen, inspiratory time, and sensitivity settings. Following HFCWO, suction was performed immediately via an endotracheal tube."
89145624|NCT02758106|Placebo Comparator|placebo intervention|the patients undergoing CCPT received cup-hand percussion with the hands positioned 3 inches from the chest, striking the chest with a waving movement while they were placed in right and left decubitus positions for 5-10 minutes each. Following CCPT, suction was performed immediately via an endotracheal tube.
89145625|NCT00954031||case|hospitalized patients, adult or child, including the diagnosis of APA was made, after consulting their physician.
89145626|NCT00954031||The control group|"Two patients witnesses will be matched to each case:~Chronological criterion: consultation for a sore throat 10 days (± 3 days) before the date of hospitalization of cases, between 13 and J-J-7.~Age criteria: year of birth ± 5 years Geographical criteria: living in the same department, failing in an adjacent Department Social criteria: beneficiary or otherwise of the CMU, to avoid a selection bias leading social most frequently at the onset of the APA"
89145627|NCT02659371|Experimental|Low energy diet|Low energy diet (800 kcal/d) for eight weeks, following 4 weeks on reintroduction supplying 1200 kcal/d.
89145628|NCT03736746|Experimental|Motivational Interviewing|"Will entail two-to-four Motivational Interviewing sessions per participant~Will include a battery of questionnaires~Investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs).~The investigator will elicit questions and goals that participants will be encouraged to discuss with their palliative care providers"
89290617|NCT05415748|Experimental|Tamsulosin 0.4 mg or 0.8 mg, Then Placebo|Participants first received Tamsulosin 0.4 mg or 0.8 mg taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks. After a washout period of 1 week, the participants then received Placebo tablet taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks.
89145629|NCT02758028|Other|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach. Counsellors will emphasizes the identification, use, and modification of personally relevant coping strategies. Advice will be provided on overcoming expected difficulty, withdrawal symptoms and relapse prevention during quitting.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
89145630|NCT00954265|Active Comparator|Urinary-HCG group|These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF
89145631|NCT00954265|Experimental|Recombinant HCG group|These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
89145632|NCT02768246|Active Comparator|Begin with BVGA|The volunteers will be asked to breathe 5 minutes of room air through the BVGA, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the BVGA. Then the same volunteers will be asked to repeat the protocol with the face mask.
89145633|NCT02768246|Active Comparator|Begin with Face-mask|The volunteers will be asked to breathe 5 minutes of room air through the face mask, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the face mask. Then the same volunteers will be asked to repeat the protocol with the BVGA.
89145634|NCT00954343|Experimental|Group I|
89145635|NCT00954343|Experimental|Group II|
89145636|NCT00954343|Experimental|Group III|
89145637|NCT00954343|Experimental|Group IV|
89145638|NCT00954343|No Intervention|Group V|
89145639|NCT00954499|Active Comparator|Standard care|
89145640|NCT00954499|Experimental|Tactile stimulation|
89145641|NCT04500236|Active Comparator|General Anesthesia (GA)|Patients undergoing thyroid or breast cancer surgery under general anesthesia
89145642|NCT04500236|Placebo Comparator|Hypno-analgesia (Hyp)|Patients undergoing thyroid or breast cancer surgery under Hypno-analgesia; i.e.hypnosis combined with the use of analgesics.
89145643|NCT04224506||Myasthenia Gravis|Patients who have been diagnosed with Myasthenia Gravis.
89145644|NCT02536521||Hemodynamically stable|
89145645|NCT02536521||Hemodynamically unstable|Hemodynamically unstable patients are defined as those with a 20% decrease in systolic blood pressure according to the change of intraabdominal pressure.
89145646|NCT02760446|Other|CAM-ICU.fr|CAM-ICU and ICDSC evaluation proceed by two investigators and a Neuropsychologist (Speech & language therapist specialized in neuropsychology)
89145647|NCT04011319|No Intervention|convention culture|Each droplet separate culturing an individual embryo.
89145648|NCT04011319|Experimental|group culture|Embryos were cultured in the same droplet.
89145649|NCT02658825|Experimental|Panel 1: Dose level 1|Participants will receive either treatment A (JNJ-63623872, 2400 milligram (mg) tablet orally once on Day 1) or treatment B [(placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1].
89145650|NCT02658825|Experimental|Panel 1: Dose level 2|Participants will receive either treatment C (JNJ-63623872, 3000 mg tablet orally once on Day 1) or treatment D [placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1].
89145651|NCT02658825|Experimental|Panel 2: Treatment EFG|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
89145652|NCT02658825|Experimental|Panel 2: Treatment FGE|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
89145653|NCT02658825|Experimental|Panel 2: Treatment GEF|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
89145654|NCT02658825|Experimental|Panel 2: Treatment GFE|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
89145655|NCT02658825|Experimental|Panel 2: Treatment FEG|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
89145656|NCT02658825|Experimental|Panel 2: Treatment EGF|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
89145657|NCT02760524|Experimental|Intervention|Subjects will receive NET intervention treatment immediately
89145658|NCT02760524|Active Comparator|Control|Subjects will receive NET intervention treatment and serve as a wait-list control
89145659|NCT00954655||Group 1|Tumor samples are used for polymorphism and mutation analysis.
89145660|NCT05343234|Experimental|patients receiving the placebo medication|tree different placebo drugs with tree different names and symbols one will be given twice daily one once in the morning one once before bedtime
89145661|NCT02760212|Experimental|Group 1 - Radial Shockwave Therapy Group|Participants in Group 1 will receive RSWT to the most painful spot within each of the 3 most painful regions as described by the participant. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with treatment to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot.
89145662|NCT02760212|Placebo Comparator|Group 2 - Placebo Group|Participants in Group 2 will receive a placebo treatment with a soft rubber cap applied to the applicator, leaving air between the transmitter and the cap and the participant's skin so that no shockwave will be generated nor applied to the participant's skin. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with placebo treatment to the painful areas will be undertaken with 2000 placebo shocks (15 Hz) producing an audible sound but no therapeutic dosage to the most painful spot. Upon completion of the placebo treatment, participant's will be offered the experimental treatment but this data will not be used for comparison and analysis.
89145663|NCT03700242|Experimental|Group 1|1 IM dose of human diploid cell vaccine (HDCV) on D0 and D7 (short HDCV IM PrEP regimen), followed by 1 IM dose of HDCV on Year (Y)1 and Y1 + 3 days
89145664|NCT03700242|Active Comparator|Group 2|1 IM dose of HDCV on D0, D7, and D21 (reference), followed by 1 IM dose of HDCV on Y1 and Y1 + 3 days
89145665|NCT03700242|Experimental|Group 3|2 intradermal (ID) doses of HDCV on D0 and D7 (short HDCV ID PrEP regimen), followed by 1 ID dose of HDCV on Y1 and Y1 + 3 days
89145666|NCT03700242|Experimental|Group 4|1 IM dose of purified Vero cell rabies vaccine (PVRV) on D0 and D7 (short PVRV IM PrEP regimen), followed by 1 IM dose of PVRV on Y1 and Y1 + 3 days
89145667|NCT03700242|Experimental|Group 5|2 ID doses of PVRV on D0 and D7 (short PVRV ID PrEP regimen), followed by 1 ID dose of PVRV on Y1 and Y1 + 3 days
89145668|NCT04011085||Group1|Patients currently undergoing treatment for early breast cancer (either targeted HER2 therapy and chemotherapy OR targeted HER therapy alone)
89145669|NCT04011085||Group2|Patients with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving locoregional treatment, chemotherapy or targeted HER2 therapy; patients may still be receiving hormone therapy)
89145670|NCT04011085||Group3|Patients receiving treatment for metastatic breast cancer
89145671|NCT00649233|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
89145672|NCT00649233|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
89145673|NCT02757716|Other|Sleeve Gastrectomy|Obese patients who undergo sleeve gastrectomy fill in questionnaire
89145674|NCT02757716|Other|Roux-en-Y-Gastric Bypass|Obese patients who undergo roux-en-y-gastric bypass fill in questionnaire
89145675|NCT02757716|Other|One anastomosis-Gastric Bypass|Obese patients who undergo one anastomosis gastric bypass fill in questionnaire
89145676|NCT00954811|Active Comparator|HCG for ovulation triggering and luteal progesterone|conventional triggering with HCG and conventional luteal support with progesterone
89145677|NCT00954811|Experimental|Agonist triggering and rec-LH luteal support plus progesterone|new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
89145678|NCT02658903|Experimental|Study arm with Oxys-Cathter|The study group is treated with a modified urinary catheter, which delivers electromagnetic therapy to prevent and treat bacterial colonization during the study period. The intervention is the insertion of the study urinary catheter (foley) into the bladder.
89145679|NCT02658903|Other|Control-arm with commercial catheter|The control group is treated with a commercial urinary catheter. The intervention is the insertion of the control urinary catheter (foley) into the bladder,
89145680|NCT02757638|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
89145681|NCT02757638|Experimental|Obese subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one pre-surgery, one post-surgery): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
89145682|NCT00954889|Experimental|Tamsulosin|
89145683|NCT00954889|Placebo Comparator|placebo|
89145684|NCT05279755|Experimental|Prosetin|Part A: single-ascending dose; Part B: multiple doses (7 days)
89145685|NCT05279755|Placebo Comparator|Placebo|Part A: single-ascending dose; Part B: multiple doses (7 days)
89145686|NCT02757560|Experimental|SFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour saturated fatty acids enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the SFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (SFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
89145687|NCT02757560|Experimental|MUFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour monounsaturated fatty acids (MUFA) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the MUFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (MUFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
89145688|NCT02757560|Experimental|CARB versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
89145689|NCT00954967|No Intervention|Usual care|The subjects in the control group will receive the usual care for smoking cessation in diabetic smokers.
89145690|NCT00954967|Experimental|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
89145691|NCT02692248|Experimental|Ibrutinib -R-GEMOX-Dexa|"Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:~Induction phase:~Rituximab 375 mg/m2 IV day 1~Gemcitabine 1000 mg/msq IV on day 1 or 2 (at investigator discretion).~Oxaliplatine 100 mg/msq on day 1 or 2 (after Gemcitabine administration);~Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.~Ibrutinib 560 mg daily for 14 days.~Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.~Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity."
89145692|NCT02851290|Experimental|Caudal block|Local anesthetic will be administered into the caudal space
89145693|NCT02851290|Active Comparator|Dorsal penile nerve block|Local anesthetic will be administered around the dorsal penile nerve
89145694|NCT02757404|Experimental|Ultrasonography guidance|Ultrasonography guidance injection of Meditoxin®.
89145695|NCT02757404|Experimental|Electrical stimulation guidance|Electrical stimulation guidance injection of Meditoxin®.
89145696|NCT02757404|Experimental|Manual needle placement|Manual needle placement injection of Meditoxin®.
89145697|NCT02686554||AD patients|
89145698|NCT02686554||AD patients immunized|
89145699|NCT00601107|Experimental|Doxercalciferol 2.5 mcg/day|Doxercalciferol 2.5 microgram (mcg) capsule orally once daily up to Week 24.
89145700|NCT00601107|Experimental|Doxercalciferol 5 mcg/day|Doxercalciferol 5 mcg capsules orally once daily up to Week 24.
89145701|NCT00601107|Experimental|Doxercalciferol 7.5 mcg/day|Doxercalciferol 7.5 mcg capsules orally once daily up to Week 24.
89145702|NCT00601107|Placebo Comparator|Placebo|Placebo matching to doxercalciferol capsules orally once daily up to Week 24.
89145703|NCT00955123||Active inflammatory bowel disease|Patients with moderate to severe active inflammatory bowel disease (ulcerative colitis and Crohn's disease)
89145704|NCT02699424|Other|Radiotherapy|
89145705|NCT02696486|Experimental|Exercise Training|
89145706|NCT02704728|Experimental|Thetanix|In Part A, 8 subjects will receive a single dose and in Part B, 8 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules
89145707|NCT02704728|Placebo Comparator|Placebo|In Part A, 2 subjects will receive a single dose and in Part B, 2 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules.
89145708|NCT04169685||with dexmedetomidine|Drugs provided moderate sedation during procedure including dexmedetomidine
89145709|NCT04169685||without dexmedetomidine|Drugs provided moderate sedation during procedure without dexmedetomidine
89145710|NCT00957385|Active Comparator|A|Arm A will receive Revlimid.
89145711|NCT00957385|No Intervention|B|Arm B will not receive Revlimid but an observational arm
89145712|NCT02622438|Other|Course and follow up of patients affected by FSHD|
89145713|NCT04011397|Experimental|Intervention group|Exercise intervention (reduced-exertion, high-intensity interval training) alongside normal treatment. [low recruitment prohibited control arm]
89145714|NCT02462538|Experimental|Brentuximab vedotin and Imatinib|Brentuximab vedotin (every 3 weeks i.v., 1.8 mg/kg) and imatinib (200mg daily orally, escalated from 100mg daily) for up to 48 weeks
89145715|NCT02752646|Active Comparator|nepafenac 0.3%|Patients in this arm will receive nepafenac 0.3% eye drops once daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
89145716|NCT02752646|Active Comparator|ketorolac 0.5%|Patients in this arm will receive ketorolac 0.5% eye drops four times daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
89145717|NCT04169919|Active Comparator|Modified method|Povidone Iodine
89145718|NCT04169919|Active Comparator|Ordinary method|normal saline
89145719|NCT02704338|Experimental|Regulatory T cells|CD4(cluster of differentiation)+CD25+CD127- T cells isolated from peripheral blood mononuclear cells were be expanded with GMP(Good Manufacturing Practice) anti-CD3/CD28 coated beads in the presence of IL-2 and all-trans retinoid acid.
89145720|NCT02757482|Experimental|intervention|Patient training
89145721|NCT02757482|No Intervention|control|no patient training
89145722|NCT04169997|Experimental|IMP4297|The starting dose is 100mg QD
89145723|NCT04169997|Placebo Comparator|Placebos|The starting dose is 100mg QD
89145724|NCT02704260|Experimental|GENETIC ANALISYS|GENETIC ANALYSIS AND RESEARCH OF GENETIC BLOOD SAMPLE
89145725|NCT02757248|Experimental|Cohort 1|Volasertib 75mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
89145726|NCT02757248|Experimental|Cohort 2|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
89145727|NCT02757248|Experimental|Cohort 3|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
89145728|NCT02757248|Experimental|Cohort 4|Volasertib 150mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
89145729|NCT02757248|Experimental|Cohort -1|Volasertib 50mg/m2 on days 1 and 8 Romidepsin 10mg/m2 on days 1, 8 and 15
89145730|NCT00649311|Experimental|Eplerenone group|
89145731|NCT00649311|Active Comparator|Losartan group|
89145732|NCT04215666||Mild ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
89145733|NCT04215666||Moderate ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
89145734|NCT04215666||Severe ARDS|Oxygenation standards were calculated based on the Berlin diagnostic high element correction formula combined with local atmospheric pressure
89145735|NCT04061499||Hip OA|Individuals with diagnosed hip osteoarthritis
89145736|NCT04061499||Control|Individuals without diagnosed hip osteoarthritis
89145737|NCT02704494|Experimental|Resveratrol|Resveratrol + Losartan
89145738|NCT02704494|Placebo Comparator|Placebo|Placebo + Losartan
89145739|NCT04221620|Experimental|EEG neurofeedback|All participants will receive 20 sessions of traditional occupational therapy services while receiving EEG neurofeedback.
89145740|NCT02658747||Cohort Docetaxel|Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)
89145741|NCT04033341|Experimental|LY3214996 + [14C]-LY3214996|A single dose of LY3214996 and [14C]-LY3214996 administered orally.
89145742|NCT00615888|Active Comparator|A|Traditional management including preoperative bowel washout, patient controlled analgesia (PCA), delayed start of enteral feeding
89145743|NCT00615888|Experimental|B|Fast track management including no bowel washout, patient controlled epidural anesthesia, early enteral feeding
89145744|NCT04221698|Experimental|Gait Retraining Group|Athletes from the Triathlon Plan in High Performance of the Valencian Community in Spain performing individual gait retraining sessions
89145745|NCT00649467|Experimental|1|Topiramate Sprinkle Capsules 25 mg
89145746|NCT00649467|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
89145747|NCT02757170|Experimental|I|Thromboelastography Acute on chronic liver failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
89145748|NCT02757170|Active Comparator|Group II|Thromboelastography Healthy Controls: Healthy persons' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation.
89145749|NCT02757170|Experimental|Group III|Thromboelastography Chronic Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
89145750|NCT02757170|Experimental|Group IV|Thromboelastography Acute Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
89145751|NCT02699346|Experimental|HS-1000 recording|Eligible patients and healthy subjects will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears. HS-1000 monitoring intervals will last from 20 minutes continuously. Following completion of data collection, HS-1000 will be removed.
89145752|NCT04169607|Experimental|individualized PEEP|"Basic ventilation: Volume-controlled ventilation mode with positive end-expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，~Recruitment maneuver: Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.~PEEP-titration maneuver: At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.~After titration: A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.~Randomization: Subsequently patient was randomized, the PEEP was then maintained (individualized PEEP arm) until extubation.~After discharged from post-anesthesia care unit (60 to 90 minutes after extubation)：A chest computerized tomography（CT） will be performed to assess the amount of atelectasis, expressed as the percentage of lung tissue in CT."
89145753|NCT04169607|Active Comparator|PEEP 8|"Bacis ventilation: Volume-controlled ventilation mode with positive end-expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，~Recruitment maneuver: Pressure-controlled ventilation mode increasing PEEP from 10 to 25cmH2O.~PEEP-titration maneuver: At this PEEP level, a decremental PEEP-titration maneuver will be started in volume-controlled ventilation mode, decreasing PEEP to 5cmH2O to confirm the highest dynamic lung compliance.~After titration: A new recruitment maneuver will be performed and the final PEEP will be the one related to the highest dynamic lung compliance plus 2cm H2O.~Randomization: Subsequently patient was randomized , the PEEP was then reduced to 8cm H2O (PEEP8 arm) until extubation.~After discharged from post-anesthesia care unit (60 to 90 minutes after extubation)：A chest computerized tomography（CT） will be performed to assess the amount of atelectasis, expressed as the percentage of lung tissue in CT."
89145754|NCT02756858|Experimental|ANAVEX2-73 Oral as assigned in ANAVEX2-73-002|
89145755|NCT02658513||All Patients|"All patients will undergo both of the following interventions:~Lancet blood sampling Standard intravenous blood sampling"
89145756|NCT02699502|Experimental|patients with osteoporotic hip fractures|The intervention includes matching an appropriate drug to patients with hip fractures. All the relevant parameters regarding the patients with osteoporotic hip fractures will be reviewed (age, kidney function, previous treatment) and an appropriate anti osteoporosis medication will be determined. A recommendation regarding treatment will be sent to the local regulatory authorities, which will send the approved recommendation the the family physician.
89145757|NCT00638144||1|patients with resolved infection
89145758|NCT00638144||2|chronically infected patients
89145759|NCT02658591|Active Comparator|Control|Crackers/pasta with no faba bean fraction
89145760|NCT02658591|Experimental|Faba bean protein concentrate|Crackers/pasta with added faba bean protein concentrate
89145761|NCT02658591|Experimental|Faba bean protein isolate|Crackers/pasta with added faba bean protein isolate
89145762|NCT02658591|Experimental|Faba bean flour|Crackers/pasta with added faba bean flour
89145763|NCT02658591|Experimental|Faba bean starch|Crackers/pasta with added faba bean starch
89145764|NCT02699268||Infants (term borns and preterm borns)|Intervention: simultaneous lung function measurement using VoluSense Pediatrics and a mask-based method with an ultrasonic flowmeter (EcoMedics Exhalyzer)
89145765|NCT02759900|Experimental|Non-thermal atmospheric plasma treatment|Device treatment
89145766|NCT02759900|Experimental|Indirect non-thermal atmospheric plasma treatment|A compound of non-thermal atmospheric plasma and medium is used to treat the target by direct application or by on-site generation of the compound
89145767|NCT02760134|Other|SMP with F14 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F14 suction-evacuation sheath.
89145768|NCT02760134|Other|SMP with F12 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F12 suction-evacuation sheath.
89145769|NCT02759978||Suspicion NVE|Patients with suspicion of native valve endocarditis, infective endocarditis and no intracardiac prosthetic material in situ
89145770|NCT02759978||Suspicion (PVE)|Patients with a suspicion of prosthetic valve endocarditis (PVE), infective endocarditis and one or more prosthetic valves in situ
89145771|NCT02759978||Suspicion pacemaker/ICD related endocarditis|Patients with a suspicion of infective endocarditis and a pacemaker or implantable cardiac defibrillator (ICD) in situ
89145772|NCT03316638|Experimental|W0101 - Cohort A1|This is a 14 days treatment cycle cohort in a 2 weeks schedule
89145773|NCT03316638|Experimental|W0101 - Cohort A2|This is a 21 days treatment cycle cohort in a 3 weeks schedule
89145774|NCT03316638|Experimental|W0101 - Expansion Phase|Will be initiated after completion of cohorts A1 and A2
89145775|NCT00635414|Experimental|1|40mg administered orally
89145776|NCT00635414|Experimental|2|15 minute intravenous infusion
89145777|NCT02658435|Experimental|Tafenoquine 300 milligram (mg) single dose|Participants will receive single dose of TQ (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
89145778|NCT02658435|Placebo Comparator|Matched Placebo 300mg single dose|Participants will receive single dose of matched placebo (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
89145779|NCT02759822||Group A: Acute Lymphoblastic Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy)~Preferred conditioning:~Total Body Irradiation 1200 cGy (TBI1200) + Fludarabine 120 mg/m2 (Flu120)~Alternative conditionings:~Melphalan 100-140 mg/m2 (Mel100-140) + Fludarabine 160 mg/m2 (Flu160) + Total Body Irradiation 200 cGy (TBI200)~Busulfan 9.6 mg/kg (Bu9.6) + Fludarabine 150 mg/m2 (Flu150) + TBI200 Graft versus host disease Prophylaxis: Post-Transplant Cyclophosphamide (PTCy) + Tacrolimus (FK) or Cyclosporin (CSA) + Mycophenolate Mofetil (MMF)"
89145780|NCT02759822||Group B: Acute Myeloid Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred Conditioning: Mel100-140 + Flu160 + TBI200~Alternative conditionings:~Bu9,6 + Flu150 + TBI200~Cyclophosphamide 29 mg/kg + Flu150 + TBI200 Graft versus host disease Prophylaxis: PTCy + FK or CSA + MMF"
89145781|NCT02704182|Active Comparator|Real tDCS|Direct current stimulation using anodal electrode, 25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
89145782|NCT02704182|Sham Comparator|Sham tDCS|Sham direct current stimulation, 25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
89145783|NCT02658123|Active Comparator|Group A: Standard of care|"Standard of care pre-operative education~Standard of care home health visits~Standard of care follow-up post-operative visits with surgeon and CWOCN~At 30-days post hospital discharge, the participant will:~See the physician~Turn in Patient Data Collection Form~Turn in Healthcare Utilization Form~Complete The City of Hope QOL Survey for Ostomy Patients~Ostomy assessment with a CWOCN, including photo of ostomy site"
89145784|NCT02658123|Experimental|Group B: Phone call|"Standard of care pre-operative education~Standard of care home health visits~Standard of care follow-up post-operative visits with surgeon and CWOCN~Telephone call 48-72 hours post-discharge from CWOCN/PA to evaluate tolerability to foods/fluids, activity level, screen for red-flags, review/assess for medication, reviewing pouching of ostomy, review patient's ability to obtain supplies, provide continued education, discuss proper use of durable medical equipment/frequency of pouch changes, and complete Patient Assessment Form.~At 30-days post hospital discharge, the participant will:~See the physician~Turn in Patient Data Collection Form~Turn in Healthcare Utilization Form~Complete The City of Hope QOL Survey for Ostomy Patients~Ostomy assessment with a CWOCN, including photo of ostomy site"
89145785|NCT02756936|Experimental|A Test|Test drug (Daclatasvir zeta)1 tablet contains 60 mg Daclatasvir
89145786|NCT02756936|Active Comparator|B Reference|Reference drug (Clatazev)) 1 tablet contains 60 mg Daclatasvir
89145787|NCT01675908|Active Comparator|Metal stent|Patients randomized to one cohort will undergo placement of fully covered self expandable metal stents. The rates (%) of stent dysfunction and complications will be evaluated.
89145788|NCT01675908|Active Comparator|Plastic Stent|At ERCP, a 10Fr plastic stent will be placed in the bile duct. The rates (%) of stent dysfunction and complications will be evaluated.
89145789|NCT02658045||Normal healthy volunteers|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in healthy volunteers during 6 min walking test
89145790|NCT02658045||COPD patients|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in COPD patients during 6 min walking test
89145791|NCT02752568|Active Comparator|Endometrial scratch group|endometrial scratch controlled ovarian hyperstimulation
89145792|NCT02752568|Active Comparator|Assisted hatching group|assisted hatching controlled ovarian hyperstimulation
89145793|NCT02752568|Sham Comparator|ovarian stimulation only group|controlled ovarian hyperstimulation
89145794|NCT02703870|Active Comparator|Verum tDCS|Verum group receiving complete treatment of tDCS
89145795|NCT02703870|Sham Comparator|sham tDCS|Sham group receiving sham tDCS
89145796|NCT02703870|Active Comparator|real VRT|Real Vision Restoration Training
89145797|NCT02658201|Other|MRI group|Ultrafast MRI
89145798|NCT02756780|Experimental|Tenovus Cancer Choir|Participants will be asked to attend 12 weeks of weekly choir rehearsals lasting approximately 1 hour. Following the first 12 weeks, participants will no longer be asked to attend rehearsals, but are welcome to do so. Whether or not they do and how many they attend will be measured as an outcome variable to assess whether initial 3-month involvement leads to long-term engagement.
89145799|NCT02756780|No Intervention|Control (no choir) Group|If eligible participants are unable to make the dates and times or live too far away but fulfil all the same criteria (including expressing an interest in singing) they will become part of the control group. This will involve the same data collection as the Cancer Choir Group but participants will not sing in a weekly choir.
89145800|NCT02704026||Inflammatory Bowel Disease|Patients 6-18 of age at the time of enrolment who have IBD at any stage of disease activity, on any or no treatment
89145801|NCT02704026||Control|Age- and sex-matched healthy controls
89145802|NCT02757014|Experimental|Coppertone (BAY987517)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89145803|NCT02703792||Care home staff|Care home staff working in the homes in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
89145804|NCT02703792||NHS staff|GPs supporting residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
89145805|NCT02703792||Service user representatives|Service or carers of an older person with dementia attending and Age UK carers group
89145806|NCT02703792||Relatives of residents|Relatives of residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
89145807|NCT02756546|No Intervention|Control|Healthy volunteers
89145808|NCT02756546|Active Comparator|Patients|SLE patients further divided into mild and severe patients
89145809|NCT02703558|No Intervention|No dye|Participants will not receive a preoperative or intraoperative dye prior to their intraoperative concomitant cystoscopy.
89145810|NCT02703558|Active Comparator|Phenazopyridine|Participants will receive a single 200mg oral dose of phenazopyridine with a sip of water 30 minutes prior to their surgery which involves an intraoperative concomitant cystoscopy.
89145811|NCT02703558|Active Comparator|Fluorescein|Participants will receive 0.25cc of 10% intravenous sodium fluorescein administered by anesthesia during their surgery, immediately prior to their intraoperative concomitant cystoscopy.
89145812|NCT02657811|Active Comparator|Bench Incubation|These embryos will be randomized to the bench incubator.
89145813|NCT02657811|Active Comparator|Time Lapse Incubation|These embryos will be randomized to the Time Lapse Incubator.
89145814|NCT02657811|Active Comparator|Time Lapse Incubation - Modified|These embryos will be randomized to the bench incubator.
89145815|NCT04222244||Headache Attributed to Rhinosinusitis Group (HAR)|No interventions will be provided.
89145816|NCT04222244||Headache-Free Control Group (Control)|No interventions will be provided.
89145817|NCT04756752||Fit and Vitaal program|People with a lower-limb amputation participating in the Fit and Vitaal rehabilitation program
89145818|NCT02759666|Experimental|SHR3162|"3 to 6 participants (traditional 3+3 design) will be enrolled in 6 dose levels. SHR3162 was administered once daily in dose levels 1 and 2 and will be administered twice daily in dose levels 3 to 6."
89145819|NCT02657733|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and Nellcor Bedside Respiratory Patient Monitoring System
89145820|NCT02657655|Experimental|Kinesia 360 Users|Parkinson's patients will be monitored continuously using wearable Kinesia 360 sensors.
89145821|NCT02752724|Experimental|Ketamine Interventional Arm|1.0 mg/kg IV ketamine (experimental arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
89145822|NCT02752724|Active Comparator|Methohexital Control Arm|1mg/kg of methohexital (standard arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
89145823|NCT02698878|Active Comparator|Control Group|Control Group consisting of six healthy male subjects wearing only the HEPHAISTOS ORTHOSIS for lower leg unloading (60 days).
89145824|NCT02698878|Experimental|Intervention Group|Intervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
89145825|NCT02756468||pts operated for pancreatic cancer|all pts operated of pancreatic resection for cancer in the involved units
89145826|NCT02699034|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
89145827|NCT00649623|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
89145828|NCT00649623|Active Comparator|2|Benicar® Tablets 40 mg
89145829|NCT02756312|Other|Intravenous anesthesia|Patients will receive total intravenous anesthesia undergoing brain tumor resection.
89145830|NCT02756312|Other|Inhalation anesthesia|Patients will receive volatile inhalational anesthesia undergoing brain tumor resection.
89145831|NCT02657499||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
89145832|NCT02657499||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
89145833|NCT02756390|Experimental|Arm A (Sleep Hygiene & CBTI-CS)|Participants receive a single educational session describing principles of Sleep Hygiene for Cancer Survivors. Those who continue to have significant symptoms of insomnia then receive 3 groups CBTI-CS sessions
89145834|NCT02756390|Other|Arm B (Telehealth Pilot of CBTI-CS)|Descriptive data collected on 10 participants (non-randomized) receiving CBTI-CS via Telehealth.
89145835|NCT00649701|No Intervention|1|
89145836|NCT00649701|Experimental|2|Text-based webpage
89145837|NCT00649701|Experimental|3|Talking about HIV video
89145838|NCT00649701|Experimental|4|The Morning After video
89145839|NCT00649701|Experimental|5|Both videos
89145840|NCT02752178||DEP+MA+|Incompletely responsive patients (approximately N ~100) who are currently depressed after greater than 6 weeks of treatment with one or more monoaminergic antidepressants
89145841|NCT02752178||DEP-MA+|Responsive patients (approximately N~50) who are not currently depressed after greater than 6 weeks of treatment with a monoaminergic antidepressant
89145842|NCT02752178||DEP+MA-|Untreated patients (approximately N~50) who are currently depressed but have not been treated with monoaminergic antidepressants in the previous 6 weeks
89145843|NCT02752178||DEP-MA-|Healthy volunteers (approximately N~50) who have no personal history of depression requiring treatment with either monoaminergic antidepressants or other clinical interventions including psychotherapy
89145844|NCT02657187|Experimental|rocuronium 1|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.24mg per muscle mass(kg).
89145845|NCT02657187|Experimental|rocuronium 2|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.32mg per muscle mass(kg).
89145846|NCT02657187|Experimental|rocuronium 3|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.40mg per muscle mass(kg).
89145847|NCT02657187|Experimental|rocuronium 4|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.48mg per muscle mass(kg).
89145848|NCT02756234||Qualifying CTP patients|A convenience sample of all qualifying patients for CTP procedure
89145849|NCT02657109|Active Comparator|Control|Participants are submitted to cardiac rehabilitation protocol of the hospital where it will be conducted the study, which consists in respiratory exercises of 3 series Inspirations Maximum Sustained for 10 reps, 3 sets of 20 repetitions metabolic exercises with dorsiflexion and plantar flexion and ankle and wrist extension and fingers of the upper limbs. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of postoperative and on the fifth postoperative day
89145850|NCT02657109|Active Comparator|Early mobilization|Participants performed exercise in cycle ergometer of lower Limbs, pedaling for 20 consecutive minutes at a moderate level with Heart Rate Assessment and the Borg scale to evaluate the Voluntary Comfort. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of oepratório post and on the fifth postoperative day
89145851|NCT01291134||Cervical Degenerative Disc Disease|Subjects suffering from symptoms of cervical degenerative disc disease in one to four contiguous levels between C3 and T1.
89145852|NCT04221308||single port laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
89145853|NCT04221308||Vaginal hysterectomies|Between 2018 and 2019, data obtained from patients in the SLH and VH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR), and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
89145854|NCT00649779|Experimental|1|albuterol sulfate extended-release 8 mg tablets
89145855|NCT00649779|Active Comparator|2|VoSpire™ ER 8 mg tablets
89145856|NCT00615186|Experimental|A|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
89145857|NCT00615186|Active Comparator|B|"Prior Surgery: Gross total resection (< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
89145858|NCT04017429|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
89145859|NCT04017429|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
89145860|NCT02698644|Experimental|isoamyl2cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
89145861|NCT04221386|Experimental|MIT group|Subjects will receive the developed Melodic Intonation Therapy.
89145862|NCT04221386|No Intervention|Control group|Subjects will not receive any intervention.
89145863|NCT00616044|Experimental|CSA|For CSA, an 22-G catheter (Spinocath, B.Braun Melsungen, Germany) over a 27-G Quincke needle was used. After identification of the epidural space with a Crawford needle, the catheter with the spinal needle inside was advanced through the epidural space until the dural puncture was felt and CSF was seen in the catheter. The catheter was then fed over the needle into the intrathecal space. The spinal needle and the modified Tuohy needle were removed and a luer connector and a filter previously filled with the anesthetic solution were attached to the catheter.
89145864|NCT00616044|Experimental|CSE|"CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany). The block consists of performing a spinal block via a 27-G spinal needle (Spinocan 125mm) introduced through an 18-G Tuohy needle (Perican 88mm) which was placed cranially directed in the epidural space. We did rotate the Tuohy needle between the spinal block and the insertion of the epidural catheter."
89145865|NCT02536911|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
89145866|NCT02536911|Experimental|GZ385660 (subjects with mild hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
89145867|NCT02536911|Experimental|GZ385660 (subjects with moderate hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
89145868|NCT02755922|Experimental|Fractures with Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, with application of autologous mesenchymal stem cells on the fracture site.
89145869|NCT02755922|No Intervention|Fractures without Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, without application of autologous mesenchymal stem cells on the fracture site.
89145870|NCT02703402|Experimental|Exercise protocol|Will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA
89290618|NCT05415748|Experimental|Placebo, Then Tamsulosin 0.4 mg or 0.8 mg|Participants first received Placebo tablet taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks. After a washout period of 1 week, the participants then received Tamsulosin 0.4 mg or 0.8 mg taken daily in 2 week treatment periods, 4 treatment periods in 12 weeks.
89145871|NCT02703402|Experimental|Manual of exercises|Treatment Group: will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises.
89145872|NCT04221152|Experimental|Treatment of empagliflozin|"The study treatment shall be started from the next day of the Week 24 visit of the EMPIRE-01 study after enrollment. The investigational drug shall be administered at the same dosage as that of the empagliflozin tablet administered from Week 12 to Week 24 of the treatment period in the EMPIRE-01 study.~The administration is oral administration with water once daily before or after breakfast."
89145873|NCT02656563|Experimental|Radium 223 Arm|Radium 223 Dichloride (Xofigo®)
89145874|NCT02656563|No Intervention|Non Treatment Arm|Control Arm
89145875|NCT02755766||Clubfeet|Babies, ages 0-1, with a diagnosis with clubfoot or clubfeet who are beginning treatment with foot abduction bracing following casting treatment.
89145876|NCT02755766||Adolescent Idiopathic Scoliosis|Patients, ages 10-14, with a diagnosis of AIS who are beginning treatment with TLSO (initial bracing).
89145877|NCT02755766||Guardians (CF babies)|Clubfoot patients' guardians.
89145878|NCT02656641|No Intervention|Control|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will not complete any scales during other sessions.
89145879|NCT02656641|Experimental|Continuous Client Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will review and discuss their results and at the beginning of each session.
89145880|NCT02656641|Experimental|Continuous Self Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will not have access to these results.
89145881|NCT02755688|Experimental|Thoracoscopic surgical ablation|Pulmonary vein isolation, ganglionic plexi ablation, left atrial appendage exclusion
89145882|NCT02755688|Active Comparator|Catheter ablation|Pulmonary vein isolation, linear lines
89145883|NCT04221854|Experimental|Stool-based SDC2 DNA methylation test group|Subjects will received the stool-based SDC2 DNA methylation test for the screening of colorectal advanced adenomatous polyps and cancer.
89145884|NCT04221854|Active Comparator|Fecal immunochemical test group|Subjects will received the fecal immunochemical test for the screening of colorectal advanced adenomatous polyps and cancer.
89145885|NCT02759510|Active Comparator|phenylephrine|phenylejphrine (one bolus for 40 ug/ml)
89145886|NCT02759510|Experimental|norepinephrine|norepinephrine (one bolus for 2 ug/ml)
89145887|NCT02759432|Experimental|Intervention|Participants in the intervention group will complete a 4-week school-based high-intensity interval exercise training programme. The intervention will take place twice per week, and comprise of 6-8 repetitions of 45 s maximal effort exercise (boxing, running, soccer and basketball drills), each interspersed with 90-s rest. Participants will be encouraged to work maximally during the 45-s repetitions.
89145888|NCT02759432|No Intervention|Control|Participants in the control group will be instructed not to change their lifestyle, dietary or physical activity habits during the intervention period, and maintain their normal school physical education routine
89145889|NCT04220528|Experimental|Radical chemoradiotherapy plus oral capecitabine/teggiol|Patients with newly diagnosed, non-metastatic stage N3 NPC was given Teggio 40-60mg bid d1-14, q4w, oral maintenance chemotherapy for 1 year or capecitabine 2500mg/m2/d twice daily oral d1-14, q4w after receiving radical chemoradiotherapy.
89145890|NCT02755454|Other|open label|Perfusion CT Imaging
89145891|NCT04365218|Experimental|Cohort 1 (Dose A)|6 subjects will be randomized to receive MEDI8367 Dose A and 2 subjects will be randomized to receive placebo.
89145892|NCT04365218|Experimental|Cohort 2 (Dose B)|6 subjects will be randomized to receive MEDI8367 Dose B and 2 subjects will be randomized to receive placebo.
89145893|NCT04365218|Experimental|Cohort 3 (Dose C)|6 subjects will be randomized to receive MEDI8367 Dose C and 2 subjects will be randomized to receive placebo.
89145894|NCT04365218|Experimental|Cohort 4 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D and 2 subjects will be randomized to receive placebo.
89145895|NCT04365218|Experimental|Cohort 5 (Dose D)|6 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 2 subjects will be randomized to receive placebo.
89145896|NCT04365218|Experimental|Cohort 6 (Dose D)|15 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 15 subjects will be randomized to receive placebo.
89145897|NCT02755532|Active Comparator|Bupivacaine 0,25%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve) In the group bupicavaine 0.25%, 10 ml of 0.25% bupivacaine was injected into each nerve, for a total of 40 ml per patient.
89145898|NCT02755532|Active Comparator|Bupivacaine 0,5%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve). In the group bupivacaine 0.5% , 5 ml of 0.5% bupivacaine was injected into each nerve, for a total of 20 ml per patient.
89145899|NCT02755376|Active Comparator|ACL reconstruction only|only ACL reconstruction without any injection
89145900|NCT02755376|Experimental|ACL reconstruction + Cartistem(TM)|ACL reconstruction and concomitant Cartistem(TM) injection which is human cord blood derived mesenchymal stem cell under arthroscopy.
89145901|NCT02755376|Experimental|ACL reconstruction + Hyaluronic acid|ACL reconstruction and concomitant hyaluronic acid injection under arthroscopy
89145902|NCT02752334|No Intervention|group Bupivacaine|patients will receive 23 mL of Bupivacaine HCL 0.5% (Marcaine, 5 mg per mL; Hospira, USA) in addition to 2 mL normal saline using Ultrasound-guided Supraclavicular Brachial Plexus Block
89145903|NCT02752334|Active Comparator|group Bupivacaine Magnesium|patients will receive 23 mL of Bupivacaine HCL 0.5% in addition to 2 mL (100 mg) Magnesium Sulphate (Magnesium Sulphate 50 %, 500 mg per mL; Hospira, USA) diluted with normal saline. using Ultrasound-guided Supraclavicular Brachial Plexus Block
89145904|NCT02755298|Experimental|Acetazolamide|Twice a day 250 mg acetazolamide for 5 weeks
89145905|NCT02755298|Placebo Comparator|Placebo|Placebo capsule 250 mg (Mannitol) twice a day 5 weeks
89145906|NCT02755142|Active Comparator|Dose level 1|0,2 mg/Kg
89145907|NCT02755142|Active Comparator|Dose level 2|2,0 mg/Kg
89145908|NCT02755142|Active Comparator|Dose level 3|20 mg/Kg
89145909|NCT02759276||Resistant Hypertension (RH)|uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.
89145910|NCT02759276||Stages 1 and 2 Hypertension (MMH)|According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.
89145911|NCT02759276||Normotensive (CG)|Blood Pressure <140/90 mmHg and without comorbidities.
89145912|NCT02759198|Experimental|YH23537|YH23537 750/1500/3000mg
89145913|NCT02759198|Active Comparator|Celebrex|Celecoxib 200mg
89145914|NCT02759198|Placebo Comparator|Placebo|YH23537 Placebo
89145915|NCT02752100|Experimental|Interventional Therapy|Percutaneous transluminal angioplasty.
89145916|NCT02752100|No Intervention|Non-Interventional Therapy|
89145917|NCT02758886|Experimental|Stress reduction method|Participants randomized into the PYSA group engaged in a 10 minute direct interaction with the animals (dogs and cats) of the Pet Your Stress Away program
89145918|NCT02758886|Placebo Comparator|Control|Participants randomized into the Control group watched a 10 minute slide show of dog and cat photos
89145919|NCT02758886|No Intervention|Non-treatment|Participants randomized into the No-treatment group silently waited for 10 minutes without engaging in any physical or electronic social interactions.
89145920|NCT02758886|Placebo Comparator|Observation|Participants randomized into the observation group observed 10 minutes of others in the general PYSA program petting cats and dogs, while they 'waited in line' for there turn.
89145921|NCT02754986|Experimental|measuring Holter electrocardiogram|Hotter ECG will be recorded continuously during hemodialysis
89145922|NCT04220606|Other|Migraine without aura subjects|Drug: Glyceryl trinitrate (GTN)
89145923|NCT04220606|Other|Healthy subjects|Drug: Glyceryl trinitrate (GTN)
89145924|NCT02755064|Experimental|Erythromycin lactobionate IV 2 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
89145925|NCT02755064|Active Comparator|Erythromycin lactobionate IV 3 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
89145926|NCT02755064|Placebo Comparator|Placebo IV|Saline was given as an initial bolus over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
89145927|NCT02755064|Experimental|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
89145928|NCT02755064|Placebo Comparator|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
89145929|NCT02751944|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 2 weeks
89145930|NCT02751944|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 2 weeks
89145931|NCT02706132|Experimental|The MSCs group|The group of patients receive allogeneic MSCs therapies.
89145932|NCT02754908|Experimental|Experimental group|In addition to medical follow-up, the subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation. Qualified orchestral performers will provide the musical training. Training will start at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song). The subjects will continue on to the next level if they successfully pass the relevant test; those who do not will be encouraged to repeat test.
89145933|NCT02754908|Placebo Comparator|Placebo Control group|"The subjects will receive medical follow-up according to the schedule of the oncology units.~They will receive the same amount of time and attention as those in the experimental group but not in a way designed to have any specific effect on the outcome measures. They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks)."
89290619|NCT03927300||Patients without Telemonitoring with ApTelecare Software|
89145934|NCT02703168||Immediate loading|Patients were allocated to treatment group in the core study. Immediate loading was defined as follows: Implant(s) will be restored with a temporary restoration on the day of surgery
89145935|NCT02703168||Early loading|Patients were allocated to treatment group in the core study. Early loading was defined as follows: Healing caps will be placed on the implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
89145936|NCT04221074|Active Comparator|Modified Pectoral Plane (PECSII ) block (P)|done after induction of general anaesthesia in supine position of the patient with his arm of the side of the operation abducted 90 degree with the probe with frequency L4-12t (Logiq e machine) at the midclavicular level and angled infero-laterally,the axillary artery and vein and the second rib identified the probe moved laterally until the pectoralis minor and serratus anterior are identified,the local anesthetic was injected at two points using (echoplext guge20 length 50 mm ) needle:the first injection of 10 ml of 0.25% Bupivacaine and 4 mg dexamethasone injected between the pectoralis major and minor muscles,and the second injection of 20 ml of 0.25% Bupivacaine and 4 mg dexamethasone between the pectoralis minor and serratus anterior muscles .
89145937|NCT04221074|Active Comparator|Erector Spinae Plane ( ESP )block (E)|after induction of general anaesthesia in lateral position of the patient where the surgical side up and at T4 level the probe with frequency L4-12t (Logiq e machine) placed lateral to the spine by 3 cm in parasagittal plane the needle (echoplext guge20 length 50 mm ) advanced between the transverse process and the erector spinae muscle at that level 20 ml of 0.25% Bupivacaine and 8 mg dexamethasone injected.
89145938|NCT04333472|Experimental|Piclidenoson|Piclidenoson 2 mg every 12 hours orally added to standard of care
89145939|NCT04333472|Placebo Comparator|Placebo|Placebo every 12 hours orally added to standard of care
89145940|NCT04215042|Active Comparator|Standard hydration|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and 6 hours after procedure
89145941|NCT04215042|Experimental|Short hydration|All patients received shot intravenous saline hydration (3 ml/kg for 1 hour before the procedure and after 1ml/kg/h for 6 hours)
89145942|NCT02698722|No Intervention|Control|This group will receive verbal education about dialytic and non-dialytic therapies via a standardized script.
89145943|NCT02698722|Experimental|Intervention|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
89145944|NCT02758574|Active Comparator|CDT without ultrasound acceleration|Standard Catheter-Directed Thrombolysis: Utilization of a standard infusion catheter, placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications to treat/dissolve pulmonary embolus
89145945|NCT02758574|Experimental|CDT ultrasound accelerated|Ultrasound Accelerated Catheter-Directed Thrombolysis: Utilization of an infusion catheter that incorporates an ultrasound emitting wire both placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications with the ultrasound emitting wire activated to treat/dissolve pulmonary embolus
89145946|NCT02698488|Active Comparator|Embryo Selection by Morphology|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study
89145947|NCT02698488|Active Comparator|Embryo Selection by Morphology and Mass Spectroscopy|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study. After dilution, embryo culture media will be analyzed by electrospray ionization quadrupole time-of-flight (ESI-QTOF) MS. The spectra will be collected in the negative ion mode. Abundance of ions in each spectrum will be further analyzed.
89145948|NCT02702934|Experimental|High-amylose rusks|Test meal with 100g of carbohydrates coming from high-amylose rusks
89145949|NCT02702934|Active Comparator|Control rusks|Test meal with 100g of carbohydrates coming from regular rusks used as control
89145950|NCT02758730|Experimental|AFFITOPE® PD01A + Adjuvant|3 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
89145951|NCT02758730|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks
89145952|NCT02703012|Experimental|Adjustment of ventilator settings by EIT|Individual Adjustment of Ventilator settings using an algorithm based on electrical impedance tomography.
89145953|NCT02752022||Heavy smokers|Heavy smokers (continuous smoking of >10 cigarettes per day) for at least 6 months who will give up smoking and switch to nicotine containing e-cigarettes for 28 days to help them quit smoking.
89145954|NCT02705976|Active Comparator|self-managing warfarin|self-managing warfarin patients who are educated in dosing warfarin to achieve target INR value
89145955|NCT02705976|Experimental|algorithm-suggested warfarin dosing|algorithm-suggested warfarin dosing, where the participants are provided with a dosage suggestion of their warfarin dosage (calculated dose) to achieve target INR
89145956|NCT02752412|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Metformin will be continued."
89145957|NCT02752412|Active Comparator|insulin glargine|"Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted.~Metformin will be continued."
89145958|NCT02705898|Experimental|LPA+Fitbit|A 12-week LPA+Fitbit intervention for depressed women in intensive alcohol treatment. This will include: 1) a single in-person physical activity (PA) counseling orientation session; 2) 6 brief, phone-based PA counseling sessions focused on increasing PA and strategically using bouts of PA to cope with affect and alcohol cravings; 3) use of the Fitbit fitness tracker for physical activity goal-setting and daily self-monitoring; and 4) weekly supportive messages delivered by email.
89145959|NCT02705898|Active Comparator|Health Education Contact Control (HEC)|The HEC condition will include: 1) an in-person orientation session, 2) 6 telephone-delivered health education sessions, and 3) weekly health-related e-mails. A variety of health and lifestyle topics will be addressed including the following: Session 1 (week 1) - Nutrition-What to Eat and What Not to Eat; Session 2 (week 2) - Sleep Problems and Sleep Hygiene; Session 3 (week 4) - Alcohol Use among Women; Session 4 (week 6) - Relaxation training; Session 5 (week 8) - Time Management and Assertiveness; and Session 6 (week 10) - Being a Smart Patient when Coordinating your Healthcare.
89145960|NCT02703090|Placebo Comparator|Placebo|Normal saline infusion
89145961|NCT02703090|Active Comparator|Drug lower dose|Remifentanil infusion
89145962|NCT02703090|Active Comparator|Drug higher dose|Remifentanil infusion
89145963|NCT02754362|Experimental|Block 1|
89145964|NCT02754362|Experimental|Block 2|
89145965|NCT02754362|Experimental|Block 3|
89145966|NCT02698332|Active Comparator|Algorithm for UTI|Practices in this groups receives a diagnostic algorithm for UTI by post
89145967|NCT02698332|No Intervention|Control|Practices in this group does not receive anything in addition to instructions in the observational registration.
89145968|NCT02754284|Experimental|Autologous fat transplantation|
89145969|NCT02754284|Experimental|Functional collagen scaffold transplantation|
89145970|NCT03373188|Active Comparator|Arm I (surgery)|Patients undergo surgery.
89145971|NCT03373188|Experimental|Arm II (VX15/2503, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
89145972|NCT03373188|Experimental|Arm III (VX15/2503, ipilimumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
89145973|NCT03373188|Experimental|Arm IV (VX15/2503, nivolumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
89145974|NCT02695940|Active Comparator|LEO 124249 ointment 30 mg/g|Drug LEO 124249 ointment 30 mg/g twice daily application for 6 weeks, maximum of 1.44 g ointment per day
89145975|NCT02695940|Placebo Comparator|LEO 124249 ointment vehicle|LEO 124249 ointment vehicle twice daily application for 6 weeks, maximum of 1.44 g ointment per day
89145976|NCT02698098||Compulsory Drug Detention Center|Conventional drug treatment in Malaysia and Southeast Asia including detention for an average of 2 years, including educational and job skills programs and physical education. Medical therapies for treating substance use disorders, such as opioid-agonist treatment (OAT), are unavailable.
89145977|NCT02698098||Voluntary Treatment Center|Voluntary drug treatment facilities, called 'Cure and Care' centers in Malaysia, that provide methadone maintenance therapy in addition to psychosocial interventions, recreational programming, and vocational training, among other activities.
89145978|NCT04220996|Experimental|Vortioxetine|10-20 mg vortioxetine tablets
89145979|NCT02702856||Men screened for prostate cancer|
89145980|NCT02754128|Active Comparator|BeFAST|Motor learning-based program involving athletic lower extremity training of gait-related skills.
89145981|NCT02754128|Active Comparator|BeSTRONG|Lower limb strength training program involving progressive muscle resistance exercises.
88805991|NCT01152359|Active Comparator|Arm 2|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
89145982|NCT02705742|Other|stem cells group|mesenchymal stem cells only
89145983|NCT02754206||Control|Subjects who are collegiate level athletes who do not have a concussion and are currently playing a contact-collision sport.
89145984|NCT02754206||Concussed|Subjects who have recently suffered a sports-related concussion and are currently a collegiate athlete playing a contact-collision sport.
89145985|NCT02702700|Experimental|Lipoplatin/Visudyne-mediated photodynamic therapy|200 mg/m2 Lipoplatin™ will be delivered as iv perfusion. Then, intrapleural photo-induction will be realized through a classical video-assisted thoracoscopic (VATS) approach using 3 mg/m2 Visudyne® activated at 689 nm. At the end of the procedure, the patients will receive chemical pleurodesis by VATS as per standard-of-care treatment for malignant pleural effusion.
89145986|NCT02758496||ASD Subjects|Approximately two hundred (200) male and female subjects of any ethnic background between the ages of 2-20 years old seen at the Brain Treatment Center (BTC) between 2010 and 2015.
89145987|NCT02758496||Healthy Controls|Twenty (20) male and female subjects of any ethnic background between the ages of 2-20 years old with 'neurotypical' EEGs will be selected for comparison to the ASD group
89145988|NCT02697942|No Intervention|Standard of care|Participants randomized to the standard of care arm will not receive any intervention.
89145989|NCT02697942|Experimental|Cognitive training (CT)|"Participants randomized to the CT arm will be given a tablet with connection to Lumosity®, which is a web-based brain game. Participants will use the tablets to play brain games at each dialysis session."
89145990|NCT02697942|Active Comparator|Exercise training (ET)|Participants randomized to ET arm will be given a stationary foot peddler. This foot peddler will be situated at a comfortable distance from the dialysis chair so that the patient can comfortably reach the peddler. Participants will use the foot peddlers at each dialysis session.
89145991|NCT02695784|Experimental|Probiotic continuation|This Group will Continue probiotics Beyond 34 weeks corrected Gestational agent standard practice
89145992|NCT02695784|No Intervention|Standard treatment Group|This group will continue current standard practice of stopping probiotics at 34 weeks corrected gestational age
89145993|NCT04214808|Experimental|Avodart Soft Capsule 0.5mg to AD-208|Period 1: Avodart Soft Capsule 0.5mg, 1 Capsule Period 2: AD-208, 1 tab
89145994|NCT04214808|Experimental|AD-208 to Avodart Soft Capsule 0.5mg|Period 1: AD-208, 1 tab Period 2: Avodart Soft Capsule 0.5mg, 1 Capsule
89145995|NCT04221776|Experimental|Intensive toilet training group|Intervention group was subjected to an intensive TT group session lasting 2-hours during 2 consecutive days in daycare centers.
89145996|NCT04221776|Active Comparator|Standard care toilet training group|Children participating in control group did not receive the intensive training, but parents got a leaflet and were encouraged to start TT their child at home, in their own manner.
89145997|NCT04215744|Experimental|Ice water immersion group|Ice water immersion of the left hands(30 minutes before the infusion, during the infusion, and 30 minutes after the end of infusion).
89145998|NCT04215744|No Intervention|Control group|No intervention of the right hands as control.
89145999|NCT04192448|Experimental|AlcoholxAnger|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
89146000|NCT04192448|Experimental|AlcoholxControl|Participant will receive alcohol, the dose of which will be administered to result in a BAC of .08%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
89146001|NCT04192448|Experimental|SoberxAnger|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive an anger emotion induction, in which the experience of frustration and irritability is induced.
89146002|NCT04192448|Sham Comparator|SoberxControl|Participant will not receive alcohol, therefore their BAC will be .00%. Participants will also receive a control emotion induction, in which they are exposed to a neutral mood induction.
89146003|NCT02697864|Experimental|48.8 mgA tafamidis free acid tablet|
89146004|NCT02697864|Experimental|58 mgA tafamidis free acid tablet|
89146005|NCT02697864|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
89146006|NCT02696174|Experimental|Health Microinsurance Scheme|Households owning the HMI package, entitling them to visit and receive treatment from the selected primary care clinic
89146007|NCT02696174|No Intervention|Out-Of-Pocket|Households who visit the selected primary care clinic, but pay by Out-Of-Pocket
89146008|NCT02753894|Experimental|4.5 g/day group|Three times a day
89146009|NCT02753894|Experimental|6.0 g/day group|Three times a day
89146010|NCT02753894|Experimental|7.5 g/day group|Three times a day
89146011|NCT02698020|No Intervention|Control|High level of supplemental inspired oxygen
89146012|NCT02698020|Experimental|Room-air|Supplemental oxygen only provided if oxygen saturation below target
89146013|NCT02695706|Experimental|Laboratoires Mercurochrome Reparador|A group of patients will be treated with a new restorative skin cream consists of hyperoxygenation essential fatty acids (60% linoleic acid) which does not contain preservatives (parabens) or known allergens.
89146014|NCT02702544|Experimental|neutral position|the patient is in the neutral position, located on his back on a flat surface
89146015|NCT02702544|Experimental|legs raised for 20 degrees|patient is placed on a flat surface, legs raised for 20 degrees, supported around ankles
89146016|NCT02702544|Experimental|legs raised for 30 degrees|patient is placed on a flat surface, legs raised for 30 degrees, supported around ankles
89146017|NCT02702544|Experimental|legs raised for 45 degrees|patient is placed on a flat surface, legs raised for 45 degrees, supported around ankles
89146018|NCT02702544|Experimental|legs raised for 60 degrees|patient is placed on a flat surface, legs raised for 60 degrees, supported around ankles
89146019|NCT02754050|Experimental|Polypectomy|When a 6-25mm polyp is identified the Tandem snare will be inserted through the colonoscope, remove and retrieve the polyp.
89146020|NCT02702778|Active Comparator|4mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 4mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
88805992|NCT01152515|No Intervention|Control|stopping of propofol and remifentanil infusion
88805993|NCT01152515|Active Comparator|Remifentanil|stopping of propofol and maintenance of remifentanil infusion
88805994|NCT03011255|Experimental|peptide specific CTL arm|peptide specific CTL, radiation
89146021|NCT02702778|Active Comparator|7mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 7mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
89146022|NCT02702778|Active Comparator|10mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 10mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
89146023|NCT04220372|Experimental|Tongxinluo Capsule|
89146024|NCT04220372|Placebo Comparator|Placebo Capsule|
89146025|NCT04215822||acute myeloid leukemia patients - control group|acute myeloid leukemia
88805995|NCT01153685|Experimental|Fluviral A Group|Subjects aged between 18 and 60 years who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
89146026|NCT02753738|Experimental|SSRI treatment|Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
89146027|NCT02753738|Placebo Comparator|Placebo treatment|Subjects will receive 21 days of placebo treatment while performing learning paradigms.
89146028|NCT02702466|Experimental|Immediate SPA Therapy|6 day immediate SPA treatment (soon after randomization) and written information with physical exercises adapted to their pathology and also a program of healthcare at the USB key
89146029|NCT02702466|Active Comparator|Late SPA Therapy|Written information with physical exercises adapted to their pathology and a program of healthcare at the USB key and late 6 day SPA treatment
89146030|NCT02751632|Experimental|Step 1-Regular SPS Therapy|Support and Problem Solving Therapy delivered to all study participants over a six-week period with a minimum of three sessions.
89146031|NCT02751632|Experimental|Responders- Monthly SPS Therapy|Participants are randomised to receive monthly Support and Problem Solving Therapy for up to 12 months.
89146032|NCT02751632|Experimental|Responders- 3-monthly monitoring|Participants are randomised to be monitored for risk every 3 months for up to 12 months.
89146033|NCT02751632|Experimental|Step 2- Regular SPS Therapy|Participants are randomised to receive regular sessions of Support and Problem Solving Therapy, with a minimum of six sessions delivered over an 18-week period.
89146034|NCT02751632|Experimental|Step 2- Regular CBCM|Participants are randomised to receive regular sessions of Cognitive Behavioural Case Management, with a minimum of six sessions delivered over an 18-week period.
89146035|NCT02751632|Experimental|Step 3- Regular CBCM + Fluoxetine|Participants are randomised to receive either Cognitive Behavioural Case Management plus an antidepressant medication for six months .
89146036|NCT02751632|Placebo Comparator|Step 3- Regular CBCM+ placebo|Participants are randomised to receive Cognitive Behavioural Case Management plus placebo medication for six months.
89146037|NCT04805268|Experimental|One subject with possible Luft's disease|18F-FDG will be administered I.V., approximately 1 hour prior to PET/CT scan.
89146038|NCT02753582|Active Comparator|Intervention|SOD+Gliadin capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
89146039|NCT02753582|Placebo Comparator|Placebo|Placebo capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
89146040|NCT02697786|Active Comparator|AVR preformed with full sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
89146041|NCT02697786|Experimental|AVR preformed with minimal invasive sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
89146042|NCT02751476|Active Comparator|standard SAM treatment (control group)|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure.
89146043|NCT02751476|Experimental|SAM treatment + flocculent-disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a flocculent-disinfectant for household level application.
89146044|NCT02751476|Experimental|SAM treatment + chlorine disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a chlorine disinfectant for household level application.
89146045|NCT02751476|Experimental|SAM treatment + ceramic water filter|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a ceramic water filter for household level application.
89146046|NCT02697708|Placebo Comparator|Control Diet|Control (no additional potassium added to diet): Arm will consist of a 16 day balance period with a basal diet set at ~2340mg K/day; based on average American intake.
89146047|NCT02697708|Active Comparator|Potassium Supplement Diet|Potassium gluconate: Arm will consist of a 16 day balance period with the basal (control) diet plus the addition of 1000mg of K/day from potassium gluconate (12 tablets).
89146048|NCT02697708|Experimental|Potato Diet|Potato diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg of K/day from white potatoes.
89146049|NCT02697708|Experimental|French fries Diet|French fry diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg K/day from French fries.
89146050|NCT04220762|Experimental|Test Group 1|The randomized patients are administered 3 tablets of the investigational product (400mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
89146051|NCT04220762|Experimental|Test Group 2|The randomized patients are administered 3 tablets of the investigational product (800mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
89146052|NCT04220762|Experimental|Test Group 3|The randomized patients are administered 3 tablets of the investigational product (1200mg) twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
89146053|NCT04220762|Placebo Comparator|Placebo group|The randomized patients are administered 3 tablets of the placebo drug twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
89146054|NCT02705430|No Intervention|A|Group A will continue their actual therapy (control).
89146055|NCT02705430|Experimental|B|Group B will continue their standard therapy with additional stress management application only using a mobile phone (Eco Fusion Mentally) for 3 months of the study
89146056|NCT02705430|Experimental|C|Group C will continue their standard therapy with additional life style program using a mobile phone (Eco Mentally and NewMe) for 3 months of the study
89146057|NCT02705430|Experimental|D|Group D will continue their standard therapy plus additional life style program using a mobile phone with additional supplemental EPA and DHA capsules of 2 g/day to be taken daily for the 3 months of the study
89146058|NCT02753660|Active Comparator|Traditional sitting position|Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.
89146059|NCT02753660|Experimental|Pendant position|Patients sit with both their underarms propped up on a metal prop, thus both arms hanging from the prop before spinal anesthesia begun.
89146060|NCT02705664|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 7 weeks on all affected toenails of one foot
89146061|NCT02705664|Active Comparator|Urea Ointment + Bifonazole Cream|"On the opposite foot:~Urea 40% ointment to be applied once a day under occlusion for 2-3 weeks depending on the achievement of optimal diseased toenail plates removal)~Bifonazole 1% cream to be applied for 4 weeks on affected toenails (after the maximum 3-week treatment period with Urea ointment)"
89146062|NCT02753348||Newborns|Newborns (within 14 days from birth)
89146063|NCT02697552|Experimental|HBI-8000|HBI-8000 at the assigned dose twice weekly.
89146064|NCT02753426|Other|Doxycycline-Placebo|Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.
89146065|NCT02753426|Other|Placebo-Doxycycline|Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.
89146066|NCT02702232||Parkinson's disease|Patients with PD will be recruited consecutively from a neurology clinic. A group of sex- and age-matched normal subjects with be recruited from the public. These patients will be evaluated by ultrasonography for shoulder.
88805996|NCT01153685|Experimental|Fluviral B Group|Subjects over 60 years of age who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
88805997|NCT03011177|Experimental|teneligliptin|teneligliptin 20mg qd
88805998|NCT03011177|Active Comparator|linagliptin|linagliptin 5mg qd
89146067|NCT02702232||Normal|Normal controls who will be evaluated by ultrasonography for shoulder
89146068|NCT02753504|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
89146069|NCT02753504|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
89146070|NCT02753504|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
89146071|NCT02702154|Experimental|High-frequency rTMS|20 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
89146072|NCT02702154|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
89146073|NCT02702154|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
89146074|NCT02753270|Active Comparator|Short catheter|Twenty-five patients will receive the sclerosant foam by a short catheter 18 G. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
89146075|NCT02753270|Experimental|Long catheter preceded by tumescence|Twenty-five patients will be receive foam sclerosant by an angiographic catheter 4 French. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
89146076|NCT02705040||Normal|bone mineral density T>=-1.0
89146077|NCT02705040||Osteopenia|bone mineral density -1.0>T>=-2.5
89146078|NCT02705040||Osteoporosis|bone mineral density T<-2.5
89146079|NCT02692014||coronary heart disease|2,400 patients who are diagnosed with CHD and have received more than 2 times of coronary angiography within 12-24 months.
89146080|NCT04219124|Active Comparator|Dapagliflozin|Investigational product: Dapagliflozin 10 mg Dosage form and strength: Green, plain, diamond shaped, film coated 10 mg tablet with frequency of 1 tablet per day for 4 weeks
89146081|NCT04219124|Placebo Comparator|Placebo|Investigational product: Matching placebo for Dapagliflozin 10 mg. Dosage form and strength: Green, plain, diamond shaped, and film coated tablet with frequency of 1 tablet per day for 4 weeks
89146082|NCT00914927|Experimental|1|
89146083|NCT00914927|Experimental|2|
89146084|NCT00914927|Placebo Comparator|3|
89146085|NCT02702076|Experimental|Apomorphine|This arm will be treated with continuous subcutaneous infusion of apomorphine. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator, aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
89146086|NCT02702076|Placebo Comparator|Placebo|This arm will be treated with continuous subcutaneous infusion of placebo. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
89146087|NCT02751398|Experimental|Dapagliflozin|Dapagliflozin 10mg/day
89146088|NCT02751398|Placebo Comparator|Placebo|
89146089|NCT00615498||Surgical cases|Subjects who are undergoing bariatric surgery
89146090|NCT00615498||Controls|Subjects who qualify for bariatric surgery but do not undergo the procedure
89146091|NCT02753114|Experimental|Intranasal Ketamine|Ketamine dosing will be weight-based as follows: 30mg of IN ketamine for patients weighing 50 kg or less; 50 mg of IN ketamine for patients weighing 50 kg to 100 kg; and 75 mg of IN ketamine for patients weighing greater than 100 kg (i.e. 0.5 mg/kg to 1.0 mg/kg of intranasal ketamine). Syringes containing ketamine will be prepared from the intravenous formulation of Ketamine (50 mg / ml) solution (Sandoz; DIN 02246796) and stored in pre-filled 5 ml syringes. Ketamine will be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses will be administered.
89146092|NCT02753114|Placebo Comparator|Placebo|"Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled Study Drug. The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered."
89146093|NCT04215354|Experimental|MAGNET GROUP|Patients were exposed to very low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional using magnet mattress.
89146094|NCT04215354|Experimental|VIRTUAL REALITY|"Balance training was done using the Wii Fit plus machine which required balance board .Using video game console designed by Nintendo.~The program consisted of three games: soccer heading, ski slalom and table tilt."
89146095|NCT04215354|Active Comparator|PLACEBO|Patients in the placebo group had identical program to magnet group. They were asked to lie down in the magnet mattress; however, the magnet was not switched on and the patient doesn't know (blind).
89146096|NCT04215354|No Intervention|HEALTHY SUBJECT|healthy subjects with age, gender and BMI matched with the patients with MS were recruited to participate in the study. This group was recruited to establish the normal balance and fatigue parameters. Subjects in this group sign the consent form of healthy subjects and all measurement was taken as balance, fatigue, depression, quality of life and urinary incontinence screening questionnaire.
89146097|NCT02690532||High risk group|Children who are at high risk for developing celiac disease (siblings diagnosed with celiac disease).
89146098|NCT02690532||Non-celiac group|Children who are self-diagnosed with non-celiac gluten sensitivity.
89146099|NCT02690532||Control Group|Healthy control group (matched for age and gender).
89146100|NCT02753192|Other|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons.
89146101|NCT02753036||Chemotherapy|patients with ovarian cancer and paclitaxel + carboplatin combination chemotherapy as well as patients with breast cancer and paclitaxel +/- carboplatin combination chemotherapy
89146102|NCT02753036||Healthy control|patients with benign gynecological tumors after laparoscopic surgical resection
89290620|NCT03927300||Patients with implementation of Telemonitoring with ApTelecare|
89146103|NCT02753036||Tumor control|patients with breast cancer with anti-hormonal and/or localized radiation treatment but no chemotherapy
89146104|NCT02705274|Active Comparator|Prompt Panretinal Photocoagulation|PRP= Panretinal Photocoagulation. PRP alone.
89146105|NCT02705274|Experimental|Bevacizumab with deferred PRP|Bevacizumab = Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
89146106|NCT00914849|Experimental|Arm 1 - Donor|"Day 1~AMD3100 320 ug/kg IV~Leukopheresis~Day 2 (if peripheral blood stem cell (PBSC) collected is not sufficient)~AMD3100 320 ug/kg IV~Leukopheresis"
89146107|NCT00914849|Experimental|Arm 2 - Recipient|"Standard of care and physician choice myeloablative or non-myeloablative chemotherapy with or without total body irradiation (permitted = cyclophosphamide and single dose total body irradiation (TBI) / fludarabine and busulfan / fractionated TBI and cyclophosphamide / fractionated TBI, etoposide, and cyclophosphamide / busulfan and cyclophosphamide / fludarabine, busulfan, and ATGAM~Day 0 = Stem Cell Transplant"
89146108|NCT02751086||Robotic Gastrectomy|Patients who will be treated for gastric cancer with the assistance of the robotic surgical system
89146109|NCT02751086||Laparoscopic Gastrectomy|Patients who will be treated for gastric cancer through laparoscopic devices.
89146110|NCT02751086||Open Gastrectomy|Patients who will be treated for gastric cancer with traditional open surgery.
89146111|NCT02705118|Experimental|Automatic registration arm|"Automatic registration for fusion imaging of US and MRI will be performed.~Automatic Imaging fusion of ultrasonography and MRI"
89146112|NCT02705118|Active Comparator|Manual registration arm|"Manual registration for fusion imaging of US and MRI will be performed.~Manual Imaging fusion of ultrasonography and MRI"
89146113|NCT02704962|Experimental|trifluoperazine plus olanzapine|trifluoperazine 5mg/day + olanzapine 5mg/day
89146114|NCT02704962|Active Comparator|full-dose olanzapine|olanzapine 10mg/day
89146115|NCT02750774|Experimental|Low-Glycemic Index Group|Women in the low- glycaemic index group received a dietary intervention based on 3 main meals and 3 snacks, with a precise macronutrient composition, and a physical activity counseling according to the ACOG and ACSM recommendations.
89146116|NCT02750774|Other|Standard Care Group|Women in the Standard Care Group received a simple nutritional booklet regarding lifestyle, which was in agreement with the Italian Guidelines for a healthy diet during pregnancy that included general advice regarding food consumption and physical activity.
89146117|NCT04438226|Experimental|Posterolateral|Patients treated with a hemiarthroplasty using the posterolateral approach
89146118|NCT04438226|Experimental|Direct lateral|Patients treated with a hemiarthroplasty using the direct lateral approach
89146119|NCT02704884|Experimental|probiotic soy milk|consume a diet containing 200 ml/day probiotic soy milk in intervention group
89146120|NCT02704884|Active Comparator|soy milk|200 ml/day soy milk in the control condition
89146121|NCT00631943|Experimental|1|
89146122|NCT05429684|Experimental|A. HER2 low expression|Phenotype was signatured by HER2 low expression.
89146123|NCT05429684|Experimental|B. HER2 amplified|Signatured by wild type HER2 amplified.
89146124|NCT05429684|Experimental|C. HER2 mutation|Signatured by HER2 mutation.
89146125|NCT05429684|Experimental|D. HER2 downstream mutation|Signatured by HER2 downstream mutation of PI3KCA, TP53 or PTEN.
89146126|NCT05429684|Experimental|E. Hormone receptor pathway activation|Signatured by both ER and PR strongly expressed,or CCND1 amplified.
89146127|NCT05429684|Experimental|F. Immune activation|Signatured by high TMB or PD-L1 positively expressed.
89146128|NCT05324592|Experimental|9MW0813|
89146129|NCT05324592|Active Comparator|aflibercept|
89146130|NCT04433858|Experimental|Psilocybin|25mg of Psilocybin
89146131|NCT02701998|Experimental|mHealth-Enhance Physical Activity Intervention|Tech-PAI participants will be given 3 goals: 1) to increase their average baseline daily walking exercise by 30 minutes at week 12; 2) to increase their average baseline daily steps by 4,000 at week 12; and 3) to get up and walk for at least 2 minutes after every 60 minutes of sitting. Participants will receive instruction on how to gradually and safely increase their bout-related walking exercise and steps over the 12 week period. In addition to goal setting, Tech-PAI participants will receive a commercially available activity tracker and accompanying that provides real-time monitoring of steps, activity minutes, and issues a text-based prompt after 60 minutes of sitting to get up and move. Also, participants will receive a weekly e-mail feedback message from research staff on goal progress and will be asked to view weekly Internet-based video lessons that will provide behavioral strategies to increase MPA and steps and decrease SB during the first 6 weeks of the intervention period.
89146132|NCT02701998|Active Comparator|Physical Activity Intervention|PAI participants will be given the same goals as Tech-PAI intervention participants and receive a pedometer and related print materials to assist them in recording and increasing daily steps and bout-related MPA (but no activity tracker, access to video-based skills training lessons, or weekly feedback).
89146133|NCT04191044||NAFLD with mild steatosis and grade <3 fibrosis in patients|NAFLD with mild steatosis and grade <3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index> 2.6) or diabetes mellitus.
89146134|NCT04191044||NAFLD with severe steatosis and grade <3 fibrosis in patients|NAFLD with severe steatosis and grade <3 fibrosis in patients with grade 1 or 2 obesity and insulin resistance (HOMA index> 2.6) or diabetes mellitus.
89146135|NCT04191044||NAFLD with advanced fibrosis|NAFLD with advanced fibrosis (i.e. grade 3 or 4 fibrosis) without previous portal hypertension-related complications
89146136|NCT04191044||Decompensated NAFLD cirrhosis|Decompensated NAFLD cirrhosis (i.e. development of ascites, variceal hemorrhage, and/or hepatic encephalopathy) up to Child B (9 points)
89146137|NCT00615576|Experimental|Subjects receiving SB-656933|Eligible subjects will be randomized to receive once daily doses of 100 milligrams of SB- 656933 for 14 days.
89146138|NCT00615576|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 14 days.
89146139|NCT02750696|Active Comparator|Co/ Ac|Codeine/acetaminophen (30 mg/500 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of codeine/acetaminophen (30 mg/500 mg) every 4 hours for 3 days.
89146140|NCT02750696|Experimental|Tr/ Ac|Tramadol/acetaminophen (37.5 mg/325 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of tramadol/acetaminophen (37.5 mg/325 mg) every 4 hours for 3 days.
88803744|NCT01246063|Experimental|Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)|"Dose Level 1: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (36 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.~Dose Level 1: Carfilzomib IV (1 dose level above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (1 dose level above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (1 dose level above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.~Dose Level 2: Carfilzomib IV (2 dose levels above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (2 dose levels above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (2 dose levels above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib."
88803745|NCT01246063|Experimental|Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)|Dose Level 2: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (45 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
88803746|NCT01246063|Experimental|Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)|Dose Level 3: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (56 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
88803747|NCT01246063|Experimental|Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)|Cohort 0: Carfilzomib IV (56 mg/^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
88803748|NCT01246063|Experimental|Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)|Carfilzomib IV (56 mg/^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
88803749|NCT04330612|No Intervention|Control|In the control pathway, the surgeons communicated with the family only once near the completion of the procedure.
88803750|NCT04330612|Experimental|Intervention|In the intervention group, the families received additional standardized electronic updates via pagers.
88803751|NCT03836014|Experimental|Fixed duration therapy for 24 months.|Daratumumab, Lenalidomide, Dexamethasone
88803752|NCT03836014|Active Comparator|Continuous therapy|Daratumumab, Lenalidomide, Dexamethasone
88803753|NCT04398160|Experimental|HVLA manipulation|"In the intervention of the experimental group, the investigator will be primarily on the right side of the volunteer and identify C3 through the cervical reference of jaw angle, which is at the disc level between C2/C3 and then contact with the phalanges of third metacarpal in the left transverse of this vertebra.~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
88803754|NCT04398160|Sham Comparator|Sham technique|"The investigator will be primarily on the right side of the volunteer and identify the C3 vertebra, having as anatomical reference the angle of the jaw, which is at the disc level between C2/C3 and then contact, with the phalanges of the third metacarpal, the left transverse apophysis of this vertebra.~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
88803755|NCT04398160|No Intervention|No intervention group|The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally.
88803756|NCT04394650|Experimental|CC-98633|Subjects will receive CC-98633 following 3 consecutive doses of lymphodepleting chemotherapy (fludarabine and cyclophosphamide).
88803757|NCT01205503|Other|Cycle 1 Saline; Cycle 2 Mesna|Saline infused over 15 minutes administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
88803758|NCT01205503|Other|Cycle 1 Mesna; Cycle 2 Saline|Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Saline administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
88803759|NCT01158157|Other|Vaccination|This study was a single arm study. All eligible subjects received ACAM2000.
88803760|NCT03187834|Active Comparator|Azithromycin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Azithromycin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm and treated for 5 days.~Children will receive treatment everyday, once a day as is:~Azithromycin: 10 mg/kg once daily on Day 1, then 5 mg/kg once daily Days 2-5"
88803761|NCT03187834|Active Comparator|Amoxicillin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Amoxicillin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, twice a day as is:~Amoxicillin: 25 mg/kg/day, divided into twice daily doses for Days 1-5"
88803762|NCT03187834|Active Comparator|Cotrimoxazole|"Comparison of nasopharyngeal and rectal microbiome in children receiving Cotri-moxazole versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, once a day as is:~Co-trimoxazole: 240 mg daily for Days 1-5"
88803763|NCT03187834|Placebo Comparator|Placebo|"Comparison of nasopharyngeal and rectal microbiome in children receiving placebo versus children receiving antibiotics Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive Placebo everyday, once a day."
88803764|NCT01206595|Active Comparator|SKY0402|Low-dose (175 mg), low-mid dose( 225 mg), and mid-dose (350 mg)
88803765|NCT01206595|Active Comparator|Bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
88803766|NCT04385992|Experimental|All enrolled patients|Enrolled patients following inclusion criteria
88803767|NCT01158703|Active Comparator|clopidogrel|aspirin and clopidogrel
88803768|NCT01158703|Placebo Comparator|sugar pill|aspirin and placebo
88803769|NCT01159015|Experimental|KetoNaph|KetoNaph Ophthalmic Solution
88803770|NCT01159015|Placebo Comparator|Vehicle|Vehicle of KetoNaph Ophthalmic Solution
88803771|NCT03009643|Experimental|iNO Group|Patients are treated with iNO at a concentration of 5-10 ppm for 3-5 days according to the clinical conditions
88803772|NCT03009643|Other|Control|Patients are treated without iNO.
88803773|NCT01207765|Experimental|Zevalin|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging on study day +1. 90Y Zevalin will be administered seven to nine days after 111In Zevalin administration. The dose of 90Y Zevalin will be 0.4 mCi/kg, capped at a maximum dose of 32 mCi.
88803774|NCT03157258|Experimental|Social Network Endorsement|All participants will receive a brief single care-related counseling session and referral to HIV medical care upon enrollment. After randomization to this arm, all members of HIV+ social networks will attend a multi-session group intervention during which they will be trained to deliver messages endorsing compliance with medical guidelines and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained how to deliver effective messages.
88803775|NCT03157258|Active Comparator|HIV Counseling and Referral to Care|All study participants will receive a brief single care-related counseling session and referral to HIV medical care at baseline.
88803776|NCT03778060|Experimental|Transcutaneous stimulation|Participants in the clinical study will consist of subjects with essential tremor who are scheduled more than 3 months in advance to undergo deep brain stimulation surgery for treatment of essential tremor at Mayo Clinic. Subjects will wear a Cala TWO stimulator to reduce hand tremors.
88803777|NCT01249027||Observational|Single arm prospective, observational, single-arm, open-label, multicenter, postapproval registry study using XIENCE V® Everolimus Eluting Coronary Stent System (EECSS).
88803778|NCT02992756|Experimental|Instillation of growth factors|Patients candidates to an IVF/ICSI cycle with low follicular reserve: after at least one cycle of stimulation obtaining 0-3 oocytes.
88803779|NCT01250899|No Intervention|Vitamin D Sufficient|HIV-infected men and women with HIV-1 viral load <200 copies/mL on stable ART and 25(OH)D level ≥30ng/mL receive no intervention.
88803780|NCT01250899|Experimental|Vitamin D Insufficient|HIV-infected men and women with HIV-1 viral load <200 copies /mL on stable ART and 25(OH)D level <30ng/mL receive 50,000 IU twice weekly for 5 weeks followed by 2000 IU daily to complete 12 weeks.
88803781|NCT03716830|Experimental|verum acupuncture + real tDCS|
88803782|NCT03716830|Experimental|sham acupuncture + real tDCS|
88803783|NCT03716830|Experimental|verum acupuncture + sham tDCS|
88803784|NCT03716830|Sham Comparator|sham acupuncture + sham tDCS|
88803785|NCT01212445|Experimental|PEG + E, 13.125 g|Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time
88803786|NCT01212445|Experimental|PEG + E, 26.25 g|Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time
88803787|NCT01212445|Experimental|PEG + E, 39.375 g|Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time
88803788|NCT00002920|Active Comparator|Tamoxifen alone|Tamoxifen alone x 5 years
88803789|NCT00002920|Experimental|Tamoxifen plus MPA|Tamoxifen Plus Medroxyprogesterone Acetate (MPA) x 5 years
88803790|NCT01250977|Placebo Comparator|Placebo|Participants are instructed to take one placebo pill every night before going to bed with a glass of water for 28 days.
88803791|NCT01250977|Experimental|Donepezil|Participants are instructed to take one 5mg pill (donepezil HCL [Aricept®]) every night before going to bed with a glass of water for 28 days.
88803792|NCT01251757|No Intervention|Usual Care (UC)|Participants in this arm received their usual care with no restrictions.
88803793|NCT01251757|Active Comparator|Interactive Voice Recognition (IVR)|automated phone calls
88803794|NCT01251757|Active Comparator|Enhanced IVR (IVR+)|automated phone calls & Educational mailings and follow-up for nonadherence
88803795|NCT01161121|Experimental|Adenosine then Regadenoson|Adenosine infusion will be compared to Regadenoson for efficacy and safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias. Adenosine infusion will be administered at 140 mcg/kg for 2 minutes and once mean coronary flow velocity returns to within 15% of pre-dose value, Regadenoson IV bolus 0.4 mg/5 ml will be administered followed by a 5 cc normal saline flush.
88803796|NCT03010579|Experimental|erythropoietin group|For those lymphoma patients with hemoglobin level less than 100 g/L on day +15 after autologous hematopoietic stem cell transplantation, erythropoietin will be administered. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
88803797|NCT03010579|Active Comparator|iron supplementation|If necessary，oral ferrous succinate, vitamins B12 and folic acid will be administered.
88803798|NCT01214083|Experimental|Arm 1|N-acetylcysteine + high-dose naltrexone (150 mg)
88803799|NCT01214083|Experimental|Arm 2|High-dose naltrexone (150 mg) alone
88803800|NCT01214083|Active Comparator|Arm 3|Low-dose naltrexone (50 mg) alone
88803801|NCT03010813|Experimental|Novel single port robotic system|A single port innovation designed to deliver an articulating 3D high definition camera and three fully articulating instruments through a single 25-mm cannula
88803802|NCT03010735|Active Comparator|Probiotics|The patient take two chewing tablet per day, which contain 4.0E+10 CFU of probiotics.
88803803|NCT03010735|Placebo Comparator|Placebo|The patient take two placebo chewing tablet per day.
88803804|NCT01254877|Placebo Comparator|Placebo Ondansetron - sugar pill|Placebo is an oral preparation made to appear and taste like the active drug preparation.
88803805|NCT01254877|Experimental|low dose ondansetron (0.2 mg bid)|
88803806|NCT01254877|Experimental|moderate dose ondansetron (0.8 mg bid)|
88803807|NCT02189317|Experimental|Exparel|This arm will receive Exparel
88803808|NCT02189317|No Intervention|Control|
88816434|NCT01191476|Active Comparator|Sevoflurane|Subjects received sevoflurane, a inhalational (volatile) anesthetic, which was administered for induction and maintenance of general anesthesia. Inhalational induction was induced via vital capacity induction at 8% and maintained at 0.8-1.5 minimum alveolar concentration (MAC).
88803809|NCT03713944|Experimental|Carboplatin, Pemetrexed, Atezolizumab plus Bevacizumab|"Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles.~Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities."
88803810|NCT01256983|Experimental|Bright Light Therapy|Bright Light Therapy with 10000 lux beginning at day 21 until day 42
88803811|NCT01256983|Other|Wait-list intervention|Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
88803812|NCT01214161|Experimental|lidocaine gel|This group will be those randomized to receiving the intervention with 2% lidocaine gel.
88803813|NCT01214161|Placebo Comparator|placebo gel (surgilube)|This group will be randomized to having the intervention with the placebo surgilube gel.
88803814|NCT02984410|Other|Intensity-Modulated Radiation Therapy (IMRT)|PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.
88803815|NCT02984410|Other|Trans Oral Surgery (TOS)|"The following surgical techniques are allowed:~Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)"
88803816|NCT01257217|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1 or AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT, lens assignment and model determined by preoperative keratometric astigmatism, bilateral implantation
88803817|NCT01257217|Active Comparator|Acri.LISA|Acri.LISA® 366D IOL or Acri.LISA® 466TD Toric IOL, lens assignment determined by preoperative keratometric astigmatism, bilateral implantation
88803818|NCT00383656|Experimental|Pulsatile GnRH|All participants will be administered GnRH intravenously by means of a portable infusion pump that delivers boluses at specific intervals.
88803819|NCT01214317|Active Comparator|mitoxantrone and plasmapheresis|Monthly Plasmapheresis (plasma exchange machine: Haemonetics, model TCS2, USA) 25 ml/kg for 5 cycles, with replacement of 0.9% saline and 5% human serum albumin followed by monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) at the end of each Plasmapheresis course for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
88803820|NCT01214317|No Intervention|mitoxantrone|Monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
88803821|NCT00383734|Experimental|1|newfill
88803822|NCT00383734|Experimental|2|Eutrophill
88803823|NCT02912104|Experimental|hAECs transplantation|To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of POF patients
88803824|NCT02189629|Experimental|CD5789 (trifarotene) cream|
88803825|NCT04330066||Exogenous hormone replacement thaw cycle|Participants in this group will follow Boston IVF's standard exogenous hormone replacement protocol. Participants will take Estrace 3mg twice daily by mouth for endometrial preparation. After 16-18 days of Estrace, endometrial thickness will be measured by transvaginal ultrasound but medication and ultrasounds will be continued until the endometrial lining is ≥ 7 mm. Once the final endometrial lining is ≥ 7 mm (T1), the doctor of record will start the participant the following day with intramuscular progesterone daily or intramuscular progesterone every 3 days with daily vaginal progesterone. Frozen embryo transfers would occur on the sixth day of progesterone.
88803826|NCT04330066||Natural thaw cycle|Participants in this group will follow Boston IVF's standard natural thaw cycle protocol. Participants will be coming for blood and transvaginal ultrasound monitoring around day 11 of the participants cycle. Once the participant has a final measurement of the endometrial lining ≥ 7 mm (T1), a 17mm ovarian follicle, and a progesterone < 1.2 ng/mL, the doctor of record will schedule the patient to receive a trigger injection to induce ovulation followed by an embryo transfer 6-7 days later. Participants may be started on vaginal progesterone 4 days after the trigger injection for added supplementation per the doctor of record.
88803827|NCT01281007|Experimental|Famciclovir 125 mg|1 tablet every 12 hours for 5 days
88803828|NCT01281007|Active Comparator|Aciclovir 200 mg|1 tablet every 4 hours (excluding nocturnal dose) for 5 days
89146141|NCT02704572|Experimental|6months to 2years after shingles|Patients will be vaccinated with Zostavax from 6 months to 2 years after zoster illness.
89146142|NCT02704572|Active Comparator|2years to 5years after shingles|Patients will be vaccinated with Zostavax from 2 years to 5 years after zoster illness.
89146143|NCT04217720|Experimental|SNS-301|SNS-301
89146144|NCT02704650|Experimental|Vaginal fluid of healthy patient|vaginal fluid sample from healthy patients
89146145|NCT02704650|Experimental|Vaginal fluid of ovary cancer patients|vaginal fluid sample from patients with ovary cancer
88803829|NCT02898610|Active Comparator|Colchicine treatment|Colchicine 0.5mg/day plus usual care for 60 months
88803830|NCT02898610|No Intervention|Usual Standard of care alone|Normal standard of care remains for these patients
88803831|NCT01281475|Experimental|Levodopa|Levodopa is prescribed as a combination of levodopa/carbidopa (4:1) to reduce the peripheral side effects. The dosage used was 15 mg/kg/day in 3 divided doses.
88803832|NCT01281475|Placebo Comparator|Placebo|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa, so it is not expected to have any effect.
89146146|NCT02695550|Experimental|CT-707|ALK-positive non-small cell lung cancer resistant to Crizotinib treatment
89146147|NCT00912743|Experimental|1|MSI - H arm
89146148|NCT02695394||MS / CIS|
89146149|NCT02695394||Healthy controls|
89146150|NCT04213872|Experimental|Meditative Movement (MM)|The Meditative Movement (Qigong/Tai Chi Easy) program will be 8 weeks in duration with sessions once a week. Each session is approximately one hour. The PI will lead the MM sessions. The PI and the CRC will maintain contact with the MM group during the 8 weeks by telephone or in person.
89146151|NCT04432610|Experimental|Bisoprolol first, Nebivolol Second|In this arm, patient will first receive bisoprolol, and after 1 week washout period, nebivolol
89146152|NCT04432610|Experimental|Nebivolol first, Bisoprolol second|In this arm, patient will first receive nebivolol, and after 1 week washout period, bisoprolol
89146153|NCT02701686|Experimental|quit immediately (QI)|Subjects in the QI group will receive a smoking cessation booklet plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit now, as quitting can greatly reduce risks, (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention during each telephone follow-up. The whole intervention will be limited to less than 1 min or slightly longer if necessary. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the counsellor will congratulate to the subjects who successfully quit smoking, while deliver the same brief intervention as a booster for those who continue to smoke.
89146154|NCT02701686|Experimental|cut down to quit (CDTQ)|Subjects in the CDTQ group will also receive the smoking cessation booklet plus a brief intervention using the AWARD model. Instead of asking them to quit immediately, they will be advised gradually cutting down on their cigarette consumption. Also, the subjects will be provided with an education card that contains reduction strategies and a suggested plan to reduce smoking. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the nurse counsellor will repeat the warning message that one out of two smokers will be killed by smoking, and remind the subjects of their next reduction target. The counsellor will congratulate subjects who quit or reduce smoking on their success. When subjects fail to quit or reduce their cigarette consumption, the counsellor will reinforce the health hazards of continued smoking and the benefits of quitting, and encourage them to try again immediately or in the near future.
89146155|NCT04643093|Active Comparator|Pitavastatin|Pitavastatin
89146156|NCT04643093|Active Comparator|Ezetimibe|Ezetimibe
89146157|NCT04643093|Experimental|1PC111|1PC111
89146158|NCT02750462|Experimental|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
89146159|NCT02750462|Active Comparator|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
89146160|NCT02701842|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
89146161|NCT02701842|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points.
89146162|NCT05429606||Group 1: Fluoride gel|The fluoride gel used as conductive media for electric pulp tester in this group
89146163|NCT05429606||Group 2:Electrode gel|In Group 2 electrode gel applied as conductive media for electric pulp test.
89146164|NCT05429606||Group 3: chlorohexidine gluconate gel|chlorohexidine gluconate gel used as conductive media for electric pulp tester in group 3.
89146165|NCT05429606||Group 4:Colgate gel toothpaste|Colgate gel toothpaste gel used as conductive media for electric pulp tester in group 4.
89146166|NCT05429606||Group 5:Dentonic Ultrawhitening gel|Dentonic Ultrawhitening gel used as a conductive media in Group 5.
89146167|NCT02701920||NICU infants and hat|Newborn infants of any gestation on the neonatal intensive care unit (NICU).
89146168|NCT02701920||NICU infants and sensor|Newborn infants of any gestation requiring heart rate monitoring on the neonatal intensive care unit.
89146169|NCT02701920||Newborns and surgical delivery|Well term newborn infants following birth by cesarean section.
89146170|NCT02701920||Newborns needing stabilisation|Newborn infants requiring resuscitation or stabilisation following birth.
89146171|NCT02701920||Parental feedback|Parental feedback of babies recruited into HeartLight will be sought.
89146172|NCT02701920||Healthcare provider feedback|Healthcare professionals caring for babies recruited into HeartLight will have their feedback on the device sought.
89146173|NCT04220138|Other|cataract patients with poor red reflex|included cataract patients with poor red reflex
89146174|NCT05324436||Cohort 1|Participants with unresectable advanced/recurrent malignant pleural mesothelioma (MPM)
89146175|NCT04217642||Delay surgery|Patients who have passed more than 48 hours from admission to surgery
89146176|NCT00616824|Active Comparator|Traditional Method|Arm which uses the Serratus Anterior muscle mobilization for lateral coverage of the tissue expander
89146177|NCT00616824|Experimental|Dermamatrix Arm|Arm which uses Dermamatrix as the lateral expander coverage
89146178|NCT02750384|Experimental|50% SDD granules, fasting|50% spray dried dispersion granules, fasting
89146179|NCT02750384|Active Comparator|25% SDD powder for suspension, fasting|25% spray dried dispersion powder for suspension, fasting
89146180|NCT02750384|Experimental|50% SDD granules, fed|50% spray dried dispersion granules, fed
89146181|NCT05324202|Other|Nd:YAG treatment arm|
89146182|NCT00914459|Other|Moroctocog alfa (AF-CC)|Open Label
89146183|NCT02701608|Experimental|Oral switch treatment|Oral switch to the combination of levofloxacin and rifampicin
89146184|NCT02701608|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of staphylococci IE (European guidelines 2015)
89146185|NCT02750150|Experimental|Freezed-dried plasma|transfusion of 4 units of freezed dried plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
89146186|NCT02750150|Active Comparator|Fresh-frozen plasma|transfusion of 4 units of fresh frozen plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
89146187|NCT00635960|Experimental|1|Patients randomly assigned to treatment
89146188|NCT00635960|Placebo Comparator|2|Patients randomly assigned to placebo
89146189|NCT04639895|Experimental|Virtual Reality|Standard treatment protocol and 12 sessions (30 minutes each) of personalized cognitive activities in a virtual city environment (Reh@City).
89146190|NCT04639895|Experimental|Paper and Pencil|Standard treatment protocol and 12 sessions (30 minutes each) of personalized paper-and-pencil cognitive activities,using the Task Generator tool.
89146191|NCT04639895|Active Comparator|Control Group|The standard treatment protocol.
89146192|NCT02701374|Experimental|1:TRK-700|high dose
89146193|NCT02701374|Experimental|2:TRK-700|low dose
89146194|NCT02701374|Placebo Comparator|3:Placebo|Placebo
89146195|NCT05429294|Experimental|Intervention|Pyrotinib combined with trastuzumab and albumin paclitaxel
89146196|NCT04219046|Experimental|Experimental Treatment|ERAS program with administration of experimental treatment: Naloxegol 25mg administrated once daily from surgery for up to 7 days
89146197|NCT04219046|Placebo Comparator|Placebo|ERAS program with administration of placebo: Placebo administrated once daily from surgery for up to 7 days
89146198|NCT00912509|Active Comparator|30 minute light duration|30 minute treatment with UVX light
89146199|NCT00912509|Active Comparator|45 minute light duration|45 minute treatment with UVX light
89146200|NCT04628741|Active Comparator|Dynamic Coaching Model|The Dynamic Coaching Model is an established treatment approach that entails training college students with executive function impairments (e.g., those with a history of traumatic brain injury) to rely on their own executive functions in order to problem solve and reason in real-life situations requiring them to do so (e.g., taking college classes).
89146201|NCT04628741|Experimental|Apprenticeship Approach for College Students|The Apprenticeship Approach is a novel treatment approach that incorporates explicit education about: (a) traumatic brain injury definition; (b) traumatic brain injury symptomatology; and (c) individuals who may be able to provide assistance to the individual with traumatic brain injury into the existing Dynamic Coaching Model.
89146202|NCT02873598|Experimental|FOLFIRINOX or gemcitabine/abraxane followed by SBRT Dose level 1|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane. Dose level 1- 9 Gy x 3 fractions.
89146203|NCT02873598|Experimental|FOLFIRINOX or gemcitabine/abraxane followed by SBRT Dose level 2|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane. Dose level 2 -10 Gy x 3 fractions
89146204|NCT02873598|Experimental|FOLFIRINOX or gemcitabine/abraxane followed by SBRT Dose level 3|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane. Dose level 3 - 11 Gy x 3 fractions.
89146205|NCT02701530|Experimental|Targeted smoking cessation|"Smoking cessation program tailored in cooperation with the target group; smokers with low education.~Peer-based anti-relapse strategy. Recruitment strategy: peer-driven, written invitations and posters."
89146206|NCT02701530|No Intervention|Control|No smoking cessation program.
89146207|NCT04217486|Experimental|A - will be shown their photograph at 2 weeks post-operative.|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
89146208|NCT04217486|Active Comparator|B - will not be shown their photograph|40-50 arms: patients undergoing a unilateral, cementless primary TKA, secondary to osteoarthritis will not be shown a photograph of their knee, photographed in maximum flexion and extension, at 2 weeks postoperatively.
89146209|NCT04241003|Experimental|SmartDrive - baseline and intervention|One arm for all users. Baseline - two weeks data collection documenting usage of wheelchair prior to intervention. Introduction of SmartDrive, a time period to get used to the SmartDrive and then two weeks data collection documenting usage of wheelchair with the intervention.
89146210|NCT02701452|Experimental|COAGO|All patients undergoing antagonist protocol and at high risk of OHSS (estradiol level ≥ 3000 pg/mL and/or more than 20 follicles ≥ 11mm on the day of triggering) were triggered by GnRH agonist.
89146211|NCT02749994|Active Comparator|R5|Rosuvastatin 5mg
89146212|NCT02749994|Active Comparator|R10|Rosuvastatin 10mg
89146213|NCT02749994|Active Comparator|R20|Rosuvastatin 20mg
89146214|NCT02749994|Experimental|R5/E10|Rosuvastatin 5mg/Ezetimibe 10mg
89146215|NCT02749994|Experimental|R10/E10|Rosuvastatin 10mg/Ezetimibe 10mg
89146216|NCT02749994|Experimental|R20/E10|Rosuvastatin 20mg/Ezetimibe 10mg
89146217|NCT04417049|Experimental|Pentoxifylline|
89146218|NCT00615654|Other|2|
89146219|NCT00615732|Experimental|1|qigong
89146220|NCT00615732|Active Comparator|2|exercise therapy
89146221|NCT00615732|No Intervention|3|
89146222|NCT04931576|No Intervention|Routine application of drainage tube|After TOETVA, patients will receive one drainage tube through anterior cervical area.
89146223|NCT04931576|Experimental|Omission of drainage tube|After TOETVA, patients will receive complete omission of drianage tube and directly close the incision.
89146224|NCT05429138||Immunotherapy cohort|Patient that received adjuvant immunotherapy
89146225|NCT05429138||Targeted therapy|Patient that received adjuvant targeted therapy
89146226|NCT05323422||Group 1|COVID-19 positive and pre-induction low-dose intravenous ketamine (0.5 mg/kg) will administering
89146227|NCT05323422||Group 2|COVID-19 positive and without intravenous ketamine (0.5 mg/kg)
89146228|NCT05323422||Group -3|COVID-19 negative and pre-induction low-dose intravenous ketamine (0.5 mg/kg) will administering
89146229|NCT05323422||Group4|COVID-19 negative and without intravenous ketamine (0.5 mg/kg)
89146230|NCT04215198|Experimental|Move3™ (NEM + fish oil)|NEM, 500 mg, #0 capsule, + fish oil, 1,500 mg, softgels, once daily orally for 2 weeks
89146231|NCT04215198|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, + placebo oil, 1,500 mg, softgels, once daily orally for 2 weeks
89146232|NCT02749916||Patients with acute or recent (within 3months) stroke|
89146233|NCT02701140|Active Comparator|Ticagrelor|Ticagrelor will be given in a loading dose of 180 mg followed by a dose of 90 mg twice daily.
89146234|NCT02701140|Active Comparator|Clopidogrel|Clopidogrel will be given in a loading dose of 600 mg followed by a dose of 75 mg once a day.
89146235|NCT04217564|Experimental|Intervention group|The intervention group will receive a counselling session then instructed on the subsequent follow up dates and final assessment by the end of the study.
89146236|NCT04217564|No Intervention|Control group|The control group will not receive nutritional counselling during the study period but will be instructed to attend for final assessment by the end of the study.
89146237|NCT04414280||type 1 diabetes patients using Medtronic MiniMed 670G|Patients with type 1 diabetes, aged 8 years or older, who start with the Medtronic MiniMed 670G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
89146238|NCT04414280||type 1 diabetes patients using Medtronic MiniMed 780G|Patients with type 1 diabetes, aged 8 years or older, who start with the Medtronic MiniMed 780G system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
89146239|NCT04414280||type 1 diabetes patients using Tandem Control-IQ|Patients with type 1 diabetes, aged 6 years or older, who start with the Tandem Control-IQ system (as part of routine clinical practice) in one of the 17 participating centers and who signed informed consent are eligible to participate. The decision about which patient to start, is left to the clinical judgement of the treating health care professional.
89146240|NCT03239418|Experimental|EyeStim Group|Receive an active NMES treatment to the targeted muscles controlling eyelid function.
89146241|NCT03239418|Sham Comparator|Control Group|Undergo all the same procedures as the EyeStim group except receive a sham NMES treatment.
89146242|NCT02701218|Experimental|Single cycle|single cycle of canalith repositioning procedure
89146243|NCT02701218|Experimental|multiple cycles of CRP|multiple cycles of canalith repositioning procedure CRP will be stopped if 1) no nystagmus and vertigo in all positions 2) complications exited 3) stable nystagmus in the 2 last cycles
89146244|NCT00616980|Active Comparator|Low Dose|
89146245|NCT00616980|Active Comparator|High Dose|
89146246|NCT00616980|Placebo Comparator|Saline|
89146247|NCT02700906|Active Comparator|Corticosteroid injection|For corticosteroid injection, triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
89146248|NCT02700906|Active Comparator|Lidocaine injection|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
89146249|NCT02749682||constipation & hernia group|The effect of constipation on study group whether there is a correlation between subgroups of operated patients on the view of direct and indirect hernias(Nyhuss classification).
89146250|NCT02749682||constipation & normal population|The level of constipation on normal population using constipation severity scale.
89146251|NCT02700672||Institutionalized older adults|Observational study
89146252|NCT02700672||Non-institutionalized older adults|Observational study
89146253|NCT02749760|Other|Minor league pitchers|Minor league pitchers from a single professional baseball organization. Strength tests of the elbows will be administered at spring training and end of season for 5 years. If strength correlates to injury, strengthening and exercise programs may be established to target the stabilizers of the elbows.
89146254|NCT04213638|Experimental|Group：1|Intervention: Other：Single Microneedle Radiofrequency therapy
89146255|NCT04213638|Active Comparator|Group：2|Intervention: Other：Photodynamic therapy
89146256|NCT02700750|Other|OCT exam|OCT exam No Arm No Intervention
89146257|NCT00616512|Experimental|1|GF Strong Water Protocol/ water allowed between meals after oral care for selected clients/ Fraser Water Protocol
89146258|NCT04188054|Experimental|Intervention|Will be asked to change the position they lie on their bed when sleeping; that is, to re-position themselves when lying on their back so that their feet (and ankles) hang over the end of the mattress.
89146259|NCT04188054|Placebo Comparator|Control|Will be asked to make no change in the way they normally lie on their mattress when sleeping
89146260|NCT04702100|Experimental|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization+conventional therapy three times per week for four week
89146261|NCT04702100|Experimental|integrated neuromuscular inhibition technique|the patients will receive integrated neuromuscular inhibition technique+ conventional therapy. three times a week for four week
89146262|NCT04702100|Active Comparator|conventional therapy|the patients will receive conventional therapy three times a week for four week
89146263|NCT02700594|Active Comparator|Hip mobilization|Prone posterior-to-anterior Grade IV hip joint mobilization: The subject will be placed in prone on a treatment table. The intervening physical therapist will place the heel of his hand on the greater trochanter of the femur on the involved side provide rhythmic anterior-directed force. The subject will receive 3 bouts of 30 seconds of continuous mobilizations with 10 seconds rest in between bouts. For the prone posterior-to-anterior Grade IV hip joint mobilization, the intervening therapist will perform all 3 bouts in the same position.
89146264|NCT02700594|Active Comparator|Spine mobilization|Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization: The subject will be placed in prone on the treatment table. The intervening physical therapist will place his thumbs on the transverse process, on the affected side, of the L3, L4 or L5 vertebrae and provide a rhythmic anterior-directed force. Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization, the intervening therapist will perform 1 bout on each of L3, L4 and L5 for a total of 3 bouts
89146265|NCT05428748|Experimental|1S|Participants will consume 1 serving/day of the test product for 28 days.
89146266|NCT05428748|Experimental|2S|Participants will consume 2 servings/day of the test product for 28 days
89146267|NCT05428748|Experimental|3S|Participants will consume 3 servings/day of the test product for 28 days
89146268|NCT05428748|Placebo Comparator|Placebo|Participants will consume 1 serving/day of the placebo for 28 days
89146269|NCT04213716|Experimental|intracanal medication|After instrumentation of the canals and drying , using Lentulo Spiral Filler medicaments will be placed under aseptic conditions into the canals experimental Intracanal medication of 1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
89146270|NCT04213716|Active Comparator|intracanal medicament|After instrumentation of the canals and drying , using Lentulo Spiral Filler comparator intracanal medicaments will be placed under aseptic conditions into the canals which is 100 mg Ca (OH) 2 mixed with 1ml sterile water
89146271|NCT04218890||SLE patients without lupus nephritis|"40 SLE patients~40SLE patients( All SLE pt. satisfied the ACR criteria for SLE diagnosis) these patients will be without any evidences of nephritis"
89146272|NCT04218890||SLE patients with lupus nephritis|40SLE patients with evidences of nephritis
89146273|NCT04218890||healthy control group|20 healthy subjects matched age and sex with be enrolled as healthy control group
89146274|NCT02774538|Other|Experimental arm|
89146275|NCT00636116|Experimental|Group 1|Anavip with Anavip Maintenance Therapy
89146276|NCT00636116|Experimental|Group 2|Anavip with Placebo Maintenance Therapy
89146277|NCT00636116|Active Comparator|Group 3|CroFab with CroFab Maintenance Therapy
89146278|NCT02749448|Other|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
89146279|NCT04215510|Experimental|endonasal endoscopic surgery group|143 participants in group 1 will undergo endoscopic surgery
89146280|NCT04215510|Active Comparator|radiation therapy group|143 participants in group 2 will undergo radiation therapy(IMRT)
89146281|NCT02749604|Active Comparator|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
89146282|NCT02749604|Experimental|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
89146283|NCT02700516||Recurrent GN|Renal transplant recipients with biopsy-confirmed recurrent primary glomerulonephritis.
89146284|NCT02700516||Non-recurrent GN|Renal transplant recipients with non-recurrent primary glomerulonephritis.
89146285|NCT02700516||Non-GN|Renal transplant recipients with etiologies other than primary glomerulonephritis.
89146286|NCT05428670|Experimental|Zanubrutinib+Rituximab+Lenalidomide|"The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 2-21;~Lenalidomide, 10-20 mg qd, po, day 2-14;~Rituximab, 375 mg/m², ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 10-20 mg qd po during 1-21 days in every 28 days, for a maximum of 2 years."
89146287|NCT05428670|Active Comparator|RCHOP/RCDOP|"The RCHOP/RCDOP regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Rituximab, 375 mg/m², ivgtt, day 1;~Cyclophosphamide, 500-750 mg/m², ivgtt, day 2;~Doxorubicin, 50 mg/m², ivgtt day 2 (liposomal doxorubicin, 20-30 mg/m², ivgtt day 2 or Epirubicin, 50-60 mg/m², ivgtt day 2);~Vincristine, 1.4 mg/m², iv day 2 or vindesine, 3mg/m², iv day 2;~Prednisone, 100 mg qd, po day 2-6."
89146288|NCT02700282|Experimental|Cystic Fibrosis children|"Children with Cystic Fibrosis will experience lung function measurement while backpack carrying.~Aerobic Capacities will also be assessed during treadmill gait."
89146289|NCT02700282|Active Comparator|Healthy Children|"Healthy Children will experience lung function measurement while backpack carrying.~Aerobic Capacities will also be assessed during treadmill gait."
89146290|NCT00635726|Experimental|1|MVAC -> GEM+CDDP
89146291|NCT02700204|Experimental|PicoWay 532nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 532nm hand-piece
89146292|NCT02700204|Experimental|PicoWay 1064nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 1064nm hand-piece
89146293|NCT04216940|Experimental|M-pro|
89146294|NCT04216940|Experimental|Hyflex|
89146295|NCT03045120||dasatinib cohort|Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
89146296|NCT03045120||imatinib cohort|Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
89146297|NCT03045120||nilotinib cohort|Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
89146298|NCT03045120||bosutinib cohort|Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
89146299|NCT05322798|Experimental|HF-SCS|SCS system implantation with high-frequency stimulation availability
89146300|NCT05322798|Active Comparator|LF-SCS|Conventional SCS system implantation
89146301|NCT05428514|Experimental|Maternity Home Bed|Receives a bed in the maternity home, wrap-around services, etc.
89146302|NCT05428514|No Intervention|Control|Referred to other services available in the community
89146303|NCT04142268||Preeclampsia group|PE was defined as diastolic BP of at least 110 mmHg on one occasion or diastolic BP of at least 90 mmHg on two consecutive occasions more than 4 hours apart, in combination with proteinuria (≥300 mg total protein in a 24-hour urine collection and, if this was not available, ≥+2 proteinuria by dipstick analysis on two consecutive occasions at least 4 hours apart) that develops after 20 weeks of gestation in previously normotensive women
89146304|NCT04142268||Control group|Normal pregnancy group
89146305|NCT04219982|Experimental|DPI-386 Nasal Gel|Active DPI-386 Nasal Gel
89146306|NCT04219982|Placebo Comparator|DPI-386 Placebo Nasal Gel|Placebo Nasal Gel
89146307|NCT04219982|Active Comparator|Transderm Scop® (TDS)|FDA approved Transderm Scop® (TDS).
89146308|NCT02700438|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
89146309|NCT02700438|Experimental|Urgent PC Neuromodulation System®|The Urgent PC Neuromodulation System® (Uroplasty, Minnetonka, MN, USA) was used for percutaneous posterior tibial nerve stimulation. Subjects underwent one 30-min session 2 days per week for 8 consecutive weeks in an outpatient clinic. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion. PPTNS was undertaken at the highest amplification (0-20 mA) at a frequency of 20 Hz, causing neither a motor response nor pain.
89146310|NCT04216706||Tailored treatment advise in suboptimal adaptation|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment are invited to participate in a follow-up program at four time-points during a subsequent pregnancy (i.e. at 12, 16, 20 and 30 weeks of gestational age). This program is additive to regular pregnancy check-ups, and all women are otherwise managed by their referring physicians. The aim of this program is to evaluate adaptation of maternal hemodynamic parameters in response to pregnancy, and to adjust deviant adaptation with tailored antihypertensive medication. Participation in this program is on voluntary basis, and not restricted to severity of complications in the first pregnancy.
89146311|NCT04216706||Care as usual during pregnancy|High-risk women admitted to a non-pregnant cardiovascular and cardiometabolic risk factor assessment who do not participate in the additional follow-up program.
89146312|NCT00617136|Experimental|III|Prewarming by HotDog
89146313|NCT00617136|Active Comparator|I|Intraoperative warming by Bair Hugger
89146314|NCT00617136|Active Comparator|II|Intraoperative warming by HotDog
89146315|NCT00913835|Experimental|Olaratumab and Liposomal Doxorubicin|Olaratumab and Liposomal Doxorubicin
89146316|NCT00913835|Active Comparator|Liposomal Doxorubicin: Optional Olaratumab Monotherapy|Liposomal Doxorubicin Monotherapy until disease progression. Upon disease progression the participant had the option to receive Olaratumab monotherapy.
89146317|NCT02700360|Experimental|Part 1(1,000mg dose): group 1|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; cross-over period: 7 days
89146318|NCT02700360|Experimental|Part 1(1,000mg dose): group 2|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; cross-over period: 7 days
89146319|NCT02700360|Experimental|Part 2(500mg dose): group 3|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; cross-over period: 7 days
89146320|NCT02700360|Experimental|Part 2(500mg dose): group 4|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
89146321|NCT02700360|Experimental|Part 2(2,000mg dose): group 5|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, after high-fat diet intake; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; cross-over period: 7 days
89146322|NCT02700360|Experimental|Part 2(2,000mg dose): group 6|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
89146323|NCT05322720|Active Comparator|EOC202 30 mg+ albumin-bound paclitaxel (100 mg/m2);|One cycle of therapy is 4 weeks (28 days), the subjects in the experimental group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on Day 1 (D1), D8 and D15 of each cycle, and EOC202 30 mg subcutaneously on D2 and D16 of each cycle; the subjects in the control group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on D1, D8 and D15 of each cycle. The treatment will continue until progression of disease, death, intolerable toxicity, start of other antitumor therapy, withdrawal of informed consent, loss of follow-up or termination of study for other reasons, whichever comes first.
89146324|NCT05322720|Active Comparator|albumin-bound paclitaxel (100 mg/m2).|One cycle of therapy is 4 weeks (28 days), the subjects in the experimental group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on Day 1 (D1), D8 and D15 of each cycle, and EOC202 30 mg subcutaneously on D2 and D16 of each cycle; the subjects in the control group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on D1, D8 and D15 of each cycle. The treatment will continue until progression of disease, death, intolerable toxicity, start of other antitumor therapy, withdrawal of informed consent, loss of follow-up or termination of study for other reasons, whichever comes first.
89146325|NCT05428280|Experimental|Muscle Energy Techniques|"Following physiotherapy will be given to the participants in this group for 4 weeks, 3 times a week:~1. Muscle Energy Technique"
89146326|NCT05428280|Active Comparator|Myofascial Mobilization Techniques|"Following physiotherapy will be given to the participants in this group for 4 weeks, 3 times a week:~1. Myofascial Mobilization"
89146327|NCT04213170|Experimental|Sintilimab and Bevacizumab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 every 21 days
89146328|NCT02749214||Parkinson's Disease (PD)|Participant's with Parkinson's Disease will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
89146329|NCT02749214||Healthy Control|Age and gender-matched healthy controls will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
89146330|NCT04866329||In Vitro Fertilisation protocol|Women followed in the department for an in vitro fertilisation protocol
89146331|NCT05322564|No Intervention|Standard of care cohort|Eligible wrist and ankle fracture patients booked for open reduction and internal fixation through our emergency day surgery program will be recruited and consented via telephone prior to their surgery date. The study participants will receive a post-operative prescription at the discretion of their attending surgeon, fellow or resident, with no intervention from the researchers involved in this study. On post-operative day three and post-operative day ten, these patients will be contacted by phone by the research team and asked to respond verbally to a questionnaire. Measures including quantity of opiates consumed, pain intensity and satisfaction with pain treatment will be recorded.
89146332|NCT05322564|Experimental|Standardized prescription cohort|Using the data collected from the standard of care cohort, a standardized pain prescription will be created. The average quantity of opiates consumed by the standard of care participants will be used to guide the quantity of opiates to be prescribed on the standardized prescription. In this arm, all eligible patients will be contacted and recruited by telephone prior to their surgery. These patients will be flagged on the day of surgery and given the standardized prescription post-operatively. They will then be asked to respond to the same questionnaires as the standard of care cohort via telephone on post-op day three and post-op day ten.
89146333|NCT02748980||Non- obstructive coronary artery disease, non- diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed without diabetes.
89146334|NCT02748980||Non- obstructive coronary artery disease, diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed with type 2 diabetes.
89146335|NCT05251649|Experimental|tACS combined with 40 Hz sound stimulation group|15 daily (Monday-Friday) 20min sessions of tACS combined with 40 Hz sound stimulation
89146336|NCT05251649|Experimental|tACS group|15 daily (Monday-Friday) 20min sessions of tACS stimulation
89146337|NCT05251649|Experimental|40 Hz sound stimulation group|15 daily (Monday-Friday) 20min sessions of 40 Hz sound stimulation
89146338|NCT02749136|Experimental|Perioperative chemotherapy|"Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~Postoperative gemcitabine, every 4 weeks, 3-6 cycles"
89146339|NCT00631631||Mifamurtide (L-MTP-PE)|Mifamurtide (L-MTP-PE), intravenous, at a dose of 2 mg/m^2 twice weekly (at least 3 days apart) for 12 weeks, and then weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
89146340|NCT04141800||Heart failure (HF) outpatients with reduced ejection fraction|"Heart Failure (HF) with reduced ejection fraction (REF): Patients with confirmed diagnosis of HF and with ejection fraction<40%.~Hyperkalaemia: K+values> 5,4 mEq/L.~Optimal doses: the maximum doses of renin-angiotensin-aldosterone related drugs that, according to the physician's judgement, the patient can receive. If any of these drugs (ACIEs, ARB-II, MRAs or sacubitril-valsartan) is de novointroducedat the initial visit, optimal doses will be not considered established.~A previous personal history of diseases and/or outcomes will be registered according to the usual practice of every centre."
89146341|NCT04219592||SSc|74 SSc patients aged 18 - 85
89146342|NCT04219592||Healthy controls|80 Healthy blood-donors aged 18 - 85
89146343|NCT04720469|Experimental|Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy|Patients with bilateral essential tremor who have undergone one MRgFUS thalamotomy
89146344|NCT02748746|Experimental|Surgery no Lymphedema|The inclusion criteria for involving the first group is surgery time. No one will be involved into the first group if surgery was applied 18 months ago before enrollment to this study. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum. Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
89146345|NCT02748746|Experimental|Surgery having Lymphedema|The second group will contain patients who had breast cancer surgery and having upper extremity lymphedema.Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
89146346|NCT02748746|Active Comparator|Healthy Women|The third group will contain healthy women. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
89146347|NCT04238429|Experimental|Toothpaste containing effective ingredients|Use the toothpaste containing 10% high cleaning silica base,0.5% sodium phytate and 0.5% sodium pyrophosphate to brush teeth twice daily for 8 weeks
89146348|NCT04238429|Placebo Comparator|Negative control toothpaste|Use the negative control dentifrice to brush teeth twice daily for 8 weeks
89146349|NCT04216862|Experimental|Strengthening exercise treatment|This exercise targets the deep flexor muscles of the upper cervical region the longus capitis and longus colli muscles.
89146350|NCT04216862|Active Comparator|Stretching exercise treatment|The subject's forearm is stabilized by a vertical plane before the trunk is rotated in the opposite direction. Therefore the arm on the involved side is externally rotated and abducted to 90.
89146351|NCT02748902|Experimental|ingenol mebutate 0.05% gel|Single group, open label. All subjects will receive active product.
89146352|NCT02691858|Experimental|Hydrocortisone|Hydrocortisone IV 10 mg/kg with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
89146353|NCT02691858|Placebo Comparator|Saline|Saline IV 100 ml with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
89146354|NCT04218500|Active Comparator|Niacinamide 4%|Niacinamide 4%, applied twice daily for 28 days
89146355|NCT04218500|Active Comparator|Virgin coconut oil 30%|Virgin coconut oil 30%, applied twice daily for 28 days
89146356|NCT04077671|Experimental|SAD - Cohort A - CHF6467 0.3 µg/mm2|Cohort A: will be administered with CHF6467 0.3 µg/mm2 ulcer area as single dose.
89146357|NCT04077671|Experimental|SAD - Cohort B - CHF6467 1 µg/mm2|Cohort B: will be administered with 1 µg/mm2 ulcer area as single dose.
89146358|NCT04077671|Experimental|SAD - Cohort C - CHF6467 3 µg/mm2|Cohort C: will be administered with 3 µg/mm2 ulcer area as single dose.
89146359|NCT04077671|Experimental|SAD - Cohort D - CHF6467 6 µg/mm2|Cohort D: will be administered with 6 µg/mm2 ulcer area as single dose.
89146360|NCT04077671|Experimental|MAD - Cohort E - CHF6467 0.3 or 1 µg/mm2|Cohort E: will be administered with 0.3 or 1 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
89146361|NCT04077671|Experimental|MAD - Cohort F - CHF6467 1 or 3 µg/mm2|Cohort F: will be administered with 1 or 3 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
89146362|NCT04598633|Active Comparator|Lactobacillus reuteri Prodentis®-lozenges|
89146363|NCT04598633|Placebo Comparator|Placebo-lozenges (BioGaia)|
89290621|NCT03924024|Experimental|Accelerated intermittent theta burst treatment|All participants will receive accelerated intermittent theta-burst stimulation.
89146364|NCT05412056|Active Comparator|Metformin|Metformin will be prescribed before 20 weeks to 33+6 weeks, started at a daily dose of 500mg in the first week, and the daily dose is increased by 500mg per week to a maximum of 2000mg in week 4 (1000mg twice per day). Women will be asked to take the maximum tolerated dose if they experience side effects from the medication.
88803833|NCT01587092|Placebo Comparator|Usual Working Condition Group|Participants assigned to the usual working condition control group will continue to work in their usual environment and accustomed manner. The control group participants will have access to the Workstations at the completion of study.
88803834|NCT01587092|Active Comparator|WorkStation Intervention Group|Participants will be asked to walk for up to 1.5 hours per day on the treadmill. This will be split into two 45 minute sessions per day. Behavioral support will focus on adherence to frequency (attending scheduled sessions). Participants self-select speed of walking and time (they have up to 45 minutes allotted, but may choose less as they like).
89146365|NCT05412056|Placebo Comparator|Placebo|Placebo will be prescribed before 20 weeks to 33+6 weeks, started at a daily dose of 1 tablet in the first week, and the daily dose is increased by 1 tablet per week to a maximum of 4 tablets in week 4 (2 tablets twice per day). Women will be asked to take the maximum tolerated dose if they experience side effects from the medication.
89146366|NCT00617214||All|Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program
89146367|NCT04453046|Experimental|Hemopurifier and Pembrolizumab|In this clinical trial, the exosome-depleting device, the Hemopurifier, will be combined with standard of care therapy, Pembrolizumab. The purpose of the combination is to more effectively reduce immune suppression and provide a combined benefit of immune restoration for patients with recurrent/metastatic HNSCC. Therapy with the Hemopurifier will be initiated on the same day as and prior to Pembrolizumab infusion. The Hemopurifier treatment will be 4h. The subject treated with the Hemopurifier will remain in the Hemopurifier treatment area for the duration of the treatment. Pembrolizumab infusion will take place shortly after Hemopurifier treatment and may take place through the next day if needed.
89146368|NCT02748590|Experimental|Neuromodulation|
89146369|NCT00913523|Experimental|Tampon with GML|Regular and Super Tampon with GML added to the cover
89146370|NCT00913523|Sham Comparator|Tampon without GML|Regular and Super Tampon without GML
89146371|NCT00913523|Sham Comparator|Tampon Normally Used|Type and Size of Tampon Normally Used by Subjects
89146372|NCT04213482||oncology patients|For this study, panoramic images were taken from pediatric patients who received radiotherapy and/or chemotherapy because of any oncologic disease.
89146373|NCT04213482||healthy|panoramic images of patients(pediatric) who have no systemic disease were collected from the archive of dental radiology clinic of the university hospital.
89146374|NCT02700126||undergoing propofol based TIVA for clip|This study is an observational study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm. We will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
89146375|NCT04217096|Experimental|paclitaxel liposome + S-1|paclitaxel liposome at 175 mg/m^2 on day 1; S-1 at a dose according to the body surface area（<1.25m^2，40mg Bid；1.25~1.5m^2,50mg Bid；>1.50m^2,60mg Bid，d1-14，q3w）
89146376|NCT02699814|Experimental|H3 Parent/Child Dyads|A child is eligible for the H3 partnered evaluation if he or she is: 1) between the ages of 0.0-16.99 years; 2) speaks Spanish or English; 3) screens positive for a developmental delay or mental health problem. For children in the intervention groups, the additional eligibility criteria are: 1) referral to the H3 care program by a pediatrician based on clinical judgment; and 2) no prior history of receiving any H3 services in the past year.
89146377|NCT05411978|Placebo Comparator|Idebenone 30 mg+ Placebo 60 mg|Idebenone 30 mg+ placebo 60 mg TID Oral ,for 12 weeks
89146378|NCT05411978|Experimental|Idebenone 90 mg|Idebenone 90 mg TID Oral ,for 12 weeks
89146379|NCT05411978|Placebo Comparator|Placebo 90 mg|Placebo 90 mg TID Oral,for 12 weeks
89146380|NCT00617292||Category 1, Group 1|Children who have 21OHD and received prenatal dexamethasone treatment
89146381|NCT00617292||Category 1, Group 2|Children who have 21OHD and did not receive prenatal dexamethasone treatment (control)
89146382|NCT00617292||Category 2|Mothers of children who received prenatal dexamethasone treatment
89146383|NCT04219748|Experimental|Intervention|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team during 2 months. They will attend weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes and will be conducted based on Motivational Interviewing techniques in order to explore values and needs and to enhance motivation to reduce alcohol use and self-efficacy.~Receiving the CM intervention doesn't exclude treatment as usual."
89146384|NCT04219748|No Intervention|Control|Only treatment as usual in the Emergency Department (and in the Health and Social Services Network).
89146385|NCT00631709|Experimental|1|Pacemaker Patients
89146386|NCT03955367|Active Comparator|Pelvic Irradiation|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, and pelvic lymph nodes regions. The upper border of CTV is at the level of aortic bifurcation. A dose of 45-50.4Gy is delivered to CTV with IMRT.
88803835|NCT01282723||Pregnant, In Labor|
89146387|NCT03955367|Experimental|Prophylactic EFI|Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, pelvic lymph nodes regions and para-aortic lymph nodes region. The upper border of CTV is at the level of renal vessels. A dose of 45-50.4Gy is delivered to CTV with IMRT.
89146388|NCT02748044|Experimental|Eligible patients for CC-Cruiser test|
89146389|NCT02748122|Experimental|Adolescents with T2DM|
89146390|NCT04513223|Experimental|SHR-A1811|
89146391|NCT00617370|Experimental|1|The regimen consists of EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 with pegfilgrastim subcutaneously (SQ) on day # 2, followed by paclitaxel (175 mg/m2) q 14 days x 6 with pegfilgrastim SQ on day # 2.
89146392|NCT02699658|Experimental|levofloxacin in healthy|
89290622|NCT01228578|Experimental|Multivitamins (B,C,E)|
88803836|NCT01572662|Experimental|Fludarabine + Busulfan|"Fludarabine administered by vein at dose of 40 mg/m2 in 100 ml of normal saline (NS) on Days -6 through -3.~First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies."
89146393|NCT00912197|Experimental|Oligofructose|Participants received 10g of Oligofructose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals.The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
89146394|NCT00912197|Placebo Comparator|Cellulose and maltodextrin|Participants received 10g of Cellulose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals. Maltodextrin was added to the cellulose supplement. The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
89146395|NCT04131920||Phase 1 and 2|10 male patients with severe Hemophilia A from the Washington Center for Bleeding Disorders
89146396|NCT04131920||Phase 3|20 subjects who are also participating in the EmiMSKUS study
89146397|NCT02699736||Cohort I|Enrolled from August 1994. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146398|NCT02699736||Cohort II|Enrolled from January 1996. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146399|NCT02699736||Cohort III|Enrolled from February 1997. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146400|NCT02699736||Cohort IV|Enrolled from March 1999. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). The eligibility criteria of a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion has been removed for patients joining the study in 1999 and beyond, since the intention of the study is to include most patients eligible for antiretroviral therapy. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146401|NCT02699736||Cohort V|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146402|NCT02699736||Cohort VI|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146403|NCT02699736||Cohort VII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146404|NCT02699736||Cohort VIII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146405|NCT02699736||Cohort IX|Enrolled from December 2011. Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89290623|NCT01228578|Placebo Comparator|Placebo|
88816435|NCT01191476|Active Comparator|Propofol|Subjects received propofol, an intravenous (IV) anesthetic, which was administered for induction and maintenance of general anesthesia.
89146406|NCT02699736||Cohort X|All patients should be consecutive patients (except those already enrolled in EuroSIDA), or patients who had a scheduled visit (i.e. those who made an appointment >2 weeks prior to their visit) in the outpatient clinic regardless of cluster of differentiation 4 (CD4) cell count and ART status). Enroll patients of 16 years or older and positive for antibodies against hepatitis C virus (regardless of HCV-RNA status, fibrosis stage and prior treatment against hepatitis C). For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
89146407|NCT02699736||Cohort XI|"HIV-1 positive persons ≥18 years of age, not already enrolled in EuroSIDA, are eligible for inclusion. Participants should be enrolled consecutively in one of the following two groups:~Participants who have started integrase inhibitor (INSTI) based antiretroviral therapy (ART) after 1/1/2012 and have a CD4 cell count and HIV-RNA available in the 12 months prior to starting INSTI or within 3 months after starting INSTI~If participants have not started INSTI, they should be included providing they have a CD4/HIV-RNA in the 12 months prior to baseline or within 3 months after baseline.~For all patients enrolled and under follow up, laboratory, therapeutic, clinical and demographic data, date on pregnancy and data on hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually."
89146408|NCT04218578||Device group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with MitraClip
89146409|NCT04218578||Control group|patients with heart failure and concomitant severe functional mitral regurgitation that were treated with optimal medical treatment
89146410|NCT04500353|Active Comparator|Routine face mask application|Routine application of a face mask shortly after birth to deliver continuous positive airway pressure (CPAP)
89146411|NCT04500353|Experimental|Selective face mask application|Selective application of a face mask to give positive pressure ventilation (PPV) for apnoea or bradycardia [heart rate (HR) < 100 beats per minute (bpm)] at any time in the delivery room (DR); or to give CPAP for signs of respiratory distress after 5 minutes of life
89146412|NCT04218734|Experimental|metformin hydrochloride+DBPR108|metformin hydrochloride 500 mg+DBPR108 100 mg
89146413|NCT04218734|Placebo Comparator|metformin hydrochloride+placepo|metformin hydrochloride 500 mg+placebo 100 mg
89146414|NCT03499691|Experimental|Expanded Hemodialysis (HDx) Therapy|Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
89146415|NCT03499691|Active Comparator|Hemodiafiltration (HDF) Therapy|Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
89146416|NCT04066478|Experimental|Teatment|75mg Dehydroepiandrosterone once daily for minimum ten weeks prior to starting ovarian stimulation
88803837|NCT04781582|Active Comparator|Lung volume reduction surgery arm|Bilateral videothoracoscopic lung volume reduction surgery by wedge resection. Unilateral procedures are possible in case of severe adhesions or intraoperative instability. In these cases a staged approach with contralateral LVRS within 3 months is possible.
88803838|NCT04781582|Active Comparator|Bronchoscopic lung volume reduction arm|Primarily unilateral bronchoscopic lung volume reduction by endobronchial valves. If a bilateral procedure is feasible it must be performed within 3 months after the first intervention.
89146417|NCT04066478|Placebo Comparator|Comaprator|75mg placebo once daily for minimum ten weeks prior to starting ovarian stimulation
89146418|NCT04185272|Experimental|non-metastatic colon cancer|
89146419|NCT04185272|Experimental|metastatic colon cancer|
89146420|NCT05227235|Experimental|3D Telemedicine|3D Telemedicine system allowing patient to be seen in 3 dimensions
88803839|NCT01258153|Experimental|Nepadutant Low Dose|
88803840|NCT01258153|Experimental|Nepadutant High Dose|
89146421|NCT05227235|Active Comparator|2D Telemedicine|2D Telemedicine system allowing patient to be seen in standard video call
89146422|NCT04218344||Acute Coronary Syndrome - Iscaemia|Patients who present with chest pain, undergo emergency angiogram and receive a cardiac stent.
88803841|NCT01258153|Placebo Comparator|Placebo|
88803842|NCT01555268|Experimental|Arm A (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22.
89146423|NCT04218344||Acute Coronary Syndrome - Non-Ischaemic|Patients who present with chest pain but angiography reveals normal coronary arteries.
89146424|NCT04032626|Experimental|Lenalidomide|Lenalidomide 10 mg/day taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
88803843|NCT01555268|Experimental|Arm B (trebananib, cytarabine)|Patients receive trebananib as in Arm A. Patients also receive cytarabine SC BID on days 1-14 of course 1 and days 1-7 of subsequent courses.
88803844|NCT00002938|Other|Surgery|Salvage prostatectomy
88803845|NCT04781270|Experimental|mFOLFOXIRI+Bev|"Patients will receive mFOLFOXIRI plus bevacizumab once every two weeks as the first-line treatment.~Drug: mFOLFOXIRI plus Bevacizumab Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles."
89146425|NCT04032626|Placebo Comparator|Placebo|Placebo taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
89146426|NCT03904472|Experimental|Web-based CBTI|Participants will have 8 weeks to receive 6 therapy sessions. Content is dynamically driven by an animated therapist who guides the user through the program.
89146427|NCT04213950|Experimental|Post-implementation group|The post-implementation group will receive care that is enhanced by the rabies PEP quality improvement bundle.
89146428|NCT04213950|No Intervention|Historical control group|The historical control group received care prior to implementation of the quality improvement bundle.
89146429|NCT05225987|Experimental|Experimantal Group|Postpartum Nurse Navigation Program based care
88803846|NCT04781270|Active Comparator|mFOLFOX6+Bev|"Patients will receive mFOLFOX6 plus bevacizumab once every two weeks as the first-line treatment.~Drug: mFOLFOX6 Plus Bevacizumab mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1). A local MDT will assess the efficiency every 4 cycles of the treatment. The maximum period of conversion therapy is 12 cycles."
89146430|NCT05225987|No Intervention|Control group|This group will take routin care
89146431|NCT04160351|Experimental|MCO Dialyser|12 treatments (4 weeks) with Medium Cut-Off Dialyzer
89146432|NCT04160351|Active Comparator|High Flux Dialyser|12 treatments (4 weeks) with High Flux Dialyzer
89146433|NCT04214106||Thiamine group|group 1: ICU patients who did not receive IV thiamine
89146434|NCT04214106||Non-thiamine group|group 2: ICU patients who received IV thiamine,100-500 mg/day for at least one day
89146435|NCT02747732|Experimental|one arm|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
89146436|NCT02747810|Experimental|New TENS design|To determine the function and safety of the strap design by evaluating the electrical connection to electrode, 2) the security in the insole and the electronic unit, and 3) facilitating observation and hand access to the top panel for adjusting the stimulation strength. 4) to elicit toe twitching with stimulation of tribal nerve
89146437|NCT03934619|Experimental|Intervention|Convenient cohort, non-randomized group will be enrolled to examine the effects of the Dolores One on improving the ease of communication and intelligibility
89146438|NCT02747654|No Intervention|standard dosing|a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight
89146439|NCT02747654|Experimental|Genotype-guided dosing|INH dose determined based on developed model
89146440|NCT02695862|Experimental|Bolus Terlipressin|Injection terlipressin after 2 mg bolus it will be given 2 mg QID
89146441|NCT02695862|Active Comparator|Terlipressin continuous(4mg/24hours)|Injection terlipressin after 2 mg bolus it will be given 4 mg over 24 hours,and dose will be titrated as per HVPG (Hepatic Venous Pressure Gradient)
89146442|NCT02695472|Placebo Comparator|Placebo Arm|One Placebo tablet, twice daily
89146443|NCT02695472|Experimental|40 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet and 1 placebo tablet per day
89146444|NCT02695472|Experimental|80 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet twice per day
89146445|NCT00617448|Active Comparator|I|conventional diathermy haemorrhoidectomy under spinal anaesthesia
89146446|NCT00617448|Active Comparator|II|conventional diathermy haemorrhoidectomy with local anaesthesia combined with intravenous sedation (group II)
89146447|NCT00617448|Active Comparator|III|Ligasure haemorrhoidectomy under spinal anesthesia
89146448|NCT00617448|Active Comparator|IV|Ligasure haemorrhoidectomy under local anesthesia
89146449|NCT04308863|Experimental|Chitosan scaffold/ MTA pulp dressing material|
89146450|NCT04308863|Active Comparator|MTA pulp dressing material|
88803847|NCT02745028|Other|With monosodium glutamate|Results of one time gastric emptying study with a single dose of monosodium glutamate; 1 g for weight greater than 45 kg, 700mg between 35 and 44,900 kg, 600mg between 25 and 34,900, 500mg between 15 and 25 kg and 250mg in less than 15 kg
88803848|NCT04348370|Experimental|BCG Group|FDA-approved BCG Tice strain, procured from Merck, will be used. The vaccine will be reconstituted according to the package insert. In brief, a vial containing ~1x10^8 CFU of lyophilized BCG will be reconstituted in 50 mL of saline. A single dose will consist of 0.1 mL (~2x10^5 CFU) will be administered by slow intradermal injection using a 25 gauge/ 0.5 mm syringe in the deltoid area.
88803849|NCT04348370|Placebo Comparator|Placebo Group|A single dose will consist of 0.1 mL saline
89146451|NCT04166162|Experimental|Focus Group|The Focus Group consists of the participating parents who are BTC employees with child/children in the range of 8 to 16 years old. The Focus Group will receive a total of 6 weekly sessions of the TBD Intervention.
89146452|NCT04166162|Experimental|Social Development Strategy (SDS) Group|All participating BTC workers will be receiving SDS intervention for a minimum of 1 session.
89146453|NCT04166162|Experimental|Brief Intervention Motivational Interviewing (BIMI) Group|Participating 11 to 16 year old children of BTC employees will be receiving the BIMI intervention.
89146454|NCT04166162|Experimental|Business that Care (BTC) Coalition Group|Participating BTC employees who are selected by the respective directors of the participating companies to be part of the BTC Coalition will receive a total of 8 BTC training sessions in the space of 6 months.
89146455|NCT00615810|Active Comparator|2|Open label Kivexa (abacavir (as sulfate) 600 mg/lamivudine 300 mg) once daily for oral administration plus Sustiva (efavirenz 600 mg) once daily for oral administration
89146456|NCT00615810|Experimental|1|Open label Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration to be taken on an empty stomach
89146457|NCT03355157|Experimental|Palbociclib + endocrine therapy|Experimental arm for testing palbociclib + endocrine therapy.
89146458|NCT03355157|Active Comparator|Chemotherapy +/- endocrine maintenance therapy|Chemotherapy +/- endocrine maintenance as comparator arm.
89146459|NCT04215432|Experimental|Test group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water, Propolis Extract (2%), Ascorbic Acid (0.2%) and Tocopherol Acetate (0.2%).
89146460|NCT04215432|Placebo Comparator|Placebo group|Gel contained in tubes with the same appearance (30g), identical in colour, flavour and density, with the following components: Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethylene glycol, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate, Deionized Water and E155/151 coloring.
89146461|NCT02747342|Experimental|SHR3680; SHR3680+SHR3162|In dose esclation and expansion phase, SHR3680 will be administered orally In combination phase, SHR3680 will be administered together with SHR3162
89146462|NCT02699580|Experimental|Biodegradable collagen implant|Both eyes are needed to correct strabismus. One eye is randomly selected for the placement of biodegradable collagen implant.
89146463|NCT02699580|Active Comparator|Without biodegradable collagen implant|Strabismus surgery is done without placing of biodegradable collagen implant in the other eye.
89146464|NCT02747030|Experimental|Ocriplasmin intravenously|All subjects included in this phase I study are in the experimental treatment arm and will undergo a vitrectomy augmented with retinal vein cannulation and intravenous Ocriplasmin infusion.
88803850|NCT00002944|Experimental|Regimen A (CV Chemotherapy)|Induction will consist of 10 weeks of therapy (carboplatin, vincristine sulfate),followed by 2 weeks without chemotherapy. Induction should only be interrupted in the event of grade 3 neurotoxicity, grade 2 renal toxicity, grade 4 hematologic toxicity, or tumor progression. Maintenance-Four Courses (2 cycles/course) commences on Day 84 (week 12) of Induction or when peripheral counts recover with ANC >1,000/$L and platelet count >100,000/$L. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine sulfate (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.
88803851|NCT00002944|Experimental|Regimen B (TPCV Chemotherapy)|Each cycle of chemotherapy consists of 4 days of oral chemotherapy (Thioguanine, procarbazine hydrochloride, Lomustine and Vincristine sulfate beginning Day 0, followed by vincristine sulfate IV on Days 14 and 28. The cycle is repeated every 6 weeks (42 days). A total of 8 cycles will be given.
88803852|NCT04778306|Active Comparator|Trans Oral Laser Surgery (Group 1)|In TOLS, the tumor tissue was removed en bloc and in one piece. The removed specimen was marked on a card with the help of pins. Permanent surgical margins were taken from the anterior, posterior, superior, inferior and deep areas of the tumor area.
88803853|NCT04778306|Active Comparator|Radiotherapy (Group 2).|. In RT; the head was routinely stabilized with the help of a thermoplastic mask and subsequently covered the primary area with a size varying from 4x4 cm to 6x6 cm. Total 63-70 Gy radiotherapy was applied 2.0-2.3 Gy/ day,5 days a week, for 6-7 weeks.
88803854|NCT04778072|Experimental|Group 1|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
88803855|NCT04778072|Experimental|Group 2|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
88803856|NCT04778072|Experimental|Group 3|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily with matching placebo
88803857|NCT04778462|Experimental|Extracorporeal shock wave|Extracorporeal shock wave group A consist of 15 subject will receive extracorporeal shock wave and conventional treatment for trigger points for two weeks four treatment sessions
88803858|NCT04778462|Experimental|High-power pain thershold ultrasound|High -power pain thershold group b consist of 15 subject will receive high power pain threshold ultrasound and conventional treatment for upper trapezius trigger points for two weeks four treatment session
88803859|NCT04778462|Other|Controlled group|controlled group consist of 15 subjects will receive conventional treatment for trigger point for two weeks
88803860|NCT02739022|Experimental|Early Psychological Support for the Critically Ill (EPSCI)|patients will receive EPSCI in parallel with medical treatment
88803861|NCT00002956|Experimental|infusions of EBV specific cytotoxic T lymphocytes|Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression
88803862|NCT00777140|Active Comparator|1. Deferoxamine|Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
88803863|NCT00777140|Placebo Comparator|2. Placebo|Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)
88803864|NCT04304768|Experimental|HIV positive opioid users|Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study
88803865|NCT04304768|Experimental|HIV positive non-opioid users|Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study
88803866|NCT04304768|Experimental|HIV negative opioid users|Participants will receive flu vaccination as part of the study
88803867|NCT04304768|Experimental|HIV negative non-opioid users|Participants will receive flu vaccination as part of the study
88803868|NCT02732080|Experimental|Deferred coronary stenting|In this arm, after establishing TIMI -3 flow in infarct related artery with balloon angioplasty, patients will undergo stent implantation when coronary autoregulatory function was recovered (initial hyperemic flow was subsided and baseline resistance was increased). Recovery of the auto regulatory function will be determined by measuring microvascular flow and resistance. After stenting microvascular flow / resistance will continue to be monitored using pressure/flow sensor tipped guide wire until the completion of 1 hour follow up period.
89146465|NCT04215276|Active Comparator|Valsalva Maneuver|Patient will do valsalva maneuver for 20 seconds
89146466|NCT04215276|Placebo Comparator|control|Patient will do nothing
89146467|NCT02747264|Experimental|eRAPID intervention|Participants in the intervention arm will receive training in using the eRAPID system to report their symptoms and side effects (at least on a weekly basis) from home via the internet whilst they are receiving treatment online and weekly for 6 weeks post treatment (a total of 12 weeks) and then at 18 & 24 weeks. Hospital staff will be able to review eRAPID reports and use the information during the consultation in clinic, when attending radiotherapy or answering phone calls. Alerts will also be sent to the relevant clinical team when severe symptoms are reported by patients.
89146468|NCT02747264|No Intervention|Usual care|The Usual care patients act as a comparison to the patients using eRAPID. They complete a paper-based quality of life questionnaire at baseline and then 6, 12 and 24 weeks after. The researchers will also collect clinical process measures for this group including number of hospital contacts and admissions.
89146469|NCT03324035|Experimental|Treatment|Patients on this arm will receive amitriptyline on flexible doses, starting from 25mg (1 capsule) and titrated to 50mg (2 capsules) or 75mg (3 capsules), based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
89146470|NCT03324035|Placebo Comparator|Placebo|Patients on this arm will receive placebo on flexible doses, starting from 1 capsule and titrated to 2 capsules or 3 capsules, based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
89146471|NCT00616746|Experimental|1|Three test days, within-subject design.
89146472|NCT02695316|Other|Migrant Women|Focus Group Discussion in native Language with n=20
89146473|NCT02695316|Other|Health Care Professionals|Focus Group Discussion with n=20 Health Care Professionals
89146474|NCT02695316|Other|Interpreters|One-to-one Interviews with n=4 intercultural Interpreters
89146475|NCT02695316|Other|Telephone Interpreting Protocols|Retrospective quantitative analysis of n=50 Telephone Interpreting Protocols (questionnairs)
89146476|NCT04404023|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
88803869|NCT02732080|Active Comparator|Immediate stenting|In this arm, patients will undergo stenting immediately after balloon angioplasty. After stent implantation, microvascular flow / resistance values will be continuously monitored using pressure/flow sensor tipped guide wire until the end of 1 hour follow up period.
89146477|NCT04404023|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
89146478|NCT04404023|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
89146479|NCT04404023|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
89146480|NCT04404023|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
89146481|NCT05173038||second ejaculate group|
89146482|NCT05173038||first ejaculate group|
89146483|NCT02746952|Experimental|UCART19|
89146484|NCT04217876||Clinically suspected infarct-like acute myocarditis|Diagnosis of infarct-like AM was based on five criteria: (a) history of flu-like symptoms within 8 weeks prior admission; (b) new onset of symptoms such as fatigue/breathlessness, chest pain, mild dyspnea, and/or palpitation; (c) ischemic ECG pattern (ST-segment elevation and/or T-wave anomalies); (d) increase of inflammatory markers (non-high- sensitivity CRP > 8 mg/L and/or white blood cell count > 11.000/mm3) and cardiac enzymes; and (e) preserved global systolic function (EF > 50%). We excluded patients with New York Heart Association (NYHA) functional heart classifications II-IV, LVEF < 50% and those patients with electrocardiographic evidence of bradyarrhythmias (≥second-degree atrioventricular block) or tachyarrhythmias (ventricular or supraventricular arrhythmias).
89146485|NCT03007511|Experimental|Fidmi|Placement of Fidmi enhanced enteral feeding device; internal tubes replacement during follow up and device removal after 3 month from placement Fidmi enhanced enteral feeding device
89146486|NCT04219436|Active Comparator|periosteal suturing technique|periosteal suture is done to close the flap
89146487|NCT04219436|Active Comparator|figure of eight suturing technique|figure of eight suture is done to close the flap
89146488|NCT00632255||1|Patients with CML who have been treated with Imatinib (Glivec) within 6 months of diagnosis as first line therapy. Initial therapy with Hydroxyurea is permitted
89146489|NCT03348878|Other|cohort of uncontrolled hypertensive patients|
89146490|NCT04072289|Experimental|Low cylinder (treatment)|0.25D and 0.50D cylinder treatments will be measured and treated by the laser.
89146491|NCT04072289|No Intervention|Low cylinder (no treatment)|0.25D and 0.50D cylinder treatments will be measured but not treated by the laser. No spherical equivalent will be used.
89146492|NCT04203485|Experimental|Camrelizumab 200mg + Apatinib Mesylate 250mg|Camrelizumab 200mg q2w ivgtt+ Apatinib Mesylate 250mg once daily po qd
89146493|NCT04203485|Experimental|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
89146494|NCT04203485|Active Comparator|Pemetrexed/Paclitaxel injection+ Carboplatin|For non-squamous NSCLC: Pemetrexed disodium for injection + Carboplatin; For squamous NSCLC: Paclitaxel injection + Carboplatin
89146495|NCT04118738||ZIKV-Exposed|Children born to women with documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery or the children's laboratory documentation of confirmed or presumptive in-utero ZIKV exposure within five days of birth.
89146496|NCT04118738||ZIKV-Unexposed|Children born to women without documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery and the children have no laboratory documentation of confirmed or presumptive in-utero ZIKV exposure at any time prior to ZIP 2.0 enrollment, if testing was performed prior to enrollment.
89146497|NCT03116126|Active Comparator|Guanfacine|
89146498|NCT03116126|Placebo Comparator|Placebo|
89146499|NCT00910247|Experimental|eslicarbazepine acetate|Open-label treatment with eslicarbazepine acetate will be at doses between 800 and 2400 mg QD
89146500|NCT04217798|Experimental|Niparib combined with oral etoposide|Subjects will received niraparib 200mg or 100mg alternate once daily and oral etoposide 50mg on day 1-20 of a 30-day cycle. Oral etoposide was administered for a maximum of 6-8 cycles. Treatment was continued until disease progression, patient withdrawal or unacceptable toxic effects.
89146501|NCT02742350|Experimental|IMT+Exercise|The inspiratory muscle training protocol (IMT) high intensity is achieved with a device with linear load pressure (POWERbreathe Plus Light Resistance®, SP, BR) that allows loads up to -90cmH2O. IMT is performed for 36 sessions (12 weeks) with weekly frequency of three times a week under supervision prior to the cardiac rehabilitation. The training protocol consists of five series with 10 repetitions each set until the 8th week with increase in the number of sets of repetitions of the 8th to 12th week, with two minutes or according to patient feedback using the modified Borg scale . Aerobic training lasts 40 minutes (5 minutes heating 30 minute workout and 5 minutes desaqueciemento. During training vital signs such as heart rate, blood pressure (BP) and peripheral oxygen saturation (SpO2) are evaluated and the feeling of effort the patient should not exceed the level of 8 according to the modified Borg scale.
89146502|NCT02742350|No Intervention|Exercise Control|Aerobic Exercise and Stretching
89146503|NCT02742428|Experimental|Ascites drainage before surgery.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. An indwelling catheter insertion into abdominal cavity and slow, systematic ascites evacuation for 7 or more days before surgery (if it cannot be scheduled immediately) will be performed. Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
89290624|NCT03923946|Experimental|Intervention|Compassionate Imagery Intervention- up to three 1:1 sessions, up to one hour each with the primary researcher
89290625|NCT03923946|No Intervention|Control|Treatment as usual arm
88803870|NCT02715622||Open Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia open repair surgical procedure
89146504|NCT02742428|Other|Observation.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. A standard of care: observation or acute paracentesis (>5000ml) will be performed while waiting for the surgery (if it cannot be scheduled immediately). Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
89146505|NCT04298957|Other|See and treat|Cone biopsi is offered to women age ≥ 45 years referred to Department of Obstetrics and Gynecology due to a positive cervical screening test and partly or invisible transformation zone.
89146506|NCT04401410|Experimental|Dose Finding Phase|"This phase is designed to evaluate the maximum tolerated dose (MTD) of partially HLA-matched SARS-CoVSTs administered to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.~The dose finding phase is a standard 3+3 safety study design. The 3 dose levels are:~DL1: 1x10^7 cells (flat dose) DL2: 2x10^7 cells (flat dose) DL3: 4x10^7 cells (flat dose)"
89146507|NCT04401410|Experimental|Randomized Pilot - SARS-CoVSTs|Partially HLA-matched Virus Specific T cells (VSTs) will be given by intravenous injection.
89146508|NCT04401410|Active Comparator|Randomized Pilot - Routine Care|Hospitalized patients with COVID-19 will be treated per current institutional guidelines.
89146509|NCT00659334|Active Comparator|1|Adults with brain tumor to receive Combidex infusion only
89146510|NCT00659334|Active Comparator|2|Adults with brain tumors to receive Combidex infusion and neurosurgery
89146511|NCT00659334|Other|3|Adults with brain tumors to receive neurosurgery only (NO Combidex)
89146512|NCT00659334|Active Comparator|4|Children with brain tumors to receive Combidex only
89146513|NCT00659334|Active Comparator|5|Children with brain tumors to receive Combidex and neurosurgery
89146514|NCT00659334|Other|6|Children with brain tumors to receive neurosurgery only, NO Combidex
89146515|NCT00659334|Active Comparator|7|Adults with Inflammatory lesions (stroke or MS) to receive Combidex only
89146516|NCT04235543||autistic children aged 6:12 years|show the occurrance of traumatic dental injury compared to normal children
89146517|NCT04235543||normal children aged 6:12 years|show the occurrance of traumatic dental injury
89146518|NCT02742038|Experimental|Fluoride varnish plus education|Biannual fluoride varnish every 6 month/ 24 months plus educational component
89146519|NCT02742038|Placebo Comparator|Placebo varnish plus education|Biannual placebo varnish every 6 month/ 24 months plus educational component
89146520|NCT02746562|Experimental|Freeze all|Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle
89146521|NCT02746562|No Intervention|Fresh embryo transfer|Standard procedure
89146522|NCT02084160||CLD from HIS-EX-408/PLT-BID-1108|"Chronic liver disease subjects from previous Exalenz trial HIS-EX-408 and PLT-BID1108"
89146523|NCT02022098|Experimental|Debio 1143|In addition to Cisplatin and Radiotherapy, Debio 1143 in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
89146524|NCT02022098|Placebo Comparator|Placebo|In addition to Cisplatin and Radiotherapy, matching placebo in solution form will be administered orally or by feeding tube (while fasting) daily for 14 days every three weeks (on days 1-14, 22-35 and 43-56).
89146525|NCT01639508|Experimental|Cabozantinib|This will be a single-institution, open label, two-stage, single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion, or MET or AXL overexpression, amplication, or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion. Patients in GROUP D will have tumors with a RET fusion and have progressed on a selective RET TKI.
89146526|NCT02741882||Cases|Mothers who delivered a baby with microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
89146527|NCT02741882||Controls|Mothers who delivered a baby without microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
89146528|NCT02746484|Experimental|Ability platform program|Multi-domain at home rehabilitation program delivered through the Ability platform.
89146529|NCT02746484|Active Comparator|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
89146530|NCT02746250|Active Comparator|Tension type headache|The investigator measures the muscle soreness and muscle stiffness before the patients starts their prescribed treatment with amitriptyline - and again after they have reached their optimal dosage of amitriptyline.
89146531|NCT02746250|No Intervention|Healthy controls|The investigator measures the muscle soreness and muscle stiffness once.
89146532|NCT02741960|Experimental|metformin|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to metformin will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
89146533|NCT02741960|Placebo Comparator|placebo|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to placebo will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
89146534|NCT00910091|Experimental|A- BN 83495- 40mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
89146535|NCT00910091|Active Comparator|B- MA - 160mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
89146536|NCT04216550||Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
89146537|NCT01442792|Active Comparator|Arm 1|
89146538|NCT01442792|Experimental|Arm 2|
89146539|NCT01442792|Experimental|Arm 3|
88803871|NCT02715622||Laparoscopic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia laparoscopic repair surgical procedure
88803872|NCT02715622||Robotic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia robotic-assisted laparoscopic repair surgical procedure
88803873|NCT04780958|Other|Study population|During the study period, babies born at this hospital with a gestational week of <30 were included .
88803874|NCT00759434|Active Comparator|Surgery|
88803875|NCT00759434|Experimental|EVLT|
88803876|NCT00002968|Experimental|Arm I (edrecolomab)|Patients receive adjuvant edrecolomab IV over 2 hours on day 1. Treatment repeats every 28 days for 5 courses. Patients must begin therapy no earlier than 7 days and no later than 42 days postsurgical resection. Patients also undergo observation at 3 and 6 months postrandomization.
88803877|NCT00002968|No Intervention|Arm II (no treatment)|Patients undergo observation at 3 and 6 months postrandomization. .
88803878|NCT04780412|Active Comparator|Misoprostol Group|
88803879|NCT04780412|Placebo Comparator|Placebo Group|
88803880|NCT00754364|Experimental|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2 infusion) plus Carboplatin (AUC5 infusion)
88803881|NCT00754364|Active Comparator|Gemcitabine|Gemcitabine 1250 mg/mq
88803882|NCT02612896|Experimental|Elimination arm|"Both human and porcine interventions at four-monthly intervals in the first two study years, for a total of six iterations (only human interventions will be detailed here):~Human: Mass drug administration, praziquantel 10mg/kg, according to the list of WHO recommended anthelmintic drugs for use in preventive chemotherapy for taeniasis. And Health Education"
88803883|NCT02612896|Experimental|Control intervention arm|Human: yearly health education, for a total of five iterations. The intervention on the pig host will not be detailed here)
88803884|NCT04777682|Other|single arm|A single-arm, open, single-center (hospital-based) prospective interventional study to compare intestinal ultrasound versus double balloon enteroscopy in diagnosis of malabsorption syndrome
88803885|NCT04777526|Active Comparator|Control group|"Thumb orthosis at night. Daily exercises program during 4 weeks grouped in 3 sets of 10 repetitions in absence of pain. Exercises will consisted of active~- resistive exercises for the first dorsal interosseous (FDI) muscle, manual distraction of the CMC joint and relaxation of the adductor thumb muscle."
88803886|NCT04777526|Experimental|Experimental group|The experimental group will also carried out a proprioceptive exercise program divided in three phases of 2 weeks per phase.
88803887|NCT04777604||Patients with resectable pancreatic cancer after neoadjuvant chemotherapy|
88803888|NCT04777838|Active Comparator|Citalopram|Citalopram 10mg
88803889|NCT04777838|Active Comparator|Amitriptyline|Amitritptyline 25 mg
88803890|NCT04777838|Active Comparator|Bite Splint|Michigan Splint, nocturnal use
88803891|NCT04777448|No Intervention|Control|Simple physical activity advices will be given to the 27 patients of the control arm
88803892|NCT04777448|Experimental|telerehabilitation|Patients in the tele rehabilitation arm will perform 24 1h-telerehabilition sessions (dance, gym, cardio training, yoga, ...)
88803893|NCT02572024|Active Comparator|Baroreflex activation therapy|BAT ON
88803894|NCT02572024|Placebo Comparator|Placebo|BAT OFF
88803895|NCT04777370|Experimental|sleeper stretch + thoracic manipulation|The group will receive the sleeper stretch at session #1, and a thoracic manipulation followed by the sleeper stretch at session #2.
88803896|NCT04777370|Experimental|posterior glenohumeral (PG) mobilization + thoracic manipulation|The group will receive a posterior glide mobilization at session #1, and a thoracic manipulation followed by posterior glide mobilization at session #2.
88803897|NCT04777136|Experimental|Geriatric home visit|Home-visit where a comprehensive geriatric assessment will be performed
88803898|NCT04777136|Active Comparator|Standard care|No follow-up.
88803899|NCT00002998|Experimental|gemcitabine + cisplatin|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, and 15 every 28 days. Patients with complete response may receive an additional 2 courses after attainment of complete response status. Treatment continues in the absence of disease progression or unacceptable toxicities for a maximum of 8 courses. Patients are followed every 3 months for 2 years and then at 3 years after treatment.
88803900|NCT02088788|Experimental|"Board (Rad Board)"|Radial artery catheterization is performed using radio-opaque armboard
88803901|NCT02088788|Active Comparator|No Board|Regular radio-penetrating armboard is used (the one normally used during non-study procedures) with a radio-opaque pelvic shield
88803902|NCT04776512|Experimental|Epidural Analgesia|Patients of this group Will receive an epidural analgesia through a lumbar epidural catheter
88803903|NCT04776512|Experimental|ESP Block|Bilateral ESP block performed at the level of the 3 rd Lumbar transverse process.
88803904|NCT04329910||Lean|BMI < 25
88803905|NCT04329910||overweight|BMI 25 - 29.9
88803906|NCT04329910||class i obesity|BMI 30 -34.9
88803907|NCT04329910||class ii obesity|BMI 35 - 39.9
88803908|NCT04329910||class iii obesity|BMI >= 40
89146540|NCT01442792|Experimental|Arm 4|
89146541|NCT02741648||ELBW Infants with Prolonged Irradiation Storage Time|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion had prolonged Irradiation Storage Time (IST) being tested with metabolomics profile.
89146542|NCT02741648||ELBW Infants without Irradiation Storage|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion did not have Irradiation Storage being tested with metabolomics profile.
89146543|NCT02741648||ELBW Infants with NEC|"Extremely Low Birth Weight Infants with Necrotizing Enterocolitis (NEC defined as Bell's Stage II or greater) and receiving Red Blood Cell (RBC) Transfusions being tested with Near Infrared Spectroscopy."
89146544|NCT02741648||ELBW Infants without NEC|Extremely Low Birth Weight Infants without Necrotizing Enterocolitis being tested with Near Infrared Spectroscopy.
89146545|NCT00582530||1 men with prostate cancer|Patients who have opted for radical prostatectomy as treatment for prostate cancer.
89146546|NCT00909857|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID (BAY86-5027) plus one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles
89146547|NCT00909857|Active Comparator|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet placebo plus one tablet SH D593B (Miranova) for 28 days without tablet-free interval for 3 treatment cycles
89146548|NCT02751242||Usual Care|All patients will receive a dose of intravenous furosemide.
89146549|NCT02741726|Experimental|dual acupoint stimulation|The acupoints of dual point group are bilateral Neiguan points(PC6) combined with Danzhong point(RN17), electric stimulation was given through electrode attached to the acupoints.
89146550|NCT02741726|Experimental|single acupoint stimulation|The acupoints of single point group is bilateral Neiguan points(PC6), Electric stimulation was given through electrode attached to the acupoints.
89146551|NCT02741726|Placebo Comparator|no stimulation|false stimulation group only attach electrodes without electric current.
89146552|NCT02741804|Active Comparator|BBH-1001 Brain Health Supplement|Patients will be given supplement containing ingredients all approved by the FDA: Turmeric (125mg), fisetin (16.65mg), green tea leaf extract (17.5mg), EPA (75mg), DHA (150mg) and Vitamin D3 (250IU). Patients will take 4 softgels once per day for entire study duration (18 months).
89146553|NCT02741804|Placebo Comparator|Brain Health Placebo|Patients will be given a pill resembling the study supplement, but instead consisting of Soybean oil (608mg). Patients will take 4 softgels once per day for the entire study duration (18 months).
89146554|NCT05629130|Experimental|Embolization|embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France) of the affected joint, until partial vascular stasis and decharacterization of pathological synovial enhancement.
89146555|NCT00911807|Experimental|Cerebrolysin + donepezil|
89146556|NCT00911807|Experimental|Cerebrolysin + placebo|
89146557|NCT00911807|Active Comparator|Donepezil + placebo|
89146558|NCT02745938||Mitochondrial disease|Patients with mitochondrial disease, investigated by blood samples and exercise test.
89146559|NCT02745938||Metabolic myopathy|Patients with metabolic myopathy, investigated by blood samples and exercise test.
89146560|NCT02745938||Muscular dystrophy|Patients with muscular dystrophy, investigated by blood samples and exercise test.
89146561|NCT02745938||Healthy controls|Healthy controls, investigated by blood samples and exercise test.
89146562|NCT02746016|Experimental|Infant Formula supplemented with Oligosaccharides|Ready to feed infant formula ; Feed ad libitum.
89146563|NCT02746094|Experimental|The study population|"The study population is comprised of adult men less than 80 years of age who are consulting for ED lasting for over 6 months following a prostatectomy that took place 18 to 60 months ago. The patients are currently in a stable relationship that has been going on for at least 3 months, have an IIEF-EF score between 6 and 25, and have at least a natural tumescence during sexual stimulation (EHS score ≥ 1).~Intervention: 8 bi-weekly LIESWT sessions"
89146564|NCT03295565|Active Comparator|A: Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
89146565|NCT03295565|Active Comparator|B: Abiraterone OR Enzalutamide|"At physician's discretion:~Abiraterone 1000mg oral, taken daily Prednisone 5mg oral, 2 times a day OR Enzalutamide 160mg oral taken daily"
89146566|NCT02751164||Weekday daytime|Admitted to the critical care unit Monday-Friday 08:00-17:59
89146567|NCT02751164||Weekend daytime|Admitted to the critical care unit Saturday-Sunday 08:00-17:59
89146568|NCT02751164||Weekday night|Admitted to the critical care unit Monday-Friday 18:00-07:59 the next day
89146569|NCT02751164||Weekend night|Admitted to the critical care unit Saturday-Sunday 18:00-07:59 the next day
89146570|NCT04127981|Active Comparator|Patients with cancer cachexia|20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC), or pancreatic cancer with documented cachexia.
89146571|NCT04127981|Active Comparator|Patients without cancer cachexia|20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC) or pancreatic cancer without cachexia.
89146572|NCT04203095||patient with PD1 antibody treatment|"Investigators will detect cfDNA CIN of lung cancer patients 1day (Day 0) before treatment with PD1 antibody, then Day 22 and Day 64 after treatment with PD1 antibody, as well as at the time of disease progression confirmed.~The correlation of CIN and drug resistance to PD1 antibody was analyzed."
89146573|NCT03934775||Patients with acute illness|Patients admitted to the acute medical/emergency department and/or Cardiology department at Bispebjerg Hospital.
89146574|NCT04117451|Sham Comparator|Chlorhexidine|Chlorhexidine mouthwash will be provided to participants for a week to rinse the mouth twice a day.
89146575|NCT04117451|Experimental|Propolis|Propolis mouthwash will be provided to participants for a week to rinse the mouth twice a day.
89146576|NCT03690089|Experimental|Intervention Group (Atropine 0.01%)|The intervention group will receive 0.01% atropine sulfate eye drops, administered once daily for two years.
89146577|NCT03690089|Placebo Comparator|Placebo Group|The control group will receive placebo eye drops, administered once daily for two years.
89146578|NCT03812588|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
89146579|NCT03812588|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
89146580|NCT03812588|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
89146581|NCT03812588|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
89146582|NCT04295525|Placebo Comparator|Controls subjects placebo|Placebo mucoadhesive oral tablet
89146583|NCT04295525|Experimental|Controls subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
89146584|NCT04295525|Placebo Comparator|Diseased subjects placebo|Placebo mucoadhesive oral tablet
89146585|NCT04295525|Experimental|Diseased subjects active Treatment|AqualiefTM 400 mg mucoadhesive oral tablet
89146586|NCT04341701|Other|COPD|COPD according to GOLD 2019 but unrestricted to any level of bronchial reversibility established by the pulmonologist
89146587|NCT04341701|Other|Asthma|asthma according to GINA 2019 but without any smoking restriction
89146588|NCT02750852||Analysis group|Create an algorithm to predict blood loss using patients data
89146589|NCT02750852||Control group|The algorithm was applied to analyze sensitivity and specificity
89146590|NCT03571958|No Intervention|Traditional OHI (Control)|"Advice giving method of OHI known as tell-show-do to inform, demonstrate, and expect patient compliance."
89146591|NCT03571958|Experimental|BMI (Test)|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
89146592|NCT02387099|Active Comparator|Conventional Everolimus dosing according to label|"everolimus 10 mg/day, week 1-3: 4x2.5 mg/day (blinded); week 4-24: 10mg/day (open according to label)~+ further treatment according to standard of care"
89146593|NCT02387099|Experimental|3 week Dose Induction of Everolimus|"an escalating dose of everolimus as follows: week 1: 1x2.5 mg verum + 3x placebo/day; week 2: 2x2.5 mg verum + 2x placebo/day; week 3: 3x2,5 mg verum + 1x placebo/day; week 4-24: 10 mg/day (open according to label)~+ further treatment according to standard of care"
89146594|NCT02746172|Experimental|Cochlear Implant Recipients|cochlear implant recipients
89146595|NCT02746172|No Intervention|Normal Hearing Volunteers|Normal hearing volunteers
89146596|NCT04116983||All patients|Recruited participants will be attending a dermatology clinic with at least one skin lesion where there is a suspicion of skin cancer. All suspicious lesions suitable for photographing will be photographed six times in a single visit. A macro and dermoscopic image of each lesion will be captured by three different mobile phones: an iPhone, a Samsung and a Nokia smart phone, without (macro image) or with (dermoscopic image) a Dermlite DL1 lens attached. Dermoscopic images of healthy skin will also be captured by each camera. Images of the lesions will be analysed by DERM. The DERM results for lesions biopsied will be compared to the biopsy result; the DERM results for lesions not biopsied will be compared to the clinical assessment.
89146597|NCT02745704|Experimental|PEG-IFN group|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks.
89146598|NCT02745704|No Intervention|NAs group|Patients do not need to change their NAs treatment.
89146599|NCT02745860|Experimental|Sequence AB|Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
89146600|NCT02745860|Experimental|Sequence BA|Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2
89146601|NCT03078023|Experimental|swallowed sponge device|Swallowing a sponge prior to a clinical upper endoscopy. Patients diagnosed with Eosinophilic Esophagitis (EoE) > than 15 Eosinophils per high power field (phf) and failed to respond to Proton Pump Inhibitors (PPI) therapy. Will be asked to swallow a sponge, this is a 10 minute procedure done in the office prior to their clinical upper endoscopy. This will be sent for histology, >15 Eos phf would be considered active disease. We will compare the results of the sponge using the EPO staining technique compared to histologic response.
89146602|NCT04788641|Experimental|Cohort 1|Subjects in Cohort 1 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: tacrolimus alone (treatment A) followed by the combination treatment of tacrolimus and SZC (treatment B) or vice versa.
89146603|NCT04788641|Experimental|Cohort 2|Subjects in Cohort 2 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: cyclosporin alone (treatment C) followed by the combination treatment of cyclosporin and SZC (treatment D) or vice versa.
89146604|NCT02736734|Other|CRH condition|All HV first underwent a baseline manometry measurement. After 30 minutes, an intravenous CRH injection was done. The same measurement was repeated but now with CRH administered.
89146605|NCT02736812|Experimental|French Lyophilized Plasma|receives French Lyophilized Plasma with the usual treatment for post traumatic hemorrhagic shock as given in the recommendations for best practice
88816436|NCT01191476|Active Comparator|Propofol Induction and Sevoflurane Maintenance|Subjects received a bolus dose of propofol of 1.5 mg/kg administered for IV induction followed by sevoflurane at 0.8-1.5 MAC for maintenance anesthesia.
89146606|NCT02736812|Active Comparator|Normal Saline Solution|receives Normale Saline Solution with the usual treatment of post traumatic hemorrhagic shock as given in the recommendations for best practice
89146607|NCT04364126|Active Comparator|Standard of care|Clinical blood pressure measured at regular visits
89146608|NCT04364126|Experimental|Home blood pressure monitoring|Home blood pressure measured daily for 1 week before regular clinical visits
89146609|NCT02745470|Experimental|Lixisenatide injection|intervention : Lyxumia® pen injection 10 microgram (Lixisenatide) subcutaneous injection 30 minutes before functional MRI
89146610|NCT02745470|Placebo Comparator|Normal saline|control : normal saline 0.3 cc subcutaneous injection before functional MRI
89146611|NCT02745236|Experimental|Nurse Practitioner Led-Care|"Nurse Practitioner (NP) Intervention Initial Visit and Interventions: An experienced nurse practitioner with extra atrial fibrillation (AF) management training will complete the initial assessment to determine a treatment plan based on current AF Guidelines. The NP will provide patient education on AF management.~Follow-up: Follow-up will occur at 3 and 6 months from baseline to evaluate the patient's response to treatment and will be modified as required based on AF symptoms, testing results and physical assessment.~A physician will be consulted for advanced specialty AF management or if a patient requires admission to hospital."
89146612|NCT02745236|Active Comparator|Cardiologist Led-Care|"Standard Care Initial Visit and Intervention: A general cardiologist will manage patients as per their usual practice.~Follow-up: As per the cardiologist's usual practice. The patient's care will remain with the family physician if no follow-up is required.~Follow-up: Follow-up will be determined as per the cardiologist's usual practice. If a follow-up appointment is required it will done in the cardiologist's own independent clinic. The patient's care will be referred back to the family physician if no follow-up is required."
89146613|NCT02741414|Experimental|H pylori culture negative group|The patients who have the negative result of H pylori culture were classified into H pylori culture negative group.
89146614|NCT02741414|Experimental|The first successful eradication group|The patients with first eradication therapy of H. pylori infection have the first successful treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and proton pump inhibitors （PPIs) dose selection from CYP2C19 gene sequencing.
89146615|NCT02741414|Experimental|The refractory infection of H. pylori group|The patients with first eradication therapy of H. pylori infection have the two failure treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and PPIs dose selection from CYP2C19 gene sequencing.
89146616|NCT02741336|Experimental|CBT-I Intervention|For those randomized to the CBT-I group, the therapist will initiate telephone-delivered cognitive-behavioral therapy within 2 weeks of baseline assessment. Participants will complete 4 telephone sessions over a period of 8 weeks. Sessions last approximately 45 minutes. CBT-I is a short-term, focused psychotherapy that is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training.
89146617|NCT02741336|Active Comparator|Self-Monitoring Control Group|Individuals randomized to the self-monitoring control group will be asked to complete a weeklong sleep diary every other week for 8 weeks. The sleep diary will inquire about (1) the time of getting into bed; (2) the time at which the individual attempted to fall asleep; (3) sleep onset latency; (4) number of awakenings; (5) duration of awakenings; (6) time of final awakening; (7) final rise time; (8) perceived sleep quality (rated via Likert scale); and (9) an additional space for open-ended comments from the respondent. The control condition is designed to increase self-monitoring, which has been demonstrated to be an effective means of inducing change for various health behaviors such as diet and exercise.
89146618|NCT02736500|Experimental|28 GBq 177Lu-DOTATATE|5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) 177Lu-DOTATATE
89146619|NCT02736500|Experimental|22 GBq 177Lu-DOTATATE|6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi) 177Lu-DOTATATE
89146620|NCT02745158||FOP Patients|
89146621|NCT02741492|Active Comparator|Block Group|Continuous Transversus Abdominis Plane Catheter
89146622|NCT02741492|Sham Comparator|Sham Group|Continuous Sham Catheter
89146623|NCT05629598|Experimental|A1|Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)* 0.004 (conversion coefficient), Q2W for administration.
89146624|NCT05629598|Experimental|B1|Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)* 0.008 (conversion coefficient), Q2W for administration.
89146625|NCT05629598|Experimental|A2|Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)* 0.004 (conversion coefficient), Q4W for administration.
89146626|NCT05629598|Experimental|B2|Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)* 0.008 (conversion coefficient), Q4W for administration.
89146627|NCT05629598|Active Comparator|C|Human erythropoietin injection；Refer to the product instructions.
89146628|NCT02745314||>74 years|Older than 74 year-old patients
89146629|NCT02740946|Experimental|Exercise therapy|Exercise therapy 5 months
89146630|NCT02736032|Active Comparator|With GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using GnRHa followed by external estradiol and progesterone. The GnRHa depot from will be given on day 21 of the preceding cycle, on day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol followed up on day 12 of the cycle, if the endometrium is less than 8 mm, till day 15 of the cycle estradiol will be increased to 8 mg/day until 8 mm or more. Then, serum estradiol and progesterone levels are collected, and progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
89146631|NCT02736032|Active Comparator|Without GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using external estradiol and progesterone only. On day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol and followed up on day 12 of the cycle, if the endometrium did not reach 8 mm, till day 15 of the cycle the dose will be increased to 8 mg/day until the endometrium is 8 or more mm. When the endometrium is ready, serum estradiol and progesterone levels are collected, then progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
89146632|NCT04287920|Experimental|Alcohol-related liver disease and AUD, MELD-NA less than 20|The first 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score less than 20.
89146633|NCT04287920|Experimental|Alcohol-related liver disease and AUD, MELD-NA more than 20|The second 5 patients enrolled = AUD (alcohol use disorder) w/MELD-Na (model for end stage liver disease sodium) score more than 20.
89146634|NCT05598944|Experimental|UGRComp group|This arm will instruct the students on the Más Presente program. This is a socio-emotional competence-based program which has been designed following the European LifeComp framework. This program is a combination of theory and practice aimed at developing the core elements of personal, social and learning to learn key competences for lifelong learning.
89146635|NCT05598944|Experimental|MBSR group|This arm will instruct the students on the Mindfulness-Based Stress Reduction (MBSR) program. The MBSR is a secular, evidence-based practice originally developed for chronic pain, but which has reported positive results among an array of clinical and nonclinical populations. This program aims to cultivate non-judgmental attention to and awareness of present moment experience while promoting stress reduction.
89146636|NCT05598944|Active Comparator|Neuro-muscular stimulation group|The students in this arm will receive training on physical wellbeing and neuro-muscular stimulation. Non-specific factors such as number and duration of sessions, or instructor training and qualifications will match the other 2 experimental groups. Active ingredients such as mindfulness or socio-emotional training are not contained in the program.
89146637|NCT02741102|Experimental|Women with AUFI|Women with AUFI must meet criteria for uterine transplant. In vitro fertilization to obtain 6 (screened) healthy embryos for cryo-preservation precedes uterine transplant from an appropriate donor The recipient will be required to take potent anti rejection medications including Thymoglobulin, Prednisone, Tacrolimus, Mycophenolate Mofetil (MMF) , later substituted with Azathioprine to avoid birth defects. One year later, up to 6 attempts using 1 screened embryo at a time will be tried to achieve pregnancy. During pregnancy, the high risk pregnancy and transplant teams will follow the recipient. The goal is a full term baby and delivery will be by Caesarian section. A second pregnancy may be attempted. Afterward, the uterus will be explanted.
89146638|NCT02744768|Experimental|Treatment|"Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84. Prednisone (PDN) will be administered from day -6 to day +0 (during which the presence of the BCR/ABL1 alteration will be established), at escalating doses up to 60 mg/m2; PDN will be continued up to day +24 and progressively tapered up to day +31.~HLA typing will be performed immediately after the diagnosis for eligible patients.~MRD will be evaluated by RT-PCR at fixed time points (days +22, +45, +57) during the induction and at day +85, the latter for molecular response evaluation."
89146639|NCT00909779|Experimental|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
89146640|NCT00909779|Placebo Comparator|Placebo twice daily|Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
89146641|NCT02744924|Experimental|Physical activity intervention|Participants undergo the community-based physical activity promotion (see Intervention)
89146642|NCT05629442||EVALUATION OF CTDNA|"This prospective observational, non-therapeutic study will enroll patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy/ All procedures involved with this trial will be done as per standard of care~- Except for the initial research biopsy, quality of life assessments and ctDNA collection"
89146643|NCT04096391|Active Comparator|Intrathecal Drug Delivery System|Subjects randomized to the Intrathecal Drug Delivery System group will be implanted with the Prometra System under sterile technique in accordance with the Instructions for Use. The pump will be filled at the time of implantation with the prescribed medication.
89146644|NCT04096391|Active Comparator|Conventional Medical Management|Subjects randomized to the Conventional Medical Management group will continue with the standard of care procedures.
89146645|NCT02744378|Active Comparator|Clobetasol Group|clobetasol propionate (0.05%) cream
89146646|NCT02744378|Active Comparator|Tacrolimus Group|tacrolimus (0.1%) cream
89146647|NCT04202939||nursing homes residents|all residents present in a nursing home unit on nutritionDay
89146648|NCT04318730|Experimental|Arm 1|
89146649|NCT00632333|Experimental|1|
89146650|NCT02744456|Other|N-of-1 trial|Patients with hypertension who are taking none or one BP medication will be will be provided with prescriptions for up to 3 BP medications representative of different BP medication classes (i.e., losartan, an angiotensin system blocking agent; amlodipine, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic). Patients will be asked to take each medication for 2 weeks at a low dose, 2 weeks at a medium dose, and then 2 weeks at a high dose; provide health information and identify which medication they prefer to remain on following the N-of-1 trial (i.e., for long-term use).
89146651|NCT04270565|Experimental|Intervention Group|The intervention group will receive real-time gait-training interventions along with a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and wear a Garmin watch to get information from the sensors to the watch for feedback. They will also do home exercises during the study, and to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises and get instructions on feedback for the next week.
89146652|NCT04270565|Active Comparator|Control Group|The control group will receive only a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and do home exercises during the study. Participants will be asked to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises.
89146653|NCT02744222|Experimental|BCD-054, 180 mcg, biweekly|Patients of Groups 1 will receive blinded BCD-054 180 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 1 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
89146654|NCT02744222|Experimental|BCD-054, 240 mcg, biweekly|Patients of Groups 2 will receive blinded BCD-054 240 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 2 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
89146655|NCT02744222|Active Comparator|Avonex®, 30 mcg, weekly|Patients of Group 3 (reference group) will receive blinded Avonex® 30 mcgintramuscularly once a week for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive).
89146656|NCT02744222|Placebo Comparator|Placebo, 0,5 ml, weekly|Patients of Group 4 (placebo) will receive blinded placebo once a week for the first 20 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive)
89146657|NCT05581355|Experimental|The effectiveness of receiving abdominal breathing training|Training for 8 weeks (1 time a week, 15 minutes each time). Performed one-on-one by a trainer in a sleep center. At home, you can use the abdominal breathing training video to train yourself (10 minutes a day, can be divided into 10 minutes), and you need to fill in the abdominal breathing training log.
89146658|NCT05581355|No Intervention|The effectiveness of not receiving abdominal breathing training|The trainer does not provide abdominal breathing training, does not perform abdominal breathing exercises at home, and does not need to fill in abdominal breathing training logs.
89146659|NCT02741024|Active Comparator|Amodiaquine-Artesunate (ASAQ)|Treatment regimen consisted of Amodiaquine-Artesunate (ASAQ) fixed dose (FD) (Winthrop Sanofi Aventis), given as 1 tablet/day 3 days (5-8 kg 1 tab of 25mg artesunate/67.5 mg amodiaquine base, 9-17 kg 50 mg artesunate/135 mg amodiaquine base)
89146660|NCT02741024|Active Comparator|Artemether-Lumefantrine (AL)|Treatment consisted of Artemether-Lumefantrine (AL) (Coartem, Novartis) given as six twice/daily doses over three days (5-14 kg 1tab of 20mg artemether/120mg lumefantrine BD, 15-24 kg 2tabs of 20mg artemether/120mg lumefantrine BD with fatty food).
89146661|NCT02761187||Relapsed/refractory (R/R) MM|Patients who have received 1 to 3 prior lines of therapy
89146662|NCT02761187||Newly diagnosed (ND) MM|Patients within 3 months from initiation of treatment
89146663|NCT02744300|Experimental|BABI-2 Lifestyle Intervention|Participants in this group will take part in the web-based lifestyle intervention which includes access to the lifestyle intervention website and personalized coaching from a Lifestyle Coach.
89146664|NCT02744300|No Intervention|Post-GDM Follow-up Group|Participants in this group will have access to a separate website containing links to information about diabetes prevention.
89146665|NCT02743988|Experimental|Low target range|Low oxygen saturation target range: SpO2 85-89%
89146666|NCT02743988|Active Comparator|High target range|High oxygen saturation target range: SpO2 91-95%
89146667|NCT02735954||Marijuana Users|Individuals who use marijuana
89146668|NCT02735954||Combined Marijuana and Tobacco Users|Individuals who use marijuana and also smoke cigarettes
89146669|NCT02735954||Non-Marijuana Users|Individuals who do not use marijuana
89146670|NCT02735876|Experimental|acalabrutinib plus rituximab|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity. Rituximab IV infusions will be administered weekly for 4 weeks and on Day 1 of Cycle 3 through 8, and thereafter every other cycle for less than or equal to two years (approximately 200 subjects).
89146671|NCT02735876|Active Comparator|ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 200 subjects).
89146672|NCT02735876|Experimental|acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 50 subjects).
89146673|NCT02744144||Non-infection|Patients without clinical infection or positive wound culture
89146674|NCT02744144||Infection|Patients with clinical infection and positive wound culture
89146675|NCT02740556|Placebo Comparator|AdhereTech Passive Monitoring|Patients not using the HepCure patient app while AdhereTech passively monitors adherence (no chimes or reminders).
89146676|NCT02740556|Experimental|HepCure Toolkit|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard with AdhereTech passively monitoring adherence (no chimes or reminders).
89146677|NCT02740556|Experimental|HepCure Toolkit and AdhereTech Active Features|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard and with AdhereTech actively monitoring adherence (chimes and reminders enabled).
89146678|NCT00910871|Experimental|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks in addition to Background Regimen (BR) for the treatment of multi-drug resistant tuberculosis (MDR-TB).
89146679|NCT02743676||Avian influenza A|Natural history of Avian influenza A, particularly H5N1 strain which has a high potential of causing a global human pandemic, and real-world treatment practices will be observed in this study. This registry program will not require, recommend, or provide any specific treatment or medications.
89146680|NCT02743754|Placebo Comparator|Standard Therapy|Standard supportive therapies for Acute Kidney Injury (AKI), which entail optimization of hemodynamics and hemoglobin levels.
89146681|NCT02743754|Active Comparator|Standard Therapy and hyperbaric oxygen|Standard therapies and treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 atmospheres absolute (ATA).
89146682|NCT02735798|Experimental|Single Arm Study - Arm 1|10 patients will receive standard imaging at baseline, incl. FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) 3 hours after unlabeled dose of MM-302. Integrated MR/PET imaging of brain and whole body will be performed at 2 time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (in brain or systemically) or unacceptable toxicity, whichever occurs soonest. MRI and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.
89146683|NCT02735564|Experimental|RYGB|Bariatric Surgery:Roux-en-y
89146684|NCT02735564|Experimental|SG|Bariatric Surgery: Sleeve Gastrectomy
89146685|NCT02735564|Placebo Comparator|Control|BMI matched control
89146686|NCT02867735|Experimental|LKA651|
89146687|NCT02867735|Sham Comparator|Sham Comparator|
89146688|NCT04067843|Experimental|Photodynamic treatment|Skin microbiome after photodynamic treatment before and after skin antisepsis
89146689|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 1|40 ml of preservative-free 1% chloroprocaine
89146690|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 2|40 ml of preservative-free 2% chloroprocaine
89146691|NCT03760718|Active Comparator|Preservative free Chloroprocaine Group 3|40 ml of preservative-free 3% chloroprocaine
89146692|NCT05575895||Energy Drink|"Ingestion of 250 ml of the energy drink (Red Bull®)~- Evaluation of systemic skin microvascular endothelial function Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function."
89146693|NCT05575895||Control|"Ingestion of 250 ml of mineral water (Minalba®)~- Evaluation of systemic skin microvascular endothelial function Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function."
89146694|NCT05590286|Experimental|vonoprazan 20mg QD|Vonoprazan 20 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
89146695|NCT05590286|Active Comparator|esomeprazole 20 mg BID|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
89146696|NCT05575193|Experimental|Acupressure Group|The patients receiving the intervention of acupressure are in the experimental group.The experimental group will receive the acupressure at the hemodialysis center for a total of 12 weeks, three times a week. The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes. The effectiveness will be evaluated at the fourth week, eighth week and twelfth week.
89146697|NCT05575193|No Intervention|Non-Acupressure Group|"Acupressure is not provided, only general routines are performed. Pre-test and 3 post-tests of Visual Analog Scale (VAS), 5D Tickling Scale, and Pittsburgh Sleep Quality Scale are also required (week 4, week 8 and week 12)."
89146698|NCT02735408|Experimental|100% KT Tension|100% KT Tension
89146699|NCT02735408|Experimental|50% KT Tension|50% KT Tension
89146700|NCT02735408|Experimental|0% KT Tension|0% KT Tension
89146701|NCT02735408|No Intervention|Control (Without KT)|Control (Without KT)
89146702|NCT03937193||Non-SMAS group|subjects in this group are not clinically diagnosed as superior mesenteric artery syndrome(SMAS).
89146703|NCT03937193||SMAS group|subjects in this group are clinically diagnosed as superior mesenteric artery syndrome(SMAS).
89146704|NCT02743286|No Intervention|Control condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
89146705|NCT02743286|Experimental|Frequent sit-to-stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 15 2-minute standing interruptions, 3 per hour, and a mid-point bathroom break.
89146706|NCT02743286|Experimental|Walking breaks (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 2-minute walking interruptions, 3 per hour, and a mid-point bathroom break.
89146707|NCT02743286|Experimental|Stand More (Protocol D)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 10-minute standing breaks, 1 per hour, and a mid-point bathroom break.
89146708|NCT02695238|Experimental|prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, prophylactic manual rotation will be performed.
89146709|NCT02695238|No Intervention|No prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, expectant management for delevery will be performed
89146710|NCT04051073|Sham Comparator|Blinded|CNAP monitoring applied, but screen and information not visible to treating anaesthetist
89146711|NCT04051073|Active Comparator|Unblinded|CNAP monitoring applied and available in full to the treating anaesthetist
89146712|NCT02743208|Experimental|Furlong Evolution femoral stem|Short stem hip arthroplasty (SHA) using a Furlong Evolution femoral stem, and a Furlong H-A.C. Cortical Scree Fit (CSF) plus acetabular cup system.
89146713|NCT02743208|Active Comparator|Furlong H-A.C. femoral stem|Total hip arthroplasty (THA) using a Furlong H-A.C. femoral stem, and a Furlong H-A.C. CSF plus acetabular cup system.
89146714|NCT02743130|Experimental|Blackcurrant nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
89146715|NCT02743130|Experimental|Lingonberry nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
89146716|NCT02743130|Active Comparator|Reference|Sugar control, contains 17.5 g glucose and 17.5 g fructose in water
89146717|NCT02965469|No Intervention|Usual care|Participants randomized to this arm will have no change to their usual care
89146718|NCT02965469|Experimental|Cell phone app|"Participants randomized to this arm will use a stress reduction cell phone app called Breathe2Relax to assess feasibility and acceptability"
89146719|NCT02735486|Experimental|Ginger drink|Experimental: Ginger drink (300 ml) to be consumed during the study visit
89146720|NCT02735486|Placebo Comparator|Placebo: Super pure water|Super Pure water low in nitrate content
89146721|NCT03744728|Active Comparator|Accelerate Pheno|Fast ID and AST of positive blood culture bottles using the Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System
89146722|NCT03744728|Active Comparator|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
89146723|NCT02740400|Experimental|CT-TTNB|patients receive CT-TTNB to diagnose PPLs.
89146724|NCT02740400|Experimental|EBUS-GS|patients receive EBUS-GS to diagnose PPLs.
89146725|NCT02742896||Restoration of Erectile dysfunction|The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.
89146726|NCT02740244|Active Comparator|active iTBS|Participants will receive 10 to 30 sessions of active intermittent theta burst stimulation (iTBS) consisting in delivering 2 s train of bursts containing three pulses at 50 Hz repeated each 200 ms every 10 s (iTBS). Each iTBS session contained 990 pulses and lasted 6 min. Stimulation intensity will be set at 80% of the patient's resting motor threshold. iTBS will be applied twice per day, with at least three hours between each session. Ten to 30 sessions will be delivered until patient achieved remission (i.e., 13-item Beck Depression Inventory (BDI13) score < 10). iTBS will be applied over the left dorsolateral prefrontal cortex (DLPFC) according to the individual's 3D-T1 MRI.
89146727|NCT02740244|Sham Comparator|sham iTBS|The same protocol (location, intensity, parameters of stimulation) will be applied using a commercial sham coil.
89146728|NCT02742974|No Intervention|FloTrac™ and EV1000™ pre and post-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the pre and post-operative period in the control arm.
89146729|NCT02742974|Experimental|FloTrac™ and EV1000™ peri-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the perioperative period for the intervention arm
89146730|NCT02742740|No Intervention|Control|Standard of care for chemotherapy treatment.
89146731|NCT02742740|Experimental|Chemo Buddy|Subject receives instructions on how to use the personalized touch screen tablet and takes it home for 2 months.
89146732|NCT02740322|Other|Hum Test|To examine and compare the Hum Test, Weber Test, and audiogram in their ability to detect and identify hearing loss, hearing loss will be simulated with the use of ear plugs (mimicking conductive hearing loss). Subjects will serve as their own control as these tests will be conducted with and without ear plugs.
89146733|NCT03724994||Study cohort|All patients with periampullary adenocarcinoma or pancreatic cancer receiving palliative or adjuvant chemotherapy (e.g. Gemcitabine, Folfirinox, etc.) in the Department of Oncology, Skåne University hospital, Malmö and Lund
89146734|NCT02742662|Experimental|Smart Technology Group|The Smart Technology Group will receive a technology-based lifestyle intervention program which uses wearable technology, smartscales and smartphone applications to track and deliver feedback on caloric expenditure, physical activity, caloric intake and body weight. Participants will receive information through smartphone applications on strategies to make changes to their diet, physical activity, and weight-related behaviors along with standard 3 monthly in-person weight management visits.
89146735|NCT02742662|Other|Standard Weight Management Group|The Standard Weight Management Group will receive 3 monthly in-person weight management visits during which they will receive standard of care lifestyle recommendations in accordance with the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline.
89146736|NCT03845660|No Intervention|Usual Care|Providers taking care of patients randomized to this arm will have no alert related to the patients prognosis.
89146737|NCT03845660|Experimental|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
89146738|NCT04326530||Persistent asthmatic children|"150 steroid-naive, persistent asthmatic children enrolled during their first consultation at the IRIB-CNR outpatient clinic.~They will underwent three visits:~screening visit (-2 days);~baseline visit (day 0);~last visit (+90 days).~They will be treated with controller medications according to GINA recommendations (http://ginasthma.org)."
89146739|NCT02742584|Experimental|Group A|Cough Stress Test with a comfortably full bladder.
89146740|NCT02742584|Experimental|Group B|Cough Stress Test with an empty bladder after straight catheterization.
89146741|NCT02742584|Experimental|Group C|Cough Stress Test with a bladder infused with 200 cc of saline.
89146742|NCT02742584|Experimental|Group D|Cough Stress Test with the bladder filled to half functional capacity as determined from the largest voided volume recorded in the patient's voiding diary.
89146743|NCT02735330|Active Comparator|GROUP 1|68 Patients undergo Frey's procedure with celiac plexus neurolysis using absolute alcohol
89146744|NCT02735330|Placebo Comparator|GROUP 2|68 Patients undergo Frey's procedure with Placebo celiac plexus injection using saline
89146745|NCT03696992|Experimental|NBI|Tandem colonoscopy with NBI follow by WL
89146746|NCT03696992|Active Comparator|BLI|Tandem colonoscopy with BLI follow by WLI
89146747|NCT03696992|Experimental|WLI|Tandem colonoscopy with WLI follow by WL
89146748|NCT02742272||ED Headache or Migraine Patients|The investigators will perform a prospective cohort study of patients ages 6-18 years presenting to the ED with a complaint of headache or migraine over a 12 month period.
89146749|NCT02631941|Experimental|A-B1-B2-C-D|"Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 days followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146750|NCT02631941|Experimental|B1-C-A-D-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146751|NCT02631941|Experimental|C-D-B1-B2-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146752|NCT02631941|Experimental|D-B2-C-A-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146753|NCT02631941|Experimental|B2-A-D-B1-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146754|NCT02631941|Experimental|D-C-B2-B1-A|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146755|NCT02631941|Experimental|B2-D-A-C-B1|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146756|NCT02631941|Experimental|A-B2-B1-D-C|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146757|NCT02631941|Experimental|B1-A-C-B2-D|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146758|NCT02631941|Experimental|C-B1-D-A-B2|"Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:~Treatment A: Z7200 without oral activated charcoal~Treatment B1: Symbicort 1 without oral activated charcoal~Treatment B2: Symbicort 2 without oral activated charcoal~Treatment C: Z7200 with oral activated charcoal~Treatment D: Symbicort with oral activated charcoal A washout period of a minimum of 5 day followed treatment periods 1 to 4.~Treatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2."
89146759|NCT02742194|Placebo Comparator|Placebo|Conventional treatment (restrictive diet) plus capsules of 200 mg of cellulose (placebo) to be taken three times a day for six months.
89146760|NCT02742194|Experimental|Ginger group|Conventional treatment (restrictive diet) plus capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
89146761|NCT02690987|Experimental|Overweight/obese subjects|Overweight/obese volunteers with BMI 28.0-50.0 kg/m2, otherwise healthy. This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design.
89146762|NCT02690987|Experimental|Ex-smokers|"Abstinent tobacco dependent individuals who score at least moderately on tobacco dependence as measured retrospectively using the Fagerström Test for Nicotine Dependence (FTND), and who have been in stable tobacco abstinence for at least 6 weeks.~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
89146763|NCT02690987|Experimental|Ex-alcohol dependent subjects|"Abstinent alcohol dependent individuals who score at least moderately alcohol dependent as measured retrospectively using the Severity of Alcohol Dependence Questionnaire (SADQ), and who have been abstinent for at least 6 weeks.~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
89146764|NCT04020731|Experimental|Right-handed healthy volunteers|Magnetoencephalography (MEG) records
89146765|NCT02740166|No Intervention|Banding ligation group|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
89146766|NCT02740166|Experimental|Propranolol group|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
89146767|NCT02735018|Experimental|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
89146768|NCT02735018|Experimental|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
89146769|NCT04189874|Active Comparator|Conventional stool testing|"All patients randomly allocated to this arm will have their stools tested for the following:~a) Bacterial culture for Salmonella, Shigella, E.coli O157 and Campylobacter - specimen in Enteric Pathogen Transport medium (EPT) planted to: i) MacConkey agar, Sorbitol-MacConkey agar, Hektoen agar and Selenite broth all incubated overnight at 350C ii) Campylobacter agar incubated for 48 hours at 420C in a microaerophilic atmosphere b) Bacterial culture for Yersinia (≤ 18 years old): EPT specimen sent to Dynacare Laboratories for processing, results back in 10-14 days c) Ova & Parasites investigation: Sodium acetate-Acetic Acid-Formalin specimen sent to the Public Health Laboratories (PHL) for testing, results back in 7-10 days d) Viral culture: rarely requested, requires a specimen in a sterile container, sent to the PHL for testing, results back in 5-7 days e) Clostridioides difficile: specimen in sterile container, results in 1h (GeneXpert)"
89146770|NCT04189874|Experimental|BioFire FilmArray Gastrointestinal Panel|All patients randomly allocated to this arm will have their stools tested using a PCR-based molecular assay that can simultaneously test for 22 different infectious pathogens with a turnaround time of approximately 1 hour. As results become available, they will be available for review by the patient's healthcare providers in the electronic medical record.
89146771|NCT02732054|Active Comparator|HIV-Group 1|Receiving three intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, and 6
89146772|NCT02732054|Experimental|HIV-Group 2|Receiving four intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, 2, and 6
89146773|NCT00908375|Active Comparator|Pregabalin|A 75mg pregabalin capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
89146774|NCT00908375|Placebo Comparator|Surgar Pill|One Sugar pill capsule will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 Sugar pill capsules twice a day. The total duration of the treatment will be 3 weeks.
89146775|NCT03903497|Other|NBI assessment using the WASP classification|
89146776|NCT02734784|Experimental|Photodynamic Therapy and SRP|
89146777|NCT02734784|Sham Comparator|SRP and Sham Photodynamic Therapy|
89146778|NCT04247867|Experimental|Interventional arm - MCO dialysis membrane|4 weeks of dialysis with MCO (Theranova) membrane then dialysis for 4 weeks with MCO membrane and increased fiber intake
89146779|NCT04247867|Active Comparator|Control arm - high-flux membrane haemodiafiltration|4 weeks of high-flux membrane haemodiafiltration and 4 weeks of high-flux membrane haemodiafiltration and increased fiber intake
89146780|NCT02731664|Experimental|GLP-1|Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute
89146781|NCT02731664|Placebo Comparator|Control|Intravenous saline
89146782|NCT04242563|No Intervention|CONTROL GROUP|No virtual reality
89146783|NCT04242563|Experimental|INTERVENTION GROUP|Patient equipped with Virtual reality in transfer room.
89146784|NCT05472272|Experimental|Formula Diet|Participants will receive a low-calorie formula diet product.
89146785|NCT05472272|Experimental|Food-Based Diet|Participants will receive a low-calorie food-based diet created by dietitians.
89146786|NCT02695004|Experimental|Donepezil 35 mg|Donepezil 35 mg or placebo
89146787|NCT02695004|Experimental|Donepezil 70 mg|Donepezil 70 mg or placebo
89146788|NCT02695004|Experimental|Donepezil140 mg|Donepezil 140 mg or placebo
89146789|NCT02695004|Experimental|Donepezil 210 mg|Donepezil 210 mg or placebo
89146790|NCT02695004|Experimental|Donepezil 280 mg|Donepezil 280 mg or placebo
89146791|NCT02512913|Experimental|Adapted/enhanced MAPS|Counseling sessions delivered by phone to the pregnant/postpartum women and to the husbands/partners
89146792|NCT02512913|No Intervention|Usual Care|Couples in the control condition will receive usual care
89146793|NCT00909389||Filipino Patients with Hypercholesterolemia|
89146794|NCT02694614|Experimental|smartphone-assisted dietary coaching|
89146795|NCT00910715|Active Comparator|EM-10 days doxycycline|
89146796|NCT00910715|Active Comparator|EM-doxycycline 15 days|
89146797|NCT00910715|Placebo Comparator|controls|
89146798|NCT02731586|Experimental|osseointegration using Allogenic MSC's|Evaluation of Osseointegration of Dental Implants to be done using Allogenic Mesenchymal Stem Cells.Primary and Secondary stability are measured using RFA.
89146799|NCT02731430|Active Comparator|group I: morphine group|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
89146800|NCT02731430|Placebo Comparator|group II: control group|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
89146801|NCT02734706|Experimental|LRC™ capsule|
89146802|NCT02734706|Placebo Comparator|Placebo capsule|
89146803|NCT02734628|Experimental|Dexpanthenol|A squeeze of ointment, approximately 0.5 cm in length corresponding to an amount of about 0.3 g of ointment, which is equal to 15 mg dexpanthenol , twice daily (once in the morning and once in the evening) over a period of 14 days was applied topically under occluded conditions
89146804|NCT02734628|Placebo Comparator|Placebo|Subjects received applications of placebo corresponding to verum
89146805|NCT05528822|Experimental|Group F: H-FICB under ultrasound guidance before general anesthesia|Group F was subjected to a high fascia iliaca compartment block under ultrasound guidance before general anesthesia.
89146806|NCT05528822|Experimental|Group P: PENG block under ultrasound guidance before general anesthesia|Group P was subjected to a pericapsular nerve group (PENG) Block under ultrasound guidance before general anesthesia.
89146807|NCT02731118|Experimental|Placebo and Salovum|6 times 4 gr placebo/Salovum day 1-2, 5 times 4 gr placebo/Salovum day 3-5, 4 times 4 gr placebo/Salovum day 6-14
89146808|NCT02731118|Experimental|Salovum and placebo|6 times 4 gr Salovum/placebo day 1-2, 5 times 4 gr Salovum/placebo day 3-5, 4 times 4 gr Salovum/placebo day 6-14
89146809|NCT02694770|Experimental|Neihulizumab|Patients will receive a total of 4 doses of Neihulizumab (AbGn-168H) on Day 1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), and Day 22 (Week 3) by 1-hour i.v. infusion.
89146810|NCT02694770|Active Comparator|"Conventional Treatment"|Patients will receive a 2nd line therapy for aGvHD at the discretion of attending physician according to the standard practice at the study center. Currently there is no treatment for sr-aGvHD is approved in USA or Europe. There is no Standard treatment of this disease is recommended by American Society for Blood and Marrow Transplantation (ASBMT). Therefore, the study is designed to allow any established institutional practice for off-label use of a commercially available product for patients in the Conventional Treatment arm. Patients in this arm may receive treatments provided in ASBMT guidance such as ATG, TNF-alpha inhibitors (such as Etanercept and infliximab), pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis, methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept, Dacliz + etanercept, Dacliz+ infliximab, and Dacliz/inflix/horse ATG.
89146811|NCT02731274|Experimental|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental one. Before the intervention of physical exercise program, subjects performed a Tapping Pedal Test to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
89146812|NCT02731274|No Intervention|Control|
89146813|NCT02731196|Experimental|Early exercise intervention group|Education, stabilization and neurodynamic level one exercises will be provided to the intervention group within one to two weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will be provided with education, stabilization and neurodynamic level two exercises and a pedometer to monitor step count between week 4 and week 10 following the surgery.
89146814|NCT02731196|Active Comparator|Late exercise intervention group|Education, stabilization and neurodynamic level one and two exercises will be provided to the active comparator group within 4-6 weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will also be given instructions and a pedometer to monitor step count between week 4 and week 10 following the surgery.
89146815|NCT02694926|Other|adrenal insufficiency|
89146816|NCT02734472||Hanzhong cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas were recruited in 1987.During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
89146817|NCT02734472||Mei county cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
89146818|NCT03695510|Experimental|Study arm|afatinib + pembrolizumab
89146819|NCT02739464|Experimental|Exercise + SOC PT/OT|SOC treatment plus a personalized, structured, and quantifiable exercise program (MP10) carried out soon after admission until hospital discharge (including during the BICU stay and time on ventilation.
89146820|NCT02739464|Active Comparator|SOC PT/OT|Only SOC for treating in-patient burn subjects
89146821|NCT02731040||Controls|Women who are/have been on bisphosphonate therapy for osteoporosis who have not suffered an atypical femoral fracture
89146822|NCT02731040||Fracture Group|Women who are/have been on bisphosphonate therapy for osteoporosis who have suffered an atypical femoral fracture
89146823|NCT02730806|Experimental|NLP PTSD intervention protocol|Behavioral intervention (NLP) - intervention method will be 5 weekly personal therapy and counseling sessions with a certified therapist specializing in NLP, implementing the NLP PTSD protocol, such as Visual Kinesthetic Dissociation (VKD) behavioral technique for PPPTSD cases
89146824|NCT02734082||Elevated Troponin and pathological EC|Patients with acute ischemic stroke with elevated Troponin
89146825|NCT02734082||No elevated Troponin or pathological EC|Patients with acute ischemic stroke without elevated Troponin
89146826|NCT02734082||Elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke with elevated Troponin T and pathological ECG and coronary angiography
89146827|NCT02734082||No elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke without elevated Troponin T and pathological ECG and coronary angiography
89146828|NCT02734160|Experimental|Galunisertib + Durvalumab|(Dose Escalation and Cohort Expansion) Galunisertib administered orally in combination with durvalumab administered intravenously (IV).
89146829|NCT02739308|Experimental|Intervention: Proprioceptive Training|"The intervention will be the implementation of a proprioceptive training program for the fencing athletes in the intervention group.~In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes, three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes, and preferably one of each category. The categories have exercises with different levels of difficulty and can change the exercises occur by different proposed levels or the complexity of the exercise by changing category. The training program will be implemented by the same evaluator over the 12 weeks."
89146830|NCT02739308|Placebo Comparator|Control|The control group will not make the intervention and will continue with the usual training fencing.
89146831|NCT02730650|Experimental|Platelet Rich Therapy|Each subject will receive six injections of Platelet Rich Plasma (PRP) at designated points on each side of their face (twelve total). Injection points are spaced evenly across the inferior border of the cheek and mid-cheek, and are consistent on each patient. Patients will receive a post-injection phone call within 48 hours of the procedure. Photographs will be taken at two time points as part of the research to serve as a point of comparison before and after platelet rich plasma. Patients will receive the Global Aesthetic Improvement Scale amd tje Face-Q Questionnaire 1 month post-op
89146832|NCT02730494|Active Comparator|Lcr Regenerans® vaginal capsule|Name: Lcr Regenerans® containing at least 10e7 CFU per intravaginal capsule. 1 vaginal capsule per day
89146833|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 3 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 3 days
89146834|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 4 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 4 days
89146835|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 5 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 5 days
89146836|NCT04167332||NMIBC|"Patients diagnosed with primary non-muscle-invasive bladder (NMIBC) cancer.~No experimental intervention will be administered. NMIBC patients will be diagnosed, treated and followed up according to guidelines-based institutional routines.~The clinical (demographic, operative and follow-up) and pathological data, and biosamples (blood, urine, bladder cancer tissue) of the patients will be collected in a completely anonymous way."
89146837|NCT02730572||Concerta to authorized generic (AG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to AG formulation will be observed.
89146838|NCT02730572||Concerta to equivalent generic (EG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to EG formulation will be observed.
89146839|NCT02739230|Active Comparator|Exparel Injection|
89146840|NCT02739230|Active Comparator|On-Q intraarthicual catheter placement|
89146841|NCT03690674|Experimental|Lifestyle Enhancement for ADHD Program|There is no comparison/control arm.
89146842|NCT02730182|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
89146843|NCT02738996|Experimental|60-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 30 min
89146844|NCT02738996|Experimental|30-15 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 15 min
89146845|NCT02738996|Experimental|15-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 60 min
89146846|NCT02738996|Experimental|60-15|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 15 min
89146847|NCT02738996|Experimental|30-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 60 min
89146848|NCT02738996|Experimental|15-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 30 min
89146849|NCT02733926|No Intervention|City kindergarten|Children living in a normal city kindergarten that hardly has vegetation in backyards
89146850|NCT02733926|Experimental|adding of vegetation into the backyards.|"Children living in a normal city kindergarten that has plenty of vegetation in backyards.~Intervention: adding of vegetation into the backyards."
89146851|NCT02733926|No Intervention|Nature kindergarten|Children living in a city kindergarten where children go regularly into a natural forest
89146852|NCT02733770|Active Comparator|Sleeve gastrectomy|US DOopler for Patient with BMI of 40 or more than 35 with co-morbidities underwent Sleeve gastrectomy
89146853|NCT02733770|Active Comparator|Mini Gastric Bypass|US DOopler for Patient with BMI of 40 or more than 35 wtih co-morbidities underwent mini gastric bypass
89146854|NCT02730026|Experimental|Surgery with Ketoprofen|Fifty healthy volunteers underwent removal one of lower third molar, will be treated to control pain, swelling and trismus with ketoprofen 100 mg
89146855|NCT02730026|Experimental|Surgery with Ketoprofen and Omeprazole|Fifty healthy volunteers underwent removal the other lower third molars, will be treated to control pain, swelling and trismus with ketoprofen 200 mg associated with Omeprazole 20 mg
89146856|NCT03682406|Experimental|CAMS-G|CAMS-G is an group-based adaptation of the Collaborative Assessment and Management of Suicidality (CAMS) that has been developed to address perceived burdensomeness and thwarted belongingness, two drivers of suicide risk. Ongoing assessment and treatment planning are completed using the CAMS Suicide Status Form in the group modality, with involvement from group members and group facilitators. Driver-focused intervention strategies and group process also occur in the group based upon the unique needs of the group members. Groups are 90-minutes in length and occur on a weekly basis.
89146857|NCT03682406|Other|Care as Usual|Care as usual includes access to all existing forms of treatment that currently exist at the Robley Rex VAMC and affiliated CBOCs, such as individual and group psychotherapy, suicide prevention programming and case management, psychiatric care, social work services, and substance use disorder counseling. We will essentially track the control condition over time as they engage in the typical services provided to suicidal Veterans through the Robley Rex VAMC. The CAMS-G study participants will have access to the same services delivered as part of care as usual, with the only difference being their participation in the CAMS-G treatment for suicidality.
89146858|NCT02730104||Cohort A: Patients with small bowel NET|Patients with small bowel NET (including appendiceal NETs)
89146859|NCT02730104||Cohort B: Patients with gastric NET|Patients with gastric NET (gastroduodenal)
89146860|NCT02730104||Cohort C: Patients with pancreatic NET|
89146861|NCT02730104||Cohort D: Patients with colorectal NET|Patients with colorectal NET (this includes mid-gut)
89146862|NCT02730104||Cohort E: Unknown primary tumor|
89146863|NCT02729948|Experimental|Screening (TCE)|Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
89146864|NCT02694692||Follow-up|No further interventions are planned for this trial and the three pain management interventions from the original study (NCT01561457) will remain our comparison groups (Kangaroo Mother Care alone, Sucrose alone, and Kangaroo Mother Care & Sucrose). All participants will be invited to back to the IWK Health Centre to receive their Vaccinations at 2, 6, 12 and 18 month time points as well as for their Neurodevelopment assessment at 18 corrected age (BSID-III).
89146865|NCT02738918|Experimental|Nulojix|
89146866|NCT02733536|Experimental|Scenario A|manikin with normal standard airway
89146867|NCT02733536|Experimental|Scenario B|Cervical immobilization using a standard Patriot cervical extraction collar (Oessur Americas, Foothill Ranch, CA, USA), applied to the manikin's neck by an instructor.
89146868|NCT02733536|Experimental|Scenario C|Cervical immobilization using a vacuum mattress (Ferno-Washington, Inc. Wilmington, OH, USA), applied to the manikin's neck by an instructor
89146869|NCT03207776|Other|Control|Treatment of patients in the usual manner based on their diagnosis and resources available at that site (Usual Care).
89146870|NCT03207776|Other|Intervention|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services (COPD Clinical Pathway).
89146871|NCT03195374||Patients with chronic non-cancer pain|Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
89146872|NCT02739386||Cohort Population|Individuals included in a large US-based administrative medical claims database with underlying autoimmune disorder exposed to ipilimumab for the treatment of melanoma.
89146873|NCT00636428|Active Comparator|1|Oral midazolam
89146874|NCT00636428|Active Comparator|2|IV Midazolam
89146875|NCT02733692|Experimental|GURHL Code Smartphone application|Experimental arm will receive the 'Understanding Reproductive Health for Ladeez (GURHL) Code 'app' (application) for their smartphone with sexual health information. The intervention is embedded in the smart phone application. This includes sexual and reproductive health knowledge, plus access to a National Planned Parenthood health educator, and directions to other nearby clinics. Participants will be assessed using A-CASI at 3 months after enrollment.
89146876|NCT02733692|No Intervention|Control|"The control arm will receive usual care. That is, they will receive a web-based flyer. This flyer will include a list of clinics and other trusted available resources, but without hyperlinks.~Participants will be assessed using A-CASI at 3 months after enrollment."
89146877|NCT02738762|Active Comparator|intervention group|enteral glutamine supplementation guided by glutamine level Enteral glutamine supplementation is started (day 1) at a dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams of L-glutamine ( Glutaperos®, GLNP Life Sciences). Enteral glutamine supplementation will be given for a maximum of 10 days or until the patient is discharged from the ICU
89146878|NCT02738762|No Intervention|control group|patients receive normal treatment, no glutamine supplementation
89146879|NCT02729870||Oral Glucose Gel|This group will consist of participants ages 1 - 7. The subject who are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
89146880|NCT02729870||Oral Placebo Gel|The group will consist of participants ages 1 - 7. The subjects who are less than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3- 7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
89146881|NCT02738684||lung cancer|A small sample exploratory study to predict gefitinib' s efficacy for late stage lung adenocarcinoma patients by plasma free nucleic acids EGFR gene mutation test
89146882|NCT02729792|Experimental|Single site rTMS|"Each treatment session will consist of:~1200 pulses of iTBS over a posterior target location followed by a 60 minute interval, then 1200 pulses of iTBS over an anterior target location."
89146883|NCT02729792|Active Comparator|Dual site rTMS|"Each treatment session will consist of:~600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location followed by a 60 minute interval, then 600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location."
89146884|NCT05628662|Experimental|Automated Insulin Delivery System (SAFE-AP)|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFE-AP) based on blood glucose estimations from CGM.
89146885|NCT02729558|No Intervention|observation|Watchful waiting
89146886|NCT02729558|Active Comparator|local stereotactic radiotherapy (SRT)|local SRT in three fractions of 8 Gy to the surgical cavity
89146887|NCT02729246|No Intervention|Control Group|
89146888|NCT02729246|Other|Surgery Group|The patients in this group will undergo Laparoscopic Gastric Bypass surgery
89146889|NCT02694848|Other|Salvianolate injection group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease
89146890|NCT02694848|Active Comparator|Aspirin group|Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
89146891|NCT02694848|Experimental|Salvianolate injection and aspirin group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
89146892|NCT04189718|Experimental|osseodensification protocol|Experimental: In the test group, osteotomy site preparation was performed using Osseodensification technique at 1100 rpm and implant was placed
89146893|NCT04189718|Active Comparator|conventional implant site preparation protocol|Control: in the control group, osteotomy site was prepared using conventional drilling protocol at 1100 rpm and implant was placed.
89146894|NCT02738528|Experimental|Experimental Group|Mental practice and brushing guidance in patients with Parkinson Disease
89146895|NCT02738528|No Intervention|Control group|Brushing guidance in patients without Parkinson Disease
89146896|NCT02729324|Experimental|FORRAD group|This group of patients will receive Medical Radiation Protectants (FORRAD®) during study for prevention and treatment of acute radiation-induced dermatitis. This is the experimental group.
89146897|NCT02729324|Active Comparator|Biafine group|This group of patients will receive Trolamine (Biafine) during study for prevention and treatment of acute radiation-induced dermatitis. This is the active comparator group.
89146898|NCT02738372||Chronic Shoulder Pain|"Men / women aged between 18 and 70 years.~Patients suffering from shoulder pain, defined as pain presented or exacerbated by movements in the shoulder, pain intensity ≥ 2 measured by a numerical scale with values from 0 to 10, meaning 0= no pain and 10= the worst pain, will be included in this study, among all these following shoulder pain conditions: (i) Rotator Cuff tendinopathy; (ii) Adhesive Capsulitis; (iii) glenohumeral instability; (iv) SLAP lesion; (v) and/or acromioclavicular pathology. Subjects will not be required to undergo diagnostic imaging (i.e. Magnetic Resonance Imaging) to diagnosis the pathology because of the recruitment will be carried out by clinical findings.~Duration of symptoms: greater than 3 months."
89146899|NCT02729168|Experimental|Human rabies vaccines|Five doses 0.5 mL vaccine INDIRAB® on D0, D3, D7, D14, D28 using administered intramuscularly.
89146900|NCT02733458|Experimental|GELAD/Radiation|Patients will be initially treated with two cycles GELAD chemotherapy, followed by 50-56Gy radiotherapy, and completed with another two cycles GELAD chemotherapy. GELAD chemotherapy will be repeated every 21 days. Radiotherapy will be delivered in 25-32 fractions.
89146901|NCT02733146||cardiac arrest patients|Patients who has suffered a cardiac arrest
89146902|NCT02738060|Experimental|Case group|The patients in case group will be received baked milk daily in the form of muffin for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.
89146903|NCT03320876|Experimental|filgotinib|
89146904|NCT02729090|Experimental|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks
89146905|NCT02729090|Active Comparator|Device: treadmill Train_Comb_aerobic|strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series.
89146906|NCT02729012|Active Comparator|Case|Allergic Rhinitis Children treated with hypertonic saline solution (NACL 3%+NAHCO3)
89146907|NCT02729012|Placebo Comparator|Control|Allergic Rhinitis Children treated with saline solution (NACL 0,9%)
89146908|NCT02728856|Experimental|Sun Protection Factor (SPF) 50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
89146909|NCT02728856|Experimental|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
89146910|NCT02728934||Golimumab Intravenous (IV)|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Golimumab IV.
89146911|NCT02728934||Infliximab|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Infliximab.
89146912|NCT02728778|Active Comparator|Botulinum toxin A|Single administration of incobotulinumtoxin A into the forehead (glabellar region); 34 U in five injection sites.
89146913|NCT02728778|Other|Acupuncture|Patients will receive four facial acupuncture treatments every two weeks.
89146914|NCT02731976|Experimental|GFD|After instruction of a dietician, participants adhered to a gluten-free diet for 4 weeks.
89146915|NCT02737904|Active Comparator|Control group|Usual care - conventional, personalised in-patient rehabilitation 4 weeks duration
89146916|NCT02737904|Experimental|Intervention group|Usual care - conventional, personalised in-patient rehabilitation - plus APT cycling programme 4 weeks duration
89146917|NCT02728700|Experimental|Treatment (sirolimus, HSCT, MMF)|Patients receive sirolimus PO starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil IV or PO TID on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.
89146918|NCT02737982||IHD Men|Men with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
89146919|NCT02737982||IHD Women|Women with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
89146920|NCT02728622|Experimental|Tamoxifen|Tamoxifen 40 mg is given orally once daily until progression
89146921|NCT02728622|Active Comparator|Chemotherapy|Paclitaxel 80 mg/m2 is given as an 1 hour infusion every 7 days or Caelyx 40 mg/m2 is given iv, first dose over 2 hours, later doses are infused over 1 hour, administered every 4 weeks or up to a maximum dose of 550 mg/m2. Until progression
89146922|NCT02728466|Active Comparator|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
89146923|NCT02728466|Active Comparator|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
89146924|NCT02728466|Placebo Comparator|Flavanols and procyanidins deprived supplement|Control supplement deprived of flavanols and procyanidins Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
89146925|NCT02728544|Experimental|Prader Willi syndrome|16 (8 males) PWS adolescents and young adults
89146926|NCT02728544|Active Comparator|Obese controls|16 - sex, age, and BMI-matched controls
89146927|NCT02733302|Experimental|Hope theory|
89146928|NCT02733380|Experimental|Chidamide combined with VDDT regimen|Chidamide 30mg，Oral twice a week with an interval of no less than 3 days combined with regimen：VDDT（Vinorelbine，Liposomal doxorubicin or mitoxantrone ，Dexamethasone and Thalidomide）：repeated every 14 days ，up to 12 cycles
89146929|NCT02737670|Active Comparator|Sulodexide|Sulodexide 25 mg twice per day for 40 days
89146930|NCT02737670|Placebo Comparator|Placebo|1 tablet twice per day for 40 days
89146931|NCT02732990|Experimental|Exercise training - Whole body exercise|Control subjects will train 2-legged cycling (whole body exercise) for 6 weeks
89146932|NCT02732990|Experimental|Exercise training - One-legged exercise|Control subjects will train high intense one-legged exercise for 6 weeks
89146933|NCT02732990|Experimental|Exercise training - 2-legged cycling CHF|CHF patients will train 2-legged cycling (whole body exercise) for 6 weeks
89146934|NCT02732990|Experimental|Exercise training - CHF|CHF Patients will train high intense one-legged exercise for 6 weeks
89146935|NCT02728310|Active Comparator|Levobupivacaine infusion|1500 mg of Levobupivacaine by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
89146936|NCT02728310|Placebo Comparator|Saline infusion|300 ml of Saline (for Levobupivacaine as placebo) by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
89146937|NCT00636584|Experimental|1|arm1: sodium nitroprusside group
89146938|NCT00636584|Placebo Comparator|2|arm2: control group,saline infused instead of sodium nitroprusside
89146939|NCT02728232|Experimental|Internal Iliac artery ligation group|in this group the patients will undergo bilateral internal iliac artery ligation prior to the hysterectomy procedure
89146940|NCT02728232|Active Comparator|Hysterectomy only|in this group patients will undergo cesarean hysterectomy only
89146941|NCT02732756|Experimental|Sleep Restriction|The Sleep Restriction condition will allow 6.5 hours in bed, which in previous research results in an average of 6.1-6.3 hours of nightly sleep. This condition reflects a realistic dose of sleep restriction (similar to the school-night sleep of 15-20% of healthy adolescents) that has been shown to be feasible and to induce daytime sleepiness, inattention, and irritability/moodiness in typically developing adolescents.
89146942|NCT02732756|Experimental|Sleep Extension|The Sleep Extension condition will allow adolescents to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep), which (a) is how long adolescents sleep during controlled trials of sleep satiation and naturally on non-school nights, (b) has been shown to result in a well-rested state, and (c) matches clinical recommendations for adolescents.
89146943|NCT02732522|Experimental|Misoprostol sublingual|
89146944|NCT02732522|Active Comparator|Misoprostol vaginal|
89146945|NCT02738294|Experimental|Suspected EGC group|Participants with suspected EGC from white light endoscopy were enrolled.The endoscopist first used white light endoscopy to identify suspected gastric lesions and assessed lesions carefully with magnifying view, non-magnifying NBI view and ME-NBI view in sequence. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
89146946|NCT02732678|Experimental|Cohort of a dose of Propranolol 80 mg/day|
89146947|NCT02732678|Experimental|Cohort of a dose of Propranolol 120 mg/day|
89146948|NCT02732678|Experimental|Cohort of a dose of Propranolol 160 mg/day|
89146949|NCT02732444||COPD and APD patients in LTOT|• COPD and APD patients in LTOT
89146950|NCT02732444||Healthy Control|• Patients without significant cardiorespiratory disease, matched for age and body mass index with the other group.
89146951|NCT02727920|Experimental|Experimental|drink containing pyridoxine, folate; B12); taurine, choline, glucuronic acid; tyrosine, phenylalanine*, malic acid, and caffeine administered one time.
89146952|NCT02727920|Placebo Comparator|Placebo drink|Placebo drink administered one time.
89146953|NCT02727764|Experimental|Cohort I|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e12 vg/ MCP joint, 0.6x10e12 vg/ PIP joint or 0.3x10e12 vg/ DIP joint single intra-articular injection
89146954|NCT02727764|Experimental|Cohort II|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint single intra-articular injection
89146955|NCT02727764|Experimental|Cohort III|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint ART-I02 or maximum Tolerated Dose (MTD) as assessed in cohorts I and II: single intra-articular injection
89146956|NCT02727686|Experimental|Water Load (WL) Post-Operative Day 1|All enrolled subjects passing conditions outlined in Intervention are eligible to be included. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Patient will have 30 minutes to consume WL, or will be excluded.
89146957|NCT02727608|Experimental|Eculizumab|Intravenous infusion
89146958|NCT02727530|Experimental|GROUP RECEIVING VISCERAL MANUAL THERAPY-ADVICES|Subjects will receive 2 manual therapy sessions and advices.
89146959|NCT02727530|Experimental|GROUP RECEIVING ADVICES|Subjects will receive advices.
89146960|NCT02727374|Experimental|EXPERIMENTAL|Physiotherapy intervention, plus cognitive-behavioural intervention
89146961|NCT02727374|Active Comparator|CONTROL|Physiotherapy intervention
89146962|NCT02727296|Active Comparator|propofol|Group 1 PROP (control): propofol: a propofol-remifentanil based general anesthesia.
89146963|NCT02727296|Active Comparator|sevoflurane|Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based general anesthesia.
89146964|NCT02732132|Active Comparator|Ketamine and Midazolam|ketamine 1 mg/kg midazolam 0.1 mg/kg
89146965|NCT02732132|Experimental|Propofol and Fentanyl|propofol 1 mg/kg fentanyl 1 mcg/kg
89146966|NCT02737514|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
89146967|NCT02737514|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
89146968|NCT02737514|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
89234872|NCT05888181|No Intervention|Control group (usual care)|No access to the study app, follow-up according to usual care standards. This includes informal screening for general wellbeing during outpatient clinic visits, with referral to specific allied health professionals for additional education or non-pharmacological support if needed. The scores derived from study-related questionnaires can be used as a guide for these discussions. As part of standard care, participants in both the control group and the intervention groups will also receive a standardised educational leaflet about RA.
89234873|NCT05888168||POAF|This group will consist of patients who have developed postoperative atrillary fibrillation (POAF) after undergoing coronary artery bypass grafting (CABG).
89146969|NCT03086876|Experimental|Stepping Stones Triple P|Trained practitioners will deliver Level 4 SSTP to parents in 6 weekly group sessions and will also provide 3 telephone of face to face contacts to each participant but they will not be involved in routine care for participants in either arm. Each therapist responsible for delivering SSTP will be trained in the Group Stepping Stones Training and Accreditation programme which includes three training days and a further half day accreditation workshop after 6 weeks. The group sessions not only educate but actively train the parents in skills and the individual consultations aim to facilitate independent problem solving. The learning objectives focus on maintaining behavioural change, using skills within a group learning environment, learning from peers in the group and sharing difficulties or achievements, providing support, considering if more intensive work is required, referring further if needed, talking about risk and protective factors operating within families.
89146970|NCT03086876|No Intervention|Treatment as usual (TAU)|"TAU will be available to participants in both arms of the trial. It may include a range of services such as:~1. Health visitor services; 2. Primary care engagement and advice; 3. Potentially some version of early intervention maybe provided by either community paediatric services or Child and Adolescent Mental Health Services, although our understanding is that very little is available for children of this age. 4. Parenting advice and support sessions by carers groups or other third sector organisations.~Parents allocated to TAU will receive a list of national and local resources and the Contact a Family guide to challenging behavior with tips and advice on social and health care supports."
89146971|NCT02737280|Active Comparator|Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
89146972|NCT02737280|Experimental|High flow oxygen therapy|High flow nasal cannula oxygen therapy with Airvo (TM, Fisher & Paykel Healthcare) device
89146973|NCT02727218|Experimental|chest tube removal after 3 hours|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal after 3 hours.
89146974|NCT02727218|Active Comparator|delayed chest tube removal|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal according to the department's protocol, most probably post operative day 1 (POD1)
89146975|NCT02721446|Other|VHA Cohort|Investigators will use Veteran Health Administration (VHA) electronic health record (EHR) data to construct patient-level Framingham stroke risk scores using previously validated methodology. Investigators will establish a cohort of live patients with at least one primary care visit 12 months prior to study initiation (Oct 1, 2015). Investigators will obtain EHR data for Framingham measurements of age, sex, systolic blood pressure (SBP), blood pressure treatment (yes/no), total cholesterol, high-density lipoprotein cholesterol, and smoking status in the prior 12 month period. SBP will be obtained from outpatient primary care visits only; if > 1 SBP is available the investigators will use the average of the last 2 outpatient SBPs prior to study initiation.
89146976|NCT02721446|Other|Eskenazi Health System Cohort|Investigators will use EHR data from Indiana Network for Patient Care (INPC) to identify a cohort of live patients with at least one primary care visit in the prior 12 months. Investigators will use identical methods to construct Framingham risk score variables from the EHR data.
89146977|NCT02727140|Experimental|Yoga with Asana (yoga postures)|
89146978|NCT02727140|Experimental|Yoga without Asana (yoga postures)|
89146979|NCT02727140|No Intervention|Wait-list control group|
89146980|NCT02737202|Experimental|Saracatinib|Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.
89146981|NCT02721602|Experimental|Intervention Group|Families in the Families Preventing Diabetes Together intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
89146982|NCT02721602|No Intervention|Measurement Only|No intervention only measurements
89146983|NCT02721368|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
89146984|NCT02721368|Active Comparator|Comparator medical device|Juvederm® Voluma® with Lidocaine
89146985|NCT02737124|Experimental|1000 Mg Acetaminophen|Acetaminophen will be given 24 hours before surgery
89146986|NCT02737124|Active Comparator|Placebo|A sugar pill will be given 24 hours before the scheduled surgery.
89146987|NCT02721524|Active Comparator|Group R (ring)|Patients in Group R will undergo tricuspid ring annuloplasty
89146988|NCT02721524|Active Comparator|Group S (suture)|Patients in Group S will undergo De Vega's suture annuloplasty
89146989|NCT02716532|Other|Peptamen AF|over 7 days
89146990|NCT02721056|Experimental|NBTXR3, IL or IA injection +SBRT|"Patients will receive a single intralesional (IL) injection of NBTXR3 at four increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 42% of the baseline tumor volume, activated by SBRT.~Patients with primary and secondary nodular intra hepatic cancers only will receive a single superselective transcatheter arterial (IA) injection of NBTXR3 at five increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 45% of the baseline tumor volume, activated by SBRT."
89146991|NCT02721290|Active Comparator|Femoral nerve block using Ultrasound and neurostimulator|Femoral block using the standard technique of ultrasound for femoral nerve identification and neurostimulator set at between 0.3-0.5 mA with quads muscle response for needle placement confirmation before injecting 20cc of Ropivacaine 0.5%.
89146992|NCT02721290|Experimental|Femoral nerve block using femoral artery target|Femoral block using the alternate technique of aiming for the inferolateral aspect of the femoral artery and injecting 20cc of Ropivacaine 0.5%.
89146993|NCT02721212|Experimental|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
89234874|NCT05888168||Non-POAF|This group will consist of patients who have not developed postoperative atrillary fibrillation (POAF) after undergoing coronary artery bypass grafting (CABG).
89146994|NCT02721212|Active Comparator|Control Group|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
89146995|NCT02855060|Experimental|Pelvic Binder|Commercially available device used to stabilize the pelvis
89146996|NCT02855060|No Intervention|No Binder|Standard of care
89146997|NCT02720978|Experimental|Intravenous oxytocin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:~Verification rupture of membranes and gestational age.~Choosing the treatment group Intravenous oxytocin from red envelope, randomly.~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way.~Data collecting after the delivery."
89146998|NCT02720978|Experimental|vaginal prostaglandin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:~Verification rupture of membranes and gestational age.~Choosing the treatment group vaginal prostaglandin from red envelope, randomly.~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way.~Data collecting after the delivery."
89146999|NCT02726984|Experimental|case|Patients with carotid plaque ≥ 50% symptomatic (ischemic stroke on CT or MR) during the last 15 days
89147000|NCT02726984|Experimental|control|Patients with asymptomatic carotid plaque ≥ 50%
89147001|NCT02726828|Active Comparator|group I: morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine in 1 ml volume intrathecally.
89147002|NCT02726828|Active Comparator|group II: ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
89147003|NCT02726828|Active Comparator|group III: morphine + ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
89147004|NCT02799134|Experimental|group1|take Dexamethasone at 22:00 on the first day, 0.5mg
89147005|NCT02799134|Placebo Comparator|group2|take Vitamin C at 22:00 on the first day, 0.5mg
89147006|NCT02799134|Other|group3|take Dexamethasone at 15:00 on the second day, 0.5mg
89147007|NCT02720822|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
89147008|NCT02720822|Experimental|Morphine Sulfate (0, 0, 8 mg)|Placebo on weeks one and two. Morphine 8 mg/day on week three.
89147009|NCT02720822|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo on week one. Morphine 8 mg/day on weeks two and three.
89147010|NCT02720822|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo on week one. Morphine 8 mg/day on week two. Morphine 16 mg/day on week three.
89147011|NCT02720822|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg/day on weeks one, two and three.
89147012|NCT02720822|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg/day on weeks one and two. Morphine 16 mg/day on week three.
89147013|NCT02720822|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on weeks two and three.
89147014|NCT02720822|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on week two. Morphine 24 mg/day on week three.
89147015|NCT02720822|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg/day on weeks one, two and three.
89147016|NCT02720822|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg/day on weeks one and two. Morphine 24 mg/day on week three.
89147017|NCT02720822|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on weeks two and three.
89147018|NCT02720822|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on week two. Morphine 32 mg/day on week three.
89147019|NCT02720900|Placebo Comparator|Maltodextrin|powder, 1.8g/day
89147020|NCT02720900|Active Comparator|B-GOS|powder, 1.8g/day
89147021|NCT02720666|Experimental|Group A:K-001 2700mg/d (1350mg BID)|K-001 1350mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
89147022|NCT02720666|Experimental|Group B: K-001 3240mg/d (1620mg BID)|K-001 1620mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
89147023|NCT02720666|Experimental|Group C: K-001 3780mg/d (1890mg BID)|K-001 1890mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
89147024|NCT02720666|Experimental|Group D: K-001 4320mg/d (2160mg BID)|K-001 2160mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
89147025|NCT02757872|Active Comparator|Vitamin D and fish oil|Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
89147026|NCT02757872|Active Comparator|Vitamin D and fish oil placebo|Dietary Supplement: Vitamin D Vitamin D3 (cholecalciferol), 2000 IU per day. Dietary Supplement: Fish oil placebo Fish oil placebo
89147027|NCT02757872|Active Comparator|Vitamin D placebo and fish oil|"Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).~Dietary Supplement: Vitamin D placebo Vitamin D3 placebo"
89147028|NCT02757872|Placebo Comparator|Vitamin D placebo and fish oil placebo|Dietary Supplement: Vitamin D placebo Vitamin D3 placebo Dietary Supplement: Fish oil placebo Fish oil placebo
89147029|NCT02720588||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV criteria
89147030|NCT02720588||Sibling group|Sex-matched unaffected siblings of ASD probands
88803909|NCT04776590|Experimental|Tislelizumab arm|Radiotherapy: PTV 41.4Gy in 23 Fractions，5 days per week; Chemotherapy: Paclitaxel (Albumin bound) (100mg per square meter of body-surface area weekly) and Caboplatin (area under the curve of 2 mg per milliliter per minute weekly) for 5 weeks, concurrent with radiotherapy; Immunotherapy: Tislelizumab (200mg per 3 weeks)
88803910|NCT00637676|Active Comparator|1|Implantation of PleurX-Pleural catheter plus talc pleurodesis
88803911|NCT00637676|Active Comparator|2|talc pleurodesis, no implantation of PleurX-Pleural catheter
88803912|NCT02469662|Experimental|Retrospective|Patients who have had primary or revision total elbow arthroplasty using the Nexel Total Elbow, and who have surgical details available
88803913|NCT02469662|Experimental|Prospective|Patients who are having primary or revision total elbow arthroplasty who will receive the Nexel Total Elbow
88803914|NCT02325154|Experimental|THA Patients|Patients undergoing unilateral total hip arthroplasty
88803915|NCT02432378|Experimental|Cisplatin + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
88803916|NCT02432378|Experimental|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
88803917|NCT00003454|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88803918|NCT04779788|Experimental|I-125 seeds loaded stent group|Patients who receive the I-125 seeds loaded stent insertion
88803919|NCT04779788|Active Comparator|Normal stent group|Patients who receive the normal stent insertion
88803920|NCT05605652|No Intervention|Control group|leveling and alignment will be commenced without micro- osteoperforations
88803921|NCT05605652|Experimental|Experimental group|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
88803922|NCT05605418|Experimental|CHESS intervention|Physicians and patients at the intervention group will receive training and support on the use of the multi-faceted CHESS system.
88803923|NCT05605418|No Intervention|Control|After site randomization, physicians at the control sites will manage their patients by usual care at hypertension clinics.
88803924|NCT04779632|Other|Crossover study: Fish Oil --> Safflower Oil|4 weeks of fish oil supplementation followed by 4 weeks of safflower oil supplementation
88803925|NCT04779632|Other|Crossover study: Safflower Oil --> Fish Oil|4 weeks of safflower oil supplementation followed by 4 weeks of fish oil supplementation
88803926|NCT04776200||Ballet Groups|It was invited the individuals, who were ongoing for at least 3 months in classical ballet dance activity in the dance studio, between December 2019 and March 2020.
88803927|NCT04776200||Control Groups|It was invited the individuals, who have just registered for classical ballet dance activity.
88803928|NCT04776122|Active Comparator|Control with no device|Breathing performed with no device
88803929|NCT04776122|Experimental|Therapy - device assisted breathing|Breathing performed with device
88803930|NCT01258387|Placebo Comparator|GGF2|Seven dosing cohorts: 2 patients randomized to receive 1 GGF2, 1 placebo; if no drug-related dose-limiting toxicities in GGF2-treated patient, other 4 patients in cohort will be randomized (3:1) and dosed
88803931|NCT05605262|Experimental|Intervention|Manukamed - 100% sterile manuka honey
88803932|NCT05605262|No Intervention|Control|No intervention was given. Participants receive standard wound care of the tympanic membrane which includes 0.3% Ofloxacin otic ear drops which were used twice a day for 5 days.
88803933|NCT02227654|Experimental|Abnormal Ovarian Ultrasound|Abnormal Ovarian Ultrasound
88803934|NCT05605184|Other|Survey|Breast cancer patients complete questionnaire concerning their use of medical apps.
88803935|NCT05605106||addict patients presenting with acute coronary syndrome|
88803936|NCT05605106||non addict patients presenting with acute coronary syndrome|
89147031|NCT02720588||TD group|Typically developing controls without lifetime ASD or a family history of ASD
89147032|NCT04167176|Active Comparator|Erector spinae plane block|ultrasound guided ESP Block after anaesthesia induction
88803937|NCT00003496|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88803938|NCT00003034|Experimental|Arm I|Patients receive ranpirnase IV over 30 minutes weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression. Patients demonstrating evidence of clinical response or stable disease may continue on maintenance therapy with ranpirnase as a single agent until disease progression.
88803939|NCT00003034|Experimental|Arm II|Patients receive doxorubicin as in arm I for up to 6 courses.
88803940|NCT03862352||Coronary artery perforation (iatrogenic)|Any coronary artery perforation defined according to the Ellis criteria.
88803941|NCT00003040|Experimental|Transoral CO2 laser laryngectomy and RT|Transoral CO2 laser supraglottic laryngectomy and irradiation
88803942|NCT04389398|Experimental|Pocket compression fixation belt|Pocket compression belt is used to compress the bleeding vessels and reduce bleeding after implantation.
88803943|NCT04389398|Active Comparator|Sand bag compression|Sand bag compression is used to compress the bleeding vessels and reduce bleeding after implantation.
88803944|NCT00383890|Experimental|Dexmedetomidine|Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
88803945|NCT00383890|Placebo Comparator|Placebo (PBO)|Placebo load for 10 min and Placebo maintenance for 15 min
88803946|NCT00003046|Experimental|Interleukin-12|
88803947|NCT04779086||1. group|Scale score results of first year physiotherapy and rehabilitation department students
88803948|NCT04779086||2. group|Scale score results of 2nd year physiotherapy and rehabilitation department students
88803949|NCT04779086||3. group|Scale score results of 3rd year physiotherapy and rehabilitation department students
88803950|NCT04779086||4. group|Scale score results of 4th year physiotherapy and rehabilitation department students
88803951|NCT03843944|Experimental|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
88803952|NCT04754828|Active Comparator|Bedside|The bedside rounding team will perform patient presentations at the bedside, with a focus on the patient, and will ensure nursing involvement when rounding on each patient,
88803953|NCT04754828|Active Comparator|Hallway|The hallway rounding team will present patients outside of the patient's room, without an emphasis on nurse participation.
88803954|NCT00003058|Experimental|Troglitazone|Patients received troglitazone 800 mg oral once-daily. Treatment continued as long as patient was responding or in stable disease clinically and ended if patient experienced progression or unacceptable toxicity.
88803955|NCT04775732|Experimental|ultra proactive arm|
88803956|NCT04775732|Active Comparator|reactive arm|
88803957|NCT04775498|Active Comparator|Face-to-face psychoeducation group|The group of face-to-face psychoeducation or standard intervention will consist of the participation by the patients include in all the sessions of a therapeutic education programme of the investigator center.
88803958|NCT04775498|Experimental|SIMPLe mobile application|The experimental intervention consists of the use of the SIMPLe application during 1 year: answers of 5 daily questions and to the weekly questions. Moreover, daily and personalized psychoeducation messages (adapted to the answers to the tests carried out) will be sent to user by notifications.
88803959|NCT00003520|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88803960|NCT04754750|Active Comparator|INVEGA Sustenna|INVEGA Sustenna is a one month long-acting injection (PP1M)
88803961|NCT04754750|Active Comparator|INVEGA Trinza|INVEGA Trinza is a three month long-acting injection (PP3M)
88803962|NCT00003532|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
88803963|NCT04779164|Experimental|Patients with type 2 diabetes|Patients with diabetes mellitus was evaluated in terms of pain scores and ultrasonographic femoral cartilage thickness and retrospective radiographic knee osteoarthritis scores.
88803964|NCT04779164|Other|Patients without type 2 diabetes|Patients without diabetes mellitus was evaluated in terms of pain scores and ultrasonographic femoral cartilage thickness and retrospective radiographic knee osteoarthritis scores.
88803965|NCT05589662||Hemophilia group|Patients with hemophilia, older than 18 years, with a diagnosis of hemophilic arthropathy of the knee and ankle. The different study variables will be evaluated following the indicated protocol.
88803966|NCT05589662||Healthy peers.group|Healthy subjects, older than 18 years, without joint damage at the time of the study, and physically active. The different study variables will be evaluated following the indicated protocol.
88803967|NCT03475394|Active Comparator|Group 1 (Chlorhexidine gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 1% chlorhexidine gel administered in subsequent visits.
88803968|NCT03475394|Experimental|Group 2 (Morus alba gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 16% Morus alba gel administered in subsequent visits.
88803969|NCT03475394|Placebo Comparator|Group 3 (Placebo)|Non surgical periodontal treatment at baseline and 0.1 ml of placebo gel administered in subsequent visits.
88803970|NCT01269424|Active Comparator|Cohort 1|LV gene transfer after concurrent chemo-radiotherapy
88803971|NCT01269424|Active Comparator|Cohort 2|LV gene transfer prior to concurrent chemo-radiotherapy
88803972|NCT01269424|Active Comparator|Cohort 3|Intra patient dose escalation of TMZ in patients with evidence of P140K marked cells
88803973|NCT03395912|Experimental|Intervention|Infiltration of the subcutaneous layer with local anesthetic and combined with adrenaline.
88803974|NCT03395912|No Intervention|control|Abdominal layers will be closed without Infiltration .
88803975|NCT00003556|Experimental|Arm I|Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally on days 1, 4, 8, and 11. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at each dose level of ALVAC-hB7.1. The maximum tolerated dose is defined as the dose of ALVAC-hB7.1 at which no more than 1 of 5 patients experiences dose limiting toxicity.
88803976|NCT03393338|Experimental|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
89147033|NCT04167176|Active Comparator|Port site infiltration technique|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of Local anesthetic (LA) mixture that will be divided equally between port sites
88803977|NCT03393338|No Intervention|Usual Medical Care|Usual medical care
88803978|NCT04778696|Active Comparator|conventional pace mapping|Conventional PVC pace mapping without visual guidance of PASO
88803979|NCT04778696|Experimental|PASO pace mapping|PASO pace mapping with visualisation in CARTO3
88803980|NCT04775576|Active Comparator|Group 1|This group will have fluid theraphy due to conventional methods. The participants in this group will have 8-10 ml/kg/hour cristalloid infusion. If the mean arterial pressure (MAP) is <65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
88805999|NCT01154699|Experimental|Usual Care first, then Bilevel PAP|"Subjects will begin the study by continuing their usual care for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period. After a Washout Period of an additional 4 weeks of usual care, they will then start Bilevel PAP therapy for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests."
89147034|NCT02726438|Experimental|Debio 1450|"Participants will receive 3 oral administrations of Debio 1450 at a dose of 240 mg approximately 12 hours apart. The last dose should be given approximately 2, 4, 6 or 12 hours prior to surgery with 3 patients each to be dosed at each of these time points.~If the surgery is delayed by more than 12 hours postdose, the patients could receive up to 2 additional administrations (approximately 12 hours apart) to ensure that the last dose is administered between 2 and 12 hours before the surgery."
89147035|NCT02726438|No Intervention|Calibration|A single participant will not receive the study drug, providing data to be used as calibration.
89147036|NCT02726516|Experimental|Treated|Treated volunteers will be administered one dose of PRJ-205 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of PRJ-205 for 4 days for the chronic testing.
89147037|NCT02726516|Placebo Comparator|Placebo|Placebo volunteers will be administered one dose of placebo 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of placebo for 4 days for the chronic testing.
89147038|NCT02726672|Experimental|Respiratory rehabilitation|Respiratory rehabilitation: Powerbreathe training of the inspiratory muscles at home twice a day (2 sessions of 30 inspirations / day) during 10 weeks
89147039|NCT02726672|No Intervention|control group|No respiratory rehabilitation
89147040|NCT02726594||Patients|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district of the University Zurich / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
89147041|NCT02726594||Subjects|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district ETH / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
89147042|NCT02720120|Experimental|Part 1: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
89147043|NCT02720120|Experimental|Part 1: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
89147044|NCT02720120|Experimental|Part 1: Ocrelizumab 2000 mg|Participants will receive single IV infusion of ocrelizumab 2000 mg.
89147045|NCT02720120|Experimental|Part 1: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)
89147046|NCT02720120|Placebo Comparator|Part 1: Placebo|Participants will receive single IV infusion of placebo matched to ocrelizumab.
89147047|NCT02720120|Experimental|Part 2: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
89147048|NCT02720120|Experimental|Part 2: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
89147049|NCT02720120|Experimental|Part 2: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 mg.
89147050|NCT02720276|Experimental|Training after acute stroke|Intervention: Outdoor walking and strength training.
89147051|NCT04189250|Placebo Comparator|Optimized carbonmonoxid rebreathing protocol (oCO)|2 min rebreathing period seated position capillary blood sampling
89147052|NCT04189250|Active Comparator|Automatized carbonmonoxide rebreathing protocol (aCO)|10 minutes rebreathing period supine position venous blood sampling
89147053|NCT02719964|Experimental|A: UCR Games→SP-Directed Therapy|Participants in Arm A will first participate in Visual Attention Program (UCR Games) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
89147054|NCT02719964|Experimental|B: Lumosity→SP-Directed Therapy|Participants in Arm B will first participate in General Cognitive Rehabilitation Games (Lumosity) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
89147055|NCT02719964|Experimental|C: SP-Directed Therapy→UCR Games|Participants in Arm C will first participate in Speech Pathologist-Directed Therapy followed by Visual Attention Program (UCR Games) with assessment sessions prior to and following each treatment intervention.
89147056|NCT02719964|Experimental|D: SP-Directed Therapy→Lumosity|Participants in Arm D will first participate in Speech Pathologist-Directed Therapy followed by General Cognitive Rehabilitation Games (Lumosity) with assessment sessions prior to and following each treatment intervention.
89147057|NCT02720354|Experimental|A single Intravenous bolus injection|A single Intravenous bolus injection of 11C[DMDPA]
89147058|NCT02719652||symptomatic ICAD|symptomatic intracranial atherosclerosis diseases
89147059|NCT02719652||asymptomatic ICAD|asymptomatic intracranial atherosclerosis diseases
89147060|NCT02719886|Experimental|Fetal growth ultrasound every 2 weeks|Ultrasound to measure fetal growth every 2 weeks (i.e. 28, 30, 32, 34, 36, 38 weeks gestation).
89147061|NCT02719886|Active Comparator|Fetal growth ultrasound every 4 weeks|Ultrasound to measure fetal growth every 4 weeks (i.e. 28, 32 and 36 weeks gestation). Usual Care.
89147062|NCT02719730|Experimental|Reimbursement arm|Participating caregivers will turn in receipts from grocery store purchases. At each of three study visits, participants in the reimbursement arm will receive reimbursement of up to 10% of their usual SNAP benefits for specific whole grain foods purchased at one of two chain stores in the previous month.
88803981|NCT04775576|Active Comparator|Group 2|Patients in the PVI group will be started on maintenance fluid therapy at 2-3 ml / kg / hour. In addition to standard monitoring, if PVI is <13% and OAB≥65mmHg in measurements made with PVI, current fluid therapy will continue. If PVI is <13% and MAP <65 mmHg, noradrenaline infusion will be started. If PVI is> 13% and OAB≥65 mmHg, 250 ml iv colloid bolus will be administered, and iv colloid bolus will be continued until the PVI is <13% in the 5-minute follow-ups. If PVI> 13% and MAP <65 mmHg, patients should receive 250 ml i.v. colloid infusion will be given, if MAP <65mmHg continues in 5 minutes follow-up, 250 ml i.v. Colloid and noradrenaline infusion will be started and repeated until the OAB≥65 mmHg and PVI <13%.
88803982|NCT00003070|Experimental|Stratum 1 < 350/mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
88803983|NCT00003070|Experimental|Stratum 2 < 350mg/m2 anthracycline dose|< 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
88803984|NCT00003070|Experimental|Stratum 3 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
88803985|NCT00003070|Experimental|Stratum 4 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
89147063|NCT02719730|No Intervention|Control arm|Participating caregivers will mail in receipts from grocery store purchases. Participants in the control arm will also be given the same guidance about preferred whole grain foods and whole grain products but will have no specific financial incentive related to purchases of whole grain foods during the 12-week study period.
89147064|NCT00636662||all|any patient exhibiting symptoms of influenza
88803986|NCT00003070|Experimental|Stratum 5 >= 350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
88803987|NCT00003070|Experimental|Stratum 6 >=350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
88803988|NCT00003070|Experimental|Stratum 7 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
88803989|NCT00003070|Experimental|Stratum 8 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
88803990|NCT03240536|Experimental|Intervention Group|Ordering physicians who have referred to a rheumatologist in the St. Joseph's rheumatology clinic randomized to the intervention group will receive a brief Choosing Wisely form (for education of guidelines) faxed with the referral notice. At one and two years all ordering physicians will receive by fax a three question survey.
88803991|NCT03240536|No Intervention|Control Group|Ordering physicians who have referred to rheumatologists in the control group will not receive the Choosing Wisely form. At one and two years all ordering physicians will receive by fax a three question survey.
88803992|NCT01896518|No Intervention|Counseling|
88803993|NCT01896518|Experimental|Nicotine lozenge|Participants will receive nicotine lozenge to use as needed for 12 weeks.
88803994|NCT01896518|Experimental|Tobacco lozenge|Participants will receive tobacco lozenge to use as needed for 12 weeks.
88803995|NCT04775186|Experimental|Laparoscopic Burch colposuspension|
88803996|NCT04775186|Experimental|midurethral sling|
89147065|NCT02726204|Active Comparator|Healthy Subjects|Seven healthy patients will serve as controls based on preliminary data in healthy volunteers using CAREX with gravity elimination alone versus gravity elimination plus path assistance.
89147066|NCT02726204|Active Comparator|Chronic Post Stroke Right Side Hemiparesis|Radiologically verified unilateral stroke patients with at least 4 months previously.
88803997|NCT00003088|Experimental|Sequential chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles followed by cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles.
88803998|NCT00003088|Experimental|Concurrent chemotherapy 14 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 2 weeks for four cycles with filgrastim days 3 to 10 of each cycle at 5 µg/kg rounded to either 300 or 480 µg total dose.
88803999|NCT00003088|Experimental|Sequential chemotherapy 14 days|Patients received doxorubicin 60 mg/m2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m2 every 2 weeks for four cycles followed by cyclophosphamide 600 mg/m2 every 2 weeks for four cycles, with filgrastim days 3 to 10 of each cycle (a total of seven doses) at 5 µg/kg, which could be rounded to either 300 or 480 µg total dose.
88804000|NCT00003088|Experimental|Concurrent chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles.
88804001|NCT04774874|Experimental|FOL- 005 (0.1 %)|topical formulation
88804002|NCT04774874|Experimental|FOL -005 (0.5 %)|topical formulation
88804003|NCT04774874|Experimental|FOL -005 (1.5 %)|topical formulation
88804004|NCT04774874|Placebo Comparator|Vehicle|topical formulation
88804005|NCT04775030|Experimental|CBD occlusal appliance|CBD occlusal appliance
88804006|NCT04775030|Placebo Comparator|occlusal appliance|Traditional material occlusal appliance
88804007|NCT00755560|Active Comparator|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
88804008|NCT00755560|Placebo Comparator|Placebo|Placebo BID for 15 days
88804009|NCT00003118|Experimental|Chemotherapy + Radiation + Surgery|
88804010|NCT00003118|Active Comparator|Surgery|
88804011|NCT05381714||Patients|Post-COVID-19 Functional Status (Post-COVID-19 Functional Status Scale), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), physical activity level (International Physical Activity Questionnaire), fatigue (Modified Borg Scale), shortness of breath (Modified Borg Scale) will be evaluated.
88804012|NCT05381714||Control|Respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), physical activity level (International Physical Activity Questionnaire), fatigue (Modified Borg Scale), shortness of breath (Modified Borg Scale) will be evaluated.
89147067|NCT02726126||C group, (n=25)|C group, (n=25) each patient received transdermal placebo patch
89147068|NCT02726126||TDF group, (n=25)|TDF group, (n=25) each patient received transdermal therapeutic system-fentanyl 50μg/h
89147069|NCT02726126||TDM group, (n=25)|TDM group, (n=25) each patient received transdermal therapeutic system containing 7 mg of melatonin
89147070|NCT02694458|Experimental|Modeling arm|Early vancomycin monitoring and bayesian dosage adjustment
89147071|NCT02694458|Sham Comparator|Control arm|Usual vancomycin dose and monitoring strategy
89147072|NCT02694302|Experimental|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
89147073|NCT02694302|Active Comparator|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
88804013|NCT00056498|Active Comparator|Active|Participants assigned to risperidone
88804014|NCT00056498|Placebo Comparator|Placebo|Participants assigned to placebo
88804015|NCT03066050||SMR MV Repair|This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.
88804016|NCT03066050||MV Replacement|This group of patients had been randomized in the SMR study to mitral valve replacement.
88804017|NCT03066050||MMR MV Repair|This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.
88804018|NCT03066050||CABG|This group of patients had been randomized in the MMR study to receive CABG
88804019|NCT04330144|Experimental|administration of hydroxychloroquine as PEP|
88804020|NCT04330144|Active Comparator|control with no PEP|
88804021|NCT00003130|Experimental|paclitaxel|Patients receive single fixed dose intravenous paclitaxel over 3 hours on day 1. Blood samples must be drawn prior to the first paclitaxel infusion and then at 1, 6, and 24 hours after the start of the infusion during course 1 only. Treatment courses of intravenous paclitaxel are repeated every 3 weeks at the discretion of the treating physician. Patients are evaluated for response after the second course. Patients are followed at the discretion of the physician.
88804022|NCT00058370|Experimental|histologic proof of medulloblastoma|This is a single-arm study of post-operative radioimmunotherapy (intrathecal 131-I-3F8), reduced-dose craniospinal radiation therapy (1800 cGy), primary site boost (to 5400 cGy) via IMRT and standard chemotherapy.
88804023|NCT00059228|Experimental|Estradiol|Experimental
88804024|NCT00059228|Placebo Comparator|Placebo|Placebo comparator
88804025|NCT00060008|Experimental|18FDG-PET scan and MR perfusion|Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.
88804026|NCT00062738|Experimental|nortriptyline|drug
88804027|NCT00062738|Experimental|paroxetine|drug
88804028|NCT00062738|Placebo Comparator|placebo|placebo
88804029|NCT00063362|Experimental|Lithium + divalproex + lamotrigine|
88804030|NCT00063362|Placebo Comparator|Lithium + divalproex + placebo|
88804031|NCT00064844|Placebo Comparator|Nicotine patch plus placebo gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
88804032|NCT00064844|Active Comparator|Nicotine patch plus active gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
88804033|NCT01896908|Experimental|Intervention|Sodium restriction (1.6g sodium daily - 4g salt) combined with 800 ml of fluid intake
88804034|NCT01896908|No Intervention|Control|Normal sodium diet (4g sodium daily - 10g salt) and free fluid intake
88804035|NCT01897376|Other|Pfannenstiel incision|
88804036|NCT01897376|Other|vertical skin incision|
88804037|NCT04774562|Experimental|Video-Assisted Discharge Education (VADE) Group|VADE group received video-assisted discharge education in addition to the physiotherapy program given to the PT group on the same day by the same physiotherapist. The VADE program included information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities, home settings. VADE was prepared as a presentation of written information and videos which is shown this information by a professional model. Video shoots were done by a physiotherapist experienced in the field of physiotherapy and rehabilitation after THR surgery. The presentation was stopped when participants have questions or have points were not understood and the necessary explanations were shown verbally and practically. Along with the physiotherapy booklet, the participants were given an educational booklet containing written and visual information prepared in the same content as VADE.
88804038|NCT04774562|Experimental|Physiotherapy (PT) Group|The physiotherapy program given to the PT group after THR surgery. The physiotherapy program included breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation. The whole program was taught verbally and practically to participants and their relatives. Information was given about the exercises to be added at the end of the first week and in the 4th week. A physiotherapy booklet prepared with the same content was given to the participants. The booklet was examined by the patient and relatives, and the questions they asked were answered by the same physiotherapist. The participants were informed that they should continue the exercises for 12 weeks.
88804039|NCT00067028|Experimental|Clofarabine + Ara-C|"Clofarabine 40 mg/m^2 by vein over 1 hour daily for 5 days.~Ara-C Starting dose: 1 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
88804040|NCT00067028|Experimental|Clofarabine + Idarubicin|"Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.~Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
89147074|NCT02716220|Experimental|'Percutaneous Coronary Intervention' /Scaffold Implantation|PCI for enrolled subjects: implantation of the DREAMS 2G Drug-Eluting Coronary Scaffold System
89147075|NCT02719808||Tenofovir1|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one week after delivery.
89147076|NCT02719808||Tenofovir2|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one month after delivery.
89147077|NCT02719808||Tenofovir3|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one week after delivery.
89147078|NCT02719808||Tenofovir4|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one month after delivery.
89147079|NCT02719808||Group without any treatment|100 patients don't receive any blockade therapies
89147080|NCT02261792|Active Comparator|A : 24 hours bed rest|24 hours bed rest
89147081|NCT02261792|Experimental|B : 24 hours Trendelenburg position|24 hours Trendelenburg position
89147082|NCT02719496|Experimental|IBEROGAST|Dose of 20 drops three times a day for 28 days, on constipation parkinsonian patients with disorders intestinal transit.
89147083|NCT02726048|Experimental|Full face/Nasal masks|Simplus/Eson
89147084|NCT02716454|Experimental|Early Surgery - ES|Early laparoscopic ileocaecal resection
89147085|NCT02716454|No Intervention|Step-up therapy - STUP|Treatment with step-up conservative approach according to good clinical practice.
89147086|NCT02725970||Children's Nutrition Research Center|Survey, no intervention.
89147087|NCT02725970||Western Human Nutrition Research Center|Survey, no intervention.
89147088|NCT02725970||Human Nutrition Research Center On Aging|Survey, no intervention.
89147089|NCT02725970||Delta Obesity Prevention Research Center|Survey, no intervention.
89147090|NCT02725970||Beltsville Human Nutr Research Center|Survey, no intervention.
89147091|NCT02725970||Grand Forks Human Nutr Research Center|Survey, no intervention.
89147092|NCT02719418||Tinzaparin|Hospitalized patients with chronic renal insufficiency (eGFR ≤ 30 mL/min/1.73 m2) at risk of VTE secondary to non-surgical reasons and receiving thromboprophylactic doses of tinzaparin 3500 or 4500 unit sub-cutaneous once daily.
89147093|NCT02716064|Experimental|TAP-CM Intervention|Patients in this arm will be encouraged to complete the Healthy Lifestyle App modules and use McMaster PHR to self manage their chronic disease. Participants will also be completing the health and life goals using the App. The TAPESTRY-CM reports generated will then be reviewed by the clinic huddle teams
89147094|NCT02719262|Experimental|Intervention|installing ventilation in the workplace
89147095|NCT05128526|Experimental|Short foot exercise without respiratory exercises|"The participant will place by the researcher in the standing position so that the width between both feet will equal the width of the pelvis and the second toe will align with the patella. During the Short Foot Exercise, the participant will ask to position the spine straight, maintain the pelvis in a neutral position, and place the centerline of the body. The starting position will be set by the researcher under the same conditions as the midway between the feet. The subjects will give feedback from the researchers to assist in the maintenance of accurate body alignment. SFE, only in a standing position.~The participants will keep in contact with the fibular head of the target bar to maintain a constant position during Short Foot Exercises. Afterward, surface EMG measurements will be taken from the same muscle groups for 10 seconds during the foot shortening exercises while without breathing."
89147096|NCT05128526|Experimental|Short Foot Exercise With Respiratory Exercise|The participants will keep in contact with the fibular head of the target bar to maintain a constant position during Short Foot Exercises. Afterward, surface EMG measurements will be taken from the same muscle groups for 10 seconds during the foot shortening exercises while with breathing.
89147097|NCT02718872|Experimental|Tobacco cessation online training|Six hour smoking cessation online training addressed to health professionals from hospitals in 3 Latin American Countries. Participants are monitored by local coordinators that act as champions. They offer their assistance to log into the online platform, fill out the questionnaires, complete the evaluation, including other technical support. Participants' progress is monitored in real time onto the web platform. The project coordinator at ICO sends a report of the participants progress every other week to coordinators, and if necessary personal emails to motivate students to finish the course and complete the evaluations.
89147098|NCT02725736|Experimental|Atosiban|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Atosiban group.
89147099|NCT02725736|Experimental|Nifedipine|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Nifedipine group.
89147100|NCT02716142|Experimental|Group A|rectal misoprostol 400 microgram
89147101|NCT02716142|Active Comparator|Group B|sublingual misoprostol 400 microgram
89147102|NCT01999556||Patient|Specimen Collection
89147103|NCT01999556||Relative|Specimen Collection
89147104|NCT02718950|Experimental|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks.
89147105|NCT04908878|Experimental|Group I (pectoral nerve (PECS) block -transversus thoracic plane (TTP) block group)|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
89147106|NCT04908878|Experimental|Group II (serratus anterior plane (SAP) block group)|Patients will receive US-guided SAP block after induction of general anesthesia.
89147107|NCT02725502|Active Comparator|Linagliptin treatment group|Group will receive linagliptin ( 5 mg / day ) for 3 months in addition to their insulin
89147108|NCT02725502|Placebo Comparator|Placebo group|Group will receive placebo for 3 months in addition to their insulin
89147109|NCT02715674|Placebo Comparator|control group|take 4lt/min oxygen with Plasti-med oxygen therapy mask
89147110|NCT02715674|Active Comparator|IS group|in postoperatively, patients will carry out Plasti-med TRIFLO 5 min per hour for 6 hours.
89147111|NCT02715674|Active Comparator|CPAP group|in postoperatively, patients will carry out 10 cmH2O noninvasive continuous positive airway pressure with BIPAP VISION 5 min per hour for 6 hours.
89147112|NCT02718794|Experimental|Simulation training first|A highly customized interactive medium or program that allows individuals to learn and practice real world activities in an accurate, realistic, safe and secure environment.
89147113|NCT02718794|Experimental|Problem-based learning first|Instructional use of examples or cases to teach using problem-solving skills and critical thinking.
89147114|NCT04125758|Experimental|Mindfulness training|Participants will listen to one to two 3-30 minute audio recordings each day for 4 weeks between study visits (28 days total) through the Healthy Minds @Work smartphone app and record when they listen to each recording on a paper log. The app will also collect data on which recordings, when, and for how long participants listen.
89147115|NCT04125758|Active Comparator|Tracking time spent on mobile device|Participants will record how much time they estimate they have spent on their phone in the past 24 hours, each day for 4 weeks (28 days total) between study visits.
89147116|NCT02718560|Experimental|Group 1 - Writing with 1 cm cue|This group uses to write space of 1 cm size
89147117|NCT02718560|Experimental|Group 2 - Writing with 1.5 cm cue|This group uses to write space of 1.5 cm size
89147118|NCT02718560|Experimental|Group 3 - Writing without cue|This group writes without using cues
89147119|NCT02718560|No Intervention|Group 4 - no writing|This group do not write. Only wrist mobilization is performed.
89147120|NCT02718638|Other|physical exercises group|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months (36 sessions). The patients remained seated while performing the exercises that were performed in both lower limbs. Ankle-cuffs and elastic bands (Theraband®, Akron-OH, USA) were used for performed the exercises. The physical exercises consisted of four different exercises and they were administered by a physical therapist following the adapted protocol.
89147121|NCT02725346|Experimental|Computer-assisted planning|Acromioplasty with planification
89147122|NCT02725346|Active Comparator|No planning|Acromioplasty without planification
89147123|NCT02715830|Experimental|One Artery|In this arm after obtain the good result after the angioplasty of one artery the procedure stops
89147124|NCT02715830|Experimental|More than one artery|In this arm, after obtain a good result of the angioplasty of one artery, we continue trying one or two more arteries
89147125|NCT05113862|Sham Comparator|LD Vehicle GNP|Low dose (LD) comparator (2.5nmol) - gold nanoparticle (12.8ug) without peptides
89147126|NCT05113862|Experimental|LD PepGNP-Covid19|Low dose (LD) peptide vaccine (2.5nmol) - gold nanoparticle (12.8ug) plus peptides
89147127|NCT05113862|Sham Comparator|HD Vehicle GNP|High dose (HD) comparator (7.5nmol) - gold nanoparticle (38.3ug) without peptides
89147128|NCT05113862|Experimental|HD PepGNP-Covid19|High Dose (HD) peptide vaccine (7.5nmol) - gold nanoparticle (38.3ug) plus peptides
89147129|NCT01959464|Experimental|Crinone vaginal progesterone gel|"Crinone is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system containing a water swellable but insoluble polymer, polycarbophil. Crinone 8% is formulated to provide a long-acting vaginal retention, and is prescribed daily. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg of progesterone. The reported time to maximum progesterone concentration is 6.8 +/- 3.3 hours with use of a single dose of Crinone 8%. Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes.~On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream."
89147130|NCT01959464|Placebo Comparator|Placebo vaginal gel|The couple will be given a prefilled applicator containing either Crinone gel (progesterone) or placebo vaginal gel, data collection sheets and laboratory requisitions. On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream.
89147131|NCT02715752||Herpes Simplex Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
89147132|NCT02715752||Human Papillomavirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
89147133|NCT02715752||Epstein-Barr Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
89147134|NCT02715752||Cytomegalovirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
89147135|NCT02715752||Varicella Zoster Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
89147136|NCT02718482|Experimental|Gemcitabine and Docetaxel|Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks
89147137|NCT02718482|Experimental|Ifosfamide|Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks
89147138|NCT05113082||Participants with SBS-IF|Participants with SBS-IF who as part of standard or routine clinical practice, that underwent intestinal transplantation over the last 10 years (both dead and alive at the time of study enrollment) will be observed in this retrospective observational study for 10 months.
89147139|NCT02725190|Other|Group 1|Normal sleep night.
89147140|NCT02725190|Other|Group 2|Sleepless night.
89147141|NCT02725034|Active Comparator|Group 1|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
89147142|NCT02725034|Experimental|Group 2|High definition endoscopy with Optic Enhancement targeted biopsies for gastric intestinal metaplasia.
89147143|NCT02715986|Experimental|Severly depressed patients|Recruitment of twenty depressive subjects will be conducted within the hospital service adult psychiatry.These patients are referred for indication of ECT sessions for severe resistant depression. Four MRI evaluations (3T MRI examination) are programmed in such patients to analyze structural changes in the hippocampus.
89147144|NCT02718014|Other|pre menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
89147145|NCT02718014|Other|post menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
89147146|NCT02718092|Active Comparator|Plastic Stent|Three 7 Fr OR two 10 Fr Plastic Stents will be used
89147147|NCT02718092|Active Comparator|Axios FCSEMS|15 mm Axios Fully Covered Self Expanding Metal Stent
89147148|NCT02717936|Other|Immunohistochemistry|Patients are investigated using immunohistochemistry with Pancytokeratin
89147149|NCT02717858|Experimental|Liraglutide|
89147150|NCT02717858|Placebo Comparator|Placebo|
89147151|NCT02725112|Experimental|Pregabalin ER- Target Release 330mg|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
89147152|NCT02725112|Experimental|Pregabalin ER - Slow Release 330mg|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
89147153|NCT02725112|Experimental|Pregabalin ER - Fast Release 330mg|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
89147154|NCT02725112|Experimental|Pregabalin IR - 300mg|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
89147155|NCT02725112|Experimental|Pregabalin ER - Target Release 82.5mg|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
89147156|NCT02725112|Experimental|Pregabalin ER - Aberrant Fast 330mg|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
89147157|NCT02724722|Experimental|Intervention|a simple flyer in one empty bag with face-to-face health education
89147158|NCT02724722|Placebo Comparator|No Intervention|a simple flyer in one empty bag with no face-to-face health education
89147159|NCT02715908|Experimental|LBEC0101|Etanercept 50mg
89147160|NCT02724566|Other|Apelin then Placebo|First clamp during which an apelin infusion will be administered followed by a wash-out period and then, a second clamp in which a placebo infusion will be administered
89147161|NCT02724566|Other|Placebo then Apelin|First clamp during which a placebo infusion will be administered followed by a wash-out period and then, a second clamp in which an apelin infusion will be administered
89147162|NCT05302310||Older adults (1A)|All older adults visiting/contacting the Information and Advice Center
89147163|NCT05302310||Older adults (1B)|These older adults will receive the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center
89147164|NCT05302310||Older adults (1C)|This group corresponds to a nested sample of older adults who will receive the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center and will participate in interviews with the research team.
89147165|NCT05302310||Informal caregivers (2)|The informal caregivers of older adults receiving the integrated care (intervention) provided by the nurse and the social worker of the Information and Advice Center will participate in interviews with the research team.
89147166|NCT05302310||IAC nurse and social worker (3)|The nurse and the social worker who provide the integrated care (intervention) in the Information and Advice Center will participate in bi-weekly meetings with the research team
89147167|NCT05302310||External collaborators (4)|The external collaborators who are involved in the care of the participating older adults and have collaborated with the nurse and the social worker of the Information and Advice Center will complete a survey sent by mail or e-mail.
89147168|NCT02724332|No Intervention|control group|Patients will be treated with radical hepatectomy only.
89147169|NCT02724332|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE
89147170|NCT02717702||ACS Patients|Subjects will be patients presenting to the Emergency Department for evaluation of ACS.
89147171|NCT02717780|Active Comparator|SEVO-FENTA|Patients scheduled for lower limb surgery will receive a balanced anesthesia with fentanyl and sevoflurane.
89147172|NCT02717780|Experimental|DES-REMI|Patients scheduled for lower limb surgery will receive a balanced anesthesia with remifentanil and desflurane.
89147173|NCT02717390|Experimental|Bright By Three (BB3) Intervention|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years
89147174|NCT02717390|Active Comparator|Texts for Child Safety (TCS) Intervention|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety [TCS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
89147175|NCT02724254|Experimental|AP611074 5% gel|100 mg twice daily doses of AP611074 5% gel
89147176|NCT02724254|Placebo Comparator|Placebo|AP611074 matching placebo gel
89147177|NCT02724176|Experimental|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
89147178|NCT02724098|Active Comparator|intravenous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.
89147179|NCT02724098|Active Comparator|subcutaneous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.
89147180|NCT04189328|Active Comparator|control group|conventional macrosurgical implant placement
89147181|NCT04189328|Experimental|test group|microsurgical implant placement
89147182|NCT02723942|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen by infusion.
89147183|NCT02723942|No Intervention|no intervention|no intervention
89147184|NCT04138316||Migraine patients|
89147185|NCT05291390|Active Comparator|Standard of care treatment plus pyronaridine|Standard of care treatment plus pyronaridine
89147186|NCT05291390|Placebo Comparator|Standard of care treatment plus placebo|Standard of care treatment plus placebo
89147187|NCT05015972|Experimental|CTA30X UCAR-T treatment|CD19+ R/R B Hematologic Malignancies patients be treated with a single dose of CTA30X UCAR-T cells. Total dose of(5-30)*10E6/kg cells will be administered at Day 0
89147188|NCT02541968|Active Comparator|Face-to-face CBT|16 sessions of individual CBT delivered in 14 weeks.
89147189|NCT02541968|Experimental|Internet-based CBT|Internet-based CBT (ICBT) with therapist support (14 weeks).
89147190|NCT02541968|Experimental|ICBT without therapist support|Internet-based CBT without therapist support (14 weeks).
89147191|NCT04189484|Experimental|Arm A: Evolocumab low dose|Single dose of evolocumab 21 mg subcutaneous (SC)
89147192|NCT04189484|Experimental|Arm B: Evolocumab intermediate low dose|Single dose of evolocumab 35 mg SC
89147193|NCT04189484|Experimental|Arm C: Evolocumab intermediate high dose|Single dose of evolocumab 70 mg SC
89147194|NCT04189484|Experimental|Arm D: Evolocumab high dose|Single dose of evolocumab 140 mg SC
89147195|NCT04189484|Experimental|Arm E: Alirocumab low dose|Single dose of alirocumab 15 mg SC
89147196|NCT04189484|Experimental|Arm F: Alirocumab intermediate low dose|Single dose of alirocumab 25 mg SC
89147197|NCT04189484|Experimental|Arm G: Alirocumab intermediate high dose|Single dose of alirocumab 50 mg SC
89147198|NCT04189484|Experimental|Arm H: Alirocumab high dose|Single dose of alirocumab 100 mg SC
89147199|NCT04189484|Placebo Comparator|Arm I: Placebo|Single dose of placebo SC
89147200|NCT02715440|Experimental|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs : 25% reduction of the benzodiazepines dose or related drugs every 2 weeks during nine weeks in order to stop the treatment .
89147201|NCT02715440|No Intervention|Delayed intervention|usual care without intervention
89147202|NCT02717000||NASH|
89147203|NCT02717000||No NASH|
89147204|NCT02716844|Experimental|Exercise Group,|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
89147205|NCT02716844|No Intervention|Control Group|Nothing given to control group, told to continue their normal life for 6 weeks.
89147206|NCT02723552|No Intervention|Control|Control participants undergo no intervention.
89147207|NCT02723552|Experimental|Exercise|Exercise group participants will undergo 16 weeks of 3x/week supervised aerobic exercise of at least 40 minutes per session. After the supervised exercise phase, they will be monitored and supported to maintain an increased physical activity level for eight months.
89147208|NCT02715596|Experimental|Intervention A|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
89147209|NCT02715596|Placebo Comparator|Intervention B|Placebo supplementation in a 15 cc emulsion stick-pack
89147210|NCT02716922|Experimental|Cervical cerclage|Women randomized to receive cerclage should receive cervical cerclage Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
89147211|NCT02716922|No Intervention|No intervention|No cerclage Women randomized to not receive cerclage represent the control arm
89147212|NCT00636740|Experimental|B|MER-101 20mg Tablets Regimen 1
89147213|NCT00636740|Experimental|C|MER-101 20mg Tablets Regimen 2
89147214|NCT00636740|Active Comparator|A|Zometa Injection
89147215|NCT01002014|Experimental|Nipple Sparing Mastectomy|Patients who undergo nipple sparing mastectomy with preservation of the nipple areolar complex.
89147216|NCT02716688|Experimental|Radiotherapy and S-1 arm|Radiotherapy will be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy. Preplanned concurrent S-1 (70mg/m²/day) will be administered on Day 1 for 14 days, every 3 weeks. After dCRT, maintenance S-1 will be given up to two cycles.
89147217|NCT02716766|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
89147218|NCT02716766|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily from Day 1 to 14
89147219|NCT02716610|Experimental|INH 69 U (low)|single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)
89147220|NCT02716610|Experimental|INH 69 U (high)|single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
89147221|NCT02716610|Experimental|INH 139 U|single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.
89147222|NCT02716610|Experimental|INH 208 U|single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
89147223|NCT02716610|Active Comparator|LIS 18 U|single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.
89147224|NCT02715362|Experimental|TAI-GPC3-CART cells|A single dose of GPC3-CART cells will be administered by transcatheter arterial infusion(TAI) mediated as one dose infusion. The dose is 1-10x106/kg GPC3-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide. Patients will undergo cannula--DSA radiography--CAR-T cells perfused into hepatic artery. The cells perfusion process would last 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
89147225|NCT02694224|Experimental|vismodegib plus chemotherapy|Vismodegib 150 mg orally during paclitaxel and then dose dense epirubicin + cyclophosphamide (EC) therapy (see active comparator arm)
89147226|NCT02694224|Active Comparator|chemotherapy|Paclitaxel 80 mg/m2 weekly on days 1, 8 and 15 each 21 days x 12 doses and then dose dense E (90 mg/m2) plus cyclophosphamide (CPA) 600 mg/m2 each 2 weeks x 4 doses
89147227|NCT00782288|Active Comparator|1|low dose 0.05mg digitoxin given once daily for 28 days
89147228|NCT00782288|Active Comparator|2|higher dose 0.1mg digitoxin daily for 28 days
89147229|NCT00782288|Placebo Comparator|3|placebo given daily for 28 days
89147230|NCT04078178|Other|Randomized Crossover|The primary outcome of this study will be objective measures of cognitive performance measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline, crossover, and the end of study. Subjects will receive 1200 mg Niagen and PBO dispensed in randomized blocks. All subjects will receive both.
89147231|NCT02723318|Experimental|Financia Coaching & Social Services Referrals|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
89147232|NCT02723318|Active Comparator|Social Services|Enrollment in the control arm offers access to social services referrals.
89147233|NCT04189094|Experimental|Sintilimab + CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions). After PCI, Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
89147234|NCT04189094|Active Comparator|CRT arm|Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
89147235|NCT03984500|Other|Education|"During phase 1 of this study parents who attend in person education sessions will be recruited to have their standard sessions video-taped, timed, and reviewed by the SCTaware Team. Subjects will complete before and after education questionnaires that will then be reviewed to see how much participants learned about SCT, how education was not clear and/or appropriate (too much medical jargon). The SCTaware education will then be created based on review of these videos and participants' survey responses.~For phase 2 of the study, the same recruitment strategy will be utilized. Participants will receive SCTaware and complete before and after questionnaires for evaluation. Participants in this phase will also complete follow-up questionnaires at 1 and 6 months."
89147236|NCT02715128|Active Comparator|real tDCS|anode over electrode position F3, cathode over F4, 20 min, 2mA intensity
89147237|NCT02715128|Sham Comparator|sham tDCS|frequency and duration correspondent active tDCS, ramp in and ramp out periods only without intermittent stimulation
89147238|NCT00611312|Experimental|1|Cognitive Training
89147239|NCT02712944|Active Comparator|Testosterone|Testosterone intramuscular every 2 weeks
89147240|NCT02712944|Placebo Comparator|Saline|Saline intramuscular every 2 weeks
89147241|NCT02712866||Patients treated with vedolizumab|
89147242|NCT02693678|Experimental|Massage|10 min massage therapy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
89147243|NCT02693678|Experimental|Diathermy|10 min diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
89147244|NCT02693678|Sham Comparator|Sham diathermy|10 min sham diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
89147245|NCT02693912||acute lung injury|Patients with a diagnosis of acute lung injury (ALI) under mechanical ventilation.Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
89147246|NCT02693912||control|Patient under mechanical ventilation without any lung diseases. Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
89147247|NCT00600483|Experimental|gentamicin Group|Insertion of 2 gentamicin-collagen sponges between the sternal halves before closure of the sternotomy
89147248|NCT00600483|No Intervention|Control Group|Standard of care, ie, insertion of no gentamicin-collagen sponge.
89147249|NCT04132232|Experimental|Treatment Group|"The patient will exhaled into the Smokerlyzer® device will at each visit~Exhaled carbon monoxide and fetal carboxyhemoglobin levels will be disclosed to the patient~Risks of adverse perinatal outcomes related to maternal carboxyhemoglobin and fetal carboxyhemoglobin level will be provided."
89147250|NCT04132232|No Intervention|Control Group|"The patient will exhale into the Smokerlyzer® device at each visit.~Exhaled carbon monoxide and fetal carboxyhemoglobin level will NOT be disclosed to the patient~No risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin levels will be provided"
89147251|NCT02656719|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
89147252|NCT02656719|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
88804041|NCT00067028|Experimental|Clofarabine + Idarubicin + Ara-C|"Clofarabine 22.5 mg/m^2 by vein over 1 hour daily for 5 days.~Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
88804042|NCT00067808|Active Comparator|Decitabine 10 mg/m^2 IV|10 mg/m^2 intravenous (IV) over 1 hour daily for 10 days
89147253|NCT00649857|Experimental|1|Cetirizine HCl Tablets 10 mg
89147254|NCT00649857|Active Comparator|2|Zyrtec® 10 mg
88804043|NCT00067808|Active Comparator|Decitabine 20 mg/m2 IV|20 mg/m2 IV over 1 hour daily for 5 days
88804044|NCT00067808|Active Comparator|Decitabine 20 mg/m2 SQ|20 mg/m2 subcutaneous (SQ) daily for 5 days
88804045|NCT00493870|Experimental|TC|docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2
88804046|NCT00493870|Active Comparator|TAC|doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2
88804047|NCT05146622||Formative Research|Outdoor workers in the United States.
89147255|NCT04856618||Massive Transfusion Positive|Massive Transfusion Positive
89147256|NCT04856618||Massive Transfusion Negative|Massive Transfusion Negative
89147257|NCT02656407|Experimental|Ultrasensitive Doppler|Intraoperative ultrasensitive Doppler acquisitions by using an ultrasound device for functional area detection
89147258|NCT00611390|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
89147259|NCT00611390|Placebo Comparator|2|spray containing placebo.
89147260|NCT04167735|Active Comparator|Hearing Aid without Reverberation Canceller (no_RevC)|Hearing Aid without Reverberation Canceller (RevC)
88804048|NCT03287336|Experimental|Cohort 1|Dose of Tranexamic acid 5mg/kg will be administered.
88804049|NCT03287336|Experimental|Cohort 2|Dose of Tranexamic acid 10 mg/kg will be administered.
88804050|NCT03287336|Experimental|Cohort 3|Dose of Tranexamic acid 15 mg/kg will be administered.
88804051|NCT00003136|Experimental|Arm A|Cyclophosphamide (40mg/kg/day on days -6, -5 and -4), Carboplatin (1600, 1700 or 1800 mg/m2 on days -6, -5, -4 and -3), Amifostine (910 mg/m2 on days -6, -5, -4 and -3), Peripheral blood stem cell transplantation (day 0), G-CSF (beginning day 4)
88804052|NCT00003610|Experimental|capsaicin + radiation therapy|Patients receive one lozenge orally of capsaicin four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
88804053|NCT00003610|Placebo Comparator|placebo + radiation therapy|Patients receive one lozenge orally of placebo four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
88804054|NCT01063829|Experimental|Dose regimen 1|60 mg AIC246, one tablet per day
88804055|NCT01063829|Experimental|Dose regimen 2|120 mg AIC246, one tablet per day
88804056|NCT01063829|Experimental|Dose regimen 3|240 mg AIC246, one tablet per day
88804057|NCT01063829|Other|Placebo|Placebo arm
88804058|NCT00072566|Experimental|Treatment (bevacizumab, cyclophosphamide)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88804059|NCT00003622|Experimental|paclitaxel + vinorelbine|
88804060|NCT04773860|Experimental|Experimental|The experimental group shall be receiving a 4 week programme of Muscle Energy Techniques on the following accessory muscles; Sternocleidomastoid, Pectoralis Minor, Trapezius, Scalene muscles and Latissimus Dorsi
88804061|NCT04773860|No Intervention|Control group|The control group will be taking their prescribed medication and continue with any conventional physiotherapy recommended for the individual.
88804062|NCT00384046|Experimental|1|300mcg/day testosterone
88804063|NCT00384046|Placebo Comparator|2|Placebo arm
88804064|NCT05074862|Experimental|Ketone monoester (3-OHB)|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US). Bolus of 300 mg/kg followed by a 2-hour continuous enteral infusion with a dosing of 100 mg/kg/hour (maximal total dose 50 grams). There is a 1-hour lag between the bolus and the continuous infusion.
88804065|NCT05074862|Placebo Comparator|Placebo Treatment|Maltodextrin- and fatbased placebo in isocaloric, isovolemic dose to the experimental arm.
88804066|NCT00002806|Experimental|procarbazine + lomustine + vincristine + radiation|PCV followed by external-beam cranial irradiation using at least 6 MV photons.
88804067|NCT00002812|Experimental|Arm A - Standard BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow. Consolidation (Phase II) (5 weeks) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
88804068|NCT00002812|Experimental|Arm B - Standard BFM with Double Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (5 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
89147261|NCT04167735|Experimental|: Hearing Aid Reverberation Canceller enabled (RevC_1)|Hearing Aid Reverberation Canceller enabled (RevC_1)
89147262|NCT00764270|Active Comparator|Lipoic acid treatment|Participants take lipoic acid with a washout period before or after placebo.
89147263|NCT00764270|Placebo Comparator|Placebo treatment|Participants take placebo with a washout period before or after lipoic acid treatment
89147264|NCT02652039||cancer patients|
89147265|NCT02651961|Active Comparator|One stage exchange|One stage exchange of the chronically infected implant
89147266|NCT02651961|Active Comparator|Two stage exchange|Two stage exchange of the chronically infected implant
89147267|NCT04188938||Occult pneumothorax in trauma patients|Age>16, multi-trauma, consulted thoracic surgeon, underwent CXR- CT.
89147268|NCT02712710|Experimental|wear a functional knee brace|20 subjects with symptomatic medial compartment knee OA, with grade 2 to 4 on Kellgren and Lawrence scale, and showing willing to wear a functional knee brace. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
89147269|NCT02712710|No Intervention|no wear a functional knee brace|Another 20 subjects with comparable body height, weight, and sex. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
89147270|NCT02651883|Active Comparator|Screening invitation (with education)|Participants will receive a phone call providing (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic.
89147271|NCT02651883|Experimental|Self-collection for HPV testing|Participants in the intervention arm will receive a kit to self-collect a sample and return it for HPV testing. Participants will then receive a phone call providing their HPV results plus (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic, if desired.
89147272|NCT02722850|Experimental|ALIVE - Physical Activity|PA CONDITION: The goal of the PA condition is to encourage participants to gradually increase moderate to vigorous PA to 150 minutes per week and to increase resistance training to a total of 15 minutes per day twice per week.
89147273|NCT02722850|Experimental|ALIVE - Dietary Modification|DIET CONDITION: The goal of the dietary condition includes increasing intake of fruit and vegetable to 5-servings per day. The program also encourages participants to increase the consumption of colorful fruits and vegetables. The fat goals consist of reducing saturated fats to <10% of total kilocalories per day, trans fats to <3 grams per day, and added sugar to <50 grams per day.
89147274|NCT00650481|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
89147275|NCT00650481|Active Comparator|2|Ditropan XL® Tablets 5 mg
89147276|NCT02715050|Experimental|Group A - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
89147277|NCT02715050|Experimental|Group B - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
89147278|NCT02715050|Experimental|Group C - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
89147279|NCT02715050|Experimental|Group D - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group D, received program 2 before strength training, and program 2 after training."
89147280|NCT02651805|Experimental|Mechanical Insufflation-Exsufflation Group|Patients will receive usual care except suctioning or cough augmentation techniques+Mechanical Insufflation-Exsufflation
89147281|NCT02651805|Active Comparator|Usual Care Group|Patients will receive the usual care provided by the hospital, all interventions to control respiratory secretion will be verified in patient chart
89147282|NCT02712476|Active Comparator|Mannitol,furosemide|Mannitol 0.5mg/kg and furosemide 0.5mg/kg IV is compared with mannitol 1mg/kg and furosemide 0.5mg/kg
89147283|NCT02712476|Placebo Comparator|Mannitol, placebo|Mannitol 0.5mg/kg and placebo is compared with mannitol+forosemide
89147284|NCT02714972|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
89147285|NCT02714972|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
89147286|NCT02715206|Experimental|Control|middle schools not receiving keepin' it REAL; continue their own programs if any.
89147287|NCT02715206|Experimental|keepin' it REAL classic|middle schools will implement keepin' it REAL classic drug prevention curriculum
89147288|NCT02715206|Experimental|keepin' it REAL rural|middle schools will implement the keepin' it REAL rural curriculum
89147289|NCT00600171|Placebo Comparator|Placebo|Placebo Multi dose dry powder inhlaer
89147290|NCT00600171|Experimental|GW642444M|GW642444M
89147291|NCT02651727|Experimental|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 1- IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
89147292|NCT02651727|Experimental|Part B, Cohort 2- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 2- IV treatment for the first 2 cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15), followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
89147293|NCT02651727|Experimental|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
89147294|NCT02651649|Experimental|Parturients with FGR/OSA who use CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for Continuous Positive Airway Pressure (CPAP). Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
89147295|NCT02651649|No Intervention|Parturients with FGR/OSA and no CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for CPAP. Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
89147296|NCT02651493|Active Comparator|Down syndrome|photographs of individuals less than 18 yo with Down syndrome
89234875|NCT05888142|Active Comparator|"Roosevelt in clinic VR"|"Patients in this group will receive VR physical therapy exercises in clinic only, during the two week treatment phase of the study (approximately 10 treatment sessions). After the first 2 weeks, all patients will do VR homeworks, including VR exercises and VR mindfulness."
89234876|NCT05888142|Experimental|"Roosevelt in Clinic VR + VR homeworks"|"Patients in this group will receive VR physical therapy exercises in clinic, during the two week treatment phase of the study (approximately 10 treatment sessions). They will also take a VR system home and will be encouraged to do VR home works at home, during this first two week period. After the first 2 weeks, all patients will do VR homeworks, including VR exercises and VR mindfulness."
89234877|NCT05888129||locally advanced pancreatic cancer|"Locally advanced pancreatic cancer (LA-PC) is classified according to the National Comprehansive Cancer Networks (NCCN) guidelines.~Patients with the above conditions underwent surgery after neoadjuvant chemotherapy."
88804069|NCT00002812|Experimental|Arm C - Augumented BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
88804070|NCT00002812|Experimental|Arm D - Augmented BFM with Dbl Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
88804071|NCT01258855|Experimental|Arm I (ziv-aflibercept and aldesleukin)|Patients receive ziv-aflibercept IV over at least 1 hour in weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only). Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
88804072|NCT01258855|Experimental|Arm II (aldesleukin)|Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
88804073|NCT00003166|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours followed immediately by vincristine IV. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy may receive subsequent courses every 3 weeks and then every 4 weeks after 24 months of treatment. Patients may return to a 2- or 3-week treatment course at the discretion of the principal investigator.~Cohorts of 3 patients receive escalating doses of bryostatin 1 until the MTD is determined. The MTD is defined as the dose preceding that at which at least 1 of 3 patients experience dose-limiting toxicity."
88804074|NCT01259011|No Intervention|control|Written information on advance directives and the patient's right to have an advance directive is provided to every patient on the first day of dialysis treatment by a social worker at the clinic. A social worker documents whether the patient has an advance directive, a surrogate decision maker, and/or a Do-Not-Resuscitate (DNR) Order on a Comprehensive Interdisciplinary Assessment form. The social worker encourages patients to complete an advance directive and addresses their questions about life-sustaining treatment options. If completed, the advance directive is placed in the medical record.
88804075|NCT01259011|Experimental|SPIRIT intervention|The SPIRIT intervention is a two-session, 1½ hour-long, structured intervention that is composed of six steps (assessing representations, identifying and exploring gaps and concerns, creating conditions for conceptual change, introducing replacement information, summarizing, and setting goals and planning), presented to both patient and surrogate by a trained nurse interventionist in a face-to-face interview format based on the representational approach.
88804076|NCT03010111|Other|health care workers|health care workers including doctors, nurses, technicians and orderly who were hired in 2016 at the Hanyang University Hospital
88804077|NCT04712578|Experimental|Caffeinated Pre-workout Supplement|This arm will consist of ingestion of the commercially available, caffeinated Pulse pre-workout, manufactured by Legion Athletics, Inc.
88804078|NCT04712578|Active Comparator|Non-Caffeinated Pre-Workout Supplement|This arm will consist of ingestion of the commercially available, non-caffeinated Pulse pre-workout, manufactured by Legion Athletics, Inc.
89234878|NCT05888129||borderline resectable pancreatic cancer|"Borderline resectable pancreatic cancer (BR-PC) is classified according to the NCCN guidelines.~Patients with the above conditions underwent surgery after neoadjuvant chemotherapy."
89234879|NCT05888129||resectable pancreatic cancer|"Resectable pancreatic cancer (PC) is classified according to the NCCN guidelines.~There are no arterial and venous contact with tumor Patients with the above conditions underwent upfront surgery"
89234880|NCT05888038|Experimental|Intervention - use of VR|
89234881|NCT05887973||Wave 1|Youth participants who are enrolled in The T.R.I.G.G.E.R Project's summer youth employment program in 2022
89234882|NCT05887973||Wave 2|Youth participants who are enrolled in The T.R.I.G.G.E.R Project's summer youth employment program in 2023
89234883|NCT05887973||Wave 3|Youth participants who are enrolled in The T.R.I.G.G.E.R Project's summer youth employment program in 2024
89234884|NCT05887973||Wave 4|Youth participants who are enrolled in The T.R.I.G.G.E.R Project's summer youth employment program in 2025
89234885|NCT05887960||1|healthy persons to see normal ratio of of neutrophil lymphocyte and monocyte lymphocyte
89234886|NCT05887960||2|CKD patients stage (4-5) not on dialysis to see impact of (NLR) and (MLR) as regard inflamation and cardiovascular complications
89234887|NCT05887960||3|patients ESRD on maintenance hemodialysis compared with CKD pre dialysis patents and see if hemodialysis is better for removal toxic granules and inflamatory markers caused by CKD
89147297|NCT02651493|Active Comparator|Control group|photographs of individuals less than 18 yo with a genetic referral (not Down syndrome) or a healthy sibling to a child with Down syndrome
89147298|NCT02651181|Experimental|Closed Loop System|
89147299|NCT00650559|Experimental|1|Experimental surgical intervention.
89147300|NCT02536131|Other|Study group|7-10 sessions gut-directed hypnotherapy within 12 weeks
89147301|NCT04167657|Experimental|Arm1|Sintilimab monotherapy every 3 weeks, after a radiation targeting a single location no less than dose 30Gy/5f.
89147302|NCT02651025|Experimental|Resistance Exercise Program|Patients included in intervention group will submit to resistance exercise training during hemodialysis, three times a week, for twelve weeks. This program includes exercises for the upper and lower limbs.
89147303|NCT02651025|No Intervention|Passive Stretching Program|Patients included in control group will submit to passive stretching program of lower limbs, during hemodialysis, three times a week, for twelve weeks.
89147304|NCT02650947|Experimental|Sucralose|Subjects in this group ate capsule filled with sucralose 200 mg for 4 weeks (week 1-4) and measured oral glucose tolerance test (OGTT), acute insulin response (AIR), and gut microbe examination at week 4.
89147305|NCT02650947|Placebo Comparator|Placebo|Subjects ate empty capsule (placebo) for 4 weeks (week 1-4) and measured OGTT, AIR, and gut microbe examination at week 4.
89147306|NCT02650791|No Intervention|Prophylactic Platelet Transfusions|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 10^9/L.
89147307|NCT02650791|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral dose of Tranexamic Acid 1 gram three times daily. Tranexamic Acid will start when Platelet count is less than 50 x 10^9/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions
89147308|NCT02650869|Experimental|Standard care + Breast milk+ Probiotics|The study group will be fed with probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU) dissolved with 6 ml of milk then give 3 ml (3 billion probiotics) once daily with breast milk from first feeding.
89147309|NCT02650869|Active Comparator|Standard care|The control group will be given standard care without the addition of probiotics
89147310|NCT04035668|Experimental|Remibrutinib 100 mg bid|Remibrutinib 100 mg twice daily (bid)
89147311|NCT04035668|Experimental|Remibrutinib 100 mg qd|Remibrutinib 100 mg once daily (qd)
89147312|NCT04035668|Placebo Comparator|Placebo|Placebo group
89147313|NCT02650713|Experimental|Dose-Escalation (Part IA): RO6958688 + Atezolizumab|Participants will receive RO6958688 weekly (QW) at escalating doses starting at 5 mg, in combination with a fixed dose (1200 mg) of atezolizumab every 3 weeks (Q3W). RO6958688 dosage will not exceed the MTD if defined in the BP29541 study.
89147314|NCT02650713|Experimental|Dose/Schedule Finding (Part IB): RO6958688 + Atezolizumab|"Part IB will explore different RO6958688 administration schedules in combination with atezolizumab, consisting of:~Cohort A: will compare the QW vs Q3W dosing schedules at a flat dose of RO6958688.~Step Up dosing schedules: RO6958688 dose will start at 40 mg and increase with each administration up to the MTD or 1200 mg, whichever occurs first."
89147315|NCT02650635|Experimental|Treatment (CTX, pegfilgrastim, TLR8 agonist VTX-2337)|Patients receive cyclophosphamide IV over 30 minutes on day 1, pegfilgrastim SC on day 2, and TLR8 agonist VTX-2337 SC on day -6 of course 1 only and on days 9 and 16. Patients achieving CR, PR, or SD may continue therapy every 21 days for 3 additional courses. Treatment may then continue in the absence of disease progression or unacceptable toxicity.
89147316|NCT02650557||CSF group|consecutive patients with angiographically documented CSF
89147317|NCT02650557||control group|age- and gender-matched control subjects
89147318|NCT00650637|Experimental|1|
89147319|NCT00650637|Experimental|2|
89147320|NCT02650479|Other|IV exenatide - pilot study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
89147321|NCT02650479|Experimental|Treatment Group A - core study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
89147322|NCT02650479|Experimental|Treatment Group B - core study|IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
89147323|NCT02650479|Experimental|Treatment Group C - core study|IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
89147324|NCT02722772|Experimental|Etanercept treatment group|Intra-articular injection of etanercept of 25 mg/w/joint and Health education, exercise and diet guidance; treatment: 5 weeks (If both knees are involved, the more significant symptomatic side is chosen for injection by etanercept)
89147325|NCT02722772|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 5 weeks
89147326|NCT02650167|Experimental|Colostrum|
89147327|NCT02650167|Experimental|Witness|
89147328|NCT00650715|Active Comparator|VG|Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.
89147329|NCT00650715|Placebo Comparator|CG|The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.
89147330|NCT02650245|Experimental|Moderate protein and 10gm lactulose|40% of daily recommended intake of protein based on weight
89147331|NCT00611546|Placebo Comparator|1|Perenteral nutrition bottle and tubing are not protected from light
89147332|NCT00611546|Active Comparator|2|Perenteral nutrition bottle and tubing are protected from light
89147333|NCT02712242|Experimental|Platelet Rich Fibrin|PRF was laid directly on the palatal wound immediately after harvesting the tissue graft and stabilized
89147334|NCT02712242|Active Comparator|Butyl cyanoacrylate|Butyl cyanoacrylate was directly applied on the palatal wound after harvesting the tissue graft
89147335|NCT02712242|Placebo Comparator|Wet Gauze|Wet Gauze was placed for 1 minute on the palatal wound after harvesting the tissue graft
88804079|NCT04712578|Placebo Comparator|Placebo|This arm will consist of a flavor-matched placebo beverage without the active components contained in the supplements administered in the other study arms.
88804080|NCT02191033|Experimental|Text messaging|Smoking counseling, nicotine patch, text messaging
88804081|NCT02191033|Active Comparator|Standard of care|Smoking counseling, nicotine patch
88804082|NCT01260493|No Intervention|Conventional care, controlgroup|conventional care, control group
88804083|NCT01260493|Experimental|integrated health care chain|integrated health care chain. Geriatric assessment at emergency department (ED), case manager with multiprofessional team in the community, support for informal caregivers
88804084|NCT00003178|Experimental|1st Untreated Relapse for AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
88804085|NCT00003178|Experimental|Primary Refractory AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
88804086|NCT00003178|Experimental|MDS|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
88804087|NCT01260649|Experimental|ketamine|ketamine (0.5 mg/kg) followed by anesthetic agent titrated to sedation and succinylcholine titrated to muscle relaxation Right unilateral ECT at 5-6x seizure threshold three times a week
88804088|NCT01260649|Placebo Comparator|placebo|"IV saline, followed by anesthestic agent titrated to sedation and succinylcholine titrated to muscle relaxation.~Right unilateral ECT at 5-6x seizure threshold three times a week"
88804089|NCT01260883|Experimental|ketorolac 1 mg/kg|ketorolac 1 mg/kg iv given by 10 min infusion
88804090|NCT01260883|Active Comparator|ketorolac 0.5 mg/kg|ketorolac 0.5 mg/kg iv given by 10 min infusion
88804091|NCT01260883|Sham Comparator|placebo|placebo group received D5W 10 min infusion
88804092|NCT00076622||Randomized to drug continuation|Participants assigned to continue current antidepressant medication
88804093|NCT00076622||Randomized to drug discontinuation|Participants assigned to discontinue current antidepressant medication (no antidepressant medication)
88804094|NCT00076622||Participant preference to continue drug|Chose to continue antidepressant medication
88804095|NCT00076622||Participant preference to discontinue drug|Chose to discontinue antidepressant medication (no antidepressant medication)
88804096|NCT00003190|Experimental|Arm I (cytarabine, daunorubicin, etoposide)|Patients receive cytarabine IV continuously over 7 days and daunorubicin IV bolus followed by etoposide IV over 2 hours on days 1-3.
88804097|NCT00003190|Experimental|Arm II (valspodar, daunorubicin, etoposide, cytarabine)|"Patients receive treatment as in arm I with the addition of PSC 833 induction. A loading dose of PSC 833 IV is given over 2 hours, followed by a 74-hour continuous infusion of PSC 833 beginning 2 hours before daunorubicin and etoposide. Patients may receive a second induction course if residual leukemia is present in the bone marrow. Patients who experience a CR and meet certain other criteria receive postremission chemotherapy consisting of cytarabine IV continuously over 5 days plus daunorubicin IV followed by etoposide IV over 2 hours on days 1 and 2. Patients who are randomized to receive PSC 833 during induction chemotherapy receive a loading dose of PSC 833 before beginning a 48-hour continuous infusion of PSC 833 concurrently with cytarabine/daunorubicin/etoposide postremission chemotherapy.~After completing postremission chemotherapy, patients are randomized to a no further treatment group or IL-2 immunotherapy."
88804098|NCT04389164|Experimental|Tissue engineering method|The thickness of scar tissue in the middle of the dermis is removed by a roller cutter with a thickness of about 0.01 -- 0.02mm. After cleaning, the dermis can be used for punching and mesh drawing in the dermal rolling machine.Autologous epidermal basal cell suspension was prepared according to the description of autologous epidermal basal cell extraction box.The size of the remaining skin should be the same as the wound surface. After washing with normal saline, the wet yarn should be wrapped for later use.The autogenous scar dermal scaffold was prepared and transplanted onto the wound surface. The autoepidermal basal cells prepared were sprayed or coated between the mesh and the dermal scaffold. Autologous skin slices were transplanted onto the wound surface and fixed with pressure bandaging.
88804099|NCT04389164|Active Comparator|Conventional therapy|Autologous skin was grafted onto the wound surface and fixed with pressure bandage
88804100|NCT04773236|Active Comparator|Buffered Local anesthesia|Sodium bicarbonate with 2% lidocaine and 1:80.000 epinphrine
88804101|NCT04773236|Placebo Comparator|Non Buffered Local anesthesia|2%lidocaine with 1:80.000 epinphrine.
88804102|NCT00078728|Experimental|Family-based anxiety prevention program|Participants will complete an 8 session (1 session/week), cognitive behavioral therapy-based, family prevention program to be administered by a trained clinician, after randomization to the study. The prevention program will include 3 booster sessions that take place after the first 8 sessions.
89147336|NCT02712164|Experimental|Experimental: Modified NPWT dressing|In the experimental group, a microporous silver-impregnated foam with a thin silicone contact layer (Mepilex Ag) will be applied. A macroporous foam layer (V.A.C. GranuFoam) and an occlusive dressing (V.A.C. Drape) will then be applied to cover the foam, plus 3-5cm border of intact skin. The occlusive dressing will then be pinched and a 2cm hole will be cut to apply the SensaT.R.A.C. Pad that supplies pressure from the NPWT unit. NPWT will be applied at 125mmHg throughout treatment using KCI's InfoV.A.C. Therapy Unit. The donor site dressing will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
89147337|NCT02712164|Active Comparator|Control: Tegaderm|In the control group, the donor sites will be dressed with an occlusive dressing only (Tegaderm). The donor site dressings will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
89147338|NCT02650089|Experimental|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
89147339|NCT02650089|Experimental|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 8 repetitions were performed for each exercise, with an interval of 90 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
89147340|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
89147341|NCT02649933||Watch PAt 200|obese pregnant women, pregnancy between 12 and 15 weeks
89147342|NCT02693756|No Intervention|Control|Participants will be allowed to perform all usual activities but should refrain from performing the motor imagery exercises.
89147343|NCT02693756|Experimental|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
89147344|NCT00910767|Experimental|Closed loop (algorithm)|
89147345|NCT00910767|Placebo Comparator|Open loop|
89147346|NCT02722694|Experimental|Subcutaneous(SC) Abatacept|
89147347|NCT02722694|Placebo Comparator|Placebo|
89147348|NCT02650011||ACLF cohort|Patients who have chronic liver disease and admitted for acute deterioration of liver function
89147349|NCT02714582|Experimental|Bedside shift report|"The experimental group (nurses and patients) will:~develop a tailored BSR-intervention by use of co-design, diagnostic interviews, and pilot testing~use the tailored BSR-intervention, with participation of the patient, instead of the regular nurse shift report"
89147350|NCT02714582|No Intervention|No bedside shift report|The control group will not use bedside shift report, but will use the regular nurse shift report without participation of the patient
89147351|NCT04111263|Sham Comparator|PL+SHAM|Placebo intervention + sea level exposure
89147352|NCT04111263|Placebo Comparator|PL+HA|Placebo intervention + high altitude exposure
89147353|NCT04111263|Experimental|FP+HA|Fiber and polyphenol supplementation + high altitude exposure
89147354|NCT02649543|Active Comparator|Primary Closure|Primary Closure is made after surgery.
89147355|NCT02649543|Active Comparator|Delayed Primary Closure|Delayed Primary Closure is made after at least 7 days.
89147356|NCT02649543|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Device is used in the wound.
89147357|NCT02711696|Active Comparator|A, GCED cohort|GCED, Gluten Contamination Elimination Diet
89147358|NCT02711696|No Intervention|B, time cohort|Cohort B consisted of patients on long term follow-up that accepted a repeated biopsies 60 or more months later the first control biopsy.
89147359|NCT02711540||Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
89147360|NCT02711540||No Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did not receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
89147361|NCT02714660||Participants with Type 2 Diabetes|Adults with type 2 diabetes will be enrolled in this mixed methods observational study.
89147362|NCT02649621|Experimental|Amniotic Membrane Extract Eye Drop recipient|patients with limbal stem cell Deficiency who receive amniotic membrane transplantation and amniotic membrane extract eye drop as eye drop.
89147363|NCT00605150||Patients enrolled|Total number of patients enrolled
89147364|NCT02649465|Active Comparator|SGLT2 inhibitor|N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.
89147365|NCT02649465|Active Comparator|Sulfonylurea|N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.
89147366|NCT02711462|Other|Cohort 1|Subjects will receive 2mg of PF 06687234 or placebo via the SC route
89147367|NCT02711462|Other|Cohort 2|Subjects will receive 20mg PF 06687234 or placebo via the SC route
89147368|NCT02711462|Other|Cohort 3|This is an optional cohort that may be added anytime during the study. In this cohort, subjects will receive PF 06687234 or placebo via the SC route
89147369|NCT02711462|Other|Cohort 4|Subjects will receive 40mg of PF 06687234 or placebo via the SC route
89147370|NCT02711462|Other|Cohort 5|Subjects will receive 80mg of PF 06687234 or placebo via the SC route
89147371|NCT02711462|Other|Cohort 6|Subjects receive a single dose of PF 06687234 or placebo via the IV route
89147372|NCT02711462|Other|Cohort 7|This is an optional cohort where Japanese subjects will receive PF 06687234 or placebo via the SC route
89147373|NCT02711462|Other|Cohort 8|Subjects in this cohort may receive 20 mg of PF 06687234 or placebo via the SC route every week with a total of 5 doses
89147374|NCT02711462|Other|Cohort 9|Subjects in this cohort may receive 40 mg of PF 06687234 or placebo via the SC route every two weeks with a total of 3 doses
88804103|NCT00078728|Active Comparator|Evaluation only|Waitlist control group. Participants in this group will receive general information (in the form of a printed packet) about anxiety after randomization to the study. Families in this group will complete all study evaluations and will then be offered the option of participating in the prevention program. Families who accept will begin the prevention sessions and will receive the same CBT-based, family-based prevention program as the other treatment arm.
88804104|NCT00002836|Experimental|Filgrastim + Chemotherapy|
89147375|NCT02711462|Other|Cohort 10|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
89147376|NCT02711462|Other|Cohort 11|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
89147377|NCT02649309|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
89147378|NCT02649309|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
89147379|NCT02649309|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
89147380|NCT02649309|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
89147381|NCT02714738|Experimental|Infraclavicular Block|The patient will be positioned supine. The operating limb may be positioned abducted or adducted by side depending on operator preference and patient factors. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. Local anaesthetic (lidocaine 2% with epinephrine 1:200.000) will be injected posterior to the artery with the intention achieving the U shape, cranio-postero-caudal spread. Local anaesthetic will be deposited to the lateral and medial cords as well, if required. The total dose of the local anaesthetic will be 20-30 ml, as clinically indicated.
89147382|NCT02714738|Experimental|Axillary Brachial Plexus Block|The patient will be positioned supine with the operative upper limb extended, flexed at the elbow, rested on a pillow to expose the axilla. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. All four nerves in the axillary region are being blocked. The local anesthetic (lidocaine 2% with epinephrine 1:200.000, 15-25 ml) will be divided among the four nerves as clinically indicated by the spread, but at least 3 ml applied to each nerve.
89147383|NCT04167501||Non exposed|Women born between 1972 and 1982 who were not exposed to HPV vaccination
89147384|NCT04167501||exposed|Women born between 1983 and 1993 who were potentially exposed to HPV vaccination
89147385|NCT02711618|Experimental|UltraShape Contour I V3 treatment|Up to 60 healthy adult volunteers seeking noninvasive fat reduction, male and females at up to four sites, age of 18 to 60, with BMI above 28
89147386|NCT00651027|Experimental|A|
89147387|NCT00651027|Experimental|B|
89147388|NCT00651027|Experimental|C|200 mg
89147389|NCT02722226|Experimental|Simulation based sedation learning (Intervention Group)|The program includes online learning. It is followed by development of interactive presentations, based on simulated cases or simulated patients (actors), low fidelity simulation for specific technical skills as well as high fidelity scenarios of complications related to sedation.
89147390|NCT02722226|No Intervention|Control Group|
89147391|NCT00651105|Experimental|1|
89147392|NCT00651105|Placebo Comparator|2|
89147393|NCT02694146|Experimental|PRP (platelet rich plasma)|"37 patients with coxarthrosis are treated with 6ml of PRP (platelet rich plasma), obtained from blood extracted from patients in the 20 minutes prior to infiltration thereof.~For PRP administration:~The injection should be performed at room temperature.~The administration should be carried out under aseptic conditions.~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.~The PRP is injected into the synovial space."
89147394|NCT02694146|Active Comparator|Hylan G-F 20 (Synvisc-One ®)|"37 patients with coxarthrosis are treated with a pre-filled syringe of hyaluronic acid 60mg / 6ml (Synvisc-One ®).~It is necessary to remove synovial fluid before injecting Hylan G-F 20.~The injection should be performed at room temperature.~The administration should be carried out under aseptic conditions.~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.~The Hylan G-F 20 is injected into the synovial space.~After injecting Hylan G-F 20 the patient should stand 5 minutes."
89147395|NCT04167267|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
89147396|NCT04167267|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
89147397|NCT02714270|Active Comparator|modified partograph|routine modified partograph
89147398|NCT02714270|Active Comparator|paperless partograph|paperless partograph with no graph paper
89147399|NCT02649075|Active Comparator|SBI 10 g BID|Serum-derived Bovine Immunoglobulin / Protein Isolate (SBI) 10.0 grams twice per day
89147400|NCT02649075|Placebo Comparator|Placebo BID|Placebo w/control protein
89147401|NCT02694380||Head and Neck|Subjects with head and neck cancer receiving radiation therapy.
89147402|NCT02694380||Prostate|Subjects with prostate cancer receiving radiation therapy.
89147403|NCT02694380||Breast|Subjects with breast cancer receiving radiation therapy.
88804105|NCT00002836|Experimental|Filgrastim|
88804106|NCT04773548|Experimental|VR-JIT|
89147404|NCT02694380||Lung|Subjects with lung cancer receiving radiation therapy.
89147405|NCT02648841|Active Comparator|Adjuvant Chemotherapy|The interventions of adjuvant chemotherapy group is 8 cycles of SOX(S-1+Oxaliplatin) chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
89147406|NCT02648841|Experimental|Adjuvant Chemo-radiotherapy|The interventions of adjuvant chemo-radiotherapy group is concurrent chemo-radiotherapy to be give after 4-6 cycles of chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral. Six cycles of SOX chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
89147407|NCT02722070||Healthy Controls|Age matched control for the various clinical groups
89147408|NCT02722070||Neurodegenerative patients|
89147409|NCT02722070||Stroke patients|
89147410|NCT02722070||Neuropsychiatric patients|
89147411|NCT02645331|Experimental|Remind-to-move|RTM involved a wristwatch device worn on more-affected arm which emitted sensory cueing continuously to remind the children to use the more-affected hand to engage in daily activities or complete bimanual tasks intensively, 5 hour per day, 5 days every week, for 3 consecutive weeks.
89147412|NCT02645331|Active Comparator|Modified constraint induced movement therapy (mCIMT)|children were encouraged to wear a customer-made volar resting splint that extended from below the elbow to the fingertips on their noninvolved hands for 5 hour daily except for toileting, writing and specific physical sports, for 3 weeks. Each child was supervised by one therapist to complete structured unimanual practice with the affected hand during the supervised session, 5 days every week, for 3 consecutive weeks.
89147413|NCT02645331|Placebo Comparator|Conventional rehabilitation|Conventional splinting, muscle strengthening, stretching, and neurodevelopmental facilitation techniques for 1hr daily, 2 day per week for 3 weeks.
89147414|NCT02711150|Experimental|EPD Measurements|"Intervention:~PLL Length Measured through US will be done with the subject placed on the Epidural Positioning Device."
89147415|NCT02711150|Active Comparator|Flexed Position Measurements|"Intervention:~PLL Length Measured through US will be done with the subject placed in a flexed lumbar spine position."
89147416|NCT02644707|Experimental|L-selenomethionine|A group randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
89147417|NCT02644707|Placebo Comparator|Placebo|A group randomized to receive placebo (control group) for 6 months
89147418|NCT02711228|Experimental|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
89147419|NCT04612712|Experimental|Donafenib+ KN046|Donafenib 50mg BID/100 mg BID/200 mg BID orally + KN046 5mg/kg Q3W iv
89147420|NCT02644863|Experimental|DC-CIK|After accepting chemotherapy according to guidelines,patients will receive 3 cycles of autologous DC-CIK treatment.
89147421|NCT02644863|Sham Comparator|Chemotherapy|After the Chemotherapy by Paclitaxel and Cisplatin, patients will just regularly follow up.
89147422|NCT00652587|Experimental|A, LRTACE|hepatectomy with adjuvant transcatheter arterial chemoembolization
89147423|NCT00652587|Active Comparator|B, LR|hepatectomy alone
89147424|NCT02711072|Placebo Comparator|control group|
89147425|NCT02711072|Active Comparator|infiltration group|
89147426|NCT02710994|Experimental|CDFR0209, Then Losec|Subjects first received CDFR0209 each morning in a fasting state for 7 days. After a washout period of 14 days, they then received Losec 40 mg in a fasting state each morning for 7 days.
89147427|NCT02710994|Experimental|Losec, Then CDFR0209|Subjects first received Losec 40 mg each morning in a fasting state for 7 days. After a washout period of 14 days, they then received CDFR0209 in a fasting state each morning for 7 days.
89147428|NCT00302744|Experimental|Psilocybin|Single, 6-hour treatment with 0.2 mg/kg active psilocybin capsule.
89147429|NCT00302744|Active Comparator|Active Niacin Placebo|Each subject functioned as their own control, receiving niacin placebo capsule in a single 6-hour session.
89147430|NCT02644629|Active Comparator|Active IV|Will receive IV Ketamine, along with IN placebo.
89147431|NCT02644629|Active Comparator|Active IN|Will receive IN Ketamine, along with IV placebo.
89147432|NCT02710838|Experimental|Cancer group|All patients receive the infrared endoscopy after injecting indocyanine green（ICG） intravenously.
89147433|NCT02710838|Other|Non-cancer group|All patients receive the infrared endoscopy after injecting ICG intravenously.
89147434|NCT00652665|Experimental|A|Subjects received kali product under fasting conditions
89147435|NCT00652665|Active Comparator|B|Subjects received Aventis product under fasting conditions
89147436|NCT02721992||Graves' Disease|Patients with Graves' disease, without Graves' Orbitopathy
89147437|NCT02721992||Graves' Orbitopathy|Patients with Graves' disease, with Graves' Orbitopathy
89147438|NCT02644551|Experimental|CELEXT07|suspension that is applied topically to the infected nail(s) daily.
89147439|NCT02644551|Placebo Comparator|placebo|placebo is a suspension that simulates the physical properties of the experimental agent CELEXT07. It is applied topically to the infected nail(s) daily.
89147440|NCT02644551|Active Comparator|Penlac|Is a standard of care for the condition and is applied topically to the infected nail(s) daily.
89147441|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|Subjects will receive 4 massotherapy sessions and 4 of HYPOPRESSIVE ABDOMINAL GYMNASTIC (HAG).
89147442|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
89147443|NCT02721914|Experimental|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
89147444|NCT02644395|Active Comparator|Amlodipine|Current treatment of choice
89147445|NCT02644395|Experimental|Chlorthalidone|Testing new indication for approved drug
89147446|NCT04166565|Experimental|Daratumumab/bortezomib/cyclophospamide/dexamethasone (daraVCD)|"Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.~Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.~Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
89147447|NCT02721836|Experimental|Yoga|12 week yoga course, two times a week 75 minutes each time
89147448|NCT02721836|Active Comparator|Nutrition|3 counselling sessions within 12 weeks
89147449|NCT02644239|Active Comparator|Group control|classical ketogenic diet
89147450|NCT02644239|Active Comparator|Group case|Group case: modified ketogenic diet to reduce at least 20% saturated fat, up> 50% of the acid supply monounsaturated, increasing> 50% polyunsaturated fatty acid content and a lower ratio w6 / w3 at least 50% compared to classic diet used by the control group
89147451|NCT02710760|No Intervention|Control|Households in the control group receive no special treatment.
89147452|NCT02710760|Experimental|Adoption Encouragement Treatment|"Households in the Adoption Encouragement Treatment group were visited between March and April 2015 and offered child nutrition focused adoption encouragement. Both the male household head and the primary female caregiver were invited to attend these meetings (though the household head is the primary target), where the nutritional benefits of Quality Protein Maize (QPM) adoption for children were emphasized along with the agronomic properties. In addition, the fact that only small amounts of QPM are necessary to nourish children was highlighted and small seed bag sizes were offered. During the adoption encouragement visit, we offered the option to order up to three 2 kg bags of QPM for free."
89147453|NCT02710760|Experimental|Consumption Encouragement Treatment|In addition to receiving the Adoption Encouragement Treatment, households in the Consumption Encouragement Treatment group received additional information, targeted to the caregiver, and tools for separating Quality Protein Maize and targeting it to young children in the household in August 2015. They will additionally receive further guidance in February 2016.
89147454|NCT02644473|Experimental|Tranexamic acid|Investigators will administer topical (1.5g) TXA during total knee arthroplasty and total hip arthroplasty
89147455|NCT02644473|Placebo Comparator|Control|
89147456|NCT02710916|Sham Comparator|perimetric glaucoma patients|
89147457|NCT02710916|Active Comparator|preperimetric glaucoma patients|
89147458|NCT02710916|Sham Comparator|perimetric glaucoma control patients|
89147459|NCT04005872|Experimental|Nano Silver Fluoride|2 drops of nano silver fluoride (NSF) applied on the last soft carious layer using micro brush
89147460|NCT04005872|Active Comparator|Calcium Hydroxide|Calcium hydroxide placed on the last soft carious layer approaching the pulp
89147461|NCT02644317|Experimental|with modified shoe inserts|wear the modified shoe inserts and shoes for balance test.
89147462|NCT02644317|No Intervention|without modified shoe inserts|only wear the shoes for balance test.
89147463|NCT00652821|Experimental|A|Subjects received Kali product under fed condition
89147464|NCT00652821|Active Comparator|B|Subjects received Ortho-Mcneil product under fed conditions
89147465|NCT02714192|Experimental|BCTT|Participants received an standardized exercise stress test within 7 days of concussive injury. Stress test is stopped when participant experiences any exacerbation of symptoms. Heart rate at time of symptom exacerbation is referred to as the threshold heart rate (THR). Stress test is known as the Buffalo Concussion Treadmill Test.
89147466|NCT02714192|No Intervention|No BCTT|All participants in the no intervention arm did not get assessed using the BCTT until they had fully recovered or when they had their second clinic visit fourteen days after their first visit.
89147467|NCT02644161|Active Comparator|Combination acupuncture treatment (CAI)|Post stroke depression patients will receive Dense Cranial Electroacupuncture Stimulation (DCEAS) and body acupuncture. Patients will continue their existing antidepressant and rehabilitation therapy as usual.
89147468|NCT02644161|Sham Comparator|Least acupuncture stimulation (LAS)|Post stroke depression patients will receive Least acupuncture stimulation (LAS). Patients will continue their existing antidepressant and rehabilitation therapy as usual.
89147469|NCT04166175|Active Comparator|group 1 botox group|48 patients subjected to 80 IU botox injection under GAin lithotomy position in the 5,7,11, and 1 O'clock positions
89147470|NCT04166175|Active Comparator|group 2 lateral sphincterotomy group|48 patients subjected to lateral internal sphincterotomy under GAin lithotomy position
89147471|NCT02714114||Cases: HPV vaccinated group|"Women (18-26 years old) whom are previously vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.~No clinical evaluations will be performed."
89147472|NCT02714114||Controls: HPV unvaccinated group|"Women (18-26 years old) whom are not vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.~No clinical evaluations will be performed."
89147473|NCT02535975|Experimental|Metformin|Metformin 500mg PO three times a day for 24 weeks
89147474|NCT02535975|Placebo Comparator|Placebo|Placebo tab. PO three times a day for 24 weeks
89147475|NCT02714036|Experimental|MN-166 (ibudilast)|MN-166 (ibudilast) 10 mg capsules administered orally. Fifty (50) mg b.i.d. (5 capsules) in the morning and 50 mg b.i.d. (5 capsules) evening will be administered for a total daily dose of 100 mg/d. Study drug dosing may vary based on individual tolerability.
89147476|NCT02643927|Experimental|standard 8-weeks MBSR|8-week program
89147477|NCT02643927|Experimental|4-week shortened MBSR|Short 4 sessions intervention
89147478|NCT02643927|No Intervention|Control Group|control group: No intervention
89147479|NCT02710448|Experimental|Metformin|Metformin in patients with renal failure
89147480|NCT02643537||Luxation erecta|All patients with Inferior shoulder dislocation in fixed abduction, also known as luxatio erecta humeri (LEH)
89147481|NCT00652977|Active Comparator|I|The delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head.
89147482|NCT00652977|Other|II|Standard care at delivery: Manual support of the perineum
89147483|NCT02643771|Experimental|Diabetic group|Subjects with Chronic Periodontitis and Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
89147484|NCT02643771|Experimental|Nondiabetic group|Subjects with Chronic Periodontitis and without Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
89147485|NCT02710058||Arab American Women with Breast Cancer|We conducted a study using an evaluation assessment survey to assess the impact of the AMBER support groups on quality of life parameters, compliance with treatment appointments, and patient/family support. After reviewing preliminary results, we identified several recurrent themes, such as the need for health information, discrepancies around the extent of family support and disease disclosure, and an overall satisfaction with the support groups. To further examine these themes, we are initiating a qualitative research study using an in-depth interview guide. A trained interviewer bilingual in Arabic and English will conduct 10-15 in-depth interviews, to saturation, with AMBER's support group participants over a 6 month period.
89147486|NCT04166253|No Intervention|Control group|Control group of breast cancer patients will receive adjuvant AC chemotherapy
89147487|NCT04166253|Experimental|Vitamin D group|Intervention group of breast cancer patients will receive adjuvant AC chemotherapy in addition to vitamin D (alfacalcidol 0.5 mcg orally once daily
89147488|NCT04165707|Experimental|Keyto intervention arm|Keyto device + app
89147489|NCT04165707|Active Comparator|Weight Watchers comparator arm|Weight Watchers app
89147490|NCT04472858|Experimental|Cholangiocarcinoma|Cholangiocarcinoma
89147491|NCT04472858|Experimental|Squamous cell carcinoma of the head and neck|Squamous cell carcinoma of the head and neck（HNSCC）
89147492|NCT04472858|Experimental|Endometrial cancer|Endometrial cancer
89147493|NCT00653055|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fasting conditions
89147494|NCT00653055|Active Comparator|B|Subjects received the reference product, Dostinex under fasting conditions
89147495|NCT02708576|Experimental|NGM313|Administration of active NGM313
89147496|NCT02708576|Placebo Comparator|Placebo|Administration of placebo comparator
89147497|NCT04165785|Experimental|OPT IPL followed by MGX|"Subjects in the experimental arm will receive OPT IPL followed by MGX: OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.~Interventions:~Device: IPL Procedure: MGX"
89147498|NCT04165785|Sham Comparator|Sham OPT IPL followed by MGX|"Subjects in the sham comparator arm will receive Sham OPT IPL followed by MGX: Sham OPT IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham OPT IPL therapy, subjects will undergo MGX of both eyelids in both eyes.~Interventions:~Device: Sham IPL Procedure: MGX"
89147499|NCT02713724|Active Comparator|DAPS-group|Physical exercise
89147500|NCT02713724|Active Comparator|Standard-group|Limited physical exercise
89147501|NCT02643147|Experimental|CA125 guided strategy|In this group loop diuretic (Furosemide) dosage will be guided by Carbohydrate Antigen 125 (CA125) plasma levels
89147502|NCT02643147|Active Comparator|Conventional strategy|Standard treatment strategy Therapy is based on established european guidelines
89147503|NCT03932630|Experimental|Study intervention|
89147504|NCT03932630|Active Comparator|Control intervention|
89147505|NCT02709980|Placebo Comparator|Sleep Education|6 sessions of sleep education.
89147506|NCT02709980|Active Comparator|Cognitive Behavior Therapy for Insomnia|6 sessions of cognitive behavioral therapy for insomnia (CBT-I).
89147507|NCT04165551|Experimental|Probiotic|Volunteers will take 1 capsule per day containing 6x109 cfu of Lactobacillus BSL_PS71 in maltodextrin.
89147508|NCT04165551|Placebo Comparator|Placebo|Volunteers will take 1 capsule per day containing maltodextrin.
89147509|NCT04503902|Experimental|JS001+Donafenib|Donafenib 100mg QD/100 mg BID/200 mg BID orally + JS001 240mg Q3W iv
89147510|NCT02642913|Experimental|Enzalutamide without Sorafenib|Will get enzalutamide, at the dose approved by the FDA for prostate cancer. If this dose has serious side effects, a lower dose will be given to new patients as they take part in the study. At the end of this part of the study, the recommended dose of enzalutamide will be set for all patients on this study. More patients will then be treated with this dose.
89147511|NCT02642913|Experimental|Enzalutamide with Sorafenib|Will get enzalutamide and sorafenib. The first group of patients will get the recommended dose of enzalutamide with sorafenib by mouth either once or twice daily. The dose of sorafenib you receive will depend on when the patient starts the study. At the beginning of the study, patients will be treated with a lower dose of sorafenib. If this dose does not have serious side effects, a higher dose will be given to new patients as they take part in the study.
89147512|NCT04165629||Aspirin responders|On impedance aggregometry- Multiplate analyzer, if ASPI < 600 or ASPI/TRAP < 0.5
89147513|NCT04165629||Aspirin non-responders|On impedance aggregometry- Multiplate analyzer, if ASPI > 600 or ASPI/TRAP > 0.5
89147514|NCT04165629||Clopidogrel responders|On impedance aggregometry- Multiplate analyzer, if ADP < 500 or ADP/TRAP < 0.5
89147515|NCT04165629||Clopidogrel non-responders|On impedance aggregometry- Multiplate analyzer, if ADP > 500 or ADP/TRAP > 0.5
89147516|NCT03395925|Experimental|Celon Pro Surge|Ablation of thyroid tissue
89147517|NCT02708420|Other|Glidescope intubation|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
89147518|NCT02708420|Other|Macintosh Laryngoscope|This standard technique involves laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
89147519|NCT02642757|Experimental|Brief intervention|AUDIT brief intervention
89147520|NCT02642757|Sham Comparator|Control group|Pamphlet on alcohol use
89147521|NCT02708264|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
89147522|NCT02708264|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
89147523|NCT02642523|Placebo Comparator|Saline Infusion|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
89147524|NCT02642523|Experimental|Insulin Clamp|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
89147525|NCT02642523|Experimental|BNP Infusion (Nesiritide)|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
89147526|NCT02713802|Experimental|Test product|Propofol solution (1% [10 mg/mL]), via intravenous injection
89147527|NCT02713802|Active Comparator|Reference product|Propofol emulsion (1% [10 mg/mL]), via intravenous injection
89147528|NCT02642445|Experimental|Renal Sympathetic Denervation|Renal sympathetic Denervation are conducted from the adventitia of renal artery
89147529|NCT02642445|No Intervention|Control Group|Renal Sympathetic Denervation are not conducted in control group.
88806000|NCT01154699|Experimental|Bilevel PAP first, then Usual Care|"Subjects will begin the study by starting on Bilevel PAP for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests. After a 4 week Washout Period of usual care, they will start a Usual Care period for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period."
89147530|NCT02713958|Experimental|Tele rehabilitation|Telerehabilitation:The subjects in the study group will receive two treatments in Telerehabilitation and one treatment in the clinic weekly . At home they will be asked practice daily active exercises with the Meditouch Ltd. system.
89147531|NCT02713958|Active Comparator|rehabilitation|Traditional Occupational Therapy:The subjects in this group will receive three treatments in the clinic every week. At home they will be asked to practice daily active exercises in the same level of difficulty and duration as the study group but without the Meditouch Ltd. system
89147532|NCT02642601|Experimental|indomethacin|one dose of indomethacin 100 mg rectal suppository;will be adminstrated1-2 hours before embryo transfer
89147533|NCT02642601|No Intervention|no medication|no indomethacine before embryo transfer
89147534|NCT02709902|Experimental|Adapalene/BP gel, 0.3%/2.5%|Topical, once daily, for 84 days.
89147535|NCT02709902|Active Comparator|EPIDUO® FORTE|Topical, once daily, for 84 days.
89147536|NCT02709902|Placebo Comparator|Placebo|Topical, once daily, for 84 days.
89147537|NCT02710604|Active Comparator|CMX157 5mg versus TDF|CMX157, 5mg tablet, 28 days versus TDF(tenofovir disoproxil fumerate) 300mg tablet, 28 days
89147538|NCT02710604|Active Comparator|CMX157 10mg versus TDF|CMX157, 10mg tablet, 28 days versus TDF 300mg tablet, 28 days
89147539|NCT02710604|Active Comparator|CMX157 25mg versus TDF|CMX157, 25mg tablet, 28 days versus TDF 300mg tablet, 28 days
89147540|NCT02710604|Active Comparator|CMX157 50mg versus TDF|CMX157, 50mg tablet, 28 days versus TDF 300mg tablet, 28 days
89147541|NCT02710604|Active Comparator|CMX157 100mg versus TDF|CMX157, 100mg tablet, 28 days versus TDF 300mg tablet, 28 days
89147542|NCT02709824|Active Comparator|Chlorhexidine gluconate with ADS|Chlorhexidine 0.12% plus Anti-Discoloration System Mouthwash
89147543|NCT02709824|Active Comparator|Chlorhexidine gluconate without ADS|Chlorhexidine 0.12% Mouthwash
89147544|NCT02642367|Experimental|no use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection without use of stylet with McGrath videolaryngoscope after endotracheal tube was rolled up circularly for 3 min
89147545|NCT02642367|Active Comparator|use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection using a styletted endotracheal tube with McGrath videolaryngoscope
89147546|NCT04699136|Experimental|Cardiovascular disease|
89147547|NCT02642289|Experimental|Probiotic1: Lactobacillus acidophilus|Dietary Supplement: Probiotics 1. 8-week probiotic food-supplement intervention with Lactobacillus acidophilus (Daily intake: 24 millions)
89147548|NCT02642289|Placebo Comparator|Placebo|Inactivate substance
89147549|NCT02642289|Experimental|Probiotic2: Lactobacillus Rhamnosus GG ®|Dietary Supplement: Probiotics 2 8-week probiotic food-supplement intervention with Lactobacillus Rhamnosus (Daily intake: 24 millions)
89147550|NCT00611780|Experimental|1|Reduced tube voltage of 100kV.
89147551|NCT00611780|Active Comparator|2|Standard tube voltage of 120kV.
89147552|NCT04165395|No Intervention|Control group|The control group will receive the standard of care adopted at Hôpital du Sacré-Coeur de Montréal in terms of pressure ulcers prevention in the SCI population.
89147553|NCT04165395|Experimental|Intervention group|In addition to undergoing the identical standard-of-care as the control group, all patients in this group will receive a prophylactic five-layer foam dressing placed directly on the sacral area and a Heelmedix boot installed alternately on both legs
89147554|NCT02642133|Other|Intervention|All patients were in the same arm - this is a cohort study where the group serves as their own control. Patients who did not undergo the procedure were not included in this outcomes study.
89147555|NCT02642211|Active Comparator|phako|eyes receiving phakoemulsification for cataract surgery
89147556|NCT02642211|Active Comparator|MSICS|Eyes undergoing manual small incision cataract surgery
89147557|NCT00653367|Experimental|NS|Nerve section of intercostal nerve during surgery
89147558|NCT00653367|No Intervention|Control|Control
89147559|NCT02642055|Experimental|Neuro+ Intervention|30 sessions (900 minutes) of Neuro+ Attention Training administered over 10 weeks.
89147560|NCT02642055|Active Comparator|Treatment as Usual|Continuation of current treatment for ADHD
89147561|NCT00653445|Experimental|1|Rosuvastatin 40mg/Ezetimibe 10mg combination therapy
89147562|NCT00653445|Experimental|2|Rosuvastatin 40 mg
89147563|NCT02641899|Experimental|Experimental Treatment|ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg
89147564|NCT04165005|Experimental|decentering group|"MBSR focused on a decentering component (i.e. individuals observe their feelings and thoughts as ephemeral events, with no reactivity, alongside with acceptance)."
89147565|NCT04165005|Experimental|guided imagery group|a group practicing in guided imagery sessions.
89147566|NCT04165005|No Intervention|control group|usual care group
89147567|NCT02641821|Experimental|Nifedipine GITS|
89147568|NCT02641743|Experimental|Inslow|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) Inslow at 7:00 AM.
89147569|NCT02641743|Placebo Comparator|standard balanced formula|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) standard balanced formula at 7:00 AM.
89147570|NCT01320345|Experimental|Fenofibrate|145 mg tablet of fenofibrate administered daily for 36 months.
89147571|NCT01320345|Placebo Comparator|Placebo|Inert lactose tablet (otherwise matching active) administered daily for 36 months.
89147572|NCT04164615|Experimental|GB221+ Capecitabine tablets|test drug+capecitabine
89147573|NCT04164615|Placebo Comparator|Placebo control + capecitabine tablets|placebo+capecitabine
89147574|NCT04164771|Experimental|Moringa Group|Participants will receive 5-7g of moringa diet daily for 6 weeks.
89147575|NCT04164771|Experimental|Aerobic training Group|Participants will receive 5-7g of moringa diet daily and will do 30 minutes of aerobic training daily for 6 weeks.
89147576|NCT04164771|Experimental|Moringa and Aerobic training|Participants will do 30 minutes of aerobic training daily for 6 weeks
88806001|NCT03465527|Experimental|Prednisolone|"Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days~Hydration, antibiotics, allopurinol, nutritional supplements, and so on."
89147577|NCT04164771|No Intervention|Control Group (T4)|Participants will not recieve any treatment
89147578|NCT04164459|Experimental|Xalost S|
89147579|NCT04164459|Active Comparator|Xalatan|
89147580|NCT04164459|Active Comparator|Taflotan-S|
89147581|NCT04164693|Experimental|anticoagulant therapy group|during hospitalization, patients began to use low molecular weight heparin subcutaneously after arteriovenous fistula operation, once or twice a day, 4000iu-8000iu a day. After discharge, the patients took warfarin sodium tablets orally, 1.25mg on dialysis day, 2.5mg on non dialysis day, for a total course of 4 weeks.
89147582|NCT04164693|Other|non anticoagulant therapy group|no anticoagulant was used after operation, but both groups could take antiplatelet drugs.
89147583|NCT02637921|Active Comparator|Hypoxic ambulatory|Participants ambulatory in normobaric hypoxia with standardised nutritional intake
89147584|NCT02637921|Experimental|Hypoxic Bed rest|Participants are on bed rest in normobaric hypoxia with standardised nutritional intake
89147585|NCT02637921|Active Comparator|Normoxic bed rest|Participants are on bed rest in normobaric normoxia with standardised nutritional intake
89147586|NCT00655239|Active Comparator|Control|Participants will use commercially available computer games.
89147587|NCT00655239|Experimental|Active|Participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
89147588|NCT00655239|Active Comparator|Healthy Control|Healthy participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
89147589|NCT04164381|Experimental|Robotic assisted intervention|Upper limb robotic therapy using a set of robotic and sensor based devices and exercises specifically selected to train cognitive functions.
89147590|NCT04164147|Active Comparator|NexGen|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet NexGen prosthesis
89147591|NCT04164147|Active Comparator|Persona MC Retained PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Retained PCL prosthesis
89147592|NCT04164147|Active Comparator|Persona MC Sacrificed PCL|Patients undergoing total knee replacement for treatment of primary knee ostearthritis with use of Zimmer Biomet Persona MC Sacrificed PCL prosthesis
89147593|NCT02637843|Active Comparator|Slender arm|Uses the terumo slender sheath for radial angiography or angioplasty
89147594|NCT02637843|No Intervention|Standard arm|Uses the terumo standard sheath (Routine) for radial angiography or angioplasty
89147595|NCT02638077||Group 1|2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. Doctors can treat the patients based on disease conditions. Investigators will record data which are related to study endpoints.
89147596|NCT04163679|Experimental|Vaginal Preparation|In addition to standard care, subjects will undergo vaginal preparation (VP). A VP kit includes sponge sticks and sponges soaked in a povidone-iodine 10% solution.
89147597|NCT04163679|Sham Comparator|Standard Infection Procedures|The very staff will follow hospital protocols for the cesarean delivery. The subject and the infant will be provided care in accordance with current medical standards and be discharged at the discretion of the attending physician.
89147598|NCT04163913|Experimental|Cirvo Device|The CirvoTM device (Figure 1) is a lightweight, mobile, active, intermittent leg compression device placed on the calf of the leg, using hook and loop (e.g. Velcro) straps in the similar manner as commercially available intermittent leg compression devices The system utilizes an electro-mechanical drive system to intermittently compress the calf from the ankle toward the knee for a duration and compression level prescribed by the physician. The level of compression delivered by the CirvoTM therapy will be in the same range as existing devices which corresponds to the type of pressure applied by a blood pressure cuff.
89147599|NCT04163913|Active Comparator|ActiveCare DVT|A commercially available device was previously used to assess patient satisfaction with compression therapy for DVT prophylaxis as per standard of care.
89147600|NCT00655317|Active Comparator|1|Treatment Acupuncture Group (Therapeutic Acupuncture Treatment): treatment with actual acupuncture needles
89147601|NCT00655317|Sham Comparator|2|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
89147602|NCT00655395|Experimental|1|"Laromustine 300 mg/m2 (cohort 1) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
88806002|NCT03010943|Experimental|Brain surgery with virtual reality headset|
88806003|NCT01180127|Active Comparator|exercise, dietary intervention|aerobic training and flavanol containing food product for 12 weeks
89147603|NCT00655395|Experimental|2|"Laromustine 400 mg/m2 (cohort 2) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
89147604|NCT00655395|Experimental|3|"Laromustine 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
89147605|NCT00655395|Experimental|5|"Laromustine will be administered at the recommended phase II dose on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
89147606|NCT00655395|Experimental|4|"Laromustine 600 mg/m2 (cohort 4) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
89147607|NCT00911079|Experimental|Hyperthermia with HDR brachytherapy|Hyperthermia will be delivered within approximately 2 hours of (HDR) brachytherapy associated with the implant session
89147608|NCT02637453|Active Comparator|PVI|Pulmonary vein isolation (PVI)
89147609|NCT02637453|Experimental|PVI+6L|PVI plus 6 additional lines at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
89147610|NCT02637609||Likert Scale|Priority elicitation survey using a Likert scale method.
89147611|NCT02637609||Best-Worst Scaling (Case 1)|Priority elicitation survey using a best-worst scaling method.
89147612|NCT04163757|Placebo Comparator|placebo|
89147613|NCT04163757|Active Comparator|crocin|
89147614|NCT02637765|No Intervention|Control Group|Usual Physical Activity
89147615|NCT02637765|Experimental|Intervention Group|8-week increased physical activity program
89147616|NCT00655785|Experimental|Phase 1/2 study|
89147617|NCT00885495|Active Comparator|B|Darunavir+ritonavir x 7 days; Rosuvastatin x 7 days; Combination x 7 days
89147618|NCT00885495|Active Comparator|A|Rosuvastatin x 7 days; darunavir+ritonavir x 7 days; Combination x 7 days
89147619|NCT00655941|Experimental|1|Dietary instruction (low-energy diet. This is given by instructions in groups of 8
89147620|NCT00655941|Active Comparator|2|Exercise
89147621|NCT00655941|No Intervention|3|Control
89147622|NCT02637297|Experimental|Group I (immediate intervention group)|Participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
89147623|NCT02637297|Active Comparator|Group II (wait-list control group)|At week 5, participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
89147624|NCT02637375|Experimental|Therapy|Patients will receive ganetespib monotherapy for two weeks followed by twelve weeks of ganetespib/paclitaxel therapy followed by 4 bi-weekly doses of doxorubicin/cyclophosphamide therapy followed by surgery.
89147625|NCT04163523|Experimental|Treatment Sequence 1|5 Subjects received Period 1- 320 mg BGB-3111 administered after an overnight fast; Period 2- 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 3 - Day 15: 320 mg BGB-3111 administered after Low Fat/Calorie Meal
89147626|NCT04163523|Experimental|Treatment Sequence 2|5 Subjects received Period 1 - Day 1: 320 mg BGB-3111 administered after High Fat/Calorie Meal; Period 2- Day 8: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 3- Day 15: 320 mg BGB-3111 administered after an overnight fast
89147627|NCT04163523|Experimental|Treatment Sequence 3|Approximately 5 Subjects receive Period 1-Day 1: 320 mg BGB-3111 administered after Low Fat/Calorie Meal; Period 2-Day 8: 320 mg BGB-3111 administered after an overnight fast; Period 3- Day 15: 320 mg BGB-3111 administered after High Fat/Calorie Meal
89147628|NCT04163445|Active Comparator|Depuy Attune|Subjects will have been implanted with the Depuy Attune PCR TKA
89147629|NCT04163445|Active Comparator|MicroPort Medial Pivot|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
89147630|NCT04163211||Group 1|Patients with complicated appendicitis who had a drain inserted
89147631|NCT04163211||Group 2|Patients with complicated appendicitis who did not have a drain inserted
89147632|NCT00885105|Experimental|Fluzone® Vaccine-Primed Group|Participants received 2 doses of Fluzone® vaccine at 2 months (in Study GRC 27)
89147633|NCT00885105|Active Comparator|Influenza Vaccine-Naive Group|Participants who have never received influenza vaccine (and not in Study GRC27)
89147634|NCT03945188|Experimental|Etrasimod 2 mg|
89147635|NCT03945188|Placebo Comparator|Placebo|
89147636|NCT02709668|Placebo Comparator|placebo|gel cap with placebo
89147637|NCT02709668|Experimental|enlyte|gel cap of B vitamins brand Enlyte
89147638|NCT04188782||Pediatric patients undergoing radiotherapy|"Pediatric patients undergoing general anesthesia for radiotherapy treatment. General anesthesia will be accomplished exclusively by the administration of sevoflurane.~The inhalatory induction will be performed with sevofluorane at 8% with O2 4Lt/min. The maintenance will be with sevofluorane at an end tidal of 2.5% with 1Lt/min of O2.~The EEG will be obtain with SedLine monitor"
89147639|NCT02709590|Experimental|Group A|oral diclofenac potassium plus lidocaine anesthetic cream placed into their cervix immediately before HSG
89147640|NCT02709590|Placebo Comparator|Group B|oral placebo tablets plus placebo cream placed into their cervix immediately before HSG
89147641|NCT02713568|Active Comparator|Ultrasound|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.~An Ultrasound scan to estimate the fetal weigth will be carried out during the 36th week of gestation."
89147642|NCT02713568|Experimental|Magnetic Resonance|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.~A Magnetic Resonance examination to estimate the fetal weigth will be carried out during the 36th week of gestation."
89147643|NCT02713412|Experimental|Glucose|75g glucose and 150mg C13-acetate in 300ml water
89147644|NCT02713412|Placebo Comparator|Control|300ml water
89147645|NCT02709434|Active Comparator|Intervention group|Patients with quiescent IBD who are randomized to receive the active intervention of the psychoeducational programme
89147646|NCT02709434|Placebo Comparator|Control group|Randomized to standard care
89147647|NCT02709356|Experimental|Alzheimer's disease|"Patients with mild Alzheimer's disease.~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
89147648|NCT02709356|Experimental|Controls|"Healthy elderly people~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
89147649|NCT04440722||Transgender individuals|All transgender individuals referred to center of gender identity Odense
89147650|NCT02708030|Active Comparator|Ketogenic Diet|Ketogenic diet (KD) will be administered by the non-fasting protocol. The child will be admitted to the hospital, and KD will be started in 1:1 ratio. The ratio will increased every 48hours to a maximum of 4:1 or ketosis (urinary ketones 40-80mg/dL) is attained. The child will thereafter be discharged and followed up on Out patient basis.
89147651|NCT02708030|Experimental|Modified Atkins Diet|Modified Atkins Diet (MAD) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
89147652|NCT02708030|Experimental|Low Glycemic Index Therapy|Low Glycemic Index Therapy (LGIT) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
89147653|NCT02707796|Experimental|Hemicolectomy|Oxygen reserve index and partial oxygen pressure will be noted for patients undergoing hemicolectomy
89147654|NCT02707874|Active Comparator|CI 0.2% ropivacaine|"Patients in Group Continuous Infusion (CI) will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.~3) Oral acetaminophen 1,000 mg 6 hourly."
89147655|NCT02707874|Active Comparator|PIB 0.2% ropivacaine|"Patients in Group programmed intermittent boluses (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.~3) Oral acetaminophen 1,000 mg 6 hourly."
89147656|NCT02709200||Dexmedetomidine|Patients that received dexmedetomidine during open heart surgery.
89147657|NCT02709200||No dexmedetomidine|Patients that didn't receive dexmedetomidine during open heart surgery.
89147658|NCT02708888|Experimental|Trunk training|Exercises: Core stability training
89147659|NCT02708888|Sham Comparator|Cognitive exercises|Exercises: The RevArte Visual Search Test (RVST) of Lafosse et al (2013) and the Visuospatial Neglect Test Battery (VNTB) of Vaes et al. (2015)
89147660|NCT02709044|Experimental|Ringer lactate 20 mL/kg|This group of subjects will receive a bolus of 20 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
89147661|NCT02709044|Experimental|Ringer lactate 40 ml/kg|This group of subjects will receive a bolus of 40 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
89147662|NCT00611936|Placebo Comparator|2|Second arm is placebo
89147663|NCT00611936|Experimental|1|One arm is atomoxetine 40 mg per day
89147664|NCT02708732||DLBCL Participants|A cohort of approximately 100 patients in first remission with DLBCL will complete questionnaires through a 15-minute postal or online survey.
89147665|NCT00611156|Experimental|A|Spice
89147666|NCT00611156|Experimental|B|Spice
89147667|NCT00611156|Experimental|C|Spice
89147668|NCT00611156|Experimental|D|Spice
89147669|NCT00611156|Placebo Comparator|E|Placebo
89147670|NCT02707406|Experimental|NEOX®CORD 1K|Intervention Other: hct/p human cell or tissue product: NEOX®CORD 1K Intervention other: human tissue application of of NEOX®CORD 1K on subject wound
89147671|NCT02707406|Active Comparator|Standard of Care|Intervention Other: standard of care alone Other intervention of Standard dressing with a non-adherent wound contact layer, a classic foam pad or gauze for moderately draining wounds, a secondary bandage, and institution of an investigator-approved off-loading device
89147672|NCT05185076|Experimental|CureSight eye-tracking-based|Device: CureSight Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day
89147673|NCT05185076|Active Comparator|Patching occlusive deprivation|"Device: Patching Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis."
88806004|NCT01180127|Active Comparator|no exercise, dietary intervention|wait list control plus flavanol containing food product for 12 weeks
89147674|NCT00612092|Experimental|1|Standard spiral CT protocol
89147675|NCT00612092|Active Comparator|2|Sequential CT protocol
89147676|NCT04189016|Active Comparator|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
89147677|NCT04189016|Placebo Comparator|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
89147678|NCT03707054|Experimental|Study Arm|Measurements of optic nerve diameter, Urine and plasma osmolality, Serum vasopressin.
89147679|NCT02707562|Experimental|GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
89147680|NCT02707328|Experimental|A|"Chemotherapy:~Gemcitabine 1000 mg/m2 and Abraxane 125 mg/m2 weekly x3 of 28 day cycle~Radiation:~20-55 GY over 5 fractions~Dosing schedule: 3 cycles of chemotherapy, followed by CyberKnife, followed by 3 additional cycles of chemotherapy."
89147681|NCT00612638|Experimental|1|Pts receiving Dilantin, Tegretol or Phenobarbital
89147682|NCT00612638|Experimental|2|Pts on anti-convulsants other than Dilantin, Tegretol / Phenobarbital / pts not on any anti-convulsants
89147683|NCT05151848|Experimental|Adalimumab group|Adalimumab 40mg injected subcutaneously every 2 weeks for 78 weeks.
89147684|NCT05151848|Active Comparator|Tofacitinib 5MG group|Tofacitinib 5mg BID taken orally for 78 weeks.
89147685|NCT05134688|Active Comparator|Grup 1|Group receive magnesium sulphate IV(4gm loading dose over 20 minutes followed by 1gm /hour for 6 hours
89147686|NCT05134688|No Intervention|Group 2|Receive no further treatment than conservative mangement( antibiotics and steroids)
89147687|NCT05116670||Qinghai Red Cross Hospital|
89147688|NCT05116670||Shenzhen Baoan Women's and Children's Hospital|
89147689|NCT02693288|No Intervention|Ultrasound-guided nerve block|
89147690|NCT02693288|Experimental|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaine 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
89147691|NCT02693054|Experimental|Hybrid Fractional Laser Treatment|Halo (1470nm and 2940 nm) laser
89147692|NCT05108480|Experimental|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 2 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; Release of the myofascial components of the back of the leg using a Foam Roller; Release of the myofascial components of the anterior part of the leg using a Foam Roller; Release of myofascial components of the hamstring region using a Foam Roller; Release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; Release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; Release of the myofascial components of the pelvitrochanterian muscles using a Foam Roller in a sitting position.
89147693|NCT05108480|No Intervention|Control group|The subjects included in the control group will not receive Physiotherapy sessions and will continue with their usual routine of activity and physical exercise, and with the same drug treatment schedule with FVIII / FIX and analgesic drugs.
89147694|NCT02693210|Active Comparator|Group A: Methotrexate|Participants will receive methotrexate at dosage >=10 milligrams per week (mg/week) orally as determined by the investigator. They also receive placebo infusion on days 1 and 15 in place of rituximab and on Days 3 and 17 in place of cyclophosphamide.
89147695|NCT02693210|Experimental|Group B: Rituximab Monotherapy|Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.
89147696|NCT02693210|Experimental|Group C: Rituximab and Cyclophosphamide|Participants will receive 1g IV infusion of rituximab on Days 1 and 15 and 750 mg infusion of Cyclophosphamide on Days 3 and 17. They also receive weekly oral placebo in place of methotrexate.
89147697|NCT02693210|Experimental|Group D: Methotrexate and Rituximab|Participants will receive >=10 mg/week methotrexate orally along with 2 times 1 gram (g) rituximab IV infusions on Days 1 and 15. Participants will also receive placebo infusions on Days 3 and 17 in place of cyclophosphamide.
89147698|NCT05057624|Placebo Comparator|non-GC-MRT|Placebo- music will play at all times during the trials.
89147699|NCT05057624|Active Comparator|GC-MRT|Music will only play when participants view angry faces and will stop when they look at neutral faces.
89147700|NCT05057624|Experimental|GC-MRT-exp|Music will only play when participants look at neutral faces and will stop when they view angry faces.
89147701|NCT03706976|Experimental|CTOM|
89147702|NCT05024006|No Intervention|LSoC|Local Standard of Care
89147703|NCT05024006|Experimental|Rem+LSoC|Remdesivir with Local Standard of Care
89147704|NCT05024006|Experimental|HCQ+LSoC|Hydroxychloroquine with Local Standard of Care
89147705|NCT05024006|Experimental|Lopi/Rito+LSoC|Lopinavir/Ritonavir with Local Standard of Care
89147706|NCT05024006|Experimental|Lopi/Rito+IFN+LSoC|Lopinavir/Ritonavir and Interferon Beta 1a with Local Standard of Care
89147707|NCT05024006|Experimental|IFN+LSoC|Interferon Beta 1a with Local Standard of Care
89147708|NCT05024006|Experimental|ACB+LSoC|Acalabrutinib with Local Standard of Care
89147709|NCT02707250|Placebo Comparator|Placebo|Oblique subcostal tap block with normal sterile saline ,20 ml, bilateral, single shot,24h
89147710|NCT02707250|Active Comparator|Bupivacaine|Oblique subcostal tap block with bupivacaine 0,25% ,20 ml, bilateral, single shot,24h
89147711|NCT02707250|Active Comparator|Pethidine|Oblique subcostal tap block with pethidine 1% ,10 ml,bilateral,single shot,24h
89147712|NCT02707250|Active Comparator|Pethidine Local Infiltration (L.I.)|Local infiltration of pethidine 1% at trocar insertion sites, 5ml /site, 24h compared with Tap Block with pethidine 1%
89147713|NCT03781544|Experimental|Diclofenac|Diclofenac (Diclofenacum natricum) A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
89147714|NCT03781544|Active Comparator|Paracetamol|"Paracetamol (Paracetamol Sintetica):~A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm)."
89147715|NCT03781544|Experimental|Tramadol|"Tramadol (Tramadol-Mepha):~A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm)."
89147716|NCT02707094|Other|Usual Care (Medication + Exercise)|Usual Care: Participants will receive guidance on over-the-counter and prescribed pain medications to use to treat their chronic low back pain symptoms. The Research Coordinator (RC) will provide instructions for low back pain stretching and strengthening exercises. The Licensed Provider (LP) will determine if any exercises should be excluded based on their physical limitations. Participants enrolled in the usual care treatment arm will track the frequency of their back stretching and strengthening exercise sessions on the Pain Medication & Exercise Diary. For the purpose of this study, treatment compliance will be met if participants complete the exercises a minimum of three times per week.
88806005|NCT01180127|Active Comparator|exercise, food product lacking flavanol|aerobic training plus food product without flavanol for 12 weeks
89147717|NCT02707094|Experimental|Biomodulator + Usual Care|Biomodulator + Usual Care treatment group: Usual care, as described above, will be provided to all participants randomly allocated to this treatment group, in addition to treatment with the Biomodulator three times per week x 4 weeks. The licensed provider will review medication and treatment logs, prescribe pain medications as indicated, and assess for treatment side effects. In addition to treatment with the Biomodulator, the participant will perform back stretching and core strengthening exercises for a minimum of three times per week as instructed and will be told to use their prescribed pain medications as needed to self-treat their low back pain symptoms (as previously described above).
89147718|NCT02707016|Other|High dose sevoflurane|"Inhaled sevoflurane 8% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
89147719|NCT02707016|Other|Low dose sevoflurane|"Inhaled sevoflurane 5% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
89147720|NCT02706782|Experimental|TAI-meso-CART|A single dose of meso-CART cells will be administered by vascular interventional mediated as one dose infusions. The dose is 1-10x106/kg meso-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. Patients will undergo cannula--DSA radiography--CAR-T cells perfusion. The cells perfusion process would lasts 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
89147721|NCT04156100|Experimental|AGEN1223|AGEN1223 is a bispecific antibody.
89147722|NCT04156100|Experimental|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody
89147723|NCT04956146|Experimental|Fruquintinib Combined With Sintilimab and Chemotherapy|
89147724|NCT00612794|Experimental|1|exenatide once weekly, 0.8mg
89147725|NCT00612794|Experimental|2|exenatide once weekly, 2.0mg
89147726|NCT00612794|Placebo Comparator|3|volume equivalent to 0.8mg of exenatide once weekly
89147727|NCT00612794|Placebo Comparator|4|volume equivalent to 2.0mg of exenatide once weekly
89147728|NCT03773276|Experimental|Norepinephrine boluses|Single arm study
89147729|NCT02706860|Experimental|"80 mg atorvastatin for 2 days regimen"|80 mg atorvastatin/ day for 2 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
89147730|NCT02706860|Experimental|"40 mg atorvastatin for 5-9 days preoperative regime"|40 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
89147731|NCT02706860|Experimental|"80 mg atorvastatin for 5-9 days preoperative regime"|80 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
89147732|NCT02706548|Experimental|Occupational Therapy Intervention Group|Thirty-minute intervention in which the participant and interventionist discuss past medication taking performance, medication-related goals, and strategies to meet goals. Intervention is enhanced with motivational interviewing and therapeutic use of self.
89147733|NCT02706548|Active Comparator|Standard Care Intervention Group|Thirty-minute educational intervention in which the participant and interventionist review a pamphlet on adherence to medication.
89147734|NCT02706470|Experimental|Cyclosporin A|Patients allocated to Cyclosporin A group will receive oral Cyclosporin A in a dose of 50 mg three times a day for 20-30 days in early pregnancy.
89147735|NCT02706470|Active Comparator|Dydrogesterone|Patients allocated to dydrogesterone group will receive oral dydrogesterone in a dose of 10 mg three times a day for 30 days in early pregnancy.
89147736|NCT03711890|Experimental|Diagnostic (resection, OCT)|Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.
89147737|NCT04924790||COVID-19 Urinary Stone|Patients diagnosed with obstructive urinary stones in the COVID-19 period
89147738|NCT04924790||PreCOVID-19 Urinary Stone|Patients diagnosed with obstructive urinary stones in the preCOVID-19 period
89147739|NCT02706236|Active Comparator|Intervention Arm|Pancreatic enzyme replacement (Pancrelipase) with meals and snacks daily, for 4 weeks.
89147740|NCT02706236|Placebo Comparator|Placebo Arm|Lactose placebo tablets with meals and snacks, for 4 weeks.
88806006|NCT01180127|Placebo Comparator|wait list control food additive without flavanol|wait list control plus food product without flavanol for 12 weeks
88806007|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fasting|One tablet of IBUCR 600 mg under fasting condition
89147741|NCT02706314||Critically ill patients with CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 with CIP
89147742|NCT02706314||Critically ill patients without CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 without CIP
89147743|NCT02706314||Healthy volunteers|Healthy volunteers with neither critical illness nor CIP
89147744|NCT04141982||Suspected of having TB infection|These donors are suspected of having TB infection and live in a high endemic area for TB infection
89147745|NCT04141982||No (or minimal) TB risk factors|These donors must have no previous medical record of TB infection and live in low endemic area for TB infection
89147746|NCT04141982||low/intermediate risk of TB infection population|These donors must live in an low/intermediate endemic area for TB infection
89147747|NCT00613496|Placebo Comparator|2|Placebo treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
89147748|NCT00613496|Active Comparator|1|Irbesartan treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
89147749|NCT04128566|Experimental|Group 1: healthy subjects aged between 20 and 30 years|healthy subjects aged between 20 and 30 years
89147750|NCT04128566|Experimental|Group 2: previous ACL injury aged between 20 and 30 years|subjects with previous Anterior cruciate Ligament (ACL) injury aged between 20 and 30 years
89147751|NCT04128566|Experimental|Group 3: healthy subjects aged between 40 and 60 years|healthy subjects aged between 40 and 60 years
89147752|NCT04128566|Experimental|previous ACL injury aged between 40 and 60 years|subjects with previous ACL injury aged between 40 and 60 years
89147753|NCT04823780||early enteral nutrition support group|Nutrient solution is provided through oral nutrient solution within 4-48 hours after endoscopic treatment
89147754|NCT04823780||parenteral Nutrition Group|Intravenous nutrition is provided within 48 hours after endoscopic treatment
89147755|NCT04820894||Observational (survey, medical records review)|Patients complete surveys over 30 minutes about sociodemographic information and perception of immunotherapy, over 10 minutes about expectations of cure, over 10 minutes about anxiety, over 10 minutes about depression, and over 30 minutes about physical well-being. Patients' medical records are reviewed.
89147756|NCT02692976|Experimental|Myeloid dendritic cells (mDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A). DC will be loaded with major histocompatibility complex (MHC) class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with keyhole limpet hemocyanin (KLH) as an immune control.
89147757|NCT02692976|Experimental|Plasmacytoid dendritic cells (pDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with pDC (3x 106 cells; n=7, arm B). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA.
89147758|NCT02692976|Experimental|mDC and pDC vaccinations|Patients will be vaccinated intranodally three times biweekly with the combination of mDC and pDC (5x 106 mDC/ 3x 106 pDC; n=7, arm C). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with KLH (mDC only) as an immune control.
89147759|NCT00612872|Experimental|Assess [123-I]CLINDE and brain imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
89147760|NCT04780022||Older patients with cryptogenic embolism and PFO closure|Data (clinical events at last follow-up) on patients older than 60 years who have experienced a previous paradoxical embolism of unknown origin and underwent transcatheter PFO closure will be collected.
89147761|NCT04188704|Placebo Comparator|Anterior cruciate ligament normal|normal Anterior cruciate ligament reconstruction
89147762|NCT04188704|Experimental|Anterior cruciate ligament reconstruction|Anterior cruciate ligament reconstruction and Position screw fixation
89147763|NCT00884949|Experimental|BMN 110|Within-patient Dose-Escalation
89147764|NCT04742816|Other|Iohexol injection|The research pharmacist will prepare the iohexol injection in a 1cc tuberculin syringe, consisting of 0.5cc sterile water for injection (SWFI) and 0.5cc iohexol (Omnipaque 300). The study coordinator/personnel (licensed RN) will inject the iohexol dose into the subcutaneous tissue on the opposite arm used for blood sampling; the time will be recorded. The participant will be monitored for adverse events 30 minutes post iohexol administration at the AVRC. If the participant has not had any adverse event within 30 minutes, they will be asked to leave the AVRC and return within 2 hours and 55 minutes post Iohexol injection for lab collection.
89147765|NCT00612950|Experimental|GLP-1|
89147766|NCT00612950|Experimental|GIP|
89147767|NCT00612950|Placebo Comparator|saline|
89147768|NCT00884793|Experimental|intensification with raltegravir +/- NNRTI or PI|Intensification with raltegravir 400mg PO BID +/- a study PI or NNRTI
89147769|NCT00656253|Experimental|A|
89147770|NCT00656253|Placebo Comparator|B|
89147771|NCT04717076|Active Comparator|App-based nutritional concept and fitness tracking|App-based nutritional concept and fitness tracking
89147772|NCT04717076|Experimental|Nutritional concept with individual nutritional counselling|Nutritional concept with individual nutritional counselling
89147773|NCT04717076|Experimental|Nutritional concept without individual nutritional counselling|Nutritional concept without individual nutritional counselling
89147774|NCT04717076|No Intervention|Control group|Control group - no intervention
89147775|NCT02636829|Experimental|Multiple Sclerosis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.~Intervention: QALCIMUM questionnaire~Intervention: Determination of calcium intake by a dietician interview"
89147776|NCT02636829|Experimental|Rheumatoid Arthritis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.~Intervention: QALCIMUM questionnaire~Intervention: Determination of calcium intake by a dietician interview"
89147777|NCT00884325|Experimental|Xyzal|
89147778|NCT00884325|Placebo Comparator|Placebo|
89147779|NCT04705844|Experimental|Adalimumab|single dose of adalimumab(160 mg administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen
89147780|NCT04705844|Placebo Comparator|Placebo|single dose of placebo (administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen
89147781|NCT03997760|Experimental|SHP655|Participants with baseline SCD will receive a single intravenous (IV) infusion at one of the 3 dose levels of 40, 80 and 160 International units per kilogram (IU/kg) in a dose escalation manner for 14 days.
89147782|NCT03997760|Placebo Comparator|Placebo|Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion for 14 days.
89147783|NCT02693366|Experimental|Autologous Cell Therapy|We are conducting a prospective, non-randomized, single-center longitudinal study in five patients with progressive chronic kidney disease and estimated clearance between 40 and 20 ml / min. Patients will be followed by clinical and laboratory examination for 3 months prior to the procedure. These previous results serve as a control for comparison with a second time when the same patients receive treatment with stem cells being subsequently followed up for 9 months a total of one year of clinical follow-up.
89147784|NCT03494348|No Intervention|Cruciate Retaining Polyethylene (CR)|This is the standard Polyethylene articular surface
89147785|NCT03494348|Active Comparator|Medial Congruent Polyethylene (MC)|The intervention here will be the MC articular surface. This is the new Polyethylene articular surface with a more congruent medial side and a more flat lateral side which should better resemble natural anatomy.
89147786|NCT04076384|Experimental|Team-based consultations|Guided Self-Determination
89147787|NCT04076384|Experimental|Standard care|Standard consultation
89147788|NCT00613184|Experimental|1|Nylon Flocked swab Left Nasal Wash right
89147789|NCT00613184|Experimental|2|Nylon Flocked swab R Nasal Wash L
89147790|NCT00613184|Experimental|3|Nasal Wash Left Nylon Flocked swab Right
89147791|NCT00613184|Experimental|4|Nasal Wash R Nylon flocked swab L
89147792|NCT04616768|No Intervention|Arm A - Control|An arm of ≤42 patients will not receive PRO surveys, a Fitbit device, or patient feedback texts messages. They will receive shortened utility surveys at 3 and 6 months following enrollment, but their clinicians will not receive dashboards or utility surveys.
89147793|NCT04616768|Experimental|Arm B - Intervention without text feedback|"An arm of ≤42 patients enrolled intervention patients will be randomized to receive weekly patient-reported outcome questionnaires, be given Fitbits to monitor weekly step counts and utility surveys at 3 and 6 months following enrollment. Their clinicians will receive a PROStep Dashboard prior to their appointments and utility surveys at 3 and 6 months."
89147794|NCT04616768|Experimental|Arm C - Intervention with text feedback|"An arm of ≤42 patients enrolled intervention patients will be randomized to receive weekly patient-reported outcome questionnaires, be given Fitbits to monitor weekly step counts and utility surveys at 3 and 6 months following enrollment. Their clinicians will receive a PROStep Dashboard prior to their appointments and utility surveys at 3 and 6 months. Patients in this arm will receive an additional text prior to appointments that summarizes their symptoms and incorporates an active nudge question."
89147795|NCT00612248|Experimental|SG|Study group
89147796|NCT00612248|No Intervention|CG|Control group
89147797|NCT05264402||PICCline group|Patients needing a vascular approach using PICCline catheters
89147798|NCT05264402||Midline group|Patients needing a vascular approach using Midline catheters
89147799|NCT03963908|Experimental|Intervention|AtEase is a mobile app designed to promote pain self-management, healthy sleep habits, and effective stress management. It includes a tailored Newsfeed that updates regularly with articles, activities, videos, and quizzes chosen for the user; a chat feature that asks questions and provide tailored feedback; a Message Center; and a Pain Tracker. Users can interact with AtEase as often as they like for six months.
89147800|NCT03963908|Active Comparator|Comparison|Chronic Pain Education for Veterans is a VA-endorsed pain management online educational curriculum that provides CBT pain self-management materials. Users randomized to the comparison condition will have unlimited access for 6 months.
89147801|NCT00636896|Experimental|1|Olanzapine 10 mg plus modafinil 200 mg
89147802|NCT00636896|Placebo Comparator|2|Olanzapine plus Placebo
89147803|NCT02709122|Experimental|With Tension pneumothorax|evaluation of the patient with the existing tension pneumothorax during a simulated CPR - breathing
89147804|NCT02709122|Experimental|Without Tension pneumothorax|evaluation of the patient without the existing tension pneumothorax during a simulated CPR - breathing
89147805|NCT05264090|Placebo Comparator|Group 1|Healthy volunteers without exercise
89147806|NCT05264090|Sham Comparator|Group 2|Healthy exercise-training volunteers
89147807|NCT05264090|Active Comparator|Group 3|Patients with ischemic coronary artery disease without exercise
89147808|NCT05264090|Experimental|Group 4|Patients with ischemic coronary artery disease following cardiovascular rehabilitation
89147809|NCT05264012||Cranial neurosurgery|Patients undergoing cranial neurosurgery
89147810|NCT05264012||Non-cranial neurosurgery|Patients undergoing non-cranial neurosurgery including spine surgery
89147811|NCT05263856|Experimental|Laser acupuncture intervention|In this arm, subjects will receive laser acupuncture (LA) intervention during hospitalization after total knee replacement (TKR) surgery until discharge once a day. LA will stimulate on the 1) bilateral reflection areas of ear associated knee and pain mechanism, including Knee, Sympathetic Autonomic, Zero, Thalamus, Master Cerebral, Master Sensorial points, with 6 points unilaterl and 12 points in total, and 2) myofascial trigger point around knee joint, which may affect function performance and prognosis after TKR, including quadriceps, tensor fascia lata,adductor major,sartorius, hamstrings, gastrocnemius muscles, with 10 points in total.
89147812|NCT00612326||1|Patients with newly diagnosed locally or regionally advanced transitional cell carcinoma of the bladder.
89147813|NCT03909698||Hemodialysis patients on amoxicillin-clavulanic acid|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for amoxicillin-clavulanic acid."
89147814|NCT03909698||Hemodialysis patients on ceftazidim|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for ceftazidim."
89147815|NCT03909698||Hemodialysis patients on piperacillin-tazobactam|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for piperacillin-tazobactam."
89147816|NCT03909698||Hemodialysis patients on vancomycin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for vancomycin."
89147817|NCT03909698||Hemodialysis patients on teicoplanin|"The antibiotic administration protocol is not changed for this study. From the first administration on, administrations (dosage and duration) are well documented. Blood samples are taken as peak, distribution and trough samples during at least 24 or 48 hours. During the first dialysis session after study start, blood samples are also taken from the arterial and venous blood line simultaneously and at different dialysis time points, to calculate dialyzer extraction ratio. When appropriate, urine is collected during a documented period. During the second dialysis after study start, arterial and venous samples are taken for different dialysis settings, in order to calculate extraction ratios for different settings.~All blood and urine samples are analyzed for teicoplanin."
89147818|NCT04470674|Active Comparator|Arm A (Durvalumab)|Durvalumab 1500 mg IV every 4 weeks for 13 cycles.
89147819|NCT04470674|Experimental|Arm B (Durvalumab plus chemotherapy)|Durvalumab 1500 mg IV plus carboplatin AUC 5 IV and pemetrexed 500 mg/m2 IV every 3 weeks for 4 cycles followed by durvalumab and pemetrexed every 3 weeks for 13 more cycles.
89147820|NCT00883779|Experimental|1|
89147821|NCT00883779|Placebo Comparator|2|
89147822|NCT04418258|Experimental|Capillary Aspiration Endoscopy Catheter group|Small intestine aspirate suction was carried out with a capillary aspiration endoscopy catheter
89147823|NCT04418258|Active Comparator|Aspiration endoscopy catheter group|Small intestine aspirate suction was carried out with an aspiration endoscopy catheter
89147824|NCT05263778|Active Comparator|Intervention|Bempedoic acid 180 mg/ezetimibe 10 mg
89147825|NCT05263778|Placebo Comparator|Placebo|Matching placebo
89147826|NCT02693600|Active Comparator|Partial Trapeziectomy (PT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with with ligamentoplasty and partial trapeziectomy.
89147827|NCT02693600|Active Comparator|Total Trapeziectomy (TT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with ligamentoplasty and total trapeziectomy.
89147828|NCT04163133|Experimental|two days delay of trigger group|Two days later of trigger than regular trigger timing day (three follicles reach 17mm) .
89147829|NCT04163133|No Intervention|regular trigger group|regular trigger timing when three follicles reach 17mm bilateral.
89147830|NCT04405934|Other|Genomic-sequence informed IPC measures|Cohort follow baseline (no report receipt), then rapid vs standard sequencing report receipt phase, then return to baseline phase (no report receipt)
89147831|NCT04163055|No Intervention|Standard of Care|Wounds will be assessed using the Clinical Signs and Symptoms Checklist (CSSC). After initial assessment, a white-light (WL) photo will be taken of the wound. The wound bed will be prepared as indicated by clinical staff based on standard of care (SoC), including irrigation and debridement. A second WL image will be taken and a swab/biopsy will be obtained from the wound. Wounds will be dressed based on SoC.
89147832|NCT04163055|Experimental|Autofluorescence guided Standard of Care|Wounds will be assessed by autofluorescence (AF)-guided SoC. A baseline WL and AF photo will be taken of the wound. AF images will guide SoC including targeted debridement of areas of bacterial growth (AF+) and targeted sampling in areas of residual bacterial growth post-debridement. If no bacterial AF is detected, sample will be obtained from the wound center by curettage technique. If AF is detected, AF-guided debridement will be repeated and additional images will be obtained until 1) no AF is detected or 2) further debridement is not medically advised. After wound bed preparation, a second set of WL and AF images will be taken. Wounds will be dressed as per SoC. At all visits, samples will be sent for microbiology analysis. At 6- and 12-week visits (or any other scheduled visits in between), microbiology reports will be shared with clinicians if they were not collected outside of SoC.
89147833|NCT04162977|Experimental|High-risk youth|The 23-item Substance Use Risk Profile Scale (SURPS) will be used to identify high-risk adolescents who enter the intervention trial. Adolescents who score high on one of SURPS subscales (i.e., high-risk youth) will be invited to participate in two group-based intervention sessions which target their dominant personality profile. The criterion for high scores on SURPS personality traits are determined based on norms from high-risk adolescents in the same age range who participated in previous trials on personality-targeted interventions.
89147834|NCT02693444|Active Comparator|Subacromial Lidocaine Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of lidocaine, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
89147835|NCT02693444|Placebo Comparator|Subacromial Saline Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of saline, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
89147836|NCT02636751|Experimental|In-person prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment. General information about pain control, such as ice application and medication usage will also be provided
89147837|NCT02636751|Experimental|Tele-prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment using a telecommunication software (Reacts®, Facetime® or Skype®). General information about pain control, such as ice application and medication usage will also be provided.
89147838|NCT02636751|Active Comparator|Usual care group|The participants in this group will be provided with the hospital's usual documentation before total joint arthroplasties, consisting of information regarding the pre- and post-surgery course and medication.
89147839|NCT03838016|Experimental|Treatment cohort with classic galactosemia|These children and their parents receive the Babble Boot Camp intervention and also participate in the close monitoring activities (progress reports that the speech-language pathologist generates during the online meeting with the family; monthly daylong audio recording; questionnaires that are sent out every three to six months; formal speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years).
89147840|NCT03838016|Experimental|Treatment cohort with classic galactosemia, delayed start|The children in the control cohort enter the study when they are younger than 5 months old and participate in the close monitoring until they are 24 months old. They start getting the same treatment type and intensity as the treatment cohort but at a delayed age, when they turn 15 months.
89147841|NCT03838016|No Intervention|Older control cohort with classic galactosemia|The children in the older control cohort are 6 months to 4 1/2 years old and provide standardized test results in the area of speech and language development at child ages 2 1/2, 3 1/2, and 4 1/2 years. They receive no treatment and no close monitoring. These families provide questionnaire information every three months until child age 24 months.
89147842|NCT03838016|No Intervention|Typical controls|These children are free of any medical or developmental diagnosis. They enter the study at ages 2 to 5 months and provide close monitoring data until they are 24 months old, then they receive standardized speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years, just like the treatment cohort, but the typical controls receive no treatment under this study.
89147843|NCT04032951|Experimental|Adominal neoplasms patients|Patients in whom EUS-FNTA is performed with a novel type of biopsy neede.
89147844|NCT04162587||1)Patients with significant carotid stenosis only|Patients with significant carotid stenosis without intracranial stenosis.
89147845|NCT04162587||2) Patients with carotid and intracranial stenosis.|Patients with carotid and intracranial stenosis.
89147846|NCT04162587||3) Patients with lone intracranial stenosis.|Patients with lone intracranial stenosis.
89147847|NCT04162587||4) Patients with no significant stenosis|Patients with no significant carotid or intracranial stenosis.
89147848|NCT03661424|Experimental|Test dose then 8 doses HER2 Bi-armed activated T-cells (BATs)|Approximately 4 weeks following registration and blood collection, participants are given a test dose of HER2 BATs followed by 8 weekly infusions. Infusions are given intraventricularly.
89147849|NCT04162743|Active Comparator|Trazodone|take trazodone 100mg hs
89147850|NCT04162743|Placebo Comparator|Placebo|take placebo pill hs
89147851|NCT00612404||1|patients with gastrointestinal disorders who need an endoscopy.
89147852|NCT02636673||Robotic-assisted sigmoid resection|Patient that have undergone robotic-assisted sigmoid resection for benign or malignant disease between 2010 and 2015
89147853|NCT02636673||Laparoscopic sigmoid resection|Patient that have undergone laparoscopic sigmoid resection for benign or malignant disease between 2010 and 2015
89147854|NCT03813992|Active Comparator|MED2005 0.2%|MED2005 0.2% w/w gel to deliver 0.6 mg dose of GTN applied topically prior to a sexual intercourse attempt
89147855|NCT03813992|Active Comparator|MED2005 0.4%|MED2005 0.4% w/w gel to deliver 1.2 mg dose of GTN applied topically prior to a sexual intercourse attempt
89147856|NCT03813992|Active Comparator|MED2005 0.6%|MED2005 0.6% w/w gel to deliver 1.8 mg dose of GTN applied topically prior to a sexual intercourse attempt
88806008|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fed|One tablet of IBUCR 600 mg under fed condition
89147857|NCT03813992|Placebo Comparator|Placebo vehicle|Placebo vehicle applied topically prior to a sexual intercourse attempt
89147858|NCT00656565||1|subjects with bronchiectasis
89147859|NCT04162821|Experimental|60mg group|
89147860|NCT04162821|Experimental|90mg group|
89147861|NCT04162821|Experimental|120mg group|
89147862|NCT02535585|Active Comparator|knotted anchors|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
89147863|NCT02535585|Active Comparator|knotless anchors|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
89147864|NCT00613340|Experimental|1|Cervical medial branch blocks with 0.25 ml of injectate
89147865|NCT00613340|Experimental|2|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
89147866|NCT00613418|Other|single|Historical control
89147867|NCT02636127|Experimental|Systemic Sclerosis (SSc) patient|15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained
89147868|NCT02636127|Other|healthy patient|15 healthy patients will be recruited and blood samples will be obtained
89147869|NCT02535663|Experimental|test group|Dietary Supplement: RG consumed one pack (150ml) of dairy yogurt containing RG (100mg Korean citrus Hallabong peel polysaccharide) per day for 8 weeks
89147870|NCT02535663|Placebo Comparator|placebo|Dietary Supplement: placebo consumed one pack (150ml) of dairy yogurt without RG per day for 8 weeks
89147871|NCT02636205|Experimental|Armeo|Group receiving Armeo therapy
89147872|NCT04302896|Experimental|dolutegravir + emtricitabine/tenofovir alafenamide|Tivicay® (dolutegravir 50 mg tablet) + Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg combination tablet), one tablet of each taken by mouth once daily for 15 days
89147873|NCT04302896|Experimental|dolutegravir + tenofovir disoproxil fumarate + lamivudine|Tivicay® (dolutegravir 50 mg tablet) + Viread® (tenofovir disoproxil fumarate 300 mg tablet) + lamivudine 300 mg tablet, one tablet of each taken by mouth once daily for 15 days
89147874|NCT00656643|Experimental|1|
89147875|NCT00656643|Experimental|2|
89147876|NCT00656643|Experimental|3|
89147877|NCT00656643|Placebo Comparator|4|
89147878|NCT02635659|Experimental|Encapsulated nutrients|The investigational product will be a shot of sterile water (80 ml) mixed with a total of 21.6 grams encapsulate consisting of 13 grams of sucrose (60% of the total) encapsulated whey protein (<5% of total). On top of the encapsulated sucrose, 6.44 grams of casein (30% of total) encapsulated in whey protein (<5% of total) will be mixed with the shot of water. The micro-beats of encapsulated sucrose and casein are 150 µm and the ratio active (sucrose and casein) : whey is 95:5%, this means that the shot of water contains 13 grams of encapsulated sucrose, 6.44 grams of encapsulated casein and 1.3 grams of whey protein required for the encapsulation.
89147879|NCT02635659|Placebo Comparator|Placebo|The placebo has the same nutrient composition (e.g. 13 grams of sucrose and 6.44 grams of casein) as the active and will be equicaloric, and will also be mixed with a shot of sterile water (80 ml). The main difference of the placebo is that this nutrient mixture will be immediately released in the stomach, instead of being delivered to the ileum (active). This immediate release of the nutrient mixture is possible by using a different micro-encapsulation technique.
89147880|NCT02635971|Experimental|TAI chemotherapy|Patients in this arm will receive transcatheter arterial infusion of chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
89147881|NCT02635971|Active Comparator|Chemotherapy|Patients in this arm will receive intravenous chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
89147882|NCT00657423|Experimental|1|
89147883|NCT00657423|Active Comparator|2|
89147884|NCT05260970||undergoing rectus muscle reapproximation|Primigravida Singleton Pregnancies Who Underwent Elective Cesarean Section with rectus muscle reapproximation procedure
89147885|NCT05260970||not undergoing rectus muscle reapproximation|Primigravida Singleton Pregnancies Who Underwent Elective Cesarean Section without rectus muscle reapproximation procedure
89147886|NCT00911235|Experimental|Fesoterodine Alone|Reference treatment
89147887|NCT00911235|Other|fesoterodine plus fluconazole|Test treatment
89147888|NCT02632851||Ectoin inhalation solution|treatment according to instructions for use
89147889|NCT02632851||Pari NaCl inhalation solution (0.9%)|treatment according to instructions for use
88806009|NCT03418805|Active Comparator|Advil Ibuprofen table 200 mg-fasting|IBUAdv with a 4-hour dosing interval for 3 tablets (3×200 mg, q4h) under fasting condition
88806010|NCT03418805|Active Comparator|Motrin IB Ibuprofen Tablets 200 mg-fasting|IBUMot with a 4-hour doing interval for 3 tablets (3×200 mg, q4h) under fasting condition
89147890|NCT05260814|No Intervention|Control|Scaling and root planing and oral hygiene instructions with use of manual tools
89147891|NCT05260814|Experimental|Experimental|Scaling and root planing, oral hygiene instructions with use of Sonicare Diamond Clean Smart®.
88806011|NCT01156571|Experimental|cangrelor|"Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.~Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered."
89147892|NCT04283318|Other|Healthy|Age >18 years; BMI 20-27 kg/m2; Fasting plasma Glucose <110 mg/dL
89147893|NCT04283318|Other|Obese people|Age >18 years; BMI >30 kg/m2; Fasting Plasma Glucose <110 mg/dL
89147894|NCT04283318|Other|Type 2 Diabetes|Age >18 years; Diagnosed Type 2 Diabetes mellitus (diet or a monotherapy or combination of metformin, DPP-4-inhibitors or sulfonylurea)
89147895|NCT04283318|Other|Type 1 Diabetes|Age >18 years; Diagnosed Type 1 Diabetes mellitus >12 months; Treated with multiple daily Insulin injections (MDII) or continuous subcutaneous Insulin Infusion (CSII); Stable Insulin therapy as clinically assessed by the study physician C-Peptide negative defined as 0.3 nmol/L; No diabetic ketoacidosis within the last 12 months; No severe hypoglycaemia requiring external assistance within the last 12 months; Running on the FreeStyle Libre 1 (Abbott, USA) intermittently-viewed continuous Glucose Monitoring System (iCGM) as Standard of care for Glucose monitoring
89147896|NCT04159623|Experimental|Belk Device|With Belk Device
89147897|NCT04159623|Other|Standard Rehabilitative treatment|With the standard rehabilitative treatment
89147898|NCT02535351|Active Comparator|A: TKIs|sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
89147899|NCT02535351|Experimental|B: TKIs + Cytoreductive Nephrectomy|Cytoreductive nephrectomy + sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
89147900|NCT00613964|Placebo Comparator|Standard Therapy|Standard heart failure therapy excluding carperitide administration
89147901|NCT00613964|Active Comparator|Carperitide Therapy|Addition of carperitide administration to standard heart failure therapy
89147902|NCT02535429|Experimental|massage|massage
89147903|NCT02535429|No Intervention|Control|
89147904|NCT05342870|Experimental|Dexmedetomidine|
89147905|NCT00657579|Experimental|1|
89147906|NCT00657579|Experimental|2|
89147907|NCT00657579|Experimental|3|
89147908|NCT00657579|Placebo Comparator|4|
89147909|NCT03730610|Experimental|Exercise intervention|Six months of exercise training
89147910|NCT03542942|Other|treatment with EXIT-target volume|The radiotherapeutic treatment plan is based on an EXIT-target volume in which the non-involved uterus is excluded from the target volume. All other delineations are performed conform standard of care.
89147911|NCT05342792|Experimental|Metronomic Capecitabine with PD-1 antibody arm|Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) and Tislelizuamb (200mg, iv drip, Q3W) for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.
89147912|NCT05342792|Active Comparator|Metronomic Capecitabine alone arm|Patients randomised to this arm will receive metronomic capecitabine (650mg/m2, BID, PO) alone for 1 year as adjuvant therapy, beginning 4-6 weeks after chemoradiation.
89147913|NCT03671486||GBS-negative pregnant women|One Hundred Healthy GBS-negative pregnant women will be follow-up since the first trimester of pregnancy until one month post-delivery
89147914|NCT05300438|Experimental|TSN084|
89147915|NCT00614042|Experimental|1|Dose escalation and expansion cohorts
89147916|NCT05260502||Autistic children|magnetic resonance imaging brain for autistic children
89147917|NCT05260502||attention deficit hyperactivity disorder children|magnetic resonance imaging brain for attention deficit hyperactivity disorder children
89147918|NCT05260502||Normal children|magnetic resonance imaging brain for Normal children
89147919|NCT04159701|Experimental|LY3454738|500 milligram (mg) LY3454738 administered intravenously (IV).
89147920|NCT04159701|Placebo Comparator|Placebo|Placebo administered IV.
89147921|NCT02632617||CTA Group|Participants in CTA group will primarily receive computed tomographic angiography examination before surgery. Those with positive findings in CTA (≥50% diameter stenosis in main coronary artery) or uncertain diagnosis caused by motion artifact or calcium artifact are required to undergo ICA, and coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis according to the ICA result. Participants with negative findings in CTA do not need further coronary artery evaluation, and CABG won't be performed during the surgery.
89147922|NCT02632617||ICA Group|Participants in ICA group will undergo ICA as guideline recommend before surgery, coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis
89147923|NCT05260190|Experimental|tSMS|Real tSMS stimulation.
89147924|NCT05260190|Sham Comparator|Sham tSMS|Sham tSMS stimulation.
89147925|NCT00657735|Experimental|1|Deep TMS treatment
89147926|NCT00657735|Sham Comparator|2|inactive stimulation
89147927|NCT02811536||Diabetic retinopathy|Patients with various degrees of diabetic retinopathy
89147928|NCT02811536||Retinal detachment|Patients with a history of retinal detachment
89147929|NCT02811536||Retinal vein occlusion|Patients with a history of retinal vein occlusion
89147930|NCT02811536||Arterial hypertension|Patients with a history of arterial hypertension
89147931|NCT02811536||Carotid artery occlusion|Patients with a history of carotid artery occlusion
89147932|NCT02811536||Age related macular degeneration|Patients with a history of Age related macular degeneration
89147933|NCT02811536||Macroaneurysms|Patients with a history of retinal macroaneurysms
89147934|NCT02811536||Central serous chorioretinopathy|Patients with a history of central serous chorioretinopathy
89147935|NCT00657813|Experimental|Access [123I]MNI-330 and SPECT Imaging|
89147936|NCT04159233|Other|Adapted 'Brief Behavioral Therapy for Insomnia' (BBTI)|All participants will receive the same intervention in this pilot study.
89147937|NCT00657891|Placebo Comparator|1|Placebo Injection
89147938|NCT00657891|Experimental|2|Xolair at 0.016 mg/kg/IgE(iu/ml)/4 wks
89147939|NCT05221112|Experimental|diagonal pattern training|diagonal pattern training group will involve performance of proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
89147940|NCT05221112|Active Comparator|control group|in control group patients will perform movements in single plane
89147941|NCT02632773|Experimental|Parent Learning Style 1|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
89147942|NCT02632773|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
89147943|NCT02632773|Other|Learning Style 1 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
89147944|NCT02632773|Other|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
89147945|NCT00657969||1|CAD-group (Cervical Artery Dissection - group): consecutive patients with cervical artery dissection, with or without associated cerebral ischemia, hospitalized in one of the participating neurological centers; standardized inclusion and exclusion criteria apply
89147946|NCT00657969||2|IS-group (Ischemic Stroke - Group): patients selected among consecutive patients hospitalized for an ischemic stroke without CAD, in the same centers as patients from group1, frequency-matched on age and gender with group1; standardized inclusion and exclusion criteria apply
89147947|NCT00657969||3|HC-group (Healthy Control - Group): DNA of healthy individuals from existing DNA-databases will be used as controls for the Belgian, French, German and Swiss centers; the other centers are recruiting their own age- and sex-matched healthy controls; individuals from the 3 groups (CAD, IS and HC) are strictly matched on geographical origin in order to avoid stratification bias
89147948|NCT05171738|Active Comparator|group(1)|Group I: will include ten patients undergo maxillary molar distalization using skeletally anchored distal jet appliance with MOPs that will be performed buccally on repeated basis on two sides before and during maxillary molar distalization
89147949|NCT05171738|Active Comparator|group(2)|Group II:will include ten patients undergo maxillary molar distalization using skeletally anchored distal jet appliance with MOPs that will be performed both buccally and palatally on repeated basis on two sides before and during maxillary molar distalization.
89147950|NCT02632695|Experimental|FOOTFIT Plus|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports and allows regular communication with the wound care provider on progress.
89147951|NCT02632695|Experimental|FOOTFIT|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports. There is not regular communication with the wound care provider on progress.
89147952|NCT05162300|Experimental|Group A|"Subjects will be given the same-day combination of VI Peel (Procedure) and Botox Cosmetic (Botulinum Toxin) (Drug). Botox will be administered via intramuscular injection via package insert to Glabella, Forehead and Crows Feet. Dosage will follow package insert guidelines.~The two interventions will be administered once at the start of the study, subsequent study visits will focus on assessment and evaluation."
89147953|NCT04159077|Experimental|Tamsulosin Hydrochloride (HCL)|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of tamsulosin HCL to be started 3 days prior to their date of surgery.
89147954|NCT04159077|Placebo Comparator|Placebo|Consenting patients undergoing pulmonary resection will receive a 5-day allotment of placebo to be started 3 days prior to their date of surgery.
89147955|NCT00612482|No Intervention|1|"Participants in the no intervention condition will receive the usual high school science curriculum."
89147956|NCT00612482|Experimental|2|"Participants in the experimental arm will receive the 5-lesson, science-based substance abuse prevention curriculum in their science classes."
89147957|NCT04158999||Mother milk|Step 1: Mothers who meet the sample selection criteria will be informed about the scope of the study and their written and verbal consent will be obtained. Data collection form will be applied to mothers who accept to participate in the study by using face to face interview technique. Mothers and newborns will be weighed and 4 ml breast milk sample will be taken from the mother for manual milking.
89147958|NCT02692820|Experimental|Probiotic|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of probiotics (containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (each at 2.5 x 109 colony forming units (CFUs)). The product contains freeze-dried bacteria and excipients in a gelatin capsule.
89147959|NCT02692820|Placebo Comparator|Placebo|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of the placebo containing excipients alone in a gelatin capsule
89147960|NCT02632539|Active Comparator|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
89147961|NCT02632539|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
89147962|NCT05240378||Pre covid|Cases operated one year prior to the date of declaration of corona pandemic in India
89147963|NCT05240378||post covid|cases operated from the date of declaration of corona pandemic to one year after
89147964|NCT00658125|Experimental|Experimental|
89147965|NCT05138276|Experimental|Autologous cord blood mononuclear cells|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg
89147966|NCT05138276|Placebo Comparator|Placebo|0.9% sodium chloride infusion 24 hours after birth
89147967|NCT00658203|Active Comparator|1|PEA optimized CRT
89147968|NCT00658203|Other|2|Standard optimized CRT
89147969|NCT02692898||1|Archived CNS neoplasm specimens, in which primary diagnostic studies are complete, and for which there is excess tissue for analysis in the form of unstained slides or paraffin blocks
89147970|NCT00658281||OBI KV System + CBCT Scanning|Breast cancer patient radiation treatment set up using OBI KV system and CBCT scanning or CT-on-rail system to verify standard EPID for positioning.
89147971|NCT05025410||General anesthesia using remimazolam and remifentanil|Adult female patients scheduled for gynecological surgery under general anesthesia using remimazolam and remifentanil
89147972|NCT05239832|Experimental|V-01 COVID-19 Vaccine|10 μg(0.5ml)/vial, one dose administrated by intramuscular injection
89147973|NCT02690480|Experimental|PD-0332991(Palbociclib)+fulvestrant(FaslodexTM)|Fulvestrant 500mg, on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
89147974|NCT02690480|Active Comparator|Placebo+fulvestrant(FaslodexTM)|Fulvestrant 500mg on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
89147975|NCT04158609||Group 1|Pregnant women with CPR value below 1, based on Doppler indices assessment
89147976|NCT04158609||Group 2|Pregnant women with CPR value equal to or above 1, based on Doppler indices assessment
89147977|NCT02535507|Experimental|Pyrotinib treatment arm|pyrotinib treatment arm
89147978|NCT04158843|Experimental|Radical local treatment|Radical resection is performed, and the cutting edge is negative, or radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy). Systemic endocrine therapy and targeted therapy are allowed after radical local therapy. However, whether systemic chemotherapy should be used is determined by clinicians according to clinical experience or guidelines.
89147979|NCT04158843|Active Comparator|Palliative treatment|No radical surgical resection or radical surgical resection or radiotherapy is performed in this group. But palliative internal fixation or radiotherapy for pain relief is permitted. Moreover, systemic chemotherapy, endocrine therapy and targeted therapy are allowed.
89147980|NCT05230862|Experimental|Ladder Supplement|Ladder Supplement
89147981|NCT05230862|Placebo Comparator|Placebo|Placebo
89147982|NCT05224700|Experimental|Intervention group|The evaluator in charge will monitor the autonomous work of the participants during all 20 sessions of the program for stimulating cognitive and socioemotional skills while also answering questions, training the educators, and solving their doubts about the program and its implementation.
89147983|NCT05224700|Sham Comparator|Painting group|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. They will play a tablet-based painting game that involves no cognitive, emotional, or social competence stimulation
89147984|NCT00658749|Experimental|1|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
89147985|NCT00658749|Placebo Comparator|2|Physiologic saline solution
89147986|NCT05220800|Experimental|Iron(III)isomaltoside 1000|Weight-dependent one-time dosage of intravenous administration of iron(III)isomaltoside given prior to surgery. Dosage: <50 kg body weight = 500 mg, 50-59 kg body weight = 600 mg, 60-59 kg body weight = 700 mg, 70-79 kg body weight = 800 mg, 80-89 kg body weight = 900 mg, and 90+ kg body weight = 1000 mg.
89147987|NCT05220800|Placebo Comparator|Placebo|500 ml isotonic saline infusion fluid
89147988|NCT00658827||Group 1a: Remicade Cohort|Female patients who were exposed to Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
89147989|NCT00658827||Group 1b: Remicade Cohort|Infants born to Group 1a patients.
89147990|NCT00658827||Group 2a: Other Anti-TNF agents Cohort|Female patients who were exposed to anti-TNFs other than Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
89147991|NCT00658827||Group 2b: Other Anti-TNF agents Cohort|Infants born to Group 2a patients.
89147992|NCT00658827||Group 3a: Non-biologic Systemic Therapy Control Cohort|Female patients who were exposed to systemic therapy other than biologic agents at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
89147993|NCT00658827||Group 3b: Non-biologic Systemic Therapy Control Cohort|Infants born to Group 3a patients.
89147994|NCT00658827||Group 4a: Population Control Cohort|Female patients with no record of the diseases of interest and no exposure to biologic or non-biologic systemic therapy at any time during pregnancy (and up to 3 months prior to LMP, if the information is available).
89147995|NCT00658827||Group 4b: Population Control Cohort|Infants born to Group 4a patients.
89147996|NCT04962542|Active Comparator|ventilated group|the lungs will be kept inflated by delivery of oxygen : air 3 liter/min with FiO2 50% pressure-controlled mode, RR 20/min, PIP will be adjusted to keep Vt 2- 4 mL/kg as possible
89147997|NCT04962542|Active Comparator|CPAP group|lungs will be kept inflated by delivery of oxygen: air 3 liters/min with FiO2 50% and CPAP will be maintained via a circle system with airway pressure maintained at 5 cm H2O by PEEP valve
89147998|NCT04962542|No Intervention|controlled group|lungs will be deflated by disconnecting the breathing circuit from the ventilator (passive deflation).
89147999|NCT00658905|Active Comparator|rhBSSL|
89148000|NCT00658905|Placebo Comparator|Placebo|
89148001|NCT03466112|Experimental|endurance training|endurance training with stationary bicycles
89148002|NCT03466112|Active Comparator|balance and tone program|flexibility, core strength, balance, relaxation
89148003|NCT02632461|Experimental|Podcast (+Bite Counter)|Participants in this group will receive podcasts twice weekly in conjunction with using a wearable wrist device called a Bite Counter. The Bite Counter tracks the number of bites/calories per bite. (Podcasts plus Bite Counter)
89148004|NCT02632461|Active Comparator|Podcast (+Mobile App)|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile application to track their diet. (Podcasts plus Mobile Diet Application)
89148005|NCT00880269|Experimental|Stratum A|patients with refractory acute myelogenous leukemia (AML) initially diagnosed as de novo AML received 60 mg of panobinostat per day on three discontinuous days per week.
89148006|NCT00880269|Experimental|Stratum B|patients with refractory AML initially diagnosed as AML secondary to myelodysplastic syndrome (MDS)/antecedent hematologic disorder (AHD) received 60 mg of panobinostat per day on three discontinuous days per week.
89148007|NCT02632383|Experimental|Test Group|"Intervention: Young with Diabetes - app The test group receives standard care and the mHealth app Young with Diabetes - app to support young people to self-manage their diabetes.~The young people's parents are also invited to download the app. The diabetes team (doctors, nurses and dieticians) also have the app and uses the app in their consultations with the young people."
89148008|NCT02632383|No Intervention|Control Group|The control group receives standard care
89148009|NCT02632149|Experimental|Vagus nerve Stimulation is on|
89148010|NCT00659217|Experimental|2|mesenchymal stem cell Autologous MSC transplantation
89148011|NCT04158531|Experimental|REC2Stim|Use electrocorticography (ECoG)-based seizure detection and cortical network stimulation upon seizure onset detection.
89148012|NCT00880191|Experimental|Arm I|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
89148013|NCT00880191|Experimental|Arm II|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.
89148014|NCT04032015|Active Comparator|rTMS treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own MRI images. Daily treatment regiments will last 30 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
89148015|NCT04032015|Sham Comparator|Sham treatment|"Sham rTMS will be delivered for 20 sessions over 4 weeks. To maximize sham validity, both 1) a direction-sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity 10Hz electrical stimulation will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS treatment. Daily treatment regiments will last 30 minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS sessions for adverse events and/or side effects.~Upon completing the 20 sham sessions, participants are unblinded and offered 20 treatments of active rTMS. The open-label treatment would follow the active rTMS treatment protocol."
89148016|NCT00659451|Experimental|2|Losartan
89148017|NCT00659451|Active Comparator|1|Amlodipine
89148018|NCT00911313|Experimental|Letrozole|
89148019|NCT00911313|Active Comparator|Metformin-CC|
89148020|NCT00659685|Experimental|A|Subjects received Kali formulated products under fasting conditions
89148021|NCT00659685|Active Comparator|B|Subjects received GlaxoSmithKline formulated products under fasting conditions
89148022|NCT00659763||A|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill the ROM III criteria for IBS
89148023|NCT00659763||B|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill he ROME III criteria for IBS
89148024|NCT00659841|Active Comparator|1|Ciclesonide 200µg
89148025|NCT00659841|Placebo Comparator|2|Placebo
89148026|NCT00659919|Placebo Comparator|Placebo|The patients in this arm received placebo
89148027|NCT00659919|Active Comparator|Trazodone|The patients on this arm received Trazodone for 3 consecutive days
89148028|NCT00659997|Active Comparator|1|1 Individuals treated with Albendazole
89148029|NCT00659997|Active Comparator|2|Individuals treated with Levamisole
89148030|NCT04158453|Active Comparator|AUT00201|
89148031|NCT04158453|Placebo Comparator|Placebo|
89148032|NCT00660153|Experimental|single arm; multiple cohort|Single arm; multiple cohort
89148033|NCT00660231|Experimental|GemBex|Gemcitabine days 1 and 8 of a 3 week cycle (4 cycles total - 12 weeks) Bexarotene daily: in combination with Gemcitabine during first 12 weeks, then Bexarotene maintenance until disease progression.
89148034|NCT04158063|Experimental|Dual Task Training (DTT)|
89148035|NCT04158063|Active Comparator|Single Mobility Training (SMT)|
89148036|NCT00660465||A18|
89148037|NCT04157907||Patients with borderline personality disorder|Patients with borderline personality disorder included in the MBT program
89148038|NCT04157829|Experimental|Scintilling lamp- Classic lamp|
89148039|NCT04157829|Experimental|Classic lamp- Scintilling lamp|
89148040|NCT00597519|Experimental|Treatment|Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy), low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.
89148041|NCT04157439|Active Comparator|Control Group|Hot fermentation, Sustain pressure on trigger point, Self-stretches
89148042|NCT04157439|Experimental|Experimental Group|Integrated Neuromuscular Inhibition Technique Post isometric stretch (MET) Strain counter strain
89148043|NCT02632227||Hypovolemia|patients with hypovolemic signs including hypotension, decreased central venous pressure (less than 5mmHg), and decreased urine output
89148044|NCT00660777|Sham Comparator|1|Control Group
89148045|NCT00660777|Active Comparator|2|Therapy Group
89148046|NCT00660855|Other|Arm 1|
89148047|NCT00660933|Active Comparator|Group A|Group A: Administration of intravenous iron sucrose.
89148048|NCT00660933|Placebo Comparator|Group B|Group B: Administration of intravenous NaCl 0,9%.
89148049|NCT02632071|Active Comparator|80 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
89148050|NCT02632071|Active Comparator|120 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
89148051|NCT02632071|Active Comparator|180 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
89148052|NCT02632071|Active Comparator|240 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
89148053|NCT00661011|Experimental|A|Lobectomy followed by mediastinal concomitant chemoradiotherapy
89148054|NCT04156971|Experimental|Intervention Group|stage-based lifestyle modification intervention and fish oil supplement (omega-3). Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring' Participants in the intervention group were also given fish oil capsules containing n-3 LCPUFA (DHA and EPA) for a duration of 16 weeks. The participants were required to consume two fish oil capsules, providing 1320 mg n-3 LCPUFA (792 mg EPA, 20:5n-3 and 528 mg DHA, 22:6n-3), and 6 IU vitamin E (D-alpha tocopherol) daily. The EPA and DHA ratio was 1.5:1.
89148055|NCT04156971|Other|Control Group|Only received Stage-based Lifestyle Modification consists of several activities that include nutrition counselling, aerobic sessions, a hands-on activity 'Let's Play' and 'Sharing is Caring'
89148056|NCT00665691||1|
89148057|NCT04154709|Experimental|CTA101|Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89148058|NCT02630979||No treatment|Clinical and medical oncology physicians.
89148059|NCT00879333|Experimental|Everolimus + BSC|All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
89148060|NCT00879333|Placebo Comparator|Placebo + BSC|All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
89148061|NCT00666081|Experimental|Cohort 1|GSK690693 for injection. This is a dose escalation study.
89148062|NCT02630901|Experimental|PRX003|
89148063|NCT02630901|Placebo Comparator|Placebo|
89148064|NCT02630823|Experimental|Arm 1: MK-3475|"Patients will undergo endometrial biopsy followed by 2 doses of MK-3475 3 weeks apart. 3-4 weeks after the second dose of MK-3475, the standard of care surgical resection will take place, followed by standard of care adjuvant therapy. Tissue and blood will be collected at the time of surgical resection for immune analysis. For patients whose pathology confirms high-risk features and advanced stage, MK-3475 will be given every 3 weeks starting 4 -6 weeks after completion of adjuvant therapy for a maximum of 4 doses post-surgery.~MK-3475 will be given intravenously at a dose of 200 mg over the course of 30 minutes.~The standard of care chemotherapy will consist of 6 cycles of paclitaxel and carboplatin AUC 5 every 3 weeks for 6 cycles.~The decision to administer radiation therapy will be per the treating physician. If the patient does not receive radiation therapy, then the patient will start MK-3475 every 3 weeks x 4 doses after the completion of chemotherapy."
89148065|NCT02630745|Active Comparator|Immediate periodontal surgery (Group 1)|periodontal surgical procedure in the form of open flap debridement will be performed immediately( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) after obturation of the root canal system( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
89148066|NCT02630745|Active Comparator|Delayed periodontal surgery (Group 2)|periodontal surgical procedure in the form of open flap debridement( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) will be performed 3 months after obturation of the root canal system ( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
89148067|NCT02630511|Experimental|Asthma Group|Asthma group to receive mannitol, methacholine or placebo challenge tests
89148068|NCT02630511|Experimental|Control Group|Control group to receive mannitol, methacholine or placebo challenge tests
89148069|NCT00666159|Experimental|1|
89148070|NCT00666159|Active Comparator|2|
89148071|NCT00666315||Harmonic|Group operated with Harmonic device
89148072|NCT00666315||Conventional|Group operated with Electrocauery and Clip/Suture
89148073|NCT00666393|Experimental|001|
89148074|NCT00666471|Experimental|1|MICE
89148075|NCT00666471|Active Comparator|2|SPA ligation
89148076|NCT00666627|Active Comparator|1|Ibandronate
89148077|NCT00666627|Active Comparator|2|Risedronate
89148078|NCT00666627|Active Comparator|3|Alendronate 70mg once weekly
89148079|NCT00666627|No Intervention|4|Young women control group
89148080|NCT00666783|Experimental|PAL|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
89148081|NCT00666783|Active Comparator|GRA|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
89148082|NCT02630433|Experimental|Index cholecystectomy|Cholecystectomy within 48 hours after inclusion.
89148083|NCT02630433|Active Comparator|Scheduled cholecystectomy|Cholecystectomy 6 weeks after inclusion.
89148084|NCT00666939|Experimental|A|
89148085|NCT00666939|Experimental|B|
89148086|NCT00666939|Placebo Comparator|C|
89148087|NCT02630667|Experimental|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response.
89148088|NCT02630667|Experimental|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response.
89148089|NCT02630667|Experimental|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response.
89148090|NCT02630667|Placebo Comparator|Non-Caloric Placebo|Non-caloric placebo consisting of artificial sweeteners
89148091|NCT00667407|Experimental|1|Levalbuterol 1.25 mg
89148092|NCT00667407|Active Comparator|2|Racemic Albuterol 2.5 mg
89148093|NCT00667485|Experimental|Weekly Rapamcyin|Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks
89148094|NCT00667485|Experimental|Daily Rapamycin|Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks
89148095|NCT00667797|Experimental|1|levalbuterol 1.25 mg
89148096|NCT00667797|Active Comparator|2|Racemic albuterol 2.5 mg
89148097|NCT03481556|Experimental|A (melflufen+bortezomib+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with bortezomib at 1.3mg/m² S.Q. on Days 1, 4, 8, 11 and dexamethasone 20 mg (12 mg ≥ 75 years) Days 1, 4, 8, 11 and 40 mg (20 mg ≥ 75 years) on Day 15 and 22 of each 28-day cycle.
89148098|NCT03481556|Experimental|B (melflufen+daratumumab+dex)|Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with daratumumab 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Dexamethasone p.o. 40 mg weekly (20 mg weekly for patients age ≥ 75 years).
89148099|NCT00668031|Experimental|Arm 1|
89148100|NCT00668031|Placebo Comparator|Arm 2|
89148101|NCT02630355|Sham Comparator|Control|Inflation of blood pressure cuff in lower limb to 40mmHg for four cycles of 5 minutes inflation and then deflation
89148102|NCT02630355|Active Comparator|Low Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for two cycles of 5 minute inflation and then deflation.
89148103|NCT02630355|Active Comparator|Standard Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and then deflation.
89148104|NCT02630355|Active Comparator|High Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and deflation on weekly basis for four consecutive weeks.
89148105|NCT00668109|Experimental|Arm 1|
89148106|NCT00668109|Active Comparator|Arm 2|
89148107|NCT04765436|Experimental|PTX-COVID19-B|Participants, 45 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of PTX-COVID19-B vaccine in doses of 16 μg, 40 μg and 100 μg on Day 1, followed by a second dose on Day 28, respectively.
89148108|NCT04765436|Placebo Comparator|Placebo|Participants, 15 healthy adults 18 to 64 years of age, will receive 1 IM injection of matching placebo on Day 1, followed by a second dose on Day 28.
89148109|NCT03480620|Experimental|Telerehabilitation|Participant randomized into the telerehabilitation group will receive verbal and written discharge recommendations from each member of the team as usual. They will also be given a login to the online telerehabilitation platform where they will find the designated flexibility routines which can be accessed from a computer, tablet/slate, or smart phone at any time. Participant will receive electronic reminders via email and/or text message to perform their home program and complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
89148110|NCT03480620|Active Comparator|Usual care|Participants randomized into the usual care group will receive verbal and written discharge recommendations from each member of the team as usual. They will be provided with a copy of the DVD and instructed to practice one of the two routines at least 5 days per week. They will also be given a login to the online platform but will only have access to complete the follow up questionnaires. Participant will receive electronic reminders via email and/or text message to complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
89148111|NCT04032249|Active Comparator|Control Group (CG)|Education and modifying diet
89148112|NCT04032249|Experimental|Intervention Group (IG)|Education, modifying diet and Indications to record self-weighing with a frequency of 2 times per week
89148113|NCT04721756|Experimental|18F-LY3546117 Scan Cohort 1|18F-LY3546117 PET scan at baseline and between 14-42 days after initiation of immune checkpoint therapy
89148114|NCT04721756|Experimental|18F-LY3546117 Scan Cohort 2|18F-LY3546117 PET scan at time of immune checkpoint therapy response
89148115|NCT00668343|Active Comparator|1|
89148116|NCT00668343|Placebo Comparator|2|
89148117|NCT04717700|Experimental|B -selinexor-lenalidomide/bortezomib-dexamethasone|"Alternating cycles of:~Selinexor oral 40mg once weekly Lenalidomide oral 25mg d 1-21 Dexamethasone 20mg d 1+2, 8+9 and 15+16 i 28 days cycles and Selinexor oral 80mg once weekly Bortezomib sc 1.3mg/sqm once weekly Dexamethasone 20mg d 1+2, 8+9 and 15+16 in 28 days cycles for up to 16 cycles (8 of each, alternating) followed by continuos selinexor 40mg(once weekly)-lenalidomide-dexamethasone~for up to 16 cycles followed by continuos lenalidomide-dexamethasone"
89148118|NCT04017507||Oscillating-rotating electric toothbrush|Twice daily brushing
89148119|NCT04017507||Side-to-side electric toothbrush|Twice daily brushing
89148120|NCT04017507||Manual toothbrush|Twice daily brushing
89148121|NCT02630277|Experimental|Arm 1|1:1 Intravitreal Aflibercept Injection once every 4 weeks
89148122|NCT02630277|Experimental|Arm 2|Intravitreal of Aflibercept once every 4 weeks for 4 months then as needed (PRN)
89148123|NCT00614276||Phase I - Focus Groups|
89148124|NCT00614276||Phase II TENDRILS|Phase II - TENDRILS Program only.
89148125|NCT00614276||Phase II TENDRILS + Counseling|Phase II - TENDRILS + Sexual Counseling Sessions.
89148126|NCT00668421|Experimental|CEP-701 (Lestaurtinib)|Subject is to receives Lestaurtinib, in Phase 1: standard cohort dose escalation; Phase 2: single stage design to estimate the percentage of subjects with a 15% or greater reduction in JAK2 V617F allele frequency in peripheral blood granulocytes in 6 months of treatment
89148127|NCT02693522|Experimental|somatropin|Subcutaneous injection
89148128|NCT02693522|Active Comparator|Eutropin|Subcutaneous injection
89148129|NCT05201846|Experimental|Continuous subcutaneous insulin infusion|Continuous subcutaneous insulin infusion using insulin pump (DIA:CONN G8) with continuous glucose monitoring
89148130|NCT05201846|Active Comparator|Multiple daily insulin injection|Multiple daily insulin injection with continuous glucose monitoring
89148131|NCT03455114|Experimental|capsular fixation surgery|patients required capsule centration safely undergo capsular fixation surgery with AssiAnchor under local anesthesia .
89148132|NCT00668967|Other|Reference|marketed extended release verapamil tablet
89148133|NCT00668967|Other|Test|reformulated extended release verapamil tablet
89148134|NCT03583658|Active Comparator|Ambroxol hydrochloride (BIH1526)|One lozenge 20 mg on as-needed basis, up to 6 times per day
89148135|NCT03583658|Placebo Comparator|Placebo|One lozenge on as-needed basis, up to 6 times per day
89148136|NCT04154475|Experimental|yogurt diet|yogurt-diet (-500 kcal/day, 500 g yogurt, high calcium)
89148137|NCT04154475|Active Comparator|dairy diet|dairy diet: -500 kcal/day, high calcium, 500 g non-yogurt dairy products
89148138|NCT04154475|Active Comparator|standard diet|standard diet: -500 kcal/day, low calcium, 500 g soya-yogurt
89148139|NCT03555968|Placebo Comparator|THC 0 + BAC 0|Participants will receive 0mg of THC in combination with blood alcohol concentrations of .000%.
89148140|NCT03555968|Experimental|THC 5 + BAC 0|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .000%.
89148141|NCT03555968|Experimental|THC 10 + BAC 0|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .000%.
89148142|NCT03555968|Experimental|THC 5 + BAC .025|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .025%.
89148143|NCT03555968|Experimental|THC 10 + BAC .025|Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .025%.
89148144|NCT03555968|Experimental|THC 0 + BAC .049|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .049%.
89148145|NCT03555968|Experimental|THC 5 + BAC .049|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .049%.
89148146|NCT03555968|Experimental|THC 10 + BAC .049|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .049%.
89148147|NCT03555968|Experimental|THC 0 + BAC .025|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .025%.
89148148|NCT00669123|Placebo Comparator|2|
89148149|NCT00669123|Experimental|1|Chondroitin sulphate
89148150|NCT04617158|Active Comparator|Early adjustable suture surgery|Suture adjustment after 2 hours of surgery
89148151|NCT04617158|Active Comparator|Late adjustable suture surgery|Suture adjustment after 24 hours of surgery
89148152|NCT04154319|Active Comparator|HPV Vaccination|Mothers participated in educational/behavior change sessions to promote HPV vaccination among their 9-12 year old daughters
89148153|NCT04154319|Active Comparator|Healthy Eating|Mothers and daughters participated in educational/behavior change sessions to promote healthy eating and appropriate nutrition label interpretation
89148154|NCT00614354|Experimental|1|
89148155|NCT00669201||1|healthy young volunteers Inclusion: age 18-40, Exclusion: wrist trauma/surgery
89148156|NCT00669201||2|"patients with know osteoarthritis wrist changes according to pre-existing x-rays No age limits~exclusion: previous wrist surgery"
89148157|NCT00669201||3|Mixed group of 50 patients that perform routine MRI of the wrist for various indications
89148158|NCT04593680|Experimental|20 HIV-negative TGM will take daily TDF/FTC-based PrEP|"MHT will be initiated on week 0 and will be last administered on week 12. PrEP will be initiated on week 6 and continued without interruption.~MHT: Intramuscular testosterone enanthate 200 mg bi-weekly, which is the treatment of choice for MHT in the Pribta Clinic, will be provided to all participants.~PrEP: Fixed-dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) will be provided for arm 1 and 2, respectively.~Pharmacokinetic measurement of study drug Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include: plasma for testosterone, emtricitabine (FTC) and tenofovir (TFV), with an additional tenofovir alafenamide (TAF)."
89148159|NCT04593680|Experimental|20 HIV-negative TGM will take daily F/TAF-based PrEP|"MHT will be initiated on week 0 and will be last administered on week 12. PrEP will be initiated on week 6 and continued without interruption.~MHT: Intramuscular testosterone enanthate 200 mg bi-weekly, which is the treatment of choice for MHT in the Pribta Clinic, will be provided to all participants.~PrEP: Fixed-dose combination of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) will be provided for arm 1 and 2, respectively.~Pharmacokinetic measurement of study drug Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include: arm 2, measurement; and peripheral blood mononuclear cells (PBMC) for emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) intracellular quantification."
89148160|NCT02692742|Experimental|Myelo001|Myelo001 100 mg QD
89148161|NCT02692742|Placebo Comparator|Placebo|Matching Placebo QD
88804107|NCT00003196|Experimental|Treatment (irradiation, transplant, immunosuppression, DLI)|"CYTOREDUCTION: If necessary, patients with advanced malignancies undergo cytoreductive chemotherapy to reduce tumor size at discretion of primary physician and study investigators.~CONDITIONING REGIMEN: Patients undergo low-dose total-body irradiation followed by allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 to 0 and then PO BID on days 1-35 with taper to day 56. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST-TRANSPLANT DLI: Patients with mixed chimerism on day 56 and no evidence of GVHD undergo DLI over 30 minutes on day 65 and may receive up to 3 additional infusions in the absence of GVHD and disease progression or persistence. Patients who have not achieved mixed chimerism at day 56 undergo DLI if complete response is not obtained after a 2 month monitoring period."
89148162|NCT00669435|Active Comparator|1|Amlodipine and Simvastatin
89148163|NCT00669435|Experimental|2|Losartan and Simvastatin
89148164|NCT00669513|No Intervention|1|
89148165|NCT00669513|Experimental|2|Partial sleep deprivation
89148166|NCT00669591|Experimental|1|Patients will receive up to six (6) 28-day cycles of docetaxel plus weekly bavituximab during the treatment phase. During the follow-up phase, patients will continue to receive weekly bavituximab until disease progression
89148167|NCT00669747|Experimental|A|Carboplatin infused into DCIS-involved duct on Days 1 & 15
89148168|NCT00669747|Experimental|B|Carboplatin infused into DCIS-involved duct Day 1 and Normal Saline infused into DCIS-involved duct on Day 15
89148169|NCT00669747|Placebo Comparator|C|Normal Saline infused into DCIS-involved duct Days 1 & 15
89234888|NCT05887947|Experimental|1 African American 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 1.8%|"1, African American, baseline smoking at enrollment is 1-10 cigarettes per day~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89148170|NCT00669825|Placebo Comparator|A|Placebo
89148171|NCT00669825|Active Comparator|B|ALV003 (Active Study Drug)
89148172|NCT04154241|Experimental|neuroendocrine tumor Patients|A cohort of patients that were diagnosed with NET using biopsy.
89148173|NCT04154397|No Intervention|error-enhancing feedback|The project of the first arm was to investigate how visualized error size affects postural training effect of the elderly, with a particular focus on error amplification strategy to optimize training benefits for postural training that favors the use of feedback mechanism on postural control and error correction. All participants were randomly assigned into the control and error amplification groups. The control group was trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. For the error amplification group, they were trained with the same postural paradigm, except that the visual guidance was virtually manipulated so that the participants visually perceived twice of the execution errors during stabilometer stance. We contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
89234889|NCT05887947|Experimental|2 African American 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 5%|"2, African American, baseline smoking at enrollment is 1-10 cigarettes per day~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234890|NCT05887947|Experimental|3 African American 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 1.8%|"3, African American, baseline smoking at enrollment is 1-10 cigarettes per day~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234891|NCT05887947|Experimental|4 African American 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 5%|"4, African American, baseline smoking at enrollment is 1-10 cigarettes per day~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234892|NCT05887947|Experimental|5 African American 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 1.8%|"5, African American, baseline smoking at enrollment is 11-30 cigarettes per day~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
88804108|NCT04777292|Experimental|Immediate-use|Immediate use of esTOCma mobile app. Participants will use the mobile application immediately after the baseline assessment (T0) during approximately 10 days or until app completion.
88804109|NCT04777292|Active Comparator|Delayed use|Delayed use of esTOCma mobile app. Participants will start using the app 10 days after the first assessment (T0), and immediately after the T1 assessment.
88804110|NCT04738682|Active Comparator|Group 1 (Digital -> Conventional)|Patients allocated to Group 1 (Digital -> Conventional) will undergo three days of digital dietary registration, using mobile devices, followed by three days of conventional dietary registration, using pen and paper.
88804111|NCT04738682|Active Comparator|Group 2 - (Conventional -> Digital)|Patients allocated to Group 2 - (Conventional -> Digital) will undergo the exact opposite sequence, commencing with three days of conventional dietary registration, using pen and paper, followed by three days of digital dietary registration, using mobile devices.
88804112|NCT00002854|Experimental|Sequential high dose chemotherapy|
88804113|NCT02308202|Active Comparator|doxazosin|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive doses of study medication as over-encapsulated doxazosin XL or placebo dosed once in the morning. Study medication will be initiated as one capsule of doxazosin XL 4 mg or placebo given in the morning. The dose will be titrated up to 16 mg/d doxazosin XL or placebo as follows: Days 1-4: 4mg, Days 5-8: 8mg, Day 9-12: 12 mg, Days 13-16: 16 mg.
88804114|NCT02308202|Active Comparator|perindopril|Subjects will be randomized to receive either perindopril 16mg or placebo for 8 days. Participants will receive doses of study medication as over-encapsulated perindopril or placebo dosed once in the morning.
88804115|NCT02308202|Placebo Comparator|placebo|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive placebo for doxazosin XL for 16 days and placebo for perindopril for 8 days.
88804116|NCT00002860|Other|surgery|
88804117|NCT03148964||Follow-up Arm|Blood sampling only
88804118|NCT04329052|Experimental|Experimental group|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
88804119|NCT04329052|No Intervention|Control group|Participants would have their usual activity without any intervention.
88804120|NCT00003934|Experimental|Arm I|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin every 12 hours on days 1-7 and daunorubicin IV on days 1-2 or days 1-3, depending on age. Patients may receive an additional course. Treatment begins no earlier than 2 weeks and no later than 4 weeks after hematopoietic recovery."
88804121|NCT00003934|Experimental|Arm II|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin as in arm I above. Patients also receive oral mercaptopurine once a day and oral methotrexate once weekly for up to 1 year."
88804122|NCT00003694|Experimental|Treatment (omacetaxine mepesuccinate, cytarabine)|Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days. Courses repeat every 28 days. Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity. Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon. Minor cytogenetic responders are switched to interferon, and nonresponders are removed from therapy and given the option to switch to interferon.
89148174|NCT04154397|Experimental|positive cerebellar transcranial stimulation|The project of the second arm was to investigate the training benefits of using combined cerebellar transcranial direct current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance.They were randomly assigned into the control (traditional error amplification)and cerebellar transcranial direct current stimulation groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
89148175|NCT04154397|Experimental|sham cerebellar transcranial stimulation|The project of the third arm was to investigate the training benefits of using combined cerebellar transcranial random current stimulation and visual error amplification on postural training during static stabilometer stance, in reference to sole visual error amplification. A particular focus was training-related alterations in error correction strategy and underlying cortical plasticity for postural balance. All participants were randomly assigned into the control (sham stimulation) and cerebellar transcranial random current stimulation and visual error amplification (ES) groups. Both groups were trained to remain static stance on the stabilometer with visual guidance that displayed the target signal and tilting angle of the stabilometer. Under the condition of visual feedback without error amplification, we again contrasted training benefits between the two groups after completion of eight training trails of 1 minute.
89148176|NCT00596427|Placebo Comparator|Placebo tablet 3 tablets 2x/day|Type-2 diabetes mellitus patients
89148177|NCT00596427|Experimental|Colesevelam HCL 625 mg: 3 tablets 2x/day|Type-2 diabetes mellitus patients
89148178|NCT00669981|Experimental|1|Participants will receive immediate cognitive behavioral couples therapy for PTSD.
89148179|NCT00669981|Active Comparator|2|Participants will receive delayed cognitive behavioral couples therapy for PTSD after a 3-month waitlist period.
89148180|NCT04154007||Adult Patients who met the diagnosis of ARDS|ARDS patients were followed for the development of AKI during their ICU stay
89148181|NCT04153773||Group 1|60 Patient
89148182|NCT04153773||Group 2|30 Control subject
89148183|NCT00670059|Active Comparator|A|group: single embryo transfer without aneuploidy screening
89148184|NCT00670059|Experimental|B|group: single embryo transfer with aneuploidy screening
89148185|NCT00670215|Experimental|Arm 1|
89148186|NCT00670215|Experimental|Arm 2|
89148187|NCT00670293||Subjects with anorexia nervosa|Underweight participants with anorexia nervosa who will restore normal weight levels after inpatient treatment will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
89148188|NCT00670293||Healthy weight controls|Participants who are healthy controls will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
89148189|NCT00670371||1|Patients having the following diagnoses are eligible for inclusion into the study: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder, affective psychosis with mood incongruent delusions, psychotic disorder not otherwise specified or patients being actively psychotic.
89148190|NCT00670371||2|Closest relative(s) /informal caregiver(s)
89148191|NCT04153695|Experimental|Experimental|To listen flamenco music during 30 minuts per day, during 2 weks
89148192|NCT04153695|No Intervention|Control|No intervention
89148193|NCT04153851|Other|neurectomy of nasopalatine nerve|"Prophylactic preoperative antibiotic will be administered prior to surgery.~Oral disinfection will be performed before surgery.~Labial infiltration anesthesia and nasopalatine nerve block anasthesia.~The nasopalatine foramen will be exposed after reflection of a palatal and buccal flap.~Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal.~Dental implant will be inserted in the central incisor location."
89148194|NCT02629887|Active Comparator|Face Mask|Standard Face Mask with T piece resuscitator for neonatal resuscitation. Face mask placement per Neonatal Resuscitation Program resuscitation guideline.
89148195|NCT02629887|Active Comparator|Non-inflatable supraglottic airway|Use of non-inflating supraglottic airway with T-piece resuscitator instead of Standard Face Mask with T piece resuscitator for neonatal resuscitation, replacing standard of care face mask in Neonatal Resuscitation Program guideline.
89148196|NCT00595959|Experimental|Laser Treatment|CLiRpath Photoablation Atherectomy System
89148197|NCT00670683||A|
89148198|NCT00670761|Active Comparator|1|treatment with 600mcg oral misoprostol
89148199|NCT00670761|Active Comparator|2|treatment with 400mcg sublingual misoprostol
89148200|NCT00670761|Active Comparator|3|treatment with Manual Vacuum Aspiration (MVA)
89148201|NCT00670839|Active Comparator|A|GenHevac-B 20 microgram intramuscular use at M0, M1 and M6
89148202|NCT00670839|Experimental|B|GenHevac-B 40 microgram intramuscular use at M0, M1 and M6
89148203|NCT00670917|Active Comparator|L14 acupoint|
89148204|NCT00670917|Sham Comparator|Sham Point|
89148205|NCT04153617|Placebo Comparator|Control honey|"Orange blossom honey.~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.~Short term trial: 20g/day in a single day."
89148206|NCT04153617|Experimental|Modified honey with soluble fiber and polyphenols|"Honey modified with soluble fiber and polyphenols~Middle term trial: 40g/day for 3 months in two daily intakes of 20 g/day.~Short term trial: 20g/day in a single day."
89148207|NCT02627391|Experimental|Early surgery|Surgical aortic valve replacement
89148208|NCT02627391|Active Comparator|Delayed surgery according to guidelines|Surgical aortic valve replacement
89148209|NCT03239678|Active Comparator|group A|100% Oxygen
89148210|NCT03239678|Experimental|group B|30% Oxygen.
89148211|NCT03239678|Experimental|group C|21% Oxygen
89148212|NCT03239678|Experimental|group D|40% Oxygen
89148213|NCT03239678|Experimental|group E|60% Oxygen
89148214|NCT03239678|Experimental|group F|80% Oxygen
89148215|NCT00680433|Experimental|Active|Ketamine
89148216|NCT00680433|Placebo Comparator|Placebo|Saline (placebo)
89148217|NCT03209258|Other|Goal-directed care bundle|Management policy to receive a goal-directed care bundle that involves the rapid correction (<1 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 7 days or hospital discharge (or death, if sooner)
89148218|NCT03209258|Other|Usual care group|Patients receive the usual management based on local guidelines and hospital's individual policy.
89148219|NCT02627157||myopia patients|20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
89148220|NCT03322280|Experimental|TACE+I-125 seeds|TACE combined with iodine-125 seeds implantation
89148221|NCT03322280|Active Comparator|TACE alone|TACE alone
89148222|NCT05345366||the good collateral group|
89148223|NCT05345366||the poor collateral group|
89148224|NCT04150575|Experimental|HLX10|HLX10+albumin-bound paclitaxel
89148225|NCT04510298|Experimental|SP-624|SP-624 oral capsule, 20 mg once daily
89148226|NCT04510298|Placebo Comparator|Placebo|Placebo oral capsule, once daily
89148227|NCT04349306|Experimental|rasburicase|rasburicase 0.20 mg/kg/day by intravenous (IV) over 30 minutes for 1 to 5 days according to the level of plasma uric acid or Investigator's clinical judgement
89148228|NCT03104192|Active Comparator|Develop & Refine MOWI w/o Amulet (2A)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults without the use of Amulet technology.
89148229|NCT03104192|Experimental|MOWI Weight Loss Maintenance|Evaluate the feasibility, acceptability, and potential effectiveness of an 8-session, tri-weekly, psychosocial skills group intervention to support weight loss maintenance post-MOWI.
89148230|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit (2B)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology.
89148231|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit/Protein (2P)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology augmented by whey protein.
89148232|NCT00614588||observation group|Patients undergoing laparoscopic surgery requiring general anesthesia and a bladder catheter.
89148233|NCT04171310|Experimental|SAR442168|Single oral dose of SAR442168 (as a nonsalified compound) containing (NMT) 3.7 MBq of [14C]-SAR442168
89148234|NCT02692274||Primary Health care clinics|A survey of 100 primary Health care clinics was carried out
89148235|NCT02692274||Pregnant and breast feeding women|208 patients were recruited from nine clinics that participated in the survey for evaluation of the accuracy of results produced by the HIV rapid test.
89148236|NCT02699840||Menactra Study Group 1|Participant aged 2 through 11 years at vaccination
89148237|NCT02699840||Menactra Study Group 2|Participant aged 12 through 17 years at vaccination
89148238|NCT02699840||Menactra Study Group 3|Participant aged 18 through 55 years at vaccination
89148239|NCT02514668|Experimental|Isatuximab|Isatuximab (escalating dose) on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression
89148240|NCT00613808|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only for the two week screening period and then for 20 weeks thereafter
89148241|NCT00613808|Active Comparator|B Same treatment for 6 weeks, 200ppm NO gas|Subjects were treated by topical application of 200ppm Nitric Oxide gas delivered to the wound area for 8 hours per day for 6 weeks
89148242|NCT05344976|Experimental|MSLN STAR-T cells|The patients will receive one dose of MSLN STAR-T.The dosage ranges from1×10^7 to 1×10^8 STAR-T+/kg.
89148243|NCT05344742|Experimental|Mitoxantrone Hydrochloride Liposome Injection and Capecitabine|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection and capecitabine followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 18 mg/m^2, and then the dose will be sequentially escalated to 24 mg/m^2 and 30 mg/m^2. The frequency of administration will be once every three weeks. The fixed dose of capecitabine will be set as 1000 mg/m^2, twice daily, from day 1 to day 14. Every 3 weeks will be set as a treatment cycle, and the administration of drugs is planned for 6 cycles.~Dose-expansion phase: one dose cohort will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection and capecitabine, and the administration of drugs is planned for 6 cycles."
89148244|NCT05344742|Experimental|Mitoxantrone Hydrochloride Liposome Injection and albumin-paclitaxel|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection and albumin-paclitaxel followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 18 mg/m^2, and then the dose is sequentially escalated to 24 mg/m^2 and 30 mg/m^2. The frequency of administration will be once every three weeks. The fixed dose of albumin-paclitaxel will be set as 260 mg/m^2, once every three weeks. Every 3 weeks will be set as a treatment cycle, and the administration of drugs is planned for 6 cycles.~Dose-expansion phase: one dose cohort will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection and albumin-paclitaxel, and the administration of drugs is planned for 6 cycles."
89148245|NCT02198768||Ankle Fracture|Patients with isolated ankle fractures.
89148246|NCT02198768||Ankle Fracture-Dislocation|Patients with ankle fracture-dislocations.
89148247|NCT02046434|Experimental|Parkinson's Diesase|Participant will take Glycerol Phenylbutyrate, participant has Parkinson's Disease
89148248|NCT02046434|Experimental|Control|Participant does not have Parkinson's Disease, Participant will be taking glycerol phenylbutyrate
89148249|NCT03930446|Experimental|Ethanol|Subjects will receive 4 color-coded beverages in green or blue cups, containing ethanol (0.2 g/kg per dose, total dose 0.8 g/kg).
89148250|NCT03930446|Placebo Comparator|Placebo (Juice)|Subjects will receive 4 color-coded beverages in green or blue cups, containing placebo (Juice).
89148251|NCT02325674||Metreleptin|"Metreleptin new-users~Metreleptin prevalent users"
89148252|NCT00614666|Experimental|A|nikkomycin Z 50 mg BID versus placebo BID x 14 days
89148253|NCT00614666|Experimental|B|nikkomycin Z 250 mg BID versus placebo BID x 14 days
89148254|NCT00614666|Experimental|C|nikkomycin Z 500 mg BID versus placebo BID x 14 days
89148255|NCT00614666|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
89148256|NCT03794336|Experimental|Alogliptin|Single dose of alogliptin once daily for 16 weeks
89148257|NCT03794336|Active Comparator|Acarbose|Thrice daily dose of acarbose Dose 1 for 7 days then titrate to thrice daily dose of of acarbose Dose 2
89148258|NCT03774914||Lemtrada|Pregnant women exposed to LEMTRADA which is administered by IV infusion for 5 consecutive days, then for 3 consecutive days, 12 months after the first/previous treatment course
89148259|NCT00956774|Active Comparator|Balloon Catheter|
89148260|NCT00956774|Active Comparator|Cervical Vacuum Cup|
89148261|NCT00956774|Active Comparator|acorn-tipped cannula|
89148262|NCT05343884|Other|Dynamic myocardial perfusion imaging|Dynamic myocardial perfusion imaging is performed to obtain additional measurements of coronary blood flow, compared to conventional imaging.
89148263|NCT05343884|Other|Conventional myocardial perfusion imaging|Conventional myocardial perfusion imaging which is based on standard routine clinical myocardial perfusion imaging.
89148264|NCT03687554|Experimental|Venglustat|Single dose of Venglustat is given, orally under fasting conditions
89148265|NCT03681158|Experimental|sodium valproate|Single oral dose of sodium valproate containing [14C]-sodium VPA
89148266|NCT02692352|Experimental|Experimental|8 sessions of Goal Management Training
89148267|NCT02692352|Active Comparator|Active control group|8 sessions of Brain Health Workshop
89148268|NCT02870582|Experimental|Donafenib|Donafenib 300mg bid on 1-21 days of each 28 days cycle.
89148269|NCT02870582|Placebo Comparator|Placebo|Placebo 300mg bid on 1-21days of each 28 days cycle.
89148270|NCT02692118||sepsis|Patients with septic shock admitted to ICU
89148271|NCT02692196|Experimental|Neurofeedback Training|Neurofeedback training - neurofeedback of fronto-limbic functional connectivity.
89148272|NCT02692196|Sham Comparator|Sham Control|Sham training - feedback that is not related with fronts-limbic connectivity (motor connectivity)
89148273|NCT05343728||Thromboelastographic Methods|Patients whose coagulation profile were done by using a thromboelastography in addition to standard coagulation profile laboratory examination (thrombocyte count, PT, APTT, D-dimer, Fibrinogen)
89148274|NCT05343728||Standard coagulation profile laboratory examination|Patients whose coagulation profile were done by using a standard coagulation profile laboratory examination (thrombocyte count, PT, APTT, D-dimer, Fibrinogen)
89148275|NCT00436748|Experimental|Darbepoetin Alfa QW|Participants received darbepoetin alfa once a week (QW) for 24 weeks. The initial dose was 0.45 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
89148276|NCT00436748|Experimental|Darbepoetin Alfa Q2W|Participants received darbepoetin alfa every 2 weeks (Q2W) and a placebo every other 2 weeks to maintain the blind for 24 weeks. The initial dose was 0.75 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
89148277|NCT02704598|Active Comparator|Rivaroxaban|Patients with deep venous thrombosis using Rivaroxaban for 6 months, and then will be evaluated with DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
89148278|NCT02704598|Active Comparator|Warfarin|Patients with deep venous thrombosis using Warfarin for 6 months, and then will be evaluated wiht DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
89148279|NCT04188626|Experimental|Driving session|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving.
89148280|NCT05343416||Open abdomen procedure|All patients underwent to open abdomen procedure
89148281|NCT02704910|Placebo Comparator|Voluntary subject|Patient without parkinson disease, without deep brain stimulation
89148282|NCT02704910|Active Comparator|Patients|Subthalamic stimulation
89148283|NCT02704832|No Intervention|Arm A|"Arm A Standard oncological care: patients will be treated according to daily oncological practices as defined for each type of cancer, in the Management protocol of Oncology written and validated by a group of expert oncologists. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months."
89148284|NCT02704832|Experimental|Arm B|"Arm B Geriatrician Intervention: patients will be treated according to the same Management protocol of Oncology than patients in the arm Standard oncological care.~Before the beginning of the medical treatment, a comprehensive geriatric assessment will be performed by the geriatrician and the nurse that will define a plan of geriatric management care, according to the Management protocol of Geriatrics.~The nurse, under the supervision of a geriatrician, will monitor implemented geriatric interventions. Phone follow-up will be performed every month for 6 months and at 9 months or during any change of situation according to a pre-established phone call plan. A full geriatric assessment by the geriatrician and the nurse will be performed at 6 and 12 months."
89148285|NCT03175718|Experimental|VAC Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 7 days of Incisional Negative pressure wound therapy.
89148286|NCT03175718|Active Comparator|Control Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive standard gauze dressing with no negative pressure application.
89148287|NCT02704286|Sham Comparator|Generic Osteoarthritis Risk Information|Participants in this arm received generic osteoarthritis information that was not personalized.
89148288|NCT02704286|Experimental|Personalized Osteoarthritis Risk|Participants in this arm obtained their personalized osteoarthritis risk from the internet-based Osteoarthritis Risk Calculator.
89148289|NCT05343338|Experimental|sivelestat sodium on the basis of the original treatment|In the perioperative period, sivelestat sodium was added, and on the basis of not terminating and changing the original treatment plans.
89148290|NCT05343338|No Intervention|the original treatment|Only accept the original clinical diagnosis and treatment and clinical management.
89148291|NCT02704520|Other|Control arm|Management according to national guidelines - conventional MDT, clinical assessment post-treatment planning
89148292|NCT02704520|Experimental|Intervention arm|mrTRG directed management 'Good response' (mrTRG 1&2) - deferral of surgery (watch & wait) offered. 'Poor response' (mrTRG 3-5) - local colorectal MDT is informed and uses information to discuss and agree next steps in treatment and surveillance.
89148293|NCT02704052|Active Comparator|Standard enoxaparin dose|We will identify a convenience sample of surgical patients placed on enoxaparin prophylaxis at their attending surgeon's discretion-the proposed research will not dictate the initial enoxaparin dose magnitude or frequency. However, we will identify patients already on enoxaparin, evaluate peak and trough steady state aFXa levels, and adjust patient's dose if necessary based on steady state aFXa levels. Eligible patients will have enoxaparin prophylaxis started within 36 after surgery at their surgeon's discretion. Steady state peak and trough aFXa levels will be drawn at 4 and 12 hours, respectively, after the third enoxaparin dose. Goal peak aFXa levels will be 0.2-0.4 IU/mL for twice daily dosing and 0.3-0.5 IU/mL for once daily dosing.
89148294|NCT02704052|Experimental|Real time enoxaparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time enoxaparin dose adjustment and will receive followup steady state peak and trough aFXa levels. aFXa monitoring will be discontinued when in range peak levels are obtained, when enoxaparin prophylaxis is discontinued at surgeon discretion, or when the patient is discharged. Patients may be continued on enoxaparin prophylaxis after discharge per attending surgeon discretion but aFXa levels will not be followed in the outpatient environment.
89148295|NCT02703896|Placebo Comparator|Group C (placebo)|"Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)"
89148296|NCT02703896|Active Comparator|Either PPIs or H2RAs|"Drug Intervention Two doses at 8.00 pm and then at 6.00 am~Group L (lansoprazole 15 mg)~Group E(esomeprazole 20 mg)~Group P (pantoprazole 20 mg)~Group R (rabeprazole 10 mg)~Group O (omeprazole 20 mg)~Group T (cimetidine 200 mg)~Group F (famotidine 20 mg)~Group N (nizatidine 150 mg)~Group Z (ranitidine 150 mg)~Group S (lafutidine 10 mg)"
89148297|NCT02703896|Active Comparator|Either PPIs or H2RAs+prokinetics|"Drug intervention Two doses at 8.00 pm and then at 6.00 am~Group L D (lansoprazole 15 mg+ domperidone 10 mg)~Group EM (esomeprazole 20 mg+metoclopramide 10 mg)~Group PD (pantoprazole 20 mg+domperidone 10)~Group RM (rabeprazole 10 mg+metoclopramide 10 mg)~Group OD (omeprazole 20 mg+domperidone 10)~Group TD (cimetidine 200 mg+domperidone 10)~Group FM (famotidine 20 mg+metoclopramide 10 mg)~Group NM (nizatidine 150 mg+metoclopramide 10 mg)~Group ZD (ranitidine 150 mg+ domperidone 10 mg)~Group SD (lafutidine 10 mg+domperidone 10 mg)"
89148298|NCT02703896|Active Comparator|Either PPIs or H2RAs+Prokinetic|Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg )
89148299|NCT02703896|Other|Intervention Orogastric intubation|After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents.
89148300|NCT02806310||Prospective|Group A: Patients with known BAV who are scheduled to have a cardiac MRI.
89148301|NCT02806310||Historic|Group B: Patients with known BAV who have already had an MRI within the past year
89148302|NCT02737436|Experimental|Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
89148303|NCT02737436|Experimental|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
89148304|NCT00614978|Experimental|I|Lapatinib plus temozolomide
89148305|NCT02703818|Experimental|Senza|Spinal Cord Stimulation for UEP
89148306|NCT05343026|Experimental|HA treatment group|Participants in the treatment group are required to wear the HAs for at least 3 hours per day, with 24 days per month. Additionally, they will receive regular counseling and lifestyle education from their physicians.
89148307|NCT05343026|No Intervention|non-HA treatment group|Non-HA treatment group is a waiting list control group (WLC) in which participants will receive the intervention after the waiting period has passed. They will only receive regular counseling and lifestyle education from their physicians in this waiting period.
89148308|NCT02703974|Experimental|Early handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and nudges built after Phase II data collection.
89148309|NCT02703974|Experimental|Late handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations and nudges built at the same time, after Phase II data collection.
89148310|NCT02703974|Active Comparator|Early handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and will receive a Hand hygiene education-based program, after Phase II data collection is complete.
89148311|NCT02703974|Active Comparator|Late handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after Phase II data collection is complete, when the Hand hygiene education-based program will commence.
89148312|NCT02703740|Experimental|HA 20 mg/mL|
89148313|NCT02703740|Experimental|HA 24 mg/mL|
89148314|NCT02535494|No Intervention|Standard Training|Participants receive our standard overdose training.
89148315|NCT02535494|Experimental|Extensive Training|Participant receives an more in-depth, extensive training concerning opioid overdose.
89148316|NCT02535494|Experimental|Extensive Training w/ Significant Other|Participant and their significant other both receive a more in-depth, extensive training concerning opioid overdose.
89148317|NCT00615368|Placebo Comparator|Placebo|Isotonic NaCl, intravenously injection
89148318|NCT00615368|Experimental|Active|Epoetin alfa, injected
89148319|NCT02699216|Experimental|Phase 1 Active Treatment|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
88804123|NCT01896596|Active Comparator|Menjugate|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menjugate (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
89148320|NCT02699216|Placebo Comparator|Phase 1 Sham Treatment|Subjects will undergo 8 sham treatments, approximately 11 minutes, with a non-functional device to the enrolled eyes daily for three consecutive days during week 1, with no treatments on day 4 and 5. Followed by 8 active treatments, for approximately 11 minutes, for three consecutive days, with an active device during week 2, with no treatments on day 4 and 5.
89148321|NCT02699216|Experimental|Phase 2 Open Label|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
89148322|NCT00615446|Experimental|A|
89148323|NCT02699372|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RO6889450 as oral capsules.
89148324|NCT02699372|Experimental|RO6889450: Part 1 Single Ascending Dose (SAD)|Participants will undergo a series of screening visits prior to treatment and 4 weeks follow-up. Healthy volunteers will be enrolled in up to 7 dose groups (5 milligram [mg] to 450 mg) and will receive single oral dose of RO6889450 in the morning of the Day 1.
89148325|NCT02699372|Experimental|RO6889450: Part 2 Multiple Ascending Dose (MAD)|The starting dose for Part 2 MAD will be determined by analysis of safety and pharmacokinetic data of Part 1 SAD. All participants will receive RO6889450 orally for 14 days.
89148326|NCT02703272|Experimental|Part 1: Ibrutinib|The first 2 participants enrolled in each age group (1-5 years, 6-11 years and 12-17 years) will receive starting dose of Ibrutinib 240 milligram per square meter (mg/m^2) for the first cycle, followed by dose escalation at the start of Cycle 2 as long as all pharmacokinetic assessments are within the expected range and there are no safety concerns. For participants being treated at 240 mg/m^2 dose level during the first cycle, the maximum dose should not exceed a total of 420 mg/day. All participants will receive rituximab, ifosfamide, carboplatin, etoposide and dexamethasone (RICE) or ituximab, vincristine, ifosfamide, carboplatin, idarubicin and dexamethasone (RVICI) background therapy (investigator's choice), during treatment phase. Participants with PR or better only will receive Ibrutinib for 3 cycles or until PD, unacceptable toxicity or until initiating antilymphoma therapy or a conditioning regimen for stem cell transplantation during post-treatment phase.
89148327|NCT02703272|Experimental|Part 2: Ibrutinib|Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.
89148328|NCT02703194|Experimental|Prednisone|Prednisone mono-therapy
89148329|NCT02703194|Experimental|Prednisone and Leflunomide|Prednisone and Leflunomide combination therapy
89148330|NCT02702960|Experimental|part. liver transplant and BMT|"Patients receive living related donor partial liver transplantation performed according to standard practices. Patients will be maintained on tacrolimus, MMF, and prednisone after liver transplantation.~Upon recovery, patient must undergo eligibility screening for bone marrow transplantation (BMT).~If eligible, patients will begin:~Antithymocyte globulin (ATG): Day -16 to Day -14; fludarabine: Days -6 to Day -2 low-dose cyclophosphamide: Day -6 and -5. Tacrolimus, mycophenolate mofetil (MMF), and prednisone: day -7 and day -6. Total body irradiation on Day -1 Bone marrow infusion on Day 0. High dose cyclophosphamide plus MESNA: Day 3 and 4th Filgrastim, tacrolimus,MMF, and prednisone: Day 5 until neutrophil counts recover.~Patients followed up through post transplant day 60, then weekly following discharge."
89148331|NCT04215770|Active Comparator|Inj Co-amoxiclav|Group A children were advised Inj Co-amoxiclav 50 units/kg/day in 3 divided doses daily
89148332|NCT04215770|Active Comparator|Inj Benzyl Penicillin|Group B patients were advised inj Benzyl Penicillin 25000 units/kg/day in 3 divided doses
89148333|NCT02703038||Cardiogenic shock|Patient with cardiogenic shock table defined by the combination of a low cardiac output even as the filling pressures are normal or high, originally of hypoperfusion and organ suffering.
89148334|NCT02022566|Experimental|Supported self-management of osteoarthrits program|Treatment with an supported self-management program for osteoarthritis.
89148335|NCT02022566|No Intervention|Control group|No intervention
89148336|NCT02699294|Experimental|Contract-relax PNF stretch|A contract-relax PNF stretching techniques of the pectoralis minor muscle including latent trigger points will be applied by Group 1 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
89148337|NCT02699294|Experimental|Z-stretch|The Z- stretch of the pectoralis minor muscle including latent trigger points will be applied by Group 2 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
89148338|NCT02699294|Experimental|Manual pressure release|The single intervention of manual pressure release will be only applied to Group 3 according to the techniques describe by Simons et al. (1999).
89148339|NCT02699294|No Intervention|Control|This is a control group.
89148340|NCT02702882|Other|Fenugreek seeds extract 500 mg|Fenugreek seeds extract ( Furosap) one caps once a day
89148341|NCT02568215|Experimental|Group 1: Low-Dose VRC01|Participants will receive an IV infusion of 10 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
89148342|NCT02568215|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
89148343|NCT02568215|Placebo Comparator|Group 3: Placebo for VRC01|Participants will receive an IV infusion of placebo for VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
89148344|NCT03293498|Experimental|Group A|Low dose NanoFlu - Day 0; Fluzone HD - Day 21
89148345|NCT03293498|Experimental|Group B|High dose NanoFlu - Day 0; Fluzone HD - Day 21
89148346|NCT03293498|Active Comparator|Group C|Fluzone HD - Day 0; Saline - Day 21
89148347|NCT02699138|Experimental|Trazodone|To determine effect of trazodone on quality of sleep as measured by apnea hypopnea index in subjects with obstructive sleep apnea and PTSD on routine overnight polysomnogram.
89148348|NCT02699138|Placebo Comparator|Placebo|To compare placebo outcomes against administration of trazodone
89148349|NCT02702648|Experimental|AC-082, Single Ascending Dose|Subjects receive AC-082 at different single dose levels in a sequential manner, starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each subject can participate in only one dose level
89148350|NCT02702648|Placebo Comparator|Placebo, Single Ascending Dose|Subjects receive a single dose of the matched placebo
89148351|NCT02702648|Experimental|AC-082, Multiple Ascending Dose|Subjects receive AC-082 at different dose levels for 4 consecutive days in a sequential manner (dose levels and duration to be adapted according to the results of the single ascending dose cohorts). Each subject can participate in only one dose level
89148352|NCT02702648|Placebo Comparator|Placebo, Multiple Ascending Dose|Subjects receive the matched placebo for 4 days
89148353|NCT02702570|Other|CASA intervention|Each participant serves as his/her own control. Measures administered before and after an intervention.
89148354|NCT04220957|Experimental|Digital Impression Technique|Impression with an intraoral scanner (TRIOS 3, 3Shape, Denmark)
89148355|NCT04220957|Active Comparator|Conventional Impression Technique|Conventional impression with alginate (Orthoprint, Zhermack)
89148356|NCT02702726|No Intervention|Congee and juice only|Control breakfast providing 50g carbohydrate
89148357|NCT02702726|Active Comparator|Congee and juice with coconut gel|Control breakfast, plus 25g coconut oleogel (solid)
89148358|NCT02702726|Active Comparator|Congee and juice with coconut oil|Control breakfast, plus 25g coconut oil (liquid)
89148359|NCT02702726|Active Comparator|Congee and juice with sunflower gel|Control breakfast, plus 25g sunflower oleogel (solid)
89148360|NCT02702726|Active Comparator|Congee and juice with sunflower oil|Control breakfast, plus 25g sunflower oil (liquid)
89148361|NCT04217291|Experimental|SY-004-1|a dose of 80mg/day taken orally for two weeks, and a dose of 80mg/day for 14 weeks from the third week
89148362|NCT04217291|Experimental|SY-004-2|a dose of 80mg/day taken orally for two weeks, and a dose of 160mg/day for 14 weeks from the third week.
89148363|NCT04217291|Experimental|SY-004-3|a dose of 80mg/day orally in the first week, a dose of 160mg/day in the second week and a dose of 240mg/day for 14 weeks from the third week.
89148364|NCT04217291|Placebo Comparator|placebo|a dose of SY-004 matching placebo taken orally
89148365|NCT02702804|Experimental|High Intensity Interval Training|Participants will attend two sessions per week for the 6 week intervention. Each session will consist of 6-10 sets of 60 second high intensity intervals interspersed with 60 seconds recovery. The workload during each interval will be set at 80-90% of peak power achieved during the VO2peak test. This is predicted to elicit 85-95% heart rate reserve in the participants. After each interval the participant's heart rate and rate of perceived exertion (RPE) will be collected. After each session a researcher will complete an Adverse Event form to record if an event occurred or not. Additionally the participant will complete a physical activity enjoyment (Perceived activity enjoyment scale) after one session per week.
89148366|NCT00615134|Experimental|1|
89148367|NCT00615134|Active Comparator|2|
89148368|NCT05572775||Chronic post-surgical pain|Living kidney donor with the incidence of chronic post-surgical pain
89148369|NCT05572775||Non-Chronic Post-surgical pain|Living kidney donor without the incidence of chronic post-surgical pain
89148370|NCT01831076|Active Comparator|Treatment (exemestane, surgery)|Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
89148371|NCT01831076|Experimental|treatment (exemestane, tamoxifen, surgery)|Patients receive exemestane plus tamoxifen orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
89148372|NCT02025257|Experimental|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
89148373|NCT02025257|No Intervention|Control|Patients are asked to live as usual.
89148374|NCT04216160|Experimental|Verum|Patients with mild to moderate acne using ACN Cream
89148375|NCT04216160|Experimental|Placebo|Patients with mild to moderate acne using the placebo cream
89148376|NCT04216082|Experimental|Anlotinib|Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89148377|NCT02698982|Experimental|Monitoring|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring accessible to the anesthesia provider.
89148378|NCT02698982|Sham Comparator|Sham|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring blinded to the anesthesia provider
89148379|NCT02698982|No Intervention|Control|elderly non scheduled for surgery
89148380|NCT02702336|Experimental|EYTO-Kids Intervention Group|Adolescents will receive 16h of training (2h healthy lifestyle training, social marketing and communication, 6h to design activities, 2h session together with all intervention high-schools, 6h to practice and standardize activities) and 4h (1h/activity) to implement 4 activities in schools. The scholars will receive 4 activities designed by adolescents, focusing on: 1) increasing fruit consumption, 2) increasing vegetable consumption, 3) increasing physical activity practice and to reduce sedentary lifestyles and, 4) decreasing sugary drinks and fast-food consumption.
89148381|NCT02702336|No Intervention|Control Group|The control group will not receive any kind of intervention (only the assessment).
89148382|NCT02698904|Experimental|Guided Relaxation Technique|Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes, one-session, guided relaxation technique Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes relaxation technique (listening via headphone to audio recording. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes.
89148383|NCT02698904|Sham Comparator|Documentary movie|"Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes documentary movie.~Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes documentary movie (listening via headphone. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes."
89148384|NCT00908141|Experimental|Arm I: sargramostim (days1-14)|Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89148385|NCT00908141|Experimental|Arm II: sargramostim (3xweek)|Patients receive GM-CSF SC three times weekly for 4 weeks. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89148386|NCT04215458|Other|sample collection|Collection of samples investigating for yeast colonization in either patients with inflammatory skin disease or healthy controls.
89148387|NCT02690909|Experimental|Redy™ Renal Denervation System|Renal Denervation System
89148388|NCT02702102|Experimental|11C-PBR28 PET scans|Participants will receive one IV injection of up to 20 millicuries of 11C-PBR28.
89148389|NCT01246310|Experimental|Inositol|
89148390|NCT01246310|Placebo Comparator|Placebo|
89148391|NCT03381170|Experimental|Ublituximab|Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E
89148392|NCT00632567|Experimental|1|caesarean section
89148393|NCT00632567|Active Comparator|2|vaginal delivery
89148394|NCT04215926||HIV-monoinfected outpatients|No intervention; cross-sectional study
89148395|NCT00700076|Active Comparator|1|
89148396|NCT00700076|Placebo Comparator|2|
89148397|NCT01653899|Experimental|IDN-6556|Drug
89148398|NCT02698514|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
89148399|NCT02698514|Experimental|Desflurane|Anesthesia was maintained with desflurane.
89148400|NCT02706158|Experimental|supplement and balanced diet|"Woman at high risk of pre-eclampsia:~supplements. 1500 mg Calcium and 1200 IU Vitamin D for 2 months. balanced diet."
89148401|NCT02706158|No Intervention|women without nutrition or supplement intervention|usual follow-up in the gynecology out patient clinic, without nutrition or supplement intervention.
89148402|NCT02702258|Experimental|MB-BP|This is the primary intervention tested in this single arm trial.
89148403|NCT00615602|Experimental|1|FEC -> TXT+H 12m
89148404|NCT00615602|Experimental|2|FEC -> TXT+H 6m
89148405|NCT03406949|Experimental|obrindatamab + retifanlimab|B7-H3 x CD3 DART protein + anti-PD-1 antibody
89148406|NCT02701946|Experimental|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US).
89148407|NCT02701946|Placebo Comparator|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
89148408|NCT02698748|Experimental|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
89148409|NCT02698748|Placebo Comparator|Placebo|Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain.
89148410|NCT04750343|Experimental|Test group 1 - Stage 1 Low dose-level Cohort|2 doses of GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 10μg/dose), 1 dose each on Days 0 and 28.
89148411|NCT04750343|Experimental|Test group 2 - Stage 1 Low dose-level Cohort|2 doses of GBP510 (RBD 10μg/dose), 1 dose each on Days 0 and 28.
89148412|NCT04750343|Placebo Comparator|Placebo group - Stage 1 Low dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
89148413|NCT04750343|Experimental|Test group 3 - Stage 1 High dose-level Cohort|2 doses of GBP510 adjuvanted with AS03 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
89148414|NCT04750343|Experimental|Test group 4 - Stage 1 High dose-level Cohort|2 doses of GBP510 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
89148415|NCT04750343|Placebo Comparator|Placebo group - Stage 1 High dose-level Cohort|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
89148416|NCT04750343|Experimental|Test group 1 - Stage 2|2 doses of GBP510 adjuvanted with AS03 (RBD 10μg/dose), 1 dose each on Days 0 and 28.
89148417|NCT04750343|Experimental|Test group 3 - Stage 2|2 doses of GBP510 adjuvanted with AS03 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
89148418|NCT04750343|Experimental|Test group 4 - Stage 2|2 doses of GBP510 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
89148419|NCT04750343|Placebo Comparator|Placebo group - Stage 2|2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
89148420|NCT02706080||Antithrombotic agents|We propose to realize a single-center prospective registry of patient under Antithrombotic agent who came to the emergency unit for any reason.
89148421|NCT00615212|Active Comparator|Subjects receiving midazolam|Eligible subjects will receive midazolam oral syrup with a dose of 5 milligrams on Day 1.
89148422|NCT00615212|Active Comparator|Subjects receiving rosiglitazone|Eligible subjects will receive rosiglitazone oral tablet with a dose of 4 milligrams on Day 2.
89148423|NCT00615212|Active Comparator|Subjects receiving flurbiprofen|Eligible subjects will receive flurbiprofen oral tablet with a dose of 50 milligrams on Day
89148424|NCT00615212|Experimental|Subjects receiving GSK376501|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams from Day 4 to Day 10.
89148425|NCT00615212|Experimental|Subjects receiving GSK376501+ midazolam|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with midazolam oral tablet of 5 milligrams on Day 11.
89148426|NCT00615212|Experimental|Subjects receiving GSK376501 + rosiglitazone|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with rosiglitazone oarl tablet of 4 milligrams on Day 12.
89148427|NCT00615212|Experimental|Subjects receiving GSK376501 + flurbiprofen|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with flurbiprofen oral tablet of 50 milligrams on Day 13.
89148428|NCT03670667||RA patients treated with abatacept|
89148429|NCT03670667||RA patients treated with anti-TNFi's|
89148430|NCT03670667||RA patients treated with other biologics|
89148431|NCT02706002|Active Comparator|hip prosthesis under fluoroscopy|implantation of femoral stem of hip prosthesis in this group of patients are under fluoroscopic guidance for stem size and stem alignment and last rap before original stem implantation will be checked for alignment , lateral and vertical offsets parameters.
89148432|NCT02706002|Sham Comparator|hip prosthesis without fluoroscopy|in this group of patients rasping of femoral canal during hip prosthesis is made via anatomic landmarks which confirmed by to senior surgeons and than original stem implanted.
89148433|NCT03356249||Sepsis Group|Patients (n=500) with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions).
89148434|NCT02701322|Experimental|Medical Clown|the study group will be accompanied by a medical clown from the arrival to the premise, through the actual examination and after exiting the exam room. The medical clown will explain about the upcoming examination and will induce a less stressed atmosphere. After the examination the clown will close the session for the patient.
89148435|NCT02701322|No Intervention|Control|The control group will do the same videofluoroscopic procedure but without a medical clown.
89148436|NCT02701478|Other|N2O exposure|"There is only one arm in this study. All patients under General Anesthesia are exposed to 4 different doses or concentrations of inhaled N2O that is combined with the anesthetic desflurane. Each patient will be submitted to the standard nociceptive stimulus when inhaled N2O is at 0, 50, 25, and finally back to 0%. ANI and NoL Indices variations between before stimulus and after stimulus at each N2O concentration will be assessed and compared. This will allow to demonstrate an analgesic effect (less variations of ANI and NoL) when inhaled N2O is high (50%) testifying for the analgesic effect of this gas N2O."
89148437|NCT02701244||Permanent Breast Seed Implant (PBSI)|Women with eligible early stage breast cancer who received a permanent breast seed implant status post lumpectomy
89148438|NCT03314363|Other|all patients|Classic CRRT with citrate predilution
89148439|NCT02700932|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
89148440|NCT00906347|Active Comparator|Oxytocin augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
89148441|NCT00906347|Active Comparator|Misoprostol augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
89148442|NCT02698592|Active Comparator|CelsiusTMDS® 8 mm catheter|50 patients underwent ablation with CelsiusTMDS® 8 mm catheter.
89148443|NCT02698592|Active Comparator|Thermocool® 3.5 mm irrigated catheter|50 patients underwent ablation with Thermocool® 3.5 mm catheter of irrigated tip.
89148444|NCT02698592|Experimental|Thermocool® SF catheter|50 patients underwent ablation with Thermocool® SF catheter.
89148445|NCT02705768|No Intervention|Healthy control|Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
89148446|NCT02705768|Experimental|Carbamazepine group|Twenty five (25) patients recruited in this group will receive Tab. Carbamazepine. Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
89148447|NCT02705768|Experimental|Oxcarbazepine group|Twenty five (25) patients recruited in this group will receive Tab. Oxcarbazepine. Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
89148448|NCT05399849|Experimental|Mindfulness Intervention|All participants will be enrolled in the mindfulness intervention arm to complete the six-week mindfulness intervention.
89148449|NCT05331677|Experimental|study group|
89148450|NCT00616070|Experimental|1|Difluprednate
89148451|NCT00616070|Placebo Comparator|2|Vehicle
89148452|NCT02705534|Experimental|Treatment|Subjects will receive sofosbuvir, ledipasvir and ribavirin
89148453|NCT02701166|Experimental|Bezafibrate|Bezalip retard 400mg tablet
89148454|NCT02701166|Placebo Comparator|Placebo|Placebo 400mg tablet
89148455|NCT03145415|Experimental|Bilateral Pudendal block|0.25 cc per kg of 0.2% ropivacaine will be injected once for right pudendal N block and the same volume for the left pudendal N block before the start of the surgery
89148456|NCT03145415|Active Comparator|Caudal block|1 cc per kg of 0.2% ropivacaine in the caudal space given before the start of surgery
89148457|NCT02700854|Experimental|5% carbon-dioxide inhalation|5% carbon-dioxide will be administered through patient circuits to asphyxiated, cooled, mechanically ventilated newborns at risk for hypocapnia
89148458|NCT03141203|Experimental|Dose Level 1|"8mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
89148459|NCT03141203|Experimental|Dose Level 2 (starting dose)|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
89148460|NCT03141203|Experimental|Dose Level 3|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
89148461|NCT03141203|Experimental|Dose Level 4|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
89148462|NCT03141203|Experimental|Dose Level 5|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
89148463|NCT03141203|Experimental|Dose Level 6|"14mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
89148464|NCT02698202|Experimental|Digital Breast Tomosynthesis|to the experimental arm will be offered twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
89148465|NCT02698202|No Intervention|standard mammography|to the control arm the usual 2D standard mammography exam will be offered
89148466|NCT05320991|Placebo Comparator|Placebo|Participants receive a saline-solution intravenously
89148467|NCT05320991|Experimental|Ketamine|Participants receive ketamine (Plasma-level 100 ng/ml with an initial bolus administered as a 2 mg/ml solution)
89148468|NCT02705456|Experimental|HA-Tooth Paste|"Tooth Brushing HA~Cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite twice daily over the duration of the study (24 weeks).~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
89148469|NCT02705456|Active Comparator|FL-Tooth Paste|"Tooth Brushing FL~Cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste twice daily over the duration of the study (24 weeks).~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
89148470|NCT04215614|Active Comparator|Group Lateral Sagittal|Ultrasound-Guided lateral sagittal brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
89148471|NCT04215614|Active Comparator|Group Costoclavicular|Ultrasound-Guided costoclavicular brachial plexus block with 1:1 ratio 2% lidocaine, and 0.5% bupivacaine
89148472|NCT00906035|Active Comparator|Dipyridamole 200mg and Aspirin 25mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
89148473|NCT00906035|Active Comparator|Dipyridamole 200 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
89148474|NCT00906035|Active Comparator|Aspirin 25 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.
89148475|NCT02698280|Experimental|Treatment|Patients are treated with bevacizumab and nimustine. Every 6 weeks is defined as one therapeutic cycle. Adverse effect is evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.03). Hematologic toxicity is evaluated every 2 weeks. Liver function, renal function, and electrolytes are assessed every 4-6 weeks. Platelet should be no less than 100*10^9/L and neutrophil count should be no less than 1.5*10^9/L.
89148476|NCT03087773|Active Comparator|Empagliflozin|The subjects will receive Empagliflozin 10mg.
89148477|NCT03087773|Placebo Comparator|Placebo Oral Tablet|The subjects will receive placebo.
89148478|NCT02705612|Other|control group|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
89148479|NCT02705612|Experimental|experimental group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group. Patients also receive nimotuzumab during the external radiotherapy.
89148480|NCT04222907||Women screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were screened for GBS during pregnancy
89148481|NCT04222907||Women not screened for GBS|All women who were pregnant during 2015-2016 and delivery was between 37-42 weeks who were not screened for GBS during pregnancy
89148482|NCT05333159||Experimental|Subjects will be treated with SGLT-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) with or without conventional hypoglycemic drugs .
89148483|NCT05333159||Control|Subjects will be only treated with conventional hypoglycemic drugs.
89148484|NCT02700776||COHORT I-BIRADS 1 or 2,|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0 and 6-12.
89148485|NCT02700776||COHORT II -BIRADS 3|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0, 3-6, and 6-12.
89148486|NCT02700776||COHORT III-BIRADS 4-6|SOC Tissue Biopsy. Occurs at months 0, 3-6, and 6-12.
89148487|NCT02698358||K-EPIC|Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific).
88804124|NCT01896596|Active Comparator|Menitorix|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menitorix (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
88804125|NCT01896596|Active Comparator|NeisVac-C|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with NeisVac-C(at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
88804126|NCT00003256|Experimental|Arm I|Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
88804127|NCT04772846|Experimental|Chloroquine group|
88804128|NCT04772846|Placebo Comparator|Placebo drug group|
88804129|NCT04695002||Control group|Citizens in the control group participate in the existing course of vocational rehabilitation offered in the municipal employment department, without the use of MIRA app.
88804130|NCT04695002||MIRA group|Citizens in the MIRA group will participate in the existing course of vocational rehabilitation offered in the municipal department. In addition they will be introduced to MIRA at the beginning of the rehabilitation course, and use MIRA throughout the course of rehabilitation.
88804131|NCT04679480|Experimental|Intervention|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion at the trial site and administered as a flat 350mg dose in 100ml sodium chloride 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
88804132|NCT02092610|Active Comparator|Standard Implant BI300|The product was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
88804133|NCT02092610|Experimental|Novel Implant BI300|The product was the novel titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
88804134|NCT00003700|Experimental|Daunorubicin, ara-C, & MTX Therapy|daunorubicin during induction, increasing doses of cytarabine during consolidation followed by methotrexate in place of cranial irradiation for treatment of ALL
88804135|NCT02093234|Active Comparator|Mobile health care application|Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
88804136|NCT02093234|Active Comparator|Community Health Worker (CHW)|CHWs assist study patients in managing there health care in various ways.
88804137|NCT02093234|Experimental|CHWs and mobile health care application|Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application
88804138|NCT00003958|Experimental|Arm I|Vincristine sulfate IV once a wk on wks 0-12, 15, 18-24, 27, 30-36, and 39. Dactinomycin IV once a wk on wks 0, 3, 6, 9, 12, 21, 24, 27, 30, 33, 36, and 39. Cyclophosphamide IV once a wk on wks 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, and 39. After 12 weeks of chemotherapy, depending on tumor shrinkage, pts may undergo surgery. After recovery from therapeutic conventional surgery, patients receive radiation therapy once a day, 5 days a wk, during wks 12-18. For pt receiving radiotherapy during wks 0-6, dactinomycin is omitted during wks 3 and 6 and during wks 15 and 18. For patients receiving radiotherapy during wks 12-18, dactinomycin is omitted during wks 15 and 18. Patients with adequate response at wk 24 continue chemotherapy during wks 24-39. All pts receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery.
88804139|NCT00003958|Experimental|Arm II|"Patients receive treatment as in arm I, except dactinomycin is replaced with topotecan hydrochloride IV over 15-30 minutes daily for 5 days during weeks 3, 9, 21, 27, 33, and 39.~All patients receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery."
88804140|NCT03044054|Experimental|ECHOPULSE|ECHOPULSE HIFU
88804141|NCT04101292|Experimental|Fluorescence characterization|
88804142|NCT00083720|Experimental|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
88804143|NCT04772924|Experimental|fasting group|those preferred to take long time fasting
88804144|NCT04772924|Active Comparator|non fasting|those preferred not to take fasting
88804145|NCT02972710|Active Comparator|Supine thoracic spine manipulation|Supine thoracic spine thrust manipulation (lying face-up on the treatment table) will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
88804146|NCT02972710|Active Comparator|Seated thoracic spine manipulation|Seated thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
88804147|NCT02024360|Experimental|patient navigation|Patient navigator visits home to encourage health eating, active living and parental skill building
88804148|NCT00003970|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 90 minutes once every 3 weeks. Treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity.
88804149|NCT00085436|Experimental|Vaccine, Aldesleukin-2, Interferon-a|All patients will be treated with autologous tumor cell vaccine administered into inguinal lymph nodes via ultrasound guidance in addition to systemic IL-2 and recombinant interferon alfa. Two cycles of induction IL-2/IFNα-2a followed by 3 cycles of maintenance IL-2 + IFNα-2a.
88806012|NCT01156571|Active Comparator|clopidogrel|"Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.~During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm."
89148488|NCT02698124||Decitabine|"Decitabine 20mg/m2 will be given IV daily on Days 1-5 in 28-day cycles. Treatment should be given for at least 4 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy.~Beyond 4 cycles, treatment should continue as long as the subject continues to benefit based on investigator's judgment of no definitive progression."
89148489|NCT00905489|Experimental|Nevirapine IR / Nevirapine XR|In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).
89148490|NCT04214912|No Intervention|General module|"General module will serve as a roadmap plan which will cover the most common problems and major issues related to current and future treatments, side effects, psychological distress, daily function and physical condition. The contents will be developed based on empirical review, our current research findings in Taiwan, OC health care experts' suggestions."
89148491|NCT04214912|Experimental|Personalized module|Personalized Survivor Care Plan (PSCP) will deliver based on what we assess or interview about patients' distress, concerns and care needs in each interview or/and assessment. We will assess OC patients of the above items by valid assessment tools. For the factors or concerns about RTW assessment, we will develop and test a modified instrument for the study purpose. For each assessment, the computer -assisted assessment will help the OC educator to immediately catch the patients care distress and care needs. It will provide the direction for caring of their personalized distress, concerns and needs.
89148492|NCT02705378|Active Comparator|Polyethylene glycol|17g power qday; reconstituted in water for naso/orogastric tube administration
89148493|NCT02705378|Experimental|naloxegol|25mg qday; crushed pill reconstituted in water for naso/orogastric tube administration
89148494|NCT03059147|Experimental|SF1126 + Nivolumab|SF1126 900-1100 mg/m2 IV twice weekly + Nivolumab 240 mg IV every 2 weeks
89148495|NCT02698046|Experimental|Ferrous sulfate|
89148496|NCT02698046|Placebo Comparator|Placebo|
89148497|NCT05333081|Other|Evaluation of the glycemic index|
89148498|NCT03356834|Experimental|TDF switch to TAF|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily
89148499|NCT03356834|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
89148500|NCT05341505|Experimental|ER intervention|Cognitive-behavioral emotion regulation intervention administered twice weekly for 8 weeks.
89148501|NCT02705144||biopsies from lung tissue affected by emphysema|analysis of the number of stem cell niches
89148502|NCT02705144||biopsies from lung tissue affected by interstitial fibrosis|analysis of the number of stem cell niches
89148503|NCT02705144||biopsies from normal appearance lung tissue|analysis of the number of stem cell niches
89148504|NCT02705066|Placebo Comparator|Placebo (Cellulose)|
89148505|NCT02705066|Experimental|Cognizin 250 mg/day|
89148506|NCT02705066|Experimental|Cognizin 500 mg/day|
89148507|NCT02700464|Experimental|Bladder EpiCheck Urine Test|Bladder EpiCheck Urine Test
89148508|NCT02700464|Active Comparator|Gold Standard|Cystoscopy and pathology
89148509|NCT02691884||Patients before/after Pressure Exertion|100 pregnant patients at term in low risk pregnancies, undergoing a routine cardiotocography, will experience different amounts of manual pressure on their abdomen. The amount of pressure applied will be recorded and the fetal heart rate will be compared before and at the time of maternal abdominal pressure.
89148510|NCT02700542|Active Comparator|Intervention|"Participants randomly assigned to the intervention group will receive the Integrated Pest Management (IPM) treatment 2-4 weeks of completion of the baseline assessment.The IPM protocol for this research will focus on pest control in the bathrooms and kitchen and will include an assessment of the pest problem, thorough cleaning, patching of small holes, identification and referral of any necessary large repairs, and targeted application of safe pesticides as needed. In cases of severe infestation, a second treatment visit might be required in the home.~In addition to the intervention, the family will be provided with basic information about good pest-control practices, such as appropriate food storage, and be given a set of food storage containers."
89148511|NCT02700542|Placebo Comparator|Control|Participants randomly assigned to the control group will be offered the equivalent intervention, information, and food storage containers after completion of their 12-month assessment.
89148512|NCT02701010|Active Comparator|Group 1|Structured training and leaflet
89148513|NCT02701010|Active Comparator|Group 2|Structured training
89148514|NCT02701010|Active Comparator|Group 3|Leaflet
89148515|NCT02701010|Sham Comparator|Group 4|Control group
89148516|NCT02697968|Experimental|Electroacupuncture|
89148517|NCT00615758|Experimental|1|Tarceva
89148518|NCT02700152|Experimental|all subjects|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
89148519|NCT02700074||Minimally Verbal|Minimally verbal adolescents with Autism Spectrum Disorder
89148520|NCT02700074||Verbal Impaired|Language impaired adolescents with ASD
89148521|NCT02700074||Verbal Normal|Language normal adolescents with ASD
89148522|NCT02700074||Typically Developing|Typically developing adolescent controls
88806013|NCT01220687|Placebo Comparator|Placebo 20ppm|Nitrogen at 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
89148523|NCT02699918|Experimental|screening oxymetry|nocturnal oxymetry to screen for sleep apnea
89148524|NCT02699762|Experimental|experimental group|self rehabilitation of upper limb in experimental group + BTI + usual physiotherapy
89148525|NCT02699762|No Intervention|control group|BTI + usual physiotherapy
89148526|NCT02705222|Active Comparator|D&C group|Women will undergo D&C
89148527|NCT02705222|Active Comparator|Hysteroscopy group|Women will undergo hysteroscopy
89148528|NCT02704988|Active Comparator|Colon Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
89148529|NCT02704988|Active Comparator|Colon Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
89148530|NCT02704988|Active Comparator|Rectal Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
89148531|NCT02704988|Active Comparator|Rectal Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
89148532|NCT02704676||control patients|normal pregnant women, 3rd trimester
89148533|NCT02704676||mild pre-eclampsia|patients with albuminuria +1 and blood pressure >140/90 and <160/110
89148534|NCT02704676||sever pre-eclampsia|patients diagnosed as sever pre-eclampsia according to criteria done by ACOG
89148535|NCT04215380|Experimental|Intervention Group|This arm will receive 100% natural Gum Arabic provided in a powder form as 30-grams-dose for 12 weeks
89148536|NCT04215380|Placebo Comparator|Control group|This group will be provided with pectin powder provided as two-gram-dose fo
89148537|NCT04215302||laryngeal mask size|laryngeal mask size determines according to weight measurement
89148538|NCT02704754|Experimental|suvorexant|10mg administered before bedtime, during the first week; if well tolerated then the dose is increased to 20 mg before bedtime.
89148539|NCT02704754|Placebo Comparator|Placebo pill|"A pill without active ingredients~Randomization occurs 1:1 with stratification for gender and PTSD status."
89148540|NCT05192096||Intervention group|It includes two 1-hour health-related information sessions.
89148541|NCT02697656|Active Comparator|Treatment as usual + self-help|Interdisciplinary treatment as usual at the outpatient pain clinic + an additional self-help binder with resources about pain management and employment advice.
89148542|NCT02697656|Experimental|Treatment as usual + IPS|Individual job support (IPS) as an integrated part of the interdisciplinary treatment at the outpatient pain clinic.
89148543|NCT04214054|Experimental|Moldable self-hardening biphasic calcium phosphate graft|Easy graft, a moldable osteocondutive allograft formed of 60% hydroxylapatite and 40% β-tricalcium phosphate (Easy-graft, Sunstar, Gruidor, Degradable solutions AG, Swizerlard).
89148544|NCT04214054|Placebo Comparator|No graft material|
89148545|NCT04213898|Experimental|SHR-1210+Albumin-bound paclitaxel+Epirubicin|Neoadjuvant therapy：SHR-1210+Albumin-bound paclitaxel+Epirubicin
89148546|NCT04213976||Ileostomy in continuity|Paediatric patients having had an ileostomy in continuity as part of the treatment for a complex intestinal obstruction, as described by Santulli or by Bishop-Koop.
89148547|NCT04213976||Conventional ileostomy|Paediatric patients having had a loop ileostomy as part of the treatment for a complex intestinal obstruction.
89148548|NCT03170882|Active Comparator|Pomalidomide 4 mg + Dexamethasone 40 mg|Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged >=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.
89148549|NCT03170882|Experimental|Ixazomib 4 mg + Dexamethasone 20 mg|Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged >=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.
89148550|NCT05309408||ALS|Patients with Amyotrophic Lateral Sclerosis (ALS)
89148551|NCT05309408||Control|Participants who do not have chronic neuromuscular diseases or diseases that mimic ALS.
89148552|NCT02891564|Placebo Comparator|Control Arm (R 33)|a mobile 3D video game to be used as placebo.
89148553|NCT02891564|Experimental|Intervention Arm (R 33)|a mobile 3D video game (Band Together) that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms.
89148554|NCT00616850|Active Comparator|Group A|Group A subjects will receive a continuous femoral block catheter and a Patient Controlled Analgesia (PCA).
89148555|NCT00616850|Experimental|Group B|Group B subjects will receive a low dose lidocaine (1.33 mg/kg/hr) infusion and a Patient Controlled Analgesia.
89148556|NCT00616850|Placebo Comparator|Group C|Group C subjects will receive placebo (preservative free normal saline) infusion and a Patient Controlled Analgesia.
88806014|NCT01220687|Experimental|Inhaled Nitric Oxide (iNO) 20 ppm|Inhaled Nitric Oxide 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
88804150|NCT00003724|Experimental|surgery|"Patients undergo open resection (thoracotomy, median sternotomy, or bilateral sternothoracotomy).~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
89148557|NCT04214132|Experimental|virtual patients group|Only nursing undergraduates from AY2017/2018 cohort, who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module will receive additional training using Virtual Patients in each semester (2 semesters per year) of year 2 and year 3 before they go for the clinical posting. Students will have unlimited access to the Virtual Patients (available scenarios depend on which semester the student is in) by logging in through the school portal.
89148558|NCT04214132|No Intervention|Blended learning group|Nursing undergraduates from AY2016/2017 cohort who who have completed the redesigned NUR1110 (Effective Communication for Health-Professionals) core module that comprised of weekly online e-lectures and face-to-face tutorials.
89148559|NCT00618644|Experimental|1|Ranibizumab injection
88804151|NCT00003724|Experimental|video-assisted surgery|"After spiral CT showing pulmonary nodules are amenable to video-assisted thoracic surgery (VATS) resection with curative intent, patients undergo minimally-invasive video-assisted resection.~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
88804152|NCT00384202|Experimental|1|
88804153|NCT00086138|Experimental|1|Participants will receive sertraline at a target dose of 100mg daily.
88804154|NCT00086138|Placebo Comparator|2|Participants will receive placebo matched to sertraline
88804155|NCT04329130|Experimental|Chidamide combined Lenalidomide|"Chidamide, 20 mg, twice per week; lenalidomide, 25 mg, d1-21, and rest for 7 days.~one treatment cycle per 28 days.For patients with limited lesions and good drug response, local radiotherapy may be assessed by the investigator."
88804156|NCT01881308|Active Comparator|Stable dose TNF inhibitor|Stable dose TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
88804157|NCT01881308|Experimental|Stepdown and withdrawal of TNF inhibitor|Half-dose of TNF inhibitor for the first four months, thereafter withdrawal of TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
88804158|NCT01881308|Active Comparator|Stable dose synthetic DMARD|Stable dose of synthetic DMARDs, either monotherapy or combination therapy.
88804159|NCT01881308|Experimental|Synthetic DMARD dose reduction|Half-dose synthetic DMARDs (monotherapy or combination therapy) for the first 12 months of the study. Patients classified as non-failures are re-randomized at 12 months to either continue half-dose synthetic DMARD(s) or withdraw all DMARD(s).
88804160|NCT01881308|Other|ARCTIC follow-up|Patients are treated according to the ARCTIC treatment schedule based on disease activity.
88804161|NCT00003292|Experimental|ifosfamide|ifosfamide
88804162|NCT00088634|Experimental|Lurasidone|80 mg AM dosing once daily
88804163|NCT00088634|Placebo Comparator|Placebo|
88804164|NCT04772066||Non adherent patients|Non adherent patients
88804165|NCT04772066||Adherent patients|Adherent patients
88804166|NCT00003994|Experimental|Arm I (cisplatin, vincristine sulfate, fluorouracil)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive cisplatin IV over 4 hours on day 1, vincristine sulfate IV on days 3, 10, and 17, and fluorouracil on day 3.
88804167|NCT00003994|Experimental|Arm II (cisplatin, vincristine, fluorouracil, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm I with the addition of amifostine trihydrate IV over 15 minutes prior to cisplatin on day 1.
88804168|NCT00003994|Experimental|Arm III (carboplatin, cisplatin)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive carboplatin IV over 1 hour on day 1 and cisplatin IV over 4 hours on day 15.
88804169|NCT00003994|Experimental|Arm IV (carboplain, cisplatin, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm III with the addition of amifostine trihydrate IV over 15 minutes prior to carboplatin on day 1.
89148560|NCT02137070||Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss at local surgical centers or UFHEALTH & Shands Hospital.
89148561|NCT02137070||Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
89148562|NCT02096432|Experimental|Behavioral: Behavioral Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
89148563|NCT02096432|Other|Usual Community Care|Community standard care as usual
88804170|NCT01636544|Experimental|contralateral healthy tissue biopsy|
88804171|NCT00519818|Experimental|Cortef and Chronocort|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days followed by Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
88804172|NCT00003748|Experimental|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
88804173|NCT00089102|Experimental|Gemcitabine + Irinotecan|
88804174|NCT00086450|Active Comparator|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
88804175|NCT00086450|Experimental|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
88804176|NCT04771910|Experimental|Topical cream with live probiotic bacteria (YUN)|Patients with atopic dermatitis using topical cream with live probiotic bacteria
88804177|NCT04771910|Placebo Comparator|Placebo cream (YUN)|Patients with atopic dermatitis using placebo cream (same formulation as probiotic cream except live probiotic bacteria)
88804178|NCT04771832||ERAS|Perioperative care with Enhanced Recovery After Surgery (ERAS) protocol
88806015|NCT03010865|Experimental|Sodium Butyrate|Dietary Supplement: Sodium Butyrate 4.38 gms of sodium butyrate per day for 12 weeks
89148564|NCT04188470|Experimental|person-centered care model|healthcare multidisciplinary team will review the appropriateness of medication by a person-centered care model and then the healtcare team will propose changes in the therapeutic plan to the patient or caregiver
89148565|NCT04188470|No Intervention|usual care|the healthcare team will practice usual care
89148566|NCT05168696|Experimental|Virtual Reality in Women with Breast Cancer|It is planned to pre-test, wear virtual reality glasses and post-test before chemotherapy for breast cancer women who will receive adjuvant treatment for the first time, who agree to participate in the study. This follow-up will be done 3 more times, and each cure will be followed for 4 cures. It will be ensured that the patients fill out the State Anxiety Scale and Cancer Fatigue Scale as a pre-test and post-test. After the chemotherapy infusion starts, the patient will listen and watch the relaxing beach and nature content with 360 degrees for 30 minutes with virtual reality glasses attached to the patient.
89148567|NCT05168696|No Intervention|Standard Care in Women with Breast Cancer|Women with breast cancer who will receive adjuvant treatment for the first time, who agree to participate in the study, will be pre-tested before chemotherapy and a post-test will be performed 30 minutes after the start of chemotherapy treatment by the nurse. This follow-up will be done 3 more times, and each cure will be followed for 4 cures. It will be ensured that the patients fill out the State Anxiety Scale and Cancer Fatigue Scale as a pre-test and post-test.
89148568|NCT05167838|Experimental|group A|Fresh embryo transfer group
89148569|NCT05167838|Experimental|Group B|Frozen embryo transfer group
89148570|NCT02093312|No Intervention|Control group|The control group is not offered any home food-delivery service, but continues with their habitual diet
89148571|NCT02093312|Experimental|Intervention group|The intervention group is offered home food-delivery service
89148572|NCT05324774|Experimental|9MW0813|
89148573|NCT05324774|Active Comparator|aflibercept|
89148574|NCT04213742|Active Comparator|Gratitude diary|
89148575|NCT04213742|No Intervention|No intervention|
89148576|NCT04213742|Active Comparator|Gratitude visit|
89148577|NCT04213508|Active Comparator|Isotonic saline with frequency of 2 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
89148578|NCT04213508|Active Comparator|Hypertonic saline with frequency of 2 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 2 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
89148579|NCT04213508|Active Comparator|Isotonic saline with frequency of 5 times per day|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
89148580|NCT04213508|Active Comparator|Hypertonic saline with frequency of 5 times per day|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for 5 times per day. Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
89148581|NCT04213586|Experimental|Whey Protein|Each participant will be supplemented with whey protein (7 d/wk) during 10 weeks.
89148582|NCT04213586|Experimental|Leucine-matched collagen|Each participant will be supplemented with collagen (7 d/wk) during 10 weeks.
89148583|NCT05324618|Active Comparator|Tacrolimus group|100 patients treated by thin layer of 0.03% topical tacrolimus ointment on the affected areas twice daily for 4 months.
89148584|NCT05324618|Active Comparator|Hydrocortisone group|100 patients treated by thin layer of 1% hydrocortisone cream on the affected areas twice daily for 4 months.
89148585|NCT04212338|Experimental|study group 1|Before intravitreal injection music intervention: These patients received the standard treatment and listened to music for a period of 15 minutes 30 minutes before the injection.
89148586|NCT04212338|Experimental|study group 2|During-intravitreal injection music intervention:These patients received the standard treatment and listened to music during the injection (approximately 5 minutes).
89148587|NCT04212338|No Intervention|control group|The music intervention was not conducted with the patients in the control group. These patients received the standard treatment.
89148588|NCT00618800|Experimental|Pharmacist Care|Pharmacist Intervention
89148589|NCT00618800|Active Comparator|Control|Written information only group
89148590|NCT00617006||Before (Control)|Study group representative of standard practice
89148591|NCT00617006||After(Treatment)|After treatment group with the personal hand hygiene device ie. Device Group.
89148592|NCT04213664||non-metastatic renal cell carcinoma|Pretreatment lymphocyte to monocyte ratio in non-metastatic patients with renal cell
89148593|NCT02082782|Experimental|irreversible electroporation (IRE)|Single arm study: percutaneous or open irreversible electropration of CRLM
89148594|NCT00618878|Active Comparator|1|Electroacupuncture
89148595|NCT00618878|Active Comparator|2|Laser Therapy
89148596|NCT02738216|Experimental|Prenatal Yoga|A 9-week prenatal yoga program
89148597|NCT02738216|Active Comparator|Mother Baby Wellness Workshop|A 9-week workshop on mother and baby wellness in the first postpartum year
89148598|NCT02733068|Experimental|HPV-16/18 vaccine|Including 6000 participants who received the HPV-16/18 vaccine 0.5ml.
89148599|NCT02733068|Placebo Comparator|HPV-16/18 placebo|Including 6000 participants who received the HPV-16/18 placebo 0.5ml.
89148600|NCT05324540|Experimental|Cool therapy|A chilled instrument that has been chilled to a proscribed temperature will be applied to the oblique sinus. The instrument may be applied for up to 3 minutes per application and up to 3 times per patient.
88806016|NCT03010865|Placebo Comparator|Placebo Oral Capsule|Placebo Oral Capsule placebo capsules containing approximately 9 mg of sodium butyrate per day
89148601|NCT00907517|Experimental|MK-8776 10 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 10 mg/m^2 intravenously (IV) on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour continuous intravenous infusion (CIV) on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
89148602|NCT00907517|Experimental|MK-8776 20 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 20 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
89148603|NCT00907517|Experimental|MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 40 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
89148604|NCT00907517|Experimental|MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 56 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
89148605|NCT00907517|Experimental|MK-8776 140 mg + Cytarabine 2 g/m^2|Participants received MK-8776 140 mg flat dose IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
89148606|NCT03043547|Experimental|Nal-IRI + 5-FU + leucovorin (Arm A)|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion), 5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
89148607|NCT03043547|Other|5-FU + leucovorin (Arm B)|Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
89148608|NCT03632603|Experimental|Radiotherapy 20 Gy / 4 F|Radiotherapy 20 Gy / 4 F
89148609|NCT03632603|Active Comparator|Radiotherapy 30 Gy/ 10 F|Radiotherapy 30 Gy/ 10 F
89148610|NCT00905255|Experimental|Lixisenatide (Two-step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
89148611|NCT00905255|Experimental|Lixisenatide (One-step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to end of treatment.
89148612|NCT00905021|Experimental|Exemestane plus Sutent|"All patients enrolled on the study will receive treatment as follows:~Exemestane 25 mg by mouth every day.~Sunitinib 37.5 mg by mouth every day."
89148613|NCT05332847|Active Comparator|intervention group|The intervention group underwent clinical evaluation and a bedside-focused sonographic assessment
89148614|NCT05332847|No Intervention|control group.|The control group underwent clinical evaluation without POC-US
89148615|NCT02965313|Active Comparator|SSLS Procedure|
89148616|NCT02965313|Active Comparator|BSSVF-M Procedure|
89148617|NCT02944877|Experimental|intervention|experimental
89148618|NCT02944877|Other|control|Other
89148619|NCT05239247|Experimental|Mckenzie extension exercise|
89148620|NCT05239247|Experimental|Eldoa stretch technique|
89148621|NCT03537131|Active Comparator|arm B1- Dapagliflozin once only dose|Participants who will take one tablet of Dapagliflozin 10 mg on the day of the exercise challenge.
89148622|NCT03537131|Active Comparator|arm B2- Dapagliflozin daily administration|Participants who will take a daily dose of Dapagliflozin 10 mg before and after the exercise challenge.
89148623|NCT05222321|Experimental|SenPlay Intervention Group|SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through activities such as pushing, pulling, climbing, jumping, and crashing. These activities are designed to facilitate changes in the child's arousal by providing sensory input and are used at random during the 15 minute window and are facilitated and monitored to ensure the child is reaching a threshold of moderate to vigorous physical activity. All participants will wear the ActiGraph accelerometer to measure the intensity of physical activity during the SenPlay intervention. Intervention sessions will occur at three time points, one per week for three weeks. Following the SenPlay intervention, participants will engage in 10 minutes of developmentally appropriate tasks (DAT) lead by the same investigator. DAT will be videotaped and coded for off task behaviors using Momentary Time Sampling (MTS).
89148624|NCT05222321|Placebo Comparator|Free play Control Group|The control group will engage in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes, prior to the assessment of off-task behaviors during 10 minutes of developmentally appropriate tasks (DAT). All participants will wear the ActiGraph accelerometer to measure the intensity of physical activity reached during spontaneous, free play. Participants in the control group will participate in three sessions, one per week for three weeks. Intervention sessions will occur at three time points, one per week for three weeks. Following the spontaneous play, participants will engage in 10 minutes of developmentally appropriate tasks (DAT) lead by the same investigator. DAT will be videotaped and coded for off task behaviors using Momentary Time Sampling (MTS).
89148625|NCT00906971|Active Comparator|Laxatives|Magnesium hydroxide for which the dosage varied according to individual needs (a minimum of 2 ml/kg), and received guidance regarding fiber-rich foods, water and toilet training. Patients attended weekly consultations with a pediatric gastroenterologist.
89148626|NCT02677805|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into glabellar area.
89148627|NCT02677805|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
89148628|NCT02677805|Experimental|Botulinum toxin A open label extension phase|Open Label Extension Phase for all Subjects of Arm 1 and 2 for up to 3 treatment cycles
89148629|NCT00903929|Experimental|Eltrombopag|
88804179|NCT00093782|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR or PR receive 2 additional courses beyond CR or PR.
88804180|NCT00003766|Experimental|Arm A|06-benzylguanine (100mg/m2 16 hrs before anticipated tumor tissue removal)
88804181|NCT04389320||Rheumatoid patients receiving hydroxychloroquine|immunoglobulin analyses of covid 19 virus in patients already on hydroxychloroquine and relation to clinical presentation and genetics
88804182|NCT00096122|Experimental|Arm I|See Detailed Description
88804183|NCT00003778|Experimental|Arm I|Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
88804184|NCT00384826|Experimental|1|
88804185|NCT00384826|Experimental|2|
88804186|NCT00384982|Experimental|A, B, C, D|Early or late; percutaneous intracoronary or combined (intramyocardial and intracoronary) administration of BM-MNCs
88804187|NCT00003370|Experimental|Arm I|"If the dose limiting toxicity is myelosuppression in stratum 1, then stratum 1 is closed and stratum 2 opens.~Stratum 2 consists of the following: patients receiving no more than 2 prior chemotherapy regimens; patients who have not received prior central axis radiation or bone marrow transplantation; and patients with no known bone marrow involvement. Patients receive intravenous 6-hydroxymethylacylfulvene over 10 minutes daily for 5 days. The course is repeated every 28 days unless disease progression or unacceptable toxic effects are observed. Patients with stable or responding disease may receive up to 1 year of therapy. If dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose is declared the maximum tolerated dose. Dose escalation will not occur until all patients within a cohort have been observed for 28 days from day 1 of therapy. Patients are followed until death."
88804188|NCT00003796|Experimental|Arm I|Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
88804189|NCT02972866|Experimental|Noex 32mcg|"Noex/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.~Tretament of 28 days."
88804190|NCT02972866|Experimental|Budecort Aqua 32 mcg|"Budecort Aqua/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.~Tretament of 28 days."
88804191|NCT00003832|Experimental|Treatment (bromodeoxyuridine)|Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later, patients undergo surgery to remove the prostate.Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.
88804192|NCT00003850|Experimental|Arm I|Patients receive 4-20 capsules of oral thalidomide once daily. Dose is escalated in individual patients on a weekly basis for the first 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
88804193|NCT00004078|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 60 minutes on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 4 years and then annually thereafter until death or until patient enters another POG study.
88804194|NCT00014222|Active Comparator|Arm 1: CEF|6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg (i.e.2x480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid
88804195|NCT00014222|Active Comparator|Arm 2: EC/T|6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5μg/kg/d - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once weekly (to begin within 1 week after start of protocol therapy as needed) 21 days from last administration of EC (EC/T) 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
88804196|NCT00014222|Active Comparator|Arm 3: AC/T|4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
88804197|NCT04394156|Experimental|Baseline phase, followed by intervention phase|"Within the baseline phase, measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary for up to three weeks (dependent on baseline length). Individual baseline phases will be used as control periods.~In the intervention phase the participant will be offered around five intervention sessions with a researcher. Each session the participant will choose which intrusive memory they would like to focus on and the cognitive task will be completed. The intervention includes a memory reminder cue, a 10-minute time gap and then around 20 minutes playing the mobile phone game Tetris, using mental rotation instructions. Participants will be given instructions to continue to use the technique self-guided in the subsequent week. Measurements of the primary outcome measure (frequency of intrusive memories of trauma) will be collected in a pen-and-paper diary."
88804198|NCT00004918|Experimental|Arm I (dose level 1 PR1 leukemia peptide vaccine)|Patients receive dose level 1 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
88804199|NCT00004918|Experimental|Arm II (dose level 2 PR1 leukemia peptide vaccine)|Patients receive dose level 2 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
88806017|NCT01156805|Experimental|Educational intervention, Control|Experimental, intervention group has received specific educational training to improve food habits and physical activity during the period of the study.
89148630|NCT03458663|Experimental|Prevena|Patients randomized to application of Prevena ™ and ACTIV.A.C ™ Therapy System 4-7 days post-operatively. Patients will return to the surgical day clinic to have the system removed either at day 7 or when/ if function ceases. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing
89148631|NCT03458663|No Intervention|Conentional postoperative care|patients randomized to convetional postoperative regime with a penrose drain (passive) and a dry draping for 24 hours and after usage of sanitary pads. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Drain is removed after 24 hours and Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing.
89148632|NCT02850497|Active Comparator|CRE8 stent|Treatment with CRE8 stent implantation and evaluated with optical coherence tomography at 6 months
89148633|NCT02850497|Active Comparator|Biomatrix stent|Treatment with Biomatrix stent implantation and evaluated with optical coherence tomography at 6 months
89148634|NCT02850497|Active Comparator|patients treated with Xience stent|Treatment with Xience stent implantation and evaluated with optical coherence tomography at 6 months
89148635|NCT00903695|Experimental|Memory XL|"Subjects will take 2 Memory XL pills daily for 12 months (a vitamin nutriceutical developed by Thomas Shea, Ph.D.).~Mild Cognitive Impairment (MCI) patients, who met inclusion/exclusion criteria, were assessed initially using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting pills assigned to them by VAMC Research Pharmacist. Each 3 months thereafter, they returned to lab to be reassessed using same instruments, and to receive the next batch of study pills from the Pharmacist. The last assessment was when the patient had just finished 12 months of pill ingestion."
89148636|NCT00903695|Placebo Comparator|placebo|"Subjects diagnosed with MCI took two placebo pills daily for 12 months; these pills are formulated to look and taste the same as the nutriceutical being studied, Memory XL, so study was double-blind. Procedures for this arm are exactly the same as the MEMORY XL arm.~MCI subjects were assessed using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting the pills assigned to them by the Research Pharmacist at VAMC. Each 3 months thereafter, they returned to lab to be reassessed using the same instruments, and to receive next batch of study pills. Last assessment was when patient had completed 12 months of pill ingestion."
89148637|NCT02850185|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
89148638|NCT02850185|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
89148639|NCT04202861|Experimental|in vitro antibiotic combination testing (iACT)|For the intervention arm, CRGNB isolates from the index culture should be transported to the Pharmacy Research Lab in Singapore General Hospital as soon as possible to begin iACT. For external sites, a licensed medical courier will be engaged. Once testing is complete, the iACT results will be sent to the physicians and the ID specialist managing the patient. Several antibiotic combinations can usually be used to treat the infection; a subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and/or the consulting infectious disease doctor may exercise their discretion in continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement, according to the clinical conditions and reactions of the patient to the treatment
89148640|NCT04202861|No Intervention|Control|The standard arm will receive standard therapy of either antibiotic monotherapy or unguided combination therapy, a choice based on treating physicians' best clinical judgment. iACT will only be performed on CRGNB isolates from the standard arm at least 30 days after enrolment for collection of microbiological, proteomic and molecular data. Antibiotic combinations found from delayed iACT will be made known to the Infectious Diseases physician caring for the participant.
89148641|NCT02850341|Experimental|Intervention group|Patients receive a pedometer and instructions how to raise their physical activity
89148642|NCT02850341|No Intervention|Control group|Patients receive treatment-as-usual
89148643|NCT02506127|Experimental|Open-label|"Theta burst stimulation (TBS) is a form of repetitive transcranial magnetic stimulation (TMS). Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.~Each treatment session thus involves < 10 minutes of stimulation. The subject and researchers know what treatment is being administered."
89148644|NCT02506127|Active Comparator|Blinded Active|"Standard TBS parameters consisting of 3-pulse, 50Hz bursts every 200 ms (5 Hz) at an intensity of 80% motor threshold (MT) will be utilized. Intermittent TBS will be delivered in 2-second trains of bursts repeated every 10 seconds for a total of 570 seconds (1800 pulses) in each session.~Each treatment session thus involves < 10 minutes of stimulation. The subject and researcher will not know what type of treatment will be administered."
89234893|NCT05887947|Experimental|6 African American 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 5%|"6, African American, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
88804200|NCT00004918|Experimental|Arm III (dose level 3 PR1 leukemia peptide vaccine)|Patients receive dose level 3 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
88804201|NCT00003892|Experimental|ISIS 5132|ISIS 5132 x 21 days IV infusion
89148645|NCT02506127|Sham Comparator|Blinded Sham|"This is a sham treatment which will mimic the open-label and blinded active to enable the effects of the supposedly active treatment to be assessed objectively. The subject and researcher will not know what type of treatment will be administered.~Each treatment session will be < 10 minutes in duration."
89148646|NCT04703231||Natural menopause(Control group)|Female patients between 45-60 years of age diagnosed with menopause without any intervention
89148647|NCT04703231||Surgical Menopause (Case group)|Female patients aged 45-60 years included in the study 3 months after bilateral oophorectomy and hysterectomy
89148648|NCT04975841|No Intervention|Standard of Care|Standard of Care (SOC) Study: The 6 subjects in the late injection group will start on Part 1. - The Part 1 study subject participation is 12 months. Two subjects will be enrolled at each of Months 0, 3 and 6. This will include an initial assessment and SOC follow-up. Subjects will continue standard of care treatment. Part 1 study duration (with staggering included) will be 18 months. After Part 1, the late injection subjects may proceed to Part 2 depending on safety data from the early injection group (see 3. below).
89148649|NCT04975841|Active Comparator|Stem Cell Injection|Stem Cell Injection: The three subjects randomized to early injections will proceed directly to Part 2 with staggered enrollment of 1 subject every 3 months. Once the safety data of the first subject at Month 3 is assessed, the second subject will be enrolled. Once the safety data of the first 2 subject (Subject 1 at Month 6 and Subject 2 at Month 3) are assessed, the third early injection subject will be enrolled in Part 2.
89148650|NCT04202471|Experimental|Chlorhexidine Cloth|The intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive preoperative abdominal application of 2% chlorhexidine cloths.
89148651|NCT04202471|No Intervention|Standard Preoperative Care|The no intervention group will be women undergoing non-scheduled cesarean delivery randomized to receive standard preoperative care.
89148652|NCT02850107|Other|Non-randomized|"Directional Atherectomy + Drug Coated Balloon: DA followed by DCB will be performed in all enrolled subjects.~DA includes the use of Intervention 'Medtronic HawkOne® or TurboHawk™.~Medtronic Spider™ Distal Protection Device (DPD) is recommended for use according to IFU.~Medtronic IN.PACT® Admiral® DCB will be used after DA.~Volcano Visions® PV .014 IVUS catheter required to assess lesion in each procedure.~Nitinol Stent Placement: Only FDA approved nitinol stents can be used if provisional stenting is required."
89148653|NCT02395601|Experimental|CPI-1205|
89148654|NCT02850029||critically ill patients|Critically ill patients admitted in intensive care units and receiving one of the following aminoglycosides: gentamicin, tobramycin and amikacin as part of their usual care.
89148655|NCT02849951|Experimental|LT-02|1.6 g PC in LT-02 BID
89148656|NCT02849951|Placebo Comparator|LT-02 Placebo|0 g PC in LT-02 Placebo BID
89148657|NCT04202315|No Intervention|Control|Standard of care, no Virtual Reality
89148658|NCT04202315|Experimental|Virtual Reality|Standard of care plus Virtual Reality
89148659|NCT05173649|Experimental|Calisthenic Training|Calisthenic Training Group
89148660|NCT05173649|Experimental|Neuromuscular Training Group|Neuromuscular Training Group
89148661|NCT00632645|Experimental|1|Olanzapine Mylan
89148662|NCT00632645|Active Comparator|2|Xenazine
89148663|NCT00632645|Active Comparator|3|Tiapridal
89148664|NCT02849873|Experimental|IDp-123 Lotion|Lotion
89148665|NCT02849873|Active Comparator|Tazorac Cream|Cream
89148666|NCT02849795|Experimental|Psoriasis and arthritic psoriasis|additional blood sample for biological analyses bone densitometry questionnaires
89148667|NCT02849483|Experimental|Ramosetron|2 ml of normal saline iv before induction, ramosetron 0.3 mg iv at the end of surgery, ramosetron 0.6 mg added to the iv PCA(Patient-Controlled Analgesia)
89148668|NCT02849483|Placebo Comparator|Control|dexamethasone 10 mg iv before induction, 2 ml of normal saline iv at the end of surgery, 4 ml of normal saline added to the iv PCA
89148669|NCT05085197|Experimental|Cohort 1:1mg/kg|All participants (fasted) received either 1mg/kg of STSA-1005 as a single dose or dose-matched placebo.
89148670|NCT05085197|Experimental|Cohort 2:2.5mg/kg|All participants (fasted) received either 2.5mg/kg of STSA-1005 as a single dose or dose-matched placebo.
89148671|NCT05085197|Experimental|Cohort 3:5mg/kg|All participants (fasted) received either 5 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
89148672|NCT05085197|Experimental|Cohort 4:10mg/kg|All participants (fasted) received either 10 mg/kg of STSA-1005 as a single dose or dose-matched placebo.
89148673|NCT02849561|Active Comparator|Favourable neurological evolution after cardiac arrest|MGOS 4-5
89148674|NCT02849561|Active Comparator|Unfavourable neurological evolution after cardiac arrest|MGOS 1-3
89148675|NCT02849327|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89148676|NCT02849327|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89148677|NCT02077361|Experimental|Open Label|"Patients will receive a subretinal injection of 0.10 ml of the rAAV2.REP1 vector drug substance. It is a colourless opalescent frozen liquid with no visible particles. Each patient will be given a one-time dose in one eye.~It is the same vector used in the United Kingdom Phase I/II trial logged at: http://clinicaltrials.gov/ct2/show/NCT01461213."
89148678|NCT05150574|Experimental|Condition 1|Core Health platform only
89148679|NCT05150574|Experimental|Condition 2|Core Health platform plus Practice with feedback coaching
89148680|NCT05150574|Experimental|Condition 3|Core Health platform plus behavioural initiation coaching
89148681|NCT05150574|Experimental|Condition 4|Core Health platform plus Practice with feedback coaching and behavioural initiation coaching
89148682|NCT05150574|Experimental|Condition 5|Core Health platform plus Momentary HRV feedback
89148683|NCT05150574|Experimental|Condition 6|Core Health platform plus Momentary HRV feedback and Practice with feedback coaching
89148684|NCT05150574|Experimental|Condition 7|Core Health platform plus Momentary HRV feedback and behavioural initiation coaching
89148685|NCT05150574|Experimental|Condition 8|Core Health platform plus Momentary HRV feedback, behavioural initiation coaching, and Practice with feedback coaching
89148686|NCT05150574|Experimental|Condition 9|Core Health platform plus Daily resting HRV
89148687|NCT05150574|Experimental|Condition 10|Core Health platform plus Daily resting HRV feedback and Practice with feedback coaching
89148688|NCT05150574|Experimental|Condition 11|Core Health platform plus Daily resting HRV feedback and Behavioural initiation coaching
89148689|NCT05150574|Experimental|Condition 12|Core Health platform plus Daily resting HRV feedback, Behavioural initiation coaching, and Practice with feedback coaching
89148690|NCT05150574|Experimental|Condition 13|Core Health platform plus Daily resting HRV feedback and Momentary HRV feedback
89148691|NCT05150574|Experimental|Condition 14|Core Health platform plus Daily resting HRV feedback, Momentary HRV feedback, and Practice with feedback coaching
89148692|NCT05150574|Experimental|Condition 15|Core Health platform plus Daily resting HRV feedback, Momentary HRV feedback, and Behavioural initiation coaching
89148693|NCT05150574|Experimental|Condition 16|Core Health platform plus Daily resting HRV feedback, Momentary HRV feedback, Behavioural initiation coaching, and Practice with feedback coaching
89148694|NCT00618696|Experimental|AHN-12|2.0, 5.0, 7.5, 10.0 or 12.5 mCi/m^2 of ^90Y-AHN-12 at Day 7/8
89148695|NCT00618852|Experimental|1|Furosemide
89148696|NCT00618852|Placebo Comparator|2|
89148697|NCT02073474||Sativex® users|UK: All patients and who are prescribed Sativex®. Germany and Sweden: Patients who are prescribed Sativex® from selected specialist neurology centres.
89148698|NCT00618930|Experimental|1|
89148699|NCT00618930|Active Comparator|2|Use of Fleet
89148700|NCT04209972|Active Comparator|Patients on CT1|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a standard CT scanner. (Aquilion One Genesis, Canon Medical Systems)
89148701|NCT04209972|Active Comparator|Patients on CT2|Patients will undergo two pre-contrast scans, and will be in between the two scans be off and on the table at a UHRCT scanner. (Aquilion One Precision, Canon Medical Systems)
89148702|NCT00637104|Experimental|A - Mar-tyn|It includes the implant of the Mar-tyn TiN coated stent
89148703|NCT00637104|Active Comparator|B - Vision|Includes all the patients treated with the Vision stent
89148704|NCT00528294|Experimental|1|GRID-radiotherapy followed by biological imaging guided IMRT
89148705|NCT04209894||Psoriasis|They will undergo dermatological assessment and a blinded ultrasound (US) evaluation.
89148706|NCT04209894||Control|They will also undergo dermatological assessment and a blinded ultrasound (US) evaluation.
89148707|NCT00620334||1|"ASTHMA:~PREVOUSLY DIAGNOSED MILD ASTHMA PATIENTS"
89148708|NCT00620334||2|"CONTROL:~PATIENTS WHO HAVE NEVER BEEN DIAGNOSED WITH ASTHMA"
89148709|NCT00617682|Active Comparator|Group 1|Group 1 (experimental)
89148710|NCT00617682|Placebo Comparator|Group 2|Group 2 (placebo comparator)
89148711|NCT02053272|Active Comparator|2 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 2 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
89148712|NCT02053272|Active Comparator|5 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 5 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
89148713|NCT02053272|Active Comparator|15 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 15 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
89148714|NCT02053272|Placebo Comparator|Placebo|Licaps® size double zero (Size 00) hard gelatin capsules containing excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
89148715|NCT04212624|Experimental|test arm|The 25G or 23G conjunctival seamless vitrectomy was performed on the anterior eye to remove the anterior-posterior direction and tangential direction of the rupture hole. The area outside the macular foveal lesion was selected, but 100 μl of HuRPE cell injection was injected within about 2 PD. In combination with the Medone syringe and the combined 35G or 37G needle, the silicone oil injection module is used for injection, and the injection is performed in an amount of 100 μl (depending on the cell concentration). The doses of the three dose groups from low to high were 300,000 cells, 500,000 cells, and 1 million cells, respectively, in a single injection.
89148716|NCT00617760|Experimental|1|Concomitant administration of MenC-TT vaccine and PCV7, 170 subjects
89148717|NCT00617760|Active Comparator|2|PCV7 administration only, 85 subjects
89148718|NCT00617760|Active Comparator|3|MenC-TT vaccine only, 85 subjects
89148719|NCT04212546|Placebo Comparator|Control drink|200 mL milk + 16 g maltodextrin
89148720|NCT04212546|Active Comparator|Test drink|200 mL milk + 16 g inulin + Lactobacillus casei [>106 cfu/mL]
89148721|NCT02030418|Experimental|Leadless Pacemaker|VVIR pacing
89148722|NCT00617838|Active Comparator|1|Optimization of gluten introduction by nutritional councelling
89148723|NCT00617838|No Intervention|2|No specific nutritional councelling. Follow-up of gluten introduction
89148724|NCT00620412|Active Comparator|treatment|
89148725|NCT00620412|Placebo Comparator|placebo|
89148726|NCT02347254|Experimental|Transcranial ExAblate|Transcranial ExAblate MRgFUS
89148727|NCT00620490|Experimental|1|Ropivacaine 0.5% 0.1 ml/kg per hour
89148728|NCT00620490|Placebo Comparator|2|
89148729|NCT00619008|Experimental|1|Ad libitum low carbohydrate diet
89148730|NCT00619008|Experimental|2|Ad libitum high complex carbohydrate diet
89148731|NCT00619008|Experimental|3|Energy-restricted high complex carbohydrate diet
89148732|NCT00619086|Placebo Comparator|A, 1|Placebo 45 minutes prior to surgery
89148733|NCT00619086|Active Comparator|A, 2|8 mg Dexamethasone 45 minutes prior to surgery
89148734|NCT04212078|Active Comparator|A-Levofloxacin|0.1 ml/0.5mg of levofloxacin 0.5% ophthalmic solution
89148735|NCT04212078|Active Comparator|B-Intracameral Cefuroxime|0.1 ml/1mg of Cefuroxime
89148736|NCT01898520|Active Comparator|Sativex|Oromucosal spray containing delta-9-tetrahydrocannabinol (THC) (27 mg/mL):cannabidiol (CBD) (25 mg/mL). Each 100 μL spray to the sub-lingual or oral mucosa delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
89148737|NCT01898520|Placebo Comparator|Placebo|Oromucosal spray containing ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum number of daily sprays was 12.
89148738|NCT00903617|Experimental|Part A Treatment A|5 mg of GSK256073
89148739|NCT00903617|Experimental|Part A Treatment B|50 mg of GSK256073
89148740|NCT00903617|Experimental|Part A Treatment C|150 mg of GSK256073
89148741|NCT00903617|Placebo Comparator|Part A Treatment D|placebo
89148742|NCT00903617|Placebo Comparator|Part B Treatment A|placebo
89148743|NCT00903617|Active Comparator|Part B Treatment B|1500 mg Niaspan
89148744|NCT00903617|Experimental|Part B Treatment C|x mg dose of GSK256073 based on data from Part A
89148745|NCT00903617|Experimental|Part B Treatment D|optional dose of GSK256073 based on data from Part A
89148746|NCT05088785|Experimental|Part A: dynamic FES PET imaging|All patients included in part A will receive a dynamic FES PET/CT scan.
89148747|NCT05088785|Experimental|Part B: whole body static FES PET imaging|All patients included in part B will receive a whole body static FES PET/CT scan twice within 1 week.
89148750|NCT00620568|Experimental|1|
89148751|NCT00620568|Experimental|2|
89148752|NCT00620568|Experimental|3|
89148753|NCT00620568|Experimental|4|
89148754|NCT02849093||Dry Eye Syndrome Patients|Patients who have been diagnosed clinically with Sjögren's will have an OCT image of their lacrimal glands and buccal mucosa taken. Imaging from patients found to have Sjögren's clinically diagnosed following examination of buccal mucosa under the microscope will be compared with images from patients without dry eye syndrome to see of any obvious differences can be identified.
89148755|NCT02849093||Epiphora Patients|Pre and post-operative OCT images of patients undergoing punctoplasty or conjunctivoplasty will be compared to images of the same structures in people without watery eyes.
89148756|NCT02849093||Asymptomatic Patients|OCT images will be captured of the cornea, conjunctiva, lacrimal gland and buccal mucosa to establish normal appearance in asymptomatic patients.
89148757|NCT02021357|Experimental|Hyperbolid combined with tongue exercises on the palate|The proprioceptive treatment protocol if run in the use of exercises with hyperboloid based on studies of Biasotto-Gonzalez (2005), for each exercise will be held 6 sets of 6 reps. Between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain, and after that period you will be asked to volunteer the proprioceptive exercise of ´ ´ tongue on the hard palate ´ ´ Biasotto-Gonzalez-based (2005), which consists of the language supported in the hard palate, you must open and close the mouth, having as the principle language as a physical reference.
89148758|NCT02021357|Active Comparator|Hyperbolid|"The proprioceptive treatment protocol if run in the use of the hyperboloid, based on studies of Biasotto-Gonzalez (2005), but without the proprioceptive exercise of language in ´ ´ hard palate ´ ´.~For each exercise will be held 6 series of 6 repetitions, and between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain."
89148759|NCT02021357|No Intervention|Control|The individuals in control group did not receive any type of intervention, being offered proprioceptive treatment after the study period.
89148760|NCT04845516||plasma exchange|All patients underwent plasma exchanges between 2014 and 2019 for a neuropediatric pathology
89148761|NCT04845516||immunoadsorption|All patients who underwent immunoadsorptions between 2014 and 2019 for a neuropediatric pathology
89148762|NCT02848937||Bath with citrate|"Each patient will participate in two phases of the study. The first phase has the aim to identify the concentration of calcium in the bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium (4 weeks). Each week, the concentration of calcium in the bath with citrate is increased from 1.5-, to 1.65, to 1.75 mM.~•Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.•All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study"
89148763|NCT02848937||Bath with citrate and Ca_eq|"Each patient will participate in two phases of the study. In the second phase will evaluate the effectiveness of the purification concentrate with 1 mM citrate and Ca_eq compared to the concentrate with 3 mM acetate and 1.5 mM calcium. For each of the sessions will be used the following materials:~Filter high permeability (Kuf> 20ml/mmHg);~Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.~All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study."
89148764|NCT00343824|Experimental|aquacel AG hydrofiber|
89148765|NCT00343824|Experimental|Acticoat burn dressing|
89148766|NCT00903383|Experimental|Low Dose|A low dose of LX3305; daily oral intake for 12 weeks
89148767|NCT00903383|Experimental|Mid Dose|A mid dose of LX3305; daily oral intake for 12 weeks
89148768|NCT00903383|Experimental|High Dose|A high dose of LX3305; daily oral intake for 12 weeks
89148769|NCT00903383|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
89148770|NCT04812210||case: children with congenital heart disease aged 2 to 4 years.|case: children with congenital heart disease aged 2 to 4 years.
89148771|NCT04812210||control children recruited in kindergartens and schools aged 2 to 4 years|control children recruited in kindergartens and schools aged 2 to 4 years
89148772|NCT02849015|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive liver cryosurgery first to destroy big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89148773|NCT02849015|Active Comparator|Cryosurgery|In this group, the patients will receive liver cryosurgery to destroy big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89148774|NCT02849249|Active Comparator|One day schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in one day schedule. The maintenance dose (0.5 mL) is reached in one day.
89148775|NCT02849249|Active Comparator|Rapid schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in a rapid Schedule.The initation phase includes 3 weekly increasing doses till the maintenance dose of 0.5 mL is reached.
89148776|NCT04704089||spectrophotometer, and numerical values of tooth color in the populations studied|at the first visit Shooting with Spectrophotometer and at the second visit for all patients except control population: Tooth extraction or restorative treatment Collection of teeth or enamel debris for analysis
89148777|NCT02848859|Active Comparator|Intervention: Go! to Sleep|We are using a web-based cognitive behavioral therapy program called Go! to Sleep. Go! to Sleep is an interactive online program developed by specialists in Cleveland Clinic's Wellness Institute and Sleep Disorders Center. The program is a 6 week self-help program that uses cognitive behavioral therapy techniques that have been proven to be effective in decreasing symptoms of insomnia.
89148778|NCT02848859|Placebo Comparator|General Sleep Hygiene Education|General Sleep Hygiene Education is the first step in the treatment of any sleep disorder. Both arms will have access to a Harvard sleep education web site that provides general information about sleep as well as sleep hygiene.
89148779|NCT00619164|Experimental|1|
89148780|NCT00619164|Experimental|2|
89148781|NCT00619164|Experimental|3|
89148782|NCT00619164|Placebo Comparator|4|
89148783|NCT02848625|Experimental|Group A|Patients randomized to 12 weeks of twice weekly yoga sessions. The yoga exercises have been designed specifically for patients with IPF.
89148784|NCT02848625|No Intervention|Group B|Patients who are not randomized to yoga sessions will continue with their usual care and usual activities
89148785|NCT01851252|Experimental|Methacetin (for BT) before / after Propanolol treatment.|The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol.
89148786|NCT02848547||Intervention - SMS|Participants in the intervention group received periodic text messages on healthy lifestyle throughout the study period.
89148787|NCT02848547||Control - Standard Care|Participants in the control group received standard one time advice at entry in the study.
89148788|NCT00619320|Experimental|Safer Sex Skill Building (SSB)|Safer Sex Skill Building Intervention (SSB) A five session behavioral intervention focused on HIV/STD prevention and safer sex negotiation skills
89148789|NCT00619320|Active Comparator|2|one group session focused on standard HIV/STD education
89148790|NCT04962971||Cranberry extract X|373 mg per Day
89148791|NCT04962971||Cranberry extract Y|404 mg per Day
89148792|NCT04962971||Cranberry extract Z|2090 mg per Day
89148793|NCT04212000|Experimental|Levoketoconazole|Levoketoconazole 150 mg
89148794|NCT04212000|Active Comparator|Ketoconazole|Ketoconazole 200 mg
89148795|NCT04212234|Experimental|free ultrasound propagation velocity|ultrasound exams will be performed using several ultrasound propagation velocities
89148796|NCT04212234|No Intervention|conventional ultrasound propagation velocity|ultrasound exams will be performed using the 1540m/s conventional celerity
89148797|NCT00619398|Active Comparator|1|
89148798|NCT00619398|Experimental|2|
89148799|NCT04213092||ERCP+LC|Patients in this group underwent 2-stage ERCP+LC in a single setting. And, it was compared with our control group
89148800|NCT04213092||OC+CBD|This group with 2-stage OC+CBD exploration in a single setting approach was taken as a control group.
89148801|NCT02848469|Active Comparator|Omega-3 fatty acids|Subjects will receive food supplements in the form of 200ml juice drinks, containing either the active component, 1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid, or matching placebo for a duration of six months. Neither the active nor the placebo food supplements taste of fish, so the subject will be blind to whether he/she is receiving the active intervention or placebo.
89148802|NCT02848469|Placebo Comparator|placebo 200ml juice drinks|200ml juice drinks
89148803|NCT00620646|Experimental|A|Aspirin plus increasing clopidogrel group
89148804|NCT00620646|Experimental|B|Aspirin, clopidogrel plus cilostazol group
89148805|NCT02314026|Experimental|Suspected NASH|13C-Octanoate, 13C-Methacetin
89148806|NCT00810017|Experimental|Single arm study|Etoposide 100mg/m2 daily x 3 days Q3W and Trastuzumab 8mg/kg loading dose then 6mg/kg, then single agent until disease progression
89148807|NCT04800900|Experimental|Pharmaceutical intervention|A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors
89148808|NCT02848391|Experimental|healthy subjects|three hour flight simulation
89148809|NCT02848391|Experimental|COPD normocapnic|three hour flight simulation
89148810|NCT02848391|Experimental|COPD hypercapnic|three hour flight simulation
89148811|NCT00618150|Experimental|A|
89148812|NCT00560651||1|Cross linked eyes
89148813|NCT00620724|Placebo Comparator|A|Placebo three times daily
89148814|NCT00620724|Experimental|B|20 mg of slow-release Nifedipine three times daily
89148815|NCT00486239|Experimental|1|Behavioral TLE 1A
89148816|NCT00486239|Experimental|2|TLE Arm II
89148817|NCT00486239|Experimental|B|Control Arm B
89148818|NCT00284310|Experimental|wrist surgery|
89148819|NCT04809545|Experimental|Intervention|The study intervention consists of the delivery of a soundscape in the private rooms of the participant during the morning and evening. The soundscape is personalized and consists of a collection of natural sounds, birdsongs, kitchen sounds, music, bell sound, outdoor sounds, water/rain sounds, and similar.
89148820|NCT04809545|Active Comparator|Treatment as Usual|As part of usual care, patients on the Specialized Dementia Unit receive a comprehensive assessment of their health and symptoms of dementia involving consultation by a geriatric psychiatrist, geriatrician, physical therapist, occupational therapist, and recreation therapist, and pharmacological and non-pharmacological treatment plans are developed and executed. All participants in the study will receive this standard of care
89148821|NCT04209426||HMB-DMR-HA|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a hydroxyapatite-coated outer surface as well as two pegs and one screw.
89148822|NCT04209426||HMB-DM-CEM|Total hip arthroplasty with hemispherical metal-back dual-mobility acetabular cup with tripod fixation consisting of a bare metal outer surface to be covered with bone-compatible cement.
89148823|NCT00428675||ACI Instrument|228 individuals completed the ACI instrument and other tools
89148824|NCT00620802|Experimental|A|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg)
89148825|NCT00620802|Active Comparator|B|Plavix (clopidogrel 75 mg)
89148826|NCT04706442|Experimental|Standard hospital care with follow up + Supportive Parenting App|Receive standard hospital care and follow up, and access to the Supportive Parenting App from pregnancy to 6 months postpartum
89148827|NCT04706442|No Intervention|Standard hospital care with follow up|Receive standard hospital care with follow up
89148828|NCT00620958|Experimental|1|Participants will receive individual cognitive behavioral therapy with parent reinforcement training.
89148829|NCT00620958|Experimental|2|Participants will receive individual cognitive behavioral therapy with parent relationship training.
89148830|NCT00620958|Active Comparator|3|Participants will receive individual cognitive behavioral therapy alone.
89148831|NCT02848157|Experimental|DR|dexmedetomidine 0.3mcg/kg and 0.25% ropivacaine 0.3ml/kg
89148832|NCT02848157|Placebo Comparator|PR|0.25% ropivacaine 0.3ml/kg
89148833|NCT04834661||inside group|laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
89148834|NCT04834661||outside group|laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
89148835|NCT00619632|Experimental|1|LC- Primary-care based lactation consultant meeting women pre- and post-natally.
89148836|NCT00619632|Experimental|2|Provider Prompt
89148837|NCT00619632|Experimental|3|LC+Provider Prompt
89148838|NCT00619632|No Intervention|Control|
89148839|NCT04211844||sofosbuvir plus daclatasvir|50 patients receiving 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
89148840|NCT04211844||sofosbuvir plus ledipasvir|50 patients receiving 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks. Blood samples are taken at baseline (week 0), week 4 (during treatment) and week 24 (post treatment after discontinuation of treatment at sustained virological response). Samples will be evaluated for lipid profiles, fasting blood sugar and glycated hemoglobin.
89148841|NCT04211454||Migraine|Patients with migraine headaches
89148842|NCT02847923|Experimental|Group Experimental|All the volunteers will use the software and then answer the questionnaire. They will be familiar with the software interface, performs an initial test to learn how to use the software, run a test script and answer the questionnaire.
89148843|NCT01776762|Experimental|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
89148844|NCT01776762|No Intervention|Standard Follow-home programme|Standard Follow-home programme without individual nutritional therapy
89148845|NCT05008835|Experimental|Drug - ACP-044 Dose A|ACP-044 Dose A
89148846|NCT05008835|Experimental|Drug - ACP-044 Dose B|ACP-044 Dose B
89148847|NCT05008835|Placebo Comparator|Placebo|Placebo
89148848|NCT00619710|Experimental|1|Meropenem
89148849|NCT00619710|Active Comparator|2|Imipenem-cilastatin
89148850|NCT04211688|Experimental|Combined individual + group Schema therapy|Those who will receive both individual plus group schema therapy
89148851|NCT04211688|Active Comparator|Only group Schema therapy|Those who will receive group schema therapy
89148852|NCT04211376||Anxiety|Patients with anxiety
89148853|NCT02847377|Experimental|[18F]-ODS2004436|Two TEP will be performed with the radiotracer [18F]-ODS2004436
89148854|NCT04212858|Experimental|case|myeloma patients
89148855|NCT04212858|Experimental|control|healthy control
89148856|NCT00619788|Experimental|1|Patients receiving 4.0-5.0mm AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for femoropopliteal use
89148857|NCT02847611|Experimental|Jamar then Labin|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
89148858|NCT02847611|Experimental|Labin then Jamar|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
89148859|NCT02847767|Experimental|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution.
89148860|NCT02847845|Experimental|Red ginseng powder capsule|People in this group take a red ginseng powder capsule.
89148861|NCT02847845|Placebo Comparator|Placebo powder capsule|People in this group take a placebo powder capsule.
89148862|NCT02846909|Active Comparator|Vaginal progesterone group|Will receive progesterone pessaries 400 mg once daily vaginally
89148863|NCT02846909|No Intervention|No progesterone group|Will receive nothing
89148864|NCT02847533|Other|resistant depression|patients suffering from resistant unipolar depression (at least 2 failed antidepressant treatments for the current episode)
89148865|NCT02847533|Other|non resistant depression|patients in remission from unipolar depressive disorder
89148866|NCT02847299|Experimental|Astral ventilator|instrumental increase of cough peak flow with air stacking
89148867|NCT02847299|Experimental|Astral ventilator - mode kiné|instrumental increase of cough peak flow with hyperinsufflation
89148868|NCT02847143|Experimental|secure|healthy adult male with secure attachement
89148869|NCT02847143|Experimental|avoidant|healthy adult male with avoidant attachement
89148870|NCT02847143|Experimental|enmeshed/fearfull|healthy adult male with enmeshed/fearfull attachement
89148871|NCT02847143|Experimental|dual style|healthy adult male with dual attachement style
89148872|NCT02847455|Experimental|5 mg ilaprazole|
89148873|NCT02847455|Experimental|10 mg ilaprazole|
89148874|NCT02847455|Active Comparator|10mg Rabeprazole|
89148875|NCT03897335|Active Comparator|Aminophylline pre CPB & immediately post CPB|
89148876|NCT03897335|Placebo Comparator|Placebo|
89148877|NCT01617096|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25mg dapivirine
89148878|NCT01617096|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
89148879|NCT00619944|Experimental|1|Lumefantrine lopinavir drug interaction arm
89148880|NCT00619944|Active Comparator|2|lumefantrine only arm
89148881|NCT02846597|No Intervention|Control|Infants in this group will not receive sustained lung inflation in the delivery room and will be put immediately on CPAP at a pressure of 5 cm H2O.
89148882|NCT02846597|Active Comparator|High pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
89148883|NCT02846597|Active Comparator|High pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
89148884|NCT02846597|Active Comparator|Low pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
89148885|NCT02846597|Active Comparator|Low pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
89148886|NCT01606488|Other|Surgical Group|"Subjects scheduled to undergo total knee or total hip replacement at the SFVAMC.~Subjects in this arm of the study will undergo the florbetapir PET scan once prior to their surgery.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
89148887|NCT01606488|Other|Non-surgical group|"Subjects being seen in at the SFVAMC orthopedic clinic for knee or hip pain but are not anticipating surgical intervention.~Subjects in this arm will not undergo the florbetapir PET scan.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
89148888|NCT04681092|Experimental|AKS-452 s.c.(A)|Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL) single-dose
89148889|NCT04681092|Experimental|AKS-452 s.c. (B)|Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL), two-dose
89148890|NCT04681092|Experimental|AKS-452 s.c. (C)|Subcutaneous injection of pre-defined dose (45 ug, 205 uL), single-dose
89148891|NCT04681092|Experimental|AKS-452 s.c. (D)|Subcutaneous injection of pre-defined dose (45 ug, 250 uL), two-dose
89148892|NCT04681092|Experimental|AKS-452 s.c. (E)|Subcutaneous injection of pre-defined dose (90 ug, 500 uL), single-dose
89148893|NCT04681092|Experimental|AKS-452 s.c. (F)|Subcutaneous injection of pre-defined dose (90 ug, 500 uL), two-dose
89148894|NCT04681092|Experimental|Phase 2, single-dose injection|Subcutaneous injection of selected dose based on phase 1 data, dose (90 ug, 500 uL)
89148895|NCT04681092|Experimental|Phase 2, two-dose injection|Subcutaneous injection of selected dose based on phase 1 data, dose (45 ug, 500 uL) twice.
89148896|NCT02846675|Experimental|SVF treatment (random knee)|A random knee (left or right) of subjects will be treated with autologous SVF.
89148897|NCT02846675|Placebo Comparator|placebo treatment (the other knee)|The other knee of subjects will be treated with placebo.
89148898|NCT00621036|Experimental|methotrexate IV once every 2 weeks|
89148899|NCT02846831|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
89148900|NCT02846831|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
89148901|NCT00621114|Active Comparator|1|Patients in group 1 will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
89148902|NCT00621114|Experimental|2|Patients in group 2 will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
89148903|NCT01497509|Experimental|Patients electing to receive intrapartum epidural analgesia|
89148904|NCT01497509|No Intervention|Patients electing not to receive epidural analgesia|
89148905|NCT04326335|Active Comparator|Felt-tip marking|
89148906|NCT04326335|Experimental|Felt-tip marking + 3D printed ostomy button|
89148907|NCT02844881|Experimental|Apatinib+MASCT|Apatinib+Multiple Antigens Specific Cellular Therapy(MASCT) in patients with advanced solid tumors,excluding T cell lymphoma
89148908|NCT04212936|No Intervention|Control group|8 mmHg pressure group
89148909|NCT04212936|Experimental|Study group|10 mmHg group
89148910|NCT04612608|No Intervention|Control|Usual Care
89148911|NCT04612608|Active Comparator|Intervention|Intervention arm
89148912|NCT01488149||Recipients of intrapartum epidural analgesia|
89148913|NCT01488149||Non-recipients of intrapartum epidural analgesia|
89148914|NCT00621270|Experimental|1|BCI-540 80 mg once a day (q.d.)
89148915|NCT00621270|Experimental|2|BCI-540 80 mg three times a day (t.i.d.)
89148916|NCT00621270|Placebo Comparator|3|Placebo
89148917|NCT02846519|Experimental|Esketamine|Participants in Cohort 1 (Han Chinese participants), Cohort 2 (Korean participants) and Cohort 3 (Japanese participants ) will receive 100-microliter (mcL) spray of 14 percent (%) esketamine solution (14 milligram [mg]) into each nostril at Time 0 and 5 minutes later for a total dose of 56 milligram (mg) in Period 1.
89148918|NCT02846519|Experimental|Esketamine+Rifampin|Participants in Cohort 4 (Caucasian participants) will receive a 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 1 followed by rifampin from Day -6 to Day -1 of treatment Period 2 and followed by 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 2.
89148919|NCT03711305|Experimental|SHR-1316 + carboplatin + etoposide|Participants will receive SHR-1316 intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) SHR-1316 until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
89148920|NCT03711305|Active Comparator|Placebo + carboplatin + etoposide|Participants will receive placebo intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
89148921|NCT01433016|Experimental|Octanaote Breath Test|A Octanoate breath test will be performed on this single arm population
89148922|NCT03664427||Group 1: Patients with VOD|paediatric patients with Veno-Occlusive Disease (VOD) complicating haematological stem cell transplantation
89148923|NCT03664427||Group 2: matched controls|Paediatric patients defined as matched controls without veno-occlusive disease complicating haematological stem cell transplantation
89148924|NCT00618384|Active Comparator|1|Patients with TACE therapy will be treated with Sorafenib (2 x 400 mg/day) until progressive disease
89148925|NCT02844803|Other|Active drug-> Placebo|Metformin + S. Baicalensis --> Metformin + Placebo
89148926|NCT02844803|Other|Placebo -> Active drug|Metformin + Placebo --> Metformin + S. Baicalensis
89148927|NCT04211298|Active Comparator|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
89148928|NCT04211298|Placebo Comparator|Propofol|Propofol will be used for sedation during bronchoscopy
89148929|NCT04201925||blepharoplasty|Patients will undergo blepharoplasty surgery
89148930|NCT04209036||3D laparoscopy arm|patients submitted to total hysterectomy using a 3D laparoscopic camera
89148931|NCT04209036||2D laparoscopy arm|patients submitted to total hysterectomy using a 2D laparoscopic camera (standard laparoscopic camera)
89148932|NCT04214405|Experimental|union of fractures|proper union of zygomatic fractures
89148933|NCT00618462|Experimental|1|Participants will receive psychoeducation therapy plus case management and a referral to Gamblers Anonymous.
89148934|NCT00618462|Experimental|2|Participants will receive cognitive behavioral therapy plus contingency management and a referral to Gamblers Anonymous.
89148935|NCT00618462|Experimental|3|Participants will receive cognitive behavioral therapy and a referral to Gamblers Anonymous.
89148936|NCT02844491||Cohort A|"In Cohort A, patients will be included either in the group sustainable responseor in the short / refractory response group.~- sustainable response group : patient with NHL diffuse large B cells, and persistent complete response for at least 6 months after first-line treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease in complete response or partial stable response for at least 1 year after first line treatment with Rituximab~short / refractory response group : patient with NHL diffuse large B cells, refractory or relapsed in less than 6 months after at least one line of treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease refractory or relapsed / progression within less than 1 year after at least one line of treatment with Rituximab"
89148937|NCT02844491||Cohort B|"For Cohort B patients will be included either in the group B hematologic therapeutic abstention or in the group any blood disease not treated with anti-CD20 antibodies.~B hematologic therapeutic abstention group : patient with hematological malignancy whatever the initial expansion stage~any blood disease not treated with anti-CD20 antibodies group : patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstorm disease without treatment criteria at diagnosis and with stable disease for at least 6 months"
89148938|NCT04210908|Experimental|Biofeedback|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the study group, patients will observe the descent of the head during contraction on the ultrasound display screen.
89148939|NCT04210908|No Intervention|Control|The patient will be instructed to bear down during 4 consecutive contractions while monitoring head descent using transperineal ultrasound. In the control group, patients will not observe the ultrasound display screen.
89148940|NCT02846363||Patients included in the Rhône region from France|public awareness campaign
89148941|NCT02846363||Patients included in the control region (Isère, France)|
89148942|NCT02844413|Experimental|study group|implementation of aerobic interval training
89148943|NCT02844413|No Intervention|control group|control group
89148944|NCT02846207|Experimental|Yiqi huoxue group|Buyang Huanwu decoction , which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
89148945|NCT02846207|Experimental|Yiqi group|Astragalus 60g. Oral administration, twice one day, for 12weeks.
89148946|NCT02846207|Experimental|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
89148947|NCT02846207|Placebo Comparator|placebo group|dextrin, Oral administration, twice one day, for 12weeks.
89148948|NCT04211064|Other|Deep neuromuscular block|Patients undergoing deep neuromuscular blockade with rocuronium (TOF -- PTC 1-5)
89148949|NCT04211064|Active Comparator|Moderate neuromuscular block|Patients undergoing moderate neuromuscular blockade with rocuronium (TOF 1-3)
89148950|NCT02691780|Experimental|Sorafenib|Sorafenib 200mg bid will be administered orally daily every 3weeks
88806018|NCT01156805|No Intervention|Educational program|No intervention has been made.
88804202|NCT00004138|Experimental|FDG-PET scan + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy, fine needle aspiration, or other imaging studies are then conducted to confirm the PET findings.~Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may undergo thoracotomy and pulmonary resection within 1 month of evaluation.~Patients are followed at 5-6 months after surgery."
88804203|NCT04712500|Experimental|AND017: Fasted - Fed|Subjects were randomized to receive single dose of AND017 under fasted condition in Period 1 and under fed condition in Period 2
88804204|NCT04712500|Experimental|AND017: Fed - Fasted|Subjects were randomized to receive single dose of AND017 under fed condition in Period 1 and under fasted condition in Period 2
88804205|NCT05777057|Other|Extracted teeth|Extracted teeth with intial caries without cavitation is examined by diagnodent and digital imaging and then by light microscope
88804206|NCT05777044|No Intervention|Control- No Intervention/treatment|Participants in the control group will maintain their usual daily routine. The participants will complete the pre-test, 10 weeks of normal daily activities, and post-test. No changes to their daily schedule will be made by the researcher.
88804207|NCT05777044|Active Comparator|Active Comparator- 10-week, 2x/week, 45-minute sessions of guided meditation|The active comparator meditation group will complete a 10-week meditation yoga intervention (2x/week, 45 minutes per session). Each session will consist of yogic breathing, imagery, and meditation, specifically with a focus on each of the yogic limbs. The yogic limbs that will be incorporated during the meditation intervention are yamas, niyamas, pranayamas, and sense withdrawal/meditative techniques.
88804208|NCT05777044|Experimental|Experimental- 10-week, 2x/week, 45-minute Hatha yoga sessions|The experimental hatha yoga group will complete a 10-week yoga intervention (2x/week, 45 minutes per session). Each session will consist of a centering, integration, awakening, vitality, equanimity, grounding, igniting, opening, release, and deep rest; all of which are specific hatha yoga practice sections. This group will complete the pre-test and post-test measures.
88804209|NCT05776940|Active Comparator|Probiotic group|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules( 250mg/time, bid,up to 3 months).
88804210|NCT05776940|Active Comparator|Control group|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics.
88804211|NCT05776810|Experimental|All eligible participants|"All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.~Interventions:~Diagnostic Test: Head Up Tilt Table (HUT) Device: Implantable Loop Recorder"
88804212|NCT05776771||Low Back Pain|Subjects with Low Back Pain
88804213|NCT05776771||Neck Pain|Subjects with Neck Pain
88804214|NCT05776771||Control/Insincere|Subjects with healthy spines, who have no neck or low back pain
88804215|NCT05776745|Experimental|Epileptic|Epileptic with stereoelectroencephalography
88804216|NCT05776732|Experimental|CaviionTM group|The first nursing is performed within 48 hours after PICC intubation, and each nursing is not more than 7 days thereafter. The nursing contents include skin disinfection, dressing replacement, flushing and locking venous catheters, needleless connector change. After the disinfectant was dried, the experimental group applied CaviionTM on the skin around the catheter and waited for 30 seconds before sticking the dressing.
88804217|NCT05776732|No Intervention|Routine care group|The first nursing is performed within 48 hours after PICC intubation, and each nursing is not more than 7 days thereafter. The nursing contents include skin disinfection, dressing replacement, flushing and locking venous catheters, needleless connector change.
88804218|NCT05776615|Experimental|Mobile Application Group|"In the collection of Mobile Application data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months. Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Detection Questionnaire in the Neonatal Intensive Care Unit; System Availability Scale will be applied."
88804219|NCT05776615|No Intervention|Control group|"Participants included in the control group, Nurse Descriptive Characteristics form; Nursing Diagnoses Perception Scale, Missing Nursing Care Detection Questionnaire will be applied in the Neonatal Intensive Care Unit. Nursing Diagnoses Perception Scale at the end of the 1st month and at the end of the 3rd month; The Missing Nursing Care Identification Questionnaire will be applied again in the Neonatal Intensive Care Unit, and the System Usability Scale will not be applied to the control group."
88804220|NCT05776589||Group PCV-VG|In this group, pressure-controlled volume guaranteed ventilation (PCV- VG) was applied in patients undergoing vertebral surgery in the prone position.
88804221|NCT05776589||Group VCV|In this group, volume-controlled ventilation (VCV) was applied in patients undergoing vertebral surgery in the prone position.
88806019|NCT02531802|Experimental|Adult: ETVAX (Full)|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) added to bicarbonate buffer solution administered orally on Day 0 and 14
89148951|NCT02846051|Other|intensive sport practice|"intensive sport practice~the subject must practice for more than six months a drive of at least 8 hours / week, intense, above the ventilatory threshold, or 60-70% of maximum consumption oxygen or 70-80% of maximum heart rate, ie beyond a moderate slowdown. If stopping the intensive sport practice, the duration of the stop at the time of the study should be less practice time.~volunteers,~from 18 to 80 years,~free to consent.~covered by social security.~reported in the national register of healthy volunteers.~The intervention is a lower limb venous examination = venous mapping"
89148952|NCT02846051|Other|control group|"&) Volunteers who do not have intensive sport practice as it is defined in the group intensive sport practice 2) from 18 to 80 years, 3) free to consent. 4) covered by social security. 5) reported in the national register of healthy volunteers.~The intervention is a lower limb venous examination = venous mapping"
89148953|NCT02845973||test cohort|The test cohort was from Fudan University Shanghai Cancer Center (August 2016 to December 2016) and ECRJ-East Campus of Renji hospital (January 2012 to March 2017);
89148954|NCT02845973||validation cohort|The validation cohort was from Shanghai Tenth People's Hospital (October 2015 to November 2016) and WCRJ-West Campus of Renji hospital (July 2016 to March 2017)
89148955|NCT02845895||Neuroscience pole|Patient hospitalized in the department of medicine-surgery-obstetric of the neuroscience pole department
89148956|NCT02845895||Respiratory tracts pole|Patient hospitalized in the department of medicine-surgery-obstetric of the respiratory tracts pole department
89148957|NCT02691390|Experimental|study group|alcoholics - dTMS group
89148958|NCT02691390|Sham Comparator|control group|alcoholics - sham group
89148959|NCT02845817|Other|Qualitative research|Semi-structured interviews
89148960|NCT00621426||Observation|Patients with end-stage renal disease (ESRD) treated with hemodialysis three (3) times per week for at least 3 continuous months
89148961|NCT02845661|Experimental|group 1|patients in group 1, aged 20~60, were accepted an initial dose of 0.9μg/kg dexmedetomidine over 15 min.
89148962|NCT02845661|Experimental|group 2|patients in group 2, aged 20~60, were accepted an initial dose of 1.0μg/kg dexmedetomidine over 15 min.
89148963|NCT02845661|Experimental|group 3|patients in group 3, aged 20~60, were accepted an initial dose of 1.1μg/kg dexmedetomidine over 15 min.
89148964|NCT04460898||Breast Cancer Patients|HR+/HER2- metastatic breast cancer patients in the US.
89148965|NCT02845583||Retrospective cohort|150 oncologic patients belonging to major complexity DRGs
89148966|NCT02845583||Perspective cohort|150 oncologic patients belonging to major complexity DRGs
89148967|NCT01259544|Active Comparator|Di -petide breath tests and ePFT secretin induced|Di peptide breath tests will be performed on subjects with known chronic pancreatitis
89148968|NCT01259544|Active Comparator|c13 di peptide breath tests|Healthy volunteers to compare breath tests results to subjects with chronic pancreatitis
89148969|NCT02845739|Experimental|kidney transplanted patient|
89148970|NCT04210752|Experimental|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
89148971|NCT04210752|Experimental|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
89148972|NCT04210752|Experimental|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
89148973|NCT04210752|Experimental|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of administration: Intramuscular injection"
89148974|NCT04210752|Experimental|Treatment 5 (Shingrix)|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: Intramuscular injection"
89148975|NCT04193657||Chemotherapy|30 participants starting chemotherapy
89148976|NCT04193657||Abiraterone|20 participants starting Abiraterone
89148977|NCT04193657||Enzalutamide|20 participants starting Enzalutamide
89148978|NCT04193657||Radium-223|20 participants starting Radium-223
89148979|NCT04210518|Experimental|Neuromuscular training|"Neuromuscular training consisting of:~Single limb balance task.~Balance training on an unstable surface.~Hop drills."
89148980|NCT04210518|Experimental|Stroboscopic glasses group|"This group performed the same neuromuscular training with the addition of stroboscopic glasses during the training performance.~Single limb balance task.~Balance training on unstable surfaces.~Hop drills."
89148981|NCT04210518|No Intervention|Control group|This group received no intervention
89148982|NCT02844023|Other|Patient with giant gells arteritis|50 patients with giant gells arteritis
89148983|NCT02844023|Other|Control patients|50 control patients : blood from French national blood service (EFS)
89148984|NCT04209816||ApoC-III LOF|Carriers of apo-CIII loss-of-function mutation
89148985|NCT04209816||ApoC-III GOF|Carriers of apo-CIII gain-of-function mutation
89148986|NCT04209816||TM6SF2-KK|Carriers of TM6SF2 E167K mutation
89148987|NCT04209816||PNLPLA3-MM|Carriers of PNLPLA3 I148M mutation
89148988|NCT04209816||Control|No ApoC-III, TM6SF2 E167K or PNLPLA3 I148M mutation
89148989|NCT04209816||ApoE variants|Carriers of E2/2, E3/3 or E4/4 mutation
89148990|NCT04209816||LIPG|LIPG gene LOF or GOF variant carriers
89148991|NCT04209816||ANGPTL3 or ANGPTL8|ANGPTL3 and ANGPTL8 gene LOF or GOF variant carriers
89148992|NCT02844335|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
89148993|NCT02844335|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
89148994|NCT02844179|Experimental|dose escalation|Single dose administration of (+)-alpha-Dihydrotetrabenazine (HTBZ), escalating dosage amounts 7.5 - 30 mg orally
89148995|NCT00880074|Experimental|Diagnostic (fluorine F-18 fluorothymidine PET)|Patients undergo fluorine F-18 fluorothymidine PET at baseline, at day 6-8 of course 1, day 20 of course 2, and prior to day 1 of course 3.
89148996|NCT02844101|Other|non-blinded group|The non-blinded subjects will be informed that the accelerometer device (GT3X Actigraph accelerometer) is an accelerometer that assessed physical activity levels and patterns
89148997|NCT02844101|Other|blinded group|The blinded subjects will be informed that they will test the reliability of a new device for body posture assessment and these youngsters will not receive any information with regards to physical activity.
89148998|NCT04208880|Experimental|TBH Brain Workout 1.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be easy to master.
89148999|NCT04208880|Experimental|TBH Brain Workout 2.0|The TBH Brain Workout program will cover education topics that encourage engagement in interventions shown to impact cognitive performance, including those to enhance intellectual (e.g., how to focus attention), physical (e.g., how to eat healthy), and socio-emotional (e.g., how to stay socially engaged) well-being. The challenge activities will be moderately difficult to master.
89149000|NCT04208880|Experimental|TBH Memory 1.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be easy to master.
89149001|NCT04208880|Experimental|TBH Memory 2.0|The TBH Memory program will cover educational topics on how memory works, what environmental factors impact memory, and memory strategies. The challenge activities will be moderately difficult to master.
89149002|NCT04208880|Active Comparator|Book Club|The Book Club will be given a book to read on how to improve brain health and will discuss separate chapters across 8 sessions. These sessions will be led by the participants and no formal structure will be provided. No personal challenges will be asked of participants and no log will be required. All groups will have a sign-in sheet to record individual participation.
89149003|NCT04208880|No Intervention|No Contact Wait List|The Wait List group will simply take the the surveys at each time point as the other groups.
89149004|NCT05337839|Experimental|Community-dwelling older adults receiving supervision|Group I; supervised home exercise group
89149005|NCT05337839|Active Comparator|Community-dwelling older adults not supervised|Group II; unsupervised home exercise group
89149006|NCT04375787|Active Comparator|Statin group|100 patients were randomly assigned to receive atorvastatin (80 mg) just before coronary intervention
89149007|NCT04375787|Placebo Comparator|Placebo group|100 patients received placebo
89149008|NCT05243069|Experimental|Screening (3D scan)|Patients undergo 3D scanning of lower head and neck region over 90-120 seconds before surgery and then every 3 months for up to 1 year after surgery.
89149009|NCT00825630|Active Comparator|Lansoprazole (Lanton)|Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning
89149010|NCT00825630|Active Comparator|Omeprazole (Losec)|Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning
89149011|NCT00825630|Active Comparator|Pantoprazole (Controloc)|Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning
89149012|NCT00825630|Active Comparator|Esomeprazole(Nexium)|Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning
89149013|NCT02845427|Active Comparator|A(drain group)|patients of primary THA will have closed suction drain introduced intraoperative at surgical site
89149014|NCT02845427|Placebo Comparator|B(No drain group)|patients of primary THA will have the surgical wound be closed with no suction drain
89149015|NCT02845349|Experimental|Drug-Vortioxetine|The treatment group will receive vortioxetine 10 mg per day, which will be increased to 20 mg or decreased to 5 mg, if deemed clinically necessary, at week 4 or 8.
89149016|NCT02845349|Placebo Comparator|Placebo|Matching placebo will be used.
89149017|NCT04117308|Active Comparator|Control group|Patients who received a classic information.
89149018|NCT04117308|Experimental|Educated group|Who have been educated to the active fetal movements count.
89149019|NCT03852251|Experimental|AK104|AK104 IV every 2 weeks (q2w)
89149020|NCT03852251|Experimental|AK104 and chemotherapy|AK104 IV Q2W or Q3W，oxaliplatin IV 85 mg/m2 Q2W or 130mg/m2 Q3W，capecitabine 1000 mg/m2#twice a day (bid) for day 1to day 10 or day 1 to day 14 per cycle
89149021|NCT04335773||Sars-CoV-2 positive|Children positive for SARS-CoV-2
89149022|NCT04335773||SARS-CoV-2 negative|Children negative SARS-CoV-2
89149023|NCT04210674|Experimental|The traditional medicinal product of Argan spinosa oil|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the traditional medicinal product of Argan spinosa oil on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
89149024|NCT04210674|Active Comparator|The conventional topical steroid ointment|The researcher talked to children's caregivers, explained the study process and provided general consistent tips to the all of them, including firstly washing the affected area only with warm water, disposing the area to the fresh air and keep the area dry; secondly spreading the conventional topical steroid ointment on the affected area sparingly over the lesions borders forth times per day, then diaper the baby; finally not to apply any on the affected area such as wet wipes, essence contained soaps, barrier cream or other medications during the seventh day of the trial. The home follow-up visits took place and the researcher re-evaluated diaper area using the 5- point grading scale in the first, third and seventh day of trial.
89149025|NCT02691546||Subjects aged 75 years or older|
89149026|NCT00620178||1|Candesartan
89149027|NCT00620178||2|Losartan
89149028|NCT05242913|Active Comparator|High Dose SolnulTM|7.0 g of Resistant Potato Starch administered daily for 4 weeks
89149029|NCT05242913|Active Comparator|Low Dose SolnulTM|3.5 g of Resistant Potato Starch (plus 3.5 g digestible corn starch for 7.0 g total carbohydrate) administered daily for 4 weeks
89149030|NCT05242913|Placebo Comparator|Placebo|7.0 g digestible corn starch administered daily for 4 weeks
89149031|NCT04349982||No cardiovascular risk|If no patients with no cardiovascular risk can be included in the study, we will divide the cohorts into different categories (e.g. low, medium and high cardiovascular risk).
89149032|NCT04349982||low cardiovascular risk|
89149033|NCT04349982||high cardiovascular risk|
89149034|NCT04178213|Experimental|ADAPT 3D ALR|Patients treated with ADAPT 3D ALR
89149035|NCT04345224|Experimental|Dynamic tape|The gluteal muscle group will be covered with a dynamic tape.
89149036|NCT04345224|Experimental|Rigid tape|The gluteal muscle group will be covered with a rigid tape.
89149037|NCT04345224|Sham Comparator|Sham tape|The gluteal muscle group will be covered with a paper tape - a sham application.
89149038|NCT05242835|Active Comparator|biliopancreatic diversion with duodenal switch|Patient randomized for a the standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
89149039|NCT05242835|Experimental|Single-anastomosis duodeno-ileal anastomosis|Patient randomized for a single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
89149040|NCT04315350|Experimental|Curcumin|Participant receives both curcumin and prednisolone. Curcumin for 11 days, prednisolone for 10 days. Curcumin: 2 tablets (each contains 100 mg curcumin) twice daily. Prednisolon: 50 mg (capsule) every morning
89149041|NCT04315350|Other|Prednisolon|Participant receives prednisolone and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon: 50 mg (capsule) every morning
89149042|NCT04315350|Placebo Comparator|Placebo|Participant receives prednisolone.placebo and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone-placebo for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon-placebo: One capsule every morning.
89149043|NCT00621660|Experimental|Acupuncture|
89149044|NCT00621660|Placebo Comparator|Sham|
89149045|NCT02845193|Experimental|Modified Nasoalveolar molding group|This group will receive nasoalveolar molding appliance in addition to taping for 3 Months with follow-up every 2 weeks.
89149046|NCT02845193|Experimental|Taping group|Tape will be used alone in this group on the upper lip segments for 3 months with follow-up every 2 weeks.
89149047|NCT02845193|No Intervention|Control group|This group will not receive any treatment.
89149048|NCT02845193|Experimental|CAD/NAM group|Computer Aided Designed Nasoalveolar molding and 3D printed.
89149049|NCT05242757|Experimental|To evaluate the safety and reliminary efficacy of MAK immune cells in the treatment of PHC.|To evaluate the safety and reliminary efficacy of MAK immune cells in the treatment of primary hepatocellular carcinoma.
89149050|NCT02845115|Other|control|standard care : usual technique for implanting
89149051|NCT02845115|Experimental|laser velocimetry|optimized implantation of laser velocimetry
89149052|NCT04288206|Placebo Comparator|Placebo control|Patient will receive 'study drug' which is comprised of 300 mL of normal saline without any medication/antibiotic, which will be delivered by intravenous means at the time of surgery.
89149053|NCT04288206|Active Comparator|Cefazolin prophylaxis|Patient will receive 'study drug' which is comprised of weight-based dose of cefazolin mixed in 300 mL of normal saline, which will be delivered by intravenous means at the time of surgery.
89149054|NCT05242211|Other|Healthy|Healthy participants will do both cycle ergometer and treadmill exercise
89149055|NCT04210440|Experimental|Hip avascular necrosis|patients affected by avascular necrosis of the Hip classified by Japanese Investigation Committee criteria
89149056|NCT04958772|Experimental|Filgrastim Megalabs|Filgrastim Megalabs injectable 5 μg/Kg/day in a single subcutaneous application during 5 days
89149057|NCT04958772|Active Comparator|Granulokine|Granulokine injectable 5 μg/Kg/day in a single subcutaneous application during 5 days
89149058|NCT02771249|Experimental|Arm B|Arm B will be comprised of two phases: (1) DRV/c once daily alone (days 1-4) and (2) DRV/c once daily + RPT and INH once weekly (days 5-19).
89149059|NCT02697318|Other|Professional Administration|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) administered by a professional, using the standard clinical method.
89149060|NCT02697318|Other|Self-Administration (new method)|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) self-administered by the participant, using the new proposed method.
89149061|NCT04095377||healthy|
89149062|NCT04095377||CVA|
89149063|NCT04095377||Hammorhage|
89149064|NCT04095377||TBI|
89149065|NCT04095377||Concussion|
89149066|NCT04095377||Fibromyalgia|
89149067|NCT04095377||ABD|
89149068|NCT04095377||ADHD|
89149069|NCT04095377||MCI|
89149070|NCT04095377||DEMENTIA|
89149071|NCT04095377||COGNITIVE IMPAIRMENT|
89149072|NCT04095377||COGNITIVE DECLINE|
89149073|NCT04095377||MS|
89149074|NCT03968874|Experimental|Light box|Commercially available lightbox emitting 10,000 lux of light. Subjects asked to use lightbox everyday for an hour for 4 weeks upon waking.
89149075|NCT03968874|Sham Comparator|Negative Ion Generator|Commercially available negative ion generator. Subjects asked to use everyday for an hour for 4 weeks upon waking.
89149076|NCT05661630|Experimental|EX-PLISSIT|
89149077|NCT05661630|No Intervention|CONTROL|
89149078|NCT02696772|Experimental|Energy balance|Intervention day diet containing 100% of estimated energy requirements
89149079|NCT02696772|Experimental|Energy restriction|Intervention day diet containing 25% of estimated energy requirements
89149080|NCT05242133|Experimental|CinnaGen peginterferon beta-1a|Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
89149081|NCT05242133|Active Comparator|CinnoVex®|Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
89149082|NCT03965832|Experimental|HFNT|Patients who meet the eligibility criteria will be randomized to receive HFNT and then crossover to other device during the study procedures.
89149083|NCT03965832|Experimental|Standard oxygen|Patients who meet the eligibility criteria will be randomized to receive Standard oxygen and then crossover to HFNT during the study procedures.
89149084|NCT02845037|Experimental|2 mg or placebo|BIA 5-453 or placebo
89149085|NCT02845037|Experimental|10 mg or placebo|BIA 5-453 or placebo
89149086|NCT02845037|Experimental|20 mg or placebo|BIA 5-453 or placebo
89149087|NCT02845037|Experimental|50 mg or placebo|BIA 5-453 or placebo
89149088|NCT02845037|Experimental|100 mg or placebo|BIA 5-453 or placebo
89149089|NCT02845037|Experimental|200 mg or placebo|BIA 5-453 or placebo
89149090|NCT02845037|Experimental|400 mg or placebo|BIA 5-453 or placebo
89149091|NCT02845037|Experimental|600 mg or placebo|BIA 5-453 or placebo
89149092|NCT02845037|Experimental|900 mg or placebo|BIA 5-453 or placebo
89149093|NCT02845037|Experimental|1200 mg or placebo|BIA 5-453 or placebo
89149094|NCT04206917|Experimental|Multi Pulse Therapy|Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.
89149095|NCT04185870|Experimental|3D scan and standard photography arm|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum. In addition, all participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
89149096|NCT02844725|Experimental|VVZ-149 injection|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 9.5 hours.
89149097|NCT02844725|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
89149098|NCT00621816|Active Comparator|1|Blinded nitroprusside infusion
89149099|NCT00621816|Placebo Comparator|2|Blinded placebo infusion
89149100|NCT04186104|Experimental|Patients with routine outpatient service process|After registration, the patient waits in line at the door of the doctor's office. His doctor uses traditional methods to enter medical records by hand and make diagnosis independently. Then the patient waits in line to pay the bill and queues up for examination. Finally, the patient would take the examination report back to the doctor.
89149101|NCT04186104|Experimental|Patients with AI assisted outpatient service process|After registration, the patient binds his information to the mobile phone application through outpatient' number. First, AI system would ask the patient a series of questions. Then it would make a judgment based on the patient's response. The system transmits the examination items to the doctor's computer and, with the doctor's approval, sends items back to the patient. So, patient could go straight to do the examination. While waiting for his turn, the patient enters the phone program again, and the AI system collects his medical history. The information is sent back to the doctor. When the patient goes to the doctor's office with the examination report, the doctor's computer already has his medical records. The doctor only needs to adjust the history according to the actual situation. After writing the medical history, the AI system could automatically make the diagnosis. Doctor uses the AI' results and his own judgment to make a comprehensive diagnosis.
89149102|NCT05662644|Active Comparator|Feasibility of Esophagectomy Esophageal Cancer|Minimally Invasive Surgery for Esophageal Cancer: feasibility
89149103|NCT05662644|Active Comparator|Outcome of Esophagectomy Esophageal Cancer|Minimally Invasive Surgery for Esophageal Cancer: outcome
89149104|NCT00621972||Observation|Chronic kidney disease patients presenting for fisulta evaluation with documented GFR<30ml/min by abbreviated MDRD calculation.
89149105|NCT04186026|Other|Saline+Saline|
89149106|NCT04186026|Other|Neurotensin+Saline|
89149107|NCT04186026|Other|GLP-1+Saline|
89149108|NCT04186026|Other|Neurotensin + GLP-1|
89149109|NCT00900731|Experimental|Indacaterol 150 µg|Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
89149110|NCT00900731|Active Comparator|Tiotropium 18 µg|Participants received tiotropium 18 μg delivered via the manufacturer's proprietary inhalation device (HandiHaler®) plus placebo to indacaterol delivered via a single-dose dry-powder inhaler (SDDPI) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
89149111|NCT00639054||Newly diagnosed patients|Newly diagnosed high-dose therapy candidates. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
89149112|NCT00639054||Relapse patients|Formerly high-dose treated patients with progressive disease. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
89149113|NCT00639054||Healthy controls|Healthy blood and bone marrow donors. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) for genetic analyses serving to compare normal bone marrow with bone marrow from multiple myeloma patients.
89149114|NCT05368662|Experimental|Children with home ventilation|
89149115|NCT00622050|Experimental|1|This arm will be experiencing the same protocol as the control group, only their TV viewing time will be reduced. The TV viewing time reduction is the experimental intervention.
89149116|NCT00622050|Active Comparator|Control|The control group will be experiencing the exact protocol; only their TV viewing time will not be reduced.
89149117|NCT05241899|Experimental|Fruquintinib + RC48|Fruquintinib + RC48
89149118|NCT02691234|Experimental|Extracorporeal Shockwave Therapy and debridement|The treatment will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing before each treatment. The transducer device will be positioned against the lesion area and shockwaves will be delivered at a gradually increasing energy, with a maximum energy level of 0.09mJ/mm2
89149119|NCT02691234|Active Comparator|debridement and cleansing.|The standard treatment to the control group and the treatment group will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing. The physician will treat the patient in regard to his medical state: antibiotic medication if needed, dressing and off loading with Orthotic devices
89149120|NCT02687490|Experimental|Abraxane|Abraxane: 125 mg/m2, D1, D8, D15 every 28 days
89149121|NCT03851783|Experimental|Solar-powered oxygen|Solar panels used to drive an oxygen concentrator will deliver medical grade oxygen at a rate of 1-5L/min, for the treatment of children with hypoxemia.
89149122|NCT03851783|No Intervention|Standard of care|Patients presenting with hypoxemia and pneumonia will be treated by standard of care prior to the implementation of solar-powered oxygen at a chosen site. This may include some allocation of oxygen via cylinders, but will likely be minimal or not available.
89149123|NCT03843840||Diseased Retina|
89149124|NCT04034160|Experimental|burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The beef patty (Beef Patty Chuck) will be 80% lean and 20% fat.
89149125|NCT04034160|Active Comparator|vegetarian burger consumption group|Each participant will consume a burger with a whole wheat bun, lettuce, tomatoes, and vegan mayonnaise (free of cholesterol) for one meal. The burger patty will be 4 ounces. The vegetarian patty (Impossible Burger) will be 18% fat.
89149126|NCT05241821||Conservative treatment|patients with periprocedural stroke after TAVI, treated conservatively
89149127|NCT05241821||Neuro-intervention|patients with periprocedural stroke after TAVI, treated with neuro-intervention
89149128|NCT05337371||Philips ePatch® 2.0|Patients who are discharged from the hospital with ECG patch (Philips ePatch® 2.0).
89149129|NCT04187508|Experimental|AZD8154|Subjects will receive AZD8154 QD dosing for 10 days
89149130|NCT04187508|Placebo Comparator|Placebo|Subjects will receive AZD8154 matching placebo QD dosing for 10 days
89149131|NCT03497507|Placebo Comparator|Sham bracelet|Patients randomized to sham group will wear bracelets on both hands which will not apply acupressure
89149132|NCT03497507|Experimental|Acupressure bracelet|Patients randomized to the experimental group will wear bracelets on both hands which will apply acupressure to the P6 acupoint.
89149133|NCT00632957|Active Comparator|Fish oil|
89149134|NCT00632957|Placebo Comparator|Placebo|
89149135|NCT00650819|Experimental|Ezetimibe + Simvastatin|
89149136|NCT00650819|Active Comparator|Simvastatin|
89149137|NCT00650819|Active Comparator|Ezetimibe|
89149138|NCT05662410|Experimental|Aflibercept treatment group|Patients receiving three monthly aflibercept injections
89149139|NCT03741179|Experimental|ASA-withdrawn group|ASA treatment will be withdrawn if patients present an sFlt/PlGF < 38 at 24+0-27+6 weeks of gestation.
89149140|NCT03741179|No Intervention|ASA group|ASA treatment will continue until 36 weeks of gestation if patients present an sFlt/PlGF ratio < 38 at 24+0-27+6 weeks of gestation.
89149141|NCT00622128|Experimental|1|Pilot study. Developing intervention
89149142|NCT02689362|Experimental|Evogliptin 2.5mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
89149143|NCT02689362|Experimental|Evogliptin 5.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
89149144|NCT02689362|Experimental|Evogliptin 10.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
89149145|NCT02689362|Active Comparator|Sitagliptin 100mg+Placebo Evogliptin|SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.
89149146|NCT02687256|Experimental|Protocol 1: Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
89149147|NCT02687256|Experimental|Protocol 1: Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
89149148|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 1|Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).
89149149|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 2|Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).
89149150|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 3|Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).
89149151|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 4|Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).
89149152|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 5|Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).
89149153|NCT02687256|Experimental|Protocol 2 (Part 2): Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
89149154|NCT02687256|Experimental|Protocol 2 (Part 1): Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
89149155|NCT05337215|Active Comparator|Control group|While the IIF was applied to control group at the first meeting in the postpartum ward, FIAS was administered by phone or home visit in the third month after the face-to-face interview.There was any intervention for this group
89149156|NCT05337215|Experimental|kangaroo father care|While the IIF was applied to control group at the first meeting in the postpartum ward, FIAS was administered by phone or home visit in the third month after the face-to-face interview.. the first KC was applied within the first 4-6 hours after birth, and the second KC was applied in the postpartum ward under the supervision of the researcher on the first day after birth. The third KC was performed by the fathers themselves at home on the third postpartum day after discharge. Immediately afterwards, the researcher observed the father and baby from an appropriate distance, and the father and the baby had skin-to-skin contact for mean 15-20 minutes.
89149157|NCT00622206|Active Comparator|1|Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
89149158|NCT03582293|Active Comparator|Tranexamic Acid|Tranexamic acid 500mg two times a day orally for a total of 28 days
89149159|NCT03582293|Placebo Comparator|PLACEBO|Placebo capsules two times a day orally for a total of 28 days
89149160|NCT04185636||Skin Graft Patients|There will only be 1 group, patients receiving a skin graft and MolecuLight i:X imaging
89149161|NCT00639210|Other|A|Supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.
89149162|NCT00639210|No Intervention|B|
89149163|NCT03574337|Active Comparator|Sugammadex|Patient's will receive sugammadex at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight and TOF ratio by the pharmacy. It will be a one time dose at the end of the case
89149164|NCT03574337|Active Comparator|Neostigmine/glycopyrrolate|Patient's will receive neostigmine/glycopyrrolate at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight (50mcg/kg of neostigmine with an equivalent volume to volume ratio of glycopyrrolate). It will be a one time dose at the end of the case
89149165|NCT03574337|No Intervention|No reversal administered|No reversal administered at the end of the case
89149166|NCT02689596|Active Comparator|OT|Oxytocin
89149167|NCT02689596|Placebo Comparator|Placebo|Placebo
89149168|NCT02691312||Type 1 diabetes (T1D)|Pediatric patients with type 1 diabetes (T1D) will have an eye exam using the Digital Retinography System (DRS) taking non-mydriatic fundus images. If the test is positive or inconclusive, subjects will be notified and referred to an ophthalmologist for a dilated retinal exam. A chart review and questionnaire will be completed to evaluate for risk factors predisposing subjects to diabetic retinopathy.
89149169|NCT00583817|Experimental|Ascending Aortic Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the ascending aorta.
89149170|NCT00583817|Experimental|Arch Branch Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the aortic arch.
89149171|NCT00583817|Experimental|Thoracoabdominal Aortic Arm|Investigational endovascular stent-graft implantation to exclude thoracoabdominal aortic pathology including aortic aneurysms, renal artery aneurysms, and superior mesenteric artery aneurysms.
89149172|NCT04185948|Experimental|Mediterranean diet plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
89149173|NCT04185948|Active Comparator|Eatwell guide plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
89149174|NCT02687334||Standard general anesthesia induction|Patients scheduled for elective surgery at the First Hospital of China Medical University will be recruited for the study beginning in February 2016.We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia
89149175|NCT00212771|Experimental|Arm 1|
89149176|NCT00212771|Active Comparator|Arm 2|
89149177|NCT03710291|Experimental|TRC101|
89149178|NCT03710291|Placebo Comparator|Placebo|
89149179|NCT03842436|Experimental|Digital Pills|Digital Pills containing Truvada ingested once daily as PrEP
89149180|NCT03836586|Experimental|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
89149181|NCT03836586|Active Comparator|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
89149182|NCT03822312|Experimental|DBT-TOBI|"Subjects will be imaged using DBT-TOBI at the time points indicated in the Study Calendar (Baseline, before cycle 2, and additional optional time points).~Both breasts will be measured in turn.~Each breast is symmetrically centered on the x-ray detector/optical illuminator and is first compressed according to standard mammography procedures to determine the amount of force needed for each given patient~An optional Magnetic Resonance Imaging TOBI (MRI-TOBI) scan will also be performed."
89149183|NCT02690753|Experimental|Tailored repositioning + Standardised incontinence care + TAP|A protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
89149184|NCT02690753|Experimental|Standard repositioning + Standardised incontinence care + TAP|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
89149185|NCT02690753|No Intervention|Usual care|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care. Instead of using comfort Shield® barrier cream cloths, incontinence care will be given to patients using the standard procedure on the ward. Instead of using the turn and position system, patients will be turned according to the standard procedure on the ward.
89149186|NCT00622362|Active Comparator|A|Subcutaneous administration
89149187|NCT00622362|Experimental|B|Sublingual administration
89149188|NCT00622362|Placebo Comparator|C|Sublingual administration
89149189|NCT02687178|Active Comparator|Canrenone 50 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
89149190|NCT02687178|Active Comparator|Canrenone 100 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
89149191|NCT03711318|Experimental|Short-term treatment with buprenorphine|Short-term treatment with buprenorphine
89149192|NCT03704298|Experimental|Axicabtagene ciloleucel plus utomilumab|"Phase 1: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by axicabtagene ciloleucel treatment on Day 0 plus utomilumab on study Day 1 or study Day 21 and continuing once every 4 weeks (Q4W) for 6 months or until Progressive Disease, whichever comes first.~Phase 2: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by axicabtagene ciloleucel and utomilumab based on the dose/regimen selected to move forward from the Phase 1 portion of the study as recommended by the internal Safety Review Team."
89149193|NCT00638430||1|low myopic group
89149194|NCT00638430||2|moderate myopic group
89149195|NCT03434652|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
89149196|NCT03434652|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
89149197|NCT02687022|Experimental|Myopia (Peramis)|Peramis aberrometry: 30 consecutive LASIK candidates with myopia and regular astigmatism who agree to participate in the study will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer.
89149198|NCT02687022|Active Comparator|Myopia (iDesign)|iDesign aberrometry: The same 30 consecutive LASIK candidates scanned in the Myopia (Peramis) arm will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
89149199|NCT02687022|Experimental|Irregular astigmatism (Peramis)|Peramis aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer
89149200|NCT02687022|Active Comparator|Irregular astigmatism (iDesign)|iDesign aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
89149201|NCT04208568|Active Comparator|Gallbladder retrieval from umbilical port|Gallbladder retrieved from 10 mm umbilical port.
89149202|NCT04208568|Active Comparator|Gallbladder retrieval from epigastric port|Gallbladder retrieved from 10 mm epigastric port.
89149203|NCT04185714|Experimental|Experimental group|Experimental group will be applied Kinesotaping , exercise programme will be given.
89149204|NCT04185714|No Intervention|Control group|Exercise programme will be given.
89149205|NCT04185714|Placebo Comparator|Placebo group|Sham taping will be applied, exercise programme will be given.
89149206|NCT04186962|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
89149207|NCT04186962|No Intervention|Usual care|Usual care
89149208|NCT02681874|Experimental|Group A (Treatment Arm)|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Sessions are 90 minutes. Groups consist of a maximum of five parents. Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions. Parent Leaders receive a week-long leadership training to deliver the program and will be supervised by the PI who is a licensed clinical psychologist.
89149209|NCT02681874|Active Comparator|Group B (Control Arm)|Parents in the control condition will receive the Smart and Secure Children (SSC) program's written handouts. Handouts include didactic curriculum content and instruct parents to write goals and document goal progress.
89149210|NCT02689050||Patients with lymphadenopathy|Patients ≥ 18 years of age, with (suspected) NSCLC or suspected sarcoidosis, and at least one suspected mediastinal/hilar lesion that are scheduled for standard diagnostic endosonographic workup will undergo additional needle based confocal laser endomicroscopy (nCLE) measurements of suspected lesions.
89149211|NCT02687100|Experimental|Beclomethasone|Patients will receive beclomethasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning. The solution will be aspirated 15 minutes after the instillation.
89149212|NCT02687100|Placebo Comparator|Placebo|Patients will receive 8 mL of saline without any drug.
89149213|NCT00639288|Experimental|1|modified CPT-C
89149214|NCT04185480|No Intervention|Conventional|Historical cohort of patients that underwent axillary clearance without hemopatch.
89149215|NCT04185480|Experimental|Intervention|Prospective cohort of patient undergoing axillary clearance with hemopatch
89149216|NCT02688972|Experimental|cold water immersion|
89149217|NCT02688972|Other|control|13 volunteers
88804222|NCT05776537|Other|Group (1) confirmed bronchial asthma and group (2) bronchial asthma rule out|After completing all the clinical, functional, radiologic, and endoscopic assessment, the patients were classified into two groups: Group (1) (89 patients) whose diagnosis confirmed to be bronchial asthma and group (2) (111 patients) with diagnoses other than bronchial asthma.
88804223|NCT05776485|Experimental|Chronic tendinopathy patients|
88804224|NCT05776485|Experimental|Healthy controls|
88804225|NCT05776433||Unilateral upper extremity lymphedema women after breast cancer treatment|The study group consisted of women aged 18-50 years with unilateral upper extremity lymphedema after breast cancer treatment.
88804226|NCT05776407|Experimental|ThisCART19A cells infusion|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used to treat patients with r/r B cell Lymphoma.
88804227|NCT05776212||Work package 1 - Optimisation of 18F-fluoride PET in ATTR-CM|Optimise 18F-fluoride PET imaging of ATTR-CM with increased myocardial tissue to background ratio (TBR) uptake values to provide a state-of-the-art imaging modality for use in the other work packages. (n=15, ATTR-CM subjects)
88804228|NCT05776212||Work package 2 - Differentiation ATTR-CM from phenocopies|Establish the optimised 18F-fluoride TBR threshold that best differentiates ATTR-CM (n=100) from phenocopies (subjects with light chain amyloidosis, n=20 and subjects with hypertrophic cardiomyopathy, n=20).
88804229|NCT05776212||Work package 3 - In vivo calibration of 18F-fluoride PET|In vivo calibration of 18F-fluoride PET as a marker of the myocardial ATTR burden, calibrating optimised TBR values against the current imaging standard cardiac magnetic resonance imaging extracellular volume. (Subjects with ATTR-CM, n=100)
88804230|NCT05776212||Work package 4 - Disease progression and treatment response|Establish ability of 18F-fluoride PET to track disease progression and treatment response in ATTR-CM at one year follow up. (Subjects with ATTR-CM, n=100)
88804231|NCT05776186||Before spinal anesthesia|Before spinal anesthesia with heavy bupivacaine 12.5 mg is administrated.
88804232|NCT05776186||After spinal anesthesia|After spinal anesthesia with heavy bupivacaine 12.5 mg is administrated.
88804233|NCT05776173|Experimental|BD211 Adult Single-Dose group|Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: 5×10*6 cells /kg ~ 10×10*6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211 for adults
88804234|NCT05776043|Active Comparator|SGLT 2 Inhibitor|Empagliflozin (n=341) or Dapagliflozin (n=341): 9 months of treatment
88804235|NCT05776043|Placebo Comparator|Placebo with a switch to SGLT 2 Inhibitor|Placebo (n=682) for 3 months of treatment with a subsequent switch to Empagliflozin (n=341) or Dapagliflozin (n=341): 6 months of treatment
88804236|NCT05775965|Experimental|Rivaroxaban 10mg|Rivaroxaban 10mg daily for 35 days post hip fracture surgery
89149218|NCT02153645|Experimental|240mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 240mg daily for 12 weeks post two week titration phase.
89149219|NCT02153645|Experimental|320mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 320mg daily for 12 weeks post a two week dose titration phase.
89149220|NCT02153645|Placebo Comparator|Placebo tablets|Placebo Tablets matching Amantadine HCl ER Tablets taken daily for 16 weeks.
89149221|NCT02688738|No Intervention|Control|Standard of care
89149222|NCT02688738|Active Comparator|Treatment|Oral doxycycline
89149223|NCT02688816||Women undergoing cervical cancer screening|"HIV-infected women will undergo a cervical cancer screening examination using the VIA method. A digital photograph of the cervix will also be taken to aide visual screening. This is known as digital cervicography, and it is currently standard of care within cervical cancer screening clinics in Zambia.~Cervical samples will be collected for molecular testing using Xpert HPV, and OncoE6. Cervical biopsy samples will also be obtained for confirmatory histopathologic diagnosis."
89149224|NCT05335265|Active Comparator|FIT (face-to-face inhaler training)|"Face-to-face inhaler training.~o The trainers watched the Turkish Thoracic Society (TTS) MDI training video before giving the training.~Training given 3 times on the first day, 2 times on the 2nd day, and once on the 3rd day.~During discharge, inhaler technic was checked according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by TTS.~The trainer and the inhaler technical controller are different."
89149225|NCT05335265|Experimental|VIT (virtual inhaler training)|"Virtual Training was gave 3 times on the first day, 2 times on the 2nd day, and once on the 3rd day (discharge) by the TTS Virtual training video.~During discharge, inhaler technics of the patient's were controlled according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by the TTS.~o The inhaler technique controller and the trainer are different."
89149226|NCT02688582|Experimental|TCI group|Patients who receive cefepime based on TCI for a maximum of 5 days with a target concentration of cefepime of 16 mg/L.
89149227|NCT05123183|Active Comparator|Acupressure group|Acupressure will be applied to ST36 and CV17 points.
89149228|NCT05123183|Active Comparator|Back Massage|Back massage will be applied.
89149229|NCT05123183|Active Comparator|Control Group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
89149230|NCT04201691|Experimental|conventional group|Conventional group is received conventional rehabilitation program.
89149231|NCT04201691|Experimental|mobilization group|Mobilization group is received cervical mobilization in addition to conventional rehabilitation program.
89149232|NCT02686788|Experimental|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
89149233|NCT02686866|Experimental|Body composition measurement|All patients will undergo body composition measurement with dual-energy X-ray absorptiometry and bioelectrical impedance analysis methods. Hand grip strength will also be performed.
88804237|NCT05775965|Experimental|acetylsalicylic acid (ASA) 81mg daily|acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
88806020|NCT02531802|Experimental|Adult: ETVAX (Full) + 10 ug dmLT|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
88806021|NCT02531802|Placebo Comparator|Adult: Placebo|Adult arm (18-45 year olds) receiving a placebo on days 0 and 14
88806022|NCT02531802|Experimental|24-59 months: ETVAX (1/4)|24-59 month old children receiving a quarter adult dose (2.5 x 10^10 inactivated E. coli bacteria) of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
89149234|NCT05083871||Learners of the European Trauma Course|Learners attending the European Trauma Course
89149235|NCT02686710|Active Comparator|VIMA|Patiens receiving volatile induction and maitenance of anesthesia
89149236|NCT02686710|Active Comparator|TIVA|Patiens receiving total intravenous anesthesia based on propofol
89149237|NCT02686710|Active Comparator|Combi|Patiens receiving total intravenous induction and volatile anesthesia
89149238|NCT01818167|Active Comparator|10% Benzoyl Peroxide Topical Body Wash|Subjects will use 10% benzoyl peroxide twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
89149239|NCT01818167|Active Comparator|Provodine Topical Cream|Subjects will use Provodine Topical Cream twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
89149240|NCT02686632|Experimental|Palate Brushing|"In this group the intervention is palatal brushing, performed by the participants following each meal for a period of 6 months. This will be performed using the provided toothbrush (device). The results will determine if brushing the palate in an efficient intervention for reducing the microbial count and inflammation associated with denture stomatitis."
89149241|NCT02686632|No Intervention|Regular Oral Hygiene|The participants in this study arm will not be prescribed or allocated any intervention. The participants will be asked to continue with the regular hygiene and denture maintenance practices for the duration of the trial.
89149242|NCT02686944|Experimental|Intuvax (ilixadencel)|"Intuvax (ilixadencel) will be administered 2 or 3 times. First injection Day 1 (pat 1-12), second injection 14 days after the first vaccination (pat 1-12), third injection 28 days after the second vaccination (only pat 7-12).~Max 10 000 000 allogeneic dendritic cells/ml per injection."
89149243|NCT01773083|Experimental|unfractionated heparin|25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)
89149244|NCT01773083|Placebo Comparator|placebo|Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)
89149245|NCT02436252|Experimental|DSP-7888|
89149246|NCT04201847|Active Comparator|Infertile women with normal ovarian reserve|Infertile women with normal ovarian reserve will be included.
89149247|NCT04201847|Active Comparator|Infertile women with high ovarian reserve|Infertile women with high ovarian reserve will be included.
89149248|NCT04201847|Active Comparator|Infertile women with poor ovarian reserve|Infertile women with poor ovarian reserve will be included.
89149249|NCT02354898|Experimental|BBI503, BBI503 and Sorafenib|
89149250|NCT04185324|Experimental|Standard zippering vest|Children receive three supervised sessions for them to practice engaging and pull up a zipper, using a standard teaching zippering vest.
89149251|NCT04185324|Experimental|Modified zippering vest|Children receive three sessions of specially designed zippering instruction using a modified zippering vest, where they can practice engaging and pulling up a zipper after being read a related story.
89149252|NCT04326660|No Intervention|Control|Participants in the control group will receive a Fitbit Alta-Heart Rate (HR) and 12 weekly non-tailored educational modules via WeChat on general health topics that are important to 20-45 year-old women in China. Topics include intimate partner violence, anxiety, depression, sexually transmitted infections, HIV, unintended pregnancy, hepatitis B, and general cancer prevention.
89149253|NCT04326660|Experimental|SCOPE-Chinese Women Intervention|"SCOPE-Chinese Women intervention content and methods: SCOPE-Chinese Women is a smartphone- based intervention.~Component 1. All study participants will receive a Fitbit Alta-HR tracking device to wear daily. Each participant will receive in-person, training on how to access the app and their tracking data. If a participant has not used the fitness device and app for more than one week, a WeChat reminder message will be sent to the participant.~Component 2. Participants will receive 12 weekly culturally appropriate and evidence-based SCOPE-Chinese Women educational modules along with tailored tips and messages via WeChat. Each module will include three educational sessions that last less than 45 minutes total.~Component 3. Six bi-weekly messages will be sent to participants via WeChat to encourage positive behavioral changes. Each participant's message content will be based on the participant's tracker information, personal goals, and preferences."
89149254|NCT03246035|Active Comparator|Control Group (Standard Care)|The control group will receive outpatient follow-up, medication advice and lifestyle guidance as prescribed at discharge from the ED or hospital.
89149255|NCT03246035|Experimental|Intervention Group|The intervention will consist of contacting the patient 5 days post-discharge and arranging definitive outpatient follow-up and providing targeted medical and lifestyle advice based on deficient domains identified at baseline.
89149256|NCT04591613|Other|Standardized clinical and paraclinical follow-up|"Standardized clinical and paraclinical follow-up will be offered in one of the referring investigator centers. Patients will be able to benefit from additional biological samples. Questionnaires will be completed by the patient or with the help of clinical research staff in paper format.~All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.~Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.~Total serum, plasma and naso-paaryngeal samples will be collected."
89149257|NCT00638586||1|Femoral access
89149258|NCT00638586||2|Radial access
89149259|NCT05337059|Experimental|Transpulmonary based ventilation strategy|PEEP and tidal volume will be set to target expiratory and inspiratory transpulmonary pressures of 0 and 20 cmH2O, respectively.
89149260|NCT04265664|Experimental|Telerehabilitation|Receives the telerehabilitation protocol
89149261|NCT05336981|Experimental|Low-Level Light Therapy ACTIVE|Patients will receive applications of photobiomodulation directly in the region extraoral of the salivary glands ( parotid and submaxilar) will be given once a week for another 6 weeks.
89149262|NCT05336981|Sham Comparator|Low-Level Light Therapy sham|Patients will receive applications of photobiomodulation sham directly in the region extraoral of the salivary glands ( parotid and submaxilar) will be given once a week for another 6 weeks
89149263|NCT04186728|Placebo Comparator|Placebo to magnesium|Participants will be asked to consume a daily placebo (cellulose) capsule for 12 weeks. They will then cross-over and consume 200mg of elemental magnesium in the form of magnesium glycinate daily for 12 weeks.
89149264|NCT04186728|Experimental|Magnesium to placebo|Participants will be asked to consume 200mg of elemental magnesium in the form of magnesium glycinate daily. They will then cross-over and consume a daily placebo (cellulose) capsule for 12 weeks.
89149265|NCT00092729|Experimental|1|etoricoxib
89149266|NCT00092729|Placebo Comparator|2|Placebo to match etoricoxib
89149267|NCT00092729|Active Comparator|3|naproxen sodium
89149268|NCT02686476|Active Comparator|Empagliflozin dose group|Patient Receive Standard of Care with Empagliflozen
89149269|NCT02686476|No Intervention|Standard dose group|Standard care for Type 2 Diabetes Mellitus upgraded without Empagliflozin
89149270|NCT04001075|Experimental|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
89149271|NCT04972175|Active Comparator|Rapid Insulin lispro - Conventional bolus|Participants will use subcutaneously-delivered rapid insulin (lispro) through pump therapy.
89149272|NCT04972175|Experimental|BC LisPram - Conventional bolus|Participants will use subcutaneously-delivered BC LisPram through pump therapy.
89149273|NCT04972175|Experimental|BC LisPram - Dual wave bolus|Participants will use subcutaneously-delivered BC LisPram through pump therapy. During dual wave bolusing, 50% of the prandial bolus is delivered immediately, and the other 50% delivered over the next 30 minutes.
89149274|NCT00616382|Experimental|Stepwise Indo|Stepwise escalating doses of indomethacin, until ductal closure or maximum of 1 mg/kg/dose.
89149275|NCT00616382|Experimental|PTX|Combined administration of indomethacin and pentoxifylline, an inhibitor of TNF alpha
89149276|NCT02690831|Active Comparator|Inspiratory Muscle training (IMT)|"The IMT program consisted of supervised and domiciliary exercises:~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 6 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~First week: 30% Maximum Inspiratory Pressure (MIP)~Second week: 40% MIP~Third week: 50% MIP~Fourth week: 50% MIP~Fifth week: 60% MIP~Sixth week: 60% MIP~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen."
89149277|NCT02690831|Experimental|IMT + Manual Therapy and Motor Control Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~- MT:~Upper cervical region mobilization in flexion~Lower cervical postero-anterior mobilization + maintained traction~Costovertebral joint postero-anterior mobilization~Thrust dorsal~Cervical postero-anterior mobilization~- MCE:~Isometric contraction of the deep neck flexors.~Isometric contraction of the neck extensors.~Neural self-mobilization.~Cervical retraction with theraband.~Sphinx.~Scapular adduction exercises in prone.~Scapular adduction exercises in sitting position with theraband."
89149278|NCT02686398|Active Comparator|Fluad|88 CKD patients were vaccinated with Fluad.
89149279|NCT02686398|Active Comparator|Agrippal|86 CKD patients were vaccinated with Agrippal.
89149280|NCT01643837|No Intervention|Standard|Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.
89149281|NCT01643837|Sham Comparator|Light Touch (LT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.~Light touch protocol."
89149282|NCT01643837|Experimental|Osteopathic Manipulative Treatment (OMT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.~OMT Protocol."
89149283|NCT04213430||Training dataset|Retinal images collected from hospitals and multiple screening sites all over China
89149284|NCT04213430||Validation dataset|Retinal images separated from training dataset
89149285|NCT04213430||Testing dataset|Retinal images prospectively collected from the hospitals and ocular disease screening sites totally different from training dataset
89149286|NCT00617318|Experimental|A|
89149287|NCT00617318|Placebo Comparator|B|
89149288|NCT04967573|Experimental|Prophylactic Anticoagulation|Rivaroxaban 10 mg od for 3 months
89149289|NCT04967573|Active Comparator|Therapeutic Anticoagulation|Rivaroxaban 20 mg od for 3 months
89149290|NCT04141280||Insomnia group|According to the inclusion and exclusion criteria, 150 patients with insomnia were selected, which were divided into five groups: liver stagnation fire syndrome, phlegm heat syndrome, yin deficiency fire dysfunction syndrome, heart spleen deficiency syndrome and heart deficiency biliary syndrome.
89149291|NCT04141280||Normal group|According to the inclusion and exclusion criteria, 30 normal people were selected.
89149292|NCT04912973|Active Comparator|inverse Kinematic Alignment|
89149293|NCT04912973|Active Comparator|adjusted Mechanical Alignment|
89149294|NCT00639444|Active Comparator|Gluten free diet|the intervention in this group is keeping a gluten-free diet from 0 to 12 months
89149295|NCT00639444|No Intervention|Gluten containing diet|infants in this group are started on gluten-containing cereals at 6 months (control group)
89149296|NCT02688504||serious road accidents|Drivers involved in serious road accidents (hospitalization > 24 hours)
89149297|NCT02688504||non-serious road accidents|drivers involved in non-serious road accidents (hospitalization < 24 hours).
89149298|NCT04213352|No Intervention|Control Group|The subjects will be asked to type on a computer for 5 minutes without splint or taping. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
89149299|NCT04213352|Experimental|Splint Group|The subjects will be asked to type on a computer for 5 minutes with a splint. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
89149300|NCT04213352|Experimental|Rigid Taping Group|The subjects will be asked to type on a computer for 5 minutes with rigid taping which limits the wrist flexion at the dominant side. The upper trapezius muscle activation will be recorded by surface EMG during the task. The mean values will be normalized according to Maximum Voluntary Isometric Contraction (MVIC) and %MVIC values.
89149301|NCT00617474|Experimental|1|Group of patient with anemia, that treated by erythropoietin
89149302|NCT00617474|Placebo Comparator|2|Patients group with anemia that treated by placebo
89149303|NCT04212104|Experimental|watch mukbang|participants are assigned to watch a dim sum mukbang by a famous host, Peggie Neo (https://youtu.be/2dRf535eAPK, accessed: 2018-9-12)
89149304|NCT04212104|Placebo Comparator|watch non-food content video|participants are assigned to watch the Big Bang Theory, The Euclid Alternative ( https://youtu.be/V8kUL9owk6Q, accessed: 2018-9-12).
89149305|NCT00619034|Experimental|latanoprost|Medical intervention cross-over
89149306|NCT00619034|Active Comparator|diclofenac|medical intervention
89149307|NCT00619034|Experimental|dorzolamide|dorzolamide eyedrops twice daily in one week
89149308|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149309|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149310|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149311|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149312|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149313|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149314|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149315|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149316|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149317|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149318|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149319|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149320|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149321|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149322|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149323|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
89149324|NCT01614912|Experimental|SM-13496|
89149325|NCT02688426|Sham Comparator|0J LLLT|The sham treatment is performed in the same way as treatment with LBP, however, with the apparatus switched off
89149326|NCT02688426|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
89149327|NCT04184856||Binge eating disorder (BED) patients|Individuals with BED diagnosis.
89149328|NCT04184856||non-BED controls|Individuals that do not experience binges
89149329|NCT04184856||subsyndromal BED controls|individuals that experience binges but do not fulfill the requirements for BED diagnosis.
89149330|NCT00622596|Experimental|Mobile Access to Buprenorphine|High risk populations accessing a mobile health care system can obtain Buprenorphine for treatment.
89149331|NCT02537886||Evaluation Group|Researchers will conduct a focus group to evaluate VIC after it has been developed and used by patients. Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC. We will use this information to enhance the generalizability of the VIC approach.
89149332|NCT02688348|Other|Ancillary-Correlative (late toxicity and QOL)|Patients complete the EORTC QLQ-BLM-C30 at baseline, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of chemo-radiotherapy.
89149333|NCT00638742|Experimental|1|
89149334|NCT02686242||spinal anesthesia|patients receive spinal anesthesia before general anesthesia
89149335|NCT02686242||general anesthesia|patients receive general anesthesia
89149336|NCT05661786||Observation cohort|
89149337|NCT05661786||Treatment cohort|
89149338|NCT00639522|Experimental|A|
89149339|NCT04186338||Patients with myelomeningocele|Patients diagnosed myelomeningocele with the neurological level between L5 and S3
89149340|NCT04186338||Healthy controls|age-, sex-, and body mass index-matched healthy controls
89149341|NCT02686086|Placebo Comparator|Standard hospital jet nebuliser|"Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a standard hospital jet nebuliser.~Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation."
89149342|NCT02686086|Active Comparator|Vibrating mesh nebuliser|Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a vibrating mesh nebuliser (Aerogen Solo) rather than the standard hospital nebuliser Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation.
89149343|NCT02685852|Active Comparator|Arm 1: Exenatide (5mcg) + Acarbose Placebo|Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose placebo immediately prior to the high-carb meal
89149344|NCT02685852|Active Comparator|Arm 2: Exenatide (5mcg) + Acarbose (25mg)|Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
89149345|NCT02685852|Placebo Comparator|Arm 3: Exenatide Placebo + Acarbose (25mg)|Exenatide placebo 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
89149346|NCT02685696|Experimental|Alexis O Retractor|Group 1 received the Alexis-O-Retractor at thet time of first Caesarean Section
89149347|NCT02685696|Active Comparator|Metal Retractor|Group 2 received the traditional self retaining metal Retractor at thet time of first Caesarean Section
89149348|NCT04185090|Active Comparator|ID1801|qd daily for 6days Intervention: Drug: administration of ID1801 for 6days.
89149349|NCT04185090|Active Comparator|ID1803|qd daily for 10days Intervention: Drug: administration of ID1803 for 10days.
89149350|NCT04185090|Experimental|ID1801 and ID1803|qd daily for 7days Intervention: Drug: administration of ID1801 and ID1803.
89149351|NCT02688036|Experimental|hypofractionated CRT|hypofractionated concurrent chemoradiotherapy
89149352|NCT02688036|Active Comparator|conventionally fractionated CRT|conventionally fractionated concurrent chemoradiotherapy
89149353|NCT02687802||Mechanical ventilation|Patients under mechanical ventilation for more than 24h
89149354|NCT02697162|Experimental|Antiseptic-coated catheter|Hydrophilic intermittent urinary catheter coated with octenidine chloride
89149355|NCT02697162|Placebo Comparator|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
89149356|NCT04185168|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 tablets)
89149357|NCT04185168|Placebo Comparator|control|2 tablets of placebo
89149358|NCT02685930||Pneumonia without ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Antibiotic choice and duration of therapy will not be influenced by the dedicated ICU stewardship team.
89149359|NCT02685930||Pneumonia with ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Recommendations for antibiotic choice and duration of therapy will be provided by the dedicated ICU stewardship team (consisting of pulmonary fellows and ICU pharmacists)
89149360|NCT04186182|Other|CICI - Feasibility trial study group|The feasibility of the entire CICI-protocol will be evaluated. See details above.
89149361|NCT00622674|Experimental|Bortezomib and Cetuximab|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2. A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
89149362|NCT02687880||All Subjects|"All subjects will undergo a surgical procedure (Testicular biopsy) to harvest their testicular tissue. In most cases, this will be done as part of their routine care but it is possible the subject may elect to have the procedure as part of a research only biopsy."
89149363|NCT02687724|Active Comparator|Standard treatment as per SmPC|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. They will then receive 100mgs/ 50mgs depending on their weight as per SmPC. Patients will report their modified partial mayo score and SHS score every 4 weeks (PRO) and provide it to the investigator site via a web based application.
89149364|NCT02687724|Experimental|Intervention Arm|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. As with Group 1, Patients will report their modified partial mayo and SHS score every four weeks ( the window for this will be +/- one week) and provide it to the investigator site via a web based application. In addition FCP, GLM DL and ADA shall be measured every four weeks.
89149365|NCT02685774|Other|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T) T: Test drug(CKD-395 0.25/500mg 2T)
89149366|NCT02685774|Other|TR group|T: Test drug(CKD-395 0.25/500mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T)
89149367|NCT00638976|Other|1.Integrilin, GSK|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
89149368|NCT00638976|Placebo Comparator|2|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
89149369|NCT00639756|Other|1|Placebo
89149370|NCT00639756|Active Comparator|2|Allopurinol given for 2 weeks with diet
89149371|NCT00622752|Experimental|1|EVT 302, 10 mg
89149372|NCT00622752|Experimental|2|EVT 302, 10 mg + NRT patch, 21 mg
89149373|NCT00622752|Experimental|3|NRT patch, 21 mg
89149374|NCT00622752|Placebo Comparator|4|Placebo to match EVT 302 and placebo patch to match NRT patch
89149375|NCT00640848|Experimental|1|
89149376|NCT00640848|Experimental|2|
89149377|NCT00640848|Experimental|3|
89149378|NCT00640848|Experimental|4|
89149379|NCT00640848|Experimental|5|
89149380|NCT03451578|Other|Advanced Dry macular degeneration|
89149381|NCT04104048||patients who were diagnosed as Anterior STEMI|"Patients who were diagnosed as Anterior STEMI according to criteria developed by the European Society of Cardiology.~Onset of maximal intensity of chest pain within 12 hours before procedure"
89149382|NCT02686008|Experimental|HPV negative tumors|10 patients with HPV negative tumors: Non-oropharyngeal tumors or p16 negative and HPV negative oropharyngeal tumors
89149383|NCT02686008|Experimental|HPV positive tumors|10 patients with HPV positive tumors: p16 positive and HPV positive tumors
89149384|NCT02685618|Experimental|Iloprost + M1006B offset by -10 mmHg|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg~Intervention: Drug: Iloprost + M1006B offset -10mmHg"
89149385|NCT02685618|Experimental|Iloprost + M1006B, No offset|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset~Intervention: Drug: Iloprost + M1006B, No offset"
89149386|NCT02685618|Placebo Comparator|Placebo + M1006B offset by -10 mmHg|"Double dummy 0.9% saline as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg~Intervention: Drug: Placebo + M1006B offset -10mmHg"
89149387|NCT02685618|Placebo Comparator|Placebo + M1006B, No offset|"Double dummy 0.9% saline as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset~Intervention: Drug: Placebo + M1006B, No offset"
89149388|NCT00602472|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
89149389|NCT00602472|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
89149390|NCT02681250|Experimental|Titanium-zirconium|Patients receiving titanium-zirconium implants
89149391|NCT02681250|Active Comparator|Titanium|Patients receiving titanium implants
89149392|NCT05664048|Experimental|Dry heat application group|"The participants were informed that they could use the thermophore whenever they felt pain throughout the menstrual cycle. On the first day of the period, they were asked to complete the Visual Analog Scale and Menstrual Symptom Questionnaire before using the thermophore; apply heat on their sole whenever they felt pain in the first three days of the menstrual period when pain is more intense; rate level of pain twice a day at 12-hour intervals on a daily basis, using the Visual Analog Scale; and complete the Menstrual Symptom Questionnaire on the last day of the period. On the other hand, the students in the control group completed only the related forms. The students who were previously trained on heat application were trained once again by the researcher as a reminder and then their written consents were obtained through the informed consent form."
89149393|NCT05664048|No Intervention|Control group|"The students in the control group completed only the related forms (Visual Analog Scale and Menstrual Symptom Questionnaire) in the period of the menstruation."
89149394|NCT00639834|Experimental|1|Active MDX-1342 given in combination with Methotrexate
89149395|NCT02685462|Active Comparator|Group 1 (Rosuvastatin)|Group 1 (12 subjects) will receive Rosuvastatin on Days 1 and 13.
89149396|NCT02685462|Active Comparator|Group 1 (Digoxin)|Group 1 (12 subjects) will receive Digoxin on Days 1 and 13.
89149397|NCT02685462|Active Comparator|Group 1 (Caffeine)|Group 1 (12 subjects) will receive Caffeine on Days 1 and 13.
89149398|NCT02685462|Active Comparator|Group 2 (Atorvastatin)|Group 2 (12 subjects) will receive Atorvastatin on Days 1 and 13.
89149399|NCT02685462|Experimental|Cenicriviroc|"Subjects in Group 1 and Group 2 will receive Cenicriviroc on Days 3-12.~Subjects in Group 3 will receive Cenicriviroc on Days 2-12."
89149400|NCT02685462|Active Comparator|Group 3 (Simvastatin)|Group 3 (12 subjects) will receive Simvastatin on Days 1 and 12.
89149401|NCT02685306|Active Comparator|Taxane|Taxane (Paclitaxel) weekly on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
89149402|NCT02685306|Experimental|Bavituximab plus Taxane|Bavituximab 3 mg/kg weekly PLUS Taxane (Paclitaxel) on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
89149403|NCT04184076|No Intervention|Dietary counseling alone|"Controls will be instructed to maintain their weight throughout the trial, and not to change their eating or physical activity habits. Controls will visit the research center on a weekly basis for weigh-ins. Body composition and metabolic disease risk variables will be assessed in control subjects every 12 weeks.~Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.~The blood draws will be taken at approximately 11:00 am. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
89149404|NCT04184076|Experimental|Time-restricted feeding (TRF) with dietary counseling|"Subjects will be instructed to eat ad libitum from 10:00 to 18:00 h daily, and fast from 18:00 to 10:00 h daily. During the 8-h feeding window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, subjects will be encouraged to drink plenty of water and will be permitted to consume energy-free beverages.~Subjects will complete a 3-d food record (2 regular day and 1 holiday) each week during the experiment.~The blood draws will be taken at approximately 11:00 am, especially prior to the first consumption of food by subjects in the TRF group. The following analyzes will be measured in plasma samples: ketones, fasting glucose, fasting insulin, hemoglobin A1c, liver function, renal function, albumin, lipid profiles, MMP-9, IL-6, TNF-alpha, exosome markers (phospho-IRS1, phospho-Tau, Abeta1-42). Metabolomic and lipidomic analyses will be performed on the baseline and 3-month time point plasma samples."
89149405|NCT00641628||1|
89149406|NCT02683044|Experimental|Li-ESWT 5 weeks|Consists of five sessions of Low-Intensity Extracorporeal Shock Wave Therapy , one per week, with 3000 pulses at 0,15 mg/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 2000 pulses to the body of the penis and 1000 pulses at its base. Total duration: 5 weeks.
89149407|NCT02683044|Active Comparator|Li-ESWT 3 weeks|Consists of six sessions of Low-Intensity Extracorporeal Shock Wave Therapy , two per week, with 1500 pulses each one at 0.1 mJ/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 900 pulses to the body of the penis and 600 pulses at its base. Total duration: 3 weeks.
89149408|NCT00639912|Active Comparator|A: low volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/kg/hour for 12 hours after the procedure, starting in the Cath Lab.
89149409|NCT00639912|Active Comparator|B: high volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath lab.
89149410|NCT00639912|Active Comparator|C: low volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
89149411|NCT00639912|Active Comparator|D: high volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
89149412|NCT04184544|Experimental|Maternal and Newborn health districts|Group one included maternal and newborn health districts. These districts are further divided into three sub groups. Sub group 1 will receive only interventions focusing on maternal health (1 district (Sangher)); sub group 2 will receive interventions focusing only on newborn health (1 district (Nasirabad)); sub group 3 will receive combined maternal and newborn interventions (two districts (, Lasbila and Badin).
89149413|NCT04184544|Experimental|Child Health|Group two will receive child health interventions focusing on the implementation of the global action plan for pneumonia and diarrhea (GAPPD [4districts, Qamabar Shahdadkot Muzaffargarh, Rahim Yar Khan Jafferabad).
89149414|NCT02683278|Experimental|Cognitive-Behavioral Therapy|Group-based cognitive-behavioral manualized treatment
89149415|NCT02683278|Experimental|Mindfulness-acceptance Therapy|Group-based mindfulness-acceptance manualized treatment
89149416|NCT02683278|Active Comparator|Education|Group-based manualized pain education
89149417|NCT02682732|Experimental|FDG-PET/CT|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be performed at diagnosis and at the end of induction chemotherapy (like cytarabine and daunorubicin). Then, patients will be followed to assess their response, and imaging-guided bone marrow sampling will be repeated in the likely event of disease relapse.
89149418|NCT02680938|Active Comparator|oxytocin group|10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
89149419|NCT02680938|Placebo Comparator|control group|1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
89149420|NCT05663970|Experimental|Virtual Group Social ABCs|- Participants complete the Group Social ABCs intervention program
89149421|NCT05663970|No Intervention|Active Control Condition|"Participants complete the active control condition:~3 bi-weekly (virtual) group-based sessions (i.e., groups of 4-8 parents, over 6 weeks)~psychoeducational curriculum not related to social-communication delivered by study personnel not directly involved in the intervention arm~Families may access any available services in their communities (i.e., treatment as usual), which are recorded~Families will be offered the option to do Group Social ABCs intervention program after completing the Control phase"
89149422|NCT02680782|Experimental|X4P-001 QD|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug once daily in the first period, followed by twice daily in the second dosing period.
89149423|NCT02680782|Experimental|X4P-001 BID|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug twice daily in the first period, followed by once daily in the second dosing period.
89149424|NCT02685228|Experimental|decitabine & gemcitabine|"This group was treated by low dose decitabine combinated with gemcitabine regimen. decitabine: 5mg/m2 d1-d5; gemcitabine: 1.0g/m2,d8,d15,d22. 28days for one cycle.~every 28days for one cycle"
89149425|NCT02685228|Active Comparator|gemcitabine|This group was treated by gemcitabine only. Gemcitabine: 1.0g/m2, d8,d15,d22; 28 days for one cycle. every 28days for one cycle
89149426|NCT02682576|Experimental|Brachial artery ultrasound imaging|Brachial artery ultrasound imaging is a non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery using high resolution continuous electrocardiogram-gated B-mode (2D) ultrasound imaging during reactive hyperemia.
89149427|NCT04183686|Experimental|Part A (SAD): Dose A1|Single dose A1 of ACT-1014-6470; soft capsule for oral use.
89149428|NCT04183686|Experimental|Part A (SAD): Dose A2|Single dose A2 of ACT-1014-6470; soft capsule for oral use.
89149429|NCT04183686|Experimental|Part A (SAD): Dose A3|Single dose A3 of ACT-1014-6470 under fasted and fed conditions, separated by at least 18 days; soft capsule for oral use.
89149430|NCT04183686|Experimental|Part A (SAD): Dose A4|Single dose A4 of ACT-1014-6470; soft capsule for oral use.
89149431|NCT04183686|Experimental|Part A (SAD): Dose A5|Single dose A5 of ACT-1014-6470; soft capsule for oral use.
89149432|NCT04183686|Experimental|Part A (SAD): Dose A6|Single dose A6 of ACT-1014-6470; soft capsule for oral use.
89149433|NCT04183686|Experimental|Part B (MAD): Dose B1|Multiple doses B1 of ACT-1014-6470; soft capsules for oral use.
89149434|NCT04183686|Experimental|Part B (MAD): Dose B2|Multiple doses B2 of ACT-1014-6470; soft capsules for oral use.
89149435|NCT04183686|Experimental|Part B (MAD): Dose B3|Multiple doses B3 of ACT-1014-6470; soft capsules for oral use.
89149436|NCT04183686|Experimental|Part B (MAD): Dose B4|Multiple doses B4 of ACT-1014-6470; soft capsules for oral use.
89149437|NCT05323760|Experimental|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
89149438|NCT00639990|Active Comparator|Control|Patients without lung injury and brain injury
89149439|NCT00639990|Experimental|Brain No ALI 1|Patients with brain injury and no lung injury within 72 hours from ICU entry
89149440|NCT00639990|Experimental|Brain No ALI 2|Patients with brain injury and no ALI after 72 hours from ICU entry
89149441|NCT00639990|Experimental|Brain ALI|Patients with brain injury and Acute Lung Injury (ALI)
89149442|NCT00616460|Experimental|Bivalirudin|
89149443|NCT00616538|Active Comparator|Cutivate(r)|Topical mid-strength steroid
89149444|NCT00616538|Experimental|EpiCeram(r)|EpiCeram(r) topical barrier repair cream.
89149445|NCT02680704|Other|PEEP Titration Arm|PEEP titrated mechanical ventilation
89149446|NCT02397746||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® Gladiator femoral stem, MicroPort acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
89149447|NCT02682654|Experimental|Ankle/Knee brace|Dr. Scholl's Prototype Ankle or Knee Brace
89149448|NCT02365610|Experimental|GWP42006|GWP42006
89149449|NCT02365610|Placebo Comparator|Placebo control|Placebo
89149450|NCT02680548|Active Comparator|0.9% saline (salt water)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.9% saline injection per nerve (20cc max)
89149451|NCT02680548|Active Comparator|local anesthetic (freezing)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine per nerve (20cc max)
89149452|NCT02680548|Active Comparator|local anesthetic (freezing) and steroid|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine and 4mg/cc methylprednisolone per nerve (20cc max)
89149453|NCT00617864|Experimental|1|Group will receive infusion of human albumin
89149454|NCT00617864|Placebo Comparator|2|Group will receive infusion of saline
89149455|NCT02680392|Experimental|Pulsed and Continuous Radiofrequency|In this group of patients undergoing total knee arthroplasty (allocation of patients is randomized), Pulsed radiofrequency (PRF) is applied to the saphenous nerve of the knee, associated to Continuous Radiofrequency (TRF) applied to the genicular nerves of the knee . A sham catheter is inserted in the mid-tigh to simulate a continuous adductor canal block, and connected to an infusion of normal saline (assessor and patient blinded to the treatment)
89149456|NCT02680392|Active Comparator|Continuous adductor canal block|"Continuous Adductor Canal Block~Continuous adductor canal block is performed in this group of patients, with a catheter infusing ropivacaine 0.2% in the first 48 hours after surgery.~The solutions bags are labelled in order to make assessor and patients, blinded to the treatment (Ropivacaine vs Normal Saline)"
89149457|NCT05663736|Experimental|Gemiglipitin|A DPP4 inhibitor gemigliptin treatment group
89149458|NCT05663736|Active Comparator|Glimepiride|A sulfonylurea glimepiride treatment group
89149459|NCT02680470|Experimental|Virtual Observed Therapy|Intervention = Virtual observed therapy of participants taking TB therapy
89149460|NCT04212182|Experimental|HFNC group|AECOPD patients receive ventilation support via HFNC.
89149461|NCT04212182|Active Comparator|NPPV group|AECOPD patients receive ventilation support via NPPV.
89149462|NCT02684916|Experimental|Chiropractic treatment|Visit with active treatment.
89149463|NCT02684916|Placebo Comparator|Placebo|Visit without active treatment.
89149464|NCT04211948|Experimental|robotic pancreatectomy|robotic pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
89149465|NCT04211948|Active Comparator|open surgery|open pancreatectomy(including pancreaticoduodenectomy and distal pancreatectomy)
89149466|NCT02685150|Experimental|Functional dyspepsia|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice and those who fulfill with Rome III criteria for functional dyspepsia are to be classified into this group.
89149467|NCT02685150|Experimental|Acid reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice. Participants with acid reflux are to confirmed by Omeprazole test, one kind of proton-pump inhibitor (PPI) tests.
89149468|NCT02685150|Experimental|Bile reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging and Analysis of gastric juice. Participants with bile reflux are to be confirmed by Analysis of gastric juice.
89149469|NCT02685150|Experimental|Health volunteers|Health volunteers for routine checkup. Participants are to undergo Endoscopic Tri-Modal Imaging as well as Analysis of gastric juice and those who show no abnormal findings are to be classified into this group.
89149470|NCT02684994|Other|Cognitive Processing Therapy|Cognitive Processing Therapy
89149471|NCT02682186|No Intervention|Control group (1)|The PECS Blocks are not (1) performed.
89149472|NCT02682186|Experimental|PECS group (2)|The PECS Blocks are performed (2): A single injection of Ropivacaine after dilution with sodium chloride 0.9% per fascial plane and per side.
89149473|NCT00640068||1|All patients in whom a clinical CCTA was ordered by their physician at a participating site. Patient must have a prescription for CCTA ordered by their physician.
89149474|NCT00619268|Experimental|A|
89149475|NCT00619268|Active Comparator|B|
89149476|NCT00619268|Active Comparator|C|
89149477|NCT04182906|Active Comparator|No ACEs screen|Participants complete all measures except an ACEs screening tool
89149478|NCT04182906|Experimental|Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences.In this version, specific ACEs items are reported, Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
89149479|NCT04182906|Experimental|De-Identified ACEs screen with Anticipatory Guidance|Caregiver-completed screening tool about child's adverse experiences. In this version,total number of ACEs items are reported, only. Pediatric medical provider offers anticipatory guidance about ACEs and toxic stress.
89149480|NCT00619346|Placebo Comparator|1|Placebo tablets resembling 100 mg tablet of active drug BID X 14 days
89149481|NCT00619346|Active Comparator|2|Pafuramidine maleate, 100 mg tablet, BID X 14 days
89149482|NCT00910026|Experimental|low tidal volume ventilation|6 ml/kg tidal volume ventilation
89149483|NCT00910026|Experimental|high tidal volume ventilation|12 ml/kg tidal volume ventilation
89149484|NCT04182828|Placebo Comparator|Placebo Group(PG)|It will be normal saline 0.9%
89149485|NCT04182828|Active Comparator|Lidocaine Group(LG)|It will be lidocaine 2%
89149486|NCT00619424|Experimental|pazopanib + erlotinib|Pazopanib and erlotinib are to be combined at different specified dose levels until an optimally tolerated dose level is identified. Pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit and erlotinib, an epidermal growth factor (EGFR) inhibitor, are to be combined in an effort to simultaneously block two tightly woven cell signaling pathways.
89149487|NCT00619424|Experimental|pazopanib + pemetrexed|Pazopanib and pemetrexed are to be combined at different specified dose levels until an optimally tolerated dose regimen is identified. Combination of an anti-VEGF therapy (such as bevacizumab) with systemic chemotherapy has demonstrated increased clinical efficacy in comparison with systemic chemotherapy alone in several malignancies. Hence, pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit, was chosen to be combined with pemetrexed, a chemotherapeutic agent that inhibits the enzyme thymidylate synthase, in an effort to determine if an anti-angiogenesis inhibitor would enhance the activity of the approved chemotherapeutic agent pemetrexed.
89149488|NCT00641004|Experimental|1|Rebamipide 100mg TID for 12 weeks
89149489|NCT00641004|Active Comparator|2|Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
89149490|NCT02289560|Experimental|Transcranial ExAblate|Transcranial ExAblate
89149491|NCT02680236||Breast Cancer Patients|"This pilot study proposes to explore the effect of art therapy on breast cancer patients' perception of pain, and its impact on daily functioning by offering four sessions of individual art therapy, spaced between one to three weeks apart.~The study will be open to breast cancer patients over the age of 18, who have been assessed by the Royal Marsden (RM) Pain Team, and who report having persistent post treatment pain of at least moderate intensity for the preceding two weeks despite having been optimally treated for their pain already, and who fulfil the inclusion criteria."
89149492|NCT02680080|Active Comparator|Positive control group|"subjects will receive a single 400 mg tablet of Moxifloxacin - the most commonly used positive control in thorough QTc (TQT) studies. Subjects will be continuously recorded by a Holter monitor for 24 hours"
89149493|NCT02680080|Active Comparator|Grapefruit group|subjects will drink one liter of fresh pink-grapefruit juice as fast as possible. The pink-grapefruit juice will be squeezed in the morning of the experiment in the cardiology department. ECG will be performed immediately pre dose and at 1, 2, 3, 4, 6, 8, 12, 24 after fresh pink-grapefruit juice administration. In addition, subjects will be continuously recorded by a Holter monitor for 24 hours
89149494|NCT03112824|Experimental|Ashwagandaha Root Extract Capsule|Participants will take one 300 mg. Ashwaganda capsule twice a day for 12 weeks.
89149495|NCT03112824|Placebo Comparator|Placebo Capsule|Participants will take one placebo capsule twice a day for 12 weeks.
89149496|NCT04183842|Experimental|LACIME Anti-hangover|Combination of plant extracts under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
89149497|NCT04183842|Placebo Comparator|Placebo|Carrot juice under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
89149498|NCT02684760|Experimental|Cohort 1: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
89149499|NCT02684760|Experimental|Cohort 2: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
89149500|NCT02684760|Experimental|Cohort 3: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
89149501|NCT02684760|Experimental|Cohort 4: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
89149502|NCT02684760|Experimental|Cohort 5: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
89149503|NCT02684760|Experimental|Cohort 6: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
89149504|NCT04183608|Active Comparator|Group Standard of care|In standard of care, patient only visits every 3 months the doctor so the optimization of treatment can be done only at this frequency.
89149505|NCT04183608|Active Comparator|Groupe T2T with telemonitoring and patient education|Treatment with e-Monitoring, home fecal calprotectin testing and therapy education.
89149506|NCT04184778|Experimental|Woman tube size 6.0|Smaller tube than normal
89149507|NCT04184778|No Intervention|Woman tube size 7.0|Usual tube size
89149508|NCT04184778|Experimental|Man tube size 7.0|Smaller tube than normal
89149509|NCT04184778|No Intervention|Man tube size 8.0|Usual tube size
89149510|NCT02684682|Other|12h Group|Intervention 'Frequency of mechanical control of plaque (12h)'
89149511|NCT02684682|Other|24h Group|Intervention 'Frequency of mechanical control of plaque (24h)'
89149512|NCT02684682|Other|48h Group|Intervention 'Frequency of mechanical control of plaque (48h)'
89149513|NCT00641082|Experimental|1|Clevudine
89149514|NCT00641082|Active Comparator|2|Adefovir
89149515|NCT02684526|Active Comparator|Eovist Contrast agent|To determine if Eovist contrast agent induces a transient abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans.
89149516|NCT02684526|Active Comparator|Non Eovist Contrast agents|To determine if using non-Eovist contrast agents produce the same abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans. Determine if this event is exclusive to Eovist contrast.
89149517|NCT00641784|Experimental|1|Oral Nifedine
89149518|NCT00641784|Active Comparator|2|Intravenous Magnesium
89149519|NCT00503178|Experimental|Patients undergoing imaging guided radiotherapy.|
89149520|NCT00641160|Experimental|Cohort 1|
89149521|NCT00641160|Experimental|Cohort 2|
89149522|NCT00641160|Experimental|Cohort 3|
89149523|NCT02679924|Experimental|Restylane Silk|Micro-injections of Restylane® Silk Hyaluronic Acid filler for correction of mid to low cheek fine lines and wrinkles.
89149524|NCT02679924|Sham Comparator|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
89149525|NCT04182282|Experimental|Immediate|Immediate participants receive the intervention (online training and certification exam) during the study.
89149526|NCT04182282|Experimental|Control|Control participants do not receive the intervention (online training and certification exam) during the study. However, they do receive access to the intervention program (at no cost) at the conclusion of the study.
89149527|NCT02679846|Experimental|Standardized protocol of AEDs withdrawal|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
89149528|NCT02679846|No Intervention|Current practice|Centers will continue their current practice
89149529|NCT02679768|Active Comparator|Circadian Reinforcement Therapy|Circadian reinforcement therapy
89149530|NCT02679768|Placebo Comparator|Standard treatment|Standard treatment
89149531|NCT04211870|Active Comparator|Group 1|Treatment with low-level laser therapy.
89149532|NCT04211870|Sham Comparator|Group 2|Sham treatment (simulated laser therapy).
89149533|NCT02537652||Major Stroke|Patients diagnosed with major stroke who will undergo blood pressure assessment
89149534|NCT02537652||Minor stroke|Patients diagnosed with minor stroke who will undergo blood pressure assessment
89149535|NCT04211792||Glaucoma suspect or patients|Patients who has or suspected Glaucoma will be approached for the recruitment into this study. IOP will be measured in the sitting position with Icare tonometers in a random order in both the eyes. IOP measurements by GAT will be taken after Icare measurements followed by CCT recording with ultrasound pachymeter.
89149536|NCT05663424|Experimental|immediate rehabilitation group|rTMS plus immediate rehabilitation programs
89149537|NCT05663424|Experimental|delayed rehabilitation group|rTMS plus delayed rehabilitation programs
89149538|NCT05663424|Sham Comparator|sham rTMS group|sham rTMS + rehabilitation programs
89149539|NCT00618176|Experimental|B|
89149540|NCT00618176|Experimental|A|
89149541|NCT00618176|Experimental|C|
89149542|NCT02684448||Robotic-Assisted Inguinal Hernia Repair|Subjects who have undergone robotic-assisted (da Vinci) inguinal hernia repair from the initiation of robotic-assisted hernia repair at site through December 2015.
89149543|NCT02684448||Open Inguinal Hernia Repair|Subjects who have undergone open inguinal hernia repair from the day prior to initiation of robotic-assisted hernia repair through 5 years prior to initiation.
89149544|NCT00616616|Experimental|1|all subjects
89149545|NCT04211558|Experimental|Ozanimod 0.46mg|Ozanimod single doses of 0.46 mg (1 x 0.46 mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
89149546|NCT04211558|Experimental|Ozanimod 0.92mg|Ozanimod single doses of 0.92 mg (1 x 0.92-mg capsule) will be administered on Day 1. Ozanimod will be administered following an overnight fast of at least 10 hours before dosing and with approximately 240 mL of nonrefrigerated, noncarbonated water (additional water may be allowed if required for the subject to complete dosing). Subjects will remain fasted for 4 hours after ozanimod dosing.
89149547|NCT04214522||Acute stroke patients|Acute stroke patients
89149548|NCT00619580||positive E coli|positive E coli at UPMC
89149549|NCT03052842|Experimental|Arm 1A: 9.2 mg C16G2|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
89149550|NCT03052842|Placebo Comparator|Arm 1B: 9.2 mg Placebo|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
89149551|NCT03052842|Experimental|Arm 2A: 18.4 mg C16G2|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
89149552|NCT03052842|Placebo Comparator|Arm 2B: 18.4 mg Placebo|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
89149553|NCT03052842|Experimental|Arm 3A: 36.8 mg C16G2|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
89149554|NCT03052842|Placebo Comparator|Arm 3B: 36.8 mg Placebo|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
89149555|NCT00901901|Experimental|Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)|Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)
89149556|NCT00901901|Active Comparator|Sorafenib (Nexavar, BAY43-9006) + Placebo|Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)
89149557|NCT00619658|Experimental|1|All women undergoing medical abortion will have telephone follow-up approximately one week after using mifepristone and misoprostol.
89149558|NCT02683980|Experimental|Ablation of the prostate|ablation of the prostate will be performed using the study device: Lumenis Pulse P120H Holmium Laser
89149559|NCT00619736|Experimental|NSA-789|
89149560|NCT00619736|Placebo Comparator|Placebo|
89149561|NCT04184232|Experimental|Dendritic cells|Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
89149562|NCT04184232|Active Comparator|Control|Patients with the recurrent bladder cancer receiving standard treatment
89149563|NCT04213040||Open-Heart Surgery for a six months duration|In a single group of patients including 146 patients undergoing openheart surgery during a period of six months, the collected parameters include; serum levels of procalcitonin, C-reactive protein, and lactate as well as postoperative complications and after this, depending on the development of postoperative complications or not in the intensive care unit patients were divided into two groups. The Group Without Complications, n=112, includes patients without a postoperative complication after open-heart surgery with cardiopulmonary bypass. The Group With Complications, n=34, includes patients with a postoperative complication after open-heart surgery with cardiopulmonary bypass.
89149564|NCT04824833|Active Comparator|Serratus anterior plane block|
89149565|NCT04824833|No Intervention|control group|
89149566|NCT04184466|Experimental|Insulin Aspart|Single subcutaneous administration of Insulin Aspart in dose 0.3 IU / kg
89149567|NCT04184466|Active Comparator|NovoRapid® Penfill®|Single subcutaneous administration of NovoRapid® Penfill® in dose 0.3 IU / kg
89149568|NCT04184310|Experimental|old patient with rectal prolapse|old co-morbid patient with complete rectal prolapse unfit for abdominal operation
89149569|NCT02143778|Experimental|Compensated cirrhotic patients|A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
89149570|NCT02683902|Active Comparator|Active tDCS + Diet|The participants will receive active tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
89149571|NCT02683902|Sham Comparator|Sham tDCS + Diet|The participants will receive sham tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
89149572|NCT03009773|Experimental|multitasking walking|Multitasking Group: rehabilitation multitasking walking.
89149573|NCT03009773|Active Comparator|walking simple task|Simple task group : Traditional walking rehabilitation
89149574|NCT02843789|Experimental|Adiponectin evaluation|Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab
89149575|NCT05664360||ED patients|
89149576|NCT04804163|Experimental|Upper urinary tract disease group|Patients with upper urinary diseases (renal cell carcinoma, nonfunctioning kidney and adrenal tumor) will be treated by telesurgery.
89149577|NCT00641940|Experimental|1|Girls in Transition (GT) program
89149578|NCT00641940|Other|2|Waitlist control
89149579|NCT02843711||Adenocarcinoma|Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.
89149580|NCT04201769|Experimental|Arm A|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~No further anti-emetic prophylaxis on days 2 thorough 4."
89149581|NCT04201769|Experimental|Arm B|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~Oral dexamethasone 4 mg once per day in the morning of days 2 and 3."
89149582|NCT04201769|Active Comparator|Arm C|"Oral Netupitant/Palonosetron (NEPA) and intravenous Dexamethasone (DEX) on Day 1 of chemotherapy.~Oral dexamethasone 4 mg twice per day on days 2 thorough 4."
89149583|NCT02679534|Experimental|hand massage|"Patients will receive a 20 minute hand massage by a trained nurse in addition to the standard ICU care. Before administering the massage, a favorable environment will be created that promotes calmness such as dampening the light, reducing the alarm intensity, closing the curtains and the door and posting the notice do not disturb, and a comfortable positioning of the patient will be ensured. The interventionist will hold each hand for 5-10 seconds, and apply 5-10 ml of unscented hypoallergenic cream to both hands and wrists. Then, she will perform massage using moderate pressure, and the stroking and kneading techniques during ten minutes on the palm and back of each hand."
89149584|NCT02679534|Active Comparator|hand holding|The active control group will receive hand holding by the same trained nurse in addition to standard ICU care. The same hand hygiene and environmental adjustments will be made as for those receiving massage. Patients will have their hands held for 5-10 seconds and unscented hypoallergenic cream applied to both hands. Then, the interventionist will hold each of the patients' hand in her hand for ten minutes without performing any tissue manipulation. The hand holding procedure will last for a total of 20 minutes.
89149585|NCT02679534|Other|rest group|The passive control group will have a 20 minutes rest period including the same environmental adjustments as the massage and hand holding groups in addition to the standard care administered in the ICU. The standard care includes the pharmacological and non-pharmacological treatments used to promote recovery and symptom relief. In the study ICU, cardiac surgery patients are automatically prescribed a pain management protocol that includes the regular administration of morphine, unless extraordinary patient circumstances require different prescriptions. Patients might equally receive breakthrough doses of analgesia in addition to regular opioids. Of the existing non-pharmacological interventions, repositioning and back rubs are commonly employed in the study ICU to provide patient comfort.
89149586|NCT02682108|Other|Diffusion-weighted imaging|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
89149587|NCT00640302||PIPET A|Patients presenting at study sites with the recognised clinical case definition for pandemic influenza (to be distributed by State and Commonwealth Departments of Health when first clinical case occurs) will be eligible to be enrolled on the study. Informed consent to participate in the study will be sought including parental/guardian consent for minors and presumed consent for adults who are incapacitated (consistent with NHMRC requirements).
89149588|NCT05336825|Experimental|CO2 laser|Mona Lisa CO2 laser will be applied externally to the vulvar vestibule in three sessions over a three month period.
89149589|NCT05336825|Active Comparator|Lidocaine|5% topical lidocaine will be applied nightly via a cotton square in participants
89149590|NCT04184388|Experimental|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng extract for 1g/day
89149591|NCT04184388|Placebo Comparator|Placebo|Hydrolysed Red Ginseng extract for 0g/day
89149592|NCT02791230|Experimental|Tafamidis|Active treatment - 61 mg or if not available, tafamidis megulmine 80 mg
89149593|NCT04748783|Placebo Comparator|Sterile water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water
89149594|NCT04748783|Active Comparator|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
89149595|NCT04748783|Active Comparator|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
89149596|NCT04748783|Active Comparator|Peroxyl & Periogard|Subject participants will complete an on-label sequential rinse starting with Peroxyl (1st) 10ml for 60 seconds and then Periogard (2nd) 15ml for 30 seconds.
89149597|NCT04748783|Active Comparator|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
89149598|NCT02777580|Experimental|Pharmaco-invasive strategy|Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.
89149599|NCT02777580|Active Comparator|Standard primary PCI|Primary PCI with a P2Y12 antagonist and antithrombin treatment according to local standards.
89149600|NCT04201613|Active Comparator|Early Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive one hour of treatment per day for 20 days.
89149601|NCT04201613|Active Comparator|Early Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 5-9 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
89149602|NCT04201613|Active Comparator|Late Robotic Rehab Low Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive one hour of treatment per day for 20 days.
89149603|NCT04201613|Active Comparator|Late Robotic Rehab High Intensity|This group will begin robotic rehabilitation using a robotic exoskeleton between days 21-25 after their stroke. They will receive 2 one-hour treatment sessions per day for 20 days.
89149604|NCT04201613|Active Comparator|Control Group|This group will receive usual care with robotic assessment.
89149605|NCT05335031||Participants with relapsing-remitting multiple sclerosis (RRMS) treated with Ozanimod|
89149606|NCT02681952|Active Comparator|Renamezin->Kremezin|
89149607|NCT02681952|Active Comparator|Kremezin->Renamezin|
89149608|NCT02843321|Experimental|T-cell infusion|Infusion of donor-derived T cells. Non randomised, prevention study arm
89149609|NCT02683590|Experimental|sternum by a ceramic implant|The replacement of the sternum by a ceramic implant
89149610|NCT00640380|Experimental|1|CPVB with NS
89149611|NCT00640380|Active Comparator|2|CPVB with LOR
89149612|NCT05336669||Non-smoking|Non-smoking patients undergoing coronary angiography or percutaneous coronary intervention
89149613|NCT05336669||Smoking|Smoking patients undergoing coronary angiography or percutaneous coronary intervention
89149614|NCT02843399||Exenatide once weekly (EQW)|EQW cohort includes patients with one or more outpatient prescription claims for EQW between 2012 and 2015.
89149615|NCT02843399||Insulin Glargine (IG)|IG cohort includes patients with one or more outpatient prescription claims for IG between 2012 and 2015
89149616|NCT02822027|Experimental|human gamma globulin|human gamma globulin for infants with encephalopathy of prematurities
89149617|NCT02822027|Active Comparator|non-human gamma globulin|non-human gamma globulin for infants with encephalopathy of prematurities
89149618|NCT00642096|Experimental|1|Metoprolol Succinate + Hydrochlorothiazide
89149619|NCT00642096|Active Comparator|2|Metoprolol Succinate
89149620|NCT00642096|Active Comparator|3|Hydrochlorothiazide
89149621|NCT00632801|Other|A|Chewing gum or not
89149622|NCT02679300|Experimental|Virtual reality group|During a single intervention session, participants will perform 2 sets of 2 minutes of pelvic tilt exercises using serious games. These serious games have to be controlled by pelvic tilts. Patients will perform the exercises in a standing position in front a TV-screen, on which the games will be displayed. Wireless motion sensors will be mounted to the patient's spine and pelvis to track the movements of the pelvis.
89149623|NCT02679300|Active Comparator|Control group|During a single session intervention, participants will perform 2 sets of 2 minutes of pelvic tilt exercises without a serious game. Patients will perform the exercises in a standing position. The number of repetitions and the tempo of the pelvic tilts will be indicated using a metronome.
89149624|NCT05336513|Other|Diet Control|"Diet Control (DC): nutritional education and adherence monitoring. DC will be based on the Portuguese Nova Roda dos Alimentos following the principles of the Mediterranean diet."
89149625|NCT05336513|Experimental|Diet Anti-inflammatory|Diet Anti-inflammatory (DAI): nutritional education and adherence monitoring. The DAI dietary intervention will be based on combining individual food items described as potential anti-inflammatory mitigators.
89149626|NCT02679456|Active Comparator|Treatment Group 1 (Fluconazole)|Fluconazole
89149627|NCT02679456|Experimental|Treatment Group 2: (SCY-078)|Dose regimen 1
89149628|NCT02679456|Experimental|Treatment Group 3 (SCY-078)|Dose regimen 2
89149629|NCT02843555||Leukodystrophy of unknown etiology|Subjects who may have an undiagnosed form of leukodystrophy
89149630|NCT02681718|Experimental|Community Health Worker education|During a six-month intervention period, the CHWs will conduct six home-based visitations and provide individualized diabetes education using an intensive diabetes lifestyle curriculum called Diabetes Learning Circle (DLC), developed and used by the Sinai Diabetes Education Program. At each visit, lasting for approximately one hour, the participants will be motivated to set SMART behavioral goals for diabetes self-management. At each visit after the initial visit, CHWs will follow-up with each participant to check their progress on their behavioral SMART goals. In addition, the CHWs will conduct intermittent phone calls (at least one monthly) and home visits as needed.
89149631|NCT02681718|Experimental|Cell phone text messaging|The participants in the text messaging group will receive weekly text messages through CareMessage. Each participant will receive 3-4 text messages per week for 6 months.
89149632|NCT02681718|No Intervention|Control|The participants in the control group will receive education as determined by the hospital's diabetes educator, dietitian, physician, or the participant's managed care provider. No additional education will be provided by the research team.
89149633|NCT04181892|Experimental|CAF+ CTG positioned apical to the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG apical of the CEJ level
89149634|NCT04181892|Other|CAF+CTG positioned on the CEJ|Connective tissue graft covered by a coronally advanced flap which CTG on the CEJ level
89149635|NCT04182438|Experimental|Low potassium then normal potassium|After giving the vegetables with low potassium content vegetables for 2 weeks, the serum potassium level was recorded; after 2 weeks of washing time, the normal potassium content vegetables was given for 2 weeks, and the serum potassium concentration was recorded and the test was terminated.
89149636|NCT04182438|Experimental|Normal potassium then low potassium|After giving the normal potassium content vegetables for 2 weeks, the serum potassium concentration was recorded; after 2 weeks of washing time, the low potassium content vegetables use for 2 weeks, then the serum potassium level was recorded at the time. The test was terminated.
89149637|NCT00640458|Placebo Comparator|Placebo|Study Period 1 or 2
89149638|NCT00640458|Experimental|Experimental|Study Period 1 or 2
89149639|NCT04494893||Cohort 1|Exposed to coronavirus disease
89149640|NCT04494893||Cohort 2|Active coronavirus disease
89149641|NCT04494893||Cohort 3|Recovered from coronavirus disease
89149642|NCT00909948|Active Comparator|Fludarabine|The patients in this cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
89149643|NCT00909948|Active Comparator|TBI only|Patients will be given 200 centiGray (cGy) total body irradiation (TBI) in one fraction. TBI will be given on day 0, 4 to 6 hours prior to HCT.
89149644|NCT02843009|Placebo Comparator|Safflower Oil plus Resistance Exercise Training|3.0g of safflower oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
89149645|NCT02843009|Active Comparator|Fish Oil plus Resistance Exercise Training|3.0g of fish oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
89149646|NCT02551146|Experimental|A Locator with retention elements|"GC Pilier Locator abutment with retention elements:~For patients in the experimental group (arm A) the connection of the full dentures to the implants will be achieved by fitting the dentures with GC Pilier Locator abutments with retention elements."
89149647|NCT02551146|Active Comparator|B Locator without retention elements|"GC Pilier Locator abutment without retention elements:~For patients with the active comparator (arm B) the full dentures will get Pilier Locator abutments without retention elements and thus no connection to the implants."
89149648|NCT02843477||Fluid loading group|Spontaneously breathing patients before induction of general anesthesia who receive fluid loading
89149649|NCT02681562|Experimental|Olaparib triple negative|Olaparib short administration in triple negative breast cancer
89149650|NCT02681562|Experimental|Olaparib BRCA mutated|Olaparib short administration in BRCA mutated patients
89149651|NCT00633035|Active Comparator|1|oral esomeprazole tablet dissolved in water given through NG tube
89149652|NCT00633035|Active Comparator|2|intravenous famotidine injection
89149653|NCT04649021|Experimental|BNT162b2 18-85 years of age|
89149654|NCT04649021|Placebo Comparator|Placebo 18-85 years of age|
89149655|NCT02842619|Experimental|Intervention Arm|1 Arm - IMP treatment arm
89149656|NCT05335577||Preterm neonates with NEC|Preterm neonates with gestational age of 28-32 weeks and diagnosed with Necrotizing Enterocolitis based on Bell's modification criteria.
89149657|NCT05335577||Preterm neonates without NEC|Preterm neonates with gestational age of 28-32 weeks and without Necrotizing Enterocolitis based on Bell's modification criteria.
89149658|NCT05335577||Healthy term neonates|Term neonates with gestational age of 37-42 weeks without any comorbidities.
89149659|NCT02511132|Experimental|Part 1: Vigil Alone|Vigil immunotherapy 1.0 x 107 cells/injection; minimum of 4 to a maximum of 12 administrations every 28 days
89149660|NCT02511132|Active Comparator|Part 1: Gemicitabine and Docetaxel|Gemcitabine 675 mg/m2 IV at 10 mg/m2/min D1 and Docetaxel 75 mg/m2 IV starting on D8 and given every 21 days.
89149661|NCT02511132|Experimental|Part 2: Vigil plus Temozolomide and Irinotecan|(i) oral temozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle), (ii) irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously (iii) peg-filgrastim 100μg/kg (Day 6) subcutaneously (optional and may be administered at home), and (iv) Vigil 1.0 x 107 cells/injection, intradermally on Day 15 and every 3 weeks thereafter. One cycle = 21 days.
89149662|NCT00640536||1|Newly diagnosed obstructive sleep apnea patients without systemic and pulmonary arterial hypertension
89149663|NCT00640536||2|Age, sex and and body mass index-matched matched healthy subjects
89149664|NCT05664282|Active Comparator|Damon self-ligating brackets|A multi-centre two-arm parallel-group randomized controlled trial with a 1:1 allocation ratio, comparing/evaluating tooth alignment, function and adverse side effects, Patients' perception of pain, function and quality of life Cost-effectiveness for adolescents with crowding and displaced teeth treated with self-ligating (Damon).
89149665|NCT05664282|Active Comparator|Victory conventional brackets|A multi-centre two-arm parallel-group randomized controlled trial with a 1:1 allocation ratio, comparing/evaluating tooth alignment, function and adverse side effects, Patients' perception of pain, function and quality of life Cost-effectiveness for adolescents with crowding and displaced teeth treated with conventional brackets (Victory).
89149666|NCT00896363|Active Comparator|Active|Parallel Group - High Dose Arm, Low Dose Arm
89149667|NCT00896363|Placebo Comparator|Placebo|Parallel Group
89149668|NCT02683434|Experimental|KT|Kinesio Taping Application
89149669|NCT02683434|No Intervention|CONTROL|
89149670|NCT02678988|Experimental|A1: Tocilizumab AI followed by PFS-NSD in abdomen|Participants will receive two single doses of 162 milligrams (mg) tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in abdomen.
89149671|NCT02678988|Experimental|A2: Tocilizumab AI followed by PFS-NSD in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2) in thigh.
89149672|NCT02678988|Experimental|A3: Tocilizumab AI followed by PFS-NSD in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in upper arm.
89149673|NCT02678988|Experimental|B1: Tocilizumab PFS-NSD followed by AI in abdomen|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in abdomen.
89149674|NCT02678988|Experimental|B2: Tocilizumab PFS-NSD followed by AI in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
89149675|NCT02678988|Experimental|B3: Tocilizumab PFS-NSD followed by AI in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
89149676|NCT05663190||1|Less than 10-year-old, with cone beam computed tomography imagess with the mental foramen included in field of vision
89149677|NCT02678910|Experimental|Ovarian Cryopreservation|Removal of the ovary for cryopreservation is an investigational procedure. 100% of the tissue will be used for the participant's future use.
89149678|NCT02681484|Experimental|Hypertensive|Patients diagnosed with hypertension (I10, either on drug therapy or verified by 24h blood pressure measurements) administered to anthroposophic speech therapy (intervention).
89149679|NCT02681484|Active Comparator|Normotensive|Patients diagnosed with tension headache (G 44.2) or anxiety disorders (F41) administered to anthroposophic speech therapy (intervention).
89149680|NCT02842775|Experimental|Dynamic balance exercise group|balance perturbation training
89149681|NCT02842775|No Intervention|Control group|No intervention
89149682|NCT02681640|Experimental|uPAR PET|One injection of 68Ga-NOTA-AE105 followed by Positron Emission Tomography (PET/CT scan) to evaluate possible axillary lymph node metastatic lesions
89149683|NCT02678520|Experimental|3-D conformal radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using a 3-D conformal radiation technique (3-D CRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
89149684|NCT02678520|Active Comparator|Intensity modulated radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using intensity modulated radiation therapy (IMRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
89149685|NCT00642252|Experimental|B|226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
89149686|NCT00642252|Active Comparator|A|ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
89149687|NCT00642330|Active Comparator|I|
89149688|NCT00642330|Active Comparator|O|
89149689|NCT00640692||1|
89149690|NCT00640692||2|
89149691|NCT00900029||No HP802 Treatment|Treatment received in Study 802-247-09-015 was HP802
89149692|NCT00900029||No HP802 Vehicle Treatment|Treatment received in Study 802-247-09-015 was HP802 Vehicle
89149693|NCT02682966||PMI|Postoperative Myocardial injury, postoperative troponin levels ≥ 60 ng/L
89149694|NCT02682966||Control|postoperative troponin levels < 60 ng/L
89149695|NCT00640770|Active Comparator|balloon angioplasty|balloon angioplasty
89149696|NCT00640770|Experimental|Drug eluting stent|CYPHER SELECT+ Coronary or Infrapopliteal Stent
89149697|NCT00633113|Active Comparator|1|- Medial Parapatellar Arthrotomy (MPPA) technique
89149698|NCT00633113|Active Comparator|2|- Subvastus (SV) technique
89149699|NCT02681796|Experimental|Study: Bupivacaine Epidural + standard of care pain regimen|-The study group will receive a T6 to T8 level epidural catheter in addition to the standardized pain regimen. Epidurals used in this study will contain a 0.125% bupivacaine-only infusion
89149700|NCT02681796|No Intervention|Control: Standard of care pain regimen|-The control group will receive a standardized pain regimen including an opioid patient controlled analgesia (PCA), IV acetaminophen, and IV ketorolac per surgeon's preference
89149701|NCT02842931|Active Comparator|R-DA-EPOCH-21|Protocol involves 6 cycles.
89149702|NCT02842931|Active Comparator|R-DA-EPOCH-21 + auto-SCT|Protocol involves 6 cycles. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
89149703|NCT02842931|Active Comparator|R-mNHL-BFM-90|"Course A:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 25 mg/m2/day IV 1, 2 days, Vincristine 2 mg IV 1 day, Cytarabine 100 mg/m2/day IV 1 h 4, 5 days.~Course B:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Cyclophosphamide 200 mg/m2/day IV 1 h 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Doxorubicin 25 mg/m2/day IV 4, 5 days, Vincristine 2 mg IV 1 day. Protocol involves 6 cycles : A-B-A-B-A-B. One cycle continues 21 days."
89149704|NCT02842931|Active Comparator|R-mNHL-BFM-90 + auto-SCT|Protocol involves 6 cycles R-mNHL-BFM-90: A-B-A-B-A-B. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
89149705|NCT02842697|Experimental|Single arm study|"Patients will receive CTA, Doppler ultrasound, HVPG measurement, and vHVPG per protocol.~Intervention: Procedure: HVPG measurement"
89149706|NCT04183296|Experimental|TIVA(Total Intravenous Anesthesia and Volatile Anesthesia )|In the TIVA group, anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
89149707|NCT04183296|Active Comparator|Inhalation|Arm Description: In the volatile group, anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
89149708|NCT02842385|Active Comparator|Nonsubmerged thick group|Nonsubmerged type of implants placed with thick (>3 mm) soft tissue
89149709|NCT02842385|Active Comparator|Nonsubmerged thin group|Nonsubmerged type of implants placed with thin (<3 mm) soft tissue
89149710|NCT02842385|Active Comparator|Submerged thick group|Submerged type of implants placed with thick (>3 mm) soft tissue
89149711|NCT02842385|Active Comparator|Submerged thin group|Submerged type of implants placed with thin (<3 mm) soft tissue
89149712|NCT00642408|Experimental|MMN|multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
89149713|NCT00642408|Active Comparator|IFA|iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
89149714|NCT04181580|Other|Fit test of made-to-measure garments|Healthy subjects will test maximum 2 compression garments out of 6 garments under investigation
89149715|NCT02678598||Micafungin group|
89149716|NCT02359019|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
89149717|NCT02678364|Placebo Comparator|Control egg group|Two or less control (non-biofortified) eggs per week
89149718|NCT02678364|Active Comparator|Vitamin D3-eggs group|Seven vitamin D3-biofortified eggs per week
89149719|NCT02678364|Active Comparator|25-Hydroxyvitamin D-eggs group|7 25-hydroxyvitamin D-biofortified eggs per week
89149720|NCT02840123|Experimental|Autologous dendritic cells|
89149721|NCT04182594|Experimental|Degarelix|GnRH Antagonist
89149722|NCT04182594|Active Comparator|GnRH-agonist|GnRH Agonist
89149723|NCT05334875|Active Comparator|Electroretinogram test (ERG)|ERG test will be done for each subject twice and compare the results to assess repeatability of the test.
89149724|NCT05334875|Active Comparator|Visual evoked potential test (VEP)|VEP test will be done for each subject twice and compare the results to assess repeatability of the test.
89149725|NCT04181814||Diabetic patients|Diagnosed as diabetes
89149726|NCT02678208|Active Comparator|Tranexamic acid|received tranexamic acid containing 1 g/10mL tranexamic acid diluted with 20 mL of 5% glucose over a 5 minute period
89149727|NCT02678208|Other|placebo|received 30 mL of 5% glucose over the same period of time.
89149728|NCT02837861|Experimental|Experimental Group|Routine Nutritional Support plus supplemental IV amino acids, to begin within 24h of injury. (Target approximately 1.5-2g protein/kg/day)
89149729|NCT02837861|Active Comparator|Control Group|Routine Nutritional Support (i.e. enteral nutrition as tolerated, to begin as early as medically feasible)
89149730|NCT00643266|Experimental|1|Recollection training via graduated increases in task difficulty, carried out over 36 sessions over 9 training days
89149731|NCT00643266|Active Comparator|2|Computer-delivered information sessions about memory and aging with Jeopardy-like games to engage participants
89149732|NCT05551182|Experimental|Nicergoline low dose|Nicergoline 10 mg bid (20 mg/day)
89149733|NCT05551182|Experimental|Nicergoline high dose|Nicergoline 30 mg bid (60 mg/day)
89149734|NCT02676102|Active Comparator|Control Group|Participant will watch an educational video produced in partnership with the community of black men including customers, employers and owners of BOBs.
89149735|NCT02676102|Active Comparator|Targeted Intervention|Participants will watch an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
89149736|NCT02676102|Active Comparator|Tailored Intervention|Participants will watch videos with content individualized to participant's pre-intervention ODBI scores representing their organ donation beliefs
89149737|NCT02842541|Experimental|Single dose arm|Subjects will receive a single intravitreal dose of EBI-031
89149738|NCT02842541|Experimental|Repeat dose arm|Subjects will receive an intravitreal dose of EBI-031 monthly for 3 months
89149739|NCT02678130|Active Comparator|InterFuse Group|Patients are randomized based on last digit (odd) of social security number to be treated with an InterFuse T device
89149740|NCT02678130|Active Comparator|Control Group: Standard of care TLIF|treated with a standard of care TLIF (Transforaminal Lumbar Interbody Fusion) device (e.g. Stryker's AVS Unilif)
89149741|NCT00642486|Active Comparator|1|laboratory-based testing
89149742|NCT00642486|Active Comparator|2|home-based testing
89149743|NCT05334095|Active Comparator|Perclose ProGlide|Perclose ProGlide 6F Suture-Mediated Closure (SMC) System
89149744|NCT05334095|Placebo Comparator|Angio-seal VIP|Angio-seal VIP Vascular Closure Device
89149745|NCT02842307|Active Comparator|A(senior acupuncturists)|Manual acupuncture implemented by senior acupuncturists (clinical experience >15 years)
89149746|NCT02842307|Active Comparator|B(junior acupuncturists)|Manual acupuncture implemented by junior acupuncturists (clinical experience <5 years)
88804238|NCT05775952||Asthma Cohort|"Subjects with well-controlled, mild-moderate asthma (≥12% post-bronchodilator reversibility or PC20 methacholine <16mg/mL at screening or within past 5 years).~Subjects will be inoculated with a total dose of 1000 tissue culture-infective dose 50% (TCID50) of rhinovirus (HRV) 39. The inoculum is diluted as appropriate in lactated Ringer's solution and delivered via a two step procedure: 0.25 ml per nostril is administered by pipette while the subject tilts their head back. It is anticipated that subjects will develop mild to moderate symptoms that are transient (lasting 3-7 days) and typically consist of nasal congestion, throat irritation, malaise and increased mucoid secretions. Subjects will record cold symptoms twice daily, using a diary card listing 8 symptoms, each of which are scored 0 to 3 on a basis of severity.~Subjects will only be inoculated with HRV-39 once at Visit 5."
88804239|NCT05775952||Healthy, Non-asthmatic Cohort|"Healthy non-asthmatic control subjects.~Subjects will be inoculated with a total dose of 1000 tissue culture-infective dose 50% (TCID50) of rhinovirus (HRV) 39. The inoculum is diluted as appropriate in lactated Ringer's solution and delivered via a two step procedure: 0.25 ml per nostril is administered by pipette while the subject tilts their head back. It is anticipated that subjects will develop mild to moderate symptoms that are transient (lasting 3-7 days) and typically consist of nasal congestion, throat irritation, malaise and increased mucoid secretions. Subjects will record cold symptoms twice daily, using a diary card listing 8 symptoms, each of which are scored 0 to 3 on a basis of severity.~Subjects will only be inoculated with HRV-39 once at Visit 5."
88804240|NCT05775874|Other|An open evaluation of AZD4547 combined with Tislelizumab in UC patients|"AZD4547 : Initiation dose 80mg BID,po;Until disease progression, death, loss to follow-up, voluntary withdrawal of informed consent, development of intolerable toxicity, investigator decision to discontinue treatment, or completion of the entire study.~Tislelizumab:200mg Q3W, Until disease progression, death, loss to follow-up, voluntary withdrawal of informed consent, development of intolerable toxicity, investigator decision to discontinue treatment, or completion of the entire study."
88804241|NCT05775835|Experimental|Whole body vibration exercise group|The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.
88804242|NCT05775835|Experimental|Strength training group|"The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
88804243|NCT05775835|Experimental|Whole body vibration and strengthening exercise group|"In the TVVE+KE group, the selected exercises will be performed with vibratory and dynamic strengthening exercises on the vibration platform. The application will be carried out on a whole body vibration device giving a constant vibration of 35 Hz. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. D For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
88804244|NCT05775835|No Intervention|Control Group|No exercise recommendations or interventions will be made to the patients in the control group.
88804245|NCT05775783||Consecutive patients with CIEDs, treated with TLE (infections)|
88804246|NCT05775783||Consecutive patients with CIEDs, treated with TLE (no-infections)|
88804247|NCT05775705|Experimental|L-DEP and PD-1 antibody|PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
88804248|NCT05775692||Newborns and children with the usage of fluconazole|Newborn with fluconazole against infectious diseases.
88804249|NCT05775679||Test-retest reliability|50 patients answer CLEFT-Q twice with 1-2 weeks in between.
88804250|NCT05775679||Secondary Nose Surgery|50 patients answer CLEFT-Q before and 6 months after secondary nose surgery.
88804251|NCT05775679||Secondary Lip Surgery|50 patients answer CLEFT-Q before and 6 months after secondary lip surgery.
88804252|NCT05775679||Jaw Surgery|50 patients answer CLEFT-Q before and 1 year after jaw surgery.
88804253|NCT05775679||Secondary Speech Improving Surgery|50 patients answer CLEFT-Q before and 1 year after secondary speech improving surgery.
88804254|NCT05775679||Health care professionals|20 health care professionals will be interviewed about their experiences on working with CLEFT-Q.
89149747|NCT02842307|Active Comparator|C(P6 points)|Manual acupuncture on P6 points by junior acupuncturists (clinical experience <5 years)
89149748|NCT02842307|No Intervention|D(no acupuncture)|No acupuncture treatment
89149749|NCT02681016|Experimental|"Sirolimus-eluting stent Calypso"|"Commercially approved coronary stent system Calypso (Angioline, Russia) Coating - Sirolimus(rapamicine) Stent diameters: 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 4.5 mm. Stent lengths: 8, 13, 15, 18, 23, 28, 33, 38 mm."
89149750|NCT02681016|Active Comparator|"Everolimus-eluting stent Xience Prime"|Commercially approved XIENCE PRIME, (Abbott Vascular, USA) Coating - Everolimus with concentration Stent diameters: 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm. Stent lengths: 8, 12, 15, 18, 23, 28, 33, 38 mm.
89149751|NCT02677584|Active Comparator|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
89149752|NCT02677584|Active Comparator|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
89149753|NCT02839967|Experimental|Photobiomodulation group|For the purposes of photobiomodulation is used a portable cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), and 1 905 nm diode LASER, 4 875 nm LED diodes and 4 670 nm diodes LED, 4 cm2 beam, emitting an energy of 39.27 J.
89149754|NCT02839967|Placebo Comparator|Photobiomodulation placebo group|"To provide the blinding of the participants of the study we will use two identical photobiomodulation equipment supplied by the manufacturer, being an active and another a placebo, but both have identical light and sound device (do not send energy and heat, non-coherent light without biological effect). The devices are named in X and Y for a researcher who does not participate in treatment and assessments."
89149755|NCT04181658|Experimental|Real tDCS and Physical Therapy|This arm combines tDCS and Physical Therapy intervention. The real tDCS will be delivered before each physical therapy visit for up to 10 combined sessions. The tDCS montage was designed to target the left dorsal lateral prefrontal cortex (DLPFC) for around 20 minutes. The direct current delivered by any electrode will not exceed 2.0 milliamp(mA) and the total amount of current from all electrodes will not exceed 4 mA.
89149756|NCT04181658|Sham Comparator|Sham stimulation and Physical Therapy|This arm combines sham stimulation and Physical Therapy intervention. The sham stimulation will be delivered before each physical therapy visit for up to 10 combined sessions. We will use an active sham stimulation in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This montage was designed to deliver currents not significantly influence their cortical tissue, but still, mimic the cutaneous sensations induced by tDCS over the same brain site (i.e. left DLPFC).
89149757|NCT02840045|Experimental|Alzheimer patients|Cerebral measurements from high-density electroencephalography are recorded in Alzheimer patients. The same protocol is applied in the 3 arms
89149758|NCT02840045|Experimental|patients with a depressive disorder|Cerebral measurements from high-density electroencephalography are recorded in patients with a depressive disorder. The same protocol is applied in the 3 arms
89149759|NCT02840045|Active Comparator|Healthy controls|Cerebral measurements from high-density electroencephalography are recorded in healthy controls
89149760|NCT02677662|Sham Comparator|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise or rest.
89149761|NCT02677662|Experimental|Diesel exhaust exposure|2 hour exposure to dilute diesel exhaust (approximate PM10 (particulate matter<10um) concentration 300 mcg/m3) during intermittent exercise or rest.
89149762|NCT02839655|Experimental|Da Vinci Xi|
89149763|NCT05662956|Experimental|Treatment group|"Induction: Subjects who meet the enrollment conditions will receive Venetoclax plus Azacitidine and CAG(VA-CAG) . Participants will receive this induction Therapy as azacitidine on days 1-7, venetoclax aily on days 1-28, cytarabine q12h on days 1-7, aclacinomycin on days 1,3,5,7, and granulocyte colony-stimulating factor on days 0-8. Participants will receive second induction if not reach complete remission.~Consolidation: If patients are intermediate or poor risk and have plans for allogeneic hematopoietic stem-cell transplantation(allo-HSCT) , high dose cytarabine (3g/m2 q12h days 1-3) for 1-2 cycles and follow up with allo-HSCT. In other cases, high dose cytarabine for 4 cycles."
89149764|NCT04250129||SLNB (-)&level 1-3 RT|SLNB (-)&level 1-3 RT
89149765|NCT04250129||SLNB (+)&level 1-3 RT|SLNB (+)&level 1-3 RT
89149766|NCT04250129||SLNB(+)&ALND&level 3 RT (+/-level 1-2)|SLNB(+)&ALND&level 3 RT (+/-level 1-2)
89149767|NCT02537496|Experimental|Alzheimer's disease rTMS|The intervention procedure done in this group is repetitive Transcranial Magnetic Stimulation.
89149768|NCT02537496|Sham Comparator|Alzheimer's disease rTMS Sham|The intervention procedure done in this group is Repetitive Transcranial Magnetic Stimulation - Sham
89149769|NCT02537496|No Intervention|Healthy Control|Healthy control group will only participate in baseline assessments which include baseline neuropsychological testing and baseline measurement of neuroplasticity. This will be used to standardize neuropsychological test scores and to compare the baseline neuroplasticity between healthy participants and Alzheimer's disease (AD) participants. Healthy control group will not get rTMS intervention.
89149770|NCT00643344|Experimental|CALMM+|Participants receiving CALMM intervention, ie program that combines stress reduction, mindful eating practices with diet and exercise
89149771|NCT00643344|Active Comparator|TLC|Participants receiving diet and exercise classes only
89149772|NCT02838173|Experimental|SPB|Serratus Plane Bloc with Ropivacaine 2mg/ml (0,3ml/kg) and tissue infiltration with placebo made once, by the anesthetist in the operating theater before surgical incision
89149773|NCT02838173|Active Comparator|tissue infiltration|tissue infiltration with Ropivacaine 2mg/ml (0,3ml/kg) and Serratus Plane Bloc with placebo made once, by the anesthetist in the operating theater before surgical incision
89149774|NCT00641394|Experimental|1|Psychotherapy: Emotional Freedom Techniques (EFT), a psychotherapy intervention with a somatic component
89149775|NCT00641394|Active Comparator|2|Psychotherapy: Cognitive Behavioral Therapy (CBT), a psychotherapy intervention
89149776|NCT00641394|No Intervention|3|
89149777|NCT02842229||Patients with Haematologic Neoplasms|"Patients with Myelodysplastic Syndromes (MDS), any IPSS (International Prognostic Scoring System) risk, or Acute Myeloid Leukemia (AML) who participated in the Geriatric Assessment in Haematology (GAH) study(CEL-GAH-2011-01).~Patients with Multiple Myeloma (MM), symptomatic or asymptomatic who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01).~Patients with Chronic Lymphocytic Leukemia who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01)."
89149778|NCT02838095|No Intervention|No nap|After each night with a 5-hour sleep opportunity, participants did not have a daytime nap opportunity, but instead watched documentaries.
89149779|NCT02838095|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants had the chance to take a daytime nap from 14:00 to 15:00.
89149780|NCT02675712||Adults with acute mood disorders|Adults aged over 18 diagnosed with an acute episode of a mood disorder using DSM-V criteria
89149781|NCT02677506|Experimental|Supraclavicular|Supraclavicular brachial plexus block will be done.
89149782|NCT02677506|Active Comparator|Infraclavicular|Infraclavicular brachial plexus block block will be done.
89149783|NCT00641472|Experimental|1|Budesonide inhalation suspension
89149784|NCT00641472|Active Comparator|2|Montelukast sodium
89149785|NCT04181268|Active Comparator|Rotational Atherectomy|"The procedure is performed by using a Rotablator system, which consists of a spring coil shaft with a burr at the tip. The front edge of the burr is the ablating portion, oval shaped, and covered with fine diamond crystals.~The rotational atherectomy catheter is introduced into the coronary artery over a dedicated long rotational atherectomy wire, which consists of a monofilament stainless steel 0.09-inch wire.~The device is connected to a console that houses the turbine that rotates the burr with pressurized nitrogen gas. Typically the rpm is set at 150,000 to 180,000 rpm.~After the lesion is crossed with the wire, the lesion is crossed with multiple pecking movements of the burr, with each run lasting not more than 20 seconds. After successful rotational atherectomy with one or more burrs, the procedure is completed with balloon angioplasty and stent placement. This can be achieved by exchanging the rota wire with a workhorse wire and using standard equipment."
89149786|NCT04181268|Active Comparator|Intravascular Lithotripsy|"The procedure is perforemed with a Coronary intravascular lithotripsy (IVL) System that consists of a generator, a connector cable with a push button to allow manually controlled delivery of electric pulses, and semi-compliant balloon catheter.~The balloon integrates two radiopaque lithotripsy emitters 6 mm that receive electrical pulses from the generator vaporising the fluid within the balloon and creating a rapidly expanding and collapsing bubble. This bubble can transmit unfocused circumferential pulsatile mechanical energy into the vessel wall, in the form of sonic pressure waves equivalent to approximately 50 atmospheres (atm). The IVL therapy consists on a maximun of 8 runs of 10 pulses (80 pulses). The number of therapies needed per lesion will depend on lesion resistance; however, a mínimum of 20 pulses is recommended.~Alter IVL, an optional additional post-dilatation with non-compliant balloons, a stent is implanted"
89149787|NCT04181268|Active Comparator|Excimer Laser|"Excimer laser is pulsed gas laser that use Xenon chloride (XeCl) as the active medium to generate pulses of short wavelength, high-energy ultraviolet (UV) light.~Excimer laser tissue ablation is mediated through three distinct mechanisms: photochemical, photo-thermal and photomechanical. UV laser light is absorbed by intra-vascular material and breaks carbon-carbon bonds (photochemical). It elevates the temperature of intra-cellular water, causing cellular rupture and generates a vapor bubble at the catheter tip (photo-thermal). Expansion and implosion of these bubbles disrupts the obstructive intra-vascular material (photomechanical). The laser catheter is advanced slowly over a conventional wire while the therapy is aplied and saline is inffused. After laser, balloon dilatation is usually performed finishing the procedure with stent implantation"
89149788|NCT02675556|Experimental|Allogeneic hMSCs|Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
89149789|NCT02675556|Placebo Comparator|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
89149790|NCT02675556|Experimental|Pilot - Allogeneic hMSCs|Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
89149791|NCT00896051|Experimental|ATV/rtv 300/100 mg (Treatment A)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pre-treatment followed by ATV/rtv 300/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will receive TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
89149792|NCT00896051|Experimental|ATV/rtv 400/100 mg (Treatment B)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pretreatment followed by ATV/rtv 400/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will take TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
89149793|NCT02675478|Experimental|AC220|This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.
89149794|NCT00641550|Experimental|2|Pregnant women starting to practice physical exercise at 13 weeks(Walking moderate activity)
89149795|NCT00641550|Experimental|3|Pregnant women starting exercise at 20 weeks
89149796|NCT00641550|No Intervention|1|Pregnant women without exercise practice.
89149797|NCT02673606|Experimental|Estradiol 2mg Dose|2mg dose of estradiol (oral administration)
89149798|NCT02673606|Experimental|Estradiol 4mg Dose|4mg dose of estradiol (oral administration)
89149799|NCT02673606|Placebo Comparator|Placebo|placebo (oral administration)
89149800|NCT02675400|Active Comparator|Medication Arm|Vyvanse Arm: 3-week open-label titration beginning at 20 mg Vyvanse (a class II drug), and be increased weekly during the titration period until an optimal response is obtained and then continue for 5 weeks. Optimal response is defined as a clinician Clinical Global Impression-Improvement score (CGI-I) ≤ 2 with minimal associated adverse events. Fathers will remain on optimal dose through the course of the study. In cases of poor tolerability or loss of efficacy the dose can be changed. If an optimal response is not achieved a trial with a long acting methylphenidate will be initiated based upon the Texas algorithm for stimulant medication. The study physician will be available by phone 24 hours/day; participants will be instructed to call with any safety concerns.
89149801|NCT02675400|Active Comparator|Behavioral Parent Training Arm|"Behavioral Parent Training (BPT) Arm: Fathers in the BPT group will receive weekly parent training sessions based on the Barkley manual, Defiant Children, Third Edition. The child participants will also come to several sessions at the clinician's and supervisor's discretion."
89149802|NCT00894647|Placebo Comparator|2|placebo cream in 250mg/packet, up to 2 packets applied daily
89149803|NCT00894647|Active Comparator|imiquimod cream|Imiquimod 3.75% cream, 250 mg single-use packets, up to 2 packets applied daily
89149804|NCT02839421|Experimental|Scaling and Root Planing plus moxifloxacin|The interventions are Scaling and Root Planing (SRP) combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days.The experimental treatment group consist of SRP combined with systemically administered MOX at the dosage of 400 mg once daily for 7 days.One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the MOX group will be extensively informed about the intake of the prescribed medication.
89149805|NCT02839421|Active Comparator|Scaling and Root Planing plus amox-metro|"The active comparator is Scaling and Root Planing (SRP) combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days. The active comparator group consist of SRP combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days.~One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the amox-metro group will be extensively informed about the intake of the prescribed medication."
89149806|NCT02839421|Placebo Comparator|Scaling and Root Planing plus placebo|Scaling and Root Planing (SRP) + placebo once daily for 7 days. The placebo comparator group consist of SRP combined with systemically administered placebo once daily for 7 days. One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The placebo agent will start at the SRP visit. Subjects in the placebo group will be extensively informed about the intake of the prescribed medication.
89149807|NCT02839577|Active Comparator|High Volume injection (HVI) with corticosteroid|"10 mls 0.5% bupivacaine hydrochloride~20 mg of Depomedrol (40 mg/ml methylprednisolonacetat)~40 mls saline (NaCl)~HVI with corticosteroid is injected one time at baseline and compared to HVI without corticosteroid."
89149808|NCT02839577|Active Comparator|High Volume injection (HVI) without corticosteroid|"10 mls 0.5% bupivacaine hydrochloride~40 mls saline (NaCl)~HVI with corticosteroid is injected one time at baseline and compared to HVI with corticosteroid."
89149809|NCT04179942|Active Comparator|Patients|full night PSG (polysomnogram) was done, fractional exhaled nitric oxide and Hs-CRP were measured
89149810|NCT04179942|Placebo Comparator|control|CRP level was measured
89149811|NCT02837549|Experimental|Occupational therapy treatment|"Participants will undergo the following as appropriate:~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~Application of the Physiotouch (a low-intensity negative pressure device)~Passive Range of Motion~Active Range of Motion~Functional Activities"
89149812|NCT02677194|Experimental|Exposition LED|The patient is his own witness. This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm. Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act : exposition to LED 590nm (4 or 12sec) or 630nm(4min30 or 15 min) or 830 nm (6 or 12 min).
89149813|NCT02677194|Other|Control|Device without any LED exposition : This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm or control (1 mini-zone)
89149814|NCT04250831|Experimental|Glucomannan, oligofructose and chromium mixture|Agglomerated glucomannan, oligofructose and chromium mixture as the functional ingredient in a calorie
89149815|NCT02841917||Transcatheter Aortic Valve Replacement|ROS Post TAVR
89149816|NCT02841917||Surgical Aortic Valve Replacement|ROS Post SAVR
89149817|NCT02841605|Other|AD group|AD group: rectosigmoidospcopy with biopsies of colon
89149818|NCT02841605|Other|PD group|PD group: rectosigmoidospcopy with biopsies of colon
89149819|NCT02841605|Other|PSP group|PSP group: rectosigmoidospcopy with biopsies of colon
89149820|NCT02841605|Other|Patient eligible for colorectal cancer screening|Patient eligible for colorectal cancer screening: colonoscopy with biopsies of colon
89149821|NCT04179630|Experimental|Aldafermin (NGM282)|Administered by subcutaneous injection
89149822|NCT02839499|Experimental|mixed food|experimental group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
89149823|NCT02839499|Other|normal texture food|control group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
89149824|NCT02675322|Experimental|Danlou Tablets|Danlou tablets (4.5 g oral dose taken once daily) for 90 days
89149825|NCT02675322|Placebo Comparator|placebo|matching placebo for 90 days
89149826|NCT00633191|Experimental|Anti-pseudomonas IgY gargle|Intervention: Gargles with anti-pseudomonas IgY every night
89149827|NCT04178382|Experimental|experiment group|Combined detection of PCR and CRISPR/Cas12a in alveolar lavage fluid to guide early target adjustment of antibiotics
89149828|NCT04178382|No Intervention|control group|Guide the target adjustment of antibiotics according to traditional microbiological detection methods
89149829|NCT02675166||Pediatric cancer young adult survivors|544 patients alive and that are min 18 years old, included in the ARCERRA population register, for a primary cancer (not leukemia), diagnosed between 15 years old, between January the 1st 1993, and December the 31st 1999, in Rhône-Alpes.
89149830|NCT04249817|Experimental|Video conferencing with extended role practitioner|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
89149831|NCT04249817|No Intervention|Usual care|Participant goes to their rheumatologist's clinic for follow-up, including physical assessment by their rheumatologist, as they would normally.
89149832|NCT02841683|Active Comparator|Lifestyle counseling|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
89149833|NCT02841683|No Intervention|Current practices|Current practices of smoking cessation in France
89149834|NCT02675088|Experimental|high-dose TRT|high-dose thoracic radiotherapy X-ray RT
89149835|NCT02675088|Active Comparator|standard-dose TRT|standard-dose thoracic radiotherapy XRT
89149836|NCT02841293|Experimental|Arm with biological mesh|The intervention consists of perinal reconstruction using biological mesh (Cellis prosthesis from Meccellis Biotech, reference C1015E size 10x15cm)
89149837|NCT02841293|Active Comparator|Arm with primary perineal wound closure|The intervention consists of perinal reconstruction by primary perineal wound closure
89149838|NCT00643422||Observation|
89149839|NCT02837393||History of Kidney Stones|Participants with a history of kidney stones who will be undergoing kidney surgery.
89149840|NCT02837393||No History of Kidney Stones|Participants without a history of kidney stones who will be undergoing kidney surgery.
89149841|NCT00910104|Experimental|Omegaven|1g/kg/day for duration of study participation for all participants
89149842|NCT02837081|Active Comparator|Preauthorization group|Strategy 1 of antimicrobial stewardship: Prescriptions of antimicrobial agents are done real-time by infectious diseases physician consultant. Use restricted without real-time authorization.
89149843|NCT02837081|Experimental|Prospective audit|Strategy 2 of antimicrobial stewardship: Prescription of antimicrobial agents are audited 48-72 hours later by infectious diseases physician consultant. Use allowed without authorization for 72 hours.
89149844|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES|ENDOSCOPIC BIOPSEIS TAKEN FROM BOTH ANTRUM AND CORPUS FOR H PYLORI DETECTION
89149845|NCT02674620|No Intervention|Conservative|Standard conservative care of concussion
89149846|NCT02674620|Experimental|Treadmill|Aerobic exercise treatment for concussion
89149847|NCT02839187|Experimental|Patients with Alzheimer Disease|Patients will have Neuroimaging by Florbetapir (AV-45)-positron emission tomography
89149848|NCT02839187|Active Comparator|Controls patients|Controls will have neuroimaging by AV45-positron emission tomography
89149849|NCT02690675|Experimental|Intervention high-iron fortified milk|This group received a high dose of iron by formula milk (1.2mg/100mL) between 6 and 12 months of age.
89149850|NCT02690675|Experimental|Intervention low-iron fortified milk|This group received a low dose of iron by formula milk (0.4mg/100mL) between 6 and 12 months of age.
89149851|NCT05658978|Experimental|Neuromuscular training of male handball players|Neuromuscular training exercises focus on improving physical fitness and skills performance. Neuromuscular training targets the neuromuscular system through engagements of muscle groups as well as nerve function to optimize movements. This training has been considered an effective treatment method to enhance the neurophysiological entity of the joints for coordinated functioning. However, the present study applied neuromuscular training to elite male handball players to assess fitness level as well as skill performance. Post-test 1 will be after 6 weeks, and post-test 2 after 12 weeks to measure performance.
89149852|NCT05658978|Active Comparator|Male handball players continue previous regular exercises|Handball players as a control group will be continuing their previous regular exercises for 12 weeks.
89149853|NCT02677350|Experimental|Pilot|Twenty (20) subjects will be treated with 20 million (2 x 10^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection.
89149854|NCT04181346|Experimental|Pregabalin|Pregabalin 75mg, twice a day, from the night before chemotherapy to day 5
89149855|NCT04181346|Experimental|Placebo|Placebo, twice a day, from the night before chemotherapy to day 5
89149856|NCT04181502|Experimental|Inflation of a pneumatic tourniquet|
89149857|NCT04181502|Sham Comparator|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
89149858|NCT05277246|Active Comparator|1% NaOCIL|2 ml of 1% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
89149859|NCT05277246|Active Comparator|2.5% NaOCI|2 ml of 2.5% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
89149860|NCT05277246|Active Comparator|5.25% NaOCI|2 ml of 5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.
89149861|NCT00642564||001|
89149862|NCT04180956|Experimental|Intervention|The bias-reduction intervention opened with a didactic on health disparities, stereotypes, microaggressions, interracial provider-patient interactions and racism. Then, a guided, interracial eye-contact mindfulness exercise was performed to increase providers' awareness and acceptance of subtle bias that occurs in interracial interactions. Then, in small, mixed-race groups, participants practiced the above mindfulness skills while reciprocally sharing and responding with empathy to each other's personal life histories and personal narratives of loss and/or betrayal. The intervention ended with explicit practice component, involving practice and feedback.
88804255|NCT05775666|Experimental|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
88804256|NCT05775640|No Intervention|control group|Sociodemographic data collection form, Clinical Information Form, The child medical fears scale, State and Trait Anxiety Inventory for Children were administered to the children in the control group, and the State-Trait Anxiety Inventory (STAI) was administered to the parents of the children in the control group on the 0th day of hospitalization. The standard clinical hospitalization process was not interfered with. On the third day of hospitalization, the children in the control group were administered the Clinical Information Form, the The child medical fears scale, the State and Trait Anxiety Inventory for Children, and the State-Trait Anxiety Inventory (STAI) for their parents. After the study, the link of the game was sent to the control group so that they could play the game in order to avoid ethical problems.
88804257|NCT05775640|Experimental|intervention group|
88804258|NCT05775614|Experimental|Uro-Tainer® catheter flushing|Uro-Tainer® catheter flushing two times weekly for 6 months.
88804259|NCT05775614|Placebo Comparator|Saline catheter flushing|Saline solution catheter flushing two times weekly for 6 months.
88804260|NCT05775575|Experimental|TQB3909 tablets|200-1000mg of TQB3909 tablets once a day; Oral administration under fast condition, 28 days as a cycle.
88804261|NCT05775536|Experimental|Aspirin® 500 mg tablets|Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening Ingredients: 500 mg acetylsalicylic acid, Cellulose powder, maize starche
88804262|NCT05775536|Experimental|Dr. Böhm® Omega 3 complex 870 mg|Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
88804263|NCT05775497|Experimental|Weight Loss Program Only|Participants complete an online behavioral weight loss program.
88804264|NCT05775497|Experimental|Weight Loss Program + Coping with Stress Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss.
88804265|NCT05775497|Experimental|Weight Loss Program + Coping with Stress Program + Body Image Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
88804266|NCT05775497|Experimental|Weight Loss Program + Coping with Stress Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (4) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
88804267|NCT05775497|Experimental|Weight Loss Program + Body Image Program + Social Support Program|Participants complete (1) an online behavioral weight loss program, (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts, and (3) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
88804268|NCT05775497|Experimental|Weight Loss Program + Coping with Stress Program + Social Support Program|Participants complete a (1) online behavioral weight loss program, (2) an adjunctive intervention that teaches strategies for coping with stress & stigma due to weight, sexual orientation, and gender & its impact on weight loss, and (3) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
88804269|NCT05775497|Experimental|Weight Loss Program + Body Image Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive intervention for improving negative body image and reducing its impact on weight loss.
88804270|NCT05775497|Experimental|Weight Loss Program + Social Support Program|Participants complete (1) an online behavioral weight loss program and (2) an adjunctive Social Support Intervention that provides participants with online opportunities to give and receive real-time social support for weight loss efforts.
88804271|NCT05775419|Sham Comparator|Group A: radical chemoradiotherapy group;|Concurrent chemotherapy (2 courses): Lipusu (T) + Cisplatin (DDP) scheme: T 135mg/m2 ivgtt, d1, 3week*2cycles; DDP 75mg/m2 ivgtt, d2, 3week*2cycles; Radiotherapy scheme: intensity modulated radiotherapy PTV50-54Gy, PGTV 56-60Gy, conventional fractionation.
88804272|NCT05775419|Experimental|Group B: radical chemoradiotherapy combined with consolidation chemotherapy group|Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen; Radiotherapy scheme: intensity modulated radiotherapy PTV50-54Gy, PGTV 56-60Gy, conventional fractionation.
88804273|NCT05775393|Experimental|Group A|Serratus anterior plane block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg)
88804274|NCT05775393|Experimental|Group B|Serratus anterior plane block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).
88804275|NCT05775302|Experimental|IASTM Gastrocnemius|"Instrument assisted soft tissue mobilization on gastrocnemius~Conventional therapy:~Cryotherapy for 10 min stretching of calf and plantar fascia strengthning of intrinsic foot muscle"
88804276|NCT05775302|Active Comparator|IASTM Achillies Tendon|"Instrument assisted soft tissue mobilization Achillies Tendon~Conventional therapy:~Cryotherapy for 10 min stretching of calf and plantar fascia strengthning of intrinsic foot muscle"
88804277|NCT05775276|Experimental|Incidence Of Mesh Infection After proline mesh Hernioplasty|Cases presented with strangulated or obstructed hernia
88804278|NCT05775224||Sickle Cell Disease|
88804279|NCT05775224||Multiple Myeloma|
88804280|NCT05775211|Experimental|Endometrial composition before and after autologous modulated PBMC administration|The endometrial cell composition in terms of cell quantities and spatial distribution will be compared before and after intrauterine administration of immunomodulated PBMC.
89149863|NCT04180956|No Intervention|Control|The control condition was a waitlist condition. Doctors were given workshop materials after the study ended.
89149864|NCT04181190||Mepolizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL-5 monoclonal antibody (Mepolizumab)
89149865|NCT04181190||Benralizumab group|atopic patients with severe eosinophilic asthma treated with anti-IL5 receptor monoclonal antibody (Benralizumab)
89149866|NCT00892775|Experimental|Priorix-Tetra new WS Group|Subjects received 2 doses of Priorix-Tetra vaccine formulated with new measles and rubella working seeds at Day 0 and Week 12.
89149867|NCT00892775|Experimental|Priorix-Tetra current WS Group|Subjects received 2 doses of Priorix-Tetra vaccine manufactured with current working seed virus at Day 0 and Week 12.
89149868|NCT02676648|Experimental|Experimental: Condition 1|1) core program; 2) breath meter; 3) text messages; 4) diet-appropriate food and cookbooks
89149869|NCT02676648|Experimental|Experimental: Condition 2|1) core program
89149870|NCT02676648|Experimental|Experimental: Condition 3|1) core program; 2) breath meter
89149871|NCT02676648|Experimental|Experimental: Condition 4|1) core program; 2) text messages
89149872|NCT02676648|Experimental|Experimental: Condition 5|1) core program; 2) diet-appropriate food and cookbooks
89149873|NCT02676648|Experimental|Experimental: Condition 6|1) core program; 2) breath meter; 3) text messages
89149874|NCT02676648|Experimental|Experimental: Condition 7|1) core program; 2) breath meter; 3) diet-appropriate food and cookbooks
89149875|NCT02676648|Experimental|Experimental: Condition 8|1) core program; 3) text messages; 4) diet-appropriate food and cookbooks
89149876|NCT04033536|Active Comparator|Involved target SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined Involved Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
89149877|NCT04033536|Active Comparator|Elective target SSRS|SSRS with 16 Gy in single fraction to the defined Elective Target Volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
89149878|NCT00642720|Other|pegvisomant-placebo|patients in this arm received(as addition)for the first 8 weeks Pegvisomant and the later for 8 weeks Placebo. This was divided by a 4 weeks wash-out period.
89149879|NCT00642720|Other|placebo-pegvisomant|Patient received for the first 8 weeks Pegvisomant and after a wash out period of 4 weeks the received 8 of placebo treatment
89149880|NCT02674698|Other|VA Integrated Service Networks Group 1|Access to the CNH Dashboard Step 1
89149881|NCT02674698|Other|VA Integrated Service Networks Group 2|Access to the CNH Dashboard Step 2
89149882|NCT02674698|Other|VA Integrated Service Networks Group 3|Access to the CNH Dashboard Step 3
89149883|NCT02674698|Other|VA Integrated Service Networks Group 4|Access to the CNH Dashboard Step 4
89149884|NCT05395338||IV rt-PA cohort|Patients who received IV rt-PA within 4.5 hours of symptom onset
89149885|NCT05395338||Non-reperfusion cohort|Patients who arrived or were admitted to the hospital within4.5 hours of symptom onset and did not receive any reperfusion treatment
89149886|NCT00643656|Experimental|A|Mixture of 50% nitrous oxide and 50% oxygen
89149887|NCT00643656|Placebo Comparator|B|Mixture of 50% oxygen and 50% nitrogen
89149888|NCT04179318||low risk|BCT Score <4
89149889|NCT04179318||high risk|BCT Score ≥4
89149890|NCT05364996||child with severe asthma|Child eligible for bronchial endoscopy with bronchoalveolar lavage (LBA) for assessment of severe asthma. The diagnosis of asthma being established by a pneumo-pediatrician in the presence of a history of respiratory symptoms such as wheezing, shortness of breath, chest tightness and coughing variable in time and intensity, associated with a variable limitation expiratory flows.
89149891|NCT02676726|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
89149892|NCT02676726|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
89149893|NCT05443464|Experimental|2M cells/kg|Dose level 1. 3 subjects will receive OSSM-001 at 2M cells/kg and followed for 28 days post dose to observe for DLT.
89149894|NCT05443464|Experimental|6M cells/kg|Dose level 2. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 6M cells/kg and followed for 28 days post dose to observe for DLT.
89149895|NCT05443464|Experimental|12M cells/kg|Dose level 3. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 12M cells/kg and followed for 28 days post dose to observe for DLT.
89149896|NCT05443464|Experimental|24M cells/kg|Dose level 4. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 24M cells/kg and followed for 28 days post dose to observe for DLT.
89149897|NCT02673216||Spontaneous abortion|Women attending for suspected spontaneous abortion
89149898|NCT02673216||Normal pregnant women|Normal pregnant women attending for nuchal translucency scan
89149899|NCT00643734|Experimental|1|
89149900|NCT00643734|Experimental|2|
89149901|NCT04181112|Experimental|Fecal microbiota transplantation|
89149902|NCT04181112|Experimental|Fecal microbiota transplantation with antibiotic pre-treatment|
89149903|NCT04181112|No Intervention|No intervention follow-up|
89149904|NCT04181034|Experimental|PYD|Case managers meet with participating pregnant and parenting females at least two times a month over 12 months. In the short term, the program seeks to improve social competence, problem-solving skills, autonomy, increased sense of purpose, improved knowledge and use of contraceptives, increased linkages and support networks, improved quality of relationships, increased access to and strengthen relationship with a trusted adult, increased knowledge of and access to healthcare and improved health and well-being of expectant or parenting mother. In the long term, the program aims to delay subsequent pregnancy and reduction in health risk behaviors, improved health and well-being of parent and child, improved educational and employment outcomes and increased self-sufficiency.
89149905|NCT04181034|Active Comparator|AFLP|Case managers meet with participating pregnant and parenting females once a month over 24 months to deliver older, business-as-usual version of the program that does not have positive youth development component.
89149906|NCT02674932|Experimental|Signature Strengths|"Patients will complete the Values in Action Youth Survey (VIA-Youth) and will receive a list of his/her top character strengths (signature strengths). The patient will then participate in the Identifying and Using Signature Strengths Intervention."
89149907|NCT02674932|Active Comparator|Coping Skills + Memory Aid|Patients will complete the VIA-Youth but will not receive any results. The patient will then participate in the Identifying and Writing Down Coping Skills Intervention.
89149908|NCT02674932|Other|Coping Skills (Treatment as Usual)|Patients will complete the VIA-Youth but will not receive any results. After completing the VIA-Youth, the study team member and patient will have a treatment-as-usual discussion about coping skills. (This is equivalent to treatment as usual that is already provided on the psychiatric unit-doctors and nurses on the unit already have this a discussion about coping skills with patients).
89149909|NCT04178226|No Intervention|Control|conventional therapy (NSAIDs and OCP)
89149910|NCT04178226|Experimental|Manual Acupuncture|manual acupuncture therpy
89149911|NCT04178226|Experimental|Laser Acupuncture|laser acupuncture therapy
89149912|NCT02674776|Experimental|HuZhen Capsule|The main elements of HuZhen Capsule include Polygonum cuspidatum, Ligustrum lucidum etc.
89149913|NCT02674776|Placebo Comparator|Placebo Capsule|Placebo appearance, content color and taste should be consistent with HuZhen Capsule.
89149914|NCT02673294|Experimental|intervention (6-12 months)|Participants with a chronicity between 6-12 months
89149915|NCT02673294|Experimental|Intervention (12-24 months)|Participants with a chronicity between 12-24 months
89149916|NCT02673294|Experimental|Intervention (>24 months)|Participants with a chronicity >24 months
89149917|NCT02673060|Experimental|dose escalation of MBC-11|MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)
89149918|NCT04180800||Folic acid deficiency|Those with a folic acid defiency
89149919|NCT04180800||No deficiency|Those with no folic acid deficiency
89149920|NCT00643812|Experimental|1|"The Early intervention arm received a gun locker at baseline"
89149921|NCT00643812|Active Comparator|2|Households in this arm received a gun locker at 12 months following the baseline survey
89149922|NCT02672904|Active Comparator|CO2 laser|Patients undergoing endoscopic treatment with CO2 laser
89149923|NCT02672904|Active Comparator|KTP laser|Patients undergoing endoscopic treatment with KTP laser
89149924|NCT02674308||Vedolizumab|
89149925|NCT02674308||Other Biologic Agents|
89149926|NCT04180878|No Intervention|Control Arm|Participants in this group were informed to continue to receive usual care.
89149927|NCT04180878|Experimental|Intervention Arm|Received an interactive physical activity monitoring system (the Gruve®).
89149928|NCT04180878|Experimental|Intervention Arm 2|Received an interactive physical activity monitoring system (the Gruve®) and group based phone counseling (GBPC).
89149929|NCT02676258|Experimental|Si-Hy soft contact lens|olifilon B daily disposable soft contact lens
89149930|NCT02676258|Active Comparator|Vistakon soft contact lens|narafilcon A daily disposable soft contact lens
89149931|NCT04180566|Other|Weekly antenatal testing|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive weekly antenatal testing (biophysical profile) starting at 34 weeks as well as growth ultrasound every 4 weeks.
89149932|NCT04180566|Other|Growth ultrasound examination every 4 weeks|Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive ultrasound examination (growth ultrasound) every 4 weeks starting at 34 weeks.
89149933|NCT04180644||Atopic Dermatitis|Participants with atopic dermatitis active lesions
89149934|NCT04180644||Healthy Control|Participants without a history of atopic dermatitis
89149935|NCT04180332|Experimental|Healthy|The patients were healthy subjects without Periodontal disease or any systemic manifestation
89149936|NCT04180332|Experimental|Periodontal disease without diabetes|Patients with periodontal diseases without diabetes
89149937|NCT04180332|Experimental|Periodontal disease with diabetes|Patients with periodontal disease and diabetes
89149938|NCT04179240|Experimental|audio and animated cartoon questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with audio and animated cartoon questionnaire. The animation was an 8-minute cartoon video divided into different parts according to different questions. The first part of the animation was the introduction of biospecific nonspecimen specimen and our survey, while the other parts showed the content of the questionnaire about donating biospecific nonspecimen specimen in a vivid way. The background music built a relaxed and pleasant atmosphere, and some cartoon pictures were made into question options to simplify the understanding and data analysis.
89149939|NCT04179240|No Intervention|text questionnaire group|After a brief introduction to our survey, participants(children) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
89149940|NCT04179240|Other|Parent group|After a brief introduction to our survey, participants(parent) were asked to complete a questionnaire on a professional platform named 'Wen juan xing app'(www.wjx.cn) with text questionnaire.
89149941|NCT04178928|Active Comparator|group A|patiWill receive L-T4 treatment at a dose 1 µg/kg/day for 12 weeks. And the dose will be titrated every 4 weeksents with SCH will be subjected to clinical, laboratory and imaging assessment and
89149942|NCT04178928|No Intervention|Group B|.pWill not receive treatment.atients with SCH will be subjected to clinical, laboratory and imaging assessment and
89149943|NCT04179006|Active Comparator|LF chocolate + antidepressant(s)|Participants with LF chocolate add-on to their antidepressants regimen.
89149944|NCT04179006|Active Comparator|Erinacine A-enriched Hericium chocolate + antidepressant(s)|Participants with Erinacine A-enriched Hericium chocolate add-on to their antidepressants regimen.
89149945|NCT04179006|Placebo Comparator|Plain chocolate + antidepressant(s)|Participants with plain chocolate add-on to their antidepressants regimen.
89149946|NCT02672670|Experimental|Coping-oriented supportive programme|Coping-oriented supportive programme: education of the SCI disease information, learning from role model by watching a well-established DVD, discussion about how to break down stressors and used appropriate coping strategies (problem-solving training, cognitive re-constructing, relaxation exercises, and activity scheduling) to manage the stressors relating to SCI. Social skills training and ways of maintaining and improving social support will also be discussed and practiced in the COSP.
88806023|NCT02531802|Experimental|24-59 months: ETVAX (1/2)|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
89149947|NCT02672670|Active Comparator|A didactic group|Usual rehabilitation care--routine inpatient rehabilitation care and brief education in groups (structured by both the rehabilitation nurses and the researcher), which will consist of similar professional contacts as the intervention (COSP) group, and thus can balance between the two study groups for the effect of social contacts and attention to SCI patients during group sessions. The intervention in the comparison group will be conducted by a rehabilitation nurse in the SCI wards. The knowledge/didactic education presented to the patients in the comparison group will be the basic health education and relevant information provided by the rehabilitation nurses in their routine care (mainly including knowledge of SCI, nutritional needs, skin care, bowel and bladder training, and other physical and psychological care of patients with SCI provided by the inpatient rehabilitation wards).
89149948|NCT00643968|Active Comparator|1|TDF+EFV
89149949|NCT00643968|Experimental|2|TDF+3TC+EFV
89149950|NCT02672592|Active Comparator|Anakinra|Anakinra//Kineret® 100mg s.c. bid
89149951|NCT02672592|Placebo Comparator|Placebo|Sodium Chloride 0.9% s.c. bid
89149952|NCT00643032|Active Comparator|I|
89149953|NCT00643032|Active Comparator|II|
89149954|NCT02676414|Other|Education program|"Group of patients participating in the interactive hypertension education program of the DHL© My blood pressure - OK!"
89149955|NCT02676414|No Intervention|Controls|"Group of patients not participating in the interactive hypertension education program of the DHL© My blood pressure - OK! (usual care)"
89149956|NCT02672436|Experimental|ENERGI-F703|ENERGI-F703, topical application, 2 times daily for 12 weeks
89149957|NCT02672436|Placebo Comparator|Placebo|ENERGI-F703 matched vehicle, topical application, 2 times daily for 12 weeks
89149958|NCT02674074|Experimental|measurement of corneal temperature by infrared thermography|
89149959|NCT02674152|Experimental|BI 836880|
89149960|NCT04179084|Experimental|fruquintinib + Sintilimab|
89149961|NCT04178850|Experimental|GB242|3mg/kg
89149962|NCT04178850|Active Comparator|Infliximab|3mg/kg
89149963|NCT04178616|Other|systemic sclerosis patients population|All the patients with systemic sclerosis disease followed in day-care in a tertiary hospital are eligible to be enrolled in the study.
89149964|NCT00644046|No Intervention|1|Chronic kidney disease patient with standardized nephrology care
89149965|NCT00644046|Active Comparator|2|chronic kidney disease patient with multidisciplinary predialysis care
89149966|NCT04180410|Other|EIT|Electrical Impedance Tomography is performed before extubation, during follow up visits of extubation and 48H after extubation
89149967|NCT02676492||Tic Disorder|Boys with a diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD) aged 11-14 years
89149968|NCT02676492||Control|Boys aged 11-14 years without a diagnosis of TS/CTD (i.e. typically developing)
89149969|NCT02676336|Active Comparator|Violet™ Iodine|3mg molecular iodine (I2) daily
89149970|NCT02676336|Placebo Comparator|Placebo|3mg placebo daily
89149971|NCT02676336|Active Comparator|Cross-over|Subjects on placebo will be offered 3 months of active post-treatment
89149972|NCT00643188|Experimental|1|"Radiofrequency ablation of atrial fibrillation:~Subjects assigned to the catheter AF ablation strategy will undergo ablation within 48 hours after baseline evaluation. The aim of the procedure is to achieve isolation of all Pulmonary Veins (PVs) and to restore sinus rhythm. Only radiofrequency catheter based AF ablation is permitted; other methods, like cryoablation, ultrasound and laser, are not permitted in this study.~Before ablation, a transesophageal echocardiogram must be performed in order to rule out presence of atrial thrombi.~Anticoagulation should be initiated, or continued, for at least six months post ablation. Six months after successful ablation and in absence of any recurrence of AF, antiarrhythmic drugs should be discontinued."
89149973|NCT00643188|Active Comparator|2|"Conventional treatment:~Subjects assigned to the conventional treatment strategy will be treated according to current guidelines for the management of patients with chronic heart failure and/or atrial fibrillation. Efforts to maintain sinus rhythm in this study arm are recommended.~Anticoagulation will be initiated, if not already started, and maintained throughout the study according to current guidelines."
89149974|NCT05314764|Experimental|Cefiderocol|Participants will receive intravenous cefiderocol at a dosing regimen consistent with the current prescribing information and according estimated renal function. Each dose will be infused over 3 hours.
89149975|NCT04180254|Experimental|Experimental: normal-hearing and hearing-impaired participants|normal and hearing-impaired participants
89149976|NCT02672358|Experimental|Dabrafenib +Trametinib|Oral Dabrafenib plus Oral Trametinib
89149977|NCT05552352|Experimental|Intervention Arm|Patients in the intervention arm receive on the day before the implantation of the artificial aortic valve, a virtual reality assisted information. On the day of the implantation the patients are informed about the process via virtual reality assisted information.
88806024|NCT02531802|Experimental|24-59 months: ETVAX (full)|24-59 month old children receiving a full adult dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
89149978|NCT05552352|No Intervention|Control Arm|Patients in the control arm receive no virtual reality assisted information.
89149979|NCT02675868|Experimental|Norepinephrine|The noradrenaline group: a group of 10 subjects that will receive noradrenaline 0.05 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
89149980|NCT02675868|Active Comparator|Vasopressins|The vasopressin group: a group of 10 subjects that will receive vasopressin 0.04 IU/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
89149981|NCT02675868|Active Comparator|Phenylephrine|The phenylephrine group: a group of 10 subjects that will receive phenylephrine 0.5 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
89149982|NCT02675868|Placebo Comparator|Placebo|The placebo group: a group of 10 subjects that will receive NaCl 0.9% infusion for 5 hours, starting 60 minutes before endotoxin administration.
88804281|NCT05775198|Experimental|Intrauterine administration of PBMC immunomodulated with IFNt|Approximately 9 ml whole blood will be collected from each patient 5 days post LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. After washing the obtained PBMCs, they will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. On day 6 after LH peak, this cultured cell suspension will be carefully introduced in the uterine cavity by catheter. The following day (LH+7), patients will undergo a standard embryo transfer (ET) procedure.
88804282|NCT05775198|No Intervention|Control Group|Participants will undergo standard embryo transfer procedure with no intervention.
88804283|NCT05775172||Waitlist control|Waitlist control (C group n=30) did not achieve any significant weight loss and did not follow lifestyle intervention
88804284|NCT05775172||Lifestyle intervention|Lifestyle intervention (LS group, n=22) follows multimodal lifestyle intervention in form of 500-100 kcal deficit , gradual physical activity and some behavioral modifications
88804285|NCT05775172||Bariatric surgery|Bariatric surgery (BS group n=27) undergoes laparoscopic sleeve gastrectomy
88804286|NCT05775120||Cohort 1|"Screening for H. pylori infection is planned in 5121 citizens living in different administrative districts of Moscow. The cohort will be formed based on age and sex structure of the Moscow population. The presence of H. pylori will be analyzed using 2 non-invasive methods - 13C-urease breath test and serological test (detection of IgG antibodies to H. pylori). An epidemiological questionnaire will be filled out for each respondent which will display basic information on the patient (gender, age, eating habits, bad habits, family history of cancer, etc.), as well as characterize the main symptoms, if any.~Based on pepsinogen (PG) I levels and PG II (serological markers of atrophy of the gastric mucosa), patients with a high risk of atrophic gastritis and precancerous lesions in the gastric mucosa will be identified and the age and sex structure of atrophic gastritis prevalence in Moscow will be constructed."
88804287|NCT05775120||Cohort 2|From 5121 respondents, 500 patients with confirmed H. pylori infection and serological markers of atrophic gastritis and a control group of infected with H. pylori without serological markers of gastric mucosa atrophy will be selected. They will undergo esophagogastroduodenoscopy with two gastric mucosa biopsies. The first will be conducted according to the OLGA system with a pathology assessment of the stage and degree of gastritis, while the second will be taken to determine the antimicrobial susceptibility of H. (polymerase chain reaction and culture). Correlations between serological and patholgy data on atrophy will be assessed in order to determine the reliability of serological screening for atrophy in the Moscow population.
88804288|NCT00004126|Experimental|Arm A|Paclitaxel 175 mg/m2 : administered by 1-hour constant rate IV infusion through a pump on day 1 of each cycle. Oxaliplatin 130 mg/m2 : On Day 1 of each 21-day treatment cycle, patients receive oxaliplatin diluted in 250-500 mL Dextrose 5% in Water infused intravenously over 2 hours.
88804289|NCT05775055|Experimental|Commercially Available Oral Rehydration Solution A|A commercially available oral rehydration solution (~2.8% carbohydrate, ~45 mmol/L sodium, ~20 mmol/L potassium, 34 mmol/L chloride)
88804290|NCT05775055|Experimental|Commercially Available Oral Rehydration Solution B|A commercially available oral rehydration solution (~0.1% carbohydrate, ~2% amino acids (protein), ~67 mmol/L sodium, ~20 mmol/L potassium, 30 mmol/L chloride)
88804291|NCT05775055|Experimental|Commercially Available Oral Rehydration Solution C|A commercially available oral rehydration solution (~2.2% carbohydrate, ~45 mmol/L sodium, ~20 mmol/L potassium)
88804292|NCT05774964|Experimental|Chemotherapy alone group|Patients treated with chemotherapy using SOX regimen alone. SOX regimen every 3 weeks,oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area, and tegafur orally on d2-d15 at 20 mg three times daily.
88806025|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 2.5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
89149983|NCT05279742|Experimental|HFpEF-CKD with MANP and oral placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug MANP and an oral placebo followed by a 1 week washout period.
89149984|NCT05279742|Experimental|HFpEF-EI with MANP and oral placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug MANP and an oral placebo followed by a 1 week washout period.
89149985|NCT05279742|Experimental|HFpEF-CKD with Sacbitril/Valsartan with an injected placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug Sacbitril/Valsartan and an injected placebo followed by a 1 week washout period.
89149986|NCT05279742|Experimental|HFpEF-EI with Sacbitril/Valsartan with an injected placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive study drug Sacbitril/Valsartan and an injected placebo followed by a 1 week washout period.
89149987|NCT05279742|Placebo Comparator|HFpEF-CKD with an oral and injected placebo|Subjects with with HFpEF volume overload in the presence of chronic kidney diseases and clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive an oral and injected placebo followed by a 1 week washout period.
89149988|NCT05279742|Placebo Comparator|HFpEF-EI with an oral and injected placebo|Subjects with with HFpEF with exercise induced dyspnea (difficult or labored breathing) without clinical symptoms at rest (e.g. peripheral edema, weight gain, and abdominal distention) will receive an oral and injected placebo followed by a 1 week washout period.
89149989|NCT04177446|Placebo Comparator|control group|Patients will be given basic energy intake according to their weight, and will be extra maltodextrin as the placebo
89149990|NCT04177446|Experimental|intervention group|Patients will be given basic energy intake according to their weight, and will be extra protein intake
89149991|NCT04177056|Experimental|Stereotactic Body Radiotherapy|High dose SBRT to lesion(s) of interest.
89149992|NCT02537340||EMVI-MR positive|Patients with primary rectal cancer and extramural vascular invasion detected by staging MR
88804293|NCT05774964|Experimental|Chemotherapy targeted group|Patients treated with cetuximab targeted therapy in combination with chemotherapy using SOX regimen.SOX regimen every 3 weeks, oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area, and tegafur orally on d2-d15 at 20 mg three times daily. Cetuximab combined with chemotherapy was administered simultaneously,once every three weeks, and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
88804294|NCT05774964|Experimental|Quintuple method group|Patients treated with a combination of SOX regimen, cetuximab, and folic acid, vitamin A, and metronidazole three-drug regimen.SOX regimen every 3 weeks, oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area, and tegafur orally on d2-d15 at 20 mg three times daily. Cetuximab combined with chemotherapy was administered simultaneously,once every three weeks, and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area. Metronidazole 0.4g/time, qd;vitamin A 5,000 units/time, qd; folic acid 5 mg/time,qd. The latter three drugs were continued until the end of all chemotherapy cycles.
89149993|NCT02537340||EMVI-MR negative|Patients with primary rectal cancer and without extramural vascular invasion detected by staging MR
89149994|NCT02673762||Normal glucose metabolism|Normal fasting blood glucose, 2 hour post prandial glucose, hemoglobin A1c and HOMA IR
89149995|NCT02673762||Pre-diabetes|Abnormal glucose tolerance tests and/or insulin resistance with fating blood glucose and hemoglobin A1c below type II diabetes levels
89149996|NCT02673762||Type II diabetes|Hemoglobin A1c 6.5% or greater, fasting blood glucose >125 mg/dl or 2 hour post-prandial blood glucose 200 mg/ml or greater
89149997|NCT02673840|Experimental|Ketotifen|
89149998|NCT02673840|Placebo Comparator|Placebo|
89149999|NCT00644124|Experimental|Aflibercept RCHOP 14|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 2 weeks. A dose of 2.0 mg/kg administered as Dose Level 1, 4.0 mg/kg as Dose Level 2, and 6.0 mg/kg dose as Dose level 3.
89150000|NCT00644124|Experimental|Aflibercept RCHOP 21|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 3 weeks. A dose of 3.0 mg/kg administered as Dose Level 1, 6.0 mg/kg as Dose Level 2, and 8.0 mg/kg dose as Dose level 3.
89150001|NCT00910182||1|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 and treated non-operatively
89150002|NCT00910182||2|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 who underwent emergency surgical treatment
89150003|NCT00910182||3|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 treated non-operatively plus transcatheter arterial embolisation
89150004|NCT00644202|Experimental|Group 1|Intervention Group
89150005|NCT00644202|No Intervention|Group 2|Usual Care Group
89150006|NCT04178694|Experimental|non-invasive ventilation|All subjects will be submitted to non-invasive ventilation with different settings. During the whole period indirect calorimetry will be performed and haemodynamic parameters will be monitored using a non-invasive device. Reversed combined RPE scale will be asked on a regular base.
89150007|NCT02673528||Directly underwent TLA|Patients with the diagnosis who underwent directly total laparoscopic appendectomy
89150008|NCT02673528||Lap Assisted App|Patients with the diagnosis of acute appendicitis who underwent a successful laparoscopic assisted appendectomy
89150009|NCT02673528||Advanced to TLA|Patients with the diagnosis of acute appendicitis in whom laparoscopic assisted appendectomy attempted; however, because it fail advanced to total laparoscopic appendectomy.
89150010|NCT02670954|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both routine analgesic and sedation(dexmedetomidine,tramadol and flurbiprofen) are applied for this group of patients.
89150011|NCT02670954|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(Tramadol and flurbiprofen) is applied for this group of patients.
89150012|NCT04176042|Experimental|Track 1|"Subjects will be randomized to one of two 4-week tracks.~Track 1 (intervention + follow-up) will consist of the following:~Subjects will be randomized to one of two 4-week tracks. Track 1 (intervention + follow-up) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention participants will complete a baseline questionnaire battery consisting of measures including demographics, medical history and sleep. After completion, a 2-hour educational presentation will take place with a question-and-answer session. Participants will then complete post-intervention questionnaires to assess immediate impact of the session on knowledge, beliefs and practices. After 4 weeks, Track 1 participants will be contacted and will be asked to re-complete all baseline questionnaires (see above), in order to evaluate changes over 4 weeks."
89150013|NCT04176042|Active Comparator|Track 2|"Subjects will be randomized to one of two 4-week tracks. Track 2 (wait list + intervention) will consist of the following: Prior to the session, within 72 hours of the scheduled 2-hour education invention for Track 1 participants will complete the same baseline questionnaire battery.~An identical intervention session, scheduled 4 weeks into the future. At that time, an identical procedure to the other track will be followed, including the pretest questionnaires, 2-hour session, and post-session assessment. No additional 4-week follow-up will be performed."
89150014|NCT00644436|Experimental|1|Single topical application
89150015|NCT00644436|Active Comparator|2|Single topical application
89150016|NCT04081740||Asthma|The patients included in this group will have asthma, as specified in the inclusion criteria.
89150017|NCT04081740||COPD|The patients included in this group will have COPD, as specified in the inclusion criteria.
89150018|NCT04081740||Bronchiectasis|The patients included in this group will have bronchiectasis, as specified in the inclusion criteria.
89150019|NCT02670798|No Intervention|Control|Standard of care hematologic management in the operating room
89150020|NCT02670798|Experimental|Study|Standard of care hematologic management plus additional monitoring with the intervention of Thromboelastography laboratory testing and use of a thromboelastography-guided transfusion protocol.
89150021|NCT02670876|Experimental|Anti-bullying intervention|An anti-bullying intervention target to perpetrators of school bullying was conducted. The program consisted of 8 sessions over 4 weeks and was conducted by a board-certified psychiatrist and a therapist with previous training in psychosocial treatments. The intervention was based on cognitive-behavioral therapy (CBT) principles and addressed various factors that have been associated with perpetrators of school bullying, including impulse control, perspective taking (empathy), and the enhancement of communication skills.
89150022|NCT00644904|Experimental|Treatment|Starting dose of 4,000 IU per day of Vitamin D3 titrating up to a dose of 40,000 IU per day of Vitamin D3 by month six. In the second six-month part of the trial, patients titrate back down to 4,000 IU per day of Vitamin D3 and then discontinue it completely at the end of the 12 month trial period.
89150023|NCT00644904|Other|Control|Patients are allowed to supplement with up to 4,000 IU per day of Vitamin D3 if desired.
89150024|NCT02670720|Experimental|avoralstat|Five avoralstat capsules (100 mg) to be taken three times daily by mouth
89150025|NCT02670564|Experimental|Total body irradiation (TBI)|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
89150026|NCT02670564|Experimental|Busulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
89150027|NCT02670564|Experimental|Treosulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
89150028|NCT02672202|Active Comparator|Duloxetine|Treatment
89150029|NCT02672202|Active Comparator|Pregabalin|Treatment
89150030|NCT02672202|Placebo Comparator|Placebo|
89150031|NCT04079400||Tb group|Subjects who underwent bronchoscopy for suspicious endobronchial pulmonary tuberculosis (Tb) observed on chest computed tomography
89150032|NCT04079400||NTM-PD group|Subjects who underwent bronchoscopy for suspicious non-tuberculous mycobacterial pulmonary disease (NTM-PD) observed on chest computed tomography
89150033|NCT04079400||LC group|Subjects who underwent bronchoscopy for suspicious endobronchial lung cancer (LC) observed on chest computed tomography
89150034|NCT04079400||HM group|Subjects who underwent bronchoscopy for hemoptysis
89150035|NCT04079400||Control group|Subjects who underwent bronchoscopy to rule out endobronchial lesion observed on chest computed tomography. Endbronchial lesion should not be typical for any category of respiratory diseases including tuberculosis, NTM-TB and lung cancer.
89150036|NCT02672280|Experimental|Medical Collagen Membrane with MSC|Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).
89150037|NCT02672280|Active Comparator|Medical Collagen Membrane|Application of medical collagen membrane only.
89150038|NCT04176900|Experimental|Alternating 3D boluses|Both rigid and flexible 3D printed boluses made for each patient. Each is used on alternate days during radiation therapy.
89150039|NCT04176822|Experimental|Educational Animated Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched an educational animated movie through VR Goggles. The educational animated movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
89150040|NCT04176822|Experimental|Documentary Movie Group|"All of the children's and parents' written and verbal informed consent were obtained before the study. Parents who did not want to participate in the study were assured that this would not have any adverse effect on their child's treatment. In the morning of surgery, the researcher administered the Child and Family Identification Data Form to the parents of children who had the following parameters. Later, both the child and the parents were asked to complete the Children's Fear Scale. Children included in the study groups with randomization watched a documentary movie through VR Goggles. The documentary movie lasted around 3-4 minutes each. After watching the movie, children and parents were asked to complete the Children's Fear Scale again. Children, parents, and nurses were asked to grade the pain of the child with Wong-Baker FACES Pain Rating Scale when the children returned to their room and after 1 hour in the postoperative period."
89150041|NCT04176822|No Intervention|Control Group|No intervention was made, pain and fear levels were measured using scales only.
89150042|NCT04175652|Experimental|Laughter yoga group, group doing laughter yoga|The duration of the laughter yoga was 30 minutes and a total of 16 sessions were performed on a twice-weekly basis.
89150043|NCT04175652|No Intervention|No laughter yoga group, group not doing laughter yoga|
89150044|NCT04033458|Experimental|Treatment Sequence ABECD|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B), then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and, then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150045|NCT04033458|Experimental|Treatment Sequence BCADE|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and, then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
88804295|NCT05774938||Standard EVAR|Infrarenal abdominal aortic aneurysms treated with standard EVAR off-the-shelf devices.
89150046|NCT04033458|Experimental|Treatment Sequence CDBEA|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then, JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then, JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150047|NCT04033458|Experimental|Treatment Sequence DECAB|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regiment 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150048|NCT04033458|Experimental|Treatment Sequence EADBC|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then, JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150049|NCT04033458|Experimental|Treatment Sequence DCEBA|Participants will receive single oral dose of JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) then JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) and then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150050|NCT04033458|Experimental|Treatment Sequence EDACB|Participants will receive single oral dose of JNJ-64140284 Regimen 5 in fed condition (Treatment E) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) then JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 3 in fed condition (Treatment C) and then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150051|NCT04033458|Experimental|Treatment Sequence AEBDC|Participants will receive single oral dose of JNJ-64140284 Regimen 1 in fasted condition (Treatment A) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) then JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 4 in fed condition (Treatment D) and then JNJ-64140284 Regimen 3 in fed condition (Treatment C) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150052|NCT04033458|Experimental|Treatment Sequence BACED|Participants will receive single oral dose of JNJ-64140284 Regimen 2 in fasted condition (Treatment B) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) then JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 5 in fed condition (Treatment E) and then JNJ-64140284 Regimen 4 in fed condition (Treatment D) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150053|NCT04033458|Experimental|Treatment Sequence CBDAE|Participants will receive single oral dose of JNJ-64140284 Regimen 3 in fed condition (Treatment C) followed by JNJ-64140284 Regimen 2 in fasted condition (Treatment B) then JNJ-64140284 Regimen 4 in fed condition (Treatment D) followed by JNJ-64140284 Regimen 1 in fasted condition (Treatment A) and then JNJ-64140284 Regimen 5 in fed condition (Treatment E) in Treatment Periods 1 to 5 respectively. All treatment periods will be separated by a wash out period of at least 5 days and maximally 12 days.
89150054|NCT04091568||Awake fibre-optic intubation|Awake fibre-optic intubation
89150055|NCT04091568||Asleep fibre-optic intubation|Asleep fibre-optic intubation
89150056|NCT04178070|Experimental|GB224 2mg|single dose
89150057|NCT04178070|Experimental|GB224 5mg|single dose
89150058|NCT04178070|Experimental|GB224 10mg|single dose
89150059|NCT04178070|Experimental|GB224 15mg|single dose
89150060|NCT04178070|Experimental|GB224 20mg|single dose
89150061|NCT04178070|Experimental|GB224 30mg|single dose
89150062|NCT04178070|Placebo Comparator|Placebo 2mg|single dose
89150063|NCT04178070|Placebo Comparator|Placebo 5mg|single dose
89150064|NCT04178070|Placebo Comparator|Placebo 10mg|single dose
89150065|NCT04178070|Placebo Comparator|Placebo 15mg|single dose
89150066|NCT04178070|Placebo Comparator|Placebo 20mg|single dose
89150067|NCT04178070|Placebo Comparator|Placebo 30mg|single dose
89150068|NCT04176744|Experimental|Magnetic Phrenic Nerve Stimulation|Each participant will be tested with 4 different stimulation setups (coils and stimulator) on 3 different days.
89150069|NCT02671578|Experimental|Nitrous oxide|Nitrous oxide sedation
89150070|NCT00644982|Experimental|Sertaline group|
89150071|NCT00644982|Active Comparator|Venlafaxine group|
89150072|NCT02670642|Experimental|On demand 20 mg esomeprazole|On demand treatment with 20-mg esomeprazole once daily when needed
89150073|NCT02670642|Active Comparator|Continuous 20 mg esomeprazole|Continuous treatment with 20 mg esomeprazole once daily
89150074|NCT02670486|No Intervention|standard of care|Usual urodynamics with no intervention.
89150075|NCT02670486|Active Comparator|Audiovisual intervention|Audiovisual stimulus during urodynamic testing.
89150076|NCT04175496|Experimental|Test Foods|Blueberry Cake, Snack with Cheese and spicy Crackers will be used as test foods.
89150077|NCT04175496|Experimental|Reference Food|Glucose solution will use as reference food.
89150078|NCT02671734|No Intervention|control|Subjects in this arm received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
89150079|NCT02671734|Active Comparator|intervention|Subjects in this arm viewed a video detailing key elements of informed consent. Subjects in this arm also received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
89150080|NCT02670018|Active Comparator|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets
89150081|NCT02670018|Experimental|C|Combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets
89150082|NCT02671968|Experimental|CGM group|
89150083|NCT02671968|No Intervention|Control group|
89150084|NCT02670096|Experimental|Reference therapy|"Baseline evaluation of subjects without acetazolamide administration~Follow up evaluation of subjects one hour after acetazolamide administration"
89150085|NCT04077840||NCGS/NCWS patients|Adult patients with a definitive diagnosis of NCWS, based on DBPC wheat challenge, most of them suffering from IBS-like-clinical presentation, according to Rome IV criteria. The patients were consecutively recruited between January 2016 and October 2017 at the outpatient clinics of the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (both in southern Italy)
89150086|NCT04077840||Heathy blood donors|Consecutive healthy blood donors sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients.
89150087|NCT04077840||IBS patients|"Consecutive patients with a diagnosis of IBS unrelated to NCWS or other types of food intolerance/allergy, who were consecutively recruited during the study period and sex- (+ 5%) and age-matched (+ 2 years) with the NCWS patients."
89150088|NCT04077138||Focus Groups|"Ten focus groups with transgender women and transgender men will be conducted. . The structure of the focus groups will utilize an interactive Rapid Approach, which differs from traditional focus groups by asking fewer questions and tightly focusing on specific areas of inquiry."
89150089|NCT04077138||In-Depth Interviews|Participants for the IDIs, 10-15 TW and TM, will be selected from among Phase 1 participants. We will create a purposive sample that represents a range of experiences that occurred during Phase 1.
89150090|NCT00645060|Experimental|Y-90-DOTA-M5A anti-CEA antibody|
89150091|NCT02537262|Experimental|carbohydrate group|
89150092|NCT02537262|Placebo Comparator|NPO(None Per Oral) group|
89150093|NCT02676024|No Intervention|Control|Resuscitation teams will participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR without being provided cognitive aids. Participants in this group will be allowed to use any cognitive aid that they happen to keep with them and would normally use in their practice, for example, flash cards or smart phone apps.
89150094|NCT02676024|Experimental|Knowledge-based cognitive aid|"Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. However, they will be trained in using a knowledge-based cognitive aid, which will be used by a dedicated team member (the cognitive aid reader)."
89150095|NCT02676024|Experimental|Cognitive aids with roles defined (CARD)|Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. Participants will be trained to use the cognitive aids with roles defined (CARD) system. However, they will not be given knowledge-based cognitive aids and there will be no dedicated cognitive aid reader in the team.
89150096|NCT02676024|Experimental|Integrated cognitive aids|Participants will be trained to use the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid, which will be used by a dedicated cognitive aid reader.
89150097|NCT02672046||Patients with knee injuries|Patients referred to assessment at the Clinic of Sports Injuries
89150098|NCT05283642|Experimental|DCI|Oral supplementation with D-chiro-inositol once a day
89150099|NCT05277090|Experimental|polyethyleneglycol only|participants take 2L of polyethyleneglycol only
89150100|NCT05277090|Experimental|polyethyleneglycol puls Inulin|participants take 2L of polyethyleneglycol, subsequently take 15g inulin per day.
89150101|NCT05277090|Experimental|polyethyleneglycol puls probiotic combination product|"Participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals."
89150102|NCT00644670|Experimental|Previous Treatment with a Usual Maintenance Dose of a Statin|
89150103|NCT00644670|Experimental|Statin-Naive|
89150104|NCT02671344||IAD group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation IAD group 'Determination of gene profiles using arrays semen'
89150105|NCT02671344||FIV group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation FIV group of gene profiles using arrays semen'
89150106|NCT02671344||ICSI group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation 'Determination of gene profiles using arrays semen'
89150107|NCT04085718||Study arm|All included patients will undergo FDGPET/CT scan
88804296|NCT05774938||Complex EVAR|Paravisceral aortic aneurysms treated with fenestrated or branched EVAR devices.
89150108|NCT02669706||IV pentamidine|Pentamidine 4mg/kg IV every month (maximum 300mg)
89150109|NCT02669628||Surgical technique|Laparoscopic ovarian cystectomy
89150110|NCT02669628||Alcohol sclerotherapy|US-aspiration and alcohol sclerosis
89150111|NCT02669550|Experimental|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
89150112|NCT02669550|Experimental|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
89150113|NCT02669472|Experimental|F&V Intervention|Housing complexes randomized to the intervention arm received a multicomponent intervention comprised of a year-round, discount, mobile fresh fruit and vegetable market ('Fresh To You') that was paired with nutrition education interventions including educational newsletters, recipe cards, campaigns, taste-testings and videos in both English and Spanish.
89150114|NCT02669472|Experimental|Control Intervention|Housing complexes randomized to the comparison arm received a year-long intervention on physical activity and stress reduction including educational campaigns and materials in both English and Spanish.and a YMCA membership for those who joined the campaigns.
88804297|NCT05774912||Pregnant women|Healthy women with singleton uncomplicated pregnancy
89150115|NCT00644514|Experimental|LPS endotoxin inh f/u bronchoscopy|Participants receive inhalation of LPS endotoxin, followed by bronchoscopy in this study.
89150116|NCT00645138|Active Comparator|Paravertebral Block|Patients receiving Paravertebral Block.
89150117|NCT00645138|Active Comparator|General Anesthesia|Patients receiving General Anesthesia.
89150118|NCT04177368||assess nutrition with regular dialysis|This study aims to assess the growth and the nutritional status in children with end-stage kidney disease on regular hemodialysis to define the degree of malnutrition , predict and quantify the risk for complications deriving from impaired nutritional status .Giving them theragran 60ml ,twice daily for 3 month.
89150119|NCT00895895|Placebo Comparator|1|Placebo
89150120|NCT00895895|Experimental|2|SAM-531 1.5 mg
89150121|NCT00895895|Experimental|3|SAM-531 3.0 mg
89150122|NCT00895895|Experimental|4|SAM-531 5.0 mg
89150123|NCT00895895|Active Comparator|5|Donepezil
89150124|NCT02671110|Experimental|Transforming Your Life|The TYL program emphasized: 1) helping participants develop and maintain healthy habits and disrupt unhealthy habits, 2) enabling participants to create a personal food and exercise environment that increases exposure to healthy eating and physical activity and encourages automatic responding to goal-related cues, and 3) facilitating participants' weight loss motivation.
89150125|NCT02671110|Active Comparator|Diabetes Prevention program|The DPP recommends that participants set a weight loss reduction goal of 7% or more of their baseline body weight, reduce consumption of high fat foods as a means to reduce caloric intake, and engage in brisk walking or other moderate intensity physical activity for 150 minutes per week. Sessions include information on changing energy intake and energy output through diet and exercise, and addressing psychological, social, environmental, and motivational challenges to health behavior change.
89150126|NCT02537184|Other|Group 1 - Recall Interval of 4 months|"Oral clinical conditions:~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
89150127|NCT02537184|Other|Group 2 - Recall Interval of 8 months|"Oral clinical conditions:~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
89150128|NCT02671188|Experimental|GSK3050002 100 mg/mL|Subjects will be administered GSK3050002 intravenously (IV) over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion. On Day 1, loading dose of GSK3050002 10 milligrams per kilogram (mg/kg) will be administered intravenously, followed by maintenance doses of 5mg/kg IV administered at Day 15 and Day 29. Each subject will receive a cumulative dose of 20 mg/kg.
89150129|NCT02671188|Placebo Comparator|Placebo|Subjects will be administered normal saline (0.9% sodium chloride) intravenously over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion.
89150130|NCT00644748|Experimental|Gabapentin group|
89150131|NCT00910338|Experimental|PFMT with Extracorporeal Biobeedback|
89150132|NCT04176276||Patients with Type2 Diabetes|200 patients with type 2 diabetes consecutively enrolled among those referring to our Diabetes outpatient clinic.
89150133|NCT04176276||Patients without Type2 Diabetes|100 patients without diabetes among those referring to our outpatient clinic most of them affected by hypercholesterolemia, obesity or CV disease.
89150134|NCT00645216|Experimental|CP-945,598 with Grapefruit Juice|CP-945,598 with Grapefruit Juice
89150135|NCT00645216|Experimental|CP-945,598 alone|CP-945,598 alone
89150136|NCT00910416||patients receiving iv anesthesia|
89150137|NCT00910416||patients receiving balanced anesthesia|
89150138|NCT02669238|Experimental|Implant|Subcutaneous insertion of an progestative implant containing 68mg of etonogestrel
89150139|NCT02669238|Active Comparator|Oral treatment|Continuous oral administration of second generation monophasic oestro-progestative (ethinyl-oestradiol)
89150140|NCT02668614|Experimental|WR-22 model microwave sensor|
89150141|NCT02669004|Active Comparator|Intermittent bolus epidural morphine|"Patients who received epidural morphine with patient- controlled intermittent bolus epidural analgesia (PCIEA) represented Group 1. Epidural catheter was inserted by surgeon under direct visualization at the midpoint of the incision and advanced 5-6 cm cephalad to thoracic 4-5 before surgical closure.~Patients received morphine 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion."
89150142|NCT02669004|Active Comparator|Continuous epidural morphine|epidural morphine with patient- controlled continuous epidural analgesia (PCCEA) represented Group 2. Infusion the following initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
89150143|NCT00895661|Other|rituximab|single-arm, open-label, interventional
89150144|NCT00645294|Other|Treatment Group A|ADV (0.14 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.3 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
89150145|NCT00645294|Other|Treatment Group B|ADV (0.3 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.14 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
89150146|NCT00645294|Other|Treatment Group C|ADV 10 mg single dose on Day 1 in 12-17 year old age group
89150147|NCT02668380||Apatinib|Apatinib Tablets: 850 mg,po, once daily , 28 days for a cycle
89150148|NCT05334719||Cohort 1|Participants with previously untreated advanced/recurrent gastric cancer (GC)
89150149|NCT02668848|Experimental|urine monitoring group|Patients of urine monitoring group will be checked for urine specific gravity (USG) once between 6a.m. to 12 m.d. in the first 5 days after admission. Patients will be advised to have water according to the level of USG.
89150150|NCT04201535||Group 1A:|at least 10 patients, maximum 70,with RA in remission, but presenting p• Group 1B: at least10 patients maximum 70, with RA in remission, without bone erosion A group of 80 controls,
89150151|NCT04201535||Group 2:|10 patients with osteoarthritis (OA) who must undergo a surgical procedure.
89150152|NCT04201535||Group 3|"70 without RA and OA but hospitalized for any other orthopedics pathology who must undergo a surgical procedure.~rogressive bone erosion who must undergo a surgical procedure."
89150153|NCT00644826|Experimental|1|
89150154|NCT00644826|No Intervention|2|
89150155|NCT05334641|Experimental|Experimental Group|
89150156|NCT05334641|Active Comparator|Control Group|
89150157|NCT02668224|Experimental|Vibrasens : Test group|Training programme: vibration training 3/week from Day 1 to Day 60 + Usual activities from day 60 to Day 75.
89150158|NCT02668224|Active Comparator|Control group|Control: Usual activities from day 1 to Day 75.
89150159|NCT02837315|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS was described to participants as the College Adjustment Session and the session was conducted using an MI plus personalized feedback approach."
89150160|NCT02837315|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, students were asked about their reaction to the relaxation techniques and were provided with relaxation training handouts.
89150161|NCT02837315|No Intervention|Assessment|Participants fill out a battery of measures and receive no intervention.
89150162|NCT02666820|Active Comparator|Large balloon dilatation|Patients underwent clearance of common bile duct stones using a papillary large balloon dilatation.
89150163|NCT02666820|Active Comparator|Mechanical lithotripsy|Patients underwent clearance of common bile duct stones using a mechanical lithotripsy.
89150164|NCT02837003||Experimental: Aspirin|Aspirin treatment for 3 months after the Ultimaster sirolimus-eluting stent implantation.
89150165|NCT02837003||Experimental: Thienopyridine|Thienopyridine treatment for 3 months after the Ultimaster sirolimus-eluting Stent implantation.
89150166|NCT02668926|Experimental|Lisdexamfetamine, d-amphetamine, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
89150167|NCT02668926|Experimental|d-amphetamine, Placebo, Lisdexamfetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
89150168|NCT02668926|Experimental|Placebo, Lisdexamfetamine, d-amphetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
89150169|NCT00910494|Experimental|12 Gray IORT|
89150170|NCT00910494|Experimental|15 Gray IORT|
89150171|NCT02668536|Experimental|UV Filter + BNP|A UV filtering agent and bioadhesive nanoparticles (BNPs) will comprise the experimental condition in this study. Participants will have 5 sites on their torso where they will have these placed.
89150172|NCT02668536|Sham Comparator|BNP only|A placebo bioadhesive nanoparticles (BNPs) (strips with no UV filtering) will comprise the sham comparison in this study. Participants will have 5 sites on their torso where they will have these placed.
89150173|NCT02668536|Active Comparator|Standard|As the active comparator, participants will have 5 sites on their torso where they will have standard sunscreen applied.
89150174|NCT02668536|No Intervention|Control|Participants will have 5 sites on their torso where no agent will be applied.
89150175|NCT00645372|Active Comparator|A|
89150176|NCT00645372|Experimental|B|
89150177|NCT02667990|Experimental|orthopaedic stilettoe|orthopaedic stilettoe will be compared to standard stilettoe and comfy trainer
89150178|NCT02668458|Experimental|NIV|NIV group, preoxygenation by NIV: pressure support set for an exhaled tidal volume of 6-8 ml / kg of ideal body weight, PEEP of 5 cm H2O and FiO2 at 100%.
89150179|NCT02668458|Active Comparator|HFNC|High-flow nasal canula oxygen therapy. NHFC group, preoxygenation by NHFC: oxygen flow rate of 60 L / min and 100% FiO2
89150180|NCT04070664||Central vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
89150181|NCT04070664||Peripheral vertigo|Patients without any pathology on MRI were included in the peripheral vertigo group, and patients whose scans demonstrated acute ischemic infarct in the posterior fossa were included in the central vertigo group.
89150182|NCT02668068|Active Comparator|Control Group|Large volume whole-lung lavage (WLL) only
89150183|NCT02668068|Experimental|Experimental Group|Combined large volume WLL with clinical grade umbilical cord mesenchymal stem cells transplantation
89150184|NCT00645918|Active Comparator|A|"Tailored clopidogrel regimen - an additional clopidogrel 600-mg loading dose (eight 75-mg tablets taken orally; daily 150 mg clopidogrel dose plus additional 450 mg clopidogrel) on the day of randomization and then 150-mg clopidogrel every day thereafter for 6 months."
89150185|NCT00645918|Placebo Comparator|B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months."
89150186|NCT00645918|Placebo Comparator|C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months.
89150187|NCT02668146|Experimental|perampanel|Perampanel administration
89150188|NCT02668146|Placebo Comparator|placebo|Placebo administered to subjects.
89150189|NCT02665182|Experimental|Up-positioning of the testes|Patients receive standard medical therapy and supportive therapy
89150190|NCT02665182|No Intervention|Medical therapy only|Patients receive standard medical therapy only
89150191|NCT02667834|Experimental|Social Cognition and Interaction Training (SCIT)|SCIT Social cognition and interaction training program.
89150192|NCT02667834|Active Comparator|Therapeutic education program (ETP)|Therapeutic education program
89150193|NCT00646854|Active Comparator|Arm A|
89150194|NCT00646854|Experimental|Arm B|
89150195|NCT04173156|Experimental|Oscillating Chitosan Device|The brush bristles of the test device (Labrida BioClean®, LABRIDA AS, Oslo, Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed, thus not causing harm to the tissues.surrounding the tooth. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
89150196|NCT04173156|Active Comparator|Regular Curettes|Standard non surgical treatment of active periodontal disease includes supra and subgingival scaling and root planing with periodontal medical grade Gracey system steel curettes
89150197|NCT04033302|Experimental|Single arm|Multiple CAR T cells to treat CD7-positive hematological malignancies
89150198|NCT04174326|Experimental|Intervention group|A weekly 2 hour CBT for chronic pain group intervention for a duration of 6 weeks
89150199|NCT04174326|No Intervention|Delayed intervention group|A waiting list for CBT for chronic pain group intervention.
89150200|NCT04173858||Experimental|Patients with confirmed opioid-induced constipation diagnosis and inadequate response to laxatives.
89150201|NCT02667678|Experimental|Cohort HIVOL, patients infected by HIV|Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2. The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.
89150202|NCT00645996|Experimental|1|
89150203|NCT00645996|Placebo Comparator|2|Cornflour
89150204|NCT00646932|Experimental|1|
89150205|NCT00646932|Experimental|2|
89150206|NCT00646932|Experimental|3|
89150207|NCT00646932|Experimental|4|
89150208|NCT02665026|Experimental|stoma closure at different times|choose different times to do stoma closure after surgery for rectal cancer
89150209|NCT05255640||patients with ischemia of the lower limbs|
89150210|NCT02667600||Cesarean Section Group|Patients undergoing cesarean section
89150211|NCT00647088||aortic stenosis|various age and disease severity
89150212|NCT00647088||Controls|Controls free of valvular disease
89150213|NCT00646074|Experimental|1|Self-Care TALK
89150214|NCT00646074|No Intervention|2|
89150215|NCT04173936||Tai Chi|All participants enrolled in a 12 week community-based tai chi program.
89150216|NCT00647166|Experimental|1|Drug: corticosteroid and azathioprine
89150217|NCT00647166|Placebo Comparator|2|Drug: corticosteroid and placebo
89150218|NCT04174950|Active Comparator|control group|Routine perioperative nursing intervention
89150219|NCT04174950|Experimental|experimental group|Perioperative ERAS Based Nursing Model
89150220|NCT02667522|Experimental|Parenting Intervention|Parenting Intervention: Parent-Child Interaction Therapy (PCIT)
89150221|NCT02667522|No Intervention|Waitlist Control|Waitlist Control Condition
89150222|NCT00647244|Active Comparator|1|Tenofovir
89150223|NCT00647244|Active Comparator|2|Abacavir
89150224|NCT00895583|Experimental|Group I - Planned transition to sirolimus from tacrolimus|
89150225|NCT00895583|Active Comparator|Group II - Continuation of tacrolimus|
89150226|NCT02664792|Experimental|Diagnosis or suspicion of non-small cell lung carcinoma|SUS patients with diagnosis or suspicion of non-small cell lung carcinoma with an indication for mediastinoscopy
89150227|NCT00647322|Experimental|1|Reduction in anti-epileptic medications
89150228|NCT00647322|Active Comparator|2|No change in medication. Unchanged treatment
89150229|NCT02666274||RK Group|participants colonised with Klebsiella spp. resistant to either 3GC or carbapenems (RK cohort of index carriers of Resistant Klebsiella)
89150230|NCT02666196|Experimental|DAA-I 6mg|Subjects given solid compound in vials containing 6mg per vial
89150231|NCT02666196|Experimental|DAA-I 50mg|Subjects given solid compound in vials containing 50mg per vial
88804298|NCT05774808||Aortic valve surgery only|
89150232|NCT02666196|Experimental|DAA-I 110mg|Subjects given solid compound in vials containing 110mg per vial
89150233|NCT02666196|Placebo Comparator|Placebo|Subjects given 25ml placebo dissolved in 200ml water
89150234|NCT04174872|Other|Dexmedetomidine|It has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
89150235|NCT04174872|Other|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
89150236|NCT02664714|Active Comparator|PFMT Individualized|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s) 4(5s/10s), 5(5s/5s), 6(5s/5s), 7(6s/6s),8(6s/6s), 9(8s/8s) 10(8s/8s), 11(10s/10s),12(10s/10s)
89150237|NCT02664714|Experimental|PFMT individualized with group|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
89150238|NCT02664714|Active Comparator|12 group PFMT|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
89150239|NCT02841137|Experimental|progesterone 5 mg|progesterone 5 mg tablet
89150240|NCT02841137|Experimental|progesterone 10 mg|progesterone 10 mg tablet
89150241|NCT02841137|Experimental|progesterone 20 mg|progesterone 20 mg tablet
89150242|NCT02841137|Active Comparator|progesterone 100 mg|progesterone 100 mg capsule
89150243|NCT00645606|No Intervention|Observation|Observation every 8 weeks during 2 years
89150244|NCT00645606|Experimental|rituximab arm|rituximab :500 mg/m² every 8 weeks during 2 years
89150245|NCT02836847|Experimental|target therapy|The patients wil receive conventional chemotherapy(GEMOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
89150246|NCT02836847|Other|GEMOX|The patients wil receive conventional chemotherapy(GEMOX).
89150247|NCT02841059||Laparoscopic subtotal hysterectomy|women with benign gynecology disease and decided to receive laparoscopic subtotal hysterectomy (LSH) after discussion with her surgeon.
89150248|NCT02841059||Laparoscopic CLSH|women with benign gynecology disease and decided to receive laparoscopic cervical ligament sparing hysterectomy (CLSH) after discussion with her surgeon.
89150249|NCT02841059||Laparoscopic AVH|women with benign gynecology disease and decided to receive laparoscopic assisted vaginal hysterectomy (LAVH) after discussion with her surgeon.
89150250|NCT04172688|Placebo Comparator|Placebo|Two 3.3g doses/day (12 kcal/dose) of maltodextrin
89150251|NCT04172688|Experimental|Prebiotic|Two 8g doses/day (12 kcal/dose) of oligofructose-enriched inulin
89150252|NCT02838953|Experimental|COPD patients|COPD patients submitted to Pulmonary Rehabilitation according to the ATS/ERS statement.
89150253|NCT02838953|No Intervention|Control|"Healthy individuals who will undergo the same COPD's evaluation protocol. As healthy individuals they will not participate to the Pulmonary Rehabilitation."
89150254|NCT02664948|Experimental|Intervention group|Early geriatric follow-up after discharge from hospital in the patient's home
89150255|NCT02664948|No Intervention|Control group|Usual care with follow-up home-visits conducted by home care and the GP after discharge, if they consider it as necessary
89150256|NCT02838875|Experimental|Pregnant women at risk population|women who arrived to the delivery room at Lis hospital and which the newborn is about to undergo glucose levels follow-up after birth regardless the study, because of their affiliation to the at-risk population.
89150257|NCT05333861||Full-analysis set (FAS)|The FAS includes all enrolled patients. The FAS will be used for all analyses.
89150258|NCT04066686||Young|Participants recruited into one of two groups on age stratification. Young cohort defined as aged 18-65yrs old
89150259|NCT04066686||Elderly|Participants recruited into one of two groups on age stratification. Elderly cohort defined as over 65yrs of age.
89150260|NCT04201379||neck pain patients|servical disk hernisi servical spondilosis servical problems
89150261|NCT04201379||control|healthy people
89150262|NCT02666040|Experimental|U - ULTRAPRO|Inguinal Hernia Surgery with ULTRAPRO® meshes, a new ULTRAPRO® mesh will be implanted in patients in the group (AG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment.
89150263|NCT02666040|Active Comparator|P - Prolene|"Inguinal Hernia Surgery with Prolene® meshes, the conventional mesh in polypropylene Prolene® will be implanted in patients in the control group (CG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment."
89150264|NCT00894413|Placebo Comparator|Placebo|
89150265|NCT00894413|Experimental|Tadalafil|Tadalafil 20 mg once per day
89150266|NCT04173468|Active Comparator|MWM Group|This group will receive Mobilization with Movement (MWM) i.e. straight leg raised with traction,Tibial Gliding
89150267|NCT04173468|Active Comparator|Mulligan Taping Group|This group will receive Mulligan knee taping
89150268|NCT04250519|Experimental|1% sodium hypochlorite & dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
89150269|NCT04250519|Active Comparator|1% sodium hypochlorite as irrigant &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
89150270|NCT04250519|Experimental|5.25% sodium hypochlorite and dexamethasone 4mg as irrigants|sodium hypochlorite is effective in any concentration as antimicrobial irrigant and dexamethasone is anti inflammatory drug
89150271|NCT04250519|Active Comparator|5.25% sodium hypochlorite &normal saline as placebo|sodium hypochlorite is effective in any concentration as irrigant
89150272|NCT04173624|Experimental|Endosonography|Endosonography is endoscopic method to diagnose pancreatic and biliary disorders. Participants randomized to this arm will undergo diagnostic endosonography under propofol sedation in supervision of trained anesthesiologists. If choledocholithiasis is diagnosed on endosonography, patient will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
89150273|NCT04173624|Experimental|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for diagnosis of pancreatic and biliary disorders. Participants randomized to this arm will undergo MRCP. If choledocholithiasis is diagnosed on MRCP, participants will be subjected for endoscopic retrograde cholangiopancreatography for clearance of stone. If choledocholithiasis is not present then participants will be kept in follow-up and further evaluation will be done if clinically indicated as per discretion of treating physician.
89150274|NCT00647478||1|AD
89150275|NCT00647478||2|Control elderly subjects with normal cognitive function
89150276|NCT00647478||3|MCI
89150277|NCT02836691|Active Comparator|EKG to Control subjects|healthy controls without asthma or other respiratory disease.
89150278|NCT02836691|Active Comparator|EKG monitoring Mild asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
89150279|NCT02836691|Active Comparator|EKG monitoring severe control asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
89150280|NCT02836691|Active Comparator|EKG monitoring severe uncontrolled asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
89150281|NCT02836535||patients with complications|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential. The interview will examine the impact of complications utilizing a semi-structured script specific to each group
89150282|NCT02836535||patients without Complications (control group)|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential.
89150283|NCT04172298|Placebo Comparator|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
89150284|NCT04172298|Experimental|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
89150285|NCT04172298|Experimental|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
89150286|NCT04172376|Experimental|Minimally invasive puncture aspiration plus rt-PA|
89150287|NCT04172376|Active Comparator|Conservative medical treatment|
89150288|NCT02840903||Setting 1 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
89150289|NCT02840903||Setting 2 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
89150290|NCT02840903||Setting 3 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
89150291|NCT02840903||Setting 4 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
89150292|NCT02840903||Setting 5 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
89150293|NCT02840903||Setting 6 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
89150294|NCT02840903||Setting 7 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
89150295|NCT02840903||Setting 8 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
89150296|NCT02664636|Experimental|The study population|"The study population consists of patients 20 and 75 years of age who have had a supra-tentorial ischemic or hemorrhagic stroke. The study covers consulting or hospitalized patients at the neurological rehabilitation service (NHS) of Grau du Roi Medical Center, part of the Nîmes University Hospital. Most patients originate from a 2-4 week stay in the neurological acute care, cardiac or polyvalent departments of the University Hospitals of Montpellier or Nîmes.~Intervention: Physiotherapy~Intervention: Occupational therapy~Intervention: Functional near-infrared spectroscopy"
89150297|NCT02665806|Experimental|Ciclesonide|
89150298|NCT02665806|Active Comparator|Fluticasone|
89150299|NCT02665884||Glaucoma EX-PRESS|Glaucoma patients who underwent glaucoma surgery between the years 2014-2015 and had diurnal intraocular pressure measurements over 24 hours.
89150300|NCT02665884||Control Group|Glaucoma patients who had been treated with anti-glaucoma drops and had diurnal intraocular pressure measurements over 24 hours.
89150301|NCT00646308||I|Adult patients with GH deficiency due to a nonsecreting pituitary tumor
89150302|NCT00646308||2|Adult patients with a nonsecreting pituitary tumor but without GH deficiency
89150303|NCT00645684|Experimental|A|one layer running suture technique
89150304|NCT00645684|Experimental|B|two-layer suture technique
89150305|NCT02665962|Other|Calorie Restricted (CR) program|The intervention will provide individualized CR program, meal replacement products and nutritional counseling sessions.
89150306|NCT00646386|Active Comparator|A|
89150307|NCT00646386|Placebo Comparator|B|
89150308|NCT00647634|Experimental|1|Alprazolam Extended-Release Tablets 3 mg;
89150309|NCT00647634|Active Comparator|2|Xanax XR® Tablets 3 mg
89150310|NCT04172064||377patients evaluated by MPS and DSE|
89150311|NCT00647712|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
89150312|NCT00647712|Active Comparator|2|Depakote ER® Tablets 500 mg
89150313|NCT02667210||No shopping behavior|
89150314|NCT02667210||Minimal shopping behavior|
89150315|NCT02667210||Marked shopping behavior|
89150316|NCT02667210||Extensive shopping behavior|
89150317|NCT04172142||Control group|Healthy individuals of similar age and sex who meet the inclusion criteria
89150318|NCT04172142||Pectus Excavatum|Individuals with pectus excavatum that meet the inclusion criteria
89150319|NCT04172142||Pectus Carinatum|Individuals with pectus excavatum that meet the inclusion criteria
89150320|NCT02537106|Experimental|1.5% NaCl|After standardized induction to general anesthesia group A patients will be given the infusion of hyperosmotic 1.5% NaCl 5 ml/kg/BW during 15 min.
89150321|NCT02537106|Experimental|3% NaCl|After standardized induction to general anesthesia group B patients will be given the infusion of hyperosmotic 3% NaCl 5 ml/kg/BW during 15 min.
89150322|NCT00647790||1|Patients with a confirmed diagnosis of invasive breast cancer who are undergoing surgery.
89150323|NCT04173390|Experimental|pregabalin|
89150324|NCT04173390|Placebo Comparator|placebo|
89150325|NCT02667366|Experimental|Tel-PT|Tel-PT receives a manualized short-term CBT. Treatment consists of one initial face-to-face appointment and 8-12 subsequent telephone sessions between patient and licensed therapist. Each telephone contact lasts between 20 and 30 minutes and take place on a weekly and later biweekly basis.
89150326|NCT02667366|Active Comparator|TAU and text messages|Control Group receives treatment as usual and additionally weekly text messages containing general information about depression.
89150327|NCT00646464||2|Children 6-12 years old diagnosed as not suffering from ADHD
89150328|NCT00646464||1|children 6-12 diagnosed as ADHD
89150329|NCT02665650|Experimental|AFM13 + Pembrolizumab|Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.
89150330|NCT04173234|Experimental|Treatment Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week. Also, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
89150331|NCT04173234|Active Comparator|Control Group|Home exercise program Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do this program for 5 days a week.
89150332|NCT02665572|No Intervention|renal transplant without bladder recycling|the patients allocated to this arm and met inclusion criteria will undergo renal transplant without prior recycling of the bladder
89150333|NCT02665572|Active Comparator|renal transplantation with bladder recycling|the patients allocated in this arm will undergo bladder recycling prior to renal transplantation
89150334|NCT00647868|Experimental|Groups 1 and 2|Twice daily (7:00 am and 12:00 am or 7:00 am and 10:00 pm) dosing with intranasal testosterone for 14 days
89150335|NCT00647868|Experimental|Groups 3a and b|Single daily administration of testosterone (at 7:00 am or 10:00 pm) for 14 days
89150336|NCT00647868|No Intervention|Group 4|24-h blood sampling in healthy eugonadal controls
89150337|NCT00647946|Experimental|A|Stop zidovudine (ZDV) or stavudine (d4T) and start tenofovir DF 300mg once daily along with the other antiviral drugs that are used as part of their HAART regimen
89150338|NCT00647946|Active Comparator|B|Stop zidovudine (ZDV) or stavudine (d4T) and start abacavir 300mg twice daily along with the other antiviral drugs that are used as part of their HAART regimen
89150339|NCT02664480||study group|Reproductive age women with polycystic ovary syndrome and irregular menses (Salivary Alpha-amylase Levels of 3rd and 24th day of menstrual cyclus)
89150340|NCT02664480||control group|Reproductive age women with regular menses (Salivary Alpha-amylase level of 3rd and 24th day of menstrual cyclus)
89150341|NCT04171986|Experimental|Test Group|
89150342|NCT02667132||medical treatment|In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). antibiotic, immunosuppressive drugs, methotrexate
89150343|NCT02667132||surgical treatment|lumpectomy, mastectomy, abscess drainage
89150344|NCT02667132||surgical+medical treatment|first medical, after surgical treatment or first surgical, after medical treatment
89150345|NCT04171596|Experimental|Primary care coordination|
89150346|NCT00648024|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
89150347|NCT00648024|Active Comparator|2|Agrylin® Capsules 1 mg
89150348|NCT02665416|Experimental|Part I: Selicrelumab, Vanucizumab/Bevacizumab|Participants will receive a fixed dose of vanucizumab, 2 grams via IV infusion on Days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC in ascending dose levels on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (expected 24 months). Due to the discontinuation of Vanucizumab development, Participants ongoing in Part I will switch from Vanucizumab to Bevacizumab. All the dose escalation has been performed using Vanucizumab.
89150349|NCT02665416|Experimental|Part II: Selicrelumab, Bevacizumab|Bevacizumab will be administered via IV infusion on days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC after the Bevacizumab infusion at the dose determined in the Part I of the study on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part II of the study (expected 18 months).
89150350|NCT00646620|Experimental|1|budesonide/formoterol
89150351|NCT00646620|Active Comparator|2|fluticasone/salmeterol
89150352|NCT00646620|Active Comparator|3|albuterol
89150353|NCT04173078|Experimental|Computerized Distress Intolerance Intervention|Two, 1-hour computerized sessions that include psychoeducation about emotional avoidance, idiographic emotional exposure, and construction of idiographic implementation intentions to practice distress tolerance skills outside of session.
88804299|NCT05774808||Aortic valve + mitral valve surgery|
88804300|NCT05774795||Mitral valve surgery only|
89150354|NCT04173078|Placebo Comparator|Computerized Healthy Behaviors Intervention|Two, 1-hour computerized sessions that focus on psychoeducation about the importance of a healthy lifestyle.
89150355|NCT02665104||patients without neurological symptoms|carotid endarterectomy patients who dont'have any neurological symptoms after carotid clamping
89150356|NCT02665104||patients with neurological symptoms|carotid endarterectomy patients who have new neurological symptoms after carotid clamping
89150357|NCT04071912||ACL|All sports patients who had a muscle evaluation at 3-4 months and 6-8 months after ACL ligamentoplasty since January 2016
89150358|NCT00646698||1|Premenopausal Upper Body Obese (UBO) women with waist-hip ratio > 0.85 and BMI > 28
88804301|NCT05774795||Mitral valve surgery + Aortic valve surgery|
88804302|NCT05773872|Experimental|NT1|type 1 narcolepsy
88804303|NCT05773872|Experimental|NT2|type 2 narcolepsy
89150359|NCT00646698||2|Premenopausal Lower Body Obese (LBO) women with waist hip ratio < 0.8 and BMI > 28
89150360|NCT00646698||3|Premenopausal lean women with BMI < 25
89150361|NCT00648180|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
89150362|NCT00648180|Active Comparator|2|Adoxa Tablets 100 mg
89150363|NCT02664168|Active Comparator|Aquacel Ag Surgical Dressing|
89150364|NCT02664168|Active Comparator|Single-Use Negative Pressure Wound Therapy (PICO)|
89150365|NCT00648492|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
89150366|NCT00648492|Active Comparator|2|Glucophage® XR 500 mg
89150367|NCT04174248|Experimental|Experimental group|Experimental group with BCSMS App using
89150368|NCT04174248|No Intervention|Control group|Control group without BCSMS App using
89150369|NCT04645446|Experimental|Pro-ocular™ 1% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.7 mg of progesterone
89150370|NCT04645446|Experimental|Pro-ocular™ 0.5% Progesterone EP topical gel|Multidose formulation despensing unit doses of 0.07 g of topical gel containing 0.35 mg of progesterone
89150371|NCT04645446|Placebo Comparator|Placebo topical gel|Multidose formulation identical in appearance to Experimental Products despensing unit doses of 0.07 g of topical gel containing 0 mg of progesterone
89150372|NCT04632732||COVID+, SARS|patients COVID+ SARS mechanically ventilated and/or needing more than 6L/min of O2-40% FiO2 for a SpO2 equal or above 90% for more than 24hours.
89150373|NCT04632732||COVID+, nonSARS|patients COVID+ nonSARS respiratory symptomatic, with or without lung infiltrates, non mechanically ventilated, and needing less than 6L/min O2-40% FiO2 for a SpO2 equal or above 90%. They are hospitalized on floors (pulmonolgy, internal medecine or in intensives cares units).
89150374|NCT04632732||COVID-, ARDS|patients are in ARDS according to the Berlin definition and the lung injury is categorized in the direct form (e.g. pneumonia, aspiration).
89150375|NCT04632732||COVID-, nonARDS|patients are not in ARDS according to the Berlin definition but are respiratory symptomatic, with or without lung infiltrates and needing less than 6L O2/min-40% FiO2 for a SpO2 equal or above 90%.
89150376|NCT04632732||COVID-, control, MV+|patients hospitalized and mechanically ventilated for non-respiratory reasons (post hoc with sex-age matching).
89150377|NCT04632732||COVID-, control, MV-|non mechanically ventilated patients hospitalized for non-respiratory reasons (post hoc with sex-age matching).
89150378|NCT02663778|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
89150379|NCT02663778|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
89150380|NCT00648570|Experimental|1|Escitalopram Oxalate Tablets 20 mg
89150381|NCT00648570|Active Comparator|2|Lexapro® Tablets 20 mg
89150382|NCT00648258|Active Comparator|Arm 1|
89150383|NCT00648258|Active Comparator|Arm 2|
89150384|NCT00648336|Experimental|1|Mercaptopurine 50 mg
89150385|NCT00648336|Active Comparator|2|Purinethol® Tablets 50 mg
89150386|NCT00648414|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
89150387|NCT00648414|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
89150388|NCT00648414|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
89150389|NCT00648414|Experimental|4|Duragesic 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
89150390|NCT00648414|Experimental|5|Duragesic 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
89150391|NCT00648414|Experimental|6|Duragesic 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
88804304|NCT05773872|Active Comparator|HSI|idiopathic hypersomnia
89150392|NCT04171752|Experimental|Young Adults|Single oral dose of elafibranor 120mg
89150393|NCT04171752|Experimental|Elderly|Single oral dose of elafibranor 120mg
89150394|NCT02666976|Experimental|ilaprazole group|ilaprazole 20mg once daily for 4 weeks.
89150395|NCT04546308|Experimental|Exercise training|The participants will undergo 8 weeks of whole-body resistance exercise training followed by a 4-week detraining. The central hemodynamic and muscle stiffness variables will be measured pre, post-training, and post-detraining.
89150396|NCT04546308|No Intervention|Sedentary control|The participants will undergo 12 weeks of intervention without exercise training. The central hemodynamic and muscle stiffness variables will be measured pre, 8th, and 12th week.
89150397|NCT04171362|Experimental|Migraine group|The study included patients diagnosed by migraine according to International Headache Community criteria with18-65 years of age followed by routine controls and who were volunteered
89150398|NCT04171362|Active Comparator|Control group|The study included patients diagnosed by migraine according to International Headache Community criteria with 8-65 years of age followed by routine controls and were volunteered
89150399|NCT02663700|Experimental|1.8x10^6 sporozoites 2 doses|To be completed after safety data from Cohorts 1 and 2 are reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 3 and 11. n=8
89150400|NCT02663700|Experimental|2.7x10^6 sporozoites 2 doses|To be completed after safety data from Cohort 3 is reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 5 and 13. n=8
89150401|NCT02663700|Experimental|2.7x10^6 sporozoites 3 doses|Subjects to be assigned 1:1 to either PfSPZ vaccine (pending safety data from cohort 4) or placebo. Subjects will be administered the intervention on a 0, 8, and 16 week schedule (study days 1, 57, and 113). n=80
89150402|NCT02663700|Experimental|4.5x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 4.5x10^5 sporozoites on study weeks 1 and 9. n=8
89150403|NCT02663700|Experimental|9x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 9x10^5 sporozoites on study weeks 1 and 9. n=8
89150404|NCT00648726|Active Comparator|Arm 1|
88804305|NCT05773677|Experimental|Case Group: with diet|Prescription of specific diet in pregnancy
88804306|NCT05773677|No Intervention|Control Group: no diet|Retrospective group with no diet
88804307|NCT05773404|Experimental|passive manual therapy|The physiotherapist performs passive techniques on the hamstring muscles of the footballers.
88804308|NCT05773404|Experimental|active therapy (exercise)|The physiotherapist does not perform passive techniques and it is the player who performs active techniques on the hamstring muscles.
88804309|NCT05773404|Active Comparator|combined therapy|The physiotherapist performs passive techniques and in addition the player performs active techniques on the hamstring muscles.
88804310|NCT05772754|Other|Chronic heart failure partecipants|Patients in the Department of Cardiovascular Sciences with signs and symptoms of chronic heart failure, elevated natriuretic peptide levels, left atrial dilatation and/or left ventricular hypertrophy, ejection fraction greater than 50% on echocardiographic evaluation HFpEF
88804311|NCT05772754|Other|Chronic hert faiure and ejection fraction less than 40% at echocardiographic evaluation|Patients admitted to the Department of Cardiovascular Sciences with signs and symptoms of chronic heart failure*, ejection fraction less than 40% at echocardiographic evaluation HFrEF
88804312|NCT05772754|Other|Partecipants with pulmonary hypertension|Patients admitted with advanced HFpEF with development of pulmonary hypertension PH-HFpEF
88804313|NCT05772754|Other|Partecipants with advanced HFrEF|Patients admitted with advanced HFrEF with development of pulmonary hypertension PH-HFrEF
88804314|NCT05772754|Other|Control Group|12 Controls (CTRL), recruited in the outpatient setting among subjects with cardiovascular disease, in the absence of heart failure
88804315|NCT05772325|Active Comparator|Brief standardized dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists.
89150405|NCT00648726|Active Comparator|Arm 2|
89150406|NCT00648726|Active Comparator|Arm 3|
89150407|NCT04171674|Experimental|Patients treated with high-dose ceftobiprole|
89150408|NCT00648804|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
89150409|NCT00648804|Active Comparator|2|Zofran ODT® Tablets 8 mg
88804316|NCT05772325|Experimental|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian.
88804317|NCT05768594||Patients with aortic stenosis, surgical valve replacement|15 patients undergoing surgical valve replacement (SAVR)
88804318|NCT05768594||Patients with aortic stenosis, undergoing transcatheter aortic valve implantation|15 patients undergoing transcatheter aortic valve replacement (TAVR)
88804319|NCT05763524||Adrenalectomy in patients operated for Adrenocortical Carcinoma|All adult (18 years old and older) patients registered in EUROCRINE® database that underwent surgery for adrenocortical carcinoma from 2015 till 2021 will be included
88804320|NCT05762393|Experimental|Cohort A|Cohort A will receive the low-dose antigen formulation(10 μg Sm-p80 + 5 μg GLA-SE) or placebo. Cohort will include 20 participants randomized to receive either Sm-p80 product or placebo in a 3:1 ratio. All participants will receive three intramuscular injections of 0.5 mL of the designated study product / placebo, on Days 0, 28, and 56 (28 days apart).
88804321|NCT05762393|Experimental|Cohort B|Cohort B will receive the low-dose antigen formulation(30 μg Sm-p80 + 5 μg GLA-SE) or placebo. Cohort will include 20 participants randomized to receive either Sm-p80 product or placebo in a 3:1 ratio. All participants will receive three intramuscular injections of 0.5 mL of the designated study product / placebo, on Days 0, 28, and 56 (28 days apart).
88804322|NCT05762393|Experimental|Cohort C|Cohort C will receive the low-dose antigen formulation(100 μg Sm-p80 + 5 μg GLA-SE) or placebo. Cohort will include 20 participants randomized to receive either Sm-p80 product or placebo in a 3:1 ratio. All participants will receive three intramuscular injections of 0.5 mL of the designated study product / placebo, on Days 0, 28, and 56 (28 days apart).
88804323|NCT05761626||Patients with MP < 17 j/min|Patients with acute respiratory distress syndrome with MP < 17 j/min
88804324|NCT05761626||Patients with MP ≥ 17 j/min|Patients with acute respiratory distress syndrome with MP ≥ 17 j/min
88804325|NCT05760443|Experimental|Mindfulness-based intervention|6 week group mindfulness-based intervention
88804326|NCT05753982|Experimental|kinesiotape|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
88804327|NCT05753982|Placebo Comparator|control|No kinesiotape, standard of care
88804328|NCT05735912|Experimental|Endoscopic ultrasound-guided radiofrequency ablation|"Endoscopic ultrasound-guided radiofrequency ablation will be performed using the EUSRA system (Taewoong, Seoul, Korea). The system consists of a 19-gauge needle electrode (140-cm long), a radiofrequency current generator (VIVA RF generator; Taewoong), and an inner cooling system that circulates chilled saline solution during the radiofrequency ablation procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to the radiofrequency current generator and to a cooling pump. The generator, in addition to providing radiofrequency current, allows the control of physical power and impedance parameters."
89150410|NCT02664012|Active Comparator|Own Brand Menthol Cigarette|Own Brand Menthol Cigarette
89150411|NCT02664012|Experimental|Electronic Menthol Cigarette #1|VUSE® (menthol flavor, 14 mg nicotine)
89150412|NCT02664012|Experimental|Electronic Menthol Cigarette #2|VUSE® (menthol flavor, 29 mg nicotine)
89150413|NCT02664012|Experimental|Electronic Menthol Cigarette #3|VUSE® (menthol flavor, 36 mg nicotine)
89150414|NCT02664012|Active Comparator|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
89150415|NCT00895037||1|Patients treated with Refacto AF
89150416|NCT04170504|Experimental|Qing Re Huo Xue (QRHX) plus methotrexate (MTX)|QRHX XXmg bid and methotrexate (MTX) 10 mg once a week for 24 weeks
89150417|NCT04170504|Active Comparator|Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)|Methotrexate (MTX) plus dummy Qing Re Huo Xue (QRHX)
89150418|NCT04170114|Experimental|Cystic Fibrosis|Children with cystic fibrosis
89150419|NCT04170114|Experimental|Bronchiectasis|Children with bronchiectasis
89150420|NCT02836301|Active Comparator|Testimonials-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
89150421|NCT02836301|Active Comparator|Testimonials-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
89150422|NCT02836301|Active Comparator|Testimonials-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
89150423|NCT02836301|Experimental|Documentary-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
89150424|NCT02836301|Experimental|Documentary-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
89150425|NCT02836301|Experimental|Documentary-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
89150426|NCT04170270|Experimental|oral omeprazole|oral omeprazole in bleeding peptic ulcer after endoscopic therapy 40 mg twice daily for 72 hours
89150427|NCT04170270|Active Comparator|intravenous omeprazole|intravenous omeprazole in bleeding peptic ulcer after endoscopic therapy as continuous infusion at rate of 8 mg/hour for 72 hours
89150428|NCT00633347|Active Comparator|A|A: Antagonist
89150429|NCT00633347|Active Comparator|B|Agonist GnRH
89150430|NCT02839031|Experimental|"CBT group"|
89150431|NCT02839031|Sham Comparator|Control group|
89150432|NCT02659644|Experimental|Oral citrulline|
89150433|NCT02838719|Experimental|Perineural group|Group 1: perineural dexamethasone acetate added to bilateral transverse abdominis plane block with levobupivacaine
89150434|NCT02838719|Active Comparator|Intravenous group|Group 2: Intravenous dexamethasone acetate added with bilateral transverse abdominal plane block with levobupivacaine
89150435|NCT02659488|Other|Lisdexamfetamine|During the Treatment Phase, subjects will be evaluated after 1, 2, 3, 4, 6, 8, 10, and 12 weeks (see Figure 2). The morning after completing the first fMRI scan, LDX will be started at 30 mg q AM (Baseline). After 1 week, LDX will then be increased to 50 mg q AM (Visit 1); after another week, LDX will be increased to 70 mg q AM (Visit 2). A single downward dose titration to 50 mg is allowed during week 3 if 70 mg/d is not tolerated. LDX dose at week 4 (50 or 70 mg/d) will be maintained for the next 8 weeks. Patients who do not tolerate 50 or 70 mg/day will be terminated. For patients who complete the 12-week treatment phase, LDX will be stopped at week 12 visit.
89150436|NCT02838797|Placebo Comparator|Placebo|"For the single ascending dose study, subjects will receive a single dose of oral acetate buffer on a single day.~For the multiple ascending dose study, subjects will receive a single daily dose of oral acetate buffer each day for 14 days."
89150437|NCT02838797|Experimental|RQ-00000010|"For the single ascending dose study, subjects will receive a single dose of either:~2 micrograms, 50 micrograms or 200 micrograms of RQ-00000010 on a single day.~For the multiple ascending dose study, subjects will receive single daily doses of either 10 micrograms, 50 micrograms or 100 vs. 200 micrograms of RQ-00000010 each day for 14 days."
89150438|NCT00649194|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
89150439|NCT00649194|Active Comparator|2|Aciphex® Tablets 20 mg
89150440|NCT02838563||Patient living in nursing home|Patient with an Alzheimer Disease or related disorder living in nursing home.
89150441|NCT02659410|Experimental|Heat stress|4h exposure to heat stress alone or in combination with different solvents. Solvent concentrations are equal to their TLV. Heat conditions are 21, 25 and 30°C (WBGT). Inhalation exposure for all solvents and demal exposure for toluene.
89150442|NCT02838485|Experimental|Amputees|The subjects will receive both mirror and imagery treatments in a cross-over design.
89150443|NCT04249349|Experimental|Robot-assisted Gait|Participants will receive assisted gait with a motorized ankle foot orthosis. Patient´s gait will be analyzed by a photogrammetry system during device assistance. Session will involve 1 hour of supervised training.
89150444|NCT04249193||Transfusion|
89150445|NCT02659332|Experimental|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)
89150446|NCT04249271||euthyroid, no antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling
89150447|NCT04249271||borderline euthyroid, no antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO <100 IU/l repeated serum sampling
89150448|NCT04249271||hypothyroidism, no antibodies|TSH >4.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling
89150449|NCT04249271||euthyroid, with antibodies|TSH 0.3 to 2.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling
89150450|NCT04249271||borderline euthyroid, with antibodies|TSH 2.5 to 4.5 mIU/l and anti-TPO >100 IU/l repeated serum sampling
89150451|NCT04249271||hypothyroidism, with antibodiesal|TSH >4.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling
89150452|NCT02659176|Active Comparator|Transperineal repair with PIS|transperineal repair of anterior rectocele with limited internal sphincterotomy
89150453|NCT02659176|Active Comparator|Transperineal repair without PIS|transperineal repair of anterior rectocele only
89150454|NCT02836223|Experimental|Interdental device|Water Flosser
89150455|NCT02836223|Other|Toothbrush|Control
89150456|NCT04170192||UCBT-IBD-Case|Very early onset IBD patients who underwent Cord Blood Stem Cell Transplantation.
89150457|NCT02836379||Breakthrough Cancer Pain|No intervention (Non-interventional study)
89150458|NCT02658864|Experimental|10-mg group|Twelve healthy subjects were administered a single oral dose of 10 mg lafutidine tablets in fasted state.
89150459|NCT02658864|Experimental|20-mg group|Twelve healthy subjects were administered a single oral dose of 20 mg lafutidine tablets in fasted state.
89150460|NCT02658864|Experimental|40-mg group|Twelve healthy subjects were administered a single oral dose of 40 mg lafutidine tablets in fasted state.
89150461|NCT02658942|Active Comparator|Ureteroscopy|Intervention: Flexible ureteroscopy for removal of lower calyceal stones using holmium:YAG laser lithotripsy
89150462|NCT02658942|Active Comparator|Shockwave lithotripsy|Intervention: Shockwave lithotripsy for lithotripsy of lower calyceal stones using Siemens Lithostar Lithotriptor
89150463|NCT00892151|Experimental|Intended Users of the Software|10 Healthcare Professionals and 40 persons with diabetes (of which 6 were parents/legal guardians of children with diabetes) using a diabetes data management program.
89150464|NCT02663544|Active Comparator|Limited dairy diet|Three 8 oz. servings per week of non-fat milk. Participants will otherwise eat their usual diet, but will be asked not to consume any dairy products not provided by the study.
89150465|NCT02663544|Experimental|Low-fat dairy diet|3.3 daily servings of non-fat and low-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
89150466|NCT02663544|Experimental|Full-fat dairy diet|3.3 daily servings of full-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
89150467|NCT04248647|Experimental|Intervention Group|4-week multimodal preoperative intervention (i.e., Prehabilitation) consisting of an aerobic and strength training program, nutritional counselling and psychological support to help improve physical and psychological health prior to surgical resection of colorectal cancer.
89150468|NCT02663466||Recurrent Group|Patients with clinically confirmed recurrence of sacrococcygeal pilonidal sinus following Limberg flap surgery were eligible (recurrent group, RG). They were evaluated for erroneous off-midline closures as an exposure variable.
89150469|NCT02663466||Nonrecurrent Group|Patients who underwent same surgery from the January 2008 to July 2015 but have not had recurrence in the five-year follow-up period (non-recurrent group, NRG) were accepted eligible. They were evaluated for erroneous off-midline closures as an exposure variable.
88804329|NCT05735912|Active Comparator|Surgery|Surgical resection will be performed in an inpatient setting. The type and extension of surgical resection, as well as need for lymphadenectomy, will be decided by the treating surgeons according to the tumor position, distance from the main pancreatic duct, and local expertise.
89150470|NCT02835833|Experimental|Nintedanib 150 mg + Bevacizumab 15 mg/kg|"The first three patients on study will be treated with 150 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.~If one dose limiting toxicity occurs in the first cohort, then three more patients will be treated at that same starting dose and assessed for toxicity after cycle two. If two or more patients have dose limiting toxicity, then dose escalation will end and the maximum tolerated dose will be reached."
89150471|NCT02835833|Experimental|Nintedanib 200 mg + Bevacizumab 15 mg/kg|If no patients experience dose limiting toxicity, then three additional patients will be treated with 200 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.
89150472|NCT02663310|Experimental|Surgery with Rehabilitation|Surgically removed cysts, and collected intracystic fluids and cerebrospinal fluid for histological and molecular analyses. Samples will be collected during the surgery and will be cryo-protected for further analyses. All subjects will enroll for intensive rehabilitation 60 days after surgery.
89150473|NCT02663310|Active Comparator|Rehabilitation|All subjects will enroll for intensive rehabilitation everyday as instruction.
89150474|NCT02835755|Active Comparator|Group I (Control)|Patients receive standard information about HPV and HPV vaccine, such as the VIS, on a mobile-friendly website study portal.
89150475|NCT02835755|Experimental|Group II (mHealth HPV vaccine)|Patients receive the mHealth HPV vaccine intervention consisting of content about HPV and HPV vaccine on the study portal for 15 minutes and vaccination reminders sent by the portal via text or e-mail.
89150476|NCT02663154|Experimental|Aromatherapy|Aromatherapy inhaler (QueaseEASE, Soothing Scents Inc, Enterprise, AL) applied to nauseous post surgical paediatric patients in the postanesthetic care unit
89150477|NCT02663154|Placebo Comparator|Placebo|Saline inhaler applied to nauseous post surgical paediatric patients in the postanesthetic care unit
89150478|NCT02165345|Experimental|Tocilizumab|Participants will receive tocilizumab until the commercial availability of the drug or up to 5 years, whichever is earlier.
89150479|NCT00648882|Experimental|1|LEVOTHYROXINE SODIUM TABLETS,USP 300 mcg;
89150480|NCT00648882|Active Comparator|2|SYNTHROID® 300 mcg Tablets
89150481|NCT05333705|Experimental|immune cell arm|Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were cultured. NK cell production will be infused after chemotherapy.
89150482|NCT02840669|Other|Friedreich's Ataxia|
89150483|NCT02840669|Other|Healthy Volunteers (Controls)|
89150484|NCT02662686|Active Comparator|Control|Embryo selection for transfer will be based initially on chromosomally normal embryos and secondly on embryo morphology criteria (specific of IVF lab, as standard practice).
89150485|NCT02662686|Experimental|MitoScore|Embryo selection for transfer will be based initially on chromosomal normality and secondly on the MitoScore value, trying to transfer chromosomally normal embryos which contain the lowest number of mitochondrial DNA copies.
89150486|NCT02838329|Active Comparator|room temperature - RT|Ropivacaine used for Epidural top-up administered at room temperature
89150487|NCT02838329|Experimental|body temperature BT|Ropivacaine used for Epidural top-up administered warmed to body temperature
89150488|NCT02662530|Active Comparator|Botulinum toxin type A clinical|Initial and optimization of BoNT-A injection parameters will be conducted by clinical visual assessment
89150489|NCT02662530|Active Comparator|Botulinum toxin type A kinematic|Initial and optimization of BoNT-A injection parameters will be conducted by kinematic assessment
88804330|NCT05727839|Experimental|Phase Ia:Dose escalation|"JCXH-211 will be delivered by intratumoral injection in 2 stages:~（Part1）Intratumoral injection stage of skin/subcutaneous lesions. According to Part 1 study results,1-2 dose groups were selected for deep lesion injection study, dose escalation will follow the 3 + 3 principle."
88804331|NCT05727839|Experimental|Phase Ib: Dose Extension|JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase Ia.
88804332|NCT05719194|Active Comparator|Standard intervention|
88804333|NCT05719194|Experimental|Personalized intervention - WIPO risk factors vs no risk factors|
88804334|NCT05716477||Screening (biospecimen collection)|Participants undergo blood specimen collection and complete survey on study. Participants may optionally undergo standard of care FIT testing on study.
88804335|NCT05676658|Experimental|Coherent breathing|
89150490|NCT01706705|Experimental|Brachytherapy Treatment Planning|"MRI-compatible intracavitary applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.~Computed tomography (CT) scan and a magnetic resonance imaging (MRI) scan performed after the implant is placed in the operating room. The CT scan should take about 20 minutes and the MRI about 45 minutes."
89150491|NCT04171206|Experimental|Free From Abuse|This is a brief internet-delivered intervention designed to boost participants' ability to recognise abusive behaviour, reduce acceptance of myths related to domestic violence and IPV, as well as decrease abuse perpetration and victimisation.
89150492|NCT04171206|Placebo Comparator|Technology and crime|This is a brief internet-delivered placebo intervention designed to inform participants about how the development of technology could affect crime.
89150493|NCT02537028|Experimental|MSC2364447C 25 mg|
89150494|NCT02537028|Experimental|MSC2364447C 75 mg|
89150495|NCT02537028|Placebo Comparator|Placebo|
89150496|NCT02835521|Experimental|Intervention Group|Patients will receive the reception treatment before the joint injection
89150497|NCT02835521|Active Comparator|Control Group|patient will receive a joint injection
89150498|NCT02658786||Hepatitis B patients|Biopsy proven Hepatitis B virus infected cases will be followed for the period of 5 years
89150499|NCT02658786||Hepatitis C patients|Biopsy proven Hepatitis C virus infected cases will be followed for the period of 5 years
89150500|NCT02658786||Non Alcoholic Fatty liver Disease patients|Biopsy proven Non Alcoholic Fatty liver Disease patients cases will be followed for the period of 5 years
89150501|NCT00649272|Experimental|1|Oxybutynin Chloride Extended-Release Tablets, 15 mg
89150502|NCT00649272|Active Comparator|2|Ditropan XL® Extended-release tablets, 15 mg
89150503|NCT02662842||FlowSmart Infusion set, then current set|Subjects will use the FlowSmart Infusion Set for a period of 9 to 11 days, then switch to their current infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period then - Subjects will use their current infusion set for a period of 9 to 11 days, then switch to the FlowSmart infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period.
89150504|NCT02666898|Experimental|Obinutuzumab and Ibrutinib CLL treatment|"3 parts~PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:~GA101:~C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v~Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO~PART 2: 4 cycles / 28 days~After evaluation at D1 month 9:~patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily~patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1~Fludarabine : 40 mg/m² per os, days 2-4, / 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days~Ibrutinib 420mg/day PO~PART 3 (only in GAI-FC+Ibru arm) :~After evaluation at D1 of M16:~patients CR with BM MRD< 10-4, treatment stopped~patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative."
89150505|NCT04248881|Active Comparator|Intervention Group|"Participants having previously attended at least once in previous years the World Cancer Day Walk will be considered as the group exposed to the health education intervention (returning)."
89150506|NCT04248881|No Intervention|Control Group|"The control/non-exposed group will be the participants who are attending the World Cancer Day Walk for the first time in 2020 (first timers) and have not yet received health education information."
89150507|NCT02658708|Experimental|Arm 1: Bright blue-green light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, -21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
89150508|NCT02658708|Active Comparator|Arm 2: Dim red light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, 21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 days randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
89150509|NCT02835053||Emergency General Surgery|All patients having emergency general surgery procedures as defined by Scott et al (JAMA Surgery 2016)
89150510|NCT04174404|Experimental|Intervention group|The participants in the intervention group will receive the routine care plus the ICory-Circumcision which is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children.
89150511|NCT04174404|Active Comparator|Control group|The participants in the control group will receive routine care provided by the hospital which consists of normal doctor consultant, preoperative preparation, and postoperative care.
89150512|NCT02835209||Work of breathing during SBT|Ventilated premature infants born 24 to 34+6 weeks gestational age.
89150513|NCT02834897|Experimental|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
89150514|NCT04170036||Protein supplement group|The group of subjects who use protein supplements at least for the preceding three months
89150515|NCT04170036||Control group|The group of subjects who never used protein supplements
89150516|NCT02834585||Ultrasound|Patients undergoing Ultrasound
89150517|NCT02834585||Magnetic Resonance Imaging|Patients undergoing Magnetic Resonance Imaging
89150518|NCT04169724|Experimental|Calm|Participants will be asked to download the Calm app on their smartphone. Participants will then receive an email containing login credentials to access the Calm app. Once they receive this email and they receive their study start date, they will be asked to meditate for at least 10 minutes a day for 8 weeks. This prescription mimics how a new, paying member would use the app. Participants in the intervention group will be emailed weekly reminders.
89150519|NCT04169724|No Intervention|Waitlist|Participants randomized to the control group will be asked to maintain their normal routine for 8 weeks and to avoid using the Calm meditation app.
89150520|NCT02834741|Placebo Comparator|SAD Phase|"Up to 36 subjects: 50 - 1200 mg NYX-2925, Up to 12 subjects: placebo~6 additional subjects will receive a fed dose of NYX-2925, 2 additional subjects will receive a fed dose of placebo (Food Effect Cohort)~6 additional subjects will receive 1 dose of 50 mg NYX-2925 followed by a lumbar puncture at 1 and 4 (3 subjects) or 2 and 8 (3 subjects) hours post dose"
89150521|NCT02834741|Placebo Comparator|MAD Phase|"Up to 24 subjects : 150 - 600 mg NYX-2925 daily for 7 days, up to 6 subjects : placebo daily for 7 days~6 additional subjects will receive 300 mg NYX-2925 daily for 7 days and undergo lumbar puncture on Day 6 in order to have two CSF samples taken (CSF Cohort)."
89150522|NCT02536560||Antibiotics|150 infants, (because of hospital protocol) treated with antibiotics because of a perinatal infection during the first week of life
89150523|NCT02536560||Controls|The control group comprises 300 healthy newborns, born in the hospital and needing clinical observation for 24-48 hours for several reasons like maternal comorbidity, low probability of neonatal infection, blood sugar monitoring, meconium containing amniotic fluid, or delivery by caesarean section
89150524|NCT02840279|Experimental|BPN14770|An oral dose of BPN14770
89150525|NCT02840279|Placebo Comparator|Placebo|An oral dose of placebo matching BPN14770
89150526|NCT04169802||Normal subjects|Age ≥ 50 years, Corrected distance or near visual acuity (VA) of ≥ 20/25 Snellen equivalent, in the study eye.
89150527|NCT04169802||Subjects with neovascular AMD|Age ≥ 50 years, History of neovascular age-related macular degeneration, in the study eye, Corrected distance or near VA of ≥ 20/200 Snellen equivalent, in the study eye.
89150528|NCT04460495|Experimental|Feasibility (ASL,pH-Weighted amine CEST, O2-Weighted SAGE-EPI)|Participants undergo ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI , while breathing normal room air (21% oxygen). Patients then undergo another ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI while breathing medical grade air (100% oxygen). Total ASL perfusion, pH-weighted amine CEST, and oxygen-weighted SAGE-EPI imaging scan time is 60 minutes.
89150529|NCT00648960|Experimental|1|
89150530|NCT00648960|Active Comparator|2|
89150531|NCT04437329|Experimental|DNF-N|"Induction chemotherapy:~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous nedaplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~Concurrent chemoradiotherapy:~three cycles of 100 mg/m² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~Radiotherapy: radical intense modulated radiation therapy"
89150532|NCT04437329|Active Comparator|DPF-P|"Induction chemotherapy:~three cycles of intravenous docetaxel 60 mg/m² on day 1, intravenous cisplatin 60 mg/m² on day 1, and continuous intravenous fluorouracil 600 mg/m² per day from day 1 to day 5, every 3 weeks~Concurrent chemoradiotherapy:~three cycles of 100 mg/m² cisplatin every 3 weeks, concurrently with intensity-modulated radiotherapy~Radiotherapy: radical intense modulated radiation therapy"
89150533|NCT04170816|Active Comparator|DN plus KT group|"DN plus KT therapy is going to be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy is going to be applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.~Kinesio Taping Application: Tapes is going to be left on the patient's body for 5 days."
89150534|NCT04170816|Active Comparator|DN group|DN will be applied 3 sessions in 1-week intervals. Dry Needling Theraphy: DN therapy was applied on active myofascial trigger points (MTrP) in quadratus lumborum, gluteus medius and lumbar multifidus muscles.
89150535|NCT02834507|Placebo Comparator|Placebo|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
89150536|NCT02834507|Experimental|Nebicapone 75 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
89150537|NCT02834507|Experimental|Nebicapone 150 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
89150538|NCT02834507|Active Comparator|Entacapone 200 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
89150539|NCT02662452|Experimental|GLPG2222 single dose|Single dose of GLPG2222 oral suspension
89150540|NCT02662452|Placebo Comparator|Placebo single dose|Single dose of placebo oral suspension
89150541|NCT02662452|Experimental|GLPG2222 multiple doses|Multiple doses of GLPG2222 oral suspension
89150542|NCT02662452|Placebo Comparator|Placebo multiple doses|Multiple doses of placebo oral suspension
88804336|NCT05676658|Placebo Comparator|Placebo coherent breathing|
88804337|NCT05666011|Experimental|Group A -- Right side is Intervention Arm, Left side is Control Arm|Right Arm will be treated with IPL activation of SNA (Silver Nanoparticles ) and left arm with IPL alone.
88804338|NCT05666011|Experimental|Group B -- Left side is Intervention Arm, Right side is Control Arm|Left Arm will be treated with IPL activation of SNA (Silver Nanoparticles ) and right arm with IPL alone.
88804339|NCT05644756|Other|Measurement Based Care Implementation|Six community mental health clinics located in Washington state will receive trainings on how to implement Measurement Based Care (MBC) in their clinics. We are creating implementation plans to improve therapists' use of measurement-based care.
88804340|NCT05638594|Experimental|Pyrotinib +trastuzumab+dalpiciclib+letrozole|Every 4 weeks for 5 cycles. Cumulative 20 weeks of treatment. Premenopausal patients need to receive ovarian function suppression
88804341|NCT05638594|Active Comparator|Trastuzumab + pertuzumab + docetaxel + carboplatin|Every 3 weeks for 6 cycles. Cumulative 18 weeks of treatment
88804342|NCT05638152||before|routine care
88804343|NCT05638152||after|routine care + natural imagery in the PACU + access to music + access to aromatherapy + use of hypnoidal communication techniques by PACU nurses
88804344|NCT05620368|Experimental|Mindfulness-based teleintervention|8-week Mindfulness and Compassionate Living Course (MCLC). The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours).
88804345|NCT05620368|Active Comparator|Usual care intervention|The facility provides psychological support for parents as needed and at the request of the parent. Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week).
88804346|NCT05612672|Experimental|GeoHAI Use|Participants will use the GeoHAI tool
88804347|NCT05585242|Experimental|Intervention|"The program consists of brief weekly videos, each addressing a particular Acceptance and Commitment Therapy technique to be implemented that week. Participants receive the videos by email from the researcher and watch them on their own. Each video also assigns a homework exercise for the participant to complete that week and includes a summary of the module."
88804348|NCT05585242|No Intervention|Waistlist|Participants in the waitlist control condition will complete the same measures as the intervention group. After they have completed their one-month follow-up measures they will be given the opportunity to receive the intervention.
88804349|NCT05570617|Experimental|Transition Coach Intervention|Half (53) of the participants will be randomly allocated to the Transition Coach Intervention arm of the study. Individuals in the Transition Coach Intervention group will receive the current standard of care (receiving the Youth Transition Roadmap) and meet with the transition coach six times and with a clinical psychologist two times over the course of six months. The meetings between the participant and TC/psychologist will occur over the phone or using the Ontario Telemedicine Network or EPIC.
88804350|NCT05570617|Active Comparator|Standard of Care|The other half of participants will only receive the current standard of care is the Youth Transition Roadmap which has been developed by Hamilton Health Sciences and provides patients information about 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation.
88804351|NCT05563909|Experimental|Virtual Reality Group|Tendon and nerve gliding exercises will be applied to the patients in the virtual reality group for 2 weeks, for a total of 10 sessions, through the developed software. Patients will be asked to come for 2 weeks for the virtual reality mediated exercise program. Patients will be asked to do their exercises in a virtual reality-mediated exercise protocol, with 1 session of approximately 30 minutes. Apart from the exercise program, patients will be asked to use wrist splints.
88804352|NCT05563909|Active Comparator|Conventional Exercise Group|For the patients in the classical exercise group; The classical exercise program will be taught in the company of a physiotherapist and they will be asked to do these exercises for a total of 10 sessions for 2 weeks. The patients' home exercise programs will be controlled by weekly phone calls. Apart from the exercise program, patients will be asked to use wrist splints.
88804353|NCT05563909|Active Comparator|Control Group|Patients in the control group will be advised to continue using splints. It will be evaluated by repeated examinations.
88804354|NCT05559658||Group 1|"A: Current chemsex users Men who have sex with men, Aged 16-35 years, Able to communicate in Thai fluently, Current chemsex users.~B: Former chemsex users (discontinued ≥90 days) Men who have sex with men, Aged 16-35 years, Able to communicate in Thai fluently, Former chemsex users (discontinued ≥90 days)."
88804355|NCT05553470|Experimental|No Hepatic Impairment|Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
88804356|NCT05553470|Experimental|Moderate Hepatic Impairment|Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
88804357|NCT05553470|Experimental|Mild Hepatic Impairment|Participants will receive a single oral dose of miricorilant (6 X100 mg) tablets.
88804358|NCT05545839|No Intervention|Standard care - control|Standard of care, appointments with adult rheumatology
89150543|NCT04481568|Experimental|The PES-4-BPSD Model|The intervention arm consists of PES and nurse assistants who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff: mental health assistants with high school level education, who receive training in de-escalation and crisis prevention techniques and provide direct personal care to psychiatric patients. On the intervention unit, these PES purposefully engage patients with BPSD. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of HCGs towards patients. IV. Staff Training (please refer to NCT# 04179721 for more details on staff support and training).
89150544|NCT04481568|Active Comparator|The attention control condition|The attention control condition will consist of a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 nursing assistants (1:8 ratio), that primarily cohorts older patients with geriatric syndromes.
88804359|NCT05545839|Experimental|Transition coaching - experimental|Participants will receive 8 transition coaching sessions (1/month) in addition to standard care
88804360|NCT05516771||group 1|toddlers and small children undergoing surgery at a tertiary referral, university-affiliated hospital
89150545|NCT02831699||Febrile Rash|
89150546|NCT02831699||Household|
89150547|NCT02831699||Guillain-Barré prospective|
89150548|NCT02831699||Prior Guillain-Barré|
89150549|NCT02831543|Experimental|Motireb 5/100 mg t.i.d|Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
89150550|NCT02831543|Active Comparator|Mosapride citrate t.i.d|Placebo of Motireb 5/100 mg t.i.d + Mosapride citrate t.i.d
89150551|NCT02831543|Placebo Comparator|Placebo t.i.d|Placebo of Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
89150552|NCT02662218||Patients with superficial wounds|A cohort of 50 patients with superficial wounds of any etiology (see inclusion criteria), who need advanced wound care treatment in any case, will be observed over a period of 14 days; the exact duration for each patient depends upon the investigator's assessment. The observation consists of an initial visit, at least one dressing change after max. 7 days and a final visit. Patients will be treated with the CE-marked wound care product. This product is already in general use in the Netherlands and Germany. It is a sterile, bacteria-binding, super-absorbent wound dressing. Apart from the predefined study visits, daily dressing changes in accordance with daily clinical practice are possible.
89150553|NCT02840591|Experimental|Drug Treatment|"First 5 consecutive subjects: Ramelteon 8 mg daily at 8 pm for 5 days~Next 5 consecutive subjects: Citicoline 250 mg daily at 8 pm for 2 days, followed by citicoline 500 mg daily at 8 pm for 3 days~All subjects: Standard medical care"
89150554|NCT02840591|No Intervention|Observation-Only|Standard medical care
89150555|NCT02667054|Active Comparator|Active 4%|One dose of 4mL of RX0041 4% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
89150556|NCT02667054|Placebo Comparator|Placebo|One dose of 4mL of RX0041 placebo for one day in the mucous membrane prior to a diagnostic or surgical procedure.
89150557|NCT02667054|Active Comparator|Active 8%|One dose of 4mL of RX0041 8% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
89150558|NCT02840513|Experimental|Smartphone app/CO self-monitoring|The app offers a coaching function where users receive personalized messages to encourage smoking cessation and advice for behavioural changes. For the first 4 weeks of the intervention, individuals will also be asked to blow daily into a breath carbon monoxide monitor before going to sleep. Depending on the results of the breath test, individualized messages will be delivered by the Smokelyzer feedback app to either enhance maintenance of abstinence or increase the motivation to quit. After the first 4 weeks, participants will use the breath carbon monoxide monitor at least twice a week until the end of the 6-month study. The app will react with positive feedback in individuals doing well with smoking cessation and messages to encourage individuals with difficulties quitting to smoke.
89150559|NCT02840513|No Intervention|Control|Participants in the control group will be managed according to usual care as regularly provided by their SHCS physicians. Physicians will motivate patients to quit, emphasise the advantage of quitting, and provide patients with an information card that contains short advices how to quit and addresses of stop smoking clinics. The Swiss HIV Cohort Study study nurse will enter past or current use as well as of nicotine replacement therapy or use of other pharmaceutical support to quit smoking in the online study form
89150560|NCT02662140|Experimental|Mobile Health Application Group|"emobile health application will enhance the existing evidence informed curriculum of a Multiple Family Group model (called 4 Rs and 2 Ss for Strengthening Families Model) for families with children who have disruptive behavior disorders. This mobile application consists of two primary components that will support engagement and integration of the model's core concepts in family life. The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
89150561|NCT02840357|Experimental|Treatment Group|Purple Wheat Convenience Bars The treatment group will consume 4 servings /day of bran-enriched purple wheat convenience bars (40g/ serving)
89150562|NCT02840357|Placebo Comparator|Control Group|Control Wheat Convenience Bars The control group will consume 4 servings /day of bran-enriched ordinary wheat convenience basr (40g/ serving)
89150563|NCT02662296|Experimental|Treatment (ibrutinib or idelalisib)|Patients receive ibrutinib PO QD on days 1-28 or idelalisib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89150564|NCT02831465|Experimental|healthy subjects|Subjects with normal lung function between 40 and 70 years old.
89150565|NCT02662374|Active Comparator|Control|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid
89150566|NCT02662374|Experimental|Group 1|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Extra soft toothbrush, brushing with saline bd
89150567|NCT02662374|Experimental|Group 2|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Supersaturated Calcium Phosphate Spray, 5ml qid
89150568|NCT02834117|Other|Natural cycle|Ovulation is not induced by drugs
89150569|NCT02834117|Experimental|Moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
89150570|NCT02661906|Experimental|SKY Pre|Sudarshan Kriya Yoga is provided to all the enrolled participants. The baseline characteristics of patient is compared with that of their characteristics after yoga intervention. All the participants were provided with yoga training for 6 days and then asked to perform the SKY at home daily till 12 week. The questionnaire on anxiety, depression and quality of life were administered at the baseline and at the end of 6 days of yoga. Biochemical parameters such as HbA1c, lipid profile, fasting glucose and post meal glucose were measured at baseline and after 12 week of intervention.
89150571|NCT02661906|Active Comparator|SKY post|The enrolled participants were provided with SKY intervention and their pre and post data were recorded.
89150572|NCT02834351|Active Comparator|Peripheral artery diseased group|pad Patients referred for femoro popliteal bypass Muscle biopsy during surgery
89150573|NCT02834351|Sham Comparator|Cardiac group|Patients referred for saphenous withdrawal for coronary bypass Muscle biopsy during surgery
89150574|NCT02661750||Step 1|Patients who had inadequate preparations for colonoscopy with a standard dose of bowel cleansing agent.
89150575|NCT02661750||Step 2|Patients who had inadequate preparations for colonoscopy with a step 1 dose of bowel cleansing agent.
89150576|NCT02661750||Step 3|Patients who had inadequate preparations for colonoscopy with a step 2 dose of bowel cleansing agent.
89150577|NCT02661750||Step 4|Patients who had inadequate preparations for colonoscopy with a step 3 dose of bowel cleansing agent.
89150578|NCT02661750||Step 5|Patients who had inadequate preparations for colonoscopy with a step 4 dose of bowel cleansing agent.
89150579|NCT05334251||general anesthesia group|Patients in this group will undergo open colon cancer surgery under general anesthesia. Epidural catheterization will be applied for postoperative analgesia.
89150580|NCT05334251||combined spinal-epidural anesthesia group|Patients in this group will undergo open colon cancer surgery under combined spinal-epidural anesthesia with ketofol sedation. Epidural catheterization will be applied for postoperative analgesia.
89150581|NCT00649350|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
89150582|NCT00649350|Active Comparator|2|Glucophage XR 750 mg
89150583|NCT04169880|Experimental|HILT Group|HILT Group (n=15)
89150584|NCT04169880|Experimental|HILT & EXERCISE Group|HILT&Exercise Group (n=15)
89150585|NCT00649506|Experimental|1|Nitrofurantoin Macrocrystals 100 mg Capsules
89150586|NCT00649506|Active Comparator|2|Macrodantin® 100 mg Capsules
89150587|NCT05272722||Infants (under age of 1 year old)|ECG assessment and Holter monitoring
89150588|NCT05272722||1 - 5 years old children|ECG assessment and Holter monitoring
89150589|NCT05272722||6 -12 years old children|ECG assessment and Holter monitoring
89150590|NCT05272722||13-18 years old adolescents|ECG assessment and Holter monitoring
89150591|NCT02658552|Experimental|HIFU treatment|To collect the data after HIFU treatment
89150592|NCT02661984||Healthy (no pulmonary disease)|Healthy children 4 - 6 years old with no pulmonary disease and not exhibiting respiratory illness or sinusitis.
89150593|NCT02661984||Asthmatic (physician diagnosed)|Asthmatic children 4 - 6 years old not exhibiting acute asthma symptoms, respiratory illness or sinusitis.
89150594|NCT04071132||Participants diagnosed with PTSD|
89150595|NCT04071132||Non-PTSD participants|
89150596|NCT00649038|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
89150597|NCT00649038|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
89150598|NCT02661516||Vitamin K Antagonists|Vitamin K Antagonists dose as specified
89150599|NCT04169412||Resuscitation Failure, High PCO Level, High RIPK3 Level|"Resuscitation failure was defined as lactate level ≥2 mmol/L or lactate reduction <20% hour-4 after initial sepsis recognition.~High PCO level was defined as PCO level ≥ cut off point.~High RIPK3 level was defined as PCO level ≥ cut off point."
89150600|NCT04169412||Resuscitation Success, Low PCO Level, Low RIPK3 Level|"Resuscitation success was defined as lactate level <2 mmol/L or lactate reduction ≥20% hour-4 after initial sepsis recognition.~Low PCO level was defined as PCO level < cut off point.~Low RIPK3 level was defined as PCO level < cut off point."
89150601|NCT04169256|Experimental|HYR-PB21 & Placebo|
89150602|NCT04169256|Active Comparator|Liposome Bupivacaine & Placebo|
89150603|NCT02658396|Experimental|GO-203-2C|"Patients who fulfill eligibility criteria will be entered into the trial to receive Bortezomib and GO-203-2C.~After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Bortezomib~GO-203-2C"
89150604|NCT02661360|Experimental|Starting condition of swaddled|
89150605|NCT02661360|Experimental|Starting Condition of Unswaddled|
89150606|NCT02656368|Experimental|Interventional, open label, Safety/Efficacy Study|SEBORRHEAMEDIS Face Cream Interventional 30
89150607|NCT02661438|Other|Placebo to Ciprofloxacin DPI|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
89150608|NCT00894803|Active Comparator|rt-PA only|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA given over 60 minutes. One out of 6 subjects will be in this group.
89150609|NCT00894803|Experimental|rt-PA and Eptifibatide|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA. This IV dose will be discontinued at 40 minutes. The subject will immediately receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours. Five out of six subjects will be in this group.
89150610|NCT02661048|Experimental|Open label|Non-randomized, open label clinical trial that intends to treat 10 subjects with refractory ventricular tachycardia with the CyberHeart system using standard radiosurgical techniques.
89150611|NCT02660970|Active Comparator|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
89150612|NCT02660970|Placebo Comparator|Placebo-band|Children will have to wear a 'placebo-wristband'
89150613|NCT02660970|Active Comparator|Iberogast|Children will have to take Iberogast drops
89150614|NCT02660970|Placebo Comparator|Placebo-drops|Children will have to take placebo-drops
89150615|NCT02840435|Active Comparator|North Carolina Quit Line: Quit for Life|Participants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
89150616|NCT02840435|Experimental|Sit to Quit|Participants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
89150617|NCT02834429||endoscopy patients|We will recruit patients (n=1000) from the endoscopy department at the Royal Hallamshire Hospital, Sheffield, United Kingdom (UK).
89150618|NCT02834273|Experimental|Therapeutic Workshop|Therapeutic Workshop (patients following therapeutic education workshops during their hospitalization)
89150619|NCT02834273|No Intervention|Usual care|
89150620|NCT00601458|Active Comparator|Arm 1: Pregabalin 300 mg|
89150621|NCT00601458|Active Comparator|Arm 2: naproxen sodium 550 mg|
89150622|NCT00601458|Placebo Comparator|Arm 3: Placebo|
89150623|NCT02834039|Active Comparator|Tidal volume 6 ml/kgBW|Tidal volume 6 ml/kgBW was given to patients after endotracheal tube was inserted properly
89150624|NCT02834039|Active Comparator|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to patients after endotracheal tube was inserted properly.
89150625|NCT02660736|Experimental|Regimen AB|"Subjects will be receive Regimen A treatment in Session 1 followed by Regimen B treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
89150626|NCT02660736|Experimental|Regimen BA|"Subjects will be receive Regimen B treatment in Session 1 followed by Regimen A treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
89150627|NCT02658318||Pierre Robin Syndrome (PRS)|Cleft palate patients with the Pierre Robin Syndrome.
89150628|NCT02658318||non-PRS|Cleft palate patients without the Pierre Robin Syndrome.
89150629|NCT02831153|Active Comparator|normal coronary anatomy|coronary angiography will be performed by transfemoral or transradial route.
89150630|NCT02831153|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
89150631|NCT02831153|Active Comparator|slow coronary flow|coronary angiography will be performed by transfemoral or transradial route.
88806026|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
89150632|NCT02831153|Active Comparator|nonobstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
89150633|NCT02831153|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
89150634|NCT04169178|Experimental|HLX55, dose finding stage, advanced solid tumor|Participants will receive HLX55 at assign dose level, e.g. 2.5, 5, 15 and 25 mg/kg every three weeks followed by a 21-day DLT observation period.
89150635|NCT04169178|Experimental|HLX55, dose expansion stage, gastric cancer|Participants diagnosed with gastric cancer with will receive HLX55 in recommended phase 2 dose (RP2D) every three weeks.
89150636|NCT04169178|Experimental|HLX55, dose expansion stage, NSCLC|Participants diagnosed with non-small cell lung cancer (NSCLC) with will receive HLX55 in RP2D every three weeks.
89150637|NCT04169178|Experimental|HLX55, dose expansion stage, colorectal cancer|Participants diagnosed with colorectal cancer (CRC) with will receive HLX55 in RP2D every three weeks.
89150638|NCT04169178|Experimental|HLX55, dose expansion stage, other solid cancer|Participants diagnosed with other solid cancer with will receive HLX55 in RP2D every three weeks.
89150639|NCT02831309|Sham Comparator|Sedentary Condition|Forty minutes of screen time. Standardized meals provided.
89150640|NCT02831309|Active Comparator|Light-Intensity Condition|Forty minutes of light-intensity activity. Standardized meals provided.
89150641|NCT02831309|Active Comparator|Moderate-Intensity Condition|Forty minutes of moderate-intensity activity. Standardized meals provided.
89150642|NCT02831309|Active Comparator|High-Intensity Condition|Forty minutes of high-intensity activity. Standardized meals provided.
89150643|NCT02658162|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
89150644|NCT02658162|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
89150645|NCT00649584|Experimental|1|SGN-35 alone or in combination with gemcitabine
89150646|NCT02658006||Cardiac surgical patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
89150647|NCT05308433|Experimental|Experimental|
89150648|NCT02141282|Experimental|ABT-199 after ibrutinib therapy|Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 593 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
89150649|NCT02141282|Experimental|ABT-199 after idelalisib therapy|Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 1023 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
89150650|NCT02141282|Experimental|ABT-199 after ibrutinib therapy: Expansion Cohort|Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 622 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. Participants enrolled into the Expansion Cohort with bulky disease at study entry who were non-responders or those who showed signs of clinical progression after completing the ramp up to 400 mg either by clinical disease assessment or by CT/MRI scan between Week 6 to Week 12 may have been permitted to escalate venetoclax to a daily dose of 600 mg.
89150651|NCT02141282|Experimental|ABT-199 after idelalisib therapy: Expansion Cohort|Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 1189 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. Participants enrolled into the Expansion Cohort with bulky disease at study entry who were non-responders or those who showed signs of clinical progression after completing the ramp up to 400 mg either by clinical disease assessment or by CT/MRI scan between Week 6 to Week 12 may have been permitted to escalate venetoclax to a daily dose of 600 mg.
89150652|NCT02657850||control cohort - study subject self-reporting|Participants who have another cancer (not head and neck cancer) and undergoing treatment will self-report their dysphagia symptoms.
89150653|NCT02657850||study cohort - study subject self-reporting|Participants who have head and neck cancer and undergoing treatment will self-report their dysphagia symptoms.
89150654|NCT02657850||study cohort - provider reporting|Participants who have head and neck cancer and undergoing treatment will have their dysphagia symptoms reported by the provider.
89150655|NCT02656212|Experimental|(+)-epicatechin 30mg|10 subjects will be randomized to a 30mg dose of synthetic (+)-epicatechin
88804361|NCT05513443|Experimental|PRIS 1, arm 1|"Men randomized to the experimental arms will be offered focal treatment of prostate cancer with IRE technology. IRE stands for irreversible electroporation and involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death."
88804362|NCT05513443|Active Comparator|PRIS 1, arm 2|Men eligible for radical prostatectomy and randomized to the control arm will undergo radical prostatectomy in line with national guidelines.
89150656|NCT02656212|Placebo Comparator|placebo|5 subjects will be randomized to a placebo
89150657|NCT02660814|Placebo Comparator|Healthy periodontium without obesity|"GCF samples were taken at baseline~Intervention: Gingival crevicular fluid collection"
89150658|NCT02660814|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
89150659|NCT02660814|Placebo Comparator|Healthy periodontium with obesity|"GCF samples were taken at baseline~Intervention: Gingival crevicular fluid collection"
89150660|NCT02660814|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
89150661|NCT00003479|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89150662|NCT00618488|Experimental|1|Bifidobacterium lactis
89150663|NCT00618488|Placebo Comparator|2|Placebo
89150664|NCT02657616||No anticoagulation with VKA/NOAC|No prescriptions of vitamin-k-antagonists/novel anticoagulants in all observational period; No prescriptions of low molecular weight heparins/Clopidogrel during observation period to the extent of more than 30 days.
89150665|NCT02657616||Anticoagulation with vitamin-k-antagonists|The patient should be treated stable during the observation period with vitamin-k-antagonists (at least one prescription per half-year). The patient should be not been around on other anticoagulants during the observation period. This means that no prescriptions of novel anticoagulants and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year.
89150666|NCT02657616||Anticoagulation with novel oral anticoagulants|The patient should be treated stable during the observation period with a novel anticoagulant (at least one prescription per half-year). This means that no vitamin-k-antagonists prescriptions and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year from the start of the observation period.
89150667|NCT02656056|Experimental|Lean Adults|Adults with a BMI between 21-25 will consume 8 oz of the fermented soybean beverage, twice daily.
89150668|NCT02656056|Experimental|Obese Adults|Adults with a BMI between 32-37 will consume 8 oz of the fermented soybean beverage, twice daily.
89150669|NCT04198025||Patients who underwent colorectal resection|"Patients in this observational study will have undergone CT scan as routine work up prior to resection of elective colorectal cancer.~Psoas muscle density will be measured (in Hounsfield units from CT images) at lumbar vertebral level L3."
89150670|NCT02657694||Sofosbuvir+Ledipasvir|Following patients treating with Sofosbuvir+Ledipasvir
89150671|NCT02657694||Sofosbuvir+Daclatasvir|Following patients treating with Sofosbuvir+Daclatasvir
89150672|NCT02657694||Sofosbuvir+Velpatasvir|Following patients treating with Sofosbuvir+Velpatasvir
89150673|NCT02833961|Experimental|ISCHEMIC STROKE|ischemic stroke admitted in the Pitié Salpêtrière Stroke unit in Paris
89150674|NCT02833961|Active Comparator|HEALTHY SUBJECTS|Age and gender-matched healthy volunteers
89150675|NCT02657460|Experimental|MTX-ATMPs|methotrexate-autologous tumor derived microparticles
89150676|NCT02657460|Sham Comparator|cisplatin|Cisplatin is a traditional treatment for lung cancer
89150677|NCT02833727||Asthmatic smokers (AS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) < 8 mg/ml with a diagnosis of asthma made by a respirologist.~Smokers or ex smokers will be defined by a smoking history of ≥ 10 pack/year."
89150678|NCT02833727||Asthmatic non-smokers (ANS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a PC20 < 8 mg/ml with a diagnosis of asthma made by a respirologist.~Never smokers will have a life-long history without smoking."
89150679|NCT00649896|Experimental|1|Mylan Estradiol Transdermal System 0.025 mg/day
89150680|NCT00649896|Active Comparator|2|Climara® Transdermal System 0.025 mg/day
89150681|NCT00618566|Experimental|Oregon|
89150682|NCT00649662|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
89150683|NCT00649662|Active Comparator|2|Cipro® XR Tablets 1000 mg
89150684|NCT02831075|Experimental|Adipose-derived stem cell|Mesenchymal stem cells derived from adipocyte transplantation
89150685|NCT02831075|Placebo Comparator|saline|saline injections
89150686|NCT04188158|Experimental|Intervention Group|3 cycles XELOX + Surgery+ 5 cycles XELOX
89150687|NCT04188158|Other|Control group|Surgery + 8 cycles XELOX
89150688|NCT02831231|Active Comparator|Xanomeline plus placebo|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID
89150689|NCT02831231|Experimental|Xanomeline plus trospium|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose
89150690|NCT02657304|Experimental|Coaching group|PPC + Coaching
89150691|NCT02657304|Active Comparator|Control group|PPC
89150692|NCT05234606|Experimental|Part 1: SBT6290|SBT6290 every 3 weeks
89150693|NCT05234606|Experimental|Part 2: SBT6290|SBT6290 every 3 weeks
89150694|NCT05234606|Experimental|Part 3: SBT6290 + pembrolizumab|SBT6290 plus pembrolizumab every 3 weeks
89150695|NCT05234606|Experimental|Part 4: SBT6290 + pembrolizumab|SBT6290 plus pembrolizumab every 3 weeks
89150696|NCT02657382|Experimental|Heart Rate Variability (HRV) Biofeedback (BF)|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests. Participants in this group will also participate in heart rate variability (HRV) biofeedback (BF) during the first six weeks of the study.
88804363|NCT05513443|Experimental|PRIS 2, arm 1|"Men randomized to the experimental arms will be offered focal treatment of prostate cancer with IRE technology. IRE stands for irreversible electroporation and involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death."
89150697|NCT02657382|Experimental|Waitlist Control|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests.Participants in this group will receive the heart rate variability (HRV) biofeedback (BF) intervention between the week 6 and week 12 study visits.
89150698|NCT04033380|Active Comparator|Resin bloc endocrown|composite-based blocs (Grandio Blocs, VOCO)
89150699|NCT04033380|Active Comparator|Ceramic endocrown|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
89150700|NCT02830919|Experimental|Glucosamine and chondroitin sulfate combination (Eurofarma)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Eurofarma Laboratórios S.A., administered once a day for 24 weeks.
89150701|NCT02830919|Active Comparator|Glucosamine and chondroitin sulfate combination (Zodiac)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Zodiac Produtos Farmacêuticos S.A. (Condroflex®), administered once a day for 24 weeks.
89150702|NCT04214444|Active Comparator|Single-dose before treatment|12 patients will receive a single-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection
89150703|NCT04214444|Active Comparator|Single-dose after treatment|12 patients will receive a singe-dose of prevenar three weeks after the beginning of the immunochemotherapy (R-CHOP) following two months later by pneumovax injection
89150704|NCT04214444|Experimental|Double-dose before treatment|12 patients will receive a double-dose of prevenar before immunochemotherapy (R-CHOP) following two months later by pneumovax injection.
89150705|NCT00633503||A-Observation|All patients undergoing pedicle and free tissue transfer.
89150706|NCT00649740|Experimental|1|Topiramate Sprinkle Capsules 25 mg
89150707|NCT00649740|Active Comparator|2|Topamax® Sprinkle Capsule 25 mg
89150708|NCT04209920|Active Comparator|PMMA crown Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
89150709|NCT04209920|Active Comparator|Cast metal coping Group|Hypomineralized first permanent molars in patients with molar incisor hypomineralization.
89150710|NCT04245761|Experimental|Sonidor®|Application: following the summary of product characteristics (l tablet per day) At the 7-day phone call the Investigator can increase the dosage to 2 tablets per day only in non-responding subjects.
89150711|NCT02536950|No Intervention|Blinded Sensor|Subjects will wear a blinded Dexcom G4P (Generation 4 Platinum) AP (Artificial Pancreas) glucose sensor for a week
89150712|NCT02536950|Experimental|Fixed set point|Subjects will be in a hotel and use a fixed set point for glucose control for two days initialized at 130 mg/dl. The setpoint will be adjusted, if necessary, over the two days in the hotel before they are sent home for 5 days
89150713|NCT02536950|Experimental|Variable Set Point|"Subjects will begin using a variable setpoint which will make adjustments based on their past glucose control over the previous day"
89150714|NCT04245917||MNGIE Patients|Patients with mitochondrial neurogastrointestinal encephalomyopathy
89150715|NCT02660892|Experimental|Protein Intake|Threonine intake - Dietary supplement
89150716|NCT02830841|Experimental|DR-RIPC (donor and recipient RIPC group)|Both donors and recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm(donor) or right lower limb(recipient) and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
89150717|NCT02830841|Sham Comparator|S-RIPC (sham RIPC)|Patients had a deflated cuff placed on the right upper arm or right lower limb for 30 min
89150718|NCT02830841|Experimental|R-RIPC (recipient RIPC group)|Recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right lower limb and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
89150719|NCT02830841|Experimental|D-RIPC (donor RIPC group)|Donors receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
89150720|NCT04211402||Obsessive-Compulsive Disorder|Patients with obsessive-compulsive disorder
89150721|NCT02660658|Other|Intrathecal dexmedetomidine|"Up-down sequential allocation~The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance"
89150722|NCT05229731||Case group|Patients with visual snow syndrome according to international criteria
89150723|NCT05229731||Control group|Patients without visual snow syndrome according to international criteria
88804364|NCT05513443|Active Comparator|PRIS 2, arm 2|Men eligible for radiation therapy and randomized to the control arm will undergo radiation therapy in line with national guidelines.
89150724|NCT00619814|Other|Cohort group|Cohort group of asymptomatic patients 50-80 years old with a positive fecal occult blood test done for colorectal cancer screening.
89150725|NCT02660502|Experimental|BioChaperone insulin lispro 0.1 U/kg|
89150726|NCT02660502|Experimental|BioChaperone insulin lispro 0.2 U/kg|
89150727|NCT02660502|Experimental|BioChaperone insulin lispro 0.4 U/kg|
89150728|NCT02660502|Active Comparator|Humalog®|
89150729|NCT04203524|Experimental|Procalcitonin Arm|The medical team will be provided with a daily PCT for the patient, along with the PCT-guided algorithm that outlines the suggested management based on the PCT levels.
89150730|NCT04203524|Other|Control Arm|Procalcitonin levels will be measured for those patients, but the medical team will be blinded from their results
89150731|NCT02830763|Experimental|Medium-chain Fatty Acid (CNT-02)|
89150732|NCT04247321|Experimental|Subjects with acute brain injury|Subjects requiring placement of a Licox Brain Tissue Oxygen device for their clinical care will also have Near-infrared spectroscopy (NIRS) monitoring system placed
89150733|NCT02660346|Active Comparator|Group A - Daptomycin or Vancomycin|Standard of Therapy of physician's choice, usually daptomycin 6-8 mg/kg IVPB daily or vancomycin IVPB adjusted dose per site protocol with a goal vancomycin trough level: 15-20 mcg/mL.
89150734|NCT02660346|Experimental|Group B - Daptomycin with Ceftaroline|Daptomycin (6-8 mg/kg/day IVPB daily) with Ceftaroline (600 mg IVPB q8hr) to start within 72hrs of hospital admission. Daptomycin will be renally adjusted per package insert. Ceftaroline will be renally adjusted per institutional renal dosing recommendations for Q8h.
89150735|NCT02833649|Experimental|Toric Implantable contact Lens|The Visian implantable collamer lens (Staar Surgical AG, Nidau, Switzerland), is a monoblock single-piece plate haptic lens made of collamer (an extremely hydrophilic and highly biocompatible flexible collagen copolymer with a refractive index of 1.452 that is permeable to oxygen and nutrients
89150736|NCT02828735|Other|Respiration assessment|
89150737|NCT02660190|Experimental|PDD|PDD at flexible cystoscopy
89150738|NCT02660190|Experimental|WL|WL only at flexible cystoscopy
89150739|NCT04211324||TENS group|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
89150740|NCT04211324||electro-acupuncture group|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
89150741|NCT00620360|Experimental|fructose|acute fructose administration
89150742|NCT04669418||Group 1|70 children with cancer and a positive blood culture.
89150743|NCT04669418||Group 2|50 children with cancer and no positive blood culture.
89150744|NCT00620438|Experimental|1|nevirapine arm
89150745|NCT00620438|Experimental|2|efavirenz arm
89150746|NCT00620438|Experimental|3|Rifampicin arm
89150747|NCT05004506|Experimental|Group A|"Group A patients will receive their treatment at the completion of the case while under general anesthesia. The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.~Group A patients will receive placebo intra-articular and arthroscopic portal site saline injections equal in volume and procedure time point as the treatment in Group B.~At the completion of the case, the patient will be extubated and transferred to the PACU."
89150748|NCT05004506|Active Comparator|Group B|"Group B will receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection. At the completion of the arthroscopic procedure the patient will receive an additional 20ccs of 0.5% marcaine with epinephrine intra-articular injection.~Group B patients will also receive 10ccs of 2% lidocaine with epinephrine injected superficially into each of the arthroscopic portal sites. Group B patients will receive a 15cc saline injection around the saphenous nerve under the same procedure as the adductor canal block for Group A.~At the completion of the case, the patient will be extubated and transferred to the PACU."
89150749|NCT00891839|Experimental|Bendamustine+Rituximab|Patients receive bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2, and 375 mg/m^2 of rituximab by iv on day 1 of each 28-day cycle. Six 28-day cycles were planned and up to 8 cycles permitted for patients who do not have progressive disease and who have not achieved a complete response (CR).
89150750|NCT00600756|Experimental|Quetiapine XR|
89150751|NCT00600756|Active Comparator|Risperidone|
89150752|NCT04246931||Pulmonologists|Interviews with pulmonologists
89150753|NCT04246931||General practitioners|Interviews with general practitioners
89150754|NCT04246931||Patients|Survey with COPD patients
89150755|NCT02830685|Active Comparator|Direct-To-Implant A|DTI with Acellular Dermal Matrix (CELLIS® Breast), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of an Acelluar Dermal Matrix (ADM)
89150756|NCT02830685|Experimental|Direct-To-Implant B|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of a titanium coated polypropylene mesh
89150757|NCT02656914|Experimental|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
89150758|NCT02656914|Placebo Comparator|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
89150759|NCT02657148||Immediate postpartum Nexplanon|Participants who choose to enroll in the immediate postpartum Nexplanon arm will have a etonogestrel contraceptive implant (68 mg) (Nexplanon) placed in the immediate postpartum period (2-4 days following delivery), prior to hospital discharge.
89150760|NCT02657148||Control|Participants who choose to enroll in the control arm will receive standard postpartum contraceptive care: condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
89150761|NCT04247087|Experimental|Intervention group|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
89150762|NCT04247087|Placebo Comparator|Control group|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
89150763|NCT00367406|Experimental|Treatment with a Gamma 3 nail.|
89150764|NCT00649116|Experimental|1|Metoprolol Tartrate Tablets 100 mg
89150765|NCT00649116|Active Comparator|2|Lopressor® Tablets 100 mg
89150766|NCT04115228|Experimental|Study device|Subjects who provide informed consent, meet all inclusion criteria, and no exclusion criterion, will have a study device implanted and followed closely for 26 weeks.
89150767|NCT02828813||Normal|healthy subjects
89150768|NCT02828813||CogImpair|persons with cognitive impairments
89150769|NCT02828813||MotorDeficits|persons with motor deficits
89150770|NCT04245527|Experimental|Study Arm|20 minutes Joovv Solo every day for 8 weeks.
89150771|NCT00620048|Experimental|Low dose of autologous CD34-positive cells (stem cells)|
89150772|NCT00620048|Experimental|High dose of autologous CD34-positive cells (stem cells)|
89150773|NCT02828501|Experimental|Lumbar manipulation group|Spinal Manipulation
89150774|NCT02828501|Experimental|Cervical manipulation group|Spinal Manipulation
89150775|NCT02828501|No Intervention|Control group|This group will receive a 2 minute supine rest between measurements
89150776|NCT00621608|Experimental|1|Hyperbaric Oxygen Therapy
89150777|NCT00621608|Sham Comparator|2|Placebo Hyperbaric Oxygen Chamber
89150778|NCT02652546|Active Comparator|A|CC-11050 200mg (2 capsules) BID with food
89150779|NCT02652546|Placebo Comparator|B|Placebo (2 capsules) BID with food
89150780|NCT02830373||LVIS stents group|patients with unruptured intracranial saccular aneurysms which located in the internal carotid artery or vertebra-basilar artery will be treated with a LVIS stent with coils
89150781|NCT04210856|Experimental|Sequence of Landscape exposures|All participants undergo the procedure of visiting all landscape exposures in a random order.
89150782|NCT02652234|Experimental|Endostar-subcutaneous injection/Chemotherapy|
89150783|NCT02830607|Experimental|Xiaomi Mi Band|participants will wear Xiaomi Mi Band .the device measures their daily steps number before and after epidural steroid injection for treatment of low back pain.
89150784|NCT04167852|Experimental|Treatment group|Subject to receive daily short message service (SMS) text message with a link to a mindfulness intervention.
89150785|NCT04167852|Experimental|Text group|Subject to receive daily text message but without the link to the mindfulness intervention.
89150786|NCT04167852|No Intervention|Standard of Care group|Subject will not receive any text message reminders or the mindfulness meditation intervention.
89150787|NCT02830529|Experimental|MAD DASH|Mindfulness based stress reduction and diet education delivered in 8 sessions lasting 2.5 hours each. Mindfulness conducted by a certified trainer. Participants were given homework and meditation CD. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
89150788|NCT02830529|Experimental|DASH diet education|Dietary approaches to stop hypertension sessions were delivered by a registered dietitian in 8 sessions lasting 1 hour each. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
89150789|NCT02830529|No Intervention|Usual Care-DASH Pamphlet Only|Dietary approaches to stop hypertension pamphlet was mailed to each participant. They continued receiving usual care from their health care provider.
89150790|NCT02657070|Experimental|Experimental Group|Virtual reality based therapy with augmented visuomotor feedback.
89150791|NCT02657070|Active Comparator|Control Group|Virtual reality based therapy without augmentation.
89150792|NCT04211012|Experimental|Treatment Arm|
88804365|NCT05507814|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future events they are looking forward to at several time points in the future (e.g., 2 weeks, 1 month, 3 months, 1 year, and 5 years). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions. This intervention will be tested in both the presence and absence of stress probes.
89150793|NCT02655978||Healthy Volunteers|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
89150794|NCT02655978||Medically Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
89150795|NCT02655978||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).
89150796|NCT00649974|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
89150797|NCT00649974|Active Comparator|2|Valtrex® Tablets 1000 mg
89150798|NCT02830295|Experimental|Basic Body Awareness Therapy|The Basic Body Awareness Therapy is usual therapy of physiotherapy in health mental in nord of europe. BBAT is based in twelve movements and massage that improve the movement quality of patient, also BBAT improves others movement qualities like biomechanical, physiologic, socio-cultural and existential.
89150799|NCT02830295|No Intervention|control|the patients which below receive the treatment as usual, according the clinic guidelines of Health government
89150800|NCT00350714|Experimental|MBT|C13 methacetin dissolved in water to be ingested after breath baseline collected. Metabolism to measured in real time.
89150801|NCT02536638||Pyelonephritis Group|patients with pyelonephritis
89150802|NCT02536638||Without pyelonephritis Group|patients without pyelonephritis
89150803|NCT04246775|Other|Treatment|Peristeen given
89150804|NCT05662670|Experimental|Experimental:WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
89150805|NCT02536482|Experimental|Amix|Dietary supplement. The formula is based in free amino-acid to treat children with cow's milk allergy. The children should have a minimum consumption of 400 mL, daily.
89150806|NCT02830217||STEMI patients having primary PCI|Patients with STEMI receiving primary PCI in Wuhan Aisa Heart Hospital are included in this study. All patients are the first time to have STEMI, and primary PCIs are performed according to 2013 ACCF/AHA guideline for the management of STEMI. Patients with previous stroke, pneumonia, cirrhosis, autoimmune diseases are excluded from this study.
89150807|NCT04209452|No Intervention|Control|No intervention will be provided for participants enrolled in the control group.
89150808|NCT04209452|Experimental|Rehearsal|Participants will receive instruction on rehearsal strategy.
89150809|NCT04209452|Experimental|Reinforcement|Participants will receive reinforcement for correct recall.
89150810|NCT04209452|Experimental|Rehearsal + Reinforcement|The participants in this group will receive instruction on rehearsal strategy and reinforcement for correct recall.
88806027|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 10 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 10 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
88804366|NCT05507814|Sham Comparator|Control Episodic Thinking (CET)|Participants will generate positive recent past events that have happened to them at several time points in the previous day (e.g., 7pm-10pm, 4pm-7pm, 1pm-4pm, 10am-1pm, and 7am-10am). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions. This intervention will be tested in both the presence and absence of stress probes.
89150811|NCT04829006|Other|Speakers|Participants will be recording sentences using a customized app, which is the focus of the current investigation. There is no arm per se, as the current investigation does not involve an intervention. The current investigation aims at developing and pilot testing an app.
89150812|NCT02536716|Active Comparator|Platform-matched dental implant|Platform-matched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
89150813|NCT02536716|Experimental|Platform-switched dental implant|Platform-switched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
89150814|NCT00620594|Experimental|BEZ235 Alone, Dose Escalation|
89150815|NCT00620594|Experimental|BEZ235 + trastuzumab, Dose Escalation|
89150816|NCT00620594|Experimental|BEZ235 Alone, MTD Expansion|
89150817|NCT00620594|Experimental|BEZ235 + Trastuzumab, MTD Expansion|
89150818|NCT04269720|No Intervention|Control|Participants will not receive biofeedback intervention.
89150819|NCT04269720|Experimental|Biofeedback|Participants will receive a biofeedback intervention daily for 8 weeks. Each biofeedback session lasts approximately 10 minutes.
88806028|NCT02531802|Placebo Comparator|24-59 months: Placebo|24-59 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
88806029|NCT02531802|Experimental|12-23 months: ETVAX (1/4)|12-23 month old children receiving a quarter adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
89150820|NCT00620672|Other|1|The dietary supplement is 400 mg/day of the omega 3 fatty acid docosahexaenoic acid . The docosahexaenoic acid is provided in triglycerides from Martek Biosciences, Maryland. The supplement is a blend of soybean and canola oil, blended to resemble the usual fat composition of the diet. Both the supplement and placebo provide a total of about 10 calories per day to the diet.
89150821|NCT00620672|Other|2|Dietary supplement is vegetable oil, the placebo.
89150822|NCT02655822|Experimental|Cohort 1 - Closed|Ciforadenant
89150823|NCT02655822|Experimental|Cohort 2 - Closed|Ciforadenant
89150824|NCT02655822|Experimental|Cohort 3 - Closed|Ciforadenant
89150825|NCT02655822|Experimental|Cohort 4|Ciforadenant + atezolizumab
89150826|NCT02655822|Experimental|Cohort 5 - Closed|Ciforadenant
89150827|NCT04209374||HMB-DMR-HA|Primary total hip arthroplasty with hemispherical dual-mobility acetabular cup
89150828|NCT00650442|Experimental|1|Estradiol Transdermal System Placebo - Alternate Adhesive
89150829|NCT00650442|Placebo Comparator|2|Estradiol Transdermal System Placebo - Current Adhesive
89150830|NCT04050956||Myocardial infarction|As it is an observational study, no intervention is planned. However, nested clinical interventional trials are planned for which a specific registration will be done
89150831|NCT00890825|Active Comparator|AZD6244 + Docetaxel|AZD6244 75 mg bd + Docetaxel 75 mg/m^2
89150832|NCT00890825|Placebo Comparator|Placebo + Docetaxel|Placebo + Docetaxel 75 mg/m^2
89150833|NCT02656758|Experimental|Executive function training|the experimental group will receive 12 sessions of intensive Executive function training weekly immediately
89150834|NCT02656758|Other|the waitlist group|the waitlist group will wait 12 weeks before receiving intensive executive function training for comparison.
89150835|NCT04780334||Positive diagnosis of SARS-CoV-2|100 patients with a positive diagnosis of SARS-CoV-2
89150836|NCT04780334||Negative diagnosis of SARS-CoV-2|100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team
89150837|NCT02656992|Experimental|High-IMT group|Intervention group receive supervised training sessions three times per week for 8 weeks. Each sessions lasted 21 minutes and comprised seven cycles of 2 minutes of breathing on an inspiratory threshold device followed by 1 minute of rest. High-IMT was performed at the maximal load tolerable for each 2-minute work interval and was progressively increased over the training period.
89150838|NCT02656992|Sham Comparator|Control group|Control group was prescribed at 10% of baseline maximal inspiratory pressure, and remained at this level during all training sessions for 8 weeks.
89150839|NCT02656602|No Intervention|Nurse Counseling|A trained endoscopy nurse provided patients with all information on their scheduled colonoscopy.
89150840|NCT02656602|Experimental|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI.All elements of informed consent for colonoscopy (risks, alternatives) were included.
89150841|NCT04760132|Active Comparator|Vaccine A - COMIRNATY COVID-19 vaccine|COMIRNATY (COVID-19, mRNA Vaccine) by BioNTech Manufacturing GmbH Marketing Authorisation EU/1/20/1528
89150842|NCT04760132|Active Comparator|Vaccine B - Moderna COVID-19 vaccine|"COVID-19 Vaccine Moderna dispersion for injection (COVID-19, mRNA Vaccine) by MODERNA BIOTECH SPAIN S.L.~Marketing Authorisation EU/1/20/1507/001"
89150843|NCT04760132|Active Comparator|Vaccine C - Astra-Zeneca COVID-19 vaccine|COVID-19 Vaccine AstraZeneca suspension for injection (ChAdOx1-S [recombinant]) by AstraZeneca AB Marketing Authorisation EU/1/21/1529/001 and /002
89150844|NCT04248101|Active Comparator|Group 1|88 cases of umbilical granulomas who were treated with double ligation
89150845|NCT04248101|Active Comparator|Group 2|88 cases of umbilical granulomas who were treated with topical silver nitrate
89150846|NCT00649818|Experimental|1|Lorazepam Tablets 2 mg
89150847|NCT00649818|Active Comparator|2|Ativan Tablets 2 mg
89150848|NCT00620906|Other|A|Manipulation
89150849|NCT02656524||Cohort1/Regorafenib|All patients with at least 1 treatment with regorafenib
89150850|NCT02833181||Awake patients|Awake patients
89150851|NCT02833181||Sedated patients|
89150852|NCT02833181||Sedated and curarized patients|
89150853|NCT02828423|Active Comparator|Control group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) alone
88806030|NCT02531802|Experimental|12-23 months: ETVAX (1/2)|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
89150854|NCT02828423|Experimental|Test group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) and Biphasic Calcium phosphate (BC)
89150855|NCT02691728|Experimental|Treatment Arm|12 Week treatment with LDV/SOF FDC
89150856|NCT05147207|Experimental|Superpath|This is a minimally invasive surgical approach.
89150857|NCT05147207|No Intervention|Posterior Approach|This is the traditional THA surgical approach used.
89150858|NCT02830061||TYAC|Teenagers and young adults who have received a cancer diagnosis which puts them at moderate-to-high risk of fertility impairment. Semi-structured interviews will take place with each individual participant.
89150859|NCT02830139|Sham Comparator|Radical colorectal resection without HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and postoperative chemotherapy (XELOX)
89150860|NCT02830139|Experimental|Radical colorectal resection with HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (XELOX)
89150861|NCT02651766|No Intervention|Waiting List control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
89150862|NCT02651766|Experimental|Cupping massage treatment|Received the 5 cupping treatments, application twice a week on the upper back and neck
89150863|NCT04245059|Experimental|Transcranial Direct Current Stimulation|Each subject will receive transcranial electrical stimulation at primary motor cortex in both hemispheres. The pilot program will include 12 sessions with a frequency of 3 times per week during 4 weeks. Therefore, during tDCS sessions, subjects will receive stimulation for 20 minutes with a current of 2.0 milliamp using 6x4 cm electrodes. The participants will also complete a set of manual dexterity, grip and pinch tests bilaterally at baseline and post-intervention to determine if the subject responds to tDCS. Thus, each session will be monitored on safety aspects of the subjects with emphasis on skin disorders and other possible side effects of tDCS.
89150864|NCT02651532||IBS + Confocal Laser Endomicroscopy|Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test.
89150865|NCT02651532||Control + Confocal Laser Endomicroscopy|Outpatients without IBS symptoms, undergoing colonoscopy for colorectal cancer screening
89150866|NCT02651610|Active Comparator|Taxane|Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
89150867|NCT02651610|Experimental|Bavituximab plus taxane|Bavituximab 3 mg/kg weekly PLUS Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
89150868|NCT02828579||Group 1|Patient with morbid obesity defined as a BMI above 40kg/m2 or 35kg/m2 with comorbidities who are qualified for bariatric surgery.
89150869|NCT02655588|Experimental|ImbPST|"ImbPST Arm: Participants in this arm will interact with imbPST program which provides a simulated therapy session based on the Problem Solving Treatment-Primary Care (PST-PC) treatment manual used in depression clinical trials . imbPST via a virtual therapist (presented via audio and video) provides programmed instructions on the steps and skills of problem solving, emotional support, and tailored feedback to the user's input."
89150870|NCT02655588|No Intervention|Control Group|Control Arm: Participants in this group will not receive any treatment for their depression and their depressive symptoms will be monitored for 6 to 9 weeks
89150871|NCT04208594|Active Comparator|GROUP (P):|will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg tablet one hour before the induction of anesthesia.
89150872|NCT04208594|Experimental|GROUP (I):|will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 5 mg tablet one hour before the induction of anesthesia.
89150873|NCT02828189|Active Comparator|Physical Exercise|"The protocol consists in:~Physical Exercise according to their preferences.~Therapeutic Education related to Health Habits and Physical Exercise."
89150874|NCT02828189|Experimental|Therapeutic Exercise-Physiotherapy|"The protocol consists in:~Cardiovascular exercise.~Force-Resistance Exercises of the principals muscle groups of the lower limbs, upper limbs and trunk.~Muscle Stretches.~Therapeutic Education related to Health Habits and Physical Exercise."
89150875|NCT04733144|Active Comparator|Prednisolone-Dexamethasone|Participants will receive 1 week of low dose (7,5 mg) prednisolone directly followed by 1 week of high dose prednisolone (30 mg). After a wash-out period, participants in this arm will receive 1 week of low dose dexamethasone (1,125 mg) directly followed by 1 week of high dose dexamethasone (4,5 mg).
89150876|NCT04733144|Active Comparator|Dexamethasone-Prednisolone|Participants will receive 1 week of low dose (1,125 mg) dexamethasone directly followed by 1 week of high dose dexamethasone (30 mg). After a wash-out period, participants in this arm will receive 1 week of low dose prednisolone (7,5 mg) directly followed by 1 week of high dose prednisolone (30 mg).
89150877|NCT04167072|Experimental|Scheduled removal|This group involves patients who will have the LAMS removed immediately after all the stones have been cleared from the gallbladder
89150878|NCT04167072|Active Comparator|Observation|This group involves patients who will be followed closely for 1 year after all the stones have been removed from the gallbladder. These patients will keep the stent in place for 1 year and at that time the patients will be offered removal of the stent.
89150879|NCT04247945|No Intervention|HSC|
89150880|NCT04247945|Experimental|MSC+HSC|
89150881|NCT04724720|Active Comparator|Famotidine|Participants in this study arm will receive standard of care and prescribed famotidine at 80mg TID for a maximum of 14 days, or until hospital admission.
89150882|NCT04724720|Placebo Comparator|Placebo|Participants in this study arm will receive standard of care and placebo for a maximum of 14 days.
89150883|NCT02655432||Spot photoscreener|Automated vision screener: Spot Vision Screener VS 100, Welch-Allyn. This photoscreener is a portable device, using an infrared light. It is built to detect amblyogenic risk factors. First of all, the spot photoscreener produces a sounds which attracts the child's attention and helps him shift his gaze towards the device, held at 1 meter in front him. The spot then evaluates for refractive errors, anisocoria, strabismus, ptosis and media opacity. The ophthalmologic evaluation consists of the measure of the visual acuity, ocular alignment, anterior and posterior segment. The patient will be cyclopleged with cycloplegic drops and will be refracted to obtain a cyclopleged refraction. This will determine his refractive error.
89150884|NCT02833103|Experimental|Pinaverium Bromide group|Able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.
88804367|NCT05493475|Experimental|Intervention Arm|Each participant in the intervention arm will receive one-on-one education on the purpose, benefits, and limitations of fentanyl test strip (FTS) testing and undergo a brief 20-minute FTS educational intervention (including a 2-3-minute video and hands-on demonstrations on how to use FTS). They will also receive a supply of 10 FTS upon enrollment and continued supply upon request throughout the 2-year follow up period. Each participant will also receive Opioid overdose education and a naloxone kit upon enrollment and re-supply of naloxone as needed throughout the 2-year follow up period.
88804368|NCT05493475|No Intervention|Non-Intervention Arm|Each participant will receive Opioid overdose education and a naloxone kit upon enrollment and re-supply of naloxone as needed throughout the 2-year follow up period. Fentanyl test strip (FTS) education and a supply of FTS will be offered to participants in the non-intervention arm of the study during the final quarter of year 3.
89150885|NCT02833103|Active Comparator|Danshu group|Contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension.
89150886|NCT04247789||Total sample|This group consists of older adults living in a rest home, who are proper for inclusion criteria
89150887|NCT02648490|Experimental|HLX07, in patients with solid cancers.|"Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive weekly infusion of assigned dose of HLX07. No intra-patient dose escalation is allowed.The proposed dose escalation sequence is 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg.~Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07, followed by dexamethasone 10 mg intravenous infusion for 10 minutes, and followed by diphenhydramine 30 mg intravenous infusion for 10 minutes. If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions."
89150888|NCT02829827|Experimental|Radiprodil|Each subject will enter an individualized dose titration schedule.
89150889|NCT02648568|Active Comparator|Hypnosis plus relaxation|Ericksonian hypnosis, based on sensations when awakening partially during N3 ; Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
89150890|NCT02648568|Active Comparator|Relaxation|Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
89150891|NCT04965272|Experimental|Cariprazine 0.75 mg/day + Antidepressant Therapy|Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 0.75 mg/day oral, once daily for 6 weeks
89150892|NCT04965272|Experimental|Cariprazine 1.5 mg/day + Antidepressant Therapy|Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 1.5 mg/day oral, once daily for 6 weeks
89150893|NCT04965272|Experimental|Cariprazine 3.0 mg/day + Antidepressant Therapy|Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + cariprazine 1.5 mg/day oral for 2 weeks followed by cariprazine 3.0 mg/day oral, once daily for 4 weeks.
89150894|NCT04965272|Placebo Comparator|Placebo + Antidepressant Therapy|Antidepressant (paroxetine, escitalopram, venlafaxine XR, or duloxetine) + oral placebo, once daily for 6 weeks
89150895|NCT02648412|Experimental|Ketamine sedation|"Procedure scheduled under ketamine sedation. Baseline pupillary diameter measurement in alert subjects. Injection of a bolus of 1 mg/kg of ketamine. Every minute, tetanic stimulations of incremental intensities (10-20-30-40-60 milliamps), during 5 seconds.~Pupillary diameter measurement before and after each stimulation. End of study period, beginning of procedure."
89150896|NCT00890201||Normal Gallbladder|"Patients with normal gallbladder (without gallstones) evidenced by preoperative ultrasonography (and postoperative biopsy) submitted to elective gastroesophageal surgery (gastrectomy for gastric cancer, bariatric surgery or esophageal surgery such as Nissen plicature or miotomy for achalasia).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography. Preoperative values of amylase and lipase must be normal."
89150897|NCT00890201||Gallbladder with gallstones|"Patients submitted to elective cholecystectomy for diseased gallbladders (gallbladder with gallstones evidenced by preoperative ultrasound).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography and the preoperative amylase and lipase levels must also be normal."
89150898|NCT02651454|Experimental|Daesiho-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
89150899|NCT02651454|Experimental|Jowiseungcheung-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
89150900|NCT02651454|Placebo Comparator|Placebo|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
89150901|NCT02651376|Experimental|Conventional plus AAIT|Participants received conventional treatment (anti-opportunistic infections and ART) plus a dose (3 times of MNCs) of AAIT.
89150902|NCT04246853|Active Comparator|Active tDCS of the resting state motor network|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
89150903|NCT04246853|Sham Comparator|Sham tDCS of the resting state motor network|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
89150904|NCT04672850|Placebo Comparator|Placebo|Rice flour
89150905|NCT04672850|Active Comparator|Probiotic|Probiotic bacteria, yeast, zinc and rice brand
89150906|NCT00650520|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
89150907|NCT00650520|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
89150908|NCT04199663||categories of Socioeconomic Status (SES)|"by proxy gender- and calendar year-specific quintiles of disposable income per household consumption unit.~In logistic regression models of associations with secondary prevention activities and established treatment goals: highest vs. lowest income quintile.~In multivariable Cox regression analyses with stepwise built models: quintiles of disposable income and models including covariates level of education and marital status."
89150909|NCT00621062|Active Comparator|High Ligation of the GSV|
89150910|NCT00621062|Active Comparator|Endovenous Laser Ablation|
89150911|NCT00621062|Active Comparator|Radiofrequency ablation|
89150912|NCT00621062|Active Comparator|Foam Sclerotherapy|
89150913|NCT05253690|Active Comparator|speculum guided|view-guided approach using a speculum
89150914|NCT05253690|Experimental|manual guided|manual guided approach at cervical examination
89150915|NCT02651298|Experimental|Fractional CO2-laser|3 treatments with fractional co2-laser
89150916|NCT02651298|No Intervention|Untreated control|untreated control side of caesarean section scar
89150917|NCT04246385|Experimental|Allocated to intervention|Participants will participate in a one on one session to complete their COPM and set their goal for the group. Participants will participate in 6 group sessions focusing on the CO-OP approach.
89150918|NCT04246385|No Intervention|Allocated to control|"The control group will receive usual care occupational therapy including a mix of individual sessions and occupational therapy groups that do not include the CO-OP group."
89150919|NCT00147992|Experimental|implants|
89150920|NCT02651142|Experimental|SLNB with para-SLN dissection|patients receive sentinel lymph node biopsy patients receive para-sentinel lymph node dissection
89150921|NCT02651142|Experimental|SLNB without para-SLN dissection|patients received sentinel lymph node biopsy
88806031|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 2.5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
89150922|NCT00621218|Active Comparator|1|
89150923|NCT00621218|Placebo Comparator|2|
89150924|NCT02655276|Experimental|100 mg microencapsulated Glycine and then Placebo tablets|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the first three weeks and then Placebo t.i.d. from Biotiki® for the second three weeks.
89150925|NCT02655276|Experimental|Placebo tablets and then 100 mg microencapsulated Glycine|Placebo t.i.d. from Biotiki® for the first three weeks and then 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the second three weeks.
89150926|NCT02651064|Experimental|HIP|Received a 30% rebate on targeted fruits and vegetables (TFV) purchased using SNAP benefits in participating retailers. TFV earning the rebate included fresh, canned, frozen, and dried fruits and vegetables without added sugars, fats, oils, or salt, excluding white potatoes, mature legumes (dried beans and peas), and 100% juice.
89150927|NCT02651064|No Intervention|Non-HIP|Received SNAP benefits as usual.
89150928|NCT02832947|Other|Rivaroxaban Arm|
89150929|NCT00651300|Experimental|Group 1|
89150930|NCT00651300|Placebo Comparator|Group 2|
89150931|NCT02832791|Active Comparator|QUADRICEPS TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING QUADRICEPS TENDON
89150932|NCT02832791|Active Comparator|HAMSTRING TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING HAMSTRING TENDON
89150933|NCT04210466|Experimental|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|an ACT intervention + 2 sessions of explicit self-compassion meditation exercises.
89150934|NCT04210466|Active Comparator|Acceptance & Commitment Therapy (ACT)|an ACT intervention + 2 Q&A sessions.
89150935|NCT02828033|Experimental|Rilonacept|A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
89150936|NCT00621998|Experimental|1|Flexible dose of olanzapine
89150937|NCT00621998|Active Comparator|2|Flexible dose of risperidone
89150938|NCT02655198|Experimental|fenfluramine|"Experimental : one armed open label study :~Add-on fenfluramine in refractory Lennox Gastaut patients. Starting dose 0.2mg/kg/day. In non-responders (<50% seizure frequency decrease), dose will be uptitrated every 4 weeks from 0,2 to 0,4 and max 0,8 mg/kg/day (max 30 mg). Total duration study and max exposure to the drug 20 weeks"
89150939|NCT04210388|Experimental|AZD5718 tablet, Treatment A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions.
89150940|NCT04210388|Experimental|AZD5718 tablet, Treatment B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions.
89150941|NCT04210388|Experimental|AZD5718 tablet, Treatment C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
89150942|NCT04210388|Experimental|AZD5718 tablet, Treatment D|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions.
89150943|NCT04210388|Active Comparator|AZD5718 film-coated tablet|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions.
89150944|NCT00650052|Experimental|1|Zonisamide Capsules 100 mg
89150945|NCT00650052|Active Comparator|2|Zonegran® Capsules 100 mg
89150946|NCT00891527|Experimental|Avastin and/or Gleevec|Patients were all treated with Gleevec (imatinib mesylate) and those without congenital heart disease and those who progressed were also treated with Avastin (bevacizumab).
89150947|NCT02648100||A|120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.
89150948|NCT02648100||B|510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.
89150949|NCT02648100||C|188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.
89150950|NCT02648100||D|93 patients from the clinical trial GETUG 19 (UNICANCER)
89150951|NCT03861078|Experimental|Cigarette smokers|"Each participant will participate in 5 sessions. During each session, participants will complete a 10-puff, directed product use bout, and then have the option later to puff as little or as much as they like during a 30-minute self administration task.~Session 1: Own brand cigarette use Session 2: ECIG 15 mg nicotine, sweetened Session 3: ECIG Lab Session ECIG 15 mg nicotine, unsweetened Session 4: ECIG Lab Session ECIG 0 mg nicotine, sweetened Session 5: ECIG Lab Session ECIG 0 mg nicotine, unsweetened"
89150952|NCT04245293|Experimental|Ainara|Experimental: Ainara Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
89150953|NCT04245293|Active Comparator|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
89150954|NCT02829359|Experimental|Entecavir therapy|Patients who received entecavir (zhengda Tianqing Co., Ltd, Lianyungang, Jiangsu Province, China; 0.5 mg/d) were submitted to antiviral group. Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month. No immunological therapy in perioperative period will be submitted to any included patients.
89150955|NCT02829359|No Intervention|No antiviral therapy|Patients who did not receive any antiviral therapies were submitted as non-antiviral group. Patients in the non-antiviral group who underwent HBV reactivation will receive entecavir therapy. No immunological therapy in perioperative period will be submitted to any included patients.
89150956|NCT03916796|Experimental|Pre-Operative Radiotherapy: Dietary Counseling/Exercise/Psychological Counsel|"Patients must be treated using daily image-guided radiotherapy~Dietary counseling at baseline~Exercise intervention throughout cancer rehabilitation protocol~Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling"
89150957|NCT03916796|Experimental|Post-Operative Radiotherapy: Dietary Counseling/Exercise/Psychological Counsel|"Patients must be treated using daily image-guided radiotherapy~Dietary counseling at baseline~Exercise intervention throughout cancer rehabilitation protocol~Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling"
89150958|NCT02829749|Experimental|NeoChord DS1000 Artificial Chordae Delivery System|Subjects randomized to the experimental group will undergo the NeoChord implantation
89150959|NCT02829749|Other|Control|traditional mitral valve repair performed under cardiac arrest
89150960|NCT00621374|Experimental|Random Order 1|Randomization Order 1= 1)CONT, 2)CBT, 3)HYP, 4) CBT-HYP
89150961|NCT00621374|Experimental|Random Order 2|Randomization order 2= 1)CONT, 2)HYP, 3)CBT, 4) CBT-HYP
89150962|NCT02650752|Experimental|Lapatinib in Tandem With Capecitabine|A minimum of one patient at each dose level will be enrolled. Patients will receive a 4 week treatment cycle consisting of lapatinib 3 day on/11 day off in tandem with capecitabine 7 day on/7 day off with lapatinib. Both drugs will be administered orally as outpatient. Safety, toxicity, and DLT will be assessed weekly during the cycle 1 (first 4 weeks). Each patient will be monitored during cycle 1 prior to enrolling the next patient to the next higher dose level. Dose escalation will take place if no DLT or less than two occurrences of grade 2 toxicity (except those listed below) is observed within a given patient. In the event that a second instance of separate grade 2 toxicity (except those listed below) is noted, the cohort will be expanded to 3 patients at the same dose level and the study will revert to the standard 3+3 design with 3 patients per cohort. There will be no intra-patient dose escalation.
89150963|NCT02832869|Experimental|short message service|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
89150964|NCT02832869|Experimental|Wechat|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
89150965|NCT02832869|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
89150966|NCT02832713|Experimental|Intra-articular injection of botulinum toxin A|
89150967|NCT02832713|Active Comparator|Intra-articular injection of hyaluronic acid|
89150968|NCT02650674|Experimental|Product A: NP-0148|Cereal product belVita Milk & Cereals - High in SDS
89150969|NCT02650674|Experimental|Product B: NP-0149|Cereal product belVita Honey & Nuts - High in SDS
89150970|NCT02650674|Experimental|Product C: NP-0150|Cereal product belVita Mixed Berry - High in SDS
89150971|NCT02650674|Experimental|Product D: NP-0151|Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat
89150972|NCT02650674|Experimental|Product E: NP-0152|Cereal product Kellogg's Trésor Duo Choco - Low in SDS
89150973|NCT02650674|Experimental|Glucose reference|Glucose solution performed on three occasions
89150974|NCT04963634||Patients with bradykinin angioedema|
89150975|NCT04963634||Patients with histamine-mediated angioedema|
89150976|NCT02654886|Experimental|Resistance Exercise Training|Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.
89150977|NCT02691650||polytrauma patients|Patients with severe traumatic injury, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
89150978|NCT02691650||burns patients|Patients with burns trauma, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
89150979|NCT02832635|Experimental|WBRT|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy without avoidance of hippocampus applied.
89150980|NCT02832635|Experimental|WBRT with avoidance of hippocampus|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus applied.
89150981|NCT02832635|Experimental|WBRT with TMZ|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with concurrent TMZ chemotherapy applied.
89150982|NCT02832635|Experimental|WBRT with avoidance of hippocampus and TMZ|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus and concurrent TMZ chemotherapy applied.
89150983|NCT02691806|Experimental|research arm|Each of the 14 participants will undergo the same 2 days experimental protocol, separated by at least 2 days rest.
89150984|NCT00650598|Active Comparator|Arm 1|
89150985|NCT00650598|Active Comparator|Arm 2|
89150986|NCT00620204|Experimental|A|Atorvastatin group
89150987|NCT00620204|No Intervention|B|Control group
89150988|NCT06096558|Active Comparator|Melatonin|
89150989|NCT06096558|Placebo Comparator|placebo|
89150990|NCT06096493||Patients with cancer rectum underwent curative surgery|Patients with cancer rectum underwent curative surgery
89150991|NCT06096480||MMA group|adolescent spinal fusion patients who received intravenous multimodal analgesic strategy alone
89150992|NCT06096480||MMA-ESP-G group|adolescent spinal fusion patients who received a multimodal analgesic strategy in combination with a preoperative ESP block and oral gabapentin
89150993|NCT06096454|Experimental|metformin ,life style|known to have hypothyroidism with insulin resistance received metformin (1000mg,once daily per oral ) and applied life style modification
89150994|NCT06096454|No Intervention|placebo|known to have hypothyroidism with insulin resistance not received metformin and not applied life style modification
89150995|NCT06096415|Experimental|Experimental: ABX-101 1mg|"Participants will be screened, enrolled and receive the assigned treatment within 12 hours of the primary TBI insult (or estimated less than 12 hours if the exact time is unknown).~Enrolled participants will be stratified 1:1 (in each arm) by GCS score (GCS 4-8 in one group and GCS 9 - 12 in the other).~The treatment period, which involves 6 hourly, i.e., quarter in die (QID), ABX 101 (1 mg OR 2 mg) intramuscular injections, is seven days."
89150996|NCT06096415|Experimental|Experimental: ABX-101 2mg|"Participants will be screened, enrolled and receive the assigned treatment within 12 hours of the primary TBI insult (or estimated less than 12 hours if the exact time is unknown).~Enrolled participants will be stratified 1:1 (in each arm) by GCS score (GCS 4-8 in one group and GCS 9 - 12 in the other).~The treatment period, which involves 6 hourly, i.e., quarter in die (QID), ABX 101 (1 mg OR 2 mg) intramuscular injections, is seven days."
89150997|NCT06096415|Placebo Comparator|Placebo Comparator: Saline|Placebo to the ABX-101 will be administered to patients.
89150998|NCT06096402||anterior gastropexy, no fundoplication|patients with indication of operative management of a paraesophageal hernia
89150999|NCT06096402||anterior gastropexy and fundoplication|patients with indication of operative management of a paraesophageal hernia
89151000|NCT06096389|Placebo Comparator|Maltodextrin (CHO)|This group will be given isocaloric carbohydrate (maltodextrin)
89151001|NCT06096389|Active Comparator|Whey Protein Isolate (WIP)|This group will receive whey protein isolate
89151002|NCT06096389|Experimental|House Cricket (HCP)|This group will receive house cricket powder
89151003|NCT06096350||patients with stroke|Inpatients admitted to the investigators' rehabilitation facility
89151004|NCT06096324|Experimental|Intervention|Job announcements plus educational sessions, mentoring, a micro-grant, and behavioral economic text messages.
89151005|NCT06096324|Other|Control|Job announcements only
89151006|NCT06096259|Experimental|Metformin|3x500mg metformin HCl extended-release tablets taken orally once a day for 1 year
89151007|NCT06096259|Placebo Comparator|Placebo|3x metformin placebo tablets matching metformin extended-release taken orally once a day for 1 year
89151008|NCT06096233|No Intervention|Control|The participants will not perform any exercise.
89151009|NCT06096233|Experimental|Short Exercise|The participants will run on the treadmill for 10 minutes.
89151010|NCT06096233|Experimental|Prolonged Exercise|The participants will run on the treadmill for 30 minutes.
89151011|NCT06096220|Experimental|Experimental group|Enucleation of OKC followed by local application of 5% 5-fluorouracil cream. Drug will be applied on the gauze left in the enucleation defect for 24 hours, after which the gauze will be removed.
89151012|NCT06096220|Active Comparator|Control group|Enucleation of OKC followed by local application Carnoy solution. Carnoy solution will be applied into the cystic cavity for 5 minutes and bone defect will be treated by Carnoy solution for 3 minutes immediately after the enucleation.
89151013|NCT06096194|Experimental|vitamin D3-enhanced egg|The experimental group consumed an vitamin D3-enhanced egg (~ 400 IU). The randomization unit was the take care SEDESOL centers. All children in 3 day-care centers were given one vitamin D3-enhanced egg at breakfast, 3 times a week for 12 weeks (Monday, Wednesday and Friday).
89151014|NCT06096194|Placebo Comparator|Control|The control group consumed unfortified egg (~ 43 IU Vitamin D). The randomization unit was the 6 day-care centers (SEDESOL). All children in 3 day-care centers were given unfortified egg at breakfast, 3 times a week for 12 weeks (Monday, Wednesday and Friday).
89151015|NCT06096181|Active Comparator|Propofol + Remifentanil|Participants are randomly selected to receive Propofol + Remifentanil TIVA as their anesthesia. Dose of IV Propofol is 100-200 mcg/kg/min and dose of Remifentanil is 0.2-0.5 mcg/kg/min. TIVA is titrated to keep bispectral index (BIS) < 55-60 to ensure patient is asleep.
89151016|NCT06096181|Active Comparator|Propofol + Dexmedetomidine|Participants are randomly selected to receive Propofol + Dexmedetomidine as their anesthesia. Dose of Propofol is 100-200 mcg/kg/min and dose Dexmedetomidine is ) 0.2-0.7 mcg/kg/hr. TIVA is titrated to beep bispectral index (BIS) < 55-60 to ensure patient is asleep.
89151017|NCT06096129||Spy PTC|People who had Spy PTC performed
89151018|NCT06095986|Active Comparator|PSC patients administered with Aramchol meglumine|Adult subjects with clinically diagnosed PSC that are administered with Aramchol meglumine
89151019|NCT06095986|Placebo Comparator|PSC patients administered with placebo|Adult subjects with clinically diagnosed PSC that are administered with matching placebo
89151020|NCT06095960|Experimental|Telehealth MOM|Telehealth MOM. Each patient will receive ESoC which includes: education on the symptoms to watch for and when to call their healthcare provider, an in-person comprehensive postpartum visit around 6 weeks postpartum, and any additional care deemed necessary by their health care providers. Patients in the Telehealth MOM arm will be also provided with a remote monitoring blood pressure cuff and thermometer and will be instructed to take their blood pressure and temperature twice a day for 14 days after discharge from the hospital. A Registered Nurse will monitor blood pressure and temperature readings over the 14-day period and will contact the patient if the readings are out of range to discuss symptoms and the recommend a course of action. A Registered Nurse will conduct an early postpartum telehealth visit between 10-14 days postpartum.
89151021|NCT06095960|Active Comparator|Enhanced Standard of Care|Enhanced standard of care (ESoC). Each patient will be provided education on the symptoms to watch for and when to call their healthcare provider. Patients will be scheduled for a comprehensive postpartum visit around 6 weeks postpartum and any additional care deemed necessary by their health care providers.
89151022|NCT06095947||There was an immunological history group|l Children who have received two or more doses of influenza vaccine (4 weeks apart) before the influenza season (2 doses of influenza vaccine do not need to be administered in the same epidemic season or consecutive epidemic season, and can be interpreted as children who have received two or more cumulative doses).
89151023|NCT06095947||There was no immunological history group|l Children who have not received or previously received <2 doses of influenza vaccine before the epidemic season.
89151024|NCT06095934|Experimental|Evaluate the efficacy and safety of neo-antigen peptide vaccine in the treatment of advanced NSCLC|
89151025|NCT06095921|Experimental|Self Management Intervention Program|That program was created by sending 40-minute videos 1 day a week for 8 weeks. The programme was developed both according to the achievements of previous self-management studies and according to the occupations that individuals with SSc have difficulty with.
89151026|NCT06095921|No Intervention|Statistical Analysis|One week after the program, the biostatistician evaluated the results.
89151027|NCT06095882|Experimental|acupuncture|
89151028|NCT06095882|No Intervention|observe|
89151029|NCT06095869|Experimental|progressive relaxation exercise group|intervention group with progressive relaxation exercise
89151030|NCT06095869|Experimental|relaxation background music group|intervention group with relaxation background music
89151031|NCT06095869|Experimental|control group|group receiving routine health protocol and no intervention
89151032|NCT06095830||Group 1|Patients that recovered from sepsis without complications
89151033|NCT06095830||Group 2|"Patients that didn't recover from sepsis.~Further subdivided into:~Group 2-A: developed complications Group 2-B: non-surviving"
89151034|NCT06095830||Group 3|Control group of healthy individuals
89151035|NCT06095817|Experimental|Intervention Condition|"Participants assigned to the intervention condition will be invited to engage with an internet-based intervention at the start of the study (12 months following their separation)~Half of those in the intervention condition will have already received two prior IDBIs (as part of the DoD funded study) within the first 6 months of separation.~The other half of those in the intervention condition will have received no prior IDBIs."
89151036|NCT06095817|No Intervention|Control|"The control group will not be offered this month-12 internet-based intervention.~Half of those in the control condition will have received two earlier IDBIs (as part of the DoD funded study) within the first 6 months of their separation.~The other half of those in the control condition will have received no prior IDBIs."
89151037|NCT06095804|Experimental|Percutaneous Ultrasound Jejunostomy|Placement of a longterm jejunostomy tube using the PUMA-J System
89151038|NCT06095739|Experimental|DA-OTC-002|A 1mL topical application of DA-OTC-002 solution was applied to a 10cm x 10xm target area of the left side of the scalp of each subject.
89151039|NCT06095726|No Intervention|Control group|Children with leukemia received routine nursing and hospital care for management of chemotherapy induced nausea and vomiting (antiemetic medications only).
89151040|NCT06095726|Experimental|Peppermint Inhalation Group|Children with leukemia received the inhalation of essential oil of peppermint 2% in addition to routine nursing and hospital care for management of chemotherapy induced nausea and vomiting.
89151041|NCT06095726|Experimental|Swedish Massage Group:|Children with leukemia received the Swedish massage therapy in addition to routine nursing and hospital care for management of chemotherapy induced nausea and vomiting.
89151042|NCT06095713||Standard of Care|Patient treated with Pegunigalsidase-alfa according to standard of care
89151043|NCT06095700|Active Comparator|Rib Resection Group|This arm undergoes first rib resection, as mentioned in the textbook.
89151044|NCT06095700|Experimental|Rib Avulsion Group|This group of patients undergo first rib avulsion
89151045|NCT06095674|Experimental|PD-1 checkpoint inhibitor and CTLA-4 inhibitor|Both antibodies will be peritumorally administered in early-stage cervical cancer prior to surgery.
89151046|NCT06095648|Active Comparator|Usual treatment arm|Babies who are randomized to this arm will receive the usual treatment of 15ml/kg platelets when they are getting a platelet transfusion
89151047|NCT06095648|Experimental|Intervention arm|Babies who are randomized to this arm will receive the experimental treatment of 5ml/kg platelets when they are getting a platelet transfusion
89151048|NCT06095635|Placebo Comparator|Placebo Protocol|exercise and placebo capsules 500 mg (starch)
89151049|NCT06095635|Experimental|Protocol Beet|exercise and beet extract 500 mg
89151050|NCT06095635|Experimental|Protocol Resveratrol|exercise and resveratrol capsules 500 mg
89151051|NCT06095635|Experimental|Protocol Beet and Resveratrol|exercise and beet extract 500mg and resveratrol capsules 500 mg
89151052|NCT06095622|No Intervention|Typical rice pulao without and herbal intervention|Normal chickpea rice pulao was used as the main arm. The control group does not contain fenugreek and Indian rennet extract.
88806032|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
89151053|NCT06095622|Experimental|Chickpea Pulao Using Fenugreek Seeds and Indian Rennet|Chickpea rice pulao added with herb (Fenugreek Seeds and Indian Rennet).
89151054|NCT06095609|Experimental|Early mobilization plus chest physiotherapy|Physiotherapy program comprised two parts early mobilization and CPT. They could be divided into different levels depended on patients' ability. In terms of the levels of early mobilization, first level was defined as patients who could only receive passive patterns of exercise. Second level would be executed to patient who could only take exercise on the bed or with back support. Third level would be implemented when patients could advance to receive physiotherapy beside the bed without support. The eventual level would be conducted when patients was able to leave beds by their own. In line with chest physiotherapy, level I was defined as patients who could only receive passive lung hygiene protocol. Level II would be executed when patient can control their breath and cough by their own. Level III would be implemented when patient can maintain their body steadily and finish the chest physiotherapy protocol.
89151055|NCT06095609|No Intervention|Routine care|no physiotherapy involved
89151056|NCT06095570|Experimental|Group C|Ciprofol + sufentanil + rocuronium bromide
89151057|NCT06095570|Active Comparator|Group R|Remimazolam+ sufentanil + rocuronium bromide
89151058|NCT06095544|Experimental|ERAS group|ERAS group was consisted of evidenced-based systematic optimization approaches
89151059|NCT06095544|No Intervention|Traditional group|The control group received routine care
89151060|NCT06095518||Adult Intensive Care Unit, Queen Mary Hospital|
89151061|NCT06095518||Department of Intensive Care Unit, Tuen Mun Hospital|
89151062|NCT06095479|Experimental|undergo standard abdominal ultrasound imaging and MRI-PDFF|"Study-related procedures will consist of one investigational exam conducted with the Philips EPIQ Ultrasound System with investigational LFQ software and a standard MRI-PDFF examination.~All imaging procedures (investigational LFQ ultrasound exam and MRI-PDFF exam) must be completed within an 8-week window (+ 5 days)."
89151063|NCT06095466||Cirrhotic cardiomyopathy|Cirrhotic cardiomyopathy, among a broad spectrum of cardiac complications in cirrhosis, is characterized by systolic and diastolic cardiac dysfunction and electrocardiographic changes. However, it is seen more in NASH related cirrhotic patients, who have an additional risk of developing cardiac complications. Cirrhosis contributes to a including cirrhotic cardiomyopathy owing to various pathological conditions interlinked at the cellular and molecular level. A hyperdynamic circulatory state caused due to excessive release of vasodilators in a pro-inflammatory condition of cirrhosis, along with negative-inotropic pathways contributes to the development of a compromised cardiac function. Electrocardiography, 2D echocardiography with tissue Doppler or speckle tracking are the routine diagnostic tests used to diagnose CCM.
89151064|NCT06095427|Experimental|LY06006|60 mg LY006006
89151065|NCT06095427|Active Comparator|US-Prolia|60 mg US-Prolia
89151066|NCT06095427|Active Comparator|EU-Prolia|60 mg EU-Prolia
89151067|NCT06095388|Experimental|JR-441 low dose|
89151068|NCT06095388|Experimental|JR-441 high dose|
89151069|NCT06095362|Experimental|Intervention group|
89151070|NCT06095336|Experimental|Telereahabilitation arm|The group receiving telerehabilitation will be given a video CD containing the exercise program that will be changed every 3 weeks, and in the first week of each change program, daily sessions will be held collectively via video conferencing under the supervision of a physiotherapist. In the first 3 weeks of the 12-week exercise program, neck joint movements, neck stretching exercises and posture exercises will be given. Between weeks 4-6, in addition to the exercises in the first 3 weeks, cervical and scapular stabilization exercises will be given in the following weeks. In the following weeks, between weeks 7-9, 4-way strengthening exercises will be included in the program in addition to the exercises performed in the previous weeks. Cervical and scapular stabilization exercises and strengthening exercises will be performed in the following weeks between weeks 10-12, Exercises will be done 10 repetitions 3 times a day.
89151071|NCT06095336|Experimental|conventional physiotherapy arm|"Superficial heat (infrared), Transcutaneous Electrical Nerve Stimulation (TENS), therapeutic ultrasound and Hotpack application will be applied to the traditional treatment group. The patients receive 20 sessions in total, 5 days a week and 1 session daily for 4 weeks; You will receive superficial heat (infrared), TENS, therapeutic US and Hotpack treatment. . Superficial heat infrared will be applied to the tissue for 20 minutes. Conventional TENS will be applied. Therapeutic US will be applied to the cervical and thoracic region with an ultrasound device for 5 minutes at 3mHz, 1W/cm² treatment dosage, in continuous mode. Hotpack application will be done for 20 minutes. At the end of the 20 sessions, a brochure containing video-supported exercises will be given to the patients in the first group and they will be asked to do it for 12 weeks without follow-up."
89151072|NCT06095336|No Intervention|control arm|The third group, the control group, will not receive any intervention and will be asked to continue their daily lives.
89151073|NCT06095310|Experimental|Homogeneous groups|
89151074|NCT06095284||All nursing home residents included in the 2009-2021 MDS|
89151075|NCT06095284||Nursing home and non-nursing home residents diagnosed with an AD/ADRD condition|
89151076|NCT06095271|Experimental|sNfL monitoring|6-monthly blood draw to measure sNfL
89151077|NCT06095271|No Intervention|Usual care|SMSC usual care
89151079|NCT06095232||Pregnant women|Primiparous women will participate in the study during the 1st - 3rd trimester of pregnancy and during the postpartum period.
89234894|NCT05887947|Experimental|7 African American 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 1.8%|"7, African American, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89151080|NCT06095232||Control group|Nulliparous women with a regular natural menstrual cycle will undergo the same study procedure as pregnant women.
89151081|NCT06095219||Asymptomatic volunteers|Healthy individuals without history of hip pain or problems willing to undergo MRI of the hip.
89151082|NCT06095219||Hip Dysplasia|This group is defined according to the following radiographic parameter: lateral center edge angle (LCE) < 23°. The data was obtained from a retrospective study.
89151083|NCT06095219||cam Deformity|This group is defined according to the following radiographic parameter: alpha angle > 60°. The data was obtained from a retrospective study.
89151084|NCT06095219||Acetabular retroversion|This group is defined according to the following radiographic parameters:positive posterior- wall- sign, positive ischial spine sign, and positive cross- over- sign. The data was obtained from a retrospective study.
89151085|NCT06095219||Acetabular protrusion|This group is defined according to the following radiographic parameter: positive protrusion sign. The data was obtained from a retrospective study.
89151086|NCT06095219||Deep hip|This group is defined according to the following radiographic parameter: LCE angle > 39°. The data was obtained from a retrospective study.
89151087|NCT06095206|Experimental|GenSci094|Participants received a single subcutaneous (SC) injection of 150 µg GenSci094 on day 1 pre-meal，PK and immunogenicity blood collection to day18， safety call follow-up completed at day 25
89151088|NCT06095193|Experimental|Experimental: menopause education|Women will be taught the physiology of female reproductive organs, physiology of menopause, vaginal symptoms in menopause, sexual myths in menopause and practices that will support sexuality in menopause, in 50 minutes for 4 weeks.
89151089|NCT06095193|No Intervention|control group|No intervention will be made
89151090|NCT06095180|Active Comparator|corticosteroid group|In the steroid group, 4 mL lidocaine 2% + 1 mL betamethasone injection will be administered under ultrasound guidance and conventional treatment will be given (conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
88804369|NCT05463341|Experimental|Intervention Arm|Each participant in the intervention arm will receive one-on-one education on the purpose, benefits, and limitations of fentanyl test strip (FTS) testing and undergo a brief 20-minute FTS educational intervention (including a 2-3-minute video and hands-on demonstrations on how to use FTS). They will also receive a supply of 10 FTS upon enrollment and continued supply upon request throughout the 2-year follow up period.
88804370|NCT05463341|No Intervention|Non-Intervention Arm|Fentanyl test strip (FTS) education and a supply of FTS will be offered to participants in the non-intervention arm of the study during the final quarter of year 5.
88804371|NCT05453708||Autism Risk|Survey for mothers 18 years or older with a child aged 3-12 years who has an official ASD diagnosis from a clinician.
89151091|NCT06095180|Active Comparator|dry needling group|In the dry needling group, a total of 3 sessions of dry needling will be performed once a week using a 0.60×100 mm sterile needle under ultrasound guidance and conventional treatment will be given ((conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
89151092|NCT06095180|Other|control group|The conventional treatment group (control group) will be given piriformis stretching exercises including hip and knee flexion, hip abduction and external rotation in the supine position. It will be stated that patients should do 2 sets a day and each set should be 10 repetitions.
89151093|NCT06095167|Experimental|The immunotherapy and induction chemotherapy plus RT alone group|Patients receive Anti-PD-1 Antibody, gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for three cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT) alone.
89151094|NCT06095167|Active Comparator|The immunotherapy and induction chemotherapy plus CCRT group|Patients receive Anti-PD-1 Antibody, gemcitabine (1000 mg/m² d1,8) , cisplatin (80mg/m² d1) every 3 weeks for three cycles and cisplatin 80-100 mg/m² every 3 weeks for 2 cycles, concurrently with intensity-modulated radiotherapy (IMRT)
89151095|NCT06095063|Experimental|20 sessions of dTMS and Cognitive Training|"Participants will receive dTMS followed by computerized cognitive training.~dTMS: The motor threshold (MT) will be measured by delivering single stimulations to the motor cortex with gradually increased intensity. After defining the MT, the coil will be positioned anterior to the hot spot using the ruler on the participant's cap, and a dTMS session will be performed with the dosing of the stimulus intensity titrated slowly to approximately 120% of the motor threshold. On Day 1 of the treatment, stimulation will be delivered at an intensity ranging from 80% to 100% of the participant's MT depending on their initial tolerance to the stimulation. Stimulation intensity will then be slowly titrated by sequentially increasing the intensity by 10% over the remaining days of the first week until a maximum intensity of 120% of MT is achieved depending on the tolerability of the patient.~Immediately following dTMS, participants will complete 20-30 minutes of cognitive training."
89151096|NCT06095063|Sham Comparator|20 sessions of sham/control stimulation and Cognitive Training|"Participants will receive sham intervention followed by computerized cognitive training.~The sham intervention consists of treatment with similar technical parameters which induce scalp sensations but do not penetrate into the brain.~Immediately following dTMS, participants will complete 20-30 minutes of cognitive training."
89151097|NCT06095024||Linked to national data|"Patients will be randomly assigned to be asked to link personal data with national cancer data.~The outcome measure will be the proportion of completed questionnaires"
89151098|NCT06095024||Linking to national data, early vs. late questions|"Subset of cohort 1: Patients will be randomly assigned to be asked the question about data linkage at the beginning vs. end of the questionnaire~The outcome measure will be the proportion answering yes in each arm"
89151099|NCT06095024||Different PROM Completion rate|"Patients will be randomised to two different PROM questionnaires~The outcome measure will be the completion rate of the two different questionnaires"
89151100|NCT06095024||Impact of additional PROMS on completion and satisfaction|"Patients will be randomised to either a standard PROM or additional, symptom directed questionnaire~The outcome measure will be the satisfaction rate of patients in each arm"
88804372|NCT05453708||Controls|Survey for mothers 18 years or older of children aged 3-12 years who do not have an ASD diagnosis so comparisons can be made between groups.
88804373|NCT05433506|Experimental|Active Treatment: HU6 Tablet|
88804374|NCT05433506|Experimental|Active Treatment: HU6 Capsule|
88804375|NCT05406973|Other|Moria SBK microkeratome|Comparative non randomized Interventional clinical study between SBK microkeratome versus femtosecond laser in flap creation during LASIK surgery for myopia
89151101|NCT06094946||Midwife administered boluses|The epidural analgesia is initiated by a manual bolus of the epidural solution (ropivacaine 1 mg/ml fentanyl 2.5 mug/ml) 10 + 10 ml and then continued on-demand by similar boluses until delivery
89151102|NCT06094946||Automated and parturient controlled epidural boluses|The epidural analgesia is initiated by a manual bolus of the epidural solution (ropivacaine 1 mg/ml fentanyl 2.5 mug/ml) 10 + 10 ml and then continued by automated boluses of the same solution (6ml every 40 minutes) with possibility for the parturient to administer 6 ml extra doses with a 20 minute lock-out. Maximum hourly dose 20 ml.
89151103|NCT06094933|Experimental|Mobile Anger Reduction Intervention (MARI)|Participants in this arm will download the MARI application (app) on their own smart phone device and will use the app for a period of 4 weeks.
89151104|NCT06094933|Active Comparator|Health Education Condition (HED)|Participants in this arm will download the HED application (app) on their own smart phone device and will use the app for a period of 4 weeks.
89151105|NCT06094920|Other|A. Good albuminuria response after 2 weeks empagliflozin 10 mg/day|Albuminuria reduction >30% and the remaining albuminuria level is <30 mg/g: continue empagliflozin 10 mg/day for an additional four weeks.
89151106|NCT06094920|Other|B. Moderate albuminuria response after 2 weeks empagliflozin 10 mg/day|Albuminuria reduction >30% or >0 and ≤30%, and the remaining albuminuria level is >30 mg/g: continue empagliflozin 10 mg/day for an additional four weeks and intensify treatment by adding finerenone 10 or 20 mg/day for four weeks (dosage depends on eGFR levels).
89151107|NCT06094920|Other|C. No albuminuria reduction after 2 weeks empagliflozin 10 mg/day|No albuminuria reduction or increase: discontinue empagliflozin and switch to finerenone 10 or 20 mg/day for four weeks (dosage depends on eGFR levels).
89151108|NCT06094907|Experimental|N,N-Dimethyltryptamine|Administration of up to 2 inhaled doses of DMT within a single day (15 mg, followed by 60 mg) with a 1-hour dose interval.
89151109|NCT06094868|Experimental|Fruquintinib in combination with Sintilimab and XELOX|"Fruquintinib: 4mg, QD, PO, D1-D14, Q3W; Sintilimab: weight < 60kg, 3mg/kg; weight≥60kg, 200 mg; I.V.， D1，Q3W； XELOX regimen: oxaliplatin: 130 mg/m2, ivgtt, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; After 6 cycles of treatment, chemotherapy was given and maintenance treatment was given with fuquitinib combined with sindillizumab. The above medication regimen can be adjusted according to the adverse reaction tolerance of the subjects.~* Maintenance of treatment until disease progression, or intolerable toxic reactions, or other conditions determined by the investigator"
89151110|NCT06094829||Smokers|Healthy subjects having smoked 100 cigarettes or more during their life.
89151111|NCT06094829||Non-smokers|Healthy subjects having smoked less than 100 cigarettes during their life.
89151112|NCT06094790|Experimental|Cohort 1|Subjects will receive CORT125134 150 mg once daily for 14 days
89151113|NCT06094790|Experimental|Cohort 2|Subjects will receive CORT125134 250 mg once daily for 14 days
89151114|NCT06094790|Experimental|Cohort 3|Subjects will receive CORT125134 once daily for 14 days at a dose level decided based on evaluation of steady state exposure from Cohorts 1 and 2
89151115|NCT06094790|Experimental|Cohort 4 (optional)|Subjects will receive CORT125134 once daily for 14 days at a dose level decided based on evaluation of steady state exposure from Cohorts 1, 2, and 3, if it is considered that this cohort would aid achievement of the study objectives
89151116|NCT06094777|Experimental|HY-0102|"Dose Escalation(Standard 3+3 Dose escalation) Cohort 1: 5 mg/kg Q2W HY-0102 ivgtt Duration: 24w,DLT observation period: 28 days.~Cohort 2: 10 mg/kg Q2W HY-0102 ivgtt Duration: 24w,DLT observation period: 28 days.~Cohort 3: 15 mg/kg Q2W HY-0102 ivgtt Duration: 24w,DLT observation period: 28 days.~Dose Expansion Within the MTD and sub-MTD dose groups, select 1-2 doses for dose expansion, including approximately 30-40 cases of tumor types that have demonstrated preliminary efficacy in the early escalation phase. Conduct safety, tolerability, and preliminary anti-tumor efficacy evaluations to provide a basis for the recommended phase II clinical dose (RP2D). PK studies will be conducted on 12 subjects in each dose group, including dose escalation trial cases."
89151117|NCT06094764|Experimental|Personal monitoring device and a cooling vest , Then personal monitoring device only|
89151118|NCT06094764|Experimental|Personal monitoring device only, Then personal monitoring device and a cooling vest|
89151119|NCT06094738|Experimental|Relacorilant under fasted conditions|Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
88804376|NCT05406973|Other|200-kHz Femtosecond laser system|Comparative non randomized Interventional clinical study between SBK microkeratome versus femtosecond laser in flap creation during LASIK surgery for myopia
89151120|NCT06094738|Experimental|Relacorilant after a high-fat meal|Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
89151121|NCT06094738|Experimental|Relacorilant after a low-fat meal|Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
89151122|NCT06094725|Experimental|No Hepatic Impairment|Subjects with no hepatic impairment will receive relacorilant 300 mg once daily on Days 1 through 10.
89151123|NCT06094725|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment (Child-Pugh Class B) will receive relacorilant 300 mg once daily on Days 1 through 10.
89151124|NCT06094725|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment (Child-Pugh Class A) will receive relacorilant 300 mg once daily on Days 1 through 10.
89151125|NCT06094712|Experimental|CORT125134|After an overnight fast, subjects will receive a single CORT125134 150-mg oral dose of the Phase 2 capsule formulation on Day 1.
89151126|NCT06094699|No Intervention|Standard of care|
89151127|NCT06094699|Experimental|Sleep intervention|
89151128|NCT06094569||Endovascular therapy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombus aspiration, others, or combination methods.
89151129|NCT06094569||Best medical management|Patients enrolled in this group received the best medical management.
88804381|NCT05376904|Experimental|HR18034 dose 1|
88804382|NCT05376904|Experimental|HR18034 dose 2|
88804383|NCT05376904|Experimental|HR18034 dose 3|
89151130|NCT06094543|Experimental|Patient Engagement Tool (PET)|Participants will use the PET weekly for 12 weeks
89151131|NCT06094543|No Intervention|Usual Care|Usual Clinic Follow up every 6 weeks for 12 weeks
89151132|NCT06094517||Observed Group|Patients with persistent lower back pain awaiting Physiotherapy care, undergoing interviews to assess their views of sleep health within and musculoskeletal outpatient Physiotherapy setting.
89151133|NCT06094491|Experimental|Virtual Group Visit Arm|These subjects will attend 6 monthly virtual group visits hosted by ACCESS or Advocate research staff.
88804384|NCT05376904|Active Comparator|ropivacaine HCl|
89151134|NCT06094491|No Intervention|Usual Care Arm|These subjects will receive usual diabetes care at ACCESS or Advocate health centers.
89151135|NCT06094478|No Intervention|Control Phase|Pre-implementation of HI-SPEED Protocol
89151136|NCT06094478|Active Comparator|Implementation Phase|Post-Implementation of HI-SPEED Protocol
89151137|NCT06094465||learning phase|According to the CUSUM curve, the phase before the peak of the curve is defined as the learning phase.
89151138|NCT06094465||proficiency phase|According to the CUSUM curve, the phase after the peak of the curve is defined as the learning phase.
89151139|NCT06094452|Experimental|Computerized Cognitive Training|Adaptive computerized cognitive training program (www.66nao.com) and the intensity is at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks.
89151140|NCT06094452|Active Comparator|Treatment As Usual|Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet.
89151141|NCT06094400|Experimental|Intervention|10-mintue headband-guided meditation session via Muse Medication App.
89151142|NCT06094400|Other|Control|10-minute resting session
89151143|NCT06094374||Community Dwellling Healthy Older Adults|"65 years or older~able to give informed consent~community dwelling~no severe illness (neurological, cardiovascular, respiratory, metabolic, cognitive disorder)~dutch language profiency"
89151144|NCT06094361|Experimental|IONTOPHORESIS|The group that received 75 mg diclofenac sodium with Chattanooga Physio device.
89151145|NCT06094361|Experimental|PHONOPHORESIS|It is a treatment performed by applying 75 mg of 1% diclofenac sodium gel to the intervention area with the Chattanooga ultrasound device.
89151146|NCT06094348||Group 1A- Thick skin, endonasal osteotomy|Patients with mean nasal soft tissue envelope thickness > 4 mm undergoing classical endonasal osteotomy procedure during rhinoplasty operation
89151147|NCT06094348||Group 1B -Thick skin, piezo osteotomy|Patients with mean nasal soft tissue envelope thickness > 4 mm undergoing piezosurgery assisted osteotomy procedure during rhinoplasty operation
89151148|NCT06094348||Group 2A- Thin skin, endonasal osteotomy|Patients with mean nasal soft tissue envelope thickness <4 mm undergoing classical endonasal osteotomy procedure during rhinoplasty operation
89151149|NCT06094348||Group 2B- Thin skin, piezo osteotomy|Patients with mean nasal soft tissue envelope thickness < 4 mm undergoing piezosurgery assisted osteotomy procedure during rhinoplasty operation
89151150|NCT06094335|Experimental|Study|Virtual reality plus traditional physical therapy
89151151|NCT06094335|Active Comparator|Control|Traditional physical therapy
89151152|NCT06094309|Active Comparator|Active Comparator: botulinum toxin|The botulinum toxin injection will be carried out by a doctor with experience in this therapeutic modality, which in turn is not part of the group of doctors who observe patients in the initial and subsequent phases. 100 Units (U) of botulinum toxin type A, in each lower limb (200 U in total), in muscle proximal thigh, once, at a moment that will be defined as T0. This group of 10 participans.
89151153|NCT06094309|Placebo Comparator|Active Comparator: Placebo|In the control group, patients will be subject to the same protocol, with the difference in that the injections will be saline, although they look the same on the outside. You doctors carrying out therapy and evaluating progress during face-to-face visits will not have access to the distribution of groups. This group of 10 participans.
89151154|NCT06094257||Nipple sparing mastectomy (NSM) and implant reconstruction|Nipple sparing mastectomy (NSM) and implant reconstruction
89151155|NCT06094257||Nipple sparing mastectomy (NSM) and autologous reconstruction|Nipple sparing mastectomy (NSM) and autologous reconstruction
88804385|NCT05348291|Active Comparator|Ventilation tubes|Ventilation tube surgery
88804386|NCT05348291|No Intervention|Active monitoring|Active monitoring of patients, with the possibility to cross over to other arm if deemed necessary.
89151156|NCT06094257||Gender mastectomy with free nipple grafting|Gender mastectomy with free nipple grafting
89151157|NCT06094257||Control patients matched by surgical procedure, age, BMI and mastectomy weight.|Control patients matched by surgical procedure, age, BMI and mastectomy weight.
89151158|NCT06094244|Experimental|Group I Patients who were not taking statins prior to the occurrence of SICH|Patients who were not taking statins prior to the occurrence of SICH.
88806033|NCT02531802|Placebo Comparator|12-23 months: Placebo|12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
88806034|NCT02531802|Experimental|6-11 months: ETVAX (1/8)|6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
89151159|NCT06094244|Experimental|Group II Patients who were taking statins prior to the occurrence of SICH|Patients who were taking statins prior to the occurrence of SICH.
89151160|NCT06094244|Experimental|Subgroup Ia Patients were not diagnosed to dyslipidemia. They did not receive statins.|Patients who were not diagnosed to have dyslipidemia during hospitalization. They did not receive statins.
89151161|NCT06094244|Experimental|Subgroup Ib Patients with dyslipidemia Received statins, recommended to take medicine for 90 days.|Patients with dyslipidemia diagnosed during hospitalization who received statins and were recommended to take this medicine for 90 days since they occurrence of SICH.
88804387|NCT05333497|Experimental|Programmed acupiont stimulation group|"On the basis of routine treatment in the Department of Acupuncture, the fourth generation of low-frequency acupoint electric stimulation therapy instrument (patent No. : ZL201610793646.9) jointly developed by our research group and the Robotics Institute of Harbin Institute of Technology is used to improve the program. The output of the improved instrument program is: the patient should complete the program of reaching and retrieving, namely shoulder joint forward flexion - elbow extension - wrist dorsal extension - finger extension ( reaching for objects ), then grasping - wrist flexion - elbow flexion - shoulder joint backward extension ( retrieve objects ). All patients were in a sitting position, the wrist of the affected limb is suspended, and the other parts do not touch any plane."
88806035|NCT02531802|Experimental|6-11 months: ETVAX (1/4)|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
89151162|NCT06094231|Experimental|Interventional Arm|The patients randomized to the interventional Arm will be simultaneously treated with therapeutic carbohydrate restriction and dapagliflozin for a period of three months. During this time repeated measurements of blood ketone levels and a continuous glucose monitoring will be performed.
89151163|NCT06094231|No Intervention|Control Arm|The patients randomized to the control arm will continue to receive the standard of care for chronic kidney disease and prediabetes or diabetes, which includes the use of dapagliflozin.
89151164|NCT06094192|Experimental|active stimulation|Memory performance data is collected during active brain stimulation and reported 1 year later
89151165|NCT06094192|Sham Comparator|sham stimulation|Memory performance data is collected during sham brain stimulation and reported 1 year later
89151166|NCT06094166||NMDCC|non-myelopathic cervical spinal cord compression
89151167|NCT06094166||healthy controls|subjects with no MR signs of cervical spinal cord compression
89151168|NCT06094140|Experimental|Single arm study, mFOLFIRINOX and durvalumab, neoadjuvant resectable pancreatic cancer.|"All patients enrolled to this study will receive mFOLFIRINOX, delivered Q2W for 6 cycles and durvalumab delivered Q4W for 3 cycles in the neoadjuvant setting for resectable or borderline resectable pancreatic cancer patients. Patients will then undergo restaging, discussion at MDM and surgical resection where appropriate. Following resection, patients will commence 6 cycles of adjuvant mFOLFIRINOX alone (or gemcitabine-based chemotherapy if deemed by investigator as more appropriate).~Patients will be followed up on study for 12 months from surgery, or from completion of neoadjuvant"
89151169|NCT06094114||Patients with Micra Av|Only patients who were previously implanted with a Micra MC1AVR01 can be enrolled in the study. Patients need to be able to perform an exercise test. All subjects provide signed and dated consent that he/she is willing and able to comply with the protocol.
89151170|NCT06094023||Teenage girls between 13 and 19 years living in the Arba Minch Demographic and Surveillance site.|Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals
89151171|NCT06093984|Experimental|Dual Stimulation Protocol|Dual stimulations were performed during the follicular and luteal phases in the same cycle.
89151172|NCT06093984|Active Comparator|Antagonist Stimulation Protocol|Antagonist stimulations were performed during two consecutive follicular phases in two cycles.
89151173|NCT06093971|Experimental|Group remimazolam|During anesthesia induction, the remimazolam group (group R) receives remimazolam (0.2 mg/kg). If necessary, an additional dose of remimazolam (0.1 mg/kg) is administered.
89151174|NCT06093971|Active Comparator|Group propofol|During anesthesia induction, the propofol group (group P) receives propofol (1.0 mg/kg). If necessary, an additional dose of propofol (0.5 mg/kg) is administered.
89151175|NCT06093854|Experimental|Decompression surgery + IORT|Decompression surgery + IORT (15-20 Gy, 20-50min）
89151176|NCT06093854|Active Comparator|Decompression surgery + postoperative SBRT|Decompression surgery + postoperative SBRT (30Gy, 5 fractions, 3 weeks)
89151177|NCT06092788|Experimental|NTP42:KVA4 Capsule|
89151178|NCT06092788|Active Comparator|NTP42:KVA4 Oral Suspension|
89151179|NCT06092606|Placebo Comparator|Control group:DH001 placebo|"Medication: Once per day on an empty stomach in the morning. Treatment cycle: 3 days before the first administration of doxorubicin to the entire treatment cycle of doxorubicin.~Dosage: DH001 placebo (8 tablets)"
89151180|NCT06092606|Experimental|Trial group: DH001 low-dose group|"Medication: once per day on an empty stomach in the morning. Treatment cycle: 3 days before the first administration of doxorubicin to the entire treatment cycle of doxorubicin.~Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)"
89151181|NCT06092606|Experimental|Trial group: DH001 high-dose group|"Medication: Once per day on an empty stomach in the morning. Treatment cycle: 3 days before the first administration of doxorubicin to the entire treatment cycle of doxorubicin.~Dosage: DH001 400mg (8 tablets)."
89151182|NCT06091735|Experimental|Magnesium sulfate sodium potassium solution group|Magnesium sulfate sodium potassium solution group: 3L magnesium sulfate sodium potassium oral concentrated solution. At 18:00 1d before the inspection, dissolve a package of contents into 200ml with water, and drink 250ml of water every half hour after that, drinking a total of 6 cups (that is, 1.5L); On the day of the examination (6 hours before the colonoscopy) repeat the same medication as the previous evening.
89151183|NCT06091735|Experimental|Magnesium sulfate sodium potassium solution group + linaclotide group|Magnesium sulfate sodium potassium solution + linaclotide group: 3L sodium magnesium sulfate potassium oral concentrated solution + linaclotide 290μg. One tablet of linalotide was taken orally at 18:00 one day before the examination, and then two packets of contents were dissolved into 300ml with water 6 hours before the colonoscopy. After that, 500ml of water was drunk every half hour, for a total of 6 cups.
89151184|NCT06091735|Placebo Comparator|PEG (Compound polyethylene glycol electrolyte powder) group|PEG (Compound polyethylene glycol electrolyte powder) group: 3LPEG. At 18:00 1d before the inspection, dissolve a package of contents into 200ml with water, and drink 250ml of water every half hour after that, drinking a total of 6 cups; On the day of the examination (6 hours before the colonoscopy) repeat the same medication as the previous evening.
89151185|NCT06091293|Experimental|NICO|The NICO intervention includes components of narrative-informed interventions, brief solution-focused therapy, and medical social work case management to examine adjustment to illness for people living with Long COVID.
89151186|NCT06091176|Experimental|Arm 1|Subjects assigned to ID1 treatment arm will receive Amicomed® for 90 days, together with Usual Care (UC) procedures.
89151187|NCT06091176|Placebo Comparator|Arm 2|Subjects assigned to ID2 treatment arm, will receive a digital Placebo, together with UC for 90 days.
89151188|NCT06090604|Experimental|Control of lateral COM motion during and after walking practiced in the MAE|"For Aim 1a, participant's preferred and fast treadmill walking speeds will be determined followed by 2-min of baseline walking. Each participant will perform eight 2-min trials of treadmill walking 1) Null Environment: no forces, 2) MAE Low Gain: 25 Nsm-1, 3) MAE Medium Gain: 35 Nsm-1, 4) MAE High Gain: 45 Nsm-1, that will be repeated at both treadmill walking speeds. The trial order will be randomized.~For Aim 1b, we will assess participant's maximum ability to control their lateral COM motion with no forces applied, using three 21-meter walking trials with visual projections on the treadmill to provide feedback used to challenge their lateral COM motion control. Five 2-min trials in a Null environment will be followed by COM control assessment. Participants will rest and repeat the above sequence in a MAE. The order of the external environments will be randomized across participants.~Participants may participate in more than one aim (1a, 1b and 2)."
89151189|NCT06090565|Experimental|Cefixime plus doxycycline|Single-dose cefixime 800 mg plus doxycycline 100 mg b.i.d. for 7 days
89151190|NCT06090565|Active Comparator|Ceftriaxone plus azithromycin|Single dose ceftriaxone 1 g plus single-dose azithromycin 2 g
89151191|NCT06089967||Immune checkpoint inhibitor treatment|Adult cancer patients starting standard of care immune checkpoint inhibitor therapy. Participants willing to provide biospecimens (blood, body fluids and/or tissue) for research purposes. Participants will be followed for samples, irAEs and clinical data for up to one year after the end of treatment.
89151192|NCT06089954|Other|ROR Arm 1|Disclosure of results with a Genetic Counselor.
89151193|NCT06089954|Experimental|ROR Arm 2|eHealth disclosure of results by private web-portal (with option to speak with a GC).
89151194|NCT06089876|Experimental|"Strava Application"|STRAVA is an application that allows you to record your physical activity. Using GPS, it allows you to record the distance traveled with different types of physical activity (walking, running, swimming, among others). In addition, it allows you to create a community and clubs within the same community with which you can propose group trails.
89151195|NCT06089876|No Intervention|Control Group|They will not use any type of sports technology application. They will continue to perform their daily activities without intervention.
89151196|NCT06088069|Experimental|Group VR|Patients will be virtually immersed into a natural universe and soft music for 15 minutes preoperatively and during surgery.
88804388|NCT05333497|Active Comparator|Conventional acupiont stimulation group|On the basis of the basic treatment in the Department of Acupuncture, the output mode of the fourth generation of low-frequency acupoint electric stimulation instrument of the original program is adopted to synchronously stimulate the flexor and extensor acupoints respectively. The selection of acupoints, treatment time and course of treatment were the same as those of the programmed acupoint electric stimulation group.
88804389|NCT05333497|No Intervention|Healthy controls|"No treatment. Ask them to do the reaching and retrieving gross motor and record the resting brain electrical and motion state of electrical parameters. Brain electric power spectrum analysis and electromyography synergy - coherence analysis are made to evaluate the brain energy state and degree of muscle coordination, for better interpreting the movement of the central nervous system control strategy and providing a reference for the prognosis of patients and the curative effect evaluation."
88804390|NCT05323448|Experimental|ARISTA|ARISTA-AH will be applied directly within the wound before closure.
89151197|NCT06088069|No Intervention|Group C|Patients will not receive Virtual reality (VR) experience.
89151198|NCT06087614|Experimental|Arm 3 - DE-HyART|The radiation dose will be similar to 'arm 2'. In addition, the HSV identified on baseline FMISO scans will be contoured, and an isotropic margin of 5 mm will be given. This volume will be boosted in phase II to a total dose of 80 Gy. (Addition of 30 Gy in 3 Gy daily fraction added in phase II as a simultaneous integrated boost - SIB).
89151199|NCT06087614|Active Comparator|Arm 2 - Hypoxic Comparator Arm|The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.
89151200|NCT06087614|Placebo Comparator|Arm 1 - Non-hypoxic arm|The patients will be treated with a standard of care where the treatment will not be controlled, and these patients will act as external control representing clinical practice. However, these patients will be discussed in the head and neck multispeciality clinic and follow the institutional approach. They will be subjected to treatment similar to 'arm 2' but are allowed protocol deviation as per treating radiation oncology discretion.
89151201|NCT06086080|Other|Control group|Standard care: knee brace for 2 weeks, physical therapy, sham taping (2-weeks)
89151202|NCT06086080|Experimental|Intervention group|Knee taping for 4-weeks, knee brace for 1 week, physical therapy
89151203|NCT06085612||Internal Carotid Artery Stenosis|Group of patients with internal carotid stenosis detected via ultrasound examination.
89151204|NCT06085612||Non stenotic Internal Carotid Artery|Group of patients without internal carotid stenosis on ultrasound examination.
89151205|NCT06084260|Active Comparator|Self-compassion group|Group meetings using a self-compassion approach related to body dissatisfaction and eating issues.
89151206|NCT06084260|Active Comparator|Diet group|Group meetings using a restricted diet approach related to body dissatisfaction and eating issues.
89151207|NCT06081257|Experimental|experimental group|"KB-120 small molecule nutrients, taken orally once a day in one bag (30ml), and vitamin E100mg taken orally 2 times a day for a total of 3 menstrual cycles"
89151208|NCT06081257|Active Comparator|control group|Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles
88804391|NCT05323448|Experimental|Control group|Participant will not receive the ARISTA-AH hemostatic agent.
88804392|NCT05318222|Other|WGS arm|All 100 patients recruited will undergo WGS
88804393|NCT05298670|Experimental|Metformin (Cidophage®) and Interferon Beta 1 a (Rebiff ® 44mcg or Avonex ®)|Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet twice daily for 6 months as add on therapy with Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®).
88804394|NCT05298670|Active Comparator|Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)|Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)
89234895|NCT05887947|Experimental|8 African America 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 5%|"8, African American, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234896|NCT05887947|Experimental|9 White 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 1.8%|"9, White, baseline smoking at enrollment is 1-10 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234897|NCT05887947|Experimental|10 White 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 5%|"10, White, baseline smoking at enrollment is 1-10 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234898|NCT05887947|Experimental|11 White 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 1.8%|"11, White, baseline smoking at enrollment is 1-10 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234899|NCT05887947|Experimental|12 White 1-10 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 5%|"12, White, baseline smoking at enrollment is 1-10 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234900|NCT05887947|Experimental|13 White 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 1.8%|"13, White, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89234901|NCT05887947|Experimental|14 White 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 1.8% 5% 5%|"14, White, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89151209|NCT06079632|Experimental|Single subject experiment|Each participant will first receive one-hour, one-on-one parent-child interaction strategy coaching every week via Telehealth until the parent's parent-child interaction skills and the child's social communication abilities reach a stable or upward trend, and the parent's sensory processing strategy utilization ability and the child's daily life participation scores that are continuously collected shows a stable or downward trend. After which, the one-hour, one-on-one sensory processing strategy coaching (C1) will be provided every week via Telehealth until the parent's sensory processing strategy utilization ability and the child's activity participation level reaches a stable trend.
89151210|NCT06079632|Experimental|RCT, Treatment group|Participant receive 12 weeks of sensory processing strategy coaching and parent-child interaction strategy coaching intervention.
89151211|NCT06079632|Active Comparator|RCT, Active Comparator|Participant will be provided with weekly self-learning materials and group discussion session for 12 weeks.
89151212|NCT06077071|Experimental|ViewRay MRidian|Participants will receive five (5) doses of radiation therapy over four (4) weeks. The first dose will be given during week 1; after at least 36 hours from the first dose, participants will receive the second dose. The remaining doses will be three (3) doses will be administered once per week during weeks 2, 3, and 4. The treatment plan may change at the discretion of the treating physician. Participants will have three additional doses each week in Weeks 2, 3, and 4.
88804395|NCT05297851||Cytoflavin|Patients who underwent reperfusion for acute stroke (intravenous thrombolysis and/or mechanical thrombectomy) and receive intravenous Cytoflavin® at a discretion of the physician, starting this treatment within the first 24 hours from the onset of stroke
88804396|NCT05297851||Control|Patients who underwent reperfusion for acute stroke (intravenous thrombolysis and/or mechanical thrombectomy) and do not receive Cytoflavin as part of their routine clinical practice, but may receive any other neuroprotective medications.
88804397|NCT05286294|Experimental|Treatment|Fecal Microbiota Transplant (FMT)
88804398|NCT05284955|Experimental|CardioMEMS HF System group|Pharmacological heart failure treatment guided by an implanted wireless pulmonary artery hemodynamic monitor (CardioMEMS HF system)
88804399|NCT05284955|Active Comparator|Standard of care|Standard heart failure medical treatment
88804400|NCT05277558||Normal Weight-Normal Glucose Tolerant (NW-NGT)|(1) a group that is the normal weight (BMI<85th%) and has normal glucose tolerance (NW-NGT)
89151213|NCT06072274|Experimental|Dementia VR education|The experimental group will participate in a dementia educational program combining VR lasting approximately 2-3 hours.The virtual reality educational modules predominantly offer first-person narratives that delineate various symptoms associated with dementia.
89151214|NCT06072274|No Intervention|Traditional dementia education (lecture)|The control group will receive traditional education on dementia which is primarily taught by instructors.
89151215|NCT06070714|Active Comparator|Holmium laser with pulse modulation|
89151216|NCT06070714|Active Comparator|Thulium fiber laser|
89151217|NCT06069531|Placebo Comparator|Lactobacillus johnsonii,|heat-killed Lactobacillus johnsonii TCI250
89151218|NCT06069531|Experimental|White pomegranate extract|White pomegranate extract, dosage of 500mg
89151219|NCT06063785||CF with liver affection|CF patients with proven CF hepatopathy
89151220|NCT06063785||CF without liver affection|CF patients without proven CF hepatopathy
89151221|NCT06063785||Healthy volunteers|Healthy volunteers without liver affection
89151222|NCT06062381|Experimental|Intervention Group|experimental group will receive abdominal massage of 20 minutes duration for 3 days.
89151223|NCT06062381|No Intervention|Control Group|control group will receive only routine care
89151224|NCT06059066|Active Comparator|Standard Injection Sites|Standard number of injections
89151225|NCT06059066|Experimental|Reduced Injection Sites|Reduced number of injections
89151226|NCT06052397||Sleep and Circadian Rhythms biomarker cohort|Cohort will complete a series of blood sample donations (both intraoperatively and postoperatively) as well as complete daily neurocognitive assessments at baseline and on PODs 1 - 3.
89151227|NCT06051539|Experimental|Cohort A: Restart Intervention|Participants in Cohort A will perform active walking for 30 minutes at a time with MR-001, at least 3 times a week, for 12 weeks in their home/community environment.
89151228|NCT06051539|No Intervention|Cohort B: Continued Washout|Participants in Cohort B will continue their washout period for another 24 weeks.
89151229|NCT06045598||type 2 diabetes group|Participants between the ages of 18-65 who have been diagnosed with Type 2 diabetes according to the criteria of the American Diabetes Association (ADA).
89151230|NCT06045598||control group|Healthy participants between the ages of 18-65 who have not been diagnosed with Type 2 diabetes
89151231|NCT06039930|Experimental|Tele-PROTECT (Effectiveness Aim, Abuse Impact Aim)|This group of participants will receive the Tele-PROTECT intervention, a behavioral intervention for depressed elder abuse (EA) victims designed to work in synergy with EA resolution services that provide safety planning, support services, and links to legal services.
89151232|NCT06039930|Active Comparator|Depression Education (DepEd) (Effectiveness Aim, Abuse Impact Aim)|This group of participants will receive the Depression Education intervention, an intervention designed with active therapeutic ingredients (education, support, empathy) and designed to be what a good clinician providing education would do with an individual with depression.
89151233|NCT06039930|No Intervention|Stakeholder Groups (Implementation Aim)|To address the Implementation Aim of the study, investigators will conduct qualitative data via surveys, interviews, and focus groups. Qualitative data from NAPSA surveys, interviews, and focus groups will be analyzed to identify barriers and facilitators to the implementation of Tele-PROTECT in elder abuse agencies nation-wide using a mixed methods design with multiple stakeholder groups (e.g., EA directors, staff) in collaboration with the National Adult Protective Services Association (NAPSA).
88804401|NCT05277558||Overweight and/or obese and has normal glucose tolerance (O-NGT)|(2) a group that is overweight and/or obese (BMI >85th%) and has normal glucose tolerance (O-NGT)
88804402|NCT05277558||Overweight and/or Obese and has dysglycemia (O-DG)|(3) group that is overweight and/or obese (BMI >85th%) and has dysglycemia (O-DG; fasting plasma glucose ≥100 mg/dl and/or 2-hour glucose ≥140 mg/dl oral glucose tolerance test (OGTT) and laboratory-based HbA1c ≥5.8 and ≤8.0%, if treatment naïve).
88804403|NCT05264038|Experimental|Cohort 1|Participants will receive either low dose level of OC514 or placebo
89151234|NCT06017869|Experimental|Autologous CD34+ cells enriched with allogenic placenta-derived mitochondria|
89151235|NCT06016608||Polyvascular disease|
89151236|NCT06011304|Experimental|18F-Florastamin Injection|
89151237|NCT06010199||Myocarditis group|All enrolled patients are administered antiviral drugs, glucocorticoids, immunoglobulins, and other standard treatments. Additionally, the decision to provide ECMO support therapy is based on the severity of the patient's condition.
89151238|NCT06006598|Experimental|BI 1584862 treatment arm|
89151239|NCT06006598|Placebo Comparator|Placebo arm|
89151240|NCT06006598|Experimental|BI 1584862 + midazolam treatment arm|
89151241|NCT06002867|Active Comparator|Group SAPB (Serratus anterior plane block)|"Active Comparator: Group SAPB (Serratus anterior plane block) After the operation is completed, the block operation will be performed while intubated. The patient will be in the supine position.~The area where the procedure will be performed will be cleaned with povidone iodine.~The latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs using a 22-gauge, 80 mm insulated Quincke type needle with the 'in plane' technique, accompanied by a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath. .~After the fascia between the two muscles is fixed, the block needle will be advanced from caudal to cranial and 40 ml (20 ml local anesthetic + 20 ml saline) 0.25% local anesthetic will be injected on the serratus muscle between the two muscles."
89151242|NCT06002867|No Intervention|Group Control|The action will not be applied
89151243|NCT05994703|Experimental|DCS with Juul e-cigarette|"d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks. There will be a 50 mg dose taken the afternoon/evening prior to the first switch date (after enrollment) to ensure serum levels of the medication are available for the first switch to e-cigarette attempt.~Participants will be instructed to use the Juul as often as they like during the 12 week period, and to switch completely to the Juul within 1 week. If, however, they do smoke any combustible cigarettes (CC), they will also be instructed to use the Juul immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The Juul will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute Juul for CCs by the end of the first week of use."
89151244|NCT05993078|Experimental|NS group|The patient will undergo NS 2000ml intravenous infusion swiftly after IVT.
89151245|NCT05993078|Placebo Comparator|Control group|The patient will not undergo 0.9% NaCl intravenous infusion after IVT.
89151246|NCT05989503|Active Comparator|Simultaneous initiation|ARNi (initial dose 24/26mg b.i.d. or 49/51mg b.i.d. titrated to 97/103mg b.i.d. preferably in the first 3-6 weeks, up to 3 months of follow-up) and SGLT2i (10mg q.d.) on the same day or within ± 5 days.
89151247|NCT05989503|Active Comparator|Sequential initiation|Initial (at randomization day) SGLT2i prescription (either empagliflozin or dapagliflozin, 10 mg q.d.) followed by an ARNi initiated between weeks 4 and 12 after randomization (sacubitril/valsartan at an initial dose of 24/26mg b.i.d. or 49/51mg b.i.d., and titrated to 97/103mg b.i.d. if tolerated, according to assistant physician decision)
89151248|NCT05978336|Experimental|Health Coaching (HC)|The health coaching program will be delivered by trained and certified kinesiologists utilizing Brief Action Planning (BAP) principals. The BAP behavior change approach utilizes the following 4 techniques: 1) goal-setting; 2 )action planning; 3) self-monitoring; and 4) feedback. Participants will utilize daily physical activity diaries to enable self-monitoring, and BAP coaches will provide feedback on progress toward individualized physical activity goals.
89151249|NCT05978336|Active Comparator|Health Education Program (ED)|This program is an attention control group, which consists of general health education. Education sessions will be delivered either by zoom or in person. The education sessions will cover the following topics: 1) falls prevention; 2) sleep; 3) healthy eating; 4) cognitive health; and 5) mental and emotional health.
89151250|NCT05976529||study group|From the 5th to 25th day of menstrual cycle, 10 mg dydrogesterone was taken orally twice a day for 3 menstrual cycles.
89151251|NCT05976529||control group|After postoperative pathological diagnosis, oral dienogest was started, 4 weeks as a course of treatment, and 3 courses of continuous treatment were given.
89151252|NCT05972018|Experimental|RSB LB/B|Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS) (30mL per side)
89151253|NCT05972018|Active Comparator|RSB/RSC Ropivacaine|"Rectus Sheath Block: Total 60mL of 0.2% ropivacaine (3 vials) (30mL per side)~+ Rectus Sheath Catheter intermittent hourly boluses of 0.2% ropivacaine 10mL/hr per side"
89151254|NCT05963828|Other|Standard group|Patients are managed according to the routine methods after enrollment.
89151255|NCT05963828|Experimental|Experimental group|Patients are managed by the social network platform.
89151256|NCT05960175|No Intervention|Standard CPAP telemonitoring|Patients are treated with CPAP and the home healthcare provider carries out monitoring in line with current practice (telemonitoring of treatment and regular home visits).
89151257|NCT05960175|Experimental|New CPAP telemonitoring approach|Patients are treated with CPAP and the home healthcare provider is offering a new approach to remote monitoring in which patients are involved in managing their CPAP treatment using two connected devices (the Scanwatch connected watch + the mobile application Asten&masanté) in the first 4 months of treatment.
89151258|NCT05953740|Experimental|Panel A|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 at a specified Dose 1 or a dose matched placebo (Period 2).
89151259|NCT05953740|Experimental|Panel B|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 2 or a dose matched placebo (Period 2).
89151260|NCT05953740|Experimental|Panel C|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 3 or a dose matched placebo (Period 2).
89151261|NCT05953740|Experimental|Panel D|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 4 or a dose matched placebo (Period 2).
89151262|NCT05953740|Experimental|Panel E|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 5 or a dose matched placebo (Period 2).
88804404|NCT05264038|Experimental|Cohort 2|Participants will receive either mid dose level of OC514 or placebo
89151263|NCT05953740|Experimental|Panel F|Participants receive 7 days of oral MK-8189 or matched placebo treatment (Period 1), followed by a single IM injection of MK-5720 at a specified Dose 6 or a dose matched placebo (Period 2).
89151264|NCT05952882|Experimental|LIME 3mg/1500mg|Metformin XR (extended-release) was initiated with a dose of 750 mg once per day for 2 week and increased to 1500 mg once per day for up to 12 weeks. Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), then titrated in increments of 0.6 mg once daily every 1 to 3 weeks to a final dose of 3.0 mg liraglutide SC daily for up to 12 weeks.
89151265|NCT05952882|Active Comparator|MET 1500mg|Metformin XR (extended-release) was initiated with a dose of 750 mg once per day for 2 week and increased to 1500 mg once per day for up to 12 weeks
89151266|NCT05951192|Experimental|Commercial daprodustat|Prescription of oral daprodustat in accordance with the FDA approved package label.
89151267|NCT05927649|Experimental|Sequence ABC|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo 450 mg and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment A (Period 1 from Day 1 - 15), Treatment B (Period 2 from Day 15 - 29), and Treatment C(Period 3 from Day 29 -32)
89151268|NCT05927649|Experimental|Sequence BAC|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo 450 mg and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment B (Period 1 from Day 1-15), Treatment A (Period 2 from Day 15 - 29, and Treatment C (Period 3 from Day 29 to 32)
89151269|NCT05927649|Experimental|Sequence ACB|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo 450 mg and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment A (Period 1 from Day 1-15), Treatment C (Period 2 from Day 15 -18), and Treatment B (Period 3from Day 18 - 32)
89151270|NCT05927649|Experimental|Sequence BCA|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment B (Period 1 from Day 1 - 15), Treatment C (Period 2 from Day 15 to 18), and Treatment A (Period 3 from Day 18 - 32)
89151271|NCT05927649|Experimental|Sequence CAB|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment C (Period 1 from Day 1 - 4), Treatment A (Period 2 from Day 4 - 18), and Treatment B (Period 3 from Day 18 - 32)
89151272|NCT05927649|Experimental|Sequence CBA|Subjects receive three treatments (A: omaveloxolone 450 mg, B: omaveloxolone matching placebo and C: moxifloxacin 400 mg) administered in a single dose with the standard FDA high-fat meal in three periods. Treatment C (Period 1 from Day 1 - 4), Treatment B (Period 2 from Day 4 - 18), and Treatment A (Period 3 from Day 18 - 32)
89151273|NCT05924295|Experimental|C8 Ketone Supplement|360mg/kg of supplement will be given on a singular testing day.
89151274|NCT05920603||School-aged children (6-12 years old) and women of reproductive age (15-49 years old)|300 healthy school-aged children (6-12 years old), and 300 healthy reproductive-aged women, aged (15-49 years old)
89151275|NCT05913713|Experimental|High Intensity Interval Training (HIIT)|Supervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
89151276|NCT05913713|Experimental|Moderate Intensity Continuous Training (MICT)|Supervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
89151277|NCT05913713|Other|Usual Care (UC)|Research participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise).
89151278|NCT05910333||Quadrilateral distribution group|Patients with quadrilateral distribution of implants
89151279|NCT05910333||Linear distribution group|Patients with lineardistribution of implants
89151280|NCT05893563||Direct Anterior|Patients who underwent the Direct Anterior (DA) surgical approach
89151281|NCT05893563||Direct Lateral|Patients who underwent the Direct Lateral (DL) surgical approach
89151282|NCT05881265|Experimental|Chi-Ven treatment|Patients receive chidamide and venetoclax treatment
89151283|NCT05879107|Experimental|Co-ad Group|Participants receive both the RSVPreF3 OA investigational vaccine and the PCV20 vaccine on Day 1.
89151284|NCT05879107|Active Comparator|Control Group|Participants receive the PCV20 vaccine on Day 1 and the RSVPreF3 OA investigational vaccine on Day 31.
89151285|NCT05871931|Experimental|Experimental|"Personal Information Form, Parents' Internalized Stigma in Mental Illnesses Scale and Psychological Well-Being Scale will be applied to the intervention group as part of the pre-test application. In order to provide individualized care in the research, face-to-face individual interviews will be conducted with each individual in the intervention group in line with the Tidal Model-based psychiatric nursing approach. The interview plan prepared in line with the Tidal Model-based psychiatric nursing approach to be applied to the mothers in the intervention group in the study consists of eight interviews. The average of the first and eighth interviews is 45-50 minutes; Other interviews are expected to last an average of 70-75 minutes."
89151286|NCT05871931|No Intervention|Control|"The mothers who met the inclusion criteria and agreed to participate in the study were informed about the research such as the subject, purpose and content of the research, their verbal and written consents were obtained, and the Personal Information Form, Parents' Internalized Stigma in Mental Illness Scale and '' An interview will be held with the aim of applying the Psychological Well-Being Scale pre-tests. A second interview will be held with the aim of applying the post-tests and conducting the interview on Self-Perception with the intervention group to the control group."
89151287|NCT05868785|Active Comparator|Nocturnal parenteral nutrition|Patients will receive nocturnal parenteral nutrition, starting at 8pm
89151288|NCT05868785|Experimental|Diurnal parenteral nutrition|Patients will receive diurnal parenteral nutrition, starting at 8am
89151289|NCT05851950|Experimental|rumination-focused cognitive behavioural group therapy|1 individual in-take session, 11 sessions of rumination-focused cognitive behavioural group therapy, 1 individual closing session.
89151290|NCT05851950|Active Comparator|Treatment as usual|standard OPUS treatment. OPUS treatment is handled by an interdisciplinary OPUS team and consists primarily of medical treatment, psychoeducation, training in symptom management and social skills as well as family discussions. All patients in OPUS have a contact doctor and a contact person who is responsible for coordinating the treatment and collaborating with municipal bodies.
89151291|NCT05841238|Experimental|LY3502970 (Part A)|The multiple doses of LY3502970 administered orally either in tablet or capsule formulations.
89151292|NCT05841238|Experimental|LY3502970 (Part B)|The multiple doses of LY3502970 administered orally in tablet formulation.
89151293|NCT05827900|Experimental|Intervention|Metacognitive Group Training
89151294|NCT05827900|No Intervention|Treatment as usual|Treatment as usual
89151295|NCT05826587|Active Comparator|Control group of cardiac rehabilitation only|
89151296|NCT05826587|Experimental|Intervention group of additional balance and muscle strength training|
89151297|NCT05816811|Experimental|Power Training|The program is intentionally designed with 3 progressive phases: Phase 1 Familiarization (Week 1) will allow participants to begin with a low-intensity version of the training program (body weight resisted or light weights at RPE 2-3 for 8 repetitions) to acclimate participants to the movements. Phase 2 Strength (Weeks 2-5) will progress in loads to achieve volitional fatigue between 5-8 repetitions (RPE 7-9). Phase 3 Power (Weeks 6-10) will use intensities between RPE 4-6 (15-20 repetitions) and execute each exercise at the highest possible velocity to focus on muscle power. The exercises, selected to emphasize functional movements relevant to daily activities.
89151298|NCT05808972|Active Comparator|Sodium chloride 0.9% (SC) arm|"The SC arm receives insulin therapy via an electric syringe (Actrapid HM ®, Novorapide®) (1 ml = 100 IU) - take 0.5 ml (= 40 IU) and complete to 50 ml with SC to obtain a solution of 1 ml = 1 IU. -Infusion rate = 0.1 IU/kg/h.~In parallel, and on an insulin-independent route, 0.9% chloride saline is started on the basis of 3 L/ 24 hours per day if capillary glyceamia>2,5 g/l . Blood samples were taken for glycemia, arterial Blood gas, electrolytes, lactate at baseline, 6, 12, 24 and 48 hours later."
89151299|NCT05808972|Active Comparator|Ringer lactate (RL) arm|"The SC arm receives insulin therapy via an electric syringe (Actrapid HM ®, Novorapide®) (1 ml = 100 IU) - take 0.5 ml (= 40 IU) and complete to 50 ml with SC to obtain a solution of 1 ml = 1 IU. -Infusion rate = 0.1 IU/kg/h.~In parallel, and on an insulin-independent route, Ringer lactate is started on the basis of 3 L/ 24 hours per day if capillary glyceamia>2,5 g/l . Blood samples were taken for glycemia, arterial Blood gas, electrolytes, lactate at baseline, 6, 12, 24 and 48 hours later."
89151300|NCT05806710|Experimental|dysphagic subjects|elderly patients with dysphagia
89151301|NCT05805592|Experimental|Intervention Group|"It is planned as 6 sessions, 1 session per week for children and parents. The program will be introduced to children and parents under the call with Screen-to-Move-Program (STEP). The symbol of the program has been created and this symbol will be hung on the classroom door. Sessions for children include story, picture, video demonstration and active playing activities. A more clear, simple and understandable language will be used for children, and reinforcements will be used. For parents; There will be 6 training sessions in the form of presentations. At the same time as the children's activities, information notes will be sent to the parents outlining the expectations. Before the intervention, after the intervention and in the 3rd month, children's screen use time, daily physical activity time, sleep time, parents' knowledge, behavior, attitude and self-efficacy about their children's screen use time will be evaluated."
89151302|NCT05805592|No Intervention|Control Group|Screen use time, daily physical activity time, sleep time, parents' knowledge, behavior, attitude and self-efficacy about children's screen use time will be evaluated simultaneously from the control group with the intervention group. After the 3rd month follow-up test, the STEP will be applied to the children and parents in the control group.
89151303|NCT05804123|Placebo Comparator|Control - Acute rhinosinusitis (ARS) subgroup|"The Control - ARS subgroup receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment (at the Thai Binh Medical University Hospital) is as follows:~Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic).~Oral-administrative expectorant: Acetylcysteine~Nasal- spraying decongestant: Xylometazoline (Otrivin®)"
89151304|NCT05804123|Experimental|Navax - Acute rhinosinusitis (ARS) subgroup|"Navax - ARS subgroup receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion Colony Forming Units (CFU)/5 mL (LiveSpo® Navax):~Routine treatment (at the Thai Binh Medical University Hospital) is as follows:~Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic).~Oral-administrative expectorant: Acetylcysteine~Nasal- spraying decongestant: Xylometazoline (Otrivin®)"
89151305|NCT05804123|Placebo Comparator|Control - ARS accompanied by the AOM (ARS & AOM) subgroup|"The Control - ARS & AOM subgroup receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment (at the Thai Binh Children's Hospital) is as follows:~Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic). Or injection or infusion-administrative antibiotics such as Imetoxim (Cefotaxime).~Antibiotic ear drops: Ciprofloxacin~Nasal- spraying decongestant: Xylometazoline (Otrivin®)"
89151306|NCT05804123|Experimental|Navax - ARS accompanied by the AOM (ARS & AOM) subgroup|"Navax - ARS & AOM subgroup receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion CFU/5 mL (LiveSpo® Navax):~Routine treatment (at the Thai Binh Children's Hospital) is as follows:~Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic). Or injection or infusion-administrative antibiotics such as Imetoxim (Cefotaxime).~Antibiotic ear drops: Ciprofloxacin~Nasal- spraying decongestant: Xylometazoline (Otrivin®)"
89151307|NCT05786469|Experimental|Participants randomized to receive one 8.4 g packet of patiromer per day|Patiromer is an organic, non-absorbed, sodium-free, potassium-binding polymer that exchanges potassium for calcium in the gastrointestinal tract.
88804405|NCT05264038|Experimental|Cohort 3|Participants will receive either high dose level of OC514 or placebo
89151308|NCT05786469|Placebo Comparator|Participants randomized to receive one identical packet containing placebo|Active study treatment and placebo will be provided by Vifor Pharma and will be indistinguishable from one another in terms of labelling and instructions
89151309|NCT05785780|Experimental|Targeted CRC Screening Toolkit|Based on national survey data and a community engagement participatory implemention planning group, a tailored combination of widely accepted implementation strategies will be adapted for targeting CRC screening for patients with diabetes. These strategies include but are not limited to: identification of patient and practice-level barriers, patient education, provider reminders, and audit and feedback.
89151310|NCT05780346|Experimental|CARE Parenting Group Treatment|Participants (i.e., caregivers of gender diverse youth) receive the CARE mentalizing-focused group parenting intervention.
89151311|NCT05777967|Experimental|Single Arm|
89151312|NCT05775432||Heart transplantation group|Patients with heart failure of different etiologies undergoing heart transplant.
89151313|NCT05775432||Control group|Individuals whose hearts are donated.
89151314|NCT05756907|Experimental|Dose Level 1|SON-1010 Dose Level 1 + Atezolizumab
89151315|NCT05756907|Experimental|Dose Level 2|SON-1010 Dose Level 2 + Atezolizumab
89151316|NCT05756907|Experimental|Dose Level 3|SON-1010 Dose Level 3 + Atezolizumab
89151317|NCT05756907|Experimental|Dose Level 4|SON-1010 Dose Level 4 + Atezolizumab
89151318|NCT05756907|Experimental|Dose Level 5|SON-1010 Dose Level 5 + Atezolizumab
89151319|NCT05756907|Experimental|RP2D Expansion in Patients with Platinum-resistant Ovarian Cancer|RP2D Dose of SON-1010 + Atezolizumab
89151320|NCT05756907|Experimental|Randomized Arm #1 in Patients with Platinum-resistant Ovarian Cancer|SON-1010 @ RP2D Alone
89151321|NCT05756907|Experimental|Randomized Arm #2 in Patients with Platinum-resistant Ovarian Cancer|SON-1010 @ RP2D + Atezolizumab
89151322|NCT05756907|No Intervention|Randomized Arm #3 in Patients with Platinum-resistant Ovarian Cancer|Standard of Care
89151323|NCT05748002||stable group|
89151324|NCT05748002||subclinical keratoconus|
89151325|NCT05748002||normal group|
89151326|NCT05748002||follow up group|
89151327|NCT05737849||Cohort 1: Participants With Positive EGFR ex20ins Detection|Participants with NSCLC having positive EGFR ex20ins detected by NGS were observed retrospectively for three years prior to leading site initiation.
89151328|NCT05737849||Cohort 2: Participants With Positive and Negative EGFR ex20ins Detection|Participants with NSCLC having positive and negative EGFR ex20ins NGS testing results were observed retrospectively for three years prior to leading site initiation.
89151329|NCT05735834|Experimental|Arm A - Rituximab + Zanubrutinib|"Zanubrutinib (160 mg BID orally continuous dosing) is administered for 12 cycles of 28 days each. After cycle 12:~Patients in Complete Response (CR) will stop treatment and enter the follow-up phase.~Patients in partial response (PR) will continue zanubrutinib treatment (160 mg BID orally continuous dosing) for 12 additional cycles of 28 days each for a total of 24 cycles.~Patients in stable disease (SD) or progressive disease (PD) will stop treatment and will enter the follow-up phase.~Rituximab is infused at the dose of 375 mg/m2 iv on days 1, 8, 15, and 22 of cycle 1 (28 days per cycle), then on day 1 of cycles 3, 6, 9, and 12 (28 days per cycle). After cycle 12:~Patients in CR will stop treatment and enter the follow-up phase.~Patients in PR will go on with rituximab 375 mg/m2 IV on day 1 of cycles 15, 18, 21, and 24 (28 days per cycle).~Patients in SD or PD will discontinue treatment and will enter the follow-up phase."
89151330|NCT05735834|Active Comparator|Arm B - Rituximab|"Rituximab is infused at the dose of 375 mg/m2 iv on days 1, 8, 15, and 22 of cycle 1 (28 days per cycle), then on day 1 of cycles 3, 6, 9, and 12 (28 days per cycle). After cycle 12:~Patients in CR will stop treatment and enter the follow-up phase.~Patients in PR will go on with rituximab 375 mg/m2 iv on day 1 of cycles 15, 18, 21, and 24 (28 days per cycle).~Patients in SD or PD will discontinue treatment and will enter the follow-up phase"
89151331|NCT05733403|Active Comparator|Stroke Volume Variation (SVV) Group|"When SVV value ≥ 14%, 250cc isotonic will be given within 10min. 250cc isotonic boluses will be repeated until the SVV drops below 14%. If MAP< 65 mmHg despite the SVV falling below 14%, a bolus of 4mcg noradrenaline(NA) will be administered. During the operation, if the SVV is below 14% and the MAP is < 65mmHg, a bolus of 4mcg NA will be administered.~Intraoperative balance, amount of bleeding, number of fluid boluses and NA administrations, total additional fluid and NA amount, total number of hypotensive episodes will be recorded.~The times when the breast tissue was removed, the weights of the removed tissues and the amount of bleeding will be recorded.~Basal and 3 more arterial blood gases will be taken when the breast tissue is removed and early postoperatively, and Hgb, lactate, and base excess values will be recorded. iNOS values in blood will be recorded after basal iNOS and breast tissue are removed.~The creatinine value will be recorded on the 1st postoperative day."
89151332|NCT05733403|Active Comparator|Mean Arterial Pressure (MAP) Group|"If MAP value under below 65mmHg, 250ml isotonic will be given within 10 min. However, if MAP is still below 65mmHg, a bolus of 4mcg NA will be administered, if no response, 4mcg NA will be repeated. If MAP falls below 65mmHg again, 250 ml isotonic will be administered again in 10 min; if it does not improve, 4mcg of NA will be given iv.~Intraoperative balance, amount of bleeding, number of fluid boluses and NA administrations, total additional fluid and NA amount, total number of hypotensive episodes will be recorded.~The times when the breast tissue was removed, the weights of the removed tissues and the amount of bleeding will be recorded.~Basal and 3 more arterial blood gases will be taken when the breast tissue is removed and early postoperatively, and Hgb, lactate, and base excess values will be recorded. iNOS values in blood will be recorded after basal iNOS and breast tissue are removed.~The creatinine value will be recorded on the 1st postoperative day."
89151333|NCT05719207|Experimental|Balloon dilation of eustachian tube|These patient will undergo balloon dilation dilation of the eustachian tube.
89151334|NCT05719207|Sham Comparator|Sham procedure|These patients will undergo a sham procedure, where the motions of balloon dilation of the eustachian tube will be simulated.
89151335|NCT05716919|Experimental|Cohort 1 - 4|Cohort 1 : 50 mg/day Cohort 2 : 100 mg/day Cohort 3: 200mg/day [Cohort 4: 300mg/day: based on the result of Safety Review Meeting (SRM)]
89151336|NCT05716919|Placebo Comparator|Placebo|
89151337|NCT05706883||Experimental group|Patients with advanced lung cancer featuring cervical and/or supraclavicular lymph node metastasis
89151338|NCT05706883||Control group|Patients with advanced lung cancer NOT featuring cervical and/or supraclavicular lymph node metastasis
89151339|NCT05681585|Other|Intervention arm|Clusters (medical/geriatric hospital units) in the intervention arm receives a comprehensive implementation support program during the trial period.
89151340|NCT05681585|No Intervention|Control arm|"Clusters (medical/geriatric hospital units) in the control arm receives no implementation support program during the trial period.~These units will receive the implementation support program after the trial period."
89151341|NCT05657873|Experimental|L-SABR Arm|Participants randomized to the experimental arm will continue with standard of care treatment but will also undergo radiation simulation for L-SABR/Liver Stereotactic Ablative Radiation Therapy.
89151342|NCT05657873|Active Comparator|Control Arm|Participants randomized to the control arm will be treated according to the standard of care.
89151343|NCT05647551|Experimental|JUVÉDERM fillers and BOTOX/VISTABEL|At Visit 1, JUVÉDERM filler injections (Juvéderm VOLBELLA with lidocaine, Juvéderm VOLIFT with lidocaine, and/or Juvéderm VOLUMA with lidocaine) will be administered. At Visit 4, JUVÉDERM VOLBELLA with lidocaine, may be administered in the infraorbital hollow (IOH)/tear trough (TT) area. At Visit 6, participants will receive BOTOX/VISTABEL. Touch-ups may be performed as required based on investigator's assessment.
89151344|NCT05641935|Experimental|Diagnostic (CEUS with MRI/CT)|Patients receive Lumason IV and undergo CEUS imaging with MRI/CT on study. Patients' electronic medical record is reviewed every 6 months throughout study.
89151345|NCT05641272|Experimental|Group I: sublingual allergoid-mannan conjugates (MM09 at 3.000 UTm/mL)|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy. The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
89151346|NCT05641272|Experimental|Group II: sublingual allergoid-mannan conjugates (MM09 at 9.000 UTm/mL)|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.. The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
89151347|NCT05641272|Placebo Comparator|Group III: sublingual placebo|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.The dose is 2 sprays daily applied to the sublingual mucosa for 6 months.
89151348|NCT05640414|Experimental|Weekly Family Food Packages|
89151349|NCT05640414|Experimental|Family Health Group Sessions|
89151350|NCT05627674|Active Comparator|Usual Care|Annual lung cancer screening with low-dose computed tomography (LDCT) is currently recommended in the U.S. for at-risk patients. Tobacco treatment and cessation is recommended for patients who smoke.
89151351|NCT05627674|Experimental|RiskProfile-Clin|RiskProfile-Clin is a clinically-informed risk feedback tool to activate cancer risk-reducing behaviors.
89151352|NCT05627674|Experimental|RiskProfile-Gen|RiskProfile-Gen is a genetically-informed risk feedback tool to activate cancer risk-reducing behaviors.
89151353|NCT05625802|Experimental|Erector Spinae Plane Block (ESPB)|
89151354|NCT05625802|No Intervention|External control|
89151355|NCT05622942|Experimental|Recombinant Pneumococcal Protein Vaccine（PBPV）|Subjects received 1 dose of PBPV
89151356|NCT05622942|Active Comparator|Pneumococcal Polysaccharide Vaccine-23-valent (PPV23)|Subjects received 1 dose of PPV23
89151357|NCT05603559|Experimental|177Lu-P17-087 arm|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
89151358|NCT05603559|Experimental|177Lu-P17-088 arm|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
89151359|NCT05602727|Experimental|MK-1942 5 mg|Participants will receive a single 5 mg MK-1942 capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
89151360|NCT05602727|Experimental|MK-1942 15 mg|Participants will receive a single 8 mg MK-1942 capsule twice daily (BID), taken orally for one week. Then the dose is titrated up to 15 mg MK-1942 capsule twice daily (BID), taken orally for up to 11 weeks.
89151361|NCT05602727|Placebo Comparator|Placebo|Participants will receive a placebo capsule twice daily (BID), taken orally for 12 weeks. A mock titration will be done to maintain the study blind despite no changes in dose.
89151362|NCT05596994|Active Comparator|Light Intervention Therapy (LIT) then Sham LIT|The LIT will begin at the patient's home and will be presented for 10 weeks. A washout period of 1 month will be scheduled to diminish carryover effects of the first therapy arm, then patients will begin the Sham LIT.
89151363|NCT05596994|Active Comparator|Sham LIT then Light Intervention Therapy|LIT will be performed identical to Arm 1, except for switchover of active LIT and Sham. A washout period of 1 month will be scheduled to diminish carryover effects of the LIT arm.
89151364|NCT05593731|Other|dental implants alone|dental implants alone
89151365|NCT05593731|Active Comparator|platelet rich fibrin|dental implants with platelet rich fibrin membrane
89151366|NCT05593731|Active Comparator|melatonin gel|dental implants with melatonin gel around dental implants
89151367|NCT05592366|No Intervention|Standard of Care|Participants in this arm will only receive standard of care.
89151368|NCT05592366|Experimental|Adjusted CHAT-AD|Using CHAT, participants will be asked questions about their needs to fully support and care for their loved one after the loved one is released from the hospital.
89151369|NCT05589870||Clinical pharmacists group|A group of patient files that were evaluated by the clinical pharmacists, Insights Insights were categorized according to five categories: 1) duplication of therapy, 2) age-related issues, 3) incorrect dose, 4) current side effects and 5) future side effects risks. An external judging committee comprised of two (2) senior clinical pharmacy doctors, who were blinded to the source of the conclusion sheets, adjudicated the MDI system and clinical pharmacist insights.
89151370|NCT05589870||MDI system group|A group of patient files that were evaluated by the MDI system. Insights were categorized according to five categories: 1) duplication of therapy, 2) age-related issues, 3) incorrect dose, 4) current side effects and 5) future side effects risks. An external judging committee comprised of two (2) senior clinical pharmacy doctors, who were blinded to the source of the conclusion sheets, adjudicated the MDI system and clinical pharmacist insights.
89151371|NCT05585164|Experimental|Engage & Connect|
89151372|NCT05581849|Experimental|Prolonged Nightly Fasting (PNF)|Participants will engage in the PNF (14+ hours a night of fasting and no calorie containing food or beverages) for 8 weeks.
89151373|NCT05581849|Active Comparator|Health Education Control (HEC)|Participants in HEC group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks.
89151374|NCT05571943|Experimental|Difamilast Ointment 1%|A thin layer of Difamilast applied to affected areas twice daily (morning and evening, approximately 12 hours apart)
89151375|NCT05565430||Healthy Control|"Acute Hyperventilation and effects on vocal cord movement.~Chronic Hyperventilation and effects on vocal cord movement.~Effects of anticholinergic medication on paradoxical vocal cord movement."
89151376|NCT05565430||Mild Asthmatics|"Acute Hyperventilation and effects on vocal cord movement.~Chronic Hyperventilation and effects on vocal cord movement.~Effects of anticholinergic medication on paradoxical vocal cord movement."
89151377|NCT05565430||Severe Asthmatics|"Acute Hyperventilation and effects on vocal cord movement.~Chronic Hyperventilation and effects on vocal cord movement.~Effects of anticholinergic medication on paradoxical vocal cord movement."
89151378|NCT05556798|Experimental|Belantamab Mafodotin and Nirogacestat|There will be a 1:1 randomization betweennirogacestat 100 mg BID or 100 mg QD during the 4day run-in period prior to starting belantamab mafodotin on Cycle 1 Day 1 (days -4 to -1). The cycle length for Cycles 1-3 is 21 days (3 weeks). Treatment with nirogacestat will be 100 mg BID continuously during each cycle for all subjects. Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3 and nirogacestat 100mg BID will be administered continuously on Days 1-21 of each cycle. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg. Pomalidomide was added, 2 mg to the 1.4 mg/kg and 1.9 mg/kg dose cohorts.
89151379|NCT05546710|Experimental|Treatment Arm|miraDry treatment
89151380|NCT05527197|Other|Patient reported function of daily ADL's post combined first MTP/TMT joint arthrodesis|Patients that meet the inclusion criteria will be contacted for participation in the study. If the patient agrees to participate in the study, informed consent will be obtained. The retrospective study will consist of a chart review and baseline radiographic analysis. The prospective follow-up will consist of the patient completing the Post-Operative Function and Satisfaction Survey via phone call with study staff. Radiographic images will be analyzed by a single central radiologist.
89151381|NCT05524428|Other|Introduction of Implementation Strategies|The investigators will determine the best intervention and strategy (and thus implementers) based on high ranking barriers/facilitators identified in focus groups. A minimum of 2 implementation strategies will be developed and implemented at each level (patient, provider, system) at each site that considers (1) implementation strategy; (2) mechanism in which the strategy impacts the identified determinant (3) the determinant; (4) moderators that may influence the impact of the strategy; (5) the preconditions necessary for successful implementation; and (6) implementation outcomes affected. Each community health center (CHC) will serve as its own separate subject, and individual strategies will be tested using single case experimental design (SCED) at each CHC using component analysis to rapidly test and optimize our strategies. In SCED each subject serves as their own control, an intervention is systematically introduced and withdrawn, and the effects of the intervention are measured.
89151382|NCT05524428|No Intervention|Withdrawal of Implementation Strategies|In SCED each subject serves as their own control, an intervention is systematically introduced and withdrawn, and the effects of the intervention are measured.
89151383|NCT05481658|Experimental|Diphencyprone (DPCP)|0.4% and 0.04% ointment
89151384|NCT05478005|Experimental|Femoral nerve block|Patients undergoing total knee arthroplasty received a single-shot femoral nerve block during the surgical procedure.
89151385|NCT05478005|Experimental|Intra-articular block|Patients undergoing total knee arthroplasty received a intra-articular block during the surgical procedure.
89151386|NCT05478005|No Intervention|Control group|Patients undergoing total knee arthroplasty and didn't receive pain block.
89151387|NCT05477277|Experimental|Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomes|
89151388|NCT05476913|Experimental|geko™ T-3 interventional|The geko™ device will be applied bilaterally as soon as possible after randomisation and each geko™ device will be used to deliver one 24-hour dose. Devices will be worn continuously and changed every 24 hours. Treatment will be continued for a maximum of 30 days or until patient recovers mobility and is discharged, whichever comes earlier.
89151389|NCT05476913|No Intervention|Intermittent Pneumatic Compression (IPC)|Control treatment will be IPC using NHS approved devices as used for standard clinical care. They will be applied to both legs as soon as possible after randomisation. They will not be changed unless damaged or soiled. Treatment will be continued for a maximum of 30 days or until patient recovers mobility and is discharged, whichever comes earlier.
89151390|NCT05459922|Experimental|Bright light therapy group|Participants will receive 30-minute morning bright light therapy for 2 weeks. Participants will start the therapy within a few minutes of their designated wake up time, which is determined by their average wake time from the baseline week of sleep assessment.
89151391|NCT05459922|Placebo Comparator|Dim light (placebo) group|Participants will receive 30-minute dim light (placebo) therapy for 2 weeks. Participants will start the therapy within a few minutes of their designated wake up time, which is determined by their average wake time from the baseline week of sleep assessment.
89151392|NCT05446038|Experimental|Multifamily Guided Self-Help Family-Based Treatment (MF-GSH-FBT)|Treatment consists of up to 12 once-weekly online group sessions, where groups are made up of parents from 4-5 different families of young people with Anorexia. Group sessions will last approximately 50-60 minutes. Prior to each group session, parents watch recorded videos about how parents can help their child with Anorexia. Only parents, and not the young person with Anorexia, attend the group sessions.
89151393|NCT05443932|Other|Washout Phase and treatment arms|"At first there will be wash-out phase I with daily placebo administration for all participants. All patients will receive blood- and 24h-urine screenings in week 0 and 6 to get baseline data and also a low-dose native CT of the urinary tract in week 6. In preparation of the HCT phase all participants will daily receive an oral placebo.~In week 7 the HCT phase will start and all patients will receive an oral therapy with 50mg of HCT daily; the treatment response will be evaluated by blood- and urine test after 4 weeks of therapy (week 10).~After that, in washout phase II, the same test as before will be performed in week 0 and 6 (weeks 15 and 20).~At the end another therapy phase with an oral administration of 10mg dapagliflozin daily will be performed; the treatment response will be evaluated by blood- and urine test after 4 weeks of therapy (week 25).~Finally, the same tests as before will be performed in wash-out phase III in week 0 and 6 (weeks 29 and 34)."
89151394|NCT05436795|Experimental|Interventional Arm|In the interventional arm, we will offer a self-administered supervised COVID-19 testing strategy with an investigational device - Abbott's Panbio COVID-19 Antigen Self-test. The self-test process will be facilitated by the COVIDSmart CARE! digital App and platform. Suspected COVID-19 patients will be triaged into one of three action plans: a) clinical care pathways, b) prevention (home quarantine, isolation) pathways, or c) social distancing.
89151395|NCT05436795|No Intervention|Conventional Arm|"Participants presenting to test for SARS-CoV-2 will be staged on their self-reported severity of symptoms (mild, moderate, severe) and tested with rapid antigen tests, followed by RT-PCR testing. Suspected COVID-19 patients will be triaged into one of three action plans: a) clinical care pathways, b) prevention (home quarantine, isolation) pathways, or c) social distancing.~Conventional arm is the standard of care arm."
89151396|NCT05429528|No Intervention|Control Arm (Arm 1)|Participants will experience a default version of NUSMart which replicates the traditional shopping experience of online grocery stores with no FOP labels.
89151397|NCT05429528|Experimental|Implicit Tax Arm (Arm 2)|Similar to Arm 1 except that an implicit tax is levied on qualifying beverages.
89151398|NCT05429528|Experimental|Explicit Tiered Tax Arm (Arm 3)|Similar to Arm 1 except that an explicit tiered tax is levied on qualifying food and beverage products.
89151399|NCT05429502|Experimental|Phase I-part A: Ribociclib+TOTEM|Participants with r/r NB, MB, HGG, MRT or RMS will be treated with ribociclib in combination with TOTEM to determine MTD and/or RP2D. Ribociclib dose will be scalated while topotecan and temozolomide will be administered at a fixed dose.
89151400|NCT05429502|Experimental|Phase I- Part B: r/r NB Cohort|Participants with r/r NB will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
89151401|NCT05429502|Experimental|Phase I- Part B: r/r MB Cohort|Participants with r/r MB will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
89151402|NCT05429502|Experimental|Phase I-Part B: r/r HGG Cohort|Participants with r/r HGG will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
89151403|NCT05429502|Experimental|Phase I-Part B: r/r MRT Cohort|Participants with r/r MRT will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
89151404|NCT05429502|Experimental|Phase I- Part B: r/r RMS Cohort|Participants with r/r RMS will be treated with ribociclib in combination with TOTEM at the PR2D identified from Phase I-Part A
89151405|NCT05429502|Experimental|Phase II- Ribociclib+TOTEM|Participants with r/r NB will be treated with ribocilib in combination with TOTEM at the RP2D defined from Phase I part A.
89151406|NCT05429502|Placebo Comparator|Phase II: Placebo+TOTEM|Participants with r/r NB will be treated ribociclib matching placebo in combination with TOTEM
89151407|NCT05426434|Active Comparator|SP + DP placebo every 4 weeks|Control arm
89151408|NCT05426434|Experimental|SP + DP given every 4 weeks|Intervention arm
89151409|NCT05426343|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89151410|NCT05426343|Active Comparator|AZD1222|n=ChAdOx1 nCoV-19 vaccine
89151411|NCT05413915|Active Comparator|Imatinib|Standard of care imatinib at 300 or 400 mg PO daily for 52 weeks
89151412|NCT05413915|Experimental|Imatinib and Asciminib|Asciminib (60 mg PO daily for 52 weeks) will be added to standard of care imatinib (300 or 400 mg PO daily for 52 weeks)
89151413|NCT05412004|Experimental|Tirzepatide Maximum Tolerated Dose|"Participants will receive a low dose and then increase to a maximum tolerated dose 1 or dose 2 subcutaneously (SC).~GPI1: Participants are unwilling or unable to use PAP therapy.~GPI2: Participants are on PAP therapy."
89151414|NCT05412004|Placebo Comparator|Placebo|"Participants will receive placebo SC~GPI1: Participants are unwilling or unable to use PAP therapy.~GPI2: Participants are on PAP therapy."
89151415|NCT05411120|Experimental|Long-term a Intervention: CLEAN-MED|Study arm will consume a Mediterranean like diet, while tracking their food intake for 12 months
89151416|NCT05411120|Experimental|Short-term, Western Diet, high MedDiet score a Intervention: C|Study arm will consume a Mediterranean like diet, while tracking their food intake for 9 weeks, With high MEdDIet score.
89151417|NCT05411120|Experimental|Short-term, Western Diet, high MedDiet score a Intervention: W|Study arm will consume a Mediterranean like diet, while tracking their food intake for 9 weeks, With high MEdDIet score.
89151418|NCT05411120|Experimental|Short-term, Western Diet, low MedDiet score a Intervention: CL|Study arm will consume a western diet eating as they normally would for 9 weeks. With low MEdDIet score.
89151419|NCT05411120|Experimental|Short-term, Western Diet, low MedDiet score a Intervention: We|Study arm will consume a Mediterranean like diet, while tracking their food intake for 9 weeks. With low MEdDIet score.
89151420|NCT05389449|Experimental|Danicopan|Participants will receive their last dose of danicopan from the parent study the night prior to Day 1 of this LTE study and will continue daily treatment with danicopan together with their background C5i therapy.
89151421|NCT05381818|Experimental|Daily IMT (dIMT)|IMT (inspiratory muscle training) is a treatment strategy aimed to strengthen the muscles of inspiration, the diaphragm and external intercostals, by increasing their force-generating capacity. Participants in the dIMT (daily IMT) will complete daily inspiratory training exercises 2-4 weeks prior to surgery. A pressure threshold training device containing an adjustable-tension spring to provide resistance during inspiration will be used. Subjects will complete 5 sets of 5 maximal volume and speed breaths daily at a pressure 70% of MIP and will rest 1 minute between sets. They will be asked to keep a log to track their sessions to evaluate compliance with the exercise regimen.
89151422|NCT05381818|Active Comparator|Acute IMT (aIMT)|Patients in the aIMT (acute IMT) experimental group will complete a single session of IMT guided by a physical therapist within 30 minutes of anesthesia induction in addition to standard of care. The adjustable pressure threshold training device to provide resistance during inspiration will be used. Subjects will complete 5 sets of 5 maximal volume and speed breaths, and rest 1 minute between sets. The training intensity will be set at 70% of MIP.
89151423|NCT05381818|Active Comparator|Standard of Care (SOC)|The SOC group will receive the usual surgical standard of care only.
89151424|NCT05377333|Experimental|LY3457263 (Alone)|LY3457263 administered subcutaneously (SC).
89151425|NCT05377333|Placebo Comparator|Placebo (Alone)|Placebo administered SC.
89151426|NCT05377333|Experimental|LY3457263 + Dulaglutide|LY3457263 in combination with dulaglutide administered SC.
89151427|NCT05377333|Experimental|Placebo + Dulaglutide|Placebo in combination with dulaglutide administered SC.
89151428|NCT05370781|Experimental|Peer led diabetes self-management support (PLDSMS)|Participants in the PLDSMS arm will receive 10 hours of diabetes self-management education (DSME) with a certified diabetes care and education specialist. This group will then transition into monthly 90-minute diabetes self-management support (DSMS) with trained peer leaders for 6 months. After the DSMS sessions, the group will transition into 6 months of ongoing support and will be encouraged to continue DSMS through initiatives that are important to them.
89151429|NCT05370781|Active Comparator|Control Group|Participants in the control group will receive 10 hours of diabetes self-management education (DSME) with a certified diabetes care and education specialist.
89151430|NCT05366816|Experimental|Group A: KIT Exon 13 receiving Sunitinib|Participants with KIT mutation on exon 13 will receive Sunitinib. Participants showing disease progression after first-assigned Sunitinib therapy have the option to receive Regorafenib therapy. Total allotted time for treatment is up to 12 months.
89151431|NCT05366816|Experimental|Group B: KIT Exon 17 receiving Regorafenib|Participants with KIT mutation on exon 17 will receive Regorafenib. Participants showing disease progression after first-assigned Regorafenib therapy have the option to receive Sunitinib therapy. Total allotted time for treatment is up to 12 months.
89151432|NCT05364762|Experimental|Prevention (PBSCs, cyclophosphamide, itacitinib, tacrolimus)|Patients undergo peripheral blood stem cell infusion on day 0. Patients receive cyclophosphamide IV QD on days 3 and 4, itacitinib PO QD on days 5-100, and tacrolimus IV or PO on days 6-65.
89151433|NCT05354505|Experimental|Treatment|GOLDBAL2 balloon will be placed for Fetus diagnosed with Congenital diaphragmatic hernia (CDH) at Gestational age of 27w0d - 29w6d and retrieved at Gestational age of 34w0d to 34w 6 days
89151434|NCT05318508||patients with low back pain|
89151435|NCT05318508||patients without low back pain|
89151436|NCT05304793|Experimental|Arm I (TAB)|Patients participate in 4 weekly TAB in-person or video conference sessions over 1 hour each that provide them with skills to cope with their dyspnea. Patients also receive treatment handouts, a CD with an audio file with instructions for progressive muscle relaxation, and a pulse oximeter. Patients may receive additional support calls over 10-15 minutes from the TAB provider within 1 week following each session.
89151437|NCT05304793|Active Comparator|Arm II (usual care)|Patients receive usual management of dyspnea from the treating physician.
89151438|NCT05301335|Experimental|Therapeutic Arm|
89151439|NCT05301335|Sham Comparator|Sham Arm|
89151440|NCT05296057|Experimental|Participants Receiving VR-Exposure Therapy Treatment|All participants will be receiving the experimental VR-exposure therapy treatment.
89151441|NCT05288855|Experimental|Voclosporin treatment group 1|2 capsules (15.8 mg) BID of voclosporin
89151442|NCT05288855|Placebo Comparator|Placebo treatment group|2 capsules BID of placebo
89151443|NCT05288855|Experimental|Voclosporin treatment group 3|3 capsules (23.7 mg) BID of voclosporin
89151444|NCT05288855|Experimental|Voclosporin treatment group 4|Maximum dose of 4 capsules (31.6 mg) BID of voclosporin.
89151445|NCT05287256|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
89151446|NCT05287256|Experimental|Oral administration of 10mg D-8-THC|Single acute administration of cannabis containing 10mg Delta-8-THC baked into a brownie
89151447|NCT05287256|Experimental|Oral administration of 20mg D-8-THC|Single acute administration of cannabis containing 20mg Delta-8-THC baked into a brownie
89151448|NCT05287256|Experimental|Oral administration of 40mg D-8-THC|Single acute administration of cannabis containing 40mg Delta-8-THC baked into a brownie
89151449|NCT05287256|Experimental|Oral administration of 20mg D-9-THC|Single acute administration of cannabis containing 20mg Delta-9-THC baked into a brownie
89151450|NCT05287256|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
89151451|NCT05287256|Experimental|Administration of vaporized 10mg D-8-THC|Single acute administration of placebo cannabis containing 10mg Delta-8-THC via commercial vaporizer
89151452|NCT05287256|Experimental|Administration of vaporized 20mg D-8-THC|Single acute administration of placebo cannabis containing 20mg Delta-8-THC via commercial vaporizer
89151453|NCT05287256|Experimental|Administration of vaporized 40mg D-8-THC|Single acute administration of placebo cannabis containing 40mg Delta-8-THC via commercial vaporizer
89151454|NCT05287256|Experimental|Administration of vaporized 20mg D-9-THC|Single acute administration of placebo cannabis containing 20mg Delta-9-THC via commercial vaporizer
89151455|NCT05258357|Active Comparator|Landmark|For a landmark bone marrow biopsy procedure, the patient is first positioned either prone or lateral decubitus. The lateral, superior iliac crest is palpated and an attempt is made to follow the course of the posterior iliac crest until the posterior superior iliac spine (PSIS) is palpated. Additionally, the gluteal cleft is visualized indicating the patient midline. The area over the sacrum at midline is then palpated, proceeding laterally until the PSIS can be felt. The skin is marked with a marker at the estimated PSIS and point of entry.
89151456|NCT05258357|Experimental|Ultrasound-Assisted|"After the usual landmark technique is performed and the potential site has been marked, procedure team physician will use the ultrasound machine to fine tune the drill site location."
89151457|NCT05256654|Experimental|LY3561774 Dose 1|Participants will receive LY3561774 subcutaneously (SC)
89151458|NCT05256654|Experimental|LY3561774 Dose 2|Participants will receive LY3561774 SC
89151459|NCT05256654|Experimental|LY3561774 Dose 3|Participants will receive LY3561774 SC
89151460|NCT05256654|Placebo Comparator|Placebo|Participants will receive placebo
89151461|NCT05255237|Experimental|Jaktinib|Patients will administer the study product twice per day for 24 weeks, for the safty assessment.
89151462|NCT05241613|Experimental|AC176 Dose Escalation as Single Agent|Single agent dose escalation of AC176. AC176 will be given orally (PO) on a 28-day cycle.
89151463|NCT05239182|Experimental|9-ING-41 plus Retifanlimab plus Gem/Abraxane|"intravenous (IV) infusion of nab-paclitaxel at a dose of 125 mg per square meter, followed by an infusion of gemcitabine according to the gemcitabine label at a dose of 1000 mg per square meter, on days 1, 8, 15 of a 28-day cycle.~Retifanlimab 500 mg IV on day 1 of a 28-day cycle. (Retifanlimab will be administered following gemcitabine/nab-paclitaxel.)~9-ING-41 administered at a dose of 9.3 mg/kg by IV infusion twice weekly on Days 1 and 4 of each week of a 28-day cycle. (9-ING-41 will be administered following retifanlimab.)"
89151464|NCT05235061|Experimental|PTE Participant Group 1|"PTE Participant Group 1 will receive the HOBSCOTCH-PTE intervention consisting of 1:1 sessions delivered once per week including:~1 pre-HOBSCOTCH Session (on webcam)~1 educational session (on webcam)~6 telephone sessions~1 wrap-up session (webcam or telephone)"
89151465|NCT05235061|Other|PTE Participant Group 2|"PTE Participant Group 2 will be on a 3-month wait list after which they will receive HOBSCOTCH-PTE consisting of 1:1 sessions delivered once per week including:~1 pre-HOBSCOTCH Session (on webcam)~1 educational session (on webcam)~6 telephone sessions~1 wrap-up session (webcam or telephone)"
89151466|NCT05235061|Experimental|PTE Caregiver Group 1|Caregiver Group 1 will receive an adapted version of HOBSCOTCH-PTE by attending session 1 of the HOBSCOTCH-PTE (virtual) program with their PTE patient as well as guidance and instructions on utilizing quick relaxation. Caregiver Group 1 will also attend session 8 of the program with the PTE patient to focus on program wrap-up and maintenance planning.
89151467|NCT05235061|Other|PTE Caregiver Group 2|Caregiver Group 2 will be on a 3 month wait list with their PTE patient after which time they will receive an adapted version of HOBSCOTCH-PTE by attending session 1 of the HOBSCOTCH-PTE (virtual) program with their PTE patient as well as guidance and instructions on utilizing quick relaxation. Caregiver Group 2 will also attend session 8 of the program with the PTE patient to focus on program wrap-up and maintenance planning.
89151468|NCT05231642|Experimental|Low GI|Consumption of standardised low-GI mixed-macronutrient breakfast-based meal followed by a standardised low-GI mixed-macronutrient lunch meal 4 hours later.
89151469|NCT05231642|Experimental|High GI|Consumption of a standardised high-GI mixed-macronutrient breakfast-based meal followed by a standardised high-GI mixed-macronutrient lunch meal 4 hours later.
89151470|NCT05226624|Experimental|Rooming-in care|Rooming-in care
89151471|NCT05226624|Active Comparator|Base line|Base line prior to implementation
89151472|NCT05214794|Experimental|nemolizumab|
89151473|NCT05207397||Healthy Control|Lactate clamp: After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. The investigator will then administer priming doses of 57.5 mg [3-13C]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of [3-13C]lactate at 10 mg/min and D2-glucose at 2 mg/min. Along with the continuous isotope infusion the investigator will begin infusion of the Na-lactate at approximately 2.6mg/kg·min. Based upon readings from blood samples during the infusion, this rate will be adjusted as needed to maintain the target lactate concentration of approximately 4-5 mM. Blood samples will be drawn at 10, 20, 30, 45, 60, 75, 90 and 120 minutes, while breath samples will be collected at 60, 75, 90 and 120 minutes.
89151474|NCT05207397||Mild Cognitive Impairment|Lactate clamp: After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. The investigator will then administer priming doses of 57.5 mg [3-13C]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of [3-13C]lactate at 10 mg/min and D2-glucose at 2 mg/min. Along with the continuous isotope infusion the investigator will begin infusion of the Na-lactate at approximately 2.6mg/kg·min. Based upon readings from blood samples during the infusion, this rate will be adjusted as needed to maintain the target lactate concentration of approximately 4-5 mM. Blood samples will be drawn at 10, 20, 30, 45, 60, 75, 90 and 120 minutes, while breath samples will be collected at 60, 75, 90 and 120 minutes.
89151475|NCT05204667|Experimental|Methocarbamol 380 mg/paracetamol 300 mg (4 times/day)|Patients treated with two oral tablets of methocarbamol 380 mg/paracetamol 300 mg 4 times/day up to 7 days (i.e., every 6 hours±1 hour).
89151476|NCT05204667|Active Comparator|Methocarbamol 380 mg/paracetamol 300 mg (6 times/day)|Patients treated with two oral tablets of methocarbamol 380 mg/paracetamol 300 mg 6 times/day up to 7 days (i.e., every 4 hours±1 hour).
89151477|NCT05198596|Experimental|MVC-COV1901|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89151478|NCT05198596|Active Comparator|AZD1222|ChAdOx1 nCoV-19 vaccine
89151479|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A
89151480|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B
89151481|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C
89151482|NCT05163561|Active Comparator|Sii Licensed IPV|Sii Licensed IPV
89151483|NCT05157620|Experimental|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
89151484|NCT05157620|Active Comparator|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
89151485|NCT05142696|Experimental|Dose Level 1 (DL1)|Dose Level 1 (DL1): [177Lu]Lu-DOTA-TATE 100 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 100 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
89151486|NCT05142696|Experimental|Dose Level 2a (DL2a)|Dose Level 2a (DL2a): [177Lu]Lu-DOTA-TATE 150 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 150 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
89151487|NCT05142696|Experimental|Dose Level 2b (DL2b)|Dose Level 2b (DL2b): [177Lu]Lu-DOTA-TATE 150 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 200 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
89151488|NCT05142696|Experimental|Dose Level 3a (DL3a)|Dose Level 3a (DL3a): [177Lu]Lu-DOTA-TATE 200 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 200 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
89151489|NCT05142696|Experimental|Dose Level 3b (DL3b)|Dose Level 3b (DL3b): [177Lu]Lu-DOTA-TATE 200 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 250 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
89151490|NCT05142696|Experimental|Dose Level 4 (DL4)|Dose Level 4 (DL4): [177Lu]Lu-DOTA-TATE 250 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 250 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
89151491|NCT05134311|Experimental|3D-US|These subjects will have a 3D rendering of their vascular testing shown to them.
89151492|NCT05134311|No Intervention|Standard US|These subjects will be shown a hand drawn sketch of the results of the vascular testing.
89151497|NCT05091021||University of Colorado Health New Nurses (Day Shift Workers)|Day shift work group nurses have greater than 50% of their shifts as day shifts.
89151498|NCT05091021||University of Colorado Health New Nurses (Night Shift Workers)|Night shift work group nurses have greater than 50% of their shifts as night shifts.
89151499|NCT05086978||Heart Failure out-patients|Subjects with heart failure of any etiology
89151500|NCT05086978||Heart Failure in-patients|Subjects with heart failure of any etiology
89151501|NCT05085275|Experimental|Ferric citrate|Supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.
89151502|NCT05085275|Placebo Comparator|Placebo|Tablets, matching in color and size to ferric citrate.
89151503|NCT05074277|No Intervention|Control (8 hours nocturnal sleep)|Inpatient protocol involves 8-hour sleep opportunity during the biological night throughout.
89151504|NCT05074277|Experimental|Simulated Night Shift Work|Two inpatient stays, each involving a baseline night, followed by a 3-hour afternoon nap opportunity, and then three 12-hour night shifts, with 8-hour daytime sleep opportunity in between.
89151505|NCT05070013|Experimental|Adaptive DBS stimulation|Subjects experience adaptive stimulation during one week of at-home night sleep.
89151506|NCT05070013|Active Comparator|Open-loop DBS stimulation|Subjects experience open-loop stimulation (standard clinical stimulation therapy based on DBS programming for the treatment of motor symptoms) during one week of at-home night sleep.
89151507|NCT05070013|No Intervention|No DBS Stimulation|DBS stimulation is turned off (control) during one week of at-home night sleep.
89151508|NCT05049785|Active Comparator|Arm I (counseling)|Patients attend 13 nutrition counseling sessions over 45 minutes each for 1 year. Patients may receive nutrition handouts.
89151509|NCT05049785|Experimental|Arm II (nutrition and PA intervention)|Patients attend 2 tasting sessions for low-fat and low-sugar recipes and complete 2 PA sessions over 1 hour for each session.
89151510|NCT05042518|Experimental|Intervention group|The participant in the intervention group will practice breathing control and self-talk with objectives for relaxation. The duration of training is 4-5 minutes in each session, 4 sessions per week for 1 month.
88804406|NCT05263440|Experimental|Experimental: Female participants with Depression|Female participants with mild to severe depression to determine if a single-session of tDCS can alter negative attention bias. The primary objective is to study if single-session tDCS will affect attention bias in depression and is not meant to treat depression.
89151511|NCT05042518|Placebo Comparator|Control group|The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month).
89151512|NCT05030012|Experimental|Automated Control (OAM)|In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be adjusted by the Oxygen Assist Module (OAM) to keep the infants pulse oxygen saturation within a target range (90-95%). Clinical staff will have the ability to override FiO2 levels when required, and instructed to do so.
89151513|NCT05030012|Active Comparator|Manual Control (Manual)|In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be manually adjusted by clinical staff to keep infants' oxygen saturation between 90-95%.
89151514|NCT05005208|Experimental|Rehabilitation Group|PD subjects will be going through a rehabilitation program based on an Irish dance with the support of the technological platform SI-ROBOTICS
89151515|NCT05002478|Experimental|Prone Group|Turn patient in prone position after surfactant administration. After 6 hours turn patient in supine position and perform EIT and LUS.
89151516|NCT05002478|No Intervention|Supine Group|Leave patient in supine position after surfactant administration. After 6 hours perform EIT and LUS.
89151517|NCT04993352|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody.
89151518|NCT04977401|Sham Comparator|Group Glycerol|Submucosal injection using glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
89151519|NCT04977401|Active Comparator|Group Gel ORISE|Submucosal injection using ORISETM gel during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.
89151520|NCT04950465|Experimental|Test Dentifrice|Apply a full ribbon of toothpaste on the head of the toothbrush provided. Brush teeth for 1*-timed minute, followed by brushing of the qualifying sensitive teeth. Following brushing rinse once with 10 milliliter (ml) of water from the rinsing cup provided.
89151521|NCT04950465|Active Comparator|Negative Control|Apply a full ribbon of toothpaste on the head of the toothbrush provided; brush teeth for 1* timed minute. Following brushing rinse once with 10 ml of water from the rinsing cup provided.
89151522|NCT04950465|Active Comparator|Positive Control|Apply a full ribbon of toothpaste on the head of the toothbrush provided; brush teeth for 1* timed minute. Following brushing rinse once with 10 ml of water from the rinsing cup provided.
89151523|NCT04936464|Experimental|Intervention Group|30-minute treatments, twice weekly x12 weeks
89151524|NCT04936464|Sham Comparator|Sham Group|30-minute treatments, twice weekly x12 weeks
89151525|NCT04931862|Experimental|WVE-004 (Dose A) or placebo|
89151526|NCT04931862|Experimental|WVE-004 (Dose B) or placebo|
89151527|NCT04931862|Experimental|WVE-004 (Dose C) or placebo|
89151528|NCT04931862|Experimental|WVE-004 (Dose D) or placebo|
89151529|NCT04927702|Experimental|Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)|Biweekly (every 2 weeks) application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
89151530|NCT04927702|Active Comparator|Diabetic Foot Ulcer Participants Assigned to Standard of Care|Weekly application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
89151531|NCT04927702|Experimental|Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)|Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
89151532|NCT04927702|Active Comparator|Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)|Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)
89151533|NCT04914663|Experimental|All-extremity exercise|
89151534|NCT04914663|Active Comparator|Treadmill exercise|
89151535|NCT04914663|No Intervention|Usual Care|
89151536|NCT04910685|Experimental|(Part 1) BLU-263 Dose 1 + BSC|Patients will receive best supportive care (BSC) and Dose 1 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
89151537|NCT04910685|Experimental|(Part 1) BLU-263 Dose 2 + BSC|Patients will receive best supportive care (BSC) and Dose 2 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
89151538|NCT04910685|Experimental|(Part 1) BLU-263 Dose 3 + BSC|Patients will receive best supportive care (BSC) and Dose 3 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily until completion of Part 1.
89151539|NCT04910685|Placebo Comparator|(Part 1) Placebo + BSC|Patients will receive best supportive care (BSC) and matching placebo tablets. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily until completion of Part 1
89151540|NCT04910685|Experimental|(Part 2) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily for approximately 24 weeks
89151541|NCT04910685|Placebo Comparator|(Part 2) Placebo + BSC|Patients will receive best supportive care (BSC) and matching placebo tablets. BSC will be determined on a per patient basis. Placebo will be administered orally, once daily once daily for approximately 24 weeks
89151542|NCT04910685|Experimental|(Part 3) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablet in an open-label fashion for up to 5 years.
89151543|NCT04910685|Experimental|(Part M) BLU-263 RD + BSC|Patients will receive best supportive care (BSC) and the recommended dose (RD) of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally, once daily for the duration of participation in the study.
89151544|NCT04910685|Experimental|PK Groups (Dose 2 or Dose 3)|Patients will receive best supportive care (BSC) and Dose 2 or Dose 3 of BLU-263 tablets. BSC will be determined on a per patient basis. BLU-263 will be administered orally for the duration of participation in the study.
89151545|NCT04907825|Experimental|Pharmacist Intervention Arm|Pharmacist to prescribe/monitor/manage oral anticoagulation therapy for atrial fibrillation stroke prophylaxis (under collaborative practice agreement with participants primary care provider) in accordance with ACC/AHA/HRS Guidelines.
89151546|NCT04907825|Active Comparator|Enhanced Usual Care Control Arm|Pharmacist to notify primary care provider that patient has 'actionable' atrial fibrillation and provide current medication list.
89151547|NCT04900935|Experimental|POISE|"The intervention will be a structured palliative care intervention in which patients will meet with a palliative care clinician who has been trained on a manual with specific topics to be covered in each of the four visits:~Three surveys: baseline, 12-week, and 20-week post-enrollment~Four 60-minute visits with a trained palliative care clinician~Semi-structured exit interview~Chart review"
89151548|NCT04900935|No Intervention|Usual care|Patients randomized to usual care will receive usual oncology care. They may access standard palliative care as clinically indicated.
89151549|NCT04889547|Experimental|Dexamethasone|Patient will receive intraoperative dexamethasone during distal radius open reduction and internal fixation
89151550|NCT04889547|Placebo Comparator|No dexamethasone|Patient will not receive intraoperative dexamethasone during distal radius open reduction and internal fixation
89151551|NCT04887285|Experimental|Virtual reality (VR)|Subjects in the VR group will be fitted with an HTC headset and headphones with disposable ear covers. They will choose from a menu of 6 different programs. They will also receive 1% superficial anesthesia.
89151552|NCT04887285|Active Comparator|Sedation|Conscious sedation will be accomplished by the use of midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). All medications will be titrated to conscious sedation by a board-certified anesthesiologist. Subjects will also receive 1% superficial anesthesia.
89151553|NCT04887285|Other|Standard care|Patients in this arm will be administered only 1% lidocaine as superficial anesthesia, similar to the other 2 arms.
89151554|NCT04887194|Experimental|Phase 1, Part 1: Sitravatinib monotherapy (DDI cohort)|To evaluate the potential for drug-drug interactions (DDI) with sitravatinib monotherapy. To determine the effect of sitravatinib on the pharmacokinetics (PK) of midazolam (CYP3A4 probe substrate), warfarin (CYP2C9 probe substrate), dextromethorphan (CYP2D6 probe substrate), rosuvastatin (BCRP probe substrate), and digoxin (P-gp probe substrate).
89151555|NCT04887194|Experimental|Phase 1, Part 1: Sitravatinib monotherapy (QTc cohort)|To evaluate the QTc prolongation risk for sitravatinib in patients with advanced/metastatic solid tumors via C-QTc modeling.
89151556|NCT04887194|Experimental|Phase 1, Part 2: Combination Therapy (both DDI and QTc cohorts)|To evaluate safety and tolerability of Sitravatinib treatment with the addition of the checkpoint inhibitor nivolumab.
89151557|NCT04857320|Experimental|Main Experimental|Each subject will receive doses applied to the skin of 0.075 IUs / Kilogram Body Weight, 0.1 IUs/Kilogram Body Weight and 0.15 IUs /Kilogram Body Weight
89151558|NCT04842266||Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis|Patients are being targeted because they have already agreed to the undergo the IlluminOss Pelvic Implant for standard clinical care. Patient-reported outcome surveys will be administered pre-operatively, as well as at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years after surgery.
89151559|NCT04842266||Pelvic fragility fracture in a geriatric patients (age 65 or older)|Patients are being targeted because they have already agreed to the undergo the IlluminOss Pelvic Implant for standard clinical care. Patient-reported outcome surveys will be administered pre-operatively, as well as at 2 days, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years after surgery.
89151560|NCT04818840||Resurfaced/non patella|Undergoing Total Knee Replacement with JOURNEY II CR Total Knee System
89151561|NCT04818840||un-resurfaced patella|Undergoing Total Knee Replacement with JOURNEY II CR Total Knee System
89151562|NCT04812444|Experimental|Zylox Peripheral Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
89151563|NCT04812444|Active Comparator|Zilver Vena Venous Stent Implantation|Percutaneous stent placement in the iliofemoral veins
89151564|NCT04807894|Experimental|Vaginal Testosterone Cream Arm|Women enrolled in this arm will receive vaginal testosterone cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.
89151565|NCT04807894|Placebo Comparator|Vaginal Placebo Cream Arm|Women enrolled in this arm will receive vaginal placebo cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.
89151566|NCT04807439||SYNERGY XLV (Megatron) Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
89151567|NCT04805866||Healthy Age-matched controls|Healthy individuals ages 18-85
89151568|NCT04805866||Inpatients poststroke|Individuals post acute or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-85
89151569|NCT04798989|Experimental|CY6463|
89151570|NCT04798989|Placebo Comparator|Placebo|
89151571|NCT04781868|Experimental|Multi-nutrient supplement|
89151572|NCT04781868|Placebo Comparator|Placebo supplement|
89151573|NCT04776317|Experimental|Stage 1 (Naïve) Group 1|5 x 10^10 viral particles of ChAdV68-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=4
89151574|NCT04776317|Experimental|Stage 1 (Naïve) Group 3A|30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=3
89151575|NCT04776317|Experimental|Stage 1 (Naïve) Group 3B|30 mcg SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-LNP-S administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=7
89151576|NCT04776317|Experimental|Stage 1 (Naïve) Group 4|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=3
89151577|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 13|5 x 10^10 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and on or after Day 113 in participants older than 60 years of age. N=7-10
89151578|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 14|1 x 10^11 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
89151579|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 15|5 x 10^11 viral particles of ChAdV68-S-TCE administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=7-10
89151580|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 10A,B|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
89151581|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 11A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8-12
89151582|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 12A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=8-12
89151583|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after approved/licensed mRNA COVID-19 Vaccines) Group 9|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=8
89151584|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 5|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
89151585|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 6|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
89151586|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 7A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=8-12
89151587|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after EUA/licensed mRNA COVID-19 Vaccines) Group 8A,B|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=8-12
89151588|NCT04772612|Experimental|Sitravatinib in healthy subjects|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in healthy subjects.
89151589|NCT04772612|Experimental|Sitravatinib in subjects with mild hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with mild hepatic impairment
89151590|NCT04772612|Experimental|Sitravatinib in subjects with moderate hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with moderate hepatic impairment
89151591|NCT04772612|Experimental|Sitravatinib in subjects with severe hepatic impairment|Participants will receive a single dose of sitravatinib 100 mg receive on Day 1 in subjects with severe hepatic impairment
89151592|NCT04756687||All Participants|RRMS participants treated with DMF will be identified in the Observatoire Français de la Sclérose en Plaques (OFSEP) database for OFSEP sites.
89151593|NCT04752332|Experimental|Abemaciclib Plus (+) Endocrine Therapy (ET)|Abemaciclib administered orally and standard adjuvant ET (physician's choice) administered according to package label.
89151594|NCT04752332|Active Comparator|Placebo + ET|Placebo administered orally and standard adjuvant ET (physician's choice) administered according to package label.
89151595|NCT04735185|Active Comparator|Intradiscal autologous stem cells|Participants in this arm will have autologous stem cells harvested through bone marrow aspiration. The stem cells that were harvested will be processed and injected into affected intradiscal spaces in the lumber spine.
89151596|NCT04735185|Active Comparator|Intradiscal corticosteroid and local anesthetic|Participants in this arm will receive an intradiscal injection of the steroid methylprednisolone and the local anesthetic bupivacaine into affected intradiscal spaces in the lumber spine.
89151597|NCT04701827|Experimental|Intervention group|AWARE intervention
89151598|NCT04701827|No Intervention|Control group|Treatment as usual (consisting of the standard out-patient mental health service routines in The Capital Region of Denmark)
89151599|NCT04701268|Experimental|Intervention/treatment|Implantation of the Hemiverse Shoulder Prothesis
89151600|NCT04689880||XLIF Decade Plate|
89151601|NCT04684264|Experimental|Pharmacist-directed collaborative practice|Participants will be referred to a pharmacist-directed collaborative practice for heart failure prevention.
89151602|NCT04684264|No Intervention|Usual care|Participants will receive usual care with their primary care physician.
89151603|NCT04671212||Orthopedic Surgery Patients|Participants receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.
89151604|NCT04670445|Experimental|Refine Intervention and Study Procedure|"Small open pilot (n=10) to refine the intervention and study procedures.~The study will involve three surveys (one before first infusion, one after, and one six weeks later).~An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video~Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team."
88804407|NCT05252598|Placebo Comparator|Placebo Arm|9 placebo pills and 1 non-hallucinogenic Chaga (Inonotus obliquus) mushroom powder capsule to mimic the after-taste of active Psilocybin pills (Psilocybe cubensis)
89151605|NCT04670445|Experimental|Educational Video and QPL List|"Randomized into Intervention Arm~The study will involve three surveys (one before first infusion, one after, and one six weeks later).~An educational video regarding the risks, benefits, and potential outcomes of immunotherapy treatment and reviewing an immunotherapy-focused QPL prior to ICI initiation or PDF alternative to the video~Question-prompt list (QPL) -list of suggested questions that participant can choose to raise with the oncology team.~Audio Recorded Conversation with oncologist"
89151606|NCT04670445|Active Comparator|Usual Care|"Randomized into Usual Care Arm~The control group will have three surveys (one before first infusion, one after, and one six weeks later)~Audio Recorded Conversation with oncologist"
89151607|NCT04647708|Experimental|Part A (Cohort 1): M5049 Dose A|
89151608|NCT04647708|Experimental|Part A (Cohort 2): M5049 Dose B|
89151609|NCT04647708|Experimental|Part A (Cohort 3): M5049 Dose C|
89151610|NCT04647708|Experimental|Part A (Cohort 4): M5049 Dose D|
89151611|NCT04647708|Placebo Comparator|Part A: Placebo|
89151612|NCT04647708|Experimental|Part B (Cohort 5): M5049 Dose E|
89151613|NCT04647708|Placebo Comparator|Part B: Placebo|
89151614|NCT04646395|Experimental|Tafasitamab and Acalabrutinib|"Acalabrutinib will be administered continuously at the dose of 100 mg BID (equivalent to a total daily dose of 200 mg), from day 1 to day 28 of each cycle for 24 cycles.~Tafasitamab will be administered 12 mg/kg iv on days 1, 8, 15 and 22 for the first 3 cycles. Then patients will continue treatment until cycle 24 with tafasitamab 12mg/kg iv on day 1"
89151615|NCT04631055|Experimental|DCB group|use intracranial drug coated balloon catheter made by Acotec Scientific Co.,Ltd.
89151616|NCT04631055|Active Comparator|Stent group|use the Intracranial Stent System made by MicroPort.
89151617|NCT04621760|Experimental|HIV Prevention DST Intervention|Participants in this arm will receive the HIV prevention DST intervention and will receive the intervention immediately before their provider visit.
89151618|NCT04621760|Active Comparator|Standard Counseling|Participants in this arm will receive usual care.
89151619|NCT04614480|Other|Metastatic breast cancers|
89151620|NCT04614480|Other|Metastatic prostate cancers|
89151621|NCT04614480|Other|Metastatic lung cancers|
89151622|NCT04614480|Other|Metastatic colorectal cancers|
89151623|NCT04614480|Other|metastatic otorhinolaryngeal cancer|
89151624|NCT04614480|Other|metastatic ovarian cancer|
89151625|NCT04614480|Other|Pancreatic cancers|
89151626|NCT04614480|Other|Others metastatic cancers|
89151627|NCT04614480|Other|Metastatic sarcoma|
89151628|NCT04588025|Active Comparator|Healthy Volunteers|
89151629|NCT04588025|Active Comparator|Pancreatic Cancer Participants|
89151630|NCT04585217|Active Comparator|Plain gut suture on right eyelid|Plain gut suture closure of blepharoplasty incision
89151631|NCT04585217|Active Comparator|Polypropylene suture on right eyelid|Polypropylene suture closure of blepharoplasty incision
89151632|NCT04566666|Placebo Comparator|Placebo of SCD-044 product|Placebo of SCD-044 study drug
89151633|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 tablets at Dose 1
89151634|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 tablets at Dose 2
89151635|NCT04566666|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 tablets at Dose 3
89151636|NCT04560803|Experimental|Epidermal Grafting|This irradiated area of the skin will be treated with autologous epidermal grafts
89151637|NCT04560803|No Intervention|No treatment|This irradiated area will not receive any treatment
89151638|NCT04552522|Experimental|Shrimp allergy with Intend to eat shrimp|Case shrimp Immunoglobulin E mediated allergy and intend to eat shrimp and start oral immunotherapy for shrimp
89151639|NCT04552522|No Intervention|Shrimp allergy with avoid shrimp|Case shrimp allergy with avoid shrimp
89151640|NCT04532411||Pre-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing prior to implementation of the Hexapod personal protective booths.
89151641|NCT04532411||Post-Booth Testing|This cohort was comprised of samples acquired as a component of outpatient SARS-CoV-2 (COVID-19) testing after implementation of the Hexapod personal protective booths.
89151642|NCT04529564||EAP patients|The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in Taiwan during 2018 to 2019.
89151643|NCT04525716||COVID-19|Patients with confirmed COVID-19 infection
89151644|NCT04525716||Non-COVID-19|Patients without confirmed COVID-19 infection
89151645|NCT04518046|Experimental|Phase 1: Dose Escalation|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment.
89151646|NCT04518046|Experimental|Phase 1b Dose Escalation Cohort A|Patients with poor- or intermediate-risk RCC with clear cell component for first-line treatment
89151647|NCT04518046|Experimental|Phase 1b Dose Escalation Cohort B|Patients with favorable-risk RCC with clear cell component for first-line treatment.
89151648|NCT04498364|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 8 hours of treatment.
89151649|NCT04495816|Active Comparator|Omega-3|1,000 mg of omega-3 fatty acid (2 softgels per day for 6 weeks)
89151650|NCT04495816|Sham Comparator|Placebo/Control|2 softgels per day for 6 weeks
89151651|NCT04485052|Experimental|IBI188+azacitidine|1L unfit AML receive IBI188 every week by intravenous(IV) and azacitidine daily in Day 1-7 of each four weeks(Q4W) by subcutaneous(IH)
89151652|NCT04485052|Experimental|IBI188+decitabine|R/R AML receive IBI188 every week by intravenous(IV) and decitabine daily in Day 1-10 of each four weeks(Q4W) by subcutaneous(IH)
89151653|NCT04476940|Experimental|COVID BF-Support|COVID-19 breastfeeding guideline education and support for pregnant women.
89151654|NCT04447183|Experimental|Test group|The test group of patients who took thyroid hormone medicine and were euthyroid [i.e. their thyroid stimulating hormone (TSH) levels are normal], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
89151655|NCT04447183|Experimental|Control group|The control group of patients did not take thyroid hormone medicine so that they were hypothyroid (i.e. their TSH levels were high,TSH≥30mU/L), and were given oral radioiodine.
89151656|NCT04445987|Experimental|Long-term safety of ARQ-154|Open-label, Long-term Safety of ARQ-154
89151657|NCT04408170||Work Stream A|Patients that are recruited in hospital with either query COVID-19 or who have tested positive for COVID-19.
89151658|NCT04408170||Work Stream B|Known COVID-positive and/or COVID-negative community testing
89151659|NCT04408170||Work Stream C|Undifferentiated community testing
89151660|NCT04392479|Active Comparator|Aflibercept-FOLFIRI (arm 1)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),~Irinotecan (D1) H+1: 180mg/m² IV infusion over 60min (+ 2-minute window),~5-fluorouracile (D1) H+3: 400mg/m² IV infusion over 15min (+ 2-minute window),~5-fluorouracile (D1 to D3): H+3.5: 2400mg/m² IV infusion over 46 hours (+ 1hour window)~H+49.5: End of treatment administration"
89151661|NCT04392479|Experimental|Aflibercept-mFOLFIRI3 (arm 2)|"Aflibercept (D1) H0: 4mg/kg IV infusion over 60min (+ 2-minute window),~Folinic acid (D1) H+1: 400mg/m² IV infusion over 120min (+ 2-minute window),~Irinotecan (D1 and D3) H+1 and H+49: 75mg/m² IV infusion over 60min (+ 2-minute window) on cycles 1 and 2, then 90mg/m² at cycle 3 and furthers in absence of AEs grade ≥2,~5-fluorouracile (D1 to D3) H+3: 2400mg/m² IV infusion over 46 hours (+ 1hour window)~H+50: End of treatment administration"
89151662|NCT04377529|Experimental|Back Skills Training Champion|In additional to access to the online provider Back Skills Training course, participants in clusters randomised to this arm will receive additional support from a local champion. The local champion will have received additional training and support on the implementation of the Back Skills Training intervention from the study team.
89151663|NCT04377529|Active Comparator|No Champion|Participants in clusters randomised to this arm will not receive any additional training or support beyond access to the online provider Back Skills Training course.
89151664|NCT04367675|Experimental|INO-5401|Participants receive INO-5401 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
89151665|NCT04367675|Experimental|INO-5401 and INO-9012|Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
89151666|NCT04366102|Experimental|Group A|Multisensory stimulation and soft tissue therapy
89151667|NCT04366102|Experimental|Group B|Routine Hospital care
89151668|NCT04344795|Experimental|TPST-1495 monotherapy dose escalation|Subjects will receive escalating doses of TPST-1495 administered orally twice daily until maximum tolerated dose is reached or until disease progression
89151669|NCT04344795|Experimental|TPST-1495 monotherapy dose and schedule optimization|Subjects will receive alternative TPST-1495 administration schedules until RP2D for the selected schedule is determined or until disease progression.
89151670|NCT04344795|Experimental|TPST-1495 monotherapy dose expansion|Subjects will receive selected dose regimen from dose and schedule optimization stage until disease progression
89151671|NCT04344795|Experimental|TPST-1495 in combination with pembrolizumab dose and schedule optimization|Subjects will receive alternative TPST-1495 administration schedules in combination with pembrolizumab until RP2D for the selected schedule is determined or until disease progression.
89151672|NCT04344795|Experimental|TPST-1495 in combination with pembrolizumab dose expansion|Subjects will receive selected dose regimen from dose and schedule optimization stage until disease progression
89151673|NCT04324359|Experimental|SURF-201|0.2% topical preservative-free corticosteroid solution (0.2% betamethasone sodium phosphate)
89151674|NCT04324359|Placebo Comparator|Vehicle|Topical preservative-free vehicle (Placebo)
89151675|NCT04309669|Experimental|Tot'hema|three ampoules per day during 12 weeks daily dose: 150mg of iron per day.
89151676|NCT04308785|Experimental|Arm A: Atezolizumab + Tiragolumab|Participants will receive atezolizumab + tiragolumab intravenously on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and tiragolumab treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
89151677|NCT04308785|Experimental|Arm B: Atezolizumab + Placebo|Participants will receive atezolizumab + placebo on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and placebo treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
89151678|NCT04289324|Experimental|Intervention|lung recruitment maneuvers performed every twelve hours during HFOV
89151679|NCT04289324|No Intervention|Control|no regular lung recruitment maneuvers during HFOV
89151680|NCT04277858|Experimental|Neoadjuvant chemotherapy and surgery|"Docetaxel and Cisplatin x 3 cycles followed by Transoral robotic surgery and neck dissection.~Carboplatin may be used instead of Cisplatin."
89151681|NCT04267562|Other|Single-Arm, Open-Label Treatment with the Minitouch System|Eligible participants will undergo a single treatment (endometrial ablation) with the Minitouch System
89151682|NCT04256850|Experimental|Acceptance and Commitment Therapy (ACT)|Focuses on addressing cognitive and emotional barriers to successful weight loss maintenance.
89151683|NCT04256850|Experimental|Self-Regulation (SR)|Focuses on using self-monitoring and self-reinforcement techniques to improve weight loss maintenance.
89151684|NCT04246489|Experimental|Bintrafusp alfa|
89151685|NCT04191486|Experimental|T-817MA (448 mg)|
89151686|NCT04191486|Placebo Comparator|Placebo|
89151687|NCT04166773|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
89151688|NCT04166773|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
89151689|NCT04166773|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
89151690|NCT04166773|Placebo Comparator|Placebo|Placebo administered SC once a week.
89151691|NCT04157790|No Intervention|Neutral|Suggested to follow European Society of Cardiology guidelines for NSTEMI
89151692|NCT04157790|Active Comparator|CARE score|calculation of the CARE score and prescription for troponins assays or not according to the result (score > 1: troponins assays ; score < 2: no troponins assays)
89151696|NCT04135963||Participants with MM|Participants diagnosed with MM from 8 investigative sites will be observed retrospectively for previous 5 years before enrollment until Day 1.
89151697|NCT04135547|Experimental|intra-osseous access, IO at the humeral site|the OHCA patients receiving IO at the humeral site by paramedics in the field
89151698|NCT04135547|Active Comparator|intravenous access; IV at the upper limb|the OHCA patients receiving IV at the upper limb by paramedics in the field
89151699|NCT04121858|Experimental|Brain Safe App|1)Brain Safe App provides conversation starters for older adult patients on target anticholinergics. The conversation starters assist the patient to have discussions with their physicians regarding reduction in exposure to prescription anticholinergics. 2) Provides anticholinergic risk assessment.
89151700|NCT04121858|Sham Comparator|Attention Control App|1) Attention Control App provides a medication list for older patients to use but lacks the conversation starters for patient to use with there physicians aimed at reduction in exposure to prescription anticholinergics.2) No anticholinergic risk assessment.
89151701|NCT04104672|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The dose expansion dose level will be determined in this part with escalating doses of AB680 in combination with Zimberelimab at the recommended phase 2 dose (RP2D) and the standard nab-paclitaxel and gemcitabine chemotherapy regimen in participants with advanced pancreatic cancer.
89151702|NCT04104672|Experimental|Dose Expansion(AB680+Zimberelimab+nab-paclitaxel(NP) & gemcitabine (Gem):Cohort A1 (front-line/1L)|Participants with advance pancreatic cancer, naïve to any prior treatment will receive AB680 (at the RP2D identified during dose escalation) combined with Zimberelimab and the standard nab-paclitaxel (NP) and gemcitabine (Gem) (NP/Gem) chemotherapy regimen
89151703|NCT04104672|Experimental|Dose Expansion (AB680 + NP/Gem): Cohort A2 (front-line/1L)|Participants with advance pancreatic cancer who are naïve to any prior treatment will receive AB680 (at the RP2D identified during dose escalation) and the standard NP/Gem chemotherapy regimen.
89151704|NCT04104672|Experimental|Dose Expansion (AB680 + Zimberelimab + NP/Gem): Cohort B (second-line/2L)|Participants with advance pancreatic cancer who have received 1 prior line of treatment will receive AB680 (at the RP2D identified during dose escalation) combined with Zimberelimab and NP-Gem chemotherapy regimen.
89151705|NCT04104672|Experimental|Dose Expansion (AB680 + Zimberelimab + NP/Gem): Cohort C (front-line/1L)|Participants with advance pancreatic cancer naïve to any prior treatment will receive AB680 combined with Zimberelimab and NP-Gem chemotherapy regimen.
89151706|NCT04101955|Other|Incisionless Threaded Carpal Tunnel|
89151707|NCT04101955|Other|Standard Mini-Open Carpal Tunnel|
89151708|NCT04095338|Active Comparator|control group|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks
89151709|NCT04095338|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks.
89151710|NCT04095338|Experimental|robotic treadmill arm|Ten traditional physical treatment sessions divided into 2 training sessions per week for 5 weeks.
89151711|NCT04091217|Experimental|Atezolizumab + Bevacizumab|
89151712|NCT04090359|Experimental|Dual Mobility|If patients are randomized to the dual mobility cohort, they will receive a dual mobility prosthesis at the surgeon's discretion. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
89151713|NCT04090359|Active Comparator|Conventional, Single-bearing hip implant|If patients are randomized to the conventional, single bearing cohort, surgeons will use their preferred implant design at their discretion using a 36 or 40mm head, depending on the diameter of the cup and manufacturer specifications. All surgeries will be performed via the posterior approach, per the participating surgeon's usual standard. Patients will be on postoperative hip precautions for 6 weeks, per departmental protocol. No braces will be utilized.
89151714|NCT04087083|Experimental|technological intervention arm|Twenty technological treatment sessions divided into 3 training sessions per week for 7 weeks.
89151715|NCT04087083|Active Comparator|Control arm|Twenty traditional treatment sessions divided into 3 training sessions per week for 7 weeks.
89151716|NCT04087031|Active Comparator|control arm|Ten traditional treatment sessions divided into 2 training sessions per week for 5 weeks
89151717|NCT04087031|Experimental|virtual reality games arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
89151718|NCT04087031|Experimental|robotic treadmill arm|Ten technological treatment sessions divided into 2 training sessions per week for 5 weeks
89151719|NCT04074564|Experimental|Part A|Subgroup 1: MASCT-I A+Camrelizumab+Apatinib combination therapy; Subgroup 2: MASCT-I B+Camrelizumab+Apatinib combination therapy
89151720|NCT04074564|Experimental|Part B|MASCT-I (based on the administration schedule selected from part A) in combination with Apatinib
89151721|NCT04072380|Experimental|SUVN-G3031 2mg|Orally taken once daily for 14 days
89151722|NCT04072380|Experimental|SUVN-G3031 4mg|Orally taken once daily for 14 days
89151723|NCT04072380|Placebo Comparator|Placebo|Orally taken once daily for 14 days
89151724|NCT04015128||T2 Alpha Femoral Nail GT|Subjects in the clinical investigation will undergo placement of the Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System which allows for insertion through the tip of the greater trochanter, according to the approved Instructions for Use and Operative Technique Manual.
88804408|NCT05252598|Experimental|1mg Psilocybin Arm|9 placebo pills and 1 capsule containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 1mg of psilocybin
89151725|NCT04012567|Experimental|The Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
89151726|NCT04012567|Active Comparator|The BIOSURE HA Interference Screw|The Biosure HA Interference Screw, an absorbable screw made of biocomposite material, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery.
89151727|NCT04008186|Experimental|Omaveloxolone and Multiple Drugs (Part 1)|Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively. Oral doses of 150 mg omaveloxolone on Days 12 to 27
89151728|NCT04008186|Experimental|Omaveloxolone & Gemfibrozil (Part 2)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18
89151729|NCT04008186|Experimental|Omaveloxolone and Itraconazole (Part 3)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.
89151730|NCT04008186|Experimental|Omaveloxolone and Verapamil (Part 4)|Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 120 mg verapamil on Days 10 to 18.
89151731|NCT03931590|Experimental|Healthy Male Subjects|Single oral dose of 150 mg of [14C] omaveloxolone containing approximately 90 μCi as a capsule after an overnight fast of at least 10 hours.
89151732|NCT03926520|Experimental|ECT+UC group|
89151733|NCT03902002|Experimental|Group 1: matched healthy subjects|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
89151734|NCT03902002|Experimental|Group 2: subjects with mild hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
89151735|NCT03902002|Experimental|Group 3: subjects with moderate hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
89151736|NCT03902002|Experimental|Group 4: subjects with severe hepatic impairment|On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.
89151737|NCT03891901|Experimental|Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid|Participants will receive 50 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
89151738|NCT03891901|Experimental|Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid|Participants will receive 100 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
89151739|NCT03891901|Experimental|Cohort 1c: Imatinib (200 mg) + Rifabutin + Isoniazid|Participants will receive 200 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
89151740|NCT03891901|Experimental|Cohort 1d: Imatinib (400 mg) + Rifabutin + Isoniazid|Participants will receive 400 mg imatinib for 14 days, followed by 14 days of imatinib together with rifabutin and isoniazid.
89151741|NCT03891901|Experimental|Cohort 2a: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
89151742|NCT03891901|Experimental|Cohort 2b: Imatinib + Rifabutin + Isoniazid|Participants will receive isoniazid and rifabutin for 14 days, followed by 14 days of combination isoniazid, rifabutin, and imatinib. Imatinib dose will be determined after analyzing data from Cohort 1.
89151743|NCT03891901|Experimental|Imatinib (100 mg)|Participants will receive 100 mg imatinib daily for 28 days.
89151744|NCT03891901|Experimental|Imatinib (200 mg)|Participants will receive 200 mg imatinib daily for 28 days.
89151745|NCT03891901|Experimental|Imatinib (400 mg)|Participants will receive 400 mg imatinib daily for 28 days.
89151746|NCT03887936|Experimental|Testosterone arm|Testosterone gel 1.62%
89151747|NCT03887936|Placebo Comparator|Placebo arm|Matching placebo will be prepared by the Michael DeBakey VA Medical Center Pharmacy.
89151748|NCT03880383|Experimental|Group 1 - Coaching|"Upon enrollment to the study, parents in this group will have immediate access to the full intervention:~Coaching: Telephone contact with coaches, who will provide information, education and support about the child's development. Coaching will be adapted to family needs, situation, preferences and child's condition.~Online parent education: Parents will be provided access to empowering online tools, such as educational resources, chosen or developed by other parents and researchers.~Peer support tools: Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge."
88804409|NCT05252598|Experimental|2mg Psilocybin Arm|8 placebo pills and 2 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 2mg of psilocybin
88804410|NCT05252598|Experimental|5mg Psilocybin Arm|5 placebo pills and 5 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 5mg of psilocybin
88804411|NCT05252598|Experimental|8mg Psilocybin Arm|2 placebo pills and 8 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 8mg of psilocybin
88804412|NCT05252598|Experimental|10mg Psilocybin Arm|0 placebo pills and 10 capsules containing encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) for 10mg of psilocybin
89151749|NCT03880383|Other|Group 2- Partial and delayed coaching|"Parents in this group will have delayed and partial access to coaching, at the end of the 18-month period. Parents in this group will have a one-time session with a developmental coach who can give them guidance about their child's development. Parents in this group will also then get access to online parent education and peer support tools, indefinitely, until the online platform is de-activated.~* Both arms/groups* will obtain usual care for their child, in addition and independent of full or partial coaching."
89151750|NCT03872388|Experimental|Group I (atorvastatin)|Patients receive standard of care atorvastatin PO QD for up to 24 months.
89151751|NCT03872388|Active Comparator|Group II (capecitabine)|Patients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.
89151752|NCT03864731|Other|Bone conduction device - ADHEAR|Patients will receive a hearing aid (ADHEAR). Hearing assessment will be carried out. Quality of life measurement will be carried out.
89151753|NCT03829761|Experimental|Cerebellar rTMS|Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
89151754|NCT03829761|Sham Comparator|Sham TMS|Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
89151755|NCT03827018|Active Comparator|mavrilimumab|Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
89151756|NCT03827018|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
89151757|NCT03819569|Active Comparator|Biopsy|Subjects receive a renal cell biopsy prior to making a decision about treatment
89151758|NCT03819569|Sham Comparator|No Biopsy|Subjects do not receive a renal cell biopsy prior to making a decision about treatment
89151759|NCT03802396|Experimental|CN-105|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
89151760|NCT03802396|Placebo Comparator|Placebo|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
89151761|NCT03796832|Experimental|Flat Flexible Shoes+Exercise Therapy|This arm will wear Flat Flexible Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
89151762|NCT03796832|Active Comparator|Stable Supportive Shoes+Exercise Therapy|This arm will wear Stable Supportive Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
89151763|NCT03777319|Experimental|Spironolactone|An anticipated twelve subjects will be prescribed a standard clinical dose of spironolactone of 1 mg/kg/day. The spironolactone will be provided as suspension.
89151764|NCT03777319|Active Comparator|Prednisolone|An anticipated twelve subjects will be prescribed a standard clinical dose of prednisolone of 0.75 mg/kg/day or weekend dosing per sites standard of care. The prednisolone will be provided will be provided as suspension.
89151765|NCT03752840|Experimental|Screening|
89151766|NCT03752840|Active Comparator|Case detection|
89151767|NCT03734536|Other|REGENETEN™ Bioinductive Implant|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
89151768|NCT03734536|Other|Arthroscopic repair of the high-grade (>50%) partialthickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
89151769|NCT03673176|Experimental|Stereotactic Ablative Radiotherapy|Experimental stereotactic ablative radiation treatment
89151770|NCT03672201|Active Comparator|The Integrated Care Pathway (ICP) Arm|The ICP consists of 1) a cleanup phase during which a thorough assessment of pharmacotherapy to discontinue unnecessary medications, is performed; 2) Structured non-pharmacological interventions, which would have started as soon as randomization occurred and would continue before any pharmacological intervention for 2 weeks as stand-alone interventions; and 3) a pharmacological intervention phase: in this phase the medications algorithm for AD-AA is initiated.
89151771|NCT03672201|No Intervention|Treatment-As-Usual (TAU) Arm|Following eligibility and baseline assessments, half of the participants will be randomized to TAU. TAU will consist of the typical care that the interdisciplinary team provides at each site for AD-AA. No predetermined cleanup phase, non-pharmacological interventions, algorithmic pharmacological interventions will be systematically part of TAU.
89151772|NCT03667378||supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinician
88804413|NCT05245526|Experimental|Healthy adult participants|All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors.
88804414|NCT05236920|No Intervention|Standard Care|Participants randomized to this arm will receive standard care for cardiac arrest, which consists of advanced cardiovascular life support (ACLS)
89151773|NCT03667378||without supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinicianTo receive the investigational cancer treatment alone (control arm) no monthly visit with a supportive care clinician.
89151774|NCT03664453|Experimental|Food Effect (Fasted)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fasted state (Period 1) with a crossover and then in the fed state (Period 2).~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
89151775|NCT03664453|Experimental|Effect (Fed)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fed state (Period 1) with a crossover and then in the fasted state (Period 2).~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
89151776|NCT03664453|Experimental|Dose Proportionality|"Subjects will be randomly assigned to one of two omaveloxolone dosages. A single dose of omaveloxolone (in either 50 mg or 100 mg) will be administered to the subjects in 50 mg capsules in a fasted state.~Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 6."
89151777|NCT03624413|Experimental|Social Media Intervention|Adolescent HIV-positive participants receiving the social media intervention.
89151778|NCT03624413|Active Comparator|Standard of Care|Adolescent HIV-positive participants receiving the standard of care.
89151779|NCT03621254|Experimental|[HI-SHORT]|High-intensity interval training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 10 x 2-min exercise intervals with 1-2 min of recovery between intervals. High intensity is achieved by high FES current amplitude (120-150 milliampere, patient dependent)
89151780|NCT03621254|Active Comparator|[LO-LONG]|Low-moderate intensity continuous training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 20+ min continuous exercise. Lower intensity is achieved by lower FES current amplitude (< 90-100 milliampere, patient dependent)
89151781|NCT03610607|Active Comparator|intense education of periodontal health maintenance|
89151782|NCT03610607|Placebo Comparator|No intense education of periodontal health maintenance|
89151783|NCT03607838|Experimental|SI-6603|
89151784|NCT03607838|Sham Comparator|Sham injection|
89151785|NCT03607799|Experimental|Dietary Intervention|"A personalized nutrition plan will be developed for each woman and will respect faith-based food choices and regional preferences. The plan will be delivered by a culturally congruent health coach, and consider baseline dietary intake, energy balance for recommended gestational weight gain, personal values and preferences, through setting 2-4 SMART goals. Participants assigned to the intervention group will receive text messages. Participants assigned to the intervention group will be given a Fitbit to track their steps and will receive simple text messages weekly, aimed at increasing walking. They will be given PDF resources that provide advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the South Asian community."
89151786|NCT03607799|Active Comparator|Control|Participants in the control group will receive simple text messages weekly, aimed at increasing walking. They will be given PDF resources that provide advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the South Asian community.
89151787|NCT03583099|Experimental|CAPTURE + COPD Education|Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.
89151788|NCT03583099|Active Comparator|COPD Education|Practice clinicians will receive basic COPD education only.
89151790|NCT03532295|Experimental|Regimen A: Retifanlimab+RT+bevacizumab|"Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.~Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy~Treatment may continue for up to two years."
89151791|NCT03532295|Experimental|Regimen B: Retifanlimab+RT+bevacizumab+epacadostat|"Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.~Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.~Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction~Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy~Epacadostat will be administered orally at 400 mg BID.~Treatment may continue for up to two years."
89151792|NCT03523793|Experimental|Physical Therapists - CPG|Cross-sectional stepped wedge design with 16 physical therapy clinics (including approximately 40 physical therapists) being allocated to one of 4 sequences that differ in CPG implementation time (each sequence consisting of 4 clinics). This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
88804415|NCT05236920|Experimental|Standard Care Plus Intervention|Participants randomized to this arm will receive standard care for cardiac arrest, which consists of advanced cardiovascular life support (ACLS) plus the study intervention
88804416|NCT05236439|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
89151793|NCT03523793|Active Comparator|Physical Therapists - Control|This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
89151794|NCT03465111|Experimental|Twice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U twice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 17, the treatment will be administered on as needed basis, based on the retreatment criteria.
89151795|NCT03465111|Experimental|Thrice Weekly Treatment Arm|Patients in this treatment arm will receive mandatory 80 U thrice weekly treatment with SC ACTH (adrenocorticotropic hormone) gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 16, the treatment will be administered on as needed basis, based on the retreatment criteria.
89151796|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg|10 mg OCA for up to 18 months
89151797|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg to 25 mg|10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
89151798|NCT03439254|Placebo Comparator|Placebo|Placebo for up to 18 months
89151799|NCT03434379|Experimental|Atezolizumab + Bevacizumab|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator
89151800|NCT03434379|Active Comparator|Sorafenib|Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator
89151801|NCT03430011|Experimental|JCARH125|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JCARH125
89151802|NCT03430011|Experimental|JCARH125 + anakinra|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by prophylactic treatment with anakinra and a single dose of JCARH125
89151803|NCT03422224||Good transplant function|Kidney transplant recipients without histological signs of rejection.
89151804|NCT03422224||Transplant Rejection|Kidney transplant recipinets experiencing a T cell mediated rejection episode.
89151805|NCT03396640|Experimental|Unicondylar Knee Arhtroplasty|Operation with insertion of a knee arthroplasty using a unicompartmental device (Oxford phase 3, mobile bearing, uncemented)
89151806|NCT03396640|Active Comparator|Total Knee Arthroplasty|Operation with insertion of a knee arthroplasty using a total condylar device (PCR, nexgen with resurfacing, cemented)
89151807|NCT03309826|Experimental|PAP Treatment Arm|Automated positive airway pressure titration then treatment with fixed PAP.
89151808|NCT03309826|Active Comparator|Nasal Dilator Strip|Nightly use of nasal dilator strip
89151809|NCT03309046|Experimental|REACH Individual Session|The individual sessions intervention focuses on education, skills building, and support. It will be delivered in six sessions by telephone over three months. A Caregiver Notebook will include comprehensive materials for all sessions and topics. Treatment fidelity will be monitored and ensured through assessment of intervention delivery, receipt, and enactment. The intervention is targeted and individualized to the concerns of the specific caregiver and care recipient through a risk assessment. The Risk Assessment (RA) assesses the main caregiving risk areas for the specific caregiving dyad. The RA is used to tailor the intervention for care recipient behaviors or safety issues and/or caregiver centered issues/concerns related to health, physical and emotional well being, and/or social support.
89151810|NCT03309046|Active Comparator|Education Webinar|For the education webinar sessions, topics addressing each of the caregiving risk factors topics but without the skills building or cognitive restructuring components present in the individual intervention sessions will be available online in webinars. The education webinar sessions will focus on general information about post 9/11 concerns, problem behaviors, caregiver health, caregiver emotional well-being, and red flags. Education webinar session participants will not receive the Caregiver Notebook until they have completed their 6 month interviews. Parents will be able to view all 6 webinars at any time during the first 3 months. Each session will last approximately thirty minutes through PowerPoint slide presentation format with a pre-recorded script.
89151811|NCT03228186|Experimental|Pevonedistat plus Docetaxel|Pevonedistat 25mg/m2 days 1, 3, 5 Docetaxel 75mg/m2 day 1 21 day cycle
89151812|NCT03206450||Observational (questionnaire, biospecimen collection)|Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
88804417|NCT05223491|Experimental|En Bloc|The bladder tumour will be resected en bloc and removed in total, if possible.
89151813|NCT03175224|Experimental|NSCLC Exon 14 Skip Treatment Naive|Cohort A-1: APL-101 Oral Capsules
89151814|NCT03175224|Experimental|NSCLC Exon 14 Skip Previously Treated|Cohort A-2: APL-101 Oral Capsules
89151815|NCT03175224|Experimental|NSCLC Exon 14 MET Inhibitor Experienced|Cohort B: APL-101 Oral Capsules
89151816|NCT03175224|Experimental|Basket of tumor types MET amplification except for primary CNS tumors|Cohort C: APL-101 Oral Capsules
89151817|NCT03175224|Experimental|NSCLC MET amplification and EGFR wild-type|Cohort C-1: APL-101 Oral Capsules
89151818|NCT03175224|Experimental|EGFR positive NSCLC MET amplification as an acquired resistance|Cohort C-2: APL-101 Oral Capsules + Standard of Care EGFR Inhibitor
89151819|NCT03175224|Experimental|Basket of solid tumor with MET gene fusions except for primary CNS tumors|Cohort D: APL-101 Oral Capsules
88804418|NCT05223491|Active Comparator|Conventional TURB|The bladder tumour will be removed by conventional piecemeal resection.
88806036|NCT02531802|Experimental|6-11 months: ETVAX (1/2)|6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
88806037|NCT02531802|Experimental|6-11 months: ETVAX (1/4) + 2.5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
89151820|NCT03175224|Experimental|Primary CNS tumors with MET alterations|Cohort E: APL-101 Oral Capsules
89151821|NCT03175224|Experimental|Basket of tumor types wild-type MET with over-expression of HGF and MET|Cohort F: APL-101 Oral Capsules
89151822|NCT03153982|Experimental|Neoadjuvant Ruxolitinib|Participants will take 15 mg or 20 mg of ruxolitinib by mouth twice daily for up to 4 weeks during the pre-operative window for 14-21 days, or up to 28 days for delays in planned surgery. Dose will be assigned based on participant platelet count at baseline. The last dose will be taken the morning of planned surgery. Ruxolitinib will be dispensed in 5 mg tablets. Participants will either take three tables (15 mg) in the morning and evening, or four tablets in the morning and evening (20 mg). Participants will be asked to fill out a drug diary indicating when doses of study drug are taken and any side effects they experience.
89151823|NCT03139916|Experimental|Bavituximab + Standard of Care Radiation + Temozolomide|"Bavituximab will be administered weekly intravenously~Temozolomide will be administered daily~Standard of Care Radiation will be administered per hospital guideline."
89151824|NCT03088540|Active Comparator|Standard-of-care chemotherapy|"Standard-of-care chemotherapy will administered from these options:~Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance"
89151825|NCT03088540|Experimental|cemiplimab|cemiplimab regimen as monotherapy as per study protocol
89151826|NCT03048331|Experimental|Functional Electrical Stimulation|"Before surgery, the donor muscle is stimulated via surface electrodes in a loaded position or against resistance 3 times a week for 30 minutes.~After surgery, the patients receive the same standard therapy as the control group. The electrical stimulation is performed once a day in combination with standard therapy for 30 minutes against gravity or resistance or in a loaded position."
89151827|NCT03048331|No Intervention|Standard therapy|Postoperatively, 20 min passive and active movements of the hand or arm are applied manually by a therapist. Additionally, the patients actively perform the same exercises once a day for 20 min. The movements are based on a standardised post-surgical treatment protocol.
89151828|NCT03003637|Experimental|Nivolumab with or without Ipilimumab|First dose scheme will be 2x nivolumab 240 mg flat dose, weeks 1 and 3. When feasible and safe, the next patients will be treated with the following dose scheme: the combination of 1x ipilimumab 1 mg/kg + nivolumab 240 mg flat dose in week 1 and nivolumab mono-therapy 240 mg flat dose in week 3
89151829|NCT02969980|Experimental|PTCy|Patients who receive post-transplantation cyclophosphamide
89151830|NCT02937272|Experimental|LY3200882 Schedule 1 Escalation|
89151831|NCT02937272|Experimental|LY3200882 Schedule 2 Escalation|
89151832|NCT02937272|Experimental|LY3200882 Schedule 1 Expansion|
89151833|NCT02937272|Experimental|LY3200882 Schedule 2 Expansion|
89151834|NCT02937272|Experimental|LY3200882 + LY3300054|
89151835|NCT02937272|Experimental|LY3200882 + Gemcitabine + nab-Paclitaxel|
89151836|NCT02937272|Experimental|LY3200882 + Cisplatin + Radiation|
89151837|NCT02937272|Experimental|Japanese Arm LY3200882|
89151838|NCT02925156||Ghana|Participants in the Ghana cohort are located at or near the the village of Nkwantakese which is approximately 20 kilometers outside of Kwame Nkrumah University of Science and Technology in Kumasi.
89151839|NCT02925156||South Africa|Participants in the South Africa cohort are located at or near Khayelitsha, the 3rd largest township in South Africa, which is an adjacent town to the city of Cape Town. The population of Khayelitsha is about 500,000 people.
89151840|NCT02925156||Seychelles|Participants in the Seychelles cohort are located at or near The Republic of Seychelles, which is an archipelago with 81,000 inhabitants located approximately 1,500 km east of Kenya in the Indian Ocean and approximately 2,000 km north of the island of Mauritius.
89151841|NCT02925156||Jamaica|Participants in the Jamaica cohort are located at or near Spanish Town, Jamaica which is an urban area 25 km from the center of Kingston. The population of Spanish Town in 1991 was estimated at 92,000 people.
89151842|NCT02925156||United States|Participants in the United States cohort are located at or near Maywood, IL, which is an African-American working class community adjacent to the western border of Chicago, IL. The population of Maywood in 2010 was estimated at 24,090 people.
89151843|NCT02888067|Active Comparator|Moderate neuromuscular blockade (MNB)|"The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
89151844|NCT02888067|Active Comparator|Deep neuromuscular blockade (MNB)|"The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
89151845|NCT02869633|Experimental|Treatment (ibrutinib)|Beginning between 60-90 days post donor stem cell transplant, patients receive ibrutinib PO QD until 1 year post donor stem cell transplant in the absence of disease progression or unacceptable toxicity.
89151846|NCT02855268|Experimental|Placebo/Lademirsen|Participants received subcutaneous (SC) doses of placebo (matched to lademirsen) every week (QW) during the 48 weeks of double blind (DB) treatment period. Participants who received placebo and completed DB treatment period entered in open-label extension (OLE) treatment period and received lademirsen at a dose of 110 milligrams (mg) QW for an additional 48 weeks (i.e., up to Week 96).
89151847|NCT02855268|Experimental|Lademirsen/Lademirsen|Participants received SC doses of lademirsen 110 mg QW during the 48 weeks of DB treatment period. Participants who completed DB treatment period entered in OLE treatment period and continued the same lademirsen treatment in OLE period for an additional 48 weeks (i.e., up to Week 96).
89151848|NCT02848820|Experimental|Augmentin + Gentamicin|"Initial non-operative treatment strategy reserving an appendectomy for those not responding or with recurrent disease. It consist of:~Clinical observation for 48 hours with administration of Intravenous administration of amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) and gentamicin 7mg/kg once daily for 48 hours. If after 48 hours the patient fulfils the predefined discharge criteria, the antibiotics will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days and discharge. An appendectomy is reserved for those patients with clinical deterioration, non-improvement after 72 hours or recurrent appendicitis.~Pain medication according to national protocol."
89151849|NCT02848820|Active Comparator|Operative treatment strategy|Clinical observation and semi-urgent appendectomy. Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics. Discharge if the patient fulfils the predefined discharge criteria. Pain medication according to national protocol.
89151850|NCT02840721|Experimental|PF-06480605|PF-06480605 500 mg IV Q2W X 7 doses
89151851|NCT02838316|Experimental|150 x 106 dosage|10 subjects will be receiving a dosage of 150 x 106 AMDC-GIR
89151852|NCT02838316|Experimental|300 x 106 dosage|10 subjects will be receiving a dosage of 300 x 106 AMDC-GIR
89151853|NCT02777593|Other|Zone 2 Aneurysm|Includes primary (hypothesis-driven) aneurysm cohort and continued access. Subjects enrolled for treatment with the TBE device with proximal implantation in aortic Zone 2.
89151854|NCT02777593|Other|Zone 2 Non-aneurysm|Includes dissection, traumatic transection and other isolated aortic lesion cohorts. Subjects enrolled for treatment with the TBE device with proximal implantation in aortic Zone 2.
89151855|NCT02701283|Experimental|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of Aortic Stenosis with the Medtronic CoreValve System Transcatheter Aortic Valve Implantation (TAVI) device or the Medtronic Corevalve Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
89151856|NCT02701283|Active Comparator|Surgical Aortic Valve Replacement (SAVR)|Treatment of Aortic Stenosis with commercial Surgical Aortic Valve Replacement (SAVR)
89151857|NCT02694783|Experimental|Treatment Arm|ex vivo generated polyomavirus-specific T cells from HLA-matched donor
89151858|NCT02668770|Experimental|Dose Escalation Group: MGN1703 + Ipilimumab|"Participants receive MGN1703 on Days 1, 8, and 15 of all cycles as an injection under the skin. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long. Participants receive a total of 4 treatment cycles for a total of 12 weeks on treatment."
89151859|NCT02668770|Experimental|MTD Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or subcutaneous manifestations.~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
89151860|NCT02668770|Experimental|MTD Group: MGN1703 (intratumoral injection) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy and cutaneous or or subcutaneous manifestations.~MGN1703 given by intratumoral injection at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
89151861|NCT02668770|Experimental|MTD Post XRT Group: MGN1703 (subcutaneously) + Ipilimumab|"Dose expansion group consists of participants with advanced malignancy treated with radiation (XRT) within the past 2 weeks.~MGN1703 given subcutaneously at MTD from the Dose Escalation Group. Ipilimumab dosed at 3 mg/kg once per cycle on Day 8 following MGN1703 administration.~Each cycle is 21 days long."
89151862|NCT02626377|Experimental|Interventional arm|'Support provided by social worker'
89151863|NCT02626377|Other|Non-interventional arm|'Information booklet receipt'
89151864|NCT02552199||with hyperhidrosis|Patients with primary palmar hyperhidrosis
89151865|NCT02552199||healthy|Healthy adult patients
89151866|NCT02482376|Other|Single arm 21Gy stereotactic radiotherapy|Subjects will receive a single fraction of 21Gy of stereotactic radiotherapy before proceeding to surgery.
89151867|NCT02417285|Experimental|CC-122 in combination with Obinutuzumab|CC-122 will be administered orally QD starting on Day 1 for 5 consecutive days followed by 2 days off study drug every 7 days (5/7-day schedule) in each 28-day cycle in combination with Obinutuzumab administered as an intravenous (IV) infusion at a dose of 1000 mg on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8.
89151868|NCT02399085|Experimental|Tafasitamab (MOR00208) + lenalidomide (LEN)|"MOR00208:~MOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle.~Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.~LEN:~Participants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings.~On days when both study drugs were given together, LEN was administered prior to MOR00208."
89151869|NCT02323581|Experimental|TAAA (thoracoabdominal aortic aneurysm) Study Arm|"Either the Off-the-Shelf TAAA device or the Physician-Specified TAAA Device will be implanted.~The Off-the-Shelf TAAA Device is a standard configuration Zenith t-Branch with four branches for the mesenteric arteries and the renal arteries.~The Physician-Specified TAAA Devices may include a combination of up to 5 fenestrations and branches for mesenteric and renal arteries. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards."
89151870|NCT02323581|Experimental|Aortic Arch Study Arm|Physician-specified double inner branch stent-graft with or without retrograde left subclavian branch or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery.
89151871|NCT02265042|Experimental|electrical stimulation|electrical Stimulation using the Stimulette device
88806038|NCT02531802|Experimental|6-11 month olds: ETVAX (1/4) + 5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
88806039|NCT02531802|Placebo Comparator|6-11 month olds: Placebo|6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
89151872|NCT02070575||Pts with prostate cancer|This study is planned to determine the kallikrein panel of 200 patients presenting with biochemical recurrence (PSA ≥ 0.05ng/ml) after radical prostatectomy prior to any additional therapy or minimum post 1 year additional therapy.
89151873|NCT02061553|Sham Comparator|Motivation|1 in person session focused on importance of motivation followed by 8 wk SMS messages with self-selected motivational statements.
89151874|NCT02061553|Active Comparator|Intention|1 session of Behavioral Activation followed by 8 wk SMS messages in the form of BA- based implementation intentions.
89151875|NCT02061553|Experimental|BA-Tech|6 in person and 2 phone sessions of Behavioral Activation with EMA-based activity monitoring and SMS-assisted scheduling of value-based activities.
89151876|NCT01985984||H&N cancer patients|"Patients with Head and Neck Cancer, treated with curative intent~Any tumor site~Stage I-IV, M0~Treated with radiotherapy alone or in combination with systemic therapy~Definitive radiotherapy or postoperative radiotherapy~Interventions:~Radiation alone~Radiation in combination with systemic therapy"
89151877|NCT01981642|Experimental|Patients with a LVAD implanted.|Recording of LVAD data during routine visits and daily life. Recording of daily activity using wristwatch accelerometers.
89151878|NCT01840306||Cohort 1: HER2 positive breast cancer|Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.
89151879|NCT01840306||Cohort 2: HER2 negative breast cancer|Female patients with newly diagnosed HER2 negative breast cancer
89151880|NCT01472588|Experimental|Community Health Coach|DPP behavioral lifestyle intervention delivered by Community Health Coach (CHWs)
89151881|NCT01472588|Experimental|Public Health Coach|DPP behavioral lifestyle intervention delivered by health professionals (PHCs)
89151882|NCT01472588|Other|Self Help|Booklet, Aim for a Healthy Weight (DHHS, NIH-NHLBI) provided.
89151883|NCT01412762||patient interviews|We aim to interview 15 patients with confirmed thyroid malignancy both pre- and postoperatively, for a total of 30 interviews. For the expansion of this study, we will accrue 25 patients with biopsy-proven thyroid cancer undergoing thyroidectomy to be educated with the CITSAV application prior to surgery.
89151884|NCT01320215|Experimental|Robot arm|The patients in this arm will have a robot-assisted promontofixation.
89151885|NCT01320215|Active Comparator|Non-robot arm|The patients in this arm with have a promotofixation via a laparoscopy, but without robot assistance.
89151886|NCT00975338||Prospective LIFEspan|LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
89151887|NCT00975338||Prospective Non-LIFEspan|LIFEspan youths with Spina Bifida
89151888|NCT00975338||Retrospective Non-LIFEspan|Non-LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
89151889|NCT00975338||LIFEspan Staff|All staff affiliated with the LIFEspan model of linked transition care
89151890|NCT00975338||Caregivers|Parents of participating youths
89151891|NCT00623389|Experimental|Implant|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
89151892|NCT00476515|Experimental|Rituximab|this study has only one arm as treatment group.
89151893|NCT00261547|Experimental|Rituximab|this study has only one arm as the treatment group
89151894|NCT02650830||1) Normal control|metabolically healthy with no obesity
89151895|NCT02650830||2) prediabetes|defined in 'inclusion criteria'
89151896|NCT02650830||3) type 2 diabetes|defined in 'inclusion criteria'
89151897|NCT02832557||MCHAT-R Positive|Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
89151898|NCT02650596|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg liraglutide once daily for 1 week, then 1.2 mg liraglutide for another 1 week, and then 1.8 mg liraglutide to the end.
89151899|NCT02650596|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg placebo once daily for 1 week, then 1.2 mg placebo for another 1 week, and then 1.8 mg placebo to the end.
89151900|NCT04490096|Other|[11C]-PBR28 ALS|Neuroinflammatory pathways have been implicated in a variety of neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), but the vast majority of this evidence is from animal or ex vivo human studies. In vivo measurement of the 18 kDa translocator protein (TSPO) has become possible with [11C]-PBR28 PET imaging. Briefly, TSPO expression is increased when microglial are activated. Cross-sectional studies have demonstrated that [11C]-PBR28 uptake is elevated in ALS compared to controls, is correlated with upper motor neuron severity, and that microglial activation is associated with more severe upper motor neuron disease and faster disease progression. We are only aware of a single 6-month study of 10 patients evaluating longitudinal change of [11C]-PBR28 in ALS. We hypothesize that we will observe increased [11C]-PBR28 uptake over a 6-month period in motor cortex and prefrontal cortex in ALS. This portion of the study will be performed at UPenn only.
89151901|NCT02650518|No Intervention|Control|Subject receives the standard of care that is provided by the primary team taking up his/her case.
89151902|NCT02650518|Experimental|Catheter change+Short-course Antibiotics|
89151903|NCT02832089|Experimental|active arm|single arm study with one group given oral carvedilol.
89151904|NCT00622076|Active Comparator|1|postoperative catheterization after anterior colporrhaphy during five days.
89151905|NCT00622076|Active Comparator|2.|postoperative catheterization after anterior colporrhaphy during two days
89151906|NCT02647710|Experimental|PHAT Life Intervention|PHAT Life: Preventing HIV/AIDS Among Teens, is a uniquely-tailored intervention designed for recently-arrested juvenile offenders on probation. The program will teach teens about HIV/AIDS, sexually transmitted infections, and safer decision-making. PHAT Life draws on social learning theory and a Social-Personal Framework to address individual and social mechanisms related to HIV-risk, including emotion regulation, peer norms, partner communication, relationship characteristics, and HIV/AIDS/STI and substance use knowledge, attitudes, and beliefs.
89151907|NCT02647710|Active Comparator|Health Promotion Control|A health promotion program focusing on nutrition, physical activity, substance use, and sexual health.
89151908|NCT04247633|Experimental|palbociclib plus endocrine therapy treatement|"Patients with Clinical high risk/Genomic High risk (in BCT score)-high and ER positive/HER2 negative EBC after Curative Surgery~Palbociclib at a dose of 125mg, orally once daily on Day 1 to Day 21 followed by 7 days off in a 28-day cycle for a total duration of 2 years~Standard adjuvant endocrine therapy for a duration of at least 5 years from the start of the treatment."
89151909|NCT04208672|Experimental|Patient attending for PSG in Sleep Assessment Unit|Subjects referred to the SAU will be invited to participate into this study
89151910|NCT02647398|Experimental|A: Supervised combined training|INTERVENTION: Two supervised 75 min-vigorous aerobic training & strength training
89151911|NCT02647398|Active Comparator|B: Supervised strength training|ACTIVE COMPARATOR: Two supervised 45-minute sessions of strength training & Participants will be advised to comply with international recommendations of physical activity (150 min pf MVPA)
89151912|NCT00891371|Experimental|lanreotide (Autogel formulation) Autogel 120mg|lanreotide (Autogel formulation) Autogel 120mg
89151913|NCT04468880|Other|Milk A1A2|Group (A1 → A2) receiving control milk A1A2 in period 1 then the milk evaluated A2A2 in period 2
89151914|NCT04468880|Other|Milk A2A2|Group (A2 → A1) receiving the milk evaluated A2A2 in period 1 then the control milk A1A2 in period 2
89151915|NCT04437056|Other|Stroke patients with upper limb spasticity|Patients with post-stroke upper limb spasticity will be operated for cognitive nerve transfers to spastic muscles to allow for volitional muscle reinnervation and disrupture of spasticity. Adequate healthy nerve donors from the ipsilateral arm will be determined clinically and electrophysiologically.
89151916|NCT02829281|Experimental|Botulinum toxin group|Patients will receive a intervention with joint injection of 100 units of botulinum toxin
89151917|NCT02829281|Active Comparator|Corticosteroid group|Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)
89151918|NCT02829281|Placebo Comparator|Saline Group|Patients will receive a joint injection of 2ml of normal saline
89151919|NCT04210544|Experimental|Dietary protein|Postprandial effects after consuming 20 g of a experimental dietary protein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
89151920|NCT04210544|Active Comparator|Casein|Postprandial effects after consuming 20 g of casein mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
89151921|NCT04210544|Placebo Comparator|Water|Postprandial effects after consuming 20 g of water mixed with 250 g of custard and to drink of 50 mL of water served in a glass.
89151922|NCT04168944|Experimental|lenvatinib group|Participants are given the same anti-rejection therapy as the control group after liver transplantation. 1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mgor 12 mg orally once a day. The initial dose was 8 mgor 12 mg orally once a day.
89151923|NCT04168944|Placebo Comparator|Placebo group|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
89151924|NCT04208438||BVI Cohort|Cohort to have ultrasound and Mespere BVI device applied.
89151925|NCT02536326|Experimental|renal denervation|
89151926|NCT02697032|Experimental|Patients|At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.
89151927|NCT00650676||A|
89151928|NCT04167384|Experimental|Hard nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
89151929|NCT04167384|Experimental|Soft nicotine lozenge arm|Subjects will use each of the 5 products sequentially during an evaluation period, followed by a 6 hour Test Session.
89151930|NCT04208204|Experimental|Somatocognitive physiotherapy|Every participant will maximally receive 15 individual sessions of somatocognitive physiotherapy
89151931|NCT00622778||1|Patients from daily practice
89151932|NCT02650362|Experimental|spinal cord stimulation|
89151933|NCT02829203||No-Frailty|Patients without frailty score submitted to a cardiac surgery
89151934|NCT02829203||Pre-Frailty|Patients with pre-frailty score submitted to a cardiac surgery
89151935|NCT02647632|Experimental|16 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 16 weeks
89151936|NCT02647632|Experimental|24 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 24 weeks
89151937|NCT02829047|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
89151938|NCT00621452|Experimental|Treatment (autologous CD20 specific T-cells)|"CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes.~IMMUNOTHERAPY: Beginning 2 days after completion of cyclophosphamide, patients receive autologous CD20-specific T-cells IV over 30 minutes. Treatment repeats every 2-5 days for 3 courses.~MAINTENANCE THERAPY: Beginning 2 hours after the last T-cell infusion, patients receive low-dose aldesleukin subcutaneously twice daily for 14 days.~Subjects who have achieved at least a partial remission lasting a minimum of 6 months may, on a case-by-case basis, receive additional stored T cells following relapse."
89151939|NCT02828891|Experimental|Experimental|Intervention: transcranial Doppler device will be utilized to measure CSF pressure.
89151940|NCT02647476|Experimental|Study group|Immunomodulating nutrition (Reconvan)
89151941|NCT02647476|Active Comparator|Control group|Standard nutrition (Peptisorb)
89151942|NCT05176847|Experimental|Gamified mLIFE app group|Participants allocated to this group will be provided with elements of social gaming and healthy competition within the mLIFE app.
89151943|NCT05176847|Active Comparator|standard mLIFE app|Participants in this group will receive the same intervention as the experimental group, but some features of the App will not facilitate gaming or competition.
89151944|NCT05662436|Experimental|Intervention group|The exposure to nature consists of teachers bringing their students to the highest quality green space within 1 km of a school which could be located on or off campus. The class will spend a total of 2 hours (i.e. 2 one hour visits or one 2 hours visits) per week for 12 weeks (transportation included). The teacher be provided with a toolkit of activities (mental health and academic competencies) that they will carry out with their students. Teachers will be provided with training and support.
89151945|NCT05662436|No Intervention|Control|Six months after the inception of the trial, elementary schools (and their teachers) in the control condition will receive an unguided version of the intervention, supplemented by an online peer support group. As the children of the control group will by then be in high school with different teachers, we will provide them with a toolkit of 10 mental health activities that they can practice alone, in addition of support via video-conference, phone or email if they require help practicing the activities from a member of the research team. As in the intervention group, we will provide support by licensed psychologists to any children who report high levels of psychological distress and orient children to appropriate services if needed.
89151946|NCT03803748|Experimental|Eyestil Plus®|"It's a clinical comparative performance study. Eyestil Plus® eyedrops multidose to be not inferior to Vismed multidose eye drops. Eyestil Plus is an ophthalmic aqueous formulation, multidose sterile preservative free, medical device, class IIB and CE marked. It contains 0.4% sodium hyaluronate. It is not available yet in the French Market.~The dosage per medical device will be 6 drops a day per dry eye during the three months study period,"
89151947|NCT03803748|No Intervention|Vismed|"Vismed Multi® is also a sterile multidose preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate.~The dosage per medical device will be 6 drops a day per dry eye during the three months study period.~The choice of Vismed Multi® as the comparator has been done since it is the current French standard of care treatment for patients with moderate to severe dry eyes."
89151948|NCT04244669|Experimental|SCS with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% of pain in that area.
89151949|NCT04244669|Experimental|SCS with SCS DTM Stimulation|IIn this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms.
89151950|NCT02828969|Other|Children and adolescents with conduct disorders|Girls and boys having less than 18 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
89151951|NCT02655120|Experimental|Bone Marrow +BMP7|The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1)
89151952|NCT02655120|Placebo Comparator|Drilling|Group I: a simple drill is practiced
89151953|NCT04336748|Active Comparator|Hydroxychloroquine|200mg once daily
89151954|NCT04336748|Placebo Comparator|Placebo|Placebo
89151955|NCT04244279|Experimental|Intervention group|The intervention group will participate in a workshop regarding ergonomic principles in baby care. Finally, a brochure will be distributed summarizing the main contents of the workshop. One month and two months after the intervention, the intervention group will receive a videotaped reminder of the principles presented at the workshop via an email or WhatsApp message.
89151956|NCT04244279|No Intervention|Control group|The control group will not receive any intervention during the data collection period. The intervention will be given three months after the beginning of the research, in the format of the brochure and videos sent via email or WhatsApp.
89151957|NCT05662748||Pro Star|patient received Pro Star Device
89151958|NCT05662748||MANTA|Patient received MANTA Device
89151959|NCT00651612|Experimental|1|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
89151960|NCT00651612|Active Comparator|2|Concurrent Brimonidine 0.2% and 0.5% Timolol
89151961|NCT02832011|Active Comparator|olive oil|After randomization, Investigators will give human milk fortiﬁed with olive oil
89151962|NCT02832011|Active Comparator|Eoprotin|After randomization, Human milk fortiﬁed with Eoprotin according to the recommendations of the manufacturer (1g per 30ml milk)
89151963|NCT00650754|Experimental|DHEA|Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.
89151964|NCT00650754|Placebo Comparator|Placebo|Blinded placebo
89151965|NCT04207970||Clients under PDS Community Team|27 adult clients under PDS Community Team
89151966|NCT02650206|Experimental|Liraglutide group|"Drug with diet control intervention: Subjects assigned to this group receive blinded pens containing liraglutide (commonly known as Victoza), manufactured by Novo Nordisk. Subjects will inject 0.6 mg daily into abdomen during the first week of the study, and if tolerated, will increase dose to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
89151967|NCT02650206|Placebo Comparator|Placebo group|"Diet control-only intervention: Subjects assigned to this group receive blinded pens containing placebo (normal saline) instead of liraglutide (commonly known as Victoza). Subjects will inject 0.6 mg of placebo daily during the first week of the study, will increase to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
89151968|NCT00891293|Experimental|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
89151969|NCT05368610||Very high power-short duration ablation|PVI performed by point-by-point very high power-short duration radiofrequency ablation (QDOT-micro catheter, Biosense Webster; Qmode+; 90 W; 4 sec; target intertag distances: posterior wall 4 mm, proximity of the esophagus 5 mm, all other 3 mm)
89151970|NCT05368610||Matched control group conventional ablation|PVI performed by conventional point-by-point radiofrequency ablation (40 W; ablation index-guided: posterior wall 350, other 450; target intertag distance 3.0 - 5.0 mm)
89151971|NCT05368142|Experimental|N-CWS treatment group|Patients with N-CWS treatment
89151972|NCT05368142|Placebo Comparator|Control group（ treatment with Silver Ion-releasin)|Patients with Silver Ion-releasin
88804419|NCT05214209|Experimental|Intervention arm|Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum over a period of 4 weeks through the app. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participant can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.
88804420|NCT05214209|Active Comparator|Usual care arm|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises."
89151973|NCT00889421|Experimental|Treatment|Patients receiving apremilast.
89151974|NCT02655042||RCT-01|Participants in previous clinical trial that received blinded injection of RCT-01
89151975|NCT02655042||Placebo|Participants in previous clinical trial that received blinded injection of placebo
89151976|NCT05367986|No Intervention|Western medicine group(WM group)|Patients in the Western medicine group received conventional treatment with Western medicine. According to International Guidelines for Management of Sepsis and Septic Shock: 2016, conventional treatment includes antibiotics and other anti-infection measures, fluid management, mechanical ventilation, and nutritional support, but does not include the use of immunosuppressants or immune enhancers including hormones, gamma globulin, and thymosin.
89151977|NCT05367986|Experimental|electro-acupuncture (EA) group|Patients in the electro-acupuncture group were treated with Western medicine and electro-acupuncture. Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.
89151978|NCT02827643|Active Comparator|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
89151979|NCT02827643|Other|TDF/3TC or FTC/EFV|the subjects in this arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
89151980|NCT02650050|Experimental|Micropulsed laser photocoagulation|
89151981|NCT02650050|Sham Comparator|Sham micropulsed laser photocoagulation|
89151982|NCT02831621|Active Comparator|diet (usual care)|All participants will receive a hypocaloric diet based on the individual resting metabolic rate. Resting metabolic rate (RMR) will be estimated using the WHO formula or measured using indirect calorimetry. Total energy expenditure will be calculated by multiplying RMR with a physical activity level (PAL). The used physical activity level will be 1.3. A hypocaloric diet with an energy deficit of 500 kcal/day will be prescribed. Participants will see a skilled dietician two-weekly the first month and on a monthly basis the next five months to discuss problems and solutions or coping strategies. The first consultation will have a duration of 60 minutes, the next consultations will have a duration of approximately 30 minutes. Each visit, nutritional compliance will be recorded on a 0 to 10 numeric rating scale. The usual care group will be asked to continue with their normal physical activity during the six-month intervention period.
89151983|NCT02831621|Experimental|diet+exercise|"For participants of this group, usual care will be supplemented with a prescribed exercise program. For this exercise program the participants will be referred to a local fitness club near home, free of charge. Aerobic training will be done at an intensity of 90-95% of the heart rate achieved at the RCP. Aerobic training will have a duration of 30 to 45 minutes, according to the training stage. Cardio training will be performed on different cardio devices and strength training will be done on isotonic strength training devices. Each training day, core stability training will be completed with four strength exercises for large muscle groups. Each exercise will be done in two sets of 15 repetitions with the goal to achieve better muscular strength endurance.~This combined training will be done individually during six months, three times/week.~In this study, an effort is made to reach a uniform manner of guidance to the physical activity program."
89151984|NCT02646930|Experimental|Incidence of CE|To determine rates of CE in women undergoing initial IVF and outcomes
89151985|NCT04168788|Other|Nephrobalstoma or ALL|Pateints treated for a nephrobalstoma or ALL in childhood or adolescence
89151986|NCT00889265|Experimental|CopiOs Pericardium Membrane|Subject's study site must exhibit a partially edentulous ridge of the maxilla or mandible with at least one tooth-span in length and less than 5.5mm in its smallest buccolingual dimension as measured by ridge-mapping calipers.
89151987|NCT02646774|Experimental|Micafungin group|Injection
89151988|NCT04244747|Active Comparator|induction of labour by breast stimulation|women at term with previous cesarean section and an indication to induce labor. In order to induce labour by breast stimulation, an electrical pump was used. The cup was alternated between the nipples every 15 minutes, with a pause of 15 minutes after each 30 minutes, with a total induction time of 6 hours.
89151989|NCT04244747|Active Comparator|induction of labour by catheter balloon|women at term with previous cesarean section and an indication to induce labor. In the catheter balloon group, a 16-F Foley catheter was inserted into the cervical canal and inflated with 60 cc sterile saline solution and was kept in place for 12 hours.
89151990|NCT04244747|No Intervention|spontaneous labour|women in latent phase of spontaneous labour .
89151991|NCT02647086|Experimental|Period 1|Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprololin) in period 1 (day 1)
89151992|NCT02647086|Experimental|Period 2|Patients will receive dupilumab starting in Period 2 (day 8) and continue weekly through day 50; Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol) in period 2 (at day 36).
89151993|NCT02827721||COPD|Patients with known or suspected COPD Patients with known or suspected obstructive ventilation disorder
88804421|NCT05212922|Experimental|YH001 + Toripalimab|This study will include two cohorts of up to 40 subjects each treated with RP2D dose of YH001 in combination with 240 mg Toripalimab to assess the antitumor activity and safety/tolerability.
88804422|NCT05199415|Experimental|HaWC Intervention|These are the buildings that are randomized to receive the intervention during the study period.
88804423|NCT05199415|No Intervention|Control|These are the buildings that are randomized to continue as normal (no intervention) during the study period.
89151994|NCT02827721||pulmonary healthy controls|Patients without known or suspected pulmonary disease
89151995|NCT04244201|Experimental|VHT treatment|Patients will be treated with VHT for 1 hour four times per week
89151996|NCT00651690|Experimental|1|Botulinum Toxin Type A
89151997|NCT00651690|Placebo Comparator|2|Saline
89151998|NCT04243655|Experimental|Hemoperfusion treatment with HA 330-II|Hemoperfusion treatment with HA 330-II, one unit for 2-4 hours treatment, for 3 consecutive days along with SMT as per patients requirement.
89151999|NCT04243655|Active Comparator|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
89152000|NCT00651768|Experimental|1|
89152001|NCT00651768|Sham Comparator|2|
89152002|NCT02826005|Experimental|cirrhotic patients|if positive for 3 bio-markers- will be followed by MRI for HCC diagnosis
89152003|NCT02826005|No Intervention|non cirrhotic patients|control group - 3 bio-markers will be measured only
89152004|NCT02646852|Experimental|PLX038 Q3W|intravenous infusion once every 3 weeks
89152005|NCT02646852|Experimental|PLX038 QW ×2|intravenous infusion once weekly for 2 consecutive weeks of a 4-week cycle
89152006|NCT02826239||pulmonary healthy controls|patients without known pulmonary disease
89152007|NCT02826239||pulmonary disease|patients with known or suspected pulmonary disease
89152008|NCT02647008|Experimental|ACTIVE TENS|ACTIVE TENS
89152009|NCT02647008|Placebo Comparator|PLACEBO|INACTIVE TENS
89152010|NCT02647008|No Intervention|CONTROL|NO TENS
89152011|NCT00651846|Experimental|Arm 1|
89152012|NCT00651846|Active Comparator|Arm 2|
89152013|NCT00603746|Experimental|GW685698X|GW685698X
89152014|NCT02646696||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
89152015|NCT02646696||Typically Developing Children|typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
89152016|NCT04167306|Experimental|1) Varenicline + Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Investigational medicinal product (IMP) 2: Bupropion SR 150 mg
89152017|NCT04167306|Experimental|2) Varenicline + Placebo for Bupropion|Investigational medicinal product (IMP) 1: Varenicline 0.5 mg and 1.0 mg and Placebo capsule for IMP 2 (bupropion)
89152018|NCT04167306|Experimental|3) Bupropion + Placebo for Varenicline|Investigational medicinal product (IMP) 2: Bupropion SR 150 mg and Placebo capsule for IMP 1 (varenicline)
89152019|NCT04167306|Placebo Comparator|4) Placebo for Varenicline + Placebo for Bupropion|Placebo capsule for IMP 1 (varenicline) and Placebo capsule for IMP 2 (bupropion)
89152020|NCT04244591|Placebo Comparator|standard care|standard care
89152021|NCT04244591|Experimental|standard care + methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
89152022|NCT02827799|Placebo Comparator|Heart Failure Self-Management Education|This treatment includes participation in 4 one hour biweekly face-face sessions of education on heart failure self-management, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
89152023|NCT02827799|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This treatment includes participation in 4 one hour biweekly face-face sessions of cognitive behavioral therapy for insomnia, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
89152024|NCT02827565|Experimental|CircuLOR-1|KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (exon 15) mutations
89152025|NCT04167696|Experimental|Dose Escalation Dose Level 1|"in case of no dose limiting toxicity (DLT) and no replacement of patients, 3 consecutive patients at the dose of 1x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
89152026|NCT04167696|Experimental|Dose Escalation Dose Level 2|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 3x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
89152027|NCT04167696|Experimental|Dose Escalation Dose Level 3|"in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 1x10e9 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.~The preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg/m²/day) and fludarabine (30 mg/m²/day), two days before the CYAD-02 infusion.~In case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy."
89152028|NCT02827487|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) and an oral placebo similar to Celecoxib 2 hours before IUD insertion.
89152029|NCT02827487|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg (Celebrex® 200, Pfizer, USA) and an oral placebo similar to Tramadol 2 hours before IUD insertion.
89152030|NCT02827487|Placebo Comparator|Placebo 1|Women will receive a placebo similar to Tramadol and a placebo similar to Celecoxib orally 2 hours before IUD insertion.
89152031|NCT02689388|Active Comparator|General Anesthesia with nerve block|Femoral Nerve Block
89152032|NCT02689388|No Intervention|General Anesthesia no nerve block|No femoral Nerve Block
89152033|NCT05088629|Other|One group|3-meter Walk Back Test, Proprioception, Trunk Control and Muscle Strength test
89152034|NCT04273373|Active Comparator|Standard dose albumin+SOC|20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours. SOC (Standard of Care)
89152035|NCT04273373|Experimental|Low dose albumin+SOC|20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg. after 48 hours SOC (Standard of Care)
89152036|NCT03709862||Syphilis|Patients with syphilis and detectable Treponema pallidum DNA in a routinely collected clinical sample
89152037|NCT04244825|Experimental|Cohort 1a BLD-2660|900 mg (6 x 150 mg capsules) BID
89152038|NCT04244825|Experimental|Cohort 1b BLD-2660|900 mg (6 x 150 mg capsules) BID (Optional)
89152039|NCT04244825|Experimental|Cohort 2 BLD-2660|600 mg (4 x 150 mg capsules) BID
89152040|NCT04244825|Experimental|Cohort 3 BLD-2660|300 mg (2 x 150 mg capsules) BID
89152041|NCT04244825|Placebo Comparator|Cohort 1a Placebo|900 mg (6 x 150 mg capsules) BID
89152042|NCT04244825|Placebo Comparator|Cohort 1b Placebo|900 mg (6 x 150 mg capsules) BID (Optional)
89152043|NCT04244825|Placebo Comparator|Cohort 2 Placebo|600 mg (4 x 150 mg capsules) BID
89152044|NCT04244825|Placebo Comparator|Cohort 3 Placebo|300 mg (2 x 150 mg capsules) BID
89152045|NCT02649504|Active Comparator|R+3D, MMF|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Mycophenolate mofetil (MMF) will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
89152046|NCT02649504|Placebo Comparator|R+3D, Placebo|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Placebo will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
89152047|NCT04260542|Active Comparator|FAST Lean|Short-term fasting (FAST), comparator group of lean subjects
89152048|NCT04260542|Experimental|FAST Obese|Short-term fasting (FAST), experimental group of obese subjects
89152049|NCT04260542|Experimental|KETO Obese|Medium-term ketogenic diet intervention (KETO), experimental group of obese subjects
89152050|NCT00650910|Experimental|lapatinib + digoxin|All subjects received 0.5mg digoxin on Days 1 and 9 with daily dosing of 1500mg oral lapatinib starting on Day 2 and continuing through Day 9. Subjects could continue past Day 9 on daily oral lapatinib until Week 10 when they could transfer into a rollover study (EGF19060 or EGF111767).
89152051|NCT02827253||Predialysis|Patients with CKD (4 and 5 stages by KDOQI guidelines) underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A MRI 6 months after starting haemodialysis will be performed to analyze changes in gray and white matter of the brain.
89152052|NCT02827253||Haemodialysis|Patients with end stage of renal disease (ESRD) in haemodialysis underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A one year follow up MRI will be performed to analyze the changes in gray and white matter of the brain.
89152053|NCT00622310|Experimental|1 Exercise|Subjects in the EX group will perform supervised exercise 5 d/wk. Exercise will consist primarily of walking on an inclined motor-driven treadmill, but alternate activities will be permitted for 20% of the total exercise sessions (1 of 5 days). Exercise sessions will be preceded by a 5 min warm-up performed at a HR corresponding to 40% of VO2max. The initial exercise duration and intensity at baseline will be 20 minutes at an intensity that elicits a heart rate (HR) corresponding to 60% of VO2max. The target EE will be achieved by a gradual progression of exercise duration and intensity over the first 8 weeks of the exercise program. The target exercise intensity will be the workload corresponding to 75% of VO2max.
89152054|NCT00622310|Experimental|2 Walk|Subjects in the WALK group will also perform exercise 5 d/wk. Exercise will consist exclusively of walking on level grades, and will be prescribed in two equal duration bouts each day. Subjects in the WALK group will be individually prescribed a walking program based on the EE during moderate intensity walking. The target exercise intensity will be walking speeds corresponding 45% of VO2max.
89152055|NCT02654574|Experimental|Face-to-face collection followed by collection by phone|Reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, followed by the collection of IADL by phone, one month later.
89152056|NCT02654574|Experimental|Collection by phone followed by face-to-face collection|Collection of IADL by phone, followed by the collection of the IADL questionnaire using the reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, one month later.
89152057|NCT02654730|Experimental|G6PD deficient 0.25 mg/kg PQ + DHAP|
89152058|NCT02654730|Experimental|G6PD deficient 0.4 mg/kg PQ + DHAP|
89152059|NCT02654730|Active Comparator|G6PD deficient DHAP only|
89152060|NCT02654730|Active Comparator|G6PD normal 0.25 mg/kg PQ + DHAP|
89152061|NCT02654730|Active Comparator|G6PD normal 0.4 mg/kg PQ + DHAP|
89152062|NCT02687672|Experimental|Stem Cell Transplantation|Injection of leukapheresis-derived, purified, autologous CD34+and CD133+ stem cells
89152063|NCT02687672|Experimental|Stem Cells|Injection of bone marrow-derived, purified, autologous CD34+and CD133+ stem cells.
89152064|NCT00888329|Experimental|Aprepitant|40 mg aprepitant
89152065|NCT00888329|Placebo Comparator|Placebo|Placebo
89152066|NCT04187222|Experimental|Test Group|Mechanical treatment + Bifidobacterium animalis subsp. lactis
89152067|NCT04187222|Placebo Comparator|Control Group|Mechanical treatment + Placebo
89152068|NCT02654496||Group 1 (Successful weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had successful weight loss
89152069|NCT02654496||Group 2 (Suboptimal weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had suboptimal weight loss
89152070|NCT02654496||Group 3 (Control group)|A control group who has not had Roux-en-Y gastric bypass surgery and are of similar age, gender, body mass index as the gastric bypass groups.
89152071|NCT00603590|Experimental|Polypill|Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg
89152072|NCT00603590|Placebo Comparator|Control|Identical placebo
89152073|NCT00650988|Experimental|Barrett's Esophagus with intramucosal carcinoma (IMCA)|
89152074|NCT00650988|Experimental|Barrett's Esophagus with High Grade Dysplasia (HGD)|
89152075|NCT02649348|Other|pre-operative prehabilitation|Patients in the pre-operative prehabilitation group required the exercise intervention protocol, which included climbing six flights of stairs at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction following abdominal surgery by using a full elastic breathable abdominal bandage.
89152076|NCT02649348|No Intervention|Comparator|Patients in the control group did not need to undergo this pre-rehabilitation protocol and prepared conventionally.
89152077|NCT04187534|Experimental|Albumin Fluid Resuscitation Optimization Intervention|Our quality improvement intervention seeking to improve appropriate use and reduce inappropriate use of albumin for fluid resuscitation will consist of establishing a clinical champion, educating clinicians, changing the process for albumin ordering through development of an albumin order sheet, and providing quarterly unit-level audit/feedback data to clinicians on albumin utilization.
89152078|NCT04187534|Active Comparator|Usual Practice|Stepped-wedge roll out of 'Albumin Fluid Resuscitation Optimization Intervention' will permit those ICUs wherein intervention has not yet been implemented to serve as controls. These ICUs will prescribe albumin according to usual practice and not be exposed to any components of the intervention.
89152079|NCT00652002|Experimental|1|
89152080|NCT00652002|Active Comparator|2|budesonide
89152081|NCT00652002|Active Comparator|3|formoterol
89152082|NCT02689700||HCMV antibody-transfer|Materno-fetal HCMV antibody-Transfer form 24-41 weeks of gestation
89152083|NCT02689700||VZV antibody-transfer|Materno-fetal VZV antibody-Transfer form 24-41 weeks of gestation
88804424|NCT05197725|Experimental|Mask intervention|Communities randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use. Every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people. In arms randomized to school promotion, secondary school children will also be encouraged to wear masks both inside and outside of school.
88804425|NCT05197725|No Intervention|Control|Control individuals will receive no masks or behavior change communication.
88804426|NCT05195827|Experimental|PRM125|PRM125
88804427|NCT05180734|Experimental|JS001 240mg, Q3W with XELOX regimen or SOX regimen|"JS001 240mg, will be intravenously administered once every 3 weeks, until 17 cycles XELOX regimen (oxaliplatin + capecitabine) or SOX regimen (oxaliplatin + S-1), given in one therapeutic cycle of 3 weeks for up to 8 cycles XELOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; capecitabine, 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W.~SOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; S-1 Capsules, 40-60mg, orally, twice per day, from day 1 to day 14, Q3W."
88804428|NCT05180734|Placebo Comparator|Placebo combine with chemotherapy|"XELOX regimen (oxaliplatin + capecitabine) or SOX regimen (oxaliplatin + S-1), given in one therapeutic cycle of 3 weeks for up to 8 cycles XELOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; capecitabine, 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W.~SOX regimen: Oxaliplatin, 130mg/m2, intravenous drip for over 3 hours, day 1, Q3W; S-1 Capsules, 40-60mg, orally, twice per day, from day 1 to day 14, Q3W."
88804429|NCT05180006|No Intervention|Arm 1A: control arm; no treatment, in TNBC patients (cohort 1)|Control arm : no treatment
88804430|NCT05180006|Experimental|Arm 1B: Atezolizumab, in TNBC patients (cohort 1)|atezolizumab alone, administered as one single IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of standard of care neoadjuvant systemic treatment.
88804431|NCT05180006|Experimental|Arm 1C: Atezolizumab + Ipatasertib, in TNBC patients (cohort 1)|atezolizumab as one single IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of standard of care neoadjuvant systemic treatment, in combination with daily oral ipatasertib for 14 days starting at the same time as atezolizumab administration
89152084|NCT02646540|Experimental|Tolvaptan 30 mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 30 mg of tolvaptan concomitantly with their standard dose of diuretics.
89152085|NCT02646540|Active Comparator|Metolazone 5mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 5mg metolazone concomitantly with their standard dose of diuretics.
89152086|NCT02646540|Active Comparator|IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive two and a half (2.5) times their standard dose of diuretics.
89152087|NCT04061148|Other|Non-Depressed Controls|"Volunteers who have screened by a clinical psychiatrist, to exclude depression and other major psychiatric and neurocognitive disorders.~They will undergo NIRSIT testing to measure frontal blood oxygenation up to 3 times, with an interval of 3 weeks between each measurement."
89152088|NCT04061148|Active Comparator|Depressed Patients|Patients diagnosed with Major Depressive Disorder by a clinical psychiatrist. They will undergo NIRSIT testing to measure frontal blood oxygenation up to 5 times, with an interval of 3 weeks between each measurement, over the course of their clinical therapy for Major Depressive Disorder.
89152089|NCT04186052|Experimental|BCMA CAR-T cells Infusion|
89152090|NCT02654418|Experimental|SIC 8000, 10 mL ampoules|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with SIC 8000 injectate solution.
89152091|NCT02654418|Active Comparator|reference comparator|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with Reference Comparator Injectate solution (site standard of care injectate solution).
89152092|NCT00639080||Entire study population|All study subjects.
89152093|NCT00651066|Experimental|1|RBT (150 mg TPW during 3 weeks switch to 150mg OD for the following 3 weeks) associated with LPV/r based ART
89152094|NCT00651066|Experimental|2|RBT (150 mg OD during 3 weeks switch to 150mg TPW for the following 3 weeks) associated with LPV/r based ART
89152095|NCT02646150||critical limb ischemia|
88804432|NCT05180006|Experimental|Arm 1D: Atezolizumab + Bevacizumab, in TNBC patients (cohort 1)|atezolizumab and bevacizumab as one single IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of standard of care neoadjuvant systemic treatment.
88804433|NCT05180006|No Intervention|Arm 2A: control arm; no treatment, in HER2+ patients (cohort 2)|no treatment
88804434|NCT05180006|Experimental|Arm 2B: Atezolizumab + Trastuzumab + Pertuzumab, in HER2+ patients (cohort 2)|atezolizumab as one single IV infusion in combination with trastuzumab + pertuzumab for one IV infusion on day -15 +/- 48 h (D1) prior to the date of surgery or the start of standard of care neoadjuvant systemic treatment.
88804435|NCT05149144|Experimental|Experimental: audiosignal dataset creation and machine learning analysis|Experimental: audiosignal dataset creation and processing; machine learning analysis, empirical evaluations
88804436|NCT05148884|Experimental|NLX-112|Patients will self-administer NLX-112 2 times each day, once in the morning and once in the evening. Up-titration over 4 weeks, maximal dose of 2 mg/day during 2 weeks, down-titration over 2 weeks.
88804437|NCT05148884|Placebo Comparator|Placebo|Patients will self-administer placebo 2 times each day, once in the morning and once in the evening. Up-titration of number of tablets over 4 weeks, number of tablets equivalent to maximal dose of 2 mg/day NLX-112 during 2 weeks, down-titration over 2 weeks.
88804438|NCT05110430||BS-UKA|Patients who underwent bone scintigraphy scanning between 2010 and 2018 at RTWH Aachen university hospital, and had a bone scan report that indicates the presence or absence of metastatic bone disease.
88806040|NCT01157429|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
89152096|NCT02687516|Experimental|Family-based behavioral social facilitation therapy.|The FBSFT condition includes 17 weekly family-based treatment sessions at the hospital obesity clinic followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital every third month for 2 years.The treatment targets both child and parent life-style; eating habits, physical activity, sedentary activity and sleep habits. Behavior modification techniques are systematically employed; such as self-monitoring, goal setting, reward systems, problem solving and stimulus control. In addition, FBSFT focuses on facilitating lifestyle change across different settings (family, friends, school and community) and harnessing social support for healthy habits, which is considered important for long-term weight control.
89152097|NCT02687516|Active Comparator|Treatment as usual|The TAU condition involves an assessment day with the multidisciplinary team (pediatrician, dietician, physical therapist and psychologist) at the hospital obesity clinic. Further a session with the nurse at the hospital clinic making a plan for behavioral lifestyle changes followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital clinic every third month for 12 months. After 12 months they will be offered treatment by family-based behavioral social facilitation therapy (as in the other treatment arm).
89152098|NCT00888173|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89152099|NCT00650130||1|drivers of motorised vehicles suspected of being under the influence of psychoactive drugs
89152100|NCT04581668|Other|Neurally adjusted ventilatory assist first|Ventilation in NAVA mode then ventilation in conventional mode
89152101|NCT04581668|Other|Conventional ventilation first|Ventilation in conventional mode then ventilation in NAVA mode
89152102|NCT02825927|Experimental|Intervention group|Intensive training with oral screen for 5 weeks.
89152103|NCT02825927|No Intervention|Control group|The control group is not offered any intervention.
89152104|NCT02654184|Active Comparator|Supine group|Anesthesia induction with sevoflurane for the patient while he is in supine position.
89152105|NCT02654184|Active Comparator|Right lateral group|Anesthesia induction with sevoflurane for the patient while he is in right lateral position position.
89152106|NCT03495596||Videolaryngoscopy patients|The patients who were attempted to be intubated with videolaryngoscopy
89152107|NCT02827409|Active Comparator|Short Delay Cord Clamping|Subject will have umbilical cord clamped and cut by 1 minute of life.
89152108|NCT02827409|Active Comparator|Extended Delay Cord Clamping|Subject will have umbilical cord clamped and cut after at least 5 minutes of delayed cord clamping. Duration of cord clamping after 5 minutes will depend on if the subject is breathing and/or if the cord has stopped pulsating
89152109|NCT02646072|Active Comparator|Diabetes mellitus patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
89152110|NCT02646072|No Intervention|Diabetes mellitus control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
89152111|NCT02646072|Active Comparator|Non diabetic patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
89152112|NCT02646072|No Intervention|Non diabetic control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
89152113|NCT03883724|Experimental|Brief behavioral treatment for insomnia|This group will undergo behavioral intervention proven to improve sleep among older adults: brief behavioral treatment for insomnia
89152114|NCT03883724|Other|Information-only control|This group is called information-only control. They will be provided sleep-related information. They will also view a video content of which overlap substantially with BBTI but without individualized behavioral instructions.
89152115|NCT02646306||Shoulder Impingement Syndrome|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
89152116|NCT02646306||Healthy Subjects|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
89152117|NCT05073887|Experimental|3 nerve|3 genicular nerve blockade and radio frequency ablation
89152118|NCT05073887|Active Comparator|5 nerve|3 genicular nerve blockade and radio frequency ablation 2 genicular nerve blockade and pulse radio frequency
89152119|NCT02654106|Experimental|Refractory Brain Metastases|Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases
89152120|NCT04244435|Experimental|Thoracic epidural analgesia|CABG and thoracic epidural analgesia will be used for perioperative analgesia postoperative period
89152121|NCT04244435|Active Comparator|Opioids|CABG and opioids will be used for perioperative analgesia
89152122|NCT04244435|Active Comparator|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
89152123|NCT04243733|Other|calcium enriched mixture material (CEM)|Using CEM as a pulpotomy agent against MTA pulpotomy agent.
89152124|NCT04243733|Experimental|Mineral trioxide aggregate material (MTA)|Using MTA as a pulpotomy agent against CEM pulpotomy agent.
89152125|NCT03434366|Experimental|ketamine and dexmedetomidine group|intranasal ketamine and dexmedetomidine was treated in the children
89152126|NCT03434366|Experimental|ketamine group|intranasal ketamine was treated in the children
89152127|NCT03434366|Placebo Comparator|control group|intranasal insaline was used in the children
89152128|NCT04167150|Active Comparator|Dose 1|Participants consume 8 fl oz of tart cherry juice per day.
89152129|NCT04167150|Experimental|Dose 2|Participants consume 2 x 8 fl oz of tart cherry juice per day.
89152130|NCT05068193|Other|Sequence 1|"The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.~*Sequence 1~[Period I] Administration of BR2008-1 (single dose)~- Wash out for 2 weeks~[Period II] Administration of BR2008 (single dose)"
89152131|NCT05068193|Other|Sequence 2|"The investigational products will be administered according to the treatment groups(BR2008, BR2008-1) assigned to each sequence group in Period I and Period II.~*Sequence 2~[Period I] Administration of BR2008 (single dose)~Wash out for 2 weeks~[Period II] Administration of BR2008-1 (single dose)"
89152132|NCT02687594||single group|sucroferric oxyhydroxide
89152133|NCT00652158|Experimental|A|
89152134|NCT04167228||CRE infected patients treated with ceftazidime-avibactam|Patients with infections caused by carbapenem resistant enterobacteria treated with ceftazidime-avibactam
89152135|NCT04167228||CRE infected patients treated with best available treatment|Patients with infections caused by carbapenem resistant enterobacteria treated with the best available treatment
89152136|NCT02689544|Experimental|static stretching|Group of 15 volunteers (gSS)
89152137|NCT02689544|Experimental|dynamic stretching|Group of 15 volunteers (gDS)
89152138|NCT02689544|Other|control|Group of 15 volunteers (gC)
89152139|NCT03372980||Case|
89152140|NCT03372980||Control|
89152141|NCT02649114|Active Comparator|Cognitive-Behavioural Therapy|This version of CBT is based on techniques employed in evidence-based approaches to a transdiagnostic sample. The programme includes; individualized formulation, taking into account different maintaining factors across cases (e.g., nutritional and/or emotional drivers for binging); agenda setting; homework; change in diet (particularly to improve carbohydrate intake); diary-keeping; exposure; behavioral experiments; cognitive restructuring; and surveys. The behavioral change is maintained as a focus, along with changes in mood and cognitions.
89152142|NCT02649114|Experimental|Compassion-Focused Therapy|There are four main treatment elements to the program. Two of these are linked to the experience of being a therapy group. This involves patients providing compassionate support to other group members.The third treatment element involves compassionate mind training which mainly focuses on activating the soothing system via imagery and related practical exercises.The final element of the program aims to help patients improve their ability to use their wider social network to access support.
89152143|NCT02687438|Experimental|Treatment|Steroid-releasing sinus implant placement following ethmoidectomy in addition to post-op standard of care (i.e. debridement, irrigation, and topical steroids)
89152144|NCT04168554||Phase 1 and Phase 2|"20 patients studied in the emergency room with a pediatrician not presen in the ER performing the telemedicine examination from a distance (ie an office down the hall) followed directly by a face-to-face~20 patients included in the general practitioners office, telemedicine is performed from within the hospital to the GPs office.~Patient is then still referred to the hospital in order to check whether the telemedicine and face-to-face examination are somewhat similarce physical examination"
89152145|NCT02537834|Experimental|Tofogliflozin ＋GLP-1 analogue|Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.
89152146|NCT02648802|Experimental|Cavity shaving and CM assessment|Standardized BCS with additional cavity shaving before CM assessment.
89152147|NCT02648802|Placebo Comparator|CM assessment|Standardized BCS with CM assessment.
89152148|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 1|An oral 25 mg dose of SEP 363856 once daily for 3 days, then 50 mg dose of SEP-363856 once daily for 7 days.
89152149|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 2|An oral 50 mg dose of SEP 363856 once daily for 3 days, then 75 mg dose of SEP-363856 once daily for 7 days.
89152150|NCT03370640|Experimental|SEP-363856 Part 2 Cohort 3|An oral 25 mg dose of SEP 363856 once daily for 3 days, 50 mg dose of SEP 363856 once daily for 4 days, and then 75 mg dose of SEP-363856 once daily for 7 days.
89152151|NCT02648958|Placebo Comparator|Control group|The control group received saline instead of dexmedetomidine.
89152152|NCT02648958|Experimental|Dexmedetomidine group|The dexmedetomidine group received the dexmedetomidine.
89152153|NCT00887549|Experimental|Pemetrexed|
89152154|NCT02649036||Emergency call population|Citizens over 18 years old from the Capital Region of Denmark with a first time emergency call within a two-year study period (1/12-2011-30/11-2013)
89152155|NCT02649036||Background population|Citizens over 18 years old from the Capital Region of Denmark with no emergency call within a two-year study period (1/12-2011-30/11-2013)
89152156|NCT04243811|Experimental|laser group|local anesthesia applyed with 940 nm diode laser
89152157|NCT04243811|Active Comparator|conventional group|local anesthesia applyed with topical anesthesia
89152158|NCT00651222||1|All deceased patients who underwent brachytherapy at Chicago Prostate Center between 10/14/1997 and 6/15/2007
89152159|NCT00638300|Experimental|1|large pore dialyzers (FX80, Fresenius, Germany)
89152160|NCT00638300|Experimental|2|small pore dialyzers ( F8HPS, Fresenius, Germany)
89152161|NCT00638300|Experimental|A|dialysate bicarbonate concentration of 33 mEq/l
89152162|NCT00638300|Experimental|B|dialysate bicarbonate concentration of 40 mEq/l
89152163|NCT00638300|Experimental|I|dialysate calcium concentration of 3 mEq/L
89152164|NCT00638300|Experimental|II|dialysate calcium concentration of 2.5 mEq/L
89152165|NCT00887315|Active Comparator|Group 1|Chemotherapy only
89152166|NCT00887315|Active Comparator|2|Chemotherapy and hypofractionated image guided radiotherapy
89152167|NCT02645916|Experimental|DSGOST|admission to Danggui-Sayuk-Ga-Osuyu-Saenggang-tang granule
89152168|NCT02645916|Placebo Comparator|Placebo|admission to placebo
89152169|NCT02688998|Active Comparator|Venous access PORT or PICC|Participants will receive a central line placement either a PORT or a PICC prior to the initiation of chemotherapy.
89152170|NCT02688998|No Intervention|No intervention|Participants will only receive a central line if required once chemotherapy has been initiated.
88804439|NCT05110430||BS-Namur|Patients who underwent bone scintigraphy scanning between 2010 and 2018 at Namur university hospital, and had a bone scan report that indicates the presence or absence of metastatic bone disease.
89152171|NCT02645994|Experimental|Target Controlled Infusion|Propofol is administered through a target controlled infusion pump based on Marsh model to achieve a BIS of 50 and manually adjusted to maintain BIS between 40 and 60
89152172|NCT02645994|Active Comparator|Closed Loop Anesthesia Delivery System|Propofol is administered through Closed Loop Anesthesia Delivery System which is titrated automatically to achieve a target BIS of 50 and maintain it between 40 and 60.
89152173|NCT04243031||All subjects|Those with TB and those without TB.
89152174|NCT02645838|Experimental|Motivational interviewing group|"Structural motivational interviewing for one section (about 20 mins)，provided by family physician~Follow-up telephone call，provided by family physician"
89152175|NCT02645838|No Intervention|Brief advice group|Brief advice without motivational interviewing (about 5 mins), provided by family physician
89152176|NCT04242719|Active Comparator|Only electromagnetic stimulation|Only rEMS was preferred as the initial step
89152177|NCT04242719|Active Comparator|Combined with electromagnetic stimulation and PRP|Order to augment the effect of the rEMS, sub-tenon aPRP injection was added.
89152178|NCT04242719|No Intervention|Natural course|Served as control group, and existing systemic disorder(s) were consulted and treated accordingly.
89152179|NCT04166760|Active Comparator|WHE (regular whey protein)|Regular whey protein. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
89152180|NCT04166760|Experimental|speWHE (specific whey protein compound)|Specific whey protein compound. The intervention will be ingested 30 min. prior to an OGTT (3 hours). The intervention will also be ingested 30 min prior to breakfast and dinner for 2 days in the patient's own environment.
89152181|NCT04243967|Experimental|MUSIC THERAPY|
88804440|NCT05110430||BS-Aalborg|Patients who underwent bone scintigraphy scanning between 2010 and 2018 at Aalborg university hospital, and had a bone scan report that indicates the presence or absence of metastatic bone disease.
88804441|NCT05099926|Experimental|Reducing Exercise Sensitivity with Exposure Training|Participants in this group complete 2, at-home reducing exercise sensitivity with exposure training (RESET) intervention visits with research-trained personnel via video visits. They complete psychoeducation, and a brief walking activity (i.e., interoceptive exposure), followed by a session reflecting upon their walking experience with research-trained personnel (i.e., interoceptive counseling). Participants also complete weekly physical activity journals throughout the intervention. Each RESET intervention visits can occur once or twice per week over the course of 2 weeks, based on patient preference.
88804442|NCT05070065|Experimental|virtual reality|The experimental group A receives the cognitive remedy intervention with virtual reality (CEREBRUM)
88804443|NCT05070065|Other|waiting list|waiting list
89152182|NCT04243967|Experimental|CONTROL|
89152183|NCT00652236||FCT|Patients passing a function- centred rehabilitation
89152184|NCT00652236||PCT|Patients passing a pain-centred rehabilitation
89152185|NCT02645682|Experimental|anti-infection CVC (Certofix®protect)|intervention group
89152186|NCT02645682|Active Comparator|normal CVC (Certofix®)|control group
89152187|NCT04244045|Experimental|Experimental group 1|suboccipital muscle inhibition plus passive stretch of hamstring muscle.
89152188|NCT04244045|Experimental|Experimental group 2|Neural slump strtch position plus passive stretch of hamstring muscle.
89152189|NCT04244045|Active Comparator|Control group|passive stretch of hamstring muscle
89152190|NCT02645058|Experimental|RIRS (retrograde intrarenal surgery)|In the first arm (RIRS) the patients will be treated by a standard retrograde ureterorenoscopy and Holmium laser lithotripsy. Preoperative exams will be abdomen ultrasound and Xray (CT in case of stones > 15 mm), urine analysis and culture (according to all the more recent guidelines). Surgeries will be performed under general or spinal anesthesia, according to anesthesiologist evaluation. According with standard technique, ureteroscopy will be performed using both rigid and flexible ureteroscope. Lithotripsy will be performed by Holmium laser. Major stone fragments will be removed at the end of the procedure. Finally a double J ureteral stent will be push in specific cases depending on intraoperative findings (length of the procedure, macroscopic view of the ureter, residual stones etc.). RIRS will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
89152191|NCT02645058|Experimental|ESWL (extracorporeal shockwaves lithotripsy)|In the second arm (ESWL) the patients will be treated by a standard extracorporeal shock waves lithotripsy (ESWL). Preoperative exams will be the same as first arm. No general or spinal anaesthesia will be used, but just intravenous medications if required. Ultrasound and/or X-Ray will be used to locate the stone. Power and number of shock waves will consist in 20-24 KV and 3000-3500 sw respectively, according to individual tolerance. ESWL will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
89152192|NCT02577224|Experimental|Intervention|Participants randomized to the intervention group (patient-initiated treatment) will be asked to initiate their own treatment during the nine months they are taking part in the trial. Intervention group participants will receive information about when and how to initiate an appointment. Contact details for the service will be provided along with information on how quickly an appointment will be made, with whom and the procedure in the case of an emergency. All patients requesting an appointment will be booked in to the next available slot within the twice weekly ring-fenced nurse-led clinics. Any subsequent scheduled appointments will be cancelled and all future treatment will be initiated by the patient.
89152193|NCT02577224|No Intervention|Control|Participants in the control group will receive treatment as usual. This consists of scheduled appointments in the hospital-based nurse-led botulinum toxin clinic. The frequency with which these appointments takes place are based on clinical judgement, but tend to range between every 6 weeks to every 4 months.
89152194|NCT02826785|Experimental|Cognitive strategy training|The cognitive strategy training intervention consists of 6 weekly ~1 hour sessions. It is delivered in an individual, face-to-face format in the client's home. It is a behavioral intervention that teaches people metacognitive, problem-solving and other compensatory strategies to address self-identified cognitive performance problems, and it uses practice and homework to promote strategy learning, retention and transfer.
89152195|NCT02826941|Experimental|Hypothermia|If randomized to hypothermia, plastic bags filled with ice wrapped in a washcloth were applied to the head and body for approximately 2 hours, then the infant was placed on an adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature to 33 ± 0.5 °C for 48 hours at the participating tertiary care center. Rewarming by 0.5°C per hour was begun after 48 hours of hypothermia.
89152196|NCT02826941|Placebo Comparator|Normothermia|If randomized to normothermia, rectal temperatures were maintained at 37 ± 0.5 °C per standard neonatal intensive care unit practice, using adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature of 37 ± 0.5 if baby was febrile.
89152197|NCT02825459|Experimental|Abstinence from e-cigarettes|Participants abstain from e-cigarettes and other nicotine/tobacco products for 6 days
89152198|NCT02825459|No Intervention|E-cigarette use|Participants use e-cigarettes and continue to abstain from tobacco/nicotine products as they normally would.
89152199|NCT02644980|Experimental|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
89152200|NCT02644980|Experimental|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
89152201|NCT04187456|Experimental|Midazolam + Savolitinib|"Treatment Period 1: Single administration of midazolam (1 mg) will occur on Study Day 1, after a high fat, high calorie breakfast, followed by PK sampling for 24 hours.~Treatment Period 2: Single administration of midazolam 1 mg in combination with a single administration of savolitinib (600 mg), after a high fat, high calorie breakfast will occur on Study Day 5 and PK sampling will occur for 24 hours."
89152202|NCT02825537|Experimental|With use of compression stocking|Use of compression stocking during 3 consecutives days
89152203|NCT02825537|Other|Without use of compression stocking|No use of compression stocking during 3 consecutives days
89152204|NCT04168476|Experimental|Treatment group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:~Visual Analogue Scale~Range of movement~Hand grip strength. After a first assessment, scapula mobilization techniques were performed and participants reassessed."
89152205|NCT04168476|Placebo Comparator|Control group|"Participants of this group were assessed by the examiner twice, pre and post intervention, having recorded two values for each of the following variables:~Visual Analogue Scale~Range of movement~Hand grip strength. The procedure was a contralateral calcaneus abduction and adduction mobilization technique was carried out."
89152206|NCT02827331||Patients exposed to benzodiazepines|"Data to be collected are :~Administrative and medical data~Exposition to hypnotics or anxiolytics benzodiazepines"
89152207|NCT02827331||Patients not exposed to benzodiazepines|"Data to be collected are :~Administrative and medical data~Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics"
88804444|NCT05049135||Sleep apnea group|Patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
88804445|NCT05049135||Control group|partners of patients with undiagnosed suspected sleep apnea who are referred to Levanger Hospital for respiratory polygraphy
89152208|NCT02827331||Control group|"Data to be collected are :~Administrative and medical data~Medical consultation without prescription of interest"
89152209|NCT02653950|Active Comparator|Traditional|a control arm of patients undergoing traditional septoplasty for DNS
89152210|NCT02653950|Experimental|Endoscopic|patients undergoing endoscopic septoplasty.
89152211|NCT04185818|Experimental|Reading group|"Participants will:~Read a book for 15 to 30 mins~Read immediately before trying to go to sleep."
89152212|NCT04185818|No Intervention|Control Group|"Participants will:~1. Not read a book"
89152213|NCT04242797|Active Comparator|Calmare|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
89152214|NCT04242797|Active Comparator|Traditional TENS|Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
89152215|NCT02645448|Other|Resistance Exercise Low intensity|"Day 1 (Control Session)~Day 2 (Resistance Exercise)~Day 3 (Duration of effect)"
89152216|NCT02645448|Other|Resistance Exercise High intensity|"Day 1 (Control Session)~Day 2 (Resistance Exercise)~Day 3 (Duration of effect)"
89152217|NCT02687204|Active Comparator|Enoxaparin prophylaxis|All enrolled patients will receive twice daily enoxaparin prophylaxis. Patients with identified out of range peak anti-Xa levels will receive real time dose adjustment and will be considered as the experimental arm.
89152218|NCT02687204|Experimental|Real time dose adjustment|Patients with identified out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment
89152219|NCT04242485|Other|AFTER MATCH + OMT|Players undertook a recording session the day after a rugby match and received osteopathic manipulative treatment
89152220|NCT04242485|Other|AFTER MATCH + sham treatment|Players undertook a recording session the day after a rugby match and received sham treatment
89152221|NCT04242485|Other|NO MATCH + OMT|Players undertook a recording session the day after a resting day and received osteopathic manipulative treatment
88804446|NCT05042817|Active Comparator|Morphine|50 mg prilocaine + 2.5 mcg sufentanil + 100 mcg morphine (0.1ml)
88804447|NCT05042817|Placebo Comparator|NaCl 0.9%|50 mg prilocaine + 2.5 mcg sufentanil + 0.1 ml saline
89152222|NCT04242485|Other|NO MATCH + sham treatment|Players undertook a recording session the day after a resting day and received sham treatment
89152223|NCT03608826|Experimental|Single Arm Study|Invesigational RAMware will be downloaded onto the LINQ device.
89152224|NCT02825615|Active Comparator|Conventional method (CM)|Radial artery cannulation has been done using the conventional method. Cannulation failure with this technique were tried with USG technique secondarily.
89152225|NCT02825615|Experimental|Ultrasound guided method (USG)|Radial artery cannulation is done with ultrasound guidance for this group of patients. Cannulation failure with this technique were tried with Conventional technique secondarily.
89152226|NCT04242641|Experimental|WW (formally Weight Watchers)|The intervention will consist of engaging with the WW programme for 12 weeks, including weekly attendance at a local WW workshop and access to digital tools. Only the parent will take part in the WW intervention. No modifications will be made to the current WW programme to support child weight loss.
89152227|NCT04242641|No Intervention|Control|Participants randomised to the control group will receive no intervention during the 3 month period. Following final data collection control participants will receive 3 month complimentary access to WW.
89152228|NCT04185740|Experimental|Home-based validation|The home-based validation of the TTT will give insight in the task performance of patients OFF-medication compared to ON-medication and on different time points in the medication cycle during 7 days
89152229|NCT00650208|Experimental|1|Lamotrigine Tablets 25 mg
89152230|NCT00650208|Active Comparator|2|Lamictal® Tablets 25 mg
89152231|NCT02689232|Experimental|Thromboelastography (TEG) level|
89152232|NCT02689232|Active Comparator|Coagulation Profile|
89152233|NCT02645370|Active Comparator|Active Comparator:Topiramate|The treatment with TPM is initiated at a 50 mg daily dose and sequentially increase every 7 days, as tolerated, in 25 mg increments up to a target dose of 150 mg total/day.
89152234|NCT02645370|Experimental|Experimental:Danzhen|The treatment with Danzhen is 3 tablets triple daily.
89152235|NCT00652392|Experimental|1|
89152236|NCT00652392|Placebo Comparator|2|
89152237|NCT02490254||1|Any child (aged 0-16 years) with a new diagnosis of uni or bilateral uveitis.
89152238|NCT04168164|Experimental|Ai Chi|Ai Chi aquatic therapy Dry land therapy
89152239|NCT00652470|Active Comparator|ETV|
89152240|NCT00652470|Active Comparator|CSF Shunt|
89152241|NCT02645526|Experimental|KMC with woolen cap|In this group, the head of the patients will be covered with a woolen cap during KMC.
89152242|NCT02645526|No Intervention|KMC without woolen cap|In this group, the head of the patients will be uncovered during KMC.
89152243|NCT02689310|Other|Standard Care - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
89152244|NCT02689310|Experimental|Honey Treatment - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
89152245|NCT02689310|Other|Standard Care - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
89152246|NCT02689310|Experimental|Honey Treatment - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
89152247|NCT02645214|Placebo Comparator|Control scrubs (non-antiseptic)|subject will wear control scrubs for the duration of a 12-hour ICU shift
89152248|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 1|subject will wear antiseptic impregnated scrubs-type 1 for the duration of a 12-hour ICU shift
89152249|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 2|subject will wear antiseptic impregnated scrubs-type 2 for the duration of a 12-hour ICU shift
89152250|NCT02644902|Experimental|Technology Arm|5 days training of health workers in THP through avatar assisted cascade training and supervision
89152251|NCT02644902|Active Comparator|Specialist Arm|5 days training and supervision of health workers in THP by specialists
89152252|NCT04166838|Experimental|CD19 UCAR-T|
89152253|NCT02644824|Experimental|Biventricular Pacing (BiVp)|Consented infants with wide QRS randomized to receive standard of care and BiVp.
89152254|NCT02644824|No Intervention|Control (wide QRS)|Consented infants with wide QRS randomized to receive standard of care alone.
89152255|NCT02644824|No Intervention|Control (narrow QRS)|This is an observation control group. Consented infants with narrow QRS will enter control group 2 without randomization.
89152256|NCT04166682|Placebo Comparator|Control Group|Routine care
89152257|NCT04166682|Experimental|Interventional Group|Home-based cardiac rehabilitation
89152258|NCT02645136|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
89152259|NCT02645136|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation (AES) associated with Pelvic Floor Muscle Training (PFMT), supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
89152260|NCT02645136|Placebo Comparator|Control|Control Group
89152261|NCT02653638|Experimental|Drug|"Control-Hypercapnic Trials: Three stepwise CO2 elevations will be applied to the patient by adding fractional concentration of inspired CO2 (FICO2) at 2%, 4%, and 6% each time, balanced with room air. The end tidal CO2 (PetCO2) will be elevated and maintained constant for three minutes at each target level. Breath-by-breath changes in minute ventilation (VE) and PetCO2 will be measured.~Drug-Indomethacin: Healthy volunteers, indomethacin suspension will be orally administered at 1.2 mg/kg. After drug administration, the patient will rest quietly for 90 minutes."
89152262|NCT02645292|Experimental|1 mile Walk using treadmill|Walking for 1 mile on treadmill (American Motion Fitness, 8800D) as fast as participant can, without any inclination
89152263|NCT02645292|Experimental|Stair Climbing|30 meters of vertical distance to be covered (14 flights of stairs with a total of 154 steps)
89152264|NCT00653484|Experimental|Physical Activity Only|Physical Activity
89152265|NCT00653484|Experimental|Dietary Energy Restriction|Energy restriction
89152266|NCT00653484|Experimental|Physical Activity+Dietary Energy Restriction|Physical Activity ad Energy Restriction
89152267|NCT02644590|Experimental|Melatonin treatment|Adolescents with Type 1 Diabetes will undergo baseline 24 hour ambulatory blood pressure monitoring, followed by treatment with Melatonin for 3 weeks, using a single tablet at bed time, and repeat of the 24-hour blood pressure test following treatment period.
89152268|NCT02644746|Experimental|Acupuncture group|Acupuncture has a long time used for chronic pain including low back pain, sciatica, and other pain related to spina via stimulating specific acupuncture points.
89152269|NCT02644746|Placebo Comparator|Placebo needle group|The placebo needle using in this trial will be unpenetrated needles. Based on our previous research, the placebo needle is a valid control for acupuncture research and may eliminate the placebo effect of acupuncture.
89152270|NCT02644200|No Intervention|ORS|Controls treated with oral rehydration solution (standard therapy)
89152271|NCT02644200|Active Comparator|ORS+GT|Group treated with oral rehydration solution plus gelatin tannate
89152272|NCT02653404||Cases|"A blood sample necessary to perform QFT-GIT will be taken, together with other routine blood samples, from children with following diagnosis:~latent tuberculous infection: active TB contact, TST positive, lack of clinical and RX signs of active-TB~active TB: clinical and radiologic evidences of active-TB, positivity to microbial tests to BK~not infected: patients evaluated as TB contacts, with negative TST and negative clinical/radiological/microbial results for TB."
89152273|NCT02641548|Experimental|Silicone sock+heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet and a sock of silicone is used every night.
89152274|NCT02641548|Active Comparator|Heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet
89152275|NCT04165278|Experimental|Hyperthermic baths|On the first, third and fifth day of the first week, each subject will take the Hyperthermic Baths (HTB) at the same time. They will receive subjective measures before and after HTB. In the second week, no subjects accepted any intervention. On the fifteenth, seventeenth and nineteenth days of the third week, these subjects will receive two subjective measures without HTB in the same environment and scoring time as the experimental group.
89152276|NCT02644434|Active Comparator|Conventional Strategy|Patients randomized to the conventional strategy group would undergo either jailed wire technique (diameter of side branch<2.5mm and ≥2.0mm) or provisional two-stent strategy (diameter of side branch≥2.5mm).
89152277|NCT02644434|Experimental|Intentional Strategy|Patients randomized to the intentional strategy group would undergo either jailed balloon technique (diameter of side branch<2.5mm and ≥2.0mm) or elective two-stent strategy (diameter of side branch≥2.5mm).
89152278|NCT04168086|Experimental|Right Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to motor area of the right cerebellum prior to completing a motor learning task.
89152279|NCT04168086|Experimental|Non-Motor Area Cerebellum|Participants will receive Focused Ultrasound stimulation to a non-motor area of the right cerebellum prior to completing a motor learning task.
89152280|NCT04168086|Sham Comparator|Control|Participants will have the Focused Ultrasound transducer placed on their neck without stimulation as a Sham present prior to completing a motor learning task.
89152281|NCT00910806|Experimental|TMC207, nevirapine|
89152282|NCT00652704|Experimental|A|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fed conditions
89152283|NCT00652704|Active Comparator|B|Subjects received the reference product, Monodox (Oclassen) under fed conditions
89152284|NCT00652704|Experimental|C|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fasting conditions
89152285|NCT00652782|Experimental|1|rolofyline 2.5 mg IV QD
89152286|NCT00652782|Experimental|2|rolofyline 15 mg IV QD
89152287|NCT00652782|Experimental|3|rolofyline 30 mg IV QD
89152288|NCT00652782|Experimental|4|rolofyline 60 mg IV QD
89152289|NCT00652782|Placebo Comparator|5|placebo for rolofyline IV QD
89152290|NCT04166370|Active Comparator|Standard of Practice|Current Standard of Practice
89152291|NCT04166370|Experimental|Strengthened Services and Social Behavioral Change (SBCC)|Increase referrals to health services, strengthen health services, and provide enhanced social and behavior change communication (SBCC)
89152292|NCT04166370|Experimental|Strengthened Services and SBCC plus Conditional Cash Transfer|Increase referrals to health services, strengthenhealth services, provide enhanced SBCC, as well as cash transfers that are conditional on a mother attending antenatal care (ANC) and monthly nutrition education SBCC group sessions.
89152293|NCT04165044|Active Comparator|L-PRF+CAF|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap
89152294|NCT04165044|Active Comparator|CTG+CAF|Connective Tissue graft plus Coronally Advanced Flap
89152295|NCT00653562|Experimental|1|Patients will receive placebo in one part and zolpidem in the other part
89152296|NCT00887159|Active Comparator|Arm A (CE)|Patients receive cisplatin IV over 1-2 hours on day 1 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89152297|NCT00887159|Experimental|Arm B (CE + GDC-0449)|Patients receive cisplatin and etoposide as in Arm A and vismodegib PO QD on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity.
89152298|NCT00887159|Experimental|Arm C (CE + IMC-A12)|Patients receive cisplatin and etoposide as in Arm A and cixutumumab IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cixutumumab alone once weekly in the absence of disease progression or unacceptable toxicity.
89152299|NCT02641470|Experimental|DA9301|Orally administration of DA9301 (Vaccinium uliginosum extract) pills (1000 mg/day) for 4 weeks.
89152300|NCT02641470|Placebo Comparator|Placebo|Orally administration of placebo pills (1000 mg/day) for 4 weeks.
89152301|NCT00650286|Experimental|1|Modafinil Tablets 200 mg
89152302|NCT00650286|Active Comparator|2|Provigil® Tablets 200 mg
89152303|NCT02641158|Other|Control Group|
89152304|NCT02641158|Experimental|Care Facilitation Group|
89152305|NCT02641002|Experimental|Dose escalation of CC-90002|CC-90002 by intravenous (IV) infusion on a 28 day cycle
89152306|NCT02640924|Experimental|Proton radiotherapy|Proton radiotherapy will be totally 66 cobalt gray equivalent (CGE) in 10 fractions and delivered once daily, 5 fractions per week, over 2 weeks for HCC more than 1 cm away from the alimentary tract.
89152307|NCT02640924|Experimental|Radiofrequency Ablation|Multiple-electrode radiofrequency with switch-controller system (ME-SWC RFA) can create a large coagulation necrosis volume and successful treat HCC sized more than 3 cm, extending to 8.5 cm. ME-SWC RFA system uses up to 3 electrodes parallel insertion to inside of the tumors with an equilateral triangular confirmation before initiation of ablation. The distances between electrodes are about 1.5-2 cm, estimated by ultrasound measuring. The switching machine is set on the auto-mode, and all electrodes work alternately and switching each other automatically after impendence surge.
89152308|NCT02535858|Experimental|Heart and respiratory rate and video|To determine the limits between normal and emotional anxious, thirty volunteers male's adults (GL) with age range between 20 and 50 years were recruited. None of them had any pathology associated with anxiety or psychiatric disorders, and none was drugs user or taking medication.
89152309|NCT02535858|Experimental|Heart and respiratory rate and VE|A second group has fifty adult volunteers (DG) ongoing outpatient chemical dependency clinic [treatment average's population: 5 months and 14 days]. The patients were abstained from drugs use for at least two months, and they were selected to test the VE. None of the DG's participants had any pathology associated with anxiety or psychiatric disorders, and none was taking medications. The DG volunteers were narcotic users of two or more illicit drugs, such as alcohol, marijuana, tobacco, cocaine and crack cocaine. Addiction for alcohol and tobacco were 72% and 56% respectively. The group's percentage for using psychoactive drugs were, 70% for cocaine and crack cocaine and 32% for marijuana.
89152310|NCT02640846|Active Comparator|Norepinephrine|Doser
89152311|NCT02640846|Active Comparator|Milrinone|Doser
89152312|NCT02640846|Active Comparator|Levosimendan|Doser
89152313|NCT00653640|Experimental|1|body weight supported treadmill training
89152314|NCT00653640|Placebo Comparator|2|traditional physical therapy
89152315|NCT03500640|Active Comparator|DPP Plus: 30-minute calls|Following the 6-month, 16-session, DPP core program, 30-minute group telephone calls will be implemented. Structured behavioral DPP maintenance sessions with a healthy aging focus occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
89152316|NCT03500640|Placebo Comparator|DPP Minimal: 15-minute calls|Following the 6-month, 16-session, DPP core program, 15-minute group telephone calls will be implemented. Social-support sessions occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
89152317|NCT00886769|Experimental|Canakinumab|Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients>37.5 kg) received two sc injections.
89152318|NCT00886769|Placebo Comparator|Placebo|Patients received a single dose matching placebo of canakinumab on day 1.
89152319|NCT02644044|Experimental|Treatment|Treatment with IT methotrexate
89152320|NCT04165980|Sham Comparator|Sham transcranial direct current stimulation (sham tDCS)|This study has a parallel design and 2 groups: Active tDCS and Sham tDCS. Sham tDCS applies a standard sham protocol consisting of ramping up and down during 30 seconds at the beginning and at the end of each tDCS session. Each tDCS session lasts 20 minutes and applies a total current of 4mA.
89152321|NCT04165980|Active Comparator|Active transcranial direct current stimulation (activetDCS)|The active comparator is the Active tDCS group. The active tDCS will target the resting-state motor network and will apply a distributed direct current during the whole session. (The TIME during the direct current is applied is the only difference with Sham tDCS) Each tDCS session lasts 20 minutes and applies a total current of 4mA.
88804450|NCT05017675|Experimental|High fructose diet|Participants will receive dietary products high in fructose for 4 weeks.
88804451|NCT05017675|Experimental|High saturated fat diet|Participants will receive dietary products high in saturated fat for 4 weeks.
88806041|NCT01157429|Placebo Comparator|Placebo pill|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
89152322|NCT04243187|Experimental|Clinical Study|"9 visits, once a week, for bean intake (80 grams of dried beans, soaked for 12 hours, cooked in new water for 1.5 - 2 hours. This is approximately 160 grams of cooked beans).~Four varieties of beans (3 native and 1 commercial) will be analyzed, which will be consumed in duplicate by participants (8 visits).~A ninth visit will be made to perform a exhaled hydrogen test with raffinose (5 grams), as a positive control."
89152323|NCT02536014|Experimental|Dexmedetomidine|
89152324|NCT02536014|Active Comparator|Saline|
89152325|NCT02643576|No Intervention|Control|Usual SNAP-like food benefits
89152326|NCT02643576|Experimental|Rewards|Usual SNAP-like food benefits, plus a modification to this food benefit program that entails a 30% bonus on eligible fruit and vegetable purchases (i.e. F&V bonus)
89152327|NCT02643576|Experimental|Restrictions|Usual SNAP-like food benefits, plus a modification that requires no sugar-sweetened beverages, candy, or sweet baked goods be purchased
89152328|NCT02643576|Experimental|Rewards plus restrictions|Usual SNAP-like food benefits, plus two modifications to this food benefit program: one modification includes a 30% bonus on eligible fruit and vegetable purchases and the other modification is that sugar-sweetened beverages, candy, or sweet baked goods are not allowed to be purchased (i.e. Bonus & Restriction)
89152329|NCT00886613|Experimental|V212|Participants randomized to receive V212 (heat treated VZV Vaccine)
89152330|NCT00886613|Active Comparator|Zostavax™|Participants randomized to receive Zostavax™ (Zoster Vaccine, live)
89152331|NCT00886613|Placebo Comparator|Placebo|Participants randomized to receive placebo
89152332|NCT02640768|Experimental|educational training|educational training
89152333|NCT02640768|No Intervention|no educational training|no educational training wards
89152334|NCT00886379|Active Comparator|1|Mongolian milk without D
89152335|NCT00886379|Experimental|2|Mongolian milk with vitamin D
89152336|NCT00886379|Experimental|3|Ultra High Temperature (UHT) milk
89152337|NCT00886379|Experimental|4|Milk Substitute
89152338|NCT00886379|Experimental|5|Seasonal D
89152339|NCT00886379|Experimental|6|Daily D
89152340|NCT00633581|Experimental|1|Intravenous injections of 10 grams(20ml as a solution) of vitamin C with 100ml of normal saline over 30 minutes.
89152341|NCT00633581|Placebo Comparator|2|Intravenous injections of 120ml of normal saline over 30 minutes.
89152342|NCT02825147|Experimental|MESA|stage I/II: methotrexate 1000mg/m2,d1 dexamethasone 40mg,d2-d4 etoposide 100mg,d2-d4 pegaspargase 2500U/m2,d5 a cycle of every 21 days with totally 4 cycles Radiotherapy at least 50Gy in dose for the involved local focus is sandwiched after 2 cycles.
89152343|NCT02825069|Experimental|Intervention group|Early introduction of solid foods starting at the age of 4 months, with foodstuff from all major groups in diet by the age of 6 months (vegetables and fruits, wheat and other grains, meat, fish, egg, dairy products). Babies presenting with mild symptoms are encouraged to continue the symptom-eliciting food.
89152344|NCT02825069|No Intervention|Control group|Families are advised to follow the official Finnish Nutrition Recommendations, including exclusive breastfeeding until the age of 6 months.
89152345|NCT02825225|Experimental|20 core-biopsy fragments|Patients submitted to experimental intervention (extended sextant biopsy with 20 cores) compared to current standard biopsy protocol (extended sextant biopsy with 12 cores) guided by transrectal ultrasound.
89152346|NCT02825225|Experimental|Base and apex local anesthesia|Patients submitted to experimental intervention in prostate-biopsy anesthetic protocol (prostate base and prostate apex bilateral local anesthetic injection) compared to participants submitted to current standard anesthetic protocol in institution (prostate base bilateral local anesthesia) guided by transrectal ultrasound. guided by transrectal ultrasound.
89152347|NCT02827097|Experimental|Rectus sheath block group|"administration of denogan~rectus sheath block with 0.375% ropivacaine"
89152348|NCT02827097|Placebo Comparator|Control group|just administration of denogan
89152349|NCT04242407|Active Comparator|DMTS|DMTS applied to the upper arm
89152350|NCT04242407|Placebo Comparator|Placebo|Placebo system (with no drug) to match DMTS applied to the upper arm
89152351|NCT00637949|Experimental|1|
89152352|NCT00637949|Active Comparator|2|
89152353|NCT02825693|Active Comparator|Femtosecond laser cataract surgery|Cataract surgery with femtosecond laser treatment for corneal incisions, astigmatic keratotomies, capsulotomy and nuclear fragmentation
89152354|NCT02825693|Active Comparator|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery
89152355|NCT00599196|Experimental|Rotigotine|Rotigotine
89152356|NCT02825303|Experimental|Novel workplace - first half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the first half of the study. Traditional workstation within the second half of the study.
89152357|NCT02825303|Experimental|Novel workplace - second half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the second half of the study. Traditional workstation within the frist half of the study.
89152358|NCT02825303|No Intervention|Control group|Control group subjects did not encounter any changes in their regular office environments. Traditional workstation for both halves of the study.
89152359|NCT04201145|Experimental|Run in cohort: pembrolizumab only|"Treatment with pembrolizumab as a single agent for 56 days~- 2 doses during treatment cycle, intravenous, at predetermined protocol dose"
89152360|NCT04201145|Experimental|Cohort 1: pembrolizumab + defactinib 12 days|"Treatment with Defactinib in combination with Pembrolizumab for 12 days~Defactinib oral, twice daily, per predetermined dose for 12 days of treatment in combination~Pembrolizumab via infusion, twice per cycle, per predetermined dose"
89152361|NCT04201145|Experimental|Cohort 2: pembrolizumab + defactinib 35 days|"Treatment with defactinib in combination with pembrolizumab to 35 days~Defactinib oral, twice daily, per predetermined dose for 35 days of treatment in combination~Pembrolizumab via infusion, twice per cycle, per predetermined dose"
89152362|NCT04201145|Experimental|Expansion cohort|Tolerated phase IA regimen will be administered in a phase IB expansion cohort
89152363|NCT02652702|Experimental|Circular Stapler-assisted Colostomy|Using Circular Stapler-assisted Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
89152364|NCT02652702|Experimental|Hand-stitching Colostomy|Using Conventional Hand-stitching Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
88804452|NCT04926675|Experimental|Combined intervention|Participants accessing one-to-one psychological therapy from the IAPT service will be asked if they have any money worries affecting their mental health. Suitable participants will be offered one-to-one support from a money advisor, who they will access in tandem to their therapy.
89152365|NCT02824601|Experimental|One-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
89152366|NCT02824601|Experimental|Two-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. In the following, 14-day inter-appointment medication with Ca(OH)2 + SSL was placed in the root canal. After 14 days with intracanal medication, the tooth was isolated for surgery and disinfection, including removal of provisional restoration. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
89152367|NCT02652858|Experimental|Pulse wave's speed observational arm|Whole patients for who the pulse wave's speed are measured during a cardiopulmonary bypass during cardiac surgery
89152368|NCT02643732|Experimental|Methylphenidate|"Methylphenidate 10mg (one tablet) twice daily, increasing to 20mg (two tablets) twice daily following assessment 2 weeks into trial.~24 weeks duration"
89152369|NCT02643732|Placebo Comparator|Placebo|"Identical, over-encapsulated placebo tablets manufactured to be identical to the experimental tablets. One tablet twice daily, increased to two tablets twice daily following assessment 2 weeks into trial.~24 weeks duration."
89152370|NCT02824757||known diabetes|Participants have been diagnosed diabetes.
89152371|NCT02824757||known prediabetes|Participants have been diagnosed impaired glucose tolerance or impaired fasting glucose before.
89152372|NCT02824757||normal glucose tolerance|Participants have done the oral glucose tolerance test and been confirmed the normal glucose tolerance.
89152373|NCT02824757||unclear glucose tolerance condition|Participants who have not done oral glucose tolerance test or been diagnosed diabetes before.
89152374|NCT04241939|Experimental|Numberless BDS and Modified-MI|Use of numberless BDS (color coded), app, and motivational interviewing. Participants will weigh daily and receive weekly motivational interviewing at clinic visits and via a weekly phone call.
89152375|NCT04241939|Active Comparator|Digital Scale|Use standard digital scale (number readout). Participants will weigh daily.
89152376|NCT02643810|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak heart rate) and low-intensity intervals (50-70% of peak heart rate).
89152377|NCT02643810|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 70-75% of peak heart rate.
89152378|NCT02643810|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
89152379|NCT04876937|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1-0.2 ug/kg/h during mechanical ventilation, for a maximum of 7 days.
89152380|NCT04876937|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 7 days.
89152381|NCT02826629|Other|Schizophrenia|40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)
89152382|NCT02826629|Other|Healthy sibling|25 healthy siblings
89152383|NCT02826629|Other|Ultra high risk for developing Schizophrenia|15 patients with ultra high risk for developing Schizophrenia
89152384|NCT02826629|Other|Controls|-25 age and gender-matched healthy controls
89152385|NCT05660993|Experimental|Main arm|"Patients will receive for a maximum of 4 cycles of nivolumab 3 mg/kg on day 0 BeGEV , with subsequent assessment of response by PET-CT. Patients with CR after 2 cycles Nivo-BeGEV will proceed to ASCT.~Patients with <CR after 2 cycles of a combination Nivo-BeGEV, with subsequent PET-CT assessment, will receive an additional 2 cycles Nivo-BeGEV. Patients with CR after 4 cycles Nivo-BeGEV will proceed to ASCT."
89152386|NCT04243265|Experimental|Patients treated with MPFL reconstruction|"Patients underwent MPFL reconstruction using a minimally invasive technique using a fascia lata allograft performed at the Rizzoli Orthopedic Institute between 2011 and 2015 by the team of Prof. Marcacci.~Clinical and radiographic evaluation will be performed during outpatients visits."
89152387|NCT02643654|Placebo Comparator|Placebo|The placebo product is manufactured following the same procedures and batch records used to manufacture the MABp1 drug product. The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
89152388|NCT02643654|Active Comparator|MABp1|MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1α (IL-1α). The entire MABp1 heavy and light chain sequences are identical to those found in naturally-occurring human IgG1κ, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual. It is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
88806042|NCT01158521|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
88806043|NCT02246933|Experimental|PUFA Diet|
88806044|NCT02246933|Placebo Comparator|Control Diet|
89152389|NCT00633659|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
89152390|NCT00633659|Experimental|Control|Voluven (HES 130/0.4)
89152391|NCT02652936|Experimental|AF-130 capsule|AF-130 oral capsules administered as a single dose or once daily for 7 days
89152392|NCT02652936|Placebo Comparator|AF-130 matching placebo capsule|Oral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days
89152393|NCT04241705|Active Comparator|Control arm|The control arm will provide optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services.
89152394|NCT04241705|Active Comparator|Reactive Case Detection (RCD) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive, passively-detected index cases at the health post or health center; individuals who reside within a 100-meter radius of the index case will receive diagnosis for malaria using a conventional RDT. Positive individuals will receive treatment and follow-up as per the national treatment guidelines. 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing. Additional procedures will include the collection of a dried blood spot.
89152395|NCT04241705|Experimental|Targeted Mass Drug Administration (tMDA) arm|Optimized malaria control interventions as in the control arm. In addition, following identification of microscopy or RDT positive index cases at the health post or health center, all eligible individuals who reside within a 100-meter radius of the index case will receive presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ) (0.25mg/kg daily). 14 days of primaquine (PQ) will only be administered to those found to be normal upon G6PD testing.
89152396|NCT02643342|No Intervention|Single-vision glasses|Subjects wearing single-vision glasses CR-39 of refractive index 1.56.
89152397|NCT02643342|Sham Comparator|Orthokeratology with normal compression factor|Subjects wearing orthokeratology lenses of normal compression factor about 0.50-0.75D.
89152398|NCT02643342|Active Comparator|Orthokeratology with increased compression factor|Subjects wearing orthokeratology lenses of increased compression factor about 1.50-1.75D.
89152399|NCT04243109|Experimental|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started.~Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
89152400|NCT02824835||adenoma group|Patients with adenoma. Biopsies are taken before endoscopic resection.
89152401|NCT02824835||cancer group|Patients with colorectal cancer. Biopsies are taken before surgical resection.
89152402|NCT02640456||Para- or retropharyngeal abscess|Patients with para- or retropharyngeal abscess.
89152403|NCT02640456||Neck abscess|Patients with neck abscess without relation to the pharynx or salivary glands.
89152404|NCT04861181|Experimental|Pharmacokinetics, Dosage of Niraparib|Patients received 3 cycles of Niraparib (200 mg or 300 mg/day). Each cycle lasts 28 days. Serum niraparib assays will be performed for all patients over 3 courses immediately prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
89152405|NCT00603512|Placebo Comparator|CP-690,550, 0mg|
89152406|NCT00603512|Experimental|CP-690,550, 10mg|
89152407|NCT00603512|Experimental|CP-690,550, 1mg|
89152408|NCT00603512|Experimental|CP-690,550, 3mg|
89152409|NCT00603512|Experimental|CP-690,550, 5mg|
89152410|NCT04167774|Experimental|Camrelizumab +nb-Paclitaxel|Participants receive Camrelizumab 200mg(3mg/kg for underweight patients) iv and nb-Paclitaxel 260mg/m2 iv every 3 weeks until disease progression or unacceptable toxicity
89152411|NCT02823509|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89152412|NCT02640300|Experimental|Immediate discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules at week 3. All capsules contained placebo (i.e., the antipsychotic drugs were abruptly discontinued). Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
89152413|NCT02640300|Experimental|Gradual discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules (i.e., the antipsychotic drugs were discontinued) at week 3. Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
89152414|NCT04241393|Experimental|Tavapadon|
89152415|NCT02823587|Experimental|Bronchiectasis Pulmonary Rehabilitation|The volunteers will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
89152416|NCT02823587|Experimental|Healthy Pulmonary Rehabilitation|In this arm, the volunteers healthy will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
89152417|NCT02823587|Sham Comparator|Bronchiectasis Group Control|The volunteers with bronchiectasis will be informed only about the benefits of physical activities
89152418|NCT02823587|Sham Comparator|Healthy Group Control|Volunteers healthy will be informed only about the benefits of physical activities
88806045|NCT01221311|Experimental|Fully Covered Metallic Stent|Among patients randomized to the covered, self-expandable metallic stent (cSEMS) group, the endoscopist will deploy a cSEMS of sufficient length to traverse the papilla. Dilation will not be performed unless the cSEMS deployment catheter cannot be advanced over a guidewire beyond the stricture. A biliary sphincterotomy may be performed at the discretion of the treating endoscopist.
89152419|NCT02640144|Active Comparator|Treatment group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of Sodium Hyaluronate 1% - ARTHREASE TM
89152420|NCT02640144|Placebo Comparator|Control group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of BPS - Buffer Phosphate Solution - as a placebo
89152421|NCT04242875||PanOptix|Participants will receive the PanOptix intraocular lens.
89152422|NCT04165668||Dispatched lay responders|Nearby mobile phone located and dispatched lay responders who reached the place of the suspected OHCA before EMS and first responders (fire and police services).
89152423|NCT04165668||Non-dispatched lay responders|Nearby mobile phone located lay responders who have neither actively, nor technically responded due to either human or technical factors.
89152424|NCT05660837|Experimental|T1: Mixed mode social support group|This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program
89152425|NCT05660837|Experimental|Online social support group|This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.
89152426|NCT05660837|No Intervention|Control|"This is the control group.~Control group will only participate in baseline and follow-up survey"
89152427|NCT02643264|Experimental|rTMS 10 Hz|Deep Repetitive Transcranial Magnetic Stimulation (rTMS, 10 Hz) of the insula ,15 stimulation sessions (1 daily, 5 days / week).
89152428|NCT02643264|Sham Comparator|rTMS Sham|Sham Repetitive Transcranial Magnetic Stimulation (rTMS, Sham),15 stimulation sessions (1 daily, 5 days / week).
89152429|NCT05029661||No intervention|No intervention
89152430|NCT02643186|Active Comparator|misoprostol group|preoperative vaginal misoprostol in decreasing blood loss in transabdominal myomectomy
89152431|NCT02643186|Active Comparator|uterine artery ligation group|bilateral uterine artery ligation in decreasing blood loss in transabdominal myomectomy
89152432|NCT02652312|Active Comparator|Group 'D'|"Dexmedetomidine group Patients received dexmedetomidine (2 ml diluted in 18 ml of saline) IV in a dose of 1 mcg/kg over 10 minutes. A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour was infused.~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
89152433|NCT02652312|Placebo Comparator|Group 'P'|"Placebo group Patients received similar volume of normal saline as the bolus and maintenance infusion as group D.~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
89152434|NCT02643030|Experimental|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
89152435|NCT02643030|Active Comparator|hypercapnia|Tidal volume (6ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
89152436|NCT05660759||NBCA|Patients that recieved portal vein embolization with n-butyl-cyanoacrylate glue.
89152437|NCT05660759||Particles|Patients that recieved portal vein embolization with micro particles.
89152438|NCT04165512|Experimental|stellate ganglion block in breast cancer related lymphedema|US-guided stellat ganglion block will be applied to the patients with breast cancer related lymphedema twice at two-week intervals.
89152439|NCT02826473|Experimental|Intervention-Group|
89152440|NCT02826473|No Intervention|Control-Group|
89152441|NCT00653094|Other|A|
89152442|NCT02642874|Experimental|Methocarbamol|Methocarbamol twice daily
89152443|NCT02642874|Placebo Comparator|placebo|Calcium carbonate twice daily
89152444|NCT02824289|Experimental|Sun Safe Workplaces Program|Program promoting the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers and in-person training of outdoor workers by research staff over two years.
89152445|NCT02824289|Active Comparator|Attention Control|Program promoting occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff.
89152446|NCT03396510|Experimental|IMPROVED intervention|Patients randomized to the IMPROVED intervention will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the study team will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the study team will not provide guidance about what actions to take in response to patients' symptoms.
89152447|NCT03396510|No Intervention|Usual Care|Usual Care per hospital standard will be administered. Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports.
89152448|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 15 mg; then RO5545965 5mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
89152449|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 5 mg; then RO5545965 15 mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
89152450|NCT02824055|Experimental|RO5545965 15 mg first; then Placebo; then RO5545965 5 mg|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
88804453|NCT04913649|Experimental|Intravenous iron (ferric derisomaltose)|The intervention consists of a single dose of ferric derisomaltose (Monofer®) 100 mg/mL solution for infusion (Monofer® is a registered product with a marketing authorization in the Netherlands (RVG number: 103070). Manufacturer: Pharmacosmos A/S, Denmark. Dutch marketing authorization holder: Cablon Medical B.V). The method of administration and dosage of the investigational medication are standard treatment. The ferric derisomaltose dose will calculated for each patient depending on body weight (20mg/kg) and diluted in 250 ml NaCl 0.9%. Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards
88804454|NCT04913649|Placebo Comparator|Placebo|Single dose of sodium chloride 0.9% (250ml). Treatment takes approximately 60 minutes. Vital signs of the patient will be monitored during administration of the investigational medication and for 30 minutes afterwards
89152451|NCT02824055|Experimental|RO5545965 15 mg first; then RO5545965 5 mg; then Placebo|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
89152452|NCT02824055|Experimental|RO5545965 5 mg first; then Placebo; then RO5545965 15 mg|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
89152453|NCT02824055|Experimental|RO5545965 5 mg first; then RO5545965 15 mg; then Placebo|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
89152454|NCT02640066|Experimental|acupuncture|acupuncture treatment with Supportive care
89152455|NCT02640066|No Intervention|standard treatment|Supportive care measures only
89152456|NCT04165200|Active Comparator|Patients receiving FMT capsules and ART|"ART Start at week 0 non-stop.~FMT. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.~Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.~Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.~Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
89152457|NCT04165200|Placebo Comparator|Patients receiving placebo capsules|"ART Start at week 0 non-stop.~Placebo capsules. The frozen capsules will be ingested orally at a frequency of 15 capsules every 12 hours for four doses 7 days prior ART start and on weeks 0, 4, 8 and 12 after ART start. Each capsule must be ingested over a period no longer than 1 hour of the anterior capsule.~Blood samples Week 0, 4, 8, 12 and 24. Taken through peripheral vein puncture with the extraction of 10 ml of venous blood to monitor the CD4 lymphocytes count and HIV viral load.~Feces samples from each patient will be taken during medical consultation on week 0, 8 and 24 after ART start to evaluate the modification of the intestinal microbiome.~Medical consultations will be made on days -7 to ART start, day 1, 30, 60, 90 and 120 after ART start, where clinical examination and elimination criteria will be evaluated."
89152458|NCT00603278|Placebo Comparator|Arm 1|
89152459|NCT00603278|Experimental|Arm 2|
89152460|NCT02824211|Experimental|Right Dose System|Use of automated oxygen titration during exertion
88804455|NCT04896398|Experimental|ESWT Group|A total of 5 sessions of ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the patients in this group for 2 weeks. Median nerve and tendon shifting exercises will be taught to the patients and they will be asked to do it regularly.
88804456|NCT04896398|No Intervention|Control Group|Patients in the control group will be asked to do median nerve and tendon shifting exercises only for the wrist.
88804457|NCT04895566|Experimental|monoclonal antibody (Mab) sB24M|Therapy by injecting 200 mg of the monoclonal antibody (Mab) sB24M into the areas affected by pyoderma
88804458|NCT04889937||PC004 Cohort|The study will include a sample of patients with specific cancer types visiting the outpatient hematologic oncology clinic for their standard of care chemotherapy administration. Participants will need to be willing to participate and be able to provide written informed consent
88804459|NCT04864561|Experimental|VLA2001|<30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222
88804460|NCT04864561|Active Comparator|AZD1222|<30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222
89152461|NCT00653874|Experimental|1: TcB|transcutaneous bilirubinometry (TcB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
88804461|NCT04864561|Experimental|VLA2001 - adolescent part|≥12 to < 18 years will be randomized 1:1 to receive VLA2001 or Placebo
89152462|NCT00653874|Active Comparator|2: CaB|clinical assessment of jaundice (CaB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
89152463|NCT04224701|Experimental|Investigational Product, 30 µg/ Placebo|30 µg IM, months 0, 2 and 6
89152464|NCT04224701|Experimental|Investigational Product, 300 µg/ Placebo|300 µg IM, months 0, 2 and 6
89152465|NCT00653952|Experimental|001|
89152466|NCT00653952|Active Comparator|002|
88804462|NCT04864561|Placebo Comparator|Placebo|≥12 to < 18 years will be randomized 1:1 to receive VLA2001 or Placebo
88804463|NCT04848298|Experimental|Mobile Health Arm|
89152467|NCT04241861|Experimental|High-flow oxygen therapy|Nasal high flow oxygen therapy will be delivered with the Optiflow system. Initial set flow will be ≥ 50 /min and flows will be decreased in case of intolerance and/or according to patients' requirements: flows≥30 L/min will be mandatory in all enrolled patients. Humidification chamber (MR860, Fisher and Paykel healthcare, New Zealand) will be set at 37 °C or 34 °C according to patient's comfort33. FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.
89152468|NCT04241861|Experimental|Helmet PSV|"Dedicated helmets for noninvasive ventilation will be used and size will be chosen according to neck circumference or according to manufacturer recommendations.~Each patient will be connected to a compressed-gas based ventilator through a bitube circuit with no humidification.~The ventilator will be set in PSV, with the following suggested settings 34-38:~initial pressure support≥8-10 cmH2O and adequate to permit of a peak in the inspiratory flow of 100 l/min;~positive end-expiratory pressure=10-12 cmH2O and increased to achieve the oxygenation target according to the choice of the attending physician.~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%.~Inspiratory flow trigger = 1 l/min or according to the practice of each institution;~fastest pressurization time;~expiratory trigger: 10-50% of the maximum inspiratory flow;~maximum inspiratory time 1.2 second."
88804464|NCT04848298|No Intervention|Control Arm|The Control Arm will receive standard of care including tailored prescription of physical activity
89152469|NCT04241861|Experimental|Helmet CPAP|"Dedicated helmets for noninvasive ventilation will be uses and size will be chosen according to neck circumference or according to manufacturer recommendations.~Treatment will be delivered through a high-flow generator. The following settings will be applied:~Continuous air flow=50-60 L/min.~Expiratory positive end-expiratory pressure valve set to achieve a PEEP==10-12 cmH2O and eventually increased to achieve the oxygenation target according to the choice of the attending physician.~FiO2 will be titrated to obtain an SpO2≥92% and ≤98%. Pressure inside the helmet will be monitored with a manometer in order to maintain the set PEEP."
89152470|NCT00650364|Experimental|1|Midodrine HCl Tablets 5 mg
89152471|NCT00650364|Active Comparator|2|ProAmatine® Tablets 5 mg
89152472|NCT04909697|Sham Comparator|Saline|
89152473|NCT04909697|Experimental|Sivelestat Sodium|
89152474|NCT00654108|Experimental|Cohort 1: vaccine dosage level 1 or placebo|Vaccine dose level 1: 1 X 10^7 colony forming unit (CFU) or placebo, treated with Cipro on days 7-11.
89152475|NCT00654108|Experimental|Cohort 2: vaccine dosage level 2 or placebo|Vaccine dose level 2: 1 X 10^8 CFU or placebo, treated with Cipro on days 7-11.
89152476|NCT00654108|Experimental|Cohort 3: vaccine dosage level 3 or placebo|Vaccine dose level 3: 1 X 10^9 CFU or placebo, treated with Cipro on days 7-11.
89152477|NCT00654108|Experimental|Cohort 4: vaccine dosage level 4 or placebo|Vaccine dose level 4: 1 X 10^10 CFU or placebo, treated with Cipro on days 7-11.
89152478|NCT04165902|Experimental|steroid plus hyaluronic acid|steroid plus hyaluronic acid injection, one time per week, for 3 weeks
89152479|NCT04165902|Active Comparator|dextrose plus hyaluronic acid|dextrose plus hyaluronic acid injection, one time per week, for 3 weeks
89152480|NCT02822339|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89152481|NCT02822417||patients after general anesthesia|Laparoscopic surgery, orthopedics surgery or open surgery patients after general anesthesia
89152482|NCT04240847|Active Comparator|Midline incision|Skin incision at the midline, 1 cm medial to tibial tubercle
89152483|NCT04240847|Experimental|Lateral incision|Skin incision at 1 cm lateral to tibial tubercle
88804465|NCT04826835|Experimental|Prehabilitation intervention|Participants in the intervention group will follow a 2-week prehabilitation program before lung resection.
88804466|NCT04826835|Active Comparator|Health education control|Participants in the control group will receive health education classes during 2 weeks before lung resection.
88804467|NCT04806113|Other|Vaccine|Study participants (People with rheumatic diseases and age matched controls).
88821401|NCT04270747|Active Comparator|Aflibercept-Treatment Group B1|Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by IVT injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8). Subjects will be re-randomized to receive aflibercept by IVT injection every 8 weeks from week 16 until week 48.
89152484|NCT02687048|Active Comparator|EX protocol|Participants will receive a revised version of the Otago exercise program (OEP) - an individualized home-based exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week. The exercises are for strength and balance and are gradually progressed over the course of the study to meet the individual's abilities.
89152485|NCT02687048|Experimental|EX Plus protocol|"These participants will receive mindful meditation coaching via 6 one-hour small group sessions with an experienced meditation instructor. They will also be expected to practice mindful meditation at home following online audio recordings (free of charge from University of California, Los Angeles; http://marc.ucla.edu/body.cfm?id=22) and written instructions a minimum of five times per week for 30 minutes. Participants will complete a meditation log to record their practice.~These participants will also receive the same revised version of the Otago exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week."
89152486|NCT02639598|Experimental|flunarizine|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 5 mg/day flunarizine once daily in the first week, followed by 10 mg/day flunarizine in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
89152487|NCT02639598|Active Comparator|topiramate|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 25 mg/day topiramate once daily in the first week, followed by 50 mg/day topiramate in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
89152488|NCT02823119|Experimental|Mini-hysteroscopy|A rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm.
89152489|NCT02823119|Active Comparator|Conventional Office Hysteroscopy|A rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm
89152490|NCT02642796|No Intervention|Group I (control)|Patient controlled analgesia (epidural fentanyl): PCA only
89152491|NCT02642796|Experimental|group II|PCA plus lumbar plexus & sciatic nerve transcutaneous electric nerve stimulation (LS-TENS)
89152492|NCT02642796|Experimental|group III|PCA plus surgical wound transcutaneous electric nerve stimulation ( SW-TENS)
89152493|NCT02642718|Placebo Comparator|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision
89152494|NCT02642718|Experimental|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision. (a single dose).
89152495|NCT00639314|Experimental|1|In PpPD, the proximal duodenum was divided 3-4cm distal to the pylorus ring
89152496|NCT00639314|Active Comparator|2|In PrPD, the stomach is divided just above the pylorus ring. the nearly total stomach more than 95% was preserved.
89152497|NCT04240769||Knee Arthroplasty Patient|Patients undergoing primary total or unicompartmental knee arthroplasty for treatment of end-stage osteoarthritis.
89152498|NCT02642484|Active Comparator|Gabapentin|Gabapentin twice daily
89152499|NCT02642484|Placebo Comparator|PLacebo|Calcium carbonate twice daily
89152500|NCT02537912|Active Comparator|Sugarlock®|Subjects ingested 2 capsules Sugarlock® (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
89152501|NCT02537912|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
89152502|NCT02823275|Active Comparator|Functional mobilisation|
89152503|NCT02823275|Experimental|plaster cast fixation|
89152504|NCT00910884||Arm I|Patients receive oral GRAS supplements daily for 12 months or as possible within the patient's parameters.
89152505|NCT00910884||Arm II|Patients do not receive supplements.
89152506|NCT04240613|Other|women treated by TVT-O|All women treated by TVT-O during the years this study was made were included.
89152507|NCT04186754|Experimental|Comprehensive functional care plan|"The intervention will be carried out thanks to the reeducation to the effort carried out in the individuals, which will have the following interventions:~The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy."
89152508|NCT04186754|Active Comparator|Traditional intervention without rehabilitation|"Nursing care.~Medical care.~Spiritual attention."
89152509|NCT02686736|Other|Internet-based educational intervention|The Internet-based educational intervention will include four educational sessions that will be provided during a four-week period. The follow up will last three-months.
89152510|NCT02686736|No Intervention|Control group|In the control group, teens will continue the usual school provided sexual education and will be invited to answer the internet-based self-applied questionnaire at the same time as the intervention group.
89152511|NCT04241471|Active Comparator|traditional incision and drainage (I&D)|
89152512|NCT04241471|Experimental|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
89152513|NCT00639392|Placebo Comparator|2|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3.
89152514|NCT00639392|Experimental|1|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive Zolendronic Acid are 2 out of 3.
89152515|NCT04185506|Experimental|DBT and behavioral weight loss|The intervention is a 16-week group-based behavioral program consisting of a combination of Dialectical Behavioral Therapy (DBT) skills and behavioral weight loss techniques.
89152516|NCT02822261|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89152517|NCT02642328|Experimental|HIIT Training|Circuit training with strength and power. The chosen exercises were (random order): Sit-Ups, Mountain Climbers, Plank, Side Skater, Push Ups, Ground Support with Vertical Jump, Overhead Squat, Box Jump.Time total = 4 minutes
89152518|NCT02642328|Active Comparator|Control|Running aerobic exercise at 65% of VO2Max
89152519|NCT04185350|Experimental|68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 60 min later.
89152520|NCT04241237||Metastatic Breast Cancer patients|Investigators plan to enroll patients who are undergoing biopsy for potential metastatic Breast Cancer any subtype ER/PgR+ and HER2, triple negative or HER2+ at least 6 months before suspected metastases were identified. The suspected metastases in these patients must be outside the ipsilateral breast, axilla infra/supraclavicular areas. In those with suspected metastases in contralateral axilla, infra/supraclavicular areas only a new contralateral breast primary must be excluded by physical exam, mammogram and MRI
89152521|NCT00653172|Experimental|1|NXL103
89152522|NCT00653172|Active Comparator|3|
89152523|NCT00653172|Experimental|2|NXL103
89152524|NCT02821949||Patients|Patients with Non Small Cells Lung Cancer PCT dosage
89152525|NCT02822105|Experimental|H3N2 M2SR monovalent influenza vaccine|This group will receive a low, medium or high dose of the H3N2 M2SR monovalent influenza vaccine administered intranasally. It will be compared with placebo in a 3:1 ratio.
89152526|NCT02822105|Experimental|placebo|This group will receive saline administered intranasally.
89152527|NCT02639520|Active Comparator|Group Canephron® N|Canephron® N & fosfomycin trometamol-placebo
89152528|NCT02639520|Active Comparator|Group Fosfomycin Trometamol|Canephron® N-placebo & fosfomycin trometamol
89152529|NCT02823197|Experimental|active transport lesson|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations.
89152530|NCT02823197|Experimental|active transport lesson and Facebook group|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations. Furthermore, they are asked to join a Facebook group on active transport in which 3 messages per week are posted during an eight-week period. The Facebook posts aim to promote the use of active transport for short distance travel.
89152531|NCT02823197|No Intervention|control group|Participants in the control group do not receive the active transport lesson or the Facebook group.
89152532|NCT05659979|Experimental|Comprehensive Geriatric Assessment|This group will receive a comprehensive geriatric assessment evaluation during the study, using the multidimensional prognostic index
89152533|NCT05659979|No Intervention|Controls|This group will receive standard/usual care
89152534|NCT02639364|Active Comparator|conventional ventilation strategy|The conventional ventilation strategy use volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, combination with low tidal volume and adequate PEEP level.
89152535|NCT02639364|Experimental|BILEVEL-APRV protocol|According to our BILEVEL-APRV protocol, BILEVEL-APRV APRV mode with specific settings,combination with spontaneous breathing.
89152536|NCT02824133|Experimental|AZD4547|AZD4547: intake of 80mg bd (160mg/day), on a continuous schedule.
89152537|NCT02639130|Active Comparator|Vildagliptin|"After a screening examination, patients were treated with vildagliptin and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
89152538|NCT02639130|Placebo Comparator|Placebo|"After a screening examination, patients were treated with placebo, and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
89152539|NCT02822729|Experimental|DE-117 ophthalmic solution (Group1)|Monotherapy
89152540|NCT02822729|Experimental|DE-117 ophthalmic solution (Group2)|Monotherapy
89152541|NCT02822729|Other|DE-117 ophthalmic solution + Timolol (Group3)|Concomitant Use
89152542|NCT05232240||Non-hypertensive patients with Ischemic Cerebrovascular Disease|The patients are diagnosed as ischemic cerebrovascular disease (ICVD) and less than 90 days after the onset of ischemic stroke or transient ischemic attack. The patients have no definite diagnosis of hypertension, and are not under anti-hypertension treatment. The blood pressure measured 5~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of ≥ 2 readings obtained on ≥ 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement).
89152543|NCT02690597|Other|Patient|"State-trait anxiety inventory Y-A form (STAI Y-A form)~Anxiety visual analog scale evaluation(A-AVS)."
89152544|NCT04165434|Experimental|Experimental|Untrained unilateral transtibial amputees who underwent the assessment and recommended training.
89152545|NCT04165434|No Intervention|Control|Untrained unilateral transtibial amputees who after the evaluation were not included for the recommended training.
89152546|NCT04239677|Active Comparator|control|Conventional crystalloid solution-based priming
89152547|NCT04239677|Experimental|RAP|Retrograde autologous priming
89152548|NCT02638038|Experimental|Oral INT 131 3 mg|Oral INT-131 Double blind study
89152549|NCT02638038|Experimental|Oral INT-131 1 mg|Oral INT-131 Double blind
89152550|NCT02638038|Placebo Comparator|Placebo|Oral placebo Double blind
89152551|NCT04241159|Experimental|Geriatric participants with frailty|"Geriatric participants aged 65-80 who have a diagnosis of frailty (Fried Frailty score of 3 or greater).~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
89152552|NCT04241159|Experimental|Geriatric participants with HFpEF|"Geriatric participants aged 65-80 who have a diagnosis of HFpEF.~Experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days)."
89152553|NCT02642250|Experimental|Entoban Capsules|Entoban is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora.
89152554|NCT02642250|Experimental|Metronidazole DS|Metronidazole DS(400 mg) is commonly used to treat diarrhea.It eliminates bacteria and other microorganisms that cause infections of the reproductive system, gastrointestinal tract, skin, vagina, and other areas of the body.
89152555|NCT00653250|Experimental|Therapeutic Intervention|Correlative
89152556|NCT02822651|Experimental|Vitamin D status|The 2500 subjects included in this unique arm will complete a self-administered questionnaire and will have a blood sampling to measure vitamin D blood concentration.
89152557|NCT02639208|Experimental|PatientsLikeMe (PLM)|"After the screening procedures confirm eligibility.~Baseline Survey Assessment and PatientsLikeMe Introduction~Treatment Evaluation on PLM website at predetermined times per protocol~Final Survey"
89152558|NCT02686580|Experimental|Collagen paste|Injection of Permacol Collagen paste into the fistula tract.
89152559|NCT02824367|Other|Parkinsonian|Patient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation
89152560|NCT02824367|Other|Dystonic|Comparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation
89152561|NCT04185662|Placebo Comparator|placebo|intake 200 ml water daily for 3 months
89152562|NCT04185662|Experimental|low dose sucrolose group|intake 12.3mg sucralose in 200 ml water daily for 3 months
89152563|NCT04185662|Experimental|moderate dose sucrolose group|intake 73.8mg sucralose in 200ml water daily for 3 months
89152564|NCT00654342|Other|1|In vivo injection group
89152565|NCT00654342|Other|2|Ex vivo injection group
89152566|NCT02688920||With T2DM|Subjects with type 2 diabetes.
89152567|NCT02688920||Without T2DM|Subjects without type 2 diabetes
89152568|NCT04186910|Placebo Comparator|Control group|The control group will not receive any feedback on levels of physical activities but will receive any planned usual care rehabilitation activities
89152569|NCT04186910|Experimental|Feedback group|The feedback group will have an active feedback intervention of physical activities, consisted of daily feedback, received through a Fitbit application, and weekly meeting group focused on enhancing behavioral strategies to increase self-efficacy and motivation. The experimental group will receive any planned usual care rehabilitation activities.
89152570|NCT04240535|Experimental|Active- onabotulinumtoxinA|BOTOX Cosmetic (onabotulinumtoxinA) for injection, is a sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strain Clostridium botulinum type A intended for intramuscular use. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. The complex is dissolved in sterile sodium chloride solution containing Albumin Human and is sterile filtered (0.2 microns) prior to filling and vacuum-drying.
89152571|NCT04240535|Placebo Comparator|Placebo-Bacteriostatic 0.9% Sodium Chloride|Placebo subjects will have injections in the same manner, but will be injected with Bacteriostatic 0.9% Sodium Chloride.
89152572|NCT02638896|Experimental|Dose reduction arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every other weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
89152573|NCT02638896|Active Comparator|Dose maintenance arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
89152574|NCT02638896|Other|Etanercept discontinuation arm|AS patients who achieved remission will take sulfasalazine (2g/d) till week24. Celecoxib will be the background therapy.
89152575|NCT04240223|Experimental|50 mg Brilacidin tablet|
89152576|NCT04240223|Experimental|100 mg Brilacidin tablet|
89152577|NCT04240223|Experimental|200 mg Brilacidin (2 x 100 mg Brilacidin tablets)|
89152578|NCT04240223|Placebo Comparator|Placebo tablet (replica of shape/size of 50 mg tablet)|
89152579|NCT04240223|Placebo Comparator|Placebo tablet (replica of shape/size of 100 mg tablet)|
89152580|NCT04240223|Placebo Comparator|Placebo (2 x replica of shape/size of 100 mg tablets)|
89152581|NCT01329926||Neural stem cells|
89152582|NCT02821871|Active Comparator|SP2086|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
89152583|NCT02821871|Other|high fat diet|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
89152584|NCT02637882|Experimental|First intervention (ear plug)|"Other: ear plug~Other Name: eastnova ear plug"
89152585|NCT02637882|Other|Second intervention (eye mask)|"Other: eye mask~The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.~Other Name: Sleeping mask"
89152586|NCT02637882|Other|Ear plug and eye mask|The patients will receive the mixed intervention (eye mask) and (ear plug ) in the first night (N1) from 9 pm to 6 am.
89152587|NCT00633737|Experimental|1|Stress reduction intervention
89152588|NCT00633737|No Intervention|2|Standard care
89152589|NCT02535780|Experimental|TMS Treatment Group|15 sessions active Transcranial magnetic stimulation (TMS) treatment
89152590|NCT02535780|Sham Comparator|TMS Sham Group|15 sessions sham Transcranial magnetic stimulation (TMS) treatment
89152591|NCT02535780|Experimental|tDCS Treatment Group|15 sessions active Transcranial direct current stimulation (tDCS) treatment
89152592|NCT02535780|Sham Comparator|tDCS Sham Group|15 sessions sham Transcranial direct current stimulation (tDCS) treatment
89152593|NCT04241081|No Intervention|Control group-no exercise|A no-exercise control. Must maintain <4,500 steps per day for 3 consecutive days followed by a high fat tolerance test on day 4.
89152594|NCT04241081|Experimental|Exercise intervention 1|Two consecutive days of <4,500 steps per day followed by an intervention day on day 3. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 2 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
89152595|NCT04241081|Experimental|Exercise intervention 2|Two consecutive days of <4,500 steps per day followed by an intervention day. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 6 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
89152596|NCT02686268||Individuals diagnosed with known positive C9ORF72 ALS|Individuals diagnosed with known positive C9ORF72 ALS
89152597|NCT04239755|Active Comparator|Doxycycline|Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days.
89152598|NCT04239755|Placebo Comparator|Placebo|group (2) will be 25 patients will receive placebo in addition to the standard treatment.
89152599|NCT04185116|Experimental|3D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
89152600|NCT04185116|No Intervention|2D Optic Surgeons|Full-trained surgeons randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
89152601|NCT04185116|Experimental|3D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 3D optic system.
89152602|NCT04185116|No Intervention|2D Optic Residents|4th and 5th year General Surgery residentes randomised into this interventional arm will be performing laparoscopic gastric bypass using a 2D optic system.
89152603|NCT02642016|Experimental|CDX-0158|
89152604|NCT02824445|Sham Comparator|Sham|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
89152605|NCT02824445|Experimental|Treatment|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
89152606|NCT02638818||minimally invasive whipple|Surgical technique (minimally invasive vs open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
89152607|NCT02638818||traditional whipple|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
89152608|NCT04185194|Active Comparator|group A|received especially designed physical therapy program
89152609|NCT04185194|Experimental|group b|received pulsed ultrasound in addition to physical therapy program
89152610|NCT04185194|Experimental|group c|received lidocaine phonophoresis in addition to physical therapy program
89152611|NCT02638662||First time IVF patients. Observational|Those who are doing IVF for the first time.
89152612|NCT02638662||Donors Observational|Those who are doing IVF for the sole purpose of donating their eggs.
89152613|NCT02638662||2 or more IVF cycles Obervational|Those who have done IVF 2 or more times with no success.
89152614|NCT02821793||Elderly patient (70 years and older)|
89152615|NCT02821793||Young patient (18 years - 69 years)|
89152616|NCT00876447|Experimental|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
89152617|NCT00876447|Experimental|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
89152618|NCT04164420|Experimental|Oral neuromuscular training and orofacial sensory-vibration|Intensive training with oral neuromuscular training and orofacial sensory-vibration stimulation for 5 weeks. The oral neuromuscular training is performed three times per session, and three times daily before eating. Regarding the orofacial sensory-vibration stimulation, the instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal by using a toothbrush.
89152619|NCT04164420|Active Comparator|Orofacial sensory-vibration stimulation|Orofacial sensory-vibration stimulation by using an electrical toothbrush for five weeks. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
89152620|NCT04239833|Experimental|SH-1028 tablets+Placebo Gefitinib|"SH-1028 tablets (200 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.~Interventions:~Drug: SH-1028 tablets 200 mg Drug: Placebo Gefitinib 250 mg"
89152621|NCT04239833|Active Comparator|Gefitinib+Placebo SH-1028 tablets|"Gefitinib (250 mg orally, once daily) plus placebo SH-1028 tablets (200mg orally, once daily), in accordance with the randomisation schedule.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets).~Interventions:~Drug: Gefitinib 250 mg Drug: Placebo SH-1028 tablets 200mg"
89152622|NCT03513770|Experimental|Ketorolac|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 ketorolac tromethamine + saline infusions into the occluded arm.
89152623|NCT03513770|Placebo Comparator|Control|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 saline only infusions into the occluded arm.
89152624|NCT02638740|Active Comparator|SCALING AND ROOT PLANING (SRP)|Scaling and root planning with ultrasonic scalar
89152625|NCT02638740|Experimental|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
89152626|NCT04240067||Acute Heart Failure|
89152627|NCT04240067||No Acute Heart Failure|
89152628|NCT02823977|Experimental|Ketamine / Dexmedetomidine|Ketamine 0.25 mg/kg bolus followed by 0.5 mg/kg per hour AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
89152629|NCT02823977|Placebo Comparator|Placebo / Dexmedetomidine|Normal saline, as a 500 mL infusion bag, to represent placebo AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
89152630|NCT04164810|Experimental|Hydrotherapy|Hydrotherapy intervention will receive the treatment for 9 weeks (2 days per week) , resulting in a total of 18 sessions of Hydrotherapy. Each session will be held for a duration of 45 minutes to 1 hour.
89152631|NCT04164810|Active Comparator|Physical therapy|Physical therapy inthervention will have 18 standard physical therapy treatment sessions during 9 weeks. Each session will be held for a duration of 45 minutes to 1 hour.
89152632|NCT04032678|Experimental|1 (DGT7)|"Cardioversion with a pulsed biphasic waveform Cardioversion is performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard Touch 7 - DGT7, Schiller Medical, France) with recommended by the manufacturer adult pads (FRED-PA1, Schiller) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.~Other Name: DGT7"
89152633|NCT04032678|Active Comparator|2 (LP15)|"Cardioversion with a biphasic truncated exponential waveform Cardioversion is performed by a biphasic truncated exponential waveform (LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA) with recommended by the manufacturer adult pads (Redipak QUICK COMBO, Physio-Control) following an energy protocol of 3 consecutive shocks with constant selected energy: 200J, 200J, 200J. The protocol is stopped at successful cardioversion (sinus rhythm at 1 minute post-shock), otherwise after the 3rd shock. Primary endpoint: The cumulative energy delivered by the consecutive defibrillation shocks during cardioversion.~Other Name: LP15"
89152634|NCT02822963||A|Non anticoagulant and/or antiplatelet users.
89152635|NCT02822963||B|Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods.
89152636|NCT02822963||C|Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods.
89152637|NCT05659433|Active Comparator|B-mode Ultrasound-guided Biopsy|
89152638|NCT05659433|Experimental|Contrast-enhanced Ultrasound-guided Biopsy|
89152639|NCT00680511|Active Comparator|1|Family therapy combined with methamphetamine-specific group treatment.
89152640|NCT00680511|Active Comparator|2|Family Therapy.
89152641|NCT00654576|Active Comparator|1|the comparator arm will only receive one of the seven antipsychotic
89152642|NCT00654576|Experimental|2|the experimental group will receive one of the seven study drugs combination with psychosocial intervention
89152643|NCT00622622|Experimental|Phase I study|
89152644|NCT02821481|Experimental|Beta-alanine and muscular endurance exercise|Receive 3.2 g/day beta-alanine and 3 days per week of endurance resistance training for 12 weeks
89152645|NCT02821481|Experimental|Beta-alanine without muscular endurance training|Receive 3.2 g/day beta-alanine with no endurance resistance training for 12 weeks
89152646|NCT02821481|Placebo Comparator|Placebo and muscular endurance exercise|Receive similar dextrose placebo and 3 days per week of endurance resistance training for 12 weeks
89152647|NCT02821481|Placebo Comparator|Placebo without muscular endurance training|Receive similar dextrose placebo with no endurance resistance training for 12 weeks
89152648|NCT00680589|Experimental|1|Injection of mouse TYRP2 DNA in patients with highrisk melanoma.
89152649|NCT04208282|Experimental|Trial Arm A|Quickset infusion system for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the 7 day set infusion set, entering Phase 2.
89152650|NCT04208282|Active Comparator|Trial Arm B|7 day set infusion set for the Phase 1. At day 28 or after using 4 sets , the patients will return to a visit, return all the extracted catheters sets and will switch to the Quickset infusion systems , entering Phase 2.
89152651|NCT00680667|Experimental|Trametes Versicolor|Females with Stage I-III infiltrating ductal adenocarcinoma of the breast being treated with Trametes versicolor capsules for 6 weeks after receiving radiation therapy.
89152652|NCT00598650|Experimental|1|
89152653|NCT02823899|Experimental|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
89152654|NCT02823899|Active Comparator|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
89152655|NCT02686190|Experimental|Luxtherapy|Luxtherapy exposition
89152656|NCT02686190|No Intervention|Not luxtherapy|Not luxtherapy exposition
89152657|NCT02641938|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
89152658|NCT02641938|Placebo Comparator|Normal Saline|IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
89152659|NCT04150185||live liver donors|Live liver donors undergoing donor hepatectomy
89152660|NCT02821637|Other|Effort rehabilitation program|"An effort rehabilitation program designed for obese and overweight children or teens : 13 weekly sessions of 1hour30 then 1 session 2 months, 6 months and 12 months later.~This program is part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse.~Child Health Questionnaire (CHQ) of quality of life are completed by parents and children on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session.~Eurofit tests of Physical Fitness performed on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session."
89152661|NCT04249076|Experimental|Clobetasol propionate|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage ofe one drop four (4) times a day during 14 days
89152662|NCT04249076|Placebo Comparator|Vehicle|First dose of the drug will be dispensed at the end of the Baseline visit at the study center. Then, study medication will be dispensed to the participant for self-administration at a dosage ofe one drop four (4) times a day during 14 days
89152663|NCT02641860|Other|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
89152664|NCT02641860|Other|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells mid-dose group
89152665|NCT02641860|Other|Mesenchymal progenitor cells Dosage 3|Mesenchymal progenitor cells high-dose group
89152666|NCT00681135|Experimental|1|
89152667|NCT00681135|Experimental|2|
89152668|NCT00681135|Experimental|3|
89152669|NCT00681135|Active Comparator|4|
89152670|NCT02821559|Experimental|triweekly then biweekly|The arm A consisted of 2 cycles of triweekly TOMOX (standard dose 3mg/m2 of Raltitrexed in 15-minutes infusion, and 130mg/m2 of oxaliplatin in 2h infusion, every 3 weeks), followed by 2 cycles of biweekly TOMOX (2mg/m2 of Raltitrexed in 15-minutes infusion, and 85mg/m2 of oxaliplatin in 2h infusion, every 2 weeks).
89152671|NCT02821559|Experimental|biweekly then triweekly|The arm B consisted of the reserve sequence starting with 2 cycles of biweekly TOMOX followed by 2 cycles of triweekly TOMOX regimen.
89152672|NCT00681213|Experimental|A|Tacrolimus/Sirolimus
89152673|NCT00681213|Experimental|B|Tacrolimus/MMF
89152674|NCT00681213|Experimental|C|Neoral/Sirolimus
89152675|NCT04165356|Experimental|Mouth-rinse with clorhexidine|Mouth-rinse with 0.12% clorhexidine + tooth brushing twice daily
89152676|NCT04165356|Active Comparator|Mouth-rinse with bicarbonate isotonic solution|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate + tooth brushing twice daily
89152677|NCT04213274|Placebo Comparator|Placebo - placebo|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to treatment (SDAS = 0) one more dose of placebo
89152678|NCT04213274|Other|Placebo - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of placebo on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) subcutaneous single injection of 80 mg RPH-104
89152679|NCT04213274|Experimental|80 mg RPH-104 - 80 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the positive response to the treatment (SDAS = 0) one subcutaneous injection of placebo
89152680|NCT04213274|Experimental|80 mg RPH-104 - 160 mg RPH-104|Subject randomized to receive subcutaneous single injection of 80 mg RPH-104 on Day 0,and then, on Day 14 - second dose of randomized treatment + based on the lack of response (no change in SDAS) or partial response to treatment (SDAS ≥ 1, and activity reduction by 1 or more points of SDAS compared to baseline) one more subcutaneous injection of 80 mg RPH-104
89152681|NCT02820701|No Intervention|Control|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. After the ultrasound assessment, the control group will wait in another room for approximately 30 minutes.
89152682|NCT02820701|Experimental|Treatment|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. Participants in the Treatment group will receive OMT to address sacral base asymmetry after the initial ultrasound assessment.
89152683|NCT02638506|Experimental|Intranasal Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
89152684|NCT02638506|Placebo Comparator|Salinex|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
89152685|NCT01124396||30 ug|30 ug
89152686|NCT01124396||60 ug|60 ug
89152687|NCT01124396||Placebo|Placebo
89152688|NCT04745975|Experimental|Personalized treatment guided by Mini-PDX|The tumor tissue is used for drug sensitivity test by Mini-PDX, and acquiring the genetic information by RNA-sequence. Patients with mTNBC will receive personalized treatment guided by the experimental results of mini-PDX and RNA sequencing.
89152689|NCT04745975|Active Comparator|Treatment of Physician's Choice (TPC)|TPC will be administered per standard of care. Patients randomized to TPC will receive chemotherapy, including but not limited to the following agents: nab-paclitaxel, eribulin, vinorelbine, gemcitabine, capecitabine.
89152690|NCT04150107|Experimental|Placebo then Treatment A then Treatment B|"Treatment administered in the following order:~Period 1: Placebo (Fish Oil Capsule)~Period 2: Treatment A: 24 mg ORMD-0801;(16 mg + 8 mg capsules) Once Daily (QD) at Bedtime~Period 3:Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals"
89152691|NCT04150107|Experimental|Placebo then Treatment B then Treatment A|"Treatment administered in the following order:~Period 1: Placebo (Fish Oil Capsule)~Period 2:Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals~Period 3: Treatment A: 24 mg ORMD-0801;(16 mg + 8 mg capsules) Once Daily (QD) at Bedtime~Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals"
89152692|NCT02638428|Experimental|Refractory/relapsed solid tumor or AML|Conventional chemotherapy (Ifosfamide carboplatin etoposide for solid tumor and fludarabine cytarabine for AML) with matched single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of CancerSCAN™
89152693|NCT01003964|Experimental|GP group|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
89152694|NCT01003964|Experimental|IP group|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
89152695|NCT02820779|Experimental|WILLIS|Patients undergo WILLIS intracranial covered stent interventional treatment
89152696|NCT02821325||MRI|Radiology
89152697|NCT00654810|Experimental|1|Low intensity group (40% of maximal exercise capacity)
89152698|NCT00654810|Experimental|2|High intensity group (80% of maximal exercise capacity)
89152699|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution A and Exercise|"Subject baseline HR, BP, EKG recorded.~Subject will ingest sucrose (150g):~30 min later, subject will exercise on a treadmill~Subjects will return each week to repeat the above procedures with a different test solution."
89152700|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution B and Exercise|"Subject baseline HR, BP, ECG recorded.~Subject will ingest sucrose (150g); caffeine (400 mg)~30 min later, subject will exercise on a treadmill~Subjects will return each week to repeat the above procedures with a different test solution."
89152701|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution C and Exercise|"Subject baseline HR, BP, ECG recorded.~Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)~30 min later, subject will exercise on a treadmill"
89152702|NCT04149717|Experimental|Changes in BP, HR and EKG with Test Solution C|"Subject baseline HR, BP, ECG recorded.~Subject will ingest sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg)"
89152703|NCT02638350|Experimental|Intervention lung ultrasound|All patients will have strategy with lung ultrasoundlung ultrasound
89152704|NCT00931970||Dialysis modality|Hemodialysis, Peritoneal dialysis
89152705|NCT02627079|Active Comparator|Cohort 1|"Cohort 1 will include 15 sedentary participants who have completed all cancer therapy except adjuvant hormonal therapy.~All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity level for 12 weeks.."
89152706|NCT02627079|Active Comparator|Cohort 2|Cohort 2 will include 15 sedentary participants in active treatment. All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity levels for 12 weeks.
89152707|NCT02820467|Experimental|patients with suspicion of CLI|patients presenting with peripheral artery disease and suspicion of critical limb ischemia as assessed by TASK II consensus 30 patients will be enrolled and will benefit of measures of TcPO2, too systolic blood pressure and skin perfusion pressure and in the same time angiography with fluorescence (Indocyanine grey 0.05 mg/kg by intravenous injection
89152708|NCT04031469||General Population|The general population will have their microbiome sequenced from stool samples provided.
89152709|NCT02823743|Experimental|Low dose aspirin|75 mg aspirin orally daily from gestational week 7-35
89152710|NCT02823743|Placebo Comparator|Placebo|Placebo pill orally daily from gestational week 7-35
89152711|NCT00654888|Active Comparator|1|Group one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
89152712|NCT00654888|Active Comparator|2|automated lamellar keratectomy without mitomycin
89152713|NCT05299203|Experimental|Dose Escalation and Expansion|In the dose escalation phase, 9 patients will be included in 3 groups with 3 patients as one group. In the dose expansion phase, the concentration of Sapropterin dihydrochloride tablets (BH4) aqueous solution will be performed according to the effective concentration of dose escalation phase, and 9 patients will be enrolled.
89152714|NCT02818829||Cohort|Collection of biological samples
89152715|NCT00654966|Experimental|1|Heart failure patients
89152716|NCT00654966|Active Comparator|2|Healthy subjects
89152717|NCT02627313|Experimental|GammaPod|GammaPod tumour bed boost
89152718|NCT02685722|Experimental|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
89152719|NCT02685722|Experimental|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
89152720|NCT02638584|Experimental|Ilaprazole|Ilaprazole tab 10mg, 2 tablets once daily for 8 weeks.
89152721|NCT02638584|Active Comparator|Rabeprazole|Rabeprazole tab 20mg, 1 tablet once daily for 8 weeks.
89152722|NCT02820545||Sociological interview|Patients will take a sociological interview with a sociologist during their hospital stay
89152723|NCT02820545||Self-administrated questionnaire|Patients will take a self-administrated questionnaire at the end of their hospital stay and one week after they left hospital
89152724|NCT02627235|Experimental|DIAL Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes daily IVR-system call feedback and monthly graphic-based feedback delivered in the mail. In addition, social support, outcome expectations and perceived physical activity enjoyment variables will be assessed at baseline, 30, 60, and 90 days. Responses will be used to select appropriate tailored feedback modules.
89152725|NCT02627235|Active Comparator|Wait List Control|Access to the intervention 12 weeks following baseline assessment.
89152726|NCT02688452|Active Comparator|Group 1|Young Healthy Adults
89152727|NCT02688452|Active Comparator|Group 2|Young Healthy Adults
89152728|NCT02626923||Patients on once daily Maraviroc|Maraviroc tablet 600 mg once daily 48 weeks
89152729|NCT00681369||1|Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
89152730|NCT00681447|Other|Group I|Lumbar interlaminar epidural injection with local anesthetic only
89152731|NCT00681447|Other|Group II|Lumbar Interlaminar Epidural Injection with local anesthetic wiht 6 mg of non-particulate Celestone
89152732|NCT02820389||Optical colonoscopy|Patients with suspected colorectal cancer will undergo optical colonoscopy as the initial imaging modality.
88804468|NCT04799496||Kynteles Injection (Vedolizumab)|Participants with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF-α) antagonist or participants with pouchitis, who have undergone proctocolectomy and IPAA for UC, and have had an inadequate response with, or lost response to antibiotic therapy and have initiated Kynteles injection (Vedolizumab) treatment in a routine clinical practical setting in South Korea, will be observed prospectively.
88804469|NCT04779320|Experimental|Induction Period: 10 to 15 kg, Vedolizumab 150 mg|Vedolizumab 150 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of 10 to 15 kg will be included in this arm group.
88804470|NCT04779320|Experimental|Induction Period: >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of >15 to <30 kg will be included in this arm group.
88804471|NCT04779320|Experimental|Induction Period: ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of ≥30 kg will be included in this arm group.
88804472|NCT04779320|Experimental|Maintenance Period: 10 to 15 kg Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.
88804473|NCT04779320|Experimental|Maintenance Period: 10 to 15 kg Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
88804474|NCT04779320|Experimental|Maintenance Period: >15 to <30 kg, Vedolizumab 200 mg|Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.
88804475|NCT04779320|Experimental|Maintenance Period: >15 to <30 kg Vedolizumab 100 mg|Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.
88804476|NCT04779320|Experimental|Maintenance Period: ≥30 kg, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.
88804477|NCT04779320|Experimental|Maintenance Period: ≥30 kg: Vedolizumab 150 mg|Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of ≥30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.
88804478|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 1)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 1 administered with a DPI.
88804479|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 2)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 2 administered with a DPI.
88804480|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI(Dose 3)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 3 administered with a DPI.
88804481|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 4)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 4 administered with a DPI.
88804482|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 5)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 5 administered with a DPI.
88804483|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 6)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 6 administered with a DPI.
88804484|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI (Dose 7)|Healthy volunteers will receive a single inhaled dose of AZD4604 Dose 7 administered with a DPI.
88804485|NCT04769869|Experimental|Part 1a (SAD): AZD4604 for inhalation via DPI|An additional cohort of healthy volunteers will receive a single inhaled dose of AZD4604 administered with a DPI.
88804486|NCT04769869|Placebo Comparator|Part 1a (SAD): Placebo for AZD4604 for inhalation via DPI|Healthy volunteers will receive placebo administered with a DPI.
88804487|NCT04769869|Experimental|Part 1b: AZD4604 for intravenous administration|Healthy volunteers will receive a single IV dose of AZD4604 administered as a 20 minute infusion.
88804488|NCT04769869|Experimental|Part 1b: AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604.
88804489|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 8)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
88804490|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 9)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
88804491|NCT04769869|Experimental|Part 2 (MAD): AZD4604 for inhalation via DPI (Dose 10)|Healthy volunteers will receive multiple inhaled dose of AZD4604 administered with a DPI.
88804492|NCT04769869|Placebo Comparator|Part 2 (MAD): Placebo for AZD4604 for inhalation via DPI|Healthy volunteers will receive placebo administered with a DPI.
88804493|NCT04769869|Experimental|Part 3 (MAD): AZD4604 for inhalation via DPI (Dose 9)|Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
88804494|NCT04769869|Experimental|Part 3 (MAD): AZD4604 for inhalation via DPI (Dose 10)|Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
88804495|NCT04769869|Placebo Comparator|Part 3 (MAD): Placebo for AZD4604 for inhalation via DPI|Patients will receive placebo administered with a DPI.
89152733|NCT02820389||CT Colonography|Patients with suspected colorectal cancer will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan.
89152734|NCT00376844|Active Comparator|External Beam Radiation Therapy|Postoperative pelvic radiotherapy
89152735|NCT00376844|Experimental|Vaginal Brachytherapy|Postoperative vaginal brachytherapy
89152736|NCT02821091|No Intervention|Control young adults|Healthy adults, age between 20 to 59 yeas old
89152737|NCT02821091|No Intervention|Control old adults|Healthy adults, age between 60 to 80 yeas old
89152738|NCT02821091|Experimental|Exercise old adults|Healthy adults, age between 60 to 80 yeas old received interactive dynamic balance training
89152739|NCT04146987|Active Comparator|Open rotator cuff repair|Patients will be positioned in a beach chair position with the affected limb pending off the table, allowing manipulation and full range of motion range. After asepsis, antisepsis and placement of sterile surgical fields, anterolateral incision will be made in the shoulder in question; the deltoid muscle belly will be gently divided along its fibers until exposure of the subdeltoid / subacromial bursa, which will be partially excised for exposure of the subacromial space and rotator cuff tendons. After mobilization and release of the ruptured tendons and debridement of the rotator cuff footprint, the tendon repair to the bone will be performed using 5.5m metal anchors, according to the preference and technique chosen by the surgeon. In all cases, the release of the coracoacromial ligament and acromioplasty will be performed.
89152740|NCT04146987|Active Comparator|Arthroscopic rotator cuff repair|The patients will be positioned in lateral decubitus position, with the arm to be operated attached to a skin traction device, which trough a traction post and 07 kg, will maintain the shoulder in the following position: abduction of 30 to 60 and flexion of 20 to 30 degrees. After asepsis, antisepsis and placement of impermeable sterile surgical fields, a posterolateral incision will be made in the shoulder for optic introduction, with a 50 mmHg pressure pump and a 0.90 flow, and inspection of the GU joint. After joint inspection, the optic will be introduced into the subacromial space with detachment of the subacromial and subdeltoid. Using shaver blades, partial bursectomy will be performed as well as debridement of the rotator cuff footprint. The tendon will then be reinserted to the bone using metallic 5.5mm anchors. After tendon repair, the coracoacromomial ligament will be released, as well as acromioplasty.
89152741|NCT02688296||Pilon Fractures|Patients who are implanted with Fibulock and have a Pilon fracture
89152742|NCT02688296||High Risk Patients|Patients who are implanted with Fibulock and are at high risk of complications from ankle surgery due to conditions such as diabetes, advanced age or osteoporosis
89152743|NCT02688296||Otherwise Healthy Patients|Patients implanted with Fibulock who are healthy other than their ankle fracture
89152744|NCT02821169|Placebo Comparator|saline solution 0.9%|injection of saline solution in the sphenopalatine area in both nasal fossa
89152745|NCT02821169|Active Comparator|ropivacaine (2mg/ml)|injection of ropivacaine in the sphenopalatine area in both nasal fossa
89152746|NCT02626767|Experimental|Intervention|Participants were required to complete a high-intensity interval exercise training intervention, which took place three time per week for 10 weeks. The exercise sessions comprised of 4 to 7 repetitions of 45 s maximal effort exercise, based on boxing, dance, soccer and basketball drills), interspersed with 90-s rest. During each repetitions participants were encouraged to reach >90% of their individual maximal heart rate. Participants were asked to maintain their dietary habits throughout the intervention period.
89152747|NCT02626767|No Intervention|Control|Participants were asked to maintain their usual diet, physical education and physical activity habits during the intervention period and were not aware that an exercise intervention was taking place at other study sites.
89152748|NCT02820935|Experimental|Part 1, Period 1: CC-220|Single dose of 0.6mg CC-220
89152749|NCT02820935|Experimental|Part 1, Period 2: itraconazole with CC-220|Multiple does of 200 mg itraconazole alone, with a single dose of 0.6 mg CC-220 plus itraconazole
89152750|NCT02820935|Experimental|Part 2, Period 1: CC-220|Single dose of 0.6mg CC-220
89152751|NCT02820935|Experimental|Part 2, Period 2: rifampin with CC-220|Multiple doses of 600 mg rifampin alone, with a single dose of 0.6 mg CC-220 plus rifampin
89152752|NCT02626845|Active Comparator|Rituximab Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional rituximab infusions at week 16 and week 32.
89152753|NCT02626845|Placebo Comparator|Placebo Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional placebo infusions at week 16 and week 32.
89152754|NCT02821247||Aflibercept|Adult wet Age Related Macular degeneration (AMD) treatment naïve partcipants were treated with intravitreal aflibercept injection
89152755|NCT00681525|Experimental|A|ABT-335 135 mg
89152756|NCT00681525|Experimental|B|Atorvastatin 80 mg and Ezetimibe 10 mg
89152757|NCT00681525|Experimental|C|ABT-335 135 mg, Atorvastatin 80 mg and Ezetimibe 10 mg
89152758|NCT02818673|Experimental|Ascites in Patients With Cirrhosis|Patients will be further classified according to the refractory or sensitive ascitis
89152759|NCT00681603|Experimental|1|13 cases that accepted subconjunctival injection of bevacizumab
89152760|NCT04146597|Experimental|Neural mobilization|The intervention is always performed after Jiu Jitsu practice and at the training site itself. Neural mobilization consisted of the execution of a sciatic nerve sliding technique in three sets of one minute for each lower limb with an interval of one minute between sets, twice a week, for five consecutive weeks, totaling 10 interventions (Garber et al., 2011). The order of the first lower limb to be submitted to the intervention is not standardized, being at the discretion of the subjects.
89152761|NCT04239443|Experimental|SHR1210 and Apatinib|"NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d).~The duration of treatment will till the disease progression, death, or unacceptable toxicity show up."
89152762|NCT00681681||1|Men and women with 1 or more cardiovascular risk factors
89152763|NCT02820155|Placebo Comparator|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
89152764|NCT02820155|Experimental|RGN1016_50mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
89152765|NCT02820155|Experimental|RGN1016_100mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
89152766|NCT02820155|Experimental|RGN1016_200mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
89152767|NCT02820155|Experimental|RGN1016_400mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
89152768|NCT02820155|Experimental|RGN1016_800mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
89152769|NCT00681759||1|Patients who have been prescribed Low Dose Aspirin (LDA) usage in the past 12 months, or those about to begin LDA, will complete a one-time in-office survey using an electronic personal digital assistant (PDA) device (termed SitePro).
89152770|NCT00681759||2|420 subjects stratified into three groups varying on length of time using Low Dose Aspirin (LDA)
89152771|NCT00681759||3|Up to 20 subjects from the three EMA groups will be interviewed to further debrief their experience with Low Dose Aspirin (LDA) and upper GI symptoms.
89152772|NCT00681837||1|children from 0 to 17 years old
89152773|NCT04200599|Experimental|Early oxytocin Infusion|labour augmentation with oxytocin was started early following amniotomy.
89152774|NCT04200599|Active Comparator|Late oxytocin infusion|oxytocin augmentation was delayed at two hours after amniotomny and this practice is currently being used as standard protocol in this hospital to manage women in labour.
89152775|NCT02820077|Experimental|Hemospray|Patients treated with hemostatic powder
89152776|NCT02820077|No Intervention|Clinical support|Patients treated with optimal clinical management, as it is been advised by the latest guidelines
89152777|NCT00681915|Experimental|1|
89152778|NCT00681993|Active Comparator|Standard ddAC chemotherapy with concurrent radiation therapy|Standard dose-dense Adriamycin and Cyclophosphamide (ddAC) chemotherapy and concurrent radiation therapy (RT)
89152779|NCT00681993|Active Comparator|Standard AC chemotherapy with concurrent RT|Standard Adriamycin and Cyclophosphamide (AC) chemotherapy and concurrent radiation therapy
89152780|NCT00681993|Active Comparator|Standard TCarbo H chemotherapy with concurrent RT|Standard Taxotere, Carboplatin and Herceptin (TCarbo H) chemotherapy and concurrent radiation therapy
89152781|NCT00681993|Active Comparator|Standard TAC chemotherapy with concurrent RT|Standard Taxotere, Adriamycin and Cyclophosphamide (TAC) chemotherapy with concurrent radiation therapy
89152782|NCT00681993|Active Comparator|Standard TC chemotherapy with concurrent RT|Standard Taxotere and Cyclophosphamide (TC) chemotherapy with concurrent radiation therapy
89152783|NCT05659043||T2DM with CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. The patients were tested by angiography, with CAD diagnosed if luminal diameter narrowing was estimated visually at ≥50% in a major epicardial coronary artery.
89152784|NCT05659043||T2DM without CAD|Diagnosis of T2DM was made according to the criteria of the American Diabetes Association. These subjects had no history of ischemic heart disease (acute myocardial infarction, unstable angina, chronic stable angina, previous percutaneous or surgical coronary revascularization, heart failure) and received CCTA in the outpatient clinics due to suspected CAD or other causes. And the luminal diameter narrowing was estimated by CCTA at ≤30%.
89152785|NCT00682071||1|transabdominal ultrasound (TAS) guided embryo transfer
89152786|NCT00682071||2|transvaginal ultrasound (TVS) guided embryo transfer
89152787|NCT02819999|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
89152788|NCT02819999|Experimental|Rovalpituzumab Tesirine followed by Cisplatin, Etoposide|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion followed by Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion
89152789|NCT02819999|Experimental|Rovalpituzumab Tesirine with Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion and Rovalpituzumab Tesirine 0.1 mg/kg IV infusion
89152790|NCT02819999|Experimental|Rovalpituzumab Tesirine following Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion followed by Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
89152791|NCT00633815||Fontan patients|Subjects will undergo exercise testing in both the supine and upright positions
89152792|NCT00633815||Healthy controls|Subjects will undergo exercise testing in both the supine and upright positions
89152793|NCT02819921|Experimental|Desvenlafaxine succinate 100mg|Titration with 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 2 tablets of 50mg Desvenlafaxine succinate tablet once daily for 3 weeks, then taper with 50 mg Desvenlafaxine succinate tablet once daily for 3 days.
89152794|NCT02819921|Experimental|Desvenlafaxine succinate 50mg|50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 1 tablets of 50mg Desvenlafaxine succinate tablet and 1 tablet of 50mg placebo tablet once daily for 3 weeks, then 50mg placebo tablet once daily for 3 days.
89152795|NCT02819921|Placebo Comparator|Placebo|50 mg placebo tablet once daily for 1 week, then 2 tablets of 50mg placebo tablet once daily for 3 weeks, then 50 mg placebo tablet once daily for 3 days.
89152796|NCT02819687|Experimental|RDX5791 10mg QD (SAD phase)|10mg of RDX5791 administered once daily PO fasting
89152797|NCT02819687|Experimental|RDX5791 50mg QD (SAD phase)|50mg of RDX5791 administered once daily PO fasting
89152798|NCT02819687|Experimental|RDX5791 150mg QD (SAD phase)|150mg of RDX5791 administered once daily PO fasting
89152799|NCT02819687|Experimental|RDX5791 450mg QD (SAD phase)|450mg of RDX5791 administered once daily PO fasting
89152800|NCT02819687|Experimental|RDX5791 900mg QD (SAD phase)|900mg of RDX5791 administered once daily PO fasting
89152801|NCT02819687|Experimental|RDX5791 3mg QD (MAD phase)|3mg of RDX5791 administered once daily PO fasting
89152802|NCT02819687|Experimental|RDX5791 10mg QD (MAD phase)|10mg of RDX5791 administered once daily PO fasting
89152803|NCT02819687|Experimental|RDX5791 30 mg QD (MAD phase)|30mg of RDX5791 administered once daily PO fasting
89152804|NCT02819687|Experimental|RDX5791 100 mg QD (MAD phase)|100mg of RDX5791 administered once daily PO fasting
88804496|NCT04769869|Experimental|Part 3 (PoM): AZD4604 for inhalation via DPI (Dose 9 or Dose 10)|Patients will receive multiple inhaled dose of AZD4604 administered with a DPI.
88804498|NCT04762199|Experimental|Treatment (osimertinib, MRX-2843)|Patients receive osimertinib PO QD and MRX-2843 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88804499|NCT04755881||All anaphylaxis reactions seen during the phase 2 period of the SHARED study.|All patients presenting to the 3 sites emergency departments (Chicoutimi, Alma, Jonquière) diagnosed with an anaphylactic reaction or a severe allergic reaction that is rapidly evolving towards anaphylaxis in the opinion of the treating physician.
88804500|NCT04750720|Experimental|Group with biological samples|Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology). In the vaccine sub-study: additional blood and nasopharyngeal samples before and after vaccination, up to 6 months.
88804501|NCT04734951|Active Comparator|Power/resistance exercise|Participants on a power/resistance exercise program
88804502|NCT04734951|Experimental|Power/resistance exercise + HMB|Participants on combined power/resistance exercise program + HMB oral supplementation
88804503|NCT04733157|Experimental|Study group/Group A|The study group will receive TXA 1g intravenously at the onset of skin incision.
88804504|NCT04733157|Placebo Comparator|Control group/Group B|There is an equivalent volume of normal saline for the control group.
88804505|NCT04711239||Two types of samples (TE and SCM) will be collected for all blastocysts included in the study|
88804506|NCT04688047|Experimental|Experimental|Women aged 18 and over with urinary incontinence will be taken. A total of seven online interviews will be conducted with the women in the experimental group, one of which is pre-test, one is the last interview where the post-tests are applied, and five of which are motivational. Women in the experimental group were interviewed every 2 weeks and the women will be followed up by phone / mail every 2 weeks.
88804507|NCT04688047|No Intervention|Control|Women aged 18 and over with urinary incontinence will be taken. A total of two online interviews will be conducted with women in the control group, one of which is a pre-test interview and one is a final interview where post-tests are applied.
88804508|NCT04685044|Other|Healthy Volunteers|BrainPET insert
88804509|NCT04653662|Experimental|Treatment group|Treatment group arm. Open label. Only 1 arm study
88804510|NCT04633122|Experimental|Ripretinib|50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle.
88804511|NCT04633122|Active Comparator|Sunitinib|12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break.
88804512|NCT04630379|Experimental|Group A (visit with neuro-oncologist)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months to address concerns that are identified via the survey and the domain of concern identified by patient and caregiver.
88804513|NCT04630379|Experimental|Group B (visit with neuro-oncologist and palliative care team)|Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist and palliative care team monthly for 6 months to address concerns that are identified by the survey and domains of concerns. Caregivers also attend support sessions led by a social worker monthly for 6 months.
88804514|NCT04630379|Active Comparator|Group C (visit with neuro-oncologist, palliative care team)|Patients and primary caregiver complete quality of life portion of the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months and address important concerns that come up on the survey. Patients may also receive palliative care consultation as deemed appropriate by the neuro-oncologist.
88804515|NCT04629924|Experimental|sleeper one|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).~Osteocentral anesthesia performed with the SleeperOne® 5 system (Dental Hi Tec) loaded with Articaine 1/200000 carpule."
88804516|NCT04629924|Active Comparator|conventional technique|"Topical anesthesia: to be applied during 1 to 2 minutes on a previously dried mucous membrane (Lidocaine Gingival Gel, Septodont).~Anaesthesia using a conventional technique, i.e. a metal syringe loaded with Articaine 1/200000 carpule."
88804517|NCT04626609||EoE group|Patients with confirmed eosinophilic esophagitis
88804518|NCT04626609||GERD group|Patients with gastro-esophageal reﬂux disease
88804519|NCT04626609||Control group|Individuals with no esophageal disease
88804520|NCT04605666|Experimental|CAR-T group|
88804521|NCT04591171|Experimental|n-of-1 trial guided clinical decision making|
88804522|NCT04535050|Experimental|DENEX Renal denervation|Subjects are treated with the renal denervation procedure after randomization
88804523|NCT04535050|Sham Comparator|Sham control|Subjects are treated with renal angiography
88804524|NCT04529343|Experimental|Virtual Reality Group|To the virtual reality group; In addition to upper extremity exercises applied 2 days a week, upper extremity rehabilitation via virtual reality glasses will be performed 3 days a week for 6 weeks and each session will be 45 minutes.
88804525|NCT04529343|Active Comparator|Control Group|Upper extremity exercises will be applied to the participants in the control group 2 days a week for 6 weeks.
88804526|NCT04519983|Experimental|Upfront TKI + Salvage SRT|Patients With Brain metastases of EGFR-mutant Non-small Cell Lung Cancer should receive Aumolertinib as upfront treatment. SRT(32Gy/4fx) is given to progressive or recurrent intracranial lesions as salvage therapy after intracranial failure.
89152805|NCT04239209|Placebo Comparator|Direct Communication (control)|A direct response where the intensivist acknowledges that he is not certain but believes the patient will not survive hospitalization.
89152806|NCT04239209|Active Comparator|Indirect - other patients|An indirect response describing the prognosis of other people similar to the patient in question.
89152807|NCT04239209|Active Comparator|Indirect - physiology|An indirect response describing the severe physiologic abnormalities present in the patient and potential future problems.
89152808|NCT04239209|Active Comparator|Redirection|Redirection to a conversation about the values of the patient and possible future decisions.
89152809|NCT02819609||Myomectomy|Women with uterine fibroids who underwent myomectomy as their index procedure as part of their routine clinical care
89152810|NCT02819609||Endometrial ablation|Women with uterine fibroids who underwent endometrial ablation as their index procedure as part of their routine clinical care
89152811|NCT02819609||Uterine artery embolization|Women with uterine fibroids who underwent uterine artery embolization as their index procedure as part of their routine clinical care
89152812|NCT02819609||MRI-guided focused ultrasound ablation|Women with uterine fibroids who underwent MRI-guided focused ultrasound ablation as their index procedure as part of their routine clinical care
89152813|NCT04184960||Gastric cancer cohort|Cohort of patients with gastric cancer
89152814|NCT04184960||Non-gastric cancer cohort|Cohort of patients without gastric cancer
89152815|NCT02817035|Experimental|noninvasive mechanical ventilation|To investigate the change of the neural inspiratory time and expiratory delay noninvasive mechanical ventilation ,in comparison to spontaneous breathing
89152816|NCT00875979|Experimental|Trastuzumab emtansine 3.0 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
89152817|NCT00875979|Experimental|Trastuzumab emtansine 3.6 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
89152818|NCT02818751|Experimental|Escitalopram|Patients being randomized to receive escitalopram, at an initial dose of 5 mg (oral) daily for 2 days. On day 3, escitalopram will be increased to 10 mg daily and continued for 7 days. Then, on day 10, escitalopram will be increased to 15 mg. At the week 4 visit, the dose of escitalopram may be increased to 20 mg, based on the investigator's clinical judgment and if significant anxiety symptoms are still present.
89152819|NCT02818751|Placebo Comparator|Placebo|Patients will receive placebo (sugar pill) at an initial dose of 5 mg daily for 2 days. On day 3, placebo will be increased to 10 mg daily and continued for 7 days to match the experimental group.
89152820|NCT02818751|No Intervention|Healthy Controls|Healthy adolescents will receive fMRI scans at the same time points, which will provide assessments of the stability of neurophysiologic measures and will be used to adjust and interpret comparisons within the patients (i.e., whether patient values are changing toward or away from those of healthy adolescents).
89152821|NCT02697110|Experimental|A: Edutainment based intervention|This group receives the usual routine immunization at 6, 10, 14 weeks and 9 months and an Edutainment intervention package of limited group (i.e., 3-5 women) drama based video session (Edutainment) followed by a Question and Answer session with mothers on early brain development, parenting skills, communication and negotiating skills at 6 weeks. Mothers will be encouraged to train fathers and other caregivers at home with reinforcement of key messages at subsequent clinic visits. Key messages will be delivered through the use of flip charts at 14 weeks and given to mothers as take home for use in engaging the fathers partners and other caregivers for their child. Reinforcement of key messages at subsequent visits will be through the use of videos and flip chart.
89152822|NCT02697110|No Intervention|B|This group receives routine immunization care (usually includes group health talk) at 6, 10, 14 weeks and 9 months.
89152823|NCT04238975|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
89152824|NCT04238975|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
89152825|NCT00682149|Placebo Comparator|Group 1|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
89152826|NCT00682149|Active Comparator|Group 2|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
89152827|NCT00639782|Active Comparator|ONX|On-X heart Valve Replacement
89152828|NCT00639782|Active Comparator|SJM|SJM heart valve replacement
89152829|NCT04238897|Experimental|Ticon Aspherical Daily Disposable Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
89152830|NCT04238897|Placebo Comparator|Ticon Daily Soft Contact Lens|The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
89152831|NCT04144881|Experimental|coronary computed tomography|
89152832|NCT04144881|No Intervention|conservative (ischemia-guided) management|
89152833|NCT02685644||Laparoscopic removal|Patients with endometrioma who will undergo laparoscopic removal of cysts.
89152834|NCT04239287||Preterm|Children age 8-16 years born at <32 weeks gestation.
89152835|NCT04239287||Control|Children age 8-16 years born at >37 weeks gestation
89152836|NCT02626689||β-thalassemia transfusion dependent subjects|Participants will complete 3 quality of life instruments (i.e. FACT-AN, the SF-36v2, and the TranQol) once every 3 weeks, in addition to a TranQol instrument on the day of a RBC transfusion. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
89152837|NCT02626689||β-thalassemia Non Transfusion Dependent (NTD) subjects|Participants will complete 2 quality of life instruments (i.e. FACT-An and the the SF-36v2l) once every 3 weeks, in addition to completing the non-transfusion dependent Patient Recorded Outcome (PRO) tool on a daily basis. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
89152838|NCT02818595|Experimental|Normal children|Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological
89152839|NCT02818595|Experimental|Abnormal children|Every child meet the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological as intraventricular hemorrhage .
89152840|NCT00602420|Experimental|Naproxen|Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
89152841|NCT00602420|Placebo Comparator|Placebo|Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
89152842|NCT02819531|Active Comparator|Rotational atherectomy|RA protocol: After IVUS protocol, patients who are randomized to RA will undergo coronary wiring of the target lesion and subsequent advancement of the RA burr. The RA system is performed using standard technique under intravenous infusion of heparin. The atherectomy burr size will be determined by the operator.
89152843|NCT02819531|Active Comparator|Orbital atherectomy|OAS protocol: After IVUS protocol, patients who are randomized to OAS will undergo coronary wiring of the target lesion and subsequent advancement of the OAS according to the manufacturer's guidelines.
89152844|NCT02819531|Active Comparator|Scoring balloon system|SBS protocol: After IVUS protocol, patients who are randomized to SBS will undergo coronary wiring of the target lesion and balloon inflation with SBS performed by standard technique under intravenous infusion of heparin. SBS will be used according to the manufacturer's guidelines.
89152845|NCT00682227|Experimental|1|
89152846|NCT04635605|Experimental|Methylene Blue|Methylene Blue 100 mg capsules. Patients will receive Methylene blue (MB) capsules of 100mg every 12 hours for a total of 5 days.
89152847|NCT04635605|Active Comparator|control group|The control intervention would be the group receiving 100 mg placebo capsules twice a day for five consecutive days
89152848|NCT00682305|Other|Single-Arm|Single-Arm
89152849|NCT02688374|Other|Treatment A:Treatment B:Treatment C|Participants will be administered with Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
89152850|NCT02688374|Other|Treatment B:Treatment C:Treatment A|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
89152851|NCT02688374|Other|Treatment C:Treatment A:Treatment B|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
89152852|NCT02688374|Other|Treatment A: Treatment C:Treatment B|Participants will be administered with Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
89152853|NCT02688374|Other|Treatment B:Treatment A: Treatment C|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
89152854|NCT02688374|Other|Treatment C:Treatment B:Treatment A|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
89152855|NCT02819375|Active Comparator|Group Propofol|anesthesia will induced 1 mg/kg propofol
89152856|NCT02819375|Active Comparator|Group propofol/remifentanil|anesthesia will induced 0.5 mg/kg propofol and 1 µg/kg remifentanil
89152857|NCT02819375|Active Comparator|Group propofol/ketamine|anesthesia will induced propofol 0.5 mg/kg and ketamine 0.5 mg/kg
89152858|NCT04144491|Experimental|Yoghurt|Yoghurt, containing Lactobacillus rhamnosus yoba 2012, Streptococcus thermophilus C104, whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence.
89152859|NCT04144491|Placebo Comparator|Custard|Custard, containing whole milk, 5% sugar, 0.1% strawberry or vanilla flavor essence, 4% modified corn starch.
89152860|NCT02819453||prior corticosteroid treatment|Patients diagnosed with acute respiratory distress syndrome(ARDS) by two clinicians on the first day of hospital admission (not receiving corticosteroids yet)
89152861|NCT02819453||after corticosteroid treatment|Patients diagnosed with acute respiratory distress syndrome(ARDS) after corticosteroids treatment
89152862|NCT00638768|Active Comparator|Physiotherapy|Including 10 individual visits with a physiotherapist and home exercises
89152863|NCT00638768|No Intervention|2|Usual care
89152864|NCT04144647|Experimental|Healthy adults 18-80 years old|Healthy adults 18-80 years old
89152865|NCT04634747|Experimental|PVX-410/pembrolizumab/chemotherapy|
89152866|NCT04187924|Active Comparator|Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage. Sputum will be collected during the session.
89152867|NCT04187924|Active Comparator|SIMEOX + Autogenic drainage|Patients will have to perform a 30-min session of autogenic drainage with the SIMEOX device. Sputum will be collected during the session.
89152868|NCT04619927|Experimental|Intervention group|The intervention includes testing of patients for carriage of the CYP2C19*2 and *3 allele (loss-of-function (LOF) alleles), followed by a genotype guided antithrombotic treatment with either clopidogrel 75mg (without LOF allele, normal metabolizers), clopidogrel 150mg (one LOF allele, intermediate metabolizers), or rivaroxaban 2.5mg twice daily plus acetylsalicylic acid 100mg (two LOF alleles, poor metabolizers).
89152869|NCT04619927|Active Comparator|Comparison group|The comparison group will not be prescribed clopidogrel 75mg without preceding testing for carriage of the CYP2C19*2 and *3 loss-of-function alleles. CYP2C19 genotyping will be performed at the end of the study.
89152870|NCT02697266||Post-call anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
89152871|NCT02697266||Regular-shift anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
89152872|NCT02626533||Total knee arthroplasty patients|Patients undergoing total knee arthroplasty for osteoarthritis are enrolled in the study. Blood and joint fluid samples will be obtained from patients, and questionnaires will be administered to assess pain and stiffness.
89152873|NCT04191707||Outpatients with Inflammatory Bowel Disease|This study was performed with plasma samples from IBD patients recruited in a previous study after informed consent. (1) IBD outpatients attending the Hospital de Sabadell Gastroenterology Day-care unit were consecutively included for analytical monitoring of immunosuppressant treatment or infliximab infusion
89152874|NCT05661656|Experimental|Advanced breast cancer patients|Tumors are staged according to the criteria of the Union for International Cancer Control (UICC). Tumor volume was determined by mammography or magnetic resonance imaging (MRI). Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
89152875|NCT05658809|Active Comparator|Total thyroidectomy for single thyroid nodule|group of participants will be treated with total thyroidectomy
89152876|NCT05658809|Active Comparator|Hemithyroidectomy for single thyroid nodule|2nd group of participants will be treated with hemithyroidectomy
89152877|NCT02688062|Experimental|NeuroRegen Scaffold with BMMCs transplantation|
89152878|NCT02688062|Experimental|Surgical intradural decompression and adhesiolysis|
89152879|NCT02819219|Placebo Comparator|Placebo|Participants will receive a flavored water placebo supplement. Part of the supplemental intervention. This, and all groups, simultaneously took part in the exercise intervention.
89152880|NCT02819219|Experimental|ElevATP|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts). Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
89152881|NCT02819219|Experimental|ElevATP w/Caffeine|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts), a 180 mg blend of caffeine (caffeine anhydrous, pterostilbene-bound caffeine), and 38mg B vitamins. Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
89152882|NCT04186364|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the ED visit will serve as our intervention group. The participants will be assigned an Ambassador throughout the child's ED visit and will complete a patient satisfaction survey afterwards. The investigators hold to enroll 120 controls.
89152883|NCT04186364|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the ED visit will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the ED visit, however no ambassador will be assigned during the ED visit. The investigators hope to enroll 120 controls.
89152884|NCT00633971|Experimental|A|Complex lymphedema therapy (which includes compression stocking use)
89152885|NCT00633971|Other|B|Standard of care (compression stocking use at 30-40 mm Hg)
89152886|NCT02818985|Active Comparator|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
89152887|NCT02818985|Active Comparator|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
89152888|NCT02818985|Placebo Comparator|Control|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
89152889|NCT02685410|Experimental|One Night Stan Pilot Testing Group|The pilot testing of the One Nigh Stan prototype intervention will utilize 20 young black women aged 18-24 as participants.
89152890|NCT02818361|Experimental|topical TwHF gel group|Topical TwHF gel recipe composes Tripterygium wilfordii Hook F, Mangxiao (Mirabilite), Chuanxiong (Rhizoma Ligustici), Ruxiang (Olibanum), Moyao (M yrrh) (prescription proportion is 4:4:2:2:1).Each gel is 20 gram(g). TwHF gel is applied for 1st to 5th metacarpophalangeal joints, 1st to 5th proximal interphalangeal joints, wrists, knees and ankles 20g for 1 hour, once per day from week 0 through week 4 and 10g for 1 hour, once per day from week 5 through week 8.
89152891|NCT02818361|Placebo Comparator|placebo group|Placebo recipe composes viscous agent which matches by the sucrose. The usage and dosage of topical TwHF and placebo are the same.
89152892|NCT00909896||Robotic Surgery candidates|Group of patients receive Robotic approach for endometrial cancer staging
89152893|NCT00909896||Open Laparotomy Surgical Candidates|Patients receiving open laparotomy for endometrial cancer surgical staging
89152894|NCT02818907|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, after neoadjuvant chemotherapy (if applicable) and before surgery, 1 month after surgery and 1 month after the last adjuvant chemotherapy cycle.~Peripheral blood mononuclear cell (PBMC), plasma and circulating tumor DNA and RNA will be collected.~Tumor tissue will be collected during surgery."
89152895|NCT03332420||Observational 1|Huaiqihuang Granule
89152896|NCT03332420||Observational 2|Standard treatment+Huaiqihuang Granule
89152897|NCT03332420||Observational 3|Standard treatment
89152898|NCT02683226|Experimental|metformin and alogliptin|Vipdomet 12.5 mg/1000 mg tablets
89152899|NCT02683226|Experimental|pioglitasone and alogliptin|Incresync 12,5 mg/30 mg tablets
89152900|NCT02818205||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation
89152901|NCT02818205||Typically Developing Children|Typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
89152902|NCT02815787|Active Comparator|SP2086 and Glyburide|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days. In this group,the subjects was given the drugs from A sequence to the B sequence.
89152903|NCT02815787|Active Comparator|Glyburide and SP2086|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days.In this group,the subjects was given the drugs from B sequence to the A sequence.
89152904|NCT00639938|Active Comparator|1|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single dose of 2 mg/kg NVP taken orally within the first week after delivery"
89152905|NCT00639938|Experimental|2|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: 2 mg/kg NVP taken orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6"
89152906|NCT00639938|Experimental|3|"Mother dosing regimen: Single 12 gm intravenous dose of HIVIGLOB at 36 - 37 weeks gestation and 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP taken orally within the first week after delivery"
89152907|NCT02685254|Experimental|Initial group therapy|'Structural skills training group' - Start up with weekly structured skills training group for 14 weeks supplemented by homework training
89152908|NCT02685254|Other|Initial control condition|Treatment as usual/clinical management the first 15 weeks pending deferred start of group therapy (partially cross-over)
89152909|NCT02687828||Subjects receiving adalimumab|The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.
89152910|NCT02687750|Experimental|MRI|"Eppendorf tubes containing 10% fluorine-19 diluted in agar were taped to the upper thigh of participants. Investigational device was used to image the phantom with Magnetic resonance imaging (MRI). Imaging was performed for anatomical (proton) and fluorine (agent detection). Total scan time was under 1 hour.~Objectives:~Verify RF coil functionality~Obtain preliminary detection threshold limits using a human coil loading"
89152911|NCT02815319|Active Comparator|Standard of care|Physician's treatment recommendation for dexamethasone premedication
89152912|NCT02815319|Active Comparator|8mg PO dexamethasone|8mg PO dexamethasone premedication
89152913|NCT02815475|Placebo Comparator|Placebo|Starch filled capsule
89152914|NCT02815475|Experimental|Curcumin|400mg of Curcumin via capsule to be consumed every other day
89152915|NCT02815475|Active Comparator|Turmeric powder|2 teaspoons of dried turmeric powder to be consumed every other day
89152916|NCT02815241|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89152917|NCT00640796|Experimental|Treatment|Participants undergo haploidentical donor derived natural killer cell infusion (cells obtained from donors and selected using CliniMACS cell selection system) and chemotherapy (cyclophosphamide, fludarabine, interleukin-2, mesna).
89152918|NCT02687984|Experimental|RBP-7000 PLGH A|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.
89152919|NCT02687984|Experimental|RBP-7000 PLGH B|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 29 kDa PLGH polymer.
89152920|NCT02687984|Active Comparator|RBP-7000 PLGH C|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 26 kDa PLGH polymer. This intermediate molecular weight treatment serves as the reference treatment.
89152921|NCT02327312|Experimental|Surgical|Implantation of two Trabecular Meshwork stents into the study eye
89152922|NCT02327312|Active Comparator|Laser|Laser Trabeculoplasty
89152923|NCT00640874||PIPET C|Contact group members of people with diagnosed influenza who are recommended to receive NA inhibitor prophylaxis for short periods of time will be enrolled following provision of informed consent.
89152924|NCT02815163|No Intervention|comparison group|The CG received no extra care; they could receive the usual routine care for THR in the unit as they had before participation in the study. The routine care included oral instruction by nurses follow by the handout. Also, a brochure was provided of the structure of hip, the risk factors of THR, care before and after THR, complications, care of discharge, and demonstration of rehabilitation with pictures) of THR designed by researchers in this study. Five orthopedics health care experts independently reviewed and rated each item in the brochure on a five-point Likert-type scale in terms of relevance, representativeness, specificity, and clarity.
89152925|NCT02815163|Experimental|Empowerment education group|"The 5 times total, 12-week EE intervention was aimed to empower older patients with THR to develop their own self-management program to meet their needs. This empowerment education intervention based on 6 empowerment components: Partnership, listening, dialogue, reflection, action, feedback and 5-step empowerment strategies: motivating patients self-awareness, assessing the causes of the problem, goal setting, individual self-care plan development, and checking whether goals or plans have been achieved who modified from Freire's 3-stage methodology. The difference between this program and the other health educations for patients with THR are that this program encourages them to explore their needs and worries, their own ability and power to meet their needs, and their capacity to seek and use their social support and resources etc."
89152926|NCT02683148|Experimental|Arm 1: DHEA Dose Level 1|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
89152927|NCT02683148|Experimental|Arm 2: DHEA Dose Level 2|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
89152928|NCT02683148|Experimental|Arm 3: DHEA Dose Level 3|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
89152929|NCT02683148|Experimental|Arm 4: DHEA Phase II|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
89152930|NCT04238507|Active Comparator|Guedel airway (OPA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
89152931|NCT04238507|Active Comparator|McKay Airway (MA)|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
89152932|NCT03992768|Experimental|NanoZoomer Whole Slide Imaging|Whole slide imaging using the Hamamatsu NanoZoomer S360MD Digital Slide Scanner System
89152933|NCT02818127|Active Comparator|normal coronary artery|coronary angiography will be performed by transfemoral or transradial route.
89152934|NCT02818127|Active Comparator|coronary slow flow|coronary angiography will be performed by transfemoral or transradial route.
89152935|NCT02818127|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
89152936|NCT02818127|Active Comparator|non-obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
89152937|NCT02818127|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
89152938|NCT02684786|Experimental|Prior right heart catheterization|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status.
89152939|NCT02684786|Experimental|Scheduled for right heart catheterization|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
89152940|NCT05656547||Encephalographic spectrogram group|The dexmedetomidine and propofol infusions were titrated to maintain robust alpha power in the encephalographic spectrogram
89152941|NCT05656547||Encephalographic index group|The dexmedetomidine and propofol infusions were titrated to maintain the bispectral index score between 40 and 60.
89152942|NCT04238273||HHHFNC|it included 63 preterm neonates on Heated, Humidified High Flow Nasal Cannula, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
89152943|NCT04238273||NCPAP|it included 60 preterm neonates on Nasal Continuous Positive Airway Pressure, of which 35 preterm underwent functional echocardiography, transcranial ultrasonography Doppler applied to the anterior cerebral artery and assessment of pre-prandial superior mesenteric artery velocity and volume of blood flow with Doppler sonography. All of which done while on non invasive ventilation and after weaning.
89152944|NCT02685020|Experimental|Group 1A|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
89152945|NCT02685020|Placebo Comparator|Group 1B|Participants will receive placebo at weeks 0, 12, 24 and 48.
89152946|NCT02685020|Experimental|Group 2A|Participants will receive Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 0, 12 and 24.
89152947|NCT02685020|Placebo Comparator|Group 2B|Participants will receive placebo at weeks 0, 12 and 24.
89152948|NCT02685020|Experimental|Group 3A|Participants will receive Ad26.Mos.HIV vaccine at Week 0; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 8 and 24.
89152949|NCT02685020|Placebo Comparator|Group 3B|Participants will receive placebo at weeks 0, 8 and 24.
89152950|NCT02815007|Experimental|Chidamide with EGFR-TKI|"Chidamide: Per Os, 30mg (5mg*6), twice a week, time interval between 2 medications should be ≥3 days, medicine taken 30 minutes after breakfast.~EGFR-TKI:~Taken according to the instruction book"
89152951|NCT02683070|Experimental|The PNB group|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) will be performed after the completion of surgery before extubation.
89152952|NCT02683070|Active Comparator|The TRAM group|Intravenous tramadol of 1.5mg/kg will be administrated after the completion of surgery before extubation.
89152953|NCT05643599||Group 1:|Mad honey
89152954|NCT05643599||Group 2:|Normal honey
89152955|NCT05643599||Group 3:|without intervention
89152956|NCT04184414|Experimental|CART cells|dosage：Once dose，1.0*10^6cells/kg CART cells Administration mode:Intravenous infusion
89152957|NCT02814851|Experimental|Non valvular cardiac surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and cardiology wards. Subjects referred for non valvular cardiac surgery will be prospectively included during the first 6 months following the onset of the protocol.
89152958|NCT02685176|Experimental|No Heat|No active heating will be provided post cooling
89152959|NCT02685176|Experimental|Head|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the head following cooling
89152960|NCT02685176|Experimental|Torso|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the torso following cooling
89152961|NCT05656391|Active Comparator|Treatment bread|Dietary treatment consisted of daily consumption of 200 grams of bread produced following traditional breadmaking techniques
89152962|NCT05656391|Placebo Comparator|Control bread|Dietary treatment consisted of daily consumption of 200 grams of bread produced following modern breadmaking techniques
89152963|NCT05656157||Antifungal treatment prescribed by the clinician for an invasive fungal disease|
89152964|NCT05656157||Antifungal treatment recommended by the clinical decision support system|
89152965|NCT04184024|Active Comparator|Massage group|Patients in this group were applied to massage plus neck stabilization exercise.
89152966|NCT04184024|Active Comparator|Kinesio taping group|Patients in this group were applied to Kinesio taping plus neck stabilization exercise.
89152967|NCT02814773||AD group|group suffering from Alzheimer-type dementia (mild to moderate dementia)
89152968|NCT02817971|Experimental|Enhanced feedback|"Monthly written feedback incorporating goal setting, and action planning delivered by a senior clinical coordinator for selected pneumonia indicators~Two-monthly written feedback on multiple quality of paediatric care indicators~Clinical network promoting clinical leadership linked to mentorship and peer to peer support~Improved use of health information on service delivery"
89152969|NCT02817971|Active Comparator|Standard feedback|"Two-monthly written feedback on multiple quality of paediatric care indicators~Clinical network promoting clinical leadership linked to mentorship and peer to peer support~Improved use of health information on service delivery"
89152970|NCT05664152|Experimental|MG1111|Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).
89152971|NCT04364633||Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
89152972|NCT04364633||Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
89152973|NCT00634205|Experimental|A|Continuous oral administration of valproate plus every 3 weeks, intravenous administration of doxorubicin
89152974|NCT02681276|Experimental|Irrigation with 3% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 3 % NaOCl irrigation during instrumentation. If the patient's first visit was on an uneven date the concentration of the irrigant was 3 %.
89152975|NCT02681276|Active Comparator|Irrigation with 0.5% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 0.5 % NaOCl irrigation during instrumentation. If the patient's first visit was on an even date the concentration of the irrigant was 0.5 %.
89152976|NCT04238195|Experimental|Treatment A|600 mg TBPM-PI-HBr (2 x 300 mg tablets) and TBPM-PI-HBr-matching placebo (2 x matching placebo tablets) administered at Hour 0 on Day 1.
89152977|NCT04238195|Experimental|Treatment B|1200 mg TBPM-PI-HBr (4 x 300 mg tablets) administered at Hour 0 on Day 1.
89152978|NCT04238195|Placebo Comparator|Treatment C|TBPM-PI-HBr-matching placebo (4 x matching placebo tablets) administered at Hour 0 on Day 1.
89152979|NCT04238195|Other|Treatment D|Positive Control - unblinded: 400 mg moxifloxacin (1 x 400 mg tablet) administered at Hour 0 on Day 1.
89152980|NCT02815085|Experimental|RecoverLINK technology|RecoverLINK is a two-part mHealth technology designed to supplement traditional care transitional programs for heart failure (HF) patients.
89152981|NCT04238351|Experimental|Control|usual mask ventilation during anethesia induction
89152982|NCT04238351|Active Comparator|THRIVE|Applying Transnasal humidified rapid insufflation ventilator exchange during anesthesia induction
89152983|NCT02817737||CT|Measured with computed tomography
89152984|NCT02817737||plain Radiography|Measured with plain Radiography
89152985|NCT02818049|Experimental|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
89152986|NCT02817425|Active Comparator|SOX Sequential S-1 Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 6 months and sequential S-1 for 6 months"
89152987|NCT02817425|Active Comparator|SOX Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 12 months"
89152988|NCT02817425|Experimental|TEGAFOX Sequential S-1|"Patients received chemotherapy with TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium)  for 6 months and sequential S-1 for 6 months"
89152989|NCT04237337||serious cancer ICSRs (cases)|
89152990|NCT04237337||other serious reactions ICSRs (non-cases)|
89152991|NCT02817503|Experimental|Standard BP control|"SBP within 140 - <150 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
89152992|NCT02817503|Active Comparator|Moderate BP control|"SBP within 130 - <140 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
89152993|NCT02817503|Active Comparator|Intensive BP control|"SBP <130 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
89152994|NCT04237415|Experimental|EMG biofeedback group|
89152995|NCT04237415|No Intervention|control group|
89152996|NCT02814461|Experimental|Axitinib|Combined axitinib and radiotherapy (fixed strength)
89152997|NCT02814617|Experimental|Cordyceps sinensis mycelium culture extract|Cordyceps sinensis mycelium culture extract 1.68 g
89152998|NCT02814617|Placebo Comparator|Placebo|Placebo
89152999|NCT02814539||congenital heart disease|children with severe congenital heart disease who undergo open heart surgery during infancy
89153000|NCT02814539||healthy controls|
89153001|NCT02814071|No Intervention|Fasting with intravenous fluids|The child will be kept fasted. Intravenous fluids will be at a rate and type as directed by the treating clinician. A low fat oral diet will be commenced once abdominal pain resolves and serum amylase/lipase levels decrease from the peak levels as per treating clinician. In the event that the patient is unable to tolerate oral feeding, tube feeding or parenteral nutrition may be commenced based on the clinical decision of the treating clinician(s). This will be recorded as an adverse event. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled as per treating clinician's discretion
89153002|NCT02814071|Experimental|Early enteral feeding|Patients will commence on an unrestricted oral diet within 24 hours of presentation, meeting 50% of EER with a regular diet and no fat restriction for the first 24 hours of enteral feeding. A 75-100% EER is targeted ≥ 24 hours of enteral feeding.If the targeted EER is not met orally, a nasogastric tube will be inserted to provide bolus feeds of a standard formula with standard fat content. If the patient fails to tolerate both oral and bolus nasogastric tube feeding, continuous nasogastric tube feeding will be provided. If all fails, enteral nutrition by nasojejunal tube feeding or parenteral nutrition may be commenced based on the clinical decision. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled.
89153003|NCT04315415|Other|6 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 6 months.
89153004|NCT04315415|Other|12 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 12 months.
89153005|NCT04315415|Other|24 month explant|Silk Voice and control material are implanted. The implanted material is explanted at 24 months.
89153006|NCT00875667|Experimental|Lenalidomide|Lenalidomide
89153007|NCT00875667|Active Comparator|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, Fludarabine
89153008|NCT02814305|No Intervention|Control|Patient receives neither educational nor financial interventions
89153009|NCT02814305|Experimental|Financial intervention only|Patient receives financial (pharmacy offer) intervention only
89153010|NCT02814305|Experimental|Educational intervention only|Patient receives educational (narrative) intervention only
89153011|NCT02814305|Experimental|Both interventions|Patient receives both educational and financial interventions
89153012|NCT02811185|Other|PET/CT Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET/CT scanning according to departmental practice.
89153013|NCT02811185|Other|PET Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET scanning according to departmental practice.
89153014|NCT02814149|Active Comparator|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
89153015|NCT02814149|Active Comparator|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
89153016|NCT02811341|Placebo Comparator|A group|Using normal saline before pcle examination
89153017|NCT02811341|Experimental|B group|Using Scopolamine Hydrobromide before pcle examination
89153018|NCT02811107||Patients in preoperative area|Patients in preoperative area before surgery or interventional procedure will complete questionnaires on tablet computers
89153019|NCT02813993|Experimental|Intervention Group|A five-minute video concerning age-related fertility decline, fertility risk factors, success of infertility treatments and emotional consequences of childlessness
89153020|NCT02813993|No Intervention|Control|No intervention
89153021|NCT02811029|Experimental|premature infants less than 32 weeks of age|measurement of phonology in premature infants less than 32 weeks of age who participated to LAMOPRESCO-1 study
89153022|NCT00682383|Other|ARM 1|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
89153023|NCT02810717|Experimental|active TBS|40 patients with TRD will receive active theta-burst stimulation using a MagPro X1000 between the two PET measurements
89153024|NCT02810717|Sham Comparator|sham TBS|40 patients with TRD will receive sham stimulation using a MagPro X1000 between the two PET measurements. After the second PET scan they will receive active TBS
89153025|NCT04237493|Experimental|Low-dosage therapy|
89153026|NCT04237493|Active Comparator|Regular-dosage therapy|
89153027|NCT00682773|No Intervention|1|Usual care, no educational intervention.
89153028|NCT00682773|Experimental|2|Usual care, nursing home nursing staff receive educational intervention on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
89153029|NCT04031625||Metastatic Colorectal Cancer|
89153030|NCT02813759|Experimental|Sucralose|14 mg sucralose (Zero K sucralose powder, IANSA®) an 200 mL of water
89153031|NCT02813759|Placebo Comparator|Water|200 mL of water
89153032|NCT00683007|Active Comparator|1|Crystalloid
89153033|NCT00683007|Active Comparator|2|Hypertonic Saline
89153034|NCT00683241|Experimental|1|Subjects with stage II to IV recurrent epithelial ovarian carcinoma or recurrent primary peritoneal cancer, from whom solid tumor, ascites or pleural effusion will be harvested and available and sufficient for lysate preparation; and whose largest tumor nodule is ≤ 2.5 cm. Subjects may have undergone chemotherapy or other therapy following tumor harvesting and prior to enrollment (apheresis).
89153035|NCT04237259|Experimental|Parent-administered TCM massage group|Parents of subjects in the parent-administered TCM massage group (n=30) will attend 2 training sessions (5 hours in total) to learn and practice the parent-administered TCM massage for ADHD before treatment starts. The parents will be told to practice the TCM massage on their child every 2 days for 2 months.
89153036|NCT04237259|Active Comparator|Parent-child interaction group|Parents in the parent-child interaction group (comparison group, n=30) will attend a 3-hour training course on line and spend extra time on interacting with their child at home.
89153037|NCT02813837|Experimental|single arm|Experimental: CD19 CART cell.The target dose range administered in this study is 1x10e5-1x10e7 CART-19 cells/kg.
89153038|NCT02813915||Use of Cheetah medical NICOM|For those who consent to the study, the Cheetah NICOM will be used to obtain cardiac output, stroke volume, and fluid responsiveness.
89153039|NCT00683397||A|Patients with acute or previous venous thromboembolism >18 years of age
89153040|NCT00634361|Experimental|A|
89153041|NCT00683553|Experimental|I5NP drug|
89153042|NCT00683553|Placebo Comparator|Placebo|
89153043|NCT05298969|Experimental|Flap survival|Harvesting temporalis myofascial flap for cranio-maxillofacial defects
89153044|NCT02813603||Study Product (19-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
89153045|NCT02813603||Control Intervention (22-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
89153046|NCT04141527||Primiparous women|82 primiparous obstetrical patients given intrathecal sufentanil for labor pain.
89153047|NCT04141527||Multiparous women|82 multiparous obstetrical patients given intrathecal sufentanil for labor pain.
89153048|NCT00683709||Counselling as Usual|Discussing Clozapine medication, diet and exercise as per clinical protocol potential weight changes
89153049|NCT00683709||Cognitive Behavoural Therapy|Counselling about Clozapine medication, diet and exercise in a structured fashion using Cognitive Behavioural Therapy about potential weight changes
89153050|NCT04187729||Diseased|Subjects with a known disease.
89153051|NCT04187729||Non-diseased|Subjects without a known disease and reportedly healthy.
89153052|NCT02810249||African American YMSM|
89153053|NCT02810483|Experimental|Arm 1: Topiramate|Topiramate Arrow 50 mg hard capsules
89153054|NCT02810483|Placebo Comparator|Arm 2: Placebo Comparator|50 mg hard capsules with the same shape, color and taste than the active product
89153055|NCT00683865|Active Comparator|Arm 1|
89153056|NCT00683865|Experimental|Arm 2|
89153057|NCT02813291|Experimental|Stimulation group (Young Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
89153058|NCT02813291|Experimental|Stimulation group (Elderly Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
89153059|NCT02813291|Sham Comparator|Sham group (Young Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
89153060|NCT02813291|Sham Comparator|Sham group (Elderly Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
89153061|NCT02813525||IUGR group|estimated fetal weight <10th percentile associated with an abnormal umbilical artery Doppler with IP>95th percentile or a confirmation of placental vascular disease by histological examination
89153062|NCT02813525||CONTROL group|non IUGR fetuses for gestational age (normal for weight, Doppler, and structural analyse)
89153063|NCT02810015|Experimental|Botulinum Toxin A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
89153064|NCT02810093||Breast cancer patients between 2000 and 2016|Patients treated for a breast cancer between 2000 and 2016 in the Hospital of Strasbourg (France).
89153065|NCT02809781|Experimental|Intravenous infusion of MSCs|Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.
89153066|NCT02809781|Active Comparator|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
89153067|NCT02809937|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
89153068|NCT02809937|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
89153069|NCT02813213|Active Comparator|Standard skin graft|"This group is comprised of patients' wound halves that will receive meshed (1:3) split thickness skin graft (0.3-0.5mm thickness). This half will be covered with a standard tie over dressing. The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day."
89153070|NCT02813213|Experimental|Skin micro graft|"This group is comprised of the patients' wound halves that will receive skin micro grafts. To obtain this grafts the investigators will use Xpansion micro-autografting system. They will use 0.8 x 0.8 mm skin grafts with a graft to graft distance of 4mm (1:50 expansion).This half will be covered with a special hydrogel dressing with keratinocyte growth factor (Epilife medium with calcium) 1.5ml for each 14 square centimeters of the wound. This half will be covered with a wet adhesive foam dressing and then it will be covered up with a non-adherent interface dressing (tegaderm). The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day. Each time of dressing change only the non-adherent interface dressing will be removed, and the area will be bathed with keratinocyte growth factor solution."
89153071|NCT02813057|Active Comparator|Stoppa repair|Stoppa inguinal hernia repair
89153072|NCT02813057|Experimental|TEP repair|Total extraperitoneal inguinal hernia repair
89153073|NCT02809547|Active Comparator|In Clinic monitoring|70 method comparison patients who represent a C-reactive protein (CRP) reference range and have retrievable study outcome measures will have a whole blood sample and DBSS taken at recruitment and at a routine six week review.
89153074|NCT02809547|Experimental|At Home monitoring|30 Prospective patients will provide (i) one whole blood sample and one set of dried blood spot samples (DBSS) at recruitment, (ii) a set of DBSS once a week for six weeks from recruitment, with a matched whole blood sample at six week appointment, (iii) two extra sets of DBSS to be taken during a flare and 24 hours after (iv) 6 prospective patients will have daily hand movement data collected for 5 minutes on each occasion using a provided data glove.
89153075|NCT02812901|Other|morning group|cardiac surgery scheduled in the morning
89153076|NCT02812901|Other|afternoon group|cardiac surgery scheduled in the afternoon
89153077|NCT02812979|Experimental|Airvo2 with Aerogen Solo|"AIRVOTM2 will be set to deliver air (21% oxygen concentration ) at a rate of 30 L / min at 100 % relative humidity at 37 ° C.~Nebulization of salbutamol will be effected by means of a nebulizer to the vibrating screen (Aerogen® Solo, Aerogen , Galway, Ireland ) which is a nebulizing device for single use, commonly used in invasive and non invasive mechanical ventilation.~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
89153078|NCT02812979|Active Comparator|Mask|"During nebulization in the usual way ( oral facial mask ) , it will be used a pneumatic nebulizer powered by a 6 L / min air flow rate ( usual method ).~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
89153079|NCT02812979|Placebo Comparator|arm control Airvo2 without nebulization of salbutamol|control procedure is to be placed under humidified high flow nasal alone
89153080|NCT02809313|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct probiotic containing one sachet Lactobacillus rhamnosus per day during 3 month
89153081|NCT02809313|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct placebo containing one sachet placebo (talc power) per day during 3 month
89153082|NCT02809391|Active Comparator|Orthotic|Recruited participants will be asked to wear the customizable foot orthotic, from baseline testing to a follow-up at 6 weeks post-baseline. Outcome measures at 6 weeks will be compared to those at baseline.
89153083|NCT02809391|Active Comparator|Orthotic+Textured Top Cover|At 6 weeks post-baseline, participants will received a different orthotic which has a textured material used as its top cover. Testing at 6 weeks post-baseline will determine if acute changes occur as a result of wearing the orthotic with textured top cover. Testing at 12 weeks post-baseline will determine if long-term changes occur as a result of the orthotic with textured top cover.
89153084|NCT02812823|Other|High resolution anorectal manometry|All subjects will be investigated by high-resolution anorectal manometry. At the beginning the anorectal cather will be used to record conventional parameters and after that 3D high-definition anorectal manometric catheter will be inserted in order to measure conventional parameters and 3D picture of anorectum.
89153085|NCT04157465|Other|Early Empiric group|Participants will receive standard medical therapy along with the empiric strategy of treatment of invasive fungal infection (based on both risk factors and clinical suspicion of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
89153086|NCT04157465|Active Comparator|Pre-emptive group|Participants will receive standard medical therapy along with the pre-emptive strategy of treatment of invasive fungal infection (based on risk factors, clinical suspicion and radiological or mycological evidence of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
89153087|NCT02812745||patients|"patients presenting an indication for general anaesthesia during elective cardiac surgery and being monitored for sedation depth~recording of cardiac output~other parameters"
89153088|NCT02812511|Experimental|Skin biopsy|
89153089|NCT02809469|Experimental|Dose reduction|Eligible patients with apixaban levels persistently above 170ng/mL on two occasions, 2 weeks apart, will undergo apixaban dose reduction.
89153090|NCT02812589|Experimental|Diffusion tensor imaging (DTI) in breast MRI|
89153091|NCT02809079|Experimental|Mycophenolate mofetil plus prednisone|Mycophenolate mofetil 500mg Bid and prednisone 10mg Qd
89153092|NCT04200521||Healthy weight individuals|Cross-sectional observation on healthy participants who will be recruited from the general population from both genders (Lebanese and Emirati Subjects).
89153093|NCT04200521||Obese individuals|Prospective study of 3 months duration (pre and post design) on obese Emirati and Lebanese participants undergoing bariatric procedure irrelevant of the study, from Qassimi Hospital In sharja and Middle East Institute of Health University Hospital, Lebanon
89153094|NCT04219475||GBM patients|Newly diagnosed patients above 18 years of age with GBM receiving standard of care, i.e., maximal surgical resection possible followed by radiation therapy (RT) plus temozolomide (TMZ) therapy and maintenance TMZ.
89153095|NCT02812277||Anastrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted anastrozole therapy with the completed follow-up data.
89153096|NCT02812277||letrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted letrozole therapy with the completed follow-up data.
89153097|NCT02812199|Experimental|pilot study group 1|Patients in pilot study group 1 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in pilot study group scheduled for 6 follow up visits at 1,2,3,4,6 and 12 weeks after implantation and for tampon removal at day 2 - 3 after FESS surgery. Stent will be removed between 14 and 28-day implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
89153098|NCT02812199|Experimental|study group 2|Patients in study group 2 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in 2nd study group scheduled for 4 follow up visits at 2, 4, 6 and 12 weeks after implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
89153099|NCT02812199|No Intervention|control group 3|control group patients will undergo post-FESS bilateral Standard of Care (tampon) placement into middle meatus as standard of care. Frontal tampon will be placed to stop bleeding. Patients in control group scheduled for 3 follow up visits at 2, 6 and 12 weeks after surgery and for tampon removal at day 2 - 3 after FESS surgery.
89153100|NCT02812121|Experimental|Group MSC-1|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.
89153101|NCT02812121|Experimental|Group MSC-2|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.
89153102|NCT02812121|No Intervention|Group Control|Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis).
89153103|NCT04237571|Experimental|CANE Adult Participants|This sample population consists of an active intervention group of prior Tanglewood to Table walking program adult participants.
89153104|NCT02808923|Experimental|Foam rolling|"Participants in the foam rolling group will perform unilateral rolling of the hamstring musculature from ischial tuberosity to posterior knee in supine for 2 repetitions of 1 minute with 15 second rest between repetitions at a consistent cadence of 1 second superiorly and 1 second inferiorly. Subjects will be asked to adjust pressure as needed to maintain a consistent moderate pressure on the treatment area. Participants will use new and individually issued high density foam rollers that are 6 diameter x 36 length."
89153105|NCT02808923|Experimental|Static stretching|Participants in the static stretching group will perform sustained static hamstring stretching for 2 repetitions of 1 minute bouts for the same leg before switching sides using moderate pressure in supine against the wall. Subjects will rest for 15 seconds between repetitions and adjust distance from the wall to perceive moderate intensity.
89153106|NCT02808923|No Intervention|Control|The control group will perform their regular baseline activities without the addition of a specific lower extremity flexibility program. If the subjects are currently performing stretching of any mode at baseline, they will be allowed to continue with that activity.
89153107|NCT02808845||microalbuminuria with eGFR≥60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
89153108|NCT02808845||normal-albuminuria group with eGFR≥60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
89153109|NCT02808845||microalbuminuria group with eGFR<60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
89153110|NCT02808845||normal-albuminuria group with eGFR<60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
89153111|NCT02809001|Experimental|Experimental: Fat grafting|Autologous fat graft transplantation subdermally to expanded skin.
89153112|NCT02809001|No Intervention|Control|Expansion was discontinued until the early signs of complication disappeared.
89153113|NCT02812043|Experimental|Amorolfine|This group of patients will receive only amorolfine nail lacquer to apply on the affected nail and the KOH examination and fungal culture will be performed every month
89153114|NCT02812043|Experimental|Long-pulsed Nd:YAG|This group of patients will receive only the long-pulsed Nd:YAG (Cynergy®, 5 Carlisle Road Westford, MA USA) fluence 35-45 J/Cm2, spot size 4mm for 2 passes each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
89153115|NCT02812043|Experimental|Amorolfine+Long-pulsed Nd:YAG|This group of patients will receive both amorolfine nail lacquer and the long-pulsed Nd:YAG laser treatment each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
89153116|NCT02808767|Experimental|Patients treated with Prasugrel|Prasugrel Loading dose: 60 mg Maintenance dose: 10 mg once-daily; patients >75 years of age or < 60 kg of weight receive a maintenance dose of 5 mg o.d.
89153117|NCT02808767|Experimental|Patients treated with ticagrelor|Ticagrelor Loading dose: 180 mg Maintenance dose: 90mg twice-daily
89153118|NCT02808689|Active Comparator|Asthma Center|"Use of Currently Accepted Asthma Care Guidelines:~Assessment and monitoring: the use of objective measures of lung function to assess severity of asthma and to monitor the course of therapy,~Control of factors contributing to symptom exacerbation: environmental control measures to avoid or eliminate factors that precipitate asthma symptoms or exacerbations,~Pharmacotherapy: comprehensive pharmacologic therapy for long-term management, and~Education for partnership in care: patient education that fosters a partnership among the patient, his/her family, and clinicians."
89153119|NCT02808689|Active Comparator|Asthma Center plus Functional Medicine|"All the factors in the Asthma Center Arm plus:~Address lifestyle factors such as nutrition and exercise that influence long-term health and chronic diseases. The intention is to reduce ongoing biologic imbalances from deficiencies in dietary oxidants/antioxidants via vitamin supplementation, hormonal imbalances through evaluation and management, and the need for medications with unwarranted side effects that compound the chronic medical conditions and adverse effects (e.g. excess use of antibiotics), and to systematically evaluate intolerances to certain foods and additives."
89153120|NCT02812355|Experimental|half heparinization|heparin I.V. 150 U/kg
89153121|NCT02812355|Active Comparator|full heparinization (300 U/kg)|heparin I.V. 300 U/kg
89153122|NCT02811731|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
89153123|NCT02811731|Experimental|CKD-330|CKD-330 16/5mg - B, PO, 1days or 22days
89153124|NCT02811809|Experimental|Apalutamide + IHT|Participants will be treated with 240 mg (4-60 mg tablets) oral Apalutamide daily plus 22.5 mg 3-month depot intramuscular leuprolide intermittently.
89153125|NCT02811809|Active Comparator|IHT only|Participants will receive 22.5 mg 3-month depot intramuscular leuprolide until PSA progression, then they will crossover to Apalutamide + IHT
89153126|NCT05569421|Experimental|Treatment A: BGF MDI HFO 160/7.2/4.8 μg ex-actuator|Participants will receive Test formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
89153127|NCT05569421|Experimental|Treatment B: BGF MDI HFA 160/7.2/4.8 μg ex-actuator|Participants will receive Reference formulation in 1 of 3 possible treatment sequences: ABB, BAB, or BBA. The reference formulation will be administered during 2 of the 3 treatment periods in order to estimate intra-subject variability.
89153128|NCT02808611|Active Comparator|Propranolol|Propranolol is a beta-blocker
89153129|NCT02808611|Placebo Comparator|Placebo|Placebo
89153130|NCT02808533|Experimental|Topiramate|Topiramate will be dispensed on a biweekly basis, and pill counts conducted at each visit.
89153131|NCT02808533|Placebo Comparator|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
89153132|NCT04103177|Experimental|Intervention group|20 participants to receive physical activity educational booklet with instructions on chair based exercises, Instructor-led training on how to perform the chair based exercises, two times a week, over a 6 week period, and motivational interviewing and prompts.
89153133|NCT02811575||Patients with diabetes|Patients with type 2 diabetes will have biopsy during coloscopy.
89153134|NCT02811575||Control|Patients without type 2 diabetes will have biopsy during coloscopy.
89153135|NCT02811497|Experimental|Azacitidine and Durvalumab|"Azacitidine will be given by mouth at a fixed dose of 300 mg daily for 14 consecutive days of every 28 day cycle for 3 cycles.~Durvalumab will be given intravenously (by vein) at a fixed dose of 1500 mg (over 1 hour) on Day 1 of every 28 day cycle for 12 months or until disease progression."
89153136|NCT00634439||A|All patients 18 years or older who received a first dispensing of atomoxetine during the time period of the study (January 1, 2003 through December 31, 2006) and had at least 6 months of continuous enrollment prior to first dispensing are included in the study cohort. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. The study entry date for this cohort is the date of first atomoxetine dispensing.
89153137|NCT00634439||B|All patients 18 years or older who received a first dispensing of a stimulant medication (methylphenidate or mixed salts of amphetamine) during the time period of the study with no dispensing of the same drug in the prior 6 months and had at least 6 months of continuous enrollment prior to the first dispensing are identified. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. Patients who are matched to atomoxetine initiators using this propensity score method are retained and followed as one comparator cohort. The study entry date is the date of the first dispensing of a comparator ADHD medication.
89153138|NCT00634439||C|Patients with at least 6 months of continuous enrollment in the database, and without a history of arrhythmia or heart failure during the baseline period are sampled and frequency matched on age and gender to the atomoxetine cohort in a 2:1 ratio. Study entry dates are assigned so as to be similar to the distribution of study entry dates in the atomoxetine cohort. Patients identified and matched as initiators of atomoxetine or stimulant ADHD medications are not eligible for inclusion in this cohort
89153139|NCT02808299||all the antigen and antibody of HBV are negative|Hepatitis B Virus surface antigen (HBsAg), Hepatitis B Virus surface antibody (HBsAb), Hepatitis B Virus e antigen (HBeAg), Hepatitis B Virus e antibody (HBeAb), Hepatitis B Virus core antibody (HBcAb) are all negative.
89153140|NCT02808299||HBV infection history|One or more of HBsAb,HBeAb, HBcAb are positive, while HBsAg and HBeAg are negative. If only HBsAb is positive, the history of HBV vaccination need to be excluded.
89153141|NCT02808299||HBV carriers|One or two of HBsAg and HBeAg are positive, accompanied by any HBV antibody is positive or not.
89153142|NCT02807909|Experimental|BMS-986177 and Itraconazole|Single dose BMS-986177 on day 1 followed by Itraconazole and BMS-986177 on specified days
89153143|NCT02807909|Experimental|BMS-986177 and Diltiazem|Single dose BMS-986177 on day 1 followed by Diltiazem ER and BMS-986177 on specified days
89153144|NCT02808377|Active Comparator|SPOP|This arm will have the soft silicone pessary inserted post operatively and it will remain in-situ for 3 weeks.
89153145|NCT02808377|No Intervention|Non Intervention|Routine post operative care
89153146|NCT02808065||Tacrolimus + Mycophenolate mofetil|
89153147|NCT02807987|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
89153148|NCT02807753||Severe Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every 6 months.~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
89153149|NCT02807753||Mild/Moderate Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every year.~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
89153150|NCT02807831|Experimental|Executive functions training|
89153151|NCT02807831|Experimental|Language skills training|
89153152|NCT02807831|Active Comparator|Regular school curriculum|
89153153|NCT05563025||General|Arthroscopic Shoulder Surgery under General Anesthesia
89153154|NCT05563025||Regional|Arthroscopic Shoulder Surgery under Regional Anesthesia
89153155|NCT00602030|Experimental|Lead-in Phase: Erlotinib + Entinostat 5 mg|Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.
89153156|NCT00602030|Experimental|Lead-in Phase: Erlotinib + Entinostat 10 mg|Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.
89153157|NCT00602030|Experimental|Double-blind Phase: Erlotinib + Entinostat 10 mg|Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.
89153158|NCT00602030|Placebo Comparator|Double-blind Phase: Erlotinib + Placebo|Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.
89153159|NCT00602030|Experimental|Crossover Phase: Erlotinib + Entinostat 10 mg|Participants in the Double-blind Phase Erlotinib + Placebo arm who experienced disease progression crossed over to receive open-label erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities.
89153160|NCT02804867||Depression|
89153161|NCT02804867||Bipolar disorder|
89153162|NCT02804867||Control|
89153163|NCT02807675|Experimental|CVT-301, levodopa inhalation powder (LIP)|designed to deliver l-dopa to the lung using the CVT-301 inhaler.
89153164|NCT02807675|Placebo Comparator|Placebo|Administered in the same way as the investigational product, except that it does not contain l-dopa.
89153165|NCT02804711|Experimental|Four doses of low dose vaccine|four doses of 15µg/0.6ml per dose
89153166|NCT02804711|Experimental|Four doses of middle dose vaccine|four doses of 30µg/0.6ml per dose
89153167|NCT02804711|Experimental|Four doses of high dose vaccine|four doses of 60µg/0.6ml per dose
89153168|NCT02804711|Experimental|Three doses of low dose vaccine and one dose of placebo|three doses of 15µg/0.6ml per dose and one dose of placebo
89153169|NCT02804711|Experimental|Three doses of middle dose vaccine and one dose of placebo|three doses of 30µg/0.6ml per dose and one dose of placebo
89153170|NCT02804711|Experimental|Three doses of high dose vaccine and one dose of placebo|three doses of 60µg/0.6ml per dose and one dose of placebo
89153171|NCT02804711|Placebo Comparator|Four doses of placebo|four doses of placebo
89153172|NCT00640094|Experimental|A: Melatonin|Melatonin: intravenous infusion and intracoronary bolus
89153173|NCT00640094|Placebo Comparator|B: Placebo of melatonin|Placebo: intravenosus infusion and intracoronary bolus
89153174|NCT04183634|Experimental|Period 1: Rotigotine TTS (Test) - Period 2: Neupro (Reference)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
89153175|NCT04183634|Active Comparator|Period 1: Neupro (Reference) - Period 2: Rotigotine TTS (Test)|For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h
89153176|NCT00549757|Experimental|Aliskiren|"In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment"
89153177|NCT00549757|Placebo Comparator|Placebo|"In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment."
89153178|NCT02804633|Active Comparator|IV acetaminophen group|In addition to PCA (morphine or hydromorphone) all patients receive 1 gram of IV acetaminophen (100 ml ) 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge.
89153179|NCT02804633|Placebo Comparator|Placebo Group|In addition to PCA (morphine or hydromorphone) all patients received placebo (100 ml normal saline) given 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge
89153180|NCT02807441|No Intervention|No aspirin|Patients will not be given any Acetylsalicylic acid in the perioperative period.
89153181|NCT02807441|Experimental|Low-dose aspirin|Patients will be given low-dose Acetylsalicylic acid (81 mg) in the perioperative period.
89153182|NCT02807441|Experimental|High-dose aspirin|Patients will be given high-dose Acetylsalicylic acid (325 mg) in the perioperative period.
89153183|NCT02684552|Experimental|Non invasive ventilation|Patients perform physical test with non invasive ventilation
89153184|NCT02684552|Active Comparator|Oxygen|Patients perform physical test with oxygen with mask
89153185|NCT02807519||Oncological patients|Children with confirmed haematological/oncological diagnosis who are admitted to the paediatric oncology ward at the Universitätsspital Beider Basel (UKBB), who will require radio- and/or chemotherapy . Collection of salivary cytokines will be performed in this group.
89153186|NCT02807519||Control group|Healthy children which are seen routinely at the Schulzahnklinik/Volkzahnklinik Basel. Collection of salivary cytokines will be performed in this group.
89153187|NCT02680886||Novosyn® Quick|Skin closure using rapid absorbable suture material
89153188|NCT05663996|Experimental|St. John's Wort oil|Experimental group participants were treated with St. John's Wort oil.
89153189|NCT05663996|Placebo Comparator|Olive Oil|Control group participants were treated with olive oil.
89153190|NCT04182698|Experimental|Experimental|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
89153191|NCT02690051|Experimental|BeSmooth Peripheral Stent system|Patients treated with the BeSmooth Peripheral Stent System
89153192|NCT03068390|Experimental|RICHH Intervention|The RICHH intervention is an educational-behavioral and counseling intervention that promotes caregivers' knowledge, skills and motivation to engage in CVD risk reduction. The intervention is delivered individually to caregivers in their homes using video-conferencing technology on mini-iPads that we provide for all participants. Participants keep the mini-iPads at the end of the study. The program consists of 12 weekly sessions [30-45 minutes] followed by 8 bi-weekly [every other week] booster sessions and 6 monthly booster sessions that will be held at the caregivers' preferred times using a video conferencing program. A cardiac psychiatric advanced practice nurse certified cognitive behavioral therapy will deliver the intervention.
89153193|NCT03068390|Active Comparator|Usual care|The usual care control group will receive an attention placebo intervention in which the caregivers will receive mini-iPads loaded with Caregiver and CVD risk reduction pamphlets in PDF format along with the associated links from the American Heart Association. Because the investigators may identify CVD risk factors in baseline testing in participants who do not know they have them, it would be unethical not to provide at least usual care for these. Thus, all individuals enrolled in the study and in whom the investigators identify CVD risk factors will receive referral to a primary care provider for management of the CVD risk factors identified.
89153194|NCT02804555|Active Comparator|Oxygen support|5 liter / minute oxygen has given to the mothers on face mask.
89153195|NCT02804555|No Intervention|Room air|Oxygen support has not given to the mothers.
89153196|NCT02682680|Experimental|Colesevelam|Colesevelam 3.75 g daily (tablets or oral suspension) for 24 weeks
89153197|NCT02682680|Active Comparator|Ezetimibe|Ezetimibe 10 mg once daily for 24 weeks
89153198|NCT02682758|Other|Patients of normal weight|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index of less than 30.
89153199|NCT02682758|Other|Obese patients|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index equal to or more than 30.
89153200|NCT04115969||Patients with non-invasive ventilation|
89153201|NCT02682524|Active Comparator|test|
89153202|NCT02682524|Active Comparator|reference|
89153203|NCT05520983|Active Comparator|Illinois MCHB Care Coordination|MCHB Care Coordination is funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, this is the oldest and most universal care coordination model for children with I/DD. The University of Illinois Chicago Division of Specialized Care for Children (DSCC) is the Illinois (IL) state Title V MCHB care coordination agency and has annual contact with over 19,000 families and youth in IL. MCHB (known as DSCC) Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
89153204|NCT05520983|Experimental|Illinois MCHB Care Coordination + CHECK tiered behavioral health|MCHB Care Coordination plus CHECK: includes all elements of MCHB care coordination, described above, plus the CHECK program. The CHECK program consists of a trained, behavioral health care team; an evidence-based treatment algorithm to classify risk for depression and anxiety (minimal, subclinical and clinical symptomatology) and guide treatment advancement [Tier 1/selective: cognitive behavioral psycho-education; Tier 2/indicated: cognitive-behavioral prevention groups; Tier 3/treatment: individualized or group cognitive-behavioral treatment (CBT)]; as well as structures and processes to support communication, coordination and data sharing between MCHB care coordinators and CHECK staff.
89153205|NCT04183556|Active Comparator|1/NSAI(nonsteroidal anti-inflammatory agent) group|Patients with naproxen drug therapy for early onset dysmenorrhea.
89153206|NCT04183556|Placebo Comparator|2/NSAI+ Turmeric (1 gram oral powder formula per day )|NSAI(nonsteroidal anti-inflammatory agent) + Turmeric for early onset dysmenorrhea (1 gram oral powder formula in mens time)
89153207|NCT02807129|Experimental|patients|
89153208|NCT02684240|Experimental|Nitazoxanide|Participants with drug-sensitive tuberculous randomized to the NTZ arm will receive nitazoxanide 1000 mg po twice daily for 14 days. After this time point, participants will be switched to WHO standard tuberculosis therapy with isoniazid, rifampin, pyrazinamide and ethambutol.
89153209|NCT02684240|Other|Control|Participants with drug-sensitive tuberculosis randomized to the standard therapy arm will receive WHO standard tuberculosis therapy involving isoniazid 300 mg po daily, rifampin 600 mg po daily, pyrazinamide 25 mg/kg po daily and ethambutol 15 mg/kg po daily.
89153210|NCT00640172||Anemic Elderly|
89153211|NCT00640172||Non-anemic adults (non-elderly, without bone marrow biopsy)|
89153212|NCT00640172||Non-anemic adults (non-elderly, with bone marrow biopsy)|
89153213|NCT00640172||Non-anemic Elderly (control without bone marrow biopsy)|
89153214|NCT00640172||Non-anemic Elderly (control, with bone marrow biopsy)|
89153215|NCT02807051|Experimental|Pacritinib and Clarithromycin|Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
89153216|NCT02684084|Active Comparator|Combination group (RBZ+DEX)|30 eyes will receive an intravitreal Lucentis (0.5 mg) injection followed by Ozurdex implant (0.7 mg) injection within 0 to 8 days.
89153217|NCT02684084|Active Comparator|Monotherapy group (DEX only)|30 eyes will receive Ozurdex implant (0.7 mg) injection only
89153218|NCT02806661|Experimental|VPRDG for AGC|Vagus nerve-preserving Robot-assisted distal subtotal gastrectomy (VPRDG) with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
89153219|NCT02806661|Active Comparator|CRDG FOR AGC|Conventional Robot-assisted distal subtotal gastrectomy (CRDG) with D2 lymphadenectomy without preserving vagus nerve will be performed for the treatment of patients assigned to this group.
89153220|NCT02684318|Experimental|Dose Level 1|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 100 mg BID
89153221|NCT02684318|Experimental|Dose Level 2|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 150 mg BID
89153222|NCT02684318|Experimental|Dose Level 3|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 200 mg BID
89153223|NCT02684318|Experimental|Dose Level 4|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 250 mg BID
89153224|NCT02684318|Experimental|Dose Level 5|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 250 mg BID
89153225|NCT02684318|Experimental|Dose Level 6|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 300 mg BID
89153226|NCT02684318|Experimental|Dose Level 7|PM01183 + olaparib PM01183 3 mg/m² IV olaparib 300 mg BID
89153227|NCT02806817|Experimental|Bevacizumab + ME-344|"Bevacizumab single dose (15 mg/kg infused IV) on day 1. ME-344 will be administered at 10 mg/kg infused IV over 30 minutes on days 8, 15 and 22 (arm 1).~ME-344 will be suspended in 250 mL sterile saline."
89153228|NCT02806817|Placebo Comparator|Bevacizumab + normal saline|Bevacizumab single dose (15 mg/kg infused IV) on day 1. Placebo: will be administered normal saline 250 mL infused IV over 30 minutes on days 8, 15 and 22 (arm 2).
89153229|NCT04104620||patients with neurological syndromes and GAD-Ab|This is a non-interventional study involving clinical data already stored in the database of the Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, or collected by the referral physicians the day of ordinary consultations. No biological sample is necessary to perform this study.
89153230|NCT02683850|Experimental|Omega-3 SPM|"Intervention: Study participants will be instructed to take 3 Omega-3 SPM™ softgel supplements in the morning and 3 Omega-3 SPM™ soft gel supplements in the evening for two weeks.~At weeks two participants whose PROMIS-43 Pain Intensity score indicates a reduction in pain levels weeks, will take 2 Omega-3 SPM™ soft gel supplements in the morning and 2 in the evening for the remaining 2 weeks of the study.~Participants whose PROMIS-43 Pain Intensity score remained the same after two weeks, or increased will take 4 Omega-3 SPM™ soft gel supplements in the morning and 4 SPM™ softgels in the evening for the remaining two weeks of the study."
89153231|NCT04182854|Experimental|diuretics|
89153232|NCT02804243|Active Comparator|nasal high flow therapy|In this group, patients have undergone rehabilitation under the nasal high flow therapy (FiO2 100%, oxygen flow from 30 to 60 L/min) during four weeks.
89153233|NCT02804243|No Intervention|oxygen therapy|In this group, patients have undergone rehabilitation under the oxygen therapy via a nasal canula (6 L/min) during four weeks.
89153234|NCT02680808|Experimental|midazolam with F901318|Pharmacokinetic profile of midazolam 2 mg orally when given after dosing with F901318 to steady state.
89153235|NCT02682446||Negative H. pylori group|The participants revealed negative findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
89153236|NCT02682446||Previous H. pylori infection group|The participants revealed positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
89153237|NCT02682446||Eradicated H. pylori group|The participants revealed to success for H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
89153238|NCT02682446||Persistent H. pylori group|The participants revealed to fail in H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
89153239|NCT02806739|Experimental|Soy Group (Soy Protein + Isoflavones)|"Intervention: Soy-based whole foods containing about 25 grams of soy protein and 60-75 mg isoflavones.~Intervention group will consume soy foods containing about 25 grams of soy protein and 60-75 mg isoflavones per day, from 16th gestational week to birth. Examples of soy foods that contain 25 grams of soy protein and 60-75mg isoflavones include: 2 cups of soy milk, or 12 ounces tofu, or a half cup of soy nuts. Women in the Soy Group will be instructed by a registered dietitian how to incorporate the soy foods into their daily diet."
89153240|NCT02806739|Placebo Comparator|Control Group (Minimize Soy Intake)|Control Group will avoid soy supplements and minimize intake of soy foods.
89153241|NCT02680418|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
89153242|NCT02680418|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
89153243|NCT02680418|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
89153244|NCT02680418|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
89153245|NCT02680418|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
89153246|NCT02680418|Experimental|Multiple dose|Repeat doses of FDL169 to be administered at a dose level to be determined
89153247|NCT01563211||Patients receiving endocrine treatment for breast cancer|Patients who are treated with tamoxifen, anastrozole or letrozole before or after surgery for breast cancer.
89153248|NCT01563211||Patients receiving chemotherapy for breast cancer|Patients receiving FEC (5-FU, cyclophosphamide, epiribicin) or FEC-D (FEC for 3 cycles, followed by 3 cycles of docetaxel).
89153249|NCT02806583|Experimental|intervention|telephone based structured support groups
89153250|NCT02806583|No Intervention|control|Active Comparator: Usual care (intervention as experimental group after 3 month (after T1)
89153251|NCT02682368||POCUSS Trial-1 Acute Biliary Disease|Patients with suspected biliary pathology which will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
89153252|NCT02682368||POCUSS Trial-2 Acute Diverticulitis|Patients with suspected diverticulitis will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
89153253|NCT02682368||Radiology Report|Departmental imaging and reports.
89153254|NCT02682368||Surgical diagnostic|Intraoperative findings of patients that undergo emergency surgery.
89153255|NCT00957463||smoker, with high apnea-hypopnea index|subjects who smoke either in the past or currently, with confirmed moderate-severe OSA
89153256|NCT00957463||smoker, mild OSA or without OSA|subjects who smoke either in the past or currently, with mild OSA or without OSA
89153257|NCT00957463||nonsmoker, with high apnea-hypopnea index|subjects who never smoke, with confirmed moderate-severe OSA
89153258|NCT00957463||nonsmoker, with mild OSA or without OSA|subjects who never smoke, with mild OSA or without OSA
89153259|NCT02806427||enterally fed adults|Adults subjects with a condition for which a calorically dense enteral formula is appropriate, with established enteral access, anticipated to require enteral tube feeding for at least 3 days.
89153260|NCT05663684|Experimental|Participants with no obstruction of the lacrimal system|Patients will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
89153261|NCT05663684|Experimental|Participants with obstruction of the lacrimal system|Participants who have a blockage in their tear drainage system on probing and irrigation. Participants will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
89153262|NCT04004819|Experimental|Rituximab group|Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
89153263|NCT04004819|No Intervention|Control group|Patients will receive usual care and drug use.
89153264|NCT02806271|Experimental|Worry Postponement|Two weeks of daily worry postponement
89153265|NCT02806271|Active Comparator|Worry Monitoring|Two weeks of daily worry monitoring
89153266|NCT02806271|No Intervention|Assessment Only Control|No intervention, participants will complete three assessment time points
89153267|NCT00641654|Active Comparator|A|Patients having previously received 24 weeks of therapy with pegylated interferon and ribavirin will be treated with pegylated interferon alfa-2a kD (PEGASYS) plus ribavirin, (Copegus) for a treatment period of 48 weeks, with a follow-up period of 24 weeks irrespective of the level of HCV-RNA measured in plasma on treatment day 27.
89153268|NCT00641654|Active Comparator|B|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having detectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 48 weeks, with a follow-up period of 24 weeks.
89153269|NCT00641654|Active Comparator|C|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having undetectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 24 weeks, with a follow-up period of 24 weeks.
89153270|NCT02804165|Other|Target high-risk subjects or subpopulations for T1D|Confirmation of the role of enteroviral infection in T1D and characterization of gene-enterovirus interactions should open up new avenues for understanding the pathogenesis of T1D and give clues on possible new therapeutic perspectives. Clinical applications might be further developed in order to extend the lag period might between positive autoantibodies detection and T1D age at onset in genetically predisposed subjects. This innovative project opens the door of the development of preventive therapy for T1D, as enterovirus vaccination.
89153271|NCT02803931|Experimental|Cardiogoniometry|Every patient in the study will have a cardiogoniometry recording performed by the Cardiologic Explorer whilst an inpatient on the ward. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI. The researcher interpreting the cardiogoniometry recording will be blind to the results of the ECG and the coronary angiography,
89153272|NCT02803931|Active Comparator|12-lead ECG|For every patient in the study, copies of their 12-lead ECGs performed during their admission will be taken for interpretation by an independent cardiologist. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI.The researcher interpreting the ECG recordings will be blind to the results of the cardiogoniometry and the coronary angiography,
89153273|NCT00549601|Experimental|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|
89153274|NCT00549601|Experimental|Rivastigmine patch (9.5 mg/day)|
89153275|NCT00549601|Active Comparator|Rivastigmine capsules (6 mg to 12 mg/day)|
89153276|NCT02683694|Other|study arm|iOCT is performed
89153277|NCT02806349|Placebo Comparator|Control|3g/d Cornstarch and 14g/d wheat bran control
89153278|NCT02806349|Experimental|K-GB&AG|3g/d American Ginseng and 7g/d Konjac-glucomannan fiber blend
89153279|NCT02682212|Experimental|Physiotherapy intervention|Intensive pelvic floor muscle training (PFMT) given by a physiotherapist with vaginal/rectal pressure feedback once a week for 12 weeks.
89153280|NCT02682212|No Intervention|No intervention|Standard care
89153281|NCT00957541|Experimental|CRT Therapy|All patients will receive CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
89153282|NCT02806193||Cardiovascular Magnetic Resonance Imaging|Cardiovascular imaging techniques (other subsidiary techniques such as CT and ECG will also be followed)
89153283|NCT04184492|Experimental|GP-40081|Single subcutaneous administration of GP-40081 in dose 0.4 IU / kg
89153284|NCT04184492|Active Comparator|NovoMix® 30 Penfill®|Single subcutaneous administration of NovoMix® 30 Penfill® in dose 0.4 IU / kg
89153285|NCT02806115|Experimental|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
89153286|NCT02680496|Experimental|Lokomat - Treadmill - Overground|Walking order: lokomat walking, treadmill walking, overground walking
89153287|NCT02680496|Experimental|Lokomat - Overground - Treadmill|Walking order: lokomat walking, overground walking, treadmill walking
89153288|NCT02680496|Experimental|Treadmill - Lokomat - Overground|Walking order: treadmill walking, lokomat walking, overground walking
89153289|NCT02680496|Experimental|Treadmill - Overground - Lokomat|Walking order: treadmill walking, overground walking, lokomat walking
89153290|NCT02680496|Experimental|Overground - Lokomat - Treadmill|Walking order: overground walking, lokomat walking, treadmill walking
89153291|NCT02680496|Experimental|Overground - Treadmill - Lokomat|Walking order: overground walking, treadmill walking, lokomat walking
89153292|NCT04010383||normal visual field subjects|"Cataract yes or no~Age range 40 - 80 years~normal visual field (MD: < +2 dB)~Refractive error within ±5 dpt. spherical equivalent~Astigmatism of < -3 dpt.~Visual acuity of ≥0.3 logMar (decimal ≥0.5)~Experience in perimetry (history of at least one perimetry examination)~False positive or negative errors each less than 20% in each examination"
89153293|NCT04010383||Glaucomatous subjects|"Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma~Early to moderate visual field loss (MD: +2 to +12 dB)~Refractive error within ±5 dpt. spherical equivalent~Astigmatism of < -3 dpt.~Visual acuity of ≥0.3 logMar (decimal ≥0.5)~Experience in perimetry (history of at least one perimetry examination)~False positive or negative errors each less than 20% in each examination~Cataract yes or no~Age range 40 - 80 years"
89153294|NCT00955591|Other|swab test|
89153295|NCT02682134|Experimental|"Xylocaine X"|Patients received xylocaine gel as lubricant on endotracheal tube
89153296|NCT02682134|Experimental|"Dexamethasone D"|Patients were given dexamethasone 8 mg intravenously
89153297|NCT02682134|Experimental|"xylocaine and dexamethasone XD"|Patients were given both xylocaine gel and dexamethasone 8 mg intravenously
89153298|NCT00957619|Active Comparator|pentoxyfilline group|pentoxyfilline group
89153299|NCT00957619|Placebo Comparator|placebo group|placebo group
89153300|NCT05550701||SEER database|Data on CRC patients with synchronous liver metastasis (LM) were derived from the US Surveillance, Epidemiology, and End Results (SEER) between January 2010 and December 2017.
89153301|NCT05550701||Chinese cohort|Data on CRC patients with synchronous liver metastasis (LM) were derived from two Chinese tertiary centers: The Second Affiliated Hospital of Harbin Medical University and National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College between January 2010 and December 2017.
89153302|NCT05299489|Experimental|Direct composite in hypomineraliztion molars.|
89153303|NCT05299489|Other|Indirect composite in hypomineraliztion molars.|
89153304|NCT04236401|Other|electrosurgery will be used inanterior abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall electrosurgically.
89153305|NCT04236401|Other|scalpel will be used in abdominal wall incision|to perform benign gynecological conditions , surgeon will need to open anterior wall sharply.
89153306|NCT00640406|Experimental|STN|Device: Dynamic Renal Stent plus Best Medical Treatment
89153307|NCT00640406|Active Comparator|BMT|Drug: Best Medical Treatment
89153308|NCT04236323|Experimental|not used intraoperative remifentanil infusion|Adult patients aged < 70 years and ASA class < III undergoing rotator cuff repair not used intraoperative remifentanil infusion
89153309|NCT04236323|No Intervention|used intraoperative remifentanil infusion|Adult patients aged < 70 years and ASA class < III undergoing rotator cuff repair used intraoperative remifentanil infusion maintaining target concentration of 2-6ng/ml
89153310|NCT04033796|Active Comparator|25,000 IU|
89153311|NCT04033796|Active Comparator|50,000 IU|
89153312|NCT04033796|Placebo Comparator|Placebo|
89153313|NCT00955669|Active Comparator|Symptoms and Objective Examination|
89153314|NCT02805959||Constipated, Elderly|Investigation with MTS for motility
89153315|NCT02805959||Constipation, Young|Investigation with MTS for motility
89153316|NCT02805959||Normal Bowel, Elderly|Investigation with MTS for motility
89153317|NCT02805959||Normal Bowel, Young|Investigation with MTS for motility
89153318|NCT02680262|Experimental|Intervention group 1|HPV self-sampling kit mailed directly
89153319|NCT02680262|Experimental|Intervention group 2|HPV self-sampling kit on demand
89153320|NCT02680262|Experimental|Intervention group 3|second reminder
89153321|NCT04206163|Experimental|Acute myocarditis|Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.
89153322|NCT04206163|Experimental|Cardiac sarcoidosis|Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.
89153323|NCT02803697||Patients|All patients who underwent surgery for a NFPA in Reims university hospital between 01/01/1991 and 31/12/2004
89153324|NCT00909974|Experimental|Food supplement (FS)|Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
89153325|NCT00909974|Active Comparator|UNIMMAP|UNIMMAPin tablet form: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
89153326|NCT00957775|Active Comparator|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, self-help groups) provided at the treatment site.
89153327|NCT00957775|Experimental|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
89153328|NCT02805881|Experimental|Neurolief System treatment|Treatment with the Neurolief system will be applied by the subject at his home and/or surrounding daily during a period of six weeks
89153329|NCT04182152|Experimental|Bronchoscopic ICG localization|The nodule will be located preoperatively by ENB-Guided bronchoscopic ICG injection; During the VATS operation, a near-infrared fluorescence thoracoscopy will be used to identify ICG distribution in the visceral pleura to guide an accurate surgical resection.
89153330|NCT04182152|Active Comparator|percutaneous hook-wire localization|The nodule will be located preoperatively by percutaneous placement of hook wire; During the VATS operation, the resection scope is determined by the location relationship between hook wire and the nodule under CT scan.
89153331|NCT02680028|Active Comparator|Standard length intramedullary nail|220mm intramedullary nail
89153332|NCT02680028|Experimental|Short length intramedullary nail|175mm intramedullary nail
89153333|NCT05299411|Experimental|IVI|patients group with intravenous iron infusion
89153334|NCT05299411|Active Comparator|OI|patients group with oral iron supplement
89153335|NCT02683538|Experimental|Separable cluster electrode|radiofrequency ablation (RFA) using separable cluster electrode in switching monopolar mode.
89153336|NCT00956059|Experimental|prednisone, MMF and FK506|
89153337|NCT00956059|Active Comparator|prednisone|
89153338|NCT04158427|Experimental|Fecal transplant|A single dose fecal transplant is given (via colonoscopy) from a healthy donor
89153339|NCT04158427|Placebo Comparator|Placebo|A single dose patient's own feces is given (via colonoscopy)
89153340|NCT02683460|Experimental|patella resurfacing group|Procedure: Patellar component Resurfacing with onlay technique
89153341|NCT02683460|Active Comparator|patella retention|Procedure: patellar retention Trimming of osteophytes when appropriate
89153342|NCT00956137|Experimental|Ultrasound|Use of ultrasound to identify vertebral interspaces for needle insertion.
88821402|NCT04270747|Active Comparator|ABP 938-Treatment group B2|Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by IVT injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8). Subjects will be re-randomized to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48
89153343|NCT00956137|Active Comparator|Palpation|Use of manual palpation to identify vertebral landmarks and vertebral interspaces for needle insertion.
89153344|NCT04183946|Other|Online Cognitive Behavioural Therapy|Screened participants diagnosed with minor to moderate anxiety and/or depression will receive online CBT therapy (8 interactive sessions) aiming to treat their symptomatology. Each session can be completed at one's own pace.
89153345|NCT04184258|Experimental|SLE patients MSC treatment|Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols
89153346|NCT04184258|Active Comparator|SLE patients standard treatment|Patients with SLE, who receive standard treatment according to the Clinical protocols
89153347|NCT02683304|Experimental|The study population|The study population consists of consecutive headache patients (visual analogue scale > 3) presenting at the emergency department of the Nîmes University Hospital
89153348|NCT04010929|Experimental|Laser+MTA group|before the MTA condensation, Er, Cr: YSGG laser was applied to the exposure area
89153349|NCT04010929|Active Comparator|MTA group|MTA was applied to the exposed area
89153350|NCT02682290|Other|rheological measurement of sputum|"patients with COPD and patient with cystic fibrosis will perform a spontaneous expectoration.~Then all participants will have an induced expectoration with hypertonic salin solution."
89153351|NCT00958087||Sarcoidosis with cardiac involvement|
89153352|NCT00958087||Dilated cardiomyopathy|
89153353|NCT00958087||Sarcoidosis without cardiac involvement|
89153354|NCT00958087||Healthy controls|
89153355|NCT02683382|Experimental|Moisturizing Eye Product (product in development)|Moisturizing eye product in liquid form (medical device product in development). Part 1 of the study: Administered to both eyes 4 times/day for 1 day. Part 2: to one eye 4 times/day for 9 days. Part 3: to one eye 4 times/day for 45 days. Parts 2 & 3: treatment eyes randomized.
89153356|NCT02683382|Active Comparator|Moisturizing Eye Product, Comparison|Moisturizing eye product in liquid form (medical device CE-marked). Part 2 of the study: Administered to one eye 4 times/day for 9 days. Treatment eyes randomized.
89153357|NCT02683382|No Intervention|No treatment|Part 3 of the study: other eye is a control eye with no treatment for 45 days.
89153358|NCT00956215|Active Comparator|80mg of Aprepitant|Patients will be randomized to receive 80mg of Aprepitant with 50 ml of water no later than 30 minutes before induction of anesthesia.
89153359|NCT00956215|Placebo Comparator|80 mg of placebo|. Patients will be randomized to placebo with 50 ml of water no later than 30 minutes before induction of anesthesia.
89153360|NCT00640640|Experimental|A|All study patients will be evaluated in a similar way
89153361|NCT00956371|Placebo Comparator|P|
89153362|NCT00956371|Experimental|E|
89153363|NCT03973177|Experimental|Treatment Group: Phenol injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target sites
89153364|NCT03973177|Other|Control Group: Methylprednisolone injection|Methylprednisolone acetate 10 mg with 2 mL preservative free saline and 0.5 mL iopamidol 300 will be injected at each of the target site
89153365|NCT00136136||Normal healthy term newborn|Normal healthy term newborns
89153366|NCT00136136||Ill term newly born without brain damage|Ill term newly borns without brain damage
89153367|NCT00136136||Preterm newly born without brain damage|Preterm newly borns without brain damage
89153368|NCT03951493|Experimental|RSHF + zoledronic acid|Patients receive RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction. combined with zoledronic acid (4 mg IV slow monthly for 12 months, dose adjusted according to creatinine clearance).
89153369|NCT03951493|Active Comparator|RSHF|Patients receive only RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction.
89153370|NCT04184102|Experimental|Intervention exercise|The experimental group received education and exercise training before a mastectomy.
89153371|NCT04184102|No Intervention|Control|Received routine hospital care which did not include any exercise education
89153372|NCT00961909|Experimental|1active|
89153373|NCT00961909|Placebo Comparator|1placebo|
89153374|NCT00961909|Experimental|2active|
89153375|NCT00961909|Placebo Comparator|2placebo|
89153376|NCT04115189||Patients with Metastatic RCC|Patients diagnosed with metastatic RCC with clear cell histology who switched from a 4/2 schedule to a 2/1 schedule of sunitinib in first-line metastatic treatment between January 1, 2014 and June 30, 2018
89153377|NCT02681822||Healthy young subjects|Healthy young Chinese Han subjects aged 18-30
89153378|NCT03940729|Other|PWID colonized with S aureus|Repeated chlorhexidin showers for PWID colonized with S aureus
89153379|NCT02678234|Experimental|Theraflu Aktiv powder for oral solution|Participants in this arm will receive a single dose (1 sachet) of Theraflu Aktiv powder for oral solution
89153380|NCT02678234|No Intervention|No Treatment|Participants in this arm will not receive any medication
89153381|NCT03892759|Other|Evaluation and Treatment|Subjects will be evaluated through inspection and palpation of the thoracic and lumbar spine, and other body regions as necessary. The provider will make a diagnosis of somatic dysfunction based off the TART (tissue texture change, asymmetry, restriction of motion, tenderness/pain) findings.
89153382|NCT02679950||Initial diagnosis|The initial diagnosis only cohort will include 3 patients with germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and one tissue sample will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
89153383|NCT02679950||Late relapse|"The late relapse cohort will include 3 patients with late relapse germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and two tissue samples will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis and the other will come from the site of late relapse.~Patients in this cohort will have biopsies at the site of late relapse as part of their routine cancer treatment. No biopsies will be performed specifically for the purposes of this study. Tissue from the site of late relapse will also be requested from the Pathology Department."
89153384|NCT04236713|Experimental|Dietary intervention 1|
89153385|NCT04236713|Experimental|Dietary intervention 2|
89153386|NCT00961987|Experimental|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
89153387|NCT00961987|Active Comparator|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
89153388|NCT00601640|Experimental|Eflornithine HCL|Patients apply Eflornithine HCL ointment to their left forearm twice daily on days 1-90.
89153389|NCT00601640|Active Comparator|Diclofenac Na|Patients apply topical Diclofenac Na gel to their left forearm once daily on days 1-90.
89153390|NCT00601640|Experimental|Eflornithine HCL and Diclofenac Na|Eflornithine HCl ointment and Diclofenac Na gel applied twice and once daily, respectively on days 1-90.
89153391|NCT00962143|Active Comparator|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
89153392|NCT00962143|Experimental|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
89153393|NCT02805725|Experimental|Cohort 1: Trabectedin 0.30 mg/m2 IV + CP|"Trabectedin 0.30 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in cohort 1 of dose escalation.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
89153394|NCT02805725|Experimental|Cohort 2: Trabectedin 0.40 mg/m2 IV + CP|"Trabectedin 0.40 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in cohort 2 of dose escalation.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
89153395|NCT02805725|Experimental|Cohort 3: Trabectedin 0.50 mg/m2 IV + CP|"Trabectedin 0.50 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in cohort 3 of dose escalation.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
89153396|NCT02805725|Experimental|Cohort 4: Trabectedin 0.60 mg/m2 IV + CP|"Trabectedin 0.60 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in cohort 4 of dose escalation.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
89153397|NCT02805725|Experimental|Phase II: Trabectedin 0.50 mg/m2 IV + CP|"Trabectedin 0.50 mg/m2 will be administered intravenously (IV), 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks, in the phase II part of the study.~Cyclophosphamide (CP) will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.~1 cycle = 28 days"
89153398|NCT00962221||subclinical hypothyroidism|Patients with subclinical hypothyroidism
89153399|NCT02805569|Active Comparator|Group A|articulating stylet
89153400|NCT02805569|Active Comparator|group C|conventional stylet
89153401|NCT02805491||with hypospadias|parent-child triads as cases (male newborns with hypospadias)
89153402|NCT02805491||without hypospadias|parent-child triads as controls (male newborns without hypospadias)
89153403|NCT02679872||VATS team 1|Video-assisted thoracoscopic surgery team, from institution/hospital 1.
89153404|NCT02679872||VATS team 2|Video-assisted thoracoscopic surgery team, from institution/hospital 2.
89153405|NCT02679872||VATS team 3|Video-assisted thoracoscopic surgery team, from institution/hospital 3.
89153406|NCT02679872||VATS team 4|Video-assisted thoracoscopic surgery team, from institution/hospital 4.
89153407|NCT02803385|Active Comparator|Continous Epidural Analgesia|Continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The Patient Controlled Analgesia pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes
89153408|NCT02803385|Active Comparator|Patient Controlled Epidural Analgesia|Patient controlled epidural analgesia in form of PCA pumps with continuous rate of 5-8ml/hour & demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .
89153409|NCT00958321|Experimental|3-DCRT|Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT
89153410|NCT02679716|Other|study group|MRI of the cerebral arteries ist performed
89153411|NCT02803463|Active Comparator|Peritoneal Closure|open appendectomy with peritoneal closure
89153412|NCT02803463|Active Comparator|Peritoneal Non Closure|open appendectomy without peritoneal closure
89153413|NCT00958399|Placebo Comparator|No fiber|No fiber added to study products
89153414|NCT00958399|Experimental|Resistant Starch|Muffins, cereal, and bars made with a resistant starch
89153415|NCT00958399|Experimental|Resistant starch + soluble fiber|Muffins, cereal, and bars made with a mixture of resistant starch and a soluble fiber
89153416|NCT00958399|Experimental|Fiber made from corn starch|Muffins, cereal, and bars made with novel corn fiber
89153417|NCT00958399|Experimental|Fiber made from corn starch + soluble fiber|Muffins, cereal, and bars made with a mixture of novel corn fiber and a soluble fiber
89153418|NCT02805413|Other|DETERMINATION OF BLOOD PRESSURE|"determination and comparison of blood pressure by/with :~Pulse Curve Analysis~Inert gas re-breathing~Central blood pressure device~Vascular ultrasound device~Thoracic Impedance (ICG) - Electrocardiography (ECG) - Phonocardiography (Phono) - Carotid plethysmography (Pneumo)"
89153419|NCT04183478|Experimental|Best Support Care Plus K-001|Best support care including analgesic treatment, anti-infection therapy, biliary obstruction treatment, nutritional support, psychological support, reasonable advice from physicians, good communication with patients and etc. K-001 9,720mg per day which means that take K-001 capsule 18 tablets (270mg per tablet) orally twice a day (morning and evening), 56 days as a cycle.
89153420|NCT04183478|Placebo Comparator|Best Support Care Plus placebo|Best support care is the same as experimental arm. Placebo is take 18 placebo tablets which is the same as K-001 in appearance orally twice a day (morning and evening), 56 days as a cycle.
89153421|NCT05352373|Active Comparator|Rett Active Supplement|Females with clinical diagnosis of Rett syndrome treated orally daily with calcium carbonate, dose based on Dietary Reference Intake for age, for one year
89153422|NCT05352373|Placebo Comparator|Rett Placebo Supplement|Females with clinical diagnosis of Rett syndrome treated orally daily with sodium bicarbonate, dose based on equivalent weight for active supplement for age, for one year
89153423|NCT04181528|Experimental|Anatomically aligned total knee arthroplasty|Use anatomically aligned TKA implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew) in patients undergoing unilateral TKA
89153424|NCT04181528|Active Comparator|Conventaional total knee arthroplasty|Use conventional TKA implant (Legion total knee system, JII-BCS, Smith & Nephew) in patients undergoing unilateral TKA
89153425|NCT02805335|No Intervention|Control group|Group with the sutureless device actually used
89153426|NCT02805335|Experimental|Innovative group|Group with the new device ( KTFIX PLUS)
89153427|NCT02677610|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
89153428|NCT02677610|Placebo Comparator|Vehicle|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
89153429|NCT02803775|Active Comparator|Paced|Paced arm in which the left heart lead electrode is selected utilizing the longest time to when patient right ventricle lead is pacing. The result of the pacing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
89153430|NCT02803775|Active Comparator|Sensed|Sensed arm is based on the longest time that patient own heart's conduction reaches the left heart lead electrode.The result of the sensing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
89153431|NCT02677532|Active Comparator|Epidural infusion|Thoracic epidural bolus of 10 ml levobupivacaine 0.25% plus sufentanil 0.15 mcg/kg before end of surgery, followed by continuous epidural infusion of 0.12% levobupivacaine plus 0.4 mcg/ml at 5 ml/h infusion rate for 48 hours.
89153432|NCT02677532|Experimental|Wound infusion plus morphine bolus|Intravenous slow bolus of 10 mg morphine, wound infiltration with 10 ml levobupivacaine 0.5%, followed by pre-peritoneal continuous wound infusion of levobupivacaine 0.25% at 4 ml/h infusion rate for 48 hours.
89153433|NCT02804945|Experimental|Mesenchymal Stem Cells|"Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).~Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1."
89153434|NCT00641810|Experimental|A|After one week at usual levels of caffeine use, patients are asked to reduce their caffeine consumption to no more than 2 cups of coffee (or equivalent) for one week and then to zero for two weeks.
89153435|NCT02803151|Experimental|Stereotactic ablative radiotherapy|Image-guided stereotactic ablative radiotherapy
89234902|NCT05887947|Experimental|15 White 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 1.8%|"15, White, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89153436|NCT04033874|Experimental|Kangaroo care|"Heel stick procedure will be performed during kangaroo care.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
89153437|NCT04033874|Experimental|Mother's lap|"Heel stick procedure will be performed during newborns who are holding on their mother's lap.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
89153438|NCT04033874|Experimental|White noise|"Heel stick procedure will be performed during newborns listened to white noise.~For the white noise; the track named do not cry your baby, pt. 2 will be played in Orhan Osman's Colic album. The white noise level will be adjusted to an average of 55 decibels. During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
89153439|NCT04033874|Experimental|Ambient sound|"Heel stick procedure will be performed during newborns listened to ambient sound.~During the application, pulse oximetry device will be placed on each newborn right wrist, then heart rate and SpO2 values will be recorded before, during and after the procedure. The device will remain attached to the baby's wrist during the procedure. Then, the pain level will be assessed with NIPS (Neonatal Infant Pain Scale) and heel-stick procedure will be initiated. To determine the crying time, the stopwatch shall be turned on and the sound decibel meter shall be turned on to determine the sound decibel. The general pain level of the newborns will be evaluated by one minute before the procedure and their response to the pain for three minutes during and after the procedure."
89153440|NCT02805101|Experimental|Biodentine|The perforation area of the root is going to be covered by Biodentine
89153441|NCT02805101|Active Comparator|MTA|The perforation area of the root is going to be covered by MTA.
89153442|NCT00641888||1|10 patients starting on non-nucleoside reverse transcriptase inhibitor based regimen. 5 women and 5 men.
89153443|NCT00641888||2|10 patients starting a protease inhibitor based regimen. 5 women and 5 men.
89153444|NCT02802995|Experimental|Treatment arm|Subjects receiving the study drug which is PRP/thrombin mixture
89153445|NCT02802995|No Intervention|Control arm|Subjects receiving the standard of care for chronic venous wounds
89153446|NCT00910052|Experimental|Fibrin sealant|received intraoperative fibrin sealant
89153447|NCT00910052|No Intervention|Control|No fibrin sealant
89153448|NCT04181216|Experimental|anatomically aligned total knee arthroplasty prosthesis|Total knee arthroplasty with anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew)
89153449|NCT04181216|Active Comparator|Conventaional total knee arthroplasty group|Total knee arthroplasty with conventional total knee arthroplasty implant (Legion total knee system, Smith & Nephew)
89153450|NCT04235933|Experimental|Tai Ai(RC18) 80mg|·Experimental: Tai Ai 80mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
89153451|NCT04235933|Experimental|Tai Ai(RC18) 160mg|·Experimental: RC18 160mg: Injection: subcutaneous injection on abdomen; Intervention:Biological: RC18
89153452|NCT04235933|Experimental|RC18 240mg|·Experimental: RC18 240mg Injection: subcutaneous injection on abdomen; Intervention: Biological: RC18
89153453|NCT02677454|Experimental|Flash Glucose Monitor|"Each patient with Type 1 diabetes will have a subcutaneous tissue FGM sensor inserted. The sensor will produce a maximum of 1440 tissue fluid glucose measurements per 24 hours and 20160 measurements during the 14 day study. The FGM data (Abbott Freestyle Libre) will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose 6 to 10 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study."
89153454|NCT02800889|Experimental|Treatment: Pixantrone|Each patient will receive pixantrone monotherapy administered intravenously once on days 1, 8, and 15 up to six 28-day cycles of pixantrone monotherapy, with two additional cycles in patients who continue to benefit from treatment. At least 6 patients each from Age Cohorts 1 and 2 will be accrued into dose escalation cohorts. The study will be opened to patients of Age Cohort 3 only after at least 6 patients in Age Cohorts 1 and 2 (combined) have been evaluated for toxicity. During the dose escalation phase, participants who are inevaluable for DLT for reasons unequivocally unrelated to toxicity will be replaced. Expansion cohort accrual quota-At least 15 evaluable patients treated with the MTD/optimal dose will be accrued in total, of which 7 patients will be in Age Cohort 2.
89153455|NCT04183400|Experimental|Safety Awareness For Empowerment (SAFE)|Brief mindfulness-based cognitive-behavioral skill-building intervention
89153456|NCT04183400|No Intervention|Usual case management only|Control condition receives only services as usual
89153457|NCT02803073|Experimental|Testosterone Replacement|The experimental group will receive 0.5 ml (100 mg) testosterone cypionate Intramuscular injections each week for 11 weeks.
89153458|NCT02803073|Placebo Comparator|Control|Patients in the control group will receive intramuscular normal saline injections.
89153459|NCT04181372|Experimental|Anlotinib plus Platinum-based chemotherapy|"Take anlotinib hydrochloride 12mg once daily for two weeks, stop for one week, the program repeats every 21 days for 2 cycles.~Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles."
89153460|NCT04181372|Active Comparator|platinum-based chemotherapy|Platinum-based chemotherapy regimens for neoadjuvant:(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
89153461|NCT02800967|Active Comparator|Pure Aronia juice|Participants will consume 100 ml of pure Aronia juice per day for 28 days
89153462|NCT02800967|Active Comparator|Aronia juice-based beverage|Participants will consume 100 ml of Aronia juice-based beverage per day for 28 days.
89153463|NCT02800967|Placebo Comparator|Placebo beverage|Participants will consume 100 ml of Placebo beverage per day for 28 days
89153464|NCT00922532|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
89153465|NCT00922532|Placebo Comparator|Nitrogen|Nitrogen Placebo
89153466|NCT02800577|Other|All participants|Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.
89153467|NCT05663450||patients with direct R0 (in primary intraoperative pathology consultation)|patients undergoing (sub)total gastrectomy for gastric or GEJ adenocarcinoma with R0 without further resection (direct R0)
89153468|NCT05663450||patients with converted R0 (in second intraoperative pathology consultation)|patients undergoing (sub)total gastrectomy for gastric or GEJ adenocarcinoma with R0 after positive IOC and extension of resection (converted R0)
89153469|NCT05663450||patients with remaining R1 (after final intraoperative pathology consultation)|patients undergoing (sub)total gastrectomy for gastric or GEJ adenocarcinoma with R1 resection.
89153470|NCT04236089|No Intervention|mirror therapy of healthy adults|Traditional mirror therapy in electroencephalography of healthy adults.
89153471|NCT04236089|Experimental|robotic mirror therapy of healthy adults|Robotic mirror therapy in electroencephalography of healthy adults.
89153472|NCT04236089|No Intervention|mirror therapy of stroke patients|Traditional mirror therapy in electroencephalography of stroke patients.
89153473|NCT04236089|Experimental|robotic mirror therapy of stroke patients|Robotic mirror therapy in electroencephalography of stroke patients.
89153474|NCT02681978|Active Comparator|Ivabradine group|Ivabradine 5 mg twice daily + standard medical therapy
89153475|NCT02681978|Other|Control group|Standard medical therapy
89153476|NCT05662904|Experimental|Donor-derived CD33-deleted CD34+ HSC combined with Gemtuzumab-Ozogamicin (GO)|Patients will be transplanted with CD33-deleted CD34+ HSC derived from the initially matched family donor. Upon HSC engraftment, patients will be treated with escalating doses of the anti-CD33 antibodydrugconjugate Gemtuzumab-Ozogamicin (GO). A conditioning regimen containing GO (d-14, d-11, d-8), Fludarabine 30 mg/m2 (d-6 to d-3) and Melphalan 140mg/m2 (d-2) is used prior to transplantation.
89153477|NCT02800733|Experimental|saffron|450 mg of saffron capsule once a day for 6 weeks
89153478|NCT02800733|Placebo Comparator|placebo|placebo capsule once a day for 6 weeks
89153479|NCT00642512|Experimental|1|
89153480|NCT00642512|Active Comparator|2|
89153481|NCT00642512|Other|3|
89153482|NCT00642512|Placebo Comparator|4|
89153483|NCT02800421||no organ damage|no evidence of HLI and CI-AKI
89153484|NCT02800421||CI-AKI only|CI-AKI, but no HLI
89153485|NCT02800421||HLI only|HLI, but no CI-AKI
89153486|NCT02800421||combined CI-AKI and HLI|Both CI-AKI and HLI
89153487|NCT02802683|Experimental|"BUPI,P"|patients who received hyperbaric bupivacaine and continous infusion of phenylephrine
89153488|NCT02802683|Placebo Comparator|"BUPI,N"|patients who received hyperbaric bupivacaine and continous infusion of normal saline
89153489|NCT02802683|Experimental|"LEVO,P"|patients who received isobaric levobupivacaine and continous infusion of phenylephrine
89153490|NCT02802683|Active Comparator|"LEVO,N"|patients who received isobaric levobupivacaine and continous infusion of normal saline
89153491|NCT04181294|Experimental|Pre-intervention|Baseline data on patient characteristics and outcomes will be collected for 4 months prior to intervention.
89153492|NCT04181294|Experimental|Post-intervention|The quality improvement intervention will be conducted sequentially at all 3 medical centers (LAC-USC, Olive View, and Harbor-UCLA Medical Centers). Data on patient characteristics and outcomes will be collected for 4 months after the intervention
89153493|NCT05484167|Active Comparator|Natesto|Natesto™ is a testosterone nasal gel that is FDA approved to treat low testosterone. It delivers testosterone through the nasal passages and it is then absorbed into the blood stream. The nasal pump is placed at the opening of each nostril and then the participant would press down on the nasal pump to apply the gel. Each application takes about 10 seconds and the nasal pump applies a thin layer of gel that absorbs through the lining of the nose.
89153494|NCT05484167|Placebo Comparator|Placebo|This study involves a placebo. The placebo will look like the Natesto™ nasal pump and will contain a nasal gel, but without any active ingredients.
89234903|NCT05887947|Experimental|16 White 11-30 Cigarettes per day Electronic Cigarette Nicotine Concentration 5% 1.8% 5%|"16, White, baseline smoking at enrollment is 11-30 cigarettes per day.~At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
89153495|NCT02800031|Experimental|Participants|"Level-II Transvaginal ultrasonography will be done by the principle investigator (who is unaware about the recognition pattern method) to confirm the presence of the ovarian mass and measure its size and to apply the IOTA simple rules on it (complimentary transabdominal ultrasound might be done for huge pelvi-abdominal masses originating from the ovary).~Level-III ultrasound will be done by expert ultrasound operator (who is blinded to the results of IOTA simple rules assessment of the examined mass) to classify the mass (either benign or malignant) using the pattern recognition method.~Plan of management for each patient will be based solely on the findings of pattern recognition and the patient's wishes.~Exploratory laparotomy for excision of the ovarian mass either by ovarian Cystectomy or oophorectomy.~All specimens will be examined histopathologically."
89153496|NCT02679794|Experimental|Egg consumption|Consuming sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
89153497|NCT02679794|Placebo Comparator|Control|Consuming sautéed vegetables and 3g canola oil without eggs
89153498|NCT02800187|Experimental|three-sessions of ESWT|Active three-sessions of ESWT ( once a week for 3 weeks) was given.
89153499|NCT02800187|Active Comparator|one-session of ESWT|One-session of ESWTactive ESWT was given.
89153500|NCT02800187|Active Comparator|Night splint|The night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study. Another 3 sessions of sham ESWT was given.
89153501|NCT04183322||Women of childbearing age|Healthy non-pregnant women between 18 and 45 years old living in Goroka, Papua New Guinea, will receive one dose of 13-valent pneumococcal conjugate vaccine (PCV).
89153502|NCT02800343||Cardiovascular surgery|All adult patients undergoing elective or emergency cardiovascular surgery at the study site
89153503|NCT02679638||Kaplan Hospital|Breast cancer survivors recruited at the Kaplan Medical Center
89153504|NCT02679638||Rambam Hospital|Breast cancer survivors recruited at the Rambam Medical Center
89153505|NCT02679638||Sheba|Breast cancer survivors recruited at the Sheba Medical Center
89153506|NCT02679638||Barzilai|Breast cancer survivors recruited at the Barzilai Medical Center
89153507|NCT02799875|Active Comparator|Higher permissive hypercapnia|Extubation criteria: partial pressure carbon dioxide (pCO2) ≥ 60mmHg with an upper limit ≤ 75mmHg; pH ≥ 7.20; oxygen saturation (SpO2) ≥ 88% with fraction of inspired oxygen (FiO2) ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 75mmHg; pH < 7.20; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
89153508|NCT02799875|Active Comparator|Lower permissive hypercapnia|Extubation criteria: pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg; pH ≥ 7.25; SpO2 ≥ 88% with FiO2 ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 55mmHg; pH < 7.25; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
89153509|NCT04181918|Experimental|AOT|This group will observe videos depicting daily actions and afterwards they will execute the seen actions
89153510|NCT04181918|Experimental|MI|This group will imagine motorically the same action as the first group and afterwards they will execute the imagined actions
89153511|NCT04181918|No Intervention|Control|This group will neither observe nor imagine actions, but simply observe videos with no motor content. Afterwards they will execute the same actions as in AOT and MI.
89153512|NCT02802917|Experimental|SPF 50 Y49 091|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
89153513|NCT02802917|Experimental|SPF 50 X15 158|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
89153514|NCT02802917|Experimental|SPF 50 X15 160|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
89153515|NCT02802917|Experimental|SPF 50 X57 162|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
89153516|NCT00642044|Experimental|A|The eye with the worst visual acuity receives the treatment. (the other eye serve as control).
89153517|NCT00642044|No Intervention|B|The eye with the best visual acuity do not receive the treatment.
89153518|NCT02802839|Experimental|Sperimental|The patient will be shown the headset for VR and a selection of age appropriate virtual realities to immerge in by the nurse not performing the procedure. There will be two lists of VRs to choose from, one for age 6 to 12 and one for age 12 to 18 with the following themes: amusement rides /carousel, space rides, zoo, safari, dinosaurs, city touring, landscapes, caverns. Once the patient is ready to wear the headset the application will start and 120 seconds later the procedure will take place. The nurse performing venipuncture will be a different one than the one handling distraction. Once the procedure ends the video will last for one more minute or up to the child' s desire. Only the first venipuncture attempt will be observed.
89153519|NCT02802839|No Intervention|Observational|Control intervention When arriving to the CF centre for routine visit that implies also the taking of blood samples, after having obtained the informed consent, a trained nurse of the CF Centre, will apply to each child recruited -in the presence of the parent, who may hold the child- the anesthetic cream. Only the first venipuncture attempt will be observed.
89153520|NCT02679482||Selective laser trabeculoplasty (SLT)|Patients who underwent to Selective laser trabeculoplasty
89153521|NCT02679482||Pattern laser trabeculoplasty (PLT)|Patients who underwent to Pattern laser trabeculoplasty
89153522|NCT04180982|Experimental|Treatment group A|SHR4640 dose1 Oral Tablet plus Febuxostat dose1 Oral Tablet Day1~Day28 qd.
89153523|NCT04180982|Experimental|Treatment group B|SHR4640 dose1 Oral Tablet plus Febuxostat dose2 Oral Tablet Day1~Day28 qd.
89153524|NCT04180982|Experimental|Treatment group C|SHR4640 dose2 Oral Tablet plus Febuxostat dose3 Oral Tablet Day1~Day28 qd.
89153525|NCT02799953|Experimental|Technology-based self-management model|Participants randomized to the intervention group will be given a tablet-based, interactive touch-screen self-monitoring system free of charge to perform disease self-monitoring in their homes.
89153526|NCT02799953|No Intervention|Conventional self-management|Participants randomized to the usual care group will not be provided access to tablet computers but a 2-in-1 blood pressure and blood glucose monitor and a paper-based log book to perform conventional self-monitoring.
89153527|NCT02681744|No Intervention|Control Group|These participants will be instructed to maintain their habits during 24 weeks. Before and after the aforementioned period, they will be asked to perform body composition and strength assessments, using DXA and isokinetic dynamometer, respectively.
89153528|NCT02681744|Experimental|Experimental group|Participants from the experimental group will assign to the resistance training program undergo physician screening at rest and under cardiopulmonary exercise test conditions before starting the program. Following a three-week familiarization process, participants undergo one repetition maximum (1-RM) testing for each of the exercises of the training program. This procedure intended to determine exercise load and will be systematically repeated in four-week intervals. Volunteers will train thrice per week during 24 weeks. The training program will involve the following exercises: chest press, lat pulldown, knee extension, hamstrings curl, leg press, hip abduction.
89153529|NCT02802605|Experimental|Bemiparin|Bemiparin 3.500 U, once a day during hospitalization
89153530|NCT02802605|No Intervention|No drug|Clinical practice as usual
89153531|NCT02802371|No Intervention|control group|Patients and caregivers randomized in the control group will receive the current management in geriatric or memory consultation without multidisciplinary psychosocial intervention and pharmaceutical collaborative care.There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, but the recommendations will not be transmitted to the referring physicians of patients and caregivers.
89153532|NCT02802371|Active Comparator|Psychosocial intervention|Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
89153533|NCT02802371|Experimental|Pharmaceutical care and psychosocial support|Pharmaceutical collaborative care integrated in a psychosocial program. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of caregivers; 2) collective session on medication management; and 3) optimization of drug prescribing. These collective and individual sessions of pharmaceutical care will allow an extended 18 month follow-up. Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
89153534|NCT02677142|Active Comparator|Attention Control Group (CG)|Behavioural: CG: Social Skills Activities: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific social skill and activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
89153535|NCT02677142|Experimental|Experimental Group (EG)|Behavioral: Structured social skills training program, SSIP. Participants in this arm will experience an 8-week manualized intervention program that addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion). Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
89153536|NCT02800265|Experimental|Avmacol during week 2 for 3 days|"Buccal cells line the inner cheek, and will be collected from the inner right cheek with a cytobrush (a q-tip like swab) by a trained investigator.~During the second week the participant will take 8 Avmacol tablets every evening for 3 evenings (Day 2, 3, 4), and record the time of each dose in the provided diary. Research blood collection: on days 1 and 5. Overnight urine collection."
89153537|NCT02676986|Active Comparator|Cohort I (ER positive cohort)|Approximately 180 patients with ER positive breast cancer will be randomised 2:1 in favour of enzalutamide to receive enzalutamide plus exemestane or exemestane alone.
89153538|NCT02676986|Active Comparator|Cohort II (AR positive, TNBC cohort)|55 patients with AR positive, TNBC will receive single agent treatment with enzalutamide.
89153539|NCT02681588|Experimental|Obese group|
89153540|NCT02681588|Active Comparator|Normal Weight group|
89153541|NCT02802215|Active Comparator|Metformin group|40 women will receive metformin in dose of 1500 mg per day orally (500 mg every 8 hrs in the middle of meal) starting from 12th week of gestation till delivery.
89153542|NCT02802215|Placebo Comparator|control group|40 women will receive placebo which will be folic acid 500 micro gram which looks like metformin tablet.
89153543|NCT00642590||1|Healthy couples who are planning their first pregnancy.
89153544|NCT02799797|Active Comparator|short axis (SAX) placement of adductor canal catheters|Procedure: Ultrasound guided short axis (SAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a PAJUNK Contiplex S catheter along the short axis of the middle part of adductor canal
89153545|NCT02799797|Experimental|long axis (LAX) placement of adductor canal catheters|Procedure: Ultrasound guided long axis (LAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a catheter along the long axis of the middle part of adductor canal
89153546|NCT05663372|Experimental|Efez (Test)|A single oral dose of the test product Efez 50 mg eplerenone film-coated tablets.
89153547|NCT05663372|Active Comparator|INSPRA®|A single oral dose of the reference product INSPRA® 50 mg eplerenone film-coated tablets.
89153548|NCT02799563|Experimental|Cohort A: Coach, Preselected number of cases|Cohort A completed the DKA simulator cases during two one-hour coached sessions. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
89153549|NCT02799563|Experimental|Cohort B: Coach, Self-selected number of cases|Cohort B completed the DKA simulator cases during two one-hour coached sessions. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
89153550|NCT02799563|Experimental|Cohort C: No coach, Preselected number of cases|Cohort C completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
89153551|NCT02799563|Experimental|Cohort D: No coach, Self-selected number of cases|Cohort D completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
89153552|NCT02638272|Other|spine surgery|The objective was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis.
89153553|NCT02799407|No Intervention|Traditional Long Form Consent|Participants will receive the traditional long-form consent form.
89153554|NCT02799407|Experimental|ResearchKit Consent|Participants will receive the Apple ResearchKit consent form.
89153555|NCT04164498|Experimental|Music exposure|will be exposed to music to investigate effects on preventing noise Adverse effects
89153556|NCT04164498|No Intervention|Control|no exposure to music
89153557|NCT02802527|Other|Bronchoscopy Guided|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
89153558|NCT02802527|Other|Direct Laryngoscopy|Performing percutaneous tracheostomy by placing the tube higher up, near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
89153559|NCT02681900|Experimental|Self-affirmation|Participants in the self-affirmation arm write about their most important value, reasons why is important and an example of when they enacted that value. This is the Self-affirmation manipulation task as described in the intervention.
89153560|NCT02681900|Active Comparator|Control|Participants in this arm complete a control equivalent of the self-affirmation task, where they write about their least important value, reasons why is may be important to someone else and an example of when another person may have enacted that value. This is the Control task as described in the intervention.
89153561|NCT02638194|Active Comparator|Hookah Smoking Group|10 participants will smoke tobacco hookah for 2 hours
89153562|NCT02638194|Active Comparator|Hookah Secondhand Smoke Group|10 individuals will be exposed to secondhand hookah tobacco smoke for 2 hours
89153563|NCT02802137|Active Comparator|Tafluprost drops|Treatment with preservative-free talfuprost drops administered once in the evening. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
89153564|NCT02802137|Active Comparator|Tafluprost and dorzolamide/timolol drops|Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
89153565|NCT02679326|Experimental|study group|will receive stretching guidance and high level active Ultrasound
89153566|NCT02679326|Placebo Comparator|control group|will receive stretching guidance and very low level of Ultrasound
89153567|NCT02641704||Multidisciplinary program|Multidisciplinary program designed and administered by the Competence- and Integration Center in Sonderborg Municipality
89153568|NCT02799251||Collection of plasma cell rate|Post operative infections and their association with lymphopenia are assessed in this study for patients over 18 years of age undergoing digestive or thoracic cancer surgery under general anesthesia.
89153569|NCT04033562|Active Comparator|Lidoderm patch|Participants will receive a topical 3.6% Lidocaine/1.25% Menthol patch at the time of their Cesarean section. Patches will be replaced every 12 hours for a total of 60 hours.
89153570|NCT04033562|Active Comparator|Infusion pump|Participants will undergo placement of Ambu ACTion drug delivery system at the time of Cesarean delivery. 0.125% of bupivacaine will be infused at a rate of 8cc/hr for a total of 48-60hrs post-operatively.
89153571|NCT02641626|Experimental|Urgent Coronary Angiography|Urgent Coronary Angiography: as soon as possible, when the patient is randomized.
89153572|NCT02641626|Active Comparator|Deferred coronariography|Deferred coronary angiography: after extubation if the patient has a good neurologic prognosis.
89153573|NCT02799173|Experimental|Systemic lupus erythematosus|RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound
89153574|NCT02681666|Active Comparator|FODMAPs CONTROL arm|Dietary intervention in this cohort with irritable bowel syndrome will be administered a low Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols diet by a dietician.
89153575|NCT02681666|Experimental|MB-IBS-EAT INTERVENTION STUDY arm|Irritable Bowel Syndrome eating awareness training intervention will be started in a comprehensive 8 weekly sessions of Mindfulness eating training.
89153576|NCT04032834|Other|Part 1, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
89153577|NCT04032834|Other|Part 1, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
89153578|NCT04032834|Other|Part 1, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
89153579|NCT04032834|Other|Part 1, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
89153580|NCT04032834|Other|Part 1, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
89234904|NCT05887921|Active Comparator|Open inguinal Lymphadenectomy|- Groin 1: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery
89153581|NCT04032834|Other|Part 1, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
89153582|NCT04032834|Other|Part 2, Arm A of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide.
89153583|NCT04032834|Other|Part 2, Arm B of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide.
89153584|NCT04032834|Other|Part 2, Arm C of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647.
89153585|NCT04032834|Other|Part 2, Arm D of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647.
89153586|NCT04032834|Other|Part 2, Arm E of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647, 10 breaths (60 µg) VR647.
89153587|NCT04032834|Other|Part 2, Arm F of single-dose, 6-treatment, 6-period crossover|Subjects received the following treatments in Periods 1 to 6 in a crossover fashion: 10 breaths (60 µg) VR647, 15 breaths (120 µg) VR647, 25 breaths (240 µg) VR647, 0.5 mg budesonide, 1 mg budesonide, 5 breaths (30 µg) VR647.
89153588|NCT04032834|Other|Part 3, Arm A of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask.
89153589|NCT04032834|Other|Part 3, Arm B of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece.
89153590|NCT04032834|Other|Part 3, Arm C of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via mouthpiece, 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask.
89153591|NCT04032834|Other|Part 3, Arm D of single-dose, 4-treatment, 4-period crossover|Subjects received the following treatments in Periods 1 to 4 in a crossover fashion: 0.5 mg budesonide via facemask, 15 breaths (120 µg) VR647 via mouthpiece, 15 breaths (120 µg) VR647 via facemask, 0.5 mg budesonide via mouthpiece.
89153592|NCT05654831|Placebo Comparator|SAD Cohorts 1 to 2: Participants receiving Placebo|Participants in each SAD cohort will be randomized to receive placebo.
89153593|NCT05654831|Experimental|SAD Cohorts 1 to 2: Participants receiving ECC5004|Participants in each SAD cohort will be randomized to receive up to 4 escalating doses of ECC5004 ranging from 1 mg to 300 mg.
89153594|NCT05654831|Placebo Comparator|MAD Cohorts 1 to 4: Participants receiving Placebo|Participants will be randomized to receive a once-daily dose of placebo for 28 days.
89153595|NCT05654831|Experimental|MAD Cohorts 1 to 4: Participants receiving ECC5004|Participants will be randomized to receive a once-daily dose of 1 of 4 escalating doses of ECC5004 ranging from 10 mg to 150 mg for 28 days.
89153596|NCT02817191|Experimental|Hylo-Comod|The patients used Hylo-Comod eye drop after phaco+IOL in this group.
89153597|NCT02817191|Experimental|Tears Naturale Forte|The patients used Tears Naturale Forte eye drop after phaco+IOL in this group.
89153598|NCT02676830|Experimental|K-312|
89153599|NCT02636010|Experimental|MK-3475 Pembrolizumab|MK-3475 at a dose of 200 mg every three weeks for 1 year with a potential expansion of 1 additional year of treatment in case of clinical benefit and patient agreement
89153600|NCT02801981|Experimental|Sequence 1: GSK2230672 10mg, 30mg, 90mg, and Placebo|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and placebo in period 4.
89153601|NCT02801981|Experimental|Sequence 2:GSK2230672 10mg, 30mg, Placebo, and GSK2230672 90mg|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, placebo in period 3, and GSK2230672 90 mg in period 4.
89153602|NCT02801981|Experimental|Sequence 3:GSK2230672 10mg, Placebo, GSK2230672 90mg and 180mg|Subjects will receive GSK2230672 10 mg in period 1, placebo in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
89153603|NCT02801981|Experimental|Sequence 4: Placebo, GSK2230672 30mg, 90mg and 180mg|Subjects will receive placebo in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
89153604|NCT02635620||e-cigarette group|Probands are smokers who intend to start vaping for the first time. The probands are recruited in e-cigarette shops. It is aimed to include 60 persons who start vaping. A baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking/vaping behaviour and health status at the beginning and after 1, 2 and 3 months.
89153605|NCT02635620||smoking cessation group|Probands are smokers who intend to quit smoking within a clinical conducted smoking cessation program. It is aimed to include 20 persons who stop smoking. Like in the e-cigarette group, a baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking behaviour and health status at the beginning and after 1, 2 and 3 months.
89153606|NCT02676908|No Intervention|4 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for four weeks (usual care)
89153607|NCT02676908|No Intervention|4 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for four weeks (usual care)
89153608|NCT02676908|Experimental|2 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for two weeks (trial group)
89153609|NCT02676908|Experimental|2 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for two weeks (trial group)
89153610|NCT02635854|Experimental|Test group|The test group (Septic choc group) includes 15 patients suffering from septic shock in intensive care unit.
89153611|NCT02635854|Other|Control group|The control group (Orthopedic surgery group) includes 15 patients recruited from the orthopedic surgical anesthesia consultation programmed for a prosthetic hip or knee pose.
89153612|NCT00642824|Experimental|1|
89153613|NCT02802059|Experimental|EcN-Suspension|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with EcN-Suspension
89153614|NCT02802059|Placebo Comparator|Placebo|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with Placebo
89153615|NCT02635698|Experimental|Intervention group, Optifast|OPTIFAST, medically supervised weight-management program
89153616|NCT02635698|Active Comparator|Control group, Low-energy, low-fat|Food-based program, current standard of care for weight management
89153617|NCT02799017|Experimental|Intensive Phonology Treatment|"The participants in the experimental group will receive an hour of phonology treatment, an hour of group therapy, and an hour of reading. They will work on writing, generative naming during group time focusing on self-cueing with the sounds they learn during the individual session. They will be read to or read aloud depending on their level.~The participants in the experimental group will be taught all consonants and vowels over the course of 16 weeks."
89153618|NCT02799017|Active Comparator|Intensive SFA Treatment|The participants in the control group will receive an hour of individual therapy, an hour of reading and an hour of group therapy in a traditional setting. They will work on writing, generative naming during group time following the semantic feature analysis to retrieve the name.They will be read to or read aloud depending on their level.
89153619|NCT05652920|Experimental|Ori-C101 ( GPC3-directed chimeric antigen receptor modified T cells )|
89153620|NCT04164108|Experimental|Intermittent feed participants|Patients admitted to medical ICU #1 (of 2 at our hospital) will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
89153621|NCT04164108|No Intervention|Control participants|Patients admitted to the medical ICU #2 (of 2 at our hospital) will receive usual care.
89153622|NCT02798939||cirrhotic patients|
89153623|NCT02676596|Other|Cohort 1|Japanese and Non-Japanese subjects receiving K-312 50 mg QD
89153624|NCT02676596|Other|Cohort 2|Japanese and Non-Japanese subjects receiving K-312 100 mg QD
89153625|NCT02676596|Other|Cohort 3|Japanese and Non-Japanese subjects receiving K-312 200 mg QD
89153626|NCT02676596|Other|Cohort 4|Japanese and Non-Japanese subjects receiving K-312 400 mg QD
89153627|NCT02676596|Other|Cohort 5|Japanese and Non-Japanese subjects receiving K-312 25 mg QD
89153628|NCT02676596|Other|Cohort 6|Japanese and Non-Japanese subjects receiving K-312 10 mg QD
89153629|NCT02801903|Experimental|SB204 4%|Topically Once Daily (AM)
89153630|NCT02537756|Experimental|1- Verbalize, Choice|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics they choose
89153631|NCT02537756|Experimental|2- Listen, Choice|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics they choose
89153632|NCT02537756|Experimental|3- Verbalize, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics assigned to them
89153633|NCT02537756|Experimental|4- Listen, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics assigned to them
89153634|NCT04238117|Experimental|LA group|The participants in LAT group underwent 10 sessions of LAT over 2 weeks, using a gallium aluminum arsenide Laser Pen. The participants in the LAT group received 0.375 J of energy at each of the following acupoints bilaterally: BL23 (Shenshu, B2), BL25 (Dachangshu, B2), BL26 (Guanyuanshu, B2), BL40 (Weizhong, B2) and SP6 (Sanyinjiao, B2).
89153635|NCT04238117|No Intervention|Control group|The participants of the control group received standard obstetric care.
89153636|NCT02679014|Placebo Comparator|Placebo|Participants will receive placebo capsules (2 capsules) twice daily for 28 days.
89153637|NCT02679014|Experimental|RO5459072|Participants will receive RO5459072 100 milligrams (mg) capsules (2*50 mg capsules) twice daily for 28 days.
89153638|NCT02801357|Experimental|lofexidine with tapering buprenorphine|Enrolled subjects must be on a daily dose of between 8 - 24 mg of buprenorphine for at least 30 days. Once enrolled, subjects will receive lofexidine as follows: Days 1 through 3, 0.6 mg 4 times daily (QID; 2.4 mg daily); Days 4 through 6, 0.8 mg QID (3.2 mg daily), and Day 7 0.8 mg at 8 AM. Subjects will take their scheduled lofexidine doses at approximately 8 AM, 1 PM, 6 PM and 11 PM. Subjects will also reduce their current buprenorphine dose by at least 4 mg on Day 1.
89153639|NCT04180826||Stenosis|Patients with stenosis
89153640|NCT04180826||No stenosis|Patients without stenosis
89153641|NCT04183244|Active Comparator|Erector spinae block|"Ultrasound guidance will be used to visualize the transverse processes of T2 and the overlying muscles.~Under sterile conditions, a 5-cm, 21-gauge needle will be inserted using the out-of-plane technique parallel to the sagittal plane directly over the transverse process,then 30mL of the local anesthetic solution will be injected and observed for the linear spread of LA the under direct ultrasound visualization"
89153642|NCT04183244|Active Comparator|infraclavicular subomohyoid block|Performing posterior approach infraclavicular BP block followed by subomohioid block via the same puncture site under ultrasound guidance.
89153643|NCT02801591||GH AQ|
89153644|NCT04236011|Experimental|GC012F treatment|BCMA+ R/R multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10E5/kg cells will be administered at Day 0.
89153645|NCT02676674|Experimental|Dose 1|Three topical applications of 100,000 units for a total of 300,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
89153646|NCT02676674|Experimental|Dose 2|Three topical applications of 300,000 units for a total of 900,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
89234905|NCT05887921|Active Comparator|Laparoscopic inguinal Lymphadenectomy|Groin 2: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
89153647|NCT02801513|Experimental|Brief Mindfulness Training|The brief mindfulness training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to engage in formal meditation practice for about 25 minutes twice per day on six out of seven days of each week using recorded guided meditations. Practices were shorter in duration than the practices in Mindfulness-Based Cognitive Therapy (MBCT, Segal et al., 2002) in order to allow for more flexibility in scheduling the practices, but followed the standard sequence of mindfulness-based interventions.
89153648|NCT02801513|Active Comparator|Resting Control Training|The resting control training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to schedule regular rest periods as a means of deliberately retreating from the activities of the day. Length and frequency of the rest periods mirrored the time demands of the meditation training. Participants received a plausible rationale for the control training that linked acute depression to stress and suggested rest, relaxation, and disengagement from negative thinking as an initial and preliminary step towards recovery.
89153649|NCT05279365|Experimental|Administration of Booster Dose|study participant will receive either 30ug in 0.3 ml of Pfizer/BioNTech (BNT162b2) or 0.25 ml of Moderna vaccine administered intramuscularly.
89153650|NCT02679248|Experimental|Neo40 Daily®|
89153651|NCT02679248|Experimental|Placebo|
89153652|NCT02798549|Other|Viraemic|
89153653|NCT02798549|Other|Remission|
89153654|NCT00962299|Active Comparator|Beclomethasone|Inhaled corticosteroids
89153655|NCT00962299|Placebo Comparator|Placebo|Placebo Comparator
89153656|NCT02678936|Experimental|PRP|The operation will be performed with application of platelet rich plasma
89153657|NCT02678936|No Intervention|non-PRP|The operation will be performed without addition of platelet-rich plasma
89153658|NCT02798393|Sham Comparator|HL-Sham|The placebo device (also referred to as the HL-SHAM device) will have an identical appearance to the HL-NIR device. Though the HL-NIR device will be applied, there will be no treatment administered.
89153659|NCT02798393|Experimental|HL-NIR|The device referred to as the HL-NIR device includes both a podiatric or foot and leg component, similar to a loose fitting boot, that is easily applied to all subjects (one size fits all). Application of the device is snug but comfortable without risk for constriction of soft tissue.
89153660|NCT02679092|Active Comparator|Dilapan (14wks 0days-15wks, 6days)|The clinician will place 1 to 2 osmotic cervical dilators (Dilapan-S) (4mm x 65mm) the day before the participant's procedure.
89153661|NCT02679092|Active Comparator|Dilapan (16wks 0days-18wks, 6days)|The clinician will place 3 to 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
89153662|NCT02679092|Experimental|Mifepristone (14wks 0days-15wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
89153663|NCT02679092|Experimental|Mifepristone (16wks 0days-18wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
89153664|NCT03878147|Other|HIV infected|HIV infected children
89153665|NCT03878147|Other|HIV exposed uninfected|HIV exposed, uninfected children
89153666|NCT03878147|Active Comparator|HIV unexposed uninfected|HIV unexposed uninfected children (community controls)
89153667|NCT00962377|Other|AlloMap Molecular testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
89153668|NCT00962377|Active Comparator|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in the monitoring of asymptomatic heart transplant patients for acute cellular rejection
89153669|NCT04183088|Experimental|Part 1: Tislelizumab intravenously + regorafenib orally|Part 1 is a single-arm study. All eligible patients will receive tislelizumab 200 mg intravenously on day 1 every 3 weeks plus regorafenib orally 80 mg per day.
89153670|NCT04183088|Experimental|Groups (1) of part 2: Tislelizumab intravenously + regorafenib|Tislelizumab 200 mg intravenously on Day 1+Regorafenib its dosage in the randomized cohort will be determined according to results in the safety cohort.
89153671|NCT04183088|Active Comparator|Groups (2) of part 2: regorafenib|"Daily dose of regorafenib 80mg/day is for week 1; Daily dose of regorafenib 120mg/day is for week 2; Daily dose of regorafenib 160mg/day is for week 3; Dosing-free interval is for week 4.~The dose of regorafenib will not be escalated if treatment-related AE > grade 1 occurs at the previous dose level.~For subjects in the group 2, when imaging evaluation of tumor response indicates stable disease or progressive disease, according to RECIST v1.1, study treatment will be shifted to regorafenib + tislelizumab combination regimen."
89153672|NCT00962455|Experimental|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
89153673|NCT00962455|Active Comparator|Usual practice|Usual practice regarding spirometry execution in family practice
89153674|NCT00642122|Experimental|1|Pulmicort RESPULES
89153675|NCT00642122|Experimental|2|Pulmicort TURBUHALER
89153676|NCT02801435|Experimental|Cohort 1-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 0.5% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
89153677|NCT02801435|Placebo Comparator|Cohort 1-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
89153678|NCT02801435|Experimental|Cohort 2-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 1.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
89153679|NCT02801435|Placebo Comparator|Cohort 2-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
89153680|NCT02801435|Experimental|Cohort 3-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 2.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
89153681|NCT02801435|Placebo Comparator|Cohort 3-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
89153682|NCT02801435|Experimental|Cohort 4-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 4.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
89153683|NCT02801435|Placebo Comparator|Cohort 4-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
89153684|NCT05300113||CNS Tumor|All patients age from 18-75 years with CNS tumors are included and count as one group
89153685|NCT02817113|Experimental|NC-6004, Cetuximab and 5-FU|Cetuximab will be administered before the start of chemotherapy at a loading dose of 400 mg/m2 given, followed by a subsequent weekly doses of 250 mg/m2; NC-6004 will be administered on Day 1 every 3 weeks, and 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
89153686|NCT02676518||polycystic ovary syndrome women|PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study
89153687|NCT04180592|Experimental|CT Fusion Biopsy + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
89153688|NCT04180592|Other|Transrectal U/S Guided Prostate Biopsy + CT Fusion Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
89153689|NCT02801123|Experimental|Preference: MBCR (im)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to immediate treatment
89153690|NCT02801123|Experimental|Preference: TCQ (im)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to immediate treatment
89153691|NCT02801123|Active Comparator|Preference: MBCR (wl)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to waitlist
89153692|NCT02801123|Active Comparator|Preference: TCQ (wl)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to waitlist
89153693|NCT02801123|Experimental|No Preference: MBCR (im)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - immediate
89153694|NCT02801123|Experimental|No Preference: TCQ (im)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - immediate
89153695|NCT02801123|Active Comparator|No Preference: MBCR (wl)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - waitlist
89153696|NCT02801123|Active Comparator|No Preference: TCQ (wl)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - waitlist
89153697|NCT02681432|Experimental|HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
89153698|NCT02681432|Active Comparator|No HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
89153699|NCT02801201|Active Comparator|sedation|Midazolam : 0,10 mg/kg
89153700|NCT02801201|Active Comparator|spinal anesthesia|Bupivacain 10 mg
89153701|NCT04182932|Experimental|CJ-40010 EV71 A dose|Inactivated EV71 vaccine(A dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89153702|NCT04182932|Experimental|CJ-40010 EV71 B dose|Inactivated EV71 vaccine(B dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89153703|NCT04182932|Experimental|CJ-40010 CVA16 C dose|Inactivated CVA16 vaccine(C dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89153704|NCT04182932|Experimental|CJ-40010 CVA16 D dose|Inactivated CVA16 vaccine(D dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89153705|NCT04182932|Experimental|CJ-40010 Bivalent E dose|Inactivated EV71/CVA16 vaccine(E dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89153706|NCT04182932|Experimental|CJ-40010 Bivalent F dose|Inactivated EV71/CVA16 vaccine(F dose) or placebo in 10 healthy adults (three doses, 28 days interval)
89153707|NCT02798237|Experimental|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
89153708|NCT02798237|Sham Comparator|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program.
89153709|NCT03951805|Experimental|Insulin 287 algorithm A|Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).
89153710|NCT03951805|Experimental|Insulin 287 algorithm B|Controlled on metformin with or without DPP4i and with or without SGLT2i.
89153711|NCT03951805|Experimental|Insulin 287 algorithm C|Controlled on metformin with or without DPP4i and with or without SGLT2i.
89153712|NCT03951805|Active Comparator|Insulin Glargine algorithm D|Controlled on metformin with or without DPP4i and with or without SGLT2i.
89153713|NCT02676362|Experimental|the first day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 5., 10., 30.
89153714|NCT02676362|Experimental|the 2nd day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 10., 30., 5.
89153715|NCT02676362|Experimental|the 3rd day|Gingival crevicular fluid collection with filter paper the length of sampling time in second: 30., 5., 10.
89153716|NCT02800811|Experimental|Part 1: Cohort A, Group 1, FR104|Dose: single 0.005 mg/kg.
89153717|NCT02800811|Experimental|Part 1: Cohort A, Group 2, FR104|Dose: single 0.05 mg/kg.
89153718|NCT02800811|Experimental|Part 1: Cohort A, Group 3, FR104|Dose: single 0.2 mg/kg.
89153719|NCT02800811|Experimental|Part 1: Cohort A, Group 4, FR104|Dose: single 0.5 mg/kg.
89153720|NCT02800811|Placebo Comparator|Part 1: Cohort A, placebo|Placebo, single administration, double blind (1/4 healthy subject in group 1, 1/4 in group 2, 2/5 in group 3 and 2/5 in group 4).
89153721|NCT02800811|Experimental|Part 1: Cohort B, Group 7, FR104|Dose: single 0.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
89153722|NCT02800811|Experimental|Part 1: Cohort B, Group 8, FR104|Dose: single 0.2 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
89153723|NCT02800811|Experimental|Part 1: Cohort B, Group 9, FR104|Dose: single 1.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
89153724|NCT02800811|Experimental|Part 1: Cohort B, Group 9 bis, FR104|Dose: single 0.02 mg/kg group. Healthy subject naïve to KLH and that will receive a KLH challenge.
89153725|NCT02800811|Placebo Comparator|Part 1: Cohort B, placebo|placebo, single administration, double-blind: healthy subjects naïve to KLH and that will receive a KLH challenge (2/5 in each group of cohort B)
89153726|NCT02800811|Experimental|Part 2: Group 10, FR104|Dose: repeat, 0.2 mg/kg. Two administrations separated by an interval of 28 days.
89153727|NCT02800811|Experimental|Part 2: Group 11, FR104|Dose: repeat, 0.5 mg/kg. Two administrations separated by an interval of 28 days.
89153728|NCT02800811|Placebo Comparator|Part 2: placebo|placebo, repeat, double-blind: 2/5 subjects in each group of Part 2. Two administrations separated by an interval of 28 days.
89153729|NCT02681198|Experimental|Lofexidine and paroxetine|Lofexidine in the presence of paroxetine
89153730|NCT00962533|Experimental|ROADMAP Group (Group I)|"Patients were to take telbivudine 600 mg orally daily from Baseline.At Week 24, patients in Group I were split into Group I-A or Group I-B based on their virologic load:~Group I-A: This group of patients was those with HBV DNA ≥300 copies/mL at Week 24 and adefovir was to be added at Week 28;~Group I-B: This group of patients was those with HBV DNA <300 copies/mL at Week 24. Telbivudine monotherapy was to be continued until there was a viral breakthrough (confirmed by two examinations with at least 1 month interval with compliance factor excluded) and then adefovir was to be added;~The total treatment duration was 104 weeks."
89153731|NCT00962533|Active Comparator|SOC (Standard of Care) Group (Group II)|patients were to take telbivudine 600 mg monotherapy from Baseline until Week 104. If viral breakthrough (defined as HBV DNA 1 log10 above nadir) was confirmed (by two examinations with at least a 1 month interval with compliance factor excluded), adefovir 10 mg daily was to be added.
89153732|NCT00642980|Active Comparator|Clindamycin Cure 1|Arm 1
89153733|NCT00642980|Active Comparator|Clindamycin Cure 2|Arm 2
89153734|NCT00642980|Placebo Comparator|Placebo|Arm placebo
89153735|NCT04235387||Robotic prostatectomy|All patients undergoing robotic assisted prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
89153736|NCT04235387||Laparoscopic prostatectomy|All patients undergoing standard laparoscopic prostatectomy in University Hospital in Motol during the project period. Monitored using standard non-invasive monitoring.
89153737|NCT02798081|Experimental|Single arm study|A minimum of 46 elderly, students of a informatics course, will participate in the study. Initially, the students will have 8 usual informatics classes in the institution where they were enrolled spontaneously. Then, during the next 8 classes (from class 9 to class 16) they will practice 10 minutes of virtual reality games, as part of the class.
89153738|NCT04180748||Normal skin|
89153739|NCT04180748||Oily skin|
89153740|NCT04180748||Dry skin|
89153741|NCT04180748||Combination skin|
89153742|NCT04180748||Sensitive skin|
89153743|NCT02798159|Experimental|Part A- Arm 1|Investigational dose = 0.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
89153744|NCT02798159|Experimental|Part A- Arm 2|Investigational dose = 0.5 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
89153745|NCT02798159|Experimental|Part A- Arm 3|Investigational dose = 1 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
89153746|NCT02798159|Experimental|Part A- Arm 4|Investigational dose = 1.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
89153747|NCT02798159|Experimental|Part B- Arm 1|"Investigational dose = optimal dose in Part A. The drug should not be taken more than one time a day or 3 times a week.~Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month"
89153748|NCT02798159|Active Comparator|Part B- Arm 2|Sildenafil Citrate 50 mg on demand The drug should not be taken more than one time a day or 3 times a week. Administered orally once a day, 1 hour before sexual activity, for 1 month
89153749|NCT00962611|Experimental|Copanlisib|
89153750|NCT04180280|Active Comparator|Phone Delivered|Participants receive 5 sessions of phone-delivered behavioral counseling to improve HIV care.
89153751|NCT04180280|Active Comparator|Office Delivered|Participants receive 5 sessions of office-delivered behavioral counseling to improve HIV care.
89153752|NCT04235621||FSGS/TR-MCD|Patients with FSGS/TR-MCD
89153753|NCT04235621||Diabetic Nephropathy (DN)|Patients with DN
89153754|NCT00962689||Chronic Rhinosinusitis|Patients with chronic rhinosinusitis as defined by American Academy of Otolaryngology-Head and Neck Surgery and American Rhinologic Society guidelines
89153755|NCT00962689||Control Group|Patients undergoing endoscopic sinus surgery for diseases other than chronic rhinosinusitis (i.e., access to pituitary gland, etc)
89153756|NCT00643058|Experimental|1|Sterile Saline, LPS endotoxin
89153757|NCT02797925||Tendinopathy|Long slow strength training for 3 months that are performed at home or gym. Participants receive initial guidance to the exercises from a physiotherapist assigned to Bispebjerg H.
89153758|NCT02797925||Healthy|No intervention. No training
89153759|NCT04180358|Experimental|Impact group|The impact group will receive the interventions in the classrooms
89153760|NCT04180358|Placebo Comparator|Comparison group|Comparison group will not receive the intervention
89153761|NCT03868709|Experimental|Penehyclidine group|Penehyclidine inhalation is administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
89153762|NCT03868709|Placebo Comparator|Placebo group|Placebo inhalation is administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
89153763|NCT05352295||infected|40 patients admitted to the IRCCS Galeazzi Orthopedic Institute for fracture with Covid 19 infection ascertained by nasal pharyngeal swab during the patients' clinical routine
89153764|NCT05352295||not infected ( control)|40 patients admitted to the IRCCS Galeazzi Orthopedic Institute for fracture without Covid 19 infection ascertained by nasal pharyngeal swab during the patients' clinical routine
89153765|NCT04180514||Intradialytic hypotension|subjects with intradialytic hypotension episode
89153766|NCT04180514||Non-intradialytic hypotension|subjects without intradialytic hypotension episode
89153767|NCT02798003||Cachectic cancer patients|Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.
89153768|NCT02798003||Non-cachectic cancer patients|Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.
89153769|NCT02798003||Cachectic COPD patients|Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
89153770|NCT02798003||Non-cachectic COPD patients|Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
89153771|NCT00962767|Experimental|a|2 doses of gemtuzumab ozogamicn administered at monthly intervals
89153772|NCT00962767|Active Comparator|b|2 years maintenance therapy with intermittent ATRA plus 6-Mercaptopurine (6-MP) and methotrexate (MTX)
89153773|NCT05663138||Early Hi-VNI|Group 1 of early shift to Hi-VNI after nasal cannula
89153774|NCT05663138||Late Hi-VNI|Group 2 of late use of Hi-VNI after NRM
89153775|NCT02817269|Experimental|Manual palpation group|For the manual palpation group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut band tried to elicit local twitch response and referred pain in the infraspinatus area. First, three attempts will be made to elicit an local twitch response (LTR) using snapping palpation if a response will be obtained. After LRT, referred pain could also be evoked by palpation.
89153776|NCT02817269|Experimental|Deep dry needling group|For the deep dry needling group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut before making the needle insertion. Sterile stainless steel needles (length 40mm/caliber 0.32 with a cylindrical plastic guide) will be used.
89153777|NCT04010149|Experimental|Active tDCS|During cognitive training in the first 2 weeks, participants will also received brain stimulation. The investigators will use a total current intensity of 2mA for 20 minutes, preceded by 30 seconds ramping up and followed by 30 seconds ramping down (total stimulation time = 21s).
89153778|NCT04010149|Sham Comparator|SHAM tDCS|During sham stimulation, concurrent with the cognitive training, The investigators will use the same setup as in the active condition but after ramping up, the current will be brought back to zero and the process repeated 30 seconds before the end of the 21 minutes time interval (total sham stimulation time = 21s).
89153779|NCT02816957|Active Comparator|patients receiving Nigella|40 patients in the treatment group that will receive nigella sativa powder (2 gm/day) for 3 consecutive months.
89153780|NCT02816957|No Intervention|patients not received nigella as controls|40 patients in the control group will not receive nigella sativa and continued on the usual chelators
89153781|NCT00642200|Active Comparator|1|Patients receive Lichtenstein hernioplasty as a treatment for recurrent inguinal hernia.
89153782|NCT00642200|Active Comparator|2|Patients receive laparoscopic TEP as a treatment for recurrent inguinal hernia.
89153783|NCT02816801|Experimental|Intervention|Access to Butler-Program 2.0
89153784|NCT02816801|No Intervention|Waitlist|
89153785|NCT04181840|Experimental|Impedance spectroscopy|"Maximum 56 women up to 16 weeks from a natural delivery, with at least one perinatal anal sphincter injury risk factor, such as: the extended second delivery phase, instrumental delivery (vacuum or forceps), shoulder dystocia, birth weight of the child > 4kg, episiotomy, uncontrolled perineal laceration (in patients with crotch protection).~The planned interventions are:~Blood and faeces tests~Impedance spectroscopy test~Full gynecological and proctological examination~Transanal ultrasonography~Anorectal manometry"
89153786|NCT02797847|Active Comparator|ALN-TTRSC02|
89153787|NCT02797847|Placebo Comparator|Sterile normal saline 0.9% for SC administration|
89153788|NCT02678780|Experimental|Cohort A|"Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent.~Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)"
89153789|NCT02678780|Experimental|Cohort B|Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of gastrointestinal tract after progression to somatostatin analogues Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)
89153790|NCT02795741|Experimental|Cooling Bolero|All participants will use the Cooling Bolero for one month
89153791|NCT02990611||Cohort 1: Nivolumab/Ipilimumab combination therapy|Participants who start a new systemic therapy with nivolumab/ipilimumab combination therapy for the first time
89153792|NCT02990611||Cohort 2: Nivolumab monotherapy|Participants who start a new systemic therapy with nivolumab monotherapy for the first time
89153793|NCT02990611||Cohort 3: Nivolumab adjuvant therapy|Participants who start adjuvant treatment with nivolumab after complete surgical tumor resection and no evidence of disease
89153794|NCT02795663|Experimental|parkinson's patient stimulated at STN level|15 parkinson's disease patients stimulated at STN level NIRS EEG HR recording
89153795|NCT02795663|Experimental|non STN|5 Parkinson's Disease patients who received stimulation in another target that the STN NIRS EEG HR recording
89153796|NCT02795663|Experimental|control|20 control patients undergoing DBS for the treatment of OCD NIRS EEG HR recording
89153797|NCT02678546||patients in outpatients departments|patients from outpatients departments in teaching hospital
89153798|NCT02678546||General|participants from center of continuing education in China Medical University
89153799|NCT04235153||Patients with solid or hematological cancer|All the patients complete the CANUT-QVA questionnaire
89153800|NCT04182542|Experimental|RF|The right side will be treated with radiofrequency
89153801|NCT04182542|No Intervention|NI|The left side will not receive treatment.
89153802|NCT05290285|Experimental|EAA supplementation|"The EAA blend consists of a complex blend of essential amino acids, including some precursors of neurotransmitters that are important for regulating mood. In particular, phenylalanine, a precursor of tyrosine (non-essential amino acid) is involved in the biosynthesis of catecholamines (noradrenaline, adrenaline, dopamine) and tryptophan is the precursor of serotonin. Furthermore, the amino acids present in the mixture and the precursors of the Krebs cycle (citrate, malate, succinate) are able to stimulate mitochondrial bioenergetics by improving metabolism and muscle function.~The EAA blend will be administered orally at 4.5 g twice daily (two sachets of Amino-Ther Pro per day)."
89153803|NCT05290285|Placebo Comparator|Placebo|Placebo is an isocaloric product containing maltodextrins instead of amino acids (Acquilani et al., 2011). The placebo will be administered orally 4.5 g twice daily.
89153804|NCT02797691|Experimental|CaCBT plus Treatment As Usual|"Receiving CaCBT intervention in addition to the Treatment as usual"
89153805|NCT02797691|Active Comparator|Treatment As Usual (TAU)|Receiving Treatment as usual
89153806|NCT00643136|Experimental|Pregabalin|
89153807|NCT00643136|Placebo Comparator|Placebo|
89153808|NCT00963079|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
89153809|NCT00963079|Active Comparator|Fresh blastocyst transfer|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
89153810|NCT02797535|Other|GI fluids samples collection|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
89153811|NCT00641342|Active Comparator|onlay mesh|
89153812|NCT00641342|Active Comparator|sublay mesh|
89153813|NCT00641342|No Intervention|no mesh|
89153814|NCT02795585||QFR group|Patients with stable angina pectoris and indication for FFR.
89153815|NCT02676128|Experimental|Mobile Health ART Adherence Application (mARTAA)|mARTAA will use a smartphone-delivered application developed by Twine Health, Inc.
89153816|NCT02676128|Active Comparator|Face-to-Face ART Adherence Intervention|A single face-to-face ART adherence intervention will be administered.
89153817|NCT03944707|Experimental|LOU064|LOU064 100 mg once daily orally
89153818|NCT03944707|Placebo Comparator|Placebo|Placebo once daily orally
89153819|NCT02795507|Experimental|Device with feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in this specialized motion control apparatus which allows movement of the non involved hand while receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).~5 days per week for 3 weeks, 1 hour per day."
89153820|NCT02795507|Active Comparator|Device without feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in a specialized motion control apparatus which allows movement of the non involved hand but without receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).~5 days per week for 3 weeks, 1 hour per day."
89153821|NCT00643214|Experimental|1|Twice daily topical application
89153822|NCT00643214|Placebo Comparator|2|Twice daily topical application
89153823|NCT05449301|Active Comparator|Control Group|The control group will receive Conventional Treadmill training for Gait & balance impairment.
89153824|NCT05449301|Experimental|Rhythmic Auditory Stimulation Training Group|Participants will be trained conventionally (bipedal) on regular treadmill along with Rhythmic Auditory Stimulation.
89153825|NCT05449301|Experimental|Unilateral Step Training Group|The participants will be trained with regular treadmill for unilateral step for both paretic and non-paretic lower extremity
89153826|NCT05448755|Experimental|Open label study drug treatment|
89153827|NCT01563367|Active Comparator|Iron isomaltoside 1000 (Monofer®)|Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion
89153828|NCT01563367|Placebo Comparator|0,9% sodium saline|Placebo (0.9% sodium saline) - Intravenous infusion
89153829|NCT00641498|No Intervention|Control|Usual therapy
89153830|NCT00641498|Experimental|Active group|Individual supportive psychotherapy initiated in the Emergency department
89153831|NCT02309593||PROFEMUR® Xm Femoral Stems|Single study group either previously implanted or will be implanted with the following combination of components: PROFEMUR® Xm Femoral Stems, with any type of Acetabular Shells.
89153832|NCT02795273|Experimental|Grass-SPIRE|Eight intradermal injections of Grass-SPIRE
89153833|NCT02795273|Placebo Comparator|Placebo|Eight intradermal injections of Placebo
89153834|NCT04180124|Experimental|GaitRite|"Patients will walk on the GaitRite.~forward walking at comfortable gait speed (6 x 10 meter)~backward walking at comfortable gait speed (4 x 10 meter)"
89153835|NCT04180124|Experimental|Treadmill walking self-paced|"Patients will walk on the treadmill in self-paced mode. They can control walking speed by themselves.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
89153836|NCT04180124|Experimental|Treadmill walking fixed speed - comfortable speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at comfortable gait speed, which is determined in the familiarization period.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
89153837|NCT04180124|Experimental|Treadmill walking fixed speed - fast speed|"Patients will walk on the treadmill in fixed speed mode. They will walk at a gait speed, which is 1 minimal clinical difference faster than their comfortable gait speed.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
89153838|NCT04180124|Experimental|Treadmill walking fixed speed - backward walking|"Patients will walk on the treadmill in fixed speed mode. Patient will walk backwards on the treadmill if they are able to.~Patient walks for 3 minutes for every condition = data will be recorded for 1 minute."
89153839|NCT00963313||Adalimumab, injection|Adalimumab, one injection every fourteen days during 24 weeks.
89153840|NCT02797301|Experimental|synthetic test & computerised test|Seventeen preschool children (G1), with no motor impairments, from a private school. The children in G1 performed the synthetic test before the computerised test.
89153841|NCT02797301|Experimental|computerised test & synthetic test|Sixteen preschool children (G2), with no motor impairments, from a private school. The children in G2 performed the computerised test before the synthetic test.
89153842|NCT02797301|Experimental|computerised test|Seven volunteers (G3), two males and five females, with moderate mobility impairment, patients from the Physical Therapy and Rehabilitation Clinic.
89153843|NCT02676440|Other|Treatment|Toothpaste containing 1.11% Fluoride as Sodium Monofluorophosphate and Zinc Citrate Trihydrate Serum containing 0.17% Fluoride as Sodium Monofluorophosphate and Zinc Sulphate Heptahydrate
89153844|NCT02676440|Other|Comparator|Silica toothpaste 1350ppm F as Sodium Fluoride
89153845|NCT02675972||patient with poor outcome|modified Rankin scale≥3
89153846|NCT02675972||patients with favorable outcome|modified Rankin scale<3
89153847|NCT00963391|Experimental|ABHS use|Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). Proper safety measures were followed. Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
89153848|NCT00963391|No Intervention|No treatment|Centers assigned to the control group received no hand hygiene recommendations other than to continue with current hand hygiene practices and no further information on hand hygiene other than the general information received before trial initiation was provided.
89153849|NCT02797145|Active Comparator|Intensive Group|Dose adjusted digoxin by the recommended range for the serum digoxin: 0.5-0.9 nanogram/mL
89153850|NCT02797145|Placebo Comparator|Conventional|Use digoxin as recommended by the guidelines.
89153851|NCT05663060|Experimental|Probiotic|Probiotic
89153852|NCT04011007|Active Comparator|vitrectomy without ILM peeling|vitrectomy without ILM peeling
89153853|NCT04011007|Active Comparator|vitrectomy with inverted ILM flap technique|vitrectomy with inverted ILM flap technique
89153854|NCT02690129|Active Comparator|Group I (Progesterone Group)|"Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours.~Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest ® 200 mg) at bedtime for 15 days.~If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic .~Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation."
89153855|NCT02690129|Placebo Comparator|Group II ( Control group)|Will follow the same plan of management without progesterone support.
89153856|NCT02681354|Experimental|A additional BioRescue training|Using a playful rehabilitation, BioRescue
89153857|NCT02681354|No Intervention|Regular training|
89153858|NCT02797379|Other|Immediate start|This group receive the intervention (psychoeducation guide) immediately following baseline assessment and are assessed 4 and 8 weeks later.
89153859|NCT02797379|Other|Delayed start|This group do not receive the intervention for 4 weeks. They are assessed after the wait period (4 weeks) and again after 4 weeks of having the intervention (psychoeducation guide) at week 8.
89153860|NCT00549055||1|Patients who obtained reimbursement of Macugen.
89153861|NCT02678468||high-risk group|children with birth history of pre-term, low birth weight children with develop delay
89153862|NCT02678468||normal group|children with normal birth history and normal development
89153863|NCT04237883|Placebo Comparator|Arm 1: Standard Communication Arm|Monthly email communication: Monthly standard communication via email informing physicians of their health maintenance completion rate over the prior three-month period. The email will also include a link to the performance dashboard, a link to a FAQ page that outlines their incentive plan, a link to helpful resources such as care guidelines, key tips from top performers, the quality measure on which they are performing the best, and the two quality measures that they could improve on the most.
89153864|NCT04237883|Experimental|Arm 2: Arm 1 Message + Social Comparison Intervention|"Monthly email communication as in Arm 1~Social comparison: In addition to the information given in Arm 1 email messaging, physicians in this arm will receive a list of the names of the top 25 performers from the prior month, and a high performer benchmark. Each physician in this group will receive a personalized message and subject line based on where in the performance distribution they fall (categories: top 25 performers, high performers, nearly high performers, and low performers). Message content will incorporate language utilizing principles of social comparison theory."
89153865|NCT04237883|Experimental|Arm 3: Arm 2 Interventions + Leadership training|"Monthly email communication as in Arm 1 and Arm 2.~Social comparison as in Arm 2.~Quality improvement leadership training: Physician leads and clinic managers within clinics randomized to Group 3 will receive an in-person quality improvement and primary care clinic performance training, using the principles of quality improvement, self-determination theory and social comparison. Clinic leaders will be trained on how to guide these conversations, formulate their own performance/quality improvement goals, design effective strategies to reach these goals, and track their clinic's progress. Check-in emails and calls will be provided on a monthly basis to follow up on clinic-based quality improvement efforts and share key take-aways from the new Primary Care Clinical Excellence Recognition Program. This program aims to support a positive and collaborative culture of clinical excellence by recognizing and sharing best practices from high performing physicians and clinical teams."
89153866|NCT05542706|Experimental|Accompanying caregivers by paramedical team|
89153867|NCT05542706|No Intervention|No dedicated accompanying by medical team|
89153868|NCT00883116|Experimental|Ixabepilone, 40 mg/m^2, intravenously (IV)|Participants received ixabepilone, 40 mg/m^2, given IV over 3 hours every 21 days until unacceptable toxicity or disease progression
89153869|NCT00883116|Active Comparator|Control chemotherapy (Paclitaxel or Doxorubicin)|Participants received either paclitaxel, 175 mg/m^2 given IV over 3 hours, or per institutional guidelines but not exceeding 3 hours, every 21 days until disease progression or unacceptable toxicity or doxorubicin, 60 mg/m^2 given IV per institutional guidelines every 21 days, depending on the prior therapy received, until disease progression, unacceptable toxicity, or cumulative dose of 500 mg/m^2.
89153870|NCT00643292|Experimental|1|
89153871|NCT00643292|Experimental|2|
89153872|NCT01969825|Experimental|Massage|Professional Swedish massage less than 15 minutes prior to semen collection for intrauterine insemination.
89153873|NCT01969825|No Intervention|No massage|Normal protocol for semen collection prior to intrauterine insemination.
89153874|NCT02816645|Experimental|<5 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
89153875|NCT02816645|Experimental|Between 5 and 10 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
89153876|NCT02816645|Experimental|Between 10 and 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
89153877|NCT02816645|Experimental|> 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
89153878|NCT00963625|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
89153879|NCT00963625|Active Comparator|Fresh blastocyst transfer.|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
89153880|NCT02675816|Other|Inspire® (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
89153881|NCT04162392|Experimental|Experimental group|
89153882|NCT04162392|Active Comparator|Control group|
89153883|NCT02797067|Experimental|Indomethacin|Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.
89153884|NCT02797067|Placebo Comparator|Glycerin|Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.
89153885|NCT00655044||Type 1 and type 2 diabetes patients|
89153886|NCT00963703|Experimental|Rituximab|
89153887|NCT02796989|Active Comparator|Healthy - Wheat Bran|Wheat bran 20 g each day
89153888|NCT02796989|Placebo Comparator|Healthy - Placebo|Placebo 20 g each day
89153889|NCT02796989|Active Comparator|Obese - Wheat bran|Wheat bran 20 g each day
89153890|NCT02796989|Placebo Comparator|Obese - Placebo|Placebo 20 g each day
89153891|NCT00655122|Active Comparator|Dalteparin sodium|
89153892|NCT00655122|Placebo Comparator|Placebo|
89153893|NCT05531630|Experimental|AB: Xylitol-Saline|Patients in the AB arm will first receive Xylitol, followed by saline
89153894|NCT05531630|Experimental|BA: Saline-Xylitol|Patients in the BA arm will first receive saline, followed by Xylitol
89153895|NCT05441579|Experimental|Phase 1 - VR-BF BE|We are applying Behavioral Economics (BE)-based messaging and presentation strategies to patient recruitment and determining whether these strategies may enhance patient recruitment into a pediatric randomized clinical trial. Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
89153896|NCT05441579|Active Comparator|Phase 1 - VR-BF Biological|A similar to BE-based recruitment video using a standard biological approach on teenagers' decision to enroll in a clinical study will be used as comparison. Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
89153897|NCT05441579|Experimental|Phase 2 - Manage My Pain BE|We are applying Behavioral Economics (BE)-based messaging and presentation strategies to patient recruitment and determining whether these strategies may enhance patient recruitment into a pediatric randomized clinical trial. Phase 2 will focus on patients that would be enrolled into the control arm of a clinical trial with a control intervention, Manage My Pain application.
89153898|NCT05441579|Placebo Comparator|Phase 2 - Manage My Pain Biological|A similar to BE-based recruitment video using a standard biological approach on teenagers' decision to enroll in a clinical study will be used as comparison. Phase 2 will focus on patients that would be enrolled into the control arm of a clinical trial with a control intervention, Manage My Pain application.
89153899|NCT02638116|Experimental|Ibrutinib + Omeprazole|Participants will receive a dose of Ibrutinib 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7 and Omeprazole at a dose of 40 mg tablets orally once on Days 3 through 7.
89153900|NCT02681042|Experimental|SentreHeart Lariat|Left atrial appendage closure with SentreHeart Lariat device
89153901|NCT04164264|Experimental|Intravenous Propofol Infusion|Quantification of the dose of propofol required to produce loss of consciousness and apnea.
89153902|NCT02795039|Experimental|Fulvestrant 50mg/mL (Fresenius Kabi)|5 mL intramuscular injection
89153903|NCT02795039|Active Comparator|Fulvestrant 50 mg/mL (Faslodex®)|5 mL intramuscular injection
89153904|NCT01633411||Cohort A|Subjects in Cohort A will receive 6 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
89153905|NCT01633411||Cohort B|Subjects in Cohort B will receive 8 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
89153906|NCT01633411||Cohort C|Subjects in Cohort C will receive 10 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
89153907|NCT02675894|Active Comparator|RFA with cooled-wet electrode|RFA is performed using three cool-wet electrodes in switching bipolar mode under the fused US guidance.
89153908|NCT02675894|Active Comparator|RFA with separable clustered electrode|RFA using separable clustered electrode in switching monopolar mode under the fused US guidance
89153909|NCT02796833|Other|SMOF/Intralipid|"Patients that are randomized to receive for the first 6 months SMOF as a lipid emulsion in their PN, and for the next 6 month (after 28 days of active washout on Intralipid) Intralipid, which is the standard lipid emulsion used in the hospital. SMOF is approved by Health Canada.~The parenteral nutrition bags are compounded individually for each patient based on their specific needs."
89153910|NCT02796833|Other|Intralipid/SMOF|Patients that are randomized to receive Intralipid, which is the standard lipid emulsion used in the hospital for the first 6 months, and for the next 6 month (after 28 days of active washout on Intralipid) SMOF as a lipid emulsion in their PN. SMOF is approved by Health Canada.The parenteral nutrition bags are compounded individually for each patient based on their specific needs.
89153911|NCT00963781|Experimental|Six months DAPT|All patients will be assigned to 6 months of DAPT
89153912|NCT02632890||Patients survey|Adult patients treated with abatacept for rheumatoid arthritis
89153913|NCT02632890||HCP survey|HCP with at least 1 patient taking abatacept
89153914|NCT02632890||Retrospective chart review study|Adult patients treated with abatacept for rheumatoid arthritis
89153915|NCT02795195|Experimental|CIRT Arm (3GyE per fraction)|Patients included in this arm were treated with carbon ion radiotherapy with a fraction size of 3GyE.
89153916|NCT02673710||Participants with metastatic colorectal cancer|Participants diagnosed with mCRC treated in first line with a combination of bevacizumab and chemotherapy for whom it is decided to continue the administration of bevacizumab beyond progression while changing CTR will be included in this study
89153917|NCT04009603|Active Comparator|Metformin|Group no 1(26 patients) Metformin tablets at a dose of 500mg BD for 12 weeks
89153918|NCT04009603|Experimental|Probiotic|Group no 2(26 patients): will be given probiotics alone at a dose of 180mg B.D for 12 weeks
89153919|NCT04009603|Experimental|Metformin and Probiotic|Group no 3(26 patients): will be given metformin 500mg B.D and probiotics 180mgram O.D. for 12 week
89153920|NCT02635230||Patients with chronic oral anticoagulation and P2Y12 inhibitor|Patients with chronic indication for chronic oral anticoagulation (OAC) because of a heart valve prosthesis and/or atrial fibrillation undergoing coronary revascularisation (by PCI or CABG) and requiring concomitant treatment with P2Y12 inhibitors.
89153921|NCT02673554|Experimental|Oral glucose tolerance test|An oral glucose challenge (75 g)
89153922|NCT02673554|Active Comparator|GIP Bolus|Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
89153923|NCT02673554|Active Comparator|GIP Infusion|Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
89153924|NCT00964015|Active Comparator|Starch group|Patients randomized to the Starch group will receive Voluven (6% Hydroxyethyl Starch 130/0.4) for their intravenous bolus and fluid resuscitation requirements.
89153925|NCT00964015|Active Comparator|Saline group|Patients randomized to the Saline group will receive 0.9% Normal Saline for their intravenous fluid bolus and resuscitation requirements
89153926|NCT04160208||IUI - Insemination|Males of couples undergoing their first IUI treatment
89153927|NCT04160208||IVF - In vitro fertilisation|Males of couples undergoing their first IVF treatment. Including males of couples who have had previous IUI treatments.
89153928|NCT04160208||ICSI - Micro Insemination|Males of couples undergoing their first ICSI treatment. Including males of couples who have had previous IUI treatments.
89153929|NCT04164030|Active Comparator|Nutrition Education Control|An evidence-based nutrition program entitled Eating Smart Being Active. Delivered in a group: Meets weekly for 2 hours for 9 weeks.
89153930|NCT04164030|Experimental|Nutrition Education +OT+Yoga|9 week group that meets twice a week for two hours each. Group occupational therapy and group yoga will be added to the nutrition program.
89153931|NCT04009525|Experimental|MSD-HSCT|matched sibling donors hematopoietic stem cell transplantation
89153932|NCT04009525|Experimental|URD-HSCT|unrelated donor hematopoietic stem cell transplantation
89153933|NCT04009525|Experimental|haplo-HSCT|haplo-identical hematopoietic stem cell transplantation
89153934|NCT02796911|No Intervention|Corticotomy alone|Group I will be treated with a modified technique of corticotomy assisted orthodontic treatment (CAOT) alone
89153935|NCT02796911|Experimental|Corticotomy + xenograft|group II (included 6 females and 5 males) that treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
89153936|NCT02796911|Experimental|Corticotomy + bioactive glass|group III (included 7 females and 4 males) that treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
89153937|NCT00643370||1|single arm study
89234906|NCT05887908|Experimental|co-administration of cefepime and nacubactam|co-administration of 2 g cefepime and 1 g nacubactam q8h (60 min. infusion)
89153938|NCT00594399|Experimental|Arm 1 Physical Activity counseling|Physical activity (PA) counseling program with the following components: baseline in-person counseling session; telephone calls, one physician endorsement of PA in a primary care clinic visit, monthly automated telephone calls from the primary care provider encouraging PA; and quarterly mailed materials providing personalized feedback.
89153939|NCT00594399|No Intervention|Arm 2|Usual care from primary, womens or geriatric clinics
89153940|NCT04032366||PEEP 5|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, without inhaled nitric oxide
89153941|NCT04032366||PEEP 10|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, without inhaled nitric oxide
89153942|NCT04032366||PEEP 10 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 10cm H2O, with inhaled nitric oxide
89153943|NCT04032366||PEEP 5 +iNO|post-surgical type A acute aortic dissection patients was ventilated with a PEEP of 5cm H2O, with inhaled nitric oxide
89153944|NCT02796599|Experimental|CWLT with facial mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
89153945|NCT02796599|Experimental|CWLT with nasal mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
89153946|NCT00964093|No Intervention|No intervention|
89153947|NCT02537600|Experimental|Cobimetinib + Vemurafenib combination|"Every patients will be treated with :~Vemurafenib 1920 mg / day from day 1 to day 28 continuously Cobimetinib 60 mg / day from day 1 to day 21 One cycle = 28 days Intervention = Cobimetinib + Vemurafenib combination treatment. Only one arm."
89153948|NCT02796443||Early laparoscopic cholecystectomy (ELC)|Operation within 72 hours after onset of symptoms
89153949|NCT02796443||Intermediate cholecystectomy (ILC)|Operation within 14 days after onset of symptoms
89153950|NCT02796443||Delayed LC (DLC)|Operation after 6-12 weeks
89153951|NCT02796443||Elective laparoscopic cholecystectomy|Biliary colic with no acute cholecystitis
89153952|NCT00657462|Experimental|A|Receives the intervention (reminders displayed at the startup of the application) for both periods (period 1 and period 2) of the study.
89153953|NCT00657462|Active Comparator|B|Receives the intervention (reminders displayed at the application startup) only during the second period (period 2) of the study.
89153954|NCT00911196||Group A|
89153955|NCT02794961|Experimental|CD22 CAR-T|Enrolled patients will receive three escalating doses of autologous CAR-T.
89153956|NCT00684099|Experimental|1|
89153957|NCT02796365|Experimental|Exercise|Patients will participate in a 10 week outpatient cardiac rehabilitation program. Exercise will consist of 3 days per week of interval training on a treadmill or bike at an intensity between 50-90% of heart rate reserve. Additionally patients will perform resistance exercises 1-2 days per week and attend 8 nutrition and lifestyle classes.
89153958|NCT02796365|No Intervention|Usual care|Control group will not be instructed on exercise, but encouraged to follow standard medical advice.
89153959|NCT04235075|Experimental|Pregnancy volunteer subjects|Subjects who will agree to participate in the study will be pregnant women referred to the Grenoble Alpes University Hospital for expert fetal cardiac ultrasound examination who have not revealed any abnormalities.
89153960|NCT00684333|Experimental|group 1|volunteers
89153961|NCT04159896|Experimental|Treatment (ESK981, nivolumab)|Patients receive ESK981 PO QD for 5 consecutive days per week, followed by a 2-day break. Patients also receive nivolumab IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89153962|NCT00546715|Active Comparator|Dose Panel A|"Daclatasvir - 1 mg~Placebo - 0 mg"
89153963|NCT00546715|Active Comparator|Dose Panel B|"Daclatasvir - 10 mg~Placebo - 0 mg"
89153964|NCT00546715|Active Comparator|Dose Panel C|"Daclatasvir - 100 mg~Placebo - 0 mg"
89153965|NCT00546715|Active Comparator|Dose Panel D|"Daclatasvir - 0.5 - 200 mg (to be determined)~Placebo - 0 mg"
89153966|NCT02816489|Experimental|Group I|"will be treated using passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA).~Intervention: Device: passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA)."
89153967|NCT02816489|Experimental|Group II|"will be treated using conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA).~Intervention: Device: conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA)."
89153968|NCT02675660|Experimental|L-Homoarginine|125 mg of L-homoarginine
89153969|NCT02675660|Placebo Comparator|Placebo|placebo capsules
89153970|NCT04031391|Experimental|physical activity group|
89153971|NCT04031391|No Intervention|Control group|
89153972|NCT02635464|Experimental|hUC-MSCs+Injectable collagen scaffold+CABG|
89153973|NCT02635464|Active Comparator|hUC-MSCs+CABG|
89153974|NCT02635464|Active Comparator|CABG|
89153975|NCT00690261||lung cancer|patients diagnosed of lung cancer with malignant pleural effusions
89153976|NCT02675582|Placebo Comparator|Control|Mix 1 flavored still beverage
89153977|NCT02675582|Experimental|Herbal beverage 1|Mix 2 flavored still beverage with a botanical extract(1)
89153978|NCT02675582|Experimental|Herbal Beverage 2|Mix 3 flavored still beverage with a botanical extract(2)
89153979|NCT02675582|Experimental|Combined Herbal Beverage|Mix 4 flavored still beverage with 2 botanical extracts (1,2)
89153980|NCT02635308|Experimental|Experimental|"High-Intensity, Unilaterally-Biased Resistance training 3x/wk x 12wk MOVE"
89153981|NCT02796521|Other|control group|The control group will receive usual dietary counseling for enrichment.
89153982|NCT02796521|Other|workshop group|The workshop group will have informations about interest of foods. They will enrich a meal with foods which can easily be added without cooking.
89153983|NCT02625597|Experimental|Dental Materials|
89234907|NCT05887908|Experimental|co-administration of aztreonam and nacubactam|co-administration of 2 g aztreonam and 1 g nacubactam q8h (60 min. infusion)
89153984|NCT02635074|Experimental|Treatment (ibrutinib, idarubicin, cytarabine)|"INDUCTION: Ibrutinib daily on days 1 to 21, idarubicin intravenously (IV) over 15 minutes on days 1 to 3 and cytarabine IV continuously on days 1 to 4.~CONSOLIDATION: Patients achieving CR or CRi may receive ibrutinib daily on days 1 to 21, idarubicin IV over 15 minutes on days 1 to 2 and cytarabine IV continuously on days 1 to 3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients maintaining a CR/CRi may receive ibrutinib daily on days 1 to 28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
89153985|NCT02796287|Experimental|Patients with Ictus amnesic|Patients admitted in the hospital as part of their medical care with amnesic Ictus episode
89153986|NCT02537366|Placebo Comparator|Placebo|Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.07 ml/kg/h Adaptation to sedation status by changing infusion speed of 0.02 ml/kg/h every 30 minutes up to 0.14 ml/kg/h Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
89153987|NCT02537366|Experimental|DEX|Dexmedetomidine diluted to 10 µg/ml in Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.7 µg/kg/h (= 0.07 ml/kg/h) Adaptation to sedation status by changing infusion speed of 0.2 µg/kg/h (= 0.02 ml/kg/h) every 30 minutes up to 1.4 µg/kg/h (= 0.14 ml/kg/h) Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
89153988|NCT02796131|Experimental|30 mg bid|30 mg of RDX5791 administered twice daily PO (60 mg total dose/day).
89153989|NCT02796131|Experimental|30 mg tid|30 mg of RDX5791 administered three times daily PO (90 mg total dose/day).
89153990|NCT02796131|Experimental|60 mg bid|60 mg of RDX5791 administered two times daily (120 mg total dose/day).
89153991|NCT02796131|Experimental|15 mg bid|15 mg of RDX5791 administered two times daily (30 mg total dose/day).
89153992|NCT02796131|Experimental|30 mg QD|30 mg of RDX5791 administered once daily (30 mg total dose/day).
89153993|NCT02796131|Experimental|Escalating dose bid|15 mg or 30 mg or 45 mg of RDX5791 administered two times daily (30, 60, or 90 mg total dose/day respectively). The stopping criteria for the dose escalation is based on Bristol Stool Score and AEs.
89153994|NCT02796131|Experimental|30 mg bid with psyllium|30 mg of RDX5791 administered two times daily (60 mg total dose/day) with psyllium taken up to three times per day (maximum of 15 g psyllium/day).
89153995|NCT00690417|Placebo Comparator|1|
89153996|NCT00690417|Active Comparator|2. 2500 IU vitamin D in a food preparation|Daily ingestion of 2500 IU vitamin D in a food preparation.
89153997|NCT04058184||Contact sports players|Athletes who engage in contact sports, football for example. Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
89153998|NCT04058184||Non-contact sports players|Athletes who engage in non-contact sports, swimming for example.Participation in this study will involve listening to sudden, very brief bursts of noise (startle blocks) and tones, and responding with a keypress to certain tones. Electromyogram (EMG) will measure the electrical activity generated from movement of the orbicularis oculi muscle during the startle blocks.
89153999|NCT00690651|Active Comparator|2|this group will rest in bed with operated leg well elevated for 48 hour and then mobilize with physiotherapist with aim for discharge home when safe.
89154000|NCT00690651|Experimental|1|mobilize with physiotherapist within 24 hours of surgical fixation of fractured ankle
89154001|NCT05434559||Study cohort|People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 in the two participating sensors
89154002|NCT02635152|Experimental|Interpretation Bias Modification (IBM)|"Treatment consists of eight brief sessions. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive positive or negative feedback based on their response."
89154003|NCT02635152|Active Comparator|Progressive Muscle Relaxation (PMR)|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups.
89154004|NCT00690729|Experimental|1|Bibliotherapy - cognitive behavior therapy focusing on exposure and response prevention directed by the family
89154005|NCT00690729|Active Comparator|2|Cognitive Behavioral Therapy - therapist-directed exposure response prevention over a 12-week period
89154006|NCT02796053|Placebo Comparator|Placebo|Placebo to TAB08
89154007|NCT02796053|Experimental|TAB08 Dose 1|Drug: TAB08 biologic
89154008|NCT02671838|Other|Musculoskeletal ultrasound program|Participants will receive the musculoskeletal ultrasound program
89154009|NCT02671838|No Intervention|Control|Participants will not be receiving the musculoskeletal ultrasound program.
89154010|NCT00655278|Experimental|1|T2000 at 600-1000 mg daily
89154011|NCT00690807|Experimental|1|PH-10 treatment
89154012|NCT04179656|Experimental|Pyrotinib Treatment|This arm for HER2-postive solid tumor
89154013|NCT04237805|Experimental|SAF-189s|The phase I dose study will enrol patients with advanced malignant solid tumors that are ALK-positive, and the phase II study will be divided into two parts, Part I Some patients with ALK/ROS1 positive advanced non-small cell lung cancer were enrolled in the 210m,80mg,120mg and 160mg dose groups for safety evaluation.In the second part, two cohorts will be included and 110 ROS1 patients will be enrolled. Except for the PK induction period, all patients will receive oral administration of SAF189s once a day for a continuous period of 21 days.
89154014|NCT02634918||Ultrasound|3 groups of hemophilia patients - Those with > 20 bleeds into a joint, those with < 2 bleeds into a joint and those with no bleeds into a joint will be enrolled into the study
89234908|NCT05887908|Active Comparator|imipenem/cilastatin|combination of 1 g imipenem/1 g cilastatin q8h (60 min. infusion)
89154015|NCT02634918||those with < 2 bleeds into a joint and|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
89154016|NCT02634918||those with no bleeds into a joint will be enrolled into the st|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
89154017|NCT00874029|Experimental|Halt Procedure|In this single-arm study, subjects who have symptomatic uterine fibroids will have the Halt Procedure in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.
89154018|NCT02675348|Experimental|Dietary Supplement: Beef Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of beef protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
89154019|NCT02675348|Experimental|Dietary Supplement: Whey Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of whey protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
89154020|NCT02675348|Active Comparator|Dietary Supplement: CHO|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of maltodextrin powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
89154021|NCT02675036|Experimental|Primary canine tooth|Extraction of primary canine tooth
89154022|NCT02675036|Experimental|Primary canine and primary molar teeth|Extraction of primary canine and primary first molar teeth
89154023|NCT00546637|Experimental|Fesoterodine 4mg or 8mg|
89154024|NCT00546637|Placebo Comparator|Placebo|
89154025|NCT04162236||High Risk of Preeclampsia|"Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they meet the following criteria:~1)High risk for preeclampsia according to first trimester screening (maternal risk factors, blood preassure, PPAP-A, mean pulsatility index (PIm) of the uterine arteries (UtA) at 11.0 to 13.6 weeks of gestation (n=280).~Women in this group will be subdivided in cases and controls according to the later development of preeclampsia:~cases: women developing PE (estimated n=40)~controls: women not developing PE (estimated n=240)"
89154026|NCT04162236||Patients with Preeclampsia|Women with a singleton pregnancies attending for prenatal care in the maternal and fetal Medicine Unit will be asked to participate if they develop PE. Inclusion criteria: Patients presented with clinical signs and symptoms of preeclampsia (N=60).
89154027|NCT04162236||Control group|Healthy pregnant women with at low risk PE screening at 11.0 to 13.6 weeks of gestation (n=100).
89154028|NCT03841253|Experimental|Observation Phase|A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.
89154029|NCT03841253|Experimental|Treatment Phase|If the transition criteria are met during the observational phase, the treatment phase will be initiated. A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser, including a refractive component according to the values determined using the EpiMaster application software.
89154030|NCT00690885|Experimental|1|lozenges containing 150 IU of natural human interferon-alpha
89154031|NCT00690885|Placebo Comparator|2|matching placebo lozenges
89154032|NCT00643526|Experimental|Injection Site: First Thigh Then Abdomen|Participants will self inject subcutaneously placebo using auto injector at thigh followed by self injection of placebo subcutaneously at abdomen on Day 1.
89154033|NCT00643526|Experimental|Injection Site: First Abdomen then Thigh|Participants will self inject subcutaneously placebo using auto injector at abdomen followed by self injection of placebo subcutaneously at thigh on Day 1.
89154034|NCT04159584|Experimental|Enrolled Subject|All subjects will undergo the medical music intervention.
89154035|NCT04138563||Case|Participants with a pack year history of more than 10 pack years, diagnosed with COPD who have FEV1/FVC ratio of less than 0.7 AND FEV1 predicted value less than or equal to 60%.
89154036|NCT04138563||Control|Participants without a diagnosis of COPD who have a smoking history of more than 10 pack years
89154037|NCT00910130||End Stage Renal Disease|Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes
89154038|NCT00910130||Control|"Healthy people, with normal Renal Function and without Diabetes, matched with ESRD group for age, gender, BMI"
89154039|NCT00657696||Group 1|Physicians and staff in VA non-contract primary care outpatient clinics and patients seen in last 12 months in the same clinics
89154040|NCT00657696||Group 2|Patients seen in last 12 months in Group 1 clinics
89154041|NCT04234685|Experimental|HIPL Therapy™ group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).~The HIPL Therapy™ group will receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks. Participants will lay in a relaxed position on a therapy plinth with the light applied using the Invitalizer 2.0. The phototherapy will illuminate the affected knee for 20 minutes. In the case of bilateral knee OA, the treatment time will be doubled and applied to both knees. The knee will be positioned at a determined distance from the lamp with an intensity setting of 150 mW/cm2."
89234909|NCT05887869|Experimental|Telehealth solution|Telehealth solution offered
89234910|NCT05887869|No Intervention|Usual care|Control
89234911|NCT05887778|Active Comparator|placebo injection|5ml of 0,9% sodium chloride - before the popliteal nerve block
89234912|NCT05887778|Active Comparator|0,1mg/kg Dexamethasone|0,1mg/kg dexamethasone sodium phosphate - before the popliteal nerve block
89154042|NCT04234685|Placebo Comparator|Placebo Control group|"All participants from both groups will take part in a standardized education and exercise intervention as suggested by best evidence. These sessions will be 20-30 minutes in length and will take place twice weekly for four weeks (8 sessions).~The placebo control group will also receive phototherapy in addition to the education and exercise intervention twice weekly for four weeks, in the same setting as the HIPL Therapy™ group and for the same duration. However, the intensity setting will be set at 5 mW/cm2, a dosage, at which there is no therapeutic benefit expected, but the light will still be visible to the participant."
89154043|NCT02674724|Experimental|Gym Group|With gym equipments, twice per week for 12 weeks.
89154044|NCT02674724|Active Comparator|Free Weights Group|With dumbbells, elastics, twice per week for 12 weeks.
89154045|NCT02674724|Placebo Comparator|Control Group|The control group will be instructed to perform stretching exercises at home in the same 12-week period, according to an illustrated booklet.
89154046|NCT02634840|Experimental|Surgical intervention|"Patients receiving our modified bilateral sagittal split osteotomy procedure during orthognathic surgery, intervention arm in prospective cohort study"
89154047|NCT04138719|Experimental|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
89154048|NCT04138719|Active Comparator|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles；
89154049|NCT02674646|Experimental|Group A: Verum Acupuncture|Group A: Verum Acupuncture (Needle Acupuncture) Needlepoints Bilateral PC 6, S 36, L 8, L 9 Unilateral R4, R 6 Acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
89154050|NCT02674646|Sham Comparator|Group B: Sham Acupuncture|Group B: Sham Acupuncture (Needle Acupuncture) Needlepoints 8 needles in the medioaxillary line below the 6th rib, bilateral 2 needles unilateral Sham-acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
89154051|NCT04162158|Experimental|Targeted drug combined with allogeneic NK cell treatment group|In addition to traditional symptomatic supportive treatment, Sorafenib, regolfinib or levabinib will be administered in combination with allogeneic NK cells (3 cycles).
89154052|NCT04162158|No Intervention|Targeted drug treatment group|Sorafenib, regolfinib or levabinib will be administered in addition to traditional symptomatic supportive care.
89154053|NCT04138407|Experimental|Intervention|
89154054|NCT04138407|Other|Control|Usual rehabilitation exercise
89154055|NCT02790203|Experimental|Celecoxib|"Celecoxib will be given orally to patients participating in the study and allocated to the treatment group, for an intervention period of 6 days, starting from the day of surgery.~Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses, a dose which is within the recommended and a widely used dosage and is expected to induce a significant inhibition of prostaglandin synthesis by the COX2 pathway. Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses."
89154056|NCT02790203|Placebo Comparator|Placebo|"Placebo will be given orally to patients participating in the study and allocated to the control group that will receive placebo, for an intervention period of 6 days, starting from the day of surgery.~Placebo will be given throughout the intervention period of the study orally in capsules that resemble the drug, twice a day."
89154057|NCT04138329|Active Comparator|Lichtenstein Technique|In this arm the inguinal hernia repair was made with the Lichtenstein technique by surgeons with experience in this kind of plasty using the conventional polypropylene mesh.
89154058|NCT04138329|Experimental|Onstep Technique|In this arm the inguinal hernia repair was made with the Onstep technique by one surgeon with experience using the Bard's 3DMAX mesh.
89154059|NCT02790125|Experimental|Dose Panel 1|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
89154060|NCT02790125|Experimental|Dose Panel 2|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
89154061|NCT02790125|Experimental|Dose Panel 3|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
89154062|NCT02790125|Experimental|Dose Panel 4|"BMS-986166 or Placebo matching BMS-986166~Multiple ascending solid dose formulation as specified"
89154063|NCT02790125|Experimental|Dose Panel 5a/b/c|"BMS-986166~Single oral solid dose formulation under fasting/fed/fasting with famotidine conditions"
89154064|NCT04179344||Integrated e-healthcare services (IeHS) web-based app|This usability study is conducted under 3 steps: IeHS simulation, user experience survey using SUS questionnaire, and qualitative study through the in-depth interview.
89154065|NCT00656760|Experimental|A|All patients have PET/CT and biopsies with the surgeon blinded to the result of PET/CT. Additional biopsies are performed (or not) after the surgeon has the PET/CT results revealed.
89154066|NCT00691041|Experimental|1|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
89154067|NCT00691041|No Intervention|2|HIV/STI counseling and testing and a single 15 minute session of resources available in the community
89154068|NCT02816567|Experimental|NMBA group|
89154069|NCT02816567|Placebo Comparator|placebo group|
89154070|NCT04162314|Experimental|Experimental|This group received combination of mycelium extract of Ganoderma lucidum capsule containing 180 mg Beta-1,3/1,6-D-Glucan with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
89154071|NCT04162314|Placebo Comparator|Control|This group received combination of placebo capsules with 3x1 dosage and methylprednisolone (0.8 mg/kgBW) 1x1 for 90 days
89154072|NCT02674802||Retrospective study|People who has successfully eradicated helicobacter pylori more than six months detected helicobacter pylori by the C-urea breath test in order to evaluate the reinfection.
89154073|NCT02674802||Prospective study|People who has infected helicobacter pylori received regular eradication therapy after the 4 weeks, 8 weeks and 6 months detected helicobacter pylori by the C-urea breath test in order to prospect the reinfection .
89154074|NCT00691119|Experimental|A|Relaxation and Visualization Therapy group
89154075|NCT00691119|Active Comparator|B|Health education group
89154076|NCT00691119|No Intervention|C|Control group
89154077|NCT04234763|Experimental|T2D patients|T2D patients (n=24) will be randomized to high GI and low GI MCT randomly.
89154078|NCT04234763|Active Comparator|Healthy individuals|Healthy individuals (n=24) will be randomized to high GI MCT only.
89154079|NCT00657774|Experimental|1|FlutiForm 250/10 ug
89154080|NCT00657774|Experimental|2|FlutiForm 100/10 ug
89154081|NCT00657774|Active Comparator|3|Oral Prednisone 10 mg
89154082|NCT00657774|Placebo Comparator|4|Placebo inhaler and/or placebo tablets
89154083|NCT02674880|Experimental|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
89154084|NCT02674880|Placebo Comparator|Placebo|5 ml of saline via nebulizer b.i.d.
89154085|NCT04138485|Experimental|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
89154086|NCT04138485|Placebo Comparator|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
89154087|NCT02789969|Experimental|Hydromorphone 15mcg/kg IV|Patient randomly assigned to hydromorphone
89154088|NCT02789969|Experimental|Fentanyl 1.5 mcg/kg IV|Patient randomly assigned to fentanyl
88804529|NCT04466852|Active Comparator|cardio-relay Family Clinic|Patients discharged from a Rio de Janeiro municipality hospital and identified as belonging to a Family Clinic randomized to cardio-share receive instruction for telemedicine consultations. These are based on their own devices, when available, or provided by their local community agents associated in the study.
89154089|NCT05407766|Experimental|100M of OSSM-001|Single injection of mesenchymal stem cells at dose of 100M
89154090|NCT05407766|Experimental|300M of OSSM-001|Single injection of mesenchymal stem cells at dose of 300M
89154091|NCT05407766|Placebo Comparator|Placebo|Single injection of normal saline
89154092|NCT04159116|Experimental|Suctioned Prior to Endoscope|This group will be suctioned prophylactically after sedation but prior to introduction of endoscope.
89154093|NCT04159116|Other|Standard of Care|This group will be suctioned by anesthesia providers when clinically indicated by copious secretions, coughing, choking or desaturation.
89154094|NCT04009993|Experimental|A-BIRTHPERFORM digital tool|interactive partogram that maternity care professionals of the experimental group use, in interactive and device will guide the professional thought the NICE guidelines on labour care
89154095|NCT04009993|No Intervention|control group with conventional partogram use|Conventional care in each participant hospital, with conventional partogram in each centre
89154096|NCT04178330|Experimental|Group A|patients with multiple brain metastases (no less than 3 lesions) ,who have not recived whole brain radiotheray (WBRT).
89154097|NCT02790047|Active Comparator|Home-base exercise|"Patients will receive intervention as following~A home-base exercise program~Health education~Breathing strategies for self secretion clearance~The medication following the COPD GOLD guidelines (2015)"
89154098|NCT02790047|Experimental|Home-base exercise with a PEP mask|"Patients will receive intervention as following~A home-base exercise program with using a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise~Health education~Breathing strategies for self secretion clearance~The medication following the COPD GOLD guidelines (2015)"
89154099|NCT00657852|Experimental|Pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
89154100|NCT00657852|Placebo Comparator|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
89154101|NCT02673164|Active Comparator|CSCC_ASC|Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASC)
89154102|NCT02673164|Placebo Comparator|Placebo|Saline
89154103|NCT00691275|Placebo Comparator|2|Saline
89154104|NCT00691275|Active Comparator|1|Zofran
89154105|NCT02794415|Other|Community-based exercise|
89154106|NCT00657930||A|
89154107|NCT04178486|Experimental|Amnesia|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions to experience amnesia for the food pictures they had just seen.
89154108|NCT04178486|Experimental|Cognitive Rehearsal|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a future where they will control their eating behaviors.
89154109|NCT04178486|Experimental|Memory Substitution|Hypnosis formed from hypnotic induction (an adapted version from Barber Suggestibility Scale) together with hypnotic suggestions about a past where they have always controlled their eating behaviors.
89154110|NCT04178486|Placebo Comparator|Control|Hypnosis formed from only hypnotic induction (an adapted version from Barber Suggestibility Scale).
89154111|NCT02789891|Experimental|D2 Lymphadenectomy including No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy including No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
89154112|NCT02789891|Active Comparator|D2 lymphadenectomy excluding No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
89154113|NCT00655434||SAA|Sexually Active Adults- Intercourse in the last twelve months with at least one sexual partner. Subjects must be ≥ 18 years old. No more than 60% of one gender.
89154114|NCT02673242|No Intervention|Control|No treatment other than medical
89154115|NCT02673242|Experimental|Intervention|Inspiratory muscle training
89154116|NCT02632734|Experimental|CoreBone Cone device|Experimental: CoreBone Cone device After extraction intervention will include the placement of CoreBone Cone device derived from coral that its dimensions is 4-5mm width and 8-10mm height. One cone for each extraction socket.Its advantage is that it fits well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month. We predict that CoreBone Cones are more effective than particulate device.
89154117|NCT02632734|Experimental|CoreBone 500 device|After extraction intervention will include the placement of CoreBone500 device derived from coral that is particulate. 0.3-0.5cc for each extraction socket.Its advantage is that it fills well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month.
89234913|NCT05887778|Active Comparator|0,2 mg/kg Dexamethasone|0,2 mg/kg dexamethasone sodium phosphate - before the popliteal nerve block
89154118|NCT04233983|Active Comparator|Study Group|The study group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will undergo laparoscopic endometriosis surgery after ICSI procedure with freezing all embryos. The patients will wait about 6 months for spontaneous conception, if there is no pregnancy during this period, frozen embryo transfer will be performed.
89154119|NCT04233983|No Intervention|Control Group|The control group consists of ERROR(endometrioma related reduction in ovarian reserve) patients who will be performed IVF&ICSI procedure with fresh embryo transfer without surgery. If there is no pregnancy, patients will be operated then.
89154120|NCT02673086|Active Comparator|coracoid approach|Patients in this group will be randomized to receive an coracoid approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
89154121|NCT02673086|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
89154122|NCT00655512|Active Comparator|1|
89154123|NCT00655512|Active Comparator|2|
89154124|NCT00655512|Active Comparator|3|
89154125|NCT00655512|Active Comparator|4|
89154126|NCT00655512|Placebo Comparator|5|
89154127|NCT02816177|Experimental|Telemedicine|Usual care and telemedicine consultations during12 months.
89154128|NCT02816177|Active Comparator|Usual care alone|Usual care during12 months.
89154129|NCT04138095|Other|Virtual Reality|As this is a within subject design, participants will act as their own control. Participants will have access to their baseline opioids and benzodiazepines for pain and anxiety. Every second day they will have access to virtual reality as an adjunct to their opioids and benzodiazepines to manage their symptoms
89154130|NCT00644306|Placebo Comparator|A|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
89154131|NCT00644306|Active Comparator|B|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
89154132|NCT04234841||Surgical Aortic Valve Replacement (SAVR)|This cohort includes patients who will be undergoing surgical aortic valve replacement
89154133|NCT04234841||Transcatheter Aortic Valve Implantation (TAVI)|This cohort includes patients who will be undergoing Transcatheter Aortic Valve Implantation
89154134|NCT02634528|Experimental|Julphar Insulin N|Julphar Insulin N, human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
89154135|NCT02634528|Active Comparator|Huminsulin® Basal|Huminsulin® Basal, neutral protamine hagedorn (NPH), human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
89154136|NCT02672774|Other|Gastric cancer|Consecutive patients with gastric cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
89154137|NCT02672774|Other|Colorectal cancer|Consecutive patients with colorectal cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
89154138|NCT02625285||G6PD Deficient Volunteers|"Subjects with age ≥ 18 years~Male and female~Previously tested G6PD deficient at SMRU clinic"
89154139|NCT02625285||G6PD Intermediate or Heterozygous Volunteers|"Subjects with age ≥ 18 years~Female~Previously tested G6PD intermediate or heterozygous for G6PD variants at SMRU clinic"
89154140|NCT02625285||G6PD-Normal Volunteers|"Subjects with age ≥ 18 years~Male and female~Previously tested G6PD normal at SMRU clinic"
89154141|NCT02794649||healthy|Individuals without a history of kidney or bowel disease
89154142|NCT02794649||primary hyperoxaluria|Patients diagnosed with type I PH by genetic testing
89154143|NCT02794649||enteric hyperoxaluria|Patients with Roux-en-Y-gastric-bypass.
89154144|NCT02794649||calcium oxalate stone formers|History of passing or having surgically removed a calcium oxalate kidney stone within 5 years of recruitment.
89154145|NCT00656838|Active Comparator|1|Patient has had PCP contact (letter, phone call, office visit, educational materials).
89154146|NCT00656838|No Intervention|2|Usual Care
89154147|NCT02673008|Experimental|MRD-directed DLI|For patients with MRD+ and without grade II/>II aGVHD by day +60 post-transplantation, DLI was given once by day +60 and was then administered based on MRD and GVHD status. If patients were MRD negative, DLI was not given again; if patients were MRD positive and without GVHD, DLI was given monthly until GVHD occurred or MRD became negative or for a total of four times. For patients with NR or PR pre-transplantation and with MRD negative by day +60 post-transplantation, DLI was given once by day +90 regardless of MRD, and was then administered when MRD became positive. For patients with CR pre-transplantation and with MRD negative post-transplantation, DLI was not given unless MRD became positive.
89154148|NCT02794493|Experimental|Arm I|Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.
89154149|NCT02794493|Placebo Comparator|Arm II|Patients receive placebo by soaking their affected hand and feet 20 min twice daily.
89154150|NCT04162002|Experimental|Restylane® Lyft Filler Injection|
89154151|NCT02625363|Experimental|Glucose Ref - Std|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
89154152|NCT02625363|Experimental|Glucose Ref and 450 ml water|250 ml glucose solution with 50 gram available carbohydrate per serving. Sample was consumed with additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
89154153|NCT02625363|Experimental|White Bread with 250 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption
89154154|NCT02625363|Experimental|White Bread and 700 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption. Moreover, subjects given additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
89154155|NCT02625363|Experimental|White Bread with 125 ml water (twice)|Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes
89234914|NCT05887674|Experimental|Multi-domain intervention group|Patients in this arm will receive multi-domain life-style intervention including low inflammatory-index diet, exercise, and cognitive training.
89154156|NCT02816411|Experimental|Protein|Milk protein isolate supplementation: orally, 20g of protein immediately post-exercise and then 20g every 3h on 3 occasions (+3, +6, +9), on the exercise day. The remaining 8 days, 20g daily with breakfast.
89154157|NCT02816411|Active Comparator|Placebo|Placebo administration: orally 500 ml, immediately post-exercise as well as at +3, +6 and +9 hours, on the exercise day. The remaining 8 days, 500 ml daily with breakfast.
89154158|NCT00655590|Experimental|Arm 1|
89154159|NCT00655590|Active Comparator|Arm 2|
89154160|NCT00655590|Placebo Comparator|Arm 3|
89154161|NCT02625129||Pharmacist-provided travel care|
89154162|NCT02672696|Experimental|FluoroMap group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).~In this group, the surgeon will use the FluoroMap 3D reconstruction system (Stryker Inc) with the standard fluoroscopy to help him place the cephalic screw in the femoral head."
89154163|NCT02672696|No Intervention|Test group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).~In this group, the surgeon will use only the standard fluoroscopy to help him visualize the position of the cephalic screw in the femoral head."
89154164|NCT02634372|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
89154165|NCT02634372|Active Comparator|Supportive therapy|Supportive therapy: 20 individual sessions 60 minutes each for 6 months.
89154166|NCT00691587|Experimental|1|Low-dose KB001, a monoclonal antibody
89154167|NCT00691587|Experimental|2|High-dose KB001, a monoclonal antibody
89154168|NCT00691587|Placebo Comparator|3|Placebo
89154169|NCT00643838|Experimental|A|Misture of 50% nitrous oxide and 50% oxygen
89154170|NCT02794025|Experimental|esmolol group|patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.
89154171|NCT02794025|Sham Comparator|control group|Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
89154172|NCT00546481|Experimental|Correction Phase: CERA|
89154173|NCT00546481|Active Comparator|Correction Phase: Epoetin Beta|
89154174|NCT04016480|Active Comparator|High Flow Nasal Cannula|High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.
89154175|NCT04016480|Active Comparator|Conventional Oxygen Therapy|Conventional oxygen therapy will be administered through common nasal cannula with a flow up to 6 Liters per minute
89154176|NCT04233905||mute children|mute children and their mothers
89154177|NCT04233905||healthy children|healthy children control group
89154178|NCT04233905||mute adults|formerly mute adults
89154179|NCT04233905||healthy adults|healthy adults control group
89154180|NCT00691743||1|Primary care
89154181|NCT02535624|Active Comparator|ANGIO|Patients with persistent hemodynamic instability (systolic blood pressure (SBP) <90 mmHg after the transfusion of 4 packed red blood cell (PRBC) units in the emergency department) were taken urgently to the angiography suite for pelvic angiography. These patients had to tolerate transfer to the suite. Patients receiving primarily angioembolization therapy were defined as the ANGIO group.
89154182|NCT02535624|Active Comparator|PACKING|Indication for pelvic packing was persistent SBP<90 mmHg during the initial resuscitation period with 3000 ml of intravenous (IV) crystalloids and transfusion of 4 PRBC units. These patients were treated primarly with retroperitoneal packing, while angioembolization OR staff was unavailable (5pm-7am), and were defined as the PACK group.
89154183|NCT04093856||Diabetic|20 men and women with type 2 diabetes and obesity
89154184|NCT04093856||Non-diabetic|20 normoglycemic men and women with obesity matched for age and sex with diabetic group
89154185|NCT02789813|Experimental|Valproic Acid and fear reactivation|This group will receive once a combination of 500mg Valproic Acid (oral solution) and fear reactivation before exposure therapy.
89154186|NCT02789813|Active Comparator|Valproic Acid and no fear reactivation|This group will receive once 500mg Valproic Acid (oral solution) before exposure therapy.
89154187|NCT02789813|Placebo Comparator|Placebo and fear reactivation|This group will receive once a combination of Placebo (oral solution) and fear reactivation before exposure therapy.
89154188|NCT02789813|Placebo Comparator|Placebo and no fear reactivation|This group will receive once Placebo (oral solution) before exposure therapy.
89154189|NCT05350735|Experimental|Intervention arm: SMS text reminders and medical card|Participants in this intervention arm will receive the routine medical card indicating return date for the subsequent doses of anti-rabies vaccine and SMS reminders sent a day before each dose until the scheduled date of the last dose of anti-rabies vaccine.
89154190|NCT05350735|No Intervention|Control arm: Medical card|Participants in the control arm will receive the routine medical card indicating return date for the subsequent doses of anti-rabies vaccine. No SMS text reminders will be sent to this group.
89154191|NCT04137861|Active Comparator|Mineral Trioxide Aggregate (MTA)|Root repair material
89154192|NCT04137861|Experimental|bioceramics|Root repair material
89154193|NCT00958867|Experimental|1|Six-month, twice-weekly aerobic training (AT) program
89154194|NCT00958867|Experimental|2|Six-month, twice-weekly resistance training (RT) program
89154195|NCT00958867|Active Comparator|3|Six-month, twice-weekly stretch & relax (S & R; control) program
89154196|NCT04179188||Bariatric OSA Group|Bariatric surgery plannified intervention patient with obstructive sleep Apnéa
89154197|NCT04179188||Bariatric without OSA Group|Bariatric surgery plannified intervention patient without obstructive sleep Apnéa
89154198|NCT03780257|Experimental|QR-421a|Single dose administration
89154199|NCT03780257|Sham Comparator|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
89154200|NCT00691821|Active Comparator|1|Standard Dressings
89154201|NCT00691821|Experimental|2|Negative Pressure Wound Therapy
89154202|NCT02632578||HIV-positive|
89154203|NCT02632578||HIV-negative|
89154204|NCT04138251|Experimental|Treatment|Oral empaglifozin 5 mg 1x/day, increase up to 10 mg 1x/day if no 25% decrease of blood1,5-anhydroglucitol level
89234915|NCT05887674|Experimental|Exercise and cognitive training|Patients in this arm will receive the intervention of exercise and cognitive training.
89154205|NCT04176926||Group 1: SR|Group 1: Subjects in the sinus rhythm (SR) cohort should not have any history of atrial fibrillation and should not be in atrial fibrillation or other atrial arrhythmia at the time of enrollment based on the screening ECG.
89154206|NCT04176926||Group 2: AF|Group 2: Subjects in the atrial fibrillation (AF) cohort must have a known history of AF and must be in AF at the time of enrollment based on the screening ECG.
89154207|NCT02816333||Type B aortic dissection|Patients with Type B aortic dissection requiring TEVAR
89154208|NCT02632500|Experimental|30 compressions and 2 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 30 compressions and 2 seconds of pause protocol (30 chest compressions followed by 2 seconds of pause) on a manikin connected to the Personal Computer."
88804530|NCT04466852|No Intervention|control Family Clinic|Patients discharged from a Rio de Janeiro municipality hospital and identified as belonging to a Family Clinic randomized to the control group or belonging who consent to participate in follow-up
89154209|NCT02632500|Experimental|50 compressions and 5 seconds of pauses|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 50 compressions and 5 seconds of pause protocol (50 chest compressions followed by 5 seconds of pause) on a manikin connected to the Personal Computer."
89154210|NCT02632500|Experimental|100 compressions and 10 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 100 compressions and 10 seconds of pause protocol (100 chest compressions followed by 10 seconds of pause) on a manikin connected to the Personal Computer."
89154211|NCT02632500|Experimental|hands-only|"After the randomization the participant will be asked to perform 8 minutes of CPR following the hands-only protocol (continuous chest compressions without any pauses) on a manikin connected to the Personal Computer."
89154212|NCT00691899|Experimental|1|
89154213|NCT00691899|Placebo Comparator|2|
89154214|NCT00964249|Experimental|LABA|After randomization subject will inhale either 12.5 microgram or 25 microgram GW642444M once daily for 7 days.
89154215|NCT00964249|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
89154216|NCT04016246|Experimental|Propofol|"Propofol (Propofol LIPURO 1% 100mL), Pharmacologic form: 10mg/ml. Considering the birthweight of most preterm babies, Propofol will be diluted to a final concentration of 1mg/ml by the nurse.~Treatment initiation: the 1st dose will be injected following usual management of LISA procedure included the installation of the newborn and the atropine and caffeine injections and sugar solution administration Dose per administration: 0.5mg/kg per dose of Propofol. Number of administrations: Several administrations of 0.5 mg/kg are possible, according the level of sedation achieved, as evaluated by the FANS score. If the FANS score is ≥6, a new dose will be injected up to a total of two (before 28 wGA) or 3 (between 28 - 31 wGA) administrations of the drug. (See paragraph 5.3)"
89154217|NCT04016246|Placebo Comparator|medialipide|"Name of treatment for placebo: Medialipide® (B. BRAUN) Pharmacological form: 20g/100ml Medialipide 20% will be used as the placebo. This is an emulsion of medium and long triglycerides based on soya oil and having same appearance organoleptic characteristics as Propofol.~Dose per administration: Same volume as for the Propofol administration~Number of administrations: according the same protocol that for the Propofol administration.~Modalities of preparation : The same dilution procedure as Propofol lipuro 1% SPC (Summary of Product Characteristics):1 part of Medialipide 20% with 9 parts of 5% w/v glucose solution or 0.9% w/v sodium chloride solution as shown in parenteral nutrition which is in accordance with medialipide 20% SPC"
89154218|NCT00691977|Experimental|A|Radiation Therapy followed by prostatectomy
89154219|NCT00658164|Experimental|1|
89154220|NCT00958945||FloSeal - Knee - control|100 Historical Control Patients, knees - no FloSeal (retrospective)
89154221|NCT00958945||FloSeal - Knee - 5ml|100 Patients, knees - 5mL FloSeal (retrospective)
89154222|NCT00958945||FloSeal - Knee - 10ml|100 Patients, knees- 10mL FloSeal (prospective)
89154223|NCT00958945||FloSeal - Hip - Control|100 Historical Control patients, hips-no FloSeal (retrospective)
89154224|NCT00958945||FloSeal - Hip - 5ml|100 retrospective patients, hips-5mL of FloSeal (retrospective)
89154225|NCT02794259|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
89154226|NCT02794259|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
89154227|NCT02794259|Sham Comparator|Sham tDCS|Sham stimulation during resting state fMRI
89154228|NCT02624895||mCRC: Anti-EGFR MAbs + FOLFOX 1st line|• Adult (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX plus panitumumab or FOLFOX plus cetuximab as upfront treatment as per clinical practice.
89154229|NCT02624895||mCRC: Anti EGFR MAbs + FOLFIRI 1st line|Adults (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFIRI plus panitumumab or FOLFIRI plus cetuximab as upfront treatment as per clinical practice
89154230|NCT05350579|Experimental|Yogurt Intervention|Participants assigned to the yogurt group were provided with a biweekly supply of yogurt at every other visit and were directed to consume one serving daily (5-ounce, 141 grams) and to store the remaining yogurt at 40˚ F or lower until consumed. Additionally, all participants were instructed to keep a log of any yogurt consumption time and changes to bowel health. The ingredients of the yogurt include Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (L. bulgaricus, S. thermophilus), and Vanilla Extract. The intervention meets the Codex Alimentarius definition of yogurt. In addition, the yogurt lacked preservatives, added fruit or pectin, was not enriched with added prebiotics or probiotics.
89154231|NCT05350579|No Intervention|Diet Control|The control group was asked to abstain from yogurt consumption. Diet (including yogurt consumption) was monitored by weekly 24-hour dietary recalls throughout the study period.
89154232|NCT02793869||Total cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
89154233|NCT02793869||Anterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
89154234|NCT02793869||Interior cataracts group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
89154235|NCT02793869||Posterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
89154236|NCT02790359|Active Comparator|Patient group 1|Air
89154237|NCT02790359|Active Comparator|Patient group 2|Carbon dioxide
89154238|NCT02789735|Active Comparator|Device: LiteCure LCT-1000®|Treatment with 10 J/cm²
89154239|NCT02789735|Sham Comparator|Device: Sham LiteCure|Sham i.e. visible red light
89154240|NCT04233437|Experimental|CYP Cohort|MLC1501 & CYP cocktail drugs
89154241|NCT04233437|Experimental|Transporter Cohort|MLC1501 & Transporter cocktail drugs
89154242|NCT02674256|Active Comparator|CRH injection|Intervention: intravenous injection of CRH 100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together then the solution will be injected IV over the course of 1 minute
89154243|NCT02674256|Placebo Comparator|placebo injection|"Intervention: intravenous saline injection~1mL of saline will be injected intravenously over the course of 1 minute"
89154244|NCT02789501|Active Comparator|Control|Non-systemic intraluminal application of 4% citrate lock solution (CitraFlow™ 4%, MedXL, Montreal, Canada) 3 times per week after dialysis.
89154245|NCT02789501|Experimental|Test|"TauroLock™ based lock solution regimen:~Non-systemic intraluminal application of TauroLock™-Hep500, Tauropharm, Waldbüttelbrunn, Germany, 2x/week after dialysis (before short intervals) and TauroLock™-U25.000, Tauropharm, Waldbüttelbrunn, Germany, 1x/ week after dialysis (before long interval).~TauroLock™-Hep500 contains 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin.~TauroLock™-U25.000 contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase."
89154246|NCT02674022|Active Comparator|Mothers of Children with ASD|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
89154247|NCT02674022|Active Comparator|Mothers of Typically Developing Children|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
89154248|NCT04178876|Experimental|Aspiration and Sclerotherapy of endometriomas|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
89154249|NCT04178876|Active Comparator|laparoscopic stripping technique|cystectomy of endometriomas during laparoscopy
89154250|NCT02789579|Experimental|levofloxacin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 3 days before Minimally invasive upper tract lithotomy.
89154251|NCT02789579|Experimental|nitrofurantoin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 3 days before Minimally invasive upper tract lithotomy.
89154252|NCT02789579|Experimental|cefuroxime group|There are 150 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and does not receive oral antibiotics 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
89154253|NCT02789579|Experimental|levofloxacin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 7 days before Minimally invasive upper tract lithotomy.
89154254|NCT02789579|Experimental|nitrofurantoin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 7 days before Minimally invasive upper tract lithotomy.
89154255|NCT02674178|Active Comparator|Age <35|< 35 years old included 201 women who are further subdivided according o FSH/LH ratio into G1A (201 patients) with FSH/LH ratio <2 and G1B (37 patients) with FSH/LH ratio ≥2.
89154256|NCT02674178|Active Comparator|Age ≥ 35|. Group 2 ≥ 35 years old included 34 women who are further subdivided according o FSH/LH ratio into G2A (25 patients) with FSH/LH ratio <2 and G2B (9 patients) with FSH/LH ratio ≥2
89154257|NCT02793791|Experimental|Ablation|
89154258|NCT02793791|No Intervention|Observation|
89154259|NCT02672540|Experimental|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
89154260|NCT02672540|Placebo Comparator|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
89154261|NCT04233203||Faster Aspart|All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII and insulin Faster Aspart.
89154262|NCT00959101|Experimental|A|
89154263|NCT00959101|Experimental|B|
89154264|NCT00959101|Active Comparator|C|
89154265|NCT00880698|Experimental|HIV-uninfected RotaTeq|HIV-1 uninfected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
89154266|NCT00880698|Placebo Comparator|HIV-uninfected Placebo|HIV-1 uninfected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
89154267|NCT00880698|Experimental|HIV-infected RotaTeq|HIV-1 infected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
89154268|NCT00880698|Placebo Comparator|HIV-1 infected Placebo|HIV-1 infected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
89154269|NCT02672618||chronic heart failure|18-85years old,having symptoms of heart failure,New York Heart Association（NYHA） class II or above American College of Cardiology/American Heart Association（ACC/AHA） class B, C, including hypertensive heart disease, rheumatic heart disease, ischemic cardiomyopathy and idiopathic cardiomyopathy
89154270|NCT02672618||normalCardiac function|18-85years old,no symptoms of heart failure,NYHA class I or above ACC/AHA class A, including controled hypertension,stability coronary heart disease and rheumatic heart disease
89154271|NCT02672618||healthy volunteers|18-85years old,Without basic cardiovascular diseases
89154272|NCT04233359|Active Comparator|US-guided pleural biopsy and thoracentesis|"Pleural biopsy:~Using ultrasound the optimal point of entry for thoracentesis is located, and local anesthesia is obtained. The area is wiped with disinfectant and a skin incision is made with a pointed scalpel. Six US-guided biopsies of 1x2 millimetres are taken from the parietal pleura using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core Biopsy Needle 18G, Tempe, Arizona, USA). Afterward, a thoracentesis is performed in the same incision as used by the pleural biopsy. A pigtail catheter is inserted and fastened and connected to a sealed bag and fluid is aspirated and sent to relevant analysis."
89154273|NCT04233359|Experimental|LAT and thoracentesis|Local anesthetic thoracoscopy: Pre-procedure a pleural pigtail catheter is inserted and pleural fluid is removed. The catheters one-way valve is opened and the patient takes several breaths thereby creating a pneumothorax prior to procedure start. The patient is sedated with midazolam and morphine. Midaxillary access through intercostal space 4-7 is achieved in local anesthesia and via a skin incision a trocar is placed for access to the thoracic space. A semi-rigid thoracoscope (model LTF 160; Olympus, Tokyo, Japan) is inserted via the trocar and the pleural cavity is inspected after removal of residual effusion whereof at least 40ml is sent to cytology. Pleural parietal biopsies are taken under direct visual guidance. The recommended number of biopsies is 10-15. If no abnormalities were seen, random biopsies are taken. After relevant biopsies are taken the instruments are removed the pigtail catheter stays inserted to allow for removal of air and expansion of the lung.
89154274|NCT05252546|Experimental|pyrotinib alone, then pyrotinib + Montmorillonite Power or Loperamide|Sequential treatments of pyrotinib alone followed by pyrotinib + Montmorillonite Power or Loperamide, with a washout period in between.
89154275|NCT00964405|Experimental|LAMA|After randomization subject will inhale either GSK233705 50, 100 or 200 microgram once daily for 7 days.
89154276|NCT00964405|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
89154277|NCT04237961|Experimental|Upper third interference|Botox & brow lift
89154278|NCT04237961|Experimental|Middle third|Botox and fat injection
89154279|NCT04237961|Experimental|Lower third|Suspension suture
89154280|NCT00658242||I|Subjects having Craniofacial surgery
89154281|NCT00959179||Device therapy patients for CHF.|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
89154282|NCT00959179||ICD and CRT-D patients|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
89154283|NCT04177160|Experimental|SCD subjects|Patients were diagnosed with subjective cognition decline and referred by neurologists.
89154284|NCT04177160|Experimental|Healthy controls|Voluntary healthy elderly recruited from the community.
89154285|NCT02637648|Experimental|Sodium oxbate|oral administration of sodium oxybate, 6-18ml per night, starting with 6ml in two nightly dosages of 1.5g each, increased by steps of 1.5g every second or third night until treatment response
89154286|NCT02637648|Placebo Comparator|Placebo|oral administration of placebo, 6-18ml per night, starting with 6ml in two nightly dosages
89154287|NCT00964483|Experimental|DASH materials|Participant randomized to a 12-week, group-based lifestyle intervention using modified DASH materials and intervention delivery approaches to help them adopt the DASH diet. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium.
89154288|NCT00964483|Active Comparator|Delayed intervention|"The intervention participants will receive an NHLBI brochure entitled Your Guide to Lowering Blood Pressure. They will then receive the modified DASH materials and the intervention at the end of the study, following the intervention group's completion of the study."
89154289|NCT04091828||Biplar patients|diagnosed by DSM-5 and divided to manic,depressed and mixed last episod
89154290|NCT04091828||controlled subject|not have any medical or psychatric problem affect cognition
89154291|NCT02793635|Experimental|SCI Patients|"10 subjects with complete or incomplete SCI (> 1 year post-injury) with preserved LE function will be recruited.~No control group"
89154292|NCT00959257||Asthma|Asthma patients on inhaled corticosteroids
89154293|NCT00959257||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
89154294|NCT02671526|Experimental|Computerized Plasticity-based Adaptive Cognitive Training|
89154295|NCT02815865|Active Comparator|Foley catheter and pitocin|Intervention: Foley catheter and pitocin Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
89154296|NCT02815865|Active Comparator|Foley catheter and dinoprostone|Intervention: Foley catheter and dinoprostone Foley catheter will be inserted through the cervix and inflated with 80 ml saline dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
89154297|NCT02815865|Active Comparator|Dinoprostone|Intervention: Dinoprostone 3 mg will be inserted to the posterior fornix
88804531|NCT04426838|Experimental|PLwD Cognitive Behavioral Therapy for Insomnia (CBTi)|Persons living with dementia in a dyad receiving the CBTi intervention in a videoconferencing format.
89154298|NCT02673866|Experimental|DS-1971a 400 mg TID|DS-1971a 400 mg three times per day (TID)
89154299|NCT02673866|Experimental|DS1971a 400 mg BID|DS1971a 400 mg twice per day (BID)
89154300|NCT02673866|Experimental|DS1971a 100 mg BID|DS1971a 100 mg BID
89154301|NCT02673866|Placebo Comparator|Placebo|Placebo
89154302|NCT02673866|Active Comparator|Pregabalin|Pregabalin
89154303|NCT00964561|Experimental|Ciprofloxacin and Valortim|First two subjects to receive treatment arm of Ciprofloxacin and Valortim. Total of sixteen volunteers to be randomized to receive Ciprofloxacin and Valortim.
89154304|NCT00964561|Experimental|Placebo Antibiotic and Valortim|Randomized such that four subjects to receive Placebo Antibiotic and Valortim.
89154305|NCT00964561|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that 4 subjects to receive Placebo Antibiotic and Placebo Valortim.
89154306|NCT03765749||Community onset 3rd generation cephalosporin resistant entero|Patient with Community onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received inappropriate Antibiotic
89154307|NCT03765749||Nosocomial onset 3rd generation cephalosporin resistant ente|Patient with Nosocomial onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received appropriate Antibiotic
89154308|NCT02671682|Experimental|Immunoadsorption|Immunoadsorption on 5 consecutive days with protein A columns and 2,5-fold patient's plasma volume
89154309|NCT02671682|Active Comparator|Plasmapheresis|Plasmapheresis on 5 consecutive days with 2l plasma exchange
89154310|NCT02793323|Experimental|Superficial cervical block|Patients will receive superficial cervical nerve block in which we inject 5 ml of local anaesthetic mixture. Each 17 ml of the mixture contain: 6 ml lidocaine 2%, 6 ml lidocaine 2% with adrenaline 5 µg/ml, and 5 ml bupivacaine 0.5. Patients will also receive 100 ml IV saline.
89154311|NCT02793323|Placebo Comparator|NSAID|Patients will receive 100 mg (100 ml) IV NSAIDs (Profenid) before induction of anesthesia. Superficial cervical nerve block containing 5 ml placebo will be performed.
89154312|NCT00964639|Placebo Comparator|Saline|
89154313|NCT00964639|Active Comparator|Naropin|
89154314|NCT06322212|Experimental|BBB function, cognition, and mood in T2DM adults with Thiamine treatment.|Analyze BBB function, cognition, and mood in T2DM adults with Thiamine treatment and compare to the placebo group.
89154315|NCT06322212|Placebo Comparator|BBB function, cognition, and mood in T2DM adults without Thiamine treatment.|Analyze BBB function, cognition, and mood in T2DM adults without Thiamine treatment and compare to the Thiamine treatment group.
89154316|NCT06322186|Experimental|Ready-Heat Blanket|Two Ready-Heat 4-panel half blankets applied indirectly (as per manufacturer's directions) with two flannel blankets placed under them.
89154317|NCT06322186|Active Comparator|Warmed blankets/FAWB|Two warmed blankets (current standard of care) will be applied to the patient.
89154318|NCT06322173|Other|NGS analysis|Residual anonymized samples stored at -80°C at the Tropica Biobank of the DITM and for which diagnostic analysis for germ infection has previously been carried out at the DITM by blood culture and MDR surveillance in routine diagnostic rectal swab will be used. DNA extraction will be carried out on these residual samples (with subsequent quality and quantification analysis of the nucleic acid) for subsequent NGS analyses.
89154319|NCT06322160||No use of PCI-TC in clinical consultations|In this phase we aim to explore the views of the current decision-making process in thyroid cancer treatment. The patients will be approached for interview within 14 days after their consultations where the treatment decisions for their low risk differentiated thyroid cancer are made. There is no time restriction to approach clinicians for interview.
89154320|NCT06322160||User experience of PCI-TC in thyroid cancer outpatient clinic setting|First, the clinicians will be trained on how to use the PCI-TC in their outpatient clinics. A new group of patients will then be identified and recruited for the phase two study. Patients from this new group will be given the PCI-TC in a quiet area just off the waiting area prior to the consultation. They will be asked to tick items on the PCI-TC list which they wish to discuss. The clinicians will conduct the consultation using the ticked PCI-TC as a guide and discuss with patients regarding the treatment plan for their thyroid cancer. The patients will be approached for interview within 14 days after their consultations. The clinicians will be approached for interview after all recruited patients in phase two study have had their consultation regarding their cancer treatment.
89154321|NCT06322147||Doublet or triplet chemotherapy combined with cetuximab|
89154322|NCT06322121||Dementia patients|Patients with a dementia diagnosis; probable Alzheimer or mixed-type dementia
89154323|NCT06322121||MCI patients|Patients with a MCI diagnosis; patients demonstrating cognitive deficits on neuropsychological testing but not fulfilling the criteria for dementia.
89154324|NCT06322121||SCI patients|Patients not demonstrating cognitive deficits on neuropsychological testing are classified as SCI
89154325|NCT06322121||Controls|Control subject without cognitive complaints
89154326|NCT06322108|Experimental|Botensilimab + Balstilimab|botensilimab 75 mg IV every 6 weeks (up to 4 doses) + balstilimab 240 mg IV every 2 weeks
89154327|NCT06322095|Experimental|'GH21+ Previous Target Therapy or Immunotherapy'Group|GH21(15mg BIW or 6mg QD) combined with previous target therapy or Immunotherapy
89154332|NCT06322069|Experimental|Self-compassion intervention group|The intervention group was granted access to a 14-day course focused on the theme of self-compassion. Participants within this group were encouraged to engage with one module per day, and completion of the entire course within a 21 days.
89154333|NCT06322069|No Intervention|waitlist group|The waitlist group received no course.
89154334|NCT06322056|Active Comparator|Intensive SBP control and Intensive LDL-C control|Targeting SBP <120 mmHg and targeting LDL-C <70 mg/dL
89154335|NCT06322056|Active Comparator|Intensive SBP control and Standard LDL-C control|Targeting SBP <120 mmHg and targeting LDL-C <100 mg/dL
89154336|NCT06322056|Active Comparator|Standard SBP control and Intensive LDL-C control|Targeting SBP <140 mmHg and targeting LDL-C <70 mg/dL
89154337|NCT06322056|Active Comparator|Standard SBP control and Standard LDL-C control|Targeting SBP <140 mmHg and targeting LDL-C <100 mg/dL
89154338|NCT06322043|Experimental|Volume correction with Investigational Device|Subjects will be injected subcutaneously with the Investigational Device to correct volume deficiencies.
89154339|NCT06322030|Experimental|Diet|15 week weight management program
89154340|NCT06322030|No Intervention|Control|waitlist control
89154341|NCT06322030|Experimental|Exercise|exercise training
89154342|NCT06322030|Experimental|Diet + Exercise|15 week weight management program + exercise training
89154343|NCT06322017|Experimental|Rhythm control by Pulmonary Vein Isolation (PVI) procedure|
89154344|NCT06322017|Active Comparator|Conventional care by antiarrhythmic drugs or bradycardic drugs|
89154345|NCT06321978||Study Group|Mepilex Border Flex dressing changes
89154346|NCT06321965|Experimental|SMA patient treated with SRT|Patients aged 0-15 with SMA type 1, 2 or 3, treated with TRS (nusinersen/risdiplam/onasemnogene abeparvovec/other).
89154347|NCT06321952|Active Comparator|ROSA robotic assist TKA|ROSA robotic assist TKA
89154348|NCT06321952|Active Comparator|iassist TKA|iassist TKA
89154349|NCT06321913|Experimental|IBI343|
89154350|NCT06321887|Experimental|STAGE 1|"The first stage shall recruit 10 patients and is used to assess the incidence of oral iron related toxicity.~Patients will be prescribed:~• Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks.~If patients experience toxicity (defined as symptoms not tolerated by the patient), the trial medication would be stopped and IV Iron treatment given.~If toxicity occurs in 2 or more patients where we have to stop treatment, we will continue to recruit 30 patients only to the Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks. If the toxicity is acceptable and the Hb improves, we will continue to recruit to 22.5mg oral iron/day.~If the toxicity is acceptable but there is no improvement in haemoglobin the next patients will be recruited to stage 2."
89154351|NCT06321887|Experimental|STAGE 2|"Ten subjects each will then be sequentially assigned to one of the following groups:~Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks.~Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks.~If 2 or more patients experience toxicity at Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) or Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) we will reduce the dose to the previous level of Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) and continue to recruit.~30 patients shall be used to estimate the change in haemoglobin between baseline and the final analysis point.~If no dose reduction is required, only the last 20 patients shall be used to assess haemoglobin.~The overall endpoint is the haemoglobin level."
89154352|NCT06321874|Experimental|Normobaric Oxygen Paradox (NOP) group|The NOP group received 60% oxygen for two hours on days 1, 3, and 5 post-surgery using a venti-mask.
89154353|NCT06321874|No Intervention|Control (CTR) group|The CTR group did not receive oxygen therapy during the post-operatory period starting from day 1.
89154354|NCT06321861|Experimental|Caffeine|Participants will take a caffeine pill (3mg/kg of body mass) 60 minutes before the physical exercise test.
89154355|NCT06321861|Placebo Comparator|Placebo|Participants will take a placebo pill 60 minutes before the physical exercise test.
89154356|NCT06321861|Other|No substance|Participants receive no pills in this condition before the physical exercise test.
89154357|NCT06321848||The ventilator weaning patients|Patients who have been on mechanical breathing for longer than 48 hours using an endotracheal tube and who fit the requirements to be weaned off of it
89154358|NCT06321835||Supine Group|The patients were divided into four groups according to the operation position as supine, lateral flank, prone and lithotomy.
89154359|NCT06321835||Prone Group|The patients were divided into four groups according to the operation position as supine, lateral flank, prone and lithotomy.
89154360|NCT06321835||Lithotomy Group|The patients were divided into four groups according to the operation position as supine, lateral flank, prone and lithotomy.
89154361|NCT06321835||Lateral flank group|The patients were divided into four groups according to the operation position as supine, lateral flank, prone and lithotomy.
89154362|NCT06321822|Experimental|Epileptic Patients recruited for observational study|Patients with epilepsy recruited for observation study. When criteria for genetic epilepsy will be met, they will undergo testing for genetic investigation through exome NGS sequencing
89154363|NCT06321796|Experimental|Group A: Treatment|"Part 1: Blinded Treatment (14 weeks)~Vancomycin, Magnesium Citrate, Antacid, MTP-101P"
89154364|NCT06321796|Placebo Comparator|Group B: Placebo|"Part 1: Blinded Placebo (14 weeks)~Placebo Vancomycin, Real Magnesium Citrate, Real Antacid, Placebo MTP-101P"
89154365|NCT06321783|Other|Group 1|Individuals with forward head posture
89154366|NCT06321783|Other|Group 2|Individuals with normal head posture
89154367|NCT06321770|Experimental|Bioactive collagen peptide|The active treatment group included 40 women who received the bioactive collagen peptide-based food supplement orally
89154368|NCT06321770|Placebo Comparator|Placebo|"Oral suspension and sealed in sachets that were identical in appearance and odor.~ingredients, which were also contained in the placebo, were 467 mg lemon flavour, 150 mg citric acid, 8.5 mg sucralose and 7.1 mg stevia (97%). The placebo did not contain any nutrients."
89154369|NCT06321744|Experimental|Adapted physical activity program (APA Program)|"An intervention (APA program) will be offered to patients hospitalized in the conventional hospitalization department of the medical oncology department.~At entry, after presenting the study and obtaining non-opposition from patients, an initial assessment will be carried out before the APA program.~At the end of the initial assessment, an APA program supervised (individually and in a room) by an APA teacher will be offered to patients. The sessions will be offered daily to patients (maximum 5 times/week). They will last on average 20 minutes each depending on the fatigue, pain and fitness of the patients. The objectives pursued are mainly an improvement in functional independence and mobility."
89154370|NCT06321731||COPD patients initiating BGF|COPD patients ≥40 years old initiating BGF (budesonide/glycopyrronium bromide/formoterol fumarate) at least 12 months before start of data collection.
89154371|NCT06321718|Experimental|1. Group (A)|will receive PENG + LFCN block
89154372|NCT06321718|Experimental|2. group (B)|will receive S-FICB
89154373|NCT06321692|Other|Evaluation of blood levels of biomarkers of cardiac damage|Evaluation of blood levels of biomarkers of cardiac damage (ultra-sensitive troponin I), hemodynamic impairment (BNP, NT-proBNP), and cardiac fibrosis (ST2) in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
89154374|NCT06321679||WB-MRI|Each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
89154375|NCT06321666|Other|WB-MRI and CT Scan|CT scan (neck/thorax/abdomen/pelvis) and WB-MRI
89154376|NCT06321653||Hypofractionated radiotherapy|Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
89154377|NCT06321640||Cohort A: primarily operable disease, candidate to adjuvant|"This cohort includes any patient with nonmetastatic disease, candidate to surgery as primary treatment, for whom adjuvant therapy with targeted or immune therapy is recommended based on prior information obtained on the diagnostic biopsy. This cohort represents a control group, for whom high-throughput DNA/RNA sequencing is considered feasible in the vast majority of cases, and will not be considered in the computation of the primary endpoint. Small groups representative of relevant diseases will be collected, as follows:~Breast~Lung~Melanoma~Head and Neck~Urothelial~Colorectal cancer~Metastasectomy from lung or liver, from any cancer"
89154378|NCT06321640||Cohort B: locally advanced disease|Patients in this cohort are eligible if diagnosed with or highly suspected of locally advanced (nonmetastatic) neoplasm and candidate to a diagnostic/confirmatory biopsy and subsequent treatment with targeted therapy, immune therapy or radiotherapy, where the treatment is administered with potentially curative intent. Patients in this cohort may be considered for enrolment prior to a formal diagnosis, so the study should be offered on the basis of a high suspicion of invasive cancer upon radiological evidence.Cohort B1: patients who, at the moment of biopsy, are expected to be subsequently treated with targeted therapy. Cohort B2: patients who, at the moment of biopsy, are expected to be subsequently treated with immune therapy. Cohort B3: patients who, at the moment of biopsy, are expected to be treated with combined chemo-immuno-radiotherapy
89154379|NCT06321640||Cohort C: metastatic disease|"In this cohort, patients are eligible if diagnosed with invasive cancer with radiologically proven metastatic localization and candidate to treatment with targeted or immune therapy.~Cohort C1: patients candidate to targeted therapy Cohort C2: patients candidate to immune therapy"
89154380|NCT06321640||Cohort D: Progressive disease|"In this cohort, patients are eligible if a tumor biopsy is considered indicated by the referring physician upon disease progression to prior treatment in the metastatic setting or for hematological neoplasms. Definition of progression is based on the investigator's judgement and does not strictly require RECIST 1.1 definition, although all relevant radiological data will be collected whenever possible. Tumor biopsy must be collected no more than 6 months after the documented date of progression.~Subgroups include: Cohort D1: progression disease to targeted. Patients whose last treatment at the moment of enrolment is a targeted agent.~Cohort D2: progression disease to immune. Patients whose last treatment at the moment of enrolment is an immunotherapeutic agent Cohort D3: potential off-label treatment. Any patient that has exhausted standard treatment and that in the judgement of the investigator may benefit from an exome-wide mutational screen to identify actionable alterations"
89154381|NCT06321640||Cohort E: Hematological neoplasms|"Cohort E1: Any patient that is expected to be treated with targeted agents. Special consideration will be given to patients affected by chronic lymphoid leukemia and follicular lymphoma treated with Bruton´s tyrosine kinase (BTK) inhibitor, Phosphoinositide 3-kinase inhibitor, B-cell lymphoma 2 inhibitor +/- monoclonal antibodies.~Cohort E2: Any patient that is expected to be treated with immunotherapy. Special consideration will be given to patients affected by Hodgkin lymphoma and Diffuse Large B-cell lymphoma treated with Immune checkpoint inhibitors, Tafasitamab/Lenalidomide, immunoconjugates."
89154382|NCT06321640||Cohort F: Toxicity|In this cohort, patients are enrolled upon experiencing an adverse event of grade 3/4 as per Common Terminology Criteria for Adverse Events version 5.0 that, in the opinion of the investigator, is unequivocally caused by a targeted or immune therapeutic. The event may occur at any time after the last dose of the drug. Events may be of any nature but particular attention will be given to those events for which pathophysiology is currently poorly understood.Cohort F1: toxicity to Targeted therapy. Patients experiencing Grade 3-Grade 4 adverse events due to targeted therapy Cohort F2: toxicity to Immune therapy. Patients experiencing Grade 3-Grade 4 adverse events due to Immune therapy.
89154383|NCT06321627||Patients with HPV-related tumors|Patients with HPV-related tumors of the oropharynx, cervix, and anus
89154384|NCT06321614||patients with normal abdominal radiographs|patients with normal abdominal radiographs, which were confirmed by extra imaging examinations and clinical data. The imaging examinations comprised CT, magnetic resonance imaging (MRI) and colonoscopy in the subsequent 72 hours, while clinical data included recent hospital admission information and surgical operation notes.
89154385|NCT06321614||patients with small bowel obstruction radiographs|patients with small bowel obstruction radiographs, which were confirmed by extra imaging examinations and clinical data. The imaging examinations comprised CT, magnetic resonance imaging (MRI) and colonoscopy in the subsequent 72 hours, while clinical data included recent hospital admission information and surgical operation notes. In terms of location, small-bowel obstruction (SBO) involves the duodenum, jejunum, and ileum
89154386|NCT06321614||patients with large bowel obstruction radiographs|patients with large bowel obstruction radiographs, which were confirmed by extra imaging examinations and clinical data. The imaging examinations comprised CT, magnetic resonance imaging (MRI) and colonoscopy in the subsequent 72 hours, while clinical data included recent hospital admission information and surgical operation notes. In terms of location, large-bowel obstruction (SBO), involves the cecum, colon, and rectum.
89154387|NCT06321601|Experimental|Avacopan|Participants will receive avacopan twice-daily (BID) administered as oral tablets or liquid formula for 52 weeks.
89154388|NCT06321575|Experimental|Golazo® Peripheral Atherectomy System|Treatment atherectomy of the peripheral vasculature with the Golazo® Peripheral Atherectomy System.
89154389|NCT06321549||Group A|Individuals who underwent surgery prior to November 2018
89154390|NCT06321549||Group B|Individuals who underwent surgery after November 2018
89154391|NCT06321536|Experimental|Group 1|Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition) during facility study period 1, followed by a wash-out period, during which several patients are expected to be discharged and new patients are expected to be admitted. In facility study period 2, all consenting MDRO-positive patients (i.e. control condition) will observed with weekly sampling during study period 2.
89154392|NCT06321536|Experimental|Group 2|Group 2 will reverse the order of the intervention and control conditions relative to Group 1 (i.e., will conduct observation during facility study period 1, have a wash-out period, and then will offer MT to all MDRO-positive patients during facility study period 2).
89154393|NCT06321523||ATTR-CM patients in Korea|transthyretin amyloid cardiomyopathy (ATTR-CM) patients in Korea
89154394|NCT06321497||Adult patients (18 years or older) with diagnosis of ARDS as per Berlin Definition|
89154395|NCT06321484|Experimental|Dose Level 0|"Participants will be enrolled in a staggered fashion into a 3+3 dose de-escalation per protocol to establish a maximum tolerated dose (MTD). Dosage will start at dose level 0.~Baseline visit.~MRIs, PET scans, and/or CT scans every 8 weeks.~Cycle 0:~Day -7 of 8 day cycle: Apheresis for autologous NK cell collection.~Days -6 through -2 of 8 day cycle: Predetermined dose of lymphodepleting chemotherapy per protocol.~Days -5 through -4 of 8 day cycle:~Predetermined dose of lymphodepleting chemotherapy per protocol.~Predetermined dose of premedication per institutional standards.~Day 0 of 8 day cycle: Predetermined dose of CIML NK cells once.~Cycle 1:~- Days 1, 8 and 15 of 21-day cycle: Predetermined dose of N-803 1x weekly.~Cycle 2 - End of Treatment~- Predetermined dose of N-803 1x every 3 weeks until disease progression.~Off-Treatment:~Long-term follow up for 5 years after last CIML NK cell infusion."
89154396|NCT06321484|Experimental|Dose Level -1|"3+3 de-escalation to dose level -1 per protocol if DLTs occur in Cohort 1 dose Level 0.~Baseline visit.~MRIs, PET scans, and/or CT scans every 8 weeks.~Cycle 0:~Day -7 of 8 day cycle: Apheresis for autologous NK cell collection.~Days -6 through -2 of 8 day cycle: Predetermined dose of lymphodepleting chemotherapy per protocol.~Days -5 through -4 of 8 day cycle:~Predetermined dose of lymphodepleting chemotherapy per protocol.~Predetermined dose of premedication per institutional standards.~Day 0 of 8 day cycle: Predetermined dose of CIML NK cells once.~Cycle 1:~- Days 1, 8 and 15 of 21-day cycle: Predetermined dose of N-803 1x weekly.~Cycle 2 - End of Treatment~- Predetermined dose of N-803 1x every 3 weeks until disease progression.~Off-Treatment:~Long-term follow up for 5 years after last CIML NK cell infusion."
89154397|NCT06321471|Other|AeviceMD|This is a single site, single arm, open label medical device (AeviceMD) pilot where only intervention groups will be recruited.
89154398|NCT06321419|Experimental|Advanced Trauma Life Support|The intervention will be ATLS® training, a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. Physicians will be trained in an accredited ATLS® training facility in India.
89154399|NCT06321419|No Intervention|Standard care|Standard care varies across hospitals in India, but trauma patients are initially managed by casualty medical officers, surgical residents, or emergency medicine residents. They are mainly first- or second-year residents who resuscitate patients, perform interventions and refer patients for imaging or other investigations. Compared with other settings where a trauma team approach is adopted, nurses and other healthcare professionals are only involved to a limited extent during the initial management.
89154400|NCT06321406|Active Comparator|Control Group|Exercises such as progressively resistant oral-facial, lingual, laryngeal exercises, tongue strengthening exercises, effortful swallowing maneuver, thermal/tactile stimulation to oropharyngeal muscles, Masako maneuver, Mendelson maneuver, Shaker maneuver, which are included in traditional swallowing treatment, will be taught and practiced for 30 minutes will be recommended for one month.
89154401|NCT06321406|Active Comparator|NMES(neuromuscular electrical stimulation) Group|One electrode will be connected to the suprahyoid region and the other electrode will be connected between the thyroid and hyoid cartilages. Superficial neuromuscular stimulation will be applied by the physiotherapist at 80 Hz, 0-25 µA current range for 20 minutes, for 5 days for the patient, for a total of 4 weeks. At the same time, each patient will be taught the exercises included in traditional swallowing treatment and will be advised to practice them for 30 minutes every day.
89154402|NCT06321393|Experimental|Telerehabilitation-Based group|A 7-week core stabilization exercise with abdominal drawing-in maneuver technique consist of 2 stages including the first stage (week 1-2) and the second stage (week 3-7) consisting of exercise program for 20-min sessions, with 3 sessions per week for 7 weeks. These exercise program will be provided to the participants via a weekly videocall with the main researcher as a telerehabilitation program.
89154403|NCT06321393|Active Comparator|Clinic-Based group|The control group or clinic-base group will be provided the 7-week core stabilization exercise with abdominal drawing-in maneuver technique, the same as the experimental group, but control groups received the exercise program at the clinic according to the usual methods. At the first session of each week, an appointment will be set, and then the specific exercise for each week will be delivered and trained by the main researcher at the clinic. After completing weekly training, participants will perform their exercise routine as part of their daily home program.
89154404|NCT06321380||Alzheimer disease|"Alzheimer's disease is define on the basis of the medical diagnostic. As part of routine care, they undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions.~For the study and during the day of medical consultations, each patient will perform a working memory task, lasting approximately 30 minutes.~If the patient is accompanied by a family member, the investigators ask the latter to complete a questionnaire on patient's daily executive functioning (French version of the Behavior rating inventory of executive function [BRIEF-A])."
89154405|NCT06321380||Vascular dementia|"Vascular dementia is define on the basis of the medical diagnostic. As part of routine care, they undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions.~For the study and during the day of medical consultations, each patient will perform a working memory task, lasting approximately 30 minutes.~If the patient is accompanied by a family member, the investigators ask the latter to complete a questionnaire on patient's daily executive functioning (French version of the Behavior rating inventory of executive function [BRIEF-A])."
89154406|NCT06321380||Mixed dementia|"Mixed dementia (i.e., Alzheimer's disease and vascular dementia) is define on the basis of the medical diagnostic. As part of routine care, they undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions .~For the study and during the day of medical consultations, each patient will perform a working memory task, lasting approximately 30 minutes.~If the patient is accompanied by a family member, the investigators ask the latter to complete a questionnaire on patient's daily executive functioning (French version of the Behavior rating inventory of executive function [BRIEF-A])."
89154407|NCT06321380||Control group|Control group includes healthy older adults (without cognitive impairment). As patient group, control group will perform the working memory task. However, control group does not undergo the clinical neuropsychological assessment.
89154408|NCT06321354|Experimental|The diprospan plus ropivacaine group|Patients in the diprospan plus ropivacaine group will receive a peri-incisional scalp infiltration with 15ml diprospan and 15mg of 1% ropivacaine and normal saline miscible liquids.
88804532|NCT04426838|Experimental|Caregiver Cognitive Behavioral Therapy for Insomnia (CBTi)|Caregivers in a dyad receiving the CBTi intervention in a videoconferencing format.
89154409|NCT06321354|Active Comparator|The ropivacaine group|Patients in the ropivacaine group will receive a peri-incisional scalp infiltration with 15mg of 1%
89154410|NCT06321341|Experimental|Vespireit, prolonged-release tablets, 15 mg|Dosage regimen: 1 tablet once a day at approximately the same time in the morning after meals for 28 days. The drug is taken orally, whole, without breaking and not chewing.
89154411|NCT06321341|Active Comparator|Arlevert, tablets, 40 mg + 20 mg|Dosage regimen: 1 tablet 3 times a day at approximately the same time after meals for 28 days. The drug is taken orally, whole, without breaking and not chewing.
89154412|NCT06321315|Experimental|Intervention group (Case-based instruction group)|Case-based teaching will be provided to second-year students who take the risky pregnancy and care course for the first time, who are included in the case-based teaching group by randomization method.
89154413|NCT06321315|No Intervention|Control|The control group is the group in which no intervention was made.
89154414|NCT06321302|Experimental|BI 764524|BI 764524
89154415|NCT06321302|Sham Comparator|Sham comparator to BI 764524|Sham comparator to BI 764524
89154416|NCT06321302|Active Comparator|Aflibercept (Eylea®) - US only|Aflibercept (Eylea®) - US only
89154417|NCT06321276|Active Comparator|two thousand pulse ESWT Group|ESWT will be applied to the patient's wrist and conventional treatment consisting of hand-wrist rest splint and nerve gliding exercises will be applied. The point of the ESWT site was located by ultrasonography interfaced with a 5-12 MHz linear array transducer, and the median nerve was visualized at the line of the proximal carpal tunnel (scaphoid pisiform level). (0,06 mj/mm2, 2000 impulses, 4 bar) (Modus ESWT Radial Shockwave Therapy)
89154418|NCT06321276|Active Comparator|one thousand pulse ESWT Group|ESWT will be applied to the patient's wrist and conventional treatment consisting of hand-wrist rest splint and nerve gliding exercises will be applied. The point of the ESWT site was located by ultrasonography interfaced with a 5-12 MHz linear array transducer, and the median nerve was visualized at the line of the proximal carpal tunnel (scaphoid pisiform level). (0,06 mj/mm2, 1000 impulses, 4 bar) (Modus ESWT Radial Shockwave Therapy)
89154419|NCT06321276|No Intervention|Conventional Control Group|The patient will receive conventional treatment consisting of hand-wrist rest splint and nerve gliding exercises as directed by the physiotherapist
89154422|NCT06321250|Experimental|Dose Escalation|Subjects will be assigned to pre-specified dose level to determine MTD/MAD of JMKX003948. Each treatment cycle will be 21 days.
89154423|NCT06321250|Experimental|Dose Expansion|Subjects will be assigned to the recommended dose level determined in dose escalation Phase. Each treatment cycle will be 21 days.
89154424|NCT06321237|Active Comparator|The true-true stimulus group|During the 8-week intervention, the patient used the ear nail stimulator to give true stimulation, that is, the vagus nerve stimulation with a pulse width of 200μs and a frequency of 30Hz
89154425|NCT06321237|Experimental|The true-false stimulus group|During the 8-week intervention, the first 4 weeks of the auricular stimulator used by the patient were given true stimulation, that is, vagus nerve stimulation with a pulse width of 200μs and a frequency of 30Hz; The next 4 weeks were given as false stimuli
89154426|NCT06321237|Experimental|The false-true stimulus group|During the 8-week intervention, the first 4 weeks of the patient's ear nail stimulator gave false stimulation; The stimulation given in the last 4 weeks is true stimulation, that is, vagus nerve stimulation with pulse width of 200μs and frequency of 30Hz
89154427|NCT06321237|Placebo Comparator|The false-false stimulus group|Over the course of the 8-week intervention, the patient used an ear nail stimulator that gave false stimulation
89154428|NCT06321224|Experimental|Exercise group|The exercise group will be given breathing exercises
89154429|NCT06321224|Other|Control group|The control group will be asked to continue their routine lives.
89154430|NCT06321198|Experimental|iMSC injection|Low dose injection once a week; Low dose injection twice a week; High dose injection once a week; High dose injection twice a week;
89154431|NCT06321159|Experimental|Intervention Group|mobile application
89154432|NCT06321159|No Intervention|Control Group|Control Group
89154433|NCT06321146||V-P shunt group|Comatose TBI patients who underwent V-P shunt surgery
89154434|NCT06321146||Cranioplasty group|Comatose TBI patients who underwent cranioplasty surgery
89154435|NCT06321146||SCS group|Comatose TBI patients who underwent spinal cord stimulation
89154436|NCT06321146||RMNS group|Comatose TBI patients who underwent right median nerve stimulation
89154437|NCT06321146||DAI group|Comatose TBI patients with diffuse axonal injury
89154438|NCT06321133|Experimental|Immediate ending|High flow is ended immediately
89154439|NCT06321133|Active Comparator|Weaning|High flow is ended by gradually reducing the flow rate
89154440|NCT06321120|Experimental|Variability-based lenvatinib treatment|Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. The first level of the algorithm, employed in the present study, utilizes a pseudo-random number generator to select dosages and administration times from the ranges stipulated by the physician.
89154441|NCT06321107||Test group|Gensci094
89154442|NCT06321107||Control group|rFSH
89154443|NCT06321094|Experimental|patients who take vericiguat|ACS patients with ejection fraction(EF)<45% are required to take vericiguat according to the guidelines from 2.5mg once a day to 5mg after two weeks.
89154444|NCT06321094|No Intervention|patients who donot take vericiguat|ACS patients with EF<45% arenot required to take vericiguat.
89154445|NCT06321081|Experimental|ICE treatment group|any RAS wild type mCRC patients who had got benefits from cetuximab or irinotecan will be treated with ICE regimen (Irinotecan 150mg/m2,Q2W, cetuximab 500mg/m2, Q2W, envafolimab 200mg, Q2w)
89154446|NCT06321068|Experimental|BAT1308|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W)
89154447|NCT06321055||Advanced Gastro-intestinal soft-tissue tumors (GIST) patients|Adult GIST patients with evidence of regorafenib treatment initiation among commercially insured or Medicare patients in the Merative MarketScan database.
89154448|NCT06321042||Patient treated with PS Link Symphoknee prosthesis and Orthokey perseus alignment device|
89154449|NCT06321029|Experimental|Single-arm waitlist control|"The initial assessment will take place at the time of study enrollment (T1). Participants will be offered a choice of assignment to either the eDTU (online Diabetes Tune-Up Group intervention participation) or iDTU (in-person Diabetes Tune-Up Group intervention participation) series. After a 3-month waiting period, participants will complete baseline assessment (T2). The group intervention will then take place over the next 6 to 8 weeks. Immediately following completion of the intervention, participants will complete surveys (T3). A final assessment will be completed 3 months after baseline, approximately 4 to 6 weeks following the completion of the intervention (T4).~The participant will participate in one series of the DTU intervention either, in person or online, at the participant's choosing. The intervention will take place over the course of 6 to 8 weeks. Participants will wear their continuous glucose monitor throughout the course of the intervention."
89154450|NCT06320990|Experimental|Tamoxifen|Tamoxifen 20mg by mouth daily for up to 6 months
89154451|NCT06320977|No Intervention|Control Condition|5-minute rest
89154452|NCT06320977|Active Comparator|Static Stretching of 30 seconds Condition|Static stretching of the gastrocnemius and tibialis anterior muscles for 30 seconds
89154453|NCT06320977|Active Comparator|Static Stretching of 90 seconds Condition|Static stretching of the gastrocnemius and tibialis anterior muscles for 90 seconds
89154454|NCT06320964|Experimental|TARANG arm|The newly married women received 16 weekly group sessions and one rapport-building session, while the husbands and mothers-in-law received four group sessions each over four months. The TARANG intervention was delivered via gender-matched moderators from Vikalp Sansthan and uses three overarching themes: sexual and reproductive health, gender norms, and empowerment.
89154455|NCT06320951|Experimental|Experimental: Vericiguat|The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
89154456|NCT06320951|Placebo Comparator|Placebo|The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
89154457|NCT06320912|Experimental|Group(A)|
89154458|NCT06320912|Active Comparator|Group(B)|
89154459|NCT06320899|Experimental|SpineShape System IV straight rod elastic|Dynamic stabilization of lumbar segments using SpineShape System IV straight rod elastic (high-flex)
89154460|NCT06320899|Experimental|SpineShape System IV straight rod medium|Dynamic stabilization of lumbar segments using SpineShape System IV straight rod medium (mid-flex)
89154461|NCT06320899|Active Comparator|SpineShape System IV straight rod stiff|Dynamic stabilization of lumbar segments using SpineShape System IV straight rod stiff (low-flex)
89154462|NCT06320873|Other|Results of sports performance parameters values in archers|Sociodemographic and physical characteristics, Pulmonary function test (PFT), respiratory muscle strength, shooting performance test, Moberg-pickup collection test, Nelson hand reaction test, and Fatigue Severity Scale (FSS)
89154463|NCT06320860|Experimental|Kidney Stone Retrieval|All patients in this group will have the EndoTheia FlexStone basket used to assist in the retrieval of kidney stones
89154464|NCT06320821||RAKT|robot-assisted kidney transplant patients
89154465|NCT06320821||OKT|open kidney transplant patients
89154466|NCT06320808|Experimental|FDA-template PMI|Patient medication information designed according to FDA template
89154467|NCT06320808|Experimental|Decision Critical PMI|Patient medication information designed according to FDA template and modified, according to decision science principles, to include benefit information
89154468|NCT06320808|Experimental|Standard Information|Standard of care patient medication information
89154469|NCT06320795|Experimental|Soundi|Soundi device compared to overnight polysomnography
89154470|NCT06320782|Experimental|Dietary intervention 1|Calorie restriction and balanced distribution of macronutrients
89154471|NCT06320782|Experimental|Dietary intervention 2|Calorie restriction and low-carbohydrate diet
89154472|NCT06320782|Experimental|Dietary intervention 3|Calorie restriction and low-fat diet
89154473|NCT06320782|Experimental|Dietary intervention 4|Collective nutritional guidance
89154474|NCT06320769|Experimental|Rotational Guided Growth|"o On a radiolucent operating table with the child supine, a torniquet is applied. The limb is prepped and draped.~oA Kirschner wire is inserted in midsagittal plane of the distal femoral physis from medial to lateral under fluoroscopic guidance.~After the initial step, One of three Surgical techniques might be used according to surgeon preference and patient age:~Plate technique~Non-absorbable suture technique~Cerclage wire technique"
89154475|NCT06320756|Experimental|Intervention arm: Wysa in Hindi + usual care|"The intervention arm will receive Wysa in Hindi and the usual care. Wysa in Hindi is a digital mental health intervention that combines Artificial Intelligence-led conversational chatbot support and human therapy in the Hindi language. The Artificial Intelligence (AI) chatbot acts as a companion, and understands, empathizes, and guides users through exercises grounded in cognitive behavioral therapy (CBT) techniques, written by qualified psychologists and clinicians.~Usual care includes access to individual and bi-weekly group sessions focused on building coping, wellbeing, and motivation by the diabetes educator team."
89154476|NCT06320756|Active Comparator|Usual care arm|Participants in the control group will only have access to usual care (which will remain the same as that for the intervention arm). This includes access to individual sessions and bi-weekly group sessions with the diabetes education team on motivation, wellbeing, and coping.
89154477|NCT06320730||Group 110 < REP BG < 180|Those with blood glucose levels over 110 and under 180 after reperfusion in liver transplantation recipients.
89154478|NCT06320730||Group REP BG ≤110 or ≥180|Those with blood glucose levels below 110 or above 180 after reperfusion in liver transplantation recipients.
89154479|NCT06320717||Patients with Borderline Resectable (Cohort A)|Pathological response of Patients with borderline resectable disease (per NCCD Criteria) treated with standard care chemotherapy
89154480|NCT06320717||Patients with Resectable (Cohort B)|Pathological response of Patients with resectable disease (per NCCN criteria) treated with standard care chemotherapy
89154481|NCT06320704||Complete Denture Group|Completely edentulous patients undergoing complete denture treatment plan effectively balanced using oculosense device
89154482|NCT06320691||General Anesthesia Group|The group that underwent direct anterior total hip arthroplasty with general-systemic anesthesia
89154483|NCT06320691||Spinal Anesthesia Group|The group that underwent direct anterior total hip arthroplasty with spinal-neuraxial anesthesia
89154484|NCT06320678|Experimental|Blended Learning|
89154485|NCT06320678|No Intervention|Education|
89154486|NCT06320665||Class I|Patient with class I occlusion, with at least one impacted third molar
89154487|NCT06320665||Class II|Patients with class II malocclusion, with at least one impacted third molar
89154488|NCT06320665||Class III|Patients with class III malocclusion, with at least one impacted third molar
89154489|NCT06320626|Other|Conventional dosing - open label|Patients will be followed 6 months retrospectively and 6 months prospectively on conventional dosing.
89154490|NCT06320626|Other|PK-guided dosing - open label|Patients with emicizumab concentration of ≥ 40 μg/mL will receive individualized PK-guided dose reduction of emicizumab targeted at a Ctrough of 30μg/mL. Patients will be followed for 12 months on reduced dosing.
89154491|NCT06320626|Other|No intervention continuation - open label|Patients with emicizumab concentration of 25-39 μg/mL will continue on their current dose regimen. Patients will be followed for 12 months on current dosing.
89154492|NCT06320626|Other|No intervention adjusted - open label|Patients with emicizumab plasma concentration < 25 μg/mL will be adjusted in dosing regimen according to local protocol. Patients will be followed for selective safety data only.
89154493|NCT06320613|Active Comparator|Experimental group acupuncture(snap-needle)|Patients in the acupuncture group received acupuncture therapy (snap-needle therapy) for 24 hours. Results of the study were collected at six assessment periods of 0-0.5 h, 0-1 h, 1-3 h, 4-6h, 6-12 h, and 12-24 h after anesthesia. Conducted by an independent researcher.
89154494|NCT06320613|Active Comparator|Experimental Ginger|Patients in the Ginger Acupuncture Point Patch group received ginger patch therapy and the ginger patch was removed within 6h. Study results were collected at six assessment periods of 0-0.5h, 0-1h, 1-3h, 4-6h, 6-12h, and 12-24h after anesthesia. Conducted by an independent researcher.
89154495|NCT06320613|Active Comparator|Experimental group Acupuncture combined with ginger|Patients in the Acupuncture combined with ginger group received acupuncture treatment (snap-needle therapy) combined with ginger compresses, which were removed within 6h and snap-needles were removed after 24 hours. Study results were collected at six assessment periods of 0-0.5h, 0-1h, 1-3h, 4-6h, 6-12h, and 12-24h after anesthesia. Conducted by an independent researcher.
89154496|NCT06320600||Retrospective PDC cohort|The study will include diabetes patients diagnosed within 1 year (including 1 year) from both inpatient and outpatient medical record systems between January 2022 and December 2022. Each center enrolls approximately 1000 new diabetes patients annually, and it is planned to include 30 centers, with an estimated total of 30,000 participants.
89154497|NCT06320600||Prospective PDC cohort|The study centers will enroll diabetes patients diagnosed within 1 year (including 1 year) from both outpatient and inpatient services between January 2024 and December 2024. Each center sees approximately 3000 new diabetes patients annually, and it is planned to include 30 centers, with an estimated total of 90,000 participants. The patients will be followed up for a period of 5 years.
89154498|NCT06320587|Experimental|Experimental group|Newborns in this group will be given kangaroo care by both their mother and father.
89154499|NCT06320587|Placebo Comparator|Control group|Newborns in this group will be given kangaroo care by only the mother.
89154500|NCT06320561||Patients in the first 3 months after stroke|"Inclusion criteria:~Adults (≥ 18 years old) Diagnosed with a first-ever stroke (as defined by WHO) Stroke onset ≤ 1 week (± 3 days) Able to provide written or verbal informed consent at admission Presence of gait problems as a consequence of the stroke (FAC≤4)~Exclusion criteria:~Presence of other neurological or orthopedic problems present prior to, or not caused as a direct consequence of, the stroke leading to impaired gait.~Modified Ranking scale pre-stroke > 1/6, meaning presence of slight disability before the stroke.~Presence of severe comorbidities (e.g. osteoporosis, cardiovascular instability or chronic obstructive pulmonary disease).~Cerebellar or bilateral stroke. Presence of severe deficits in communication, memory or understanding precluding informed consent."
89154501|NCT06320548|Experimental|Low-residue diet|Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
89154502|NCT06320548|Active Comparator|Free diet|Patients had free diet.
89154503|NCT06320535|Experimental|Group 1: Escalating dose R21/Matrix M™|12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, and 56 via intramuscular (IM) injection in the deltoid region of the same arm
89154504|NCT06320535|Experimental|Group 2: Escalating dose R21/Matrix M™ with delayed booster|12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, 168 via intramuscular (IM) injection in the deltoid region of the same arm
89154505|NCT06320535|Experimental|Group 3: Standard dose R21/Matrix-M™|12 volunteers receiving two 10mcg doses of R21 in 50mcg of Matrix M™ adjuvant at days 0 and 56 via intramuscular (IM) injection in the deltoid region of the same arm
89154506|NCT06320522|Active Comparator|Fed - Ketone Monoester|Ketone monoester drink (573 mg∙kg-1 body weight) provided 1 hour after a 2 g∙kg-1 bodyweight of carbohydrate mixed nutrient breakfast meal
89154507|NCT06320522|Placebo Comparator|Fed - Placebo|Placebo drink provided 1 hour after a 2 g∙kg-1 bodyweight of carbohydrate mixed nutrient breakfast meal
89154508|NCT06320522|Active Comparator|Fasted - Ketone Monoester|Ketone monoester drink (573 mg∙kg-1 body weight) provided whilst fasted
89154509|NCT06320522|Placebo Comparator|Fasted - Placebo|Placebo drink provided whilst fasted
89154510|NCT06320509|Other|Shock population|Insertion of bladder urine probe (Oxylite Pro ® device) and assessment of continuous uPO2
89154511|NCT06320509|Other|Without Shock Population|Insertion of bladder urine probe (Oxylite Pro ® device) and assessment of continuous uPO2
89234916|NCT05887674|No Intervention|Standard health counseling at baseline|Patients in this arm will have their habitual diet and life style. No particular intervention or consultation would be provided.
89234917|NCT05887661|Experimental|hypovolemic phlebotomy (HP)|patients in this group undergoing laparoscopic hepatectomy was performed with goal-directed LCVP based on hypovolemic phlebotomy (HP)
89154512|NCT06320496||Deconditioning to physical exertion|The children taking part in the return-to-physical-activity program are referred to the Flavigny-sur-Moselle CMPRE for medical consultation due to a state of deconditioning to physical exertion concomitant with a pathological situation. The pathology most frequently encountered during this stay is cerebral palsy. However, the Flavigny CMPRE is accredited in a number of fields (orthopedics, burns, neurology, oncology), and the pathologies of the children referred to this stay are representative of these. These include children with scoliosis, obesity, Guillain-Barré syndrome, cystic fibrosis, Charcot's disease and cancer.
89154513|NCT06320483||Group with percussion massage|
89154514|NCT06320483||Group with vibroacoustic massage|
89154515|NCT06320470|Experimental|Education|"Prior to the educational sessions, study participants will be given access to educational materials (e.g., handouts, videos) that provide an overview of information regarding cannabis products, effects, and pain. These materials will be developed with insight from the study team and the Community Advisory Board.~Educational content will include known side effects of cannabis (e.g., common effects like dizziness or sedation, rare side effects like hallucinations or vomiting) as well as specific risks associated with administration routes, such as respiratory harm from smoking or unregulated vaporized concentrate products, and the delayed onset of edible products. Sessions will help the participants appropriately select products for use."
89154516|NCT06320444||Controls|Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis
89154517|NCT06320444||Amyotrophic lateral sclerosis Patients|
89154518|NCT06320444||Multiple Sclerosis patients|
89154519|NCT06320444||Postpoliomyelitis syndrome patients|
89154520|NCT06320444||Muscular Atrophy patients|
89154521|NCT06320431|No Intervention|Standard-dose intravenous tenecteplase (0.25 mg/kg body weight)|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization.
89154522|NCT06320431|Active Comparator|2) IVT with tenecteplase at low-dose: 0.18 mg/kg|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.18 mg/kg body weight (maximum dose 18 mg) over 10-20 seconds as soon as possible after randomization.
89154523|NCT06320431|Active Comparator|3) No IV thrombolysis [(only in those undergoing EVT or those on DOACs)|No intravenous tenecteplase only applied to subjects on DOACs over the last 24 hours or those planned for emergency EVT
89154524|NCT06320418||Patients group|A total of 39 female patients in their age range (13-75 years) diagnosed with primary malignant ovarian tumors were enrolled in the study. OC patients were a treatment-naïve Egyptian patients' cohort admitted to the Gynecology and Obstetrics Department or the Oncology Dept., Ain Shams University Hospitals, Cairo, Egypt. Ovarian cancer tissue samples were collected during surgical resection and confirmed by postoperative pathological examinations.
89154525|NCT06320418||Control group|A total of 17 normal ovarian tissue samples were collected from patients with benign uterine diseases, such as myoma, who underwent uterine and ovarian resection. The control's age range is 45-62 years
89154526|NCT06320405|Experimental|Treatment (axatilimab, retifanlimab, paclitaxel)|Patients receive axatilimab IV over 30 minutes on day -8, prior to cycle 1. Beginning in cycle 1 day 1, patients receive axatilimab IV over 30 minutes on days 8 and 21 of each cycle, retifanlimab IV over 30-60 minutes on day 1 of each cycle, and paclitaxel IV over 60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsy, CT scan, and blood sample collection at screening and on study and may undergo MRI and/or PET scan at screening and on study.
89154527|NCT06320392||metastatic|44 female BC patients, volunteered in the study, diagnosed with metastatic BC. Patients were enrolled randomly from the Clinical Oncology Department, Faculty of Medicine, Mansoura University Hospitals, Mansoura University, Mansoura, Egypt, after signing the IC.
89154528|NCT06320392||non-metastatic|46 female BC patients, volunteered in the study, diagnosed with primary naive (non-metastatic) invasive BC . Patients were enrolled randomly from the Clinical Oncology Department, Faculty of Medicine, Mansoura University Hospitals, Mansoura University, Mansoura, Egypt, after signing the IC.
89154529|NCT06320379|Experimental|Zypan|
89154530|NCT06320379|Placebo Comparator|Placebo|
89154531|NCT06320353|Experimental|RPH-075|"Pembrolizumab will be administered as an intravenous infusion every 3 weeks, at a fixed dose of 200 mg, for 30 minutes (it is permissible, but not desirable, to carry out an infusion in the range from 25 to 40 minutes).~Premedication before administration of pembrolizumab is not mandatory."
89154532|NCT06320353|Active Comparator|Keytruda®|"Pembrolizumab will be administered as an intravenous infusion every 3 weeks, at a fixed dose of 200 mg, for 30 minutes (it is permissible, but not desirable, to carry out an infusion in the range from 25 to 40 minutes).~Premedication before administration of pembrolizumab is not mandatory."
89154533|NCT06320340|Active Comparator|Group I|
89154534|NCT06320340|Experimental|Group II|
89154535|NCT06320327|Experimental|CBD Group|This group will apply the CBD cream in accordance with the manufacturer's recommendations at designated time points throughout the study.
89154536|NCT06320327|Placebo Comparator|Placebo Group|This group will apply a placebo moisturizer cream that will match the scent, volume, and viscosity of the CBD cream.
89154537|NCT06320327|No Intervention|Control Group|This group will not apply any cream and will skip all cream-related procedures during the study.
89154538|NCT06320314|Experimental|mild to moderate melasma|adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)
89154539|NCT06320314|Experimental|mild to moderate acne induced PIHP|adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e., less than 10 inflammatory lesions)
89154540|NCT06320314|Experimental|solar lentigo|adult patients suffering from solar lentigo with a pigmentation score > 5
89154541|NCT06320301|Experimental|Adebrelimab + GEMOX + TKI|"Adebrelimab, 20 mg/kg, 30-minute intravenous infusion, once every 3 weeks (Q3W)~TKI:~Lenvatinib: 12 mg (3 capsules 4 mg) or 8 mg (2 capsules 4 mg) QD Apatinib: 250 mg orally, QD, 5 days on 2 days off or QOD Sorafenib: 0.4g (2 × 0.2g) twice or once daily Anlotinib: 12 mg orally before breakfast, QD. The drug was taken continuously for 2 weeks and stopped for 1 week.~GEMOX:~Gemcitabine 800mg/m2 and oxaliplatin 85mg/m2, IV, D2, D15, D29, until 6 cycles of treatment"
89154542|NCT06320288||Children with cerebral palsy|"All children will undergo :~A neuro-articular assessment~A gait analysis on a walking track and with three inertial units to analyze the behavior of their trunk and center of mass during walking.~Assessment of gross motor function~Static posturography~Functional assessment of the trunk~Functional assessment of balance"
89154543|NCT06320288||Children with typical development|"All children will undergo :~A neuro-articular assessment~A gait analysis on a walking track and with three inertial units to analyze the behavior of their trunk and center of mass during walking.~Static posturography~Functional assessment of the trunk~Functional assessment of balance"
89154544|NCT06320275|Experimental|Storytelling Intervention|The Storytelling video intervention created is approximately 20 minutes long.
89154545|NCT06320275|Active Comparator|control group|Routine hospital protocol was applied to the women in this group. Storytelling fertility awareness video intervention was also given to the control group after the study.
89154546|NCT06320249|Experimental|The high-frequency manipulation group|In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.
89154547|NCT06320249|Experimental|The low-frequency manipulation group|In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
89154548|NCT06320249|Active Comparator|The cervical traction group|The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
89154549|NCT06320236||Emergency department patients tested for pulmonary embolism.|
89154550|NCT06320223||Prostate cancer patients with PSMA PET|"Inclusion:~Adult patients with~biopsy/histo proven prostate cancer who~underwent PSMA PET (any type)~for staging or re-staging at any stage and who~have at least 3-year overall survival follow-up data available will be included consecutively.~Exclusion:~Patients with neuroendocrine prostate cancer~Patients with metastasized or disseminated malignancy other than prostate cancer."
89154551|NCT06320210||Children with asthma, parents/guardians of children with asthma, school staff|"Children will be recruited from two University of Chicago Charter elementary schools. Children with a diagnosis of asthma and their parents will be eligible for inclusion in the study and will specifically be targeted for study recruitment. Staff and administrators at each school will also be recruited through in-person, phone, and email communication, primarily through word of mouth and professional development days. UCCS teachers, staff, and administrators will also be included in the program evaluation and we will obtain appropriate consent.~Up to 400 families with a child/children with asthma from two UCCS schools will be added to a registry database. A total of 68 children with a diagnosis of asthma and their parents will be recruited for evaluation of the multi-component program, resulting in a total of 136 children and parents. We will also recruit 24 teachers, staff, and administrators across the two schools to participate in the evaluation of the overall program."
89154552|NCT06320197||Passed in situ assessment|This group passed their in situ assessment (summative assessment)
89154553|NCT06320197||Failed in situ assessment|This group failed their in situ assessment (summative assessment)
89154554|NCT06320171|Experimental|15 min|"The intervention in the study involves a unique application of 15 min of NESA microcurrents~The applied program, designated as Program 7, is aimed exclusively at affecting the autonomic nervous system of the patient. Therefore, no start-up or current preparation programs are applied for this particular intervention. This program involves changes in stimulus times and frequencies, varying from 192 Hz to 1429 Hz, generating symmetrical positive and negative polarity impulses."
89154555|NCT06320171|Experimental|30 min|"The intervention in the study involves a unique application of 30 min of NESA microcurrents~The applied program, designated as Program 7, is aimed exclusively at affecting the autonomic nervous system of the patient. Therefore, no start-up or current preparation programs are applied for this particular intervention. This program involves changes in stimulus times and frequencies, varying from 192 Hz to 1429 Hz, generating symmetrical positive and negative polarity impulses. These impulses elicit responses from the autonomic nervous system (ANS), with the goal of measuring changes in various vascular and ultrasonographic variables proposed by the research team of the Universidad Europea de Madrid.~The intensity for all sessions is set to low, following the Arndt-Schulz law. A maximum total time of 10 minutes is considered for connecting the patient to the device at the beginning and for removing the device at the end of the session."
89154556|NCT06320171|Experimental|45 min|"The intervention in the study involves a unique application of 45 min of NESA microcurrents~The applied program, designated as Program 7, is aimed exclusively at affecting the autonomic nervous system of the patient. Therefore, no start-up or current preparation programs are applied for this particular intervention. This program involves changes in stimulus times and frequencies, varying from 192 Hz to 1429 Hz, generating symmetrical positive and negative polarity impulses."
89154559|NCT06320145|Experimental|Group A (Cryotherapy Group)|About 15 Women suffering from primary dysmenorrhoea who will receive cryotherapy sessions (3 days per week for 20 minutes), in addition to core stability exercise.
89154560|NCT06320145|Experimental|Group B (core stability Group)|About 15 Women suffering from primary dysmenorrhoea who will receive core stability exercises only
89154561|NCT06320132||Retrospective group|Patients treated for spontaneous intracranial hemorrhage before March 13, 2024.
89154562|NCT06320132||Prospective group|Patients treated for spontaneous intracranial hemorrhage after March 13, 2024.
89154563|NCT06320119|Experimental|Personal approach on asthma control (PDO group)|
89154564|NCT06320119|No Intervention|Non-personalized approach (UC group)|
89154565|NCT06320106|Experimental|CP group|Participants with cerebral palsy are recruited.
89154566|NCT06320106|Experimental|TD group|Typically developing children are recruited.
89154567|NCT06320093|Experimental|Sound intervention|the SOUND intervention is a new and innovative method of applying musical activities in a circle consisting of elderly people with mild-to-moderate dementia, caregivers, family caregivers and young people.
89154568|NCT06320080|Experimental|TQB2223 injection+ AK105 Injection|TQB2223 injection combined with AK105 (Penpulimab) injection, once every three weeks. 21 days as a treatment cycle.
89154569|NCT06320067|Active Comparator|Arm A of SABR Comparison|SoC (ADT + ARSI ± docetaxel + local RT)
89154570|NCT06320067|Experimental|Arm S of SABR Comparison|SoC (ADT + ARSI ± docetaxel + local RT) + SABR
89154571|NCT06320067|Active Comparator|Arm A of 177Lu-PSMA-617 Comparison|SoC (ADT + ARSI ± docetaxel ± local RT)
89154572|NCT06320067|Experimental|Arm P of 177Lu-PSMA-617 Comparison|SoC (ADT + ARSI ± docetaxel ± local RT) + 177Lu-PSMA-617
89154573|NCT06320067|Active Comparator|Arm A(N) of Niraparib Comparison|SoC (ADT + Apalutamide ± docetaxel ± local RT)
89154574|NCT06320067|Experimental|Arm N of Niraparib Comparison|SoC (ADT ± docetaxel ± local RT) + Nira-AA+P
89154575|NCT06320054|No Intervention|Standard Prenatal Care|Standard Prenatal Care, biometric screenings, and surveys (baseline, 4-12 weeks postpartum).
89154576|NCT06320054|Experimental|Maternal Health Management Program|Program participants will receive 10 fresh, local meals each week, delivered to their homes, health coaching including cooking and physical activity, biometrics screenings, and educational support to enable sustainable lifestyle change.
89154577|NCT06320041|Experimental|low dose oxelidine group|Oxelidine fumarate (10ml, 20mg) + normal saline 190ml diluted to 200ml. PCIA parameters were set as follows: background infusion rate was 0, self-controlled dosage was 0.35mg (3.5ml), locking time was 6min, and load was 1.5mg
89154578|NCT06320041|Experimental|high dose oxelidine group|Oxelidine fumarate (10ml, 20mg) + normal saline 190ml diluted to 200ml. PCIA parameters were set as follows: background infusion rate was 0, self-controlled dosage was 0.5mg (5ml), locking time was 6min, and load was 1.5mg
89154579|NCT06320041|Active Comparator|hydromorphone group|Hydromorphone (6ml, 12mg) + normal saline (194ml) diluted to 200ml. PCIA parameters were set as follows: background infusion rate was 0, self-controlled dosage was 0.3mg (5ml), locking time was 6min, and load was 1mg
89154580|NCT06320028|Experimental|Non-invasive Transcranial Focused Ultrasound|"Device: Transcranial Ultrasound Power~The ultrasound will be delivered using a custom Neuromodulation device consisting of 128 element ultrasound array (Openwater) with the ultrasound beam having the following parameters: acoustic frequency = 400 kHz, pulse duration = 5 ms, pulse repetition rate (PRR) = 10 Hz, spatial peak/temporal average acoustic intensity = 435 mW /cm2, peak negative pressure 650 kPa. The ultrasound probe will be secured by a custom-designed headset created by Openwater. The Localite Neuronavigation Software (TMS Navigator 3.3 adapted for ultrasound device), including a 3D camera, fiducial markers on the headset and pointer, and software will register the position of the probe with respect to the patient's structural MRI."
89154581|NCT06320015||SMART Participant|Emergency department patients at with a substance use disorder who have received SMART services
89154582|NCT06320015||Usual Care|Emergency department patients with a substance use disorder who have not received SMART services
89154584|NCT06319989|Other|Biplane Ultrasound|The intervention group will receive caudal epidural block under the guidance of biplane ultrasound.
89154585|NCT06319989|Other|Single plane Ultrasound|The procedures for patients in the control group will be guided by conventional single-plane ultrasound.
89154586|NCT06319976|Experimental|open chain exercises for rotator cuff muscles and advices for postural correction|Group will be subdivided into three subgroups according to their body mass index to normal, over weight and obese type1. All subjects will receive open chain exercises for rotator cuff muscles and advices for postural correction.
89154587|NCT06319976|Active Comparator|Advices for Postural correction|Group will be subdivided into three subgroups according to their body mass index to normal, over weight and obese type1. All subjects will receive advices for postural correction. .
89154588|NCT06319963|Experimental|Arm A : Refractory newly diagnosed|Refractory recurrent and/or metastatic cervical or oropharyngeal cancer that is not amenable to local therapy with curative intent (ie, surgery or radiation therapy with or without chemotherapy).
89154589|NCT06319963|Experimental|Arm B : newly diagnosed locally advanced|Participants who have newly diagnosed locally advanced HPV-related oropharyngeal cancer (defined by AJCC 8th edition [ie, T1-2N2-N3, T3-T4N0-N3]) or cervical cancer (stages IB to IVA) that has never been treated with curative intent, and who are candidates to begin an SoC treatment (surgery, radiation therapy with or without chemotherapy).
89154590|NCT06319950|Experimental|High-dose Furmonertinib group|Furmonertinib, 160mg po qd
89154591|NCT06319950|Active Comparator|Osimertinib group|Osimertinib, 80mg po qd
89154592|NCT06319937|Experimental|OA Group|Knee OA were included in the study. All patients exhibited evident radiographic changes in either unilateral or bilateral knees, consistent with a diagnosis of osteoarthritis, and were classified as Kellgren Lawrence (K-L) grade 2.
89154593|NCT06319911||Primary Anatomic|Those subjects who have the AETOS implanted in the Primary Anatomic configuration
89154594|NCT06319911||Primary reverse|Those subjects who have AETOS implanted in the Reverse configuration
89154595|NCT06319898|Experimental|Lavender aromatherapy sticker|Lavender aromatherapy sticker on patient Calming music from Sirius station 68 (Spa) playing via overhead speakers Overhead lights off, two lanterns lit to provide dim lighting Avoid stirrup use
89154596|NCT06319898|No Intervention|Control - no Intervention|Non-aromatic (placebo) sticker on patient No music playing Overhead lights on Stirrups used
89154597|NCT06319885|Experimental|Gain-framed|One daily text-message and weekly alcohol use assessment. The text-messages focus on the positive consequences of drinking less.
89154598|NCT06319885|Experimental|Loss-framed|One daily text-message and weekly alcohol use assessment. The text-messages focus on the negative consequences of a high alcohol-intake.
89154599|NCT06319885|Experimental|Static-tailored|One daily text-message and weekly alcohol use assessment. The text-messages are adapted to the participant's gender and to baseline information on (e.g.) participants' drinking patterns, social network, and self-efficacy. One message per week is adapted to the day on which the participants find it most challenging to reduce their drinking.
89154600|NCT06319885|Experimental|Adaptive-tailored|One daily text-message and weekly alcohol use assessment. The text-messages are adapted to the participant's gender and to baseline information on (e.g.) participants' drinking patterns, social network, and self-efficacy. One message per week is adapted to the day on which the participants find it most challenging to reduce their drinking. In addition, text messages are adapted to the weekly alcohol-assessment over time and participants can demand supportive Just-In-Time messages.
89154601|NCT06319885|Experimental|Combined|This arm combines all features of the arms Adaptive-tailored and Gain-framed.
89154602|NCT06319885|No Intervention|Assessment-only|The control group. Participants do only receive 4 questions on their alcohol intake once a week.
89154603|NCT06319872|Experimental|All participants|Participants will receive either drug or placebo for 180 days.
89154604|NCT06319859|Active Comparator|Group A|patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
89154605|NCT06319859|Active Comparator|Group B|patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
89154606|NCT06319846|Experimental|Tirofiban treatment group|Patients in this arm will receive a total of 48.5 hours of tirofiban in addition to standardized secondary prevention therapy.
89154607|NCT06319846|Placebo Comparator|Tirofiban placebo group|Patients in this arm will receive a total of 48.5 hours of tirofiban placebo in addition to standardized secondary prevention therapy.
89154608|NCT06319833|Experimental|Physical activity interacting with a video|This experimental condition involves engaging in physical activity interspersed with rest periods. The type of exercises are based on phase I.
89154609|NCT06319833|No Intervention|Control condition|
89154612|NCT06319807|Experimental|Digital Health Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, and 3) tips to foster self-efficacy and skills training around responsive feeding - provide fully automated tailored feedback, which will include theory-driven content that aims to normalize common issues and problems, provide active solutions to feeding problems and affirm positive behavior. Participants will receive daily text messages for 12 weeks. Twice a week participants will be asked to self-monitor their adherence to goals in response to a text messaging prompt and will immediately receive tailored feedback and tips.
89154613|NCT06319807|Active Comparator|Safety Control|Participants will receive tips to foster self-efficacy and skills training around infant safety. Participants will receive daily text messages for 12 weeks. Twice a week participants will be asked to self-monitor their adherence to safety goals in response to a text messaging prompt and will immediately receive tailored feedback and tips.
89154614|NCT06319781||Atopic dermatitis|"In addition to all other basis assessments, subjects diagnosed with AD are to complete the following forms: EASI, vIGA-AD, SCORAD, TIS, and POEM."
89154615|NCT06319781||Alopecia areata|"In addition to all other basis assessments, subjects diagnosed with AA are to complete the following forms: SALT and PGIS"
89154616|NCT06319781||Psoriasis|"In addition to all other basis assessments, subjects diagnosed with psoriasis are to complete the following forms: PASI, SAPASI, PGA, PLSI"
89154617|NCT06319781||Vitiligo|"In addition to all other basis assessments, subjects diagnosed with vitiligo are to complete the following forms: VASI, VETF, and VIDA"
89154618|NCT06319768|Active Comparator|- In group A (PTX group) (n:25):|Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection.
89154619|NCT06319768|Active Comparator|- In group B(PRP group) (n:25):|Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP.
89154620|NCT06319768|Active Comparator|- In group C (combined PTX & PRP) (n:25):|Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes.
89154621|NCT06319755||Post-surgical patients|Adults having had pancreatoduodenectomy (Whipple's) surgery for curative intent.
89154622|NCT06319755||Matched controls|Participants matched to each post-surgical participant by age, sex, body mass index (BMI), smoking status.
89154623|NCT06319742||Stroke|
89154624|NCT06319742||TIA|
89154625|NCT06319742||Stroke Mimic|
89154626|NCT06319716|Experimental|VIDEO|Participants assigned to the VIDEO arm will receive one brief Diabetes Self-Management Education and Support (DSMES) video per week for 24 weeks. The videos will be delivered via text message.
89154627|NCT06319716|Experimental|VIDEO+CHW|Participants assigned to the VIDEO+CHW arm will receive one brief DSMES video per week, in addition to bi-weekly support calls from a community health worker (CHW), for 24 weeks. The DSMES videos will be delivered via text message.
89154628|NCT06319716|No Intervention|CONTROL|Participants assigned to the CONTROL group will continue to receive usual care.
89154629|NCT06319703|Experimental|DSMES+CHW (IDEAL)|Participants in this group will receive brief pre-recorded DSMES videos, which include both educational and Social Cognitive Theory-based behavioral content. Participants will receive 1 DSMES video via text message each week for a total of 24 weeks with each video lasting about 5 minutes in duration. In addition, they will also receive brief phone calls from CHWs every 2 weeks during the 24 weeks video program. During these calls, CHWs will assess whether participants need assistance on social determinants of health (SDOH) barriers. If needed, CHWs will link participants to available services within the community. CHWs will also provide assistance on navigating the complex health care systems and serve as an advocate for patients during doctor visits if needed.
89154630|NCT06319703|No Intervention|Wait-list control group (CONTROL)|Participants in this group will continue to receive the standard of usual care for their T2D at their doctor's office during the course of our study.
89154631|NCT06319690|Experimental|Group A|Lion's Breath Technique + Chest Percussion Therapy
89154632|NCT06319690|Active Comparator|Group B|Chest Percussion Therapy only
89154633|NCT06319677||ECMO treatment group|Critically ill adult patients treated with ECMO using one or more antimicrobial agents
89154634|NCT06319677||Non-ECMO treatment group|Critically ill adult patients using one or more antimicrobial agents not receving ECMO
89154635|NCT06319664||Clivus type|The dural attachment originates from petroclival fissure, and the main portion of lesion is situated on middle-upper clivus, mainly grows toward the median line and even the heterolateral direction, could involve in the whole clivus region from dorsum sellae to foramen magnum.
89154636|NCT06319664||Petroclival type|The dural attachment originates likewise from petroclival fissure, but primarily extends toward the homolateral dorsal petrosum region, and the main portion is center on middle-upper clivus and grows toward petrous apex region forward and cerebellopontine angle region backward, leading to the homolateral trigeminus being compressed outwards.
89154637|NCT06319664||Petroclivosphenoidal type|The site of origin lies on petroclival region, while the main part of lesion is located in posterior cranial fossa and extends forward and upward along petroclival fissure, and could spread to posterior clinoid process, dorsum sellae and parasellar area with striding petrous ridge, or expanding into Meckel's cave (MC) and even reaching posterior wall of cavernous sinus (CS) through MC. Overall, the growth pattern direction is basically from posterior cranial fossa to middle cranial fossa and from the infratentorial to supratentorial compartment.
89154638|NCT06319664||Sphenopetroclival Subtype I|Sphenopetroclival type (S-PC type): The site of origin saddles the petrous ridge and invades the CS and parasellar region widely. The growth pattern is different from the PC-S type, mainly from the middle cranial fossa to the posterior cranial fossa. This type is then further classified into two subtypes based on the relationship between CS and the lesion site of origin. Subtype I (S-PC I type): The lesion mainly originates from posterior part of CS and posterior clinoid process region, could invade and break though the CS wall, and the main part of lesion expands towards parasellar, middle cranial fossa, and petrous apex, even invades the dorsum sellae and posterior cranial fossa through tentorium. As a result, the CS wall is mostly rough, and the dural space between the lesion and the temporal lobe is not well-defined on MRI.
89154639|NCT06319664||Sphenopetroclival Subtype II|The dural attachment of lesion entirely originates within the CS leading to CS region expansile hyperplasia with the virtually intact sinus wall, and part of lesion could spread into the petrous apex and posterior cranial fossa through posterior sinus wall; the large partial lesions may also encroach on the lateral wall of the CS expansion towards the middle cranial fossa. The lateral sinus wall is relatively smooth and maintains the dural space between the lesion and the temporal lobe on MRI.
89154640|NCT06319664||Central Skull Base type|The dural attachment originates from the petroclival fissure, but growth pattern is widespread invasion of central skull base region and structures bilaterally and the site of origin extensively involves in dorsum sellae, clivus and bilateral suprasellar, parasellar and CS areas even cerebellopontine angle region.
89154641|NCT06319651|Experimental|Experimental Group|"In addition to the routine Phase 1 cardiac rehabilitation, Resistance Exercises~Extending thighs~Closing thighs~Opening thighs~Bending thighs~Bending ankles~Ankle opening"
89154642|NCT06319651|Active Comparator|Routine Phase 1 cardiac rehabilitation|Routine Phase 1 cardiac rehabilitation only.
89154643|NCT06319638|Experimental|Rehabilitation therapy+Stellate ganglion block|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
89154644|NCT06319638|Placebo Comparator|Rehabilitation therapy+placebo block|The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
89154645|NCT06319625|Experimental|Stellate ganglion block+Rehabilitation therapy|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
89154646|NCT06319625|Placebo Comparator|Rehabilitation therapy+placebo block|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
89154647|NCT06319612|Experimental|Stellate ganglion block+routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.The experimental group was given Stellate Ganglion Block.
89154648|NCT06319612|Placebo Comparator|placebo+routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.
89154649|NCT06319599|Experimental|Routine therapy+Stellate ganglion block|"The study lasts 10d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.~Based on the invention above, the patients in the experimental group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
89154650|NCT06319599|Placebo Comparator|Routine therapy+placebo|The study lasts 10d for each patient. During the treatment, All the participants are provided with the routine rehabilitation therapy.
89154651|NCT06319573|Active Comparator|Standard Counseling|Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
89154652|NCT06319573|Experimental|Counseling Supported by Univfy® Report|Patients in this group will be counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill out the same anonymous online questionnaire.
89154653|NCT06319560|Experimental|Intervention Group (Group 1)|Oral hydroxychloroquine 200mg daily will be prescribed to women in this group from recruitment (14-20 weeks) till delivery
89154654|NCT06319560|No Intervention|Control Group (Group 2)|Women will receive standard treatment for diabetes such as metformin and insulin.
89154655|NCT06319547|Experimental|hepatic hydrothorax|patient with hepatic hydrothorax that develop pleural effusion either unilateral or bilateral
89154656|NCT06319534|Experimental|Comprehensive rehabilitation+Stellate ganglion block|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
89154657|NCT06319534|Placebo Comparator|Comprehensive rehabilitation+placebo|Patients enrolled are firstly numbered for privacy with software and divided into the observation group and the control group with. Additionally, the staffs involved in assessment would not participate in the intervention of the study. The treatment lasts 10 days.
89154658|NCT06319521|Experimental|Rehabilitation therapy+Stellate ganglion block|The study lasts 10d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
89154659|NCT06319521|Placebo Comparator|Rehabilitation therapy+placebo block|The study lasts 10d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy.
89154660|NCT06319508|Experimental|routine rehabilitation treatment+Stellate ganglion block|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The experimental group was given Stellate Ganglion Block.
89154661|NCT06319508|Placebo Comparator|routine rehabilitation treatment+Placebo|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
89154662|NCT06319495|Experimental|Rehabilitation therapy+Stellate ganglion block|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)."
89154663|NCT06319495|Placebo Comparator|Rehabilitation therapy+placebo|The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
89154664|NCT06319482|Experimental|Proactive CPAP Therapy (Intervention)|Patients will undergo CPAP enabled with proactive therapy.
89154665|NCT06319482|Active Comparator|Conventional APAP Therapy (Control)|Patients will undergo conventional APAP therapy.
89154666|NCT06319469|Experimental|group B|8 mg silodosin
89154667|NCT06319469|Experimental|group A|silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet
89154668|NCT06319456|Experimental|Lisaftoclax (APG-2575) combined with Acalabrutinib|
89154669|NCT06319456|Active Comparator|Immunochemotherapy regimens|
89154670|NCT06319443|Experimental|Liquid vinegar|Liquid vinegar (6% acidity) consumed at a dosage of 2 tablespoons (diluted in water and consumed at mealtime) twice daily (4 tablespoons total per day).
89154671|NCT06319443|Placebo Comparator|Vinegar pill|One pill consumed daily in the morning.
89154672|NCT06319430|Experimental|robots|Participants will be randomly allocated to groups A or B. Those in group A will co-design and build their LEGO™ robot, using the researcher's assistance, as led by the child. A go-along interview will be conducted during the co-design with the child . The co-design session will be video recorded to provide context, visual data, and to inform the qualitative analysis. Videos will be deleted right after analysis. A research assistant (RA) will visit the participant's home twice a week for 30 to 45 minutes (after school or on the weekend) to play with the child and their built LEGO™ robots for four weeks (8 sessions total).
89154673|NCT06319430|Experimental|conventional toys|Group B will engage in the same process of 8 play intervention sessions over four weeks with the research assistant; however, they will receive conventional play tools. The RA will carry a prepared play pack for the play intervention session.
89154674|NCT06319417|Experimental|HT treatment|Every caramel contained 15 mg of HT, cyclodextrins and xylitol. Patients consumed 4 caramels/day, totalling 60 mg of HT/day.
89154675|NCT06319417|Placebo Comparator|Placebo treatment|Every caramel contained cyclodextrins and xylitol. Patients consumed 4 caramels/day.
89154676|NCT06319404||negative lymph node|
89154677|NCT06319404||postive lymph node|
89154678|NCT06319391||donor/acceptor expression group|
89154679|NCT06319391||donor expression/acceptor non-expression|
89154680|NCT06319391||donor non-expression/acceptor expression|
89154681|NCT06319391||donor/acceptor non-expression group|
89154682|NCT06319339|Experimental|Control: Vumerity intake, then Placebo|Participants will receive a single dose of VUMERITY (diroximal fumarate, 462mg). After a minimum period of 7 days, they will then receive a single dose of the placebo (microcrystalline cellulose, 462 mg).
89154683|NCT06319339|Placebo Comparator|Control: Placebo intake, then Vumerity|Participants will receive a single dose of placebo (microcrystalline cellulose, 462 mg). After a minimum period of 7 days, they will then receive a single dose of VUMERITY (diroximal fumarate, 462mg).
89154684|NCT06319339|Experimental|PAD: Vumerity intake, then Placebo|Participants with peripheral artery disease (PAD) will receive a single dose of VUMERITY (diroximal fumarate, 462mg). After a minimum period of 7 days, they will then receive a single dose of the placebo (microcrystalline cellulose, 462 mg).
89154685|NCT06319339|Placebo Comparator|PAD: Placebo intake, then Vumerity|Participants with peripheral artery disease (PAD) will receive a single dose of placebo (microcrystalline cellulose, 462 mg). After a minimum period of 7 days, they will then receive a single dose of VUMERITY (diroximal fumarate, 462mg).
89154686|NCT06319326||Preterm infants|Preterm infants (≤33 weeks gestational age) of any birth weight receiving full bolus enteral feeding, aged 1-4 weeks.
89154687|NCT06319326||Term infants|Term infants of any birth weight aged 1-4 weeks.
89154688|NCT06319313|Experimental|JMT101+ docetaxel|
89154689|NCT06319313|Experimental|JMT101+HB1801|
89154690|NCT06319313|Experimental|HB1801|
89154691|NCT06319300|Experimental|AI group|AI-assisted insulin dosage adjustment
89154692|NCT06319300|Active Comparator|Doctor group|doctor adjust insulin
89154693|NCT06319287|Active Comparator|PEP-TISSEEL+SOC|"Treatment for the PEP-TISSEEL+SOC arm is:~PEP-TISSEEL~Mepitel dressing followed by Tegaderm® (Mepilex can be used if subjects are allergic to Tegaderm)~3M Cavilon® (may be used on the borders prior to placing the Tegaderm or Mepilex)~Padded 3-layer secondary outer layer dressing (Profore (Smith and Nephew (Memphis, TN)); and~Offloaded with an offloading Controlled Ankle Movement (CAM) Boot (Foot Defender (Miami, FL) or Total Contact Cast (TCC)) Use of an alternate offloading device (e.g., Charcot Restraint Orthotic Walker (CROW) boot, custom shoe, etc.) may be approved on a case-by-case basis"
89154694|NCT06319287|Sham Comparator|Standard of Care|"Fibracol~Mepitel dressing followed by Tegaderm (Mepilex can be used if subjects are allergic to Tegaderm)~3M Cavilon (may be used on the borders prior to placing the Tegaderm or Mepilex )~Padded 3-layer secondary outer layer dressing (Profore (Smith and Nephew (Memphis, TN)) or equivalent); and~Offloaded with an offloading CAM Boot (Foot Defender (Miami, FL) or TCC)~Use of an alternate offloading device (e.g., Charcot Restraint Orthotic Walker (CROW) boot, custom shoe, etc.) may be approved on a case-by-case basis"
89154695|NCT06319274|Experimental|Iloprost|Patients randomized to active treatment (n=225 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
89154696|NCT06319274|Placebo Comparator|Isotonic saline|Patients randomized to placebo treatment (n=225 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
89154697|NCT06319261|Active Comparator|guided biofilm therapy group|Sites treated with guided biofilm therapy.
89154698|NCT06319261|Other|conventional root debridement group|Sites treated with conventional manual instrumentation only.
89154699|NCT06319248|Placebo Comparator|Standard of Care Group with Placebo|Subjects will receive standard of care for sepsis and three doses of placebo every 8 hours .
89154700|NCT06319248|Experimental|Standard of Care with Midodrine Group|Subjects will receive standard of care for sepsis and three doses of midodrine every 8 hours.
89154701|NCT06318923|Other|Multiple sclerosis patients|MS patients with the relapsing-remitting form (RRMS) and Expanded Disability Status Scale (EDSS) ≤ 4
89154702|NCT06318923|Other|Control participants|Patients without global cognitive impairment
89154703|NCT06318819|Experimental|Dental Floss Holders|Dental Floss Holders was constructed.
89154704|NCT06318819|Active Comparator|conventional flossing|conventional flossing to the opposite arch.
89154705|NCT06318793||Group without POC|
89154706|NCT06318793||Group with POC and major POC|
89154707|NCT06318702|No Intervention|KETEM|This group was given a three-week standard gynecological cancer education program by the Cancer Early Diagnosis, Screening and Education Centers (KETEM) unit.
89154708|NCT06318702|Experimental|constructivist model group|Gynecologic cancer education was given to the intervention group for 3 weeks based on the constructivist education model, taking into account the assimilation, adaptation and balancing stages of education.
89154709|NCT06318663|Active Comparator|Survivor Mom Companion Program|Participants in the Survivor Moms' Companion intervention will complete a minimum of 4 Survivor Moms' Companion psychoeducational modules with weekly tutor support and will then complete an ending assessment. Sessions with tutors are conducted over the phone or in person at the Buffalo Prenatal and Perinatal Network and last for 45 minutes.
89154710|NCT06318663|Placebo Comparator|Waitlist Control|Participants in the waitlist control group will complete the baseline assessment over the phone, wait six weeks, and then complete the ending assessment. Those on the waitlist will then be offered the Survivor Moms' Companion intervention. Sessions with tutors are conducted over the phone or in person at the Buffalo Prenatal and Perinatal Network and last for 45 minutes.
89154711|NCT06318520|Experimental|Arm 1|Calcium silicate based resin cement
89154712|NCT06318520|Experimental|Arm 2|Resin modified glass ionomer cement
89154713|NCT06318052|Experimental|CO2 laser treatment|The FemTouch delivery system is used in conjunction with the AcuPulse CO2 laser system and the AcuScan120 microscanner to provide fractional treatments in gynecology. The system enables the delivery of laser energy along the vaginal walls. Through the use of the scanner, this laser energy is delivered in a fractional manner, selectively treating less than 100% of the tissue surface. This allows the tissue to heal much faster than when treating non-fractionally (100% of the surface) because much of the tissue is left unharmed, while the efficacy of the treatment remains significant.
89154714|NCT06318052|Active Comparator|Gynomunal gel treatment|Gynomunal is a hormone/free, vaginal moisturizing gel for women with vaginal dryness. Gynomunal has been clinically proven in treating vaginal dryness, and its symptoms, including itching, burning, and pain (as well as discomfort during sex). Gynomunal is a liposomal formulation containing natural hop extract, Vitamin E and hyaluronic acid.
89154715|NCT06318026|Experimental|Centralized Intervention|A centralized intervention by a social worker or counselor, added to usual care that systematically offers outreach and shared decision-making for symptoms due to alcohol use.
89154716|NCT06318026|Experimental|Primary Care Intervention|A primary care intervention added to usual care that uses state-of-the-art implementation interventions to systematically encourage primary care providers to offer routine shared decision-making for symptoms due to alcohol use.
89154717|NCT06318026|No Intervention|Usual Care|Usual primary care
89154718|NCT06318000||Persons with visual impairments|Youth aged 7-17 years, male and female, with congenital or acquired visual impairment
89154719|NCT06318000||Able bodied persons|Youth aged 7-17 years, male and female, without impairments
89154720|NCT06317922|Experimental|treatment arm|"Installation of artificial tears of Thealoz DUO (Investigational medical device containing trehalose 3 g and hyaluronic acid 0.15 g ), 10 ml.~Dosage:1 drop x 4 times/day by 1 week before the Intravitreal injection until 3 months afterward."
89154721|NCT06317922|Placebo Comparator|control arm|"Installation of saline solution (Hydrabak containing Sodium Chloride 0,9 g, Sodium Dihydrogen Phosphate Dihydrate, Disodium Hydrogen Phosphate Dodecahydrate),10 ml.~Dosage: 1 drop x 4 times/day by 1 week before the Intravitreal injection up to 3 months after it."
89154722|NCT06317571|Experimental|fertility support training|The group will receive fertility support training.
89154723|NCT06317571|No Intervention|routine care|They will receive routine care.
89154724|NCT06317532|Active Comparator|Lifestyle modification advice|It will include 29 females suffering from primary dysmenorrhea. They will be asked to follow lifestyle modification advice during the program duration.
89154725|NCT06317532|Experimental|Lifestyle modification advice + Functional exercises|It will include 29 females suffering from primary dysmenorrhea. They will be given the same lifestyle modification advice as group A, in addition to performing a combination of various functional exercises (including two stretching exercises, one yoga position, two core-strengthening exercises, two pelvic area exercises, and Kegel exercises), for 45 minutes per session, three times /week for eight weeks.
89154726|NCT06317415|Experimental|Intervention group|
89154727|NCT06317415|Placebo Comparator|control group|
89154728|NCT06317350|Experimental|GNS-212-E1|
89154729|NCT06317350|Experimental|GNS-212-E2|
89154730|NCT06317350|Active Comparator|GNS-212-ER|
89154731|NCT06317259|Experimental|Breathwork, music, messaging|Subjects will perform a 40 min initial breathwork/music/messaging session with a full EEG cap followed by 7 days of twice daily practice of a 20 min breathwork/music/messaging session. At the end of 7 days, they will again perform the 40 min breathwork/music/messaging session with a full EEG cap.
89154732|NCT06317259|Active Comparator|Breathwork only|Subjects will perform a 40 min initial breathwork only session with a full EEG cap followed by 7 days of twice daily practice of a 20 min breathwork only session. At the end of 7 days, they will again perform the 40 min breathwork only session with a full EEG cap.
89154733|NCT06317259|Active Comparator|Music and messaging|Subjects will perform a 40 min initial music/messaging session with a full EEG cap followed by 7 days of twice daily practice of a 20 min music/messaging session. At the end of 7 days, they will again perform the 40 min music/messaging session with a full EEG cap.
89154734|NCT06316895||surgery group|patients with low-risk papillary thyroid carcinoma who chose thyroid surgery
89154735|NCT06316895||ablation group|patients with low-risk papillary thyroid carcinoma who chose thermal ablation
89154736|NCT06316843|Experimental|1500 Valacyclovir 200 Celecoxib|Treatment will consist of four blue 375mg valacyclovir capsules and one white 200 mg celecoxib capsule
89154737|NCT06316843|Experimental|750 Valacyclovir 200 Celecoxib|Treatment will consist of two blue 375mg valacyclovir capsules, two blue placebo capsules, and one white 200 mg celecoxib capsule
89154738|NCT06316843|Placebo Comparator|Matched Color Placebo Capsules|Treatment will consist of four blue placebo capsules and one white placebo capsule
89154740|NCT06316245||Group DASI ≤ 34|Patients with Duke Activity Status Index (DASI) scores are ≤ 34 before the surgery.
89154741|NCT06316245||Group DASI > 34|Patients with Duke Activity Status Index (DASI) scores are > 34 before the surgery.
89154742|NCT06315985|Experimental|Experimental Group|This was a parallel group, randomized controlled trial. Experimental Group will listen to the music for three days.
89154743|NCT06315985|No Intervention|Control Group|Control Group will take routine care
89154744|NCT06315972|Experimental|Experimental intervention|Application of double-blind add-on clemastine at a dosage of 8 mg/day (morning: 4 mg; evening: 4 mg) + aerobic exercise training 50 min 3x/week over a period of 3 months
89154745|NCT06315972|Placebo Comparator|Control intervention|Application of double-blind add-on placebo (morning and evening) + aerobic exercise training 50 min 3x/week
89154746|NCT06314646||Transanal Transection and Single-Stapled anastomosis (TTSS)|Patients will undergo rectal cancer surgery through low rectal resection with Transanal Transection and Single-Stapled anastomosis (TTSS)
89154747|NCT06314646||Double-stapled Total Mesorectal Excision (TME)|Patients will undergo rectal cancer surgery through low rectal resection with double-stapled anastomosis Total Mesorectal Excision (TME)
89154748|NCT06314568||Patients with vaginal cancer|Patients affected by vaginal cancer
89234918|NCT05887661|No Intervention|Control|patients in this group undergoing laparoscopic hepatectomy was performed with LCVP but no hypovolemic phlebotomy (HP)
89154749|NCT06314451||Patients with respiratory, gastroenterology and dermatology inflammatory conditions|Patients will be purposively sampled to include a spectrum of participants with a range of different diseases and demographics (age, gender, country) for each indication. Sample size will also be led by the point at which no further issues are emerging during the cognitive interview process.
89154750|NCT06314451||Clinicians and researchers skilled in inflammatory diseases|Clinician researchers from each country (UK, USA) will be purposively sampled to include a spectrum of participants with a range of clinical experience and demographics (age, gender, country). Sample size will also be led by the point at which no further issues are emerging during the cognitive interview process.
89154751|NCT06314269||Perioperative cerebrovascular stroke patients|all Patients admitted to General surgery, cardiothorasic surgery and vascular surgery Depatments in assuit university hospitals during one year that will going to operation
89154752|NCT06314152|Experimental|3-point fixation group|During laparoscopic transabdominal preperitoneal inguinal hernia repair, lightweight Mesh Fixation with 3-point Fixation. First fixation is in cooper ligament. Second fixation is in the back of rectus abdominis. Third fixation is in the later of tractus iliopubicus.
89154753|NCT06314152|Active Comparator|1-point fixation group|During laparoscopic transabdominal preperitoneal inguinal hernia repair, lightweight Mesh Fixation with 1-point Fixation in the back of rectus abdominis.
89154754|NCT06313736|Experimental|15-minute single-session depression intervention|This is the adult version of the Action Brings Change (ABC) Project.
89154755|NCT06313736|Experimental|10-minute single-session depression intervention|This includes a shortened version of the ABC Project.
89154756|NCT06313736|Experimental|6-minute single-session depression intervention|This includes a shortened version of the ABC Project.
89154757|NCT06313736|Experimental|2-minute single-session depression intervention|This includes a shortened version of the ABC Project.
89154758|NCT06313632|Experimental|ESP with Bupivacaine Group|Erector spinae plane block with bupivacaine.
89154759|NCT06313632|Sham Comparator|ESP with Placebo|Erector spinae plane injection with a placebo (normal saline).
89154760|NCT06313580|Experimental|Intervention Arm - Yogurt with added Spices|Consumption of twice daily yogurt with added spices for four weeks.
89154761|NCT06313580|Sham Comparator|Sham Arm - Yogurt without added Spices|Consumption of twice daily yogurt without added spices for four weeks.
89154762|NCT06313281|Active Comparator|Group 1|External 0.9% NaCl nasal preparation
89154763|NCT06313281|Active Comparator|Group 2|External nasal preparation with antisepsis by CHG 0.05%
89154764|NCT06313281|Active Comparator|Group 3|Intranasal irrigation with 80 mg of gentamicin added to 1000 ml of 0.9% NaCl plus external nasal preparation with antisepsis by CHG 0.05%
89154765|NCT06311747|Experimental|Oculo-motor exercise|Additional oculo-motor exercises will be administered to participants' warm-up before forehand and backhand stroke evaluation. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight).
89154766|NCT06311162|Experimental|Treatment group (Life-style app)|Parents receive a smartphone app during the main intervention period of 20 weeks. The app (life-style app) aims to promote healthy behaviour through cognitive-behavioural impact factors.
89154767|NCT06311162|Sham Comparator|Control group|The parents get an information sheet with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
89154768|NCT06310330|Active Comparator|Usual care|Standard of care echocardiographic follow-up
89154769|NCT06310330|Experimental|Simplified care|Simplified echocardiographic follow-up
89154770|NCT06310161|Experimental|Bright Light|Light therapy will be delivered by the Re-Timer glasses for 60 minutes during dialysis sessions.
89154771|NCT06310161|Placebo Comparator|Dim Light|Dim light therapy will be delivered by the Re-Timer glasses for 60 minutes during dialysis sessions.
89154772|NCT06308094|Other|Afib with ECV measurement|patients who are referred for catheter ablation will undergo additional CT acquisition for measurement of ECV to determine if there is any association between ECV expansion and Afib burden.
89154773|NCT06307470|Experimental|EMBRACE Group|Immediately following consent, participants randomized to the EMBRACE Group will begin with the EMBRACE intervention. Participants will meet with a registered nurse certified in sexuality and sex education once weekly for 8 - 10 weeks depending on scheduling. Each of the 8 sessions will last between 60 - 90 minutes. Participants will complete baseline measures, immediately following the intervention, and six weeks after the last session. Participants will be compensated for their time with a total up to $150.
89154774|NCT06307470|Active Comparator|Delayed EMBRACE Group|After consenting, participants randomized to the Delayed EMBRACE Group will begin with the EMBRACE intervention 8 weeks after enrollment. Participants will meet with a registered nurse certified in sexuality and sex education once weekly for 8 - 10 weeks depending on scheduling. Each of the 8 sessions will last between 60 - 90 minutes. Participants will complete baseline measures, immediately following the intervention, and six weeks after the last session. Participants will be compensated for their time with a total up to $150.
89154775|NCT06305806|Experimental|Ivabradine + Coordinated Care|"The starting dose will be 5 mg twice a day, and the dose will be modified if needed at the 1 month clinic visit. At this visit, HR will be measured and the dose will be modified as applicable. The maximum dose will be 7.5 mg twice daily if HR is ˃ 90 bpm.~The table below provides the dosing of ivabradine based on HR.~Supine Resting HR 60-80 2.5 mg BID Supine Resting HR >80 5 mg BID Supine Resting HR >90 7.5 mg BID~*Resting HR should be measured 5 minutes after lying down"
89154776|NCT06305806|Experimental|Ivabradine Placebo + Coordinated Care|
89154777|NCT06305806|Experimental|Ivabradine + Usual Care|"The starting dose will be 5 mg twice a day, and the dose will be modified if needed at the 1 month clinic visit. At this visit, HR will be measured and the dose will be modified as applicable. The maximum dose will be 7.5 mg twice daily if HR is ˃ 90 bpm.~The table below provides the dosing of ivabradine based on HR.~Supine Resting HR 60-80 2.5 mg BID Supine Resting HR >80 5 mg BID Supine Resting HR >90 7.5 mg BID~*Resting HR should be measured 5 minutes after lying down"
89154778|NCT06305806|Experimental|Ivabradine Placebo + Usual Care|
89154779|NCT06305793|Experimental|IVIG + Coordinated Care|IVIG (Gamunex); 2g /kg monthly for 9 months (36 weeks)
89154780|NCT06305793|Experimental|IVIG Placebo + Coordinated Care|Saline: Same dosage as IVIG; monthly for 9 months (36 weeks)
89154781|NCT06305793|Experimental|IVIG + Usual Care|IVIG (Gamunex); 2g /kg monthly for 9 months (36 weeks)
89154782|NCT06305793|Experimental|IVIG Placebo + Usual Care|Saline: Same dosage as IVIG; monthly for 9 months (36 weeks)
89154783|NCT06305780|Experimental|IVIG|In the IVIG study, randomization will be implemented with 1:1:1:1 allocation among the combination of IVIG/placebo and coordinated/ usual non-pharmacologic care. All participants will receive IVIG or placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months). See NCT06305793 for additional details.
89154784|NCT06305780|Experimental|Ivabradine|In the ivabradine study, randomization will be implemented with 1:1:1:1 allocation among the combinations of ivabradine/placebo and coordinated/usual care. All participants receive either ivabradine or placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months). See NCT06305806 for additional details.
89154785|NCT06305364|Experimental|Gixam followed by standard of care colonoscopy|This is a single-arm study. All participants will undergo the Gixam test following a standard of care colonoscopy
89154786|NCT06305273|Experimental|Supine|Participant will be ventilated with facemask while in supine position.
89154787|NCT06305273|Experimental|Head elevated|Participant will be ventilated with facemask while in head elevated position.
89154788|NCT06305260|No Intervention|Traditional Lumbar Palpation|This group will include parturients who are randomized to traditional lumbar palpation prior to epidural placement. This is the current standard of care.
89154789|NCT06305260|Experimental|Pre-procedural Lumbar Ultrasound|This group will include parturients who are randomized to a pre-procedural lumbar ultrasound prior to epidural placement.
89154790|NCT06305156|Other|Bone mineral density CT vs DXA|Single arm study, all participants receive CT and DXA.
89154791|NCT06301503|Experimental|1. USG Guided Combined LPB-SNB with Isobaric Bupivacaine|"After completing the surgical procedure under spinal anaesthesia, participants are positioned in the lateral decubitus position with the side to be blocked facing upwards. Identification of the lumbar plexus nerves is carried out with ultrasound guidance using the trident approach. Under aseptic conditions, local anesthetic infiltration with 2% lidocaine (3ml)was given, and a lumbar plexus block (LPB) technique was performed by inserting a 100mm insulated nerve block needle through the transverse process, delivering a bolus of 0.25% isobaric bupivacaine (20ml).~Without changing the participant's position, the sciatic nerve is identified by the gluteal approach. After local anesthetic infiltration with 2% lidocaine (3ml), sciatic nerve block (SNB) was performed by inserting a 100 mm insulated nerve block needle to the sciatic nerve, delivering a bolus of 0.25% isobaric bupivacaine (20ml).~Aspiration is carried out before injecting anaesthetic agent on each puncture sites."
89154792|NCT06301503|Active Comparator|2. Control|Postoperatively, participants in this group was positioned in the lateral decubitus position and both the lumbar plexus and sciatic nerves were identified using ultrasound. Local anesthetic infiltration was given at both puncture sites, but participants of this group did not receive a combination of LPB-SNB with bupivacaine.
89154793|NCT06298877|Experimental|Frailty|Single arm study evaluating frailty by assessment of questionnaires and three different frailty tools
89154794|NCT06295432|Experimental|DZD9008+AZD4205|All subjects will receive both DZD9008 tablets and AZD4205 capsules orally. DZD9008 dosing will start at 200 mg daily, AZD4205 dosing will start at 75 mg daily.
89154795|NCT06295120|Experimental|3 days|3 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
89154796|NCT06295120|Experimental|4 days|4 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
89154797|NCT06295120|Experimental|5 days|5 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
89154798|NCT06295120|Experimental|6 days|6 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
89154799|NCT06295120|Active Comparator|7 days|7 days of treatment with phenoxymethylpenicillin 1.2 MIE 4 times daily.
89154800|NCT06292351|Experimental|DMB-I (Dimebon) + Placebo|
89154801|NCT06292351|Experimental|DMB-I (Dimebon)|
89154802|NCT06292351|Placebo Comparator|Placebo|
89154803|NCT06291857|Experimental|Group-1A CIC|1M injection of SARs-CoV-2 antigen (35 μg), tNIV antigens, 60 μg/strain and Matrix-M adjuvant (75 μg)
89154804|NCT06291857|Experimental|Group-1A placebo|IM injection of 0.5 mL
89154805|NCT06291857|Experimental|Group-1B Novavax|IM injection, Each 0.5 mL
89154806|NCT06291857|Experimental|Group-1B Fluarix|IM injection syringe, at 0.5 mL with 15 µg per strain.
89154807|NCT06291857|Active Comparator|Group-2A CIC|1M injection of SARs-CoV-2 antigen (35 μg), tNIV antigens, 60 μg/strain and Matrix-M adjuvant (75 μg)
89154808|NCT06291857|Active Comparator|Group-2A Placebo|IM injection of 0.5 mL of placebo
89154809|NCT06291857|Active Comparator|2B Novavax|IM injection, Each 0.5 mL dose
89154810|NCT06291857|Active Comparator|Group-2B Fluarix|IM injection in prefilled syringes, at 0.7 mL with 60 µg per strain. of Fluarix
89154811|NCT06286423|Experimental|Colchicine 0.6 mg treatment group|Treatment group will be given active drug (0.6mg Colchicine) 2x/day (once if subject has kidney disease) for 14 days. Subsequently treatment group subjects will be given active drug (0.6mg Colchicine) 1x/day for 76 +/- days (or once every other day if subject has kidney disease).
89154812|NCT06286423|Placebo Comparator|Control/Placebo group|Control/Placebo group will be given placebo that looks identical to study drug with no active ingredients and will take 2x/day (once if subject has kidney disease) for 14 days. Subsequently Control/Placebo group will be given placebo 1x/day for 76 +/- days (or once every other day if subject has kidney disease).
89154813|NCT06283888|Experimental|CYP2C19 Genotype Guided DAPT|"Patients with CYP2C19 *2 or *3 carrier will be received ticagrelor 60mg or 45mg bid (if <50 kg, ≥75 years) + aspirin 100 mg Patients with CYP2C19 *2 or *3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd~At post-PCI 3 months, monotherapy P2Y12 inhibitor (ticagrelor or clopidogrel) will be treated for a further 9 months."
89154814|NCT06283888|Experimental|Conventional DAPT|"Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd~At post-PCI 3 months, monotherapy P2Y12 inhibitor (ticagrelor or clopidogrel) will be treated for a further 9 months."
88804533|NCT04396834|Experimental|Lorcaserin first, then placebo|Participants first receive lorcaserin (10 mg BID) for 7 days. After a washout period of 7 days, they then receive placebo tablets (BID) for 7 days.
88804534|NCT04396834|Experimental|Placebo first, then lorcaserin|Participants first receive placebo (BID) for 7 days. After a washout period of 7 days, they then receive lorcaserin (10 mg BID) for 7 days.
89154815|NCT06282523|Experimental|Healthy Minds Program (HMP) - Awareness first|Participants will be assigned to use the HMP mobile app on symptoms of psychological distress, and will complete the Awareness module first.
89154816|NCT06282523|Experimental|Healthy Minds Research Platform (HMRP) - Awareness first|Participants will be assigned to use the HMRP web app on symptoms of psychological distress, and will complete the Awareness module first.
89154817|NCT06282523|Experimental|HMP - Connection first|Participants will be assigned to use the HMP mobile app on symptoms of psychological distress, and will complete the Connection module first.
89154818|NCT06282523|Experimental|HMRP - Connection first|Participants will be assigned to use the HMRP web app on symptoms of psychological distress, and will complete the Connection module first.
89154819|NCT06281756|Placebo Comparator|Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with placebo|Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received placebo for 8 weeks.
89154820|NCT06281756|Active Comparator|Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with Trazodone|Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received trazodone for 8 weeks.
89154821|NCT06281366||Control|Pregnant women with a positive first-trimester screening for preeclampsia (high risk) and no pregnancy complications (preeclampsia, fetal death, preterm birth, PPROM, low birthweight).
89154822|NCT06281366||Cases|Pregnant women with a positive first-trimester screening for preeclampsia (high risk) and any of the following pregnancy complications: preeclampsia, fetal death, preterm birth, PPROM, low birthweight.
89154823|NCT06280976|Active Comparator|SOC: Statin ± Aspirin (per ACC guidelines)|The SOC group: participant receive routine care as per cardiologist. Study doctor will prescribe medications that they choose themselves.
89154824|NCT06280976|Experimental|AT: Statin, Aspirin, Nexlizet, Leqvio, Vascepa, Jardiance, Colchicine|An AT group: FDA-approved drugs will be used to reduce cholesterol and cardiovascular risk.
89154825|NCT06279208||Children with Down Syndrome|30 boys with Down Syndrome, between 6 and 12 years old, coming for a routine car consultation during which blood sampling is scheduled (6 different care dedicated centers).
89154826|NCT06279208||Children without genetic abnormality|30 boys without genetic abnormality, between 6 and 12 years old, coming to an analysis laboratory for a blood test (3 different laboratories)
89154827|NCT06273774|Experimental|Panel A: MK-8189 Dosing Regimen 1|Participants will receive MK-8189 once daily (QD) at dosing regimen 1 for up to 14 days.
89154828|NCT06273774|Experimental|Panel B: MK-8189 Dosing Regimen 2|Participants will receive MK-8189 QD at dosing regimen 2 for up to 14 days.
89154829|NCT06273774|Experimental|Panel C: MK-8189 Dosing Regimen 3|Participants will receive MK-8189 QD at dosing regimen 3 for up to 14 days.
89154830|NCT06273774|Placebo Comparator|Placebo|Participants will receive MK-8189-matching placebo QD for up to 14 days.
89154831|NCT06273683||Complete salpingectomy using a hand-held bipolar energy instrument|
89154832|NCT06273683||Complete salpingectomy using traditional suture ligation|
89154833|NCT06271616|Experimental|Prevention (ibrutinib)|Patients receive ibrutinib PO QD on days 1-30 of each cycle. Cycles repeat every 30 days for up to 12 cycles on study. Additionally, patients undergo and echocardiography prior to registration and blood sample collection throughout study.
89154834|NCT06271291||Observational|Participants undergo blood sample collection, complete questionnaires, have their medical records reviewed and undergo pancreatic cyst fluid collection during standard of care endoscopic ultrasounds fine needle aspiration.
89154835|NCT06269107|Experimental|IcoSema|Participants will receive once weekly IcoSema subcutaneously with or without oral anti diabetic drugs for 40 weeks.
89154836|NCT06269107|Experimental|Insulin glargine|Participants will receive once daily insulin glargine subcutaneously with or without oral anti diabetic drugs for 40 weeks.
89154837|NCT06258304|Experimental|GIGA-564: Dose Escalation (Phase 1A)|Up to 5 dose levels [0.3, 1.0, 3.0, 10.0, and 20.0 milligrams per kilogram (mg/kg)] will be evaluated sequentially. Participants will receive GIGA-564 intravenously over at least 60 minutes on Day 1 of every 3 weeks (3 weeks = 1 cycle) for up to 4 cycles until time of confirmed disease progression, unacceptable toxicity, or other reason for treatment discontinuation.
89154838|NCT06258304|Experimental|GIGA-564: Dose Expansion (Phase 1B)|Dose expansion will be initiated following the completion of dose escalation (Phase 1A). Participants will receive up to 4 cycles of one of up to two tolerable dose levels of GIGA-564. If two dose levels are selected, participants will be randomized 1:1 to the two dosing cohorts. GIGA-564 will be given intravenously over at least 60 minutes on Day 1 of every 3 weeks (3 weeks = 1 cycle) for up to 4 cycles until time of confirmed disease progression, unacceptable toxicity, or other reason for treatment discontinuation.
89154839|NCT06257147|Placebo Comparator|Group 1 wards (physician education)|For Group 1 wards, physician education will be provided. All physicians treating patients in general medical wards will undergo a training session at the start of the study. Education content includes latest evidence on short-course antibiotic therapy and criteria for de-escalation to oral antibiotics for BSI-E. The educational materials will be prepared by Infectious Diseases physicians, and will be presented during one of the monthly departmental meetings, which routinely involve physician education. Ample time will be provided for answering questions from physicians. During the study period, the same material will be presented to new medical staff joining the department. The educational materials will be sent to all physicians in the department regardless of their attendance of the meeting. Patients will receive standard of care.
89234919|NCT05887648|Experimental|SinDance|Participants in the SinDance group will attend an educational briefing session on the importance of exercising, and participate in a 6-week SinDance exergame intervention
89234920|NCT05887648|No Intervention|Control|Participants in the control group will attend usual activities offered by the senior activity centres. The control group will be offered an opportunity to play the SinDance exergame after completing the last data collection (i.e. 3-months from baseline).
89154840|NCT06257147|Active Comparator|Group 2 wards (physician education + paper reminder)|For Group 2 wards, physician education will be provided as in Group 1. A paper reminder will be attached in the medical records of all consecutive patients on the first working day after Enterobacterale is isolated from blood culture. The reminder documents (1) the clinical and host criteria that should be considered for prescribing short-course antibiotic therapy, and (2) options of oral antibiotics to complete the treatment course. These recommendations are based on results of the trials demonstrating non-inferiority of short-course and oral-switch therapy for BSI-E.
89154841|NCT06257147|Active Comparator|Group 3 wards (multifaceted antibiotic stewardship intervention)|Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.
89154842|NCT06256432|Experimental|Ambrisentan - Low Dose 1|Liquid solution for oral administration, dose < 250 µg/day, up to 60 days
89154843|NCT06256432|Experimental|Ambrisentan - Low Dose 2|Liquid solution for oral administration, dose < 250 µg/day, up to 60 days
89154844|NCT06256432|Active Comparator|Terlipressin|Sterile liophyilized powder, to be reconstituted for intravenous administration, at a dose indicated by the study investigator and administered for up to 14 days, considering the following recommendation: 1 mg terlipressin administered in 2-minute bolus every 6 hours for 3 days, and dose of terlipressin increased to 2 mg every 6 hours in the absence of a decrease of at least 30% in serum creatinine by day 4
89154847|NCT06253156|Experimental|virtual reality|The experimental group will be given virtual reality-based training in addition to standard training.
89154848|NCT06253156|No Intervention|standard training|The control group will be given only standard training.
89154849|NCT06247371|Experimental|Decision aid|Patients will be presented with a decision aid featuring personalized cost information, as well as other information about angiotensin receptor neprilysin inhibitor (ARNI) and angiotensin-converting enzyme inhibitor (ACEI) medications. These patients will then be tasked to choose a preferred medication and reflect on which attribute holds the most significance for them. The preferred medication will be communicated to the clinicians during the clinic session.
89154850|NCT06247371|No Intervention|Usual care|Patients are managed as per usual clinical routine without the decision aid.
89154851|NCT06245655|Active Comparator|Active TENS|For the Active TENS group, the device will be set to 80 Hz (hfTENS) and device intensity (0-8) will be titrated to patient comfort, as is the standard protocol for TENS use.
89154852|NCT06245655|Placebo Comparator|Placebo TENS|For the placebo TENS group, setup will be identical, but the device will not be turned on.
89154853|NCT06245213|Active Comparator|ANAVEX3-71 30 mg TID (Part A)|The first active treatment arm of the study during Part A (multiple ascending doses).
89154854|NCT06245213|Active Comparator|ANAVEX3-71 60 mg TID (Part A)|The second active treatment arm of the study during Part A (multiple ascending doses).
89154855|NCT06245213|Placebo Comparator|ANAVEXX3-71 Placebo TID (Part A)|The placebo arm of Part A (multiple ascending doses).
89154856|NCT06245213|Active Comparator|ANAVEX3-71 TBD mg TID (Part B)|The active arm of Part B of the study. The dose will be determined based on data obtained in Part A.
89154857|NCT06245213|Placebo Comparator|ANAVEX3-71 Placebo TID (Part B)|The placebo arm of Part B of the study.
89154858|NCT06244914|Experimental|tDCS + taVNS|tDCS + taVNS will be applied before rehabilitation.
89154859|NCT06244914|Active Comparator|tDCS + sham-taVNS|tDCS + sham-taVNS will be applied before rehabilitation.
89154860|NCT06244914|Active Comparator|sham-tDCS + taVNS|sham-tDCS + taVNS will be applied before rehabilitation.
89154861|NCT06244914|Sham Comparator|sham-tDCS + sham-taVNS|sham-tDCS + sham-taVNS will be applied before rehabilitation.
89154862|NCT06242574||Adults with Alzheimer's disease and related dementia|75 patients with ADRD
89154863|NCT06242574||Care partners of Adults with Alzheimer's disease and related dementia|75 care partners for adults with ADRD
89154864|NCT06242574||Clinicians who treat patients with Alzheimer's disease and related dementia|25 healthcare practitioners
89154865|NCT06242379|Experimental|Bone marrow-mesenchymal stem cell-derived small extracellular vesicles|Single intravitreal injection of Good Manufacturing Practice (GMP) compliant bone marrow (BM)-mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) (50 μg) for single eye
89154866|NCT06239896|Active Comparator|Facilitated Group ACP Session|Participants in the group ACP visit arm will attend a one-time 90-minute facilitated group ACP session where they will review the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video and PREPARE easy-to-read ADs with the new PSH-specific content and cover letters.
89154867|NCT06239896|Active Comparator|Facilitated one-on-one ACP visits|Participants in the one-on-one ACP visit arm will attend a one-time 90-minute ACP session with a facilitator where they will review the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video and PREPARE easy-to-read ADs with the new PSH-specific content and cover letters.
89154868|NCT06239116|Experimental|RM-718 (Cohort A1)|Single dose of RM-718 (4) or placebo (2)
89154869|NCT06239116|Experimental|RM-718 (Cohort A2)|Single dose of RM-718 (4) or placebo (2)
89154870|NCT06239116|Experimental|RM-718 (Cohort A3)|Single dose of RM-718 (4) or placebo (2)
89154871|NCT06239116|Experimental|RM-718 (Cohort A4)|Single dose of RM-718 (4) or placebo (2)
89154872|NCT06239116|Experimental|RM-718 (Cohort A5)|Single dose of RM-718 (4) or placebo (2)
88804535|NCT04396262|Experimental|HTD-blueberry beverage with white bread|The beverage prepared using hydro-thermodynamic processing of whole wild blueberries.
89154873|NCT06239116|Experimental|RM-718 (Cohort A6)|Single dose of RM-718 (4) or placebo (2)
89154874|NCT06239116|Experimental|RM-718 (Cohort B1)|Multiple doses of RM-718 (4) or placebo (2)
89154875|NCT06239116|Experimental|RM-718 (Cohort B2)|Multiple ascending doses of RM-718 (4) or placebo (2)
89154876|NCT06239116|Experimental|RM-718 (Cohort B3)|Multiple ascending doses of RM-718 (4) or placebo (2)
89154877|NCT06239116|Experimental|RM-718 (Cohort B4)|Multiple ascending doses of RM-718 (4) or placebo (2)
89154878|NCT06239116|Experimental|RM-718 (Cohort B5)|Multiple ascending doses of RM-718 (4) or placebo (2)
89154879|NCT06239116|Experimental|RM-718 (Cohort C1)|Multiple ascending doses of RM-718 (8)
89154880|NCT06239116|Experimental|RM-718 (Cohort C2)|Multiple ascending doses of RM-718 (8)
89154881|NCT06239116|Experimental|RM-718 (Cohort C3)|Multiple ascending doses of RM-718 (8)
89154882|NCT06238414|Experimental|Intervention/case participant|The case group will receive an 8-session early psychological intervention
89154883|NCT06238414|No Intervention|Control case/participant|The control group will be treated as usual (TAU)
89154884|NCT06233747|Experimental|I-CARE|I-CARE (Improving Care, Accelerating Recovery & Education) is a quality improvement program designed to deliver evidence-based psychosocial skills to adolescents during mental health boarding. The program consists of 7 web-based animated videos and workbook exercises, facilitated by licensed nursing assistants/behavioral health technicians/safety attendants who provide one-on-one safety supervision during boarding. I-CARE will be offered to all eligible adolescents who are boarding and only those who agree to participate in a program evaluation will be involved in the research component.
89154885|NCT06233747|No Intervention|Usual Care|"These hospitals currently offer basic safety supervision and medical monitoring for adolescents during mental health boarding. This is the usual care condition."
89154886|NCT06231719|Experimental|Anti-D Immunglobulin Injection with Cold Spray|Using cold spray before the Anti-D immunoglobulin injection
89154887|NCT06231719|Experimental|Anti-D Immunglobulin Injection with Manuel Pressure|Apply Manuel pressure before the Anti-D immunoglobulin injection
89154888|NCT06231719|Placebo Comparator|Standard Anti-D Immunoglobulin Injection|Standard procedure for Anti-D immunglobulin injection
89154889|NCT06225596|Experimental|Cohort 1: BT8009 Arm1|Participants will receive BT8009 and a standard dose of pembrolizumab.
89154890|NCT06225596|Experimental|Cohort 1: BT8009 Arm 2|Participants will receive BT8009 and a standard dose of pembrolizumab.
89154891|NCT06225596|Active Comparator|Cohort 1:Arm 3:Participants receiving Platinum-based combination chemotherapy + avelumab maintenance|
89154892|NCT06225596|Experimental|Cohort 2: BT8009 Arm 1|Participants will receive IV dose of BT8009.
89154893|NCT06225596|Experimental|Cohort 2: BT8009 Arm 2|Participants will receive IV dose of BT8009.
89154894|NCT06225596|Experimental|Cohort 2: Arm 3: BT8009 (Not Recruiting)|Participants will receive BT8009 and a standard dose of pembrolizumab.
89154895|NCT06224283||Performed cryotherapy|Patients who received cryoablation for desmoid tumor and no chemotherapy
89154896|NCT06223828|Experimental|Azithromycin Intervention|Participants in this arm will receive Azithromycin 10mg/kg/dose (max dose 500mg) once daily for 3 days.
89154897|NCT06223828|No Intervention|Standard Care|Participants will receive standard care without Azithromycin.
89154898|NCT06223360|Experimental|Low Dose Benfotiamine|Participants will take 300mg benfotiamine capsules twice a day (BID; once in the morning and once in the evening).
89154899|NCT06223360|Experimental|High Dose Benfotiamine|Participants will take 600mg benfotiamine capsules twice a day (BID; once in the morning and once in the evening).
89154900|NCT06223360|Placebo Comparator|Placebo|Participants will take placebo capsules twice a day (BID; once in the morning and once in the evening). In the placebo group, capsules will be filled with inactive microcrystalline cellulose. The other capsule components, shape and color are identical between benfotiamine and placebo arms.
89154901|NCT06221683|Experimental|SDC group|Patients with CBF fusion gene (RUNX1: : RUNX1T1 and CBFB: : MYH11) or KMT2A: : MLLT3(AF9) , KMT2A: : MLLT10(AF10) , KMT2A: : MLLT4(AF6) fusion gene or KIT mutation will receive SDC regimen, including one course of HAE (Homoharringtonine, cytarabine, etoposide) in induction I. These patients will continue on the SDC (HAE) regimen in the second course if the MRD is < 1% after induction I, otherwise venetoclax will be added to the SDC group sequentially on Day 2 after the end of HAE. FLT3-ITD will be given sorafenib or gilteritinib as early as possible, and patients with KIT mutations will be recommended to add avapritinib as appropriate. These targeted drugs will not be combined with venetoclax.
89154902|NCT06221683|Experimental|LDC group|Patients with the exception of the CBF fusion gene (RUNX1: : RUNX1T1 and CBFB: : MYH11) or those with the KMT2A: : MLLT3(AF9) , KMT2A: : MLLT10(AF10) , KMT2A: : MLLT4(AF6) fusion gene or KIT mutation will receive the LDC (MAG/IDAG+ venetoclax) regimen in induction I. Patients with MRD ≥1% or KIT mutations, assessed after induction I, will receive the HAE plus venetoclax (or targeted drugs) regimen, otherwise, they will receive MAG/IDAG + venetoclax. FLT3-ITD will be given sorafenib or gilteritinib as early as possible, and patients with KIT mutations will be recommended to add avapritinib as appropriate. These targeted drugs will not be combined with venetoclax.
89154903|NCT06221111|Experimental|rimegepant|"Rimegepant 75mg oral dissolving tablet (ODT)~Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days"
89154904|NCT06221111|Placebo Comparator|placebo|Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
89154905|NCT06220669|Experimental|LY3541860 Phase 2a Dose Level 1|LY3541860 will be given intravenously (IV)
89154906|NCT06220669|Experimental|LY3541860 Phase 2a Dose Level 2|LY3541860 will be given IV.
89154907|NCT06220669|Placebo Comparator|Placebo Phase 2a|Placebo will be given IV.
89154908|NCT06220669|Experimental|LY3541860 Phase 2b Dose Level 3|LY3541860 will be given IV.
89154909|NCT06220669|Experimental|LY3541860 Phase 2b Dose Level 4|LY3541860 will be given IV.
89154910|NCT06220669|Placebo Comparator|Placebo Phase 2b|Placebo will be given IV.
89234921|NCT05887622|Experimental|Moderate potassium/low sodium|Subjects will consume a diet moderation in potassium and low in sodium.
89234922|NCT05887622|Experimental|Moderate potassium/high sodium|Subjects will consume a diet moderation in potassium and high in sodium.
89234923|NCT05887622|Experimental|High potassium/high sodium|Subjects will consume a diet moderation in potassium and high in sodium.
89154911|NCT06217757|Experimental|Low-dose radiotherapy combined with sugemalimab, olaparib, etoposide and cisplatin|Participants will receive the following treatment regimens: LDRT cisplatin + etoposide + sugemalimab+olaparib. Induction treatment will be administered on a 21-day cycle for four cycles. LDRT will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with sugemalimab and olaparib. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
89154912|NCT06217328|Other|Device: Revi System Treatment Arm|Subjects will be implanted with a Revi System and activation of therapy will occur ~4 weeks post implantation and continue for the duration of the study.
89154913|NCT06217328|Other|Device: Revi System - Delayed Activation Control Arm|Subjects will be implanted with a Revi System and activation of therapy will be delayed until 4 months post implantation. At this time the Revi System will be activated to begin therapy and will continue for the duration of the study.
89154914|NCT06217081|Experimental|Investigational Topical Tissue Adhesive|3M Topical Tissue Adhesive
89154915|NCT06217081|Active Comparator|Control Topical Tissue Adhesive|Histoacryl® Blue Topical Skin Adhesive
89154916|NCT06216665|Active Comparator|Continuous insulin at 40mU/m2/min|Paricipants will receive insulin infused continuously during the hyperinsulinemic euglycemic clamp test of insulin sensitivity.
89154917|NCT06216665|Experimental|Pulsatile insulin at 40mU/m2/min|Participants will receive insulin infused every five minutes during the hyperinsulinemic euglycemic clamp test of insulin sensitivity
89154918|NCT06215534|Other|arm 1|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154919|NCT06215534|Other|arm 2|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154920|NCT06215534|Other|arm 3|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154921|NCT06215534|Other|arm 4|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154922|NCT06215534|Other|arm 5|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154923|NCT06215534|Other|arm 6|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154924|NCT06215534|Other|arm 7|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154925|NCT06215534|Other|arm 8|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154926|NCT06215534|Other|arm 9|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154927|NCT06215534|Other|arm 10|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154928|NCT06215534|Other|arm 11|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154929|NCT06215534|Other|arm 12|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154930|NCT06215534|Other|arm 13|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154931|NCT06215534|Other|arm 14|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154932|NCT06215534|Other|arm 15|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154933|NCT06215534|Other|arm 16|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154934|NCT06215534|Other|arm 17|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154935|NCT06215534|Other|arm 18|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89154936|NCT06215144|Experimental|Experimental Arm|Up to 2,000 mg/day
89154937|NCT06215144|Placebo Comparator|Control Arm|Matching placebo
89154938|NCT06213883|Experimental|Response to Exercise and Rest|Study participants undergo Prescribed Exercise, Self-Paced Exercise, and Rest conditions over the course of 3 study days
89154939|NCT06208345|Experimental|Treatment as usual (TAU) with Life-Style app|Children in the intervention group receive treatment as usual (TAU) and the parents receive a smartphone app during the main intervention period of 20 weeks. The app (life-style app) aims to promote healthy behaviour through cognitive-behavioural impact factors.
89154940|NCT06208345|No Intervention|Treatment as usual (TAU)|The children in the control group only receive treatment-as-usual (TAU) and the parents do not have an active app during the main intervention period of 20 weeks. TAU includes lifestyle behaviour counselling, dietary counselling by specialized dieticians, prescriptions for physiotherapy, as provided at the last clinical visit.
89154941|NCT06207981|Active Comparator|Control arm|"Pelvic chemoradiotherapy Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~49.5 Gy (5 x 1.65 Gy/week) to the pelvis~60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes~Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given"
89154942|NCT06207981|Experimental|Exeprimental arm|"Induction chemotherapy with mDCF (4 cycles) followed by pelvic chemoradiotherapy~Induction chemotherapy consists of mDCF administered every 2 weeks:~Docetaxel (40 mg/m², day 1),~Cisplatin (40 mg/m², day 1)~5-FU (1200 mg/m²/day IV for 2 days) Chemoradiotherapy is the same as described above in control arm"
89154943|NCT06203665|Experimental|Patients enrolled in the protocol|An alveolar recruitment nameuver will be performed after the release of pneumoperitoneum
89234924|NCT05887050|Active Comparator|Active|Tablet containing 400 mcg chromium (delivered as Crominex® 3+, a blend of chromium, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and 325 mg of MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoid Complex)
89234925|NCT05887050|Placebo Comparator|Placebo|Identical size, shape, and weight maltodextrin tablet
89154944|NCT06203340|Experimental|Lumbar school training|"Lumbar back school is a programme for patient groups that provides information about the anatomy, biomechanics, optimal posture, ergonomics and lumbar exercises.~The aim of the lumbar lumbar school school is to reduce low back pain and to teach the individual to take care of his lumbar. It is applied to increase the skills of individuals to solve the problems they encounter in daily life and to teach them ways of coping. Assessment of the patient, explanation of the anatomy, functions and pathophysiology of low back pain, appropriate posture, use of correct body mechanics and theoretical explanation of exercise."
89154945|NCT06203340|Experimental|Core stabilisation training|Core exercise programmes are designed to improve stabilisation, strength and power. Core exercise programmes are aimed to improve the sense of bodily movement and position (proprioception), which systematically progresses, prepares for activities and goals. Patients are started from the beginning level of the core exercises and in the following weeks, to the extent that the patients can do will be made more difficult.
89154946|NCT06203340|No Intervention|Control group|Patients with a previous diagnosis of pain in the lumbar region will be sought. Patients will be invited to the institution and will be informed about low back pain. Patients with low back pain will be evaluated with self-report scales and functional tests. No treatment will be applied as a treatment.
89154947|NCT06196879|Experimental|Verekitug (UPB-101): 100 mg Q12W / Placebo|Participants will receive 0.5 milliliter (mL) of verekitug (UPB-101) formulated solution (containing 100 milligrams [mg] of verekitug [UPB-101]) and 2.0 mL of placebo subcutaneously in two separate injections every 12 weeks up to Week 48.
89154948|NCT06196879|Experimental|Verekitug (UPB-101): 400 mg Q24W / Placebo|Participants will receive 2.0 mL of verekitug (UPB-101) formulated solution (containing 400 mg of verekitug [UPB-101]) and 0.5 mL of placebo subcutaneously in two separate injections every 24 weeks up to Week 48. Participants will also receive 2 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.
89154949|NCT06196879|Experimental|Verekitug (UPB-101): 100 mg Q24W / Placebo|Participants will receive 0.5 mL of verekitug (UPB-101) formulated solution (containing 100 mg of verekitug [UPB-101]) and 2.0 mL of placebo subcutaneously in two separate injections every 24 weeks up to Week 48. Participants will also receive 2 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits.
89154950|NCT06196879|Placebo Comparator|Placebo|Participants will receive 0.5 mL of matching placebo and 2.0 mL of matching placebo subcutaneously in two separate injections every 12 weeks up to Week 48.
89154951|NCT06193811|Experimental|R-T1-T2-T3|Reference (R): Avenciguat (BI 685509) (TF2), fasted Test 1 (T1): Avenciguat (BI 685509) (iCF), fasted Test 2 (T2): Avenciguat (BI 685509) (iCF), fed Test 3 (T3) Nexium mups from Day -4 to 1; on Day 1 intake of Nexium mups is followed by the intake of Avenciguat (BI 685509) (iCF), fasted There will be a washout period of at least 6 days between Avenciguat (BI 685509) administrations.
89154952|NCT06193811|Experimental|T1-T3-R-T2|
89154953|NCT06193811|Experimental|T2-R-T3-T1|
89154954|NCT06193811|Experimental|T3-T2-T1-R|
89154955|NCT06192953|Experimental|Stimulated group|5 sessions per week for 6 weeks maximum of reeducation with Functional Proprioceptive Stimulation
89154956|NCT06192953|No Intervention|Simulated group|5 sessions per week for 6 weeks maximum with the device of Functional Proprioceptive Stimulation settled but not activated
89154957|NCT06191887|Experimental|Treatment (BARRF based chimeric antigen receptor T-cells)|Patients undergo leukapheresis. Patients then receive cyclophosphamide IV, over 60 minutes and fludarabine IV over 30 minutes on day -5 to -3 or bendamustine IV over 10 minutes on days -4 and -3. Patients receive BAFFR based chimeric antigen receptor T-cells IV on day 0. Patients undergo echocardiography and MRI at screening, CT scan, PET scan, bone marrow biopsy/aspirate and blood sample collection throughout the study and tumor biopsy at progression.
89154958|NCT06191159|Active Comparator|Standard of Care|The Standard of Care arm will consist of the scalpel for the initial skin incision and further randomization to have completion of the surgery with standard electrocautery or PEAK PlasmaBlade.
89154959|NCT06191159|Experimental|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the surgery, including the initial skin incision.
89154960|NCT06191159|Experimental|Standard Electrocautery|Standard electrocautery will be used for the entirety of the surgery, including the initial skin incision.
89154961|NCT06183723|Experimental|People living with HIV with poor adherence to HAART|People living with HIV (PLWH) with adherence below the specific proportion of days covered (PDC), which is defined as the specific level that corresponds to 90% at viral suppression (< 200 copies/mL).
89154962|NCT06182774|Experimental|Lenalidomide & Dexamethasone|
89154963|NCT06182774|Active Comparator|Daratumumab, Lenalidomide & Dexamethasone|Standard of Care
89154964|NCT06182176|Experimental|SMC plus anthelminthics group|Anthelminthic drugs (albendazole and praziquantel) will be administered 24 hours (on Day 0) before administration of the following SMC drugs: Sulphadoxine-pyrimethamine (SP) on Day 1 and Amodiaquine (AQ) daily on Days 1, 2 and 3.
89154965|NCT06182176|Active Comparator|SMC group|Participants randomized into the control communities will receive Vitamin A and Zinc supplements as control drugs on Day 0. On Day 1, these participants will receive the SMC drug (Sulphadoxine-pyrimethamine) (SP) and Amodiaquine (AQ) daily on Days 1,2 and 3.
89154966|NCT06181201||Person with rectal cancer|People with locally advanced rectal cancer who are to receive induction chemotherapy with FLOFIRINOX followed or not by neo-adjuvant radio-chemotherapy of the Cap50 type.
88804536|NCT04396262|Experimental|Sweetened water (control) with white bread|The water control of the same volume and with the same amount of available carbohydrate as HTD-blueberry beverage.
89154969|NCT06176248|Active Comparator|Block and arthrodistension|
89154970|NCT06176248|Placebo Comparator|Placebo and arthrodistension|
89154971|NCT06175000|Experimental|Arm I (obinutuzumab|Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity.
89154972|NCT06175000|Active Comparator|Arm II (observation)|Patients undergo observation for a total of 2 years.
89154973|NCT06157424|Experimental|Acupuncture + Standard treatment|Standard treatment plus thread embedding acupuncture and auricular acupuncture
89154974|NCT06157424|Active Comparator|Standard treatment|Standard treatment
89154975|NCT06155084|Experimental|Part 1 - Dose Escalation, 400mg/d (Cohort1)|Oral tablet(s), once daily in 28-day cycles
89154976|NCT06155084|Experimental|Part 1 - Dose Escalation 500mg/d (Cohort 2)|Oral tablet(s), once daily in 28-day cycles
89154977|NCT06155084|Experimental|Part 2 - Dose Expansion Oral tablet(s)|Oral tablet(s), once daily in 28-day cycles
89154978|NCT06154252|Experimental|CABA-201|DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with DM ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with ASyS IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with IMNM
89154979|NCT06153095|Experimental|Phase 1 Lupus Nephritis|Administration of IMPT-514
89154980|NCT06153095|Experimental|Phase 2 Lupus Nephritis|Administration of IMPT-514
89154981|NCT06153095|Experimental|Phase 2 SLE without Lupus Nephritis|Administration of IMPT-514
89154982|NCT06151938||Standardised allergen extract from house dust mites (ACARIZAX®)|Observational study to collect real-world data: patients will be treated with ACARIZAX house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet for one tablet per day.
89154983|NCT06149169|Experimental|Relma-cel|The PK, safety and efficacy of Relma-cel will be evaluated in 1 x 10^8 CAR+T cells dose level
89154984|NCT06148766|Experimental|Eternal Renewal Regenerating Face Cream|"Participants will be required to apply the test product in the morning and before bedtime at night.~After thoroughly cleansing and toning the face, the participants will take a pea-sized amount of face cream and apply it to the face, massaging over the entire face with small circular movements until the cream has fully absorbed."
89154985|NCT06148753|Experimental|Eternal Renewal Regenerating Face Serum|"Participants will be required to apply the test product in the morning and before sleeping at night.~After thoroughly cleansing and toning the face, the participants will apply 2-3 drops onto clean dry fingers and massage over the entire face until fully absorbed.~The product should be followed with the participants' preferred moisturizer."
89154986|NCT06148714|Experimental|Provitalize Probiotic|Participants will take 2 capsules every morning on an empty stomach before their first meal of the day.
89154987|NCT06148714|Placebo Comparator|Placebo|Participants will take 2 capsules every morning on an empty stomach before their first meal of the day.
89154988|NCT06148506||Ribociclib Arm|ribociclib (600 mg, 3 weeks on/1 week off)+ IA/FUL + goserilin for premenopausal patients
89154989|NCT06148506||Combination chemotherapy|The choice of which chemotherapy combination used on study is decided by the physician
89154990|NCT06146582|Experimental|Intervention Arm|Group received support from Laguna Coaches
89154991|NCT06146582|No Intervention|Control Arm|Group received no support from Laguna Coaches
89154992|NCT06145152|Experimental|Adaptive|Subjects in the Adaptive group will get updated and adjusted training programs based on daily readiness level
89154993|NCT06145152|Active Comparator|Static|Subjects in the Static group will get the same inital training program as the Adaptive group but will not get updated and adjusted training programs based on daily readiness level
89154994|NCT06142630|No Intervention|Supine group|Patients remained supine
89154995|NCT06142630|Experimental|Prone group|Patient remained prone
89154996|NCT06142630|Experimental|Lateral position group|Patient remained in a lateral position
89154997|NCT06140524|Experimental|Safety Run-In (Part 1)|Sequential groups of participants will be enrolled to assess the initial safety and tolerability of the step-up regimen leading up to the start of different full doses of linvoseltamab.
89154998|NCT06140524|Experimental|Expansion (Part 2) - Dose regimen 1|Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens
89154999|NCT06140524|Experimental|Expansion (Part 2) - Dose regimen 2|Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens
89155000|NCT06140524|Experimental|Expansion (Part 2) - Dose regimen 3|Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens
89155001|NCT06140524|Experimental|Expansion (Part 2) - Dose regimen 4|Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens
89155002|NCT06136559|Experimental|Nemtabrutinib|Participants will receive nemtabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met.
89155003|NCT06136559|Active Comparator|Ibrutinib/Acalabrutinib|Participants will receive investigator's choice of ibrutinib or acalabrutinib at specified dose until disease progression, unacceptable toxicity or until discontinuation criteria are met.
89155004|NCT06131619||Experimental|Parkinson's disease patients with cognitive impairment
89155005|NCT06131619||Active Comparator|Parkinson's disease patients without cognıtıve impairment
89155006|NCT06131619||other|Health geriatric persons
89155007|NCT06128356|Experimental|Sublingual dexmedetomidine|Participants will be administered two 60 micrograms sublingual films of IGLMI following start of an autonomic crises. The maximum amount for the study is four oral films of 60 micrograms in 24 hours, two at the beginning of the crises and if needed, two additional within two hours.
89155008|NCT06122467|Experimental|Test group: EQ Product Line|"The following regimen should be completed in both the morning and the evening. The order of use is:~Cleanser Gel Moisturizer."
89155009|NCT06121713|Active Comparator|GCE + Low ALA|Green coffee extract and a low dose of alpha-lipoic acid prior to an oral glucose tolerance test
89155010|NCT06121713|Active Comparator|GCE + High ALA|Green coffee extract and a moderate dose of alpha-lipoic acid prior to an oral glucose tolerance test
89155011|NCT06121713|Placebo Comparator|Placebo|Inert placebo pill prior to an oral glucose tolerance test
89155012|NCT06121297|Experimental|CABA-201|"LN Cohort: Infusion of CABA-201 with preconditioning in subjects with LN~Non-renal SLE Cohort: Infusion of CABA-201 with preconditioning in subjects with SLE who do not meet criteria for inclusion in the LN cohort"
89155013|NCT06119607|Experimental|TRIFLO|
89155014|NCT06119204|Experimental|Intervention (Oviva ODR-I programme)|The intervention arm will follow Oviva ODR-I programe: a 12-week TDR of approximately 850 calories per day through four TDR products daily, supported by the digital scales, CBG meters and link to the OVIVA app.
89155015|NCT06119204|Active Comparator|Control (NHS 12 weeks programme)|The control group will follow usual care, which will be the NHS 12-week digital weight-loss programme
89155016|NCT06117345|Experimental|Parents/Caregivers|Parents/caregivers of children hospitalized in the PICU at Monroe Carell Jr. Children's Hospital at Vanderbilt who will participate in the PICU journal intervention
89155017|NCT06117345|No Intervention|Patients|Pediatric patients ages 8 to 18 years whose parents/caregivers participated in the PICU journal intervention
89155018|NCT06117345|No Intervention|PICU providers and staff|PICU providers and staff who observed or participated in the PICU journal intervention during its use with parents/caregivers
89155019|NCT06113562|Experimental|Persistent hypoxemia after Obstructive sleep apnea group|Participants will receive Patent Foramen Ovale (PFO) closure and followed until repeat sleep apnea testing up to 6 months.
89155020|NCT06113536|Experimental|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
89155021|NCT06111937|Experimental|colonoscopy within 2-4 h|"Patients received ultrasound gastric assessment every 15 minutes 2 hours immediately after taking the last dose of MgSO4 solution. During this period, if the gastric ultrasound assessment showed that the patient had an empty stomach, and painless colonoscopy was performed within 2 hours while the gastric is empty."
89155022|NCT06111937|No Intervention|colonoscopy within 4-6 h|"The patients received ultrasound gastric assessment every 15min 4h immediately after taking the last dose of MgSO4 solution on the examination day, and colonoscopy was to completed within 4-6h after taking the MgSO4 solution if the gastric ultrasound assessment showed that the patient had an empty stomach."
89155025|NCT06103864|Experimental|Dato-DXd + durvalumab|Arm 1: Dato-DXd + durvalumab
89155026|NCT06103864|Active Comparator|Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab|Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin)
89155027|NCT06103864|Experimental|Dato-DXd|Arm 3: Dato-DXd
89155028|NCT06103643|Experimental|High Reality Simulator|Breech birth management training will be given by the responsible investigator, and then one of the groups will be allocated by randomization. Using High Reality Simulator will perform emergency breech birth. These trainings will first be in the form of the instructor responsible for the groups demonstrating the application, and then the students will apply it one by one.
89155029|NCT06103643|Sham Comparator|control group|Using model will perform emergency breech birth. These trainings will first be in the form of the instructor responsible for the groups demonstrating the application, and then the students will apply it one by one.
89155030|NCT06091618|Active Comparator|new technique of ejaculatory preserving laser vaporization prostatectomy|"laser will be employed to preform vaporization. The ejaculatory preserving procedure will be done in the following steps:~Setting a mark cut 1 cm proximal of the verumontanum as orientation.~Complete resection of the middle lobe to the abovementioned mark.~Vaporization of lateral lobes to the capsule and the ventral side to the level of the verumontanum with avoidance of paracollicular digging.~Circular resection of the internal bladder neck.~Apical resection utilizing the colliculus seminalis as a distal resection border and maintaining a 1cm safety area for preservation of ejaculation.~Total removal of prostate cuts and final check to confirm that there are no obstructive components."
89155031|NCT06091618|Active Comparator|conventional technique laser vaporization prostatectomy|non ejaculatory preserving laser vaporization of the prostate
89155032|NCT06091020|Experimental|NT 201|Subcutaneous injections of up to 300 units NT 201 into the peripheral neuropathic pain area
89155033|NCT06091020|Placebo Comparator|Placebo|Subcutaneous injections of placebo into the peripheral neuropathic area
89155034|NCT06085274|Experimental|ICG-SLNB|This is a prospective within-patient clinical study to assess the accuracy of ICG SLNB compared to standard dual-tracer SLNB in breast cancer patients treated with neoadjuvant chemotherapy. For SLNB, triple localization of the sentinel lymph nodes using blue dye, Tc-99m and ICG will be utilized in each patient.
89155035|NCT06082349|Experimental|Lymphaticovenous anastomosis (LVA)|Patients in this group will undergo lymphaticovenous anastomosis at one or more locations on the affected limb, and the procedure will be performed under local anesthesia. During the operation, patients will be blinded using a noise-canceling headphone and blindfolds. Incisions will be made at the sites where lymphatic vessels are obstructed, ensuring no harm to the viable part of the lympahtic system. The locations will be determined prior to the surgery using ICG lymphography. The LVA(s) will be made in the subdermal plane with the aid of a surgical microscope. Generally, 1 to 4 LVAs are made. The LVA(s) is made using a surgical microscope and the operation will take approximately 60 to 90 minutes.
89234926|NCT05886283|Active Comparator|ultrasound phaco groupe|this group had US PHACO using the phaco-chop technique (Stellaris PC: Bausch + Lomb®)
89234927|NCT05886283|Active Comparator|nanolaser phaco group|this group underwent an NL PHACO (Cetus A.R.C. Laser system®)
89234928|NCT05885789||Paediatric patients|
89234929|NCT05885581|Experimental|Group A|Grow Well and will receive the adapted Healthy Beginnings Curriculum (n= 15 mother-infant-caregiver triad) determine the feasibility, acceptability, and preliminary efficacy of the adapted intervention. The intervention will be on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.
89155036|NCT06082349|Sham Comparator|Sham surgery|Patients in this group will undergo sham surgery at one location on the affected limb, and the procedure will be performed under local anesthesia. During the operation, patients will be blinded using a noise-canceling headphone and blindfolds. The locations for LVA surgery will be determined prior to the surgery using ICG lymphography. However, the incision for the sham procedure will be made 2 centimeters medial or lateral to the predetermined site. This is done in order to avoid damage to the lymph vessels as to allow for future LVA surgery. After the incision, no LVA is made. Rather than performing the actual operation, the plastic surgeon will simulate the procedure by applying pressure in the surgical area. To mimic the approximate duration of a regular LVA procedure, the sham operation will take approximately 60 to 90 minutes.
89155037|NCT06081309|Experimental|Open-Label active EEG-based personalized TMS treatment|20 sessions of EEG-based personalized TMS over a maximum of 21 days. Two sessions per treatment day. Each session consists of TMS treatment at 50% Motor Threshold, pulse frequency between 8-13 Hz. TMS delivery of 5 second pulse train, with an inter-train interval of 20 seconds. Session duration is 15 minutes. A rest period of at least 30 minutes is required between the 2 sessions in a treatment day.
89155038|NCT06079931|Experimental|Babaodan combined with standard concurrent chemoradiotherapy treatment group|60-66Gy/30-33F radiotherapy, 2Gy/dose; During radiation therapy, concurrent chemotherapy including paclitaxel 45 mg/m2 and carboplatin (AUC 2) was administered once a week on the first day. From the start of radiation therapy to the completion of concurrent chemoradiotherapy (CCRT) for 2 months, the patient took 2 capsules of Babaodan orally every day, tid (1.8 g/day). Systemic corticosteroids can be used in patients with acute radiation pneumonia with G ≥ 2.
89155039|NCT06076291|Experimental|SG1827|SG1827 monotherapy intravenous (IV) infusion - administered every three weeks (Q3W)
89155042|NCT06071468||CTR-US|Ultrasound Guided Carpal Tunnel Release (CTR-US)
89155043|NCT06067243||HIP MRI-3 T|Young patients with coxalgia and clinical and imaging suspect for cartilage and/or labral lesion of the hip
89155044|NCT06062238|Experimental|Participants receiving M72/AS01E-4|
89155045|NCT06062238|Experimental|Participants receiving placebo|
89155046|NCT06061068|Experimental|Hernia belt compressing group|Patients were given hernia belt compression of the inguinal region after laparoscopic inguinal hernia repair surgery in the operating room. The silicone pad of the hernia belt was placed in the inguinal region of the surgical side for compression for a period of 2 weeks.
89155047|NCT06061068|No Intervention|No hernia belt compressing group|"Patients were should not have the intervention Hernia belt compression ."
89155048|NCT06060665|Experimental|Seladelpar 10 mg|
89155049|NCT06060665|Experimental|Placebo|
89155050|NCT06058156|Experimental|SAR444656 dose 1|Participants will receive SAR444656 dose 1 orally
89155051|NCT06058156|Experimental|SAR444656 dose 2|Participants will receive SAR444656 dose 2 orally
89155052|NCT06058156|Placebo Comparator|Placebo|Participants will receive placebo orally
89155053|NCT06056895|Experimental|Treatment (retifanlimab, tuparstobart, and verzistobart)|"INDUCTION PHASE: Patients receive retifanlimab IV over 30 minutes every 4 weeks and tuparstobart and verzistobart IV over 30 minutes every 2 weeks. Treatment continues for up to day 169 in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography CT/MRI during screening and on study and blood sample collection on study and may undergo during screening. Patients may also undergo a tumor biopsy during screening and on study.~MAINTENANCE PHASE: Patients receive retifanlimab, tuparstobart and verzistobart IV over 30 minutes every 6 weeks. Treatment continues for up to day 715 in the absence of disease progression or unacceptable toxicity. Patients undergo CT/MRI on study and blood sample collection on study and may undergo during follow-up. Patients may also undergo tumor biopsy on study and during follow-up."
89155054|NCT06056011|Experimental|Oral Temperature Measurement|Oral temperature measurements for subjects age Group C as 5 years or older. Both febrile and non-febrile subjects included in this arm.
89155055|NCT06056011|Experimental|Axillary Temperature Measurement|"Adult Axillary temperature measurement supports age Group C where C contains 18 years and older subjects.~Pediatric Axillary temperature measurement supports newborn to 5 years and less than 18 years old.~Both febrile and non-febrile subjects included in this arm."
89155056|NCT06056011|Experimental|Rectal Temperature Measurement|Rectal temperature measurements for all age groups (newborn to subjects older than 18 years of age) with no restrictions. Both febrile and non-febrile subjects included in this arm.
89155057|NCT06051617|Experimental|Seladelpar 10 mg|
89155058|NCT06051617|Placebo Comparator|Placebo|
89155059|NCT06050070|Sham Comparator|Sham controlled feedback|Subjects will complete three visits with one or two fMRI sessions after initial assessment and training visit. The first session will be to introduce practice tasks using the mock scanner. In the second visit participants will have an fMRI. The study team will review the fMRI results to decide if participants will continue on the study (must exhibit a specific pattern of activation) and have the second fMRI at the third visit.
89155060|NCT06050070|Experimental|Real-time neurofeedback|Subjects will complete three visits with one or two fMRI sessions after initial assessment and training visit. The first session will be to introduce practice tasks using the mock scanner. In the second visit participants will have an fMRI. The study team will review the fMRI results to decide if participants will continue on the study (must exhibit a specific pattern of activation) and have the second fMRI at the third visit.
89155061|NCT06049056||General Practice 1|"General Practice 1 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link to an online questionnaire"
89155062|NCT06049056||General Practice 2|"General Practice 2 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link to an online questionnaire"
89155063|NCT06049056||General Practice 3|"General Practice 3 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link to an online questionnaire"
89155064|NCT06049056||General Practice 4|"General Practice 4 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link to an online questionnaire"
89155065|NCT06049056||General Practice 5|"General Practice 5 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a QR code providing access to an online questionnaire"
89155066|NCT06049056||General Practice 6|"General Practice 6 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a QR code providing access to an online questionnaire"
89155067|NCT06049056||General Practice 7|"General Practice 7 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a QR code providing access to an online questionnaire"
89155068|NCT06049056||General Practice 8|"General Practice 8 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a QR code providing access to an online questionnaire"
89155069|NCT06049056||General Practice 9|"General Practice 9 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link and a QR code providing access to an online questionnaire"
89155070|NCT06049056||General Practice 10|"General Practice 10 use the following methods to invite participation to the study:~Recruitment Method 1 (RM1): Automated check-in screens containing research questions Recruitment Method 2 (RM2): SMS invites with URL link to an online questionnaire Recruitment Method 3 (RM3): Mailing containing a URL link and a QR code providing access to an online questionnaire"
89155071|NCT06045689|Experimental|Cohort 1: erythropoiesis-stimulating agents (ESA) naïve|
89155072|NCT06045689|Experimental|Cohort 2: ESA relapsed or refractory|
89155073|NCT06044922||Post-cardiac arrest patients|
89155074|NCT06040385|Active Comparator|• Group I (control group)|Final impression will be done by conventional one-step impression technique. For the same patient, another final impression using unmodified scan bodies will be done by direct intraoral scan technique.
89155075|NCT06040385|Active Comparator|• Group II (Test Group)|Final impression will be done by conventional one-step impression technique. For the same patient another final impression using subtractive modified scan bodies will be done by direct intraoral scan technique
89155076|NCT06035497|Experimental|Administration of BMS-986369|
89155077|NCT06034834|Experimental|Traumatic injuries|"Acute patients treated surgically for:~Open deglovement (n=20)~Crush injury (n=20)~Open fractures (n=20)~The setting is defined acute when there is less than 24 hours between sustaining the injury and surgery.~Elective patients treated surgically for:~Fracture related infection (FRI) (n=10)~Non-union of fractures (n=50) Subdivided into 5 groups of 10.~Elective osteosynthesis of non-union clavicula fracture N=10~Primarily operated on N=5~Primarily treated conservatively N=5~Elective osteosynthesis of non-union tibia. N=10~Elective osteosynthesis of non-union ulna. N=10~Primarily operated on N=5~Primarily treated conservatively N=5~Elective osteosynthesis of non-union humerus. N=10~Elective osteosynthesis of non-union of the rib. N=10"
89155078|NCT06034405||ATTR Negative|Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data and spinal specimen for analysis of presence of ATTR amyloid.
89155079|NCT06034405||ATTR Positive|Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data, spinal specimen, prospective data from cardiac workup with confirmed ATTR amyloid in spinal specimen then undergo cardiac workup for cardiac phenotyping/genotyping.
89155080|NCT06034093|Experimental|Real-time AI-assisted muscle ultrasound|RAIMUS software provides automatic segmentation and size measurement for the RFCSA
89155081|NCT06034093|No Intervention|Manual muscle ultrasound|Manual segmentation and size measurement for the RFCSA
89155082|NCT06033391|Experimental|GGOC-AD (GG Obsessive-Compulsive Disorder - Adolescents)|The experimental group will use the GGOC-AD module for 14 days after the first assessment.
89155083|NCT06033391|Active Comparator|GGN-AD (GG Neutral - Adolescents)|The control group will use the GGN-AD module for 14 days after the first assessment.
89155084|NCT06030089|Experimental|AML patients ineligible for intensive chemotherapy and treated with azacitidine and venetoclax|Newly diagnosed AML patients
89155085|NCT06021145|Experimental|Empagliflozin 2.5 mg daily|Empagliflozin is a sodium/glucose cotransporter 2 inhibitor (SGLT2i) that inhibits glucose reabsorption in the kidney. In this study, a capsule of empagliflozin 2.5 mg will be taken daily in conjunction with the participant's personal automated insulin delivery system for 26 weeks.
89155086|NCT06021145|Active Comparator|Placebo|As a control, a placebo capsule will be taken daily in conjunction with the participant's personal automated insulin delivery system for 26 weeks.
89155087|NCT06020118|Experimental|Group i|Simultaneous Vaccination (Influenza vaccine and mRNA COVID booster) at Visit 1
89155088|NCT06020118|Experimental|Group ii|Sequential vaccination with Influenza vaccination at Visit 1 and mRNA COVID booster at Visit 2
89155089|NCT06020118|Experimental|Group iii|Sequential vaccination with mRNA COVID booster at Visit 1 and Influenza vaccination at Visit 2
89155090|NCT06018025||NPDH (New Persistent Daily Headache)|Patients with new persistent daily headache (NDPH) ages 12-18 years will be recruited and consented by the study coordinator. Patients will be recruited from patients already established with the Duke Pediatric Neurology clinic with a diagnosis of NDPH, or after their initial visit to establish the diagnosis of NDPH through the Duke, pediatric neurology clinics, personal communication and networking, and through the Duke adult headache clinic.
89155091|NCT06018025||Healthy (Normal) Controls|"Children with normal development, aged 12-18 years, will be identified via the electronic health records of well-child visits in Duke Children's Hospital, community advertising and through networking with colleagues and friends.~Exclusion: 1) History of concussion or head injury 2) Psychiatric disorders 3) History of migraines or other headache disorder treated in the past 4) Known structural brain lesions (tumor, hydrocephalus, congenital anomalies)"
89155092|NCT06018025||Chronic Migraine|"Patients between 12-18 yrs of age:~A) Headache (migraine-like or tension-type-like) on ≥15 days/month for >3 months, and fulfilling criteria B and C, B) Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 Migraine without aura and/or criteria B and C for 1.2 Migraine with aura C) On ≥8 days/month for >3 months, fulfilling any of the following (1) criteria C and D for 1.1 Migraine without aura 2) criteria B and C for 1.2 Migraine with aura 3) believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative D) Not better accounted for by another ICHD-3 diagnosis"
89155093|NCT06009159|Experimental|Transcutaneous Vagus Nerve Stimulation(tVNS)|receive tVNS 30 minutes per session, twice/day for 4 weeks and maintain regular medication treatment without change.
89155094|NCT06009159|No Intervention|Sham Control group|receive sham point stimulation 30 minutes per session, twice/day for 4 weeks and maintain regular medication treatment without change.
89155095|NCT06008522|Experimental|OCT with IV in colorectal polyps|OCT and FME imaging of Barret and colorectal lesions during endoscopy.
89155096|NCT06008093|Experimental|Arm A: Durvalumab + Tremelimumab + Platinum-based Chemotherapy|Participants will receive durvalumab plus tremelimumab q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (durvalumab plus pemetrexed maintenance) every 4 weeks (q4w) until disease progression or unacceptable toxicity or treatment discontinuation. During the maintenance therapy phase, participants will receive an additional cycle of durvalumab plus tremelimumab (plus pemetrexed, where applicable) at Week 16.
89155097|NCT06008093|Experimental|Arm B: Pembrolizumab + Platinum-based Chemotherapy|Participants will receive pembrolizumab regimen q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (pembrolizumab plus pemetrexed maintenance) q3w until disease progression or unacceptable toxicity for up to 24 months or treatment discontinuation.
89155098|NCT06005610|Experimental|Group 1: BIC-treated|Participants taking bictegravir (BIC) + tenofovir alafenamide (TAF) + emtricitabine (FTC)
89155099|NCT06005610|Experimental|Group 2: DTG-treated|Participants taking dolutegravir (DTG) once daily + tenofovir disoproxil fumarate (TDF) + (FTC or lamivudine [3TC])
89155100|NCT06005610|Experimental|Group 3: Boosted DRV-treated|Participants taking any regimen containing darunavir plus cobicistat (DRV/c)
89155101|NCT06005428|Experimental|Dose 1|CRD-4730 Dose 1 capsule
89155102|NCT06005428|Experimental|Dose 2|CRD-4730 Dose 2 capsule
89155103|NCT06005428|Placebo Comparator|Dose 3|Placebo capsule to match CRD-4730
89155104|NCT06004050|Experimental|Double-Blind Period: Twice-Daily Delgocitinib Cream|20 mg/g twice daily
89155105|NCT06004050|Placebo Comparator|Double-Blind Period: Twice-Daily Vehicle Cream|20 mg/g twice daily
89155106|NCT06004050|Experimental|Open Label Period: Twice-Daily Delgocitinib|20 mg/g twice daily
89155107|NCT06002477|Experimental|Anticholinergic Challenge|All participants will receive oral mecamylamine for 1 day
89155108|NCT06002477|Placebo Comparator|Placebo Challenge|All participants will receive oral placebo for 1 day
89155109|NCT05999435|Experimental|LAU-7b for 3 cycles|Each study arm will consist of three (3) cycles of 14 days of treatment intake each spaced by a treatment holiday of 14 days.
89155110|NCT05999435|Experimental|LAU-7b for 1 cycle, then placebo|Each study arm will consist of three (3) cycles of 14 days of treatment intake each spaced by a treatment holiday of 14 days.
89155111|NCT05999435|Placebo Comparator|Placebo for 3 cycles|Each study arm will consist of three (3) cycles of 14 days of treatment intake each spaced by a treatment holiday of 14 days.
89155112|NCT05993377||Derivation and testing cohort|It will contain 1000 ARDS patients
89155113|NCT05993377||Confirmatory cohort|It will contain 303 patients (for external validation)
89155114|NCT05991934|Experimental|Single arm pilot|The micro-randomized trial will determine if CBT and Mindfulness/ACT messages are superior to control messages in reducing the primary outcome momentary smoking urges. Based on participants' training data collected in the initial 14 days of EMA monitoring, intervention messages will be delivered during time-periods and at high-risk locations for smoking. In the intervention phase, participants will be prompted to complete 3 geofence-triggered EMAs per day for a total of 30 days. Each EMA will be followed by an intervention message and the type of message (CBT, Mindfulness/ACT, control) will be randomly selected at each time point (within-subject randomization).
89155115|NCT05987007|Active Comparator|Cognitive Behavioral Therapy for Insomnia|Participants assigned to the CBTI treatment group will receive 8 weeks of weekly telehealth sessions with a masters-level therapist. Each session is approximately 50 minutes in duration.
89155116|NCT05987007|Active Comparator|Acoustic Slow-Wave Activity Enhancement|Participants assigned to the SWAE group will be instructed to use the Dreem2 headband at least four nights out of seven nights of the week.
89155117|NCT05984784|Experimental|IMG-007 Dose 1|IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks
89155118|NCT05984784|Experimental|IMG-007 Dose 2|IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks
89155119|NCT05984784|Placebo Comparator|Placebo|Placebo will be administered intravenously 3 times over 4 weeks
89155120|NCT05983185|Active Comparator|Prism adaptation Therapy|People with spatial neglect will receive this effective treatment to reduce symptoms, which the investigators' previous work indicated may be particularly effective for Aiming SN symptoms.
89155121|NCT05983185|No Intervention|No spatial neglect|People without spatial neglect symptoms will not receive an intervention for spatial neglect.
89155122|NCT05982847||Boys|
89155123|NCT05982847||Girls|
89155124|NCT05967286|Experimental|Cohort 1, Arm A (olaparib, alpelisib)|Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
89155125|NCT05967286|Experimental|Cohort 2, Arm B (olaparib, alpelisib)|Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
89155126|NCT05967286|Active Comparator|Cohort 2, Arm C (olaparib)|Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
89155127|NCT05967286|Experimental|Cohort 3, Arm D (olaparib, alpelisib)|Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.
89155128|NCT05965700|Experimental|NVG-291 for Injection|Injected under the skin (subcutaneous).
89155129|NCT05965700|Placebo Comparator|Placebo|Injected under the skin (subcutaneous).
89155130|NCT05965336|Active Comparator|Able-Bodied Participants|Able-bodied participants will complete a total of three study sessions. The three sessions include a clinical evaluation, gait biomechanics, and gait biofeedback for comparison with participants with DPN.
89155131|NCT05965336|Experimental|Plantar Pressure Biofeedback Gait Training Followed by Propulsion Biofeedback Gait Training|Participants with DPN will complete a total of seven study sessions. The first three sessions include a clinical evaluation, gait biomechanics, and gait biofeedback for comparison with able bodied participants. Sessions four through seven involve two different biofeedback training sessions followed by a retention gait analysis test 24-48 hours after training. Participants in this study are are randomized to receive plantar pressure biofeedback gait training first and propulsion biofeedback gait training at least three weeks later.
89155132|NCT05965336|Experimental|Propulsion Biofeedback Gait Training Followed by Plantar Pressure Biofeedback Gait Training|Participants with DPN will complete a total of seven study sessions. The first three sessions include a clinical evaluation, gait biomechanics, and gait biofeedback for comparison with able bodied participants. Sessions four through seven involve two different biofeedback training sessions followed by a retention gait analysis test 24-48 hours after training. Participants in this study are are randomized to receive propulsion biofeedback gait training first and plantar pressure biofeedback gait training at least three weeks later.
89155133|NCT05959083||Upadacitinib|Adolescent and adult participants will receive upadacitinib as prescribed by their physician irrespective of the study participation.
89155134|NCT05955339|Active Comparator|NOTES|Patients in this arm will receive only the NOTES intervention.
89155135|NCT05955339|Active Comparator|NOTES + AUDIO|Patients in this arm will receive both the NOTES and AUDIO intervention.
89155136|NCT05950373|Experimental|Intervention group|"The Intervention group will get access to a six-minute long education video five days after being discharges from the hospital. The video is focusing on protein and energy meals for older adults.~The educational film is available via a link on a tablet/ computer or mobile phone.~The education video vil only be given one time."
89155137|NCT05950373|No Intervention|Control group|The control group will not be given any intervention.
89155138|NCT05945264|Experimental|Music Intervention (MI) Group|Music therapist will meet individually with each participant and provide music therapy content that reflects their culture and mood states.
89155139|NCT05945264|Active Comparator|Sham Control (SC) Group|Music/Verbal therapist will meet individually with each participant but will provide verbal discourse only (i.e., no music therapy and verbal intervention only).
89155140|NCT05942820|Experimental|BWC0977|"MAD Cohorts: Subjects will receive multiple doses of 240mg BID 7 days, 750mg BID 10 days,1250mg BID 10 days and 1000mg TID 10 days BWC0977 via IV infusion over 2 hours in the first 4 cohorts. The dose for the A5 cohort will be determined based on safety and tolerability data from the previous cohorts Up to five dose groups will be studied.~SAD Cohorts: Subjects will receive single doses of BWC0977 via IV infusion over 2 hours. The planned dose to be studied are 1500mg. Upto 2 cohorts will be studied"
89155141|NCT05942820|Placebo Comparator|Placebo|Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hours. MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hours for 7 or 10 consecutive days.
89155142|NCT05941013|Experimental|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
89155143|NCT05935241|Experimental|mPATH|mPATH is a personalized physical activity intervention that includes personalized physical activity plans and training sessions, exercise at home by following personalized exercise videos, and biweekly phone coaching over 24 weeks, supported by wearable devices-enabled mHealth strategies. mHealth strategies and exercise videos will be used to support participant's physical activity during 6-12months
89155144|NCT05935241|Active Comparator|Education and Social control|This attention control group is designed to match the intervention for mPATH's staff-subject interaction duration through monthly home visits in the first 6 months
89155145|NCT05933577|Experimental|V940 + Pembrolizumab|Participants receive up to 9 doses of V940 via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
89155146|NCT05933577|Active Comparator|Placebo + Pembrolizumab|Participants receive up to 9 doses of dose matched placebo to V940 via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
89155147|NCT05928559||Young Male Basketball Players|Male athletes between the ages of 10-24 who are involved in a local basketball academy and have been involved in basketball for more than a year
89155148|NCT05921760|Experimental|Safety Lead-In Phase - ivosidenib|First phase of the study.
89155149|NCT05921760|Experimental|Experimental Phase - Cohort 1|Second phase of the study. Cohort 1 will include the anti-PD1/L1-naïve subpopulation.
89155150|NCT05921760|Experimental|Experimental Phase - Cohort 2|Second phase of the study. Cohort 2 will include the anti-PD1/L1 previously treated subpopulation.
89155151|NCT05919264|Experimental|Part 1a|Solid Tumors with Any WNT-Pathway Activating Mutations (WPAMs) or Microsatellite Stable (MSS) Colorectal Cancer (Irrespective of WPAM Status)
89155152|NCT05919264|Experimental|Part 1b|Microsatellite Stable Colorectal Cancer (Irrespective of WPAM Status)
89155153|NCT05919264|Experimental|Cohort 2a|Microsatellite Stable Colorectal Cancer (Irrespective of WPAM Status)
89155154|NCT05919264|Experimental|Cohort 2b|Non-Small Cell Lung Cancer with a WNT-Pathway Activating Mutation (WPAM) in Adenomatous Polyposis Coli (APC) or Beta-Catenin
89155155|NCT05919264|Experimental|Cohort 2c|Gastric Cancer/Gastroesophageal Junction Carcinoma (GEJ) with a WNT-Pathway Activating Mutation (WPAM) in Adenomatous Polyposis Coli (APC) or Beta-Catenin
89155156|NCT05919264|Experimental|Cohort 2d|Solid Tumors with Any WNT-Pathway Activating Mutations (WPAMs)
89155157|NCT05910567|Other|Focused Assessment with Sonography for Trauma (FAST) Examination Arm|Patients in this arm will under the FAST examination (abdominal ultrasound) for diagnostic purposes to detect the presence of blood in injured patients with blunt abdominal trauma.
89155158|NCT05910567|Other|No Intervention - Standard of Care - Without the FAST Examination|Institution will use their standard operating procedures to deliver the usual care for injured patients with blunt abdominal/torso trauma.
89155159|NCT05907291|Experimental|Sequential Dose|Sequential, open-label, 12-week fixed-dose cohorts.
89155160|NCT05906784|No Intervention|usual care|Participants will receive care as usual provided through their primary care providers. Usual care includes medical diagnostic evaluation, analgesic drug therapies, recommendations for physical activity, and sometimes referral to specialist physicians or physical therapy. Usual care was chosen as a comparison arm for this study because it is practical and clinically relevant. Participants randomized to usual care will be put on a waitlist and can access group acupuncture or IGMV after their final study visit.
89155161|NCT05906784|Experimental|group acupuncture|Participants randomized to acupuncture will receive 12 weeks of acupuncture treatments delivered in a group setting, dosing similar to prior research. Acupuncture point selection and other treatment details will follow responsive manualization, a protocol developed for the largest clinical trial of group acupuncture to date. A licensed acupuncturist experienced with administering group acupuncture treatments will determine each participant's traditional Chinese medicine diagnosis and administer 8-10 acupuncture needles on distal points of participant's body (below the knees, from the elbows to the hands, and on the head). Duration of assessment, needle placement and retention will be 30-45 minutes. Details of acupuncture treatments (e.g., frequency and duration, traditional Chinese medicine diagnosis, number of needles and points used) will be documented in electronic health records.
89155162|NCT05906784|Experimental|Integrative Group Medical Visits (IGMV)|IGMV will consist of a 12-week program that provides education on the biopsychosocial model of pain and multimodal treatments; physical movement; mindfulness training; and peer support. Non-pharmacologic approaches are based on guidelines on chronic pain management; feedback of experts, staff, and patients; and feasibility with the greatest potential to benefit participants. Participants will receive a binder with educational materials.
89155163|NCT05906784|Experimental|group acupuncture and IGMV|Both group acupuncture and IGMV. Along with usual care, participants will be offered weekly group acupuncture treatments and integrative group medical visits as described above.
89155164|NCT05900986|Experimental|LS301-IT|LS301-IT will be adminstered by IV injection
89155165|NCT05900154|Experimental|standard dose in 5 to <18 years olds, healthy|standard dose (120 µg)
89155166|NCT05900154|Experimental|standard dose in 5 to < 18 years olds, with chronic high risk conditions|standard dose (120 µg)
89155167|NCT05900154|Experimental|standard dose in 2 to < 5 years olds|standard dose (120 µg)
89155168|NCT05900154|Experimental|low dose in 5 to <18 years olds, healthy|low dose (60 µg)
89155169|NCT05900154|Experimental|low dose in 5 to <18 years olds, with chronic high risk conditions|low dose (60 µg)
89155170|NCT05900154|Experimental|low dose in 2 to < 5 years olds|low dose (60 µg)
89155171|NCT05896254|Experimental|MAR001|Subcutaneous injection
89155172|NCT05896254|Placebo Comparator|Placebo|Subcutaneous injection
89155173|NCT05892341|Active Comparator|AQUACEL® Ag+ Extra™|AQUACEL® Ag+ Extra™ is approved, needle-bonded nonwoven fabric layered and stitch-bonded wound dressing
89155174|NCT05892341|Active Comparator|Cutimed® Sorbact®|Cutimed® Sorbact® is approved, bacterial and fungi binding wound dressing
89155175|NCT05891743||Epoxy_Group|Workers who are exposed to epoxy handling procedures, specifically filling and lamination tasks performed by production workers, mainly in finishing areas.
89155176|NCT05891743||Non_exposed|Workers from other areas unrelated to epoxy handling procedures, that will be included in the study as the non-exposed control group.
89155182|NCT05889507|Experimental|Whole body hypothermia|Whole-body hypothermia (33.5±0.5°C) will be initiated within 6 hours of birth and continued for 72 hours using a servo-controlled cooling machine at the nearest available neonatal intensive care unit (cooling centre).
89155183|NCT05889507|Active Comparator|Normothermia|The rectal temperature will be maintained at 36.5±0.5°C using servo-controlled incubators for the first 80 hours and any hyperthermia will be treated with a standardised protocol.
89155184|NCT05886036|Experimental|Arm I (Mosunetuzumab)|Patients receive mosunetuzumab SC on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience PD will be permitted to crossover to arm II at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT at week 12. Patients also undergo bone marrow biopsy and tissue biopsy at baseline and end of treatment, and blood sample collection at baseline, weeks 4 and 7, end of treatment, and then every 6 months for 2 years.
89155185|NCT05886036|Active Comparator|Arm II (Rituximab, Rituximab and hyaluronidase human)|Patients receive rituximab IV on day 1 and rituximab and hyaluronidase human SC on days 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 2 cycles 8 weeks apart in the absence of disease progression or unacceptable toxicity. Patients may receive rituximab IV on days 8, 15, and 22 of each cycle if rituximab and hyaluronidase human is not available. Patients who experience PD will be permitted to crossover to arm I at week 12. Patients also receive FDG and undergo PET/CT at baseline and end of treatment. Patients who are positive at pre-treatment bone marrow biopsy also receive FDG and undergo PET/CT at week 12. Patients also undergo bone marrow biopsy and tissue biopsy at baseline and end of treatment, and blood sample collection at baseline, weeks 4 and 7, end of treatment, and then every 6 months for 2 years.
89155186|NCT05884528||Complex-free BoNT/A formulation|Patients exclusively treated with the complex-free (CF) formulation (incobotulinumtoxinA). A maximum of 328 patients will be enrolled in this group.
89155187|NCT05884528||Complex-containing BoNT/A formulations|Patients exclusively treated with a single complex-containing (CC) formulation (onabotulinumtoxinA or abobotulinumtoxinA). A maximum of 328 patients will be enrolled in this group.
89155188|NCT05884528||Switcher CF to CC BoNT/A formulations|The CF to CC switcher group includes all patients that were switched from a CF to a CC BoNT/A formulation. If more than one switch occurred, the first switch determines the group. Both switcher groups will in sum not exceed 325 patients.
89155189|NCT05884528||Switcher CC to CF BoNT/A formulations|The CC to CF switcher group includes all patients that were switched from a CC to a CF BoNT/A formulation. If more than one switch occurred, the first switch determines the group. Both switcher groups will in sum not exceed 325 patients.
89155190|NCT05882565|Experimental|Mindfuness training group|This is a group that will receive mindfulness intervention for 14 days. Participants in this group will also be asked baseline, daily and post questions, as well as follow up questions (3 months after the intervention). During the intervention, they can fill out an optional daily journal.
89155191|NCT05882565|Active Comparator|Psychoeducation group|This is a group that will receive psychoeducation intervention for 14 days. Participants in this group will also be asked baseline, daily and post questions, as well as follow up questions (3months after the intervention). During the intervention, they can fill out an optional daily journal.
89155192|NCT05882565|No Intervention|Waitlist control group|This is a group that will not receive any training, however, this group will be asked several questions (baseline, daily and post questions, as well as follow up questions (3-months later)). They can also fill out an optional daily journal.
89155193|NCT05880446|Other|Bowel symptoms & QoL assessment|This single arm study represent a group a patient with prostate cancer who are candidate for pelvic radiotherapy. Patient reported outcomes on bowel toxicity and overall quality of life will be systematically assessed right before and after RT. Various potential predictive factors will be analysed.
89155194|NCT05873205|Experimental|Participants with Refractory Immune Cytopenias|Participants will be adults who develop Immune Cytopenias/ICs after Allogeneic Hematopoietic Cell Transplantation/allo-HCT and who did not respond to initial immunosuppressive therapy.
89155195|NCT05872620|Experimental|Orforglipron Dose 1|Participants will receive orforglipron administered orally.
89155196|NCT05872620|Experimental|Orforglipron Dose 2|Participants will receive orforglipron administered orally.
89155197|NCT05872620|Experimental|Orforglipron Dose 3|Participants will receive orforglipron administered orally.
89155198|NCT05872620|Placebo Comparator|Placebo|Participants will receive placebo
89155199|NCT05867966|Experimental|Intervention group|These participants will benefit from an 8-week group intervention combining psychoeducation, self-care learning and hypnosis exercises.
89155200|NCT05867966|No Intervention|Control group|These participants will not benefit from any intervention. After the end of the study, they will have the possibility to participate in the group intervention if they want to.
89155201|NCT05861284|Experimental|Single-pulse TMS over the primary motor cortex|We will administer single-pulse TMS to the primary motor cortex while measuring motor responses and just before a skill-learning task.
89155202|NCT05861284|Experimental|Paired-pulse TMS over the primary motor cortex|We will administer paired-pulse TMS to the primary motor cortex while measuring motor responses and just before a skill-learning task.
89155203|NCT05861284|Sham Comparator|Sham TMS over the primary motor cortex|We will administer sham TMS to the primary motor cortex while measuring motor responses and before a skill-learning task.
89155204|NCT05860140|Experimental|Intervention group|will get access to a six-minute educational video five days after being discharged from the hospital. The video is focusing on protein and energy meals for older adults.
89155205|NCT05860140|No Intervention|Control group|Control group, not given any intervention
89155206|NCT05857878|Placebo Comparator|Placebo|
89155207|NCT05857878|Experimental|Dose Group 1|
89155208|NCT05857878|Experimental|Dose Group 2|
89155209|NCT05857878|Experimental|Dose Group 3|
89155210|NCT05857878|Experimental|Dose Group 4|
89155211|NCT05857878|Experimental|Dose Group 5|
89155212|NCT05857878|Experimental|Dose Group 6|
89155216|NCT05856162|Experimental|Full Intervention|Participants randomized to this arm will receive the full ENRICH pilot which will consist of content on diet, physical activity, sleep, stress/mental health, and tobacco cessation. They will also receive usual home visiting services.
89155217|NCT05856162|Active Comparator|Diet/Physical Activity Intervention|Participants randomized to this arm will receive the partial ENRICH pilot which will consist of content on diet and physical activity. They will also receive usual home visiting services.
89155218|NCT05856162|No Intervention|Control|Participants randomized to this arm will receive no ENRICH intervention content. They will only receive usual home visiting services.
89155219|NCT05851157|Experimental|VX-548|Participants will be randomized to receive a single dose of VX-548 in 1 of 6 treatment sequences with 3 dosing periods to assess different fed conditions and timing of meal administration on the PK of VX 548. There will be a 14 day washout period between each dosing period.
89155220|NCT05849844|Experimental|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.
89155221|NCT05849831||Adult critically ill septic patients|
89155222|NCT05846802||Gastroparesis|Gastroparesis symptoms with delayed emptying
89155223|NCT05846802||Functional Dyspepsia|Gastroparesis symptoms without delayed emptying
89155224|NCT05844501|Experimental|Ondansetron|Patients with atrial fibrillation scheduled for electrical conversion to sinus rhythm will receive treatment with ondansetron 8 mg orally twice daily for 28 days (n=40)
89155225|NCT05844501|Placebo Comparator|Placebo|Patients with atrial fibrillation scheduled for electrical conversion to sinus rhythm will receive treatment with matching placebo orally twice daily for 28 days (n=40)
89155226|NCT05839015|Experimental|Intervention|"This is group wil use Eu + Compassivo app."
89155227|NCT05839015|No Intervention|Control|This group will be made up of a waiting list.
89155228|NCT05831319||Above the knee (ATK) group|Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
89155229|NCT05831319||Below the knee (BTK) group|Target lesions involve arteries below the tibial plateau
89155230|NCT05827237|Experimental|Clinical decision rule|Patients in whom the clinical decision rule is used to exclude acute coronary syndrome
89155231|NCT05827237|No Intervention|Standard care|Patients in whom the general practitioner decides upon referral following local guidelines.
89155232|NCT05823948|Experimental|Insulin Icodec|Participants will receive 70 Units (U) insulin icodec subcutaneously once-weekly for 26 weeks.
89155235|NCT05819268|Experimental|ReACT Intervention|"During the initial visit participant will be randomized to either Retraining and Control Therapy (ReACT) or Competent Adulthood Transition with Cognitive Behavioral, Humanistic, and Interpersonal Training (CATCH-IT) intervention.~ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.~Participants will have 12 therapy sessions. The first session will be in-person which will last 2 hours and the subsequent 11 sessions will be conducted via video telehealth and each session will last 1 hour."
89155236|NCT05819268|Active Comparator|CATCH-IT Intervention|"During the initial visit participant will be randomized to either Retraining and Control Therapy (ReACT) or Competent Adulthood Transition with Cognitive Behavioral, Humanistic, and Interpersonal Training (CATCH-IT) intervention.~CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.~Participants will have 12 therapy sessions. The first session will be in-person which will last 2 hours and the subsequent 11 sessions will be conducted via video telehealth and each session will last 1 hour."
89155237|NCT05818852|Experimental|Group 1|Participants will receive VX-548-matching placebo, moxifloxacin-matching placebo and VX-548 at different time points.
89155238|NCT05818852|Active Comparator|Group 2A|Participants will receive VX-548-matching placebo, moxifloxacin and moxifloxacin-matching placebo at different time points.
89155239|NCT05818852|Active Comparator|Group 2B|Participants will receive VX-548-matching placebo, moxifloxacin-matching placebo and moxifloxacin at different time points.
89155240|NCT05814458|Active Comparator|tDCS group|The tDCS group will receive the active brain stimulation.
89155241|NCT05814458|Sham Comparator|Placebo group|The placebo group will receive the sham brain stimulation.
89155242|NCT05813912|Experimental|Insulin Icodec + Semaglutide|Participants will receive insulin icodec once weekly for 26 weeks in run-in period to ensure the dose optimization. Thereafter, participants meeting intensification criteria will proceed to the 26-week treatment period to receive once weekly semaglutide subcutaneously starting from 0.25 milligrams (mg) and dose increased up to 1 mg along with 700 units per milliliter (U/mL) insulin icodec therapy. There are no maximum or minimum insulin doses.
89155243|NCT05813457|Experimental|PRESTO program|"The PRESTO programs consists of an early identification program for First Episod Psychosis, called PRESTO (First Episodes Raise Awareness Treat Referral), including 3 complementary components:~Information campaign for the general population~Training of front-line actors~Facilitating access to specialized care by setting up mobile teams made up of pivotal workers who provide the link between front-line actors and specialized psychiatric care"
89155244|NCT05813457|No Intervention|Usual Care|No change in the conditions of referral of First Episod Psychosis (emergencies, hospitalizations, consultations)
89155245|NCT05803473|Active Comparator|POC-arm|Subjects are monitored by point-of-care (POC) glucose testing. Diabetes management is done by usual ward nurses and guided by an in-hospital diabetes team. A blinded CGM is mounted in the POC-arm for outcome analysis.
89155246|NCT05803473|Experimental|CGM-arm|CGM-arm subjects are monitored by CGM viewed by the in-hospital diabetes team in addition to POC glucose testing performed by usual ward nurses. Diabetes management is done by usual ward nurses by POC glucose testing and guided by an in-hospital diabetes team with acces to CGM data.
89155247|NCT05800015|Experimental|Phase 2 - Arm A|Randomized 1:1:1 fianlimab (higher dose) + cemiplimab + platinum-doublet chemotherapy
89155248|NCT05800015|Experimental|Phase 2 - Arm B|Randomized 1:1:1 fianlimab (lower dose) + cemiplimab + platinum-doublet chemotherapy
89155249|NCT05800015|Experimental|Phase 2 - Arm C|Randomized 1:1:1 cemiplimab + platinum-doublet chemotherapy + placebo
89155250|NCT05800015|Experimental|Phase 3 - Arm A or B|Randomized 1:1 fianlimab (chosen dose) + cemiplimab + platinum-doublet chemotherapy
89155251|NCT05800015|Experimental|Phase 3 - Arm C|Randomized 1:1 cemiplimab + platinum-doublet chemotherapy + placebo
89155252|NCT05799118||Cohort|Individuals with hemoglobinopathies
89155253|NCT05787496|Experimental|NC525|Escalating dose levels will be explored.
89155254|NCT05786573|Experimental|Safety and Dose Confirmation Run-in Period (SRP): Obexelimab|Obexelimab will be administered as an SC injection for 24 weeks.
89155255|NCT05786573|Experimental|Randomized Control Period (RCP): Obexelimab|Obexelimab will be administered as an SC injection for 24 weeks.
89155256|NCT05786573|Placebo Comparator|Randomized Control Period (RCP): Placebo|Placebo will be administered as an SC injection for 24 weeks
89155257|NCT05784792|No Intervention|Lugol -|No pre-operative Lugol Solution preparation
89155258|NCT05784792|Active Comparator|Lugol +|Pre-operative Lugol preparation (10 drops per day orally three times a day for 7 days for an amount of 10,5 ml of Lugol solution that contains 1,68 gr of Iodine).
89155259|NCT05784363|Experimental|NT 201|Single NT 201 injection treatment.
89155260|NCT05784363|Placebo Comparator|Placebo|Single placebo injection treatment.
89155261|NCT05784155|Other|Group 1|Test Drug for Period I Reference Drug for Period II
89155262|NCT05784155|Other|Group 2|Reference Drug for Period I Test Drug for Period II
89155263|NCT05782790|Experimental|Action Observation Therapy Group|In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done. Patients; While watching the videos, they will not be asked to do any movement, they will be asked to imitate the exercises after the videos are finished.
89155264|NCT05782790|Experimental|Classic Swallowing Exercise Group|Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature.
89155265|NCT05772533|Active Comparator|Group A (SAPB)|Ultrasound-guided SAPB will be applied while the patient is in the supine position.
89155266|NCT05772533|Active Comparator|Group B (PENG block)|Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees
89155267|NCT05769777|Experimental|Amlitelimab|Subcutaneous injection as per protocol
89155268|NCT05760248|Experimental|10XB-101 Solution for Injection, 6.0%|Participants receive 10XB-101 Solution for Injection, 6.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4 weeks for up to 6 treatments.
89155269|NCT05760248|Placebo Comparator|Placebo Solution for Injection|Participants receive Placebo Solution for Injection, via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4 weeks for up to 6 treatments.
89155270|NCT05758363|Experimental|Experimental Group|Consumption of dietary supplement capsules for 6 months.
89155271|NCT05758363|Placebo Comparator|Control Group|Identically appearing placebo capsules consumed for 6 months.
89155272|NCT05755815|Active Comparator|Group A (RLB block)|Ultrasound-guided RLB block will be performed under strict aseptic precautions with patient turned to the lateral position.
89155273|NCT05755815|Active Comparator|Group B (Peritoneal block)|Peritoneal block will be performed under strict aseptic precautions before giving an incision for the ports, and at the end of surgery and before the removal of trocars
89155274|NCT05755802|Active Comparator|Group A (PENG block)|Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees.
89155275|NCT05755802|Active Comparator|Group B (Shoulder block)|Ultrasound-guided shoulder block will be performed under strict aseptic precautions with patient in semi-recumbent position with the operating arm on the contra-lateral shoulder.and then, the patients will be positioned in a semi-recumbent position with the arm slightly flexed and adducted at the elbow for axillary nerve block.
89155276|NCT05753384|Experimental|continued treatment with TKI at 50% dose reduction|continued treatment with TKI at 50% dose reduction compared to dosing received at randomization and then stopped treatment 12 months after randomization
89155277|NCT05753384|Active Comparator|continuation of TKI treatment without dose change|continued treatment with TKI at same dose compared to dosing received at randomization and then stopped treatment 12 months after randomization
89155278|NCT05749562||Adolescent Idiopathic Scoliosis with right thoracic or thoraco-lumbar curvature|Patients will be treated with a Cheneau-Toulouse-Munster (CTM) brace, with a wearing time of more than 12 hours/24h, for more than 1 month.
89155279|NCT05742841|Experimental|EMERALD protocol|1) ordering a lipid panel during the index ED encounter and 30-days (+/- 5 business days) after ED discharge, 2) completion of the Pooled Cohort Equations by the patient's ED provider at the index visit, and 3) starting medical therapy (moderate- or high-intensity statin/ rosuvastatin) in the ED
89155280|NCT05742802|Experimental|Tozorakimab Dose 1|Injection subcutaneously Tozorakimab via pre-filled syringe.
89155281|NCT05742802|Experimental|Tozorakimab Dose 2|Injection subcutaneously Tozorakimab via pre-filled syringe.
89155282|NCT05742802|Placebo Comparator|Placebo|Injection subcutaneously with equivalent volume to Tozorakimab via pre-filled syringe.
89155283|NCT05739383|Experimental|Inclisiran sodium 300mg|"Inclisiran sodium 300 mg in 1.5 mL solution for injection (subcutaneous) in pre-filled syringe.~Randomized in a 1:1 ratio with matching placebo"
89155284|NCT05739383|Placebo Comparator|Placebo|Matching placebo in 1.5ml pre-filled syringe. Randomized in a 1:1 ratio with Inclisiran.
89155285|NCT05735340|Active Comparator|Diabetes Education|Participants in this arm will receive traditional diabetes education following a baseline assessment. During months 1-3, participants will attend 5 sessions. Follow-up will be conducted at 3-months and 6-months.
89155286|NCT05735340|Experimental|T1DES|Participants in this arm will receive a emotion regulation intervention called T1DES following a baseline assessment. During months 1-3, participants will attend 5 sessions. Follow-up will be conducted at 3-months and 6-months.
89155287|NCT05722886|Experimental|Treatment Arm 1: Alectinib|This alectinib treatment arm is for adult, teenage/young adults (TYA) and paediatric participants with ALK-positive cancers.
89155288|NCT05722886|Experimental|Treatment Arm 2: Atezolizumab|This atezolizumab treatment arm is for adult, teenage/young adults (TYA) and paediatric participants with high tumour mutational burden (TMB) or microsatellite instability high (MSI-high) or proven (previously diagnosed) constitutional mismatch repair deficiency (CMMRD) only.
89155289|NCT05722886|Experimental|Treatment Arm 3: Entrectinib|This entrectinib treatment arm is for adult, teenage/young adult (TYA) and paediatric participants with ROS1 gene fusion-positive malignancies only.
89155290|NCT05722886|Experimental|Treatment Arm 4: Trastuzumab in combination with pertuzumab|This trastuzumab and pertuzumab treatment arm is for adult, teenage/young adult (TYA) and paediatric participants with malignancies with HER2 amplification or activating mutations.
89155291|NCT05722886|Experimental|Treatment Arm 5: Vemurafenib in combination with cobimetinib|This vemurafenib and cobimetinib appendix is for BRAF V600 mutation-positive malignancies occurring in adults only.
89155292|NCT05722418|Experimental|CB-011|"Part A Escalation with CB-011 in ascending doses using a traditional 3+3 design.~Part B Expansion. Up to 30 participants will be enrolled to receive CB-011 at the RDE/MTD and/or RP2D determined in Plan A"
89155293|NCT05721729|Experimental|Cohort 1|Subjects will receive placebo and two doses of encapsulated mizagliflozin over three dosing periods. Once and twice daily dosing will be examined.
89155294|NCT05721729|Experimental|Cohort 2|Subjects will receive placebo and two doses of encapsulated mizagliflozin over three dosing periods. Twice and three times daily dosing will be examined.
89155295|NCT05716906|Experimental|Melatonin|5mg melatonin gummy 30 min before bedtime for 2 consecutive nights
89155296|NCT05715255|Experimental|Adaptive Intervention|The adaptive intervention sequence is assumed to affect psychological distress (depression and anxiety) severity of other symptoms and irAEs, as tested in Aim 1. Both the Automated Telephone Symptom Management (ATSM) system and the Telephone Interpersonal Counseling (TIP-C) interventions help participants to identify and understand troublesome symptoms, with suggestions to effectively self-manage these symptoms. The proposed interventions are expected to alleviate burdensome symptoms through several key mediating variables, as tested in Aim 2.
89155297|NCT05715255|Active Comparator|Active Control|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe. An active control comparator was purposively selected to enable a more rigorous testing of intervention effectiveness in Aims 1 and 2. Also, the study team will be better able to address the question about which channel of communication (automated versus survivor initiated) results in better outcomes.
89155298|NCT05714956|Experimental|Intervention|eMB consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention.
89155299|NCT05714956|No Intervention|Home Visiting Usual Care|Core content of home visiting program services typically address: (a) preparation for childbirth and having a young child in the home, (b) provision of emotional and tangible [e.g., diapers, formula] support, (c) discussion of infant and young child development, (d) linkages to prenatal and pediatric care, and (e) referrals to community resources for social and health services. Those receiving usual care home visiting will not receive any eMB or MB course content. Once study participation is completed, the home visitor may introduce eMB to the participant if they are interested. Participants in the control group will also complete assessments at baseline, 1 week post-intervention (i.e., following 8 weeks of usual home visiting services), and 3 months post-intervention (i.e.g, following 8 weeks of usual home visiting services).
89155300|NCT05714514||Imlifidase administered in the ConfIdeS study|
89155301|NCT05714514||Best available treatment administered in the ConfIdeS study|
89155304|NCT05711628|Active Comparator|Arm A (chemotherapy regimen, HDT-ASCT)|"SALVAGE THERAPY: Patients receive 1 of 3 chemotherapy regimens as clinically indicated: 1) ifosfamide IV, carboplatin IV, and etoposide IV; 2) gemcitabine IV, vinorelbine IV, and pegylated liposomal doxorubicin IV; or 3) brentuximab vedotin IV and bendamustine IV. Patients then undergo a PET/CT scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment.~HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant.~MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated."
89155305|NCT05711628|Experimental|Arm B (chemotherapy regimens+pembrolizumab, HD-ASCT)|"SALVAGE THERAPY: Patients receive pembrolizumab IV plus 1 of 3 chemotherapy regimens specified in Arm A as clinically indicated. Patients then undergo a PET scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment.~HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant.~MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated."
89155306|NCT05711485|Experimental|Whole blood transfusion|Whole blood transfusion x1 (20 mL/kg)
89155307|NCT05711485|No Intervention|Control|Standard-of-care
89155308|NCT05710757|Experimental|Myofascial Release|The Experimental group will receive a myofascial release pectoralis minor release intervention.
89155309|NCT05710757|Sham Comparator|Sham Myofascial Release|The Control group will receive a sham myofascial release pectoralis minor release intervention.
89155310|NCT05708911|Experimental|Pharyngeal exerciser group|"Test that application of the pharyngeal exerciser increases the workload of muscles involved in pharyngeal phase of swallowing as evidenced manometrically by changes in~Pharyngeal peak pressures Pharyngeal (velopharynx, oropharynx and hypopharynx) contractile duration Pharyngeal (velopharynx, oropharynx and hypopharynx) contractile integral Hypopharyngeal intrabolus pressure and duration UES nadir pressure UES relaxation time Baseline UES pressure"
89155311|NCT05708898|Experimental|Pharyngeal exerciser group|In this group, the device will be placed around the neck overlying the laryngeal cartilage. Patients are asked to follow exercise regimen: to perform 30 swallows at 15 seconds interval against minimal resistance of 20 mm Hg applied by pharyngeal exerciser over larynx during the first 2 weeks. This is repeated 3 times per day and the external resistance is increased every 2 weeks from 20 to 30 mm Hg and subsequently from 30 to 40 mm Hg in another 2 weeks.
89155312|NCT05708898|Sham Comparator|Sham exerciser group|In this group, sham device will be placed around the neck overlying the laryngeal cartilage. No external pressure will be applied during exercise. These patients will be asked to follow the exercise regimen: to perform repetitive tongue protrusion for 5 times without any pressure. This will be repeated 3 times a day for 6 weeks.
89155313|NCT05708885|Active Comparator|Striated esophagus deglutitive motor function healthy adults|Testing of manometric, impedance and biomechanical measurements during swallowing in healthy volunteer adult subjects.
89155314|NCT05708885|Active Comparator|Striated esophagus deglutitive motor function in patients with ineffective esophageal motility|Testing of manometric, impedance and biomechanical measurements during swallowing in adult patients with ineffective esophageal motility.
89155315|NCT05708885|Active Comparator|Striated esophagus deglutitive motor function patients with symptoms but normal esophageal manometry|"Testing of manometric, impedance and biomechanical measurements during swallowing in adult patients with symptoms of dysphagia but normal esophageal manometry by the Chicago Classification criteria."
89155316|NCT05706311|Experimental|Intervention Pharmacy Site|"Pharmacies randomized to the experimental arm will be exposed to the intervention condition.~Patients at the intervention pharmacy identified as at elevated risk will receive confirmatory screening for opioid risk. Those with confirmed moderate risk will receive a brief motivational intervention for medication misuse and an offer of naloxone dispensation. Those with high risk will receive a brief motivational intervention leading to warm handoff treatment linkage intervention to primary or specialty substance use care with an offer for naloxone dispensation."
89155317|NCT05706311|Other|Control Pharmacy Site|Standard of Care is the treatment as usual condition, which follows federal and Ohio state pharmacy requirements for pharmacists where in patients filling prescriptions receive information and opt-in counseling. Ohio State law requires pharmacist to not dispense an opioid supply >90 days, with a specific prohibition on dispensations ≥14 days after prescriptions are issued. Pharmacists are also required to perform a universal prescription drug medication review before initial dispensation and offer brief counseling (e.g., unstandardized information about medication safety) for new/modified prescription therapies.
89155318|NCT05697393|Active Comparator|Shaker Pressure Band GERD patients with external laryngeal pressure|One week of Shaker pressure band
89155319|NCT05697393|Placebo Comparator|Shaker Pressure Band GERD patients without external laryngeal pressure|One week of sham Shaker pressure band (no external laryngeal pressure)
88804540|NCT04320810||mNGS diagnosis|Using mNGS to diagnosis infectious disease of this group
89155320|NCT05696652|Experimental|Active arm: Acute exercise + 12 weeks Cardiac Rehabilitation|This arm includes two-thirds of enrollees and focuses on both acute and chronic effects of exercise. Qualifying participants with heart failure randomized to this arm will undergo a 40 minute bout of moderate intensity exercise on a date prior to beginning in cardiac rehabilitation. Blood samples will be collected before and after the acute bout at 10, 30, and 210 minutes after exercise. Participants will then go to cardiac rehabilitation for a 12 week period. A single blood sample will be obtained at 6 weeks. The participants will return after the 12 weeks of cardiac rehabilitation for a second bout of acute exercise and blood sampling identical to the first. Finally, 12 weeks after completion of cardiac rehab, patients will return for another single blood sample.
89155321|NCT05696652|Active Comparator|Control arm: No exercise|This arm includes one-third of enrollees and serves as control. Qualifying participants with heart failure randomized to this arm will begine with a 40 minute period of rest on a date prior to beginning in cardiac rehabilitation. Blood samples will be collected before and after the the 40 minute period at 10, 30, and 210 minutes after exercise. Participants will then defer cardiac rehabilitation for a 12 week period. A single blood sample will be obtained at 6 weeks of this control intervention period. The participants will return after the 12 weeks of control intervention for an actual bout of acute exercise and blood sampling identical to those completed by the active arm. They will then enter cardiac rehabilitation as per standard of care. Finally, 12 weeks after completion of cardiac rehab, patients will return for another single blood sample.
89155322|NCT05696184|Active Comparator|GERD patients with complaint of regurgitation and supra-esophageal reflux disease (SERD)|GERD patients with complaint of regurgitation and one of the following supra-esophageal symptoms attributed to reflux of gastric content: chronic cough, frequent throat clearing, history of non-deglutitive aspiration pneumonia, hoarse voice, chronic sinusitis and dental erosion i.e. SE-GERD. Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
89155323|NCT05696184|Active Comparator|Age and gender matched healthy controls|Controls will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
89155324|NCT05696184|Active Comparator|Age and gender matched patient controls (GERD without regurgitation and supra-esophageal complaint)|Age and gender matched patient controls (GERD without regurgitation and supra-esophageal complaint). Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
89155325|NCT05696184|Active Comparator|Asthma patients with and without supra-esophageal symptoms|Asthma patients with and without supra-esophageal symptoms (these symptoms include chronic cough, frequent throat clearing, history of non-deglutitive aspiration pneumonia, hoarse voice, chronic sinusitis, and dental erosion). Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
89155326|NCT05696184|Active Comparator|Age and gender matched patient controls for diagnosed Barrett's esophagus patients|Patient controls for diagnosed Barrett's esophagus patients. Patients will undergo endoscopic evaluation of reflux and upper esophageal sphincter (UES) manometric testing.
89155327|NCT05691465|Experimental|Treatment (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30 minutes. Cycles repeat Q6W for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT scan at baseline and collection of blood throughout the trial.
89155328|NCT05686824||Midwives and student midwives at one Trust|No intervention - this is an exploratory case study
89155329|NCT05685836||Bevacizumab|After determining eligibility, all patients will undergo standard-of-care treatment with the sole addition of a pre-treatment 89Zr-Bevacizumab PET/CT-scan. Patients will first receive 5 mg 89Zr-Bevacizumab 4 days before PET/CT scan. This is followed by standard-of-care intravenous 7.5mg/kg bevacizumab (Avastin) therapy, administered every three weeks for six months
89155330|NCT05681546||Observational Group|The investigators are going to observe the risk factors about inferior alveolar nerve block anesthesia.
89155331|NCT05677763|Experimental|BV-12|Subjects will receive OM-85 treatment for 12 consecutive months. (10 days per month)
89155332|NCT05677763|Experimental|BV-3|Subjects will receive OM-85 treatment for 3 consecutive months, followed by matching placebo for 9 consecutive months. (10 days per month)
88804541|NCT04304755|Experimental|Investigational Medical Product : Zoledronic acid|Zoledronic acid 5 mg IV at baseline and after 26 weeks.
89155333|NCT05677763|Placebo Comparator|Placebo|Subjects will receive matching placebo for 12 consecutive months. (10 days per month)
89155334|NCT05674929|Experimental|BPL-003 arm|
89155335|NCT05674578|Experimental|Health services research (patient navigator)|Patients are assigned a Black patient navigator for racial concordance and receive coaching from patient navigator over 30 minutes every other week for 3 months and then monthly for 3 months.
89155336|NCT05672342|Experimental|Arm I (CBD)|Patients receive CBD PO on study.
89155337|NCT05672342|Experimental|Arm II (CBD + THC)|Patients receive CBD PO + THC PO on study.
89155338|NCT05672342|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO on study.
89155339|NCT05671107||PTEN - with NDD|Patients diagnosed with PTEN Hamartoma Tumor Syndrome and a neurodevelopmental disorder including but not limited to autism spectrum disorder, attention-deficit disorder / attention-deficit hyperactivity disorder, speech language disorder(s), intellectual disability, global developmental delay, oppositional defiant disorder, and / or motor or developmental disorders.
89155340|NCT05671107||PTEN - without NDD|Patients diagnosed with PTEN Hamartoma Tumor Syndrome
89155341|NCT05671107||Sibling Controls|Siblings related to patients with diagnosis of PTEN Hamartoma Tumor Syndrome
89155342|NCT05671107||Unrelated Controls|Unrelated participants with no known genetic or neurodevelopmental disorder
89155343|NCT05664802|Experimental|e-HERO 2.0|The e-HERO intervention includes 10 modules, totaling approximately 2.5 hours of content. Across these modules, e-HERO uses diverse delivery methods to address HIV and STI knowledge, behavioral skills, HIV and STI testing intention, and instill self-efficacy to primary and secondary prevention behaviors. Those in the intervention condition will also engage in three virtual group discussion sessions with peer mentors.
89155344|NCT05664802|Active Comparator|e-HERO 1.0|e-HERO 1.0 contains the same number of modules as e-HERO. The control arm reflects HIV and STI information that is currently publicly available.
89155345|NCT05660538|Experimental|VX-548|Participants will be randomized to receive different dose levels of VX-548.
89155346|NCT05660538|Active Comparator|Pregabalin|Participants will receive pregabalin.
89155347|NCT05650021|Other|SpaceOAR Vue and fiducial marker|After enrollment, patients will be treated per the standard of care, including the use of daily CBCT for image guided radiotherapy. The investigator will review the CBCT on the first day of treatment and align in such a way that the fiducials match up but also that the radio-opaque SpaceOAR lines up to within 5mm. If the SpaceOAR does not line up to within 5mm, the investigator will consider an intervention such as having the patient get off the table to pass gas, have a bowel movement, additional counseling about diet and bowel movement habits, or potentially even re-simulation. These daily CBCT images are aligned to the CT simulation images by way of aligning the fiducial markers on the respective imaging data sets. The CBCT images acquired during their first five fractions of radiotherapy will be imported into MIM software.
89155348|NCT05648591|Experimental|Iloperidone|Open-label iloperidone
89155349|NCT05644496|Experimental|Intervention|In addition to the standard-of-care arm description, single administration of Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release in the surgical site before complete wound closure.
89155350|NCT05644496|No Intervention|Standard-of-care|Usual standard of care procedure for knee replacement and pain management before, during and immediately following surgery.
89155351|NCT05619042||Presence / absence of CAC|Participants with or without a level/extension of CAC
88804542|NCT04304755|Placebo Comparator|Placebo: NaCl 0,9%|100 ml 0.9% NaCl IV at baseline and after 26 weeks.
89155352|NCT05617807|Experimental|Nanoscopic Partial Meniscectomy|This is the experimental group. patients will have a partial meniscectomy performed using the arthrex nanoscope
89155353|NCT05617807|Active Comparator|Standard Partial Meniscectomy|Patients will have a partial meniscectomy performed using standard arthroscopic equipment which is the current gold standard
89155354|NCT05617599||Coronary Artery Disease (CAD)|
89155355|NCT05613946|Other|Microbubble contrast agent Lumason|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
89155356|NCT05613946|Other|Microbubble contrast agent Optison|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
89155357|NCT05613946|Other|Microbubble contrast agent Definity|While subjects are undergoing standard of operation for arm with lymphedema, the healthy arm will receive intradermal injection of microbubbles and imaged immediately by ultrasound.
89155358|NCT05613010|Experimental|Mobile health (mHealth) text messaging intervention|During baseline (4 weeks), adherence will be monitored daily via electronic pill boxes and no text messages will be sent. After baseline, participants will begin the 12-week micro-randomized trial of the intervention (a within-person study design). During this 12-week micro-randomized trial, daily adherence will be electronically monitored with the electronic pill boxes and participants will be randomized to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. For 12 months post-intervention, participants will keep using the electronic pill boxes (no text messages will be sent).
89155359|NCT05612789|Experimental|Cohort A (Prehab)|Pre-frail and frail subjects will attend at least twice weekly exercise sessions with a physical therapist and be given an exercise program to complete at home prior to admission for HCT. Patients enrolled in this cohort can continue on to Cohort B.
89155360|NCT05612789|Experimental|Cohort B (Rehab)|All patients 60 years and older upon discharge from their initial hospital stay for HCT will attend at least weekly exercise sessions with a physical therapist and be given an exercise program to complete at home with sessions continued through Day +100 after HCT.
89155361|NCT05609578|Experimental|Cohort A: PD-L1 TPS≥ 1% (Closed)|Adagrasib 400 mg BID for 2 cycles followed by adagrasib 400 mg BID + pembrolizumab 200 mg every 3 weeks (Q3W) up to 35 cycles
89155362|NCT05609578|Experimental|Cohort C|Adagrasib 400 mg BID + pemetrexed 500 mg/m2 Q3W + pembrolizumab 200 mg Q3W up to 31 cycles
89155363|NCT05609578|Experimental|Cohort E|Adagrasib 400 mg BID + pembrolizumab 200 mg Q3W + pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 4 cycles, followed by adagrasib 400 mg BID + pemetrexed 500 mg/m2 Q3W + pembrolizumab 200 mg Q3W (up to 31 cycles)
89155364|NCT05608603||3 months postcovid patients|"Included 100 patients, aged 18-80 years old, at 3 months after infection COVID-19.~Intervention: cardiorespiratory stress test to determine the patient's oxygen consumption; electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; the analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)."
89155365|NCT05608603||9 months postcovid patients|"Included the same 100 patients, aged 18-80 years old, at 9 months after infection COVID-19.~Intervention: cardiorespiratory stress test to determine the patient's oxygen consumption; electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark; the analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)."
89155366|NCT05608434|Experimental|Floreo VR group|This group will undergo up to 20 daily sessions (20 minutes each) of the Floreo VR training.
89155367|NCT05608291|Experimental|Fianlimab HD + Cemiplimab|Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab
89155368|NCT05608291|Experimental|Fianlimab LD + Cemiplimab|Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab
89155369|NCT05608291|Active Comparator|Pembrolizumab|Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo
89155370|NCT05606653|Other|didgeridoo players|subjects having a regular practice of didgeridoo
89155371|NCT05606653|Other|oboe players|subjects having a regular practice of the oboe
89155372|NCT05606653|Other|control|control subjects without diagnosed SAS, at low risk of SAS on the Berlin questionnaire and the STOP BANG questionnaire
89155373|NCT05601245|Experimental|High voltage pulsed current|Twenty patients with chronic wounds will be managed by the high-voltage pulsed current for 45 as the total treatment duration and the polarity will be reversed after 22 minutes, three sessions per week for six weeks.
89155374|NCT05601245|Experimental|Microcurrent therapy|Twenty patients with chronic wounds will be managed by microcurrent therapy for 40 minutes, three sessions per week for six weeks.
89155375|NCT05600894|Experimental|Arm I (ASTX727, venetoclax)|Patients receive ASTX727 PO QD for 5 consecutive days starting on day 3 of treatment cycle 1; followed by day 1 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD on days 1 through 14 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsies, and collection of blood and buccal samples throughout the study.
89155376|NCT05600894|Active Comparator|Arm II (ASTX727)|Patients receive ASTX727 PO QD for 5 consecutive days starting on day 3 of treatment cycle 1; followed by day 1 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not have response to treatment may cross over to Arm I. Patients also undergo bone marrow biopsies, and collection of blood and buccal samples throughout the study.
89155377|NCT05596474|Experimental|Beet-root juice plus red-light therapy|
89155378|NCT05596474|Sham Comparator|Beet-root juice plus sham light therapy|
89155379|NCT05596474|Placebo Comparator|Placebo plus red-light therapy|
89155380|NCT05596474|Active Comparator|Placebo plus sham light therapy|
89155381|NCT05579652||Patients with open abdomen|All non-pregnant adults with an open abdomen who are consentable or who have a legally authorized representative will have the tension on each side of their abdominal wall measured using a tensiometer at each abdominal exploration
89155382|NCT05574010|Experimental|Cohort 1 in Part A|All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 1
89155383|NCT05574010|Experimental|Cohort 2 in Part A|All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 2
89155384|NCT05574010|Placebo Comparator|Group 1 in Part B and Part C|All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of placebo
89155385|NCT05574010|Experimental|Group 2 in Part B and Part C|All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 3
89155386|NCT05574010|Experimental|Group 3 in Part B and Part C|All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 4
89155387|NCT05574010|Experimental|Group 4 in Part B and Part C|All eligible Part B and Part C participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 5
89155388|NCT05566704||Modulus ALIF System|
89155389|NCT05561140|Experimental|Voxeletor + SOC (Standard of Care)|
89155390|NCT05561140|Placebo Comparator|Placebo + SOC (Standard of Care)|
89155391|NCT05560464|Experimental|Cohort 1: Mild Hepatic Impairment|Participants will receive multiple doses of VX-548 every 12 hours (q12h) from Day 1 through Day 14.
89155392|NCT05560464|Experimental|Cohort 2: Matched Healthy Participants|Healthy participants matched to cohort 1 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
89155393|NCT05560464|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
89155394|NCT05560464|Experimental|Cohort 4: Matched Healthy Participants|Healthy participants matched to cohort 3 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
89155395|NCT05558410|Experimental|VX-548|Participants will receive VX-548.
89155396|NCT05558410|Active Comparator|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will receive HB/APAP.
89155397|NCT05558410|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
89155398|NCT05553366|Experimental|VX-548|Participants will be randomized to receive VX-548.
89155399|NCT05553366|Active Comparator|Hydrocodone bitartrate/acetaminophen (HB/APAP)|Participants will be randomized to receive HB/APAP.
88804543|NCT04302428||Pediatric CF Patients|Pediatric patients ages 3 months to 3 years with CF identified via newborn screening.
89155400|NCT05553366|Placebo Comparator|Placebo|Participants will be randomized to receive placebo matched to VX-548 and HB/APAP.
89155401|NCT05553353|Experimental|Active rTMS|Active repetitive transcranial magnetic stimulation (rTMS) that will be administered 5 days/week for 6 weeks. Intensity will be individualized based on reverse-calculation electric-field modeling.
89155402|NCT05553353|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation (rTMS) that will be administered 5 days/week for 6 weeks. Intensity will be individualized based on reverse-calculation electric-field modeling, but a sham treatment coil will be used; thus, no active treatment will be administered.
89155403|NCT05552755|Placebo Comparator|Placebo (Part 1)|Participants will receive placebo PO dosed once daily
89155404|NCT05552755|Experimental|REC-4881 4mg (Part 1)|Participants will receive REC-4881 4mg PO dosed once daily
89155405|NCT05552755|Experimental|REC-4881 4mg (Part 2)|Participants will receive REC-4881 4mg PO dosed once daily
89155406|NCT05552755|Experimental|REC-4881 8mg (Part 2)|Participants will receive REC-4881 8mg PO dosed once daily
89155407|NCT05552755|Experimental|REC-4881 12mg (Part 2)|Participants will receive REC-4881 12mg PO dosed once daily
89155408|NCT05552469|Experimental|DFV890 low dose|DFV890 given as single agent at a low dose
89155409|NCT05552469|Experimental|DFV890 high dose|DFV890 given as single agent at a high dose
89155410|NCT05541848|No Intervention|Control group|Participants in the control group will not receive any intervention and will continue with their normal combat and flight exercise activities. They will be asked not to take medication or seek alternative treatments.
89155411|NCT05541848|Experimental|Experimental group|Participants in the experimental group will follow a supervised ELGF program. Subsequently, they will receive an intervention based on manual therapy combined with electrical stimulation called electro-massage.
89155412|NCT05541471|Experimental|Arm 1|Participants will receive a single dose of midazolam and digoxin on Day 1 in dosing period 1 followed by VX-548 every 12 hours (q12h) on Days 6 through 23 in dosing period 2. On Day 19, single doses of midazolam and digoxin will be administered with the morning dose of VX-548.
89155413|NCT05528588|Experimental|> 11 BAN-ADHF, Furoscix|Patients with diuretic resistance as determined by a BAN-ADHF score > 11 will receive Furoscix over 5 hours at 8 mg/mL.
89155414|NCT05528588|Experimental|<= 11 BAN-ADHF, Furoscix|Patients without diuretic resistance as determined by BAN-ADHF score <= 11 will receive Furoscix over 5 hours at 8 mg/mL.
89155415|NCT05528588|Active Comparator|> 11 BAN-ADHF, control|Patients with diuretic resistance as determined by a BAN-ADHF score > 11 will receive home dose oral diuretic.
89155416|NCT05528588|Active Comparator|<= 11 BAN-ADHF, control|Patients without diuretic resistance as determined by BAN-ADHF score <= 11 will receive home dose oral diuretic
89155417|NCT05520346|Experimental|Device|Patients use toilet device to measure fluid output and self-report event types
89155418|NCT05520346|No Intervention|Control|Collection in standard hats + nurses visually assessing fluid volumes
89155419|NCT05517902|Experimental|2 to < 12 years Age Group Cohort|Participants of age 2 to < 12 years will receive a single application of StrataGraft to 0.5% to 10% total body surface area (TBSA) on Day 1.
89155420|NCT05517902|Experimental|12 to ≤ 17 years Age Group Cohort|Participants of age 12 to ≤ 17 years will receive a single application of StrataGraft to 0.5% to 10% TBSA on Day 1.
89155421|NCT05515978|Active Comparator|Metformin and Lifestyle Modification Arm|For the metformin arm: metformin will be obtained as a standard of care medication from the patient's general pharmacy. This will be given for a clinical indication (e.g. prediabetes or overweight/obese). It will not be supplied by the study, but billed to Medicare, self pay or 3rd party payer. Lifestyle modification and prediabetes information will be provided via MHC or other electronic means on a quarterly basis.
89155422|NCT05515978|Placebo Comparator|Lifestyle Modification Only Arm|Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.
89155423|NCT05514769|Experimental|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty (GAP)|The reconstruction including esophagogastric anastomosis and pyloroplasty for patients who underwent proximal gastrectomy . The anastomosis locate in the anterior of gastric stump.
89155424|NCT05514769|Active Comparator|Control|The reconstruction including esophagogastric anastomosis and pyloroplasty for patients who underwent proximal gastrectomy . The anastomosis locate in the posterior or side of gastric stump.
89155425|NCT05500391|Experimental|Experimental|Telesurveillance by a nurse
89155426|NCT05500391|Other|Control|On-site surveillance by a hospital physician
89155427|NCT05499091|Experimental|Study Arm|"Specific interventions:~Blood samples, skin biopsy, urine collection or operational waste qualified as research sample."
89155428|NCT05498792|Experimental|CBL0137 (Dose level 1) +Ipilimumab + Nivolumab|Dose level 1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
89155429|NCT05498792|Experimental|CBL0137 ( Dose level 2) +Ipilimumab + Nivolumab|Dose level 2 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
89155430|NCT05498792|Experimental|CBL0137 ( Dose level -1) +Ipilimumab + Nivolumab|Dose level -1 CBL0137 on Days 1 and 8, Nivolumab and Ipilimumab on days 8 and 29 administrated IV of 8 weeks treatment cycles.
89155431|NCT05485831||Lennox Gastaut and Dravet Syndrome|Participants aged 6-17 years of age diagnosed with LGS and DS.
89155432|NCT05477901|Experimental|Intervention|High supplemental transfer: $40 a month
89155433|NCT05477901|No Intervention|Control|Low supplemental transfer: $2 a month
89155434|NCT05470010|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes everyday, with a minimum of 4 days of activity in a week.
89155435|NCT05470010|Other|Control Mindfulness|No intervention and usual care for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
89155436|NCT05467007|Experimental|BioFire® Respiratory Panel 2.1-EZ|EXP group will receive the BioFire RP2.1-EZ panel, designed to test for a variety of bacterial and/or viral causes for illness
89155437|NCT05467007|No Intervention|Standard of Care|Standard care procedures are essentially yes/no to patient having SARS-COV-2, the SC group will receive the standard nasal swab used in the IPCs.
89155438|NCT05465928|Experimental|Personalized rTMS|"The active arm will receive the personalized rTMS treatment with parameters as follows:~Neuroimaging biomarker-guided personalized selection for stimulation frequency: low frequency(1HZ) or high frequency (10HZ);~Neuroimaging biomarker-guided personalized selection for stimulation site: dorsalmedial prefrontal cortex or occipital cortex;~Schedule: 2 sessions per day, five days per week for a total of 20 sessions over 2 weeks."
89155439|NCT05465928|Sham Comparator|sham stimulation rTMS|Sham stimulation arm will receive the same scheme of rTMS but with a sham coil.
89155440|NCT05461079||subfertile men|10 infertile men with shortened AGD (< 40 mm)
89155441|NCT05461079||fertile semen donors|10 fertile semen donors with normal AGD (>40 mm)
89155442|NCT05455606|Active Comparator|Arm 1 (usual care)|Participants receive usual care. This consists of physicians ordering GTT for patients and reviewing the results without the GTB being involved.
89234930|NCT05885581|Active Comparator|Group B:|Group B will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
89234931|NCT05884515|Other|PCR comparator|Another molecular test like PCR will be done to confirm the positive and negative antigen test
89234932|NCT05883072||Intervention|Patients will be provided access to Chatbot to enquire their querries regarding diabetic complications.
89234933|NCT05883007|Experimental|Dose-optimized BNCT with borofalan(10B)|
89234934|NCT05882617|Experimental|experimental|single impalnts supported overdenture
89234935|NCT05882617|Active Comparator|active comparator|two implants supported overdenture
89234936|NCT05882617|Other|others|four implants supported overdenture
89234937|NCT05882188|Experimental|Tubal flushing during HSG with oil-based contrast|Tubal flushing during HSG HSG will be performed by a gynaecologist, fertility doctor or nurse according to local protocols. HSG will be performed in the follicular phase of the cycle. Preferably, HSG is performed in the next cycle after randomization, but if this is not feasible the procedure may be postponed up till one month after randomization. After cleaning the vagina and cervix, a vacuum cervix adapter will be applied to the cervix or a Lipiodol resistant balloon catheter or hysterophore will be placed through the cervix. Up to 15ml of Lipiodol Ultra Fluid will be injected into the uterine cavity and its spread directly monitored by fluoroscopy. Six to eight radiographs will be taken and assessed by a gynaecologist or radiologist. The maximum amount of oil-based contrast medium is set at 15ml.
89234938|NCT05882188|Active Comparator|Tubal flushing HyFoSy|Tubal flushing during HyFoSy will be performed by a gynaecologist, fertility doctor, sonographer or nurse according to local protocols. HyFoSy will be performed in the follicular phase of the cycle. Preferably, HyFosy is performed in the next cycle after randomization, but if this is not feasible the procedure may be postponed up till one month after randomization. During HyFoSy approximately 5-10cc of foam will be introduced through a little cervical balloon-less applicator into the uterine cavity. During infusion of the foam into the uterine cavity, a transvaginal ultrasound will be performed which shows whether the Fallopian tubes are patent. The assessment of the procedure will be done by the one who performed the procedure.
89234939|NCT05882149|Experimental|Probiotic|Sugar-free chewing gum with single strain probiotic and zinc. A daily dose of 2 chewing gums containing 1x10^10 Colony Forming Unit (CFU) for 12 weeks.
89234940|NCT05882149|Placebo Comparator|Placebo|Sugar-free chewing gum for 12 weeks.
89234941|NCT05881382|Active Comparator|Dutogliptin + Filgrastim|Participants will receive BID SC injections of 60 mg dutogliptin for 14 days in co-administration with 10 µg/kg filgrastim for 5 days.
89234942|NCT05881382|Placebo Comparator|Placebo-Dutogliptin + Placebo-Filgrastim|Randomized participants will receive BID SC injections of dutogliptin placebo for 14 days in co-administration with filgrastim placebo for 5 days.
89234943|NCT05879393|Experimental|Multistrain Probiotic OMNi-BiOTiC® Active|Lacticaseibacillus casei W56, Lactobacillus acidophilus W37, Ligilactobacillus salivarius W24, Levilactobacillus brevis W63, Lactococcus lactis W58, Lactococcus lactis W19, Bifidobacterium animalis subsp. lactis W52, Bifidobacterium longum subsp. longum W108, Bifidobacterium breve W25, Bifidobacterium animalis subsp. lactis W51 and Bifidobacterium bifidum W23. Additional ingredients:corn starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate and vanillin
89234944|NCT05879393|Placebo Comparator|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
89234945|NCT05879094|Experimental|Morton extension|Experimental group con Morton Extension application
89234946|NCT05875415|Experimental|Bilateral dry needling in Flexor Brevis Digitorum in subjects with latent trigger point|
89234947|NCT05875415|Sham Comparator|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|
89234948|NCT05857345||Lactating individuals|Lactating adults (age >= 18) with children aged 2 weeks to 6 month
89234949|NCT05854472|Experimental|Use of smartphone application|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
89234950|NCT05854472|No Intervention|not use a smart phone application|In this group, patients who have liver transplantation and do not use a smart phone application for liver transplantation patients after discharge will be included.
89234951|NCT05848817||Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK.
89234952|NCT05845931|Active Comparator|woman|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between arm 1 and arm 2.
88804544|NCT04273165|Active Comparator|Etravirine Dose 1|Etravirine dose 200 mg per diem(100+100)
88804545|NCT04273165|Active Comparator|Etravirine Dose 2|Etravirine dose 400 mg per diem (200+200)
88804546|NCT04179968|Experimental|Patients with suspected prostate cancer|Patients with suspected prostate cancer who have at least one PI-RADS 5 lesion, or at least one PI-RADS 4 lesion and PSA ≥10 nanograms/milliliter (ng/mL), on standard of care mpMRI of the prostate, who are scheduled for biopsy or radical prostatectomy
88804547|NCT04110236|Experimental|Immediate PriCARE|Caregiver-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 1-2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
89234953|NCT05845931|Active Comparator|men|The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between arm 1 and arm 2.
89234954|NCT05843708|Experimental|Fasting condition / Low-fat meal|A single oral dose of 1×40 mg vorasidenib tablet administered under fasted conditions or following a low-fat meal.
89234955|NCT05843708|Experimental|Low-fat meal / Fasted condition|A single oral dose of 1×40 mg vorasidenib tablet administered following a low-fat meal or under fasted conditions.
89234956|NCT05843708|Experimental|Vorasidenib|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1.
89234957|NCT05843708|Experimental|Vorasidenib and ciprofloxacin|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 and twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14.
89234958|NCT05841563|Experimental|PM54|"Phase Ia (dose escalation) stage: Patients will receive PM54 i.v. at a starting dose of 0.3 mg/m2.~Phase Ib (expansion) stage: Patients will receive PM54 i.v. at the RD determined during the Phase Ia stage."
89234959|NCT05840991|Experimental|Short-term compression group|Patients randomised to group A will be provided with bandages to wear for 48 hours only
89155443|NCT05455606|Experimental|Arm 2 (EGTB)|Patients and physicians receive the EGTB intervention. This is comprised of 2 components: the structured GTB and the supporting education. Physicians submit cases for discussion to the GTB within 2 weeks of GTT results. The GTB sessions are held weekly and conducted virtually over a video-conferencing platform. Each case presentation is 10 to 15 minutes long, and 4 to 6 cases are discussed during each 60 minute GTB session. GTT results and clinical data are presented and expert interpretation of genomic test results is provided to help prioritize potential treatment options and provide a framework for interpretation. Supporting education materials are also available online to participants to support GTT decision making.
89155444|NCT05455502|Experimental|Sequence 1|Participants will receive VX-548 reference tablet (TF1) under fasted condition in dosing period 1, then VX-548 test tablet (TF2) under fasted condition in dosing period 2, and finally VX-548 test tablet (TF2) under fed condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
89155445|NCT05455502|Experimental|Sequence 2|Participants will receive VX-548 TF1 under fasted condition in dosing period 1, then VX-548 TF2 under fed condition in dosing period 2, and finally VX-548 TF2 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
89155446|NCT05455502|Experimental|Sequence 3|Participants will receive VX-548 TF2 under fasted condition in dosing period 1, then VX-548 TF1 under fasted condition in dosing period 2, and finally VX-548 TF2 under fed condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
89155447|NCT05455502|Experimental|Sequence 4|Participants will receive VX-548 TF2 under fasted condition in dosing period 1, then VX-548 TF2 under fed condition in dosing period 2, and finally VX-548 TF1 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
89155448|NCT05455502|Experimental|Sequence 5|Participants will receive VX-548 TF2 under fed condition in dosing period 1, then VX-548 TF1 under fasted condition in dosing period 2, and finally VX-548 TF2 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
89155449|NCT05455502|Experimental|Sequence 6|Participants will receive VX-548 TF2 under fed condition in dosing period 1, then VX-548 TF2 under fasted condition in dosing period 2, and finally VX-548 TF1 under fasted condition in dosing period 3. A washout period of 12 days will be maintained between 3 dosing periods.
89155450|NCT05452603||Study group|Thirty consecutive patients with GERD symptoms and an acid exposure time (AET) measured by impedance measurement/pH between 4 and 6% will be included.
89155451|NCT05448326||Work package 1 (WP1)|Patients without a diagnosis who consulted for a developmental anomaly in 2012 and 2022 and agree to resume a diagnostic approach
89155452|NCT05448326||Work package 2 (WP2)|Part 1 (Lab): Patients with developmental abnormalities with or without neurodevelopmental disorders who have had a CNV (Copy Number Variation) rendering that remained of unknown significance or classified as (probably) benign Part 2 (Clinical part): Patients who agree to resume the diagnostic process following a CNV report of unknown significance or classified as (probably) benign
89155453|NCT05448326||Work package 3 (WP3)|Patients with an established clinical diagnosis belonging to the characteristic syndromes of the AnDDI-Rares network (known gene(s) but negative molecular diagnosis)
89155454|NCT05437640|Active Comparator|Protein Redistribution Diet|PD participants may first be randomized to follow the Protein Redistribution Diet followed by the Protein Consistent Diet.
89155455|NCT05437640|Active Comparator|Protein Consistent Diet|PD participants may first be randomized to follow the Protein Consistent Diet followed by the Protein Redistribution Diet.
89155456|NCT05427695|Active Comparator|Saline Nasal Irrigation (Control)|Patients will perform nasal irrigation with an isotonic saline solution, using a 240ml NeilMed sinus rinse bottle, 2 times/day for 14 days. A blinded packet supplied by IDS containing a premeasured amount of saline to be mixed with 240ml of distilled water will be provided to patients for each irrigation.
89155457|NCT05427695|Experimental|Lactobacillus sakei nasal irrigation|Patients will perform nasal irrigation with Lactobacillus sakei, using a 240ml NeilMed sinus rinse bottle, 2 times/day for 14 days. A blinded packet provided by IDS containing a premeasured amount of Lactobacillus sakei to be mixed with 240ml of distilled water will be provided to patients for each irrigation.
89155458|NCT05423158|Experimental|d-Coaching|Will receive home-based cardiac rehabilitation (HBCR) with digital coaching (d-Coaching) intervention
89155459|NCT05423158|No Intervention|Usual Care|Will receive home-based cardiac rehabilitation (HBCR) alone
89155460|NCT05417555|Active Comparator|LIFUP Dose Group 1|Administration of low intensity focused ultrasound (LIFUP) dose level 1 to the entorhinal cortex.
89155461|NCT05417555|Active Comparator|LIFUP Dose Group 2|Administration of low intensity focused ultrasound (LIFUP) dose level 2 to the entorhinal cortex.
89155462|NCT05417555|Active Comparator|LIFUP Dose Group 3|Administration of low intensity focused ultrasound (LIFUP) dose level 3 to the entorhinal cortex.
89155463|NCT05417555|Sham Comparator|Sham LIFUP|"No administration of LIFUP. The device will be affixed to the user's head but not turned on.~Additionally, if at the end of the study, the treatment has been shown to be effective, placebo subjects will be offered a free session using the optimally effective dose, if they consented to being contacted for this purpose."
89155464|NCT05408975|Experimental|Active to Sham Transcranial direct current stimulation|Subjects in this arm will first be randomly assigned to receive active stimulation. After completion of active stimulation, subjects will be assigned to sham stimulation.
89155465|NCT05408975|Experimental|Sham to Active transcranial direct current stimulation|Subjects in this arm will first be randomly assigned to receive sham stimulation. After completion of sham stimulation, subjects will be assigned to active stimulation.
89155466|NCT05399888|Placebo Comparator|Placebo Q12W|Participants will receive BIIB080-matching placebo, intrathecal (IT) injection, once on Day 1 and then once every 12 weeks (Q12W) for up to 72 weeks, during the placebo-controlled period. Eligible participants will enter the long-term extension (LTE) period, during which they will be randomized to receive BIIB080 high dose, IT injection, either Q12W or once every 24 weeks (Q24W) for an additional 96 weeks.
89155467|NCT05399888|Experimental|BIIB080 Low Dose Q24W|Participants will receive a low dose of BIIB080, IT injection, Q24W from Week 1 up to 72 weeks and BIIB080-matching placebo, IT injection, once at Weeks 12, 36, and 60 during the placebo-controlled period. Eligible participants will enter the LTE period, during which they will continue to receive BIIB080 low dose, IT injection, Q24W for an additional 96 weeks.
89155468|NCT05399888|Experimental|BIIB080 High Dose Q24W|Participants will receive a high dose of BIIB080, IT injection, Q24W from Week 1 up to 72 weeks and BIIB080-matching placebo, IT injection, once at Weeks 12, 36, and 60 during the placebo-controlled period. Eligible participants will enter the LTE period, during which they will continue to receive BIIB080 high dose, IT injection, Q24W for an additional 96 weeks.
89155469|NCT05399888|Experimental|BIIB080 High Dose Q12W|Participants will receive a high dose of BIIB080, IT injection, once on Day 1 and then Q12W for up to 72 weeks during the placebo-controlled period. Eligible participants will enter the LTE period, during which they will continue to receive BIIB080 high dose, IT injection, Q12W for an additional 96 weeks.
89155470|NCT05397600|Experimental|T4032|
89155471|NCT05397600|Active Comparator|Lumigan|
89155472|NCT05392621|Experimental|Yoga+Progressive Muscle Relaxation+Deep Breathing|Participants engage in a single session combining yoga, progressive muscle relaxation, and deep breathing.
89155473|NCT05392621|Experimental|Yoga+Progressive Muscle Relaxation|Participants engage in a single session combining yoga and progressive muscle relaxation
89155474|NCT05392621|Experimental|Yoga+Deep Breathing|Participants engage in a single session combining yoga and deep breathing.
89155475|NCT05392621|Experimental|Yoga|Participants engage in a single session of yoga.
89155476|NCT05392621|Experimental|Progressive Muscle Relaxation+Deep Breathing|Participants engage in a single session combining progressive muscle relaxation and deep breathing.
89155477|NCT05392621|Experimental|Progressive Muscle Relaxation|Participants engage in a single session of progressive muscle relaxation.
89155478|NCT05392621|Experimental|Deep Breathing|Participants engage in a single session of deep breathing.
89155479|NCT05392621|Sham Comparator|Quiet sitting|Participants engage in a low-touch relaxation condition.
89155480|NCT05391295||6 CTCL patients, and 6 chronic cluster headache patients|The patients will be treated according to standard regular care, which is a corticosteroid treatment regime.
89155481|NCT05379673|Active Comparator|"Conservative O2 Supplementation"|Oxygen administration will be titrated to a oxyhemoglobin saturation (SpO2) between 90 and 94%.
89155482|NCT05379673|Experimental|"Liberal O2 Supplementation"|Oxygen administration will be titrated to an SpO2 > 96%.
89155483|NCT05377996|Experimental|XMT-1660|Single arm XMT-1660 alone (monotherapy)
89155484|NCT05369403|Experimental|Lebrikizumab|Participants will receive Lebrikizumab by subcutaneous (SC) injection.
89155485|NCT05362903||Oral LLT|Patients who newly initiated oral Lipid lowering treatment (LLT) on top of a statin
89155486|NCT05362903||Inclisiran|"Patients who newly initiated Inclisiran~Inclisiran in a PCSK9-treatment naive cohort~Inclisiran in patients with prior PCSK9-antibody treatment"
89155487|NCT05362903||Apheresis plus Inclisiran|Patients who newly initiated Inclisiran on top of lipid apheresis
89155488|NCT05362149||Darolutamide cohort (daro)|Adult men with nmCRPC previously untreated with a Novel antihormonal (NAH) agent and starting the first treatment with Darolutamide during the study period.
89155489|NCT05362149||Enzalutamide cohort (enza)|Adult men with nmCRPC previously untreated with a Novel antihormonal (NAH) agent and starting the first treatment with Enzalutamide during the study period.
89155490|NCT05362149||Apalutamide cohort (apa)|Adult men with nmCRPC previously untreated with a Novel antihormonal (NAH) agent and starting the first treatment with Apalutamide during the study period.
89155491|NCT05359536|Experimental|E-learning Intervention|Early career educators in the intervention condition will be asked to complete a 5-hour e-learning course over a two week timeframe. The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
89155492|NCT05359536|No Intervention|Usual Practice Control|Early career educators in the control condition will be asked to continue with their usual practices. They will be invited to complete the e-learning course after the study period.
89155493|NCT05358392|Experimental|emotional freedom technique|5 sessions of EFT* will be applied to this group on the first day of the treatment, 1st Control, 2nd Control, before the OPU procedure and before the embryo transfer. Subjective discomfort level will be measured with SUD** before and after each application.
89155494|NCT05358392|No Intervention|control|No application will be made to this group. Infertility stress scale will be filled in the case and control group at the beginning of the treatment and after the embryo transfer.
89155495|NCT05358171|Experimental|HIgh UPF (Ultra-processed foods)|Participants will consume a diet containing 81% total energy from UPF for 6 weeks
89155496|NCT05358171|Active Comparator|No UPF|Participants will consume a diet containing 0% total energy from UPF for 6 weeks
89155497|NCT05358158|Experimental|Drain-free group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
89155498|NCT05358158|Active Comparator|Chest drain group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard postoperative chest tube.
89155499|NCT05352815|Experimental|IcoSema|
89155500|NCT05352815|Active Comparator|Insulin icodec|
89155501|NCT05343143|Other|NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
89155502|NCT05339594||NeuraGen Nerve Guide|Integra NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
89155503|NCT05339594||NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
89155504|NCT05327296|Experimental|Isoflurane|Inhaled isoflurane administered via Sedaconda ACD-S
89155505|NCT05327296|Active Comparator|Propofol|Propofol administered as intravenous infusion
89155506|NCT05316350|Experimental|Atrial Fibrillation|
89155507|NCT05316350|Experimental|Normal Sinus Rhythm|
89155508|NCT05316337|Experimental|Atrial fibrillation|
89155509|NCT05316337|Experimental|Normal Sinus Rhythm|
89155510|NCT05314998|Experimental|Test Arm A: mFOLFIRINOX or Gem/Cap according to transcriptomic treatment specific signature|mFOLFIRINOX-therapy (5-FU, Folinic Acid, Irinotecan, Oxaliplatin) according to individual transcriptomic treatment specific signature or Gem/Cap-therapy (Gemcitabine and Capecitabine) according to individual transcriptomic treatment specific signature
89155511|NCT05314998|Active Comparator|Control Arm B: mFOLFIRINOX or Gem/Cap according to standard clinical criteria|mFOLFIRINOX-therapy (5-FU, Folinic Acid, Irinotecan, Oxaliplatin) according to standard clinical criteria or Gem/Cap-therapy (Gemcitabine and Capecitabine) according to standard clinical criteria
89155512|NCT05312385|Experimental|Isoflurane|Inhaled isoflurane administered via Sedaconda ACD-S
89155513|NCT05312385|Active Comparator|Propofol|Propofol administered as intravenous infusion
89155514|NCT05310032|Experimental|HSG4112 800 mg Single Dose|Single oral dosing of HSG4112 800 mg
89155515|NCT05310032|Experimental|HSG4112 1200 mg Single Dose|Single oral dosing of HSG4112 1200 mg with a high-fat meal or fasting condition, with a washout period of 21 days in between each dosing
89155516|NCT05310032|Experimental|HSG4112 800 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg for 14 days
89155517|NCT05310032|Placebo Comparator|Placebo 800 mg Multiple Dose|Multiple oral dosing of placebo 800 mg for 14 days
89155518|NCT05310032|Experimental|HSG4112 1200 mg Multiple Dose|Multiple oral dosing of HSG4112 1200 mg for 14 days
89155519|NCT05310032|Placebo Comparator|Placebo 1200mg Multiple Dose|Multiple oral dosing of placebo 1200 mg for 14 days
89155520|NCT05308017|Active Comparator|Richard Wolf 24F Laser scope|
89155521|NCT05308017|Active Comparator|Karl Storz 28F Laser scope|
89155522|NCT05307705|Experimental|Phase 1A: LOXO-783 Monotherapy Dose Escalation|LOXO-783 administered orally
89155523|NCT05307705|Experimental|Phase 1B: Part A|LOXO-783 administered orally in combination with fulvestrant intramuscularly, imlunestrant orally, or an aromatase inhibitor orally
89155524|NCT05307705|Experimental|Phase 1B: Part B|LOXO-783 orally in combination with abemaciclib and either physician's choice aromatase inhibitor orally, fulvestrant intramuscularly, or imlunestrant orally
89155525|NCT05307705|Experimental|Phase 1B: Part C|LOXO-783 orally in combination with fulvestrant intramuscularly
89155526|NCT05307705|Experimental|Phase 1B: Part D|LOXO-783 orally in combination with paclitaxel intravenously
89155527|NCT05307705|Experimental|Phase 1B: Part E|LOXO-783 orally
89155528|NCT05307705|Experimental|Phase 1B: Part F|Multiple randomized dose levels of LOXO-783 orally with fulvestrant intramuscularly
89155529|NCT05302934||Pheno4U|The study will collect data for each patient receiving an Aesculap TKA implant. The data set will be analyzed for critical risk factors among implant and patient data in order to optimize patient-centered therapies.
89155530|NCT05302375|Experimental|iPath*D|An online platform that connects patients screening positive for clinically significant depression in cancer settings to a range of online and inperson evidence-based treatments, facilitated by an interactive DA.
89155531|NCT05300490||Knee infiltration|Patients requiring prednisolone knee infiltration as part of routine medical management
89155532|NCT05285982|Experimental|Patients rolling over from the InPedILD® study|
89155533|NCT05285982|Experimental|Patients newly enrolled in this study|
89155534|NCT05282901|Experimental|Metastatic Uveal MElanoma patients|Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of metastatic uveal melanoma (UM)
89155535|NCT05273463|Experimental|Video-Based Education Group|Approximately 4 weeks before scheduled surgery, participants will receive the video-based intervention regarding pre-and postoperative care for ACL reconstruction.
89155536|NCT05273463|Experimental|Virtual Classroom Course Group|Approximately 4 weeks before scheduled surgery, participants will receive the classroom-based intervention regarding pre-and postoperative care for ACL reconstruction.
89155537|NCT05273463|No Intervention|Standard of Care Group|Participants will receive verbal and written pre-and postoperative instruction as typically received by all ACL reconstruction patients treated by the attending physicians before and after surgery.
89155538|NCT05266664||preterm|preterm infants gestational age less than 32 weeks
89155539|NCT05266664||healthy controls|healthy term infants
89155540|NCT05257564|Other|Diagnostic|Fingerstick collection and venous whole blood collection.
89155541|NCT05249543|Experimental|Unified protocol|Transdiagnostic cognitive-behavioral therapy focusing on emotional processes central to the development and maintenance of anxiety disorders, particularly neuroticism.
89155542|NCT05249543|Active Comparator|Diagnosis-specific cognitive-behavioral therapy|Cognitive-behavioral therapy specifically designed for a particular anxiety disorder as specified in evidence-based treatment protocols, which are commonly based on a specific theory or model of the development and maintenance of an anxiety disorder.
89155543|NCT05248035||Patient|Adult patient hospitalized in ICU for a duration of mechanical ventilation longer than 48 hours
89155544|NCT05246839||Arm 1 - Usual Care (No Video)|Subjects will receive the usual care pertaining to colorectal cancer (CRC) screening according to their respective clinical site and will not view either of the study videos.
89155545|NCT05246839||Arm 2 - Brief Video|Subjects will watch a video pertaining to the importance of CRC screening.
89155546|NCT05246839||Arm 3 - Brief Video Plus|Subjects will watch the same video as described in Arm 2, immediately followed by a second video pertaining to 3 CRC screening modalities: colonoscopy, FIT, and Cologuard.
89155547|NCT05225324||Equfina 50 mg|Participants who will be prescribed with Equfina 50 mg tablets, orally within the scope of the approved label for Korea under the medical judgment of the investigator will be observed prospectively for 24 weeks.
89155548|NCT05220033|Experimental|Journey Ahead|Experimental: Journey Ahead intervention focusing on coping and communication skill development during the course of 8 sessions and 6 phone calls.
89155549|NCT05215912|Experimental|Single Ascending Dose (SAD -Arm A)|Up to 5 cohorts of subjects receiving sequentially ascending dose of TNB-738 or placebo are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified
89155550|NCT05215912|Experimental|Multiple Ascending Dose (MAD- Arm B)|An expansion cohort (upto 4 cohorts) will be enrolled after maximum tolerated dose or recommended phase 2 dose is established.
89155551|NCT05213624|Experimental|BI 764198 - low dose|BI 764198 - low dose
89155552|NCT05213624|Experimental|BI 764198 - medium dose|BI 764198 - medium dose
89155553|NCT05213624|Experimental|BI 764198 - high dose|BI 764198 - high dose
89155554|NCT05213624|Placebo Comparator|Placebo|Placebo
89155555|NCT05211895|Experimental|Arm A: Durvalumab + Domvanalimab|Durvalumab and domvanalimab as an IV infusion q4w, starting on Day 1 for up to a maximum of 12 months
89155556|NCT05211895|Active Comparator|Arm B: Durvalumab + Placebo|Durvalumab + placebo as an IV infusion q4w starting on Day 1 for up to a maximum of 12 months
89155557|NCT05211726|Experimental|Low Added Sugar Diet|Subjects will be provided with a diet that is low in added sugars.
89155558|NCT05211726|Experimental|High Added Sugar Diet|Subjects will be provided with a diet that is high in added sugars.
89155559|NCT05209841|Experimental|Catheter sealing with low dose heparin|Catheters will be sealed with 3mL of Fibrillin Ⓡ (heparin 20UI/mL)
89155560|NCT05209841|Active Comparator|Catheter sealing with normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
89155561|NCT05201820|No Intervention|Standard of care|Epidural analgesia
89155562|NCT05201820|Experimental|Cryoanalgesia|Cryoanalgesia
89155563|NCT05201248|Experimental|Cohort 1 Part 1: Epcoritamab Monotherapy|Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles.
89155564|NCT05201248|Experimental|Cohort 1 Part 2: Epcoritamab Expansion|Participants will receive SC epcoritamab in 28 day cycles.
89155565|NCT05201248|Experimental|Cohort 2: Epcoritamab + RCHOP|Participants will receive SC epcoritamab in combination with [intravenously (IV) infused rituximab, IV injected cyclophosphamide, IV infused doxorubicin, IV infused vincristine, and oral prednisone (R-CHOP)] in 21 day cycles followed by 28 day cycles.
89155566|NCT05201248|Experimental|Cohort 3: Epcoritamab + R2|Participants will receive SC epcoritamab in combination with [intravenously (IV) infused rituximab, and oral lenalidomide (R2)] in 28 day cycles.
89155567|NCT05193721|Experimental|Treatment group|SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
89155568|NCT05175196|Experimental|Pediatric Participants with GAS|"Children age 5-17 years old diagnosed via standard Rapid Antigen Detection Test with acute pharyngitis caused by Group A Streptococcus (GAS), along with their parent or legal guardian (aka caregiver)."
89155569|NCT05173714|Placebo Comparator|SLIMM + Standard RT + Placebo|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo
89155570|NCT05173714|Active Comparator|SLIMM + Guided RT + Placebo|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo
89155571|NCT05173714|Experimental|SLIMM + Guided RT + Semaglutide|SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide
89155572|NCT05170425||Cohort 1|1) Cohort 1: Previously enrolled AND randomized in LAMBDA 001 Participants enrolled to Cohort 1 will be enrolled at least 12 and up to 18 months post-transplant.
89155573|NCT05170425||Cohort 2|2) Cohort 2: Not previously randomized in LAMBDA 001 Participants who were enrolled in LAMBDA 001 but who were not randomized in LAMBDA 001 may be enrolled to Cohort 2.
89155574|NCT05158413|Experimental|High dose|Experimental: high dose of sesame 20 patients
89155575|NCT05158413|Active Comparator|Low dose|Active Comparator: low dose of sesame 20 patients
89155576|NCT05147922|Experimental|Booster Training Group|Participants randomized to intervention will undergo booster training sessions with the RQI cart (including audiovisual feedback) at 3, 6 and 9 months post instructor-led training session. Following each of these booster sessions, the participants will undergo 1 minute assessments, without feedback.
89155577|NCT05147922|No Intervention|No Booster Training Group|Participants randomized to the control group will undergo 1 minute assessments, without feedback, at 6 and 9 months. Participants will not be able to access the RQI cart outside of their assessment.
89155578|NCT05143970|Experimental|IPH5301 administration|"Part I- Dose escalation:~Escalating dose levels of IPH5301 will be evaluated.~Part II-Cohort Expansion:~IPH5301 will be administrated in combination with trastuzumab and paclitaxel"
89155579|NCT05132673||Participants|Those who meet the Eligibility Criteria will be asked to complete online questionnaires and wear a device on your wrist for two weeks that measures your heart rate, physical activity, and sleep. A WHOOP® wrist monitor and charging equipment will be used.
89155580|NCT05129709|Experimental|"My Health Priorities Identification Program"|"The intervention, the My Health Priorities Identification Program consists of four self-directed, web-based modules intended to guide patients with MCCs in identifying their own health priorities. These priorities can then be used to guide discussions with family caregivers and clinicians regarding specific goals and preferences that they wish to guide future treatment decisions. Most models of palliative care have been developed based on white middle-class populations and may not apply to African Americans (AA) who have a very different cultural value set."
89155581|NCT05127226|Experimental|Part 1 MAD: Cohort A|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
89155582|NCT05127226|Experimental|Part 1 MAD: Cohort B|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
89155583|NCT05127226|Experimental|Part 1 MAD: Cohort C|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
89155584|NCT05127226|Experimental|Part 1 MAD: Cohort D|ION582 will be administered as IT injection over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
89155585|NCT05127226|Experimental|Part 1 MAD: Cohort E|ION582 will be administered as IT injection of over a period of 13 weeks, with a minimum of approximately 4 weeks between each dose administration.
89155586|NCT05127226|Experimental|Part 2 Group 1|ION582 will be administered as IT injection of over a period of 49 weeks, with additional dosing intervals.
89155587|NCT05127226|Experimental|Part 2 Group 2|ION582 will be administered as IT injection of over a period of 49 weeks, with additional dosing intervals.
89155588|NCT05127226|Experimental|Part 3 Group 1|ION582 will be administered as IT injection of over a period of 145 weeks, with additional dosing intervals.
89155589|NCT05127226|Experimental|Part 3 Group 2|ION582 will be administered as IT injection of over a period of 145 weeks, with additional dosing intervals.
89155590|NCT05125302|Experimental|PK Cohort: Ubrogepant Dose A|Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.
89155591|NCT05125302|Experimental|PK Cohort: Ubrogepant Dose B|Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.
89155592|NCT05125302|Experimental|Main Study: Children Ubrogepant Low Dose|Participants aged 6 to 11 (after dose selection) will receive oral tablets of low dose ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
89155593|NCT05125302|Experimental|Main Study: Children Ubrogepant High Dose|Participants aged 6 to 11 (after dose selection) will receive oral tablets of high dose ubrogepant Dose B for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
89155594|NCT05125302|Placebo Comparator|Main Study: Children Ubrogepant Placebo|Participants aged 6 to 11 (after dose selection) will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
89155595|NCT05125302|Experimental|Main Study: Adolescents Ubrogepant Low Dose|Participants aged 12 to 17 will receive oral tablets of ubrogepant low dose for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
89155596|NCT05125302|Experimental|Main Study: Adolescents Ubrogepant High Dose|Participants aged 12 to 17 will receive oral tablets of ubrogepant high dose or qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
89155597|NCT05125302|Placebo Comparator|Main Study: Adolescents Ubrogepant Placebo|Participants aged 12 to 17 will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.
89155598|NCT05111899|Experimental|Intervention|
89155599|NCT05111899|No Intervention|Control|
89155600|NCT05106647|No Intervention|Control|This group would complete a survey that measures stress before and after leisure time with no added instructions.
89155601|NCT05106647|Experimental|Reduce screen time|Participants randomized to the intervention group are encouraged to set up an automated response to emails received during their weekend off, reduce their screen time for duration of leisure time, and uninstall work applications from their mobile device. Surveys are sent prior to and after leisure time.
89155602|NCT05092503|Experimental|JINZHEN low dose arm|Patients will take 0.375 gram of JINZHEN Granules twice a day for 14 days.
89155603|NCT05092503|Experimental|JINZHEN middle dose arm|Patients will take 0.75 gram of JINZHEN Granules twice a day for 14 days.
89155604|NCT05092503|Experimental|JINZHEN high dose arm|Patients will take 1.5 gram of JINZHEN Granules twice a day for 14 days.
89155605|NCT05092503|Placebo Comparator|Placebo arm|Patients will take placebo granules twice a day for 14 days.
89155606|NCT05090501|Experimental|Green|Green exercise participants will exercise in the nature-based condition.
89155607|NCT05090501|Experimental|Indoor|Indoor participants will exercise in the indoor condition.
89155608|NCT05081700||Patients with relapsing MS|Patients with relapsing remitting MS who are intending to receive ocrelizumab.
89155609|NCT05069259||Patients with active Ulcerative Colitis|
89155610|NCT05065996||Different 4D flow MRI parameters in aortic dilatation and controls|Patients with aortic dilatation (n=20) scheduled for aortic MRI and healthy controls (n=20) without aortic dilatation. One time aortic MRI with 4D flow imaging.
89155611|NCT05065996||Value of aortic 4D flow MRI parameters to predict aortic dilatation in 5 years follow up|Patients with aortic dilatation (n=100) scheduled for aortic MRI follow up in Kuopio University Hospital. Aortic 4D flow MRI will be done yearly for 5 years and flow parameters predicting aortic dilatation will be analysed.
89155612|NCT05065996||Histology, molecular biology and genetics behind aortic dilatation|Patients scheduled for aortic operation (n=20+100) in Kuopio University Hospital. Aortic tissue samples and blood will be collected for analysis and compared to 4D flow MRI parameters. Control samples will be collected from healthy organ donors (n=5+5) operated in Kuopio University Hospital.
89155613|NCT05065671|Experimental|Tolcapone|Tolcapone 100 mg by mouth once
89155614|NCT05065671|Experimental|Duloxetine|Duloxetine 20 mg by mouth once
89155615|NCT05056896|Experimental|Low Dose Aspirin|Participants will be randomly assigned to aspirin group and receive a daily low dose aspirin (81 mg) for the duration of the study up to 12 weeks.
89155616|NCT05056896|Experimental|Placebo|Participants will be randomly assigned to placebo group and receive a daily placebo capsule for the duration of the study up to 12 weeks.
89155617|NCT05048199|Experimental|pressure regulated volume-controlled mode of ventilation (PRVC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
89234960|NCT05840991|Active Comparator|Long-term compression group|Patients randomised to group B will be asked to wear bandages for the first 24h and then a Class 2 compression full-length stocking (23-32mm Hg) for 1 week
89155618|NCT05048199|Active Comparator|volume-controlled mode of ventilation (VC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
89155619|NCT05041712||Case cohort|Observational study of children between the ages of 2 days to < 18 years who are cannulated onto ECMO at participating sites
89155620|NCT05041712||Control cohort|Observational study of children between the ages of 2 days to < 18 years admitted to the Johns Hopkins Pediatric Intensive Care Unit (PICU) or Pediatric Cardiac Intensive Care Unit (PCICU) for any reason.
89155621|NCT05036226|Experimental|Dose level 1|
89155622|NCT05036226|Experimental|Dose level 2a|
89155623|NCT05036226|Experimental|Dose level 2b|
89155624|NCT05036226|Experimental|Dose level 3a|
89155625|NCT05036226|Experimental|Dose level 3b|
89155626|NCT05036226|Experimental|Dose level 4|
89155627|NCT05036122|Experimental|Whole-body exercise in healthy adults (Aim 1)|Subjects will have blood [lactate] measurement obtained with the LabClasp device while completing an exercise stress test on a treadmill or bicycle.
89155628|NCT05036122|Experimental|ICU patients susceptible to developing sepsis (Aim 2)|Subjects will have blood [lactate] measurement obtained with the LabClasp device as frequently as required for clinical purposes
89155629|NCT05034536|Experimental|Pembrolizumab + Infliximab|"Participants will be randomly assigned to receive pembrolizumab and infliximab.~Pembrolizumab will be administered every 3 weeks for up to 2 years~Infliximab will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
89155630|NCT05034536|Experimental|Pembrolizumab + Placebo|"Participants will be randomly assigned to receive pembrolizumab and placebo.~Pembrolizumab will be administered every 3 weeks for up to 2 years~Placebo. will be administered on weeks 0, 2, and 6 (+/- 3 days) for a total of 3 doses"
89155631|NCT05022550|Experimental|DEEP VR Experiment Group|Participants identified from the Dane County Juvenile Court Program will be asked to experience up to 6 VR-B sessions. Participants will wear a lightweight, ultra-high-resolution, wireless, head-mounted display (Oculus Quest 2 Enterprise VR Headset). Each session will proceed through a series of four stages. First, participants will begin with a 5 minute acclimation period inside a demo VR environment. Second, baseline levels of physiological arousal will be captured over a 5 minute resting period where participants will be asked to sit quietly in a serene virtual environment. Third, participants will progress through the DEEP VR experience for 15 minutes. Finally, participants will complete a short series of online questionnaires.
89155632|NCT05019937|Experimental|Multifaceted implementation strategy|Schools randomized to this arm will be exposed to a multifaceted implementation strategy, which contains five implementation components
89155633|NCT05019937|Active Comparator|Single implementation strategy|Schools randomized to this arm will be exposed to a single implementation strategy, which contains one implementation component
89155634|NCT05015660|Experimental|left bundle branch pacing|
89155635|NCT05015660|Active Comparator|Right ventricular pacing|
89155636|NCT05013892|Experimental|NTS-WBRT (normal tissue sparing whole brain radiation therapy) + Memantine|"Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive:~NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks.~Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor"
89155637|NCT05004298|Experimental|Animal assisted terapy|The Experimental Group, in addition to receiving the usual activities of the rehabilitation device. You will receive the ten weekly sessions of the TAA Program.The program structure will aim to influence the 6 specific factors, described in the Multifactorial Model of Positive Mental Health of Dr. Lluch, which are: F1-Personal Satisfaction, F2-Prosocial Attitude, F3-Self-control, F4-Autonomy, F5- Problem Solving and Self-actualization and F6 Interpersonal Relationship Skills. For this reason, direct contact exercises with the dog will be designed and defined to work on them.
89155638|NCT05004298|No Intervention|Control Group|The Control Group will receive the usual activities of the rehabilitation device.
89155639|NCT05003115|No Intervention|Standard of Care|Standard of Care
89155640|NCT05003115|Experimental|Intervention|Motivational interviewing intervention
89155641|NCT05001711|Experimental|WHO Group 2|
89155642|NCT05001711|Experimental|WHO Group 3|
89155643|NCT04991142||Persons with Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c greater than or equal to 6.5%
89155644|NCT04991142||Persons with Pre-diabetes|Venous blood draw of fasting HbA1c greater than or equal to 5.7% and less than 6.5%
89155645|NCT04991142||Persons without Pre-diabetes or Diabetes Mellitus, Type 2|Venous blood draw of fasting HbA1c less than 5.7%
89155646|NCT04985565|Experimental|Treatment (dietary intervention, radical prostatectomy)|Patients participate in the Mediterranean diet for 6 days per week for 4 weeks before undergoing standard of care radical prostatectomy.
89155647|NCT04984759|Experimental|Primaquine in colostrum and transitional milk (mother-neonate pairs)|12 women who are breast feeding neonates ≤5 days old will be recruited into the primaquine arm. They will receive primaquine 0.5 mg/kg daily for 14 days directly observed in the clinic.
89155648|NCT04984759|Experimental|Tafenoquine in mature milk (mother-child pairs)|24 women who are breast feeding infants or young children > 14 days will be recruited into Arm 2. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic. We will begin with recruiting 2-4 women breastfeeding young children ≥12 months old.
89155649|NCT04984759|Experimental|Tafenoquine in colostrum and transitional milk (mother-neonate pairs)|12 women who are breast feeding neonates ≤ 5 days old will be recruited into Arm 3. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic.
89155650|NCT04982614|Experimental|2-dose regimen group|Boys and girls (aged 9-14 years) and young women (aged 15-26 years) living with HIV will receive a two-dose regimen of the HPV vaccine at baseline (Month 0) and Month 6.
89155651|NCT04982614|Active Comparator|3-dose regimen group (SOC)|HIV-uninfected young women (aged 15-26 years) will receive the standard of care three-dose regimen of the HPV vaccine at baseline (Month 0), Month 2 and Month 6.
89155652|NCT04980833|Experimental|Alpelisib|All participants will receive alpelisib once a day
89155653|NCT04963283|Experimental|Cabozantinib 40 mg orally daily in combination with nivolumab 480 mg IV every 28 days.|"Cabozantinib is supplied as 20-mg tablets and will be administered orally at a dose of 40 mg/day.~Nivolumab is supplied in 100 mg/Vial (10 mg/mL) vials and will be administered IV at a dose of 480 mg every 28 days."
89155654|NCT04960787|Active Comparator|Group I (usual care)|Patients and spouse caregivers receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients and spouses also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.
89155655|NCT04960787|Experimental|Group II (financial navigation intervention)|Patients and spouse caregivers receive financial literacy training consisting of watching online educational videos over 2-8 minutes. Patients also meet with CENTS counselor and PAF case manager over approximately 1 hour every month for 6 months (with each group). Patients and spouses also complete questionnaires over 30-60 minutes about education, employment, finances (assets, debt), insurance, and quality of life (financial worry) and have credit reports assessed at baseline and 3, 6, and 12 months.
89155659|NCT04940052|Experimental|Dabrafenib plus trametinib|Participants will be treated with dabrafenib twice daily and trametinib once daily
89155660|NCT04940052|Placebo Comparator|Placebo dabrafenib plus placebo trametinib|Participants will receive placebo dabrafenib twice daily and placebo trametinib once daily
89155661|NCT04938232|Experimental|Disease Progression after previous therapy|"Participants will receive Ipilimumab alone and depending on response will receive either a maintenance course of Ipilimumab or a course of Nivolumab and Ipilimumab in combination followed by a maintenance course of Ipilimumab. Patients who have progressive disease after fewer than 4 cycles of ipilimumab are also eligible to proceed to combination therapy with nivolumab and ipilimumab, if they are clinically stable.~Ipilimumab Monotherapy: Every 3 weeks for 4 study cycles~Complete Response/Partial Response: Maintenance Ipilimumab every 12 weeks for 8 cycles~Stable or Progressive Disease Response: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles, followed by Maintenance Ipilimumab every 12 weeks for 7 cycles"
89155662|NCT04934436|Experimental|Intervention Group|According to their chronotype, the intervention group will then be given sleeping glasses and earplugs at night for those who are in the morning type, and till afternoon during the day for those who are in the evening type. Moreover, patients in the intervention group will be given 5000 Lux daylight during the time they are awake depending on their circadian rhythms. An Android smartwatch will be used to determine patients' sleeping and waking up times, sleep quality and sleep depth. Nursing care will also be provided when patients are awake per their chronotype. Before the study, intensive care nurses will be trained to provide appropriate care according to the circadian rhythm and chronotype to have consistency in the care. Patients will be observed for three days and during this time cortisone and melatonin levels will be checked in both control and intervention groups. At the end of the third day, surveys will be conducted once again with both groups.
89155663|NCT04934436|No Intervention|Control Group|All surveys that will be used in the study will be applied to both groups during the first and last interviews. The control group will not have any interventions, only the standard ICU care to be provided.
89155665|NCT04933097|Experimental|Sarcopenia|Only one arm with the sarcopenia assessment.
89155666|NCT04928885|Experimental|WW Treatment Group|Individuals will receive the 12-week Wits Workout Program. Individuals will take the baseline, 3 mos and 6 mos follow-up surveys. They will also take the Wits Workout satisfaction survey and participate in the 6 mos focus-groups.
89155667|NCT04928885|Other|WW Control Group|Individuals will be on a waitlist and will take the baseline, 3 mos and 6 mos. assessments. They will receive the Wits Workout workshop after the 6 month study period is completed.
89155668|NCT04925154||Group A: Patients|Recruitment for this group will take place at either the radiation-oncology department or at the colorectal surgery department, at the time of consultation or at the time of diagnosis, before the treatment setting. Once clinical staging is available, the surgeon and/or radiation-oncologist and/or research assistant should identify eligible patients. Patients that comply with selection criteria (inclusion/exclusion) will be approached by a research team member. For those patients interested in participating, the e-link to the consent form for this group will be sent by email. Once a patient decides to sign the consent form, the link for the questionnaire Q1 will be sent by email.
89155669|NCT04925154||Group B: Physicians|Health professionals will be approached by the research team. The study aim will be explained, and participants that agree to participate will be provided an e-link to consent for this group. Once the health care participant decides to sign the consent form, the link for the questionnaire Q1 will be sent by email.
89155670|NCT04921917|No Intervention|Control|Standard of care: neoadjuvant radiation therapy (NRT).
89155671|NCT04921917|Experimental|Neoadjuvant Exercise Regimen|Subjects will receive conventional NRT in conjunction with a prescribed exercise regimen during the usual 10-week duration of NRT treatment prior to tumor resection.
89155672|NCT04915846|Experimental|Drug: ApoTamox 10mg|Drug: Tamoxifen (tamoxifen citrate); ApoTamox 10 mg tablets orally twice daily for 6 months
89155673|NCT04915846|Placebo Comparator|Placebo|Placebo (no active ingredients) tablets orally twice daily for 6 months
89155674|NCT04905160|Experimental|Subjects Hospitalized with a Primary Diagnosis of ADHF or Acute MI|Phase 1 subjects 18 years or above hospitalized with a primary diagnosis of ADHF or acute MI. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct/treat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
89155675|NCT04905160|Experimental|Subjects Testing Positive Covid-19 Antigen Test|Phase 2 subjects 50 years or older with positive Covid-19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in this arm of the study. Subjects will be randomized within 48 hours of Covid-19 antigen positive status. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct/treat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
89155676|NCT04894890||secukinumab|Patients administered secukinumab by prescription
89155677|NCT04875871|Experimental|High-dose group|3 fractions of 12 Gy Relative Biological Effectiveness (RBE)
89155678|NCT04875871|Experimental|Reduced-dose group|3 fractions of 8-10 Gy RBE
89155679|NCT04867954||Healthy volunteers|7 healthy participants will be recruited.
89155680|NCT04867954||Patients with small, low-risk GEV|Patients with small, low-risk Gastroesophageal varices (GEV) will be recruited.
89155681|NCT04867954||Patients with large, high-risk GEV|Patients with large, high-risk Gastroesophageal varices (GEV) will be recruited.
89155682|NCT04867954||Patients scheduled for screening or surveillance esophagogastroduodenoscopy (EGD)|"100 patients diagnosed with cirrhosis and scheduled for screening or surveillance esophagogastroduodenoscopy (EGD) procedure will be recruited. Participants will complete a single research visit, lasting approximately 2 hours, that will include the following procedures:~Participants will fast for 12 hours prior to arriving.~An IV will be placed and a blood sample collected (~11 mL, if necessary).~All participants will undergo research MRI lasting approximately 1.5 hours"
89155683|NCT04867954||Obese patients|20 obese patients will be recruited
89155684|NCT04864106|Experimental|Study Group|Participants will undergo a endoscopic airway assessment in addition to the airway classification using the Mallampati score.
89155685|NCT04864054|Experimental|ECT204|Nine (9) subjects were treated to determine the RP2D. At the designated RP2D approximately fifteen (15) subjects will be treated.
89155686|NCT04862585|Active Comparator|Arm I (paclitaxel, pre-medications)|Patients continue on pre-medications (dexamethasone, diphenhydramine, famotidine/ranitidine/cimetidine) with all future doses of paclitaxel.
89155687|NCT04862585|Experimental|Arm II (paclitaxel)|Patients discontinue premedications (dexamethasone, diphenhydramine, famotidine/ranitidine/cimetidine) with all future doses of paclitaxel, unless patient develops a subsequent infusion HSR.
89155688|NCT04852653||Patients with adenocarcinoma of rectum histologically proven|
89155689|NCT04850495|Experimental|Treatment (zanubrutinib, R-CHOP)|Patients receive zanubrutinib PO on days 1-21, rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89155690|NCT04847453|Experimental|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO QD on days 1-28, ixazomib citrate PO on days 1, 8 and 15, and dexamethasone PO on days 1, 8, 15 and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo x-ray imaging and abdominal ultrasound during screening. Patients undergo bone marrow biopsy and/or aspiration as well as blood sample collection throughout the study. Patients may undergo CT scans, and/or MRI, and/or PET scans throughout the study.
89155691|NCT04840147|Experimental|Intervention|JointRep® plus microfracture
89155692|NCT04840147|Other|Control|Microfracture alone
89155693|NCT04837521|Experimental|Therapist Delivered Unified Protocol|This is a five session psychotherapy designed to help people with problems such as anxiety and depression.
89155694|NCT04837521|Experimental|Self-Guided Unified Protocol|This is a five session treatment that patients can complete independently.
89155695|NCT04830124|Experimental|Advanced Cutaneous Melanoma Subcutaneous Dosing (Cohort 1)|Patients with unresectable and/or metastatic cutaneous melanoma
89155696|NCT04830124|Experimental|Advanced mucosal melanoma with IV Dosing (Cohort 2)|Patients with unresectable and/or metastatic mucosal melanoma
89155697|NCT04830124|Experimental|Advanced Cutaneous Melanoma with Less Frequent IV Dosing (Cohort 3)|Patients with unresectable and/or metastatic cutaneous melanoma
89155698|NCT04823455|Experimental|Allo Omero 2020|Humeral allograft group 12 patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.Included patients were clinically and radiographically re-evaluated for the purpose of this study by examiners not involved in the primary treatment at a mean of 66 months postoperatively. The clinical examination consisted of a physical examination and structured interview. Computed tomography (CT) was carried out at the medium follow-up of 66 months in all patients to evaluate OA progression and allograft resorption.
89155699|NCT04820647|Experimental|Kessler Foundation STRength IDentification and Expression (KF-STRIDE)|
89155700|NCT04820647|No Intervention|Services as Usual|
89155701|NCT04820634|Experimental|VR-JIT|In this arm, participants would participate in simulated interviews utilizing a software program and virtual interviewer, once a week for 90 minutes.
89155702|NCT04820634|Placebo Comparator|Wonderworks|In this arm, participants would participate in a similar intervention, also once a week for 90 minutes. However, in this arm, the intervention would be in a virtual office environment completing office tasks.
89155703|NCT04818177||Normal Weight|Normal weight is defined as BMI 18.5 - 25 kg/m2. Subjects will receive the institutional standard intravenous immune globulin treatment.
89155704|NCT04818177||Overweight or Obese|Overweight or obese is defined as BMI > 25 kg/m2. Subjects will receive the institutional standard intravenous immune globulin treatment.
89155705|NCT04817267|Experimental|reSET-O + Treatment-As-Usual (TAU)|Participants randomly assigned to this group will receive the TAU plus the reSET-O app.
89155706|NCT04817267|No Intervention|Treatment-As-Usual (TAU)|Participants randomly assigned to this group will receive the TAU only (no use of the reSET-O app).
89155707|NCT04816773||Newly or previously implanted patients|Multicenter, non-interventional prospective follow-up of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 14 months of the study index surgery. Single study group with either newly or previously implanted patients with all EVOLUTION® NitrX™ components: Non-Porous Keeled Tibia, CS/CR Non-Porous Femur component, and EVOLUTION® MP CS tibial insert
89155708|NCT04814108|Experimental|ZN-c3 Single Agent|ZN-c3 (azenosertib) taken orally with food
89155709|NCT04809974|Placebo Comparator|Placebo|Placebo: 40 participants will take placebo in the form of a capsule.
89155710|NCT04809974|Experimental|Niagen|Supplement: 60 participants will take Niagen 2000mg in the form of capsules daily.
89155711|NCT04800237|Experimental|VQW-765|
89155712|NCT04800237|Placebo Comparator|Placebo|
89155713|NCT04785820|Experimental|Lomvastomig|
89155714|NCT04785820|Experimental|Tobemstomig|
89155715|NCT04785820|Active Comparator|Nivolumab|
89155716|NCT04783571|Experimental|Schizophrenia|Adult outpatients with a diagnosis of schizophrenia.
89155717|NCT04783571|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use.
89155718|NCT04765202|Experimental|All participants|"Each participant will receive both treatments.~On each participant, similar wounds will be identified as treatment sites.~Treatment sites will be randomized to receive either AG Tx (control) or SOMA Tx (experimental)."
89155719|NCT04756804|Experimental|70% Isopropyl Alcohol novel preoperative skin antiseptic|70% v/v Isopropyl Alcohol novel preoperative skin antisepsis preparation
89155720|NCT04756804|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antiseptic|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antisepsis preparation
89155721|NCT04756245|Experimental|Virtual Reality|Participants engage in intervention procedures using virtual reality software.
89155722|NCT04756245|Active Comparator|Video Conference|Participants engage in intervention procedures using video conference software.
89155723|NCT04743141|Experimental|Rimegepant / BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
89155724|NCT04736121|Experimental|Open-label Single Arm|Open-label single arm study evaluating treatment with hepatic arterial injection of SIR-Spheres.
89155725|NCT04721041|Experimental|Washed Microbiota Transplantation (WMT)|Patients undergo once WMT a day for three consecutive days.
89155726|NCT04717466|Experimental|Psoriasis Group|Psoriasis participants will be given Secukinumab for a total of 4 months. This is a 300mg subcutaneous injection that will occur at weeks 0, 1, 2, 3, 4, 8, and 12.
89155727|NCT04717466|No Intervention|Healthy Group|Healthy participants will not receive any intervention.
89155728|NCT04704193|Experimental|Electronic Decision Aid|Participants in this arm will complete an electronic decision aid for genetic testing.
89155729|NCT04697966|Experimental|Mindfulness (Headspace app)|
89155730|NCT04697966|Active Comparator|Active Control Condition|
89155731|NCT04689828|Experimental|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used.
89155732|NCT04689828|Active Comparator|Androgen receptor-directed therapy (ARDT)|For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used.
89155733|NCT04682691|Sham Comparator|Group (C)|will be receive flavored water in total volume 15 ml
89155734|NCT04682691|Active Comparator|Group (M)|will be receive 10 ml of oral metoclopramide (10mg)
89155735|NCT04682691|Active Comparator|Group (E)|will be receive 10 ml of oral Erythromycin (400mg)
89155736|NCT04679402|Experimental|Respiratory Muscle Training Breathing Low Dose Carbon Monoxide|Carbon monoxide 200 ppm in air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe the experimental gas through a mouthpiece with nose-clip in place.
89155737|NCT04679402|Sham Comparator|Respiratory Muscle Training Breathing Air|Air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe air through a mouthpiece with nose-clip in place.
89155738|NCT04678193||COVID19 PCR positive test and negative or high risk asymptomatic|Patient population COVID-19 infection risk assessment real time epidemiology with 27000 subjects
89155739|NCT04678193||COVID19 PCR positive test Stage 1 infection|Patient population of PCR positive COVID-19 Stage 1 infection in registry targeted for ECL-19 treatment for reduced hospitalization with 2700 subjects (10% ECL-19 and 20% Placebo)
89155740|NCT04674969||Clinical Cohort|All enrolled patients are included in the Clinical Cohort. Patients will complete assessments per standard of care through 2-year follow-up in Australia, Austria, Canada, France, Germany, Poland, Spain, Taiwan, Thailand, and the United States. Patients will complete assessments per standard of care through 5-year follow-up in China.
89155741|NCT04674969||Outcomes Cohort|Patients at select sites will complete the Clinical Cohort standard of care assessments and additional assessments as part of the Outcomes Cohort, including Quality of Life questionnaires, six-minute walk test (6MWT), and Healthcare Utilization data collection.
89155742|NCT04671381|Experimental|Audiology Best Practices plus Aural Rehabilitation (ABP+AR)|This experimental group will receive a hearing evaluation, an over-the-counter hearing aid fitting and orientation, and four-weeks of an aural rehabilitation program conducted by specially-trained community health workers. Additionally, these adults will complete pre- and post-questionnaires and speech perception testing.
89155743|NCT04671381|Active Comparator|Audiology Best Practices (ABP)|This comparison group of adults with hearing loss will receive a hearing evaluation and over-the-counter hearing aid fitting and orientation. The aural rehabilitation program will not be provided initially. These participants will complete pre- and post-questionnaires and speech perception testing.
89155744|NCT04671381|Active Comparator|Over-the-Counter Only (OTC-Only)|This comparison group of adults with hearing loss will receive a hearing evaluation. They will be provided with over-the-counter hearing aids but the audiologist will not assist with fitting the aids or providing an orientation. This arm mimics what would happen when a consumer privately purchases over-the-counter hearing aids. They will complete pre- and post-questionnaires and speech perception testing.
89155745|NCT04668144|Active Comparator|Prasugrel|Prasugrel only administered at the start of PCI
89155746|NCT04668144|Experimental|Prasugrel + Cangrelor|Cangrelor plus prasugrel concomitantly administered at the start of PCI
89155747|NCT04668144|Active Comparator|Cangrelor followed by Prasugrel|Cangrelor administered at the start of PCI plus prasugrel administered at the end of the cangrelor infusion
89155748|NCT04667416|No Intervention|Standard of Care (SOC)|Participants will receive SOC for chronic ulcers of the lower extremities.
89155749|NCT04667416|Experimental|PalinGen Flow Treatment plus SOC|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
89155750|NCT04655001|Experimental|MORPH|Participants engage in 12 weeks of group and 1-on-1 coaching meant to promote physical activity throughout the day and caloric restriction. Participants engage with a custom smartphone application, use a smart scale and physical activity monitor, and meet using video conference software. At the end of 12 weeks, participants are provided with tools to continue meeting virtually on their own if desired, and will be followed for an additional 12-week maintenance phase.
89155751|NCT04655001|No Intervention|Control|This condition receives the wearable activity monitor and simply asked to use it and continue in their daily lives for 24 weeks.
89155752|NCT04640194|Experimental|Part 1: Alteplase low dose|0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5), plus Standard of Care (SOC). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement. Part 1 subjects were randomized equally (1:1:1) across the three Part 1 arms.
89155753|NCT04640194|Experimental|Part 1: Alteplase high dose|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5), plus Standard of Care (SOC). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement. Part 1 subjects were randomized equally (1:1:1) across the three Part 1 arms.
89155754|NCT04640194|Other|Part 1: Standard of Care|Standard of Care included best possible treatment regimen established locally and was in line with current guidelines for Acute respiratory distress syndrome treatment. Part 1 subjects were randomized equally (1:1:1) across the three Part 1 arms.
89155755|NCT04640194|Experimental|Part 2: Alteplase high dose - non-invasive mechanical ventilation (NIV) patients|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5), plus Standard of Care (SOC). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement. Non-invasive mechanical ventilation (NIV) patients are those with a baseline World Health Organization (WHO) Clinical Progression Scale value of 6. Part 2 subjects were randomized 2 (Alteplase) to 1 (SOC).
89155756|NCT04640194|Other|Part 2: Standard of Care - non-invasive mechanical ventilation (NIV) patients|Standard of Care included best possible treatment regimen established locally and was in line with current guidelines for Acute respiratory distress syndrome treatment. Non-invasive mechanical ventilation (NIV) patients are those with a baseline World Health Organization (WHO) Clinical Progression Scale value of 6. Part 2 subjects were randomized 2 (Alteplase) to 1 (SOC).
89155757|NCT04640194|Experimental|Part 2: Alteplase high dose - invasive mechanical ventilation (IMV) patients|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5), plus Standard of Care (SOC). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement. Invasive mechanical ventilation (IMV) patients are those with a baseline World Health Organization (WHO) Clinical Progression Scale value of 7, 8 or 9. Part 2 subjects were randomized 2 (Alteplase) to 1 (SOC).
89155758|NCT04640194|Other|Part 2: Standard of Care - invasive mechanical ventilation (IMV) patients|Standard of Care included best possible treatment regimen established locally and was in line with current guidelines for Acute respiratory distress syndrome treatment. Invasive mechanical ventilation (IMV) patients are those with a baseline World Health Organization (WHO) Clinical Progression Scale value of 7, 8 or 9. Part 2 subjects were randomized 2 (Alteplase) to 1 (SOC).
89155759|NCT04632485||Aim 1: Ultrasound Only|Approximately 280 asymptomatic participants will participate in ultrasound (US) studies and blood work.
89155760|NCT04632485||Aim 2: Ultrasound and MRI|A sub-group of 40 at risk volunteers determined from the clinical ultrasound scans and bloodwork from Aim 1 will be asked to participate in a longitudinal US and MRI study. Participants will be selected from a population of individuals that do not have significant atherosclerosis, but present with increased risk due to the presence of soft, lipid rich plaque that are hypoechogenic or echolucent on ultrasound B-mode images. These participants may also satisfy the current clinical guidelines of increased vessel diameter and decreased blood flow velocity with ultrasound that may result in plaque deposition for being in the at risk population. Participants will receive US, strain and shear wave imaging every 2 years after the first scan in Aim 1 and MRI Imaging in Year 1 and Year 5: separated by 4 years
89155761|NCT04630964|Experimental|psilocybin|25 mg Single Oral Dose
89155762|NCT04630964|Active Comparator|placebo|100 mg Single Oral Dose
89155763|NCT04622228|Experimental|LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab|Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with atezolizumab. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
89155764|NCT04615715|Experimental|CMV Risk-Reduction Intervention|One-on-one CMV prevention and education visit followed by 12 weeks of CMV prevention and education text messages
89155765|NCT04615715|Placebo Comparator|Stress Reduction Messaging|One-on-one stress reduction messaging visit followed by 12 weeks of reducing stress text messages
89155766|NCT04596631|Experimental|Semaglutide - max. tolerated dose|Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
89155767|NCT04596631|Placebo Comparator|Placebo (semaglutide)|Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
89155768|NCT04590014|Experimental|Conventional HVNI First, Then New HVNI Second (Randomized)|The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.
89155769|NCT04590014|Experimental|New HVNI First, Then Conventional HVNI Second (Randomized)|The purpose of this intervention is to evaluate the efficacy of the conventional HVNI device design (Precision Flow) to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a new HVNI device design (V2.0) to provide targeted relief of dyspnea.
89155770|NCT04588259|Experimental|Faster aspart|4 daily injections of faster aspart given with insulin degludec and with or without metformin
89155771|NCT04588259|Active Comparator|Insulin aspart|4 daily injections of insulin aspart given with insulin degludec and with or without metformin
89155772|NCT04583293||COVID AKI|Participants who were admitted to the hospital with COVID-19 and developed AKI during their hospital stay.
89155773|NCT04583293||COVID non-AKI|Participants who were admitted to the hospital with COVID-19 and did not develop AKI during their hospital stay.
89155774|NCT04575909|Experimental|Explicit Expressive Prosody Intervention|Explicit cues will be provided to help participants improve expression of targeted affective prosody.
89155775|NCT04575909|Experimental|Implicit Expressive Prosody Intervention|Implicit cues will be provided to help participants improve expression of targeted affective prosody.
89155776|NCT04575909|Experimental|Explicit Receptive Prosody Intervention|Explicit cues will be provided to help participants improve recognition of targeted affective prosody.
89155777|NCT04575909|Experimental|Implicit Receptive Prosody Intervention|Implicit cues will be provided to help participants improve recognition of targeted affective prosody.
89155778|NCT04575909|Active Comparator|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention [if relevant]), hobbies, and other similar topics.
89155779|NCT04572750|Experimental|EMPOWER-ED|Individuals will be given access on their preferred platform to an electronic self-help app focused on reducing benzodiazepine use
89155780|NCT04572750|No Intervention|Control|Individuals will be provided care as usual
89155781|NCT04544800|Experimental|Use of Splint for UADT Visualization|Use of device to view UADT
89155782|NCT04541654||Variant in the TP53 Gene in blood or saliva|Variant in the TP53 gene found on a blood or saliva test, have a relative with a variant in the TP53 gene, or because participant meets genetic testing criteria for Li-Fraumeni Syndrome (LFS) based on personal or family cancer history
89155783|NCT04535193|Other|Low likelihood of coronary heart disease|Thorax and total body imaging for quantification of normal biodistribution and myocardial sympathetic innervation. PET imaging to 210 minutes post-administration.
89155784|NCT04535193|Other|Heart Failure + left ventricular function (LVEF ≤ 35%)|Thorax and total body imaging for quantification of myocardial sympathetic innervation. PET imaging to 100 minutes post-administration
89155785|NCT04526184|Active Comparator|healthy group|25 healthy individuals between the ages of 40-70 will be contacted by phone and included in the initiative.
89155786|NCT04526184|Active Comparator|patient group|25 individuals will be selected randomly from 103 patients with COPD from hospital records.
89155787|NCT04522804|Experimental|Treatment: all patients|"Subjects will participate in a total of seven group sessions. There will be 4 or 6 subjects per group and one therapist will be assigned to each subject for a total of 4 or 6 therapists. In addition, there will be one Group Leader that will facilitate the group sessions. Group sessions will occur once per week for approximately five weeks. The first three sessions are Preparatory sessions followed by three Integration sessions. During the week following the third Preparatory session and prior to the first Integration session, participants will participate in a psilocybin session."
89155788|NCT04521959|Active Comparator|Blood Flow Restricted Aerobic and Resistance Exercise Group|kan akımı kısıtlanarak.direnç ve bisikletle aerobik egzersiz uygulanacak
89155789|NCT04521959|Active Comparator|Normal aerobik ve direnç egzersiz grubu|Normal şartlarda aerobik ve direnç egzersizi uygulanacak
89155790|NCT04506853|Other|Study Procedure|
89155791|NCT04504669|Experimental|Monotherapy|Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years.
89155792|NCT04504669|Experimental|Combination Therapy|Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years.
89155793|NCT04503265|Experimental|AMXI-5001 Treatment|Single Arm Study, all participants will receive AMXI-5001.
89155794|NCT04493424|Experimental|Treatment group|Up to 260 weeks
89234961|NCT05836142|Experimental|Experimental: progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
89234962|NCT05835843||Cohort 1: ≥0.5 to <5% BSA affected|Approximately 10 subjects with psoriatic plaques covering at least 0.5% but less than 5% of their body surface area
89155795|NCT04476537|Experimental|Intervention Arm|Individuals who meet the eligibility criteria based on their provided tissue sample will be followed by the investigators to obtain medical information every 4 weeks. This follow-up will consist of a review of medical records, contact with the participant's treating physician, or personal contact between the participant and the investigators at Columbia University Irving Medical Center (CUIMC). During the study, their tumor tissue will be evaluated to identify medications that may help treat the cancer. The results of these tests will be reviewed by experts on a Precision Medicine Tumor Board (PMTB) and these experts may recommend a specific treatment to the participant or participant's physician.These participants will continue to be followed until death or withdrawal of consent from the study.
89155796|NCT04476537|No Intervention|Observation Arm|Individuals who do not meet the eligibility criteria based on their provided tissue sample will be provided follow-up with their treating physicians up to every 4 weeks to gather clinical information related to their disease.
88804548|NCT04110236|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
89155797|NCT04476433|No Intervention|Control Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group).
89155798|NCT04476433|Experimental|Experimental Group|Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 months of this evaluation the treatment program will be started. In the first contact session at 6 months after T1 all subjects (patients and relatives) will be re-evaluated (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 5 months). After the completion of the patient and family treatment sessions, a new diagnostic test pass will be performed (T3) (within an estimated maximum period of 15 days from the completion of treatment) in order to evaluate the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 months.
89155799|NCT04459715|Experimental|Xevinapant (Debio 1143)|"Participants will receive:~Concomitant chemo-radiation therapy period (Cycles 1-3):~Radiotherapy~Cisplatin~Xevinapant (Debio 1143)~Monotherapy period (Cycles 4-6):~• Xevinapant (Debio 1143)"
89155800|NCT04459715|Active Comparator|Placebo|"Participants will receive:~Concomitant chemo-radiation therapy period (Cycles 1-3):~Radiotherapy~Cisplatin~Matched placebo~Monotherapy period (Cycles 4-6):~• Matched placebo"
89155801|NCT04457492|Experimental|Acute Facial Nerve Injury with Intact Facial Nerve|"40 sessions of FES (in a 14 week period)~Assessments will be taken during the beginning, middle, and end of each study arm."
89155802|NCT04457492|Experimental|Facial Nerve Grafting After Surgical Excision|"40 sessions of FES (in a 14 week period)~Assessments will be taken during the beginning, middle, and end of each study arm."
89155803|NCT04457492|No Intervention|Standard of Care Group|"No FES~Assessments will be taken at the same intervals as the interventions group."
89155804|NCT04440657|Experimental|Immigrant parents|All enrolled parents will be included in the parenting program
89155805|NCT04418817||Modulus XLIF Interbody System|
89155806|NCT04415593|Experimental|high dose of peanut|20 patients
89155807|NCT04415593|Active Comparator|low dose of peanuts|20 patients
89155808|NCT04414917|Experimental|Twin Block local anesthetic|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block local anesthetic (using the standard dental anesthetic 1.8 cc 2% lidocaine with 1:100,000 epinephrine), once, on the side/s of their extraction/s
89155809|NCT04414917|Sham Comparator|Control|Patients undergoing extractions of lower wisdom molar/s under intravenous sedation will receive the Twin block injection but with no medication administered/dispensed from the syringe, on the side/s of their extraction/s
89155810|NCT04414787|Active Comparator|Intervention|PCplanner intervention during hospitalization
89155811|NCT04414787|No Intervention|Usual care control|Usual care
89155812|NCT04411147||Close Contacts|Individuals without COVID-19 diagnosis, lived in same home as a survivor during illness, were within 6 feet of a COVID-19 case for a prolonged period of time or had direct contact with secretions
89155813|NCT04411147||COVID-19 Survivor|Individuals with documented prior COVID-19 infection and who have recovered
89155814|NCT04410900|Experimental|Experimental (anti-rabies vaccine, collection of blood)|"BOLUS COHORT: Patients receive the inactivated rabies vaccine IM on day 1 and 6-10 weeks later. Patients also undergo a blood collection prior to each vaccine, and at approximately 1, 2, and 4 weeks after each vaccination. A final blood collection occurs 6 months after the first immunization.~FRACTIONAL DOSE COHORT: Patients receive the inactivated rabies vaccine fractionated primary dose IM on days 1, 3, 7, 10, 14, and 17 and the second dose 6-10 weeks later. Patients also undergo a blood collection prior to each vaccine, and at approximately 1, 2, and 4 weeks after each vaccination. A final blood collection occurs 6 months after the first immunization."
89155815|NCT04410900|Active Comparator|Control (anti-rabies vaccine, collection of blood)|Patients receive anti-rabies vaccine IM on day 1 and 6-10 weeks later. Patients also undergo collection of blood samples at baseline, and at approximately 1, 2, and 4 weeks after each vaccination. There will be an additional blood draw 6 months (+/- 14 days) after the first immunization.
89155816|NCT04394858|Experimental|Arm I (temozolomide, olaparib)|Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
89234963|NCT05835843||Cohort 2: ≥5 to <10% BSA affected|Approximately 10 subjects with psoriatic plaques covering at least 5% but less than 10% of their body surface area
89234964|NCT05835843||Cohort 3: ≥10% BSA affected|Approximately 10 subjects with psoriatic plaques covering at least 10% of their body surface area
89155817|NCT04394858|Active Comparator|Arm II (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
89155818|NCT04384172|Experimental|Tibial e-stim followed by genital e-stim|Tibial e-stim followed by genital e-stim
89155819|NCT04384172|Experimental|Genital e-stim followed by tibial e-stim|Genital e-stim followed by tibial e-stim
89155820|NCT04380051|Experimental|Arm 1 : skin-to-skin contact associated with a sensory-tonic s|skin-to-skin contact left free for parents associated with a sensory-tonic stimulation five times a week during 15 minutes at each time
89155821|NCT04380051|Active Comparator|Arm 2 : skin-to-skin contact only|skin-to-skin contact left free for parents
89155822|NCT04366284|Active Comparator|NOCTEM only (NOCTEM)|No external or internal facilitation
89155823|NCT04366284|Active Comparator|External Facilitation (NOCTEM+EF)|External facilitation only
89155824|NCT04366284|Active Comparator|External and Internal Facilitation (NOCTEM+EF/IF)|External and internal facilitation
89155825|NCT04336202|Other|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
89155826|NCT04312802||Observational|Single arm observational study
89155827|NCT04310358|Experimental|PLM group 1|Participants will do a pretest (Test 1), the 4 short PLMs, an immediate post-test (Test 2) and a remote post-test (Test 1).
89155828|NCT04310358|Experimental|PLM group 2|Participants will do a pretest (Test 2), the 4 short PLMs, an immediate post-test (Test 1) and a remote post-test (Test 2).
89155829|NCT04308603|Experimental|pregnant patient whose fetuses have an antenatal NIH|All pregnant patients whose fetuses have an antenatal revelation of NIH from the first trimester ultrasound scan will be included in this study.
89155830|NCT04279522|Experimental|Group 1 - active stimulation|
89155831|NCT04279522|Placebo Comparator|Group 2 - sham stimulation|
89155832|NCT04271358|Experimental|Peer Coaching|Participant receive a 6 month peer health coaching intervention.
89155833|NCT04271358|No Intervention|Education only|Participants receive education-only material (newsletter) biweekly for 6 months
89155834|NCT04266301|Experimental|MBG453 (Sabatolimab) + Azacitidine|Participants will receive MBG453 plus Azacitidine
89155835|NCT04266301|Placebo Comparator|Placebo + Azacitidine|Participants will receive Placebo plus Azacitidine
89155836|NCT04243785|Experimental|Part 1a (Monotherapy Cohort Escalation)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). The BTX-A51 starting dose for Cohort 1 is 1 mg, to be given 5 days per week (maximum weekly dose of 5 mg). Beginning with Cohort 2, doses are intended to be administered 3 days per week. Barring dose-limiting toxicity (DLT), sequential dose escalation of BTX-A51 is planned with up to a total of eight dose levels to a maximum of 21 mg (63 mg/week); on the basis of these an MTD will be identified. The numbers of participants and actual doses administered will be determined using a Bayesian optimal interval (BOIN) design to determine the DLTs and MTD of BTX-A51.
89155837|NCT04243785|Experimental|Part 1b (Monotherapy Cohort Expansion)|Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). Part 1b will continue at the MTD or the highest dose achieved in Phase 1a.
89155838|NCT04243785|Experimental|Part 1c (Azacitidine Combination Dose Escalation)|After determination of MTD and RP2D from Part 1a, combination dose escalation in Part 1c may begin. Patients with AML will receive BTX-A51 combined with azacitidine in escalating BTX-A51 dose cohorts. Dosing in this stage of the study consists of the first cycle of therapy (i.e., 28 days). The starting dose of BTX-A51 will be RP2D. Part 1c will follow a BOIN design as described for Part 1a. The numbers of patients and actual doses administered will be determined in response to DLTs a. There will be at least 3 patients per cohort.
89155839|NCT04227431||Tresiba®|A broad real world type 2 diabetes (T2D) patient population in China, treated with oral anti-diabetic drugs (OAD(s)) or basal insulin prior to treatment initiation with Tresiba®
89155840|NCT04195945|Experimental|Arm I (CPX-351)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of CPX-351 intravenously IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients who achieve a CR/CRi receive a reduced dose of CPX-351 IV over 90 minutes on days 1, 3, and 5 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
89155841|NCT04195945|Experimental|Arm II (CLAG-M)|"INDUCTION: Patients receive cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients who achieve a response other than an MRDneg CR receive a second course of cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, G-CSF SC on days 0-5, and mitoxantrone IV over 60 minutes on days 1-3 in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients who achieve a CR/CRi receive an intermediate dose of cytarabine IV over 2 hours on days 1-6 for up to 4 additional courses in the absence of disease progression or unacceptable toxicity."
89155842|NCT04193709|No Intervention|Measure symptomatic indices of autonomic dysreflexia|The purpose of this arm is to systematically measure symptomatic indices of autonomic nervous system activation and corresponding cardiovascular changes in persons with spinal cord injuries during bladder filling and bowel stimulation.
89155843|NCT04193709|Experimental|Cardiovascular spinal cord epidural stimulation|The purpose of this arm is to use spinal cord epidural stimulation for maintenance of blood pressure and heart rate in the lab during cystometry (bladder filling) and anorectal filling (bowel distension) and in the at-home setting for maintenance of normative blood pressure and heart rate that can be triggered from bladder filling and during bowel evacuation.
89155844|NCT04163367|Active Comparator|Intervention as usual|The social services standard process for families reported for violence or abuse towards children. The standard process always includes a formal investigation of the suspected violence/abuse. The investigation may or may not result in voluntary or mandatory interventions, such as family support or parent training.
89155845|NCT04163367|Experimental|Intervention as usual + Safer Kids|The procedure in this arm is exactly the same as in the active comparator arm (i.e., investigation that may be followed by interventions). In addition, the general parent training program Safer Kids is offered during the investigation to all participants in this arm.
89155846|NCT04160039|Experimental|Cycle Ergometry + Standard PT/OT|The study intervention will include the same standard PT/OT procedures as the control arm (Standard PT/OT alone) with the addition of the Motomed Letto 2 lower extremity cycle ergometry sessions.
89155847|NCT04160039|No Intervention|Standard PT/OT alone|"The control arm will involve standard PT/OT procedures that patients in the transplant intensive care unit receive routinely, with frequency to be determined by a physical and/or occupational therapist, and may include but are not limited to the following:~Passive and active upper and lower extremity strength exercises, while in bed, sitting upright, and standing; stretching various muscle groups while supine in bed, sitting upright, and standing; in-bed mobility training including rolling and boosting; transfer training with and without an assistive device; gait training with and without an assistive device; balance exercises while sitting and standing; activities of daily living while sitting and standing; cognitive retraining"
89155848|NCT04145297|Experimental|Treatment: all patients|"Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily.~Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level. Both medications will be administered in 28-day cycles"
89155849|NCT04142658|Experimental|Apixaban|Apixaban 5 mg twice daily(BID) or 2.5 mg BID
89155850|NCT04142658|Active Comparator|Warfarin|Patients randomized to the warfarin arm will continue warfarin in the INR range of (2.0-3.0)
89155851|NCT04138277|Experimental|ATB200/AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
89155852|NCT04137263|Experimental|Treatment|Subjects will receive dose formulation for treatment of melasma
89155853|NCT04128501|Experimental|Treatment (azacitidine, venetoclax)|Patients receiving venetoclax and azacitidine for maintenance after allogeneic stem cell transplantation, receive azacitidine SC on days 1-5 and venetoclax PO QD on days 1-7. Patients receiving venetoclax and azacitidine for minimal residual disease after allogeneic stem cell transplant, receive azacitidine SC on days 1-7 and venetoclax PO QD on days 1-14. Treatment repeats every 4-8 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89155854|NCT04112823|Active Comparator|Dexamethasone 4mg|Dexamethasone 4mg, administered intravenously
89155855|NCT04112823|Active Comparator|Dexamethasone 16mg|Dexamethasone 16mg, administered intravenously
89155856|NCT04104893|Experimental|Single Arm|This is a single-arm, open-label study of the checkpoint inhibitor, pembrolizumab, in Veterans with mCRPC who have progressed on at least 1 prior novel androgen receptor (AR) signaling inhibitor, inclusive of abiraterone acetate, enzalutamide, apalutamide, and darolutamide. In addition to progressive mCRPC, a patient must have a somatic tumor mutation characterized by dMMR or CDK12-/- detected by next generation sequencing (NGS). Patients enrolled in this study will be treated with pembrolizumab at the FDA approved dosage of 200 mg intravenously every 3 weeks (21 days) until disease progression or unacceptable toxicity. During study, patients will maintain a castrate level of testosterone, = 50 ng/dL by ongoing treatment with a GnRH analogue or prior bilateral orchiectomy. Prior to initiating treatment with pembrolizumab, patients will undergo a baseline biopsy of a metastatic lesion. An additional biopsy of a metastatic lesion at the time of progression will be encouraged as well.
89155857|NCT04088162|No Intervention|Standard Dressing|In case of Control group. After Ileostomy closure skin will be closed by 6 to 8 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures, and sterile standard dressing will be placed.
89155858|NCT04088162|Experimental|Postoperative NPWT dressing|"In case of NPWT group. After Ileostomy closure skin will be closed by 3 or 4 single no absorbable Monosyn 3-0 (Ethicon, Cincinnati, Ohio., USA) sutures. Between them small sponge tongues 1x 0,5x2 cm were placed and over whole incision an NANOVA (KCI USA) negative pressure dressing will be placed. In control group first dressing change was made in 48 hours after operation and then every day until suture removal at 7 postoperative day. In NPWT group NANOVA dressing was taken out at 72 hours. 3 steri-streps were placed between sutures and standard sterile dressing was placed. After it dressing was changed every 24 hours until suture removal at 7 postoperative day."
89155859|NCT04052685|Experimental|Selective removal to soft dentin (SRSD)|The patients in SRSD group will be randomized into two subgroups as Group A and Group C. After caries removal to soft dentin calcium silicate based material (Biodentine) will be applied in Group A while will not be applied in Group C prior to placement of the resin composite restoration. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel.Carious tissue at the periphery of the cavity will be prepared to hard dentin using round tungsten carbide burs and/or an excavator, while soft carious dentin will remain in the pulpal aspect of the cavity to prevent pulp exposure. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration.
89155860|NCT04052685|Active Comparator|Selective removal to firm dentin (SRSD)|Procedures will be done using local anesthesia. The procedure, starts with access to caries tissue by the removal of surrounding unsupported enamel. Caries tissue in the periphery including the enamel-dentinal junction will be removed using round tungsten carbide burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries tissue will be removed until hard or leathery dentin remains. Operative procedures will be performed by an experienced (over 10 years) specialist. Moisture control will be provided using cotton rolls and continuous aspiration. Restoration will be performed after caries removal to firm dentin and placement of calcium silicate based material (Biodentine).
89155861|NCT04041973|Experimental|ACT arm|Artemether-lumefantrine (AL) x 3 days followed by 1 day per week
89155862|NCT04041973|Active Comparator|Multivitamin arm|Multivitamin x 3 days followed by 1 day per week
89155863|NCT04039789|Active Comparator|Control|Usual Care: that consists of healing the wound (assessment, cleaning, disinfection, debridement and topical treatment) and compression therapy multilayer usual practice, according to the recommendations for the treatment of cutaneous ulcers of the Region of Madrid.
89155864|NCT04039789|Experimental|Intervention|"ACTIVE LEGS: The usual care plus experimental intervention. It is a structured educational intervention, directed by nurses and carried out in the health center consultations. The intervention Active Legs has been designed based on the available evidence. It incorporates a program of lower limb exercise at home and daily walking patterns.~Home program of lower limb exercises. The nurse will instruct the patients in the performance of 4 exercises of lower limbs of progressive difficulty that must be performed at home 5 days a week, twice a day Daily walking program. In addition, patients must ambulate progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)) .~At the start of the study, the Active Legs diary will be provided, showing the patterns of the exercise and walking program graphically and a pedometer."
89155865|NCT04033718|Experimental|Inpatient lab bundling plus navigation|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA with samples collected in a bundle-type approach. Additional inpatient support from a patient navigator
89155866|NCT04033718|Experimental|Inpatient lab bundling alone|Testing for CD4 count, tuberculosis, cryptococcus, and HIV RNA with samples collected in a bundle-type approach.
89155867|NCT04029480|Experimental|Ertugliflozin 5 mg/5 mg|"All participants will initially receive ertugliflozin (ERTU) 5 mg once daily (QD) and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at Week 12 (WK12), all participants that do not meet the up-titration criteria will remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54. Approximately half the participants who meet the up-titration criteria at the second randomization at WK12 will also remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54.~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a fasting fingerstick glucose (FFSG) of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
89155868|NCT04029480|Experimental|Ertugliflozin 5 mg/15 mg|"All participants will initially receive ERTU 5 mg QD and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at WK12, approximately half the participants who meet the up-titration criteria at the second randomization will up-titrate to ERTU 15 mg and placebo to ERTU 5 mg from WK12 to WK54.~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a FFSG of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
89155869|NCT04029480|Placebo Comparator|Placebo|At the first randomization, participants receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD for 12 weeks. Participants in the placebo group with HbA1C ≥7.0% (53 mmol/mol) at WK12 will be mock titrated. Note: The up-titration criteria for participants on insulin will include a FFSG of ≥110 mg/dL (6.1 mmol/L) in addition to HbA1C ≥7.0% (53 mmol/mol) at WK12. Participants will continue to receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD from WK24 to WK54. Participants will remain on their background metformin with/without insulin treatment throughout the study.
89155870|NCT03992781||Newly prescribed tofacitinib|patients who were newly prescribed tofacitinib at baseline and who scored at least 11 points on CUDOS scale
89155871|NCT03987802||Fiasp®|Adult patients with diabetes mellitus (type 1 and type 2) under routine clinical practice in India.
89155872|NCT03986736||Patients with major trauma|Patients with major trauma will be included in the study.
89155873|NCT03980184|Experimental|Study Medication|guanfacine 3mg/day (GUA)
89155874|NCT03980184|Placebo Comparator|placebo|placebo (PBO)
89155875|NCT03971253||Peficitinib|Participants will receive peficitinib once daily after meal.
89155876|NCT03971071|Placebo Comparator|Placebo|After participants complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
89155877|NCT03971071|Active Comparator|Erenumab 70 mg|After participants complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
89155878|NCT03971071|Active Comparator|Erenumab 140 mg|After participants complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
89155879|NCT03952078|Experimental|CPI-818 Dose Escalation|Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for >2 months or if dose determined to be unsafe.
89155880|NCT03952078|Experimental|CPI-818 Dose Expansion phase|"Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study.~CPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for > 2 months."
89155881|NCT03939104|Active Comparator|Artemether-lumefantrine+amodiaquine (AL+AQ)|Triple ACTs
89155882|NCT03939104|Active Comparator|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|Triple ACTs
89155883|NCT03939104|Active Comparator|artemether-lumefantrine+placebo (AL+PBO)|ACTs
89155884|NCT03939104|Active Comparator|Artesunate-mefloquine+placebo (AS-MQ+PBO)|ACTs.
89155885|NCT03935269|Experimental|Intervention with Ambulatory Therapy|Caregivers of participants with high-grade glioma will undergo standard Cereset Research Office (CRO) in-office treatment for a total of five (5) treatments. Ambulatory therapy with the Cereset Research Wearable (CRW) will be available to caregivers while they are attending routine radiation therapy with glioma patients.
89155886|NCT03921944|Other|total shoulder replacement surgery|Subjects will be assessed for the outcome measures at one year and two year timepoints post total shoulder replacement surgery
89155887|NCT03921294|Experimental|Single Arm|Patients with hemophilic pseudotumor will be treated with prophylactic emicizumab and assessed for improvement.
89155888|NCT03914924|Active Comparator|Exercise Program|Ex: The participants will be submitted to only a 12-week exercise intervention.
89155889|NCT03914924|Experimental|Exercise and Lifestyle Education Program|ExLE: The participants will be submitted to a 12-week intervention consisting of exercise and education.
89155890|NCT03914326|Experimental|Oral semaglutide|One tablet daily for 3.5 to 5 years
89155891|NCT03914326|Placebo Comparator|Placebo|One tablet daily for 3.5 to 5 years
89234965|NCT05833035|Experimental|All participants|
89234966|NCT05814822|Experimental|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Delivered via telemedicine
89155892|NCT03905421||usual care|The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. They will not be randomized to palliative care.
89155893|NCT03905421||palliative care|The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. Based on the patients in Group 1 and 3 PH and a high SYMPACT score> 1.0 in any domain they will be randomized to receive standard care or a palliative care initial consult.
89155894|NCT03897244|Experimental|High-dose dual therapy|group A - HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
89155895|NCT03897244|Experimental|Bismuth High-dose dual therapy|group B - Bis-HDDT (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
89155896|NCT03897244|Active Comparator|Amoxicillin-Metronidazole Bismuth quadruple therapy|group C - AM-BQT (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
89155897|NCT03881371|Experimental|Safinamide|Patient will receive film-coated Safinamide tablets orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
89155898|NCT03881371|Placebo Comparator|Placebo|Patient will receive matching placebo orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
89155899|NCT03878446|Experimental|Somapacitan 0.24 mg/kg/week|Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
89155900|NCT03878446|Experimental|Somapacitan 0.20 mg/kg/week|Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
89155901|NCT03878446|Experimental|Somapacitan 0.16 mg/kg/week|Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
89155902|NCT03878446|Active Comparator|Norditropin® 0.035 mg/kg/day|Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
89155903|NCT03878446|Active Comparator|Norditropin® 0.067 mg/kg/day|Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.
89155904|NCT03873805|Experimental|Treatment (PSCA CAR T cells)|Patients may receive lymphodepleting regimen (either standard or modified) including fludarabine IV on days -5 to -3 and cyclophosphamide IV on days -5 to -3 or on days -4 and/or -3. The study PI and the protocol team will choose a chemotherapy regimen, for lymphodepletion prior to the PSCA-CAR T cell infusion (with the exception of cohorts 1 and -1 which will not receive lymphodepletion), based on the research participant's disease type and prior therapies. Patients then receive autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes IV over 10-15 minutes at day 0.
89155905|NCT03870451|Experimental|Cohort 1 VascuTherm5 vascular compression device|VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
89155906|NCT03870451|Experimental|Cohort 2 VascuTherm5 vascular compression device|VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.
89155907|NCT03849989|Experimental|Hailey-Hailey disease|"Patients with Hailey Hailey, diagnosis confirmed by histopathology or genetics, with therapy resistant skin lesions suitable for ablative lasertherapy.~Skin biopsy specimens will be taken before and after lasertherapy at three time points.~Before treatment:~Affected skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy Healthy skin within same anatomical region 4 mm punch for immunofluorescence and RNA extraction~Immediately after treatment of the treated area:~2 mm punch for histopathology~Six weeks after treatment:~Treated skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy~2mm punch biopsy of clinically uninvolved skin of the upper arm for electron microscopy~Patients without Hailey-Hailey disease:~2mm punch biopsy of skin of the upper arm for electron microscopy"
89155908|NCT03849898||Mandibular Fracture|"Elderly patients of > 60 years who present a mandibular fracture~Surgery or Non-surgical fracture treatment will be applied according to routine clinical practice"
89155910|NCT03823768|Active Comparator|Arm 1: Control|Tacrolimus immediate release twice daily for 6 months
89155911|NCT03823768|Experimental|Arm 2: Intervention|Envarsus daily for 6 months.
89155913|NCT03813056|Experimental|Glanatec|Glanatec eye drops will be administered 6x per day for 2-4 weeks
89155914|NCT03813056|Placebo Comparator|Placebo Control|Optive artificial tears will be administered 6x per day for 2-4 weeks
89155915|NCT03812289|Experimental|Treatment (SBRT)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
89155916|NCT03803696|Active Comparator|Enhanced Standard Care|"Baseline data collection, registration and randomization~Inform primary transplant clinician of sexual dysfunction causing distress~Receive American Cancer Society sexual educational material"
89234967|NCT05814822|Active Comparator|Sleep Hygiene Education|Delivered via telemedicine
89234968|NCT05796297||Patient with significant patient ventilator asynchrony|Active Comparator
89155917|NCT03803696|Active Comparator|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~3 Monthly visits with trained study nurse practitioners~Referral to specialist if~Psychological etiology~Sexual Trauma~Relationship Discord~Concern for Malignancy or anatomic scarring requiring surgery"
89155918|NCT03803553|Experimental|ctDNA-POSITIVE: FOLFIRI Protocol|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- ctDNA-POSITIVE: FOLFIRI Protocol~FOLFIRI chemotherapy via intravenous infusion on days 1-3 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~infusions will consist of the drugs~5-Fluorouracil~Irinotecan~Leucovorin"
89155919|NCT03803553|Active Comparator|ctDNA-POSITIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~-- Active surveillance.~Observation and monitoring with imaging (every 3 months), tumor markers, and ctDNA draws every 1 month for the initial 6 months.~After 6 months, followed with ctDNA, tumor markers, and scans every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician. ."
89155920|NCT03803553|Active Comparator|ctDNA-NEGATIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- Observation and monitoring with imaging, tumor markers, and ctDNA collections every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician"
89155921|NCT03803553|Experimental|ctDNA-POSITIVE MSI-H: NIVOLUMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and MSI-H, the participant will not be randomized and will be placed into the group: ctDNA positive, MSI-H: Nivolumab~-ctDNA-Positive, MSI-H: Nivolumab Protocol~Nivolumab treatment via intravenous infusion on day 1 of each cycle. Cycle is 28 days long. This will occur for up to 12 cycles (48 weeks).~infusions will consist of the drug Nivolumab"
89155922|NCT03803553|Experimental|ctDNA-POSITIVE BRAF Mutant: ENCORAFENIB/BINIMETINIB/CETUXIMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and has a BRAF mutation, the participant will not be randomized and will be placed into the group: ctDNA positive, BRAF mutant: Encorafenib/Binimetinib/Cetuximab~-ctDNA-Positive, MSI-H: Encorafenib/Binimetinib/Cetuximab Protocol~Encorafenib/Binimetinib treatment is received orally every day and Cetuximab via intravenous infusion on day 1 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~infusions will consist of the drug Cetuximab"
89155923|NCT03803553|Experimental|6 Months Additional Trastuzumab and Pertuzumab|Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. Participants that are eligible to receive Trastuzumab and Pertuzumab will be placed in this HER2 cohort: ctDNA-positive & HER2 amplification and MSS Trastuzumab and Pertuzumab. Trastuzumab is received via intravenous administration, and Pertuzumab treatment is received intravenously by infusion. Cycle is 21 days. This will occur for up to 8 cycles.
89155924|NCT03795337|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
89155925|NCT03787290|Experimental|Tocilizumab|Participants will receive tocilizumab followed by whole-body hyperthermia
89155926|NCT03787290|Active Comparator|Placebo|Participants will receive a placebo followed by whole-body hyperthermia
89155927|NCT03781154|Experimental|Group-based exercise|Virtually-delivered supervised exercise sessions will take place twice per week for approximately one hour, and include aerobic, muscular strength and endurance, balance, and flexibility components.
89155928|NCT03781154|No Intervention|Control Group|A physical activity education control group
89155929|NCT03759379|Experimental|Vutrisiran + Vutrisiran (HELIOS-A)|Participants will receive vutrisiran 25 mg subcutaneous (SC) injection once every 3 months (q3M) for 18 months during the Treatment Period followed by vutrisiran SC injection once every 6 months (q6M) or q3M during the Randomized Treatment Extension (RTE) Period.
89155930|NCT03759379|Active Comparator|Patisiran + Vutrisiran (HELIOS-A)|Participants will receive patisiran 0.3 mg/kg intravenous (IV) infusion once every 3 weeks (q3w) for 18 months during the Treatment Period followed by vutrisiran SC injection q6M or q3M during the RTE Period.
89155931|NCT03757949|Experimental|Arm I (SIM)|Patients receive SIM PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
89155932|NCT03757949|Placebo Comparator|Arm II (placebo)|ARM II: Patients receive placebo PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
89155933|NCT03740191|Other|Proton Therapy of Prostate Cancer|"Patients with low and intermediate risk are included. The following interventions are performed:~'Expanded Prostate Cancer Index Composite' (EPIC) questionnaire~kV x-ray images~Conebeam CT"
89155934|NCT03726489|Other|Office Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a clinical setting via narrow band phototherapy clinic units.
89155935|NCT03726489|Active Comparator|Home Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a home setting via Daavlin 7 series 3 panel narrow band phototherapy home units.
89155936|NCT03668613|Experimental|secukinumab low dose|secukinumab low dose
89155937|NCT03668613|Experimental|secukinumab high dose|secukinumab high dose
89155938|NCT03659773|Experimental|hematopoietic stem cell transplant (HSCT)|immune biomarkers to evaluate vaccine response in HSCT recipients
89155939|NCT03657108|Experimental|group 1 of 60 Gy dose|The first 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
89155940|NCT03657108|Experimental|group 2 of 60 Gy dose|The second 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 60 Gy + Adjuvant external beam radiation therapy
89155941|NCT03657108|Experimental|group 1 of 75 Gy dose|The third 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
89155942|NCT03657108|Experimental|group 2 of 75 Gy dose|The fourth 3 subsequent patients with high risk prostate cancer will be undergoing radical prostatectomy Interventions: Civasheet 75 Gy + Adjuvant external beam radiation therapy
89155943|NCT03650699|Experimental|Self-Directed Tongue Strengthening Rehab|"8 sessions of self-directed tongue strengthening exercises followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
89155944|NCT03650699|Experimental|SLP Directed Face-to-Face Rehab|"8 sessions of SLP-directed face-to-face rehabilitation program followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
89155945|NCT03644563||Follow-up|Those subjects with oncogenic oral HPV infection and/or HPV oncogene serum antibodies from screening.
89155946|NCT03635164|Experimental|Dose Escalation and Expansion|"Part 1 of this trial will use a traditional 3+3 design will be used for this trial (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level). Dose escalation will occur as long as there are minimal dose limiting toxicities.The expectation is that 9 patients will be enrolled to the trial during part 1.This is based on the expectation that all dose levels are safe (i.e. patients will not experience DLTs at all dose levels). The range of patients needed will be 6-12 patients.~Part 2 of this trial will be an expansion cohort. A total of 8 additional patients will be enrolled at the dose level determined to be the MTD in part 1 of the study. These 8 patients will be used to confirm that the MTD is a safe combination, as well as provide additional patients to investigate the efficacy for the treatment combination.~Note: Standard of care surgery will follow 3-6 weeks after medication and radiation treatment."
89155947|NCT03627403|Experimental|Selinexor, all patients|Single Arm Study, all patients will get selinexor
89155948|NCT03608150|Experimental|Therapeutic Group|Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.
89155949|NCT03608150|Active Comparator|Control Group|Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.
89155950|NCT03602066|Experimental|Arm I (chlorine dioxide sterilization)|Patients receive chlorine dioxide sterilization oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
89155951|NCT03602066|Placebo Comparator|Arm II (placebo)|Patients receive placebo oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
89155952|NCT03583086|Experimental|Escalation|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
89155953|NCT03583086|Experimental|Dose Expansion - Non Small-Cell-Lung Cancer Acquired Resistance|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
89155954|NCT03583086|Experimental|Dose Expansion - Non Small-Cell-Lung Cancer Naive|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
89155955|NCT03583086|Experimental|Dose Expansion - Non Small-Cell-Lung Cancer Primary Refractory|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
89155956|NCT03583086|Experimental|Dose Expansion - Small Cell Lung Cancer - Progressed on Platinum-based Chemotherapy|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
89155957|NCT03583086|Experimental|Dose Expansion - Thymic Carcinoma|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
89155958|NCT03582774|Active Comparator|Arm I (standard of care)|Participants receive standard of care SRT.
89155959|NCT03582774|Experimental|Arm II (68Ga-PSMA-11 PET/CT)|Participants receive 68Ga-PSMA-11 IV and 50-100 minutes later undergo whole-body (skull base to mid-thighs) PET/CT. Participants then undergo SRT per the discretion of the treating radiation oncologist.
89155960|NCT03559036||Locomotor Training|Assessments for bladder function will be conducted pre-training and following 80 sessions of locomotor training. Locomotor training consists of body-weight supported stepping on a treadmill for one hour.
89155961|NCT03534804|Experimental|Cabozantinib and Pembrolizumab, all patients|
89155962|NCT03527732|Placebo Comparator|Arm A: albendazole|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of placebo at day 0 administered orally
89155963|NCT03527732|Experimental|Arm B: albendazole and ivermectin|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally
89155964|NCT03500133|Experimental|Group A|"Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.~No radiotherapy if CR at the end of chemotherapy."
89155965|NCT03500133|Experimental|Group B|"Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.~No radiotherapy if CR at the end of chemotherapy"
89234969|NCT05796297||Patient without significant patient ventilator asynchrony|Active Comparator
89155966|NCT03500133|Experimental|Group B2|"Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
89155967|NCT03500133|Experimental|Group C|"Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.~No radiotherapy if CR at the end of chemotherapy."
89155968|NCT03500133|Experimental|Group D|"Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
89155969|NCT03500133|Experimental|Group E|"High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy"
89155970|NCT03500133|Experimental|Group F|"High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
89155971|NCT03486067|Experimental|Administration of CC-93269|
89155972|NCT03467750|Experimental|Ketorolac|Participants randomized to the ketorolac group will receive 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis has been achieved
89155973|NCT03467750|Active Comparator|Standard of Care|Participants randomized to this group will receive the pain management standard of care for the adenotonsillectomy procedure.
89155974|NCT03421782|Experimental|Exercise - Arm I|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks.
89155975|NCT03421782|Experimental|Exercise plus PROSPECT Cognitive Behavior Therapy (CBT)|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks. Patients also undergo PROSPECT internet-based CBT intervention over 12 weeks.
89155976|NCT03382951||Healthy children|Each study is an observational study with no group assignments and no control/placebo.
89155977|NCT03340454|Active Comparator|Health systems-level intervention|using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies;
89155978|NCT03340454|Active Comparator|CHW-led patient navigation program|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability
89155979|NCT03322072|Experimental|Real-Time Position Transponder Beacons|Patients in this arm will each be receiving 3 implanted real-time position transponder beacons (Calypso beacons)
89155980|NCT03317158|Experimental|Phase 1: Cohort 1|Durvalumab monotherapy
89155981|NCT03317158|Experimental|Phase 1: Cohort 2|Durvalumab plus BCG
89155982|NCT03317158|Experimental|Phase 1: Cohort 3|"Durvalumab plus External Beam Radiotherapy (EBRT)~(BCG re-treatment) - Cross-over to Durvalumab Monotherapy"
89155983|NCT03317158|Experimental|Phase 1: Cohort 4|"Durvalumab + Gemcitabine/Intravesical Docetaxel (Gem/Doc)~The sequence of administration is flexible to allow for scheduling of both the infusion and intravesical treatments."
89155984|NCT03317158|Experimental|Phase 1: Cohort 5|"NOTE: Cohort 5 was abandoned prior to any patients enrolled.~Durvalumab + Tremelimumab + Gem/Doc~The sequence of administration is flexible to allow for scheduling of both the infusion and intravesical treatments. For the intravenous medications, durvalumab should be administered first followed by tremelimumab."
89155985|NCT03317158|Experimental|Phase 1: Cohort 6|Additional Regimens (to be determined)
89155986|NCT03317158|Experimental|Phase 2: Cohort 4 Expansion|"Durvalumab + Gemcitabine/Intravesical Docetaxel (Gem/Doc)~The sequence of administration is flexible to allow for scheduling of both the infusion and intravesical treatments."
89155987|NCT03307330||Obstructive Sleep Apnea|Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) >=5
89155988|NCT03307330||Non-Obstructive Sleep Apnea|Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) < 5
89155989|NCT03302494|Experimental|WaveCrest|WaveCrest left atrial appendage occluder
89155990|NCT03302494|Active Comparator|Watchman (control)|Watchman left atrial appendage closure device
89155991|NCT03300830||group 1|Viral-assoc. cancer; HIV-neg pts with cancer that occurs in HIV pos; KSHV-assoc. cancer or related diseases e.g. multicentric Castleman disease; retrovirus-induced cancer; Idiopathic Castleman disease
89155992|NCT03283449|Experimental|AV-1451 Recipients|Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
89155993|NCT03281954|Placebo Comparator|Placebo|IV infusion once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
89155994|NCT03281954|Experimental|Atezolizumab|IV infusion, 1200mg, once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
89155995|NCT03276676|Experimental|All Enrolled participants|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
89155996|NCT03243396|Experimental|Health-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in a community setting from Community Health Volunteers.
89155997|NCT03243396|Experimental|Education-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in their school setting from teachers employed by their school.
89155998|NCT03225417|Experimental|Experimental group|"Phase I: Ixazomib + Tacrolimus + Sirolimus. Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.~Phase II: Ixazomib+ any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.~Starting Dose of Ixazomib according to phase I."
89155999|NCT03225417|Other|Control group|Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
89156000|NCT03171025|Experimental|Nivolumab, all patients|
89156001|NCT03148106|Experimental|Somatosensory Electrical Stimulation|
89156002|NCT03147885|Experimental|Treatment (selinexor, RCHOP)|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. RCHOP will be given at standard dosing every 21 days. In the phase 1 part there is dose escalation for Selinexor in a 3+3 design. Treatment will be given for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or better will receive maintenance selinexor PO on days 1, 8, 15, and 22 every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
89156003|NCT03107780|Experimental|Treatment (MDM2 inhibitor AMG 232 [KRT-232])|See Detailed Description
89156004|NCT03051464|Experimental|Chemoradiation + EBRT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders
89156005|NCT03051464|Experimental|Chemoradiation + HDRBT Boost|standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders
89156006|NCT03036007|Active Comparator|Prescribed Physical Activity|General physical exercises combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
89156007|NCT03036007|Experimental|Exercises with Internet support|Neck-specific exercises with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
89156008|NCT03031821|Experimental|Metformin|Metformin 850 mg PO OD X 30 days, then 850mg PO BID for a total of 18 months
89156009|NCT03031821|Placebo Comparator|Placebo|"Placebo Oral Tablet~1 tablet (850mg) PO OD X 30 days, then 850mg PO BID for a total of 18 months"
89156010|NCT03020277|Other|ASD children families|
89156011|NCT02998567|Experimental|Escalation|Fixed dose of Pembrolizumab with escalating dose of Guadecitabine to establish the phase 2 recommended dose.
89156012|NCT02998567|Experimental|Expansion|Continuation of the Guadecitabine and Pembrolizumab dose established in arm 1: expansion in the recommended patient population.
89156013|NCT02998567|Experimental|B2: Lung Expansion|To further explore the safety and activity of the combination of ASTX727 (replacement of guadecitabine to an oral dose tablet) with pembrolizumab in patients with NSCLC with primary or secondary resistance to PD-1/PD-L1 inhibitors.
89156014|NCT02991521|Experimental|FAST examination after Right sided roll (FASTeR)|Subjects will have a standard FAST exam, and will then be rolled onto their right side and the FAST exam will be repeated.
89156015|NCT02983981|Experimental|open label|Topicort topical spray
89156016|NCT02975934|Experimental|Rucaparib|Oral rucaparib (monotherapy).
89156017|NCT02975934|Active Comparator|Abiraterone acetate or Enzalutamide or Docetaxel|Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).
89156018|NCT02962414|Experimental|everolimus|everolimus, 2mg dispersible tablets
89156019|NCT02962167|Experimental|Locally Recurrent Medulloblastoma/ATRT|Patients must have local recurrent disease (defined as negative spine MRI and negative cytology within 21 days prior to study registration) and undergo resection of local recurrence as part of their standard of care. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, directly into the tumor bed during standard of care resection.
89156020|NCT02962167|Experimental|Disseminated Recurrent MB/ATRT|Patients must have disseminated recurrent medulloblastoma (MB) or ATRT (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
89156021|NCT02962167|Experimental|Disseminated Recurrent Medulloblastoma|Patients must have disseminated recurrent medulloblastoma (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
89156022|NCT02935556||post partum pre-eclampsia|women with normal deliveries followed by post partum pre-eclampsia within 1 month of delivery.
89156023|NCT02935556||controls|women with normal deliveries and normal post part courses who match the post partum pre-eclampsia women in age, BMI, smoking status, gestational age and race/ethnicity.
89156024|NCT02932501||MRONJ|"Patients diagnosed of medication-related osteonecrosis of the jaw (MRONJ). Treatment strategies vary depending on the stage of MRONJ and can be of different nature as:~Conservative treatment Surgical treatment Adjuvant non-surgical treatment"
89156025|NCT02911129||Healthy Volunteer|Inclusion Criteria for Healthy Volunteers/Age-matched Controls
89156026|NCT02911129||Patients|Patients with neglect after a right hemisphere brain lesion
89156027|NCT02906839|Experimental|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
89156028|NCT02906839|No Intervention|Control group|No SAS screening will be performed in this group before the end of the 2 year follow up period.
89156029|NCT02906631||patients admitted to the ICU for AE|Adult patients with all-cause encephalitis admitted to an intensive care unit.
89156030|NCT02889627|Experimental|FMT with microbiota suspension|Participants undergo repeated FMT with ~50ml microbiota suspension.
89156031|NCT02884765||Bicondylar Fracture|Patients presenting a bilateral condylar fracture of the mandible with or without additional symphyseal fracture. Bilateral condylar fractures will be treated non-surgical, surgical or combining both.
89156032|NCT02843425|Experimental|Regular Diet + Beans, Then Regular Diet - Beans|
89156033|NCT02843425|Active Comparator|Regular Diet - Beans, Then Regular Diet + Beans|
89156034|NCT02797171|Experimental|Group 1|Participants will receive 10 mg/kg of VRC01 at Months 0, 2, 4, and 6.
89156035|NCT02797171|Experimental|Group 2|Participants will receive 30 mg/kg of VRC01 at Months 0, 2, 4, and 6.
89156036|NCT02797171|Experimental|Group 3|Participants will receive 30 mg/kg of VRC01LS at Months 0, 3, and 6.
89156037|NCT02797171|Experimental|Group 4|Participants will receive 30 mg/kg of VRC01 at Month 0.
89156038|NCT02797171|Experimental|Group 5|Participants will receive 30 mg/kg of VRC01LS at Month 0.
89156039|NCT02782715|Experimental|Radiotherapy & Microwave Ablation|"3+3 dose-escalation wherein three dose levels of stereotactic body radiation therapy (SBRT) would be evaluated:~Dose level I: 6 Gy x 5 fractions~Dose level II: 8 Gy x 5 fractions~Dose level III: 10 Gy x 5 fractions~Radiation treatments will be delivered two to three times a week, with five fractions completed over two weeks.~Four to six weeks after radiation treatment, patients will undergo repeat CT or MRI imaging to assess tumor response and suitability for microwave ablations.~Eight weeks after the conclusion of SBRT, patients will undergo microwave ablation (approximately 12 weeks after registration)."
89156040|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise and Resistance Training (NS-ART)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity and resistance training. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
89156041|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise (NS-A)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
89156042|NCT02774759|Active Comparator|Standard Care Control Group (CG)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants receive standard of care consisting of phone calls asking about their health and self-help materials.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
89156043|NCT02764541|Experimental|Arm A Tamoxifen followed by Endocrine Therapy|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
89156044|NCT02764541|Experimental|Arm B Letrozole Followed By Endocrine Therapy|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
89156045|NCT02764541|Experimental|Tamoxifen Followed By Endocrine Therapy and Palbociclib|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
89156046|NCT02764541|Experimental|Letrozole Followed By Endocrine Therapy and Palbociclib|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
89156047|NCT02728388|Experimental|PDT Treatment|"Each subject will have either placebo or Levulan Kerastick topical application applied to matched sets of neurofibromas. Each subject will have both sets, in order to serve as his/her own control subject.~16 to 24 hours post study drug treatment, both sets of neurofibromas, Levulan and placebo treated, will be irradiated with red light (630 nm) from an Omnilux Revive light device at 100 mW/cm2 for 1000 seconds (16.7 minutes)."
89156048|NCT02697448|Active Comparator|propofol|Participants receiving propofol as anesthetic for cardiac ablation.
89156049|NCT02697448|Active Comparator|sevoflurane|Participants receiving sevoflurane as anesthetic for cardiac ablation.
89156050|NCT02623075|Experimental|Transplant recipients (Chimeric)|Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).
89156051|NCT02623075|Experimental|Transplant recipients (IS)|Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).
89156052|NCT02623075|Active Comparator|Controls|Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).
89156053|NCT02613650|Experimental|MEK162 and mFOLFIRI, all patients|
89156054|NCT02576574|Experimental|Avelumab Biweekly|
89156055|NCT02576574|Experimental|Avelumab Weekly|
89156056|NCT02576574|Active Comparator|Chemotherapy|
89156057|NCT02535338|Experimental|Treatment (erlotinib hydrochloride, onalespib lactate)|Patients receive erlotinib hydrochloride PO daily and onalespib lactate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
89156058|NCT02532244||sample collection|Each participant will have blood drawn for genetic analysis and for establishment of a lymphoblastoid cell line.
89156059|NCT02502266|Active Comparator|Phase II Arm I (reference regimen)|Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
89156060|NCT02502266|Experimental|Phase II Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
89156061|NCT02502266|Experimental|Phase II Arm III (cediranib maleate)|Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
89156062|NCT02502266|Experimental|Phase II Arm IV (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).
89156063|NCT02502266|Active Comparator|Phase III Arm I (reference regimen)|Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
89156064|NCT02502266|Experimental|Phase III Arm II (cediranib maleate, olaparib)|Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.
89156065|NCT02502266|Experimental|Phase III Arm III (single-agent cediranib maleate)|Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
89156066|NCT02478697|Experimental|Tobacco Treatment|The tobacco treatment includes: (a) the ProChange ExpertSystem, a Transtheoretical-model (TTM) tailored, computer-assisted web-delivered program focused on increasing intrinsic motivation, (b) a stage-tailored treatment manual with goal setting for quitting tobacco, and (c) education on proper use of nicotine replacement therapy (NRT, patch plus gum or lozenge) with guidance on obtaining low-cost or free NRT through MediCal, private insurance plans, and community programs.
89156067|NCT02478697|No Intervention|Usual Care|"Usual care includes: completing the study assessments at baseline, 3- and 6-months and receiving referrals to tobacco treatment in the community, including the state quitline, in line with the public health Ask, Advise, Refer model of tobacco cessation intervention."
89156068|NCT02460302|Experimental|Vaginal Progesterone|"In the experimental arm, the participants will be randomized (1:1 allocation) to receive a vaginal progesterone suppository (100mg) as the intervention.~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the drug three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
89156069|NCT02460302|Placebo Comparator|Placebo Comparator|"In the placebo arm, the participants will be randomized (1:1 allocation) to receive a vaginal suppository (100mg) containing hard fat without any active hormonal ingredient as the intervention.~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the placebo three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
89156070|NCT02453620|Experimental|Treatment (entinostat, nivolumab, ipilimumab)|Patients receive entinostat PO on days -14 and -7 and then weekly, nivolumab IV over 60 minutes on day 1 and then every 2 weeks, and ipilimumab IV over 90 minutes on day 1 and then every 6 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT as clinically indicated throughout the trial. Patients may undergo PET/CT or bone scan throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
89156071|NCT02420912|Experimental|Cohort I (nivolumab, ibrutinib) Chronic Lymphocytic Leukemia (CLL)|Patients receive nivolumab IV over 1 hour on days 1 and 15 and ibrutinib PO QD on days 1-28 of courses 2-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89156072|NCT02420912|Experimental|Cohort II (nivolumab, previous ibrutinib) Chronic Lymphocytic Leukemia (CLL)|Patients receive nivolumab as in Cohort I and continue previous ibrutinib treatment.
89156073|NCT02420912|Experimental|Cohort III (nivolumab, ibrutinib) Richters Transformation (RT)|Patients receive nivolumab and ibrutinib as in cohort I. Ibrutinib may be given earlier than course 2 in case of worsening disease after discussion with study principal investigator. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89156074|NCT02414139|Experimental|Cohort 1a: Pre-treated patients with MET GCN ≥ 10 (2/3L)|Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)
89156075|NCT02414139|Experimental|Cohort 1b:Pre-treated patients with MET GCN ≥ 6 and < 10 (2/3L)|Pre-treated patients with MET GCN ≥ 6 and < 10 treated with INC280 at 400 mg BID as second or third line (2/3L)
89156076|NCT02414139|Experimental|Cohort 2: Pre-treated patients with MET GCN ≥ 4 and < 6 (2/3L)|Pre-treated patients with MET GCN ≥ 4 and < 6 treated with INC280 at 400mg BID as second or third line (2/3L)
89156077|NCT02414139|Experimental|Cohort 3: Pre-treated patients with MET GCN < 4 (2/3L)|Pre-treated patients with MET GCN < 4 treated with INC280 at 400mg BID as second or third line (2/3L)
89156078|NCT02414139|Experimental|Cohort 4: Pre-treated patients with MET mutation regardless of MET GCN (2/3L)|Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)
89156079|NCT02414139|Experimental|Cohort 5a: Treatment-naïve patients with MET GCN ≥10 (1L)|Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)
89156080|NCT02414139|Experimental|Cohort 5b: Treatment-naïve patients with MET mutation regardless of MET GCN (1L)|Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)
89156081|NCT02414139|Experimental|Cohort 6.1 (expansion of Cohort 1a): Pre-treated patients MET GCN ≥ 10 without MET mutation (2L)|Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)
89156082|NCT02414139|Experimental|Cohort 6.2 (expansion of Cohort 4): Pre-treated patients with MET mutation (2L)|Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)
89156083|NCT02414139|Experimental|Cohort 7 (expansion of Cohort 5b): Treatment-naïve with MET mutation regardless of MET GCN (1L)|Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)
89156084|NCT02412696|Active Comparator|Positive Airway Pressure|Positive airway pressure and nasal dilator strips during sleep.
89156085|NCT02412696|Placebo Comparator|Nasal Dilator Strips|Nasal dilator strips during sleep.
89156086|NCT02400281|Experimental|Arm 1 crenolanib besylate combination|Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin
89156087|NCT02400281|Experimental|Arm 2 crenolanib besylate combination|Arm 2 patients will receive crenolanib besylate and azacytidine.
89156088|NCT02398773|Experimental|Diagnostic (FES PET/CT)|Between 0 to 30 days before start of endocrine therapy, patients receive F-18 16 alpha-fluoroestradiol IV over 2 minutes and undergo PET/CT. Patients may undergo a second FES-PET/CT study at least 24 hours after the first study and no later than 10 days after the initial study.
89156089|NCT02344290|Experimental|Pitavastatin|Participants will receive pitavastatin once a day for the entire time they are enrolled in the study.
89156090|NCT02344290|Placebo Comparator|Placebo|Participants will receive placebo for pitavastatin once a day for the entire time they are enrolled in the study.
89156091|NCT02298816||new B-Cell Hematologic Malignancy diagnosis|All adult patients who are newly diagnosed at Aurora Health Care with the following B-Cell Hematologic Malignancies: Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma (SMM), Multiple myeloma (MM), Waldenstroms Macroglobulinemia (WM), Monoclonal B-cell lymphocytosis (MBL), Chronic lymphocytic leukemia (CLL), or B-Cell Non-Hodgkin lymphoma (NHL).
89156092|NCT02294461|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once a day during double blind period until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer. Eligible participants who received enzalutamide during double blind and who provided consent to take part in open-label period continued to receive 160 mg of enzalutamide in open-label period orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
89156093|NCT02294461|Experimental|Placebo|Participants received enzalutamide matching placebo orally once a day during double-blind period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
89156094|NCT02294461|Experimental|Placebo followed by Enzalutamide|Eligible participants who received enzalutamide matching placebo during double-blind period and who provided consent to take part in open-label period, received 160 mg of enzalutamide orally once a day during open-label period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
89156095|NCT02273284|Experimental|Buzzy|Participants will use the Buzzy, a small vibration device during their Botulinum toxin treatments. The Buzzy will be held over the injection site for 30 sec prior to the injection, then will be moved more rostral during the actual injection. The Buzzy will be applied in the same fashion to each targeted muscle.
89156096|NCT02273284|No Intervention|control - no Buzzy|Participants in the control group will receive their regular Botulinum toxin treatment without the use of the Buzzy
89156097|NCT02260895|No Intervention|Control|Standard 2-hour 75-gram oral glucose tolerance test
89156098|NCT02260895|Experimental|Almond Pre-test snack|1/2 ounce (14 g) almond snack 30 minutes prior to a 2-hour 75-gram oral glucose tolerance test
89156099|NCT02259621|Experimental|Arm B- Nivolumab|"Nivolumab administration:~Three doses of nivolumab will be administered to enrolled patients on Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days."
89156100|NCT02259621|Experimental|Arm C- Nivolumab, Carboplatin, & Paclitaxel|Nivolumab 360 mg IV, Carboplatin AUC 5 or 6 IV, and Paclitaxel 175 or 200 mg/m2 IV every 21 days for 3 cycles prior to planned surgery on Day 0.
89156101|NCT02259621|Experimental|Arm A- Nivolumab and Ipilimumab|One dose of Nivolumab 3mg/kg IV & Ipilimumab 1mg/kg will be administered to enrolled patients on Day-42, then 2 doses of Nivolumab 3mg/kg will be administered to enrolled patients on Day-28 and Day-14
89156102|NCT02237625||Medical History of HPP Patients|Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
89156103|NCT02146495|Experimental|Simultaneous EEG/ fMRI Recordings during Amyg-EFP-NF|Patients with FM will undergo concurrent EEG and fMRI recordings. During the fMRI scans, they will engage in Amyg-EFP NF training.
89156104|NCT02146495|Active Comparator|Amyg-EFP-NF Trial|The EFP-NF procedure will include a multisession NF trial (10 sessions) using feedback driven by the Amyg-EFP model.
89156105|NCT02146495|Sham Comparator|Amyg-EFP-NF Sham Trial|The sham NF procedure will include a multisession NF trial (10 sessions) using sham feedback; in this condition, the feedback will be provided based on a randomized Amyg-EFP signal.
89156106|NCT02146495|No Intervention|Treatment As Usual|Patients in this group will continue their usual treatment without any intervention. Patients in this control group will undergo a complete clinical and neural evaluation at the beginning and end of a defined period, similar to the NF intervention period, and a clinical follow-up (after 10-12 months).
89156107|NCT02088658|Experimental|Techonology Intensified|Subjects randomized to this group will receive: 1) the FORA system for self-monitoring; 2) weekly telephone-delivered diabetes education/skills training; 3) patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions); and 4) patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools). The intervention will be delivered by telephone once a week for 12 weeks with each session lasting ~30 minutes.
89156108|NCT02088658|No Intervention|Usual Care|Apart from study visits, patients will be followed by their primary care providers. The provider will be responsible for determining treatment parameters, making changes in the treatment regimen, and determining the timing of follow up visits. Between scheduled office encounters, contact between patient and provider will be patient initiated. The provider may use clinic nurses to follow up on problematic patients or patients with abnormal results. In essence, this group will receive the current standard of care at the study clinics.
89156109|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 8 mg|Participants with or without fibroblast growth factor [FGF]/fibroblast growth factor receptor [FGFR] gene abnormalities received orally TAS-120 8 milligrams (mg) orally every other day (QOD; Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156110|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 16 mg|Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 16 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156111|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 24 mg|Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 24 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156112|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 36 mg|Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 36 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156113|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 56 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 56 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156114|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 80 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 80 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156115|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 120 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 120 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156116|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 160 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 160 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156117|NCT02052778|Experimental|Phase 1: Dose Escalation: QOD Dosing: 200 mg|Participants with FGF/FGFR gene abnormalities received orally TAS-120 200 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156118|NCT02052778|Experimental|Phase 1: Dose Escalation: QD Dosing: 4 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 4 mg orally once daily (QD) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156119|NCT02052778|Experimental|Phase 1: Dose Escalation: QD Dosing: 8 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 8 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156120|NCT02052778|Experimental|Phase 1: Dose Escalation: QD Dosing: 16 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 16 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156121|NCT02052778|Experimental|Phase 1: Dose Escalation: QD Dosing: 20 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 20 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156122|NCT02052778|Experimental|Phase 1: Dose Escalation: QD Dosing: 24 mg|Participants with or without FGF/FGFR gene abnormalities received a dose between 24 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156123|NCT02052778|Experimental|Phase 1: Dose Expansion Cohort 1|Participants with intra-hepatic or extrahepatic cholangiocarcinoma (iCCA or eCCA) harboring FGFR2 gene fusions or rearrangements and who were treated or not treated with prior FGFR inhibitors received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156124|NCT02052778|Experimental|Phase 1: Dose Expansion: Cohort 2|Participants with primary central nervous system (CNS) tumors harboring FGFR gene fusions or FGFR1 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156125|NCT02052778|Experimental|Phase 1: Dose Expansion: Cohort 3|Participants with advanced urothelial carcinoma harboring FGFR3 gene fusions or FGFR3 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156126|NCT02052778|Experimental|Phase 1: Dose Expansion: Cohort 4|Participants with breast or gastric cancer with harboring FGFR2 amplification received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156127|NCT02052778|Experimental|Phase 1:Dose Expansion: Cohort 5|Participants with tumor types harboring FGFR gene fusions or activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156128|NCT02052778|Experimental|Phase 1: Dose Expansion: Cohort 6|Participants who were not included in Cohorts 1 to 5 received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156129|NCT02052778|Experimental|Phase 1: Dose Expansion: Sub-cohort 1|Participants with iCCA who were enrolled prior to the confirmation of the recommended Phase 2 dose (RP2D) received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156130|NCT02052778|Experimental|Phase 1: Dose Expansion: Sub-cohort 2|Participants with other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156131|NCT02052778|Experimental|Phase 2|Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
89156132|NCT01915810|Experimental|Arm I (pre-quit physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning 2 weeks before the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise activity per week for 5 weeks.
89156133|NCT01915810|Experimental|Arm II (quit day physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning on the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise per week for 5 weeks.
89156134|NCT01915810|Active Comparator|Arm III (no physical activity)|Participants quit smoking on an assigned date and receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks.
89156135|NCT01915225||1/ Cohort 1|Subjects with or without solid tumors in whom diagnostic, preventative, or therapeutic intervention is being performed
89156136|NCT01789983||Breast Cancer Patients 60+|Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease.
89156137|NCT01789983||Lung Cancer Patients 60+|Lung Cancer Patients age 60 and above who have stage I, II or III disease
89156138|NCT01789983||Colon Cancer Patients 60+|Colon cancer patients age 60 and above who have stage II or III disease.
89156139|NCT01787500|Experimental|Treatment (vemurafenib, cetuximab, irinotecan hydrochloride)|Patients receive vemurafenib PO BID on days 1-14, cetuximab IV over 90 minutes, and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89156140|NCT01725165|Experimental|Arm I (immediate LCT)|Patients undergo ablation of all residual local and metastatic sites of disease by surgery and/or EBRT. After completion of LCT, patients undergo either surveillance or maintenance treatment at the discretion of the treating physician.
89156141|NCT01725165|Active Comparator|Arm II (delayed/no LCT)|Patients undergo standard maintenance therapy or clinical observation, based on physician choice. Patients may cross-over to Arm I due to RECIST progression or toxicity at the treating physician's discretion.
89156142|NCT01700166|Experimental|Biologic; Cord Blood Stem Cells; Intravenous injection|Autologous Human Umbilical Cord Blood derived Stem Cell injection
89156143|NCT01672749||Spine based dual growing rod or VEPTR|Patients treated with the TROLLEY system will be compared with patients from the Chest Wall and Spine Deformity Study Group (CWSDSG) and the Growing Spine Study Group (GSSG) treated with a spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America). For each patient in the TROLLEY group a patient from each of the databases will be selected to be matched based on diagnosis, age, gender, and spine deformity classification.
89156144|NCT01672749||TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs). The TROLLEY system is CE marked at the time of the study conduct.
89156145|NCT01627821|Active Comparator|Jarvik 2000 Treatment|Jarvik 2000 VAS, Post-Auricular Cable
89156146|NCT01627821|Active Comparator|HeartMate II Control|HeartMate II VAS Control
89156147|NCT01621854|Experimental|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
89156148|NCT01614990|Active Comparator|Macimorelin|
89156149|NCT01614990|Placebo Comparator|Placebo|
89156150|NCT01585194|Experimental|Treatment (nivolumab, ipilimumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity."
89156151|NCT01508312|Experimental|FDG-PET abnormal|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
89156152|NCT01508312|Experimental|FDG-PET normalization|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
89156153|NCT01424982|Experimental|Treatment (combination chemotherapy, ponatinib hydrochloride)|See Detailed Description.
89156154|NCT01349881|Placebo Comparator|eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets, PO, daily for 3 years. Sulindac placebo, 1 tablet, PO, daily for 3 years.
89156155|NCT01349881|Experimental|Eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.
89156156|NCT01349881|Experimental|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
89156157|NCT01349881|Experimental|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
89156158|NCT01343394|Experimental|Biologic; Autologous Cell Injection|
89156159|NCT01334749||Acute Stroke|Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German
89156160|NCT01334021|Experimental|Diagnostic (biopsy, surgery, genetic testing)|Patients undergo biopsy or surgery to obtain tumor sample for genetic testing. Patients are then assigned to 4 treatment cohorts as determined by genetic test results.
89156161|NCT01328860|Experimental|Biologic; Stem Cells|
89156162|NCT01294020|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B of the study.
89156163|NCT01278225||EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
89156164|NCT01278225||Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
89156165|NCT01246869|Experimental|All Participants|All enrolled participants will complete three imaging sessions on separate days, beginning with a research MRI, then a PET scan with FDG and [15O]water, and a PET scan with FMISO. The two PET scans will be in any order on different days within one week of each other, and preferably on consecutive days. The research MRI will be within 14 days of the first PET scan.
89156166|NCT01120249|Experimental|Arm I|Patients receive oral everolimus once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
89156167|NCT01120249|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
89156168|NCT00981058|Experimental|Necitumumab + Gemcitabine + Cisplatin|
89156169|NCT00981058|Active Comparator|Gemcitabine + Cisplatin|
89156170|NCT00877500|Experimental|Group I (ixabepilone)|Participants receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89156171|NCT00877500|Active Comparator|Group II (standard of care)|Participants receive standard of care for 18 weeks.
89156172|NCT00863369|Experimental|Treatment (bortezomib, gemcitabine hydrochloride, rituximab)|Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
89156173|NCT00498875||Questionnaire + Depression Intervention|
89156174|NCT00093470|Experimental|Arm A (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89156175|NCT00093470|Other|Arm B (clinical observation)|Patients undergo observation only.
89156176|NCT00001373||Affected|Patients with auto-inflammatory disorders
89156177|NCT00001373||Family Members|Family members of patients
89156178|NCT00001373||Healthy Volunteers|Healthy Volunteers
89156179|NCT00964717|Active Comparator|Chiropractic|Real Chiropractic treatment
89156180|NCT00964717|Sham Comparator|Sham Chiropractic|stimulation utilizing 'activator' thumper
89156181|NCT00964717|No Intervention|No treatment|No add on therapy - patients lay down for a period of 15 minutes without any treatment or intervention
89156182|NCT02793401|Active Comparator|HILT group|71 of the patients were in the HILT group
89156183|NCT02793401|Active Comparator|US Group|70 of the patients were in the US group.
89156184|NCT05343715|Experimental|Agalsidase Beta from Biosidus|Participants received a single infusion at a dose 1 mg/kg
89156185|NCT05343715|Active Comparator|Fabrazyme (Sanofi-Genzyme)|Participants received a single infusion at a dose 1 mg/kg
89156186|NCT00644150|Experimental|1|Physicians of county level will receive Ai Shi Zi training provided by experts in the fields of HIV/STIs, behavioral counseling, and stigma reduction.
89156187|NCT00644150|Experimental|2|Physicians of township level will receive Ai Shi Zhi training provided by the county level physicians.
89156188|NCT00644150|Experimental|3|HIV/STI patients will receive standard of care and specialized care from physician participants trained in Ai Shi Zi.
89156189|NCT00644150|No Intervention|4|Physicians of county level who will not participate in Ai Shi Zi training
89156190|NCT00644150|No Intervention|5|Physicians of township level who will not participate in Ai Shi Zi training
89156191|NCT00644150|Sham Comparator|6|HIV/STI patients who will receive standard care only
89156192|NCT05307913|Experimental|EIT-guided PEEP|PEEP titration by EIT
89156193|NCT05307913|Active Comparator|Table-guided PEEP|PEEP selection by the lower PEEP/FiO2 table
89156194|NCT02672384|Experimental|patients in ICU|"Dental examination will be performed to diagnose CP based on the Centre for Diseases Control definition.~A point of care P. gingivalis test (Denka Seiken Co (Japan) ) on saliva and detection of antibodies against P. gingivalis in sera will be performed.~In case of discrepancies between both diagnoses methods, RT-PCR for identification of P. gingivalis and other pathogens will be performed on samples of periodontal pocket performed in routine."
89156195|NCT02793557|Placebo Comparator|Placebo|Intradermal injection of 50 μl solution. One application in SAD part for each dosing occasion. 2 or 3 times weekly for 3 month in MD part.
89156196|NCT02793557|Experimental|FOL-005: Solution 1|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
89156197|NCT02793557|Experimental|FOL-005: Solution 2|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
89156198|NCT02793557|Experimental|FOL-005: Solution 3|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
89156199|NCT02793557|Experimental|FOL-005: Solution 4|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
89156200|NCT00880620|Placebo Comparator|Placebo|One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).
89156201|NCT00880620|Experimental|IPX066 145 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
89156202|NCT00880620|Experimental|IPX066 245 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
89156203|NCT00880620|Experimental|IPX066 390 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).
89156204|NCT00959335|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
89156205|NCT00959335|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
89156206|NCT02672462|Experimental|Renal denervation|
89156207|NCT00644618|Active Comparator|A|
89156208|NCT00644618|Experimental|B|
89156209|NCT03967847|No Intervention|Control|
89156210|NCT03967847|Experimental|Ketorolac|
89156211|NCT00959413||A|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load greater than 1,000 copies/ml
89156212|NCT00959413||B|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load of 1,000 copies/ml or less
89156213|NCT00959413||C|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is greater than 1,000 copies/ml
89156214|NCT00959413||D|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is 1,000 copies/ml or less
89156215|NCT02672306|Experimental|UCMSCs|Subjects with Alzheimer's Disease Intervention: UCMSCs
89156216|NCT02672306|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)
89156217|NCT00658398|Experimental|ICP to prevent alcohol misuse.|Interactive Computer Program (ICP) to prevent alcohol misuse.
89156218|NCT00658398|Sham Comparator|ICP to enhance balanced diet|2. Interactive Computer Program to enhance balanced diet (sham intervention)
89156219|NCT03755063|Experimental|Treatment arm|Tablet with speech therapy apps
89156220|NCT03755063|No Intervention|Standard of Care|The standard care provided by speech language therapists.
89156221|NCT00910286|Other|VENTILATOR WEANING|Two ventilators with different flow termination criteria (TC) were compared: Servo 300 (Siemens-Elema, Sweden) with fixed TC (5% of peak inspiratory flow) and Newport E500 (Newport Medical Instruments, CA) with automatic TC (varies between 5% to 55%). Each patient remained three hours in the protocol, one hour in each ventilator, after been randomized to one of two sequences of 3 steps: Fixed 5% / Automatic / Fixed 5% or Automatic / Fixed 5% / Automatic . The PS, the positive end expiratory pressure (PEEP), the inspiratory oxygen fraction (FiO2) and the pressure trigger sensitivity levels were unchanged during the protocol.
89156222|NCT00658476|Experimental|Omega-3 Fatty Acids|Adolescents receive cognitive behavior therapy in combination with Omega-3 fatty acid supplements.
89156223|NCT00658476|Placebo Comparator|Placebo|Adolescents receive cognitive behavior therapy in combination with placebo.
89156224|NCT00959491||Colonoscopy indication|All outpatients referred to colonoscopy according to inclusion criteria in the specified period time of one year .
89156225|NCT04175990|Experimental|Progestogen|Oral Dydrogesterone 10mg tds was given from day 1 of menses till day of trigger
89156226|NCT04175990|No Intervention|standard combine minimal stimulation protocol|Oral clomiphene citrate 100mg daily given from day 1 till day 10 of menses with additional gonadotrophin (Menopur 225mg daily) from day 3 of menses till trigger day
89156227|NCT05258227|Experimental|Proprioceptive Strength Training|"Conservation physical therapy includes TENS 15 min + Infrared 15 min simultaneously.~Proprioceptive strength training for 30 min includes following exercises:~Strengthening of Quadriceps Ankle extensors and Hip abductors strengthening Zigzag walking Heel to toe walk forward and backwards toe to heel Standing on one leg while holding wall, eyes open and eyes closed"
89156228|NCT05258227|Experimental|Core Instability Strength Training|"Conservational therapy includes TENS for 15 min+ Infrared for 15 min simultaneously.~Core instability strength training for 30 minutes includes following exercises:~Quadriceps stretch, crook lying, abdominal hallowing Dynamic Hamstrings stretch Bridging arms at side Crook lying+lifting both legs at right angle with hands resting on thighs"
89156229|NCT04087148||patients|patients who were diagnosed as having CAH of at least 1 y duration. and On glucocorticoid replacement therapy .
89156230|NCT04087148||controls|A comparable number of age and sex matched apparently normal children will be included as control.
89156231|NCT00959569|Experimental|esmolol|the study group will receive esmolol (1-3 mg/kg)
89156232|NCT00959569|Placebo Comparator|normosaline|normosaline (same ml of the study drug)
89156233|NCT00881868|Active Comparator|Clobex Spray|
89156234|NCT00881868|Placebo Comparator|Vehicle spray|
89156235|NCT02793479||BE|Patients presenting Barrett's Esophagus as a complication of a gastroesophageal reflux disease.
89156236|NCT00964873|Experimental|1 Part 1|
89156237|NCT04527419|Active Comparator|Systematically mediastinal lymph node dissection group|Systematically mediastinal lymph node dissection will be performed.
89156238|NCT04527419|Experimental|No mediastinal lymph node dissection group|Mediastinal lymph node dissection will not be performed.
89156239|NCT04176068|Experimental|Combined microfocused ultrasound and calcium hydroxylapatite|One-time intense microfocused ultrasound with calcium hydroxylapatite injection to one anterior lower thigh with option for additional filler injection at 6 weeks, 12 weeks, and 24 weeks. Optional combined treatment of the opposite lower anterior thigh at week 24 with no further follow up.
89156240|NCT04057560||SIBO Group|
89156241|NCT04057560||Control Group|
89156242|NCT00959725|Experimental|Intravitreal infliximab.|
89156243|NCT04176146|Experimental|Nudge Letter|Participants receive a letter that highlights their performance vs. peer organizations on up to seven care delivery practices featured in the National Survey of Healthcare Organizations and Systems (NSHOS). The letter includes a link to access technical assistance resources and is sent alongside the participant's NSHOS respondent report.
89156244|NCT04176146|No Intervention|Control Letter|Participants receive a letter with a link to technical assistance resources; the letter is sent alongside the participant's NSHOS survey respondent report.
89156245|NCT02793245|Experimental|Studied population|Patients will be questioned about their main characteristics (age, gender, height, weight, smoking), they will also perform a simplified a pulmonary function test (if possible).
89156246|NCT00656994|Experimental|Ramelteon 16 mg QD|
89156247|NCT00656994|Placebo Comparator|Placebo|
89156248|NCT02672228|Experimental|MalariaSense device|This study will involve the evaluation of a medical diagnostic device. All participants enrolled in the study will be assessed for malaria using MalariSense Technology and will aslo get rapid diagnostic tests (RDTs), microscopy, PCR
89156249|NCT00964951|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
89156250|NCT00964951|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
89156251|NCT00964951|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
89156252|NCT00964951|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
89156253|NCT00964951|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
89156254|NCT03807713|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
89156255|NCT04233281|Experimental|Kori-tofu added to a carbohydrate rich meal|Kori tofu as part of a carbohydrate rich meal
89156256|NCT04233281|Active Comparator|Whey protein added to a carbohydrate rich meal|Whey protein as part of a carbohydrate rich meal
89156257|NCT02671994|Experimental|A (experimental group)|Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
89156258|NCT02671994|No Intervention|B (control group)|Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).
89156259|NCT02789189|Experimental|nedaplatin combined with gemcitabine|
89156260|NCT02670590|Experimental|NAFLD|diet
89156261|NCT00881712|Experimental|PET positive nodal disease measuring 15 mm or greater|Proton radiation with concomitant chemotherapy
89156262|NCT00881712|Experimental|PET positive nodal disease measuring less than 15 mm|Proton radiation
89156263|NCT00881712|Experimental|Patients considered resectable|Proton radiation plus surgery
89156264|NCT00644930|Experimental|1|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated.
89156265|NCT00644930|Active Comparator|2|Patients in the standard therapy group without indications for urgent intubation were only given standard medical therapy (such as oxygen, antibiotics, and bronchodilators), and IMV through an endotracheal tube was applied when intubation criteria were met.
89156266|NCT04081142||acute respiratory failure group|acute respiratory failure (ARF) group: arterial oxygen partial pressure to fractional inspired oxygen ratio, PaO2/FiO2<300 mmHg and/or peripheral oxygen saturation SaO2<94% under air condition and/or severe dyspnea with respiratory rate >30bpm.
89156267|NCT04081142||control group|postoperative ICU patients without ARF were included
89156268|NCT02634450|No Intervention|Control|Current practice of Early Infant Diagnosis in Mozambique: using conventional system of collecting blood on Dried Blood Spot and sending it to central laboratory for PCR processing and receiving result by SMS printer.
89156269|NCT02634450|Active Comparator|Intervention|Point Of Care Device (Alere q) is used for Early Infant Diagnosis, with the sample collected and processed in the consultation room with the device
89156270|NCT03723239|Experimental|TricValve® System Single-Arm|Minimally invasive catheter-supported, bicaval tricuspid valve (self-expanding) replacement
89156271|NCT04176770|Experimental|ESP group|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
89156272|NCT04176770|Experimental|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
89156273|NCT02634216|Experimental|Type 1 Diabetics using CGM|Type 1 diabetics using Continuous Glucose MonitoringCGM to take 500 mg daily of Capros supplement (250 mg twice a day) at lunch and dinner.
89156274|NCT04234607|Experimental|TQB2450+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89156275|NCT04234607|Experimental|TQB2450（blank）+Anlotinib+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+ Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89234970|NCT05790590|Active Comparator|Standard dose CT|Standard dose protocol CT using standard radiation dose (120 kVp) and standard dose of contrast media, and reconstructed with commercially available reconstruction algorithm of the CT scanner.
89234971|NCT05790590|Experimental|Double low dose CT|Double low dose protocol CT using low radiation dose (120 kVp & 70% of reference mAs of standard dose CT) and low dose of contrast media, and reconstructed with commercially available vendor-agonistic AI-based software.
89156276|NCT04234607|Active Comparator|TQB2450（blank）+Anlotinib（blank）+ etoposide + carboplatin|Induced stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib (blank) capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) +Etoposide (100mg/m2 IV continuously on Day 1,2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1（ maximum dosage: 800 mg）） maintenance stage：TQB2450 (blank) 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules (blank) 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89156277|NCT02670746||Nab-paclitaxel in combination with gemcitabine (AG)|The objective is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma. In all cases, the decision to treat the patient with nab-paclitaxel in combination with gemcitabine was already made prior to the decision to enter the subject into the study. Treatment will be according to routine clinical practice and based on recommendations as per Summary of Product Characteristics (SPC).
89156278|NCT03955471|Experimental|Niraparib+Dostarlimab (TSR-042)|Participants with body weight ≥77 kilogram (kg) and platelet count ≥150,000/microliter (μL) at baseline were administered Niraparib 300 milligram (mg) once daily (QD) and participants with body weight <77 kg or platelet count <150,000/μL at baseline were administered Niraparib 200 mg QD. Niraparib was administered continuously until Progressive disease (PD) or toxicity. Dostarlimab (TSR-042) was administered as an intravenous (IV) infusion of 500 mg once every three weeks (Q3W) from Cycle 1 Day 1 through Cycle 4. Beginning at Cycle 5, Dostarlimab (TSR-042) was administered via an IV infusion of 1000 mg on Day 1 of each 6-week cycle until PD or toxicity, up to 27 months.
89156279|NCT02637726|Experimental|TIVA0|Propofol : TIVA guided by clinical signs. Remifentanil
89156280|NCT02637726|Experimental|TIVA BIS|propofol : TIVA guided by EEG Monitoring. Remifentanil
89156281|NCT02637726|Experimental|TCI KBIS|Propofol : TCI Kataria guided by EEG Monitoring. Remifentanil.
89156282|NCT02637726|Experimental|TCI SBIS|Propofol : TCI Schnider guided by EEG Monitoring. Remifentanil.
89156283|NCT04161768|Active Comparator|Norfloxacin|Norfloxacin 400 mg daily
89156284|NCT04161768|Experimental|Norfloxacin and Itopride|Norfloxacin 400 mg daily and Itopride 50 mg three times daily.
89156285|NCT02793089||First quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
89156286|NCT02793089||Second quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
89156287|NCT02793089||Third quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
89156288|NCT02793089||Fourth quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
89156289|NCT02634060|Experimental|Home Based Fecal Calprotectin|"IBDoc® at week 0, 4 and 8 using smartphone. All material will be provided by the third party The same stool sample of the home base faecal calprotectin will be brought to the hospital and used for ELISA faecal calprotectin measurement at week 0, 4 and 8 for UC patients and week 0 and 4 for CD patients.~IBDoc® results will be forwarded to the patient and the health care professional."
89156290|NCT02789267|No Intervention|Control|"Group of patients with standard of care: the nutritional support is conducted by physicians.~No systematic dietary support"
89156291|NCT02789267|Experimental|Regular dietary support|Group of patients will benefit from a systematic and regular dietary support. Patients will be followed by a dietitian 1 month and 3 month after radiotherapy in hospital. Then, dietitian will realize a telephon interview 2 and 5 months after radiotherapy
89156292|NCT00959803|Experimental|Single dose|3 way crossover with randomized placebo substitution to evaluate single escalating oral doses of PF 04447943 in 9 healthy young adult subjects.
89156293|NCT00959803|Experimental|Multiple dose|3:1 active PF 04447943 to placebo randomization in 8 healthy elderly subjects.
89156294|NCT02672150|No Intervention|Control|During the Baseline Control data is collected in all 36 sites at the agency, staff, and youth level on the 6 months prior to the interventions in Arms 2 & 3 to document what practice was before the study.
89156295|NCT02672150|Active Comparator|Core|"In the second phase (after baseline) all 36 sites receive a Core condition that includes five interventions: (1) JJ-TRIALS Orientation Meetings, (2) Needs Assessment, (3) Behavioral Health Training, (4) Site Feedback Report, (5) Goal Achievement Training, (6) Monthly Site Check-ins, and (7) Quarterly Reports. As part of Goal Achievement Training, sites receive assistance in using their Site Feedback Reports to select goals to meet their local needs. Sites are trained on using Data-Driven Decision Making (DDDM) to inform decisions (e.g., selecting a goal, monitoring progress) and enlisting DDDM templates and tools (developed as part of the project) to plan and implement proposed changes.~these principles to their improvement efforts during the implementation phase."
89156296|NCT02672150|Experimental|Enhanced|While the core intervention and DDDM are expected to facilitate change, organizations may need additional support to apply these principles to their improvement efforts during the implementation phase. In the third phase (after Core), 1/2 of the sites are randomly assigned to an Enhanced condition that provides continuing support for the use of DDDM tools by adding research staff facilitation of DDDM over a 12-month period and formalized Local Change Teams (LCTs) featuring representation from the JJ agency and a local BH provider, with meetings facilitated by research staff).
89156297|NCT04161924||X-ray imaging with physical grid using conventional processing|
89156298|NCT04161924||X-ray without physical grid using conventional processing|
89156299|NCT04161924||X-ray imaging without physical grid using experimental SimGrid|
89156300|NCT02793011|Experimental|Dexamethasone|Liquid or capsule dexamethasone - to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
89156301|NCT02793011|Placebo Comparator|Placebo|Placebo liquid or capsule to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
89156302|NCT04010617|Experimental|Pharyngeal Electrical Stimulation|Orotracheal intubated patients at high risk of extubation failure will receive open-label PES
89156303|NCT02671214|Placebo Comparator|Control|100 g high fibre flour
89156304|NCT02671214|Active Comparator|Active 1|85 g high fibre flour + 15 g legume flour
89156305|NCT02671214|Active Comparator|Active 2|98 g high fibre flour + 2 g guar gum
89156306|NCT02671214|Active Comparator|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
89156307|NCT02671214|Active Comparator|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
89156308|NCT02671214|Active Comparator|Active 5|96 g high fibre flour + 4 g guar gum
89156309|NCT02671214|Active Comparator|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
89156310|NCT02671214|Active Comparator|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
89156311|NCT02671214|Active Comparator|Active 8|94 g high fibre flour + 6 g guar gum
89156312|NCT02671214|Active Comparator|Active 9|98 g high fibre flour + 2 g konjac mannan
89156313|NCT02671214|Active Comparator|Active 10|96 g high fibre flour + 4 g konjac mannan
89156314|NCT02671214|Active Comparator|Active 11|100 g low fibre flour
89156315|NCT00965107|Experimental|Thiopental|Thiopental for induction of anaesthesia.
89156316|NCT00965107|Active Comparator|Propofol|Propofol for induction of anaesthesia.
89156317|NCT02788877|Experimental|treat-and-extend|Aflibercept 2mg is injected into the vitreous cavity. An injection is given every 4 weeks five times and then the Treat-and-Extend process begins. If 1mm central subfield macular thickness (CSMT) improved (10% or more reduction) compared to the previous visit, the next treatment will be performed at the same interval. If CSMT is maintained (less than 10% changes), the next interval will be extended by two weeks (up to 12 weeks). If CSMT is worsened (10% or more increase), the next interval will be shortened by two weeks (minimum 4 weeks). If CSMT is stable two times at 12 weeks-interval, the injection will be deferred, and the next visit will be 8 weeks later. These process will be continued for 2 years.
89156318|NCT00959881|Experimental|Donepezil plus placebo|
89156319|NCT00959881|Experimental|Donepezil plus begacestat|
89156320|NCT00644462||1|Asthmatic subjects
89156321|NCT00644462||2|Healthy subjects
89156322|NCT00959959|Experimental|650 mg TOK-001|
89156323|NCT00959959|Experimental|1300 mg TOK-001|
89156324|NCT00959959|Experimental|1950 mg TOK-001|
89156325|NCT00959959|Experimental|975 mg TOK-001|
89156326|NCT00959959|Experimental|975 mg TOK-001, supplement|
89156327|NCT00959959|Experimental|1950 mg TOK-001, split dose|
89156328|NCT00959959|Experimental|2600 mg TOK-001|
89156329|NCT00959959|Experimental|2600 mg TOK-001, split dose|
89156330|NCT04234451|Active Comparator|SPA acupuncture|active SPG acupuncture plus rescue medication (AA group)
89156331|NCT04234451|Sham Comparator|sham acupuncture|sham-SPG acupuncture plus rescue medication (SA group)
89156332|NCT04033484|Active Comparator|Biological Mesh|Using biological mesh to recnostruct the pelvic floor following ELAPE
89156333|NCT04033484|Experimental|Biological Mesh With Negative Pressure Wound Therapy|Using biological mesh compined with negative pressure wound therapy to recnostruct the pelvic floor following ELAPE
89156334|NCT03651011|Active Comparator|Aflibercept + Navigated laser|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase) and in addition receive navigated retinal laser photocoagulation at M3. Patients will receive aflibercept according to pro re nata regimen from M3-M12.
89156335|NCT03651011|Active Comparator|Aflibercept only|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase). Patients will receive aflibercept according to pro re nata regimen from M3-M12.
89156336|NCT00880542|Experimental|Sorafenib + Ifosfamide|"* Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.~NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.~Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.~Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy."
89156337|NCT05251597|Experimental|green exercise group-1 (aerobic)|Forty participants who meet the inclusion criteria will first be given warm-up exercises for 10 minutes, then walking at a moderate intensity (65% of heart rate) for 40 minutes and then stretching exercises for 5 minutes
89156338|NCT05251597|Experimental|green exercise group-2 (aerobic+resistance)|For 40 participants who met the inclusion criteria, first 10 minutes of warm-up exercises, then 20 minutes of moderate-intensity (65% of heart rate) walking, followed by 10 minutes of low-intensity (50% of the maximum repetitions) and 10 minutes of high-intensity (80% of the maximum repetitions) resistance exercises will be applied in the presence of a physiotherapist. resistance exercises; shoulder flexors and abductors, elbow flexors and extensors, hip flexors and extensors, knee flexors and extensors, hip abductor muscle group will be performed. At the end of each session, 5 minutes of stretching exercises will also be applied.
89156339|NCT05251597|No Intervention|Control group|The exercise program will not be implemented. Evaluations will be made at the beginning and end of the study.
89156340|NCT04085978||Pre implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2014 - November 30, 2016 who qualify for hypoglycemia protocol
89156341|NCT04085978||Post implementation of hypoglycemia protocol with glucose gel|All neonates born at Banner University Hospital during January 01, 2018 - November 30 2018 who qualify for hypoglycemia protocol
89156342|NCT02670668|Experimental|Mutation analysis- NACwith PCR|consisting of 50 patients undergoing NACwith pathological compete response
89156343|NCT02670668|Experimental|Mutation analysis-NAC with SD/PD.|consisting of 50 patients undergoing NAC with SD/PD
89156344|NCT00960037|Experimental|Vitamin D|Vitamin D3 supplementation based on baseline 25(OH)D level
89156345|NCT00960037|Placebo Comparator|Placebo|
89156346|NCT02792933|Active Comparator|air in epidural space|When the ALOR epidural localization technique will be used, an intermittent pressure with fast movements will be exerted on the plunger of the syringe while the Tuohy needle will be inserted until loss of resistance was felt.
89234972|NCT05777356||Omivorous|Healthy volunteers without dietary restrictions
89156347|NCT02792933|Experimental|saline in epidural space|When the SLOR technique is used, a continuous pressure will be exerted on the plunger of the Tuohy needle until loss of resistance was felt.
89156348|NCT00658710|Active Comparator|1|patients who continue physical therapy sessions during two months.
89156349|NCT00658710|No Intervention|2|patients who stop physical therapy sessions during two months
89156350|NCT04079036||Underweight Adult Male|Male patients with Underweight BMI classification and more than 20 years old https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
89156351|NCT04079036||Healthy Weight Adult Male|Male patients with Healthy Weight BMI classification and more than 20 years old
89156352|NCT04079036||Overweight Adult Male|Male patients with OverWeight or Obese BMI classification and more than 20 years old
89156353|NCT04079036||Underweight Adult Female|Female patients with Underweight BMI classification and more than 20 years old
89156354|NCT04079036||Healthy Weight Adult Female|Female patients with Healthy Weight BMI classification and more than 20 years old
89156355|NCT04079036||Overweight Adult Female|Female patients with Overweight or Obese BMI classification and more than 20 years old
89156356|NCT04079036||Underweight children Male|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
89156357|NCT04079036||Healthy Weight children Male|Male patients less than 20 year old, and with Healthy Weight BMI classification
89156358|NCT04079036||Overweight children Male|Male patients less than 20 year old, and with Overweight or Obese BMI classification
89156359|NCT04079036||Underweight children Female|Male patients less than 20 year old, and with Underweight BMI classification https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html
89156360|NCT04079036||Healthy Weight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
89156361|NCT04079036||Overweight children Female|Female patients less than 20 year old, and with Overweight or Obese BMI classification
89156362|NCT04009369|No Intervention|Emergency Physician Group|Usual care by the EP without the intervention of the ED PT.
89156363|NCT04009369|Experimental|Physical Therapist Group|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
89156364|NCT05380661|Experimental|Individuals with motor-complete SCI|Individuals with motor sensory complete injury (AIS A/B)
89156365|NCT05380661|Experimental|Individuals with motor-incomplete SCI|Individuals with motor sensory incomplete injury (AIS C/D)
89156366|NCT04161690|Active Comparator|Group IV|Dexketoprofen 50mg is given intravenous 10 min before the start of the surgery. Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
89156367|NCT04161690|Active Comparator|Group Periarticular|Dexketoprofen 50mg is given as part of the local infiltration analgesia with 300mg ropivacaine. Local infiltration analgesia is proceeded by the orthopedic surgeon.
89156368|NCT04161690|Placebo Comparator|Group P|Local infiltration analgesia is proceeded by the surgeon with 300mg ropivacaine.
89156369|NCT02671292|Experimental|Interpersonal Psychotherapy (IPT-WG)|IPT-WG targets the difficult social functioning and stressful events that are associated with loss of control eating and that are highly relevant to the adolescent children of military personnel.
89156370|NCT02671292|Active Comparator|Health Education (HE)|HE improves knowledge on various health topics including, alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
89156371|NCT00960271||NON SMALL CELL LUNG CANCER|Non small cell lung cancer, with clinical N2 disease, otherwise operable.
89156372|NCT04233125|Active Comparator|Core Decompression (CD) Only|Participants in this group receive standard care
89156373|NCT04233125|Experimental|Added Polymethylmethacrylate (PMMA)|Participants in this group receive standard care with an additional treatment
89156374|NCT02637414|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
89156375|NCT02637414|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
89156376|NCT04085588||Group 1|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 2 μg / kg / min ketamine was started in Group 1. By the end of the operation ketamine infusion was reduced to 1 μg / kg / min."
89156377|NCT04085588||Group 2|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 4 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 2 μg / kg /min and continued."
89156378|NCT04085588||Group 3|"All patients were revived spinal anesthesia with 3 mL marcaine 0.5% and after surgery a 2 mg bolus morphine PCA pump was connected to them.~Before the skin incision, when sensorial block reached T10 dermatome level 6 μg / kg / min ketamine was started . By the end of the operation ketamine infusion was reduced to 3 μg / kg /min and continued."
89156379|NCT00885534|Experimental|Chemotherapy|This is a single institution phase II trial in stage III or IV melanoma patients with measurable disease but no prior cytotoxic chemotherapy and not thought to be curable by surgery.Before starting the chemotherapy, you may need to have a fresh biopsy of your tumor. If you have already had a tumor biopsy that we can use, you may not need another biopsy. Your study doctor will review with you the biopsies you have had. We will try to obtain biopsy material that already exists but if we cannot, you will need another biopsy.
89234973|NCT05777356||Vegetarians|Healthy volunteers who do not consume meat products
89234974|NCT05777356||Vegans|Healthy volunteers who do not consume any animal product
89234975|NCT05768607|Other|Patients undergone Laparoscopic Extraperitoneal Burch Colposuspension|
89234976|NCT05768477||Chronic pain patients|Chronic pain patients with a dominant nociceptive pain mechanism, a dominant neuropathic pain mechanism and a dominant nociplastic pain mechanism. They will receive different treatments: Consultations, Interventions (injections, denervations...), Baxter therapy and interdisciplinary treatment.
89234977|NCT05754918|Active Comparator|TnoFS then TFS|Cochlear Implant with TnoFS first during 6 weeks then with TFS during 6 weeks
89156380|NCT05277038||Clonidine vs Zopiclone for insomnia|Consecutive adult patients who underwent pain management at a Canadian pain clinic. The patients were subsequently prescribed and provided zopiclone 3.75mg tablet (1-2 tablets per dose), and clonidine 0.1mg tablet (1-2 tablets per dose). They were advised to take either clonidine or zopiclone on alternate nights. For each medication, they alternated the doses of 1 tablet or 2 tablets at subsequent nightly administrations. The four possible medication doses were zopiclone 3.75mg, zopiclone 7.5mg, clonidine 0.1mg, and clonidine 0.2mg; as shown on the sleep diary in Figure 1. The recommended orders of treatment were zopiclone 7.5mg, clonidine 0.1mg, zopiclone 3.75mg, clonidine 0.2mg; or clonidine 0.2mg, zopiclone 3.75mg, clonidine 0.1mg, zopiclone 7.5mg. Each patient participated in the study treatment and completed the sleep diary for 3 continuous weeks. Therefore, each of the four medication doses was used five times by each patient.
89156381|NCT02634138|Experimental|Intervention|Revitive IX Neuromuscular Electrical Stimulation Device
89156382|NCT02670824|Experimental|CN-105 Active Drug|"The CN-105 drug administered via IV at an escalating scale of mg/kg.~A1-0.01 mg/kg A2-0.03 mg/kg A3-0.1 mg/kg A4-0.3 mg/kg A5-1.0 mg/kg B1-1.0 mg/kg"
89156383|NCT02670824|Placebo Comparator|Placebo|Normal Saline
89156384|NCT00960349|Other|Treatment A|Cediranib 20mg + Cisplatin + S-1
89156385|NCT00960349|Other|Treatment B|Cediranib 20mg + Cisplatin + Capecitabine
89156386|NCT04161846|Experimental|Virtual World Program|Participants take part in a group training delivered using a virtual world approach.
89156387|NCT04161846|Active Comparator|In Person Program|Participants take part in a group training delivered using an in person approach.
89156388|NCT02670434|Experimental|NK-104-CR|Controlled release NK-104
89156389|NCT02670434|Placebo Comparator|Placebo|Livalo Placebo
89156390|NCT02670434|Active Comparator|Livalo® Immediate Release IR|Immediate Release Livalo®
89156391|NCT02788409||Medicare CRPC|Men in the US older than 65 years old having CRPC
89156392|NCT05206344|Other|Without Clowns - Clowns (WC-C)|Firstly a painful act without the presence of the clown duo, then in a second time the same painful act in the presence of the clown duo
89156393|NCT05206344|Other|Clowns- Without clowns (C-WC)|Firstly a painful act with the presence of the clown duo, then in a seconde time, the same painful act without the presence of the clown duo
89156394|NCT00960583|Experimental|Exercise program|"Exercise program comprising muscle strengthening, cardiovascular training and stretching exercises.~Program duration : 12 weeks Sessions frequency : twice per week Session duration : 1h30"
89156395|NCT00960583|Active Comparator|Routine follow-up|Routine follow-up after functional multidisciplinary rehabilitation by attending physician (Advice to stay active)
89156396|NCT02787941|Experimental|Intervention group|The intervention group will receive the pharmacist-delivered multifaceted intervention with two counselling sessions in addition to usual care.
89156397|NCT02787941|No Intervention|Control group|The control group will receive usual care without the pharmacist-delivered multifaceted intervention.
89156398|NCT02670356|Experimental|Fish oil|fish oil, 1500 mg/day, EPA:DHA ratio of 4:1, each capsule containing 750 mg total EPA+DHA, 2 capsules/day for 10 weeks
89156399|NCT02670356|Experimental|krill oil|krill oil, 300 mg/day, each capsule containing 74 mg total EPA+DHA , 1 capsule/day for 10 weeks
89156400|NCT02789423|Active Comparator|Dycal|Intervention: drug: Dycal, Other names: Calcium Hydroxide. Intervention Description:DPC using Dycal for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria evaluated were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility. Radiographic criteria:Defective restoration/Recurrent caries,Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
89156401|NCT02789423|Active Comparator|Biodentine|Intervention: drug: Biodentine, Other names: Calcium Silicate. Intervention Description:DPC using Biodentine for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility.Radiographic criteria:Defective restoration/Recurrent caries, Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
89156402|NCT00658944||A|Patients suffering from stress or mixed urinary incontinence
89156403|NCT02672072||Control group|5-day specific training with dedicated scenario done by an ICU expert simulation team after the period of the study
89156404|NCT02672072||Simulation group|5-day specific training with dedicated scenario done by an ICU expert simulation team
89156405|NCT00965653|Experimental|1|
89156406|NCT00965653|Active Comparator|2|
89156407|NCT02788799||Control|
89156408|NCT02788799||Intervention|
89156409|NCT00644696|Experimental|Irinotecan and Bortezomib|Irinotecan and Bortezomib will both be administered
89156410|NCT02788721|Experimental|GLPG2451 single dose|Single dose of GLPG2451 oral suspension at up to 4 dose levels in ascending order
89156411|NCT02788721|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension
89156412|NCT02632266|Active Comparator|Powder HMF|Once patient has reached 80ml/kg/day of enteral feedings, 1 pack of powder HMF will be added to 50 ml of human or donor breast milk, then increased to a maximum of 2 packs for 50 ml following the unit feeding advancement protocol and this will be continued up until 48 hours prior to discharge.
89156413|NCT02632266|Active Comparator|Liquid HMF|Once patient has reached 80ml/kg/day of enteral feedings, researchers will add 1 packet (5 ml) of liquid HMF to 50 ml of human or donor breast milk, then increase to 2 packs to 50 ml following the unit feeding protocol and this will be continued up until 48 hours prior to discharge.
89234978|NCT05754918|Active Comparator|TFS then TnoFS|Cochlear Implant with TFS first during 6 weeks then with TnoFS during 6 weeks
89234979|NCT05750160|No Intervention|Control|Given education only
89234980|NCT05750160|Experimental|Intervention|Given education and music therapy
89234981|NCT05743946|Experimental|Trikafta|Participants with NCFBE and one known CFTR mutation and/or mildly elevated sweat chloride measurements (i.e., 30-60 mEq/L) receiving Trikafta for four weeks.
89234982|NCT05742789|Other|Propofol|Anesthesia
89156414|NCT00960739|Experimental|Topotecan / 131-iodine MIBG association|"The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle). *~Iobenguane I 131: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity up to 11,100 MBq per injection. *~A dosimetry is performed during hospitalization.~A second dose of 131-iodine MIBG (maximum 11 100 MBq) is administered to D21 so as to obtain a total body irradiation of 4 Gy. *~Autologous hematopoietic stem cell transplantation : Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG.~If the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled."
89156415|NCT02788487|Active Comparator|CPAP1 use and TRD 2use|Wash-in period 1 week and Continuous positive airway pressure (CPAP) is used for 3 weeks then wash-out 1 week and Tongue retaining device (TRD) is used for another 3 weeks
89156416|NCT02788487|Experimental|TRD1 use and CPAP2 use|Wash-in period 1 week and Tongue retaining device (TRD) is used for 3 weeks then Wash-out period 1 week and Continuous positive airway pressure (CPAP) is used for another 3 weeks
89156417|NCT00659022|Active Comparator|A|immediate surgery of the primary colorectal tumor, no neoadjuvant therapy
89156418|NCT00659022|Experimental|B|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
89156419|NCT00659022|Experimental|C|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
89156420|NCT00659022|Experimental|D|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
89156421|NCT02670278||US-Washington, Idaho|healthy breastfeeding women and their infants
89156422|NCT02670278||US-California|healthy breastfeeding women and their infants
89156423|NCT02670278||Sweden|healthy breastfeeding women and their infants
89156424|NCT02670278||Spain|healthy breastfeeding women and their infants
89156425|NCT02670278||Peru|healthy breastfeeding women and their infants
89156426|NCT02670278||Kenya|healthy breastfeeding women and their infants
89156427|NCT02670278||Ethiopia-rural|healthy breastfeeding women and their infants
89156428|NCT02670278||Ethiopia-urban|healthy breastfeeding women and their infants
89156429|NCT02670278||The Gambia-rural|healthy breastfeeding women and their infants
89156430|NCT02670278||The Gambia-urban|healthy breastfeeding women and their infants
89156431|NCT02670278||Ghana|healthy breastfeeding women and their infants
89156432|NCT05100667|Experimental|Mental fatigue|Stroop task
89156433|NCT05100667|Placebo Comparator|Control MF|Emotionally neutral documentary
89156434|NCT04175522|Experimental|Experimental|Investigational product(IP)
89156435|NCT02637570|Experimental|Hibiscus tea|420 mg Hibiscus 2 hour after dinner with 1 glass of cool water every day
89156436|NCT02637570|Experimental|green tea|450 mg green tea 2 hour after dinner with 1 glass of cool water every day
89156437|NCT02637570|Placebo Comparator|control group|450 mg placebo (dextrose) 2 hour after dinner with 1 glass of cool water every day
89156438|NCT02788331||Hospitals with increasing activity|Hospitals experiencing an increase in the volume of surgical procedures over the study period
89156439|NCT02788331||Hospitals with decreasing activity|Hospitals experiencing a decrease in the volume of surgical procedures over the study period
89156440|NCT02788331||Hospitals with stable activity|Hospitals experiencing no change in the volume of surgical procedures over the study period
89156441|NCT00960817|Active Comparator|1. Routine treatment|Control group
89156442|NCT00960817|Experimental|2. Dipyridamole treatment|Group that receives Dipyridamole treatment
89156443|NCT02670200|Experimental|intervention arm / verum arm|Participants can work on ten modules specialized cognitive behavior treatments to learn and deal with mindfulness, acceptance and commitment. They should learn to handle their emotions, to accept the situation and to get in an active future. The participants can direct contact a psychotherapist via email, Chat or Skype/tokbox. The modules based on Cognitive Behavior Therapy.
89156444|NCT02670200|Active Comparator|non-intervention arm / control group|Participants can work on six modules with information und education goals for learning something about their possibilities to become a better mood, better psychovegetative or psychosocial situation as cancer patient. This modules are based on Cognitive Behavior Therapy. The non-intervention arm will only allow contact to the platform, no direct contact to a psychotherapist (in opposite to the intervention arm) is available.
89156445|NCT04161222|Experimental|Experimental group|The control group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
89156446|NCT04161222|Experimental|Control group|The control group will perform a typical warm-up of competitive football.
89156447|NCT03674021|Experimental|Intervention Arm|Patients in the intervention arm will receive the Chest Pain Choice visual aid prior to discussion with their primary physician regarding disposition.
89156448|NCT03674021|No Intervention|Control Arm|Patients in the control arm will not receive the Chest Pain Choice visual aid and will receive standard care.
89156449|NCT00965809|Experimental|ACTIVE THC|Subjects will take 5MG of THC in 6 drops of olive oil orally.
89156450|NCT00965809|Placebo Comparator|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
89156451|NCT04177784|Experimental|Intervention (I)|This arm was randomized to a 20 min video that emphasized information about factors other than individual behaviors that influence weight, weight loss and ability to maintain weight. It also indirectly addressed weight bias by explaining how to have conversation about weight and health with a patient with obesity that is free of biases.
89156452|NCT04177784|Active Comparator|Weight Control (C1)|This arm was randomized to a 20 min video that emphasized the controllable aspects of weight and gave dietitians an overview of a tool to help plan and monitor weight loss.
89156453|NCT04177784|Placebo Comparator|Weight Neutral Control (C2)|The arm was randomized to a 20 min video about the role dietitians play in society, that made no mention of weight or obesity.
89156454|NCT05247073|Other|Patients of controlled group with routine closure of the episiotomy|The vagina will be stitched using a continuous locking stitch and the perineal muscles and skin are repaired using approximately three or four individual stitches, each needing to be knotted separately to prevent them from dislodging.
89234983|NCT05742789|Other|Isofluran|Anesthesia
89156455|NCT05247073|Active Comparator|Patients of study group with Mostafa Maged technique for closure of the episiotomy|The vagina will be stitched with the Mostafa Maged technique, The Mostafa Maged four-stitch technique uses absorbable vicryl threads with round needles 75 mm. The technique will prevent dead space formation, Good and tight hemostasis of the episiotomy strong approximation of the two edges of the episiotomy.
89156456|NCT00885378|Active Comparator|Saxagliptin plus metformin IR|
89156457|NCT00885378|Placebo Comparator|Placebo plus metformin IR|
89156458|NCT02787161|Active Comparator|Hemodialysis|Patients who are treated with high flux hemodialysis will continue the same treatment with high flux hemodialysis.
89156459|NCT02787161|Experimental|Hemodiafiltration|Patients who are treated with high flux hemodialysis will be switched to hemodiafiltration for 6 months.
89156460|NCT00965887|Active Comparator|1|MK0974 Ethanolate
89156461|NCT00965887|Active Comparator|2|MK0974 Hydrate
89156462|NCT02537210|Active Comparator|Mesalazine|mesalazine 2g od po for 12 months
89156463|NCT02537210|Placebo Comparator|Placebo oral capsule|placebo 5 capsules od po for 12 months
89156464|NCT01563289|Placebo Comparator|placebo|
89156465|NCT01563289|Experimental|Ibuprofen|
89156466|NCT02786849|Experimental|Group of high frequency and intensity|Group realized high frequency and intensity neuromuscular electrical stimulation
89156467|NCT02786849|Experimental|Group of low frequency and intensity|Group realized neuromuscular electrical stimulation of low frequency and intensity
89156468|NCT04078412||NTM pulmonary disease|Cohort Description: adults NTM pulmonary disease patients diagnose by criteria of American thoracic society guideline
89156469|NCT00960973|Experimental|Vitamin K|Vitamin K supplementation (menatetrenone 30 mg, 3 times a day for 4 weeks)
89156470|NCT00960973|Placebo Comparator|Placebo control|Placebo control
89156471|NCT04184219||Group|People potentially interested in health issues
89156472|NCT02633904|Active Comparator|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
89156473|NCT02633904|Experimental|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
89156474|NCT05143892|Experimental|Avatrombopag|In the 4-weeks'study,the initial dose of avatrombopag is 20 mg/d. If the patient's PLT count remains less than 20*10^9/L after one week, the maximum dose was increased to 40 mg/d. Avatrombopag will be taken orally with food.
89156475|NCT05143892|Other|Supportive care|Patients in this arm receive same treatment as in the avatrombopag group,except any TPO-RAs or recombinant human thrombopoietin.
89156476|NCT04099849|Experimental|Group A|"Diet-ZnBfR zinc biofortified rice-based diet~Diet- CR conventional rice-based diet"
89156477|NCT04099849|Experimental|Group B|"Diet-ZnBfR zinc biofortified rice-based diet~CR + Zn conventional rice-based diet plus zinc fortificant (Diet-CR+Z)."
89156478|NCT00659100|Experimental|A|
89156479|NCT05375357|Experimental|APF + L-PRF|Application of a layer of L-PRF to protect the donor area after uncovering implant procedure using Apically Positioned Flap (APF).
89156480|NCT05375357|Active Comparator|APF without L-PRF|The donor area is left to heal by secondary intention after APF in the implant uncovering procedure.
89156481|NCT02669966|Experimental|Study Arm|Donor candidates with their intended recipients who meet criteria will be enrolled into this, the sole arm of our study. Donor-recipient pairs will be screened to meet criteria, and will proceed to kidney transplantation and post-transplant monitoring
89156482|NCT00965965|Experimental|Experimental patient education document|
89156483|NCT00965965|Active Comparator|Traditional patient education document|
89156484|NCT02792543|Active Comparator|parenteral nutrition|Parenteral nutrition consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
89156485|NCT02792543|Experimental|chyme reinfusion|Chyme reinfusion consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
89156486|NCT02669888|Experimental|Indigo naturalis ointment|"Form: ointment~Dose: each gram of ointment contains 200µg of indirubin~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
89156487|NCT02669888|Placebo Comparator|Placebo|"Form: ointment~Dose: vehicle~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
89156488|NCT05027347||100 healthy people|10 ml blood and tissue biopsy were collected from each patient
89156489|NCT05027347||100 gastric cancer patients|10 ml blood and tissue biopsy were collected from each patient
89156490|NCT00659178|Experimental|SB-485232 plus pegylated liposomal doxorubicin|Subjects will receive one dose of pegylated liposomal doxorubicin on Day 1 plus two doses of SB-485232 on Day 3 and Day 9 in each cycle.
89156491|NCT02792621|Experimental|active oral supplement|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for a 14 day period.
89156492|NCT02792621|Placebo Comparator|placebo supplement|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
89156493|NCT04009759|Active Comparator|Morphine|"Morphine group (M) (n=80), where patients will be treated with i.v. injection of Morphine 2 mg/ml - 5 ml - 10 mg Epidural. The treatment will be given during CPR as soon as possible."
89156494|NCT04009759|Active Comparator|Ketamine|"Ketamine (K) group (n=80), where patients will be treated with i.v. injection of S-Ketamine 10 mg/ml - 5 ml - 50 mg Ketamin Abcur. The treatment will be given during CPR as soon as possible."
89156495|NCT04009759|Placebo Comparator|Saline|"Control group (n=80), where patients will be treated with i.v. 5 ml of NaCl 0,9% B. Braun. The treatment will be given during CPR as soon as possible."
89234984|NCT05742789|Other|Sevofluran|Anesthesia
89156496|NCT04158960|No Intervention|Control|Control period; no equine-assisted activities or brain-building activities occurred
89156497|NCT04158960|Active Comparator|Equine-assisted activities period|Period in which only equine-assisted activities were performed
89156498|NCT04158960|No Intervention|Washout|Washout period; no equine-assisted activities or brain-building activities occurred
89156499|NCT04158960|Experimental|GaitWay period|Period in which both equine-assisted activities and brain-building activities were performed
89156500|NCT02792309|Experimental|MotherWise Programming|Three components: (1) 18 hours of core workshop sessions using the Within My Reach relationship education curriculum supplemented with content on mother-infant relationships; (2) case management services; and (3) optional relationship education workshops for couples.
89156501|NCT02792309|No Intervention|Control|No program services
89156502|NCT00645086|Active Comparator|A|
89156503|NCT00645086|Active Comparator|B|
89156504|NCT00655902|Experimental|1|
89156505|NCT00655902|Placebo Comparator|2|
89156506|NCT03312803|Active Comparator|Mini autogenous skin grafts|we take the autogenous skin graft from the same patient then cut it into small pieces then we spread it over the burn wound on one limb then cover these small pieces with homogenous skin graft taken from another person.
89156507|NCT03312803|Active Comparator|Autogenous skin graft|we take the regular autogenous one piece skin graft from the same patient and cover the burn wound on the other limb then we make a comparison between both limbs
89156508|NCT04183439||Surgeons Interviewed|We recruited surgeons from two University academic health centers, one specializing in adults and the other in children. The surgeons were selected through a snowball technique and emailed to participate. DK and GS interviewed eleven surgical attendings representing 10 surgical specialties. (Table 2) Each subject had at least 10 years of experience in their respective fields and regularly taught residents.
89156509|NCT04009915|Experimental|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer
89156510|NCT04009915|Active Comparator|open surgery|Patients undergo a standard open operation for stage II-III lung cancer
89156511|NCT02633748|Other|Intervention|The twenty participants in the intervention arm will undergo a pre-assessment, post assessment, and a three month follow-up assessment. The pre and post assessments will ask participants to 1) fill out questionnaires to measure lifestyle, stress, meditations habits, and sleep impairment, 2) take a blood sample, 3) use a BodyMedia's Sensewear® armband for a week, and 4) provide salivary cortisol levels. The three month follow-up will repeat everything done if the first two assessments, excluding the blood sample. The intervention arm will also attend the weekly two and a half hour Mindfulness-Based Cancer Survivorship (MBSC) four-week program between the pre and post assessments.
89156512|NCT02633748|No Intervention|Control|The twenty participants in the control arm will undergo the same pre assessment as the intervention arm, receive a presentation on breathing exercises, and undergo the same post and three-month follow-up assessments. The control arm will also be offered the same Mindfulness-Based Cancer Survivorship program given to the intervention arm following the three month follow-up.
89156513|NCT05238649|Experimental|V-01 10 μg|10 μg(0.5ml)/vial, one dose administrated by intramuscular injection
89156514|NCT05238649|Experimental|V-01 25 μg|25 μg(0.5ml)/vial, one dose administrated by intramuscular injection
89156515|NCT05238649|Active Comparator|Inactivated vaccine|0.5ml/vial, containing 100U inactivated COVID-19 virus antigen. One dose administrated by intramuscular injection
89156516|NCT02637336|Experimental|Acupuncture|acupuncture session were inserted, and maintained for 20 minutes in paragraph 6 of the channel the pericardium (Neiguan).
89156517|NCT02637336|Experimental|Aerobic Exercise|The aerobic exercise session was conducted through 20 minutes.
89156518|NCT02637336|Experimental|Aromatherapy|Eucalyptus essential oil was inhaled by volunteers for 20 minutes
89156519|NCT02637336|No Intervention|Control|In the control session the volunteers remained seated at rest for 20 minutes without performing therapy.
89156520|NCT02792153|Experimental|Estrogen|AN participants receive a course of transdermal estradiol treatment.
89156521|NCT04161300|Active Comparator|Foam Rolling Group (FR)|
89156522|NCT04161300|Active Comparator|Orthopaedic Manual Physical Therapy Group (OMPT)|
89156523|NCT04161300|Other|Control Group (CG)|
89156524|NCT00644540|Experimental|1|
89156525|NCT00644540|Active Comparator|2|
89156526|NCT00961129||patients with colorectal cancer|patients with colorectal cancer in any stage or survivors
89156527|NCT03275129|Experimental|Ultrasound assessment of heart and lungs|Patients (over the age of 18) who will be undergoing surgery for hip fracture repair. These patients will receive an ultrasound of the heart and lungs to determine whether or not information gained from this ultrasound assessment is significant enough to influence their anesthetic care plan.
89156528|NCT02633826||kidney transplant recipients|kidney transplant recipients of an allograft from a living donor, no intervention
89156529|NCT02669732|Experimental|DS-8500a 75 mg once daily (QD)|tablets, orally, once daily for up to 28 days
89156530|NCT02669732|Placebo Comparator|Placebo|tablets, orally, once daily for up to 28 days
89156531|NCT05003245|Experimental|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody
89156532|NCT05003245|Active Comparator|Ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
89156533|NCT05367089|Active Comparator|Fluconazole|"Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months."
89156534|NCT05367089|Experimental|L-Mesitran|"Way of administration: intra-vaginal application using an applicator.~Dosage:~As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months."
89156535|NCT02671058|Active Comparator|Cortenema|Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.
89156536|NCT02671058|Experimental|Hydrocortisone acetate|Hydrocortisone acetate suppository 90 mg administered rectally as a single dose with the Sephure Rectal Suppository Applicator
89156537|NCT04158414|Experimental|Different types of cancer Patients|Lymphoma,Nasopharyngeal Cancer; Esophageal Cancer, Cervical cancer; Hepatobiliary and pancreatic cancer; Sarcoma; Prostate Cancer
89156538|NCT02671916||all patients|questionnaire for patients with ICU stay at least 5 days or longer without interruption at the ICU
89156539|NCT02791919|Experimental|Treatment (AZD1775, FLAG chemotherapy)|Patients receive filgrastim IV or SC daily, fludarabine intravenously IV over 30 minutes, cytarabine IV over 1-3 hours and wee1 kinase inhibitor AZD1775 PO on days 1-5. Patients who meet criteria for CR, CRp or PR may receive a second course of therapy. Courses repeat every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89156540|NCT00961207|Active Comparator|Aliskiren in Macroalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300 mg daily for 4 weeks.
89156541|NCT00961207|Active Comparator|Aliskiren Microalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300mg daily for 4 weeks
89156542|NCT04177472|Experimental|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
89156543|NCT04177472|No Intervention|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
89156544|NCT00966121|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
89156545|NCT00966121|Active Comparator|EBL+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
89156546|NCT02537288|Experimental|Placebo matched to fedovapagon|One dose of placebo (matched to fedovapagon)
89156547|NCT02537288|Experimental|Fedovapagon 2 mg|One dose of 2 mg fedovapagon
89156548|NCT02537288|Experimental|Fedovapagon 20 mg|One dose of 20 mg fedovapagon
89156549|NCT02537288|Experimental|Moxifloxacin 400 mg (open label)|One dose of moxifloxacin 400 mg (open label)
89156550|NCT05346263|Experimental|Intermittent Abdominal Pressure Ventilation|Patients in experimental group will be adapted to Intermittent Abdominal Pressure Ventilation (IAPV). Abdominal ventilation replaces part of usual ventilation (non invasive ventilation with mouthpiece or nasal-pillow)
89156551|NCT05346263|Active Comparator|Usual ventilation|Patients in control group continue with usual ventilation (NIV through mouthpiece or nasal-pillow)
89156552|NCT04032054||A|mono-axial
89156553|NCT04032054||B|poly-axial
89156554|NCT02669654|Experimental|Day-care management of Severe Pneumonia|management in Day-care clinic
89156555|NCT02669654|No Intervention|Existing Treatment Centre (ETC)|Severe Pneumonia management in Existing Treatment Centre
89156556|NCT03207191|Experimental|F16IL2 + BI 836858|"Successive cohorts of patients will receive increasing doses of FI6IL2 and BI 836858 until the MTD is reached. The MTD will be defined following a Bayesian logistic regression model (BLRM) with overdose control.~Patients will go off treatment after 6 months (i.e. after 6 cycles of induction combination therapy). Patients achieving CR or CRi will receive maintenance therapy for a maximum of 6 months."
89156557|NCT00659412|Experimental|Course A1|
89156558|NCT00659412|Placebo Comparator|Course A2|
89156559|NCT00659412|Experimental|Course B|Open-label extension
89156560|NCT04009135|Experimental|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
89156561|NCT04009135|Experimental|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind & acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
89156562|NCT04009135|Placebo Comparator|Attention Control (AC)|Patients in the control condition will be given access online psychoeducation about depression and chronic pain. They will be provided weekly phone calls to query symptoms and well-being.
89156563|NCT00966199|Experimental|Hypertensive elderly|community dwelling hypertensive elderly from general practices
89156564|NCT00910364|Experimental|Exercise testing|Feasibility study; all participants receive intervention
89156565|NCT04158102|Experimental|20 mg single dose cohort|Subjects would receive a 20 mg single dose of EXPAREL®
89156566|NCT04074278||development groups|The development groups included 150 patients derived from outpatients in Peking University First Hospital, between March 1st, 2014 and November 26th 2014.
89156567|NCT04074278||validation groups|The validation groups included 150 patients derived from outpatients in Peking University First Hospital, between November 27th 2014 and December 1st, 2015.
89156568|NCT00911352|Experimental|Frozen gel glove (Elasto-Gel Mitten)|Cryotherapy hand
89156569|NCT00911352|No Intervention|No frozen glove therapy|Usual care
89156570|NCT02689895|Other|Intervention|Research assistants visit participants at home, and send SMS texts on scheduled days for 3 months to encourage adherence to ART. Pill charts, visit charts and text charts are completed. this is called modified directly administered anti-retroviral therapy (mDAART). In addition to the intervention, participants receive standard care at their usual clinic which comprises 3 monthly doctor reviews and adherence counseling at each review visit.
89156571|NCT02689895|No Intervention|Control|Participants get usual care at their clinic, which comprises 3 monthly doctor review visits and adherence counseling at each visit.
89156572|NCT04176536|Experimental|All participants|
89156573|NCT02633592|Active Comparator|HRARM|Patients and healthy volunteers are subjected to position change ( LLP to SP) during pressure measurements with HR-ARM.
89156574|NCT02633592|Active Comparator|MRI Defecography|Patients and healthy volunteers are subjected to position change during MRI Defecography
89156575|NCT03161249|Experimental|Experimental group|Mobile psychotherapy (5 modules) plus treatment as usual
89156576|NCT03161249|Other|Control group|"Control group: Treatment as usual~The description of this group, the control group, corresponds to the treatment to receive the usual treatment that is received on a regular basis, we will not perform any additional intervention"
89156577|NCT02668484|Experimental|repositionable valve prosthesis|Lotus
89156578|NCT02668484|Active Comparator|balloon-expandable valve prosthesis|Sapien
89156579|NCT02633280||COPD-Untreated (Group 1)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that did not receive COPD treatment in the last 6 months (beta 2 agonists, corticosteroids, anticholinergics).
89156580|NCT02633280||COPD-uncontrolled (Group 2)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that receive a COPD treatment (e.g. beta 2 agonists, corticosteroids, anticholinergics) but with a post-bronchodilator FEV1< 80% and an FEV1/FVC < 0.7 or with 1-2 exacerbation/year
89156581|NCT02633280||Control subjects (Group 3)|In this Group will be enrolled patients of both sex and older than 40 years; (2) will be free from lung disease as determined by a physician; (3) will have a normal spirometry (FEV1> 85% and FEV1/FVC > 0.7)
89156582|NCT00961363|Experimental|Sitagliptin|Sitagliptin
89156583|NCT00961363|Placebo Comparator|Placebo|Placebo
89156584|NCT02668328|Experimental|Behavioral Intervention|The proposed study involves a 2-phase randomized clinical trial in adults with recently diagnosed T2D. Participants will be randomized to a wait-list Control group, BI, or Tailored-BI. In Phase 1, wait-list Control participants will receive 6 months of standard care; BI and Tailored-BI participants will receive 6 months of Active Intervention. In Phase 2, wait-list Control group participants will cross-over to the delayed Tailored-BI, and the BI and Tailored-BI participants will enter a 6-month observation phase to examine maintenance effects of the intervention.
89156585|NCT02633202|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone: Patients receive intensity modulated-radiotherapy (IMRT) alone
89156586|NCT02633202|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
89156587|NCT04926415|Experimental|Normal Weight|This arm consists of study participants with a body mass index (BMI) of less than 25. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
89156588|NCT04926415|Experimental|Overweight|This arm consists of study participants with a body mass index (BMI) of more than 25 but less than 30. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
89156589|NCT04926415|Experimental|Obese|This arm consists of study participants with a body mass index (BMI) of more than 30. These study participants will participate on two study days. On one study day non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) and on the other study day a sham procedure will be performed. Capillary blood samples (finger prick) will be obtained before and after the interventions on both study days. The ECG will be recorded before, during, and after the intervention on both study days.
89156590|NCT02669420|Experimental|extra amniotic misoprostol|misoprostol dissolved in warm saline , become dissolute misoprostol saline solution(200 microgram every 4 hours)
89156591|NCT02669420|Experimental|vaginal misoprostol|misoprostol tablet soaked with distilled water and inserted in the posterior fornix of the vagina( 200 microgram every 4 hours)
89156592|NCT02791841|Experimental|RRT|Rhythmic Reading Training, administered for 13 hours over 9 days (two 45-minute training sessions per day).
89156593|NCT02791841|Experimental|VHSS+AVG|Visual Hemispheric-Specific Stimulation + Action Video Games, administered for 13 hours over 9 days (two 45-minute training sessions per day).
89156594|NCT02791841|Experimental|AVG|Action Video Games only, administered for 13 hours over 9 days (two 45-minute training sessions per day).
89156595|NCT00645242|Experimental|Arm A|
89156596|NCT02786459|Experimental|Post Radical Prostatectomy|"Up to n=30 evaluable male patients, between ages 30-75, who were previously diagnosed with PCa, have undergone a RP at least 6 months before imaging and who experience rising PSA (biochemical failure). The RP group (n=30) will be stratified into PSA subgroups <0.005, 0.005-<0.2, >0.2.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI."
89156597|NCT02786459|Active Comparator|Active Surveillance|"Up to n=10 men, between ages 30-75, on active surveillance with known prostate adenocarcinoma diagnosis and multiple positive biopsies.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
89156598|NCT02786459|Experimental|Multiple Negative Biopsies|"Up to n=20 men, between ages 30-75, who have previously undergone one/or multiple negative biopsies, with elevated PSA (≥4 ng/mL) and/or an abnormal digital rectal exam suspicious for prostate cancer with a planned sextant prostate biopsy but who do not have a definitive PCa diagnosis.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
89156599|NCT00966511||Lung resection candidates|Study participants will be patients who are candidates for lung resection (lobectomy or greater)
89156600|NCT02786693||FUO and SII patients|Patients with fever > 38,3°C for more than a week, OR CRP> 5mg/L, without diagnosis after a first step clinical examination and paraclinical exams.
89156601|NCT02669342|Active Comparator|Group A: Sharklet Catheter for 2 weeks first|"Arm A will have catheters inserted according to the schedule below:~Sharklet catheter inserted for 2 weeks~Standard catheter inserted for 2 weeks~Sharklet catheter inserted for 4 weeks~Standard catheter inserted for 4 weeks"
89156602|NCT02669342|Active Comparator|Group B: Sharklet Catheter for 4 weeks first|"Arm B will have catheters inserted according to the schedule below:~Sharklet catheter inserted for 4 weeks~Standard catheter inserted for 4 weeks~Sharklet catheter inserted for 2 weeks~Standard catheter inserted for 2 weeks"
89156603|NCT00961597|Experimental|Meniscus repair with PRP|Meniscus repair for tears extending into the red/white region with PRP
89156604|NCT00961597|Active Comparator|Meniscus repair without PRP|
89156605|NCT02637180||patients with low-energy fracture(s)|"The study will include patients from pre-defined groups of individuals (postmenopausal, perimenopausal, male, and steroid induced osteoporosis) who would be anyway eligible to receive treatment for their condition according to standard medical practice and Greek treatment guidelines.~Drug: anti-osteoporotic medication (bisphosphonates, denosumab, strontium ranelate, teriparatide, SERMs)"
89156606|NCT02791529|Active Comparator|Scalpel|Skin incision performed by scalpel
89156607|NCT02791529|Experimental|Electrocautery|Skin incision performed by electrocautery
89156608|NCT00961753|Experimental|Optimized Ibuprofen|
89156609|NCT00961753|Active Comparator|Standard Ibuprofen|
89156610|NCT02670980|Experimental|Retina Implant|Intelligent Retinal Implant System
89156611|NCT04232813|Active Comparator|Estradiol 10 micrograms vaginal tablets|One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
89156612|NCT04232813|Active Comparator|Promestriene 10mg./g vaginal cream|One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response.
89156613|NCT00966589|Sham Comparator|conservative treatment|physiotherapy
89156614|NCT00966589|Active Comparator|surgery|laparoscopic hernioplasty (TEP)
89156615|NCT02668406||Burkholderia pseudomallei|Patients for whom blood cultures grew Burkholderia pseudomallei
89156616|NCT02668406||No pathogen|Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis
89156617|NCT02668406||Another pathogen|Patients for whom blood cultures grew another pathogen
89156618|NCT02791295|Experimental|Diet and physical activity program|Diet and physical activity program with individual coaching
89156619|NCT02791295|No Intervention|control|standard care
89156620|NCT00659958|Experimental|1|
89156621|NCT00644774|Active Comparator|1|
89156622|NCT00644774|Active Comparator|2|
89156623|NCT02791217||Diffused Large B cell Lymphoma|
89156624|NCT02791217||Follicular Lymphoma|
89156625|NCT02791217||Multiple Myeloma|
89156626|NCT02791217||Hodgkin Lymphoma|
89156627|NCT02791217||Healthy individuals|
89156628|NCT00545779|Experimental|Ibandronate|Participants completed Candidate Identification Questionnaire (CIQ) in Part A and received Ibandronate 150 milligram (mg) tablet orally once-monthly up to 6 months in Part B of the study.
89156629|NCT02791451|Experimental|Telemonitoring|Exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep.
89156630|NCT00910442|Experimental|Patient Group|Dietary supplement:N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
89156631|NCT00910442|Active Comparator|Control Group|Healthy HIV negative subjects submitted to the same dietary supplement than experimental group: N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
89156632|NCT00660036|Experimental|Gemtuzumab ozogamicin/Mitoxantrone/Etoposide|
89156633|NCT02791373|Active Comparator|Mobilisation Chemotherapy: Vinorelbine|Vinorelbine is given at a standard dose of 35mg/m2 i.v. at day 1 as an infusion over 10 minutes, on an ambulatory basis.
89156634|NCT02791373|Experimental|Mobilisation Chemotherapy: Gemcitabine|Gemcitabine is given at the standard dose of 1250 mg/m2 i.v. in 500ml NaCl 0.9% (sodium chloride) as an infusion over 30 minutes, on an ambulatory basis.
89156635|NCT02669108|Other|PET/MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
89156636|NCT00967681|Experimental|A|Oncoxin, a nutritional supplement
89156637|NCT00967681|Placebo Comparator|B|
89156638|NCT02537132|Experimental|Home Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at home
89156639|NCT02537132|Active Comparator|Outpatient Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at the outpatient clinic
89156640|NCT02787707|Active Comparator|intervention|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour from 24 hour before to fifth day after chemotherapy.
89156641|NCT02787707|Placebo Comparator|control|2.7 grams Lactose every 8 hour from 24 hour before to fifth day after chemotherapy.
89156642|NCT04160754|Experimental|MBRP|The experimental group will receive treatment as usual plus eight Mindfulness based relapse prevention (MBRP) therapy sessions.
89156643|NCT04160754|Active Comparator|Control (CTL)|The CTL group will receive treatment as usual plus information on the neurobiology of addiction and healthy behaviors.
89156644|NCT00966667||cancer survivor|cancer survivor
89156645|NCT03102047|Experimental|durvalumab|IV infusion once every 2 weeks for 4 total doses
89156646|NCT00966745|Active Comparator|milrinone|milrinone infusion
89156647|NCT00966745|Placebo Comparator|placebo|
89156648|NCT02633436||cancer tissues|SLC1A5 expression of esophageal cancer tissues from patients
89156649|NCT02633436||paired adjacent tissues|SLC1A5 expression of paired adjacent esophageal tissues from patients
89156650|NCT00967759|Experimental|Decongex Plus|
89156651|NCT00967759|Active Comparator|Bronpheniramine isolated|
89156652|NCT00967759|Active Comparator|Fenilefrine isolated|
89156653|NCT02669030|Experimental|Suvorexant|suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment
89156654|NCT02669030|Placebo Comparator|Placebo|no augmentation of FDA-approved antidepressant treatment
89156655|NCT02791139||Control|Healthy Volunteers will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Hand-Grip Strength Measurement Body Fat Mass Analysis
89156656|NCT02791139||Ageing|"Ageing cohort will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Body Fat Mass Analysis"
89156657|NCT02668796|Experimental|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
89156658|NCT02668796|Active Comparator|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
89156659|NCT02668796|Placebo Comparator|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
89156660|NCT02791061||Control|"Healthy Volunteers will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
89156661|NCT02791061||Congenital Disease|"Patients will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
89156662|NCT02668718|Other|Adjuvant radiotherapy|Patients who were randomized to adjuvant radiotherapy following radical prostatectomy
89156663|NCT02668718|No Intervention|Watchful waiting|Patients who were randomized to watchful waiting following radical prostatectomy
89156664|NCT04175366|Experimental|Shared Decision Making|Intervention with Shared Decision Making procedure regarding decision on planning of care and treatment before discharge.
89156665|NCT04175366|No Intervention|Care as usual|Discharge planning as usual.
89156666|NCT04198103|Experimental|SoracteLite|Transperineal Focal Laser Ablation (TPLA)
89156667|NCT00597714|Experimental|Cohort A - Lymphoid Disease|Group A: Patients with a high chance of progressive lymphoid or myelomatous disease undergo Non-myeloablative Stem Cell Transplantation.
89156668|NCT00597714|Experimental|Cohort B - Myeloid Disease|Group B: Patients with a high chance of progressive myeloid diseases, marrow failure syndromes or myeloproliferative disorders undergo Non-myeloablative Stem Cell Transplantation.
89156669|NCT00597714|No Intervention|Donor|Donor priming and apheresis will include filgrastim 8 mcg/kg subcutaneously twice daily for 4 days prior to stem cell collection and continuing until pheresis is completed. Alternative mobilization strategies may be employed at the investigator's discretion.
89156670|NCT00645320|Experimental|A|
89156671|NCT02790827|Experimental|CETA|Participants in the experimental arm will receive the CETA intervention. The intervention period will last for approximately 4 months with weekly sessions. There will be separate groups for men, women, and children. Each group will have approximately six participants. Individuals who cannot attend group therapy (e.g., conflicting work schedules) may be offered the therapy individually.
89156672|NCT02790827|Active Comparator|Treatment as usual|There is no standard of care for domestic violence or alcohol use problems in Zambia. We will track any treatment or care that families receive during the course of the study. The active comparator arm will not receive any formal services provided by the study.
89156673|NCT04017312|Active Comparator|HFCWO group|Subjects in this arm of treatment will use The Vest® as their primary airway clearance modality for the duration of the study.
89156674|NCT04017312|Active Comparator|OPEP group|Subjects in this arm of treatment will use the Acapella® as their primary airway clearance modality for the duration of the study.
89156675|NCT02787629|Experimental|Simultaneous|Simultaneous Intubation with GlideScope and ETT inserted simultaneously
89156676|NCT02787629|Active Comparator|Control Standard|Standard Intubation with GlideScope inserted first and ETT inserted after the GlideScope view is obtained
89156677|NCT02667860|Experimental|Intracorporeal anastomosis|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
89156678|NCT02667860|Active Comparator|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Rel Stapler
89156679|NCT03938857|Placebo Comparator|Fen. SOC+saline placebo (bolus+infusion)|Fentanyl standard of care (SOC) titrated to sedation + saline placebo (bolus + infusion)
89156680|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2mcg/kg/hr infusion)
89156681|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .5mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion)
89156682|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion)
89156683|NCT04163562|Experimental|INP20 (Oral Immunotherapy)|
89156684|NCT04163562|Placebo Comparator|Placebo|
89156685|NCT00644852||001|
89156686|NCT04032600|Other|Full paracentesis|All ascites is drained
89156687|NCT04032600|Other|Fractioned paracentesis|3 Liters are drained, then the drain is clamped and the rest of the ascites is drained on the next day
89156688|NCT02667938|Experimental|Treatment 1|HCP1303 capsule 5/0.2mg + HCP1303 capsule 5/0.4mg placebo+ HGP1201 placebo
89156689|NCT02667938|Experimental|Treatment 2|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg + HGP1201 placebo
89156690|NCT02667938|Active Comparator|Active Comparator|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg placebo+ HGP1201
89156691|NCT04160598|Placebo Comparator|Placebo group|bolus 50 ml nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
89156692|NCT04160598|Experimental|IV Mg ++ group|continuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate.
89156693|NCT04174430||mild to moderate bronchiolitis|Bronchiolistis patients without Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks, Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency and Neurologic disease
89156694|NCT02633124|Experimental|Edelvaiss Multiline NEO|The Edelvaiss Multiline NEO design allows to position the access to the infusion line outside of the incubator, without increasing the residual volume and this device has been validated by the manufacturer as part of CE marking for a period of 21 days.
89156695|NCT02633124|Other|Standard Infusion Set|The infusion set used for the standard group is the infusion set usually used.
89156696|NCT00967837|Experimental|Diabetes with non healing wounds|To determine and monitor progress of diabetic patients with non healing wounds that have failed conventional 60 day treatment respond to pulsatile intravenous insulin therapy in improving and completing healing in non healing wounds
89156697|NCT02668016|Experimental|Atorvastatin 20mg Daily|Atorvastatin 20mg daily for 1 month
89156698|NCT02668016|Placebo Comparator|Placebo|Placebo daily for 1 month
89156699|NCT02668016|No Intervention|No Treatment|No Atorvastatin or placebo for 1 month
89156700|NCT00966901|Experimental|Three Treatment Sites UV Exposed|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
89156701|NCT04157868|Experimental|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
89156702|NCT04157868|Placebo Comparator|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour after randomization.
89156703|NCT02668172|Experimental|Pasireotide LAR 60 mg monotherapy week 12|"After enrollment, acromegaly patients on combination treatment will half their regular weekly dose of pegvisomant (PEGV) for 12 weeks (run-in period).~When insuline-like growth factor 1 (IGF-I) remains within the age adjusted normal limits after 12 weeks, PEGV and the LA-SSA (Octreotide Long Acting Release (LAR) or Lanreotide Autogel) with Pegvisomant (PEGV) are discontinued and patients are switched to pasireotide LAR 60 mg for 12 weeks."
89156704|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 12|When IGF-I rises above the adjusted normal limits after 12 weeks (run-in period), these subjects will switch their LA-SSA to Pasireotide LAR 60 mg every 4 weeks and continue with the reduced PEGV dose of the run-in period, for the remaining 12 weeks.
89156705|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 24|"Between week 12 and 24 dose adaptations of PEGV are not permitted unless IGF-I drops below the age adjusted normal limits, then the dose of PEGV will be decreased stepwise with 20 mg weekly until IGF-I is within the age adjusted normal limits.~At week 24, efficacy will be assessed, as the number of patients with a normal IGF-I in the two different groups; the combination Pasireotide LAR 60 mg / PEG V dose and monotherapy Pasireotide LAR 60 mg.~From week 24 patients will continue with Pasireotide LAR 60 mg monotherapy, or Pasireotide LAR will be combined with 50% of the original dose of PEGV, or with an increasing dose of PEGV every 8 weeks depending on the treatment arm."
89156706|NCT02790749|Experimental|PAO with adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) with adjunctive hip arthroscopy.
89156707|NCT02790749|Active Comparator|PAO WITHOUT adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) WITHOUT adjunctive hip arthroscopy.
89156708|NCT04175132|Experimental|Healthy subjects|
89156709|NCT04175132|Experimental|PD patients|
89156710|NCT04157946||Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
89156711|NCT04157946||Non-Focal|ARDS was classified according to the pattern that adopted the loss of aeration in the chest CT in the two groups: focal (predominant commitment in the dependant region) and non- focal (patched or diffused involvement of the entire lung)
89156712|NCT04805047|Experimental|Intervention:education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
89156713|NCT04805047|No Intervention|control|regular care
89156714|NCT04175288|Experimental|Ultrasound, manual therapy and exercise|This group will receive Ultrasound, manual therapy and exercise
89156715|NCT04175288|Active Comparator|manual therapy and exercise|This group will receive manual therapy and exercise
89156716|NCT00660270|Experimental|Arm 1|"Surgery (pancreaticoduodenectomy, either standard or pylorus-preserving, with either standard or extended lymph node dissection, with or without portal vein resection) should occur at 8 weeks (plus or minus 2, not to exceed 10)~Radiation therapy will occur 8 weeks (plus or minus 2, not to exceed 10) postoperatively. Daily dose of 1.8 Gy five days per week. The first 45 Gy will be given to planning target volume 1. After 45 Gy, portals will be reduced to encompass planning target volume 2. The boost dose will be 5.4 Gy.~Cisplatin IV 25 mg/m2 on days 1, 8, 15, 22, 29, and 36 during radiation.~5-FU CIVI at 175 mg/m2/d on days 1-38 without interruption during radiation.~Alpha-interferon SQ 3,000,000 units on Mondays, Wednesdays, and Fridays during radiation therapy.~Gemcitabine IV 1000 mg/m2 4 weeks after conclusion of radiation (on a 3 weeks on/1 week off schedule) on days 71, 78, 85, 99, 106, and 113."
89156717|NCT02790593|Experimental|Juxta-Cures™|Patients randomised to the Juxta-Cures™ device. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
89156718|NCT02790593|Active Comparator|Standard compression|Patients randomised to standard compression. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
89156719|NCT02666924|Experimental|Cooking class|The addition of diabetes cooking educational classes to standard diabetes education classes. Cooking classes are a series of four, four-hour sessions. These cooking classes will be led by a registered dietitian, a registered nurse and a chinese chef. Conducted in Mandarin or Cantonese. The cooking education focus is culturally specific teaching for Chinese-Canadian persons living with diabetes.
89156720|NCT02666924|Active Comparator|Control|Type 2 diabetes educational classes, consisting of two sessions, one week apart, four-hour classes. These classes are taught by a registered dietitian and nurse, in Mandarin or Cantonese.
89156721|NCT00967915|Experimental|Frenotomy|Group of neonates that will receive frenotomy for tongue-tie
89156722|NCT00967915|Sham Comparator|No frenotomy|Group of infants that will undergo sham procedure (no frenotomy performed)
89156723|NCT04032132|Experimental|curcumin paste in conjunction with open flap debridement surge|curcumin paste (2% circumin) in conjunction with open flap debridement surgery
89156724|NCT04032132|Placebo Comparator|open flap debridement surgery only|surgical treatment for periodontal pocket
89156725|NCT02668250|Experimental|Experimental group : OPTI-AGED|The OPTI-AGED group will receive a combined optimization strategy of anesthesia concerning hemodynamic, ventilation, and depth of anesthesia.
89156726|NCT02668250|Active Comparator|Control Group :|The control group will not benefit from the OPTI-AGED intervention but patients will receive the usual care.
89156727|NCT00967057|Experimental|Arm I (induction therapy)|Patients receive idarubicin IV over 1 hour on days 1 and 2; oral dexamethasone twice daily on days 1-5 and 15-19; intrathecal (IT) methotrexate on days 1 and 8; vincristine sulfate IV on days 3, 10, 17, and 24; and pegaspargase intramuscularly (IM) on days 3 and 17 or asparaginase IM on days 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25.
89156728|NCT00967057|Experimental|Arm II (induction therapy)|Patients receive mitoxantrone IV over 1 hour on days 1 and 2. Patients also receive dexamethasone, methotrexate, vincristine sulfate, and pegaspargase or asparaginase as in arm I.
89156729|NCT02633514|Experimental|Radiochemotherapy|adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)
89156730|NCT02633514|Sham Comparator|radiotherapy|adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)
89156731|NCT00656214|Active Comparator|A|Patients with symptomatic oral lichen planus
89156732|NCT00656214|Placebo Comparator|B|Patients with symptomatic oral lichen planus
89156733|NCT00968305||Children with asthma|African American children with clinically diagnosed stable asthma
89156734|NCT02790671|Experimental|single study arm|DS-8500a and itraconazole
89156735|NCT02668094|Active Comparator|Group L|Lidocaine 40mg was given intravenously before injection of propofol
89156736|NCT02668094|Active Comparator|Group LP|Pregabalin 75 mg was given orally 2 hour before surgery
89156737|NCT02668094|Active Comparator|Group HP|Pregabalin 150 mg was given orally 2 hour before surgery
89156738|NCT02785523|Experimental|G. SPORE LIPIDS|"Form: Capsule Dosage and frequency: This group receives ganoderma spore lipids capsules 600mg TID in addition to the chemotherapy.~Duration: 6 chemotherapy cycles."
89156739|NCT02785523|Placebo Comparator|Placebo|"Form: Capsule Dosage and frequency: This group receives placebo capsules 600mg TID in addition to the chemotherapy.~Duration: 6 chemotherapy cycles."
89156740|NCT00967135|Experimental|Pregabalin|Study subjects will be randomized to receive on the morning of surgery, at least 30 minutes before induction, a 150 mg oral dose of pregabalin. Patients will then receive a 150 mg oral dose of pregabalin on the evening of the surgery. Subsequently, patients will receive a 150 mg oral dose of pregabalin twice daily on the following four postoperative days.
89156741|NCT00967135|Placebo Comparator|Placebo|Study subjects will be randomized to receive a matching placebo on the morning of surgery, at least 30 minutes before induction. Patients will then receive a placebo on the evening of the surgery. Subsequently, patients will receive a placebo twice daily on the following four postoperative days.
89156742|NCT02632968|Active Comparator|Pinhole surgery with orthodontic buttons|Pinhole surgery with orthodontic buttons The selected participants were assigned in test and control. In the test group orthodontic buttons were cemented on the bid-buccal region of the crown with dual cure GIC. After administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions. The sling sutures 5-0 mersilk were placed to hold the tunnel in an advanced location using orthodontic buttons as anchoring units. Inter-dental sutures with 6-0 mersilk were also placed for stabilization of the advanced gingival tissue.
89156743|NCT02632968|Active Comparator|Pinhole surgery without buttons|Pinhole surgery without orthodontic buttons The selected participants were assigned in test and control. In the control group, after administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions till the recession defects were covered. No sutures or orthodontic buttons were used in the control site.
89156744|NCT00967213|Experimental|Ranibizumab|three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
89156745|NCT04160676|Active Comparator|Group I|"The patients in this group will be managed only according to the surviving sepsis campaign 2016 and the surviving sepsis campaign bundle 2018 update.~The patients will receive 50 ml normal saline I.V within 30 mins / 6 h, 10 ml normal saline I.V / 6 h, 5 ml normal saline I.V / 12 h."
89156746|NCT04160676|Experimental|Group II|The patients will receive the conventional therapy of sepsis and combined therapy of hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml normal saline IV / 6 h, ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5 gm diluted in 50 ml normal saline IV within 30 min /6 h , and thiamine (Vitamin B1-injektopas®, Ampoule, Germany, 100 mg / 2 ml) 200 mg diluted in 10 ml normal saline IV /12 h This combined therapy will be given for 4 days or to the time of discharge if the admission period is less than 4 days
89156747|NCT04175054|Active Comparator|Low Intensity Group|Less than 40% Heart Rate Reserve
89156748|NCT04175054|Experimental|Vigorous Intensity Group|More than 60% Heart Rate Reserve
89156749|NCT02786225|Experimental|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a Vanderbilt University Medical Center (VUMC) perinatologist and a Vanderbilt University School of Nursing (VUSN) nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
89156750|NCT02786225|Active Comparator|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
89156751|NCT00660426|Experimental|Dose Level 1 (starting level)|"Oxaliplatin 85 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
89156752|NCT00660426|Experimental|Dose Level 2|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
89156753|NCT00660426|Experimental|Dose Level 3|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
89156754|NCT00660426|Experimental|Dose Level 4|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 1000 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
89156755|NCT00645398|Experimental|A|
89156756|NCT00645398|Experimental|B|
89156757|NCT00645398|Experimental|C|
89156758|NCT00645398|Placebo Comparator|D|
89156759|NCT02786303|Other|arm whole-body MRI|
89156760|NCT04197791|Experimental|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular Electrical Stimulation will be applied to 18 patients with idiopathic pulmonary fibrosis. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
89156761|NCT04197791|Experimental|Core Stabilization Exercises|Core stabilization exercises will be applied to 18 patients with idiopathic pulmonary fibrosis. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
89156762|NCT00884832|Experimental|Oral Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
89156763|NCT00884832|Placebo Comparator|Oral Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
89156764|NCT05299645|Experimental|Arm 1 - Transvestites and young transsexual women|Qualitative interviews
89156765|NCT02665130|Active Comparator|Tai-Chi group|Tai-Chi exercise plus Indacaterol 150ug/day
89156766|NCT02665130|Placebo Comparator|Pulmonary rehabilitation group|Conventional exercise plus Indacaterol 150ug/day
89156767|NCT04232345|Experimental|Cohort 1 (Part 1): AZD4831 Dose 1|Randomized subjects will receive oral suspension of AZD4831 Dose 1 once daily in the morning for a period of 10 days
89156768|NCT04232345|Experimental|Cohort 2 (Part 1): AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
89156769|NCT04232345|Experimental|Cohort 3 (Part 1): AZD4831 Dose 3|Randomized subjects will receive oral suspension of AZD4831 Dose 3 once daily in the morning for a period of 10 days.
89156770|NCT04232345|Experimental|Cohort 4 (Part 2): AZD4831 Dose 2|Randomized subjects will receive oral suspension of AZD4831 Dose 2 once daily in the morning for a period of 10 days.
89156771|NCT04232345|Experimental|Placebo (Part 1)|Randomized subjects will receive oral suspension of placebo once daily in the morning for a period of 10 days.
89156772|NCT04232345|Experimental|Placebo (Part 2)|Randomized subjects will receive oral suspension of placebo once daily in the morning for a period of 10 days.
89156773|NCT00646724|Experimental|1|cotransplantation of islet and mesenchymal stem cell
89156774|NCT00967525|Experimental|1|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
89156775|NCT04157712|Experimental|Cohort A Capsule - Fasted|ALZ-801 171 mg or matching placebo once daily Day 1, ALZ-801 171 mg or matching placebo twice daily Days 2-7, ALZ-801 256.5 mg or matching placebo once daily Days 8-14
89156776|NCT04157712|Experimental|Cohort B Capsule - Fasted|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 or matching placebo mg twice daily Days 2-7, ALZ-801 340 mg or matching placebo once daily Days 8-14
89156777|NCT04157712|Experimental|Cohort C Capsule - Fed|ALZ-801 256.5 mg or matching placebo once daily Day 1, ALZ-801 256.5 mg or matching placebo twice daily Days 2-7, ALZ-801 340 mg or matching placebo twice daily Days 8-13, ALZ-801 340 mg or matching placebo once daily Day 14
89156778|NCT04157712|Experimental|Cohort D Tablet - Fed|ALZ-801 265 mg or matching placebo once daily Day 1, ALZ-801 265 mg or matching placebo twice daily Days 2-6, ALZ-801 265 mg or matching placebo once daily Day 7
89156779|NCT00646802|Active Comparator|A|Progesterone 200 mg
89156780|NCT00646802|Placebo Comparator|B|Placebo
89156781|NCT00968383|Active Comparator|Optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification
89156782|NCT00968383|Experimental|PCI with optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification plus percutaneous coronary intervention and coronary stenting
89156783|NCT00657228|Placebo Comparator|2|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) plus an equal volume bolus of normal saline after the first doses are administered.
89156784|NCT00657228|Experimental|1|Standard therapy plus a one-time bolus of heparin at 80 U/kg (maximum dose of 10,000 Units) given immediately after the first doses of standard treatment.
89156785|NCT02666534|Experimental|AFL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
89234985|NCT05729607|Active Comparator|Connective tissue graft|Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized
89156786|NCT02666534|Active Comparator|MAL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
89156787|NCT02787473|Experimental|pemetrexed+carboplatin/cisplatin+radiation therapy->docetaxel|Patients received pemetrexed 500mg/m2 days 1,29+cisplatin 25 mg/m2 days 1-3,29-31 + Radiation 6000 cGy (200 cGy/day). Patients with complete response(CR), partial response(PR) or stable disease(SD) with manageable toxicity received docetaxel 60 mg/m2 days 57,78.
89156788|NCT00657306|Experimental|1|Hydrocortisone, 50 mg/6 h per day
89156789|NCT00657306|Placebo Comparator|2|dextrose solution 5%
89156790|NCT00967603|No Intervention|observation|no therapy until progression
89156791|NCT00967603|Experimental|sunitinib|sunitinib until progression or for a maximum of 6 months
89156792|NCT02665442|Experimental|Stylet|This group will receive an Esophageal stylet; EsoSure during the ablation procedure in attempt of moving the esophagus away from the ablation site.
89156793|NCT02665442|No Intervention|Non-Stylet|This group will receive the ablation procedure without any modifications or interventions. No esophageal stylet will be used in this group.
89156794|NCT02785679|No Intervention|Exclusive breast feeding|Exclusive breast feeding
89156795|NCT02785679|No Intervention|Exclusive CMF feeding|Exclusive CMF feeding
89156796|NCT02785679|Active Comparator|Breast feeding with small amount of CMF|Breast feeding with addition (as intervention) of 20 cc of cow's milk formula (CMF) per day
89156797|NCT02785679|Active Comparator|Breast feeding with one meal of CMF|Breast feeding with addition (as intervention) of one meal per day of cow's milk formula (CMF)
89156798|NCT00657384|Experimental|acid tranexamic|acid tranexamic
89156799|NCT00657384|Placebo Comparator|2|Nacl 0.9%
89156800|NCT00973453|Other|Slow regimen|
89156801|NCT00973453|Other|Intermediate regimen|
89156802|NCT00973453|Other|Fast regimen|
89156803|NCT00646880|Active Comparator|Propiverine/tolterodine group|
89156804|NCT00646880|Active Comparator|Tolerodine/propiverine group|
89156805|NCT04232111|Sham Comparator|Thermoneutral|Neither heat nor vacuum applied to hand
89156806|NCT04232111|Experimental|Heat and Vacuum|Heat and vacuum applied to hand
89156807|NCT04232111|Experimental|Heat only|Only heat applied to hand
89156808|NCT04163250||Patients with ACS undergoing cardiac catheterization|"Adults with moderate / high risk acute coronary syndrome undergoing coronary intervention.~The sample will be selected consecutively, including patients admitted to the Cardiac Coronary Unit and who require a radiological test with intra-arterial IC administration, for diagnostic or diagnostic / therapeutic purposes"
89156809|NCT04033016|Experimental|Facebook and motivational interviewing group|Women from this group were included in social media intervention and in two sessions of motivational interviewing.
89156810|NCT04033016|Experimental|Facebook only group|Women from this group were included in the social media intervention only.
89156811|NCT04033016|No Intervention|control group|women from this group only received the information on the benefits of physical activity during pregnancy.
89156812|NCT02787395|Experimental|Milch|modified Milch technique for self reduction
89156813|NCT02787395|Experimental|Boss Holtzach|Boss Holtzach technique for self reduction
89156814|NCT02787395|Experimental|Stimson|Stimson technique for self reduction
89156815|NCT04157244|Experimental|Experimental: Tailored Music|4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet.
89156816|NCT04157244|No Intervention|4-week Wait-list control|4-week wait-list control (Note: participants will be crossed over to 4-week tailored music listening intervention delivered to persons with dementia and their caregivers via a tablet)
89156817|NCT00973531|Other|Ambulatory APAP and SMT|Subjects placed on the APAP machine
89156818|NCT00973531|Other|Titration Polysomnogram with CPAP and SMT|Subjects placed on CPAP machine
89156819|NCT02786069|Experimental|Single arm|
89156820|NCT00910598|Experimental|glatiramer acetate|glatiramer acetate 20 mg s.c. daily for 1 year
89156821|NCT00910598|No Intervention|no treatment|No disease modifying treatment allowed
89156822|NCT04156932|Active Comparator|OUC|Origin uterine artery closure
89156823|NCT04156932|Active Comparator|IUC|Cervical-isthmic uterine artery closure
89156824|NCT00968461|Experimental|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
89156825|NCT03564041|Experimental|Sahaj Samadhi Meditation (SSM)|SSM will be taught to participants over 4 consecutive days, for 2 hours each day. Participants will initially learn about the nature of meditation and will be taken through a guided meditation. Afterwards, participants will undergo training which includes understanding the nature of the mind and the thoughts arising from it, guided meditation by the instructor, and a discussion of what is correct and incorrect meditation. Follow-ups will be conducted once every week for the following 11 weeks, each including guided meditation. Participants will be encouraged to practice the meditation at home for 20 minutes per session and will be given weekly practice logs to complete.
89156826|NCT03564041|Other|Health Enhancement Program (HEP)|"Arm type: Active control group~HEP controls for several non-specific factors found in a meditation group such as Sahaj Samadhi, including: group support and morale, behavioral activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP has been tailored to be structurally equivalent to a SSM intervention, with similar-sized groups, meeting for 4 days for 2 hours, and then a one-hour follow up session weekly for the subsequent 11 weeks, and completing the same amount of home practice (20 minutes twice daily, every day), and will be asked to complete weekly practice logs."
89156827|NCT00647114|Experimental|1|V930
89156828|NCT00647114|Experimental|2|V932
89156829|NCT00968695|Experimental|Albumin|The subjects will be receiving albumin 20% infusions
89156830|NCT04157010|Experimental|TCZ monotherapy|Tocilizumab (TCZ) monotherapy 8mg/kg 4-weekly for a total of 48 weeks.
89156831|NCT04157010|Experimental|TCZ+MTX combination therapy|Tocilizumab (TCZ) and methotrexate (MTX) combination therapy 8mg/kg 4-weekly for a total of 48 weeks.
89234986|NCT05729607|Experimental|Dermal matrix + EMD|Acellular dermal matrix and enamel matrix derivative
89156832|NCT02785211|Experimental|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
89156833|NCT02785211|Placebo Comparator|control group|"For the control group, participants will receive regular physical examinations and education by village doctors weekly during the 8 week intervention.The weekly visits for every old people whose age above 65 by country doctors are not arranged by our study, it is the country doctors routine work by government health policy. This study was permitted by the local community health center, the director with specific responsibility will inform all country doctors to support our study."
89156834|NCT04172792|Active Comparator|high-caloric fatty diet|intake of 405 kcal (45g fat) per day in addition to normal food intake
89156835|NCT04172792|Experimental|ultra-high-caloric fatty diet|intake of 810 kcal (90g fat) per day in addition to normal food intake
89156836|NCT04172792|Experimental|ultra-high-caloric carbohydrate-rich diet|intake of 900 kcal (111.4g carbohydrate, 34.9g fat, 36.0g protein) in addition to normal food intake
89156837|NCT04172792|No Intervention|control|normal food intake (no intervention)
89156838|NCT02632032|Other|Insulin therapy and diabetes education|Children and adolescents living with type 1 diabetes already on insulin therapy received collective diabetes education during a five days camp.
89156839|NCT00973609|Active Comparator|Fluoropyrimidine + Bevacizumab|Standard therapy
89156840|NCT00973609|Experimental|Bevacizumab monotherapy|
89156841|NCT00973609|Experimental|No maintenance treatment|
89156842|NCT02786147||Patient Initiated|Patients randomized into this group will receive a standard handout explaining their result, which includes information on how to obtain cancer genetics services through Winship. However, neither the patient nor their ordering clinician will be directly contacted regarding the B-RST result.
89156843|NCT02786147||Physician Notification|Patients randomized into this group will also receive the standard handout explaining their result. In addition, their primary care physician or ordering physician will be notified via Emory Electronic Medical Record (EeMR) that the patient screened positive on the B-RST. The note will provide specific instructions on how to refer the patient for cancer genetic counseling services.
89156844|NCT02786147||Automatic Follow-Up By Genetic Counseling Staff|Patients randomized into this group will also receive the standard handout explaining their result. Within 1-2 weeks after their mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment. This call may take up to 10 - 15 minutes.
89156845|NCT02537054|Experimental|Aflibercept|2 mg/ dose (pro re nata, maximum 1 dose/ month), intravitreal use
89156846|NCT02636790|Active Comparator|Surgery wait time (< 8 weeks)|Outcomes of patients with sinus surgery of less than 8 weeks.
89156847|NCT02636790|Active Comparator|Surgery wait time (> 1 year)|Outcomes of patients with sinus surgery of more than 1 year.
89156848|NCT00973687|Placebo Comparator|10 mg/mL Unsweetened Formulation|no prior vomiting
89156849|NCT00973687|Experimental|1 mg/mL Ora Sweet Formulation|no prior vomiting
89156850|NCT00973687|Active Comparator|10 mg/mL Unsweetened with prior vomiting|with prior vomiting
89156851|NCT00973687|Experimental|1 mg/mL Ora Sweet with prior vomiting|with prior vomiting
89156852|NCT02785757|Experimental|Patients with adenocarcinoma|60 Patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy
89156853|NCT04174898|Experimental|Treatment Population|100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours
89156854|NCT05279521|Experimental|Experimental group|Mandatory exercise the lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
89156855|NCT05279521|No Intervention|Control group|Voluntary exercise the lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
89156856|NCT04157634|Experimental|Prognostication model|In a prospective cohort of children hospitalized in a PICU, development of a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
89156857|NCT00660738||01|Patients with clinical and spirometric diagnosis of COPD, with FEV1<80%
89156858|NCT02785601|Experimental|I-1|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
89156859|NCT02785601|Experimental|I-2|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times)
89156860|NCT02785601|Experimental|I-3|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;
89156861|NCT02785601|Experimental|I-4|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
89156862|NCT02667548||patients receiving PCI|patients receiving PCI
89156863|NCT02667782|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is developed by Jon Kabat-Zinn in 1979 (Kabat-Zinn, 1990). It is an eight-week Program that includes practices such as gentle mindful movement (awareness of the body), a body scan (to systematically nurture awareness of the body region by region), and sitting meditation (awareness of the breath to include the four foundations of mindfulness, namely, body, feeling tone, mental state, and mental content) (Cullen, 2011).
89156864|NCT02667782|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT), developed by Zindel Segal, Mark Williams and John Teasdale, employs a cognitive theoretical framework (Cullen, 2011; Segal, Williams, & Teasdale, 2002). It is also delivered as an eight-session group treatment. The first four sessions teach the fundamental concepts and skills of the practice of mindfulness. The remaining four sessions teach the individual how to notice his/her own thoughts and the impact of such thoughts on his/her own physical and emotional experiences.
89156865|NCT05299567|Active Comparator|azitrhomycin|Group1 Azitrhomycin 250 or 500 mg in capsuls tree days a week for 6 months if the patiens are less or more than 40 kg respectively Exposure
89156866|NCT05299567|Placebo Comparator|Placebo|Group 2 placebo Not exposure Placebo in capsuls tree days a week for 6 months
89156867|NCT02785133|Experimental|Treatment group|Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by a light emitting diode. Small adapter attaches directly to a standard 20-gauge catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the distal end of the catheter. Polychromatic light is emitted to illuminate the catheter and site of catheter entrance. Concurrently, normal saline flows through the optic adapter and through into the 20-gauge catheter.
89156868|NCT00660894|Experimental|tegafur-gimeracil-oteracil potassium|Patients receive tegafur-gimeracil-oteracil potassium(S-1) orally twice daily for 28 days with a subsequent pause of 14 days. This repeats 4 times every 6 weeks.
89156869|NCT00660894|Active Comparator|tegafur-uracil and folinate calcium|Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days. This repeats 5 times every 5 weeks.
89156870|NCT05062148|No Intervention|Standard of Care|Subjects will follow the standard of care, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
89156871|NCT05062148|Active Comparator|Float-REST|Subjects will do Flotation Restricted Environmental Stimulation Therapy, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
89156872|NCT05062148|Active Comparator|Photobiomodulation|Subjects will do photobiomodulation, complete a daily log of symptoms, wear a fitness tracker daily for the length of the study.
89156873|NCT00660972|Experimental|1|Oral RAL and FTC/TDF for 72 weeks
89156874|NCT02667470|Experimental|Solifenacin|
89156875|NCT04157556|Experimental|Group of athletes|Age: 18-35 Gender: Male Basketball, volleyball, handball players who have been training regularly for at least last 3 months.
89156876|NCT04157556|Experimental|Group of sedentary people|Age: 18-35 Gender: Male Individuals with similar physical characteristics to the group of athletes and who have not exercise regularly for at least last 3 months.
89156877|NCT02784197|Other|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
89156878|NCT04157478|Experimental|Radiation therapy, Temozolomide and anlotinib|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
89156879|NCT04157478|Active Comparator|Radiation therapy and temozolomide|Patients will receive standard radiation therapy plus temozolomide (Stupp regimen).
89156880|NCT04231175|Experimental|experimental arm A|patients will undergo dedicated MRI imaging of the pelvis, abdomen, and thorax. Based on the findings of the MRI scan patients will be allocated to one of the diagnostic/treatment options
89156881|NCT04231175|No Intervention|arm B|patients will undergo the current standard diagnostic work-up of DLS at indication (MDT decision) and otherwise continue to CRS-HIPEC.
89156882|NCT02632188|Active Comparator|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
89156883|NCT02632188|Experimental|DC-PMAT treatment|On the basis of postoperative routine treatment, patients will receive 3 cycles of dendritic cell-precision multiple antigen T (DC-PMAT) cells treatment.
89156884|NCT04184765||Total laparoscopic hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
89156885|NCT04184765||Abdominal hysterectomies|Between 2018 and 2019, data obtained from patients in the LH and AH groups were reviewed retrospectively. The preoperative and postoperative hematocrit (HCT), hemoglobin (HB), white blood cell (WBC), platelet (PLR) and neutrophil-lymphocyte (NLR) ratios and values were compared as well as the demographic characteristics of the patients.
89156886|NCT04174820||Retrospective Low-Grade Glioma|Inclusion of patients with Low-Grade Glioma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
89156887|NCT04174820||Retrospective Medulloblastoma|Inclusion of patients with Medulloblastoma treated one year ago, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
89156888|NCT04174820||Prospective patients|Inclusion of prospective patients with an indication to surgery of a Posterior Fossa Tumor, with evaluation of post-operative mutism and then one year after the end of mutism, an evaluation with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
89156889|NCT04174820||Control patients|Inclusion of patients without Posterior Fossa Tumor, with functional Magnetic Resonance Imaging, speech therapy, neuropsychological, balance and dexterity tests
89156890|NCT00661128||1|European American people who have experienced SCA.
89156891|NCT00661128||2|European American people who have not experienced SCA.
89156892|NCT00661128||3|African American people who have experienced SCA.
89156893|NCT00661128||4|African American people who have not experienced SCA.
89156894|NCT04073732||family physician team|Family physician team in four regions (Beijing, Shanghai, Hangzhou and Xia'men), including general practitioners, nurses and public health personnel.
89156895|NCT04156776|Experimental|Group A (MET)|Muscle Energy Technique Conventional Treatment
89156896|NCT04156776|Experimental|Group B (AIS)|Active Isolated Stretching Conventional Treatment
89156897|NCT00647192|Active Comparator|1|Eplerenone treatment
89156898|NCT00647192|Placebo Comparator|2|
89156899|NCT03466697|Other|Healthy subjects|All subjects will be injected twice for each visit (normal saline or glucose)
89156900|NCT02664818||Heart failure|Hospitalized patients with primary discharge diagnosis of heart failure and who were aged 18 years or older.
89156901|NCT02785367|Experimental|Cord blood samples|8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml washed with Heparin.
89156902|NCT02631720||Adult Lung Transplant Recipients|Adult lung transplant recipients undergoing lung transplant at each of the participating centers.
89156903|NCT02666300|Experimental|TaperGuard ETT|tracheal intubation with the TaperGuard ETT，the ETT cuff is Taper-shangped.
89156904|NCT00661206|Active Comparator|Clopidogrel|
89156905|NCT00661206|Placebo Comparator|Placebo|
89156906|NCT04172870||Group I|Healthy group ( No generalised periodontitis and no CAD)
89156907|NCT04172870||Group II|Generalised periodontitis patients without CAD
89156908|NCT04172870||Group III|CAD patients without generalised periodontitis
89156909|NCT04172870||Group IV|Generalised periodontitis with CAD
89156910|NCT02689739||Obese Pregnant cohort|Women will be consented to participate and then separated into a study group of obese women (BMI >/= 30).
89156911|NCT02689739||Non-obese Pregnant cohort|This will be the control group of non-obese women (BMI <30).
89156912|NCT02664896||Knee Osteoarthritis Cohort|Subjects with knee osteoarthritis will be asked to participate in the knee osteoarthritis testing session. This group will participate in 1 three hour testing session.
89156913|NCT02664896||Healthy Subject Cohort|Healthy subjects will be asked to participate in the healthy control testing session. This group will participate in 1 two hour testing session.
89156914|NCT04230629|Active Comparator|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
89156915|NCT04230629|Active Comparator|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
89156916|NCT03938545|Experimental|Regimen A-RVT-1401|Regimen A= RVT-1401 680 mg weekly for 12 weeks
89156917|NCT03938545|Experimental|Regimen B-RVT-1401|Regimen B= RVT-1401 340 mg weekly for 12 weeks
89156918|NCT03938545|Experimental|Regimen C-RVT-1401|Regimen C= RVT-1401 255 mg weekly for 12 weeks
89156919|NCT03938545|Placebo Comparator|Placebo|for 12 weeks
89156920|NCT04156542|No Intervention|Control|In this school, we collected data throughout the entire study without implementing any intervention.
89156921|NCT04156542|Experimental|5-week Intervention with Post-intervention Data Collection|In this school, we collected baseline data for 5 weeks, implemented the intervention for five weeks, then removed the intervention and collected post-intervention data for five weeks.
89156922|NCT04156542|Experimental|Implement intervention for 15 weeks|In this school, we implemented the intervention on January 11, 2016, the day the study began.
89156923|NCT04156542|Experimental|Implement intervention for 12 weeks|In this school, we collected baseline data for three weeks and then implemented the intervention for the remaining twelve weeks.
89156924|NCT04156542|Experimental|Implement intervention for 9 weeks|In this school, we collected baseline data for six weeks and then implemented the intervention for the remaining nine weeks.
89156925|NCT04156542|Experimental|Implement intervention for 6 weeks|In this school, we collected baseline data for nine weeks and then implemented the intervention for the remaining six weeks.
89156926|NCT05276960|Active Comparator|Regular supplementation|Baseline dose of 2000 IU of vitamin D3, based on Cystic Fibrosis Foundation (CFF) treatment guidelines. According to serum vitamin D levels, 2000 IU increments will be performed whenever 25-OH-VitD (25-hydroxy vitamin D) values < 30 ng/ml are found.
89156927|NCT05276960|Experimental|Enhanced Supplementation|Basal dose of 4000 IU of vitamin D3. According to serum vitamin D levels, increments of 4000 IU will be made each time 25-OH-VitD values < 30 ng/ml are found.
89156928|NCT04173884|Active Comparator|Live Surgical Peer Coaching|Coaches will facilitate an initial, individual, introductory phone call with participants prior to the first formal coaching session. The objective of this call is to develop rapport, explore each other's background, experience, and motivation for participation in the program, set overall goals for the program, set specific goals for the first coaching session, develop an action plan including identification of the key characteristics of the first case for review, and develop a timeline and plan for meetings. Peer coaching sessions will be scheduled at three national meetings that are commonly attended by ACHQC surgeons. In advance of each meeting, participants will record and upload a self-selected video to a secure server maintained by the study team, and coaches will have the opportunity to review the video if they wish to prepare. A live coaching session will be organized at the meeting where the coaches and participants will have parallel one-hour coaching sessions.
89156929|NCT04173884|Active Comparator|Asynchronous Video-based Constructive Feedback|There will be no real-time interpersonal contact between coaches and participants in this arm. Participants will upload their self-selected procedural video to the video review platform, together with a short description of the case and any specific questions. The coach will review the video within one week of its posting and provide time-stamped feedback on the video platform. Participants will then review the coach's feedback within one week with the ability to respond to the comments. The coach and participant will continue communication via the internet-based review platform until no further comments are made by either party. Coach-participant dyads are expected to review three videos during the 6 month intervention period.
89156930|NCT04173884|Active Comparator|Wait-List Control|One-third of participants will be randomized to an intervention, but wait-listed to provide a control group. These surgeons will submit two videos for technical skill evaluation during each of the baseline and follow-up periods, and ACHQC data will be tracked for short-term outcomes prior to their crossover to the intervention for long-term follow-up. Selecting the control group using the identical sampling frame of ACHQC surgeons participating in the interventions affords the opportunity for a comparable group with outcome metrics recorded systematically.
89156931|NCT00661284||Ⅰ|Subject who have participated in previous studies and achieved DAS28 of < 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
89156932|NCT02787317|Active Comparator|heparin|For the heparin group, a bolus dose of 100 U/kg was administered according to current guidelines.
89156933|NCT02787317|Experimental|not prolong infusion Bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure .
89156934|NCT02787317|Experimental|prolong infusion bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and prolong for 4 hours after procedure.
89156935|NCT04156464|Active Comparator|Phenobarbital based treatment|"The phenobarbital group will undergo management with a phenobarbital based treatment protocol with additional symptom triggered therapies.~On day 1, the phenobarbital group receive a loading dose of phenobarbital intravenous 10mg/kg (actual body weight) with a maximum dose of 1 g/100 mL~On day 2 of study protocol, and no sooner than 12 hours after loading dose, phenobarbital 64.8 mg is administered every 12 hours for two doses.~On day 3 of study protocol, patients will receive phenobarbital 32.4 mg every 12 hours for two doses.~On day 4 of study protocol, patients will receive phenobarbital 32.4 mg once, to be given 24 hours after last scheduled dose.~Throughout the 4 day protocol, the patient will have phenobarbital 65 mg every 6 hours as needed available either IM or IV, starting no sooner than 30 minutes after the loading dose."
89156936|NCT04156464|Active Comparator|Lorazepam based treatment|"The lorazepam group will undergo management with a lorazepam based treatment protocol with additional symptom triggered therapies.~On Day 1, the lorazepam group will be started on scheduled lorazepam 4 mg every 6 hours~After day 1, the scheduled lorazepam dose will be modified based on the total lorazepam requirements from the previous day and divided into 4-6 doses.~A lorazepam infusion, at physician discretion, will be available at any point if the dose of scheduled and PRN lorazepam being given is too high or frequent to effectively be administered.~Once symptoms are well controlled on lorazepam based therapy, the total dose given over the past 24 hours will be calculated and weaned by approximately 10-20% per day when clinically appropriate.~Throughout the entire protocol, 2-4 mg lorazepam IV q 30 minutes PRN will be available for a goal CIWA <6 or RASS -1 to 0."
89156937|NCT02666456||Cross-sectional cohort|Patients with chronic peripheral neuropathic pain
89156938|NCT02666456||Longitudinal cohort|Painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, Operation)
89156939|NCT00968773|Experimental|The Rebound hernia repair device with no fixation|Competent adults who have a unilateral, bilateral inguinal hernia that is primary in nature.
89156940|NCT00968773|Active Comparator|Standard Hernia Mesh using fixation|Competent adults who have a unilateral or bilateral inguinal hernia that is primary in nature.
89156941|NCT02607215|Experimental|Vinorelbine Plus DDP|"Vinorelbine:25 mg/m2, D1, D8 every 21 days~DDP:75 mg/m2, D1 every 21 days"
89156942|NCT02607215|Active Comparator|Vinorelbine|Vinorelbine:30 mg/m2, D1, D8 every 21 days
89156943|NCT04936724|Experimental|Condition A (Lesser-known harms)|Participants randomized to this condition will view cigarette warning labels highlighting lesser-known harms of tobacco use.
89156944|NCT04936724|Experimental|Condition B (Well-known harms)|Participants randomized to this condition will view cigarette warning labels highlighting the well-known harms of tobacco use.
89156945|NCT00661440|Other|1|
89156946|NCT00661440|Other|2|
89156947|NCT00973999|Experimental|Injection into salivary gland|
89156948|NCT04232579||Chronic obstructive respiratory disease|The out-patient population with chronic obstructive respiratory disease consulted at Nguyen Tri Phuong Hospital, Ho Chi Minh city, Vietnam.
89156949|NCT00661518||1|Patients scheduled for conventional aneurysm repair
89156950|NCT00661518||2|Patients scheduled for endovascular aneurysm repair
89156951|NCT00968929|Experimental|r-SK group|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
89156952|NCT00968929|Active Comparator|UK group|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
89156953|NCT02785445|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated device urine cups. The urine sample was then tested sequentially; first by the Dip.io Home Based Dipstick Analyzer (first intervention) and by the ACON U500 Mission® U500 Urine Analyzer (comparative device - second intervention). Part of the participants (100 out of 302) were asked to perform the Dip.io urine test by themselves for the user performance evaluation.
89156954|NCT04918940|Experimental|Post-vaccination immunity|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
89156955|NCT00661596|Experimental|Arm 1|
89156956|NCT00661596|Placebo Comparator|Arm 2|
89156957|NCT00969007|Experimental|Lifestyle counseling|
89156958|NCT05008562||COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|"Patients over the age of 18 who are hospitalized in our intensive care unit with a diagnosis of COVID-19 will be included in the study.~The day the patients are admitted to the intensive care unit will be considered the 1st day of the study. SOFA, qSOFA, APACHE II, CRP, procalcitonin values will be recorded on the first day. On the first day of our patients, rectus femoris muscle thickness measurement will be done ultrasonographically (bilateral). In addition, bilateral thigh circumference will be measured anthropometrically (with a tape measure). It is planned to evaluate the muscle strength of the patients according to the MRC (Medical Research Council) scoring.~In addition to these measurements, the creatine kinase values in the routine clinical follow-up of the patients, the differences between the fluid intake and output values, inotropic supplements used in their treatment, diuretic needs, and neuromuscular blocker use will also be noted."
89156959|NCT02636634|Other|diagnostic imaging strategy|PET-FET (positron emission tomography using 1-Fluoro-Ethyl-Tyrosine) and MSR (magnetic resonance spectroscopy) before biopsy
89156960|NCT00974077|Other|Wait List Control|Patients do ot receive psychotherapy. The wait list control group will be assessed according to study protocol and offered MBCT after 6 month
89156961|NCT00974077|Experimental|Mindfulness Based Cognitive Therapy|The published protocol of MBCT will be used. This is an eight week group program. Participants learn mindfulness techniques but also cognitive techniques to prevent new depressive episodes
89156962|NCT02631642|Experimental|HMPL-689|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
89156963|NCT02631642|Placebo Comparator|HMPL-689 placebo|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
89156964|NCT00969085|Experimental|Curcumin|
89156965|NCT04157166|Other|group 1 in pair week|In pair week, patients will inclued in group1: the conventional recording followed by complementary images SPECT/CT, will be realized in first intention and the procedure of recording in camera VERITON will be recorderd in second intention
89156966|NCT04157166|Other|group 2 in odd week|in odd week, patients will inclued in group2: the procedure of recording of 25 minutes in camera VERITON-CT ™, will be realized in first intention and the procedure of conventional recording followed by complementary images SPECT/CT will be recorded in second intention
89156967|NCT00647504||1|Restenosis in Bare metal stent
89156968|NCT00647504||2|Restenosis in Drug eluting stent
89156969|NCT00647504||3|Stent thrombosis
89156970|NCT00647504||4|Control group
89156971|NCT00974155|Experimental|EMC (Early Medication Change)|
89156972|NCT00974155|Active Comparator|TAU (Therapy As Usual)|
89156973|NCT04231955|Experimental|pain rating scales|"patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10, on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end and on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
89156974|NCT02664974|Experimental|HEN group|Home Enteral Nutrition
89156975|NCT02664974|Active Comparator|Control group|Dietary Counseling
89156976|NCT00879996|Active Comparator|1|Methadone 10-60 mg per day in 2-4 divided doses for 6 months
89156977|NCT00879996|Experimental|2|Buprenorphine 4-16 mg per day in 2-4 divided doses for 6 months (using tablets of buprenorphine/naloxone:4/1 mg)
89156978|NCT00969163|Experimental|1|2.5 mg testosterone gel
89156979|NCT00969163|Experimental|2|300 ug testosterone gel
89156980|NCT00969163|Placebo Comparator|3|placebo gel
89156981|NCT02784041|Experimental|single adductor-canal-block|Patients in this group will receive ultrasound guided single adductor-canal- block with 0.35% ropivacaine 25ml.
89156982|NCT02784041|Experimental|periarticular infiltration|patients in this group will receive periarticular infiltration of local anesthetic.
89156983|NCT00873093|Experimental|Pre-B ALL Relapse<18 mths from diagnosis (chemo) age<=21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
89156984|NCT00873093|Experimental|Pre-B ALL Relapse 18-36 mths from diagnosis (chemo) age<=21 yr|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
89156985|NCT00873093|Experimental|Pre-B ALL Relapse<36 mths from diagnosis (chemo) age>21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
89156986|NCT00873093|Experimental|T-cell ALL (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
89156987|NCT00873093|Experimental|T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
89156988|NCT00661752||FBP studies|standard filtered backprojection image processing/reconstruction of full-time acquisition data
89156989|NCT00661752||half-time WBR|wide-beam reconstruction of simulated half-time acquisitions from standard full-time acquisitions
89156990|NCT00661752||Quarter-time stress|4 seconds per stop post-stress SPECT acquisitions reconstructed by the wide-beam reconstruction method
89156991|NCT00661752||Quarter-time rest|6 seconds per stop rest SPECT acquisitions reconstructed by the wide-beam reconstruction method
89156992|NCT02664662|Experimental|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
89156993|NCT02664662|No Intervention|standard education|Only provide one paper of post operation and give education of rehabilitated exercise
89156994|NCT02183987|Experimental|Active Knowledge Translation Group|CKD clinics receiving the active knowledge translation intervention.
89156995|NCT02183987|No Intervention|Passive Knowledge Translation Group|Clinics will have access to the Canadian Society of Nephrology (CSN) guidelines on the optimal timing of dialysis initiation (current practice). These guidelines have been published in the Canadian Medical Association Journal (CMAJ) and have been recently presented at the annual meeting of the Canadian Society of Nephrology.
89156996|NCT04008667|Experimental|Intervention arm|"Receiving the acupoint application and optimal supports.~The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
89156997|NCT04008667|Placebo Comparator|Placebo arm|"Receiving the fake acupoint application and optimal supports.~The fake acupoint is~The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
89156998|NCT04008667|No Intervention|Control arm|"Receiving the optimal supports.~All patients will receive optimal supports during the observation period, including preoperative gastrointestinal preparation, inserting gastric tube, postoperative fasting, necessary antibiotic use, rational fluid management, detaining drainage tube, etc."
89156999|NCT04174040|No Intervention|Control 1|Applied any intervention.
89157000|NCT04174040|Active Comparator|Control 2|Gross's Process of Emotion Regulation Model interventions applied.
89157001|NCT04174040|Active Comparator|Control 3|Musical rhythm interventions applied.
89157002|NCT04174040|Experimental|Experimental|Musical rhythm integrated Gross's Process of Emotion Regulation Model interventions applied.
89157003|NCT02785289|Experimental|Flocked|Patients will perform vaginal cell collection beginning with the flocked swab, followed by the coton swab.
89157004|NCT02785289|Experimental|Coton|Patients will perform vaginal cell collection beginning with the coton swab, followed by the flocked swab.
89157005|NCT00969319||Group 1|
89157006|NCT02784899|Experimental|iloprost group|iloprost inhalation group
89157007|NCT02784899|Placebo Comparator|control group|normal saline inhalation group
89157008|NCT00646100|Active Comparator|TACE|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization
89157009|NCT00646100|No Intervention|control|best support care
89157010|NCT00969397|Experimental|Topical Antiangiogenic|Topical Antiangiogenic Agents
89157011|NCT00969397|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
89157012|NCT00647660|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
89157013|NCT00647660|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
89157014|NCT00974467|Experimental|After The Injury website|
89157015|NCT00974467|Other|Usual care|Treatment as usual
89157016|NCT00634595|Experimental|A|E10A combined with Cisplatin and Paclitaxel
89157017|NCT00634595|Active Comparator|B|Cisplatin and Paclitaxel
89157018|NCT04899752|Experimental|Traditional OPCR|Those who are in the traditional group will discuss topics like medication adherence, physical activity questions, or eating habits without a clear from of autonomy or nonautonomy basis as is currently completed in OPCR. This will occur in a face to face format.
89157019|NCT04899752|Experimental|OPCR + MI|The MI group will be consistent with the spirit of MI and utilize a high autonomy communication style to provide support for behavior change across multiple behaviors. This will occur in a face to face format.
89157020|NCT04899752|Experimental|OPCR + Clinician centered|The OPCR + CC group will participate in low-autonomy face to face interviews. Meaning the communication style will be clinician centered, providing goals to the participants without valuing their input.
89157021|NCT00969475|No Intervention|Control|Half of each subject's wound will not be treated.
89157022|NCT00969475|Experimental|Laser resurfacing|Half of each subject's wound will be treated with a fractional CO2 laser.
89157023|NCT00647738|Experimental|1|
89157024|NCT00647738|Active Comparator|2|
89157025|NCT02783963|Other|MI with nonobstructive CAD at coronary angiography|MI with nonobstructive CAD investigated by means of OCT and CMR
89157026|NCT04008511|Experimental|Phase Ib: Regorafenib plus XELOX|"Phase Ib followed a Modified toxicity probability interval (mTPI) design to determine the maximum administered dose (MAD), there are 3 dose levels, and the dose level started from Group A:~Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX. (Regorafenib qd po for 14 days, every 3 weeks; XELOX: Oxaliplatin 130 mg/m2 IV, day 1, Capecitabine 1000 mg/m2 bid po for 14 days)"
89157027|NCT04008511|Experimental|Phase II: Regorafenib plus XELOX|Regorafenib MAD qd po for 14 days, every 3 weeks, Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
89157028|NCT04008511|Active Comparator|Phase II: XELOX|Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.
89157029|NCT02783807|Experimental|Eyenez Retinal Camera v200|Retinal images from Eyenez Retinal Camera v200 of healthy and diseased subjects
89157030|NCT02783807|Active Comparator|Volk Pictor Ret 1|Retinal images from Volk Pictor Ret 1 of healthy and diseased subjects
89157031|NCT00979537|Experimental|Test: Nisoldipine ER Tablets, 40 mg|Nisoldipine Extended-release Tablets, 40 mg
89157032|NCT00979537|Active Comparator|Reference: Sular Tablets 40 mg|Sular Tablets, 40 mg
89157033|NCT02667314|Experimental|Jigsaw Puzzle Group|Jigsaw puzzles & Cognitive health counseling
89157034|NCT02667314|Active Comparator|Cognitive Health Counseling Group|Cognitive health counseling only
89157035|NCT02783651||No treatment 1|It is planned to have 20-30 sites participating on the trial for chart review of approximately 200-235 patients initiating treatment for Philadelphia chromosome-negative (Ph-) Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) between January 2013 and March 2019.
89157036|NCT02783651||No Treatment 2|Initial record abstraction will occur at study site with subsequent reviews occurring at the site every 3 months thereafter until study conclusion on March 2020.
89157037|NCT00692055|Experimental|1|PN400
89157038|NCT00692055|Active Comparator|2|naproxen 375 mg
89157039|NCT04174976||Wall hernia repair|"All patients admitted for wall hernia repair with mesh between 28/12/2017 and 28/12/2020.~."
89157040|NCT04232501|Experimental|Cirvo Compression device post surgery|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
89157041|NCT04232501|No Intervention|Standard of Care Post Surgery|Patients receive standard-issue SCDs (pneumatic compression) and wear in surgery and after surgery until they are discharged home.
89157042|NCT02625051|Active Comparator|Ureteroscopy|Kidney stone of participants in this arm will be treated with ureteroscopy (URS). A ureteral stent will be inserted at the end of the procedure.
89157043|NCT02625051|Active Comparator|Percutaneous nephrolithotomy|Kidney stone of participants in this arm will be treated with percutaneous nephrolithotomy (PNL). A percutaneous nephrostomy tube will be inserted at the end of the procedure.
89157044|NCT04033250|Experimental|Interventional arm (group A)|"Patients with risk factors for IBP who will receive intensified bowel preparation"
89157045|NCT04033250|Active Comparator|Control arm (group B)|Patients with risk factors for IBP who will receive standard bowel preparation
89157046|NCT04033250|Active Comparator|Control arm (group c)|Patients without risk factors for IPB who will receive standard bowel preparation
89157047|NCT02624973|Experimental|A|ER/PGR>50% TP53 wt
89157048|NCT02624973|Experimental|B|ER/PGR>50% TP53 mutated
89157049|NCT02624973|Experimental|C|ER/PGR<50% TP53 wt
89157050|NCT02624973|Experimental|D|ER/PGR<50% TP53 mutated
89157051|NCT02624973|Experimental|E|HER2+ TP53 wt
89157052|NCT02624973|Experimental|F|HER2+ TP53 mutated
89157053|NCT02624973|Experimental|G|Triple negative breast cancer TP53 wt
89157054|NCT02624973|Experimental|H|Triple negative breast cancer TP53 mutated
88816437|NCT02404350|Experimental|Secukinumab 150 mg load (Group 1)|"Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks until week 100"
89157055|NCT00647816|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
89157056|NCT00647816|Active Comparator|2|Inderal® LA Capsules 160 mg
89157057|NCT04173806|Experimental|Facebook group|"Participants will be included in an online classroom through a closed group of Facebook to receive an asynchronous course of telemedicine."
89157058|NCT04173806|Active Comparator|Control group|In this group the participants are exposed to the same course of telemedicine but on the Moodle educational platform.
89157059|NCT00647894|Experimental|1|Alprazolam Extended-Release Tablets 1 mg
89157060|NCT00647894|Active Comparator|2|Xanax XR Tablets 1 mg
89157061|NCT02782559|Experimental|Sildenafil|Sildenafil 40mg oral tablet three times a day from randomization until delivery
89157062|NCT02782559|Placebo Comparator|Placebo|Matched to oral capsule of active treatment three times a day from randomization until delivery
89157063|NCT00647972|Experimental|1|Olanzapine Tablets 20 mg
89157064|NCT00647972|Active Comparator|2|Zyprexa® Tablets 20 mg
89157065|NCT02782403|Experimental|Treatment (alternating therapy)|Patients with chronic phase CML receive either bosutinib PO QD or axitinib PO BID alone for 3 months. Patients then switch to the other drug for 3 months and alternate between the two every 3 months in the absence of disease progression or unacceptable toxicity.
89157066|NCT02782403|Experimental|Treatment (combined therapy)|Patients with accelerated or blastic phase CML receive bosutinib PO QD and axitinib PO BID for 3 months. Courses repeat every 3 months in the absence of disease progression or unacceptable toxicity.
89157067|NCT00646178|Active Comparator|A|
89157068|NCT00646178|Placebo Comparator|B|
89157069|NCT02624817|Experimental|Drug: Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to glucagon have been tested.
89157070|NCT04172168||Heart rupture|Include left ventricular free-wall ruptrue after AMI
89157071|NCT04172168||Non heart rupture|AMI with non heart rupture
89157072|NCT02783417|Experimental|Training with vascular occlusion|Strength Training: intensity of 30% of 1RM, with vascular occlusion pressure in members.
89157073|NCT02783417|Experimental|Traditional strength training|Strength Training: intensity of 80% of 1RM, without vascular occlusion pressure in members
89157074|NCT02783417|No Intervention|Control|Subject untrained.
89157075|NCT00692367|Other|Exercise|Structured exercise program
89157076|NCT02664584||Cross-sectional cohort|Cohort who took part in the cross-sectional study (n=5186)
89157077|NCT02664584||Cross-sectional cohort + follow-up|Cohort who took part in both the cross-sectional and follow-up study (planned n=500 (on-going))
89157078|NCT04230863|Experimental|Neuroplasticity-based Computerized Cognitive Remediation|Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation.
89157079|NCT02666144||Glaucoma|
89157080|NCT02666144||Normal|
89157081|NCT04137549||Nocturnal controlled hypertension|Nocturnal blood pressure was controlled under 120/70 mmHg after aggressive anti-hypertensive therapy.
89157082|NCT04137549||Nocturnal uncontrolled hypertension|Nocturnal blood pressure was still over 120/70 mmHg after aggressive anti-hypertensive therapy.
89157083|NCT04230551|Active Comparator|Reference Group|Five symptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
89157084|NCT04230551|Experimental|Study Group|Five asymptomatic HOCM patients with severe LVOT obstruction will undergo PTSMA
89157085|NCT04230551|No Intervention|Observation Group|Five asymptomatic HOCM patients with severe LVOT obstruction will not undergo PTSMA
89157086|NCT00692523|Active Comparator|1|The control group will receive 8 recreational therapy sessions over a 2-week (14 day) period, to be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
89157087|NCT00692523|Experimental|2|Patients randomized to Wii technology will receive an intensive program consisting of 8 Wii gaming sessions, 60 minutes each, over a 2-week (14 day) period. These 8 sessions can be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
89157088|NCT02664116|Experimental|Cambia|Diclofenac postassium powder for oral solution and placebo injection
89157089|NCT02664116|Active Comparator|ketorolac|ketorolac intramuscular injection and placebo oral solution
89157090|NCT00692601|Experimental|1|acute oral ingestion of 3 mg capsiate
89157091|NCT00692601|Experimental|2|acute oral ingestion of 10 mg capsiate
89157092|NCT00692601|Placebo Comparator|3|acute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules)
89157093|NCT02664194|Active Comparator|Control Group|Primary percutaneous coronary intervention only
89157094|NCT02664194|Experimental|03 Hours Hypothermia Group - Proteus® Cooling System|03 hours of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
89157095|NCT02664194|Experimental|01 Hour Hypothermia Group - Proteus® Cooling System|01 hour of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
89157096|NCT02785055|Active Comparator|Ultrasound-Assisted|Ultrasound assisted marking of the thoracic spine on the skin for Thoracic Epidural Placement
89157097|NCT02785055|Active Comparator|Palpation|Palpation marking of the thoracic spine on the skin for Thoracic Epidural Placement
89157098|NCT02624661|Experimental|Glycerol injection|The patients will be injected with glycerol using a new neuronavigation-based technique in the trigeminal ganglion.
89157099|NCT02689817|Experimental|Monitoring patch, no display|Participants in this condition will receive a padded bandage that monitors pressure over time. In this arm, healthcare providers will not be able to view the pressure data collected.
89157100|NCT00648050|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
89157101|NCT00648050|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
89157102|NCT00692757|Experimental|A|Hypochlorous acid
89157103|NCT00692757|Active Comparator|B|Iodopovidone
89157104|NCT02783495|Experimental|Device: iPad|Patients with brain tumors receive an iPad with the ReMind app. The patients will use the app to train neurocognitive and compensatory skills for 3 hours per week over the course of 12 weeks (36 hours in total)
89157105|NCT00646256|No Intervention|no training|
89157106|NCT00646256|Experimental|COGPACK training|
89157107|NCT00974623||Spinal Fusion|Patients who undergo a planned spinal fusion procedure requiring approved bone grafting materials (e.g., bone grft substitutes, allograft or autograft).
89157108|NCT02624505|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
89157109|NCT02624505|Active Comparator|90 mcg Reference Product|Drug : 90 mcg Reference Product One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
89157110|NCT02624505|Active Comparator|180 mcg Reference Product|Drug: 180 mcg Reference Product One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
89157111|NCT02624505|Experimental|90 mcg Test Product|Drug: 90 mcg Test Product One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
89157112|NCT02664350|Experimental|Genotype Arm|Participants in this arm will have genotyping performed for CYP2D6 variants. Based on the CYP2D6 the treating physicians will be provided with an interpretation of genotype results, and a recommendation will be provided by a pharmacist on the UF Health Personalized Medicine team through one-on-one consultation with the physician for the type of pain medication. These participants will also be genotyped for OPRM1 variants at the end of the study which is performed for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
89157113|NCT02664350|Active Comparator|Traditional Arm|Participants in this arm will have genotyping for CYP2D6 and OPRM1, however this information will not be provided to the physicians for treatment of the analgesic therapy but will be used for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
89157114|NCT00969631|Experimental|Metformin-CC|
89157115|NCT00969631|Active Comparator|Laparoscopic ovarian diathermy (LOD)|
89157116|NCT02783261||Post Y90 hypertrophy measurement|All prospective patients who undergo unilobar SIRT for HCC at SGH or NCC are potential candidates for this study. The study aims to recruit 25 subjects and it is anticipated that 50% will be from SGH and 50% will be from NCC
89157117|NCT00912561|No Intervention|Sedentary|patients who train after an 8 week observational period
89157118|NCT00912561|Active Comparator|patients who train immediately after enrollment|patients who train immediately after enrollment
89157119|NCT00974701|Experimental|Patients to undergo PillCam procedure|Patients presenting to ER with acute overt upper GI bleeding
89157120|NCT02782481|Experimental|ND0612 High dose (Levodopa/Carbidopa solution)|High dose ND0612 SC infusion over 24 h
89157121|NCT02782481|Experimental|ND0612 Low dose (Levodopa/Carbidopa solution)|Low dose ND0612 SC infusion over 24 h
89234987|NCT05723822|Experimental|Walkasins and PhySens-IMM System--Single Arm|Participants who meet the eligibility criteria will don a pair of Walkasins and the PhySens-IMM System. They will perform some brief balance exercises (i.e., sensory integration exercises) and then complete the outcome assessments with their Walkasins turned off and without the use of an assistive device. After a rest period of about five minutes, they will repeat the outcome assessments with their Walkasins turned on.
89234988|NCT05721846|Experimental|Experimental|"SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1~Immunotherapy:~Nivolumab 3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle Ipilimumab 1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days).~Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)"
89234989|NCT05715489|Other|Patients with pelvic organ prolapse undergone pectopexy without using mesh|
89234990|NCT05704712|Experimental|Message 1 - $100|Participants are offered an incentive of $100 to complete 50 exercise sessions at the YMCA within 6 months (Description of incentive 1)
88816438|NCT02404350|Experimental|Secukinumab 150 mg no load (Group 2)|"Secukinumab 150 mg sc injection every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
88816439|NCT02404350|Experimental|Secukinumab 300 mg load (Group 3)|Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks until week 100
88821424|NCT04163796|Experimental|UPnRIDE Training|During each session, heart rate (HR), blood pressure (BP), total session time, time in standing posture, count of sit-to-stand positioning, total distance of overground movement, and rating of perceived exertion (Borg scale) for mobility skills will be monitored. At all study visits during the training period, participants will be asked to answer general health questions about the occurrence of any pressure ulcers or infections.
89234991|NCT05704712|Experimental|Message 2 - $100|Participants are offered an incentive of $100 to complete 50 exercise sessions at the YMCA within 6 months (Description of incentive 2).
88821425|NCT04160429||Device feasibility (Macroduct Sweat Collection System)|Patients undergo collection of sweat samples via Macroduct Sweat Collection System 3710S and saliva and blood samples within 24 hours after medication administrations. Patients also complete questionnaires over 5-10 minutes and have medical charts reviewed.
88821426|NCT04126278|Experimental|Barbotage Injection|Subjects receiving barbotage with saline injection
88821427|NCT04126278|Active Comparator|Barbotage with Cortisone Injection|Subjects receiving barbotage with cortisone injection
88821428|NCT04111536|Active Comparator|Liothyronine (LT3)|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose will be 2.5 mcg three times daily and the maximum LT3 dose will be 12.5 mcg three times daily.
88821429|NCT04111536|Placebo Comparator|Placebo|A placebo tablet matching in appearance to LT3 tablets, dosed equivalently. Minimum placebo tablet dose will be 1/2 tablet (2.5 mcg equivalent) three times daily and the maximum placebo dose will be 2 1/2 tablets (12.5 mcg equivalent) three times daily.
88821430|NCT04106557|Experimental|OV101 once daily (weight-based dosing) Other Name:Gaboxadol|OV101 (gaboxadol), oral, provided once daily at bedtime for 12 week duration
88821431|NCT04106557|Placebo Comparator|Placebo once daily|Matching placebo,oral, provided once daily at bedtime for 12 week duration
88821432|NCT04105010|Experimental|AZD4205 Group A|Group A: Open label AZD4205 at dose A, once daily (Phase 1)
88821433|NCT04105010|Experimental|AZD4205 Group B|Group B: Open label AZD4205 at dose B, once daily (Phase 1)
88821434|NCT04105010|Experimental|AZD4205 Group C|Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
88821435|NCT04105010|Experimental|AZD4205 Group D|Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)
88821436|NCT04098770|Experimental|Conventional treatment plus Allogeneic Adoptive Immune Therapy|Participants will receive conventional treatment (anti-opportunistic infections, cART and other treatments) plus a dose (2-3 times) of Allogeneic Adoptive Immune Therapy
88821437|NCT04098770|No Intervention|Conventional treatment|Without Allogeneic Adoptive Immune Therapy but conventional treatment (anti-opportunistic infections , cART and other treatments) should be received
88821438|NCT04095039|Experimental|Hi Arm|Patients to allow blood serum phosphate levels to rise to 6.5 mg/dl or above
88821439|NCT04095039|No Intervention|Lo Arm|Patients to titrate blood serum phosphate levels to the standard <5.5mg/dl
88821440|NCT04094298|Experimental|Treatment Group|Patients receiving the 32-unit injection of FX006.
88821441|NCT04085614|Experimental|Dynamic Coronary Roadmap group|Patients will be treated via standard of care for Percutaneous Coronary Intervention (PCI) with navigation support of Dynamic Coronary Roadmap.
88821442|NCT04085614|Active Comparator|Control group|Patients will be treated via standard of care for Percutaneous Coronary Intervention (PCI) without navigation support of Dynamic Coronary Roadmap.
88821443|NCT04083950|Experimental|Single group|All participants will receive the vaccine and aspirin.
88821444|NCT04083508|Experimental|Malaria challenge|Malaria Sporozoite Challenge by mosquito bites.
88821445|NCT04080466|Experimental|Cam Group|This group will consist of patients that are scheduled for surgery to undergo cam resection by hip arthroscopy.
88821446|NCT04080466|Active Comparator|Control Group|This group will consist of a matched cohort of control participants.
88821447|NCT04063878|Experimental|Single tooth restorations using Acuris conometric concept|
88821448|NCT04056455|Experimental|Severe Renal Impairment: Mobocertinib 80 mg|Participants with severe renal impairment received a single dose of mobocertinib 80 mg, capsule, orally, on Day 1.
88821449|NCT04056455|Experimental|Normal Renal Function: Mobocertinib 80 mg|Participants with normal renal function received a single dose of mobocertinib 80 mg, capsule, orally, on Day 1.
88821450|NCT04051606|Experimental|Regorafenib|160 mg regorafenib 3 weeks on/ one week off in participants with Avastin refractory Glioblastoma, continued until progression or toxicity. Participants will receive an MRI every 8 weeks.
88821451|NCT04047979|Experimental|Younger Group|Participants between the ages of 50 to 60 years will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
89157122|NCT02782481|Placebo Comparator|Placebo|Placebo SC infusion over 24 h
89157123|NCT04137081|Experimental|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
89157124|NCT00884286|Experimental|Arm One|Aplidin® given as a 1-hour weekly IV infusion
89157125|NCT02664428|Active Comparator|PREBIOIL TEST|Product tests prepared with olives flour, buckwheat flour, pea flour, chestnut flour, oil chemical leavening agents, salt, sucrose. Baked
89157126|NCT02664428|Placebo Comparator|CONTROL|Product control prepared with wheat flour, oil, chemical leavening agents, salt, sucrose. Baked
89157127|NCT00692835|Active Comparator|A|Patients with mini Video Assisted Thyroidectomy (miVAT)
89157128|NCT00692835|Active Comparator|B|Immediate postoperative course of patients with classic Thyroidectomy (cTT)
89157129|NCT04229927|Experimental|Arm 1|
89157130|NCT04229927|Placebo Comparator|Arm 2|
89157131|NCT00648128|Active Comparator|2|
89157132|NCT00648128|Experimental|1|
89157133|NCT00969787|Experimental|DWP05195|
89157134|NCT00974779|Experimental|HCO dialyzer|Hemodialysis with the HCO1100 hemodialyzer membrane with high molecular weight cut off.
89157135|NCT00974779|Active Comparator|Placebo|Regular dialysis using a polyamide high-flux hemodialyzer
89157136|NCT02667158||No shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
89157137|NCT02667158||Minimal shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
89157138|NCT02667158||Marked shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
89157139|NCT02667158||Extensive shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
89157140|NCT00692991||1|People undergoing percutaneous coronary interventions.
89157141|NCT02784821|Other|Antibiotics Control|"These neonates have a clinical indication to receive antibiotics, such as maternal chorioamnionitis with fetal tachycardia. The standard of care antibiotics include Ampicillin and Gentamicin or Cefotaxime and as part of standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome."
89157142|NCT02784821|Other|No Antibiotics Control|"These neonates show no signs of respiratory distress(RDS) or have no indications of maternal chorioamnionitis. Antibiotics is not indicated for this group as standard of care.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins."
89157143|NCT02784821|Other|Randomized to pre-emptive antibiotics|"This group will be randomized to receive standard of care antibiotics which include Ampicillin and Gentamicin or Cefotaxime. Standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome."
89157144|NCT02784821|Other|Randomized to no pre-emptive antibiotics|This group will be randomized not to receive standard of care antibiotics. Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins.
89157145|NCT00665730|Experimental|Sepraspray|Sepraspray Powder applied on the viscera directly under the midline incision followed by incision closure. Sepraspray dose applied was between 2 g and 4 g per patient.
89157146|NCT00665730|No Intervention|Control|No anti-adhesion treatment used.
89157147|NCT00974857|Active Comparator|Study group|"Pre-dialytic overhydration(OH) will be estimated by Body Composition Monitor (BCM) at least once a month.~If OH is positive, dry weight will be reached by ultrafiltration without regard to the level of blood pressure.~If OH is negative and:~Systolic blood pressure(SBP)< 100 mmHg with/or intradialytic hypotension episodes(IDHE) and/or clothing and/or erythrocytosis(htc>36%);dry weight will be increased.~SBP normal(100-150 mmHg) w/o IDHE and clothing and erythrocytosis;dry weight will not be changed.~SBP normal(100-150 mmHg) with IDHE and/or clothing and/or erythrocytosis;dry weight will be increased.~SBP>150 mmHg captopril test(CT)will be done. If CT is positive, ACEI/ ARBs will be used and dry weight will be increased if IDHE and/or clothing and/or erythrocytosis(htc>36%) are present.~If CT is negative, BCM measurement will be repeated and if same,ABPM will be performed for confirmation."
89157148|NCT00974857|Other|Control Group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
89157149|NCT00646334|Experimental|A|Optilene® Mesh Elastic
89157150|NCT00646334|Active Comparator|B|Ultrapro® Mesh
89157151|NCT04137393|Experimental|Salvadora persica|"brush teeth with Salvadora persica Miswak"
89157152|NCT04137393|Active Comparator|tooth brush|brush with fluoridated tooth paste
89157153|NCT00969865||Individualized Managment Group|Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.
89157154|NCT00969865||Standard Management Group|Participants who receive standard of care.
89157155|NCT04229537|Experimental|SCT-I10A combined SCT200 in ESCC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
89157156|NCT04229537|Experimental|SCT-I10A combined SCT200 in CRC|SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
89157157|NCT04229537|Experimental|SCT-I10A combined SCT200 plus Chemotherapy in CRC|"SCT-I10A: 200 mg intravenous (IV) on Day 1 of Q3W. SCT200: 6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W.~Chemotherapy: Capecitabine and Oxaliplatin."
89157158|NCT04154592|Experimental|Experimental Group|In addition to the conservative treatment of the control group, humeral head depressor muscle co-activation training will be applied for 14 weeks.
89157159|NCT04154592|Active Comparator|Control Group|The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., & Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).
89157160|NCT00693069|Active Comparator|1|Clopidogrel 300 mg the day before PCI
89157161|NCT00693069|Experimental|2|Clopidogrel 600 mg the day before PCI
89157162|NCT00693069|Experimental|3|300 mg followed by 75 mg daily started one week prior to angiography
89157163|NCT00693069|Experimental|4|300 mg followed by 150 mg daily started one week prior to angiography
89157164|NCT04949282||Lutathera|
89157165|NCT00974935|Experimental|Cohort 1|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01 mcg intramuscular.
89157166|NCT00974935|Experimental|Cohort 2|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.1 mcg intramuscular.
89157167|NCT00974935|Experimental|Cohort 3|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.5 mcg intramuscular.
89157168|NCT00974935|Experimental|Cohort 4|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 2.5 mcg intramuscular.
89157169|NCT00974935|Experimental|Cohort 5|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 10 mcg intramuscular.
89157170|NCT00974935|Experimental|Cohort 6|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular.
89157171|NCT00974935|Experimental|Cohort 7|Two doses of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular 21 days apart.
89157172|NCT00665808||A|
89157173|NCT00665808||B|
89157174|NCT05342207|Experimental|cases|
89157175|NCT04230317|Experimental|Low dose chest CT simulation|VBN result driven using raw data acquired with low dose CTs taken with three different protocols
89157176|NCT04230317|Active Comparator|Standard protocol chest CT simulation|VBN result driven using raw data acquired with standard protocol CT
89157177|NCT00873015|Experimental|Nitrite|Continuous intravenous infusion of Sodium Nitrite
89157178|NCT00873015|Placebo Comparator|Vehicle control|Continuous intravenous infusion of saline
89157179|NCT03978325|Active Comparator|Control|This arm will complete a standard prehabilitation intervention.
89157180|NCT03978325|Experimental|HIIT Intervention|This group will complete a pre-operative high intensity interval training programme.
89157181|NCT02667080|Active Comparator|Ejaculate 1|Semen sample after 2-7 days of sexual abstinence
89157182|NCT02667080|Active Comparator|Ejaculate 2|Semen sample after 2 hours of sexual abstinence
89157183|NCT04230083|Experimental|Dienogest Test Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
89157184|NCT04230083|Active Comparator|Dienogest Reference Product|Participants will receive one tablet of the test formulation containing Dienogest 2.0 mg. The tablets will be taken with water.
89157185|NCT00975013||Bone Density Study Group|Morbidly obese, (BMI >40 kg/m2, or 35 kg/m2 with comorbidities) female patients who have given consent to undergo additional testing including bone densitometry, and lab testing preoperatively and at 6 and 12 months after undergoing elective laparoscopic roux-en-Y gastric bypass.
89157186|NCT00693147|Active Comparator|A|mini Video Assisted Thyroidectomy (miVAT)
89157187|NCT00693147|Active Comparator|B|Classic Total Thyroidectomy
89157188|NCT05221151|Active Comparator|melatonin|26 patients will receive melatonin 10 mg
89157189|NCT05221151|Active Comparator|pregabalin|26 patients will receive pregabalin 150 mg
89157190|NCT05221151|Active Comparator|melatonin and pregabalin|26 patients will receive melatonin 5 mg plus pregabalin 75 mg
89157191|NCT02666690|Experimental|Patients with metastatic cancer treated with anti angiogenics|
89157192|NCT04008043|Experimental|Dexamethasone|Participants in this arm will take a 6mg dexamethasone tablet the day before surgery, a 6 mg tablet the day of surgery, a 4mg tablet the day after surgery and a 2mg tablet the second day after surgery. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
89157193|NCT04008043|Active Comparator|Vicodin|Participants in this arm will take a vicodin tablet every 4-6 hrs as needed to a maximum of 8 tablets after surgery. Each tablet has 300 mg acetaminophen and 5 mg hydrocodone. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
89157194|NCT02783183|Experimental|YHD1119|Pregabalin 300mg
89157195|NCT02783183|Active Comparator|Lyrica|Pregabalin 150mg
89157196|NCT02666612|Other|Patients with metastatic cancer|
89157197|NCT00693381|Experimental|1|Tacrolimus/MMF/steroids throughout the study
89157198|NCT00693381|Experimental|2|Tacrolimus/MMF/steroids with MMF reduction from week 7 to 12 and MMF discontinuation at month 3
89157199|NCT00969943||Cocaine-dependent Men|
89157200|NCT00969943||Cocaine-dependent Women|
89157201|NCT00969943||Control Men|
89157202|NCT00969943||Control Women|
89157203|NCT00693537|Experimental|A|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
89157204|NCT00693537|No Intervention|B|Control
89157205|NCT04007731|Experimental|High protein, high fibre and creatine load bar (DrRip)|1 new protein bar (260 kcal) after training every day
89157206|NCT04007731|Active Comparator|Voltage energy bar|1 control commercially available protein bar (260 kcal) after training every day
89157207|NCT00693615|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
89157208|NCT00693615|Experimental|Group B|Formulation 2 of the vaccine [with Al(OH)3]
89157209|NCT00693615|Experimental|Group C|Formulation 3 of the vaccine (without adjuvant)
89157210|NCT00648206||1|drivers of motorised vehicles suspected of driving under the influence of psychoactive drugs or alcohol
89157211|NCT00648206||2|drivers stopped in police traffic controls and breathalysed positive for alcohol
89157212|NCT00979849|Experimental|A|AZD8683
89157213|NCT00979849|Placebo Comparator|B|Placebo
89157214|NCT02782793||Patient's with complex colon polyps|
89157215|NCT02663960|Experimental|fixed citrate doses protocol|Fixed citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which was set to meet a circuit citrate concentration of 4 mmol/l (duration: the maximum time is 72 hrs).
89157216|NCT02663960|Active Comparator|adjusted citrate doses protocol|Adjusted citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which the starting infusion rate be set 2.5 % of blood flow ( dosage range: 160-250ml/h) and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l (duration: the maximum time is 72 hrs. )
89157217|NCT02624427|Experimental|Glaucoma Eyes|Measurement of intraocular pressure (IOP)
89157218|NCT02624427|Active Comparator|Healthy Eyes|age-matched healthy eyes as controls will undergo Measurement of intraocular pressure (IOP)
89157219|NCT00975169||TZDs User|
89157220|NCT04229849|Experimental|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
89157221|NCT04229849|Active Comparator|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days; Until disease progression according to the RECIST 1.1 and irRECIST standard, intolerance of toxicity, withdrawal of informed consent from the subject, or tripleuriumab administration up to 2 years.
89157222|NCT00693771|Experimental|1|
89157223|NCT02663804|Active Comparator|Implant design 1|Journey II, BCS, Smith&Nephew
89157224|NCT02663804|Active Comparator|Implant design 2|Persona, Zimmer
89157225|NCT02663804|Active Comparator|Implant design 3|Unity, Corin
89157226|NCT00970021|Placebo Comparator|Water with artificial colour|Placebo
89157227|NCT00970021|Active Comparator|Extract of agaricus blazei Murill|Agaricus blazei Murill
89157228|NCT00693849|Active Comparator|A|Escitalopram
89157229|NCT00693849|Active Comparator|B|Sertraline
89157230|NCT00693849|Active Comparator|C|Venlafaxine-XR
89157231|NCT00693849|No Intervention|D|Healthy matched controls
89157232|NCT00975247|Active Comparator|Received Booklet|Patients who have received colonoscopy preparation booklet
89157233|NCT00975247|No Intervention|Did not receive booklet|Patients who did not receive colonoscopy preparation booklet
89157234|NCT05342129|Experimental|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
89157235|NCT05342129|No Intervention|regular rehabilitation exercises|walking exercise
89157236|NCT04650932|Experimental|Sustained Dual Frequency, Dual Region, Stimulation|
89157237|NCT00979927|Placebo Comparator|Saline|
89157238|NCT00979927|Active Comparator|SPC3649|
89157239|NCT00693927|Active Comparator|1|Unmanipulated PBSC
89157240|NCT00693927|Experimental|2|CD8-Depleted PBSC
89157241|NCT02510885|Experimental|SD-OCT Angiography|Study participants will undergo imaging of both eyes with the AngioVue unit (approximately 60 seconds/eye), per standard operating protocol. Imaging is noncontact, and pharmacologic dilation will not be used for the purposes of this study. In most instances, study participants will undergo only a single imaging session on a single day. However, potential participants will be asked to consent for additional imaging sessions (up to 12) that may occur over the course of subsequent future visits to the clinic. Additionally, study participants will be asked to consent to prospective collection of clinical and demographic data, to correlate findings of OCT-A imaging to subsequent clinical course.
89157242|NCT00648362|Experimental|1|Glimepiride Tablets 1 mg
89157243|NCT00648362|Active Comparator|2|Amaryl® Tablets 1 mg
89157244|NCT00970099|Active Comparator|Exercise|12 week exercise regimen
89157245|NCT00970099|Placebo Comparator|non-exercise|Normal lifestyle routine with no exercise for 12 weeks.
89157246|NCT00648440|Experimental|1|Midodrine HCl Tablets 5 mg
89157247|NCT00648440|Active Comparator|2|ProAmatine® Tablets 5 mg
89157248|NCT04137003|Experimental|Rouge et Or program|Rouge et Or program group follow a detailed program that they do on their own. It is made of three cycles of four weeks each. Every cycle contains 3 training sessions by week with a minimum of 24 hours between sessions. The training volume is modulated for every cycle and every week. Each training sessions is made of 6 warm-up exercises followed by 6 training exercises. The exercises are a mix of strengthening, endurance, plyometric, neuromuscular control and dynamic stability. The exercises change every month with a progressively increasing difficulty towards the end to mimic return to sport demands.
89234992|NCT05704712|Experimental|Message 1 - $200|Participants are offered an incentive of $200 to complete 50 exercise sessions at the YMCA within 6 months (Description of incentive 1).
89157249|NCT04137003|Active Comparator|CHU intervention guide|CHU intervention guide group follow the standard CHU protocol. At three months post-surgery, the protocol suggests progressing the exercises without precisely suggesting exercise, parameter or frequency.
89157250|NCT00980083|Placebo Comparator|Placebo|
88821452|NCT04047979|Experimental|Older Group|Participants who are ≥70 year old will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
88821453|NCT04046887|Experimental|Combination of lonsurf + gemcitabine + nab-paclitaxel|
88821454|NCT04045431|Experimental|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
88821455|NCT04045431|Active Comparator|Synvisc-One|Intra-articular injection with Synvisc-One (hyaluronic acid)
88821456|NCT04041622|Other|Endoscopy and biopsy|Participants of the HUNT study with a positive serological assay for celiac disease are invited to attain a diagnostic endoscopy with duodenal biopsies
89157251|NCT00980083|Active Comparator|Exendin(9-39)|
89157252|NCT04172090|Other|Control|2 consecutive days of standardised daily levels of moderate physical activity (PAL=1.85 reflecting their habitual levels), and matched energy (food) intake
89157253|NCT04172090|Experimental|SIT+E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst maintaining the level of food intake prescribed in the Control trial, thus creating a positive energy balance
89157254|NCT04172090|Experimental|SIT=E|2 consecutive days of reduced physical activity induced by prolonged periods of sitting (PAL=1.4) whilst reducing food intake to match the reduction in energy expenditure induced by inactivity, thus maintaining energy balance
89157255|NCT05264363|Experimental|Intervention|The main intervention is the application of the Investigational Medical Device (VIPUN Gastric Monitoring System prototype) together with the reference device (solid state high-resolution manometry) to record intraluminal pressure. The planned procedures are identical for all subjects in this single-arm investigation.
89157256|NCT00694005|Active Comparator|bifurcation stent techniqe|"cross over stenting without kissing balloon angioplasty leave alone"
89157257|NCT00694005|Experimental|bifurcation stent technique|kissing balloon angioplasty
89157258|NCT00975325|Active Comparator|"Yohimbine, Yohimbine Spiegel"|
89157259|NCT00975325|Active Comparator|Yohimbine Yocon-Glenwood|
89157260|NCT00910676|Experimental|DIPROSONE|
89157261|NCT00970177|Experimental|low dose of antigen + low dose of adjuvant|
89157262|NCT00970177|Experimental|high dose of antigen + high dose of adjuvant|
89157263|NCT00970177|Experimental|high dose of antigen|
89157264|NCT00634673|Other|TT|patients homozygous for Thr54 (TT)
89157265|NCT00634673|Other|AA|patients homozygous for Ala54 (AA)
89157266|NCT04136847|Experimental|Hand Aging|Microneedling treatment of the dorsum of the hands
88821459|NCT04036448||Lenalidomide in IPSS Low-or intermediate-1-risk del population|For the IPSS Low- or intermediate-1-risk del (5q) (MDS), Lenalidomide treatment must not be started if the ANC < 0.5 x 109/L and/or platelet counts < 25 x 109/L. The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1 to 21 of repeated 28-day cycles.
88821460|NCT04036448||Lenalidomide in Refractory/relapsed rrMC/ Follicular lymphoma population|For the Refractory/relapsed Mantle cell lymphoma (rrMCL), the recommended starting dose of lenalidomide is 25 mg orally once daily on days 1 to 21 of repeated 28-day cycles. For the Follicular lymphoma (FL), the recommended starting dose of rituximab is 375 mg/m2 intravenously (IV) every week in Cycle 1 (days 1, 8, 15, and 22) and day 1 of every 28-day cycle for Cycles 2 through 5.
88821461|NCT04030052|Experimental|Untreated/minimally treated moderate HA no inhibitors|Previously untreated patients (PUPs) and minimally treated patients (MTPs) <3 years of age with moderately severe (≤2% FVIII) HA and no inhibitors.
88821462|NCT04030052|Experimental|Treated any moderate HA with existing inhibitors|Children <21 years of age with moderately severe (≤2% FVIII) HA and with already existing inhibitors (LTI or HTI).
88821463|NCT04021043|Experimental|Group I (ipilimumab, BMS-986156, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 5 (day 85), patients receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
88821464|NCT04021043|Experimental|Group II (ipilimumab, BMS-986156, SBRT, nivolumab)|Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
88821465|NCT04021043|Experimental|Group III (nivolumab, BMS-986156, SBRT)|Patients receive nivolumab IV over 30 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 over 60 minutes on day 1. Patients also undergo SBRT over 30-45 minutes on days 1-4 for 4 fractions or on days 1-12 for 10 fractions. Treatment repeats every 28 days for up to 26 cycles of nivolumab and for up to 4 cycles of anti-GITR agonistic monoclonal antibody BMS-986156 in the absence of disease progression or unacceptable toxicity.
88821466|NCT04012073|Experimental|IPERPEEP|"End expiratory lung volume (EELV) will be measured at each step during a 5-step decremental PEEP trial.~PEEP will be ≥5 cmH2O and set to ensure the maximum recruitment observed in the PEEP trial, with a maximum permitted PPLAT of 30 cmH2O.~In particular, when interpreting the results of the PEEP trial, recruitment-to-inflation (RI) ratio calculated across two adjacent PEEP levels will drive PEEP setting.~RI≥1.5 between two PEEP levels will lead to the setting of the higher PEEP.~RI<0.5 will lead to the setting of the lower PEEP value.~In case of RI≥0.5 and <1.5, the choice among two adjacent PEEP levels will be left to the attending physician, who will indicate the set PEEP in order to best balance between the commitment of limiting total, static and dynamic strain and of optimizing oxygenation and haemodynamics."
88821467|NCT04012073|Active Comparator|EXPRESS|PEEP set so that the plateau pressure is within the following limits: 28 cmH2O≤Pplat≤ 30 cmH2O
88821468|NCT04007289|Active Comparator|APIXABAN|Apixaban, 1 pill of 2.5 mg per os twice a day (one in the morning and one in the evening) for 24 months.
89157267|NCT00648518|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
89157268|NCT00648518|Active Comparator|2|Glucophage® XR Tablets 750 mg
89157269|NCT04136691|Experimental|simulation training|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed. In the research, the application of burn patient scenario was performed only with the intervention group.
89157270|NCT04136691|No Intervention|Control|In the application process of the research, knowledge tests were administered as a pretest, second test, and posttest, and first and second applications of burn patient care plans were performed.
89157271|NCT04008589|Experimental|rtACS|repetitive transorbital ACS
89157272|NCT04008589|Experimental|tDCS/rtACS|Sequential tDCS - tACS
89157273|NCT04008589|Sham Comparator|Sham stimulation|
89157274|NCT04623632|Active Comparator|Bupivacaine|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique; syringes contained bupivacaine 0.25% 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
89157275|NCT04623632|Placebo Comparator|Placebo|the landmark is at the level of umbilicus 8 to 10 cms from midline bilaterally. A tiny nick is made in the skin with a 18G sharp needle to obliterate the cushion effect. Then an 18 G Tuohy needle will be insert perpendicular to skin directing the needle slightly towards the ipsilateral anterior superior iliac spine just before the closure of peritoneum. After feeling 2 pops of external and internal oblique aponeurosis the drug will be injected after aspiration. The injectate syringes will be prepared under aseptic technique syringes contained either normal saline 40 ml. Once the plane is reached the surgeon places his hand inside the abdominal cavity at the level of needle insertion to reconfirm needle placement. A bleb is palpated by the surgeon as the injection continues. The back flow of drug after injection is one of the signs that drug has been deposited in the TAP plane
89157276|NCT00648596|Placebo Comparator|Arm 2|
89157277|NCT00648596|Active Comparator|Arm 1|
89157278|NCT03921151|Other|Cocaine-dependent|Participants who use and are dependent on cocaine
89157279|NCT03921151|Other|Non-drug using Healthy Controls|Participants who are not drug users
89157280|NCT02784665|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
89157281|NCT02784665|Active Comparator|577-TL|"577nm Traditional laser(577-TL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area."
89157282|NCT00970255|Active Comparator|Frenotomy|
89157283|NCT00970255|Sham Comparator|Sham Frenotomy|
89157284|NCT04007965|Experimental|Opacified posterior capsule|PCO
89157285|NCT04007965|Active Comparator|Clear posterior capsule|CPC
89157286|NCT00975403|Experimental|Dead space breathing|
89157287|NCT00975403|Sham Comparator|Room air breathing|
89157288|NCT02665910|Experimental|SHR0302|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets
89157289|NCT02665910|Placebo Comparator|SHR0302 placebo comparator|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets (matching corresponding study medication)
89157290|NCT00970333|Experimental|assess [18F]-FEPPA PET imaging|
89157291|NCT04171388|Placebo Comparator|Routine care: Placebo|"In all pregnancies presenting at all centers, routine antenatal care will be strengthened:~Provision of iron-folic acid and tetanus toxoid vaccine~Screening for anemia and blood pressure~Screening/treatment of HIV, syphilis, malaria, tuberculosis~Placebo tablets will be administered twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
89157292|NCT04171388|Experimental|Routine care: Azithromycin|Azithromycin will be provided twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later.
89157293|NCT04171388|Experimental|Routine care: Enhanced Infection Management Package (EIMP)|At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrhea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment.
89157294|NCT04171388|Experimental|Enhanced Nutrition Package (ENP): Placebo|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.~Placebo tablets will be administered twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
89157295|NCT04171388|Experimental|ENP: Azithromycin|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.~Azithromycin will be provided twice in pregnancy: at enrollment (<=24 weeks) and a follow up ANC visit at least 4 weeks later."
89234993|NCT05704712|Experimental|Message 2 - $200|Participants are offered an incentive of $200 to complete 50 exercise sessions at the YMCA within 6 months (Description of incentive 2).
89234994|NCT05704712|No Intervention|Control|Participants complete all assessments, and are eligible to receive compensation for participating in the research components of the study.
89157296|NCT04171388|Experimental|ENP: EIMP|"Pregnant women will receive a daily multiple micronutrient. Women with undernutrition, identified with mid-upper arm circumference <23 cm, will receive a daily fortified balanced energy protein supplement.~At the study enrollment visit, pregnant women will receive presumptive deworming (albendazole) and screening for urinary tract infection and sexually transmitted infections (chlamydia and gonorrohea). Women with identified infections will be treated with appropriate antibiotics. A second dose of albendazole will be given at a follow up ANC visit at least 4 weeks after enrollment."
89157297|NCT02782637||Survey and interviews|"*part one* (quantitative)~Survey on:~A. prenatal counseling at the limits of viability, within three domains of interest:~organization of prenatal counseling~content of prenatal counseling~decision-making in prenatal counseling Domains used to evaluate current counseling and counseling preferences~B. decision-making at the limits of viability: evaluation of the made decision (decisional conflict and regret)~*part two* (qualitative)~Individual interviews (qualitative) to in-depth explore preferences in prenatal counseling~insight in the specific preferred content of prenatal counseling.~study influencing factors on preferences in the domains of organization and decision-making."
89157298|NCT00970411|Experimental|KRN951|
89157299|NCT04229069|Active Comparator|Basica|4-week dietary supplementation with an alkaline salt (Basica)
89157300|NCT04229069|Placebo Comparator|Placebo|4-week dietary supplementation with a placebo
89157301|NCT00646412|Experimental|A|A-Part® Gel
89157302|NCT00646412|No Intervention|B|untreated control group
89157303|NCT05341193|Experimental|low risk|Patients will receive induction therapy with toripalimab plus bevacizumab and gemcitabine every 3 weeks for 3 cycles before radiotherapy, then followed by IMRT and concurrent therapy with toripalimab plus bevacizumab for 2 cycles, then followed by adjuvant therapy with toripalimab every 3 weeks for a maximum of 1 year after radiotherapy.
89157304|NCT05341193|Experimental|high risk|Patients will receive induction therapy with toripalimab plus bevacizumab and gemcitabine every 3 weeks for 3 cycles before radiotherapy, then followed by IMRT and concurrent therapy with toripalimab plus bevacizumab for 2 cycles, then followed by adjuvant therapy with toripalimab and bevacizumab every 3 weeks for a maximum of 1 year after radiotherapy.
89157305|NCT00975559||Normal volunteers|Normal study volunteers with no prior history of coronary artery disease
89157306|NCT00975559||Apical Ballooning Syndrome|Women who have had a documented Apical Ballooning event as shown by coronary angiogram
89157307|NCT00975559||Coronary Endothelial Dysfunction|Patients who have been diagnosed with Endothelial Dysfunction via a coronary angiogram with acetylcholine challenge
89157308|NCT00975559||Myocardial Infarction|Women diagnosed with a Myocardial Infarction who subsequently had a Percutaneous Intervention
89157309|NCT00648674|Experimental|1|Apligraf
89157310|NCT00975793|No Intervention|Standard Care|Randomised allocation of standard care at the clinician's discretion in accordance with current best practice.
89157311|NCT00975793|Experimental|Early Goal Directed Therapy|Randomised allocation of early goal-directed therapy (EGDT).
89157312|NCT04229459|Experimental|Neoadjuvant Treatment|All subjects will receive induction chemotherapy and chemoradiation combined with cetuximab followed by nivolumab and cetuximab as neoadjuvant treatment
89157313|NCT02663726|Experimental|Yoga intervention group|10 weekly 75-min sessions of specialised yoga plus written advice about physical activity for older adults
89157314|NCT02663726|Active Comparator|Waiting list control group|Usual care plus written advice about physical activity for older adults
89157315|NCT04174586|Experimental|cord blood group|standard induction and consolidation chemotherapy with cord blood microtransplantation
89157316|NCT05341973|Experimental|Education|The Self- Management Program Developed will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
89157317|NCT05341973|No Intervention|Control|It will not change the Self-Efficacy, Self-Care Management in Hypertension Patients of the Self-Management Program.
89157318|NCT00980161||Peg-IFN + RBV with SVR|HCV patients receiving peginterferon alfa-2a and ribavirin with sustained virologic response
89157319|NCT00980161||Peg-IFN + RBV without SVR|HCV patients receiving peginterferon alfa-2a and ribavirin without sustained virologic response
89157320|NCT04174274||positive|ventilator-associated pneumonia-developed group followed by mechanical ventilation
89157321|NCT04174274||negative|not ventilator-associated pneumonia-developed group followed by mechanical ventilation
89157322|NCT05279443|Experimental|yoga-based exercises|
89157323|NCT04229225|Experimental|UBX0101 single dose (SD)|"Cohort 1 (n=18): UBX0101 8.0 mg or placebo IA at Week 0~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
89157324|NCT04229225|Experimental|UBX0101 repeat dose (RD)|"Cohort 2 (n=18): UBX0101 4.0 mg or placebo IA at Weeks 0 and 4~Patients will be randomized in a 2:1 ratio to UBX0101 and placebo"
89157325|NCT00980239|Experimental|Group 1|Group 1 = Irinotecan + Bevacizumab
89157326|NCT00980239|Experimental|Group 2|Group 2 = Irinotecan, Bevacizumab + Oxaliplatin
89157327|NCT00980239|Experimental|Group 3|Group 3 = Irinotecan, Bevacizumab + Cetuximab
89157328|NCT05341895|Other|kinesiotape|Kinesiotape applied to the paraspinal muscles
89157329|NCT05341895|No Intervention|Placebo|No intervention
89157330|NCT02665832|Experimental|AB|Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351
89157331|NCT02665832|Experimental|BA|DWJ1351 followed by Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
89157332|NCT02781467|Experimental|Cyclophosphamide + Fludarabine + PNK-007 + rhIL-2|Fludarabine Day -6 to -2 and Cyclophosphamide Day -5 and -4. On Day 0 PNK-007 at 4 varying dose levels followed by Human recombinant Interleukin-2 (rhIL-2) every other day, Day 0 to Day 10.
89157333|NCT00648830|Experimental|1|Clarithromycin 250 mg immediate-release oral tablet
89157334|NCT00648830|Active Comparator|2|Biaxin® (Clarithromycin) 250 mg tablet
89157335|NCT00970567|Other|Arm 1|stop after positive ketone bodies in urine
89157336|NCT00970567|Other|Arm 2|stop after positive ketone bodies in blood, normal therapy
89157337|NCT00970567|Other|Arm 3|stop after positive ketone bodies in blood, additional therapy
89157338|NCT02663570|Experimental|open|therapy with melatonin 2 mg daily for six months
89157339|NCT05091229||Cohort A|Blood specimen collection. Study samples must be collected prior to any treatment.
89157340|NCT05091229||Cohort B|Blood specimen collection. Study samples must be collected prior to any treatment.
89157341|NCT05091229||Cohort C|Blood specimen collection. Study samples must be collected prior to any treatment.
89157342|NCT02781233|Experimental|Training group|Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.
89157343|NCT02781233|Placebo Comparator|Control group|Usual daily activities
89157344|NCT00970645|Active Comparator|traditional mediastinoscopy/thoracoscopy|Traditional Mediastinoscopy used to detect or stage lung cancers.
89157345|NCT00970645|Active Comparator|EBUS/EUS|Minimal invasive technique for staging/detecting lung cancer.
89157346|NCT02663492|Experimental|TEAS group|Patients with transcutaneous electrical acupoint stimulation (TEAS) group receive electrical stimulation of acupoints including Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4).
89157347|NCT02663492|Active Comparator|Medication group|On the basis of routine nursing care, patients need to take Sanguisorba officinalis L., named Diyu Shengbai Pian (a Traditional Chinese Medicine) 3 times per day.
89157348|NCT02663492|No Intervention|Control group|The patients of control group receive routine nursing care, including (1) to be observed the changes in patient condition, (2) to eat high-calories, high-protein, high-vitamin, easy-to-digest foods during chemotherapy, (3) to be treated by psychological care, (4) to be prevented against the occurrence of phlebiti, and (5) to use Ondansetron and Omeprazole as direction.
89157349|NCT00980473|Active Comparator|Iridoplasty|
89157350|NCT00980473|Active Comparator|Control (Medication)|
89157351|NCT02663414|Experimental|Atlas device|Each patient in this arm will receive the Atlas Knee System device on the medial side of the symptomatic knee.
89157352|NCT05341739|Experimental|Pre-Operative Stereotactic Radiosurgery (SRS)|Subjects are treated using the standard of care SRS to a total dose of 24-27 Gray (Gy) in 3 fractions with a once daily fractionation or every other day at treating physician discretion. The preferred dose will be 27 Gy, with ability to drop dose down to 24 Gy if normal tissue constraints cannot be met. It should be noted, that while the dosing remains within standard of care, the timing of the radiation (pre-operative) is still not considered standard of care but is supported by emerging data as described in the study background. Additional metastatic lesions may be treated using SRS according to institutional practices. The radiation dose prescribed to the non-index lesions is at the discretion of the treating physicians. Surgical resection will be performed within 2 weeks of completion of SRS.
89157353|NCT00649142|Active Comparator|A|Open sutured mesh repair
89157354|NCT00649142|Active Comparator|B|Laparoscopic mesh glue fixation
89157355|NCT00970723|Experimental|intensive treatment|with a systematic screening for sleep apnea and/or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected
89157356|NCT00970723|Active Comparator|conventional treatment|in accordance with national guidelines
89157357|NCT02784743|Experimental|albendazole and ivermectin|Before and after design with all eligible volunteers receiving the study drugs. Administration of a yearly unique dose of albendazole 400mg and ivermectin 150ug/kg weight ( according to the height).
89157358|NCT00975949||Fluconazole Group|These subjects received fluconazole in our NICU fluconazole prophylaxis study during 1998-2000
89157359|NCT00975949||Placebo Group|These subjects received a placebo during our NICU fluconazole prophylaxis study during 1998-2000
89157360|NCT00980551|Experimental|Topotecan/Vincristine with subtenon Carboplatin|
89157361|NCT02660060|Experimental|Pramipexole Dexa Medica|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
89157362|NCT02660060|Active Comparator|Pramipexole Boehringer Ingelheim Pharma|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
89157363|NCT05340881|Active Comparator|Bright Light Exposure|Participants are exposed to bright light (1,000 lux at eye level) using light glasses (Luminette Version 3) for a maximum duration of 30 minutes upon awakening each day from Monday to Friday for 6 weeks while wearing an actigraph and periodic completion of questionnaires, cognitive assessments, and lab work.
89157364|NCT05340881|Placebo Comparator|Dim Light Exposure|Participants are exposed to exposed to dim light (equivalent intensity of <25 lux) using light glasses (Luminette) for a maximum duration of 30 minutes upon awakening each day from Monday to Friday for 6 weeks while wearing an actigraph and periodic completion of questionnaires, cognitive assessments, and lab work.
89157365|NCT04008979|Experimental|PL-ASA 325 mg|Novel aspirin formulation being tested
89157366|NCT04008979|Active Comparator|IR 325 mg|Immediate release aspirin
89157367|NCT04008979|Experimental|PL-ASA-650|Novel aspirin formulation being tested
89157368|NCT04008979|Active Comparator|IR 650|Immediate release aspirin
89157369|NCT04171154|Experimental|Expectation|Participants are asked to think of three strength which have helped them in prior stressful events. They then have to think of ways how these strength may help them in future stressful situations, i.e. a test in this experiment.
89157370|NCT04171154|Experimental|Acceptance|Participants listen to an audio-instruction on cognitive defusion. They shall observe the thoughts and feelings of stress and, with the help of the instruction, distance themselves from it.
89157371|NCT04171154|No Intervention|Control|Participants wait for the stress-test to start.
89157372|NCT05263583|Experimental|Cohort 1|Cohort 1 will receive a dose of 3.6 mg/m2/day of sepantronium bromide
89157373|NCT05263583|Experimental|Cohort 2|Cohort 1 will receive a dose of 4.8 mg/m2/day of sepantronium bromide
89157374|NCT05263583|Experimental|Recommended Phase 2 Dose - Cohort 3|The recommended Phase 2 dose will be established based on the safety, pharmacokinetic and pharmacodynamic data from Cohort 1 and Cohort 2
88821469|NCT04007289|Placebo Comparator|PLACEBO|Placebo, 1 pill per os twice a day (one in the morning and one in the evening) for 24 months.
89234995|NCT05688696|Experimental|Orelabrutinib Lower Dose|
89234996|NCT05688696|Experimental|Orelabrutinib Higher Dose|
89234997|NCT05688696|Placebo Comparator|Placebo|
89234998|NCT05688254|Experimental|Intervention group|The intervention group will get a 4-week online stress recovery intervention.
89234999|NCT05688254|No Intervention|Control group|The control group will take care as usual.
89235000|NCT05671237|Experimental|bilateral infraorbital+infratrochlear block group|For this group we will perform bilateral infraorbital+infratrochlear block before surgery
89157375|NCT04171232|Active Comparator|Balance It (Group 1)|Children with spastic hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Balance It group. Each subject in first group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
89157376|NCT04171232|Active Comparator|Bubble Pop (Group 2)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Bubble Pop group. Each subject in second group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance.
89157377|NCT04171232|Active Comparator|Scoop'd (Group 3)|Children with hemiplegic cerebral palsy were assessed by Manual Muscle Testing (MMT) to determine the muscle power/strength, Goniometer to determine the Range of Motion (ROM), Disability of Arms, Shoulders, and Hand (DASH) questionnaire to assess the function of upper extremity, and Pediatric Balance Scale to determine the body balance and were assigned in the Scoop'd group. Each subject in third group would complete 8 weeks of augmented reality(AR) therapy sessions which would be aimed to improve the muscle power/strength, range of motion, balance and function. . Each subject would be evaluated before their first AR therapy session (pre- interventionally) and after their last AR therapy session (post-interventionally) for changes in muscle power, ROM, upper extremity function and balance
89157378|NCT00970879|Experimental|cotrimoxazole (high)|CD4 cell count≥350/mm3
89157379|NCT00970879|Active Comparator|mefloquine|CD4 cell count≥350/mm3
89157380|NCT00970879|Experimental|cotrimoxazole (low)|CD4 cell count<350/mm3
89157381|NCT00970879|Active Comparator|mefloquine & cotrimoxazole|CD4 cell count<350/mm3
89157382|NCT05340803|Active Comparator|Group A|Sedation by midazolam alone
89157383|NCT05340803|Active Comparator|Group B|Sedation by midazolam and dexmedetomidine during the first 24 hours
89157384|NCT05340803|Active Comparator|Group C|Sedation by midazolam and magnesium sulfate during the first 24 hours
89157385|NCT02663258|Experimental|Pembrolizumab arm|All participants treated with Pembrolizumab, 200mg iv, 3weekly
89157386|NCT04033172|Experimental|Pyrotinib plus Fulvestrant|
89157387|NCT04231721||Healthy controls|
89157388|NCT00980707|Experimental|inhaled corticosteroid|All asthmatics will start inhaled corticosteroids.
89157389|NCT02665754|Experimental|Active group|In active group, extract of causal allergen will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
89157390|NCT02665754|Placebo Comparator|Placebo group|In placebo group, normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
89157391|NCT05340725|Active Comparator|DEX-IV|Patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. and rectal placebo 30 min. before induction of anesthesia.
89157392|NCT05340725|Active Comparator|DEX-Rectal|Patients will receive rectal DEX suppository formulation at approximately 1µ/kg an iv. saline placebo. at 30 min. before induction of anesthesia.
89157393|NCT05340725|Active Comparator|DEX Nano-Rectal|Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg an iv. saline placebo at 30 min. before induction of anesthesia
89157394|NCT00970957|Experimental|Central RVO - Macular edema - Avastin|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
89157395|NCT00970957|Sham Comparator|Central RVO - Macular edema - Sham|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
89157396|NCT00970957|Experimental|Branch RVO - Macular edema - Avastin|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
89157397|NCT00970957|Sham Comparator|Branch RVO - Macular edema - Sham|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
89157398|NCT02659904|Active Comparator|Less than 2 mm|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: Less than 2 mm remaining palatal tissue thickness
89157399|NCT02659904|Active Comparator|2 mm or more|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: 2 mm or more remaining palatal tissue thickness
89157400|NCT02780999|Experimental|Experimental group|It is a thumb orthotic that does not include wrist joint but includes the metacarpophalangeal joint.
89157401|NCT02780999|Active Comparator|Control group|It is a thumb orthotic that does not include wrist joint neither metacarpophalangeal joint.
89157402|NCT02663180|Experimental|Intervention group|they will be enrolled in an educational program and video contact.
89157403|NCT02663180|No Intervention|Control group|No intervention
89157404|NCT00976105|Active Comparator|Part A: Zolpidem or placebo|This part is designed to examine the acute effects of up to 10mg of a known hypnotic sedative drug (Zolpidem) on cognitive and mood changes sensitve to sedation and tiredess.
89157405|NCT00976105|Experimental|Part B: GSK1521498 or placebo|At least 15 hours after Part A is completed subjects will enter Part B of the study.
89157406|NCT02780921|Experimental|Prehab Group|In the experimental group (Prehab group) compared to the control group, the main objective will be to demonstrate an improvement of the percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board
89157407|NCT02780921|Other|control group|The control group will be treated according to conventional care; will not receive any specific intervention before surgery except nutritional support and physiotherapy at the surgeon's discretion
89157408|NCT04865432|Experimental|UVB treatment|Participants will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined, participants will participate in a 4-week intervention where they will be exposed to their individualized titration evaluation.
89157409|NCT00971113|Experimental|sc-FOS+Sideritis euboea group|Jelly supplemented with short chain fructooligosaccharides and Sideritis euboea extract
89157410|NCT00971113|Placebo Comparator|placebo group|Jelly without short-chain fructooligosaccharides and Sideritis euboea
89157411|NCT00976261|Experimental|GSK1614235|Glucose lowering agent under investigation.
89157412|NCT00976261|Active Comparator|Sitagliptin|Glucose lowering comparator
89157413|NCT00976261|Placebo Comparator|Placebo|Placebo to match GSK1614235 and placebo to match Sitagliptin
89157414|NCT02663024|Experimental|Arm 1|0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
89157415|NCT02663024|Experimental|Arm 2|1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
89157416|NCT02663024|Experimental|Arm 3|1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
89157417|NCT02663024|Active Comparator|Arm 4|0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks
89157418|NCT02780843|Experimental|Computerized Tomography|Patients will be examined with Computerized Tomography (CT) at admission
89157419|NCT02780843|Experimental|Magnetic Resonance Imaging|Patients will be examined with Magnetic Resonance Imaging (MRI) at admission
89157420|NCT02659826|Experimental|anodal tsDCS and gait training|Volunteers will be submitted to anodal transcutaneous spinal cord stimulation and gait training
89157421|NCT02659826|Experimental|cathodal tsDCS and gait training|Volunteers will be submitted to cathodal transcutaneous spinal cord stimulation and gait training
89157422|NCT02659826|Sham Comparator|sham tsDCS and gait training|Volunteers will be submitted to sham transcutaneous spinal cord stimulation and gait training
89157423|NCT02659826|Experimental|High frequency rTMS and gait training|Volunteers will be submitted to high frequency transcranial magnetic stimulation and gait training
89157424|NCT02659826|Experimental|Low frequency rTMS and gait training|Volunteers will be submitted to low frequency transcranial magnetic stimulation and gait training
89157425|NCT02659826|Sham Comparator|sham rTMS and gait training|Volunteers will be submitted to sham transcranial magnetic stimulation and gait training
89157426|NCT00980863|Active Comparator|Lifestyle intervention to increase physical activity|
89157427|NCT00980863|No Intervention|waiting control group|
89157428|NCT00980941|Experimental|Soup with no added starch|
89157429|NCT00980941|Experimental|Soup + 50 g of whole grain starch|
89157430|NCT00980941|Experimental|Soup + 50 g of high amylose corn starch|
89157431|NCT00980941|Experimental|Soup + 50 g of regular corn starch|
89157432|NCT00980941|Experimental|Soup + 50 g maltodextrin starch|
89157433|NCT02781155|Other|Self administration of moxibustion|Participants will be taught to self administer moxibustion to the acupuncture point Zusanli St-36, and apply it daily throughout their chemotherapy treatments
89157434|NCT00976417||1. Patients in the control group|
89157435|NCT00976417||2. Patients in the intervention group|
89157436|NCT02659748|Experimental|Milk fat|A 21-day low-fat (E%) experimental diet including milk fat with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single (bioactive) fatty acids.
89157437|NCT02659748|Experimental|Control Fat|A 21-day low-fat experimental diet. Eucaloric diet to Arm #1 with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single fatty acids. A control fat is used to replace dairy fats.
89157438|NCT00971191|Experimental|treatment|Patients treated with brief exposure to PF-00299804 prior to surgical resection
89157439|NCT02659592|Experimental|infertile cancer survivors|infertile cancer survivors who seek to conceive and had frozen ovarian tissue when diagnosed years before
89157440|NCT02662946|Experimental|ICG- angiography|"Colonic resection margins and colo-rectal anastomosis are intraoperatively assessed using fluorescence angiography to evaluate colonic perfusion. If perfusion at the resection margin is judged insufficient the colon is re-resected to obtain a satisfactory perfusion"
89157441|NCT02662946|Active Comparator|No angiography|Subjective measures are employed to determine anastomotic perfusion
89157442|NCT04007653||Patients treated with heparin+edoxaban for VTE|Patients treated with heparin+edoxaban for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
89157443|NCT04007653||Patients treated with heparin+VKA for VTE|Patients treated with heparin+VKA for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
89157444|NCT02662790|Experimental|Preterm|
89157445|NCT00971347|Active Comparator|Nutrition brochure|Control participants will receive only a nutrition brochure, Finding Your Way to a Healthier You, based on a USDHHS/USDA publication, Dietary Guidelines for Americans 2005.
89157446|NCT00971347|Experimental|Chewing gum + nutrition brochure|Participants in the experimental arm will be instructed to incorporate gum chewing in their diet with a goal of at least 90 minutes per day. The schedule is 20 minutes each after breakfast, lunch and dinner plus 10 minutes mid-morning, mid-afternoon and 1 to 2 hours after dinner. Experimental participants also will be told to chew gum instead of unplanned eating in response to hunger, cravings, preoccupation with eating, or negative feelings.
89157447|NCT02662712|Experimental|Part 1: Single Dose Escalation|The single dose escalation phase of the study will consist of 6 dosing sessions (Sessions I to VI) evaluated in 2 panels (Panels 1 and 2). The dose of JNJ-56136379 will be consecutively escalated over 5 levels, alternating between the 2 panels. Panel 1 will receive 3 single doses (SD1, SD3 and SD3fed) in Sessions I, III and V, respectively. Panel 2 will receive 3 single doses (SD2, SD4 and SD5) in Sessions II, IV and VI, respectively. There will be a washout period of at least 14 days between consecutive JNJ-56136379/placebo dosing in each individual participant.
89235001|NCT05671237|No Intervention|non-block group|For this group we will start the surgery without performing a block
89157448|NCT02662712|Experimental|Part 1: Multiple dose session|After completion of the fifth single dose session another panel of healthy participant (panel 3) receive multiple doses of JNJ-56136379 at one dose level (MDx) or placebo for 12 or 19 consecutive days (Session VII) in fed or fasted conditions.
89157449|NCT02662712|Experimental|Part 2: Multiple dose escalation|Multiple dose levels will be given in Panel 4 in Session VIII (European sites), Sessions IX and X (European and/or Asian sites) Session XI (Asian sites) for 28 consecutive days in fed conditions. Optional Sessions A-B-C (Panel 4) used for further dose evaluations at European and/or Asian sites. Per session, participants will receive JNJ 56136379 or placebo. Dose progression to the next multiple dose level may be adapted based on the emerging safety and PK outcome of the previous dosing levels.
89157450|NCT00976651|Active Comparator|Recombinant FSH|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins. Histology and gene expression is studied on the endometrium.
89157451|NCT00976651|Experimental|human chorionic gonadotropin|"Patients undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.~Histology and gene expression is studied on the endometrium"
89157452|NCT02780141|Experimental|ASP1517 Low dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
89157453|NCT02780141|Experimental|ASP1517 High dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
89157454|NCT04171076|Experimental|Intervention|Intervention: non-invasive spinal cord stimulation
89157455|NCT00976729|Placebo Comparator|Placebo i.v.|
89157456|NCT00976729|Experimental|0.03 mg/kg i.v.|
89157457|NCT00976729|Experimental|0.09 mg/kg i.v.|
89157458|NCT00976729|Experimental|0.25 mg/kg i.v.|
89157459|NCT00976729|Experimental|0.5 mg/kg i.v.|
89157460|NCT00976729|Experimental|1.0 mg/kg i.v.|
89157461|NCT00976729|Experimental|2.0 mg/kg i.v.|
89157462|NCT00976729|Placebo Comparator|Placebo s.c.|
89157463|NCT00976729|Experimental|0.25 mg/kg s.c.|
89157464|NCT00976729|Experimental|0.5 mg/kg s.c.|
89157465|NCT00971503|Sham Comparator|saline injection|
89157466|NCT00971503|Experimental|Autologous bone marrow implantation|
89157467|NCT02659436|Active Comparator|Verbal-linguistic CBT|Participants will receive 4 sessions of verbal cognitive restructuring and exposure therapy delivered in an individual therapy format.
89157468|NCT02659436|Experimental|Imagery-based CBT|Participants will receive 4 sessions of imagery-based cognitive work and behavioural experiments delivered in an individual therapy format.
89157469|NCT00976807|No Intervention|Control|
89157470|NCT00976807|Experimental|Intervention|Pulmonary Rehabilitation
89157471|NCT05341271|Other|digital reminiscence group (DRG)|Experiment group A accepted the planned digital nostalgic group activities using the official account platform of line as a medium, one class per week, 45-50 minutes each time, lasting 8 times.
89157472|NCT05341271|Other|general reminiscence group (GRG)|Experiment group B participated in a general traditional nostalgic group, using actual nostalgic objects or utensils to carry out nostalgic activities, one class per week, 45-50 minutes each time, lasting 8 times
89157473|NCT00976885||Subjects with normal health|
89157474|NCT00976885||Subjects with Stroke|
89157475|NCT00646490||A|patients with parapneumonic pleural effusion due to community acquired pneumonia
89157476|NCT00646490||B|patients with pleural effusion of other etiologies
89157477|NCT02662478||primary gastric GIST|Consisted of all consecutive cases of primary gastric stromal tumors (PGST) that underwent laparoscopic surgery (LS).
89157478|NCT04170842|Experimental|Music intervention|"The music intervention used in the study will be a patient selected list of songs or other music delivered to the participant by passive listening via in-ear or on-ear headphones. They will be given the choice of using their own personal headphones or use a pair provided by the hospital. If choosing to use a hospital device, the earphones provided will be disposable to minimise infection risk from re-use.~Patient preferred music has shown to be more effective than preselected, or prescriptive music. Prescriptive music, if not of the patient's preference, could cause further discomfort, distress or anxiety. Therefore, investigators will use streaming services to provide a bank of music containing a wide range of music and genres to suit the majority of music preferences. Music will also be curated based on feedback from age-appropriate sources to identify common and popular music in the target participant age group."
89157479|NCT04170842|No Intervention|Control|Wound dressing procedure conducted according to clinical practice
89157480|NCT00981097||Specimen Collection|Subjects with a diagnosis of HIV and an untreated aggressive B-cell lymphoma.
89157481|NCT02665520|Active Comparator|stem cells injection in penis|Treatment Injection of adipose derived cells into penis experimental;randomised
89157482|NCT02665520|No Intervention|controled arm|
89157483|NCT00971581|Experimental|FDC KETOPROFEN+OMEPRAZOLE|One capsule of Ketoprofen 200 mg + Omeprazole 20 mg FDC once daily Treatment duration: 4 weeks
89157484|NCT04228913|Other|Ah plus|The root canals obturated with Ah plus root canal sealer (Dentsply, Sirona) and gutta-percha cones with cold lateral condensation technique.
89157485|NCT04228913|Other|ROEKO GuttaFlow® 2|The root canals obturated with GuttaFlow 2 root canal sealer (Coltene,Whaledent) and single tapered gutta-percha cone with cold free flow compaction technique.
89157486|NCT04228913|Other|GuttaCore Obturators|The root canals obturated with GuttaCore obturators (Dentsply,Sirona) and Ah plus root canal sealer with thermoplasticized solid-core carrier technique
89157487|NCT02662400|Experimental|MNCs GROUP|Patients with Type 2 Diabetes mellitus
89157488|NCT00981331|Experimental|Subtalar joint manipulation|Each subject in this group will recieve a subtalar joint manipulation to their symptomatic ankle
89157489|NCT00981331|Sham Comparator|Sham Manipulation|Each subject in this group will recieve a sham subtalar joint manipulation to their symptomatic ankle
89157490|NCT02662322|Experimental|HYPNOSIS|hypnotic communication, confusion procedure during peripheral intravenous catheterization
89157491|NCT02662322|Active Comparator|NOCEBO|negative connotation communication during peripheral intravenous catheterization
89157492|NCT02662322|Placebo Comparator|NEUTRAL|neutral connotation communication during peripheral intravenous catheterization
89157493|NCT00971659|Experimental|insulin glargine + exenatide + metformin|
89157494|NCT00971659|Experimental|Insulin glargine + sitagliptin + metformin|
89157495|NCT00971659|Active Comparator|insulin glargine + metformin|
89157496|NCT02662088||Laparoscopic-lavage|Patients with colonic diverticulitis submitted to laparoscopic lavage
89157497|NCT00977041|Experimental|Neurofeedback|See Intervention description below.
89157498|NCT00648986|Experimental|1|Uncontrolled, Open-Label Pilot Study
89157499|NCT00971815|Active Comparator|escitalopram|A pill containing Escitalopram
89157500|NCT00971815|Placebo Comparator|placebo|a placebo pill
89157501|NCT02662166|Experimental|MRI and biomarkers in bladder cancer|Utilization of MR-imaging and biomarkers to stage bladder cancer and in estimation of chemosensitivity
89157502|NCT02659358||Biosensor + Patient Reported Outcomes (PRO)|Participants will wear a biosensor (Fitbit Charge HR®) continuously for a period of 15 days and respond to PROMIS questionnaires. This is not a chemotherapy or treatment-intervention trial.
89157503|NCT02659280|Active Comparator|Standard of Care Therapy|Home Health or Outpatient Physical therapy services (a minimum of 1x/week).
89157504|NCT02659280|Experimental|Adjunct Therapy|"Home Health or Outpatient Physical therapy services (a minimum of 1x/week) with an adjunct Home Exercise Program given up to 1x/wk via Store and Forward tele-health through the Hudl Technique app."
89157505|NCT05340101|Experimental|experimental group|This group will practiced progressive muscle relaxation exercise
89157506|NCT05340101|No Intervention|control group|This group will not practiced progressive muscle relaxation exercise
89157507|NCT04061486||Experimental arm|One half of the oocyte cohort is microinjected with sperm selected by the Fertile technique, while the other half of the patient's oocyte cohort is microinjected with sperm selected by the MACS technique.
89157508|NCT00872001|Active Comparator|Acadesine|Acadesine intravenous (IV) infusion, plus cardioplegia solution with acadesine, and priming solution with acadesine in the heart lung machine during cardiopulmonary bypass (CPB)
89157509|NCT00872001|Placebo Comparator|Placebo|Normal saline, IV infusion, plus cardioplegia solution with added normal saline, and priming solution with added normal saline in the heart lung machine during CPB
89157510|NCT00981487|Experimental|Fed|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.
89157511|NCT00981487|Experimental|Fasting|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
89157512|NCT04228835|Experimental|ICGFC-LC|ICG fluorescence cholangiography assisted laparoscopic cholecystectomy (ICGFC-LC) arm patients received intravenous bolus of 2.5mg of ICG before the induction of anaesthesia. Near infrared laparoscopic light camera was utilized intermittently during dissection of Calot's triangle until critical view of safety was achieved.
89157513|NCT04228835|No Intervention|Conventional LC|Conventional laparoscopic cholecystectomy (LC) arm patients underwent standard white light laparoscopic cholecystectomy without fluorescence cholangiography.
89157514|NCT00971893||Methylprednisolone Group|
89157515|NCT00694083|Experimental|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles).
89157516|NCT02665208|Active Comparator|Treatment As Usual (TAU)|Participants will receive informational pamphlets and information for a 1800 quit line, and a prescription for a nicotine replacement therapy (NRT) for 7 Days
89157517|NCT02665208|Active Comparator|Nicotine Replacement Therapies|Participants will receive a prescription for a nicotine replacement therapy (NRT) for 7 Days.
89157518|NCT02665208|Active Comparator|Text Message Intervention|Participants will receive up to 5 messages a day with message content informed by principles of cognitive behavioral therapy using software developed and maintained by the National Cancer Institute.
89157519|NCT00977353|Experimental|sarcosine|sarcosine
89157520|NCT00977353|Active Comparator|citalopram|citalopram
89157521|NCT00871923|Experimental|Tarceva + RT|Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
89157522|NCT00971971|No Intervention|Control|Traditional SLED
89157523|NCT00971971|Experimental|Profiling|dialysate temperature reduction with Na and ultrafiltration (UF) profiling
89157524|NCT04170530|Experimental|mFOLFOXIRI|patients received FOLFOXIRI alone for 6 cycles before surgery.
89157525|NCT00981565|Active Comparator|Operative|
89157526|NCT00981565|Active Comparator|Conservative|
89157527|NCT02661854|Experimental|MM09 Mannosylated 5.000 subcutaneous|5.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
89157528|NCT02661854|Experimental|MM09 Mannosylated 10.000 subcutaneous|10.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
89157529|NCT02661854|Experimental|MM09 Mannosylated 30.000 subcutaneous|30.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
89157530|NCT02661854|Experimental|MM09 Mannosylated 50.000 subcutaneous|50.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
89157531|NCT02661854|Experimental|MM09 Mannosylated 5.000 sublingual|5.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
89157532|NCT02661854|Experimental|MM09 Mannosylated 10.000 sublingual|10.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
89157533|NCT02661854|Experimental|MM09 Mannosylated 30.000 sublingual|30.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
89157534|NCT02661854|Experimental|MM09 Mannosylated 50.000 sublingual|50.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
89157535|NCT02661854|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
89157536|NCT00694239|No Intervention|B|Standard Care
89157537|NCT00694239|Experimental|A|Risk Assessment plus standard care
89157538|NCT02779517||Focus groups- Patients|Subjects with or without an upper extremity disability will be asked to observe and interact with the mobile service robot.
89157539|NCT02779517||Focus Groups-clinicians|Clinicians with neuro-rehab experience.
89157540|NCT05161897|No Intervention|Control Group|"This arm will receive generalized nutrition therapy throughout the study.~Participants will receive dietary recommendations based on their needs and will be educated about the recommended amount of carbohydrates for each meal and the carbohydrate choices. Participants will also be provided with a CGM device; however, participants will be blind to the CGM recordings until the end of the study."
89157541|NCT05161897|Experimental|Intervention Group|"This arm will receive both individualized nutrition therapy and generalized nutrition therapy throughout the study.~Participants will receive dietary recommendations based on their needs and will be educated about the recommended amount of carbohydrates for each meal and the carb choices. Participants will also be provided with a CGM device and will be educated to review their blood glucose measurements and record above range measures along with time, types and amount of food items consumed, cooking method, and any type of physical activity within one hour before or after the meal. This information will be reviewed by one of the research staff at each visit and will be used to set individualized goals for modifying diet and controlling blood glucose. Participants will visit every 10 days for 30 days to conduct measurements, replace their CGM, set new goals based on their food diary and CGM recordings, and receive further dietary recommendations."
89157542|NCT02617017|Experimental|Buspirone|
89157543|NCT02617017|Placebo Comparator|Placebo|
89157544|NCT02780219|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
89157545|NCT02780219|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
89157546|NCT00981643|Experimental|Multiple Sclerosis, Meditation group|Multiple Sclerosis, Meditation instruction and practice group
89157547|NCT00981643|No Intervention|Multiple Sclerosis, Control group|Multiple Sclerosis, Control group
89157548|NCT00981643|Experimental|Peripheral Neuropathy, Meditation group|Peripheral Neuropathy, Meditation instruction and practice group
89157549|NCT00981643|No Intervention|Peripheral Neuropathy, Control group|Peripheral Neuropathy, Control group
89157550|NCT05298111|Active Comparator|Formulation 3|Formulated MMT peel powder (provide 5 g dietary fiber per day)
89157551|NCT05298111|Placebo Comparator|Control|Glucose
89157552|NCT02779439|Experimental|3rd party CTL infusion|Virus specific CTLs
89157553|NCT02661698|Placebo Comparator|Placebo 1|"Placebo~All participants will be given a placebo for the first visit. The other 3 arms will be randomised in a counterbalanced order."
89157554|NCT02661698|Placebo Comparator|Placebo 2|Placebo
89157555|NCT02661698|Active Comparator|DHA rich oil|Omega-3 oil: DHA enriched
89157556|NCT02661698|Active Comparator|EPA rich oil|Omega-3 oil: EPA enriched
89157557|NCT00977587|Active Comparator|Saccharomyces Cerevisiae CNCM I-3856|2 weeks of treatment with Saccharomyces Cerevisiae CNCM I-3856 1 capsule twice a day, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).
89157558|NCT00977587|Placebo Comparator|placebo|"Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~Calcium phosphate, Dibasic 472.0 mg~Maltodextrin DE14 112.1 mg~Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
89157559|NCT02616861|Experimental|IW-1973|1973 Escalating Doses
89157560|NCT02616861|Placebo Comparator|Placebo|Matching Placebo
89157561|NCT02779595||Lung surgery|26 patients (up to 36) undergoing lung surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
89157562|NCT02779595||Flail chest|8 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
89157563|NCT00972049|Experimental|1|Capsule administered once orally
89157564|NCT00972049|Placebo Comparator|2|Capsule administered once orally
89157565|NCT02616939||Patients with suspected cardiac disease|"Patients eligible for cardiac CT will be included with a focus on symptomatic patients with low-intermediate risk for obstructive coronary artery disease.~Patients will undergo Cardiac CT scanning (with the SpotLight CT)."
89157566|NCT02656316|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
89157567|NCT02656316|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
89157568|NCT00981721|Experimental|1|cediranib 20mg
89157569|NCT00981721|Experimental|2|cediranib 30mg
89157570|NCT02617095|Experimental|T2762|One drop of T2762 in each eye 3 to 6 times daily
89157571|NCT02617095|Active Comparator|Optive|One drop of Optive in each eye 3 to 6 times daily
89157572|NCT02659046||FH30|Patients treated by Pirkanmaa physician-staffed emergency medical service (EMS) unit
89157573|NCT02659046||FH10|Patients treated by Helsinki and Uusimaa physician-staffed emergency medical service (EMS) unit
89157574|NCT04133181|Experimental|Guided endodontic surgery|Use of a 3D surgical guide in endodontic surgery
89157575|NCT04133181|Placebo Comparator|Conventional endodontic surgery|Use of a mock guide in endodontic surgery
89157576|NCT04007887|Experimental|Intervention|Post-MI patients attending an adult education program designed to inform and motivate them on how to best control cardiovascular risk factors as a means to offer optimized secondary prevention of cardiovascular events
89157577|NCT04007887|No Intervention|Controls|Usual care for post-MI patients
89157578|NCT05339867|No Intervention|Mothers following Standard of Care|Participants randomized to this group will receive standard of Care for Postpartum. The standard of care control condition will be what women would typically get at hospital discharge (typically an Electronic Medical Record (EMR) generated document; a non-standardized, generalized brief review of how to care for self and the baby).
89157579|NCT05339867|Experimental|Mother Using PM3 Intervention|Participants in this group will be using the PM3 intervention. PM3 is a maternal mortality prevention and optimal reproductive health promotion mobile app created based on formative work with Black women to ultimately increase postpartum comorbidity self-management, promote timely provider notification of postpartum-related complications, and ensure access to social support and community resources.
89157580|NCT00649298|Experimental|extended hours|24 or more hours per week of hemodialysis
89157581|NCT00649298|Active Comparator|standard hours|18 or less hours per week of hemodialysis
89157582|NCT04133337|Experimental|Apatinib Combined With SHR-1210 Injection|"Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery.~Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion.~Surgery:~The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose."
89157583|NCT02780453|Experimental|Negative pressure dressing|Negative pressure dressing
89157584|NCT02780453|Active Comparator|Standard dressing|Standard wound dressing
89157585|NCT04133259|Experimental|HLX10, in patients with CHB|HLX10: 1 mg/kg at 0, 4th, 8th week (maximum 3 doses). Concomitant antiviral medications: take Nucleoside/nucleotide analogues (NAs) starting from at least 2 weeks before the first dose of HLX10 until 12 weeks after the last dose of HLX10 infusion.
89157586|NCT04169984|Active Comparator|Myofunctional Therapy|This therapy consists of the practice of isotonic, isokinetic and isometric exercises that improve mobility and coordination and increase the muscular strength of the orofacial structures that contribute to the obstructive sleep apnea etiopathogenesis.
89157587|NCT04169984|Placebo Comparator|Placebo|The placebo group will be instructed in simulation exercises that do not alter the function or morphology of the upper airway.
89157588|NCT00977821|Active Comparator|fresh|Embryo transfer with fresh oocytes
89157589|NCT00977821|Experimental|Frozen|Embryo transfer with vitrified oocytes
89157590|NCT02780063|Experimental|Lenstar Biometry|Lenstar biometry will be performed on each eye prior to dilation. Subjects eyes will be dilated and subject will wait 20 minutes. Lenstar biometry will be performed after the 20 wait time.
89157591|NCT02616471|Experimental|High-fat cheese (HFC) group|"The subjects in the HFC group will be supplied with equal amounts of two types of regular/high fat cheeses. The cheeses are normal-fat Danbo (Riberhus, 25% fat, Arla, DK) and normal-fat Cheddar (Sharp Cheddar, 32% fat, Cabot, US).~No further dairy and cheese consumption is allowed"
89157592|NCT02616471|Experimental|Low-fat cheese (LFC) group|The subjects in the LFC group will be supplied with equal amounts of two types of reduced/low fat cheeses. The cheeses are reduced-fat Danbo(Cheasy, 13% fat, Arla, DK) and reduced-fat Cheddar (Sharp Light Cheddar, 16% fat, Cabot, US). No further dairy/cheese consumption is allowed.
89157593|NCT02616471|Active Comparator|No-cheese/carbohydrate group (CTR)|For subjects in the CTR group, cheese is replaced by simple and starchy carbohydrates in jam and white bread, which will be supplied by the department. The daily energy and sodium contents will be matched to those of the cheese in the HFC group. No dairy/cheese consumption is allowed.
89157594|NCT04169750|Experimental|Exergames|
89157595|NCT04169750|Active Comparator|Adaptive COGNI-TRAcK|
89157596|NCT04169750|Sham Comparator|Sham COGNI-TRAcK|
89157597|NCT04228133|Experimental|Home-delivered attention control training (ACT)|A home-delivered ACT comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV).
89157598|NCT04228133|Placebo Comparator|Home-delivered attention bias modification (ABM)|A home-delivered ABM comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat.
89157599|NCT02616549|Experimental|Sudarshan Kriya Yoga|
89157600|NCT02616549|No Intervention|Waitlist Control|
89157601|NCT00972673|Experimental|arm 1|In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.
89157602|NCT00972673|Placebo Comparator|arm 2|In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.
89157603|NCT02661386|Other|Manometry Device|"During the last 10 minutes of subjects waking up from anesthesia, the motility procedure will be performed."
89157604|NCT04228055|Experimental|CLIPP2|24 Week Lifestyle Modification Intervention
89157605|NCT02616315|Placebo Comparator|Group A: Placebo|Naltrexone hydrochloride (HCl)/bupropion hydrochloride (HCl) placebo-matching tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
89157606|NCT02616315|Experimental|Group B: Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg, tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
89157607|NCT00978055|Experimental|1|Liothyronine Sodium Tablets, 50 mcg
89157608|NCT00978055|Active Comparator|2|Cytomel® Tablets, 50 mcg
89157609|NCT02661230|Experimental|COGNIPLUS|Exercise-Gaming
89235002|NCT05597085||Adult relapsed or refractory B Cell ALL|Adult patients whose B Cell ALL has occurred again after the last treatment or patients who never responded to prior treatment
89235003|NCT05577481|Sham Comparator|functional MRI-guided iTBS(sham group)|The stimulating site of the left DLPFC is targeted based on functional MRI, where the most negative functional connectivity with the left pgACC. The MNI coordinate is (-10, 42, 6).
89235004|NCT05577481|Experimental|functional MRI-guided iTBS (pgACC-DLPFC)|The stimulating site of the left DLPFC is targeted based on functional MRI, where the most negative functional connectivity with the left pgACC. The MNI coordinate is (-10, 42, 6).
89157610|NCT02779283|Experimental|Arm I (AML)|Patients receive cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 30 minutes on days 1-3.Patients receive cyclophosphamide IV over 3 hours twice daily (BID) on days 1-3, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV on day 4, dexamethasone PO on days 1-4 and 11-14, and rituximab IV on day 1 and 11 (day 11 only of course 1). Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
89157611|NCT02779283|Experimental|Arm II (ALL)|Patients receive cytarabine IV over 2 hours BID on days 2-3, methotrexate IV over 2-22 hours on day 1, methylprednisolone sodium succinate IV BID on days 1-3, leucovorin calcium IV every 6 hours until methotrexate level is < 0.05 uM and rituximab IV on days 1 and 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
89157612|NCT04133103|No Intervention|First ambulation at 24 hours after operation|
89157613|NCT04133103|Experimental|First ambulation at 4 hours after operation|
89157614|NCT00978133|Active Comparator|Skin Staples|Skin closure with skin staples
89157615|NCT00978133|Experimental|Dermabond|Closure of abdominal wound with dermabond (2-octylcyanoacrylate)
89157616|NCT02661308|Experimental|Systematic bright light exposure|Systematic bright light exposure for 30 min. for 4 weeks
89157617|NCT02661308|Active Comparator|Systematic dim light exposure|Systematic dim light exposure for 30 min. for 4 weeks
89157618|NCT02616003|Other|Super-super Obese Patients|Multimorbid, super-super obese patients that need preoperative conditioning therapy (intervention 1: Liraglutide, intervention 2: aminosteril hepa 8%, intervention 3: Caloric diet with 1000 kcal) for weight loss surgery to achieve technical operability.
89157619|NCT02661152|Experimental|Radio-/Chemoradiotherapy + nimorazole|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole but receiving the drug, which is normal standard radiotherapy of HNSCC in Denmark.
89157620|NCT02661152|No Intervention|Radio-/Chemoradiotherapy|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole and not receiving the drug, that is normally part of standard radiotherapy of HNSCC in Denmark.
89157621|NCT00697671|Other|Strata A|Patients with ALL, CML, JMML, MDS, or NHL with bone marrow relapse after stem cell transplant.
89157622|NCT00697671|Other|Strata B|Patients with ALL, CML, JMML , MDS, or NHL with primary induction failure and persistent disease; or participants with relapsed ALL, CML, JMML, MDS, or NHL with persistent disease after re-induction
89157623|NCT03922945|Experimental|VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg)|Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-56: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily
89157624|NCT03922945|Experimental|VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)|Weeks 1-2: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Weeks 3-12: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Weeks 13-14: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 15-56: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
89157625|NCT03922945|Placebo Comparator|Placebo|Subjects will receive placebo oral capsule, once daily for up to 56 weeks
89157626|NCT02616159|Experimental|Oatmeal 1|40 g cereal
89157627|NCT02616159|Experimental|Oatmeal2|40 g cereal
89157628|NCT02616159|Experimental|Oatmeal 3|40 g cereal
89157629|NCT02616159|Placebo Comparator|Ready to eat cereal|32.2 g cereal
89157630|NCT02616159|Placebo Comparator|Hot cereal|28.8 g cereal
89157631|NCT02616237|Experimental|Intervention Group|"Lifestyle Intervention: The interventions include participation in a private research group on Facebook for health education, self monitoring and social support. Participants will receive 12 weekly lessons related to nutrition, physical activity, Chinese food therapy, acupressure, weight loss. A registered nutritionist and a registered Chinese medicine practitioner will join the Facebook group as health partners. Both of them are also registered nurses.~Besides the Facebook contents, the participants will also receive government printed health information on healthy eating, physical activity, obesity and cancers."
89157632|NCT02616237|No Intervention|Control Group|The participants randomized into the Control Group will only receive government printed health information on healthy eating, physical activity, obesity and cancers.
89157633|NCT00697749|Experimental|Group A|
89157634|NCT00697749|Active Comparator|Group B|
89157635|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation, it is proposed by one of the investigators, patients that clinical data from this psychiatric examination, conducted as part of their usual care, are recorded as part of the research that their is proposed and explained. An information note is then distributed and not collected their opposition
89157636|NCT02615847|Experimental|Memantin arm|Memantinhydrochlorid, administered once per day during 12 month. Dosage is from 0-20 mg.
89157637|NCT02779907||Study Population|Children aged 4-6 years resident in Chikwawa District.
89157638|NCT02615769|Experimental|Invitation with focused information of spirometry|
89157639|NCT02615769|Active Comparator|Standard invitition|
89235005|NCT05574634|Experimental|Older adult participants|Older adult participants in the study will complete one of two variants of an attention practice program and that will be preceded by, and followed by, an fMRI scan session featuring an attention task
89235006|NCT05574634|No Intervention|Younger adult participants|Younger adult participants in the study will complete one fMRI scan session featuring an attention task
89235007|NCT05557474||Lung cancer post surgery recurrence follow up|Lung adenocarcinoma, stage IA/IB/II/IIIA post-surgery follow up
89235008|NCT05544981|Active Comparator|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
88821470|NCT03997474|Experimental|Cohort A|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.
89157640|NCT05236985|Active Comparator|Bolus arm|Patients will receive 3 IU oxytocin IV bolus over 15 seconds after delivery of the baby/uterine cord clamping and a maintenance infusion of 0.9% Saline will be started at 225ml/hr. If uterine tone is inadequate after 3 minutes, a second bolus of 3 IU oxytocin will be given. If uterine tone is inadequate after an additional 3 minutes, a third bolus of 3 IU Oxytocin IV is given over 15 seconds. If after an additional 3 mins uterine tone is still inadequate, a second infusion consisting of oxytocin 3 IU/hr is started at 100ml/hrs and continued for a total of 4 hours, second line uterotonic agents (Methergine, Hemabate and/ or Cytotec) will be given, and the maintenance 0.9% Saline infusion will be changed to 450 ml/hr for a total of 1 hour, then changed to 38 ml/ hour for the following 3 hours. If uterine tone is considered adequate at 3, 6 or 9 minutes, a second infusion of oxytocin 3 IU/hr (100ml/hr) is started and maintained for 4 hours.
89157641|NCT05236985|Active Comparator|Infusion arm|Patients will receive a bolus of IV 0.9% Saline over 15 seconds after delivery of the baby/uterine cord clamping and a maintenance infusion of 18 IU/hr Oxytocin IV (225ml/hr). If uterine tone is inadequate after 3 minutes, a second bolus of 0.9% Saline will be given. If uterine tone is inadequate after another 3 minutes, a third bolus of 0.9% Saline will be given. If after another 3 mins uterine tone is inadequate, a second infusion of 0.9% Saline will be started for 4 hours, second line uterotonic agents (Methergine, Hemabate and/or Cytotec) will be given, and the Oxytocin infusion will be changed to 36 IU/hour (450 ml/hr) for a total of 1 hour, and then changed to 38 ml/hr for the following 3 hours. If uterine tone is considered adequate at 3, 6 or 9 minutes, a second infusion of 0.9% Saline at 100 ml/hr will be started and maintained for 4 hours, along with the maintenance infusion of 18 IU/hr (225 ml/ hr) for a total of 1 hour, then changed to 38 ml/hr for an additional 3 hours.
89157642|NCT02615613|Experimental|High acceptability meal|A custard recipe was used as the high acceptability meal
89157643|NCT02615613|Experimental|Low acceptability meal|The regular custard recipe was reformulated to yield a low acceptability version
89157644|NCT04196153|Active Comparator|Neuronavigation / O-arm group|Under neural navigation with the use of intraoperative three dimensional imaging quality O-arm , pedicle screws inserted at the thoraolumbar/lumbar spine after insertion of the reference frame at the spinous process above or below the level of instrumentation followed by O-Arm imaging and uploading the images to the stelth navigation system and pedicle tract identification using instrumented tools guided by the Navigation polyaxial screws is inserted.
89157645|NCT04196153|Active Comparator|Cervical distractor screws group|pedicle screws inserted using marker screws after posterior exposure of thoracolumbar /lumbar spine by either open midline posterior exposure or minimal invasive posterior wiltse style exposure with expandable tubular retractor, anatomical landmark for insertion of pedical screws identified and followed by inserting of a cervical distraction screw size 3 / 12 mm as a stable marker using high speed drill. C-arm floro is used to take antroposterior and lateral view to confirm the position of the marker screws at this stage.free hand technique supported by the images provided to cannulate the pedicle with the use of information on the images taken for all the marker screws simultaneously.
89157646|NCT04133025|Active Comparator|Conventional vestibular rehabilitation|Conventional vestibular rehabilitation
89157647|NCT04133025|Active Comparator|Vestibular rehabilitation with software|
89157648|NCT03922477|Experimental|Atezolizumab + Hu5F9-G4|An initial safety evaluation will be performed in participants with relapsed AML. If atezolizumab in combination with Hu5F9-G4 is initially safe and tolerable in participants an additional cohort with R/R AML will be evaluated to further test the safety and anti-tumor activity. If dose-limiting toxicities (DLT) are observed in >=33% of participants in this initial cohort, a dose de-escalation cohort will be enrolled. If less than 33% of enrolled and dosed participants in any given cohort experience a DLT, an expansion cohort of 15 participants will be enrolled at the highest tolerated dose for this combination. If a dose de-escalation cohort is needed, an expansion cohort will be enrolled at the lower tolerated dose for this combination.
89157649|NCT00978211|Experimental|DOTA-TOC|Treatment arm
89157650|NCT02780375||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
89157651|NCT00981877|Active Comparator|1|This group will receive S. Boulardii Probiotic and Oral rehydration as needed
89157652|NCT00981877|Active Comparator|2|This group will receive a mixed Probiotic preparation and oral rehydration as needed
89157653|NCT00981877|Placebo Comparator|3|This group will receive a placebo, and oral rehydration as needed
89157654|NCT00867165|Experimental|Ezetimibe|Ezetimibe 10-mg tablet once daily for 12 weeks
89157655|NCT00867165|Placebo Comparator|Placebo|Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks
89157656|NCT05071469|No Intervention|Control Group (CG)|Control group
89157657|NCT05071469|Experimental|Kinesiotaping Group (KG)|Experimental group
89157658|NCT05071469|Experimental|Mulligan Mobilization Technique Group (MG)|Experimental group (2)
89157659|NCT00981955|Active Comparator|75mg caffeine|
89157660|NCT00981955|Active Comparator|50mg l-theanine|
89157661|NCT00981955|Active Comparator|75mg caffeine and 50mg l-theanine|
89157662|NCT00981955|Placebo Comparator|0mg caffeine/l-theanine|
89157663|NCT00972829|Experimental|Crestor|Crestor 10 or 20 milligrams
89157664|NCT00972829|Active Comparator|Ezetimibe|Ezetimibe 5 or 10 milligrams
89157665|NCT05339009||All patients receive conventional dialysis treatment at inclusion|All patients receive conventional dialysis treatment at inclusion
89157666|NCT00978367|Experimental|Drug, intradermal avotermin (Juvista)|
89157667|NCT00978367|Placebo Comparator|Placebo (vehicle)|
89157668|NCT00972907|Experimental|Treatment|Nifedipine coated suppositories BID.
89157669|NCT02595593|Active Comparator|Rib Fixation System|This group of subjects will receive a surgical rib plating procedure after trauma
89157670|NCT02595593|No Intervention|Critical Care and Pain Control|This group will receive critical care and pain control after trauma
89157671|NCT02615457|Experimental|Arm I|Patients taking Huaier Granule for adjuvant treatment after the triple negative breast cancer has been surgically removed. The Huaier Granule (Qidong Gaitianli Medicines Co., Ltd.) should be given orally from the 3rd day after surgery up to 5 years after surgery or until study termination.
89157672|NCT02615457|No Intervention|Arm II|Patients not taking Huaier Granule after the triple negative breast cancer has been surgically removed.
89157673|NCT04008433|Experimental|Lidocaine pre-intravenous injection|The initial dose of lidocaine for pre-injection was set at 0.5mg /kg according to previous literature and preliminary test results. The dose of lidocaine was according to the patients' pain level. If there is no pain (negative reaction), the dose of lidocaine in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of lidocaine will be increased in the next patient until the patient is painless.
89157674|NCT00978523|Experimental|Treatment with AR-12|This is a single-agent, open-label, Phase 1, dose-escalation study in adult patients with advanced or recurrent solid tumors or lymphoma. Patients will receive orally administered AR-12 once daily for 28 consecutive days. The first dosing cycle will be followed by at least a 7 day off-treatment period; however, no off-treatment period will be scheduled between subsequent treatment cycles
89157675|NCT04132479|Experimental|Sequential therapy|Sequential Clarithromycin + Amoxycillin + Tinidazole + rabeprazole by mouth (Both amoxycillin 1000mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days, followed by clarithromycin 500 mg every 12 hours, tinidazole 500mg every 12 hours and rabeprazole 20 mg every 12 hours for 5 days)
89157676|NCT04132479|Active Comparator|Concomitant therapy|Concomitant clarithromycin 500mg every 12 hours + amoxycillin 1000mg every 12 hours + tinidazole 500mg every 12 hours + rabeprazole 20mg every 12 hours (all drugs by mouth for 14 days).
89157677|NCT00972985|Experimental|modafinil|All healthy control subjects receive modafinil in this crossover design
89157678|NCT00972985|Experimental|methylphenidate|All healthy control subjects receive methylphenidate in this crossover design
89157679|NCT00972985|Experimental|lorazepam|All healthy control subjects receive lorazepam in this crossover design
89157680|NCT00972985|Placebo Comparator|placebo|All healthy control subjects receive placebo in this crossover design
89157681|NCT02779361|Experimental|Green tea|Green tea consumption along 7 days.
89157682|NCT02779205|Other|0-1 year old child|Adipose tissue sample in 0-1 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
89157683|NCT02779205|Other|>1-10 year old child|Adipose tissue sample in >1-10 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
89157684|NCT02779049||MAC-LD|patients with MAC-LD Do Blood examination
89157685|NCT02779049||Control|controls without NTM or tuberculosis infection Do Blood examination
89157686|NCT02779049||Tuberculosis infection|patients with tuberculosis infection which diagnosis by culture or typical pathology Do Blood examination
89157687|NCT02779049||MAC colonization|patients with MAC pulmonary colonization by American Thoracic Society guideline Do Blood examination
89157688|NCT02779127|Other|Intervention|"Subjects exposed to passive smoking at least 1 hour per day since 1 year, non active smokers, non exposed to passive smoking at home~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
89157689|NCT02779127|Other|Control|"Subjects non expose to passive smoking at home or at work, non active smokers~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
89157690|NCT00867087|Experimental|Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2|Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
89157691|NCT04227743|Experimental|patients with endobronchial lesions|flexible bronchoscoy will be performed to patients with endobronchial lesions and biopsy from the lesions by forceps and cryoprope will be obtained
89157692|NCT02778425|Experimental|Secondary prevention-1|Endoscopic therapy+ beta blockers
89157693|NCT02778425|Experimental|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
89157694|NCT02778425|Experimental|Primary prevention-1|Beta blockers
89157695|NCT02778425|Experimental|Primary prevention-2|Endoscopic therapy
89157696|NCT02778425|Experimental|Primary prevention-3|Endoscopic therapy+ PSE
89157697|NCT02778425|Experimental|Acute bleeding-1|Somatostatin+endoscopic therapy
89157698|NCT02778425|Experimental|Acute bleeding-2|Somatostatin+endoscopic therapy+PSE
89157699|NCT04228757|Experimental|Investigational Herbal Blend|A phytoestrogen herbal blend
89157700|NCT04228757|Placebo Comparator|Placebo|Tablet without active ingredients
89157701|NCT04993469|Experimental|Genital sensation and sexual functioning assessment|"Genital sensation testing with clinical assessment and self-examination questionnaire.~Sexual functioning testing with questionnaires."
89157702|NCT04227041|Experimental|HER2 positive metastatic colorectal cancer|
89157703|NCT05058131|Active Comparator|Dietary fibre|Butyrate-promoting dietary fibre
89157704|NCT05058131|Placebo Comparator|Placebo compound|Placebo compound
89157705|NCT02778737|Experimental|ACT-based intervention|The Acceptance and Commitment Therapy + MTAU consists of an unpublished manual developed for the purposes of the project (Karekla et al., 2013). The 8, 90-min weekly group sessions focus in fostering psychological flexibility or the capacity to engage or change behaviors based on what a situation affords and an individual's goals, needs, and desires (Hayes et al., 2004). The ACT protocol involves helping patients to engage in values-based behaviors while remain in contact with pain, especially, when efforts to control or reduce it fail or contribute to suffering.
89157706|NCT02778737|Active Comparator|CBT-based intervention|The Cognitive Behavioral group + MTAU consists of an unpublished manual developed by Kalantzi-Azizi & Karademas (2003). It includes 8, 90-min weekly group session and primarily focuses on teaching patients to manage their pain by utilizing various techniques, such as activity pacing, muscle relaxation(i.e., progressive muscle relaxation, diaphragmatic breathing, guided imagery), pain recording, thought challenging, problem solving skills, relapse prevention, etc. The CBT protocol involves helping patients to learn to control their pain and to modify dysfunctional thoughts that accompany it.
89157707|NCT02778035|Experimental|60 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 60 min).
89157708|NCT02778035|Experimental|30 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 30 min).
89157709|NCT02778035|Experimental|0 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 0 min).
89157710|NCT00545233|Experimental|PEG-INF alpha-2a + ribavirin+ pioglitazone|Participants received pioglitazone in a 16 week run-in period (30 mg per day orally for 8 weeks followed by 45 mg per day orally for 8 weeks). Participants then received piogliatzone 45 mg daily orally plus 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase. Participants received 45 mg of pioglitazone per day orally in the 24 week follow-up period.
89157711|NCT00545233|Active Comparator|PEG-INF alpha-2a + ribavirin|Participants received 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase followed by a treatment free 24 week follow-up period.
89157712|NCT02778815|Experimental|Kindness for Mums|An online self-help course designed to promote self-kindness and self-compassion in new mothers
89157713|NCT02778815|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help intervention once the RCT is complete.
89157714|NCT05190731|Sham Comparator|Contact touch at occipital region, but no actual cranial manipulation|Each subject was treated with Sham by CSPOMM and NMM board-certified osteopathic physicians. The physician's finger pads of both hands were placed underneath the supine subject's head in contact on the occipital squama medial to the lambdoidal and occipitomastoid sutures. The subject's head rested passively on the finger pads for 3 minutes. No cranial manipulative forces were applied.
89157715|NCT05190731|Active Comparator|Osteopathic cranial manipulative medicine|Each subject was treated with CV4 technique by CSPOMM and NMM board-certified osteopathic physicians. All CV4 treatments were performed by one individual according to standardized protocol. The physician's hands were placed underneath the occiput with the thenar eminences in contact on the occipital squama medial to the lambdoidal and occipitomastoid sutures. Inherent cranial rhythmic motion was identified and thenar eminences followed occipital motion anteriorly during the extension phase until a still point was attained. This position was held until the still point released (usually about 3 minutes) and normal cranial motion ensued.
89157716|NCT02393248|Experimental|Part 1: Intermittent pemigatinib 1/2/4 mg QD|Participants self-administered oral pemigatinib 1/2/4 milligrams (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
89157717|NCT02393248|Experimental|Part 1: Intermittent pemigatinib 6 mg QD|Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
89157718|NCT02393248|Experimental|Part 1: Intermittent pemigatinib 9 mg QD|Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
89157719|NCT02393248|Experimental|Part 1: Intermittent pemigatinib 13.5 mg QD|Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
89157720|NCT02393248|Experimental|Part 1: Intermittent pemigatinib 20 mg QD|Participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
89157721|NCT02393248|Experimental|Part 1: Continuous pemigatinib 9 mg QD|Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
89157722|NCT02393248|Experimental|Part 1: Continuous pemigatinib 13.5 mg QD|Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
89157723|NCT02393248|Experimental|Part 1: Continuous pemigatinib 20 mg QD|Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
89157724|NCT02393248|Experimental|Part 1: Continuous pemigatinib 7.5 mg BID|Participants self-administered oral pemigatinib 7.5 mg twice daily (BID) on Days 1 through 21 of each 21-day cycle.
89157725|NCT02393248|Experimental|Part 1: Continuous pemigatinib 10 mg BID|Participants self-administered oral pemigatinib 10 mg BID on Days 1 through 21 of each 21-day cycle.
89157726|NCT02393248|Experimental|Part 2: Intermittent pemigatinib 9 mg QD|Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
89157727|NCT02393248|Experimental|Part 2: Intermittent pemigatinib 13.5 mg QD|Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
89157728|NCT02393248|Experimental|Part 2: Continuous pemigatinib 9 mg QD|Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
89157729|NCT02393248|Experimental|Part 2: Continuous pemigatinib 13.5 mg QD|Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
89157730|NCT02393248|Experimental|Part 2: Continuous pemigatinib 20 mg QD|Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
89157731|NCT02393248|Experimental|Part 3: Gem/Cis/intermittent pemigatinib 9 mg|Participants received gemcitabine (Gem) intravenously starting at 1000 mg/meters squared (m^2) (30 minutes) on Days 1 and 8 of each 21-day cycle. Cisplatin (Cis) was administered intravenously starting at 70 mg/m^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.
89235009|NCT05544981|Placebo Comparator|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
89235010|NCT05516069|Experimental|Intervention|All participants
89157732|NCT02393248|Experimental|Part 3: Gem/Cis/intermittent pemigatinib 13.5 mg|Participants received gemcitabine intravenously starting at 1000 mg/m^2 (30 minutes) on Days 1 and 8 of each 21-day cycle. Cisplatin was administered intravenously starting at 70 mg/m^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle. Both gemcitabine and cisplatin doses could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of gemcitabine/cisplatin.
89157733|NCT02393248|Experimental|Part 3: Tras/intermittent pemigatinib 13.5 mg|Trastuzumab (Tras) was administered as an open-label, commercial product at an initial dose of 8 mg/kilograms (kg) over a 90-minute intravenous infusion, followed by 6 mg/kg over a 30- to 90-minute intravenous infusion once every 3 weeks. The dose could have been adjusted for toxicity management, per commercial labeling. The investigator could have interrupted, modified, or discontinued trastuzumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of trastuzumab.
89157734|NCT02393248|Experimental|Part 3: Doc/intermittent pemigatinib 13.5 mg|Participants received docetaxel (Doc) intravenously starting at 75 mg/m^2 (1 hour) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued chemotherapy with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of docetaxel.
89157735|NCT02393248|Experimental|Part 3: Pem/intermittent pemigatinib 9 mg|Participants received pembrolizumab (Pem) intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
89157736|NCT02393248|Experimental|Part 3: Pem/intermittent pemigatinib 13.5 mg|Participants received pembrolizumab intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
89157737|NCT02393248|Experimental|Part 3: Pem/continuous pemigatinib 13.5 mg|Participants received pembrolizumab intravenously at 200 mg (30 minutes) once every 3 weeks on Day 1 of each cycle. The dose could have been adjusted for toxicity management per commercial labeling. The investigator could have interrupted, modified, or discontinued pembrolizumab with medical monitor approval. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle. It was permissible to continue pemigatinib administration during the toxicity break of pembrolizumab.
89157738|NCT02393248|Experimental|Part 3: Ref/continuous pemigatinib 9 mg|Retifanlimab (Ref) was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.
89157739|NCT02393248|Experimental|Part 3: Ref/continuous pemigatinib 13.5 mg|Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.
89157740|NCT02393248|Experimental|Part 3: Ref/continuous pemigatinib 20 mg|Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.
89157741|NCT00601484|Experimental|1|
89157742|NCT00601484|Placebo Comparator|2|
89157743|NCT04228601|Experimental|Fluzoparib+mFOLFIRINOX|Fluzoparib+mFOLFIRINOX followed by Fluzoparib maintenance monotherapy
89157744|NCT04228601|Placebo Comparator|Placebo+mFOLFIRINOX|Placebo+mFOLFIRINOX followed by placebo maintenance monotherapy
89157745|NCT00978601|Experimental|Multimodal analgesic protocol group|Women who received the multimodal analgesic protocol during minimally invasive myomectomy.
89157746|NCT00978601|No Intervention|No use of multimodal analgesic protocol group|Women who did not receive the multimodal analgesic protocol during minimally invasive myomectomy.
89157747|NCT00883896|Placebo Comparator|Arm 1|Part 1: Placebo
89157748|NCT00883896|Experimental|Arm 2|Part 1: 100 mg ILV-094 SC Q4W
89157749|NCT00883896|Experimental|Arm 3|Part 1: 100 mg ILV-094 SC Q2W
89157750|NCT00883896|Placebo Comparator|Arm 4|
89157751|NCT00883896|Experimental|Arm 5|Part 2: 200 mg ILV-094 SC Q2W
89157752|NCT00973063|No Intervention|conventional gloving|
89157753|NCT00973063|Experimental|routine sterile gloving|
89157754|NCT02778191||Concomitant cisplatin|Patients treated with concomitant cisplatin
89157755|NCT02778191||Carboplatin plus 5-FU|Patients treated with carboplatin plus 5-FU
89157756|NCT00982267|Experimental|SU014813|
89157757|NCT02779829|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89157758|NCT00978679|Experimental|Orthokeratology|Myopic children wearing orthokeratology at night will be the study group
89157759|NCT00978679|Other|Others|Myopic children wearing single-vision spectacles in the daytime will serve as control group
89157760|NCT02777957||mPAP ≥ 25 mmHg|mean pulmonary artery pressure (mPAP) ≥ 25 mmHg (37 patients)
89157761|NCT02777957||mPAP < 25 mmHg|mean pulmonary artery pressure (mPAP) < 25 mmHg (28 patients).
89157762|NCT04114409||1|OSAS and type D personality
89157763|NCT04114409||2|OSAS without type D personality
89157764|NCT04007263|Placebo Comparator|Placebo|Placebo intravenous infusion over 30 minutes, five days of once daily dosing
89157765|NCT04007263|Experimental|NP10679 25 mg|NP10679 25 mg intravenous infusion over 30 minutes, five days of once daily dosing
89157766|NCT04007263|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion over 30 minutes, five days of once daily dosing
89157767|NCT04007263|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion over 30 minutes, five days of once daily dosing
89157768|NCT02778269|Experimental|Study Treatment|The patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System.
89157769|NCT02778893|Experimental|Conmana and Thalidomide|"Conmana(Icotinib Hydrochloride Tablets) and Thalidomide:~Conmana(Icotinib Hydrochloride Tablets) will be administered at 125mg three times a day(TID）continuously; Thalidomide will be administered at 100mg one a day（QD)at night continuously,If can tolerance after 1 weeks to add to 200mg."
89157770|NCT05298059|Placebo Comparator|CPP-ACPF PASTE APLICATION|Apply the cpp-acpf paste, at four different times (one each week of whitening treatment), for five minutes in each application and evaluate if it was able to reduce the sensitivity after home whitening with 22% carbamide peroxide.
89157771|NCT05298059|No Intervention|Evaluate the effectiviness at home bleaching|To evaluate the effectiveness of at-home bleaching with 22% carbamide peroxide, with the help of the VITA Easyshade 4.0 spectrophotometer
89157772|NCT05298059|Placebo Comparator|LASER APLICATION|Apply the laser at four different times (one every week of whitening treatment), using the spectrum of infrared light with a wavelength of 808 nm with its active medium of Arsento Gallium and Aluminum (AsGaAl), at three points, one in the center of the crown of the tooth, another in the center of the cervical region and the last one in the incisal region, with the light beam directed apically, from all teeth to the second premolar of each upper and lower hemi-arch, with energy of of 1 Joule per point for 10 seconds. and evaluate if it was able to reduce the sensitivity after home whitening with 22% carbamide peroxide.
89157773|NCT05298059|Placebo Comparator|Associate the CPP-ACPF paste with the LASER|Associate the CPP-ACPF paste with the LASER, following the same clinical protocol mentioned above and assess whether the association is more efficient than both treatments alone.
89157774|NCT02778581|Active Comparator|Lipidic Blend 1|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
89157775|NCT02778581|Active Comparator|Lipidic Blend 2|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
89157776|NCT02778581|Placebo Comparator|Placebo|Glass bottle with 45 ml of Olive oil. 1 bottle per day
89157777|NCT00665886|Experimental|1|"Experimental Group (Closed System):~Nexiva® Safety IV Catheter from BD (Becton Dickinson). The catheter has wings, a passive safety feature, an integrated Y extension tubing integrated and needle-less access using a split septum BD QSyte®. In order to completely close the Y connector a second Q-Syte® is added from the moment of catheter insertion"
89157778|NCT00665886|Active Comparator|2|"Control group (Open System):~A 'mounted' system consisting of the Vasocan® Safety catheter of B. Braun Medical, SA. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3, from BD) is added. This comes as one unit (tap and tubing are integrated). When not in use the three-way tap ('stopcock') remains closed using a red cork Luer/Luer-Lock Sollner®, made by Amebil, SA."
89157779|NCT02671864|Other|1: incretin-based therapy|Patients with incretin-based therapy
89157780|NCT02671864|Other|2: other antidiabetic|Patients with other antidiabetic
89157781|NCT02661074||Fishermen|"Fisherman followed by the Service de Santé des Gens de Mer of Boulogne-sur-Mer, France (occupational exposure to fish).~A questionnaire will be completed."
89157782|NCT02661074||Fish processing factories|"Workers of fish processing factories who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France (occupational exposure to fish).~A questionnaire will be completed."
89157783|NCT02661074||Control|"Workers who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France, but do not work in fish processing factories.~A questionnaire will be completed."
89157784|NCT00665964|Experimental|X-3|X-3 polyethylene which is a new highly cross-linked poly that is theorized to be more durable in vivo
89157785|NCT00665964|Active Comparator|N2Vac polethylene|conventional polyethylene
89157786|NCT00867009|Experimental|Induction/maintenance Therapy|pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
89157787|NCT00666042|Experimental|A|Vigamox delivered as spray
89157788|NCT00666042|Active Comparator|B|Patients will receive the commercially available Vigamox drops
89157789|NCT05038241||Active VKC|All females and males of pubertal age with active VKC undergo a blood sample for the determination of serum hormone levels, an allergological evaluation and an endocrinological evaluation. All is done at the time of enrollment.
89157790|NCT05038241||Previous active VKC|All females and males of pubertal age who suffered of VKC undergo a blood sample for the determination of serum hormone levels, an allergological evaluation and an endocrinological evaluation. All is done at the time of enrollment.
89157791|NCT02660840|Experimental|0.5 mg Test, then 0.5 mg reference|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first test, then reference)
89157792|NCT02660840|Experimental|0.5 mg reference, then 0.5 mg Test|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first reference, then test)
89157793|NCT02660840|Experimental|1 mg Test, then 1 mg reference|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first test, then reference)
89157794|NCT02660840|Experimental|1 mg reference, then 1 mg Test|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first reference, then test)
89157795|NCT02660840|Experimental|5 mg Test, then 5 mg reference|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first test, then reference)
89157796|NCT02660840|Experimental|5 mg reference, then 5 mg Test|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first reference, then test)
89157797|NCT02777801|Experimental|Prophylactic Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the initiation of chemotherapy till 6 months after the end of chemotherapy.
89157798|NCT02777801|Active Comparator|Preemptive Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the time that the DNA copies of hepatitis B virus are more than 100 IU/ml till 6 months after the end of chemotherapy.
89157799|NCT04074694|No Intervention|Watchfull waiting|
89157800|NCT04074694|Active Comparator|Interventional|
89157801|NCT00649064|Experimental|Ziprasidone|
89157802|NCT04132713||Control group|20 healthy volunteers were included in the healthy control group
89157803|NCT04132713||Disease group|30 patients with advanced breast cancer developed hand-foot syndrome after capecitabine administration
89157804|NCT03343522|No Intervention|Sedentarism|Patients assigned to this arm shall not perform regular exercise training.
89157805|NCT03343522|Experimental|Exercise Training|Patients assigned to this arm will be enrolled in exercise training program.
89157806|NCT04007341|No Intervention|Saline group|Patients in the saline group were infused with an identical volume of normal saline.
89157807|NCT04007341|Experimental|Dexmedetomidine group|Patients in the dexmedetomidine group were infused with a loading dose of dexmedetomidine (1.0 mcg/kg over 10 min) and were thereafter infused at a rate of 0.5 mg/kg/h.
89157808|NCT02656082|Experimental|Etanercept|Intradermal injection of etanercept. The dosage is determined based on discoid lesion radius. Weekly injection up to 12 weeks.
89157809|NCT02631486|Experimental|Early|"The first group will use sling for comfort only. Active assisted exercises in closed chain and in safe zone are allowed in the first 4 weeks.~The rehabilitation stages will start from active assisted progressing to more active stages phases until full recovery. The whole program will last about 3 months."
89157810|NCT02631486|Active Comparator|Conservative|The second group will use a sling for 6 weeks. The rehabilitation stages will start with active assisted/closed chain movements with short levers, it will progress to more active stages phases until full recovery. The whole program will last about 3 months.
89157811|NCT04132635|Experimental|artificial dermis with growth factor|
89157812|NCT04132635|Experimental|artificial dermis only|
89157813|NCT04007185||Control group|30 patients undergoing biopsy for brain tumour. They have the effect of the tumour but not the impact of surgery. Changes in QoL will inform the RCI measures planned
89157814|NCT04007185||Surgery Group|The main test group. This group have been determined by their treating surgeon to undergo a resection of the tumour so will be different from the control arm by undergoing a safe, maximal resection of their tumour
89157815|NCT00661908||1|insulin-treated diabetic subjects of North-western part of Switzerland
89157816|NCT00982501|Experimental|WS® 1442 900 mg|
89157817|NCT00982501|Experimental|WS® 1442 1800 mg|
89157818|NCT00982501|Active Comparator|Nordic walking training 2x30 min|
89157819|NCT00982501|Active Comparator|Nordic walking training 4x45 min|
89157820|NCT04156308|Experimental|Combined exercises+OMT weekly|"This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality~This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions with a weekly frequency (with + -2 days of margin: between 5 and 9 days)."
89157821|NCT04156308|Experimental|Combined exercises+OMT once every 3 weeks|"This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality~This group will also receive Osteopathic Manipulative Treatment (OMT): exactly 3 sessions at the rate of one session every 3 weeks (with + -2 days of margin: between 19-23 days)."
89157822|NCT04156308|Experimental|Combined exercises|This group will conduct a home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality.
88821471|NCT03997474|Experimental|Cohort B|Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL-2.
89157823|NCT02623504|Experimental|Equetro|200-1200 mg of Equetro (carbamazepine) by mouth given in divided doses in the morning and in the evening. Dosage is titrated in 200 mg increments weekly as needed according to subject response.
89157824|NCT02623504|Placebo Comparator|Placebo|Placebo dosage to match the active Equetro treatment given in 2 daily doses in the morning and in the evening.
89157825|NCT02777723|Experimental|CKD-350|Xenobella
89157826|NCT02777723|Active Comparator|Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
89157827|NCT00601250|Experimental|Linagliptin|Patients receive linagliptin 5 mg tablets once daily
89157828|NCT00601250|Placebo Comparator|Placebo|Patients receive placebo tablets matching linagliptin 5 mg tablets once daily
89157829|NCT04226885|Active Comparator|fentanyl|patients will be given nebulized fentanyl 2μg/kg body weight 30 min before surgery
89157830|NCT04226885|Active Comparator|midazolam|The patients will be given nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
89157831|NCT04226885|Active Comparator|dexmedetomidine|The patients will be given nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
89157832|NCT00982579|Experimental|Vaccinees|Vaccinated at 20 weeks of age (n=24)
89157833|NCT00982579|No Intervention|Controls|No experimental vaccine (n=24)
89157834|NCT04226651|Active Comparator|First dental visit|Virtual Reality Exposure Therapy
89157835|NCT04226651|Placebo Comparator|Second Dental Visit|Protective Glasses
89235011|NCT05499585|Other|Arm One|Habitual diet for 12 weeks followed by experimental diet for 12 weeks
89235012|NCT05486507|Experimental|Montmorency tart cherry juice|
89235013|NCT05486507|Placebo Comparator|Placebo|
89235014|NCT05468515||High altitude group|altitude level range from 2500 to 4500 meters
89235015|NCT05468515||mild altitude group|altitude level range from 500 to 2500 meters
89235016|NCT05465135|Experimental|Dihydroartemisinin Group|The subjects take Dihydroartemisinin, 40mg tid for 12 weeks
89235017|NCT05464342|Experimental|Evening LGI Carbohydrate Consumption|Dietary Intervention: Consumption of Low Glyceamic Index (LGI) carbohydrates intake post-workout/evening.
88821472|NCT03997474|Experimental|Cohort C|Following lymphodepletion, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.
88821473|NCT03984578|Experimental|Colon cancers|Pre-operative CAPEOX 1 cycle Pre-operative Pembrolizumab 2 cycles with cycle 1 on Day 1 (concurrent with start of CAPEOX) and cycle 2 on Day 22
88821474|NCT03984578|Experimental|Rectal Cancers|Following completion of neo-adjuvant chemo-radiotherapy, 2 cycles of pre-operative Pembrolizumab administered 3 weeks apart.
88821475|NCT03968120|No Intervention|Group Fix:One-lung ventilation with constant PEEP|Controll group: lung protective one-lung ventilation with fix positive end-expiratory pressure (PEEP)
88821476|NCT03968120|Active Comparator|Group Variable:One-lung ventilation with variable PEEP|Variable group: lung protective one-lung ventilation with variable positive end-expiratory pressure (PEEP)
88821477|NCT03967106|Experimental|Remote Ischaemic preconditioning|Remote IPC (RIPC) intervention daily for six weeks.
88821478|NCT03967106|Sham Comparator|Sham|Remote sham intervention daily for six weeks.
88821479|NCT03962764||Community|Community fathers include fathers who are recruited through community partners and self-referrals. Only fathers 18 years of age and older are included in program analysis
88821480|NCT03938454|Experimental|Crizanlizumab|5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51
88821481|NCT03936218|Experimental|Inj. Goserelin (Test) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
88821482|NCT03936218|Active Comparator|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
88821483|NCT03935451|Placebo Comparator|Placebo|The placebo group will receive a similarly appearing full supply of a twice daily placebo oral tablet.
88821484|NCT03935451|Experimental|Experimental|The treatment arm will receive a full supply of twice daily 2.5 milligram (mg) dosing of apixaban beginning on the first day of hospital discharge.
88821485|NCT03901274|Active Comparator|Clinical Services Support Condition|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework.
88821486|NCT03901274|Experimental|Patient-Centered Enhancements|Participants in this condition will receive school-based behavioral health services from clinicians who are trained in the evidence-based Clinical Services Support (CSS) Framework. The clinicians in this condition will receive additional training on two Patient-Centered Enhancements (PCE).
88821487|NCT03894917||Group 1|Participants 65 years or older
88821488|NCT03894917||Group 2|Participants less than 65 years
88821489|NCT03886246|Experimental|Spesolimab (every 6 weeks)|
88821490|NCT03886246|Experimental|Spesolimab (every 12 weeks)|
88821491|NCT03886246|Experimental|Spesolimab (every 4 weeks)|
88821492|NCT03884998|Experimental|Treatment (copanlisib and nivolumab)|Patients receive copanlisib IV over 60 minutes on days 1, 8, and 15 and nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
88821493|NCT03866967|Experimental|AK105|Subjects receive AK105 200 mg intravenously (IV) once every 2 weeks (Q2W) until progression.
88821494|NCT03863574|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
89235018|NCT05464342|Experimental|Evening HGI Carbohydrate Consumption|Dietary Intervention: Consumption of High Glyceamic Index (HGI) carbohydrates intake post-workout/evening.
88821495|NCT03863574|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
88821496|NCT03863574|Placebo Comparator|Placebo|Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
88821497|NCT03856658|Experimental|Floxuridine (FUDR) via HAI pump|Once enrolled, patients will undergo surgical placement of the HAI pump. This can be accomplished using minimally invasive or open techniques with an anticipated hospital stay of approximately 3-5 days. Prior to discharge from the hospital or at the first postoperative visit the pump is filled with FUDR according to the following equation: 0.12 mg/kg/d (using ideal body weight). This fill initiates day 1 of a 4-week cycle. The chemotherapy is infused by the pump continuously over 14 days. On day 15 (+/-4 days), the remaining chemotherapy is removed from the pump which is refilled with heparinized saline (30,000 units). This remains for an additional 2 weeks until the pump is refilled with FUDR at the start of the next cycle. Treatment is continued for a maximum of 6 cycles or as limited by toxicity. This regimen has been utilized with an acceptable safety profile in the setting of colorectal liver metastases.
88821498|NCT03850418|Experimental|AZA|azacitidine
88821499|NCT03850366|Experimental|Bortezomib|
88821500|NCT03825744|Experimental|Hetrombopag Olamine+Standard Therapy|
88821501|NCT03825744|Placebo Comparator|Placebo+Standard Therapy|
88821502|NCT03811821|Active Comparator|Biofeedback (BIO)|Participants will receive biofeedback intervention during five (5) required weekly 1-hour sessions. A 6th treatment session will be made available for participants if it is shown through anorectal manometry that they are having trouble understanding directions given during the first five sessions.
88821503|NCT03811821|Active Comparator|Injection (INJ)|Bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
88821504|NCT03806296|Experimental|Manipulation|"For ~2 weeks, participants will be asked to adhere to the following:~Sleep scheduling--advance bedtime by 1.5 hours ( + sleep duration)~Decrease evening blue light exposure via blue blocker goggles (2 h before bed)~Increase morning bright light exposure via bright light goggles (30 m after rise)~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
88821505|NCT03806296|Active Comparator|Control|"For ~2 weeks, participants will asked to adhere to the following:~- Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
88821506|NCT03806244|No Intervention|PREOP|Navigation without intraoperative acquisition of images: Use of conventional preoperative images (CT-MRI) to establish intraoperative navigation.
89157836|NCT04007419|Experimental|Single Arm|The Promotoras de Donación eLearning module will be launched and 40 participating lay health educators trained. Access to the module will be provided via a link to the website embedded in an announcement email. To assess the impact of the Promotoras de Donación eLearning module on lay health educators' knowledge of organ donation and the need for Hispanic donors, and confidence communicating about donation and promoting the act of donor registration, participating lay health educators will complete a brief online survey upon enrollment (pre) and after completing the module (post). Then, trained lay health educators will hold at least 2 small group sessions with mature Latina (6-8 per session); in all, 80 sessions are anticipated with 480 to 640 mature Latina. Participating mature Latina will complete anonymous paper-pencil surveys before and after each session to assess changes in attitudes toward organ donation and donor registration and intent to register as posthumous organ donors.
89157837|NCT02779985|Experimental|Lycium Barbarum mixed meal|Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
89157838|NCT02779985|Active Comparator|Control mixed meal|Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
89157839|NCT00866775|Experimental|Eslicarbazepine 1600 mg QD|"Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD (Day 0) to 1200 mg QD (Week 1) to 1600 mg QD (Weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
89157840|NCT00866775|Experimental|Eslicarbazepine 1200 mg QD|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day 0) to 800 mg QD (week 1) to 1200 mg QD (weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
89157841|NCT02777411|Experimental|Group A1|3 to 6 years
89157842|NCT02777411|Experimental|Group A2|3 to 6 years
89157843|NCT02777411|Experimental|Group A3|3 to 6 years
89157844|NCT02777411|Experimental|Group A4|3 to 6 years
89157845|NCT02777411|Experimental|Group B2|6 to 35 months
89157846|NCT02777411|Experimental|Group B3|6 to 35 months
89157847|NCT02777411|Experimental|Group B4|6 to 35 months
89157848|NCT02536820|Other|Conventional treatment + PNIT|PNIT: Psychoneuroimmuno therapy Conventional treatment: Usual treatment that each diabetic patient recieved
89157849|NCT02536820|Active Comparator|Conventional treatment|Conventional treatment: Usual treatment that each diabetic patient recieved
89157850|NCT02777489|Experimental|Perindopril Bluepharma 8 mg|Each participant will have an at least 4-week run-in period, followed by a 6 weeks treatment period with Perindopril 8 mg.
89157851|NCT02660762|Experimental|Modified MRCUKALLⅫ/ECOGE2993 Regimen|"All patients received phase 1 of induction therapy, which consisted of daunorubicin,vincristine,Pegaspargase,prednisone and methotrexate (intrathecally).Patients went on to phase 2 at the end of phase 1.Phase 2 therapy consisted of cyclophosphamide,cytarabine,6-Mercaptopurine and methotrexate intrathecally. After Induction therapy, all patients received intensification therapy with high-dose methotrexate followed by Pegaspargase. After intensification therapy,patients received consolidation(cytarabine, etoposide,Pegaspargase,dexamethasone,vincristine,cyclophosphamide,daunorubicin,thioguanine)and maintenance therapy(vincristine,6-mercaptopurine,methotrexate~,prednisone). Intrathecal methotrexate and intrathecal cytarabine were given as CNS prophylaxis."
89157852|NCT05021471|Experimental|Group A|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
89157853|NCT05021471|Active Comparator|Group B|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
89157854|NCT04897906|Experimental|Experimental group|Experimental group; It is the group that will be given mother and neonatal care education.
89157855|NCT04897906|No Intervention|Control Group|Control group; It is the group in which no intervention will be made other than data collection.
89157856|NCT02660684|Experimental|Prograf + MTX|
89157857|NCT02660684|Active Comparator|Cyclosporine + MTX (historical control)|
89157858|NCT00982891|Experimental|Morphine, low dose, in addition to conventional treatment|Morphine dose titration
89157859|NCT05021003|Experimental|Group A|: Core stabilization training with pressure biofeedback unit
89157860|NCT05021003|Active Comparator|Group B|: Core stabilization training without pressure biofeedback unit
89157861|NCT02615223|Experimental|Arm1|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
89157862|NCT02615223|Experimental|Arm2|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
89157863|NCT00978835|Experimental|Nurse case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
89157864|NCT00978835|Active Comparator|Nurse Education|Didactic, non-interactive education by a nurse on general health topics.
89157865|NCT05017805|Experimental|3 doses of vaccine|Covid-19 vaccination on day 0, day 25±3, and 6 months after the second dose , respectively，and follow up one and half a year
89157866|NCT05017805|Experimental|1 dose of the third vaccination|One dose of COVID-19 vaccine and 1 year of follow-up
89157867|NCT04132557||Cohort 1 (Target): Methylphenidate Monotherapy|Participants will be analyzed for Attention Deficit Hyperactive Disorder (ADHD) who are new users of methylphenidate monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
89157868|NCT04132557||Cohort 2 (Comparator [C]): Lisdexamfetamine Monotherapy|Participants will be analyzed for ADHD who are new users of lisdexamfetamine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
89157869|NCT04132557||Cohort 3 (C): Atomoxetine Monotherapy|Participants will be analyzed for ADHD who are new users of atomoxetine monotherapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
89157870|NCT04132557||Cohort 4 (C):Amphetamine/Dextroamphetamine Combo Therapy|Participants will be analyzed for ADHD who are new users of amphetamine/dextroamphetamine combo therapy. Analysis of data will be performed between 1 January 2001 to 30 September 2018.
89157871|NCT00978913|Experimental|DC vaccination and Cyclophosphamide|
89157872|NCT03265210|Experimental|Relief|Relief relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
89157873|NCT03265210|No Intervention|Referral|Referral for mental health based on clinical indication.
89157874|NCT04227509|Experimental|Experimental|
89157875|NCT04227509|Placebo Comparator|Placebo|
89157876|NCT00979225|Experimental|Medication report|Medication reports delivered to providers at the point of care
89157877|NCT00979225|Experimental|Med. report plus care manager notices|Medication reports delivered to providers at the point of care and notices sent electronically to care managers
89157878|NCT00979225|No Intervention|Control|
89157879|NCT00979381||1|Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks
89157880|NCT00979381||2|patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
89157881|NCT00979381||3|healthy volunteers
89157882|NCT03229876|Experimental|CD19-UCART|All patients will be treated with 1 injection of CD19-UCART. Three escalating dose-levels (1.0-2.0x10^6/kgBW, 2.5-5.0x10^6/kgBW, 5.5-10.0x10^6/kgBW) of CD19-UCART will be evaluated using a 3+3 design. Each CD19-UCART injection will be administered at Day 0.
89157883|NCT00984529||1|Cardiologist´s office patients
89157884|NCT04915937|Experimental|Study Infant Formula|Feed ad libitum during study period
89157885|NCT02778503|Active Comparator|High Cost|Restoration using a high-cost glass ionomer cement.
89157886|NCT02778503|Experimental|Low Cost|Restoration using a low-cost glass ionomer cement.
89157887|NCT00984607|Experimental|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring.
89157888|NCT02778659|Experimental|Zolpidem Normoxia|Acute zolpidem intake at sea level
89157889|NCT02778659|Sham Comparator|Placebo Normoxia|Acute placebo intake at sea level
89157890|NCT02778659|Experimental|Zolpidem Hypoxia|Acute zolpidem intake at high altitude
89157891|NCT02778659|Sham Comparator|Placebo Hypoxia|Acute placebo intake at high altitude
89157892|NCT04072900|Experimental|Intervention/Treatment|"Personalized NeoAntigen Cancer Vaccine- Neo-Vac-Mn (peptides + rhGM-CSF+anti-PD1+Imiquimod 5% Topical Cream)~NeoAntigen peptides:4 x 2 mg the total peptides given on days 84，87，91，98，105，133，and 161~Anti-PD-1 Toripalimab: 3mg/kg, ivgtt, Q2w~rhGM-CSF: 3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160~Imiquimod 5% Topical Cream:topical application on the injection site 6 hours before each NeoAntigen peptides injection"
89157893|NCT00984685||depression|Patients diagnosed with depression before April 15, 2009
89157894|NCT05092607|Experimental|Venous and Capillary blood sampling|Venous and Capillary blood sampling
89157895|NCT04072666|Experimental|ASSIP plus SPP|Participants in the ASSIP group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the ASSIP psychological intervention where they will receive three therapy sessions followed by regular ongoing contact through individually focused letters sent over 24 months.
89157896|NCT04072666|Experimental|CBT plus SPP|Participants in the CBT group will receive a combination of the comprehensive clinical SPP (i.e. standardised assessment, risk evaluation and formulation, safety planning and follow-up), and the CBT psychological intervention where they will receive five CBT 60-minute individual sessions.
89157897|NCT04072666|Active Comparator|SPP alone|"The Suicide Prevention Pathway (SPP) comprises seven steps:~i) Initial screening - persons experiencing suicide ideation and who may also have a history of, or recent, suicide attempt, are placed on the pathway; ii) Assessment of suicide risk iii) Formulation of suicide risk (based on a prevention oriented approach) iv) Safety planning (collaboratively developed with the client) and Counselling on access to lethal means v) Structured follow-up (within 24-48 hrs); vi) Transition of care plan; and vii) Caring contacts - ongoing contact/support for the person for the next 2 years (through personalised letters or phone texts)."
89157898|NCT00984763|Experimental|Group 1|AMA1-C1/Alhydrogel® + CPG 7909 vaccine given twice two months apart followed by malaria parasite challenge
89157899|NCT00984763|No Intervention|Group 2|Control: malaria parasite challenge without prior vaccinations
89157900|NCT00984841|Experimental|Tailored letter|Patients in the tailored letter group received by mail a tailored letter detailing their diabetes measures, together with enclosed orders for lab tests when due, and reminder of or scheduling for an office appointment.
89157901|NCT00984841|Active Comparator|Usual Care|Patients in the usual care group were part of a practice wide quality improvement process.
89157902|NCT02578108|Active Comparator|no diagnostic genicular nerve blocks|no diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
89157903|NCT02578108|Active Comparator|diagnostic genicular nerve blocks|Set of diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
89157904|NCT02776163|Experimental|Cisplatin Group|Intensity-modulated radiotherapy+concurrent chemotherapy with cisplatin for squamous carcinoma of salivary gland
89157905|NCT02776163|Experimental|Docetaxel+Cisplatin|Intensity-modulated radiotherapy+concurrent chemotherapy with docetaxel and cisplatin for adenogenous types carcinoma of salivary gland
89157906|NCT02578030|Experimental|SHP465 12.5 mg|A single dose of SHP465 12.5 mg for Subjects aged 6-12 years
89157907|NCT02578030|Experimental|SHP465 25 mg|A single dose of SHP465 25 mg for Subjects aged 13-17 years
89157908|NCT05325346|Experimental|VLX-1005|Intravenous administration of VLX-1005 with measurements of PK and PD
89157909|NCT05325346|Active Comparator|Argatroban|Intravenous administration of argatroban with measurements of PK and PD
89157910|NCT05325346|Other|VLX-1005 and Argatroban|Intravenous co-administration of VLX-1005 and argatroban with measurements of PK and PD
89157911|NCT00984997|Experimental|Surgery + Radiotherapy + Chemotherapy|"Surgery followed by radiotherapy and chemotherapy started at the beginning of radiotherapy. Segmentectomy or lobectomy with en bloc resection of the involved chest. Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week. Cisplatin 50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.~Etoposide given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29. Prophylactic Cranial Irradiation 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional."
89157912|NCT05673616|Experimental|Interventional group|Mckenzie Extension Exercises
89157913|NCT00982969||TB suspected|Soldiers who are clinically suspected with tuberculosis
89157914|NCT02777645||Study group|Study group(n=50) included CP children with chewing disorder. Growth, feeding evaluation will be done.
89157915|NCT02777645||Control group|Control group(n=35)= healthy children without chewing disorder Growth, feeding evaluation will be done.
89157916|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Adefovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Adefovir for a period of 48 weeks.
89157917|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Tenofovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Tenofovir for a period of 48 weeks.
89157918|NCT00973219|No Intervention|no treatment|50 HBeAg negative chronic hepatitis B patients with low viral load will not receive treatment during a period of 48 weeks
89157919|NCT04226573||Low anxiety, Middle and High anxiety|State Trait Anxiety İndex Scale: Values of less than 60, Low anxiety State Trait Anxiety İndex Scale: Values above 60, Middle and High anxiety
89157920|NCT04194125|Experimental|177Lu-DOTATOC combined with CAPTEM|"The therapy will include 4 courses (14 days per one) with 8-week intervals;~177Lu-DOTATOC in doses from 5,55GBq up to 7,4 GBq will be administered i.v. up to four times at 10th day;~Concomitant amino acids will be given with each administration;~Capecitabine will be administrated for 14 days (twice a day) followed by Temozolomide at 10-14th days in each therapy sessions."
89157921|NCT00973297|Experimental|Falls prevention|
89157922|NCT00973297|No Intervention|Control group|Routine rehabilitation treatment
89157923|NCT04973891|Experimental|Experimental: Canagliflozin/metformin group|Intervention with canagliflozin combined with metformin for three months
89157924|NCT04973891|Active Comparator|Active Comparator: Metformin group|Intervention with metformin for three months
89157925|NCT00983047|Active Comparator|Docetaxel|The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.
89157926|NCT00983047|Experimental|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2,efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD.No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment:Dose of 200mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxic."
89157927|NCT05268575|Experimental|endoscopic sclerotherapy|Patients with hemorrhoids will be treated with endoscopic sclerotherapy. Injection site is submucosa of hemorrhoid nucleus. Sclerosing agent makes the submucosal tissue fibrotic, and then fixes the hemorrhoidal tissue.
89157928|NCT05268575|Experimental|endoscopic rubber band ligation|Patients with hemorrhoids will be treated with endoscopic rubber band ligation. The ligature position is above the mucosa of the hemorrhoid nucleus. Ligation of hemorrhoidal tissue can lead to ischemic necrosis of the prolapsed mucosa, which in turn leads to scar fixation. At the same time, the ligature also has the effect of lifting the tissue upward.
89157929|NCT05268575|Experimental|endoscopic sclerotherapy combined with rubber band ligation|Patients with hemorrhoids will be treated with endoscopic sclerotherapy combined with rubber band ligation. Sclerotherapy first, followed by rubber band ligation. Sclerotherapy injection reduces the likelihood of ligature dislodgement.
89157930|NCT00973375||Endeavor group and Excel group|Endeavor group: measurements from the vessels implanted Endeavor stent(s). Excel group: measurements from the vessels implanted Excel stent(s).
89157931|NCT04193969|Experimental|Radiculopathy due to nerve root compression|"Participants with radicular leg pain due to lumbar disc herniation or to foraminal- or recess stenosis.~Baseline assessments of pain intensities are performed through questionnaires prior to protocol. Data regarding initial pain, function, age, gender, pain-duration, weight and height is retrieved from the clinical registry SpineData.~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit in the treatment program. The protocol is repeated at the last visit in the treatment program."
89157932|NCT04193969|Experimental|Healthy controls|"Healthy controls Healthy age and gender-matched controls. Gender, weight and height are registered on questionnaires prior to protocol.~Pain sensitivity, temporal summation and conditioned pain modulation are assessed at the first visit. The tests are repeated at the next visit. The interval between the two sessions will be determined by the averaged interval between tests in the patient group."
89157933|NCT00983125|Experimental|clonidine|
89157934|NCT00983125|Other|no clonidine|
89157935|NCT00988039|Active Comparator|bPI + 2NRTIs|
89157936|NCT00988039|Experimental|bPI + raltegravir|
89157937|NCT00988039|Experimental|bPI monotherapy|
89157938|NCT02776241|No Intervention|water restriction|20 patients will be subjected to 3 hours of water restriction following MR scan of the kidneys.
89157939|NCT02776241|Active Comparator|high water intake|20 patients will be subjected to 1 hour of high water intake (20 ml/kg) following MR scan of the kidneys.
89235019|NCT05464342|Experimental|Evening NO-CHO Carbohydrate Consumption|Dietary Intervention: No consumption of carbohydrates intake post-workout/evening.
89235020|NCT05425732|Experimental|Cohort 1 V116|Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of V116 on Day 1.
89157940|NCT05258201|Experimental|Muscle Energy Technique|Muscle energy Technique will be applied on the subjects, when they will be lying supine and on the effect side therapist will stabilize shoulder by one hand, while the ear / mastoid area of the affected side will be hold by opposite hand. The head and neck will be bend to contralateral side, then bends on the same side. Subject will raise his shoulder with the shoulder fixed to the ear with less effort than the maximum. Isometric contraction will be maintain for 7-10 seconds. This position will be held for 30 seconds and repeat three to five times per on treatment session
89157941|NCT05258201|Experimental|Strain-counterstrain|Strain And Counter Strain will be applied on subject in normal position and will be produced by placing the muscle in a short / relaxed position, the point where the pain will reduce of at least 70% will be produce will easily define. The patient will be in a supine position while the doctor will place the labial arm in flexion, abduction and external rotation to reduce the reported Trp pain. Once the position is easy to find, the pressure will be apply to the Trp and will be hold for 20-30 seconds and repeat this process for up to five times
89157942|NCT04865809|Experimental|Trial Group|Patients from this group will use Peribioma Toothpaste and Mousse for home oral care.
89157943|NCT04865809|Active Comparator|Control Group|Patients from this group will use Biorepair Plus Parodontgel for home oral care.
89157944|NCT04934111|Experimental|LNP-nCOV saRNA-02 Vaccine arm|Participants that have evidence of previous infection with SARS-CoV-2 and those with no evidence of previous infection will all receive receive LNP-nCOV saRNA-02 Vaccine. Both groups will be given a dose of 5.0ug at 0 weeks and 4 weeks.
89157945|NCT04855513|No Intervention|standard care|The control group will receive standard care treatment including aspirin according to ACOG guidelines. The control group estimated number of enrollment is 207 patients.
89157946|NCT04855513|Experimental|Metformin|The intervention group will be give metformin 500 mg orally three times daily in addition to standard of care. The estimated number to be enrolled are 207 patients.
89157947|NCT02776319|Experimental|Active|Non-invasive brain stimulation (active)
89157948|NCT02776319|Placebo Comparator|Sham/Placebo|Non-invasive brain stimulation (sham)
89157949|NCT00543985|Experimental|Stress Echocardiography|Echocardiography was performed prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
89157950|NCT04226183|No Intervention|control group|pregnant women without pregnancy workout and consume guava juice
89157951|NCT04226183|Experimental|positive control group|prenatal pregnant women with pregnancy workout but not consume guava juice
89157952|NCT04226183|Experimental|treatment group|prenatal pregnant women with pregnancy workout and consume guava juice
89157953|NCT04948073|Experimental|Experimental Group|The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment. DNS group's protocol will involve 5 min warm-up, 40 min DNS movements (4 different parts, each part lasts for 10 min) accompanied with breathing exercises, and 5 min cool-down. DNS exercises will include diaphragmatic breathing, Baby Rock, Rolling, Side Lying, Oblique Sit, Tripod, Kneeling, Squat, Prone, and Czech Get Up (CGU). Week one specifically will involve training and practicing basic DNS exercises. The complexity of the exercises will increase gradually by adding a new task to an already practiced task every week. An increase in the complexity of a task will help the performer to automate performance. We will use the dual-task paradigm to examine if the task is automated or not (e.g. no new task should disturb the diaphragmatic breathing).
89157954|NCT04948073|Active Comparator|Control Group|Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration). All patients will also continue their usual activities and receive advices related to the daily living activites in the form of a leaflet. Participants will be asked to refrain from seeking any other types of rehabilitation treatments during the trial. The conventional physical therapy program for both groups includes: TENS therapy for the low back (15 min 3 days/week), with a frequency of 100 Hz and fixed pulse; ultrasound for 5 minutes, 1 Hz, continuous mode of application 1.5 w/cm2. The exercise programs will consist strengthening, stretching exercises for the abdominal, back, pelvic, and lower limb muscles.
89157955|NCT00983203|Experimental|FID 114657|FID 114657
89157956|NCT00983203|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
89157957|NCT00988195|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
89157958|NCT04943393||Individuals with PKU|Adults with early-treated PKU
89157959|NCT04943393||Individuals without PKU|Adults without PKU who are otherwise healthy
89157960|NCT02777099|Experimental|RIPostC|Receiving RIPostC with pressure set at 200 mmHg. Intervention:Procedure:Remote Ischemic Postconditioning
89157961|NCT02777099|Sham Comparator|sham RIPostC|"Receiving sham RIPostC with pressure set at the patient's diastolic blood pressure.~Intervention:Procedure:Sham Remote Ischemic Postconditioning"
89157962|NCT00988273||Control|In patients undergoing endoscopy for indications other than Crohn's disease or ulcerative colitis
89157963|NCT00988273||Diseased group|Patients with Crohn's disease or ulcerative colitis undergoing endoscopy.
89157964|NCT00634985|Experimental|A|
89157965|NCT00985387||Solifenacin treatment|Male and female OAB patients who were treated with solifenacin
89157966|NCT02776943|Experimental|Mesenchymal stem cell treatment|Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10^6 of UCMSC per cm^2 of the cartilage defect.
89157967|NCT02776943|Active Comparator|Hyaluronic acid treatment|Administer hyaluronic acid (30 mg) in a single injection
89157968|NCT02776709||Bile duct Stricture|Patients referred for the evaluation of indeterminate strictures.
89157969|NCT02776709||Common bile duct Stones|Patients referred for the removal of difficult stones.
89157970|NCT04006327||Palliative care patients and their family caregivers|The present study is a cross-sectional study with single group study design. Only palliative care patients and their family caregivers will be recruited.
89157971|NCT04005781|Experimental|Hydroxychloroquine sulphate|Plaquenil (hydroxychloroquine sulphate) will be acutely administered per os with 240 ml of water. Two tablets of 200 mg hydroxychloroquine sulphate each will be given.
89157972|NCT04005781|Placebo Comparator|Placebo|Two placebo tablets will be acutely administered per os with 240 ml of water.
89157973|NCT02779673|Experimental|Test group|Subjects randomized to the test group consumed yoghurt drink containing 3.4g plant stanol as ester for 1 per day for a period of 4 weeks.
89157974|NCT02779673|Placebo Comparator|Placebo group|Subjects randomized to the placebo group consumed yoghurt drink without plant stanol as ester for 1 per day for a period of 4 weeks.
89157975|NCT04654351|Experimental|TAK-667|TAK-667, single SC administration on the abdomen on Day 1. The dose of TAK-667 will be dependent on the participant's body weight (Up to 30 mg; 10 mg for 12 kg to 25 kg, 15 mg for 26 kg to 40 kg, 20 mg for 41 kg to 50kg, 25 mg for 51 kg to 65 kg, 30 mg for >65 kg).
89157976|NCT00635063|Experimental|AD 923|
89157977|NCT00635063|Active Comparator|MSIR|
89157978|NCT00582556|Active Comparator|1|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
89157979|NCT00582556|Active Comparator|2|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given at mo 6
89157980|NCT00582556|Active Comparator|3|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
89157981|NCT04226417|Active Comparator|Dual-tDCS & home program exercise|Dual transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered for 20 minutes before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
89157982|NCT04226417|Sham Comparator|Sham-tDCS & home program exercise|Sham transcranial direct current stimulation (tDCS) will be applied over C3-C4 by using a reference to the international 10-20 electrode placement system for EEG electrode placement. The current intensity will be 2 mA, delivered only 30 seconds before the home-based exercise program by themselves and/or caregiver. Anodal electrode will be applied over the M1 of the affected hemisphere, while the cathodal electrode will be applied over the M1 of the non-lesioned. In all sessions of intervention at participant's resident, the investigator will supervise the processes of setting tDCS and exercise in all sessions (total 12 sessions, 3 days per week for 4 weeks).
89157983|NCT00983593|Experimental|Group Therapy|Group therapy following the Mind-Body Bridging program.
89157984|NCT02776397|Active Comparator|Hp 2-2 Vitamin E|The Haptoglobin 2-2 group randomised to Vitamin E
89157985|NCT02776397|Placebo Comparator|Hp 2-2 Placebo|The Haptoglobin 2-2 group randomised to placebo
89157986|NCT02776397|Active Comparator|Non Hp 2-2 Vitamin E|The Non Haptoglobin 2-2 group randomised to Vitamin E
89157987|NCT02776397|Placebo Comparator|Non Hp 2-2 Placebo|The Non Haptoglobin 2-2 group randomised to placebo
89157988|NCT03918655||Patient newly diagnosed with AML (prospectively)|Patient newly diagnosed with AML in Saint Antoine hospital or Tours University hospital
89157989|NCT03918655||Patient diagnosed with AML (retrospectively)|Patient diagnosed with AML in Saint Antoine hospital in 2015 to 2019
89157990|NCT03177616|No Intervention|Usual Care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician. They are not to use any chiropractic treatment or begin new therapies.
89157991|NCT03177616|Experimental|Chiropractic Treatment + Usual Care|Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.
89157992|NCT04224857|Experimental|AMT-101|AMT-101
89157993|NCT04224857|Placebo Comparator|Placebo|Placebo
89157994|NCT00983671||children with asthma|children with diagnosed asthma, age 6-18 years
89157995|NCT00983671||cystic fibrosis|children with cystic fibrosis, age 6-18 years
89157996|NCT00983671||chronic lung disease|children with chronic lung disease, also known as bronchopulmonary dysplasia, age 6-18 years
89157997|NCT00983671||pneumonia|children with clinical signs of pneumonia, age 6-18 years
89157998|NCT03167554|Sham Comparator|Sham group|Simulating of the electrolysis application.he electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
89157999|NCT03167554|Experimental|Experimental group 1|Electrolysis application with monopolar needle.
89158000|NCT03167554|Experimental|Experimental group 2|Electrolysis application with bipolar needle.
89158001|NCT04225949|Experimental|line graph|
89158002|NCT04225949|Active Comparator|bar graph|
89158003|NCT02775929|Other|PrEP as a bridge to ART|FTC-TDF PrEP for HIV uninfected partners and ART for HIV infected partners
89158004|NCT00985777|Experimental|Phase I Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days and one dose on Day 15.
89158005|NCT02773121|Experimental|Physical activity monitoring|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their physical activity level to at least 150 min of moderate-intensity physical activity per week. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
89158006|NCT02773121|Active Comparator|Flexibility and balance|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their balance and flexibility over the 12 week period of the intervention. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
89158007|NCT01563601|Experimental|Obatoclax mesylate, Carboplatin and Etoposide (CEO)|
89158008|NCT01563601|Active Comparator|Carboplatin and Etoposide (CE)|
89158009|NCT04225637|Experimental|Slow maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw once every other day.
89158010|NCT04225637|Experimental|Rapid maxillary expansion|The miniscrew-supported maxillary expander is activated by turning the expansion screw twice daily.
88821507|NCT03806244|Experimental|PEROP|Navigation with intraoperative acquisition of images: Intraoperative acquisition (robotic c-Arm) of images to establish intraoperative navigation.
89158011|NCT05325268||Monteggia Cohort|Including all Patients. Patients who had suffered a Monteggia fracture and were treated with osteosynthesis
89158012|NCT00988507|Experimental|Ferroquine high dose + artesunate|Ferroquine at 6 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
89158013|NCT00988507|Experimental|Ferroquine medium dose + artesunate|Ferroquine at 4 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
89158014|NCT00988507|Experimental|Ferroquine low dose + artesunate|Ferroquine at 2 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
89158015|NCT00988507|Experimental|Ferroquine alone at medium dose|Ferroquine at 4 mg/kg/d OD alone for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
89158016|NCT00985855|Experimental|Cisplatin, vinorelbine|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy.
89158017|NCT00985855|Experimental|Cisplatin, etoposide|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.
89158018|NCT04226105|Experimental|GP40081|Subcutaneous (SC), up to Week 26
89158019|NCT04226105|Active Comparator|NovoMix® 30 FlexPen®|Subcutaneous (SC), up to Week 26
89158020|NCT00988585|Placebo Comparator|Olive Oil|Olive Oil 600 mg/day
89158021|NCT00988585|Active Comparator|EPA 1800|1800 mg/day
89158022|NCT00988585|Active Comparator|DHA|DHA 600 mg/day
89158023|NCT00988585|Active Comparator|EPA 600|EPA 600 mg/day
89158024|NCT02776865|Experimental|physical therapy and suprascapular nerve block|patient received ultrasound-guided suprascapular nerve block as well as physical therapy.
89158025|NCT02776865|Active Comparator|physical therapy only|patient received physical therapy only.
89235021|NCT05425732|Active Comparator|Cohort 1 PCV20|Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of PCV20 on Day 1.
88821508|NCT03797001|Experimental|anakinra|Anakinra subcutaneous injection, 100 mg daily for 24 weeks
88821509|NCT03797001|Placebo Comparator|placebo|Placebo subcutaneous injection, daily for 24 weeks
88821510|NCT03779620|Experimental|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
88821511|NCT03754049|Experimental|TLC599 12 mg|12 mg DSP with 100 μmol phospholipid via IA injection;
88821512|NCT03754049|Experimental|TLC599 6 mg|6 mg DSP with 50 μmol phospholipid via IA injection.
88821513|NCT03754049|Active Comparator|DSP 4mg|Dexamethasone Sodium Phosphate (DSP): 4 mg/mL, 1 mL via IA injection.
88821514|NCT03754049|Active Comparator|DSP 10mg|Dexamethasone Sodium Phosphate (DSP): 4 mg/mL, 2.5 mL via IV injection.
88821515|NCT03747939|Experimental|Apremilast 30 mg twice daily ± NSAIDs, ≤ 1 csDMARD|Subjects will take ORAL tables of apremilast for up to 48 weeks (30 mg twice daily). Subjects may also receive stable doses of background therapy (standard or care) with NSAIDs, glucorticosteroids and 1 csDMARD as permitted by protocol. After wk. 24, subjects may change the dose /type of permitted Psoriatic Arthritis medications
88821516|NCT03747939|Placebo Comparator|Placebo|Subjects will take placebo for up to 24 weeks (twice daily). Subjects may also receive stable doses of background therapy ( standard of care) with NSAIDs, glucocorticosteroids and 1 csDMARD as permitted by protocol. After wk 24, subjects may change the dose /type of permitted PsA medications.
88821517|NCT03712189|No Intervention|Alaris Pump|Participants will receive IV fluids delivered by the Alaris IV Pump (standard of care) until their bladder is full.
88821518|NCT03712189|Experimental|LifeFlow|Participants will receive IV fluids delivered by the LifeFlow Fluid Device until their bladder is full.
88821519|NCT03704974||Children of Parents Receiving IY|Children ages 3 to 6 years at start of group with behavior concerns whose parents are referred by their pediatricians for participation in a video-based parent training program from 2014 through 2018.
88821520|NCT03702725|Experimental|Dose Escalation|"Dose escalation will consist of three different drug levels of Ibrutinib, Lenalidomide, and Dexamethasone.~Dose Escalation (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
88821521|NCT03702725|Experimental|Dose Expansion|"Dosage of the combination will depend on the determine of maximum tolerated dose learned from the Dose Escalation phase.~Dose Expansion (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
88821522|NCT03688620|Other|Vaccinated_AlphaRix Tetra Group|Volunteered male and female subjects, 18 years of age and above, who received in Belgium one dose of GlaxoSmithKline's (GSK's) quadrivalent seasonal influenza vaccine (AlphaRix Tetra) between 01 October and 31 December 2018.
88821523|NCT03688620|Other|Vaccinated_Influsplit Tetra Group|Volunteered subjects male and female subjects, 18 years of age and above, who received in Germany one dose of GSK's quadrivalent seasonal influenza vaccine (Influsplit Tetra) between 01 October and 31 December 2018.
88821524|NCT03688620|Other|Vaccinated_Fluarix Tetra Group|Volunteered male and female subjects, between 6 months and 65 years of age, who received in Spain one or two dose(s) of GSK's quadrivalent seasonal influenza vaccine (Fluarix Tetra) between 01 October and 31 December 2018.
88821525|NCT03683173|Experimental|Multilevel Intervention|Participants will receive the multilevel intervention consisting of community events, walking group formation, and short messaging service.
88821526|NCT03683173|No Intervention|Control|Does not receive the multilevel intervention.
88821527|NCT03671811|Experimental|Arm I (pterostilbene, megestrol acetate)|Patients receive pterostilbene PO BID and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
88821528|NCT03671811|Experimental|Arm II (megestrol acetate)|Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
88821529|NCT03663257||AneurysmFlow Observational Cohort|Subjects with unruptured, >5mm saccular aneurysm(s) located in the anterior intracranial circulation and suitable for an endovascular treatment with a Flow Diverter Stent enrolled at the centers participating in this CARO study.
88821530|NCT03657251||CureCloud Direct to Patient|
89158026|NCT04072510|Experimental|Case: Self-esteem group + Treatment as Usual|"Self-esteem group is based on a cognitive behavioral model of low self-esteem addressing thoughts, feelings and behaviour. The self-esteem group is designed to be administered in 6 weekly sessions.~Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.Treatment as usual occurred alongside the self-esteem group."
89158027|NCT04072510|Active Comparator|Control: Treatment as Usual Only|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
89158028|NCT02772653||Severe trauma patients|"No interventions are done. It's a prospective and descriptive observational study where different markers are analyzed:~Blood Lactate levels~Blood Base Excess levels~Blood B-type Natriuretic Peptide levels~Blood Thromboelastometry (ROTEM) alterations~Near-infrared spectroscopy alterations~Sublingual videomicroscopy alterations~All these markers are analyzed at the 1rst, 8th and 24th hour from hospital admission."
89158029|NCT00542269|Experimental|Aliskiren / ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
89158030|NCT00542269|Experimental|Aliskiren / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
89158031|NCT00542269|Active Comparator|Ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
89158032|NCT02776631|Experimental|Pinloc|Plate and 3 interlocked pins. A new device for fixation of femoral neck fractures.
89158033|NCT02776631|Active Comparator|LIH (Hansson pins)|2 pins. An established method for fixation of femoral neck fractures.
89158034|NCT02579434|Experimental|Male young adults|Arm 1: Male healthy volunteers aged from 20 to 45 years Midazolam (IV) on day 1
89158035|NCT02579434|Experimental|Male elderly adults|Arm 2: Male healthy volunteers aged over 45 years Midazolam (IV) on day 1
89158036|NCT02579434|Experimental|Female elderly adults|Arm 3: Female healthy volunteers aged over 45 years Midazolam (IV) on day 1
89158037|NCT02579434|Experimental|Female young adults|Arm 4: Female healthy volunteers aged 20 to 45 years Midazolam (IV) on day 1, Day 15
89158038|NCT00866697|Placebo Comparator|Placebo|matched placebo tablet administered orally once daily for up to 24 months
89158039|NCT00866697|Experimental|Pazopanib|Pazopanib tablet administered orally at 800 mg once daily for up to 24 months
89158040|NCT02577952||People with Lipodystrophy & family|People currently living with lipodystrophy and their family members.
89158041|NCT00635141|Experimental|1|
89158042|NCT00635141|Experimental|2|
89158043|NCT00985933|Experimental|1|180 mg of AZD8529
89158044|NCT00985933|Experimental|2|50 mg AD8529
89158045|NCT00985933|Placebo Comparator|3|Placebo
89158046|NCT02577874||Chinese Subjects|7 blood glucose tests taken over a two hour period
89158047|NCT02577874||European Subjects|7 blood glucose tests taken over a two hour period
89158048|NCT02767739|Experimental|Physical, social and cultural activities|"Physical Activity: The training program will be supervised by a physical activity specialist and will consiste of two aerobic exercise sessions per week, including walking and stretching exercises after walking. Each session will be 60 minutes and the size of groups will be from 15 to 30 participants. Additionally, participants will receive advice about the health benefits of PA and PHC nurses using different strategies to encourage the adherence of participants to the program.~Social and cultural support activities. Activities will include: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons. These activities will be performed once a month."
89158049|NCT02767739|No Intervention|Control Group|No intervention. We will measure the variables at the begining and after 9 months.
89158050|NCT04073914|Active Comparator|Intervention|Type 1 Teamwork program
89158051|NCT04073914|No Intervention|Control|Standard of care
89158052|NCT02767817|Sham Comparator|Stereotactic Hematoma Evacuation|
89158053|NCT02767817|Experimental|MSCs Transplantation|
89158054|NCT02767817|Experimental|Injectable Collagen Scaffold with MSCs Transplantation|
89158055|NCT00542191|Experimental|Neoadjuvant metronomic AC followed by weekly TC|Neoadjuvant chemotherapy with metronomic AC followed by weekly TC then surgery
88821531|NCT03654209|Experimental|Argon Plasma Coagulation|Following polyp removal using standard of care methods, Argon Plasma Coagulation (APC) will be applied to the perimeter of the resection site before any clips are added.
89158056|NCT00600938|Experimental|Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
89158057|NCT00600938|Active Comparator|Deferasirox Placebo|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
89158058|NCT00600938|Experimental|Extension: deferoxamine to deferasirox|"DFO to ICL (patients who switched from DFO to deferasirox in extension)"
89158059|NCT00600938|Experimental|Extension: deferasirox to deferoxamine|"ICL to DFO (patients who switched from deferasirox to DFO in extension)"
89158060|NCT03069742|Experimental|Decision Aid|Women at high risk for developing breast cancer will use a decision support tool, RealRisks, that facilitates discussion of breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
89158061|NCT03069742|No Intervention|Control Group|Women at high risk for developing breast cancer will receive standard breast health education brochures.
89158062|NCT02767583|Experimental|Non diabetic obese|Non diabetic obese with BMI 35-55 kg / m2 consulting for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group will got a themotest and Sudoscan exams de determine their neuropathology.
89158063|NCT00988663|Active Comparator|Memantine arm|Patient receiving ECT and Memantine
89158064|NCT00988663|Placebo Comparator|placebo|25 patients receiving ECT will will receive placebo
89158065|NCT04224389||Radiotherapy|IMRT on the primitive site and the lymph nodes. +/- Concomitant chemotherapy at the discretion of the meeting multidisciplinary
89158066|NCT04224389||Surgery|transoral resection of the primary tumor, with cervical lymph node dissection. Radiotherapy complementary according to the histological criteria of severity
89158067|NCT04671017|Experimental|Low Dose: VLA2001|
89158068|NCT04671017|Experimental|Medium Dose: VLA2001|
89158069|NCT04671017|Experimental|High Dose: VLA2001|
89158070|NCT04671017|Experimental|Booster: High Dose: VLA2001|
89158071|NCT04072198|Experimental|FOLFOXIRI/Bevacizumab + Nivolumab|Bevacizumab 5 mg/m2 Nivolumab 240 mg Irinotecan 165 mg/m2 iv (max 8 cycles) Oxaliplatin + leucovorin 200 mg/m2 (max 8 cycles) Fluorouracil 3200 mg/m2 (max 8 cycles)
89158072|NCT02772419|Experimental|benralizumab A|Subcutaneous (SC) administration
89158073|NCT02772419|Experimental|benralizumab B|SC administration
89158074|NCT02772419|Placebo Comparator|Placebo|Placebo SC administration
89158075|NCT00543439|Experimental|1|On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.
89158076|NCT00543439|Experimental|2|Routine Prophylaxis Crossover
89158077|NCT02772497|Experimental|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0.05ml) every 4 weeks
89158078|NCT04071886|Experimental|Mindfulness-Based Training|Participants in the Mindfulness-Based Training arm will receive 2 weeks of Mindfulness-Based Training for at least 30 minutes every day.
89158079|NCT04071886|Active Comparator|Relaxation Training|Participants in the Relaxation Training arm will receive 2 weeks of Relaxation Training for at least 30 minutes every day.
89158080|NCT02615379|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 weeks + standard wound care
89158081|NCT02615379|No Intervention|Standard of care|standard wound care for 2 weeks
89158082|NCT02767349|Experimental|MNK-155|MNK-155, initial dose of two or three tablets followed by 2 tablets every 12 hours up to a maximum of five doses.
89158083|NCT04132167|Experimental|training group|perturbation balance training
89158084|NCT04132167|Active Comparator|control group|traditional physical therapy that including strengthening and stretching
89158085|NCT02767193|Experimental|DCV3|Autologus differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus
89158086|NCT02767193|Experimental|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG-INF
89158087|NCT02767193|Placebo Comparator|CD placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded
89158088|NCT02767193|Placebo Comparator|CD placebo + PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG-INF
89158089|NCT00582166|Experimental|Ibritumomab Tiuxetan (Zevalin) with Rituximab maintenance|
89158090|NCT02775539|Active Comparator|Mirabegron|Oral mirabegron, starting with 50 mg once a day and titrated till a maximum of 200 mg once a day.
89158091|NCT02775539|Placebo Comparator|Placebo|Oral placebo, similarly titrated to ensure blindness.
89158092|NCT04840459|Experimental|BAMLANIVIMAB|The dosage of bamlanivimab in adults and pediatric patients 12 years of age and older weighing at least 40 kg is a single IV infusion of 700 mg bamlanivimab administered over at least 60 minutes
89158093|NCT04840459|Experimental|CASIRIVIMAB + IMDEVIMAB|10 mL of casirivimab and 10 mL of imdevimab from each respective vial using two separate syringes and dilute together in the infusion bag containing 0.9% Sodium Chloride Injection
89158094|NCT02772575||patients with primary liver or liver metastases|A biopsy will be performed as standard of care either at time of Hepatic trans-arterial embolization (TAE) or within 4 months prior to TAE. TAE is a standard of care procedure. Within 8 weeks of TAE, patient will have a clinic visit which will include medical history, physical examination, vital signs, EKG (if one is not available), and ECOG assessment. Additionally a dedicated liver CT or MR will be obtained as well as standard of care labs. IMPACT blood test will be performed at the time of any of the standard of care labs. As IMPACT platform at MSKCC continually evolves to include more genes, we will use the platform available at the time of initiation of the protocol, therefore all patients will be subjected to the same platform. RNA-seq has been demonstrated to be superior in detecting low abundance transcripts, demonstrating a broader dynamic range, and detecting different isoforms and genetic variants.
89158095|NCT04666961|Experimental|Extended ductal carcinoma in situ with mastectomy indication|"Patients receive 6 months of tamoxifen or anastrozole in a neoadjuvant situation.~Tamoxifen and Anastrozole will be delivered in their original packaging at J0 and M3 :~Tamoxifen: box of tablets dosed at 20 mg~Anastrozole: box of tablets 1 mg. Tamoxifen will be initiated in premenopausal patients orally at a standard dose of 20mg/day as a single dose for 6 months.~Anastrozole will be administered orally to postmenopausal patients at the standard dose of 1mg/day in a single dose for 6 months."
89158096|NCT04618393|Experimental|EMB-02|"In Phase I part: participants enrolled in the different time will receive EMB-02 once weekly (IV) at different ascending dose levels.~In Phase II part: participants will receive EMB-02 once weekly (IV) at previously defined RP2D."
89158097|NCT02772341|Active Comparator|Salt room with halogenerator|Asthmatic patients sitting in a salt room with salt aerosol produced by a halogenerator.
89158098|NCT02772341|Placebo Comparator|Salt room without halogenerator|Asthmatic patients sitting in a salt room without salt aerosol
89235022|NCT05425732|Experimental|Cohort 2 V116|Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of V116 on Day 1.
89235023|NCT05425732|Active Comparator|Cohort 2 PCV20|Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of PCV20 on Day 1.
88821532|NCT03654209|Experimental|Snare Tip Soft Coagulation|Following polyp removal using standard of care methods, Snare Tip Soft Coagulation (STSC) will be applied to the perimeter of the resection site before any clips are added.
88821533|NCT03654209|No Intervention|No treatment|Following polyp removal using standard of care methods, neither APC nor STSC will be applied to the perimeter of the resection site. Clips may be added at the discretion of the PI.
88821534|NCT03652961|Experimental|Abatacept plus DMARD|"Abatacept will be used concomitantly with standard of care disease-modifying anti-rheumatic drugs (DMARDs), other than tumor necrosis factor (TNF) antagonists or Janus kinase (JAK) inhibitors.~Intravenous (IV) Abatacept will be administered as a 30-minute IV infusion utilizing weight range-based dosing:~Less than 60 kg: 500 mg~60 to 100 kg: 750 mg~More than 100 kg: 1000 mg~Following the initial IV Abatacept administration, an IV infusion will be given at Weeks 2 and 4 after the first infusion and every 4 weeks thereafter for a total of 7 Abatacept doses.~Abatacept will be discontinued after 6 months in all patients. Patients who have flared or failed to achieve low disease activity at 6 months will exit the trial except for one post-study visit for lab work at 9 months. In patients who have achieved low disease activity, Abatacept will be held for 6 months or until a flare results while DMARD use is continued."
88821535|NCT03646617|Active Comparator|No HFRT|ipilimumab and nivolumab once every 3 weeks for up to 4 doses, followed by nivolumab once every 2 weeks or every 4 weeks until disease progression.
88821536|NCT03646617|Experimental|HFRT|The dose of hypofractionated radiation therapy (HFRT) will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
88821537|NCT03638505||patients|patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group
88821538|NCT03638505||caregiver|the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group
88821539|NCT03625349||PLM participants|Participants who undergo passive leg movement, with and without LNMMA.
88821540|NCT03624517|Experimental|24-hour octreotide infusion|Patients will receive octreotide infusion over 24 hours
88821541|NCT03624517|Active Comparator|72-hour octreotide infusion|Patients will receive octreotide infusion over 72 hours
88821542|NCT03608670|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
88821543|NCT03590821|Experimental|Aspirin 81 mg/Placebo|Participants will receive aspirin in Phase 1 followed by matched placebo in Phase 2, or vice versa, over 14 days. The order will be randomized and aspirin/placebo will be double-blinded.
88821544|NCT03590821|Experimental|Celecoxib 200mg capsule|Participants will receive celecoxib in Phase 1 and Phase 2 over 7 days. This is open, meaning participant and investigator will recognize celecoxib capsules.
88821545|NCT03572348|Active Comparator|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
88821546|NCT03572348|Active Comparator|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
88821547|NCT03554902||Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
88821548|NCT03552965|Active Comparator|Margin-Based Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated by introducing a margin to the target area.
88821549|NCT03552965|Active Comparator|Robust Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated to minimize the dose of radiation to normal tissue.
88821550|NCT03538925|Experimental|Treatment Group|AAC Generative Language Intervention
88821551|NCT03538925|Active Comparator|Business as Usual|Standard of Care / Business as Usual
88821552|NCT03535727|Experimental|Phase 1, Cohort 1, Dose level 1|"Gemcitabine: 500 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel: 40 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin: 20 mg/m^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan: 20 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
88821553|NCT03535727|Experimental|Phase 1, Cohort 1, Dose level 2|"Gemcitabine 500 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel 60 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID: PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin: 20 mg/m^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan: 20 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
88821554|NCT03535727|Experimental|Phase 1, Cohort 1, Dose level 3|"Gemcitabine: 500 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel: 80 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin 20 mg/m^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan:20 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
88821555|NCT03535727|Experimental|Phase 1, Cohort 1, Dose level 4|"Gemcitabine:500 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel:100 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine:500 PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin:20 mg/m^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan:20 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
88821556|NCT03535727|Experimental|Phase 1, Cohort 1, Dose level 5|"Gemcitabine:500 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel:125 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin:20 mg/m^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan: 20 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
88821557|NCT03535727|Experimental|Phase 1, Cohort 2, Dose level 1|"Gemcitabine: 500 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Nab-paclitaxel:40 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle~Cisplatin:20 mg/m^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle~Irinotecan: 20 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle"
89158099|NCT04006639|Active Comparator|Bilateral superficial cervical plexus block with Bupiv|Patients, who will have tracheostomy procedure, might receive bilateral superficial cervical plexus block with 10 mL of Bupivacaine 0.5% (20 mL spuit with 25 G 1.5 inch needle) on each side before tracheostomy procedure.
89158100|NCT04006639|Active Comparator|Local infiltration of Lidocaine 2%|Patients, who will have tracheostomy procedure, might receive local infiltration of Lidocaine 2% (5 mL spuit with 25 G 1.5 inch needle) before tracheostomy procedure.
89158101|NCT00601172|Placebo Comparator|Control|Placebo + standard antiemetics
89158102|NCT00601172|Experimental|Single Dose IV|Casopitant + standard antiemetics
89158103|NCT02767115|Experimental|GSE mucoadhesive gel|2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
89158104|NCT02767115|Placebo Comparator|Control mucoadhesive gel|GSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
89158105|NCT00986089||women who have an IUD placed at the time of c-section|
89158106|NCT04225793|Active Comparator|Eziklen®|potassium, magnesium and sodium sulphates-based laxative
89158107|NCT04225793|Active Comparator|Macrogol|Macrogol-3350 + Sodium Sulfate + Potassium Chloride+ Sodium Chloride + Ascorbic Acid-based and Sodium Ascorbate-based Moviprep
89158108|NCT00988819||No treatment|
89158109|NCT02772107|Experimental|BSC group|Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. Radiotherapy was allowed. Follow-up until disease progression.
89158110|NCT02772107|Experimental|TMZ group|"Patients will receive platinum-based first-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cyclesfor the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study, radiotherapy was allowed."
89158111|NCT00986167|Experimental|Quetiapine XR|The study population will be patients admitted to the acute psychiatry inpatient wards of St Vincent's or the Alfred and determined by a Psychiatrist to be experiencing a psychotic illness (including mania with psychotic features and drug-induced psychosis) and acting in an aggressive manner (determined by a score of at least 1 on the OAS).
89158112|NCT00988897|Experimental|1|"Patients will receive modified FOLFOX-6 regimen:~oxaliplatin 85mg/m2, day 1 (given as a 2-hour infusion)~LV 400mg/m2, day 1 (given as a 2-hour infusion simultaneous to oxaliplatin)~5-FU given as a bolus IV 400mg/m2 dose on day 1 followed by 2400mg/m2 continuous infusion over 46 hours (day 1 and 2)~A cycle is defined as 2 weeks. Patients will receive cycles of modified FOLFOX-6 regimen every 2 weeks up to a maximum of 8 cycles. Use of bevacizumab is at the discretion of the treating physician."
89158113|NCT04225169|Experimental|Exercises|diaphragmatic breathing exercises
89158114|NCT04225169|No Intervention|Control|Patients in the control group received routine patient care consisting of cold therapy
89158115|NCT00988975|Active Comparator|Pelvicol graft|
89158116|NCT00988975|No Intervention|No graft material|No graft material
89158117|NCT02775227|Experimental|Hydrocortisone|
89158118|NCT02775227|Active Comparator|Pasireotide|
89158119|NCT04074382||Prospective Cohort|Prospective cohort (Phase 1, and Phase 2 Group A: explained in detailed description earlier) We will recruit and consent patients on the ward in the first few weeks following their admission for major trauma when the consultant in charge of their care feels that they are physically and emotionally/mentally ready and appropriate to take part in the study. A member of the research team will ask whether they want to take part in the study and offer them the participant information sheet. If happy to take part, the patient will have an account set up on the online questionnaire service we will be using called QTool. The consent form will be completed online at baseline along with the initial baseline PROM questionnaires. This group of people will then be sent reminders at 3, 6, 9 and 12 months to complete follow-up questionnaires, up to 28 days before or after these timepoints. They will then enter Phase 2 (Group A).
89158120|NCT04074382||Retrospective Cohort|"Retrospective cohort (Phase 1/2):~Patients between 1 to 10 years following their major trauma will be identified using a database. We will randomly select which of these patients to include in our study, using computer software, to reduce selection bias, and those selected will be sent a recruitment pack in the post. We have calculated that we need at least 320 patients in the retrospective cohort to show any important changes.~This group of patients will only complete the questionnaires once in phase 1, and once per year up to 10 years after their trauma in phase 2 (Group B)."
89158121|NCT00986323|Active Comparator|Temeperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
89158122|NCT00986323|Placebo Comparator|Placebo TLA|Placebo TLA treatment
89158123|NCT02775305|No Intervention|Not frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants do not meet criteria for frailty, baseline screening data will be used for comparative analysis as the no intervention arm.
89158124|NCT02775305|Experimental|Frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants meet criteria for frailty participants will be enrolled in the intervention arm. Participants who are ambulatory regardless of co-morbidities will not be excluded from the study.
89158125|NCT02875132|Experimental|pembrolizumab|
89158126|NCT02772185|Experimental|active tDCS plus real CT|Participants will receive active transcranial direct current stimulation and real cognitive training.
89158127|NCT02772185|Experimental|sham tDCS plus real CT|Participants will receive sham transcranial direct current stimulation and real cognitive training.
89158128|NCT02772185|Experimental|active tDCS plus placebo CT|Participants will receive active transcranial direct current stimulation and placebo cognitive training.
89158129|NCT02772185|Placebo Comparator|sham tDCS plus placebo CT|Participants will receive sham transcranial direct current stimulation and placebo cognitive training.
89158130|NCT00984217|Experimental|Panitumumab|Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-8 doses).
89158131|NCT02656004|Experimental|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
89158132|NCT02656004|Experimental|Control|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
89158133|NCT03918772||Perioperative immediate hypersensitivity|Patients having experienced perioperative immediate hypersensitivity
89158134|NCT00989053|Active Comparator|escitalopram|
89158135|NCT00989053|Placebo Comparator|placebo|
89158136|NCT02660450|Experimental|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
89158137|NCT02660450|Experimental|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
89158138|NCT02660450|Experimental|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
89158139|NCT04170452||Chronic Hepatitis Delta patients|Patients infected with delta virus
89158140|NCT04614493|Experimental|Ultrasound experimental arm|Standard of Care + 15 Ultrasound BBB opening
89158141|NCT04614493|Other|Control arm|Standard of Care
89158142|NCT02841748|Experimental|Pembrolizumab|200mg, every three weeks, iv, x 1 year
89158143|NCT02841748|Experimental|Placebo|iv, every 3 weeks, x 1 year
89158144|NCT04033094||MorphaBond ER|
89158145|NCT04033094||Comparator Group|
89158146|NCT04073758|Sham Comparator|Remifentanil group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted Minimal Alveolar Concentration (MAC). As explained above, remifentanil is infused with Target Controlled Infusion pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Remifentanil is usually infused with the effect site concentration of 2.0 to 6.0 ng/ml during general anesthesia. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, remifentanil infusion will be stopped.
89158147|NCT04073758|Active Comparator|Dexmedetomidine group|In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted MAC (Minimal Alveolar Concentration). As explained above, dexmedetomidine is infused with syringe pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Dexmedetomidine is loaded for 10 minutes in 1mcg/kg, and then infusion rate is set between 0.4 to 0.6mcg/kg/hour for this study. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, dexmedetomidine infusion will be stopped.
89158148|NCT03890497|Active Comparator|Full dose of IPV|IPV first dose between 9 -13 months with second dose administered 2 months later.
89158149|NCT03890497|Active Comparator|Fractional Dose of IPV|fIPV first dose between 9 -13 months with second dose administered 2 months later
89158150|NCT02655848|Active Comparator|@ Cuff repair with LHB tenodesis|In case of pathologic changes of the long Head Biceps tendon, a tenodesis is performed in adjunct to performing an arthroscopic rotator cuff repair.
89158151|NCT02655848|Active Comparator|@ cuff repair with LHB tenotomy|In case of pathologic changes of the long Head Biceps tendon, a tenotomy is performed in adjunct to performing an arthroscopic rotator cuff repair.
89158152|NCT02576236|Experimental|Triple therapy guided by result of the molecular resistance|"If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
89158153|NCT02576236|Active Comparator|Quadruple concomitant therapy|high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days
89158154|NCT00989131|Experimental|Paclitaxel, micellar (Paclical®)|
89158155|NCT00989131|Active Comparator|Paclitaxel, CrEL (Taxol®)|
89158156|NCT02660606||Group 1: Opioid abusers|
89158157|NCT02660606||Group 2: Abusers of other substances|
89158158|NCT02660606||Group 3: Non-opioid abusers|
89158159|NCT02660606||Group 4: Non-opioid users|
89158160|NCT02660372|Experimental|Imonogas|Imonogas 120 mg, 1 capsule three times daily for 8 weeks
89158161|NCT02660372|Active Comparator|Espumisan|Espumisan 40 mg, 2 capsules four times daily for 8 weeks
89158162|NCT00582010|Experimental|1. Experimental|iNO administration
89158163|NCT00582010|Placebo Comparator|2. Placebo|Placebo (nitrogen)
89158164|NCT02660294|Experimental|Platlet rich plasma|For those with endometrial thickness less than 7 mm intrauterine injection of platlet rich plasma (PRP) for enhancing endometrial thickness and receptivity
89158165|NCT02660294|No Intervention|Hormone replacement therapy|Oral intake of estradiol valerate for those with endometrial thickness less than 7 mm will improve endometrial receptivity
89158166|NCT00989209|Active Comparator|A: myofunctional prior to botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group A, botulinum toxin was applied after myofunctional therapy.
89158167|NCT00989209|Active Comparator|B: myofunctional after botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group B, botulinum toxin was applied before myofunctional therapy.
89158168|NCT00649922|Placebo Comparator|Double Blind|
89158169|NCT00649922|Experimental|Open Label|
89158170|NCT00910754|Experimental|Abiraterone acetate|Patients will take 1000 mg of abiraterone acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease progression.
89158171|NCT02576002||Pediatric PAH patients|US pediatric population with PAH in MarketScan database during the period 2010-2013
89158172|NCT05712733||Case group|"Patients suffering from acute calculous cholecystitis undergoing subacute laparoscopic cholecystectomy.~Samples of bile and gallbladder wall specimens will be taken during surgery and will be sent for microbiological and pathological investigation"
89158173|NCT05712733||Control group|"Patients suffering from painattacks due to gallstones, who have not symptoms of cholecystitis. The patients will undergo elective laparoscopic cholecystectomy.~Samples of bile and gallbladder wall specimens will be taken during surgery and will be sent for microbiological and pathological investigation"
89158174|NCT02577484||Participants|Subjects who satisfy both general and angiographic inclusion/exclusion criteria, and who have the pressure measurement taken with the Navvus catheter.
89158175|NCT02536586|Experimental|LY3023414|LY3023414 administered orally, twice daily in 21-day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
89158176|NCT00649376|Experimental|1|Fexofenadine Tablets 180 mg
89158177|NCT00649376|Active Comparator|2|Allegra® Tablets 180 mg
89158178|NCT04167800|No Intervention|Control group|All patients will be instructed to wear the device for 23 weeks for 12 weeks after being instructed on how to use the appropriate compression orthosis. The patient's relatives will be asked to keep a book in order to monitor their use. Patients who have not used the device for 5 consecutive days will be excluded from the study. The first group will be given awareness training on using one session orthosis and posture correction.
89158179|NCT04167800|Active Comparator|Exercise Group|In addition to the applications to the first group, mobilization, strengthening, posture and segmental breathing exercises will be given . All of these exercises will be combined with segmental breathing exercises depending on the location of the PC. Exercise therapy will be administered by a physiotherapist with 20 years of experience once a week and will be designed as a home program on the remaining days and will be asked to do 45 minutes twice a day (at least 4 times a week). The patient's relatives will be asked to keep a book to monitor the exercise. Patients who do not perform 5 consecutive exercise sessions will be excluded from the study. All treatments will be given for 12 weeks.
89158180|NCT02652182||1|patients with acute ST (S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Huai'an first people's hospital
89158181|NCT02652182||2|patients with acute ST(S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Nanjing Drum Tower hospital
89158182|NCT02655926|Active Comparator|STN Arm|Participants would only have STN deep brain stimulation switched at optimal settings for that participant on for 12 weeks.
89158183|NCT02655926|Active Comparator|VC/VS Arm|Participants would only have VC/VS deep brain stimulation switched on at optimal settings for that participant for 12 weeks.
89158184|NCT00649454|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
89158185|NCT00649454|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
89158186|NCT02766959||PAV/PAV Tasters|Individuals homozygous for the taster allele of the TAS2R38 gene, PAV/PAV.
89158187|NCT02766959||AVI/PAV.|Individuals heterozygous for the taster allele of the TAS2R38 gene, AVI/PAV.
89158188|NCT02766959||AVI/AVI|Individuals homozygous for the non-taster allele of the TAS2R38 gene, AVI/AVI.
89158189|NCT02658578|Active Comparator|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
89158190|NCT02658578|Placebo Comparator|Sham PNS|In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
89158191|NCT02772263|Experimental|CHAP-EMS Intervention|Participants guided through a 15-20 minute defined risk assessment by a trained paramedic. Risk factors assessed were those related to cardiovascular and diabetes risk (blood pressure, diabetes-risk status, lifestyle factors), and potential for falls. Based on these, the paramedic provided education and developed an individualized action plan directing participants to use available community resources to assist them in addressing their risk factors. They were advised to return to CHAP-EMS sessions regularly for BP monitoring and follow-up. Each participant's information was faxed to his/her family physician once a month.
89158192|NCT02655770|Active Comparator|Liraglutide arm|Patients will be treated with liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks.
89158193|NCT02655770|Placebo Comparator|Placebo arm|Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment.
89158194|NCT02767037|Active Comparator|Parkinson's disease (PD) patients|40 patients will be recruited. All will meet criteria for probable PD, according to the new MDS Clinical Diagnostic criteria. All participants will be 40 or older (young-onset PD includes many genetic causes, which often have normal autonomic function).
89158195|NCT02767037|Active Comparator|parkinsonsism (non-PD) patients|20 patients will also be recruited. These will include patients with progressive supranuclear palsy, multiple system atrophy, 'vascular parkinsonism' or corticobasal syndrome. All patients will have parkinsonism according to UK brain bank criteria, with a diagnosis of one of the above conditions made according to gold-standard expert evaluation. No patient will meet MDS Criteria for probable PD.
89158196|NCT02767037|Active Comparator|idiopathic REM sleep behavior disorder patient|40 patients will be recruited. All patients will have polysomnogram-confirmed RBD according to American Academy of Sleep Medicine Criteria. Patients will be free of parkinsonism and dementia according to neurological examination and will have no untreated sleep apnea, epilepsy, or other abnormalities that could cause dream enactment behavior.
89158197|NCT02767037|Placebo Comparator|Controls|40 controls will be age matched (within 5 years) and sex-matched (with >90% concordance). All controls will have an examination confirming the absence of parkinsonism, and will have no symptoms of REM sleep behavior disorder, as assessed with the RBD1Q and expert interview.
89158198|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
89158199|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
89158200|NCT02651870|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
89158201|NCT02766803|Active Comparator|Simvastatin + resveratrol|simvastatin 20 mg daily micronized trans-resveratrol 500 mg daily
89158202|NCT02766803|Placebo Comparator|simvastatin+ placebo|simvastatin 20 mg daily Placebo
89158203|NCT02771951|Experimental|Special Intervention|Study participants randomized to receive Special Intervention receive a series of 7 group classes taught by trained clinic health educators; a series of phone calls; clinical visits with a mid-level provider; and a series of 6 booster group classes over 1 year.
89158204|NCT02771951|Placebo Comparator|Usual Care|Study participants randomized to receive Usual Care receive up to 2 visits with a usual care health educator over 1 year.
89158205|NCT04861090||Participants With Hereditary Angioedema|Participants with HAE type I or type II who had initiated long-term prophylaxis (LTP) treatment with lanadelumab which was administered every two weeks (Q2W) or every four weeks (Q4W) or every six weeks (Q6W) or every eight weeks (Q8W) in accordance to Summary of Product Characteristics (SmPC), during a routine clinical setting will be followed up to 38 months.
89158206|NCT00635297|Active Comparator|1|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty
89158207|NCT00635297|Experimental|2|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty. The adjacent vertebrae will be treated with 3-5 ml of PMMA
89158208|NCT00650468|Experimental|1|early steroid cessation
89158209|NCT00650468|Experimental|2|long-term maintenance steroids
89158210|NCT02576080|Active Comparator|Standard Group|The Standard Group will receive adjuvant imatinib at a dose of 400 mg per day for a period of 3 years. Patients will be assessed for metastases every three months for three years with thoraco-abdominal and pelvic CT scan.
89158211|NCT02576080|Other|Experimental Group|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan. Surveillance
89158212|NCT02766881||Patients with DCIS|Whether patients with DCIS receive radiotherapy based on Oncotype DX DCIS score, radiation oncologist treatment recommendation and patient's decision.
89158213|NCT04225247|Active Comparator|Group-I Single Bond Universal|"it is a seventh generation bonding agent used as desensitizer, manufactured by 3M ESPE.~applied on the affected surface of the group-I participants."
89158214|NCT04225247|Active Comparator|Group-II Xeno V+|"it is a seventh generation bonding agent used as desensitizer, manufactured by Dentsply.~applied on the affected surface of the group-II participants."
89158215|NCT04225247|Placebo Comparator|Group-III Bifluorid 12|it is a fluoride varnish used as desensitizer, manufactured by VOCO. applied on the affected surface of the group-III participants.
89158216|NCT02652026|Experimental|Treatment Group|The Treatment Group (TG) received full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron, Acteon, Merignac, France) and Gracey curettes (Hu- Friedy, Chicago, USA).Also received Oral Hygienic Instructions
89158217|NCT02652026|Active Comparator|Control Group|The Control Group (CG) received periodontal prophylaxis at baseline, by removal of supragingival deposits (plaque and calculus) with ultrasonic scaler. Also received Oral Hygienic Instructions
89158218|NCT02651792|Active Comparator|ketamine- propofol|IV Ketamine 1mg/kg + Propofol 1.2 mg/kg will be given for sedation.
89158219|NCT02651792|Active Comparator|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
89158220|NCT04754815|Experimental|Pembrolizumab + Pemetrexed|Pembrolizumab 200mg intravenous (IV) infusion on Day 1 of each 21 day cycle. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity + pemetrexed 500mg intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21 day cycle up to 35 cycles or until disease progression.
89158221|NCT04754815|Experimental|Pembrolizumab + Paclitaxel OR Paclitaxel|"Pembrolizumab 200mg intravenous (IV) infusion on Day 1 of each 21 day cycle. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity~+ Paclitaxel 100 mg/m2 intravenous (IV) infusion on days 1 and 8 of each 21 day treatment cycle~OR Paclitaxel100 mg/m2 intravenous (IV) infusion on days 1 and 8 of each 21 day treatment cycle until disease progression."
89158222|NCT02775149||Reflux patients|Patients who are treated at the Clinic for Gastroenterology and Gastrointestinal Oncology and have a 24-hours pH monitoring or impedance measurement performed for medical reasons
89158223|NCT02658500|Experimental|Infant Formula|200 newborns just consume the infant formula from 0-42 days to six months age.
89158224|NCT02658500|Other|Breast Milk|100 newborns were just fed with breast milk from after birth to six months age.
89158225|NCT05712499|Experimental|Mindfulness-based psychoeducation program|The group in which the mindfulness-based psychoeducation program was applied.
89158226|NCT05712499|Active Comparator|control group|The group in which no intervention was made and only the pre-test and post-test were applied for comparison.
89158227|NCT00986791|No Intervention|Control group|Treatment as usual
89158228|NCT00986791|Experimental|GSP-A|Gold-Standard-Program for Alcohol cessation intervention (GSP-A): 6-week intensive patient education program with pharmaceutical support
89158229|NCT00649532|Experimental|1|Ondansetron Tablets 24 mg
89158230|NCT00649532|Active Comparator|2|Zofran® Tablets 24 mg
89158231|NCT02655614|Experimental|SAD Stage: GDC-0134|Participants in multiple cohorts and treatment periods will receive single doses of GDC-0134 oral capsules under fed/fasting conditions. To study the effect of proton pump inhibitor (PPI) medication rabeprazole on PK properties of GDC-0134, few participants may receive rabeprazole 20 milligrams (mg).
89158232|NCT02655614|Placebo Comparator|SAD Stage: Placebo|Participants in multiple cohorts and treatment periods will receive placebo matching to GDC-0134 under fed/fasting conditions. Few participants may receive rabeprazole 20 mg.
89158233|NCT02655614|Experimental|MAD Stage: GDC-0134|Participants will receive multiple doses of GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
89158234|NCT02655614|Placebo Comparator|MAD Stage: Placebo|Participants will receive placebo matching to GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
89158235|NCT02655614|Other|Open-Label Safety Expansion (OSE)|Participants will receive GDC-0134 at a dose determined by the corresponding MAD cohort.
89158236|NCT02772029|Experimental|Apatinib Mesylate Tablets|Apatinib (Apatinib Mesylate Tablets) 750 mg is administered orally daily, until disease progression or intolerable toxicity.
89158237|NCT00986869||echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
89158238|NCT02766725|Experimental|preparation F12 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F12 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
89158239|NCT02766725|Active Comparator|preparation F2 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F2 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
89158240|NCT02766725|Placebo Comparator|placebo gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + placebo gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator
89158241|NCT02658422|Experimental|Sequence A-B (Test Montelukast then Reference Montelukast)|Subjects will receive Treatment A- Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 1 and then Treatment B - Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 2.
89158242|NCT02658422|Experimental|Sequence B-A (Reference Montelukast then Test Montelukast)|Subjects will receive Treatment B- Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 1 and then Treatment A Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 2.
89158243|NCT02658344|Experimental|Jointstem|Autologous Adipose Tissue derived MSCs
89158244|NCT02658344|Placebo Comparator|Saline solution|Sodium chloride
89158245|NCT02771795||Herceptin (trastuzumab)|Intravenous administration
89158246|NCT02771795||SB3 (proposed trastuzumab biosimilar)|Intravenous administration
89158247|NCT05577247||Before antidepressant treatment|
89158248|NCT05577247||After antidepressant treatment|
89158249|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the chest
89158250|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST & FINGER|Cohort of 10 patients undergoing general anesthesia, monitored by optical signals at the chest and at the fingertip
89158251|NCT02651558|Experimental|OBPM 2015-MD-0022 - FINGER|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the fingertip
89158252|NCT04224077|Experimental|Intervention|Healthy volunteers
89158253|NCT02655536|Experimental|bevacizumab plus erlotinib|bevacizumab 15mg/kg every 3 weeks plus erlotinib 150mg per day
89158254|NCT02655536|Active Comparator|erlotinib|erlotinib 150mg per day
89158255|NCT02766647|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
89158256|NCT02766647|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
89158257|NCT02651636|Experimental|Open label|Therapy with alpha-lipoic acid (800 mg), myoinositol (2000 mg) and folic acid (400 mcg) daily for six months
89158258|NCT04005937|Experimental|H-reflex|H-reflex with different interstimulus interval of the plegic side soleus muscle were tested
89158259|NCT02774993|Experimental|Doxycycline|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
89158260|NCT02774993|Placebo Comparator|Placebo|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
89158261|NCT02651402|Active Comparator|FRIENDS for Life Train-the-Trainer|Therapists implement FRIENDS (a CBT protocol for students with anxiety) in the school setting, while supported by their supervisor assigned to the Train-the-Trainer (TT) implementation strategy (supervisors participate in training workshops on conducting supervision with active therapists).
89158262|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer|Therapists implement an adapted version of FRIENDS (aFRIENDS) in the school setting while supported by their supervisor assigned to the TT strategy.
89158263|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer Plus|Therapists implement aFRIENDS in the school setting while supported by their supervisor assigned to the Train-the-Trainer Plus (TT+) implementation strategy (supervisors participate in training workshops and receive further/on-going consultation on conducting supervision with active therapists).
89158264|NCT02774837|Experimental|combination|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks and Telbivudine 600mg oral tablets once daily for 96 weeks
89158265|NCT02774837|Active Comparator|mono therapy|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks
89158266|NCT00987025|Experimental|Telehealth|Telehealth participants will be recruited from centers that have a telehealth blood pressure station installed. Participants will be asked to use the station once per week. Blood pressure measures will be monitored by nurse researchers - out of range values will result in appropriate medical recommendations.
89158267|NCT00987025|Active Comparator|Control|Control participants will receive education material.
89158268|NCT02658188|Experimental|ASP8825 group|
89158269|NCT05712031|Experimental|Group2|Mandibular first or second premolar is combined with standard length(8-12mm) dental implants to support 3 unit Fixed Partial Dentures
89158270|NCT05712031|Experimental|Group3|Mandibular first or second premolar is combined with short dental implants(5-6mm) to support 3 unit Fixed Partial Dentures
89158271|NCT05712031|Active Comparator|Group1|Standard length (8-12mm) dental implants are inserted in posterior mandible replacing either first premolar and first molar or second premolar and second molar to support 3 unit fixed partial dentures.
89158272|NCT02771717|Experimental|Budesonide (Pulmicort)|Low dose inhaled corticosteroid.
89158273|NCT02771717|Placebo Comparator|Placebo - dummy inhaler|Placebo - dummy inhaler
89158274|NCT02655380|Experimental|ketamine 1|Anesthesia induction with ketamine 1 mg followed by remifentanil.
89158275|NCT02655380|Experimental|ketamine 2|Anesthesia induction with ketamine 2 mg followed by remifentanil.
89158276|NCT00580840|Active Comparator|Certolizumab pegol 400 mg and placebo|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
89158277|NCT00580840|Experimental|Certolizumab pegol 200 mg and placebo|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
89158278|NCT00580840|Placebo Comparator|Placebo|Placebo administered as two injections every 2 weeks
89158279|NCT00987103|Experimental|Sublingual - Rectal - Oral|Administration order of rank: Sublingual - Rectal - Oral
89158280|NCT00987103|Experimental|Sublingual - Oral - Rectal|Administration order of rank: Sublingual - Oral - Rectal
89158281|NCT00987103|Experimental|Oral - Sublingual - Rectal|Administration order of rank: Oral - Sublingual - Rectal
89158282|NCT00987103|Experimental|Oral - Rectal - Sublingual|Administration order of rank: Oral - Rectal - Sublingual
89158283|NCT00987103|Experimental|Rectal - Sublingual - Oral|Administration order of rank: Rectal - Sublingual - Oral
89158284|NCT00987103|Experimental|Rectal - Oral - Sublingual|Administration order of rank: Rectal - Oral - Sublingual
89158285|NCT02655458|Experimental|autologous PBMC reconstitution, Elotuzumab, Lenalidomide|Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.
89158286|NCT04006093|Experimental|participants with normal renal function|
89158287|NCT04006093|Experimental|participants with end-stage renal disease|
89158288|NCT00879684|Experimental|1|
89158289|NCT02658266|Experimental|Resistance training|Home based resistance training 12 weeks home based resistance training 3 times per week, 10-12 reps, 2 sets
89158290|NCT02658266|No Intervention|Control group|No instructed exercise training. Continue with habitual physical activity.
89158291|NCT02766491|Experimental|Strengthening and stretching|The intervention group will follow a strengthening-stretching program of the calf muscles.
89158292|NCT02766491|Active Comparator|conventional stretching|The control group will receive conventional stretching and strengthening exercises to the upper limb to assure that the same systemic physiological stimuli and a similar number of contact hours is received.
89158293|NCT02655302|Other|Bacterial exacerbations|Patients with at least 10^7 UFC/ml bacteria in their sputum during their first COPD exacerbation.
89158294|NCT02655302|Other|Non-bacterial exacerbations|Patients without detected bacteria or below 10^7 UFC/ml in sputum during their first COPD exacerbation.
89158295|NCT02766179|Active Comparator|CPAP Therapy|Continuous Positive Airway Pressure
89158296|NCT02766179|Experimental|Somnoguard|Somnoguard
89158297|NCT05255120|Experimental|Intensified preoperative information|The patient participating in the intervention group is evaluated preoperatively based on an algorithm. This information is designed according to a checklist which includes how the procedure is performed, rules of conduct in connection with and after the procedure and what the patient can expect after surgery.
89158298|NCT05255120|No Intervention|Control group|The patient who participates in the control group receives information about participation in the study as a control, ie without information about the intervention. The patient will then be planned for the procedure according to current, local routines.
89158299|NCT00661986|Experimental|1|dark chocolate 6 g/day
89158300|NCT00661986|Active Comparator|2|dark chocolate 25 g/day
89158301|NCT04223921||Patients who will be discharged from hospital (acute geriatric|Patients who will be discharged from hospital (acute geriatric care unit) between January and March 2020
89158302|NCT00662064||1|Patients with lower urinary tract dysfunction
89158303|NCT00662064||2|Controls with normal lower urinary tract function
89158304|NCT00987181||Angiography high risk|Patients with multiple risk factors, positive non-invasive test, or known pre-existing coronary artery/vascular disease. Patients with diabetes mellitus will be identified, and subject to a sub-group analysis.
89158305|NCT00987181||Angiography Low Risk|Patients with chest pain symptoms, minimal risk factors, and inconclusive evidence of myocardial ischaemia on non-invasive testing.
89158306|NCT02658110|Sham Comparator|Non Protein Trial|Mixed Macronutrient Breakfast Meal and Mixed Macronutrient Lunch Meal served without additional whey protein
89158307|NCT02658110|Experimental|Preload Trial|Whey protein (20g) administered 15 minutes prior to Mixed Macronutrient Breakfast Meal
89158308|NCT02658110|Experimental|With Meal Trial|Whey protein (20g) administered alongside Mixed Macronutrient Breakfast Meal
89158309|NCT02658110|Experimental|Post Meal Trial|Whey protein (20g) administered 15 minutes after Mixed Macronutrient Breakfast Meal
89158310|NCT02766257|Other|children undergoing ambulatory surgery|
89158311|NCT00662142|Experimental|1|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
89158312|NCT05711875|Experimental|Virtual Reality Glasses|Virtual Reality (VR) glasses applied group
89158313|NCT05711875|No Intervention|Standard of care|group without Virtual Reality (VR) glasses
89158314|NCT02651714|Placebo Comparator|Placebo|Oral
89158315|NCT02651714|Experimental|Tradipitant|Oral
89158316|NCT02576158||Subjects will be women, 30-65 years of age|Patients who are at average risk of developing cervical intraepithelial neoplasia or cervical cancer who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT. Subjects with HPV positive will undergo colposcopy within 90 days of enrollment.
89158317|NCT04005469|Experimental|Trepostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
89158318|NCT02651324|Experimental|Treatment Group|A ketamine bolus of 0.5mg/kg will be given and then the ketamine infusion of 0.2 mg/kg/hr will be initiated prior to incision. Intra-operative opioids will be at the discretion of the attending anesthesiologist. Postoperative management will include continuation of the study drug as well as a standardized morphine patient-controlled analgesia (PCA) and acetaminophen 15 mg/kg IV every 6 hours. On postoperative day 1, patients are started on ketorolac 0.5 mg/kg up to 15 mg IV q8h. On postoperative day 2 they are transitioned to ibuprofen 10 mg/kg up to 600 mg. The ketamine infusion will continue for 48 hours post operatively at which point the PCA is discontinued and patients are transitioned to oral pain medications (Roxicet or Lortab and Flexeril) as per the current protocol.
89158319|NCT02651324|Placebo Comparator|Placebo|A placebo (saline) will be given in place of ketamine
89158320|NCT02696603|Experimental|Participants with Parkinson disease|People who report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
89158321|NCT02696603|Experimental|Participants without Parkinson disease|People who do not report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
89158322|NCT00662220|Active Comparator|Standard dose|Standard-dose ribavirin (12-15 mg/kg/day) in combination with peginterferon 180µg QW
89158323|NCT00662220|Experimental|High dose|High-dose ribavirin (25-29 mg/kg/day) in combination with peginterferon 180µg QW
89158324|NCT02651090|Experimental|sonazoid|treatment arm with sonazoid
89158325|NCT02575924|Active Comparator|sequential medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
89158326|NCT02575924|Active Comparator|sequential medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
89158327|NCT02575924|Active Comparator|sequential medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
89158328|NCT02575924|Active Comparator|one step medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
89158329|NCT02575924|Active Comparator|one step medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
89158330|NCT02575924|Active Comparator|one step medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
89158331|NCT02766101|Experimental|Aerobic Exergaming PE|Progressive aerobic curriculum utilizing virtual reality exergaming stationary bicycles. Classes held 2 times per week for 30-40 minutes, aerobic exercise beginning at 10 minutes at moderate to vigorous intensity and building to 20 minutes plus.
89158332|NCT02766101|Active Comparator|Standard PE|Traditional PE focused on gross motor skill and sports skill acquisition, and team building. Typically non-aerobic.
89158333|NCT02631096|Experimental|0.2 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
89158334|NCT02631096|Experimental|0.4 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
89158335|NCT02631096|Experimental|ARB-001467 or Placebo|HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
89158336|NCT02631096|Experimental|0.4 mg/kg ARB-001467|HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks
89158337|NCT02651168|Other|aflibercept|aflibercept treatment aflibercept, 40 mg/mL Solution for Intravitreal Injection
89158338|NCT02765711||the use of ticagrelor in hospital|
89158339|NCT00650000|Experimental|1|Modafinil Tablets 200 mg
89158340|NCT00650000|Active Comparator|2|Provigil® Tablets 200 mg
89158341|NCT02630862|Active Comparator|aspirin|acetylsalcylic acid 100 mg per day give orally for six months, starting the day of carotid endoartherectomy
89158342|NCT02630862|Active Comparator|aspirin plus dipyridamole|acetylsalicylic acid 25 mg plus dipyridamole extended release 200 mg, combined in a capsule, per day starting the day of carotid endoartherectomy
89158343|NCT02536430|Active Comparator|Buccal infiltration of Ketorolac|A buccal infiltration of 30 mg/mL of Ketorolac Tromethamine was applied for the patients in case group.
89158344|NCT02536430|Placebo Comparator|buccal infiltration of Normal Saline|A buccal infiltration of Normal Saline was applied for the patients in control group.
89158345|NCT02765867|Experimental|RBP-6000|A single dose of RBP-6000 will be administered on Study Day 1
89158346|NCT02631174|No Intervention|cohort 1|Cohort 1 (Aim 1) - 6 participants Cohort 1 will be comprised of 6 neonates (≤28 days of age) admitted to the CICU or NICU who are neither undergoing ECMO nor CPB. Cohort 1 will receive a single dose of ATIII by short 15 minute infusion.
89158347|NCT02631174|Active Comparator|cohort 2.1|"• Cohort 2.1 - 6 neonates undergoing ECMO.~Three participants will receive a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume followed by a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume~Three participants will receive a single dose 15 minute infusion of hpATIII that is not dose adjusted to account for circuit volume followed by a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume"
89158348|NCT02631174|Active Comparator|cohort 2.2|"• Cohort 2.2 - 12 neonates who will undergo open-heart surgery with CPB~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
89158349|NCT02631174|Active Comparator|cohort 2.3|"• Cohort 2.3 - 12 infants who will undergo open-heart surgery with CPB~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
89158350|NCT02631174|Active Comparator|cohort 3|Cohort 3 (Aim 3) - 6 participants Six participants (neonates or infants) who will undergo ECMO and receive ATIII as standard of care will be enrolled and have a baseline ATIII level measured within 6 hours of ATIII administration and repeated within 15 minutes of initiation of extracorporeal support. If post-support level is < 80% normal activity then an ATIII level will be repeated and participants will be assigned to one of two hpATIII dosing regimens in which one formula accounts for additional circuit volume and one formula does not account for additional circuit volume, as described in section 7.4. Upon completion and 120 hr follow up after the first dose, participants still having ATIII activity less than 80% will then receive a second dose
89158351|NCT04167956|Experimental|ultrasound combined with CT guided|ultrasound combined with CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
89158352|NCT04167956|Sham Comparator|CT guided|CT guided lumbar sympathetic ganglion block in patients with intractable pain caused by sympathetic neuropathy of lower extremities
89158353|NCT02630784|Experimental|Homecare ventilator|NIV with a dedicated ventilator for homecare, functioning with a turbine and with vented mask (exhalation by a calibrated leak)
89158354|NCT02630784|Active Comparator|ICU ventilator|NIV with a dedicated ICU ventilator, functioning with non-vented masks and an exhalation valve.
89158355|NCT04168034|Experimental|Experimental: iParent2Parent Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 2 to 3 months
89158356|NCT04168034|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iParent2Parent program
89158357|NCT04686929|Experimental|Cohort 1|The participants in Cohort 1 will receive abatacept s.c
89158358|NCT02650934||Adverse remodelling|EF below 40% following MI and remain below 40% after reperfusion
89158359|NCT02650934||not adverse remodelling|EF below 40% following MI and remodelling after reperfusion or EF above 40 % following MI
89158360|NCT02535468||Prospective Arm|
89158361|NCT02535468||Contrived Arm|
89158362|NCT02765633|Experimental|Cangrelor|Cangrelor in up to four (4) dose cohorts consisting of a minimum of five participants in each cohort. One cohort of five participants will be enrolled at a time. Cohort 1 subjects will receive Cangrelor at 0.5 mcg/kg/min. Cohort 2 subjects will receive Cangrelor at 0.25 mcg/kg/min. Subsequent cohort dosing decisions are made at the completion of enrollment in each cohort.
89158363|NCT00662376|Experimental|Test|oral nutritional supplement (assignment: according to consecutive random numbers)
89158364|NCT00662376|Placebo Comparator|Control|placebo (assignment: according to consecutive random numbers)
89158365|NCT04167488|Experimental|Actigraphic measurement|
89158366|NCT00581776|Experimental|VCR-CVAD with rituximab maintenance|Induction chemotherapy with Bortezomib, cyclophosphamide, rituximab, vincristine, doxorubicin, and dexamethasone. Subjects will receive 6 cycles of induction chemotherapy, of 21 days each. After completing induction, subjects will receive rituximab consolidation (4 weeks), and then rituximab maintenance therapy for up to 5 years.
89158367|NCT02765243|Experimental|effectiveness of Anti-GD2 CART|Anti-GD2 CART cells can recognize and kill neuroblastoma through the recognition of GD2. This study will evaluate the side effects and effective doses of Anti-GD2 CART cells in treating refractory and/or recurrent neuroblastoma
89158368|NCT04167410|No Intervention|control group|We did not perform any intervention on the patients in the control group. These patients received routine glycaemia control and healthcare provided to diabetic patients undergoing surgical intervention in the department of general surgery.After receiving written informed consent, the first part of the data collection form on the socio-demographic and disease characteristics of the patients were completed face-to-face. The BG levels of the patients and the medications and insulin used for glycaemic control were recorded one night before surgery. The anxiety levels of the patients were evaluated on the morning of surgery using State-Trait Anxiety Inventory . The second part of the data collection form , which included information on glycaemic management, glycaemia levels and the medications and insulin used on the morning of surgery and during surgery, intensive care stay and the clinical period, was filled in by the nurse on the monitoring and anaesthesia forms.
89158369|NCT04167410|Experimental|intervention group|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. management was conducted by nurses in line with the protocol. Data on glycaemic management of the intervention group was similar to the control group.the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protoco
89158370|NCT00662454|Active Comparator|I|10 normal weight women (BMI < 25 kg/m2)
89158371|NCT00662454|Active Comparator|II|10 obese women (BMI >30 kg/m2)
89158372|NCT02765477||Angiogram Cohort w Acute Coronary Occlusion|Inclusion Criteria: Angiogram Cohort. Patients who present 1) directly through the study site Emergency Department (ED) OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1.Underwent urgent or emergent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to chest pain [CP] and/or shortness of breath [SOB]) AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, a group of patients will be identified who had angiographic evidence of ACO, defined as an acute lesion with TIMI flow 0 or 1 when evaluated by an experienced study-site adjudicator.
89158373|NCT02765477||Non-ACO Angiogram Cohort|Inclusion Criteria: Angiogram Cohort. Each study site will first identify adult patients (age 18 years or older) who presented to the study site 1) directly through the study site ED OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1. Underwent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to CP and/or SOB AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, those who had TIMI-2 or greater flow will be identified for several research questions.
89158374|NCT02765477||Random ED Sample w Paced Rhythm but No AMI|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.~Each study site will randomly select 5 unique encounters for every one 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.~The primary control group selected from this search will be all patients in this group who do not meet criteria for acute myocardial injury, as defined by 1) all troponins below the 99th percentile or 2) Peak troponin < 3x the upper limit of normal AND no rise and/or fall of > 30%."
89158375|NCT02765477||ED Patients w Paced Rhythm Without AMI excluded|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.~Each study site will randomly 5 unique encounters for every 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.~The secondary control group will include patients in this group in whom Acute MI cannot be excluded because they either have at least 1 troponin > 3x the upper limit of normal or they have at least 1 troponin between 1x and 3x the ULN AND have a rise and/or fall of at least 30%."
89158376|NCT04073524|Experimental|Nature-Body-Mind-Community (NBMC) + treatment as usual|9 weeks of nature-based therapy (Nature-Body-Mind-Community (NBMC)) treatment as usual
89158377|NCT04073524|Other|Treatment as usual|Treatment as usual
89158378|NCT04156152|Active Comparator|Grupo I|16 patients
89158379|NCT04156152|Active Comparator|Grupo II|16 patients
89158380|NCT02774603|Active Comparator|Aquatic Locomotor Training|Aquatic Locomotor Training is a Locomotor Training technique utilizing an underwater treadmill to help increase a patient's independence and function. Aquatic Locomotor Training may require up to three people to obtain desirable gait kinematics: one at each of the patient's legs, and one at the patient's pelvis; however, typically with ambulatory patients, only one therapist is utilized. Therapists are highly trained, using their legs and feet to provide properly timed underwater cues throughout the gait cycle.
89158381|NCT02774603|Active Comparator|Land Locomotor Training|Locomotor Training encompasses a variety of interventions ranging from BWSTT to overground gait training to robotic-assisted walk training. Overground Locomotor Training, depending upon the technique used, can require up to four people to complete the intervention (one at each participant's leg, one at the participant's trunk and/or pelvis, and one monitoring the computer and/or treadmill).
89158382|NCT02657798||Depressed patients taking sertraline|Patients with depression who have been randomised to the sertraline arm in the PANDA trial
89158383|NCT02657798||Depressed patients taking placebo|Patients with depression who have been randomised to the placebo arm in the PANDA trial
89158384|NCT02657798||Healthy controls|Healthy participants with no history of depression
89158385|NCT02575846|Active Comparator|Human Milk|Neonates fed human milk
89158386|NCT02575846|Placebo Comparator|Formula|Neonates fed formula
89158387|NCT00662610|Experimental|naproxcinod 375 mg - 750 mg -1125 mg bid|dose escalating
89158388|NCT00662610|Active Comparator|naproxen 250 mg -500 mg -750 mg bid|dose escalating
89158389|NCT04225481||SVF from healthy subjects from aesthetic plastic surgery|Subjects undergoing plastic surgery as scheduled by clinic routine to obtain waste adipose tissue
89158390|NCT04225481||OA patients|Subjects undergoing prosthetic surgery as scheduled by clinic routine to obtain waste synovium and cartilage
89158391|NCT02657876|Experimental|ExpressGraft-C9T1 Skin Tissue|Enrolled participants receive one application of ExpressGraft-C9T1 skin tissue
89158392|NCT04225325|Active Comparator|A: SYMTUZA|TAF/FTC 245 mg/200 mg single tablet QD +DRV /cobicistat 800 mg /150 mg single tablet QD
89158393|NCT04225325|Active Comparator|B: DESCOVY+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DTG 50 mg QD
89158394|NCT04225325|Experimental|C: SYMTUZA+DOLUTEGRAVIR|TAF/FTC 245 mg/200 mg single tablet QD+DRV/cobicistat single tablet QD + +DTG 50 mg QD
89158395|NCT00649610|Active Comparator|Arm 1|
89158396|NCT00649610|Active Comparator|Arm 2|
89158397|NCT02631330|Experimental|Falls prevention group|"Intervention group that will receive a monthly talk (individual or collective) of 30 minutes on the advantages of having a free fall hazards environment and multiple physical exercise component: balance,muscle strength and aerobic capacity and risk polypharmacy and abuse of drugs, especially benzodiazepines). In the same monthly meeting, subjects will be train Multicomponent physical activity program during 60 minutes. 15 minutes of gait and balance training; 15 minutes of endurance training; 30 minutes of aerobic training according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459"
89158398|NCT02631330|No Intervention|Control group|Subjects will receive the same information provided at the beginning to Falls prevention group. They will not receive further information during the follow-up period.
89158399|NCT01050881||Positive Blood Donors|Blood donors testing positive for HIV, HBV, HCV or HTLV in 2008 and 2009. Donors notified of increased risk of vCJD in 2005.
89158400|NCT02655146|Experimental|GnRHa protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 (Progynova) 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2.In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .A single dose of Triptorelin 0.1mg is administrated on the 3rd day after embryo implanted with routine luteal phase support.
89158401|NCT02655146|Other|routine luteal phase protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2. In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .
89158402|NCT00662688|Active Comparator|chemotherapy|chemotherapy at investigator's discretion
89158403|NCT00662688|Experimental|dalteparin|dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.
89158404|NCT02774525|Active Comparator|Treatment as Usual (TAU)|Outpatient substance-abuse treatment plus drug and alcohol screening plus brief support for personal goal setting
89158405|NCT02774525|Experimental|Contingency Management|Contingency management for drug and alcohol abstinence plus TAU
89158406|NCT02774525|Experimental|Parenting Intervention|Parenting intervention plus TAU
89158407|NCT02774525|Experimental|Parenting Intervention + Contingency Management|Parenting intervention plus contingency management for drug and alcohol abstinence plus TAU
89158408|NCT00666120|Active Comparator|1|Cow's milk based infant formula
89158409|NCT00666120|Active Comparator|2|Partially hydrolyzed cow's milk based infant formula
89158410|NCT04169126|Experimental|F-18-PMPBB3|F-18-PMPBB3 imaging
89158411|NCT02774369|Experimental|Physical exercise|A 6-week individualised, aerobic intervention program elaborated by a kinesiologist following a complete assessment of the individual's physical condition.
89158412|NCT02774369|Active Comparator|Cognitive-behavioral therapy|A 6-week self-administered cognitive-behavioral therapy for insomnia composed of a 60-min video (DVD format) and 6 booklets.
89158413|NCT04169048|Experimental|Intervention group (BPD)|Participants (N=60) receive the weekly conducted intervention (group training for mothers with BPD) over the period of 12 weeks (12 sessions). Assessments of each participant: T0 (pre-intervention), T1 (post-intervention) and follow-up (6 months after T1).
89158414|NCT04169048|No Intervention|waiting control group (BPD)|Members of this group (N=60) receive no intervention but treatment as usual (TAU). After completing all assessment points (T0, T1, T2), they can receive the intervention of the intervention group (group training).
89158415|NCT04169048|No Intervention|clinical control group (AD/MDD)|Mothers with anxiety and/or depression (N=60) receive no intervention. Assessment point only T0.
89158416|NCT04169048|No Intervention|healthy control group|Mothers with no actual mental disorder (N=60) receive no intervention.# Assessment points T0, T1, T2.
89158417|NCT04162626|Experimental|Intervention|Supportive home visits by public health nurses to new parents from 28 weeks in pregnancy until the child is two years.
89158418|NCT04162626|Other|Control|Follow up as usual at the Child health center
89158419|NCT02774447||Rectal cancer patients with ileostoma|"In association with anterior resection of rectal cancer these patients obtain loop-ileostoma in order to avoid complications. These are closed within a few months and according to previous studies the admission time is 3-5 days after operation. This study is a single-arm study. The arm include patients having had rectal cancer operation and who have obtained a loop-ileostoma and that meet the inclusion criteria.~The operation procedure is standardized; shortly described by dissecting the ileostoma from the abdominal wall and everting the stoma ledges, which will be sutured or stapled. The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will be followed up."
89158420|NCT04167566|Other|Intervention Communities|All participants confirmed using rapid diagnostic test (RDTs) to be carrying the malaria parasite will be treated using artemisinin combination therapy (ACT) following the Ghana National Malaria Treatment Guidelines and followed up on days 1, 2, 3 during treatment as DOTs (Directly observed therapy) and on day 7 post treatment. The research team together with Community volunteers will be provided the treatment guidelines which specify the dosage for each treatment regimen. Participants who receive the treatment will be observed for five minutes to ensure that they retain the drug. Those who vomit within this period will have the treatment repeated.
89158421|NCT02630550||Aortic Aneurysm Repair|The impact of large abdominal retractors and an abdominal aortic cross-clamp on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
89158422|NCT02630550||Femoral Endarterectomy|The impact of the clamping of a large peripheral arterial vessel on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
89158423|NCT04839887||Validation study|Three hundred patients with ischemic stroke (18-65 years) will be enrolled for the validation of the Czech version of the the Stroke Impact Scale 3.0. The reliability and validity study will have a cross-sectional design.
89158424|NCT04839887||Prospective quantitative study|Two hundred enrolled IS patients (100 young IS patients < 50 years and 100 IS patients of 50-65 years) will undergo a serial of structured and standardized questionnaires during scheduled outpatients' controls three, six and 12 months after IS. In all enrolled patients, the functional outcome, neuropsychological status and quality of life will be assessed using standardized scales and tools.
89158425|NCT04839887||In-depth interview qualitative study|twenty young IS patients < 50 years will undergo an in-depth, semi-structured interview with explanatory questions that will allow a detailed understanding of the patient's experience. Interpretative phenomenological analysis (IPA) study design will be used.
89158426|NCT02636556|Experimental|chemoradiation|concurrent chemoradiation.
89158427|NCT00650624|Active Comparator|Arm 1|
89158428|NCT00650624|Active Comparator|Arm 2|
89158429|NCT00650624|Active Comparator|Arm 3|
89158430|NCT00650624|Placebo Comparator|Arm 4|
89158431|NCT04225403|Experimental|Telephone-based motivational interviewing|Experimental intervention consisted of a motivational intervention for smoking cessation through telephone every 3 months for one year, performed by IBD nurse
89158432|NCT04225403|No Intervention|usual care|No intervention consisted of a single telephone contact one year after the star of the study
89158433|NCT00666354|Active Comparator|1|
89158434|NCT00666354|Active Comparator|2|
89158435|NCT00666354|Active Comparator|3|
89158436|NCT02655068|Other|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
89158437|NCT02655068|Other|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
89158438|NCT00666432||1|Controls
89158439|NCT00666432||2|Patient Family
89158440|NCT00666432||3|Patients
89158441|NCT02654912|Experimental|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
89158442|NCT02654912|No Intervention|Reactive Focal Test and Treat|This is the current standard of care in Southern Province and is described by a reactive response to passively detected index case of malaria. The reactive response consists of testing all individuals within a defined radius of each RDT-confirmed incident malaria case with an RDT and treating all positive individuals with artemether-lumefantrine (AL).
89158443|NCT02536352|Experimental|Fluoride prenatal vitamin|Prenatal vitamin-mineral containing 3 mg fluoride
89158444|NCT02536352|Active Comparator|Standard prenatal vitamin|Prenatal vitamin-mineral containing 0 mg fluoride
89158445|NCT02774057|Experimental|Initial therapy with Captafer®|This arm will consist of 10 patients who will begin Captafer® therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Iron Sulfate therapy twice daily for an additional 6 weeks.
89158446|NCT02774057|Experimental|Initial therapy with Iron Sulfate|This arm will consist of 10 patients who will begin Iron Sulfate therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Captafer® therapy twice daily for an additional 6 weeks.
89158447|NCT02636400|No Intervention|expectant|7 menstrual cycles of expectant management
89158448|NCT02636400|Experimental|postop IUI|4 IUI cycles within 7 menstrual cycles
89158449|NCT02773979|Active Comparator|Group 1: PfSPZ 51200 sporozoites/Placebo|Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1
89158450|NCT02773979|Active Comparator|Group 2: PfSPZ 102400 sporozoites/Placebo|CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1
89158451|NCT02773979|Active Comparator|Group 3: PfSPZ 102400 sporozoites|CQ/PfSPZ Challenge 102400 sporozoites N=9
89158452|NCT00662844|Placebo Comparator|A1 vitamin D3 400IU|Orally for one year
89158453|NCT00662844|Placebo Comparator|A2 vitamin D3 800IU|Orally for one year
89158454|NCT00662844|Placebo Comparator|A3 vitamin D3 1600IU|Orally for one year
89158455|NCT00662844|Placebo Comparator|A4 Vitamin D3 2400 IU|Orally for one year
89158456|NCT00662844|Placebo Comparator|Placebo|Placebo for one year
89158457|NCT04168658|Experimental|Physical activity and education intervention|
89158458|NCT04168658|Active Comparator|Education intervention|
89158459|NCT04224935|Active Comparator|Leukocyte Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin will be used
89158460|NCT04224935|Active Comparator|connective tissue|connective tissue will be used
89158461|NCT00666510||Bronchospasm|Patients who presented bronchospasm during anesthesia induction
89158462|NCT00666510||Asthma|Patients who presented bronchospasm during anesthesia induction and were identified as asthmatics
89158463|NCT00666510||Control|Patients who were submitted to anesthesia induction and showed no complications
89158464|NCT02650544|Experimental|mirtazapine|Mirtazapine arm will be orally administered with mirtazapine 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
89158465|NCT02650544|Placebo Comparator|Placebo|Placebo arm will be orally administered with placebo 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
89158466|NCT02773745|No Intervention|Standard of Care|Participant will receive standard of care and a brochure on healthy eating.
89158467|NCT02773745|Active Comparator|Aquatic Prehabilitation Group|The prehabilitation group will undergo 6-8 weeks of individualized aquatic exercise in a heated pool (60 min/session, 3 times per week). Aquatic equipment maybe used to challenge balance and trunk stabilization.
89158468|NCT02774135||direct occupational therapy intervention|group will be evaluated 4 times: on referral to waiting list for treatment, before and after 9-12 direct individual treatments of 45 minutes, and follow-up after 3 months.
89158469|NCT02650388|Other|Post TAVI neurocognitive outcome|"TAVI with CoreValve will be done for all the patients and outcome will be assessed as Cognitive fuction, quality of life, Gait speed, Hand grip strength, Activities of daily living (ADL), Instrumental activities of daily living (IADL), Short- Form Mini Nutritional assessment (SF-MNA), Serum albumin level, Hemoglobin level, BMI, Montreal cognitive Assessment (MOCA), EQ-5D-3L-questionnaire, Ferreans and Powers Quality of life Index (QLI), MOCA, RBANS, Wisconsin test, Stroop test, Fluency test, Subjective Eyeball test, Serial Transcranial Doppler (TCD) during TAVI. Finally, Hungarian frailty score will be deduced."
89158470|NCT00883740|Experimental|Lyrica|flexible dosing Lyrica 300-450mg/day
89158471|NCT00883740|Placebo Comparator|Placebo|Placebo
89158472|NCT02773823|Active Comparator|Intervention|"Lifestyle intervention includes diet instruction and exercise intervention:~Diet instruction: The children were asked to increase fruit/vegetables consumption, reduce high fat food, etc.~Exercise intervention: The children participated sports 60 min/day,5d/week for 8 months."
89158473|NCT02773823|No Intervention|Control|"No intervention in the group with control."
89158474|NCT02650154||Pre-ketamine group|Blood samples are taken prior to the administration of ketamine.
89158475|NCT02650154||Post-ketamine group|Blood samples are taken several hours after the administration of ketamine.
89158476|NCT04830917|Experimental|Treatment with Kinesiotape and Oval 8|
89158477|NCT04830917|Experimental|Treatment with quick cast|
89158478|NCT04183712|Experimental|Afatinib with GEMOX|Patients will receive targeted therapy(Afatinib 40mg orally from day 1 to day 21 combined with GEMOX chemotherapy(gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion)
89158479|NCT04183712|Active Comparator|GEMOX|Patients will receive conventional GEMOX chemotherapy (gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion）
89158480|NCT04225091|Placebo Comparator|Placebo drink|
89158481|NCT04225091|Experimental|Triple up® Collagen Drink|
89158482|NCT04167644||Unfavorable outcome|80 patients with poor outcome were classified according to mRS score after discharge (mRS range from 3 up to 6).
89158483|NCT04167644||Favorable outcome|70 patients with better outcome were classified according to mRS score after discharge (mRS range from 0 up to 2) .
89158484|NCT02773901|Experimental|HS-1000 recording|ICP monitoring will be done with the HS-1000 to compare to CSF measurement from lumbar puncture (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals last 10 minutes.
89158485|NCT02650076|Experimental|Healthy|
89158486|NCT02771327|Experimental|CPAP plus gas|Treatment with Boussingnac valve CPAP during 6 hour, starting immediately after weaning
89158487|NCT02771327|Active Comparator|Usual treatment(ventimask plus gas)|ventimask
89158488|NCT00650780||1|All of the subjects will have measurements of Gc concentration and phenotype
89158489|NCT02773589|Experimental|Peroral endoscopic myotomy|
89158490|NCT02650310|No Intervention|Conventional transfer|This arm is the control group (conventional embryo transfer protocol) where there is no intervention.
89158491|NCT02650310|Experimental|Thermostable device transfer|This arm is the study group: embryo transfer protocol using a new thermostable device.
89158492|NCT00666744|Experimental|1|Exercise Intervention - additional lower limb exercises will be completed by the person with stroke with the assistance of his/her family for 35 minutes daily for a period of 8 weeks.
89158493|NCT00666744|No Intervention|2|Participants in this group will receive routine exercise therapy following stroke
89158494|NCT02773199||Cohort 1- Morning Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in morning hours (until 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for 8 hours
89158495|NCT02773199||Cohort 2- Afternoon Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in afternoon hours (after 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for more than 12 hours
89158496|NCT02650232|Other|Young Healthy Volunteers|We will evaluate in this group (18 - 40 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
89158497|NCT02650232|Other|Old Healthy Volunteers|We will evaluate in this group (50 - 80 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
89158498|NCT02650232|Other|Patients with heart failure|We will evaluate in this group (50 - 80 y + Heart failure) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
89158499|NCT02773277|Experimental|Single intervention arm|All patients will be assigned the intervention arm and will receive head-impulse testing before and in the days after skull base surgery.
89158500|NCT02657720|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and PTAF2 (flow meter)
89158501|NCT00662922||1|patients with hypoglycemia during intensive care
89158502|NCT00662922||2|patients without hypoglycemia during intensive care
89158503|NCT02765555|Experimental|RBP-7000|All subjects that meet initial study entry criteria will receive a test dose of 0.25mg of oral risperidone. Subjects who continue to be eligible will return to the clinical unit in one week and receive a single dose of 60mg RBP-7000 after a 2 hour fast. Subjects will remain in the clinical unit for 14 days, then return for 10 additional weeks after discharge.
89158504|NCT02657642||Cohort 1 (exposed)|cohort 1: patients who will receive the OMAGE-P transitional care in geriatric or internal medicine departement of the Eaubonne Hospital
89158505|NCT02657642||Cohort 2 (non exposed)|Cohort 2: : patients included in the usual care arm of the OMAGE RCT study in 2007-2008
89158506|NCT02765321|Experimental|Physical activity and healthy eating promotion|
89158507|NCT02654834||Pediatric Operating Room (OR) Staff|OR Staff exposed to nitrous oxide, and other volatile anesthetics
89158508|NCT02654834||Pediatric Intensive Care Unit (ICU) Staff|ICU Staff unexposed to any volatile anesthetics
89158509|NCT02764931|Experimental|Oat meal 1|A single gluten-free oat containing meal number 1 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
89158510|NCT02764931|Placebo Comparator|Placebo meal|A single meal which does not contain oats before ingesting the SmartPill capsule. Dietary intervention: gluten-free oats and gastrointestinal health.
89158511|NCT02764931|Experimental|Oat meal 2|A single gluten-free oat containing meal number 2 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
89158512|NCT00656526|Placebo Comparator|A01L|
89158513|NCT00656526|No Intervention|B01C|
89158514|NCT02657330|Experimental|SBP-101|SBP-101 is administered as a subcutaneous injection once daily, Monday through Friday for 3 weeks (total of 15 doses) followed by a 5-week rest period (3 weeks on, 5 weeks off = 1 treatment cycle). Dose escalation in phase 1a will continue until the maximum tolerated dose is determined.
89158515|NCT02765009|No Intervention|Control|Usual care provided according to the ward policy. Patients have to be weighed at least on admission (day 0), day 7 and day 14.
89158516|NCT02765009|Experimental|Strategy|Patients have to be weighed every day. Use of an algorithm based on weight changes from day 2 to day 14 in order to reduce weight gain (fluid overload) using diuretics, fluid restriction,albumin, and ultrafiltration (the latter when ongoing renal replacement)
89158517|NCT02636478||reference group|therapy naive patients with a sleep related breathing disorder
89158518|NCT02636478||therapy group|patients with devices treating their sleep related breathing disorder
89158519|NCT02649920|Experimental|Cervical ripening balloon|Prospective
89158520|NCT02649920|Active Comparator|Dinoprostone|Retrospective
89158521|NCT00663000||acromegalics|"Acromegaly in adult subjects either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).~Written informed consent"
89158522|NCT02765087|Experimental|Pleural TB|"This group consist of patients with TB pleural effusion.~Intervention:~Inform Consent~Medical History~E-Nose Device~Chest CT~Cytomorphologic & Cytochemistry of pleural Fluid.~Adenosine Deaminase value of pleural Fluid."
89158523|NCT02765087|Active Comparator|Control|"Patients with pleural effusion with different aetiologies than Tuberculosis.~Intervention:~Inform Consent~Medical History~E-Nose Device~Chest CT~Cytomorphologic & Cytochemistry of pleural Fluid.~Adenosine Deaminase value of pleural Fluid."
89158524|NCT04167722||Obese patients|BMI > 25
89158525|NCT04167722||Lean patients|BMI < or = 25
89158526|NCT02764853|Experimental|STEP-AD (10 sessions)|"Participants in this arm will receive the manualized 10 session behavioral medicine intervention titled Striving Towards EmPowerment and Medication Adherence."
89158527|NCT02764853|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive 1 session of Lifesteps and appropriate services and referrals as needed, followed by bi-weekly check-ins with a study research assistant.
89158528|NCT00663078|Experimental|A|Group A: Women from GP practices and area of Knowle West, Bristol
89158529|NCT00663078|Experimental|B|Group B: Women from Wellspring, GP practice or geographical area of Barton Hill Bristol.
89158530|NCT02771561|Other|Patent Foramen Ovale Closure|All eligible participants undergo a patent foramen ovale closure procedure
89158531|NCT00649688|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
89158532|NCT00649688|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
89158533|NCT00597012|Experimental|Surgical|Participants will undergo arthroscopic partial menisectomy (APM) surgery and offered postoperative rehabilitative physical therapy.
89158534|NCT00597012|Active Comparator|Nonoperative|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks.
89158535|NCT04631003|Other|Dynamic testing|"There are only one arm in this study. All patients get the same diagnostics and therapy. The preoperative assessments consist of an arthroCT of the wrist as well as the collection of demographic data, accident mechanism, medication intake, etc. within the scope of the usual medical history on the emergency ward. With the arthro-CT, in addition to the fracture balance, the proof of a possible rupture of the scapholunary tape apparatus takes place.~The dynamic determination of the scapholunary instability takes place during the osteosynthesis of the radius fracture.~With the dynamic functional test, the change of the scapholunary distance is assessed by illumination by movement of the wrist from the radial abduction into the ulnar abduction, before and after the execution of the osteosynthesis of the distal radius fracture.~Subsequently, the results of the scapholunary dissociation of the arthro-CT are checked with the results of the intraoperative dynamic test for correlation."
89158536|NCT02773433|Experimental|PAV group|Using Proportional Assist Ventilation after failed Spontaneous Breathing Trial
89158537|NCT02773433|No Intervention|Control group|Using Volume Assist Control mode after failed SBT
89158538|NCT02773511|Other|Bone healing|Bone healing in surgical or conservative treatment for children type 1 humeral condyle fracture
89158539|NCT02773511|Other|Fracture displacement|Fracture displacement in surgical or conservative treatment for children type 1 humeral condyle fracture
89158540|NCT00667056|Experimental|1|
89158541|NCT00667056|Placebo Comparator|2|
89158542|NCT02771639||Femoral neck fractures|Patients admitted to Sundsvall hospital for a displaced femoral neck fracture and treated with a hip arthroplasty
89158543|NCT00667134||1|Subjects with diffuse scleroderma
89158544|NCT00667134||2|Subjects with limited scleroderma
89158545|NCT00667134||3|Subjects without a fibrosing or autoimmune disease.
89158546|NCT02772887|Experimental|Citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
89158547|NCT02772887|Placebo Comparator|Placebo|Placebo, 3 grams once per day for 3 weeks.
89158548|NCT02764619|Active Comparator|Aldo group|Fixed dose of spironolactone, Spirix (Takeda Pharma A/S), 25 mg once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
89158549|NCT02764619|Placebo Comparator|Control group|Matched placebo, 1 pill once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
89158550|NCT00663156|Experimental|subject|10 subjects receiving breast augmentation with fat grafting
89158551|NCT00663156|Other|control|10 control will have breast augmentation using breast implants
88804549|NCT04110236|Experimental|Immediate PriCARE Positive Discipline Module|A subset of participants (up to 40 caregiver-child pairs) who were assigned to the immediate PriCARE group will be offered to participate in the PriCARE Positive Discipline Module if they attended at least 4 PriCARE sessions and completed both main study interviews. If they are randomized to the immediate PriCARE Positive Discipline group, they will attend an additional 4-6 sessions 4-6 weeks after completion of the 6-week PriCARE intervention. This module teaches techniques related to behavior reward charts, appropriate timeout protocol, and other positive discipline techniques for handling persistent behaviors not addressed by the other PriCARE skills.
88804550|NCT04110236|No Intervention|Delayed PriCARE Positive Discipline Module|The delayed Positive Discipline group will not receive the Positive Discipline Module intervention until after their third interview data collection is complete (in 2-3 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment.
88804551|NCT04072055||MOTO medial|Patients suitable fulfilling the standard criteria for the implantation of unicondylar implant.
88804552|NCT04041128|Experimental|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
88804553|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1A|Administration of AGN-242428 ophthalmic solution
88804554|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1B|Administration of AGN-242428 ophthalmic solution
88804555|NCT04030962|Experimental|Stage 1: AGN-242428 Cohort 1C|Administration of AGN-242428 ophthalmic solution
88804556|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1A|Administration of AGN-231868 ophthalmic solution
88804557|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1B|Administration of AGN-231868 ophthalmic solution
88804558|NCT04030962|Experimental|Stage 1: AGN-231868 Cohort 1C|Administration of AGN-231868 ophthalmic solution
88804559|NCT04030962|Placebo Comparator|Stage 1: AGN-242428 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
88804560|NCT04030962|Placebo Comparator|Stage 1: AGN-231868 Vehicle|Administration of matching placebo (vehicle) ophthalmic solution
88804561|NCT04030962|Experimental|Stage 2: AGN-242428 Group 1|Administration of AGN-242428 ophthalmic solution
88804562|NCT04030962|Experimental|Stage 2: AGN-242428 Vehicle Group 2|Administration of matching placebo (vehicle) ophthalmic solution
88804563|NCT04030962|Experimental|Stage 2: AGN-231868 Group 3|Administration of AGN-231868 ophthalmic solution
88804564|NCT04030962|Experimental|Stage 2: AGN-231868 Vehicle Group 4|Administration of matching placebo (vehicle) ophthalmic solution
88804565|NCT04030962|Active Comparator|Lifitegrast|Administration of Lifitegrast ophthalmic solution
88804566|NCT04009837|Experimental|Hip-focused|Hip-focused rehabilitation intervention
88804567|NCT04009837|Active Comparator|Spine-focused|Spine-focused rehabilitation intervention
88804568|NCT03951753|Experimental|Tirzepatide 15 mg|Participants received 15 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 28 weeks.
88804569|NCT03951753|Active Comparator|Semaglutide 1 mg|Participants received 1 mg Semaglutide administered SC once weekly for 28 weeks.
88804570|NCT03951753|Placebo Comparator|Placebo|Participants received Placebo administered SC once weekly for 28 weeks.
88804571|NCT03947671|Experimental|Body wrap|This group will receive the body wraps post surgery to maintain normothermia.
88804572|NCT03947671|Active Comparator|Tylenol|This group will receive the standard of care of monitoring temperature and administering Tylenol if a fever develops.
88804573|NCT03947671|Experimental|Tylenol with body wrap|This group will receive the standard of care of monitoring temperature but will be administered Tylenol and body wraps if a fever develops.
88804574|NCT03944499|Experimental|FS-1502|"Phase Ia:~Patients enrolled on the 1.2 and 2.0 regimens: FS-1502 monotherapy every 4 weeks with intravenous drip, 28 days as a cycle; Patients enrolled on the 3.0 regimens: starting from the 1.0mg/kg dose group, FS-1502 monotherapy every 3 weeks with intravenous drip, 21 days as a cycle;~Phase Ib:~FS-1502 monotherapy, the dose and frequency of administration for Stage Ib will be obtained according to Phase Ia (RP2D). All patients will continue treatment until no clinical benefit occurs, or intolerable toxicity occurs, or death occurs, or the investigator decides, or patients voluntarily withdraw from the study.~Study end is defined as the last patient's treatment ended or 2 years after the last patient's treatment began(depending on which happens earlier)."
88804575|NCT03941964|Experimental|Venetoclax 400 mg + azacitidine 75 mg|Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Azacitidine (75 mg/m^2) was administered subcutaneously or intravenously per investigator's choice and institutional practice for 7 days beginning on Day 1 of each 28-day cycle.
88804576|NCT03941964|Experimental|Venetoclax 400 mg + decitabine 20 mg|Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Decitabine (20 mg/m^2) was administered intravenously per investigator's choice and institutional practice for 5 days beginning on Day 1 of each cycle.
88804577|NCT03935100|Experimental|Treatment Group|All visible diverticula clipped during index colonoscopy
89158552|NCT04223375|Experimental|Nutrition Group|"After the health status of the mothers in the experimental group was stabilized, approximately 20-30 minutes of nutritional education was given at the first interview before the hospital discharge. After nutrition education, motivational messages were sent to women's phones once a week. In addition, mothers were given nutritional counseling during their home visits during the 1st and 3rd months, and their questions and problems regarding nutrition were evaluated. The mother was supported where she needed it.~In nutritional education, information was given such as adequate and balanced nutrition in the postpartum period, adequate fluid intake, consumption and importance of prebiotic and probiotic foods, the importance of healthy microbiota for infant health and the amount of nutrients equivalent to one serving. In addition, the handbook which contains the educational content is given to the mothers to facilitate the recall."
89158553|NCT04223375|No Intervention|Control Group|No intervention was made to the control group.
89158554|NCT04162860|Experimental|minimally invasive esophagectomy with preemptive ENP|Patients will undergo a standard total minimally invasive transthoracic Ivor Lewis esophagectomy with preemptive ENP. After completion of the esophago-gastric anastomosis, an Eso-SPONGE® system will be inserted via an intraoperative gastroscopy. ENP will be carried out upon completion of the esophago-gastrostomy, but no later than 12 hours after the surgical intervention. Postoperatively, secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg. ENP will remain for 4 days and will be monitored with clinical parameters.
89158555|NCT04162860|No Intervention|Standard minimally invasive esophagectomy|Patients in the control group will undergo a standard minimally invasive transthoracic Ivor Lewis esophagectomy without preemptive ENP.
89158556|NCT02771483||Suspected GCA (GCA final diagnosis)|
89158557|NCT02771483||Suspected GCA (alternative final diagnosis)|
89158558|NCT04032210|Experimental|Regimen using dual Zinc plus Arginine based toothpaste|
89158559|NCT04032210|Experimental|Regimen using Zinc based toothpaste (Crest complete)|
89158560|NCT04032210|Active Comparator|Fluoride based toothpaste (Signal)|
89158561|NCT04223219|Active Comparator|High Opioid Group|-The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate >20% of baseline or hypertension: increase of mean blood pressure >20% of baseline).
89158562|NCT04223219|Placebo Comparator|Low Opioid Group|The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).
89158563|NCT04223219|Experimental|Non-Opioid Group|The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.
89158564|NCT02631252|Experimental|Open-label, Single-arm|"Hydroxychloroquine + Mitoxantrone + Etoposide~Hydroxychloroquine is given up to 21 days, started concurrently with both Mitoxantrone, administered by IVPB over 15 minutes each day for 5 days and Etoposide, administered intravenously over 2 hours each day for 5 days"
89158565|NCT02764463|Other|FRCFPDs|Fiber reenforced Composite Fixed Partial Dentures
89158566|NCT02631408|No Intervention|Control Group|No additional treatment. Routine iv. antibiotic prophylaxis only.
89158567|NCT02631408|Experimental|Vancomycin Group|Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged
89158568|NCT02773043|Other|non invasive imaging technique|
89158569|NCT00667212|Active Comparator|2|Supportive Psychotherapy
89158570|NCT00667212|Active Comparator|1|Cognitive Behavioral Therapy (Cognitive Restructuring, Relaxation, and Coping Skills Training: CRCST)
89158571|NCT02762747|Experimental|Drain|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
89158572|NCT02762747|No Intervention|No-drain|No drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
89158573|NCT00667290|Experimental|1|
89158574|NCT00667290|No Intervention|2|
89158575|NCT02762903|Active Comparator|Tenotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with tenotomy technique.
89158576|NCT02762903|Active Comparator|Osteotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with lesser tuberosity osteotomy technique.
89158577|NCT02630394|Experimental|Azithromycin prophylaxis|Azithromycin will be supplied as a 250-mg tablet. Participants weighing less than 40 mg will be instructed to take 1 tablet 3 days a week (Monday, Wednesday, and Friday), and participants who weigh more than 40 kg will be instructed to take 2 tablets on the same 3 days per week.
89158578|NCT02771873|No Intervention|Usual care|Screening for CVD risk factors plus one time education regarding management of risk factors will be provided to all family members.
89158579|NCT02771873|Experimental|Life style Intervention and care coordination|Integrated cardiovascular disease risk management.
89158580|NCT00667524||I|
89158581|NCT00667680|Active Comparator|1|anodal tDCS
89158582|NCT00667680|Sham Comparator|2|Sham tDCS
89158583|NCT02771405|Experimental|Sofosbuvir +Ribavirin|Sofosbuvir 400 mg/day +ribavirin for 24 weeks
89158584|NCT02771405|Experimental|Sofosbuvir+Simeprevir±Ribavirin|Sofosbuvir 400 mg/day +Simeprevir 150 mg/day ± ribavirin for 12 weeks
89158585|NCT02771405|Experimental|Sofosbuvir+Daclatasvir±Ribavirin|Sofosbuvir 400 mg/day +Daclatasvir 60 mg/day ± ribavirin for 12 weeks
89158586|NCT02771405|Experimental|Sofosbuvir+Ledipasvir±Ribavirin|Sofosbuvir 400 mg/day +Ledipasvir 90 mg/day ±ribavirin for 12 weeks
89158587|NCT00656604|Experimental|Women with breast cancer|Patients undergo DCE-MRI and MRS prior to their breast cancer surgery.
89158588|NCT00656604|No Intervention|Healthy volunteers|Women without breast cancer undergo DCE-MRI and MRS.
89158589|NCT02696447||Cancer treated by radiotherapy|Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent
89158590|NCT00667758|Experimental|1|Cetrorelix
89158591|NCT00667758|Placebo Comparator|2|NaCl solution
89158592|NCT02770937|Active Comparator|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
89158593|NCT02770937|Active Comparator|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on box trainer.
89158594|NCT02770937|No Intervention|Control|The control group will not receive further training.
89158595|NCT02630238|Experimental|Branched-Chain Amino Acid group|The branched-chain amino acid group will be on a hypocaloric diet, exercise and receive 0.342g/kg of BCAA per day, partially accounted for through their diet with the rest provided by a BCAA supplement
89158596|NCT02630238|Placebo Comparator|Placebo Group|The placebo will be on a hypocaloric diet, exercise and receive isoenergetic beverage with carbohydrate instead of branched-chain amino acids
89158597|NCT02764307|Experimental|Aerosolized drug depositions|Aerosol drug deposited on the inhaled and exhaled filters and the residual dose were evaluated delivered by four types of nebulizer: 1) a constant jet nebulizer, a breath enhanced nebulizer, a manual-actuated nebulizer, and a breath-actuated nebulizer.
89158598|NCT00542815|Experimental|1|
89158599|NCT00542815|Active Comparator|2|
89158600|NCT00667914|Experimental|Orthogeriatric unit|Geriatric work-up on hip-fracture patients
89158601|NCT00667914|Active Comparator|Orthopedic care as usual|Traditional care in the orthopedic unit
89158602|NCT02696369|Experimental|2% Lidocaine HCL:Epinephrine inj.|2% Lidocaine HCL with epinephrine 1:200,000
89158603|NCT02696369|Active Comparator|2% Lidocaine HCL:Epinephrine inj. (3M)|2% Lidocaine HCl with epinephrine 1:80,000
89158604|NCT02771015|Active Comparator|Mepilex Border®|Mepilex Border® wound dressing at patients after hip-knee or primary spine surgery
89158605|NCT02771015|Active Comparator|Cosmopor steril®|Standard wound dressing at patients after hip-knee or primary spine surgery
89158606|NCT02636244|Experimental|SHAPE Gel|1% SHAPE Gel applied twice daily for 12 weeks.
89158607|NCT00987259||Post MI patients|Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.
89158608|NCT04559633|Experimental|Anxious school refusal|Adolescents with anxious shool refusal will beneficiate of cognitive and behavioral therapy (CBT) in order to help them to return back to school
89158609|NCT00663390|Experimental|I|
89158610|NCT02762357||Novosyn® Quick|episiotomy closure using suture material
89158611|NCT00668070|Experimental|ASP9831 Low Dose|
89158612|NCT00668070|Experimental|ASP9831 Higher Dose|
89158613|NCT00668070|Placebo Comparator|Placebo|
89158614|NCT04732013||Study cohort|Single observational cohort of patients who meet study criteria
89158615|NCT04154436|Experimental|Sodium Bicarbonate (NaHCO3) Plus Solution|15 cc of Sodium Bicarbonate (NaHCO3) plus Solution will be sprayed on left or right side of the patient's face based on randomisation
89158616|NCT04154436|Placebo Comparator|Water (H2O)|15 cc of Water (H2O) will be sprayed on the left or right side of the patient's face based on randomisation
89158617|NCT02762435|Placebo Comparator|control|No pressure applied to the 3 points
89158618|NCT02762435|Sham Comparator|sham|Light touch applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
89158619|NCT02762435|Experimental|acupressure|Moderate pressure applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
89158620|NCT04154670|Experimental|Normal kidney function|MGTA-145 single dose
89158621|NCT04154670|Experimental|Mild decrease in GFR|MGTA-145 single dose
89158622|NCT04154670|Experimental|Moderate decrease in GFR|MGTA-145 single dose
89158623|NCT02762279|Experimental|Patients|"Patient baseline characteristics will be collected.~Specific nasogastric tube installation: a specific nasogastric tube equipped with pressure transducers (Gaeltec® probe) will be installed.~Connection of a pressure transducer to the existing chest-tube.~Simultaneous recordings of PES (Gaeltec®), PPL, PAW, respiratory volume and flow (5 minutes).~Removal of the Gaeltec® probe, and repositioning of the pre-existing nasogastric tube in the esophagus for PES measurement.~Simultaneous recordings of PES (feeding tube), PPL, PAW, respiratory volume and flow (5 minutes).~Repositioning of the nasogastric tube in the stomach, and disconnection of the different recording equipment."
89158624|NCT02763995|Experimental|Pharmaceutical care|Dader method. Health education for lifestyle modification. Improve adherence. Resolution of negative outcome associated with medication.
89158625|NCT02636166|Other|Pregnancy test|"Clearblue investigational Pregnancy test~Clearblue Marketed pregnancy test~Professional pregnancy test"
89158626|NCT02763605||patients diagnosed with acanthamoeba keratitis|"Inclusion Criteria:~- All patients presenting to National Taiwan University Department from Jun. 1st, 2003 to dec. 30th , 2016 with the tissue proven corneal AK will be included.~Exclusion Criteria~- Patients with tissue proven corneal AK during from Jun. 1st, 2003 to dec. 30th , 2016, but without in vivo confocal data, or complete chart records."
89158627|NCT02636088|Experimental|Cetuximab|Cetuximab is administered once a week. The initial dose is 400 mg/m2 body surface area. First Cetuximab infusion should start day 15 in cycle 1.The subsequent weekly doses are 250 mg/m2.
89158628|NCT02630160|Active Comparator|Intraarticular Catheter with anesthesic|Intraarticular infusion with Bupivacaine Hydrochloride
89158629|NCT02630160|Placebo Comparator|Intraarticular Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by intraarticular catheter
89158630|NCT02630160|Active Comparator|Perifascial Catheter with anesthesic|Perifascial infusion with Bupivacaine Hydrochloride
89158631|NCT02630160|Placebo Comparator|Perifascial Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by Perifascial catheter
89158632|NCT00668304|Experimental|Arm 1|
89158633|NCT00542425|Placebo Comparator|Placebo|
89158634|NCT00542425|Experimental|BA058 20 µg|
89158635|NCT00542425|Experimental|BA058 40 µg|
89158636|NCT00542425|Experimental|BA058 80 µg|
89158637|NCT00542425|Active Comparator|teriparatide|
89158638|NCT02770781|Experimental|Personal Trainer|All subjects will meet a set amount of times with a personal trainer over the course of the study to participate in an exercise regimen.
89158639|NCT00668616|Active Comparator|1|
89158640|NCT00668616|Experimental|2|
89158641|NCT02761889|Experimental|IGRT 45 Gy in 5 fractions of 9 Gy|Patients will be treated using volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
88804578|NCT03935100|Placebo Comparator|Control Group|5 clips fired at random into colon lumen. No diverticula closed.
88806046|NCT01221311|Active Comparator|Plastic Stent|Patients randomized to the plastic stent (PS) group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and multiple (as many as technically feasible) PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing endoscopic retrograde cholangiopancreatography (ERCP), until the stricture has been obliterated using clinical and fluoroscopic criteria (details below).
88806047|NCT04352075|Experimental|Microfat + PRP 3M platelets|microfat (5 ml) associated with PRP with a dose of 3 billions of platelets (5 ml)
89158642|NCT00668694|No Intervention|1|Anemia without stimulation.
89158643|NCT00668694|Experimental|2|Anemia with stimulation
89158644|NCT00668694|No Intervention|3|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled without stimulation
89158645|NCT00668694|No Intervention|4|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled with stimulation
89158646|NCT02763761|Experimental|Infliximab + Prednisone|Infliximab intravenous solution (single dose) + low dose prednisone per oral for 18 days
89158647|NCT02763761|Experimental|Methylprednisolone + Prednisone|Methylprednisolone intravenous solution (single dose) + high dose prednisone per oral for 40 days
89158648|NCT04155918|Experimental|AR882/FBX|
89158649|NCT04155918|Experimental|AR882/ALLO|
89158650|NCT02763839|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Sinemet 25/100 BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
89158651|NCT02763839|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
89158652|NCT02763839|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
89158653|NCT02763839|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
89158654|NCT02763839|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
89158655|NCT00663468||A|
89158656|NCT00541099|Experimental|Avastin & Docetaxel|Avastin 10.0 mg/kg on days 1 and 15; Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel; Docetaxel 35 mg/m2 on day 1, 8, 15
89158657|NCT00580606|Experimental|Low Dose Peanut SLIT (Double Blind to Open Label)|Subjects ingest peanut protein (glycerinated peanut allergenic extract) daily starting with 0.000165 mcg, followed by a build-up phase (escalating peanut doses every 2 weeks, achieving maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and continue on an open label peanut protein maintenance dose of 1,386 mcg/day or may attempt escalation up to this dose. Subjects who at the Week 116 OFC are unable to consume >= 5,000 mg peanut powder or 10-fold the amount of peanut powder compared to the baseline OFC will discontinue study therapy. SLIT=Sublingual Immunotherapy.
89158658|NCT00580606|Placebo Comparator|Placebo (DB) Crossed Over to High Dose Peanut SLIT (OL)|Subjects ingest placebo (glycerin) daily beginning with a dose of 0.000165 mcg, followed by a build-up phase (escalating placebo doses every 2 weeks, achieving a maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and subjects no longer receive placebo dosing but are crossed over and receive open label high dose peanut SLIT; the study procedures and schedule are the same as for the Low Dose Peanut SLIT group, the only difference is the maximum maintenance dose is almost 3-fold higher at 3,696 mcg/day. DB=Double Blind, SLIT=Sublingual Immunotherapy, OL=Open Label.
89158659|NCT04637945|Placebo Comparator|placebo|The placebo will be delivered in softgels consisting of colorant, olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, glycerin and water.
89158660|NCT04637945|Experimental|ACRB|The ACRB product will be delivered in softgels consisting of anthocyanin-rich blend. Each softgel will contain: i) 49 mg bilberry extract; ii) 101 mg black currant extract; and iii) 303 mg black rice extract. The high ACRB will deliver at least 108 mg anthocyanins. The product will also contain olive oil, sunflower lecithin, yellow beeswax, bovine gelatin, and water.
89158661|NCT04155762|Experimental|Intervention|Both suspension systems were applied consecutively to the participants. Initially, participants used the Pin Suspension System (PSS) for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period. They then employed the Vacuum-Assisted Suspension System (VASS) for three months after a similar training period.
89158662|NCT02575768||Severe AS: asymptomatic|Asymptomatic
89158663|NCT02575768||Severe AS: pure angina|Presence of exertional chest pain
89158664|NCT02575768||Normal controls|Healthy controls
89158665|NCT00987493|Experimental|Treatment with rituximab, bendamustine and lenalidomide|
89235024|NCT05403177||MOHCCN-O|Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.
89158666|NCT04727567||Multiple Visit Patient (MVP) Program|"The MVP program aims to manage health and lower hospital utilization among patients with a history of high inpatient hospital stays at Atrium Health. Patients eligible for the program have four or more inpatient visits over the 12-month period prior to enrollment. Once enrolled, each MVP program participant receives on-going support from an assigned MVP care manager and larger care management team, including the following core program components:~customized care plan developed for each patient at the time of enrollment routine, virtual health monitoring and collaborative care management team-based review personalized navigation and coordination across multidisciplinary Atrium Health services, as needed.~Education, health coaching, and support via telephonic and in-person interactions, as needed."
89158667|NCT04727567||Usual Care|Atrium Health standard of care. Patient's post-discharge usual care depends on the inpatient care management assessment at last hospital admission. Patients can be discharged to home and receive no further care, or home with home health, or to a skilled nursing facility (SNF) or another type of Continuing Care facility. Patients can be referred to advanced illness management, hospice, and Community Care Partners by the inpatient care manager. Patient can be referred to Ambulatory Care Management for care management also via telehealth, by a primary care physician or the Transitions Clinic.
89158668|NCT02579356|Experimental|Part1-A|The Part1-A of groups take Telmisartan once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
89158669|NCT02579356|Experimental|Part1-B|The Part1-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan once a day for 6 days in period 2.
89158670|NCT02579356|Experimental|Part2-A|The Part2-A of groups take Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
89158671|NCT02579356|Experimental|Part2-B|The Part2-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Atorvastatin once a day for 6 days in period 2.
89158672|NCT00987571||Carpal Tunnel patients|These patients have documented carpal tunnel syndrome
89158673|NCT00987571||Normal Subjects|These individuals have no carpal tunnel syndrome
89158674|NCT02763449|Experimental|Sedentary|Individuals will reduce their physical activity level for 14-days
89158675|NCT02763449|Experimental|Active|Individuals will increase their physical activity level for 14-days
89158676|NCT02535390|Experimental|Action based cognitive remediation|Participants in this condition will engage in simulated real world tasks in addition to standard cognitive remediation and group therapy sessions.
89158677|NCT02535390|Active Comparator|Standard cognitive remediation|Participants in this condition will engage in computerized cognitive training exercises in addition to standard cognitive remediation and group therapy sessions.
89158678|NCT04223063|Experimental|Exercise Intervention|Participants allocated to the exercise intervention will engage in a multimodal, home-based program including strength and endurance exercises. Participants will initially be seen in person and instructed to begin a moderate-intensity (i.e., 3-4 on 10-point Borg Scale) walking (or preferred aerobic exercise) program for a minimum of 30 minutes/day, 3-5 days/week and perform strength exercises at least 2 days/week.
89158679|NCT04223063|No Intervention|Control|Participants allocated to the control group will not receive any formal exercise prescription or guidance, however they will be offered the opportunity to participate in a home-based intervention pending the completion of data collection.
89158680|NCT04005313|Experimental|Comparison between unisensory and multisensory stimulation|The same person receive unisensory and multisensory stimulation on separate day.
89158681|NCT04005313|Experimental|The treatment effect of multisensory stimulation|The persons living in long-term care facility would receive multisensory stimulation for one month.
89158682|NCT04005313|Experimental|Multisensory stimulation and virtual reality.|The subjects would receive vibroacoustic therapy or virtual reality.
89158683|NCT04005313|Experimental|Vibroacustic therapy on neck pain.|The subjects would receive either vibroacustic therapy or music therapy.
89158684|NCT00663624|Experimental|Experimental|Subcutaneous aspart insulin every 2 hours
89158685|NCT00663624|Placebo Comparator|Active Comparator|Usual care as prescribed by the ED physicians
89158686|NCT02762045|Experimental|Low dose Ad5-gag or Placebo|1ml low dose Ad5-gag(2x10^9VP) or Preservation solution at weeks 0 and weeks 4.
89158687|NCT02762045|Experimental|Medium dose Ad5-gag or Placebo|1ml medium dose Ad5-gag(2x10^10VP) or Preservation solution at weeks 0 and weeks 4.
89158688|NCT02762045|Experimental|High dose Ad5-gag or Placebo|1ml high dose Ad5-gag(2x10^11VP) or Preservation solution at weeks 0 and weeks 4.
89158689|NCT00656682|Active Comparator|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian. Registered Dietitian Counseling Alone
89158690|NCT00656682|Experimental|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based diabetes prevention lifestyle intervention offered by the community. Dietitian Counseling Plus Community Group Lifestyle Intervention.
89158691|NCT02577250|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 2 weeks.
89158692|NCT04193111||Positive TMD pain screener|Patients who have ≥3 points on the TMD pain screener (0-7 range) are anticipated to have a painful TMD based on the DC/TMD and are therefore considered having a positive outcome on the TMD pain screener.
89158693|NCT04193111||Negative TMD pain screener|Patients who have <3 points on the TMD pain screener (0-7 range) are anticipated NOT to have a painful TMD based on the DC/TMD and are therefore considered having a negative outcome on the TMD pain screener.
89158694|NCT00668850|Experimental|1|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
89158695|NCT00668850|Active Comparator|2|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
89158696|NCT05711563||Autoimmune Encephalitis (Ireland)|
89158697|NCT05711563||Autoimmune Encephalitis (UK)|
89158698|NCT05711563||Other neurological controls|
89158699|NCT02762201|Experimental|PASI|PASI dental prosthesis delivery
89158700|NCT02762201|Active Comparator|PAC|PAC dental prosthesis delivery
89158701|NCT05483335||Medical Student in the final two clinical years (Clerkship years)|All the current medical students of College of Medicine and Health Sciences in United Arab Emirates University in the clinical years (fifth and sixth years in a 6-year MD programme) also called as clerkship years, will be invited into this study to assess for burnout syndrome using a validated tool via Mind GardenTM using Malasch Inventory for Burnout Syndrome and also to identify any other factors which may be contributing to stress/burnout.
89158702|NCT02762123|Experimental|Cohort 1 (BMS-986142: 200 mg)|200mg BMS-986142 administered orally once daily on specified days.
89158703|NCT02762123|Experimental|Cohort 2 (BMS-986142: 350 mg)|350mg BMS-986142 administered orally once daily on specified days.
89158704|NCT02579200|Active Comparator|Inspiratory Muscle Training (IMT)|POWERbreathe®KHA (IMT group)
89158705|NCT02579200|Sham Comparator|Sham Training|POWERbreathe®KH2 (sham group)
89158706|NCT00635375|Experimental|1|LED fiberoptic blanket phototherapy
89158707|NCT00635375|Experimental|2|metal halide phototherapy
89158708|NCT00635375|Active Comparator|3|LED bank phototherapy
89158709|NCT00635375|Experimental|4|Combination metal halide phototherapy plus LED fiberoptic blanket phototherapy
89158710|NCT04153734|Experimental|Immunotherapy plus chemotherapy|Combination of CDDP at 75 mg/m2 (day 1) or CBDCA at Area Under the Curve=6 (AUC=6) (day 1) + PEM at 500 mg/m2 (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, CBDCA at AUC=6 (day 1) + nab-PTX at 100 mg/m2 (days 1, 8, and 15) will be administered at 3-week intervals. If there is no progression after the 4th course of induction therapy, it will be switched to maintenance therapy. For maintenance therapy, the combination of PEM at 500 mg/m2 (day 1) + Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
89158711|NCT02761655|No Intervention|Control Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement.
89158712|NCT02761655|Experimental|Intervention Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement. The intervention group will further receive memory strategies training on encoding and retention, retrieval, as well as execution and monitoring.
89158713|NCT04073680|Experimental|Serabelisib|"Part 1 is dose escalation of Serabelisib Cohort 1 = 600mg; Cohort 2 = 900mg; Cohort 3 = 1200mg~Part 2 is expansion of mutational cohorts with selected dose as follows:~Cohort 4 = PIK3CA-mutated breast cancer; Cohort 5 = PIK3CA-mutated Non breast cancer; Cohort 6 = KRAS mutated"
89158714|NCT02761577|No Intervention|control|perorally 1500 ml water on the day of the procedure
89158715|NCT02761577|Experimental|Sodium bicarbonate|3 mL/kg/hour IV (in vein) of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
89158716|NCT02761577|Experimental|N-acetylcysteine plus Sodium bicarbonate|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure in addition to Sodium bicarbonate solution on the day of the angiography.
89158717|NCT04154202|Experimental|Bone inaction patients|Three months or more post joint replacement, or post tibial ORIF, or last surgical intervention adult patients suspected of bone infection and or mechanical loosening.
89158718|NCT04006249|Other|diagnostic test|
89158719|NCT02761421||patients with IOPD|observation all patients with IOPD
89158720|NCT00669006||1|New patients with a diagnosis of Neuropathic Pain
89158721|NCT00987805|Experimental|Banhasasim-tang|
89158722|NCT00987805|Placebo Comparator|Placebo drug|The placebo of this study is corn-starch granules. It has the same form, color, flavor and amount like experimental herbal extracted formula
89158723|NCT00579982|Experimental|Arm 1|Lamictal orally disintegrating tablet (ODT)
89158724|NCT05711329||All patients|Patients in this group will serve to validate the accuracy of the French method to detect OSA patients in comparison with PSG results.
89158725|NCT02763527|Experimental|Smoking reduction|"Subjects will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet. They will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor. The trained counsellor will negotiate a schedule with subjects to reduce their smoking over an acceptable level. For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a booster intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target. Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted over the telephone by trained interviewers."
89235025|NCT05341882|Experimental|Mindfulness|The seven weekly sessions teach veterans how to use mindfulness techniques in everyday life and when dealing with stress and negative emotions related to moral injury.
89158726|NCT02763527|Placebo Comparator|Smoking Cessation|"Subjects in the QI group will always be advised to quit immediately rather than to quit progressively. Subjects will receive a brief advice on quitting with a warning message similar to subjects in the QP group. In addition, subjects will receive a self-help quitting pamphlet published by the Hong Kong Council on Smoking and Health (COSH). Unlike the QP group, subjects in the QI group will not receive smoking reduction intervention and leaflet, and booster intervention during telephone follow-ups. However, they will undergo a similar schedule of telephone follow-up as those in the QP group."
89158727|NCT02630082|Other|Intervention|Circumcision and flexible sigmoidoscopy
89158728|NCT00987883||Malnutrition cohort|The patients with undernutrition
89158729|NCT00987883||Well nourished cohort|Patient that well nourished and without undernutrition
89158730|NCT02763371|Experimental|Dietary: high GI lunch|High GI-rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
89158731|NCT02763371|Experimental|Dietary: low GI lunch|Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
89158732|NCT00987961|No Intervention|Treatment as usual|Participants in this arm will receive the standard detox treatment for individuals hospitalized with opioid dependence.
89158733|NCT00987961|Experimental|Linkage|Participants in this arm will receive a maintenance schedule of Suboxone during their hospital stay, and an appointment with an outpatient Suboxone provider for after their discharge.
89158734|NCT02575612|Experimental|vacuum-assisted biopy|All patients enrolled in this study received a vacuum-assisted biopsy before surgery.
89158735|NCT00596466|Experimental|1|
89158736|NCT02763293|Experimental|Manual Therapy|Cranial therapy (CT). Neuro-lymphatic reflexes treatment (NL) Viscerosomatic reflexes (VR) Induction myofascial Visceral osteopathic therapy (VOT)
89158737|NCT02763293|No Intervention|Control Group|Patients only came to make assessments, without receiving any treatment.
89158738|NCT02763059|Active Comparator|Group 1- Received Ibuprofen (N=44)|
89158739|NCT02763059|Active Comparator|Group 2- Received Dexamethasone (N=44)|
89158740|NCT02763059|Placebo Comparator|Group 3 - Received Placebo (N=44)|
89158741|NCT05708677||Long-Term Extension|This study will follow one group of participants who were enrolled in a previous EB-101 study.
89158742|NCT02758379|Experimental|Shockwave Coronary Lithoplasty System|Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.
89158743|NCT04155372|Experimental|30min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 30 min.
89158744|NCT04155372|Experimental|60min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 60 min.
89158745|NCT04155372|Experimental|90min|The participants arrived to the trials euhydrated and were dehydrated to 2% of body weight (BW) by running. After a rest, they ingested sports drink in a volume equivalent to 150% of BW loss in 90 min.
89158746|NCT02771171||Age groups|The cohort is divided into on the basis of age
89158747|NCT02761343|Other|MRI scan|Post ablation MRI scan will be performed for all subjects who are clinically stable.
89158748|NCT00596934|Experimental|Metreleptin treatment group|Treatment group
89158749|NCT04222517|Experimental|Standart sublay retromuscular technique|Apply standard intervention (sublay retromuscular)
89158750|NCT04222517|Experimental|Standart sublay retromuscular technique with Hemoblock|Local hemostatic Hemoblock is used in retro-muscular and subcutaneous spaces
89158751|NCT02758145|Active Comparator|Influenza vaccine information (G1)|During the recruitment visit at the occupational medicine unit between the 04/29/16 and the 10/31/16, the workers in this group (G1) in addition to their recruitment visit, will benefit from a short intervention given by the nurse concerning the flu, the advantages of the flu vaccination, and how they can be vaccinated in the institution. The nurse also transmits an information sheet concerning the benefits of the vaccination. 2 weeks after the beginning of the next flu vaccination campaign, they will receive a reminder letter to encourage vaccination.
89158752|NCT02758145|No Intervention|No information (G2)|Workers in the control group (G2) receive no intervention, only recruitment visit.
89158753|NCT04155528|Experimental|Study group|The intervention group will receive routine hospital care alongside 30 minutes of music therapy per day for three consecutive days. The music therapy will be initiated on the second day postoperatively. The assessment of baseline data and the music therapy will be applied at least three hours after analgesics administration.
89158754|NCT04155528|No Intervention|Control group|Patients in the control group will receive routine hospital care only.
89158755|NCT02761265|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
89158756|NCT02761265|Other|Control Group|Gait and balance testing to be administered once in healthy subjects
89158757|NCT00671112|Experimental|Everolimus and Bortezomib|Patients will receive a combination of Everolimus by mouth and Bortezomib intravenously for a 21 day cycle.
89158758|NCT04154358|Experimental|HPV Testing|Will perform HPV testing with self-collected specimen
89158759|NCT04857385|Active Comparator|Terumo TR Band|Physical standard of care radial hemostasis device.
89158760|NCT04857385|Experimental|StatSeal|Potassium-ferrate based chemical hemostasis device.
89158761|NCT04857385|Experimental|Axiostat|Chitosan based biological hemostasis device.
89158762|NCT00671190|Experimental|Ramelteon 1 mg QD|
89158763|NCT00671190|Experimental|Ramelteon 2 mg QD|
89158764|NCT00671190|Experimental|Ramelteon 4 mg QD|
89158765|NCT00671190|Experimental|Ramelteon 8 mg QD|
89158766|NCT00671190|Placebo Comparator|Placebo QD|
89158767|NCT02770235|Experimental|DE assessment and AGE measurements|To evaluate the association between erectile dysfunction (DE) and AGE levels by using non-invasive measurement AGE-ReaderTM, in diabetic patients
89158768|NCT00669474|Other|1|Suction curettage
89158769|NCT00669474|Active Comparator|2|Treatment with Botox
89158770|NCT03911401|Experimental|0.3% OPA-15406|Twice daily
89158771|NCT03911401|Experimental|1% OPA-15406|Twice daily
89158772|NCT03911401|Placebo Comparator|Placebo|Twice daily
89158773|NCT00664014|Experimental|Tolvaptan|
89158774|NCT00664014|Placebo Comparator|Placebo|
89158775|NCT02770313|Experimental|Intermittent Fasting|Water-only Intermittent Fasting
89158776|NCT02770313|No Intervention|Control|ad libitum Usual Diet
89158777|NCT00664092|No Intervention|1|Usual Aftercare Condition
89158778|NCT00664092|Experimental|2|Oxford House Condition
89158779|NCT00664092|Experimental|3|Therapeutic Community Condition
89158780|NCT04825951|Active Comparator|CS 2000 appliance|treating growing skeletal Class III patients
89158781|NCT04825951|Active Comparator|Reversed Forsus Fatigue resistant appliance|treating growing skeletal Class III patients
89158782|NCT04825951|No Intervention|Control|"A group of untreated skeletally growing class III patients will be recruited to account for the possible effects of growth in the treatment groups.~This group matches the treated groups in malocclusion, stages of skeletal maturation, and mean observation period. Those patients will be treated after the period of the study."
89158783|NCT02696915|Placebo Comparator|Placebo|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of saline 0.9%. Then intrathecal medications will be administered.
89158784|NCT02696915|Active Comparator|Bupivacaine|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of 0.25% bupivacaine. Then intrathecal medications will be administered.
89158785|NCT00911664|Placebo Comparator|1|
89158786|NCT00911664|Experimental|2|
89158787|NCT00911664|Experimental|3|
89158788|NCT02770079||Gestational diabetes|10 women with gestational diabetes
89158789|NCT00664170|Experimental|1|ANX-514
89158790|NCT00664170|Active Comparator|2|Taxotere
89158791|NCT02758067|Experimental|brexpiprazole|
89158792|NCT02758067|Experimental|risperidone|
89158793|NCT02757677||Longitudinal arm|Evaluate optic nerve head blood flow using the new OCT-A software in surgically and medically treated glaucoma patients and in different types of glaucoma
89158794|NCT02757677||24-h Intraocular pressure (IOP) arm|Evaluate the correlation between circadian IOP changes and optic nerve head blood flow using the new OCT-A software
89158795|NCT02757677||Surgery arm|Evaluate blood flow using the new OCT-A software in surgically treated glaucoma patients
89158796|NCT00664248|Experimental|1|
89158797|NCT00664248|Active Comparator|2|
89158798|NCT00664248|Active Comparator|3|
89158799|NCT00664248|Placebo Comparator|4|
89158800|NCT02757755|Experimental|Cohort 10^8|AB-SA01 (10^8) and Placebo
89158801|NCT02757755|Experimental|Cohort 10^9|AB-SA01 (10^9) and Placebo
89158802|NCT04529239||Low to Moderate Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
89158803|NCT04529239||High Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
89158804|NCT04529239||Very High Risk|The CANRISK Canadian Diabetes Risk Questionnaire will be used for study group categorization to assess who is at risk of having prediabetes or type 2 diabetes. Participants will be categorized into one the following groups: i) low to moderate risk; ii) high risk, iii) very high risk.
89158805|NCT04221347||Group A - Hepatocellular carcinoma|"Patients with with proved hepatocellular carcinoma in cirrhosis.~N=100"
89158806|NCT04221347||Group B - Cirrhosis|"Cirrhotics of multiple aethiology will be sampled for spectroscopy in order to detect possible differences among cirrhotics with and without subsequent hepatocellular carcinoma.~N=100"
89158807|NCT04221347||Group C - Healthy controls|Healthy controls - healthy military personnel. N=50
89158808|NCT04808167|Experimental|Therapeutic Group|Therapeutic group receives remote ischemic conditioning.
89158809|NCT04808167|No Intervention|Control Group|Control group does not receive remote ischemic conditioning.
89158810|NCT04484519||Cognitively unimpaired|
89158811|NCT00669708|Active Comparator|1|ph5 Eucerin Lotion with cooling compound
89158812|NCT00669708|Placebo Comparator|2|ph5 Eucerin Lotion
89158813|NCT04222439|Experimental|AI monitoring gastrointestinal endoscopy|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
89158814|NCT00669786|Active Comparator|HMG|Human Menopausal Gonadotropin (HMG)
89158815|NCT00669786|Active Comparator|r-FSH|Recombinant Follicle Stimulating Hormone
89158816|NCT02760953|Experimental|TUR with Cryoablation|Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
89158817|NCT02760953|Active Comparator|TUR with instant instillation|Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
89158818|NCT00671268|Experimental|1|strict subcutaneous
89158819|NCT00671268|Placebo Comparator|2|strict subcutaneous
89158820|NCT05691127||Respiratory Diseased children|
88806048|NCT04352075|Experimental|Microfat + PRP 1M platelets|microfat (5 ml) associated with PRP with a dose of 1 billion of platelets (5 ml)
89158821|NCT02760797|Experimental|Part I (Dose-Finding Stage)|Emactuzumab and RO7009789 will be administered intravenously (IV) at a starting dose of 500 milligrams (mg) for emactuzumab and 2 mg for RO7009789. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
89158822|NCT02760797|Experimental|Part II (Dose Expansion Stage)|Emactuzumab and RO7009789 will be administered IV at the maximum tolerated dose defined in Part I of the study. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
89158823|NCT02630004|Experimental|Melatonin|Melatonin oral gel 3%
89158824|NCT02630004|Placebo Comparator|Placebo|Placebo oral gel
89158825|NCT02760641|Experimental|Egg-based diet (EBD)|This arm will provide ≤25% energy from CHO, 25% energy from protein, and ≥50% energy from fat. EBD participants will be asked to consume ≥2 eggs per day along with other protein sources including meat, fish, pork, and poultry. Carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day.
89158826|NCT02760641|Placebo Comparator|Carbohydrate-based diet (CBD)|The CBD group will be asked to avoid whole egg consumption when possible during the 8 week intervention period. They will be counseled to consume a low fat diet with 55:25:20 %energy from CHO:protein:fat. This diet will place an emphasis on consuming lean meats, low fat dairy, whole grains, legumes, fruits and vegetables.
89158827|NCT04154280|Experimental|prostate cancer Patients|patients over the age of 18 with diagnosed prostate cancer at different stages of the disease.
89158828|NCT00129922|Active Comparator|Fluorouracil+Epirubicin+Cyclophosphamide|5-FU+4-Epirubicin+Cyclophosphamide
89158829|NCT00129922|Experimental|FEC followed by Paclitaxel|5-FU+4-Epirubicin+Cyclophosphamide
89158830|NCT00664404|Other|fMRI|Functional Magnetic Resonance Imaging (fMRI)
89158831|NCT02760719|Experimental|hypertonic saline|4 ml of nebulized 3 % hypertonic saline + salbutamol 0,03 ml/kg every 8 hours for the time of hospitalisation and standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
89158832|NCT02760719|No Intervention|supportive care|Standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
89158833|NCT00671346||1|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg and vitamin B12 0.4 mg
89158834|NCT00671346||2|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg, vitamin B12 0.4 mg and B6 40 mg.
89158835|NCT00671346||3|Participants in NORVIT and WENBIT allocated to daily oral treatment with vitamin B6 40 mg.
89158836|NCT00671346||4|Participants in NORVIT and WENBIT allocated to daily oral treatment with placebo
89158837|NCT02696213|Experimental|SCOOT Immediate|This group will receive SCOOT immediately
89158838|NCT02696213|Other|SCOOT Delayed|This group will receive SCOOT after 6 weeks
89158839|NCT03909295|Experimental|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
89158840|NCT02696057|Active Comparator|Manual technics|Manual technics was consisted of soft tissue technics, muscle energy technics, joint mobilization.
89158841|NCT02696057|Active Comparator|Exercise|Spinal stabilization exercises were applied all the patients in this group accompanied by physiotherapist.
89158842|NCT02757599|Other|Top-down (TD)|The group having the transvaginal ultrasound image top-down. During training and transfer test.
89158843|NCT02757599|Other|Bottom-up (BU)|The group having the transvaginal ultrasound image bottom-up. During training and transfer test.
89158844|NCT04154124|Experimental|Rectal Cancer Patients|
89158845|NCT01439776|No Intervention|Peginterferon alfa 2a+Ribavirin|standard of care for HCV : peginterferon alfa 2a and ribavirin
89158846|NCT01439776|Experimental|Vit D+Peginterferon alfa 2a+Ribavirin|VitD+Peginterferon alfa 2a+Ribavirin
89158847|NCT02770157|Experimental|DA-3002|1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
89158848|NCT02770157|Active Comparator|Genotropin®|1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).
89158849|NCT02770157|Other|Non-treatment control group|After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
89158850|NCT04153968|Experimental|Phase 1|Determination absorption and bioconversion kinetics of [13C14]β-cryptoxanthin and provide external validation for single-sample prediction methods.
89158851|NCT04153968|Experimental|Phase 2|Test the bioefficacy of provitamin A carotenoids (pVACs) in maize by comparing a high β-cryptoxanthin:β-carotene (βCX:βC) variety to a low βCX:βC variety in combination with external [13C]-labelled pVACs.
89158852|NCT02577172|Experimental|Exercise group|Aerobic- and Strength Training program
89158853|NCT02577172|Active Comparator|Control group|One lifestyle counseling session
89158854|NCT00599924|Experimental|Single arm|"SU011248 [sunitinib] in combination with FOLFOX; FOLFOX is a chemotherapy regimen that combines oxaliplatin and leucovorin with bolus and infusion 5-FU. The modified FOLFOX 6 (mFOLFOX6) regimen is one of several different regimens of FOLFOX used in clinic, according to different dosages of the 4 drugs. mFOLFOX6 was administered every 2 weeks on Days 1 and 2 of each cycle.~25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in three different dosing regimens: schedule 2/2 (2 weeks on, 2 weeks off), schedule 4/2 (4 weeks on, 2 weeks off), and continuous daily dosing (every day); FOLFOX will be administered every 2 weeks, using the modified FOLFOX 6 (mFOLFOX6) regimen, consisting of: oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 as a 2-hr IV infusion; 5-FU 400 mg/m2 IV bolus, followed by - 5-FU 2400 mg/m2 as a 46-hr IV infusion"
89158855|NCT02760875||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
89158856|NCT02760875||control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
89158857|NCT00670020|Experimental|1|supplemental perioperative oxygen
89158858|NCT00670020|No Intervention|2|Normal
89158859|NCT02757833|Other|Late Life Depressed Arm|Participants in the Late Life Depressed arm will have a confirmed diagnosis of late-life depression.
89158860|NCT02757833|Other|Healthy Control Arm|Participants in the Healthy Control Arm will have no history of mental illness.
89158861|NCT00670098|Experimental|1|
89158862|NCT00670098|Experimental|2|
89158863|NCT02769923|Active Comparator|Arm A|Westpharma ID Adapter
89158864|NCT02769923|Active Comparator|Arm B|Star ID syringe
89158865|NCT02769923|Active Comparator|Arm C|BCG NS
89158866|NCT04004689||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join the rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
89158867|NCT00670176|Experimental|I|
89158868|NCT02757209|Active Comparator|Spiromax Inhaler|"Evaluation of correct use of Spiromax inhaler - DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
89158869|NCT02757209|Active Comparator|Turbohaler inhaler|"Turbohaler® - Symbicort® 160/4.5 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate). Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
89158870|NCT02757209|Active Comparator|Diskus Inhaler|"Diskus® inhaler - Seretide Diskus 50/250 mcg ® or 50/500 mcg (50 mcg salmeterol & 250/500 mcg fluticasone propionate). Dose of one inhalation twice a day for 1 week.~Additional 8 weeks in one subgroup"
89158871|NCT04004923|Active Comparator|Monopolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
89158872|NCT04004923|Active Comparator|Bipolar hysteroscopy|This group of patients will receive Monopolar hysteroscopy for uterine distention.
89158873|NCT00670254|Experimental|Hydrocortisone|
89158874|NCT00670254|Placebo Comparator|Placebo|
89158875|NCT00581542|Active Comparator|Moxifloxacin Opthalmic solution|
89158876|NCT00581542|Active Comparator|Polymyxin B-trimethoprim opthalmic solution|
89158877|NCT02757287|Experimental|FSH-CTP + DESOGESTREL|Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation
89158878|NCT02757365|Experimental|the NSAIDs group|Patients in the this Group will received the aspirin 100mg qd until the experiment finished
89158879|NCT02757365|Experimental|the antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks
89158880|NCT02757365|Experimental|the NSAIDs+antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks and aspirin 100mg qd until the experiment finished
89158881|NCT02757365|No Intervention|the control group|No treatment
89158882|NCT05250440||(a1)Emmetropia: +0.75 to -0.75 D|age: 12 to 18 years old
89158883|NCT05250440||(a2)Mild myopia: -1.00 to -3.00 D|age: 12 to 18 years old
89158884|NCT05250440||(a3)Moderate myopia: -3.25 to -6.00 D|age: 12 to 18 years old
89158885|NCT05250440||(a4)High myopia: >-6.00 D|age: 12 to 18 years old
89158886|NCT05250440||(b1)Emmetropia: +0.75 to -0.75 D|age: 18 to 35 years old
89158887|NCT05250440||(b2)Mild myopia: -1.00 to -3.00 D|age: 18 to 35 years old
89158888|NCT05250440||(b3)Moderate myopia: -3.25 to -6.00 D|age: 18 to 35 years old
89158889|NCT05250440||(b4)High myopia: >-6.00 D|age: 18 to 35 years old
89158890|NCT04808674|Experimental|Group-based cognitive remediation program|Patients are admitted to the day hospital 2 days a week for 6 weeks and participate in a group-based (4 patients per group) rehabilitation program conducted by a multidisciplinary team including a PMR doctor, a neuropsychologist, an occupational therapist, and a physical activity monitor).
89158891|NCT04808674|Experimental|One-on-one cognitive remediation program|Patients are admitted to the day hospital 5 days a week for 6 weeks and participate in a one-on-one intensive rehabilitation program conducted by a multidisciplinary team including a speech therapist, neuropsychologist, occupational therapist, physiotherapist, physical activity monitor and a psychologist.
89158892|NCT02631018|Experimental|Physical Activity Enhanced Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations. This arm, uniquely, will receive a culturally based physical activity component.
89158893|NCT02631018|Active Comparator|Standard Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations.
89158894|NCT02654444||GenASIs HiPath IHC #1|Expression of HER2 antibody. Semi-Quantitative value
89158895|NCT02654444||GenASIs HiPath IHC #2|Expression of HER2 antibody. Semi-Quantitative value
89158896|NCT02654444||GenASIs HiPath IHC #3|Expression of HER2 antibody. Semi-Quantitative value
89158897|NCT02769767||Cases|Subjects with Relapsing-Remitting Multiple Sclerosis. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
89158898|NCT02769767||Controls|Healthy subjects. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
88806049|NCT04352075|Experimental|Microfat|microfat (5 ml) and saline solution (5 ml)
88806050|NCT05410080||good perinatal outcome|Fasting blood sugar 2 hours postprandial HBA1C Ultrasound and Doppler
89158899|NCT02769767||Responders|Subjects with MS treated for at least two years that have less than one relapse per year or who had an increase of <1.5 points on the Expanded Disability Status Scale (EDSS) (if baseline EDSS was 0) or no increase in EDSS (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
89158900|NCT02769767||No responders|Subjects with MS that have more than one relapse per year treated for at least two years, and who had ≥1 relapse(s) or an increase of 1.5 points on the EDSS (if baseline EDSS was 0) or an increase of ≥0.5 points (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
89158901|NCT02575690|Placebo Comparator|Placebo group|Obese patients with well-treated hypertension that receive placebo (pure microcrystalline cellulose)
89158902|NCT02575690|Experimental|Spirulina group|Obese patients with well-treated hypertension that receive Hawaiian spirulina (Cyanotech Corporation, Hawaii, US)
89158903|NCT02630940||Idiopathic pulmonary fibrosis sufferers|Male or female idiopathic pulmonary fibrosis (IPF) sufferers over the age of 40, with a confirmed diagnosis of IPF against international guidelines. Patients are devoid of significant other medical, surgical or psychiatric illnesses that may affect respiratory symptoms or disease progression.
89158904|NCT02649530|Experimental|WNT974|Patients will receive 10 mg of WNT974 daily by mouth.
89158905|NCT02575456|Experimental|Group A|(4×10^10vp/vial, 4 vials): 1 ml sterilization injection water per dose to dilute 2 vials (4×10^10 vp/vial), one shot in each arm, total dose of 1.6×10^11vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
89158906|NCT02575456|Experimental|Group B|(4×10^10vp/vial, 2 vials): 1 ml sterilization injection water per dose to dilute 1 vial (4×10^10vp/vial), total dose of 8×10^10vp, one shot in each arm. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
89158907|NCT02575456|Placebo Comparator|Group C|(0 vp/ vial, 2 vials):1 ml sterilization injection water per dose to dilute 1 vial, total dose of 0 vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
89158908|NCT04005157|Experimental|Patients undergoing bronchoscopic MWA|Patients meeting the inclusion criteria will be enrolled in the study and undergo ENB guided MWA. Chest CT will be performed at 1 day after the procedure to confirm the complications and then at 1 month, every 3 months for 2 years, and every 6 months for 3 years thereafter after the procedure. PET/CT will be performed 3 months after MWA to assess the treatment response.
89158909|NCT00664794|Active Comparator|without acromioplasty|
89158910|NCT00664794|Active Comparator|with acromioplasty|
89158911|NCT02760563|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89158912|NCT02649296|Other|Treatment with Skanlab Bodywave|Treatment with Skanlab Bodywave twice a week for four weeks at the affected knee.
89158913|NCT02649296|No Intervention|No treatment|Treatment with Skanlab Bodywave without function twice a week for four weeks.
89158914|NCT02575534|Experimental|observational|"All patients will undergo 12-lead ECG and transthoracic echocardiography on the day of the study. These studies will be performed on patients as their previously implanted device is reprogrammed to pace in different modes. Patients will then receive an infusion of procainamide (12 mg/kg up to a maximum of 1 g) at a rate of 20 mg/min. Repeat ECG and echocardiograms will then be performed.~The patient's device will be programmed to a specific setting before and after the procainamide infusion."
89158915|NCT02696681|Experimental|Cognitive Behavioral Therapy|Integrating CBT for any substance use or mental health problems with CBT for adherence/self-care
89158916|NCT00664872|Experimental|case management|
89158917|NCT02649374|No Intervention|Gestational diabetes mellitus|women diagnosed with GDM during pregnancy, either treated by diet or pharmacological therapy
89158918|NCT02649374|Active Comparator|No GDM, Dietary Modifications|Women without GDM, will be advised and monitored for dietary, Exercise and lifestyle modifications
89158919|NCT02649374|No Intervention|No GDM, free diet|Women without GDM, for whom diet. exercise are continued regulary without any modifications
89158920|NCT02757443|Experimental|Phosphocreatine|"Participants randomly assigned to the phosphocreatine arm receive:~after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV);~together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L);~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV;~immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV"
89158921|NCT02757443|Placebo Comparator|Control|"Participants randomly assigned to the placebo arm receive:~after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;~together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany);~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;~immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes"
89158922|NCT00671580|Experimental|A|PZ-601
89158923|NCT00671580|Experimental|B|PZ-601
89158924|NCT00671580|Active Comparator|C|Standard of Care
89158925|NCT00649766|Active Comparator|1|tailored print messages to encourage eye examination behavior
89158926|NCT00649766|Active Comparator|2|targeted print messages to encourage eye examination behavior
89158927|NCT04071262|Experimental|Abemaciclib + Abiraterone Acetate + Prednisolone|Abemaciclib, abiraterone acetate and prednisolone given orally.
89158928|NCT05659225|Other|electronic stethoscope group|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the control group and the electronic stethoscope group, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children. The patient's caregiver will be instructed to use an electronic stethoscope to coordinate treatment and complete follow-up."
89158929|NCT05659225|Other|control group|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the control group and the electronic stethoscope group, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children."
89158930|NCT04224779|Experimental|Tumors and blood collection|"For all the patients included in the study :~Blood samples will be collected at different times T1 (Baseline), T2 (1 or 2 weeks after the beginning of the treatment), T3 (3 or 4 weeks before the surgery) and T4 (1 month after the surgery).~Tumors biopsy will be collected for some patients who will benefit from an initial biopsy in the course of his management care in our Institute (before the surgery).~In parallel to this biological collection, imaging and clinical data will be entered into a database treatment."
89158931|NCT02657174|Experimental|G1- experimental active comparator group|G1 - (Experimental) 40 third molars surgeries will be performed in a conventional manner. At the end of surgery low level laser in auricular acupuncture points will be applied for prevention of inflammation and pain in a split-mouth design.
89158932|NCT02657174|Placebo Comparator|G2- control group|G2 - (Control) 40 third molars surgeries will be performed in the conventional manner, identically to the G1. At the end of surgery low level laser device off in auricular acupuncture points will be applied. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1, with split-mouth design.
89158933|NCT02757131|Experimental|Intervention|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the Physical Therapy (PT) staff 3 times daily under the supervision of the dedicated ambulator PCNA.~The ambulator will be trained by the physical therapy team on how to implement the protocol prior to initiation of the study."
89158934|NCT02757131|No Intervention|Control|"The cohort of patients randomized to usual care will not be seen by the dedicated ambulator, but will not otherwise be restricted in nursing's baseline ability to execute nursing specific recommendations placed by the PT team."
89158935|NCT00664950|Active Comparator|SHS|sliding hip screw
89158936|NCT00664950|Active Comparator|InterTAn IM Nail|interTAN IM nail
89158937|NCT02656784|Experimental|Trial-Based Cognitive Therapy (TBCT)|"Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach, based on the work of Franz Kafka The Trial and developed by Professor Irismar Reis de Oliveira at Federal University of Bahia, Brazil. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All individuals in the group will be submitted to MRI"
89158938|NCT02656784|Experimental|Behavioral Therapy (ERP)|The Behavioral Therapy is an intervention of first choice for treatment of OCD , which employs the technique of Exposure and Response Prevention (ERP) , considered the gold standard to the disorder. The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All individuals in the group will be submitted to MRI
89158939|NCT02656784|No Intervention|Control Group|The control group consisted of individuals without OCD, matched with the experimental group in terms of gender,age and education. In this group are not included in individuals in psychotherapeutic care and with a history of neurological or psychiatric disorder; however, all them will be submitted to MRI .
89158940|NCT02769377|No Intervention|Control|patients who decline or unable to do self-monitoring of blood glucose
89158941|NCT02769377|Active Comparator|Breeze2 glucometer|patients who do self-monitoring of blood glucose, but do not transfer data via mobile-phone
89158942|NCT02769377|Experimental|Breeze2 glucometer and H2|patients who do self-monitoring of blood glucose and transfer data via mobile-phone
89158943|NCT04154748|Experimental|APC 90W / PPI 120mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
89158944|NCT04154748|Active Comparator|APC 90W / PPI 40mg|treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with standard dose oral omeprazole (40 mg q.d)
89158945|NCT04154748|Active Comparator|APC 60 W/ PPI 120mg|treatment with standard-power argon plasma coagulation (60 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
89158946|NCT02657096|Experimental|Hybenx treatment|Both quadrants included maxillary teeth 11-16 and 21-26. Each selected subject underwent randomly, without anaesthesia, at the same time and after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional SRP + desiccant (Hybenx). In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the marginal gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
89158947|NCT02657096|Sham Comparator|Scaling and Root Planing|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
89158948|NCT03140371|Experimental|High energy high protein peptide feed|"This is a one-arm study. Each patient recruited onto the study will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
89158949|NCT02756975|Experimental|transperineal prostate biopsy with coaxial method|The patients undergo transperineal biopsy with a coaxial Tru-Cut needle (18-gauge Core Biopsy Instrument with a 17-gauge Disposable Coaxial Needle).
89158950|NCT02756975|Experimental|transperineal prostate biopsy with noncoaxial method|The patients undergo transperineal biopsy with a noncoaxial 18-gauge needle.
89158951|NCT00665028||1|Postoperative myocardial ischemia
89158952|NCT02657018|Experimental|Intervention|MOBIGAME group
89158953|NCT02657018|Active Comparator|Control|Lifestyle counseling group
89158954|NCT04155138|Other|Naida Hearing Aid|"Adults (> 18 years of age)~Unilaterally implanted with an Advanced Bionics implant (CII or later)~At least six months of CI use experience~Limited bimodal benefit as perceived by the recipient and/or the clinician~Participants may or may not currently be using a hearing aid in the unimplanted ear.~Open set performance with current device configuration:~≥40% AzBio sentence score in quiet (S0)~If currently bimodal:~Hearing aid ear only CNC score <50%~AzBio Scores bimodal benefit <15%~Unaided audiometric threshold of ≤100 dBHL up to 500 Hz~Ability and willingness to participate in multiple sets of open speech testing (and chronically evaluate HA and CROS benefit)"
89158955|NCT04155138|Other|Naida CROS Device|The same cohort will cross over to each arm.
89158956|NCT04559945|Experimental|Aveir VR Leadless Pacemaker|VVIR pacing
89158957|NCT00665106|Experimental|cohort 1|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
89158958|NCT00665106|Experimental|cohort 2|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
89158959|NCT00665106|Experimental|cohort 3|5 up to 6 patients per arm. Emulsion at 3.2% of drug product.
89158960|NCT00665106|Experimental|cohort 4|5 up to 6 patients per arm. Oily solution at 3.4% of drug product.
89158961|NCT00670410|Experimental|Arm A - Related Donor|Related donor transplant: Patients with a related donor (5/6 or 6/6 HLA matched) will receive immunotherapy with a non-myeloablative preparative regimen of Busulfan and Fludarabine followed by allogeneic stem cell transplant (AlloSCT).
89158962|NCT00670410|Experimental|Arm B - Cord Blood Donor|Unrelated cord blood transplant: Patients without a related donor will receive immunotherapy with a non-myeloablative preparative regimen of busulfan and fludarabine followed by allogeneic stem cell transplant (AlloSCT) with either an unrelated umbilical cord blood donor (4/6, 5/6, or 6/6 HLA matched), or a related umbilical cord blood donor (3/6, 4/6, 5/6, or 6/6 HLA matched). Patients will receive Thymoglobulin ((rabbit) Anti-Thymocyte Globulin (ATG)) during the preparative regimen. GVHD prophylaxis will be Tacrolimus and mycophenolate mofetil (MMF).
89158963|NCT02756663|Experimental|Arm A: PAN (10mg) + CFZ + Dex|Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
89158964|NCT02756663|Experimental|Arm B: PAN (20mg) + CFZ + Dex|Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
89158965|NCT02756663|Active Comparator|Arm C: CFZ + Dex|Carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
89158966|NCT04244461|Experimental|Personalized normative feedback|Personalized feedback about drinking behavior compared to peers
89158967|NCT04244461|No Intervention|Control|Control participants will receive content similar in length but different in content from the PNF (i.e., non-drinking focused). These participants will receive information based on their actual and perceived behavior of playing video games, a strategy used in prior PNF work to balance attention to non-targeted behaviors.
89158968|NCT02654678|Experimental|Enalapril Orodispersible Minitablets|Individually adapted dose of enalapril consisting of 1 to maximum 4 enalapril ODMTs of 0.25 mg and/or 1 mg and/or other prescribed treatment of heart failure.
89158969|NCT04392401||Cohort|Patients over 18 years with a confirmed diagnosis of COVID 19 hospitalized in intensive care unit
89158970|NCT04153656|Other|Nurses|Subjects will be asked to commit to reading and studying Spiritual Flow.
89158971|NCT05253872|Experimental|Intervention group|Patients in the intervention arm will receive follow-up conducted by melanoma nurses, where the patients will get tools to cope with the melanoma diagnosis and structured training in skin self-examination
89158972|NCT05253872|No Intervention|Control group|Patients in the control arm will receive clinical follow-up according to the current standard of care for their clinical stage.
89158973|NCT03750175||Colorectal cancer patients|"Clinical utility of ctDNA analysis for treatment decision~Use of ctDNA for KRAS, NRAS and BRAF testing prior to potential anti-EGFR monoclonal antibody treatment for metastatic colorectal cancer"
89158974|NCT02756741|Active Comparator|STANDARD DOSE|Albumin 1.5gm/kg on day 1 and 1gm/kg on day 3
89158975|NCT02756741|Placebo Comparator|LOW DOSE|Albumin 20g/d for 5 days
89158976|NCT02654522|Experimental|Filler|Each subject will have one product in one forearm and another product in the other. Products: JUVEDERM Ultra Plus (24 mg/mL of HA) and VOLUMA (20 mg/mL of HA). Subjects will be randomized as to which forearm will receive which product. In one forearm, subject will receive four injections of the assigned HA filler (0.2mL). HA injections will be placed along a line from the wrist to the antecubital fossa. The initial 0.2mL HA injection will be placed in the deep dermis 5 cm from the wrist and the subsequent three 0.2mL HA injections will be place in 5 cm increments in the deep dermis along the line noted above. Same process will be used on the contralateral forearm using the other HA filler.1-3 hours post injection, these 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
89158977|NCT02654522|No Intervention|Scale Validation|"One forearm of one of three subjects will be randomized to the scale control forearm. The opposite forearm of this subject as well as the forearms of the two remaining subjects will receive treatment in this study. The forearm that has been designated as the scale control forearm will be injected with VOLUMA in a straight line into the mid-dermis in the following manner: 0.05ml of VOLUMA will be injected 5 cm proximal to the wrist, 0.1ml of VOLUMA will be injected 10 cm proximal to the wrist, 0.15ml of VOLUMA will be injected 15 cm proximal to the wrist and 0.2ml of VOLUMA will be injected 20 cm proximal to the wrist. The remaining randomized forearms (the non-injected forearm from the subject above and the forearms from the two additional subjects) will be injected in a similar fashion to the control forearm as noted above; however, the dose at each location will be randomized. Control subject will receive no Hylenex until after pertinent data is collected for the study."
89158978|NCT00670566|Experimental|1|
89158979|NCT04595903|Experimental|Hemopurifier®|The Hemopurifier® will be placed within the extracorporeal circuit, all connections secured, treatment will utilize a blood pump at a flow rate of up to 200mL/min. The patients will be monitored for adverse events, device deficiencies and the development of hemodynamic instability. The treatment session will be for 4-6 hours once daily for 4 consecutive days.
88806051|NCT05410080||poor perinatal outcome|Fasting blood sugar 2 hours postprandial HBA1C Ultrasound and Doppler
89158980|NCT02654366|Experimental|Community Supported Risk Reduction Group|Six weekly sessions will be scheduled during daytime and evening hours to accommodate the daily schedules of BNEP registrants and their CSPs. Each session meets for 60 minutes. Groups will consist of 5-6 BNEP registrant-CSP dyads (10-12 individuals). While BNEP registrants and CSPs attending the group together will receive an attendance incentive, BNEP registrants attending without a CSP will not earn one. The group leader will follow a manual that includes a structured outline. The group manual content combines risk reduction / treatment readiness and community outreach approaches. Following the introduction, each group session is divided into two components: 1) Risk Reduction and Treatment Readiness (30 min) and 2) Community Outreach skills (20 min).
89158981|NCT02629848|Experimental|Motesanib + Paclitaxel + Carboplatin|Motesanib 125 mg, (5 x 25 mg) tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target Area Under the Curve (AUC) of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib 125 mg, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
89158982|NCT02629848|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Motesanib placebo-matching tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target AUC of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib placebo-matching, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
89158983|NCT02760173|Experimental|Single intervention arm|This is the only arm in this study, measuring verticality perception after prolonged roll-tilt over 5min.
89158984|NCT02656628||Fractures of humerus femur tibia|Dynamic Locking Screw 3.7mm and 5.0mm
89158985|NCT02629926||Patients to receive GH replacement|30 patients will be recruited to the study who wishes to continue receiving growth hormone replacement, all of whom will receive NutorpinAq Recombinant growth hormone
89158986|NCT02629926||Patients who will not receive GH replacement|An additional 30 patients who elect not to receive growth hormone replacement will provide a parallel control data.
89158987|NCT02769455|No Intervention|Control|The control group will not be exposed to any FOP nutrition labels
89158988|NCT02769455|Experimental|Front-of-pack labelling (Reference Intakes)|The second group will be exposed to a FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are presented in the form of a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.
89158989|NCT02769455|Experimental|Front-of-pack labelling (5-CNL)|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format of the 5-CNL system therefore includes five categories of nutritional quality of food products, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the letter/colour corresponding to the product being enlarged."
89158990|NCT03912337|Placebo Comparator|Placebo|After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
89158991|NCT03912337|Experimental|Erenumab|After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
89158992|NCT00650156|Experimental|40 mg adalimumab|
89158993|NCT00650156|Experimental|80 mg Adalimumab|
89158994|NCT04153266||Patients with oral epithelial dysplasia|"INCLUSION CRITERIA~These include:~Adults aged 18 or above at the time of the screening visit.~Good command of English language both written and spoken [this is necessary as questionnaires are in English and cannot be translated unless through a cross-cultural validation study].~Being able to consent.~Diagnosed with OED as per current standard diagnostic criteria.~No concurrent malignancy in the head and neck or elsewhere."
89158995|NCT02576782|Active Comparator|perineural dexamethasone group|21 patients received perineural dexamethasone plus bupivacaine 0.5%
89158996|NCT02576782|Active Comparator|systemic dexamethasone group|21 patients received systemic (intravenous) dexamethasone plus perineural bupivacaine 0.5%
89158997|NCT02576782|Sham Comparator|control group|21 patients received only perineural bupivacaine 0.5% plus intravenous saline
89158998|NCT02756585|Other|ct perfusion|All participants will undergo the imaging protocol with CTP of head at the time of initial diagnostic imaging upon hospital arrival.
89158999|NCT04169360|Experimental|ANS-6637|ANS-6637 600mg once daily for 12 weeks
89159000|NCT04169360|Placebo Comparator|Placebo arm|Placebo 600 mg once daily for 12 weeks
89159001|NCT01372228|Experimental|Inherited Metabolic Disorder Patients|Recipients are treated with hematopoietic stem cell infusion from living donors
89159002|NCT02656940|Experimental|Group 1 - diet rich in n-3 and n-6 PUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.~Group 1 received diet rich in n-3 and n-6 polyunsaturated fatty acids (PUFA). The volunteers were asked to consume daily a mixture of virgin olive oil and soybean oil, totaling 35.2g to 52.8g, and 2 g of fish oil."
89159003|NCT02656940|Experimental|Group 2 - diet rich in MUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.~Group 2 received diet rich in monounsaturated fatty acids (MUFA). The volunteers were asked to consume daily virgin olive oil, totaling 35.2g to 50.6g, and 1 capsule of 1g of soybean oil."
89159004|NCT02656940|Experimental|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming 1 sachet of 2g of soybean oil and 1 capsule of 1g of soybean oil by day.
88806052|NCT00234884||Adalimumab|RA patients in treatment with commercial adalimumab
88806053|NCT04423380|Experimental|SH3051 capsules treatment|Oral Twice Daily Administration of SH3051
89159005|NCT00665184|Experimental|High force LE resistance training|High force lower extremity resistance training + Standard exercise care. The high force lower extremity resistance training group will participate in a 3 day per week progressive eccentric ergometry program that will be gradually increased over 3 weeks from 5-20 minutes per day and remain at that duration for the next 9 weeks. In addition, they will engage in exercises including moderate intensity aerobic training, concentric upper extremity resistance training and stretching (axial mobility exercises).
89159006|NCT00665184|Active Comparator|Standard Care Control Group|"Standard care exercise group: The standard care control group is an active control group, i.e., individuals who will engage in our standard of care (an evidence based exercise program). These exercises include moderate intensity aerobic training (15 minutes), concentric upper extremity resistance training (5-10 minutes), balance training (5 minutes), and stretching (axial mobility exercises-5-10 minutes)."
89159007|NCT02760251|Experimental|Romiplostim|Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be adjusted based on platelet counts as described in the summary of Product Characteristics (SmPC). Followup examination at week 52.
89159008|NCT00665262|Experimental|1|comibined use of tramacet and naloxone infusion perioperatively
89159009|NCT00649844|Active Comparator|A|
89159010|NCT00649844|Experimental|B|
89159011|NCT04222127|Experimental|EUS-guided injection of CYA of GVs|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate & lipidol using 19G EUS-FNA needle
89159012|NCT04222127|Experimental|Direct endoscopic injection of CYA of GVs|Direct endoscopic injection of CYA of the gastric varix using standard endoscopy
89159013|NCT02656472|Active Comparator|Tranexamic Acid Arm|TXA arm will include 10 subjects who will receive TXA for duration of surgery.
89159014|NCT02656472|Active Comparator|Epsilon Aminocaproic Acid Arm|EACA arm will include 10 subjects who will receive EACA for the duration of surgery.
89159015|NCT00665340|Placebo Comparator|Arm 1|
89159016|NCT00665340|Experimental|Arm 2|
89159017|NCT00651092|Active Comparator|A1|since the two methods of turbinectomy are in used on a regular basis there is no way to perform double blind study- both the surgeon and the patients are well aware of the operation they are about to go. we just compare several parameters in patients who are anyway about to undergo an operation in a specific method that is used by their surgeon
89159018|NCT00651092|Active Comparator|A2|the resection of the inferior turbinates will be performed endonasally with an endoscopical instruments
89159019|NCT00665418|Experimental|1|
89159020|NCT02769143|Experimental|Whole-Body Vibration Group (WBV)|Will be exposed to five minutes on a vibrating platform (Oscillating Platform Semi-Professional Horizontal - Arktus, Cascavel, Brazil), this type of platform vibrates through an anteroposterior axis, causing the right and left sides alternate horizontally denominated: alternating side vibration platforms, will be performed three times per week on alternate days (5 minutes). a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. The volunteers will be guided to stand on the platform with semi-flexed knees, barefoot and apart about hip width.
89159021|NCT02769143|Experimental|Pilates Group (PG)|Will be exposed to 60 minutes, held three times a week on alternate days. Pilates equipment used for the exercises are: Combo Chair, Cadillac Trapeze, Ladder Barrel, Reformer Universal, Step Barrel and Wall Unit. Will be selected for this study, 21 strengthening exercises and stretching to the main body segments. All exercises are performed in a series of ten repetitions with one minute interval between exercises. To determine the level of effort and consequently to changing loads, will be used verbal command according to the Borg CR10 scale. The level of effort will be maintained during the session heavy (Borg between 5 and 6).
89159022|NCT02769143|No Intervention|Control Group (CG)|The control group will be instructed to maintain their usual activities both in relation to their daily activities, dietary habits, failure to use drugs that can influence the increase in bone mass and participate in monthly meetings to address on issues osteoporosis and postmenopausal women. After the end of the interventions with WBV and GP groups, GC volunteers will be invited to also perform whole body vibration for six months. Exposure of vibration will be for five minutes on a vibrating platform, three times per week on alternate days. a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. Likewise which was offered for the WBV group.
89159023|NCT02121652|Active Comparator|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
89159024|NCT02121652|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
89159025|NCT02756429|Experimental|atrial fibrillation|Patients with atrial fibrillation
89159026|NCT02756429|Experimental|Control|Patients without atrial fibrillation
89159027|NCT04222049|Experimental|spastic Tongue Dysarthria|The purpose of gadget is to transmit the mechanical vibration waves to the brain of the subjects.
89159028|NCT00595920|Experimental|Tovaxin, open-label|Tovaxin; 30-45 million autologous myelin reactive T cells
89159029|NCT02756117|Experimental|Healthy|"10 Healthy subjects will be enrolled and each will undergo study procedures at one study visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of L-lysine (10 g) in 100 ml water. This amount of lysine is equivalent to that which is found in a 10oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
89159030|NCT04070950||Single group|Interview of patients with cancer of the cervix or uterine body, or ovary between the time of diagnosis and 3 months after the end of their last cancer treatment (not the object of the study).
89159031|NCT02546713|Other|Group 1|Abutments with a concave configuration of the subcritical contour (emergence shape).
89159032|NCT02546713|Other|Group 2|Abutments with convex configuration of the subcritical contour (emergence shape)
89159033|NCT04222361|Experimental|KDIGO guide recommendations|Preventive recommendations the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for AKI
89159034|NCT04222361|No Intervention|Standard care|The patients assigned to the control group will receive the current standard care of the septic patients of the Unit according to our protocols
89159035|NCT02654288||single arm|The pancreatic cancer patients without history of chemotherapy who will receive gemcitabine-based chemotherapy will be recruited and the sera IgG4 and IL-10 will be detected before and after chemotherapy.
89159036|NCT02769221|Experimental|Optiscope|Endotracheal intubation by rigid video stylet, manufactural named Optiscope.
89159037|NCT02769221|Active Comparator|McGrath|Endotracheal intubation by video laryngoscope, manufactural named McGrath.
89159038|NCT00595764|Active Comparator|1|Physician Management
89159039|NCT00595764|Experimental|2|Physician Management plus Cognitive Behavioral Therapy
89159040|NCT04466215|Active Comparator|Miricorilant|900 mg (6 x 150 mg) tablets daily taken orally for two weeks
89159041|NCT04466215|Placebo Comparator|Placebo|Six placebo tablets taken orally for two weeks
89159042|NCT02578966|Experimental|Motivational Interview|INTERVENTION GROUP: in this group, composed of 6 UBS, the children and their respective mothers/fathers/responsible adults will be attended by the dentists at least once a year with an approach based on the Motivational Interview.
89159043|NCT02578966|Active Comparator|Traditional health education|CONTROL GROUP: in this group, composed of 6 UBS, the children and their respective mother/fathers/responsible adults will be attended by the dentists at least once a year based on the recommendations by the Brazilian Ministry of Health (BRASIL,2008-a) and on SSC-GHC's protocol (BRASIL, 2008-b). Additionally, the professional guidance script and the parents' booklet of SSC-GHC's oral health Program may be used.
89159044|NCT02649140|No Intervention|Group 1|Group1 is control group and participants do not need intervention.
89159045|NCT02649140|Experimental|Group 2|Group 2 is vinegar Group and participants in this group are asked to drink 15ml vinegar(Ninghuafu, Sanxi, China)after dinner at noon and evening respectively for a period of four weeks.
89159046|NCT02755961|No Intervention|Control group|No intervention was performed
89159047|NCT02755961|Experimental|Education group|Dietary education and education on phosphate binder use. Pharmacists instructed patients about how to take phosphate binders properly. Dietitians educated on dietary phosphate restriction.
89159048|NCT02578888|Active Comparator|Palliative Therapy|EORTCQLQ-30 and FAMCARE questionnaire every 6 weeks for 3 visits.
89159049|NCT02578888|Experimental|Palliative Therapy+ idiographic|EORTC QLQ-30, and FAMCARE questionnaire every 6 weeks for 3 visits plus patients undergo idiographic assessment.
89159050|NCT00665496|Experimental|Arm 1|
89159051|NCT00665496|Placebo Comparator|Arm 2|
89159052|NCT04440631||Antibiotic therapy including rifampicin|
89159053|NCT04440631||Non-rifampicin antibiotic therapy|
89159054|NCT04440631||Control group (healthy volunteers)|
89159055|NCT02653898|Active Comparator|Focused Screening and Treatment + ITU|Approved antimalarial based on the malaria species identified on the monthly follow ups, following national treatment guidelines in Cambodia AND Insecticide Treated Uniform with 40% Permethrin; DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
89159056|NCT02653898|Active Comparator|Focused Screening and Treatment + sITU|Approved antimalarial based on the malaria species identified at the monthly follow up and following national treatment guidelines in Cambodia AND sham treated uniform. DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
89159057|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + ITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive insecticide treated uniforms with 40% Permethrin
89159058|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + sITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive sham treated uniforms
89159059|NCT02768909|Experimental|Pulmonary TB|"This arm will enroll 100 patients older than 15 years old, from Caracas, with pulmonary TB, culture proved.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J.~Follow Up 5 days after beginning of Tx~Follow Up 15 days after beginning of Tx~Follow Up 30 days after beginning of Tx~Follow Up 60 days after beginning of Tx"
89159060|NCT02768909|Active Comparator|Non - Pulmonary TB|"This arm will enroll 75 patients older than 15 years old, from Caracas, with non TB pulmonary infections, culture negative.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
89159061|NCT02768909|Active Comparator|Healthy Individuals|"This arm will enroll 75 patients older than 15 years old, from Caracas, without any symptom or sign of lower track infection.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
89159062|NCT02649452|Experimental|vibration|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between. After exercise, this group had to undergo vibration exercise by using whole body vibration machine.
89159063|NCT02649452|Active Comparator|Exercises|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between
89159064|NCT02755727|Experimental|Platelet Rich Plasma injection|"In the outpatient setting a sample of venous whole blood will be taken from the patient (40mls), from the antecubital fossa using standard phlebotomy techniques. The Angel™ system will be in the available also in the outpatient clinic and will be used to separate the blood to yield a PRP sample (approximately 15 minutes preparation time). The PRP sample is then injected into the common extensor origin.~2 injections will be used per patient over 2 weeks."
89159065|NCT02755727|Active Comparator|Open Surgical Release|Standardised surgical technique based on the Nirschl technique will be used. The patient will then have a small scar centred over the lateral epicondyle and the plane opened between ECRL (Extensor Carpi Radialis Longus) and EDC (Extensor Digitorum Communis) to expose the damaged ECRB (Extensor Carpi Radialis Brevis) tendon. The amount of abnormal tendon will be documented and excised. EDC will also be inspected and any abnormal tissue documented then excised. The footprint of the excised ECRB +/- EDC is cleared of soft tissue and the bone scored with an osteotome to promote bleeding. The interval is closed with suture material and the skin wound closed.
89159066|NCT02629536|Experimental|Active-verum-NAC tablet|Intervention: Twice-daily administration of N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablets
89159067|NCT02629536|Placebo Comparator|Sham-placebo tablet|Intervention: Twice daily administration of sham/placebo tablet
89159068|NCT04167098|Experimental|Platelet-Rich Plasma|
89159069|NCT04167098|Active Comparator|Corticosteroid|
89159070|NCT04167098|Placebo Comparator|0.9% saline|
89159071|NCT04153500|No Intervention|Traditional Methodology|A professor/lecturer of anatomy will carry out the session in the control group. The traditional (40 minutes total) will consist of 30 minutes of lecture (75% out of the total time), where female pelvic floor will be presented throughout theory and images. In the 2nd part, during 10 min (25%), participants will review anatomical drawings /atlases.
89159072|NCT04153500|Experimental|Pelvic+ method|The second researcher will carry out the session in the intervention group. The interventional session (40 minutes total) will consist of two parts: The 1st one is a lecture of 10 minutes (25% out of the total time) on female pelvic floor anatomy. In the 2nd part, during 30 min (75%), participants, in small groups of 4 people, will assemble the female pelvic floor interactive model, following the indications suggested by the second researcher. Pelvic+ is supported by an assembling manual that participants will be allowed to use.
89159073|NCT04071106|Active Comparator|Turmeric Extract group|10 psoriasis patients receiving turmeric based ointment levigated in glycerin twice daily and assessed for response and side effects weekly for 12 weeks
89159074|NCT04071106|Active Comparator|Turmeric extract + olive oil group|10 psoriasis patients receiving turmeric extract levigated in olive oil instead of glycerin. The ointment will be applied twice daily for 12 weeks & will be assessed weekly
89159075|NCT04071106|Placebo Comparator|Petrolatum group|10 Psoriasis patients will receive the base of the therapeutic ointment which is the petrolatum. Patients will apply it twice daily and will be assessed weekly clinically and dermoscopically for 12 weeks
89159076|NCT04071106|Active Comparator|NBUVB group|10 Psoriasis patients will receive two sessions of NBUVB weekly for 12 weeks and will be assessed weekly clinically and with dermoscope.
89159077|NCT04071106|Active Comparator|Established ttt group|10 Psoriasis patients will receive topical betamethasone dipropionate or calcipotriol cream twice daily for 12 weeks and will be assessed on weekly basis clinically and by dermoscope
89159078|NCT04167254|Experimental|Sit Down and Play|
89159079|NCT04167254|No Intervention|Usual Care|
89159080|NCT00670722||A|
89159081|NCT00670722||B|
89159082|NCT00670722||C|
89159083|NCT00670722||D|
89159084|NCT02755883|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
89159085|NCT02755883|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
89159086|NCT02629458|Experimental|Patients requiring surgery|
89159087|NCT02575378|Other|Metronomic chemotherapy|Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
89159088|NCT02575378|Experimental|Metronimic chemotherapy plus Chinese Traditional Medicine|"Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.~Chinese Traditional Medicine"
89159089|NCT02755415|Active Comparator|Static Standing Table Training|Patients in this group will receive standard hospital based rehabilitation as well as static standing table training
89159090|NCT02755415|Experimental|Robotic Gait Training|Patients in this group will receive standard hospital based rehabilitation as well as robot-assisted gait rehabilitation training
89159091|NCT02653820|Experimental|Chemotherapy patients|Chemotherapy patients will receive reflexology treatment
89159092|NCT00665574|Experimental|1|ActaVisc
89159093|NCT00665574|Experimental|2|ActaVisc Mx Intra-articular Injection
89159094|NCT00665574|Placebo Comparator|3|Saline
89159095|NCT00665574|Active Comparator|4|Corticosteroid
89159096|NCT04071184|Experimental|Dose cohorts|"Part 1 (dose escalation): 3+3 design will be used. Alofanib (dose levels of 50, 100, 165, 250, 350 mg/m2) will be given i.v. daily (1-5 days on, 6-7 days off, every week) till progression or unacceptable toxicity.~Part 2 (dose expansion): Afterwards the dosing regimen identified in Part 1 will be evaluated in a single-arm study focused on clinical efficacy."
89159097|NCT02648906|Experimental|Choline alfoscerate|"Drug: Choline alfoscerate and Donepezil~concomitant administration"
89159098|NCT02648906|Placebo Comparator|Placebo|Drug: Donepezil only
89159099|NCT04031898||full analysis set|All eligible patients who meet all inclusion criteria and none of the exclusion criteria
89159100|NCT02755493|Experimental|Sleep Deprivation|Sleep deprivation
89159101|NCT02648828||Intern|Interns are in their first year of residency.
89159102|NCT02648828||Residents|Residents are in their 2nd or 3rd year of residency.
89159103|NCT02648828||Attendings|Attendings are physicians who have completed their residency.
89159104|NCT00670878|Experimental|A|
89159105|NCT00670878|Active Comparator|B|
89159106|NCT02760017|Placebo Comparator|placebo|capsules containing placebo for B forticata
89159107|NCT02760017|Experimental|B. forficata|capsules of B. forficata containing 200 mg of plant extracts
89159108|NCT03652909||Adults with difficulty hearing in some daily listening situations|Patients listen to sounds with and without the personal sound amplification smartphone application
89159109|NCT02648984|Other|Patient group|Patients with ventricular septal defect
89159110|NCT02648984|Other|Control group|Healthy control subjects
89159111|NCT00671736|Experimental|1|daily inhalation
89159112|NCT00671736|Experimental|2|inhalation every other day
89159113|NCT00671736|Experimental|3|inhalation twice a week
89159114|NCT00671736|Placebo Comparator|4|daily inhalation
89159115|NCT02760095||Children with EED|Children are placed in this arm if they screen positive for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
89159116|NCT02760095||Children without EED|Children are placed in this arm if they screen negative for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
89159117|NCT04071028|Active Comparator|Footbath group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes,"
89159118|NCT04071028|No Intervention|Control group|"All the participants were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
89159119|NCT00675870|Experimental|1|
89159120|NCT02648750|Experimental|Rehabilitation Assistant|Bridges stroke self-management programme. Delivered by rehabilitation assistants. Participants will receive a minimum of 4 sessions over a 4-6 week period.
89159121|NCT02648750|Active Comparator|Therapist|"Bridges stroke self-management programme. Delivered by registered stroke therapists (Occupational therapists or physiotherapists).~Participants will receive a minimum of 4 sessions over a 4-6 week period."
89159122|NCT02759783|Active Comparator|Standard of Care|Standard of care (SOC) is at the discretion of the local oncologist.
89159123|NCT02759783|Experimental|Standard of Care + SBRT|Patients randomised to SBRT will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC.
89159124|NCT02645006|Experimental|Intervention arm- 3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
89159125|NCT02645006|Other|Control arm- 1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention
89159126|NCT00581308|Experimental|GORE® HELEX® Septal Occluder|Subjects who received a GORE® HELEX® Septal Occluder
89159127|NCT04407481||Adults with autosomal dominant polycystic kidney disease|All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
89159128|NCT04407481||Healthy Controls|Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance).
89159129|NCT02645084|Active Comparator|Intervention|Intervention: offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
89159130|NCT02645084|No Intervention|Control|Control: Hospital-based standard practice for the detection of colorectal cancer patients with hereditary or familial colorectal cancer, informed by the referral criteria that are being used in the intervention group
89159131|NCT03536767|Experimental|Open-Label|
89159132|NCT02576626|Other|A|Participants start with Ultibro (indacaterol/glycopyrronium 110/50) + placebo nebulization , then after a new washout period of 7 days they will receive ipratropium/salbutamol nebulization and placebo Breezhaler Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation
89159133|NCT02576626|Other|B|"Participants start with ipratropium/salbutamol nebulization and placebo Breezhaler , then after a new washout period of 7 days they will receive Ultibro(indacaterol/glycopyrronium 110/50) + placebo nebulization.~Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation"
89159134|NCT02759549|Experimental|eSMART-MH|Participants undergoing radiation treatment for breast cancer will receive the Electronic Self-Management Resource Training for Mental Health (eSMART-MH) intervention.
89159135|NCT02759549|Other|Theater Testing|Participants undergoing radiation treatment for breast cancer will participate in a theater testing workshop.
89159136|NCT02648516|Experimental|Conventional plus AAIT|Participants will receive ART plus a dose of allogenic adoptive immune transfusion (3 times of MNCs transfusions) from day 0 through the week 2 study visit.
89159137|NCT00877890|Experimental|1|
89159138|NCT00877890|Active Comparator|2|
89159139|NCT02648672|Experimental|BPN14770|A single oral dose of BPN14770.
89159140|NCT02648672|Placebo Comparator|Placebo|A single oral dose of placebo matching BPN14770
89159141|NCT02576470|Experimental|Videofluoroscopy (VF) and Barium|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium to provide biofeedback for targeted dysphagia swallowing maneuver.
89159142|NCT02576470|Active Comparator|Surface Electromyography (sEMG)|This group will receive the following types of procedures during visits. sEMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
89159143|NCT02576470|Active Comparator|Mixed VF and sEMG|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium, and EMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
89159144|NCT02576470|Experimental|VF with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
89159145|NCT02576470|Experimental|sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with anodal transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
89159146|NCT02576470|Experimental|Mixed VF, sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
89159147|NCT02576470|Sham Comparator|VF with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images without the transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
89159148|NCT02576470|Sham Comparator|sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images without the transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
89159149|NCT02576470|Sham Comparator|Mixed VF, sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images without transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
89159150|NCT02576470|Experimental|VF with reward|This group will receive the following the procedure outlined below for biofeedback. The biofeedback is based on the videofluoroscopy (VF) and Barium with financial reward.
89159151|NCT02576470|Experimental|sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3-days.
89159152|NCT02576470|Experimental|Mixed VF, sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3 days.
89159153|NCT02759627|No Intervention|Conventional Training|Conventional physical therapy consisted of neurophysiological concepts such as Bobath and Brunnstrom.Training sessions focused on static and dynamic postural tasks, improving lower and upper extremity range of motion, strengthening and overground walking. During walking training, emphasis was on distance walked than on gait quality. Symmetrical weight distribution was encouraged through verbal and tactile cues and was made more difficult by the addition of arm activities or actions requiring trunk rotation. In an effort to improve rhythmic weight-shifting ability, subjects practiced shifting their weight in forward and backward directions and side to side while performing reaching tasks. A session lasted 45 minutes, for 5 days per week for 6 weeks.
89159154|NCT02759627|Experimental|Robotic-Assisted Gait Training|Lokomat (Hocoma) was used in Robotic-Assisted Gait Training group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait. Robotic-Assisted Gait Training sessions lasted 45-minute sessions, 2 days a week during 6 weeks.
89159155|NCT02759627|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-Robotic-Assisted Gait Training, 2 days a week during 6 weeks.
89159156|NCT02648594|Experimental|Intervention: Hook wire CT guided|"There is only one arm. When patient undergo surgery , the radiologist will place a CT-guided Hook wire in order to localize it in patient lung. The intervention consists to place a CT-guided hook wire in contact with the pulmonary nodule under local anesthesia.~Then, the thoracoscopy will be realised. Then, the surgery piece will be examined to confirm if the node is in the surgery piece"
89159157|NCT04221971|Experimental|AML patients with NK cells infusion|The relapsed/refractory AML patient received Flu+CTX (Flu 25mg/m2 (-6d to -2d)，CTX 1.0g/m2 (-6d to -5d) and haploidentical NK cells infusion postchemotherapy for at least 48 hours. NK cell dose was over 1+E07/ kg with 3 consecutive infusions. NK cells infusion interval was 1 day.
89159158|NCT03495895|Experimental|Minding the Baby|Families are visited weekly beginning in the mother's third trimester of pregnancy up through the child's first birthday, at which point visits take place biweekly up through the child's second birthday.
89159159|NCT03495895|Other|Control|Usual care control condition. Families in the control Group receive the usual care that is offered to families in the target group
89159160|NCT02644694|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
89159161|NCT02768987|Experimental|Overweight|Sedentary adolescents with T1D and overweight
89159162|NCT02768987|Experimental|Normal Weight|Sedentary adolescents with T1D and normal weight
89159163|NCT02653742|Experimental|Ketorolac|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use.
89159164|NCT02653742|Experimental|Fentanyl|Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
89159165|NCT02653742|Experimental|Ketorolac and Fentanyl|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use and Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
89159166|NCT02755259|Experimental|Acetazolamide|Diamox 500mg i.v. (1x)
89159167|NCT02755259|Placebo Comparator|Placebo|Placebo Saline injection (1x)
89159168|NCT02575222|Experimental|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
89159169|NCT00680394|Experimental|mifepristone+misoprostol|200 mg mifepristone+ 800 mcg buccal misoprostol
89159170|NCT00680394|Experimental|misoprostol|800 mcg buccal misoprostol+placebo
89159171|NCT02768675|Experimental|LOADPRO arm|Participants will temporarily receive a LOADPRO device affixed to kyphotic corrective rods. The device will not be implanted and will be removed prior to surgery closure.
89159172|NCT04150848|Experimental|Goal Focused Emotion-Regulation Therapy (GET)|GET is a 6-session intervention delivered over 8 weeks to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses. GET has an emphasis on goal navigation skill building. This includes work on goal setting with a focus on assessing progress toward achieving specific, realistic, and measurable goals. Emotion regulation components include basic cognitive restructuring skills, cognitive distancing, and coping efficacy skills (matching the correct coping skill to specific circumstances).
89159173|NCT04150848|Active Comparator|Individual Supportive Psychotherapy (ISP)|"ISP includes 6-sessions of individual supportive psychotherapy and includes components of genuineness, unconditional positive regard, and empathic understanding through reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis. ISP emphasizes maintaining focus on the cancer experience, supporting participants in the here and now, fostering expression of emotion and discussion of difficult topics, and creating a sense of being understood."
89159174|NCT02768519|Experimental|OTS167IV|Cohort 1: 0.5 mg, Cohort 2: 1.0 mg, and Cohort 3: 2.0 mg without food on Period 1 Day 1 and with food on Day 1 Period 2.
89159175|NCT02768519|Placebo Comparator|Placebo|Cherry syrup
89159176|NCT04031664|Experimental|Qianjin Capsule of Gynaecology|"On the basis of the antibiotic levofloxacin + metronidazole for 14 days, Gynecological Qianjin Capsule for 28 days.~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
89159177|NCT04031664|Placebo Comparator|Antibiotics alone group|"Levofloxacin + metronidazole for 14 days, and gynecological Qianjin capsule simulator for 28 days.~One of the levofloxacin quinolones has broadspectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gramnegative bacteria. Bacterial activity. Metronidazole is mainly used to treat or prevent systemic or local infections caused by the abovementioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
89159178|NCT02755181||BPD|Borderline Personality Disorder as diagnosed by DSM-5
89159179|NCT02755181||normal volunteers|normal volunteers
89159180|NCT00671814|Experimental|1|Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.
89159181|NCT00671814|Placebo Comparator|2|Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.
89159182|NCT00671814|Active Comparator|3|Oral doses of 600mg linezolid given twice daily for 21 days.
89159183|NCT04548869|Experimental|CDX-0159|20 patients with Cold Contact Urticaria, 10 patients with Symptomatic Dermographism, and 10 patients with Cholinergic Urticaria will be enrolled and treated with a single dose of CDX-0159
89159184|NCT03526562|Experimental|Single arm phase I trial with 3 exercise dose-escalation arms|exercise dose-escalation: aerobic, resistance and flexibility training
89159185|NCT02627430|Experimental|Treatment (talazoparib and Hsp90 inhibitor AT13387)|Patients receive talazoparib PO QD on days 1-7 (course 0). Beginning in course 1, patients receive talazoparib PO QD on days 1-28 and HSP90 inhibitor AT13387 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89159186|NCT04348955||women with adjuvant breast cancer|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized
89159187|NCT02648360|Experimental|Text Messaging Intervention Arm|Participants will be enrolled in either a dietary or physical activity text messaging program. The dietary program will include nutritional education, reading nutrition labels, portion control, making lifestyle changes, finding social support, and identifying triggers. The physical activity program will provide information on the benefits of physical activity, exercise tips, and encouragement to live more active lifestyles. The programs have limited interactive capability; patients will be asked to respond to specific questions, but questions asked by the participants will be answered with an automated message asking them to contact their health care provider.
89159188|NCT02627352|Experimental|Transscleral Cyclophotocoagulation|Subjects undergo a Micropulse Transscleral Cyclophotocoagulation(TSCPC) laser surgery, where a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
89235026|NCT05341882|Active Comparator|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
89235027|NCT05327790|Experimental|LFMT capsules + vedolizumab|The initial loading dose is 15 capsules, administered on day 0, in the clinic under direct observation, followed by 5 capsules daily starting on day 1 for 8 weeks at home. All subsequent doses will be dispensed to participants.
89159189|NCT03945500|Experimental|Standardized Home Spirometry (SHS) Method|"The Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded in an Android Tablet & FDA approved spirometer & pulse oximeter.~Participants will be trained with the SHS method, perform an initial home spirometry test session & a lab-based spirometry test (if practicable).~Pre-surveillance Phase:Daily SHS Testing for 4 to 10 weeks to enable the Mobile Medical application to generate volunteer specific normal range.~Surveillance Phase: At least weekly SHS Testing. During approximately two months of the surveillance phase, the volunteer will test one to four times per week to assess the SHS neural pathways as directed by the study team. Test sessions will be documented on a test log. Subjects may be asked to perform additional SHS pathway test logs, continue at least weekly testing, pause testing or end participation following completion of the initial SHS neural pathway test log."
89159190|NCT02759393|Experimental|DEX group|receiving 8-week dexlansoprazole 60 mg per day
89159191|NCT02759393|Active Comparator|Double-dose PPI group|receiving 8-week lansoprazole 30 mg twice daily
89159192|NCT04150926|Experimental|Black currant puree|Black currant puree
89159193|NCT04150926|Active Comparator|Black currant-quinoa product|Black currant-quinoa product
89159194|NCT04150926|Active Comparator|Quinoa base|Quinoa base is used for the black currant-quinoa product.
89159195|NCT04150926|No Intervention|Liquid with glucose, fructose and sucrose|Liquid with glucose, fructose and sucrose
89159196|NCT02759081|Active Comparator|water exchange|The air was turned off at the beginning of colonoscopy. Water was infused and suctioned at the same time during insertion. The air was turned on when the colonoscope reached the cecum.
89159197|NCT02759081|Experimental|cap-assisted water exchange|Cap was mounted to the tip of the colonoscope when water exchange was performed.
89159198|NCT02576548|Experimental|MEDI4276 0.05 mg/kg|Participants received IV dose of 0.05 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159199|NCT02576548|Experimental|MEDI4276 0.1 mg/kg|Participants received IV dose of 0.1 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159200|NCT02576548|Experimental|MEDI4276 0.2 mg/kg|Participants received IV dose of 0.2 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159201|NCT02576548|Experimental|MEDI4276 0.3 mg/kg|Participants received IV dose of 0.3 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159202|NCT02576548|Experimental|MEDI4276 0.4 mg/kg|Participants received IV dose of 0.4 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159203|NCT02576548|Experimental|MEDI4276 0.5 mg/kg|Participants received IV dose of 0.5 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159204|NCT02576548|Experimental|MEDI4276 0.6 mg/kg|Participants received IV dose of 0.6 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159205|NCT02576548|Experimental|MEDI4276 0.75 mg/kg|Participants received IV dose of 0.75 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159206|NCT02576548|Experimental|MEDI4276 0.9 mg/kg|Participants received IV dose of 0.9 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
89159207|NCT02759003|Active Comparator|inpatients group|"In-hospital nightime NIV initiation. For the inpatients Group, NIV was initiated in the respiratory wards of the two hospitals and continued during night for a minimum of 4 hours/night.~Inpatients had a 24-h availability of health staff care. During the night, they had nurses and physicians available on-hand."
89159208|NCT02759003|Experimental|outpatients group|"Home nightime NIV initiation. For the outpatients group, diurnal NIV was initiated during a scheduled visit in a hospital dedicated room(at least 4 hours/day of care), the trial proceeded at home during the night with a personal caregiver.~A minimum of 4 hours/night was required. No support during the night was provided to these patients."
89159209|NCT02759237||Patient Group|Patients identified for treatment of symptomatic aortic sten
89159210|NCT04565704|Experimental|Development of novel optical imaging technologies|Consented participants will allow their endoscopist to collect 3 additional biopsies from the participants. These biopsies will be used to develop our imaging techniques at our lab. We will use the standard of care histology images from the endoscopy procedure as a control comparison.
89159211|NCT00676104|Experimental|Treatment|
89159212|NCT00676104|Sham Comparator|Control|
89159213|NCT04325126||RBP4 in diabetes|RBP4 in diagnosed diabetes.
89159214|NCT04325126||RBP4 in pre-diabetes (pre-DM)|RBP4 in pre-diabetes (pre-DM).
89159215|NCT04325126||RBP4 in DM-CVD|RBP4 in diabetic cardiovascular disease.
89159216|NCT04325126||RBP4 in CVD|RBP4 in single coronary artery disease.
89159217|NCT04325126||RBP4 in NC|RBP4 in healthy controls.
89159218|NCT02758925|Experimental|DLBCL patients|they will receive a combination of: Rituximab 375mg/m2 IV at Day 1 Bendamustine 90mg/m2 IV at Day 1 and 2 Cytarabine 1000mg/m2 IV at day 2 every 21 days for 6 cycles
89159219|NCT00676260|Experimental|Pioglitazone QD|
89159220|NCT00676260|Placebo Comparator|Placebo QD|
89159221|NCT02768441|Experimental|Study group|Participants receiving Dexamphetamine 60 mg SR
89159222|NCT04152096|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
89159223|NCT04152096|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
89159224|NCT02644616|Active Comparator|trial group(tolvaptan group)|trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)
89159225|NCT02644616|Placebo Comparator|control group|control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)
89159226|NCT02759159|Experimental|AD-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on AD patients"
89159227|NCT02759159|Sham Comparator|AD-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on AD patients"
89159228|NCT02759159|Experimental|Mild Cognitive Impairment(MCI)-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on MCI patients"
89159229|NCT02759159|Sham Comparator|MCI-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on MCI patients"
89159230|NCT02648048|Experimental|Vismodegib and Pirfenidone|Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.
89159231|NCT02578654|Experimental|Interventions|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
89159232|NCT00671892|Experimental|Challenge|"Experimental Challenge Challenge 1 saline 5000EU 10,000EU 20,000EU~Challenge 2 Saline 40,000EU 80,000EU"
89159233|NCT02754869||Control Subject-Drug Study|The first part of this investigation is an interventional blinded cross over study with two dosing dates spread at least one week apart. Each volunteer will receive baseline scans before drug/placebo which will be used to assess intra---patient variation over the two study dates after which the drug or saline placebo will be administered with each volunteer acting as their own control to assess software ability to quantify changes in bowel motility.
89159234|NCT02754869||Dysmotility Subjects-Drug Study|The second component of this study will be exactly the same for the participants with dysmotility except the time to repeat scan will be reduced with a follow up time aimed at around 1---3 days reducing patient time off medication
89159235|NCT02754869||Reference Range Study|The third component of this study will assess basal small bowel motility in larger numbers of healthy controls, dysmotility subjects and irritable bowel syndrome to establish reference ranges to inform future clinical investigations and guide clinical decision making using global motility scoring. Each scan will last around 20 minutes and will not involve follow up or use of pharmaceutical agents.
89159236|NCT02754869||Desmotility Reversibility Study|The fourth component of the study will assess small bowel motility in a cohort of Crohns disease patients will small bowel disease before and 11---16 weeks after starting anti TNF alpha therapy, or undergoing endoscopic dilatation of a small bowel stricture. Each scan will last around 45 minutes
89159237|NCT03474679|Experimental|Ibrutinib|Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
89159238|NCT02574988||SCAR Patients|Patients diagnosed with severe cutaneous adverse reactions with be recruited
89159239|NCT00676416||1|Propofol general anesthesia for asthmatic patients
89159240|NCT00676416||2|Propofol general anesthesia for non-asthmatic patients
89159241|NCT04225013||Control (no CIN)|Patients who receive contrast media but do not develop contrast-induced nephropathy
89159242|NCT04225013||Case (yes CIN)|Patients who receive contrast media and develop contrast-induced nephropathy
89159243|NCT02653430|Experimental|Bariatric Surgery|Sleeve Gastrectomy
89159244|NCT04153110|Experimental|Real tDCS - Real tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
89159245|NCT04153110|Sham Comparator|Sham tDCS - Real tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks).
89159246|NCT02754791|No Intervention|Monthly report|A monthly report will be submitted to department heads describing their departments rate of blood culture contamination and comparing it to blood culture contamination rate in previous months and to blood culture contamination rate of the hospital as a whole
89159247|NCT02754791|Experimental|Steripath|The Steripath device (Magnolia) will be used to take blood cultures in this arm instead of standard methods. This will be in addition to a departmental monthly report (described above).
89159248|NCT02754791|Experimental|Soluprep wipes|In this arm, skin sterilization will be achieved using Soluprep wipes (3M) instead of standard methods (alcohol wipes).This will be in addition to a departmental monthly report (described above).
89159249|NCT04150536|Experimental|Lidocaine Topical System with Moderate Exercise (Treatment A)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. Subjects are instructed to exercise 30 minutes on an exercise bicycle, achieving at heart rate of approximately 108 bpm. Exercise is performed after 2.5 hours, 5.5 hours, and 8.5 hours after topical system application.
89159250|NCT04150536|Experimental|Lidocaine Topical System with Heat Applied (Treatment B)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. A heating pad is applied for 20 minutes at 2.5, 5.5, and 8.5 hours after the product is applied.
89159251|NCT04150536|Experimental|Lidocaine Topical System under normal conditions (Treatment C)|Three lidocaine topical systems 1.8% are applied to mid-lower back for 12 hours. No heat application or exercise is performed during this period.
89159252|NCT05167123|Experimental|Indirect Pulp Capping|TheraCal (LC) will be applied to affected dentin after excavation of infected dentin
89159253|NCT05167123|Experimental|Direct Pulp Capping|TheraCal (LC) will be applied to pinpoint pulp exposures (less than 1mm ) in vital pulps surrounded by sound dentin.
89159254|NCT02578576||patients with flare-up|Disease flare-up is demonstrated by coloscopy at one month after resection.
89159255|NCT02578576||patients without flare-up|No flare-up is found by coloscopy at one month after resection.
89159256|NCT02644538|No Intervention|nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) are still using the original treatment for 72 weeks
89159257|NCT02644538|Active Comparator|PegIFN alfa-2a + nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir), then will add PegIFN alfa-2a to the original nucleot(s)ides for 48 weeks, then follow up for 24 weeks
89159258|NCT02754635|Active Comparator|Induction of labour|Induction of labour at 38-39 weeks
89159259|NCT02754635|Active Comparator|Expectant management|Expectant management until 41 weeks.
89159260|NCT02576314|Active Comparator|Sofosbuvir and Daclatasvir|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
89159261|NCT02576314|Active Comparator|Ledipasvir/sofosbuvir|Participants will receive Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet daily for 12 weeks.
89159262|NCT00650234|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
89159263|NCT00650234|Active Comparator|2|Glucophage® XR Tablets 500 mg
89159264|NCT06262256|No Intervention|Control|Regular medical treatment for patients with metabolic syndrome.
89159265|NCT06262256|Experimental|High-intensity interval training|Regular medical treatment for patients with metabolic syndrome plus, 16 weeks of high-intensity interval training (3-times/week, 50 min/session conducted on stationary bike).
89159266|NCT06262243|Experimental|experimental group|The group that will receive routine care and electric blankets after cesarean section.
89159267|NCT06262243|No Intervention|control group|The group that will receive routine care after cesarean section.
89159268|NCT06262230|Experimental|paired ASD and ordinary children|In this prevent study, ordinary children will be paired with children with ASD based on ages, hobbies, and other aspects.
89159269|NCT06262217||Mobile MRI|Mobile MRI scan
89159270|NCT06262204|Other|conventional group|standard surgery with metal screw
89159271|NCT06262204|Experimental|Shark Screw® group|new surgical procedure with human allogeneic cortical bone screw
89159272|NCT06262178|Experimental|Parenting-STAIR|PSTAIR is a 23 session intervention which combines elements of two existing EBTs: Skills Training in Affective and Interpersonal Regulation (STAIR), targeting maternal trauma and emotion dysregulation, and dyadic Parent-Child Care (PC-CARE), targeting parenting. We propose to shorten PSTAIR into a 10-15 session modular intervention and individualize treatment using an adaptive decision rule and shared decision making (SDM).
89159273|NCT06262178|Active Comparator|Treatment As Usual|Participants in the comparison condition will be assigned to treatment as usual. All participating clinics offer Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT), both trauma-focused EBTs. Though some differences have been noted, evidence suggests outcomes for PE and CPT are broadly equivalent. Participants in the comparison condition will receive PE or CPT, as determined by Cohen Veterans Network (CVN) clinics' standard treatment assignment procedures, and will participate in assessments on the same schedule as the treatment condition.
89159274|NCT06262152||Patients with Septo-optic dysplasia, visual deficit and agenesis of corpus callosum|"age 3-18 years~availability of at least 2 serial sleep EEGs performed during clinical follow-up~stable drug therapy in the last three months"
89159275|NCT06262139|Experimental|MT218|Each patient will receive a single intravenous injection of MT218 while being scanned with standard MR imaging sequences/protocol. The first cohort of four subjects will receive 0.02 mmol/kg, second cohort of four subjects will receive 0.04 mmol/kg, and third cohort of four subjects will receive 0.06 mmol/kg of MT218.
89159276|NCT06262126|Other|VR Arm|Viritual Reality therapy arm. All patients will receive virtual reality therapy.
89159277|NCT06262113|Experimental|Intervention Arm|
89159278|NCT06262113|Experimental|Enhanced Usual Care Arm|
89159279|NCT06262100|Other|Carragelose|Treatment with Carragelose containing eye drops
89159280|NCT06262087|Experimental|FIFA 11+ program combined with COD training|Participants in an experimental group will perform the FIFA 11+ program combined with COD training.
89159281|NCT06262087|Active Comparator|FIFA 11+|Participants in the control group will perform the FIFA 11+ program.
89159282|NCT06262074|Experimental|Group-1 (Structured Exercise Program)|Patients undergo structured exercise sessions lasting 30 minutes, encompassing activities such as range of motion, flexibility exercises, strength training, balance exercises, and aerobic exercises, with designated intervals between each session.
89159283|NCT06262074|Other|Group-2 (Non-Structured Exercise Program)|Patients are provided with a simple exercise routine that lacks a structured format.
89159284|NCT06262061|Active Comparator|Propranolol Group|The propranolol group will receive 20mg of oral propranolol twice daily for 14 days (or until hospital discharge or death).
89159285|NCT06262061|Placebo Comparator|Control Group|Control group will receive an oral placebo.
89159286|NCT06262048|Experimental|Treatment|Tamsulosin
89159287|NCT06262048|Placebo Comparator|Placebo|Placebo
89159288|NCT06262022|Experimental|experimental arm|A cold ice pack will be applied to the patient's knee for 20 minutes every hour for three days, starting after total knee arthroplasty.
89159289|NCT06262022|No Intervention|control arm|Only unit-specific routine treatment and care interventions will be applied to the patients in the control arm by the team in the unit, and no intervention will be applied by the researcher.
89159290|NCT06262009||household|House Members (adults and minors) from 175 households owning a dog
89159291|NCT06261996|Active Comparator|Fospropofol group|Fospropofol is administered to patients after admission to the roomat a pumping rate of 1 mg/kg/h.
89159292|NCT06261996|Placebo Comparator|Propofol group|Propofol is administered after admission to the room at a pumping rate of 0.5 mg/kg/h.
89159293|NCT06261983||Patients diagnosed with oral squamous cell carcinoma at stages I-II|The patients underwent sentinel node biopsy and posterior neck dissection
89159294|NCT06261957|Experimental|Salbutamol Test Arm|
89159295|NCT06261957|Active Comparator|Salbutamol Reference Arm|
89159296|NCT06261918||Patients without metabolic syndrome|Pre/postmenopausal patients diagnosed with breast cancer undergoing NCT and subsequent surgery with long follow-up
89159297|NCT06261918||Patients with metabolic syndrome|"Pre/postmenopausal patients diagnosed with breast cancer undergoing NCT and subsequent surgery with long follow-up~Metabolic syndrome evaluated on the basis of the following criteria:~BMI≥30~Glycosylated hemoglobin/baseline blood glucose~Triglycerides~Hypertension~Lipid profile"
89159298|NCT06261892|Experimental|Collect HPV DNA from urine|
89159299|NCT06261879|Experimental|A sanitary pad as a menstrual blood collector|The sanitary pad is similar to the normal sanitary pad.
89235028|NCT05327790|Placebo Comparator|Placebo capsules + vedolizumab|The placebo capsules will appear identical to the LFMT capsules; however, the capsules will contain 2 ingredients: trehalose and neusilin, which are components in LFMT capsules.
89159300|NCT06261866||Patients with chronic coronary syndromes identified with intermediate grade coronary stenosis|Patients chronic coronary syndrome identified with intermediate grade coronary stenosis undergo coronary angiography according to current practice and guidelines recommendations. FFR will be measured, in consistency with the guidelines and recommended clinical practice. In case of FFR > 0.8 optimal pharmacotherapy will be prescribed; on the contrary, in case of FFR ≤ 0.8 PCI will be performed. OCT imaging will be performed with commercially available device (Abbott, C7XR Dragonfly TM LightLab Imaging Inc., MA, USA) using the non-occlusive flushing technique.
89159301|NCT06261840|Experimental|Oral Multi-Dose Metronidazole|Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men
89159302|NCT06261840|Experimental|Single-Dose Secnidazole|Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men
89159303|NCT06261814|Experimental|Diagnostic (CEUS)|"Patients receive lumason IV and undergo CEUS 2 weeks prior to TACE, during TACE, 1-2 weeks after TACE, and then 1-2 months after TACE.~Intervention(s)"
89159304|NCT06261801|Active Comparator|Medication Group|Participants in the medication group would take 150-mg pregabalin capsules orally twice daily (total daily dose, 300 mg) for 4 weeks. The follow-up period is 3 months.
89159305|NCT06261801|Experimental|EA Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The follow-up period is 3 months.
89159306|NCT06261801|Experimental|EA+Medication Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with pregabalin (0.15g each time, twice daily). The follow-up period is 3 months.
89159307|NCT06261736|Experimental|Antibiotic Group|Those randomized to this group will receive a one-time dose of an oral antibiotic prior to the urethral bulking procedure. The antibiotic will be based on the participants' allergies, medical history, and current medication list.
89159308|NCT06261736|Other|No antibiotic group|Those randomized to this group will not receive an antibiotic prior to the urethral bulking procedure.
89159309|NCT06261723||Control Group without obesity|Control Group with periodontitis and without obesity
89159310|NCT06261723||Obesity Group|Obesity Group with periodontitis
89159311|NCT06261684|Experimental|Intralesional Acyclovir|Intralesional acyclovir will be prepared by diluting 1 ampoule of Acyclovir 250mg into 3.5ml of saline solution to achieve a concentration of approximately 70mg/ml. Then 0.1ml will be injected intra-lesionally into the base of the wart. Any hyperkeratotic lesions should be pared before the treatment. This process will be repeated every 2 weeks for 5 sessions, and can be discontinued if complete resolution is achieved early.
89159312|NCT06261684|Active Comparator|Cryotherapy|Patients allocated to Group B will undergo cryotherapy using a liquid nitrogen spray gun. Any hyperkeratotic lesions should be pared before the treatment. Two freeze-thaw cycles will be applied each session, the spray gun should be held 1cm away from the wart and maintained until the wart and the 1-3mm of surrounding skin shows freezing, and each cycle should last 15 seconds. Next, the lesion will be left to thaw completely before starting the second cycle. This process will be repeated every 2 weeks for 5 sessions, and can be discontinued if complete resolution is achieved early
89159313|NCT06261671|Active Comparator|Group 1: antioxidants-enriched culture medium (Gx)|Blastocyst exposed to antioxidants-enriched culture medium (Gx) in continuous culture conditions, without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
89159314|NCT06261671|Active Comparator|Group 2: Global total one step media (GT)|Blastocyst exposed to Global total one step media (GT) in continuous culture conditions, without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
89159315|NCT06261658|Experimental|Study group|Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
89159316|NCT06261580||Healthy Volunteers|Adult volunteers (18 years of age and older) who self-identify as being in general good health.
89159317|NCT06261528|Experimental|Circadian Focused Light Therapy for Fatigue Reduction in Progressive Multiple Sclerosis (NO-FATIGUE)|This will be an open label, single arm, single center phase 1 research study designed to generate safety data, biomarker data, and preliminary efficacy data to reduce fatigue in patients with progressive MS, to include PPMS and SPMS
89159318|NCT06261515|Experimental|Conventional periodontal treatment|Periodontal treatment of stage III-IV periodontitis patients according to the guideline recommendation from the European Federation of Periodontology will be provided.
89159319|NCT06261502|Experimental|CBD First|Participants will start with CBD to stimulate the eCB for 12 weeks, undergo an 8-week washout period, and then receive a 12-week placebo.
89159320|NCT06261502|Experimental|Placebo First|Participants will start with a placebo for 12 weeks, undergo an 8-week washout period, and then receive a 12-week CBD to stimulate the eCB system.
89159321|NCT06261489|Experimental|Tetrahydrocannabinol (THC) 25 mg|THC oil will be administered orally once a day for 15 weeks.
89159322|NCT06261489|Experimental|Cannabidiol (CBD) 50 mg|CBD oil will be administered orally once a day for 15 weeks.
89159323|NCT06261476|Experimental|Ashwagandha (Withania somnifera) Root Extract|Participants will take two Ashwagandha capsules containing 500 mg standardized root extract twice daily after breakfast and dinner, for a duration of 12 weeks.
89159324|NCT06261463|Experimental|CAFES2 family and social strengthening intervention|Families randomized into CAFES2 receive a home visit and participate in six multiple family group sessions in addition to any outside services or programs they are participating in.
89159325|NCT06261463|No Intervention|Enhanced Control|Families randomized to the enhanced control arm will not receive the CAFES2 intervention Instead, they will continue with their usual care, and also receive healthy lifestyle materials.
89159326|NCT06261450|Experimental|CBD first|A single dose of CBD dose administered followed by a dose of placebo 3 weeks later.
89159327|NCT06261450|Experimental|Placebo first|A single dose of placebo dose administered followed by a dose of CBD 3 weeks later.
89159328|NCT06261437|Experimental|Close Combat Assault Ration|The CCAR will be consumed as the sole nutrition source during a 7-day physically demanding military training exercise
89159329|NCT06261437|Active Comparator|First Strike Ration|The FSR will be consumed as the sole nutrition source during a 7-day physically demanding military training exercise
89159330|NCT06261424|No Intervention|Control group|The control group will receive their usual care and will be asked to continue their usual activities and exercises for the whole project duration. Only one clinical guide exists for ataxia interventions and no specific guidelines for physiotherapy and occupational therapy interventions are specified in this guide in terms of frequency, duration and type of interventions that are effective with this population. Patients generally have an annual follow-up with a doctor or a clinical nurse at a Neuromuscular Diseases Clinic. Patients are then referred if needed for follow-up with the physiotherapist and occupational therapist. Typically, patients are referred to physiotherapy for mobility-related needs such as the introduction of a walking aid, orthotic and sometimes teaching an exercise program. In occupational therapy, patients are referred for needs such as the introduction of technical aids, home adaptation or the introduction of a wheelchair.
89159331|NCT06261424|Experimental|Intervention group|The intervention group will follow a 12-week rehabilitation program, 3 times a week (two sessions in a therapy room and one session of aquatherapy).
89159332|NCT06261385|Experimental|Intervention group|In the intervention group, in addition to routine counselling (15-30 minutes), they will classify their identity with our screening tool (developed in Phase 2) and then apply the counselling protocol for the participants (5-10 minutes). After the counselling session, the personalized e-messages will be sent to the participants by our research staff for 4 weeks.
89159333|NCT06261385|No Intervention|Control Group|In the control group, the routine smoking cessation counselling, including generic advice on preventing smoking relapse, will be retained, and no e-messages will be sent.
89159334|NCT06261372|No Intervention|control group|The control group received conventional dialysis treatment.
89159335|NCT06261372|Other|intervention group|In addition to conventional treatment, mindfulness meditation combined with progressive muscle relaxation training was implemented during the interdialytic period.
89159336|NCT06261359|Experimental|CEND-1+ nab-paclitaxel + gemcitabine|Participants will receive nab-paclitaxel 125mg/m2; CEND1 3.2mg/kg IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
89159337|NCT06261359|Placebo Comparator|Placebo+ nab-paclitaxel + gemcitabine|Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
89159338|NCT06261346|Active Comparator|PRGF group|Immediately prior to endothelial keratoplasty, the graft will be incubated for 15 minutes in plasma rich in growth factors obtained from the transplant recipient.
89159339|NCT06261346|No Intervention|Control group|Standard endothelial keratoplasty procedure
89159340|NCT06261320|Experimental|Experimental group|
89159341|NCT06261307|Experimental|Music intervention|"Groups: Children with (risk group, appr. 50%) or without (control group, appr. 50%) familial risk for dyslexia.~In each arm, the children will follow the same training protocol consisting of weekly 0.5-1-hour training sessions for six months. Training sessions are organized at fixed times and locations in fixed groups of 5-10 parent-child dyads and an experienced instructor.~The music intervention consists of social, structured and playful group sessions that involve joint singing, playing with musical instruments, moving to and listening to music. Based on the results of a previous intervention study by the investigators on the benefits of vocal music exposure on speech processing (Virtala et al., 2023), joint singing will be emphasized in the music intervention. The aims of the music intervention are to support caregiver-child interaction and the development of musical abilities."
89159342|NCT06261307|Active Comparator|Circus intervention|"Groups: Children with (risk group, appr. 50%) or without (control group, appr. 50%) familial risk for dyslexia.~In each arm, the children will follow the same training protocol consisting of weekly 0.5-1-hour training sessions for six months. Training sessions are organized at fixed times and locations in fixed groups of 5-10 parent-child dyads and an experienced instructor.~The circus intervention consists of social, structured and playful group sessions that involve acrobatics and other age-appropriate motor exercises with the caregiver, and familiarizing with the art and equipment of circus and acrobatics. The aims of the circus intervention are to support caregiver-child interaction and the development of motor skills."
89159343|NCT06261294||two group Study arm determination based|"Subjects will be assigned into Test group or Control group based on the criteria:~Test group: Individual who has been diagnosed with lung nodule(s) or mass by his/ her healthcare provider utilizing LDCT or CT scan and has already scheduled for interventional procedure;~Control group: Individual is willing to undergo COPD examination and LDCT or CT scan with 3-5 mm spatial z-axis resolution and has no findings from the scan and examination"
89159344|NCT06261268|Experimental|Strip graft with Mucograft|An apically repositioned flap is prepared then, a free epithelialized gingival strip graft is harvested from the molar area of the palate and sutured to the apical part of the recipient area. A xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) covers the remaining uncovered part of the periosteal bed.
89159345|NCT06261268|Active Comparator|Free gingival graft|Apically repositioned flap is prepared. An epithelialized free gingival graft is harvested from the molar area of the palate, and sutured to the recipient area
89159346|NCT06261255|Experimental|ATT + EMD|There is only 1 arm, autotransplantation (ATT) + adjunctive EMD
89159347|NCT06261229|Experimental|Intermittent fasting|
89159348|NCT06261229|Experimental|Intermittent fasting + Behavioral economic|
89159349|NCT06261229|Experimental|Intensive Lifestyle Modification|
89159350|NCT06261216||wild-type transthyretin amyloid cardiomyopathy|
89159351|NCT06261216||heart failure with preserved ejection fraction|
89159352|NCT06261216||heart failure with reduced ejection fraction|ischemic or inflammatory origin
89159353|NCT06261216||healthy controls|
89159354|NCT06261203|Experimental|Group A (Experimental Group)|About 125 Participants in the treatment group will receive 81 mg low-dose aspirin once daily starting from the time of enrollment and continuing until the end of pregnancy
89159355|NCT06261203|Placebo Comparator|Group B (Control Group)|About 125 Participants will receive only the routine care of pregnancy until the end of pregnancy
89159356|NCT06261177|Experimental|Active FES|300μs long charge-balanced biphasic pulses delivered at 40 Hz, with amplitudes in the range of 5-20 mA
89159357|NCT06261177|Sham Comparator|Sham FES|Sensory stimulation (below 8 mA)
89159358|NCT06261164||Patients on hemodiafiltration with Cytosorb®|
89159359|NCT06261164||Patients on hemodiafiltration with Oxiris®|
89159360|NCT06261138||TACE group|Patients included in the study underwent either conventional TACE (cTACE) or drug-eluting beads TACE (DEB-TACE) procedures performed by experienced interventional radiologists, taking into account tumor burden, patient tolerance, and individual preferences.
89159361|NCT06261138||Combination group|Systemic treatment commenced within one month after the initial TACE procedure, depending on the proper liver function. Anti-angiogenic agents involved in this study mainly comprised multikinase tyrosine kinase inhibitors. ICIs included therapies targeting programmed cell death protein 1 and its ligands.
89159362|NCT06261112|Experimental|Experimental group|Experimental group kaleideskope, pain and fear
89159363|NCT06261112|No Intervention|No intervention group|No intervention group Control not pain and fear
89159364|NCT06261099|No Intervention|Control Group|Exercises including upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group, 5 sessions per week for 6 weeks. Since the functional recovery of the upper extremity after stroke will be slow, the exercise program is planned to be 5 days a week due to the necessity of applying an intense exercise program in the early period. All patients will be asked to perform exercises under the supervision of a physiotherapist as a home program on other days of the week.
89159365|NCT06261099|Experimental|kontrol+ working group|Upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group using the telerehabilitation method, which was applied to the control group in 5 sessions per week for 6 weeks. The telerehabilitation program will be carried out using an application that provides remote video access called Zoom. Since the functional recovery of the upper extremity after stroke will be slow, the exercise program is planned to be 5 days a week due to the necessity of applying an intense exercise program in the early period. All patients will be asked to perform exercises under the supervision of a physiotherapist as a home program on other days of the week.
89159366|NCT06261086|Active Comparator|patient with vitiligo group|"Patients with vitiligo ≥ 18 years old, both male and female patients will be included.~Exclusion criteria:~Patients with the following criteria will be excluded from our study:~Pregnancy and breast-feeding women.~patients on antioxidants or anti-inflammatory drugs~Patients on topical/systemic treatment for vitiligo in the last 4weeks prior to enrollment in the study~Patients with other dermatological diseases as psoriasis, lichen planus, viral infection, etc.~Patients suffering from chronic medical illness such as; diabetes mellitus, thyroid disease, and cancer."
89159367|NCT06261086|Active Comparator|control group|"control criteria with the following criteria will be excluded from our study:~1- Pregnancy and breast-feeding women."
89159368|NCT06261073|Active Comparator|Patients with non-segmental vitiligo|30vitiligo patients their age above 18 years attending dermatology outpatient clinics of Sohag University hospital.
89159369|NCT06261073|Active Comparator|healthy volunteers.|.A group of age and sex- matched healthy participants will be included as a control group.
89159370|NCT06260969||Endovascular therapy|Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting
89159371|NCT06260956|Active Comparator|Arm 1 Avoidance|Subjects must avoid eating peanuts and peanut products and egg and egg products.
89159372|NCT06260956|Active Comparator|Arm 2 Consumption|Subjects must consume peanuts and peanut products and egg and egg products.
89159373|NCT06260943|Experimental|Aim 3: Targeted Navigation Pilot Program|Participants in this group will be enrolled in a Targeted Navigation Pilot Program for up to 12 months.
89159374|NCT06260917||urination through zipper|
89159375|NCT06260917||urinating by pulling down trousers|
89159376|NCT06260904|Active Comparator|Prednisolone and Methotrexate (Control Arm)|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) and Methotrexate 15 mg weekly for 12 weeks.
89159377|NCT06260904|Experimental|Prednisolone and Apremilast (Test Arm)|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) and Apremilast 30 mg twice daily for 12 weeks.
89159378|NCT06260878|Experimental|Ringer's lactate 2500 cc IV|
89159379|NCT06260878|Experimental|Ringer's lactate 2000 cc IV|
89159380|NCT06260878|Experimental|Ringer's lactate 1500 cc IV|
89159381|NCT06260878|Experimental|Ringer's lactate 1000 cc IV|
89159382|NCT06260878|Active Comparator|Ringer's lactate 500 cc IV|
89159383|NCT06260865|Experimental|MORA Cure|Participants randomly assigned to this arm will use the digital therapeutics, MORA Cure.
89159384|NCT06260865|Active Comparator|Treatment as Usual|Participants randomly assigned to this arm will receive their treatment as usual only.
89159385|NCT06260826|Experimental|Auto-CPAP via nasal mask|Patients connected to the JPAP system (Metran, Saitama, Japan) via a nasal mask with the initial CPAP 2 cmH2O, then reach CPAP 7.5 cmH2O after a ramping time of 5 minutes.
89159386|NCT06260826|Active Comparator|Constant-CPAP via facial mask|Patients connected to the O2-Max Trio CPAP system (Pulmodyne, Indianapolis, USA) with a facial mask and maintained a CPAP at 7.5 cm H2O
89159387|NCT06260813|Experimental|PTTD patients (PTTD I, II and III)|75 patients with PTTD (25 patients in Stage I, 25 patients in Stage II, 25 patients in Stage III)
89159388|NCT06260813|Experimental|Healthy control group|25 healthy volunteers
89159389|NCT06260800||CEQ Validation|In initial assessment, EQ-5D-5L and HADS questionnaires were completed. After sessions 1 and 2, CEQ and WAI-S were filled. Finally, EQ-5D-5L was completed before the fourth session.
89159390|NCT06260787||In Vitro Fertilisation|Patients undergoing in vitro fertilisation at our tertiary fertility center facility
89159391|NCT06260774|Experimental|Dose level 1|0.4 mg/kg of TTX-MC138
89159392|NCT06260774|Experimental|Dose level 2|0.8 mg/kg of TTX-MC138
89159393|NCT06260774|Experimental|Dose level 3|3.2 mg/kg of TTX-MC138
89159394|NCT06260761|Experimental|MIPO|isolated close fracture of distal end radius
89159395|NCT06260761|Active Comparator|Conventional|isolated close fracture of distal end radius
89159396|NCT06260748|Experimental|Group 1 Diarrhea-Evaluable|Diarrhea-evaluable participants aged 12-75 years old who did not use continence aids that precluded assessment or evaluation of stool frequency and consistency during the screening/baseline period; randomized 1:1 to receive either placebo or CDCA.
89159397|NCT06260748|Active Comparator|Group 2a Non-Diarrhea Evaluable|Non-diarrhea-evaluable participants aged 12-75 years old who do not have stable, clinically burdensome diarrhea or their diarrhea cannot be fully characterized.
89159398|NCT06260748|Active Comparator|Group 2b Pediatrics|Participants aged 2 to less than 12 years old with or without clinically burdensome diarrhea.
89159399|NCT06260735|Experimental|Treadmill training combined with muscle and spinal cord stimulation|Locomotor training is defined as walking on a treadmill with appropriate bodyweight support and augmented with muscle activation either by electrical nerve or muscle stimulation based on individual needs. Then, spinal stimulation will be integrated during training with on/off bouts alternating.
89159400|NCT06260696||Normal weight|Adults with normal weight, recruited to complete self-administered online service
89159401|NCT06260696||Overweight|Adults with overweight, recruited to complete self-administered online service
89159402|NCT06260696||Obesity Class I|Adults with obesity class I, recruited to complete self-administered online service
89159403|NCT06260696||Obesity Class II|Adults with obesity class II, recruited to complete self-administered online service
89159404|NCT06260696||Obesity Class III|Adults with obesity class III, recruited to complete self-administered online service
89159405|NCT06260670|Experimental|EGF Mapping|"Subjects will be treated with catheter ablation of atrial fibrillation as is clinically indicated according to standard hospital ablation procedures (pulmonary vein isolation in de novo, pulmonary vein isolation touch-up in redo).~In addition, subjects will receive electrographic flow mapping (EGF) and concomitant high density mapping to collect electrogram patterns and morphology using both mapping methods."
89159406|NCT06260657||Fetal ethmoids|
89159407|NCT06260644|Active Comparator|Conventional flowable nano filled resin composite|Repairing the old defective class I composite restoration by conventional nano filled flowable resin composite.
89159408|NCT06260644|Experimental|Self adhesive flowable resin composite|Repairing the old defective class I composite restoration by self adhering flowable resin composite.
89159409|NCT06260592||intensive care nurses|Ethical compliance and humanistic care of intensive care nurses.
89159410|NCT06260579|Sham Comparator|Low intensity training (LIT)|6 months of low-intensity flexibility and balance exercises, not followed by a formal physical activity intervention
89159411|NCT06260579|Experimental|Moderate-intensity training (MIT)|6 months of exercise intervention (moderate intensity), followed by a co-developed physical activity intervention
89159412|NCT06260579|Experimental|Moderate- and high-intensity training group (MHIT)|6 months of exercise intervention (moderate-intensity followed by high-intensity), followed by a co-developed physical activity intervention
89159413|NCT06260553|Experimental|tislelizumab plus metronomic oral vinorelbine|
89159414|NCT06260527|Experimental|Single ascending dose (SAD)|ARTS-011 and placebo will be randomized assigned and single dose administrated.
89159415|NCT06260527|Experimental|Multiple ascending dose (MAD)|ARTS-011 and Placebo will be randomized assigned and continuously administrated once daily for 7 days.
89159416|NCT06260527|Experimental|Food effect study|ARTS-011 will be single administered under the fasting and high-fat meal condition.
89159417|NCT06260514|Experimental|APR-1051|3+3 Dose Escalation Design
89159418|NCT06260501||High volume liposuction under general anesthesia with super-wet technique|Patients who underwent high-volume liposuction with super-wet technique using wetting-solution containing 0.5 gr lidocaine and 0.5 mg epinephrine in each liter under general anesthesia
89159419|NCT06260488|Other|transfemoral amputation|Subject with a planned transfemoral amputation in the vascular surgery department of the Hôpitaux Universitaires de Strasbourg as standard care
89159420|NCT06260475||Patients with symptomatic peripheral artery disease and aortoiliac obstrutive disease|Chronic limb-threatening ischemia or claudicants due to extensive Aortoiliac Occlusive Disease (AIOD), particularly in Trans-Atlantic Inter-Society Consensus II (TASC-II) type C and D lesions
89159421|NCT06260462|Experimental|Conventional steroid treatment|Cortisone acetate and hydorocortisone will be administered in two daily doses
89159422|NCT06260462|Experimental|Dual-release hydrocortisone|Dual-release hydrocortisone will be administered once daily
89159423|NCT06260449|Experimental|Surgical removal|Surgical removal of the whitish granuloma
89159424|NCT06260449|No Intervention|Medical treatment|Topical and systemic steroid
89159425|NCT06260449|Experimental|Laser treatment|Argon laser
89159426|NCT06260436||pelvic organ prolapse patients with lower urinary tract symptoms|this group for patient who have pelvic organ prolapse and lower urinary tract symptoms
89159427|NCT06260436||pelvic organ prolapse patients without lower urinary tract symptoms|this group for patient who have pelvic organ prolapse but do not have any lower urinary tract symptoms
89159428|NCT06260423|Experimental|Experienced dentist using lateral compaction with bioceramic sealer group.|The canals in this group obturation were obturated by an Experienced dentist using lateral compaction with bioceramic sealer.
89159429|NCT06260423|Experimental|Unexperienced dentist using lateral compaction with bioceramic sealer group.|The canals in this group obturation were obturated by an Unexperienced dentist using lateral compaction with bioceramic sealer.
89159430|NCT06260423|Experimental|Experienced dentist using Single cone with bioceramic sealer group.|The canals in this group obturation were obturated by an Experienced dentist using Single cone with bioceramic sealer.
89159431|NCT06260423|Experimental|Unexperienced dentist using Single cone with bioceramic sealer group.|The canals in this group obturation were obturated by an Unexperienced dentist using Single cone with bioceramic sealer.
89159432|NCT06260332|Experimental|Supportive Care (Fitbit)|Patients wear a Fitbit and use the Fitbit application to monitor their physical activity daily in weeks 2-12 with the goal of increasing their number of steps per day and their number of active hours per day. Starting at week 2, patients also receive educational materials and attend 6 calls over 20-60 minutes each with their health coach in weeks 2, 3, 5, 7, 9, and 11.
89159433|NCT06260306|Active Comparator|Hip Activation Group|The hip activation HEP group will receive a combination of hip musculature activation exercises used by previous researchers that show an increase in hip muscle recruitment.
89159434|NCT06260306|Experimental|Combined Hip Activation and Core Stabilization Group|The hip activation plus core stabilization HEP group will receive the same hip exercises as the other group, plus core stabilization exercises used by previous researchers.
89159435|NCT06260293|Experimental|Exercise group|
89159436|NCT06260293|No Intervention|Usual care group|
89159437|NCT06260280||First-year medical residents|All first-year residents entering our department for any of the different specialties will undergo a nuclear magnetic resonance scan before starting their shifts and a control scan 2 months into their residency to evaluate if there is an association between chronic sleep deprivation and changes in cortical and hippocampal volume.
89159438|NCT06260267|Experimental|FE 999322|Microbiota suspension
89159439|NCT06260267|Experimental|FE 999324|Microbiota capsule
89159440|NCT06260267|Placebo Comparator|Placebo FE 999322|Placebo suspension
89159441|NCT06260267|Placebo Comparator|Placebo FE 999324|Placebo capsule
89159442|NCT06260254|No Intervention|Control Night|Single study night with no noise exposure, to determine normal baseline sleep.
89159443|NCT06260254|Experimental|Low Vibration Night|Single study night with railway vibration and noise events, to determine consequences of sleep disturbance by railway vibration at a lower level
89159444|NCT06260254|Experimental|Intermediate Vibration Night|Single study night with railway vibration and noise events, to determine consequences of sleep disturbance by railway vibration at an intermediate level
89159445|NCT06260254|Experimental|High Vibration Night|Single study night with railway vibration and noise events, to determine consequences of sleep disturbance by railway vibration at a higher level
89159446|NCT06260241|Other|With Traction Dressing|Traction dressing will be applied to patients after phalloplasty for 24 hours.
89159447|NCT06260241|Other|Without Traction Dressing|No traction dressing will be applied to patients after phalloplasty for 24 hours.
89159448|NCT06260228|Other|PD Participant with Cognitive Dysfunction|"Participants will receive the HOBSCOTCH-PD intervention consisting of 1:1 sessions delivered once per week including:~1 pre-HOBSCOTCH Session (on webcam or by phone)~1 educational session (on webcam)~6 HOBSCOTCH intervention sessions (webcam or phone)~1 wrap-up session (webcam or phone)"
89159449|NCT06260189||Lichen Planus Cases|40 cases with lichen planus from who skin biopsies and blood samples will be taken to assess cold inducible RNA binding protein levels in both tissues and serum.
89159450|NCT06260189||Healthy control group|40 healthy controls from who skin biopsies and blood samples will be taken to assess serum and tissue levels of cold-inducible RNA binding protein and compare them to active cases.
89159451|NCT06260176|Experimental|Green labels|"green label added to healthy product slots; no additional labels shown for less healthy products and 1 poster per machine explaining the labels"
89159452|NCT06260176|Experimental|Traffic light labels|red/yellow/green labels added to slots for less healthy/moderately healthy/healthy products, respectively and 1 poster per machine explaining the labels
89159453|NCT06260176|Experimental|Physical activity calorie equivalent labels|labels added to slots that display products' calorie content in terms of physical activity required to burn those calories and 1 poster per machine explaining the labels
89159454|NCT06260176|Experimental|Sweetened beverage tax posters|1 poster per machine; no labels; posters reminded consumers of the Philadelphia sweetened beverage tax and encouraging healthier choices
89159455|NCT06260150|Experimental|Experimental group|On the basis of routine nursing, the intermittent pneumatic compression device was used, lasting from the start of the operation to the end of the operation.
89159456|NCT06260150|No Intervention|control group|The control group received routine nursing during the operation, including upper limb intravenous puncture to establish infusion channel, and anesthesiologist performed radial artery puncture and catheterization. The patients were placed in a 30° head-up, legs-down position with their legs apart, and were warmed up by a warm air blanket. The intraoperative warming device was set to infuse at 38℃, and bladder temperature was monitored. Knee-length graded compression stockings (GCS) were used for both legs during the operation.
89159457|NCT06260137|Active Comparator|Rhomboid İntercostal Block (RIB)|
89159458|NCT06260137|Active Comparator|Rhomboid intercostal and subserratus plane block (RISS)|
89159459|NCT06260124|Experimental|Pre-menopausal women|Pre-menopausal healthy, inactive women that will participate in a random order in three dancing sessions (Greek traditional dancing) of different tempo on non-consecutive days.
89159460|NCT06260124|Experimental|Post-menopausal|Post-menopausal healthy, inactive women that will participate in a random order in three dancing sessions (Greek traditional dancing) of different tempo on non-consecutive days.
89159461|NCT06260111|Experimental|Photobiomodulation group|Photobiomodulation and usual care (education, cryotherapy, and mouth hygiene).
89159462|NCT06260111|Other|Control group|Usual care (education, cryotherapy, and mouth hygiene).
89159463|NCT06260098|Experimental|Yoga with High Breath work & meditation; Low movement/postures|
89159464|NCT06260098|Experimental|Yoga with Low Breath work & meditation; High movement/postures|
89159465|NCT06260085|No Intervention|Control|After the condition of the patients in the control group was stable, the pre-test was administered, then the patient was given routine information (Your mother/father/daughter/son/... is at the door, is there anything you want to tell them? I can convey and give feedback.). After the information, two more tests were administered at 15 and 30 minutes.
89159466|NCT06260085|Experimental|İntervention|In this randomised, controlled, experimental study, patients were randomised into intervention and control groups according to gender and age groups. In the preliminary interviews with the family members of the patients in the intervention group, the message content was discussed with the relatives of the patients before the voice recording was taken and carefully prepared to prevent negative effects. After the patient's condition was stable, the pretest was administered 15 minutes before (T1) the voice recording of the patient's relative was played through the music pillow.After the application, two more tests were applied at 15 (T2) and 30 (T3) minutes.
89159467|NCT06260059|Experimental|Empagliflozin 10 MG|Empagliflozin 10 mg daily will be administered for 1 year. The patient and the PI will be blinded (unaware) of the group they are assigned to.
89159468|NCT06260059|Placebo Comparator|Placebo|Placebo for 1 year
89159469|NCT06260046|Experimental|sufentanil group|sufentanil is administered for analgesic during general anesthesia
89159470|NCT06260046|Active Comparator|remifentanil group|remifentanil is administered for analgesic during general anesthesia
89159471|NCT06260033|Experimental|Treatment (SBRT, FES PET/CT)|Patients currently taking SERMs/ SERDs immediately undergo 3 or 5 treatment fractions of SBRT within 3 weeks in the absence of unacceptable toxicity or evidence of > 4 sites of disease progression. Patients not currently taking SERMs/SERDs first receive F-FES IV and undergo PET/CT scans at baseline. After baseline FES PET/CT, patients with ≤ 4 sites of progressive disease then undergo 3 or 5 treatment fractions of SBRT within 3 weeks in the absence of unacceptable toxicity or evidence of > 4 sites of disease progression. All patients undergo FES PET/CT at 12 and 24 weeks. Patients with SD after 12 or 24 week FES PET/CT may continue standard systemic therapy. Patients with ≤ 4 sites of progressive disease after 12 or 24 week FES PET/CT may receive SBRT to additional sites in the absence of unacceptable toxicity or evidence of > 4 sites of disease progression. All patients also undergo CT, PET/CT, or bone scans, and blood samples collection during screening and on study.
89159472|NCT06260020|Experimental|Children [4-10 years] with ASD with sleep disorder|"Development of module by Delphi method:components of Module include Behavioural intervention Modifying stimulus by change in location,using bedtime stories. Giving schedules to activities which interfere with sleep before bedtime. Using a bedtime pass to allow child to make a prefixed number of requests for parental attention while in bed.~Giving sleep items like cuddle toys to replace parental presence. Gradually delaying the bedtime so the child feels urge to sleep. Sleep hygiene by providing suitable environment to sleep, proper bedtime routine, sleep wake schedules Providing rewards for following good bedtime routine as positive reinforcement. Pharmacological intervention Sleep disorders due to underlying ENT, pulmonary conditions, to be treated as per standard protocol Usage of melatonin if required for sleep onset difficulty An 80%agreement over an intervention will be included in the module"
89159473|NCT06259799|Experimental|Smart Water Bottle|Participants in the intervention group will be prompted by the water bottle to drink (bottle will light up red) whenever they are behind on fluid intake recommendations for the day. The bottle will be linked to a smart phone application that participants will be instructed to download on their personal mobile device, but they will log into this device using a researcher provided username and password. The bottle will encourage male participants to consume 2.5 L and for female participants to consume 2.0 L of fluid. Participants will be asked to use this bottle to consume all water and enter any additional sources of fluid using the mobile application. The intervention group will also be asked to record their daily perceived thirst, first morning urine color, and body mass as a means of self-monitoring daily changes in hydration status, using a provided paper log.
89159474|NCT06259799|No Intervention|Control|The control group will be asked to go about daily activities as normal. They will not receive the water bottle and will not be asked to track daily measures of thirst, morning urine color, or body mass.
89159475|NCT06259357|Experimental|Protocolized protective mechanical ventilation in prone position|
89159476|NCT06259357|No Intervention|Protocolized protective mechanical ventilation in supine position|
89159477|NCT06259123|Experimental|Oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA-11 PET imaging|Patients with oligometastatic PCa diagnosed using [68Ga]Ga-PSMA-11 imaging defined as M1a and/or M1b positive with ≤5 osseous metastases and/or M1c ≤3 lung metastases will receive 2 cycles of 5 GBq [177Lu]Lu-PSMA I&T at 6-week intervals prior radical prostatectomy.
89159478|NCT06258941|Experimental|12-Week Mindful High-Intensity Interval Training (MF-HIIT)|
89159479|NCT06258941|Active Comparator|12-Week High-Intensity Interval Training (HIIT-only)|
89159480|NCT06258941|Active Comparator|12-Week Mindfulness (MF-only)|
89159481|NCT06258941|Placebo Comparator|12-Week Sedentary Activities|
89159482|NCT06258785|Experimental|Tizanidine|Tizanidine 2mg will be given preoperatively prior to scheduled sacrospinous ligament suspension
89159483|NCT06258733|Experimental|Lay-led FL workshops|Community lay leaders who underwent training in a manualized program will disseminate the workshop to women in their communities through engaging visual and game-based tools.
89159484|NCT06258733|Experimental|Expert-led FL workshops|Trained health experts will disseminate the same manualized program in community groups recruited by research staff to match lay-led groups.
89159485|NCT06258603|Experimental|Patients who received oral care bundle|"A oral care bundle protocol created by the researchers and it was applied by a researcher to experimental group."
89159486|NCT06258603|Other|Patients receiving routine clinical oral care|Routine oral care protocol used in intensive care unit was applied to control group by the patient's primary nurse.
89159487|NCT06258564||single cohort of women with cervical excision for CIN2+|single cohort of women with cervical excision for CIN2+; those with HPV vaccination and those without HPV vaccination
89159488|NCT06258447|Experimental|Study (ABM MNC) Treatment|Left ventricular catheterization with treatment consisting of autologous bone marrow mononuclear cells (ABM MNC) processed and delivered using the CardiAMP cell therapy system
89159489|NCT06258447|Sham Comparator|Control Treatment|Left ventricular (diagnostic) catheterization but no administration of ABM MNC
89159490|NCT06257888||breast cancer patients under navigation|breast cancer patients, intervention = patient navigation
89159491|NCT06257810|Active Comparator|Intervention Site|In the interventional sites, bioMérieux teams provided training to raise awareness of the diagnosis of dengue, chikungunya and malaria. In addition, a VIDAS instrument was installed and dengue and chikungunya diagnostic kits were supplied so that diagnosis could be carried out systematically for each patient included.
89159492|NCT06257810|Placebo Comparator|Control Site|In the control centres, only routine practices were observed.
89159493|NCT06257654||singel|
89159494|NCT06257641|Experimental|High-intensity Mediterranean diet|Patients assigned to the intervention group will undergo dietary education for the adoption of the Mediterranean diet, with monthly monitoring - mostly online - by nutritionists with experience in the field. Patients will be given 500 ml of extra virgin olive oil per week and informative material about the Mediterranean diet, as well as recipes and weekly menus.
89159495|NCT06257641|No Intervention|Standard of care|Patients assigned to the control group will be provided with standard recommendations for a low-fat diet with no monitoring by nutritionists.
89159496|NCT06257550|Experimental|THRIVE Intervention Arm|The THRIVE intervention arm will receive produce prescription, personalized dietitian coaching, adaptive bi-directional messaging; and linkages to social services.
89159497|NCT06257550|Active Comparator|Comparator Arm|The comparator arm will receive standard produce bags; and linkages to social services.
89159498|NCT06257316|Active Comparator|0.1mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
89159499|NCT06257316|Active Comparator|0.2mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
89159500|NCT06257316|Active Comparator|0.3mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, and 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
89159501|NCT06257316|Active Comparator|0.5mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, and 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
89159502|NCT06257316|Active Comparator|1.0mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, and 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
89159503|NCT06257316|Active Comparator|1.2mg/kg of ephedrine|"If the mean arterial pressure decreases by more than 20% from baseline after induction of anesthesia and infusion of fluids until the start of surgery, a randomized dose of ephedrine will be administered.~Six single doses were evaluated using six cohorts (N=20 per cohort). Subjects received single doses of ephedrine intravenously: 0.1, 0.2, 0.3, 0.5, 1.0, and 1.2 mg/kg.~Initially, 3 cohorts received the study drug at a given dose, after assessing the safety of ephedrine by the Korean Ministry of Food and Drug Safety, the additional 60 subjects in 3 cohorts received the study drug."
89159504|NCT06257173|Experimental|Experimental groups|"The experimental group will be selected among the students who do not take the Patient and Employee Safety course and who volunteer to participate in the study.The experimental group will receive 2 hours of patient safety training with a peer educator. Data collection forms will be applied at the end of the training, and data collection forms will be applied again 6 weeks after the training."
89159505|NCT06257173|No Intervention|Control groups|"The control group will be selected among the students taking the Patient and Employee Safety course who volunteer to participate in the studyThe control group will be given 2 hours of patient safety training in the curriculum by the researcher. Data collection forms will be applied at the end of the training, and data collection forms will be applied again 6 weeks after the training."
89159506|NCT06257069|Experimental|Intervention Arm|All subjects will receive intervention with Tremor Retrainer smartphone application
89159507|NCT06256679||Group 1: SHP pulsed radiofrequency and TTNS|Patients with interstitial cystitis who received superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation.
89159508|NCT06256679||Group 2: SHP pulsed radiofrequency|Group 2 included patients with interstitial cystitis who received only superior hypogastric plexus pulsed radiofrequency.
89159509|NCT06254950|Experimental|TAK-279 Dose 1|TAK-279, capsules, orally at Dose 1 up to Week 52 as per investigator's discretion.
89159510|NCT06254950|Experimental|TAK-279 Dose 2|TAK-279, capsules, orally at Dose 2 for 12 weeks followed by TAK-279 capsules, orally at Dose 1 up to Week 52 as per investigator's discretion.
89159511|NCT06254950|Placebo Comparator|Placebo|TAK-279 matching placebo capsules, orally, for 12 weeks followed by TAK-279 capsules, orally at Dose 1 up to Week 52 as per investigator's discretion.
89159512|NCT06254807|Experimental|CT-0525|"Cohort 1: 3 participants will be treated with a single IV administration of CT-0525 (3 billion CAR positive cells) on Day 1.~Cohort 2: 3 participants will be treated with a single IV administration of CT-0525 (10 billion CAR positive cells) on Day 1."
89159513|NCT06253871|Experimental|IAM1363 Monotherapy|Treatment with single-agent IAM1363 capsules, administered orally once daily in 21-day cycles from planned dose levels of 120mg to 480mg.
89159514|NCT06253871|Experimental|IAM1363 + trastuzumab|Treatment with single-agent IAM1363 capsules, administered once daily in 21-day cycles from planned dose levels of 120mg to 480mg, in combination with trastuzumab, administered per prescribing information as an IV infusion weekly or every 3 weeks, or subcutaneously every 3 weeks.
89159515|NCT06253793||ASD Experimental group|Children with Autism Spectrum Disorder (ASD) enrolled in the DENVER protocol. Same chronological age (1.5 years to 5 years of age) than children with ASD NOT enrolled in the DENVER protocol. Those children will be recruited and tested at the Alps-Isere Hospital Center (Saint-Egreve, France)
88804579|NCT03931772|Experimental|Automated Self-Hypnosis Intervention for Smoking Cessation|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health. Participants will be provided with the Amazon Alexa device to take home (necessary for using the program), or the interactive Reveri (www.reveri.com) mobile app. After the lab visit participants will continue using the intervention at home as needed throughout the 24 months of study participation (recommended every few hours or whenever they feel the urge to smoke). Furthermore, participants will be taking an online 15-minute survey at the baseline visit, and then 1, 3, 6, 12 and 24-month online follow-up surveys at home.
88804580|NCT03931772|Experimental|Automated Self-Hypnosis Intervention for Pain Reduction|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health, or remotely during the COVID-19 pandemic. Participants will be provided with the Amazon Alexa device to take home (necessary for using the program), or the interactive Reveri (www.reveri.com) mobile app. After the lab or remote visit participants will continue using the intervention at home as needed (recommended every few hours or whenever they experience an increase in pain). Furthermore, participants will be taking an online 15-minute survey at the baseline visit, and then 1, 3, 6, 12 and 24-month online follow-up surveys at home.
88806054|NCT02531646|Experimental|Predicate & Invest. DE - Human Subjects|Radiation -Thirty to forty (30-40) patients will receive a DR standard of care chest exam using the DRX Plus detector and a DE exam. Each DE patient exam includes high energy and low energy image exposures using the investigational device. These images are used by the DE console software to generate additional DE images (e.g. bone and soft tissue).
89159516|NCT06253793||ASD Control group|Children with Autism Spectrum Disorder (ASD) en NOT enrolled in the DENVER protocol. Same chronological age (1.5 years to 5 years of age) than children with ASD enrolled in the DENVER protocol. Those children will be recruited and tested at the Savoie Hospital Center (Chambery, France) and at the Grenoble University Hospital (Grenoble, France).
89159517|NCT06253793||TD control group|Typically developing (TD) children with the same developmental age than children with ASD. Those children will be recruited and tested at the University Grenoble Alps (Grenoble, France).
89159518|NCT06253559||ovarian cancer patients|all ovarian cancer patients that meet the criteria of the study
89159519|NCT06252545|Other|Interview Group|Subjects with pancreatic carcinoma who joined the interview group.
89159520|NCT06252545|Other|User Testing Group|Subjects with pancreatic carcinoma who joined the user testing group
89159521|NCT06252519|Experimental|NAC, then neuro-NAC, then Neuro-NAC XS|Participants receive single dose of NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.
89159522|NCT06252519|Experimental|NAC, Neuro-NAC XS, then Neuro-NAC|"Participants receive single dose of NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.~One week later, participants receive 1 dose Neuro-NAC while on controlled diet."
89159523|NCT06252519|Experimental|Neuro-NAC, then NAC, then Neuro-NAC XS|Participants receive single dose of Neuro-NAC while on controlled diet. One week later, participants receive 1 dose NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.
89159524|NCT06252519|Experimental|Neuro-NAC, then Neuro-NAC XS, then NAC|"Participants receive single dose of Neuro-NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC XS while on controlled diet.~One week later, participants receive 1 dose NAC while on controlled diet."
89159525|NCT06252519|Experimental|Neuro-NAC XS, then NAC, then Neuro-NAC|Participants receive single dose of Neuro-NAC XS while on controlled diet. One week later, participants receive 1 dose NAC while on controlled diet. One week later, participants receive 1 dose Neuro-NAC while on controlled diet.
89159526|NCT06252519|Experimental|Neuro-NAC XS, then Neuro-NAC, then NAC|Participants receive single dose of Neuro-NAC XS while on controlled diet. One week later, participants receive 1 dose Neuro-NAC while on controlled diet. One week later, participants receive 1 dose NAC while on controlled diet.
89159527|NCT06252259|Experimental|Ethnicity and Culture in Focus|"CTM (Phase 5) is a 3-month, flexible, choice-based health-promoting program for low active older adults that can be delivered in-person or online. The program includes:~1-on-1 Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop a physical activity action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings: Participants will attend eight, 1-hour group-based meetings (max of 15 participants) led by their activity coach. Meetings cover a health-related discussion topic and provide time and space for social connection among participants. Meetings can be held online or in-person.~The CTM program will be adapted for South Asian older adults, and may include additional intervention components customized for this population."
89159528|NCT06252259|Experimental|Men on the Move|"CTM (Phase 5) is a 3-month, flexible, choice-based health-promoting program for low active older adults that can be delivered in-person or online. The program includes:~1-on-1 Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop a physical activity action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings: Participants will attend eight, 1-hour group-based meetings (max of 15 participants) led by their activity coach. Meetings cover a health-related discussion topic and provide time and space for social connection among participants. Meetings can be held online or in-person.~The CTM program will be adapted for older men, and may include additional intervention components customized for this population."
89235029|NCT05327790|Experimental|LFMT capsules + ustekinumab|The initial loading dose is 15 capsules, administered on day 0, in the clinic under direct observation, followed by 5 capsules daily starting on day 1 for 8 weeks at home. All subsequent doses will be dispensed to participants.
89159529|NCT06252259|Experimental|The Forgotten North|"CTM (Phase 5) is a 3-month, flexible, choice-based health-promoting program for low active older adults that can be delivered in-person or online. The program includes:~1-on-1 Consultation: Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop a physical activity action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~Group Meetings: Participants will attend eight, 1-hour group-based meetings (max of 15 participants) led by their activity coach. Meetings cover a health-related discussion topic and provide time and space for social connection among participants. Meetings can be held online or in-person.~The CTM program will be adapted for older adults living in Northern BC, and may include additional intervention components customized for this population."
89159530|NCT06252233|Experimental|Patient- and physician-centered QoL monitoring|Quality of life (QoL) of patients is assessed with an electronic patient- and physician-centered QoL monitoring system using the questionnaires EORTC QLQ-C30 and QLQ-LC29 at study entry and at 1, 2, 3, 4, 5, and 6 months during follow-up care. Results of QoL monitoring are automatically transferred to a QoL profile. Patients and their treating physicians receive the results of their QoL monitoring in real-time. In order to be able to treat QoL deficits a multiprofessional network of therapists is established (e.g. pain therapy, psychotherapy, social support, nutrition counselling, physiotherapy, fitness, respiratory therapy). Intervention group physicians and patients receive complete lists of QoL healthcare professionals of this network practicing in their region. To provide continuous medical education, quality circles for therapy options have been founded.
89159531|NCT06252233|Placebo Comparator|Routine care|QoL of patients is also assessed with the same QoL monitoring system used in the intervention group at study entry and at 1, 2, 3, 4, 5, and 6 months but neither patients nor treating physicians have access to the QoL profiles. The therapist network is also available for control arm.
89159532|NCT06251726||Cohort of patients with stage T1 CRC treated by primary endoscopic resection.|Secondary surgery is performed in patients with pejorative histopathologic feature(s) of the tumor.
89159533|NCT06250205|Experimental|Treatment B+C: Obicetrapib + Drospirenone/Ethinyl Estradiol (COC)|Obicetrapib 10 mg tablets and Drospirenone (3mg)/Ethinyl Estradiol (0.02mg) tablet
89159534|NCT06250205|Experimental|Treatment B: Obicetrapib|Obicetrapib 10 mg tablets (daily)
89159535|NCT06250205|Experimental|Treatment C: Drospirenone/Ethinyl Estradiol tablets (COC)|Drospirenone (3mg)/Ethinyl Estradiol tablets (0.02mg) tablet
89159536|NCT06246253||Virtual implant placement following safe angle concept|
89159537|NCT06246253||actual implant placement following safe angle concept|
89159538|NCT06243562|Active Comparator|combined exercises and progressive muscle relaxation group|Participants in this group will be given combined exercises consisting of aerobic exercise, strengthening exercise and stretching exercise, as well as progressive muscle relaxation training. The studies will be carried out under the supervision of a physiotherapist.
89159539|NCT06243562|Active Comparator|combined exercises group|Participants in this group will be given combined exercises consisting of aerobic exercise, strengthening exercise and stretching exercise. They will rest for 10-15 minutes in a relaxation position only. The studies will be carried out under the supervision of a physiotherapist.
89159540|NCT06242951||Cystic fibrosis|Patients with cystic fibrosis
89159541|NCT06242951||Control|
89159542|NCT06240052|Experimental|Conditioning and active avoidance paradigm (CAAP)|
89159543|NCT06236165|No Intervention|Control arm|22 patients who will receive supportive treatment for jaundice only, for 3 months.
89159544|NCT06236165|Experimental|NAC arm|22 patients who will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
89159545|NCT06236165|Experimental|PTX arm|22 patients who will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
89159546|NCT06235970|Experimental|Device: Transcranial electrical stimulation (tES) including SHAM|healthy adults
89159547|NCT06235814|Active Comparator|Thyroid Lobectomy|"Randomization Protocol~Patients with intermediate molecular-risk thyroid nodules will be randomized to thyroid lobectomy or total thyroidectomy. We will perform a 1:1 randomization in a consecutive manner. Patients will be informed of what operation they will receive and providers will also be aware what operation was performed as it dictates care moving forward. Details of operative management will be discussed further.~Peri-operative Protocol~Thyroid Lobectomy Patients undergoing thyroid lobectomy will have the thyroid lobe containing the cancer removed in the standard surgical technique. These operations will be performed at either the UCLA Health Westwood Ambulatory Surgery Center, UCLA Ronald Reagan Medical Center, or UCLA Santa Monica Medical Center. Patients will undergo our usual postoperative care."
89159548|NCT06235814|Active Comparator|Total Thyroidectomy|"Randomization Protocol~Patients with intermediate molecular-risk thyroid nodules will be randomized to thyroid lobectomy or total thyroidectomy. We will perform a 1:1 randomization in a consecutive manner. Patients will be informed of what operation they will receive and providers will also be aware what operation was performed as it dictates care moving forward. Details of operative management will be discussed further.~Total Thyroidectomy and Completion Thyroidectomy~Patients undergoing total thyroidectomy will have their whole thyroid gland removed in the standard surgical technique. Patients undergoing a completion thyroidectomy will have their remaining thyroid lobe removed. These operations will be performed at UCLA Ronald Reagan Medical Center or UCLA Santa Monica Medical Center. Patients will undergo our usual postoperative care."
89159549|NCT06234761||patients with nasal polyposis|Patients with nasal polyposis will be treated with dupilumab following the clinical care path available in the hospital
89159550|NCT06234228|Experimental|BHD synced with mobile game|At the beginning of the vascular access procedure, the BHD will be applied 5 cm above the needle insertion site and maintained in place throughout the procedure. It delivers a constant low-frequency vibration as well as tactile feedback from the game (GF).
89159551|NCT06234228|Other|BHD only|The patient will wear the BHD 5 cm above the needle insertion site for the duration of the procedure. The BHD will deliver constant low-frequency vibration (CF).
89159552|NCT06233734||Robot Assisted Gait Training|This group of stroke patients will receive their standard care. For these participants, at this site (University Hospitals Dorset NHS Foundation Trust), this includes robot-assisted gait training.
89159553|NCT06233734||Conventional care|This group of stroke patients will receive their standard care. For these participants, at this site (Hampshire Hospitals NHS Foundation Trust), this does not include any robot-assisted gait training.
89159554|NCT06232187|Experimental|Feedback Group 1 (FG1)|"Participatns in FG1 will receive basic black box AI support, with simple explanation like standard plane, non standard plane or off plane."
89159555|NCT06232187|Experimental|Feedback Group 2 (FG2)|Participants in FG2 will receive explainable AI support, with more elaborate description of the anatomical structures and segmentation of the anatomy.
89159556|NCT06232187|No Intervention|Control group (CG)|Participants in the CG will have a standard plane poster to help guide them to the EFW ultrasound standard plane images.
89159557|NCT06229678|Experimental|Empagliflozin Group|Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months
89159558|NCT06229678|Placebo Comparator|Placebo group|Subjects will be randomized to receive the empagliflozin placebo for 3 months
89159559|NCT06227845|Experimental|Intervention|10 infants born by CS to screening negative mothers receive an oral maternal fecal transplant (from their own mother) containing 0.35mg/kg of maternal fecal content at the age of 2-7 days of age.
89159560|NCT06227845|No Intervention|Control|12 infants born by CS (8 to screening negative mothers and 4 to screening positive mothers in case of Blastocystis hominis or Dientamoeba fragilis).
89159561|NCT06227845|No Intervention|Comparison|Infants born vaginally to mothers with screening negative or mild pathogene findings (Blastocystis hominis or Dientamoeba fragilis)
89159562|NCT06226467|Experimental|N-ACT without delay|"After a baseline in-person assessment session (Week 1), participants randomly assigned to the experimental condition (i.e., N-ACT without delay) will complete one week of pre-intervention ecological momentary assessment (EMA; Week 2), then the intervention (Weeks 3-10), followed by a second week of (post-treatment) EMA (Week 11), and then a post-treatment in-person assessment session with comparable measures to baseline (Week 12). Participants will also complete an online follow-up remote assessment to re-evaluate outcomes of interest six weeks later (Week 18)."
89159563|NCT06226467|Other|Waitlist control|"Participants randomly assigned to the two-month waitlist control condition will be recontacted approximately 10 weeks after their initial (pre-waitlist) baseline assessment (Week 1) to complete a second pre-intervention (post-waitlist) assessment prior to starting the N-ACT program. The second in-person assessment session (Week 11) after the waitlist period (Weeks 2-10) will precede a series of procedures equivalent to the experimental (N-ACT without delay) arm: one week of pre-intervention ecological momentary assessment (EMA; Week 12), then eight weeks of N-ACT (Weeks 13-20), followed by a second week of post-treatment EMA (Week 21), a post-treatment assessment (Week 22) with parallel procedures to pre-intervention, and the final remote follow-up assessment (Week 28). All study procedures are identical between the two trial arms, with the exception of an added eight-week waitlist and third (post-waitlist/pre-intervention) assessment for participants in the control condition."
89159564|NCT06226051||PEAPOD device|Premature babies will be evaluated using the PEAPOD Infant Body Composition measuring device
89159565|NCT06214338|Experimental|Low Dose|10 mg of β-alanine
89159566|NCT06214338|Experimental|High Dose|20 mg of β-alanine
89159567|NCT06213324|Experimental|Ketamine|Participants in the ketamine arm will receive a single infusion of ketamine
89159568|NCT06213324|Placebo Comparator|Placebo|Participants in the placebo arm will receive a single placebo infusion of normal saline
89159569|NCT06212544|Experimental|Immediate Intervention|The intervention condition builds on our community partners' existing microeconomic intervention of: (1) a one-time emergency cash grant and (2) peer and legal support to obtain legal gender affirmation - plus a 12-week microeconomic intervention that adds: (3) weekly educational sessions and HIV prevention; (4) community mentoring; and (5) weekly posts of job openings in Detroit; and (6) a micro-grant for use towards acquiring self-led or formal employment
89159570|NCT06212544|Active Comparator|Delayed Arm|Participants randomized to the control condition will receive UC during the 12-week period following randomization. Usual care consists of emergency assistance and access to legal name/gender marker change. After the RCT follow-up period is complete, waitlist control participants will be offered delayed access to the same intervention that is provided immediately to intervention arm participants.
89159571|NCT06211972|Experimental|Intervention|In this study, there is only one study arm, and all eligible participants will be assigned to a treatment group and will participate in three treatment sessions of the OpiVenture program, in addition to the Opioid therapy agonist treatment they are receiving through the recruiting clinic.
89159572|NCT06195358|Active Comparator|Control Arm|The control arm will receive printed caregiving materials.
89159573|NCT06195358|Experimental|Intervention Arm|The intervention arm will receive the smartphone application.
89159574|NCT06186622|Experimental|Orforglipron (Part 1)|Participants will receive Orforglipron capsule and tablet formulation with Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam and Sodium Bicarbonate administered orally.
89159575|NCT06186622|Experimental|Orforglipron (Part 2)|Participants will receive Orforglipron capsule and tablet formulation with Simvastatin, Digoxin and Sodium Bicarbonate administered orally.
89159576|NCT06177964|Experimental|Lerapolturev Arm (Stage 1)|"Lerapolturev (intratumoral) will be dosed by Convection Enhanced Delivery (CED), infused twice, 4 days apart, in the remaining disease of recurrent Glioblastoma (rGBM) subjects following maximal safe resection of the disease recurrence.~To assess treatment response and/or immunologic responses in the brain, a tissue biopsy of the area infused will be recommended 5 weeks (± 1 week) after the 2nd lerapolturev infusion via CED, in the event that changes suggestive of tumor progression are seen on the MRI obtained 4-5 weeks after the 2nd lerapolturev infusion via CED.~."
89159577|NCT06177964|Experimental|Lerapolturev Arm (Stage 2 - Arm 1)|Lerapolturev (intratumoral) will be given by Convection Enhanced Delivery (CED), infused twice, 4 days apart, in the remaining disease of recurrent Glioblastoma (rGBM) subjects following maximal safe resection of their disease recurrence. This will be followed by subcutaneous injections of lerapolturev in the cervical perilymphatic (CPL) area on the same side as their tumor, weekly for 4 weeks and afterward every 3 weeks for about a year.
89159578|NCT06177964|Active Comparator|Lomustone (Stage 2 Arm 2)|Following maximal safe resection of their tumor recurrence subjects will receive Lomustine as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
89159579|NCT06170450|Experimental|Cyclic SNM|Programming of the SNM device will occur as per standard protocol in discussion between patient and SNM representative. The intervention will be to set the device to cycling stimulation program mode.
89159580|NCT06170450|Active Comparator|Continuous SNM|"Programming of the SNM device will occur as per standard protocol in discussion between patient and SNM representative. The intervention will be to set the device to continuous stimulation programming (SNM is continuously stimulating without off periods)"
89159581|NCT06168799|Experimental|Ilofotase alfa|
89159582|NCT06168799|Placebo Comparator|Placebo|
89159583|NCT06161857||Normal Hearing Group|Participants with hearing levels of 20dBHL or better at 6 and 8kHz frequencies of sound
89159584|NCT06161857||Mild Hearing Loss Group|Participants with hearing levels of 25-40dBHL at 6 and 8kHz frequencies of sound
89159585|NCT06161857||Moderate Hearing Loss Group|Participants with hearing levels of 45-70dBHL at 6 and 8kHz frequencies of sound
89159586|NCT06161857||Severe Hearing Loss Group|Participants with hearing levels of 75- 90dBHL at 6 and 8kHz frequencies of sound
89159587|NCT06160973|Active Comparator|Feed the household; Dedicated driver|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household; Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
89159588|NCT06160973|Active Comparator|Feed the individual; Dedicated driver|Medically tailored meals will be provided for the enrolled individual; Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
89159589|NCT06160973|Active Comparator|Feed the individual; Commercial shipper|Medically tailored meals will be provided for the enrolled individual; Meals will be delivered by a commercial shipping organization
89159590|NCT06160973|Active Comparator|Feed the household; Commercial shipper|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household; Meals will be delivered by a commercial shipping organization
89159591|NCT06156345|Active Comparator|Conservative|consists of teaching the patient the relaxed jaw position and stretching exercises for masseter and pterygoid muscles with hold of 20-30 seconds and 3-5 repetitions. In addition to placebo traction.
89159592|NCT06156345|Experimental|Conservative with Denneroll|"Participants will be supine lining with the orthotic will be placed under participants' neck.~Treatment session time begin with 3 minutes then increase of 2-3 minutes until they reach 15 to 20 minutes in each session with the conservative management for TMD."
89159593|NCT06147037|Experimental|Dose Exploration and Dose Escalation|"The study conducted in two parts: Part A Dose Exploration and Part B Dose Escalation~FPI-2053 dose exploration to determine the optimal pre-dose administration of FPI-2053 with a fixed dose of [225Ac]-FPI-2068.~[225Ac]-FPI-2068 dose escalation with the optimal dose of FPI-2053 as determined in Part A."
89159594|NCT06145737|Other|MS Participant with Cognitive Dysfunction|"Participants will receive the HOBSCOTCH-MS intervention consisting of 1:1 sessions delivered once per week including:~1 pre-HOBSCOTCH Session (on webcam or by phone)~1 educational session (on webcam)~6 HOBSCOTCH intervention sessions (webcam or phone)~1 wrap-up session (webcam or phone)"
89159595|NCT06144203|Experimental|Light-intensity aerobic exercise|
89159596|NCT06144203|Experimental|Moderate-intensity aerobic exercise|
89159597|NCT06144203|Experimental|High-intensity aerobic exercise|
89159598|NCT06140264|Active Comparator|Acupuncture dry needle|This group received acupuncture dry needle over trigger points of back muscles followed by stretching and strengthening exercises for back muscles, 2 sessions per week for 2 weeks.
89159599|NCT06140264|No Intervention|Stretching and strengthening exercises|This group received only stretching and strengthening exercises for back muscles.
89159600|NCT06140121|Experimental|Experimental: VRPT then Traditional PT|Participants will receive Virtual Reality assisted Physical Therapy sessions (VRPT) in the first Physical Therapy (PT) session and will receive traditional Physical Therapy sessions (standard care) in the second Physical Therapy session under the supervision of the accredited physical therapist.
89159601|NCT06140121|Experimental|Traditional PT then VRPT|Participants will receive traditional Physical Therapy (PT) sessions (standard care) in the first Physical Therapy session and receive Virtual Reality assisted Physical Therapy sessions (VRPT) in the second Physical Therapy session under the supervision of the accredited physical therapist.
89159602|NCT06139055|Experimental|Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet|Participants will receive a single dose of GSBR-1290 oral capsule formulation on Day 1 in Treatment Period 1 followed by GSBR-1290 oral tablet formulation on Day 8 (Day 1 of Treatment Period 2).
89159603|NCT06139055|Experimental|Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule|Participants will receive a single dose of GSBR-1290 oral tablet formulation on Day 1 in Treatment Period 1 followed by GSBR-1290 oral capsule formulation on Day 8 (Day 1 of Treatment Period 2).
89159604|NCT06139055|Experimental|Part 2 (Cohort 1): GSBR-1290/Placebo Tablet|Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks.
89159605|NCT06139055|Experimental|Part 2 (Cohort 2): GSBR-1290/Placebo Tablet|Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks.
89159606|NCT06139055|Experimental|Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule|Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks. In the last 4 weeks, participants will be further randomized to GSBR-1290 capsules or tablets or matching-placebo at Week 9 to 10 followed by alternate (capsule or tablet) formulation of either GSBR-1290 or placebo at Week 11 to 12.
89159607|NCT06135454|Experimental|Open Wedge High Tibial Osteotomy|
89159608|NCT06135454|Experimental|Double Level Osteotomy|
89159609|NCT06134687|Experimental|Treatment arm|Will have endoscopic submucosal dissection performed with the use of the Pathfinder Endoscope Overtube.
89159610|NCT06134687|Active Comparator|Control arm|Will have endoscopic submucosal dissection performed through conventional means (i.e. without the Pathfinder Endoscope Overtube).
89159611|NCT06130995|Experimental|Prostate Cancer Combo Therapy Trial|A single-arm Phase Ib study explores the effectiveness and safety of neoadjuvant and adjuvant hormonal therapy combining relugolix and enzalutamide in high-risk locally advanced prostate cancer patients eligible for ADT followed by radiation therapy or surgery.
89159613|NCT06129591|Experimental|Split-scar randomized trial arm with CBD oil|The study targets the vertical forehead scar, treating half with CBD oil and a silicone patch (experimental).
89159614|NCT06129591|Placebo Comparator|Split-scar randomized trial arm without CBD oil|The study targets the vertical forehead scar, treating half with a silicone patch (control).
89159615|NCT06128174|Experimental|Patients with longstanding persistent atrial fibrillation (AF)|All subjects will undergo Pulmonary vein isolation (PVI) and Posterior wall isolation (PWI) with the Farapulse catheter.
89159616|NCT06121063|Active Comparator|CCT-102 Regimen|CCT-102 A/B regimen
89159617|NCT06121063|No Intervention|Expectant management|Non-treatment, 'waitful watching'
89159618|NCT06119191|Experimental|Control Lenses|Participants will wear Control Lenses for 4 weeks
89159619|NCT06119191|Experimental|Test Lenses|Participants will wear Test Lenses for 4 weeks
89159620|NCT06112275|Experimental|Cohort X|Cohort X will consist of 2 participants and will evaluate ETX101 dose level 1.
89159621|NCT06112275|Experimental|Cohort Y|Cohort Y will consist of 2 participants and will evaluate ETX101 dose level 2.
89159622|NCT06106620|Placebo Comparator|Placebo|12 oz of flavor-matched water.
89159623|NCT06106620|Experimental|Safety Shot|12 oz of Safety Shot containing a blend of vitamins, minerals and botanical extracts.
89159624|NCT06103760|Other|Participants with Major Depressive Disorder|Intranasal esketamine to be self-administered by participants under direct supervision of a healthcare professional. First initial dose is 56mg and subsequent doses will be 56mg or 84mg. Esketamine will be administered twice weekly for weeks 1-4, once weekly for weeks 5-8, and once weekly/once fortnightly/once monthly as clinically indicated for weeks 9-25. After each treatment phase, participants will be re-assessed through a comprehensive battery of assessments and dose adjustments will be performed by the study psychiatrist base on tolerability, treatment response, and ongoing consent.
89159625|NCT06097468|Experimental|Phase I, Dose Finding - Starting Dose (20,000 mg)|Participants will ingest oral nisin once daily starting two weeks before planned complete OSCC resection surgery and will continue once daily administration for 6 additional months post-surgery (concurrent with adjuvant radiation/chemoradiation, for participants whose routine treatment plan includes adjuvant therapy). Nisin will be temporarily withheld at the time of OSCC resection surgery while the participant is under inpatient care. The starting dose level, with dose modification permitted for toxicity management or intolerability will be 20,000 mg (2 x 10 g bottles) per day.
89159626|NCT06097468|Experimental|Phase IIa, Dose Expansion (MTD/RP2D)|Participants will ingest oral nisin once daily starting two weeks before planned complete OSCC resection surgery and will continue once daily administration for 6 additional months post-surgery (concurrent with adjuvant radiation/chemoradiation, for participants whose routine treatment plan includes adjuvant therapy). Nisin will be temporarily withheld at the time of OSCC resection surgery while the participant is under inpatient care. The dose level will be determined by the outcomes in Phase 1 (RP2D), with dose modification permitted for toxicity management or intolerability.
89159627|NCT06096597|Experimental|Amniotic Membrane Therapy|Under general anesthesia, cystoscopy will be performed. A needle will be inserted into the detrusor muscle to a depth of approximately 2 mm. 100mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride, and 0.5 mL of the solution will be injected into 20 equally spaced sites into the posterior and lateral walls of the bladder, sparing the dome and the trigone.
89159628|NCT06096597|Placebo Comparator|Placebo|Under general anesthesia, cystoscopy will be performed. A needle will be inserted into the detrusor muscle to a depth of approximately 2 mm. 0.5 mL of 10 mL of 0.9% preservative-free sodium chloride will be injected into 20 equally spaced sites into the posterior and lateral walls of the bladder, sparing the dome and the trigone.
89159629|NCT06093997|Experimental|Experimental Group|Cupping and bloodletting therapy
89159630|NCT06093997|Experimental|Control Group|Massage treatment
89159631|NCT06087692|Other|Aerobic Exercise|Patients in the aerobic exercise group will be included a medium intensity (%40-60 of the maximum heart rate or 4-6 intensity according to the Modified Borg Scala) aerobic exercise program with a horizontal bicycle ergometer, 2 days a week for 8 weeks, lasting an average of 20-30 minutes, accompanied by a physiotherapist.
89159632|NCT06087692|Other|Nintendo +aerobic exercise|Nintendo group will be included a medium intensity (40-60% of the maximum heart rate or 4-6 intensity according to the Modified Borg scale) aerobic exercise program with a horizontal bicycle ergometer 2 days a week for 8 weeks, lasting an average of 20 minutes, accompanied by a physiotherapist, and then they will be included in ''Wii Fit'' exercise program an average of 40 minutes.
89159633|NCT06087692|No Intervention|Control|Physical activity recommendation and respiratory exercises
89159634|NCT06079216|Experimental|MCTM Intervention|Activity sessions will be led by activity volunteers
89159635|NCT06079216|Active Comparator|Control|Activity sessions will be led by activity professionals
89159636|NCT06077552|Experimental|experimental group|pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises.
89159637|NCT06077552|No Intervention|control group|receive diet health advises.
89159638|NCT06076473||Confirmed Primary Aldosteronism|Confirmed Primary Aldosteronism
89159639|NCT06076473||Non-Primary Aldosteronism|Other causes of hypertension
89159640|NCT06065488|Experimental|1.Group A (Ankle KT group):|This group includes 35 patients with chronic unhealed plantar foot ulcers for longer than three months; they will receive functional ankle taping, medical treatment, and dressing according their cases. The tape was applied for 5 days and then removed for 1 day to allow skin perspiration. This process was repeated for successive 8 weeks. The patient was instructed to avoid vigorous activities for 30 min, which is required for the glue to become fully activated (Andrýsková et al., 2020)
89159641|NCT06065488|Sham Comparator|2.Group B (Control group Ankle shame KT ):|This group includes 35 patients with chronic unhealed plantar foot ulcers for longer than three months. Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension , they will receive medical treatment, and dressing according their cases The shame tape was applied for 5 days and then removed for 1 day to allow skin perspiration. This process was repeated for successive 8 weeks. The patient was instructed to avoid vigorous activities for 30 min, which is required for the glue to become fully activated. (Andrýsková et al., 2020)
89235030|NCT05327790|Placebo Comparator|Placebo capsules + ustekinumab|The placebo capsules will appear identical to the LFMT capsules; however, the capsules will contain 2 ingredients: trehalose and neusilin, which are components in LFMT capsules.
89159642|NCT06060223|Experimental|Teach Back Method|"Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary."
89159643|NCT06060223|No Intervention|Control|Patients in the control group will participate in standard educational practices implemented in the clinic.Patients will be contacted by phone 3 months after discharge. Data collection forms will be applied as a final test.
89159644|NCT06057402|Experimental|Elranatamab|Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
89159645|NCT06052852|Experimental|Single agent BDC-3042|Escalating doses followed by expansion targeting advanced malignancies
89159646|NCT06052852|Experimental|Combination BDC-3042 plus pembrolizumab|Escalating doses followed by expansion targeting advanced malignancies
89159647|NCT06039579|Experimental|Part 1a - Participants Receiving VH4004280 Dose 1|
89159648|NCT06039579|Experimental|Part 1a - Participants Receiving VH4004280 Dose 2|
89159649|NCT06039579|Placebo Comparator|Part 1a - Participants Receiving VH4004280 Matching Placebo|
89159650|NCT06039579|Experimental|Part 1b - Participants Receiving VH4011499 Dose 1|
89159651|NCT06039579|Experimental|Part 1b - Participants Receiving VH4011499 Dose 2|
89159652|NCT06039579|Placebo Comparator|Part 1b - Participants Receiving VH4011499 Matching Placebo|
89159653|NCT06039579|Experimental|Part 2a - Participants Receiving VH4004280 Dose 3|
89159654|NCT06039579|Placebo Comparator|Part 2a - Participants Receiving VH4004280 Matching Placebo|
89159655|NCT06039579|Experimental|Part 2b - Participants Receiving VH4011499 Dose 3|
89159656|NCT06039579|Placebo Comparator|Part 2b - Participants Receiving VH4011499 Matching Placebo|
89159657|NCT06033547|Experimental|Part A: Participants receiving Cabotegravir Formulation F|
89159658|NCT06033547|Experimental|Part B: Participants receiving Cabotegravir Formulation G|
89159659|NCT06029907|Other|Study population|All patients will receive a smoking cessation and pain management intervention combined with clinician-prescribed varenicline.
89159660|NCT06026761||Healthy individuals|Metabolic study protocol
89159661|NCT06019195|Experimental|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
89159662|NCT06018116|Experimental|Bicalutamide|standard of care (SOC) avelumab with 150mg daily oral bicalutamide
89159663|NCT06018116|Placebo Comparator|Placebo|standard of care (SOC) avelumab with daily oral placebo
89159664|NCT06014411|Active Comparator|Delayed Bathing|Delayed bathing-- patients will be told to begin showering after wound exam and suture removal (10-20 day postoperative).
89159665|NCT06014411|Active Comparator|Early Bathing|Early bathing--Patients will be told to remove dressings and begin showering with body soap on postoperative day 3.
89159666|NCT06014307|Experimental|Plant-Based Meat Alternatives (PBMA)|Up to 2 servings per day of plant-based meat alternatives (Beyond Beef, Impossible Burger, Gardein Chick'n) OR as many plant-based meat alternative servings as available per day in the dining halls.
89159667|NCT06014307|Experimental|Animal|2 servings/day of traditional meat products (beef burger, pork, chicken)
89159668|NCT06002100||Ketamine|Adult participants starting ketamine treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).
89159669|NCT06002100||SPRAVATO|Adult participants starting SPRAVATO treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).
89159670|NCT06002100||TMS|Adult participants starting TMS treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment, early-treatment, and post-treatment visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).
89159671|NCT06002100||Antidepressants|Adult participants starting antidepressant treatment for depression at a participating clinic. fNIRS measurements using Kernel Flow2 will be taken at a pre-treatment and short-term efficacy visit. No clinical decisions will be made based on the data acquired for this study, and participation in the study has no influence on treatment decisions (including dosage form, frequency, and duration).
89159672|NCT05998642|Experimental|Methotrexate, Ibrutinib +/- Rituximab|Cycles 1-6, q14 days Day 1: Methotrexate + Rituximab Days 6-14: Ibrutinib daily orally
89159673|NCT05996822||AcF injection|Patient having received an AcF injection 1 month after a DXM injection for the treatment of Diabetic Macular Edema or Uveitic Macular Edema
89159674|NCT05996575||MCI Patients|Adult participants who are seeking neurological assessments for Mild Cognitive Impairment (MCI) at a participating clinic/study site.
89159675|NCT05996575||Healthy Controls|Healthy participants without a prior MCI or memory impairment diagnosis.
89159676|NCT05995717|Experimental|PKU UP|All participants will be assessed by their dietitian and prescribed an appropriate amount of the study product, PKU UP, to manage their phenylketonuria.
89159677|NCT05988411|Experimental|Catheter ablation + renal denervation|Catheter ablation + renal denervation
89159678|NCT05988411|Active Comparator|Catheter ablation only|Catheter ablation
89159679|NCT05987423|Experimental|Satralizumab|In the Part I period, participants will receive satralizumab every 4 weeks (q4w) followed by proptosis response-based individualized treatment in Part II of the study
89159680|NCT05987423|Placebo Comparator|Placebo|In the part I period, participants will receive placebo every 4 weeks (q4w) followed by proptosis response-based individualized treatment in part II of the study
89235031|NCT05327777|No Intervention|Control|Normal standard practices
89235032|NCT05327777|Experimental|Opioid Sparing|Providers required to prescribe 10 narcotic pills only
89159681|NCT05983562|Experimental|Experimental: Exogenous Ketone Supplement|Participants will be instructed to consume a total of 177 mL of the exogenous ketone supplement drink (for a total of 30 g of beta-hydroxybutyrate) per day (3 doses at 59 mL containing 10 g of beta-hydroxybutyrate each) for a period of 90 days.
89159682|NCT05983562|Placebo Comparator|Placebo Comparator: Inert placebo|Participants will be instructed to consume an equivalent volume (177 mL) of taste- and volume-matched placebo per day (3 doses at 59 mL) for 90 days.
89159683|NCT05983159|Experimental|Module 1: Slow-flow vascular malformations|Slow-flow vascular malformations with identified causative variants in the phosphoinositide 3-kinase (PI3K) signalling pathway will receive alpelisib (provided by Novartis Pharmaceuticals), an oral alpha-specific PI3-kinase inhibitor for a total duration of 48 weeks as monotherapy, followed by 24 weeks of follow-up.
89159684|NCT05983159|Experimental|Module 2: Fast-flow vascular malformations|Fast-flow vascular malformations with identified causative variants in the RAS-MEK-ERK signalling pathway will receive mirdametinib (provided by SpringWorks Therapeutics, Inc.), an investigational oral MEK inhibitor for a total duration of 48 weeks as monotherapy, followed by 24 weeks of follow-up.
89159685|NCT05977556|Experimental|Experimental|"Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours."
89159686|NCT05977556|No Intervention|Standard of care|The control group will receive standard of care that is provided as part of the perioperative surgical procedure and subsequent rehabilitation.
89159687|NCT05962489|Experimental|OFF DBS followed by ON DBS|
89159688|NCT05962489|Experimental|ON DBS followed by OFF DBS|
89159689|NCT05959447|Experimental|Gemfibrozil effet on camlipixant pharmacokinetics|
89159690|NCT05959447|Experimental|Camlipixant effect on dabigatran etexilate pharmacokinetics|
89159691|NCT05954143|Experimental|BDC-1001 Single Agent|BDC-1001 administered intravenously (IV) every 2 weeks
89159692|NCT05954143|Experimental|BDC-1001 in Combination With Pertuzumab|BDC-1001 administered intravenously (IV) every 2 weeks, in combination with pertuzumab administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose every 3 weeks.
89159693|NCT05952258|Active Comparator|Magnetic stimulation therapy|Participants will sit fully clothed on the magnetic stimulator chair, with knees apart at about the width of their shoulders, feet flat on the floor. The stimulator will be activated and the intensity gradually increased as tolerated by the participant up to an intensity of 100%. There are a total of 6 treatment sessions (twice per week) over 3 weeks.
89159694|NCT05952258|Placebo Comparator|Sham therapy|Participants will sit fully clothed on the magnetic stimulator chair, with knees apart at about the width of their shoulders, feet flat on the floor. The stimulator will be activated and the intensity gradually increased as tolerated by the participant up to an intensity of 5%. There are a total of 6 treatment sessions (twice per week) over 3 weeks.
89159695|NCT05952232|Active Comparator|PA-GH-01|1 capsule after breakfast once a day
89159696|NCT05952232|Active Comparator|MK-GH-04|1 capsule after breakfast once a day
89159697|NCT05952232|Active Comparator|TSH-GH-03|1 capsule after breakfast once a day
89159698|NCT05952232|Placebo Comparator|PA-GH-02|1 capsule after breakfast once a day
89159699|NCT05932979|Experimental|L-arginine|L-arginine 3 grams per day, divided into doses of 1 g every 8 hours during 90 days.
89159700|NCT05932979|Placebo Comparator|Placebo|Starch 1 gr every 8hr, during 90 days.
89159701|NCT05929287|Experimental|Experimental group 1. Tablet-based CT (NeuroAIreh@b)|"Participants in the NeuroAIreh@b group will perform tablet-based CT tasks personalized to their underlying deficits and performance in each iteration.~Biweekly 30-minute sessions until reaching 12 sessions."
89159702|NCT05929287|Experimental|Experimental group 2. Paper-and-pencil CT (Task Generator).|"Participants in the paper and pencil group will perform CT tasks personalized to their cognitive deficits (according to the MoCA) and generated automatically through the Task Generator website (https://neurorehablab.arditi.pt/TaskGenerator/).~Biweekly 30-minute sessions until reaching 12 sessions."
89159703|NCT05929287|No Intervention|passive control group (Waiting-list).|Participants in this group will not be enrolled in any intervention during the course of the study. At the end of the study, participants can integrate a CT intervention of their choice (e.g., CT through the NeuroAIreh@b platform or the TG).
89159704|NCT05926102|Experimental|Precision screening intervention|The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
89159705|NCT05926102|Experimental|Usual care|Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
89159706|NCT05916417|Active Comparator|TMS-fNIRS over the dl-PFC (Active)|TMS-fNIRS dl-PFC data will be acquired with participants being randomized to active or sham stimulation of the dl-PFC, with the randomizing of the order of four different TMS-fNIRS protocols.
89159707|NCT05916417|Sham Comparator|TMS-fNIRS over the dl-PFC (Sham)|TMS-fNIRS dl-PFC data will be acquired with participants being randomized to active or sham stimulation of the dl-PFC, with the randomizing of the order of four different TMS-fNIRS protocols.
89159708|NCT05914948|Other|Subjects implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.|Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
89159709|NCT05911750||Male IBD patients|Male patients with a confirmed diagnosis of Inflammatory Bowel Disease (Crohn´s disease or Ulcerative colitis).
89159710|NCT05899829|Experimental|Rifampin effect on camlipixant pharmacokinetics|
89159711|NCT05899829|Experimental|Rabeprazole effect on camlipixant pharmacokinetics|
89159712|NCT05899153|Experimental|Audiovisual Biofeedback|Participants will complete 12 sessions (20 minutes of walking on a treadmill) over a 6-8 week period while receiving audiovisual biofeedback based on the muscle activity of their ankle plantarflexors. The visual feedback will be provided on a screen with a bar showing real-time muscle activity and the audio feedback will be a sound played when they reach the target level of muscle activity.
89159713|NCT05899153|Experimental|Sensorimotor Biofeedback|Participants will complete 12 sessions (20 minutes of walking on a treadmill) over a 6-8 week period while receiving sensorimotor biofeedback with an ankle exoskeleton that provides resistance to ankle plantarflexion during the stance phase of gait.
89159714|NCT05899153|Experimental|Audiovisual + Sensorimotor Biofeedback|Participants will complete 12 sessions (20 minutes of walking on a treadmill) over a 6-8 week period while receiving both audiovisual and sensorimotor biofeedback. Sensorimotor biofeedback will be provided with an ankle exoskeleton that provides resistance to ankle plantarflexion during the stance phase of gait. The visual feedback will be provided on a screen with a bar showing real-time muscle activity and the audio feedback will be a sound played when they reach the target level of muscle activity from the plantarflexors.
89159715|NCT05896202|Experimental|Transcutaneous Auricular Vagus Nerve stimulation (taVNS) group|This group will receive supplemental videos on taVNS and TMS. Participants will be in this group for approximately 7 hours.
89159716|NCT05896202|Active Comparator|Transcranial Magnetic Stimulation (TMS) group|This group will receive a supplemental video on TMS only. Participants will be in this group for approximately 7 hours.
89159717|NCT05893706||Dual task|A dual-task paradigm is a procedure in experimental neuropsychology that requires an individual to perform two tasks simultaneously, in order to compare performance with single-task conditions.
89159718|NCT05893706||Single task|Single task
89159719|NCT05892094|Experimental|Exercise Group|Participants will participate in a 12-week full-body resistance and aerobic exercise program. It will include full body resistance exercises two days a week and aerobic exercise program three days a week. For aerobic exercise, participants will be asked to do brisk walking 3 days a week. Participants will be called regularly to monitor their participation in the aerobic exercise program. Resistance exercises sessions will be supervised by a physical therapist. Each resistance training session will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. Resistance exercises will consist of weight-bearing exercises performed with the participant's own body weight. Participants in the exercise group will complete the questionnaires at baseline and after 12 weeks at the end of the intervention.
89159720|NCT05892094|No Intervention|Control Group|Participants in the control group were instructed not to change their physical activity habits during 15 weeks and to avoid any other treatment for vasomotor symptoms. Participants in the control group will complete the questionnaires at baseline and after 12 weeks.
89159721|NCT05884320|Experimental|Cohort 1: ACC|Paritcipants will receive sacituzumab govitecan by vein on Days 1 and 8 of each cycle. The first dose will be given over about 3 hours. All other doses will be given over about 1-2 hours. Premedication for prevention of infusion reactions will be administered prior to each sacituzumab govitecan infusion.
89159722|NCT05884320|Experimental|Cohort 2: Non-ACC|Paritcipants will receive sacituzumab govitecan by vein on Days 1 and 8 of each cycle. The first dose will be given over about 3 hours. All other doses will be given over about 1-2 hours. Premedication for prevention of infusion reactions will be administered prior to each sacituzumab govitecan infusion.
89159723|NCT05859074|Experimental|Dose Escalation Group|"MQ710~The dose levels will be escalated following a standard 3+3 dose escalation scheme."
89159724|NCT05859074|Experimental|Dose Expansion Group|"MQ710 + pembrolizumab~Approximately 8 patients will be recruited into the dose expansion group for monotherapy dosing of MQ710. Approximately 12 patients will be recruited for dosing at the MTD/maximally administered dose established in combination with pembrolizumab."
89159726|NCT05846880|Experimental|Lenalidomide + intensified VitD|In this arm, patients will receive the standard lenalidomide dose along with an intensified level of Vitamin D maintenance regimen.
89159727|NCT05846880|Active Comparator|Lenalidomide + therapeutic VitD|In this arm, patients will receive the standard lenalidomide dose along with a therapeutic level of Vitamin D regimen.
89159728|NCT05840965|No Intervention|Asymptomatic flexible flatfoot|This group undergoes no intervention.
89159729|NCT05840965|Experimental|Symptomatic flexible flatfoot: foot core strengthening|"The investigators put together a specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The most recognized exercise of our program is the short foot exercise. However, as recently other exercises were validated by Gooding et al., we also included following exercises: toe spread out, first-toe extension and second- to fifth-toes extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
89159730|NCT05840965|Active Comparator|Symptomatic flexible flatfoot: foot orthotics|"Custom-made foot orthotics are the current standard of care (SOC) therapy within this population. Patients choose their own health care provider to customize these orthotics. The sole is made of EVA material whose color and hardness is determined by the podiatrist or bandage maker. Digital scans or plaster of Paris cast will be taken of the participant's non-weightbearing foot (placed in a neutral or corrected position) by a certified pedorthist following the prescription of the orthopaedic surgeon.~The geometry of the foot orthotic will encompass a total contact principle with respect to the medial arch. The orthotics will be manufactured using ethyl vinyl acetate (EVA) with a shore ranging between 45 and 60"
89159731|NCT05837754|Active Comparator|C8-C12|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP
89159732|NCT05837754|Placebo Comparator|Placebo|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP
89159733|NCT05834049|Experimental|Virtual Parental Presence on Induction of Anesthesia group|Use of Facetime with child and parents during induction
89159734|NCT05834049|Experimental|Midazolam Group|0.5 mg/kg oral midazolam (max 20 mg) will be given preoperatively.
89159735|NCT05821049|Active Comparator|UPI65 (Low Dose)|One capsule to be taken 60 ± 10 mins before bed
89159736|NCT05821049|Active Comparator|UPI65 (High Dose)|One capsule to be taken 60 ± 10 mins before bed
89159737|NCT05821049|Placebo Comparator|Placebo|One capsule to be taken 60 ± 10 mins before bed
89159738|NCT05815368|Experimental|REMO training|REMO training will consist of sEMG-biofeedback exercises provided by REMO device.
89159739|NCT05815368|Active Comparator|Task-Oriented training|Task-Oriented training will consist of task-specific functional exercises
89159740|NCT05813548|Experimental|Treatment|FASTer Way Application-Based Lifestyle Program
89159741|NCT05813548|Active Comparator|Control|General health and dietary guidelines
89159742|NCT05807646|Experimental|Vein ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
89159743|NCT05807646|Active Comparator|Artery ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
89159744|NCT05805410|Experimental|Robotic hippotherapy|For the robotic training group, each subject will be trained for 40 minutes. Specifically, each participant will sit astride on a robotic horse with the force perturbation will be applied in the anterior-posterior direction and up/down direction.
89159745|NCT05805410|Active Comparator|Conventional physical therapy|For the conventional physical therapy group, each subject will be trained for 40 minutes, which will include 10 minutes of stretching, followed by 10 minutes of sitting and 10 minutes of standing balance training, and 10 minutes of treadmill walking.
89159746|NCT05796440|Experimental|LUM-201 (1.6 mg/kg/day)|
89159747|NCT05795855|Experimental|ADEPT|Individuals receiving prenatal care at a practice that was randomized to deliver the ADEPT intervention.
89159748|NCT05795855|No Intervention|Standard of Care|Individuals receiving prenatal care at a practice that was randomized to deliver the standard of care.
89159749|NCT05779735|No Intervention|Group 1 : control|The mode of delivery will be determined by clinical examens (digital examination)
89159750|NCT05779735|Experimental|Group 2 : Transperineal ultrasound measurements of AOP|"The mode of delivery will be determined by clinical examens (digital examination) and ultrasound measurement of the AOP :~vaginal delivery is encouraged if AOP measurement is >120°~cesarean delivery is encouraged if AOP measurement is <= 120°"
89159751|NCT05770505|Experimental|Supervised exercise|
89159752|NCT05770505|No Intervention|Control group|
89159753|NCT05769959|Experimental|Part I Single Participant Cohort RO7515629 Dose Escalation|Participants will receive a fixed dose of RO7515629 intravenously as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
89159754|NCT05769959|Experimental|Part II Multiple Participant Cohort RO7515629 Dose Escalation|Participants will receive RO7515629 intravenously, as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. In case of toxicity, step up dosing (single or double) may be implemented. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
89159755|NCT05769959|Experimental|Part III Multiple Participant Cohort RO7515629 Dose Expansion|Participants with selected solid tumors will receive a selected dose of RO7515629 intravenously as a single agent based on the recommended dose sequence for expansion (RDE) and dosing regimen selected from Part I and Part II. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
89159756|NCT05765903|Active Comparator|Arm 1: Intervention A|"Diagnosis education includes verbal 1:1 patient education by the Transitional Nurse Navigator (TNN) and a folder with Epic printed education and other handouts specific to that disease process.~Follow-up appointment scheduling assistance, including transportation to the follow-up appointment. The Community Health Worker (CHW) or TNN will schedule the appointments for the PCP and other specialists within 1 week when available.~Offer resources in the community post the 1:1 meeting with the patient to meet specific access to care challenges identified for that patient by the TNN or CHW.~Provide weekly follow-up calls for one month by TNN or delegate.~Social Determinants of Health (SDOH) assessment. Screenings by CHW regarding patients' SDOH and documentation in the EHR (Epic) of this SDOH assessment. If a patient demonstrates a need, a CHW will help identify and offer opportunities for the patient."
89159757|NCT05765903|Experimental|"Arm 2: Receives Intervention A and Intervention B"|"Additional educational training using iPads. Education using iPad and/or teach-back components to reinforce the individualized disease and medication specific education. iPads are programmed with patient education from The Patient Channel. This visit will be completed by a TNN.~Focus on readmission risk during Care Transition Rounds. Multi-disciplinary team conducts daily rounds to discuss patient. TNNs share the risk scores for the patients and discuss coordination of the patient receiving interventions and other resources suggested by team members.~Home health care from Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH). Involves home visits to the patient, environmental assessments, and medication reconciliation from a home health nurse. Duration and specifications of home health care depend on the patient's needs. Participants will be assigned based on program eligibility and availability."
89159758|NCT05746572|Experimental|Medicine Session|3,4-methylenedioxymethamphetamine (MDMA) in combination with massed exposure therapy for PTSD
89159759|NCT05743244|Experimental|Abrocitinib|Abrocitinib will be self-administered as 200-milligram (mg) tablet daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
89159760|NCT05743244|Experimental|Ritlecitinib|Ritlecitnib will be self-administered via oral administration as a 100-mg capsule daily for 52 weeks (12 months). The final prepared product is to be labeled to protect the blind.
89159761|NCT05743244|Placebo Comparator|Placebo|200 mg tablet or 100 mg capsule matching either abrocitinib or ritlecitinib will be self-administered via oral administration daily for 52 weeks (12 months). The final product is to be labeled to protect the blind.
89235033|NCT05327777|Experimental|Zero Opioid|No narcotic prescription is provided to patient at discharge
89159762|NCT05738330|Active Comparator|SMaRRT-HD (Symptom Monitoring on Renal Replacement Therapy - Hemodialysis)|Dialysis clinics randomized to SMaRRT-HD will implement the SMaRRT-HD symptom monitoring system. SMaRRT-HD consists of 1) tablet-based symptom reporting using a patient reported outcome measure (PROM) and 2) supported clinician follow-up consisting of symptom alerts, guidances for symptom management, and symptom tracking reports that are shared with patients. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
89159763|NCT05738330|Active Comparator|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
89159764|NCT05737641|Placebo Comparator|water ingestion|Ingestion of 102 mL of fresh water
89159765|NCT05737641|Active Comparator|jelly ingestion|ingestion of 100 gr strawberry jelly
89159766|NCT05726253|Placebo Comparator|Placebo|Randomization to receive either oral placebo or amoxicillin for a standard course (7 days)
89159767|NCT05726253|Active Comparator|Amoxicillin|Randomization to receive either oral amoxicillin or placebo for a standard course (7 days)
89159768|NCT05725954|Experimental|GUT LINK SmartPath|physicians will use the interactive GUT LINK Smartpath tool in virtual hallway platform to guide their care and referral practices
89159769|NCT05725954|No Intervention|control|physicians will provide care and refer as per their usual practices
89159770|NCT05722080|Other|simulator Eyesi - new residents|Eyesi simulator learning curve for new ophthalmology residents
89159771|NCT05722080|Other|simulator Eyesi/sleep deprivation -confirmed residents|See how experienced residents perform after sleep deprivation using the Eyesi simulator
89159772|NCT05713032|Active Comparator|standard voltage group|The Standard voltage group will be given a onetime pulsed radiofrequency (PRF) therapy. All subjects in this group will be given radiofrequency therapy on the dorsal root ganglion using the same tools and procedures by the same operator. Pulsed RF mode of RF generator will be used with following parameters --Temperature 42°C -- Frequency 2 Hertz - Pulse Width 20msec-Amplitude output voltage 45 Volt for Duration of 480sec done in 2 cycles.
89159773|NCT05713032|Active Comparator|high voltage group|The High voltage group will be given a onetime pulsed radiofrequency (PRF) therapy. All subjects in this group will be given radiofrequency therapy on the dorsal root ganglion using the same tools and procedures by the same operator. Pulsed RF mode of RF generator will be used with following parameters --Temperature 42°C -- Frequency 2 Hertz - Pulse Width 20msec-Amplitude output voltage will be gradually increased to reach the highest voltage for each patient (55-75 Volt) for Duration of 480sec done in 2 cycles.
89159774|NCT05712395|Experimental|Non-Ischemic Exercise (NICE) exercise program|Patients will perform supervised treadmill walking for 3 months. Patients randomized to the NICE program will walk intermittently at a slow speed of approximately 1.4 mph for only 2-3 minute bouts that do not elicit claudication pain.
89159775|NCT05712395|Active Comparator|Standard exercise program|Patients will perform supervised treadmill walking for 3 months. Patients randomized to the Standard program will walk intermittently at a speed of approximately two mph to near maximal claudication pain.
89159776|NCT05708547||Atheromatous coronary patients|patients scheduled for coronary artery bypass surgery with extracorporeal circulation
89159777|NCT05708547||Non-atheratomous patients|Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease
89159778|NCT05705518|Experimental|Systane Complete PF (Treatment)|Masked subjects assigned to Arm 1 will use Systane Complete PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
89159779|NCT05705518|Placebo Comparator|Refresh Relieva PF (Control)|Masked subjects assigned to Arm 2 will use Refresh Relieva PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
89159780|NCT05705518|Active Comparator|Refresh Optive Mega-3 PF (Active Comparator 1)|Masked subjects assigned to Arm 3 will use Refresh Optive Mega-3 PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
89159781|NCT05705518|Active Comparator|CVS Health Lubricant Eye Drop (PG 0.6%) (Active Comparator 2)|Masked subjects assigned to Arm 4 will use CVS Health Lubricant Eye Drop (PG 0.6%) artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
89159782|NCT05704205|Experimental|NB-UVB+OTT|8-16 weeks of NB-UVB phototherapy combined with (a minimum of) 3 months of optimal topical therapy
89159783|NCT05704205|Active Comparator|Optimal topical therapy (OTT)|(a minimum of) 3 months of optimal topical therapy
89159784|NCT05702931|Active Comparator|Semaglutide treated group|Oral semaglutide once-daily as add-on to standard-of-care for post-transplant hyperglycaemia
89159785|NCT05702931|Placebo Comparator|Placebo treated group|Oral placebo once-daily as add-on to standard-of-care for post-transplant hyperglycaemia
89159786|NCT05701358|Active Comparator|Physiology-guided Non-Culprit-Lesion (NCL) PCI|Patients randomized to this group will have their physiology assessment using RFR and/or FFR of all qualifying NCLs that were identified prior to randomization. Other validated non-hyperemic physiology ratios (eg. iFR) may only be used when RFR is not available.
89159787|NCT05701358|Other|Angiography-guided NCL PCI|Patients randomized to this group will undergo routine staged PCI of all qualifying NCLs that were identified prior to randomization.
89159788|NCT05696990|Experimental|3/7 RT method|perform interval- type endurance exercise at high intensity and resistance training with the 3/7 method
89159789|NCT05696990|Active Comparator|3X9 RT method|perform interval- type endurance exercise at high intensity and resistance training with the 3X9 method
89159790|NCT05695196|Experimental|direct NMT|swab parent nares then insert swab directly into neonate nares
89159791|NCT05695196|Experimental|indirect NMT|swab parent nares, inoculate swab into saline, instill liquid into neonate nares
89159792|NCT05695196|Placebo Comparator|placebo|instill sterile saline into neonate nares
89235034|NCT05326074|Experimental|Animal assisted therapy cohort|This arm will be the group that is randomized to receiving animal assisted therapy during outpatient office visits.
89235035|NCT05326074|No Intervention|Control therapy cohort|This arm will be the group that will receive the standard outpatient psychiatric treatment without animal therapy.
89159793|NCT05686590|Experimental|Augmented Reality Enhanced Simulation (Treatment group)|Each simulation will have between two and five participants. After consent, demographic data will be collected. Then, a study RA will fit a Magic Leap One (ML1) headsets (Magic Leap Inc., Plantation, FL) to participants. Following a scripted briefing, the instructor will also orient the participants to the ML1 headset for those in that group. After orienting the participant to the use of the headsets, the instructor will remain in a room separate from the participants, who will conduct the scenario outside. This will enable assessment of the feasibility of providing simulation instruction remotely. Prior to starting the scenario, the simulation instructor will conduct an orientation to review the core tenets of effective communication skills during prehospital care.
89159794|NCT05685511|No Intervention|Usual Care|
89159795|NCT05685511|Experimental|Intervention Bundle (Behavioral Activation + Medication Optimization)|"Behavioral activation (BA) will span across 3 months postoperatively & will begin pre-operatively, with sessions approximately every two weeks. After discharge, the behavioral intervention will continue for 10-12 sessions, or out to approximately 3 months postoperatively.~Medications will be reviewed & optimized by a team of interventionists including a psychiatrist, pharmacologist, & pharmacists. While the participant is in-hospital, the interventionist's role will include coordinating with the hospital team to ensure that medication changes that were introduced preoperatively are maintained in-house & that no new inappropriate medications are initiated. After discharge, & up to approximately 3 months postoperatively, the interventionist will ensure that medication changes are reconciled during transitions of care. The interventionists will ensure the agreed-upon changes are implemented, or an alternative course of action is justified."
89159796|NCT05682872|Experimental|Experimental Group|"Experimental group receive multifactorial intervention (based on the GBPC Prevention of Falls and reduction of Injuries derived from falls - RNAO)."
89159797|NCT05682872|Active Comparator|Control Group|Control group receive activities on falls prevention by Primary Care professionals on a care routine.
89159798|NCT05682027||Patients suspected of diaphragm dysfunction|"After inclusion, participants will be evaluated for diaphragm dysfunction with fluoroscopy, as in standard of care. Additionally, during the same hospital visit ultrasound will be performed.~The sonographer and the radiologist assessing the ultrasound and fluoroscopy, respectively, will be blinded to each other's' test results. Further assessment, and possible treatment, for diaphragm dysfunction is performed at the discretion of the treating physician.~The primary outcome is the concordance of diaphragm paralysis as determined by ultrasound compared with the construct for diaphragm paralysis based on traditional measurements."
89159799|NCT05677100|Experimental|Treatment Arm|Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management. Randomization will be stratified by ejection fraction.
89159800|NCT05677100|No Intervention|Control Arm|The Control arm should receive standard of care therapy as per the study directed Diuretic Care Treatment Algorithm.
89159801|NCT05677100|Experimental|Advanced HF Registry|For the Advanced HF registry, all eligible enrolled subjects will receive Aortix system support.
89159802|NCT05670782|Experimental|Part 1a: Cohort 1.1a Dose 400 mg|Healthy older adult participants will receive oral 400 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
89159803|NCT05670782|Experimental|Part 1a: Cohort 1.2a Dose 600 mg|Healthy older adult participants will receive oral 600 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
89159804|NCT05670782|Experimental|Part 1a: Cohort 1.3a Dose 800 mg|Healthy older adult participants will receive oral 800 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
89159805|NCT05670782|Experimental|Part 1b: Cohort 1.1b Dose 200 mg|Participants with Parkinson's disease will receive oral 200 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
89159806|NCT05670782|Experimental|Part 1b: Cohort 1.2b Dose 400 mg|Participants with Parkinson's disease will receive oral 400 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
89159807|NCT05670782|Experimental|Part 1b: Cohort 1.3b Dose 600 mg|Participants with Parkinson's disease will receive oral 600 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
89159808|NCT05670782|Experimental|Part 2: Cohort 2.1 Dose X|Participants with Parkinson's disease will receive oral doses of KM-819 (dose to be determined based on the findings from Part 1) or matching placebo once-daily for 730 days and will be allowed to take study intervention with or without fasting.
89159809|NCT05670782|Experimental|Part 2: Cohort 2.2 Dose Y|Participants with Parkinson's disease will receive oral doses of KM-819 (dose to be determined based on the findings from Part 1) or matching placebo once-daily for 730 days and will be allowed to take study intervention with or without fasting.
89159810|NCT05669989|Experimental|Isatuximab|Participants will receive isatuximab as monotherapy or in a combination regimen, according to the treatment the patient received on the parental protocol
89159811|NCT05663710|Experimental|Cohort 1 (Biopsy)|Participants within 2 weeks of starting the first dose of 177Lu-girentuximab
89159812|NCT05663710|Experimental|Cohort 2 (Biopsy)|Participants within 2 weeks of Cycle 4
89159813|NCT05663710|Experimental|Cohort 3 (Biopsy)|Participants at the time of progression or at 20 months post treatment
89159814|NCT05661617||Czech healthy women tested in normative study|"Czech healthy women aged 20-24 years tested in study called Establishing Czech Norms of Selected Standardized Tests."
89159815|NCT05661617||Czech healthy women (experimental group)|Czech healthy women aged 20-24 years (inclusive) who participated in the research in the period from January 2023.
89159816|NCT05658302||Parkinson's disease|"Diagnosis of idiopathic PD~Surgery at UMN to implant DBS system with directional lead(s) and multiple independent current control IPG is planned as part of routine clinical care~At least 21 years old~Existing or planned 7T brain imagery"
89159817|NCT05646407|Experimental|Exercise training with Fan-to-face|Participants randomized to the fan-to-face group will perform supervised exercise training with a basic, portable fan (Honeywell HT-900 Turbo Force Air Circulator). The fan will be placed to the front of the treadmill with airflow directed toward the area of the face innervated by the second and third branches of the trigeminal nerve. The airflow speed will be chosen by each participant so that it is most comfortable to them. An anemometer will measure the airflow from the fan.
89159818|NCT05646407|No Intervention|Exercise training with no fan|Participants randomized to the no fan group will perform supervised exercise training with no fan. The exercise duration and intensity titration will follow the same format as the experimental group.
89159819|NCT05646355|Experimental|Proactive Screening Outreach|"Participants will receive a letter from their clinic explaining CRC screening options (fecal immunochemical test (FIT) vs colonoscopy) including a FIT kit with completion and return instructions. The letter will also include information for navigation to a screening colonoscopy instead of FIT testing, if deemed to be the participant's preference.~Approximately 10-14 days after mailing the FIT kit, participants who have not completed screening will receive a telephone call (with voice message left) and text message, querying whether the FIT kit was received and reminding the participant to complete the test or request a new kit, if needed.~If the FIT kit has not been submitted after about two weeks from the reminder call/text message, the study team will mail a final letter to the participant on behalf of the clinic, reminding them to complete and return the FIT kit."
89159820|NCT05646355|Active Comparator|Usual Care|Individuals in the usual care group will not be approached or notified of their enrollment in the study.
89159821|NCT05645861|Active Comparator|Augmented - Systolic Blood Pressure (SBP) at 170mmHg +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
89159822|NCT05645861|Active Comparator|Standard - Systolic Blood Pressure (SBP) at 140mmHg +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
89159823|NCT05645718|Experimental|Leukemia CNS1 or 2|Each study block, or cycle, is 28 days. Between every cycle below, Participants will have a 7-day rest period in which no study drug is given.
89159824|NCT05645718|Experimental|Leukemia CNS 3|Each study block, or cycle, is 28 days. Between every cycle below, Participants will have a 7-day rest period in which no study drug is given.
89159825|NCT05609435|Experimental|REASSURE Follow Up care|
89159826|NCT05609435|No Intervention|Usual Follow Up Care|
89159827|NCT05609136|Experimental|Bobath+ Scapular Stabilization Group|In addition to the Bobath approach, which is one of the neurophysiological treatment methods for the upper extremity, 5 sessions a week for 6 weeks, scapular stabilization exercises will be applied to this group for an additional 6 weeks from the beginning of the treatment. Scapular Stabilization Exercises will be performed with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
89159828|NCT05609136|Active Comparator|Bobath Group|The Bobath approach, one of the neurodevelopmental treatment methods for the upper extremities, was applied to all participants included in the study for 6 weeks, 5 sessions per week. Before starting the Bobath exercises, preparation was made with 10 minutes of stretching and upper extremity mobilization. The Bobath approach included functional exercises that patients could perform at home. Bobath program; shoulder flexion, protraction, abduction and extranal rotation; It included extension of the elbow and wrist, extension and opposition of the fingers. After these exercises, task-specific functional upper extremity exercises were performed with or without an object that could help the treatment. These tasks are; required reaching, grasping, or lifting objects such as a cup, pen, cylindrical box, etc., in different body positions. Each session lasted for 1 hour and at the end of each session, patients were given a home exercise program.
89159829|NCT05603195|Experimental|Cohort 1 Lowest IV Dose|Randomized 3:1
89159830|NCT05603195|Experimental|Cohort 2 Low IV Dose|Randomized 3:1
89159831|NCT05603195|Experimental|Cohort 3 Mid IV Dose|Randomized 3:1
89159832|NCT05603195|Experimental|Cohort 4 High IV Dose|Randomized 3:1
89159833|NCT05603195|Experimental|Cohort 5 Higher IV Dose|Randomized 3:1
89159834|NCT05603195|Experimental|Cohort 6 High SC Dose|Randomized 3:1
89159835|NCT05603195|Experimental|Cohort 7 Higher SC Dose|Randomized 3:1
89159836|NCT05603195|Experimental|Optional: Cohort 8 Highest IV or SC Dose|Randomized 3:1
89159837|NCT05603195|Experimental|Cohort 9 High SC Dose|Randomized 3:1
89159838|NCT05603195|Experimental|Optional: Cohort 10 Highest SC Dose|Randomized 3:1
89159839|NCT05600777|Experimental|BLU-5937 25 mg|BLU-5937 oral dose 25 mg twice a day.
89159840|NCT05600777|Experimental|BLU-5937 50 mg|BLU-5937 oral dose 50 mg twice a day.
89159841|NCT05600777|Placebo Comparator|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
89159842|NCT05599620|Experimental|AWARE Program|The AWARE program addresses alcohol use, sexual distress and sexual revictimization risk.
89159843|NCT05599620|Placebo Comparator|General Health Promotion|The General Health Promotion program is a attention and dose-matched comparison condition.
89159844|NCT05599438||Current users anabolic steroids|Current users of anabolic steroids with a use of more than 4 weeks
89159845|NCT05599438||Former users of anabolic steroids|Former users of anabolic steroids with a use of more than 4 weeks
89159846|NCT05599438||Healthy controls|"100 participants with no former use of anabolic steroids~80 Male~20 Female"
89159847|NCT05599191|Experimental|BLU-5937 25 mg|BLU-5937 oral dose 25 mg twice a day.
89159848|NCT05599191|Experimental|BLU-5937 50 mg|BLU-5937 oral dose 50 mg twice a day.
89159849|NCT05599191|Placebo Comparator|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
89159850|NCT05590624|Experimental|Mediterranean-type Diet(s)-Arm 1|Diet randomization occurs two weeks prior to the Standard of Care (SOC) diagnostic biopsy. If patient is randomized to Arm 1, they will receive Low Fat (LF) Mediterranean Diet first. The results of the diagnostic biopsy determines how the patient will proceed on the trial. If there is a confirmed Prostate Cancer (PCa) diagnosis AND is a candidate for Active Surveillance (AS) per SOC, then patient will undergo a washout period and cross-over to the Lower Carbohydrate (LC) Mediterranean Diet two weeks prior to the SOC confirmatory biopsy. A long-term follow-up (LTFU) visit will occur 3 months after the second dietary intervention has concluded. If patient does not have PCa or is not placed on AS, then they will only have the first dietary intervention and a LTFU visit 3 months after
89159851|NCT05590624|Experimental|Mediterranean-type Diet(s)-Arm 2|Diet randomization occurs two weeks prior to the Standard of Care (SOC) diagnostic biopsy. If patient is randomized to Arm 2, they will receive Lower Carbohydrate (LC) Mediterranean Diet first. The results of the diagnostic biopsy determines how the patient will proceed on the trial. If there is a confirmed Prostate Cancer (PCa) diagnosis AND is a candidate for Active Surveillance (AS) per SOC, then patient will undergo a washout period and cross-over to the Low Fat (LF) Mediterranean Diet two weeks prior to the SOC confirmatory biopsy. A long-term follow-up (LTFU) visit will occur 3 months after the second dietary intervention has concluded. If patient does not have PCa or is not placed on AS, then they will only have the first dietary intervention and a LTFU visit 3 months after.
89159852|NCT05589896|Experimental|Cohort 1|"Bone Marrow Transplant with Ossium HPC, Marrow~Pre-transplant myeloablative conditioning treatment with: Regimen A(MAC): Busulfan and Fludarabine [OR] Regimen B(MAC): Fludarabine and Total Body Irradiation~Post-Transplant treatment with Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, and Filgrastim"
89159853|NCT05589896|Experimental|Cohort 2|"*Open to enrollment after DSMB review of Cohort 1 safety events through Day 56*~Bone Marrow Transplant with Ossium HPC, Marrow~Pre-transplant conditioning treatment with:Regimen A(MAC): Busulfan and Fludarabine [OR] Regimen B(MAC): Fludarabine and Total Body Irradiation [OR] Regimen C(RIC): Fludarabine, Cyclophosphamide, and Total Body Irradiation~Post-Transplant treatment with Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, and Filgrastim"
89159854|NCT05584046|Experimental|CDAM group|Patients receive the CDAM patch and a standard home stretching exercise program
89159855|NCT05584046|No Intervention|Untreated group|Patients receive a standard home stretching exercise program
89159856|NCT05564936|Experimental|MG patients|MG patients will perform 3 in-clinic visits and use the ME&MG app at-home during 12 months
89159857|NCT05564936|Other|Healthy volunteers|Healthy volunteers will perform one in-clinic visit and will use the app at-home once
89159858|NCT05563649|Experimental|Online Guided Self-Help-Family-based Treatment (GSH-FBT)|"GSH-FBT consists of 10 20-minute parent-only sessions over 9 months. The guidance portion is manualized and will be delivered by a clinician familiar with both the online modules and FBT, who acts as a coach. Sessions follow an online curriculum containing a total of 65 short videos. Each lecture series is comprised of a written introduction orienting the viewer to the videos, 5-9 short videos (< 7 minutes each), and assigned reading from the parent education manual, Help Your Teenager Beat an Eating Disorder. In line with GSH approaches, coaches direct parents to watch or re-watch specific videos contained in the online platform related to their questions."
89159859|NCT05563649|Active Comparator|FBT via Videoconferencing (FBT-V)|15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
89159860|NCT05562947|Experimental|Implant arm|Participants will have the implant (pre-filled intraoperatively with ranibizumab 100 mg/mL) surgically inserted on Day 1. After Day 1, patients in the implant arm will attend monthly study visits, and receive implant refill-exchanges with ranibizumab 100 mg/mL at Week 24 and Week 48. At the Week 48 study visit, patients will move to the long term extension phase of the study and continue receiving refill-exchanges Q24W until the end of study. Patients will attend monthly visits up to Week 96 and bi-monthly visits, thereafter
89159861|NCT05562947|Experimental|Intravitreal arm|Participants will receive intravitreal ranibizumab 0.5 mg injections starting on Day 1. Patients will receive intravitreal ranibizumab 0.5 mg Q4W until Week 44. At the Week 48 study visit, patients will receive the PDS implant (pre-filled intraoperatively with ranibizumab 100 mg/mL), move to the long-term extension phase of the study and receive Q24W refill exchanges until the end of study. If patients are unable to attend the Week 48 visit due to extenuating circumstances, they should return no later than the next scheduled visit (Week 52), when they will receive the PDS implant. Patients will attend monthly visits up to Week 96 and bi-monthly visits, thereafter.
89159862|NCT05562557|No Intervention|Services as Usual|Randomly assigned to receive services as usual
89159863|NCT05562557|Experimental|Enhanced Fatherhood Services through Regional Partnership Grant Round 7 (RPG7)|Randomly assigned to receive enhanced RPG7 services (motivational enhancement, fatherhood engagement services, contingency management, case management)
89159864|NCT05557695||Group 1|Patients with chronic lymphocytic leukaemia treated with acalabrutinib in first line
89159865|NCT05547620|Experimental|Low Intensity Focused ultrasound|NeuroFUS device stimulation with 4 channel transducer Stimulation target = Cerebellum
89159866|NCT05544708|Experimental|Intervention|Wellness Ambassadors will undergo training to recruit and deliver a lifestyle intervention to members of their social networks. HCL in the intervention group will deliver the intervention immediately following baseline visits and randomization.
89159867|NCT05544708|No Intervention|Delayed Intervention|Wellness Ambassadors will undergo training to recruit and deliver a lifestyle intervention to members of their social networks. HCL in the delayed intervention group will deliver the intervention after 24 week data collection visits are complete.
89159868|NCT05531513|Experimental|Virtual Reality (VR) Meditation|The VR Meditation intervention will be administered in Arm 1.
89159869|NCT05531513|Active Comparator|Psychoeducational Pamphlets|The Psychoeducation Pamphlet intervention will be administered in Arm 2.
89159870|NCT05530343|Other|Seattle protocol, then WATS3D brushings.|Participants in the screening or surveillance population that receive the Seattle protocol, then WATS3D brushings, during the same procedure.
89159871|NCT05530343|Other|WATS3D brushings, then Seattle Protocol.|Participants in the screening or surveillance population that receive the WATS3D brushings, then the Seattle protocol, during the same procedure.
89159872|NCT05527548|Experimental|ALN group|Patients receive weekly dose of 70mg of ALN and a standard rehabilitation program
89159873|NCT05527548|No Intervention|Untreated group|Patients receive a standard rehabilitation program
89159874|NCT05523440|Active Comparator|Arm 1: Niraparib|Niraparib (200mg or 300 mg based on body weight and blood platelet count), oral, once daily.
89159875|NCT05523440|Experimental|Arm 2: Niraparib and Bevacizumab|Niraparib (200mg or 300 mg based on body weight and blood platelet count), oral, once daily. Bevacizumab (15 mg/kg, IV on day 1 of each cycle).
89159876|NCT05507528|Experimental|Reborn treatment group|The Lightfective ReBorn System is a Diode Light Emitting Diode (LED) System, Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
89159877|NCT05503264|Experimental|NMDAR autoimmune encephalitis (AIE) cohort|Adults and adolescents with definite or probable NMDAR encephalitis
89159878|NCT05503264|Experimental|LGI1 AIE cohort|Adults with LGI1 encephalitis
89159879|NCT05503264|Placebo Comparator|NMDAR autoimmune encephalitis (AIE) Placebo cohort|Adults and adolescents with definite or probable NMDAR encephalitis
89159880|NCT05503264|Placebo Comparator|LGI1 AIE Placebo cohort|Adults with LGI1 encephalitis
89159881|NCT05500092|Active Comparator|Nivolumab + Platinum Doublet Chemotherapy|All participants will receive platinum-based doublet chemotherapy (PDC) along with nivolumab for 3 cycles every 3 weeks. Carboplatinum (AUC=5) can be used instead of Cisplatin (75 mg/m2) from cycle 2 for Cisplatin induced neuro/oto/nephrotoxicity as long as the subject remains eligible for doublet chemotherapy. Participants with nonsquamous tumors will receive pemetrexed (500 mg/m2). Participants with squamous tumors will receive either docetaxel (75 mg/m2 on day 1) or gemcitabine (1000 mg/m2 on days 1, 8). Cycles will be every 3 weeks and a maximum of a 2 week delay will be permitted for resolution of toxicities.
89159882|NCT05500092|Experimental|Nivolumab + Platinum Doublet Chemotherapy + SBRT (8gy x 3)|SBRT will be delivered near the conclusion of cycle 1 with platinum-based doublet chemotherapy (PDC) along with nivolumab for 3 cycles every 3 weeks. The intent is to deliver SBRT on three consecutive days when the concentration of radiosensitizing chemotherapy agents in the subject's system is at a minimum, to minimize toxicity risks. It is expected that some subjects may not receive SBRT on three consecutive days due to machine breakdown, inclement weather, or other logistic issues. Subjects must not receive SBRT within 72 hours after a cisplatin or carboplatin infusion
89159883|NCT05496881|Experimental|Exercise Group 1|The intervention will focus on mobility and balance.
89159884|NCT05496881|Active Comparator|Exercise Group 2|This intervention will focus on physical fitness.
89159885|NCT05496881|Sham Comparator|Exercise Group 3|This intervention will focus on flexibility, range of motion, and muscle tone.
89159886|NCT05470478|Experimental|Evaluation of an enhanced iBCI|Performance of new decoding algorithms and methods will be developed and embedded in a small, mobile neural processor. The utility of these will be assessed separately with participants in the BrainGate pilot clinical trial, IDE.
89159887|NCT05469698|Other|Standard Care|All participants will receive standard care by the Tobacco Treatment Research Program. This includes nicotine replacement therapy such as patches, gum, or lozenges, counseling by a Tobacco Treatment Specialist, and complete questionnaires.
89159888|NCT05464823|Other|Molecular Testing|Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
89159889|NCT05456503|Experimental|Cognitively and neurologically normal seniors (CN)|One PET imaging scan using the PI-2620 tracer
89159890|NCT05456503|Experimental|Non-amnestic Alzheimer's Disease (AD)|One PET imaging scan using the PI-2620 tracer
89159891|NCT05456503|Experimental|Frontotemporal lobar degeneration from tauopathy (FLTD-tau)|One PET imaging scan using the PI-2620 tracer
89159892|NCT05456503|Experimental|Frontotemporal lobar degeneration from TDP-43 (FLTD-TDP)|One PET imaging scan using the PI-2620 tracer
89159893|NCT05456503|Experimental|Frontotemporal lobar degeneration from mutation in the MAPT gene (genetic FLTD-tau)|One PET imaging scan using the PI-2620 tracer
89159894|NCT05456503|Experimental|Frontotemporal lobar degeneration from mutation in the GRN gene or frame 72 of chromosome 9|One PET imaging scan using the PI-2620 tracer
89159895|NCT05456503|Experimental|Amnestic Mild Cognitive Impairment Alzheimer's Disease (MCI/aAD)|One PET imaging scan using the PI-2620 tracer
89159896|NCT05443126|Experimental|RET fusion-positive NSCLC|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
89159897|NCT05443126|Experimental|RET mutation-positive MTC|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
89159898|NCT05443126|Experimental|Other RET-altered solid tumours|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
89159899|NCT05443126|Experimental|RET fusion-positive NSCLC (no prior SRI therapy)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
89159900|NCT05443126|Experimental|RET mutation-positive MTC (no prior SRI therapy)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
89159901|NCT05443126|Experimental|Other RET-altered solid tumours (no prior SRI therapy)|EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
89159902|NCT05442697|Experimental|Knee OA KL Grade2 PEMF Treatment|Patients with knee OA grade 2 will accept PEMF treatment
89159903|NCT05442697|Placebo Comparator|Knee OA KL Grade2 Placebo Treatment|Patients with knee OA grade 2 will accept placebo treatment
89159904|NCT05442697|Experimental|Knee OA KL Grade3 PEMF treatment|Patients with knee OA grade 3 will accept PEMF treatment
89159905|NCT05442697|Placebo Comparator|Knee OA KL Grade3 Placebo Treatment|Patients with knee OA grade 3 will accept placebo treatment
89159908|NCT05418634||Pediatric Emergency Department (PED)|"PED: Patients presenting with unexplained impaired consciousness or active SE:~To investigate the role of pocEEG in the PED, we will collect all pocEEG tracings of all children with unexplained impaired consciousness or active SE, for whom written consent has been obtained. We will document the interpretation of the respective pocEEGs by the PEM physician and compare it to the interpretation of the neuropediatrician on call. The research team will also perform a post-hoc analysis."
89159909|NCT05418634||Epilepsy Clinic|CLINIC: Patients with either suspected epilepsy or established diagnosis of epilepsy will be recruited for simultaneous recording of cEEG and pocEEG in the epilepsy outpatient clinic will help define and investigate the limitations of pocEEG.
89159910|NCT05417802||Stroke with acute stroke|"Inclusion criteria~Episode of single stroke within the past twelve weeks~Individuals' age over 18 years old.~Exclusion criteria~Pregnant women , neurological disorders other than stroke (i.e. Parkinson's), non-ischemic stroke~Individuals with severe cognitive impairments (demonstrating difficulty to understand, read, and answer the questions in writing)~Individuals with difficulties to listen the instruction and video of the robotic device"
89159911|NCT05408871|Experimental|Head and neck cancer|Participants with head and neck squamous cell carcinoma who plan to undergo tumor resection and lymph node resection.
89159912|NCT05408871|Experimental|Brain Metastases|Participants with metastases to the brain from melanoma, lung cancer, breast cancer.
89159913|NCT05407623|Experimental|PAX Good Behavior Game|PAX Good Behavior Game (GBG) is based on its precursor programme Good Behavior Game (GBG) that trains teachers to use principles of social learning in order to maximize the childrens' task-oriented and prosocial behaviors and minimize the occurrence of disruptive and off-task behaviors.
89159914|NCT05407623|Active Comparator|Active control (choice between on of two active interventions)|"[The project has two alternative control interventions for the schools to choose between, in order to increase their engagement in the control intervention. They are hence only provided with one of these interventions, not both.]~Count On Me! is an adaptive application teaching fluency in addition and subtraction facts (i.e., math facts), equality, compose and decompose numbers and a few more basic mathematical skills taught in the first grades of schooling.~Collegial earning is based on five cyclical steps for professional learning for teachers."
89159915|NCT05403151||1|Healthy Adults
89159916|NCT05381103|Experimental|PSMA-PET and SOC MRI prior to surgery|
89159917|NCT05381103|Active Comparator|SOC MRI prior to surgery|
89159918|NCT05380037||Veterans with chronic stroke|Veterans with chronic stroke (n=50) must 1) have ischemic or hemorrhagic stroke, primary intracerebral hematoma, or subarachnoid hemorrhage with at least 6 month chronicity; 2) demonstrate ability to perform the interview and complete questionnaires and 3) endorse mild to severe psychosocial impairment
89159919|NCT05380037||Caregiver/Loved ones|Caregiver/Loved ones (n=25) must be familiar with the trajectory of function and recovery of the identified Veteran with chronic stroke
89159920|NCT05380037||Rehabilitation providers|Rehabilitation providers (n=25) of Veterans with chronic stroke must provide stroke-related care in the VA Healthcare system including (but not limited to) physical, speech, and occupational therapists, neurologists, and neuropsychologists
89159921|NCT05378763|Experimental|Poziotinib 8 mg|Participants will receive poziotinib 8 mg, orally, BID, in 21 day cycles or until disease progression, death, intolerable adverse events (AEs), initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons for participant withdrawal from the study.
89159922|NCT05378763|Active Comparator|Docetaxel 75 mg/m^2|Participants will receive docetaxel 75 mg/m^2, intravenously (IV) on Day 1 of each 21-day treatment cycle or until disease progression, death, intolerable AEs, initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons for participant withdrawal from the study.
89159923|NCT05369429|Experimental|Intervention|The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
89159924|NCT05369429|No Intervention|Control|The control application will provide links to helpful resources for patients with cancer, such as the contact information for cancer support services at Northwestern University and the University of Miami, and the link to the National Cancer Institute website, and the American Cancer Society website. Control participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
89159925|NCT05356871||Healthy participants|Healthy men and women within the age of 18 and 75 yrs.
89159926|NCT05354024|Experimental|NDV-HXP-S 10μg (Phase II)|In the Phase III, 200 adult subjects will be assigned to receive NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety and immunogenicity.
89159927|NCT05354024|Active Comparator|BNT162b2 30μg (Phase II)|In the Phase III, 200 adult subjects will be assigned to receive vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety and immunogenicity.
89159928|NCT05354024|Experimental|NDV-HXP-S 10μg batch 1 (Phase III)|In the Phase III, 1000 adult subjects will be assigned to receive the first consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
89159929|NCT05354024|Experimental|NDV-HXP-S 10μg batch 2 (Phase III)|In the Phase III, 1000 adult subjects will be assigned to receive the second consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
89159930|NCT05354024|Experimental|NDV-HXP-S 10μg batch 3 (Phase III)|In the Phase III, 1000 adult subjects will be assigned to receive the third consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
89159931|NCT05354024|Active Comparator|BNT162b2 30μg (Phase III)|In the Phase III, 1000 adult subjects will be assigned to receive the vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity only.
89159932|NCT05350137|Active Comparator|Group A: 100% oxygen|After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen.
89159933|NCT05350137|Experimental|Group B: Carbon dioxide|After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide.
89159934|NCT05349292||Acute Normovolemic Hemodilution|Patients undergoing CABG surgery with acute normovolemic hemodilution and autologous blood donation
89159935|NCT05349292||non Acute Normovolemic Hemodilution|Patients undergoing CABG surgery without acute normovolemic hemodilution and autologous blood donation
89159936|NCT05346575|Active Comparator|Usual Care|Participants randomized to this arm will receive the usual obesity care, but will complete assessments every 6 months.
89159937|NCT05346575|Experimental|TOTAL intervention|Participants randomized to this arm will watch the TOTAL intervention video and participate in 1:1 motivational sessions every 6 months. Participants will also complete assessments every 6 months.
89159938|NCT05345496||WORKERS GROUP|44 physiotherapists with a history of at least 1 painful episode of work-related thumb pain in the last 3 months will be enrolled.
89159939|NCT05345496||STUDENT GROUP|44 physiotherapy students in their first academic year will be enrolled.
89159940|NCT05335616|Experimental|"Intervention Guideline"|Participants are given written information (a hypothetical new guideline).
89159941|NCT05335616|Experimental|"Intervention Treatment fee item"|Participants are given written information about a hypothetical new treatment fee item.
89159942|NCT05332223||Chronic Heart Failure Patients|All patients in our specialised heart failure clinic will be screened by the investigator/s.
89159943|NCT05321628|Experimental|iCBT + Decision Support Tool|Internet-based Cognitive Behavioural Therapy where therapists have traditional clinical routines and supervision and also use a clinical decision support tool.
89159944|NCT05321628|Active Comparator|Traditional iCBT|Internet-based Cognitive Behavioural Therapy with traditional clinical routines and supervision.
89159945|NCT05319561|Experimental|VAST+|Sites that implement the VAST augmented by quarterly facility-level Antibiotic Use Reports (VAST+).
89159946|NCT05319561|No Intervention|VAST -|to sites that implement the VAST and do NOT receive a quarterly facility-level Antibiotic Use Reports (VAST-).
89159947|NCT05300126|Experimental|Usual care|No hypnosis session are proposed
89159948|NCT05299944|Active Comparator|Full-spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing less than 0.3%THC.
89159949|NCT05299944|Active Comparator|Broad-spectrum Cannabidiol|210mg/day of broad-spectrum cannabidiol, containing 0%THC.
89159950|NCT05299944|Placebo Comparator|Hemp Seed Oil Placebo|210mg/day of hemp-seed oil with no cannabinoids present.
89159951|NCT05286749|Active Comparator|Control|Participants take a workshop where they are provided education on standard-of-care for cervical cancer screening such as pap smear and HPV testing through clinician-collection methods using speculum and cervical swabs.
89159952|NCT05286749|Experimental|Intervention|Participants take a workshop where they are provided all the same education as control as well as additional education on self-collection for HPV-only testing using vaginal swab as an additional method.
89159953|NCT05284825|Experimental|12 Gy in 6 daily fractions|
89159954|NCT05280197|Experimental|liposomal bupivacaine plus free bupivacaine|
89159955|NCT05280197|Placebo Comparator|normal saline|
89159956|NCT05279690|Experimental|Cohort 1 low-dose colchicine|Participants with advanced/recurrent solid tumors who will receive low-dose colchicine (0.6 mg oral BID)
89159957|NCT05279690|Experimental|Cohort 1 high-dose colchicine|Participants with metastatic solid tumors who will receive high-dose colchicine (0.6 mg oral TID)
89159958|NCT05279690|Experimental|Cohort 2 Participants with post-radical surgery|Participants with post-radical surgery for high-risk clinically localized urothelial cancer will receive colchicine 0.6 mg oral BID.
89159959|NCT05275075||Pancreatic Cancer Cohort|All eligible adenocarcinoma pancreatic cancer patients with operable cancer.
89159960|NCT05273164|Experimental|Perceptual Discrimination Training|Training will involve Gabor patch and other visual stimuli discrimination exercises that focus on improving signal-to-noise resolution and attentional control with minimal working memory/cognitive control effects. On each training trial, participants are required to distinguish a target stimulus among a set of distractor stimuli. The similarity between target and distractors increases in level of difficulty based on an adaptive perceptual processing staircase function. Consecutive correct responses lead to increased modulation of the distractors to be more similar to the target, while 1 incorrect response drops the user to an easier level. Difficulty is adapted to maintain an 80% correct response rate. Each session will consist of 4 exercises requiring ~45 minutes. with 40 trials for each exercise.
89159961|NCT05273164|Active Comparator|Cognitive Control Training|"Training will involve maintaining accurate representations of cognitive context (the rule) in working memory during response selection. On each training trial, participants must observe stimuli, and hold the correct response context on-line in order to select the correct response from among the stimuli. Training is adaptive using a staircase function, such that two consecutive correct responses increases either the speed of stimuli presentation or the working memory load via an increased number of stimuli that are presented; one incorrect response reduces the cognitive load. Each session will consist of 45 exercises requiring ~45 minutes."
89159962|NCT05262205|Active Comparator|sevoflurane group with BIS monitor for depth of anesthesia|child will be anesthetized with sevoflurane 2% and atracurium 0.25mg/kg and paracetamol 15mg/kg, then bispectral index will be recorded after intubation and every five minutes till end of surgery. Position of the globe will recorded every five minutes. Angle of deviation of the globe will be calculated via withdrawing horizontal line passing from the lateral and medial canthi, and another vertical one passing the medial canthus(90-0--90 degree). Bis should be 40-65 to ensure adequate depth of anesthesia. If more than 65 or less than 40, sevoflurane concentration will be adjusted till having the target range. pupillary dilation in surgical eye will be assessed after speculum insertion, 20 minutes after speculum insertion, and before speculum removal by pupil ruler((pupil gauge), whether it will be maintained or not (considered maintained if pupil size equal or more than 5mm).
89159963|NCT05262205|Active Comparator|propofol-midazolam group with BIS monitor for depth of anesthesia|Child will be anesthetized with midazolam 0.05 mg/kg IV bolus and propofol 1mg/kg IV bolus, paracetamol 15mg\kg IV infusion, and atracurium 0.25mg/kg IV bolus ,then anesthesia will be maintained with propofol infusion according to Mcfarlan protocol, then BIS will be recorded after intubation and every five minutes till end of surgery. Position of the globe will recorded every five minutes till the end of surgery. Angle of deviation will be calculated in same way as group A. Bis should be 40-65. If more than 65 or less than 40, sevoflurane concentration will be adjusted till having the target range. pupillary dilation in surgical eye will be assessed after speculum insertion, 20 minutes after speculum insertion, and before speculum removal by pupil ruler((pupil gauge) and will be observed all over the surgery with the help of surgeon feedback whether it will be maintained or not (considered maintained if pupil size equal or more than 5mm).
89159964|NCT05259137|No Intervention|Intra-lesional triamcinolone acetonide|This arm will will be our control. They will receive current standard of care of a single intra-lesional injection of 1 mL of 10mg/mL triamcinolone acetonide at 0 weeks, 6 weeks, and 12 weeks.
89159965|NCT05259137|Experimental|Intra-lesional triamcinolone acetonide + enalaprilat|This will be our intervention experiment. They will receive a single intra-lesional injection of 1.0 mL of 1.25 mg/mL of enalaprilat at 0 weeks, 6 weeks, and 12 weeks.
89159966|NCT05249907|No Intervention|Control|No application will be made this group
89159967|NCT05249907|Experimental|VIBRATION GROUP|Vibration will be applied this group.
89159968|NCT05249907|Experimental|MASSAGE GROUP|Massage will be applied this group.
89159969|NCT05224778||Congenital Myotonic Dystrophy (CDM)|CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
89159970|NCT05224778||Childhood Myotonic Dystrophy (ChDM)|ChDM group includes those aged 1 to 4 years, 11 months at enrollment. Individuals must have a diagnosis of ChDM, which is defined as symptoms associated with DM1, absence of symptoms at birth, and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
89159971|NCT05224609|Experimental|Cohort 1|Moderate hepatic impairment group
89159972|NCT05224609|Experimental|Cohort 2|Severe hepatic impairment group
89159973|NCT05224609|Experimental|Cohort 3|Normal hepatic function
89159974|NCT05215574|Experimental|NGM831 Monotherapy Dose Escalation|Part 1a Single Agent Dose Escalation
89159975|NCT05215574|Experimental|NGM831 combination dose finding with pembrolizumab (KEYTRUDA®)|Part 1b NGM831 plus pembrolizumab (KEYTRUDA®)
89159976|NCT05215574|Experimental|NGM831 and NGM438 Combination Dose Finding with pembrolizumab (KEYTRUDA®)|Part 1c NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
89159977|NCT05210998|Active Comparator|grup 1:|"Combined Exercise Group:~Gradual aerobic exercise training AND Respiratory muscle training"
89159978|NCT05210998|Active Comparator|grup 2:|"Aerobic Exercise Group:~Gradual Aerobic exercise training"
89159979|NCT05209789|Experimental|HUGS therapy|A structured group intervention that aims to observe mother's behavior and responses with her baby, promote mother-baby interaction through play, and provide tools for positive interaction. This therapy involves cognitive and behavioral work. Therapists observe the mother-baby duo and share their observations from a perspective of encouragement and support. A playful and non-judgmental interaction is cultivated within the group. The main objective is to change the negative trajectory of mother-child interactions through tools from cognitive-behavioral therapies as well as using knowledge about child development.
89159980|NCT05209789|Active Comparator|Playtime|The participants assigned to the control group will also be in the presence of two therapists, allowing to reproduce the framework of the HUGS therapy. The difference will be the lack of direct therapeutic intervention from the therapists, but only classic psychoeducational guidance. The mothers are offered a time to play with their baby as well as the opportunity to discuss and share their experiences with other mothers, which is generally seen as supportive by them.
89159981|NCT05205837|Placebo Comparator|Active Comparator - placebo|Intervention: Intramuscular injection - placebo Intervention: Drug: placebo
89159982|NCT05205837|Active Comparator|Active comparator - treatment|Intervention: intramuscular injection - hCG Intervention: Drug: Letrozole
89159983|NCT05199701|Other|Screening Subjects|Screening Subjects
89159984|NCT05199701|Other|Subjects recommended for biopsy|Subjects recommended for biopsy
89159985|NCT05179759|Experimental|Tealeaf - Year 1: Clusters (schools) and associated participants assigned to sequence 1|Clusters (schools) and associated participants assigned to sequence 1 will be under the EUC condition in the 1st year of trial participation and under the Tealeaf condition in all subsequent years.
89159986|NCT05179759|Active Comparator|Enhanced Usual Care - Year 1: Clusters (schools) and associated participants assigned to sequence 2|Clusters (schools) and associated participants assigned to sequence 2 will be under the EUC condition in the 1st and 2nd year of trial participation and under the Tealeaf condition in all subsequent years.
89159987|NCT05179759|Experimental|Tealeaf - Year 2: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
89159988|NCT05179759|Active Comparator|Enhanced Usual Care - Year 2: Clusters (schools) and associated participants assigned to sequence 2|EUC (control arm)
89159989|NCT05179759|Experimental|Tealeaf - Year 3: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
89159990|NCT05179759|Active Comparator|Enhanced Usual Care - Year 3: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
89159991|NCT05179759|Experimental|Tealeaf - Year 4: Clusters (schools) and associated participants assigned to sequence 1|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
89159992|NCT05179759|Active Comparator|Enhanced Usual Care - Year 4: Clusters (schools) and associated participants assigned to sequence 2|Active intervention: Behavioral: Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
89159993|NCT05163665|Experimental|Through-the-Scope clip group|Through the scope Dual Action Tissue Clip (DAT) clipping equipment and technique performed in closure of GI defect area after polyp removal.
89159994|NCT05163665|Active Comparator|X-Tack suturing group|Use of Endoscopic Helix Tacking System (X-Tack) by Apollo Endosurgery for the closure of GI defect after polyp removal.
89159995|NCT05160480|Experimental|Total-body PET scan|All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.
89159996|NCT05156385|Experimental|Hypertensive women|
89159997|NCT05153759|Active Comparator|High protein|Consuming a meal composed of 2:1 grams of protein to carbohydrate during the night shift between 7pm-7am
89159998|NCT05153759|Placebo Comparator|Moderate protein|Consuming a meal composed of 1:1 grams of protein to carbohydrate during the night shift between 7pm-7am
89159999|NCT05141214|Active Comparator|Dietary Consult with Virtual Reality (intervention)|Those in the VR group will receive the same educational dietary review by the registered dietician, and additionally participate in a VR experience through an application called Chaos Café. In Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
89160000|NCT05141214|No Intervention|Dietary Consult without Virtual Reality (SOC)|Those in the SOC group will have the typical appointment, which includes a review of healthy diet choices with a registered dietitian and follow up according to clinic's SOC.
89160001|NCT05141032||Research Subject|Only one group will be made which will contain all subjects recruited into research study.
89160002|NCT05139225|Experimental|TTI-622 dosing will occur over 8 weeks + Daratumumab Hyaluronidase-fihj|TTI-622 will be administered weekly at the assigned dose levels per the ramp-up schedule. Daratumumab hyaluronidase-fihj 1800 mg will administered on a standard schedule consisting of weekly administration for 8 weeks, every other week administration for 16 weeks, followed by every 4-week administration thereafter.
89160003|NCT05139225|Experimental|TTI-622 dosing will occur over 4 weeks + Daratumumab Hyaluronidase-fihj|TTI-622 will be administered weekly at the assigned dose levels per the ramp-up schedule. Daratumumab hyaluronidase-fihj 1800 mg will administered on a standard schedule consisting of weekly administration for 8 weeks, every other week administration for 16 weeks, followed by every 4-week administration thereafter.
89160004|NCT05132504|Experimental|Neoadjuvant Folfirinox and Pembrolizumab followed by sx for patients with pancreatic cancer|Patients will receive 6 cycles of Folfirinox (Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2,400 mg/m2) with 2 cycles of Pembrolizumab 400 mg before surgical resection. Following surgery patients will receive 5-Fluorouracil based chemotherapy for up to 6 cycles with 7 more cycles of Pembrolizumab. Patients will receive a total of 9 doses of Q6week cycles of Pembrolizumab.
89160005|NCT05130151|Experimental|Intervention|Participants in this arm will receive the mobile phone-based intervention.
89160006|NCT05130151|No Intervention|Standard of care|Participants in this arm will receive only standard of care.
89160007|NCT05129696|No Intervention|Control (C): Status quo health and nutrition program|
89160008|NCT05129696|Experimental|Treatment (T): adaption of Reach Up and Learn home visiting program to a group setting|
89160009|NCT05129696|Experimental|Treatment + (T+): Enhanced play materials/activities package|
89160010|NCT05123703|Experimental|Ocrelizumab|Participants will receive Ocrelizumab by IV infusion every 24 weeks. The first dose is given as dual infusions of half the dose of ocrelizumab on Days 1 and 15 and subsequent doses are given as single infusions of ocrelizumab every 24 weeks. Participants will also receive a placebo of fingolimod (administered as QD capsule).
89160011|NCT05123703|Active Comparator|Fingolimod|Participants will receive Fingolimod PO QD as per the prescribing information provided with fingolimod. Patients will also receive a placebo of ocrelizumab (administered as IV infusions on Days 1 and 15, and every 24 weeks thereafter).
89160012|NCT05123534|Experimental|Cohort 1|5 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 1
89160013|NCT05123534|Experimental|Cohort 2|5 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 2
89160014|NCT05123534|Experimental|Cohort 3|10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy Level 3
89160015|NCT05123534|Experimental|Cohort 4 - DIPG Cohort at RP2D|The RP2D of SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy
89160016|NCT05123534|Experimental|Cohort 5 - DMG Cohort at RP2D|The RP2D of SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS) Energy
89160017|NCT05094622|Experimental|Physical exercise|Physical exercise program
89160018|NCT05090839|Active Comparator|Spanish-Only Writing Group|Participants in this group will be required to write once weekly for 4 consecutive weeks. Participants will be instructed to write objectively about what they did the day prior and to avoid writing about their emotions or opinions. The participant will be required to write in their preferred language (English or Spanish).
89160019|NCT05090839|Experimental|English-Only Writing Group|Participants in this group will be asked to write about their most traumatic or upsetting experiences for a total of 4 sessions (one session a week for 4 consecutive weeks). The participant will be required to write in their preferred language (English or Spanish).
89160020|NCT05083741||Chitogel|Chitodex gel plus Kenalog inserted into the middle meatus
89160021|NCT05083741||Nexfoam|NexFoam plus Kenalog inserted into the middle meatus
89160022|NCT05081063|Experimental|Low Titer O+ Whole Blood|Low Titer O+ Whole blood provided to Level A trauma patients
89160023|NCT05081063|Active Comparator|Component Therapy|Component Therapy of O+ pRBC and FFP dispatched to trauma bay for level A traumas
89160024|NCT05061745|Active Comparator|Guided Meditation VR for Wellness|Selected modules of commercially available meditation VR
89160025|NCT05061745|Active Comparator|Accelerated Transcranial Magnetic Stimulation: Treatment A|Intermittent theta-burst over dlPFC
89160026|NCT05061745|Active Comparator|Accelerated Transcranial Magnetic Stimulation: Treatment B|Intermittent theta-primed 10Hz over mPFC
89160027|NCT05061394||Second division football players|Players competing in the third best league in Denmark
89160028|NCT05061394||"Danmarkserien football players"|Players competing in the fourth best league in Denmark
89160029|NCT05047185|Experimental|Part 1: Low dose|BID low dose of deucrictibant
89160030|NCT05047185|Experimental|Part 1: High dose|BID high dose of deucrictibant
89160031|NCT05047185|Placebo Comparator|Part 1: Placebo|BID placebo
89160032|NCT05047185|Experimental|Part 2: Open-label|BID high dose of deucrictibant
89160033|NCT05034640||Conventional Multiport Thoracoscopic Surgery for Pediatric Pneumothorax|Patients who had multiport video assisted thoracoscopic surgery for pediatric pneumothorax.
89160034|NCT05034640||Single Port Thoracoscopic Surgery for Pediatric Pneumothorax|Patients who had single port video assisted thoracoscopic surgery for pediatric pneumothorax.
89160035|NCT05028725|Experimental|Esophageal Squamous Cell Carcinoma (ESCC) Cases|Each study participant will undergo esophageal sponge sampling using the 'EsophaCap' sponge device. Group 1 will include a safety-phase, which will consist of a lead-in cohort of 8 patients with ESCC. Subsequent recruitment of ESCC Cases (Group 1) will not commence until the Data Safety Monitoring Board (DSMB) has deemed the safety lead-in data appropriate for continuation. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
89160036|NCT05028725|Experimental|Non-ESCC, Esophageal squamous dysplasia (ESD) Cases|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
89160037|NCT05028725|Experimental|Non-ESCC, Control Group|Each study participant will undergo (1) Esophagogastroduodenoscopy (EGD) with chromoendoscopic screening and possible biopsy, and (2) esophageal sponge sampling using the 'EsophaCap' sponge device. Pathology from chromoendoscopic screening will be used to categorize non-ESCC study participants as esophageal squamous dysplasia (ESD) cases and controls. Following collection of esophageal cells, samples will be assessed using the EsoCAN assay. Study participant evaluations will be taken at baseline, immediately after undergoing esophageal sponge sampling, and 7 days following administration of the 'EsophaCap' device.
89160038|NCT05025787|Experimental|300mg BID|The higher dose (i.e., 300mg BID) demonstrated good tolerability and safety, as well as over 90% inhibition of the binding of monocyte chemoattractant protein-1 to its CCR-2 receptor. Moreover, this dose produced nearly 90% binding inhibition at the CCR-5 receptor as well.
89160039|NCT05025787|Placebo Comparator|Placebo|Placebo
89160040|NCT05024474|Experimental|Intervention: inspiratory muscle training + physical exercise|Inspiratory muscle training (IMT) twice a day for 8 weeks combined with a physical exercise program at least two times a week for 8 weeks.
89160041|NCT05024474|Active Comparator|Active control: physical exercise|A physical exercise program at least two times a week for 8 weeks.
89160042|NCT05023018|Experimental|Patients with high-grade meningioma|30 patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma
89160043|NCT05016960|Experimental|Sleep-SMART|Sleep-SMART intervention
89160044|NCT05013788|Experimental|Treatment|
89160045|NCT05013788|Active Comparator|Control Group|
89160046|NCT05010993||Czech healthy people|Czech healthy men and women will be asked to fill in a questionnaire. Then they will be tested by the Nine Hole Peg Test, the Purdue Pegboard Test and the Box and Block Test.
89160047|NCT05007132|Experimental|Arm A|Trifluridine/tipiracil, 35 mg/m² body surface area (BSA), twice daily, orally on days 1-5 and 8-12 Panitumumab at 6 mg/kg bodyweight, intravenous infusion on days 1 and 15
89160048|NCT05007132|Active Comparator|Arm B|Trifluridine/tipiracil, 35 mg/m² body surface area, twice daily, orally on days 1-5 and 8-12 Bevacizumab at 5 mg/kg bodyweight, intravenous infusion on days 1 and 15
89160049|NCT04998604|Experimental|Dupilumab|Dosing every 2 weeks (Q2W)
89160050|NCT04998604|Experimental|Omalizumab|Dosing Q2W or every 4 weeks (Q4W)
89160051|NCT04998110|Experimental|Supportive Care Intervention|The supportive care intervention arm will receive their usual ambulatory longitudinal nephrology care integrated with ambulatory supportive care through monthly supportive care visits over six months.
89160052|NCT04998110|No Intervention|Usual Care Control|The usual care control arm will be seen at the discretion of their nephrologist, or receive their usual dialysis if on dialysis.
89160053|NCT04989556|Active Comparator|Arm I (standard symptom management)|Patients receive standard symptom management by palliative care team once every 4 weeks for 12 weeks. Patients and caregivers also may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
89160054|NCT04989556|Experimental|Arm II (weekly provider-initiated remote contact)|Patients in Phase I immunotherapy trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact every week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
89160055|NCT04989556|Experimental|Arm III (weekly provider-initiated remote contact)|Patients in Phase I non-immunotherapy clinical trials will receive in-person clinic visits or standard remote care encounters at least once every 4 weeks and the e-ESAS and PC provider-initiated remote contact once a week. Patients and caregivers may participate in an interview with supportive care nurse over 30-45 minutes during week 8.
89160056|NCT04981236|Active Comparator|Pericapsular nerve group block|Participants receiving pericapsular nerve group block
89160057|NCT04981236|Experimental|Periarticular block|Participants receiving periarticular block
89160058|NCT04975399|Experimental|Administration of CC-92328|CC-92328 administered intravenously in 28-day cycles
89160059|NCT04963764|Placebo Comparator|Placebo|Randomization to receive either oral placebo or amoxicillin for a standard course (10 days)
89160060|NCT04963764|Active Comparator|Amoxicillin|Randomization to receive either oral amoxicillin or placebo for a standard course (10 days)
89160061|NCT04957238|Experimental|ARBORea decision-making tool|After a period of presentation and training on the dedicated decision-making tool (face-to-face, video and paper supports), nurses will be asked to use ARBORéa decision tree. This will be in the form of an electronic file and will give a suggestion of whether or not to use physical restraints. This is based on an algorithm based on specific and mandatory elements (neurological state : RASS (Richmond assessment sedation scale) and CAM-ICU (confusion assessment method-ICU) scores, modification of sedation dosage, equipment levels, presence and adhesion of the family) that will be completed online. ARBORea's suggestion will be collected as well as final caregiver's decision in order to evaluate relevance of the tool. Observations will also be made at least every 8 hours. This period will also be of random duration (stepped wedge)
89160062|NCT04957238|No Intervention|Subjective physical restraints use|After study presentation and required data collection description, nurses will complete elements related to ARBORea's tool variables, and inform their actual practices of physical restraints use, at least every 8 hours. ARBORea data concern patient's neurological state (RASS and CAM-ICU scores) and changes in sedation doses. The conditioning will then be filled in to stratify the risk incurred. Pain management will be notified. Finally, the presence and involvement of the families will be collected. Other data, relating to working conditions of the nurses will be collected: nurse to patient ratio, special and time consuming events (new patient admission, in ICU emergencies, need to conduct a patient to CT-scan facility or operative room, change of patient's equipment). Nurse seniority in ICU will be specified. Incidents that have occurred (fall, self-injury, removal of a level C2 equipment). The random duration of this control period will be determined by stepped wedge sequencing.
89160063|NCT04950309|Experimental|OPM Array studies|Testing of a final 49-61 channel OPM MEG system and any interim arrays
89160064|NCT04950127|Experimental|Participants receiving linerixibat|
89160065|NCT04950127|Experimental|Participants receiving linerixibat followed by placebo|
89160066|NCT04950127|Placebo Comparator|Participants receiving placebo|
89160067|NCT04950127|Experimental|Participants receiving placebo followed by linerixibat|
89160068|NCT04944017|Experimental|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
89160069|NCT04944017|Placebo Comparator|Saline Infusion|Participants will receive 6 infusions of placebo (saline IV), administered over 40 minutes while on continuous cardiac monitoring and oximetry
89160070|NCT04930991|Experimental|Arm A (High Dose)|Omeprazole, 80 mg, PO, BID for 2 weeks prior to surgical therapy of pancreatectomy. All 30 subjects in Arm A to be enrolled prior to Arm B cohort enrollment.
89160071|NCT04930991|Placebo Comparator|Arm B (Normal Dose)|Omeprazole, 20 mg, PO, QD for 2 weeks prior to surgical therapy of pancreatectomy.
89160072|NCT04930107|Active Comparator|Recurrent Infection Cohort - symptomatic|Participants with a history of recurrent vulvovaginal candidiasis infections who have an active symptomatic infection when they come to clinic
89160073|NCT04930107|No Intervention|Asymptomatic Cohort|Participants with no history of vulvovaginal candidiasis
89160074|NCT04930107|No Intervention|Recurrent Infection Cohort - asymptomatic|Participants with a history of recurrent vulvovaginal candidiasis infections who do not have an active symptomatic infection when they come to clinic
89160075|NCT04922320|Experimental|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
89160076|NCT04922320|Placebo Comparator|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. UC participants will not receive any additional preparation
89160077|NCT04919811|Experimental|Taletrectinib|Single-arm trial whereby all consented, enrolled, eligible patients receive taletrectinib
89160078|NCT04910152|Experimental|Treatment for aGVHD (BRD4 inhibitor PLX51107)|Patients receive BRD4 inhibitor PLX51107 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89160079|NCT04906447|No Intervention|Control arm|Participants randomized to the control arm will receive usual care
89160080|NCT04906447|Experimental|Acupuncture|Acupuncture treatments twice a week for five weeks
89160081|NCT04906447|Experimental|Guided Relaxation|Daily use of a guided relaxation app for 6 weeks
89160082|NCT04900064|Experimental|Diagnostic Assessment - Given self-help CBT|"The diagnostic assessment includes screening instruments, a structured interpretation of the screening instruments, a structured interview (MINI - International Neuropsychiatric Interview) and a medical anamnesis. If deemed appropriate, the patient can be offered treatment with guided self help. If the patient's problem is not deemed appropriate for this type of care or if the patient is not interested in guided self-help, they are offered brief interventions (BI).~In the primary analysis, only patients receiving treatment with self-help CBT are included."
89160083|NCT04900064|Active Comparator|Contextual Assessment - Suitable for self-help CBT but given brief interventions|"The contextual assessment includes screening instruments and a contextual interview. Patients in this arm will always be treated with brief interventions.~In the primary analysis, only patients suitable for self-help CBT are included. This is decided by an algorithm based on data from their screening, which takes into account symptom severity and type, patient preference and known variables that make self-help CBT a worse fit."
89160084|NCT04900064|Experimental|Diagnostic Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they receive treatment with self-help CBT or brief interventions."
89160085|NCT04900064|Active Comparator|Contextual Assessment - All patients|"Same as the other arm marked as Experimental, but for the purpose of a secondary analysis all patients randomised to Diagnostic Assessment are included, regardless if they are deemed suitable for self-help CBT or not."
89160086|NCT04898829|Experimental|PKU Explore|PKU Explore will be prescribed by the study dietitian based on the patient's individual requirement.
89160087|NCT04885127|Experimental|All patients|All patients enrolled in this trial will be referred to palliative care for planned monthly virtual visits, be instructed on the use of a digital application Noona that can be downloaded on their personal electronic device, and will be prompted to fill out symptom questionnaires using Noona prior to palliative care visits (required) as well as weekly (optional).
89160088|NCT04872166|Experimental|BTX-A51 Dose Cohort 1|Starting dose (SD) of BTX-A51 administered orally 5 times per week in a 28-day cycle
89160089|NCT04872166|Experimental|BTX-A51 Dose Cohort 2|Up to 2-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
89160090|NCT04872166|Experimental|BTX-A51 Dose Cohort 3|Up to 3.5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
89160091|NCT04872166|Experimental|BTX-A51 Dose Cohort 4|Up to 5-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
89160092|NCT04872166|Experimental|BTX-A51 Dose Cohort 5|Up to 7-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
89160093|NCT04872166|Experimental|BTX-A51 Dose Cohort 6|Up to 10-times the SD of BTX-A51 administered orally 5 times per week in a 28-day cycle
89160094|NCT04855695|Experimental|Acalabrutinib, Venetoclax, and Obinutuzumab|"This study will consist of 3 parts (Parts A, B, and C). In the relapsed/refractory (R/R) MCL setting (Part A), the phase 1 portion consists of a dose finding stage to determine the recommended phase 2 dose (RP2D). It will follow a 3+3 dose finding schema, with a safety pause and evaluation after the first 3 participants have completed through cycle 5, day 1. If there are no dose limiting toxicities (DLTs), an additional 3 participants will be treated and if there are 0 or 1 DLTs seen, the RP2D will have been determined.11 participants will be enrolled in the Part A expansion cohort.~Part B will enroll 24 participants with untreated mantle cell lymphoma who are transplant ineligible and/or TP53 mutated.~Part C will enroll 12 participants with untreated mantle cell lymphoma who are transplant eligible and TP53 wild type.~Each study drug is given according to a different schedule. Each treatment cycle lasts 28 days (4 weeks).~Acalabrutinib:~Obinutuzumab:~Venetoclax:"
89160095|NCT04851288|Experimental|MitoQ, 20 mg/day|Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.
89160096|NCT04851288|Placebo Comparator|Placebo|Matched placebo capsules.
89160097|NCT04828330||Observational cohort|This is a case-crossover study nested within a cohort study.
89160098|NCT04827901|Active Comparator|XEN1101|Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.
89160099|NCT04827901|Placebo Comparator|Placebo|Subjects will take a matching placebo daily for eight weeks.
89160100|NCT04817202|Experimental|Group A1 (hzVSF-v13 50mg, intravenous, single dose)|Single administration (intravenous) of 50mg hzVSF-v13 on Day 1.
89160101|NCT04817202|Experimental|Group A2 (hzVSF-v13 100mg, intravenous, single dose)|Single administration (intravenous) of 100mg hzVSF-v13 on Day 1.
89160102|NCT04817202|Experimental|Group A3 (hzVSF-v13 200mg, intravenous, single dose)|Single administration (intravenous) of 200mg hzVSF-v13 on Day 1.
89160103|NCT04817202|Experimental|Group A4 (hzVSF-v13 400mg, intravenous, single dose)|Single administration (intravenous) of 400mg hzVSF-v13 on Day 1.
89160104|NCT04817202|Experimental|Group A5 (hzVSF-v13 800mg, intravenous, single dose)|Single administration (intravenous) of 800mg hzVSF-v13 on Day 1.
89160105|NCT04817202|Experimental|Group A6 (hzVSF-v13 1200mg, intravenous, single dose)|Single administration (intravenous) of 1200mg hzVSF-v13 on Day 1.
89160106|NCT04817202|Experimental|Group A7 (hzVSF-v13 100mg, subcutaneous, single dose)|Single administration (subcutaneous) of 100mg hzVSF-v13 on Day 1.
89160107|NCT04817202|Experimental|Group B1 (hzVSF-v13 100mg, intravenous, multiple dose)|Multiple administration (intravenous) of 100mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
89160108|NCT04817202|Experimental|Group B2 (hzVSF-v13 400mg, intravenous, multiple dose)|Multiple administration (intravenous) of 400mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.
89160109|NCT04817202|Placebo Comparator|Placebo (intravenous, single dose)|Single administration (intravenous) of placebo on Day 1.
89160110|NCT04817202|Placebo Comparator|Placebo (subcutaneous, single dose)|Single administration (subcutaneous) of placebo on Day 1.
89160111|NCT04817202|Placebo Comparator|Placebo (intravenous, multiple dose)|Multiple administration (intravenous) of placebo on Day 1, Day 15, Day 29, Day 43, Day 57.
89160112|NCT04788043|Experimental|Magrolimab (Hu5F9 G4) and pembrolizumab|All subjects will have a baseline PET CT and excisional or core needle biopsy within 1 month of study enrollment and baseline electrocardiogram and laboratory studies within 1 week of study enrollment. All subjects will receive treatment with magrolimab and pembrolizumab according to the dosing schedule. Magrolimab IV given on cycle 1, 2 and 3. Pembrolizumab 200 mg IV given on Cycle 1, 2 and 3. Patients may continue to receive treatment on the study for a maximum of 24 months or until progression of disease, unacceptable toxicity, or bridge to stem cell transplantation (SCT).
89160113|NCT04783857|Active Comparator|Group 1|Participants in this group will receive progesterone
89160114|NCT04783857|No Intervention|Group 2|Participants in this group will not receive progesterone
89160115|NCT04783428||Prior TIO Burosumab Clinical Trial Participants|
89160116|NCT04783428||Adults Who Have Not Participated In Prior Burosumab Clinical Trials|
89160117|NCT04783428||Pediatrics Who Have Not Participated In Prior Burosumab Clinical Trials|
89160118|NCT04774380|Experimental|Durvalumab - (cisplatin or carboplatin) - Etoposide|Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met.
89160119|NCT04761588|Experimental|Tyr sphere|All patients to receive Tyr sphere as part of their dietary management for tyrosinaemia or alkaptonuria (AKU).
89160120|NCT04757298|Other|Navigation only|Participants are randomized to receive navigation services only.
89160121|NCT04757298|Other|Navigation + Brief Counseling|After initial randomization into NS, some participants are randomized to receive Brief Counseling (BC)
89160122|NCT04757298|Other|Navigation + Critical Dialogue|After initial randomization into NS, some participants are randomized to receive Critical Dialogue (CD)
89160123|NCT04757298|Other|Brochure only|Participants are randomized to receive Brochure only.
89160124|NCT04757298|Other|Brochure + Brief Counseling|After initial randomization to receive a brochure, some participants are randomized to receive Brief Counseling (BC)
89160125|NCT04757298|Other|Brochure + Critical Dialogue|After initial randomization to receive a brochure, some participants are randomized to receive Critical Dialogue (CD)
89160126|NCT04756193||Asymptomatic/Mild COVID-19 Group|50 confirmed COVID-19 patients who showed no or only mild respiratory/GI symptoms (not admitted to the hospital at all)
89160127|NCT04756193||Moderate COVID-19 Group|50 confirmed COVID-19 patients who were able to maintain oxygen saturation above 92% (or above 90% for patients with chronic lung disease) with up to 4 L/min oxygen via nasal prongs (admitted to the hospital, but never to the ICU and no obvious cardiac complications during the stay)
89160128|NCT04756193||Severe COVID-19 Group|50 confirmed COVID-19 patients who had oxygen saturation lower than 92% at rest and PaO2/FiO2 between 200 and 300 (High-flow oxygen group, mostly in the ICU, and may have some cardiac complications)
89160129|NCT04756193||Critical COVID-19 Group|50 confirmed COVID-19 patients who had PaO2/FiO2 less than 200 or required mechanical ventilation (in the ICU, need mechanical ventilation and more likely to have cardiac complications)
89160130|NCT04756193||Control Group|50 age and sex-matched controls from our hospital admission database
89160131|NCT04747821|Experimental|First group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the first week of study The vaccine is administrated in two doses with a four-weeks interval
89160132|NCT04747821|Experimental|Second group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the second week of study The vaccine is administrated in two doses with a four-weeks interval
89160133|NCT04747821|Experimental|Third group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the third week of study The vaccine is administrated in two doses with a four-weeks interval
89160134|NCT04747821|Experimental|Fourth group of clusters|Adsorbed COVID-19 (Inactivated) vaccine offered in the fourth week of study The vaccine is administrated in two doses with a four-weeks interval
89160135|NCT04747327|Experimental|specific vaccine policy 1|Those in this arm will learn about a specific financial incentive or mandate policy.
89160136|NCT04747327|Experimental|specific vaccine policy 2|Those in this arm will learn about a specific financial incentive or mandate policy.
89160137|NCT04747327|Experimental|specific vaccine policy 3|Those in this arm will learn about a specific financial incentive or mandate policy.
89160138|NCT04747327|Experimental|Specific vaccine policy 4|Those in this arm will learn about a specific financial incentive or mandate policy.
89160139|NCT04747327|Experimental|specific vaccine policy 5|Those in this arm will learn about a specific financial incentive or mandate policy.
89160140|NCT04747327|Experimental|specific vaccine policy 6|Those in this arm will learn about a specific financial incentive or mandate policy.
89160141|NCT04747327|Experimental|specific vaccine policy 7|Those in this arm will learn about a specific financial incentive or mandate policy.
89160142|NCT04747327|Experimental|specific vaccine policy 8|Those in this arm will learn about a specific financial incentive or mandate policy.
89160143|NCT04747327|Experimental|specific vaccine policy 9|Those in this arm will learn about a specific financial incentive or mandate policy.
89160144|NCT04747327|Experimental|specific vaccine policy 10|Those in this arm will learn about a specific financial incentive or mandate policy.
89160145|NCT04747327|Experimental|sleep financial incentive|Those in this arm will invite adults to join an RCT that uses financial incentives to reward those who increase their sleep.
89160146|NCT04747327|Experimental|sleep social incentive|Those in this arm will invite adults to join an RCT that uses social (gamification) incentives to reward those who increase their sleep.
89160147|NCT04747327|Experimental|exercise financial incentive|Those in this arm will invite adults to join an RCT that uses financial incentives to reward those who increase their exercise.
89160148|NCT04747327|Experimental|exercise social incentive|Those in this arm will invite adults to join an RCT that uses social incentives to reward those who increase their exercise.
89160149|NCT04746053|Other|patient with a mutation in the HNF1B gene|Patient with a mutation in the HNF1B gene and which are followed in the reference centers
89160150|NCT04743466||Observational (biobank review)|Patients' records from institutional or national biobanks are reviewed.
89160151|NCT04735731||EBV-patients|Patients who are scheduled for a bronchoscopic lung volume reduction treatment using endobronchial valves
89160152|NCT04727736|Experimental|18F-DCFPyL + PET imaging|"Participants will receive a single dose of 18F-DCFPyL and undergo a PET imaging study.~(The PET imaging may be repeated at a later date if the biopsy of the lesion is negative and if the lesion is present on follow-up imaging.)"
89160153|NCT04721886|Experimental|Diagnostic (CEUS)|Patients undergo ultrasound without contrast. Patients then receive Definity IV over 15 minutes and undergo CEUS.
89160154|NCT04720326|Experimental|Envarsus®|Participants take prolonged-release tacrolimus tablets orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
89160155|NCT04720326|Active Comparator|Advagraf®|Participants take prolonged-release tacrolimus capsules orally once daily and additionally receive standard-of-care immunosuppressive background therapy as per routine practice.
89160156|NCT04711135|Experimental|GEP-NET and PPGL|All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
89160157|NCT04704609||Imaging Analysis of patients with uveitis|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist
89160158|NCT04704323||Experimental: Phase Ia - Dose escalation|Cohorts of 3 subjects will receive intravenous [IV] administrations of escalating doses of CAP-100.
89160159|NCT04704323||Experimental: Phase Ib - Dose expansion|Six subjects will receive intravenous [IV] administrations of CAP-100 at the Recommended Phase 2 Dose determined in Phase Ia - Dose Escalation of this trial.
89160160|NCT04679415|Experimental|Standard of care + hzVSF-v13 200 mg at D1, hzVSF-v13 100mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
89160161|NCT04679415|Experimental|Standard of care + hzVSF-v13 400 mg at D1, hzVSF-v13 200mg at D3 and D7 IV|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
89160162|NCT04679415|Placebo Comparator|Standard of care + 3 doses of the placebo (normal saline) IV|Drug: Placebo (Normal saline solution) Dosage form: 0.9% NaCl Solution Frequency Frequency: Dose at Day 1, 3, 7 Other names: 0.9% Normal saline
89160163|NCT04679350|Experimental|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 50 mg/dose IV
89160164|NCT04679350|Experimental|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV|Standard of care + 3 doses of hzVSF-v13 200 mg/dose IV
89160165|NCT04679350|Experimental|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo|Standard of care + 1 dose of hzVSF-v13 200 mg/dose IV + 2 doses of the placebo
89160166|NCT04679350|Placebo Comparator|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)|Standard of care + 3 doses of the placebo to match hzVSF-v13 (normal saline)
89160167|NCT04678713|Experimental|Fat rich diet|Participants consuming 3 days of fat rich diet
89160168|NCT04678713|Experimental|Carbohydrate rich diet|Participants consuming 3 days of carbohydrate rich diet
89160169|NCT04675476|Experimental|Multilevel Intervention|
89160170|NCT04675476|No Intervention|Nonequivalent Control Group|
89160171|NCT04670640|Experimental|Breath Focus|Participants receiving the breath focus study intervention.
89160172|NCT04670640|Experimental|Vibration|Participants receiving the vibration study intervention.
89160173|NCT04670640|Experimental|Vibration With Breath Focus|Participants receiving the vibration with breath focus study intervention.
89160174|NCT04670640|Experimental|Screens Free|Participants receiving the screens free study intervention.
89160175|NCT04649086|Experimental|Eccentric group|The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation and will be adapted according to the pain felt at the end of the session.
89160176|NCT04649086|Active Comparator|Concentric group|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
89160177|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes
89160178|NCT04641221|Active Comparator|No Video/No One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, but DOES receive financial Incentives to attend yoga classes
89160179|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, or financial Incentives to attend yoga classes, but DOES receive prompting Text messages
89160180|NCT04641221|Active Comparator|No Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, or One-on-One individual sessions with a Yoga Instructor, but DOES receive prompting Text messages and financial Incentives to attend yoga classes
89160181|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/No Incentive|This group does not receive Personal Practice Videos or prompting Text messages or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor
89160182|NCT04641221|Active Comparator|No Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive Personal Practice Videos or prompting Text messages, but DOES receive One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
89160183|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive Personal Practice Videos or financial Incentives to attend yoga classes, but DOES receive One-on-One individual sessions with a Yoga Instructor and prompting Text messages
89160184|NCT04641221|Active Comparator|No Video/Yes One-on-One/Yes Text/Yes Incentive|This group does not receive Personal Practice Videos, but DOES receive One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
89160185|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, or prompting Text messages, or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos
89160186|NCT04641221|Active Comparator|Yes Video/No One-on-One/No Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or prompting Text messages, but DOES receive Personal Practice Videos and financial Incentives to attend yoga classes
89160187|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/No Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and prompting Text messages
89160188|NCT04641221|Active Comparator|Yes Video/No One-on-One/Yes Text/Yes Incentive|This group does not receive One-on-One individual sessions with a Yoga Instructor, but DOES receive Personal Practice Videos, prompting Text messages, and financial Incentives to attend yoga classes
89160189|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/No Incentive|This group does not receive prompting Text messages or financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos and One-on-One individual sessions with a Yoga Instructor
89160190|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/No Text/Yes Incentive|This group does not receive prompting Text messages, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, and financial Incentives to attend yoga classes
89160191|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/No Incentive|This group does not receive financial Incentives to attend yoga classes, but DOES receive Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor and prompting Text messages
89160192|NCT04641221|Active Comparator|Yes Video/Yes One-on-One/Yes Text/Yes Incentive|This group receives Personal Practice Videos, One-on-One individual sessions with a Yoga Instructor, prompting Text messages, and financial Incentives to attend yoga classes
89160193|NCT04641026|Active Comparator|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
89160194|NCT04641026|Active Comparator|Deuterium oxide-labeled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
89160195|NCT04641026|Placebo Comparator|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
89160196|NCT04641026|Placebo Comparator|Deuterium oxide-labeled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labeled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
89160197|NCT04639219|Experimental|T-DXd|T-DXd monotherapy
89160198|NCT04638153|Experimental|Low Dose|Low Dose
89160199|NCT04638153|Experimental|Medium Dose|Medium Dose
89160200|NCT04638153|Experimental|High Dose|High Dose
89160201|NCT04638153|Experimental|PK Phase 2 Formulation|Phase 2 formulation [process 1c] 3mg/kg
89160202|NCT04638153|Experimental|PK Phase 3 Formulation|Phase 3 formulation [process 2] 3mg/kg
89160203|NCT04614155|Experimental|Screening (questionnaire, health education, self-collection)|Participants complete questionnaires, take part in a health education session, and receive HPV self-collection kit.
89160204|NCT04611087||Observational (focus group, interview)|"PHASE I: Participants attend 4 sessions of focus groups.~PHASE II: Participants attend virtual Zoom interviews or one-on-one interviews."
89160205|NCT04603807|Experimental|Entrectinib|Participants will be enrolled to receive 600 mg entrectinib orally once daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
89160206|NCT04603807|Active Comparator|Crizotinib|Participants will be enrolled to receive 250 mg crizotinib orally twice daily until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.
89160207|NCT04598932||1: Normal Controls|Patients with normal corneas without any prior surgery to serve as the control group
89160208|NCT04598932||2 Keratoconus|Patients with various stages of keratoconus
89160209|NCT04598932||3: LASIK|Patients with normal corneas who are undergoing laser in situ keratomileusis (LASIK)
89160210|NCT04598932||Group 4: PRK|Patients with normal corneas who are undergoing photorefractive keratectomy (PRK)
89160211|NCT04598932||5: SMILE|Patients with normal corneas who are undergoing small incision lenticular extraction (SMILE)
89160212|NCT04598932||6: CXL|Patients with keratoconus who are undergoing corneal cross-linking (CXL)
89160213|NCT04583150||Obese women with planned surgery (BS group)|Obese women with planned BS procedure in standard care
89160214|NCT04583150||Obese women with no planned surgery (control group)|Obese women matched for age and BMI who did not undergo surgery
89160215|NCT04565431||Group 1: Multiple Sclerosis|"Individuals with RRMS who are going to be starting Tysabri as determined by Neurologist as part of clinical care.~Intervention: Drug: Tysabri"
89160216|NCT04565431||Group 2: Healthy Controls|Healthy individuals who are age, gender and education matched to the MS group.
89160217|NCT04563728|Active Comparator|Camera Group|"1) The camera(s) will be a stationary device installed by the study technician on the ceiling of a common living area of the participant's home. The camera(s) will record video and audio data to be stored in our secure data base. The cameras will be purchased from YI Technology (see more details in Section 1.7). A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Highlighted video and audio data will be reviewed daily by the study technician. If there is evidence of abuse, exploitation, and neglect on these video and audio data, a report will be made to APS and the IRB."
89235036|NCT05304546|Experimental|Single Arm MK3475, encorafenib and binimetinib|Intravenous pembrolizumab 400 mg Q6W + oral encorafenib 450 mg QD + oral binimetinib 45mg BID, for the first 4 weeks of the study. Starting week 5, monotherapy pembrolizumab 400 mg Q6W.
89160218|NCT04563728|Active Comparator|Mock Camera Group|"2) The mock camera(s) will be a stationary device installed on the ceiling of a common living area of the participant's home. They will not record video or audio but will be installed with a sensor chip and a Wi-Fi connection, which will notify the study team if the device has been touched, tampered, altered, or disrupted power sources. After installing the device, the study technician and study coordinator will test the anti-tampering sensor to ensure potential future tampering will be detected. A sign will be placed outside the home to notify individuals regarding the potential recording, reading, NOTICE Audio and/or video surveillance may be in use on these premises. Daily check-ins to assess whether elder abuse may have been experienced by the participant will occur by phone or other preferred mode of communication. In the event of reported abuse, exploitation, and neglect, despite not being mandatory reporters, we will report to NJ APS and the IRB."
89160219|NCT04563728|No Intervention|Usual Care|Each participant will receive educational packages about elderly community-living.
89160220|NCT04559217|Experimental|Single arm with 68Ga-DOTATATE|all participants will undergo a PET scan with 68Ga-DOTATATE
89160221|NCT04558567|Other|Open-Label|
89160222|NCT04529941|Experimental|Experimental Group|Will receive stimulation ScNS at 3.5mA output
89160223|NCT04529941|Sham Comparator|Control Group|Does not receive therapy
89160224|NCT04526691|Experimental|Datopotamab deruxtecan (Dato-DXd)|Dose Escalation and Dose Expansion: Datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic NSCLC
89160225|NCT04522661|Experimental|Early Vitrectomy Group|Vitrectomy surgery plus intravitreal antibiotics
89160226|NCT04522661|Active Comparator|Control Group|Intravitreal antibiotics
89160227|NCT04516122||Observational (biospecimen collection, DXA scan)|Patients undergo collection of blood samples after starting immunotherapy and then at 6 and 12 months. Patients also undergo DXA scan over 5-10 minutes after starting immunotherapy and at 12 months.
89160228|NCT04506164|Other|Stepped-wedge|This stepped-wedge trial relies on sequential roll-out of eScreening to participating sites over time, while using other sites as controls until they begin implementation.
89160229|NCT04504318|Experimental|Apixaban|Patients assigned to this group will receive Apixaban 2.5 mg PO BID starting 12 hours after completing skin closure.
89160230|NCT04504318|Active Comparator|Enoxaparin|Patients assigned to this group will receive Enoxaparin 40 mg SC QD starting 12 hours after completing skin closure.
89160231|NCT04504227|Placebo Comparator|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
89160232|NCT04504227|Experimental|Slightly thick liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
89160233|NCT04504227|Experimental|Mildly thick liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
89160234|NCT04504227|Experimental|Moderately thick liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
89160235|NCT04503512|Active Comparator|Non removal of fat pad|Non removal of fat pad
89160236|NCT04503512|Active Comparator|Removal of fat pad|Removal of fat pad
89160237|NCT04488900|Experimental|Part 1. CKD-508 Capsule in Single Dose|Single dose of CKD-508 capsules
89160238|NCT04488900|Placebo Comparator|Part 1. Placebo Capsule in Single Dose|Single dose of Placebo capsules
89160239|NCT04488900|Experimental|Part 2. CKD-508 Tablet in Single Dose|Single dose of CKD-508 tablets for biocompartibility
89160240|NCT04488900|Placebo Comparator|Part 2. Placebo Tablet in Single Dose|Single dose of Placebo tablets for biocompartibility
89160241|NCT04488900|Experimental|Part 3. CKD-508 Tablet in Single Dose|Single dose of CKD-508 tablets for food effect
89160242|NCT04488900|Placebo Comparator|Part 3. Placebo Tablet in Single Dose|Single dose of Placebo tablets for food effect
89160243|NCT04488900|Experimental|Part 4. CKD-508 Tablet in Multiple Dose|Multiple dose of CKD-508 tablets
89160244|NCT04488900|Placebo Comparator|Part 4. Placebo Tablet in Multiple Dose|Multiple dose of placebo tablets
89160245|NCT04478318|Experimental|uEXPLORER/mCT|Each patient will undergo a scan on a total-body PET/CT scanner (uEXPLORER) and then undergo an additional scan on a conventional PET/CT scanner (mCT). The first scan will take place 60 minutes after injection with 18F-FDG and the second scan will be 90 minutes after injection with 18F-FDG.
89160246|NCT04478318|Experimental|mCT/uEXPLORER|Each patient will undergo a scan on a conventional PET/CT scanner (mCT) and then undergo an additional scan on a total-body PET/CT scanner (uEXPLORER) . The first scan will take place 60 minutes after injection with 18F-FDG and the second scan will be 90 minutes after injection with 18F-FDG.
89160247|NCT04474353|Experimental|Novo-TTF|"Day 1: Subjects will wear the Optune (TTFields device) for ≥ 18 hours/day. They will take off the device when receiving stereotactic radiosurgery and brain MRI scans.~Days 1 to 8: Subjects will take oral temozolomide 75 mg/m2/day Days 2 to 8: Subjects will receive stereotactic radiosurgery (total of 35 Gy) divided equally over 5 days~• After the interventional treatment, subjects will receive standard of care adjuvant chemotherapy and routine surveillance brain MRI scans."
89160248|NCT04464720|Other|Intervention after One Week|This arm will have baseline data on air pollutant levels, stove use and range hood use collected for one week prior to receiving an educational intervention aimed at increasing use of the range hood. Data following the intervention will be collected for an additional week.
89160249|NCT04456595|Experimental|Adult - Vaccine|Participants aging 18-59 years receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
89160250|NCT04456595|Experimental|Elderly - Vaccine|Participants aging 60 years or above receiving two doses with 14-days interval of Adsorbed COVID-19 (inactivated) Vaccine
89160251|NCT04456595|Placebo Comparator|Adult - Placebo|Participants aging 18-59 years receiving two doses with 14-days interval of placebo
89160252|NCT04456595|Placebo Comparator|Elderly - Placebo|Participants aging 60 years or above receiving two doses with 14-days interval of placebo
89160253|NCT04454489|Experimental|Quad-shot palliative radiotherapy and Immunotherapy|Systemic therapy (ICI) and radiotherapy will be administered according to the standard of care, according to the treating medical oncologist and radiation oncologist, respectively
89160254|NCT04449679|Experimental|Health Services Research (RT-CAMSS)|Patients receive RT-CAMSS over 2 months or until chemotherapy is discontinued, whichever is earlier. RT-CAMSS consists of text messages addressing knowledge about specific cancer type and chemotherapy, side-effect prevention, suggestions of lifestyle behavioral changes and emotional support, and preparation for surgery. Patients then record their symptoms through answering a series of questionnaires and receive tailored feedback according to their answers, including a consultation with a nurse.
89160255|NCT04437836|Experimental|Control arm|Participants will receive standard treatment of rifampicin
89160256|NCT04437836|Experimental|First High dose|Participants will receive 30mg per kg body weight of rifampicin
89160257|NCT04437836|Experimental|Second high dose|Particpants will receive 40mg per kg body weight of rifampicin
89160258|NCT04433975|Experimental|Psychosocial Pain Management (PPMI)|Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
89160259|NCT04433975|Active Comparator|Enhanced Usual Care (EUC)|Two individual telephone educational sessions with research study therapist.
89160260|NCT04430725||Observational (microwave ablation, wedge excision, CT)|Patients undergo standard care microwave ablation or wedge resection followed by contrast-enhanced CT imaging at 1, 6, 12, 18 and 24 months. Patients also complete questionnaires over 10-15 minutes at baseline up to 9 months.
89160261|NCT04428333|Experimental|Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy|
89160262|NCT04428333|Placebo Comparator|Placebo + Pembrolizumab + 5-FU-platinum chemotherapy|
89160263|NCT04419168|Experimental|cCBT|Computerized cognitive behavioral therapy (cCBT) for pain. The cCBT program will teach users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; this intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
89160264|NCT04419168|Experimental|m-Education|Mobile-delivered pain and sickle cell disease education (m-Education). The m-Education program will teach users about chronic pain, healthy lifestyle tips (e.g., nutrition and exercise), and facts about SCD. This program is consistent with the education patients and families would receive with a patient educator.
89160265|NCT04419168|No Intervention|Convenience Comparison|Not participating in the intervention. Participants will complete the baseline questionnaire battery only and the investigational team will abstract their medical record data for the 12-months before enrollment and 12-months post enrollment.
89160266|NCT04408014||HC-USP|Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
89160267|NCT04408014||CORAS|Refugees living in the city of São Paulo
89160268|NCT04408014||Hemocenter|Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
89160269|NCT04408014||CPP - Butantan Penitentiary Progression Center|Participants of the CPP - Butantan Penitentiary Progression Center
89160270|NCT04408014||CHSP - Penitentiary System Hospital Center|Participants of the CHSP - Penitentiary System Hospital Center
89160271|NCT04408014||SABE (Health, Wellness and Aging)|Participants of the SABE Project (Health, Wellness and Aging)
89160272|NCT04408014||ILPI - Long-Term Care Institution for the Elderly|Residents of the Long-Term Care Institution for the Elderly of Botucatu
89160273|NCT04408014||ICR-USP - Children's Institute of HCFMUSP|Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children's Institute of HCFMUSP
89160274|NCT04399954|Experimental|Ketoflo|Ketoflo to be incorporated into each participant's usual ketogenic diet for 28 days. Amount taken and frequency of intake to be determined by the dietitian.
89160275|NCT04389866|Experimental|Both Jawline and Lateral (Zygomatic) Cheek Area Injections|JUVÉDERM VOLUMA™ XC 1-3 syringes (each syringe is 1 cc) will be injected bilaterally into the lateral cheek (zygomatic) area plus JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation). Total syringes used per person will have a range of 2-5)
89160276|NCT04389866|Experimental|Jawline Injections|JUVÉDERM VOLUMA™ XC 1-2 syringes (each syringe is 1 cc) will be injected bilaterally into the lateral jawline and inferior cheek area (preauricular area) (the latter area will be added if necessary to achieve visual improvement in jowl attenuation). Total syringes used per person will have a range of 1-2)
89160277|NCT04359784|Experimental|Prevention (anakinra, lisocabtagene maraleucel)|Patients receive anakinra SC or IV daily on days 0-13 and lisocabtagene maraleucel via infusion on day 0. Patients should also undergo at screening a x-ray, PET/CT or CT, BMA and biopsy (as clinically indicated), and lumbar puncture (as clinically indicated), and at follow-up as clinically indicated. Patients also undergo blood sample collection on study.
89160278|NCT04355338||0-9 years|Participants aging 0-9 years
89160279|NCT04355338||10-19 years|Participants aging 10-19 years
89160280|NCT04355338||20-29 years|Participants aging 20-29 years
89160281|NCT04355338||30-39 years|Participants aging 30-39 years
89160282|NCT04355338||40-49 years|Participants aging 40-49 years
89160283|NCT04355338||50-59 years|Participants aging 50-59 years
89160284|NCT04355338||60-69 years|Participants aging 60-69 years
89160285|NCT04355338||70-79 tears|Participants aging 70-79 years
89160286|NCT04355338||80+ years|Participants aging 80 years or more
89160287|NCT04348747|Experimental|Treatment (anti-HER2/3 dendritic cell vaccine)|"TREATMENT PHASE: Patients receive anti-HER2/HER3 dendritic cell vaccine ID on days 1, 22, and 43. Patients will also receive pembrolizumab IV on the same days.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive a booster dose of anti-HER2/3 dendritic cell vaccine ID, every 3-6 months in the opinion of principal investigator."
89160288|NCT04341311|Experimental|Marizomib|"All patients will initially receive marizomib (MRZ) alone (Course A1) The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design~-Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses."
89160289|NCT04341311|Experimental|Marizomib + Panobinostat|"If tolerated,combination of Marizomib: and panobinostat on subsequent cycles. The dose escalation and de-escalation for single agent and combination will be guided using the Bayesian optimal interval (BOIN) design.~Intravenously initially given every other week over a 28 day course but may go to weekly x 3 and weekly x 4 as the dose levels increase. Up to 26 courses.~Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course"
89160290|NCT04340505||Active uveitis patients.|Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist and requires an injectable fluocinolone acetonide implant to treat their inflammation.
89160291|NCT04322162|Experimental|Active implementation - Wave 1 (First and Second Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites. Active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves two phases at each of the 6 sites: a variable number of 7-month data periods during baseline period (three 7-month periods for Wave 1 sites, four 7-month data periods for Wave 2 sites, five 7-month data periods for Wave 3 sites), three 7-month data periods in active implementation phase for each wave. Wave 1 and Wave 2 sites will also each have one 7-month period of sustainability. The stepped-wedge design allows for 6 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 21 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on six different cross-sectional samples. Investigators will have repeated information on each site. Arm 1 corresponds to Wave 1."
89160292|NCT04322162|Experimental|Active implementation - Wave 2 (Third and Fourth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites. Active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves two phases at each of the 6 sites: a variable number of 7-month data periods during baseline period (three 7-month periods for Wave 1 sites, four 7-month data periods for Wave 2 sites, five 7-month data periods for Wave 3 sites), three 7-month data periods in active implementation phase for each wave. Wave 1 and Wave 2 sites will also each have one 7-month period of sustainability. The stepped-wedge design allows for 6 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 21 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on six different cross-sectional samples. Investigators will have repeated information on each site. Arm 2 corresponds to Wave 2."
89160293|NCT04322162|Experimental|Active implementation - Wave 3 (Fifth and Sixth Sites)|"This four-year stepped-wedge evaluation includes a total of 6 sites. Active implementation is initiated in 3 waves, each of which includes 2 sites. The project involves two phases at each of the 6 sites: a variable number of 7-month data periods during baseline period (three 7-month periods for Wave 1 sites, four 7-month data periods for Wave 2 sites, five 7-month data periods for Wave 3 sites), three 7-month data periods in active implementation phase for each wave. Wave 1 and Wave 2 sites will also each have one 7-month period of sustainability. The stepped-wedge design allows for 6 mutually exclusive, 7-month data periods. The baseline data period is the time prior to the date of the baseline site visit. The active implementation data period extends 21 months after the site visit. The stepped-wedge design allows site-level estimates of proportions on six different cross-sectional samples. Investigators will have repeated information on each site. Arm 3 corresponds to Wave 3."
89160294|NCT04304495|Experimental|Intervention|"In addition to the usual care arm, the Intervention arm will receive a physical therapy and pharmacy consultation in the ED. PTs will perform a fall risk assessment and provide recommendations on the safety of discharge. Pharmacists will perform medication review, recommend cessation or tapering of medication that increase fall risk using motivational interviewing (MTM) techniques.~The participants will also receive Apple Watch training and an Apple Watch to perform tasks that test their memory and mobility during their ED visit and during our home visits at 1,3, 6, and 12 month after enrollment."
89160295|NCT04304495|No Intervention|Usual care arm|"The ED clinician will perform a standard medical evaluation, including a focused history and exam to identify injuries, laboratory tests and radiologic imaging. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics).~The participants will also receive Apple Watch training and an Apple Watch to perform tasks that test their memory and mobility during their ED visit and during our home visits at 1,3, 6, and 12 month after enrollment."
89160296|NCT04286438|Experimental|Bentracimab (PB2452) Infusion - Open Label Active Drug|Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration. For patients with uncontrolled major or life-threatening bleeding or in need of urgent surgery or invasive procedure.
89160297|NCT04276415|Experimental|Dose Escalation: DS-6157a|Participants with advanced gastrointestinal stromal tumor (GIST) who will receive an intravenous infusion of DS-6157a (escalating doses starting at 1.6 mg/kg).
89160298|NCT04276415|Experimental|Dose Expansion: Cohort 1 (3rd line or later) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on or are intolerant to imatinib (IM) and at least one post-IM treatment will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
89160299|NCT04276415|Experimental|Dose Expansion: Cohort 2 (2nd line) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on imatinib (IM) and had not received a post-IM treatment (2nd line) will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
89160300|NCT04260477|Experimental|6EH³R3Z|(Rifampicin (R)/ Isoniazid (H) / Pyrazinamide (Z)/Ethambutol (E)) 6-month high-dose treatment; New high-dose isoniazid / high-dose rifampicin retreatment regimen (6EH³R3Z) - that includes triple-dose rifampicin (R3; 30 mg/kg), and triple-dose isoniazid (H3; 15 mg/kg), complemented with pyrazinamide (Z) and ethambutol (E).
89160301|NCT04260477|Active Comparator|6EHRZ|Standard of care: 6-month 6RHZE regimen with dose combination tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E)
89160302|NCT04232761||CRPC patients|Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases who are treated with radium-223 dichloride in routine clinical practice in Taiwan
89160303|NCT04227028|Experimental|Treatment (brigatinib, bevacizumab)|Patients receive brigatinib PO QD on days 1-28 of cycle 1 and days 1-21 of subsequent cycles. Patients also receive bevacizumab IV on day 8 of cycle 1 and day 1 of subsequent cycles. Starting cycle 2, cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89160304|NCT04224493|Experimental|Tazemetostat + R2 arm|"Stage 1 (Phase 1b):~Tazemetostat will be escalated from a starting dose of 400 mg PO twice daily to 600 mg PO twice daily to 800 mg PO twice daily in 28-day cycles.~Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.~Lenalidomide 20 mg or 10 mg (if creatinine clearance ≥60 mL/minute or <60 mL/minute), administred PO QD on days 1 to 21 for 12 cycles.~Stage 2 and Optional Stage 3 (Phase 3):~Tazemetostat 800 mg administered PO twice daily in continuous 28-day cycles.~Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.~Lenalidomide 20 mg or 10 mg (if creatinine clearance ≥60 mL/minute or <60 mL/minute), PO QD on days 1 to 21 for 12 cycles.~Maintenance Therapy (Stage 1, 2, and Optional Stage 3):~Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
89160305|NCT04224493|Placebo Comparator|Placebo + R2 Arm|"Stage 2 and Optional Stage 3 (Phase 3):~Placebo administered PO twice daily in continuous 28-day cycles.~Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.~Lenalidomide 20 mg or 10 mg (if creatinine clearance ≥60 mL/minute or <60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.~Maintenance Therapy (Stage 1, 2, and Optional Stage 3):~Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy. During maintenance, placebo will be continued until disease progression or unacceptable toxicity, or participant withdraws consent."
89160306|NCT04224142||PKU sphere|PKU sphere (an FSMP) as per individual requirements determined by a dietitian.
89160307|NCT04223752|Experimental|Group 1: Ceftolozane/Tazobactam 12 to <18 Years of Age|Participants 12 to <18 years of age with nosocomial pneumonia receive intravenous (IV) ceftolozane/tazobactam every 8 hours for 8-14 days.
89160308|NCT04223752|Experimental|Group 2: Ceftolozane/Tazobactam 7 to <12 Years of Age|Participants 7 to <12 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
89160309|NCT04223752|Experimental|Group 3: Ceftolozane/Tazobactam 2 to <7 Years of Age|Participants 2 to <7 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
89160310|NCT04223752|Experimental|Group 4: Ceftolozane/Tazobactam 3 Months to <2 Years of Age|Participants 3 months to <2 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
89160311|NCT04223752|Experimental|Group 5: Ceftolozane/Tazobactam Birth to <3 Months of Age|Participants from birth to <3 months of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.
89160312|NCT04219397|No Intervention|Control|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol. There will be no interventions provided. They will receive a follow up phone call survey and be asked to return a completed medication education calendar that is provided as a part of usual APS care.
89160313|NCT04219397|Experimental|Medication take back education intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive a standardized education intervention. This intervention will educate patients and their families about medication take back programs, and will provide tailored directions to the closest medication take back center from their home, and also an option for medication take back that is located in close proximity to Riley Hospital clinics.
89160314|NCT04219397|Experimental|Home disposal kit intervention|Patients in this group will receive usual care from the acute pain medicine service, and will go home with standardized multimodal analgesic protocol as described in the control group. They will receive standardized education about how to use the medication home disposal kit : Dispose Rx(r), and they will be instructed to use this kit to dispose of any left over opioid medications that they may have after they have competed therapy for pain management at home.
89160315|NCT04216251|Experimental|AMR101|"Study procedures include screening for eligibility and study treatment including ARM101 Lifestyle questionnaire, Nutritional survey. Flexible sigmoidoscopy (24 biopsies of normal colorectal mucosa, one stool sample),blood, evaluations, and follow up visits.~- AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks"
89160316|NCT04210557|Active Comparator|TMS to insula|"This study will recruit 30 clinical voice hearers (P+H+). They will complete two parallel forms of the conditioned hallucinations task (with different visual and auditory stimuli) on two occasions, separated by a week.~TMS and sham will be delivered in a randomized counterbalanced order. Hypothesis: Inhibiting the insula will decrease prior over-weighting. If this computational perturbation is responsible for conditioned hallucinations, then ameliorating it with TMS that increases insula engagement will decrease conditioned hallucination responses. Furthermore, the prior weighting parameter will be reduced following active TMS compared with sham."
89160317|NCT04210557|Active Comparator|TMS to cerebellum|This study will recruit a further 70 clinical voice hearers. Again, they will complete parallel forms of the conditioned hallucinations task on two occasions, separated by a week. They will receive excitatory TMS over the cerebellum (and sham on the other occasion, in a randomized counterbalanced order). Hypotheses: Exciting the cerebellum will increase belief-updating. If poor belief-updating contributes to conditioned hallucinations, increasing cerebellum engagement should decrease conditioned hallucinations and alter the belief-updating model parameter compared with sham TMS.
89160318|NCT04207346|Experimental|TMS|transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex at 1 Hz
89160319|NCT04207346|Sham Comparator|Sham|sham transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex
89160320|NCT04205565|Active Comparator|L-oxiracetam|
89160321|NCT04205565|Active Comparator|Oxiracetam|
89160322|NCT04205565|Placebo Comparator|Plaecbo|
89160323|NCT04203693||Cohort 1: Tildrakizumab Treated Participants|Participants will be treated with tildrakizumab who have participated in prior tildrakizumab studies
89160324|NCT04203693||Cohort 2: Newly Tildrakizumab Prescribed Participants|Participants will be newly prescribed tildrakizumab (a prescription has occurred independently of the enrolment in the study)
89235037|NCT05267340|Experimental|Experimental: TARA Training|"Behavioral: Training for Awareness, Resilience, and Action (TARA)~This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)"
89160325|NCT04188912||Observational (sample collection, survey, imaging, spirometry)|Patients undergo collection of tears, saliva, buccal mucosa, and fecal samples before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also undergo collection of blood samples before stem cell transplant, at 1-2, 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients may undergo skin and mouth biopsy over 15-30 minutes before stem cell transplant, at 2-3 and 12 months after stem cell transplant, and at cGVHD onset. Patients undergo digital pictures of the eyes, mouth and skin, and optical coherence tomography before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients without standard of care formal pulmonary function test undergo portable spirometry at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also complete surveys and have their medical records reviewed.
89160326|NCT04186832|Active Comparator|Group I (pedometer)|Patients wear a pedometer for step count monitoring over 6 weeks.
89160327|NCT04186832|Experimental|Group II (FitBit)|Patients wear a FitBit for step count monitoring over 6 weeks.
89160328|NCT04182620|Experimental|Catheter ablation + renal denervation|Catheter ablation + renal denervation
89160329|NCT04182620|Active Comparator|Catheter ablation only|Catheter ablation
89160330|NCT04181606|Active Comparator|Esmolol Infusion|Drug: Esmolol Hydrochloride Dosage form: Intravenous Infusion Dosage/Frequency: 0.5 mg/(kg Fat Free Mass·min) for 3 min followed by a maintenance infusion of 0.25 mg/(kg Fat Free Mass·min) for remainder of trial, up to a maximum of 1 hour.
89160331|NCT04181606|Placebo Comparator|Saline Infusion|Saline infusion volume/rate matched to the calculated dose of esmolol.
89160332|NCT04175912|Experimental|Arm A (pevonedistat)|Patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89160333|NCT04175912|Experimental|Arm B (pevonedistat, paclitaxel, carboplatin)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 15-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Starting cycle 5, patients may receive pevonedistat monotherapy at the discretion of treating physician.
89160334|NCT04149223|No Intervention|Control|Current practice at baseline, routine cirrhosis care.
89160335|NCT04149223|Experimental|Intervention|Use of a standardized cirrhosis order set.
89160336|NCT04149223|Active Comparator|Intervention + EMR|Use of a standardized cirrhosis order set embedded within an electronic medical record.
89160337|NCT04146909|Active Comparator|Breast Feeding|This group will consist of women who exclusively or mostly breast-fed for at least 4-6 months (< 6 ounces of formula/24 hours at 6-9 weeks of delivery)1 and who delivered within the past 18 months.
89160338|NCT04146909|Active Comparator|Formula Feeding|This group will consist of women who exclusively or mostly formula-fed (no breastfeeding or < 3 weeks of breastfeeding)1 and who delivered within the past 18 months.
89160339|NCT04145778||Patient|
89160340|NCT04145778||Control|
89160341|NCT04134845|Experimental|Dantrolene/Ryanodex|Dantrolene/Ryanodex; intravenous administration of dantrolene; 1 mg/ kg IV over 3 minute, one time dose
89160342|NCT04134845|Placebo Comparator|Placebo|controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
89160343|NCT04132440||Observational (questionnaire, interview)|Patients and physicians complete a questionnaire over 5 minutes and an interview over 30-45 minutes about thoughts on NAFLD, including what they know about NAFLD and its diagnosis, management, and monitoring, and other thoughts on NAFLD.
89160344|NCT04115501|Experimental|Restrictive Oxygen|The restrictive oxygen patients' Fraction of Inspired Oxygen (FiO2) will be set at a minimum of 0.3 to maintain their oxygen saturations (SpO2) greater than or equal to 95% intraoperatively. During CPB a blended air/oxygen mixture will be titrated to arterial blood gas analysis with aim of maintenance of PaO2 between 100 and 150 mmHg. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
89160345|NCT04115501|No Intervention|Liberal Oxygen|The liberal oxygen group will consist of subjects exposed to a Fraction of Inspired Oxygen (FiO2) set at 1.0 throughout the intraoperative period, including during cardiopulmonary bypass. After transfer to ICU, all patients' FiO2 will be set to 50% initially, and titrate to minimal FiO2 (not less than 21%) for maintain SPO2≥95% until extubation.
89160346|NCT04092283|Experimental|Arm A (durvalumab, chemotherapy, durvalumab)|"STEP 1 (CONCURRENT THERAPY): Patients receive durvalumab IV over 60 minutes on days 1 and 15 of cycle 1 and day 1 of cycle 2. Patients also receive 1 of 3 treatment regimens per investigator choice: 1) etoposide IV over 60 minutes on days 1-5 and cisplatin IV over 60 minutes on days 1 and 8 every 28 days for 2 cycles; 2) pemetrexed disodium IV over 60 minutes and cisplatin IV over 60-120 minutes on day 1 every 21 days for 2 cycles; or 3) paclitaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1 every 7 days for 6 cycles. Treatment continues in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of chemotherapy, patients receive radiation therapy 5 days a week for 6 weeks.~STEP 2 (CONSOLIDATION THERAPY): Within 14 days after the last dose of radiation (from Step 1), all patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
89160347|NCT04092283|Active Comparator|Arm B (chemotherapy, durvalumab)|"STEP 1 (CONCURRENT THERAPY): Patients receive 1 of 3 investigator's choice treatment regimens and radiation therapy as in Arm A.~STEP 2 (CONSOLIDATION THERAPY): Within 14 days after the last dose of radiation (from Step 1), all patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
89160348|NCT04088240|Experimental|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (~980 mg DPA, 380 mg EPA, 1720 mg DHA)
89160349|NCT04088240|Active Comparator|n-3 control|4 g/d n-3 control (~980 oleic acid, 380 mg EPA, 1720 mg DHA)
89160350|NCT04088240|Placebo Comparator|Placebo|"4 g/d placebo control (light olive oil)"
89160351|NCT04088071||Patients with atrial fibrillation|Subjects with symptomatic PAF or PsAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements.
89160352|NCT04082884|Experimental|Very Low Carbohydrate Diet|Participants will follow a high protein very low carbohydrate diet (VLCD) for 2 weeks. This will be 11% of caloric intake from carbohydrates, 54% of calories from protein, and 35% of calories from fat. Immediately following this, participants will follow a high protein very low carbohydrate diet (VLCD) which will be 11% of caloric intake from carbohydrates, 23% of calories from protein, and 66% of calories from fat.
89160353|NCT04079764||active surveillance|Patient with Bosniak III or IV lesion that decide to be followed under active surveillance
89160354|NCT04079764||Surgery|Patient with Bosniak III or IV lesion that decide to undergo a definitive treatment such as surgery
89160355|NCT04068753|Experimental|Niraparib + dostarlimab|
89160356|NCT04068597|Experimental|CCS1477 dose escalation NHL/MM|CCS1477 monotherapy
89160357|NCT04068597|Experimental|CCS1477 dose escalation AML/Higher risk MDS|CCS1477 monotherapy
89160358|NCT04068597|Experimental|CCS1477 expansion phase NHL/Peripheral T-cell lymphoma|CCS1477 monotherapy
89160359|NCT04068597|Experimental|CCS1477 monotherapy expansion and combination dose finding and expansion - MM|CCS1477 monotherapy, CCS1477 combination with pomalidomide-dexamethasone
89160360|NCT04068597|Experimental|CCS1477 monotherapy expansion and combination dose finding and expansion - AML|CCS1477 monotherapy, CCS1477 combination with azacitidine, CCS1477 combination with azacitidine and venetoclax
89160361|NCT04068597|Experimental|CCS1477 monotherapy expansion and combination dose finding and expansion - Higher risk MDS|CCS1477 monotherapy, CCS1477 combination with azacitidine, CCS1477 combination with azacitidine and venetoclax
89160362|NCT04053439||Lymphoma patients >=60 receiving cytotoxic chemotherapy|Lymphoma patients >=60 receiving cytotoxic chemotherapy who have consented to DNA extraction and analysis for CHIP.
89160363|NCT04046042|Active Comparator|Conventional exercise time|During 12 months subjects will exercise during the first two hours of the hemodialysis session. A virtual reality exercise program will be implemented
89160364|NCT04046042|Experimental|Experimental group|During 12 months subjects will exercise during the last two hours of the hemodialysis session. A virtual reality exercise program will be implemented
89160365|NCT04042766|Active Comparator|laser treatment|
89160366|NCT04042766|Sham Comparator|sham treatment|
89160367|NCT04035005|Experimental|Ocrelizumab|Participants will receive ocrelizumab by IV infusion every 24 weeks.
89160368|NCT04035005|Placebo Comparator|Placebo|Participants will receive placebo matched to ocrelizumab by IV infusion every 24 weeks.
89160369|NCT04033120||Cohort 1|"Cohort 1: Symptomatic hospitalized patients: 900 patients admitted to the participating hospitals whom doctors suspect to have an infection and will perform TmAg testing alongside routine diagnostics and the following additional diagnostics:~MycoF/lytic blood culture system~Fujifilm lateral flow urine lipoarabinomannan (LF-LAM) test for tuberculosis~Cryptotoccoal antigen in sera (CrAg) LFA for cryptococcosis~Histoplasma antigen in urine (HAg) LFA for histoplasmosis~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a six-month follow up period"
89160370|NCT04033120||Cohort 2|"Cohort 2: Asymptomatic outpatients: 500 patients registered at the outpatient clinics at the participating hospitals whom doctors do not suspect of having an active infection and will perform TmAg testing alongside the following diagnostics:~CrAg LFA for cryptococcosis~HAg LFA for histoplasmosis~We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a twelve-month follow up period."
89160371|NCT04004507|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye (QD) for one day.
89160372|NCT04004507|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye (QD) for one day.
89160373|NCT03996239|Experimental|patients with clonal hematopoiesis|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
89160374|NCT03996239|Experimental|post treatment patients with breast or colorectal cancer|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
89160375|NCT03996239|Experimental|men with localized prostate cancer undergoing active surveillance|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
89160376|NCT03996239|Experimental|Individuals with Lynch Syndrome|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
89160377|NCT03995225|Experimental|Smokers|This study involves wearing a smartband to monitor, record and notify smokers of smoking events and deliver real-time brief mindfulness exercises by smartphone app. There is only one arm.
89160378|NCT03995069|Experimental|3D|The participant's voluntary grip forces in all 3 dimensions will be shown to the participant via computer screen.
89160379|NCT03995069|Active Comparator|1D|The participant's voluntary grip force in 1 dimension will be shown to the participant via computer screen.
89160380|NCT03994588|Active Comparator|study arm|In this arm a light weight, wide pore, soft polypropylene mesh will be used for intraperitoneal hernia repair
89160381|NCT03994588|Active Comparator|control|in this arm a double mesh (vicryl + polypropylene mesh) will be used for intraperitoneal hernia repair.
89160382|NCT03990025|Other|Linked Color Imaging - White Light Imaging|Participant undergoes gastroscopy via Linked Color Imaging first, then followed by White Light Imaging
89160383|NCT03990025|Other|White Light Imaging - Linked Color Imaging|Participant undergoes gastroscopy via White Light Imaging first, then followed by Linked Color Imaging
89160384|NCT03969836||NeurOS Group|All patients will have both INVOS and NeurOS systems placed before and during cardiac surgery for monitoring cerebral oxygenation and brain blood volume.
89160385|NCT03966131|Experimental|patients with complete denture for the first time|Arm that allows to follow the adaptation of this population to the new complete denture during the tasks of speech production and swallowing.
89160386|NCT03966131|Experimental|patients with complete denture used to their complete denture.|Arm that allows a descriptive cross-sectional study of tongue pressure measurements during the tasks of speech production and swallowing
89160387|NCT03963440|Experimental|Cohorte 1|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
89160388|NCT03961672|Experimental|Treatment (duvelisib)|"INDUCTION: Patients receive duvelisib PO BID on days 1-28. Cycles repeat every 28 days for 12 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive duvelisib PO BID on days 1-2, 8-9, 15-16, and 22-23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89160389|NCT03959046|Experimental|GIST|"GIST is an alternative way of speaking to patients. In order for patients to get the gist, Hematologists will ensure that patients walk away from their initial consultation understanding: why they are candidates for bone marrow transplant (BMT), what the process for BMT is, and the major risks involved."
89160390|NCT03959046|No Intervention|Usual Care|These are physician and patient participants that will communicate in their normal, unchanged way.
89160391|NCT03953300|Experimental|Benralizumab|Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
89160392|NCT03953300|Placebo Comparator|Placebo|Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
89160393|NCT03950453|Experimental|Parenting Mindfully for Health Nutrition (PMH)|Parenting Mindfully for Health (PMH) + nutrition and physical activity counseling to promote healthy eating and physical activity in parent and child.
89160394|NCT03950453|Active Comparator|Contact Control Nutrition (C+N)|Contact control intervention (C) + nutrition and physical activity counseling (N).
89160395|NCT03950453|Other|Historical Control (WLC) non-randomized|Non-randomized, historical control group with only assessments during intervention and follow-up period.
89160396|NCT03943550|Experimental|RO7049665|Participants will receive a subcutaneous (SC) dose of RO7049665 every 2 weeks for 4 doses.
89160397|NCT03943550|Placebo Comparator|Placebo|Participants will receive a SC dose of matching placebo every 2 weeks for 4 doses.
89160398|NCT03926052|Active Comparator|LDX|
89160399|NCT03926052|Placebo Comparator|Placebo|
89160400|NCT03908450|Active Comparator|Control intervention|Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)
89160401|NCT03908450|Experimental|Experimental intervention|Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)
89160402|NCT03900260|Other|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
89160403|NCT03899155|Experimental|Nivolumab Dose 1|Specified Dose on Specified Days
89160404|NCT03899155|Experimental|Nivolumab Dose 2|Specified Dose on Specified Days
89160405|NCT03880032|Experimental|Cognitive Behavioral Therapy Intervention for Anxiety|Pregnant women experiencing anxiety randomized to the Happy Mother Healthy Baby (HMHB) intervention receive a CBT-based psychosocial intervention (with six core and up to six booster sessions). HMHB is a facility-based intervention delivered by non-specialist providers. It is aimed to raise psychosocial awareness and facilitate positive change inter personal wellbeing, social support, and bonding with their baby during pregnancy. It addresses with relapse prevention, planning for the baby's arrival, and in management of emotional challenges in the early postnatal period. Family member/s will be invited to attend 3 core sessions.
89160406|NCT03880032|No Intervention|Enhanced Usual Care|Women randomized to the control group will receive enhanced usual care (EUC). The World Health Organization (WHO) recommends 8 antenatal visits for a positive pregnancy experience, the number of visits our EUC control group participants will receive (depending on their gestational week). Usual care will also be enhanced by hospital staff receiving additional training in mental health treatment and counseling. Reminder calls were given, provider visits were facilitated (shorter wait times), and transportation to assist participants in attending appointments and medically indicated ultrasounds were paid for (as in the intervention group).
89160407|NCT03845036|Experimental|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
89160408|NCT03845036|Active Comparator|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
89160409|NCT03840148|Experimental|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period.
89160410|NCT03840148|Active Comparator|Meropenem|Meropenem will be administered q8h IV over 30 minutes.
89160411|NCT03836248|Other|1-Current practice Medication treatment|Medication treatment according to current practice.
89160412|NCT03836248|Sham Comparator|2- Sham osteopathic treatment|Medication treatment according to current practice + sham osteopathic treatment.
89160413|NCT03836248|Experimental|3- Osteopathic treatment|Medication treatment according to current practice + osteopathic treatment.
89160414|NCT03818776|Experimental|Arm 1 - 60 CGyE in 20 fractions|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.~Radiation will follow dose escalation scheme:~60 CGyE in 20 fractions (3+3 participants, 3-6 total)"
89160415|NCT03818776|Experimental|Arm 2 - 69 CGyE in 23 fractions followed by expansion cohort a|"Proton based external beam radiation therapy with concurrent Durvalumab starting one week before RT.~Radiation will follow dose escalation scheme:~69 CGyE in 23 fractions (3+3 participants, 3-6 total) Followed by expansion cohort at identified RP2 dose (12 participants)"
89160416|NCT03802721|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
89160417|NCT03802721|Experimental|Brussels sprouts before 50 ng dose|Subjects will consume 50 g (about 1/2 cup) of lightly steamed Brussels sprouts each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
89160418|NCT03802721|Experimental|DIM supplement before 50 ng dose|Subjects will consume 300 mg DIM supplement ( 2 capsules of BioResponse DIM® 150) each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP). A 300 mg DIM dose will be co-administrated with the 50 ng BaP dose
89160419|NCT03799341|Experimental|Tangible Prize-Based Contingency Management (TangiblePBCM)|For participants assigned to TangiblePBCM, prize draws resulting in one or more small, large, or jumbo wins will result in access to a prize cabinet stocked with small, medium, large, and jumbo financial incentive items. Medium incentive items are included for selection in the event that a patient draws several small prize slips on the same day and are considered equivalent to 4 small prizes. Selection of specific prize items will be informed by patient preference and items will be restocked at least every 2 weeks. The prize cabinet will be open during TangiblePBCM sessions such that prize items are readily visible. Selection of prizes, maintenance of the prize cabinet, and policies regarding prize redemption will follow published guidance on administration of TangiblePBCM within the context of research protocols.
89160420|NCT03799341|Experimental|Voucher Prize-Based Contingency Management (VoucherPBCM)|For participants assigned to VoucherPBCM, prize draws resulting in one or more small, large, or jumbo wins will be reinforced with VA Canteen vouchers in the specified incentive range (i.e., small, large, or jumbo).
89160421|NCT03789396||Pre-implementation|The control groups will be trauma patients admitted to the ICU 12 months prior to targeted normoxia
89160422|NCT03789396||Post-implementation|The intervention group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation.
89160423|NCT03780829|Experimental|hypoxia plus training|combined hypoxia treatment with exercise training
89160424|NCT03780829|Sham Comparator|sham hypoxia plus training|combined sham hypoxia treatment with exercise training
89160425|NCT03780829|Experimental|hypoxia plus training plus NMDA agonist|combined hypoxia treatment with exercise training and with NMDA agonist treatment
89160426|NCT03780829|Placebo Comparator|hypoxia plus training plus sham NMDA agonist|combined hypoxia treatment with exercise training and with sham NMDA agonist treatment
89160427|NCT03777163|Other|Butantan Trivalent Influenza Vaccine|"Butantan Institute Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen~Patients will receive one dose (0,5 ml) via intramuscular injection."
89160428|NCT03777163|Other|Sanofi Trivalent Influenza Vaccine|"Sanofi Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen~Patients will receive one dose (0,5 ml) via intramuscular injection."
89160429|NCT03771105|Experimental|Patients with hereditary hypophosphatemic rickets with HHRH|Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
89160430|NCT03771105|Active Comparator|Patients with X-linked Hypophosphatemia|Patients with X-linked hypophosphatemia
89160431|NCT03771105|Active Comparator|15 Patients with X-linked Hypophosphatemia|15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.
89160432|NCT03771105|Active Comparator|15 Patients Hereditary hypophosphatemic rickets with HHRH|15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.
89160433|NCT03769168|Experimental|Group 1 - Secukinumab 75 mg|Group 1 - Secukinumab (AIN457) 75 mg/0.5mL
89160434|NCT03769168|Experimental|Group 2 - Secukinumab 150 mg|Group 2 - Secukinumab (AIN457) 150 mg/1.0mL
89160435|NCT03767621||Patients with intermediate lesions.|Patients with intermediate lesions (stenosis in angiography between 25% and 60%) in LMCA.
89160436|NCT03724396|Experimental|Novel Executive Function Training - NEXT|Same as BWL with some additional strategies targeted at improving executive function to help adherence to BWL skills.
89160437|NCT03724396|Active Comparator|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
89160438|NCT03715933|Experimental|Dose Escalation|INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas.
89160439|NCT03715933|Experimental|Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
89160440|NCT03715933|Experimental|Expansion Gastric Adenocarcinoma|Subjects with gastric adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
89160441|NCT03715933|Experimental|Expansion Colorectal Adenocarcinoma|Subjects with colorectal (CRC) adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
89160442|NCT03715933|Experimental|Expansion Sarcomas|Subjects with certain sarcoma subtypes will be treated with single-agent INBRX-109 at either the MTD or RP2D.
89160443|NCT03715933|Experimental|Combination Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with INBRX-109 in combination with chemotherapies (carboplatin, cisplatin, carboplatin and pemetrexed, or cisplatin and pemetrexed)
89160444|NCT03715933|Experimental|Combination Expansion Pancreatic Adenocarcinoma|Subjects with pancreatic adenocarcinoma will be treated with INBRX-109 in combination with 5FU/irinotecan based chemotherapy
89160445|NCT03715933|Experimental|Combination Expansion Ewing Sarcoma|Subjects with Ewing Sarcoma will be treated with INBRX-109 in combination with irinotecan and temozolomide
89160446|NCT03715933|Experimental|Combination Expansion Colorectal Adenocarcinoma|Subjects with colorectal adenocarcinoma will be treated with INBRX-109 in combination with FOLFIRI based chemotherapy
89160447|NCT03715933|Experimental|Expansion Solid Tumors|Subjects with Solid tumors and high BMI will be treated with single-agent INBRX-109 at either the MTD or RP2D.
89160448|NCT03715933|Experimental|Combination Expansion SDH-deficient solid tumors or GIST|Subjects with SDH-deficient solid tumors or GIST will be treated with INBRX-109 in combination with temozolomide
89160449|NCT03713034|Experimental|Active Game|"PlayTest! is an interactive world in which the player, using an avatar they have created, travels through life in high school. They face challenges that bring different risks and benefits, requiring them to practice decision-making skills. The player learns skills that aim to empower them to make safe choices in situations that may otherwise increase their risk for HIV/STI infection. The game also provides opportunities for the player to practice advocating for their health by modeling a conversation with a medical professional. PlayTest! incorporates evidence-based tools for behavior change including social learning theory and self-efficacy. message framing, motivational interviewing to identify the variables that must be targeted to increase HTC among adolescents."
89160450|NCT03713034|Active Comparator|Control Game|Some examples of control games that participants could play are: The Sims, Harry Potter, Subway Surfer, Tetris. The control games contained not relevant content related to HIV Testing and Counseling.
89160451|NCT03705897|Other|Screening|Employ innovative methods for assessing personalized guideline-based screening in the clinic setting to evaluate guideline-based, over- and under-screening. Interventions include Computerized Risk Stratification Tool, Algorithmic Risk Stratification Tool, and Step completion assessment.
89160452|NCT03698019|Experimental|Arm I (adjuvant pembrolizumab)|Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
89160453|NCT03698019|Active Comparator|Arm II (adjuvant and neoadjuvant pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
89160454|NCT03695146|Experimental|Paced breathing|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals in this arm will engage in a paced breathing. Initial respiratory rate will be measured with a transducer. Participants will be connected to a paced breathing device (RESPERATE) that will gradually reduce the pace of audio tones presented to those individuals from spontaneous breathing rate down to 6 - 8 breaths per minute.
89160455|NCT03695146|Active Comparator|Relaxing music|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals will be provided with an audio device that plays soothing/relaxing music at a similar range (beats per minute) of the auditory signal presented during the experimental condition. Subjects will not be instructed how to breathe in this arm.
89160456|NCT03695146|No Intervention|No intervention|Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes.
89160457|NCT03691428|Experimental|Intervention|
89160458|NCT03691428|Other|Wait-list|Participants will get the WOOP training after the last outcome assessment.
89160459|NCT03686007|Experimental|Group I (MSM intervention)|Patients and FCGs receive the MSM intervention consisting of videos, a handbook, and research nurse coaching over 40-60 minutes, approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive research nurse support via telephone(separate sessions for FCGs and patients) over 20-30 minutes at 2 and 7 days, and 2 months post-discharge.
89160460|NCT03686007|Active Comparator|Group II (Attention Control)|"Patients and FCGs receive attention control intervention consisting of videos (American Cancer Society video on Clinical Trials), American Cancer Society print materials, and assistance from a CRA approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive assistance from CRAs via telephone at 2 and 7 days, and 2 months post-discharge."
89160461|NCT03684096|Active Comparator|non-estrogenic pollen extract PCC-100|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
89160462|NCT03684096|Placebo Comparator|placebo|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
89160463|NCT03673800|Experimental|Cognitive Training|Online Cognitive training on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
89160464|NCT03673800|Sham Comparator|Online sensorial program|Online sensorial program on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
89160465|NCT03671694|Active Comparator|laser treatment|Erbium-YAG laser treatment to the vagina
89160466|NCT03671694|Placebo Comparator|sham treatment|sham treatment with laser placebo
89160467|NCT03666533|Active Comparator|Active tDCS|active tDCS plus gait training
89160468|NCT03666533|Sham Comparator|Sham tDCS|sham tDCS plus gait training
89160469|NCT03659695|Experimental|Grape Powder|69 g/d freeze dried grape powder
89160470|NCT03659695|Placebo Comparator|Placebo powder|69 g/d placebo powder matched for taste and appearance
89160471|NCT03655028|Experimental|RAS-music group|Home-based, exercise program augmented with rhythmically auditory stimulation enhanced music
89160472|NCT03655028|Active Comparator|Control group|Home-based, exercise program without rhythmically auditory stimulation enhanced music
89160473|NCT03634839|Experimental|Sweet non-menthol, nicotine 36mg/ml|Sweet flavor non-menthol (Watermelon) with 36mg/ml Nicotine
89160474|NCT03634839|Experimental|Sweet menthol, nicotine 36mg/ml|Sweet flavor with menthol (Watermelon-menthol) with 36mg/ml Nicotine
89160475|NCT03631667|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
89160476|NCT03631667|Experimental|50 ng dose plus 1250 ng phenanthrene|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP) and 1250 phenanthrene
89160477|NCT03623386|Experimental|Patients with PD neurofeedback training|Patients will receive neurofeedback training.
89160478|NCT03623386|Active Comparator|Patients with PD control|Patients will not receive neurofeedback training.
89160479|NCT03623386|No Intervention|Patients with PD|Patients perform mental imagery (motor and visual aspects combined) in the MRI scanner without neurofeedback training.
89160480|NCT03587701|Experimental|Group A|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2
89160481|NCT03587701|Experimental|Group B|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2
89160482|NCT03587701|Experimental|Group C|This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2
89160483|NCT03587038|Experimental|OKN-007 3 days per week plus temozolomide|OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
89160484|NCT03587038|Experimental|OKN-007 5 days per week and temozolomide|OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
89160485|NCT03574974|Experimental|Experimental Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators believe may help them learn to control their PTSD symptoms.
89160486|NCT03574974|Placebo Comparator|Control Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators do not believe can help their PTSD symptoms.
89160487|NCT03569553||AIGIV|Inhalational anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
89160488|NCT03569514||AIGIV|Anthrax patients who have been administered AIGIV (ANTHRASIL®) as per licensed US prescribing information.
89160489|NCT03531645|Experimental|Fulvestrant + Abemaciclib|
89160490|NCT03522974|Placebo Comparator|Placebo|40 g/d placebo powder
89160491|NCT03522974|Experimental|Strawberry powder (high dose)|40 g/d freeze dried strawberry powder
89160492|NCT03522974|Active Comparator|Strawberry powder (low dose)|13 g/d freeze dried strawberry powder
89160493|NCT03516214|Experimental|EGF816 (nazartinib) and trametinib|Patients will receive oral EGF816 (nazartinib) and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
89160494|NCT03476798|Experimental|Bevacizumab + Rucaparib|
89160495|NCT03464019|Experimental|Etripamil 70 mg Single Dose|Self- administration of a single dose of 70 mg of etripamil.
89160496|NCT03464019|Placebo Comparator|Placebo Single Dose|Self- administration of a single dose of placebo.
89160497|NCT03464019|Experimental|Etripamil 70 mg with Optional Second Dose|Dosing regimen that permits a second dose of etripamil 70 mg
89160498|NCT03464019|Placebo Comparator|Placebo with Optional Second Dose|Dosing regimen that permits a second dose of placebo.
89160499|NCT03444714|Experimental|RiMO-301+Radiotherapy|3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study
89160500|NCT03399773|Experimental|Treatment (chemotherapy, TBI, NLA101)|"Patients receive either regimen A or regimen B.~REGIMEN A: Patients (10 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by dilanubicel IV within the next 24 hours on day 0.~REGIMEN B: Patients (10 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 2-4 hours on days -5 and -4. Patients undergo TBI QD on days -2 and -1. Patients receive unmanipulated cord blood unit IV followed by dilanubicel IV within the next 24 hours on day 0.~All patients undergo bone marrow aspirate and biopsy as clinically indicated during screening and on study. Patients undergo MUGA or ECHO, and CT during screening. Patients also undergo blood sample collection on study."
89160501|NCT03397251|Experimental|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
89160502|NCT03395197|Experimental|Combination arm|Talazoparib plus enzalutamide
89160503|NCT03395197|Active Comparator|Monotherapy arm|Ezalutamide plus placebo
89160504|NCT03388346|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
89160505|NCT03376867||Healthy volunteers|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
89160506|NCT03376867||Volunteers with chronic pain|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
89160507|NCT03376152|Active Comparator|Treatment Arm|"Poverty households invited to attend cluster-level electric kettle promotion events and offered free kettles, information, and promotional materials 450 households in 15 clusters (30 households per cluster)"
89160508|NCT03376152|No Intervention|Control Arm|450 households in 15 clusters (30 households per cluster)
89160509|NCT03372733|Experimental|Group 1|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2weeks and cross-over to the palmitoleate-rich oil
89160510|NCT03372733|Experimental|Group 2|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the control olive oil
89160511|NCT03354585|Experimental|mindfulness group|"Study volunteers will participate in a six-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
89160512|NCT03354585|Sham Comparator|non-mindfulness group|Study volunteers will participate in a six-session meditation training regimen. In brief, subjects will be taught to take deep breaths and relax.
89160513|NCT03354585|Active Comparator|book-listening|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 6 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
89160514|NCT03352245|Experimental|Intervention Group|Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
89160515|NCT03352245|No Intervention|Control Group|Usual care group will receive standard of care management from their Oncologist.
89160516|NCT03348215|Other|Enhanced Treadmill Training|Treadmill walking with an immersive environment and bio mechanical support (body weight, ankle-foot -orthosis and functional electrical stimulation)
89160517|NCT03332264|Experimental|Drug coated balloon catheter|"PTA with paclitaxel coated SeQuent Please OTW"
89160518|NCT03332264|Active Comparator|Drug coated stent|"PTA with paclitaxel coated Eluvia Vascular Stent System"
89160519|NCT03332264|Active Comparator|Uncoated stent|PTA with bare nitinol stent (as commonly used in site)
89160520|NCT03307967|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
89160521|NCT03301506|Experimental|Seladelpar 5 mg Capsules|
89160522|NCT03301506|Experimental|Seladelpar 10 mg Capsule|
89160523|NCT03290300||Long-Term Study Subjects|This cohort will consist of all subjects who were treated with the Vivaer Stylus in the 50-subject TP258 interventional study, who consent to continue to provide quality of life data.
89160524|NCT03287583|Experimental|SBIRT|SBIRT intervention for Gambling
89160525|NCT03287583|Other|Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
89160526|NCT03282981|Experimental|Timolol|Timoptic-XE plus standard of care (SOC)
89160527|NCT03282981|Placebo Comparator|SOC plus non biologically active gel|SOC plus non biologically active gel (hydrogel as placebo medication)
89160528|NCT03264261|Experimental|robotic training|For the robotic training group, a controlled resistance load will be applied to the unaffected leg at the ankle and an assistance load will be applied to the pelvis.
89160529|NCT03264261|Active Comparator|treadmill training|For the treadmill training only group, a physical therapist will provide manual assistance to the affected leg at the knee and/or ankle joints as necessary during treadmill training.
89160530|NCT03239470|Experimental|Cohort 1: 1.0 x 10^8 PolyTregs|A single intravenous infusion of 1.0 x 10^8 PolyTregs will be administered.
89160531|NCT03239470|Experimental|Cohort 2: 2.5x10^8 PolyTregs|A single intravenous infusion of 2.5x10^8 PolyTregs will be administered.
89160532|NCT03206645|Experimental|Carboplatin/Paclitaxel + PTC596|Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 175mg/m2 IV on day 1; Unesbulin PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.
89160533|NCT03199209|Experimental|Group I (home visit, information about healthy lifestyles)|Participants and their family member meet with a community health worker in their home over 90 minutes to learn about physical activity, healthy eating, and to set goals, once a month for 6 months. Participants also receive 2-5 text messages per week that contain health tips related to healthy lifestyles and information about local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
89160534|NCT03199209|Experimental|Group II (home visit, information about healthy homes)|Participants and their family member meet with a community health worker in their home over 90 minutes to receive information on how to be safe and healthy at home and information about indoor air quality, home safety, CPR/first aid, how to prepare for emergencies, and keeping pests away, once a month for 6 months. Participants also receive 2-5 text messages per week that contain information about healthy homes and local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
89160535|NCT03190941|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
89160536|NCT03190941|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
89160537|NCT03188432|Experimental|Treatment - Carboplatin, CRS, HIPEC|Beginning 4-8 weeks after completion of chemotherapy, patients undergo CRS. Patients then receive carboplatin IP over 90 minutes immediately following CRS.
89160538|NCT03171129|Experimental|High flow nasal cannula system w/ ADINA|The intervention is the insertion of the the ADINA device into the high flow nasal cannula system. ADINA will be placed according to weight class recommendations to increase the positive end expiratory pressure (PEEP). ADINA is actually a combination of the Neotech RAM Cannula and a clear Regulator/Pop off valve.
89160539|NCT03171129|Active Comparator|high flow nasal cannula system|High flow nasal cannula will deliver oxygen at 2-4 lpm of flow. High flow cannula are used to provide the control interface.
89160540|NCT03157323|Other|Low Glycemic Index Diet|Following a low glycemic index diet verses a standard american diet.
89160541|NCT03143374|Experimental|Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative Disease|Individuals who have been diagnosed with FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD-ALS may participate in this study if they are 18 years of age or older; most participants will be receiving care at the clinical practices of the of the University of Pennsylvania and at Pennsylvania Hospital Department of Neurology. Healthy control subjects will also be recruited for this study.
89160542|NCT03122418|Experimental|Exercise Study Group|All subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
89160543|NCT03059264||CDM|Children with Congenital Myotonic Dystrophy
89160544|NCT03059264||Control|Healthy Children
89160545|NCT03053791|Experimental|Intervention group|Single-armed study. All patients will receive treatment.
89160546|NCT03035643|Experimental|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
89160547|NCT03035500|Experimental|Supportive Care (long-term follow-up)|Patients undergo long-term follow-up and receive a written survivorship care plan including comprehensive health evaluation and health education beginning 1 year post surgery.
89160548|NCT03033992|Experimental|Treatment (Optune System)|Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory. All patients will use the study device Optune System (Tumor Treating Fields, TTFields).
89160549|NCT03033992|Experimental|Treatment (Concurrent Optune/focal radiation therapy followed by Optune-only therapy)|Patients must have newly diagnosed DIPG (a typical DIPG on MR imaging, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, without histologic confirmation; atypical DIPG undergoing a biopsy and the tumor is a diffuse glioma WHO Grade II-IV with OR without H3 K27M mutation; or pontine lesions that do not meet these MR imaging criteria with histologically confirmed diffuse glioma WHO Grade II-IV with H3 K27M- mutation). This arm will consist of two parts: a phase I component to evaluate the safety and tolerability of concurrent Optune and RT, and a phase II component to evaluate the feasibility of concurrent Optune and RT and the efficacy associated with this approach compared to historical controls.
89160550|NCT03018366|Active Comparator|17Beta Estradiol, Progesterone|17Beta Estradiol (0.1mg/day) , Progesterone (100mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 100mg is a peanut based product
89160551|NCT03018366|Placebo Comparator|Transdermal Placebo Patch, Placebo Pill|Placebo Transdermal Patch, Placebo Pill
89160552|NCT03016533|Experimental|Dolutegravir (Tivicay)|All participants will receive dolutegravir film-coated tablets or film-coated dispersible tablets at appropriate doses selected as per their age and weight bands. For those participants who were previously receiving dolutegravir in study P1093 (parent study), dolutegravir will be supplied as film-coated tablets containing 50 mg; and 5 mg film-coated dispersible tablets of dolutegravir. Participants will receive dolutegravir until age-appropriate formulations are available to them from some other source, or until participant is no longer deriving benefit from treatment, or participant is discontinued, or until development of dolutegravir is terminated.
89160553|NCT03016533|Experimental|ABC/DTG/3TC|All participants will receive ABC/DTG/3TC immediate release tablets or film-coated dispersible tablets at appropriate doses selected as per their weight bands. For those participants who were previously receiving ABC/DTG/3TC in study P2019 (parent study), ABC/DTG/3TC will be supplied as immediate release tablets containing 600 mg, 50 mg and 300 mg of ABC, DTG, and 3TC respectively and film-coated dispersible tablets containing 60 mg, 5 mg and 30 mg of ABC, DTG, and 3TC respectively. Participants will receive ABC/DTG/3TC until age-appropriate formulations are available to them from some other source, until participant is no longer deriving benefit from treatment, or until participant is discontinued, or until development of ABC/DTG/3TC is terminated.
89160554|NCT02991248|Experimental|robotic training & stimulation|Device: robotic treadmill training paired with active spinal cord electrical stimulation, three times a week for 6 weeks.
89160555|NCT02991248|Active Comparator|robotic training & sham|Device: robotic training paired with sham spinal cord stimulation, three time a week for 6 weeks.
89160556|NCT02991248|Placebo Comparator|treadmill only|Device: treadmill Conventional treadmill training only, three time a week for 6 weeks.
89160557|NCT02970045||Ancillary-Correlative (biospecimen collection)|Patients undergo collection of blood during a regular care visit or not up to 4 times a year. Extra tissue is collected after removal during standard of care surgery and patients may undergo additional tumor sampling (needle passes) at the time of planned diagnostic biopsies. During bone marrow biopsy, the doctor may reposition the needle up to 3 times, and bone marrow for research will not be collected more than 4 times per year. Patients may undergo additional collection of other biological samples such as saliva, sputum, urine, feces, hair, and surface skin swabs for analysis. Patients also receive surveys or questionnaires to collect demographics, medical, family, and nutritional history, cancer predisposing risk factors, quality of life data, and quality of care data.
89160558|NCT02963649|Experimental|drug-eluting balloon IN.PACT 014|product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.
89160559|NCT02963649|Active Comparator|Standard angioplasty balloon|standard PTA balloon
89160560|NCT02938520|Experimental|CAB LA + RPV LA every 4 weeks|After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.
89160561|NCT02938520|Active Comparator|ABC / DTG / 3TC (600 mg/50mg/300mg) once daily|After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).
89160562|NCT02918162|Experimental|Pembrolizumab|"All study subjects will receive standard of care chemotherapy regimen for 3 cycles prior to and 3 cycles following surgery in combination with Pembrolizumab with an additional cycle of Pembrolizumab (4 total) in the pre-operative period. Additionally subjects will complete 12 months of maintenance Pembrolizumab (14 additional doses to complete 17 post-operative cycles) following completion of post-operative chemotherapy.~Standard of care combination chemotherapy regimen has a 21-day cycle."
89160563|NCT02851979|Experimental|S0 - S1 - S2|S0 = no stimulation; washout; S1 = vehicle; washout; S2 = olfactory stimulation
89160564|NCT02851979|Experimental|S0 - S2 - S1|S0 = no stimulation; washout; S2 = olfactory stimulation; washout; S1 = vehicle
89160565|NCT02851979|Experimental|S1 - S0 - S2|S1 = vehicle; washout; S0 = no stimulation; washout; S2 = olfactory stimulation
89160566|NCT02851979|Experimental|S1 - S2 -S0|S1 = vehicle; washout; S2 = olfactory stimulation; washout; S0 = no stimulation
89160567|NCT02851979|Experimental|S2 - S0 - S1|S2 = olfactory stimulation; washout; S0 = no stimulation; washout; S1 = vehicle
89160568|NCT02851979|Experimental|S2 - S1 - S0|S2 = olfactory stimulation; washout; S1 = vehicle; washout S0 = no stimulation
89160569|NCT02779855|Experimental|Talimogene laherparepvec + Chemotherapy|Talimogene laherparepvec with Neoadjuvant Paclitaxel Chemotherapy treatment administration on an outpatient basis. Phase I: Dose Escalation to Determine Maximum Tolerated Dose (MTD). Phase II: Treatment at MTD.
89160570|NCT02771977|No Intervention|Usual Care|No alert will be fired.
89160571|NCT02771977|Experimental|Drug-specific alert|A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.
89160572|NCT02755623|Active Comparator|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|low-frequency (1 Hertz) rTMS
89160573|NCT02755623|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|sham TMS
89160574|NCT02740699|Other|Moderate to High Statin Treatment in Participants with Coronary Artery Plaque|Participants with coronary artery plaque will receive moderate to high statin treatment at either 20-40 mg once daily Rosuvastatin or 40-80 mg once daily of Atorvastatin.
89160575|NCT02717156|Experimental|Treatment (EphB4-HSA and pembrolizumab)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1, 8, and 15 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89160576|NCT02704858|Experimental|NEO100 Phase 1|Intranasal delivery of NEO100 (perillyl alcohol) four times a day, escalation up to four different doses to determine maximum tolerated dose.
89160577|NCT02704858|Experimental|NEO100 Phase 2A|Intranasal delivery of NEO100 (perillyl alcohol) four times a day. Treatment of total of 25 patients at maximum tolerated dose.
89160578|NCT02669251|Experimental|Phase 1b|Phase Ib dose escalation
89160579|NCT02669251|Experimental|Phase 2|MTD po bid on days 1-28
89160580|NCT02645487|Experimental|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Dose-Escalation
89160581|NCT02636517|Other|C. Difficile without IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile
89160582|NCT02636517|Other|C. Difficile with IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease
89160583|NCT02595905|Active Comparator|Arm I (cisplatin and placebo)|Patients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89160584|NCT02595905|Experimental|Arm II (cisplatin and veliparib)|Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89160585|NCT02520921|Active Comparator|Arm 1 : Novel strategy|enteric coated aspirin 100 mg in the morning and 100 mg in the evening
89160586|NCT02520921|Active Comparator|Arm 2 : Conventional strategy|enteric coated aspirin 100 mg in the morning
89160587|NCT02504372|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).
89160588|NCT02504372|Placebo Comparator|Placebo|Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).
89160589|NCT02443077|Experimental|Arm I (ibrutinib, chemotherapy, autoHCT)|"CONDITIONING REGIMEN: Investigators may choose to use either the BEAMi or CBVi regimen.~BEAMi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV BID over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1.~CBVi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2.~TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.~CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity."
89160590|NCT02443077|Placebo Comparator|Arm II (placebo, chemotherapy, autoHCT)|"CONDITIONING REGIMEN: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I.~TRANSPLANT: Patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.~CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I."
89160591|NCT02439060|Experimental|Arm I (biologic mesh)|Patients undergo placement of biologic mesh during radical cystectomy and placement of the ileal conduit.
89160592|NCT02439060|No Intervention|Arm II (no intervention)|Patients undergo standard of care radical cystectomy and placement of the ileal conduit.
89160593|NCT02420613|Experimental|Arm I (vorinostat, radiation therapy, temsirolimus)|"CHEMORADIOTHERAPY PHASE: Patients receive vorinostat QD and undergo radiation therapy QD for 30 fractions over 6-7 weeks.~MAINTENANCE PHASE: Four to six weeks after the completion of radiation therapy, patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8 of each cycle. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity."
89160594|NCT02420613|Experimental|Arm II (vorinostat, temsirolimus)|Patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
89160595|NCT02406729|Experimental|Dengue 1,2,3,4 (attenuated) vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
89160596|NCT02406729|Placebo Comparator|Placebo|Placebo Single dose, SC
89160597|NCT02357238||Uveitis|Uveitis or infectious uveitis patients
89160598|NCT02354365||Normal lungs|Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
89160599|NCT02354365||Acute Hypoxic Respiratory Failure|Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS).
89160600|NCT02354365||Obstructive airway disease|Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
89160601|NCT02311335||1|Dyslipidemia patients
89160602|NCT02266719|Experimental|Fenestrated CMD cohort|Patients enrolled in this arm will be implanted with the custom made fenestrated device. The device is aimed to treat complex abdominal aortic aneurysms including juxtarenal, suprarenal and type IV thoracoabdominal aneurysms.
89160603|NCT02266719|Experimental|Type I - III TAAA cohort|Patients enrolled in this arm will be implanted with the custom made/ off-the-shelfp branched devices. The device is aimed to treat type I-III TAAAs.
89160604|NCT02266719|Experimental|Arch cohort|Patients enrolled in this arm will be implanted with patient-specific stent-grafts with one to three inner branches or a scallop.
89160605|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 1 (brentuximab 1.2mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.2mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
89160606|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 2 (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
89160607|NCT02227199|Experimental|Phase II: Dose Expansion (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
89160608|NCT02224469|Experimental|ECoG (electrocorticography) sensing|Use ECoG-based Brain Computer interface to control assistive technology
89160609|NCT02181881|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
89160610|NCT02181881|Active Comparator|Life Steps|A 3-session HIV medication adherence support program for individuals.
89160611|NCT02181881|No Intervention|Treatment as usual (TAU)|HIV positive individuals will continue to follow their current HIV treatment plan.
89160612|NCT02180867|Experimental|Regimen A (pazopanib, chemoradiation)|See Regimen A Detailed Description.
89160613|NCT02180867|Experimental|Regimen B (chemoradiation)|See Regimen B Detailed Description.
89160614|NCT02180867|Experimental|Regimen C (pazopanib, radiation therapy)|"INDUCTION PHASE: Patients receive pazopanib PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.~SURGERY: Patients undergo surgery on week 10.~CONTINUATION PHASE: Patients receive pazopanib PO QD on weeks 13-25. If applicable, patients undergo additional radiation therapy at week 13."
89160615|NCT02180867|Experimental|Regimen D (radiation therapy)|"INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.~SURGERY: Patients undergo surgery on week 10.~CONTINUATION PHASE: If applicable, patients undergo additional radiation therapy at week 13."
89160616|NCT02163408||Healthy Volunteers|100 healthy volunteers will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality and image contrast will be compared between the two protocols.
89160617|NCT02163408||Patients with Carotid Artery Disease|40 patients will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality, image contrast, and composition analysis will be compared between the protocols.
89160618|NCT02143414|Experimental|Cohort I (blinatumomab, POMP)|See Detailed Description
89160619|NCT02143414|Experimental|Cohort II (dasatinib, prednisone, blinatumomab)|See Detailed Description
89160620|NCT01997840|Experimental|ACY-1215 in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
89160621|NCT01867411||ex-smokers|former smokers who have quit
89160622|NCT01867411||never smokers/vapers|never smoked/vaped nicotine
89160623|NCT01867411||non-treatment seeking smokers/vapers|smokers/vapers not interested in quitting nicotine
89160624|NCT01867411||Treatment seeking smokers/vapers|smokers/vapers interested in quitting nicotine
89160625|NCT01856192|Experimental|Arm A (rituximab, combination chemotherapy, lenalidomide)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1; prednisone PO on days 1-5; and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89160626|NCT01856192|Active Comparator|Arm B (rituximab, combination chemotherapy)|Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89160627|NCT01841736|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening. Patients also undergo CT, MRI, and chest x-ray throughout the trial. Patients may optionally undergo blood sample collection during screening and on study.
89160628|NCT01841736|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I. Patients undergo ECHO or MUGA during screening. Patients also undergo CT, MRI, and chest x-ray throughout the trial. Patients may optionally undergo blood sample collection during screening and on study.
89160629|NCT01812252|Other|Arm A (decitabine or azacitidine)|Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.
89160630|NCT01812252|Other|Arm B (induction-like chemotherapy regimen)|Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.
89160631|NCT01782638|Experimental|deep brain stimulation with high frequency|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
89160632|NCT01782638|Other|low frequency on gait of patients|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
89160633|NCT01708954|Experimental|Arm A (erlotinib)|Patients receive erlotinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89160634|NCT01708954|Experimental|Arm B (cabozantinib)|Patients receive cabozantinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89160635|NCT01708954|Experimental|Arm C (erlotinib+cabozantinib)|Patients receive erlotinib as patients in Arm A and cabozantinib as patients in Arm B. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89160636|NCT01708954|Experimental|Arm Z (erlotinib+cabozantinib; step II)|Patients achieving disease progression in Arm A or Arm B may receive erlotinib and cabozantinib as patients in Arm C. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89160637|NCT01684839|Other|new surgical treatment|Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap taken from the homolateral dorsal branch of the digital nerve.
89160638|NCT01654133|Experimental|Endovascular TAAA Repair|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
89160639|NCT01654133|Experimental|Endovascular Ascending/Aortic Arch Branch Repair|Endovascular repair of aortic ascending/arch aneurysm using branched stent grafts
89160640|NCT01586130|Other|isokinetic exercises in eccentric mode|
89160641|NCT01586130|Other|isokinetic exercises in concentric mode|
89160642|NCT01542580||Vanguard SSK 360 with PS Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized (non-constrained) tibial bearing.
89160643|NCT01542580||Vanguard SSK 360 with PSC Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized Constrained tibial bearing.
89160644|NCT01542580||Vanguard DA 360|Patients enrolled using a Vanguard DA 360 component.
89160645|NCT01542580||Vanguard 360 TiNbN Femur with PS Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
89160646|NCT01542580||Vanguard 360 TiNbN Femur with PSC Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
89160647|NCT01479218|Other|PDA Occluder|single arm
89160648|NCT01386385|Experimental|Arm I (RT, veliparib, carboplatin, paclitaxel)|Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
89160649|NCT01386385|Active Comparator|Arm II (3D-CRT, placebo, carboplatin, paclitaxel)|Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
89160650|NCT01288274|Active Comparator|Injection by Health Extension Worker|Women who receive injectable contraceptive from clinic based health extension workers (HEWs) during the study period
89160651|NCT01288274|Active Comparator|Injection by Community Health Worker|Women who receive injectable contraceptive through community based distributors from community based reproductive health agents (CBRHAs) during the study period
89160652|NCT01275677|Active Comparator|Arm I (chemotherapy)|"GROUP IA: Patients receive docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.~GROUP IB: Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-3 weeks after last dose of doxorubicin hydrochloride and cyclophosphamide, patients also receive paclitaxel IV over 60 minutes once weekly for 12 doses in the absence of disease progression or unacceptable toxicity."
89160653|NCT01275677|Experimental|Arm II (chemotherapy, trastuzumab)|"GROUP IIA: Patients receive docetaxel and cyclophosphamide as in Group IA. Patients also receive trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity.~GROUP IIB: Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in Group IB. Patients also receive trastuzumab IV over 30-90 minutes weekly for 12 doses and then every 3 weeks for subsequent doses. Treatment repeats every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity."
89160654|NCT01251861|Active Comparator|Arm A (observation and bicalutamide)|Patients undergo observation on weeks 1-12. Patients then receive bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
89160655|NCT01251861|Experimental|Arm B (Akt inhibitor MK2206 and bicalutamide)|Patients receive Akt inhibitor MK2206 PO once per week on weeks 1-44 and bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on Akt inhibitor MK2206 and bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
89160656|NCT01175993|Active Comparator|Eliptical training|Home base exercise
89160657|NCT01142388|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
89160658|NCT01142388|Experimental|Arm II (cixutumumab, paclitaxel)|Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
89160659|NCT01134614|Experimental|Arm A (ipilimumab and sargramostim)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment repeats every 21 days for 4 cycles. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment with ipilimumab repeats every 12 weeks and treatment with sargramostim repeats every 21 days. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and patients with responsive or stable disease then continue maintenance therapy until disease progression or unacceptable toxicity.
89160660|NCT01134614|Active Comparator|Arm B (ipilimumab)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy of ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 12 weeks. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity
89160661|NCT01125228||AZT Alone|Zidovudine 200mg by mouth every 4hr
89160662|NCT01125228||AZT plus IFN|-Zidovudine 200mg by mouth every 4hr -Alpha Interferon 1 million units once a day, escalating
89160663|NCT01125228||IFN Alone|-Alpha Interferon 1 million units once a day, escalating
89160664|NCT00601900|Experimental|Arm I (endocrine therapy with monoclonal antibody)|Patients receive endocrine therapy* (tamoxifen citrate* or letrozole) PO QD on days 1-21 and bevacizumab 15 mg/kg IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89160665|NCT00601900|Active Comparator|Arm II (endocrine therapy)|Patients receive endocrine therapy* (tamoxifen citrate* or letrozole) PO QD on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89160666|NCT00561223|Experimental|1|"This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with COPD as reflected by 1) a constant or reduced alveolar to arterial O2 difference as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in the lung diffusing capacity for carbon monoxide that occurs in the absence of a change in spirometry, 3) an improvement in the ventilatory equivalent for oxygen and CO2 measured by expired gas analysis.~It is anticipated that a positive result in this pilot study would lead to a larger long-term study examining the effect of iloprost on gas exchange, exercise tolerance and quality of life in patients with COPD."
89160667|NCT00488878||Observational (electronic health record review)|Patients' medical records are reviewed for retrospective and prospective data collection. Patients may also have residual tissue samples collected and stored.
89160668|NCT00455104||National Registry|To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
89160670|NCT00217737|Active Comparator|Arm A (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
89160671|NCT00217737|Experimental|Arm B (combination chemotherapy, bevacizumab)|Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity.
89160672|NCT00217737|No Intervention|Arm C (observation)|Patients undergo observation.
89160673|NCT00111384||Group A|Affected participants, must have a correct clinical diagnosis of NF1.
89160674|NCT00111384||Group B|Unaffected individuals greater than 2 years of age who are relatives of participants.
89160675|NCT00005909||Alkaptonuria|Patients with confirmed or suspected alkaptonuria
89160676|NCT00001594||Children with OI|Children with OI
89160679|NCT00680940|Active Comparator|Chemotherapy|Paclitaxel + Cisplatin
89160680|NCT00680940|Experimental|Chemoimmunotherapy|Paclitaxel + Cisplatin + Mycobacterium w
89160681|NCT02755025||Prospective cohort|This group will include ICU patients for the two month period after the automated SOFA score has been activated within the electronic patient care dashboard.
89160682|NCT02576392|Experimental|Intervention|Informational letter mailed approximately 2 weeks prior to surgery, informational letter mailed approximately 2 weeks post surgery, pharmacist call if refill opioid medicine more than 28 days after surgery
89160683|NCT02576392|No Intervention|Control|Usual Care
89160684|NCT02644304|Active Comparator|Clomiphene citrate plus cabergoline|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus cabergoline 0.25 mg from second day every 3 days (4 doses only)
89160685|NCT02644304|Active Comparator|Clomiphene citrate plus placebo|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus placebo tablets from second day every 3 days (4 doses only)
89160686|NCT02754713||Patients with acute pericarditis|300 patients with a first episode of acute pericarditis
89160687|NCT00681018|Experimental|1|Liquid human milk fortifier
89160688|NCT00681018|Active Comparator|2|Powder human milk fortifier
89160689|NCT02648126|Other|Pure red cell aplasia participants|Group of participants with pure red cell aplasia and chronic kidney disease, that have resistance criteria to treatment with epoetin alfa produced by Bio-Manguinhos / Fiocruz. The Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation.
89160690|NCT04221113|Active Comparator|Group A ( Immobilization protocol)|Group A patients will receive static splints.By the end of 4 weeks the splint will be modified and patients will start doing physiotherapy. Movement at MCPJ will be from 0 to 45 degrees.
89160691|NCT04221113|Active Comparator|Group B( early active mobilization protocol).|Group B patients will receive splints in such a way that from 3rd post operative day patients will be instructed to do physiotherapy. Initially MCPJ movement will be from 0 to 30 degrees.
89160692|NCT00681174|Active Comparator|Control|Control intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
89160693|NCT00681174|Experimental|CROxy|The intervention group will receive controlled-release oxycodone 1 h pre-operatively
89160694|NCT02653352|No Intervention|Control|The control group received two one-hour general sessions on health issues and printed general advices regarding healthy diets.
89160695|NCT02653352|Experimental|Lifestyle modification|Intervention was focused on the reduction in consumption of sugar-sweetened carbonated beverages by students. During seven months of one school year, a healthy lifestyle education programme was implemented using simple messages encouraging water consumption instead of sugar-sweetened carbonated beverages. Education was delivered via classroom activities; banners were hung promoting water consumption, and water bottles with the logo of the campaign were given to children and schoolteachers.
89160696|NCT02575066|Other|radiotherapy combined with pazopanib|patients during the first part of the study received concurrent radiotherapy (25x2Gy) and pazopanib (QD 800 mg). The patients of the second part of the study will receive concurrent radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
89160697|NCT02647970|Experimental|Group A|Dietary intervention
89160698|NCT02647970|Active Comparator|Group B|Dietary intervention
89160699|NCT02758769||ORENCIA with Exposure|ORENCIA with Exposure
89160700|NCT04272931|Experimental|Portal and Hepatic Vein Embolization|3 patients per center over one year approximately 90 patients in total. Patients will undergo portal vein and hepatic vein embolization instead of only portal vein embolization.
89160701|NCT04150146|Other|Sequence A (RT)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
89160702|NCT04150146|Other|Sequence B (TR)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:~• Rebamipide SR 150 mg: At 9 am on 1d (8d), take with 150 mL of water under the fasting condition for ≥10 hours or after a high-fat meal."
89160703|NCT00652730|Experimental|A|Subjects received the Par formulated product under fasting conditions
89160704|NCT00652730|Experimental|B|Subjects received the Par formulated product under fed conditions
89160705|NCT00652730|Active Comparator|C|Subjects received the Bristol-Myers Squibb formulated product under fed conditions
89160706|NCT02758535|Experimental|Core needle biopsy with coaxial method|The patients undergo renal biopsy with a coaxial Tru-Cut needle
89160707|NCT02758535|Experimental|Core needle biopsy with noncoaxial method|The patients undergo renal biopsy with a noncoaxial Tru-Cut needle
89160708|NCT00681252|Experimental|A|
89160709|NCT02653586|Experimental|"program In Favor of Resilience Self"|"The program In Favor of Resilience Self was delivered to adolescence aged 15-17, over 2 months. The program contained nine weekly, 90-min lessons that focus on enhancing self- resilience, self-esteem, self-image, body image. All students completed a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
89160710|NCT02653586|No Intervention|control group|The control group didn't receive the intervention program, instead they received a lecture on wised nutrition. In addition the control group completed the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program.
89160711|NCT04271683|Experimental|Pressure controlled ventilation with PEEP|In this group, ventilation after apnoea during induction of general anesthesia starts with pressure controlled ventilation with PEEP.
89160712|NCT04271683|Active Comparator|Manual ventilation without PEEP|In this group, ventilation after apnoea during induction of general anesthesia starts with manual ventilation without PEEP.
89160713|NCT04224467|Experimental|Indocyanine Green Fluorescent Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then, a NIR imaging systems included the NIR (800-900 nm) and white-light (400-650nm) dual-channel will be used to detect In situ lesions, metastatic lesions, lymph nodes, obturator nerve, pelvic autonomic nerve, etc during surgery according to disease and clinical needs.
89160714|NCT02644148|Other|Conventional Roux-en-Y anastomosis|Conventional Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
89160715|NCT02644148|Experimental|Uncut Roux-en-Y anastomosis|Uncut Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
89160716|NCT00681330|Experimental|A|
89160717|NCT04070872|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
89160718|NCT04070872|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
89160719|NCT03437161|Experimental|Radiation Therapy (RT)|Patients attend a simulation visit and undergo two CT scans, one in the prone position and one in the supine position with DIBH. Within 1 week after the simulation visit, patients undergo radiation therapy either in the supine position with DIBH or in the prone position daily for 15-30 consecutive days as per physician's prescription.
89160720|NCT02768051|Experimental|AF Ablation Intervention|Subjects who are scheduled to undergo ablation procedure due to atrial flutter.
89160721|NCT02627040|Active Comparator|InterTan Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail with an InterTan device (two-integrated screws)
89160722|NCT02627040|Active Comparator|Gamma 3 Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail and Gamma 3 locking nail (single screw)
89160723|NCT00652808|Active Comparator|Arm 1|
89160724|NCT00652808|Active Comparator|Arm 2|
89160725|NCT04073212|Experimental|Intervention 1 DN+HSLE|Patients in the intervention 1 Dry Needling (DN)+heavy Slow Load Exercise (HSLE) group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon followed by DN, HSLE and a standardized shoulder strengthening exercise program.
89160726|NCT04073212|Active Comparator|Intervention 2 Control|"Patients in the control group will attend physical therapy one to two sessions per week for up to 4 weeks for a total of 6 sessions. Each treatment session will last for a total of 45 minutes. A standardized physical therapy program will be used and will include soft tissue mobilization to the shoulder and biceps tendon and a standardized exercise program. Dry needling nor heavy slow load exercise will not be integrated into the control plan of care."
89160727|NCT00635531|Placebo Comparator|Placebo group|
89160728|NCT00635531|Active Comparator|Alprazolam XR group|
89160729|NCT05137795|Experimental|Severe COVID-19 ZYESAMI™|Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
89160730|NCT05137795|Experimental|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
89160731|NCT02535156|Experimental|Schizotypal Personality Disorder|Schizotypal Personality Disorder (SPD) patients. They received two interventions: risperidone 1 mg and placebo (lactose).
89160732|NCT02535156|Experimental|Healthy controls|Control group consisting of healthy volunteers.They received two interventions: risperidone 1 mg and placebo (lactose).
89160733|NCT02578264||All participants|All subjects enrolled in the study will provide tumor and normal tissue and blood samples.
89160734|NCT03417895|Experimental|A(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
89160735|NCT03417895|Experimental|B(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（5 Days on, 2 Days off）
89160736|NCT03417895|Experimental|C(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（7 Days on, 7 Days off）
89160737|NCT02754401|Other|group 1|non-periodontitis persons (PSI 0-2)
89160738|NCT02754401|Other|group 2|periodontitis persons (PSI 3-4)
89160739|NCT02653508|Experimental|Diet and Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, while the nutritional education comprised of a supplementary 15 minutes of group-based sessions that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
89160740|NCT02653508|Experimental|Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
89160741|NCT02653508|No Intervention|Control|61 overweight and obese adolescents aged 13-15 years old were the control group of the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
89160742|NCT02578420|Placebo Comparator|open-label placebo|"Participants (N=40) will have the information that they are receiving an inert cream (i.e. placebo). Placebo will be described as an inert or inactive cream, with no medication in it. Additionally, participants will be told that placebo has been shown in rigorous clinical testing to produce significant mind-body self-healing processes. The placebo administration will be combined with the following scientific rationale/verbal suggestion: (a) placebos are effective analgesics, (b) classical conditioning as a possible mechanism of this effect, (c) compliance is important for outcome and (d) positive expectations increase placebo effects, but are not necessary."
89160743|NCT02578420|Sham Comparator|deceptive placebo|"Participants (N=40) will have the information that they are receiving an analgesic cream (Antidolor, containing Lidocain), while in fact they will receive an inert cream, only. Antidolor will be described as an analgesic cream."
89160744|NCT02578420|Placebo Comparator|control group|Participants (N=40) will have the information that they are receiving an inert control cream.
89160745|NCT02578420|No Intervention|no treatment group|"Participants (N=40) will be told that they are in the no treatment group and that they will not receive an analgesic cream."
89160746|NCT01563835|Active Comparator|Epidural (PCEA)|bupivacaine, fentanyl
89160747|NCT01563835|Active Comparator|IV PCA|Intravenous fentanyl patient controlled analgesia
89160748|NCT02768207|Experimental|Treatment Phase: Vemurafenib+Cobimetinib|Participants with BRAF V600 mutation will receive vemurafenib 960 milligrams (mg) tablets orally twice daily (BID) on Days 1 to 28 along with cobimetinib 60 mg tablets orally once daily (OD) for 21 consecutive days (Days 1 to 21) of each 28-day cycle until disease progression, consent withdrawal, or the development of unacceptable toxicity.
89160749|NCT02653196|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|"Matched Unrelated Donor HSCT (minimum 9/10 human leukocyte antigen [HLA] match) OR Matched Related Donor HSCT (10/10 HLA match). Conditioning regimen begins 12 days prior to stem cell infusion and includes the following drugs:~Keratinocyte Growth Factor Alemtuzumab Thiotepa Etoposide Melphalan Fludarabine Tacrolimus (Cyclosporine A may be substituted for Tacrolimus) Mycophenolate mofetil"
89160750|NCT00676728|Experimental|JNJ-26481585|
89160751|NCT02754245||JPS|study sample at JPS included for analysis
89160752|NCT02754245||BUMC Dallas|study sample at Baylor University Medical Center Dallas included for analysis
89160753|NCT02754245||BUMC at Gardin|study sample at Baylor University Medical Center Gardin included for analysis
89160754|NCT02754245||BUMC Waxahachie|study sample at Baylor University Medical Center Waxahachie included for analysis
89160755|NCT02754245||BUMC Carrolton|study sample at Baylor University Medical Center Carrolton included for analysis
89160756|NCT02754245||BUMC McKinney|study sample at Baylor University Medical Center McKinney included for analysis
89160757|NCT00709384|Experimental|Prophylactic intervention|"We performed a prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone). Conduction times between electrodes placed on both sides of the lesions are measured on the second postoperative day. Coronary angiography and electrophysiology study using an electroanatomic mapping system to assess conduction across the line and to try to induce atrial flutter are performed three month after the operation.~There is only an intervention arm, no control arm"
89160758|NCT00676884|Experimental|1|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
89160759|NCT00676884|Placebo Comparator|2|placebo control
89160760|NCT02027155|Active Comparator|AR09 solution|AR09, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
89160761|NCT02027155|Placebo Comparator|Placebo (for AR09 solution)|Placebo; normal saline
89160762|NCT04479436|Experimental|Cohort 1: HER3 High (IHC 3+, 2+)|Cohort 1 participants will have high tumor expression levels of human epidermal receptor 3 (HER3) in a pre-treatment biopsy specimen.
89160763|NCT04479436|Experimental|Cohort 2: HER3 Low/Negative (IHC 1+, 0)|Cohort 2 participants will have low or negative tumor expression levels of human epidermal receptor 3 (HER3) expression levels in a pre-treatment biopsy specimen.
89160764|NCT00676962|Experimental|Facilitation|Therapists receive assistance with adopting CBT
89160765|NCT02754167|Experimental|PRS-080#022-DP|Hepcidin antagonist, single administration, ascending doses
89160766|NCT02754167|Placebo Comparator|PRS-080-Placebo#001|Comparator treatment, single administration
89160767|NCT02653274|Active Comparator|OATS PORRIDGE|Oats breakfast porridge
89160768|NCT02653274|Active Comparator|RYE PORRIDGE|Rye breakfast porridge
89160769|NCT02653274|Active Comparator|FINGER (RAGI) MILLET PORRIDGE|Finger (ragi) millet breakfast porridge
89160770|NCT02653274|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge
89160771|NCT00677118|Experimental|Concurrent and adjuvant|Concurrent chemoradiotherapy plus adjuvant chemotherapy
89160772|NCT00677118|Active Comparator|Concurrent|Concurrent chemoradiotherapy
89160773|NCT02644226||Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
89160774|NCT02644226||Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
89160775|NCT04220879||Malignant Glaucoma|To determine the biometric measurements.
89160776|NCT04220879||Fellow Eyes|To determine the biometric measurements.
89160777|NCT04220879||Matched Eyes|To determine the biometric measurements.
89160778|NCT04004377||acoustic neuroma monitored radiologically|patient with an acoustic neuroma (vestibular schwannoma) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, monitoring by radiology
89160779|NCT04004377||acoustic neuroma whose treatment is surgical|patient with an acoustic neuroma (vestibular schwannoma or) with MRI confirmed, unilateral, not yet operated at baseline, aged over 18 years, resection surgery planified
89160780|NCT00714220||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
89160781|NCT00714220||Neurological Control|Subjects having been diagnosed with a non-ALS neurological condition
89160782|NCT00714220||Healthy Control|Subjects in good health without any neurological conditions
89160783|NCT02753855|Experimental|Telavancin Administration|Single dose of telavancin administered as a 1-hour intravenous infusion
89160784|NCT04151862|Active Comparator|tight eye bandage|Both eyes will be operated at two separate sessions. In the first session the first 25 patients will be bandaged postoperatively with tight eye bandage patching.
89160785|NCT04151862|Active Comparator|therapeutic contact lenses (TCL)|Both eyes will be operated at two separate sessions. In the second session the 25 patients will be bandaged postoperatively with therapeutic contact lenses (TCL).
89160786|NCT02647814|Experimental|Salud al Día|The participants in the intervention group will receive interactive text-messages with a link to support if needed for: clinic appointment reminders, follow-up on medicine and referral adherence, and illness care needs and use. Participants will additionally receive reminders for insurance renewal, food stamp applications, and health-promoting community events. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
89160787|NCT02647814|No Intervention|Usual Care|The participants in the usual care group will receive the clinic's usual care in terms of receiving no text messages. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
89160788|NCT00714298|Other|1|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. Treating physicians, biologist physician will be blinded to the results of the markers.
89160789|NCT02758691|Experimental|Intranasal Insulin|Healthy participants will self-administer 20 IU of Humulin® R U-100 with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
89160790|NCT02758691|Placebo Comparator|Saline Placebo|Healthy participants will self-administer a saline solution with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
89160791|NCT00677196|Active Comparator|1|The LMA StoneBreakerTM
89160792|NCT00677196|Active Comparator|2|Pneumatic Lithotripsy
89160793|NCT02768285|Experimental|Intervention|Endodontic treatment was performed in posterior teeth with necrotic pulp and periapical periodontitis using a reciprocating single-file system (Reciproc). Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 2.5 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 K-files in patency group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills was done. The canals were obturated with gutta-percha and epoxy resin sealer. The treatments were carried out in one-visit.
89160794|NCT02768285|No Intervention|Control|In the control group, apical patency did not maintained.
89160795|NCT00714376|Experimental|Docetaxel|Docetaxel (Taxotere) 75 mg/m² IV every 3 weeks for 8 cycles.
89160796|NCT04151784||Pulmonary Group|Pulmonary Group who have evidence of pulmonary diseases
89160797|NCT04151784||Healthy Control|Health Group who have no evidence of pulmonary diseases
89160798|NCT02758457|Active Comparator|metal-based restorations|single crown with a metal framework and pressed ceramic
89160799|NCT02758457|Experimental|zirconia-based restorations|single crown with a zirconia framework and pressed ceramic
89160800|NCT00714454|Active Comparator|APS|
89160801|NCT00714454|Placebo Comparator|Vehicle|
89160802|NCT00677274|Active Comparator|1|Epidural analgesia initiated at the cervix 0cm
89160803|NCT00677274|Active Comparator|2|Epidural analgesia initiated at the cervix 0.5cm
89160804|NCT00677274|Active Comparator|3|Epidural analgesia initiated at the cervix 1.0cm
89160805|NCT00677274|Active Comparator|4|Epidural analgesia initiated at the cervix 1.5cm
89160806|NCT00677274|Active Comparator|5|Epidural analgesia initiated at the cervix 2.0cm
89160807|NCT00677274|Active Comparator|6|Epidural analgesia initiated at the cervix 3.0cm
89160808|NCT00677274|Active Comparator|7|Epidural analgesia initiated at the cervix 4.0cm
89160809|NCT00677274|Active Comparator|8|Epidural analgesia initiated at the cervix 5.0cm
89160810|NCT04221659|Experimental|tDCS over M1 and DLPFC|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC). Duration: 20 minutes; Intensity: 2mA.
89160811|NCT04221659|Experimental|tDCS over M1 and FPA|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1) and left frontal polar area (FPA). Duration: 20 minutes; Intensity: 2mA.
89160812|NCT04221659|Active Comparator|tDCS over M1|Anodic transcranial direct current stimulation (tDCS) over right primary motor cortex (M1). Duration: 20 minutes; Intensity: 2mA.
89160813|NCT02753933||MRI scan|Direct referral from Primary Care (GPs) to an MRI scan as the initial Secondary Care point of contact.
89160814|NCT02753933||Neurology Appointment|Referral from Primary Care (GPs) to Neurology Services in Secondary Care as the initial Secondary Care point of contact.
89160815|NCT00709540|Experimental|single|10 subjects (8 active and 2 placebo)
89160816|NCT04068766|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
89160817|NCT04068766|Placebo Comparator|Paracervical block with normal saline|ck with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
89160818|NCT02754089|Experimental|Rhus|500 mg twice daily after meal for 6 weeks
89160819|NCT02754089|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
89160820|NCT00912210|Active Comparator|Higher protein|
89160821|NCT00912210|Placebo Comparator|Higher carbohydrate|
89160822|NCT00714532|Active Comparator|1|Expert system only, which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months.
89160823|NCT00714532|Experimental|2|"The intervention consists of 3 components:~Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
89160824|NCT02753543|Experimental|Chidamide plus previous chemotherapy|Chidamide 20mg/d Biw p.o. on d1,4,8,11 for of each cycle for 3 cycles
89160825|NCT00677430||Questionnaire + Digital Imaging|A brief questionnaire packet will be completed. Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
89160826|NCT02753621|Experimental|Singing Intervention|Twelve weekly group singing classes lasting 60-90 minutes under the direction of a professional choir director and a social worker with a music background.
89160827|NCT02753621|Active Comparator|Discussion/Support Group Intervention|Twelve weekly 60-90 minute discussion groups led by a facilitator trained in discussion group facilitation; occurring at the same time and in the same location (next door) as experimental intervention (group singing).
89160828|NCT00714610||1|Unilateral or bilateral large head metal on metal primary total hip arthroplasty
89160829|NCT03267199||patients with high MPV,PDW,PFT|patients with high MPV,PDW,platelet function test
89160830|NCT03267199||patients with normal or low MPV,PDW, PFT|patients with normal or low MPV,PDW,platelet function test
89160831|NCT00677508||C FR|Children with constipation and fecal incontinence.
89160832|NCT00677508||C|Children with constipation but without fecal incontinence.
89160833|NCT00677508||P-C FR|Parents of children with constipation and/or fecal incontinence.
89160834|NCT04725695|Experimental|Viscous lidocaine|Oral viscous lidocaine 20 mg/ml, 10 ml
89160835|NCT04725695|Placebo Comparator|Placebo|Oral viscous solution without active drug, 10 ml
89160836|NCT04070794|Active Comparator|FDC Zemimet® SR Tab. 50/1000(Fasting)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fasting condition
89160837|NCT04070794|Active Comparator|FDC Zemimet® SR Tab. 50/1000(Fed)|Gemigliptin/Metformin Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg (Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg) under fed condition
89160838|NCT02753465|Experimental|left colic artery group|Laparoscopic D3 Lymph Node Dissection with preservation of the left colic artery
89160839|NCT02753465|Active Comparator|High ligation group|Laparoscopic D3 Lymph Node Dissection with high ligation
89160840|NCT00718744|Experimental|A|In each individual patient, 10 mg/ml histamine dihydrochloride solution and a phenolated saline solution will be applied as positive and negative control respectively.
89160841|NCT02696135||Hypertrophic cardiomyopathy|Individuals with an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM, in the absence of other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.
89160842|NCT00672048|Other|1|
89160843|NCT00672048|Other|2|Control group to receive annual continuing education
89160844|NCT02572648||Participants with Heart Failure|Participants with heart failure will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
89160845|NCT02572648||Healthy Controls|Healthy controls will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
89160846|NCT02695901|Experimental|Chlorhexidine gluconate (0,12%)|Subjects will rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%).
89160847|NCT02695901|Experimental|M. alternifolia oil (Nanoparticle solution)|Subjects will rinse twice daily with 15 ml mouthrinse containing nanoparticles of M. alternifolia oil (0.3%).
89160848|NCT00677664|Active Comparator|A|Group which received Copaxone
89160849|NCT00677664|Placebo Comparator|B|Group which received Mannitol
89160850|NCT02572492|Experimental|Carfilzomib/dexamethasone maintenance|Carfilzomib/dexamethasone maintenance after salvage HDT
89160851|NCT02572492|Sham Comparator|Observation without maintenance|Observation without maintenance after salvage HDT
89160852|NCT03905863|No Intervention|Standard of care arm|SOC was defined to include wound cleansing with sterile water or saline solution, and gentle irrigation of the study ulcer with warm tap water; sharp debridement using a standardised protocol based on TIME principles for wound bed preparation; offloading with a TCC twice in the first week and weekly thereafter (all exceptions had to be agreed by the lead investigator; a fixed ankle walker boot or similar device was acceptable as an alternative, but shoe inserts were not deemed to provide sufficient offloading); moisture balance was provided using a hydrofibre or alginate dressing. In addition, patients were instructed on adherence to the protocol and given instructions to call their clinic if they suspected any signs of an infection.
89160853|NCT03905863|Active Comparator|Intervention arm|Same protocol as SOC only but were also provided with a Natrox® Oxygen Wound Therapy System, consisting of two elements: the Natrox® OG and the Natrox® ODS. The OG is a multi-use battery powered device which generates oxygen though water electrolysis at a rate of 15mL/hr. The ODS is a sterile, single use device that allows wound exudate to pass through to the secondary dressing while allowing the diffusion of oxygen across the wound bed. It connects directly to the OG via a thin flexible fine-bore tube. While the ODS can remain in situ for 7 days, it should be changed at each dressing change, based on exudate level or clinical judgement. This is a battery-operated system with a 30-hour battery life; the kit includes two interchangeable, rechargeable batteries. Each participant was advised to charge one battery while the other was in use, as the battery required changing daily. The oxygen generator is worn in a holster so that patients can remain ambulatory.
89160854|NCT02628288|Active Comparator|PCI with Axxess device + AbsorB BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with AXXESS device and additional Absorb BVS.
89160855|NCT02628288|Active Comparator|PCI with Modified T with Absorb BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with a modified T stenting technique using Absorb BVS.
89160856|NCT00718822|Experimental|I|5% oxygen concentration in the culture atmosphere
89160857|NCT00718822|Experimental|II|20% oxygen concentration in the culture atmosphere
89160858|NCT02626884|Experimental|Ibrutinib|All patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles
89160859|NCT02753387|Experimental|CHLORHEXIDINE|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of chlorhexidine
89160860|NCT02753387|Placebo Comparator|NaCl 0.9 %|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of NaCl 0.9%
89160861|NCT00672282|Placebo Comparator|A|
89160862|NCT00672282|Active Comparator|B|
89160863|NCT02753309|Active Comparator|Rapamycin 0.5mg|Subject will take Rapamycin (Sirolimus) 0.5mg once daily for approximately 28 days
89160864|NCT02753309|Active Comparator|Rapamycin 2.0mg|Subject will take Rapamycin (Sirolimus) 2.0mg once daily for approximately 28 days
88806055|NCT02531646|Experimental|Predicate & Invest. DT - Human Subjects|Radiation - Fifteen to twenty (15-20) patients will receive a DR standard of care chest exam using the DRX Plus detector, and a DT exam. Each DT patient exam includes a scout image (chest PA) and a DT scan using the investigational DT SW. The DT scan is used by the DT console software to generate tomographic images.
88806056|NCT02531646|Experimental|Predicate & Invest. DT - Phantom Images|Radiation - Eleven (11) phantoms of various anatomy will be imaged with linear tomography (LT) as predicate and DT for investigational.
89160865|NCT02753309|No Intervention|Control|Subject will be apart of the control group and won't take the study drug being tested
89160866|NCT00714766|Experimental|A|
89160867|NCT02753231|Experimental|Low physical activity program|Three Physical Education sessions / week
89160868|NCT02753231|Experimental|High physical activity program|Three Physical Education sessions / week (increased volume)
89160869|NCT02753231|Experimental|Low and High physical activity program|Three Physical Education sessions / week (increased volume and intensity)
89160870|NCT02753231|Active Comparator|Conventional physical activity program|One Physical Education sessions / week
89160871|NCT02573662||Case subjects|Physical active non-diabetic individuals of age 18 to 50 years, who are undergoing knee surgical procedures at the Arthroscopic Center at Amager/Hvidovre Hospitals are recruited as cases for this case-control study. OGTT, blood- and urine sampling and DXA scans will be performed 3 times throughout the study period.
89160872|NCT02573662||Control group|Non-diabetic individuals matched for age, gender and physical activity are recruited as control subjects to establish a reference level likely to image the cases before they experienced their knee injury. Blood- and urine sampling, OGTT and DXA scans will be carried out 1-3 times for each control subject. No lifestyle intervention is implemented.
89160873|NCT04330885|Experimental|Prehab group|"The patients in the PREHAB group will meet with a PT for 6 weeks pre surgery. The PT will coach the patient in 1:1 visits with a graded activity program with the purpose to affect fear of movement and raising level of self-efficacy with physical activity. The intervention comprises; cycling on a stationary cycle. Instructions of exercises that strengthen the deep and the superficial abdominal muscles and the back muscles. Information to contract the abdominal muscles in posturally loaded position to support their back. Information on flexion exercises of their lumbar spine and to keep the back in a flexed position when standing and walking (as opposed to extension). Recommendation to use Nordic walk (stavar) for outdoor walking"
89160874|NCT04330885|No Intervention|Care as usual|Control group will be treated with care as usual meaning information from a PT two weeks prior to the surgery with information on the surgery and to stay active. Both groups will be given information on to stay active and home exercises following the surgery.
89160875|NCT00681408|Active Comparator|Omega 3 recipient arm|
89160876|NCT00681408|Placebo Comparator|Placebo|Placebo fish oil
89160877|NCT02753153|Experimental|Mucograft®, Geistlich Biomaterials|A Mucograft membrane will be used in state of a connective tissue graft. The dimension of the Mucograft® will be previously calculated according to the site dimensions and inserted into buccal pouch and sutured to be stabilized on the buccal aspect. The membrane is then positioned to cover the socket and inserted and sutured in the palatal pouch by the means of vertical interrupted sutures
89160878|NCT02753153|Active Comparator|Soft tissue graft|
89160879|NCT02573740|Experimental|ABT-957|ABT-957 given twice a day for 84 days
89160880|NCT02573740|Placebo Comparator|Placebo|Placebo given twice a day for 84 days
89160881|NCT03113461|Experimental|CPAP adherent|Study participants in this arm are using the CPAP intervention consistently
89160882|NCT03113461|Active Comparator|CPAP non-adherent|Study participants in this arm are not using the CPAP intervention consistently
89160883|NCT03113461|No Intervention|No OSA|Study participants who do not have OSA
89160884|NCT04147728|Experimental|SRS Combination With Anlotinib|Stereotactic Radiosurgery Combination With Anlotinib
89160885|NCT04004299|Other|HCV self-test intervention|Diagnostic intervention: participant performs capillary blood sampling at home in between outpatient clinic visits (3 months after) and sends the sample to the investigator's laboratory by regular post mail for HCV RNA analysis. This is on top of standard of care ALT measurement at every 6-monthly outpatient clinic visit, followed by HCV RNA testing if ALT is elevated. Follow-up period is 2 years, in which participants will perform and send in 4 self-tests, in combination with filling out 4 questionnaires into sexual risk behavior.
89160886|NCT04147026|Experimental|SinnoTest® software|SinnoTest® is a therapeutic guidance device for patients suffering from rheumatoid arthritis. Prescription of an original or biosimilar biotherapy (rituximab, adalimumab, abatacept) is possible.
89160887|NCT04147026|Active Comparator|Current practice|Prescription of biotherapy without the SinnoTest® software which corresponds to current practice (all biotherapies).
89160888|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 250mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD
89160889|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 500mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD
89160890|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 375mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
89160891|NCT00681486|Active Comparator|A, 1|Ghrelin
89160892|NCT00681486|Active Comparator|A, 2|Ghrelin.
89160893|NCT02767895|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health
89160894|NCT02767895|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
89160895|NCT05361265|Experimental|Experimental Group|pregnant women were trained about fetal movements and fetal movement counting was taught. The training was given verbally. Pregnant women were asked to perform ten fetal movements by counting once a day after any meal, lying in the left side position for one hour. When ten fetal movements could not be reached within the first hour, pregnant women were instructed to count the fetal movements for one hour after walking for five minutes. When ten fetal movement counts could not be obtained at the end of two hours, they were asked to apply to the hospital immediately. Pregnant women were expected to perform fetal movement counting after the same meal every day (breakfast, lunch or dinner) and record the start and end times of the ten movements on the Fetal Movement Monitoring Card.
89160896|NCT05361265|No Intervention|Control Group|Routine follow up
89160897|NCT00677742|Experimental|1|enhanced initial supply of oral contraception
89160898|NCT00677742|Active Comparator|2|conventional initial supply of oral contraception
89160899|NCT02752919|Experimental|Part A Galunisertib - 1 tablet|Single oral dose of galunisertib in Japanese participants
89160900|NCT02752919|Experimental|Part A Galunisertib - 2 tablets|Single oral dose of galunisertib in Japanese participants
89160901|NCT02752919|Experimental|Part B Galunisertib - 1 tablet|Single oral dose of galunisertib in non-Japanese participants
89160902|NCT02752919|Experimental|Part B Galunisertib - 2 tablets|Single oral dose of galunisertib in non-Japanese participants
89160903|NCT00672360|Experimental|1|
89160904|NCT00672360|Placebo Comparator|2|
89160905|NCT00714922|Active Comparator|1|PRK
89160906|NCT00714922|Active Comparator|2|SBK
89160907|NCT02752997|Experimental|Intervention|"Discharge medication services included:~Discharge medication reconciliation~Identification of medication discrepancies and resolution~Medication counseling using health coaching techniques with short term goal setting and follow up phone call"
89160908|NCT02752997|No Intervention|Comparator|Current standard of care provided by nursing staff.
89160909|NCT02628522|Experimental|ADRCs therapy|"Infiltration with 20mL Lidocaine 2% and Epinephrine 1:100 000. Liposuction will be done from the abdomen using Tulip cannulas. Fat will be processed with Celution system.~Isolated ADRCs will be administered in chronic anal fissures."
89160910|NCT02572414|Experimental|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention consisted of three, 3-hour weekly small-group intervention sessions led by a trained facilitator using a detailed, scripted manual designed to increase adherence to guidelines for physical activity, 5-a-Day diet, and colon cancer screening.
89160911|NCT02572414|Active Comparator|Health Awareness Control|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
89160912|NCT02751047|Placebo Comparator|Manual ventilation|During anesthetic induction, facemask ventilation is performed by manual bagging, after setting adjustable pressure limiting (APL) valve at 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
89160913|NCT02751047|Active Comparator|Pressure controlled mechanical ventilation|During anesthetic induction, facemask ventilation is performed with mechanical ventilator by pressure controlled mode, with inspiratory pressure of 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
89160914|NCT00677976||IBS|Children between the ages of 10 and 18 who meet Rome III criteria for IBS as determined by a pediatric gastroenterologist.
89160915|NCT00677976||Control|Healthy children between the ages of 10 and 18.
89160916|NCT02572336|Active Comparator|THR-18|Single administration of intravenous THR-18 solution
89160917|NCT02572336|Placebo Comparator|Placebo|Single administration of intravenous THR-18 lookalike solution
89160918|NCT00715000|Experimental|1|SRO
89160919|NCT00715000|Active Comparator|2|classical hydration via intravenous infusion
89160920|NCT02750969|Experimental|1. lidoderm patches first|"29 tinnitus patients treated first with 3 patches of lidoderm for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 neutral patches (containing no drug) attach to their back for 12 hours.~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
89160921|NCT02750969|Experimental|2. tegaderm patches first|"29 tinnitus patients treated first with 3 patches of tegaderm (neutral patch containing no drug) for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 lidoderm patches attach to their back for 12 hours.~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
89160922|NCT00681642||1|Corneal epithelial tissue with wound cultured in human autoserum
89160923|NCT00681642||2|Corneal epithelial tissue with wound cultured in umbilical cord serum
89160924|NCT00715156||A|Subjects with mild (S1) reaction to peach fruit
89160925|NCT00715156||B|Subjects with severe reaction to peach fruit
89160926|NCT00678054|Experimental|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
89160927|NCT04062409||Sickle cell patients|
89160928|NCT04062409||Asmathic patients|
89160929|NCT02751125|Experimental|Augmentation of new alveolar bone|Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)
89160930|NCT00715234|Experimental|Reminder/recall notices for vaccines|This group will receive up to 4 recall messages (both letters and computer-generated phone messages) reminding them to get their vaccines. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
89160931|NCT00715234|No Intervention|Usual Care|This group will receive usual care. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
89160932|NCT00709930|Active Comparator|1,Exposed to ELF-EMF|Device: Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF
89160933|NCT00709930|Placebo Comparator|2,Placebo|Device: Placebo device with no magnetic fields
89160934|NCT04990219|Experimental|Lu AG06466|Participants will receive Lu AG06466 at a starting dose orally once daily for 4 days (Day 1 to Day 4), followed by Lu AG06466 at a higher titrated dose orally once daily for 4 days (Day 5 to Day 8), followed by Lu AG06466 at a higher titrated treatment dose orally once daily from Day 9 until Day 35/Week 5.
89160935|NCT04990219|Placebo Comparator|Placebo|Participants will receive Lu AG06466-matching placebo orally once daily until Day 35/Week 5.
89160936|NCT04488575|Experimental|EDP1815|Patients will receive EDP1815 in addition to standard of care
89160937|NCT04488575|Placebo Comparator|Placebo|Patients will receive placebo in addition to standard of care
89160938|NCT00715312|Experimental|A|
89160939|NCT02573506|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
89160940|NCT04003831|Other|Optical Coherence Tomographer|
89160941|NCT04217759|Experimental|Intervention group|Intervention group went through a healthy lifestyle intervention using evidence-based SCT strategies emphasising on PA and diet for 12 weeks via face-to-face sessions and social media tools (Facebook and WhatsApp)
89160942|NCT04217759|No Intervention|Control group|Control group only received leaflets on healthy lifestyle with no further guidance.
89160943|NCT05361187||single arm, observational post market study|Patients with an acute ischemic stroke with treatment including the BOBBY™ BGC
89160944|NCT02750891|Experimental|DSP-7888|
89160945|NCT00718978|Other|B|the investigators grafted sheets based on the HYAFF11p80® scaffold (the one with the lowest degree of esterification)
89160946|NCT00718978|Other|A|the investigators grafted sheets based on the HYAFF11® scaffold (the one with the highest degree of esterification).
89160947|NCT00718978|Other|A-B|the investigators grafted sheets based on the HYAFF11® scaffold and sheets based on the HYAFF11p80 ® scaffold
89160948|NCT04481087|Experimental|Clearfil Universal Bond Quick, self-etch mode (CU-SE)|
89160949|NCT04481087|Experimental|Clearfil Universal Bond Quick, selective etch mode (CU-SLE)|
89160950|NCT04481087|Experimental|Clearfil Universal Bond Quick, etch&rinse mode (CU-ER)|
89160951|NCT04481087|Experimental|Clearfil SE Bond (CSE)|
89160952|NCT04481087|Experimental|Tetric N-Bond (TB)|
89160953|NCT00719056|Experimental|1|Surgical chemoprophylaxis of one dose of teicoplanin upon introduction of anesthesia for total hip or knee arthroplasty.
89160954|NCT00719056|Active Comparator|2|Surgical chemoprophylaxis with multiple dose of other antimicrobials for up to six consecutive days for total hip or knee arthroplasty.
89160955|NCT02750735||Retrospective NCWS patients|The clinical charts of NCWS patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca were retrospectively reviewed. Patients had all been diagnosed with NCWS between January 2001 and June 2011, by a DBPCC method, and included in a previously published study. These charts included specific sections for the presence of associated atopic diseases, including nickel allergy. In this way, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy. Incomplete clinical charts were excluded.
89160956|NCT02750735||Prospective NCWS patients|The investigators also prospectively surveyed adult patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS. The patients were recruited between December 2014 and March 2016 at 3 centers: the two already mentioned and the Gastroenterology Unit of the ARNAS Civico Hospital of Palermo, Italy. Most of the patients had been referred due to gastrointestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. Again, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy.
89160957|NCT02750735||Retrospective NCWS control patients|To compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 irritable bowel syndrome (IBS) patients, was selected. These controls were randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- (+/-2 years) and sex-matched (+/-5%) with the NCWS patients. The IBS controls had been receiving the same elimination diet as the NCWS patients and had not shown any clinical improvement; they belonged to the cohort of subjects the investigators had studied previously.
89160958|NCT02750735||Prospective NCWS control patients|As for the retrospective study, to compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 patients with functional gastroenterological symptoms, was selected, with the same criteria adopted for the retrospective study.
89160959|NCT04217837||Major Depressive Disorder|Participants who meet the DSM-5 clinical diagnostic criteria, in the opinion of the treating clinician, for primary diagnosis of unipolar, non-psychotic MDD.
89160960|NCT04004143||Cross-sectional|a cross-sectional study.
89160961|NCT04069546|Experimental|AIS-RIC|RIC is a physical strategy performed through cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times. This group of patients received regular therapy of acute ischemic stroke plus unilateral arm of RIC intervention.
89160962|NCT04069546|No Intervention|AIS|This group of patients received regular therapy of acute ischemic stroke.
89160963|NCT04469699|Experimental|Treatment arm|Stereotactic biopsy followed by stereotactical photodynamic therapy
89160964|NCT04469699|Other|Control arm|Stereotactic biopsy
89160965|NCT02573428||Autism Spectrum Disorder|Individuals who receive a clinical diagnosis of Autism Spectrum Disorder
89160966|NCT02573428||Developmental/Psychiatric Controls|Individuals who receive a clinical diagnosis of another developmental or psychiatric disorder
89160967|NCT02573428||Healthy Controls|Individuals who have no specific developmental or psychiatric diagnosis
89160968|NCT05279209|Experimental|Sclerotherapy|Patients who receive uterine artery embolization for symptomatic fibroids
89160969|NCT05279209|Active Comparator|Surgery|Patients who receive uterine artery embolization for symptomatic fibroids
89160970|NCT02695745|Experimental|V116517|V116517 aqueous suspension; 300 mg
89160971|NCT02695745|Active Comparator|Celecoxib|Celecoxib capsules; 400 mg (2 capsules of 200 mg each)
89160972|NCT02695745|Placebo Comparator|Placebo|Placebo
89160973|NCT00990067|Other|duloxetine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
89160974|NCT02750423|Active Comparator|DHCA+RCP|Participants undergoing ascending aortic and hemiarch replacement will receive deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP).
89160975|NCT02750423|Active Comparator|MHCA+uSACP|Participants undergoing ascending aortic and hemiarch replacement will receive moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA+uSACP).
89160976|NCT00719290|Active Comparator|1|Phacoemulsification with intraocular lens implant alone
89160977|NCT00719290|Active Comparator|2|Phacoemulsification with intraocular lens implant and goniosynechialysis
89160978|NCT00635921|Active Comparator|I ziprasidone|
89160979|NCT00635921|Placebo Comparator|II placebo|
89160980|NCT00990145|Experimental|Intervention|EDP-322 v. Placebo
89160981|NCT04218305||The first group|Include One hundred patients with type 2 diabetes mellitus with average body mass index.
89160982|NCT04218305||The second group|Include One hundred patients whose body mass index is 30 or over without diabetes.
88806057|NCT00300482|Active Comparator|A|ABT-335 + 10 mg rosuvastatin
88806058|NCT00300482|Active Comparator|B|ABT-335 + 20 mg rosuvastatin
88806059|NCT00300482|Placebo Comparator|C|ABT-335 monotherapy
88806060|NCT00300482|Placebo Comparator|D|10 mg rosuvastatin monotherapy
89160983|NCT04218305||The third group|Include One hundred type 2 diabetic obese patients whose body mass index is 30 or over.
89160984|NCT04218305||The fourth group|Include One hundred apparently healthy adult person as a control.
89160985|NCT04166006|Experimental|Experimental|"7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by Interleukin (IL) - 2 (IL-2), at a dose of 3 Million Units (MU), given by subcutaneous injection daily for five days (days 3-7). This constitutes a treatment cycle.~Treatment cycles are repeated every 28 days up to a maximum of six cycles."
89160986|NCT03993691|Experimental|All Participants|Participants that have undergone standard of care, conventional 2D radiographic imaging of wrist for presumed or known scaphoid, wrist or distal radius fractures will receive the Tomo-E scans within two weeks.
89160987|NCT04069858|Experimental|Baracle|Chronic hepatitis B patients who swiched to Baracle® 1 mg from Baraclude® 1 mg treatment as mono- or combination therapy after the development of antiviral resistance to nucleos(t)ide analogues
89160988|NCT02750579|Active Comparator|Control group|control group: Percutaneous coronary intervention for revascularization delayed intervention (12 to 72 hours)
89160989|NCT02750579|Experimental|experimental group|experimental group: early Percutaneous coronary intervention for revascularization intervention (<2 hours)
89160990|NCT02644382||Key Informant interviews|20 in-person or phone qualitative interviews with patients.
89160991|NCT02644382||Focus Groups|four qualitative focus groups of 6-10 women each.
89160992|NCT02644382||Physician Interviews|physician qualitative interviews over the telephone.
89160993|NCT02644382||Usual care cohort (pilot)|50 women who will be surveyed before and after their surgical consult
89160994|NCT02644382||Decision aid cohort (pilot)|50 women who will be surveyed before and after their surgical consult and will also be sent a web-based decision aid
89160995|NCT00710086|Active Comparator|1|Intravenous administration of hydromorphone intermittently
89160996|NCT00710086|Experimental|2|Remifentanil intravenous patient-controlled analgesia
89160997|NCT00652886|Experimental|A|Subjects received Kali's products under fasting conditions
89160998|NCT00652886|Active Comparator|B|Subjects received BTG products under fasting conditions
89160999|NCT00719368||pain-free control|Pain-free controls from previous prospective study (KF 01294867), operated >2 years previously
89161000|NCT00719368||Pain Patients|Patients with persistent postherniotomy pain lasting >1 year and pain related impaired daily function
89161001|NCT01563757||Fontan Patients with PLE and PB|Fontan Patients with Protein Losing Enteropathy and Plastic Bronchitis
89161002|NCT01563757||Fontan Patients w/out PLE & PB|Protein Losing Enteropathy and Plastic Bronchitis
89161003|NCT01563757||Glenn Physiology Patients|
89161004|NCT01563757||2 ventricle heart with ASD|2 ventricle heart with Atrial Septal Defect
89161005|NCT00710164|Experimental|A|
89161006|NCT00710164|Placebo Comparator|B|
89161007|NCT02647736|Experimental|Copeptin values in normo- to hyperosmolar states|
89161008|NCT01563991|Active Comparator|Standard fluid volume|Subject receives normal fluid volume during peri-operative period
89161009|NCT01563991|Experimental|Reduced Fluid Volume|Subject receives a reduced fluid volume during the peri-operative period
89161010|NCT03742999|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
89161011|NCT03742999|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
89161012|NCT03742999|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
89161013|NCT02653040|Experimental|Dynamic lighting|Indoor lighting with low-lux no-blue wavelengths at night.
89161014|NCT02653040|No Intervention|Treatment as usual|Characterized by full white light with little variation through a day cyclus.
89161015|NCT04218929|Experimental|Study Formula (SF)|New infant formula for term infants
89161016|NCT04218929|Active Comparator|Comparator Formula (CF)|Commercially available infant formula for term infants
89161017|NCT04218929|No Intervention|Human Milk Reference Group|Human milk
89161018|NCT02573272||Epileptic patients with AEDs and eslicarbacepine|
89161019|NCT04166084|Active Comparator|Control Group|Patients in this group will receive active ROM exercises, 10 repeats X 3 times a day, 5 days a week for 6 weeks. All exercises will be performed at home .
89161020|NCT04166084|Experimental|Training group|I addition to active ROM exercises, patients in this group will also receive trunk stabilization exercises training for 45 minutes, 2 times a week for 6 weeks. All exercises sessions will be supervised by a physiotherapist in a clinic per week.
89161021|NCT00539305|Experimental|Study drug; testosterone transdermal gel|Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
89161022|NCT00539305|Placebo Comparator|2|
88806061|NCT00300482|Placebo Comparator|E|20 mg rosuvastatin monotherapy
88806062|NCT00300482|Placebo Comparator|F|40 mg rosuvastatin monotherapy
89161023|NCT02573116|Experimental|Obstructive sleep apnea with chronic parodontis|patients with severe obstructive sleep apnea (OSA) and chronic parodontis treated for OSA by continuous positive airway pressure (CPAP) and intensive periodontal treatment
89161024|NCT02573116|No Intervention|Obstructive sleep apnea without chronic parodontis|patients with severe OSA treated by CPAP
89161025|NCT02643914|Experimental|Nicotine Cravings|
89161026|NCT00715702|Experimental|1|Patients with Moderate renal impairment and matched volunteers
89161027|NCT00715702|Experimental|2|Patients with Mild or Severe renal impairment and matched volunteers. Type of patient group determined after safety review of 1st group data
89161028|NCT04217213|Experimental|ropivacaine combined with mecobalamine|Intercostal nerve block with 0.5% ropivacaine combined with mecobalamine (0.5mg).
89161029|NCT04217213|Active Comparator|ropivacaine|Intercostal nerve block with 0.5% ropivacaine alone.
89235038|NCT05267340|Active Comparator|Control: Psycho-Education|"Behavioral: Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components~This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components"
89235039|NCT05263544||Patients with displaced IUD|
89161030|NCT02536274|Experimental|Schwertbad Aachen|20 Patients with specific back pain will get Lumbo Sensa® bandage. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
89161031|NCT02536274|Experimental|Schön Klinik Fürth|20 Patients with specific back pain will get Dynaflex® flexion orthosis. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
89161032|NCT02536274|No Intervention|Schön Klinik Fürth & Schwertbad Aachen|20 Patients with specific back pain will get no intervention. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
89161033|NCT02536274|No Intervention|RPE|20 healthy Subjects of the same age without back pain participate in the course for one time to prove the significance of the procedures. (control group) Study related procedures include a course with 6 exercises: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
89161034|NCT00710242|Experimental|1|DF01
89161035|NCT00710242|Placebo Comparator|2|
89161036|NCT02643836|Experimental|Treatment PEMF|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The experimental group will contain 38 subjects. Each study subject will receive two hats, which contain the integrated PEMF device, this will be done to ensure continuity of treatment in case that one of the hats stops working due to the battery running out. The subjects will receive PEMF treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
89161037|NCT02643836|Sham Comparator|Sham Treatment|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The sham group will contain 38 subjects. Each study subject will receive two hats, which contain a de-activated PEMF device, the device will still be blinking to show sham treatment activity. The sham subjects will receive the sham treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
89161038|NCT00990223|Experimental|Cohort 1|Healthy Volunteers - eplerenone versus placebo.
89161039|NCT00715780||A|
89161040|NCT02652884|Experimental|Group 1|will receive single dose intramuscular corticosteroid deltoid deposit (as phosphate and betamethasone acetate, 2 mL) for immediate postintubation.
89161041|NCT02652884|Placebo Comparator|Group 2|will receive 2 ml saline 0.9% NaCl in deltoid immediately postintubation.
89161042|NCT00990301|Experimental|Moexipril HCl/ Hydrochlorothiazide 15mg/25mg Tablets|
89161043|NCT00990301|Active Comparator|Uniretic® 15mg/25mg Tablets|
89161044|NCT04460027|Experimental|W-SUDs|
89161045|NCT04460027|No Intervention|Wait List Control|
89161046|NCT00652964||Observation|a family of congenital central hypoventilation syndrome
89161047|NCT00715858|Active Comparator|1 AD doxycycline + rifampin|Participants with AD allocated to doxycycline 100 mg bid od and rifampin 300 mg od for 12 months
89161048|NCT00715858|Active Comparator|2 AD doxycycline|
89161049|NCT00715858|Active Comparator|3 AD rifampin|Participants with AD allocated to rifampin 300 mg od od and placebo matched to doxycycline bid for 12 months
89161050|NCT00715858|Placebo Comparator|4 AD placebo|Participants with AD allocated to placebo matched to doxycycline and placebo matched to rifampin for 12 months
89161051|NCT00715858|No Intervention|5 Control|Age-matched cognitively healthy participants (untreated)
89161052|NCT04003909|Experimental|ESP group|patients will have ultrasound guided ESP block before spinal anesthesia.
89161053|NCT04003909|Experimental|Control group|patients will have spinal Anesthesia without ESP block
89161054|NCT02643680|Experimental|The novel biocellulose wound dressing|
89161055|NCT02643680|Active Comparator|Bactigras|
89161056|NCT05361031|Experimental|Engensis (VM202)|56 (ea) 0.25mg (0.5 mL) injections in each of the left and right lower limbs on Days 0, 14, 90, and 104.
89161057|NCT02573194|Experimental|Animal source of proteins|Breakfast based on animal proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
88806063|NCT01791062|Experimental|HYTOP®|
88806064|NCT00301028|Experimental|Cetuximab + Carboplatin/Paclitaxel|Cetuximab beginning weekly dose 400 mg/m^2 intravenous (IV), and 250 mg/m^2 weeks 2-6; Weekly Carboplatin area under the curve (AUC) 2 and Paclitaxel 135 mg/m^2 for 6 courses.
88806065|NCT00301418|Experimental|Tarceva (Erlotinib)|
89161058|NCT02573194|Experimental|Plant source of proteins|Breakfast based on plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
89161059|NCT02573194|Experimental|Animal and plant source of proteins|Breakfast based on both animal and plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
89161060|NCT02573194|Experimental|Low protein|Breakfast very low in protein: 1700 kJ, 5 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
89161061|NCT04700033|Experimental|Somatic IVR|Participants with participate in Somatic IVR protocol three times per week for four weeks.
89161062|NCT04700033|Active Comparator|Distractive IVR|Participants with participate in Distractive IVR protocol three times per week for four weeks.
89161063|NCT04700033|Placebo Comparator|Control IVR|Participants with participate in Control IVR protocol three times per week for four weeks.
89161064|NCT02643758|Experimental|Bifocal soft contact lenses|Device: Bifocal soft contact lenses Use of bifocal contact lenses with nasally decentered optical zone to control the progression of myopia
89161065|NCT02643758|No Intervention|Single vision spectacles|Control: Single vision spectacles
89161066|NCT04069780|Active Comparator|Study group I : Intravitreal injection|A single intravitreal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
89161067|NCT04069780|Active Comparator|Study group II: Suprachoroidal injection of full dose|A single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 4 mg / 0.1 ml.
89161068|NCT04069780|Active Comparator|Study group III : Suprachoroidal injection of half dose|They will receive a single suprachoroidal injection of 0.1 ml triamcinolone acetonide in a concentration of 2 mg / 0.1 ml.
89161069|NCT02643524|Active Comparator|Nutrition and Exercise Counseling|CAM boot prescribed as standard of care Nutritional counseling provided Upper body exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit Patients in this arm compared with patients in control arm
89161070|NCT02643524|Active Comparator|Control|CAM boot prescribed as standard of care No nutritional or exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit
89161071|NCT00715936|Active Comparator|Control|Routine services for infants and young children delivered by the Lady Health Workers of the National Programme for Family Planning and Primary Healthcare (Basic Health and Nutrition Education and Services)
89161072|NCT00715936|Experimental|ECD Group|Stimulation and care for development (plus basic health and nutrition education and services)
89161073|NCT00715936|Experimental|Enhanced Nutrition|Care for Nutrition: Enhanced education messages and Sprinkles for children aged 6-24 months (plus basic health and nutrition education and services)
89161074|NCT00715936|Experimental|ECD and Enhanced Nutrition|Stimulation and care for development and care for nutrition (plus basic health and nutrition education and services)
89161075|NCT02749877|Experimental|Cognitive Training|"This group will undergo a working memory training program (Training A). The children will receive individual memory training based on the computer program Cogmed RM and will be supervised by trained neuropsychologists. Its efficacy in the use with children with cancer has been recently published. The children will undergo 25 training sessions online; each session takes about 45 minutes and consists of a selection of various tasks that target the different aspects of working memory."
89161076|NCT02749877|Experimental|Physical Training|This group will receive a physical training that can be executed at home (Training B). The training will be based on xbox Kinect games and comprise games and activities such as jump'n'run games, physical training, and dance activities. One training session will last approximately 45 minutes and will be performed 3 days a week over a period of 8 weeks (in total 25 sessions).
89161077|NCT02749877|Active Comparator|Waiting Control Group|This group will serve as a waiting control group and will receive either the physical or the working memory training program after completion of the Neuropsychological Assessment II
89161078|NCT05360953|Experimental|Arm Clonidine|
89161079|NCT05360953|Experimental|Arm Doxazosin|
89161080|NCT05360953|Placebo Comparator|Placebo|
89161081|NCT02750189||Mild Group|FEV₁/FVC <70% and FEV₁≥80% direct/indirect cost
89161082|NCT02750189||Moderate Group|FEV₁/FVC <70% and 50%≤FEV₁≤80% direct/indirect cost
89161083|NCT02750189||Severe Group|FEV₁/FVC <70% and 30%≤FEV₁≤50% direct/indirect cost
89161084|NCT02750189||Very Severe Group|FEV₁/FVC <70% and FEV₁<30% direct/indirect cost
89161085|NCT00990379||Controls|Healthy men and women, 18 years of age or older, who have no history of significant medical conditions.
89161086|NCT00990379||HIV positive|Men and women, 18 years of age or older, who have been diagnosed with HIV infection. Patients may be on or off of ARVs.
89161087|NCT00990379||Parkinson's Disease|Men and women, 18 years of age or older, who have been diagnosed with Parkinson's Disease.
89161088|NCT00719524|Experimental|1|
89161089|NCT02647424|Other|PCOS group|PCOS women with anovulation
89161090|NCT02647424|Other|Ovulatory group|Ovulatory group planned for intra-uterine insemination
89161091|NCT02574754|Experimental|warfarin|Subjects will receive a single dose of warfarin 10 mg PO at each of 3 visits. The study days will be separated by at least 14 days to allow adequate time for the drug to reach washout.
89161092|NCT02647502|Active Comparator|Continuous calorie restriction|Participants will be provided with a diet that includes approximately 78% of calories each day that would be needed to maintain current BMI.
89161093|NCT02647502|Experimental|Intermittent calorie restriction|Participants will be provided a diet that with a daily calorie intake required to maintain current BMI, except only 25% of this calorie intake will be provided for 2 days a week.
89161094|NCT02647502|Placebo Comparator|Control calorie intake|Participants will be assigned to consume enough calories each day required to maintain current BMI
89161095|NCT00719602|Active Comparator|1|Previously received single-dose nevirapine (SD NVP); assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
89161096|NCT00719602|Active Comparator|2|Have not previously received SD NVP; assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
89235040|NCT05263544||Patients without displaced IUD|
89161097|NCT02652650|Experimental|Ethinylestradiol/Norethindrone|During the first oral contraceptive (OC) cycle participants will receive ethinylestradiol/norethindrone 35 microgram (mcg)/1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in). During the second OC cycle (from Day 29 to Day 56), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg alone qd for 21 days on Days 29 to 49 (Cycle II: OC alone, reference). During the third OC cycle (from Day 57 to Day 84), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg qd for 21 days on Days 57 to 77 and in addition JNJ-63623872, 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test).
89161098|NCT00716014|Active Comparator|Foot 1|An active drug injection of TD101 is injected into a callus on the bottom of one foot.
89161099|NCT00716014|Placebo Comparator|Foot 2|An injection of placebo (normal saline) is injected into a callus on the bottom of one foot.
89161100|NCT02643602|Experimental|Bicarbonate and theophylline|Hydration with bicarbonate in addition to theophylline
89161101|NCT02643602|Active Comparator|Sodium and theophylline|Hydration with sodium chloride in addition to theophylline
89161102|NCT02652962|Experimental|Gelesis200 x 2, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
89161103|NCT02652962|Experimental|Gelesis200 x 2, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
89161104|NCT02652962|Placebo Comparator|Placebo x 2, 10 min|3 x Placebo capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
89161105|NCT02652962|Placebo Comparator|Placebo x 2, 30 min|3 x Placebo capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
89161106|NCT02652962|Experimental|Gelesis200 x 3, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
89161107|NCT02652962|Experimental|Gelesis200 x 3, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
89161108|NCT02652962|Placebo Comparator|Placebo x 3, 10 min|3 x Placebo capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
89161109|NCT02652962|Placebo Comparator|Placebo x 3, 30 min|3 x Placebo capsules administered 30 minutes before each of 3 meals (breakfast, lunch, dinner).
89161110|NCT00710320||Cover and Uncover|Procedure/Surgery
89161111|NCT04164316|Sham Comparator|Kinesio Tape No Tension|Kinesio Tape No Tension
89161112|NCT04164316|Active Comparator|Kinesio Tape with Tension|Kinesio Tape with Tension
89161113|NCT02643446||G1: IPV+OPV, 1 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV.
89161114|NCT02643446||G2: IPV+OPV, 1 m+7d followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV.
89161115|NCT02643446||G3: IPV+OPV, 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
89161116|NCT02643446||G4: IPV+OPV, 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 5 months of age, that is one month after the second dose of OPV.
89161117|NCT02643446||G5: OPV, 3 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 5 months of age, that is one month after the third dose of OPV.
89161118|NCT02643446||G6: OPV, 1 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
89161119|NCT02643446||G7: OPV, 1 m+7d followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of OPV.
89161120|NCT02643446||G8: IPV+IPV, 1 m+7d followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV.
89161121|NCT02643446||G9: IPV+IPV, 2 m followup|Using 2 doses of IPV and 1 doses of OPV at 2, 3,4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the second dose of IPV and just before the first dose of OPV.
89161122|NCT02643446||G10: IPV+OPV, 1 m and 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV;the third sample at 5 months of age, that is one month after the second dose of OPV.
89161123|NCT02643446||G11: IPV+OPV, 1 m+7d and 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV,the third sample at 4 months of age, that is one month after the first dose of OPV.
89161124|NCT02643446||G12: IPV+IPV,1 m+7d and 2 m followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV,the third sample at 4 months of age, that is one month after the second dose of IPV.
89161125|NCT00716170||A:|Patients with type 2 diabetes mellitus
89161126|NCT02652806|Experimental|FG-4592|Intervention is investigational treatment FG-4592
89161127|NCT02652806|Active Comparator|EPO|Intervention is subject's current dose of Li Xue Bao (epoetin alfa)
89161128|NCT04159714|Experimental|Bandage Contact Lens (BCL) group|Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have a bandage contact lens soaked in antibiotic solution placed in the affected eye
89235041|NCT05263076|Experimental|Uterine Transplant|uterus transplantation from living or deceased donor.
88806066|NCT00302042|Experimental|1: Brief Counseling Plus Group Lifestyle|Brief counseling plus group diabetes prevention in community
89161129|NCT04159714|No Intervention|Usual Care Group|Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have usual care provided in the Emergency Department
89161130|NCT04070716|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
89161131|NCT04070716|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
89161132|NCT04529135|Experimental|Dexmedetomidine|IV,0.2~0.8 µg/kg/hr
89161133|NCT04529135|Active Comparator|Remifentanil|IV,0.05~0.2 µg/kg/min
89161134|NCT04168346|Experimental|Intervention|IV-iron substitution: The intravenous iron formulation used in the study is ferric carboxymaltose and it will be administered two to four weeks before the surgery, aiming at four weeks. The dose of intravenous iron will be calculated according to the weight and haemoglobin level of the patients, however so that all the patients receive minimum 1000mg iv iron and the maximum dose is 20 mg/kg per day.
89161135|NCT04168346|Placebo Comparator|Placebo|Placebo is NaCl 0.9% solution, which is administrated in the same way as the study drug
89161136|NCT02647190|Experimental|Erwinia Chrysanthemi asparaginase|This is a phase I trial designed to assess the safety of IV Erwinia Chrysanthemi asparaginase during initial induction in patients aged 60 years or older with newly diagnosed Ph-negative ALL. A total of 12 patients will be accrued to the study.
89161137|NCT02643368|Active Comparator|mOPV2 at 6 and 7 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 7 weeks of age
89161138|NCT02643368|Active Comparator|mOPV2 at 6 and 8 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 8 weeks of age
89161139|NCT02643368|Active Comparator|mOPV2 at 6 and 10 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age
89161140|NCT02643368|Active Comparator|mOPV2 at 6 and 10 week of age and IPV at 6 weeks of age|Participants enrolled in this arm would receive a dose monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age. In addition, the participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age
89161141|NCT02750033||Basal Cell Carcinoma (BCC)|Adult patients undergoing Mohs surgery to remove basal cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
89161142|NCT02750033||Squamous Cell Carcinoma (SCC)|Adult patients undergoing Mohs surgery to remove squamous cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
89161143|NCT04165538|Experimental|TEG group|
89161144|NCT04165538|No Intervention|Non-TEG group|
89161145|NCT04165850|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
89161146|NCT02572258|Experimental|Nutritional oats cookie and educational session|Nutritional cookie with oats and nuts
89161147|NCT02572258|No Intervention|Educational session only|
89161148|NCT02643290|Other|Patients|Adult patients with low back pain secondary to an high degree scolisis are treated by fiting with a brace 2-4 hours a day and tracked for 6 months.
89161149|NCT00719758|Experimental|1|Cross-over study
89161150|NCT04167878|Experimental|ACDF with 3D printed biodegradable cervical fusion cage|A resorbable cervical interbody cage made of PCL-TCP.
89161151|NCT04167878|Active Comparator|ACDF with PEEK cage|A structural PEEK cage with autologous bone.
89161152|NCT04197167|Experimental|Women undergoing hysteroscopy|Patients scheduled to undergo hysteroscopy for the evaluation of abnormal bleeding or abnormal cervical or uterine findings.
89161153|NCT02643134|Other|Group 1|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
89161154|NCT02643134|Other|Group 2|Patients in Group 2 undergo external physical vibration lithecbole for the treatment after extracorporeal shockwave lithotripsy(ESWL).A multi-dimensional physical harmonic vibration inertial guidance technology
89161155|NCT04000841|Experimental|Intervention|Intervention participants receive access to the Mindful You app for 12 weeks. They will use the app to listen to guided meditations and to receive notifications, messages, and reminders that they select and ones sent to all participants by the app.
89161156|NCT04000841|No Intervention|Waitlist Control|Waitlist control participants will continue business as usual with regards to stress-management and reduction.
89161157|NCT00710398|Experimental|Control|A group consuming twice daily (post-exercise and in morning/afternoon) drinks containing no dairy protein or calcium. Daily protein intake (15% total kcals) should be from non-dairy sources (i.e. meat, egg, fish, chicken, wheat gluten).
89161158|NCT00710398|Experimental|Dairy Protein|A group consuming twice daily drinks (post-exercise and morning) containing 1% chocolate milk (in 1.5 cup servings = 3 cups/d). Daily protein intake is set at 15% total kcals with ~8% coming from dairy sources.
89161159|NCT00710398|Experimental|High Dairy Protein|A group consuming twice daily drinks of 1% artificially sweetened chocolate milk (in 1.5 cup servings = 3 cups/d). Their diet contains 30% protein (as opposed to only 15% in the Con and DairyPro groups) with at least 50% of that coming from dairy sources.
89161160|NCT02647268|No Intervention|Control (no oxytocin) pretreatment|The myometrial samples are bathed in physiological saline solution (PSS).
89161161|NCT02647268|Active Comparator|Magnesium Sulphate|The myometrial samples are bathed in a 3.5mM magnesium sulphate solution.
89161162|NCT02647268|Active Comparator|Magnesium Sulphate + oxytocin|The myometrial samples are bathed in a 3.5mM magnesium sulphate plus 10-5M oxytocin solution.
89161163|NCT04218149|Active Comparator|Group S|Serratus plane block with 25 ml %0.25 bupivacaine
89161164|NCT04218149|Active Comparator|Grup E|Erector spinae plane block with 25 ml %0.25 bupivacaine
89161165|NCT00710476|Experimental|1|Insemination of the oocytes with a lower concentration of spermatozoa.
89161166|NCT00710476|No Intervention|2|Insemination with a normal concentration of spermatozoa.
89161167|NCT04032860|Experimental|ETV group|group in which patients take ETV as antiviral therapy after curative treatment
89161168|NCT04032860|Experimental|TDF group|group in which patients take TDF as antiviral therapy after curative treatment
89161169|NCT04217369|No Intervention|Control|A control arm. The participant will be given a version of the Diabits app without predictions of blood glucose enabled. They will then use the Diabits app as if they were using their usual companion app to manage their diabetes for the duration of the study.
89161170|NCT04217369|Experimental|Intervention|The intervention arm. The participants in this arm will be provided with a version of the Diabits app which provides predictions of where their blood glucose will be one hour into the future, based on historic data and user inputs. The participant will then manage their blood glucose using these predictions for the duration of the study.
89161171|NCT00716248|Experimental|1|
89161172|NCT00716248|Active Comparator|2|
89161173|NCT02647034||pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
89161174|NCT02647034||non-pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
89161175|NCT04218383|Active Comparator|Experimental: Active Left OFC Group|2mA will be applied for 20 minutes with the tDCS anode applied to the left OFC and Cathode applied to the right primary motor cortex.
89161176|NCT04218383|Sham Comparator|Sham Comparator: Sham left OFC Group|Current will be ramped up for 30s followed by a 30s ramp down to mimic the physical sensation of stimulation and habituation. The anode placed over the left OFC and cathode placed over the right primary motor cortex.
89161177|NCT00716326|Active Comparator|1|Subjects in this study arm will receive active treatment with Cefar TENS device which delivers therapeutic electrical currents 2-3x over sensory threshold in the area of pain.
89161178|NCT00716326|Placebo Comparator|2|Subjects in this study arm will receive placebo treatment with manipulated Cefar TENS device which delivers electrical currents just below sensory threshold in the area of pain.
89161179|NCT02643212|Placebo Comparator|Placebo|
89161180|NCT02643212|Experimental|Rivaroxaban|Rivaroxaban 10mg, 1 once a day
89161181|NCT04218227||Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
89161182|NCT04218227||Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
89161183|NCT04218227||Self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life.
89161184|NCT04218227||Psycho-education|It is a 7-months 2 hours-session (1 session per month) of psycho-education training. Psycho-education aims to empower and encourage the patient to become an actor in his therapeutic management, while offering a comprehensive model of the mechanisms of pain, the benefits of pharmacological treatments at a physical and psychological level as well as ways to change the way one lives every day.
89161185|NCT04218227||Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercice is conducted at the end of each session. A CD with the audiotaped hypnosis exercice is given to each patient so that they can practice also every day.
89161186|NCT00716404||1|All (consecutive) patients in whom one or more components of the Benephit Infusion System are planned to be used are eligible for enrollment in the study and should be offered informed consent.
89161187|NCT02642978|Experimental|RSRCLM|robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).Three different liver resection procedures were chose to personalized patients. Generally, when the size of liver metastasis was ≤ 3 cm, a wedge resection was chose without Hilar vessels blocking. The segmentectomy was performed using the Glissonian approach when tumor size was among 3-5 cm, and Hilar vessels was blocked, if necessary. For resection of Couinaud's segments II and III, left lateral sectionectomy (LLS) was performed commonly. Intraoperative ultrasound can help us find intrahepatic pedicles and follow the proper resection line. When liver tumor size was more than 5 cm or more than 3 tumors with the size over 3cm, hemicolectomy was applied usually.
89161188|NCT02642978|Active Comparator|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis. The DFS and safety event were evaluated.
89161189|NCT00719992|Experimental|1|positive ETT, High HS-CRP
89161190|NCT00719992|Active Comparator|2|positive ETT, Low HS-CRP
89161191|NCT02642900|Experimental|Nystatin 100.000 units|Patients were treated with a topical antifungal nystatin oral suspension(1000.000 units) 5mL every six hours/14 days. Patients were instructed to rinse the solution for 5 minutes and then to spit the solution out. Samples were collected on days 7, 14 and 30 after the end of treatment (follow-up).
89161192|NCT02642900|Active Comparator|Photodynamic Therapy|Patients used mouthwash with methylene blue 0.005% for 20 minutes (pre-irradiation time). The palatal mucosa was irradiated using a low level laser with the following settings: wavelength of 660 nm, energy density of 120 J/cm ², output power of 40 milliwatt, 2 minutes per point. PDT was performed in two sessions (one session per week). Samples were collected immediately after each clinical procedure and 30 days after the second procedure (follow-up).
89161193|NCT02749643|Experimental|Vibrotactile feedback|Vibrotactile system - comprises of force sensors, attached to the fingertips of the prosthetic hand, and a set of 8 vibration actuators attached to a fabric arm cuff. When the subject applies force on the sensors with his prosthetic hand, he receives a vibration on the skin of his arm. The sensors and actuators are connected to an electronic control board, which transforms the resistance from the sensors to an electric signal that activates the vibration actuators.
89161194|NCT04068532|Placebo Comparator|Placebo|Participants will receive matching placebo to BIIB104 on Days 1-4 in treatment periods 1 or 2.
89161195|NCT04068532|Experimental|BIIB104|Participants will receive BIIB104 on Days 1-4 in treatment periods 1 or 2.
89161196|NCT02652728|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
89161197|NCT00720070|Experimental|Arm I|Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of primary site undergo neck dissection within 4 weeks.
89161198|NCT00720070|Active Comparator|Arm II|Patients undergo neck dissection and receive standard concurrent CRT. Patients undergo PET/CT scan at 9-13 weeks after completion of CRT.
89161199|NCT02749565||asthmatic patients with OSA|
89161200|NCT02749565||asthmatic patients without OSA|
89161201|NCT04216979|Experimental|randomization|Patients are randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site. Group (B):- The umbilicus is the primary entry site.
89161202|NCT04216979|Experimental|group A|these are the patient with palmars point as primary entry site
89161203|NCT04216979|Experimental|group B|these are the patient with umbilicus as primary entry site
89161204|NCT00710788|Experimental|1|sevelamer as Phosphate-binder treatment
89161205|NCT00710788|Active Comparator|2|Calcium carbonate
89161206|NCT04068220|Other|Intraoperative FVEPs monitoring|adult patients admitted to TOH - Civic Campus, for chiasmal or pre-chiasmal lesions undergoing a first time minimally invasive endoscopic skull base surgery.
89161207|NCT02646800|Experimental|Micafungin group|Intravenous (IV)
89161208|NCT02749409|Active Comparator|Control group|The control group will be given Morphine prn after admission
89161209|NCT02749409|Experimental|Experimental group|the experimental group will be given parecoxib after admission by intravenous method every 12 hours for 4 days. Then Morphine agent will be given prn usage
89161210|NCT02647112|Experimental|Bladder EpiCheck|Urine sample will be tested with the Bladder EpiCheck in conjunction with cystoscopy and cytology
89161211|NCT02647112|No Intervention|Practice of medicine|Practice of medicine including cystoscopy and cytology
89161212|NCT02652494||Patients receiving Apremilast per daily clinical practice|Dutch patients receiving Apremilast according to daily clinical practice
89161213|NCT03449459|Experimental|oral probiotics|
89161214|NCT03449459|Experimental|aerosol inhaled amikacin|
89161215|NCT03449459|Experimental|combined vaccination|
89161216|NCT03449459|No Intervention|conventional therapy (blank control)|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.
89161217|NCT02646878|Other|Harmony 1 Sensor Group A|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 90 minutes after sensor insertion.
89161218|NCT02646878|Other|Harmony 1 Sensor Group B|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 12 hours after sensor insertion.
89161219|NCT00653120|Experimental|A|Subjects received Par Products under fasting conditions
89161220|NCT00653120|Active Comparator|B|Subjects received Wyeth Pharmaceuticals product under fasting conditions
89161221|NCT02695511|Experimental|25% CR|25% caloric restriction
89161222|NCT02695511|No Intervention|CO (control)|healthy lifestyle recommendation
89161223|NCT00877032|Experimental|Arm 1|
89161224|NCT02652338|Active Comparator|MNC-01|potassium, magnesium, and vitamins (MNC-01)
89161225|NCT02652338|Placebo Comparator|Placebo|cellulose, microcrystalline [NF], HPMC E15,
89161226|NCT03318809|Experimental|Group 1: Severely Renal Impaired Participants|Participants with severely impaired renal function (estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m^2) receive a single oral dose of 200 mg AMG 986.
89161227|NCT03318809|Active Comparator|Group 2: Healthy Participants|Participants with normal renal function (eGFR >= 90 mL/min/1.73 m^2 or above) receive a single oral dose of 200 mg AMG 986.
89161228|NCT02642510|Experimental|DVD Structured Education|Participants in this group will watch an educational DVD in addition to standard teaching by nursing staff.
89161229|NCT02642510|Active Comparator|Standard Educational Teaching|Participants in this group will receive educational teaching by their assigned nursing staff.
89161230|NCT02642666|Experimental|Yoga intervention|While in the yoga intervention arm of the study participants will practice yoga at home and at school for six weeks with the goal of practicing yoga daily during that time period. Yoga classes will be held twice a week at school. On the days that the children do not practice yoga at school, they will practice yoga at home with the use of a children's yoga video that mirrors the yoga class that they attend at school.
89161231|NCT02642666|No Intervention|Normal school and home activities|While in the wait-list group the children will continue with their regular activities both at home and at school.
89161232|NCT02628210|Other|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
89161233|NCT00910832|Experimental|Eductyl suppository|
89161234|NCT00910832|Placebo Comparator|Placebo suppository|
89161235|NCT00651716||Allogeneic Stem Cell Transplant Patients|Patients undergoing allogeneic stem cell transplant (SCT). Potential study candidates will be identified by participating physicians.
89161236|NCT02628054|Active Comparator|Typhoid Vaccine|Typhoid vaccination in single 0.5mL injections into the non-dominant deltoid muscle in the arm
89161237|NCT02628054|Placebo Comparator|Placebo|A single 0.5mL injection of 0.9% sodium chloride saline solution into the non-dominant deltoid muscle in the arm
89161238|NCT02652572|Experimental|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
89161239|NCT02772965|Experimental|Methotrexate|"Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.~Folic Acid (1 mg) daily"
89161240|NCT02772965|Placebo Comparator|Sugar pill (placebo)|"Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose.~Folic Acid (1 mg) daily"
89161241|NCT00681720|Experimental|1|
89161242|NCT00650312|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
89161243|NCT00650312|Active Comparator|2|Glucophage® XR Tablets 500 mg
89161244|NCT02749253|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
89161245|NCT02646956||Age Group-Children|Children between ages of 7 and 14
89161246|NCT02646956||Age Group-Adults|Healthy adults who are the parent of the children
89161247|NCT02626806||patients with hemodynamic significant CAD;|
89161248|NCT02626806||patients without hemodynamic significant CAD|
89161249|NCT02106689|Experimental|Needle free system|"Intervention will consist of the gonadotropin BRAVELLE being injected using the Comfort-in™ needle free system for the duration of a standard superovulation cycle"
89161250|NCT02106689|Active Comparator|Standard needle injection system|Control patients will undergo their superovulation cycle using the gold standard subcutaneous needle injection system for their gonadotropin injections
89161251|NCT04165304|No Intervention|control|the range of products offered by the vending machines remains unchanged
89161252|NCT04165304|Other|Intervention group 1|vending machines will be re-equipped to contain 60% drinks containing a maximum of 6.7g sugar/100ml, 20% drinks containing more than 6.7g sugar/100ml and 20% water
89161253|NCT04165304|Other|Intervention group 2|In the second intervention group, the vending machines offer 80% water and 20% products with a maximum of 6.7g sugar/100ml.
89161254|NCT00681798|Active Comparator|Dose level 1|Vandetanib 100mg/day plus Gemcitabine
89161255|NCT00681798|Active Comparator|Dose level 2|Vandetanib 300mg/day plus Gemcitabine
89161256|NCT00681798|Active Comparator|Dose level 3|Vandetanib 100mg/day plus Gemcitabine plus CapecitabineDose
89161257|NCT00681798|Active Comparator|Dose level 4|Vandetanib 300mg/day plus Gemcitabine plus CapectiabineDose
89161258|NCT02749487||cured (c)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
89161259|NCT02749487||Died ( M)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
89161260|NCT04152876||Cases|Patients with rare disease
89161261|NCT04152876||controls|Healthy parents and relatives
89161262|NCT00538681|Experimental|Enzastaurin + Pemetrexed + Cisplatin|
89161263|NCT00538681|Placebo Comparator|Placebo + Pemetrexed + Cisplatin|
89161264|NCT00636233||Anencephaly|Fetuses with anencephaly, parents and siblings
89161265|NCT00681876|Experimental|1|Irinotecan+Avastin+Erbitux
89161266|NCT00653198||A|Cases
89161267|NCT00653198||B|Controls
89161268|NCT00533663|Experimental|Standard Care + Healing Touch (HT)|A a gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy. It occurs every other week (during their infusion).
89161269|NCT00533663|Active Comparator|Standard Care + Guided relaxation|Guided relaxation every other week (during their infusion).
89161270|NCT00533663|Active Comparator|standard care only|Standard care
89161271|NCT02642276|Active Comparator|Maximal walking group|Patients to be randomized to the 'maximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to the point of pain-free walking distance.
89161272|NCT02642276|Active Comparator|Submaximal walking group|Patients to be randomized to the 'submaximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to 2/3 of pain-free walking distance.
89161273|NCT02642276|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
89161274|NCT00681954||1, 2, 3|
89161275|NCT02642120|Experimental|Receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
89161276|NCT02642120|No Intervention|Do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
89161277|NCT05405647|Experimental|shock wave therapy|received a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session, and a frequency of 5 Hz., 1 sessions per week for 6 weeks.
89161278|NCT05405647|Experimental|kinesio tape|kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6 weeks.
89161279|NCT02646722||No pain|patients show no pain on rocuronium injection
89161280|NCT02646722||mild pain|patients move a hand only on rocuronium injection
89161281|NCT02646722||moderate pain|patients move a arm on rocuronium injection
89161282|NCT02646722||severe pain|patients show generalized movement because of pain
89161283|NCT05358457|Experimental|Online Familiar Metacognitive Training|Metacognitive training for psychosis. The MCTf consists of 11 therapeutic units developed during weekly sessions lasting 45 and 60 minutes. Each unit contains abundant therapeutic material that includes psychoeducational information, exercises and case examples.The group will be composed of 3-4 mothers with psychosis and her adolescent children and two therapists. The application of the intervention will be by a secure videoconfering method.
89161284|NCT05358457|No Intervention|Control group|The control group will be receive treatment as usual (TAU).
89161285|NCT02751203|Experimental|Make Safe Happen App Intervention|Pre- and post-test delivered to online survey panel participants. Instruction to download and use the intervention (Make Safe Happen Mobile App) for 1 week.
89161286|NCT02751203|No Intervention|Make Safe Happen App Control|A subset of online survey panel participants (n=200) will complete a pre- and post-test survey but will receive a non-safety app (e.g. a free recipe app). After the study, participants will be asked to download the intervention app.
89235042|NCT05243602|Experimental|Switch to B/F/TAF|Participants in this arm will switch from their current ARV regimen to the study drug B/F/TAF. This is an oral drug administered once daily for the duration of the study.
89161287|NCT05404243|Experimental|phenolization group|Curettage of the sacral cyst is performed using a disposable otorhinolaryngologists curette. The perimeter of the cyst is covered with petroleum jelly to protect the skin, and an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
89161288|NCT05404243|Active Comparator|conventional surgery|entire exeresis is performed by means of an electric scalpel
89161289|NCT04217681|Experimental|Self-hypnosis/self-care group|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
89161290|NCT04217681|Experimental|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
89161291|NCT04217681|Experimental|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
89161292|NCT04217681|Experimental|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
89161293|NCT02749097|Experimental|Cohort 1|Single oral dose of 10 mg SHR0534 or matching placebo
89161294|NCT02749097|Experimental|Cohort 2|Single oral dose of 25 mg SHR0534 or matching placebo
89161295|NCT02749097|Experimental|Cohort 3|Single oral dose of 50 mg SHR0534 or matching placebo
89161296|NCT02749097|Experimental|Cohort 4|Single oral dose of 100 mg SHR0534 or matching placebo
89161297|NCT02749097|Experimental|Cohort 5|Single oral dose of 200 mg SHR0534 or matching placebo
89161298|NCT05402215|Experimental|experimental group|The flipped classroom model was used in teaching the clinical practice skills of the students in the experimental group. First of all, videos for clinical applications were prepared by the researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
89161299|NCT05402215|Active Comparator|control group|"To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher. While the students were doing the applications, one of the researchers observed the application and marked only the skill level in the checklists (applied, incompletely applied and did not apply) without making any comments or directions."
89161300|NCT00876018|No Intervention|No intervention|No intervention
89161301|NCT00876018|Experimental|Nutritional supplement|Fortified nutritional powder
89161302|NCT00876018|Placebo Comparator|Placebo|Un-fortified nutritional powder
89161303|NCT02749175|Experimental|Cricoid force sensor monitor system|Nurse applied cricoid pressure with a sensor guided by monitoring Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons.
89161304|NCT02749175|Sham Comparator|Sham cricoid force sensor monitor system|Nurse applied pressure on a sham sensor with no monitor input. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
89161305|NCT02749175|No Intervention|Current standard|Nurse applied cricoid force according to memory. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
89161306|NCT02226367|Active Comparator|prazosin hydrochloride|Prazosin hydrochloride taken orally. Titrated to a maximum dose 4 mg in the morning, 6 mg in the afternoon, and 10 mg at bedtime. (20 mg total daily at maximum dose) Dose increase will occur if the participant does not have unacceptable side effects.
89161307|NCT02226367|Placebo Comparator|placebo|Placebo. Oral capsule with comparable appearance to active treatment. Titrated in same manner as active treatment.
89161308|NCT02747147|No Intervention|A- Control|Group A will have their PIVs assessed daily and record kept of PIV dislodgement or replacement
89161309|NCT02747147|Experimental|B - Device Intervention|patients will have their PIVs assessed daily and record kept of PIV displodgement or replacement. patients will additionally have a single blood collection attempted using the study device
89161310|NCT03885934|Experimental|V114, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL intramuscular (IM) injection for 7 to 11 months of age (Pneumococcal conjugate vaccine [PCV]-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
89161311|NCT03885934|Active Comparator|Prevnar 13®, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL IM injection for 7 to 11 months of age (PCV-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
89161312|NCT03885934|Experimental|V114, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
89161313|NCT03885934|Active Comparator|Prevnar 13®, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
89161314|NCT03885934|Experimental|V114, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced) (1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
89161315|NCT03885934|Active Comparator|Prevnar 13®, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced)(1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
89161316|NCT02746913|Experimental|Urodynamics, followed by Pessary|
89161317|NCT02746913|Experimental|Pessary, followed by Urodynamics|
89161318|NCT02628132|Experimental|Durvalumab and Paclitaxel|After one cycle of paclitaxel, durvalumab will be given concurrently with paclitaxel. Once paclitaxel cycles are completed, durvalumab will be continued alone until disease progression or unacceptable toxicity.
89161319|NCT05387473|Experimental|cognitive behavioral therapy for insomnia (CBT-I) integrated in best-evidence usual care (CBTi-UC)|18 individual sessions provided by physiotherapists, over 14 weeks.
89161320|NCT05387473|Active Comparator|Best-evidence usual care (UC) plus information sessions|18 individual sessions provided by physiotherapists, over 14 weeks.
89161321|NCT02695355|Experimental|ADHD medication effects|Single dose methylphenidate (Ritalin tablets); 10 mg for ages 8-13; 15 mg for ages 13-17
89161322|NCT02627820|Experimental|Experimental Drug|Isis 420915/GSK 299872, an antisense oligonucleotide. Administered subcutaneously three times per week for the first week, and then weekly for 18 months. Each dose shall contain 300 mg of active drug.
89161323|NCT02749019|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
89161324|NCT00990457|Active Comparator|Low-carbohydrate Diet Plus Exercise|Participants will follow a low-carbohydrate weight loss diet plus participate in a supervised exercise training program for 6 months.
89161325|NCT00990457|Active Comparator|Low-Fat, Low-Calorie Diet Plus Exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
89161326|NCT00716560||A|Metastatic melanoma treatment with Dartmouth regimen
89161327|NCT00672750||I|Patients of Dr C Miller who have undergone laparoscopic myomectomy from 1999- to present
89161328|NCT02748629|Active Comparator|ProGrip Mesh Repair|80 patients are randomized to inguinal hernia repair using selfgripping ProGrip Mesh (Covidien Parietex ProGrip Self-Fixating Mesh) - sutureless fixation.
89161329|NCT02748629|Active Comparator|Lichtenstein Operation|80 patients are randomized to inguinal hernia repair using lightweight polypropylene mesh (<40 g/m2) with standard Lichtenstein technique.
89161330|NCT02573038|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
89161331|NCT00678366|Experimental|1|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
89161332|NCT00678366|Active Comparator|2|pure carbon dioxide pneumoperitoneum
89161333|NCT02746835|Experimental|Exercise Protocol|Set of exercises for balance, endurance, muscle strength and flexibility
89161334|NCT00716638|Experimental|Treatment group 1|Trauma-focused Cognitive Behavior Therapy (TF-CBT)
89161335|NCT00716638|Experimental|Treatment group 2|Eye Movement Desensitization and Reprocessing (EMDR)
89161336|NCT02627976|Active Comparator|breast edema vest|
89161337|NCT02746757|No Intervention|Ischemia-reperfusion no intervention|Ischemia-reperfusion without intervention
89161338|NCT02746757|Experimental|Ischemia-reperfusion with RIPC|Ischemia-reperfusion with intervention by RIPC
89161339|NCT02746757|Experimental|Ischemia-reperfusion with RIPC and Ex 9-39|Ischemia-reperfusion with RIPC and Ex 9-39
89161340|NCT01822015|Experimental|Treatment (sirolimus, idarubicin, cytarabine)|Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
89161341|NCT02627898|Experimental|Green tea extract|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
89161342|NCT02627898|Placebo Comparator|Placebo|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
89161343|NCT02746601|Experimental|Risk Assessment, Counselling & Resources|Patients complete an electronic preconception health risk assessment tool. Results from the tool are directly uploaded or scanned into the patients' electronic medical record. A healthcare provider provides behavioural counselling, based on results of the risk assessment. Patients are given a customized handout that includes health recommendations and resources based on the patient's identified risk factors.
89161344|NCT04417894|Experimental|dupilumab|Administered subcutaneously (SC) once every 2 weeks (Q2W), following a loading dose on Day 1
89161345|NCT04417894|Experimental|Matching Placebo|Administered SC Q2W, following a loading dose on Day 1
89161346|NCT04144686|Active Comparator|Group A|Vestibular participants undertaking a single-task vestibular rehabilitation
89161347|NCT04144686|Experimental|Group B|Vestibular participants undertaking a dual-task vestibular rehabilitation
89161348|NCT00990535|Experimental|Octreotide-LAR|Patients will receive every 21 days an injection of octreotide-LAR 30 mg until progression is documented.
89161349|NCT00716716|Experimental|rFIXFc|Six intravenous (IV) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg
88806067|NCT00302042|Active Comparator|2: Brief Counseling Alone|Brief Counseling for pre-diabetes alone
89161350|NCT00990613|Other|Cohort 1|
89161351|NCT00990613|Other|Cohort 2|
89161352|NCT00875706|Other|Training Feasibility|"4 sites will receive the training intervention to determine the feasibility of the train-the trainer approach.~The educational intervention is included in this arm."
89161353|NCT00875706|Other|Data Collection - Survey|Survey data collection tools will be piloted to assess feasibility of survey administration and development of the survey for future studies. This tools were piloted in sites where the educational intervention was administered.
89161354|NCT00875706|Other|Data Collection - Interview|Interview data collection tools will be piloted to assess feasibility of interview administration and development of the interview protocol for future studies. This tools were piloted in sites where the educational intervention was administered.
89161355|NCT05590897|Experimental|Tongue Scraping Group|Participants in this group will receive treatment with tooth brushing, dental flossing and tongue scraping.
89161356|NCT05590897|Experimental|Antimicrobial Photodynamic Therapy Group|Participants in this group will receive treatment with tooth brushing, dental flossing and antimicrobial photodynamic therapy in the tongue.
89161357|NCT05590897|Experimental|Probiotics Group|Participants in this group will receive treatment with tooth brushing, dental flossing and probiotics.
89161358|NCT05590897|Experimental|Antimicrobial Photodynamic Therapy and Probiotics Group|Participants in this group will receive treatment with tooth brushing, dental flossing, antimicrobial photodynamic therapy in the tongue and probiotics.
89161359|NCT02572180|Active Comparator|NIRS-based NF in 3D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 3D virtual reality classroom environment.
89161360|NCT02572180|Active Comparator|NIRS-based NF in 2D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 2D (normal computer screen) classroom environment.
89161361|NCT02572180|Active Comparator|EMG-based BF in 3D|An electromyogram (EMG)-based biofeedback training in which participants learn to self-regulate activity of the musculi supraspinatus will take place in a 3D virtual reality classroom environment.
89161362|NCT04399889|Experimental|Open Label infusion of hCT-MSC|The first 10 consecutive patients will all receive investigational product.
89161363|NCT04399889|Experimental|Randomized infusion of hCT-MSC|An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo. The investigational product will be further randomized to the MSCs manufactured by Duke or University of Miami. These products are considered to be comparable.
89161364|NCT04399889|Placebo Comparator|Randomized infusion of Placebo|An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo
89161365|NCT00682188|Experimental|CI|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
89161366|NCT00682188|Active Comparator|II|Six individual sessions with the school nurse over 2 months to check weight and behavior changes and provide a series of six pamphlets on weight and weight management
89161367|NCT05590663||Patients with knee osteoarthritis|Individuals who are medically diagnosed with knee osteoarthritis and eligible for physiotherapy care in SingHealth Polyclinics will be recruited. Inclusion criteria include: individuals above the age of 45, proficient in colloquial/conversational English, and diagnosed with knee osteoarthritis. Exclusion criteria include additional underlying medical or trauma conditions of the knees (e.g., trauma, fracture, infection, inflammatory disease, tumour), history of knee surgery within the last three months, or clinically recognizable cognitive impairment that inhibits the completion of the questionnaires.
89161368|NCT02629068|Experimental|PURPOSE|"Parents in the PURPOSE group will join a secret Facebook group for 2 months. Groups will be lead by 2 peer leaders and include 20 parent participants."
89161369|NCT02629068|No Intervention|Treatment as Usual (TAU)|Treatment as Usual parents will be contacted after 8 weeks to complete follow-up interview. Will not receive PURPOSE intervention.
89161370|NCT00720304|Experimental|oral erlotinib hydrochloride|
89161371|NCT02746523||Case / Retired NHL Players|"All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
89161372|NCT02746523||Age Matched Controls|"All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
89161373|NCT04152720|Active Comparator|Prevention of infection Foley catheter|
89161374|NCT04152720|Active Comparator|Conventional Foley catheter|
89161375|NCT05360875|Experimental|Endometrial scratching group|
89161376|NCT05360875|No Intervention|Non-scratching group|
89161377|NCT02746367||MDD|Patients diagnosed with Major Depressive Disorder
89161378|NCT02746367||BPI|Patients diagnosed with bipolar I
89161379|NCT02746367||BPII|Patients diagnosed with bipolar II
89161380|NCT02574364|Active Comparator|traditional incision|traditional incision : McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
89161381|NCT02574364|Experimental|modified incision|modified incision :The application of abdomen CT before surgery provides a new approach to the incision and new perception.
89161382|NCT00682266|Experimental|Aerobic interval training|intensity-controlled interval training
89161383|NCT00682266|Experimental|MTG|multidisciplinary approach
89161384|NCT02746445||ASD Subjects|No interventions. This is an observation of subjects who received MeRT utilizing assessment documentation.
89161385|NCT01564147|Other|Immediate Education therapeutic|Access to the course of immediate therapeutic education
89161386|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
89161387|NCT00720460||Experimental|Healthy Volunteers
89161388|NCT00990691|Experimental|Desipramine high dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~From 15 to 25 kg : 50 mg ;~From 26 to 35 kg : 75 mg ;~From 36 to 45 kg : 100 mg ;~> 46 kg : 150 mg."
89161389|NCT00990691|Experimental|Desipramine low dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~From 15 to 25 kg : 25 mg ;~From 26 to 35 kg : 50 mg ;~From 36 to 45 kg : 75 mg ;~> 46 kg : 100 mg."
89161390|NCT00990691|Placebo Comparator|Placebo|12 patients with Rett syndrome receiving a daily dose of placebo.
89161391|NCT02626650|Active Comparator|Check symptoms one has experienced|This is the baseline condition. When asked to indicate concussion symptoms (or most other kinds of symptoms for medical conditions), people usually place a check mark next to each symptom they have experienced.
89161392|NCT02626650|Experimental|Check symptoms one has not experienced|Participants place a check mark next to each symptom they have NOT experienced in the most recent sports season.
89161393|NCT02626650|Experimental|Uncheck symptoms one has experienced|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have experienced in the most recent sports season.
89161394|NCT02626650|Experimental|Uncheck symptoms one has not experienced.|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have NOT experienced in the most recent sports season.
89161395|NCT02748473|Other|pelvic floor muscle strength|evaluated pelvic floor muscle strength before and after Pilates exercises program on sedentary nulliparous women
89161396|NCT02748473|Other|Device: 3D perineal ultrasound|evaluated the pubovisceral muscle thickness and the levator hiatus area before and after Pilates exercises program on sedentary nulliparous women
89161397|NCT00716872|Experimental|ImmedSHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
89161398|NCT00716872|Experimental|ImmedSHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
89161399|NCT00716872|Experimental|DelaySHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
89161400|NCT00716872|No Intervention|DelaySHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
89161401|NCT05359471|Active Comparator|HIV with NAFLD|HIV Nonalcoholic fatty liver disease patients
89161402|NCT05359471|Active Comparator|HIV without NAFLD|HIV without Nonalcoholic fatty liver disease patients
89161403|NCT00678600|Active Comparator|Standard (static) Computer Alerts|Participants in this arm will be assigned to standard care. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Provider computer alerts will be posted on the participant's electronic health record summary page.
89161404|NCT00678600|Experimental|Enhanced Computer Alerts|Participants in this arm will be assigned to the enhanced alert arm. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Providers will receive population and asynchronous computer alerts with improved functionality.
89161405|NCT04391855|Experimental|Tramadol with ropivacaine|Tramadol 2mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
89161406|NCT04391855|Experimental|Dexmedetomidine with ropivacaine|Dexmedetomidine 1μg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
89161407|NCT04391855|Experimental|Magnesium with ropivacaine|Magnesium sulfate 10 mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration
89161408|NCT04391855|Placebo Comparator|Placebo with ropivacaine|Ropivacaine (10mg/ml) 100mg with 5ml isotonic saline for wound infiltration
89161409|NCT00716950|Experimental|1|valsartan/amlodipine
89161410|NCT00716950|Active Comparator|2|losartan/amlodpine
89161411|NCT00678678|Active Comparator|I - Spirometer|
89161412|NCT00678678|Active Comparator|II - Kit Epap®|Device with Spring load by mask,produced by Brazil (critical med)
89161413|NCT02748239|Active Comparator|MEDIAS 2 CT|The MEDIAS CT is a newly developed education program for the initiation of a conventional insulin therapy in type 2 diabetic patients.
89161414|NCT02748239|Placebo Comparator|Current CT program|This program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients.
89161415|NCT00711178|Active Comparator|A|2 hours sunlight
89161416|NCT00711178|Active Comparator|B|3 hours of sunlight
89161417|NCT02748395|Placebo Comparator|Placebo|Injection of 3.5mL of normal saline into the point of maximal tenderness in the abdomen
89161418|NCT02748395|Experimental|Treatment|Injection of 20mg triamcinolone and 1% lidocaine into the point of maximal tenderness in the abdomen
89161419|NCT02745977|Other|Dairy Free Diet- guaiac + on dairy free diet|Dairy Free Diet x 3 weeks then stool guaiac positive
89161420|NCT02745977|Other|Guaiac negative on dairy free diet|on dairy free diet x 3 weeks, then stool guaiac negative
89161421|NCT02629224|Experimental|Renal impairment|
89161422|NCT02629224|Experimental|Haemodialysis|
89161423|NCT02572804|Active Comparator|Rectus Sheath Catheter Group|Patients will have rectus sheath catheters surgically inserted with infusion of 0.125% Bupivicaine at 5mls an hour.
89161424|NCT02572804|Active Comparator|Epidural Group|Patients will have a standard epidural placement with infusion of 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response
89161425|NCT02746133||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
89161426|NCT04152174|Experimental|Combined extracorporeal blood purification|CRRT with CVVHDF mode plus treatment with CytSorb adsorber
89161427|NCT04152174|Active Comparator|Control|CRRT with CVVHDF mode
89161428|NCT02748551|Experimental|Laparoscopic surgery|Traditional open procedure for patient with locally advanced gastric cancer
89161429|NCT02748551|Active Comparator|Open surgery|Minimum invasive procedure (laparoscopic) for patient with locally advanced gastric cancer
89161430|NCT02626416|Experimental|telemedicine group|Congenital cataract patients use telemedicine to pursue and adjust the time of follow-up under non-clinical settings
89161431|NCT02626416|No Intervention|non-telemedicine group|Congenital cataract patients pursue and adjust the time of follow-up through outpatient visit in the hospital
89161432|NCT00711256|Active Comparator|1|No sunscreen applied
89161433|NCT00711256|Active Comparator|2|Sunscreen applied 0.5 mg/cm2
89161434|NCT00711256|Active Comparator|3|Sunscreen applied 1mg/cm2
89161435|NCT00711256|Active Comparator|4|Sunscreen applied 2mg/cm2
89161436|NCT04069234|Experimental|Ticagrelor|ticagrelor 60mg BID for 30 Days and ASA 75 - 150 mg once daily
89161437|NCT04069234|Active Comparator|Clopidogrel|clopidogrel 75mg OD for 30 Days and ASA 75 - 150 mg once daily
89161438|NCT00672828|Active Comparator|Non-tailored CRC screening brochure|Participants undergo a baseline interview via telephone and receive a non-tailored CRC screening brochure in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
89161439|NCT00672828|Experimental|Interactive computer intervention|Participants undergo a baseline interview via telephone and complete an interactive computer intervention in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
89161440|NCT04379063||Canadian physicians during COVID-19 pandemic|Any physician who is practicing in Canada during the COVID-19 pandemic, whether they hold a full, provisional, or post-graduate in-training license.
89161441|NCT03860740||High intensity physical exercise|Supervised Exercise Group: Customized and supervised exercise high intensity training program during 2-3 weeks previous surgery.
89161442|NCT03860740||Control|Supervised Stretching Group: a stretching and body balance classes will be developed to control the possible confounders and to control the exercise level of participants.
89161443|NCT00678912|Experimental|1|Children are mechanically ventilated with Smartcare/PS
89161444|NCT00678912|No Intervention|2|Children are mechanically ventilated with usual care
89161445|NCT00672906|Experimental|1|Group Parent Training/Adolescent Skills Training
89161446|NCT00672906|Active Comparator|Active Comparator|Family Therapy according to the Maudsley Model
89161447|NCT00720538|Experimental|1|Thalidomide
89161448|NCT00720538|Placebo Comparator|2|Placebo
89161449|NCT02746211|Experimental|High Titre Influenza virus|High Titre Influenza virus
89161450|NCT02746211|Experimental|Medium - High Influenza virus|Medium - High Influenza virus
89161451|NCT02746211|Experimental|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
89161452|NCT02746211|Experimental|Low titre Influenza Vaccine|Low titre Influenza Vaccine
89161453|NCT00678990|Experimental|Open, single arm|Transplantation of islets with heparin coating.
89161454|NCT00679068|Experimental|1|treatment with Bosentan
89161455|NCT02745899|Active Comparator|Soy milk substitute Healthy|Healthy children aged 6-18 will drink 240 ml of soy milk substitute.
89161456|NCT02745899|Active Comparator|Soy milk substitute Asthma|Asthmatic children aged 6-18 will drink 240 ml of soy milk substitute.
89161457|NCT02745899|Experimental|Cow milk Healthy|Healthy children aged 6-18 will drink 240 ml of cow milk.
89161458|NCT02745899|Experimental|Cow milk Asthma|Asthmatic children aged 6-18 will drink 240 ml of cow milk.
89161459|NCT02572102|Experimental|Energy Drink|Two 16 ounce containers of an Energy Drink
89161460|NCT02572102|Active Comparator|Panax Ginseng|800 mg of Panax Ginseng in 70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
89161461|NCT02572102|Placebo Comparator|Placebo|70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
89161462|NCT00679146|Active Comparator|1|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
89161463|NCT00679146|Active Comparator|2|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
89161464|NCT02748161|Active Comparator|DEB-TACE: Standard Endhole Catheter|Subjects will undergo DEB-TACE using a standard endhole catheter.
89161465|NCT02748161|Active Comparator|DEB-TACE: Surefire Infusion System|Subjects will undergo DEB-TACE using the Surefire Infusion System.
89161466|NCT00679224||ambrisentan prescribed subjects|ambrisentan prescribed subjects
89161467|NCT02748083|Active Comparator|tDCS group|The active tDCS group will be stimulated with transcranial Direct Current Stimulation (tDCS).
89161468|NCT02748083|Sham Comparator|Sham tDCS group|The sham tDCS group will have stimulation with sham transcranial Direct Current Stimulation (tDCS).
89161469|NCT00837265|Experimental|Pilot Phase: Balugrastim Low Dose|Participants will receive balugrastim low dose administered by subcutaneous (SC) injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
89161470|NCT00837265|Experimental|Pilot Phase: Balugrastim Medium Dose|Participants will receive balugrastim medium dose administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
89161471|NCT00837265|Experimental|Pilot Phase: Balugrastim High Dose|Participants will receive balugrastim high dose administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
89161472|NCT00837265|Active Comparator|Pilot Phase: Pegfilgrastim|Participants will receive pegfilgrastim 6 mg administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
89161473|NCT00837265|Experimental|Main Phase: Balugrastim Medium Dose|Participants will receive balugrastim medium dose administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
89161474|NCT00837265|Experimental|Main Phase: Balugrastim High Dose|Participants will receive balugrastim high dose administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
89161475|NCT00837265|Active Comparator|Main Phase: Pegfilgrastim|Participants will receive pegfilgrastim 6 mg administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days).
89161476|NCT02748005|Experimental|Fenugreek seeds extract 500 mg|Fenugreek seeds extract(Furosap) 500 mg
89161477|NCT00990847|Experimental|Procaterol|Procaterol inhalation solution 50 micro g per 0.5 mL diluted in 2mL of NaCl 0.9%, so that the volume of the inhalation solution will be similar to that of the comparator drug. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
89161478|NCT00990847|Active Comparator|Salbultamol|Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
89161479|NCT02745743|Experimental|Arm 1|Biomarker-enriched advanced hematological neoplasms
89161480|NCT02745743|Experimental|Arm 2|Other selected advanced hematological neoplasms
89161481|NCT00594516|Experimental|001|tapentadol (CG5503) Immediate Release (IR) Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100 150 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second,tapentadol (CG5503) Immediate Release IR 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
89161482|NCT00594516|Experimental|002|tapentadol (CG5503) Extended Release (ER) During 2 double blind periods: Tapentadol ER 100 150 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
89161483|NCT05629793|Experimental|Persistent COVID group|Patients with persistent COVID will be recruited by the physicians of the Post COVID-19 Multidisciplinary Clinic of the Complexo Hospitalario Universitario de Ourense.
89161484|NCT05629793|Experimental|Recovered COVID group|The controls will be recruited in a matched manner with the clinical sample in age, sex, epidemic wave and vaccination status, from among previously COVID-positive patients cured without sequelae and attended in Primary Care in the Health Centers of A Cuña, Valle Inclán and Novoa Santos in Ourense.
89161485|NCT00682422||Parent & Child Dyad|
89161486|NCT02745665||1-Elite Cyclist|"10 symptomatic cyclists with unilateral diagnosis of iliac EF,~FLOW MEDIATED DILATION Ankle brachial pressure index (ABPI) PULSE WAVE VELOCITY AND AUGMENTATION INDEX Blood pressure RAMP Test"
89161487|NCT02745665||2-Amateur Cyclist|"10 asymptomatic cyclists with no evidence of EF~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
89161488|NCT02745665||3-Control|"10 age-matched healthy male group~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
89161489|NCT00682500|Experimental|1|Calfactant treatment
89161490|NCT00682500|Placebo Comparator|2|
89161491|NCT00538291|Experimental|Arm 1|Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.
89161492|NCT02745509|Experimental|Extensive Intraoperative Peritoneal Lavage|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles), followed by complete aspiration of the fluid . The abdomen will be closed as per standard.
89161493|NCT02745509|No Intervention|Standard Treatment|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal lavage will be done < 3 cycles with 3 liters or less of warmed normal saline. The abdomen will be closed as per standard.
89161494|NCT00682578|Experimental|Artekin|Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)
89161495|NCT00682578|Active Comparator|Standard treatment|"The standard treatment for uncomplicated falciparum and vivax malaria are as follows:~Uncomplicated falciparum: artesunate-sulphadoxin/pyrimethamine Vivax malaria: chloroquine"
89161496|NCT04351685|Experimental|VPM1002|"Total 3470 subjects will be enrolled in VPM1002 arm.~Single dose of VPM1002 will be administered."
89161497|NCT04351685|Active Comparator|BCG SII|"Total 3470 subjects will be enrolled in BCG SII arm.~Single dose of BCG SII will be administered."
89161498|NCT00594906|Active Comparator|Injection|30 participants will receive teriparatide (Forteo) injection pens.
89161499|NCT00594906|Placebo Comparator|Placebo|30 participants will receive placebo injection pens.
89161500|NCT05590351|Experimental|Intervention|m-health coaching application
89161501|NCT05590351|Active Comparator|Standard of care|Face to face counselling
89161502|NCT02745431|Experimental|Oxytocin nasal spray|Oxytocin nasal spray
89161503|NCT02745431|Placebo Comparator|Placebo nasal spray|Placebo nasal spray
89161504|NCT04143360|Experimental|New Closed Drainage Device|We further improve the new closed thoracic drainage system by changing the material of drainage tube, adding external fixator control valve and increasing the gas flow monitoring kit for special patients, and apply it in clinical practice.
89161505|NCT04143360|Experimental|Traditional Closed Drainage Device|We use traditional closed drainage devices for patients with hemothorax and pneumothorax.
89161506|NCT05360797|Experimental|Outpatient|The Mild AP patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
89161507|NCT05360797|Experimental|Medical home care|The mild AP patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
89161508|NCT05360797|Active Comparator|Hospitalization|The mild AP patient is hospitalized
89161509|NCT02745041|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm [FIBTEM ≤ A5 10mm]
89161510|NCT02745041|Active Comparator|Cryoprecipitate|Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm [FIBTEM A5 ≤ 10mm]
89161511|NCT00682656|Active Comparator|A - N- methyl glucamine|Glucantime® , max day of 1,215 mg
89161512|NCT00682656|Experimental|B - Azithromycin|Zithromax ® , one dose 500 mg
89161513|NCT05590117|Placebo Comparator|Group 1 placebo|n=24 which will receive 12 cycles of FOLFOX-6 regimen plus placebo tablets twice daily.
89161514|NCT05590117|Active Comparator|Group 2 pentoxifylline|n=24 which will receive FOLFOX-6 regimen in addition to pentoxifylline 400 mg twice daily.
89161515|NCT00636311|Active Comparator|1|IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine)
89161516|NCT00636311|Experimental|2|B-IGEV (Bortezomib + IGEV)
89161517|NCT02629302|Experimental|animal assisted therapy|"Standard therapy (speech therapy, occupational therapy and physiotherapy) that is done in the presence and with Integration of an animal."
89161518|NCT02629302|Active Comparator|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
89161519|NCT04151238|Experimental|Exercise intervention|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home. Data on training at home and other items of physical activity is recorded in a diary.
89161520|NCT00990925|Experimental|Weight Loss Education Group|Involvement in weekly manualized, educational group on nutrition and lifestyle modifications to help with weight loss.
89161521|NCT00990925|Other|Usual Care|Treatment as usual
89161522|NCT04151316|Experimental|vertical group|
89161523|NCT04151316|Experimental|horizontal group|
89161524|NCT00673140|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
89161525|NCT02695199|Experimental|laparoscopic varicocelectomy|laparoscopic Doppler ultrasound assisted laparoscopic varicocelectomy group
89161526|NCT02695199|Sham Comparator|microscopic varicocelectomy|conventional Microscopic Subinguinal varicocelectomy group
89161527|NCT00991003|Experimental|Colon capsule endoscopy and colonoscopy|Patients underwent CCE on day 1 and conventional colonoscopy on day 2
89161528|NCT05629559|Experimental|4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A|4D-310 Dose Level 1 - AAV NAb Titer Group A patients
89161529|NCT05629559|Experimental|4D-310 Dose Level 1 - AAV NAb Titer Group B|4D-310 Dose Level 1 - AAV NAb titer Group B patients
89161530|NCT05629559|Experimental|4D-310 Dose Level 2 - AAV NAb Titer Group A and/or B|4D-310 at Dose Level 2 in AAV NAb titer Group A and/or B patients
89161531|NCT05629559|Experimental|4D-310 Dose Expansion|Dose expansion cohort of 4D-310 at the selected dose and selected AAV Nab titer group(s) patients
89161532|NCT05589961|Experimental|integrated treatment regimen(TRPP)|
89161533|NCT00679458|Experimental|1.|Study drug: buprenorphine and ultra-low-dose naloxone
89161534|NCT00679458|Active Comparator|2.|Study drug: buprenorphine
89161535|NCT02745197|Experimental|Nutritional Supplement|2 nutritional supplement capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
89161536|NCT02745197|Placebo Comparator|Placebo|2 placebo capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
89161537|NCT04003753|Experimental|Exposure|"Study phase 1: The experimental intervention in the experimental group consists of three 20-minutes VR exposures (total duration in VR: 60 minutes).~Study phase 2: The experimental intervention in the experimental group consists of six 30-minutes VR exposures as home training (total duration in VR: 3 hours) within two weeks."
89161538|NCT04003753|No Intervention|Control|"Study phase 1: The control group will not receive any active treatment. Instead they will use an App to make virtual tours (three times 20 minutes, total duration in VR: 60 minutes).~Study phase 2: The control group will not receive any active treatment (untreated comparison group)."
89161539|NCT04216511||Case-Lung Cancer|Patients with definite lung cancer diagnosis
89161540|NCT04216511||Control|Either patients with benign pulmonary nodule, or healthy individuals without pulmonary nodule but with risk factors to develop lung cancer matched to lung cancer group
89161541|NCT02627586|Active Comparator|Moderate intensity continuous exercise|Moderate intensity continuous exercise (MICE) is performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group will perform MICE training three times per week. Cycling resistance will be adjusted weekly according to heart rate and Borg scale.
89161542|NCT02627586|Experimental|High-intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. Moderate intensity continuous exercise (MICE) is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group performs two HIIT sessions and one MICE session per week.~In both training forms cycling resistance will be adjusted weekly according to heart rate and Borg scale."
89161543|NCT05589805|Experimental|ESWT group|In addition to wrist splint, ESWT treatment (1.5 bar, 5Hz, 1000 beats) will be applied to the patients with the Elmed Vibrolith Ortho brand ESWT device, which we routinely use in the treatment of carpal tunnel syndrome, for 3 weeks, once a week.
89161544|NCT05589805|Experimental|Laser group|In addition to the wrist splint, the patients will be treated with the BTL-4110 Laser Topline model low-intensity laser device, which we routinely use in the treatment of carpal tunnel syndrome in our hospital, 5 days a week for 15 sessions of laser treatment.
89161545|NCT05589805|Active Comparator|Control group|Patients will only be given a wrist splint to keep the wrist in neutral position.
89161546|NCT02745275|Experimental|Peer-led Health Education|A single 60 minute interactive workshop led by the trained health coach followed by a series of three one hour discussion groups
89161547|NCT02745275|No Intervention|Control|No intervention
89161548|NCT02747537|Experimental|Arm 1: Sorafenib and Irinotecan|"Sorafenib is an oral drug which will be administered on an outpatient basis twice a day continuously (every day of a 21-day cycle) at approximately the same times each day. For patients unable to swallow whole pills, an oral suspension may be prepared with tablets.~Irinotecan will be administered orally (mixed with cranberry type juice) on an outpatient basis once a day on Days 1-5 of a 21-day cycle. Irinotecan should be given at least 1 hour after sorafenib."
89161549|NCT04031586||Children diagnosed with Solid Tumors|Children diagnosed with solid tumors in Managua, Nicaragua in Central America
89161550|NCT00989365|Other|Patient cousenling|Improve medicine use Self control asthma crisis Ambient hygiene
89161551|NCT00912366||Group A|VATS
89161552|NCT00912366||Group B|Open Surgery
89161553|NCT02747381|Experimental|intervention|receive Alfacalcidol 1 mcg daily for 4 months beside the conventional asthma medications
89161554|NCT02747381|No Intervention|control|Asthmatic patients receiving conventional asthma medications
89161555|NCT00673218|Placebo Comparator|1|Saline injection to match active
89161556|NCT00673218|Experimental|Treatment|Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks
89161557|NCT00673296|Other|A|Patients receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
89161558|NCT04216355|Experimental|AZA with CAG derived regimen|Azacitidine 50mg/m²/day, D1-D5 (IV) Aclarubicin 5mg/m²/day, D1-D4 (IV) Cytarabine 10mg/m²/12h, D1-D6 (IV) G-CSF 5-10ug/kg/day, D1-D7 (SC)
89161559|NCT02744963|Experimental|Free and convenient medicine access|Free access to a list of essential medicines. Medicines are either mailed to the patient or dispensed at the point of care.
89161560|NCT02744963|No Intervention|Usual medicine access|Usual access to medicines.
89161561|NCT00683124|Experimental|Losartan|Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.
89161562|NCT00683124|Experimental|Nebivolol|Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years.
89161563|NCT00683124|Experimental|Losartan+Nebivolol|"Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.~Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years."
89161564|NCT02744807||non-Chronic endometritis|patients with intrauterine adhesion only
89161565|NCT02744807||Chronic endometritis|patients with intrauterine adhesion as well as Chronic endometritis
89161566|NCT04141566||PCPC|pseudocontinent perineal colostomy using shmidt technique for perineal reconstruction after abdominoperineal resection
89161567|NCT04141566||PLIC|Permanenet left iliac colostomy , the standard technique after abdominoperineal resection and primary closure of the perineal wound
89161568|NCT02744729|Experimental|Esophagus Cancer, 99mTc-3PRGD2, SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis of Esophagus cancer patients.
89161569|NCT00683202|Active Comparator|1|Acetylsalicylic acid 100 mg daily perorally
89161570|NCT00683202|Placebo Comparator|2|Placebo daily perorally
89161571|NCT02744885|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
89161572|NCT02744885|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
89161573|NCT00679536|Experimental|A|All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)
89161574|NCT00537979|Active Comparator|Paricalcitol injection|ABT-358 Zemplar
89161575|NCT00537979|Active Comparator|Paricalcitol capsules|ABT-358 Zemplar
89161576|NCT02744573||General Anaesthesia|ANI and SPI values under general anaesthesia
89161577|NCT02744573||Spinal Anaesthesia|ANI and SPI values under spinal anaesthesia
89161578|NCT02744573||Spinal Anaesthesia + Sedation|ANI and SPI values under spinal anesthesia in combination with sedation
89161579|NCT02744573||Control|ANI and SPI values under no anaesthesia
89161580|NCT00679614|Experimental|1|Group A oral tramacet 2 tablets preoperatively, 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. Naloxone infusion starting preop at 0.25ug/kg/hr and continuing during hospital stay (an equivalent of 400ug over 24 hours in a 70 kg man). The infusion will be discontinued 1 hour before patient discharge.
89161581|NCT00679614|Active Comparator|2|Group B will receive oral tramacet 2 tablets preoperatively and then 2 tablets every 6 hours for five days. ( or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). This group will also receive saline infusion at 4-6mls / hour for the duration of the hospital stay.
89161582|NCT00679614|Active Comparator|3|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay.
89161583|NCT02744417|Experimental|Smoking cessation therapy|Non-surgical periodontal therapy and concurrent smoking cessation therapy, with Smoking cessation counseling, Nicotine replacement therapy, use of bupropion hydrochloride and varenicline
89161584|NCT02627664||observational study|natural history of non dopaminergic signs
89161585|NCT02629146|Experimental|Midazolam|Drug: Midazolam (experimental)
89161586|NCT02629146|Placebo Comparator|Isotonic saline|Drug: Isotonic saline (placebo)
89161587|NCT02629146|Active Comparator|Fentanyl|Drug: Fentanyl (active comparator)
89161588|NCT02744339|Experimental|Riociguat|Riociguat up-titrated to a maximum of 1.5mg TID
89161589|NCT02744339|Placebo Comparator|Placebo|Placebo sham-titrated TID
89161590|NCT05360563|Experimental|Physical training group|In addition to receive regular medical care, the physical training group will participate in a tailored home-based exercise program (remotely supervised by healthcare professionals).
89161591|NCT05360563|No Intervention|Control group|The control group will receive regular medical care.
89161592|NCT00679692||3:|three arms for study
89161593|NCT02747069||NICU electronic stethoscope|Neonatal patients of any gestation admitted to the neonatal intensive care unit (NICU) and undergoing routine monitoring with ECG and pulse oximetry Heart rate will be evaluated using an electronic stethoscope
89161594|NCT02747069||Newborns <32 weeks and ECG|Neonatal patients <32 weeks gestation Heart rate will be assessed at the time of delivery with both an electronic stethoscope and ECG using a pre placed lead system
89161595|NCT00991159|Experimental|RN316|
89161596|NCT00679770|Experimental|Group 1|AN2690 Solution: 2.5%
89161597|NCT00679770|Experimental|Group 2|AN2690 Solution: 5%
89161598|NCT00679770|Experimental|Group 3|AN2690 Solution: 7.5%
89161599|NCT00679770|Placebo Comparator|Group 4|AN2690 Solution Vehicle
89161600|NCT05589493|Experimental|All-on-4 PEEK routine|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
89161601|NCT02744495|Experimental|postoperative nausea and vomiting risk factors|Preoperative collection of postoperative nausea and vomiting risk factors available for practicians.
89161602|NCT02744495|No Intervention|control|No prophylaxis whatever risk score is. Postoperative nausea and vomiting risk factors not available for practicians.
89161603|NCT00679848|Experimental|1|Transoral Suturing
89161604|NCT02744027|Other|Dynamic Contrast Enhanced Magnetic Contrast Imaging|Dynamic Contrast Enhanced Magnetic Resonance (MR) Lymphangiogram and heavy T2 Magnetic Resonance imaging data will be evaluated for abnormal lymphatic perfusion of the lung parenchyma. Abdominal and thoracic lymphatic malformations will be characterized by location, number, size, relationship to other organs and perfusion patterns in order to create a basis of imaging classification of lymphatic abnormalities (LA). Subjects will undergo both Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram (DCMRL) and Heavy Weighted T2 Imaging.
89161605|NCT02742155|Experimental|Play2Sleep|For the experimental intervention, Play2Sleep consists of video-recording the mother and father separately while engaged in a structured play session. Immediately following the play session, the home visitor will review the video recording with each parent separately to provide positive feedback on parental behaviors that promotes contingent interaction and identification of infant cues. At the end of the visit, standard public health handouts on infant sleep will be provided to both parents.
89161606|NCT02742155|Active Comparator|Comparison|In the comparison group, only standard public health handouts on infant sleep will be reviewed with parents.
89161607|NCT05360407|Experimental|Intervention Group|The mobile information application was downloaded from the Android market and installed on the patients' phones, and the patients were taught about how to use it. The patients were given a short information brochure on the use of the mobile application. One week after the surgery, the patients were called and reminded about the use of the application. Three weeks after the surgery, data were collected through telephone interviews using the Patient Follow-up Form, Anxiety, Distress and Quality of Life measurement tools, the Patient Information Satisfaction Questionnaire, and the Mobile Application Evaluation Form.
89161608|NCT05360407|No Intervention|Control Group|The patients received routine care and training in the clinic, and no additional intervention was applied. Three weeks after the surgery, data were collected through telephone interviews using the Patient Follow-up Form, Anxiety, Distress and Quality of Life measurement tools, and the Patient Information Satisfaction Questionnaire
89161609|NCT00683280|Active Comparator|Standard of Care|Medication (varenicline) for 12 weeks (Day 1 through 84) and brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35).
89161610|NCT00683280|Experimental|Standard of Care plus Contingency Management|Medication (varenicline) for 12 weeks (Day 1 through 84), brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35), plus prize-based contingency management for carbon monoxide samples and urinary cotinine samples that meet smoking abstinence criteria.
89161611|NCT05629403||exclusive breastfeeding|breastfeeding exclusively
89161612|NCT05629403||formula feeding|formula feeding
89161613|NCT05358223|No Intervention|Prostatic block|Patients who will be treated with periprostatic block
89161614|NCT05358223|Active Comparator|Prostatic block+Music|Patients who will be treated with periprostatic block and who will be simultaneously listened to music
89161615|NCT05358223|Active Comparator|Prostatic block+Tens|Patients who will undergo periprostatic block and concomitant TENS
89161616|NCT05358223|Active Comparator|Music|Patients who will only listen to music without periprostatic block
89161617|NCT05358223|Active Comparator|Tens|Patients who will only be treated with TENS without periprostatic block
89161618|NCT00683358|Experimental|1|
89161619|NCT02744105|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
89161620|NCT02744105|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
89161621|NCT00991237|Experimental|Pain reduction|
89161622|NCT00683436|Experimental|1|adipiplon 6 mg
89161623|NCT00683436|Experimental|2|adipiplon 9 mg
89161624|NCT00683436|Placebo Comparator|3|Placebo
89161625|NCT00683436|Experimental|4|Ambien CR 12.5 mg
89161626|NCT00989443|Experimental|Cidofovir|
89161627|NCT02743637|Experimental|SDX-7320|Increasing dose cohorts, until the maximum tolerated dose (MTD) is determined.
89161628|NCT00683514|Other|A|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~cycle 3 & 4 (q 21 days) = chemotherapy : oral vinorelbine (60 mg/m2 d1, d8 for cycle 1, 80 mg/m2 d1 & d8 for cycle 2) and cisplatin (80 mg/m2 d1) plus Best Supportive Care"
89161629|NCT00683514|Other|B|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~Best Supportive Care only"
89161630|NCT02743715|Active Comparator|Active tDCS|Electric current of 2mA delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
89161631|NCT02743715|Sham Comparator|Sham tDCS|In this group, the cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
89161632|NCT00683670|Experimental|Dendritic Cell Vaccine (First Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
89161633|NCT00683670|Experimental|Dendritic Cell Vaccine (Second Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
89161634|NCT00683670|Experimental|Dendritic Cell Vaccine (Third Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 6 weeks for a total of 3 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 in order to collect PBMC for immune monitoring.
89161635|NCT05629325|Experimental|Buspirone => Washout => Placebo|Patients will take Buspirone hydrochloride 10mg oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will also report their perceived symptoms of dysphagia during the HRiM. A washout period of two weeks will take place. Afterwards, the second treatment period starts. Patients will take Placebo oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will also be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will again report their perceived symptoms of dysphagia during the HRiM.
89161636|NCT05629325|Experimental|Placebo => Washout => Buspirone|Patients will take Placebo oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will also report their perceived symptoms of dysphagia during the HRiM. A washout period of two weeks will take place. Afterwards, the second treatment period starts. Patients will take Buspirone hydrochloride oral once a day (in the evening) for 3 days, twice a day (morning and evening) for 4 days, three times a day for 2 weeks and 20mg oral three times a day for one week. Esophageal motility will also be assessed with high resolution impedance manometry (HRiM) after 4 weeks of treatment. Patients will again report their perceived symptoms of dysphagia during the HRiM.
89161637|NCT02743559|Active Comparator|Vitamin D group|Children born to mothers who received vitamin D during pregnancy will undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform(LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
89161638|NCT02743559|Placebo Comparator|Placebo group|Children born to mothers who received placebo during pregnancy will also undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform (LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
89161639|NCT00989521|Placebo Comparator|placebo|normal saline for inhalation
89161640|NCT00989521|Active Comparator|PUR003|PUR003 for inhalation
89161641|NCT00680004||1|Preoperative patients planned for a CT prior to an endograft implantation procedure
89161642|NCT00680004||2|Patients who underwent a complicated endograft implant and/or with increased risk of complications
89161643|NCT00989599|Experimental|compress of Chamomilla recutita infusion|Patients who developed phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
89161644|NCT00989599|Active Comparator|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
89161645|NCT05629247|Other|Screening|
89161646|NCT00683748||Kidney transplant|
89161647|NCT00683748||Liver transplant|
89161648|NCT02743325|Active Comparator|ALARA protocol|SVT ablation by ALARA protocol
89161649|NCT02743325|Active Comparator|current treatment|SVT ablation by conventional protocol
89161650|NCT02629380|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (Hymovis, Fidia Farmaceutici SpA, Padova, Italy) at the end of the arthroscopic meniscectomy
89161651|NCT02629380|Other|meniscectomy alone|Arthroscopic meniscectomy alone
89235043|NCT05243602|Active Comparator|Continue current regimen|Participants in this arm will be maintained on their pre-enrollment ARV regimen for the duration of the study.
88806068|NCT01892228|Experimental|Two counties: Zhongshan and Pubei|"Immediate post-screening treatment education for HIV-positive participants residing in the Zhongshan and Pubei pilot sites in the Treat-All HIV Pilot Program"
89161652|NCT02743403|Active Comparator|Neurodyn Portable TENS|"Subjects in this study arm will receive active treatment. The active TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.~The subject receives both devices at the same time. The parameters of the active TENS are: frequency (f) of 100 Hertz (Hz) oscillator every 0.5 seconds pulse duration (T) 200 microseconds (microsiemens) and the amplitude (I) will be adjusted at the time of application the carboxiterapia.~The application of Carboxytherapy is realized by a carboxy Derm S20-1C equipment Derm® mark, which uses carbon dioxide (CO2) medical and non-toxic.~Each prick with a needle carboxiterapia will 100ml / min and will last 1 minute long.~Before each puncture will be adjusted to the intensity of TENS as sensitivity of the subject."
89161653|NCT02743403|Placebo Comparator|Placebo TENS- Neurodyn Portable TENS|"Subjects in this study arm will receive placebo treatment. The placebo TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.~The application of placebo TENS will be made by the same unit of active TENS; however, it is used a device specially developed for this study. The device remains active only during the first 30 seconds of application. After this time, the current amplitude will gradually decrease over the next 15 seconds until it reaches zero, thereby interrupting the emission of electrical power to the remainder of the application time. The display of placebo TENS device shows a light on all the time of application, indicating the patient that the device is active."
89161654|NCT02743403|No Intervention|Control|"Subjects in this study arm only receive the application carboxiterapia through Carboxyderm S20-1C equipment, Tone Derm® brand.~The group (active - control Carboxytherapy) will be submitted to the application of Carboxytherapy and off TENS."
89161655|NCT04141332||Group 1|80 Patient
89161656|NCT04141332||Group 2|80 Control subject
89161657|NCT02743247|Experimental|Tacrolimus and Mycophenolate mofetil|Tacrolimus 5mg single dose, Mycophenolate 1,000mg single dose, Tacrolimus 5mg and Mycophenolate 1,000mg single dose.
89161658|NCT00989677||Rheumatoid Arthritis|
89161659|NCT04190615||0 to 3 months|0 (term newborns) to 3 month of age
89161660|NCT04190615||4 to12 months|infants from 4month to 12month of age
89161661|NCT04190615||13 to 24 months|children from 13month to 2years of age
89161662|NCT04190615||2 to 5 years|children from 2 to 5 years of age
89161663|NCT04190615||6 to 10 years|children from 2 to 10 years of age
89161664|NCT04190615||11 to16 years|children from 11 to 16 years of age
89161665|NCT00680082||1|Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
89161666|NCT02743169||Standard Practice|This group will consist of ambulance calls under the standard practice of Aman Foundation for ambulance placement.
89161667|NCT02743169||Post-Intervention|This group will consist of ambulance calls after the spatially-optimized placement of ambulances.
89161668|NCT00673374||1|All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
89161669|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI|with/without Charcoal Block
89161670|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI (replicate)|with/without Charcoal Block
89161671|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI VHC|with/without Charcoal Block with Valved Holding Chamber
89161672|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 1|with/without Charcoal Block
89161673|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 2|with/without Charcoal Block
89161674|NCT02742857|Experimental|Treatment Group|
89161675|NCT00680238|No Intervention|A|Embryo selection for transfer based on a Day 3 score only.
89161676|NCT00680238|Active Comparator|B|Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
89161677|NCT02742779|Experimental|High-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
89161678|NCT02742779|Experimental|High-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 3.
89161679|NCT02742779|Experimental|Low-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
88806069|NCT01898702|Experimental|Diabetes expert patients programme|Diabetes expert patients programme: Participate in a scheduled and standardized expert patients programme course
89161680|NCT02742779|Experimental|Low-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
89161681|NCT02742779|Experimental|MD Cohort: PIC (Part 2)|Participants will receive multiple ascending dose administered orally using PIC from Day 1 to Day 13 twice daily (BID) or may even be thrice daily (TID) or four times a day (QD) depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
89161682|NCT02742779|Experimental|MD Cohort: Solution Formulation (Part 4)|Participants will receive multiple ascending dose in fed or fast condition, administered orally using solution from Day 1 to Day 13 BID or may even be TID or QD depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
89161683|NCT02742779|Placebo Comparator|Placebo PIC|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
89161684|NCT02742779|Placebo Comparator|Placebo Solution|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
89161685|NCT02742779|Experimental|SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using PIC on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 1.
89161686|NCT02742779|Experimental|SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using solution formulation on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 3.
89161687|NCT04141176|Experimental|Spiri+|new CPAP device
89161688|NCT00683982|Active Comparator|1|This group will receive oral nitazoxanide preparation
89161689|NCT00683982|Active Comparator|2|This group will receive a mix combination of probiotics
89161690|NCT00683982|Placebo Comparator|3|This is the control group receiving only oral or systemic hydration solutions
89161691|NCT04190381|Experimental|FR-Mask application|
89161692|NCT00537823|Experimental|Arm 1 - Wildtype|"Neoadjuvant therapy~Week 1~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly~Weeks 3, 5, 7~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Week 1, 3, 5, 7, 9, 11, 13, 15~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Weeks 2, 4, 6, 8, 10, 12, 16~*Cetuximab 250 mg/m^2 IV weekly"
89161693|NCT00537823|Experimental|Arm 2 K-Ras 12/13 codon mutation|"Neoadjuvant Therapy~Weeks 1, 3, 5~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~Bevacizumab 5 mg/kg IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Week 7~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Weeks 1, 3, 5, 9, 11, 13~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~Bevacizumab 5 mg/kg IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Week 7, 15~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2"
89161694|NCT04139928|Experimental|Picometer-ionic form of magnesium chloride|
89161695|NCT04139928|Active Comparator|Magnesium citrate or magnesium oxide|
89161696|NCT04139928|Placebo Comparator|Placebo|
89161697|NCT00673530|Experimental|1|evidence based clinical nutrition concept
89161698|NCT00673530|Other|2|care as usual
89161699|NCT00991393||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
89161700|NCT02742389|No Intervention|Standard counseling|This group will receive the standard counseling that all our patients would receive if they are scheduled to have urodynamic testing. This counseling will include a description of the procedure and a handout about urodynamic testing
89161701|NCT02742389|Other|Standard + Preprocedure Telephone Call|The participants will receive the standard counseling that all our patients who are scheduled for urodynamic testing receive (just like those who are assigned to group 1). In addition, the participants will receive intervention: a pre-procedural telephone call from the investigators 1 week before their testing to talk about the procedure.
89161702|NCT02626572|Experimental|S47445 5mg|
89161703|NCT02626572|Experimental|S47445 15mg|
89161704|NCT02626572|Experimental|S47445 50mg|
89161705|NCT02626572|Placebo Comparator|Placebo|
89161706|NCT05589025|Active Comparator|treatment group|pulpotomy: amputation of coronal pulp
89161707|NCT05589025|Active Comparator|control group|Pulpectomy: complete removal of the pulp tissues from the canals
89161708|NCT02742545|Experimental|MayoExpertAdvisor|Clinicians in care teams assigned to the intervention arm will have access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
89161709|NCT02742545|No Intervention|Usual Care|Clinicians in care teams assigned to the standard of care arm will continue to provide up-to-date, patient-specific guideline-based treatment recommendations as is the standard of care at Mayo Clinic.
89161710|NCT00989755|Experimental|Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD)|Clinics in this group receive Fax to Quit materials and in person training from a Regional Outreach Specialist (ROS). The ROS also provides on-going training/technical assistance and performance feedback.
89161711|NCT00989755|Placebo Comparator|Fax to Quit alone|Clinics in this group receive Fax to Quit materials and can download materials from a website.
89161712|NCT02626494|Experimental|Cocaine Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
89161713|NCT02626494|Active Comparator|Healthy Control Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
89161714|NCT02742233|Experimental|saxagliptin|"saxagliptin & Regular treatment:~saxagliptin, brand name，Bristol-Myers, Squibb, dose: 5mg, po, qd"
89161715|NCT02742233|Placebo Comparator|placebo|"placebo & Regular treatment:~placebo, dose: 5mg, po, qd"
89161716|NCT00673608|Experimental|Deferasirox|
89161717|NCT00537277|Experimental|BIAsp 30|Biphasic insulin aspart 30 administered once daily for 16 weeks. If HbA1c is higher than 7.0 % after 16 weeks of treatment, dose is increased to twice daily for another 16 weeks. If HbA1c is higher than 7.0 % after 32 weeks of treatment, dose is increased to three times daily until week 48 (end of trial).
89161718|NCT02742467|Experimental|1|Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.
89161719|NCT02742467|Active Comparator|2|Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.
89161720|NCT02742467|Active Comparator|3|Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.
89161721|NCT00684216|Active Comparator|1|capecitabine followed by hormonal treatment
89161722|NCT00684216|Active Comparator|2|hormonal treatment followed by capecitabine
89161723|NCT02741921|Experimental|Normal airway|intubation with normal airway Cormack-Lehane classivication I
89161724|NCT02741921|Experimental|difficult airway|intubation with difficult airway Cormack-Lehane classivication III
89161725|NCT00684294|Experimental|TAG Vaccine 1 x 10^7 cells/ injection|TAG Vaccine 1 x 10^7 cells/injection
89161726|NCT00684294|Experimental|TAG Vaccine 2.5 X 10^7 cells/injection|TAG Vaccine 2.5 X 10^7 cells/injection
89161727|NCT05586997|Active Comparator|Bonded Rapid Maxillary Expansion|Bonded-hyrax with a 7mm expansion screw activated a full turn twice daily
89161728|NCT05586997|Experimental|Bonded Rapid Maxillary Expansion and low-Level Laser|Bonded-hyrax with a 7mm expansion screw activated a full turn twice daily with 10 sessions of Indium Gallium Arsenide Phosphoride (940nm) semiconductor diode laser
89161729|NCT02736851|No Intervention|Control group|Usual care
89161730|NCT02736851|Active Comparator|Home-based telemedicine group|Nurse-tutor support at home for 6 months
89161731|NCT00684450|Active Comparator|1|in vivo protamine titration in cardiac surgery. The titration is done during administration of protamine each 3 minutes to reach 2 consecutive ACT defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds. .The protamine is stopped when this values are obtain. Follow-up is done 15 minutes and 3 hours post-protamine
89161732|NCT00684450|Active Comparator|2|standard protamine administration ACT is done during administration of protamine each 3 minutes the values are recorded but the totality of protamine is given. Follow-up is done 15 minutes and 3 hours post-protamine
89161733|NCT00991471|Experimental|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
89161734|NCT00991471|Experimental|Control: No MDRNSTAT|Control group
89161735|NCT02736773|Experimental|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
89161736|NCT02741609|Experimental|Early/Late Stage Lyme disease|Have early Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with early stage Lyme disease. Subjects must have a physician-diagnosed erythema migrans (EM) rash and should have systemic symptoms indicative of disseminated infection. Symptoms may include fever, headache, fatigue, myalgias, arthralgias, and stiff neck. Paired acute and convalescent titers will be drawn (first draw at time of initial visit and second draw 4 weeks later). Have late Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with late stage Lyme disease, including but not limited to disseminated rash, arthritis, meningitis, facial palsy, or carditis. Qualified subjects will be administered the Borrelia Diagnostic Test.
89161737|NCT00684528|Active Comparator|a|This group will receive Metformin and placebo.
89161738|NCT00684528|Experimental|2|The second arm will receive Metformin and Januvia
89161739|NCT05360251|Experimental|Pulsed dye laser(PDL)|The patients were randomly categorized into the following four groups based on the treatments they received: PDL, DPL, M22 590, M22 vascular filter
89161740|NCT05360251|Experimental|IPL(Delicate Pulsed Light)|The patients were randomly categorized into the following four groups based on the treatments they received: PDL, DPL, M22 590, M22 vascular filter
89161741|NCT05360251|Experimental|IPL(M22 590)|The patients were randomly categorized into the following four groups based on the treatments they received: PDL, DPL, M22 590, M22 vascular filter
89161742|NCT05360251|Experimental|IPL(M22 vascular filter)|The patients were randomly categorized into the following four groups based on the treatments they received: PDL, DPL, M22 590, M22 vascular filter
89161743|NCT00684606|Experimental|1|Transcervical Foley catheter with IV Oxytocin
89161744|NCT00684606|No Intervention|2|Transcervical Foley catheter only
89161745|NCT00991549|Experimental|1|interdisciplinary weight loss intervention
89161746|NCT00991549|Active Comparator|2|Small group seminars without interdisciplinary intervention
89161747|NCT02736461||Group 1- With strabismus|Study group with strabismus happening after floor fracture repair
89161748|NCT02736461||Group 2- Without strabismus|No strabismus happening after floor fracture repair
89161749|NCT00684684|Experimental|1|
89161750|NCT02736539|Experimental|Active|galacto-oligosaccharides
89161751|NCT02736539|Placebo Comparator|Placebo|Placebo
89161752|NCT00673686|Active Comparator|Arm 2|
89161753|NCT00673686|Experimental|Arm 1|
89161754|NCT02741843|Experimental|Patient Education|
89161755|NCT02741843|No Intervention|Control|
89161756|NCT05582941||Control|20 individuals with no cognitive alterations or any other pathology which could alter cognitive performance or blood cells
89161757|NCT05582941||Mild Cognitive Impairment Due to Alzheimer's Disease: MCI group|20 individuals diagnosed with Mild Cognitive Impairment Due to Alzheimer's Disease with positive AD markers in cerebrospinal fluid
89161758|NCT05582941||Dementia due to Alzheimer Disease: AD group|20 individuals diagnosed with Dementia Due to Alzheimer Disease with positive AD markers in cerebrospinal fluid
89161759|NCT03820973|Experimental|Brief CBT for Anxiety|Participants will receive Brief Cognitive Behavioral Therapy for Anxiety (bCBT). Sessions with clinicians will be provided via VA Video Connect to Home (VVC-H). Participants will have the option to select from a list of skills to tailor to his/her preferences. Participants will be able to receive up to 9 total sessions and generally last 30 to 40 minutes. For the purpose of this study, treatment duration will be limited to 3 months to ensure standardization of study outcome measures.
89161760|NCT04334915|Experimental|Arm A: Cenicriviroc Mesylate (CVC)|"Cenicriviroc mesylate (CVC) 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing antiretroviral (ARV) regimens.~For participants who are on an efavirenz (EFV)-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
89161761|NCT04334915|Placebo Comparator|Arm B: Placebo for CVC|"Placebo for CVC 150 mg tablet once a day for at least 24 weeks will be added to the participants' pre-existing ARV regimens.~For participants who are on an EFV-based regimen, dosing will be 300 mg, administered as two 150-mg tablets, once a day."
89161762|NCT03743077|Experimental|Individuals with spinal cord injury|Volunteers will participate in the the spinal mobility fitness training program which includes exercise training with inspiratory muscle training.
89161763|NCT04888429|Experimental|Camrelizumab + Famitinib|Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.
89161764|NCT02741765|Active Comparator|Group 1: Sham Group|Sham group will receive Sham rTMS+Aerobic Exercise
89161765|NCT02741765|Experimental|Group 2: Real Group|rTMS+Aerobic Exercise
89161766|NCT03815591|Experimental|adolescents between ages of 10-16|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, attitudes, intentions, social norms, and behaviors around tobacco use, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
89161767|NCT00991627|Active Comparator|Pharmacological|Patients in this group will receive a basal infusion of ephedrine. Hypotension will be treated for a reduction in systolic blood pressure 20% below baseline values.
89161768|NCT00991627|Experimental|Non-Pharmacological|Patients in this group will undergo uterine lateral displacement through the use of a wedge-shaped cushion placed under their right hip. Hypotension will be treated for a reduction in systolic blood pressure 40% below baseline values.
89161769|NCT02741375||Brain Death Group (BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely brain-dead on the basis of this evaluation were classified as the BD group.
89161770|NCT02741375||Non-Brain Death Group (Non BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely not brain-dead on the basis of this evaluation were classified as the non-BD group.
89161771|NCT02626260|Experimental|Cohort 1b|The subject test one adhesive strip on the peristomal area
89161772|NCT05357209|Other|Arm A|Arm A of the Avidhrt study will contain subjects that have been/are diagnosed with AF. Arm A of the study will have the participants complete the Human Factors sub-study in addition to the primary clinical study.
89161773|NCT05357209|Other|Arm B|Arm B of the Avidhrt study will contain all other subjects (those non diagnosed with AF), and participants will receive the option whether to participate in the Human Factors sub-study.
89161774|NCT03562871|Experimental|Cohort A1|Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle
89161775|NCT03562871|Active Comparator|Cohort A2|Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle
89161776|NCT03562871|Experimental|Cohort B1|Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
89161777|NCT03562871|Active Comparator|Cohort B2|Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
89161778|NCT00685074|Experimental|Brief computer-delivered intervention for drug use|A single interactive computer intervention based primarily on Motivational Interviewing principles.
89161779|NCT00685074|Placebo Comparator|Time control for drug use|An series of innocuous and therapeutically inactive computer segments.
89161780|NCT00690222|No Intervention|TM|Topical mydriasis without pseudoexfoliation
89161781|NCT00690222|Experimental|ICM|Intracameral mydriasis without pseudoexfoliation
89161782|NCT00690222|No Intervention|TM - PXF|Topical mydriasis with pseudoexfoliation
89161783|NCT00690222|Experimental|ICM - PXF|Intracameral Mydriasis with pseudoexfoliation
89161784|NCT02736071|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
89161785|NCT02736071|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
89161786|NCT02736071|Placebo Comparator|Placebo|Women will receive an oral placebo similar to Tramadol and an oral placebo similar to Celecoxib 2 hours before the procedure
89161787|NCT00537199|Other|OraTest + Visual Exam|OraTest dye
89161788|NCT03812627|Experimental|Re-intervention of hip prosthesis made of ceramic or metal|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 patients for re-intervention of hip prosthesis with friction couples of: ceramic-on-ceramic or metal-on-metal~(25 patients by group)"
89161789|NCT03812627|Experimental|Re-intervention of hip prosthesis of stainless steel ball|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 patients for re-intervention of hip prosthesis of stainless steel ball."
89161790|NCT03812627|Experimental|Re-intervention of knee prosthesis|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 inpatient subjects for re-intervention of knee prosthesis polyethylene-on-metal."
89161791|NCT03812627|Experimental|Dead patients IMD holders autopsied|Autopsy: 80 dead patients IMD holders will be autopsied.
89161792|NCT03812627|Active Comparator|Dead patients non-IMD holders autopsied|Autopsy: dead patients non-IMD holders autopsied, 30 subjects in this arm.
89161793|NCT03812627|Active Comparator|patients before first prosthesis surgery|Before the initial prosthesis surgery: 30 patients Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections will be done
89161794|NCT02628990|Experimental|1.6 g plant stanols|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols), consumed with a meal daily for 4 weeks
89161795|NCT02628990|Experimental|2 g plant stanols|A yoghurt drink containing plant stanol ester (2 grams plant stanols), consumed with a meal daily for 4 weeks
89161796|NCT02628990|Experimental|1.6 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
89161797|NCT02628990|Experimental|2 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (2 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
89161798|NCT02628990|Placebo Comparator|Placebo|A placebo yoghurt drink, consumed with a meal daily for 4 weeks
89161799|NCT02741219|Placebo Comparator|Control Group|Parturients in this group receive 20ml intravenous normal saline immediately after delivery. Their patient controlled analgesia (PCA) protocol after surgery consists of 100 mcg sufentanil diluted into 100ml and administer at a background infusion of 1ml/h,and a bolus of 2ml, with a lock-out of 8min.
89161800|NCT02741219|Experimental|Dex Group|Parturients in this group receive 0.5mcg/kg intravenous dexmedetomidine diluted to 20ml with normal saline. Their PCA protocol after surgery is 100mcg sufentanil and 300mcg dexmedetomidine diluted to 100ml in saline, with the continuous infusion of 1ml/h, and a bolus of 2 ml, with a lock-out of 8min.
89161801|NCT00690534|Active Comparator|CMAY|Insulin in young
89161802|NCT00690534|Experimental|IMAY|L-NMMA + insulin in young
89161803|NCT00690534|Experimental|SNPY|SNP in young
89161804|NCT00690534|Active Comparator|CSNP|Insulin in elderly
89161805|NCT00690534|Experimental|ISNP|SNP in elderly
89161806|NCT00690534|Experimental|SNPE|SNP in elderly
89161807|NCT00690534|Active Comparator|CMealO|Meal in elderly
89161808|NCT00690534|Experimental|SMealO|SNP+meal in elderly
89161809|NCT00690534|Active Comparator|MealY|meal in young
89161810|NCT00690534|Experimental|ExIns|insulin+exercise in elderly
89161811|NCT00690534|Experimental|ExMeal|meal+exercise in elderly
89161812|NCT03556475||Disease 1|Moderate to severe COPD Patients(n=90)
89161813|NCT03556475||Disease type 2-1)|Patients with Mild/moderate AECOPD (n=60)
89161814|NCT03556475||Disease type 2-2)|Patients with Severe AECOPD( n=60)
89161815|NCT03556475||Disease type 3|Non-COPD Patients with high risk factors (n=90)
89161816|NCT00991705|Other|Group B|Atorvastatin (7 days) → Fimasartan + Atorvastatin (7 days)
89161817|NCT00991705|Other|Group A|Fimasartan (7 days) → Fimasartan + Atorvastatin (7 days)
89161818|NCT02735837|Active Comparator|doxycycline gel|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
89161819|NCT02735837|Placebo Comparator|placebo gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
89161820|NCT04810429|Placebo Comparator|Placebo|TMJ arthroscopy and Saline solution NaCl 0,9% in 2 syringes with 1 ml each. Injected in Right Masseter (0.5ml), Left Masseter (0.5ml), Right Temporalis (0.5ml) and Left Temporalis (0.5ml).
89161821|NCT04810429|Active Comparator|IncobotulinumoxinA|TMJ arthroscopy and Dose of IncobotulinumoxinA to be injected 100 U distributed in 2 syringes with 1 ml each: 25U (0.5ml) in Right Masseter / 25U (0.5ml) in Left Masseter / 25U (0.5ml) in Right Temporalis / 25U in Left Temporalis.
89161822|NCT02625558|Active Comparator|Riociguat|Active drug
89161823|NCT02625558|Placebo Comparator|Placebo|placebo
89161824|NCT02741453|Active Comparator|Standard Practice|Placement of a CVC by standard practice
89161825|NCT02741453|Experimental|Bilateral IJ Ultrasound Scanning|Placement of a CVC after mandatory ultrasound scanning of both right and left internal jugular veins
89161826|NCT04809415|Sham Comparator|Sham Group (G-S)|The LED blanket will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
89161827|NCT04809415|Experimental|300J Infrared Blanket LED Group (Blanket-300J)|The LED blanket with a wavelength of 940nm, energy of 300J, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
89161828|NCT04809415|Experimental|300J Infrared Cluster LED Group (Cluster-300J)|The LED Cluster with a wavelength of 850 nm, energy of 300 J, will be applied to the quadriceps (5 points) and hamstrings (5 points), bilaterally, just before the strength training protocol.
89161829|NCT00685152|Experimental|Active rTMS|Repetitive Transcranial Magnetic Stimulation
89161830|NCT00685152|Sham Comparator|2|Device: Sham (placebo)
89161831|NCT04002895|Experimental|Foliglurax|
89161832|NCT00685230|Experimental|1|Alacramyn and midazolam as needed
89161833|NCT00685230|Placebo Comparator|2|placebo and midazolam as needed
89161834|NCT05472025||Changes in blood pressure|Blood pressure assessment：The blood pressure and heart rate before induction and the blood pressure and heart rate per minute within 10 minutes after induction intubation were recorded. After induction of anesthesia, MAP < 60 mmHg, or the decrease rate exceeded 30% of the baseline value, was defined as the occurrence of hypotension
89161835|NCT02628756|Experimental|Endometrial injury|Hysteroscopic-guided endometrial injury (Karl Storz, Tuttlingen, Germany).
89161836|NCT05455879||Impact of antenatal corticosteroid therapy on surfactants use postnatal|Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal
89161837|NCT05357131|Experimental|Healthy Volunteers - Hypnosis without VR (HYP )|Cross-over and within-participant control design: Participants will receive recorded hypnosis without VR.
89161838|NCT05357131|Experimental|Healthy Volunteers - Hypnosis with VR (VRH)|Cross-over and within-participant control design: Participants will receive hypnosis with VR.
89161839|NCT00685386|Experimental|I|
89161840|NCT00685386|Placebo Comparator|II|Room air will be used for insufflation as the placebo comparator arm.
89161841|NCT04722055||Study group|Single arm of continuously enrolled participants. All eligible participants will be included in the study according to the inclusion criteria. In addition to giving stool samples for multigene methylation test, eligible participants need to undergo colonoscopy examination and have their biopsies taken when necessary (gold standard).
89161842|NCT00690690|Experimental|video|
89161843|NCT00690690|Active Comparator|HCT|Offer of HIV counseling and testing
89161844|NCT02735759|Other|Healthy Volunteers|This cohort will consist of ten healthy volunteers. The photoacoustic flow cytometry device will be used to establish device settings. The intervention with the subject will include the PAFC device to establish appropriate device settings.
89161845|NCT02735759|Other|Venous Thromboembolism|This cohort will consist of ten patients with newly diagnosed, non-life threatening acute venous thromboembolism. The intervention with the subjects is to perform the photoacoustic flow cytometry device to detect circulating emboli in vivo in patients with venous thromboembolism at diagnosis, during and after anticoagulation therapy.
89161846|NCT00690768|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
89161847|NCT00690768|Active Comparator|B|Pars plana vitrectomy only
89161848|NCT02735681|Active Comparator|Probing Treatment Right Eye|Meibomian gland will be performed on the right upper eye lid of each participant.
89161849|NCT02735681|Placebo Comparator|Fellow Eye (Left) Untreated|The fellow eye (left) will be used at the untreated control
89161850|NCT03898063|Active Comparator|Control|participants will receive a standard-of-care brochure detailing HIV status disclosure.
89161851|NCT03898063|Experimental|intervention: 90 DAYS film|participants will watch the film, 90 DAYS
89161852|NCT04048746||ASTHMA|"The patient presents to the emergency department for an aggravation of his asthma. The patient later sees an emergency investigator for medical care for his aggravation of asthma. When the patient's condition is stabilized, the investigator checks his eligibility for study and offers to participate. If the patient agrees, the investigator gives him the questionnaire and possibly helps to fill it out.~When the investigator returns to see the patient for a reassessment of his condition, he retrieves the completed questionnaire. He verifies that the patient has completed the questionnaire. Prescriptions and action plans are retrieved by the principal investigator either in digitized format from the patient's computerized medical record or in paper format. Each medication prescription and each action plan are read by the principal investigator and evaluated according to the grids."
89161853|NCT02735525|Experimental|Smartphone monitoring|Intervention arm
89161854|NCT01564069||IT opioids|Patients with IT pumps receiving IT opioids
89161855|NCT01564069||Systemic opioids|Patients taking oral or transdermal opioids for chronic pain
89161856|NCT01564069||Non-opioid management|Patients managing chronic pain without taking opioids
89161857|NCT00690846|Experimental|1|40 mg weekly subcutaneous injection of adalimumab
89161858|NCT00685464|Active Comparator|2|Intravenous bolus Abciximab.
89161859|NCT00685464|Active Comparator|Abciximab|Intracoronary bolus abciximab.
89161860|NCT02740829|Placebo Comparator|Intranasal placebo|placebo comparator
89161861|NCT02740829|Experimental|Intranasal glucagon|active intervention
89161862|NCT00685542|Experimental|1|Diacerein 50mg bid
89161863|NCT00685542|Placebo Comparator|2|placebo 50mg bid
89161864|NCT02741063|Experimental|high autistic and oxytocin group|subject with high ASQ scores will receive oxytocin treatment
89161865|NCT02741063|Experimental|low autistic and oxytocin group|subject with low ASQ scores will receive oxytocin treatment
89161866|NCT02741063|Placebo Comparator|high autistic and placebo group|subject with high ASQ scores will receive placebo treatment
89161867|NCT02741063|Placebo Comparator|low autistic and placebo group|subject with low ASQ scores will receive placebo treatment
89161868|NCT00674076||sleep apnea|a patient has been diagnosed as having obstructive sleep apnea
89161869|NCT00674076||control|a case who has a negative polysomography or noraml score of Pittsburg sleep questionaire
89161870|NCT00685620|No Intervention|Group 1|Standard care following detoxification
89161871|NCT00685620|Active Comparator|Group 2|Recovery housing following detoxification
89161872|NCT00685620|Experimental|Group 3|Recovery housing plus counseling
89161873|NCT04138602|Active Comparator|Emsella Chair Active Treatment with Dietary Counseling|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%. During the visit the subject will also receive dietary counseling.
89161874|NCT04138602|Placebo Comparator|Emsella Sham Treatment with Dietary Counseling|Sham subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power). During the visit the subject will also receive dietary counseling.
89161875|NCT04138836|Experimental|Midazolam|
89161876|NCT04138836|Experimental|Itraconazole|
89161877|NCT04138836|Experimental|Esomeprazole|
89161878|NCT05558033|Experimental|Plyometric Training Group|Individuals in the plyometric training group will receive plyometric training. In this training, individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery). All trainings will be given on the basis of telerehabilitation via distance education tools.
89161879|NCT05558033|Active Comparator|Control Group|Athletes in this group will continue their routine training programs like the athletes in the plyometric training group.
89161880|NCT02735369|Placebo Comparator|Placebo|Placebo Comparator
89161881|NCT02735369|Experimental|2% OC-10X|2% OC-10X
89161882|NCT00922584|Experimental|sorafenib|Patients with stage IIIB/IV NSCLC who failed EGFR-TKI therapy will receive oral sorafenib 400 mg twice daily until disease progression or unacceptable toxicity.
89161883|NCT04003597|Placebo Comparator|Usual-salt diet|Usual-salt diet followed for 5 weeks
89161884|NCT04003597|Active Comparator|Reduced-salt diet|Reduced-salt diet followed for 5 weeks
89161885|NCT02740751|Active Comparator|Still-Tee|Generic name: galactogoe herbal tee, still-tee Dosage: Three cups (each 200 ml) of tea of Still-Tee galactogogue tea will be used Frequency: Three times in a day Duration: for 4 weeks after birth
89161886|NCT02740751|Placebo Comparator|Placebo|The mothers of the babies will receive placebo tea which does not contain galactogogue herbs
89161887|NCT02740751|No Intervention|Water|The mothers of the babies will receive water
89161888|NCT04139694|Experimental|Cinnamon with Food Plan|Group of ladies who will undergo testing, receive dietary intervention, and take cinnamon supplements.
89161889|NCT04139694|Active Comparator|Food Plan Only|Group of ladies who will undergo testing, receive dietary intervention, but will not get cinnamon supplements.
89161890|NCT02735603|Experimental|Nalterxone/Bupropion + Placebo + Moxifloxacin|Naltrexone hydrochloride (HCl) 8 milligram (mg)/bupropion HCl 90 mg (NB) placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
89161891|NCT02735603|Experimental|Placebo + Moxifloxacin + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
89161892|NCT02735603|Experimental|Moxifloxacin + Naltrexone/Bupropion + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Day 4 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in the treatment period 3.
89161893|NCT02735603|Experimental|Naltrexone/Bupropion + Moxifloxacin + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 3.
89161894|NCT02735603|Experimental|Placebo + Naltrexone/Bupropion + Moxifloxacin|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
88806070|NCT01898702|Placebo Comparator|No intervention|Don't participate in a scheduled and standardized expert patients programme course
89161895|NCT02735603|Experimental|Moxifloxacin + Placebo + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
89161896|NCT04152798|Active Comparator|ProGrip™ mesh repair|Laparoscopic hiatal hernia repair with ProGrip™ mesh
89161897|NCT04152798|Active Comparator|Primary crural repair|Primary posterior crura repair
89161898|NCT00685776|Experimental|Anacetrapib|Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
89161899|NCT00685776|Placebo Comparator|Placebo|Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.
89161900|NCT02735291|Experimental|Single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
89161901|NCT04138368|Experimental|dyadic treatment|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
89161902|NCT04138368|Active Comparator|supportive treatment|mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
89161903|NCT04138290|Experimental|Predictix Antidepressant Software tool|Predictix Antidepressant Software tool will be used when prescribed with a medication for their MDD, by their treating physician.
89161904|NCT04003207|Experimental|Phelan-McDermid syndrome|Patients with Phelan-McDermid syndrome receive 12 weeks of growth hormone therapy
89161905|NCT04138446|Experimental|200-3000|Day 1: 200m (above sea level) asl Day 2: 3000m asl
89161906|NCT04138446|Experimental|3000-200|Day 1: 3000m asl Day 2: 200m asl
89161907|NCT04138446|Experimental|200-5000|Day 1: 200m asl Day 2: 5000m asl
89161908|NCT04138446|Experimental|5000-200|Day 1: 5000m asl Day 2: 200m asl
89161909|NCT04138446|Experimental|3000-5000|Day 1: 3000m asl Day 2: 5000m asl
89161910|NCT04138446|Active Comparator|5000-3000|Day 1: 5000m asl Day 2: 3000m asl
89161911|NCT02735213|Experimental|577-MPL|"577nm subthreshold micropulse laser(577-MPL) will be performed on the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein. Multiple laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
89161912|NCT02735213|Active Comparator|TLT|"Traditional laser will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
89161913|NCT05295355|Experimental|Tiotropium Bromide Combined With Odaterol|Tiotropium O Datlow inhalation spray 60 bottles per bottle, each containing 2.5 tiotropium ammonium g (equivalent to 3.124 g of thiotropium bromide) and 2.5 2.5 g (equivalent to 2.736 2.736 g of hydrochloric acid) by O Datlow. ® The inhaler was inhaled and administered twice a time, once a day, at the same time every day for 52 weeks
89161914|NCT05295355|Experimental|Tiotropium Bromide|Tiotropium Bromide Spray (Si Lihua ® Neng Beile ®）： 0.22624mg/ml (calculated by tiotropium), 60 strokes per bottle, containing 2.5 µ g of tiotropium bromide per stroke, through Neng Beile ® Inhaler inhalation administration, 2 presses per inhalation, once a day, administered at the same time every day for 52 weeks.
89161915|NCT02740673|Other|Driving simulator|Using the driving simulator for 30 min.
89161916|NCT00873912|Experimental|Monovalent influenza virus vaccine|Frozen monovalent vaccine containing new strain
89161917|NCT00873912|Placebo Comparator|Placebo|Placebo
89161918|NCT05628935||Group G|Patients Undergoing Forearm Surgery under general anesthesia
89161919|NCT05628935||Group P|Patients Undergoing Forearm Surgery under peripheral nerve block
89161920|NCT05408689|Experimental|T1 TENS|In this study, participants will be treated 30 min per day, 3 days per week, for 10 consecutive weeks
89161921|NCT05408689|Experimental|Concha TENS|In this study, participants will be treated 30 min per day, 3 days per week, for 10 consecutive weeks
89161922|NCT05408689|Placebo Comparator|Control|In this study, participants will be treated 30 min per day, 3 days per week, for 10 consecutive weeks
89161923|NCT00691080||ASD children|"ASD children as defined by:~Age greater than or equal to 4 or less than or equal to 9 years~Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects).~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~No current or use within the last 1 month of beta-blockers or melatonin~No current use of sleep aids~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness."
89161924|NCT00691080||"Healthy control children"|"Healthy control children as defined by:~Age greater than or equal to 4 or less than or equal to 9 years~A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children.~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~No current or use within the last 1 month of beta-blockers or melatonin~No current use of sleep aids;~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness. (7) No current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions.~(8) No sibling with a diagnosis of Autism Spectrum Disorder."
89161925|NCT02740439|Experimental|Intervention Meal|Intervention meals will contain 1 large avocado and be consumed daily for 12 weeks.
89161926|NCT02740439|Placebo Comparator|Control Meal|Control meals will be isocaloric to the intervention meals but without avocado. They will also be consumed daily for 12 weeks.
89161927|NCT01564303|No Intervention|2. Acetylcysteine group (NAC+S) , aside with the saline, will|2. Acetylcysteine group (NAC+S) , aside with the saline, patients will be given orally Acetylcysteine at a dose of 600 mg twice daily, on the day before and on the day of administration of the contrast agent.
89161928|NCT01564303|Experimental|CAR+S , aside with the saline, carnitne will be adminstrated|Carnitine group (Car+S), aside with the saline, patients will be administrated with 20 mg/kg carnitine over 10 minutes 2 hours prior to the administration of the contrast agent and 8 hours after CT.
89161929|NCT01564303|Experimental|Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with|4. Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with the saline patients will be given orally 20 mg tablets of PDE5 Tadalafil once daily 2 hours prior to the administration of the contrast agent and in the subsequent day.
89161930|NCT01564303|No Intervention|Control group (S) will be treated without any extra agents|Control group ( S ) , which will be treated without any extra agents, just Saline (0.9 %) will be given I.V. at a rate of 1 ml per kilogram of body weight per hour for 12 hours before and 12 hours after administration of the contrast agent.
89161931|NCT00674232|Experimental|Misoprostol|Group 1 randomized to take single dose of 600 mcg oral misoprostol
89161932|NCT00674232|Other|Surgical treatment|Group 2 randomized to receive standard surgical treatment as per local protocol (D&C or MVA)
89161933|NCT02740283|Experimental|Pregnant women|As a diagnostic study, the cohort will recruit 300 pregnant women who meet inclusion and exclusion criteria outlined below. OGTTs will be performed between 18 and 20 gestational weeks (early-OGTT) and 24 to 28 gestational weeks (regular-OGTT). Clinical and laboratory information of the mother and their offspring will be collected for analysis.
89161934|NCT05359159||Post-COVID patients|Patients recovered from Sars-CoV2 infection
89161935|NCT05359159||healthy control patients|Patients who did not have Sars-CoV2
89161936|NCT04031274||TAVI no MR|Patients undergoing TAVI with MR up to moderate following the procedure
88804581|NCT03931772|Experimental|Automated Self-Hypnosis Intervention for Stress Reduction|Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health, or remotely during the COVID-19 pandemic. Participants will be provided with the Amazon Alexa device to take home (necessary for using the program), or the interactive Reveri (www.reveri.com) mobile app. After the lab or remote visit participants will continue using the intervention at home as needed (recommended every few hours or whenever they experience an increase in stress). Furthermore, participants will be taking an online 15-minute survey at the baseline visit, and then 1, 3, 6, 12 and 24-month online follow-up surveys at home.
89161937|NCT04031274||TAVI + MR no further intervention|Patients undergoing TAVI with MR more than moderate following the procedure, no further mitral valve intervention
89161938|NCT04031274||TAVI + MR undergoing TMVR/r|Patients undergoing TAVI with MR more than moderate following the procedure, underwent transcatheter mitral valve intervention
89161939|NCT02735135|Experimental|Airsoft Duo First|"Patients randomized to this arm will be placed on an AIRSOFT DUO mattress for day 0. They will then be switched to a SENTRY 1200 mattress until the end of month 1.~Intervention: AIRSOFT DUO for 1 day Intervention: SENTRY 1200 for 1 month"
89161940|NCT02735135|Experimental|SENTRY 1200 First|"Patients randomized to this arm will be placed on a SENTRY 1200 mattress for day 0. They will then be switched to an AIRSOFT DUO mattress until the end of month 1.~Intervention: SENTRY 1200 for 1 day Intervention: AIRSOFT DUO for 1 month"
89161941|NCT05274997|Experimental|YY-20394|Administer linperlisib (YY-20394) 80 mg (4 tablets) orally with water, once daily, in a 28-day cycle.
89161942|NCT02740361|Experimental|Deprexis|This group will receive access to the web-based Deprexis program, an online tool based on principles of cognitive behavioral therapy. Contents include (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving, (8) expressive writing and forgiveness, (9) positive psychology, and (10) emotion-focused interventions.
89161943|NCT02740361|Experimental|DeprexisPlus|This group will receive the web-based Deprexis program (see above) plus scheduled e-mail contact (1x/week)
89161944|NCT02740361|No Intervention|Waitlist Control|Participants randomized to the control group will wait for access to the Deprexis program (waitlist control) for 6 months. After the 6-month waiting period, participants in this group will have full access to Deprexis.
89161945|NCT04494841|Experimental|DuoTherm VibraCool Back Device|Patients will be offered a pain relief belt device incorporating multiple speeds of vibration and optional heat, cold, and pressure delivered through a sculpted metal plate. They will be able to choose from 8 patterns of vibration with the multiple motors (50, 100, 200Hz), and hot or cold, and will wear the device for 20 minutes.
89161946|NCT00912522|Active Comparator|LT PFC HIGH FREQ TMS|
89161947|NCT00912522|Active Comparator|LT PFC LOW FREQ TMS|
89161948|NCT00912522|Active Comparator|RT PFC HIGH FREQ TMS|
89161949|NCT00912522|Active Comparator|RT PFC LOW FREQ TMS|
89161950|NCT00912522|Sham Comparator|SHAM STIMULATION|
89161951|NCT02734901|Active Comparator|400 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
89161952|NCT02734901|Active Comparator|200 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
89161953|NCT02734901|Placebo Comparator|Placebo control|Raspberry deprived supplement Acute intake of 600 mL (1x daily)
89161954|NCT00686010|Placebo Comparator|1|Placebo
89161955|NCT00686010|Experimental|2|JTT-705 300mg
89161956|NCT00686010|Experimental|3|JTT-705 600mg
89161957|NCT00686010|Experimental|4|JTT-705 900mg
89161958|NCT02739971|Active Comparator|Low AGEs diet|Participants randomized to this arm will receive active instruction on reducing dietary AGEs intake, in addition to standard of care dietary guidance for type 2 diabetes.
89161959|NCT02739971|Placebo Comparator|Standard of care dietary guidance|Participants randomized to this arm will only recieve standard of care dietary guidance for type 2 diabetes.
89161960|NCT00674544|No Intervention|Control group|No intervention, regular kindergarten program
89161961|NCT00674544|Experimental|Intervention group|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
89161962|NCT03823300|Experimental|Arm A: Faricimab|
89161963|NCT03823300|Active Comparator|Arm B: Aflibercept|
88804582|NCT03931746|Experimental|Porcine Xenograft placement|Porcine xenograft will be placed on the wound.
89161964|NCT00686244|Experimental|Training Group|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
89161965|NCT00686244|No Intervention|Control Group|No guided training. Exercise optional after detailed consulting and handing over an information dossier for adequate physical activity.
88804583|NCT03931746|No Intervention|No porcine xenograft|The wound will be allowed to heal via second intention.
88804584|NCT03920410|Experimental|stimulated serotonergic activity|
89161966|NCT00537745|Experimental|Vivitrol|Vivitrol 380 mg/monthly, plus individual compliance enhancement therapy (Medication Management Therapy).
89161967|NCT00686322|Other|1|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
89161968|NCT05243095|Experimental|Cognitive training group|The training group received 20 minutes of cognitive training every day for 8 weeks
89161969|NCT05243095|No Intervention|Control group|No training was applied to the control group.
89161970|NCT00686400||1: FE|FE = first episode schizophrenia
89161971|NCT00686400||2: CO|CO = age and gender-matched control subjects
89161972|NCT04494061||HSCT - Hematopoetic Stem Cell Proliferation|Patients who received hematopoietic stem cell transplant
89161973|NCT04494061||IHSCP - Impaired HSC proliferation|Patients with impaired hematopoietic stem cell proliferation
89161974|NCT02734745|Experimental|flash glucose monitoring|Patients will use a device: Freestyle Libre for 14 days
89161975|NCT02734511|Experimental|Drug: sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
89161976|NCT04003441|Experimental|Sequence 1 (Tablet B - Tablet A)|Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A
89161977|NCT04003441|Experimental|Sequence 2 (Tablet A - Tablet B)|Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B
88804585|NCT03920410|Experimental|unstimulated serotonergic activity|
88804586|NCT03888053|Active Comparator|BB-101 Treatment Arm|BB-101 liquid formulation concentration of 2 µg/mL or 20 µg/mL will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
88804587|NCT03888053|Placebo Comparator|Placebo Arm|Placebo will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
89161978|NCT02695043|Experimental|MMPET Group|This group of subjects will be comprised of a subset of culturally diverse patients admitted to the Bellevue the Traumatic Brain Injury Unit at Bellevue. Treatment will focus on improving awareness and comprehension of TBI and its long-term consequences, fostering increased trust in the TBI rehabilitation team, and conveying the importance of continued TBI follow up to maximize recovery.
89161979|NCT02695043|Active Comparator|Control Group|The Control Group will be comprised of equally diverse subset of patients who will receive Standard of Care Treatment.
89161980|NCT04380805|Experimental|AK104|AK104 monotherapy
89161981|NCT02739893|Experimental|Scope Guide Assisted|Scope Guide Assist to be utilized during colonoscopy
89161982|NCT02739893|Placebo Comparator|Standard|Colonoscopy completed using current SOC without scopeguide assist.
89161983|NCT05408299||Immunocompetent|100 healthy persons not suffering of any systemic diseases or malignancy of whatever nature.
89161984|NCT05408299||Immunocompromised|100 B thalassemia splenectomised patients.
89161985|NCT02739815|Placebo Comparator|Placebo|Will receive a placebo (10 ml of distilled water) in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
89161986|NCT02739815|Active Comparator|T1|Will receive Tranexamic acid 15 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
89161987|NCT02739815|Active Comparator|T2|Will receive Tranexamic acid 20 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
89161988|NCT02739815|Active Comparator|T3|Will receive Tranexamic acid 25 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
89161989|NCT01564225|Experimental|EDI200|
89161990|NCT00720616|Experimental|1|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
89161991|NCT04002739|Experimental|Patients with Acute Coronary Syndrome (ACS)|Patients admitted to a Coronary Care Unit (CCU) with a new diagnosis of ST Elevation Myocardial Infarction (STEMI) or Non ST Elevation Myocardial Infarction (NSTEMI). Patients are eligible within 72 hours from the admission in CCU. All patients admitted to CCU are going to perform the following procedures/exams as standard clinical practice: coronary angiogram, blood samples, echocardiogram, 24-hour Holter EKG Monitoring. The experimental arm will also perform a polygraphy during CCU stay, a bioelectrical impedance and will complete baseline questionnaires assessing daytime sleepiness such as Epworth Sleepiness Scale (ESS), STOP-BANG and Mallampati score. After the discharge from CCU, patients that had a diagnosis of Obstructive Sleep Apnea Syndrome are going to complete a follow up visit in 90 days undergoing a new polygraphy, bioelectrical impedance, questionnaires (ESS, STOP-BANG and Mallampati Score), echocardiogram.
89161992|NCT02734121|Experimental|Educational group intervention|The pre-consultation educational group intervention will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
89161993|NCT02734121|No Intervention|Standard Care|Routine pre-consultation education
89161994|NCT02734199||Enrollment Period 1 Cohort|Cohort 1 includes approximately 650 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Contraceptive access will be the same as it was prior to the study beginning, meaning participants either have to use insurance or self-pay for their method of choice.
89161995|NCT02734199||Enrollment Period 2 Cohort|Cohort 2 includes approximately 1000 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 2 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
89161996|NCT02734199||Enrollment Period 3 Cohort|Cohort 3 includes approximately 1350 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 3 participants and they can initiate which ever contraceptive method they want at no cost to them for three years. During enrollment period 3, a community-wide, media driven intervention will be implemented and population level changes in HER-C initiation will be examined.
89161997|NCT00720694|Active Comparator|Verum|"Device: Duolith SD1 (Storz Medical AG) - Focused Extracorporeal shock wave therapy.~The total energy flux density was increased continuously from 0.01 to 0.25 mJ/mm 2 within 500 introductory impulses. Thereafter, 2000 treatment impulses with 0.25 mJ/mm 2 (four impulses per second) were administered per session,and the interventionwas repeated up to a total of three sessions in weekly intervals."
89161998|NCT00720694|Sham Comparator|Placebo / Sham|Sham Duolith SD1 (Storz Medical AG). The placebo group received identical sham intervention with an air- filled standoff that prevented the transmission of shock waves. The placebo handpiece was identical in design, shape, and weight to ensure that there was no way for the participants to identify the placebo handpiece.
89162001|NCT02739737|Experimental|Blinded Reviewers|Subjects receiving randomized sham manuscript for review
89162002|NCT02739737|Experimental|Unblinded Reviewers|Subjects receiving randomized sham manuscript for review
89162003|NCT00720772|Experimental|A|
89162004|NCT00720772|No Intervention|B|
89162005|NCT02739425|Other|Standard Procedure plus use of sentimag|Detection of the nodes carried out using the gamma probe and also the sentimag - all patients receive both diagnostic interventions
89162006|NCT05177965||Shift workers|Measurements repeated during a series of day shifts and during a series of night shifts
89162007|NCT00720850|Experimental|lenalidomide|lenalidomide therapy p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
89162008|NCT02733965|Other|standard course|"The patients in the control group will have a classic course of treatment. They will receive -An educational assessment consisting on evaluating the patient's educational needs.~Group workshops entitled Disease and drugs, Dietary and sports activity, Psychology Workshop during which the patient will be able to participate in order to get all the information he needs.~Individual therapeutic education sessions to specifically and personally highlight certain non-pharmaceutical educational needs identified at the time of the educational assessment.~Moreover, in the control arm, a systematic short pharmaceutical interview with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12):"
89162009|NCT02733965|Other|Long Pharmaceutical Consultations|The patients will receive the same course of treatment as in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program. Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes. The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient. Additional consultations are possible on the request of the oncologist and/or patient. The consultations carried out at the request of the oncologist and/or the patient will be counted The first part of the pharmaceutical consultation focuses on a complete clinical medication review including Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity
89162010|NCT00720928|Other|single group|"Posterior uveitis patients having complete or incomplete type of Behcet's disease; typical ocular lesion and at least, one of the main symptoms or two of the additional symptoms.~Selection of study eye : For patients with unilateral uveitis, the study eye will be the affected eye; for patients with bilateral uveitis, the study eye will be the more severely affected eye (i.e., the eye having suffered more recurrences in the previous year, or if equal, the eye having received more therapy in the previous year, or if equal, the eye having the worse VA, or if equal, the eye clinically judged to be the more severely affected eye)."
89162011|NCT03785158|Active Comparator|Melatonin|3 mg of liquid melatonin by oral route for 8 days. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
89162012|NCT03785158|Placebo Comparator|Placebo Group|Similar looking/tasting 3 mg (5 ml) placebo syrup administered preoperatively by oral route and for the next 7 days or until discharge. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
89162013|NCT02739581|Experimental|Endoscopic variceal ligation with Non-selective B-blockers|
89162014|NCT02739581|Active Comparator|Endoscopic variceal ligation with Placebo|
89162015|NCT00721006|Experimental|MESENDO|All subjects will receive active treatment in a blinded fashion in the left or right lower limb. The opposite lower limb will receive placebo.
89162016|NCT00721006|Placebo Comparator|placebo|All subjects will receive placebo injections in a blinded fashion in the left or right lower limb. The opposite lower limb will receive active stem cell infusion
89162017|NCT02733809|Experimental|Sorafenib|Group under the treatment ( sorafenib ) Maximum dose of 400 mg BID If subjects devolves adverse events, dose can be reduced.
89162018|NCT05109715|Active Comparator|Control group|"Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure.~Blood will be drawn:~At baseline: before general anaesthesia~After start of heart-lung machine~After clamping the aorta~Before unclamping the aorta~After the operation~5 h after clamping the aorta~12 hours after clamping the aorta~24 hours after aortic clamping~48h after clamping the aorta~72 hours after clamping the aorta"
89162019|NCT05109715|Experimental|Ventilation group|"Ventilation is continued from going on CPB until clamping of the ascending aorta.~Blood will be drawn:~At baseline: before general anaesthesia~After start of heart-lung machine~After clamping the aorta~Before unclamping the aorta~After the operation~5 h after clamping the aorta~12 hours after clamping the aorta~24 hours after aortic clamping~48h after clamping the aorta~72 hours after clamping the aorta"
89162020|NCT00717262|Experimental|1|HQK-1001
89162021|NCT00717262|Placebo Comparator|2|
89162022|NCT05056441||Cohort 1: Vedolizumab|Biologic-naïve participants diagnosed with CD, who have initiated vedolizumab treatment will be observed from the data of diagnosis of CD until the date of index when vedolizumab treatment was initiated during the eligibility period until the earliest of chart abstraction initiation, death or last contact with the site. Index date is defined as the date when vedolizumab treatment was initiated.
89162023|NCT05056441||Cohort 2: Ustekinumab|Biologic-naïve participants diagnosed with CD, who have initiated ustekinumab treatment will be observed from the data of diagnosis of CD until the date of index when ustekinumab treatment was initiated during the eligibility period until the earliest of chart abstraction initiation, death or last contact with the site. Index date is defined as the date when ustekinumab treatment was initiated.
89162024|NCT02695433|Experimental|Active treatment (AT) diet plan|1 Avocado 7 days/week (5-7 days is acceptable) over a 12 week period
89162025|NCT02695433|Placebo Comparator|Control (CT) diet plan|at least 1 serving of a low fat, low fiber, high glycemic carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week period
89162026|NCT00717340|Experimental|tivozanib (AV-951) + paclitaxel|
89162027|NCT05357287|Experimental|Prevena|
89162028|NCT02733887|Experimental|lymphoma|The lymph nodes or masses, fludeoxyglucose F18 positron emission tomography/computed tomography(PET/CT) standard uptake value(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D*,f values and MRI volumes of lymphoma were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation.
89162029|NCT00874848|Experimental|Imprime PGG|Imprime PGG Injection + Cetuximab + Paclitaxel/Carboplatin
89162030|NCT00874848|Active Comparator|Control|Cetuximab + Paclitaxel/Carboplatin
89162031|NCT02733575|Other|Compassion Focused Therapy|Intervention
89162032|NCT00691236|Active Comparator|A|standard chemotherapy which is Adriamycin, Cisplatinum and Ifosfamide
89162033|NCT00691236|Experimental|B|zoledronic acid prior to standard chemotherapy
89162034|NCT00691236|Experimental|C|zoledronic acid alone 4mg IV 3 weekly for 6 doses
89162035|NCT04837729|Experimental|Experimental (acupressure) group|Acupressure (complementary and integrative medicine method) Acupressure will be applied individually to the experimental group for 20-25 minutes three times a week for four weeks. Data collection forms will be applied 3 times in total, before the intervention, in the second and the fourth week.
89162036|NCT04837729|No Intervention|Control group|No intervention will be made to women in the control group. However, data collection forms will be applied 3 times in total, before the intervention, in the second and the fourth week.
89162037|NCT02733731|Experimental|Chinese Herbal Compound Ointment|This kind of CHCO composed of several chinese herbs,dong quai,angelica,resina draconis and lithospermum.The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks.
89162038|NCT02733731|Active Comparator|Estriol|The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks in two groups.
89162039|NCT00691314|Experimental|1|
89162040|NCT00691314|Active Comparator|2|
89162041|NCT02739191|Experimental|Intervention|Prophylactic negative pressure wound therapy
89162042|NCT00578812|Experimental|PCM Cervical Disc - Investigational|PCM Cervical Disc replacement at one level from C3 to T1
89162043|NCT00578812|Active Comparator|ACDF - Control Group|Anterior cervical discectomy and fusion (ACDF) at one level from C3 to T1
89162044|NCT05358769|Experimental|Incoxil supplement group|Incoxil supplement-group: receive daily oral Incoxil supplementation and perform pelvic floor muscle exercise (PFME) for 6 weeks.
89162045|NCT05358769|Active Comparator|Control group|Control group: receive placebo oral daily supplementation and perform pelvic floor muscle exercise (PFME) for 6 weeks.
89162046|NCT02733497|Active Comparator|Sympathectomy Group|Excision of ganglia at T3 level
88804588|NCT03878030||Subjects with spinal muscular atrophy types 2 and 3|Intrathecal nusinersen will be administered to all subjects per FDA approved label.
89162047|NCT02733497|Active Comparator|Sympathicotomy Group|Resection of sympathetic chain at T3 level
89162048|NCT00691392|Experimental|1|Linezolid 600 mg po daily for 16 weeks (112 doses) given in addition to optimized background therapy for MDR TB
89162049|NCT00691392|Placebo Comparator|2|Over-encapsulated microcrystalline methylcellulose (Avicel) - an inert filler
89162050|NCT02738957|Other|Prenatal Counseling Group|"Patients in the PCG will receive specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one two midwives involved in the study. The information will include: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models. During the counseling sessions patients will have the opportunity to discuss questions on breastfeeding."
88804589|NCT03837509|Experimental|INCB001158 + daratumumab SC|INCB001158 + daratumumab
89162051|NCT02738957|No Intervention|Control Group|No breastfeeding counseling during the antenatal period will be provided. The Control Group will receive non-specific counseling with standard orientation regarding breastfeeding after delivery and during their postpartum hospitalization period. This standard orientation will be provided by one of the midwives of the hospital during a single counseling session with brief guidance covering the following topics: starting breastfeeding, hygiene, infants' conditions, colostrum/breast milk, infants' positions, duration of breastfeeding, frequency of feeds, mammary milking, and stopping breastfeeding.
89162052|NCT00717496|Experimental|A|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. This group will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
89162053|NCT00717496|No Intervention|B|Mothers assigned to the control group will receive usual care. This group will also receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream.
89162054|NCT05407831||LDM|Lean Diabetes Mellitus
89162055|NCT05407831||ODM|Obese Diabetes Mellitus
89162056|NCT02625168|Experimental|Afatinib|Afatinib 30 or 40 or 50mg daily orally after study recruitment until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
89162057|NCT02625168|Experimental|Erlotinib|Erlotinib 150mg daily until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
89162058|NCT02738723|Experimental|GROUP 1|SBRT plus EP
89162059|NCT02738723|Active Comparator|GROUP 2|IMRT plus EP
89162060|NCT00717730|Placebo Comparator|A|Placebo dietary supplement
89162061|NCT00717730|Experimental|B|Folic acid
89162062|NCT00717730|Experimental|C|Vitamin B12
89162063|NCT00717730|Experimental|D|Folic acid and Vitamin B12
89162064|NCT05407753|Experimental|Ketone ester|Subjects receive the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
89162065|NCT05407753|Placebo Comparator|Con|Subjects receive a non-caloric, taste matched placebo (water and sucrose octaacetate).
89162066|NCT00691470|Experimental|1. ATI-5923|Dose adjusted ATI-5923
89162067|NCT00691470|Active Comparator|2. Coumadin|Dose adjusted Coumadin (warfarin)
89162068|NCT05628701|Experimental|IPAA CRUISE|Patients eligible for both operations choosing ileal pouch anal anastomosis.
89162069|NCT05628701|Experimental|IRA CRUISE|Patients eligible for both operations choosing ileorectal anastomosis.
89162070|NCT05628701|Active Comparator|IRA Control|Patients only eligible for ileorectal anastomosis.
89162071|NCT05628701|Active Comparator|IPAA Control|Patients only eligible for ileal pouch anal anastomosis.
89162072|NCT05628701|Active Comparator|Ileostomy Control|Patients who decline reconstruction.
89162073|NCT05407597|Active Comparator|Icatibant and Standard of care (SOC)|Icatibant will be given as a single, subcutaneous injection
89162074|NCT05407597|Placebo Comparator|0.9% Sodium Chloride and Standard of care (SOC)|Placebo will be given as a single, subcutaneous injection
89162075|NCT04169165||compliant patients|Patients with compliance to suggestions on metabolic evaluation and dietary/medical advices
89162076|NCT04169165||non-compliant patient|Patients without compliance to suggestions on metabolic evaluation and dietary/medical advices
89162077|NCT04069390|Experimental|Cardioskin-Neuronaute|
89162078|NCT05407207|Active Comparator|Intervention group|The intervention group will take part in a 12-week plantar electrical stimulation intervention using the proposed technology 3 times per week during HD either in a sitting or supine position under the supervision of a research staff member. The duration of each treatment session will be one hour. Patients who receive an activated electrical stimulation unit will receive a standard dose of 30 milliamps as described in the following during each HD session (3 times per week for 12 weeks).
89162079|NCT05407207|Sham Comparator|Control group|Placebo controls will have an electrical stimulation unit programmed not to provide any electrical current, while all other lights and programming indicators will be functional. Both active and inactive electrical stimulation units will be programmed to download the period that they are used on a weekly basis in order to verify that the units are used for the prescribed time period.
89162080|NCT02738021|Experimental|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
89162081|NCT02574208|Active Comparator|"HIV testing by ELISA"|Patients enrolled in this arm will be tested by usual HIV Elisa
89162082|NCT02574208|Experimental|"HIV testing by rapid test"|Patients enrolled in this arm will be tested by the new rapid HIV test
89162083|NCT05493995|Experimental|Penpulimab+Anlotinib+Nab-paclitaxel+Gemcitabine|
89162084|NCT02738099||Arrest from presume Cardiac etiology|Comatose patients following arrest of presumed cardiac etiology arriving to receiving facility within 12 hours of event.
89162085|NCT00717808|Active Comparator|1|During the study the patient will either receive tranilast (300mg twice a day) or a placebo drug for a period of seven days. The patient will then have a seven day break followed by another period of seven days in which the patient will receive the other medication.
89162086|NCT00717808|Placebo Comparator|2|The patient will receive the placebo twice a day for 7 days whilst taking their weekly methotrexate dose
89162087|NCT02738177|Active Comparator|misoprostol group|30 candidates were receive 2 tablets of misoprostol (PGE1) 200ug (i.e. 400 ug) 4 hrs prior to surgical evacuation
89162088|NCT02738177|Active Comparator|Effox group|30 candidates were received 2 tablets of Effox (Isosorbide mononitrate) 20 mg (i.e 40 mg) 4 hrs prior to surgical evacuation
89162089|NCT02738177|Active Comparator|combination therapy group|30 candidates were received 1 tablets of misoprostol 200ug & 1 tablets of Effox 20 mg 4 hrs prior to surgical evacuation.
89162090|NCT00711568|Experimental|Arm 1|Left dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
89162091|NCT00711568|Experimental|Arm 2|Right dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
89162092|NCT00711568|Sham Comparator|Arm 3|Left or right dorsolateral frontal 20 Hz sham TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
89162093|NCT04043806|Experimental|ELX/TEZ/IVA|"Part A: Participants received ELX 200 milligram (mg) once daily (qd),TEZ 100 mg qd, and IVA 150 mg every 12 hours (q12h) in the treatment period for 96 weeks.~Part B: Participants from certain countries participated in Part B and continued to received ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 48 weeks."
89162094|NCT02737943|Experimental|Arm1 Mebo|20 : receiving Moist Exposed Burn Ointment (MEBO) at sites of donor graft and recipient at time of operation and in dressing
89162095|NCT02737943|Placebo Comparator|Arm2 Placebo|20 : receiving Standard cream Zagazig University Hospital (Antibiotics & analgesics)
89162096|NCT05290753|Other|Prokinetic use in accelerate healing of urgent intestinal anastomosis|Prikinetic agents administered immediately post operative and time of stay at hospital twice daily
89162097|NCT02737709|Experimental|Paclitaxel and Carboplatin regimen|Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection. 21 days per cycle; 6 cycles in total.
89162098|NCT02572960|Placebo Comparator|Cholecalciferol|Cholecalciferol 70 mcg/day for 12 weeks Placebo Valsartan daily for 2 weeks
89162099|NCT02572960|Active Comparator|Valsartan|Placebo cholecalciferol/day for 12 weeks Valsartan 80 mg/day for 2 weeks
89162100|NCT02572960|Placebo Comparator|Placebo|Placebo cholecalciferol/day for 12 weeks Placebo Valsartan daily for 2 weeks
89162101|NCT02572960|Active Comparator|Cholecalciferol and Valsartan|Cholecalciferol 70 mcg/day for 12 weeks Valsartan 80 mg/day for 2 weeks
89162102|NCT04001959|Active Comparator|Silver Diamine Fluoride|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Next, dry the tooth for 30 seconds with air jet followed by a drop of 30% Diamino Fluoride Silver with a disposable applicator brush for 3 minutes and after that time washing for 1 minute.
89162103|NCT04001959|Experimental|Silver Diamine Fluoride with Potassium Iodide|Initially a prophylaxis will be done on the tooth to be treated with Robinson brush and prophylactic paste and then the relative isolation (with mouth openers and cotton rollers) and protection of the soft tissues with vaseline in the region to be treated to protect the surrounding tissues will be carried out. Then the tooth is dried for 30 seconds with an air jet and applied one drop of the Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the surface treated with Diamino , until the formed creamy white color becomes transparent. After these steps have been completed, rinse with water for 1 minute.
89162104|NCT02737865|Experimental|SMI and sonazoid (single arm)|Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line
89162105|NCT00721084||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
89162106|NCT00721084||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
89162107|NCT04267159|Active Comparator|Conventional treatment by acute cardioversion|Participants in the conventional treatment arm will be returned to sinus rhythm in the emergency department within 48 hours of symptom onset unless they convert to sinus rhythm spontaneously.
89162108|NCT04267159|Experimental|Elective treatment by delayed cardioversion|Participants in the elective treatment arm will be returned to sinus rhythm in an out-patient clinic approximately one week after randomizatio unless they convert to sinus rhythm spontaneously.
89162109|NCT02738567||local anesthesia with adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia with adrenaline
89162110|NCT02738567||local anesthesia without adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia without adrenaline
89162111|NCT00721240|Experimental|single-arm|This investigation is a single-center, two-phase, single-arm study. In order to detect a potential placebo effect, the treatment phase will be preceded by a single-blinded two-week placebo run-in phase, followed by a 12 week open-label treatment phase.
89162112|NCT02737319|Experimental|Rosuvastatin|40 mg of Rosuvastatin up to 6 hours before elective percutaneous coronary intervention.
89162113|NCT02737319|No Intervention|Control|Use of standard therapy in elective angioplasty.
89162114|NCT00721318||1|Patients diagnosed with rheumatoid arthritis
89162115|NCT00721318||2|Population controls to the subjects of group 1
89162116|NCT04001335||CL suspicion|Patients with skin lesions suspected to be cutaneous leishmaniasis
89162117|NCT02737241|Active Comparator|LP-HoLEP|Low power Holmium laser enucleation of the prostate
89162118|NCT02737241|Active Comparator|HP-HoLEP|High power Holmium laser enucleation of the prostate
89162119|NCT05356819|Other|Endoscopy|"Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.~Patients were administered 2 mg midazolam as premedication for 5 minutes before the procedure and propofol 1-1.3 mg/kg bolus for sedation, followed by repeated doses (10-30 mg) according to the Ramsey sedation score. All patients were given 2 lt/min oxygen via nasal cannula during the procedure."
89162120|NCT02737085|Experimental|Diffuse Large B Cell Lymphoma(DLBCL)|The trial will be conducted in a manner of simon two-stage design with Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with Diffuse Large B Cell Lymphoma(DLBCL). Only when the expected reaction rate is achieved the 30 patients left can be recruited.
89162121|NCT00711724||MGH 1|Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
89162122|NCT00991861|Experimental|LAS41007 o.d.|Once daily
89162123|NCT00991861|Experimental|LAS41007 b.i.d.|Twice daily
89162124|NCT00991861|Active Comparator|LAS106521|
89162125|NCT02737007|Experimental|[14C]-GSK3191607 IV Microdose|Subjects will receive a single microdose of 100 micrograms (mcg) of [14C]-GSK3191607 by intravenous infusion over 15 minutes on Day 1 of the study.
89162126|NCT00721474|Experimental|1|Bosutinib fasting
89162127|NCT00721474|Experimental|2|Bosutinib fed
89162128|NCT02736929|Active Comparator|Cognitive Processing Therapy - Cognitive|Cognitive Processing Therapy - Cognitive (CPT-C), is a brief cognitive behavioral treatment for PTSD. CPT-C consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
89162129|NCT02736929|No Intervention|Waiting Period Control (WP-CON)|WP-CON group will receive minimal attention in the form of weekly telephone calls to assess current emotional state and to provide supportive, nondirective, brief counseling if participants report experiencing a crisis. Any participant assigned to the WP-CON group will be given the opportunity to receive CPT-C after the post-waiting period assessment.
89162130|NCT05355727|Other|Arm A: Visible to MDTM|Patients going through this arm have the decision support tool outcome visible to the MDTM
89162131|NCT05355727|Other|Arm B: Not-visible to MDTM|Patients going through this arm will not have the decision support tool outcome visible to the MDTM
89162132|NCT00721552|Experimental|I|prednisolone + sitagliptin
89162133|NCT00721552|Experimental|II|prednisolone + sitagliptin-placebo
89162134|NCT00721552|Experimental|III|prednisolone-placebo + sitagliptin
89162135|NCT00721552|Placebo Comparator|IV|prednisolone-placebo + sitagliptin-placebo
89162136|NCT00721552|No Intervention|Healthy controls|12 healthy men will be included to assess postprandial microvascular function.
89162137|NCT00721552|No Intervention|Type 2 diabetic subjects|12 men with type 2 diabetes will be included in order to assess postprandial microvascular function.
89162138|NCT04619485|Sham Comparator|SHAM LASER|Group A: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to zero potence.
89162139|NCT04619485|Active Comparator|EFFECTIVE LASER|Group B: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to regular potence.
89162140|NCT04069078|Active Comparator|Hyoscine butylbromide|
89162141|NCT04069078|Placebo Comparator|Control|
89162142|NCT02732249|Active Comparator|Triple regimen group|Esomeprazole 20mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
89162143|NCT02732249|Experimental|Low metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg bid for 14 days
89162144|NCT02732249|Experimental|High metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
89162145|NCT04561063|No Intervention|Arm A: No pharmacological intervention (PPE only)|No intervention
89162146|NCT04561063|Active Comparator|Arm B: Nitazoxanide (NTZ)|Nitozoxanide administered
89162147|NCT04561063|Active Comparator|Arm C: Sofosbuvir/daclatasvir (SOF/DCV).|Sofosbuvir/daclatasvir administered
89162148|NCT02732093|Active Comparator|stellate block|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml of lidocaine 2% after routine induction of general anesthesia and before endotracheal intubation
89162149|NCT02732093|Placebo Comparator|control|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml normal saline (Na.Cl 0.9%) (control group) after routine induction of general anesthesia and before endotracheal intubation
89162150|NCT00718276|Active Comparator|1|25(OH)D
89162151|NCT00718276|Active Comparator|2|vitamin D3
89162152|NCT00718354|Active Comparator|B|Standard Chemotherapy (upto 6 cycles)
89162153|NCT00718354|Experimental|A|Enoxaparin: 1 mg/kg once daily in addition to standard chemotherapy up to 6 months
89162154|NCT02731937|Other|GE Healthcare CT Revolution (CT scanner)|Each subject will be scanned twice: the first time will be the subjects' clinically indicated CT exam and the second scan will be performed on the GE Healthcare CT Revolution (CT scanner) both scans will will be obtained.
89162155|NCT00718432|Active Comparator|UC group|Usual care with education
89162156|NCT00718432|Experimental|ENIC group (IC group in 2009 study)|Exercise and nutritional integrated care
89162157|NCT00718432|Experimental|PSTIC group (IC group in 2009 study)|Problem solving therapy integrated care
89162158|NCT00536809|Experimental|Phase I|Dose escalation of lapatinib along with capecitabine and oxaliplatin until the maximum tolerated dose is reached.
89162159|NCT00536809|Experimental|Phase II|Treatinng subjects at the maximum tolerated dose of lapatinib, capecitabine, and oxaliplatin
89162160|NCT02572726|Active Comparator|active rTMS|active repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
89162161|NCT02572726|Sham Comparator|'sham' rTMS|'sham' repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
89162162|NCT04189601||Study subjects|Patients with Fabry disease, Gaucher disease, or Niemann-Pick disease, type D
89162163|NCT04189601||Controls|Age- and sex-matched to Study subjects
89162164|NCT02731859||EndoBarrier|All patients with EndoBarrier treatment
89162165|NCT05274295|Experimental|Cytori Celution System in Chronic Non-Healing diabetic Leg Ulcers|On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
89162166|NCT00721708|Experimental|1|Carnosine(450 mg)
89162167|NCT00721708|Experimental|2|Beef (150g)
89162168|NCT00721708|Experimental|3|chicken (150g)
89162169|NCT00721708|Experimental|4|Chicken broth (obtained from 150 g of chicken breast)
89162170|NCT02731625|Experimental|Kettlebell Training|Army Physical Readiness Training (PRT) with kettlebell training in place of strength training circuits
89162171|NCT02731625|Active Comparator|Army Physical Readiness Training|Army Physical Readiness Training (PRT) per Army Field Manual 7-22
89162172|NCT02731547|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
89162173|NCT02731547|No Intervention|Control group|
89162174|NCT02731391|Experimental|Mesh repairment|patients undergoing pelvic floor Reconstruction using mesh
89162175|NCT02731391|Active Comparator|Tradition Neoplasty|patients undergoing traditional surgical approaches
89162176|NCT00721786|Experimental|San Francisco Internet Stop Smoking Site|"UCSF/SFGH Internet Stop Smoking Study site~Internet Stop Smoking site (TC4) with several intervention elements from which the participants may choose as many as they wish~The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: www.dejardefumar.ucsf.edu"
89162177|NCT02731001|Experimental|Proton therapy|Patients within the proton arm will receive 66 Gy(RBE) delivered with 6 fractions per week.
89162178|NCT02731001|Active Comparator|Photon therapy|Patients within the photon arm will be treated by intensity modulated radiotherapy with 6 fractions per week to a total dose of 66 Gy.
89162179|NCT04067986|Other|Camrelizumab + Apatinib|Camrelizumab + Apatinib
89162180|NCT02731079|Active Comparator|Covidien|Group that will have sleeve gastrectomy performed using the Covidien iDrive powered stapler with absorbable polymer membrane staple line reinforcement.
89162181|NCT02731079|Active Comparator|Ethicon|Group that will have sleeve gastrectomy performed using the Ethicon Echilon powered stapler with absorbable polymer membrane staple line reinforcement.
89162182|NCT00536731|Active Comparator|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
89162183|NCT00536731|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
89162184|NCT00536731|Active Comparator|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
89162185|NCT04189523|Active Comparator|Standard of Care Pain Management|
89162186|NCT04189523|Experimental|Early Administration of US Guided Nerve Blocks|
89162187|NCT02571712|Other|GANFORT®|One drop of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) instilled in each affected eye once daily in the evening for 24 weeks.
89162188|NCT02730845|Active Comparator|Intra-articular dexmedetomidine|Patients will be subjected for elective knee arthroscopy under local anesthesia (Intra-articular dexmedetomidine + Intra-articular bupivacaine).
89162189|NCT02730845|Placebo Comparator|Intravenous dexmedetomidine|patients will be subjected for elective knee arthroscopy under local anesthesia (i.v. dexmedetomidine + Intra-articular bupivacaine).
89162190|NCT02730767|Experimental|Intervention Group|Partially supervised exercise intervention: Survivors in the intervention group will be asked to add at least 2.5 hours of intense physical activities per week. These should include at least 30 min of strength building exercises and 2 hours of aerobic exercises per week. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
89162191|NCT02730767|No Intervention|Control Group|The control group will keep their physical activity level constant over the 1 year of the study. Thereafter, they will have the opportunity to receive the same intervention than the intervention group had received (off-trial) to benefit in the same way from an active lifestyle.
89162192|NCT00721864||Affected Population|Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)
89162193|NCT02730689|Experimental|A group|DP-R207 >> rosuvastatin+ezetimibe
89162194|NCT02730689|Active Comparator|B group|rosuvastatin+ezetimibe >> DP-R207
89162195|NCT02730533|Active Comparator|Control group|No PPI treatment should given after the initial allocation. Patient will be admitted, and ESD will be performed. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
89162196|NCT02730533|Experimental|Esomeprazole group|Esomeprazole should start as soon as possible after the initial allocation. During the 7 days of p.o. treatment, patient will be admitted, and ESD will be performed as soon as completing the p.o. treatment. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
89162197|NCT00712036|Active Comparator|Interim|Methadone maintenance for up to 4 months with emergency counseling only for individuals on program waiting lists.
89162198|NCT00712036|Active Comparator|Comprehensive|Methadone Treatment provided with counseling as usual.
89162199|NCT00712036|Active Comparator|Restored|Methadone Treatment with counseling provided by a clinician with a lower caseload than counseling as usual.
88804590|NCT03837509|Active Comparator|Daratumumab monotherapy and crossover to INC001158+ daratumumab SC|Daratumumab will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
89162200|NCT02730611||Patients|Patients with morbid obesity and vertical sleeve gastrectomy
89162201|NCT04067362|Placebo Comparator|no fiber|Breakfast with hot chocolate with no fiber
89162202|NCT04067362|Experimental|chicory root flour|Breakfast with hot chocolate with chicory root flour
89162203|NCT04067362|Experimental|chicory root fiber supplement|Breakfast with hot chocolate with chicory root fiber supplement
89162204|NCT00536575|Experimental|Intervention|The trial was designed as a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. Phase I consisted of cohorts of 3 patients at each of three dose levels. Patients received bortezomib (Dose Level 1 - 1.3 mg/m2; Dose Level 2 - 1.6 mg/m2) by IV bolus on days 1, 8, 15, and 22 of each 5-week cycle with continuous oral dosing of sorafenib at 200 mg twice daily. Dose level 3 was planned as bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 with sorafenib 400 mg by mouth twice daily throughout each 5-week cycle.
89162205|NCT02730143|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure after 6 days at low altitude
89162206|NCT00712114|Experimental|Cohort 1|10 mg HE3286 (1 x 5 mg HE3286, BID)
89162207|NCT00712114|Experimental|Cohort 2|20 mg HE3286 (2 x 5 mg HE3286 BID)
89162208|NCT00712114|Experimental|Cohort 3|40 mg HE3286 (4 x 5 mg HE3286 BID)
89162209|NCT02730065|Active Comparator|Structured Aerobic Dance Training Group|Active intervention will last for 24 weeks and consists of 60-minute/session, which includes 10 minutes warm-up, 40 minutes of dancing and 10 minutes of cool down. In groups of 5, participants will practice the dance led by a physiotherapist once per week for the first 2 months and twice per week for 3rd to 6th month.
89162210|NCT02730065|Placebo Comparator|Stretching plus education|Participants in the control group will receive a weekly 3-hour group-based (group of 5 participants) programme containing stretching exercise, stress reduction and health education on dementia and stroke prevention for 6 months. The programme consists of low-intensity seated stretching, psychoeducation on stress management, various relaxation methods with practice as well as education on the causes, identification, treatment and prevention of stroke and dementia. Benefits of physical exercise will also be discussed but will its weight will be evenly balanced with other forms of evidence-based preventive strategies.
89162211|NCT05355649|Other|PREGNOLIA TEST|Women at the time of triage will be tested with TVU CL (transvaginal ultrasound cervical length) and with the PREGNOLIA system
88806071|NCT05414604||PV group|Patients who had a spine CT
89162212|NCT02730221||Patients admitted during measurement 1|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period before the implementation of a new electronic patient data management system
89162213|NCT02730221||Patients admitted during measurement 2|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period after the implementation of a new electronic patient data management system
89162214|NCT03214250|Experimental|Gem/NP/nivolumab|Gemcitabine+Nab-Paclitaxel+nivolumab
89162215|NCT03214250|Experimental|Gem/NP/APX005M|Gemcitabine+Nab-Paclitaxel+APX005M
89162216|NCT03214250|Experimental|Gem/NP/nivolumab/APX005M|Gemcitabine+Nab-Paclitaxel+nivolumab+APX005M
89162217|NCT02729987|Experimental|Minimum Support Group (MSG)|Intervention group with 8 week access to the online stress management programme with minimal support from a coach (WorkGuru).
89162218|NCT02729987|Experimental|Discussion Group|Intervention group with 8 week access to the online stress management programme with minimal support from a coach, plus access to an online facilitated messaging board (WorkGuru).
89162219|NCT02729987|No Intervention|Waiting List Control (WLC)|Control group with access to the intervention after 16 weeks
89162220|NCT00722098|Experimental|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
89162221|NCT00722098|Placebo Comparator|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
89162222|NCT04067440||Patients|Subjects to undergo surgery including opening of the jejunum with non-inflammative condition.
89162223|NCT05245591|Experimental|Pentosan Polysulfate Sodium|U101 is available as a capsule containing 100 milligrams (mg) of pentosan polysulfate sodium. Subjects will be administered U101 at a dose of 300 milligrams (mg) three times daily (tid) for the initial 8 weeks and then 200 milligrams (mg) twice daily (bid) for another 8 weeks during the study.
89162224|NCT05245591|Placebo Comparator|Placebo Control|Placebo to match U101 is available as a capsule in 100 milligrams (mg). Subjects will be administered placebo at a dose of 300 milligrams (mg) three times daily (tid) for the initial 8 weeks and then 200 milligrams (mg) twice daily (bid) for another 8 weeks during the study.
89162225|NCT04067206|Experimental|Recorded mothers' voice group.|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
89162226|NCT04067206|Experimental|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
89162227|NCT04067206|Experimental|MiniMuffs|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
89162228|NCT04067206|No Intervention|Control Group|The control group who were administered standard care.
89162229|NCT00653354|Active Comparator|Arm 1|
89162230|NCT00653354|Active Comparator|Arm 2|
89162231|NCT00653354|Placebo Comparator|Arm 3|
89162232|NCT04067128|Experimental|Health coaching arm|For the health coaching arm, an unlicensed, trained health coach called patients three times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.
89162233|NCT04067128|No Intervention|Usual care arm|Patients assigned to usual care had access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.
89162234|NCT02729675|Experimental|Access Intervention|Worksites in this condition received weekly Fruit and Vegetable markets
89162235|NCT02729675|Experimental|Enhanced Intervention|Worksites in this condition received weekly Fruit and Vegetable markets and Educational Interventions including Campaigns, Newsletters, DVDs, A Website, and Chef Demonstrations
89162236|NCT02729675|Active Comparator|Comparison Intervention|Worksites in this condition received Stress and Physical Activity Interventions
89162237|NCT02646488|Active Comparator|Cluster 1|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
89162238|NCT02646488|Active Comparator|Cluster 2|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
89162239|NCT02646488|Active Comparator|Cluster 3|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
89162240|NCT02646488|Active Comparator|Cluster 4|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
89162241|NCT02571322|Experimental|Whole Body Vibration training|Use of the HyperVibe Whole Body Vibration training device for 12 weeks 3 times per week crossover to aerobic exercise
89162242|NCT02571322|Placebo Comparator|Aerobic Exercise|Aerobic exercise training for 12 weeks 3 times per week crossover to use of the HyperVibe Whole Body Vibration training device
89162243|NCT00651872||Marx|
89162244|NCT00712504|Experimental|1|SU011248 in combination with docetaxel
89162245|NCT02641574||previous 1|women who have had in their past one cesarean section
89162246|NCT02641574||previous 2|women who have had in their past 2 cesarean sections
88804591|NCT03837509|Experimental|INCB001158 monotherapy and crossover to INC001158+ daratumumab SC|INCB001158 will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
88806072|NCT01898780|Experimental|horizontal mattress|pancreaticojejunostomy with horizontal mattress suture
89162247|NCT02641574||previous 3|women who have had in their past 3 cesarean sections
89162248|NCT02641574||previous 4|women who have had in their past 4 cesarean sections
89162249|NCT03558022|Experimental|Salt Pills|One week on low salt diet plus salt pills
89162250|NCT03558022|Placebo Comparator|Placebo Pills|One week on low salt diet plus placebo pills
89162251|NCT00653510|Experimental|Euglycemic|The patients will be examined with a blood glucose at around 5-7 mmol/L.
89162252|NCT00653510|Experimental|Hyperglycemic|The patients will be examined with a blood glucose at around 18-20 mmol/L
89162253|NCT05355493|Experimental|Mental Fatigue condition|"A Stroop task, of approximately 60 min, partitioned in 6 blocks of 336 stimuli, will be used as the mentally fatiguing task. In this task, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself. If, however, the ink color is red, the button to be pressed will be the button linked to the real meaning of the word, not the ink color. The word presented and its ink color will be randomly selected by the computer (100% incongruent), with all incongruent word-color combinations being equally common (meaning, in each block 84 words will be presented in the color red, yellow, green and blue). Subjects will be instructed to respond as quickly and accurately as possible. To assess performance accuracy (ACC) and reaction time (RT) will be collected and averaged every block."
88806073|NCT01898780|Experimental|interrupted suture|pancreaticojejunostomy with interrupted suture
89162254|NCT05355493|Active Comparator|Control condition|"In the control task subjects will have to watch a documentary during 60 min on the same computer screen as that used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several episodes (One Planet, Frozen Worlds, Jungles, Costal Seas, From Desserts to Grasslands, The High Seas, Fresh Water and Forests) of the Netflix documentary Our Planet, 2019 as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial."
89162255|NCT02694653|Active Comparator|Drug Arm|Acetaminophen 1000 mg in 100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
89162256|NCT02694653|Placebo Comparator|Placebo Arm|100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
89162257|NCT00722956|Experimental|1|AZD5672 + atorvastatin
89162258|NCT01700374||Women without Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~Adverse Childhood Events (ACE) Questionnaire;~Perceived Stress Scale (PSS);~A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 0 or 1 adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
89162259|NCT01700374||Women with Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~Adverse Childhood Events (ACE) Questionnaire;~Perceived Stress Scale (PSS);~A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 2 or more adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
89162260|NCT02694731|Experimental|Mobile application intervention|Participants receive a mobile app with a 5-week mindful eating program and ongoing tools for coping with cravings
89162261|NCT04165226|Active Comparator|Low level light therapy (LLLT)|Low level light therapy using 808/915 nm infra red diode laser
89162262|NCT04165226|Active Comparator|Fractional CO2|Fractional carbon dioxide laser 10600 nm
89162263|NCT04165226|Active Comparator|Combined fractional CO2 and LLLT|Combined fractional CO2 laser and low level light therapy
89162264|NCT01682668|Experimental|Frequency of subthalamic stimulation|Comparison between healthy controls and PD patients (non-operable patients or who will be operated or already operated)
89162265|NCT02729597||Myotonic dystrophy type 1 patients|"Patients with myotonic dystrophy type 1 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
88806074|NCT05414214||Elderly|Elderly patients who are scheduled for elective surgeries under general anesthesia with endotracheal intubation accomplished using conventional laryngoscopy will be included.
89162266|NCT02729597||Myotonic dystrophy type 2 patients|"Patients with myotonic dystrophy type 2 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
89162267|NCT02729597||Controls|"Healthy control subjects who meet all inclusion and exclusion criteria for healthy controls.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
89162268|NCT00992173|Experimental|Ultratrace Iobenguane I 131|
89162269|NCT00723112||Affected Group|Adult subjects with the diagnosis of MDS based on the French-American-British classification system.
89162270|NCT00723112||Healthy Controls|Control subjects will be selected using frequency matching on gender and age by decade. That is for each MDS patient a healthy volunteer of the same gender and decade (50-59, 60-69, 70-79, etc) will be selected
89162271|NCT00651950||Operator Dependence|
89162272|NCT02641886|Experimental|Jian Pi Yi Shen Hua Tan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
89162273|NCT02641886|Placebo Comparator|the Placebo Group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
89162274|NCT02729285|Experimental|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 minutes before scleral buckle surgery.
89162275|NCT02729285|Placebo Comparator|placebo|On operation day, the patients were randomly assigned to receive placebo before scleral buckle surgery.
88806075|NCT01898858||HYPOXIA|
89162276|NCT00722176|Experimental|1|BL-1020 10 mg
89162277|NCT00722176|Experimental|2|BL-1020 10-30 mg
89162278|NCT00722176|Active Comparator|3|risperidone
89162279|NCT04165382|Other|Pre-implementation study group|Preterm infants receiving NIV before the implementation of the guideline
89162280|NCT04165382|Other|Post-implementation study group|Preterm infants receiving NIV after the implementation of the guideline
89162281|NCT02729441|Active Comparator|Ramipril|"Maximal recommended dose of ramipril Altace® (10 mg/d) given as an active comparator for 12 week."
89162282|NCT02729441|Experimental|Perindopril|"Perindopril Coversyl® at maximal recommended dose (8 mg/d) as experimental therapy for 12 weeks."
89162283|NCT00722254||PPH|Subjects diagnosed with primary pulmonary hypertension (PPH)
89162284|NCT00722254||Myelofibrosis|Subjects diagnosed with Primary or Secondary Myelofibrosis
89162285|NCT02729363|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline visit to determine the immediate effects of guided relaxation intervention on stress and pain in outpatients with sickle cell disease.
89162286|NCT02729363|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients talk about their sickle cell disease experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
88806076|NCT01898858||HYPERCAPNIA|
89162287|NCT00722332|Experimental|1|HBV-related liver transplant patients
89162288|NCT02646410|Other|FPD+NDOT|Fixed-point delivery (FPD) combined with non directly observed treatment (NDOT)
89162289|NCT02646410|Other|FPD+DOT|Fixed-point delivery (FPD) combined with directly observed treatment (DOT)
89162290|NCT02646410|Other|DDD+NDOT|door-to-door delivery (DDD) combined with non directly observed treatment (NDOT)
88806077|NCT01898858||HYPOXIA + HYPERCAPNIA|
88806078|NCT01791140||Cohort|
89162291|NCT02646410|Other|DDD+DOT|door-to-door delivery (DDD) combined with directly observed treatment (NDOT)
89162292|NCT02729129|Experimental|Commercially available highly-efficient facemask|
89162293|NCT02729129|Sham Comparator|Sham facemask|
89162294|NCT00712660|Experimental|A|In the active-ITAREPS group, the e-mail ALERT message feedback to the investigator will be activated. The core study intervention was 20% antipsychotic dose increase within 24 hours in response to a Pharmacological Intervention Requiring Event (PIRE) defined as either: A) the receipt of any INITIAL ALERT (IA) e-mail. A dose increase was obligatory in such cases regardless of the current clinical status of the patient; or B) the receipt of an ALERT EMERGENCY (AE) e-mail after which the investigator confirmed clinical worsening via phone contact with the patient. AE is defined as further worsening in EWSQ scores during 3 week period after announcement of IA.
89162295|NCT00712660|Placebo Comparator|TAU|In the treatment-as-usual study arm (control, non-active ITAREPS), the e-mail ALERT message feedback will not be activated. In this group, even in the presence of early warning sings, the investigators will be kept blinded to the EWSQ scores, will receive no ALERT message and thus no early pharmacologic intervention based on the ITAREPS program will be prompted. Treatment in the control group will consist of routine clinical and medication management with the frequency of visits common in the outpatient clinical settings. There will be no intevention based on ITAREPS.
89162296|NCT02646644||Metastasized intestinal NET|We will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.
89162297|NCT00636545|Experimental|Part 1|Cohort 1- Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a dose of 300 mg to the first subject enrolled and, in the absence of dose-limiting toxicity, in increasing increments of 100 mg to each successive subject enrolled to a maximum dose of 1000 mg.
89162298|NCT00636545|Experimental|Part 2|Genasense will be administered as a 2-hour intravenous infusion twice weekly for 3 weeks at a dose established based on Part 1 of the study.
89162299|NCT00636545|Experimental|Cohort 2|Also in Part 1 of the study, Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a starting dose of 1100 mg and increasing in increments of 100 mg to the MTD. Patients will be pretreated with a corticosteroid.
89162300|NCT00722410|No Intervention|A|
89162301|NCT00722410|Experimental|B|VSL#3 for 4 weeks
89162302|NCT00722410|Experimental|C|Mechanical bowel cleansing followed by VSL#3 for 4 weeks.
89162303|NCT02641418|Other|Exercise|only 1 arm to trial
89162304|NCT02728973||ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
89162305|NCT02728973||conventional treatment program|conventional treatment
89162306|NCT00722488|Experimental|1|MLN4924
89162307|NCT00652106|Experimental|1|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
89162308|NCT00652106|Active Comparator|2|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
89162309|NCT00652106|Active Comparator|3|0.2% brimonidine ophthalmic solution
89162310|NCT02641808|Experimental|follicular flushing group|Monofollicular IVF therapy with follicular flushing up to five times after aspiration of the follicule at the time to the oocyte pick-up
89162311|NCT02641808|Active Comparator|aspiration group|Monofollicular IVF therapy with aspiration only at the time of the oozyte pick-up
89162312|NCT02728739|Experimental|Acute Heart Failure Patients|Acute Heart Failure patients with elevated levels of BNP ( >30pg/ml) will undergo Transthoracic Echocardiogram (TTE) for grading of MR severity within 7 days.
89162313|NCT00723268|Active Comparator|Prednisolone|
89162314|NCT00723268|Active Comparator|Colchicine|
89162315|NCT02728583|Active Comparator|Margarine enriched with plant sterols and fish oil|Low-fat margarine (25 g per day) with added plant sterols and Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) from fish oil
89162316|NCT02728583|Placebo Comparator|Placebo margarine|Low-fat margarine (25 g per day) without added plant sterols and EPA + DHA
89162317|NCT00874770|Experimental|Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)|Active Comparator
89162318|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (B)|Active Comparator
89162319|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (C)|Active Comparator
89162320|NCT00874770|Active Comparator|Placebo, Peginterferon alpha-2a, ribavirin (D)|
89162321|NCT00536263|Active Comparator|PEG 1.0 mcg/kg weekly (QW) * 24 weeks|PegIntron 1.0 mcg/kg weekly (QW) * 24 weeks + 24 weeks follow-up
89162322|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 24 wks|PegIntron 1.5 mcg/kg QW * 24 wks + 24 wks follow-up
89162323|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 48 wks|PegIntron 1.5 mcg/kg QW * 48 wks + 24 wks follow-up
89162324|NCT02641964||ARDS group|patients with acute necrotizing pancreatitis complicated by ARDS
89162325|NCT02641964||non-ARDS group|acute necrotizing pancreatitis patients without ARDS
89162326|NCT00578344|Experimental|Allogeneic BMT/SCT Transplant|"Busulfan, Campath 1H, Cyclophosphamide and MESNA:~Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.~Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest."
89162327|NCT00653588|Experimental|1|rosuvastatin (40 mg)
89162328|NCT00653588|Active Comparator|2|atorvastatin (80 mg)
89162329|NCT02728505|Active Comparator|SinuSurf irrigation twice daily|This arm is going to get low-concentration SinuSurf sinus irrigation solution, then a washout period, then standard NeilMed Sinus rinse.
88806079|NCT05014230|Other|Treatment as Usual|Opioid medication, as prescribed in routine care
88806080|NCT05014230|Experimental|Open Label Placebo + Treatment as Usual|Opioid medication, as prescribed in routine care + Honest placebos
89162330|NCT02728505|Placebo Comparator|NeilMed Sinus rinse irrigation twice daily|This arm is going to get standard NeilMed Sinus rinse, then a washout period, then low-concentration SinuSurf sinus irrigation solution.
89162331|NCT00723346|Experimental|1|
89162332|NCT00723346|Experimental|2|
89162333|NCT00723346|Experimental|3|
89162334|NCT00723346|Active Comparator|4|
89162335|NCT02728427|Experimental|Suprapubic Catheterization|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients in this group.
89162336|NCT02728427|Active Comparator|Transurethral Catheterization|Transurethral catheterization using Foley catheter will be performed for patients in this group.
89162337|NCT02628834|Experimental|Fascial mobilization|First day intervention: Patients will take fascial mobilization techniques to management of plantar flexor spasticity
89162338|NCT02628834|Experimental|Stretching exercise|Second day intervention:Patients will take fascial mobilization techniques to management of plantar flexor spasticity
89162339|NCT02628834|No Intervention|Healthy Volunteers|Healthy individuals will only be evaluated with no intervention
89162340|NCT02571400||Patients scheduled to undergo surgery|Patients scheduled to undergo surgery at St Vincent's Private Hospital Sydney
89162341|NCT02641652|Active Comparator|Sertraline|sertraline, 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
89162342|NCT02641652|Placebo Comparator|Placebo|placebo
89162343|NCT02626104|Experimental|A - Lactoferrin|Bovine lactoferrin orally - 100 mg twice a day, for whole antibiotic treatment period.
89162344|NCT02626104|Placebo Comparator|B - Maltodextrin|Maltodextrin orally - 100 mg twice a day, for whole antibiotic treatment period.
89162345|NCT02728349|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
89162346|NCT02571166|Experimental|HSV529|
89162347|NCT02646254|Active Comparator|blood cardioplegia|these patients received blood cardioplegia
89162348|NCT02646254|Active Comparator|del nido cardioplegia|these patients received del nido cardioplegia
89162349|NCT02728193|Experimental|RFA|Radiofrequency ablation
89162350|NCT02728193|Experimental|MWV|Microwave ablation
89162351|NCT02728193|Experimental|PEI|Percutaneous ethanol injection
89162352|NCT00686478|Experimental|interferon alpha 2b (Intron A)|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
89162353|NCT00686478|Placebo Comparator|Placebo|Placebo administered subcutaneously once a day for 7 days, then three times a week for 23 weeks.
89162354|NCT00723424|Experimental|1|AZD5672 + Digoxin (single dose on day 12)
89162355|NCT00723424|Experimental|2|AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12)
89162356|NCT02641340|Experimental|Cycle 1, Cohort 1|Fentanyl Sublingual Spray (FSS) low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
89162357|NCT02641340|Experimental|Cycle 1, Cohort 2|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
89162358|NCT02641340|Experimental|Cycle 1, Cohort 3|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
89162359|NCT02641340|Experimental|Cycle 1, Cohort 4|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
89162360|NCT02641340|Experimental|Cycle 2, Cohort 1|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
89162361|NCT02641340|Experimental|Cycle 2, Cohort 2|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
89162362|NCT02641340|Experimental|Cycle 2, Cohort 3|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
89162363|NCT02641340|Experimental|Cycle 2, Cohort 4|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
89162364|NCT02641340|Experimental|Cycle 3, Cohort 1|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
89162365|NCT02641340|Experimental|Cycle 3, Cohort 2|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
89162366|NCT02641340|Experimental|Cycle 3, Cohort 3|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
89162367|NCT02641340|Experimental|Cycle 3, Cohort 4|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
89162368|NCT02728271|Experimental|HPC cell infusion|Autologous HPC will be infused within 24 hours of completing the chemotherapy. A total of 5 x 106/kg CD34+ HPC will be infused. The remaining HPC will be stored as back-up, to be used in case of graft failure.
89162369|NCT02625948|Active Comparator|tranexamic acid|tranexamic acid
89162370|NCT02625948|Placebo Comparator|Placebo|0.9% NaCl
89162371|NCT02625948|No Intervention|observation(spot sign -)|regular clinical treatment
89162372|NCT02571556|Experimental|Dexamethasone Phosphate Ophthalmic Solution|
89162373|NCT00691548|Experimental|1|
89162374|NCT02727959||Patients newly diagnosed with IBD|
89162375|NCT02727959||Symptomatic non IBD-controls|Patients referred with symptoms suspicious of IBD, but who, after examination, are found not to have the diagnosis.
89162376|NCT00691626|Experimental|Arm 1: CBT for Insomnia plus Imagery Rehearsal|CBT for Insomnia plus Imagery Rehearsal
89162377|NCT00691626|Active Comparator|Arm 2: CBT for Insomnia|CBT for Insomnia
89162378|NCT02571010|Experimental|Vibrotactile stimulation|"Patients in this arm will have~treatment by medications and rehabilitation~treatment by vibrotactile at medical center~stimulation at home by soft tissue~non stimulation on allodynia area"
89162379|NCT02571010|Sham Comparator|Sham Stimulation with Vibradol device switched off|"Patients in this arm will have~treatment by medications and rehabilitation~Sham vibrotactile treatment at medical center but with Vibradol device switched off~abdominal breath exercises at home~non stimulation on allodynia area"
89162380|NCT02571010|Other|Standard Medical treatment|Observational group, treated as usually by medications and rehabilitation.
89162381|NCT05340647||Group 1 Preserflo microshunt|
89162382|NCT05340647||Group 2 Trabeculectomy|
89162383|NCT05340647||Group 3 Other MIGS|Other micro-invasive glaucoma surgery (MIGS) than Preserflo microshunt (e.g., Xen gel stent, iStent inject)
89162384|NCT00686556|Experimental|Cohort -1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 12 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
89162385|NCT00686556|Experimental|Cohort 1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 15 Gy on Days -5 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
89162386|NCT00686556|Experimental|Cohort 2|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 18 Gy on Days -6 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
89162387|NCT00686556|Experimental|Cohort 3|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 21 Gy on Days -7 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
89162388|NCT00686556|Experimental|Cohort 4|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 24 Gy on Days -8 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
89162389|NCT04070482||HIV-exposed uninfected infants|These are children to women who are living with HIV but who are not infected with the virus (HIV PCR results at 6 weeks is negative)
89162390|NCT04070482||HIV-unexposed uninfected infants|These are children born to women who are not infected with HIV
89162391|NCT04166786|Experimental|Testosterone + Ethanol|Subjects receive a 3-day treatment with testosterone in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
89162392|NCT04166786|Other|Testosterone placebo + Ethanol|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol consumption. Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
89162393|NCT04166786|Other|Testosterone + Ethanol placebo|Subjects receive a 3-day treatment with testosterone in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
89162394|NCT04166786|Placebo Comparator|Testosterone placebo + Ethanol placebo|Subjects receive a 3-day treatment with testosterone placebo (vaseline) in combination with ethanol placebo (lemon-flavoured water). Subjects have to collect urine in different fractions until 48h post-administration. Blood and saliva samples are also obtained.
89162395|NCT02727647|Experimental|Arm 1|FVIII concentration at 35-40 U/kg/dose 1 time/week for 5 months
89162396|NCT02727647|Experimental|Arm 2|FVIII concentration at 15-20 U/kg/dose 2 time/week for 5 months
89162397|NCT00723502|Experimental|1|
89162398|NCT00723502|Experimental|2|
89162399|NCT02727881|Experimental|Squalamine solution, 0.2% BID|Squalamine lactate ophthalmic solution, 0.2% bis in die (BID) + ranibizumab every 4 weeks
89162400|NCT02727881|Placebo Comparator|Placebo solution BID|Placebo ophthalmic solution BID + ranibizumab every 4 weeks
89162401|NCT01298024|Experimental|Early neuromusclar exercise|
89162402|NCT01298024|Active Comparator|Treatment as usual (late training)|
89162403|NCT04066972|Experimental|Single arm|
89162404|NCT02628678|Other|Fructooligosaccharide (FOS)|Subjects will be required to take 8 grams of FOS per day for a total of 10 days.
89162405|NCT01564381|Experimental|Resveratrol|The capsules will contain 90mg of resveratrol.
89162406|NCT01564381|Experimental|ResA|ResA is a product produced by using patented technology that physically binds resveratrol to arginine, creating a novel conjugate. The capsules will contain 90mg of resveratrol.
89162407|NCT01564381|Placebo Comparator|Placebo|The placebo will be cellulose.
89162408|NCT04164524||Group; A|Open technique Hernioplasty for abdominal hernia in which 160 mg Gentamycin spray applied over the mesh
89162409|NCT04164524||Group; B|Open technique Hernioplasty for abdominal hernia in which no Gentamycin spray applied over the mesh
89162410|NCT02570854|Experimental|CSJ137|In Part 1 up to 48 subjects will receive a single dose of CSJ137. In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
89162411|NCT02570854|Placebo Comparator|Placebo|In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
89162412|NCT00691782||1|African American females between the ages of 21 and 60
89162413|NCT04002427|Experimental|Only one study arm|"[14C]AZD7594 Solution for Infusion 5 µg/mL (1.1 kBq/mL)~AZD7594 Inhalation Powder, SD3FL Inhaler"
89162414|NCT04164446|Placebo Comparator|Placebo|Two capsules containing starch and glucose, once per day, 60 days duration
89162415|NCT04164446|Active Comparator|Oil Palm Phenolics 250 mg|One capsule 250 mg active compound (OPP) and one capsule containing starch and glucose, once per day, 60 days duration
89162416|NCT04164446|Active Comparator|Oil Palm Phenolics 1000 mg|One capsule containing 1000 mg active compound (OPP) and one capsule starch and glucose, once per day, 60 days duration
89162417|NCT04164446|Active Comparator|Oil Palm Phenolics 2000 mg|Two capsules, 1000 mg active compound (OPP) each, once per day, 60 days duration
89162418|NCT00674778|Experimental|1|Radial approach
89162419|NCT00674778|Active Comparator|2|Femoral approach
89162420|NCT00723658|No Intervention|Observation|Non-symptomatic patients are monitored monthly for 3 months, then every 3 months thereafter.
89162421|NCT00723658|Experimental|Treatment|"Symptomatic pts: 2 cycles VTDPACE+R:~dex 40 mg PO D1-4 thalid 200 mg PO D1-4 cisplatin 10 mg/m2 IV D1-4 dox 10 mg/m2 IV D1-4 cyclophos 400 mg/m2 IV D1-4 etoposide 40 mg/m2 IV D1-4 bortezomib 1.0 mg/m2 IV D1,4,8,11 ritux 375 mg/m2 IV D1,8,15 lovenox 40 mg/d SQ D1-platelets >50,000/mcl GCSF 10 mcg/kg/d IV D9-WBC <2,000/mcl apheresis >/= 20x10^6 when WBC and CD34 within normal range, up to 4 cycles~st Trans: mel 200 mg/m2 IV D-1 bortezomib 1.3 mg/m2 IV D-4, -1 PBSC >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 500 ml IV D-1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1~nd Trans: BCNU 300 mg/m2 IV D-5 etoposide 200 mg/m2 IV D-5 to -2 AraC 400 mg/m2 IV D-5 to -2 mel 140 mg/m2 IV D-1 PBSC infusion >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 150 ml/hr IV D-5 to -1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1"
89162422|NCT00691860|Experimental|1|Patients receiving conventional sigmoid end colostomy plus a lightweight mesh Ultrapro®
89162423|NCT00691860|Other|2|Patients receiving conventional sigmoid end colostomy, without mesh
89162424|NCT02727725|Experimental|Traminer MRI Sequence|The TRAMINER MRI sequence implementation to be tested allows the acquisition of high resolution MR images in the free-breathing patient, by combining multiple averages and motion correction with the TRAMINER preparation.
89162425|NCT04139850||Korean chronic hepatitis B patients cohort|Korean patients with chronic hepatitis B with or without antiviral therapy on a regular follow-up in tertially medical institution
89162426|NCT02638142||Continuous Furosemide Infusion|continuous intravenous furosemide infusion
89162427|NCT02638142||Intermittent Furosemide Infusion|bolus intermittent intravenous furosemide infusion
89162428|NCT02727491|Experimental|dextromethorphan|1 mg/kg of dextromethorphan syrup orally 30 min preoperatively and then again 8 hours post-tonsillectomy
89162429|NCT02727491|Placebo Comparator|Placebo|30 min preoperatively and then again 8 hours postoperatively, received inactive placebo syrup identical in volume, appearance and taste as the experimental group
89162430|NCT03562195|Experimental|Subjects receiving Mepolizumab|Eligible subjects will randomized in 1:1 ratio to Mepolizumab group or Placebo group. Subjects in Mepolizumab group will receive Mepolizumab 100mg subcutaneously into the upper arm or thigh every 4 weeks during the total treatment period of 52 weeks in addition to their baseline SOC of asthma treatment. Subjects will be provided with salbutamol MDIs as a rescue medication to be used on an needed basis in this study.
89162431|NCT03562195|Placebo Comparator|Subjects receiving Placebo|Eligible subjects in placebo group will receive placebo (0.9 percent sodium chloride) matching to Mepolizumab administered subcutaneously into the upper arm or thigh every 4 weeks during the total treatment period of 52 weeks in addition to their baseline SOC of asthma treatment. Subjects will be provided with salbutamol MDIs as a rescue medication to be used on an as needed basis in this study.
89162432|NCT00686868|Experimental|30mg|active
89162433|NCT00686868|Experimental|3mg|active
89162434|NCT00686868|Experimental|0.3mg|active
89162435|NCT00686868|Placebo Comparator|placebo|placebo
89162436|NCT00686868|Experimental|60mg|60mg
89162437|NCT00686868|Experimental|100mg|100mg
89162438|NCT02641106|Experimental|Video Directly Observed Therapy|VDOT arm participants use a smartphone to make a video recording of each weekly medication dose ingested using the VDOT mobile phone app. The VDOT app is programmed to send encrypted, time/date stamped videos to a HIPAA-compliant server as soon as the video recorder is stopped. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken. Dose 1 is observed in-person; doses 2-12 are observed via videos.
89162439|NCT02641106|Active Comparator|In-Person DOT|In-Person DOT arm participants follow standard-of-care procedures for monitoring ingestion of all medication doses. Participants take their first medication dose at the enrollment visit and return to the clinic once weekly to be observed taking the remaining 11 doses of medication until they complete the 12-dose regimen.
89162440|NCT04067908|Experimental|woman giving birth prematurely|Proteome: by liquid chromatography coupled with tandem mass spectrometry. Fibronectin: by vaginal sampling. Ultrasound of the cervix. Cytokines: ELISA kit of a panel of several cytokines.
89162441|NCT00992329|Experimental|ciprofloxacin tab1|formulation 1
89162442|NCT00992329|Experimental|ciprofloxacin tab2|formulation 2
89162443|NCT00992329|Experimental|ciprofloxacin tab 3|formulation 3
89162444|NCT00992329|Active Comparator|ciprofloxacin reference|reference product
89162445|NCT02727569||Feasibility Study|10 subjects. Subjects will performed two different versions of the new visual field algorithm with DLS (differential light sensitivity) strategies. Two repeats of each strategy will be performed.
89162446|NCT02727569||Clinical evaluation study|100 subjects. Subjects will performed a visual field assessment with the new visual field algorithm with MMDT (Moorfields Motion Displacement Test) and DLS -like stimuli and a commercial available SITA algorithm (DLS-like strategy). Two repeats of each strategy will be performed.
89162447|NCT00712816|Experimental|A|
89162448|NCT00712816|Active Comparator|B|
89162449|NCT02727257|Experimental|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. All the exercises are aerobic. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
89162450|NCT02727257|No Intervention|healthy controls|we assessed the attentive Reaction Times in healthy controls, that don't receive rehabilitative treatment
89162451|NCT03482089|Experimental|Cystoprostatectomy|(Open, laparoscopic or robot-assisted ) cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection; without adjuvant androgen deprivation therapy;
89162452|NCT03482089|Active Comparator|Radiotherapy|Radiotherapy by external beam radiotherapy (81 Gy，2.4-4 Gy per fraction over 4-6 weeks); with adjuvant androgen deprivation therapy for the least 3 years
89162453|NCT02571478|Experimental|7-Month Wait List Group|Couples will be randomly assigned to a wait list group. This group will wait seven months before starting The Marriage Checkup.
89162454|NCT02571478|Experimental|MC Right Away|Couples will be randomly assigned to receive The Marriage Checkup right away.
89162455|NCT02727413||Infective endocarditis|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with infective endocarditis in accordance with Duke criteria and scheduled for valve surgery
89162456|NCT02727413||Valvular heart disease|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with valvular heart disease, with no signs of infection, scheduled for valve replacement surgery
89162457|NCT05253313|No Intervention|Conventional|Patients who are eligible for surgery are randomized to MRI scan or standard curative surgery. Patients in this arm will receive standard care according to danish standards without pre-operative MRI scans.
89162458|NCT05253313|Other|MRI scan|This arm includes patients who have been randomized to pre-operative MRI scans.
89162459|NCT02645864|Experimental|Apatinib and Irinotecan|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and irinotecan 150mg q2w. Cohort 2: apatinib 500 mg per day and irinotecan 150mg q2w. Cohort 3: apatinib 750 mg per day and irinotecan 150mg q2w.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event~Grade 3 non-hematologic toxicity including fever, nausea, vomiting, and diarrhea that continues despite optimal medical management) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If two (2) DLTs are experienced in any cohort, the study will stop and the dose of combination treatment in this cohort will be documented."
89162460|NCT02727101|Active Comparator|phenobarbital|"After 12 weeks of baseline observation on phenobarbital medication, the treatment with perampanel will introduced as add on medication."
89162461|NCT02727101|Active Comparator|valproate|"After 12 weeks of baseline observation on valproate medication, the treatment with perampanel will introduced as add on medication."
89162462|NCT02727101|Active Comparator|lamotrigine|"After 12 weeks of baseline observation on lamotrigine medication, the treatment with perampanel will introduced as add on medication."
89162463|NCT02727101|Active Comparator|levetiracetam|"After 12 weeks of baseline observation on levetiracetam medication, the treatment with perampanel will introduced as add on medication."
89162464|NCT02727101|Active Comparator|zonisamide|"After 12 weeks of baseline observation on zonisamide medication, the treatment with perampanel will introduced as add on medication."
89162465|NCT02727101|Active Comparator|pregabalin|"After 12 weeks of baseline observation on pregabaline medication, the treatment with perampanel will introduced as add on medication."
89162466|NCT02727101|Active Comparator|lacosamide|"After 12 weeks of baseline observation on lacosasmide medication, the treatment with perampanel will introduced as add on medication."
89162467|NCT02727101|Active Comparator|clobazam|"After 12 weeks of baseline observation on clobazam medication, the treatment with perampanel will introduced as add on medication."
89162468|NCT02727101|Active Comparator|ezogabine|"After 12 weeks of baseline observation on ezogabine medication, the treatment with perampanel will introduced as add on medication."
89162469|NCT02727101|Active Comparator|eslicarbazepine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
89162470|NCT02727101|Active Comparator|topiramate|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
89162471|NCT02727101|Active Comparator|tiagabine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
89162472|NCT03991351||Men aged 18-34|Participants will be males aged 18-34. Each individual will be exposed to images of men with either a muscular, skinny or overweight physique or the control images of landscapes.
89162473|NCT02645942|Experimental|Intervention group|L-carnitine 1400 mg daily for 8 weeks
89162474|NCT02645942|Placebo Comparator|Placebo group|Placebo
89162475|NCT03076385|Experimental|VAL-506440|
89162476|NCT03076385|Placebo Comparator|Placebo|
89162477|NCT00992485|Experimental|autologous adipose derived stem cell|
89162478|NCT00674856|Experimental|naproxcinod|naproxcinod 750mg(375mg caps x2), administered twice a day.
89162479|NCT02574130|Experimental|Nebulized amikacin|Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days
89162480|NCT02574130|Placebo Comparator|placebo|nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.
89162481|NCT00652184|Placebo Comparator|1|Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
89162482|NCT00652184|Active Comparator|2|Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10
89162483|NCT00652184|Experimental|3|Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
89162484|NCT00652184|Other|4|Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10
89162485|NCT02727179|Experimental|Laparoscopic group|Liver resection performed by laparoscopic approach
89162486|NCT02727179|Active Comparator|Open group|Liver resection performed by open approach
89162487|NCT05356663|Experimental|Mulligan Mobilization with movement|Mulligan Mobilization with movement + Baseline treatment (Moist Heat Pack) Group will receive mulligan mobilization with movement with the frequency of 3 sets and 10 repetitions 3 times a week for 6 weeks.
89162488|NCT05356663|Experimental|Hold relax technique|Hold relax technique + Baseline treatment (Moist Heat Pack) Group will receive Hold Relax Technique of PNF included, 5 repetitions will be given 3 times/week for 6 weeks.
89162489|NCT02726867|Active Comparator|levetiracetam|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 4000 mg levetiracetam.
89162490|NCT02726867|Active Comparator|lacosamide|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 600 mg lacosamide.
89162491|NCT02726867|Active Comparator|ketamine|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 2.5 mg/kg ketamine.
89162492|NCT02726867|Active Comparator|phenobarbital|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin (PHT) with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after PHT loading will receive intravenously (i.v.) phenobarbital 15 mg/kg.
89162493|NCT00687180|Active Comparator|I|MMF
89162494|NCT00687180|Active Comparator|II|
89162495|NCT02645786||Case|"Differentiated thyroid cancer group:~who received total- or near-total thyroidectomy, and thereafter regularly visited the endocrine out-patient department (OPD) of Chuncheon Sacred Heart Hospital.~1) age less than 45 years old when receiving total or near-total thyroidectomy, 2) serum level of TSH<0.1 mU/L in the intermediate recurrence-risk or TSH<0.3 mU/L in the low recurrence-risk group13, 14 over 2 years before study entry, 3) receiving TSH suppressive therapy for 5 to 9 years with fixed dose of LT4 more than 2 years before study entry, and 4) no history of structural heart disease, arrhythmia, or cardiac symptoms (palpitation, exertional dyspnea and chest discomfort) during therapy."
89162496|NCT02645786||Control|"Control group As each DTC patient was enrolled, control subjects were selected from patients who visited endocrinology department for thyroid nodule work-up. The control group had to meet the following criteria~1) the subject matched to a patient by age (±2 years), sex, and body mass index (BMI) (±2 kg/m2), 2) within the reference range of serum TSH (0.3-4.6 mU/L), 3) no history of structural heart disease, arrhythmia, or cardiac symptoms, 4) no history of comorbid diseases which affect thyroxine metabolism and cardiac structure, including hepatic or renal disease, anemia, and hypertension."
89162497|NCT00723970|Experimental|A|Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase
89162498|NCT02637908|Experimental|Mindfulness training|The mindfulness training (experimental condition) will receive 6-weeks of mindfulness training for parents provided in a group setting.
89162499|NCT02637908|No Intervention|Wait-list control|The wait-list control group will receive no intervention during the course of the study. The control group will be offered training following the completion of the study.
89162500|NCT00636623|Other|2|Pilates exercises
89162501|NCT00636623|Other|1|Connective tissue massage
88804592|NCT03822117|Experimental|Pemigatinib|"Cohort A (Solid tumor malignancies with FGFR1-3 in frame fusions; any FGFR2 rearrangement; FGFR1/3 rearrangement with known partner*). Cohort B (Solid tumor malignancies with known or likely activating mutations (excluding kinase domain) in FGFR1-3) Cohort C (Solid tumor malignancies with FGFR1-3 known activating mutations in kinase domain; FGFR1-3 putatively activating mutations; other FGFR1/3 rearrangements* (not eligible for Cohort A)).~*Only FGFR fusions or rearrangements with an intact kinase domain are eligible"
88804593|NCT03810404|Experimental|Sodium bicarbonate supplementation|Group taking oral SB supplementation in a different-dose regimen.
89162502|NCT02727023|Experimental|Osteopathic Manipulative Medicine|The thoracic inlet release, The Miller Thoracic Pump, Pedal Pump will be performed. These techniques are gentle and would be rhythmic in motion.
89162503|NCT00655226|Experimental|CBT skills based group sessions|Cognitive Behavioral Therapy skills based group sessions
89162504|NCT00655226|Active Comparator|Hepatitis C educational support groups|Hepatitis C educational support groups
89162505|NCT00712894|Experimental|D|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.
89162506|NCT00712894|Active Comparator|V|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.
89162507|NCT00712894|Active Comparator|N|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.
89162508|NCT04164368|Experimental|R2-CHOP|Lenalidomide combined with rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone
89162509|NCT04070248||Group 1|50 HIV-seropositive with spirometry confirmed COPD
89162510|NCT04070248||Group 2|50 HIV-seropositive without COPD
89162511|NCT04070248||Group 3|50 HIV-seronegative with spirometry confirmed COPD
89162512|NCT04070248||Group 4|50 HIV-seronegative without COPD
89162513|NCT02726477|Experimental|Wuling San|"This is a double-blinded, randomized placebo-controlled, multi-center clinic trial, using before and after treatment measurements.~A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the intervention group administers Wuling San, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry."
89162514|NCT02726477|Placebo Comparator|placebo|A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the placebo group administers a placebo powder, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.
89162515|NCT02625246|Experimental|Group 1|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
89162516|NCT02625246|Experimental|Group 2|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
89162517|NCT00724204|Placebo Comparator|A|Children that consumed a follow on formula without Lactobacillus salivarius CECT5713
89162518|NCT00724204|Active Comparator|B|Children that consumed a follow on formula with Lactobacillus salivarius CECT5713
89162519|NCT02726555|Experimental|Red yeast rice and atorvastatin|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 300mg of red yeast rice and 2 10mg of atorvastatin.
89162520|NCT02726555|Active Comparator|Atorvastatin alone|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 placebo and 2 10mg of atorvastatin.
89162521|NCT00536107|Active Comparator|Docetaxel|docetaxel
89162522|NCT00536107|Experimental|Gefitinib|Gefitinib (IRESSA)
89162523|NCT01022138|Experimental|HER2Bi-armed activated T cells/Cyclophosphamide/biomarker|"HER2Bi-armed activated T cells Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.~Cyclophosphamide After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide~Laboratory biomarker analysis The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored."
89162524|NCT02690519|Experimental|GLPG1837 dose 1 and GLPG1837 dose 2|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
89162525|NCT04139460|Active Comparator|CRT-D|Implantation of cardiac resynchronization therapy with a defibrillator (CRT-D)
89162526|NCT04139460|Active Comparator|CRT-P|Implantation of cardiac resynchronization therapy pacemaker (CRT-P)
89162527|NCT00726778||A, Observational|Healthy European American, African American, and Hispanic American children aged 7-12
89162528|NCT04164056|Experimental|stimulation on the hippocampus|deep brain stimulation on the hippocampus
89162529|NCT04164056|Active Comparator|stimulation on the anterior nucleus of the thalamus|deep brain stimulation on the anterior nucleus of the thalamus
89162530|NCT02628912||long-term survivors of HPV-related oropharyngeal cancer|This is a cross-sectional pilot study of long-term survivors of HPV-related oropharyngeal cancer treated with CTRT who are at least three years from treatment completion. This study consists of a onetime assessment of cardiopulmonary fitness, physical function status, measurement of lean body mass, endothelial function quality of life assessment, medical history and blood laboratory evaluation for traditional cardiac risk factors, endocrine derangement and inflammation.
89162531|NCT02571088|Experimental|Training Program|The treatment will consist in an endurance training program. Only patients of the trained group will be subjected to this training program which will typically consist in 3 training sessions per week during 8 weeks i.e., 24 training sessions. Each training session will last 45 min. All training sessions will take place at the hospital and will be under medical supervision.
89162532|NCT02571088|No Intervention|No Training Program|It will be asked to the control patients to not change their habitual physical activity during the entire period of observation
89162533|NCT02637830|Experimental|Fluoride varnish and fluoride toothpaste|Application of fluoride varnish (Duraphat) at the begining of the study. Application of fluoride toothpaste (Crest) twice a day for 3 days.
89162534|NCT02637830|Placebo Comparator|placebo toothpaste|Application of placebo toothpaste twice a day for 3 days
89162535|NCT02637830|Active Comparator|Fluoride toothpaste|Application of fluoride toothpaste (Crest) twice a day for 3 days
89162536|NCT02694575||Other|Other - currently on other treatment (i.e., non-incretin based therapies)
89162537|NCT02694575||GLP-1|Currently on GLP-1 analogue therapy
89162538|NCT02694575||DPP-4|Currently on DPP-4 inhibitor therapy
89162539|NCT00687258|Experimental|1|VitabranE ViE: Vitamin E-bonded polysulfone dialyzer
89162540|NCT00687258|No Intervention|2|APS-U (Asahi Polysulfone APS): Polysulfone dialyzer
89162541|NCT00712972||1|"Patients enrolled in this study are those whom present to our institution for elective knee arthroscopy. All patients scheduled to receive a knee arthroscopy scheduled through the office of Dr. Harold Battenfield will be asked to participate in the study on the day of their procedure as long as they do not fall into one of the exclusion criteria categories.~Patients will not be allowed to participate in this study if they have an allergy to iodine or shell fish, if they have a knee effusion diagnosed clinically on the day of surgery, if the knee or surrounding tissues display cellulitis or other signs of infection, or if the patient has had a traumatic accident to their knee which significantly changes its anatomical relationships"
89162542|NCT00687336|Active Comparator|1|Empirical eradication treatment
89162543|NCT00687336|Active Comparator|2|Eradication treatment according to a diagnostic test (URT, histological test, breath test or serology).
89162544|NCT04001569|Experimental|AZD8186 in combination with paclitaxel|
89162545|NCT02694341|Active Comparator|Bakri Balloon with abdominal traction stitch|bakri balloon will be inserted with abdominal traction stitch
89162546|NCT02694341|Experimental|Bakri Balloon without abdominal traction stitch|bakri balloon will be inserted with no performance of abdominal traction stitch
89162547|NCT00713050|Experimental|Experimental|Computer-based Aphasia therapy
89162548|NCT00713050|Active Comparator|Control|Control Arm - Healthy subjects.
89162549|NCT00674934|Experimental|1|Radiation
89162550|NCT00724438||1|Obese women: women with a body mass index (BMI) >30
88804594|NCT03810404|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (NaCl).
89162551|NCT00724438||2|Normal weight women: women with a BMI <25
89162552|NCT03352531|Experimental|AK-105|Single-arm
89162553|NCT00692016|Other|Arm 1|
89162554|NCT00692016|Other|Arm 2|
89162555|NCT02733263|Experimental|Group 1|Participants will first consume in the the order of 0 g RMD, 15 g RMD, 25 g RMD for 3 weeks each
89162556|NCT02733263|Experimental|Group 2|Participants will first consume RMD in the the order of 0 g RMD, 25 g RMD, 15 g RMD for 3 weeks each
89162557|NCT02733263|Experimental|Group 3|Participants will first consume RMD in the the order of 15 g RMD, 0 g RMD, 25 g RMD for 3 weeks each
89162558|NCT02733263|Experimental|Group 4|Participants will first consume RMD in the the order of 15 g RMD, 25 g RMD, 0 g RMD for 3 weeks each
89162559|NCT02733263|Experimental|Group 5|Participants will first consume RMD in the the order of 25 g RMD, 15 g RMD, 0 g RMD for 3 weeks each
89162560|NCT02733263|Experimental|Group 6|Participants will first consume RMD in the the order of 25 g RMD, 0 g RMD, 15 g RMD for 3 weeks each
89162561|NCT00724516|Experimental|Novel Breast Compression Paddle|Women scheduled to undergo a breast mammography wire localization procedure will have a new breast compression paddle will be used Instead of using the regular wire localization mammography compression paddle.
89162562|NCT00655304|Active Comparator|1|Treatment with 6-8 hours of Prometheus (R) liver support dialysis
89162563|NCT00655304|Active Comparator|2|Treatment with 6-8 hours of CVVHDF
89162564|NCT02570620|Experimental|Observational cohort of patients|Patients will benefit from an ultrasonography of the cervix through endovaginal before induction of prostaglandins
89162565|NCT02733107|Other|Apatinib+Etoposide|Apatinib combined with Etoposide
89162566|NCT02645708|Other|Retrograde Intrarenal Surgery (RIRS)|Patients in Group 1 undergo Retrograde Intrarenal Surgery
89162567|NCT02645708|Other|EPVL after RIRS|"Patients in Group 2 undergo external physical vibration lithecbole after Retrograde Intrarenal Surgery.~with the help of changing the position and direction of the extracorporeally physical vibration machine, the urinary stone was discharged from the urinary collecting system"
89162568|NCT02726087|Experimental|ministernotomy|"Minimally invasive aortic valve replacement with Partial J upper hemisternotomy through right 4th intercostal space, performed according to current standard of care practice."
89162569|NCT02726087|Active Comparator|full sternotomy|Full sternotomy AVR through a standard median sternotomy, performed according to current standard of care practice.
89162570|NCT00992641|Experimental|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
89162571|NCT00992641|Active Comparator|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
89162572|NCT00675012|Experimental|A|
89162573|NCT00652262|Experimental|Arm 1|
89162574|NCT05373628|Experimental|Gradient and pulse imaging|All subjects used standardized breast MRI scanning schemes, including T2 weighted imaging (T2WI), T1 weighted imaging (T1WI), diffusion weighted imaging (DWI), PGSE, OGSE and contrast dynamic enhancement (DCE). Three quantitative parameters of VIN, DEX and D are derived on MATLAB software
89162575|NCT05355103|No Intervention|Control Group|Women having received epidural analgesia after a standard verbal consent provided by the anesthesiologist before doing the epidural technique, representing the standard of practice in our institution
89162576|NCT05355103|Active Comparator|Exposed group|Woman having received epidural analgesia after having received and read an educational tool at her admission to labour and delivery unit, in addition to the standard verbal consent.
89162577|NCT02640794|Active Comparator|Aspirin +clopidogrel|Patients would be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d) + clopidogrel (75 mg/d)
89162578|NCT02640794|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d)
89162579|NCT00687570|Other|B|Nutritional drinks 7 days before surgery instead of traditional Bowel preparation with Laxabon®
89162580|NCT00687570|Other|A|Traditional bowel preparation with Laxabon®
89162581|NCT00724672||ETA|RA patients who were scheduled to receive etanercept 50 mg subcutaneously once weekly
89162582|NCT00724672||IFX|RA patients who were scheduled to receive infliximab 3 mg/kg IV at Weeks 0, 2, and 6
89162583|NCT00724672||ADA|RA patients who were scheduled to receive adalimumab 40 mg subcutaneously biweekly
89162584|NCT00724672||non-diseased controls|Healthy individuals who contributed their RNA/cDNA samples prior to the study and for whom ethical approval has already been obtained.
89162585|NCT02570932|Experimental|Autologous Mesenchymal Bone Marrow Cell|"All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)~Pharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration."
89162586|NCT02624856|Experimental|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
89162587|NCT02624856|Active Comparator|Standard bupivacaine plus dexamethasone|Bupivacaine 0.5% 10 mL plus 2 mg dexamethasone for quadriceps sparing femoral nerve block and bupivacaine 0.25% 20 mL plus 2 mg of dexamethasone for posterior knee compartment periarticular injection.
89162588|NCT02646020|Experimental|Aprepitant and placebo|aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;
89162589|NCT02646020|Active Comparator|desloratadine and placebo|placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28
89162590|NCT02733419|Experimental|Enfuvirtide + OB (Not Randomized)|Participants will receive enfuvirtide 90 milligram (mg) twice daily (b.i.d.) and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants not meeting the randomization criteria will receive enfuvirtide 90 mg b.i.d and OB for next 24 weeks (up to Week 52).
89162591|NCT02733419|Experimental|Enfuvirtide + OB (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive enfuvirtide 90 mg b.i.d. and OB for next 24 weeks (up to Week 52).
89162592|NCT02733419|Experimental|OB alone (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive OB alone for next 24 weeks (up to Week 52).
89162593|NCT00724828||1|
89162594|NCT02624778|Experimental|LY3002813 Single dose 1|LY3002813 administered intravenously (IV) once
89162595|NCT02624778|Experimental|LY3002813 Single dose 2|LY3002813 administered IV once
88804595|NCT03737500|Active Comparator|Standard silicone-based breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of standard silicone-based breast implant (i.e. the breast implant commonly used in our institution)
88804596|NCT03737500|Experimental|B-Lite® light weight breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of B-Lite® light weight breast implant
88804597|NCT03681132|Other|Low-threshold re-start|Re-start antiviral therapy if HBV DNA viral load >2000 IU/ml and ALT >80 U/L.
88804598|NCT03681132|Other|High-threshold re-start|"Re-start antiviral therapy if:~ALT >100 U/L persisting for more than 4 months without any spontaneous decline toward normal; OR~ALT >400 U/L persisting for more than 2 months in consecutive assays."
88804599|NCT03676647||Diagnostic (biospecimen collection)|Previously collected FNA aspiration specimen samples are analyzed via DDMS assay. Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS assay.
88804600|NCT03603184|Experimental|Experimental arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
88804601|NCT03603184|Placebo Comparator|Control arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
89162596|NCT02624778|Experimental|LY3002813 Single dose 3|LY3002813 administered IV once
89162597|NCT02624778|Experimental|LY3002813 Multiple dose 1 x 24 wks|LY3002813 administered IV for 24 wks
89162598|NCT02624778|Experimental|LY3002813 Multiple dose 2 x 24 wks|LY3002813 administered IV for 24 weeks
89162599|NCT02624778|Experimental|LY3002813 Multiple dose 3 x 72 wks|LY3002813 administered IV for 72 wks
89162600|NCT02624778|Experimental|LY3002813 Multiple dose 4 x 72 weeks|LY3002813 administered IV for 72 wks
89162601|NCT02624778|Placebo Comparator|Placebo given once|Placebo administered IV once
89162602|NCT02624778|Placebo Comparator|Placebo x 24 weeks|Placebo administered IV for 24 wks
89162603|NCT02624778|Placebo Comparator|Placebo x 72 weeks|Placebo administered IV for 72 wks
89162604|NCT02640872||HAPPY Cohort|A elderly cohort for chronic diseases
89162605|NCT00724906|Experimental|Parkinsonian Syndromes|Subjects with Parkinsonian Syndromes
89162606|NCT00724906|Experimental|Non-Parkinsonian Syndromes|Subjects with Non-Parkinsonian Syndromes
89162607|NCT02725775|Active Comparator|100% OJ|240ml 100% Florida Orange Juice consumed on a daily basis for 10 weeks.
89162608|NCT02725775|Placebo Comparator|Equicaloric Orange Drink|An equicaloric placebo orange drink (containing equivalent dose of sucrose, glucose, fructose, vitamin C and citric acid for flavour) consumed daily for 10 weeks.
89162609|NCT00675090|Experimental|GSK239512|GSK239512 oral tablets
89162610|NCT00675090|Placebo Comparator|Placebo|Placebo to match tablets
89162611|NCT02574052|Other|Behavioral|"The whole experiment was divided into three phases with each phase lasting two weeks.~First Stage-Behavioral: just record participants' food choices Second Stage-Behavioral: menu labelling without nutrition education Third Stage- Behavioral; menu labelling with nutrition education"
89162612|NCT04163510|Experimental|Reading Intervention Group|A group of parents and their children will participate in this single arm, pre-/post-intervention study. This 10-week study will include 10 sets of parents of low-reading elementary school children, recruited from Harlem Grown Community Center. Intervention will be implemented in a 9-week period, with data collection during the first intervention week and one week post-intervention. Three large-group sessions will be held in a central location (at Harlem Grown Community Center), to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. The reading program will help parents identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading.
89162613|NCT00992797|Experimental|Cholecalciferol|
89162614|NCT00992797|Placebo Comparator|Placebo|
89162615|NCT02725541|Experimental|Experimental|Trastuzumab emtansine at a dose of 3.6 mg/kg will be administered via intravenous infusion for 6 weeks (two 21-day cycles).
89162616|NCT02625012||Vitiligo|A serial of vitiligo patients under treatment with UVB-NB
89162617|NCT00911066|Experimental|MLN4924|
89162618|NCT00911066|Experimental|Azacitidine|
88806081|NCT00237770|Placebo Comparator|Arm 1|Placebo control (normal saline) is employed on a separate visit during procedure.
89162619|NCT00725062|Experimental|Patients Receiving CD4+/CD25+ cells|CD4+/CD25+ cells given intravenously over 15-60 minutes on Day -2 (prior to peripheral blood progenitor cell transplant)
89162620|NCT02733341|Active Comparator|Oral Ticagrelor|Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.
89162621|NCT02733341|Active Comparator|Intravenous Cangrelor|Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months
89162622|NCT00692172|Experimental|1|
89162623|NCT02645630|Experimental|Right Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the right side.
89162624|NCT02645630|Experimental|Left Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the left side.
89162625|NCT02645630|Active Comparator|Sham Cervical Manipulation|Patients assigned to this group will receive a sham cervical spine manipulation targeting the C3/C4 segment on both sides. No therapeuthic thrust will be applied.
89162626|NCT00725140||Single|
89162627|NCT02725697||TCM treatment|TCM treatment (e.g. acupuncture, Tuina massage, Chinese herbal medicine, moxibustion, electroacupuncture, ear acupuncture)
89162628|NCT02640560||Children with food allergy|"Children with food allergy to nuts, hazelnuts, walnuts, shellfish and mollusks (1-14 years old).~The Parents of the cases children will compile a Food allergy questionnaire"
89162629|NCT02640560||Healthy Children|Healthy Children (1-14 years old) The Parents of the control children will compile a Control questionnaire
89162630|NCT02434393||Late Life Depression|120 participants who meet the criteria for Major Depression or Late Life Depression (LLD)
89162631|NCT02725931|Experimental|Activity group|Pulmonary rehabilitation plus physical activity intervention
89162632|NCT02640326|Active Comparator|Active Comparator|The catheterized arm will have Standard of care Foley urinary catheter insertion according to usual institutional care pathways in the operating room prior to surgery initiation. The urinary catheter will be assessed for removal on the morning of post-operative day 1, and patients will be monitored for urinary complications once catheter is removed until patient has successfully voided spontaneously within 8 +/- 2 hours.
89162633|NCT02640326|Experimental|Experimental Arm|The non-catheterized arm will have standard of care Foley urinary catheter insertion, with no Foley Urinary Catheter inserted prior to, during, or after surgery unless the patient is showing signs of urinary retention after surgery. Patient will be monitored for urinary complications starting in the recovery room until patient has successfully voided spontaneously within 8 +/- 2 hours
89162634|NCT03675139|Experimental|Medroxyprogesterone Acetate|EH patients will take MPA (Medroxyprogesterone Acetate) 10mg daily from tenth day of menstruation for 15 days for 3months. Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium. All of the findings will be recorded.
89162635|NCT03675139|Experimental|dydrogesterone|EH patients will take dydrogesterone 10 mg, 2 tablets twice daily from tenth day of menstruation for 15 days for 3-6 months. Endometrial Biopsy (Pipelle) will be performed every 3-month to examine the endometrium. All of the findings will be recorded.
89162636|NCT00636467|Experimental|No label|Injection of Nanocis® or Nanocoll® (Tc-colloid) on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
89162637|NCT02645552|Experimental|Tranexamic acid|Focused intervention
89162638|NCT02645552|Placebo Comparator|Sodium chloride|Placebo control
89162639|NCT00692328|Active Comparator|1|The subjects will be told they receive levodopa or acupuncture.
89162640|NCT00692328|Placebo Comparator|2|The subjects will be told they receive placebo/sham levodopa or acupuncture.
89162641|NCT00692328|Experimental|3|The subjects will be told they have 50% chance of receiving real or placebo/sham levodopa or acupuncture.
89162642|NCT03650803|Experimental|3D MR Fingerprinting scan|Three separate 3D MR fingerprinting scans: Before the start of chemotherapy, 7-10 days after the first cycle of chemotherapy, and within 1 month of the end of chemotherapy treatment.
89162643|NCT00652418|Active Comparator|Arm 1|
89162644|NCT00652418|Experimental|Arm 2|
89162645|NCT00687648|Experimental|Arm I|Patients receive aromatase inhibitor (anastrozole, letrozole, or exemestane) as previously prescribed. Patients also receive oral cyclophosphamide once daily on days 1-28 and oral methotrexate twice on days 15, 16, 22, and 23 of course 1. For all subsequent courses, patients receive oral cyclophosphamide once daily and oral prednisolone once daily on days 1-28 and oral methotrexate twice on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment with cyclophosphamide, methotrexate, and prednisolone repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89162646|NCT00687648|Active Comparator|Arm II|Patients receive cyclophosphamide, methotrexate, and prednisolone as in arm I.
89162647|NCT00725218|Placebo Comparator|1|Saline 5 ml injection 10 min prior to propofol administration.
89162648|NCT00725218|Experimental|2|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
89162649|NCT02732795|Experimental|Morphine dosing|Evaluating morphine pharmacokinetics (PK) in 3 groups: normal controls, children with severe OSAS, and obese children with OSAS. Morphine is dosed on ideal body weight in obese children, as recommended by manufacturer. Biomarkers were taken from patients to evaluate their relation to changes in morphine PK.
89162650|NCT03638011|No Intervention|Standard of Care|These participant will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They standard neuraxial anesthesia with neuraxial Duramorph for post-operative pain.
89162651|NCT03638011|Active Comparator|Bilateral TAP Block|These participants will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They will receive standard neuraxial anesthesia without neuraxial Duramorph and a transverse abdominal plane (TAP) blocks immediately after surgery, with a mixture of bupivacaine and Exparel, for post-operative analgesia.
89162652|NCT00655460|Experimental|eProtocol|
89162653|NCT00687726|Experimental|G1|Standing balance and mini squat training
89162654|NCT00687726|Active Comparator|G2|Isometric knee extension exercise
89162655|NCT02732717||abnormal ultrasound index|twin pregnancy with abnormal ultrasound index
89162656|NCT02732717||normal ultrasound index|twin pregnancy with normal ultrasound index
89162657|NCT03623737|Experimental|paclitaxel plus cisplatin|A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT. B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.
89162658|NCT03623737|Active Comparator|cisplatin plus 5-fluorouracil|A. P: Cisplatin 75 mg/m2, 2 h IVF, on day 1 of week 1 and week 5 during CRT. B. F: 5-FU 1,000 mg/m2, 24 h IVF, on day 1, 2, 3, 4 of week 1 and week 5 during CRT.
89162659|NCT02625714|Other|A group|Renexin® → SID142
89162660|NCT02625714|Other|B group|SID142 → Renexin®
89162661|NCT02637752|Active Comparator|Lifestyle counseling|Intervention: Lifestyle counseling or nutrition/physical counselling
89162662|NCT02637752|No Intervention|No Intervention|To ensure that both groups benefited equally from the study, the control group received the counselling and the handouts at the end of the study.
89162663|NCT05373004|Experimental|Empagliflozin 25 mg arm (SGLT2 inhibitor)|empagliflozin 10 mg once daily plus a placebo enalapril 10 mg tab, along with conventional antihypertensive (for hypertension patients) & glycemic control therapies (if present). After four weeks, the dose of empagliflozin will be increased to 25 mg once (with Enalapril 20 mg placebo) daily throughout the study for one year.
89162664|NCT05373004|Active Comparator|Enalapril 20 mg arm (ACE inhibitor)|enalapril 10 mg tab once daily plus a placebo empagliflozin 10 mg tab, along with conventional antihypertensive (for hypertension patients) & glycemic control therapies (if present). After four weeks, the dose of enalapril will be increased to 20 mg once (with Empagliflozin 25 mg placebo) daily throughout the study for one year.
89162665|NCT00655616|Active Comparator|1|The active comparator arm consists of Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per current inhaled steroid dose plus oral montelukast
89162666|NCT00655616|Placebo Comparator|2|The placebo comparator arm consists of Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid dose plus placebo for montelukast
89162667|NCT02725385||Ancillary-Correlative (stress and coping)|"PART I:~Participants complete a questionnaire that measures several psychological constructs including stress, anxiety, depression, coping mechanisms, uncertainty, positive and negative emotions, and life satisfaction over 15-30 minutes.~PART II:~Participants undergo a Trier Social Stress Test during a laboratory session over 1.5 hours."
89162668|NCT00713362|Active Comparator|1|Surgery: Video-assisted thoracoscopic surgery
89162669|NCT00713362|Active Comparator|2|Chest tube drainage
89162670|NCT00992953|Experimental|Virtual Reality Therapy|10 Weeks of Virtual Reality Exposure with Stimulus Control, with up to twice a week, 90 min sessions
89162671|NCT00992953|Active Comparator|Treatment As Usual|Traditional Therapy and Psychiatric Medication
89162672|NCT00687960|Experimental|1|Resistant Starch Type 4-Raw
89162673|NCT00687960|Experimental|2|Resistant Starch Type 4-cooked
89162674|NCT00687960|Active Comparator|3|Puffed wheat
89162675|NCT00687960|Placebo Comparator|4|Dextrose
89162676|NCT02637674|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF
89162677|NCT00713440|Experimental|1|10 healthy Caucasian subjects without family history of diabetes
89162678|NCT02732483|Experimental|Endo-Clot(TM)|
89162679|NCT00922740|Placebo Comparator|Sugar pill|
89162680|NCT00922740|Experimental|VA106483 1 mg|
89162681|NCT00922740|Experimental|VA106483 2 mg|
89162682|NCT00922740|Experimental|VA106483 4 mg|
89162683|NCT05372848|Other|Group 1|Group 1 includes volunteers who used to use manual toothbrushes and started to use an electric toothbrush for 1 month with the same daily brushing routine. Fifteen healthy individuals between the ages of 20 and 30 years with no systemic disease, restoration or caries, and whom have the criteria for using a manual toothbrush for at least 2 years included in Group 1.
89162684|NCT05372848|Other|Group 2|Group 2 includes volunteers who used to use an electric toothbrush and started to use a manual toothbrush for 1 month with the same daily brushing routines. Fifteen healthy individuals between the ages of 20 and 30 years with no systemic disease, restoration or caries, and whom have the criteria for using an electric toothbrush for at least 2 years included in Group 2.
89162685|NCT00993109|Experimental|Arm 1|
89162686|NCT00993109|Active Comparator|Arm 2|
89162687|NCT02725229|Active Comparator|parasternal block group|Patients in this group will be randomized to receive an parasternal block and PCA.
89162688|NCT02725229|Active Comparator|TENS group|Patients in this group will be randomized to receive an TENS and PCA.
89162689|NCT02725229|Active Comparator|control group|Patients in this group will be randomized to receive an PCA.
89162690|NCT00675246|Experimental|A|Antenatal corticoid therapy
88806082|NCT04228484|Placebo Comparator|Placebo|Placebo infusion
89162691|NCT02732405|Experimental|MK5172 /MK8742|
89162692|NCT02637596|Experimental|RFA group|Twenty-fourth consecutive patients with histologically proved pancreatic cancer [stage IIb (n=4), III (n=15), IV (n=5) ]underwent intraoperative RFA of primary tumor.
89162693|NCT04001725|Active Comparator|A (Dexamethasone)|Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route (control arm). The total dose can either administered once a day or through a refracted schedule
89162694|NCT04001725|Experimental|B (Dexamethasone and Metformin)|"Patients subjected at a minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route.The total dose can either administered once a day or through a refracted schedule.~The same patients subjected at a metformin. Metformin initial dosage will be 850 mg per day, and will be escalated based on patient tolerability up to a maximum of 2550 mg daily (experimental arm)."
89162695|NCT04137744|Active Comparator|ARM preservation ALND|ARM +ve LN PRESERVED , ALND COMPLETED LATER ON
89162696|NCT04137744|Active Comparator|conventional ALND|ARM +VE NODES MARKED AND TAKEN WITH ALND
89162697|NCT03302273|Experimental|Corneal Epithelial Stem Cell Transplant|The treatment will consist of transplantation (via self-administration) of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material four times daily in both eyes for a three month interval.
88806083|NCT04228484|Active Comparator|GIP receptor antagonization|GIP(3-30)NH2 infusion
89162698|NCT00692562|Experimental|A|
89162699|NCT02637518||Hospital Universitario de Getafe|"Assessment of frailty tools in elderly people~The Geriatric Department attends patients:~1800/year - acute unit. 800/year - Orthogeriatrics and Interconsultation Unit. 300/year - Day Hospital. 4000/year - Outpatient office. 1200/year - Domiciliary Care."
89162700|NCT02637518||Diabetes Frail Ltd.|Assessment of frailty tools in elderly people Has significant experience in managing research studies in older people.
89162701|NCT02637518||Università Cattólica del Sacro Cuore|"Assessment of frailty tools in elderly people~The Geriatric Unit is compounded by:~24 beds of Acute Care Ward 46 beds of Intensive Rehabilitation Unit 20 beds of Day Hospital Outpatient clinic"
89162702|NCT02637518||Gérontopole de Toulouse|"Assessment of frailty tools in elderly people~The Geriatric Unit is compounded by:~5 Acute Care Units - 100 beds. 3 Rehabilitation Unit - 75 beds. Long term care Unit - 140 beds. 2 Day Hospitals Outpatient Clinic"
89162703|NCT02637518||Jagiellonian University Medical College|Assessment of frailty tools in elderly people The Department of Internal Medicine and Gerontology is the largest centre in Poland limited to the Geriatric market.
89162704|NCT02573974|Other|Case group|the intervention, specific to the study, is to take samples on patients with advanced gastrointestinal cancer
89162705|NCT02573974|Other|Control group|the intervention, specific to the study, is to take samples on non-undernourished patients supported for adjuvant chemotherapy as part of colorectal cancer
89162706|NCT02637440|No Intervention|Conservative|After the index primary PCI. The control group will receive best medical therapy and regular follow up and only PCI for recurrent angina with evidence of inducible ischaemia.
89162707|NCT02637440|Active Comparator|FFR guided|FFR group will undergo FFR at 4 weeks of the index primary PCI as OPD. If FFR is less than 0.8, then PCI will be performed
89162708|NCT02637440|Active Comparator|angiogram guided|The group will undergo PCI for all significant lesions more than 50
89162709|NCT02721563|Active Comparator|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
89162710|NCT02721563|Placebo Comparator|Control Group|"Placebo：dissolved in 100mlphysiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 6 weeks course.Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
89162711|NCT00688038|Experimental|Laser Ablation + MRTI|Magnetic resonance thermal imaging = MRTI
89162712|NCT00713674|No Intervention|1|No Treatment
89162713|NCT00713674|Experimental|2|Theraworx intranasal
89162714|NCT00713674|Active Comparator|3|mupirocin antibiotic ointment intranasal
89162715|NCT00885482|Experimental|Single arm|"Treatment simplification from a standard combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy."
89162716|NCT05349799|Experimental|TEOSYAL RHA® 1|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, not further treated with TEOSYAL® PureSense Redensity 1 during the skin redensification phase."
89162717|NCT05349799|Experimental|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 with a needle|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, further treated with TEOSYAL® PureSense Redensity 1 using a needle during the skin redensification phase."
89162718|NCT05349799|Experimental|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 with a cannula|"Subjects injected with TEOSYAL RHA® 1 during the skin beautification phase, further treated with TEOSYAL® PureSense Redensity 1 using a cannula (optional for perioral lines) during the skin redensification phase."
89162719|NCT04139226|Experimental|Administration of CC-11050|Part 1: Single Ascending Dose Part 2: drug-drug interaction/ food effect (DDI/FE)
89162720|NCT00688116|Experimental|ganetespib|
89162721|NCT05366062|Experimental|Treatment Arm|This is a Treatment Protocol for patients with severe and immediately life-threatening GBM that had surgical resection and first line treatment with radiation therapy and temozolamide per current standard of care. Patients will be treated with recurring 28-day cycles of ERC1671, GM-CSF, Cyclophosphomide, Bevacizumab, and Pembrolizumab until progression of disease and at the discretion of the treating physician.
89162722|NCT02645240|Experimental|Heparin injection|Injection of low molecular weight heparin in patients with acute mesenteric ischemia to assess outcome
89162723|NCT02724917|Experimental|APN1125, Low Dose|APN1125, Low Dose
89162724|NCT02724917|Experimental|APN1125, Mid Dose|APN1125, Mid Dose
89162725|NCT02724917|Experimental|APN1125, High Dose|APN1125, High Dose
89162726|NCT02724917|Placebo Comparator|Placebo|Placebo to match
89162727|NCT00688194|Active Comparator|Arm I|Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course 1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89162728|NCT00688194|Active Comparator|Arm II|Patients receive fulvestrant and placebo as in arm I. Patients also receive aromatase inhibitor (AI) therapy (e.g., exemestane, anastrozole, or letrozole) according to standard treatment regulations.
89162729|NCT00688194|Active Comparator|Arm III|Patients receive fulvestrant as in arm I and oral lapatinib tosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89162730|NCT00688194|Active Comparator|Arm IV|Patients receive fulvestrant as in arm I and lapatinib as in arm III. Patients also receive AI therapy according to standard treatment regulations.
89162731|NCT00653744|Experimental|1|Rosuvastatin
89162732|NCT00653744|Active Comparator|2|Atorvastatin
89162733|NCT04019158|Experimental|Parkinson's Disease patients|Parkinson's Disease patients will walk in three conditions for +- 15 minutes per condition: walking over ground, walking on a treadmill, walking on a treadmill in virtual reality
89162734|NCT03009227|Active Comparator|D2 lymph node dissection|Colonic resection with D2 lymph node dissection
89162735|NCT03009227|Experimental|D3 lymph node dissection|Colonic resection with D3 lymph node dissection
89162736|NCT03322267|Experimental|Pembrolizumab|Adjuvant cisplatin-chemoradiotherapy followed by pembrolizumab
89162737|NCT00652496|Experimental|1|Bimatoprost 0.01% ophthalmic solution
89162738|NCT00652496|Experimental|2|Bimatoprost 0.015% formulation 1 ophthalmic solution
89162739|NCT00652496|Experimental|3|Bimatoprost 0.015% formulation 2 ophthalmic solution
89162740|NCT00652496|Experimental|4|Bimatoprost 0.02% ophthalmic solution
89162741|NCT00652496|Active Comparator|5|Bimatoprost 0.03% ophthalmic solution
89162742|NCT00688272|Experimental|Arm 1|Eltrombopag 75 mg QD x 6 days
89162743|NCT00688272|Active Comparator|Arm 2|Ciprofloxicin 500mg BID x 6 days
89162744|NCT00688272|Placebo Comparator|Arm 3|Placebo QD x 6 days
89162745|NCT02570776||observation|Cohort of patients for Endoscopy & they are assessed for Helicobacter pylori through the histopathology & also throgh C14 C UBT.
89162746|NCT00993343|Active Comparator|Cyclosporine + Methotreaxte|
89162747|NCT00993343|Active Comparator|sirolimus + tacrolimus|
89162748|NCT02974049|Active Comparator|Standard Treatment|Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
89162749|NCT02974049|Experimental|ALB 400 mg x2 per year|Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
89162750|NCT02974049|Experimental|ALB 800 mg x2 per year|Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
89162751|NCT02974049|Experimental|ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg|Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only
89162752|NCT02645162|Experimental|Preschool|"This arm will receive the community-based preschool intervention.~The preschool sessions will include 2 groups per day (3 years 6months to 4 years 6 months in the morning session and 4 years 7 months to 5 year 6 months in the afternoon session at the time of enrolment)~Each session will last 3 hours for 5 days per week.~The expected CYL-to-child ratio will be 1:15; however, given the expected high level of local demand it may exceed to a maximum of 1:20 ratio."
89162753|NCT02645162|No Intervention|Control|The control group will receive standard services available in the community.
89162754|NCT04070092||TBI group|"A cohort of patients admitted to UZ Leuven from 2019 to 2023 due to Traumatic Brain Injury and fulfilling our inclusion and exclusion criteria will be recruited.~Inclusion criteria will be: ≥ 65 years old, admitted to UZ Leuven between 2019 and 2023 due to TBI, all injury severities (mild (GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤8)), and having signed the informed consent to participate in the study.~Exclusion criteria will be: < 65 years old, admitted to UZ Leuven before 2019, diagnose of neurodegenerative diseases before the TBI, cognitive and motor disturbances caused by any other pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
89162755|NCT04070092||Control group|"A cohort of healthy volunteers with similar demographic characteristics will be recruited as a control group.~Inclusion criteria will be: ≥ 65 years old and having signed the informed consent to participate in the study.~Exclusion criteria will be: < 65 years old, diagnose of neurodegenerative diseases, cognitive and motor disturbances caused by any pathology, previous alcohol/drugs abuse, and not having signed the informed consent to participate in the study."
89162756|NCT00911976|Experimental|Xience V|Implantation of the Xience V stent in saphenous vein graft lesions
89162757|NCT05356429||experimental group|In the experimental group, LCDM was added to the general mature culture medium.
89162758|NCT05356429||control group|In the control group, he culture medium was general mature culture medium.
89162759|NCT02637284|Experimental|Intervention 1a (cohort 1)|Single dose of 1 oral tablet of PCO-02 containing 1 mg of Bepecin (12 subjects)
89162760|NCT02637284|Experimental|Intervention 1a (cohort 2)|Single dose of 3 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
89162761|NCT02637284|Experimental|Intervention 1a (cohort 3)|Single dose of 6 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
89162762|NCT02637284|Placebo Comparator|Control group 1a (cohort 1)|Single dose of 1 oral tablet of PCO-03 as placebo (2 subjects)
89162763|NCT02637284|Placebo Comparator|Control group 1a (cohort 2)|Single dose of 3 oral tablets of PCO-03 as placebo (2 subjects)
89162764|NCT02637284|Placebo Comparator|Control group 1 a (cohort 3)|Single dose of 6 oral tablets of PCO-03 as placebo by mouth (2 subjects)
89162765|NCT02637284|Experimental|Intervention 1b|Multiple dose regime of 3 oral tablets of PCO-02 containing 1 mg Bepecin every 8 hours during 2 weeks (36 subjects)
89162766|NCT02637284|Placebo Comparator|Control group 1b|Multiple dose regime of 3 oral tablets of PCO-03 as placebo every 8 hours during 2 weeks (6 subjects)
89162767|NCT02570464|Experimental|Patients undergoing aortic aneurysm surgery with RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery with Remote ischemic preconditioning (RIPC)
89162768|NCT02570464|Sham Comparator|Patients undergoing aortic aneurysm surgery without RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery without Remote ischemic preconditioning (RIPC)
89162769|NCT04138992|Experimental|study group A|"bevacizumab combined with neoadjuvant chemotherapy and concurrent chemoradiotherapy：~bevacizumab combined with neoadjuvant chemotherapy for 2 cycles: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; Docetaxel 75mg/m2, intravenous injection，once three week;~bevacizumab combined with concurrent chemoradiotherapy: Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor"
89162770|NCT04138992|Experimental|study group B|study arm: bevacizumab combined with concurrent chemoradiotherapy： Bevacizumab will be used as 7.5 mg/kg, once every three weeks; DDP 75mg/m2, intravenous injection，once three week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
89162771|NCT04138992|Active Comparator|control|standard concurrent chemoradiotherapy: DDP 40mg/m2, intravenous injection，once a week; pelvic radiotherapy will be delivered with 45-50Gy/25f; enlarged lymph nodes be irradiated by 62.5Gy/25f with sib-IMRT; brachytherapy be delivered to cervix and primary tumor
89162772|NCT02721485|Other|Normal Saline|Half of the hospitals will be allocated to start the 90-day test period using Normal Saline administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Ringer's Lactate following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
89162773|NCT02721485|Other|Ringer's Lactate|Half of the hospitals will be allocated to start the 90-day test period using Ringer's Lactate administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Normal Saline following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians in for the final 90-day test period.
89162774|NCT00585715|Experimental|Candela DCD with cooling|Laser treatment with Candela DCD cooling which produces a cryogenic fluid that cools the epidermis prior to each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will receive a coolant during the laser procedure.
89162775|NCT00585715|Active Comparator|Candela DCD without Cooling|Laser treatment without cooling before each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will not receive a coolant during the laser procedure.
89162776|NCT02637362|Active Comparator|Ankle + Sham metatarsal|Ankle block + sham metatarsal block
89162777|NCT02637362|Active Comparator|Ankle + Metatarsal|Ankle block + metatarsal block
89162778|NCT02637362|Active Comparator|Metatarsal + sham ankle|Metatarsal block + sham ankle block
89162779|NCT04137588||Group A|antiangiogenesis 7.5mg/Kg q3w+pemetrexed 500mg/m2 q3w+ platinum 75mg/m2 q3w
89162780|NCT04137588||Group B|immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
89162781|NCT04137588||Group C|antiangiogenesis 7.5mg/Kg q3w+immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w
89162782|NCT02721329|Active Comparator|APAP without SensAwake|Auto CPAP delivered from the ICON+ CPAP device.
89162783|NCT02721329|Experimental|APAP with SensAwake|Auto CPAP with SensAwake turned on and set at a pressure of 4cmH2O. SensAwake is a pressure relief function that reduces the CPAP pressure on the transition from sleep to wake.
89162784|NCT02637128|Experimental|artemether-lumefantrine (AL)|"20mg artemether/120 mg lumefantrine per tablet, Coartem-D™; Novartis, Basel, Switzerland administered following manufacturer's prescribed weight-based dosing, twice daily for 3 days.~5-14 kg: 1 tablet; 15-24: 2 tablets; 25-34 kg: 3 tablets; >34 kg: 4 tablets per dose"
89162785|NCT02637128|Experimental|artesunate-amodiaquine (ASAQ)|25mg artesunate/67.5 mg amodiaquine or 50 mg artesunate/135mg amodiaquine per tablet, Coarsucam™; Sanofi-Aventis, Paris, France administered following manufacturer's prescribed weight-based dosing, once daily for 3 days 4.5-8.9 kg: 1 25mg/67.5 mg tablet; 9-17.9 kg: 1 50mg/135 mg tablet; 18-35.9 kg 2 50mg/135 tablets; >36 kg: 4 50mg/135mg tablets per dose
89162786|NCT02624622|Active Comparator|CHW applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. The community health worker is given the chlorhexidine to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
89162787|NCT02624622|Experimental|Mother applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. Mother is given the chlorhexidine during the first prenatal care visit to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
89162788|NCT05353660||chronic kidney disease|
89162789|NCT05353660||maintenance hemodialysis|
89162790|NCT02640092|Experimental|[18F]GTP1|Participants will complete [18F]GTP1 PET imaging at four time points: Baseline, 6 months, 12 months and 18 months. For each [18F]GTP1 imaging session, the following procedure will be performed: a catheter will be placed for intravenous (IV) administration of [18F]GTP1. Participants will receive an IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]GTP1.
89162791|NCT00912054|Experimental|1|DuoTrav APS
89162792|NCT00912054|Active Comparator|2|Xalacom
89162793|NCT00585247|Experimental|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
89162794|NCT00585247|Placebo Comparator|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
89162795|NCT02721407|Experimental|Anti-CD22 CAR-T|Administrated with CD22.CAR-T cells on day 0,1,2 in the lympho-depleted patients
89162796|NCT00688350|Experimental|Behavioral feedback|Behavioral feedback intervention to improve adherence to antihypertensive medication
89162797|NCT00688350|No Intervention|Control|Control group
89162798|NCT02725073|Experimental|photodynamic therapy|Photodynamic therapy with a novel photosensitizer and flexible laser catheter
89162799|NCT04002349|Placebo Comparator|A: Placebo group|Treated by 0.9% Natural saline (NS) nasal spray: 2 sprays each side daily in the morning
89162800|NCT04002349|Experimental|B: Budesonide Nasal Spray (Rhinocort)|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning
89162801|NCT04002349|Experimental|C: Levocabastine Nasal Spray (Livostine)|Treated by Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
89162802|NCT04002349|Experimental|D: Combined Treatment|Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
89162803|NCT04152408|Experimental|FiberSense System|6 diabetic patients will wear a FiberSense system at the upper arm for up to 30 days. and a comparator CGM system at the abdomen (replaced every 7 days).
89162804|NCT02950649||Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed and the data will be used for comparison with routine subjective preoperative assessment assessment.
89162805|NCT02950649||No Hemodynamic Monitored Guided Assesment|This group will have subjective assessment by the provider and this data will be compared to the device assessment of cardiac index..
89162806|NCT05356351|Experimental|test group|RC48-ADC 2.0 mg/kg）D1,Triplizumab 3mg/kg D2，Q2W
89162807|NCT00688428|Experimental|1|combination capsule of Esomeprazole 40mg + ASA 325mg
89162808|NCT00688428|Experimental|2|Esomeprazole 40 mg capsule and ASA 325 mg tablet
89162809|NCT02724761|Experimental|Experimental: Racemic Epinephrine|Over the Counter (OTC) - 0.5 mL Nebulized Racemic Epinephrine
89162810|NCT02724761|Placebo Comparator|Placebo: 0.9% Normal Saline|0.5 mL 0.9% Normal Saline
89162811|NCT00688506|Experimental|1|Combined sono-electro-magnetic therapy
89162812|NCT00688506|Placebo Comparator|2|placebo therapy
89162813|NCT02721095|Experimental|0.9%NaCl|KCl plus 0.9%NaCl
89162814|NCT02721095|Active Comparator|0.45%NaCl|KCl plus 0.45%NaCl
89162815|NCT04350190|Experimental|Apatinib combined with PD-1|Eligible patients begin to use apatinib mesylate tablets and PD-1, apatinib mesylate tablets at the recommended dose of 250mg,oral, QD, continuous administration, 4 weeks (28 days) as an observation cycle. Until the disease progressed or unbearable adverse reactions appeared. If missed medication occurs during the medication period, it is confirmed that the next medication time is less than 12 hours, then there will be no replenishment. The recommended dose of PD-1 is 200mg/time, Q2W, intravenous injection, 4 weeks (28 days) as an observation cycle, until disease progression or intolerable toxicity.
89162816|NCT02624466||CKD - no dialysis|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
89162817|NCT02624466||Patients on PD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and PD fluid, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
89162818|NCT02624466||Patients on HD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and spent dialysate, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
89162819|NCT00993577|Experimental|Exercises|Global Postural Reeducation Static Stretching Exercises
89162820|NCT02721173|Experimental|Tazarotene group|This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.
89162821|NCT02721173|Active Comparator|Adapalene group|This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.
89162822|NCT00713986|Sham Comparator|Noanalgesia|Patients in this group wil receive 2 mL of water PO 2 minutes prior to vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
89162823|NCT00713986|Experimental|Skin-to-skin|Patients in this group wil receive 2mL of water 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
89162824|NCT00713986|Experimental|Glucose|Patients in this group wil receive 2mL of glucose 25% 2 minutes prior vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
89162825|NCT00713986|Experimental|Skin&Glucose|Patients in this group wil receive 2mL of glucose 25% PO 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
89162826|NCT00675324|Active Comparator|A|Traditional bowel preparation with Laxabon
89162827|NCT00675324|Active Comparator|B|Bowel preparation with nutritional drinks
89162828|NCT00993733|Experimental|CVVHDF on-line|CVVHDF using a central water treatment plant, providing dialysate directly to the patient. They will perform a continuous veno-venous haemodiafiltration.
89162829|NCT00993733|Experimental|classical CVVHDF|CVVHDF using a mobile generator with dialysate bags. They will perform a continuous veno-venous haemodiafiltration.
89162830|NCT00692640|Experimental|1|
89162831|NCT05150717|Experimental|[14C]-Jaktinib|Subjects will receive single dose of [14C]-Jaktinib (Suspension, 100mg/150μCi)
89162832|NCT00993811|Experimental|Circumcision|Males undergoing circumcision
88804602|NCT03507452|Experimental|Dose escalation cohort a|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 mg."
88804603|NCT03507452|Experimental|Dose escalation cohort b|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with a total antibody dose within the range of 10 - 50 mg."
88804604|NCT03507452|Experimental|Dose Expansion Cohort 1|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options~Dose / Regimen 1 (to be determined after completion of the dose escalation)"
88804605|NCT03507452|Experimental|Dose Expansion Cohort 2|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options~Dose / Regimen 2 (to be determined after completion of the dose escalation)"
88804606|NCT03507452|Experimental|Dose expansion Cohort 3 (optional)|"Subjects with histologically or cytologically confirmed unresectable, metastatic or locally advanced pancreatic ductal adenocarcinoma~Dose / Regimen to be determined"
88804607|NCT03507452|Experimental|Dose escalation cohort c|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 150 mg mg."
88804608|NCT03507452|Experimental|Dose escalation cohort d|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 400 mg."
88804609|NCT03497897|Experimental|LYS006 20 mg BID|LYS006, 20 mg, orally, twice daily (BID), for 12 weeks
88804610|NCT03497897|Experimental|LYS006 2 mg BID|LYS006, 2 mg, orally, BID, for 12 weeks
88804611|NCT03497897|Placebo Comparator|Placebo BID|Matching placebo, orally, BID, for 12 weeks
89162833|NCT02720939||ASD group|ASD patients who met the diagnostic criteria of either autistic disorder or Asperger's disorder defined by the DSM-IV criteria
89162834|NCT02720939||TD group|Typically development controls without lifetime diagnosis with ASD or any psychiatric disorders
89162835|NCT00725998||1|"The ECAP characteristics have been analyzed in 13 children implanted younger than three years old.~Series Study Results:~During the first year of CI use there was a significant statistical growth for the amplitude of N1 peak, in basal electrodes, between the second and third returns. There were not any significant differences obtained for N1 peak, latency, slope, neither for p-NRT nor recovery time, among the returns."
89162836|NCT02724527|Placebo Comparator|Placebo|Matching capsule (BID administration Q12H)
89162837|NCT02724527|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) at 400 mg dose (100 mg x 4 capsules) (BID administration Q12H)
89162838|NCT04137432|Experimental|Oxytocin (24 IU)|Intranasal administration of 24 international units (IU) of oxytocin (OT) 30 minutes before the start of four intervention sessions
88804612|NCT03493490|Experimental|Neodolpasse|"In the Neodolpasse® arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~Neodolpasse® Infusion Solution combines 75 mg (250 mL) of the NSAID diclofenac with 30 mg of the muscle-relaxant orphenadrine."
88804613|NCT03493490|Active Comparator|Diclofenac|"In the Diclofenac arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~The Infusion solution contains 75 mg (250 mL) of the NSAID diclofenac."
88804614|NCT03493490|Placebo Comparator|Placebo|In the Placebo arm patients receive two physiologic saline infusion (250 mL) over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
89162839|NCT04137432|Placebo Comparator|Placebo|Intranasal administration of a placebo spray 30 minutes before the start of four intervention sessions
89162840|NCT00885170|Experimental|Odanacatib 50 mg|Odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
89162841|NCT00885170|Placebo Comparator|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
89162842|NCT02720783|Experimental|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg|One vaginal pessary (2.7 g) of Econazole nitrate 150 mg plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
89162843|NCT02720783|Active Comparator|Placebo plus Econazole nitrate 150 mg|One vaginal pessary (2,7 g) of Placebo plus Econazole nitrate 150 mg, once daily, for 3 consecutive days
89162844|NCT02720783|Active Comparator|Placebo plus Benzydamine HCl 6 mg|One vaginal pessary (2,7 g) of Placebo plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
89162845|NCT02720783|Placebo Comparator|Placebo|One vaginal pessary (2.7 g) of Placebo, once daily, for 3 consecutive days
89162846|NCT00688584|Experimental|1|
89162847|NCT00688584|Placebo Comparator|2|
89162848|NCT00688584|No Intervention|No intervention control|
89162849|NCT00714064|Active Comparator|23vPPV in Pregnancy|
89162850|NCT00714064|Active Comparator|23vPPV at Birth|
89162851|NCT00714064|Other|Control|Control
89162852|NCT05339503|Experimental|GROUP A (HYDROCHLORIC ACID)|Total 30 teeth in each group were included. Preoperatively shade was checked with VITA classical A1-D4® shade guide. The mixture (hydrochloric acid pumice compound) was applied 10 times or more during the same session. Total treatment time was around 30 minutes. Every patient received entire microabrasion treatment. At the end of the treatment, neutral sodium fluoride gel was applied. Then change in shade was checked again with VITA classical A1-D4® shade guide.
89162853|NCT05339503|Experimental|GROUP B ( SODIUM HYPOCHLORITE)|"Total 30 teeth in each group were included. Preoperatively shade was checked with VITA classical A1-D4® shade guide.The mixture (sodium hypochlorite pumice compound) was applied 10 times or more during the same session. Total treatment time was around 30 minutes. Every patient received entire microabrasion treatment. At the end of the treatment, neutral sodium fluoride gel was applied. Then change in shade was checked again with VITA classical A1-D4® shade guide.~."
89162854|NCT02720705|Active Comparator|DEX I|active comparator receive 0.5µg/kg dexmedetomidine orally half an hour before operation
89162855|NCT02720705|Placebo Comparator|Saline Control|2ml oral 0.9%saline half an hour before operation
89162856|NCT02720705|Active Comparator|DEX II|active comparator receive,1µg/kg dexmedetomidine orally half an hour before operation
89162857|NCT02625792|Experimental|Endo-Clot(TM)|The intervention group
89162858|NCT04019236|Other|" interventional "|New other than Routine nursing care will be used.
89162859|NCT04019236|No Intervention|" Control group "|Routine care only will be done for this group
89162860|NCT02720861||non embolic ischemic stroke|acute ischemic stroke from atherosclerosis or lacunar stroke
89162861|NCT00692796|Experimental|1|
89162862|NCT00726076|Experimental|Treatment|The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment.
89162863|NCT00726076|Experimental|Control|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
89162864|NCT02724605|Other|Group A|Red blood cells unit age 14 days or less
89162865|NCT02724605|Other|Group B|Red blood cells unit age more than 14 days
89162866|NCT00675402||1|Patients referred to the vascularsurgeon with complaints of claudication for their first time, will be asked to participate with the study, with respect toward the in- and exclusion criteria.
89162867|NCT02573818||SEDASYS System|
89162868|NCT05097313|Experimental|consumption of 250 mg of β-glucan|Patients with oral consumption of 250 mg (one capsule) of β-glucan from Yeast Plus once a day for 84 days without interruption.
89162869|NCT05097313|Experimental|consumption of 500 mg of β-glucan|Patients with oral consumption of 500 mg (two capsules) of β-glucan from Yeast Plus once a day for 84 days without interruption.
89162870|NCT05097313|Placebo Comparator|200 mg or 400 mg placebo|Placebo patients, with oral soy protein consumption, half of the group 200 mg (one capsule) and the remaining 400 mg (two capsules) once a day for 84 days without interruption
89162871|NCT02720471|Active Comparator|Locoregional anesthesia|Classical locoregional analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh will be performed in patients of this arm
89162872|NCT02720471|Experimental|Peroperative infiltration|Peroperative infiltration of local anesthetics (IAL) will be performed in patients of this arm
89162873|NCT00688818|Experimental|Quetiapine and existing psychotropics|
89162874|NCT00688818|Placebo Comparator|Placebo and existing psychotropics|
89162875|NCT00726154|Other|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
89162876|NCT00726154|Other|Collaborative care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
89162877|NCT02720549|Experimental|post-ischemic conditioning group|
89162878|NCT02720549|Placebo Comparator|valvular surgery with bypass group|
89162879|NCT00993889|Experimental|VR during Physical Therapy|The subject will receive virtual reality during painful physical therapy sessions.
89162880|NCT00993889|Experimental|VR background pain|The subjects receives virtual reality, not during a physical therapy procedure, another time of the day for background pain.
89162881|NCT00993889|Experimental|No VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
89162882|NCT05143606|Experimental|3D printed simulator|"The participants in this arm will undergo two self-directed training sessions on a custom-made 3D-printed airway simulator. The participants will use a standard intubating fiberoptic bronchoscope to practice fiberoptic-assisted nasal intubation.~The sessions will be one week apart. Each session is 30 minutes per participant."
89162883|NCT05143606|Experimental|Virtual reality software|"The participants in this arm will practice fiberoptic-assisted nasal intubation using the free virtual reality software (AirwayEX) on their mobile phones or computer tablets. Two practice sessions are required by the investigators. The sessions will be one week apart. Each session is 30 minutes per participant.~The participants in this arm will have the opportunity to practice on the software as often as they feel necessary. All the additional practice data will be recorded."
89162884|NCT00688896|Experimental|1|JTT-705 600 mg and pravastatin 40 mg
89162885|NCT00688896|Experimental|2|JTT-705 300 mg and pravastatin 40 mg
89162886|NCT00688896|Placebo Comparator|3|Placebo and pravastatin 40 mg
89162887|NCT02724215||Patients with Sleep Apnea|Patients with increased apnea-hypopnea-index (>5/h)
89162888|NCT02724215||Patients without Sleep Apnea|Patients with normal apnea-hypopnea-index (5/h and below)
89162889|NCT00995137|Experimental|relapse B-Lineage ALL|"All patients meeting the eligibility criteria.~Intervention: NK Cell Infusion"
89162890|NCT00688974||Roux-en-Y gastric bypass|Patients with class 3 obesity and type 2 diabetes submitted to Roux-en-Y gastric bypass
89162891|NCT00688974||Adjustable gastric banding|Patients with class 3 obesity and type 2 diabetes submitted to adjustable gastric banding
89162892|NCT00688974||Healthy controls|Non-obese, non-diabetic adults
89162893|NCT05142280|Experimental|Active choice|This intervention contains information and an assignment to foster an active choice regarding coping with an increased CVD risk. Participants will be presented a hypothetical 'heart age' of 16 years older than their actual age. They will be asked to imagine that this heart age really applies to them. Next, participants will receive information about the meaning of the risk, including its causes and potential consequences, and about four coping strategies: changing one's lifestyle; taking medication; doing both; or changing nothing. The pros and cons of each strategy will be presented, followed by a value-clarification exercise.
89162894|NCT05142280|Other|Control|The control group will receive online information and advice that resembles GP's usual care. The information contains a hypothetical CVD risk: a risk of 31% to get CVD within 10 years. They will be asked to imagine that this risk really applies to them. Participants will read about an imaginary GP who advices to change one's lifestyle (i.e., quitting smoking; healthy diet; more physical activity), and to use medication to decrease the risk.
89162895|NCT02720393|Placebo Comparator|Regular diet|Meals and snacks will contain carrageenan in the amount consumed in the typical daily diet and will be selected by the study dietician and distributed to study subjects randomized to the regular diet study arm.
89162896|NCT02720393|Experimental|No-carrageenan diet|No-carrageenan diet will be composed of meals and snacks selected by the study dietician and distributed to study participants who are randomized to the no-carrageenan diet study arm.
89162897|NCT02640014|Experimental|Study 1: Milk OIT follow up|Follow up on patient with severe milk allergy how have participated to milk OIT.
89162898|NCT02640014|No Intervention|Study 1: Follow up|Follow up on patient with severe milk allergy how have not participated to milk OIT.
89162899|NCT02724293|Placebo Comparator|Group I (placebo)|patients received placebo.
89162900|NCT02724293|Active Comparator|Group II (pregabaline 300 once)|patients received pregabalin 300 mg 2 hours preoperatively.
89162901|NCT02724293|Active Comparator|Group III (pregabaline 300 twice)|patients received pregabalin 300 mg 2 hours preoperatively and 12 hours after the preoperative dose.
89162902|NCT02724293|Active Comparator|Group IV (pregabaline 600)|patients received pregabalin 600 mg 2 hours preoperatively
89162903|NCT00675480|Experimental|T|Patients treated with thrombectomy: T
89162904|NCT00675480|Active Comparator|P|Patients treated with standard PCI with stent implantation
89162905|NCT05092828|Active Comparator|Study Group|Patients in this group will receive intrathecal morphine in addition to standard post-operative pain medications
89162906|NCT05092828|Active Comparator|Control Group|Patients in this group will receive standard post-operative pain medications but will not receive intrathecal morphine
89162907|NCT05327335|Experimental|Intervention Group|Older adults without mobility and/or manipulability difficulties will be treated as reference group while older adults with mobility and/or manipulability difficulties will use the robotics system and integrated environment to perform daily self-care.
89162908|NCT02720159|Experimental|TREATMENT|
89162909|NCT04137198|No Intervention|control|classic analgetic protocol
89162910|NCT04137198|Experimental|intervention|intranasal Sufentanil
89162911|NCT02637206|Experimental|Part 1 (Single Application)|All subjects will have two sets (left and right) of 4 semi-occlusive test patches applied to randomized test sites on their upper backs on Day 1. Test patches on left back will be for simple-patch test and those on right back will be for photo-patch test. Each set will consist of approximately 150 micro liter (0.15 mL) of the following study treatments: GSK2894512 0.5% cream, GSK2894512 1% cream, placebo (cream vehicle without the active ingredient) and an empty patch. The test patches will be applied for 24 hrs (photo-patch test) or 48 hrs (simple-patch test).
89162912|NCT02637206|Experimental|Part 2 (Repeat Application)|All subjects will have repeat applications of GSK2894512 0.5%, 1% cream and placebo twice a day for 7 days on both side (left and right, 3 in total) of their upper back (approximately 5 centimeter (cm) in diameter >10 cm away from another application area) under non-occlusive conditions and covered with gauze using adhesive. GSK2894512 0.5% and 1% cream and placebo will be randomized according to the randomization code in the same manner as Part 1.
89162913|NCT00995293|Experimental|Docetaxel Cisplatin 5-Fluorouracil (DCF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~Docetaxel 60mg/m² on day 1~Cisplatin 75mg/m² on day 1~5-FU 750mg/m²/day on day 1 to day 5"
89162914|NCT00995293|Experimental|Cisplatin 5-Fluorouracil (CF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~Cisplatin 75mg/m² on day 1~5-FU 750mg/m²/day on day 1 to day 5"
89162915|NCT02720315|Experimental|Intensive cryotherapy|Application of ice in a plastic bag wrapped to the patient's site of pain, and kept in place for 20min.
89162916|NCT02720315|No Intervention|Control|Existing pain control practice of physicians and nurses, which includes application of a chemical cold pack.
89162917|NCT02637050||CTEPH Patients|Patients with confirmed diagnosis of CTEPH
89162918|NCT02720003|Experimental|LTX DCB|Patients treated with Bard Lutonix DCB
89162919|NCT00726310||SpineLink® , SpineLink® II Group|Spinal fusion surgery with SpineLink®
89162920|NCT02639936||Immunocompetent controls|Control persons without immunodeficiency with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
89162921|NCT02639936||Solid organ transplant recipients|Patients after solid organ transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
89162922|NCT02639936||Stem cell transplant recipients|Patients after stem cell transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
89162923|NCT02639936||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
89162924|NCT02639936||Patients with chronic renal failure|Patients with chronic renal failure with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
89162925|NCT02639936||Individuals with HIV infection|Individuals with HIV infection with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
89162926|NCT00714142|Active Comparator|1|Normal volunteers
89162927|NCT00714142|Active Comparator|2|Renal failure patients on dialysis
89162928|NCT00714142|Active Comparator|3|Renal artery stenosis patients
89162929|NCT02720237|Experimental|Brief Intervention|Brief Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the ART clinic
89162930|NCT02720237|Experimental|MET+CBT Intervention|MET+CBT Intervention (6 in-person sessions and 3 optional group sessions), study assessment visits, and standard of care from providers at the ART clinic
89162931|NCT02720237|No Intervention|Assessment-Only Control|Study assessment visits and standard of care from providers at the ART clinic
89162932|NCT00692952|Experimental|1|120 subjects using BenZalkonium Chloride Contraceptive Gel
89162933|NCT00692952|Active Comparator|2|120 subjects using Nonoxynol-9 contraceptive gel
89162934|NCT02724137|Experimental|Physical Therapy Rehab and Fitbit®|Standard outpatient physical therapy rehabilitation after total knee replacement with the addition of a Fitbit® to promote physical activity.
89162935|NCT02724137|Active Comparator|Physical Therapy Rehab|Standard outpatient physical therapy rehabilitation after total knee replacement.
89162936|NCT02639858|Experimental|Docetaxel-PM|Docetaxel-PM 75mg/m2 IV infusion
89162937|NCT00726466|Experimental|I|This is an open-label, study of 0.5 mg intravitreal dose of Ranibizumab in combination with 1 mg/kg/wk subcutaneous dose of Efalizumab in in subjects with AMD.
89162938|NCT02694263|Experimental|Canagliflozin + Metformin|Canagliflozin + metformin (using the participant's current dose, or dose recommended by the study clinician). An initial dose of 100mg once daily of Canagliflozin will be prescribed, and this will be titrated up to a maximum of 300mg once daily.
89162939|NCT02694263|Active Comparator|Repaglinide + Metformin|Repaglinide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). An initial dose of 0.5mg once daily where no prior treatment has been given will be prescribed. However, where prior treatment has been in place, an initial dose of 1-2mg once daily will be started and this will be titrated up to a maximum dose of 4mg daily.
89162940|NCT02694263|Active Comparator|Pioglitazone + Metformin|Piogliazone + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Pioglitazone dose will initially be 15mg or 30mg once daily. If the response is inadequate, the maximum daily dosage will be increased to 45mg once daily.
89162941|NCT02694263|Active Comparator|Gliclazide + Metformin|Gliclazide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Gliclazide dose will initially be 40-80 mg once daily, up to maximum dose of 160mg twice daily..
89162942|NCT02694263|Active Comparator|Glimepiride + Metformin|Glimepiride + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). Glimepiride will initially be administered as 1mg once daily, up to a maximum dose of 4mg once daily.
89162943|NCT04162574||BEGIN Case|Enrolled participants with BN/BED will participate in a 30-day observational study.
89162944|NCT04139070|Experimental|Treátment group|8 patients are expected to be included in this study. The patients will be treated once with bleomycin in combination with elektroporation
89162945|NCT00726544|Placebo Comparator|Placebo|
89162946|NCT00726544|Active Comparator|Low Dose|
89162947|NCT00726544|Active Comparator|Medium Dose|
89162948|NCT00726544|Active Comparator|High Dose|
89162949|NCT02719925|Experimental|Mineral water rich in magnesium|- 1,5 L per day of mineral water containing 160 mg/L of magnesium
89162950|NCT02719925|Active Comparator|Water low in magnesium|- 1,5 L per day of mineral water containing 50 mg/L of magnesium
89162951|NCT00693030|Active Comparator|1|Device, Sirolimus drug-eluting stents implanted in overlap
89162952|NCT00693030|Active Comparator|2|Device, paclitaxel polymer drug eluting stent
89162953|NCT00693030|Active Comparator|3|Device, zotarolimus drug eluting stent
89162954|NCT00693030|Active Comparator|4|bare metal coronary stents
89162955|NCT00653822|Experimental|1a|IV
89162956|NCT00653822|Placebo Comparator|1b|IV
89162957|NCT00653822|Experimental|2a|Lower SC dose
89162958|NCT00653822|Placebo Comparator|2b|SC to match lower dose
89162959|NCT00653822|Experimental|3a|Higher SC dose
89162960|NCT00653822|Placebo Comparator|3b|SC to match higher dose
89162961|NCT00653900||1|All patients undergoing elective, invasive cardiac procedure on plavix prior to admission
89162962|NCT04137276|Experimental|vitamin C and thiamine|patients who received intravenous vitamin C and thiamine
89162963|NCT04137276|Active Comparator|thiamine|patients who received thiamine
89162964|NCT02724059|Experimental|Patients with mediastinal lesions|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA
89162965|NCT02636972||Group 1|Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.
89162966|NCT02636972||Group 2A|History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
89162967|NCT02636972||Group 2B|History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
89162968|NCT02636972||Group 3|Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.
89162969|NCT02636972||Group 4|Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).
89162970|NCT02636972||Group 5|Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use
89162971|NCT02636972||Group 6|Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).
89162972|NCT02723981|Experimental|COMBO-Stent|Implantation of COMBO-Stent and medication with (N)OAC and clopidogrel for 3 months followed by (N)OAC alone
89162973|NCT02723981|Active Comparator|Any Drug eluting or bare metal stent|Implantation of any drug eluting oder bare metal stent combined with anticoagulant medication according to ESC guidelines
89162974|NCT00912444|Experimental|TAC Arm|six cycles of neoadjuvant Docetaxel, Anthracycline and Cyclophosphamide
89162975|NCT00912444|Experimental|TC Arm|six cycles of neoadjuvant Docetaxel and Cyclophosphamide
89162976|NCT02644525|Placebo Comparator|Placebo|Subjects given vitamin placebo
89162977|NCT02644525|Experimental|Imatinib 200mg|Subjects given a single dose of imatinib 200mg PO
89162978|NCT02644525|Experimental|Imatinib 400mg|Subjects given a single dose of imatinib 400mg PO
89162979|NCT02644525|Experimental|Imatinib 600mg|Subjects given a single dose of imatinib 600mg PO
89162980|NCT02636894|Other|Restylane Silk|Restylane Silk
89162981|NCT00726700|Active Comparator|Arm I (without rituximab)|Patients receive pegfilgrastim subcutaneously (SC) on day 2 or 4 and CHOP comprising cyclophosphamide IV, doxorubicin IV, vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 2 weeks for up to 6-8 courses in the absence of disease progression or unacceptable toxicity.
89162982|NCT00726700|Experimental|Arm II (with rituximab)|Patients receive pegfilgrastim and CHOP for up to 6-8 courses as in arm I. They also receive rituximab (administered 2 hours before beginning CHOP) on day 1. Treatment with rituximab repeats every 2 weeks for up to 8 courses.
89162983|NCT02535962|Experimental|Corticosteriod + Probiotic Treatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.~Investigational drug (Intervention is Lactobacillus acidophilus and Bifidobacterium lactis): Patients will be instructed to take one sachet of the study product mixed into a 60 ml of water that is not hot. Each sachet will contain Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 at a dose of 5*109 CFU of each strain. The investigational product will be taken daily for the duration of the study, which is a year."
89162984|NCT02535962|Placebo Comparator|Corticosteriod + PlaceboTreatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.~Placebo: will be taken daily and patients will be instructed to take one sachet of placebo mix into 60ml of water that is not to hot. The placebo will be taken daily for the duration of the study, which is one year. Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product."
89162985|NCT02723903|Other|with CAD and somatic symptom|Patients with the coronary artery disease and with the somatization symptom, the investigators treat the patients according to the guideline for coronary artery disease and anti-somatic agents (Deanxit, Prozac according to the somatization type)
89162986|NCT02723903|Other|without CAD, with somatic symptom|Only somatic symptom is presented, anti-somatic agents is prescribed (Deanxit, Prozac according to the somatization type)
89162987|NCT02723903|No Intervention|without CAD, without somatic symptom|Have neither coronary artery disease nor somatic symptom, continue follow-up.
89162988|NCT02723903|Other|with CAD, without somatic symptom|Patient with the coronary artery disease, without the somatization symptom, the investigators treat the patients according to coronary artery disease treatment guideline including coronary artery stent implantation,medication according to the severity of stenosis of the coronary arteries.
89162989|NCT00675714|Experimental|1|Humatrope subcutaneous(SQ) 0.05-0.2 mg/kg/day for up to 2 years post burn
89162990|NCT00675714|Experimental|2|Ketoconazole by mouth (PO) given twice a day throughout hospitalization for up to 2 years post burn
89162991|NCT00675714|Experimental|3|Oxandrolone PO given daily throughout hospitalization for up to 2 years post burn
89162992|NCT00675714|Experimental|4|Propranolol PO given daily throughout hospitalization for up to 2 years post burn
89162993|NCT00675714|Experimental|5|Oxandrolone and propranolol PO to be given daily for up to 2 years post burn
89162994|NCT00675714|Experimental|6|Humatrope SQ and Propranolol PO to be given daily for up to 2 years post burn
89162995|NCT00675714|Placebo Comparator|7|Placebo PO to be given for up to 2 years post burn
89162996|NCT00675714|Experimental|8|Exercise--hospital supervised intensive exercise program
89162997|NCT00675714|Experimental|9|Exercise--home or community based exercise program
89162998|NCT00656240|Experimental|1|
89162999|NCT00656240|Experimental|2|
89163000|NCT00729976|Experimental|1|Ibuprofen Suppository
89163001|NCT00729976|Active Comparator|2|Ibuprofen suspension
89163002|NCT00656318||Group 1 (Zovia)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
89163003|NCT00656318||Group 2 (Necon)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
89163004|NCT02451553|Experimental|Treatment (afatinib dimaleate, capecitabine)|Patients receive afatinib dimaleate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89163005|NCT02719301||Men/Women between 18 & 85|Accepting both healthy and non-healthy subjects. A portion of the subjects will have a fluid management issue or heart failure.
89163006|NCT04065646|Experimental|Intervention|The intervention group will receive daily text messages with information on: (i) HMM stop locations and schedule; (ii) information on HMM weekly produce specials and sales; (iii) motivational messages encouraging use of the HMM; and (iv) links to produce coupons that they can exchange at HMM- $5 coupons received weekly for the four-week texting period.
89163007|NCT04065646|No Intervention|Control|The control group will receive the same dosage of daily text messages covering free activities taking place at the Hartford Public Library and other community locations. The control group will not receive incentive coupons.
89163008|NCT02636816|Experimental|Infusion|carbetocin is given slowly
89163009|NCT02636816|Active Comparator|Bolus|carbetocin is given quickly
89163010|NCT02723825|Placebo Comparator|Less or equal to 2mm|the residual displacement is less than or equal to 2mm
89163011|NCT02723825|Placebo Comparator|Between 2-4mm|the residual shift is between 2-4mm, manual reset once again, as still between 2-4mm
89163012|NCT02723825|Active Comparator|Greater than 4mm|the residual displacement is greater than 4mm
89163013|NCT00730054|Active Comparator|1|Clonidine
89163014|NCT00730054|Active Comparator|2|Remifentanil
89163015|NCT00730054|Experimental|4|Remifentanil+clonidine
89163016|NCT00730054|Placebo Comparator|3|Placebo
89163017|NCT00866619|Experimental|GSK257049 [5-17M] Group|Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
89163018|NCT00866619|Experimental|GSK257049 [6-12W] Group|Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
89163019|NCT00866619|Active Comparator|VeroRab Comparator [5-17M] Group|Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
89163020|NCT00866619|Experimental|Menjugate Comparator [6-12W] Group|Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
89163021|NCT00693108|Experimental|1|Transdermal testosterone treatment during the five days preceding gonadotropin therapy in IVF cycles
89163022|NCT00693108|No Intervention|2|
89163023|NCT02913131|Experimental|Part A: Feasibility Run-In|Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s).
89163024|NCT02913131|Experimental|Part B: Biomarker Cohort|Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.
89163025|NCT00689286|Experimental|"BION twitch stimulation"|"The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation."
89163026|NCT00689286|Experimental|BION tetanic-frequency stimulation|The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions.
89163027|NCT00689286|No Intervention|Standardized program|A third group of experimental subjects will have a standardized program of voluntary exercise.
89163028|NCT03342274|Experimental|Lifestyle Program Intervention|Participants receive usual care and group weight loss sessions adapted from the Diabetes Prevention Program delivered by Community Health Workers.
89163029|NCT03342274|Other|Wait list|Participants receive usual care and after 1 year receive the Lifestyle Program intervention
89163030|NCT00884390|Experimental|ReFacto AF|
89163031|NCT02723669|Experimental|AR10|AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g)
89163032|NCT02723669|Active Comparator|acetylcysteine|acetylcysteine solution; oral 20% (200 mg/mL)
89163033|NCT03269500||malnourished older people|The hospitalized elderly with swallowing and/or Mastication problems.
89163034|NCT02719379|Experimental|Asthmatics|19-20 year old asthmatics who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. They will also be follow up after 1 year to assess for asthma control and outcomes. This arm will additionally allow for comparison of asthma outcomes and vaccine response
89163035|NCT02719379|Active Comparator|Non-asthmatics|19-20 year old non-asthmatic smokers who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. This arm will allow for comparison of vaccine response between asthmatics and non-asthmatics (smokers)
89163036|NCT02719379|Other|Asthmatics - Serum Stored|Once the accrual for the experimental arm is met, 19-20 year old asthmatics who wish to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. This arm will allow for study of baseline vaccine titers to pneumococcus in asthmatics at same time increase the vaccine uptake in the community.
89163037|NCT00689364||CTTCT+CWMT|"CTTCM:taking TCM decoction based on syndrome differentiation daily and each dosage is decocted two times for intervention one year with a Chinese patent medicine at least.~CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline)."
89163038|NCT00689364||CWMT cohort|CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).
89163039|NCT02569528||Patients|Patients of consenting providers will complete a short survey and interview.
89163040|NCT02569528||Providers|Physicians treating patients with atrial fibrillation will complete a short survey and interview.
89163041|NCT02719223|Experimental|High Flux Hemodialysis|
89163042|NCT02719223|Experimental|OL-HDF|
89163043|NCT04139148|Active Comparator|True tDCS Combined With CCAT|Ture transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including drug knowledge every week, self-evaluation every two weeks and outpatient follow-up reminder every four weeks.
89163044|NCT04139148|Sham Comparator|Sham tDCS Combined With CCAT|Sham transcranial direct current stimulation (tDCS) intervention combined with computerized cognitive addiction therapy(CCAT) group, last 25 minutes per day for 4 weeks(5 days/week). Electronic follow-up for 6 month including only outpatient follow-up reminder every four weeks.
89163045|NCT04139148|No Intervention|Control group|During the treatment, the participants in control group only received treatment such as education of psychology, health and judicature, physical training as well as vocational training as usual in the compulsory rehabilitation center.
89163046|NCT04065412|Active Comparator|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed to localize the cricothyroid membrane
89163047|NCT04065412|Experimental|Modified laryngeal handshake technique|The modified laryngeal handshake is performed to localize the cricothyroid membrane
89163048|NCT00689442|Experimental|1|JTT-705 600 mg and atorvastatin 20 mg
89163049|NCT00689442|Placebo Comparator|2|Placebo and atorvastatin 20 mg
89163050|NCT02719457|Other|6 minute walk test (6 MWT)|patients will be perform the six minute walk test (6 mwt) to evaluate their exercise capacity.
89163051|NCT02719457|Other|spot marching test (SMT)|patients will be perform the spot marching test (SMT) to evaluate their exercise capacity.
89163052|NCT02570386|Active Comparator|Control arm|Women allocated to the control arm will either undergo fresh embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
89163053|NCT02570386|Active Comparator|Intervention arm|Fresh embryo transfer will not be undertaken in this group. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
89163054|NCT02625636|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions
89163055|NCT02625636|Experimental|SAR438544 dose 2|Single dose of SAR438544 given SC under fasting conditions
89163056|NCT02625636|Experimental|SAR438544 dose 3|Single dose of SAR438544 given SC under fasting conditions
89163057|NCT02625636|Placebo Comparator|Placebo|Single dose of placebo given SC under fasting conditions
89163058|NCT02625636|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions
89163059|NCT02625636|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions
89163060|NCT02719145||Control group (group 1)|10 healthy volunteer subjects.
89163061|NCT02719145||Asthma group (group 2)|10 asthmatic patients.
89163062|NCT02719145||COPD group (group 3)|10 COPD patients.
89163063|NCT03012100|Experimental|Arm I (FRalpha peptide vaccine, sargramostim)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of cycle 1 only. Starting cycle 2, patients receive multi-epitope folate receptor alpha peptide vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
89163064|NCT03012100|Placebo Comparator|Arm II (placebo, sargramostim)|Patients receive cyclophosphamide as in Arm I. Starting cycle 2, patients receive placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
89163065|NCT02379247|Experimental|Dose level 1 BYL-719/alpelisib (250mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 250mg daily on day 1-28~Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
89163066|NCT02379247|Experimental|Dose level 2 BYL-719 (alpelisib) (300mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 300mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
89163067|NCT02379247|Experimental|Dose level 3 BYL-719 (alpelisib) (350mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 350mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
89163068|NCT02379247|Experimental|BYL-719 (alpelisib) Dose Expansion|"BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
89163069|NCT00689520|Experimental|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months.
89163070|NCT00689520|Active Comparator|acenocoumarol|tinzaparin for 1 weeks followed by acenocoumarol for 6 months
89163071|NCT02719067||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV and ICD-10 criteria
89163072|NCT02719067||TD group|Typically developing controls without lifetime ASD or a family history of ASD
89163073|NCT00693186|Experimental|1|
89163074|NCT00693186|Experimental|2|
89163075|NCT05308615|Experimental|Active (Investigational Product)|"Investigational (Active) product:~Rhea® Health Tone (1.8 mg of Gardenia jasminoides; 1.8 mg Commiphora myrrha oil; 1.8 mg Boswellia serrata oil; 1.8 mg Daucus carota oil; 1.8 mg of Foeniculum vulgarae oil and 0.99 mg of Olea europeae oil or Olive oil as a solvent.)~Regimen:~Subjects will receive Rhea® Health Tone 2 times supplementation 1 ml a day for 84 days"
89163076|NCT05308615|Placebo Comparator|Placebo (Control Product)|"Placebo (Control Product):~Using olive oil without the active ingredients contained in the Rhea® Health Tone test product.~Regimen:~Subjects will receive Placebo 2 times supplementation 1 ml a day for 84 days"
89163077|NCT00693264|Experimental|1|Participants will take 1- 750 mg capsule of Hoodia gordonii and have the primary and secondary outcomes measured over an 8 hour visit.
89163078|NCT00693264|Placebo Comparator|2|Participants will take a placebo capsule and have the primary and secondary outcome measures taken over an 8 hour study day.
89163079|NCT02723279|Experimental|EPNS group|
89163080|NCT02723279|Active Comparator|TT group|
89163081|NCT02615301|Experimental|Salmon (HD+HK)|Tailor-made salmon with high levels of vitamin D3 and K1
89163082|NCT02615301|Experimental|Salmon (LD+HK)|Tailor-made salmon with low levels of vitamin D3 and high K1
89163083|NCT02615301|Experimental|Salmon (HD+LK)|Tailor-made salmon with high levels of vitamin D3 and low K1
89163084|NCT02615301|Experimental|Supplement (vitamin D + Calcium)|Supplement with vitamin D and Calcium
89163085|NCT00994045|Active Comparator|Fresh Frozen Plasma|
89163086|NCT00994045|Experimental|Fibrinogen concentrate|
89163087|NCT02570230|Placebo Comparator|Control|NSS infusion
89163088|NCT02570230|Experimental|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
89163089|NCT00693342|Experimental|Arm I|Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
89163090|NCT00693342|Experimental|Arm II|Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
89163091|NCT00697905|Experimental|A|
89163092|NCT00697905|Active Comparator|B|
89163093|NCT04785898|Other|Screening patients COVID-19 test|"As part of the patient's management, two nasopharyngeal swabs will be taken from the same nostril:~The first swab will be sent to the microbiology laboratory for analysis with the Simplexa ™ COVID-19 Direct assay so as not to impact the patient's diagnostic result.~The second swab taken as part of the research will be analyzed with the ID NowTM COVID-19 test located in the UAS by one of the nurses trained and authorized to use it. The choice to perform the ID Now ™ COVID-19 test in the emergency room and not in the laboratory is based on the supplier's instructions. Indeed, the nasopharyngeal swab is intended to be analyzed directly and not to be transported in a container which could hinder the quality of the sample.~The discomfort or pain felt by the patient during the first sample can possibly influence the quality of the second. This could induce a bias. To minimize this bias, staff will be specifically trained in sampling."
89163094|NCT02718755|Experimental|Fludarabine + Cytarabine + Erwinase|"Induction Phase: Participants receive 1-2 cycles during the Induction phase.~Participants receive 1-2 cycles during the Induction phase.~Participants receive Fludarabine by vein on Days 1-5 and Cytarabine by vein.~Participants receive Erwinase by vein or as an injection into the muscle on Days 1-7.~Consolidation Phase: Participants receive up to 3 cycles during the Consolidation phase.~Participants receive Fludarabine by vein on Days 1-4 and Cytarabine by vein.~On Day 1 and then every other day for 15 days (3, 5, 7 and so on), participant receives Erwinase by vein or as an injection into the muscle."
89163095|NCT00730210|Active Comparator|a: PTH (1-84) 100 ug s.c.inj. once a day|PTH (1-84) 100 ug subcutaneous injections once a day
89163096|NCT00730210|Placebo Comparator|b: placebo 100 ug s.c. inj. once a day|placebo 100 ug sub cutaneous injection once a day
89163097|NCT02614989|Experimental|MRI guided Focused Ultrasound treatment|"MRI guided focused ultrasound thalamotomy~Patients will undergo unilateral thalmotomy using MRI guided Focused Ultrasound intervention for the treatment of the tremor"
89163098|NCT04132089|No Intervention|Control|This was the control group for the messaging component of the study (push notifications). These participants only received the mobile health application called capABILITY without messages.
89163099|NCT04132089|Other|Facilitator Message Group|This group of participants received the mobile health application called capABILITY and received three facilitator messages per week. Facilitator messages are designed to help people who lack ability to do something.
89163100|NCT04132089|Other|Spark Trigger Group|This group of participants received the mobile health application called capABILITY and received three spark messages per week. Spark messages are designed to help people who lack ability to do something.
89163101|NCT00730288|Experimental|1|Received monovalent Vero dengue vaccine in Study DIV12
89163102|NCT00730288|Experimental|2|Received Yellow fever vaccine in Study DIV12
89163103|NCT00730288|Experimental|3|Flavivirus-naive subjects
89163104|NCT02718989|Experimental|10 Kilohertz (KHz)|"Transcutaneous application of 10 Kilohertz (KHz) current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
89163105|NCT02718989|Experimental|Transcutaneous Electrical Stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 100 Hz and pulse width 100 microseconds"
89163106|NCT02718989|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
89163107|NCT00872898|Experimental|1|Once daily oral administration of memantine for 12 weeks.
89163108|NCT00872898|Placebo Comparator|2|Once daily oral administration of placebo for 12 weeks.
89163109|NCT02723435|Experimental|Midostaurin|Beginning 30 days post-HCT, participants receive oral midostaurin twice-a-day in 28-day treatment cycles, continuing up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89163110|NCT02718677||1. Refacto AF (NIS)|Non-Interventional Study
89163111|NCT04132011|Active Comparator|Shortened interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals less than every 12 hours.
89163112|NCT04132011|Active Comparator|Standard interval extended release opioid|Extended release opioid, individualized total daily dose, dosing intervals every 12 hours
89163113|NCT02723357|Experimental|Financial Coaching & Access to Services|Participants in this arm will receive monthly financial coaching and access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
89163114|NCT02723357|Active Comparator|Access to Services|Participants in this arm will receive access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
89163115|NCT00697983||Fracture cohort|Patients of 50 years and above with a clinical, non-pathological fracture, who attend an osteoporosis outpatient clinic at the Maastricht University Medical Center for standard medical care (including bone densitometry by DXA-scan).
89163116|NCT02723123|Experimental|CPAP|CPAP will be provided for a approximately 45 minutes.
89163117|NCT02723123|Experimental|NIPPV|NIPPV will be provided for a approximately 45 minutes.
89163118|NCT02723123|Experimental|NIV-NAVA|NIV-NAVA will be provided for a approximately 45 minutes.
89163119|NCT00693576|Experimental|A|patients who will take simvastatin 20 mg daily
89163120|NCT00698061|Experimental|Group A|
89163121|NCT00698061|Active Comparator|Group B|
89163122|NCT04116047|Active Comparator|Arm 1 (control): chemoradiotherapy|Concomitant chemoradiotherapy, 3-weekly cisplatin 100mg/m2 or weekly 40mg/m2 with Intensity Modulated Radiotherapy (IMRT) using 70 gray (Gy) in 35F(fractions) +/- neck dissection as indicated by clinical and radiological assessment 3-months post treatment. This is the international gold standard.
89163123|NCT04116047|Experimental|Arm 5: Durvalumab + Arm 1|One dose of induction durvalumab 1500mg by intravenous (IV) infusion followed by arm 1 within four weeks. Within one-two weeks after the completion of arm 1, durvalumab 1500mg every four weeks will be initiated for a total of 6 months
89163124|NCT00693732|Active Comparator|1, IBS patients|
89163125|NCT00693732|Experimental|2,Healthy controls|
89163126|NCT04132245|Experimental|obesity prevention|Families were randomized to an obesity prevention intervention arm or a general health control arm.
89163127|NCT04132245|Experimental|behavioral intervention|there are two arms in this study. An active intervention arm and a control arm
89163128|NCT00689598|Placebo Comparator|III|Placebo
89163129|NCT00689598|Experimental|Experimental|Drug intervention
89163130|NCT04131777||Roll-in|Initial patients enrolled until optimal RF algorithm is determined
89163131|NCT04131777||Optimized|Patients treated using optimal RF algorithm
89163132|NCT00884312|Experimental|Carfilzomib|Participants received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.
89163133|NCT02693873|Other|Single Arm Study:|All participants will receive GLA:D Canada, an education and neuromuscular exercise program
89163134|NCT00689676||Study Group|20 very low birth weight preterm toddlers
89163135|NCT00689676||Control Group|20 full-term toddlers
89163136|NCT04131699||pediatric thoracoscopic group|record hemodynamic changes and cardiac output at different intrathoracic pressures ( insufflation pressures 4, 5, 6 mmHg)
89163137|NCT00689754|Active Comparator|NGA|Patients will receive the standard of care to proceed with nasogastric tube placement, aspiration and lavage up to 1L of normal saline
89163138|NCT00689754|No Intervention|NO NGA|Patient presenting with Upper GI hemorrhage going straight to endoscopy.
89163139|NCT04131855|Active Comparator|Pumice prophylaxis.|Will receive pumice prophylaxis in a slurry of plain pumice and water for 5 seconds per tooth using a rubber cup in a slow contra-angle handpiece. The teeth involved will then be washed and dried prior to using the self etch primer.
89163140|NCT04131855|Experimental|No pumice prophylaxis.|Will not receive pumice prophylaxis. Teeth will be washed and dried before using the self etch primer.
89163141|NCT02722889||Healthy controls|Healthy control patients
89163142|NCT02722889||Type A dissection|Patients with proven type A dissection,
89163143|NCT04163354|Active Comparator|NaF varnish|Application of a 5% NaF varnish (Duraphat, Colgate-Palmolive Ltd, Waltrop, Germany) on the occlusal surfaces of primary second molars and all other teeth, every 3 months during the study period;
89163144|NCT04163354|Experimental|GI sealant|Glass ionomer sealant (GC Fuji VII® (pink)) on all primary second molars included in the studies, with no further repair/replacement of the sealant
89163145|NCT04131621|Experimental|Nivolumab/Ipilimumab|
89163146|NCT02718365|Experimental|Group A|Wedge resection
89163147|NCT02718365|Active Comparator|Group B|Segmentectomy
89163148|NCT00689832|Experimental|A|
89163149|NCT00689832|Active Comparator|B|
89163150|NCT00653978|Experimental|1|patients receiving one stent
89163151|NCT00653978|Active Comparator|2|patients receiving two stents
89163152|NCT02718521|Experimental|Hydration Therapy Combined With Isosorbide Dinitrate|Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography
89163153|NCT02718521|Active Comparator|Conventional hydration group|normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography
89163154|NCT04131543|Experimental|Cabozantinib|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
89163155|NCT02718443|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
89163156|NCT00689988|Experimental|SG|Study Group: five children with Down syndrome submitted to speech-language intervention with AAC intervention
89163157|NCT02723045|Active Comparator|Open modified Lichtenstein repair|Patients will undergo open repair of their inguinal hernias
89163158|NCT02723045|Active Comparator|Laparoscopic TEP inguinal hernia repair|Patients will undergo laparoscopic repair of their inguinal hernias
89163159|NCT04131465|Experimental|Home HIV self-testing|Fieldworkers will visit potential participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing.
89163160|NCT04131465|Experimental|Home HIV rapid testing|Fieldworkers will visit potential participants in their homes and offer home-based HIV rapid testing and counselling.
89163161|NCT04131465|Experimental|Home HIV self-testing and rapid testing|Fieldworkers will visit participants in their homes and offer 3 oral HIV self-testing kits with a short introduction to HIV self-testing as well as home-based HIV rapid testing and counselling.
89163162|NCT02718599|Active Comparator|Terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
89163163|NCT02718599|Placebo Comparator|CONTROL|Patients receive the same volume of 0.9% saline in place of terlipressin for the same duration(50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours).
89163164|NCT00693888|Experimental|interventional group|individual comprehensive primary advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)
89163165|NCT00693888|No Intervention|Control group|only informative flyer, no further advice in any direction
89163166|NCT04016064|Other|group 1;|Er:YAG laser
89163167|NCT04016064|Other|group 2|Nd:YAG laser
89163168|NCT04016064|Other|group 3|Electrosurgery
89163169|NCT04112381|Experimental|Exablate Secondary Procedure|Thalamotomy
89163170|NCT00693966|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
89163171|NCT00693966|Experimental|Group B|Formulation 2 of the vaccine
89163172|NCT00693966|Experimental|Group C|Formulation 3 of the vaccine
89163173|NCT00693966|Experimental|Group D|Formulation 4 of the vaccine [with Al(OH)3]
89163174|NCT02718287|Experimental|Treatment:|Home visiting with PCCSF
89163175|NCT02718287|Experimental|Control|Home visiting no PCCSF
89163176|NCT02655575|Experimental|BI + VR + CBT|"Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Vestibular Rehabilitation (VR) includes active exercises that provokes dizziness, Balance exercises and body awareness exercises in a group format.~Cognitive Behavioral Therapy (CBT) includes conversation and reflection about factors that may be a barrier to Activity and participation"
89163177|NCT02655575|Active Comparator|BI + phone calls|Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Phone Calls as follow-up at week 2 and 6 to reassure
89163178|NCT00694044|Active Comparator|Weekly titration|
89163179|NCT00694044|Active Comparator|Two Week QD|
89163180|NCT00694044|Active Comparator|Two Week BID|
89163181|NCT00694044|Placebo Comparator|Placebo|
89163182|NCT02722811|Experimental|Etanercept treatment group|Subcutaneous injection etanercept of 50 mg/w and Health education, exercise and diet guidance; treatment: 8 weeks
89163183|NCT02722811|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 8 weeks
89163184|NCT04136886|Active Comparator|IMRT and concurrent cisplatin|IMRT and concurrent cisplatin to treat T3/T4 locally recurrent NPC patients. Cisplatin 100mg/M2 is to give D1,D22 of IMRT for 2 cycles. IMRT is to give GTV 60Gy in 27 fraction
89163185|NCT04136886|Experimental|IMRT alone|IMRT alone to treat T3/T4 locally recurrent NPC patients. IMRT is to give 60Gy in 27 fraction
89163186|NCT02718209|Experimental|Frozen section|Frozen sections taken from women operated on for possible gynecologic malignancies.
89163187|NCT00690144|Experimental|simulation group|the trainees in the simulation group receive simulation-based training
89163188|NCT02717975|Active Comparator|Without valve|"Trial removal of catheter without catheter valve in patients with urinary retention. These are those patients who have catheter on free drainage, attend the clinic for catheter removal and bladder to be filled naturally ( which may take upto 4-5 hours). After removal of catheter they will be asked to drink plenty of fluids while waiting for the bladder to fill up.~This is the traditional method of catheter removal."
89163189|NCT02717975|Experimental|With valve|"Trial removal of catheter in patients with urinary retention with closed catheter valve. These patients will be asked to close the valve 3-4 hours before attending the clinic prior to catheter removal. Here the intervention is catheter valve that allows bladder to be comfortably full by the time patient arrives in the clinic. By this intervention the investigators hypothesise that the investigators can save the clinic time as the patient will not need to wait for natural bladder filling which generally takes 4-5 hours.~Intervention: Urinary catheter valve"
89163190|NCT04136964||Patients group|Patients who have pain located in the anatomical region of the neck for more than three months due to mechanical causes; with or without radiation to the head, trunk, and upper limbs. Posteriorly, pain may be present in the neck region from the superior nuchal line to the spine of the scapula and the side region down to the superior border of the clavicle and the suprasternal notch.
89163191|NCT02625870|Experimental|Omega-3-Acid Ethyl Esters 90 Soft Capsules|
89163192|NCT02625870|Placebo Comparator|Corn Oil|
89163193|NCT02718053||spasticity|patients affected by spasticity of the lower limbs
89163194|NCT02718053||controls|healthy subjects
89163195|NCT05298852||Study population|This is a prospective multicenter study that included patients aged more than 21 years old with different clinical presentations other than pulmonary manifestation presenting to different healthcare facilities from June to December 2020. HRCT scan of the chest in order to detect COVID-19 patients was offered after signing an informed consent. Demographic data, clinical presentations, laboratory data, oxygen saturation, radiological findings in HRCT scan of the chest, SARS-CoV-2 PCR results and the need for mechanical ventilation were reported. Effects of different baseline characteristics, findings in HRCT scan of the chest on patient outcomes were analyzed.
89163196|NCT00534313|Active Comparator|Abatacept (30/10)|Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg) thereafter.
89163197|NCT00534313|Active Comparator|Abatacept (10/10)|Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg).
89163198|NCT00534313|Active Comparator|Abatacept (3/3)|Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.
89163199|NCT00534313|Placebo Comparator|Placebo|Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.
89163200|NCT00694434||1|Patients with 2 or more frozen blastocyst that scored GES 70 or better in the fresh cycle.
89163201|NCT00694434||2|Patients with 2 or more frozen blastocysts scoring GES <70 in the fresh cycle.
89163202|NCT02722655||Type 1 diabetes mellitus|Sudden onset of symptoms and non-overweight/obese
89163203|NCT02722655||Type 2 diabetes mellitus|Insidious onset of symptoms and overweight/obese
89163204|NCT02722655||Type 1.5 diabetes mellitus|Overlap of type 1 and type2 diabetes mellitus clinical characteristics
89163205|NCT02722655||Other types of diabetes mellitus|According American Diabetes Association criteria
89163206|NCT00694512|Placebo Comparator|1|low fat diet for two weeks.
89163207|NCT00694512|Active Comparator|2|High fat diet for two weeks followed by blood sampling.
89163208|NCT00694512|Active Comparator|3|Medium Chain Triglyceride diet
89163209|NCT00694200|Experimental|1|Vinorelbine metronomic + bevacizumab
89163210|NCT02722733|Active Comparator|G-CSF (filgrastim)|1.G-CSF at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days.
89163211|NCT02722733|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|"Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2).~G-CSF 5-10 μg/kg per day (divided into two doses every 12 hours) will be started on day 5 subcutaneously and continued until last leukapheresis."
89163212|NCT02617368||KC group|KC group included patients those were diagnosed and classified for moderate keratoconus according to the Amsler-Krumeich classification system
89163213|NCT02617368||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
89163214|NCT02617368||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
89163215|NCT02617290|Experimental|Ticagrelor Arm|Ticagrelor is an oral antiplatelet agent which was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. It is available as round, yellow tablets (90 mg). The standard dose is 90 mg twice a day during the maintenance phase and 180 mg once for the loading dose. It is approved for duration of 12 month in ACS patients and will be used for duration of one month in the ALPHEUS Study.
89163216|NCT02617290|Active Comparator|Clopidogrel Arm|Clopidoprel is an oral antiplatelet agent which was approved for use in the European Union by the European Commission in 1997 and available as generic since 2007. The standard dose of clopidogrel is one 75 mg tablet once a day. The dosage for the loading dose is normally 300 mg but 600 mg is also used. Clopidogrel is the standard of care for PCI at the moment.
89163217|NCT02717819|Experimental|Resistance training and protein|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x 125 ml protein-enriched, milk-based supplements (whey protein), in the same period (additional ~25 g protein and 1953 kJ per day). Daily vitamin D supplements.
89163218|NCT02717819|Placebo Comparator|Resistance training and placebo|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x125 ml iso-energetic placebo-supplements, in the same period. Daily vitamin D supplements.
89163219|NCT04134858|Experimental|The health coaching group|The experimental group (n = 52) consisted of frequent attenders who had chosen the health-coaching program. The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
89163220|NCT04134858|No Intervention|The control group|The control group consisted of 58 frequent attenders. They, along with the experimental group, received the usual care regarding their health problems from the physicians and nurses at the primary healthcare centres if they needed it. The usual care for frequent attenders included assessment for the need of treatment, physical examination, problem assessment, laboratory and X-ray tests, medical advice and patient support and education during their visits.
89163221|NCT02007655||Eliquis on Nonvalvular Atrial Fibrilliation patients|Patients who are beginning to receive the treatment with Eliquis under the approved indications, dosage, and administration will be included in this study
89163222|NCT02717741|Experimental|tafetinib|tafetinib administered daily for 2 weeks, followed by a 1-week off period
89163223|NCT05298618||All Participants|All patients undergoing CPB with dNC cardioplegic arrest shall have two magnesium levels measured. The first sample shall be taken prior to magnesium administration and within 30 minutes of cross-clamp removal. The second sample will be drawn 10 +/- 5 minutes after cross-clamp removal and magnesium administration. Magnesium levels will be analyzed and compared against normally expected values.
89163224|NCT00995605|Experimental|Groups SAD|AMAP102 or Placebo as single ascending doses in five groups
89163225|NCT00995605|Experimental|Groups MAD|AMAP102 or Placebo as multiple ascending doses twice daily for seven days in two groups
89163226|NCT02717585|No Intervention|Control Group|For the no intervention group (Control), patients will only receive standardized treatment for FM at the Pain Clinic. All patients will receive a multifaceted tailored regimen that incorporates one or more lines of pharmacological and/or non-pharmacological therapy. All assessment and management will be performed according to evidence-based therapeutic recommendations put forward by the Canadian Rheumatology Association and Canadian Pain Society.
89163227|NCT02717585|Active Comparator|Treatment Group (CPAP)|In addition to standard FM treatment at the Pain Clinic, patients who are randomized to the treatment will meet with a sleep physician for possible therapy with a Continuous Positive Airway Pressure (CPAP) machine. A CPAP titration study will be arranged for in a laboratory setting, where in addition to the regular parameters of a diagnostic sleep study, CPAP will be titrated upwards starting from 5cm H2O to an optimal setting where the obstructive respiratory events are abolished. Patients will undergo regular follow-up as determined by their sleep physician. Adherence to CPAP treatment will be recorded at follow-up visits.
89163228|NCT05298462|Other|Patients|
89163229|NCT05298462|Other|Hospital staff|
89163230|NCT00995683|Experimental|half sodium lactate|infusion of 0.5 ml/kg/day during 48 hours
89163231|NCT00995683|Active Comparator|isotonic sodium chloride|infusion of 0.5 ml/kg during 48 hours
89163232|NCT02717429|Experimental|Mindfulness Meditation Training (MMT)|Participants will attend four weekly group mindfulness meditation sessions of a 2-hour duration. The classes are a mixture of experiential practices, discussions surrounding the experiences, and didactics on mindfulness. In addition to the time spent in session, participants will be asked to complete 40 minutes of daily homework, which includes further practice of in-session meditative exercises and brief readings.
89163233|NCT02717429|Active Comparator|Computerized Cognitive Training|The active control group will be in the form of a cognitive training course where the participants will meet for the same amount of time as the MMT group. Homework will be reading and engaging in cognitive video game exercises for the same duration, around 40 minutes daily, as the MMT group.
89163234|NCT02717429|No Intervention|Wait-List Control Group|This group will be used to compare the effects of the two active comparison groups and will not receive any intervention for the four week period.
89163235|NCT02621814|Experimental|Experimental 1|Formula feeding
89163236|NCT02621814|Experimental|Experimental 2|Formula feeding
89163237|NCT00998959|Experimental|Mindfulness based stress reduction and problem solving therapy|
89163238|NCT00998959|Other|Psychoeducation|
89163239|NCT00730366|Experimental|1|Experimental: IPTp-SP + promotion: Active Comparator
89163240|NCT00730366|Experimental|2|IPTp-SP alone (without promotion)
89163241|NCT00730366|Active Comparator|3|Weekly CQ prophylaxis
89163242|NCT02722343|Experimental|Tenofovir intravaginal ring|The tenofovir intravaginal ring (TFV IVR) is 55.0 mm in diameter, consisting of a single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. The IVR delivers 8-10mg/day of TFV.
89163243|NCT02722343|Active Comparator|Truvada oral tablets|"The tablets contain 200mg emtricitabine combined with 300mg tenofovir disoproxil fumarate (300mg). The tablets are commercially available as Truvada. The tablets are blue, capsule-shaped, film-coated, debossed with GILEAD on one side and with 701 on the other side"
89163244|NCT00694590|Experimental|plerixafor|
89163245|NCT00994357|Experimental|Real-time Continuous Glucose Monitoring|Real-time Continuous Glucose Monitoring at five times for up to 6 days during pregnancy, and during delivery, in addition to standard monitoring and treatment.
89163246|NCT00994357|Active Comparator|Control group|Standard monitoring and treatment of diabetic patients during pregnancy.
89163247|NCT02717117|Experimental|Feeding|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
89163248|NCT04018534|Experimental|Control group|The patients in control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society(BOS) educational goals.
89163249|NCT04018534|Experimental|Video assisted education group|The patients in one of the study groups received a video assisted education
89163250|NCT04018534|Experimental|Hands-on training group|The patients in other study group received a hands-on training.
89163251|NCT02722187|Experimental|microsurgery|40 patients will undergo subinguinal microscopic varicocelectomy
89163252|NCT02722187|Active Comparator|laparoscopy|20 patients will undergo laparoscopic varicocelectomy
89163253|NCT02717351|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
89163254|NCT03888391|Experimental|Active TNS|Participants will receive trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for up to 12 months of this open-extension trial.
89163255|NCT00594204|Active Comparator|varenicline|
89163256|NCT00594204|Placebo Comparator|placebo|
89163257|NCT00730600|Experimental|1|1= THAI traditional massage
89163258|NCT02694419||obese/PCO|Women with PCOS who are overweight\obese with BMI ≥ 25 kg/m2.
88804615|NCT03489746|Experimental|Inhaled corticosteroid withdrawal|Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
89163259|NCT02694419||normal weight/PCO|Women with PCOS who are normal weight with BMI < 25 kg/m2.
89163260|NCT02694419||Obese/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are overweight\obese with BMI ≥ 25 kg/m2.
89163261|NCT02694419||normal weight/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are normal weight with BMI < 25 kg/m2.
89163262|NCT00999115|Experimental|Allogenic ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million in case of incomplete fistula closure following week 12 assessment.
89163263|NCT02694107|Experimental|Proprioceptive exercises|Proprioceptive exercises performed 3 sessions per week for 4weeks
89163264|NCT02694107|No Intervention|Control|Without any exercises
89163265|NCT00999193|Active Comparator|Conservative Treatment|
89163266|NCT00999193|Experimental|ORIF w. locking plate, no luxation|
89163267|NCT00999193|Experimental|Hemiarthroplasty, no luxation|
89163268|NCT04000945|Experimental|BTL-899 Therapy Arm|
89163269|NCT04000945|Sham Comparator|Sham Arm|
89163270|NCT02621658|Active Comparator|Clear Liquid Diet|Clear Liquid Diet the day before colonoscopy.
89163271|NCT02621658|Experimental|Full Liquid Diet|Full Liquid Diet the day before colonoscopy.
89163272|NCT00999271||Healthy subjects|30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
89163273|NCT02722265|Experimental|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
89163274|NCT00912600||1|Elderly individuals presenting to one of 15 emergency departments and possibly qualifying for admission to an ICU
89163275|NCT02717039||Blood Draw|A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
88804616|NCT03489746|Active Comparator|Standard care|Patients will continue on their current recommended regimen including ICS.
89163276|NCT02621502|Experimental|Quinoa variety 1|1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
89163277|NCT02621502|Experimental|Quinoa variety 2|1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
89163278|NCT02621502|Experimental|Quinoa variety 3|1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
89163279|NCT02621502|Experimental|Quinoa variety 4|1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
89163280|NCT02621502|Active Comparator|Anhydrous Glucose|1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
89163281|NCT02716961|No Intervention|Monotherapy|Barely epirubicin was instilled after TURBT. Epirubicin was immediately instilled in 24h after TURBT. Instillation was conducted regularly for a year: once in a week for 8 times, once in two weeks for 8 times, once in a month for 6 times.
89163282|NCT02716961|Experimental|Combination|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. Intervention: GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
89163283|NCT03742843||Group of adenomyosis|Patients with adenomyosis with or without endometriosis
89163284|NCT03742843||Group of endometriosis|Patients with endometriosis without adenomyosis
89163285|NCT03742843||Group of control|Patients without adenomyosis or endometriosis
89163286|NCT05216627||PSOM staff, trainees, or faculty who participate in the point of care testing|The cohort will be offered access to a self-administered saliva-based viral test is a small funnel and a tube in which participants will put their saliva into. When they are ready to self-collect their saliva sample, they will be instructed to not eat or drink for 30 minutes prior to collecting their saliva and to collect saliva in an isolated room. We will evaluate the implementation of this viral test.
89163287|NCT02704156|Experimental|SBRT plus Pembrolizumab and Trametinib|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
89163288|NCT02704156|Active Comparator|SBRT plus Gemcitabine|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
89163289|NCT00912678|Active Comparator|MMF and Steroid Group|Group of Patients randomized to MMF and Steroid maintenance immunosuppression after 3 months (Tacrolimus withdrawal)
89163290|NCT00912678|Active Comparator|Low-Dose Tacrolimus Group|Patients randomized to withdrawal of MMF after 3 months and maintenance immunosuppression with low-dose tacrolimus and Steroids
89163291|NCT00995839|Experimental|continuous terlipressin|
89163292|NCT00995839|Experimental|vasopressin|
89163293|NCT00995839|Experimental|terlipressin bolus dose|
89163294|NCT00994513|Active Comparator|ALA|alpha lipoic acid 1200 mg/day
89163295|NCT00994513|Placebo Comparator|Placebo|placebo 1200 mg/day
89163296|NCT02616744|Experimental|Arm A: Ibandronic acid|Ibandronic acid 150 mg per os per month for two years
89163297|NCT02616744|Placebo Comparator|Arm B: Placebo|Placebo per os per month for two years
89163298|NCT00995917|Experimental|Vitamin K acupoint injection|Participants will receive the vitamin K intervention within 2 days of the onset of painful menstrual cramps.
89163299|NCT00995917|Sham Comparator|Saline Injection|Participants will receive the saline treatment within 2 days of the onset of painful menstrual cramps.
89163300|NCT02616822|Experimental|trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
89163301|NCT02616822|Placebo Comparator|Placebo|Used for placebo substance single dose
89163302|NCT00912756|Experimental|1cilostazol|Cilostazol group: Treatment with cilostazol 200 mg/day BID (morning and evening) and aspirin at 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
89163303|NCT00912756|Active Comparator|2aspirin|Non-cilostazol group: Treatment with aspirin 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
89163304|NCT04568980||Hormonal contraceptive users|Persons exposed to any hormonal method of birth control. This includes combined oral contraceptive pills, combined transdermal patch, combined vaginal ring, progestin-only pills, depo-medroxyacetate, levonorgestrel intrauterine system/device, hormonal subdermal implant
89163305|NCT04568980||Non-hormonal contraceptive users|Persons exposed to any non-hormonal method of birth control. This includes male or female sterilization methods, Copper intrauterine device, internal/external condoms, diaphragm, cervical cap, withdrawal, sponge, fertility based methods, spermicide
89163306|NCT04568980||Non-contraceptive users|Persons who did not use any method of birth control
89163307|NCT02716883|No Intervention|Non AMT|"Freshly prepared fortified eye drops (cefazolin 50 mg/mL and amikacin 14 mg/mL) were applied as starting treatment. In the first 3 days, eye drops are applied round the clock followed by drops every 2 h during waking hours until results of laboratory investigation were available.~After preparation of the culture results, the antimicrobial treatment was narrowed according to bacterial sensitivity. Also topical betamethasone 0.1% four times a day on a tapering weekly dosage until 3-4 weeks is used for all patients. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented"
89163308|NCT02716883|Active Comparator|AMT|"This group (case group) received above mentioned routine antibiotic therapy followed by double-layer amniotic membrane transplantation 2-5 days after the start of medications and the second group (control group) only received routine antibacterial therapy.~The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented."
89163309|NCT02621346|Experimental|Imagery Group|The imagery group, will sit on the leg press and image completing 3 sets of leg press. The imagery group will be asked to fill out the Movement Imagery Questionnaire -revised as this gives us a measure of imagery ability. The imagery group will be given an imagery script prior to imaging. Weekly manipulation checks will be completed to ensure that participants are imagining what they are supposed to.
89163310|NCT02621346|Active Comparator|Maintenance Group|The maintenance group will continue to perform the leg press three times per week at 1/3rd of final strength assessment. This is the percentage of intensity recommended to maintain muscle mass and strength gains by the American College of Sports Medicine.
89163311|NCT02621346|Active Comparator|Control Group|Control group will come in 3 times per week for 20 minutes and complete 3 sets of 8-12 of a bicep curl 1/3 of predicted 1 RM
89163312|NCT03888235|Experimental|Immediate corrective exercises|"At this visit, participants will be examined as described in the protocol and given an exercise to correct their sacroiliac malrotation. They will use this exercise as needed for pain control. They will be reassessed one month later.~At that time they will be given the pelvic support belt and the concurrent use of both treatments will be assessed at their last visit one month after that."
89163313|NCT03888235|Experimental|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their pelvis. They will use this belt for activities likely to precipitate back pain. They will be reassessed one month later.~At that time they will be given the exercises and the concurrent use of both treatments will be assessed at their last visit one month after that."
89163314|NCT03888235|Active Comparator|Delayed treatment|"These participants will continue using their current therapies to deal with their low back pain for one month prior to being scheduled for a treatment visit. At the treatment visit, one month later they will be given both the exercise and the belt.~The concurrent use of both treatments will be assessed at their last visit one month after that."
89163315|NCT04080245|Experimental|Treatment Group|
89163316|NCT04500028|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) ( inserted by the study nurse 4 hours before IUD insertion.
89163317|NCT04500028|Placebo Comparator|Placebo Comparator|one tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
89163318|NCT00694668|Experimental|1|Cognitive Behavioural Treatment
89163319|NCT00694668|Experimental|2|Mindfulness Based Cognitive Therapy-training
89163320|NCT02716649||All participants|No intervention
89163321|NCT02621268|Experimental|Indocyanine Green|Dosage calculated by weight of individual, 5mg/kg.
89163322|NCT04487470|Experimental|Flavored Filtered Cigars|Half of the group will be randomized to start with flavored filtered cigars (FCs) at the second visit and cross over to unflavored FCs at the third visit. FCs will be Cheyenne filtered cigars.
89163323|NCT04487470|Experimental|Unflavored Filtered Cigars|Half of the group will be randomized to start with unflavored FCs at the second visit and cross over to flavored FCs at the third visit. FCs will be Cheyenne filtered cigars.
89163324|NCT02621580|No Intervention|Control|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and do not require laser or anti-VEGF treatment in at least one eye.
89163325|NCT02621580|Experimental|Treatment: Pan-Retinal Photocoagulation|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and require PRP laser in at least one eye.
89163326|NCT02721953|Experimental|Hypocaloric diet plus butyrate|Hypocaloric diet plus butyrate
89163327|NCT02721953|Placebo Comparator|Hypocaloric diet plus placebo|Hypocaloric diet plus placebo
89163328|NCT04426240|Active Comparator|Cyclosporine|Subject who use cyclosporine and hyaluronate artificial tear 1 month before cataract surgery
89163329|NCT04426240|No Intervention|non-Cyclosporine|Subject who use only hyaluronate eye drop 1 month before cataract surgery
89163330|NCT00995995||All patients|
89163331|NCT00694746|Experimental|Fish oil|Omega-3-acid ethyl esters in the form of fish oil capsules with ram up from 1g to 4 g/day (capsules 1g)
89163332|NCT00694746|Placebo Comparator|Placebo|Placebo
89163333|NCT00999349|Experimental|Silymarin (LEGALON)|
89163334|NCT00999349|Placebo Comparator|Placebo|
89163335|NCT02621112|Experimental|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccination with topical imiquimod pretreatment. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical imiquimod ointment pretreatment 5 minutes before injection at 0, 1, 3, 6 months
89163336|NCT02621112|Active Comparator|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccination with topical aqueous cream. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
89163337|NCT02621112|Active Comparator|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccination with topical aqueous cream. Subjects to receive intramuscular 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
89163338|NCT02693795|Experimental|Baduanjin exercise group|"The participants randomized to Baduanjin exercise will collectively practice at cardiac rehabilitation centre in Guangdong Provincial Hospital of Chinese Medicine. A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
89163339|NCT02693795|Active Comparator|usual exercise control group|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
89163340|NCT04000789|Experimental|NPDR|
89163341|NCT04000789|Active Comparator|NPDR Comparator|
89163342|NCT04000789|Experimental|PDR|
89163343|NCT04000789|Active Comparator|PDR Comparator|
89163344|NCT02621190|No Intervention|A|patients without CTCs or AR-V7 negative CTCs are treated according to their physician's discretion
89163345|NCT02621190|Experimental|B|patients with AR-V7 positive CTCs are treated with cabazitaxel 25mg/m2 q3w
89163346|NCT02721797||Skin|Patients with EDS diagnosis having surgery, have debrided skin retained for this research
89163347|NCT02721797||Tendon|Patients with EDS diagnosis having surgery, have debrided tendon retained for this research
89163348|NCT02721797||Uterine tissue|Patients with EDS diagnosis having surgery, have debrided uterine tissue retained for this research
89163349|NCT02721797||Vaginal tissue|Patients with EDS diagnosis having surgery, have debrided vaginal tissues retained for this research
89163350|NCT02721797||Ligaments|Patients with EDS diagnosis having surgery, have debrided ligaments retained for this research
89163351|NCT00697554|Experimental|Group A|
89163352|NCT00697554|Active Comparator|Group B|
89163353|NCT00730990|Experimental|Cohort 1|This arm will have no active treatment.
89163354|NCT00730990|Experimental|Cohort 2|
89163355|NCT02716571|Other|Healthy Donors|Healthy Donors will given white blood cell and plasma
89163356|NCT04133454|Experimental|subjects treated with LGT|subjects will be treated with a single dose of LGT (AAV-hTERT)
89163357|NCT00731068|Experimental|1|PRGF
89163358|NCT00731068|Placebo Comparator|2|
89163359|NCT00866307|Experimental|Arm I (HR-average)|See Detailed Description.
89163360|NCT00866307|Experimental|Arm II (HR-high)|See Detailed Description.
89163361|NCT00731146|Active Comparator|1 - Ultrasound|Participants will receive an ultrasound guided interscalene brachial plexus block
89163362|NCT00731146|Active Comparator|2 - Nerve Stimulator|Participants will receive a nerve stimulator guided interscalene brachial plexus block
89163363|NCT02716415|Active Comparator|Calmoseptine Ointment|Calmoseptine Ointment as part of a structured skin care regimen.
89163364|NCT02716415|Active Comparator|Destin Maximum Strength 40% Zinc|Destin Maximum Strength 40% Zinc as part of a structured skin care regimen.
89163365|NCT02616354|Active Comparator|Group I|"Group I received intravenous imipenem/cilastatin 1 g every 8 h (q8h) or 0.5g every 6 h (q6h) with optimized two-step infusion therapy (OTIT; rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours) Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
89163366|NCT02616354|Placebo Comparator|Group II|"group II received intravenous imipenem/cilastatin 1g q8h or 0.5g q6h with extended infusion therapy (2-hours continuous infusion in a constant speed).~Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
89163367|NCT02569372|Experimental|GC1102 80,000 IU(Single does)|GC1102 80,000 IU(Single does) I.V.
89163368|NCT02569372|Experimental|GC1102 120,000 IU(Single does)|GC1102 120,000 IU(Single does) I.V.
89163369|NCT02569372|Experimental|GC1102 180,000 IU(Single does)|GC1102 180,000 IU(Single does) I.V.
89163370|NCT02569372|Experimental|GC1102 240,000 IU(Single does)|GC1102 240,000 IU(Single does) I.V.
89163371|NCT02569372|Experimental|GC1102 80,000 IU(Multiple does)|GC1102 80,000 IU(Multiple does) I.V.
89163372|NCT02569372|Experimental|GC1102 120,000 IU(Multiple does)|GC1102 120,000 IU(Multiple does) I.V.
89163373|NCT02569372|Experimental|GC1102 180,000 IU(Multiple does)|GC1102 180,000 IU(Multiple does) I.V.
89163374|NCT02569372|Experimental|GC1102 240,000 IU(Multiple does)|GC1102 240,000 IU(Multiple does) I.V.
89163375|NCT00731224|Experimental|1|
89163376|NCT00531427|Experimental|1|Buprenorphine transdermal system 10 and 20 applied for 7-day wear
89163377|NCT00531427|Placebo Comparator|2|Placebo transdermal system to match BTDS patches, applied for 7-day wear
89163378|NCT00731302|Experimental|Aspirin and Meloxicam|Arm: Aspirin and Meloxicam Each participant will receive 81 mg aspirin per day for 7 days, followed by meloxicam 7.5 mg daily plus aspirin 81 mg daily for 5 days
89163379|NCT00871728|Experimental|Itraconazole|
89163380|NCT00611273|Experimental|1|Patients who have presented to the investigator for correction of glabellar furrows, as classified per the Rated Numeric Kinetic Line Scale Score for Facial Wrinkles Secondary to Hyperkinetic Function (Note: Class 1 or Higher)7 (Appendix R) are candidates for this study.
89163381|NCT00731380|Experimental|ABI-007 escalation; then radiation + AUC|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-FU 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
89163382|NCT00999427|Experimental|A|The randomly selected group of subjects who will receive the intervention. The radiologist performing the transrectal prostate biopsy on these subjects will have a gauze soaked with Povidone-iodine over his/her index finger, and will insert this into the rectum. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin to the other. This will be allowed to dry for 2 minutes before proceeding with the biopsy.
89163383|NCT00999427|No Intervention|B|The randomly selected group of subjects who will receive the standard of care biopsy without any added intervention.
89163384|NCT04189211|Experimental|1.2mg/kg of BAT8001|BAT8001 100mg/box, 1.2mg/kg IV infusions
89163385|NCT04189211|Experimental|2.4mg/kg of BAT8001|BAT8001 100mg/box, 2.4mg/kg IV infusions
89163386|NCT04189211|Experimental|3.6mg/kg of BAT8001|BAT8001 100mg/box, 3.6mg/kg IV infusions
89163387|NCT04189211|Experimental|4.8mg/kg of BAT8001|BAT8001 100mg/box, 4.8mg/kg IV infusions
89163388|NCT04189211|Experimental|6.0mg/kg of BAT8001|BAT8001 100mg/box, 6.0mg/kg IV infusions
89163389|NCT00364780|Experimental|1|Patients received XL647 at an intermittent dosing schedule receiving drug for 5 days followed by 9 days without drug.
89163390|NCT00364780|Experimental|2|Patients received drug at a daily dosing schedule
89163391|NCT02716337|Other|Intervention group|In the intervention group VLBW infants were fed target fortified human milk Growth and safety were compared to a historical group of VLBW infants fed with standard fortified human milk
89163392|NCT00994591|Experimental|Pharmacokinetic dosing|
89163393|NCT02716493|Experimental|Telerehabilitation group|Patients with unresectable thoracic neoplasia receiving chemotherapy treatment
89163394|NCT00868998|Experimental|Treatment|Gemcitabine, docetaxel, and capecitabine
89163395|NCT04000711|Experimental|Outpatient oral antibiotic treatment group.|After randomization, participants assigned to receive outpatient treatment with oral cefixime at a dose of 8 mg/kg/day were discharged. Treatment was provided by the researchers. Subjects were evaluated daily at the outpatient clinic of the hospital. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed in the outpatient group, they were re-admitted to the hospital to receive intravenous antibiotics. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
89163396|NCT04000711|Active Comparator|Inpatient intravenous antibiotic treatment group.|After randomization, participants continued intravenous inpatient antibiotic with cefepime 150 mg/kg/day according to local standard of care guidelines. Subjects were evaluated daily. All patients underwent a blood count every 48 to 72 hours. FN event resolution was defined as when the patient remained afebrile and the ANC increased to above 500 per microliter. If fever resumed, treatment was changed according to clinical guidelines. Resolution of the FN event was defined as the end of participation of the subjects in the study, and they were followed up for an additional 72 hours.
89163397|NCT04131387|Experimental|Test Group|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
89163398|NCT04131387|Placebo Comparator|Control Group|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
89163399|NCT04065724|Other|Physical training resistance and aerobic|Physical training as resistance and aerobic training
89163400|NCT02716181|Active Comparator|"Атопик phase 1"|"For the first phase of the study, subjects will be randomized to receive treatment with Атопик Soothing Cream."
89163401|NCT02716181|Placebo Comparator|Placebo - phase 1|For the first phase of the study, subjects will be randomized to receive treatment with Placebo Cream.
89163402|NCT02716181|Active Comparator|"Атопик phase 2"|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
89163403|NCT02716181|Placebo Comparator|Placebo - phase 2|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
89163404|NCT04001023|Experimental|PDS|18F-EF5 PET/CT and 18F-FDG PET/CT scan prior to primary cytoreductive surgery and targeted sample collection during primary cytoreductive surgery
89163405|NCT04001023|Experimental|IDS|"18F-EF5 PET/CT and 18F-FDG PET/CT scans prior to diagnostic laparoscopy and after neoadjuvant chemotherapy before interval cytoreductive surgery .~Targeted sample collection during diagnostic laparoscopy and interval cytoreductive surgery"
89163406|NCT04131153|Other|Conventional radiofrequency ablation group|Conventional radiofrequency ablation procedures
89163407|NCT04131153|Experimental|Three-step radiofrequency ablation group|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
89163408|NCT00731536||Patients with Hepatosplenic T-cell Lymphoma (HSTCL)|
89163409|NCT00996073|Active Comparator|Autograft|Lumbar Interbody Fusion with Autograft
89163410|NCT00996073|Experimental|Low Dose|Lumbar Interbody Fusion with NeoFuse-Low Dose
89163411|NCT00996073|Experimental|High Dose|Lumbar Interbody Fusion with NeoFuse-High Dose
89163412|NCT04131231|Experimental|microparticles packaging methotrexate (MPs-MTX) group|"Patients are first treated with microparticles packaging methotrexate (MPs-MTX) via intrapleural infusion four times on day5,6,7,8 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.~MPs-MTX: 5 U of MPs-MTX containing a total dose of more than 25μg of MTX dissolving in 50ml of physiological saline solution"
89163413|NCT04131231|Active Comparator|recombinant human interleukin-2(rhIL-2) group|"Patients are first treated with rhIL-2 via intrapleural infusion three times on day5,8,11 and then undergo chemotherapy 1 cycle from day12. After 4 weeks from the beginning of the treatment (day1 of treatment), ORR is assessed.~rhIL-2: 2 million IU of rhIL-2 dissolving in 50ml of physiological saline solution"
89163414|NCT00994669||healthy control male|
89163415|NCT00994669||lung cancer male|
89163416|NCT02716259|Experimental|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and oral antiseptics (clorhexidine 0.12% rinse),
89163417|NCT02716259|Placebo Comparator|Supragingival prophylaxis|Two sessions of supragingival prophylaxis under local anesthesia and an oral rinse with no antiseptic properties.
89163418|NCT04131075||Study group|Patients with CAD undergoing FFR-guided revascularisation. FFR, coronary flow reserve (CFR) and the index of hyperemic microvascular resistance (HMR) will be measured with the Doppler guidewire (Combowire, Volcano - Philips corporation) under steady state hyperemia.
89163419|NCT00996229|Experimental|Caloric restriction + placebo supplementation|
89163420|NCT00996229|Experimental|Omega-3 supplementation|
89163421|NCT00996229|Placebo Comparator|Placebo supplementation|
89163422|NCT00996229|Experimental|Resveratrol supplementation|
89163423|NCT02712671||Enrolled subjects|Subjects attending the Ian Charleson Centre and agreeing to be tested for latent, subclinical and active tuberculosis using Chest radiograph, Blood interferon gamma release assay, Tuberculin skin testing, Sputum induction for mycobacterial microscopy and culture with spirometry, and Mycobacterium tuberculosis polymerase chain reaction testing.
89163424|NCT02614833|Experimental|Paclitaxel + IMP321 at the RPTD|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, either IMP321, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (IMP321) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
89163425|NCT02614833|Active Comparator|Comparator: Paclitaxel + Placebo|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, placebo, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (placebo) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
89163426|NCT04925843||Patients undergoing liver transplant for end-stage liver disease|The investigators propose to conduct a retrospective cohort study to explore the association between fibrinogen concentration and intraoperative bleeding in patients who underwent a liver transplant between July 2008 and January 2021.
89163427|NCT00999505|Active Comparator|Amantadine|Amantadine 200mg twice a day
89163428|NCT00999505|Placebo Comparator|Placebo|Placebo capsules twice a day
89163429|NCT04920929|Active Comparator|Hydrophilic BioMaterial|Hydrophilic BioMaterial- HydroPICC
89163430|NCT04920929|Active Comparator|Thermoplastic Polyurethane|TPU- 4 French Single Lumen PowerPICC
89163431|NCT00996385|Experimental|Velcade plus Eloxatin|Six 20-day cycles
89163432|NCT02616276|Active Comparator|Control|Control breakfast
89163433|NCT02616276|Experimental|Intervention 1|High glycemic index breakfast
89163434|NCT02616276|Experimental|Intervention 2|Low glycemic index breakfast
89163435|NCT04130841|Experimental|Spontaneous ILM peeling|
89163436|NCT04130841|Active Comparator|Active ILM peeling|
89163437|NCT04130841|No Intervention|No ILM peeling|
89163438|NCT02716103||Initial Cohort: feasibility|Bone marrow collection and peripheral blood collection from ten patients with untreated AL amyloidosis will be evaluated to determine feasibility of isolating a plasma cell clone. An additional three teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving any treatment. There will be no extra procedures or visits specifically for this research.
89163439|NCT02716103||2nd Cohort - pre-treatment|If feasibility is determined with initial cohort, bone marrow collection and peripheral blood collection from 20 patients with untreated AL amyloidosis who are scheduled to undergo antineoplastic therapy will be evaluated to isolate a plasma cell clone. An additional 3 teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving therapy. For those who complete therapy and achieve complete response or very good partial response, subsequent samples of bone marrow and peripheral blood will be sent for minimal residual disease detection (based on the previously identified cancer clone) at 6 to 12 months post treatment.
89163440|NCT00999583|Experimental|EPO|five injections maximum of 40000 UI EPO
89163441|NCT00999583|Active Comparator|Control|Classical take care
89163442|NCT02614599|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
89163443|NCT02614599|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
89163444|NCT02716025||Case Group|
89163445|NCT02716025||Control Group|
89163446|NCT00533845|Experimental|On-Q pain pump|Bupivacaine
89163447|NCT00533845|Placebo Comparator|Placebo/control|Saline
89163448|NCT04295915||Specimens that meet inclusion criteria|
89163449|NCT04000867|Active Comparator|real TCMS treatment|Subjects with DN located in their bilateral feet that have been previously identified and have a graded average baseline score of at least 5 in each foot will receive either TCMS treatment or Sham treatment on clinic day-1 according to the contents of a sealed opaque envelope corresponding to the subject's number in the series and opened immediately before treatment on day 1. (Our statistician will have generated these envelopes and their contents in advance.) Subjects and staff evaluating the subject's response will remain blinded to treatment assignment; only the staff member setting the treatment mode will know whether it is active or sham.
89163450|NCT04000867|Sham Comparator|Sham TCMS treatment|Patients in the sham treatment group, will use the same device. The device will be switched into sham mode by the clinician by pressing a small, non-descript button on the backside of the pulse generator. The treatment device in sham mode will produce a clicking sound once every 6 seconds like the TCMS treatment mode, but no magnetic pulses will be output.
89163451|NCT02752763|Experimental|preservative free artificial tear drop|preservative free artificial tears drop is a drop group declaring different kind of active agent like hydroxypropyl methylcellulose, carboxymethyl cellulose etc commonly used in dry eye treatment. Preservative free artificial tear( carboxymethyl cellulose, hydroxypropyl methylcellulose) was used as four times one drop daily. In our study, we prescribed to patients preservative free artificial tears drop(hydroxypropyl methylcellulose or carboxymethyl cellulose) four times one drop daily.
89163452|NCT02752763|Experimental|%40 Autologous serum(AS)|peripheral venous blood (14-20 ml) that drawn from antecubital vein of patients to prepare Autologous Serum. Blood sample was left at room temperature over 2 hours for clotting. Serum was obtained after centrifugation at 4000 revolutions per minute (rpm) for 10 minutes at 4 °C using a Nuve NF1200R. Next, in a laminar flow cabinet under sterile conditions, approximately 10 mL of supernatant was collected and diluted to 40 % with isotonic saline solution. It is recommended for dry eye diseases, too. %40 diluted Autologous Serum used as four times one drop daily.
89163453|NCT02715713||testosterone deficiency group|Men between the ages of 40 to 80-years-old with testosterone deficiency
89163454|NCT02715713||prostate cancer group|Men between the ages of 40 to 80-years-old with prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.
89163455|NCT00857649|Experimental|Memantine|
89163456|NCT00857649|Placebo Comparator|Placebo|
89163457|NCT02712749|Experimental|Group A : Sound with Binaural Beats|"Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz through generated by the software Gnaural in stereo option"
89163458|NCT02712749|Active Comparator|Group B : Sound without Binaural Beats|"Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the software Gnaural in mono option"
89163459|NCT02752841|Experimental|Intervention|Nutritional vitamin D repletion and maintenance
89163460|NCT04119219|Active Comparator|Ranibizumab|Arm 1
89163461|NCT04119219|Active Comparator|Aflibercept|Arm 2
89163462|NCT00857415|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy.
89163463|NCT00857415|Experimental|Specificity Cohort|Younger healthy controls presumed to be devoid of beta-amyloid plaques.
89163464|NCT00611429|Experimental|Group A|Participants will receive treatment consisting of at least three individual counseling sessions and one group workshop over 12 months
89163465|NCT00611429|Active Comparator|Group B|Participants will receive treatment consisting of one individual counseling session and one group workshop during the last month of the study
89163466|NCT02715869|Active Comparator|A pharmacologic cardiac preconditioning|Sevoflurane as a pharmacologic preconditioner for the heart
89163467|NCT02715869|Active Comparator|B ischeamic preconditioning|ischemic preconditioning by inflation the cuff of blood pressure
89163468|NCT00532441|Experimental|Erlotinib and Docetaxel: Biliary|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
89163469|NCT00532441|Experimental|Erlotinib and Docetaxel: Hepatocellular|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
89163470|NCT04118985|Active Comparator|Self-implementation|Individuals randomized to this group will be given all the materials about cognitive compensations techniques and brain health behavior guidelines and encouraged to implement those on their own.
89163471|NCT04118985|Experimental|Health-behavior intervention|Individuals randomized to this group will attend 10 weekly classes designed to provide information about cognitive compensation techniques and brain health behaviors as well as interventional support to implement those recommendations with homework and follow-up classes.
89163472|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of study will receive access to the Healthy Lifestyle App and the McMaster PHR
89163473|NCT02715791|Other|TAP-HC-DM|Patients randomized to the intervention group will get TAP-HC-DM intervention from time zero
89163474|NCT00699543|Experimental|C|Coroflex Please stent implantation
89163475|NCT00699543|Active Comparator|T|Taxus stent implantation
89163476|NCT02712827|Experimental|Progrip|The Progrip group is the intervention group. Patients will undergo laparoscopic total extraperitoneal repair of inguinal hernia. The surgeon will use a self-gripping mesh to repair the hernia. No fixation is required for the mesh.
89163477|NCT02712827|Active Comparator|Non-Progrip|"The Non-Progrip group is the control group.~Operation is performed under general anesthesia. A standard three-trocar technique is used: one infra-umbilical camera trocar (1cm) and two 5mm trocars placed at midline between the umbilicus and pubic bone (or one at the side of inguinal hernia). A laparoscope is inserted to the preperitoneal space through the incision. The space is insufflated with carbon dioxide. Dissection is performed, hernia content (if any) is reduced.~A non self-gripping synthetic mesh is placed. Fibrin glue is used for fixation."
89163478|NCT00999739|Experimental|two vaccines|people allocated to arm two vaccines will receive one dose of heptavalent pneumococcal conjugate vaccine at day 0 and 23-valent polysaccharide vaccine at week4 , 110 HIV-infected people will be included Intervention: administration of two vaccines
89163479|NCT00999739|Experimental|One vaccine|people allocated to arm one will receive only one doses of pneumococcal polysaccharide 23-valent vaccine. 110 HIV-infected adults will be included in this arm Intervention: administration of one vaccine
89163480|NCT00996463|Active Comparator|IL SSG|Intralesional sodium stibogluconate
89163481|NCT00996463|Experimental|ETC+MWT|Electro-thermo-coagulation with subsequent moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
89163482|NCT00996463|Experimental|MWT|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
89163483|NCT01886963|Active Comparator|Control - Blinded use of SPY Elite|Group A will consist of intraoperative abdominal wall imaging prior to incision, followed by ventral hernia repair with subcutaneous advancement flaps without viewing the imaging contained within the Spy Elite system. A digital photograph will be taken before and immediately after initial incision, as well as immediately prior to and after closure. The patient will have digital photographs of the surgical wound taken by the surgical team daily until discharge, and on follow-up visits at one week, two weeks, four weeks and twelve weeks. After twenty patients have completed phase I, the surgical team will be unblinded to Spy Elite imaging. The Spy Elite imaging and all digital photographs of all patients will be reviewed.
89163484|NCT01886963|Experimental|SPY - Unblinded Use of SPY Elite|Group B will have incision and advancement flap performed based on assessment of blood supply using the Spy Elite system, as well as potential flap revision if portions of the flap appear under-perfused in the pre-closure imaging. Patients will be blinded to whether or not their intraoperative Spy Elite imaging was used for operative planning. All patients will have digital photographs of the surgical wound taken by a blinded member of the surgical team daily until discharge, and on follow-up visits at one to two weeks, four weeks, and 12 weeks post-operatively. Digital photographs will be reviewed by a blinded surgeon, who will assess the wound for complications.
89163485|NCT00999817|Other|A|Single 30 mg dose of dextromethorphan
89163486|NCT00999817|Experimental|B|Single 45 mg dose of PF-00299804 plus a single 30 mg oral dose of dextromethorphan
89163487|NCT00857259|Experimental|Everolimus 5 mg|5 mg orally once daily plus sham ocular injection on Day 1 (Baseline) until Day 28
89163488|NCT00857259|Active Comparator|Ranibizumab 0.5 mg|Ranibizumab intra-vitreal therapy (IVT) 0.5 mg on Day 1 (baseline)
89163489|NCT00857259|Active Comparator|Oral Everolimus (5mg) and Ranibizumab (0.5mg)|Everolimus orally 5 mg once daily plus Ranibizumab Intra-vitreal therapy (IVT) 0.5 mg on day 1 (baseline)
89163490|NCT04871009|Placebo Comparator|Standard of Care|routine clinical psychotherapy
89163491|NCT04871009|Experimental|Neurofeedback Intervention plus standard of care|routine clinical psychotherapy plus 3 to 4 neurofeedback interventions per week.
89163492|NCT00994747|Active Comparator|Group EEEEEEE|Infant is fed Enfamil from 0.5-7.5 months of life
89163493|NCT00994747|Experimental|Group ENEEEEE|Infant is fed Enfamil during 0.5-1.5 months of life, Nutramigen from 1.5-2.5 months of life and then Enfamil 2.5-7.5 of life.
89163494|NCT00994747|Experimental|Group EENEEEE|Infant is fed Enfamil 0.5-2.5 months of life, Nutramigen from 2.5-3.5 months of life and then Enfamil from 3.5 to 7.5 months of life
89163495|NCT00994747|Experimental|Group EEENEEE|Infant is fed Enfamil from 0.5-3.5 months of life, Nutramigen from 3.5-4.5 months of life and then Enfamil from 4.5-7.5 months of life.
89163496|NCT00994747|Experimental|Group ENNNEEE|Infant if fed Enfamil from month 0.5-1.5 months of life, Nutramigen from 1.5 to 3.5 months of life and then Enfamil again 3.5-7.5 months of life.
89163497|NCT00994747|Experimental|Group NNNNNNN|Infant is fed Nutramigen from 0.5-7.5 months of life.
89163498|NCT04220801|Experimental|Cohort 1 of Part 1 (SAD)|300 mg ZM-H1505R or placebo
89163499|NCT04220801|Experimental|Cohort 2 of Part 1(SAD)|450 mg ZM-H1505R or placebo
89163500|NCT04220801|Experimental|Cohort 3 of Part 1(SAD)|150 mg ZM-H1505R or placebo (2 periods)
89163501|NCT04220801|Experimental|Cohort 4 of Part 1(SAD)|75 mg ZM-H1505R or placebo
89163502|NCT04220801|Experimental|Cohort 5 of Part 1(SAD)|25 mg ZM-H1505R or placebo
89163503|NCT04220801|Experimental|Cohort 1 of Part 2 (MAD)|75 mg ZM-H1505R or placebo
89163504|NCT04220801|Experimental|Cohort 2 of Part 2 (MAD)|150 mg ZM-H1505R or placebo
89163505|NCT04220801|Experimental|Cohort 3 of Part 2 (MAD)|300 mg ZM-H1505R or placebo
89163506|NCT00868608|Experimental|inotuzumab ozogamicin|inotuzumab ozogamicin
89163507|NCT00699621|Active Comparator|1|Platelet transfusion
89163508|NCT00699621|No Intervention|2|No platelet transfusion
89163509|NCT04000633|Active Comparator|lidocaine group|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
89163510|NCT04000633|Placebo Comparator|Placebo group|the patients of this group will recieve nebulization of 5 ml of normal saline prior to induction of general anesthesia
89163511|NCT04118751||parents of preterm babies (born before 37 weeks of pregnancy|
89163512|NCT04118751||parents of full-term babies (over 37 weeks of pregnancy)|
89163513|NCT04294355|Experimental|Artificial intelligence-Assisted colonoscopy|Tandem colonoscopy of proximal colon assisted with artificial intelligence followed by conventional colonoscopy
89163514|NCT04294355|Active Comparator|Conventional colonoscopy|Tandem conventional colonoscopy of proximal colon followed by usual conventional colonoscopy
89163515|NCT00994825|Placebo Comparator|Placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
89163516|NCT00994825|Experimental|Levosimendan|Levosimendan
89163517|NCT02752529|Experimental|Tacrolimus/dose1|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
89163518|NCT02752529|Active Comparator|Tacrolimus/dose2|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
89163519|NCT00856635|Experimental|Glatiramer acetate|Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.
89163520|NCT00856635|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a day for up to 6 months.
89163521|NCT02620956|Active Comparator|obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
89163522|NCT02620956|Experimental|asthmatic obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
89163523|NCT02712593|Experimental|Niagen™ 100|
89163524|NCT02712593|Experimental|Niagen™ 300|
89163525|NCT02712593|Experimental|Niagen™ 1000|
89163526|NCT02712593|Experimental|Placebo|
89163527|NCT02620800|Experimental|FABLOx|5 fluorouracil (5-FU ) (180 mg/m^2/day for 14 days), by continuous intravenous infusion (CIVI) via ambulatory pump, nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15, bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15, calcium leucovorin (20 mg/m^2) IV bolus on Days 1, 8, 15, and oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15. First bevacizumab infusion is given over 90 minutes.
89163528|NCT00999895||Antipsychotic outpatients with schizophrenia|Switched treatment of antipsychotic outpatients with schizophrenia
89163529|NCT04118907|Experimental|acoustic stimulation|Pink noise in both ears is given to tinnitus patients. The pink noise is removed by notch filter from tinnitus frequencies that are 20 decibel higher than the threshold.
89163530|NCT04118907|Experimental|somatic stimulation|Three stimulation points were selected for each ear of tinnitus patients, namely ear door (CN.V), auditory Palace (CN.VII) and Yifeng (C2/3). The stimulation intensity should be needle-sensed.
89163531|NCT04118907|Experimental|vestibular stimulation|The patient sat on a rotating chair with sinusoidal harmonic acceleration and rotated without causing the greatest frequency of discomfort.
89163532|NCT04118907|Experimental|acoustic + somatic stimulation|Combination of auditory and somatic stimulation for tinnitus patients
89163533|NCT04118907|Experimental|acoustic + vestibular stimulation|Combination of auditory and vestibular stimulation for tinnitus patients
89163534|NCT04118907|Experimental|acoustic + somatic + vestibular stimulation|Combination of auditory stimulation, somatic stimulation and vestibular stimulation for tinnitus patients
89163535|NCT02752451|Other|CO|8 subjects who did not undergo arthroscopy simulation training prior to assessment on cadaveric specimens. These served as controls.
89163536|NCT02752451|Experimental|CBAT|8 Subjects who received 4 hours of simulation training on the Cigar Box Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
89163537|NCT02752451|Experimental|AKAT|8 Subjects who received 4 hours of simulation training on the Anatomic Knee Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
89163538|NCT04118829|Experimental|Group one|The Group 1 patients will be taking PER up to 14 days following surgical intervention as per discretion of the treating neurosurgeon.
89163539|NCT04118829|Experimental|Group Two|The Group 2 patients will be taking PER as part of their maintenance AED regimen and will continue on the same maintenance dosage postoperatively.
89163540|NCT04135014|Placebo Comparator|Midazolam|Patients were assigned to receive oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
89163541|NCT04135014|Experimental|Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 2ug/kg approximately 30-40 minutes before surgery using a computer-generated random number table.
89163542|NCT04135014|Experimental|Midazolam and Dexmedetomidine|Patients were assigned to receive intranasal dexmedetomidine 1ug.kg-1 and oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
89163543|NCT02712437|Experimental|PROSPECT|Participants who have received treatment for early stage breast cancer and who experience chronic insomnia as assessed by difficulty sleeping for >30 days with an insomnia severity index score of >14. Participants will complete baseline symptom questionnaires and actigraphy, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 6 weeks. Participants will then repeat questionnaires and actigraphy at 6 weeks and questionnaires at 12 weeks.
89163544|NCT00996619||People undergoing GI tract endoscopy|
89163545|NCT02752295|No Intervention|Waiting list, intervention after EOS|control group / waiting list one week stress-coping intervention planned after end of study (EOS) without one week stress-coping intervention AND without an additional two days follow-up care
89163546|NCT02752295|Active Comparator|Stress-coping week without follow-up|active comparator with one week stress-coping intervention BUT without an additional two days follow-up weekend
89163547|NCT02752295|Active Comparator|Stress-coping week with follow-up|active comparator with one week stress-coping intervention AND with an additional two days follow-up weekend
89163548|NCT02620722|Experimental|LOP Measurement|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument and the gold-standard technique with the handheld Doppler ultrasound.
89163549|NCT00856557|Experimental|Seminar and Practicum|Seminar and practicum that occurs over 4 week period for internal medicine residents, designed to provide a systematic approach to identifying and addressing contextual factors essential to planning patient care.
89163550|NCT00856557|No Intervention|No intervention|No educational intervention.
89163551|NCT00996697|Active Comparator|Triple therapy|Symbicort and tiotropium
89163552|NCT00996697|Placebo Comparator|Combination therapy|Symbicort and placebo
89163553|NCT00694824||A|
89163554|NCT00999973|Active Comparator|Mitomycin c 0.02%|
89163555|NCT00999973|Placebo Comparator|Placebo|
89163556|NCT04118673|No Intervention|Control (Standard Care)|Standard care during consultations. Advice and guidance offered by clinicians verbally and sometimes the addition of leaflets or a referral.
89163557|NCT04118673|Experimental|Intervention (Standard Care plus Lifestyle prescription - LRx)|Standard care during consultations with the addition of a physical lifestyle prescription. Advice and guidance will be offered by clinicians verbally, whilst being supported with a lifestyle prescription and a possible referral if required.
89163558|NCT00696852|Active Comparator|Mindfulness Meditation|
89163559|NCT00696852|Active Comparator|Yoga|
89163560|NCT00696852|Active Comparator|Conventional Stress Reduction|
89163561|NCT00996853||Total vaccinated cohort|The Total vaccinated cohort will include all subjects with at least one vaccine administration documented.
89163562|NCT02715947|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial.Methotrexate:2.5mg per piece, oral.
89163563|NCT00856323|Experimental|PEP/CM|Participants are provided contingency management vouchers for methamphetamine abstinence, and can initiate postexposure prophylaxis (Truvada; 1 pill daily for 28 days) after non-occupational exposure to HIV.
89163564|NCT02616588|Experimental|Intervention Arm|All participants are enrolled into the intervention arm and receive the Veteran Patient Navigator and Social Work Intervention.
89163565|NCT01666145|Experimental|Intraoperative Imaging|Laparoscopic microwave ablation surgery utilizing the Advanced Image Guidance system for needle placement.
89163566|NCT02616510||PCOS|Rotterdam criteria (at least 2 out of three criteria present) oligo-anovulation polycystic ovarian morphology hyperandrogenism
89163567|NCT02616510||POI|amenorrhea of at least 4 months prior to age 40 years, with follicle stimulating hormone (FSH) levels above 40 IU/L
89163568|NCT00856245|Other|Rituximab|Patients will be treated IV with rituximab at the rate of 50 milligrams per hour (mg/hour) for 1 hour. If patient tolerates the infusion, the rate is increased by increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. If patient has a severe reaction, the infusion is stopped temporarily and the infusion rate is decreased by 50%. Subsequent infusions are started at the rate of 100 mg/hour, increased by 100 mg/hour every 30 minutes to a maximum of 400 mg/hour if tolerated. Vital signs are monitored every 15 minutes for 2 hours and every 30 minutes thereafter.
89163569|NCT01193777|Placebo Comparator|Saline|
89163570|NCT01193777|Experimental|L-Carnitine|
89163571|NCT01000207|Experimental|1|Dose ranging
89163572|NCT01000207|Experimental|2|Dose ranging
89163573|NCT00855933|No Intervention|Control - no flossing|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily.
89163574|NCT00855933|Experimental|Experimental Floss|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily. Subjects flossed once daily with the experimental floss.
89163575|NCT02715557|Experimental|Full Access to the relapse prevention program|The participants will receive access to the relapse prevention program throughout the entire 6-week trial period.
89163576|NCT02715557|Experimental|TAU|The participants will receive treatment as usual (TAU) for 6-weeks, and will receive access to the relapse prevention program after the completion of the 6 month follow-up.
89163577|NCT00994903|Placebo Comparator|Placebo|Placebo tablets (Inert calcium lactate)
89163578|NCT00994903|Experimental|Simvastatin|40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
89163579|NCT00699777|Experimental|1|One risedronate 150 mg tablet administered orally after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
89163580|NCT00699777|Active Comparator|2|Two risedronate 75 mg tablets administered as a single oral dose after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
89163581|NCT02712125|Active Comparator|isosorbide mononitrate|Received 20 mg isosorbid mononitrate (IMN) (Effox, Mina Pharma Co, Egypt; under license of Schwartz Pharma, Germany) vaginally once daily until delivery
89163582|NCT02712125|Placebo Comparator|Control|Received placebo vaginal tablets once daily until delivery
89163583|NCT05192785|No Intervention|Control group|"In the control group, patients who met the sampling criteria filled out the Consent and Information Forms with the researcher, and the breathing and coughing exercises, and early mobilization and pain control practices that were part of the routine clinical procedure were continued.~Arterial and venous oxygen saturation values and vital signs were measured and recorded at the end of the first, second and third postoperative days on the Application Information form. The researchers and clinic nurses were responsible for the execution of applications and the follow-up and monitoring of the pulmonary rehabilitation care throughout the hospitalization of the patient."
89163584|NCT05192785|Experimental|Incentive Spirometry Group|"The patients who met the sampling criteria were given consent and information forms in the preoperative period from their admission to the clinic by the researcher and the incentive spirometry (IS) application along with respiratory and cough exercises was explained, demonstrated and performed.~In addition, all postoperative patients underwent a pain assessment using the visual analogue scale (VAS) pain scale every 4-6 hours every day prior to incentive spirometry implementation, and pain control was provided based on the results (with paracetamol and opioids in the clinical routine). The patients whose pain levels were moderate and low continued the incentive spirometry application. Arterial and venous oxygen saturation values and vital signs were measured and recorded at the end of the first, second and third days postoperatively on the Application Information form."
89163585|NCT04118439|Experimental|Motor Imaginery|Patients allocated in this arm will recieve a training on the first day after recruitment on a motor imaginery task and will be asked to do the task every day during 30 days until they start the usual care. Then after the physical therapy treatment with a pragmatic perspective will be meassured just inthe last session, after 1 month an.d after 3 moths of the treatment for the follow up
89163586|NCT04118439|No Intervention|Control Group|Patients allocated in this arm will be meassured at the start, again after 30 days and at the end of the physical therapy usual care with a pragmatic perspective. Then will be meassured again after 1 and 3 months.
89163587|NCT02613429|Active Comparator|Cranial horizontal|identification of the airway by from the cranial end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination from the cranial end at the level of the thyroid catilage , horizontally and thereafter moving caudally
89163588|NCT02613429|Active Comparator|caudal longitudinal|identification of the airway from the distal end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination caudally, and then moving cranially
89163589|NCT00994981|Experimental|magnesium|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
89163590|NCT00994981|Placebo Comparator|normal saline|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
89163591|NCT02715479|Experimental|Treatment A|Single DTG tablet under fed conditions for a specified period
89163592|NCT02715479|Experimental|Treatment B|Two BMS955176 tablets under fed conditions for a specified period
89163593|NCT02715479|Experimental|Treatment C|Single DTG tablet and Two BMS955176 tablets under fed conditions for a specified period
89163594|NCT00699933||1|Evaluation of one study cohort
89163595|NCT01000363||Spanish speaking group|Diabetes medical group visits will be held at the Grady North DeKalb satellite clinic the third Thursday of the month starting in October 2009. There will be two cohorts of patients- English speaking patients and Spanish speaking patients. Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.
89163596|NCT01000363||English speaking group|"Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.~This visit will only focus on the patient's diabetes care. Each patient will continue to see their regular physician for their health care.~All of the services that will be provided at the medical group visit are standard of care and are the same that the patient will receive in a one-on-one visit. However, this format will allow the patient to been seen by the physician and receive diabetes education in one visit."
89163597|NCT01043315||Hospitalized Cardiac Patient|Adults admitted to Coronary intensive unit being treated for acute cardiovascular conditions
89163598|NCT01000441|Active Comparator|arm 1 (2d anti-TNF):|infliximab, etanercept, adalimumab
89163599|NCT01000441|Active Comparator|arm 2 (other biotherapy)|abatacept, rituximab or tocilizumab
89163600|NCT02752217|Experimental|Inspiratory Muscle Training (IMT)|"Subjects in the inspiratory muscle training (IMT) group will perform loaded deep breathing exercise at 6 breaths/min using BreatheMaxยฎ device. The IMT protocol at 6 breathing rate (inspiratory time = 4 seconds and expiratory time = 6 seconds) with load at 25 percent of MIP for eighth weeks.~The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks"
89163601|NCT02752217|Placebo Comparator|Control|Subjects in the control (CON) group will perform breathing exercise with inspiratory load at 2 cmH2O at 6 breathing rate using one BreatheMAXยฎ device. The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks
89163602|NCT04220567|Experimental|Exercise and Patient-centred education|
89163603|NCT04220567|Active Comparator|Exercise|
89163604|NCT00997087|Placebo Comparator|Sugar Pill, Placebo|
89163605|NCT00997087|Active Comparator|Flumazenil|
89163606|NCT02752139||patients with sleep disorders|
89163607|NCT02752139||normal individuals without sleep disorders|
89163608|NCT00997165||Metabolic syndrome (MS)|Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
89163609|NCT00997165||MS with sleep apnea|Metabolic syndrome with sleep apnea
89163610|NCT00997165||MS with Liver steatosis|Metabolic syndrome with liver steatosis
89163611|NCT02752061|Experimental|Kweneng East District|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in Kweneng East District during study period.
89163612|NCT02752061|No Intervention|All other districts|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in all other districts of Botswana (or Kweneng East prior to implementation of intervention).
89163613|NCT01000519|Active Comparator|Aerobic Training|50 minutes of aerobic training, 18 sessions within 2 months period
89163614|NCT01000519|Experimental|Progressive Resistance Training|50 minutes of progressive resistance training consisting of nine resistance exercises, each conducted 3 sets of 10 repetitions. 18 sessions over 2 months period.
89163615|NCT02751905|Experimental|BIIB074|Single oral dose on Day 1
89163616|NCT01000597|Other|Treatment Y|Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).
89163617|NCT01000597|Other|Treatment Z|A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
89163618|NCT02751593|Experimental|dexamethasone|dexamethasone 40mg/d for 4 days
89163619|NCT00997399|Experimental|LBH589|
89163620|NCT02751671|Experimental|POCUS before clean catch sampling|The intervention of interest will be the use of emergency point-of-care ultrasound performed by a research assistant to evaluate bladder fullness before clean-catch stimulation manoeuvre. More specifically, following randomisation, children in the experimental group will have ePOCUS to measure the transversal bladder diameter. If the transversal bladder diameter is > 2 cm, the CCU procedure will be started without a prior feeding period. If the diameter is < 2 cm, the CCU will be postponed for a 20 minute feeding period and a new ePOCUS will be done. After the second ePOCUS, the CCU will be done if the transversal bladder diameter reaches > 2cm. If not, the child will have another 20 minute feeding period and a third ePOCUS prior to proceeding to the CCU regardless the bladder diameter.
89163621|NCT02751671|Experimental|Standard clean catch sampling|Patients allocated to this arm will have a 20 minute feeding period either being breastfed or provided with formula intake appropriate to the infant's age and weight. If possible, the genital areas of the infant will be cleaned with warm water and soap and dried with sterile gauze prior to the feeding. The parents will let the diaper opened and will be will be ready to collect urine if the child voids during the feeding period. After the feeding, the stimulated clean-catch procedure will be performed without prior ultrasound
89163622|NCT02695979||Patients undergoing OLT|Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).
89163623|NCT01003873||Bypass gastric|First arm is represented by obese patients that will be studied before and after a gastric bypass. They will be studied before surgery as well as 1 month and 6 months after surgery.
89163624|NCT01003873||Lifestyle intervention|The second group is represented by obese patients that will be studied before lifestyle intervention, 6 months after the beginning of the intervention and after a time that will allow patients to lose the same amount of weight that patients that had been through surgery had lost one month after surgery.
89163625|NCT01003873||Control subjects|The third group is a control group of normal weight people that will be studied at one time and after 6 months with stable weight.
89163626|NCT02751749|Experimental|Unified Protocol|"CBT based Internet delivered treatment targeting transdiagnostic vulnerability and maintaining factors for chronic pain and emotional problems.~Since this is a new target Group, a replicated single case design was used and participants are their own Control Group (no other treatment arms)."
89163627|NCT00997477|Experimental|Formoterol and Budesonide|
89163628|NCT02751437|No Intervention|Low Arginine unsupplemented|These infants identified as having low blood arginine levels will receive standard care.
89163629|NCT02751437|Experimental|Low Arginine supplemented|These infants identified as having low arginine levels will receive an additional arginine infusion between days 3 and 10 of life.
89163630|NCT02751437|No Intervention|Normal Arginine|These infants identified as having normal arginine levels will receive standard care.
89163631|NCT01003951|Experimental|Acupuncture|Each patient will receive two acupuncture treatments each week for four consecutive weeks. At the end of four weeks, the intervention will be complete.
89163632|NCT04189289|Active Comparator|ESP block group|Before anaesthesia induction; bilateral ESP block will be performed under the guidance of USG. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. patient controlled analgesia (PCA) protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
89163633|NCT04189289|Sham Comparator|Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Standardized postoperative tramadol i.v. PCA analgesia protocol will be performed (3 mg/ml, total volume 100 ml, 10 mg bolus dose, 20 min locked period, without continuous delivery, no basal infusion).
89163634|NCT01000831|Active Comparator|Adjuvanted Arepanrix 2 doses|Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart
89163635|NCT04189367|Experimental|Western medicine + TCM|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.~Blood test and physiological assessment, and do the TCM model.~Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks~Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks.~TCM therapy: one bag of Qingre Liangkou Ningxin Fang, three times a day for 12 weeks."
89163636|NCT04189367|Active Comparator|Western medicine|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the informed consent.~Blood test and physiological assessment, and do the TCM model.~Primary type BMS patients receive clonazepam 0.5 mg PO every day before sleep or twice a day for 12 weeks~Secondary BMS patients receive nutritional supplements according to the patient's hematic deficiency status for 12 weeks."
89163637|NCT05170789|Experimental|Intervention arm|This study employs a single, intervention arm or group, anticipated size of which is 18 patients, in which all enrolled subjects will receive the study drug, ESd.
89163638|NCT00997633||Peritoneal carcinomatosis|Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment
89163639|NCT02715401|Experimental|Sequence 1|"T → R~T : HCP1303 R : HGP1201 + HIP1402"
89163640|NCT02715401|Experimental|Sequence 2|"R → T~T : HCP1303 R : HGP1201 + HIP1402"
89163641|NCT02693951|Experimental|the prophylactic use of antibiotics group|Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
89163642|NCT02693951|No Intervention|Control|Routine endoscopic examination and treatment. Antibiotics are not used before endoscopic treatment
89163643|NCT02715089||Precise treatment|All patients should accept next-generation sequencing (NGS) test before treatment.
89163644|NCT00871572|Placebo Comparator|Placebo|
89163645|NCT00871572|Experimental|LY2409021 10 milligrams (mg)|
89163646|NCT00871572|Experimental|LY2409021 30 mg|
89163647|NCT00871572|Experimental|LY2409021 60 mg|
89163648|NCT00997711|Experimental|Cypher|Sirolimus-eluting stent
89163649|NCT02715245|Experimental|Experimental Group|Patients with multiple chronic disease referred to Mobile Rehabilitation and Physical therapy team (MRPTT) and Nurse-led case Management in the province of Almeria that comply the inclusion criteria; as well as their caregivers.
89163650|NCT02715245|No Intervention|Control Group|Patients with multiple chronic disease and their caregivers belonging to health centers or areas where there is no figure MRPTT or Nurse-led case Management to reach this population
89163651|NCT01001143|Experimental|Dose Level 1|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 100 mg/m2 PO daily for each 28 day cycle."
89163652|NCT01001143|Experimental|Dose Level 2|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 200 mg/m2 PO daily for each 28 day cycle."
89163653|NCT01001143|Experimental|Dose Level 3|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 300 mg/m2 PO daily for each 28 day cycle."
89163654|NCT02715011|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-63709178 in Part 1 (in different cohorts). Each subsequent cohort will receive JNJ-63709178 at an increased dose level. Ascending doses may be given initially to minimize or prevent cytokine release syndrome. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
89163655|NCT02715011|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-63709178 at the recommended Phase 2 dose(s) (RP2D) determined in dose expansion phase.
89163656|NCT02715167|Active Comparator|Group Budesonide|Inhaled corticoids
89163657|NCT02715167|Placebo Comparator|Group Placebo|Placebo by inhalation
89163658|NCT00997789|Experimental|Rebamipide, Serum concentration, Tablet|The test preparation, Rebamide® (containing 100 mg of rebamipide; lot No. KP005; expiration date, April 2010; Kyungdong Pharmaceutical Company, Seoul, Korea) and the reference preparation, Mucosta® (containing 100 mg of rebamipide; lot No. MC704067; expiration date, May 2010; Korea Otsuka Pharmaceuticals Co., Ltd., Seoul, Korea)
89163659|NCT02714933|Experimental|MRI sequence Advanced ZTE|
89163660|NCT03885661|Experimental|Icosapent ethyl|Icosapent ethyl with a total daily dose of 4 grams, as 2 x 1 gram capsules by mouth twice daily, against a statin background
89163661|NCT03885661|No Intervention|Usual Care|Statin background
89163662|NCT00697632|Experimental|1|
89163663|NCT00997867|Active Comparator|Catheter 0-1cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 0-1cm past the needle tip. The patient will be called the following day by research staff to assess their post-surgical pain.
89163664|NCT00997867|Active Comparator|Catheter placed 5-6cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 5-6cm past the needle tip. Patients will be called the following day by research staff to assess their post-surgical pain.
89163665|NCT00496613||1|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with a combination of chemotherapy and hormonal therapy, matched on age and education
89163666|NCT00496613||2|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with hormonal therapy only matched on age and education
89163667|NCT00496613||3|Healthy women matched on age and education
89163668|NCT01001455||blood pressure monitor|Cuff circumference:22cm-36cm
89163669|NCT01001455||stethoscopy|Cuff circumference: 22cm-36cm
89163670|NCT04034615|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
89163671|NCT04034615|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
89163672|NCT04034615|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
89163673|NCT00868530|Experimental|Xyntha|This trial was an open-label and included assessments of safety, clinical efficacy, and Factor VIII (FVIII) recovery in Chinese subjects with hemophilia A. Subjects received on-demand treatments with Xyntha over a 6-month (calendar day) period.
89163674|NCT01001533||Children sedated by DEX|All pediatric patients (1 month to 18 years of age) eligible for Radiology Sedation Service for CT scan and Nuclear Medicine Scan procedure.
89163675|NCT02714777||Pediatric population from 4 to 8 years-old|Description of the Autonomic nervous system activity (parasympathetic activity)
89163676|NCT01004341|Other|Family-based weight control|Group-based family therapy for weight loss in children age 8-12 years.
89163677|NCT02620566|Active Comparator|Bupivacain -Caudal|Single shot Caudal Block will receive Group C with 1ml per kg Bupivacain 0,25%.
89163678|NCT02620566|Active Comparator|Bupivacain- Local|Single shot Local Infiltration will receive Group L with 0,2ml per kg Bupivacain 0,25%.
89163679|NCT02714621|No Intervention|Feasibility of MR-HIFU for painful gynaecological metastases|Investigating whether it would be possible to use the MRgHIFU system to treat recurrent gynaecological cancers.
89163680|NCT02714621|Experimental|Treatment using MR-HIFU of painful gynaecological metastases|Testing whether MRgHIFU could be an effective treatment for the symptoms of recurrent gynaecological cancers (pain and bleeding)
89163681|NCT01001611|Experimental|CKD-501 0.5mg|
89163682|NCT01001611|Placebo Comparator|Placebo|
89163683|NCT04134546|Experimental|group with biliary injury|group for Early versus late intervention after biliary tract injury post cholecystectomy
89163684|NCT00997945|Experimental|1|ZD4054 (Zibotentan) 10mg
89163685|NCT04134624|Active Comparator|Prehospital intervention|All subjects enrolled in this study will receive a sepsis intervention bundle in the prehospital setting, including blood cultures, IV fluids, and antibiotics. These patients will be compared to historical controls.
89163686|NCT04134624|No Intervention|Control arm|Historical controls without prehospital sepsis intervention.
89163687|NCT02714699|Experimental|diclofenac potassium|oral diclofenac potassium
89163688|NCT02714699|Active Comparator|hyoscine butyl bromide|oral hyoscine butyl bromide
89163689|NCT02714699|Placebo Comparator|placebo|oral placebo
89163690|NCT01004419|Experimental|Vandetanib plus fulvestrant|vandetanib by mouth once daily for 28 days plus fulvestrant intra-muscular injection each cycle
89163691|NCT02620644|Other|G1 Diabetics with no retinpathy|Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). OCT retinal GCC measurements.
89163692|NCT02620644|Other|G2 Non diabetics|Group consists of non-diabetic subjects, free from any ocular pathology(21 eyes).OCT retinal GCC measurements.
89163693|NCT00694902|Experimental|Sequence 1 of Cohort-I|Subjects in Sequence 1 will receive Placebo during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
89163694|NCT00694902|Experimental|Sequence 2 of Cohort-I|Subjects in Sequence 2 will receive 10 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
89163695|NCT00694902|Experimental|Sequence 3 of Cohort-I|Subjects in Sequence 3 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
89163696|NCT00694902|Experimental|Sequence 4 of Cohort-I|Subjects in Sequence 4 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
89163697|NCT00694902|Experimental|Sequence 5 of Cohort-II|Subjects in Sequence 5 will receive Placebo during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
89163698|NCT00694902|Experimental|Sequence 6 of Cohort-II|Subjects in Sequence 6 will receive 30 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
89163699|NCT00694902|Experimental|Sequence 7 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
89163700|NCT00694902|Experimental|Sequence 8 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
89163701|NCT00694902|Experimental|Cohort III|Subjects in Cohort III after randomization will either receive 1000 microgram GSK610677 or placebo.
89163702|NCT02712203||12 months|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age
89163703|NCT02712203||13 months|MMR vaccine / MMRV vaccine : administration of the first dose at 13 months of age
89163704|NCT02712203||14 months|MMR vaccine / MMRV vaccine : administration of the first dose at 14 months of age
89163705|NCT02712203||15 months or more|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age or older
89163706|NCT02620488|Active Comparator|Healthy Control|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
89163707|NCT02620488|Experimental|Sickle Cell Disease|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
89163708|NCT00598442|Experimental|Peginesatide 0.025 mg/kg|
89163709|NCT00598442|Experimental|Peginesatide 0.04 mg/kg|
89163710|NCT00598442|Active Comparator|Darbepoetin alfa|
89163711|NCT04132752|Experimental|Intervention|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
89163712|NCT04132752|No Intervention|Control|Parents were informed about obstetric brachial plexus palsy, given home exercise program and exercise diary.
89163713|NCT02714543|Experimental|aloevera group|aloevera juice twice daily for 3 months. aloevera gel one scoop to be applied 3-4 times daily for 3 months
89163714|NCT02714543|Active Comparator|steroid group|intralesional injection of hydrocortisone 100mg and injection hyaluronic acid 1500IU once a week for 6 weeks with Capsules SM Fibro once daily for 3 months.
89163715|NCT02714231|Experimental|diclofenac|oral diclofuhenac sodium
89163716|NCT02714231|Active Comparator|hyoscine|oral hyoscine butyl bromide
89163717|NCT00855309|Experimental|Arm I|Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.
89163718|NCT00855309|Experimental|Arm II|Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.
89163719|NCT00532129|Experimental|Rituximab plus Chlorambucil|Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.
89163720|NCT02616120|Placebo Comparator|Placebo|placebo identified to SQJZ herbal mixtures, 29.375g, 2 times per day.for 12 weeks.
89163721|NCT02616120|Active Comparator|SQJZ herbal mixtures|SQJZ herbal mixtures 29.375g, 2 times per day.for 12 weeks.
89163722|NCT02714309|Experimental|Control Trial|A mixed macronutrient breakfast meal is consumed without additional protein, following a period of rest. An ad libitum lunch meal is subsequently consumed.
89163723|NCT02714309|Experimental|Exercise No Preload Trial|Following an exercise bout a mixed macronutrient breakfast meal is consumed without additional protein. An ad libitum lunch meal is subsequently consumed.
89163724|NCT02714309|Experimental|Exercise With Preload Trial|Following low/moderate intensity exercise bout, whey protein (20g) administered prior to consumption of mixed macronutrient breakfast meal. An ad libitum lunch meal is subsequently consumed.
89163725|NCT04163276||Group 1|20 patients without anomaly of brain metabolism
89163726|NCT04163276||Group 2|20 patients with Alzheimer's disease
89163727|NCT00854607||Invasive Aspergillosis|Observational
89163728|NCT02616198|Active Comparator|EquiaFil G-coat|EquiaFil G-coat combination was applied on one randomly selected cavity to be restored
89163729|NCT02616198|Active Comparator|EquiaFil Fuji Varnish|EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored
89163730|NCT02616198|Active Comparator|Riva SC G-coat|River SC G-coat combination was applied on one randomly selected cavity to be restored
89163731|NCT02616198|Active Comparator|Riva SC Fuji Varnish|River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored
89163732|NCT00656396|Active Comparator|Control|Standard care
89163733|NCT00656396|Experimental|Intervention|Point of care monitoring used
89163734|NCT02751281|Active Comparator|pneumatic percutaneous nephrolithotomy|pneumatic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
89163735|NCT02751281|Active Comparator|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
89163736|NCT02616042|Experimental|Centella asiatica and bamboo salt|Participants received a dentifrice which contains Centella asiatica, bamboo salt, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime). All participants used the assigned dentifrices for 4 days in each trial cycle.
89163737|NCT02616042|Experimental|Centella asiatica|Participants received a dentifrice which contains Centella asiatica, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
89163738|NCT02616042|Placebo Comparator|Control dentifrice|Participants received a plain dentifrice which contains dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
89163739|NCT04163588|Active Comparator|Standard therapy|intravenous loop diuretics as recommended by current guidelines plus placebo
89163740|NCT04163588|Experimental|SNB|loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
89163741|NCT05167513|Experimental|Uncontrolled Diabetes with Metformin or Metformin resistant|
89163742|NCT00635687|Experimental|Fibroscan|
89163743|NCT04118127|Experimental|2mg conventional tablet, once-weekly tablets|
89163744|NCT02751515|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
89163745|NCT00654056|Experimental|L1|Actrapid infusion, 0.5 mU/kg/min.
89163746|NCT00654056|Experimental|L2|Actrapid infusion 1.5 mU/kg/min
89163747|NCT00654056|Experimental|H1|Actrapid infusion 3.0 mU/kg/min
89163748|NCT00654056|Experimental|H2|Actrapid infusion 5.0 mU/kg/min
89163749|NCT02615886|Experimental|Observational Control|Randomized participants will be observed for diarrhea incidences throughout the 6 month trial with no intervention.
89163750|NCT02615886|Experimental|Rice Bran|Randomized participants will consume a measured dose of rice bran daily throughout the 6 month trial.
89163751|NCT00854373|Experimental|1|Bravelle
89163752|NCT00854373|Placebo Comparator|2|Saline
89163753|NCT01001689|Experimental|Nutritional counseling + exercise groups|Women in this arm will receive 2 telephone consultations on nutritional health during pregnancy, be invited to 2 evening meetings with nutritional topics and have access to a password protected internet site with topics related to nutrition and fitness in pregnancy. They will also be enrolled in an exercise group which will meet twice weekly, and be encouraged to exercise on their own 1-2 times each week.
89163754|NCT01001689|No Intervention|control|Women in this arm of the study will receive routine pregnancy care.
89163755|NCT04220333|Placebo Comparator|Control|Participants received the instruction: 'please, lie down, relax and pay attention to your breath'. This procedure was carried during 15 minutes. Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings.
89163756|NCT04220333|Experimental|Intervention|"The intervention protocol was divided in two steps: first, patients spent 5 minutes in the phase of harmonization with five colored stones of a size of a walnut (green, red, yellow, white and black) placed around their bodies.~Second, in accordance to the emotion chosen by the participant, a matching mandala was placed next to the feet, on the abdomen, or next to the head depending on the self-perceived personality type, intuitive, emotive and rational for the remaining 10 minutes (Figure 3B). The researcher also checked the control subjects once during the 15 fifteen minutes of experiment.~Soon after the experiment, individual assessment was performed blinded to who received intervention using a structured questionnaire and Likert-scales about the degree of relaxation and feelings."
89163757|NCT01001845|No Intervention|Lifestyle counseling|
89163758|NCT01001845|Active Comparator|vit E|200mg 2 times per day for 3 weeks
89163759|NCT01001845|Experimental|Milk Thistle extract|1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks
89163760|NCT01001845|Experimental|vit E + Milk Thistle Extract|200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks
89163761|NCT02712281|Experimental|Autism MEAL Plan|Parents of eligible children who are randomized to the Autism Managing Eating Aversions and Limited variety (MEAL) Plan will participate in group-based parent training sessions (4 parents per group).
89163762|NCT02712281|Active Comparator|Parent Education|Parents of eligible children who are randomized to the Parent Education Arm will receive group-based parent education (PE). Each group includes 4 parents.
89163763|NCT02635334|Experimental|Montelukast 10 mg daily for 8 weeks|Study subjects will take montelukast 10 mg orally daily for 8 weeks
89163764|NCT02635334|Placebo Comparator|Placebo daily for 8 weeks|Study subjects will take placebo orally daily for 8 weeks
89163765|NCT00853905|Experimental|Treatment 1(Triesence)|glaucoma surgery with 0.2cc Triesence adjunct.
89163766|NCT00853905|Active Comparator|Treatment 2 (balanced salt solution BSS)|glaucoma surgery with balanced salt solution, the standard technique.
89163767|NCT04162496|Experimental|Treatment with Restylane Refyne Group 1|Treat right side with Restylane Refyne with a cannula and left side with a needle
89163768|NCT04162496|Experimental|Treatment with Restylane Refyne Group 2|Treat left side with Restylane Refyne with a cannula and right side with a needle
89163769|NCT05429801|Experimental|Ozone Therapy|Rectal ozone treatment along with medical treatment was administered to the patients in this group, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks.
89163770|NCT05429801|Active Comparator|Control group|The patients in this group continued only their current medical treatment.
89163771|NCT04163120|Experimental|Intervention|In this single arm study subjects follow a low calorie mediterranean ketogenci diet
89163772|NCT00998179|Active Comparator|Acu-TENS|Application of Acu-TENS prior to exercise
89163773|NCT00998179|Placebo Comparator|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine) prior to exercise
89163774|NCT04234217|No Intervention|Untreated|Untreated condition (obstructive sleep apnea)
89163775|NCT04234217|Active Comparator|Continuous positive airway pressure (CPAP) treatment|Continuous positive airway pressure (CPAP) treatment
89163776|NCT04234217|Active Comparator|Niacin|Untreated, pharmacological suppression of lipolysis by Niacin
89163777|NCT01002079|Experimental|BMS-708163|
89163778|NCT01002079|Other|Rifampin|
89163779|NCT01002079|Experimental|Rifampin + BMS-708163|
89163780|NCT02639624|Experimental|Low bicarbonate dialysate First|Dialysis with low bicarbonate dialysate (expected normal for an adult ~24 mEq) for the first half of dialysis then switched over to normal bicarbonate dialysate for the second half.
89163781|NCT02639624|Active Comparator|Normal bicarbonate dialysate First|Dialysis with normal (37 mEq) for the first half of dialysis then switched over to low bicarbonate dialysate
89163782|NCT05429567|Experimental|fentanyl infusion Group|According to the body weight, 2 ug/kg fentanyl was diluted to 100 ml with normal saline. with rate of 2 mL/h infusions, 10 min lockout time and Initial PCIA analgesia regimen consisting of a 0.5 mL bolus was commenced to be given to the patients postoperative with evaluation the pain
89163783|NCT05429567|Experimental|NO fentanyl infusion Group|All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine only
89163784|NCT00868296|Active Comparator|Low dose|
89163785|NCT00868296|Active Comparator|High dose|
89163786|NCT01002157|Experimental|Vitamin K2 supplementation|
89163787|NCT01002157|Placebo Comparator|Placebo control|
89163788|NCT02636738|Experimental|experiment|Vela XL thulium laser, laser fiber and accessories
89163789|NCT01004497|Experimental|Modified Hyper-CVAD + Dasatinib|Dasatinib: 100 mg once daily, PO, for 4 weeks Cyclophosphamide: 300 mg/m2, IV, every 12 hours, days 1~3 Vincristine: 1.4 mg/m2/day (maximum 2 mg/day), IV, days 4 & 11 Daunorubicin: 45 mg/m2/day, IV, days 4 & 11 Dexamethasone: 40 mg/day, IV, days 1~4 & days 11~14 Cytarabine: 2 g/m2, IV, every 12 hours, days 1~5 Mitoxantrone: 12 mg/m2/day, IV, days 1~2
89163790|NCT02713919|Experimental|Intervention Group|Adapted German PRO-SELF© Plus Pain Control Program
89163791|NCT02713919|No Intervention|Control Group|No intervention
89163792|NCT02713841|Experimental|Inhaled insulin (LOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a low output mesh (aerosol particles sized 3.5-4.0 μm)
89163793|NCT02713841|Experimental|Inhaled insulin (MOM1)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
89163794|NCT02713841|Experimental|Inhaled insulin (MOM2)|repeat of single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
89163795|NCT02713841|Experimental|Inhaled insulin (HOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a high output mesh (aerosol particles sized 5.0-5.5 μm)
89163796|NCT02713841|Active Comparator|subcutaneous insulin lispro (LIS)|single 6 unit dose of insulin lispro administered subcutaneously
89163797|NCT01004575|Experimental|Kaname|patients that are treated by implanting Kaname Cobalt-Chromium coronary stent
89163798|NCT02615730|Experimental|Paclitaxel & GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily) in combination with a fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
89163799|NCT00656708|Experimental|PB|All patients admitted to the burn unit during the prospective portion (interventional portion) of the study who have open wounds will have Kerlix AMD applied to their wounds; only those patients consenting to the study will have data abstracted.
89163800|NCT00998257||Group 1|
89163801|NCT02713685|Experimental|Subarachnoid block|Subarachnoid block will be given in lateral position
89163802|NCT02713685|Active Comparator|Peripheral nerve block|Combined Femoral and Sciatic nerve block will be given using nerve stimulation technique
89163803|NCT02615808|Experimental|Oxygen saturation data visualization|During intervention periods staff in both units will have access to the data visualization tool in the electronic health record.
89163804|NCT02615808|No Intervention|Control|During control periods, the staff will not have access to the data visualization and will continue to use standard of care electronic health record and monitor data to understand oxygen status and trends.
89163805|NCT02635490||prophylactic antibiotics|
89163806|NCT01004653|Experimental|H1N1 influenza A Vaccine (Split virion), Inactivated|15 μg H1N1 influenza A Vaccine (Split virion), Inactivated
89163807|NCT02711891|Experimental|5% Loperamide gel|Participants received 5% loperamide gel (0.2gm equivalent to 10 mg) applied following a single surgilance to the 5th digit. The loperamide gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the loperamide gel which was left in place for 30 minutes. The placebo gel contained the same ingredients without the loperamide. The loperamide gel formulation includes: Loperamide 5%, Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
89163808|NCT02711891|Placebo Comparator|Placebo gel|Participants received placebo gel (0.2gm) applied following a single surgilance to the 5th digit. The placebo gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the placebo gel which was left in place for 30 minutes. .The placebo gel contained the same ingredients without the loperamide. The placebo gel formulation includes: Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
89163809|NCT02615496||Educational materials: Physicians|
89163810|NCT02615496||Educational materials: Patients|
89163811|NCT02639468|Experimental|Tomographie par impédance électrique|Tomographie par impédance électrique
89163812|NCT02714075|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
89163813|NCT02635412|Placebo Comparator|Scheduled delivery at 34 weeks|Scheduled delivery at 34 weeks (range 33 weeks 5 days to 34 weeks 3 days)
89163814|NCT02635412|Active Comparator|Scheduled delivery at 36 weeks|Scheduled delivery at 36 weeks (range 35 weeks 5 days to 36 weeks 3 days)
89163815|NCT04132908|Experimental|Sclerocarya birrea|
89163816|NCT04132908|Placebo Comparator|Placebo|
89163817|NCT05175157||General practitioner|Answer the Gut Fellings questionnaire
89163818|NCT05175157||Internal|Answer the Gut Fellings questionnaire
89163819|NCT02636426|Experimental|sorafenib|In this phase I study patients are treated with high-dose, pulsatile sorafenib in escalating AUC0-12h cohorts.
89163820|NCT02713763|Experimental|Sunitinib|Sunitinib 37.5 mg/day
89163821|NCT01002313||normal control|
89163822|NCT01002313||Patient treatment group|Treatment with prednisone
89163823|NCT00867360|Experimental|Mifepristone|Receive mifepristone for 8 days
89163824|NCT00867360|Placebo Comparator|Placebo|Receive placebo rather than mifepristone
89163825|NCT04219943|Experimental|Conservative Treatment for Impacted Femoral Neck Fracture|Conservative Treatment for Impacted Femoral Neck Fracture
89163826|NCT04000477|Experimental|Kevorkian curette|
89163827|NCT04000477|Experimental|Cytobrush|
89163828|NCT01002391|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
89163829|NCT01002391|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
89163830|NCT04132518|Experimental|Treatment Group|Each subject assigned to Treatment Group will receive up to 4 injection sessions with 5(±1) weeks intervals.
89163831|NCT04132518|No Intervention|Control Group|Subjects assigned to the Control Group will not receive treatment during the study.
89163832|NCT04220177|Experimental|treatment arm|SETA LATECBA Stent Grafts, are tube shaped implantable devices, delivered by balloon catheter system which are intended to the treatment of infrarenal AAA by sealing the affected areas, avoiding the bleeding or perfusion inside the aneurysm and restoring the normal hemodynamics in the affected vessels. The product family is composed by a set of endovascular stent grafts, that can be used alone or in combination, according to the treatment strategy, extension and complexity of the AAA. One aortic bifurcated stent graft, ABK SETA LATECBA model, is the aortic trunk and two straight iliac stent grafts, RIK SETA LATECBA model, are the connections to both iliac arteries.
89163833|NCT00998413|Experimental|Multifaceted intervention|Multifaceted intervention:physical exercise, nutrition, and behavioural intervention.
89163834|NCT00998413|No Intervention|Control|standard usual care
89163835|NCT04220099||schizophrenia patients needed ECT treatment|Whether patients need ECT treatment are assessed by clinicians according to American Psychiatric Association(APA) guidelines.
89163836|NCT01002469|Experimental|sodium [1-13C] acetate|
89163837|NCT05429333|No Intervention|Control group|After randomization control group was recommended to continue their regular diet with increased fluid (2 lt/day) and fiber intake (30 g/day) and received 5 mg of sodium picosulfate daily for 10 weeks.
89163838|NCT05429333|Experimental|Treatment group|In the study group, after fecal samples were taken, patients were recommended to continue their regular diet with increased fluid (2 lt/day) and fiber intake (30 g/day) for 4 weeks until the microbiome analysis resulted. During subsequent 6 weeks, they received the personalized microbiome modulatory diet.
89163839|NCT01004809||Dutasteride|Patients administrated dutasteride with male hair loss
89163840|NCT02711813|Placebo Comparator|Placebo|Placebo to TAB08
89163841|NCT02711813|Experimental|TAB08 Dose 1|
89163842|NCT02711813|Experimental|TAB08 Dose 2|
89163843|NCT00998569|Experimental|Neurocognitive Enhancement|neurocongnitive enhancement
89163844|NCT00998569|Other|Wait List|no intervention
89163845|NCT04161911||Advanced Hepatocellular Carcinoma (aHCC) cohort|aHCC cohort selected from the Flatiron Health Oncology electronic health record (EHR) data from January 2011 to the most recent data available. The index date will be defined as the start of second or third line nivolumab therapy for aHCC between January 1, 2011 and the most recent data available.
89163846|NCT01004887||Single group|Patients with newly diagnosed high-grade gliomas participating in NCCTG/Alliance or Mayo protocols. Previously collected blood and tissue samples are analyzed via PCR, IHC, flow cytometry, and FISH.
89163847|NCT04727255|Experimental|Intervention|The intervention will be implemented through a group-based delivery format involving internal educated resilience trainers. The Engaged and Resilient training program consists of twenty weekly, short-term sessions to build resilience skills in leaders.
89163848|NCT04727255|No Intervention|Control|Participants in the (waitlist) control group will be exposed to their usual activities in the organization and will not perceive any interventions from the resilience curriculum. After the final data is collected, the control participant will be offered the opportunity to be trained by the internal trainers, educated in the research study.
89163849|NCT02711423|Experimental|Part I (Dose Escalation): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1.
89163850|NCT02711423|Placebo Comparator|Part I (Dose Escalation): Placebo|Participants will receive a single SC dose of matching placebo on Day 1.
89163851|NCT02711423|Experimental|Part II (PK Extension): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1. The dose range will be determined by safety and tolerability data collected from Part I.
89163852|NCT00593736|Experimental|Ramelteon 1 mg QD|
89163853|NCT00593736|Experimental|Ramelteon 4 mg QD|
89163854|NCT00593736|Experimental|Ramelteon 8 mg QD|
89163855|NCT00593736|Placebo Comparator|Placebo QD|
89163856|NCT00636779||1|Up to five hundred eligible patients seen at each of the nine participating Integrative Medicine Centers will be approached (by mail, phone, at the time of their visit, etc.) and invited to consent to the paper and pencil study.
89163857|NCT03742765|Experimental|Incentivizing Planning|Participants will receive three texts each week asking a question to help plan for the next workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout).
89163858|NCT03742765|Experimental|Incentivizing Exercise|Participants will receive three texts each week asking a question about their workout. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout).
89163859|NCT02713451|Active Comparator|Liberal Oxygenation (LO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
89163860|NCT02713451|Experimental|Conservative Oxygenation (CO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
89163861|NCT01002625|Experimental|1. PF-04457845 followed by placebo|PF-04457845 followed by placebo
89163862|NCT01002625|Experimental|2. Placebo followed by PF-04457845|Placebo followed by PF-04457845
89163863|NCT00883688|Experimental|Bevacizumab + Lapatinib|"Bevacizumab 10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle). Lapatinib Pills of 700 mg/m^2/dose given orally 2 times each day."
89163864|NCT04191863||Children with enuresis|28 epileptic children with induced secondary nocturnal enuresis in valproate monotherapy.
89163865|NCT04191863||Children without enuresis|232 epileptic children without induced secondary nocturnal enuresis in valproate monotherapy.
89163866|NCT03883477|Experimental|Endoscopic Release|12 patients recommended for surgical treatment of trigger finger will undergo endoscopic release.
89163867|NCT03883477|Active Comparator|Standard Open Release|12 patients recommended for surgical treatment of trigger finger will undergo standard open surgical release.
89163868|NCT02711501|Experimental|Laser irradiation|laser-assisted surgery with the following parameters: Wavelength:810 nanometer, power: 3 W, pulse mode,pulse length 100 µs, pulse interval 200 µs
89163869|NCT02711501|Experimental|blade|conventional surgery by blade
89163870|NCT02636348|Experimental|Calcium/Vitamin D Bar|Dietary supplement consumed as 2 calcium and vitamin D fortified snack bars per day
89163871|NCT02636348|Experimental|Calcium/Vitamin D Pill|Dietary supplement consumed as several capsules per day
89163872|NCT02636348|Placebo Comparator|Placebo Bar|Placebo consumed as 2 isocaloric, unfortified snack bars per day
89163873|NCT02636348|Placebo Comparator|Placebo Pill|Placebo consumed as several capsules per day
89163874|NCT04162340|Experimental|CD4 CAR T cells|Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg
89163875|NCT00998647||with modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
89163876|NCT00998647||without modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
89163877|NCT05428553|Experimental|CSP/p-CSP|Prospective allocation
89163878|NCT05428553|Active Comparator|EMR/EPMR|Historical control
89163879|NCT00654212|Active Comparator|1|endoluminal stenting followed by laparoscopic resection (endo-laparoscopic limb, the study group)
89163880|NCT00654212|Other|2|emergency open surgery (open limb, the control group)
89163881|NCT04219865|Active Comparator|Compound Edaravone|10 mL per vial (containing edaravone 10 mg and 2-aminoethanesulfonic acid 200 mg)
89163882|NCT04219865|Placebo Comparator|Placebo|10 mL per vial
89163883|NCT01002703|Experimental|RBP|Lenalidomide and Bendamustine and Prednisone
89163884|NCT04162886|Experimental|Exercise Group|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
89163885|NCT04162886|No Intervention|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
89163886|NCT02713295||Subjects with Moderate to Severe Plaque Psoriasis|Subjects with Moderate to Severe Plaque Psoriasis in Greece
89163887|NCT02639234|Experimental|Vigil™ + Nivolumab|Patients meeting study eligibility criteria will receive doublet therapy comprising of (i) Vigil™ 1 x 10^7 cells by intradermal injection every 2 weeks (for a minimum of 4 and a maximum of 12 doses) and (ii) nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks.
89163888|NCT01002859|Active Comparator|cyclosporin|Intravenous cyclosporin injection.
89163889|NCT01002859|Placebo Comparator|Pacebo|Intravenous injection of NaCl solution.
89163890|NCT00654290|Experimental|P|Propranolol from 7 days pre-operation to 5 days post CABG
89163891|NCT00654290|Active Comparator|A|Amiodarone treated 7 days pre-operation to 5 days post CABG
89163892|NCT00654290|Active Comparator|AP|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
89163893|NCT02713217||Pre-Implementation Cohort|Eligible patients will be recruited and enrolled prior to implementation of the blended integrated care model in each study site. They will be exposed to care as usual in the CBOCs.
89163894|NCT02713217||Post-Implementation Cohort|"Eligible patients will be recruited and enrolled following implementation of the blended integrated care model in each study site. These participants are thus exposed to the intervention model."
89163895|NCT01005043|Experimental|heavy ion radiotherapy|Heavy ion radiotherapy of osteosarcoma with 60 to 66 GyE (20-22 days). Before and after radiotherapy, but not during radiotherapy, chemotherapy is recommended to standard therapy protocols like EURAMOS 1 which is not part of this study.
89163896|NCT02636192||Cohort 1|Cohort 1 included participants who were exposed to sodium-glucose co-transporter 2 (SGLT2) inhibitor (canagliflozin, dapagliflozin and empagliflozin).
89163897|NCT02636192||Cohort 2|Cohort 2 included participants who were exposed to other non-SGLT2 antihyperglycemic agents (AHA).
89163898|NCT00998725||HIV+ARV+|
89163899|NCT00998725||HIV+ARV-|
89163900|NCT00998725||HIV negative|
89163901|NCT02713139|Experimental|Colpistatin 5DT|
89163902|NCT02713139|Active Comparator|Gynecological Flagyl|
89163903|NCT02713139|Active Comparator|Gino-Canesten 3|
89163904|NCT02634944|Experimental|mTBI|mTBI (concussed) participants will be administered the VOMS after concussive event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
89163905|NCT02634944|Sham Comparator|Healthy Control|Healthy controls will be administered the VOMS tool. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
89163906|NCT02634944|Experimental|BLAST mTBI|Blast mTBI (concussed) participants will be administered the VOMS after concussive blast event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
89163907|NCT02634944|Experimental|BLUNT mTBI|Blunt mTBI (concussed) participants will be administered the VOMS after concussive blunt event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
89163908|NCT00853827|Placebo Comparator|1|
89163909|NCT00853827|Experimental|2|Aliskiren 300 mg
89163910|NCT03990545||Cases with stroke|
89163911|NCT03990545||Controls without stroke|
89163912|NCT01005121|Experimental|colchicine|patients will receive 2 mg of colchicine daily
89163913|NCT02634866||Group N|The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
89163914|NCT02634866||Group D|The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
89163915|NCT02634866||Group D_HF|The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
89163916|NCT02711579|Experimental|Celecoxib for electroencephalography|Electroencephalography will be performed before and after celecoxib administration
89163917|NCT02711579|Placebo Comparator|Placebo for electroencephalography|Electroencephalography will be performed before and after placebo administration
89163918|NCT02711579|Experimental|Celecoxib for motor evoked potential|Motor evoked potential will be measured before and after celecoxib administration
89163919|NCT02711579|Placebo Comparator|Placebo for motor evoked potential|Motor evoked potential will be measured before and after placebo administration
89163920|NCT00998803||Immunocompromised participants|Immunocompromised (<= 21 years of age) due to cancer, receipt of stem cell transplant, human immunodeficiency virus (HIV) or Sickle cell disease
89163921|NCT02635178|Experimental|Active|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
89163922|NCT02635178|Placebo Comparator|Control|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
89163923|NCT00611195|Other|1|Larynx assessment under stimulation
89163924|NCT01002937||Tumour tissue, renal cell carcinoma|> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.
89163925|NCT02636114|Active Comparator|scaling and root planing|this was an international study in which scaling and root planing was done in systemically healthy patients patients with chronic periodontitis
89163926|NCT02636114|No Intervention|control group|Scaling and planing was not done that no intervention is carried out in this group
89163927|NCT01003015|Experimental|Arm 1|
89163928|NCT02713061|Experimental|TAK-850 0.5 mL|TAK-850 0.5 mL (15 µg of hemagglutinin [HA] antigen per strain), subcutaneous injection, once on Day 1.
89163929|NCT02635100|Experimental|MNT Algorithm|All participants will be monitored using an existing (FDA approved) CPAP machine that has been modified to be externally controlled by a computer with the MNT algorithm, for titration.
89163930|NCT02711657|Experimental|Fibrocyte measurement and lung function test|All participants has a peripheral blood sample taken, where fibrocytes are measured using flowcytometry. Further peripheral blood mononuclear cells (PBMC) are isolated and cultured. All, except healthy controls, have their lung function measured.
89163931|NCT01008709|Placebo Comparator|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur
89163932|NCT01008709|Active Comparator|Aesculap U-Clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur.
89163933|NCT02639156|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing at least 300kcal/day will be changed onto an equivalent prescription of AYMES LONDON for a period of 9 days.
89163934|NCT02615574|Experimental|αDC1 vaccine + CKM|all subjects enrolled in study
89163935|NCT01003093|Experimental|Antigen group + high adjuvans|The antigen group + high adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (500 nmol KLK + 20 nmol ODN1a) two months apart.
89163936|NCT01003093|Experimental|Antigen group|The antigen group received two injections of antigen (Ag85B + ESAT-6) two months apart.
89163937|NCT01003093|Experimental|Antigen + low adjuvans group|The antigen group + low adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (100 nmol KLK + 4 nmol ODN1a) two months apart.
89163938|NCT04032938||the control group|30 healthy people as the control group.
89163939|NCT04032938||the case group|60 patients were admitted to intensive care unit (ICU) as the case group after cardiac surgery and extracorporeal circulation. This group should contain 30 patients with fever and/or hemodynamic instability and 30 patients with normothermia and normal hemodynamic.
89163940|NCT01003171|Experimental|MCS-2|
89163941|NCT05428241|Experimental|Experimental|Study group intervention consists 6-session Motivational Interviews and 3-month follow-up.
89163942|NCT05428241|No Intervention|No Intervention|Control group receives general care and the training booklet at the end of the study. Also includes 3-month follow-up.
89163943|NCT02639000|Experimental|Blastocyst|Embryo transfer of at maximum 2 embryos at blastocyst stage
89163944|NCT02639000|Active Comparator|Cleavage|Embryo transfer of at maximum 2 embryos at cleavage stage
89163945|NCT02708693|Experimental|experimental: steroid injection and splinting|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine) and a customized volar thermoplastic wrist splint
89163946|NCT02708693|Active Comparator|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
89163947|NCT02638922||no treatment|girls who never received estradiol treatment
89163948|NCT02638922||Estradiol treatment|girls who received estradiol treatment
89163949|NCT01005199|Experimental|Arm A: Sorafenib standard|• Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).
89163950|NCT01005199|Experimental|Arm B: Sorafenib + everolimus|• Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)
89163951|NCT02711189|Active Comparator|Oxytocin|Intranasal oxytocin will be delivered on twice daily basis in this crossover trial.
89163952|NCT02711189|Placebo Comparator|Placebo|Within Subject Design
89163953|NCT02635802|Experimental|Remifentanil|injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time >1min,then 5μg/kg·h pumping until the operation is finished.
89163954|NCT02635802|Experimental|Lidocaine|injection form concentration 10mg/ml loading dose 100-400mg local anesthesia
89163955|NCT02635802|Experimental|Remifentanil+Lidocaine|"injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time >1min,then 5μg/kg·h pumping until the operation is finished~+ injection form concentration 10mg/ml loading dose 100-400mg local anesthesia"
89163956|NCT00853749|Other|Single|All subjects will receive a single dose of 13vPnC
89163957|NCT02708771|Experimental|Intervention|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
89163958|NCT02708771|Placebo Comparator|Control|Capsules of similar appearance and flavor without active drug
89163959|NCT05093569||Iteration|35 patients will be included in 7 iterations.
89163960|NCT02635958||Group 1|BMI 18.5 to 24.9
89163961|NCT02635958||Group 2|BMI 25 to 29.9
89163962|NCT02635958||Group 3|BMI 30 to 34.9
89163963|NCT02635958||Group 4|BMI ≥ 35
89163964|NCT01008865|Experimental|Studer Pouch|Studer Pouch orthotopic urinary diversion
89163965|NCT01008865|Experimental|T-Pouch|T-Pouch orthotopic urinary diversion
89163966|NCT00657410|Experimental|ARM A - PDN|PDN is administered orally at the daily dose of 1 mg/Kg for 4 consecutive weeks (from day 0 to day 28), then, therapy is tapered within 14 days. The patients considered NOT RESPONDER at day 42 or WHO HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be crossed to ARM B.
88804617|NCT03428217|Placebo Comparator|Pbo-Cabo|Placebo twice daily (BID) + cabozantinib (60 mg once daily [QD]) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or unacceptable toxicity, whichever occurred first.
89163967|NCT00657410|Experimental|ARM B - DXM|"DXM is administered orally at single fixed daily doses of 40 mg for 4 consecutive days, every 14 days, for 3 consecutive courses. If platelet count is £ 20x109/L or bleeding symptoms related to thrombocytopenia are present, lowdose DXM (0.035 mg/Kg/day) between courses is given. The patients (either from ARM A+B or from ARM B) considered NOT RESPONDER at day 46 or who HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be considered OFF TREATMENT.~For these patients a second line therapy will be considered, according to the medical practice of the Centre (splenectomy or other)."
89163968|NCT01009021|Other|Placebo first (scheme 2)|scheme 2 patients (n=15) received a brown-coated tablet of saccharine (placebo) 45 minutes before the first PRP episode [placebo treatment episode (PTE)] at baseline to the right eye and two weeks after received one 50 mg tablet of potassium diclofenac 45 minutes before the second PRP episode [diclofenac treatment episode (DTE)] to the left eye
89163969|NCT01009021|Other|Diclofenac first (scheme 1)|scheme 1 patients (n=15) received one 50 mg tablet of potassium diclofenac 45 minutes before the first PRP episode [diclofenac treatment episode (DTE)] at baseline to the right eye and two weeks after received an identical brown-coated tablet of saccharine (placebo) 45 minutes before the second PRP episode [placebo treatment episode (PTE)] to the left eye
89163970|NCT01005433|Active Comparator|Dexmedetomidine 0.6 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
89163971|NCT01005433|Active Comparator|Dexmedetomidine 0.4 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 4 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
89163972|NCT01005433|Active Comparator|Dexmedetomidine 0.2 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia.
89163973|NCT01005433|Placebo Comparator|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 20 min before induction of anesthesia
89163974|NCT01003327|Other|I-gel inserted first|The I-gel airway is insewrted first, then the LMA-Unique
89163975|NCT01003327|Other|LMA-Unique inserted first|LMA-Unique airway is inserted first, then the I-gel
89163976|NCT04162262|Experimental|Stretching, Strengthening, and IASTM|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. This group will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
89163977|NCT04162262|Active Comparator|Strengthening and Stretching|This group will attend eight weekly sessions, which will include initial screening tests and exercise education on visit 1 and strengthening and stretching exercise progression on visits 1-8. Data measurements will occur at weeks 0, 4, 8, and 12. To equalize visit time with the Stretching, Strengthening, and IASTM group, subjects will perform 15 minutes of self-paced bicycle riding at the beginning of each session. They will then perform stretching and strengthening exercises under the supervision of an investigator masked to treatment group weekly for eight visits. Exercise resistance will be increased as needed each week. In addition, participants will perform daily stretching and strengthening exercises at home.
89163978|NCT04162262|Other|Pain-free Comparison Group|The third group is a pain-free comparison group. This group will come to the laboratory once. They will perform a 5-minute, self-paced warmup on a stationary bicycle followed by a 10-minute IASTM treatment. Test measurements will be performed before and immediately following the warmup and IASTM treatment. These measurements will be compared to the same measures from the Stretching, Strengthening, and IASTM group to examine outcome measure differences in those with and without plantar fasciopathy following a single IASTM treatment.
89163979|NCT01003405|Experimental|KUC-7483|
89163980|NCT00654446|Experimental|1|Rosuvastatin
89163981|NCT00654446|Active Comparator|2|Simvastatin
89163982|NCT01003483|Experimental|Orlistat|The dose of 120 mg orlistat was taken three times daily and the dose remained constant throughout the study period.
89163983|NCT01003483|Experimental|Metformin|The dose of metformin was increased step - wise, from 500 mg once daily for the first week to 500 mg twice daily for the next week, and to 500 mg three times daily for the remaining study period .
89163984|NCT00592839|Experimental|1|0.3 mg SCE-B Daily
89163985|NCT00592839|Experimental|2|0.625 mg SCE-B Daily
89163986|NCT00592839|Placebo Comparator|3|Placebo
89163987|NCT00911222||antiemetic treatment|epidemiological registry
89163988|NCT01009177|Experimental|Bosentan|
89163989|NCT01009177|Placebo Comparator|Placebo|
89163990|NCT00598832|Experimental|Adapalene lotion 0.1%|
89163991|NCT00598832|Placebo Comparator|Adapalene Lotion vehicle|
89163992|NCT01003561|Experimental|ultrasonographic exam|
89163993|NCT04117737|Experimental|Intervention|Single-arm
89163994|NCT01005511|Experimental|Grindcare|24 patients receiving active treatment
89163995|NCT01005511|Placebo Comparator|Placebo treatment|24 patients receive a placebo treatment
89163996|NCT02711267|Experimental|Phase 1: Optimization Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes (OFM Probe) will be implanted per site resulting in 12 dOFM probes per subject (operated by OFM pump). On each the arm and the leg the proximal and distal site of the 3 adjacent sites will be treated by 5% Zovirax® cream. The central site on arm and leg will be left untreated in order to test a potential lateral carry-over of acyclovir from one application site to the other. Blood samples will be taken to test for uptake into the blood stream and redistribution to other application sites.
89163997|NCT02711267|Experimental|Phase 2: Formulation Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. Different topical 5% acyclovir formulations currently available on the market will be tested. One application site on the arm and one on the leg will be used for U.S. Zovirax® cream 5% application. The remaining two application sites on the arm and the remaining 2 on the leg will be used to randomly administer two of the remaining formulations (5% Aciclostad cream, 5% Aciclovir cream 1A Pharma, 5% Zovirax® cream (Austria), 5% Zovirax Cold Sore Cream) according to an application pattern.
89163998|NCT02711267|Experimental|Phase 3: Pilot BE study|4 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug product (R) and one test drug product (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied, and to test for non-BE between application sites with R and T applied.
89163999|NCT02711267|Experimental|Phase 4: Main BE Study|20 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug (R) and one test drug (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied and to test for non-BE between application sites with R and T applied.
89164000|NCT00700089|Experimental|A|The concept is to support and guide the person shortly after the in-hospital treatment for self-injury through a recommended follow-up or after treatment based on assertive principles. The intervention is an indicated prevention strategy targeting people with suicide attempts and deliberate self-harm as a high-risk group. They will be offered 8-20 assertive outreach contacts. The outreach contacts will be home visits focusing on providing support and motivating patients to comply with follow-up treatment.
89164001|NCT00700089|Placebo Comparator|B|Standard treatment consists of referral to a range of different treatment modalities depending on the diagnosis and clinical and social condition of the patient. In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
89164002|NCT03999619|Experimental|Experimental|Children will enter into the Move 2 Learn program immediately following their first assessment (between week 0 to 10)
89164003|NCT03999619|Other|Wait-list Control|Children will not participate in the program until after their second assessment (between week 11 to 21). Their control period will take place between week 0 and 10.
89164004|NCT00700167|Experimental|1|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.~The vaccines will be given during an outpatient visit. If for some reason, you happen to be in the hospital, you can still receive the vaccines. These visits should take no longer than 15-30 minutes."
89164005|NCT04219553|Other|Retrospective group|Comparator group (pre-intervention)
89164006|NCT04219553|Experimental|Prospective group|Study group (post-intervention)
89164007|NCT01003717||Endeavor|Patients treated with at least 1 Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome
89164008|NCT01009255|Experimental|GSK239512|Oral tablets
89164009|NCT01009255|Placebo Comparator|Placebo|Placebo to match GSK239512.
89164010|NCT00638261|Other|left/right|left or right body side
89164011|NCT02708225|Experimental|interventional - with a medical clown|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test with a medical clown present
89164012|NCT02708225|No Intervention|non interventional|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test without a medical clown present
89164013|NCT04459871|Experimental|The experimental group|The topical recombinant human thrombin(rhThrombin) was prepared into 1000IU/mL solution with 10ml normal saline and used in combination with absorbable gelatin spongeat at appropriate bleeding evaluation site(s).
89164014|NCT04459871|Placebo Comparator|The control group|The placebo was prepared into a solution with 10mL normal saline and used in combination with absorbable gelatin sponge at appropriate bleeding evaluation site(s).
89164015|NCT01005667|Experimental|BirthTrack Monitor|
89164016|NCT01005667|No Intervention|Control - no BirthTrack Monitor|
89164017|NCT02708459|Active Comparator|Control|Control group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.
89164018|NCT02708459|Active Comparator|Bupevecaine group|Postoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
89164019|NCT02708459|Active Comparator|Dex group|catheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
89164020|NCT01003795||Promus|Patients treated with at least one Promus, everolimus-eluting, Stent
89164021|NCT02711033|Experimental|Laparoscopic-assisted total gastrectomy|Patients including in the laparoscopic-assisted total gastrectomy (LATG) group will undergo LATG with spleen-preserving splenic hilum lymph nodes dissection.
89164022|NCT02711033|Active Comparator|Open total gastrectomy|Patients who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
89164023|NCT00853593|Experimental|Model 4396 LV Lead|Non-randomized study.
89164024|NCT05610241|Experimental|Compression Therapy System Prototype|Identifies legs randomized to receive the experimental intervention
89164025|NCT05610241|Active Comparator|Coban 2 (2 Layer Compression Wrap)|Identifies the legs randomized to receive the control intervention
89164026|NCT02708069|Other|e-Unstuck condition|Parents in the e-Unstuck condition will be asked to complete each of the e-Unstuck modules (one per week) over the course of the nine-week intervention, in addition to reading the UOT manual.
89164027|NCT02708069|Other|In-Person condition|Parents participating in the in-person condition will be asked to attend two in-person trainings (approximately 125 and 100 minutes respectively) on the Unstuck and On Target (UOT) curriculum, in addition to reading the UOT manual.
89164028|NCT01005823|Active Comparator|LEO 29102 cream 0.3 mg/g|
89164029|NCT01005823|Active Comparator|LEO 29102 cream 1.0 mg/g|
89164030|NCT01005823|Active Comparator|LEO 29102 cream 2.5 mg/g|
89164031|NCT01005823|Placebo Comparator|LEO 29102 placebo cream|
89164032|NCT02707835|Active Comparator|control group|self massage, skin care education, manual lymph drainage exercise, compression garment
89164033|NCT02707835|Active Comparator|manual lymph drainage group|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
89164034|NCT02707835|Experimental|experimental group|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
89164035|NCT00700245|Active Comparator|EXO|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction),
89164036|NCT00700245|Active Comparator|DIO|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet)
89164037|NCT00700245|Active Comparator|DEX|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).
89164038|NCT01005979|Experimental|A|
89164039|NCT00913029|Active Comparator|Stent|One hundred patients will be randomized to implantation of two G2 stents in at least one eye.
89164040|NCT00913029|Active Comparator|Medication|One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.
89164041|NCT00635843|Experimental|MAVERICK™ Disc|
89164042|NCT00635843|Active Comparator|Fusion|
89164043|NCT00700323|Active Comparator|1|Patients receiving active product
89164044|NCT00700323|Placebo Comparator|2|Patients receiving placebo
89164045|NCT01006057|Experimental|ESRD|
89164046|NCT01006057|Experimental|Mild|
89164047|NCT01006057|Experimental|Moderate|
89164048|NCT01006057|Experimental|Normal|
89164049|NCT01006057|Experimental|Severe|
89164050|NCT00853125|Experimental|Sunitinib plus Irradiated Allogeneic Lymphocytes|
89164051|NCT02707913|Experimental|BF-Amlodipine Tablet 10mg|During the study session, healthy subjects will be administered a single dose of BF-Amlodipine Tablet 10mg after an overnight fast of approximately 10 hours
89164052|NCT02707913|Active Comparator|Norvasc Tablet 10mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablet 10mg after an overnight fast of approximately 10 hours
89164053|NCT05734027|Experimental|Sectional matrix band|precontoured sectional matrix band
89164054|NCT05734027|Active Comparator|Circumferential matrix band|Circumferential matrix band applied by tofflemire retainer
89164055|NCT02711111|Experimental|orthodontic bone anchor|new bone anchor device, which creates anterior traction on the upper jaw. Placed on the chin-region intra-orally.
89164056|NCT02711111|Active Comparator|face mask protraction|control group, conventional treatment method. Face mask creates anterior traction on the upper jaw
89164057|NCT02707679|Other|Effects of Mulligan's Mobilization|The patients in this arm (n=18) received two techniques pertaining to Mulligan's Mobilization with movement approach (Mulligan's Straight Leg-Raise with Traction and Tibial Gliding) along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. Primary outcomes: pain severity, knee range of motion, hamstring flexibility, and physical performance (10-step stair climbing test, timed up and go test), Kujala Patellofemoral Pain Scoring and Y-Balance test were assessed before the treatment, 45 minutes after the initial treatment, at the end of the 4-session-treatment during 2-week period and 6 weeks later.
89164058|NCT02707679|Other|Effects of Kinesiotaping|Patients in this arm were applied kinesiotaping on quadriceps and hamstring muscle along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. The same assessment parameters was conducted on this arm too.
89164059|NCT02710877|Experimental|Programmed Intermittent bolus (PIEB)|Intervention: epidural analgesia through administration of a mixture of levobupivacaine 0,0625% and sufentanil 4 mcg. Intermittent bolus of 10 ml mixture every 75 minutes. Patient controlled bolus of 5 ml same mixture, lock-out 15 minutes.
89164060|NCT02710877|Active Comparator|Manuale epidural bolus (TOP-UP)|Intervention: manual epidural bolus of 15 ml levobupivacaine 0,0625% and sufentanil 5 mcg on maternal request.
89164061|NCT04219631|Experimental|WINNER- FLOW-URO-MG GROUP|After admission to the delivery room, all women assigned to WF + group will have an interview with one of the midwifes responsible for the study. The latter will explain the use of the WINNER FLOW®-URO MG® device which is the expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate. Then, WF+ patients will use the expiratory mouthpiece device during all their childbirth process.
89164062|NCT04219631|No Intervention|NO WINNER-FLOW-URO-MG GROUP|Women enrolled in WF- group will be managed classically during their child birth process regardless to the study participation.
89164063|NCT02695823|Experimental|Patients undergoing liver transplantation|
89164064|NCT00636857|Experimental|I|Perioperative fluid management based on body weight
89164065|NCT00636857|Active Comparator|II|Perioperative fluid management based on Lean Body Mass (LBM)
89164066|NCT00530023|Active Comparator|1. 722|722 arm: MiniMed Paradigm REAL-Time System
89164067|NCT00530023|No Intervention|2. Multiple Daily Injections (MDI)|MDI arm: Continue with currently prescribed Multiple Daily Injection therapy. No change in treatment or regime for study.
89164068|NCT02707367|Experimental|Recovery Roadmap (RR) Wave 1|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include two pre-tests and two post-tests, building in an observation period that is not present in Wave 2.
89164069|NCT02707367|Experimental|Recovery Roadmap (RR) Wave 2|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include one pre-test and three post-tests.
89164070|NCT05733949|Experimental|Treatment (ST-SBRT)|Patients undergo ST-SBRT on study. Patients also undergo collection of blood samples at screening and on study and undergo CT at screening, on study, and during follow up.
89164071|NCT02710799|Active Comparator|Control|Referrals will be evaluated through the state's protocols
89164072|NCT02710799|Experimental|Intervention|Referrals will be evaluated through the state's protocols associated with telephone-based teleconsultations.
89164073|NCT01006213|Experimental|Lifestyle counseling vs motivational intervention|
89164074|NCT02707445|Experimental|GENIUS|All comer patients who had undergone percutaneous coronary intervention with administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months
89164075|NCT05733871|Experimental|Active group|Participants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management
89164076|NCT05733871|Active Comparator|Active control|Participants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).
89164077|NCT05733871|No Intervention|Control group|Participants receive personalized advice on proper nutrition for a reduction diet in which they use common food.
89164078|NCT02710955|Experimental|Thickened infant formula|
89164079|NCT03999697|Experimental|CAR-CD22 Cell immunotherapy|Enrolled patients will receive CAR-CD22 cell immunotherapy with a novel specific chimeric antigen receptor targeting CD22 antigen by infusion.
89164080|NCT03999775|Active Comparator|Calcium, vitamin D and bioactive collagen peptides supplement|In this arm, all patients received a sachet containing 5mg bioactive collagen peptides, 500 mg calcium lactate and 400 IU vitamin D3 per day.
89164081|NCT03999775|Active Comparator|Calcium and vitamin D supplement|In this arm, all patients received a chewable tablet containing 500 mg calcium carbonate and 400 IU vitamin D3 per day.
89164082|NCT02706977|Experimental|Diabetes Group - Low Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive low dose Sinemet CR twice daily for two weeks.
89164083|NCT02706977|Experimental|Diabetes Group - High Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive high dose Sinemet CR twice daily for two weeks.
89164084|NCT02706977|Other|Diabetes Group - No Electroretinogram (ERG) Delays|Participants with diabetes mellitus type-2 who do not have electroretinogram (ERG) delays. Participants in this group will have one baseline visit only.
89164085|NCT02706977|Other|Age-Matched Controls|Participants will serve as age-matched controls for participants with diabetes. This group will participate in the baseline, week 2, and week 4 visits only.
89164086|NCT02707211|Experimental|Anti-oxLDL IgM antibodies|administration Anti-oxLDL IgM antibodies
89164087|NCT01006447|Active Comparator|Instructor contact 1 class|
89164088|NCT01006447|Active Comparator|Instructor contact 4 classes|
89164089|NCT02710487|Experimental|REM Sleep Awakening (REMSA)|The investigators will actively awaken each subject from nocturnal REM sleep in a sleep laboratory setting, in the hour preceding her/his habitual wake time.
89164090|NCT02710487|Experimental|NREM Sleep Awakening (NREMSA)|Awakening from the NREM sleep stage N2 will be the control intervention.
89164091|NCT01006525||Insomniacs|Primary insomniacs, ages 21-70, in good general health.
89164092|NCT04219241|Experimental|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
89164093|NCT01006681|Experimental|Monovalent MF59-Adjuvanted vaccine|
89164094|NCT05189561|Experimental|Cerebo®|Participants undergoing scanning using NIRS device.
89164095|NCT03893903|Experimental|IDH1 peptide vaccine|IDH1R132H peptide vaccine alone
89164096|NCT03893903|Experimental|combination|IDH1R132H peptide vaccine and Avelumab
89164097|NCT03893903|Experimental|Avelumab|Avelumab alone
89164098|NCT01006759|Experimental|leprosy disability|intervention of a series of cases with leprosy that made treatment in a Clinical Hospital
89164099|NCT02706587|Experimental|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
89164100|NCT02706587|Sham Comparator|Sham Control|No electrostimulation
89164101|NCT02706821|Active Comparator|Treatment sequence 1|PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.
89164102|NCT02706821|Active Comparator|Treatment sequence 2|Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.
89164103|NCT02706509|Active Comparator|oral tramadol|Patients will receive oral Tramadol 50 mg capsules (n=50)' . After an hour, Jaydess intrauterine device will be inserted.
89164104|NCT02706509|Sham Comparator|verbal anesthesia|'verbal anesthesia' (n=50) After an hour, Jaydess intrauterine device will be inserted
89164105|NCT02706431|No Intervention|Normoventilation|The patients will be normoventilated before anesthesia
89164106|NCT02706431|Experimental|Hyperventilation|Prior to anesthesia, the patients will hyperventilate during 2 mins or until symptoms from the central nervous system (e.g. dizziness).
89164107|NCT02706275|Experimental|Warming Group|External warming via forced air warming
89164108|NCT02706275|No Intervention|Control Group|Standard of care body temperature management
89164109|NCT02710565|Other|Cohort|"Participants who are scheduled to have an endo bronchial ultrasound (EBUS) trans bronchial needle aspiration (TBNA) will provide additional samples. These samples will then be sent to Imperial College London to see whether a cell line can be grown.~If growth is successful then the samples will be returned to our pathology department to see if grading is possible and then to compare these results with the previous diagnostic samples.~The cell line samples will not be used for patient diagnosis."
89164110|NCT02710409|Experimental|Quadrivalent influenza vaccine|
89164111|NCT02710409|Active Comparator|Trivalent influenza vaccine A|Active Comparator A
89164112|NCT02710409|Active Comparator|Trivalent influenza vaccine B|Active Comparator B
89164113|NCT03879239|Active Comparator|Vibrant Capsule mode A|Vibrant Capsule mode A administered 5 times per week
89164114|NCT03879239|Active Comparator|Vibrant Capsule mode B|Vibrant Capsule mode B administered 5 times per week
89164115|NCT03879239|Placebo Comparator|Placebo Capsule|Placebo Capsule administered 5 times per week
89164116|NCT05265143|Other|bolus feeding group|In bolus feednig group preterm fed by via gravity drip over a short period, usually 15-20 min. it administrated 8-12 times daily
89164117|NCT05265143|Other|intermittant feeding group|Intermittant feeding is delivered over a 30-60 min by infusion pump. it administrated 8-12 times daily
89164118|NCT05119361||before protocol implementation|"A control group reflecting usual practice about net ultrafiltration and deresuscitation strategy in patients with continuous renal replacement therapy in our Department.~All patients meeting eligibility criteria between 01/01/2020 and 31/12/2021 will be include."
89164119|NCT05119361||after protocol implementation|All patients treated by our deresuscitation protocol between 15/02/2020 and 15/08/2021 will be included.
89164120|NCT00529087|Placebo Comparator|1|
89164121|NCT00529087|Experimental|2|
89164122|NCT00529087|Experimental|3|
89164123|NCT00731848|Experimental|1|Intervention 1
89164124|NCT04318210|Experimental|TDF-FTC as PrEP|Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.
89164125|NCT03999385|Experimental|Immediate Training Group|8 weeks of training in Mindful Self-Compassion.
89164126|NCT03999385|Other|Waitlist Control Group|No intervention for approximately 12 weeks. After this waiting period, participants will complete 8 weeks of training in Mindful Self-Compassion.
89164127|NCT04066582||Experimental|Suspected skin inflammations or skin tumors
89164128|NCT05465395|Experimental|Upper Cervical Adjustment|Upper cervical adjustemnt
89164129|NCT05465395|Active Comparator|Thoracic Adjustment|Thoracic adjustment
89164130|NCT05733247|Active Comparator|Copenhagen adductor exercise|"The modified Copenhagen adductor exercise consists of 6 levels through which the participant will progress when able to complete one level adequately (able to complete the exercise in the given timeframe with adequate control). The first 5 levels are isometric contractions progressing in difficulty with the 6th level including concentric and eccentric components.~Participants perform a supported isometric adduction hold off a 30cm support in a short-lever side-lying position. The participants then raise their pelvis from the floor, keeping their lower knee on the ground for support and hold for 20 seconds, repeating it twelve times on each side.~Participants progressed level 1 by lifting their supporting leg, bringing their knees together and holding position for 20 seconds, repeating it twelve times on each side."
89164131|NCT05733247|Experimental|adduction and abduction partner exercise|"Participants are in a sitting position with their knees extended and hips abducted, supporting themselves with their hands behind their trunks, facing each other. For the adduction exercise, the participant will place his feet and lower leg on the outside of his partner's lower legs and feet. He will then adduct his hips, bringing his feet slowly together while his partner slowly resists this movement.~For the abduction exercise, the participant will place his feet and lower legs on the inside of his partner's feet and lower legs. The participant will slowly abduct the hips while the partner resists this movement.~Both exercises are performed over 6 seconds (a three second concentric and three second eccentric contraction) with as maximal effort."
89164132|NCT00611663|Experimental|1|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE) at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)
89164133|NCT00611663|Placebo Comparator|2|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
89164134|NCT05448235|Experimental|conventional treatment|the patient will receive conventional treatment daily for up to one week
89164135|NCT05448235|Experimental|thoracic cage mobilization|the patient will receive thoracic cage mobilization added to conventional treatment daily for up to one week
89164136|NCT05264519|Experimental|intervention|foot bath intervention
89164137|NCT05264519|No Intervention|control|follow-up
89164138|NCT05060029|Experimental|Lactobacillus Species Suppositories|Coconut oil fatty acids, hyaluronic acid, patented VagiBIOM Probiotic complex CFU (Lactobacillus crispatus Bi16, Lactobacillus gasseri Bi19, Bacillus coagulans Bi34, Lactobacillus acidophilus Bi14) hydrolyzed cellulose, oligofructose, silica gel, lactic acid
89164139|NCT05060029|Placebo Comparator|Coconut Oil Suppositories|Coconut oil fatty acid suppositories
89164140|NCT00612209|Experimental|1|
89164141|NCT01006915|Experimental|Surgical decompression|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
89164142|NCT01006915|No Intervention|Standard medical care|Standard diabetic care and medical care provided for diabetic sensorimotor polyneuropathy
89164143|NCT03809117|Experimental|Experimental|Gastrointestinal Polymerase Chain Reaction test performed and results communicated to treatment provider. Followed by usual care per treating physician.
89164144|NCT03809117|Active Comparator|Control|Gastrointestinal Polymerase Chain Reaction test performed at the conclusion of the study. Clinician will not be informed of results. Usual Care performed per treating physician.
89164145|NCT00870870|Experimental|GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)|"Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
89164146|NCT00870870|Active Comparator|GCiC (Gemcitabine/Cisplatin/Cetuximab)|"Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
89164147|NCT02569840|Other|Amino Acid Feed|An amino acid based multi-nutrient powdered feed
89164148|NCT01006993|Experimental|NeuroFlo Treatment|
89164149|NCT05264441|Other|Asthma and COPD patients|There will be only 1 arm in this study. COPD and asthma patients will be in the same arm.
89164150|NCT04969003|Active Comparator|Transgender male (TM)|~90-second video of depressed transgender male
89164151|NCT04969003|Active Comparator|Cis-gender male (CM)|~90-second video of depressed cis-gender male
89164152|NCT04969003|Active Comparator|Transgender female (TF)|~90-second video of depressed transgender female
89164153|NCT04969003|Active Comparator|Cis-gender female (CF)|~90-second video of depressed cis-gender female
89164154|NCT00731926|Experimental|1|
89164155|NCT00731926|Active Comparator|2|
89164156|NCT00731926|Placebo Comparator|3|
89164157|NCT02709941|Active Comparator|IMST Training Group|Subjects in inspiratory muscle strength training group will complete 30 breaths against a resistance set at 75% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
89164158|NCT02709941|Placebo Comparator|Placebo Training Group|Subjects in placebo training group will complete 30 breaths against a resistance set at 15% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
89164159|NCT02620176|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve.
89164160|NCT02620176|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation stimulation. The stimulator is attached to the left ear, but rotated 180 degrees, so that it is not stimulating the auricular branch of the vagal nerve.
89164161|NCT04134702|Experimental|Acupuncture|30 patients will receive acupuncture additionally to standard pharmacological therapy of postoperative pain
89164162|NCT04134702|No Intervention|No intervention|30 patients will receive just standard pharmacological therapy of postoperative pain
89164163|NCT00697008||GERD patients|Patients with typical GERD symptoms
89164164|NCT00732004|Experimental|1|Group 1
89164165|NCT00732004|Experimental|2|Group 2
89164166|NCT00732004|Experimental|3|Group 3
89164167|NCT02710019|Experimental|Psychoeducational video games|Participants in this group will play the Back to Reality Series video games: (1) Harry's Journey which delivers experiential knowledge about psychosis and marijuana use; (2) Harry's Journal which challenges their understanding of 12 psychiatric symptoms associated with psychosis and (3) the PathwaysToCare Map which uses colourful 3D images and voice-overs to depict actual mental health and addictions services for youth available in Hamilton. These in
89164168|NCT02710019|Other|Control video game|The control video game is a spelling/memory quiz involving with themes from pop culture. The control game will not provide any education about mental health and addictions issues It should be noted that all participants will play both sets of games during their initial and only visit. Participants are randomized to determine which game they will play first during this visit. This is not an RCT or a crossover design. There is no follow up or clinical assessments.
89164169|NCT00732082|Active Comparator|Dose Level 0|Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
89164170|NCT00732082|Experimental|Dose Level 1|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 3 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free period."
89164171|NCT00732082|Experimental|Dose Level 2|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 6.5 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
89164172|NCT00732082|Experimental|Dose Level 3|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 13 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
89164173|NCT00732082|Experimental|Dose Level 4|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 26 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
89164174|NCT05221177|Experimental|Training|Participants in this arm will perform six suspension training exercises (acute bout per exercise) at two different conditions (30 and 45 seconds).
89164175|NCT05221177|No Intervention|Control|Participants in this arm will receive no intervention.
89164176|NCT02620098|Experimental|Size Matters Handwriting Program|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The intervention group consisted of 23 kindergarten students comprising all students in two kindergarten support classrooms, one in each of two neighboring schools. All students in the group received the Size Matters Handwriting Program.
89164177|NCT02620098|No Intervention|Control|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The control group consisted of 12 kindergarteners comprising all students in a kindergarten support classroom at a third school. They received no additional interventions.
89164178|NCT00611741|Experimental|Drug intervention, longitudinal|Furosemide and Na supplements
89164179|NCT02620332|Placebo Comparator|Placebo injection|Water for injection
89164180|NCT02620332|Experimental|MultiPepT1De injection low dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
89164181|NCT02620332|Experimental|MultiPepT1De injection medium dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
89164182|NCT02620332|Experimental|MultiPepT1De injection high dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
89164183|NCT04158011||CNS ALL at lymphodepletion|Patients with active CNS leukemia at the time of lymphodepletion
89164184|NCT04158011||CNS ALL at inclusion|Patients who were referred to CAR T-cells with CNS disease, which was cleared by the time of lymphodepletion
89164185|NCT00726934|Active Comparator|Neutropenic Diet|Participants will be instructed to follow a Neutropenic Diet. This group will receive the same information as the Food Safety Arm with some additional recommendations for avoiding high bacteria foods during length of time on study.
89164186|NCT00726934|Active Comparator|FDA Food Safety Guidelines|Participants will be instructed to follow the FDA Food Safety Guidelines
89164187|NCT04134468|Experimental|Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine|Pegvorhyaluronidase alfa 3ug/kg IV twice weekly during Cycle 1 and then weekly on days of chemotherapy during Cycles 2-4. Abraxane 125mg/m2 IV and Gemcitabine 1000mg/m2 IV on Day 1, 8, 15 of Cycles 1-4. All cycles will be 28 days.
89164188|NCT02709863|Active Comparator|Sevoflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
89164189|NCT02709863|Active Comparator|Desflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
89164190|NCT02709863|Active Comparator|Propofol|6-10 mg/kg/h, iv infusion, during operation
89164191|NCT02619942|Active Comparator|D2 radical operation group|In D2 radical operation group(D2), the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes, which along the feeding vessels.
89164192|NCT02619942|Experimental|CME group|In complete mesocolic excision group (CME), in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodesmshould be entirely removed.
89164193|NCT04065490|Experimental|PBM Treatment|The Valeda™ Light Delivery System
89164194|NCT04065490|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System non-effective treatment
89164195|NCT03877237|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
89164196|NCT03877237|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
89164197|NCT02619786|Experimental|inhaled colistin|Inhaled colistin 75 mg mixed with normal saline up to 4 ml every 12 hours at least 5 days
89164198|NCT00727012|Other|SJM® Rigid Saddle Ring|The SJM® Rigid Saddle Ring is an annuloplasty ring comprised of a titanium core surrounded by a double-velour, polyester fabric sewing cuff.
89164199|NCT00697086|Experimental|1|
89164200|NCT00697086|Placebo Comparator|2|
89164201|NCT04066660|Experimental|Treatment & Oligo Fucoidan|4.4 g Oligo Fucoidan powder by six months, BID
89164202|NCT04066660|Placebo Comparator|Treatment & Placebo|4.4 g Placebo powder by six months, BID
89164203|NCT02709707||Patients with diabetes|
89164204|NCT05372029|Experimental|Approach Avoidance Training|"AAT condition, participants use a joystick to respond to the color of the border surrounding the stimulus images presented (i.e., pull for green, push for blue). The stimuli used are alcohol-related images and neutral beverage images. To experimentally manipulate automatic action tendencies, a contingency is set between alcohol stimuli and avoidance behaviors"
89164205|NCT05372029|Sham Comparator|Sham Training|In the Sham participants use a joystick to respond to the color of the border surrounding stimulus images presented. There is no contingency between instruction type and pictures (i.e., non-training version of the task)
89164206|NCT00697164|Placebo Comparator|1|Patients in group I received intravenous quinine followed by oral ACT for a total period of 6 days.
89164207|NCT00697164|Experimental|2|Patients in group II received antimalarial drug as in group I and in addition 1500U/kg/day of rHUEPO for the initial 3 days.
89164208|NCT01007227|Other|Lifestyle instruction|
89164209|NCT00694980|Experimental|1|
89164210|NCT00732550|Experimental|Single trocar|Patients will undergo cholecystectomy by the single trocar approach
89164211|NCT00732550|Active Comparator|Standard lap cholecystectomy|Standard lap choly
89164212|NCT01007305|Experimental|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy for benign conditions.
89164213|NCT01007305|Active Comparator|Ovarian conservation|No ovaries or fallopian tubes removed at the time of hysterectomy for benign conditions.
89164214|NCT00612755|Experimental|1|Peginterferon alfa-2a 180 mcg/week + 1000-1200 mg/day ribavirin during 24 weeks
89164215|NCT00612755|No Intervention|2|
89164216|NCT05298228|Experimental|Remimazolam|A bolus dose of remimazolam is administered to facilitate LMA insertion
89164217|NCT01007383|Experimental|LEO 27847 oral solution (0.05 mg/mL)|LEO 27847
89164218|NCT01007383|Experimental|LEO 27847 oral solution (0.75 mg/mL)|LEO 27847
89164219|NCT01007383|Placebo Comparator|LEO 27847 oral solution (placebo)|Placebo
89164220|NCT00727324|Experimental|1|BIAP
89164221|NCT00697242|Experimental|Group A|
89164222|NCT00697242|Experimental|Group B|
89164223|NCT00697242|Experimental|Group C|
89164224|NCT00697242|Active Comparator|Group D|
89164225|NCT00697242|Experimental|Group E|
89164226|NCT05263817|Experimental|POEMS Syndrome|
89164227|NCT05263817|Experimental|Amyloidosis|
89164228|NCT05263817|Experimental|Autoimmune Hemolytic Anemia|
89164229|NCT05263817|Experimental|Vasculitis|
89164230|NCT05732857|Sham Comparator|trocar standard|patients in whom the standard trocar will be used to perform robot-assisted complex partial nephrectomy surgery
89164231|NCT05732857|Active Comparator|trocar valveless|patients in whom the valveless trocar will be used to perform robot-assisted complex partial nephrectomy surgery
89164232|NCT00732628||Boomerang percutaneous closure unit|patients having a Boomerang percutaneous closure device after a Neurointerventional study
89164233|NCT04132674|Other|B/F/TAF|Switching participants who are currently on multi-tablet HIV antiretroviral therapy, including multi-tablet regimens and/or two drug combinations (dual therapy) to one oral tablet of B/F/TAF once-daily for 72 weeks
89164234|NCT00612287|Experimental|A|
89164235|NCT03999541|Experimental|Freeze-all|Good quality embryos (either day 3 or 5) will be frozen and subsequent frozen embryo transfer will be arranged within three months of the egg retrival.
89164236|NCT03999541|No Intervention|Fresh embryo transfer|Women will undergo fresh embryo transfer at the cleavage (day 3) or blastocyst stage (day 5).
89164237|NCT00732706|Other|Sartorius Twitch|Femoral Nerve detection using Sartorius Twitch
89164238|NCT00732706|Other|Quadriceps Twitch|Femoral Nerve detection using Quadriceps Twitch
89164239|NCT00612365||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) for abdominal aortic calcium (AAC) who have undergone computed tomography (CT) scans of the abdomen
89164240|NCT00732784|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and calcium supplement on day 15).
89164241|NCT00732784|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and calcium supplement on day 1, Gleevec® alone on day 15).
89164242|NCT00528931|Experimental|AA4500 0.58 mg|
89164243|NCT00866814||Ventrio Group|Patients diagnosed with a ventral hernia requiring an open surgery for repair.
89164244|NCT02947126|Experimental|Cystic Fibrosis (HS, IS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive HS dose on first imaging day and IS dose on the second imaging day,~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
89164245|NCT02947126|Experimental|Cystic Fibrosis (IS, HS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive IS dose on first imaging day and HS dose on the second imaging day.~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
89164246|NCT02947126|Experimental|Parents of CF subjects|"Ages 18 and older, biological parent of a CF patient who is also enrolled in the study~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)"
89164247|NCT02947126|Experimental|non CF controls|"Ages 18 and older with no history of lung disease~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)."
89164248|NCT04492553|Experimental|Testogel|All patients will be treated with Testogel. Starting dose is 1 sachet of gel daily applied to the skin of arms, thighs or abdomen. Dose adjustments are made after serum-levels of testosterone. All patients will be treated for a total of 52 weeks, unless they exit the study early because of side-effects or other reasons.
89164249|NCT04136106||Low-dose IL-2 group|Patients in this group were treated with low-dose IL-2 combined with corticosteroid and immunosuppressor, and low-dose IL-2 is defined as 100IU subcutaneously every other day for two weeks, followed by two-week break, as one treatment cycle, and at least three cycles.
89164250|NCT04136106||Non IL-2 group|Patients in this group were only treated with corticosteroid and immunosuppressor,
89164251|NCT00727480|Experimental|A|Ultrasound Imaging of fingertips
89164252|NCT02619708|No Intervention|Standard Preoperative Experience|The preoperative visit will be performed, as it would be normally. Patients will be given a description of the preoperative experience, they will be told what to expect, they will be given brochures detailing what will happen on the day of the surgery, and will be given the opportunity to ask questions. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
89164253|NCT02619708|Experimental|Immersive Preoperative Experience|The preoperative visit will be performed, as it would be normally, with the only addition of a 5-minute video for the patients randomized to the intervention group. Patients will be given a few minutes to watch the video, and will have the chance to ask questions. The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
89164254|NCT00732862|Experimental|1|Baseline clamp study before treatment phase.
89164255|NCT00732862|Active Comparator|2|Final clamp experiment after 6 months intensive therapy.
89164256|NCT02709551|Experimental|HRV-Bfb|HRV biofeedback, training about 30 minutes/day
89164257|NCT02709551|Experimental|MBI|Mindfulness based intervention, training about 30 minutes/day
89164258|NCT02709551|Other|MBI_HRV-Bfb|Mindfulness based HRV biofeedback. Wait list control group for the interventions HRV-Bfb and MBI, after the main phase intervention with combined method.
89164259|NCT01007461|Experimental|IK-1001|IK-1001 Sodium Sulfide (Na2S) for Injection
89164260|NCT01007461|Placebo Comparator|Placebo|0.9% Sodium Chloride (NaCl)
89164261|NCT00733018|Active Comparator|A|Diet A - Western diet
89164262|NCT00733018|Active Comparator|B|Diet B - Balanced diet
89164263|NCT00871494|Experimental|Azithromycin switch therapy (switch from intravenous to oral).|
89164264|NCT01007539|Experimental|CDP-choline|
89164265|NCT01007539|Placebo Comparator|Placebo (fructose)|
89164266|NCT02569216|Experimental|Electrical Inhibition (EI) intervention|Electrical Inhibition (EI) uterine pacemaker is activated only when there is a preterm uterine contraction. The EI uterine pacemaker delivers a 1-15mA (20mA maximum) constant direct current for only 2 seconds only while there is a preterm uterine contraction.
89164267|NCT05261165||NonManip|In the group of female patients operated without a uterine manipulator (NonManip), we included the female patients who were operated by abdominal approach without no need to use a manipulator. These female patients did not meet the predominantly anesthesiological requirements for the tolerance of the Trendelenburg position; respectively, the likelihood of adhesions in the abdominal cavity after previous laparotomy operations was there. Therefore, from a safety point of view, due to the risk of damage to the abdominal organs and the need for extensive adhesiolysis, the primary endoscopic surgery was not performed.
89164268|NCT05261165||Manip|The female patients suitable for endoscopic performance to laparoscopic, respectively the robotic hysterectomies, in whom the use of a uterine manipulator (Manip) was planned, were assigned random into two groups.
89164269|NCT05261165||ManipHe|Subgroup of Manip group patients, in whome we used the Hegar's dilator as intrauterine manipulator.
89164270|NCT05261165||ManipKoRu|Subgroup of Manip group patients, in whome we used the Koh-Rumi device as intrauterine manipulator.
89164271|NCT02569918|Experimental|Surface electrical stimulation|Operation of hand prosthesis with surface electrical sensory feedback
89164272|NCT04967027|Experimental|TTFields group|patients with brain metastases who have been resistant to drug or radiation therapy, to be treated by continuous TTFields treatment using the ASCLU-300 TTF device.
89164273|NCT02619630|Experimental|High-Risk (HR) patients|Nelarabine during consolidation and maintenance
89164274|NCT02615418|Active Comparator|Fully active treatement|
89164275|NCT02615418|Sham Comparator|partially active|first 2.5 weeks will receive sham treatment followed by active
89164276|NCT02569762|Experimental|Sucralose-Aspartame|Generic name: sucralose or aspartame, Dosage form: powder, Duration:seven days.
89164277|NCT02569762|Experimental|Aspartame-Sucralose|Generic name: aspartame or sucralose, Dosage form: powder, Duration:seven days.
89164278|NCT04951817|Experimental|Ga68-PSMA ligand|Glass vial with 5~20 mCi(185-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), ≧ 0.33 mCi/mL @ EOS。
89164279|NCT00695058|Experimental|1|Women with stress incontinence treated with active TMNS (vibration)
89164280|NCT00695058|Placebo Comparator|2|Women with stress incontinence treated with placebo TMNS (vibration)with an amplitude of 0
89164281|NCT00695058|Experimental|3|Women with overactive bladder syndrome treated with active TMNS (vibration)
89164282|NCT00695058|Placebo Comparator|4|Women with overactive bladder syndrome treated with placebo TMNS (vibration)with an amplitude of 0
89164283|NCT00695058|Experimental|5|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with active TMNS (vibration)
89164284|NCT00695058|Placebo Comparator|6|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with placebo TMNS (vibration)with an amplitude of 0
89164285|NCT00733876|Experimental|A|
89164286|NCT04047966||Fetal growth restriction|63 fetuses with defects in fetal growth qith an estimated fetal weight below 10th percentile
89164287|NCT04047966||Control group|63 control fetuses with an estimated fetal weight about the 10th percentile
89164288|NCT02619474|Experimental|Experimental|Patients who have been admitted to the 3F or 3M wards under the care of the clinical teaching unit (CTU) after the introduction of the new, labelled whiteboard.
89164289|NCT02619474|No Intervention|Control|Patients who have been admitted to the 3R surgical ward under the care of any of the nursing groups without the introduction of the new labelled whiteboard.
89164290|NCT04948931|Experimental|Lavender aromatherapy|As an intervention to this group, lavender application will be made by inhalation. Participants will apply lavender oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.
89164291|NCT04948931|Experimental|Rosemary aromatherapy|As an intervention to this group, rosemary application will be made by inhalation. Participants will apply rosemary oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.
89164292|NCT04948931|Placebo Comparator|Control|Distilled water will be used for the application to this group. The application will be made every night for a month, half an hour before going to bed, under the supervision of a relative. Participants will apply distilled water by dropping three drops on cotton, holding it 5-10 cm away from the nose, for five minutes and breathing normally.
89164293|NCT00733174|Experimental|1|Rosiglitazone
89164294|NCT00733174|Placebo Comparator|2|Placebo
89164295|NCT00529789|Experimental|Duloxetine|
89164296|NCT04136028|Experimental|intervention/treatment|Anakinra (Kineret)
89164297|NCT00611819|Experimental|1|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks
88804618|NCT03428217|Experimental|CB-Cabo|CB-839 800 mg BID + cabozantinib (60 mg QD) administered orally on Days 1 through 28 of each 28-day cycle until disease progression per RECIST v1.1 or unacceptable toxicity, whichever occurred first.
89164298|NCT00611819|Active Comparator|2|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
89164299|NCT00577642|Other|Single arm|Single arm biomarker study after a single dose of zoledronic acid
89164300|NCT02619240||patients suspected of TB|patients suspected of TB requiring to undergo bronchoscopy as part of the investigation
89164301|NCT02709629|Experimental|Individualized and adaptive computerised cognitive training|Training in this group is individualized using a computer algorithm which assigns tasks (from a pool of 33 training tasks) on the basis of cognitive strengths and weaknesses as determined by the training program. In addition, task difficulty is adaptive and responsive to performance level. Participants are able to see feedback on their progress each training session in the form of a session-score. A range of behavior change techniques are used throughout the training period (delivered via scheduled monitoring phone calls, and email contact with participants) to support the compliance and adherence of participants. These include a range of motivation and confidence building strategies, based on a theoretical framework. Participants are required to train for approx. 30 min., 3 times per week, for 8 weeks.
89164302|NCT02709629|Active Comparator|Active control|"Training in this group is generic, and tasks (from the same pool of 33 training tasks) are randomly selected by the training program. In addition, task difficulty is fixed, such that irrespective of performance, each time a participant is presented with a given task, the level of difficulty returns to the basic level. Participants in this arm do not receive feedback on their progress at the end of each training session. The same protocol of behavior change techniques is used in this intervention arm.~Participants are also required to train for approx. 30 min., 3 times per week, for 8 weeks."
89164303|NCT02619162|Experimental|Letrozole+Nintedanib|Letrozole+Nintedanib
89164304|NCT04018690|Experimental|Experimental|24 patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.
89164305|NCT04018690|Active Comparator|Control Group|24 patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine
89164306|NCT02619318|Experimental|The Balancing Everyday Life (BEL) intervention|The BEL was developed on the basis of previous research on lifestyle interventions made by our own group and other researchers [1, 2]. It is a group-based programme (5-8 participants) with 12 sessions, one session a week, and 2 booster sessions with two-week intervals. The themes for the group sessions are, e.g., activity balance, healthy living, work-related activities, and social activities. Each session contains a main group activity and a home assignment to be completed between sessions. The main group activity starts with analysing the present situation and proceeds with identifying desired goals and finding strategies for how to reach them. The home assignment is aimed at testing one of the proposed strategies. Self-analysis, setting goals, finding strategies and evaluating the outcome of tested strategies form a process for each session, but also for the BEL intervention as a whole.
89164307|NCT02619318|Active Comparator|Care as usual (standard occupational therapy)|Standard occupational therapy involves support to open-market employment and support in managing everyday life in general.
89164308|NCT00697866|Experimental|Group A|HBV-MPL Lot A
89164309|NCT00697866|Experimental|Group B|HBV-MPL Lot B
89164310|NCT00697866|Experimental|Group C|HBV-MPL Lot C
89164311|NCT00697866|Active Comparator|Group D|Engerix™-B
89164312|NCT00733486|Other|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
89164313|NCT00727792|Experimental|Group 2 - Research MRI|Subjects will have additional sequences and/or modification to MRI sequences.
89164314|NCT00727792|Active Comparator|Group 1 - Clinical MRI|Clinically ordered MRI scan. Subjects will not have any additional sequences or modifications to their clinically ordered MRI
89164315|NCT04935385||Study Cohort|Patients aged 18 and above undergoing elective surgeries (including general surgery, neurosurgery, ear nose and throat surgeries, cardiac surgery, orthopedic surgeries, vascular surgeries and urological surgeries) at Rabin Medical Center under general anesthesia
89164316|NCT00733564|Active Comparator|1|Paracervical block will be performed
89164317|NCT00733564|Experimental|2|Propofol anesthesia will be performed
89164318|NCT00733564|Experimental|3|Sevoflurane anesthesia will be performed
89164319|NCT05732623||Early onset colorectal cancer|Patients with colorectal cancer diagnosed before the age of 50 years
89164320|NCT05732623||Control|"Individuals meeting all the following:~aged <50 years~no history of colorectal cancer~at least one negative screening test (at least a fecal occult blood test with high sensitivity)"
89164321|NCT04065178||Level of Activity|Level of activity for all patients admitting to the inpatient neurological rehabilitation unit.
89164322|NCT00727870|Other|1|After the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem dressing.
89164323|NCT00727870|Other|2|Arm 2: after the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem Silver dressing.
89164324|NCT00727870|Other|3|Arm 3: after the two biopsies, one site will be covered with Shapes by PolyMem dressing and the other site will be covered the Shapes by PolyMem Silver dressing.
89164325|NCT01007695|Experimental|All patients|All participants enrolled.
89164326|NCT02709473|Active Comparator|propofol|Propofol arm includes patients that induction of general anesthesia started with propofol and followed by remifentanil and rocuronium administration
89164327|NCT02709473|Active Comparator|remifentanil|Remifentanil arm include patients that induction of general anesthesia started with remifentanil and followed by propofol and rocuronium administration
89164328|NCT00734110|Experimental|P.F.C. Sigma Total Knee Replacement System|Primary total knee arthroplasty using the fixed bearing P.F.C. Sigma Total Knee Replacement System.
89164329|NCT00866658|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
89164330|NCT00866658|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
89164331|NCT04064866|Experimental|PRP/Hemocyte Autograft Intervention Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to active condition will have exactly 3 cc of hemocyte autograft placed in a 3 cc syringe. The syringe barrels and tubing were covered with opaque tape so that the injector was blinded to the contents. 1-2 cc of PRP was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
89164332|NCT04064866|Placebo Comparator|Placebo Control Arm|All subjects will have blood drawn (50 cc) from any access site and have it prepared for hemocyte autograft. Using a 20 gauge introducer and 25 gauge disc needle, subjects randomized to placebo condition will have exactly 3 cc of saline placed in a 3 cc syringe. 1-2 cc of saline was injected into the nucleus pulposus of each identified treatment level disc for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
89164333|NCT05732467|Experimental|experimental group|
89164334|NCT05732467|Other|control group|
89164335|NCT00612833|Active Comparator|cautery excision with fascial interposition|Contraception using cautery and excision with fascial interposition
89164336|NCT00612833|Active Comparator|B|Cautery and excision without fascial interposition
89164337|NCT00612833|Active Comparator|C|Ligation and excision with fascial interposition
89164338|NCT02615340|Active Comparator|Enteral melatonin 0.5 mg|Melatonin 0.5 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration of 0.1 mg/mL; final volume in the oral syringe will be 5 mL)
89164339|NCT02615340|Active Comparator|Enteral melatonin 2 mg|Melatonin 2 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0.4 mg/mL; final volume in the oral syringe will be 5 mL)
89164340|NCT02615340|Placebo Comparator|Enteral matched placebo|Melatonin 0 mg qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0 mg/mL; final volume in the oral syringe will be 5 mL)
89164341|NCT00734266||1 Control|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
89164342|NCT00734266||2 COPD|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
89164343|NCT04899791|Experimental|Wheat bread enriched with hydroxytyrosol|
89164344|NCT04899791|Active Comparator|Wheat bread|
89164345|NCT02615028|Other|Closed eyes double-leg stance|Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
89164346|NCT00733642|Experimental|PF-04360365 1 mg/kg|
89164347|NCT00733642|Experimental|PF-04360365 3 mg/kg|
89164348|NCT00733642|Experimental|PF-04360365 5 mg/kg|
89164349|NCT00733642|Experimental|PF-04360365 10 mg/kg|
89164350|NCT02615106|Experimental|Endostar Combined With Radiotherapy|Drug: Endostar Endostar 7.5 mg/m2/day, day 1-14 Radiation: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
89164351|NCT02569138|Experimental|Insole (Experimental)|specially designed insole, featuring hard and thin design, modified insole
89164352|NCT02569138|Experimental|Insole (Control)|usual insole found in footwear, non-modified insole
89164353|NCT04930237||Experimental Group|Patients who receive RELISTOR
89164354|NCT04930237||Observational Group|Patients that receive standard of care
89164355|NCT02615262|Experimental|Experimental|Dexamethasone 1 mg per 1 kg of body weight intravenously immediately after induction of anesthesia
89164356|NCT02615262|Placebo Comparator|Control|0.9% Sodium Chloride 0.25 ml per 1 kg of body weight intravenously immediately after induction of anesthesia
89164357|NCT00733720|Active Comparator|1|Each subject will receive all 3 doses of suboxone and placebo
89164358|NCT05262829|Experimental|MSCs local treatment group/combined treatment group|In the local treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day. In the combined treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day; on the second day, 1 million cells/kg of body weight were administered intravenously.
89164359|NCT04134312|Experimental|MVA-BN-Brachyury IV|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
89164360|NCT02624388|Experimental|Arm A: Genistein followed by Placebo|Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
89164361|NCT02624388|Experimental|Arm B: Placebo followed by Genistein|Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4
89164362|NCT00733798|Experimental|1|
89164363|NCT05731453|Experimental|Polygenetic risk score|Assessment of polygenetic risk score for breast cancer
89164364|NCT04134156|Active Comparator|Sleeve gastrectomy|5-port standard sleeve gastrectomy was conducted
89164365|NCT04134156|Active Comparator|one anastomosis gastric bypass|5-port standard one-anastomosis gastric bypass was performed
89164366|NCT00727948|Experimental|receive aspirin|
89164367|NCT01007851|Experimental|GnRH agonist|
89164368|NCT01007851|Placebo Comparator|Saline|
89164369|NCT00697320||A|
89164370|NCT05580016||Soluble Urokinase Plasminogen Activation Receptor measurement|
89164371|NCT05730673|Experimental|Leronlimab in combinatiob with Regorafenib|Leronlimab (PRO 140) will be administered subcutaneously at a weekly dose of 700 mg in combination with staring dose of 80 mg Regorafenib at first week of the Cycle 1, followed by escalation of Regorafenib dose to 120 mg and 160 mg in second and third weeks of Cycle 1, respectively. No Regorafenib will be administered during the fourth week.
89164372|NCT01701388|Experimental|Ekso Safety and Efficacy|Observational study on the first time use of a robotic exoskeleton.
89164373|NCT04134078|Experimental|inhaled nitric oxide|Inhaled Nitric Oxide at 40 ppm will be administered in adults who suffer in hospital cardiac arrest. The administration of inhaled nitric oxide at 40 ppm will be provided upto 24 hours once ROSC is achieved.
89164374|NCT01007929|Experimental|1|14C-AZD1236
89164375|NCT05260931||Gestational diabetes group|This group will be formed by women with gestational diabetes (GD). The diagnosis of GD was made when one or more of the venous plasma glucose measurements met or exceeded the following thresholds after a 75 g Oral Glucose Tolerance Test (75 g OGTT): fasting blood glucose ≥ 92 mg/dL, 1 h plasma glucose level ≥ 180 mg/dL or 2 h plasma glucose level ≥ 153 mg/dL, as recommended by the International Association of the Diabetes and Pregnancy Study Groups.
89164376|NCT05260931||Control group|This group will be formed by women with normal 75 g OGTT findings.
89164377|NCT00728026||1|Cyclic Vomiting Syndrome
89164378|NCT00728026||2|Irritable Bowel Syndrome
89164379|NCT00728026||3|Postural Orthostatic Tachycardia Syndrome
89164380|NCT00728026||4|Functional Abdominal Pain
89164381|NCT00728026||5|Chronic Nausea
89164382|NCT05729815|Experimental|Relaxation group|Relaxation program sessions had 3 phases: initial dialogue (2 min); a main section (25 min); final ritual (3 min). During the main section, participants listened and observed the therapist, who described and demonstrated all the exercises of the session, which were focused on Jacques Choque Method (Choque, 1994).
89164383|NCT05729815|Experimental|Loose parts play group|Loose Parts Play program sessions had 3 phases: initial dialogue (2 min); main section (25 min); final ritual (3 min). During the main section, participants were allowed to play freely with any materials (loose parts) available in the playground.
89164384|NCT05729815|Experimental|Combined group|In the combined program, the sessions had 4 phases: initial dialogue (3 min); loose parts play moment (20 min); relaxation exercises moment (5 min); final ritual (2 min).
89164385|NCT05729815|No Intervention|Control group|No intervention. Maintained their usual routines.
89164386|NCT00738478|Experimental|A|Arm A: with nasogastric tube
89164387|NCT00738478|Active Comparator|B|Arm B: without nasogastric tube
89164388|NCT02619084|Experimental|STN DBS ON First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
89164389|NCT02619084|Experimental|STN DBS OFF First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
89164390|NCT00738556|Active Comparator|1|Full cover stenting of coronary lesions
89164391|NCT00738556|Active Comparator|2|Spot-stenting of significantly stenotic parts of a coronary lesion
89164392|NCT01008007|Experimental|A|Viusid in combination with the conventional treatment for acute fever of viral etiology
89164393|NCT01008007|Active Comparator|B|Conventional treatment for acute fever of viral etiology
89164394|NCT00597584|Experimental|Peginesatide|
89164395|NCT00597584|Active Comparator|Epoetin|
89164396|NCT02614950|Experimental|Treatment interuption|
89164397|NCT00734422|Experimental|VRET with yohimbine|Virtual Reality Exposure Therapy will be combined with the administration of yohimbine hydrochloride
89164398|NCT00734422|Placebo Comparator|VRET with placebo|Virtual Reality Exposure Therapy will be combined with an inactive placebo pill (Albochin).
89164399|NCT03999307|Experimental|Low-Level Laser Therapy (LLLT)|In the LLLT group, a low-level laser with wavelength of 808 nm, output of 250 mW, energy of 4 Joules per point and application time of 16 seconds per point will be applied on each tooth of the six maxillary anterior teeth according to this protocol: the root will be divided theoretically into 2 halves; gingival and cervical, and laser will be applied in the center of each half from both buccal and palatal sides which means 4 application points and a total energy of 16 Joules per tooth.
89164400|NCT03999307|Experimental|Flapless Corticopuncture|In the flapless corticopuncture group, 3 interdental punctures located between the roots of the six maxillary anterior teeth from both the buccal and palatal sides, will be done using a 1-mm diameter round surgical Tungsten bur with 1 mm depth and 1.5 mm space between each puncture. These punctures start 2 mm from the free gingiva. Besides, an additional 2 parallel set of punctures with the same dimensions of the interdental ones will be done in the extraction sockets from both the buccal and palatal sides.
89164401|NCT03999307|Experimental|Control|Patients in control group will undergo typical orthodontic treatment only with no LLLT or flapless corticopuncture application.
89164402|NCT05260853|Experimental|Intervention|High-risk patients as identified by the computer model. Treating staff are supported by specialised staff from the local certified weaning-center
89164403|NCT05260853|No Intervention|Control|clinical date gathered from AOK BW insured patients on invasive ventilation outside the participating centers
89164404|NCT00695448|Experimental|Cohorts|The starting dose is 6mg once daily (QD); dose is to be escalated using a standard 3 + 3 dose escalation scheme.
89164405|NCT00728104||1|The General Questionnaire: help to understand which characteristics of CVS patients are associated with both beneficial and harmful effects of these treatments
89164406|NCT00728104||2|The Co-Enzyme Q10 Questionnaire: to be completed by individuals who ever taken co-enzyme Q10
89164407|NCT00728104||3|The L-Carnitine Questionnaire: to be completed by individuals who have ever taken L-carnitine
89164408|NCT00728104||4|The Amitriptyline Questionnaire: to be completed by individuals who have ever taken amitriptyline
89164409|NCT05260775||Development Dataset|12 cataract surgery steps including(1) main incision formation, (2) side incision formation, (3) ophthalmic viscoelastic device (OVD) injection, (4) capsulorrhexis formation, (5) hydrodissection, (6) phaco, (7) cortical material removal, (8) intraocular lens (IOL) implantation, (9) OVD removal, (10) IOL centration and (11) wound closure through corneal hydration, and (12) idle phases.
89164410|NCT05260775||Validation Dataset|12 cataract surgery steps including(1) main incision formation, (2) side incision formation, (3) ophthalmic viscoelastic device (OVD) injection, (4) capsulorrhexis formation, (5) hydrodissection, (6) phaco, (7) cortical material removal, (8) intraocular lens (IOL) implantation, (9) OVD removal, (10) IOL centration and (11) wound closure through corneal hydration, and (12) idle phases.
89164411|NCT05260775||Test Dataset|12 cataract surgery steps including(1) main incision formation, (2) side incision formation, (3) ophthalmic viscoelastic device (OVD) injection, (4) capsulorrhexis formation, (5) hydrodissection, (6) phaco, (7) cortical material removal, (8) intraocular lens (IOL) implantation, (9) OVD removal, (10) IOL centration and (11) wound closure through corneal hydration, and (12) idle phases.
89164412|NCT00529633|Active Comparator|Thalidomide|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~Serum C reactive protein level of ≥ 0.8 mg/dl~Serum albumin < 3.8 g/dl (BCG)~Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide."
89164413|NCT00529633|Placebo Comparator|No Drug|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~Serum C reactive protein level of ≥ 0.8 mg/dl~Serum albumin < 3.8 g/dl (BCG)~Patients will receive Placebo (Sugar pill) for a period of 24 weeks."
89164414|NCT05260697|Experimental|Sexual Counselling Group|Sexual Counselling with PLISSIT model
89164415|NCT05260697|No Intervention|Control Group|no intervention group
89164416|NCT02619006||Immediate Cord Clamping|Healthy term infants who were previously randomized or assigned at birth to the control group known as immediate cord clamping. The cord was clamped and cut within10 seconds after birth.
89164417|NCT02619006||Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
89164418|NCT04160234||Elderly patient|Preoperative elderly patients, who are planned for a surgical intervention
89164419|NCT02693639||liver transplantation grafts|
89164420|NCT00657488|Experimental|A|Thalidomide 100mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
89164421|NCT00657488|Active Comparator|B|Thalidomide 400mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
89164422|NCT00530335|Experimental|Atomoxetine|
89164423|NCT00712270|No Intervention|Standard of Care|Screening and Baseline Procedures followed by Referral to Community Care. Baseline Procedures may be repeated at a later time if appropriate.
89164424|NCT00712270|Active Comparator|Drug: Aripiprazole|Screening and Baseline Procedures followed by 16 weeks of treatment with aripiprazole, followed by repeat of baseline procedures and referral to community care.
89164425|NCT00712270|Active Comparator|Risperidone|Screening and Baseline Procedures followed by 16 weeks of treatment with Risperidone,followed by repeat of baseline procedures and referral to community care.
89164426|NCT04188821|Active Comparator|output based group|Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days with no further signs of infection, fluid collection or impaired wound healing
89164427|NCT04188821|Experimental|early-removal group|Investigators remove the drains at hospital discharge, 3-4 days after surgery, regardless of the output at that time
89164428|NCT04131816|Experimental|HeartHome Intervention|Participants will be in the HeartHome program for a total of 12 weeks.
89164429|NCT04131816|No Intervention|Control|De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation
89164430|NCT00738634|Experimental|Physical activity mediated|"Self-motivated physical activity intervention~Materials mailed to participants"
89164431|NCT00738634|Active Comparator|Nutrition control|"Nutrition attention-control arm.~Delivered by researcher."
89164432|NCT00738634|Experimental|Physical activity researcher contact|"Self-motivated physical activity intervention~Delivered by researcher."
89164433|NCT00695526|Active Comparator|A|
89164434|NCT03860597|Active Comparator|Memantine|
89164435|NCT03860597|Placebo Comparator|Placebo|
89164436|NCT04159844|Active Comparator|Short stretch bandage|Application with 50% overlap in combinaison with wading
89164437|NCT04159844|Active Comparator|Multi componant bandage|Application with 50% overlap
89164438|NCT04159844|Active Comparator|Short stretch bandage bis|Application with 50% overlap in combinaison with wading
89164439|NCT02614872|Experimental|GLASSIA®|Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
89164440|NCT02614872|No Intervention|Institution standard of care (SOC)|Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
89164441|NCT04064320|Experimental|Intervention group|Received lullaby intervention and usual care
89164442|NCT04064320|No Intervention|Control group|No intervention other than usual care
89164443|NCT04162106|Active Comparator|Ultravision™ System|Smoke management during laparoscopic cholecystectomy performed with the Ultravision™ System
89164444|NCT04162106|Active Comparator|Airseal® iFS|Smoke management during laparoscopic cholecsystectomy performed with the Airseal® iFS
89164445|NCT01008085|Experimental|Self-expanding stent|Stentys stent
89164446|NCT01008085|Active Comparator|Balloon-expandable stent|VISION/Driver
89164447|NCT00695604|Placebo Comparator|1|"Placebo Comparator~All patients assigned to this group will receive:~Placebo via Metered Dose Inhaler (MDI).~Albuterol via MDI."
89164448|NCT00695604|Active Comparator|2|"Active Comparator~All patients assigned to this group will receive:~Fluticasone via MDI.~Albuterol via MDI."
89164449|NCT00612443|Experimental|1|non-contact Healing Touch treatment for 20-30 minutes once a week during the course of radiation therapy
89164450|NCT00612443|Sham Comparator|2|A RN graduate assistant will provide a sham treatment of 20-30 minutes of presence.
89164451|NCT02638688||2D ultrasound|2D-US measurements are the most accurate method for measuring fibroid volumes
89164452|NCT02638688||3D ultrasound|3D-US measurements are the most accurate method for measuring fibroid volumes
89164453|NCT02638688||postoperative|actual volume using change in water path measurements are the most accurate method for measuring fibroid volumes
89164454|NCT01008163|Experimental|1|YY-351, PO, 1T tid. / Placebo, 1T tid.
89164455|NCT01008163|Experimental|2|YY-351. PO, 2T bid. / Placebo 2T qd.
89164456|NCT01008163|Experimental|3|YY-351, PO, 2T tid.
89164457|NCT01008163|Placebo Comparator|4|Placebo, PO, 2T tid.
89164458|NCT00738712|Experimental|New MRI techniques|New hardware or software technologies designed to improve MRI (Magnetic Resonance Imaging) exams.
89164459|NCT02708927|Experimental|patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
89164460|NCT02708927|Experimental|Control|healthy subject
89164461|NCT00654524|Experimental|1|Patients in this arm will be treated with goserelin depot-3.6mg plus add-back therapy.
89164462|NCT00654524|No Intervention|2|The patient with advanced endometriosis（stage III-IV）confirmed histologically after conservative laparoscopic surgery will be suggested to prepare for spontaneous pregnancy rather than any medical administration.
89164463|NCT04064554|Experimental|MicronJet600|BCG vaccination with MicronJet600
89164464|NCT04064554|Active Comparator|Conventional needle|BCG vaccination with conventional needle
89164465|NCT02618460|Experimental|Whole Group|
89164466|NCT05260619|Experimental|Single arm|lenalidomide will be given as maintenance treatment to 28 PCNSL patients after achieving response to high-dose methotrexate-based immunochemotherapy
89164467|NCT04160156||Type 1 diabetes|Subjects attending metabolic clinic who were suggested to use long term sensor due to persistent hyperglycemia and hypoglycemia
89164468|NCT04000087|Experimental|Intervention|Care teams randomized to intervention will have access to the screening tool.
89164469|NCT04000087|No Intervention|Control|Care teams randomized to control will continue routine practice.
89164470|NCT00657566|Active Comparator|1|antibiotics received for up to two days following normalization of white blood cell count, temperature, and gastrointestinal function
89164471|NCT00657566|Experimental|2|4 +/- 1 days of antibiotics
89164472|NCT03998995|Experimental|IVR rehabilitation game intervention|Clinical trial patients' use the IVR rehabilitation game for two 15 minute sessions during one physical therapy session with their usual practitioner, with support from the physiotherapist and the game expert on the team.
89164473|NCT00738790|Experimental|1|Preoperative radiotherapy with five fractions of 5 Gy during one week and boost 4 Gy after 1 week interval, total dose 29 Gy; after 6 weeks full-thickness local excision
89164474|NCT00738790|Active Comparator|2|"Radiochemotherapy with 28 fractions of 1,8 Gy plus boost 5,4 Gy in 3 fractions~+ simultaneous bolus 5-Fluorouracil and leucovorin; after 6 weeks full-thickness local excision"
89164475|NCT04164992|Experimental|not resectable pancreatic cancer patients|Patients with not-resectable pancreatic adenocarcinoma will be treated with endoscopic ultrasound radio frequency ablation
89164476|NCT00728338|Experimental|1|Martek Biosciences Corporation Neuromins Capsules 7.5 g DHA oil/day
89164477|NCT00728338|Placebo Comparator|2|7.5 g/ day olive oil
89164478|NCT03827291|Experimental|Quadratus lumborum block|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
89164479|NCT03827291|Other|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia.
89164480|NCT00530257|Placebo Comparator|Placebo|Placebo (sugar pill);Subjects will be equally randomized and will receive one week of treatment with placebo and compared to subjects who were randomized to receive one week of OROS-methylphenidate.
89164481|NCT00530257|Active Comparator|OROS-methylphenidate|Subjects will be equally randomized and will receive one week of treatment with the optimal dose of OROS methylphenidate compared with subjects randomized to receive one week of placebo.
89164482|NCT04159766|Active Comparator|NLY01 (2.5 mg)|
89164483|NCT04159766|Active Comparator|NLY01 (5.0 mg)|
89164484|NCT04159766|Active Comparator|NLY01 (10 mg)|
89164485|NCT04159766|Placebo Comparator|Placebo|
89164486|NCT03942263||Newly Diagnosed and RR cHL Participants|Participants diagnosed with RR cHL at the time of enrollment and RR cHL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed cHL, or RR cHL at the time of enrolment, or RR cHL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
89164487|NCT03942263||Newly Diagnosed and RR sALCL Participants|Participants diagnosed with RR sALCL at the time of enrollment and RR sALCL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed sALCL, or RR sALCL at the time of enrolment, or RR sALCL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
89164488|NCT00738946|Experimental|2|Amodiaquine+pyrimethamine versus placebo
89164489|NCT00657644|Experimental|Arm 1|
89164490|NCT00869778|Experimental|εPA-44 900μg|Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
89164491|NCT00869778|Experimental|εPA-44 600μg+Placebo 300μg|Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
89164492|NCT00869778|Placebo Comparator|Placebo 900μg|Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
89164493|NCT00739180|Other|Control|Standard care control
89164494|NCT00739180|Active Comparator|Aerobic Exercise|
89164495|NCT00739180|Active Comparator|Resistance Exercise|
89164496|NCT04159610|Experimental|WO 3970|Formulation containing WO 3970 for topical application
89164497|NCT04159610|Active Comparator|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
89164498|NCT04162028|Experimental|Nebulized Ketamine|sub-dissociative dose ketamine administered prehospitally via breath-actuated nebulizer at 1.0 mg/kg for patients with acute pain
89164499|NCT05260151||Cross-sectional validation study|Each tracer's study will enroll 5 normal controls and 5 cases for each relevant disease, which means [18F]APN-1607 imaging with arterial line will be performed in 5 normal controls, 15 patients with Alzheimer's disease patients, progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD), and [18F] MNI-1126 imaging with Aline test will be performed in 5 normal controls, 15 patients with Alzheimer's disease, progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD); a total of 40 patients will be enrolled in this study group. Patients may choose to participate in the cross-sectional validation study for both tracers, or only for one of them.
89164500|NCT05260151||Longitudinal study|A total of 115 patients are planned to be enrolled in the study. Among them, AD group will enroll 10 cognitive normal controls, 15 prodromal Alzheimer's disease patients and 15 mild Alzheimer's disease patients. Non-AD group will enroll 15 patients with progressive supranuclear palsy (PSP) , 15 patients with frontotemporal dementia (FTD) carrying MAPT gene, 15 patients with FTD without MAPT gene (carrying other FTD related genes such as C9Orf, Progranulin, CHCHD10 or svPPA with TDP43 gene), 15 non-symptomatic carriers with MAPT mutation and 15 normal controls. Subjects who participated in cross-sectional validation study could also participate in this longitudinal study. Patients may also choose to participate only in the longitudinal study.
89164501|NCT00549172|Active Comparator|Operative (O)|Partial resection of degenerative tear of medial meniscus
89164502|NCT00549172|Sham Comparator|Conservative (K)|Arthroscopy (diagnostic)
89164503|NCT00656786|Experimental|Group 1|Subjects will be treated if, after starting treatment with an EGFRi, acute signs and symptoms of rash on the face/neck and/or upper chest emerge, that are suspected of being related to the EGFRi treatment.
89164504|NCT00656786|Experimental|Group 2|Subjects will receive pre-emergent rash treatment starting 1 day prior to beginning EGFRi therapy
89164505|NCT05259761||PLHIV Kalangala District|250 People living with HIV registered for care at Bufumira Health Centre and Mazinga Health Centre, Kalangala District
89164506|NCT05259761||NonPHLIV Kalangala District|100 People not living with HIV attending for medical services at Bufumira Health Centre and Mazinga Health Centre, Kalangala District
89164507|NCT05259761||COVID Suspects Moyo District|1200 people attending for COVID tests at Moyo Hospital
89164508|NCT01008397|Experimental|AHIST for seasonal allergic rhinitis|AHIST for SAR: each green tablet contains 12mg chlorpheniramine tannate.
89164509|NCT02618226||Optic nerve ultrasound|Optic nerve sheath diameter (ONSD) measurement will be performed in subjects with concomitant measurement of Intracranial Pressure (ICP) from an invasive ICP monitor. The operator measuring ONSD will be blinded to concomitant ICP.
89164510|NCT00734812|Active Comparator|1|Laparoscopic supracervical hysterectomy (LSH)
89164511|NCT00734812|Active Comparator|2|Total Laparoscopic Hysterectomy (TLH)
89164512|NCT01008631|Experimental|dialysis|Two doses of sodium thiosulfate
89164513|NCT01008631|Experimental|healthy volunteer|One dose of sodium thiosulfate
89164514|NCT04131894|No Intervention|Control|Extraction sockets with spontaneous healing (16 sockets).
89164515|NCT04131894|Active Comparator|Dentin|Extraction sockets were filled with undemineralized autogenous dentin graft (20 sockets).
89164516|NCT04131894|Active Comparator|Dentin+PRF|Extraction sockets were filled with mixture of undemineralized autogenous dentin graft and platelet rich fibrin (PRF) (21 sockets).
89164517|NCT04857073|Active Comparator|Control group - glucose check every day|Patients will be instructed to check their glucose 4 times a day, every day. This is currently the standard of care.
89164518|NCT04857073|Experimental|Experimental group - glucose check every other day|Patients will be instructed to check their glucose every other day, 4 times glucose monitoring
89164519|NCT04131660|Experimental|AVAPS-AE mode|A volume targeted pressure support ventilation mode
89164520|NCT04131660|Active Comparator|S/T mode|A pressure support ventilation mode
89164521|NCT04817735|Other|Cohort|
89164522|NCT04933825|Experimental|"Four escalating dose-levels of ET-02 will be evaluated using a 3+3 design."|
89164523|NCT05325190|Experimental|Intervention group|Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
89164524|NCT02624310|Experimental|Droxidopa First, Placebo Second|Participants in this arm will receive droxidopa first, then cross over and receive placebo
89164525|NCT02624310|Experimental|Placebo First, Droxidopa Second|Participants in this arm will receive placebo first, then cross over and receive droxidopa
89164526|NCT04800185|Other|Treatment group|
89164527|NCT00735046||1|Intervention
88804619|NCT03410927|Experimental|TAS0728|Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)
89164528|NCT00735046||2|control
89164529|NCT04135872||hypoalbuminemia|hypoalbuminemia was classified as serum albumin level (SAL) <35g/L
89164530|NCT04135872||normal albumin level|patients with serum albumin level (SAL) of 35g/L or higher
89164531|NCT00612521|Other|1|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
89164532|NCT00612521|Other|2|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
89164533|NCT00735124|Active Comparator|Single pre-op dose of Gabapentine|Active treatment with the study drug
89164534|NCT00735124|Placebo Comparator|Placebo|Placebo arm for blinding the medication
89164535|NCT04131348|Other|CSG|patients underwent open CST (component separation group or CSG)
89164536|NCT04131348|Other|BTG|patients with preoperative BT administration and following open RSR (botulinum toxin group or BTG).
89164537|NCT00698100|Experimental|1|Patients will get human tyrosinase vaccination.
89164538|NCT00698100|Experimental|2|Patient will get mouse tyrosinase DNA vaccination.
89164539|NCT04246541|Experimental|Control|Patients will receive standard of care Percocet for post-operative pain control following meniscus debridement surgery
89164540|NCT04246541|Experimental|Ketorolac|Patients will receive IV ketorolac during surgery. They will then receive 3 days of oral ketorolac every 6 hours for pain control following surgery.
89164541|NCT00739258||HIDU|intravenous drug user (IDU) with HIV infected
89164542|NCT00739258||IDU|intravenous drug user (IDU) without HIV
89164543|NCT00739258||MH|persons receiving methadone maintenance treatment
89164544|NCT02618304|Experimental|moderate to severe meibomian gland dysfunction|
89164545|NCT04778423|Experimental|Avatar Therapy|AVATAR therapy for eating disorders
89164546|NCT02618694|Experimental|Group 1|patient had posterior retroperitoneoscopic adrenalectomy
89164547|NCT02618694|Active Comparator|Group 2|patient had Transperitoneal laparoscopic adrenalectomy
89164548|NCT03999073||Subjects with coarctation|
89164549|NCT03999073||Controls|
89164550|NCT00612911||Major group|Patients with Idiopathic dilated cardiomyopathy
89164551|NCT04902859|Experimental|Clonidine with eye speculum|4 mcg/kg Clonidine given orally in GI-tube.
89164552|NCT04902859|Placebo Comparator|Placebo with eye speculum|Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.
89164553|NCT04902859|Experimental|Clonidine without eye speculum|4 mcg/kg Clonidine given orally in GI-tube.
89164554|NCT04902859|Placebo Comparator|Placebo without eye speculum|Sterile water corresponding to the same volume as 4 mcg/kg of Clonidine given orally in GI-tube.
89164555|NCT00912834||1|tract and field athletes
89164556|NCT00912834||2|swimming athletes
89164557|NCT00912834||3|tennis athletes
89164558|NCT00912834||4|football athletes
89164559|NCT00912834||5|basketball athletes
89164560|NCT00912834||6|Badminton athletes
89164561|NCT00912834||7|control group
89164562|NCT00695838||1|
89164563|NCT05227313|Experimental|Eefooton oral solution|20ml, 3 times per day (daily dose: 60 ml)
89164564|NCT05227313|Placebo Comparator|Placebo oral solution|oral solution matched placebo
89164565|NCT05127967|Other|Patients with neurological symptoms and two mutations in the SPG7 gene|Symptomatic patients with SPG7 mutations (homozygous or compound heterozygous)
89164566|NCT05127967|Other|Patients with neurological symptoms and one mutation in the SPG7 gene|Patients presenting neurological symptoms corresponding to SPG7 disease (adult onset spastic ataxia with CPEO and/or optic atrophy) with only one mutation found in the SPG7 gene
89164567|NCT05127967|Other|Controls|Patients without mutations in the SPG7 gene requiring spinal surgery because of a non-genetic neurologic disorders
89164568|NCT05217095|Other|Interventional Group|Each patient will be treated for one session of dialysis after enrolled. Each of them will have only one treatment in the middle of the week (Wednesday or Thursday). The patients will be treated using 4008A dialysis machines in combination with a sidecar and the convergence dialyzer as investigational devices.Each patient will be treated according their regular treatment and laboratory analysis will be taken. The blood level of free hemoglobin ( fHb ) will be taken on 30 min by use of HemoCue device. ACT time will be measured on 15 min and for that 0.5 ml blood from venous line will be taken.
89164569|NCT00711958|Experimental|HX575 epoetin alfa Hexal AG|HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
89164570|NCT00711958|Active Comparator|ERYPO® Janssen-Cilag|ERYPO® Janssen-Cilag, Germany. Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
89164571|NCT04180943|Active Comparator|liposomal bupivicaine|interscalene nerve block using liposomal bupivacaine (Exaprel) 10 ml mixed with 0.5% bupivacaine in same syringe - volume of bupivacaine per MD based on pt weight, etc but CANNOT EXCEED 13mL
89164572|NCT04180943|Active Comparator|bupivicaine|interscalene block using standard bupivicaine (combination of ropivacaine 0.5% and lidocaine 2%) (volume per MD based on pt weight) + decadron
89164573|NCT04694261|Experimental|SM-ART Intervention|Intervention group will receive SM-ART module training along with the flyers on resilience building tips.
89164574|NCT04694261|No Intervention|Control Group|Control group will only receive flyer on resilience building tips
89164575|NCT02693327||Mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
89164576|NCT02693327||Non-mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
89164577|NCT02693405|Experimental|child and adult survivors of brain tumor|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
89164578|NCT02693405|Experimental|healthy controls|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
89164579|NCT00711880|Experimental|Sativex|
89164580|NCT00711880|Placebo Comparator|Placebo|
89164581|NCT00528775|Experimental|HPPH|Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.
89164582|NCT02693483|Active Comparator|povidone iodine|153 cases undergoing cesarean sections will have preoperative vaginal cleansing with 10% povidone iodine
89164583|NCT02693483|No Intervention|no vaginal cleansing|153 cases undergoing cesarean sections
89164584|NCT04873063|Experimental|Reference/Test|"3 mg BDP suppositories (R product) delivered twice daily for 7 days~Washout period (at least 7-day and preferably no more than 9 days)~6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product."
89164585|NCT04873063|Experimental|Test/Reference|"6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product.~Washout period (at least 7-day and preferably no more than 9 days)~3 mg BDP suppositories (R product) delivered twice daily for 7 days"
89164586|NCT05198687|Active Comparator|overdentures|implant overdentures
89164587|NCT05198687|Active Comparator|sinus lift|sinus lift and long implants and screw-retained prosthesis
89164588|NCT05198687|Active Comparator|short implants|short implants and screw-retained prosthesis
89164589|NCT05197361||Global cohort|"Invasive coronary physiology parameters estimation, including:~FFR, CFR, IMR, Absolute coronary flow (AF). AF derived resistances"
89164590|NCT00739414|Experimental|LBH589 (Panobinostat)|
89164591|NCT02693561|Active Comparator|Deep Breathing Exercises|Technical Deep Breathing.
89164592|NCT02693561|Active Comparator|Self-Help Book|Reading the self-help book.
89164593|NCT02693561|Active Comparator|Deep Breathing Exercises and Book|"Technical Deep Breathing and Reading the self-help book.~Reading the self-help book and will be trained by the physical therapist to perform deep breathing."
89164594|NCT02693561|No Intervention|Control|Not suffer any intervention
89164595|NCT02569684|Active Comparator|Arm A|Prebiotic fibers: Oligofructose and inulin
89164596|NCT02569684|Placebo Comparator|Arm B|Maltodextrin
89164597|NCT01564615|Experimental|AgION catheter|Patients in this arm received an AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
89164598|NCT01564615|Active Comparator|Non-impregnated polyurethane catheter|Patients in this arm received a non-impregnated polyurethane umbilical catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
89164599|NCT00735280|Experimental|Reduced dose of unfractionated heparin|
89164600|NCT01564849||chronic rhinitis,|
89164601|NCT01564849||chronic sinusitis|
89164602|NCT01564849||nasal polyps|
89164603|NCT01564849||control rhinitis|
89164604|NCT01564849||control sinusitis|
89164605|NCT01564849||control polyps|
89164606|NCT04172909|Experimental|Child life group with LEGO bricks|Patients in this group will be prepped by a Certified Child Life Specialist with the use of LEGO bricks model MR
89164607|NCT04172909|No Intervention|Control group|Age matched controls will be found retrospectively, and will be patients of the same age, undergoing their first non-contrast brain MRI with no Child Life intervention.
89164608|NCT04172909|Experimental|Child life group with Mock MRI tube|Patients in this group will be prepped by a Certified Child Life Specialist with the use of a Mock MRI tube
89164609|NCT00728572|Experimental|Experimental|Participant will receive a brief exam, a Basic Technique apex contact adjustment and Surface EMG.
89164610|NCT00728572|Sham Comparator|Sham|Participants will receive a sham Basic Technique adjustment (an adjacent contact not indicated by examination)and surface EMG.
89164611|NCT01564927|Experimental|Electroacupuncture to right LI4 and LI11|
88804620|NCT03399851|Active Comparator|Amplatzer Amulet|Left atrial appendage closure (LAAC) with Amplatzer Amulet implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
88804621|NCT03399851|Active Comparator|Watchman/FLX|Left atrial appendage closure (LAAC) with Watchman/FLX implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
88804622|NCT03377491|Experimental|NovoTTF-200T|Patients receive TTFields using the NovoTTF-200T System together with gemcitabine and nab-Paclitaxel
89164612|NCT01564927|Sham Comparator|Electroacupuncture to knee caps|Electroacupuncture to knee caps
89164613|NCT01564927|Placebo Comparator|Sham electroacupuncture to LI4 & LI11|
89164614|NCT05342909|Experimental|5x a week BFR training group|Subjects will perform 2 exercises (LAQ and squat) with BFR applied to dominant thigh daily (5x/wk). Exercises performed for 4 sets (30/15/15/15 reps) initially at 30% 1RM; with load increased by 5% every 2 weeks. Training program lasts for 8 weeks. They are also to continue with their regular independent exercise program.
89164615|NCT05342909|Experimental|2x a week BFR training group|Subjects will perform 2 exercises (LAQ and squat) with BFR applied to dominant thigh twice a week (2x/wk). Exercises performed for 4 sets (30/15/15/15 reps) initially at 30% 1RM; with load increased by 5% every 2 weeks. Training program lasts for 8 weeks. They are also to continue with their regular independent exercise program.
89164616|NCT05342909|No Intervention|Control group|This group will not perform any BFR exercises. They are to continue with their regular independent exercise program.
89164617|NCT00728650||Observation|Patients with primary or metastatic hepatic malignancies
89164618|NCT04764487|Other|Standard follow-up|Patients will have no intervention. It is the comparator group. Patients will have the usual follow-up for clinical, biological and imaging exams.
89164619|NCT04764487|Experimental|KidneyPRO web-application follow up|"Patients will have to connect to the KidneyPRO web-application weekly to complete a questionnaire about their symptoms in addition to usual follow-up.~Appropriate care will be offered if necessary (depending on the symptoms assessment)"
89164620|NCT00612989|Experimental|1|Schedule 1
89164621|NCT00612989|Experimental|2|Schedule 2
89164622|NCT00612989|Experimental|3|Schedule 2, Neulasta-supported
89164623|NCT00735358|Active Comparator|A|Single dose cyanoacrylate in one shot
89164624|NCT00735358|Experimental|B|Double doses cyanoacrylate in one shot
89164625|NCT05342831|Experimental|Experimental: experimental group|Biological Nutrition Technique
89164626|NCT05342831|No Intervention|Assigned Interventions|standard care group
89164627|NCT04763941||Memory consultation patient|The study will be conducted on the basis of the patient consulting in Memory Consultation, specifically with the information already collected in normal care and the MEMORA cohort.
89164628|NCT00739492|Active Comparator|1|deposit based incentive
89164629|NCT00739492|Active Comparator|2|"deposit based incentive framed with maintenance period"
89164630|NCT00739492|No Intervention|3|Control arm, no financial incentive
89164631|NCT04141865||Xen|Patients treated with a Xen microstent for glaucoma.
89164632|NCT04141865||Aqueous shunt|Patients treated with an aqueous shunt for glaucoma.
89164633|NCT04929067|Experimental|Immunotherapy combined with neoadjuvant chemotherapy forlocally advanced HNSCC|
89164634|NCT03742609|No Intervention|Information only|provision of written information regarding consequences of using a hearing aid and not using a hearing. For example using a hearing aid will improve ability to hear others.
89164635|NCT03742609|Active Comparator|Physical reminder only|provision of written information regarding consequences of using a hearing aid and not using a hearing and physical reminder to use a hearing aid. For example, a hearing aid box as a physical reminder to use the hearing aids.
89164636|NCT03742609|Active Comparator|Behaviour Plan only|provision of written information regarding consequences of using a hearing aid and not using a hearing and creation of behaviour plan to use a hearing aid. For example, when and where to use the hearing aids.
89164637|NCT03742609|Experimental|Info, Reminder and Plan|provision of written information regarding consequences of using a hearing aid and not using a hearing, physical reminder and creation of behaviour plan to use a hearing aid
89164638|NCT00614003|Experimental|1|decision support
89164639|NCT04188587|Experimental|177Lu-PSMA-I&T|177Lu-PSMA-I＆Tradioligand therapy with 2.0-8.0GBq in every circle were performed. And then 177Lu-PSMA post-therapy scans were performed at 24 h and 48 h respectively, and the fusion phenomenon was performed at the second day to pre evaluate the efficacy of the patients.
89164640|NCT05300321|Experimental|Single Vision Lens|The sunbjects were randomized to allocate in single vision lens group.
89164641|NCT05300321|Experimental|Defocus Incorporated Multiple Segments (DIMS) Lens|The sunbjects were randomized to allocate in Defocus Incorporated Multiple Segments (DIMS) Lens group.
89164642|NCT04875247||Single arm|All patients will be assigned to this cohort.
89164643|NCT05273411|Active Comparator|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|1 x 20 mL
89164644|NCT05273411|Experimental|Beta-hydroxybutyric acid|1 x 237 mL
89164645|NCT05273411|Experimental|1,3-Butanediol|1 x 35 mL
89164646|NCT00613067|Experimental|GAD|35 patients with Generalized Anxiety disorder
89164647|NCT00613145|Active Comparator|A|Treatment with Capecitabine and Sorafenib
89164648|NCT00613145|Active Comparator|B|Treatment with Capecitabine and Sorafenib
89164649|NCT04593095|Experimental|Experimental|Each SSC session will last 2-hr during the day including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise. The 2-hr SSC will be followed by a 1-hr quiet period where infants will rest in their incubator/crib with a pad immersed with their mother breast milk for olfactory stimulation and where the control of light and noise levels will be continued. The NeuroN-QI will be done 4 times/wk for each dyad.
89164650|NCT04593095|No Intervention|Control|Mothers-infant dyads will do 4 SSC/wk. During these sessions, no attempt will be made by the RA to control the light and noise levels nor to encourage auditory stimulation. The SSC periods will not be followed by a quiet period nor olfactory stimulation.
89164651|NCT04578743|Experimental|Graded Exercise|ClearPlay(TM): a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, will provide a telemetry-based graded exercise program for 20 minutes each day, identifying a heart rate target that will be advanced weekly for up to 8 weeks as symptoms resolve.
89164652|NCT04578743|Experimental|Passive Stretching|ClearPlay(TM): we have created a passive stretching program (placebo arm) downloadable to an Apple i-touch or i-phone device, that will provide a telemetry-based guided passive stretching program for 20 minutes each day for up to 8 weeks as symptoms resolve.
89164653|NCT04570085|Experimental|Caffeine|after a 3 weeks up titration period, 1 capsule of 200 mg twice a day during 27 weeks (ie 400mg/day)
89164654|NCT04570085|Placebo Comparator|placebo|after a 3 weeks up titration period, 2 capsules per day during 27 weeks
89164655|NCT02624232||Patients with anorectal malformations|"Participants are identified through relevant diagnostic codes in ICD-10(Q 42) and ICD-9(75.120, 75.121) in patients which underwent surgery for ARM in the years 1985-2005 are included if informed consent is obtained.~Relevant questionnaires regarding symptoms and QoL are completed before the following examinations:anorectal manometry, endoanal ultrasonography, pudendal nerve conduction velocity, colon transit time, Magnetic resonans(MR)-scan of the pelvis and uroflowmetry."
89164656|NCT00529399|Experimental|1|3 injections of GAD-Alum vaccine
89164657|NCT00529399|Experimental|2|2 injections of GAD-Alum vaccine and one injection with Aluminum hydroxide alone
89164658|NCT00529399|Placebo Comparator|3|3 injections of Aluminum hydroxide alone
89164659|NCT00614081|Experimental|1|Renal transplant recipients
89164660|NCT00700479|Experimental|A|Aldosterone plus low salt diet
89164661|NCT00700479|Experimental|B|Aldosterone plus high sodium diet
89164662|NCT00700479|Placebo Comparator|C|Placebo plus low sodium diet
89164663|NCT00700479|Placebo Comparator|D|placebo plus high sodium diet
89164664|NCT02624076|Experimental|Acupuncture plus expectant management|
89164665|NCT02624076|Active Comparator|expectant management|
89164666|NCT05268419|Active Comparator|Ethanol inhalation|100 ml spray of 35% ethanol were provided and all of participants were instructed to use spray three times every 6 hours from a distance of 20-30 cm from their face, while wearing a mask and closing their eyes, and take a deep breath as they feel nebulized liquid droplets in their nose, mouth, throat, larynx and lungs. Investigators emphasized participants that this protocol must be repeated every six hours to 7 days.
89164667|NCT05268419|Placebo Comparator|Water Distilled inhalation|100 ml spray of water distilled (placebo) were provided and all of participants were instructed to use spray three times every 6 hours from a distance of 20-30 cm from their face, while wearing a mask and closing their eyes, and take a deep breath as they feel nebulized liquid droplets in their nose, mouth, throat, larynx and lungs. Investigators emphasized participants that this protocol must be repeated every six hours to 7 days.
89164668|NCT02617992||EMR Surveillance|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions undertaking a surveillance visit will be included in this cohort.
89164669|NCT00852969|Active Comparator|Niacin|
89164670|NCT00852969|Placebo Comparator|Placebo|
89164671|NCT02618070|Experimental|Functional dyspepsia patient|Yogurt ingestion
89164672|NCT02618070|Experimental|Healthy|Yogurt ingestion
89164673|NCT03870997|Experimental|Diabetes Digital Intervention|
89164674|NCT03870997|Experimental|Generic Digital Intervention|
89164675|NCT03870997|No Intervention|No Influenza Vaccination Intervention|
89164676|NCT00613457|Experimental|I|o Arm I (closed to accrual as of 6/30/2006): Patients receive prednisone (PRED) on days 8-28.
89164677|NCT00613457|Experimental|II|o Arm II (closed to accrual as of 6/30/2006): Patients receive dexamethasone (DEXA) on days 8-28.
89164678|NCT00613457|Experimental|Reintensification Arm I|o Arm I (standard reinduction therapy, protocol II [closed to accrual as of 6/30/2006]): SR and IR patients receive DEXA on days 1-22; VCR and doxorubicin hydrochloride (DOX) in weeks 2-5; ASP on days 8, 11, 15, and 18; CPM on day 36; ARA-C and thioguanine (TG) on days 36-49; and MTX IT on days 38 and 45. Patients then proceed to maintenance therapy.
89164679|NCT00613457|Experimental|Reintensification Arm II|• Arm II (reduced-intensity reinduction therapy, protocol III [closed to accrual as of 6/30/2006]): SR patients receive DEXA on days 1-15; VCR and DOX on days 1 and 8; ASP on days 1, 4, 8, and 11; CPM on day 15; ARA-C and TG on days 15-28; and MTX IT on days 16 and 23. Patients then proceed to maintenance therapy.
89164680|NCT00613457|Experimental|Reintensification Arm III|• Arm III (reduced-intensity reinduction/second delayed reinduction therapy [double reintensification therapy] [closed to accrual as of 6/30/2006]): IR patients receive reduced-intensity reintensification therapy as in arm II. After a 10-week interim maintenance phase, treatment repeats once for a second delayed course of reintensification therapy. Patients then proceed to maintenance therapy.
89164681|NCT00613457|Experimental|Reintensification Arm IV|"• Arm IV (standard reintensification therapy [closed to accrual as of 6/30/2006]): HR patients receive one sequence of the following HR therapy elements, in this order: 1, 2, 3, following standard reinduction therapy protocol II repeated twice after a four weeks Interim Maintenance phase. Patients then proceed to maintenance therapy.~Element HR-1: Patients receive DEXA on days 1-5; VCR on days 1 and 6; ARA-C twice on day 5; MTX and CPM every 12 hours on days 2-4 (5 doses); ASP on day 6 ; and MTX/ARA-C/PRED IT on day 1.~Element HR-2: Patients receive DEXA on days 1-5; vindesine on days 1 and 6; DNR on day 5; MTX and ifosfamide every 12 hours on days 2-4 (5 doses); ASP on day 6; and MTX/ARA-C/PRED IT on day 1.~Element HR-3: Patients receive DEXA on days 1-5; ARA-C every 12 hours on days 1-2 (4 doses); etoposide five times daily on days 3-5; ASP on day 5; and MTX/ARA-C/PRED IT on day 1."
89164682|NCT00613457|Experimental|Reintensification Arm V|"• Arm V (extended reintensification therapy [triple protocol III] [closed to accrual as of 6/30/2006]): HR patients receive HR therapy elements 3, 2, and 1 following reintensification therapy repeated the therapy element three times with 4-week interim maintenance phases in between. Patients then proceed to maintenance therapy.~Interim maintenance/maintenance therapy: Patients receive MTX once weekly and MP daily until week 104 plus IT MTX every eight weeks.~Radiotherapy: HR patients or patients with T-cell acute lymphoblastic leukemia or CNS disease undergo CNS radiotherapy."
89164683|NCT04131582|Experimental|Empagliflozin + linagliptin + metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5 mg + metformin 850 mg every 12 hours and empagliflozin 12.5 mg + metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
89164684|NCT04131582|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 850 mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the complete dose. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90/150 min/week
89164685|NCT05632939|Experimental|ASKB589 +CAPOX+Sintilimab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
89164686|NCT00700557|Active Comparator|Probiotics - Lactobacillus casei and Bifidobacterium breve|"Yakult LB®~1 sachet (1g) of Lactobacillus casei and Bifidobacterium breve - 6 x 108 UFC/g on a juice three times a day"
89164687|NCT00700557|Placebo Comparator|maize starch|725mg on juice three times a day
89164688|NCT04116957|Other|Time 1|First two months of data collection at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
89164689|NCT04116957|Other|Time 2|Second two months of data collection at an ICU at the University Hospital, University of Missouri Health Care in Columbia, Missouri.
89164690|NCT00521365|Experimental|Quetapine 600 mg|
89164691|NCT00695994|Experimental|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle.
89164692|NCT00695994|Experimental|Gemcitabine and carboplatin|Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
89164693|NCT00711802|Experimental|Daptomycin|"Administered intravenously (IV) every 24 hours for up to 14 days at the following age-dependent dosages.~Participants ages 7 to 17 years: daptomycin was dissolved in a volume of 50 milliliters (mL) 0.9% sodium chloride for injection over 30 minutes (min) with an infusion rate of 1.67 mL/min.~Participants 1 to 6 years-old: daptomycin was dissolved in a volume of 25 mL 0.9% sodium chloride for injection over 60 min with an infusion rate was 0.42 mL/min.~Age Group 1 (for ages 12 to 17 years): 5 milligrams/kilogram (mg/kg)~Age Group 2 (for ages 7 to 11 years): 7 mg/kg~Age Group 3 (for ages 2 to 6 years): 9 mg/kg~Age Group 4 (for ages 1 to <2 years): 10 mg/kg"
89164694|NCT00711802|Active Comparator|Standard of Care (SOC)|The comparator agent for this study was the SOC treatment and dosage deemed appropriate by the Investigator. The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.
89164695|NCT00851877|Experimental|arm one|Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
89164696|NCT00698178||NERD|patients with typical gastro-reflux symptoms but no erosions were discernible on upper gastrointestinal endoscopy
89164697|NCT00698178||EE|Patients with both typical gastroesophageal reflux symptoms and characteristic flam-like erosions as demonstrated on upper gastrointestinal endoscopy
89164698|NCT00698178||FD|Patients report no typical reflux symptoms but fulfill diagnostic criteria of functional dyspepsia, whose upper gastrointestinal endoscopy are negative.
89164699|NCT00613223|Experimental|Vandetanib and Etoposide|Patients will be stratified based on whether they are receiving an enzyme-inducing anti-epileptic drug (EIAED). The dose level of vandetanib will be increased in successive cohorts of subjects. Etoposide will be given daily at a dose of 50 mg/ day for 21 days followed by 7 days with no etoposide.
89164700|NCT00882908|Experimental|TMC435 75 mg 12 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
89164701|NCT00882908|Experimental|TMC435 75 mg 24 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
89164702|NCT00882908|Experimental|TMC435 150 mg 12 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
88804623|NCT03377491|Active Comparator|Best Standard of Care|Patients receive best standard of care with gemcitabine and nab-Paclitaxel
89164703|NCT00882908|Experimental|TMC435 150 mg 24 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
89164704|NCT00882908|Placebo Comparator|Placebo 24 Wks + PR48|Participants will receive Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.
89164705|NCT00739570|No Intervention|1|
89164706|NCT00739570|Active Comparator|2|Activator chiropractic technique basic scan protocol
89164707|NCT03580967|Other|Drug: Vortioxetine|
89164708|NCT00851799||Cohort A|"ATV/RTV + FTC/TDF~Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily."
89164709|NCT00851799||Cohort B|"RAL + FTC/TDF~FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily."
89164710|NCT00851799||Cohort C|"DRV/RTV + FTC/TDF~FTC/TDF, darunavir (DRV), and RTV, orally, once daily."
89164711|NCT00521053|Experimental|PV-10|
89164712|NCT00853047|Experimental|Telotristat Etiprate 150 mg Core Phase|Telotristat etiprate capsules,150 mg orally 3 times daily for 28 days in the double-blind treatment period (core phase) in combination with stable-dose octreotide long-acting release (LAR) depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
89164713|NCT00853047|Experimental|Telotristat Etiprate 250 mg Core Phase|Telotristat etiprate capsules, 250 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
89164714|NCT00853047|Experimental|Telotristat Etiprate 350 mg Core Phase|Telotristat etiprate capsules, 350 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
89164715|NCT00853047|Experimental|Telotristat Etiprate 500 mg Core Phase|Telotristat etiprate capsules, 500 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with a stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
89164716|NCT00853047|Experimental|Placebo Core Phase|Placebo-matching telotristat etiprate capsules, orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to receive telotristat etiprate in the optional open-label extension period.
89164717|NCT00853047|Experimental|Telotristat Etiprate Open-Label Extension Phase|Telotristat etiprate at assigned dose level for 8 weeks in combination with stable-dose octreotide LAR depot therapy given once per month in the open-label extension period. Upon completion of the 8-week period, participants could enter an additional extension period of 172 weeks, receiving telotristat etiprate at the assigned dose or maximum tolerated dose (500 mg 3 times daily).
89164718|NCT04164914|Experimental|Healthy subjects|Prebiotic administration
89164719|NCT02613351|Experimental|scooting|incremental test to establish the relationship between leg and breathing heaviness with increasing demand (speed) during scooting
89164720|NCT00657722|Experimental|1|Angiography and Computed Tomography
89164721|NCT04102475|Experimental|eatline group|
89164722|NCT04102475|Sham Comparator|control group|
89164723|NCT04117191|Experimental|Tryptophan loading|All participants are introduced to receive tryptophan loading test.
89164724|NCT02632604|Active Comparator|Bottom-up to top-down cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes
89164725|NCT02632604|Active Comparator|Top-down to bottom-up cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes
89164726|NCT02632604|Placebo Comparator|Computer games|Participants are given 40 hours of computer games commonly found on the internet and which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc).
89164727|NCT05171699|Experimental|electroacupuncture|The investigators choose Zusanli (ST36) and Baihui (DU20) acupoints to investigate the effect of electroacupuncture on patients with sepsis-associated brain injury.
89164728|NCT05171699|Sham Comparator|shame electroacupuncture|The shame electroacupuncture were performed at a shallow depth and 1 mm lateral to Zusanli (ST36) and Baihui (DU20) acupoints.
89164729|NCT02638610|Experimental|Sensation measurement|patients with eyelid pathology going through eyelid surgery.
89164730|NCT05115227|Experimental|Multidisciplinary|A pragmatic team-based management approach is individualized for each patient.
89164731|NCT00520975|Active Comparator|Arm A (chemotherapy and placebo)|"INDUCTION THERAPY: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
89164732|NCT00520975|Experimental|Arm B (chemotherapy and bevacizumab)|"INDUCTION THERAPY: Patients receive trastuzumab and paclitaxel with or without carboplatin as in Arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
89164733|NCT03886415|Experimental|Jaktinib hydrochloride tablets 1|This is the dose group was given once a day. Jaktinib hydrochloride tablets 1 200mg qd dose group
89164734|NCT03886415|Experimental|Jaktinib hydrochloride tablets 2|This is the dose group was given twice a day. Jaktinib hydrochloride tablets 2 100mg bid dose group
89164735|NCT04159298|Experimental|Intervention|Intervention group who will undergo the Top Spin 360 study protocol.
89164736|NCT04159298|No Intervention|Traditional|Control group who undergo traditional usual clinical care comprised of bi-weekly physiotherapy sessions and home-based exercise programs.
89164737|NCT04451681|Other|Ankylosing spondylitis|A total of 42 patients, who were diagnosed with AS with modified New York Criteria, and who agreed to participate in the study, will be included in this group.
89164738|NCT04451681|Other|Control|A total of 42 control participants between the ages of 18-65 who agreed to participate in the study will be included in this group.
89164739|NCT02638532|Other|Foot Fat Pad Grafting|All subject who enter into the study will undergo the fat pad grafting procedure to either the Heel or Forefoot based on the discretion of the PI, Co-investigator and the study subject.
89164740|NCT00657800|Experimental|Group 1|Behavioral - Intensified coordinated inpatient diabetes education program (IDEP)
89164741|NCT00657800|No Intervention|Group 2|Diabetes education as is typically provided by clinical staff
89164742|NCT00614159||GI Endoscopy|
89164743|NCT04159532|Experimental|Monoglyceride (MAG)|Group A will receive the omega-3 fatty acids in monoglyceride formulation (MAG). Subjects will receive 1.5g per day of MAG-EPA/MAG-DHA in a proportion of 460:200 for 12 consecutive weeks.
89164744|NCT04159532|Active Comparator|Triglyceride (TG)|Group B will receive the omega-3 fatty acids in triglyceride formulation (TG). Subjects will receive 1.5g per day of TG-EPA/TG-DHA in a proportion of 460:200 for 12 consecutive weeks.
89164745|NCT04159532|Active Comparator|Ethyl Ester(EE)|Group C will receive the omega-3 fatty acids in Ethyl ester formulation (EE). Subjects will receive 1.5g per day of EE-EPA/EE-DHA in a proportion of 460:200 for 12 consecutive weeks.
89164746|NCT03548675|Experimental|Genotype-guided TCA treatment|Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.
89164747|NCT03548675|Active Comparator|Standard TCA treatment|Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test
89164748|NCT00735592||A|Children discharged with the recommendation of performing a follow up X rays after lobar pneumonia
89164749|NCT04159064||Minimal Invasive Extracorporeal Circulation(MIECC)|"Monitoring coagulation using thromboelastometry and platelet function using impedance aggregometry. Samples at the following phases:~Time 0: Baseline, upon arrival at the operation room (samples for thromboelastometry and impedance aggregometry), Time 2: after aortic cross clamp off (only sample for thromboelastometry), Time 2': 20 minutes post protamine administration (only sample for impedance aggregometry )."
89164750|NCT00613535|Active Comparator|Lavage debridement to remove loose fragments|Articular cartilage defect left untreated by surgical tool during partial meniscectomy
89164751|NCT00613535|Active Comparator|Mechanical Debridement|Remove large chondral flaps and loose fragments
89164752|NCT00613535|Active Comparator|RF based Debridement|Debridement to remove loose fragments followed by use of Paragon T-2 RF wand to smooth the base of the shoulder of the tear
89164753|NCT04064398|Active Comparator|Routine aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
89164754|NCT04064398|No Intervention|No aspiration of gastric residuals|Infants will not have routine aspiration of gastric contents prior to each feeding.
89164755|NCT00729040|Active Comparator|1|Stepping Up to Health only
89164756|NCT00729040|Experimental|2|Stepping up to Health PLUS online message boards to talk with other participants
89164757|NCT05042531|Experimental|experimental group|Patients with intermediate and high risk AML were negative for minimal residual disease after intensive induction and consolidation chemotherapy,the patients were randomly divided into two groups, and one group was given azacitidine(75mg/m2, per day on day 1-7]. Dasatinib 100 mg p.o. qd was administered on days 1-28 of each consolidation cycle.
89164758|NCT05042531|Active Comparator|control group|Patients with intermediate and high risk AML were negative for minimal residual disease after intensive induction and consolidation chemotherapy,the patients were randomly divided into two groups, and the other group was given azacitidine(75mg/m2, per day on day 1-7)on days 1-28 of each consolidation cycle.
89164759|NCT00851721|Experimental|Prophylaxis arm|
89164760|NCT00851721|Active Comparator|On-demand arm|
89164761|NCT02634632|Experimental|Subjects with cancer|choose to write advance directives
89164762|NCT05563714|Experimental|Clinician Notification with Nurse Facilitation (CNNF)|
89164763|NCT05563714|Other|Wait List Control (Usual care)|
89164764|NCT04071119|Active Comparator|Oxytocin nasal spray|
89164765|NCT04071119|Placebo Comparator|Placebo|
89164766|NCT00740038|Active Comparator|1|Active Control: Usual Care
89164767|NCT00740038|Experimental|2|Stress Management Intervention
89164768|NCT00740038|Experimental|3|Exercise Intervention
89164769|NCT00740038|Experimental|4|Combined Stress Management and Exercise Intervention
89164770|NCT02634476|Experimental|cognitive bias modification training|Participants complete four sessions of the alcohol approach/avoidance task.
89164771|NCT02634476|Sham Comparator|sham training|Participants complete four sessions of the sham approach/avoidance task.
89164772|NCT04385303|Experimental|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1.
89164773|NCT04385303|Placebo Comparator|Vehicle|Healthcare professional-administered intra-articular injection; performed on Day 1.
89164774|NCT00740194|Experimental|1|Aromatase inhibition
89164775|NCT00740194|Active Comparator|2|Estradiol
89164776|NCT00658034|Active Comparator|1|Acupuncture
89164777|NCT00658034|Sham Comparator|2|Placebo Acupuncture
89164778|NCT00740272|Experimental|1|AF ablation + pacemaker
89164779|NCT00740272|Active Comparator|2|Pacemaker
89164780|NCT04159376|Experimental|Bone Metastases Patients|
89164781|NCT04064944|Experimental|Immunoadsorption group|patients' blood purification treatment protocal is Protain A Immunoadsorption method.
89164782|NCT04064944|Experimental|Plasma exchange group|patients' blood purification treatment protocal is Plasma exchange method.
89164783|NCT04969055||patients with liver cirrhosis|cirrhosis based on either clinical/radiological parameters or liver histology
89164784|NCT04969055||control group|Healthy ubjects without known heart disease
89164785|NCT04159142|Experimental|Nab-paclitaxel + Carboplatin|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
89164786|NCT04159142|Experimental|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles； Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
89164787|NCT00736060||1|Sickle cell anemia
89164788|NCT00736060||2|Sickle cell thalassemia
89164789|NCT04879121|Experimental|Treatment (larotrectinib sulfate)|Patients receive larotrectinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of unacceptable toxicity. Patients who experience disease progression and are deriving clinical benefit from larotrectinib may continue treatment per physician discretion.
89164790|NCT00654680|Experimental|Arm 1|
89164791|NCT00654680|Placebo Comparator|Arm 2|
89164792|NCT00520741|Experimental|Lacosamide 400 mg/day|Lacosamide 400 mg/day
89164793|NCT00520741|Active Comparator|Lacosamide 300 mg/day|Lacosamide 300 mg/day
89164794|NCT00729118|Experimental|Lenalidomide + Vorinostat|Maintenance post autologous transplant
89164795|NCT04064632|Experimental|RPV +DRV/cobi|The experimental receives rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day) since randomization.
89164796|NCT04064632|Active Comparator|baseline therapy (CAR)|The control arm continues the baseline therapy (CAR) based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine (a tablet/day) and cobicistat/darunavir co-formulated tablets (a tablet day).
89164797|NCT03868007|Experimental|RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent RIC twice daily for 14 days.And the RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
89164798|NCT03868007|Sham Comparator|sham-RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent sham-RIC twice daily for 14 days.And the sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
89164799|NCT04064710|Other|Allograft Tissue|Allograft tissue product for patients with painful vertebral compression fractures
89164800|NCT04032509||Mild TBI|Mild TBI (GCS 13-15 on admission) within 12 hours after injury
89164801|NCT00882518|Experimental|1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) extended-release (300 mg/1st day, 600 mg/2nd day, 400 or 600 or 800 mg/3-42 day)
89164802|NCT00882518|Active Comparator|2-Chlorpromazine|Chlorpromazine (50 or 100 mg/1st day; 100-200 mg/2nd day; 150-300 mg/3rd day; 200-400 mg/4th day; 300 or 400 or 500 or 600 mg/5-42 days)
89164803|NCT00736138|Active Comparator|1|training and pellots
89164804|NCT00736138|No Intervention|2|control
89164805|NCT00740350|Experimental|Experimental|Logan Basic chiropractic adjustments during pregnancy.
89164806|NCT03847337|Experimental|New to diagnosis|We will test two telemedicine tools with children who have not been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
89164807|NCT03847337|Experimental|Previously diagnosed|We will test two telemedicine tools with children who have been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
89164808|NCT00740428|Experimental|G1|pregnants for the first time who will receive the physical therapy guide
89164809|NCT04327037|Experimental|NK cells + IL-2|After cycle of chemotherapy patient receive one intravenous infusion of expanded haploidentical NK cells on day 0. On alternate days, 6 doses of subcutaneous IL-2 is administered with start on day -1.
89164810|NCT00882362|Experimental|1|
89164811|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase A Control|Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS) and Octavalent HPV with 30 mcg IMX / AAHS during Phase A.
89164812|NCT00851643|Experimental|Octavalent HPV with 15 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg AAHS and 15 mcg IMX.
89164813|NCT00851643|Experimental|Octavalent HPV with 30 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX.
89164814|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase B Control|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 60 mcg IMX / AAHS and Octavalent HPV with 120 mcg IMX / AAHS during Phase B.
89164815|NCT00851643|Experimental|Octavalent HPV with 60 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX.
89164816|NCT00851643|Experimental|Octavalent HPV with 120 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX.
89164817|NCT00529243|Experimental|MK-0518 (raltegravir)|Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.
89164818|NCT00636935|Experimental|1|Antibiotic only therapy in patients with PCP and a pO2 of > 70mmHg.
89164819|NCT00636935|Experimental|2|Antibiotics and Corticosteroid therapy in patients with PCP and pO2 >70 mmHg.
89164820|NCT00636935|Active Comparator|3|Standard of care therapy for patients with PCP and pO2 < 70mmHg.
89164821|NCT00654758|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 (or 15) mg/kg with carboplatin and paclitaxel.
89164822|NCT00700869|Experimental|1|Tracheal tube withdrawal governs by respiratory behaviour status
89164823|NCT00656864|Active Comparator|1|Pioglitazone arm
89164824|NCT00656864|Placebo Comparator|2|Placebo arm
89164825|NCT04116801|Experimental|Fluorescence arm|fluorescence guided microsurgical resection (under 560 nm filter) in addition to the usual techniques, after iv injection of 200 mg (i.e. 3-4 mg/kg) of fluorescein sodium at the time of skin incision.
89164826|NCT04116801|Active Comparator|Standard excision|microsurgical resection with usual techniques
89164827|NCT00658190||1|Women obtaining routine Pap tests for cervical cancer screening
89164828|NCT00658268|Experimental|1|
89164829|NCT00658268|Placebo Comparator|2|
89164830|NCT03728309|Experimental|JUVÉDERM® VOLITE™|Participants received an initial treatment of JUVÉDERM® VOLITE™ XC injectable gel, intradermally up to 4 milliliters (mL) on Day 1 followed by an optional touch-up treatment up to 2 mL on Day 30, if applicable. Participants were eligible to receive repeat treatment up to 4 mL at Month 6, if applicable.
89164831|NCT03728309|Experimental|Control Group: No Treatment Then Optional JUVÉDERM® VOLITE™|Participants received no treatment for up to 30 days and then received an optional JUVÉDERM® VOLITE™ XC injectable gel initial treatment intradermally up to 4 mLs and an optional touch-up treatment up to 2 mL 30 days later, if applicable.
89164832|NCT03683719|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
89164833|NCT03683719|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
89164834|NCT03683719|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
89164835|NCT03683719|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
89164836|NCT03683719|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 16 weeks.
89164837|NCT00851253|Experimental|Group 1 (CK SRS boost therapy)|Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy.
89164838|NCT00851253|Experimental|Group 2 (CK SRS salvage therapy)|Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly.
89164839|NCT00613613||1|High drug metabolism genotype All receive fenofibrate
89164840|NCT00613613||2|Low drug metabolism genotype All receive fenofibrate
89164841|NCT04298099|Active Comparator|Ropivacaine 0.2% at 0.3ml/kg|Ropivacaine 0.2% at 0.3ml/kg
89164842|NCT04298099|Active Comparator|Ropivacaine 0.5% at 0.3ml/kg|Ropivacaine 0.5% at 0.3ml/kg
89164843|NCT04030845||breast reconstruction|
89164844|NCT04030845||oncoplastic breast-conserving surgery|
89164845|NCT04041817|Experimental|Trigger increasing steps|"Trigger variations will be performed following increasing steps of 2 L/min every 15 minutes. End expiratory lung volume and lung aeration will be conducted using elecrical impedance tomography. Diaphragmatic motion and thickening will be analyzed by ultrasonography. Work of breathing will be evaluated using gastric and oesophageal pressure measurements.~Measurements will be conducted during the last minute of each step."
89164846|NCT02613195|Experimental|Hydrogen-rich Celsior solution|Using aging liver grafts（≥60 years old)，lavaged and cold stored with hydrogen-rich Celsior solution for 2-4 hours.
89164847|NCT02613195|No Intervention|Celsior solution|Using aging liver/kidney grafts（≥60 years old）, lavaged and cold stored with common Celsior solution for 2-4 hours.
89164848|NCT00520351|Active Comparator|1|
89164849|NCT00520351|Active Comparator|2|
89164850|NCT03722459|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
89164851|NCT00850395||1|Non-Interventional
89164852|NCT03951935||sLSS|patients diagnosed with sLSS scheduled for decompression surgery
89164853|NCT03951935||control subjects|healthy, age-matched control subjects
89164854|NCT04188431|Experimental|Dexamethasone|Single intraoperative administration of 0.15 mg/kg of Dexamethasone intravenously with a maximum dose of 5 mg
89164855|NCT04188431|Placebo Comparator|Sodium chloride|Single intraoperative administration of Sodium Chloride (NaCl) 0.9% intravenously
89164856|NCT04819945|Experimental|GATT-Patch|GATT-Patch will be used to control bleeding during open liver surgery. Each surgery will be performed according to the standard procedures at the hospital, with the exception of the use of GATT-Patch.
89164857|NCT03998215|Experimental|Diphtheria booster vaccination|One booster dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
89164858|NCT03436823|Experimental|R.TMS + nurse semi-structured interview|Repeated Transcranial Magnetic Stimulation sessions associated with nurse semi-structured interview
89164859|NCT03436823|Sham Comparator|R.TMS + Music & Relaxation|Repeated Transcranial Magnetic Stimulation sessions associated with music listening & relaxation with eyes closed
89164860|NCT03630809|Active Comparator|Previously enrolled in study or have been previously treated with DC1 Vaccines - Arm A|Participants currently enrolled into arm A will offered randomization into arms C or D. If study participants decline randomization or are ineligible, they will complete study follow up visits as stated in the schedule of events per Arm A.
89164861|NCT03630809|Active Comparator|Participants receiving first 3 boosters at 3 month intervals - Arm B|A history and physical exam will be taken at 3-month intervals. Any changes in history or physical condition will be documented. Patient currently enrolled into arm B will offered randomization into arms C or D once finished with arm B. If patients decline randomization or are ineligible, they will complete study follow up visits as stated in the schedule of events per Arm B.
89164862|NCT03630809|Experimental|Participants receiving 3 booster vaccines at 3-month intervals (+/- 30 days window) - Arm C|A history and physical exam will be taken at 3-month intervals. Any changes in history or physical condition will be documented
89164863|NCT03630809|Experimental|Participants receiving 6 booster vaccines at 3-month intervals (+/- 30 days window) - Arm D|A history and physical exam will be taken at 3-month intervals. Any changes in history or physical condition will be documented.
89164864|NCT00520039|Experimental|Standard Care Plus OMM|Subjects will receive active intervention with osteopathic manipulative medicine (OMM) using a prescribed standardized treatment protocol which is age appropriate. Subjects will also receive standard care for otitis media from their referring physician.
89164865|NCT00520039|No Intervention|Standard Care Only|Subjects will receive standard care only for otitis media from their regular referring physician
89164866|NCT00577720|Active Comparator|35 mg IRBB|35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
89164867|NCT00577720|Experimental|35 mg DRFB|35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
89164868|NCT00577720|Experimental|50 mg DRFB|50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
89164869|NCT00577720|Experimental|50 mg DRBB|50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
89164870|NCT03630653|Experimental|Sentinel LN in breast cancer recurrence|"Patients with a biopsy assessing an ipsilateral breast tumor recurrence, and a diagnosis of invasive carcinoma after a previous diagnosis of breast cancer that has been treated by breast conservative surgery at least one year before.~Before the SLNB procedure, each patient will have a lymphoscintigraphy to evaluate axillary and extra axillary lymphatic mapping.~Patients will be operated by breast conservative surgery (BCS) or mastectomy. Each patient will have a second SLND followed by a systematic complete ALND."
89164871|NCT00519649|Experimental|Group Engerix|Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)
89164872|NCT03384173||NIRS monitoring|These infants will be monitored with NIRS
89164873|NCT04588129|Experimental|LB-102 50 mg, single dose Cohort 1|LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
89164874|NCT04588129|Experimental|LB-102 100 mg, single dose Cohort 2|LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
89164875|NCT04588129|Experimental|LB-102 75 mg, single dose Cohort 3|LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.
89164876|NCT04588129|Experimental|LB-102 100 & 50 mg, multiple dose Cohort 4|LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for four days in 4 subjects: 2 subjects @ 100 mg and 2 subjects @ 50 mg.
89164877|NCT03625973|Experimental|16 Weeks of 3D-RT|Participants will receive 16 weeks of Reminiscence Therapy using 3D printed objects as stimuli.
89164878|NCT03625973|Experimental|8 Weeks of 3D-RT|Participants will receive 8weeks of Reminiscence Therapy using 3D printed objects as stimuli and 8 weeks of RT using verbal stimuli.
89164879|NCT03625973|Active Comparator|16 Weeks of RT using Verbal Stimuli|Participants will receive 16 weeks of RT using verbal stimuli to reminiscence.
89164880|NCT02569606||Timeframe 2005 - 2007|Data of timeframe 2005 up to 2007 will be included
89164881|NCT02569606||Timeframe 2012 - 2014|Data of timeframe 2012 up to 2014 will be included
89164882|NCT00729196|Experimental|1|Low-Glycemic Load Diet
89164883|NCT00729196|Active Comparator|2|Low-Fat Diet
89164884|NCT00736294|Experimental|Ramipril|Inhibition Conversion Enzyme
89164885|NCT00736294|Placebo Comparator|Placebo|Placebo
89164886|NCT03478397|Active Comparator|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
89164887|NCT03478397|No Intervention|Usual Care|Women with HPV self-collected tests receive usual care. Upon opting for the HPV self-collected test, women will be instructed to go to the health care center in 30 days to pick up the results.
89164888|NCT00736372|Experimental|Investigational Drug|Dose Escalation
89164889|NCT00740662||1|Distal gastric bypass
89164890|NCT00512707|Experimental|Active Testosterone Gel|Active Testosterone Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
89164891|NCT00512707|Placebo Comparator|Placebo Gel|Placebo Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
89164892|NCT00740740||1|Patients scheduled for elective conventional aneurysm repair
89164893|NCT00740740||2|Patients scheduled for emergent conventional aneurysm repair
89164894|NCT00740740||3|Patients scheduled for aortic bypass surgery
89164895|NCT00729274|Active Comparator|hypertonic saline solution|Hypertonic Saline 3% solution alone.
89164896|NCT00729274|Placebo Comparator|nebulized normal saline solution|2 nebulisation with 30 minute interval (max 4ml)
89164897|NCT03852953||Study 1: Under- and overdiagnosed group|Non-proportional stratified sample of women diagnosed with interval or screen-detected breast cancers after participation in BreastScreen Norway. This sample will include under- or overdiagnosed cancers, as well as cancers that were not under- or overdiagnosed.
89164898|NCT03852953||Study 2: Rate of overdiagnosis group|Women residing in Norway, born between 1927 and 1934 (inclusive). This cohort will include women who have attended screening and who have not attended screening.
89164899|NCT03852953||Study 3: Awareness and knowledge group|Women aged 50-69, and practising family doctors aged 25-75, currently living in Norway.
89164900|NCT00740818|No Intervention|A|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
89164901|NCT00740818|Sham Comparator|B|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
89164902|NCT00740818|Experimental|C|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
89164903|NCT00740896|Active Comparator|1|Participants smoke 8 cigarettes in 4 hours.
89164904|NCT00740896|Sham Comparator|2|Participants are not allowed to smoke for 4 hours.
89164905|NCT00736528|Experimental|PF-04447943 05 mg dose|
89164906|NCT00736528|Experimental|PF-04447943 15 mg dose|
89164907|NCT00736528|Experimental|PF-04447943 45 mg dose|
89164908|NCT00736528|Placebo Comparator|Placebo|
89164909|NCT00729352||Control group|18-35 yr old healthy subjects with wild type genotype for NQO1.
89164910|NCT00729352||Case group|18-35 yr old healthy subjects who are homozygotic for minor allele of NQO1 Pro187Ser polymorphism
89164911|NCT03471767|Experimental|AXS-05|Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
89164912|NCT03471767|Active Comparator|Bupropion SR|Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
89164913|NCT00849693|Placebo Comparator|Placebo|
89164914|NCT00849693|Active Comparator|Fluoxetine|
89164915|NCT00849693|Experimental|Duloxetine 60 mg|
89164916|NCT00849693|Experimental|Duloxetine 30 mg|
89164917|NCT02569294|Experimental|Choice 1: Yoga intervention|See intervention description
89164918|NCT02569294|Experimental|Choice 2: Hypnosis intervention|See intervention description
89164919|NCT02569294|Experimental|Choice 3: CBT intervention|See intervention description
89164920|NCT02569294|No Intervention|Control group|Participants who agreed not to participate in any of the interventions proposed.
89164921|NCT03465761|Experimental|ExAblate 4000 System|ExAblate treatment of Bilateral Essential Tremor
89164922|NCT00736606|Experimental|Period 1|simvastatin
89164923|NCT00736606|Experimental|Period 2|simvastatin + AZD9056
89164924|NCT03842345||Psychiatric patients|Major depression, Bi-polar, schizophrenia, ADHD, OCD, PTSD
89164925|NCT03842345||healthy controls|young healthy controls to serve as norm.
89164926|NCT02569060|Experimental|Immediate Intervention|"Participants randomized to the Intervention Arm will immediately begin a four-component intervention.~Testing and monitoring of blood glucose levels~Referral to and/or coordination with primary care provider~Diabetes-appropriate food packages~Diabetes self-management education and support"
89164927|NCT02569060|Active Comparator|Waitlist Control|"Participants randomized to the Waitlist Control arm will receive no intervention for six months, after which time they will begin a modified, four-component intervention.~Testing and monitoring of blood glucose levels~Referral to and/or coordination with primary care provider~Diabetes-appropriate food packages~Limited diabetes self-management education and support"
89164928|NCT00527605|Experimental|A|dutasteride 0.5mg once daily orally
89164929|NCT00527605|Placebo Comparator|B|Placebo matched once daily orally
89164930|NCT00736684|Active Comparator|1|Proximal Femoral Nail AntirotationTM (PFNA)
89164931|NCT00736684|Other|2|Gamma Nail 3TM (Gamma3)
89164932|NCT00849381|Experimental|Cervarix Compliance Issue Centre Group|Subjects from one centre where compliance issues were discovered, who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study
89164933|NCT00849381|Experimental|Cervarix All Centres Group|Subjects from all study centres who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study.
89164934|NCT02568982||patient with Cushing's disease|
89164935|NCT04480697|Experimental|SAD 10mg|A single oral dose of 10 mg
89164936|NCT04480697|Experimental|SAD 20mg|A single oral dose of 20 mg. Food effect will also be assessed at the same dose level.
89164937|NCT04480697|Experimental|SAD 40mg|A single oral dose of 40mg
89164938|NCT04480697|Experimental|SAD 80 mg|A single oral dose of 80 mg
89164939|NCT04480697|Experimental|SAD 120 mg|A single oral dose of 120 mg
89164940|NCT04480697|Experimental|SAD 150 mg|A single oral dose of 150 mg
89164941|NCT04480697|Experimental|MAD 10mg|Dose regimen is once daily 10 mg for 14 consecutive days.
89164942|NCT04480697|Experimental|MAD 30mg|Dose regimen is once daily 30 mg for 14 consecutive days.
89164943|NCT04480697|Experimental|MAD 90 mg|Dose regimen is once daily 90mg for 14 consecutive days.
89164944|NCT02609269||Decipher GRID Patients|Patients who have been tested with any of the Decipher clinical tests
89164945|NCT00741052|Experimental|1|Ciprofloxacin
89164946|NCT00741052|Active Comparator|2|Azithromycin
89164947|NCT04116411|Placebo Comparator|Placebo|Patients will receive placebo tablets with similar appearance as the active drug. Patients receive two 450 mg tablets twice daily taken per orally for 6 weeks, thereafter two 450 mg tablet once daily for an additional 22.5 months; a total treatment time of 24 months.
89164948|NCT04116411|Active Comparator|Valganciclovir|Patients will receive valganciclovir tablets with similar appearance as the placebo tablets. Patients receive two 450 mg valganciclovir tablets twice daily taken per orally for 6 weeks, thereafter two 450 mg valganciclovir tablets once daily for an additional 22.5 months; a total treatment time of 24 months.
89164949|NCT02612883||Esophagus|Measuring of tissue perfusion of the esophagus
89164950|NCT02612883||Liver|Measuring of tissue perfusion of the liver
89164951|NCT02612883||Stomach|Measuring of tissue perfusion of the stomach
89164952|NCT02612883||Pancreas|Measuring of tissue perfusion of the pancreas
89164953|NCT02612883||Colon|Measuring of tissue perfusion of the colon
89164954|NCT04469621|Experimental|SAR443122|SAR443122 dose 1, twice daily for 14 days
89164955|NCT04469621|Placebo Comparator|Placebo|matching placebo
89164956|NCT00706875||1|30 patients survived GTD post treatment for 0 - 5 years.
89164957|NCT00706875||2|30 patients survived GTD post treatment 6 - 10+ years.
89164958|NCT00706953|Active Comparator|001|
89164959|NCT04431947||Youth|Youth, between the ages of 2 and 17, with type 1 diabetes
89164960|NCT04431947||Parent|Parents of youth with type 1 diabetes
89164961|NCT03462017|Experimental|SAR247799|SAR247799 repeated doses once daily in the morning under fasted condition for 28 days according to a sequential dose design
89164962|NCT03462017|Placebo Comparator|Placebo|Identical matching placebo for SAR247799 and for sildenafil once daily in the morning under fasted condition for 28 days
89164963|NCT03462017|Active Comparator|Sildenafil|Sildenafil once daily in the morning under fasted condition for 28 days
89164964|NCT00913419|Experimental|1|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
89164965|NCT00913419|Active Comparator|2|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
89164966|NCT00711412|Experimental|Induction, Combination and surgery|"Weeks 1-6:~Capecitabine 1000mg/m2 twice daily Oxaliplatin 70mg/m2 on days 1 and 8~Weeks 7-12:~Capecitabine 825 mg/m2 twice daily Oxaliplatin 50mg/m2 weekly Radiation 1.8 Gy Monday-Friday~Evaluation for response and resection surgery"
89164967|NCT01840007|Experimental|Metformin|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
89164968|NCT00741130||C|normal volunteers
89164969|NCT00741130||G|glaucoma patients
89164970|NCT03801941|Experimental|Group A|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with the ATLAS Device at the 4th day and without the device at the 5th day of a 4 weeks rehabilitation program.
89164971|NCT03801941|Experimental|Group B|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without the ATLAS Device at the 4th day and with the device at the 5th day of a 4 weeks rehabilitation program.
89164972|NCT00741208|Other|1|Patients randomized to receive soy isoflavone twice daily for 2 weeks. Patients will cross-over and receive placebo medication for 2 weeks later in the study
89164973|NCT00741208|Other|2|Patients randomized to receive placebo medication twice daily for 2 weeks. Patients will cross-over and receive soy isoflavone for 2 weeks later in the study
89164974|NCT03746951|Active Comparator|Fascia iliaca compartment block (FICB)|FICB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the groin.
89164975|NCT03746951|Active Comparator|Lumbar plexus block (LPB)|LPB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the back.
89164976|NCT02571673||Survivors of head and neck cancer|Data collection will take place in two parts. Aim 1: Part 1 will enroll 10 patients at MSK to participate in component pilot testing and usability testing of HN-STAR and the associated surveys. We will also elicit feedback from the NP. After incorporating any changes to HN-STAR or the surveys based on findings from Aim 1: Part 1, Aim 1: Part 2 will enroll 30 additional patients from MSK and 15 from HH to provide feedback on usability. We will also survey each patient's PCP in Aim 1: Part 2.
89164977|NCT00577408|Experimental|Depot Naltrexone|Depot Naltrexone. Vivitrol (380 mg)given monthly
89164978|NCT00577408|Active Comparator|Oral Naltrexone|Oral Naltrexone. For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday).
89164979|NCT03391193|Experimental|Multi-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal containing) in multi-dose presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
89164980|NCT03391193|Active Comparator|Single-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal free) in single-dose syringe presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
89164981|NCT00741364|Active Comparator|1|vitamin D3 (400 IU/d)
89164982|NCT00741364|Active Comparator|2|vitamin D3 (10,000 IU/d)
89164983|NCT00741364|Active Comparator|3|vitamin D3 (40,000 IU/d)
89164984|NCT03998137||Autograft|Standard Rigid Fixation plus autograft
89164985|NCT03998137||AUGMENT® Injectable|Standard rigid fixation plus AUGMENT® Injectable Bone Graft
88804624|NCT03331250|Experimental|Eribulin|"Eribulin administered twice per cycle intravenously~Each cycle contains 21 days~Dosing is per the FDA label for other cancers"
89164986|NCT04745611||COVID-19 non-ICU patients|Patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were not admitted to an intensive care unit.
89164987|NCT04745611||COVID-19 ICU patients|Patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were admitted to an intensive care unit.
89164988|NCT04745611||COVID-19 non-ICU family members|Close family members of patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were not admitted to an intensive care unit.
89164989|NCT04745611||COVID-19 ICU family members|Close family members of patients who were admitted to one of six recruiting hospitals in the Netherlands due to COVID-19 during the first patient wave (march-june 2020) and who were admitted to an intensive care unit.
89164990|NCT00729508|Experimental|1|
89164991|NCT00729508|Experimental|2|
89164992|NCT00729508|Experimental|3|
89164993|NCT00729508|Experimental|4|
89164994|NCT00729508|Placebo Comparator|5|
89164995|NCT00614471|Active Comparator|1|
89164996|NCT00614471|Experimental|2|
89164997|NCT00614471|Experimental|3|
89164998|NCT05742256|Experimental|Test group 1(OCA group)|
89164999|NCT05742256|Experimental|Test group 2(OCB group)|
89165000|NCT05742256|Active Comparator|Control group(SF group)|
89165001|NCT03841513|No Intervention|Control|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, without the addition of a laparoscopic/robotic Burch colposuspension
89165002|NCT03841513|Active Comparator|Laparoscopic Burch Colposuspension|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, with the addition of a laparoscopic/robotic Burch colposuspension
89165003|NCT02568748|Experimental|CIK with TACE for HCC stage B|HCC patients stage B treated with TACE and CIK as adjuvant therapy.
89165004|NCT02568748|Experimental|TACE only for HCC stage B|HCC patients stage B treated with TACE without receiving CIK cells infusion
89165005|NCT02568748|Experimental|CIK in HCC stage C or D|HCC stage C or D will receive supportive treatment in addition to CIK cells infusion
89165006|NCT02568748|No Intervention|Supportive treatment in HCC stage C or D|HCC stage C or D will receive supportive treatment only .
89165007|NCT02692781|Experimental|Dose Cohort 1|20mg MOD-6031 / Placebo
89165008|NCT02692781|Experimental|Dose Cohort 2|50mg MOD-6031 / Placebo
89165009|NCT02692781|Experimental|Dose Cohort 3|100mg MOD-6031 / Placebo
89165010|NCT02692781|Experimental|Dose Cohort 4|150mg MOD-6031 / Placebo
89165011|NCT02692781|Experimental|Dose Cohort 5|200mg MOD-6031 / Placebo
89165012|NCT00736762|Experimental|GPR|Global postural re-education intervention
89165013|NCT00614549||Levetiracetam|Patients treated with Levetiracetam
89165014|NCT00713596|Sham Comparator|Control group|Septorhinoplasty with postoperative application of nasal taping and an external nasal cast. The tape and cast will be left in place for one week. No tissue glue will be used during the operation, although the nurse and surgical assistant will simulate the preparation and insertion of tissue glue using a syringe containing saline.
89165015|NCT00713596|Experimental|Fibrinogen, tape, and cast|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, fibrin sealant will be applied by the surgical assistant to the surgical site. Approximately 0.5 cc to 2 cc of tissue sealant will be applied. After closure, tape and cast will be applied and left in place for one week.
89165016|NCT00713596|Experimental|Fibrinogen and tape|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, 0.5 cc to 2 cc of tissue sealant will be applied. Nasal tape will be applied after closure.
89165017|NCT04306445|Active Comparator|GF-IGB: Obalon Balloon|Obalon balloons are gas-filled balloons used for weight loss by taking up more space in the stomach. There are three separate balloons that are placed. They are inflated once the capsules containing the balloons are swallowed. The second balloon is swallowed two weeks after the first balloon, and the third balloon is swallowed four to eight weeks after the second balloon. All three balloons are removed six months after the first balloon is placed.
89165018|NCT04306445|Active Comparator|Medically Supervised Meal Replacement Program: My New Weigh|Meal Replacements are used for weight loss in order to achieve a very low-calorie diet that is nutritionally balanced. Four to five meal replacements are consumed per day. If only four meal replacements are consumed per day, three servings of vegetables and two servings of fruit are consumed as well. This program lasts for about five months or twenty weeks.
89165019|NCT04306445|Active Comparator|Endoscopic Sleeve Gastroplasty: ESG|Endoscopic sleeve gastroplasty (ESG) is a weight loss procedure that uses an endoscopic suturing device known as Overstitch to reduce the size of the stomach. This decreases the amount of food one can consume, which leads to the consumption of fewer calories throughout the day, resulting in weight loss.
89165020|NCT00880568|Experimental|MK-1496 20 mg (21-Day Cycle)|Participants receiving MK-1496 20 mg on Day 1 of each 21-day cycle
89165021|NCT00880568|Experimental|MK-1496 40 mg (21-Day Cycle)|Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle
89165022|NCT00880568|Experimental|MK-1496 80 mg (21-Day Cycle)|Participants receiving MK-1496 80 mg on Day 1 of each 21-day cycle
89165023|NCT00880568|Experimental|MK-1496 120 mg (21-Day Cycle)|Participants receiving MK-1496 120 mg on Day 1 of each 21-day cycle
89165024|NCT00880568|Experimental|MK-1496 20 mg (28-Day Cycle)|Participants receiving MK-1496 20 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
89165025|NCT00880568|Experimental|MK-1496 40 mg (28-Day Cycle)|Participants receiving MK-1496 40 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
89165026|NCT00880568|Experimental|MK-1496 80 mg (28-Day Cycle)|Participants receiving MK-1496 80 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
89165027|NCT00880568|Experimental|MK-1496 100 mg (28-Day Cycle)|Participants receiving MK-1496 100 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
89165028|NCT00880568|Experimental|MK-1496 120 mg (28-Day Cycle)|Participants receiving MK-1496 120 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
89165029|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 1)|BMS-936559 (MDX-1105)
89165030|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 2)|BMS-936559 (MDX-1105)
89165031|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 3)|BMS-936559 (MDX-1105)
89165032|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 4)|BMS-936559 (MDX-1105)
89165033|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 5)|BMS-936559 (MDX-1105)
89165034|NCT04229615|Experimental|Safety Lead-in, Doublet Arm|Fluzoparib+Apatinib
89165035|NCT04229615|Experimental|Single Arm|Fluzoparib
89165036|NCT04229615|Placebo Comparator|Placebo|Placebo
89165037|NCT00881894|Experimental|Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)|Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days
89165038|NCT00881894|Experimental|Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)|Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days
89165039|NCT04215107|Other|Control group|Crossover study Group. Each patient will be examined 2 seperate days. Randomized to standard breakfast meal or prolonged fasting. The examinator will be blinded to patient meal status.
89165040|NCT04215107|Other|IUGR group|Will only be examined one day. First ultrasound during fasting, and the second ultrasound 2 hours after a standard breakfast meal.
89165041|NCT00711100|Experimental|Camel Snus|Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.
89165042|NCT00711100|Experimental|Marlboro Snus|Marlboro Snus (oral smokeless tobacco product). Dosage: 0.14 - 0.38 mg nicotine per portion.
89165043|NCT00711100|Experimental|Stonewall|Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.
89165044|NCT00711100|Experimental|Ariva|Ariva (oral dissolvable tobacco product). Dosage: 0.24-0.25 mg nicotine per portion.
89165045|NCT00711100|Experimental|General Snus|General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine.
89165046|NCT02638376|Active Comparator|KXL treatment only|
89165047|NCT02638376|Active Comparator|KXL and topography-guided PRK|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
89165048|NCT02568514|No Intervention|Usual care|Patients admitted to hospital floors without any other intervention.
89165049|NCT02568514|Experimental|Secure text messaging|Patients admitted to hospital floors on which physicians and other staff are able to communicate with each other (not to the patient) using mobile secure text messaging.
89165050|NCT02634398||Treated subjects|All subjects recruited and treated wiht the Axium neurostimulator
89165051|NCT02568592|Experimental|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
89165052|NCT02568592|Experimental|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
89165053|NCT02568592|Experimental|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORM (Normal), with an additional 30% extra energy coming from fat.
89165054|NCT00656942||Healthy|"subjects with no pain and no opioid treatment for at least six months~subjects receive quantitative sensory testing (QST)"
89165055|NCT00656942||Pain, no opioid|"subjects have chronic pain but have not taken any opioid medication for at least 3 months~subjects receive QST"
89165056|NCT00656942||Pain, opioid|"subjects have chronic pain and have been taking opioid medication for at least 3 months~subjects receive QST"
89165057|NCT00827931|Experimental|A|end of the operation and on the mornings of the first, second, fourth and seventh postoperative days.
89165058|NCT00827931|Other|B|Standard of Care
89165059|NCT04158674|Experimental|Levosimendan|
89165060|NCT04158674|Sham Comparator|Placebo|
89165061|NCT02474927|Experimental|Carfilzomib Treatment Arm|Carfilzomib will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for 1-2 complete cycles in the study.
89165062|NCT00658346||1|HIV-1 group O infected patients
89165063|NCT00658346||2|HIV-1 group M infected patients
89165064|NCT00710866|Experimental|1|2 doses 0.5mL VAXIGRIP® at months 0, 1
89165065|NCT00710866|Active Comparator|2|2 doses 0.25mL VAXIGRIP® at months 0, 1
89165066|NCT04158596|Experimental|Treatment|The applied therapeutic vibrations generated by an acoustic coil have a defined sweeping frequency range.
89165067|NCT04158596|Active Comparator|Control|A control device with a different vibration pattern will be used as comparator intervention
89165068|NCT03640949|Experimental|Vasopressin and methylprednisolone|The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).
89165069|NCT03640949|Placebo Comparator|Placebo|"The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl."
89165070|NCT00827775|No Intervention|Control|Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling >10 mmhg for more than 4/6 of the last dialysis treatment sessions
89165071|NCT00827775|Active Comparator|Intervention|Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of >10 mmhg for more than 4/6 of the last dialysis treatment sessions
89165072|NCT02544308|Active Comparator|No further treatment|No further treatment
89165073|NCT02544308|Experimental|Lenalidomide + Dexamethasone|Lenalidomide 25mg orally daily on days 1-21 Dexamethasone 20mg orally on days 1, 8, 15 & 22 Up to 9 cycles
89165074|NCT04617808||Headache pattern|Telephone call from center 15 for the headache pattern
89165075|NCT00707187|Experimental|1|35 doses of study medication, IC 351 (20 mg) -- crossover to placebo
89165076|NCT00707187|Experimental|2|35 placebo pills followed with 35 study medication (20 mg)
89165077|NCT03998761|Active Comparator|Micronized progesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening).
89165078|NCT03998761|Active Comparator|Micronized progesterone plus dydrogesterone|Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening).
89165079|NCT00658502||1|
89165080|NCT00658502||2|
89165081|NCT00736918|Experimental|Case management|Case management
89165082|NCT00736918|Active Comparator|Enhanced usual care|Enhanced usual care
89165083|NCT00658580|Active Comparator|A|Every 3 weeks intravenous cisplatin plus etoposide
89165084|NCT00658580|Experimental|B|Every 3 weeks intravenous epirubicin plus ifosfamide plus etoposide
89165085|NCT03624491|No Intervention|Standard of care mechanical ventilation|Anesthesia and surgical procedures will be performed following standard of care for mechanical ventilation during surgery.
89165086|NCT03624491|Active Comparator|Transpulmonary pressure guided mechanical ventilation|Same treatment as the control group with the addition of esophageal pressure measurements used to guide mechanical ventilation during surgery.
89165087|NCT00729742|Experimental|Part 1|erlotinib
89165088|NCT00729742|Experimental|Part 2|erlotinib + dalotuzumab
89165089|NCT04074863|Active Comparator|Darrach|Surgical procedure: resection of distal ulna
89165090|NCT04074863|Active Comparator|Prosthesis|Surgical procedure: ulnar head replacement
89165091|NCT04801693|Experimental|BI 1819479|single rising doses (SRD) part
89165092|NCT04801693|Placebo Comparator|Placebo|Single rising doses (SRD) part
89165093|NCT04801693|Experimental|BI 1819479 fed - fasted arm|Food effect part
88804625|NCT03307044|Experimental|Treatment (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
88804626|NCT03189719|Experimental|Pembrolizumab + SOC|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) plus standard of care (SOC) chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
89165094|NCT04801693|Experimental|BI 1819479 fasted - fed arm|Food effect part
89165095|NCT05742100||Group of patients treated with darvadstrocel|
89165096|NCT03435107|Experimental|Durvalumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were refractory to fluoropyrimidines, irinotecan and oxaliplatin with or without targeted agents will be accrued.~After checking the eligibility for the study entry, patients will be entered into the study treatment with durvalumab monotherapy."
89165097|NCT02147600||Chronic plaque psoriasis|Patients suffering from chronic plaque psoriasis, treated with adalimumab (40mg) subcutaneously every other week after an initial dose of 80 mg. Treatment duration of at least 24 weeks.
89165098|NCT02568436|No Intervention|Conventional Decrowding|Crowded upper incisors will be treated in the conventional manner with a fake irradiation without using low level laser therapy.
89165099|NCT02568436|Experimental|Low Level Laser Therapy|Each maxillary incisor will be subjected to low level laser therapy at specific times in order to accelerate tooth movement
89165100|NCT03612791|Active Comparator|Standard Treatment Arm|"Radiotherapy (RT):~Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a minimal total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~Total duration of RT (including brachytherapy) should be ≤ 55 days.~Chemotherapy:~- Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5)."
89165101|NCT03612791|Experimental|Experimental Treatment Arm|"Same treatment as described above (CRT, followed by uterovaginal brachytherapy), plus~atezolizumab administered IV 1200 mg Q3W, starting on the same week as EBRT (Week 1) and continued as an adjuvant for a total maximum of 20 cycles (approximately 14 months total of treatment)."
89165102|NCT03998449|Experimental|Cholera vaccination|Two doses of the vaccine against cholera
89165103|NCT00614861||001|
88804627|NCT03189719|Placebo Comparator|Placebo + SOC|Participants receive placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
88804628|NCT02969525|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
89165104|NCT05742022|Experimental|"Phospholipovit"|Powder for preparing a solution for oral administration. 500 mg orally 2 times a day, for 12 weeks
89165105|NCT05742022|Experimental|Placebo|Powder for preparing a solution for oral administration. 500 mg orally 2 times a day, for 12 weeks
89165106|NCT02692937|Experimental|Surgery and exercise|Neurolysis of peripheral nerves in the back of the head and/or neck. Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
89165107|NCT02692937|Active Comparator|Exercise, Active Comparator|Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
89165108|NCT00827541||1|Patients hospitalized because of cIAI or cSSTI
89165109|NCT03916601|Experimental|Test (T)|SAR341402 Mix 70/30: single dose injection
89165110|NCT03916601|Active Comparator|Reference 1 (R1)|NovoLog Mix 70/30: single dose injection
89165111|NCT03916601|Active Comparator|Reference 2 (R2)|NovoMix30: single dose injection
89165112|NCT03916601|Experimental|Reference 3 (R3)|SAR341402 rapid-acting solution: single dose injection
89165113|NCT04065022|Experimental|Head stimulation|Each subject will be stimulated at two different days. One day with the presence of topical anesthetic cream on the scalp above the MC and in the other day with absence of the anesthetic cream. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex. Each subject follows three sessions of 12 min length each day. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
89165114|NCT04065022|Experimental|Arm stimulation|Each subject will be stimulated on only one day. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 2*1 gel-filled cup-electrodes is placed over the contralateral arm. Each subject follows three sessions of 12 min length. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
89165115|NCT00613691|Experimental|SPI-1620|SPI-1620 an endothelin B agonist
89165116|NCT00518323|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
88804629|NCT02969525|Experimental|Bimekizumab dosage regimen 1|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
89165117|NCT00518323|Experimental|002|Paliperidone ER 3 mg or 6 mg tablet once daily for 6 weeks
89165118|NCT00518323|Experimental|003|Paliperidone ER 6 mg or 12 mg tablet once daily for 6 weeks
89165119|NCT00518323|Placebo Comparator|004|Placebo Once daily for 6 weeks
89165120|NCT00707421|Placebo Comparator|1|placebo, artificial tears
89165121|NCT00707421|Active Comparator|3|corticosteroid , CS
89165122|NCT00707421|Active Comparator|2|non-steroidal anti-inflammatory drug, NSAID
89165123|NCT00707499|Experimental|1|
89165124|NCT03255707|Experimental|Group A|50 patients will receive the gold standard occlusion therapy
89165125|NCT03255707|Experimental|Group B|50 patients will receive dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
89165126|NCT03570437|Active Comparator|Arm 1: Paclitaxel|Paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles.
89165127|NCT03570437|Experimental|Arm 2: Cediranib and paclitaxel|Cediranib 20 mg once daily for 28 days given with weekly paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue cediranib once daily until disease progression.
89165128|NCT03570437|Experimental|Arm 3: Cediranib and olaparib|Cediranib 20 mg once daily with olaparib 300 mg twice daily, continuously on a 28 day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue with olaparib and cediranib until disease progression.
89165129|NCT00826449|Experimental|Phase I|Dasatinib + Erlotinib
89165130|NCT03632213|Active Comparator|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
89165131|NCT03632213|Placebo Comparator|Placebo|Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
89165132|NCT02611401|Experimental|Mindulness Based Intervention|intervention with group-based Mindfulness Based Intervention
89165133|NCT02611401|Active Comparator|Active Control|intervention with group-based Psychoeducation and Relaxation
89165134|NCT00825825|Active Comparator|Escitalopram|One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.
89165135|NCT00825825|Active Comparator|Citalopram|One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.
89165136|NCT00825825|Placebo Comparator|Placebo|Two weeks of placebo in healthy volunteers.
89165137|NCT03802487|Experimental|Sotagliflozin|One treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer plus charcoal. The other treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer without charcoal.
89165138|NCT03483233|Experimental|fMRI and EEG study|
89165139|NCT03783767|Experimental|Leadership Intervention Group|Teachers in the intervention group will receive a half day workshop from a member of the research team. These teachers will then provide a four week training program to Grade 6/7 students, who will then deliver a 10-week fundamental movement skill (FMS) training program to Grade 3/4 students.
89165140|NCT03783767|No Intervention|Waitlist Control|This group of students and teachers will act as a waitlist control group. Therefore, during the same time that the other group is receiving the intervention, this group will proceed with their normal practices.
89165141|NCT00710710|Experimental|BI 2536 High dose|Day 1
89165142|NCT00710710|Experimental|BI 2536 Low dose|Day 1 - 3
89165143|NCT02692547|Other|Hybrid-logic closed loop system|All patients get to wear the pump. only 1 arm. There is no comparator in this study, as all patients wear the pump.
89165144|NCT00880334|Experimental|vandetanib & Docetaxel|vandetanib orally and Docetaxel intravenously
89165145|NCT00880334|Active Comparator|Placebo and Docetaxel|Placebo orally and docetaxel intravenously
89165146|NCT05741554||Myometrial involvement|Myometrial involvement by cancer metastasis after pathology examination
89165147|NCT05741554||No myometrial involvement|Absence of myometrial involvement by cancer metastasis after pathology examination
89165148|NCT04063930|Active Comparator|Lokelma|"Sodium zirconium cyclosilicate Lokelma® 5 g, powder (Astra Zeneca)~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.~Duration: 12 weeks"
89165149|NCT04063930|Placebo Comparator|Placebo|"Matching placebo (indistinguishable from the active comparator)~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.~Duration: 12 weeks"
89165150|NCT04161872|Active Comparator|Uricemin|
89165151|NCT04161872|Placebo Comparator|Placebo|
89165152|NCT03364439|Experimental|One arm for all patients|Patients eligible for the study will receive 6 courses of R-CHOP14 or R-CHOP21.
89165153|NCT04063774|Experimental|Dengue diagnostic algorithm|single arm of consecutive enrolled subjects with fever in whom the dengue diagnostic algorithms were applied by study physician and blood sample taken for hemogram and dengue reference tests (gold standard)
89165154|NCT02634242|Experimental|Si-Wu-Tang (SWT)|Subjects are recommended to drink 125 mL of SWT (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
89165155|NCT02634242|Placebo Comparator|placebo|Subjects are recommended to drink 125 mL of Placebo (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
89165156|NCT00654914|Experimental|Arm 1|
89165157|NCT02638454|Active Comparator|HL-YNG|"Healthy young sedentary males and females 20-30 yrs old~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
89165158|NCT02638454|Experimental|FL-OLD|"Functionally-limited older sedentary males and females without sarcopenia (70-85 yrs old)~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
89165159|NCT02638454|Experimental|SR-OLD|"Functionally-limited older sedentary males and females with clinically defined sarcopenia (70-85 yrs old)~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
89165160|NCT00865566|Experimental|1|Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
89165161|NCT00865566|Placebo Comparator|2|Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
89165162|NCT02632370||Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials. The formulation contains 1.5 g 5-aminolevulinic acid hydrochloride corresponding to 1.17 g of 5-aminolevulinic acid. The oral solution is intended for single (partial) use.
89165163|NCT03866473|Experimental|Photobiomodulation (PBM)|670nm wavelength device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device).
89165164|NCT03866473|Sham Comparator|Placebo|Broad spectrum light device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device)
89165165|NCT00659048|Active Comparator|1|Ciclesonide 200µg
89165166|NCT00659048|Placebo Comparator|2|Placebo
89165167|NCT02623920|Experimental|Brentuximab, Bendamustine, Rituximab|Brentuximab Vedotin in Combination with Bendamustine and Rituximab
89165168|NCT02634086||Percutaneous coronary intervention|Patients with triple-vessel coronary artery disease underwent percutaneous coronary intervention.
89165169|NCT02634086||Coronary artery bypass graft|Patients with triple-vessel coronary artery disease underwent coronary artery bypass graft.
89165170|NCT02634086||Optimal medication therapy|Patients with triple-vessel coronary artery disease underwent optimal medication therapy only.
89165171|NCT00525499|Placebo Comparator|1|Vehicle control cream applied topically to the face twice daily for 12 weeks
89165172|NCT00525499|Experimental|2|0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks
89165173|NCT00525499|Experimental|3|0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks
89165174|NCT00525499|Experimental|4|0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks
89165175|NCT00698256|Experimental|1|
89165176|NCT00698256|Placebo Comparator|2|
89165177|NCT00824655|Experimental|Group 1|
89165178|NCT00824655|Experimental|Group 2|
89165179|NCT02614638|Active Comparator|1st observational period (before experimental intervention)|"Patients in this arm are included during a first month of observation before the intervention is implemented.~Intervention: One month of department-wide observation"
89165180|NCT02614638|Experimental|2nd obs. period (during experimental intervention)|"Following a one-month wash-out period, patients in this arm are included during a second month of observation during which the intervention is implemented.~Intervention: Pharm Tech participates in department"
89165181|NCT04576546|Active Comparator|comparator group|myo-inositol treatment
89165182|NCT04576546|Experimental|study group|D-chiro-inositol treatment
89165183|NCT04133844||Extracorporeal membrane oxygenation|
89165184|NCT02617680|Experimental|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Concentration of oxygen should be 50%.
89165185|NCT02617680|Experimental|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially.Concentration of oxygen should be 50%.
89165186|NCT02568280|Experimental|Faster aspart|
89165187|NCT02568280|Active Comparator|Insulin aspart|
89165188|NCT04161794|Experimental|Intervention group|2 g EPA/DHA via fish oil daily Regular dietary counselling Twice weekly strength and cardiovascular exercise
89165189|NCT04161794|No Intervention|Historical control group|Standard of Care
89165190|NCT02617524|Experimental|Valve Medical Dedicated Sheath|Valve Medical Dedicated Sheath version 00
89165191|NCT00525265|Experimental|1|OPC-41061
89165192|NCT00525265|Placebo Comparator|2|placebo
89165193|NCT00659204|Experimental|nano-silver gel|
89165194|NCT00659204|Active Comparator|alcohol-based gel|
89165195|NCT02623842|Experimental|Radiofrequency|
89165196|NCT02568202||Survey|
89165197|NCT04158830|Other|Group 1 - ACOG recommended dose|oral dose: 81 mg aspirin daily; designated by odd number assignment [1-001, 1-003, 1-005, etc. to 899]
89165198|NCT04158830|Active Comparator|Group 2 - Comparison Dose|oral dose: 162 mg aspirin daily; designated by even number assignment [2-002, 2-004, 2-006, etc. to 900]
89165199|NCT03998917||Chronic Kidney Disease (CKD) Patients|Patients with chronic kidney disease and a glomerular filtration rate less than 60 ml/min of creatinine. Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
89165200|NCT03998917||Control cohort|The control cohort will consist of a group of people from the same age group as the CKD group but without chronic kidney disease. The exclusion criteria apply to this group. They will be selected from the spouses and other volunteers. This group will also perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
89165201|NCT02623764||MCI due to Alzheimer´s disease|Individuals with MCI diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or Cerebro Spinal Fluid (CSF) analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
89165202|NCT02623764||Mild dementia due to Alzheimer´s disease|Individuals with mild dementia and diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or CSF analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
89165203|NCT02623764||Mild dementia due to Lewy body disease|Individuals with mild Lewy body dementia. The intervention is Exelon patches in recommended doses, 4.6mg/day for a month and then 9.5mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
89165204|NCT04158518|Experimental|Toxicities reduced treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).
89165205|NCT04158518|Active Comparator|Conventional treatment|Patients receive docetaxel(75mg/m2 d1) and cisplatin(25 mg/m2 d1-3) every 3 weeks for 3 cycles as induction chemotherapy, followed by concurrent cisplatin chemotherapy with standard radiation dose when responses to induction chemotherapy are less than 50% Partial Response(PR).
89165206|NCT02617602|Experimental|Goal directed therapy|Based on transpulmonary thermodilution, hemodynamic management will be implemented to achieve predefined goals
89165207|NCT02617602|Active Comparator|Control|Conventional therapy
89165208|NCT00737152|Experimental|1|All subjects will take RAS 130 administered orally in tablet form at a starting dose of 4 mg once a day or 2 mg tablets twice a day.
89165209|NCT00659282||A|biphasic insulin aspart
89165210|NCT02617758|Experimental|Treatment AB|Participants will receive Treatment A (single application of DURAGESIC fentanyl transdermal system 100 microgram per hour (µg/h) dose) as Reference in Period 1; followed by Treatment B (single application of Fentanyl transdermal system [JNJ-35685-AAA-G021] 100 µg/h dose) as test in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
89165211|NCT02617758|Experimental|Treatment BA|Participants will receive Treatment B [single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose] as test in Period 1; followed by Treatment A (single application of DURAGESIC fentanyl transdermal system 100 µg/h dose) as Reference in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
89165212|NCT02614716|Experimental|LY3090106|LY3090106 given subcutaneously (SC) in escalating dose cohorts once every 2 or 4 weeks for 16 weeks.
89165213|NCT02614716|Placebo Comparator|Placebo|Placebo given subcutaneously (SC) once every 2 or 4 weeks for 16 weeks.
89165214|NCT00737308|Experimental|A|crown for clasp
89165215|NCT00880256|Experimental|MBSR|Patients who undergo mindfulness-based stress reduction will fill out measures of IBS severity before and after the mindfulness course.
89165216|NCT04064788|Experimental|Consecutive mCIMT group|6 hours / day, 10 consecutive days, 60 hours mKZHT + 2 days 45 minutes / day traditional physiotherapy
89165217|NCT04064788|Experimental|Intermittent mCIMT group|6 hours / day 2 days a week 5 weeks, a total of 60 hours mKZHT + 2 days 45 min / day traditional physiotherapy
89165218|NCT04064788|Active Comparator|Traditional physiotherapy control group|45 min / day, 2 days a week traditional physiotherapy
89165219|NCT02623686|Experimental|Aroma group|"two massages delivered within a two day period~the patient will choose the essential oils used from blend A and blend B (if no choice is made, therapist will choose blend A and B alternately). One drop of the essential oil blend will be added to 5 mls of grapeseed base oil.~an Inhalation Patch with the same blend of oils as used in the massage will be left by the therapist for use on each of the two nights following the aromatherapy massage intervention. Its use will be explained to the patient and to the member of nursing staff. The Inhalation Patch will be applied to the patient's upper chest when it is time to sleep at approximately 11 pm and will be removed the following morning at approximately 6 am."
89165220|NCT02623686|No Intervention|Control Group|Normal Care
89165221|NCT03767881|Experimental|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
89165222|NCT04032392|Experimental|Autologous γδT cells|"Subjects will receive 3 cycles of γδT cells treatments, at four-week intervals, each cycle has 2 infusions.~Dose escalation subjects will receive 6 infusions with dose of γδT cells escalation from 1×10e9 to 6×10e9.~Constant dose subjects will have single infusion intravenously at a target dose of 1~2×10e9 γδT cells."
89165223|NCT00737542|Placebo Comparator|A|
89165224|NCT00737542|Experimental|B|
89165225|NCT00737620|Active Comparator|propaten graft|
89165226|NCT00737620|Active Comparator|Standard graft|
89165227|NCT04032002|Other|Patients hereditary bradykinetic angioedema|
89165228|NCT04032002|Other|healthy volunteers|
89165229|NCT03865381|Other|Virtual Diabetes Clinic|The Onduo Virtual Diabetes Clinic (VDC) is the suite of diabetes management services including remote monitoring, diet/lifestyle coaching, medication management accessed via Onduo App and partner apps. Subjects will engage with a Care Lead through the App and will have a medical consultation via telemedicine with an Onduo VDC Physician.
89165230|NCT00865098|Experimental|Cetuximab With Radiotherapy|
89165231|NCT00880100|Experimental|Ultrase® MT12|
89165232|NCT00729898||A|
89165233|NCT04130880||Children with cerebral palsy|Children with CP who aged between 18 months and 6 years will be evaluated.
89165234|NCT04130880||Children with typical development|Children with typical development who aged between 18 months and 6 years will be evaluated.
89165235|NCT00659516||1|intubated patients
89165236|NCT00659516||2|non intubated patients
89165237|NCT05741242|Experimental|Personalized Synthetic Long Peptide Vaccine|
89165238|NCT00697398|Placebo Comparator|1|Sound placebo
89165239|NCT00697398|Experimental|2|Sound
89165240|NCT00659594|Active Comparator|1|Ciclesonide 200µg
89165241|NCT00659594|Placebo Comparator|2|Placebo
89165242|NCT04133610|Experimental|Self-sampling device in media|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using self-sampling device in STM media. HPV will be detected by hybridization technique.
89165243|NCT04133610|Experimental|Dry self-sampling device|Women will undergo clinician-obtained cervical swab and self-sampled cervicovaginal swab using dry self-sampling device. HPV will be detected by hybridization and PCR techniques.
89165244|NCT04133766|Experimental|Community-Based Nutrition Package|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
89165245|NCT04133766|No Intervention|Standard of care|Current standard of existing community health services.
89165246|NCT02623608|Experimental|High fat meal|Subjects eat a high fat breakfast (reference breakfast) at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h.
89165247|NCT02623608|Experimental|High fat meal + Active Ingredient 1|"Subjects eat the same high fat breakfast with the active ingredient 1 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
89165248|NCT02623608|Experimental|High fat meal + Active Ingredient 2|"Subjects eat the same high fat breakfast with the active ingredient 2 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
89165249|NCT02623608|Experimental|High fat meal + Active Ingredient 3|"Subjects eat the same high fat breakfast with the active ingredient 3 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
89165250|NCT02623608|Experimental|High fat meal + Active Ingredient 4|"Subjects eat the same high fat breakfast with the active ingredient 4 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
89165251|NCT00659750|Active Comparator|1|Ciclesonide 200µg
89165252|NCT00659750|Placebo Comparator|2|Placebo
89165253|NCT00697476|Experimental|Vorinostat/Topotecan|"Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.~Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2"
89165254|NCT00659906|Experimental|1|Progressive resistance training program 3 times a week for 12 months
89165255|NCT00659906|Active Comparator|2|Flexibility training 3 times a week for 12 months
89165256|NCT00696150|Placebo Comparator|loss of resistance|Anterior psoas compartment nerve block inserted using loss of resistance
89165257|NCT00696150|Active Comparator|nerve stimulator|Anterior psoas compartment nerve block inserted using nerve stimulator
89165258|NCT00696150|Active Comparator|ultrasound|Anterior psoas compartment nerve block inserted using ultrasound
89165259|NCT00660062|Experimental|Escitalopram 10 mg daily|Escitalopram 10 mg daily
89165260|NCT00660062|Experimental|Escitalopram 20 mg daily|Escitalopram 20 mg daily
89165261|NCT00660062|Experimental|escitalopram 30 mg daily|escitalopram 30 mg daily
89165262|NCT00660062|Active Comparator|Nortriptylin 100 mg daily|Nortriptylin 100 mg daily
89165263|NCT02617134|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
89165264|NCT02634164|No Intervention|control|"Control Treatment with Oral Glucose Tolerance Test:~Blood glucose and insulin will be obtained following the protocol of Eicher et al (4). Participants will ingest a Placebo (inert, calorie free, stevia sweetener) with blood collections at 0,2,4,6,8,10,30 prior to a standard 75 g glucose solution, followed by blood collections at 0,2,4,6,8,10,30,60,90,120 minutes post glucose ingestion. A total of 16 blood collections will be taken."
89165265|NCT02634164|Experimental|Leucine Supplement|Control Treatment with Oral Glucose Tolerance Test:
89165266|NCT02634164|Experimental|Isoleucine Supplement|Isoleucine Combined with Oral Glucose Tolerance Test:
89165267|NCT02634164|Experimental|Leucine and Isoleucine Supplement|Leucine and Isoleucine Combined with Oral Glucose Tolerance Test:
89165268|NCT04063540|Other|placebo-amiloride|Patients will be treated for 12 weeks with placebo and then after a 4 week wash-out period, will be treated for 12 weeks with amiloride.
89165269|NCT04063540|Other|amiloride -placebo|Patients will be treated for 12 weeks with amiloride and then after a 4 week wash-out period, will be treated for 12 weeks with placebo.
89165270|NCT02623374|Experimental|SH-CBT|This intervention will be a tailored CBT intervention adapted from the previously validated (Ayres, et al., 2012) self-help CBT intervention that comprises of a self-help booklet containing information, advice, a relaxation CD and daily diaries. This intervention lasts 4 weeks (approx. 4 hours per week) and the materials guide the individual through each chapter and exercise, including the homework set out for each chapter.
89165271|NCT02623374|No Intervention|No Treatment-Wait Control (NTWC)|Women will be offered no intervention but will complete questionnaires at the same assessment points as the intervention/treatment arm participant group (i.e. baseline (A0), 6 weeks (A1), 20 weeks (A2) post randomisation). They will be offered the SHCBT intervention off trial following the final assessment (i.e. A2).
89165272|NCT04161560|Experimental|use of the cetuximab-IRDye800|four groups : control group, 1% dose group (1% of therapeutic dose; 2.5 Mg/m2) and 10% dose groups (10%of therapeutic dose ;25mg/m2) and 25% dose group (25%of therapeutic dose; 62.5mg/m2)
89165273|NCT02617212|Experimental|Definitive abutment|Implant surgery. No abutment dis-/reconnections.
89165274|NCT02617212|Active Comparator|Conventional treatment|Implant surgery. Three abutment dis-/reconnections.
89165275|NCT00518011|Experimental|Erlotinib + Gemcitabine|Participants received Erlotinib 150 mg/day orally as a continuous schedule with Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
89165276|NCT00518011|Active Comparator|Gemcitabine|Participants received Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
89165277|NCT00737776||A|
89165278|NCT02633930|Experimental|berberine quadruple therapy|Berberine 300 mg, three times daily for 14 days,lansoprazole 30 mg,amoxicillin 1000 mg, and Bismuth 220 mg by mouth, twice daily for 14 days.
89165279|NCT02633930|Active Comparator|clarithromycin quadruple therapy|Bismuth 220 mg, lansoprazole30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
89165280|NCT00698334|Experimental|HIV infected|HIV infected patients with active TB
89165281|NCT00698334|Active Comparator|HIV negative|HIV negative patients with active TB
89165282|NCT02568826|Experimental|IDN 5243|IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities for intramuscular administration in 4 mg/mL vials. It will be administered twice daily for 5 consecutive days with the first administration in the morning (8.00-10.00 AM) and the second in the evening (6.00-8.00 PM).
89165283|NCT04161482|Experimental|Cohort One|A bi-phasic delivery over 5 hours
89165284|NCT04161482|Experimental|Cohort 2a|Continuous infusion over 2 hours
89165285|NCT04161482|Experimental|Cohort 2b|Bi-phasic delivery over 2 hours
89165286|NCT04161482|Experimental|Cohort 3|Continuous infusion over 1 hour.
89165287|NCT04161482|Experimental|Cohort 4|Continuous infusion over 30 minutes.
89165288|NCT02623530|Active Comparator|Control group|Control group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), not based on the Active Learning Model for Critical Thinking (MEAPC).
89165289|NCT02623530|Experimental|Experimental group|Experimental group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), based on the Active Learning Model for Critical Thinking (MEAPC).
89165290|NCT02568904||Alcohol binge|Healthy volunteers receive 2ml vodka 40% per kg bodyweight as a binge
89165291|NCT02568904||Fructose|75 g Fructose orally
89165292|NCT02568904||Glucose|75 g Glucose orally
89165293|NCT02568904||Vehicle|2ml tap water per kg body weight
89165294|NCT02623452|Experimental|Part A:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin once in each of 3 periods
89165295|NCT02623452|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin once in each of 3 periods
89165296|NCT02623452|Experimental|Part B:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin with each meal for 14 days
89165297|NCT02623452|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin with each meal for 14 days
89165298|NCT02633696|Active Comparator|Legalón Sil i.v 350 mg|8 healthy volunteers received 1 vial of 350 mg iv of sylibin lyophilisate for solution for infusion (legalon sil) in two hours (single dose).
89165299|NCT02633696|Experimental|Silybin-phosphatidylcholine oral 360 mg|8 healthy volunteers received 9 capsules of 40 mg of sylibin each one (360 mg in total) orally.
89165300|NCT00737854|Experimental|1 ARM|Otherwise healthy patients with oral lichen planus (precancerous/erosive OLP)
89165301|NCT04130724||Ketogenic diet|Subjects consuming either a ketogenic (<30g carbohydrate per day) or a low-carb (<100g carbohydrate per day) diet.
89165302|NCT04130724||High-carbohydrate diet|Subjects consuming a high carbohydrate (>100g carbohydrate per day) diet.
89165303|NCT04161170|No Intervention|Control A|no intervention conventional diabetes treatment and clinic visit every 3 months
89165304|NCT04161170|Active Comparator|Intervention B|apply digital integrated healthcare platform clinic visit every 3 months
89165305|NCT04161170|Experimental|Intervention C|apply digital integrated healthcare platform, CGMS, and medical team monitoring, and education clinic visit every 3 months
89165306|NCT02633852|Experimental|Aflibercept (EYLEA) 2mg /0.05 ml|Aflibercept (EYLEA) 2mg /0.05 ml
89165307|NCT00737932|Experimental|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day (sequential cohorts)
89165308|NCT00737932|Placebo Comparator|Placebo|Matching placebo
89165309|NCT02633774|Active Comparator|Rhythm control group|1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation 2. check the echo, brain perfusion CT and K-MOCA on baseline 3. confirm a thrombus through the TEE 4. Cardioversion after 1 month 5. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines) 6. If AF recur, RFCA 7. check the brain perfusion CT, K-MOCA after 3M and 12M
89165310|NCT02633774|Active Comparator|Rate control group|1. No AAD, just anticoagulation 2. HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin) 3. check the echo, brain perfusion CT and K-MOCA on baseline 4. check the brain perfusion CT and K-MOCA after 3M and 12M 5. Without the treatment about antiarrythmia and rhythm control, diffication of rate control, the subject will be drop out for study.
89165311|NCT05741008|Experimental|Reduced target radiotherapy|"According to our institutional guidelines, GTVnx included the primary tumor volume and the enlarged retropharyngeal nodes, while GTVnd was the volume of involved gross cervical lymph nodes.~The clinical tumor volume (CTV) includes the primary tumor with potential subclinical disease. The high-risk clinical target volume (CTV1) was defined as the GTVnx plus a 5-mm margin to encompass the high-risk sites of microscopic extension, the whole nasopharynx, retropharyngeal nodal regions and . The low-risk clinical target volume (CTV2) was defined as the whole neck area.(Ib, VIIb, and the commom carotid artery are not included)."
89165312|NCT02633618|Experimental|Analgecine|3ml, 2 times per day, continuous infusion for two weeks.
89165313|NCT02633618|Active Comparator|Neurotropin|3ml, 2 times per day, continuous infusion for two weeks.
89165314|NCT00865020|Experimental|Aliskiren 300 mg|Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
89165315|NCT00865020|Active Comparator|Telmisartan 80 mg|Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.
89165316|NCT00517933|Active Comparator|Sildenafil|20 mg of sildenafil 3 times a day (TID) for 12 weeks followed by 20 mg of sildenafil TID for an additional 12 weeks
89165317|NCT00517933|Placebo Comparator|Placebo / Sildanafil|20 mg of placebo TID for 12 weeks followed by 20 mg of sildenafil citrate TID for an additional 12 weeks
89165318|NCT02633384|Experimental|SMOFlipid|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a new generation intravenous lipid emulsion
89165319|NCT02633384|Other|Lipofundin|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a current intravenous lipid emulsion
89165320|NCT04031196|Active Comparator|QLB group, Quadratus Lumborum Block group|the patient placed in the lateral decubitus position, the low-frequency convex probe of Sonosite M Turbo ultrasonography was placed in the anterior axillary line midway between subcostal margin and iliac crest to identify the abdominal muscle layers, then the probe was moved to the posterior axillary line to visualize the quadratus lumborum muscle attached to the transverse process of the L4, With the psoas major muscle placed anteriorly, the erector spinae muscle posteriorly, a 22-gauge, 80 mm needle was inserted in-plane into the posterior aspect of QL muscle (between quadratus lumborum and erector spinae muscle), and then 0.5ml/kg of 0.25% levobupivacaine local anesthetic was injected behind the muscle as a bolus dose. The block was performed bilaterally.
89165321|NCT04031196|Active Comparator|TAP block group,Transversus Abdominis Plane Block group|patient placed in the supine position, a linear multifrequency 6-13 MHz probe of Sonosite M Turbo ultrasonography was placed posterior to the midaxillary line at the midpoint between the inferior costal margin and the iliac crest, a 22-gauge, 50 mm needle was placed using an in-plane technique between the internal oblique and transversus abdominis muscle then local anesthetic was injected in a bolus dose 0.5ml/kg of 0.25% levobupivacaine, the block was done bilaterally.. after ultrasound Identification of the plane between the internal oblique and transversus abdominis muscle,
89165322|NCT02633462|Active Comparator|Test Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis and treated with scaling and root planing(SRP) along with Myo-inositol supplementation
89165323|NCT02633462|Active Comparator|Control Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis treated with Myo-inositol along with oral hygiene instructions.
89165324|NCT00701038|Experimental|Device|Provided with an auto adjusting bi-level positive airway pressure device
89165325|NCT00701038|No Intervention|Control|No device
89165326|NCT02638064|Experimental|Surgiflo injection|Injection of surgiflo in the pilonidal sinus cavity after curettage of its content
89165327|NCT05740852||Infection|Patients who developed pulmonary infection after radical resection of tumor
89165328|NCT05740852||Without infection|Patients without pulmonary infection after radical resection of tumor
89165329|NCT00655148|Experimental|A|DTaP-IPV vero vaccination at 2, 3½, 5 and 16 months of age
89165330|NCT00655148|Active Comparator|B|DTaP-IPV mkc vaccination at 2, 3½, 5 and 16 months of age
89165331|NCT03899272||Osteoarthritis|All new patient present to clinic referred for osteoarthritis for considering joint replacement Present with knee pain (unilateral or bilateral) contributed by osteoarthritis
89165332|NCT02631902|Experimental|Exercise|Community-based exercise program
89165333|NCT02631902|Experimental|Exercise plus dietary intervention|Community-based exercise and dietary intervention program
89165334|NCT02631902|No Intervention|Control|Habitual physical activity and habitual dietary pattern
89165335|NCT05740774|Experimental|Tongue tumor resection|
89165336|NCT00857766|Active Comparator|ADVAIR DISKUS|Subjects receive blinded Fluticasone Propionate/Salmeterol. At 4 months subjects will receive open label SPIRIVA HANDIHALER
89165337|NCT00857766|Placebo Comparator|Placebo|Subjects will receive placebo ADVAIR DISKUS. At 4 months subjects will receive open label SPIRIVA HANDIHALER
89165338|NCT04161404|Experimental|Period 1|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
89165339|NCT04161404|Experimental|Period 2|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
89165340|NCT04161404|Experimental|Period 3|Subjects will randomized to either of the intervention drug in a ratio of 1:1:1 following three period, cross-over study design.
89165341|NCT00517699|Experimental|1|
89165342|NCT04161092|Other|Liver transplantation + best alternative care|"Patients subjected to Ltx will during the waiting time receive individualized chemotherapy, with the aim to avoid side effect that make them not transplantable.~If possible, patients randomized to Ltx should be treated within 12 weeks after randomization.~If the patients progress systemically they will be treated with best alternative care.~If they progress only within the liver they continue to be transplantable until they are deemed technically not transplantable by the transplant surgeon."
89165343|NCT04161092|Other|Best alternative care|The treating physician will together with the patient decide the treatment.
89235044|NCT05234099|Experimental|Control subjects|"Visit 1 (V1) (Duration: 2.5h)~Information, verification of inclusion and exclusion criteria, information note.~Consent form.~Location of the diaphragm and parasternal intercostal muscle using ultrasound.~Measurements at rest (mouth pressures, sEMG, ultrasound imaging).~Injection of 3 MBq/kg of 18F-FDG.~1h resting period.~18F-FDG PET-MRI scan.~Visit 2 (V2) 3-10 days after V1 (Duration: 3h)~Location of the diaphragm and parasternal intercostal muscle.~Measurements at rest (mouth pressures, sEMG, ultrasound imaging)~Magnetic stimulation of the phrenic nerves~Ventilation against inspiratory loading~Magnetic stimulation of the phrenic nerves~Injection of 3 MBq/kg of 18F-FDG~1h resting period~18F-FDG PET-MRI scan~Visit 3 (V3) 3-10 days after V2 (Duration: 3h)~- Identical to visit 2"
89165344|NCT02613468|Placebo Comparator|Periodontally healthy|"Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.~Intervation: Collection of periodontal records and pregnancy parameters."
89235045|NCT05192863||Participants with CD|Participants diagnosed with moderately to severely active CD who are initiating vedolizumab intravenous (IV) induction treatment with the option to switch to vedolizumab subcutaneous (SC) treatment, as maintenance therapy in accordance with the current SmPC will be observed prospectively for 18 months.
89165345|NCT02613468|Placebo Comparator|Periodontally diseased, untreated|"This group is comprised of individuals who do not accept treatment Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.~Birth weight was recorded at the end of pregnancy."
89165346|NCT02613468|Active Comparator|Periodontally diseased, treated|"This group is comprised of individuals who agree to treatment. Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.~Initial Periodontal Therapy is completed (calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.~Birth weight was recorded at the end of pregnancy. Intervation: Collection of periodontal records and pregnancy parameters."
89165347|NCT04161014|Other|Treatment Arm|Nintedanib 150mg twice daily for 3 years
89165348|NCT00699504|Experimental|Lead in Phase|Supratherapeutic dose of cangrelor
89165349|NCT00699504|Experimental|A|therapeutic dose cangrelor treatment
89165350|NCT00699504|Experimental|B|supratherapeutic dose cangrelor treatment
89165351|NCT00699504|Active Comparator|C|active comparator treatment
89165352|NCT00699504|Placebo Comparator|D|placebo treatment
89165353|NCT02997605|Active Comparator|Glucocorticoid (GC) tapering|"GC tapering group: patients will be asked to taper prednisone taken every morning at 8.00 AM by decreasing the daily dose by 1 mg every month as soon as they are in remission or Low Disease Activity (LDA). In addition they will receive a placebo of 20 mg/day of hydrocortisone (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg/day (at 8.00 AM) of hydrocortisone placebo for 3 months before discontinuing the hydrocortisone placebo."
89165354|NCT02997605|Active Comparator|Hydrocortisone replacer|"Hydrocortisone replacer group: patients will replace prednisone with 20 mg of hydrocortisone on a daily basis (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg daily (at 8.00 AM) for 3 months then stop as soon as they are in remission or LDA, as well as a prednisone placebo (at 8.00 AM) with a schedule to taper the prednisone placebo by 1mg/day every month until discontinuation."
89165355|NCT04156724|Experimental|HV|6MWT with helmet ventilation
89165356|NCT04156724|No Intervention|Control|6MWT alone according to ATS guideline
89165357|NCT04491487|Experimental|Experimental group|
89165358|NCT04491487|No Intervention|Control group|
89165359|NCT00657098||Observation|
89165360|NCT03767543|Experimental|iGlarlixi DAILY|Titration Group 1: Addition of 1 unit per day until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
89165361|NCT03767543|Active Comparator|iGlarlixi WEEKLY|Titration Group 2: Algorithm of weekly adjustment until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
89165362|NCT00857454|Experimental|Testosterone MD-lotion|"In this open-label extension of the MTE08 trial, participants received Testosterone Metered Dose (MD)-Lotion for 60 days (dosing from Day 121 of the MTE08 trial to Day 180 of the MTE09 trial). Participants in MTE08 initially received 3.0 milliliters (mL) (60 micrograms [mg]) of 2% Testosterone MD-Lotion, and may have had their dose of testosterone adjusted upwards or downwards.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg)of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg)of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 2 x 1.5 mL to the other axilla).~6.0 (120 mg)of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
89165363|NCT00660140|Experimental|Gemcitabine + Carboplatin|"Gemcitabine 1000 mg/m2 IV for 30 minutes on days 1 and 8 of 21 day cycle. Maximum of 9 cycles.~Carboplatin AUC 5 IV for 1 hour on day 1 of 21 day cycle. Maximum of 9 cycles."
89165364|NCT03765437|Experimental|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine (split-virion, inactivated) Northern hemisphere seasonal formulation 2018-2019
89165365|NCT04156958|Other|Fruquintinib Arm|Fruquintinib, 5 mg once daily for 21 days, followed by 7 days off (28 days/cycle) treatment until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
89165366|NCT00696228|Placebo Comparator|AFN A|High Fat Diet Placebo
89165367|NCT00696228|Experimental|AFN B|MUFA
89165368|NCT00696228|Experimental|AFN C|PUFA
89165369|NCT00696228|Experimental|AFN D|SFA
89165370|NCT03760991|Experimental|Insulin glargine (U300)|Insulin glargine (U300) (Gla-300) once daily for 26 weeks on top of any other antidiabetic treatment except other basal insulin
89165371|NCT02623296|Experimental|GLPG1205 and single CYP450 substrate cocktail dose|Daily GLPG1205 administration from Day 1 to Day 12 Single GLPG1205 co-administration on Day 13 with CYP450 substrate cocktail
89165372|NCT02623296|Placebo Comparator|Placebo and single CYP450 substrate cocktail dose|Daily Placebo administration from Day 1 to Day 12 Single Placebo co-administration on Day 13 with CYP450 substrate cocktail
89165373|NCT00525031|Experimental|Temozolomide (TMZ)|Temozolomide = TMZ - 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
89165374|NCT00525031|Experimental|Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)|"Temozolomide = TMZ and PGI = Pegylated Interferon-alpha 2b~Temozolomide 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks. Pegylated Interferon-alpha 2b 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks."
89165375|NCT02692469|Active Comparator|Duodenal Switch Surgical Intervention|a DS procedure involves creating a sleeve gastrectomy with preservation of the pylorus, and creation of a Roux limb with a short common channel
88804630|NCT02969525|Experimental|Bimekizumab dosage regimen 2|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.
89165376|NCT02692469|Experimental|Single Anastomosis Duodenal-Ileal Bypass|The SADI defers from the DS in that after the duodenum is separated from the stomach, preserving the pylorus, a loop of bowel 200 cm from the ileo-cecal valve is anastomosed with the pylorus, thus requiring only one anastomosis
89165377|NCT02631824|Active Comparator|Standard treatment|open reduction and internal fixation TFNA
89165378|NCT02631824|Experimental|Augmentation|open reduction and internal fixation TFNA Augmentation (Cement)
89165379|NCT02692157|Placebo Comparator|Placebo|Placebo Comparator: Placebo - During this arm, Placebo medication will be administered orally each evening at 8pm.
89165380|NCT02692157|Active Comparator|NT-814 50 mg|Active Comparator: NT-814 50 mg - During this arm, 50 mg NT-814 will be administered orally each evening at 8pm.
89165381|NCT02692157|Active Comparator|NT-814 100 mg|Active Comparator: NT-814 100 mg - During this arm, 100 mg NT-814 will be administered orally each evening at 8pm.
89165382|NCT02692157|Active Comparator|NT-814 200 mg|Active Comparator: NT-814 200 mg - During this arm, 200 mg NT-814 will be administered orally each evening at 8pm.
89165383|NCT04118634||Group with PE|"The criteria for confirmation of PE are:~PE on spiral computed tomography (CT) proximal deep vein thrombosis on ultrasound (US) thromboembolic events objectively confirmed during the follow up"
89165384|NCT04118634||Group without PE|"The criteria for exclusion of PE are:~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up low and moderate clinical probability and negative CT and negative follow up high clinical probability and negative CT, US and follow up."
89165385|NCT01973725|Experimental|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
89165386|NCT00660296|Other|2|Air insufflation in colonoscopy
89165387|NCT00660296|Other|1|CO2 insufflation in colonoscopy
89165388|NCT00660374|Active Comparator|A|
89165389|NCT00660374|Experimental|B|
89165390|NCT00524485|Experimental|Arm 1 - ALA|Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
89165391|NCT00524485|Experimental|Arm 2|Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
89165392|NCT00524485|Experimental|Arm 3|Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment
89165393|NCT00524485|Experimental|Arm 4|Vbeam laser pulse (photodynamic therapy) is applied to the subunit
89165394|NCT00524485|Experimental|Arm 5|Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart
89165395|NCT02704949|Experimental|Low-dose|The intervention is to use 1/4 fluoroscopy dose while the ureteroscopy is being performed
89165396|NCT02704949|Active Comparator|Full-dose|The intervention is to use full fluoroscopy dose while the ureteroscopy is being performed
88804631|NCT02969525|Experimental|Bimekizumab dosage regimen 3|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.
88804632|NCT02969525|Experimental|Bimekizumab dosage regimen 4|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.
89165397|NCT00660452|Active Comparator|1|360 active patients with house dust mites related asthma with or without allergic rhinitis
89165398|NCT00660452|Placebo Comparator|2|180 patients in the placebo group with house -dust mites related asthma with or without allergic rhinitis.
89165399|NCT00857220|Experimental|2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)|
89165400|NCT02704793|Experimental|Bilateral 1 Hz Cerebellar rTMS|Patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days.
89165401|NCT02704793|Sham Comparator|Sham (electrical stimulation)|Sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS.
89165402|NCT00524173|Active Comparator|Tenofovir only|Tenofovir 300mg by mouth daily for 192 weeks
89165403|NCT00524173|Experimental|Tenofovir & emtricitabine|Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
89165404|NCT04157816|Experimental|Digital Training (DGT)|Participants allocated to this arm receive a low-intensity digital program accessible by smart phone app for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
89165405|NCT04157816|Experimental|Digital Training with Coaching Support (DGT+)|Participants allocated to this arm receive a high-intensity digital program accessible by smart phone app augmented with weekly telephone coaching support for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
89165406|NCT04157816|Active Comparator|Face-to-Face Training|Participants allocated to this arm receive a traditional classroom-based (face-to-face) program hosted in community settings for training non-specialist health workers to deliver an evidence-based brief psychological treatment for depression, called the Healthy Activity Program (HAP), in primary care settings in India.
89165407|NCT02704559|Experimental|Study effect of DWC20156 on DWC20155 PK|To study effect of DWC20156 on DWC20155 PK
89165408|NCT02704559|Experimental|Study effect of DWC20155 on DWC20156 PK|To study effect of DWC20155 on DWC20156 PK
89165409|NCT02704481|Experimental|Mifepristone-misoprostol|Women randomized to receive 200 mg mifepristone to take on Day 1, 800 mcg buccal misoprostol to take 24-48 hours after later, and four placebo misoprostol pills to take a further 3-12 hours later.
89165410|NCT02704481|Experimental|Misoprostol-misoprostol|Women randomized to receive a placebo mifepristone pill to take on Day 1 and two doses of 800 mcg buccal misoprostol, the first of which should be taken 24-48 hours after the placebo and the second of which should be taken 3-12 hours after the first misoprostol dose.
89165411|NCT04158206|Experimental|Maternal voice|The mother's voice recordings are compiled for 13 minutes. When the premature infants undergoing heel lance procedure, the experimental group were explored maternal voice, which start from 3 minutes before the procedure, once a day and for three consecutive days.And then recorded the process by the camera, uploaded to YouTube within 24 hours and sent to their mother.
89165412|NCT04158206|No Intervention|control group|When the premature infants undergoing heel lance procedure, the control group were under routine care.And then recorded the process by the camera for three consecutive days, uploaded to YouTube within 24 hours and sent to their mother.
89165413|NCT04130412|Active Comparator|Open release of lateral retinaculae|This group was treated by open release of lateral retinaculae after diagnosis of lateral compression syndrome by arthroscopy
89165414|NCT04130412|Active Comparator|Arthroscopic release of lateral retinaculae|This group was treated by arthroscopic release
89165415|NCT02704325|Experimental|GALGT2 Viral Vector|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
89165416|NCT02704325|Experimental|Saline|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
89165417|NCT04160702|Experimental|Motivate-The-Bystander|Participants assigned to the MTB condition arm.
89165418|NCT04160702|No Intervention|Assessment only control condition|Participants assigned to the assessment only condition arm.
89165419|NCT04130256|Experimental|Active Reminders|43 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will provide daily medication reminders for participants to take their pill.
89165420|NCT04130256|Experimental|Passive Adherence Monitoring|42 patients, each assigned to use the electronic pill bottle for 90 days. Participants will use the bottle to house their multiple sclerosis medication. The electronic pill bottle will not provide medication reminders and will only track medication use.
89165421|NCT02704247|Experimental|Testing CARDIOSPACE System|Healthy volunteers have to test CARDIOSPACE System
89165422|NCT04156568|Experimental|6INH Group|10mg/kg 6INH were used in this group.
89165423|NCT04156568|Experimental|3INH+RFT group|3INH+RFTwere used in this grroup.
89165424|NCT04478071|Experimental|vadadustat|
89165425|NCT04478071|Placebo Comparator|placebo|
89165426|NCT04215575|Active Comparator|BGI model 101-350 placement (BGI group)|A 350 mm2 Baerveldt glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP >16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits.The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures.
89165427|NCT04215575|Experimental|AGV model FP7 or S2 placement (AGV group)|A 184 mm2 Ahmed glaucoma implant was placed. Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP >16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits. The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures
89165428|NCT02614482|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 1 month and 4 months.
89165429|NCT04130334|Active Comparator|horizontal meridian of donor's cornea sutured to horizontal|horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
89165430|NCT04130334|Active Comparator|horizontal meridian of donor's cornea sutured to vertical|horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
89165431|NCT04713709|Experimental|FMXIN001 4 mg Naloxone microspheres powder,|Naloxone powder nasal spray from Nasus Pharma, Israel
89165432|NCT04713709|Active Comparator|Narcan® 4 mg/0.1 mL nasal spray|Naloxone solution nasal spray from Adapt Pharma, Inc., USA
89235046|NCT05188521|Experimental|Cutaneous LP|Subjects with a diagnosis of cutaneous LP will receive Baricitinib (LY3009104) for a 16 weeks treatment period
89165433|NCT00879710|Other|Subjects with type 1 diabetes mellitus, option 1|"Half the subjects will start with arm (i.e. every other subject in order)~Simvastatin 40 mg tablet by month daily for 6 weeks,~4 weeks washout period~Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks~4 weeks washout period~Simvastatin 40 mg tablet by month daily for 6 weeks"
89165434|NCT00879710|Other|Subjects with type 2 diabetes mellitus option 1|"Half the subjects will start with arm (i.e. every other subject in order)~Simvastatin 40 mg tablet by month daily for 6 weeks,~4 weeks washout period~Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks~4 weeks washout period~Simvastatin 40 mg tablet by month daily for 6 weeks"
89165435|NCT00879710|Other|Subjects with type 1 diabetes mellitus, option 2|"Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks,~4 weeks washout period"
89165436|NCT00879710|Other|Subjects with type 2 diabetes mellitus option 2|"Half the subjects will start with arm (i.e. every other subject in order) Ezetimibe 10 mg by month for 6 weeks,~•4 weeks washout period"
89165437|NCT04130178|Active Comparator|Bupivacine injected|Half ml of Bupivicaine hydrochloride .5% (Marcaine, Pfizer) was injected through a 27G needle at the level of the volar proximal digital crease of the 2nd and 3rd PIP on each side of the selected joint.
89165438|NCT04130178|Placebo Comparator|Control group|Saline was injected subcutaneously in the 2nd and 3rd PIP on each side of the selected joint.
89165439|NCT02703935|Experimental|health talk and adventure-based training|Participate will join a four-day adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 12 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
89235047|NCT05188521|Experimental|Dose Escalation Extension Group|Subject that demonstrate a response to the 16 weeks of treatment with 2 mg of Baricitinib (LY3009104), but have not achieved a PGA 0 will receive 4 mg of Baricitinib (LY3009104) for 16 weeks
89235048|NCT05179577|Active Comparator|Arbaclofen Extended-Release|Extended-release oral tablet, twice daily dosing (80 mg/day)
89235049|NCT05179577|Placebo Comparator|Placebo|Extended-release oral tablet, twice daily dosing
89165440|NCT02703935|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
89165441|NCT01565161|Experimental|Home-Based Health Coaching|Intervention delivered in the home.
89165442|NCT01565161|Active Comparator|Control Arm|Mailed educational materials
89165443|NCT02623062|Active Comparator|Compound Sodium Alginate Oral Suspension sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
89165444|NCT02623062|Placebo Comparator|Matching placebo sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
89165445|NCT04135638|Other|Cover Group (CG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.~In the Cover Group the ILM flap will be folded as a single layer to bridge tissue dehiscence during air-fluid exchange. All eyes will recive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
89165446|NCT04135638|Other|Fill Group (FG)|"All patients will undergo a 25G standard 3-port PPV with posterior vitreous detachment induction (if not already present), ILM staining with 0,25 g/l of brilliant blue-G and creation of a 360°ILM flap around the MH rim.~Phakic patients will undergo combined phacoemulsification with IOL implant in-the-bag.~In the Fill Group, multiple layers of ILM will be deliberately folded within the loss of tissue before air-fluid exchange. All eyes will receive a mixture of 20% sulfur hexafluoride tamponade and will be instructed to position face down for 4 hours a day during the first 3 days post-operative"
89165447|NCT00597506|Experimental|Bevacizumab and Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28 10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
89165448|NCT03393611|Experimental|CPX-351 Salvage Therapy and Transplant|Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.
89165449|NCT00698412|Experimental|1|Cane group
89165450|NCT00698412|No Intervention|2|Control Group
89165451|NCT04157582|Experimental|Study group|will consist of 20 hemiparetic patients and will receive Pilates training in addition to conventional physical therapy program consists of (manual stretching exercises, Strengthening Exercises and Wobble board training ) for 18 sessions every other day for one and half month , 3 sessions /week ,each session for 1.30 hours (40 minutes for pilates then 10 minutes rest then 40 minutes conventional physical therapy).
89165452|NCT04157582|Experimental|Control group|will consist of 20 hemiparetic patients and will receive conventional physical therapy program only same as group I for 18 sessions every other day for one and half month, 3 sessions /week, each session for (40 minutes ).
89165453|NCT03689023|Experimental|A controlled multimodal intervention|A uniform and systematic patient education about cardiovascular risk factors, physical activity and a healthy diet lifestyle starting early in the primary rehabilitation process with 6 months of follow up.
89165454|NCT02622984|Experimental|RBIRT|Telehealth model or the remote administration of SBIRT, a short term, brief intervention and referral to treatment for alcohol abuse.
89165455|NCT02622984|Active Comparator|SBIRT|Face-to-face intervention and referral to treatment for alcohol abuse.
89165456|NCT04032548|Placebo Comparator|Placebo|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
89165457|NCT04032548|Experimental|Propolis|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
89165458|NCT04032548|Active Comparator|Chlorhexidine|Subjects were asked to rinse 10 ml of mouthwash twice daily for 21 days.
88804633|NCT02889081||infants from birth cohort with AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of suffering from atopic dermatitis
89165459|NCT02373683|Experimental|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
89165460|NCT02373683|No Intervention|Standard Care|Care dictated by clinical team.
89165461|NCT04032236|Other|smoking group|35 smoking case
89165462|NCT04032236|Other|nonsmoking group|35 nonsmoking case
89165463|NCT02313389|Experimental|maintenance chemotherapy|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
89165464|NCT02313389|No Intervention|observation|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
89165465|NCT00708682|Experimental|A|
89165466|NCT00661310|Experimental|I|Intervention by team consisting of Doctor, pharmacist and nurse
89165467|NCT00661310|No Intervention|C|
89165468|NCT02632292|Experimental|Absorb GT1|Bioresorbable everolimus-eluting scaffolds
89165469|NCT02632292|Active Comparator|Promus|Everolimus-eluting stents
89165470|NCT02632916|Active Comparator|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg
89165471|NCT02632916|Experimental|Denosumab|Subcutaneous denosumab 1.0mg/kg
89165472|NCT04156412|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
89165473|NCT00712348|Experimental|Taliglucerase alfa|Open label taliglucerase alfa treatment
89165474|NCT00881504|Experimental|"FOLFOX6 and Bevacizumab"|"Intervention = bevacizumab in combination with chemotherapy~Treatment of biliary system carcinoma using Bevacizumab in combination with modified FOLFOX6."
89165475|NCT04160624|Active Comparator|Non-ECLS GROUP|For AS/R patients with normal EF, only TAVR was performed
89165476|NCT04160624|Experimental|ECLS GROUP|For AS/R patients with low EF, TAVR under ECLS-assisted was performed
89165477|NCT00660686|Experimental|1|Progressive resistance training program 3 times a week for 12 months
89165478|NCT00660686|Active Comparator|2|Seated flexibility training 3 times a week for 12 months
89165479|NCT00660764||1|Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca
89165480|NCT02131493|Active Comparator|Gemcitabine|Gemcitabine：1000mg/m2，iv 30min，d1, d8,d15 q4w, 6 cycles
89165481|NCT02131493|Experimental|S-1+ Gemcitabine|S-1：40~60mg bid，d1~14; (S-1 dosage：BSA <1.25m2，40mg bid，1.25m2≤BSA≤1.5m2，50mg bid，BSA>1.5m2， 60mg bid) Gemcitabine：1000mg/m2，iv 30min，d1, d8 q3w, 8 cycles
89165482|NCT02096159|Experimental|Antibiotics|trimethoprim-sulfamethoxazole oral suspension, 4 mg/kg (0.5 mL/kg) twice daily for 10 days
89165483|NCT02096159|Placebo Comparator|Placebo|placebo oral suspension, 0.5 mL/kg twice daily for 10 days
89165484|NCT02632136|Active Comparator|TAP block group|"This group will receive 30 ml of 0.25% Bupivacine given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine.~They will also receive normal saline injections at port sites, which will be injected before the ports are inserted. 15 ml of normal saline will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports."
89165485|NCT02632136|Placebo Comparator|Peri-Portal block Group|"They will receive 0.5% Bupivacaine injections at port sites, which will be injected before the ports are inserted. 15 ml of 0.5% Bupivacaine will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports.~This group will also receive 30 ml of Normal Saline Injection given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine."
89165486|NCT00615095||1|Cases will be patients 18 years or older with a histologically confirmed, second or multiple primary melanoma.
89165487|NCT00615095||2|Controls will be patients 18 years or older with a histologically confirmed first primary melanoma diagnosed no earlier than 12 months prior to the study start date.
89165488|NCT00615095||3|Healthy controls will be subjects 18 years or older recruited from the general population through random digit dialing. These subjects will have no history of melanoma. They will also be frequency matched to cases on the basis of sex and 10-year age group.
89165489|NCT02631980|Experimental|IV iron|Postoperative iv iron administration (Ferinject) upon arrival in after surgery recovery room
89165490|NCT02631980|Placebo Comparator|IV placebo|Postoperative iv placebo administration upon arrival in after surgery recovery room
89165491|NCT04216199|Experimental|Point of care Ultrasound|Point of care Ultrasound for placement of endotracheal tube
89165492|NCT04216199|No Intervention|Traditional|Traditional method of insertion of endotracheal tube
89165493|NCT00660920|Experimental|ponatnib|Comparison of different dosages of ponatinib given orally once per day.
89165494|NCT04157660|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
89165495|NCT04157660|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
89165496|NCT01936831|Experimental|Group 1: 5mg Cohort|Group 1 participants had an M. tuberculosis strain with an inhA mutation only. 5 mg cohort received Isoniazid 5 mg/kg daily plus vitamin B6 >=25 mg daily for 7 days
89165497|NCT01936831|Experimental|Group 1: 10mg Cohort|Group 1 participants had an M. tuberculosis strain with an inhA mutation only. 10 mg cohort received Isoniazid 10 mg/kg daily plus vitamin B6 >=25 mg daily for 7 days
89165498|NCT01936831|Experimental|Group 1: 15mg Cohort|Group 1 participants had an M. tuberculosis strain with an inhA mutation only. 15 mg cohort received Isoniazid 15 mg/kg daily plus vitamin B6 >=25 mg daily for 7 days
89165499|NCT01936831|Active Comparator|Group 2: 5mg Cohort|Group 2 participants had an M. tuberculosis strain with neither inhA nor katG mutations. All Group 2 participants received Isoniazid 5 mg/kg daily plus vitamin B6 >=25 mg daily for 7 days
89165500|NCT01936831|Experimental|Group 3: 15mg Cohort|Group 3 participants had an M. tuberculosis strain with a katG mutation with or without an inhA mutation. 15mg cohort received Isoniazid 15 mg/kg daily plus vitamin B6 >=25 mg daily for 7 days
89165501|NCT01936831|Experimental|Group 3: 20mg Cohort|Group 3 participants had an M. tuberculosis strain with a katG mutation with or without an inhA mutation. 20mg cohort received Isoniazid 20 mg/kg daily plus vitamin B6 >=25 mg daily for 7 days
89165502|NCT04157504|Experimental|Experimental Group: Physical Function|Forty patients with burn injury will be evaluated in this study. Lower extremity function, functional capacity, functional mobility, quality of life an scar tissue will be evaluated.
89165503|NCT00615173|Experimental|1|tacrolimus(fk506) treatment in induction and maintenance phase
89165504|NCT00615173|Active Comparator|2|intravenous cyclophosphamide pulses treatment in induction phase; and Aza in the maintenance phase
89165505|NCT00660998|Experimental|Arm 1|
89165506|NCT00660998|Placebo Comparator|Arm 2|
89165507|NCT01467245|Experimental|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
89165508|NCT01467245|Experimental|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
88804634|NCT02889081||infants from birth cohort without AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of not suffering from atopic dermatitis
89165509|NCT00657254|Experimental|Arm 1|
89165510|NCT01455389|Experimental|DOTAP + Erlotinib|DOTAP:Chol-TUSC2 0.045 mg/kg by vein over 25-35 minutes on day 1 of each 21 day cycle; and Erlotinib 100 mg by mouth daily for each 21 day cycle.
89165511|NCT00911378|Active Comparator|Pressure support ventilation|Patients in this arm are weaned by gradual reduction of pressure support
89165512|NCT00911378|Active Comparator|Spontaneous breathing trials|Patients in this arm are weaned by T piece trials
89165513|NCT03863353|Experimental|Education Intervention|This group will receive the scenario-tailored STOMP educational feedback
89165514|NCT03863353|No Intervention|Control|This group will receive only standard of care information.
89165515|NCT00661076|Experimental|1|
89165516|NCT00661076|Experimental|2|
89165517|NCT00661076|Active Comparator|3|
89165518|NCT04215965|Experimental|Experimental Standard citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Biphozyl in the dialysate and postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
89165519|NCT04215965|Active Comparator|Conventionnal citrate protocol|CVVHDF will be performed using Regiocit solution in the predilution mode, Prismocal B22 (calcium and phosphate free) in the dialysate mode, and Phoxilium in the postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
89165520|NCT04692649|Experimental|PPCS|Novel intervention
89165521|NCT04692649|Active Comparator|CBS|Cross arm stretch gave to individuals
89165522|NCT02632214|Experimental|Deaf|Group of early profound deaf participants fMRI measure
89165523|NCT02632214|Experimental|Hearing signers|Group of hearing signer controls fMRI measure
89165524|NCT02632214|Sham Comparator|Hearing non signers|Group of hearing non signer controls fMRI measure
89165525|NCT03998371||Urothelial carcinoma group|Pre-surgery patients with urothelial carcinoma will be the experimental group to determine the sensitivity and specificity of UCAD analysis, the result will be compared with cytology and FISH.
89165526|NCT03998371||Non-cancer participants group|Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UCAD analysis.
89165527|NCT00661700|Placebo Comparator|Arm 2|
89165528|NCT00661700|Experimental|Arm 1|
89165529|NCT00613769|Active Comparator|ordinary per operative prophylaxis|cefuroxime(1500mg) i.v.+ metronidazole (1500mg)i.v.given at the time point of induction of anesthesia
89165530|NCT00613769|Experimental|Per oral alternative|Trimethoprim-sulfamethoxazole(160mg/800mg)p.o.+metronidazole (1200mg)p.o.given 06.00 am on the day of operation
89165531|NCT04157270||Patients with acute ischemic stroke|Patients with acute ischemic stroke secondary to intracranial large vessel occlusion (LVO)
89165532|NCT00523705|Experimental|escitalopram|Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
89165533|NCT00523705|Placebo Comparator|placebo|Placebo tablets matched to drug.
89165534|NCT04157114|Active Comparator|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
89165535|NCT04157114|Placebo Comparator|Placebo|Subjects will receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
89165536|NCT00193427|Experimental|Intervention|Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered
89165537|NCT00665678|Experimental|1|paroxetine
89165538|NCT00665678|Placebo Comparator|2|placebo
89165539|NCT00523549|Experimental|Standard treatment regimen|(Valsartan + Amlodipine to target SBP of < 140 mmHg)
89165540|NCT00523549|Experimental|Intensive treatment regimen|(Valsartan + Amlodipine to target SBP < 130 mm Hg)
89165541|NCT04160312|Experimental|Mitopure™ (Proprietary Urolithin A)|Fruit flavored food sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
89165542|NCT04160312|Experimental|Pomegranate Juice|100% Pomegranate juice equivalent to a glass of juice
89165543|NCT04215653|Experimental|Anaprazole Sodium + Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
89165544|NCT04215653|Active Comparator|Rabeprazole +Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
89165545|NCT04160780|Experimental|L-PRF as sole graft material|lateral sinus augmentation using L-PRF as sole graft material
89165546|NCT04160780|Experimental|xenograft as sole graft material|lateral sinus augmentation using xenograft as sole graft material
89165547|NCT04160780|Experimental|Xenograft mixed with L-PRF as graft material|lateral sinus augmentation using L-PRF mixed with xenograft as graft material
89165548|NCT02706119|Experimental|Glargine insulin|Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
89165549|NCT02706119|Active Comparator|Regular insulin|Regular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag
89165550|NCT02631668|Experimental|ferrous succinate and vitamin C|In this group, the patients received 100mg ferrous succinate and 200mg vitamin C three times per day for 3-4 months
89165551|NCT02631668|Active Comparator|ferrous succinate with normal dosage|In this group, the patients received 100mg ferrous succinate three times per day for 3-4 months
89165552|NCT02631668|Active Comparator|ferrous succinate with double dosage|In this group, the patients received 200mg ferrous succinate three times per day for 3-4 months
89165553|NCT00665756|Active Comparator|1|second trabeculectomy
89165554|NCT00665756|Active Comparator|2|Ahmed silicone drainage device implantation
89165555|NCT02705885|Experimental|Gingipain IgY|Participants consume lozenges containing IgY against gingipains of Porphyromonas gingivalis
89165556|NCT02705885|Placebo Comparator|Placebo IgY|Participants consume lozenges containing placebo IgY
89165557|NCT00661856|Active Comparator|1|Soy Protein group 25g of Soy protein with no Isoflavones
89165558|NCT00661856|Experimental|2|Soy Isoflavone group 25g of Soy Protein with 90mg of Isoflavones
89165559|NCT00661856|Placebo Comparator|3|25g of Milk protein
89165560|NCT04215731|Experimental|mFOLFOXIRI Plus Bevacizumab|Patients will receive neoadjuvant mFOLFOXIRI plus bevacizumab once every two weeks for 4 cycles and the same mFOLFOXIRI for 2 cycles. After completing all 6 cycles chemotherapy, the patient will have an MRI scan to examine the tumor. If MRI restaging is ycT4a/b, or MRF involved, the patient will receive concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks). If MRI restaging is ycT0-3 and MRF negative, then the patient will proceed directly to surgery.
89165561|NCT04215731|Active Comparator|Induction FOLFOX Followed by Concomitant Chemoradiotherapy|Patients will receive induction FOLFOX chemotherapy for 4 cycles and followed by concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks), then the patient will proceed to surgery.
89165562|NCT04383769||5,000 participants:|"2,500 are PLHIV receiving standard care in the hospital and 2,500 are PLHIV receiving care in DSD-ART model~Inclusion criteria:~Thai citizenship~Age ≥ 18~HIV positive~Received ART for at least 6 months at a participating hospital (Except for After hour ART clinic model that will allow participants who receive ART less than 6 months into service)~One of the following:~Accept DSD-ART, OR~Already receiving DSD-ART, OR~Decline DSD-ART and will continue standard ART service at the hospital."
89165563|NCT00665834|Placebo Comparator|1|Rosuvastatin 20 mg versus placebo 20 mg
89165564|NCT00665834|Active Comparator|2|rosuvastatin 20 mg versus atorvastatin 80 mg
89165565|NCT02704013|Other|Intervention|Patients with overactive bladder will receive anticholinergic therapy: oral oxybutynin in daily dose 0.2-0.5 mg/kg divided in two daily doses for 3 to 6 months depending on treatment outcome assessed 3 months after start of intervention.
89165566|NCT00665912|Other|1|Standard post-lobectomy wound care plus use of PRP and PPPc in the thoracic cavity.
89165567|NCT00665912|Active Comparator|2|Standard post-lobectomy wound care in the thoracic cavity
89165568|NCT04327687|Experimental|remote ischemic conditioning|remote ischemic conditioning is a physical strategy performed by an electric auto-control device with cuffs placed on bilateral arms: five cycles of 5-min inflation and 5-min deflation one or two times per day. The duration of the treatment is six months.
89165569|NCT04327687|Active Comparator|conventional therapy|conventional therapy
89165570|NCT00665990|Other|Treatment|All participants will receive bevacizumab, sorafenib, and cyclophosphamide until maximum tolerated dose is reached.
89165571|NCT02703701||Usual Care|Group enrolled during normal emergency department operating procedures (without a physician present at triage).
89165572|NCT02703701||Physician at Triage|Group enrolled while a physician is present at triage.
89165573|NCT00615329||Soft tissue tumor|Any patient with soft tissue tumor will be asked to give a sample for this study
89165574|NCT00666068|Experimental|1|"Patients with hypopituitarism~Cross over design: see interventions 1-2"
89165575|NCT00666068|Placebo Comparator|2|"Parallel design:~Healthy controls to be compared with placebo condition in patients with hypopituitarism"
89165576|NCT04215497|Experimental|Physiotherapeutic Scoliosis-Specific Exercises|PSSE group will receive corrective exercise for scoliosis
89165577|NCT04215497|No Intervention|Control|Control group will be taken to the queue list.
89165578|NCT04153526||Surgical Cohort|Surgical Cohort: Patients offered surgery, with or without adjuvant chemotherapy.
89165579|NCT04153526||Non Surgical Cohort|Non-Surgical Cohort: Stage I/II/IIIB patients undergoing radical radiotherapy (with or without chemotherapy) or stereotactic ablative radiotherapy (SABR).
89165580|NCT03121391|No Intervention|Control|The medical intensive care unit in four hospitals will comprise the clusters. All four clusters begin the study under the control condition. Ventilator withdrawal is conducted by the usual personnel in those units. Data is collected through observation of the process and the respiratory comfort of the enrolled patients. Each cluster is randomly selected to sequentially cross over to the intervention. The remaining clusters continue with usual care (control) until selected for crossover.
89165581|NCT03121391|Active Comparator|Intervention|Each cluster is randomly selected to sequentially crossover to the intervention. When crossed over to the intervention the assigned intensive care nurse conducts the ventilator withdrawal according to the algorithm. The algorithm is informed by an objective measure of patient respiratory comfort. Data is collected through observation of the process and the respiratory comfort of the enrolled patients.
89165582|NCT00671138|Active Comparator|I|Arm I will be inoculated with the human hookworm necator americanus at weeks 0 and 12.
89165583|NCT00671138|Placebo Comparator|II|Arm II participants will receive and identical sham-inoculums comprising a diluted amount of 0.2ml McIlhenny & Co Tabasco Pepper Sauce®
89165584|NCT03504085|Experimental|Hatha Yoga|This arm will receive the active Hatha yoga intervention. Instructors lead participants through various yoga poses for 60-minutes, 1-2x weekly for 12 weeks, and daily home practice is recommended.
89165585|NCT03504085|Active Comparator|Restorative Yoga|This arm will receive a restorative yoga intervention. Instructors guide participants through relaxation exercises, typically with eyes closed, laying down, and minimal movement 60-minutes, 1-2x weekly for 12 weeks.
89165586|NCT00700102|Active Comparator|Chemotherapy|Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
89165587|NCT00700102|Experimental|Chemotherapy + Bevacizumab|Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
89165588|NCT04156256|Experimental|CD123-CD33 cCAR T cells|C123-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs
89165589|NCT00615407||Alcohol Drinkers|Asthmatics who consume 3 or more alcoholic beverages per day (on average)
89165590|NCT00615407||Non Drinkers|Asthmatics who do not drink alcohol or consume less than or equal to 2 alcoholic beverages per month
89165591|NCT00671216|Experimental|Period 1|Subjects will receive first placebo, then GSK233705, GW642444 and combination of GSK233705 and GW642444
89165592|NCT00671216|Experimental|Period 2|Subjects will receive first combination of GSK233705 and GW642444, then placebo, GSK233705 and GW642444
89165593|NCT00671216|Experimental|Period 3|Subjects will receive first GSK233705, then GW642444, combination of GSK233705 and GW642444 and later placebo
89165594|NCT00671216|Experimental|Period 4|Subjects will receive first GW642444, then combination of GSK233705 and GW642444, placebo, and later GSK233705
89165595|NCT02705729|Active Comparator|Ketac Universal|Simplified glass ionomer tooth filling
89165596|NCT02705729|Active Comparator|Ketac Molar Quick|Glass ionomer tooth filling
89165597|NCT02631512|Other|Woulgan Gel|Primary dressing with Woulgan Gel with Soluble Beta-Glucan (SBG)
89165598|NCT02631512|Other|Intrasite Hydrogel|Primary dressing with Intrasite Hydrogel
89165599|NCT02705573|Experimental|Mannitol 20%|Mannitol 1g/ kg BW
89165600|NCT02705573|Placebo Comparator|Nacl 0.9%|NaCl 0.9% 5ml/ kg BW
89165601|NCT00613847|Active Comparator|1|Patients with invasive solid tumors
89165602|NCT00613847|Active Comparator|2|Patients with advanced solid tumors that express HER2 with tumors that are HER2 1+ by IHC or FISH.
89165603|NCT00595478|Experimental|1|Motivational Enhancement Therapy (MET)/CBT+CM/BPT
89165604|NCT00595478|Active Comparator|2|Motivational Enhancement Therapy (MET)/CBT
89165605|NCT02703389|Experimental|Video|An innovative video will be developed to explain the nature of non-severe acute otitis media and the rationale for watchful waiting and antimicrobial stewardship. This video will be viewed at recruitment and will be available online for further viewing later.
89165606|NCT02703389|Active Comparator|Pamphlet|Informative pamphlet containing the same information as the video.
89165607|NCT02703389|No Intervention|No intervention|This is the reference standard currently.
89165608|NCT00516295|Experimental|Arm I (Feasibility assessment of VTCB)|Patients receive bevacizumab IV over 30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days (except during weeks 14, 15 [course 5], 17, 18 [course 6], 26, 27 [course 9], 29, and 30 [course 10] when no chemotherapy is given) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89165609|NCT00516295|Experimental|Arm II (VTCB)|Patients receive bevacizumab, vincristine sulfate, topotecan hydrochloride, and cyclophosphamide as in Arm I.
89165610|NCT00516295|Active Comparator|Arm III (CTC)|Patients receive vincristine, topotecan hydrochloride, and cyclophosphamide as in arm I.
89165611|NCT00911690||Cognitively Impaired|Patients in this cohort with be diagnosed with mild to moderate cognitive impairment, Alzheimers disease, Dementia, or any other form of cognitive impairment.
89165612|NCT00911690||Non-cognitively impaired|Patients in this cohort will be normal healthy adults over the age of 60 years that have no cognitive impairment.
89165613|NCT03362099|No Intervention|Group Varenicline|Patients randomized to this group will collect polymorphisms at time zero and will receive varenicline for smoking cessation. The polymorphism result will only be known at the end of the protocol. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
89165614|NCT03362099|Active Comparator|Group Genetic|"The patients randomized to this arm will collect polymorphisms and could receive varenicline or bupropion or both depending on genetic polymorphisms for each one these drugs.~Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve."
89165615|NCT04153370|Active Comparator|intubation time airtraq|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
89165616|NCT04153370|Active Comparator|intubation time glidescope|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
89165617|NCT04153370|Active Comparator|intubation time c-mac|inserting the device through the oral cavity till the visualization of the endotracheal tube passing through the vocal cords
89165618|NCT03861559|Experimental|mometasone furoate nasal spray|Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days.
89165619|NCT03861559|Placebo Comparator|placebo nasal spray|Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.
89165620|NCT00738010|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
89165621|NCT00738010|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
89165622|NCT00738010|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
89165623|NCT02705417||Group A|Patients in whom selection of vascular access relied upon physical examination and medical history, during pre-operative surgical assessment
89165624|NCT02705417||Group B|Patients who underwent vascular mapping using color Doppler Ultrasonography in addition to physical examination and history during pre-operative evaluation.
89165625|NCT02705651|Experimental|Somatostatin-Analog|A long acting somatostatin analog will be applied.
89165626|NCT02705651|No Intervention|No treatment|This arm will be be the observational control according to the endpoints of the study. No intervention will be made.
89165627|NCT02568670|Experimental|according to clinical signs|removal the peripheral catheter according to clinical signs
89165628|NCT02568670|No Intervention|sistematically every 96 hours|removal the peripheral catheter every 96 hours
89165629|NCT02705339|Experimental|Arm 1: Rociletinib|"Rociletinib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg twice per day during each 28-day cycle.~After completion of cycle 1, patients who tolerate the 500 mg twice per day dose without significant adverse effect may increase dosing to 625 mg twice per day at the discretion of the investigator"
89165630|NCT00738088|Experimental|1|Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c
89165631|NCT04651855|Experimental|Treatment arm|It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture.
89165632|NCT02703233|Active Comparator|Nitrous Oxide|Patients receive nitrous oxide via mask.
89165633|NCT02703233|Placebo Comparator|Placebo (Oxygen)|Patients receive oxygen via mask.
89165634|NCT05740696||ALF|acute liver failure
89165635|NCT05740696||SALF|subacute liver failure
89165636|NCT05740696||ACLF|acute-on-chronic liver failure
89165637|NCT02703155|Other|Home Oral Glucose tolerance test kit|Providing children with Cystic Fibrosis between 10 and 17 years of age with Home Oral glucose tolerance test kit to screen Cystic fibrosis related Diabetes.
89165638|NCT02705183|Active Comparator|A: Surgery & Post-operative radiotherapy|Surgery & Post-operative radiotherapy
89165639|NCT02705183|No Intervention|B: Surgery only|Surgery only
89165640|NCT04062760|Active Comparator|Standard diuretic therapy (SDT)|Furosemide +/- spironolactone or potassium canrenoate
89165641|NCT04062760|Experimental|Early sequential nephron blockade (ESNB)|Furosemide + metolazone + acetazolamide +/- spironolactone or potassium canrenoate
89165642|NCT05344781||ileostomy|Patients with ileostomy
89165643|NCT05344781||colostomy|Patients with colostomy
89165644|NCT02705261|Experimental|Cognitive-behavior therapy|Cognitive-behavior therapy to teach parents the skills to help their children. Participants will have access to the program as often as they wish and have the post assessment at week 12.
89165645|NCT02703077|Active Comparator|1: ERCP + Spyglass + EHL|This group after the diagnosis of difficult bile duct stones, will be submitted to spyglass cholangioscopy + EHL (electrohydraulic lithotripsy)
89165646|NCT02703077|Active Comparator|2: ERCP + Balloon Dilation|This group after the diagnosis of difficult bile duct stones, will be submitted to Balloon dilation of the papilla
89165647|NCT05344703|Active Comparator|Standard Y Balance|Subjects will perform Y-balance lower quarter
89165648|NCT05344703|Active Comparator|Y Balance Plus Stroboscopic Glasses|Subjects will perform Y-balance lower quarter with and without stroboscopic lenses
89165649|NCT02702843|Active Comparator|Xenon Light|Laparoscopic cholecystectomy with Xenon Light
89165650|NCT02702843|Experimental|Near infrared light|Laparoscopic cholecystectomy with Near infrared light
89165651|NCT02705027|Active Comparator|Standard|"After randomization one half of the patients receive a Freka®-Trilumina probe, which is inserted in nasogastric route an then pushed  using a small forceps which is inserted through the endoscope into the small intestine."
89165652|NCT02705027|Experimental|Freka®-EasyIn|The other half of the patients will receive a Freka®-EasyIn probe which is directly placed in the small intestine inserted over the endoscope, after endoscopy was initially pushed - as far as possible - into the small intestine.
89165653|NCT05344547||PCOS Patient|
89165654|NCT05344547||Non-PCOS Patient|
89165655|NCT02704637|Experimental|HS-1000 recording|Each non-invasive recording session with the HS-1000 device will be done for 10 consecutive uninterrupted minutes. Patients will be recorded once daily for the duration of their time in ICU or for up to 14 days total. In the case the PI or a member of the study team positively confirms vasospasm based on clinical assessment or follow-up care during the monitoring period, the patient will be recorded twice daily for up to 14 consecutive days or for their duration in the ICU.
89165656|NCT00516139|Experimental|Lamotrigine|Open-label lamotrigine
89165657|NCT02704715|Other|general anesthesia,orbital operation|"diagnosed as orbital disease and ocular tumor~over 16 years old~orbital operation under general anesthesia"
89165658|NCT05344391|Experimental|BFR cycling|This group will perform cycling with BFR applied bilaterally at 80% LOP for 10 min and cycling at 40% HRR. Next they will perform 3x15 of the scaption and sidelying external rotation exercises. These will initially be performed at 30% 1RM; every 2 weeks load increased by 1lbs.
89165659|NCT05344391|Active Comparator|Cycling without BFR|This group will perform cycling and the same shoulder exercises using the same training parameters; however, BFR will not be applied.
89165660|NCT05343923||paroxistical AF|
89165661|NCT05343923||persistent AF|
89165662|NCT02702531|Experimental|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
89165663|NCT02702531|Experimental|Water + Povidone-iodine Solution|Clearify Visualization with Water + Povidone-iodine Solutionused during laparoscopic surgery
89165664|NCT00515827|Experimental|Raltegravir then Placebo (Arm A)|400 mg raltegravir (MK-0518) administered twice daily in addition to optimized background regimen (OBR) from entry to Week 12; halt raltegravir at Week 12 and add placebo twice daily for 12 weeks
89165665|NCT00515827|Experimental|Placebo then Raltegravir (Arm B)|Placebo administered twice daily in addition to OBR from entry until Week 12; halt placebo at Week 12 and add 400 mg raltegravir tablet twice daily for 12 weeks
89165666|NCT02702453|Experimental|Development and Testing|Develop an online interactive, tailored intervention to address the needs of men and partners interested in sexual recovery after treatment for localized prostate cancer during the first 6 months after treatment. The intervention will undergo content testing through 4 focus groups with prostate cancer survivors and partners and usability testing with 5 survivors and partners
89165667|NCT04154696|Experimental|Normothermic perfusion of a graft|
89165668|NCT04031924||Liver Transplantation|Sixteen individuals with liver transplantation were included in the study, and their physical and demographic characteristics of the individuals recorded. The Senior Fitness Test (SFT) was used to evaluate to physical fitness. The Tampa Scale for Kinesiophobia (TSK) was used to assess kinesiophobia; the Fatigue Impact Scale (FIS) and Fatigue Severity Scale (FSS) to evaluate fatigue; the Berg Balance Scale (BBS) and the Timed Up and Go test (TUG) to evaluate the balance; the International Physical Activity Questionnaire (IPAQ) to determine the level of physical activity;and the Hospital Anxiety and Depression Scale (HADS) to evaluate psychological status.
89165669|NCT04031924||Healthy Subjects|Sixteen age- and sex-matched healthy subjects were included in the study.
89165670|NCT02702297||Single arm|daily multimodal monitoring during pregnancy after PPROM, Analysis of neonatal routine parameters and histologic examination of placenta
89165671|NCT00661934||1|Dialysis Group
89165672|NCT00661934||2|Cardiac Malfunction Group
89165673|NCT00615875|Active Comparator|A|
89165674|NCT00615875|Placebo Comparator|P|
89165675|NCT02630810|Experimental|Early oral hydration|Early oral intake of 100 ml clear unsweetened water 1 hour following the Cesarean Section, then upon patient's desire, then starting semisolid, solid food when participant passed flatus.
89165676|NCT02630810|Active Comparator|Delayed oral hydration|Oral intake of 100 ml clear unsweetened water after 6 hours from the end of CS then upon patient's request,then starting semisolid, solid food when participant passed flatus.
89165677|NCT05343845||Group NS, Nonsmoker (n= 50)|Pregnant women who did not smoke during pregnancy will be separated as Group NS. Local anesthetic dose adjusted for height and weight and 20 µg fentanyl will be administered intrathecally. Results regarding the effectiveness of spinal anesthesia will be monitored.
89165678|NCT05343845||Group S, Smoker (n= 50)|Pregnant women who smoked 5 or more cigarettes in a day will be separated as Group S. A local anesthetic dose adjusted for height and weight and 20 µg fentanyl will be administered intrathecally. Results regarding the effectiveness of spinal anesthesia will be monitored.
89165679|NCT02630888|Active Comparator|Memantine|Patients randomized to this group will receive a dose of 15 mg / day of memantine during the first week (V0); all have the dose of memantine increased on the second week (V1) at the dose of 30 mg / day (in two divided doses of 15 mg).
89165680|NCT02630888|Placebo Comparator|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine.
89165681|NCT02699411|Active Comparator|dry needling|Dry needling on the vastus is performed in patients undergoing ACL fortnight after the intervention and then evaluated. REL dry needling while supplies last twenty insertions before treatment, at midnight, a week and five weeks.
89165682|NCT02699411|Active Comparator|Stability and propioception|Proprioception and stability exercises in patients undergoing ACL fortnight after the intervention and then evaluates performed before treatment, at midnight, a week and five weeks.
89165683|NCT00671294|Experimental|Ramelteon and Placebo QD (9 possible combinations total)|
89165684|NCT02630576|Experimental|Men - Left Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
89165685|NCT02630576|Experimental|Men - Right Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
89165686|NCT02630576|Experimental|Women - Left Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
89165687|NCT02630576|Experimental|Women - Right Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
89165688|NCT02692625|Experimental|Group A|"Group A (test group): This group consist of 80 children receiving the probiotic lozenges.~The Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). The probiotic lozenge is used twice daily for two months."
89165689|NCT02692625|Placebo Comparator|Group B|"Group B (control group): This group consist of 80 children receiving the placebo lozenges.~The placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.The placebo lozenges is used twice daily for two months."
89165690|NCT00662168||observation|Individuals with a diagnosis of carcinoid carcinoma
89165691|NCT02841761|Experimental|Treatment A (Midazolam)|Single dose of Midazolam 8 mg on Day 1
89165692|NCT02841761|Experimental|Treatment B1 (ACT-132577)|Single dose of ACT-132577 150 mg on Day 2; single dose of ACT-132577 50 mg on Day 3, Day 4, and Day 5.
89165693|NCT02841761|Experimental|Treatment B2 (Midazolam + ACT-132577)|Single dose of Midazolam 8 mg and single dose of ACT-132577 50 mg on Day 6
89165694|NCT02699489|Experimental|Laparoscopic donor nephrectomy arm|This group will undergo laparoscopic donor nephrectomy
89165695|NCT02699489|Active Comparator|Open donor nephrectomy arm|This group will undergo open donor nephrectomy
89165696|NCT04143503||adult critically ill patients|
89165697|NCT00666146||1|Case Families ( Family with a schizophrenia proband)
89165698|NCT00666146||2|Control Families
89165699|NCT00666146||3|Control subjects
89165700|NCT00666302|Experimental|1|
89165701|NCT00666302|Active Comparator|2|
89165702|NCT00671372|Experimental|Cohorts 1-5|
89165703|NCT00671372|Experimental|Cohorts 6, 6A, 7, 7A|
89165704|NCT00671450||Group 1|Participants will be patients diagnosed with PTSD but with no history of TBI. Participants must be between the ages of 19 and 39. Participants must be compentent to sign a consent form and be willing ot participate in a vision screening.
89165705|NCT00666380|Experimental|10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
89165706|NCT00666380|Experimental|50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
89165707|NCT00856986|Experimental|Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
89165708|NCT00856986|Experimental|Insulin detemir + Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
89165709|NCT00856986|Experimental|Non-Randomised Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%
89165710|NCT00856986|Other|Early Withdrawals Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial
89165711|NCT00856986|Other|Intensified group|Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c ≥ 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.
89165712|NCT00662246|Experimental|1|"Primary objectives :~to determine the recommended dose (i.e., the safest and most effective dose) by evaluating frequency of patients developing unacceptable (grade 3 or higher) acute toxicities attributable to proton beam radiotherapy for HCC."
89165713|NCT02702141|Experimental|SGN-CD19B|
89165714|NCT02630732|Active Comparator|Brain School|Pain Neuroscience Education Program
89165715|NCT02630732|Active Comparator|Back School|Classical Back School
89165716|NCT05343533|Experimental|Active Probiotic|A mixture of probiotic strains (2.5 gram daily doses of 4 x 109 CFU/packet) of the following species (Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium longum).
88804635|NCT02866578|Experimental|Open lung protective ventilation|"Recruitment maneuvers (30 cmH2O during 30 seconds) after intubation, after CPB initiation, before aortic declamping and at ICU arrival.~PEEP at 8 cmH2O.~Ultraprotective ventilation during CPB: PEEP 8 cmH2O, Tidal volume 3mL/kg, Respiratory rate 12 cycles per minute, FiO2 40%.~Assigned intervention - Procedure: patients are randomized and ventilated with the open lung strategy from intubation to detubation."
89165717|NCT05343533|Placebo Comparator|Placebo|Maltodextrin capsule
89165718|NCT00666614|Other|Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
89165719|NCT00666614|Other|Standard Care|Normal Hospital Environment
89165720|NCT02699177||Suspected PCD but negative|"CBF measurements:~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.~The two methods will be compared."
89165721|NCT02699177||Suspected PCD but positive|"CBF measurements:~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.~The two methods will be compared."
89165722|NCT00666692|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 mg/kg with carboplatin, paclitaxel, and bevacizumab
89165723|NCT00707746|Placebo Comparator|Placebo|1 mL placebo saline, weekly subcutaneous injections for 26 weeks
89165724|NCT00707746|Experimental|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
89165725|NCT02702063|Other|TTE vs. EC + calibration group|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial."
89165726|NCT02702063|Other|Right heart catheterisation|Twenty five patients undergoing routine right heart catheterization (RHC) at the department of cardiology for the evaluation of suspected pulmonary hypertension or heart failure will be included in this trial. EC measurements will be obtained during RHC, and a TTE (for measuring LVOT-area) will be performed immediately before undergoing RHC. Inclusion and exclusion criteria are similar as described above.
89165727|NCT02702063|Other|Passive leg raising test|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial.~SV and CO will be measured using TTE and EC. Patient's legs will then be raised by 45degree, and SV and CO measurements will be repeated after 1 minute. Changes in SV and CO observed with both methods will be compared."
88804636|NCT02866578|No Intervention|Conventional strategy|No recruitment maneuvers. PEEP at 2 cmH2O. During CPB: continuous positive pressure at 2 cmH2O.
89165728|NCT00662324||1|Trial experienced cancer patients and their primary caregivers.
89165729|NCT00662324||2|Trial naive cancer patients and their caregivers.
89165730|NCT00662324||3|Health care professionals who are involved in running Phase I, II or III clinical trials.
89165731|NCT05343377|Experimental|circulate free methylated EBV DNA predicts PFS rate in ENKTCL|
89165732|NCT00666770|Experimental|Gabapentin 250 mg|
89165733|NCT00666770|Experimental|Gabapentin 500 mg|
89165734|NCT00666770|Placebo Comparator|Placebo|
89165735|NCT00615563||genotype test|
89165736|NCT00615563||combined phenotype/genotype test|
89165737|NCT00662402|Experimental|1-Extensive Consultations|Intervention- Receives extensive consulting services
89165738|NCT00662402|No Intervention|2-Regular levels of service|Control - Receives regular levels of service; one hour free services from each of the 4 units, with option to pay for more.
89165739|NCT04135716|Experimental|Exposed group|Patients will receive colonoscopy with assistance of Endo.Angel
89165740|NCT04135716|Sham Comparator|Non-exposed group|Patients will receive colonoscopy without assistance of Endo.Angel
89165741|NCT05735158|Experimental|KB105|Weekly topical application
89165742|NCT05735158|Placebo Comparator|Placebo|Weekly topical application
89165743|NCT02698943||Study Group|Participants who underwent phacoemulsification surgery and implantation of the Envista MX-60 IOL
89165744|NCT02623140|Experimental|Biofreedom|Biofreedom stent treatment at index procedure
89165745|NCT02623140|Active Comparator|Orsiro|Orsiro stent treatment at index procedure
89165746|NCT00662480|Experimental|1|Invited to screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm
89165747|NCT00662480|No Intervention|2|Participants which are not offered vascular screening
89165748|NCT03583697|Experimental|Active BMN111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111 daily
89165749|NCT03583697|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
89165750|NCT02630420|Experimental|cetuximab and savolitinib|Following assessment in Part 1 of dose-limiting toxicity and maximum tolerated dose, this drug combination will be administered in Part 2 of the study to assess safety, tolerability, response rate, and progression-free survival.
89165751|NCT00738166|Experimental|II|organic animal manure
89165752|NCT00738166|Active Comparator|III|conventional
89165753|NCT00738166|Experimental|I|organic green manure
89165754|NCT00667082|Experimental|NPI-0052 + Vorinostat Dose-Escalation|4 dose-escalation cohorts
89165755|NCT05343299|Experimental|Patients undergoing hand surgery with a combination of lidocaine and ropivacaine|Patients undergoing Wide Awake Local Anesthesia No Tourniquet -type hand surgery with lidocaine
89165756|NCT05343299|Active Comparator|Patients undergoing hand surgery with lidocaine alone|Patients undergoing Wide Awake Local Anesthesia No Tourniquet -type hand surgery with lidocaine
89165757|NCT00738244||1|Normal hearing listeners
89165758|NCT00738244||2|Listeners with mild-to-moderate sensorineural hearing loss
89165759|NCT00667160|Experimental|1|
89165760|NCT00667160|Active Comparator|2|
89165761|NCT02701673|Experimental|Belinostat/Gem/Bu/Mel + AutoSCT|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1.~Caphosol oral rinses 30 mL four times a day used from Day -8. Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.~Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1. Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2. Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2. Participants with cluster of differentiation antigen 20 (CD20+) tumors receive Rituximab 375 mg/m2 by vein on Day -9.~Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.~Melphalan 60 mg/m2/d by vein on Day -2. Stem cell transplant by vein given on Day 0."
89165762|NCT00738322|Experimental|1|
89165763|NCT00738322|Placebo Comparator|2|
89165764|NCT00856908|Experimental|1|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
89165765|NCT00856908|Placebo Comparator|2|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
89165766|NCT00522379|Experimental|Rotigotine 2 mg/24 hr|
89165767|NCT00522379|Experimental|Rotigotine 4 mg/24 hr|
89165768|NCT00522379|Experimental|Rotigotine 6 mg/24 hr|
89165769|NCT00522379|Experimental|Rotigotine 8 mg/24 hr|
89165770|NCT00522379|Placebo Comparator|Placebo|
89165771|NCT05343221|Experimental|Haptic|"Practice in Haptic Group: Students will be taught cardiopulmonary resuscitation skills with the 3D Systems Touch Haptic Simulator. During the application, there will be 2 researchers and the student who made the application in the room. While one of the researchers will be with the student only for support during the practice, the other researcher will fill the Cardiopulmonary Resuscitation Skills Checklist by evaluating the cardiopulmonary resuscitation skill of the student."
89165772|NCT05343221|Experimental|High Fidelity Simulator|Application in the Simulator Group with High Fidelity: Students will be taught cardiopulmonary resuscitation skills with the CPR Simulator. The student and 2 researchers who will practice will remain in the environment, and the student will also be asked to practice.
89165773|NCT04156178|Experimental|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD20 and CD19 CARs
89165774|NCT02567890|Experimental|Internet-based DBI|Internet-based DBI, which consists of four interactive occasions, some homework assignments, and monitoring
89165775|NCT02567890|Placebo Comparator|Expressive writing|Expressive Writing (placebo/attention control) where participants write texts. This is the active control condition.
89165776|NCT02567890|No Intervention|Waiting list|A wait-list control condition.Those in the wait-list condition will not receive any treatment until they have done the 6-month follow-up assessment.
89165777|NCT00856830|Experimental|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin.~This study has only one arm but it incorporates two phases. Phase I utilizes a combination of bendamustine and irinotecan for Regimen A followed by etoposide and carboplatin for Regimen B."
89165778|NCT04154228|Experimental|Lymphoma Patients|
89165779|NCT04062916||women with endometriosis|65 women whose main symptom was pain and who did not respond to medical treatment and underwent endometriosis surgery
89165780|NCT02631356|Placebo Comparator|Ringer's lactate solution|Infusion of Ringer's lactate solution (10ml/kg) in the control group
89165781|NCT02631356|Active Comparator|Succinylated gelatin|Infusion of Succinylated gelatin (10ml/kg) in the test group
89165782|NCT02614326|Experimental|Memory Flexibility (MemFlex) Training|MemFlex training draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014). MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks used throughout the workbook, and guides the participant in completion of the tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive a phone call at the beginning of week three to check progress, and clarify any difficulties.
89165783|NCT02614326|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. The workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The participant will receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties.
89165784|NCT04063462|Experimental|Cohort 1|Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC
89165785|NCT04063462|Experimental|Cohort 2|Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC
89165786|NCT04153448||Bronchiectasis|Children with bronchiectasis
89165787|NCT04153448||Healthy Controls|Age-matched healthy volunteers
89165788|NCT02614404|Experimental|Imatinib combination therapy|Administration of imatinib (400 mg/day) plus dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.
89165789|NCT02614404|Active Comparator|dihydroartemisinin plus piperaquine|Administration of dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.
89165790|NCT00522301|Experimental|Oral Sorafenib (BAY43-9006)|Sorafenib is supplied as 200-mg tablets. Sorafenib will be administered as 400 mg orally daily x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating). In the absence of intolerable toxicity, a patient may continue to receive treatment with sorafenib until disease progression, or until 24 months have elapsed.
89165791|NCT00662636|Experimental|Arm I|Patients receive oral dasatinib and lapatinib ditosylate once daily on days 1-28.
89165792|NCT00696462|No Intervention|A|Patients in Group A will undergo passive warming with a warmed cotton blanket placed over their upper extremities
89165793|NCT00696462|Active Comparator|B|Patients in Group B will have a forced-air warming device applied to the upper body above the waist at the 43 degree Celsius setting.
89165794|NCT02629484|Active Comparator|Focused Cardiac Ultrasound|participants randomised to receive focused cardiac ultrasound prior to surgery for hip fracture
89165795|NCT02629484|No Intervention|Standard care (clinical assessment)|Participants randomised to standard care receive clinical assessment of the patient
89165796|NCT00863928|No Intervention|Control Arm|No suppository given
89165797|NCT00863928|Experimental|B & O suppository|B & O suppository, belladonna 16.2 mg and opium 60 mg suppository (Paddock Laboratories, Minneapolis, MN)
89165798|NCT04153214|Experimental|Cycling workstation|Participants will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 6 months
89165799|NCT04153214|Placebo Comparator|control|Daily activities unchanged during 3 months. Then they will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 3 months.
89165800|NCT00667316||A|Workers from companies and workers' health care organizations who go for their periodic medical checkup.
89165801|NCT00856518|Active Comparator|Arm 1: EMST|The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
89165802|NCT00856518|Sham Comparator|Arm 2: Sham group|The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load
89165803|NCT00506389|Experimental|Esmirtazapine 3.0 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 3.0 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
89165804|NCT00506389|Experimental|Esmirtazapine 4.5 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 4.5 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
89165805|NCT00506389|Placebo Comparator|Placebo|Participants took placebo tablets on Days -7 and -6, placebo tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
89165806|NCT00667472|Experimental|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
89165807|NCT00667472|Experimental|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
89165808|NCT01012375|Experimental|1|AZD1446 tid
89165809|NCT01012375|Experimental|2|AZD1446 tid
89165810|NCT01012375|Experimental|3|AZD1446 qd
89165811|NCT01012375|Placebo Comparator|4|Matching placebo capsule
89165812|NCT00667706|Active Comparator|1|Patients who will undergo Laparoscopic Sleeve Gastrectomy
89165813|NCT00667706|Active Comparator|2|Patients who will undergo Laparoscopic Roux-en-Y Gastric Bypass
89165814|NCT01012453|No Intervention|Hand Eczema in health care workers|
89165815|NCT00667784||Anxiety Assessment|Minor Donors + Sibling Non-Donors + Parents or Legal Guardians
89165816|NCT01565395|Experimental|Xeomin Injections|Fifteen units (0.15 ml) of incobotulinum toxin A injected into each parotid gland and 20 units (0.2 ml) to each submandibular gland for a total dose of 70 units using anatomical landmarks for ALS Twenty units (0.2ml) injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks for PD/parkinsonism
89165817|NCT01565395|Placebo Comparator|Placebo|0.15 ml sterile 0.9% saline injected into each parotid gland and 0.2 ml to each submandibular gland using anatomical landmarks for ALS 0.2ml injected into each parotid gland and 0.3 ml to each submandibular gland using anatomical landmarks for PD/parkinsonism
89165818|NCT00667940|Experimental|Workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
89165819|NCT00667940|No Intervention|Delayed workshop|No specific intervention until after follow-up assessment, then receives same workshop.
89165820|NCT04063228|Active Comparator|Standard of care|
89165821|NCT04063228|Active Comparator|Simple Skill Group|
89165822|NCT00662714|Experimental|1|Repaglinide; oral
89165823|NCT00662714|Active Comparator|2|short-acting Insulin (Actrapid)
89165824|NCT00668018|Experimental|Arm 1|
89165825|NCT00871338|Experimental|GSK2197870A Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2197870A vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2 and a booster dose of Menitorix™ vaccine at Month 10. All vaccines were administered intramuscularly. GSK2197870A and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh.
89165826|NCT00871338|Active Comparator|Pediacel Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of Pediacel™ vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2, 2 doses of Menjugate™ vaccine at Months 1 and 2 and a booster dose of Menitorix™ at Month 10. All vaccines were administered intramuscularly. Pediacel™ and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh and Menjugate™ vaccine in the left lower anterolateral thigh.
89165827|NCT00824421|Experimental|UK- 453,061 Dose One|UK 453,061 Dose One plus Truvada
89165828|NCT00824421|Experimental|UK-453,061 Dose Two|UK 453,061 Dose Two plus Truvada
89165829|NCT00824421|Active Comparator|Efavirenz + Truvada|Efavirenz + Truvada
89165830|NCT04130100|Experimental|Low Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of low dose of mesenchymal stem cells.
89165831|NCT04130100|Experimental|High Dose of Mesenchymal stem cell|Patients receiving intraarticular injection of high dose of mesenchymal stem cells.
89165832|NCT04130100|Active Comparator|Sodium Hyaluronate|Patients receiving intraarticular injection of Sodium Hyaluronate
89165833|NCT00514813|Experimental|Dynepo (Epoetin delta)|Subjects received Dynepo (Epoetin delta) either twice weekly (BIW), once weekly (QW), once every 2 weeks (Q2W) or once every 4 weeks (Q4W) based on what is appropriate for the subject
89165834|NCT04129632|Other|IEPF intervention|Survey respondent voluntary decides to do a 4 weeks mindfulness intervention
89165835|NCT00708279|Experimental|A|After establishing a baseline for the first 4 weeks of trial involvement, thereby providing their own control group, all participants begin the intervention phase of osteopathic manipulation.
89165836|NCT00597116|Active Comparator|1|Vinorelbine
89165837|NCT00597116|Experimental|2|Vandetanib
89165838|NCT04135404||Pulmonary Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; pulmonary group are those who have reported any pulmonary diseases and they will be included in this study as pulmonary group.
89165839|NCT04135404||Control Group|This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; The control group are subjects without pulmonary diseases and they will be included as (control group).
89165840|NCT00668096|Placebo Comparator|Arm 2|
89165841|NCT00668096|Experimental|Arm 1|
89165842|NCT00668174|Experimental|1|Exercise
89165843|NCT00668174|No Intervention|2|Control
89165844|NCT00514735|Experimental|1|Ablation Management
89165845|NCT00514735|Active Comparator|2|Medical Management
89165846|NCT00668252||1|Non menopausal women
89165847|NCT00668252||2|age matched men
89165848|NCT00668252||3|Menopausal women
89165849|NCT00668252||4|age matched men
89165850|NCT00671996|Active Comparator|A|Mangafodipir treatment
89165851|NCT00671996|Placebo Comparator|B|
89165852|NCT00672152|Experimental|A-WT1 derived peptides|"Wilms' tumor gene 1 (WT1) derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg Granulocyte-macrophage colony-stimulating factor (GM-CSF) in a total volume of 2ml:~WT peptide #1: (human leukocyte antigen) HLA-A2 restricted: RMFPNAPYL~WT peptide #2: HLA-A24 restricted: CMTWNQMNL~WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
89165853|NCT00662870|Experimental|DAPTACEL Lot 1|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 1
89165854|NCT00662870|Experimental|DAPTACEL Lot 2|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 2
89165855|NCT00662870|Experimental|DAPTACEL Lot 3|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 3
89165856|NCT00662870|Active Comparator|Pentacel|Participants receiving Pentacel vaccine
89165857|NCT00672230|Experimental|Lut Supp|
89165858|NCT00672308|Experimental|1|Benefiber (25 g/L)
89165859|NCT00672308|Experimental|2|Benefiber (50 g/L)
89165860|NCT00672308|Experimental|3|the reduced-osmolarity WHO-ORS without Benefiber.
89165861|NCT03252587|Experimental|BMS-986165 Dose 1 oral administration|
89165862|NCT03252587|Experimental|BMS-986165 Dose 2 oral administration|
89165863|NCT03252587|Experimental|BMS-986165 Dose 3 oral administration|
89165864|NCT03252587|Placebo Comparator|Placebo oral administration|
89165865|NCT02630264|Experimental|Combination therapy|"E10A+chemotherapy group (360 subjects):~E10A (Endostatins) of 1.0×1012VP on day 1 and 6~Paclitaxel Injection 160mg/m2 on day 3~Cisplatin Injection 25mg/m2 on day 3, 4, and 5. Repeat every 21 days."
89165866|NCT02630264|Experimental|Chemotherapy|"Chemotherapy-alone group (180 subjects):~Paclitaxel Injection 160mg/m2 on day 1~Cisplatin Injection 25mg/m2 on day 1, 2, and 3. Repeat every 21 days"
89165867|NCT00668330|Active Comparator|Ibandronate+alfacalcidol+calcium|Bonviva
89165868|NCT00668330|Active Comparator|Placebo ibandronate+alfacalcidol+calcium|
89165869|NCT03998059||30 immune thrombocytopenia(ITP) patients|A total of 30 cases. The investigators plan to take 20ml of peripheral blood (PB) of these 30 ITP patients at 6 time points, including 1 day before surgery, 1 week, 1 month, 3 months, 6 months, and 12 months after surgery
89165870|NCT03998059||20 normal controls|A total of 20 cases.18 age- and gender- matched healthy donor will also be enrolled as controls and taken 20ml of peripheral blood.
89165871|NCT03998059||Spleens of the 30 cases patients(ITP)|These 30 ITP patients agree to have splenectomy.The investigators will take a small amount of spleen tissue during surgery.
89165872|NCT03998059||Spleens of the 10 cases patients(normal controls)|The investigators also plan to take splenic tissue from 10 patients who have splenectomy due to hereditary spherocytosis or trauma.
89165873|NCT00668408|Other|LTOT group|Study group: optimal medical therapy plus LTOT = or > 15 hours pro die
89165874|NCT00668408|Other|Non LTOT group|control group: optimal medical therapy without LTOT
89165875|NCT04630483||Group I: INHA|Inhalational anesthesia (INHA)
89165876|NCT04630483||Group II: TIVA|Total intravenous anesthesia (TIVA)
89165877|NCT01012531|Active Comparator|highly polymerized allergen extract|
89165878|NCT01012531|Placebo Comparator|Placebo|
89165879|NCT00662948|Experimental|A|Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg
89165880|NCT00662948|Active Comparator|B|Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months
89165881|NCT00511147|Experimental|IGIV3I Grifols 10% (All Subjects)|All subjects with Chronic ITP
89165882|NCT04153058|Experimental|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
89165883|NCT04153058|Active Comparator|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
89165884|NCT00663104|Active Comparator|1|exercise (3 sessions/week)
89165885|NCT00663104|Active Comparator|2|"exercise and phytoestrogen (cimicifuga racemosa)"
89165886|NCT00663104|Placebo Comparator|3|wellness control, placebo
89165887|NCT00672464|Active Comparator|Olanzapine only|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine
89165888|NCT00672464|Experimental|Added Metformin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin
89165889|NCT00672464|Experimental|Added Simvastatin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Simvastatin
89165890|NCT00672464|Experimental|Added Metf. + Simv.|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin and Simvastatin
89165891|NCT00672464|No Intervention|Matched Controls|Matched Control Subjects by age, race, and gender
89165892|NCT02701595|Experimental|Oral switch treatment|Oral switch to amoxicillin
89165893|NCT02701595|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of streptococci/enterococci IE (European guidelines 2015)
89165894|NCT01009411||Control|Patients in active phase of labor not augmented
89165895|NCT01009411||Augmented|Augmentation leading to normal progress
89165896|NCT01009411||Caesarean section|Augmentation leading to Caesarean section
89165897|NCT01565629|No Intervention|Waitlist Condition|Children in this condition will withhold from any type of intervention for a period of 12 weeks.
89165898|NCT01565629|Experimental|Computer Assisted CBT|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
89165899|NCT00668720|Experimental|1|
89165900|NCT00668720|Sham Comparator|2|
89165901|NCT00668798||A|mother CMV positive
89165902|NCT00668798||B|mother CMV negative
89165903|NCT00668876|Active Comparator|1|Group A: perioperative immunonutrition
89165904|NCT00668876|Active Comparator|2|Group B: postoperative immunonutrition
89165905|NCT00668876|Active Comparator|3|Group C: control
89165906|NCT02698553|Experimental|Bupropion XL once daily|Healthy subjects will receive Bupropion XL 150milligram (mg) once daily for 5 days (Day 1 to Day 5) and then Bupropion XL 300 mg once daily from Day 6 to Day 14.
89165907|NCT00668954|Active Comparator|Pomegranate Juice|
89165908|NCT00668954|Placebo Comparator|Placebo Juice (non-Pomegranate)|
89165909|NCT02698631|Active Comparator|Conventional AF ablation.|A standard radiofrequency AF ablation procedure will be carried out without LGE information.
89165910|NCT02698631|Experimental|LGE-MRI guided AF ablation.|Fibrosis information obtained from post-processed LGE-MRI will be used to guide AF ablation procedures.
89165911|NCT02629562|Experimental|Arm 1|first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously
89165912|NCT02629562|Experimental|Arm 2|first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously
89165913|NCT04215263||Geriatric patient underwent general anesthesia procedure|geriatric patients (≥60 years) ware assessed for cognitive impairment after general anesthesia for non-neurologic noncardiac surgery.
89165914|NCT00510835|Experimental|1|Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
89165915|NCT00510835|Experimental|2|Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
89165916|NCT00510835|Active Comparator|3|Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
89165917|NCT00663182|Experimental|A|Patients with decompensated HBV-related cirrhosis
89165918|NCT00663182|No Intervention|B|Untreated
89165919|NCT02629406||Diabetes typ 1|Patients with typ 1diabetes with a duration of the disease between 10-20 years (HbA1C >65 mmol/l) and age 20-50 will be exposed to intermittent hypoxia.
89165920|NCT02629406||Healthy controls|Healthy controls, age 20-50 will be exposed to intermittent hypoxia.
89165921|NCT00615641||1|3 year old children
89165922|NCT00615641||2|4 year old children
89165923|NCT00615641||3|5 year old children
89165924|NCT00672542|Experimental|A|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from untreated monocytes
89165925|NCT00672542|Experimental|B|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with control siRNA
89165926|NCT00672542|Experimental|C|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with siRNA targeting the three inducible immunoproteasome subunits
89165927|NCT04213937|Experimental|nab-paclitaxel|nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles
89165928|NCT04213937|Active Comparator|Topotecan|Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
89165929|NCT02630342|Experimental|Group 1: preparation materials only|This group will receive preparation materials for a clinical MRI scan. These include links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur only at home.
89165930|NCT02630342|Experimental|Group 2: Materials with review|This group will receive in preparation for a clinical MRI scan links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur at home and include a visit with research team to review preparation materials with the research team
89165931|NCT02630342|Experimental|Group 3: Mock MRI scanner|This group will receive the same materials as training group 1. In addition they will attend the mock scanner where the research team will utilise a mock MRI scanner to practice lying down in a scanner, staying still , wearing headphones and watching a movie/video on the mirror system.
89165932|NCT02630342|No Intervention|Neuro-oncology retrospective controls|A retrospective control group of neuro-oncology patients from the 3 years prior to the study initiation. This group will be used to determine the age at which patients were able to complete a diagnostic MRI without GA
89165933|NCT02630342|Experimental|Neuro-oncology prospective|Child life specialist preparation will be provided to these patients. This preparation for Diagnostic MRI scanning in which utilise the Mock MRI scanner as preparation for the scan.
89165934|NCT02701439||HIV-infected|"Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB.~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~Abbreviated demographic and clinical evaluation~TB history and evaluation~Obtain three sputum samples - one early morning sample and two spot samples~HIV testing (and CD4 if positive)~Chest radiograph~Small membrane filtration intervention"
89165935|NCT02701439||HIV negative|"Enrollment of 350 HIV negative adults with suspicion of pulmonary TB.~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~Abbreviated demographic and clinical evaluation~TB history and evaluation~Obtain three sputum samples - one early morning sample and two spot samples~HIV testing (and CD4 if positive)~Chest radiograph~Small membrane filtration intervention"
89165936|NCT00506077|Experimental|MK0249|
89165937|NCT00506077|Placebo Comparator|Placebo|
89165938|NCT02701517|Active Comparator|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by folinic acid rescue. All patients will receive CSA from day -7.
89165939|NCT02701517|Experimental|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
89165940|NCT02630108|Experimental|Thermal Ablation & TACE|"Transarterial chemoembolization (TACE) is performed immediately following thermal ablation.~EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
89165941|NCT02630108|Active Comparator|TACE alone|Only TACE is performed. EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
89165942|NCT02700971|Experimental|Cutaneous Biopsy for microarray analysis|To determine whether outcomes improve as a function of anti-tumor immunity which may enable the use of this technique as a predictive biomarker of treatment response.
89235050|NCT05161689|Experimental|Mpowerment-based intervention|YMSM in this arm may be exposed to a multicomponent, multi-level, community mobilization, combination intervention to address the entire HIV Continuum of Prevention and Care.
89235051|NCT05161689|No Intervention|Standard of care|YMSM in this arm will not be exposed to the intervention.
89165943|NCT00505921|Experimental|Campath-1H|"3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.~Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)~Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0."
89165944|NCT02698709||Healthy corneas (C)|Corneas of normal candidates to refractive surgery who did not develop any sign of corneal ectasia after laser in situ keratomileusis during a two year follow-up period were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
89165945|NCT02698709||Overt keratoconus (Kc)|Whether both eyes manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers. Such eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
89165946|NCT02698709||Forme fruste keratoconus (FFKc)|Whether only one eye manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers, and the fellow eye seemed unaffected. Such unaffected eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
89165947|NCT00596960|Experimental|Motivational Enhancement Therapy|Motivational enhancement therapy
89165948|NCT00596960|Active Comparator|Health Education|health education intervention
89165949|NCT02631434|Experimental|sit-to-stand|To perform a sit-to-stand test
89165950|NCT02631434|Active Comparator|six minute walking test|To perform a six minutes walking test
89165951|NCT02631278|Other|single arm|Intraoperative radiofrequency ablation
89165952|NCT00505765|Experimental|AL-108, 30 mg/day|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
89165953|NCT00505765|Experimental|AL-108, 5 mg/day|AL-108, 5 mg/day- one spray in each nostril once per day
89165954|NCT00505765|Placebo Comparator|Placebo, 3 sprays BID|Placebo- 3 sprays in each nostril, twice per day
89165955|NCT00505765|Placebo Comparator|Placebo, 1 Spray Daily|Placebo- one spray in each nostril, once per day
89165956|NCT00669344|Placebo Comparator|II|Placebo
89165957|NCT00669344|Experimental|I|Rivastigmine
89165958|NCT02698319|No Intervention|Conventional Triage|Conventional triage using Danish Emergency Process Triage (DEPT).
89165959|NCT02698319|Experimental|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is used as triage form in the ED. The Copenhagen Triage Algorithm consists of a few vital parameters and a clinical assessment from the ED nurse.
89165960|NCT03243149|Sham Comparator|False Feedback|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. False feedback (sham) shows a thermometer that indicates false feedback consisting of noise.
89165961|NCT03243149|Active Comparator|View Condition|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. View condition shows a thermometer that indicates true activation of ventromedial PFC minus amygdala but the participant is asked not to attempt neuroregulation.
89165962|NCT03243149|Experimental|Free Regulate|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. Free regulate shows a thermometer that indicates true activation of ventromedial PFC minus amygdala while the participant attempts neuroregulation.
89165963|NCT02701127|Active Comparator|Niacinamide 1 gram|Oral niacinamide, 1 gram daily
89165964|NCT02701127|Active Comparator|Niacinamide 3 grams|Oral niacinamide, 3 grams daily
89165965|NCT02701127|Placebo Comparator|Placebo|Oral placebo pill
89165966|NCT00672698||I|VASCULAR SURGERY
89165967|NCT00672698||II|DIGESTIVE SURGERY
89165968|NCT00672698||III|BILIARY TRACT SURGERY
89165969|NCT02700893|Experimental|Atropine + propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
89165970|NCT02700893|Active Comparator|Atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
89165971|NCT04154306|Placebo Comparator|Placebo|
89165972|NCT04154306|Experimental|Red clover|
89165973|NCT04213781|Other|Usual care|Sedation according to Dixon's up-and-down method.
89165974|NCT04213781|Experimental|Audiovisual distraction|Audiovisual distraction using HappyMed Video Glasses during procedure. Sedation according to Dixon's up-and-down method.
89165975|NCT02700737|Active Comparator|Group A|"Interventional cardiologists presented with limited dataset including only information that is available from imaging parameters currently recommended by clinical practice guidelines."
89165976|NCT02700737|Experimental|Group B|Interventional cardiologists presented with the full dataset, including imaging parameters currently recommended by clinical practice guidelines and image-based simulation modelling.
89165977|NCT00505687|Experimental|Rotigotine|Rotigotine
89165978|NCT02631122|Active Comparator|Supraclavicular BPNB|Patients in this group will be randomized to receive an Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
89165979|NCT02631122|Active Comparator|Retroclavicular BNPB|Patients in this group will be randomized to receive an Ultrasound Guided Retroclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
89165980|NCT02700659||UC monitoring patients|"Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations.~All patients will have urine samples taken and analyzed for NMP22 ELISA, NMP22 BladderChek, urine cytology and Cxbladder.~No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes."
89165981|NCT00669656|Experimental|Prostate Health Cocktail|
89165982|NCT02700581|Active Comparator|low PEEP conventional ventilation|PEEP 2 mmHg tidal volume 10ml/kg
89165983|NCT02700581|Experimental|moderate PEEP conventional ventilation|PEEP 7 mmHg tidal volume 10ml/kg
89165984|NCT02700581|Experimental|low PEEP protective ventilation|PEEP 2 mmHg with tidal volume 6 ml/kg
89165985|NCT02700581|Experimental|moderate PEEP protective ventilation|PEEP 7 mmHg tidal volume 6ml/kg
89165986|NCT00672776|Experimental|1|paroxetine
89165987|NCT00672776|Placebo Comparator|2|placebo
89165988|NCT02698085|Experimental|Intervention Goup|Actual Diacutaneous Fibrolysis
89165989|NCT02698085|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis
89165990|NCT02629250|Placebo Comparator|SV maximization|Goal-directed fluid therapy with stroke volume maximization. Device: The Volume-View system from Edwards Co.
89165991|NCT02629250|Experimental|supernormal DO2|"Goal-directed fluid therapy with stroke volume maximization and supernormal oxygen delivery.~Device: The Volume-View system from Edwards Co."
89165992|NCT00616187|Active Comparator|interferon|
89165993|NCT00616187|Sham Comparator|untreated|
89165994|NCT00663338|Experimental|A|All patients receive placebo or rotigotine at some stage in the trial but the exact point is randomized.
89165995|NCT02863757||CHB Group|Patients with chronic hepatitis B
89165996|NCT02863757||CHB/NAFLD Group|Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease
89165997|NCT02863757||NAFLD Group|Patients with nonalcoholic fatty liver disease
89165998|NCT04152902||PULL-DOWN HELLER-DOR|The PD-HD procedure aimed to restore the vertical axis of the intraabdominal portion of the oesophagus as much as possible. In brief, before performing the myotomy and the anterior fundoplication according to Dor, at least 6 cm of the mediastinal oesophagus was fully isolated; two or more U intramuscular stitches were applied on the curling of the right side of the oesophagus, pulled down and rotated towards the right side of the gastro-oesophageal junction. The PD-HD operation was performed under manometric control
89165999|NCT04152902||OESOPHAGECTOMY|OE was performed with open technique, or recently, with a minimally invasive technique. The stomach was always the oesophageal substitute, and the oesophagogastric anastomosis was preferably located at the thoracic dome or at the neck to minimize the risk of postoperative reflux oesophagitis or cancer growth in the residual dilated oesophagus
89166000|NCT02698007|No Intervention|without lma|standard fiberoptic bronchoscopy without lma
89166001|NCT02698007|Experimental|with lma|fiberoptic bronchoscopy with the use of lma
89166002|NCT01009567|Sham Comparator|Control|Receive human albumin 20% infusion
89166003|NCT01009567|Experimental|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
89166004|NCT02697851|Experimental|Group 1|Microgynon 30® for 21 days, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Evotaz® for 14 days
89166005|NCT02697851|Experimental|Group 2|Evotaz® for 14 days followed by 7 days wash-out, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Microgynon 30® for 14 days (participants may chose to complete a 21 day pack). The total duration of the study is 57 days (+screening and follow up visits) and patients will have 3 intensive pharmacokinetic days on days 14, 35 and 56
89166006|NCT01012843|Active Comparator|Antibiotic|Patients who received antibiotic treatment after abscess drainage
89166007|NCT01012843|Placebo Comparator|Placebo|Patients who received placebo after abscess drainage
89166008|NCT00669890|Experimental|study 515|
89166009|NCT02697929|Active Comparator|sugammadex|at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation
89166010|NCT02697929|Active Comparator|neostigmine|at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation
89166011|NCT00616265|No Intervention|B|Group B. Only Usual Control
89166012|NCT00616265|Experimental|A|Group A: Cpap treatment plus Usual control
89166013|NCT00663416|Experimental|1|
89166014|NCT00663416|Placebo Comparator|2|
89166015|NCT04215341|Experimental|1|The study contains a single arm. All children participating in the study will receive the primary intervention which is physiotherapy.
89166016|NCT02700503|Experimental|Intervention|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
89166017|NCT00505375|Experimental|1|Intravenous infusions of CTLA-4 Ig
89166018|NCT00505375|Placebo Comparator|2|Intravenous infusions of placebo
89166019|NCT04153994|Experimental|Erector Spinae Plane Blockade Treatment|Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique.
89166020|NCT04153994|No Intervention|Erector Spinae Plane Blockade Control - Standard of Care|Patients will receive the standard of care for pediatric scoliosis surgery including multi-modal opioid pain management. If the patient declines to consent to enrollment into the randomized study, patients may still participate by allowing prospective data and samples collection/analysis with respect to perioperative choice.
89166021|NCT02700347|Experimental|Low dose pyrazinamide|Day 0: Pyrazinamide 10mg/kg, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 10mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
89166022|NCT02700347|Experimental|Standard dose pyrazinamide|Day 0: Pyrazinamide 25mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 25mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
89166023|NCT02700347|Experimental|High dose pyrazinamide|Day 0: Pyrazinamide 35mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 35mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
89166024|NCT00594932|Active Comparator|Arm I:|Participants randomly assigned to Arm I will receive mycophenolate mofetil in ascending doses during Month 1, and 3 grams/day (or less if there are tolerance issues) for Months 2 through 6. During Month 1 these participants receive the same number of pills as every other month, but with ascending doses of mycophenolate mofetil and descending numbers of placebo pills. Week one for a total of 1.5 gm/day of mycophenolate mofetil, Week two 2.0 gm/day, Week three 2.5 gm/day and Week 4 3 gm/day. Dose can be held or decreased for tolerance issues at any time.
89166025|NCT00594932|Placebo Comparator|Arm 2|Patients Randomly Assigned to Arm 2 will receive a placebo comparator. The placebo treatment will be structured so that they will undergo the same type of dosing in Month 1 that the ascending dose patient from Arm 1 undergo, but will have placebo in both bottles of pills. At the end of three months, after assessment of primary outcome, these patients enter open label treatment for three more months. During the fourth month this group continues to receive the same number of pills as they received before, with ascending doses of mycophenolate mofetil given vs descending placebo pills so that their induction is the same as those in Arm 1 at the first month.
89166026|NCT02700191|No Intervention|Control|For subjects in the Control arm, the parameters measured by the (µ-Cor) µ-Cor system will not be analysed or made available to the investigator.
89166027|NCT02700191|Experimental|uCor|For subjects in the Interventional arm, all of the parameters measured by the (µ-Cor) µ-Cor system will be available to the investigator and will remain blinded to the subjects. The investigator will use µ-Cor information to aid in therapy adjustment decisions during the study period.
89166028|NCT02692079|Experimental|T-PRF+Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Test group sites were treated with T-PRF+allograft
89166029|NCT02692079|Experimental|Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Control group sites were treated with only allograft
89166030|NCT00616889||1|Seroquel added to medication regime and sleep quality measured
89166031|NCT04152746||Adenoid group|Periostin levels in the adenoid group
89166032|NCT04152746||Control Group|Periostin levels in the control group
89166033|NCT02697539|Placebo Comparator|AmF/SnF2 group|Patients in this arm were adviced to use a standart dentifrice over the course of the study (AmF/SnF2, Meridol®, GABA, Lörrach, Germany).
89166034|NCT02697539|Active Comparator|mHA group|Patients in this arm were adviced to use the new dentifrice over the course of the study (mHA, BioRepair®, Wolff, Bielefeld, Germany).
89166035|NCT02697695||laparoscopic sleeve gastrectomy|patients who underwent laparoscopic sleeve gastrectomy (LSG) due to obesity and/or metabolic syndrome
89166036|NCT02697695||laparoscopic Roux-en-Y- gastric bypass|patients who underwent laparoscopic Roux-en-Y- gastric bypass (LRYGB) due to obesity and/or metabolic syndrome
89166037|NCT02697695||laparoscopic omega-loop gastric bypass|patients who underwent laparoscopic omega-loop gastric bypass (LOLGB) due to obesity and/or metabolic syndrome
89166038|NCT00670124|No Intervention|1|Standard medical treatment
89166039|NCT00670124|Active Comparator|2|Standard medical treatment plus hypothermia (33°C) maintained for 72 hours
89166040|NCT02692001|No Intervention|Current MealTrain menu|This is the current menu being employed for food ordering in the pediatric inpatient wards.
89166041|NCT02692001|Experimental|Intervention MealTrain menu|The intervention menu included child-friendly labeling (attractive characters, fun food names and traffic light system) to encourage healthier choices.
89166042|NCT02629952|Experimental|Blueberry Tea|3 cups of blueberry tea per day x 4 weeks
89166043|NCT02629952|No Intervention|No Treatment|No Treatment
89166044|NCT04213703||Patients with Epidermolysis Bullosa|Patients who have been diagnosed with Epidermolysis Bullosa
89166045|NCT00504829|Experimental|LCP-AtorFen|LCP-AtorFen 40/100mg fixed-dose combination tablet of 40mg atorvastatin and 145mg fenofibrate for treatment of mixed dyslipidemia
89166046|NCT00504829|Active Comparator|atorvastatin|atorvastatin 40mg tablet (Lipitor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
89166047|NCT00504829|Active Comparator|fenofibrate|fenofibrate 145mg tablet (Tricor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
89166048|NCT02701205|Experimental|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 50mg twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
89166049|NCT02701205|Experimental|etanercept (half dose)|One vial of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®） 25mg and one vial of placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
89166050|NCT02701205|Placebo Comparator|Placebo|Two vials of Placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 25mg twice a week from Week 12 to Week 24
89166051|NCT00670280|Experimental|Intervention Group|Those randomized to the Intervention group will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit.
89166052|NCT00670280|Active Comparator|UC Group|Those randomized to the Usual Care group will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
89166053|NCT00670280|Active Comparator|UC-RM Group|Those randomized to the Usual Care - Reduced Measurement group will receive the same information as the Usual Care group but will be measured less often (only at 6 months post-intervention).
89166054|NCT00670436|Active Comparator|A 1|paclitaxel eluting PTCA balloon (SeQuent please) after bare-metal stenting of a chronic total occlusion in a native coronary artery
89166055|NCT00670436|Active Comparator|A2|historical population of patients with a chronic total occlusion in a native coronary artery treated with the paclitaxel eluting Taxus stent (Boston Scientific)
89166056|NCT02699879||Pirfenidone|Participants will receive pirfenidone orally according to the physician discretion.
89166057|NCT00670514|Active Comparator|1 Nix Individual|High Treatment Intensity
89166058|NCT00670514|Placebo Comparator|2 Fimpa dig fri|Low Treatment Intensity
89166059|NCT02699723|Experimental|Treatment (arsenic trioxide, itraconazole)|Patients receive arsenic trioxide PO and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
89166060|NCT02629874|Active Comparator|EA-230 (30mg/kg)|Subjects will receive EA-230, 30 mg/kg
89166061|NCT02629874|Active Comparator|EA-230 (90mg/kg)|Subjects will receive EA-230, 90 mg/kg
88804637|NCT02856594|Experimental|Dexmedetomidine-induced sleep|Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
88804638|NCT02856594|Placebo Comparator|Placebo|Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.
89166062|NCT02629874|Active Comparator|EA-230 (180mg/kg)|Subjects will receive EA-230, 180 mg/kg
89166063|NCT02629874|Placebo Comparator|Placebo|subjects receive placebo
89166064|NCT00504595|Experimental|ACZ885|"Healthy Volunteers: Single administration of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1, Day 15, and Day 43."
89166065|NCT00504595|Placebo Comparator|Placebo|"Healthy Volunteers: Single administration of 600 mg of Placebo Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of Placebo Intravenous (IV) on Day 1, Day 15, and Day 43."
89166066|NCT02699645|Experimental|Triple Pill (active treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
89166067|NCT02699645|Placebo Comparator|Placebo|received via blinded study capsules
89166068|NCT00673322|Experimental|Gene Modified T Cells|Modified T cells
89166069|NCT04152434||Reduction in monthly migraine days all cohorts at 4 months|Migraineurs with 15-30 headache days per month at baseline were clustered in 3 categories. Failure of Erenumab was defined as no improvement in the frequency of monthly headache days. Group I: no preventive therapy, prior to the start of Erenumab. (No botox cohort). Group II: on Botulinum Toxin A (Botox), prior to the add on therapy with Erenumab. (Botox cohort).Group III: on an oral preventive drug, prior to the add on therapy with Erenumab. (No Botox cohort)
89166070|NCT04152434||Selection of elegible paitients|A total of 158 patients were involved in this study. 118 patients (75%), received Erenumab 140 mg., and 40 patients (25%) received 70 mg. In the Botox cohort, of 650 patients, 90 (13%) patients were eligible. In the no Botox cohort, 533 patients, 83 (15%) patients were eligible.
89166071|NCT04152434||Rate of adverse events related to Erenumab|72 adverse events were experienced during the 4 months of treatment, mostly with the 140 mg. dose. The most frequent were: constipation 34%, fatigue 19%, itching 7.5%, muscle cramps 6.3%, increased headache 4.4%, rhinitis 4.4%, injection site discomfort 3.7%, lack of energy 3.1%
89166072|NCT02822521|Experimental|Mobile Application + Population Manager|This arm of the study will contain half the study population after randomization. The participants in this arm will receive the mobile application with daily questions after the first visit. A population manager will review patient-reported symptoms via a web-base dashboard and contact the subject based on pre-specified guidelines.
89166073|NCT02822521|No Intervention|No Mobile Application|This arm of the study will contain half the study population after randomization. The participants in this arm will not receive the mobile application after the first visit. Although participants will be provided with the contact information of a study staff member, there will be no active contact with the subject unless he/she initiates.
89166074|NCT00911846||Buprenorphine|opioid-dependent patients with buprenorphine substitution
89166075|NCT00911846||methadone|opioid-dependent patients substituted with methadone
89166076|NCT00911846||no substitution|opioid-dependent patients without substitution
89166077|NCT00911846||therapists|therapists of the patients
89166078|NCT00615797|Experimental|1|Group randomized to receive intravenous immunoglobulins in addition to standard therapy for sydenham's chorea
89166079|NCT00615797|Placebo Comparator|2|Group randomized to receive standard intervention for sydenham's chorea alone
89166080|NCT02700113||ASD|There is only one group; minimally verbal individuals with Autism Spectrum Disorder aged 4 to 17 years.
89166081|NCT02631200|Experimental|Advance care plan|Participants will be offered the opportunity to complete an advance care plan.
89166082|NCT02631200|No Intervention|Usual care|Participants will be offered usual care for 12 weeks (and only then be offered the opportunity to complete an advance care plan).
89166083|NCT05324813|Experimental|Domain-Specific Episodic Future Thinking|
89166084|NCT05324813|Active Comparator|Episodic Recent Thinking Control Condition|
89166085|NCT00513409|Experimental|Synflorix Booster Group|Subjects previously primed with Synflorix™ and receiving in the current study Havrix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
89166086|NCT00513409|Experimental|Synflorix Catch-up Group|Subjects previously primed with Havrix™ co-administered with Infanrix™ hexa and receiving in the current study Synflorix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
89166087|NCT02629640||Research Participants|Medical history questionnaire; clinical assessment and review; participant follow-up; blood or buccal sample; post mortem examination.
89166088|NCT03150095|Experimental|Health coaching|Patients will work with a health coach to improve self-management skills
89166089|NCT03150095|No Intervention|Control|Patients will receive usual pre-transplant education to improve self-management skills
89166090|NCT00705016|Experimental|Cilengitide 2000 mg once weekly+Cetuximab+5-FU+Cisplatin|
89166091|NCT00705016|Experimental|Cilengitide 2000 mg twice weekly+Cetuximab+5-FU+Cisplatin|
89166092|NCT00705016|Active Comparator|Cetuximab+5-FU+Cisplatin|
89166093|NCT02794805|Experimental|HCC positive|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
89166094|NCT02794805|Experimental|HCC negative|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
89166095|NCT00595868|Experimental|Varenicline|
89166096|NCT00595868|Placebo Comparator|Placebo|
89166097|NCT02699801|Active Comparator|Propofol|Patients received propofol for post-operative sedation
89166098|NCT02699801|Active Comparator|Dexmedetomidine|Patients received dexmedetomidine for post-operative sedation
89166099|NCT02727907|Experimental|BCD-033|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
89166100|NCT02727907|Active Comparator|Rebif|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage
89166101|NCT02727907|Placebo Comparator|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage
89166102|NCT00663650|Active Comparator|1|Permanent Section Control
89166103|NCT00663650|Active Comparator|2|Frozen Section Control
89166104|NCT02699567||Lean AA|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
89166105|NCT02699567||Obese AA|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
89166106|NCT02699567||Lean GG|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
89166107|NCT02699567||Obese GG|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
89166108|NCT00663728|Experimental|Arm 1|
89166109|NCT00663728|Placebo Comparator|Arm 2|
89166110|NCT02699333||Microscopic colitis cases|Patients found to have microscopic colitis based on colonic biopsies.
89166111|NCT02699333||Controls|Patients who meet eligibility requirements but do not have microscopic colitis on biopsy.
89166112|NCT01009801|Active Comparator|Arm I|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
89166113|NCT01009801|Experimental|Arm II|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
89166114|NCT00670826|Experimental|1|Use of the Dynatherm Medical vitalHEAT vH2 Temperature Management System to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
89166115|NCT00670826|Active Comparator|2|Use of the Arizant Healthcare Bair Hugger Temperature Management System & Bair Hugger Upper Body Blanket to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
89166116|NCT00617045|Experimental|Duloxetine|type of experimental agent
89166117|NCT02629718|Experimental|A(NACT)|Neoadjuvant Chemotherapy followed by Radical Surgery
89166118|NCT02629718|Active Comparator|B(RS)|Radical Surgery alone
89166119|NCT01009879|Experimental|Etanercept|
89166120|NCT01009957|Experimental|Everolimus|Everolimus + standard therapy for CKD
89166121|NCT01009957|No Intervention|Control|Standard therapy for CKD
89166122|NCT00670904|Active Comparator|1|Pharmacist-delivered group program for smoking cession.
89166123|NCT00670904|Placebo Comparator|2|Brief standard care session for tobacco smoking cessation delivered over the telephone.
89166124|NCT04214795||Infants born after a complete course of antenatal steroids.|Preterm Infants born with less than 32 w GA whose mothers had received a complete course (two doses of celestone in the period between 24 hours and 7 days before delivery.
89166125|NCT04214795||Infants born without a complete course of antenatal steroids|Preterm Infants born with less than 32 w GA whose mothers did not received any dose of celestone or an uncompleted course (less than 24 hours or more than 7 days from delivery).
89166126|NCT01010035||type 2 diabetes|patients with diagnosis of Type 2 diabetes mellitus
89166127|NCT01010035||Control|non type 2 diabetes mellitus
89166128|NCT02629172||Chronic infection of hepatitis C virus (HCV) Genotype 1 (GT1)|Participants with confirmed chronic hepatitis C genotype 1, receiving paritaprevir/ritonavir/ombitasvir according to standard of care and in line with the current local label
89166129|NCT04062136|Experimental|Stem cell transplantation|1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation
89166130|NCT03996733|Active Comparator|GControl|Participants will attend the lecture for 30 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.
89166131|NCT03996733|Experimental|GModel|"Participants will attend the lecture for 30 minutes and watch a demo video showing the procedure. Later, they will practice ultrasound imaging of right jugular vein on a real human subject.~Participants in this group will also practice jugular vein puncture on our homemade jugular central venous catheterization training model."
89166132|NCT04213625|No Intervention|Control Group|Information sheet with only their surgeon's educational background.
89166133|NCT04213625|Experimental|Intervention|Experimental group will receive an information sheet with their surgeon's educational and personal background.
89166134|NCT04062370|Experimental|1+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 1 time ( month 1), and then IVR is required if central macular thickness (CMT) greater than 300 μm during the follow-up observation (Pro re nata, PRN, means if necessary).~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
89166135|NCT04062370|Active Comparator|3+PRN|"Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 3 consecutive times ( months 1, 2 and 3 ),and then IVR is required if CMT greater than 300 μm during the follow-up observation (PRN).~After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN.~IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6.~Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm."
89166136|NCT01015183|Experimental|Intervention|Received Zinc Sulfate
89166137|NCT01015183|Placebo Comparator|Control|Control group
89166138|NCT01013077|Experimental|Optive|Commercial drop.
89166139|NCT01013077|Experimental|Soothe|Commercial drop.
89166140|NCT01013077|Experimental|New Emulsion|New formulation.
89166141|NCT02566954|Experimental|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
89166142|NCT05297981|Experimental|Group E|Erector spinae plane block
89166143|NCT05297981|Experimental|Group Q|Quadratus lumborum block
89166144|NCT00856284|Experimental|Metformin + Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
89166145|NCT00856284|Experimental|Metformin + Alogliptin 25 mg|Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
89166146|NCT00856284|Active Comparator|Metformin + Glipizide|Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.
89166147|NCT04212377|Experimental|exploratory|single arm exploratory, single-centre study
89166148|NCT00510289|Experimental|all patients|sorafenib
89166149|NCT04062682|No Intervention|Controls|No changes in dietary habits
89166150|NCT04062682|Experimental|Healthy Diet|Changes in dietary habits only
89166151|NCT00618761|Experimental|1|kidney-pancreas recipients
89166152|NCT00618761|Active Comparator|2|kidney recipients
89166153|NCT00618761|Active Comparator|3|healthy controls
89166154|NCT00618761|Active Comparator|4|beta-cell recipients
89166155|NCT01013233|Experimental|training|Patients in this group start the cognitive training over 6 weeks directly after randomization.
89166156|NCT01013233|Placebo Comparator|control|In this control group begin the training in a cross-over design 7 weeks after randomization.
89166157|NCT00921076|Active Comparator|Ankle Arthoplasty|Patients will undergo a Total Ankle Replacement procedure
89166158|NCT00921076|Active Comparator|Ankle fusion|Patients will undergo an Ankle Arthrodesis procedure
89166159|NCT01013311||Cardiac Sarcoidosis|Patients with Cardiac Sarcoidosis who had an ICD implanted
89166160|NCT05490472|Experimental|JAB-2485 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-2485 will be administered as monotherapy to determine the MTD and RP2D.
89166161|NCT05490472|Experimental|JAB-2485 monotherapy, Phase 2a, Dose Expansion|JAB-2485 will be administered as monotherapy in patients with specific tumor types to evaluate the preliminary antitumor activity.
89166162|NCT00663806|Experimental|Arm 1|
89166163|NCT00663806|Experimental|Arm 2|
89166164|NCT01015261|Experimental|Bone Marrow Transplantation|
89166165|NCT01015261|Active Comparator|Chemotherapy|
89166166|NCT04155242|Experimental|Study group|As part of the post RFA treatment follow up patients will receive a Cytosponge test followed by an endoscopy with NBI magnification and biopsies. Four endoscopies will be performed during 2 years of active follow up together with up to 2 Cytosponge procedures. Molecular biomarkers including a methylation panel on DNA and immunohistochemical markers on formalin fixed paraffin embedded samples obtained during the examinations will be assessed. Patients will be then followed up for up to 3 years with standard endoscopy to assess for relapse of Barrett's oesophagus/IM/dysplasia.
89166167|NCT01015339|Active Comparator|Cisplatin plus capecitabine|
89166168|NCT01015339|Experimental|Paclitaxel plus Capecitabine|
89166169|NCT02622906|Placebo Comparator|Placebo|1 injection per month during 6 months of the placebo product
89166170|NCT02622906|Active Comparator|Pasireotide|1 injection per month during 6 months of the Pasireotide LP (60mg/injection)
89166171|NCT00673556|Experimental|Course A1|
89166172|NCT00673556|Placebo Comparator|Course A2|
89166173|NCT00673556|Experimental|Course B|Open label extension
89166174|NCT01010113|Placebo Comparator|Test formula 1|Standard formula with prebiotics
89166175|NCT01010113|Experimental|test product|Infant formula with synbiotics
89166176|NCT05101733||Alternaria allergy sufferers|50 people suffering from an allergy to Alternaria. These participants receive a questionnaire, a Skin-Prick-Test, a blood draw and nasal provocation with collection of nasal secretion
89166177|NCT05101733||Non-allergic participants|Non allergic participants (20) receive a questionnaire, a blood draw and collection of nasal secretion
89166178|NCT00699738|Experimental|1|Healthy women during pregnancy and in the postpartum period, breastfeeding
89166179|NCT00699738|Active Comparator|2|Healthy women during pregnancy and in the postpartum period,bottlefeeding
89166180|NCT00699738|No Intervention|3|Healthy non-pregnant women
89166181|NCT01010191|Experimental|Cellulose pill|The active intervention is a sugar pill.
89166182|NCT01010191|No Intervention|No treatment|The control arm is wait list control
89166183|NCT00675896|Experimental|1|Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator, using patient tolerance and response as guidelines over the duration of the trial.
89166184|NCT00675896|Placebo Comparator|2|Placebo
89166185|NCT05667688|Active Comparator|Cohort 1: 5 mg, fasted|A single dose (5 mg) of tinlarebant will be administered to each study participant on study Day 1.
89166186|NCT05667688|Active Comparator|Cohort 2: 10 mg, fasted|A single dose (10 mg) of tinlarebant will be administered to each study participant on study Day 1.
89166187|NCT04212611|Experimental|Group L|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L)
89166188|NCT04212611|Experimental|Group R|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% ropivacaine (group R).
89166189|NCT01015417|Active Comparator|Amoxicillin clavulanic acid|Postoperative administration of 2g of Augmentin, 3 times daily for 5 days.
89166190|NCT01015417|Other|No medication|no postoperative antibiotics
89166191|NCT00675974|Experimental|1|Pressure garment therapy
89166192|NCT00675974|No Intervention|2|No pressure garment therapy
89166193|NCT04061824|Experimental|Patients with fixed-dose combination of 2 drugs|Medication for hypertension and dyslipidemia in these group was fixed-dose combination of 2 drugs
89166194|NCT04061824|Active Comparator|Patients with 2 separated drugs|Medication for hypertension and dyslipidemia in these group was 2 separated drugs for each disease.
89166195|NCT04212533|Active Comparator|supplementation arm|43 patients undergoing total thyroidectomy received 40000 IU vit D and once before operation and 500mg calcium tab 4 times in the day before surgery
89166196|NCT04212533|Active Comparator|non-supplementation arm|43 patients undergoing total thyroidectomy received rice starch tablets /6 hrs in the day before surgery
89166197|NCT04155554|Experimental|Bictegravir/emtricitabine/tenofovir alafenamide|Patients with suppressed viral load switching from dolutegravur/lamivudina/abacavir (50/300/600 mg) 1 tablet OD to bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) 1 tablet OD
89166198|NCT04155554|Active Comparator|Dolutegravir/lamivudine/abacavir|Patients with suppressed viral load continuing dolutegravir/lamivudine/abacavir (50/300/600 mg) 1 tablet OD
89166199|NCT04212299|Experimental|Baseline ischial containment to subischial socket|
89166200|NCT00663884|Experimental|M|Mitiglinide
89166201|NCT00663884|Active Comparator|V|Voglibose
89166202|NCT05324189||More than mild (mtm) Diabetic Retinopathy (DR) Not Detected or Non referable DR|More than mild Diabetic Retinopathy (mtm DR) not detected or non referable DR using the iPredict's AI-based DR screening software utilizing color fundus imaging.
89166203|NCT05324189||More than mild (mtm) Diabetic Retinopathy (DR) Detected or Referable DR|More than mild Diabetic Retinopathy (mtm DR), moderate to severe DR detected, non proliferative DR detected, proliferative DR detected or referable DR using the iPredict's AI-based DR screening software utilizing color fundus imaging.
89166204|NCT00492115|Active Comparator|"therapeutic CPAP Treatment (6 weeks)"|Intervention - The active comparator is an intervention of nightly therapeutic CPAP (continuous positive airway pressure) treatment for 6 weeks. Patients will use CPAP every night for the full duration of the study, i.e., 6 weeks
89166205|NCT00492115|Placebo Comparator|"Sham CPAP/therapetuic CPAP (6 weeks)"|"The placebo comparator is an intervention of placebo CPAP (continuous positive airway pressure) nightly for 3 weeks followed by therapeutic CPAP treatment nightly for 3 weeks.~Patients will use a sham CPAP (no real pressure) for 3 weeks and then will be switched to real CPAP for 3 weeks."
89166206|NCT05347030|Experimental|Acupuncture Group|"The acupuncture points are: EX-B3, BL18, BL20, BL21, GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40, SP6.~After piercing 15-35mm into the skin, the needles will be gently rotated and lifted three times to achieve a sense of sourness, distention, and heaviness (de qi). For EX-B3, BL18, BL20, and BL21, withdrawn afterward immediately. For GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40 and SP6, The needles will be maintained for 30 minutes."
89166207|NCT05347030|Sham Comparator|Sham Acupuncture Group|"sham acupoints are located at a horizontal distance of 20 mm to those points used in the acupuncture group, and no manipulation was carried out after piercing the skin for 1-2mm to avoid de-qi sensation.~For sham EX-B3, BL18, BL20, and BL21, withdraw immediately after piercing. For sham GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40 and SP6, The needles will be maintained for 30 minutes after puncture."
89166208|NCT00673634|Active Comparator|1|Standard preoxygenation
89166209|NCT00673634|Active Comparator|2|BiPAP assisted preoxygenation
89166210|NCT05324111|Experimental|12 Lead ECG|Application of hand held electrocardio gram
89166211|NCT00856206|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
89166212|NCT00856206|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
89166213|NCT03997279|Experimental|S.boulardi|Quadruple eradication therapy with S. boulardi
89166214|NCT03997279|Placebo Comparator|Placebo|Quadruple eradication therapy without S. boulardi
89166215|NCT04214171||group 2 years|The group underwent total hip arthroplasty at 2 years
89166216|NCT04214171||group 5 years|The group underwent total hip arthroplasty at 5 years
89166217|NCT04214171||group 10 years|The group underwent total hip arthroplasty at 10 years
89166218|NCT04214171||group control|healthy patients
89166219|NCT00664118|Active Comparator|1|Doula combined epidural analgesia in the latent phase of first stage of labor
89166220|NCT00664118|Sham Comparator|2|Epidural analgesia in the latent phase of the first stage of labor without doula accompany
89166221|NCT01013389|Experimental|Actifuse ABX|Actifuse ABX bone substitute
89166222|NCT01013389|Active Comparator|INFUSE, plus master granules (MGG)|synthetic bone substitute used in posterolateral instrumented lumber fusion with interbody fusion
89166223|NCT05323877|Experimental|Investigational Device Arm (PerQseal+)|Large hole percutaneous arterial closure device - PerQseal+
89166224|NCT02629328|Other|CardioCel|Treatment with CardioCel implant
89166225|NCT05641714||multiple sclerosis|Patients with Multiple Sclerosis
89166226|NCT05641714||healthy controls|healthy controls
89166227|NCT01013467|Active Comparator|color coded bloodpressure booklet|
89166228|NCT00673868|Experimental|1|
89166229|NCT00673868|No Intervention|2|
89166230|NCT00920998|Experimental|1. Z-338|3-way cross-over study (drug administration 3-times in fasted and 2 fed conditions)
89166231|NCT01010269|Active Comparator|Vanguard Complete Knee|Vanguard Completed Knee with Microplasty Tibial Tray is designed to hold the tibial knee bearings in a microplsty knee procedure. The Co-Cro-Mo trays are designed with a shorter stem.
89166232|NCT01010269|Active Comparator|Vanguard High Flex RP|VGRD High Flex RP knee is an extension to the exsting Vanguard Knee and has been specifically desinged to facilitate greather than 135 degrees of knee flextion as required by certain patients.
89166233|NCT04152044||Liver biopsy, Visceral and subcutaneous obesity|Those with histology and LFT's and quantificaiton of obesity
89166234|NCT00593112|Experimental|OROS Methylphenidate|
89166235|NCT00593112|Other|Control|Healthy Volunteer Control group
89166236|NCT05323565|Active Comparator|Group A (n=15): (Dexamethasone group)|Patients will receive 20 ml 0.25% bupivacaine plus 4 mg dexamethasone on each side TAB bock.
89166237|NCT05323565|Active Comparator|Group B (n=15): (Dexmedetomidine group)|Patients will receive 20 ml 0.25% bupivacaine plus 0.5 mcg/kg of dexmedetomidine on each side TAB block.
89166238|NCT05323565|Sham Comparator|Group C (n=15): (control group)|Patients will receive 20 ml 0.25% bupivacaine on each side TAB block.
89166239|NCT01015495|Experimental|ranibizumab|
89166240|NCT05320354||Patients suspected of PJI|Adult patients, both male and female, scheduled for a puncture or surgery of their prosthetic joint due to suspected PJI.
89166241|NCT04188275||Metastatic Castration Resistant Prostate Cancer|Metastatic Castration Resistant Prostate Cancer patients who are eligible for endocrine therapy with ARTA plus LHRH agonist.
89166242|NCT00699894|Experimental|1|aprepitant 40 mg + normal saline IV
89166243|NCT00699894|Active Comparator|2|placebo PO + ondansetron 4 mg IV
89166244|NCT01010347|Active Comparator|Splint|Preformed velcro volar splints are compared to traditional circumferential casting.
89166245|NCT01010347|Placebo Comparator|Cast|The circumferential cast is the standard of treatment against which the splint is compared.
89166246|NCT00676442|Other|1|PN400 administered after meal
89166247|NCT00676442|Other|2|PN400 administered prior to meal
89166248|NCT00676442|Other|3|PN400 administered prior to meal
89166249|NCT00676442|Other|4|PN400 followed by fast
89166250|NCT02595281|Experimental|Study arm|
89166251|NCT00698490|Experimental|Group A|HSV-seronegative subjects
89166252|NCT00698490|Experimental|Group B|HSV-seropositive subjects
89166253|NCT00698490|Experimental|Group C|HSV-seronegative subjects
89166254|NCT00698490|Experimental|Group D|HSV-seronegative subjects
89166255|NCT00698490|Experimental|Group E|HSV-seronegative subjects
89166256|NCT00664196|Experimental|1|
89166257|NCT05535010|Experimental|Those with active trigger points before TFESI|Transforaminal epidural steroid injection
89166258|NCT05535010|Active Comparator|Those who do not have an active trigger point before TFESI|Transforaminal epidural steroid injection
89166259|NCT04544761||1-5 Years post|Persons with Spinal Cord Injury occurring between 1-5 years prior
89166260|NCT04544761||5-15 Years post|Persons with Spinal Cord Injury occurring between 5-15 years prior
89166261|NCT04544761||>15 Years post|Persons with Spinal Cord Injury occurring at least 15 years prior
89166262|NCT04128384|Other|EPS arm|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR
89166263|NCT02614248|Experimental|Coconut Oil|Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
89166264|NCT02614248|Active Comparator|Standard of Care|Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
89166265|NCT00673946|Active Comparator|1|In this arm, patients are monitored with oximeters displaying true saturation values
89166266|NCT00673946|Experimental|2|In this arm, patients are monitored with oximeters with displayed saturations 3 percentage points above true values
89166267|NCT05322863|Active Comparator|active HD-tDCS|The participants will be instructed to relax during the first 5 minutes of the session while the equipment is set up. A mild stimulation (with a level of only 2 milliamps stimulation) will be delivered for 20 minutes, with the current gradually increased and decreased over 30 seconds. The patients will be instructed to relax and remain motionless during the intervention. The administrator will closely monitor the impedance throughout each session and record any side effects experienced by the participants. The participants will be allowed 5 minutes of rest after the intervention and will be actively asked about any discomfort. Each session will last around 30 minutes, with a total of 10 sessions (two consecutive weeks of treatment for 5 days per week).
89166268|NCT05322863|Sham Comparator|sham-HD-tDCS|The procedure for sham stimulation will be identical, except that the current will be gradually ramped down to zero after the first 30 s, thus giving the same initial sensation of HD-tDCS. The stimulator will be programmed to switch the current on and off, so no intervention by the operator will be required. The computer will be placed behind the subjects' heads so they cannot see the readout.
89166269|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 1|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks for HCV genotype 1
89166270|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 2|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks for HCV genotype 2
89166271|NCT05622292|No Intervention|Control|Subjects in the control group will receive education on the day of enrolment in NCCHK. Subjects are instructed to take medications and conduct hospital visits as usual.
89166272|NCT05622292|Experimental|I-Care|"Subjects will be instructed to download the HARKIT I-Care app from the google play store on their smartphones. Then, they will be guided to create an account and explained how to use the application, including how to log their progress (laboratory parameters and exercise tracking) and how to see messages from their physician. All follow-ups regarding treatment progress, education, and reminders will be done through the app. Patients are directed to conduct hospital visits once per month, where patients will be prescribed cardiovascular medications according to their current condition."
89166273|NCT04155476|Experimental|Nitroglycerin exposure|
89166274|NCT04155476|Placebo Comparator|Non-Nitroglycerin exposure|
89166275|NCT00921232|Other|dyad|life-ending patient and its caregiver
89166276|NCT00664274|Other|CRT Group|
89166277|NCT00674102|Experimental|ASA404|
89166278|NCT00503581|Experimental|Regimen 1 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily every day for 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after completing the megestrol treatment.
89166279|NCT00503581|Experimental|Regimen 2 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily for two weeks continuously followed by no treatment for two weeks. This course is repeated for a total of 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after the megestrol treatment.
89166280|NCT00503581|Active Comparator|Regimen 3 (surgery/biopsy)|(Closed as of 6/3/2010) Patients do not receive megestrol. At the discretion of the managing physician, patients undergo the re-evaluation biopsy and hysterectomy anytime between 2-20 weeks after enrollment and randomization.
89166281|NCT00676988||Observation|Subjects with Luminal Crohn's Disease receiving infliximab
89166282|NCT00677066|Experimental|1|Children discharged home with oxygen
89166283|NCT00677066|No Intervention|2|Children remain in hospital for oxygen therapy
89166284|NCT05614258|Experimental|ADG206 dose escalation|
89166285|NCT00677144|Experimental|OS (oxalipaltin+S-1)|OS (oxaliplatin + S-1): Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
89166286|NCT00677144|Active Comparator|XELOX (oxalipaltin+capecitabine)|XELOX (oxalipaltin+capecitabine): Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
89166287|NCT04151654|Other|assessment1|İt is assessment study. Assessment1 was evaluated for all test with and without footwear.
89166288|NCT00664352|Experimental|1|
89166289|NCT00664352|Experimental|2|
89166290|NCT00664352|Experimental|3|
89166291|NCT00664352|Experimental|4|
89166292|NCT00664352|Other|5|
89166293|NCT04151810|Experimental|anti-EGFR monoclonal antibody|"Single-dose Phase:This is a dose-escalation trial, all participants will receive treatment with CDP1. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.~Cohort 1:400mg/m2;Cohort 2: 500mg/m2;Cohort 3: 750mg/m2;~Multi-dose Phase:Multiple administrations of three Cohorts of subjects were followed by continuous administration of CDP1."
89166294|NCT00703534|Experimental|AZD3355|
89166295|NCT00703534|Placebo Comparator|Placebo|
89166296|NCT00503425|Experimental|1|
88804639|NCT04232215|Experimental|HeraBEAT™ Intervention Group|Subjects will monitor their fetal heart beat once weekly using the HeraBEAT™ device. After approximately 8 weeks of monitoring subjects will crossover to using the doppler fetal heart rate monitor
89166297|NCT00674180||1|a workbook alone
89166298|NCT00674180||2|a workbook alone and the addition of computerized tailoring using onsite computer kiosks with touch screen monitors
89166299|NCT00674180||3|a workbook, the addition of computerized tailoring using onsite computer kiosks with touch screen monitors, and staff consultations.
89166300|NCT01013545|Experimental|JAE-EMT|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. This intervention condition uses spoken language as the mode of communication. Individual, single word targets will be selected based on the child's level of language production and specific interests. The targets are systematically modeled in response to child actions and attention during play. A sequence of milieu teaching prompts will also be used to elicit targets from the child when use of the target language is functional for the child.
89166301|NCT01013545|Experimental|JAE-AAC|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. The mode of communication introduced in this intervention condition is a developmentally chosen augmentative communication device. These devices are provided with a set of individually selected visual-graphic symbols and a relevant lexicon. The use of the device is taught within natural communicative exchanges within play routines and daily activities.
89166302|NCT00674258|Experimental|B|
89166303|NCT05598736|Experimental|Investigational device|FlowOx 2.0 (-40mmHg intermittent negative pressure)
89166304|NCT00677222|Experimental|1|Treatment arm
89166305|NCT00677222|No Intervention|2|Registry Arm -standard of care
89166306|NCT00863772|Experimental|Tanezumab 5 mg|
89166307|NCT00863772|Experimental|Tanezumab 10 mg|
89166308|NCT00863772|Placebo Comparator|Placebo|
89166309|NCT01015573|Experimental|healthy subjects|
89166310|NCT01010425|Experimental|ACP-001, dose-level 1|
89166311|NCT01010425|Experimental|ACP-001, dose-level 2|
89166312|NCT01010425|Experimental|ACP-001, dose-level 3|
89166313|NCT01010425|Experimental|ACP-001, dose-level 4|
89166314|NCT00912236||1|BMI 20-25 kg/m2
89166315|NCT00912236||2|BMI > 30 kg/m2 with low TG (<150) and normal HDL (>50 for females, >40 for males)
89166316|NCT00912236||3|BMI > 30 kg/m2 with high TG (>150) and low HDL (<50 for females, <40 for males)
89166317|NCT00677300|Experimental|Group A|Will receive Raltegravir (400mg twice daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
89166318|NCT00677300|Active Comparator|Group B|Will receive Tenofovir (300mg once daily) + Emtricitabine (200mg once daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
89166319|NCT01013623|Active Comparator|Best Medical Therapy|The best medical therapy group will not initially undergo surgery, but will be treated with the therapy that medical oncologists or surgeons feel is best for the patient. This treatment may include standard or experimental therapies.
89166320|NCT01013623|Active Comparator|Surgery Alone|The surgery alone group will undergo complete resection (surgical removal) of all known disease, if possible. After surgery, patients will be followed regularly and monitored for disease recurrence.
89166321|NCT01013623|Active Comparator|Surgery + BCG|The Surgery + BCG group will first have a complete resection (surgical removal) of all known disease, if possible. After recovery from surgery, two doses of BCG will be given two weeks apart. Each dose is given as 8 separate injections into the skin (called intradermal injections).
89166322|NCT05293678|Experimental|Lower IV Dose|Randomized 3:1
89166323|NCT05293678|Experimental|Mid IV Dose 1|Randomized 3:1
89166324|NCT05293678|Experimental|Mid IV Dose 2|Randomized 3:1
89166325|NCT05293678|Experimental|Higher IV Dose|Randomized 3:1
89166326|NCT05293678|Experimental|Lower SC Dose|Randomized 3:1
89166327|NCT05293678|Experimental|Mid SC Dose|Randomized 3:1
89166328|NCT05293678|Experimental|Higher SC Dose|Randomized 3:1
89166329|NCT00677378||EXPERIMENTAL|Children undergoing an endoscopy for retrosternal chest pain, epigastric pain, regurgitation, heart burn or dyspepsia.
89166330|NCT00677378||CONTROL|Children undergoing an endoscopy for reasons not stated in the experimental group condition (i.e. celiac disease, rectal bleeding, polyps, weight loss, malabsorption).
89166331|NCT01565317|Experimental|Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
89166332|NCT01565317|No Intervention|Control Group|Matched control group will be recruited from obese patients with diabetes followed at Joslin Clinic. This group will receive the routine standard diabetes care.
89166333|NCT00674336|Experimental|Shellfish with Norovirus|We dosed shellfish with Norovirus and challenged human volunteers with Shellfish that had norovirus
89166334|NCT02628392|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule
89166335|NCT02628392|Experimental|DS-8500a 50 mg QD|DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
89166336|NCT02628392|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
89166337|NCT02628392|Placebo Comparator|placebo|placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.
89166338|NCT02628392|Active Comparator|Sitagliptin|capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet
89166339|NCT02622750|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
89166340|NCT02622750|Active Comparator|four-branched Dacron graft|"A four-branched Dacron graft (Boston Scientific Inc, Boston, MA) and a stent graft (MicroPort Medical Co Ltd, Shanghai, China) were used in total arch replacement combined with stented elephant trunk (SET) implantation.The SET was inserted into the true lumen of the descending aorta.The proximal edge of the residual aorta was trimmed to match the proximal end of the stent graft.The anastomosis between the four-branched prosthetic graft and the distal aorta containing the intraluminal stented graft was carried out using open aortic technique."
89166341|NCT00664586|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) will be administered as an intravenous infusion over 24 hours, weekly. Dose will commence in the first cohort with 100 mg per hour (2400 mg in a 24 hour period)with escalation in the 5 cohorts of 3 to 6 patients with increments of 25 mg per hour to a maximum of 200 mg/hr (4800 mg/24 hour period) or until MTD is defined. When the MTD has been declared, then 11 additional subjects will be enrolled at the MTD dose level (to total 14 subjects treated in dosage cohort).
89166342|NCT02628782|Experimental|InSeal VCD|InSeal's Vascular Closure Device Use of the experimental VCD to close the access site of the artery
89166343|NCT02614092|Experimental|Water based Activity+ Cognitive Training|water-based physical activity + classroom based cognitive training
89166344|NCT00502801|Experimental|Doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
89166345|NCT04154852|Experimental|TNF-antagonist|Adalimumab, 40 mg, 2-weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
89166346|NCT04154852|Active Comparator|Placebo + MTX|Placebo, 2 weekly Methotrexate, rapid escalation to 25mg, weekly Folic Acid 5mg, 6 days a week
89166347|NCT00677456|Active Comparator|1|Patients will receive R-Y reconstruction after total gastrectomy as intervention
89166348|NCT00677456|Active Comparator|2|Patients will receive P-Y reconstruction after total gastrectomy as intervention
89166349|NCT00677456|Active Comparator|3|Patients will receive Pouch reconstruction after total gastrectomy as intervention.
89166350|NCT00677456|Active Comparator|4|Patients will receive P-I reconstruction after total gastrectomy as intervention.
89166351|NCT04127448|Experimental|Exergaming Training Group|Training was given using X-box 360 Kinect.
89166352|NCT04127448|Active Comparator|Aerobic Exercise Group|Session using treadmill (model no TMX58 220).
89166353|NCT00664820|Experimental|Treatment group|Will receive two Urex-CAP-5 (probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14) capsules daily for 3 months.
89166354|NCT00921154|Experimental|Ivermectin|Ivermectin
89166355|NCT04126902||late-onset preeclampsia|The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria (urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case these values exceeded this level, it was accepted as severe. The study population consisted of 50 late-onset preeclampsia patients as study group and 50 patients with normal pregnancies as control group.
89166356|NCT04126902||Control|The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
89166357|NCT01015651|Active Comparator|remifentanil-2|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 2 ng/ml.
89166358|NCT01015651|Active Comparator|remifentanil-4|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 4 ng/ml.
89166359|NCT00677612|Experimental|A|
89166360|NCT04127136|Experimental|Study Group|The cases were analyzed for the change in the severity of binge eating disorder in the program. The data collection was performed via socio-demographic information form, binge eating disorder evaluation (BEDE) form, and progress record forms. BEDE was a structured form exclusively using DSM-5 BED diagnosis and the severity criteria. Progress record form included weekly session content that was administered by a physician, dietitian, psychologist, and the physiotherapist and the monthly individual meetings data. BEDE and progress record forms were applied before the trainings that focuses on cognitive change and repeated every four weeks for 20 weeks. The patients were planned to receive 80 hours of training by the physician, dietitian, psychologist, and the physiotherapist.
89166361|NCT00677768||Early ALS|
89166362|NCT00677768||Suspected ALS|
89166363|NCT00677768||Disease Mimics of ALS|
89166364|NCT00677768||Healthy Controls|
89166365|NCT04118478|Experimental|Multi-component phased training program|"The intervention of the program consists of conducting a multi-component training in a neighborhood unit.~The intervention will consist of the realization of a multi-component program in a training center adapted for the elderly. The duration of the program will be 27 weeks with a frequency of two weekly sessions and an intervention duration of 45 to 60 minutes"
89166366|NCT04118478|No Intervention|CONTROL|Older people assigned to the GC do not do any training programming. Only attend the measurement dates.
89166367|NCT00674414|Active Comparator|Arm I|Patients receive trastuzumab (Herceptin®) IV once weekly for 6 weeks. Patients then undergo surgery.
89166368|NCT00674414|Experimental|Arm II|Patients receive trastuzumab as in arm I and oral everolimus once daily for 6 weeks. Within 24 hours after completing everolimus, patients undergo surgery.
89166369|NCT02613390|Experimental|MRI-Based Image Guidance|"MRI images of the spine taken of anesthetized participant in the operative prone position. These images are exported into a computer navigation program, and used to help the doctor perform surgery.~Pain and symptom questionnaires completed at baseline and at follow up."
89166370|NCT02566876|Active Comparator|Mixture of three Bifidobacteria|Patients were administered 1 sachet per day of a mixture of three Bifidobacteria (namely, 3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®) for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
89166371|NCT02566876|Placebo Comparator|Placebo|Patients were administered 1 sachet per day of placebo for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
89166372|NCT00674648|Experimental|1|This is a non-randomized single institution phase I dose escalation trial, designed to evaluate the toxicity and anti-viral activity of CMV-pp65 peptide-specific T cell lines, generated in vitro from CMV seropositive normal HSCT and 3rd party donors, when adoptively transferred to treat recipients of these transplants who have a CMV infection or persistent CMV antigenemia and are therefore at high risk of a life-threatening CMV infection.
89166373|NCT04063072|No Intervention|Usual care|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to current hospital clinical practice.
89166374|NCT04063072|Experimental|ERAS protocol|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to ERAS protocol.
89166375|NCT00824265|Experimental|Ofatumumab, Fludarabine, Cyclophosphamide|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
89166376|NCT00824265|Active Comparator|Fludarabine, Cyclophosphamide|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
89166377|NCT00677846||3|Patients with symptoms of deep venous thrombosis less than for 2 weeks, with thrombus occluding without any reperfusion in color mode in the common femoral vein (CFV), the femoral vein (FV) or the popliteal vein (PV)
89166378|NCT04155086|Experimental|Exposed group (patient with an autoimmunise disease)|Any patient with an autoimmune disease followed at one of the 14 centres who wants to be screened for T21.
89166379|NCT04155086|Other|Non Exposed group (patient without an autoimmunise disease)|
89166380|NCT02628470|Experimental|group cervical manipulation|The patient is supine without a pillow and physiotherapist standing in the ipsilateral corner of the hand of the thrust.
89166381|NCT02628470|Placebo Comparator|Placebo group|Participants will receive a protocol of domiciliary cervical control exercises.
89166382|NCT02628470|Active Comparator|Group cervical mobilization|Oscillatory mobilization technique. With the patient in prone, the investigator applies an oscillatory motion in the most painful cervical segment for three minutes
89166383|NCT00855894|Experimental|Pertuzumab + erlotinib|Patients received pertuzumab 840 mg intravenously (IV) 1 time (loading dose) followed by 420 mg IV (maintenance dose) every 3 weeks (q3w) plus erlotinib 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
89166384|NCT02566096|Placebo Comparator|TAP with bupivicaine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
89166385|NCT02566096|Active Comparator|TAP with bupivicaine with morphine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
89166386|NCT00678002||QOL###|All child subjects in this cohort will be listed for or already have received a solid organ transplant (kidney, heart, or liver).
89166387|NCT02622594|Active Comparator|1|Treatment 1 will include microneedling performed prior to ALA application to their right face and ALA application only to the left face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
89166388|NCT02622594|Active Comparator|2|Treatment 2 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
89166389|NCT02622594|Active Comparator|3|Treatment 3 will include microneedling performed prior to ALA application to their right face and ALA application only to the left side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
89166390|NCT02622594|Active Comparator|4|Treatment 4 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
89166391|NCT02628860|Experimental|Ferinject|"Ferinject to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .~Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® must be diluted only in sterile 0.9% sodium chloride.~Strength/Packaging: 10 mL vials containing 500 mg iron as iron per vial."
89166392|NCT04874272|No Intervention|Pre-Intervention|Pre-intervention: participants complete research surveys about codes and are asked to participate in an interview with the research team.
89166393|NCT04874272|Experimental|Pilot (Single Unit Recruitment)|Pilot intervention: participants participate in a chaplain led post-code debrief, participants complete research surveys about codes.
89166394|NCT04874272|Experimental|Pilot (Hospital-wide Recruitment)|Pilot intervention: participants participate in a chaplain led post-code debrief, participants complete research surveys about codes.
89166395|NCT00674726||Group I|Patients with acute appendicitis
89166396|NCT00674726||Group II|Patients with acute gastroenteritis
89166397|NCT00855816|Experimental|Breathing training|relaxation training
89166398|NCT00855816|No Intervention|Treatment as usual|treatment as usual
89166399|NCT04061668|Other|single needle path PECS I and II block group(|The probe is placed inferior to the clavicle . A probe and needle is introduced with in-plane technique . The US is placed below outer third of the clavicle showing pectoralis major and minor muscles then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles is visualised . The US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle is inserted from caudal to cranial using an inclined manner, 15mL of bupivacaine 0.25% is put between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject 15 ml of bupivacaine in thel plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection will be visualized .
89166400|NCT04061668|Sham Comparator|double needle path PECS I and II block group|The probe will be placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles are visualised, then the needle is inserted in plane with probe and 15mL of bupivacaine are put into between pectoralis muscles. In the second puncture , the US probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles are identified , the needle will be inserted in plane with the probe from caudal to cranial , 15mL of bupivacaine will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
89166401|NCT00708357|Other|1|homozygous mutant: CC allele of the eNOS T-786C gene
89166402|NCT00708357|Other|2|homozygous mutant: TT allele of the eNOS T-786C gene
89166403|NCT00664976|Experimental|1|Electroconvulsive therapy
89166404|NCT00664976|Active Comparator|2|Treatment as usual
89166405|NCT00855738|Other|1.0|
89166406|NCT02628002|Experimental|Test arm|The subjects randomized to the anti-gravity treadmill arm will be instructed on the safe use of the Alter-G treadmill by the study staff. After this instruction, subjects will be exercised on the Alter-G anti-gravity treadmill using the conventional Bruce protocol with unweighting to 75% of their body weight to reach target heart rate. If the subject is unable to reach the target heart rate, they will be further unweighted to 50% of their body weight to enable the subject to reach target heart rate on the Bruce protocol. If the subject is still unable to reach target heart rate with 50% unweighting, the patient's subsequent SPECT images will be excluded from use in the research comparison to control subject images.
89166407|NCT02628002|Active Comparator|Control arm|The control arm subjects will undergo the conventional treadmill/regadenoson pharmacological stress SPECT. Consistent with standard practice, these patients will perform adjunctive low-intensity walk on a conventional treadmill prior to regadenoson and Tc-99m injection if tolerated.
89166408|NCT00665054|Experimental|Arm 1|
89166409|NCT00665054|Placebo Comparator|Arm 2|
89166410|NCT02566798|Experimental|Oleogrape|Patients are taking capsules of OleograpeSEED (Extract of grape and olive) 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days
89166411|NCT02566798|Placebo Comparator|Placebo|Patients are taking capsules of placebo (lactose) 3 times a day in the morning, at noon and in the evening during 7 days
89166412|NCT00674960|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
89166413|NCT02622516|Active Comparator|Intervention Group (IG)|Participants in the intervention group subjects (IG) will receive physiotherapy treatment in vestibular rehabilitation based on multisensory exercises consisting of the group of therapeutic proposals that stimulation of the vestibular, proprioceptive and visual associated with manual therapy treatment proposed by the techniques cervical global pompage and classic massage therapy on neck and shoulder girdle .
89166414|NCT02622516|Experimental|Control Group (CG)|Participants in the control group subjects (CG) will receive physiotherapy treatment in vestibular rehabilitation based on Cawthorne and Cooksey Exercises, consisting of eye movements in different directions, slowly and quickly; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.
89166415|NCT00675038||1|Study participants will be patients who are cared for by the St. Jude Hematology Division and have developed iron overload and require liver biopsy.
89166416|NCT02622672|Experimental|Placebo|glycerin.soy-lecithin, and water
89166417|NCT02622672|Experimental|Supplement|water-soluble Ubiquinol 100 mg/d
89166418|NCT04377724||ETH cohort|employees or students at ETH Zurich, Switzerland
89166419|NCT06157489|Active Comparator|Hamza|
89166420|NCT06157489|Sham Comparator|Noor mohamed|
89166421|NCT06157489|Active Comparator|Janna ahmed|
89166422|NCT06157489|Active Comparator|Hamza salah|
89166423|NCT06157489|Sham Comparator|Mohammed asel|
89166424|NCT06157489|Active Comparator|Ali ahmed|
89166425|NCT06157489|Sham Comparator|Malek Mohamed|
89166426|NCT06157489|Active Comparator|Sayed Mohamed|
89166427|NCT06157489|Active Comparator|Omar ahmed|
89166428|NCT06157489|Sham Comparator|Ahmed Mohamed|
89166429|NCT06157489|Sham Comparator|Yousef salah|
89166430|NCT06157489|Active Comparator|Rofan ahmed|
89166431|NCT06157489|Sham Comparator|Kinesio tape hasnot assigned to arm group Exercise only|
89166432|NCT06157489|Active Comparator|Fareda salah|
89166433|NCT06157489|Active Comparator|Abd elrahman ahmed|
89166434|NCT06157476|Experimental|SSC-Ex group|Children in this group received the SSC-Ex program
89166435|NCT06157476|Active Comparator|Control group|Children in this group received the standard exercise program.
89166436|NCT06157450|Experimental|Experimental: young participates|16 young participants(between 18~45 years old) will be given 600mg of ZSP1273.
89166437|NCT06157450|Experimental|Experimental:elder participates|16 elder participants(Age≥65 years old) will be given 600mg of ZSP1273.
89166438|NCT06157437|Experimental|Focal pulse ablation system|
89166439|NCT06157398|Other|Diet Intervention|Participants will be provided with a diet that has an increased intake of fish high in Omega-3 fatty acids as well as fruits and vegetables in comparison to their baseline intakes as assessed by the study dietician.
89166440|NCT06157385|Experimental|Culinary Medicine|The participants in this group will receive culinary medicine in the form of videos that will include cooking demonstrations and nutrition education based on lean beef to enhance protein intake.
89166441|NCT06157385|Other|Control|This group will only receive recipes based on lean beef to enhance protein intake.
89166442|NCT06157372||Non-Infection group|Participants received traditional etiological culture of suspected site of infection.
89166443|NCT06157372||Infection group|Participants received traditional etiological culture, metagenomic next-generation sequencing of infectious sites.
89166444|NCT06157359|No Intervention|control group|Patients in the control group will receive general anesthesia without the nerve blocks.
89166445|NCT06157359|Experimental|SNB group|Participants randomized to the SNB group will receive general anesthesia combined with SNB using 0.75% ropivacaine, which will be performed by the same attending anesthesiologist.
89166446|NCT06157346||High-altitude|Children live in a high-altitude area of more than 3000 meters.
89166447|NCT06157346||Low-altitude|Children live in a low-altitude area of less than 500 meters.
89166448|NCT06157333|Active Comparator|Active rTMS group|We determined the motor threshold (MT) of the contralateral abductor pollicis brevis muscle as the target muscle by stimulating the left motor cortex. The MT was defined as the stimulus intensity required to produce motor evoked potentials of> 50 mV peak-to-peak amplitude in five out of ten consecutive trials in the right abductor pollicis brevis. The rTMS was performed over the left F3 on the scalp according to the 10/20 electroencephalography system with an 8-shaped 70-mm coil. The protocol included high frequency (10 Hz) rTMS applied over the left DLPFC at 110% RMT for two sessions per day, over two weeks for a total of 20 sessions. In each session, a total of 2000 pulses were stimulated for 5 seconds, applied at 25-second intervals, and each rTMS session lasted 20 minutes. Patients were given the opportunity to rest for 1-3 hours in between sessions. A total of 4000 pulses were applied to the patients in one day.
89166449|NCT06157333|Placebo Comparator|Sham group|Similar protocol was applied and sham rTMS treatment was given with a sham coil to the sham group.
89166450|NCT06157320|Experimental|Shenfu Injection group|within 24 hours after the diagnosis of sepsis, Shenfu injection 100 ml/day, intravenous use, continuous application for 7 days.
89166451|NCT06157320|Placebo Comparator|Control group|sepsis was treated with standardized western medicine methods
89166452|NCT06157307|Experimental|Test subjects|Four different hand placements for aortic compression.
89166453|NCT06157294|Active Comparator|Intra-articular pulsed radiofrequency group|This arm consists of patients who received intra-articular pulse radiofrequency treatment.
89166454|NCT06157294|Active Comparator|Median branch pulsed radiofrequency group|This arm consists of patients who received median branch pulse radiofrequency treatment.
89166455|NCT06157281|Experimental|Connect Intervention|"HIV providers withing each clinic will participate in the Intervention. The intervention, called Connect, consists of several strategies within three domains, as follows:~Domain 1: Engage, Encourage, Support Staff~Strategy 1a: Monthly staff huddle with staff recognition activities and compassion-focused rounds~Strategy 1b: Compassion training~Domain 2: Create a welcome physical environment~Strategy 2a: Aesthetic improvements toward a warm, welcoming environment~Domain 3: Expedite and workflow practices~Strategy 3a: Pre-pull patient folders; hold folders for immediate tracking; map patients to identify locations~Strategy 3b: Integrate welcome-back services for those who miss follow-up appointments"
89166456|NCT06157281|No Intervention|Control|Staff in control clinics will not receive an intervention.
89166457|NCT06157268||Core myopathies|Patients with a genetically confirmed core myopathy
89166458|NCT06157268||Nemaline myopathy|Patients with a genetically confirmed nemaline myopathy
89166459|NCT06157268||Centronuclear myopathy|Patients with a genetically confirmed centronuclear myopathy
89166460|NCT06157229|Experimental|Multifactorial Approach Training (MAT)|MAT involves an evidence-based core outcome-set of interventions aimed at both regaining functional stability of the shoulder and also diminishing fear of (recurrent) dislocation and kinesiophobia. The protocol is based on a recent international Delphi-based consensus study, initiated since no protocol yet existed focusing on this psychological component of traumatic anterior shoulder instability.
89166461|NCT06157229|Active Comparator|Conventional Arthroscopic Bankart Repair Rehabilitation (CABRR)|The original guidelines which most physiotherapists use throughout the rehabilitation of their patients following ABR is the ASSET guideline [2].
89166462|NCT06157216|Experimental|MRD-guided treatment|Patients post-surgery will receive MRD tests and receive MRD-guided adjuvant therapies. After that, MRD status will be continuously monitored for three years to guide the following therapies.
89166463|NCT06157190||patients with knee replacement|"The knee replacement patient cohort in this study consists of individuals who underwent Total Knee Arthroplasty (TKA) and utilized the moveUP digital application for at least six weeks post-surgery. The criteria include:~Total Knee Arthroplasty (TKA): Individuals who had surgical intervention for total knee replacement.~moveUP Digital Application Usage: Patients actively engaged with the moveUP digital therapies platform, using the associated application for rehabilitation. The application aids and monitors the recovery process.~Post-Surgery Duration of Six Weeks: To be part of the study, patients in this cohort used the digital application for a minimum of six weeks after knee replacement surgery. This duration aims to evaluate the effectiveness of technology-assisted rehabilitation during the critical early recovery phase."
89166464|NCT06157190||patients with hip replacement|"The hip replacement cohort likely comprises individuals who had total hip arthroplasty. Similar to the knee replacement cohort, inclusion criteria may involve using the moveUP digital application for at least six post-surgery weeks. Characteristics include:~Total Hip Arthroplasty (THA): Patients underwent surgical intervention for total hip replacement.~moveUP Digital Application Usage: Cohort members actively engaged with the moveUP digital therapies platform, utilizing the associated app for post-surgery rehabilitation.~Post-Surgery Duration of Six Weeks: To join the study, patients likely used the digital application for a minimum of six weeks post-hip replacement surgery. This period helps assess technology-assisted rehabilitation effectiveness during early recovery."
89166465|NCT06157164||Simultaneous UroLift™ and HoLEP|UroLift System
89166466|NCT06157112||Norwegian University students|Norwegian fulltime University students
89166467|NCT06157099|Placebo Comparator|Arm I (Placebo)|Patients receive placebo PO once per day in the absence of disease progression or unacceptable toxicity for up to 5 years and undergo CT and/or MRI throughout the study.
89166468|NCT06157099|Experimental|Arm II (Atorvastatin)|Patients receive atorvastatin PO once per day in the absence of disease progression or unacceptable toxicity for up to 5 years and undergo CT and/or MRI throughout the study.
89166469|NCT06157073|Active Comparator|Open-loop ventilator|Prior to the rapid sequence intubation, patients' gender and height are set on the ventilator. The physician in-charge will setup the ventilator based on the lung condition, following the research protocol. Patients will be connected to this ventilator upon securing the airway. Ventilator setting parameters will be manually adjusted by the in-charge physician following local guidelines.
89166470|NCT06157073|Experimental|Closed-loop ventilator|Prior to the rapid sequence intubation, patients' gender and height are set on the ventilator. Patients' condition settings are selected depending on the lung condition. The sensors for end-tidal carbon dioxide (EtCO2) and oxygen saturation (SpO2) will be connected. Patients will be connected to this ventilator upon securing the airway. Ventilator setting parameters will be set following the study protocol.
89166472|NCT06157047|Experimental|Patients included|Patients' recruitment was guided by their actual need to solve edentulism through the use of implant therapy. The diagnosis was made clinically and radiographically.
89166473|NCT06157034|No Intervention|Exploratory|"After sampling the study population of 200 will be divided into four (04) treatment groups i.e. T1 (Placebo), T2 (Zingiber officinale), T3 (Carum carvi, L), and T4 (Mentha spicata L).~Each group will be allotted 50 subjects"
89166474|NCT06157034|Experimental|T1|"In the pursuit of scientific understanding, clinical studies play a pivotal role in evaluating the efficacy of treatments. One essential aspect is the inclusion of a placebo group, denoted as the T1 group in this study. Participants in this group will be administered inert material in the form of 100 mg capsules, serving as a baseline for comparison against the active treatment groups.~Group Designation: T1 Placebo Group~Intervention: 100 mg capsule containing inert material~Dosage Frequency: Daily~Duration: 3 months~Number of Participants: 50 subjects~Participants in the T1 Placebo Group are fully informed about the nature of the study, including the possibility of receiving a placebo.~Informed consent is obtained from each participant, ensuring that they are aware of the study's objectives and the potential for receiving an inactive treatment."
89166475|NCT06157034|Experimental|T2|"Zingiber officinale, commonly known as ginger, has been of interest for its potential health benefits.~In this clinical study, the T2 treatment group is designated to receive Zingiber officinale powder.~Intervention Details:~Group Designation: T2 Treatment Group~Intervention: Zingiber officinale powder~Dosage: 500 mg capsules~Dosage Frequency: Twice daily~Total Daily Dosage: 1000 mg~Administration Timing: After breakfast and dinner~Duration: 3 months~Throughout the study duration, data will be systematically collected from participants in the T3 treatment group. This data may include subjective reports, clinical assessments, and laboratory analyses."
89166476|NCT06157034|Experimental|T3|"Carum carvi, L, commonly known as caraway, is a botanical with a rich history of traditional use. In this clinical study, a treatment group, denoted as T3, is established to investigate the effects of encapsulated Carum carvi, L powder in alleviating the gastrointestinal disturbances among TB patients.~Intervention Details:~Generic Name: Carum carvi, L powder~Dosage Form: Encapsulated~Dosage: 1 g per capsule~Frequency: Twice daily~Total Daily Dosage: 2 g/day~Administration Timing: After breakfast and dinner~Duration of Treatment: 3 months~Throughout the study duration, data will be systematically collected from participants in the T3 treatment group. This data may include subjective reports, clinical assessments, and laboratory analyses."
89166477|NCT06157034|Experimental|T4|"Mentha spicata L, commonly known as spearmint, is renowned for its aromatic properties and potential health benefits. In this clinical study, a treatment group, designated as T4, is established to explore the effects of encapsulated Mentha spicata oil.~Intervention Details:~Generic Name: Mentha spicata oil~Dosage Form: Encapsulated~Concentration: 2% of Spearmint essential oil~Dosage: 1.5 ml per capsule~Frequency: Twice daily~Total Daily Dosage: 30 ml/day~Administration Timing: After breakfast and dinner~Duration of Treatment: 3 months~Throughout the study duration, data will be systematically collected from participants in the T4 treatment group. This data may include subjective reports, clinical assessments, and laboratory analyses."
89166478|NCT06157034|No Intervention|Washout period|"In this phase impact of withholding the intervention on all parameters will be studied.~All parameters included in phase1 and 2 will be repeated after one month accordingly, to observe any change in selected parameters after discontinuation of intervention."
89166479|NCT06157021|Experimental|Rotary pulpectomy|Rotary pulpectomy using rotary files (Fanta AF baby* rotary files and Endo Radar* rotary device
89166480|NCT06157021|Active Comparator|Manual pulpectomy|Manual pulpectomy using manual H files, Mani*)
89166481|NCT06156995|Experimental|Treatment group|Using 0.30mm × 75mm millineedle (produced by Suzhou Medical Equipment Factory, Huatuo brand) deeply punctures the Zhongliao acupoint to reach the sacral nerve. The acupuncture needle is connected using the MuhiStim Sensor nerve stimulator produced by Pajunk in Germany. Connect the positive pole to the left Zhongliao hole and the negative pole to the right Zhongliao hole. The frequency, current, and pulse width of sacral nerve electrical stimulation are 2 Hz, 5mA, and 0.1 ms, respectively.Electroacupuncture stimulates the sacral nerve for 30 minutes, once a day, five times a week. After the treatment, rest for two days before starting the next treatment. Five sessions are considered as one course of treatment, with a total of four courses for four consecutive weeks.
89166482|NCT06156995|Active Comparator|control group|Mosapride citrate tablets (produced by Lunan Beite Pharmaceutical Co., Ltd., with the national drug approval number H19990317), oral administration, 5mg once, three times a day, taken before meals. 5 days is one course of treatment, with 2 days of rest during the treatment period. The total treatment period is 4 weeks, with a total of 4 courses.
89166483|NCT06156956|Experimental|Fecal Microbiota Transplantation|Antibiotics pre-treatment on days 1-5 and a bowel cleansing on day 6. Days 7-14 are dedicated to active eradication treatment with FMT. First dose on day 7 and second dose in days 9-14 (1/6 of full dose every day).
89166484|NCT06156943|Experimental|Optimized group managed by the Starling device|In the optimized group, patients will be managed intraoperatively with the Starling device. It is a non-invasive fluid management monitoring system provides continuous hemodynamic monitoring and empowers fluid management across the continuum of care. Thanks to this device, patients will be managed according to the following protocol: fluid responsiveness will be systematically assessed by repetitive fluid challenges (2-3 ml/kg of Ringer Lactate) given to increase SV by at least 10% when mean arterial pressure falls below 65 mmHg and/or perfusion index falls below 1.5. Vasoactive and/or inotropic agents will be used at the discretion of the attending anesthesiologists in case of fluid unresponsiveness.
89166485|NCT06156943|Other|Control group managed by standard of care|In the control group, patients will be managed intraoperatively at the discretion of the attending anesthesiologists, in accordance with their institutional protocols (i.e. fluids and/or vasoactive agents are given to maintain mean arterial pressure ≥ 65 mmHg).
89166486|NCT06156891|Experimental|Toxicities reduced treatment arm|"Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-related patients.~Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) combined with concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-urelated patients."
89166487|NCT06156891|Active Comparator|Conventional treatment arm|Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70.4Gy/32Fx) when responses to induction chemotherapy are less than 70% Partial Response (PR) regardless of HPV status.
89166488|NCT06156878|Experimental|Anti-EGFR and PD-1 inhibitor arm|Two cycles of TP (docetaxel+cisplatin), TPF(docetaxel+cisplatin+5-FU), TPX (docetaxel+cisplatin+capecitabine) or GP regimen (gemcitabine+cisplatin) followed by radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week) when responses to induction chemotherapy are less than 50% Partial Response (PR) or EBVDNA copy number decreased by less than 50%.
89166489|NCT06156865|Experimental|Intervention to address late talking|half the participants receive an intervention program addressing late talking. The intervention is comprised of adult learning (to teach parents) and direct support for children who are late talkers. The intervention occurs over 6 to 8 weeks and is designed to improve grammar, vocabulary, and functional communication
89166490|NCT06156865|No Intervention|Waitlist controls|half the participants are waitlist controls who receive intervention at a later date, after the study has ended
89166491|NCT06156852|Active Comparator|Mindfulness-based stress reduction group (MBSR)|Medical faculty students who volunteered to participate in the study were assessed by a senior psychiatry resident. The students who were found to be eligible to take part in the study were randomized to two groups (MBSR and CBSR groups).
89166492|NCT06156852|Active Comparator|Cognitive behavioral based stress reduction group (CBSR)|Medical faculty students who volunteered to participate in the study were assessed by a senior psychiatry resident. The students who were found to be eligible to take part in the study were randomized to two groups (MBSR and CBSR groups).
89166493|NCT06156774||Patients with Non-Hodgkin Lymphoma B cell|Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug
89166494|NCT06156761|Experimental|Experimental: 3-week arm|Patients will receive mitoxantrone hydrochloride liposome combined with capecitabine therapy in a 3-week treatment cycle.
89166495|NCT06156761|Experimental|Experimental: 4-week arm|Patients will receive mitoxantrone hydrochloride liposome combined with capecitabine therapy in a 4-week treatment cycle.
89166496|NCT06156748||Hepatectomy alone|
89166497|NCT06156748||PA-TACE|
89166498|NCT06156735|Experimental|Passive Music Therapy (P)|The therapist read a standardized relaxation script in the research participant's selected preferred language while improvising on the keyboard. The script was inclusive of deep breathing and imagining a positive image. The research participants were asked to close his or her eyes while relaxing and imagining. The entire intervention lasted approximately 15 minutes. The research participants were allowed to request to stop the intervention at any time
89166499|NCT06156735|Experimental|Active Music Therapy (A)|The research participants were given a standardized assortment of percussion instruments to choose from. The therapist provided instructions of playing instruments along with the therapist. The research participant was allowed to change his or her instrument at any time and was advised to sing along with the therapist. Based on the research participant's age, the therapist selected the songs to sing and accompany on either the guitar or the keyboard. The duration of the intervention was approximately 15 minutes, which allowed about five to six songs to be sung. The research participants were allowed to request to repeat or skip any of the songs at any time.
89166500|NCT06156735|Active Comparator|Standard Care Control Condition (C)|The control condition involved mundane activities such as chatting, resting, or reading magazines, with the MT, in the treatment room.
89166501|NCT06156709|Active Comparator|Group I|"The patients will be given 10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether. Level of sensory block will be tested by testing with ice from S2 dermatome cephally.~Analgesia will be maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every hour, starting 1 hour after the loading dose. In addition, patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered. Breakthrough pain that requires even further analgesia will be treated with an epidural bolus of 5 ml of 0,125% bupivacain solution."
89166502|NCT06156709|Active Comparator|Group II|"The patients will be given 20 ml of a solution containing 0,0625% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether. Analgesia will be maintained by programmed intermittant epidural boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. In addition, patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered. Breakthrough pain that requires even further analgesia will be treated with an epidural bolus of 5 ml of 0,125% bupivacain solution."
89166503|NCT06156683||Kesimpta-exposed|exposure to Kesimpta during the risk period
89166504|NCT06156683||MSDMD-exposed|exposure to at least one Multiple sclerosis disease modifying drug (MSDMD) (other than Kesimpta) during the risk period
89166505|NCT06156683||MSDMD-unexposed|no exposure to Kesimpta or any other Multiple sclerosis disease modifying drug (MSDMD) during the risk period
89166506|NCT06156657|Active Comparator|TAP group|patients candidate for laparoscopic sleeve gastrectomy to receive GA and subcostal TAP block to control postoperative pain and minimize opioid consumption
89166507|NCT06156657|No Intervention|Control group|healthy controls candidate for laparoscopic sleeve gastrectomy to receive GA only opioids were used
89166508|NCT06156631|Experimental|Participants receive DASH-ExMAMI intervention.|Jordanian participants who are adults (age between ≥ 18 and 65 years), have had diagnosed with hypertension and has started his or her treatment plan, and have uncontrolled hypertension (The average systolic blood pressure reading that is equal to or higher than 130 mmHg and/or diastolic blood pressure that is equal to or higher than 90 mmHg for the last two patients' records available at the health centre.
89166509|NCT06156631|No Intervention|Participants who do not receive DASH-Ex MAMI|Jordanian participants who are adults (age between ≥ 18 and 65 years), have had diagnosed with hypertension and has started his or her treatment plan, and have uncontrolled hypertension (The average systolic blood pressure reading that is equal to or higher than 130 mmHg and/or diastolic blood pressure that is equal to or higher than 90 mmHg for the last two patients' records available at the health centre.
89166510|NCT06156618|Active Comparator|Active nitrate|"Arm Description: Nitrate Intervention Arm~Intervention: Beetroot Juice (BJ) with Nitrate Supplements~Dosage Form: Liquid Dosage: 70 ml Frequency: Twice daily Duration: Seven days Participants assigned to this arm will receive Beetroot Juice (BJ) containing nitrate supplements. The intervention involves the ingestion of 70 ml of BJ twice daily for a duration of seven days. The BJ are designed to be indistinguishable in taste and appearance, ensuring blinding during the study. This arm is a crucial component of the double-blind, randomized crossover trial investigating the effects of nitrate supplements on oral microbiome recovery, blood pressure, and arterial stiffness in both healthy individuals and those with Dental Erosion. Detailed protocol and participant information available in attached documentation."
89166511|NCT06156618|Placebo Comparator|Placebo nitrate|"Arm Description: Placebo Intervention Arm~Intervention: Placebo ( Beetroot Juice depleted from nitrate), Identical to the active nitrate in texture, taste, colour and smell.~Dosage Form: Liquid Dosage: 70 ml Frequency: Twice daily Duration: Seven days Participants in the placebo intervention arm will receive a liquid placebo consisting of flavored water with discolouring dyes. The placebo is administered in the same manner as the active intervention, with participants ingesting 70 ml twice daily for a duration of seven days. This arm serves as a control group in the double-blind, randomized crossover trial, allowing for a comparison with the effects observed in the Beetroot Juice (BJ) with nitrate supplements arm. The order of treatment (BJ or placebo) is randomly assigned and reversed during the second phase of the study to ensure unbiased results. Detailed protocol and participant information available in attached documentation."
89166512|NCT06156605|Experimental|Sidelying lumbar manipulation|Right sided lumbar manipulation
89166513|NCT06156605|Active Comparator|Sham ultrasound|Sham (non-therapeutic settings) ultrasound at the right PSIS
89166514|NCT06156592||Severe aortic stenosis group|Patients with severe aortic stenosis who are undergoing open aortic valve replacement under high spinal in combination with light general anesthesia.
89166515|NCT06156592||Severe mitral regurgitation group|Patients with severe mitral regurgitation who are undergoing open mitral valve replacement under high spinal in combination with light general anesthesia.
89166516|NCT06156579|Experimental|Treatment|Salvage therapy with Venetoclax and intensified Decitabine
89166517|NCT06156566|Active Comparator|Tecovirimat|Oral treatment with tecovirimat 200 mg capsules. Twice daily three capsules orally. Duration of treatment: 14 days (28 administrations).
89166518|NCT06156566|Placebo Comparator|Placebo|Matching placebo to tecovirimat capsules. Twice daily three capsules orally. Duration of treatment: 14 days (28 administrations).
89166519|NCT06156553|Experimental|Students in 9. grade participating in a school-based intervention|Students from 9. grade at 4 schools in a Norwegian municipality. The students will take part in a school and curriculum based intervention delivered by a combination of educators from a science center (1 session) and teachers (5 sessions)
89166520|NCT06156527|Active Comparator|single arm|lazertinib single arm
89166521|NCT06156527|Experimental|combination arm|Lazertinib plus bevacizumab
89166522|NCT06156501|Experimental|ACL Reconstruction|Patients undergoing ACL reconstruction
89166523|NCT06156488|Active Comparator|Anorganic bovine bone|Maxillary sinus floor augmentation grafted with anorganic bovine bone
89166524|NCT06156488|Experimental|Anorganic bovine bone + polynucleotides and hyaluronic acid|Maxillary sinus floor augmentation grafted with anorganic bovine bone + polynucleotides and hyaluronic acid
89166525|NCT06156397|Active Comparator|Standard Physiotherapy Exercise Group|The exercise protocol will transition from simple to difficult as a result of literature research, and a standard exercise program will be applied, each session lasting 45 minutes.
89166526|NCT06156397|Active Comparator|Telerehabilitation Based Supervised Exercise Group|Telerehabilitation exercise protocol exercises will last 45 minutes in total, transitioning from simple to difficult, and will be implemented with patients via Zoom.
89166527|NCT06156397|Active Comparator|Mobile Application Supported Exercise Group|In the Mobile Application-Based exercise group, a virtual clinic will be created for the patients through the Becure application, and the patients will apply a gradual exercise program that will last approximately 45 minutes, determined by the physiotherapist, and the patients will be followed for 6 weeks through this application.
89166528|NCT06156384||Patients|Patients aged ≥12 years with congenital or acquired lower limb discrepancy, greater than 30mm
89166529|NCT06156332|Experimental|surufatinib combined with serplulimab|"surufatinib: 250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab: 300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy."
89166530|NCT06156319||Group 1|"CHIP group: Patients diagnosed with AMI combined with CKD stage II-IV underwent PCI and were identified as CHIP carriers by gene targeted sequencing.~Non-chip group: Patients diagnosed with AMI combined with CKD stage II-IV underwent PCI and were identified as non-CHIP carriers by gene targeted sequencing."
89166531|NCT06156319||Group 2|CHIP group: Patients diagnosed with AMI combined with ESRD underwent PCI and were identified as CHIP carriers by gene targeted sequencing Non-chip group: Patients diagnosed with AMI combined with ESRD underwent PCI and were identified as non-CHIP carriers by gene targeted sequencing
89166532|NCT06156306|Active Comparator|CBT-I|A total of 6 sessions of face-to-face group CBT-I therapy will be provided. Each session will last 90-120 mins, with each group 8-10 subjects.
89166533|NCT06156306|Experimental|CBT-I combined ACT|A total of 6 sessions of face-to-face group CBT-I+ACT therapy will be provided. Each session will last 90-120 mins, with each group 8-10 subjects.
89166534|NCT06156293|Experimental|Stepped-care CBT-I group|"A total of 3 steps of sleep focused intervention will be provided, with the objectives to increase the awareness of sleep health, increase sleep literacy, establish good sleep hygiene and treat insomnia.~Step 1: self-help digital sleep focused program; Step 2: guided intervention; Step 3: individualized consultation."
89166535|NCT06156293|No Intervention|Control group|Participants in the control group remain unexposed to the stepped-care sleep-focused intervention.
89166536|NCT06156267|Experimental|Part A: Dose Escalation, Part B: Dose Expansion|
89166537|NCT06156254|Experimental|Community Health Worker (CHW) Intervention to Enhance Vaccination Behavior|Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
89166538|NCT06156254|No Intervention|Usual Care|Patients will receive the care that they would usually receive independent of the study but won't have access to the intervention.
89166539|NCT06156241|Experimental|4x10^6 Cells/kg Dose Group|This is a adaptive Baysian dose escalation study. The first 3 subjects will receive one stem cell infusion of 4x10^6 Cells/kg. If no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose.
89166540|NCT06156241|Experimental|6x10^6 Cells/kg Dose Group|"The next cohort of 3 subjects will receive one stem cell infusion of 6x10^6 Cells/kg.~If no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose."
89166541|NCT06156241|Experimental|8x10^6 Cells/kg Dose Group|"The next cohort of 3 subjects will receive one stem cell infusion of 8x10^6 Cells/kg.~If no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose."
89166542|NCT06156241|Experimental|10x10^6 Cells/kg Dose Group|The last cohort of 3 subjects will receive one infusion of 10x10^6 Cells/kg.
89166543|NCT06156189||Critically ill patients|All adult patients ventilated and intubated. These patients should also have enteral nutritional supplement initiated.
89166544|NCT06156176|Experimental|COVIDEx|This arm will receive 2 50-minute rehabilitation sessions each week for 8 weeks.
89166545|NCT06156176|No Intervention|Standard of Care|This arm will receive standard of care (no intervention) for the 8-week intervention period.
89166546|NCT06156150||glioma patients receiving conventional treatment|surgery+radiotherapy+chemotherapy
89166547|NCT06156150||glioma patients with tumor vaccine|surgery+radiotherapy+chemotherapy+tumor vaccine
89166548|NCT06156137||adverse outcomes|The composite adverse outcomes are defined as either a >20-day length of stay intensive care unit admission, mechanical ventilation use, or death.
89166549|NCT06156137||favorable outcomes|favorable outcomes the patient are defined as discharged with improvement and hospitalization less than 20 days.
89166550|NCT06156124||Adolescents having sibling with intellectual disability|Dyads of healthy Polish adolescents 16-18 y.o., who have sibling with intellectual disability and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
89166551|NCT06156124||Adolescents having sibling with motor disability|Dyads of healthy Polish adolescents 16-18 y.o., who have sibling with motor disability and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
89166552|NCT06156124||Adolescents having sibling with diabetes|Dyads of healthy Polish adolescents 16-18 y.o., who have sibling with chronic somatic disease - diabetes, and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
89166553|NCT06156124||Adolescents having healthy sibling|Dyads of healthy Polish adolescents 16-18 y.o., who ave healthy sibling, and one of their parent. The parent's participation is necessary to assess the presence of possible disorders in a healthy child.
89166554|NCT06156111|Other|Transepithelial abutment|The patients randomized to the transepithelial abutment group will receive a fixed screw implant-supported zirconia prosthesis which will be attached to the implants through an implant-abutment connection.
89166555|NCT06156111|Experimental|Direct to implant|The patients randomized to the direct to implant group will receive a fixed screw implant-supported zirconia prosthesis which will be attached direct to the implants connection.
89166556|NCT06156085|Experimental|VA14|Vonoprazan-Amoxicillin Dual Therapy for 14days
89166557|NCT06156085|Active Comparator|S14|Sequential therapy for 14 days
89166558|NCT06156046||Group 1|Individuals naïve to beekeeping (<2 previous bee stings, non in the last 24 months). No history of anaphylaxis
89166559|NCT06156046||Group 2|Beekeepers with > approximately 10 stings/year who have been beekeeping for >3 years. No history of anaphylaxis.
89166560|NCT06156046||Group 3|Beekeepers with diagnosis of anaphylaxis to bee venom in the last 12 months who are sensitised to bee venom ( as evidenced by positive IgE and positive skin test to bee venom)
89166561|NCT06155994|Experimental|Group A and B|"Group A: six patients with advanced medullary thyroid carcinoma~Group B: six patients with advanced gastroenteropancreatic and bronchopulmonary neuroendocrine tumours"
89166562|NCT06155942|Other|Patients with Parkinson Disease|
89166563|NCT06155942|Other|Patients with Progressive Supranuclear Palsy|
89166564|NCT06155942|Other|Healthy volunteers|
89166565|NCT06155929|Other|Flight|The intervention is the flight to turkey and home to Denmark again.
89166566|NCT06155916|Experimental|High ISI|Patients that have clinically significant insomnia according to ISI questionnaire (score 15 or more) at baseline.
89166567|NCT06155916|Experimental|Low ISI|Patients with no clinically significant insomnia according to ISI questionnaire (score 14 or less) at baseline.
89166568|NCT06155903|Active Comparator|Spinal Anesthesia|The participant will receive a spinal anesthesia.
89166569|NCT06155903|Active Comparator|Peripheral nerve block|The participant will receive a combination of femoral nerve block, sciatic nerve block with parasacral approach, lateral femoral cutaneous nerve block and obturator nerve block.
89166570|NCT06155877|Experimental|LAMAP intervention|"Teachers receive two sets of activities, accompanied by a tutorial. Both sets of activities also include evaluation tools that teachers can use to clarify the objectives of the lesson and to assess the pupils' learning progress. The estimated length of each set is 5 hours.The activities and the tutorials were created by pedagogical experts of the Fondation La Main à la pâte, an NGO whose goal is to foster science education. Activities and tutorials are now freely available on the La Main a la pâte website. Teachers were free to choose whether to present the first or the second set of activities, and to choose how many of the activities to conduct. The actual length of the intervention thus varied from one classroom to another, which mimics ecological conditions. Teachers were asked to devote at least one hour to the activities.~LAMAP activities are available on the experiment's OSF repository"
89166571|NCT06155877|Experimental|Chatbot intervention|Teachers, and then pupils, receive a link to a chatbot. This chatbot is a basic conversational agent that can answer the most common questions about vaccination. The chatbot is entirely scripted, providing users with a limited choice of questions at each stage. These questions are the most commonly raised questions about vaccination in adolescents, based on existing literature, and on focus groups conducted by our team. In this intervention, teachers will be asked to supervise the use of the chatbot in class. Pupils will use the chatbot either individually or in groups depending on the number of computers available. Teachers will be encouraged to conclude the intervention by a class discussion. Teachers will be asked to devote about one hour to this intervention (use of the chatbot and class discussion). The full chatbot text is available on the experiment's OSF repository
89166572|NCT06155877|No Intervention|Control|In the control group, teachers were not sent any extra materials, and pupils were exposed to the standard curriculum. Teachers in the control group received the material after the end of the intervention. French teachers most commonly offer the course on vaccination during the last year of middle school (the equivalent of 9th grade). Time spent on this course varies and can be quite small.
89166573|NCT06155864||1|To study the reproducibility of anatomical measurements of the superficial temporal artery using X-ray angio-modensitometry.
89166574|NCT06155864||2|Investigate different CT techniques for studying the superficial temporal artery.
89166575|NCT06155864||3|Study the anatomy of the superficial temporal artery on CT.
89166576|NCT06155864||4|Study the anatomy of the superficial temporal artery on MRI.
89166577|NCT06154161|Experimental|Whey protein consumption|Participants will receive 20g total protein of whey protein isolate in 115 mls of water to consume daily for up to 6 months
89166578|NCT06152952||Group 1 : The rhomboid flap Approach|The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers (gluteal fascia with 2/0 Vicryl, subcutaneous fat with 3/0 Vicryl, and the skin with 4/0 Prolene). As all sides will be equal in length, the flap fits in place without tension. A suction drain will be left behind and the wound will be dressed as usual. Pressure wound dressing will be applied and removed on the third postoperative day.
89166579|NCT06152952||Group 2 : The deep suturing approach|A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. Tension will be released by a limited sharp dissection above the fascia. After haemostasis is ensured using electrocautery, a suction drain will be inserted through a separate incision, then the deep fascia will be approximated and the wound will be closed in layers using polyglactin 0 sutures. Finally, the skin will be closed with 2/0 polypropylene interrupted mattress sutures.
89166580|NCT06152341|Experimental|Patients with Acute Pulmonary Embolism|Patients undergoing mechanical thrombectomy for acute pulmonary embolism.
89166581|NCT06151171|Experimental|Lipomicel Q10|Lipomicel Q10 (Natural Factors, Burnaby, BC, Canada). One soft gel capsule contains: 100 mg ubiquinone (oxidized form of CoQ10)
89166582|NCT06151171|Active Comparator|CoQ10 NOW® Ubiquinol|CoQ10 (NOW® Ubiquinol, Bloomingdale, IL, USA). One soft gel capsule contains: 100 mg ubiquinol (reduced form of CoQ10).
89166583|NCT06151171|Active Comparator|Qunol Ultra CoQ10|Qunol Ultra CoQ10 (Quten Research Institute, LLC, USA). One soft gel contains: 100 mg ubiquinone.
89166584|NCT06150118|Experimental|CBT+VR (Cognitive behavioral therapy and virtual reality)|
89166585|NCT06150118|Experimental|VR (Virtual reality)|
89166586|NCT06150118|Experimental|CBT (Cognitive behavioral therapy)|
89166587|NCT06150118|Placebo Comparator|Control|
89166588|NCT06149650||Full cohort|Intravascular lithotripsy of femoropopliteal and crural lesions as per standard of care
89166589|NCT06149442|Experimental|Dose of five muscle incisions|Subjects treated in this group will receive an in-out technique with a dosage of five incisions in the myofascial trigger point of the levator scapulae muscle.
89166590|NCT06149442|Experimental|Dose of ten muscle incisions|Subjects treated in this group will receive an in-out technique with a dosage of ten incisions in the myofascial trigger point of the levator scapulae muscle.
89166591|NCT06149442|Experimental|Dose of fifteen muscle incisions|Subjects treated in this group will receive an in-out technique with a dosage of fifteen incisions in the myofascial trigger point of the levator scapulae muscle.
89166592|NCT06145620|Experimental|Therapeutic exercise, back care and pain neuroscience education group|
89166593|NCT06145620|Active Comparator|Standarized written exercise group|
89166594|NCT06139380|Active Comparator|Intranasal ketamine|
89166595|NCT06139380|Placebo Comparator|Intranasal sterile water|
89166596|NCT06135740|Active Comparator|Intervention|Notification on Nutrition, Sleep, and Physical Activity based on fitbit-based data
89166597|NCT06135740|Sham Comparator|Control|Regular Care
89166598|NCT06134752|Active Comparator|Radiofrequency ablation|Pulmonary vein and left atrial posterior wall isolation with point by point radiofrequency ablation.
89166599|NCT06134752|Experimental|Pulse field ablation|Pulmonary vein and left atrial posterior wall isolation with point by point pulse field ablation.
89166600|NCT06134375|Experimental|TM and Capecitabine with or without Pembrolizumab|Tetrathiomolybdate (TM) and Capecitabine +/- Pembrolizumab will be administered concurrently for 6 months, TM will continue for 2.5 more years (total duration of TM treatment is 3 years)
89166601|NCT06134375|Active Comparator|Capecitabine with or without Pembrolizumab|Capecitabine +/- Pembrolizumab will be administered for 6 months (participants will remain on study for 2.5 more years).
89166602|NCT06124248|Experimental|Experimental group|RISE intervention and usual care
89166603|NCT06124248|No Intervention|Control group|Usual care
89166604|NCT06123325||Treatment group|Patients with unruptured intracranial aneurysms, opting for active intervention undergo microsurgical clipping or endovascular therapy to preemptively secure the aneurysm and prevent rupture.
88804640|NCT04232215|Active Comparator|Standard Fetal Doppler Group|Subjects will monitor their fetal heart beat once weekly using the doppler fetal heart rate monitor. After approximately 8 weeks of monitoring subjects will crossover to using the HeraBEAT™ device
88804641|NCT02840539|Experimental|Experimental|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
89166605|NCT06123325||Observation group|Patients with unruptured intracranial aneurysms, opting for conservative management undergo regular monitoring with serial imaging to track aneurysm stability, deferring interventional treatment unless changes indicate an increased risk of rupture.
89166606|NCT06112054|Experimental|Treatment Arm|One arm only - in all eligible study patients, the study device will be used.
89166607|NCT06109506||Patients with diverticular abscess classified as Hinchey 2b (Subgroup)|
89166608|NCT06109506||Patients with diverticular abscess >5 cm (Subgroup)|
89166609|NCT06106503|Other|patients will not underwent chest x-ray|
89166610|NCT06106503|Other|patients underwent chest x-ray|patients underwent chest x-ray
89166611|NCT06103019|Active Comparator|Conventional (complete denture)|Each patient received two prostheses: 1) Conventional Maxillary and mandibular complete denture. 2) 3D printed complete Maxillary and mandibular complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing denture then the other type of denture was delivered and used for another 3 months.
89166612|NCT06103019|Active Comparator|3D printed complete denture|Each patient received two prostheses: 1) Conventional Maxillary and mandibular complete denture. 2) 3D printed complete Maxillary and mandibular complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing denture then the other type of denture was delivered and used for another 3 months.
89166613|NCT06099184|Experimental|EYP-1901 1343 µg|EYP-1901 1343 µg, single dose
89166614|NCT06099184|Experimental|EYP-1901 2686 µg|EYP-1901 2686 µg, single dose
89166615|NCT06099184|Active Comparator|Aflibercept|Aflibercept 2 mg/0.05mL solution, single dose
89166616|NCT06097689|Experimental|Investigational arm|Induction of different glycaemia states via intravenous regular insulin and intravenous glucose administration and measurements of transcutaneous spectral data with the investigational device and reference blood glucose values.
89166617|NCT06096272|Experimental|Augment Therapy app|The app will be implemented with the participant's compatible iPad that will be securely integrated with a network-server for real-time data access and storage. If the participant does not have a compatible device, this will be provided by the research team. Participants will be provided an on-site or virtual CHLA tutorial about using the app and set up of the gaming system. Participants will access their home program on the app at least for 20 minutes, 3 times a week over a 12-week period. A coach will check in virtually with the participant during the program. They will complete baseline and final surveys and functional tests. Exercise data will be collected and stored through the Augment Therapy™ app and self log book.
89166618|NCT06096272|No Intervention|Standard Exercise Handouts|Participants will be given an home based exercise program consisting of virtual coaching and handouts showing the exercises. They will complete baseline and final surveys and functional tests. They will record their exercise activity in a self log book. They will be given the opportunity to use the AR mobile app after their final outcome assessment so all participants have access to trying the mobile app.
89166619|NCT06094660|Active Comparator|Chemical ablation of the genicular nerves with Phenol 6%|Chemical ablation with phenol is done by injection of 1,5ml of phenol 6 % at the superomedial, the superolateral and the inferomedial genicular nerve.
89166620|NCT06094660|Active Comparator|Radiofrequency ablation (RFA) of the genicular nerves|In our study we will make two RFA lesions at every target with 80°C for 90 seconds with a 5mm active tip. So we will make 6 lesions in total. The targets are the superomedial, the superolateral and the inferomedial genicular nerve.
89166621|NCT06094660|No Intervention|Conservative treatment|Examples of allowed conservative treatments during the study are patient education, physical therapy, weight loss and different pharmacological treatments.
89166622|NCT06093945|Experimental|SHR2554 and omeprazole|Sequential treatments of SHR2554 alone followed by SHR2554+ omeprazole, with a washout period in between.
89166623|NCT06092528|Experimental|Pulmonary Rehabilitation Group|Pulmonary rehabilitation practices (inspiratory muscle training, aerobic exercise training, resistance exercise training) will be performed 3 sessions a week for 6 weeks under the supervision of a physiotherapist to the training group.
89166624|NCT06092528|Sham Comparator|Control Group|Control group will be given breathing exercises as a home program for 6 weeks.
89166625|NCT06090799|Experimental|Treatment group A|SHR-3032
89166626|NCT06090799|Placebo Comparator|Treatment group B|SHR-3032 Placebo
89166627|NCT06087198||Healthy Donors|Ostensibly healthy subjects with a normal platelet count and without a history of hemostasis abnormalities, for establishing expected values for quality control
89166628|NCT06087198||Thrombocytopenia Patients|Subjects with thrombocytopenia who are planned to receive a platelet transfusion who have pre-transfusion and post-transfusion blood samples collected for testing
89166629|NCT06087146|Experimental|Athletes supplemented with sauerkraut|10 professional athletes (9 male) who will during 10 days consume approximately 250 g of sauerkraut (Brassica oleracea v. capitata) daily.
89166630|NCT06086964|Experimental|Group A|15 autistic child will receive gluten and casein free diet.
89166631|NCT06086964|Experimental|Group B|15 autistic child will receive physical therapy program.
89166632|NCT06086964|Experimental|Group C|15 autistic child will receive combination of gluten and casein free diet with physical therapy program.
89166633|NCT06086964|No Intervention|Group D|the group of no intervention as a control group.
89166634|NCT06085053|Experimental|TQA3038 injection|One dose of TQA3038 injection in Day 1.
89166635|NCT06085053|Placebo Comparator|TQA3038 injection matching placebo|One dose of TQA3038 injection matching placebo in Day 1.
89166636|NCT06083493|Experimental|LIFUP excitation|Our study will involve the enrollment of 60 participants, who will be randomly assigned to two groups, with each group consisting of 30 participants. The participants will be divided based on the type of transcranial LIFUP they will receive, either excitation or inhibition, targeting four specific thalamic areas.
89166637|NCT06083493|Experimental|LIFUP inhibition|Our study will involve the enrollment of 60 participants, who will be randomly assigned to two groups, with each group consisting of 30 participants. The participants will be divided based on the type of transcranial LIFUP they will receive, either excitation or inhibition, targeting four specific thalamic areas.
89166638|NCT06083272||Study population|"The study population is comprised of two subgroups;~Adult patients admitted to the Emergency Ward (EW). Patients are recruited after the treatment and examination in EW are finished and the patient is waiting for transfer to a hospital ward.~If there is a prolonged period of waiting time for a control blood sample, chest CT or any other examination which usually incurs significant waiting time in the EW. This will be evaluated by a specialist in emergency medicine based on the premise that the inclusion in the study will not delay or interfere with these examinations."
89166639|NCT06076174|Experimental|Tele-rehab|6-week home-based exercise programme, will be monitored via the software that records each session so the therapist can review
89166640|NCT06076174|Active Comparator|Conventional|6-week home-based exercise programme, will have written instructions on paper to follow through by participant themselves
89166641|NCT06071351|Experimental|Experimental intervention group|In addition to the informative brochure prepared by the researcher, a 6-session motivational interview-based training program will be given. The training program will include topics such as nutrition, physical activity, smoking and alcohol use.
89166642|NCT06071351|Active Comparator|Control Group|An informative brochure prepared by the researcher and traditional consultancy services will be provided.
89166643|NCT06070116|Active Comparator|Ivermectin + Albendazole (IA)|Dose of oral Ivermectin (150 µg/kg) plus Albendazole (400 mg)
89166644|NCT06070116|Experimental|Ivermectin + Diethylcarbamazine + Albendazole (IDA)|Dose of oral Ivermectin (150 µg/kg), Diethylcarbamazine (6 mg/kg) and Albendazole (400 mg)
89166645|NCT06070116|Experimental|Moxidectin + Albendazole (MoxA)|Dose of oral Moxidectin (8mg) plus Albendazole (400 mg)
89166646|NCT06070116|Experimental|Moxidectin+ Diethylcarbamazine + Albendazole (MoxDA)|Dose of oral Moxidectin (8mg), Diethylcarbamazine (6 mg/kg) and Albendazole (400 mg)
89166647|NCT06066749|Experimental|NIOSH certified N95 personal face covering (mask)|During the third woodsmoke exposure, half of the subjects will be randomly assigned to wear a NIOSH (National Institute of Occupational Safety & Health) certified N95 personal face covering (mask) while undergoing an exposure to approximately 500 μg/m^3 wood smoke for 2 hours while exercising intermittently (15 min exercise followed by 15 min rest) on a stationary bike at a workload sufficient to maintain approximately 12 L/min/m^2 minute ventilation.
89166648|NCT06066749|Experimental|Surgical Mask|During the third woodsmoke exposure, half of the subjects will be randomly assigned to wear a surgical mask while undergoing an exposure to approximately 500 μg/m^3 wood smoke for 2 hours while exercising intermittently (15 min exercise followed by 15 min rest) on a stationary bike at a workload sufficient to maintain approximately 12 L/min/m^2 minute ventilation.
89166649|NCT06061978|Experimental|left bundle branch of His pacing (LBTP) then right ventricular pacing (RVP)|
89166650|NCT06061978|Experimental|right ventricular pacing (RVP) then left bundle branch of His pacing (LBTP)|
89166651|NCT06057233||Patients|mqMRI and GABA-MRS data will be collected in patients suffering from mesial temporal lobe epilepsy
89166652|NCT06057233||Volunteers|mqMRI and GABA-MRS data will be collected in healthy volunteers
89166653|NCT06056180|Experimental|Balance Training+ Action Observation Training + Motor İmagery Training|The study group (23 cases) will be given motor imagery training and virtual reality-based balance training along with action observation.
89166654|NCT06056180|Active Comparator|Balance Training|Only virtual reality-based balance training will be given to the control group (23 cases).
89166655|NCT06055933||ESWT|To the ESWT group, with the ESWT device (BTL-6000SWT, UK); Extracorporeal shock wave therapy at 10Hz frequency, 2.5 Barr energy and 2000 shock/session values was applied with a 15 mm head in a single session. Shock waves were applied directly to the most sensitive point detected in the medial of the calcaneus.
89166656|NCT06055933||Placebo ESWT|The placebo ESWT group was given the ESWT device sound recorded from the external audio device and the application was performed without the ESWT device operating.
89166657|NCT06055933||ESWT+KT|With ESWT device (BTL-6000SWT, UK); Extracorporeal shock wave therapy at 10Hz frequency, 2.5 Barr energy and 2000 shocks/session was applied in a single session with a 15 mm head. Shock waves will be applied directly to the most sensitive point detected in the medial calcaneus, then a tape consisting of 96% cotton and 4% lycra, water-resistant, porous and adhesive, 5 cm wide and 0.5 mm thick will be used. Taping will be done after the ESWT session and the tape will be asked to remain for a week.
89166658|NCT06053125|Experimental|Older adults with obesity|Participants with a body mass index (BMI) between 30 and 40 and aged 65-85 years will have an adipose tissue biopsy taken from the abdomen before and after exercise.
89166659|NCT06053125|Experimental|Older adults without obesity|Participants with a BMI between 18.5 and 28 and aged 65-85 years will have an adipose tissue biopsy taken from the abdomen before and after exercise.
89166660|NCT06053125|Experimental|Young adults with obesity|Participants with a BMI between 30 and 40 and aged 18-35 years will have an adipose tissue biopsy taken from the abdomen before and after exercise.
89166661|NCT06053125|Experimental|Young adults without obesity|Participants with a BMI between 18.5 and 28 and aged 18-35 years will have an adipose tissue biopsy taken from the abdomen before and after exercise.
89166662|NCT06042400|Experimental|EASE Written Exposure Intervention|Assigned Intervention
89166663|NCT06038734||GLP-1 agonists|Pre-operative gastric ultrasound to evaluate for retained gastric contents in appropriately fasted patients
89166664|NCT06038513|Experimental|Transnasal Thermal Regulating Device|Consented subjects who develop fever will undergo cooling via transnasal thermal regulating device for a period of 24 hours
89166665|NCT06037915|Active Comparator|low flow oxygen|
89166666|NCT06037915|Active Comparator|high flow oxygen|
89166667|NCT06035822|Experimental|Debriefing with TeamGAINS|"The Intervention Group debriefings (n=15) were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool (Kolbe et al., 2013).~The intervention consisted of using the TeamGAINS tool as a debreifing script, during the debriefing, in accordance with the objectives of the clinical simulation scenario (CSC)."
89166668|NCT06035822|No Intervention|Debriefing free|"The Control Group debriefings (n=15) were conducted by a teacher trained in clinical simulation methodology, with no experience in the use of any debriefing guide.~The intervention consisted of the debriefer applying his or her simulation experience and training to perform the debriefings freely, in accordance with the objectives of the clinical simulation scenario (CSC)."
89166669|NCT06034912|Experimental|Low-Intensity Red Light Therapy|Intervention method：Daily wearing myopia frame glasses (optical monofocal lenses) and Low-Intensity Red Light therapy during the study to control myopia.
89166670|NCT06034912|No Intervention|Control group|Intervention method: Daily wearing myopia frame glasses (optical monofocal lenses) during the study, no other treatment is used to control myopia.
89166671|NCT06033079|Experimental|CDS Intervention|The prognostic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive usual care and all treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
89166672|NCT06033079|No Intervention|Control|No experimental decision support will be provided to those randomized to the control arm. All children will receive usual care and treatment will not be restricted or altered in any way by the study.
89166673|NCT06030206|Experimental|Intervention|Access to an investigator-designed web-based educational resource with information about lung transplant for three months.
89166674|NCT06030206|Active Comparator|Attention-control|Access to a publicly available web-based educational resource with information about transplant for three months.
89166675|NCT06025435|Experimental|SAIA-HIV-SSP|SAIA-HIV-SSP is an intervention that facilitates an organizational, SSP-level analysis of the delivery of HIV services by assigning a trained SAIA specialist to apply tools and techniques and engage staff to define barriers, identify solutions, and evaluate their success in cycles until achieving desired change regarding HIV service delivery. The scientific premise of this RCT is that SAIA will effectively boost and extend HIV service delivery cascades within SSPs assigned to the SAIA-HIV-SSP intervention condition (relative to IAU). SAIA specialists will meet with SSP staff biweekly for the first 3 months and then once monthly for the remaining 9 months during the 12-month intervention period.
89166676|NCT06025435|No Intervention|Implementation as usual|SSPs randomized to the IAU arm will not receive support from a SAIA specialist. Though many SSPs in the US already offer HIV services, the investigators are testing the ability of SAIA-HIV-SSP to optimize the delivery of HIV services within SSPs. As such, the IAU condition is characterized by the absence of SAIA-HIV-SSP with the goal of comparing whether SAIA-HIV-SSP improves SSPs' HIV service delivery cascades.
89166677|NCT06012305|No Intervention|Only Exercise Group|"They will be included in the exercise program that includes postural exercises after ischemic compression and stretching. Stretching exercises will be aimed at stretching the upper trapezius muscle. In the sitting position, the person whose head will be flexed and lateral flexed to the opposite side will stay in this position for 30 seconds and then come back to the same position.~This will be practiced 15 times a day, 3 days a week. Ischemic compression will then be applied. In ischemic compression, the therapist will apply pressure on the trigger points detected by palpation for 1 minute, and the application will be completed with a total of 5 repetitions at 1-minute intervals. It will continue to be applied 3 sets a day, 3 days a week. Posture exercises were determined as scapular retraction and chin tuck exercises. The exercises will be done in 3 sets of 15 repetitions per day, 3 days a week."
89166678|NCT06012305|Active Comparator|Taping Group with Muscle Technique|In addition to the exercise program in the first group, upper trapezius inhibition tape will be applied on the myofascial trigger points in the upper trapezius 3 times a week. The KT (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, USA) used in this study will be waterproof, porous and adhesive. 5 cm wide and 0.5 mm thick kinesio tape will be used. Before the application, the patient will be seated and asked to bring the neck to the opposite side lateral flexion and the head to the same side rotation. In this position, the Kinesiotape inhibition technique will be applied. The tape will be asked to stay on the person for 2 days, then it will be interrupted for 1 day and then the same application will be made. This practice will continue during the 4 weeks of treatment.
89166679|NCT06012305|Experimental|Taping Group with Epidermis Dermis Fascia Technique|In addition to the exercise program in the first group, kinesio taping will be applied with web cut cutting with EDF technique on myofascial trigger points in the upper trapezius. Before the application, the patient will be seated and asked to bring the neck to the opposite side lateral flexion and the head to the same side rotation. Tape will be applied with EDF technique. The band will be asked to stay on the person for 2 days, then a break for 1 day and then the same application will be made again. This practice will continue during the 4 weeks of treatment.
89166680|NCT06007183|Active Comparator|Group 1a|PXVX0317 vaccine booster, 3 years post initial vaccination
89166681|NCT06007183|Placebo Comparator|Group 1b|Placebo booster, 3 years post initial vaccination
89166682|NCT06007183|Active Comparator|Group 2a|PXVX0317 vaccine booster, 4 years post initial vaccination
89166683|NCT06007183|Placebo Comparator|Group 2b|Placebo booster, 4 years post initial vaccination
89166684|NCT06007183|Active Comparator|Group 3a|PXVX0317 vaccine booster, 5 years post initial vaccination
89166685|NCT06007183|Placebo Comparator|Group 3b|Placebo booster, 5 years post initial vaccination
89166686|NCT06007183|No Intervention|Group 4|Unrandomized or unboosted participants, for any reason
89166687|NCT06005662|Experimental|High-dose psilocybin + buprenorphine|High-dose psilocybin (30 mg) session following standard-of-care buprenorphine induction
89166688|NCT06005662|Active Comparator|Very low-dose psilocybin + buprenorphine|Very low dose psilocybin session (1 mg) following standard-of-care buprenorphine induction
89166689|NCT05996471|Experimental|Participants Receiving VH3810109 Plus Cabotegravir|
89166690|NCT05996471|Experimental|Participants Receiving VH3810109 Plus rHuPH20 Plus Cabotegravir|
89166691|NCT05996471|Active Comparator|Participants Receiving Standard of Care (SOC) Antiretroviral Therapy (ART)|
89166692|NCT05989750|Active Comparator|Control procedure|Ultrasonic scaling and polishing will be performed every 6 months for subgingival cleaning
89166693|NCT05989750|Experimental|Test procedure|AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning
89166694|NCT05986929||Staff on the neurology and geriatric units|Staff that will participate in the electronic survey (N=100) and focus group (N=6-8)
89166695|NCT05986916||Single arm|This is a single arm study in which all participants undergo the same research procedures.
89166696|NCT05986526|Active Comparator|Pulmonary vein isolation without posterior wall ablation|Pulmonary vein isolation without left atrial posterior wall ablation
89166697|NCT05986526|Active Comparator|Pulmonary vein isolation with posterior wall ablation|Pulmonary vein isolation with left atrial posterior wall ablation
89166698|NCT05976919||COPD|
89166699|NCT05976919||Asthma|
89166700|NCT05976919||Bronchiectasis|
89166701|NCT05976919||Cystic fibrosis|
89166702|NCT05976919||Primary ciliary dyskinesia|
89166703|NCT05975905|Experimental|Arm 1 (N=20)|KER-012 (Dose A) subcutaneously (SC) (every 4 weeks [Q4W]) Treatment Period: Dose A for 24 weeks; Extension Period: Dose A for another 72 weeks
89166704|NCT05975905|Experimental|Arm 2 (N=20)|KER-012 (Dose B) SC (Q4W) Treatment Period: Dose B for 24 weeks; Extension Period: Dose B for another 72 weeks
89166705|NCT05975905|Experimental|Arm 3 (N=20)|KER-012 (Dose C) SC (Q4W) Treatment Period: Dose C for 24 weeks; Extension Period: Dose C for another 72 weeks
89166706|NCT05975905|Placebo Comparator|Arm 4 (N=30)|Treatment Period: Placebo for 24 weeks; Extension Period: Dose B for another 72 weeks
89166707|NCT05974345||Virtual Patient with ASCVD|Virtual Patient with ASCVD and LDL-C ≥ 70 mg/dL despite receiving a well-tolerated high-intensity statin with or without ezetimibe. Each virtual patient is his own control.
89166708|NCT05959486|Active Comparator|BR6002A+BR6002B|
89166709|NCT05959486|Experimental|BR6002|
89166710|NCT05952024|Experimental|Acalabrutinib and Rituximab|Patients will receive Dose A of acalabrutinib orally in X dosing schedule beginning on Cycle 1 Day 1 for a maximum of 28 cycles or until 2014 Lugano Classification for Non-Hodgkin's Lymphoma (NHL)-defined disease progression or another discontinuation criterion is met. Patients will also receive an intravenous (IV) infusion of Dose B rituximab on Cycle 1 Day 15 and Dose C of rituximab as an subcutaneous (SC) injection on Day 1 of Cycle 2 through Cycle 8.
89166711|NCT05950022|Experimental|Endoscopic tenotomy at the level of the lesser trochanter|Patients will benefit from endoscopic tenotomy surgery of the iliopsoas tendon at the level of the lesser trochanter.
89166712|NCT05950022|Experimental|Endoscopic tenotomy at the level of the acetabular notch|Patients will benefit from endoscopic tenotomy surgery of the iliopsoas tendon at the level of the acetabular notch.
89166713|NCT05946395|Experimental|Hearing aid and synchronous speech therapy|This arm will begin speech therapy at the same time as the fitting of the hearing aid.
89166714|NCT05946395|Active Comparator|Hearing aid and deferred speech therapy|This arm will begin speech therapy 3 months after fitting the device.
89166715|NCT05946057||Otoferlin participant group|Individuals with hearing impairment who have a molecular genetic diagnosis involving otoferlin
89166716|NCT05945290||Observational (Biospecimen collection, medical record)|Patients undergo blood sample collection throughout the study. Patients also undergo collection of leftover tissue samples from SOC procedures and have medical records reviewed.
89166717|NCT05938725|Experimental|KYV-101 CAR-T cells with lymphodepletion conditioning|Dosing with KYV-101 CAR T cells
89166718|NCT05937009|Experimental|Experimental: Experimental Orienteering group program|The experimental group intervention will attend the orienteering program. The program integrates 3 sessions / week during 12 consecutive weeks.
89166719|NCT05937009|No Intervention|The control group|"The control group will maintain the usually daily activities, not attending any exercise program.~After study end, the control group will have the opportunity to participate on an exercise program."
89166720|NCT05935995|Experimental|Microscopy confocal|
89166721|NCT05933161||Left Ventricular Assist Device (LVAD) supported Type 2 Diabetes Mellitus (T2DM) Subjects|Subjects diagnosed with T2DM who have a LVAD will be provided a Freestyle Libre 3 CGM.
89166722|NCT05932901||Dapagliflozin 10mg initiators|Adult patients (aged ≥18 years) with chronic kidney disease, who received a dapagliflozin 10mg prescription on or after the country-specific CKD indication approval date, and who did not previously have a prescription for dapagliflozin.
89166723|NCT05932901||Dapagliflozin 10mg eligible but untreated|Adult patients (aged ≥18 years) with chronic kidney disease, who meet the country-specific approved dapagliflozin 10mg treatment criteria for CKD on or after the local CKD indication approval date, but have not received a prescription
89166724|NCT05932901||Incident CKD|Adults patients (aged ≥18 years) who newly meet the CKD definition (diagnosis or laboratory indication) during the study period.
89166725|NCT05930028|Experimental|Fimasartan/Ezetimibe/Atorvastatin|BR1017A+BR1017B(Experimental Group)
89166726|NCT05930028|Active Comparator|Fimasartan|BR1017A(Control Group 2)
89166727|NCT05930028|Active Comparator|Ezetimibe/Atorvastatin|BR1017B(Control Group 1)
89166728|NCT05925920|Active Comparator|Active|Receive a single dose of ENT-03 sub-cutaneously
89166729|NCT05925920|Placebo Comparator|Placebo|Receive a single dose of placebo sub-cutaneously
89166730|NCT05925569|Experimental|BPA Alert Intervention|An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the clinician that their patient should be screened for Primary Aldosteronism and provides an order set for the corresponding laboratory evaluation. Details of the electronic alert are provided in the Intervention description.
89166731|NCT05925569|No Intervention|No Alert Intervention|No electronic alert will be issued in the No Intervention group. Providers will continue standard of care with their patients.
89166732|NCT05923827|Active Comparator|Intervention Group|Omnipod 5 System with FreeStyle Libre 2 continuous glucose monitor
89166733|NCT05923827|No Intervention|Control Group|Multiple daily injections of insulin with FreeStyle Libre 2 continuous glucose monitor
89166734|NCT05915455|Experimental|HCP resource evaluation|HCP will be provided with resources to evaluate
89166735|NCT05915195|Active Comparator|Routine Physical Therapy|routine physical therapy including range of motion exercises (Active assisted), stretching exercises, strengthening and positioning. Daily session was of 1 hour, 5 times weekly for 6 weeks.
89166736|NCT05915195|Experimental|Routine Physical Therapy and Postural and Kinesthetic Awareness|routine physical therapy and additionally postural and kinesthetic Awareness in front of mirror by emphasizing proper body positioning, movements & balance in sitting and standing position by using interoceptive and exteroceptive reinforcement (verbal, tactile & visual).
89166737|NCT05909605||Ultrasound blood pressure sensor|
89166738|NCT05900700|Experimental|eYST website|
89166739|NCT05899140|Other|Standard of care|"Participants with skin and soft-tissue infections requiring systemic treatment (oral or intravenous). Treatment according to local guidelines = standard of care: usually an anti-staphylococcal penicillin with or without incision and drainage, as required.~Treatment can be with (local guidelines) cloxacillin (non-severe) po 500g QIDfor 5-7 days ceftriaxone (severe infections) 2g iv OD with step-down to cloxacillin po 500 mg QID for a total of 7 days"
89166740|NCT05899140|Active Comparator|Standard of care + clindamycin|"Participants with skin and soft-tissue infections requiring systemic treatment (oral or intravenous).~Addition of clindamycin: 10 mg/kg/dose QID iv (maximum 600mg QID iv) or oral clindamycin 450 mg TDS for adults for a total of 7 days from randomisation."
89166741|NCT05898191|Experimental|laser|laser treatment (Laser CO² MIXTO PRO, LASERING SRL, Modena, Italy; three sessions, one per month)
89166742|NCT05898191|No Intervention|control|no intervention
89166743|NCT05893108|Experimental|Losartan|ethosomal gel bearing losartan 5% applied two times a day for three consecutive months on keloids
89166744|NCT05893108|Active Comparator|Triamcinolone|Intralesional injection of triamcinolone acetonide 10 mg/ml every two weeks for three consecutive months on keloid
89166745|NCT05885516|Placebo Comparator|Single intrauterine insemination group|When the leading follicle is greater than 17 mm following ovulation induction with follicle stimulating hormone (FSH) daily injections, ovulation trigger injection will be given to the participant. 36 hours after ovulation trigger injection single intrauterine insemination with partner's sperm collected on the same day will be done.
89166746|NCT05885516|Experimental|Double intrauterine insemination group|When the leading follicle is greater than 17 mm following ovulation induction with follicle stimulating hormone (FSH) daily injections, ovulation trigger injection will be given to the participant. 24 and 48 hours after ovulation trigger injection intrauterine insemination will be done twice with partner's sperm collected on the specified days.
89166747|NCT05885152|Experimental|Whole-body electrical stimulation, Protocol 1|A whole body electrical stimulation session. Symmetrical biphasic current will be used, pulse width of 400µs, frequency of 75Hz, contraction time of five seconds, rest time of 10 seconds, for eight minutes, totaling 32 muscle contractions. During the first two minutes of stimulation, the patient will remain in isometry to become familiar with the electrical current. Then with the use of a stick (for proprioception), a series of biceps exercises and a series of triceps exercises, a series of sit-ups and a squat, a series of step ups and downs, and a series of plantings.
89166748|NCT05885152|Experimental|Whole-body electrical stimulation, Protocol 2|A whole body electrical stimulation session. Symmetrical biphasic current will be used, pulse width of 400µs, frequency of 75Hz, contraction time of five seconds, rest time of 10 seconds, for 16 minutes, totaling 64 muscle contractions. During the first two minutes of stimulation, the patient will remain in isometry to become familiar with the electrical current. Then with the use of a stick (for proprioception), a series of biceps exercises and a series of triceps exercises, a series of sit-ups and a squat, a series of step ups and downs, and a series of plantings.
89166749|NCT05881681|Experimental|App-Delivered Mindfulness Training (MT)|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
89166750|NCT05880836|Experimental|Path A (vibrating mesh nebulizer (VMN) with the high flow nasal cannula)|Enrolled patients will receive two standard forms of inhaled medications as ordered by the physician. Patients will be randomized into two paths of the cross over study. There will be no blinding involved in this randomization. Path A will have medications delivered trans-nasally in line via the vibrating mesh nebulizer (VMN) with the high flow nasal cannula followed by standard jet nebulization (SJN) with face mask at the next time of medication dosing 3-6 hours later.
89166751|NCT05880836|Active Comparator|Path B (standard jet nebulization (SJN) with face mask)|Path B will receive standard jet nebulization without HFNC followed by the trans-nasal in line nebulization via the HFNC. Patients agreed to enroll in day 2 of the trial will have their clinical path alternated in attempt to control for diurnal variability. All patients will also receive as-needed nebulized treatments as well as usual supportive care provided by respiratory therapists. As needed therapy will be delivered via the method of the current arm of the study they are in, and the washout period will subsequently reset.
89166752|NCT05880212|Active Comparator|Usual physiotherapy care|One physiotherapy assessment, 10 x 45-minute sessions of usual care physiotherapy (over a 10-week period), plus 1 x 45-minute followup session of usual care physiotherapy after 6 months.
89166753|NCT05880212|Experimental|Individualized (STOPS) physiotherapy|One physiotherapy assessment, 10 x 45-minute sessions of individualised (STOPS) physiotherapy (weekly for 10 weeks), plus 1 x 45-minute followup session of individualised (STOPS) physiotherapy after 6 months.
89166754|NCT05879185|Experimental|XmAb23104 in People With Sarcoma|Patients will receive the recommended phase II dose of XmAb23104 monotherapy on day 1 and 15 of each 28-day cycle. Patients will continue XmAb23104 (day 1 & 15, q 28 days) for up to 24 months depending on their response and tolerability to treatment. Treatment will be continued until progressive disease (PD) or toxicity or a total of 24 months of study therapy has been completed.
89166755|NCT05878093|Experimental|Dupilumab|Dupilumab every 2 weeks (Q2W) via SC injection
89166756|NCT05878093|Placebo Comparator|Placebo|Placebo matching dupilumab Q2W via SC injection
89166757|NCT05874921||Jelmyto|Patients with UTUC treated with Jelmyto
89166758|NCT05870046|Experimental|power exercise group|"The main part of the muscle power exercise program will have the following exercises: wall push-ups, arm raises, elbow push-ups and extensions, weighted pronosupination, hand press, knee and hip hinge squat, dead weight, front and sagittal plan stride, and heel raises.~It will have different phases:~1st phase: exercise adaptation: the correct execution of upper and lower limb exercises will be taught for one month.~2nd phase: Resistance training: During the following two months, strength exercises will be performed at slow and normal speed of the movement patterns learned in the training course.~3rd phase: Muscle power training: During the last five months. A correct progression of the load and a progressive increase in the speed of execution of the different exercises will be carried out, gradually increasing the levels of difficulty and intensity."
89166759|NCT05870046|Active Comparator|multimodal exercise group|"The main part of the multicomponent exercise program integrates different exercise modalities: Aerobic, mobility, strength, balance and coordination exercises, playful activities or games are also included with some activities aimed at working on cognitive functions to reinforce the overall effects of the program, such as games with colors, numbers, letters, right-left laterality, memory, etc.~The progression of the different models is as follows:~E. Aerobic: Start with continuous work, then intervallic, and decrease rest times in intervallic work.~E. Strength: Increase sets, repetitions and decrease rest time.~Balance: start with static and evolve with blindfolds, perturbations, dynamic balance, etc.~Coordination, and cognitive games will also become more complicated, with more complicated and faster decision making."
89166760|NCT05870046|No Intervention|Control group|Participants in this group should continue with their usual dietary pattern and level of physical activity, without changing their lifestyle habits during the study period. They will not participate in the strength exercise program based on muscle power, nor will they perform systematic, programmed and supervised physical exercise in any other program.
89166761|NCT05869331|Experimental|Nonoperative treatment|Patients in this group were treated with early mobilization.
89166762|NCT05869331|Active Comparator|Operative treatment|Patients in this group were treated surgically.
89166763|NCT05867238||Student nurse anaesthetists with no training in stress management|Student nurse anaesthetists who participated in the previous study: stress of anaesthesia professionals in the operating theatre and did not receive stress management training.
89166764|NCT05867238||Student nurse anaesthetists with training in stress management|Volunteer nurse anaesthetist students who have received training in stress management this year.
89166765|NCT05866679|Experimental|Hyperpolarized 13-C-pyruvate|
89166766|NCT05857930|Experimental|OM-85|Patients will receive OM-85 capsules as a treatment for 6 months and will be under observation for 6 months.
89166767|NCT05857930|Placebo Comparator|Placebo|Patients will receive placebo capsules as a treatment for 6 months and will be under observation for 6 months.
89166768|NCT05856123|No Intervention|Standard of Care Transfer|After cardiac catheterization lab or electrophysiology lab procedure, the subject will be moved from one bed to another using the current standard of practice lateral patient transfer methods by nursing staff.
89166769|NCT05856123|Experimental|SimPull Device Transfer|After cardiac catheterization lab or electrophysiology lab procedure, the subject will be moved from one bed to another using the SimPull device.
89166770|NCT05854407|Other|pasteurized skim milk|300 mL of commercial pasteurized skim milk (heated for 15s at ~72 °C)
89166771|NCT05854407|Other|High-pasteurized skim milk|300 mL of High-pasteurized skim milk prepared by heating commercial pasteurized skim milk for 30 min at 80 °C
89166772|NCT05843318|Experimental|Pre-meal water + Hypocaloric diet|premeal water ( 500 ml) before each main meal, three times per day + hypocaloric diet
89166773|NCT05843318|Experimental|Daily water + Hypocaloric diet|total daily water prescription (1500 ml/d) + hypocaloric diet
89166774|NCT05843318|Active Comparator|Hypocaloric Diet alone|hypocaloric diet with not instructions regarding water intake
89166775|NCT05842330|Experimental|Pharmaceutical intervention (OROS-MPH)|Participants will receive OROS-MPH (Concerta® available in Switzerland as first-line treatment for ADHD). Dosages will be defined according to the Swiss Compendium. The psychiatrist (blinded during detention) will start with the smallest dosage (18 mg, Concerta®). The treatment will be monitored weekly the first month, and then monthly. The pharmacy of the Geneva University Hospitals will be in charge of over-encapsulating medications.
89166776|NCT05842330|Placebo Comparator|Placebo|
89166777|NCT05841953|Experimental|Single arm|All participant will be exposed to the full stimulation protocol 2 different protocols using 2 different electrode arrays will be studied in random order.
89166778|NCT05838677|Experimental|Intervention Group: Pain at Work Toolkit|Intervention participants receive the PAW toolkit plus 3 x optional occupational therapy calls (approximately 30 minutes each) involving orientation to the PAW Toolkit and individually tailored advice and behavioural strategies for managing pain at work. This digital web-based toolkit is designed to support people with chronic pain in self-managing their condition at work. PAW offers evidence-based advice about chronic or persistent pain, disability rights, work capacity, pain self-management strategies and signposting to support.
89166779|NCT05838677|Active Comparator|Active Control Group: Treatment as Usual|Participants do not receive the PAW Toolkit but instead have treatment as usual (TAU) from their employer. The nature of TAU will be recorded as part of the feasibility study. Depending on the employing organisation, TAU may consist of (but is not limited to) any combination of the following: occupational health, counselling, line manager support, signposting to education about factors that may have positive or negative effects on chronic pain. Participants can access non-specialist telephone calls from a researcher to discuss their participation in the study.
89166780|NCT05835440||staff stakeholders|The potential stakeholders are a diverse population and will include managers, emergency department clinicians and practitioners, radiologists, radiographers, administrative staff and surgeons. A maximum total of 4 staff stakeholder interviews shall be undertaken.
89166781|NCT05835440||patient participants|The patient population are adults who have sustained a traumatic wrist injury with normal X-rays and have been treated by NHS services.
89166782|NCT05829655|Experimental|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge
89166783|NCT05829655|Placebo Comparator|Placebo|Double blind administration of placebo once per day during residential stay until discharge
89166784|NCT05827146|Experimental|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 4 week
89166785|NCT05827146|Experimental|Hepalatide 4.2mg|4.2 mg/day subcutaneously (s.c.) for 4 week
89166786|NCT05827146|Experimental|Hepalatide 6.3mg|6.3 mg/day subcutaneously (s.c.) for 4 week
89166787|NCT05827146|Placebo Comparator|Placebo 2.1mg/4.2mg/6.3mg|Placebo 2.1 mg/4.2mg/6.3mg, once a day subcutaneously (s.c.) for 4 week
89166788|NCT05820308|Experimental|Intervention Group|Companion dog walking
89166789|NCT05820308|Active Comparator|Attention Control Group|Educational resources about dog health
89166790|NCT05811416||Cohort 1|Participants that have initiated ozanimod.
89166791|NCT05810714|Active Comparator|Arm I (FIT, usual care)|Participants receive the FIT kit and usual care on study.
89166792|NCT05810714|Experimental|Arm II (FIT, audio brochure, reminder)|Participants receive the FIT kit with an audio brochure, disposable gloves and stool collection device, and scheduled reminder on study.
89166793|NCT05810714|Experimental|Arm III (FIT, video brochure, reminder)|Participants receive the FIT kit with a video brochure, disposable gloves and stool collection device, and scheduled reminder on study.
89166794|NCT05807867|Experimental|WMM-based intersectional stigma intervention|"N=90 Women with SMI and HIV in arm 1 will receive WMM stigma intervention as clients transition from psychiatric hospitalization to outpatient care. The curriculum, co-led by a trained clinician and a peer woman with SMI and HIV, will comprise of 8 group sessions at ~60 minutes each. Following psychiatric stabilization, but while still an inpatient, women participants will receive 5 (delivered 2x weekly) of 8 session anti-stigma intervention. To facilitate community integration, the final 3 WMM-based intervention sessions will be delivered once every two weeks at a community-based setting in Gabarone.~Parallel Group Stigma intervention: N=90 Family members will receive an adapted 3-session WMM-based group intervention that uses the same intervention components. The first 2 sessions will be held weekly in a private room at Sbrana Hospital, while the final session will be held 2 weeks following client discharge in the same community-based setting as above."
89166795|NCT05807867|Active Comparator|Attention placebo control|To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content. Control co-leaders will receive a 1-day training on the control manual and facilitation techniques. Sessions will focus on general health education (i.e., diet, exercise, avoiding alcohol, and healthy sleep habits) for women with SMI and HIV adapted from Ministry of Health materials. The investigators will offer in-person sessions including facilitated discussions to encourage interaction (per the WMM intervention). The investigators expect participation in the attention control arm (~84% retention) to approximate that of women (and family members) attending the intervention arm. While intended to be salient to women participants and their family members, this program should not decrease stigma nor has it been shown to impact MH outcomes.
89166796|NCT05807321|Experimental|Fecobionics|
89166797|NCT05806255|Experimental|RELIEF Intervention Group|"The RELIEF App will be implemented according to a standardized procedure at the six following sites, with 100 patients recruited at each site:~Home and Community Care Support Services Central West~Home and Community Care Support Services Central~Home and Community Care Support Services Champlain~Home and Community Care Support Services North East~Curve Lake First Nation (CLFN)~St. Mary's Hospital"
89166798|NCT05802550|Other|Longitudinal cohort study in cataract patients|Longitudinal, open-label, single-center cohort study in cataract patients.
89166799|NCT05798338||Early Breast Cancer patients|"Diagnosis of early breast cancer;~Indication for surgery after multidisciplinary discussion."
89166800|NCT05798338||Metastatic Breast Cancer patients|"First diagnosis of metastatic breast cancer confirmed by cytological/histological examination or by imaging;~Indication to chemotherapy."
89166801|NCT05798338||Healthy patients|- Patients having a negative mammography or breast ultrasound within 12 months from the study enrollment.
89166802|NCT05796531|Active Comparator|Active intervention arm|Participants will complete the intervention on a mobile device.
89166803|NCT05796531|Sham Comparator|Control arm|Participants will complete the sham comparator on a mobile device.
89166804|NCT05794230|Experimental|Groups 1a, 1b and 1c Cohort Ia (India)|2 injections of MenACYW conjugate vaccine: at 6 months of age and second dose at 12 months of age (group 1a) or at 15 months of age (group 1b) or at 16 months of age (group 1c) + co-administered routine pediatric vaccines
89166805|NCT05794230|Active Comparator|Group 2 Cohort Ia (India)|2 injections of Menactra vaccine: at 9 months of age and second dose at 16 months of age + co-administered routine pediatric vaccines
89166806|NCT05794230|Experimental|Groups 3 Cohort Ib (RSA)|2 injections of MenACYW conjugate vaccine: at 6 months of age and second dose between 12 and 16 months of age + co-administered routine pediatric vaccines
89166807|NCT05794230|Active Comparator|Group 4 Cohort Ib (RSA)|2 injections of Menactra vaccine: at 9 months of age and second dose between 12 and 16 months of age + co-administered routine pediatric vaccines
89166808|NCT05794230|Experimental|Groups 5a and 5b Cohort IIa (India)|3 injections of MenACYW conjugate vaccine: at 6-8 weeks of age and second dose at 14-16 weeks of age with a booster dose administered at 12 months of age (group 5a) or at 15 months of age (group 5b) + co-administered routine pediatric vaccines
89166809|NCT05794230|Other|Group 6 Cohort IIa (India)|routine pediatric vaccines only
89166810|NCT05794230|Experimental|Group 7 Cohort IIb (RSA)|3 injections of MenACYW conjugate vaccine: at 6-8 weeks of age and second dose at 14-16 weeks of age with a booster dose administered between 12 and 15 months of age + co-administered routine pediatric vaccines
89166811|NCT05794230|Other|Group 8 Cohort IIb (RSA)|routine pediatric vaccines only
89166812|NCT05793944|Active Comparator|Intervention: SmartMom messaging|Participants receive three text messages per week with evidence-based information to promote healthy behaviours during pregnancy.
89166813|NCT05793944|Placebo Comparator|Control messaging|Participants receive one text message per week with general information about pregnancy but not about making healthy choices.
89166814|NCT05788679|Experimental|Intervention in MRD positive patients|Azacitidine and / or Donor lymphocytes or tapering of immune suppression
89166815|NCT05784298|Experimental|Real low-intensity rTMS|One 45 minutes session of stimulation. The stimulation coil will be located in the precuneus, located in the Pz area of the 10-20. The coil will emit a pulsed magnetic field at a frequency of 40 Hz with a magnetic field strength of 150 gauss.
89166816|NCT05784298|Sham Comparator|Sham low-intensity rTMS|One 45 minutes session of stimulation. The stimulation coil will be located in the precuneus, located in the Pz area of the 10-20. The coil will not emit any magnetic field.
89166817|NCT05777759|Experimental|New Dermal Filler for indication|hyaluronic acid dermal filler
89166818|NCT05777759|Active Comparator|Active Comparator: FDA approved Dermal Filler|hyaluronic acid dermal filler
89166819|NCT05776095|Experimental|Eyedeal® IOL|Eyedeal® Model PX65AS1 IOL
89166820|NCT05774639|Experimental|ADL-018 300 mg Main Treatment period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
89166821|NCT05774639|Active Comparator|Xolair-300 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
89166822|NCT05774639|Experimental|ADL-018 150 mg Main Treatment period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
89166823|NCT05774639|Active Comparator|Xolair-150 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
89166824|NCT05774639|Experimental|ADL-018 300 mg Main / ADL-018 300 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to ADL-018 300 mg in the Main Treatment period.
89166825|NCT05774639|Experimental|Xolair-300 mg Main / ADL-018 300 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
89166826|NCT05774639|Active Comparator|Xolair-300 mg Main / Xolair-300 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
89166827|NCT05774639|Experimental|ADL-018 150 mg Main / ADL-018 150 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to ADL-018150 mg in the main treatment period.
89166828|NCT05774639|Experimental|Xolair-150 mg Main / ADL-018150 mg Transition Period|ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
89166829|NCT05774639|Active Comparator|Xolair-150 mg Main / Xolair-150 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
89166832|NCT05770193|Experimental|pursed lip breathing and CBT in addition to kinesio tape.|patients will receive pursed lip breathing and cognitive-behavioral therapy in addition to kinesio tape.
89166833|NCT05770193|Experimental|pursed lip breathing and CBT in addition to diaphragmatic breathing exercise.|patients will receive pursed lip breathing and cognitive-behavioral therapy in addition to diaphragmatic breathing exercise
89166834|NCT05770193|Active Comparator|pursed lip breathing and CBT.|patients will receive pursed lip breathing and cognitive-behavioral therapy.
89166835|NCT05762887|Experimental|Probiotic group|"In addition to the usual medication treatment for bipolar disorder, following the main international guidelines for the treatment of bipolar disorder, subjects will receive food supplementation with a probiotic formulation, twice daily, with food. We will use Pendulum Therapeutics' Glucose Control, probiotic formulation patented in the United States.~Probiotic Ingredients: Clostridium butyricum WB-STR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WB-STR-0001, and Bifidobacterium infantis.~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit & vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
89166836|NCT05762887|Placebo Comparator|Placebo Group|"In addition to the usual medication treatment for bipolar disorder, following the main international guidelines for the treatment of bipolar disorder, the subjects will receive food supplementation with a placebo formulation, twice daily, with food We will use Pendulum Therapeutics' placebo formulation that contains:~Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit & vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
89166837|NCT05756738|Experimental|Alternative sentences to prison|Persons with alternative sentences to prison will be informed of the study and, according to the randomization code, will be: a) given an envelope with all the necessary material to carry out the test at home and send it to the hospital for processing or, b) be tested on site at the the Social Insertion Center premises, who will also send it to the hospital for processing by the Central Laboratory of the University Hospital of the Canary Islands.
89166838|NCT05756738|Experimental|Open system|They will be offered to take the diagnostic test in situ at the the Social Insertion Center premises.
89166839|NCT05734768||Preterm newborns and their parents|Thirty premature children born between 32 and 36+6 weeks of gestation, and their parents.
89166840|NCT05734768||term newborns and their parents|Thirty children, born at more than 37 weeks (≥37+0), and their parents
89166841|NCT05732454|Experimental|etrasimod|2 mg, oral tablet, once daily
89166842|NCT05732454|Placebo Comparator|Placebo (Part 1 DB period only)|Oral sham comparator
89166843|NCT05721521|Experimental|High intensity|
89166844|NCT05721521|Experimental|Moderate intensity|
89166845|NCT05721521|Experimental|Low intensity|
89166846|NCT05721521|Placebo Comparator|No exercise (control)|
89166847|NCT05715970|Experimental|General population|25,000 subjects, divided between Sicily and Malta. Approximately 10,000 students aged between 12 and 18 will be enrolled in Malta and approximately 15,000 adults (>18 years) will be enrolled in Sicily. These numbers are dictated by the need to obtain heterogeneous samples comparable with the subjects diagnosed in the previous ITAMA project (20,000). In Sicily, screening will be carried out in the GPs (Italian takers) clinics. In Malta the recruitment will be performed in the schools (Maltese takers). Furthermore, in Malta, a further extension of the results provides for the execution of the PoCT+questionnaire in the asymptomatic first-degree relatives of the pediatric subjects with an ascertained diagnosis of CD identified in the previous project.
89166848|NCT05710549|Experimental|neurophysiological measurements|40 cognitively-unimpaired healthy young adults (age 18-35 years old), 40 cognitively-unimpaired healthy older adults (age 55+ years old), and 40 age-matched patients with mild cognitive impairment (MCI) (age 55+ years old) will be assessed using high-density electroencephalography (hdEEG) to characterize the spatiotemporal dynamics of brain oscillations during personalized, autobiographical memory (ABM) tasks.
89166849|NCT05710549|Experimental|neuropsychological examination|40 MCI patients (age 55+ years old) will undergo 20min multi-channel protocols of transcranial alternating current stimulation; tACS (either gamma, beta, or ActiSham stimulation randomized across the three laboratory sessions) to modify cognitive functioning (MoCA score), and oscillatory brain activity during performing personalized, autobiographical memory (ABM) tasks and resting-state EEG.
89166850|NCT05708001|Experimental|Transcranial alternating current stimulation (tACS)|The randomized, sham-controlled, parallel-arm, double-blind clinical trial will include 12 weeks of daily, home-based stimulation sessions. MCI patients will be randomly assigned to the active or sham group.
89166851|NCT05708001|Experimental|neurophysiological (hdEEG)|At the baseline, after the first 4 weeks, and at the end of 12 weeks, MCI patients will be evaluated in the laboratory using hdEEG.
89166852|NCT05708001|Experimental|clinical measures (MoCA)|At the baseline, after the first 4 weeks, and at the end of 12 weeks, MCI patients will be evaluated in the laboratory using MoCA.
89166853|NCT05705999|Active Comparator|Active rTMS|Patients receiving active rTMS
89166854|NCT05705999|Sham Comparator|Sham rTMS|Patients receiving sham rTMS
89166855|NCT05702853|Experimental|Dose Level 1|1 x 10^6 transduced T cells/kg (± 20%)
89166856|NCT05702853|Experimental|Dose Level 2|1.5 x 10^6 transduced T cells/kg (± 20%)
89166857|NCT05702853|Experimental|Dose Level 3|2 x 10^6 transduced T cells/kg (± 20%)
89166858|NCT05695976||Pilot|"The first 20 patients accrued to this study will be assayed to validate the performance of the assays developed by Personalis. This pilot sub-study will be analyzed in a blinded manner without clinical information."
89166859|NCT05695976||Full Study|"The remaining 80 patients accrued to this study (after the initial 20 patients accrue to the Pilot cohort)."
89166860|NCT05695391|Experimental|Coagulation Factor VIIa (Recombinant)|
89166861|NCT05688280|Experimental|Colorectal Cancer (CRC)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
89166862|NCT05688280|Experimental|Non-Small Cell Lung Cancer (NSCLC)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
89166863|NCT05688280|Experimental|Soft Tissue Sarcoma (STS)|Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.
89166864|NCT05682625||Participants|Adults who are receiving a COVID-19 vaccine
89166865|NCT05680727|Other|real individualized resting state functional connectivity targeting|Participants in this group will receive aiTBS with neuronavigation to a treatment target identified with individualized resting state functional connectivity.
89166866|NCT05680727|Other|sham individualized resting state functional connectivity targeting|Participants in this group will receive aiTBS with neuronavigation to a treatment target identified with head measurements (i.e., Beam F3)
89166867|NCT05676710|Experimental|Experimental|PI3K inhibitors
89166868|NCT05674526|Experimental|WU-NK-101 Monotherapy/Cetuximab combo Run-in|"WU-NK-101 is a non-engineered Natural Killer (NK) cell derived from peripheral blood mononuclear cells (PBMC) that is cytokine-reprogrammed, expanded, and cryopreserved to create an allogeneic enhanced memory-like anti-tumor NK cell therapy product.~Each 8 week cycle in dose escalation is divided into two 28- days segments. Patients will receive WU-NK-101 (Days 1 and 15) in the first segment and a combination of cetuximab (500mg/m2 on Days 29 and 43) plus WU-NK-101 (Days 30 and 44) in the second segment."
89166869|NCT05674526|Experimental|WU-NK-101 /Cetuximab Combo|Patients will receive cetuximab dosed at 500 mg/m2 on Days 1 and 15, and WU-NK-101 on Days 2 and 16, in each 4-week cycle. Depending on response patients may receive up to 6 cycles of treatment.
89166870|NCT05665543|Experimental|GLAm App|Participants will have access to Game based Learning Avatar navigated mobile (GLAm ) app and will receive the receive the quality improvement (QI) intervention plus the GLAm app.
89166871|NCT05665543|No Intervention|Usual care|Participants in the control group will not receive the access to the GLAm app. They will receive the quality improvement (QI) intervention only.
89166872|NCT05664776|Experimental|Arm A (control first)|The pre-existing static office chair will be used in the personal workplace for the first 6 weeks within the first half of the study. A wash-out period of a minimum of 4 weeks will be executed after the first half of the study. A dynamic office chair will be used on the personal workstation for 6 weeks within the second half of the study after the wash-out period.
89166873|NCT05664776|Experimental|Arm B (intervention first)|A dynamic office chair will be used in the personal workplace for the first 6 weeks within the first half of the study. A wash-out period of a minimum of 4 weeks will be executed after the first half of the study. The pre-existing static office chair will be used on the personal workstation for 6 weeks within the second half of the study after the wash-out period.
89166874|NCT05664451|Active Comparator|Streamlined Practice Facilitation (SPF) implementation of UI-Assist|Streamlined practice facilitation encompasses multiple well-established strategies from the Expert Recommendations for Implementing Change (ERIC) as field-tested in and updated after EvidenceNOW. To ensure the interventions and tools offered are consistent across practices, practice facilitators will receive training and support on UI-Assist, milestones, tracking tools for documenting changes made by sites, etc. according to a Practice Facilitation Training Manual and toolkit that will be built based on ones used for prior EvidenceNOW initiatives.
89166875|NCT05664451|Experimental|Streamlined Practice Facilitation (SPF) + Partnership Building (PB) implementation of UI-Assist|In addition to streamlined practice facilitation, those practices allocated to Streamlined Practice Facilitation plus Partnership Building (SPF+PB) will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a MetaStar practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner.
89166876|NCT05664412|Active Comparator|Active group|Participants will receive 20 sessions of In-phase online theta tACS paired with working memory training.
89166877|NCT05664412|Sham Comparator|Control group|Participants will receive 20 sessions of sham tACS paired with working memory training. After unblinding (by someone from our lab but external to the study), they will receive 20 sessions of in-phase offline theta tACS.
89166878|NCT05648344|Experimental|Access to WW app for 6 months|Participants will be randomized to access the WW application for 6 months
89166879|NCT05648344|Placebo Comparator|Control|Participants will be randomized to receive emails with information available from myplate.gov
89166880|NCT05641350|Experimental|Emotional eating intervention|Emotional eating intervention
89166881|NCT05641350|No Intervention|Waiting list|Waiting list
89166882|NCT05625373|Experimental|Vancomycin powder|Women randomized to receive vancomycin powder will receive 1g into each of the irrigated inguinal surgical beds (maximum of 2g dose per patient). After dissection and irrigation of the surgical bed, the operating room staff will open the medication vial and sterilely dispense the medication into a sterile container. The surgeon will place the medication powder into the irrigated and hemostatic surgical bed. The procedure will be repeated on the opposite side after dissection.
89166883|NCT05625373|No Intervention|No vancomycin powder|Patient randomized to the no vancomycin arm will not receive the intraoperative antibiotic. Their surgery will follow standard protocol. No placebo will be utilized.
89166884|NCT05618717||Surpoint Index Guided Ablation Group|Maximum Radiofrequency delivery duration cannot exceed Surpoint Index of 550
89166885|NCT05618717||Conventional Ablation Group|Operator determined ablation duration regardless of Surpoint Index Value
89166886|NCT05614583|Experimental|MORT-PFPS|Participants randomly assigned to this arm will use the app, MORT-PFPS.
89166887|NCT05614583|Active Comparator|treatment as usual (TAU)|Participants randomly assigned to this arm will receive their TAU only (no use of the app, MORT-PFPS).
89166888|NCT05605366|Experimental|Treatment arm (1)|This arm will receive 200mg of minocycline in a single capsule per day.
89166889|NCT05605366|Active Comparator|Treatment arm (2)|This arm will receive 300 mg of minocycline in a single capsule per day. This capsule is identical in size and appearance as the 200 mg capsule
89166890|NCT05605366|Placebo Comparator|Placebo|This arm will receive the placebo which is similar in size and appearance as the 200 mg and 300 mg capsules.
89166891|NCT05600933||1 - premalignant, primary or metastatic solid tumor|Participants >= 18 with a suspected or confirmed solid tumor malignancy that requires surgery or biopsy.
89166892|NCT05600933||2 - known or suspected hematologic malignancy|Participants >= 18 who have a known or suspected hematologic malignancy that requires surgery or biopsy.
89166893|NCT05597007|Experimental|Treatment|Clinic participation
89166894|NCT05596331|Other|Group of adult subjects without ASD (Autism Spectrum Disorders)|Age between 18 and 50 years
89166895|NCT05596331|Other|Group of children without ASD|Age between 2 and 12 years
89166896|NCT05596331|Other|Group of children with ASD|Age between 2 and 12 years Conformity with the diagnostic criteria of ASD according to DSM-V, ICD-10 or ICD-11
89166897|NCT05596331|Other|Group of children without NDD (NeuroDevelopmental Disorders)|Age between 0 and 12 years
89166898|NCT05596331|Other|Group of children with NDD, or whose diagnosis is in progress|Conformity to the diagnostic criteria of NDD
89166899|NCT05588388|Experimental|Experimental Treatment|"Induction (ABCE): Atezolizumab 1200 mg, Bevacizumab 15 mg/kg, Carboplatin AUC5, Etoposide 100 mg/m2, given IV Q3weeks~Maintenance (AB): Atezolizumab 1200 mg and Bevacizumab 15 mg/kg given IV Q3weeks for 1 year, or until disease progression, or unacceptable toxicity"
89166900|NCT05575167||single Zol group|postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive a single zoledronate infusion (5mg) at 6 months after the last denosumab dose
89166901|NCT05575167||double Zol group|postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive two zoledronate infusions (5mg) at 6 and 12 months after the last denosumab dose
89166902|NCT05575167||ALN group|postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia with denosumab and will receive alendronate 70mg orally weekly for 12 months
89166903|NCT05571293|Experimental|Botensilimab and balstilimab (bot/bal)|Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. A single dose of botensilimab (75 mg IV), and two doses of balstilimab (240 mg IV), will be administered on the same day. A second dose of balstilimab (240 mg IV) will be administered 14 days later (-2 +5 days). Surgical resection will occur 1-6 weeks following the second dose of balstilimab.
89166904|NCT05571124|Experimental|Therapeutic exercise|It consists of implementing active breaks at the workstation through the use of the open source Learning Management System Sakai [33], It will be easy to use by the participants due to the platform is used by them in their daily work. Also, an administrative worker from the university will be involved in creating the modules where the content will be allocated to ensure that the navigation in the platform is user-friendly for them.musculoskeletal pathologies with sedentary lifestyles and maintained postures. The type of online application will depend on the results obtained in the qualitative phase, as we will adapt to the workers' preferences to facilitate accessibility to the content and make the experience as satisfactory as possible for them.
89166905|NCT05571124|No Intervention|No intervention|Participants of the control group will be on a waiting list, encouraging them to maintain the same as usual in their daily activities and working hours. Once the intervention is finished, they will have access to the platform with the same content as the intervention group.
89166906|NCT05569759|Experimental|zetomibzomib + standard-of-care (glucocorticoids)|Initial 30 mg dose of zetomipzomib, followed by weekly 60 mg doses of zetomipzomib, for the remaining 23 weeks of the treatment period.
89166907|NCT05569759|Placebo Comparator|placebo + standard-of-care (glucocorticoids)|Initial 30 mg dose of placebo (sterile water for injection), followed by weekly 60 mg doses of placebo, for the remaining 23 weeks of the treatment period.
89166908|NCT05569759|Experimental|zetomipzomib + standard-of care (glucocorticoids) open-label extension period|Initial 30 mg dose of zetomipzomib at the open-label extension (OLE) Week 1 visit, followed by weekly doses of 60 mg of zetomipzomib, for a total of 24 additional weeks of treatment.
89166909|NCT05564637|Other|Healthy Volunteers|Healthy volunteers will undergo RHC while exercising and an optional muscle biopsy.
89166910|NCT05564637|Experimental|PAH-ILD Patients|Patients diagnosed with PAH-ILD will undergo RHC while exercising, receive inhaled treprostinil, and undergo an optional muscle biopsy.
89166911|NCT05560763|Experimental|Completed Cases|
89166912|NCT05559710||DMD Group|Children with Duchenne Muscular Dystrophy (DMD) between the ages of 7 and 18 who have been diagnosed with DMD as a result of genetic testing
89166913|NCT05559710||Healthy Controls|Helathy children with similar physical characteristics between the ages of 7 and 8
89166914|NCT05551364|No Intervention|Conventional Treatment|The children will continue with their current rehabilitation program
89166915|NCT05551364|Experimental|Treatment with the ATLAS 2030 Exoskeleton|The children will receive 2 hours of exoskeleton ATLAS 2030 gait training a week for 3 months
89166916|NCT05543577||Pharmacists|community, hospital and clinical pharmacists
89166917|NCT05543577||Medical interns|Medical interns of both sexes
89166918|NCT05538728|Active Comparator|8ml|Device: Sculptra current label dilution for treatment of wrinkles in the decolletage area
89166919|NCT05538728|Active Comparator|17ml|Experimental: PLLA new dilution volume for treatment of wrinkles in the decolletage area
89166920|NCT05532137|No Intervention|Control group|This arm uses the 'non-feedback' e-12HR. This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index.
89166921|NCT05532137|Experimental|Intervention group|This arm uses the 'feedback' e-12HR. This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet.
89166922|NCT05526937|Experimental|Sprouted wholemeal bread|
89166923|NCT05526937|Active Comparator|Unsprouted wholemeal bread|
89166924|NCT05526937|Placebo Comparator|White bread|
89166925|NCT05519605||PTBD after failed ERCP|Patients with a distal malignant obstruction undergoing placement of a percutaneous transhepatic biliary drain after failed ERCP.
89166926|NCT05519605||EUS-BD after failed ERCP|Patients with a distal malignant obstruction undergoing EUS-guided biliary drainage after failed ERCP.
89166927|NCT05514821|Experimental|Experimental condition 1|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd (~400mg dietary nitrate)
89166928|NCT05514821|Experimental|Experimental condition 2|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd (~400mg dietary nitrate)
89166929|NCT05514821|Placebo Comparator|Control condition 1|Acute supplementation with 140 ml nitrate-depleted Beet It Sport Shots, James White Ltd (~0mg dietary nitrate)
89166930|NCT05514821|Placebo Comparator|Control condition 2|Acute supplementation with 140 ml nitrate-depleted Beet It Sport Shots, James White Ltd (~0mg dietary nitrate)
89166931|NCT05510817|Other|RRMS patients|RRMS patients initiating a new DMT
89166932|NCT05506683|Experimental|MotoMeds users (parent/chid participant pairs)|
89166933|NCT05499637|Experimental|acute cellular cardiac allograft rejection|[68Ga]Ga-PentixaFor PET/CT
89166934|NCT05499637|Experimental|cardiac sarcoidosis|[68Ga]Ga-PentixaFor PET/CT
89166935|NCT05499637|Experimental|immune checkpoint inhibitor induced myocarditis|[68Ga]Ga-PentixaFor PET/CT
89166936|NCT05499377|Active Comparator|Tobacco-Flavored IQOS|Tobacco - where menthol smokers will only have access to tobacco-flavored HeatSticks to use in the IQOS 2.4 Tobacco Heating System
89166937|NCT05499377|Experimental|Menthol-Flavored IQOS|Menthol - where menthol smokers will only have access to menthol-flavored HeatSticks to use in the IQOS 2.4 Tobacco Heating System
89166938|NCT05498376|Active Comparator|Conventional pacemaker DDD|Implantation of a conventional dual-chamber PM
89166939|NCT05498376|Active Comparator|Leadless pacemaker Micra AV|Implantation of a leadless pacemaker system (Micra AV™)
89166940|NCT05495061|Experimental|STN1012600 0.002%|
89166941|NCT05495061|Active Comparator|Latanoprost 0.005%|
89166942|NCT05487131|Experimental|Men|Individuals will participate in 1 familiarization and 3 test sessions
89166943|NCT05487131|Experimental|Women|Individuals will participate in 1 familiarization and 3 test sessions
89166944|NCT05479565||50 pregnant women with patological OGTT|50 pregnant women with patological OGTT ( glucose load test) and after delivery - 50 women with GDM in previous pregnancy.
89166945|NCT05479565||50 pregnant women with regular OGTT|50 pregnant women with regular OGTT ( glucose load test) and after delivery - 50 women without GDM in previous pregnancy
89166946|NCT05473416|Experimental|1- McKenzie (Group A)|Back extension exercise. Total 10 repetitions in 1 set. Total 3 sets in a session. Total 3 sessions in a week. Total 12 sessions in a month.
89166947|NCT05473416|Experimental|2- Pilates (Group B)|Pelvic tilt exercise Total 10 repetitions in 1 set. Total 3 sets in a session. Total 3 sessions in a week. Total 12 sessions in a month.
89166948|NCT05472155|Experimental|Oropharyngeal suctioning with a bulb syringe|Newborn infants who have obvious obstruction to spontaneous breathing or who require positive pressure ventilation immediately after birth will be suctioned with a bulb syringe
89166949|NCT05472155|Active Comparator|Oropharyngeal suctioning with a suction catheter|Newborn infants who have obvious obstruction to spontaneous breathing or who require positive pressure ventilation immediately after birth will be suctioned with a suction catheter
89166950|NCT05470114|Experimental|LEO 138559|Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
89166951|NCT05470114|Active Comparator|Dupixent®|Participants will receive injections of Dupixent® from Week 0 (baseline) to Week 16 (end of treatment).
89166952|NCT05468333|Experimental|Main arm|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time.
89166953|NCT05464810|Experimental|Arm I (letrozole, simvastatin)|Patients receive letrozole PO QD and simvastatin PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
89166954|NCT05464810|Active Comparator|Arm II (letrozole)|Patients receive letrozole PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
89166955|NCT05464758|Experimental|Cold habituation|8-day cold habituation
89166956|NCT05464355||Biomarker monitoring|
89166957|NCT05462925|Experimental|Functional electrical stimulation therapy|Participants will receive 30 sessions of upper limb functional electrical stimulation therapy. Sessions will be 1 hour in length and take place 3-5 times per week.
89166958|NCT05456802||Acute Coronary Syndrome (ACS)|Patients presenting to the clinic with acute coronary syndrome. This includes: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina pectoris (UAP) with confirmed diagnosis of coronary artery disease.
89166959|NCT05456802||Chronic Coronary Syndrome (CCS)|Patients presenting to the clinic with chronic coronary syndrome and confirmed diagnosis of coronary artery disease.
89166960|NCT05456802||Critical limb ischemia (CLI)|Patients presenting to the clinic with critical limb ischemia. This includes: Resting limb pain (Fontaine III), ulcerations (Fontaine IV) and Ankle brachial index (ABI) < 0,6 and confirmed diagnosis of peripheral artery disease.
89166961|NCT05452889|Experimental|18F-FGLN PET Imaging|10.0 mCi of 18F-FGln will be injected intravenously as a slow bolus (20 sec)
89166962|NCT05450042|Experimental|SELUTION SLR DCB|Sustained Limus Release drug eluting balloon
89166963|NCT05450042|Active Comparator|Paclitaxel eluting balloon|Conventional: Medtronic INpact
89166964|NCT05447052|Experimental|Bio-MIMICS Stent|Helical shaped BioMimics 3D Stent
89166965|NCT05447052|Active Comparator|Innova Stent|Conventional: Nitinol Stent
89166966|NCT05445856|Experimental|Methadone|Single-shot intravenous methadone 0.2 mg/kg administered intraoperatively
89166967|NCT05445856|Active Comparator|Fentanyl|Single-shot intravenous fentanyl 3 microgram/kg administered intraoperatively
89166968|NCT05436860||presence of hepatic hyperechogenicity on ultrasound evaluation|
89166969|NCT05436860||absence of hepatic hyperechogenicity on ultrasound evaluation|
89166970|NCT05430490||HIV+ Cannabis User|Persons diagnosed with HIV who identify as using medical or recreational marijuana
89166971|NCT05430490||HIV+ Cannabis Non-User|Persons diagnosed with HIV who identify as not using medical or recreational marijuana
89166972|NCT05430490||HIV- Cannabis User|Persons without HIV who identify as using medical or recreational marijuana
89166973|NCT05430490||HIV- Cannabis Non-User|Persons without HIV who identify as not using medical or recreational marijuana
89166974|NCT05424250|Experimental|Exposure + occasional aversive imagination|repeated imaginations of the participants' most feared apprehension during extinction training with seven standardized exposure steps
89166975|NCT05424250|Active Comparator|Exposure|Standard extinction training with seven standardized exposure steps
89166976|NCT05423093|Experimental|Intervention delivery|Participants will receive a 45-60 minute single-session video group psychoeducational intervention delivered by clinic staff.
89166977|NCT05421598|Experimental|Amlitelimab dose level 1|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 1 every 4 weeks (Q4W) until Week 20 (inclusive) and every 12 weeks (Q12W) starting from Week 24 and thereafter.
89166978|NCT05421598|Experimental|Amlitelimab dose level 2|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 2 Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
89166979|NCT05421598|Experimental|Amlitelimab dose level 3|Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 3 Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
89166980|NCT05421598|Placebo Comparator|Placebo|Initial loading dose of amlitelimab matching placebo on Day 1, followed by one injection of amlitelimab matching placebo Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
89166981|NCT05410002|Active Comparator|Vegetarian N-111 group|The group will use a vegetarian diet with the active compactor N-111.
89166982|NCT05410002|Active Comparator|Non-vegetarian N-111 group.|The group will use a non-vegetarian diet with the active compactor N-111.
89166983|NCT05410002|Placebo Comparator|Vegetarian placebo group|The group will use a vegetarian diet with a placebo.
89166984|NCT05410002|Placebo Comparator|Non-vegetarian placebo control group|The group will use a non-vegetarian diet with a placebo.
89166985|NCT05410002|No Intervention|Vegetarian control group|The group will use a vegetarian diet without the active compactor N-111 or the placebo.
89166986|NCT05410002|No Intervention|Non-vegetarian control group|he group will use a non-vegetarian diet without the active compactor N-111 or the placebo.
89166987|NCT05404295|Active Comparator|Umbilical cord blood platelel lysate group|A Umbilical cord blood platelel lysate gel will be applied in diabetic foot ulcer every three days for one month.
89166988|NCT05404295|Placebo Comparator|Control group|The control group will receive the clinical standard of care; removable of any necrotic, hyperkeratotic and infected tissue, cleansing of the wound with normal saline and covering of the ulcer with dressing with normal saline and then with a few layers of sterile gauze, and non-compressible bandage.
89166989|NCT05403983|Experimental|In person movement intervention|In person yoga movement intervention (Les Mills BodyBalance: mixture of yoga, tai chi, pilates) two times per week
89166990|NCT05403983|Active Comparator|Online yoga movement intervention|Pre-recorded video of yoga movement intervention (Les Mills BodyBalance: mixture of yoga, tai chi, pilates) two times per week
89166991|NCT05403983|Active Comparator|Education|Education control group using a recently published postpartum physical activity guidebook through the Sport Information Resource Center
89166992|NCT05402358||Specific-Diagnosis|There were four specific-diagnosis groups covering four specialities: Dermatology, Rheumatology, Diabetes and Cardiology. Participants were categorised into these groups dependent on the speciality from which the referral originated or the participants primary condition. Participants attending a specific-diagnosis group were required to have a diagnosis relating to that speciality. All participants received the Living Well with a Long-Term Condition intervention
89166993|NCT05402358||Mixed-Diagnosis|There were four mixed-diagnosis groups; participants who do not fall into the above specialities, or had number of co-morbid conditions, or were unable to attend the specified dates for any of the four specific-diagnosis groups, were invited to attend a mixed-diagnosis group.All participants received the Living Well with a Long-Term Condition intervention
89166994|NCT05401838|Experimental|G-BCBT|68 active duty service member participants assigned to G-BCBT will undergo 12 group therapy sessions scheduled on a weekly basis.
89166995|NCT05401838|Active Comparator|DBT|68 active duty service member participants in the DBT condition will receive 24 weekly group therapy sessions each lasting 90 minutes.
89166996|NCT05400538|Experimental|Trial group|Biorepair Toothpaste + Mousse domiciliary use
89166997|NCT05400538|Active Comparator|Control group|Biorepair Toothpaste domiciliary use.
89166998|NCT05397821||Radboudumc recipients|NTX performed with a refluxing technique
89166999|NCT05397821||Winsconsin recipients|NTX performed with a non-refluxing technique
89167000|NCT05389683|Experimental|Elimination Diet|Participants will be suggested an 'Elimination diet' that will be devoid of the reaction-inducing foods and it shall be followed for 4 weeks.
89167001|NCT05388240|Active Comparator|Education Group|"The Education Group will be provided with standard education by the physiotherapist at the hospital prior to surgery and will be advised to continue with their normal activities of daily living (ADL). They will have access to the standard education and resources tabs on the mobile app. Shoulder specific exercises tab on the app will be available to them upon their completion of the study (eight weeks post-intervention)."
89167002|NCT05388240|Experimental|Education plus Exercise Group|"The Exercise plus Education Group will be provided with standard education by the physiotherapist at the hospital prior to surgery. Participants in this group will have access to the education and resources tabs on the app."
89167003|NCT05380726|Experimental|Experimental group|"A pilot study will be conducted for 2 months with a sample of 10 participants, in order to gather initial data to test the algorithm from the eHealth tool. During the QUAN phase the algorithm will provide individualized feedback and responses to the patients based on their different variables analyzed in real-time by the wrist receiver device: cardiovascular parameters, sleep quality and structure of sleep, physical activity, oxygen saturation.~The eHealth tool will contain all the educational materials developed by the researchers of the study. Depending on the information received from the electronic wrist device the eHealth tool will make recommendations of educational topics as hygienic-dietary measures, sleep related habits, or physical activity. The information provided in this regard will be dependent upon the subjects' knowledge gaps/beliefs identified in the QUAL phase and the parameters measures by the electronic wrist device in each subject."
89167004|NCT05380726|Active Comparator|Control group|In the control group, the participants will be provided with the same electronic wrist device and access to the eHeatlh tool as the experimental group. However, the electronic wrist device will not provide feedback based on the parameters of each individual. The information provided by the eHealth tool will be general information from the sleep unit of the Arnau de Vilanova - Santa María Hospital instead of the materials developed from the QUAL phase.
89167005|NCT05379686|Experimental|150 ug glucagon before exercise|150 ug glucagon will be administered subcutaneously just before exercise
89167006|NCT05376293|Active Comparator|Behavioral internet program|Participants randomized to the Internet program will receive a 12-week behavioral Internet program designed to increase physical activity to recommended levels.
89167007|NCT05376293|Sham Comparator|Informational newsletter condition|Participants randomized to the newsletter condition will receive 6 newsletters, delivered every other week during the 3-month program.
89167008|NCT05361486||Health Care Provider managing vivax patients in study facilities|All HCPs working in the selected facilities who are involved in the management of vivax patients will be approached to participate in the study.
89167009|NCT05361486||Patients with confirmation of vivax, attending one of the study facilities|All patients aged 6 months onward, who have a confirmed P. vivax infection and who are in a study HF will be approached to participate in the study. This includes pregnant and lactating women, who have a contra-indication to both PQ and TQ, but for whom correct case management will be evaluated as part of the primary endpoints.
89167010|NCT05345561||Pregnant women|Women with higher risk of FNAIT
89167011|NCT05344261|Active Comparator|Control Arm|Standard Post-Amputation Surgical Care: Briefly, the transected nerves will be blindly tucked into surrounding bulky soft tissue to protect the nerve ends before the wound is closed.
89167012|NCT05344261|Experimental|Targeted Muscle Re-innervation|Briefly, each transected nerve is identified after amputation using 6-0 Prolene suture and is dissected proximally for length. With minimal dissection, a nerve stimulator is used to identify functional motor nerve branches. Near the point where the motor branch enters the muscle, the motor nerve branch is transected and an end-to-end coaptation is performed with a nearby tagged amputated nerve.
89167013|NCT05344261|Experimental|Regenerative Peripheral Nerve Interface|Briefly, a muscle graft (usually from the amputated limb) is wrapped around the clean ends of the transected nerve(s).
89167014|NCT05343988|Experimental|Percutaneous Electrical Nerve Field Stimulation (PENFS) device application|The peripheral neurostimulator, PENFS device, will be placed over the external ear of enrolled patients. The device will continuously stay in place for 120 hours.
89167015|NCT05293444|Other|Overnight fasting|overnight fasting(minimum 6 hrs) for control group.
89167016|NCT05293444|Experimental|Maltodextrin|"Route: Oral Dose:~400 ml at 10PM night before surgery(12.5g/100ml)~200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery."
89167017|NCT05292664|Experimental|Cohort A|"For Part 1, participants will receive:~Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 14-20 people will participate in Part 2 (Dose Expansion) of this cohort Treatment cycle is approximately 28 days for up to 4 cycles~Venetoclax-once daily on predetermined days per protocol~Azacitidine-once daily on predetermined days per protocol~Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician"
89167018|NCT05292664|Experimental|Cohort B|"Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) with an underlying genetic condition that increases their risk for developing treatment-related toxicities. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 6 people will participate in Part 2 (Dose Expansion) of this cohort.~Venetoclax-once daily on predetermined days per protocol~Azacitidine-once daily on predetermined days per protocol~Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician"
89167019|NCT05292664|Experimental|Cohort C|"Patients with relapsed/refractory acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL) or acute leuekmai of ambiguous lineage. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 12 people will participate in Part 2 (Dose Expansion) of this cohort.~Cohort C: Treatment cycle is approximately 32 days for one cycle and will be a single treatment cycle:~Dosage, duration and timings as outlined in protocol.~Venetoclax~Dexamethasone~Vincristine~Doxorubicin~Dexrazoxane~Calaspargase pegol~---Short acting Erwinia preparations (recombinant or native Erwinia asparaginase) may be used for participants with known pegaspargase or calaspargase pegol allergy~Cytarabine~Methotrexate~Hydrocortisone~Leucovorin- *Cytarabine, Methotrexate, Hydrocortisone and Leucovorin may be given more frequently if leukemia/lymphoma cells are detected in spinal fluid),"
89167020|NCT05291689|Experimental|MORF-057|
89167021|NCT05287230|Experimental|Intervention|
89167022|NCT05287230|Other|Control|
89167023|NCT05274919||Patients scheduled for brain MRI with contrast injection|Inclusion at Erasmus MC and LUMC: The first cohort consists of 60 patients scheduled for brain MRI as part of their standard clinical diagnostic procedure and in whom contrast agent administration is part of their standard radiological assessment. These patients do not necessarily have a brain tumor as the purpose here is to develop and evaluate the vascular signature mapping sequence in general. Usually, such testing would be done in healthy volunteers, but contrast agent is required for the vascular signature mapping sequence. To avoid unnecessary contrast agent administration, the sequence will be tested in this patient cohort instead. In this study part, the outcome is the optimized protocol itself, with which the investigators could obtain additional information about the vascular structure throughout the brain. Therefore this group of subjects is expected to be sufficiently homogeneous for the research aim of this part of the study.
89167024|NCT05274919||Patients diagnosed with suspected glioma scheduled for brain MRI|Inclusion at Erasmus MC and LUMC: The second cohort consists of 20 glioma patients in whom the vascular signature mapping sequence is tested specifically for glioma and for a direct comparison between 3T and 7T, where the 3T scan is an extension of the diagnostic care and the additional 7T scan is optional. This number of patients is sufficient to provide information on differences in the ability to measure tumor vascularity between 3T and 7T, while minimizing the extra patient burden.
89167025|NCT05274919||Patients with (suspected) glioma|"Inclusion at Erasmus MC and LUMC: The third cohort consists of 100 adult patients referred for biopsy or surgery of suspected glioma. The diagnosis of glioma is based on a multitude of factors, such as initial presentation (headaches, vomiting, potential changes in character). Based on the initial presentation a patient may be suspected of having a glioma, which is often confirmed using imaging. Although a true conclusion requires analysis of tissue, in an overwhelming majority of the cases (99%), analysis of the imaging is sufficient to confirm the presence of glioma. Thus, the investigators can be relatively certain about the inclusion of glioma patients based on the initial presentation and imaging alone.~Since there is a close collaboration with the Neurology departments of both the LUMC and Haaglanden Medical Center (HMC) in The Hague, the investigators broaden their inclusion capacity also to this hospital."
89167026|NCT05268341|Experimental|Treatment|computer assisted intervention targeting expressive grammar for preschoolers with DLD
89167027|NCT05268341|No Intervention|No treatment|business as usual classroom (educational) services
89167028|NCT05257590|Experimental|Nivolumab + CVM-1118|"1 Cycle = 28 days~Nivolumab, 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting from Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.~CVM-1118, 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. Escalation of the starting dose will be dependent on the absence of Dose Limiting Toxicity in at least 7 of the initial 10 subjects treated at 200 mg, PO, BID.~Individual subjects receiving a starting dose of 200 mg, PO, BID and who tolerate the initial 2 cycles with no more than Grade 2 related toxicity, will have the option of increasing their dose of CVM-1118 to 300 mg, PO, BID (600 mg total daily dose) starting with cycle 3~Tolerable dose of Nivolumab and CVM-1118 will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal."
89167029|NCT05257005||Patient cohort|Non interventional study
89167030|NCT05246618|Experimental|TUM012|Ex-vivo infusion
89167031|NCT05246618|Placebo Comparator|Placebo|Ex-vivo infusion
89167032|NCT05244057|Experimental|Hepalatide + TAF + PEG-IFN|Patients will receive 4.2mg Hepalatide +25mg Tenofovir alafenamide+ 90ug Pegylated Interferon for 48 weeks with a further follow-up period of 24 weeks.
89167033|NCT05244057|Placebo Comparator|Placebo+ TAF + PEG-IFN|Patients will receive Placebo +25mg Tenofovir alafenamide + 90ug Pegylated Interferon for 48 weeks with a further follow-up period of 24 weeks.
89167034|NCT05242978|Experimental|Impact of GT, coffee, OJ, PGJ, milk, SSB on exercise induced oxidative stress&inflammation|single consumption of one cup of green tea (GT), coffee, orange juice (OJ), pomegranate juice (PGJ), milk and sugar sweetened beverage (SSB) 2 hours prior to a 30-min- HIIT resistance circuit exercise in healthy human subjects
89167035|NCT05242978|Experimental|Impact of choc, bcc, fl-oil, blueb., r&w bread on exercise induced oxidative stress&inflammation|single consumption of one proportion of dark chocolate (choc), broccoli (bcc), flaxseed oil, blueberries, white bread and whole grain bread (r = refined & w = whole grain) 2 hours prior to a 30-min-HIIT resistance circuit exercise in healthy human subjects
89167036|NCT05242978|Experimental|Impact of r&p meat, cheese, eggs, tofu, salmon, on exercise induced oxidative stress&inflammation|single consumption of one proportion of red meat (r meat), full fat cheese, eggs, tofu, salmon and processed meat (p meat) 2 hours prior to a 30-min- HIIT resistance circuit exercise in healthy human subjects
89167037|NCT05239533|Experimental|Safety lead-in Phase: Participants with Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC|Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. The protocol will start with a safety-lead in phase using a 3+3 design to establish the maximal tolerated dose (MTD) of 177Lu-labeled-girentuximab in combination with standard-dose nivolumab. The initial starting dose of 177Lu-labeled-girentuximab is 1804 MBq/m2 which is 75% of the single agent dose established in prior studies and will proceed as shown in the schema below. Once the MTD is established, a Simon two-stage optimal design will commence. 10 patients will be enrolled in the first stage and if no responses are observed, the study will be terminated. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
89167038|NCT05239533|Experimental|Phase 2 Participants|Participants have Advanced or Metastatic Clear Cell Renal Cell Carcinoma/RCC. If 1 or more responses are observed in the first 10 patients, we will extend enrollment to a total of 29 patients (19 additional patients) in the second stage.
89167039|NCT05236725|No Intervention|Standard of Care (SOC)|Subjects randomized to SOC arm are provided with the appropriate standard of care depending upon their risk level (as determined by their individual provider or WFBMC Maternal-Fetal Medicine provider)
89167040|NCT05236725|Experimental|Remote Blood Pressure Monitoring (rBPM)|"Subjects randomized to rBPM arm receive the appropriate standard of care depending upon their risk level, as well as the remote BP monitoring app (BabyScripts) and Bluetooth enabled BP cuff/monitor, and will receive the following equipment and monitoring:~a specialized, Bluetooth enabled BP monitoring cuff (Clinically Validated, A&D Medical Wireless Blood Pressure Monitor-Upper Arm (Appendix 2)~BP monitoring smart phone app, BabyScripts™~Verbal and written instructions, to conduct BP checks at home"
89167041|NCT05229822||Malignant ABO|60 patients with malignant acute bowel obstruction
89167042|NCT05229822||CRC without ABO (control)|60 colorectal cancer patients without acute bowel obstruction (planned operations)
89167043|NCT05229822||Benign ABO|30 patients with benign acute bowel obstruction
89167044|NCT05229705|Experimental|Resistance exercise|Exercises will be completed in Kevin Shoemaker's (Co-I) exercise lab in the Health Sciences Building. Participants will use the programmable weight machines along with free weights to target the primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. We will record the number of sets completed and the load lifted for each exercise for each participant at every class.
89167045|NCT05229705|No Intervention|Control (balance and tone exercise)|Exercises will be completed in the Health Science Exercise lab. These will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation (Liu-Ambrose et al., 2010; Liu-Ambrose et al., 2012; Nagamatsu et al., 2012; Nagamatsu et al., 2013).
89167046|NCT05229003|Experimental|cohort A|"Anlotinib + Irinotecan:~Anlotinib, 10mg, oral, once daily, D1-10, q2W; Irinotecan, 180mg/m2, iv drip, d6, q2w."
89167047|NCT05229003|Experimental|cohort B|"Anlotinib + Penpulimab + Irinotecan:~Anlotinib, 8mg, oral, once daily, d1-10, q2w; Penpulimab 200mg, i.v. d6, q2w; Irinotecan, 180mg/m2, iv infusion, d6, q2w."
89167048|NCT05227430|Experimental|Surgical trainees|Surgical trainees that would be given educational video tutorials before entering gynecological laparoscopic surgeries
89167049|NCT05227430|No Intervention|Control|Surgical trainees that would not be given educational video tutorials before entering gynecological laparoscopic surgeries
89167050|NCT05225727|Experimental|Intervention|Students randomized to the intervention group will receive Me & You Tech in place of their standard health education.
89167051|NCT05225727|No Intervention|Control|Students assigned to the standard care condition will receive their usual health education which usually includes knowledge-based content on violence prevention taught from the state textbook
89167052|NCT05220462|Experimental|Remimazolam|"White to off-white lyophilised powder, presented in a 12 mL clear glass vial with a grey bromobutyl stopper, fitted with an aluminium crimp and a blue plastic flip-off cap. Each 20 mg vial of remimazolam, will be reconstituted with sterile 0.9% NaCl solution to yield a 2.5 mg/mL solution for injection.~An initial dose of 5mg (2mL) over 60 seconds, pausing for 90 seconds, followed by 2.5mg (1mL) over 30 seconds and waiting 30 seconds will be titrated to response end point. Subsequent doses of 2.5mg (1 mL) increments can be administered if required should the procedure take longer, or the patient recover more quickly than expected, to maintain the sedation level. Top-up doses will be administered slowly, at least 2 minutes apart. Top-up doses will be limited to a maximum of 5 doses in a 15-minute window. Additionally, a maximum dose of 40mg of remimazolam (16mL) will be set."
89167053|NCT05220462|Active Comparator|Midazolam|"Midazolam will be presented as a solution in a 5 mL ampoule. Each ampoule will contain 5 mg of midazolam, yielding a 1 mg/mL solution for injection.~Dosing of midazolam was based on local formulary and standard of care / local guidance. An initial dose of 2mg (2mL) over 60 seconds, pausing for 90 seconds, followed by 1mg (1mL) over 30 seconds and waiting 30 seconds will be titrated to response end point. Subsequent doses of 1mg (1 mL) increments can be administered if required should the procedure take longer, or the patient recover more quickly than expected, to maintain the sedation level. Top-up doses will be administered slowly at least 2 minutes apart. Top-up doses will be limited to a maximum of 5 doses in a 15-minute window. Additionally, a maximum of dose of 16mg of midazolam (16mL) will be set."
89167054|NCT05210985||premature babies|Fifty infants between 4-18 months with a history of premature birth and with the consent of their parents will be included in the study. Babies with the chromosomal anomalies, serious congenital problems, and whose parents are not willing to work will not be included in the study.
89167055|NCT05205603|Placebo Comparator|Biologics group|"Biologics including infliximab and vedolizumab. infliximab: 5mg/kg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 5mg/kg every 8 weeks.~vedolizumab: 300mg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 300mg every 8 weeks."
89167056|NCT05205603|Experimental|5-ASA group|"5-ASA combined with biologics (including infliximab and vedolizumab). infliximab: 5mg/kg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 5mg/kg every 8 weeks.~vedolizumab: 300mg, intravenously administration at week 0, 2, and 6 as induction therapy; subsequently by maintenance therapy at a dose of 300mg every 8 weeks.~mesalazine: at a dose of 4-6g/d systemic or topical therapy"
89167057|NCT05198739|Experimental|Video Interaction Project (VIP) Group|Parent-Child dyads will participate in a Video Interaction Project to encourage parenting practices/relationships and child development by promoting positive parenting practices.
89167058|NCT05196581|No Intervention|No intervation|Thirty-four subjects receive no intervention.
89167059|NCT05196581|Active Comparator|Experimental intervation one|Thirty-three subjects receive dispersible NaCl powder, 8 mg per session per hour (one administration in each nostril and two oral inhalations), totaling 10 times a day, for ten days.
89167060|NCT05196581|Active Comparator|Experimental intervation two|Thirty-three subjects will receive dispersible NaCl powder, 8 mg per session (one administration in each nostril and two oral inhalations) every 3 hours, totaling 5 times a day, for ten days.
89167061|NCT05196568|No Intervention|patients not treated with the mimic fasting diet|Group treated with the mimic fasting diet
89167062|NCT05196568|Experimental|patients treated with the mimic fasting diet|Group treated with the mimic fasting diet
89167063|NCT05196074||Acute hypoxemic respiratory failure patients on VV-ECMO|
89167064|NCT05181527|Placebo Comparator|Control group|Patients in the control group will get an identical-looking capsule containing placebo (starch) once daily in addition to SSRI.
89167065|NCT05181527|Experimental|Test group|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment.
89167066|NCT05174208||CD|
89167067|NCT05173194|Experimental|Telematic Exercise|A remotely supervised resistance exercise program will be carried out for 8 weeks, with three weekly sessions lasting approximately 60 minutes each. Training will be performed in groups of four patients, according to their lung function/physical fitness. The first training session will be on site (University) for familiarization, planning and adjustment of the exercises, and the following sessions will be performed online. Each session is divided into: (i) Warm-up and joint mobility; (ii) main part: strength exercises for different muscle groups; and (iii) cool down: stretching and breathing exercises.
89167068|NCT05173194|No Intervention|Control|Control group will follow routine recommendations from the multidisciplinary CF team.
89167069|NCT05153980|Experimental|Blood Flow Restriction|Incorporation of Blood Flow Restriction within the warm-up routine.
89167070|NCT05153980|Active Comparator|Control Group|Warm-up routine without any special intervention (no Blood Flow Restriction).
89167071|NCT05148715|Experimental|Tacrolimus|Tacrolimus 0.02 mg/kg ideal body weight 4-8 hours before organ recovery
89167072|NCT05148715|Placebo Comparator|Placebo|0.9% sodium chloride 4-8 hours before organ recovery
89167073|NCT05147961|Experimental|mHealth|A mHealth automated behavioral intervention via E-mail, web, and mobile phone will be developed and tested in the intervention trial trial (phase 4 of the project)
89167074|NCT05147961|Active Comparator|Standard care|Traditional recommendations (lifestyle modification) (phase 4 of the project)
89167075|NCT05146609|Experimental|HR-HOSPITAL|Patients assigned to the strategy HR-HOSPITAL, who are high risk population (HR), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.
89167076|NCT05146609|Experimental|HR-DDP|Patients assigned to the strategy HR-DDP, who are high risk population, will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the drug dependence center (DDP) the participants used to attend.
89167077|NCT05146609|Experimental|GP-HOSPITAL|Patients assigned to the strategy GP-HOSPITAL, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.
89167078|NCT05146609|Experimental|GP-PCC|Patients assigned to the strategy GP-PCC, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the primary care center (PCC) to be performed by the general practitioner.
89167079|NCT05140226|Experimental|Physical Training (PT)|Participants in the PT group will perform eight weeks of home-based physical exercise training.
89167080|NCT05140226|Experimental|Cognitive-Physical Training (C-PT)|Participants in the C-PT will perform eight weeks of home-based cognitive and physical training.
89167081|NCT05115825|Experimental|Supportive care (Mobile Pain Coping Skills Training)|Patients attend 5 sessions of Mobile Pain Coping Skills Training for 45 minutes each over 8 weeks.
89167082|NCT05108818|Experimental|Influenza vaccination|Adults will receive a seasonal, inactivated, quadrivalent influenza vaccine administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
89167083|NCT05107518||children with physical disabilities|his study was designed to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire-(CSA) scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
89167084|NCT05095350|Experimental|Probiotic powder|The probiotic powder contains 10 strains from Lactobacillus and Bifidobacterium genus. Participants will orally take two sachets daily and last for 8 weeks.
89167085|NCT05095350|Placebo Comparator|Placebo powder|The placebo powder consists of maltodextrin and contains no probiotics. Participants will orally take two sachets daily and last for 8 weeks.
89167086|NCT05094271|Active Comparator|Supplemental Oxygen during PSG|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
89167087|NCT05094271|Placebo Comparator|Room Air during PSG|Subjects will be instrumented with a nasal cannula to receive 2L/min of pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats >90% based on oximetry readings.
89167088|NCT05094271|Experimental|Supplemental Oxygen for 3 Months|Over a 12-week period, participants randomized to receive supplemental Oxygen for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
89167089|NCT05094271|Experimental|PAP Therapy for 3 Months|Over a 12-week period, participants randomized to receive supplemental PAP therapy for treatment of OSA will be contacted weekly to be asked about their adherence. Participants' adherence will also be monitored remotely through cloud-based monitoring.
89167090|NCT05093790|Experimental|Treatment Arm 1: Ticagrelor + BMS-986141|
89167091|NCT05093790|Experimental|Treatment Arm 2: Aspirin + BMS-986141|
89167092|NCT05093790|Experimental|Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141|
89167093|NCT05093790|Experimental|Treatment Arm 4: BMS-986141|
89167094|NCT05090800|Experimental|Definity contrast agent|
89167095|NCT05081895||Respiratory failure|
89167096|NCT05079594|No Intervention|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, when the baby starts to cry, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
89167097|NCT05079594|Experimental|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb. It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvey Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies. In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position.
89167098|NCT05079594|Experimental|Mother Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks. Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks. The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it. It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements.
89167099|NCT05076292|Experimental|150 ug glucagon before exercise|150 ug glucagon will be administered subcutaneously just before exercise and placebo will be administered after exercise.
89167100|NCT05076292|Experimental|2*75 ug glucagon before exercise and after exercise|75 ug glucagon will be administered subcutaneously just before exercise and another 75 ug of glucagon will be administered immediately after exercise.
89167101|NCT05076292|Active Comparator|Saline as placebo|Saline as placebo will be administered in the same amount as glucagon before and after exercise.
89167102|NCT05074485|Experimental|Placebo plus nociceptive pain challenge, then anakinra plus nociceptive pain challenge|Pharmacological challenge (with placebo) plus nociceptive pain challenge, then pharmacological challenge (with anakinra) plus nociceptive pain challenge
89167103|NCT05074485|Experimental|Anakinra plus nociceptive pain challenge, then placebo plus nociceptive pain challenge|Pharmacological challenge (with anakinra) plus nociceptive pain challenge, then pharmacological challenge (with placebo) plus nociceptive pain challenge
89167104|NCT05071807|Active Comparator|Pecan Group|Participants will consume their usual diet, but replace one snack with unsalted raw pecans incorporated as a snack
89167105|NCT05071807|Active Comparator|Usual Care Group|Participants will consume their usual diet devoid of nuts
89167106|NCT05067140|Experimental|ARV-766|Oral tablets, once daily in 28 day cycles
89167107|NCT05067140|Experimental|ARV-766 + Abiraterone|Oral tablets, once daily in 28 day cycles
89167108|NCT05063760|Experimental|TGCT patients - exercise|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
89167109|NCT05063760|No Intervention|TGCT patients - nonexercising controls|TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist
89167110|NCT05063240|Experimental|Mobile phone text messaging plus prospective motivational interviewing|Experimental: Text messaging-motivational interviewing. Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding the infants. Participants will be asked to respond within 48 hours, indicating no problem or a problem with breastfeeding that requires help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, and 10. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
89167111|NCT05063240|Active Comparator|Standard infant feeding counselling|Standard infant feeding counselling as part of routine primary healthcare practice
89167112|NCT05047120|Experimental|Hypnosis Enhanced Cognitive Therapy|This arm will receive 4 sessions of hypnosis enhanced cognitive therapy for pain. Subjects will receive recordings of sessions for practice between therapist sessions.
89167113|NCT05047120|Active Comparator|Pain Education|This arm will receive 4 sessions of spinal cord injury pain education. Subjects will receive pain education materials for review between therapist sessions.
89167114|NCT05038709|Experimental|Pink Pad|Hip arthroscopy using The Pink Pad Hip Kit Patient Positioning System (Xodus Medical, New Kensington, PA). The pad is placed between the patient and the traction table, using a perineal post.
89167115|NCT05038709|No Intervention|Control (No pad)|Hip arthroscopy in the usual fashion, no pad, using traction table with perineal post.
89167116|NCT05027035|Active Comparator|Surgical plication|Surgical plication of the diaphragm
89167117|NCT05027035|Active Comparator|Mechanical ventilation|Non-invasive ventiatilatory support while on the waiting list for surgical plication
89167118|NCT05018221|Placebo Comparator|Placebo (Double-Blind Period)|Placebo Vitamin K1 Placebo Magnesium Citrate Placebo Sodium Thiosulphate
89167119|NCT05018221|Experimental|Vitamin K1 (Double-Blind Period)|"Dose: 10mg Vitamin K1 capsules, administered 3 times per week following the subject's hemodialysis session.~Placebo Magnesium Citrate~Placebo Sodium Thiosulphate"
89167120|NCT05018221|Experimental|Magnesium Citrate (Double-Blind Period)|"Dose: 150mg Magnesium Citrate tablets, administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.~Placebo Vitamin K1~Placebo Sodium Thiosulphate"
89167121|NCT05018221|Experimental|Sodium Thiosulfate (Double-Blind Period)|"Dose: 25g Sodium Thiosulfate injection, administered intravenously 3 times per week, during the subject's last hour of hemodialysis.~Placebo Vitamin K1~Placebo Magnesium Citrate"
89167122|NCT05018221|Active Comparator|High Flux Hemodialysis|Hemodialysis using a high flux dialyser
89167123|NCT05018221|Experimental|Medium Cut-off Hemodialysis|Hemodialysis using a medium cut-off dialyser
89167124|NCT05014958|Experimental|40 hz frequency exercise group|Individuals in this study group will receive exercise training at 40 hz frequency on whole body vibration device.
89167125|NCT05014958|Experimental|25 hz frequency exercise group|Individuals in this study group will receive exercise training at 25 hz frequency on whole body vibration device.
89167126|NCT05014958|Active Comparator|0 hz frequency exercise group|Individuals in this study group will receive exercise training at 0 hz frequency on whole body vibration device.
89167127|NCT05011331|Experimental|MedCline Shoulder Relief System|Patients who will receive the MedCline Shoulder Relief System pillow
89167128|NCT05011331|Active Comparator|Control|Patients who will not receive the MedCline Shoulder Relief System pillow
89167129|NCT05003323||High Knee Pain with Osteoarthritis|Adults 45-80 years old who have moderately severe knee osteoarthritis and rate their daily knee pain at >=6 on a 0-10 numeric rating scale
89167130|NCT05003323||Low Knee Pain with Osteoarthritis|Adults 45-80 who have moderately severe knee osteoarthritis and rate their daily knee pain at <=5 on a 0-10 numeric rating scale
89167131|NCT05003323||Healthy Controls|Age matched, BMI matched adults who do not have knee osteoarthritis or chronic pain
89167132|NCT04996875|Experimental|bezuclastinib|
89167133|NCT04994418|Experimental|Arm 1. Recommended sodium and low fructose diet|7 day consumption of low fructose drink (20g) and recommended sodium (2300mg) from whole food while consuming placebo from pills
89167134|NCT04994418|Experimental|Arm 2. High sodium and low fructose diet|7 day consumption of low fructose drink (20g) and recommended sodium (2300 mg) from whole food while consuming high sodium from pills (3400 mg)
89167135|NCT04994418|Experimental|Arm 3. High sodium and high fructose diet|7 day consumption of high fructose drink (200g) and recommended sodium (2300 mg)from whole food while consuming high sodium pills from pills (3400 mg)
89167136|NCT04984837|Experimental|Lacutamab|Lacutamab 750 mg/IV + GEmOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase Lacutamab 750 mg/IV for a maximum of 20 additional cycles of 4 weeks during the maintenance phase
89167137|NCT04984837|Active Comparator|Standard of care|GemOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase
89167138|NCT04983095|Active Comparator|Standard treatment|ADT and local RT to de novo patients
89167139|NCT04983095|Experimental|SBRT+Standard treatment|SBRT to all PSMA+ lesions in addition to ADT and local RT to de novo patients
89167140|NCT04978870||1 - Validation|Group 1 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison. A subgroup of patients will receive an additional delirium screening using the CAM-PACU. This screening will be performed by another operator blinded for the results from the initial delirium screening.
89167141|NCT04978870||2 - Cognition|"Group 2 will be screened for delirium during the PACU stay using the CAM-PACU. Delirium criteria as defined by ICD-10 will be assessed in comparison.~This group will undergo additional assessment of preoperative and postoperative cognitive function as well as a POD screening using the 3D-CAM starting at postoperative day 1 until discharge from hospital but no longer than postoperative day 5."
89167142|NCT04977362|Experimental|ERAS protocol (intervention group)|The innovative care process in the intervention group is characterized by an interdisciplinary approach according to the previously established enhanced recovery after surgery protocol. This process aims at improving the clinical outcome after cardiac surgery, increasing patient satisfaction and quality of life, enabling early professional reentry and participation, and optimizing the cost-effectiveness of service provision. In addition, intersectoral barriers are being broken down in order to establish an interdisciplinary and cross-sectoral overall care process for patients with heart valve surgery as a new form of care in the future.
89167143|NCT04977362|Active Comparator|Treatment as usual (control group)|The control group undergoes standard heart valve surgery. In this case, no preoperative interventions take place, the patient is operated on the affected heart valve in a minimally invasive procedure without prehabilitation. After surgery, the patient is transfered to an intensive care unit (not a specialized postanesthesia care unit) depending on the individual condition and then transfered to the general ward. Patients receive medical, nursing, and physiotherapeutic care in accordance with current hospital standards.
89167144|NCT04975685|Experimental|TAU + SMART|Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)
89167145|NCT04975685|Sham Comparator|TAU + Sham training|Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention
89167146|NCT04975685|No Intervention|TAU (treatment-as-usual)|Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
89167147|NCT04965142|Experimental|Home Exercise Group|The home-based exercise group will be asked to exercise 3 to 5 times per week (≥ 150 minutes of aerobic exercises (i.e. walking, cycling, or treadmill) of at least moderate intensity) and to also complete resistance training (resistance bands or free weights) at least twice weekly over a 12-week period supervised by an exercise professional. The resistance training will be personalized, aiming for 6 to 10 exercises targeting the major muscle groups, progressing to 3 sets of 8 to 12 repetitions. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials. Participants will receive one counselling session on healthy eating and physical activity at the start of the study along with an exercise manual.
89167148|NCT04965142|No Intervention|Control Group|Participants will receive one counselling session on healthy eating and physical activity at the start of the study.
89167149|NCT04961255||Control group|Healthy individuals will be evaluated only once throughout the study. Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated.
89167150|NCT04961255||COVID-19 positive participants who had moderate symptoms group|"These participants will be evaluated 4 times throughout the study.~Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.~Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.~Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.~Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.~Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment."
89167151|NCT04961255||COVID-19 positive participants who had severe symptoms group|"These participants will be evaluated 4 times throughout the study.~Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.~Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.~Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.~Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.~Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment."
89167152|NCT04959734||Bronchiolitis|Infants less than 2 years who the clinician has diagnosed Bronchiolitis
89167153|NCT04959734||LRTI|Infants less than 2 years who the clinician has diagnosed a viral or bacterial lower respiratory tract infection
89167154|NCT04959734||Wheeze|Infants less than 2 years who the clinician has diagnosed the first presentation of a viral wheeze
89167155|NCT04953286|Other|Case group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients with Amyotrophic Lateral Sclerosis
89167156|NCT04953286|Other|Control group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients without neurological disease
89167157|NCT04948268|Experimental|Adaptive digital mental health intervention without coaching|The adaptive intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Psychoeducational content will be delivered via a URL in an SMS message. Machine learning will be used to tailor messages and timing to meet participant preferences.
89167158|NCT04948268|Experimental|Non-personalized digital Mental Health intervention without coaching|The non-personalized intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Messages and content will not be tailored based on participants profile or usage.
89167159|NCT04948268|Experimental|Adaptive digital mental health intervention with coaching|The adaptive intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Psychoeducational content will be delivered via a URL in an SMS message. Machine learning will be used to tailor messages and timing to meet participant preferences. Coaching will be provided to support engagement and intervention use via medium of participants choice (texts, calls, or emails).
89167160|NCT04948268|Experimental|Non-personalized digital Mental Health intervention with coaching|The non-personalized intervention will consist of SMS messages, symptom tracking, and psychological content that centers on evidence-based psychological strategies. Messages and content will not be tailored based on participants profile or usage. Coaching will be provided to support engagement and intervention use via medium of participants choice (texts, calls, or emails).
89167161|NCT04948268|Active Comparator|Active control|The active control condition will provide brief text messages that include a URL link to psychoeducational content, but will not include the interactive messaging component described in experimental arms.
89167162|NCT04936282|Experimental|Experimental|Normal treatment (Steroids, tacrolimus and mycophenolate) for first 90 days, then add Grafalon single-dose if borderline lesions are present in protocol biopsy (performed at third month post-transplantation).
89167163|NCT04936282|Active Comparator|Normal treatment|Normal treatment (Steroids, tacrolimus and mycophenolate) arm
89167164|NCT04920539|Experimental|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
89167165|NCT04898595|No Intervention|Usual Process of Care|No intervention
89167166|NCT04898595|Experimental|Standardized approach to discontinuation of CRRT|Criteria-driven approach
89167167|NCT04894994|Experimental|FLX475 and ipilimumab combination therapy|Participants received FLX475 tablets orally and ipilimumab by IV infusions
89167168|NCT04887116|Experimental|Virtual Reality Exposure Therapy|Virtual Reality Exposure Therapy
89167169|NCT04885101|Experimental|LISWT Group|Participants who will submitted to active procedure with Low Intensuty Shockwave Therapy.
89167170|NCT04885101|Experimental|NARFT Group|Participants who will submitted to active procedure with Non-Ablative Radiofrequency Therapy
89167171|NCT04885101|Sham Comparator|Sham Group|Participants who submitted to sham procedure with vaccum therapy.
89167172|NCT04879940|Experimental|Prostatic Artery Embolization (PAE)|Participants who receive PAE with Merit Medical Embospheres.
89167173|NCT04875078|Experimental|UVA-1 Treated hand|This hand will be treated with UVA-1 phototherapy.
89167174|NCT04875078|No Intervention|The untreated hand|This hand will be gloved when the patient undergoes UVA-1 phototherapy treatments.
89167175|NCT04870307|Other|Primary Care Practices|A practice-based implementation study will be conducted with 50 practices, with baseline data collection, and overlapping with interim measurements of care quality and process outcomes, followed by a final data collection at the end of the intervention (including baseline measures plus semi-structured interviews. The practice based approach to increasing testing will be compared to a community-based approach using mobile-setting to increase testing. Additional, non-clinical trial components of this study include patient surveys to understand facilitators and barriers to SARS-CoV-2 testing and identification of legal/ethical, socioeconomic, and behavioral implications of increased testing. Patients are not direct subjects in this part of the study. Intervention will target practices and practice members.
89167176|NCT04865718||neurovascular surgery group|Subjects undergoing neurovascular surgery including aneurysm clipping
88804642|NCT02774954|Experimental|Change the cycle|CTC uses the Information-Motivation-Behavioral skills (IMB) model to achieve changes among active PWID through seven short modules. Information and motivational domains are addressed in guided conversations about (1) their own first injection episode and consequences, (2) past experiences initiating injection-naive people and consequences, (3) health, legal, and social risks related to injection drugs, (4) health, legal, social risks of initiating people, and (5) identifying their own behaviors that might promote injection among others. The behavioral skills domain is addressed through a (6) skill-building discussion and rehearsal of responses to possible initiation scenarios, and (7) safer injection education.
89167177|NCT04865315||Low grade glioma patients|Patients who have a MRI lesion suspected for a low grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
89167178|NCT04865315||High grade glioma patients|Patients who have a MRI lesion suspected for a high grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor
89167179|NCT04859153||Sprinter|All sex of healthy adolescent athletes of the athletics sprint
89167180|NCT04859153||Non-sprinter|All sex of healthy adolescent athletes of other kinds of sports
89167181|NCT04856072|Experimental|Treatment|All patients will be implanted with a deep brain stimulation system and will receive personalized fornix stimulation; parameters will be selected based on the dose finding cognitive tests.
89167182|NCT04838210|Experimental|Group Prenatal Care|Group prenatal care model
89167183|NCT04838210|Active Comparator|Individual Prenatal Care|Individual prenatal care
89167184|NCT04837495|Active Comparator|Stellate Ganglion block group|will include 20 patients: each one will receive 10 ml lidocaine 2% right stellate ganglion block (RSGB) under sonar guidance
89167185|NCT04837495|No Intervention|Control group|will include 20 patients: a control group
89167186|NCT04836910||Study Group: Women with Polycystic Ovary Syndrome|Woen diagnosed with Polycystic Ovary Syndrome according to the Rotterdam Criteria (requires 2 out of 3 symptoms: 1. Hyperandrogenism or excess levels of androgen. 2. Oligo or anovulation. 3. Polycystic ovaries on ultrasound - over 12 follicles, 2-9 mm or increased ovarian volume),who haven't started any treatment
89167187|NCT04836910||Cohort Group: Women without Polycystic Ovary Syndrome|
89167188|NCT04826757|No Intervention|standard care|standard care for low back pain management by general practioners (GPs). the physiotherapist and occupational health services can be solicited independently by the patient or GP.
89167189|NCT04826757|Experimental|coordinated care|"Coordinated care between general practioners, physiotherapist and occupational health services.~An intervention training will be performed before the start of the study for any care professional's to elaborate coordination tools and have an active communication."
89167190|NCT04803955|Experimental|16mg,KB|Group A:16mg,Q8h±3min,Day1-Day7
89167191|NCT04803955|Placebo Comparator|Placebos|Group B:Placebos,Q8h±3min,Day1-Day7
89167192|NCT04802512||patients|patients who were used telehealth
89167193|NCT04802512||health professional|health professional who were used telehealth.
89167194|NCT04802499||persons who using telehealth (patients)|patients who have received telehealth
89167195|NCT04802499||caregivers|family member of the patients who recieved telehealth
89167196|NCT04802499||health professions|persons who use the telehealth.
89167197|NCT04801498||Healthy controls|Men and women ages 18-65 years old with no major medical problems and no history of chronic pain or opioid use.
89167198|NCT04801498||Chronic pain patients not taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) that have not used any opioid medication within the past one year.
89167199|NCT04801498||Chronic pain patients taking opioids|Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) using chronic daily opioid use for longer than 3 months duration and taking stable doses of opioid medications for at least 30 days prior to study visit.
89167200|NCT04800510|Experimental|NoCDO, CDOA, CDOB, CDOC|Participants will be evaluated without a CDO, then with CDOA, then with CDOB, then with CDOC.
89167201|NCT04800510|Experimental|NoCDO, CDOA, CDOC, CDOB|Participants will be evaluated without a CDO, then with CDOA, then with CDOC, then with CDOB.
89167202|NCT04800510|Experimental|NoCDO, CDOB, CDOA, CDOC|Participants will be evaluated without a CDO, then with CDOB, then with CDOA, then with CDOC.
89167203|NCT04800510|Experimental|NoCDO, CDOB, CDOC, CDOA|Participants will be evaluated without a CDO, then with CDOB, then with CDOC, then with CDOA.
89167204|NCT04800510|Experimental|NoCDO, CDOC, CDOA, CDOB|Participants will be evaluated without a CDO, then with CDOC, then with CDOA, then with CDOB.
89167205|NCT04800510|Experimental|NoCDO, CDOC, CDOB, CDOA|Participants will be evaluated without a CDO, then with CDOC, then with CDOB, then with CDOA.
89167206|NCT04797273|Experimental|Internet-based cognitive behavior therapy|
89167207|NCT04797273|Active Comparator|Internet-based structured treatment-as-usual|
89167208|NCT04777097||healthy pregnant women|Healthy patients who receive a cesarean operation
89167209|NCT04777097||Pre-eclampsia|Patients with pre-eclampsia who receive a caesarean operation
89167210|NCT04774419|Experimental|Radiation and Dostarlimab|Patients will undergo standard intensity modulated radiation therapy (IMRT) to the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks and receive IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
89167211|NCT04773392|Active Comparator|Twice-daily Regimen|Twice-daily regimen of immediate release tacrolimus, mycophenolate mofetil (MMF)/mycophenolic acid (MPA) plus daily methylprednisolone or prednisone.
89167212|NCT04773392|Active Comparator|Once-daily Regimen|Once-daily regimen of Envarsus, azathioprine plus methylprednisolone or prednisone.
89167213|NCT04769167|Placebo Comparator|Healthy Non Pregnant Women (HNPW)|HNPW are healthy women and not pregnant
89167214|NCT04769167|Active Comparator|Diabetic Non Pregnant Women (DNPW)|DNPW are diabetic and not pregnant
89167215|NCT04769167|Placebo Comparator|Healthy Pregnant Women (HPW)|HNPW are healthy women and currently pregnant
89167216|NCT04769167|Active Comparator|Diabetic Pregnant Women (DPW)|DNPW are diabetic and currently pregnant
89167217|NCT04765813|Experimental|CBT and active smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components
89167218|NCT04765813|Active Comparator|CBT and control smartphone mobile application|Participants receive a cognitive-behavioral treatment to quit smoking along with a control App
89167219|NCT04765189|Placebo Comparator|Placebo|
89167220|NCT04765189|Experimental|Verum A|
89167221|NCT04765189|Experimental|Verum B|
89167222|NCT04765189|Experimental|Verum C|
89167223|NCT04764292|Experimental|Contrast-enhanced mammography|Women who meet criteria for supplemental screening MRI, but who are unable to have MRI for medical/access/cost reasons, will be invited to have screening with contrast-enhanced mammography. Women will also have standard-of-care mammography/tomosynthesis per usual clinical practice.
89167224|NCT04754425|Experimental|Treatment (erdafitinib, biospecimen collection)|Patients receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may also undergo collection of blood and bone marrow via biopsy and aspirates.
89167225|NCT04747418||Study Group: Women with low segment uterine scar following cesarean delivery|Women with low segment uterine scar following cesarean delivery, with no other abnormalities observed during diagnostic hysteroscopy
89167226|NCT04747418||Cohort Group: Women with no uterine scar|Women with no uterine scar, with no other abnormalities observed during diagnostic hysteroscopy
89167227|NCT04746859|Experimental|Intervention|Patients will have a prevention visit with a Prevention Practitioner (a healthcare provider who has received additional training), complete the baseline survey then be invited to receive ongoing support from a trained, volunteer peer health coach, for up to six months. The coach will support the patient as she works towards achieving personalized health goals to reduce her risk of chronic diseases, including cancer. Patients will be administered additional surveys at 3 and 6 months and a final survey at 12 months.
89167228|NCT04746859|Other|Wait-list Control|Patients will have a prevention visit with a Prevention Practitioner (a healthcare provider who has received additional training) and complete a baseline survey, after which they will receive usual care from their healthcare providers. Patients will be administered another survey at 3 months and a final survey at 6 months. After study completion (about 6-months after the initial prevention visit), patients will be invited to receive ongoing support from a trained, volunteer peer health coach, for up to six months. The coach will support the patient as she works towards achieving personalized health goals to reduce her risk of chronic diseases, including cancer.
89167229|NCT04739306|Experimental|CT-P42|
89167230|NCT04739306|Active Comparator|Eylea|
89167231|NCT04735952||AIM 1|No-Intervention. Participants in this group will have 1 study visit only. During that visit, breath and sputum samples will be collected.
89167232|NCT04735952||AIM 2|No-Intervention. Participants in this group will have up to 8 study visits over a 2 year period. During the study visits, breath and sputum samples will be collected.
89167233|NCT04732533|Experimental|tDCS|Active transcranial direct current stimulation (tDCS) will be administered with the goal of facilitating the excitability of the left dorsolateral prefrontal cortex (dlPFC). Electrode placement and current parameters for each electrode have been optimized using a standard brain with the goal of generating an average electric field of 0.25 V/m67 within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
89167234|NCT04726085|Active Comparator|Ibuprofen|Ibuprofen 600 mg q6 hours for 24 hours- total dose of 2400mg- after emergent cerclage placement
89167235|NCT04726085|Active Comparator|Indomethacin|Indomethacin 50 mg q8 hours for 24 hours- total dose of 150mg- after emergent cerclage placement
89167236|NCT04724213|Other|Testing of reliability / validity of new questionnaire|
89167237|NCT04713514|No Intervention|Arm A : Best Supportive Care|Observational arm (Standard of care)
89167238|NCT04713514|Experimental|Arm B : OSE2101|"OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.~OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion."
89167239|NCT04713514|Experimental|Arm C : OSE2101 + Pembrolizumab|OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
89167240|NCT04711031||Usual care + FLUS|At index consultation, patients will receive a FLUS examination in addition to the GP's usual care of adults presenting with symptoms of an acute LRTI.
89167241|NCT04703686|Experimental|Obinutuzumab + RO7082859|
89167242|NCT04693988|Experimental|Case management|Patient receives case management while in hospital.
89167243|NCT04693988|No Intervention|Usual Care|This control condition does not receive intervention of case management
89167244|NCT04680910|Experimental|Propofol infusion - moderate dose|Serial propofol infusions to maximally and safely induce unconsciousness and EEG slow waves while minimizing burst suppression.
89167245|NCT04680910|Active Comparator|Propofol infusion - low dose|Serial propofol infusions to safely induce unconsciousness while minimizing EEG slow waves and burst suppression.
89167246|NCT04680013||Cognitive Control|Participants in this group are cognitively intact.
89167247|NCT04680013||Mild Cognitive Impairment|Participants in this group have mild cognitive impairment.
89167248|NCT04680013||Dementia Group|Participants in this group have dementia.
89167249|NCT04677595|Experimental|Cohort 1|Treatment Naive participants
89167250|NCT04677595|Experimental|Cohort 2|Participants received one or two prior lines of treatment
89167251|NCT04665505|Experimental|ICU Staff|The study group is composed of ICU care providers at the Ottawa Hospital Civic campus and the Montfort Hospital, including intensivists, fellows, nurses and allied health professionals. The study site participant breakdown is approximately 58 TOH staff respondents and 15 Montfort respondents.
89167252|NCT04650425|Experimental|Intervention group|Each participant will undergo one or two sessions, consisting of cognitive tasks, video-EEG recording and administering of questionnaires.
89167253|NCT04634084|Experimental|Experimental group|
89167254|NCT04634084|Active Comparator|Control Group|
89167255|NCT04628780|Experimental|Dose Escalation (Part 1)|Participants will receive PF-07209960 at escalating dose levels
89167256|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07209960 at the recommended dose from Part 1
89167257|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 2 (RCC)|Participants with renal cell carcinoma (RCC) will receive PF-07209960 at the recommended dose from Part 1
89167258|NCT04628780|Experimental|Dose Expansion (Part 2) - Cohort 3 (UC)|Participants with urothelial carcinoma (UC) will receive PF-07209960 at the recommended dose from Part 1
89167259|NCT04626362|Experimental|Experimental: Cranberry juice consumption|Participants will be provided cranberry juice to consume for 21 days
89167260|NCT04626362|Experimental|Placebo juice consumption|Participants will be provided placebo juice to consume for 21 days
89167261|NCT04620759|Experimental|Psilocybin Treatment|Participants will be administered 25mg of psilocybin in a clinical setting. Psilocybin is administered orally as a capsule and taken with water.
89167262|NCT04620759|Placebo Comparator|Placebo|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water.
89167263|NCT04601805||Group (1) : Patient diagnosed with IBD with no treatment received|
89167264|NCT04601805||Group(2): Patient diagnosed with IBD and received treatment for a long time|
89167265|NCT04596735||Patients undergoing general endotracheal anesthesia that will be extubated following the procedure|Patients 60 years of age and older undergoing general anesthesia and non-cardiac surgery will be observed by a member of the research team independent from the team caring for the patient at the time of emergence and extubation
89167266|NCT04594603||Group(1): Cataract with no diabetic retinopathy|
89167267|NCT04594603||Group (2): Cataract associated with diabetic retinopathy|
89167268|NCT04592120|Experimental|Coalition Check-Up|The 4-step Coalition Check-Up technical assistance process provides proactive data-driven continuous quality improvement cycles. Step 1 assesses critical dimensions of the coalition's capacity and program implementation. A coalition profile based on assessment data is reviewed in step 2. Here the technical assistance provider works with the coalition to consider several dimensions of coalition capacity and program implementation, celebrating strengths and prioritizing weaknesses. Once priorities are set, the technical assistance provider uses structured action planning in step 3 to help coalition members establish consensus on how to improve prioritized weaknesses. In step 4, technical assistance providers review and support progress on action plan implementation with the coalition. Efforts are evaluated a year after the initial assessment in a continuous quality improvement cycle.
89167269|NCT04592120|No Intervention|Technical assistance as usual|Coalitions in the comparison condition will receive a feedback report but no additional support from technical assistance providers beyond what is already available to them.
89167270|NCT04591119|Active Comparator|Transversus Thoracic Muscle Plane Block (TTMPB) Group|At the TTMPB group, the block will be performed by the surgeon before the closure of the sternum by visualizing the muscles and identifying them. In the TTMPB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between internal intercostal muscle and transversus thoracic muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space.
89167271|NCT04591119|Active Comparator|Parasternal Intercostal Block (PSIB) Group|At the PSIB group, the block will be performed by ultrasound guidance after completion of surgery. PSIB Blocks will be performed under ultrasonography guidance using a linear 6 to 13 megahertz ultrasound probe by the anesthesist.In PSIB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between psoas major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally.
89167272|NCT04591119|No Intervention|Control Group|At the control group, no intervention for pain management will be done.
89167273|NCT04580888|Experimental|Intervention arm|Assessment using an early transthoracic echocardiography (after 500 mL of fluids) to identify the hemodynamic profile responsible for the acute circulatory failure associated with sepsis / septic shock and to guide ongoing treatment (therapeutic algorithm) and monitor its efficacy and tolerance.
89167274|NCT04580888|Other|Control arm|Conventional management according to current standards of care based on SSC recommendations, including a standardized fluid resuscitation of 30 mL/kg.
89167275|NCT04578249|Placebo Comparator|Clear goggles|Patients recovering from CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery will be given clear goggles to wear at nighttime.
89167276|NCT04578249|Experimental|Blue-light blocking goggles|Patients recovering from CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery will be given blue-light blocking goggles to wear at nighttime.
89167277|NCT04558788||Uninflamed intestine|Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
89167278|NCT04558788||Colitis|Patients with active colitis
89167279|NCT04558788||Acute GVHD|Patients with acute gastrointestinal (GI) GVHD
89167280|NCT04543877|Experimental|Inulin and Ty21a Vaccine|Participants will consume 12 grams/day of inulin for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
89167281|NCT04543877|Placebo Comparator|Maltodextrin and Ty21a Vaccine|Participants will consume 12 grams/day of maltodextrin (control) for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
89167282|NCT04537403|Experimental|Aim 1A|Normal volunteers and patients with Carotid and Femoral Atherosclerosis who will be having surgery
89167283|NCT04537403|Experimental|Aim 1B|Patients with Carotid and Femoral Atherosclerosis who will be managed medically and not having surgery
89167284|NCT04537026|Experimental|Transforaminal epidural Amniotic Fluid injection|"Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7) will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position will be confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. Then 3 mL of Amniotic Fluid will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups."
89167285|NCT04537026|Active Comparator|Transforaminal epidural dexamethasone injection|"Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7) will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. 1 mL of dexamethasone sodium phosphate (10 mg/mL) combined with 2 mL of sterile water will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups."
89167286|NCT04527445|Experimental|Reduced Radiation Fluoroscopy|Reduced radiation fluoroscopy technique is performed by the C-arm set at 1 pulses-per-second and reduction of current.
89167287|NCT04527445|Active Comparator|Conventional Fluoroscopy|The standard of care is the conventional fluoroscopy, the C-arm is set at 30 pulses-per-second and the current set as the default.
89167288|NCT04524442|Experimental|GEP-NET|One dose of arginine/lysine solution administered intravenously over a 4-hour period
89167289|NCT04524000|Experimental|Cohort 1:CDK4/6 inhibitor naive or pre-treated (Part 1)|Participants regardless of prior CDK4/6 inhibitor will be treated at escalating doses (200 mg, 250 mg and 300 mg, orally) of BYL719 in combination with Fulvestrant (500 mg, intramuscular).
89167290|NCT04524000|Experimental|Cohort 2: CDK4/6 inhibitor naive (Part 2)|Participants who are CDK4/6 inhibitor naive will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
89167291|NCT04524000|Experimental|Cohort 3: CDK4/6 inhibitor pre-treated (Part 2)|Participants who are CDK4/6 inhibitor pre-treated will be treated with BYL719 at the recommended dose identified in Part 1 in combination with Fulvestrant (500 mg, intramuscular).
89167292|NCT04515589||Main study cohort|The main study cohort in this single-arm cohort is 250 adults with rheumatoid arthritis
89167293|NCT04512235|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|The study is divided into 2 parts, the Primary Study and the Open-Label Extension Study. CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 88 deaths have been observed.
89167294|NCT04512235|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 88 deaths have been observed.
89167295|NCT04509115||Patients given short-acting opioid prescription|Patients not currently using opioids who receive a new short-acting opioid prescription for acute pain will be recruited.
89167296|NCT04506073|Experimental|MSC+placebo|2 treatment doses + 1 placebo 3 months apart
89167297|NCT04506073|Experimental|MSC|3 treatment doses 3 months apart
89167298|NCT04506073|Placebo Comparator|Placebo|3 placebo doses 3 months apart
89167299|NCT04505865|No Intervention|Usual care|Optimally tolerated medical therapy
89167300|NCT04505865|Experimental|Stress reduction|Optimally tolerated medical therapy and stress reduction course for 8 weeks
89167301|NCT04484987|Other|TRE group|Time-restricted eating group
89167302|NCT04484987|Other|Control group|Time-unrestricted eating group
89167303|NCT04469075|Experimental|topical clindamycin and triamcinolone|Patients who are scheduled to receive TTFields therapy for newly diagnosed GBM will be treated with: topical clindamycin (or approved equivalent) 1% and triamcinolone 0.1%. Participating sites may use an alternative equivalent form of clindamycin, such as a gel, with MSK PI approval
89167304|NCT04467333||All lung cancer patients|There will not be an intervention.
89167305|NCT04467255|Active Comparator|group a|aerobic training
89167306|NCT04467255|Active Comparator|group b|endurance training
89167307|NCT04463615|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
89167308|NCT04450732|Experimental|Dose Escalation|GQ1001 will be administered intravenously every 21 days. Dose Escalation will be guided by a modified 3+3 design.
89167309|NCT04450732|Experimental|Dose Expansion|GQ1001 at the Dose Recommended for Dose Expansion will be administered intravenously every 21 days. Dose expansion will further evaluate the MTD or DRDE in different types of malignant solid tumor in four cohorts.
89167310|NCT04448483|Experimental|Group A|Patients belonging to group A will start intervention I, immediately after baseline. We will recruit about 25 for group A (randomization will take into account the two to one study design) in order to have about 20 patients in Group A that will complete the study.
89167311|NCT04448483|Experimental|Group B|Patients belonging to group B will follow an observation period (max. 3 months) before starting intervention I. We will recruit about 15 patients for group B (randomization will take into account the two to one study design) in order to have about 10 patients in Group B that will complete the study.
89167312|NCT04444492|Experimental|Ranibizumab+Laser-arm|Ranibizumab injections and additional targeted laser
89167313|NCT04444492|Active Comparator|Ranibizumab-arm|Only Ranibizumab injections
89167314|NCT04442490|Placebo Comparator|Placebo|Participants self-administered SAGE-217 matched-placebo capsules, once daily at approximately 8 PM with fat-containing food for 14 days.
89167315|NCT04442490|Experimental|SAGE-217 50 mg|Participants self-administered SAGE-217 50 mg capsules, once daily at approximately 8 PM with fat-containing food for 14 days. Participants who could not tolerate 50 mg received 40 mg for the remainder of the treatment period as per discretion of investigator.
89167316|NCT04402801||Standard of Care Telemedicine Cohort|This cohort will have telemedicine visits in lieu of in-person clinic visits
89167317|NCT04402801||Standard of Care In-Person Cohort|
89167318|NCT04393350|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatments repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89167319|NCT04389593||Single arm|This is a single arm study in which all participants have one MRI
89167320|NCT04375761||SARS-CoV-2 Surveillance: Total Group|"Participants either currently or in the past, enrolled in National Institutes of Health (NIH)-funded cohort studies, and their families (household contacts).~Active surveillance for detection of SARS-CoV-2 for 6 months, beginning with enrollment. During surveillance, biological samples will be collected by the family at established intervals and symptom and exposure surveys will be completed at the time that biological samples are collected."
89167321|NCT04372524||Allogeneic HSC Transplant recipients|"Five possible patient scenarios are anticipated to occur in those who underwent allogeneic HSCT:~Early event (e.g. death, non-engraftment) occurring before day 100.~No late-acute or chronic GvHD ever develops at any time point in the first year post-transplant (regardless of whether or not classical acute GvHD develops in the first 100 days after transplant).~Early-onset chronic GvHD (including overlap syndrome) occurred before day 60.~Early-onset chronic GvHD (including overlap syndrome) occurred between day 60 and day 100.~Chronic GvHD after Day 100, Late-acute GvHD (de-novo or recurrent) after day 100, or cases of overlap syndrome occurred after day 100."
89167322|NCT04364334||Knee registry patients|
89167323|NCT04361058|Experimental|Arm A - HLA-matched unrelated donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with an HLA-matched unrelated donor will be separated into Arm A and treated with Nivolumab post-SCT
89167324|NCT04361058|Experimental|Arm B - HLA-haploidentical donor SCT treated with Nivolumab|AML/MDS participants who have allogeneic stem cell transplants with a HLA-haploidentical donor will be separated into Arm B and treated with Nivolumab post-SCT
89167325|NCT04357912|Experimental|Experimental group|
89167326|NCT04357912|Active Comparator|Control Group|
89167327|NCT04341155|Active Comparator|Dexamethasone|"Sixty nine patients will be administered randomly dexamethasone 20 mg IV for 7 days.~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
89167328|NCT04341155|Placebo Comparator|Placebo|"Sixty nine patients will be administered randomly Normal Saline 0,9% IV (4 cc) for 7 days.~Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines."
89167329|NCT04339036|Experimental|Oral CapTem + Y90 Radioembolization|"Capecitabine 750 mg/m2 twice daily orally for 14 days and temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles, to be continued until 1) disease progression or 2) intolerable toxicities.~Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4."
89167330|NCT04327700|Experimental|Regorafenib and TheraBionic|"TheraBionic is a device that consists of battery-driven radiofrequency electromagnetic field generator. The metal mouth spoon antenna is placed on the anterior part of the tongue during treatment.~Regorafenib is a 40 mg tablet administered orally."
89167331|NCT04325022||Primary Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in primary THA
89167332|NCT04325022||Revision Total Hip Arthroplasty (THA)|OR3O Dual Mobility System used in revision THA
89167333|NCT04315558|Experimental|Revefenacin|Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered.
89167334|NCT04315558|Active Comparator|Ipratropium|Nebulized ipratropium will be delivered via nebulizer Q6 hours.
89167335|NCT04307849|Experimental|Adolescent Health Club|A systematic approach for the adaptation of sexual health/HIV-related evidence-based interventions
89167336|NCT04307849|Placebo Comparator|Wait-list Control|
89167337|NCT04297761|Placebo Comparator|Filtered air|Subjects will be exposed once to filtered air for 2 hours with alternating 15 minutes of exercise (cycle ergometer) and rest.
89167338|NCT04297761|Experimental|Wood Smoke|Subjects will be exposed to air containing wood smoke for 2 hours with alternating 15 minutes of exercise (cycle ergometer) and rest.
89167339|NCT04292873|No Intervention|Control|
89167340|NCT04292873|Experimental|Vitamin D|Enteral supplement of 569,600 IU vitamin D
89167341|NCT04286386||Arm Ia (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy.
89167342|NCT04286386||Arm Ib (MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy and at a second time 3-4 weeks after.
89167343|NCT04286386||Arm II (MRSI, surgery)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRSI at least 5 weeks after prostate cancer biopsy, followed by standard of care surgery within 6 months after.
89167344|NCT04286191|Experimental|Up-conditioning (UC) Group|
89167345|NCT04286191|Sham Comparator|Control (NC) Group|
89167346|NCT04275557||Retrospective Cohort|Retrospective chart review of pathologically-confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) cases
89167347|NCT04275557||Prospective Cohort|Blood, tumor tissue samples and data will be collected.
89167348|NCT04265794|Experimental|Intervention|6-week community-based behavioral program consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. The intervention targets knowledge, attitudes, and skills related to sugar-sweetened beverage consumption and water consumption, with reduction in sugar-sweetened beverage consumption and increase in water consumption being the primary behavioral targets.
89167349|NCT04265794|No Intervention|Comparison|Parent-child pairs in comparison sites will receive usual care (standard Boys and Girls Club programming) during the study and the intervention upon study completion.
89167350|NCT04262089|Experimental|primary dMMR uterine cancer patients|primary dMMR uterine cancer patients
89167351|NCT04262089|Experimental|primary POLE-EDM uterine cancer patients|primary POLE-EDM uterine cancer patients
89167352|NCT04235231|Experimental|Lateral tilt bed|Bed tilting (15° lateral tilt, original product brand name LINET Eleganza 5)
89167353|NCT04235231|Experimental|Body positioning|Manual positioning of body by nurse.
89167354|NCT04225598|Experimental|XR-BUP|Injectable buprenorphine
89167355|NCT04225598|Active Comparator|Standard SL-BUP|Sublingual buprenorphine
89167356|NCT04219189|Experimental|Vaping to Control Group|Participants in this arm will undergo the vaping condition during the first visit and the control condition during the second visit.
89167357|NCT04219189|Experimental|Control to Vaping Group|Participants in this arm will undergo the control condition during the first visit and the vaping condition during the second visit.
89167358|NCT04217694|Experimental|Prevention (memantine, CogState)|Patients receive memantine PO BID beginning at the time of study enrollment (no later than 1st day of RT) up to 6 months after completion of standard of care RT in the absence of unacceptable toxicity. Patients also complete CogState cognitive testing at baseline, at completion of RT, and at 3, 6, and 12 months after completion of RT.
89167359|NCT04214626|Experimental|R-CHOP regimen Combined With Lenalidomide|"Experimental: R-CHOP regimen Combined With Lenalidomide Induction Chemotherapy: Rituximab, 375mg/m2, Intravenous administration on day 0, Lenalidomide, 25mg oral administration on day 1 to 10, combined with regimen：CHOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone): repeated every 3 weeks, up to 6 cycles.~Patients will exit and receive salvage treatment for the following situations: disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles.~PS: Methotrexate, 1g/m2, Intravenous administration on day 3 of each 3-week cycle, from 2 to 5 cycles for patients with high recurrence risk of the central nervous system."
89167360|NCT04214210|Experimental|Tailored Family Gene Toolkit|"The tailored FGT will include 5 modules designed to increase knowledge of cancer genetics (1); provide decisional support for genetic testing (2); increase active coping to challenges faced by HBOC families (3); provide a 5-steps, skills-building communication training (4); and provide information about management of hereditary cancer risk (5).~Messages will involve shallow tailoring (e.g. sex of mutation carrier), and deep tailoring with complex elements of relevance (e.g. coping style). Tailoring will be based on personalization, tailored feedback, and content matching, based on Swiss and Korean languages and legislation, health insurance policy, and cultural values.~Participants will be asked to complete the 5 modules within 4 weeks after they first engage with the intervention. The 4-week interval will enable learning new information while having time to reflect and act. They will receive email alerts to complete the 5 modules with the URL link directing them to the FGT."
89167361|NCT04214210|Active Comparator|Targeted intervention|The comparator will provide targeted information about HBOC and enable sharing genetic test results. The Korean team will define the contents of the comparator that will mimic the structure and function of an existing website, already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and the three Swiss national languages. Both trial arms the tailored and the targeted platform will be technically implemented in the same system, in order to track access and usage of the platform and provide a user-friendly experience to participants. The Swiss team will also provide the implementation of the comparison website.
89167362|NCT04213859|Experimental|Virtual Reality Exposure Therapy (VRET)|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.~nd stage: During the week prior to treatment, participants will complete a brief measure of emotion-related variables every evening at a fixed time (08:00 pm).~rd stage: Participants will receive therapy for fear of flying using a Virtual Reality (VR) simulator. Therapy sessions will be held once a week during 4 weeks. Participants will complete a brief measure of emotion-related variables at a random time during the 12 hours before the therapy session at a random time during the 12 hours after the therapy session. This will occur for every therapy session.~th stage: After treatment, participants will complete measures of fear of flying and emotional variables."
89167363|NCT04213859|No Intervention|control|"st stage: Participants will receive information about the study, complete measures of fear of flying and emotional variables, and undergo a diagnostic interview for flight phobia and additional disorders.~nd stage: During five weeks no therapy will be administered. Participants will fill questionnaires as follows: During the first week, participants will complete emotional measures every evening at a fixed time (08:00 pm)~rd stage: During each of the following 4 weeks, participants will complete two emotional measures during a 24 hour period.~th stage: Participants will complete measures of fear of flying and emotional variables."
89167364|NCT04209725|Experimental|CPX-351 and Quizartinib treatment|Participants with FLT3 mutation positive AML will be given CPX-351 followed by quizartinib in three phases: induction, consolidation, and maintenance.
89167365|NCT04201821|Experimental|FMT Administration|This is a single arm study in which all eligible participants will receive FMT.
89167366|NCT04196868|Experimental|Experimental arm|
89167367|NCT04196868|Placebo Comparator|Control arm|
89167368|NCT04193189|Experimental|Group A, Arm 1: HEPLISAV-B (two injections)|Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.
89167369|NCT04193189|Experimental|Group A, Arm 2: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
89167370|NCT04193189|Experimental|Group A, Arm 3: ENGERIX-B (three injections)|Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.
89167371|NCT04193189|Experimental|Group B: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
89167372|NCT04192097|No Intervention|Traditional teaching|No specific curriculum about professionalism
89167373|NCT04192097|Experimental|Professionalism curriculum|Traditional teaching + professionalism curriculum
89167374|NCT04179162|Experimental|Bacillus Calmette-Guérin (BCG) and Gemcitabine|Eligible patients will receive combination intravesical chemoimmunotherapy. Treatment is sequential, with twice-weekly intravesical gemcitabine given at weeks 1, 4, 7, and 10, for a total of 8 doses, administered in a standard fashion. In phase I, the dose of gemcitabine will depend on the dose level being assessed for the determination of the MTD. phase II, 1 dose level will be given (the MTD from phase I). Fixed doses of once-weekly intravesical BCG therapy (TICE strain, 50 mg) will be given at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6 (+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days), for a total of 6 doses, also administered in a standard fashion. All intravesical therapy will be administered in the chemotherapy suite on an outpatient basis, in accordance with standard clinical practice. Intravesical therapies will be retained in the bladder for up to 2 h (BCG) or 1 h (gemcitabine), or as tolerated.
89167375|NCT04173702|Experimental|Healthy Group|Postural sway and stability limits in assessment of healthy individuals
89167376|NCT04171323|Experimental|CTa|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
89167377|NCT04171323|Experimental|CTab|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
89167378|NCT04171323|Experimental|CTac|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
89167379|NCT04171323|Experimental|CTabc|Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
89167380|NCT04171323|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
89167381|NCT04164901|Experimental|Vorasidenib|Vorasidenib 40 mg, continuous daily dosing.
89167382|NCT04164901|Placebo Comparator|Matching Placebo|Matching placebo 40 mg, continuous daily dosing.
89167383|NCT04160221|Active Comparator|12 hours interval|Mifepristone followed by Misoprostol treatment
89167384|NCT04160221|Active Comparator|24 hours interval|Mifepristone followed by Misoprostol treatment
89167385|NCT04155892||URI group|This group includes participants <8 years of age undergoing elective procedures with a score of at least 3 on our pre-operative URI survey.
89167386|NCT04155892||non-URI group|This group includes participants <8 years of age undergoing elective procedures with no URI symptoms or recent URI.
89167387|NCT04142307|Active Comparator|Group A (treatment)|Each session includes 20 minutes of training each with rest as needed. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. A fixation training target (FTT) will be selected by the trainer at a perceived better fixation point. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look in the direction of the FTT and listen simultaneously to the audio feedback. As performing this task, the participant will actively control the eye movements until the audio feedback becomes more frequent and then becomes a continuous sound pattern. This continuous sound will signalize to the patient that the FTT location was reached. Participants will be given take-home efficiency reading exercises.
89167388|NCT04142307|Sham Comparator|Group B (control)|"The simulated biofeedback training for Group B involves the following procedure:~For four weeks, presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button. Participants will be given take-home efficiency reading exercises."
89167389|NCT04140162|Experimental|Dara-Rd followed by Dara-RVd|"Induction regimen with Daratumumab, Lenalidomide and Dexamethasone (Dara-Rd) in all study subjects, weeks 1-24~Consolidation regimen with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (Dara-RVd) in post-induction MRD+ population, weeks 25-36~Maintenance regimen with Daratumumab and Lenalidomide (Dara-R) in all study subjects, weeks 37-88~Maintenance regimen with lenalidomide (R) until progression or intolerance"
89167390|NCT04115098|Experimental|Drug order 1|
89167391|NCT04115098|Experimental|Drug order 2|
89167392|NCT04115098|Experimental|Drug order 3|
89167393|NCT04115098|Experimental|Drug order 4|
89167394|NCT04115098|Experimental|Drug order 5|
89167395|NCT04115098|Experimental|Drug order 6|
89167396|NCT04111107|Experimental|Drug Administration Based on Next Gen Sequencing Report|Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.
89167397|NCT04079855|Experimental|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
89167398|NCT04079855|Experimental|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
89167399|NCT04079855|Experimental|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
89167400|NCT04078477|Experimental|Lateral tilt bed|Special lateral tilt bed.
89167401|NCT04078477|No Intervention|Body positioning|Standard NICU preventive strategy
89167402|NCT04072354|Experimental|SEP-363856 50mg|SEP-363856 50mg dosed once daily
89167403|NCT04072354|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
89167404|NCT04072354|Placebo Comparator|Placebo|Placebo dosed once daily
89167405|NCT04050202|Experimental|ABC|ABC delivers therapy through 10, home-based, in-person sessions led by a trained professional. Treatment content is based on attachment theory and an understanding of children's stress neurobiology. Components aim to improve parental sensitivity, nurturance, and responsivity, as well as children's biological and behavioral reactivity through dyadic interactions between parents and children.
89167406|NCT04050189|Active Comparator|prenatal probiotic|will take probiotics every day from the 34th week of pregnancy until delivery; taking placebo for 10 days after delivery
89167407|NCT04050189|Active Comparator|postnatal probiotic|will take placebo every day from the 34th week of pregnancy until delivery; taking probiotics for 10 days after delivery
89167408|NCT04039581|Experimental|Group 1: Kinesio Taping and Conventional treatment|"The number of participants in this group is anticipated to be 30. The treatment method for this group is the conventional treatment + KT (Kinesio Taping) relaxation technique (muscle inhibition technique).~In the conventional treatment therapeutic exercises (active and passive Range Of Motion (ROM) and strengthening exercise of the neck and shoulder) and TENS (Transcutaneous electrical nerve stimulation) applications on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist. In KT technique, while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position on the upper trapezius muscle."
89167409|NCT04039581|Active Comparator|Group 2: Conventional treatment|The number of participants in this group are anticipated to be 30. This group will be receiving only conventional treatment. In the conventional treatment therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise of the neck and shoulder) and TENS (Transcutaneous electrical nerve stimulation) applications on the painful area, every day and 2 channels with 4 electrodes in the acute period (first 72 hours) will be applied. These exercises will be taught to participants from the first treatment session and will be performed under the supervision of a physiotherapist.
89167410|NCT04039581|Active Comparator|Group 3: Kinesio Taping|The number of participants in this group are anticipated to be 30. This group will be receiving only Kinesio Taping relaxation technique (muscle inhibition technique). In kinesio taping technique while participants are sitting on the edge of the bed, the shoulder area will be depressed and I banding will be done by applying 25-50% tension horizontally in this position on the upper trapezius muscle.
89167411|NCT04038346|Experimental|NSAID|Naproxen at weight based standard dose given bid daily until symptoms resolve
89167412|NCT04038346|Active Comparator|Acetaminophen|Acetaminophen at weight based standard dose given qid until symptoms resolve
89167413|NCT04038346|Experimental|NSAID first, then Acetaminophen|Naproxen at weight based standard dose given bid for one week, then acetaminophen at weight based standard dose given qid until symptoms resolve
89167414|NCT04038346|No Intervention|Standard Care|Symptom observation only
89167415|NCT04037176|Active Comparator|Omalizumab|"Omalizumab is a sterile solution in a prefilled syring for subcutaneous injection. The syrings contains 75 mg or 150 mg omalizumab.~75 patients will have Omalizumab in doses depending of body weight and IgE every 2. or 4. week for 6 month Omalizumab is administered subcutaneously"
89167416|NCT04037176|Placebo Comparator|Placebo|"Placebo contains sodium chloride 0,9 % in a prefilled syring for subcutaneous injection.~25 patients will have placebo depending of the body weight and IgE every 2. or 4. week in 3 month. They will subsequently get Omalizumab for 3 month if nonresponders.~Placebo is administered subcutaneously"
89167417|NCT04036305||EDS Patients|Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome
89167418|NCT04036305||Healthy Volunteers|Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome
89167419|NCT04020874|No Intervention|Baseline|Year 1, no intervention to generate baseline, comparative data for subsequent years
89167420|NCT04020874|Experimental|HuTT-2x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 2 times each week throughout the regular season.
89167421|NCT04020874|Experimental|HuTT-4x|The HuTT® program emphasizes proper tackling and blocking techniques using a progressive series of closely supervised drills. Skill rehearsal is done without helmets and shoulder pads and is the inherent element of HuTT® in order to reinforce behaviors which remove the head as a point of contact. The HuTT® program is modeled after basic tackling/blocking drills familiar to the sport of football. Feedback to confirm or correct proper skill development is provided by coaches trained in the HuTT® technique. HuTT® drills are conducted at an intensity of 50-75% effort and over a period of approximately 10 minutes. The intervention will be conducted 4 times each week throughout the regular season.
89167422|NCT04016896|Experimental|Widowed Elders' Lifestyle after Loss (WELL)|digital monitoring of sleep, meals, physical activity; motivational health coaching; personalized feedback
89167423|NCT04016896|Active Comparator|Enhanced Usual Care|enhanced usual care
89167424|NCT04012710|Active Comparator|Laparoscopy|Abdominal conventional laparoscopy for salpingo-oophorectomy
89167425|NCT04012710|Active Comparator|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
89167426|NCT04009928|Experimental|Active followed by sham stimulation|2 weeks of active stimulation of the medial forebrain bundle or subcallosal cingulate at the optimized stimulation settings derived during the open-label phase. After 1 week of washout period (with no stimulation), subjects undergo 2 weeks of sham stimulation
89167427|NCT04009928|Sham Comparator|Sham followed by active stimulation|"2 weeks of sham-stimulation, followed by 2 weeks of active stimulation, separated with 1 week washout period.~This is a crossover study, patients will undergo both arms, the order of which they do is randomized."
89167428|NCT04008576|Other|Group Blended Transdiagnostic treatment|
89167429|NCT03993197|Experimental|Patients suffering from severe endometriosis and chronic pain|Patients suffering from severe endometriosis and chronic pain that have been identified during a gynecological consultation (individual or during a multidisciplinary team meetings) or during a pain consultation on the same site of the Croix-Rousse Hospital and having signed a consent form
89167430|NCT03983837|Experimental|1|Participants will be on this diet for 4 weeks. The amount per serving will be determined on the basis of the participant s weight and caloric needs, as determined by a staff dietician.
89167431|NCT03975309||Previous DHS Participants|Observational
89167432|NCT03972384|Experimental|Post-ICU Problem Solving|The PIC-UPS intervention focuses on self-regulation activities and environmental cues to overcome problems with memory, planning and decision-making. The interventionist uses guided discovery, reviews progress, and emphasizes generalization and transfer to other patient-identified problems. This approach may be more acceptable to participants because they can see the relevance of tasks to everyday life. Activities such as goal-setting, self-evaluation and reflective thinking behaviors enhance self-efficacy and increase the likelihood that the individual will engage in self-management behaviors. The first session of PIC-UPS will be delivered after enrollment to those participants randomized to the intervention group. Weekly intervention sessions will be conducted by a trained interventionist and supplemented by telephone reminders to complete daily homework. Follow-up data collection will be conducted in the home by a blinded data collector three months post-enrollment.
89167433|NCT03972384|No Intervention|Control Group|Participants in the control group will complete several surveys upon enrollment and randomization. Follow-up data collection will be conducted in the home for all participants control group by a blinded data collector three months post-enrollment.
89167434|NCT03970499|Experimental|glial cerebral tumor|patient with an indication of glial cerebral tumor surgery
89167435|NCT03969264|Active Comparator|Carb Snacks|Will follow study diet based on the Dietary Guidelines and consume study carbohydrate snacks between meals.
89167436|NCT03969264|Experimental|Tree Nut Snacks|Will follow study diet based on the Dietary Guidelines and consume study tree nut snacks between meals.
89167437|NCT03967977|Active Comparator|Tislelizumab in combination with chemotherapy|Tislelizumab: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
89167438|NCT03967977|Placebo Comparator|Placebo in combination with chemotherapy|Placebo: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
89167439|NCT03945760|Experimental|Subjects Taking Baricitinib 2 mg|Subjects will be taking Baricitinib 2mg
89167440|NCT03945760|Placebo Comparator|Subjects Taking Placebo|Subjects will be taking placebo
89167441|NCT03914508|Experimental|Memory + Behavioral Weight Loss (M+BWL)|The M+BWL program will integrate memory interventions to the BWL program. The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
89167442|NCT03861065|Experimental|Tertiary Wound Closure|In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.
89167443|NCT03861065|Active Comparator|Historical Wound Closure|"The standard approach to your wound would be to leave it partially open and let it heal over a period of 3-6 months (secondary closure)."
89167444|NCT03856879|No Intervention|Usual care|Providers in this arm will provide usual care to their HIV+ patients with COPD.
89167445|NCT03856879|Experimental|Proactive E-consult|Providers in this arm will receive proactive E-consults with expert recommendations for COPD care prior to appointments with HIV+ patients with COPD.
89167446|NCT03839394|Experimental|Educational pamphlets + telephone|
89167447|NCT03839394|Active Comparator|Educational pamphlets|
89167448|NCT03833726|Experimental|LED group|Participants who will submitted to active procedure with LED. Both groups will be submitted to kinesiotherapy.
89167449|NCT03833726|Sham Comparator|Control group|Participants who will submitted to sham procedure with heated gel. Both groups will be submitted to kinesiotherapy.
89167450|NCT03820193|Experimental|Post-Operative Non Opioid Pain Protocol|Patients will be administered a post-operative non-opioid pain protocol consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
89167451|NCT03820193|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
89167452|NCT03780881|Experimental|Expectation confirmation|The participants in this group receive manipulated feedback indicating that their performance was very good in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
89167453|NCT03780881|Experimental|Expectation disconfirmation|The participants in this group receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
89167456|NCT03776799|Other|Stent-avoiding approach|using clinically proven drug coated balloons
89167457|NCT03776799|Other|Stent-based approach|using drug eluting nitinol stents. Interwoven nitinol stents in heavily calcified lesions at the operator's discretion.
89167458|NCT03763643|Experimental|Rituximab + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day -1, 0 and +1 prior to or after kidney transplantation in addition to standard plasmapheresis.
89167459|NCT03763643|Placebo Comparator|Placebo + plasmapharesis|This is a phase III, multicenter, randomized, open-label clinical trial. Participants with FSGS will be randomized 1:1 to receive rituximab or placebo on day -1, 0 and +1 prior to or after kidney transplantation in addition to standard plasmapheresis.
89167460|NCT03753204|Experimental|Weinberger protocol|During the Weinberger protocol, salt loading will be achieved by the combination of a high-salt diet (isocaloric, 160 mEq Na and 70 mEq K), and an infusion of 2L of saline (300 mEq Na+). Patients will have free access to water but their food will be limited to that provided by the protocol. Salt depletion will be accomplished by administering an isocaloric diet containing 10 mEq Na and 70 mEq K and continued unlimited water intake. At 8 am, 12 noon and 4 pm, subjects will be given 40 mg of furosemide or lasix orally.
89167461|NCT03751709|Experimental|Subjects|Blinatumomab+Haplo-Mismatched Cell Therapy (HMCT)
89167462|NCT03739762|Experimental|i-STAND|i-STAND participants have a Baseline visit followed by the 1st Coaching visit. They receive wristbands that vibrate every 15 minutes to prompt a standing break, standing desks, workbook & 10 phone-based coaching calls focused on sitting less/standing more. There is a 3 month measurement visit. Program ends at 6 months when they wear an activPAL & have a measurement visit. Coach provides feedback on activPAL sitting time after all activPAL wears (Bsln, 3, 6 & 12 month). They may opt to wear activPAL at 6 weeks & get feedback. They are re-randomized at 6 months; half to be assigned to intervention boosters (5 more phone sessions/a 9-month optional activPAL) before the 12 month final activPAL & final measurement visit. Those not randomized to boosters will have no contact until the 12 month visit. UPDATE: As of 3/31/2022, (final year 5), i-STAND ppts will no longer be re-randomized at 6 months. We will no longer follow to the 12-month timepoint & will end all activities after 6-months.
89167463|NCT03739762|Active Comparator|Healthy Living control|In this arm, participants have a phone-based Baseline visit followed by the 1st phone-based Coaching visit. No prompting devices/desks are offered; coaching focuses on topics related to healthy living, but with no focus on sitting less/standing more. They have 10 phone calls with a health coach. Participants receive a workbook. All content is from KaiserPermanente WA and is available to all members. Participants select topics & review them with their health coach. At 3 months, participants have a measurement visit. The program ends at 6 months where participants will wear an activPAL and have a measurement visit. After that, there is no contact with the study team until 12 months when they will again wear an activPAL & have a final measurement visit. UPDATE: As of 3/31/2022, our final year (year 5) of the study, participants randomized to the control arm will no longer be followed to the 12-month timepoint and will end all activities after the 6-month timepoint.
89167464|NCT03735979|Experimental|Argatroban|100µg/kg bolus followed by 3µg/kg per minute for 12 hours
89167465|NCT03735979|Experimental|Eptifibatide|135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours
89167466|NCT03735979|Placebo Comparator|Placebo|
89167467|NCT03732352|Experimental|Treatment (18F-FDG PET, osimertinib)|Within days -28 to -4, patients receive fludeoxyglucose F-18 IV and after 60 minutes undergo PET scan over 15 minutes. After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89167468|NCT03725605|Experimental|LTX-315 plus TIL infusion|LTX-315 intratumoural injection, TILs expansion and infusion.
89167469|NCT03713671|Other|PHPT Group|Spatio-Temporal gait analysis and balance assessment of subjects with Primary Hyperparathyroidism
89167470|NCT03713671|Other|Control Group|Spatio-Temporal gait analysis and balance assessment of healthy subjects
89167471|NCT03707366|Experimental|FHF-T Intervention Group|9 months of 1:1 youth mentoring by graduate-student mentors; workshops; educational advocacy
89167472|NCT03707366|No Intervention|Control group|Services as usual
89167473|NCT03707106|Experimental|VR based cue exposure smoking cessation|an established CBT intervention for smoking cessation supported by cue exposure in virtual reality
88821558|NCT03535727|Experimental|Phase 1, Cohort 2, Dose level 2|"Gemcitabine: 500 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Nab-paclitaxel:60 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Capecitabine:500mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle~Cisplatin:20 mg/m^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle~Irinotecan: 20 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle"
89167474|NCT03707106|Active Comparator|PMR supported smoking cessation|an established CBT intervention for smoking cessation supported supported by specific stress reduction (Progressive Muscle Relaxation, Jacobson)
89167475|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
89167476|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challenge|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
89167477|NCT03676764|Active Comparator|Biannual mass oral azithromycin|Bi-annual Mass Azithromycin distribution to all children 1-60 months old in participating communities
89167478|NCT03676764|Placebo Comparator|Biannual mass oral placebo|Bi-annual Mass Placebo distribution to all children 1-60 months old in participating communities
89167479|NCT03676764|Placebo Comparator|Targeted oral placebo|Targeted placebo to children 5 to 12 weeks old at vaccine visit or other healthy child visit
89167480|NCT03676764|Active Comparator|Targeted oral azithromycin|Targeted azithromycin to children 5 to 12 weeks old at vaccine visit or other healthy child visit
89167481|NCT03674944|Experimental|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|This program includes: 1) Dialectical Behavior Therapy (DBT) skills 2) Behavioral coaching 3) Emotional Focused Parent Training (EFPT) 4) Behavioral Weight Loss (BWL) skills.
89167482|NCT03674944|Active Comparator|Behavioral Weight Loss (BWL)|This program includes information about diet and physical activity education, in addition to parent management skills, and behavioral modification principles including: modeling, reinforcement, and operant conditioning.
89167483|NCT03674138|Active Comparator|DNA-guided choice of therapy|DNA-guided choice of antidepressant therapy
89167484|NCT03674138|Active Comparator|Clinical management|Clinical management
89167485|NCT03667482|Experimental|Cabozantinib in Combination With Cetuximab|Cetuximab will be administered at 500 mg/m^2 intravenously every other week. Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
89167486|NCT03660124|Experimental|Deep Brain Stimulation Treatment|
89167487|NCT03655808|Experimental|Cell treatment group|Patients receive both autologous BBCs transplantation and B-ACT therapy.
89167488|NCT03655808|Sham Comparator|Control group|Patients only receive B-ACT therapy.
89167489|NCT03651778||Suspected spiked drink exposure, no assault|
89167490|NCT03651778||Suspected spiked drink exposure, sexual assault|
89167491|NCT03651778||Suspected GHB exposure|
89167492|NCT03650387|Experimental|RADIESSE® (+) Lidocaine|
89167493|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort A dose)|"Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab, as specified per protocol (Cohort A dose).~Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted."
89167494|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort B dose)|Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab as specified per protocol (Cohort B dose). Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted.
89167495|NCT03636412|Experimental|Ambulatory Intervention|Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
89167496|NCT03636412|No Intervention|No Ambulator|Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
89167497|NCT03620721|Experimental|M-Body|mindfulness group intervention
89167498|NCT03620721|No Intervention|Usual Care|treatment as usual
89167499|NCT03618758|Experimental|Gastric Cancer with Peritoneal Carcinomatosis|Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
89167500|NCT03618550|Experimental|pembrolizumab plus GVD|"Part 1: Patients will receive 2-4 cycles of pembrolizumab plus GVD~Part 2: up to 40 patients will be enrolled onto an expansion cohort. On the expansion, patients who achieve CR to 4 cycles of pembro-GVD will receive 13 cycles of pembrolizumab maintenance (instead of HDT/ASCT)."
89167501|NCT03611738|Experimental|Phase I Dose Escalation|"The design will recruit participants in cohorts of three patients each and will not allow for dose-skipping during escalation. A maximum of 18 participants will be enrolled for the phase I dose escalation. Three ceritinib dose levels have been identified for dose escalation (150 mg, 300 mg, and 450 mg), plus docetaxel at 75 mg. A backup dose (ceritinib 150 mg with docetaxel at 60 mg) is also prepared in case the three dose levels are too toxic. Therefore, four potential dose levels will be used for determination of maximum tolerated dose (MTD). The first cohort will start at dose level 1 (ceritinib 150 mg with docetaxel at 75 mg).~Level -1 Backup Cohort: 150 mg ceritinib; 60 mg/m^2 docetaxel Level 1 Starting Cohort: 150 mg ceritinib; 75 mg/m^2 docetaxel Level 2 Cohort: 300 mg ceritinib; 75 mg/m^2 docetaxel Level 3 Cohort: 450 mg ceritinib; 75 mg/m^2 docetaxel"
89167502|NCT03611738|Experimental|Phase Ib Dose Expansion|Treatment at recommended dose. Investigators plan to have 30 patients for the expansion cohort. This will include participants from the dose escalation portion receiving the recommended dose.
89167503|NCT03600233|Experimental|CVM-1118|CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)
89167504|NCT03596268||Persons Living with HIV (PLWH)|Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (<50 copies/ml).
89167505|NCT03596268||HIV- Controls|Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
89167506|NCT03595917|Experimental|ABL001, Dasatinib, Prednisone, Blinatumomab|"- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D)~Dasatinib-Fixed doses oral once a day per cycle~ABL001 is administered orally daily per cycle~Prednisone-Fixed doses oral once a day per cycle.~--- Prednisone will be tapered and stop during cycle 2.~Blinatumomab - intravenous continuous infusion beginning no earlier than cycle 2 day 1~Blinatumomab - Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles"
89167507|NCT03584490|Active Comparator|Pen-and-paper format|Based on randomization, participants in this group will receive traditional pen-and-paper questionnaires about health.
89167508|NCT03584490|Experimental|Computerized Talking Touchscreen|"This group will receive the Computerized Talking Touchscreen intervention.~Based on randomization, participants in this group will receive a computerized talking touchscreen version of our health questionnaires, which allows the participant to have questions and answer choices read aloud to them by the computer."
89167509|NCT03582800|Experimental|Treated|M0-M6: run-in phase (control) M6-M12: STS treatment phase
89167510|NCT03570463||GLA:D Back|Two 1-hour group sessions of patient education 8 weeks of twice-weekly 1-hour supervised group exercise sessions
89167511|NCT03566966||Non-organ-specific Ab positive|Patients who had detectable circulating autoantibodies before treatment with antivirals.
89167512|NCT03566966||Non-organ-specific Ab negative|Patients who did not have detectable circulating autoantibodies before treatment with antivirals.
89167513|NCT03555422|Experimental|Selinexor|Participants will receive fixed dose of selinexor 80 mg (or 60 mg for participants with a body mass index [BMI] less than [<] 20 kilogram per meter square [kg/m^2]) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
89167514|NCT03555422|Placebo Comparator|Matching placebo for selinexor|Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
89167515|NCT03536754|Placebo Comparator|Group A|Placebo (N=10)
89167516|NCT03536754|Experimental|Group B|CCX140-B 5 mg once daily (N=10)
89167517|NCT03536754|Experimental|Group C|CCX140-B 10 mg twice daily (N=10)
89167518|NCT03536754|Experimental|Group D|CCX140-B 15 mg twice daily (N=10)
89167519|NCT03535922|Experimental|The disease-specific PROM group|Hemodialysis (HD) units randomized to this PROMs assessment group will administer a disease-specific PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The disease-specific PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed disease-specific PROM is the ESAS-r:Renal or the IPOS-Renal.
89167520|NCT03535922|Experimental|The generic PROM group|HD units randomized to this PROMs assessment group will administer a generic PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The generic PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed generic PROM is the EQ-5D-5L.
89167521|NCT03535922|Experimental|Disease-specific and generic PROMs group|HD units randomized to this PROMs assessment group will administer a disease-specific and generic PROM every 2 months to all patients able to complete the instrument for a period of 12 months. Patients will receive a copy of both their PROMs results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the two PROMs. The disease-specific and generic PROMs reports will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROMs reports will be accompanied by treatment aids for all symptoms.
89167522|NCT03535922|No Intervention|The control or 'usual care' group|HD units randomized to this group will follow usual care and patients will not have any PROMs assessment; however, all the treatment aids will be made available for clinicians in this study group during the 12 months trial period.
89167523|NCT03535545|Experimental|Healthy Individuals|Healthy volunteers will receive [68Ga]CBP8 and undergo PET imaging.
89167524|NCT03535545|Experimental|Lung Cancer Subjects|Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging.
89167525|NCT03535545|Experimental|Pulmonary Fibrosis Subjects|Idiopathic pulmonary fibrosis patients or patients with other types of interstitial lung disease with a fibrotic component will receive [68Ga]CBP8 and undergo PET imaging.
89167526|NCT03524235|Experimental|Subjects|Pre-Transplantation Conditioning (Bendamustine, Fludarabine, and Rituximab + Total Body Irradiation) + Haploidentical Stem Cell Transplantation with CD56-enriched donor lymphocyte infusion
89167527|NCT03524235|No Intervention|Controls|Patients undergoing standard-of-care reduced-intensity peripheral blood allogeneic stem cell transplantation (any indication, donor source, conditioning regimen) using PTCy GVHD prophylaxis.
89167528|NCT03517904|Experimental|IVUS-guided group|Intravascular ultrasound-guided intervention group
89167529|NCT03517904|Active Comparator|Angiography-guided group|Angiography-guided intervention group
89167530|NCT03491176|Experimental|Diagnostic (MRI, blood sample collection)|Patients undergo MRI scans and collection of blood samples for biomarker testing pre-radiation therapy, weekly during radiation therapy, and at 2-3 months post-radiation therapy.
89167531|NCT03462342|Experimental|A. Olaparib Pill + AZD6738.|"Cohort A: Recurrent platinum-sensitive ovarian cancer (progression greater than 6 months from last receipt of platinum-based chemotherapy), approximately 37 patients could be treated with an interim analysis after 17 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
89167532|NCT03462342|Experimental|B. Olaparib Pill + AZD6738.|"Cohort B: Recurrent platinum-resistant ovarian cancer (progression less than or equal to 6 months of the last receipt), approximately 37 patients could be treated with an interim analysis after 12 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
89167533|NCT03462342|Experimental|C. Olaparib Pill + AZD6738.|"Cohort C: PARP inhibitor (PARPi) resistant (subjects who have progressed on a PARPi), patients must be platinum-sensitive, and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 subjects could be treated.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
89167534|NCT03462342|Experimental|D-1. Olaparib Pill + AZD6738.|"Cohort D Part I: Patients will be platinum sensitive/platinum resistant ovarian cancer. Patient may or may not have received prior PARPi and will be enrolled irrespective of their BRCA status. The number of subjects treated will depend on the number of dose levels explored with a minimum of 12 subjects up to 30 subjects.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
89167535|NCT03462342|Experimental|D-2 Olaparib Pill + AZD6738.|"Cohort D Part II: Patients with ovarian cancer who are PARP inhibitor (PARPi) resistant (patients who have progressed on a PARPi). Patients must be platinum-sensitive and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 patients will be treated.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
89167536|NCT03461445|Active Comparator|Immediate Release Tacrolimus|Patients will receive immediate release tacrolimus
89167537|NCT03461445|Experimental|Envarsus|Patients will be converted to Envarsus formulation of tacrolimus
89167538|NCT03460067|Experimental|Arm A|Patient is required to have lumpectomy with sentinel lymph node biopsy shows pCR and will complete 1 year of trastuzumab +/- pertuzumab treatment. No radiation, or an omission of radiation, will be given on this arm, including external beam, brachytherapy or intraoperative radiation. Patients will be required to follow up with a medical, surgical, or radiation oncologist every 3 months for 5 years. At these follow up visits, a physical exam will be performed to assess for any disease recurrence. Screening mammogram or MRI is recommended every 6 months for patients on this arm.
89167539|NCT03460067|No Intervention|Arm B|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. Patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens such as blood and urine, for correlative studies.
89167540|NCT03460067|No Intervention|Arm C|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will not undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens, such as blood and urine, for correlative studies.
89167541|NCT03436862|Experimental|Nivolumab|Patients will receive Nivolumab 240 mg by intravenous infusion (IV) starting Day 45-120 post-transplant (±10 days) every 2 weeks for up to a maximum of 6 months of treatment.
89167542|NCT03426943|Experimental|CVVH using oXiris™ filter|"Patients included in this arm will have renal replacement therapy by performing Continuous Veno-Venous Hemofiltration (CVVH) using oXiris™ membrane.~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
89167543|NCT03426943|Active Comparator|CVVH using PrismafleX HF1400 filter|"Patients included in this arm will have renal replacement therapy by performing CVVH using a standard polysulfone filter (PrismafleX HF1400).~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
89167544|NCT03421574|Experimental|MR-Guided Focused Ultrasound|
89167545|NCT03417635|Experimental|Guided focused attention|"Participants will take part in a guided focused attention practice led by the researcher. This will include strategies used in meditations where participants focus on their breathing. More specifically, they will be instructed to close their eyes and focus on the sensation of breathing in one area of the body for the entire session. They will be given reminders throughout the session to remain on task (focusing on the breath) and not to let their thoughts wander.~Participants will be asked to either sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much that they might fall asleep."
89167546|NCT03417635|Active Comparator|Acoustic music|"Participants will be instructed to listen to a prepared soothing acoustic music track. The sessions will be led by a researcher. Participants will be asked to close their eyes and relax while listening to the music.~Participants will be asked to sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much they might fall asleep This group is used as active control group to control for socialization in group settings and any effects of consciously relaxing for the meetings."
89167547|NCT03416894|Experimental|Deep Brain Stimulation|
89167548|NCT03399396|Experimental|Web-Based Coaching|Web-based delivery of practice facilitation for HPV vaccine
89167549|NCT03399396|Experimental|In-Person Coaching|In-person delivery of practice facilitation for HPV vaccine
89167550|NCT03334617|Experimental|Durvalumab + olaparib|Durvalumab given in combination with olaparib .
89167551|NCT03334617|Experimental|Durvalumab + AZD9150|Durvalumab given in combination with AZD9150.
89167552|NCT03334617|Experimental|Durvalumab + AZD6738|Durvalumab given in combination with AZD6738.
89167553|NCT03334617|Experimental|Durvalumab + vistusertib|Durvalumab given in combination with Vistusertib (AZD2014).
89167554|NCT03334617|Experimental|Durvalumab + Oleclumab|Durvalumab given in combination with Oleclumab
89167555|NCT03334617|Experimental|durvalumab + trastuzumab deruxtecan|durvalumab given in combination with trastuzumab deruxtecan (DS-8201a)
89167556|NCT03334617|Experimental|durvalumab + cediranib|durvalumab given in combination with cediranib (AZD2171)
89167557|NCT03334617|Experimental|AZD6738 (ceralasertib) monotherapy|AZD6738 (ceralasertib) given as monotherapy
89167558|NCT03334617|Experimental|durvalumab & AZD6738 (ceralasertib)|durvalumab given in combination with AZD6738 (D15-D28)
89167559|NCT03334617|Experimental|durvalumab & AZD6738 (ceralasertib) (240 mg or 160 mg)|durvalumab in combination with twice daily 160 mg or 240 mg AZD6738 (D22-D28)
89167560|NCT03334617|Experimental|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 (ceralasertib) monotherapy on D1-7 of every 28 days
89167561|NCT03329313|Active Comparator|Low sodium concentration|Concentration of sodium in dialysate at 140 mmol/l ( Lowering sodium concentration dialysate)
89167562|NCT03329313|Sham Comparator|High Sodium Concentration|Concentration of sodium in dialysate at 145 mmol/l (Highing sodium concentration dialysate)
89167563|NCT03298802|Active Comparator|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
89167564|NCT03298802|Placebo Comparator|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum
89167565|NCT03291496||Preterm Neonates|Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
89167566|NCT03291496||Term Neonates|Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
89167567|NCT03291496||Healthy Adult|One-time whole blood draw of 1ml collection
89167568|NCT03282968|Experimental|Experimental|Regular neurophysiotherapy plus REWIRE exercises
89167569|NCT03282968|Active Comparator|Control|Regular neurophysiotherapy plus standing balance exercises
89167570|NCT03280836|No Intervention|Control|We ask that participants in the control arm do not start an exercise program.
89167571|NCT03280836|Experimental|Exercise|"Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.~Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level."
89167572|NCT03271814|Experimental|LPS-Patient|Schizophrenia patients who are randomized to receive LPS injection.
89167573|NCT03271814|Active Comparator|LPS-Healthy|Healthy controls who are randomized to receive LPS injection.
89167574|NCT03271814|Placebo Comparator|Placebo-Patient|Schizophrenia patients who are randomized to receive placebo injection.
89167575|NCT03202316|Experimental|Cohort I (atezolizumab, cobimetinib, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off for 4 weeks of the safety lead-in course. Patients then receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-4. Cycles 1-4 repeat every 21 days and subsequent cycles with atezolizumab and cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89167576|NCT03202316|Experimental|Cohort II (atezolizumab, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 3 weeks for cycles 1-6 and every 4 weeks for subsequent cycles, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-6. Cycles 1-6 repeat every 21 days and subsequent cycles with atezolizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89167577|NCT03160131|Active Comparator|Intervention|All participants receive NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
89167578|NCT03160131|No Intervention|Control|All participants receive no NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
89167579|NCT03156335|Experimental|Focused Ultrasound|
89167580|NCT03131765|Experimental|YS-ON-001|"Phase 1- Dose escalation based on YS-ON-001 safety and tolerability obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur.~Phase 1b- recommended dose determined in Phase 1. Enrollment of two expansion cohorts will be restricted to the tumour types, breast cancer and liver cancer"
89167581|NCT03118752|Experimental|Collaborative Care|Participants randomized to collaborative care (CC) will receive a 26-week, telephone based CC intervention. Care managers will monitor participants' psychiatric symptoms, review current treatments for their psychiatric and cardiac illnesses, deliver psychotherapeutic interventions, provide education about self-monitoring for cardiac symptoms, perform motivational interviewing to encourage health behavior adherence, and coordinate care between psychiatric/cardiac specialists and participants' primary care physicians. CC will utilize a treat-to-target approach, with a goal of remission of psychiatric and cardiac symptoms.
89167582|NCT03118752|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care (eUC) arm will not receive any specific intervention, though they will be free to receive any treatment for psychiatric or cardiac illness. Participants' outpatient providers will be informed of their psychiatric diagnosis, which may lead to higher-than-usual treatment for psychiatric illness.
89167583|NCT03109444||Hip Ultrasound of Newborn infants|Newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age). This will include newborns cared for in the neonatal intensive care unit (NICU) over 32 weeks gestational age, and newborns cared for on the normal labor and delivery floor. the newborn will receive an ultrasound of their hips while in the hospital (done by a trained sonographer). This will happen in the patient's room with the LAR present. An ultrasound of the hip takes approximately 15 minutes and is non-invasive, non-painful and does not utilize any ionizing radiation. Newborns will be scheduled to return once a week until the newborn's hips reach criteria for normal hip morphology or the newborn reaches 6 weeks of corrected age.
89167584|NCT03100747|Active Comparator|Bilamellar 3 mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3 mm from the eyelid margin.
89167585|NCT03100747|Active Comparator|Bilamellar 5mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5 mm from the eyelid margin.
89167586|NCT03100747|Active Comparator|Trabut 3mm|Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.
89167587|NCT03095781|Experimental|Treatment (pembrolizumab, XL888)|Patients receive pembrolizumab IV over 30 minutes on day 1 and XL888 PO on days 1, 4, 8, 11, 15, and 18. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89167588|NCT03094715|Active Comparator|Thrombectomy|Endovascular thrombectomy and best medical care
89167589|NCT03094715|Other|Best medical care|Best medical treatment
89167590|NCT03088098|Active Comparator|Treatment|Patient receiving LAAO
89167591|NCT03088098|No Intervention|Control|Patient undergoing medical therapy for stroke prevention
89167592|NCT03039751|Experimental|AdvVEGF-D|Intramyocardial AdVEGF-D
89167593|NCT03039751|Placebo Comparator|Control|Intramyocardial placebo (buffer solution without gene)
89167594|NCT02960555|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity.
89167595|NCT02918565|Experimental|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
89167596|NCT02918565|Experimental|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
89167597|NCT02918565|Experimental|Adaptive Goal Support (AGS)|10 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
89167598|NCT02918565|Experimental|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
89167599|NCT02918565|No Intervention|Control|12 weeks of text message assessments without any feedback
89167600|NCT02917421|Experimental|Cohort 1|"(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.~Radiation therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
89167601|NCT02917421|Experimental|Cohort 2|"In addition to receiving radiation to the original tumor bed, patients will also receive radiation to Level III axillary nodes and Supraclavicular nodes: 3D-CRT or IMRT at 2.7 Gy X 15 fraction (40.50 Gy)~Radiation Therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
89167602|NCT02905422|No Intervention|Waitlist Control Group|Six month delayed access to the H.E.A.L.T.H. II Intervention - Intensive intervention (wait-list control)
89167603|NCT02905422|Active Comparator|Active Intervention Group|Immediate access to the H.E.A.L.T.H. II Intervention - Intensive intervention
89167604|NCT02887248|Experimental|nab-paclitaxel+gemcitabine|"Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy.~Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
89167605|NCT02878850|Experimental|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
89167606|NCT02878850|No Intervention|Conventional Blood Pressure|Subjects will have their blood pressure kept in a normal range.
89167607|NCT02873962|Experimental|Cohort 1: Nivolumab with Bevacizumab|Patients will receive treatment every 14 days with Nivolumab and Bevacizumab administered on day 1 of each cycle.
89167608|NCT02873962|Experimental|Cohort 2: Nivolumab with Bevacizumab and Rucaparib|Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
89167609|NCT02873962|Experimental|Cohort 3: Nivolumab with Bevacizumab and Rucaparib|Patients will receive treatment every 14 days with Nivolumab, Bevacizumab administered on day 1 of each cycle and Rucaparib will be taken orally twice daily on days 1-14 .
89167610|NCT02871856|Other|Single|Single arm only, CT screening of lung
89167611|NCT02859064|Experimental|Lanreotide/Y-90 microspheres|"Lanreotide: 120 mg by subcutaneous injection (SQ) on Day 1 of every cycle (every 28 days) in combination with SIR-Spheres therapy.~Y-90 (Yttrium-90) microspheres [SIR-Spheres therapy]: dose and treatment day to be determined by treating radiation oncologist."
89167612|NCT02843074|Experimental|ERd Therapy|"INDUCTION:~Cycles 1-2: elotuzumab 10mg/kg IV days 1, 8, 15, 22; lenalidomide (len) 25mg orally (PO), once daily (QD) on days 1-21; dexamethasone (dex) 28 mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1, 8, 15, 22.~Cycles 3-4: elotuzumab 10mg/kg IV days 1 and 15; len 25mg PO QD days 1-21; dex 8mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.~CONSOLIDATION:~Four 28-day cycles: elotuzumab 10mg/kg IV days 1 and 15; len 15mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.~MAINTENANCE:~After completing consolidation therapy patients without progressive disease will receive, for up to 24 months, 28-day cycles of elotuzumab 20mg/kg IV day 1; len 10mg +/- 5mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes prior to elotuzumab) day 1."
89167613|NCT02798185||Former NFL Players|120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
89167614|NCT02798185||Former College Football Players|60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
89167615|NCT02798185||Control Group|60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study.
89167616|NCT02795156|Experimental|Arm 1|Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
89167617|NCT02795156|Experimental|Arm 2|Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
89167618|NCT02795156|Experimental|Arm 3|Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
89167619|NCT02795156|Experimental|Arm 4|Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
89167620|NCT02777762|Experimental|Fun First|Strategies to promote enjoyment of physical activity
89167621|NCT02777762|Active Comparator|Close at Hand|Strategies to promote tracking of physical activity
89167625|NCT02649673|Experimental|LCL161+topotecan+Pegylated GCSF (PEG-GCSF)|"Dose Escalation: Groups of 3-6 patients per dose level (DL) will initiate treatment in escalating doses until the maximum tolerated dose (MTD) is reached. MTD is defined as the highest combination of doses that results in dose-limiting toxicities for 2 of 6 patients per dosing group.~LCL161: orally, on Days 1, 8, 15 of each 21-day cycle. Maximum dose not to exceed 1200 mg/week.~topotecan: orally, for first 5 days of each 21-day cycle. Maximum dose not to exceed 2.3 mg/m2 per day.~Pegylated GCSF (PEG-GCSF) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.~Dose Expansion: 24 additional patients will be treated at the MTD in 2 cohorts (SCLC-12 patients; ovarian cancer-12 patients)"
89167626|NCT02642094|Experimental|The effect of short-term rapamycin treatment|Subjects will be given a low dose of rapamycin at 2 mg/day for 5-7 days of treatment. A surgical specimen will be taken 3-7 days after the last dose of rapamycin. The specimens will be evaluated for lesion size, nuclear grade, presence of necrosis in each patient's core biopsy and surgical specimens, as well as IHC (ImmunoHistoChemistry) for biomarkers including p16, COX2 (cyclooxygenase-2), and Ki-67. Specimens will also be tested for rapamycin treatment on the properties of mammary stem/progenitor cells as another biomarker for gauging the efficacy of rapamycin treatment.
89167627|NCT02636582|Experimental|Arm I (nelipepimut-S plus GM-CSF vaccine)|Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.
89167628|NCT02636582|Active Comparator|Arm II (sargramostim)|Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
89167629|NCT02628314||Osteoarthritis|Study population to include adult men and women with osteoarthritis.
89167630|NCT02627443|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, VX-970)|Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89167631|NCT02616666|Experimental|Dapagliflozin 10 mg|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
89167632|NCT02616666|Active Comparator|Standard of Care (SOC)|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
89167633|NCT02615054||treated with trastuzmab no cardiac effects|
89167634|NCT02615054||treated with trastuzmab with cardiac effects|
89167635|NCT02615054||healthy volunteers no cancer treatment|
89167636|NCT02613546|Experimental|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~evaluation session;~sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
89167637|NCT02613546|Other|Control|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
89167638|NCT02598726|Experimental|Supportive care (curcumin, piperine)|Patients receive curcumin PO BID or TID and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
89167639|NCT02578914|Experimental|NS2 Ophthalmic Drops (0.5%)|NS2 Ophthalmic Drops (0.5%)
89167640|NCT02578914|Sham Comparator|NS2 Ophthalmic Drops Vehicle (0.0%)|NS2 Ophthalmic Drops Vehicle (0.0%) control
89167641|NCT02577731|Other|Severe Trauma|Bone marrow collection. Blood collection. Clinical data collection.
89167642|NCT02577731|Other|Elective Hip Repair|Bone marrow collection. Blood collection. Clinical data collection.
89167643|NCT02577731|Other|Healthy Young Bone Marrow Control|Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.
89167644|NCT02564848|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and hormonal therapy.
89167645|NCT02544035|Experimental|36-71 month-old Play Partner|36-71 month-olds (1.5-2 year olds)
89167646|NCT02544035|Experimental|72-107 month-old Play Partner|72-107 month-olds (6-8 year-olds)
89167647|NCT02544035|Experimental|12-18 month-old Toy Type|12-18 month-olds (1-1.5 year olds)
89167648|NCT02544035|Experimental|19-35 month-old Toy Type|19-35 month-olds (1.5-2 year-olds)
89167649|NCT02544035|Experimental|36-71 month-old Toy Type|36-71 month-olds (3-5 year-olds)
89167650|NCT02544035|Experimental|72-107 month-old Toy Type|72-107 month-olds (6-8 year-olds)
89167651|NCT02544035|Experimental|12-18 month-old Play Partner|12-18 month-olds (1-1.5 year olds)
89167652|NCT02544035|Experimental|19-35 month-old Play Partner|19-35 month-olds (1.5-2 year olds)
89167653|NCT02540109|Experimental|High-Definition tDCS (Active)|
89167654|NCT02540109|Experimental|High-Definition tDCS (Sham)|
89167655|NCT02509546|Experimental|Phase I - 100mg/m^2 1-hour infusion|100mg/m^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
89167656|NCT02509546|Experimental|Phase I - 200mg/m^2 1-hour infusion|200mg/m^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
89167657|NCT02509546|Experimental|Phase I - 400mg/m^2 1-hour infusion|400mg/m^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
89167658|NCT02509546|Experimental|Phase I - 800mg/m^2 1-hour infusion|800mg/m^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
89167659|NCT02509546|Experimental|Phase I - 400mg/m^2 4-hour infusion|400mg/m^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
89167660|NCT02509546|Experimental|Phase I - 600mg/m^2 4-hour infusion|600mg/m^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
89167661|NCT02508571|Sham Comparator|Control|Two 15-minute sessions of sham intervention/day, five days a week
89167662|NCT02508571|Experimental|DST group|One session of DST and the other of sham intervention/day, five days a week
89167663|NCT02508571|Experimental|DST+OSMS group|One session of DST and the other of OSMS/day, five days a week
89167664|NCT02501954|Experimental|Regimen I|Cisplatin 50 mg/m2 IV Days 1 and 29 plus Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 4 cycles
89167665|NCT02501954|Active Comparator|Regimen II|Carboplatin AUC 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles followed by Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles
89167666|NCT02394834||Group P; mFOLFOX6 + panitumumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks
89167667|NCT02394834||Group B; mFOLFOX6 + bevacizumab combination therapy|OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks
89167668|NCT02355457||Suspected acute myocardial infarction|Patients with recent onset symptoms suggesting acute myocardial infarction
89167669|NCT02318784|Experimental|Carfilzomib|"Carfilzomib will be administered as intravenous (IV) infusion over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of each 28-day cycle.~Cycle 1: First two doses of Carfilzomib 20 mg/m2 IV; subsequent doses at 56 mg/m2 IV~Cycle 2 onwards: Carfilzomib 56 mg/m2 IV"
89167670|NCT02311062|Experimental|Eccentric hamstring exercises|Three workouts per week on non-consecutive days for 6 weeks. 1)Assisted Nordic Curl: Kneeling on the ground with ankles fixed by a partner, participant lowering the trunk to the ground by eccentrically contracting the hamstrings. 2) Eccentric single stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the support leg knee and raising the other leg until form an straight line with the trunk4 3) Eccentric double stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the knees until the body parallel with the floor.
89167671|NCT02311062|Experimental|Unistable exercises|Trained 3 times per week on non-consecutive days for 6 weeks for a total of 18 training sessions. UNS training consisted in the following three exercises: 1) One leg squat: Standing on the floor on one leg only and squat down until knee flexed to 900 and press back up with just that single leg. 2) One leg Squat on Bosu® balance Trainer: Standing on the Bosu® balance Trainer on one leg only and squat down until supported leg knee flexes to 900 and press back up with just that single leg. 3) Forward lunges on a Bosu® balance Trainer: position the forward leg on the Bosu® balance Trainer and squatting with the forward leg.
89167672|NCT02311062|Active Comparator|Control|Participants did not undergo any resistance training and continued with their regular soccer training.
89167673|NCT02276417||Sepsis|Blood Collection. Urine collection. Bioimpedance analysis. Quality-of-life questionnaires, physical function tests and cognitive function tests.
89167674|NCT02276417||Healthy Controls|Blood Collection.
89167675|NCT02201758|Placebo Comparator|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
89167676|NCT02201758|Experimental|flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
89167677|NCT02195011|Experimental|Cohort 1: Regorafenib/SIR-Spheres/Regorafenib|"Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.~Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration."
89167678|NCT02195011|Experimental|Cohort 2: SIR-Spheres/Regorafenib|"SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.~SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle."
89167679|NCT02170090|Experimental|Gemcitabine plus Cisplatin|"Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter) for 24 weeks (8 cycles)~and Observation"
89167680|NCT02170090|Active Comparator|Capecitabine|"Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily) for 24 weeks (8 cycles)~and Observation"
89167681|NCT02089607|Experimental|Thoracoabdominal Aortic Aneurysm Arm|The TAAA study arm will include patients treated by endovascular aortic repair of thoracoabdominal aortic aneurysms (Extent I to IV) using either an off-the-shelf Zenith t-Branch or patient-specific stent-graft with a combination of fenestrations and/or branches. The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
89167682|NCT02089607|Experimental|Aortic Arch Aneurysm Arm|Aortic Arch study arm will include patients with aortic arch aneurysms treated by Patient-specific stent-grafts with one to three inner branches or a scallop. The study will include patients with thoracoabdominal and/or aortic arch aneurysms due to degenerative aneurysms or chronic aortic dissections. The stent-graft design for this study will be individually selected based on anatomy at the discretion of the principal investigator, including an off-the-shelf stent-graft (t-Branch stent-graft) or patient-specific stent-graft with a combination of fenestrations and/or branches.
89167683|NCT02087501|Other|HORIZON AAA Stent Graft|All patients will received the HORIZON AAA Stent Graft
89167684|NCT02076074|Experimental|Treatment (HG-PBI)|Patients undergo single fraction high gradient-partial breast irradiation within 8 weeks after partial mastectomy.
89167685|NCT02070809|Experimental|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
89167686|NCT02070809|Active Comparator|split-thickness skin graft method|This method is traditional split-thickness skin graft
89167687|NCT02003976|Experimental|Non-Surgical Treatment plus HTO|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will undergo a medial opening wedge high tibial osteotomy (HTO). They will continue with their home program and will be followed up for 2 years after baseline.
89167688|NCT02003976|Active Comparator|Non-Surgical Treatment|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will continue with their home program and will be followed up for 2 years after baseline.
89167689|NCT01947023|Experimental|Treatment (lapatinib, dabrafenib)|"Patients receive dabrafenib* PO BID on days 1-28 and lapatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients also receive dabrafenib PO for 2 weeks prior to beginning treatment with lapatinib."
89167690|NCT01941251|Active Comparator|Navigated individualized αTMS|navigated Transcranial Magnetic Stimulation
89167691|NCT01941251|Sham Comparator|Sham TMS|navigated Transcranial Magnetic Stimulation using sham coil
89167692|NCT01937949|Other|Endovascular|"The study will include patients treated by endovascular aortic repair of juxtarenal, suprarenal and type IV thoracoabdominal aortic aneurysms using custom-made Cook Zenith® Fenestrated AAA Endovascular Graft. The graft includes combinations of scallops, holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.~Other names:~Endovascular stent Stent-graft"
89167693|NCT01918839|Experimental|VINCI Plus|One side has been treated with VINCI Plus
89167694|NCT01918839|Active Comparator|Restylane-L|One side has been treated with Restylane-L
89167695|NCT01897454|Experimental|Treatment (FOLFIRINOX, IMRT, and gemcitabine hydrochloride)|"CHEMOTHERAPY REGIMEN: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on day 1, and fluorouracil IV over 46 hours on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving disease progression proceed to chemoradiotherapy.~CHEMORADIOTHERAPY REGIMEN: Beginning 4-6 weeks after completion of chemotherapy, patients undergo IMRT on 5 consecutive days per week for a total of 28 fractions and receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity."
89167696|NCT01865110|Experimental|Induction experimental arm|R-CHOP / R-HAD : Alternating 3 cycles of R-CHOP administered in 3 week cycles + 3 cycles of R-HAD administered in 4 week cycles.
89167697|NCT01865110|Active Comparator|Standart induction arm|8 cycles of R-CHOP administered in 3 week cycles
89167698|NCT01865110|Experimental|Maintenance experimental arm|lenalidomide + rituximab : 13 cycles of rituximab SC 1400 mg administered in 8 week cycles + 26 cycles Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
89167699|NCT01865110|Active Comparator|Maintenance standart arm|13 cycles of rituximab SC 1400 mg administered in 8 week cycles for 24 months
89167700|NCT01856023|Active Comparator|Treatment Arm 1|Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
89167701|NCT01856023|Active Comparator|Treatment Arm 2|Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
89167702|NCT01815359|Experimental|Appendiceal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
89167703|NCT01815359|Experimental|Appendiceal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
89167704|NCT01815359|Experimental|Colorectal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
89167705|NCT01815359|Experimental|Colorectal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
89167706|NCT01791478|Experimental|Treatment (PI3K inhibitor BYL719, letrozole)|Patients receive PI3K inhibitor BYL719 PO QD and letrozole PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89167707|NCT01787487|Experimental|Arm I (MF patients)|Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
89167708|NCT01787487|Experimental|Arm II (MDS/MPN patients)|Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
89167709|NCT01776905||Healthy control subjects|Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays.
89167710|NCT01776905||Advanced-Stage Melanoma|To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects.
89167711|NCT01776905||Early-Stage Melanoma|To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects.
89167712|NCT01751425|Experimental|Treatment (TKIs, ruxolitinib)|Participants receive commercially available TKIs (imatinib mesylate, nilotinib, or dasatinib) as they had been receiving during the last 6 months and ruxolitinib PO BID. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
89167713|NCT01731353||Emerging fungal infections|Web-based registry of invasive infections by emerging fungi
89167714|NCT01655030|Experimental|creatine monohydrate|6g qd for 6 weeks
89167715|NCT01655030|Placebo Comparator|placebo|6g qd for 6 weeks
89167716|NCT01624220|Experimental|Hypofractionated Radiation|"All patients receive CT-guided spinal SBRT using IMRT to maximize conformality of treatment plan to target volume, while sparing normal structures. Dose given to tumor and number of treatments received determined by patient's doctor.~In second stage, characterize tolerance of esophagus to hypofractionated radiation doses through prospective constraint relaxation and toxicity monitoring. Data collected from Group 1 in first stage will give data on dose delivered to esophagus. Second stage of protocol will begin accrual once Group 1 has filled. Dose constraints used for Groups 3 allow higher dose. Dose constraints for Group 4 represent modest increase of esophageal dose maximums."
89167717|NCT01624220|Experimental|ExacTrac Positioning System|Analysis performed of ExacTrac positioning system with and without fiducial guidance. Four dimensional CT datasets for simulation will allow use of data from this portion of protocol to characterize degree to which organ at risk (OAR) motion is relevant at each spinal level. 20 patients accrued in two groups of 10, with 10 patients in each rostral-caudal position in the spine (Group 1: T4-T12, Group 2: L1-L5). Imaging done with fiducial markers for this study will not impact patient management. Patients will treated with standard dose constraints to normal tissues.
89167718|NCT01612949||easy to intubate, model derivation|easy to intubate, model derivation. photographing head and neck
89167719|NCT01612949||difficult to intubate, model derivation|difficult to intubate, model derivation.photographing head and neck
89167720|NCT01612949||easy to intubate, model validation|easy to intubate, model validation. photographing head and neck
89167721|NCT01612949||difficult to intubate, model validation|difficult to intubate, model validation. photographing head and neck
89167722|NCT01612949||Test|A group of unlabeled subjects (mix of easy and difficult intubations) to test the reproducibility of the derived and validated model(s)
89167723|NCT01538056|Experimental|Fenestrated procedure|Fenestrated device with fenestrations for bilateral renal ateries and SMA. May include all three fenestrations or only one
89167724|NCT01393756|Experimental|Lenalidomide dose 25 mg|
89167725|NCT01364597|Experimental|Brivaracetam|
89167726|NCT01311648|Experimental|PTPs 0-12 years|Previously treated patients (PTPs) aged below 12 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (EDs) in main study - Part A. Participants having reached at least 50 EDs in main study - Part A were offered participation in an open label extension study (optional). Participants who transitioned from main study - Part A to the extension study received BAY81-8973, 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study).
89167727|NCT01311648|Experimental|PUPs/MTPs 0-<6 years|Previously untreated patients (PUPs) or minimally treated patients (MTPs, patients who had no more than 3 exposure days (EDs) with any FVIII product) received BAY81-8973 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development in main study - Part B. Participants having reached at least 50 EDs in main study - Part B were offered participation in an open label extension study and received BAY81-8973 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study); participants who developed an inhibitor in main study - Part B were offered participation in open label extension study and received Immune Tolerance Induction (ITI) treatment with BAY81-8973 until successful eradication of the inhibitor, or until failure, for approximately 18 months.
89167728|NCT01146249||1: healthy subject|
89167729|NCT01146249||3: post stroke patients|
89167730|NCT01146249||2: vestibular patients|Vestibular patients with a unique history of peripheric vestibular disorder
89167731|NCT01146249||4: ataxic patients|Patient with proprioception disorder related to peripheral neuropathy
89167732|NCT01146249||5: Old fallers|Old subjects with a history of falls (one or more during the last year)
89167733|NCT00962728|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
89167734|NCT00962728|Sham Comparator|Sham Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
89167735|NCT00869804|Experimental|Exercise|combination aerobic (walking) and resistance (strength training) exercise
89167736|NCT00869804|Sham Comparator|attention control|attention control with daily journal and cancer-related education
89167737|NCT00762333||Myocardial Infarction|
89167738|NCT00762008||Heart Failure|
89167739|NCT00759096|Experimental|Acrysof ReSTOR IOL|AcrySof ReSTOR Intraocular lens (IOL) implanted
89167740|NCT00758342|Experimental|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
89167741|NCT00758342|Active Comparator|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
89167742|NCT00470704|Other|Cohort 1|"This cohort is made up of participants without prior trastuzumab for MBC. Adjuvant or neoadjuvant trastuzumab was allowed, if the interval from trastuzumab completion to recurrence exceeded 1 year.~1000 mg daily Lapatinib~2 mg/kg weekly or 6 mg/kg every 3 week dose of trastuzumab"
89167743|NCT00470704|Other|Cohort 2|"This cohort is made up of participants with one to two lines of chemotherapy for metastatic disease with at least one trastuzumab-containing regimen or patients who recurred within 12 months of adjuvant or neoadjuvant trastuzumab with up to one line of metastatic trastuzumab-based therapy~1000 mg daily Lapatinib~2 mg/kg weekly or 6 mg/kg every 3 week dose of trastuzumab"
89167744|NCT00385697|Experimental|Double-blind Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
89167745|NCT00385697|Experimental|Double-blind 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
89167746|NCT00385697|Experimental|Double-blind Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
89167747|NCT00385697|Placebo Comparator|Double-blind Placebo|Placebo IV dosing daily for 14 days repeated at Week 26
89167748|NCT00385697|Experimental|Open-label Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
89167749|NCT04152122||Intermittent exotropia group|Intermittent exotropia group
89167750|NCT04152122||Normal group|Normal group
89167751|NCT04118400||Experimental: NIN-NAVA|"Premature>30weeks with respiratory distress~PI to determine eligibility or exclusion~Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization~PI will not be blinded to the intervention (not feasible)~Place the catheter to optimize position~ABG or VBG to be obtained at 2 hrs. post NIV-NAVA~NIV-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
89167752|NCT04118400||Active Comparator: Nasal CPAP or NIMV|"Premature>30weeks with respiratory distress~PI to determine eligibility or exclusion~Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization~PI will not be blinded to the intervention (not feasible)~Place the catheter to optimize position~ABG or VBG to be obtained at 2 hrs. post Nasal CPAP or NIMV~NCPAP or NIMV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
89167753|NCT02567734|Experimental|Irreversible electroporation|In this group，eligible patients were selected to receive the CT-guided percutaneous irreversible electroporation ablation.
89167754|NCT04152356||PD-1|
89167755|NCT04152356||Sorafenib|
89167756|NCT02622360||Dyslexia|Individuals with confirmed dyslexia.
89167757|NCT02622360||Control|Healthy control subjects.
89167758|NCT04271956|Experimental|Tislelizumab + Zanubrutinib|"Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib~Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib~Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation"
89167759|NCT00911924|Experimental|iStent|
89167760|NCT02628080|Experimental|Cohort 1|Atovaquone suspension, 750mg/5ml bd and 1000mg (6.25ml) bd for 7-17 days. Device: PET-CT, Device: DWI-MRI
89167761|NCT02628080|No Intervention|Cohort 2|Device: PET-CT, Device: DWI-MRI
89167762|NCT00678158|Experimental|1|Patients with metastatic disease to soft tissue.
89167763|NCT00678158|Experimental|2|Patients with metastatic disease to lymph nodes.
89167764|NCT00678158|Experimental|3|Patients with metastatic disease to the bone.
89167765|NCT00678236|Active Comparator|1|Refobacin Bone Cement R
89167766|NCT00678236|Active Comparator|2|Refobacin Plus Bone Cement
89167767|NCT04279093||Pregnant/postpartum women and their partners|"The investigators aim to recruit 20 women in late pregnancy from the Antenatal Assessment Unit and the Antenatal Clinic at St Mary's Hospital. Their partners will be invited to participate where applicable.~Inclusion and exclusion criteria for pregnant women are as follows:~Inclusion: after 36 weeks gestation, aged over 18 years and fluent in English, under the care of Manchester University NHS Foundation Trust~Exclusion: current stillbirth (women experiencing a stillbirth during the study will be withdrawn from the study), fetal abnormality, or multiple pregnancy~Inclusion criteria for partners: male or female partners of a mum participating in the study, aged over 18 and fluent in English."
89167768|NCT00678314|Active Comparator|Group A|
89167769|NCT00678314|Active Comparator|Group B|
89167770|NCT00678314|Placebo Comparator|Group C|
89167771|NCT02566720|Other|Treatment and MRI scanning|After informed consent has been obtained, the subjects will be examined by a physician and assigned a Disability Ratings Scale (DRS) score. Subjects will undergo MRI tractography study, which does not require the administration of contrast. All participants will receive oral amantadine at escalating doses to ensure tolerance (50mg twice daily for 7 days, then 100mg twice daily for 1 week, then 150mg twice daily, then 200mg twice daily). The usual length of stay on the inpatient brain injury program is ninety days. The MRI tractography study and DRS score will be repeated near the time of discharge or ninety days from enrollment.
89167772|NCT04151576|Experimental|Experimental|The patients received medical treatment. The intervention: An aromatic oil mixture (lavender and peppermint) was massaged for 15 minutes on the temple and root of the neck of the patients, and this application continued for three weeks
89167773|NCT04151576|No Intervention|Control|The patients received only medical treatment
89167774|NCT00665522||001|fentanyl iontophoretic transdermal system (40mcg) No Placebo 40 mcg per dose maximum of 6 doses/hourtotal maximum 80 doses/24 hours
89167775|NCT00665522||002|IV PCA with standard of care opioid analgesia per 24 hour period
89167776|NCT00675272|Active Comparator|1|hydrocortisone treatment 50mg iv x4
89167777|NCT00675272|Placebo Comparator|2|Placebo iv every 6 hours
89167778|NCT00912080|Experimental|good signature|"Patients who have a good signature for the genomic analysis. They will receive the standard chemotherapy."
89167779|NCT02567812||In-patient with PID|In-patient with PID who diagnosed at Kangbuk Samsung Hospital
89167780|NCT00678548|Experimental|guided imagery|CD
89167781|NCT00678548|Active Comparator|pain diary|Pain diary
89167782|NCT02627612|Experimental|TM RWB PLUS Pro Vetus|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this group and request that they voluntarily join TM RWB and receive mentorship from their matched and assigned mentor. In addition to TM RWB membership, research participants will also receive approximately four months of mentorship from a ProVetus mentor to assist them in further transitioning within the five domains.
89167783|NCT02627612|Active Comparator|TM RWB ONLY|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this arm and request that they voluntarily join TM RWB. Weekly emails will provide lists of voluntary physical/social activities available to all Chapter members. No participation is required in these activities.
89167784|NCT02627612|No Intervention|Control Group (Waitlist)|Research participants (recent Veterans) will be placed on a waitlist for approximately sixteen months. Based on their desires, the research participants in this group will have opportunity to belong to TM RWB plus receive approximately four months of mentorship from trained, peer-mentors (who are TM RWB volunteers).
89167785|NCT05324956||Postmenopausal Women|Postmenopausal women be between 40-79 years and being diagnosed with osteoporosis or osteopenia
89167786|NCT00678626|Experimental|Arm A|combination of CP-751,871 + docetaxel administered
89167787|NCT00678626|Active Comparator|Arm B|chemotherapy
89167788|NCT00678704|Placebo Comparator|Arm 3|
89167789|NCT00678704|Experimental|Arm 1|
89167790|NCT00678704|Experimental|Arm 2|
89167791|NCT04707352|Experimental|Dapagliflozin|The baseline procedures will be performed on the same day of screening or within the next five working days. All the baseline procedures will be performed on the same day. The baseline procedures include biobank, clinical assessment and echocardiogram, on the same day. In the following 24 hours, the patient will initiate Dapagliflozin at the recommended dose of 10 mg daily during 6 months. Temporary discontinuation may be considered at investigator criteria as in cases of symptomatic hypotension or acute declines in renal function and after discarding other potential causes.
89167792|NCT04152590|Experimental|Uincare|Exercise using Uincare
89167793|NCT00678938|Experimental|1|
89167794|NCT00678938|Experimental|2|
89167795|NCT00678938|No Intervention|3|
89167796|NCT04061278|Experimental|4 Cycles of Neoadjuvant Chemotherapy With Radiotherapy|Four cycles of neoadjuvant chemotherapy combined with radical radiotherapy
89167797|NCT04061278|Active Comparator|3cycles of Neoadjuvant Chemotherapy With chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy
89167798|NCT00679094|Experimental|Arm I|Participants receive a single dose of oral BBIC or placebo, as an orange juice suspension, immediately followed by consumption of a defined low-fat breakfast. Participants continue to consume a low-fat diet for the next 48 hours and then resume their normal diet.
89167799|NCT04061200|Active Comparator|Semaglutide 1,34 mg/ml|Semaglutide 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
89167800|NCT04061200|Placebo Comparator|Placebo 1,34 mg/ml|Placebo 1,34 mg/ml (solution for subcutaneous injection in pre-filled pen-injector). At randomisation, the participants start with doses of 0.25 mg/week for 4 weeks, then escalate to doses of 0.5 mg/week for 4 weeks, and thereafter escalate to 1.0 mg/week if tolerated until 52 weeks of total treatment.
89167801|NCT00675350|Experimental|Homoharringtonine|
89167802|NCT02565862|Active Comparator|Treatment A|"Day 1-2: 500mg twice daily (BID) metformin film-coated tablets~Day 3-8: 1000mg BID metformin film-coated tablets"
89167803|NCT02565862|Experimental|Treatment B|"Day 15-16: 500mg BID metformin film-coated tablets + 60mg once daily (QD) daclatasvir film-coated tablets~Day 17-22: 1000mg BID metformin film-coated tablets~+ 60mg QD daclatasvir film-coated tablets"
89167804|NCT04152278||study group|The study group included 300 women presenting with unexplained spontaneous miscarriage or missed abortion during the first and early second trimester of pregnancy (8-16 weeks gestational age). The included women aged 18 to 45 years old.
89167805|NCT04152278||control group|The control group included 300 women with normal pregnancy, recruited from women attending the antenatal clinic of gestational age 8-16 weeks. The included women aged 18 to 45 years old.
89167806|NCT00912314|Active Comparator|Monthly Maintenance PTNS|After 12 weeks of PTNS, patients will be randomized to either the monthly PTNS arm, or the no maintenance PTNS arm.
89167807|NCT00912314|No Intervention|No maintenance PTNS|After 12 weeks of PTNS, patients will either be randomized to the Monthly PTNS arm or the No maintenance PTNS arm.
89167808|NCT04060888|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
89167809|NCT04060888|Placebo Comparator|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
89167810|NCT00879398||OAB-Toviaz|All patients who enrolled in this study
89167811|NCT04061122||EX + / ECTS +|Patients suffering COPD exacerbation in last 7 days; active tobacco smokers
89167812|NCT04061122||EX - / ECTS +|Patients without COPD exacerbation in last 6 months; active tobacco smokers
89167813|NCT04061122||EX + / ECTS -|Patients suffering COPD exacerbation in last 7 days; quited tobacco smoking at least 12 months earlier
89167814|NCT04061122||EX - / ECTS -|Patients without COPD exacerbation in last 6 months; quited tobacco smoking at least 12 months earlier
89167815|NCT04031534|Experimental|Measure of hypoxia by F-Miso PET scan and RMI|Patient will undergo F-Miso PET scan and MRI to detect hypoxia. Imaging will be correlated with immunohistochemistry on tumour biopsy
89167816|NCT00679250|Experimental|Levocetirizine|Active drug
89167817|NCT00679250|Placebo Comparator|placebo|placebo to levocetirizine
89167818|NCT00679328|Experimental|1|Surgical implantation of OP-1
89167819|NCT00679328|Active Comparator|2|Surgical implantation of bone graft material
89167820|NCT00679406|Experimental|1|Brief Behavioral Treatment for Insomnia
89167821|NCT04150952|Experimental|HRV-Group|Athletes will train according to their basal HRV scores. If the resting HRV is higher tan their basal HRV, they will perform a high or moderate intensity training. If the resting HRV is lower, they will perform a low intensity training. If the resting HRV still lower, they will rest. They will not accumulate two or more days of high-moderate intensity training, nor two or more days of rest.
89167822|NCT04150952|Active Comparator|TRAD-Group|Athletes will train according to their trainer plan. Training will not be guided by their basal HRV scores.
89167823|NCT02627768||Cohort 1: Ustekinumab Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
89167824|NCT02627768||Cohort 2: TNFi Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
89167825|NCT00675662|Experimental|1|Stratification by angiotensin converting enzyme (ACE) genotype
89167826|NCT00675662|Placebo Comparator|2|Waiting list controls
89167827|NCT00696436|Experimental|Azilsartan Medoxomil 40 mg QD|
89167828|NCT00696436|Experimental|Azilsartan Medoxomil 80 mg QD|
89167829|NCT00696436|Active Comparator|Valsartan 320 mg QD|
89167830|NCT00696436|Active Comparator|Olmesartan 40 mg QD|
89167831|NCT00696436|Placebo Comparator|Placebo QD|
89167832|NCT00878072|Experimental|Famciclovir|
89167833|NCT00617435|Experimental|V|
89167834|NCT00617435|Experimental|N|
89167835|NCT00617435|Experimental|J|
89167836|NCT02627378|Active Comparator|Extracorporeal Membrane Oxygenation|Patients received Extracorporeal Membrane Oxygenation (ECMO) support
89167837|NCT02627378|Placebo Comparator|Non Extracorporeal Membrane Oxygenation|Patients did not receive Extracorporeal Membrane Oxygenation (ECMO) support
89167838|NCT04150484|Other|interventional group|dietary intervention, physical exercise and mindfulness
89167839|NCT04150484|No Intervention|control group|Group without any intervention.
89167840|NCT00675740|Experimental|1|
89167841|NCT00675740|Active Comparator|2|physical exercise
89167842|NCT00675740|No Intervention|3|control
89167843|NCT03045341|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
89167844|NCT03045341|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
89167845|NCT03045341|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
89167846|NCT03045341|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
89167847|NCT00675818|Experimental|1|CVVH: Patients in this arm will receive CVVH at a replacement fluid rate of 35 mL/kg/h.
89167848|NCT00675818|Active Comparator|2|CVVHD: Patients in this arm will receive CVVHD at a dialysate flow rate of 35 mL/kg/h.
89167849|NCT00679484|Experimental|1|
89167850|NCT00679484|Experimental|2|
89167851|NCT04214483||Diagnosis of Acne|Patients who have been diagnosed with acne, subdivided into the various types.
89167852|NCT00679562|Experimental|1|
89167853|NCT00679562|Placebo Comparator|2|
89167854|NCT00679640||1|Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
89167855|NCT02523287|Active Comparator|Fluad - 5 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
89167856|NCT02523287|Active Comparator|Fluad - 3 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
89167857|NCT02523287|Placebo Comparator|Saline - 5 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
89167858|NCT02523287|Placebo Comparator|Saline - 3 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
89167859|NCT00921388|Experimental|1|Exercise program
89167860|NCT00921388|Other|2|Relaxation program
89167861|NCT04672564|Experimental|Carrimycin|Patients will receive oral dose of 400 mg carrimycin once-daily and SOC for 14 days.
89167862|NCT04672564|Placebo Comparator|Placebo|Patients will receive oral dose of Placebo once-daily and SOC for 14 days.
89167863|NCT04212065|Active Comparator|Sublingual Suboxone|Women randomized to sublingual dosing will be provided prescription to fill.
89167864|NCT04212065|Active Comparator|Subcutaneous Sublocade|Women randomized to subcutaneous administration will have drug administered by nurse during routine prenatal care visits.
89167865|NCT02627534|Active Comparator|Ultrasonic Debridement (UD)|Ultrasonic Debridement (UD) (n=20)
89167866|NCT02627534|Experimental|UD + Antimicrobial Photodynamic Therapy|Ultrasonic Debridement + aPDT (UD+aPDT) (n=20)
89167867|NCT02566330||EndoBarrier|Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen.
89167868|NCT04213235|Experimental|Physical exercise|
89167869|NCT02627456|Experimental|1A|(n=5), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (4.5x105) via DVI. All 5 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination.
89167870|NCT02627456|Experimental|1B|(n=S), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (9.0x10S) via DVI. All S subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination
89167871|NCT02627456|Experimental|1C|(n=30), will be the targeted dose for the Pilot Safety Group. Subjects will receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. 15 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to each administration of PfSPZ Vaccine, while 15 will not, except prior to PfSPZ Vaccine #3 when all 30 subjects will receive antimalarial treatment with ASAQ.
89167872|NCT02627456|Experimental|1D|(n=15), will be the CHMI control group. Subjects will not receive any PfSPZ vaccinations but will serve as infectivity controls for CHMI. All 15 subjects will receive antimalarial treatment with ASAQ prior to PfSPZ Challenge.
89167873|NCT02627456|Experimental|2|(n=60), will be the targeted vaccine dose arm and receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the pilot study indicate otherwise.
89167874|NCT02627456|Placebo Comparator|3|(n=60), will be the placebo arm and receive vaccinations with normal saline via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the Pilot Study indicate otherwise.
89167875|NCT02627456|Active Comparator|4|(n=SS), will be group- matched (age, sex, village) controls for Arm 2 for the duration study. Subjects previously enrolled in Arm 3 may re-enroll in Arm 4. All subjects will receive antimalaria treatment at enrollment
89167876|NCT02566408|Experimental|Supportive Care (interview about KAPs towards PA)|"Participants undergo a 2-hour one-on-one interview and answer survey questions about their beliefs, attitudes, and preferences (KAPs) towards physical activity (PA). Ten topics will be used to explore older women's attitudes toward PA. Six topics will also be used to explore ethnic-specific and culture-specific contexts that surround older women's participation in PA.~REFINEMENT OF THE PA INTERVENTION: Approximately 1-2 months after the conclusion of interviews, participants are invited to a joint session and presented with results of analyzed data. Participants are asked to review results and themes identified from interviews, and to concur whether conclusions capture their KAPs. Through this process a set of preferences that is agreed upon by all as most critical for enhancing PA participation, adherence, and retention will be identified."
89167877|NCT00617513|Active Comparator|1|
89167878|NCT00617513|Active Comparator|2|
89167879|NCT00617513|Active Comparator|3|
89167880|NCT00617513|Placebo Comparator|4|
89167881|NCT02627222|Active Comparator|Treatment|Daily consumption of two cassava-based meals prepared with pro-vitamin A rich biofortified cassava
89167882|NCT02627222|Placebo Comparator|Control|Daily consumption of two cassava-based meals prepared with common white cassava
89167883|NCT00619463|Experimental|exercise then monitor|8 weeks of aerobic exercise followed by 16 weeks of monitoring
89167884|NCT00619463|Experimental|monitor than exercise|8 weeks of monitoring followed by 16 weeks of aerobic exercise
89167885|NCT02566486|Other|Reciprocating system|Waveone root canal instrumentation file
89167886|NCT02566486|Other|Rotational system|ProTaper Next root canal instrumentation file
89167887|NCT04214015||Patients with metastatic mesothelioma|Patients who have been diagnosed with metastatic mesothelioma
89167888|NCT02466737|Experimental|no axillary surgery|
89167889|NCT02466737|Active Comparator|sentinel lymph node biopsy|standard arm in first randomization
89167890|NCT02466737|Experimental|sentinel lymph node biopsy alone|
89167891|NCT02466737|Active Comparator|completion axillary lymph node dissection|standard arm in second randomization
89167892|NCT00594854|Experimental|PN400|PN 400 (esomeprazole/naproxen) dosed twice daily
89167893|NCT00594854|Active Comparator|Diclofenac/Misoprostol|diclofenac 75mg/misoprostol 200 mcg dosed twice daily
89167894|NCT02566564|Experimental|open label, single arm|Open label, single arm, dose escalating
89167895|NCT00684632|Experimental|1|KW-2246
89167896|NCT00684632|Placebo Comparator|2|Placebo
89167897|NCT00855582|Experimental|Tadalafil 2.5 mg|
89167898|NCT00855582|Experimental|Tadalafil 5 mg|
89167899|NCT00855582|Placebo Comparator|Placebo|
89167900|NCT00619541|Experimental|A|"5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days~Sorafenib 400 mg bid orally continuously~5-FU will be administered for a maximum of 12 cycles.~Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease."
89167901|NCT00680498|Active Comparator|1|
89167902|NCT00680498|Active Comparator|2|
89167903|NCT04211597|Sham Comparator|Group 1: Control|Participants receive no scar prevention and treatment for Cesarean wounds.
89167904|NCT04211597|Active Comparator|Group 2: Silicone gel|Each participant in Group 2 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months.
89167905|NCT04211597|Experimental|Group 3: Silicone gel plus Me-EGF|"The day of Cesarean delivery was recorded as Day 0. For participants in Group 3, on day 0 prior to final dermal closure, 4ml of Me-EGF (containing 40mcg microencapsulated polysaccharide and rhEGF) was sprayed evenly along the incision site, subsequently covered with antibiotic ointment and sterile gauze. Another 0.5 ml (5 mcg of Me-EGF) was sprayed during dressing change on day 1 and day 5 respectively. At each dressing change, the sutured wound was cleaned by sterile normal saline, followed by Me-EGF sprays, and waited for two minutes to allow for absorption, then covered with dry sterile gauze.~Each participant in Group 3 brought home two tubes of silicone gel when they returned for their follow-up visits on day 14. They were instructed to start applying silicone gel evenly to the wound twice a day for two months."
89167906|NCT04151030|Experimental|Endoscopic-PEG|"The patients who are unable to undergo an endoscopic pull PEG placement, will undergo an Endoscopic introducer style Direct-PEG procedure at the time of the index endoscopy"
89167907|NCT04151030|Active Comparator|IR-PEG|Patients who underwent PEG placement by interventional radiology (IR-PEG).
89167908|NCT00679796||Group A|Subjects with PCR confirmed varicella
89167909|NCT00679796||Group B|Age- and practice-matched control subjects
89167910|NCT04211519|Experimental|Permanent teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
89167911|NCT04211519|Experimental|Primary teeth group|For the disinfection of teeth, 30% hydrogen peroxide and 2.5% sodium hypochlorite solution were used for 30 seconds each. Then, 5% sodium thiosulfate solution was used to inactivate the disinfectant agents. Cavity preparation and root canal access were accomplished using sterile high-speed diamond burs under water cooling. Microbial samples were taken immediately by the same researcher from the largest root canal under strict aseptic conditions by using paper point method. Sterilized minimum four paper points were placed to the same level in root canal and the root canal content was absorbed. Each paper point was kept into the canal for at least 30 seconds. Then, paper points were placed into the Eppendorf tubes and refrigerated at -80 °C within 10 min.
89167912|NCT00680576|Active Comparator|1|Eight weeks of individual CBT for adolescents who have completed six weeks of group therapy and continue to use drugs.
89167913|NCT00680576|Active Comparator|2|Eight weeks of FFT for adolescents who have received six weeks of group therapy and continue to use drugs.
89167914|NCT02369471|Experimental|Group 1a|Subjects on inducer AEDs will administer GWP42006.
89167915|NCT02369471|Active Comparator|Group 2a|Subjects on inhibitor AEDs will administer GWP42006.
89167916|NCT02369471|Experimental|Group 3a|Subjects on AEDs that are neither inducers nor inhibitors will administer GWP42006.
89167917|NCT02369471|Placebo Comparator|Group 1b|Matching placebo control for Group 1a.
89167918|NCT02369471|Placebo Comparator|Group 2b|Matching placebo control for Group 2a.
89167919|NCT02369471|Placebo Comparator|Group 3b|Matching placebo control for Group 3a.
89167920|NCT00679874||I|Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.
89167921|NCT01793129|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
89167922|NCT01793129|Placebo Comparator|Normothermia|Control group (with esophageal temperature at or near 37.0°C) for 72 hours
89167923|NCT00684710|Experimental|PAZ-417|
89167924|NCT00684710|Placebo Comparator|Placebo|
89167925|NCT01788683|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged tendon.
89167926|NCT01788683|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.
89167927|NCT00684866|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (8 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (8 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects."
89167928|NCT00684866|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects.
89167929|NCT00854724|Active Comparator|Puerarin|
89167930|NCT00854724|Placebo Comparator|Placebo|Sugar beet filler in capsule
89167931|NCT00680654|Experimental|Arm 1|
89167932|NCT00698568|Experimental|Group A|
89167933|NCT00698568|Placebo Comparator|Group B|
89167934|NCT00680030||1|
89167935|NCT00616733|Experimental|1|
89167936|NCT00616733|Experimental|2|
89167937|NCT00616733|Experimental|3|
89167938|NCT02945969|Experimental|Low Sodium Diet|Behavioral modification to decrease dietary sodium intake to ≤2,300 mg/day for 24 weeks. The intervention program consists of two phases. An initial 12-week intensive phase will include weekly individual and group sessions. This will be followed by a 12-week maintenance phase that includes telephone counseling sessions every 2 weeks.
89167939|NCT02945969|No Intervention|Usual Diet|No dietary intervention.
89167940|NCT00680732|Experimental|A1|Multiple micronutrients supplements (MMS) and weekly chloroquine (CQ)
89167941|NCT00680732|Experimental|A2|Multiple micronutrients supplements (MMS) and intermittent suplphadoxyne-pyrimethamine (SP)
89167942|NCT00680732|Experimental|B1|Iron and folic acid (IFA) and weekly chloroquine (CQ)
89167943|NCT00680732|Experimental|B2|Iron and folic acid (IFA) and intermittent sulphadoxyne-pyrimethamine (SP)
89167944|NCT04210193|Active Comparator|Active booster|After three basic open label grass allergen ILIT injections the patient is randomized to an active ILIT booster 1 year after the first treatment.
89167945|NCT04210193|Placebo Comparator|Placebo booster|After three basic open label grass allergen ILIT injections the patient is randomized to a placebo ILIT booster 1 year after the first treatment.
89167946|NCT04653766|Experimental|Ir-CPI - Dose 1|Participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
89167947|NCT04653766|Experimental|Ir-CPI - Dose 2|Participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
89167948|NCT04653766|Experimental|Ir-CPI - Dose 3|Participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
89167949|NCT04653766|Experimental|Ir-CPI - Dose 4|Participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
89167950|NCT04653766|Placebo Comparator|Placebo|Participants received a single intravenous dose of placebo during 6 hours
89167951|NCT00620243|Experimental|1|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
89167952|NCT04151186|Experimental|TM4SF1 and EpCAM positive CAR-T cells for solid tumors|The present study is proposed to study advanced malignant solid tumors in adults, and the three escalating doses, namely, 2.0~2.5. 4.0~5.0 and 8.0~10.0 (×10 ^6/kg), will be given.
89167953|NCT00698932|Experimental|Saxagliptin 5mg|
89167954|NCT00698932|Placebo Comparator|Placebo|
89167955|NCT02566252|Experimental|PUL-042|PUL-042 Inhalation Solution
89167956|NCT02566252|Experimental|Cromolyn sodium|Pre-Treatment with cromolyn sodium followed by PUL-042 Inhalation Solution Administration
89167957|NCT02566252|Experimental|Albuterol sulfate|Pre-Treatment with albuterol sulfate followed by PUL-042 Inhalation Solution Administration
89167958|NCT00823719|Experimental|ofatumumab + DHAP or ICE chemotherapy regimen|This study is a single arm study, but the Investigators are required to prospectively choose to treat all of their subjects with either ICE or DHAP chemotherapy regimens in combination with ofatumumab. Regardless of whether the subject receives ICE or DHAP chemotherapy, all subjects will receive the same ofatumumab regimen and dose.
89167959|NCT03953170|Active Comparator|Teduglutide|Teduglutide 0.05 g/kg/day
89167960|NCT03953170|Placebo Comparator|Placebo|Placebo
89167961|NCT02565550|Experimental|IBS patients|eat the low FODMAPs diet for one week
89167962|NCT02565550|Active Comparator|healthy controls|eat the low FODMAPs diet for one week
89167963|NCT02567500|Experimental|Patients with auditory hallucination|"Patients with auditory hallucination:~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NeuroPsychologic assessment (NEPSY) II) : theory of mind and affect recognition~The emotional marker:~Differential Emotion Scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:~Mini International Neuropsychiatric Interview (MINI) -Kids~Psychosis section of Kiddie-SADS"
89235052|NCT05159713|Other|Treatment as Usual (TAU)|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
89235053|NCT05159713|Experimental|dCBI + Treatment as Usual|Participants randomly assigned to the intervention group (dCBI+TAU) will receive standard care and also gain access to the dCBI. The dCBI, RxWell, is a trans-Cognitive Behavioral Therapy (CBT) mobile app product addressing depression and anxiety that was developed based on standard CBT techniques.
89167964|NCT02567500|Placebo Comparator|Patients without auditory hallucination|"Patients without auditory hallucination:~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:~Mini International Neuropsychiatric Interview (MINI) -Kids~Psychosis section of Kiddie-SADS (Schedule for Affective Disorders and Schizophrenia )"
89167965|NCT00921466||Hospital Patients/Hospital Employees|
89167966|NCT00921466||Hospital employees|A group of 10 hospital employees used as baseline
89167967|NCT00708591|Experimental|1|
89167970|NCT00708669|Active Comparator|TAXUS group|
89167971|NCT00708669|Active Comparator|Cypher group|
89167972|NCT02565940||diabetic patient with foot infection|
89167973|NCT04062604||Femur fracture|Stabilization of femur fracture according to the AO fundation guidelines
89167974|NCT04062604||Hip alloplasty|Endoprothesis
89167975|NCT04062604||Knee alloplasty|Endoprothesis
89167976|NCT04062604||Knee arthroscopy|Resection of the meniscus lesion or anterior cruciatus ligamentum reconstruction
89167977|NCT00708747|Experimental|B|Patients were randomised to receive a commercially available standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) containing all important transport and inhibitor proteins as well as immunoglobulins
89167978|NCT00708747|Active Comparator|A|Patients were randomised to receive a 5% albumin solution
89167979|NCT00875420|Experimental|RAD1901 10 mg|Oral once a day for 28 days
89167980|NCT00875420|Experimental|RAD1901 25 mg|Oral once a day for 28 days
89167981|NCT00875420|Experimental|RAD1901 50 mg|Oral once a day for 28 days
89167982|NCT00875420|Experimental|RAD1901 100 mg|Oral once a day for 28 days
89167983|NCT00875420|Placebo Comparator|Placebo|Oral once a day for 28 days
89167984|NCT00708825||1|surgical outcome, observation
89167985|NCT02567344|Experimental|Active rTMS|Active rTMS will be delivered to the Left DLPFC at 10Hz. A total of 4000 pulses will be delivered.
89167986|NCT02567344|Sham Comparator|Sham rTMS|Sham rTMS will be delivered to the Left DLPFC at 10 Hz using an electronic sham system used in multiple other investigations. A total of 4000 pulses of sham rTMS will be delivered.
89167987|NCT00685022|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study."
89167988|NCT00685022|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study.
89167989|NCT04209881||Patients with Ankylosing spondylitis|"Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
89167990|NCT04209881||Healthy women as controls|"Regular menstruation with intervals of 21-35 days; cycle length variations <4 days; and both ovaries still present healthy women will create the control group.In order to evaluate the ovarian reserve of the patients, the parameters we routinely look at will be evaluated as follows. the results of these tests will be observed.~Amh will be looked for. (pmol / l). Antral folukul census in the overin folukular stage will be valued as number. Fsh (iu / l) and Estradiol (pmol / l) values will also be recorded."
89167991|NCT00822237|Experimental|VARIVAX 2007 process + M-M-R II|
89167992|NCT00822237|Active Comparator|VARIVAX 1999 process + M-M-R II|
89167993|NCT02626286|Other|HIV quarterly global care|HIV quarterly global care including i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) prevention counselling adapted for MSM, v) the provision of condoms and lubricants, and vi) HIV screening test at each quarterly visit for HIV-negative MSM or immediate support of HIV infection including antiretroviral therapy for HIV-positive MSM.
89167994|NCT00617747|Experimental|1|
89167995|NCT00617747|Placebo Comparator|2|
89167996|NCT00680888||1|Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006
89167997|NCT04560400|Sham Comparator|No Concussion Conventional KD|Participants without concussion history perform conventional King-Devick Test.
89167998|NCT04560400|Active Comparator|No Concussion Reverse KD|Participants without concussion history perform reverse King-Devick Test.
89167999|NCT04560400|Sham Comparator|Single Concussion Conventional KD|Participants with 1 concussion history perform conventional King-Devick Test.
89168000|NCT04560400|Active Comparator|Single Concussion Reverse KD|Participants with 1 concussion history perform reverse King-Devick Test.
89168001|NCT04560400|Sham Comparator|Multiple Concussion Conventional KD|Participants with 2 or more concussion history perform conventional King-Devick Test.
89168002|NCT04560400|Active Comparator|Multiple Concussion Reverse KD|Participants with 2 or more concussion history perform reverse King-Devick Test.
89168003|NCT00708903|Experimental|1|HKI-272
89168004|NCT00708903|Placebo Comparator|2|Placebo
89168005|NCT00708903|Active Comparator|3|Moxifloxacin
89168006|NCT00690248||1|Bipolar patients admitted to a psychiatric Unit due to an acute mania episode.
89168007|NCT00708981|Active Comparator|Study Group|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.~Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.~Patient enhanced self-management provided by combined diabetes-renal education curriculum.~Behavior and social intervention~Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
89168008|NCT00708981|No Intervention|Control Group|Control Group will keep on receiving the usual treatment that they used to receive from their respective clinics and the Diabetes-Renal team would not alter their therapy or interfere in their management.
89168009|NCT00637091|Experimental|EGFR expression|Patients' accrual will be adjusted by EGFR expression (positive vs. negative)
89168010|NCT04138784|Experimental|Comprehensive Rehabilitation program|19 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks individualized comprehensive rehabilitation program administered once a day.
89168011|NCT04138784|Experimental|Aquatic training|18 women will be recruited in order to the inclusion criteria for the study and they will receive an 8-weeks hydrotherapy intervention once a day.
89168012|NCT00922857|Experimental|Respiratory rehabilitation|
89168013|NCT04213391|Experimental|sulforaphane group|The patients will take sulforaphane for 24 weeks, 2550mg once a day.
89168014|NCT04213391|Placebo Comparator|Placebo group|The patients will take placebo for 24 weeks, 2550mg once a day.
89168015|NCT00690326|Experimental|A|"treatment type: behavioral(lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
89168016|NCT00690326|Placebo Comparator|B|Arm B given placebo comparator ie pamphlets
89168017|NCT00709137|Active Comparator|1|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and spironolactone will be added (dose range 12.5mg-50mg)
89168018|NCT00709137|Active Comparator|2|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and amiloride will be added (dose range 2.5-10mg)
89168019|NCT04150406|Active Comparator|Flexofytol|2 capsules containing 42mg of curcumin will be administered twice a day for a duration of 4 months.
89168020|NCT04150406|Placebo Comparator|Placebo|2 capsules of the placebo, identical in appearance to Flexofytol, will be administeres twice a day for a duration of 4 months.
89168021|NCT03659266|Active Comparator|Group 1|"D0: Injection of Botulinum toxin A in triceps surae, according to pre-established modalities (no influence of the experimental protocol on this stage) W2-W4: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization)"
89168022|NCT03659266|Active Comparator|group 2|"D0: Injection of Botulinum toxin A in triceps surae W2-W4: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization)"
89168023|NCT04150172|Other|Sequence A (RT)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:~Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.~Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
89168024|NCT04150172|Other|Sequence B (TR)|"[Sequence A (RT) & Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:~Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.~Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours."
89168025|NCT02611245|Experimental|Indocyanine green|This group of patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. Before systematic lymphadenectomy, four-point of ICG with 10mg was injected in normal lung tissue around the tumor. After 3-5 minutes, fluorescence and white-light images were collected and recorded in real-time. With the guidance of intraoperative images, all fluorescent lymph nodes were removed and sent to routine pathological confirmation.
89168026|NCT02325011|Experimental|Treatment Sequence 1|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 1 is as follows;~Visit 2 (Treatment A)~Visit 3 (Treatment B)~Visit 4 (Treatment A)~Visit 5 (Treatment B)~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
89168027|NCT02325011|Experimental|Treatment Sequence 2|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 2 is as follows;~Visit 2 (Treatment B)~Visit 3 (Treatment A)~Visit 4 (Treatment B)~Visit 5 (Treatment A)~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
89168028|NCT00690404|Experimental|1|
89168029|NCT00620009|No Intervention|Control|Therapists and patients record their estimates of the patient's Global Assessment of Functioning, but do not discuss these estimates in therapy sessions.
89168030|NCT00620009|Experimental|Empathy Feedback|Therapists and patients record their ratings of the patient's Global Assessment of Functioning and discuss these ratings.
89168031|NCT02625584|Other|Shared Reading Control|Reading Together - Shared Reading Control. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will not be trained to read with their child. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
89168032|NCT02625584|Experimental|Dialogic Reading|Reading Together - Dialogic Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a dialogic reading style. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
89168033|NCT02625584|Experimental|Pausing for Reading|Reading Together - Pausing for Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a style which involves pausing, recasting and open questioning. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
89168034|NCT00577096|Experimental|Exercise|Study participants were computer randomized to an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
89168035|NCT00577096|Active Comparator|usual care|Study participants were asked to remain as active as possible but not prescribed an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
89168036|NCT04211285||community dwelling elderly|community dwelling elderly patients (60 years or older), can read and write, able to use the android software applications
89168037|NCT02625506|Placebo Comparator|Levobupivacaine|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine
89168038|NCT02625506|Active Comparator|Levobupivacaine and Tramadol|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine and tramadol
89168039|NCT00620399|Experimental|1|brace
89168040|NCT00620399|Placebo Comparator|2|no brace
89168041|NCT04209959|Experimental|low dose group|
89168042|NCT04209959|Experimental|middle dose group|
89168043|NCT04209959|Experimental|high dose group|
89168044|NCT04209647|Active Comparator|Continuous Exercise|At %60 of maximal heart rate, 30-60 minutes exercise
89168045|NCT04209647|Experimental|REHIT Exercise|At %100 of heart rate 15 seconds, after this period 15 sec recovery period for all step
89168046|NCT02565472|Experimental|Apple Juice|12 oz apple juice
89168047|NCT02565472|Experimental|Grape Juice|12 oz grape juice
89168048|NCT04209803|Active Comparator|Minoxidil group|The first group will receive Minoxidil 5% topically twice daily for 4 months.
89168049|NCT04209803|Active Comparator|NAC group|The second group will receive NAC orally 600 mg 3 times a day for 4 months.
89168050|NCT04209803|Active Comparator|Minoxidil + NAC group|The third group will receive combined treatment of Minoxidil 5% twice daily and oral NAC 600 mg 3 times a day for 4 months.
89168051|NCT04209803|No Intervention|Control group|The fourth group will be the patients who are refusing the treatment and will be followed-up over 4 months.
89168052|NCT02567032|Experimental|Oxytocin|40 IU Oxytocin
89168053|NCT02567032|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
89168054|NCT04701047||pessary|Vaginal prolapse being treated by pessary
89168055|NCT04701047||surgery|Vaginal prolapse being treated by surgical repair
89168056|NCT05118334|Experimental|IBI310 (anti-CTLA-4) 1mg/kg(Q3W until progressive disease)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
89168057|NCT05118334|Experimental|IBI310 (anti-CTLA-4) 1mg/kg(Q3W*4cycles)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W*4cycles,and then Sintilimab 200 mg IV, Q3W single until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
89168058|NCT05118334|Experimental|IBI310 (anti-CTLA-4) 1mg/kg(Q6W)in combination with Sintilimab|The test group will be treated with IBI310 1mg/kg IV, Q6W+ Sintilimab 200 mg IV, Q3Wuntil progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
89168059|NCT05118334|Experimental|IBI310 (anti-CTLA-4) 0.5mg/kg in combination with Sintilimab|The test group will be treated with IBI310 0.5mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
89168060|NCT00863304|Experimental|1|
89168061|NCT00863304|Experimental|2|
89168062|NCT00863304|Active Comparator|3|
89168063|NCT00863304|Placebo Comparator|4|
89168064|NCT04210973|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
89168065|NCT04210973|Placebo Comparator|Placebo|Placebo,oral, twice per day
89168066|NCT00695110|Experimental|All study participants|"Treatment Period 1: Three capsules each containing 100 mg testosterone (T) as testosterone undecanoate (TU), twice daily (BID) for 7 days.~Treatment Period 2: Two capsules each containing 200 mg T as TU and testosterone enanthate (TE), BID for 7 days.~Treatment Period 3: Two capsules each containing 100 mg T as TU, BID for 8 days.~Treatment Period 4: Two capsules each containing 150 mg T as TU and TE, BID for 7 days."
89168067|NCT04211051|Experimental|Arm A|LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery
89168068|NCT04213313||Control Group|health volunteers
89168069|NCT04213313||Infectious Keratitis Group|Infectious corneal patients
89168070|NCT03892954||adolescents with CFS ( n= 100)|Participants with CFS who had constant or persisting fatigue lasting 3 months with the severe functional disability to such extent that prevents normal school attendance and also had no drug prescriptions (including hormone contraceptives), any medical or psychiatric disorder that might explain the fatigue were included in this study
89168071|NCT03892954||health control ( n=50).|healthy control subjects with no CFS
89168072|NCT04187963|Experimental|Group physical therapy|Groups of 6 patients and 1 physical therapist for the 1.5 hour physical therapy session
89168073|NCT04187963|Active Comparator|Individual physical therapy|1.5 hour physical therapy session 1 on 1 (1 patient and 1 physical therapist)
89168074|NCT04210817||Patients|Patients who have been diagnosed with Rheumatoid Arthritis
89168075|NCT03264352|Active Comparator|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
89168076|NCT03264352|Placebo Comparator|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
89168077|NCT04897919|Experimental|dihydroartemisinin-piperaquine|"First dose will be given supervised. The rest will be provided and the parents should take it at home.~Dihydroartemisinin-piperaquine dosing as recommended by manufacturer"
89168078|NCT04897919|Active Comparator|artemether-lumefantrine|"First dose will be given supervised. The rest will be provided and the patients should take it at home.~Artemether-lumefantrine dosing as recommended by manufacturer"
89168079|NCT00921544|Active Comparator|Oral Sucrose|Oral sucrose administered 2 mins prior to eye exam
89168080|NCT00921544|Placebo Comparator|Sterile water|0.2 mls of sterile water
89168081|NCT04060732||Flash Glucose Monitoring Device|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid used by Diabetes Mellitus type 1 patients."
89168082|NCT04139447||Healthy subjects|
89168083|NCT00594386|Experimental|Rotigotine|
89168084|NCT00742612|Active Comparator|1|ARC1779 Injection
89168085|NCT00742612|Placebo Comparator|2|Placebo (normal saline)
89168086|NCT00680966|Experimental|TX1|Functional Family Therapy (FFT) followed by Adolescent Coping With Depression (ACWD)
89168087|NCT00680966|Experimental|TX 2|ACWD (Adolescent Coping With Depression) followed by FFT (Functional Family Therapy)
89168088|NCT00680966|Experimental|TX 3|Combination of an augmented FFT and ACWD - Integrated treatment
89168089|NCT00358943||Patients in ICGG Gaucher Registry|No experimental intervention is given. A patient with Gaucher Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
89168090|NCT00358943||Pregnant women with confirmed diagnosis of Gaucher disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Gaucher disease who are participating in the ICGG Gaucher Registry and consented to participate in the Gaucher Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy and irrespective of the commercial product with which she may be treated.
89168091|NCT02565394|Experimental|Micro-Break with Dynamic Activity|Micro Break with web based application of a video to lead surgeons through dynamic exercise activities
89168092|NCT02565394|No Intervention|Comparator|A baseline survey will be completed following a surgical day with no dynamic activities
89168093|NCT04138862|Active Comparator|Sensory Matched/Unlabelled|Sensory-matched covert calorie reduction, unlabelled
89168094|NCT04138862|Experimental|Sensory Matched/Labelled|Sensory-matched explicit calorie reduction, labelled
89168095|NCT04138862|Experimental|Sensory Reduced/Labelled|Sensory-reduced explicit calorie reduction, labelled
89168096|NCT04138862|Experimental|Sensory Enhanced/Labelled|Sensory-enhanced explicit calorie reduction, labelled
89168097|NCT04150016|Experimental|Firehawk implantation|22 subjects will be enrolled to receive Firehawk™ sirolimus target-eluting stent(s).
89168098|NCT04150016|Active Comparator|XIENCE implantation|22 subjects will be enrolled to receive XIENCE™ everolimus target-eluting stent(s).
89168099|NCT00690560|Experimental|R-CHOP14 chemotherapy|
89168100|NCT00742690|Active Comparator|1|35 patients with cirrhosis and type 1 HRS
89168101|NCT00742690|Experimental|2|35 patients with cirrhosis and type 1 HRS
89168102|NCT00690638|Placebo Comparator|1|Placebo
89168103|NCT00690638|Experimental|2|PHX1149T 200 mg
89168104|NCT00690638|Experimental|3|PHX1149T 400 mg
89168105|NCT00742768|Active Comparator|1|softgel capsules
89168106|NCT00742768|Active Comparator|2|Gelpell capsules
89168107|NCT03195400||CC Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 obese CC adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20.
89235054|NCT05097898|Experimental|Patients with chronic HFpEF coming for scheduled day hospitalization or consultation|"Clinical examination focusing on congestion~Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone follow-up"
89168108|NCT03195400||TT Genotype|Subjects who have not already been tested previously will be tested for the TCF7L2 genotype to determine if they are TT or CC. An anticipated 50 TT subjects will be enrolled in this group. An anticipated 50 obese TT adolescents with IGT or pre-IGT with similar age, pubertal stage, ethnicity and Body Mass Index (BMI) will be enrolled. Subjects will undergo Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test IsoG IVGT and Hyperinsulinemic Euglycemic Clamp and 2H20
89168109|NCT00685412|Experimental|0.6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
89168110|NCT00685412|Experimental|2mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
89168111|NCT00685412|Experimental|6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
89168112|NCT00681122||1|Standard therapy
89168113|NCT00681122||2|Standard therapy + educational material
89168114|NCT04656431|Experimental|Cohort 1: Hyperpolarized pyruvate (13C)|Histologically proven relapsed PCNSL patients will receive hyperpolarized carbon C 13 pyruvate intravenously (IV) and undergo MRI at baseline. An optional second HP 13C pyruvate injection and MRI acquisition will be offered on same day following completion of the first scan.
89168115|NCT04656431|Experimental|Cohort 2: Hyperpolarized pyruvate (13C)|Newly diagnosed PCNSL participants with planned treatment of standard high-dose methotrexate,temozolomide plus rituximab (MT-R) regimen will receive hyperpolarized carbon C 13 pyruvate intravenously (IV) and undergo MRI at baseline and again after three cycles of of standard induction chemotherapy. An optional second HP 13C pyruvate injection and MRI acquisition will be offered on same day following completion of the first scan. Participants in Cohort 2 will also have option to undergo an additional imaging at a later time if the participant's cancer progresses.
89168116|NCT04210895|Experimental|Warm footbath with ginger powder|Participants receive a daily warm water footbath with added ginger powder over a two-week period
89168117|NCT04210895|Active Comparator|Warm water only footbath|Participants receive a daily warm water footbath over a two-week period
89168118|NCT00862992|Experimental|1|
89168119|NCT00862992|Experimental|2|
89168120|NCT00862992|Experimental|3|
89168121|NCT02565316|Active Comparator|Nepeta menthoides Boiss & Bohse freeze dried extract capsule|
89168122|NCT02565316|Active Comparator|Sertraline capsule|
89168123|NCT00742846|Active Comparator|Group 1|The patient receives intra-articular steroid and local anesthetic injection under fluoroscopy.
89168124|NCT00742846|Active Comparator|Group 2|The patient receives subacromial steroid and local anesthetic injection under fluoroscopy.
89168125|NCT00742846|Active Comparator|Group 3|The patient receives intra-articular local anesthetic injection under fluoroscopy.
89168126|NCT00742846|Active Comparator|Group 4|The patient receives subacromial local anesthetic injection under fluoroscopy.
89168127|NCT00620087|Other|Diagnostic Arm|Women with core-biopsy proven atypia, LCIS, or radial scar who have not yet undergone surgical excision were enrolled in the diagnostic arm. A molecular breast imaging study will be obtained.
89168128|NCT00620087|Other|Surveillance arm|Women with a diagnosis of ADH, ALH, or LCIS within the past 5 years were enrolled in the surveillance arm. A molecular breast imaging study was done at enrollment (Year 0) and repeated at Yer 2 and Year 4. Patients continued with routine screening mammography during this time period.
89168129|NCT04123860|Experimental|buccal fat pad|will undergo sinus lifting using intralift technique then placement of buccal fat pad followed by immediate implant placement.
89168130|NCT04123860|Active Comparator|prf|will undergo sinus lifting using intralift technique the prpration of PRF and immediate implant placement.
89168131|NCT00685490||Surgical|Retrospective chart review of 70 eyes of 70 consecutive patients who underwent PPV, with and without ILM peeling, for persistent macular edema associated with BRVO
89168132|NCT04135560|Experimental|Part A Cohort 1 (1% Body Surface Area)|Each participant in this cohort will receive both PF-07038124 0.06% and vehicle applied to the skin (1% Body Surface Area)
89168133|NCT04135560|Experimental|Part B Cohort 1 (10% Body Surface Area)|
89168134|NCT04135560|Experimental|Part B Cohort 2 (10% Body Surface Area)|
89168135|NCT04135560|Experimental|Part B Cohort 3 (10% Body Surface Area)|
89168136|NCT04135560|Experimental|Part B Cohort 4 (10% Body Surface Area)|
89168137|NCT04135560|Experimental|Part B Cohort 5 (20% Body Surface Area)|
89168138|NCT04135560|Experimental|Part B Cohort 6 (10% Body Surface Area)|Optional cohort of Japanese participants
89168139|NCT00694096|Experimental|1|
89168140|NCT04123080|Experimental|EBL group|Removal of large long-stalked pedunculated colonic polyps using band ligations
89168141|NCT04150094|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training without stimulus.
89168142|NCT04150094|Experimental|Pelvic floor muscle training + intravaginal vibratory stimulus|Pelvic floor muscle training with intravaginal vibratory stimulation.
89168143|NCT04808531|Placebo Comparator|Double Placebo Arm|"Spray Placebo + Tablet Placebo~Spray Placebo is a nanoparticle water soluble solution without cannabinoids containing a small amount of hemp seed oil (for fragrance purposes only) as defined by Australian Office of Drug Control (ODC) (https://www.odc.gov.au/hemp-products). One dose is equivalent to 2 actuations of the pump delivering 280 µL volume.~Tablet Placebo will be identical to the Oxycontin tablets."
89168144|NCT04808531|Experimental|Treatment NanaBis™ Arm|"NanaBis™ + Tablet Placebo~NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC and CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD. The dose administered will be 1 - 3.5 doses (2 sprays to 7 sprays) per 4 hours unless asleep."
89168145|NCT04808531|Active Comparator|Comparator (Oxycodone) Arm|"Spray Placebo + Oxycodone CR~Spray Placebo is a nanoparticle water soluble solution without cannabinoids containing a small amount of hemp seed oil (for fragrance purposes only) as defined by Australian ODC (https://www.odc.gov.au/hemp-products). One dose is equivalent to 2 actuations of the pump delivering 280 µL volume.~Oxycodone controlled release (CR) used as a comparator will be Oxycontin tablets 10 mg - 70 mg po bd."
89168146|NCT02613780|Active Comparator|Sequential group|Photorefractive keratectomy will be performed 12-18 months after participants had crosslinking
89168147|NCT02613780|Active Comparator|Simultaneous group|Photorefractive keratectomy and crosslinking will be performed on the same day
89168148|NCT02625194|Experimental|Oxygen|Oxygen is supplied through suction port in bronchoscope during bronchoscope-guided intubation.
89168149|NCT02625194|No Intervention|Control|Bronchoscope-guided intubation is performed without oxygen supply.
89168150|NCT02622126|Active Comparator|Normotensive pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
89168151|NCT02622126|Active Comparator|Mild preeclampsia pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
89168152|NCT02625272|Experimental|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
89168153|NCT02625272|No Intervention|Group B|novel laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were divided at the beginning of the operation intracorporeally.
89168154|NCT02625272|No Intervention|Group C|the traditional laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer.
89168155|NCT00620633|Experimental|1|Patients with leukemia or myelodysplastic syndrome (MDS) who, following an HLA-matched allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated morphologically on peripheral blood smear or bone marrow aspirate
89168156|NCT04140188|Active Comparator|Axilla no touch|Volunteer patients who did not underwent to SLNB or axillary lymph node dissection during previous NSM
89168157|NCT04140188|Active Comparator|Axilla with previous SLNB|Volunteer patients who has underwent to SLNB but not axillary lymph node dissection during previous NSM
89168158|NCT00314015|Experimental|Patients with immediately loaded implants.|
89168159|NCT02622282|Experimental|Experimental Group|Participants will receive text messages and telephone calls during the length of their participation. Participants will receive a handout with information on PAD and physical activity.
89168160|NCT02622282|Active Comparator|Control Group|Participants will receive a handout with information on PAD and physical activity.
89168161|NCT00685568|Experimental|Arm I|Patients receive oral celecoxib twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
89168162|NCT00685568|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
89168163|NCT00306059|Experimental|patients having acute kidney injury|
89168164|NCT04121988||Denoising MRI group|Patients suspected of Cushing disease undergoing deep learning based denoising MRI
89168165|NCT02626208|Experimental|Nestorone®/ Estradiol 75|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 75 ug/day of estradiol
89168166|NCT02626208|Experimental|Nestorone®/Estradiol 100|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 100 ug/day of estradiol
89168167|NCT02626208|Experimental|Nestorone®/ Estradiol 200|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 200 ug/day of estradiol
89168168|NCT04210739|Experimental|trus guided betamethason injection arm|
89168169|NCT00696540|Experimental|1|Salbutamol is diluted in hypertonic (3%) saline.
89168170|NCT00696540|Active Comparator|2|Salbutamol is diluted in normal (0.9%) saline.
89168171|NCT04212845|Active Comparator|Group ESP|Ultrasound-Guided erector spinae plane block with 30 ml of 0.25% bupivacaine and 8 mg dexamethasone
89168172|NCT04212845|Active Comparator|Group TF|Fluoroscopy-guided transforaminal injection with 4 ml of 0.25% bupivacaine and 8 mg dexamethasone
89168173|NCT00681278||1|Hypertension patients with Type II Diabetes mellitus
89168174|NCT00620165|Experimental|1|
89168175|NCT00620165|Placebo Comparator|2|
89168176|NCT00685646|Experimental|Arm I|Patients receive maximum androgen-blockade therapy and zoledronic acid for up to 24 courses.
89168177|NCT00685646|Active Comparator|Arm II|Patients receive maximum androgen-blockade therapy for up to 24 courses.
89168178|NCT04209257|Experimental|Functional Electrical Stimulation protocol|Participants will be evaluated with and without the use of functional electrical stimulation while walking to determine the neuroprosthetic and neurotherapeutic effects.
89168179|NCT00685724|Experimental|1|Following 2 sessions of MET intervention received by all patients, patients in Condition 1 receive no further intervention.
89168180|NCT00685724|Experimental|2|Patients in Condition 2 will receive 8 sessions of the CBT (Cognitive Behavioral Therapy) intervention.
89168181|NCT00685724|Experimental|3|Patients in Condition 3 will receive 8 sessions of CBT plus aftercare treatment.
89168182|NCT04139720|Experimental|e-book|e-book learning mode of sexual harassment prevention training
89168183|NCT04139720|No Intervention|audio-visual and booklet|sexual harassment prevention audio-visual and booklet learning mode
89168184|NCT00284297|Experimental|knee arthrodesis|
89168185|NCT04784507|Experimental|En Bloc Resection Bladder Tumor (Any energy source)|Patients with suspicion of NMIBC (primary or recurrent) that underwent en bloc resection (EBRT
89168186|NCT04784507|Active Comparator|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Patients with suspicion of NMIBC (primary or recurrent) that underwent conventional TURBT
89168187|NCT04138472|Experimental|Dexmedetomidine|Group A patients receive intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
89168188|NCT04138472|Experimental|Fentanyl|Group B receives intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
89168189|NCT04138472|Experimental|Lidocaine|Group C patients receives intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
89168190|NCT00620789|Active Comparator|1|Cognitive-Behavior Therapy for insomnia (CBT-I) + Antidepressant medication
89168191|NCT00620789|Placebo Comparator|2|Cognitive Behavior Therapy for Insomnia (CBT-I) + placebo medication
89168192|NCT00620789|Sham Comparator|3|Antidepressant medication + Sleep Hygiene Control (SH)
89168193|NCT00691184|Experimental|Group 1|0% Terbinafine HCl Nail Lacquer for 28 days.
89168194|NCT00691184|Experimental|Group 2|10% Terbinafine HCl Nail Lacquer.
89168195|NCT00691184|Active Comparator|Group 3|1% Lamisil® Cream
89168196|NCT00691184|Active Comparator|Group 4|Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.
89168197|NCT00854100|Placebo Comparator|Placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo
89168198|NCT00854100|Experimental|Cariprazine 0.1 - 0.3 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR)+ cariprazine low dose
89168199|NCT00854100|Experimental|Cariprazine 1.0 - 2.0 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine high dose
89168200|NCT00509899|Experimental|Ruxolitinib|All participants received oral ruxolitinib. Patients began treatment with either 10 mg twice a day (bid), 15 mg bid, 25 mg bid, 50 mg bid, 25 mg once a day (qd), 50 mg qd, 100 mg qd, or 200 mg qd, depending on the time period when they entered the study. The doses were titrated based on efficacy and safety to a maximum of 25 mg bid for patients who entered the study after sufficient dosing information had been obtained to define the maximum dose for patients in the study. Patients could continue receiving treatment indefinitely if receiving benefit at a dose that continues to maintain benefit but does not exceed a maximum dose of 25 mg BID.
89168201|NCT04212767|Experimental|Test group|Post-extraction sockets covered with Platelet-Rich Fibrin membrane (n=16)
89168202|NCT04212767|No Intervention|Control Goroup|Post-extraction sockets left to spontaneous healing/clot and primary closure (n=16).
89168203|NCT00691262|Experimental|1|
89168204|NCT00620867|Experimental|Ibuprofen|
89168205|NCT00620867|Experimental|Celecoxib|
89168206|NCT00620867|Placebo Comparator|placebo|
89168207|NCT00922688|Active Comparator|Dipeptiven Arm Enteral|
89168208|NCT00922688|Placebo Comparator|Placebo Arm Enteral and Intravenously|
89168209|NCT00922688|Active Comparator|Dipeptiven ARM Intravenously|
89168210|NCT02622204||Corrective osteotomy|patients with knee osteoarthritis undergoing corrective osteotomy
89168211|NCT04271917|Active Comparator|Treatment As Usual (TAU)|"Participants will receive a 5-day supply of acetaminophen 500mg and ibuprofen 200mg.~Instructions for use: Take one tablet of each medication at the same time every 4-6 hours as needed for pain."
89168212|NCT04271917|Placebo Comparator|Placebo|"Participants will receive a 5-day supply (15mL) of inactive placebo in a dropper vial.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
89168213|NCT04271917|Experimental|CBD 17mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 17mg/mL.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
89168214|NCT04271917|Experimental|CBD 37 mg/mL|"Participants will receive a 5-day supply (15mL) of cannabidiol 37mg/mL.~Instructions for use: Place 0.5mL of oil under tongue for 30 seconds then swallow. Use every 4-6 hours as needed for pain."
89168215|NCT00691340||1|Control 1 (young subjects)
89168216|NCT00691340||2|Control 2 (old subjects)
89168217|NCT00691340||3|Glaucoma patients
89168218|NCT00691340||4|Alzheimer patients
89168219|NCT04643639|Experimental|Active|
89168220|NCT04643639|No Intervention|Control|
89168221|NCT04122222|Active Comparator|Hemodialysis|ESRD patients treated by hemodialysis
89168222|NCT04122222|Active Comparator|Hemodiafiltration|ESRD patients treated by on-line hemodiafiltration
89168223|NCT00686114|Experimental|A|Enlarged field + Paclitaxel + Cisplatin + Tarceva
89168224|NCT00686114|Experimental|B|Enlarged field + Paclitaxel + Cisplatin
89168225|NCT00686114|Active Comparator|C|Conventional field + Paclitaxel + Cisplatin + Tarceva
89168226|NCT00686114|Active Comparator|D|Conventional field + Paclitaxel + Cisplatin
89168227|NCT01015729|Active Comparator|1|Esomeprazole 20 mg/ASA 81 mg Fixed Dose Combination Capsule
89168228|NCT01015729|Active Comparator|2|Esomeprazole Clinical Trial Capsule 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
89168229|NCT01015729|Active Comparator|3|Esomeprazole MUPS Tablet 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
89168230|NCT00698724|Active Comparator|1|Group 1: Xibrom, Optive
89168231|NCT00698724|Active Comparator|2|Group 2: Xibrom, Pred Forte
89168232|NCT02535260||Fertility Monitor|Clearblue Fertility Monitor
89168233|NCT02622048|Experimental|Stage 2 Parents experiencing psychosis|Parents all receive the self-directed Triple P Positive Parenting Programme
89168234|NCT05299190|Experimental|Yoga intervention plus TAU|"Participants randomized to the yoga intervention will attend 8-weekly 90-minute group sessions. The intervention will be delivered by certified instructors with experience facilitating yoga classes for pregnant women. Monthly drop-in classes will be scheduled in order to motivate women to maintain their practice during the follow-up period. The yoga intervention will be based on the hatha yoga system modified for pregnancy. TAU will include treatment based on the recommendation of participants' healthcare provider/team."
89168235|NCT05299190|Other|Clinical Monitoring plus TAU|Clinical monitoring will be conducted by telephone and include a 15-20 minutes discussions of how the participant has been feeling over the past two weeks. A standard format will be used for conducting the clinical monitoring telephone calls. TAU will include treatment based on the recommendation of participants' healthcare provider/team.
89168236|NCT04117776||Patients|Patient benefiting during the same hospitalization of the loss or the gain of a central venous catheter.
89168237|NCT00922610|Experimental|1|
89168238|NCT04135170|Experimental|Plain bone cement|
89168239|NCT04135170|Active Comparator|Antibiotic loaded bone cement|
89168240|NCT00686270|Experimental|1|apricitabine
89168241|NCT04117698|Experimental|Antitubercular treatment and local corticosteroid therapy|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~associated with a treatment similar to the control group."
89168242|NCT04117698|No Intervention|Local Corticosteroid Therapy Only|"Treatment of Ocular Inflammation by Local Corticosteroid Therapy Only comprising:~Dexamethasone (DEXAFREE® eye drops) at an attack dose for one week (4 to 6 drops / d maximum and if severe inflammation 1 drop / hour) then decrease and stop over 3 weeks, with relay by fluorometholone (Flucon®) for 2 months maximum. The modalities of the decrease of the local steroids are left to the ophthalmologists own judgment. Maximum total duration of 3 months.~Mydriatic (tropicamide) 1gx3 / d if necessary.~Neosynephrine 5% if posterior synechiae.~Atropine (Alcon 0.3%) if pain."
89168243|NCT04210271|Experimental|HIV Self-testing|brief intervention to teach and support consistent self-testing with a friend
89168244|NCT04210271|Active Comparator|Generic Self-screening|time and attention control providing basic self-screening education on a range of health outcomes
89168245|NCT04118322|Experimental|intervention group|The patients in the intervention group applied peppermint oil (3%) on lips three times a day, during the five days following chemotherapy administration, in addition to the standard antiemetic treatments. The data were collected using a Patient Information Form, Rhodes Index of Nausea, Vomiting and Retching (INVR), Visual Analog Scale (VAS) Patient Nausea Severity Follow-up Form, Patient Watch Chart, and Oil Application Protocol. Besides, patients in the intervention group were questioned thoughts associated with peppermint oil application using individual in-depth interview method.
89168246|NCT04118322|No Intervention|control group|The control group underwent only the routine treatment.
89168247|NCT04031612||Neoadjuvant Breast Cancer|Patients undergoing neoadjuvant therapy for breast cancer
89168248|NCT00700050||CF Females|CF females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
89168249|NCT00700050||Non-CF Females|Non-CF control females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
89168250|NCT00700050||CF Males|CF males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
89168251|NCT00700050||Non-CF males|Non-CF control males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
89168252|NCT05662709|Experimental|L-PRF|Test group, alveolar ridge preservation with L-PRF after tooth extraction.
89168253|NCT05662709|No Intervention|Spontaneous Healing (SH)|Control group, spontaneous healing of the socket after tooth extraction
89168254|NCT00698802|Experimental|A|
89168255|NCT00698802|Active Comparator|B|
89168256|NCT00686426|Active Comparator|1|Low Dairy
89168257|NCT00686426|Experimental|2|Adequate Dairy
89168258|NCT00618215|Experimental|I|"ROE Group~Interventions:behaviorial"
89168259|NCT00618215|Experimental|2|"MIM Group~Interventions:behaviorial"
89168260|NCT00698880|Active Comparator|HVE|Hepatic vein embolization after portal vein embolization
89168261|NCT00698880|No Intervention|PVE|Only portal vein embolization, historical control group
89168262|NCT02626988|Experimental|Intervention|The intervention group will receive capacity building sessions on the 'Promotion of a biodiverse diet' and will include both Agriculture and Nutrition topics, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal. 5 Sessions will be held in each village over 12 months.
89168263|NCT02626988|No Intervention|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
89168264|NCT04213001|Other|measure|circumference measure, ultrasonographic measure
89168265|NCT00691418|Active Comparator|1|600 mg per day of docosahexaenoic acid (DHA)
89168266|NCT00691418|Placebo Comparator|2|Placebo
89168267|NCT00691496|Experimental|1|Receives HIV testing and counseling and 5 week intervention
89168268|NCT00691496|No Intervention|2|Receives only HIV Testing and Counseling
89168269|NCT02626442|Experimental|Group Exercise Class|6 month group balance/exercise class, three days a week - up to one hour. Exercise program includes walking around a track, bodyweight/balance exercises, and an obstacle course.
89168270|NCT02626442|No Intervention|Testing|Subjects enrolled in other MERCE exercise and robotics interventions will receive balance/walking tests, MRI with famous name recognition task, and cognitive testing pre and post their intervention.
89168271|NCT00618293|Active Comparator|1|intravenous infusion of Haemate (dosage dependent on body weight)
89168272|NCT00618293|Placebo Comparator|2|intravenous infusion of 0.9% NaCl solution
89168273|NCT02627066|Active Comparator|Volume Control|This group of patients will receive a volume reduction protocol that includes two primary components: 1) persistent ultrafiltration to slowly reduce patient's post-dialysis weight; and 2) persistent dietary education focused on reducing intake of dietary sodium and phosphorus additives
89168274|NCT02627066|Active Comparator|Volume Control + Exercise|This group of patients will receive the volume control intervention in addition to intensive counseling to increase their physical activity levels.
89168275|NCT00621569|Active Comparator|1|Group intervention with no dietary focus
89168276|NCT00621569|Experimental|2|DASH diet intervention
89168277|NCT00862836|Experimental|1|Vandetanib added to standard therapy (pegliposomal doxorubicin)
89168278|NCT00621647|Experimental|1|1st fixed dose
89168279|NCT00621647|Experimental|2|2nd fixed dose
89168280|NCT00621647|Sham Comparator|3|Placebo
89168281|NCT02625350|Experimental|Instant noodle without soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes and drained
89168282|NCT02625350|Experimental|Instant noodle with soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes, drained, and given additional 250 ml of water as soup
89168283|NCT02625350|Experimental|Glucose reference|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
89168284|NCT04209179|Experimental|PCO371 Low Dose and Low administration frequency|PCO371 low dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
89168285|NCT04209179|Experimental|PCO371 High Dose and Low administration frequency|PCO371 high dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
89168286|NCT04209179|Experimental|PCO371 High Dose and High administration frequency|PCO371 high dose and high administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).
89168287|NCT04209179|Placebo Comparator|Placebo|Placebo by oral administration.
89168288|NCT00681356|Experimental|1|4975 - 15 mg
89168289|NCT00681356|Placebo Comparator|2|Placebo
89168290|NCT00681356|Experimental|3|4975 - truncated for Phase 3
89168291|NCT02621970|Experimental|IC plus CC plus IMRT plus AC|Induction chemotherapy: TP -- Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 2 cycles; Concurrent chemotherapy: PX -- Cisplatin 25 mg/m2, D1-3 and Xeloda 2000mg/m2, D1-14, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy; Adjuvant chemotherapy: Xeloda 2500mg/m2, D1-14, every 3 weeks for 2 cycles
89168292|NCT02621970|Active Comparator|CC plus IMRT|Concurrent chemotherapy: Cisplatin 100 mg/m2, D1, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
89168293|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy|
89168294|NCT00820755|Active Comparator|Cetuximab 500 mg/m^2 every 2 weeks|
89168295|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 weekly|
89168296|NCT04671173|Experimental|Experimental arm (only one arm)|Only one arm, the participants will all received the device to measure Intra-compartmental pressure after consenting to study participation.
89168297|NCT00700128|Experimental|Group 2|Frovatriptan or placebo given in a certain sequence depending on what group that the woman are randomized to.
89168298|NCT00700128|Experimental|Group1|Group I will receive in a different sequence either frovatriptan 2.5 mg or placebo bid starting the last day of taking OC and continuing during the hormone free interval (HFI) of 4 days.
89168299|NCT04212689|Active Comparator|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. Physiotherapy approaches include stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
89168300|NCT04212689|Active Comparator|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
89168301|NCT04135326|Experimental|Supportive care (tDCS)|Patients undergo tDCS QD over 20 minutes 5 days each week (Monday-Friday) for 3 weeks.
89168302|NCT04117542||Overweight/Obesity Control|Adolescents who have overweight/obesity, but do not report loss of control eating.
89168303|NCT04117542||Overweight/Obesity Experimental|Adolescents who have overweight/obesity, and report loss of control eating.
89168304|NCT04660097|Other|Outcome of Durvalumab-Etoposide-platinum in untreated ES-SCLC(CASPIAN trial)|The outcome of CASPIAN
89168305|NCT04117464|Experimental|Behavioral activation therapy|Behavioral activation therapy was applied following the protocol designed by Martell, Dimidjian & Herman-Dunn (2013).
89168306|NCT04117464|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment therapy was applied following the protocol designed by Hayes, Strosahl & Wilson, (2011).
89168307|NCT04117464|Experimental|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy was applied following the protocol designed by Barlow, Allen and Choate (2004).
89168308|NCT04117464|Other|Wait List Group|Participants at Wait List Group will be evaluated pre-post and 3, 6, 9 and 12 months follow up periods, like experimental groups.
89168309|NCT00820599|Experimental|TAVR|Transaortic Valve Replacement
89168310|NCT00700206|Experimental|1|Dose Schedule 1: Two weeks treatment with Telintra 3000 mg per day in two divided doses followed by one week with no treatment per three week cycle.
89168311|NCT00700206|Experimental|2|Dose Schedule 2: Three weeks treatment with Telintra 2000 mg per day in two divided doses followed by one week with no treatment per four week cycle.
89168312|NCT00621101|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
89168313|NCT00621101|Active Comparator|B|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
89168314|NCT00621101|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
89168315|NCT04622657|Experimental|parkinson disease|Assessment
89168316|NCT00698958|Active Comparator|1|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
89168317|NCT00698958|Experimental|2|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
89168318|NCT04617743||High residual volume|Bladder tumor patients with high residual volume
89168319|NCT04617743||Low residual volume|Bladder tumor patients with low residual volume
89168320|NCT00699036|Experimental|1|avandia
89168321|NCT00699036|Experimental|2|avandia plus metformin
89168322|NCT00699036|Experimental|3|avandia plus losartan
89168323|NCT00709293|Placebo Comparator|1|
89168324|NCT00709293|Active Comparator|2|
89168325|NCT04139369||Type 1 Diabetes Mellitus (T1DM)|Type 1 Diabetes Mellitus (T1DM) Children and adolescents with Type 1 Diabetes Mellitus
89168326|NCT04139369||Controls (C)|Controls (C) Healthy individuals matched for gender and age without any autoimmune disease of their own or their first degree relatives
89168327|NCT04116216|Active Comparator|High frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
89168328|NCT04116216|Active Comparator|Low frequency rTMS + physical therapy|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
89168329|NCT04116216|Sham Comparator|Sham rTMS + physical therapy|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
89168330|NCT04208711|Other|positive HIV patient not treated by ARV yet|"Before starting HIV treatment, 15 patients will be included in the study and 50mL of whole blood will be taken. After treatment initiation 8 of the 15 patients will entered in the follow-up phase for 1 year (5 followup visit, M1, M3, M6, M9, M12) and 30mL of whole blood will be taken at each visit.~The duration of the study for the 7 other patients will be 1 day."
89168331|NCT00819741|Experimental|Repaglinide + metformin|Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.
89168332|NCT00819741|Active Comparator|Repaglinide|Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.
89168333|NCT04208555|Experimental|Boric acid vaginal suppository|
89168334|NCT04208555|Active Comparator|Terconazole vaginal suppository|
89168335|NCT00621725|Experimental|1|
89168336|NCT00862134|Active Comparator|Docetaxel 75 mg/m^2|Subjects randomized to the docetaxel arm will be administered 75 mg/m^2, IV, every 21 days (an approved dose and schedule)
89168337|NCT00862134|Experimental|PR104 + 60 mg/m^2 docetaxel|Subjects randomized to the PR104/docetaxel arm will be administered 60 mg/m^2 docetaxel, IV, every 21 days plus 770 mg/m^2 PR104, IV, every 21 days and prophylactic G-CSF.
89168338|NCT04188197|Experimental|e-Cigarette Matched to Usual Brand Cigarette|"JUUL and cigarette flavor matched (Mint for menthol smokers and Virginia Tobacco for non-menthol smokers);"
89168339|NCT04188197|Experimental|e-Cigarette Unmatched to Usual Brand Cigarette|"JUUL and cigarette flavor unmatched (Virginia Tobacco for menthol smokers and Mint for non-menthol smokers)."
89168340|NCT04120428|Experimental|Experimental protocol|24-week aquatic exercise training program
89168341|NCT04120428|No Intervention|Control protocol|Maintain lifestyle routine as usual
89168342|NCT02614014|Experimental|Psychological intervention|Cognitive-behavior interventional program
89168343|NCT02614014|No Intervention|Control|No intervention
89168344|NCT04527029||limb deformity children|the imaging of limb deformity diagnosis by AI
89168345|NCT00700284|Placebo Comparator|A|
89168346|NCT00700284|Experimental|B|
89168347|NCT04187885|Active Comparator|Group/Cohort 1 : CTL|"Label : control~Type : comparator~Description: Outside academic stress period (represented by exams), without the physical activity program (no Intervention)."
89168348|NCT04187885|Experimental|Group/Cohort 2: PAP|"Label : physical activity program without stress Type : experimental~Description: outside academic stress period (exams), with the physical activity program:60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday."
89168349|NCT04187885|Experimental|Group/Cohort 3: AS|"Label : academic stress Type : experimental~Description: during academic stress period (exams), without the physical activity program (no Intervention)"
89168350|NCT04187885|Experimental|Group/Cohort 4: ASPAP|Label : academic stress and physical activity program Type : experimental Description: during academic stress period (exams), with the physical activity program: 60 min of mederate to vigorous leisure activities and exercises will be proposed from Monday to Thursday.
89168351|NCT00618527|Experimental|1|Rebif with Cellcept
89168352|NCT00618527|Placebo Comparator|2|Rebif alone
89168353|NCT02691533|Experimental|ω3 PUFA(10% Omegavan 100 ml)|
89168354|NCT02691533|Experimental|ω6 PUFA (20% Intralipid 50 ml)|
89168355|NCT02691533|Placebo Comparator|Placebo Arm|No Lipid Emulsion will be given in this arm
89168356|NCT00848484|Experimental|1|MK5757
89168357|NCT00848484|Placebo Comparator|2|Placebo
89168358|NCT00621881|Experimental|1|750 mg naproxcinod
89168359|NCT05214053|Experimental|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
89168360|NCT04115982|Experimental|Cholecalciferol|Cholecalciferol (Vitamin D3) 100 000 IU/2 mL
89168361|NCT04115982|Placebo Comparator|Placebo|Placebo of Cholecalciferol (Vitamine D3) 100 000 IU/2 mL
89235055|NCT05096130|No Intervention|Control Group - No intervention|The control group will not participate in any intervention for the duration of the study. In addition, the participants will be instructed to follow their usual daily schedule for 6 months. Changes in health, medication, or habits will be discussed by the investigators' team and reassess the continuation or the termination of the investigated participant.
89168362|NCT05662631|Experimental|Bone Marrow Transplant Participants|Study participants will complete an onboarding session into the Oncology at Home care program prior to discharge from the hospital. During the onboarding process, participants will be introduced to the RC care team, confirm understanding of their customized care plan treatment and goals as established by their BMT care provider, will receive an oral thermometer for use during the study, and will complete patient education. Working with the study team and RC RN, participants will receive, affix, activate, and test a wearable RPM device (the BioIntellisense BioSticker) prior to discharge from the BMT unit. As the BioSticker needs to be replaced every 30 days, patients will also receive three additional BioStickers new in packaging for use during months 2 and 3 as well as to have a back-up device in case of malfunction. Patients will return the BioSticker to BioIntelliSense with the postage paid return envelope provided at discharge.
89168363|NCT00622037|Active Comparator|1|PEG-400 based artificial tear
89168364|NCT00622037|Active Comparator|2|Systane
89168365|NCT04208789||Positive Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Positive Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
89168366|NCT04208789||Negative Rifampicin-Resistant Tuberculosis|All suspected cases that yielded Negative Rifampicin-Resistant Tuberculosis under the Gold-Standard Test (Culture on Lowenstein-Jensen Medium)
89168367|NCT02691611||Alpha-1 Antitrypsin|All AATD patients who will start treatment with alpha-1 antitrypsin augmentation therapy
89168368|NCT02691611||Healthy Control|Healthy controls with no lung diseases
89168369|NCT02691377|Experimental|Acupuncture group|Participants will receive acupuncture for 8 weeks. In particular, acupuncture will be performed three times a week in earlier 4 weeks and twice a week in later 4 weeks.
89168370|NCT02691377|Sham Comparator|Sham Acupuncture group|Participants will receive sham acupuncture for 8 weeks. The procedure is the same as the acupuncture arm.
89168371|NCT00618605|Experimental|1|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
89168372|NCT00618605|Experimental|2|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^10 VP given at Days 0, 28, and 168
89168373|NCT00618605|Experimental|3|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^11 VP given at Days 0, 28, and 168
89168374|NCT00618605|Experimental|4|2 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at a dose to be determined by the safety data from Arms 1, 2 and 3 given at Days 0 and 168
89168375|NCT00509821|Experimental|Enzastaurin Once Daily (QD)|Enzastaurin given orally (PO) once daily (QD). 1125 mg loading dose D(-)7 then 500 mg PO,QD with concomitant radiotherapy.
89168376|NCT00509821|Experimental|Enzastaurin Twice Daily (BID)|Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO, with concomitant radiotherapy.
89168377|NCT04208165|Active Comparator|Group P (ultrasound-guided PVB)|In group P, the patient is in sitting position, a linear transducer (6-15 MHz) placed just lateral to the spinous process. Once the transverse processes and ribs are identified, the transducer is moved slightly cauded into the intercostal space between adjacent ribs to identify the thoracic paravertebral space (PVS) and the adjoining intercostal space. The hyper echoic line of the pleura and underlying hyper echoic air artifacts move with respiration. The needle stimuplex needle will be inserted and 0.5- 1 ml local anesthetic injection administered to show the displacement of pleura downward followed by 15 cc bupivacaine 0.25% into each side the PVS. A pop often is felt as the needle penetrates the internal intercostal membrane. Intravascular injection will be eliminated by negative aspiration before injection. Local anesthetic (15- 20 ml) is slowly injected in small increments, avoiding forceful high-pressure injection to reduce the risk of bilateral epidural spread.
89168378|NCT04208165|Active Comparator|Group T (ultrasound-guided TAB)|In group T, Subcostal blockage will be done in plane technique with 22 G needle (BRAUN Stimuplex D Plus 0,71 50- 80 mm 22 G). The puncture area and the ultrasound probe will be prepared in an aseptic manner. The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. On each side, The rectus abdominis and underlying transverses abdominis muscles near the costal margin and xiphoid process will be identified. In-plane image will be obtained and the needle will be inserted through the rectus muscle 2-3 cm medial to the probe. Once the tip of the needle is visualized to be in the plane, 0.25% bupivacaine will be administered incrementally. The drug will be injected along the oblique subcostal line, extending inferolaterally from the xiphoid towards the anterior part of the iliac crest by multiple punctures; a total of 15 ml will be given on each side.
89168379|NCT01010581|Experimental|SC12267 (4SC-101) + Methotrexate|
89168380|NCT01010581|Placebo Comparator|Placebo + Methotrexate|
89168381|NCT04382885|Experimental|Cohort 1 (10-17 years)|10 to 12 years: 0.75 mg/day cariprazine oral solution 13 to 17 years: 1.5 mg/day cariprazine oral solution
89168382|NCT04382885|Experimental|Cohort 2 (10-17 years)|10 to 12 years: 1.5 mg/day cariprazine oral solution 13 to 17 years: 3.0 mg/day cariprazine oral solution
89168383|NCT04382885|Experimental|Cohort 3 (5-9 years)|0.5 mg/day cariprazine oral solution
89168384|NCT04382885|Experimental|Cohort 4 (5-9 years)|1.5 mg/day cariprazine oral solution
89168385|NCT01010659|Experimental|Lacrimal Tube|Dacryocystorhinostomy with silicone lacrimal intubation
89168386|NCT04208867|Experimental|Intervention - Women|Women who receive MH services from a facility participating in the QI collaborative to improve PCC
89168387|NCT04208867|No Intervention|Control - Women|Women who receive MH services from a facility not participating in the QI collaborative to improve PCC
89168388|NCT04208867|Experimental|Intervention - Provider|Provider working at a facility participating in the QI collaborative to improve PCC
89168389|NCT04208867|No Intervention|Control - Provider|Provider working at a facility not participating in the QI collaborative to improve PCC
89168390|NCT01015963||Ancillary-correlative (DNA sample analysis)|Blood samples collected on clinical trial CLB-9871 are examined via ABCC2 and SLC01B3 genotyping using TaqMan analysis. Other genes related to the pharmacokinetics and side effects of docetaxel may be considered for future genotyping. In some cases, panels of drug response SNPs on high-density arrays may be genotyped.
89168391|NCT04208945|Experimental|Inhaled colistin|Inhaled colistin three times daily for 10 days
89168392|NCT04208945|No Intervention|Standard management|
89168393|NCT01016041|Experimental|everolimus stent|
89168394|NCT01016041|Active Comparator|paclitaxel eluting|
89168395|NCT03820661|Other|High Resolution Ultasound|Diagnostic high resolution ultrasound pre-operatively and intraoperatively
89168396|NCT05662475|Experimental|group 1: Systemically Healthy, Periodontally Healthy (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment level were measured at 6 sites (buccomesial, midbuccal, buccodistal, lingual/palatal mesial, midlingual/palatal, lingual/palatal distal) of each tooth to evaluate the periodontal status of the patients. On the day of examination, panoramic radiographs were taken from all patients to determine alveolar bone loss. Gingival crevicular fluid is collected from the patients. Gingival crevicular fluid samples were collected from 5 randomly selected teeth with GI=0, PI=0 and PPD ≤3. Then, each paper strip from each tooth was individually placed in sterile 0.5 ml eppendorf tubes. Eppendorf tubes were stored at -80°C. Oral hygiene education was given to each patient. Modified Bass technique was explained as a brushing technique. Interdental brush or dental floss was recommended for interdental cleaning according to the condition of the patient's interdental areas and its use was demonstrated.
89168397|NCT05662475|Experimental|group 2: Systemically Healthy, Periodontitis (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment levels were measured from 6 sites of each tooth to evaluate the periodontal status of the patients. Panoramic radiographs were taken from all patients. Vertical/horizontal bone loss on the radiographs was evaluated to determine the stage and grade of periodontitis. Gingival crevicular fluid samples were collected from the 5 periodontal pockets with the deepest PPD before and 3 months after treatment. Eppendorf tubes were stored at -80°C. Non-surgical periodontal treatments were started under local anesthesia. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained. The patient was told not to use any chemical agent for plaque removal. 3 months after the treatment gingival crevicular fluid samples are collected and clinical examination parameters were measured again.
89168398|NCT05662475|Experimental|grup 3: Controlled Type 2 Diabetes, Periodontally Healthy (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment level were measured at 6 sites (buccomesial, midbuccal, buccodistal, lingual/palatal mesial, midlingual/palatal, lingual/palatal distal) of each tooth to evaluate the periodontal status of the patients. On the day of examination, panoramic radiographs were taken from all patients to determine alveolar bone loss. HbA1c values were measured. Gingival crevicular fluid is collected from the patients. Gingival crevicular fluid samples were collected from 5 randomly selected teeth with GI=0, PI=0 and PPD ≤3. Then, each paper strip from each tooth was individually placed in sterile 0.5 ml eppendorf tubes. Eppendorf tubes were stored at -80°C. Oral hygiene education was given to each patient. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained.
89168399|NCT05662475|Experimental|group 4: Controlled Type 2 Diabetes, Periodontitis (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment levels were measured from 6 sites of each tooth to evaluate the periodontal status of the patients. Panoramic radiographs were taken from all patients. Vertical/horizontal bone loss on the radiographs was evaluated to determine the stage and grade of periodontitis. HbA1c levels are determined. Gingival crevicular fluid samples were collected from the 5 periodontal pockets with the deepest PPD before and 3 months after treatment. Samples were stored at -80°C. Non-surgical periodontal treatments were started under local anesthesia. Oral hygiene education was given after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained. The patient was told not to use any chemical agent for plaque removal. 3 months after the treatment gingival crevicular fluid samples are collected and clinical examination parameters were measured again.
89168400|NCT05662475|Experimental|grup 5: Uncontrolled Type 2 Diabetes, Periodontally Healthy (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment level were measured at 6 sites (buccomesial, midbuccal, buccodistal, lingual/palatal mesial, midlingual/palatal, lingual/palatal distal) of each tooth to evaluate the periodontal status of the patients. On the day of examination, panoramic radiographs were taken from all patients to determine alveolar bone loss. HbA1c values were measured. Gingival crevicular fluid is collected from the patients. Gingival crevicular fluid samples were collected from 5 randomly selected teeth with GI=0, PI=0 and PPD ≤3. Then, each paper strip from each tooth was individually placed in sterile 0.5 ml eppendorf tubes. Eppendorf tubes were stored at -80°C. Oral hygiene education was given to each patient. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained.
89168401|NCT05662475|Experimental|group 6: Uncontrolled Type 2 Diabetes, Periodontitis (n:11)|Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment levels were measured from 6 sites of each tooth to evaluate the periodontal status of the patients. Panoramic radiographs were taken from all patients. Vertical/horizontal bone loss on the radiographs was evaluated to determine the stage and grade of periodontitis. HbA1c levels are determined. Gingival crevicular fluid samples were collected from the 5 periodontal pockets with the deepest PPD before and 3 months after treatment. Samples were stored at -80°C. Non-surgical periodontal treatments were started under local anesthesia. Oral hygiene education was given after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained. The patient was told not to use any chemical agent for plaque removal. 3 months after the treatment gingival crevicular fluid samples are collected and clinical examination parameters were measured again.
89168402|NCT02697305|Experimental|IV BCAA test|IV application of BCAA solution
89168403|NCT02697305|Experimental|ORAL BCAA test|At once oral ingestion of BCAA capsules
89168404|NCT02697305|Placebo Comparator|ORAL PLACEBO test|At once oral ingestion of placebo capsules
89168405|NCT00622115|Experimental|A|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 4 hours following the last injection of enoxaparin
89168406|NCT00622115|Experimental|B|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 6 hours following the last injection of enoxaparin
89168407|NCT00622115|Experimental|C|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 10 hours following the last injection of enoxaparin
89168408|NCT04208633|Other|Horizontal placement of the intraocular lens|The eyes randomised to have horizontal placement of intraocular lenses
89168409|NCT04208633|Other|Vertical placement of the intraocular lens|Fellow eye receiving vertical placement of intraocular lens.
89168410|NCT00508651|Experimental|Cohort 1 MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM Luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
89168411|NCT00508651|Placebo Comparator|Cohort 1 Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM Luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
89168412|NCT02696837|Active Comparator|ETT & Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and Muscle Relaxant
89168413|NCT02696837|Active Comparator|ETT & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and No Muscle Relaxant
89168414|NCT02696837|Active Comparator|Proseal LMA & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and NO Muscle Relaxant
89168415|NCT02696837|Active Comparator|Proseal LMA & Subparalytic Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and subparalytic dose Muscle Relaxant
89168416|NCT03997045|Experimental|Intervention group|Pregnant women receiving usual care and participating in supervised physical exercise program.
89168417|NCT03997045|No Intervention|Control group|Pregnant women that are receiving usual care but are not participating in supervised physical exercise program.
89168418|NCT03996889||Popliteal aneurysm patients with GORE VIABAHN®|The study population will include all popliteal aneurysm patients treated with GORE VIABAHN® stent graft in scheduled elective surgery, whether symptomatic or asymptomatic.
89168419|NCT01016119|Placebo Comparator|Placebo|In this group we will use Placebo cream, in the early rehabilitations in the upper extremity
89168420|NCT01016119|Experimental|Folrex|In this group we will use Folrex cream, in the early rehabilitations in the upper extremity
89168421|NCT01016197|Active Comparator|Conservative|Four weeks of splinting followed by mobilisation.
89168422|NCT01016197|Experimental|Surgery|Surgical repair of the tendon with a bone anchor followed by four weeks of splinting and then mobilisation.
89168423|NCT01016275||Iliac lesions TASC A or B|All lesion types belonging to the iliac TASC A or B.
89168424|NCT00490555|Placebo Comparator|1|Placebo gel + Placebo pill + placebo injection
89168425|NCT00490555|Active Comparator|2|Testosterone 1% transdermal gel 10 g + placebo pill + placebo injection
89168426|NCT00490555|Active Comparator|3|Testosterone 1% transdermal gel 10 g + dutasteride 0.5 mg Orally + placebo injection
89168427|NCT00490555|Active Comparator|4|Testosterone 1% transdermal gel 10 g + placebo pill + DMPA 300 mg injection (IM)
89168428|NCT00501085||LAP-BAND|Patients who receive the LAP-BAND AP Adjustable Gastric Banding System.
89168429|NCT01014247|Active Comparator|Arm 1|
89168430|NCT01014247|Placebo Comparator|Arm 2|
89168431|NCT01014325|Experimental|Allergen extract|
89168432|NCT01014325|Placebo Comparator|Placebo|
89168433|NCT01010737|Experimental|Multimeric-001 250 mcg|250mcg of Multimeric-001 was administered twice at an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
89168434|NCT01010737|Active Comparator|Adjuvant: Montonide isa 51 VG|Adjuvanted PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
89168435|NCT01010737|Active Comparator|Placebo|PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
89168436|NCT01010737|Experimental|Multimeric-001 500 mcg|500mcg of M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
89168437|NCT01010737|Experimental|Adjuvanted Multimeric-001 500mcg|5000mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
89168438|NCT01010737|Experimental|Adjuvanted Multimeric-001 250mcg|250mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
89168439|NCT00501007||Non-psychiatric smokers|Smokers not meeting criteria for Schizophrenia or Schizoaffective Disorder
89168440|NCT00501007||Smokers with Schizophrenia|Smokers meeting criteria for schizophrenia or schizoaffective disorder
89168441|NCT00873860|Placebo Comparator|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
89168442|NCT00873860|Experimental|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
89168443|NCT00873860|Experimental|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
89168444|NCT00873860|Experimental|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
89168445|NCT03854227|Experimental|Dose Escalation|Participants will receive PF-06939999 orally at escalating doses in 28 day cycles on a continuous basis
89168446|NCT03854227|Experimental|Non small cell lung cancer monotherapy|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
89168447|NCT03854227|Experimental|Urothelial carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
89168448|NCT03854227|Experimental|Head and neck squamous cell carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
89168449|NCT03854227|Experimental|Non small cell lung cancer PF-06939999 plus docetaxel|Participants will receive PF-06939999 on a continuous basis in combination with docetaxel
89168450|NCT03854227|Experimental|Non small cell lung cancer dose finding|Participants will receive PF-06939999 on a continuous basis at escalating doses in combination with docetaxel
89168451|NCT04350905|Experimental|Mosquito Feeding|Each participant will receive one mosquito feeding with 5 starved female Aedes aegypti mosquitoes.
89168452|NCT05368961|Active Comparator|Usual care|Usual care (midazolam) is administered pre-operatively
89168453|NCT05368961|Experimental|Distraction|Distraction (interactive tablet) is given to children pre-operatively
89168454|NCT03853291|Experimental|PICT Workbook|PICT Workbook components includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set through routine practice.
89168455|NCT03853291|Active Comparator|Information Pamphlet|Informational pamphlet about pain in dementia and a link to the Alzheimer's Association website.
89168456|NCT03853291|No Intervention|Family Caregivers - Interview Phase|Interviews will be conducted with family caregivers and health care providers in-person in private offices at WCMC/NYP or over the telephone. The primary objectives of the qualitative interviews are to: a) adapt the PAINAD for use with caregivers by asking them to comment on its format and content; and b) generate an initial question pool for the Question Prompt List. After reviewing the PICT workbook, caregivers will complete a brief qualitative questionnaire about the content, format, and perceived utility of PICT, as well as ways to enhance its cultural relevance. They will also complete a semi-structured interview to clarify their perspectives. Health care providers will answer a similar set of questions. Results from this first field-test will inform the next version of PICT and address key issues, such as the feasibility of using research nurses to administer the intervention, anticipation of participant burden for caregivers, and adequacy of PICT format and instructions.
89168457|NCT03853291|No Intervention|Healthcare Providers - Interview Phase|Interviews will be conducted with family caregivers and health care providers in-person in private offices at WCMC/NYP or over the telephone. The primary objectives of the qualitative interviews are to: a) adapt the PAINAD for use with caregivers by asking them to comment on its format and content; and b) generate an initial question pool for the Question Prompt List. After reviewing the PICT workbook, caregivers will complete a brief qualitative questionnaire about the content, format, and perceived utility of PICT, as well as ways to enhance its cultural relevance. They will also complete a semi-structured interview to clarify their perspectives. Health care providers will answer a similar set of questions. Results from this first field-test will inform the next version of PICT and address key issues, such as the feasibility of using research nurses to administer the intervention, anticipation of participant burden for caregivers, and adequacy of PICT format and instructions.
89168458|NCT03853291|No Intervention|Family Caregivers - Field Test Phase|Once initial versions of the PICT manual and workbook are developed, they will be iteratively field-tested and vetted by family caregivers and health care providers. After reviewing the PICT workbook, caregivers will complete a brief qualitative questionnaire about the content, format, and perceived utility of PICT, as well as ways to enhance its cultural relevance. They will also complete a brief (15-20 minute) semi-structured interview to clarify their perspectives. Health care providers will answer a similar set of questions. Results from this first field-test will inform the modified version of PICT and will address key issues, such as the feasibility of using research nurses (and other practice staff) to administer the intervention, anticipation of participant burden for caregivers, and adequacy of PICT format and instructions.
89168459|NCT03853291|No Intervention|Healthcare Providers - Field Test Phase|Once initial versions of the PICT manual and workbook are developed, they will be iteratively field-tested and vetted by family caregivers and health care providers. After reviewing the PICT workbook, caregivers will complete a brief qualitative questionnaire about the content, format, and perceived utility of PICT, as well as ways to enhance its cultural relevance. They will also complete a brief (15-20 minute) semi-structured interview to clarify their perspectives. Health care providers will answer a similar set of questions. Results from this first field-test will inform the modified version of PICT and will address key issues, such as the feasibility of using research nurses (and other practice staff) to administer the intervention, anticipation of participant burden for caregivers, and adequacy of PICT format and instructions.
89168460|NCT00622271|Other|Wait List Control|Patients and their families will be enrolled into either a treatment group or a wait list control (WLC) group to receive the group therapy intervention.
89168461|NCT04207853|Experimental|whole body vibration in diabetics (G1)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
89168462|NCT04207853|Sham Comparator|the sham vibration group in diabetics (G2)|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
89168463|NCT04207853|No Intervention|diabetic control group (G3)|no treatment
89168464|NCT04207853|Active Comparator|whole body vibration group in non-diabetics (G4)|One 24Hz session, 4mm amplitude, 8 rep series, 45s intervention time, 30s recovery
89168465|NCT04207853|Sham Comparator|"the vibration group  sham in non-diabetics (G5)"|dummy vibration (sound stimulus), 8-rep series, 45s intervention time, 30s recovery
89168466|NCT04207853|No Intervention|non-diabetic control group (G6)|no treatment
89168467|NCT03853213|Experimental|Cognitive Bias Modification Training|"Participants in this intervention group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is Cognitive Bias Modification Training for Attention. It is designed to reinforce attention away from ACS threat-related stimuli (e.g., death, chest pain) and toward neutral stimuli (e.g., curve, barn doors). The second task is Cognitive Bias Modification Training for Interpretation. It is designed to train participants to appraise ambiguous information that is potentially related to ACS threat as benign."
89168468|NCT03853213|Sham Comparator|Attention Control Training|Participants in this placebo control group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is the placebo version of Cognitive Bias Modification Training for Attention. It is designed NOT to train attention toward or away from threatening or neutral information. The second task is the placebo version of Cognitive Bias Modification Training for Interpretation. It is designed NOT to train the interpretation of information as either threatening or benign.
89168469|NCT04138160|Experimental|5:2 intermittent energy restriction|The 5:2 intermittent energy restriction (IER) of 70% restriction (~600 kcal) delivered for two non-consecutive days/week and no restriction (so sufficient energy to meet the requirement of participants) on the other 5 days/week.
89168470|NCT04138160|Other|Continuous energy restriction|The continuous energy restriction (CER) of 20% restriction below the estimated requirement of participants (~1600 kcal) 7 days/week.
89168471|NCT04274231||TKI best effect group|TKI best effect was defined achieve complete cytogenetic response (CCyR)after 3 months of treatment and the level of BCR/ABL<10% after 3 months of treatment,the level of BCR/ABL<1% .
89168472|NCT04274231||TKI resistance group|TKI resistance was defined as the lack of a complete hematologic response (CHR) after 3 months of TKI treatment, the lack of any cytogenetic response after 6 months of treatment, the lack of major cytogenetic response (MCyR) (Ph-positive cells > 35%) after 12 months of treatment, an increase of white blood cell (WBC) count in at least two consecutive samplings (with a doubling of the count from the nadir to ≥ 20×109/L or an absolute increase of ≥ 50×109/L), or a relapse after a CHR or MCyR.
89168473|NCT04274231||TKI intolerance group|TKI intolerance was defined as at least grade 3 nonhematologic toxicity or grade 4 hematologic toxicity persisting for more than 7 days, related to TKIs at any dose.
89168474|NCT04031378|Active Comparator|A|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation using PET/CT imaging studies every 6 months
89168475|NCT04031378|Experimental|B|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months stratified by whether disease is castrate-sensitive (mCS-PCa) or castrate-resistant (mCR-PCa)
89168476|NCT02626754|Experimental|Sunitinib|Sunitinib malate, 12.5mg/capsule, 50mg/day
89168477|NCT00691886|No Intervention|1|Subjects randomized to arm 1 of the study will recieve standard of care conscious sedation for EBUS; midasolam and or fentanyl.
89168478|NCT00691886|Active Comparator|2|Subjects undergoing EBUS randomized to arm 2 of the study will recieve demedetomadine hydrochloride plus standard of care conscious sedation
89168479|NCT04148456|Other|Aortoiliac occlusive disease|This study will be carried out on patients with extensive Aortoiliac occlusive disease using the CERAB technique.
89168480|NCT04138004|Experimental|2-L PEG with LB|"PEG used in the present study was Niflec® (Meiji, Japan), which composed of macrogol 4,000 plus electrolytes (sodium sulfate, sodium hydrogen carbonate, sodium chloride, and potassium chloride) and is taken by diluting one sachet into 2-L of plain water. The patients were instructed to take 250 mL every 15 min untill the entire solution was consumed.~In this group (2-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 9.00 pm and the remaining dose was given in the morning at about 5.00 to 6.00 am on the procedure day. And these patients, one 24 mcg tablet of LB was given 2 hours before PEG ingestion (at 6.00 pm of the pre-procedure day)."
89168481|NCT04138004|Active Comparator|4-L PEG|In this group (4-L PEG), half dose preparation started in the evening of the pre-procedure day at about 8.00 to 10.00 pm and the remaining dose was given in the morning at about 5.00 to 7.00 am on the procedure day.
89168482|NCT04236635|Experimental|Group 1: CCH Single Injection Technique|"Participants were administered 0.07 milligrams (mg) CCH subcutaneously using a single injection technique.~Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -43 and -22. Area 2 was administered CCH on Day -14."
89168483|NCT04236635|Experimental|Group 2: CCH Single Injection Technique|Participants were administered 0.07 mg CCH subcutaneously using a single injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -24 and -3. Area 2 was administered CCH on Day -3.
89168484|NCT04236635|Experimental|Group 3: CCH Single Injection Technique|Participants were administered 0.07 mg CCH subcutaneously using a single injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -22 and -1. Area 2 was administered CCH on Day -1.
89168485|NCT04236635|Experimental|Group 4: CCH Multiple Injection Technique|"Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique.~Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -43 and -22. Area 2 was administered CCH on Day -14."
89168486|NCT04236635|Experimental|Group 5: CCH Multiple Injection Technique|"Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique.~Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -24 and -3. Area 2 was administered CCH on Day -3."
89168487|NCT04236635|Experimental|Group 6: CCH Multiple Injection Technique|"Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique.~Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -22 and -1. Area 2 was administered CCH on Day -1."
89168488|NCT04138082|Experimental|High-dB Environment|While performing the spinal anesthesia, the participants were exposed to a pre-recorded soundtrack of one of the investigators' operating rooms while the anesthesiology team was performing a spinal anesthesia. It included instruments noise and discussion but alarms, pulse oximetry and discussion with the patient were removed. The level of the soundtrack was set to be at 70 dB with peaks up to 100 dB, this level was recorded for every participant with Iphone™ application SoundMeter X 10.3 by Faber Acoustical, which has been both choosed in accordance with similar studies. The average noise was measured using the LEq value on a ''A'' scale (dB(A)) which correlate with frequencies perceived by the human ear. Speakers where placed at each corner of the room. Since literature describe that noise can initially enhance performance but is a transitory effect, the investigators decided to expose the experimental group to the maximum level of noise without any gradation.
89168489|NCT04138082|No Intervention|Low-dB Environment|The control group performed the same spinal anesthesia simulation scenario but without any soundtrack. The ambient noise in the room was recorded with the same method for each participant.
89168490|NCT00621491|Placebo Comparator|1|Single daily dose of Placebo during six months
89168491|NCT00686660|Experimental|1|C-W G: in training period, patients do cycling on cycle ergometry at hospital. in non-training period, patients walk at community.
89168492|NCT00686660|Other|2|C-nonW G: in training period, patients do cycling at cycle ergometry at hospital, in non-training period, patients don't walk at community.
89168493|NCT00686660|Experimental|3|W-W G: in training period, patients do walking along 60 meters place at hospital, in non-training period, patients do walking in community
89168494|NCT00686660|Other|4|W-nonW G: in training period, patients do walking along 60 meter place, in non-training period,patients don't walk at community.
89168495|NCT00686738||A|"Study group will be made up of patients hospitalized to National Cancer Center, Korea, aged between 5 and 40 years, and diagnosed with high grade osteosarcoma by histological exam.~In this group, TGF-b1 measurement, PET/CT and MRS examination at diagnosis, after 1st cycle chemotherapy, and 2nd or 3rd chemotherapy (just before surgery) will be made.~In addition, evaluation of NF-kB expression status in tumor specimens at diagnostic biopsy and tumor removing surgery will be done.~The results of above studies will be correlated with the necrosis fractions of the tumor tissues removed by surgery."
89168496|NCT00622349|Experimental|A|
89168497|NCT00622349|Active Comparator|B|
89168498|NCT00622349|Experimental|C|
89168499|NCT00681434|Experimental|1|bilateral training
89168500|NCT00681434|Active Comparator|2|Unilateral training
89168501|NCT00686816|Placebo Comparator|1|
89168502|NCT00686816|Experimental|2|
89168503|NCT02625896|Experimental|Intervention|A sequence of free fall manoeuvres performed using the human body: A free fall velocity reduction prior to main parachute deployment followed by a head high body attitude prior to main parachute extraction.
89168504|NCT02625896|No Intervention|Control|Normal main parachute extraction performed in a manner that is typical for the study participant.
89168505|NCT02625038|Experimental|Interventional|3D-planned osteotomies with patient-specific guides
89168506|NCT05368181|Experimental|Prevention group|Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
89168507|NCT02626676|Experimental|Educational Programme Group|Stage 5D Chronic Kidney Disease Patients on high-efficiency hemodialysis programme - 4-hour sessions, 3 times a week will be followed up
89168508|NCT05662163|Active Comparator|GROUP TIVA|Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min). Blood will be taken from the patients at 0, 1 and 4 hours, centrifuged and stored at -80 degrees. From these examples, CK, CKMB, HIGH SENSITIVE TROPONIN, HFABP, IMA AND ALBUMIN will be studied.
89168509|NCT05662163|Active Comparator|GROUP INHALATION ANESTHESIA|Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min). Blood will be taken from the patients at 0, 1 and 4 hours, centrifuged and stored at -80 degrees. From these examples, CK, CKMB, HIGH SENSITIVE TROPONIN, HFABP, IMA AND ALBUMIN will be studied.
89168510|NCT02624960|Experimental|Accucinch Implant|Accucinch Implant procedure is completed
89168511|NCT02687633|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
89168512|NCT02687633|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
89168513|NCT00687050|Active Comparator|1|HIV-positive hemodialysis patients (as a high risk group for cachexia) will be given daily drinks of Renilon 7.5 (125 ml, 2 kcal/ml) as peroral supplemental nutrition on top to their recommended high-protein, high-caloric diet.
89168514|NCT00687050|No Intervention|2|Chronic hemodialysis patients randomized to no peroral supplemental nutrition
89168515|NCT00687050|Active Comparator|3|Chronic hemodialysis patients randomized to peroral supplemental nutrition.
89168516|NCT00639041|Placebo Comparator|placebo|
89168517|NCT00639041|Active Comparator|n-3 LC-PUFA|
89168518|NCT00687128|Experimental|1|Low-intensity aerobic exercise
89168519|NCT00687128|Experimental|2|Moderate-intensity aerobic exercise
89168520|NCT00687128|Active Comparator|3|Non-aerobic stretching exercise
89168521|NCT00692042|Experimental|1|
89168522|NCT02666105|Experimental|Exemestane Therapy|
89168523|NCT04138238||Supraflex Cruz Sirolimus-eluting Stent|
89168524|NCT00622817|Active Comparator|1|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
89168525|NCT00622817|Experimental|2|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
89168526|NCT04146740|Experimental|Structured Exercise Group|"Structured Exercise Group will receive medical and dietary interventions like insulin plus structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min The combination of Stabilization exercise (10 repetitions) and PFM training ( 20 repetitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repeatitions) alongwith deep breathing exercises.~Life style modification with postural guidance and back care would also be followed.~Exercise dosage would be twice a week for 05 weeks while exercise duration will be 45 to 50 min session under Physio supervision and home plan of 10 min exercise daily. Total 150 min per week. Data will be recorded at baseline then after treatment of 5 weeks."
89168527|NCT04146740|Active Comparator|Control Group|Control Group will receive no structured exercise regime only the group will be receiving medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist due to ethical concerns and their outcomes will be observed at the baseline and then after 05 weeks.
89168528|NCT04033913||Adult patient learning self-catheterization|Patients who have successfully perform self-catheterization during a day hospital in a neuro-urology department complete a questionnaire validated by experts on the different criteria that guided the final choice of the catheter
89168529|NCT04137926|Experimental|Alzheimer's disease|
89168530|NCT04137926|Experimental|MCI due to AD|
89168531|NCT04137926|Experimental|Normal Elderly|
89168532|NCT00692120|Experimental|1|
89168533|NCT00692120|Experimental|2|
89168534|NCT00692120|Experimental|3|
89168535|NCT00692120|Experimental|4|
89168536|NCT02429609|Experimental|Keratoconic subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)~Anterior eye examination (approx. 4 minutes)~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)~Two measurements of visual acuity will be made:~Standard ETDRS logMAR acuity measurement (5 minutes)~Vanishing Optotype logMAR acuity measurement (5 minutes)"
89168537|NCT02429609|Experimental|Healthy subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)~Anterior eye examination (approx. 4 minutes)~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)~Two measurements of visual acuity will be made:~Standard ETDRS logMAR acuity measurement (5 minutes)~Vanishing Optotype logMAR acuity measurement (5 minutes)"
89168538|NCT04137848|Experimental|Experimental|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
89168539|NCT04137848|Sham Comparator|Control|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT) Osteopathic Manipulative Treatment (OMT) is manipulative therapy that was performed once a week along 30 days.
89168540|NCT00819585|Experimental|Core study: Canakinumab 25 mg|Canakinumab 25 mg subcutaneously (sc) once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
89168541|NCT00819585|Experimental|Core study: Canakinumab 50 mg|Canakinumab 50 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
89168542|NCT00819585|Experimental|Core study: Canakinumab 100 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
89168543|NCT00819585|Experimental|Core study: Canakinumab 200 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
89168544|NCT00819585|Experimental|Core study: Canakinumab 300 mg|Canakinumab 300 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
89168545|NCT00819585|Experimental|Core study: Canakinumab q4wk|Canakinumab 50 mg sc at Days 1, and 29 followed by canakinumab 25 mg sc on Days 57, and 85 plus daily placebo capsules for 16 weeks, repeated every 4 week (q4wk). Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
89168546|NCT00819585|Active Comparator|Core study: Colchicine 0.5 mg|Colchicine 0.5 mg capsule orally once daily throughout the whole treatment phase of 16 weeks plus placebo matching canakinumab s.c. at Days 1, 29, 57, and 85. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
89168547|NCT00819585|Experimental|Extension study: Group A|Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.
89168548|NCT00819585|Experimental|Extension study: Group B|Patients who were randomized to canakinumab in the core study but did not receive treatment with canakinumab in the extension study.
89168549|NCT00819585|Experimental|Extension study: Group C|Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.
89168550|NCT00819585|Experimental|Extension study: Group D|Patients who were randomized to colchicine in the core study but did not receive treatment with canakinumab in the extension study.
89168551|NCT00687206|Experimental|1|
89168552|NCT00687284||A|
89168553|NCT02358395|Experimental|BBI608 puls Sorafenib|
89168554|NCT00508261|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™
89168555|NCT00508261|Experimental|Group B|Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™
89168556|NCT00508261|Active Comparator|Group C|Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612
89168557|NCT00508261|Active Comparator|Group D|Meningitec™ vaccination
89168558|NCT04146350|No Intervention|Control|
89168559|NCT04146350|Active Comparator|PPV+/-Cat|
89168560|NCT04146350|Active Comparator|PPV+/-Cat+Gas|
89168561|NCT04146350|Active Comparator|PPV+ILM+/-Cat+/-Gas|
89168562|NCT04146350|Active Comparator|PPV+ILM+/-Cat+/-Oil|
89168563|NCT04146350|Active Comparator|PSR|
89168564|NCT04146350|Active Comparator|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|
89168565|NCT04146350|Active Comparator|Gas|
89168566|NCT03928847|Other|EGCG PK in healthy volunteers 450 mg|Healthy volunteers: 450 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
89168567|NCT03928847|Other|EGCG PK in healthy volunteers 600 mg|Healthy volunteers: 600 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
89168568|NCT03928847|Other|EGCG PK in healthy volunteers 750 mg|Healthy volunteers: 750 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth
89168569|NCT03928847|No Intervention|No treatment control in ILD patients|Patients: not treated with EGCG
89168570|NCT03928847|Experimental|EGCG treatment in ILD patients|Patients: 600 mg EGCG capsules once daily by mouth for two weeks
89168571|NCT02624726|Experimental|FOLFIRI/Aflibercept|5 Fluorouracil/Leucovorin/Irinotecan/Aflibercept
89168572|NCT02687555|Experimental|Intervention|Computerized Cognitive Bias Modification of Appraisals (CBM-App), developed from that used by Woud et al. (2012,2013). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
89168573|NCT02687555|Sham Comparator|Control|Computerized Peripheral Vision Task (PVT), developed from that used by Calkins et al. (2015). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
89168574|NCT00681746|Experimental|1|
89168575|NCT02687399|Experimental|TT-173|It will be sprayed using this syringe and a nozzle tip couplet to it one time over the surgical lesion surfaces on the exposed tissues of the knee
89168576|NCT02687399|Placebo Comparator|placebo|It will be sprayed over the surgical lesion surfaces on the exposed tissues of the knee
89168577|NCT02624882|Experimental|Positive rapid Group A Streptococcus (GAS) test|In case of positive rapid GAS test, patients will be treated by antibiotics: amoxicillin 50mg/kg/d during 10 days or cefpodoxime 8mg/kg/d during 10 days in case of betalactamine allergy
89168578|NCT02624882|Active Comparator|Negative rapid GAS test|If case of negative rapid GAS test, usual care: local antiseptic or surgical intervention
89168579|NCT04265911|Experimental|ASP3772 (subcutaneous) in Adults|Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.
89168580|NCT04265911|Experimental|ASP3772 ((intramuscular) in Adults|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.
89168581|NCT04265911|Experimental|ASP3772 (subcutaneous) in Elderly|Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.
89168582|NCT04265911|Experimental|ASP3772 (intramuscular) in Elderly|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels
89168583|NCT04265911|Active Comparator|PPSV23 (subcutaneous) in Elderly|Participants will receive a single subcutaneous injection of the standard dose of PPSV23 on Day 1.
89168584|NCT04265911|Active Comparator|PPSV23 (intramuscular) in Elderly|Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.
89168585|NCT02687477|Sham Comparator|Sham procedure|Patients in the sham group will take sham procedure like PADN.
89168586|NCT02687477|Experimental|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
89168587|NCT00819039|Experimental|Part 1: Oral Aprepitant|In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
89168588|NCT00819039|Experimental|Part 2: Oral Aprepitant|In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
89168589|NCT00819039|Active Comparator|Part 2: Intravenous Ondansetron|In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.
89168590|NCT00692510|Experimental|1|AZD3480 + cocktail
89168591|NCT00692510|Placebo Comparator|2|Placebo + cocktail
89168592|NCT02687321||Advanced ovarian cancer patients|Patient with histologically confirmed advanced (FIGO III and IV) epithelial ovarian, fallopian tube or primary peritoneal carcinoma with complete remission after first line treatment are included into the study. The patient is regularly followed up every 3-4 months, blood sample collection is performed to determinate tumor marker found in blood, elevated by the presence of cancer recurrence. In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
89168593|NCT05758623|Placebo Comparator|magnesium containing biodegradable polymer bone repair material|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd.
89168594|NCT05758623|Placebo Comparator|β- Tricalcium phosphate bioceramics|Control group application β- Tricalcium phosphate bioceramics for treatment.
89168595|NCT00692588||Placebo|Subjects who received placebo in DARAD Trial
89168596|NCT00692588||Doxycycline|Subjects who received doxycycline in DARAD Trial
89168597|NCT00692588||Rifampicin|Subjects who received rifampicin in DARAD Trial
89168598|NCT00692588||Doxycycline and Rifampicin|Subjects who received doxycycline and rifampicin in DARAD Trial
89168599|NCT00692588||Control|Normal controls
89168600|NCT00687518|Experimental|1|erythropoietin
89168601|NCT00687518|Placebo Comparator|2|Saline serum
89168602|NCT02303795|Active Comparator|Rivaroxaban 20mg|Oral Rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
89168603|NCT02303795|Active Comparator|Warfarin|Warfarin Warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
89168604|NCT04139408|Experimental|Disposable Pulmonary Surgical Marker|Locate the pulmonary nodules with Disposable Pulmonary Surgical Marker before VATS.
89168605|NCT04187417|Experimental|Topical tetracaine|Topical tetracaine hydrochoride 1%
89168606|NCT04187417|Placebo Comparator|Balanced artificial tear solution|Balanced artificial tear solution (Systane)
89168607|NCT01010815||UC group|clinically and microscopically confirmed UC patients between the age of 19 and 75 years
89168608|NCT01010815||Control group|normal healthy controls
89168609|NCT04145726||Patients undergoing esophageal resection|All patients undergoing esophageal resection will be included and tested if frail or non-frail. Which means there is no intervention
89168610|NCT01016431|Experimental|Rate adaptive|Patients will have their ICD programmed in a AAI-R mode, with peak atrial rate set at 85% of age-adjusted predicted maximal HR
89168611|NCT01016431|Active Comparator|Control|ICDs will be programmed in the usual VVI backup pacing mode at 40 bpm
89168612|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD|
89168613|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD|
89168614|NCT01014481|Experimental|start antiretroviral treatment|the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment
89168615|NCT02167763|Experimental|VeraCept Intrauterine Contraceptive|The VeraCept low-dose Intrauterine Copper Contraceptive
89168616|NCT02167763|Active Comparator|TCu380|A commercial standard T-shaped copper IUD (TCu380)
89168617|NCT02624648|Placebo Comparator|Placebo Group|"The effects of Placebo on sexual function, desire and depression in postmenopausal women.~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).~The Beck Depression Inventory II will be used to ward off depression"
89168618|NCT02624648|Experimental|Maca (Lepidium Meyenii Walp) Group|"The effects of Lepidium Meyenii Walp on sexual function, desire and depression in postmenopausal women.~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).~The Beck Depression Inventory II will be used to ward off depression"
89168619|NCT00508027|Other|Simvastatin, Dose Escalation|There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
89168620|NCT02626598||Treated patients|Patients treated with blended Belotero for etched-in fine lines of the cutaneous lip, and/or radial cheek area, and/or nasolabial folds, and/or melolabial folds, and/or forehead area will be evaluated with photographs, physician ratings, and patient improvement assessments.
89168621|NCT00692744||Randomized microsurgical|After randomization, this group was constituted of patients treated by microsurgical clipping.
89168622|NCT00692744||Randomized endovascular|After randomization, this group was constituted of patients treated by endovascular coiling.
89168623|NCT00692744||Prospective observational microsurgical|The randomization was ethically unsuitable because of the aneurysm predisposed to the microsurgical clipping after discussion into the neurovascular interdisciplinary team.
89168624|NCT00692744||Prospective observational endovascular|The randomization was ethically unsuitable because of the aneurysm morphology predisposed to the endovascular coiling after discussion into the neurovascular interdisciplinary team.
89168625|NCT00692744||Prospective observational conservative|This group was constituted of patients whom no curative treatment of the aneurysm sac could not be proposed.
89168626|NCT01986101|Placebo Comparator|Placebo|once daily orally
89168627|NCT01986101|Experimental|SM-13496 20 - 60 mg/day|once daily orally
89168628|NCT01986101|Experimental|SM-13496 80 - 120 mg/day|once daily orally
89168629|NCT00687752||1|hydramnios
89168630|NCT00687752||2|normal
89168631|NCT00500149|Experimental|1|
89168632|NCT00500149|Placebo Comparator|2|
89168633|NCT04139330|Experimental|NPC-06 (high dose)|Infuse diluted NPC-06 18mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 18 minutes.
89168634|NCT04139330|Experimental|NPC-06 (low dose)|Infuse diluted NPC-06 12mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 12 minutes
89168635|NCT04139330|Placebo Comparator|NPC-06 (placebo)|Infuse NPC-06 (placebo) over 12 minutes or 18 minutes
89168636|NCT04185779||Group A (Cross-sectional arm)|This group will comprise of 10,000 patients who have been referred for a colonoscopy. We will be collecting information on their past medical history, smoking history, alcohol history, medication history and family history in addition to their colonoscopy findings. In 6000 of these patients, they will have blood tests, Faecal Immunochemical Test (FIT) level, blood or saliva for DNA extraction and stool microbiome taken. In 4000 of these patients, we will record recent blood tests of interest and they will have no new samples taken. All 10000 patients will also either complete a food frequency questionnaire or endoscopy patient experience questionnaire.
89168637|NCT04185779||COLO-SPEED (Group B, consent for contact arm)|This will be 10,000 patients who will consent for future contact for future research studies.
89168638|NCT03997591||Conventional therapy|Group doing conventional rehabilitation was assessed at T0 and then after 6 weeks of conventional therapy (occupational therapy, physical therapy, aquatic therapy, musicotherapy, others)
89168639|NCT03997591||Ready2E.A.T. therapy|Group doing Ready2E.A.T. program received a mean of 1 hour per week and was assessed at T0 and then after 6 weeks of this program implementation.
89168640|NCT00681902|Experimental|1|Jet lidocaine
89168641|NCT00681902|Placebo Comparator|2|Jet saline
89168642|NCT04185857||Patients with primary aldosteronism (PA)|"After two biochemical and clinical evaluations under baseline conditions PA patients will be treated with canrenone 50-100 mg orally once a day.~After one month of such therapy they will undergo the a clinical and biochemical evaluation (FW1). After, they will continue with a combination therapy with canrenone, plus olmesartan starting with 10 mg a day for oral administration, a dose that can be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2)."
89168643|NCT01016509|No Intervention|control|No hyperglycemia patient group
89168644|NCT01016509|Active Comparator|Insulin 1|Conventional insulin treatment
89168645|NCT01016509|Experimental|Insulin|Intensive insulin treatment
89168646|NCT02626832|Experimental|Healthy Control|This group is represented by healthy controls
89168647|NCT02626832|Experimental|Depression|This experimental group is represented by subjects with depression
89168648|NCT02626832|Experimental|Schizophrenia|This experimental group is represented by subjects with schizophrenia
89168649|NCT02626832|Experimental|Prodromal subjects|This experimental group is represented by subjects with prodromal symptoms for schizophrenia
89168650|NCT01010893|Experimental|Influenza vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose).
89168651|NCT01010893|Experimental|Influenza vaccination and co-vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
89168652|NCT02625662||iFSHD group|First recruitment group
89168653|NCT02689661||Obese participants|Obese participants recruited from the University of Michigan Investigational Weight Management Clinic. Subjects in this group complete the five surveys, undergo extensive metabolic phenotyping, and a comprehensive neuropathy assessment at study entry and again at 2 years.
89168654|NCT02689661||Lean participants|Healthy lean age and gender matched controls recruited via the umclinicaltrials.org complete the five surveys, complete an oral glucose tolerance test and cholesterol panel, as well as the complete comprehensive neuropathy assessment.
89168655|NCT01011127||pravastatin|
89168656|NCT01011127||rosuvastatin|
89168657|NCT00639197|Active Comparator|1|To Tunnel
89168658|NCT00639197|Active Comparator|2|Not to tunnel
89168659|NCT01016587||COPD patients|Not hospitalized COPD patients, degree 2-4.
89168660|NCT00912548|Experimental|TAM+OFS(E) group|"Patients should be premenopausal women ,prior to the start of chemotherapy, less than or equal to 45 years of age with oestrogen receptor positive ± progesterone receptor positive who have undergone a primary mass excision, received an neo-/adjuvant chemotherapy ± radiotherapy for their stage I, II or III breast cancer. This arm is ovarian suppression group which have a various starting time of ovarian function suppression after neo-/adjuvant chemotherapy.~Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. After that, the patients will complete taking tamoxifen 20mg/day for 5 years."
89168661|NCT00912548|Active Comparator|TAM(D) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 0, 6, 12, 18 and 24 months since the baseline asTsessment(0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. The latter will complete taking tamoxifen 20mg/day for 5 years.
89168662|NCT00912548|No Intervention|Permanent postmenopausal(A) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. Eligible patients except for premenopausal status at the baseline will be followed up until 2 years after the baseline assessment for evaluating the menopausal status. This group still remains to postmenopausal status and will taking tamoxifen 20mg/day for 5 years if they remain in the study.
89168663|NCT00912548|Active Comparator|TAM(B)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. This group, patients are premenopausal women, they will be randomized into tamoxifen only group, complete taking tamoxifen 20mg/day for 5 years.
89168664|NCT00912548|Experimental|TAM+OFS (C)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized. This group, patients are premenopausal women, they will be randomized into the additional ovarian function suppression group. Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. Then, Patients will complete taking tamoxifen 20mg/day for 5 years.
89168665|NCT01016665|Placebo Comparator|Placebo|Placebo
89168666|NCT01016665|Other|Tamoxifen|Tamoxifen 20 mg day 26 days
89168667|NCT01016665|Other|Anastrozole|Anastrozole 1mg 26 days
89168668|NCT00681980|Experimental|A, 2, III|Patients with side effects to corticosteroids
89168669|NCT00681980|Experimental|B|patient with corticosteroids
89168670|NCT00681980|Experimental|3|Valproic acid and corticosteroids
89168671|NCT01016743|Active Comparator|Active repetitive transcranial Stimulation|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
89168672|NCT00692900|Experimental|1|intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin
89168673|NCT00692900|Experimental|2|intravenous (IV) oxaliplatin and intraperitoneal(IP) docetaxel
89168674|NCT00682058||LABS patients|Bariatric surgery patients with 35>BMI kg/m2<60 prior to surgery will undergo follow-up post-bariatric surgery.
89168675|NCT00489853|Experimental|Symbicort then Formoterol then Placebo|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
89168676|NCT00489853|Experimental|Formoterol then Symbicort then Placebo|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
89168677|NCT00489853|Placebo Comparator|Placebo then Formoterol then Symbicort|Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily
89168678|NCT04137146|Experimental|Sacral Nerve Stimulation|Intervention: Sacral nerve Stimulation Stimulation sites：S3 Postoperative study visits lasted approximately 3 hours and were conducted in 3 months.
89168679|NCT04137146|No Intervention|No SNS Intervention|
89168680|NCT04185467|No Intervention|Usual care(both arms)|Usual care (both arms): Patients in both arms will receive usual medical, physiotherapy and nursing care according to usual protocols. This does not involve exercise rehabilitation or advice.
89168681|NCT04185467|Experimental|Intervention (exercise rehabilitation)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
89168682|NCT00682136|Active Comparator|1|Open Laparotomy Arm: All patients enrolled in the study who are undergoing elective open laparotomy surgery.
89168683|NCT00682136|Active Comparator|2|Laparoscopic Arm: All patients enrolled in the study who are undergoing elective laparoscopic abdominal surgery.
89168684|NCT00693056|Placebo Comparator|1|
89168685|NCT00693056|Experimental|2|
89168686|NCT00693056|Experimental|3|
89168687|NCT00693056|Experimental|4|
89168688|NCT04137302|Active Comparator|Topical hydrocortisone administration|dermal cream (twice a day, 2.5 g of cream, 1% hydrocortisone during 5 days)
89168689|NCT04137302|Active Comparator|Systemic hydrocortisone administration|tablets (once a day, 50 mg, morning, during 50 days)
89168690|NCT00688142||1|Individuals with shift work sleep disorder
89168691|NCT00688142||2|Healthy night shift workers without shift work sleep disorder
89168692|NCT04145336|Active Comparator|5cm PDS group|All patients in this group receive 5cm 5-Fr PDS.
89168693|NCT04145336|Experimental|7cm PDS group|All patients in this group receive 7cm 5-Fr PDS.
89168694|NCT03686423|Experimental|Patients with Type 2 Diabetes and Clinical Symptoms of DPN|Patients will be individually prescribed to a 10-week exercise program with both aerobic and resistance components. Prior to beginning the intervention, patients will participate in a maximal graded exercise test (VO2R) using a cycle ergometer with a metabolic cart and integrated ECG.
89168695|NCT00688220||1|Those wearing garments fabricated with Celliant
89168696|NCT00688220||2|Those not wearing garments fabricated using Celliant (placebo).
89168697|NCT00499681|Experimental|Arm I|Patients receive Lapatinib and Letrozole once daily for two weeks, following tumor measurement patients receive Lapatinib and Letrozole once daily for 14 weeks.
89168698|NCT00499681|Experimental|Arm II|Patients receive Letrozole and placebo once daily for 2 weeks, following tumor measurement patients receive Letrozole and Lapatinib once daily for 14 weeks.
89168699|NCT02687009|Experimental|Niclosamide|
89168700|NCT00693134||Myocarditis Patients|Patients initially diagnosed with myocarditis.
89168701|NCT00693134||Control Patients|Patients with no known cardiomyopathies
89168702|NCT00693212|Experimental|a|This arm was only open to subjects entering the second, open-label phase. All subjects were given open-label methylphenidate. Dosing was flexible.
89168703|NCT00693212|Experimental|MPH|This is the active treatment arm of the double-blind placebo controlled phase. Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
89168704|NCT00693212|Placebo Comparator|PBO|This 2 week arm is the placebo part of the crossover design. Subjects receive placebo in a manner similar to the MPH arm. It lasts 2 weeks.
89168705|NCT03673943|Experimental|PET/CT imaging with 64Cu-DOTATATE|64Cu-DOTATATE is an investigational radioactive drug that binds to somatostatin receptors on neuroendocrine cancer cells.
89168706|NCT00693290|Active Comparator|1|Fleet plus low residue diet sheet.
89168707|NCT00693290|No Intervention|2|No intervention, usual care, Fleet plus liquid only diet
89168708|NCT04471285|Active Comparator|true acupuncture|patient will get treatment according to the point the will help the symphysiolysis according to the Alternative medicine
89168709|NCT04471285|Sham Comparator|Sham acupuncture|patient will get treatment according to the point the will NOT help the symphysiolysis according to the Alternative medicine
89168710|NCT00688298|Experimental|Arm 1|Female patients Greater than or 18 years of age, diagnosed with Stress Urinary Incontinence (SUI).
89168711|NCT02687087|Experimental|Visco-ease|Visco-ease is a suspension of multilamellar vesicles comprising lipids in ratios which mimic the lipidic composition of endogenous extra-alveolar lamellar bodies. Visco-ease is suspended in physiological saline (0.9% NaCl) to provide a final dose concentration of 19.6 mg/mL. Visco-ease is a white to off-white turbid suspension. The device under evaluation in this clinical investigation is Visco-ease at a concentration of 19.6 mg/mL.
89168712|NCT02687087|Placebo Comparator|RIX-Placebo|Physiological Saline (sodium chloride 0.9% (w/v)
89168713|NCT02686931||Control|Control: Normal developmental children with orthopedic disease
89168714|NCT02686931||Experimental|Experimental: Developmental delayed children
89168715|NCT02686775|Experimental|Patient coach|Standard care and patient coach. 5 face-to-face sessions of approximately 1-2 hours duration and 3 phone calls from inclusion to one month after end of first line treatment. Deviations from this schedule might depend on the treatment modules and on the wishes and needs of the patient. Several patients will continue directly into palliative care and the coach will thus support this transition.
89168716|NCT02686775|Active Comparator|Standard treatment|Standard care.
89168717|NCT00499603|Experimental|Paclitaxel + FEC|Paclitaxel 80 mg/m^2 intravenously (IV) on day 1(+/- 2 days) of each week, followed by four cycles of combination 5-Fluorouracil at 500 mg/m^2, Epirubicin at 100 mg/m^2 and Cyclophosphamide at 500 mg/m^2 (FEC) on day 1 every 3 weeks (+/- 7 days).
89168718|NCT00499603|Experimental|Paclitaxel + RAD001 + FEC|Paclitaxel + RAD001 Followed by FEC (5-Fluorouracil + Epirubicin + Cyclophosphamide)
89168719|NCT04144868|Experimental|Experimental: NBO group|"For eligible patients into the group of cerebral hemorrhage,Low-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours.~Regular treatment is based on associated guidelines for ICH ."
89168720|NCT04144868|No Intervention|Control group|"Low-flow oxygen is delivered through the facemask at a rate of 2 L/min, once a hour, every 4 hours.~Regular treatment is based on associated guidelines for ICH ."
89168721|NCT00639353|Active Comparator|spherical contact lens|Subjects will wear and evaluate a spherical soft contact lens daily for 2 weeks
89168722|NCT00639353|Experimental|toric contact lens|Subjects will wear and evaluate a toric soft contact lens daily for 2 weeks
89168723|NCT04144556|Experimental|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
89168724|NCT04144556|Active Comparator|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
89168725|NCT00688454||Pt with hypercholesteremia|Patients treated with CRESTOR because of hypercholesteremia
89168726|NCT01946711|Experimental|Buparid; Treatment A|Buparid 1 mg budesonide/2 ml nebuliser solution
89168727|NCT01946711|Active Comparator|Budes; Treatment B|Budes® Nasal Spray 50 µg budesonide/pump
89168728|NCT00693446|Other|2|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time."
89168729|NCT00693446|Other|1|Patients receive Tacrolimus from day 0 to the end of the study (Arm Tacrolimus).
89168730|NCT01663181||urogynecologic patients undergoing outpatient cystoscopy|
89168731|NCT01663181||urogynecologic patients undergoing outpatient-urodynamics|
89168732|NCT00693524|Experimental|1|Tacrolimus + Anti-IL2R AB + Mycophenolate mofetil
89168733|NCT00693524|Active Comparator|2|Tacrolimus + Steroid
89168734|NCT00693602|Experimental|1|
89168735|NCT00682214|Active Comparator|A, Choelcalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
89168736|NCT00682214|Placebo Comparator|B, Lactose|
89168737|NCT00688532||1|Prostate cancer patients treated with bicalutamide or not
89168738|NCT00688532||2|General population cohort
89168739|NCT00693680|Active Comparator|1|zinc + imipramine
89168740|NCT00693680|Placebo Comparator|2|placebo + imipramine
89168741|NCT00682292|Active Comparator|1, ATG|Thymoglobulin induction during 8 days (1.25 mg/kg per day) associated with tacrolimus, mycophenolate mofetil and steroids
89168742|NCT00682292|Active Comparator|2, Daclizumab|Dacluzamb induction (five infusions, 1 mg/kg per infusion) associated with tacrolimus, mycophenolate mofetil and steroids
89168743|NCT02624336|Active Comparator|DTC1 mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
89168744|NCT02624336|Placebo Comparator|Oradex mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
89168745|NCT02624336|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
89168746|NCT00810069|Experimental|Early Intervention|Escitalopram 10 milligrams per day for 4 weeks (one 10 milligram [mg]-capsule) followed by Duloxetine flexible dose (60 or 120 mg daily) for 12 weeks.
89168747|NCT00810069|Experimental|Delayed Intervention|Escitalopram 10 mg per day for 4 weeks (one 10 mg-capsule) followed by Escitalopram 10 to 20 mg per day for 4 weeks (one or two 10 mg capsule[s]). Then, non-responders switched to Duloxetine 60 or 120 mg per day for 8 weeks , and responders continued on Escitalopram 10 to 20 mg per day for 8 weeks.
89168748|NCT00693758|No Intervention|1|healthy volunteers without intervention
89168749|NCT00693758|No Intervention|2|patients with suspected coronary artery disease without intervention
89168750|NCT00693758|Experimental|3|Healthy volunteers during adenosine infusion
89168751|NCT00693758|Experimental|4|Healthy volunteers during changes of breathing gases (CO2, O2)
89168752|NCT00693758|Experimental|5|patients with suspected coronary artery disease during adenosine infusion
89168753|NCT00693758|Experimental|6|patients with suspected coronary artery disease during changes of breathing gases
89168754|NCT00693758|Experimental|7|Assessment of reactive hyperemia in arms of healthy volunteers to improve sequences
89168755|NCT00682370|Experimental|A1|0.3 mg/kg heme arginate
89168756|NCT00682370|Experimental|A2|1 mg/kg heme arginate
89168757|NCT00682370|Experimental|A3|3 mg/kg heme arginate
89168758|NCT00682370|Placebo Comparator|P|Placebo
89168759|NCT02625740|Experimental|Study group|After crossing the lesion with a guidewire, patients will be treated with intravascular high intensity, low-frequency ultrasound followed by local administration of liquid mixture of Paclitaxel and Iopromide-370 with predetermined dosage of 1.0 µg/mm
89168760|NCT02625740|Active Comparator|Control group|After crossing the lesion with a guidewire, patients will be treated with drug eluting ballon angioplasty with the In.Pact Admiral ballon (Medtronic)
89168761|NCT00693914||1: Brain Tumor Survivors (n=50)|
89168762|NCT00693914||2: Healthy Sibling Controls (n=40)|
89168763|NCT00693914||Solid Tumor Survivors (n=40)|
89168764|NCT02609373|Other|Sleep intervention|Sleep intervention
89168765|NCT02609217||Multiparous|12 multiparous women and their partners, planned to undergo elective term cesarean section.
89168766|NCT02609217||Nulliparous|12 nulliparous women and their partners, planned to undergo elective term cesarean section.
89235056|NCT05096130|Experimental|Lifestyle Medicine Strategies Groupo|The LSM (LifeStyle Medicine) group, will receive a 6-month lifestyle change intervention targeting the correction of diet, improving physical activity and exercise levels, reducing stress levels, and improving sleep hygiene by LSM registered professionals.
89235057|NCT05091593|Experimental|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
89168767|NCT00694226|Experimental|1|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
89168768|NCT00694226|Active Comparator|2|Treatment as usual (TTU): Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol. After completing the assessment individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis
89168769|NCT02626364|Experimental|Treatment|crenolanib 100mg PO TID
89168770|NCT02609139|Experimental|<=400mg Modified Release Tablets, Fasted|Up to 400 mg PF-06650833 modified release tablets administered under fasted conditions
89168771|NCT02609139|Experimental|100mg Modified Release Tablets, Fasted|100 mg PF-06650833 modified release tablets administered under fasted conditions
89168772|NCT02609139|Experimental|20mg Modified Release Tablets, Fasted|20 mg PF-06650833 modified release tablets administered under fasted conditions
89168773|NCT02609139|Experimental|<= 400mg Modified Release Tablets, Fed|Up to 400 mg PF-06650833 modified release tablets administered with high fat meal food intake
89168774|NCT02609139|Experimental|100mg Modifed Release Tablets, Fed|100 mg PF-06650833 modified release tablets administered with high fat meal food intake
89168775|NCT02609139|Experimental|20mg Modified Release Tablets, Fed|20 mg PF-06650833 modified release tablets administered with high fat meal food intake
89168776|NCT00682526||Pre-study Period (Group 1 and Group 2).|"The TIME-MC study was conducted from June 2003 to June 2008 at NEMC (Figure 1) and from May 2005 to September 2008 at the six larger medical centers (Figure 2). Two groups were studied. Group 1 included patients at NEMC and Group 2 included patients at the other six medical sites. The study was divided into three periods:~Pre-study period (Group 1 and Group 2). No PH-ECG transmission system was available."
89168777|NCT00682526||Study Period (Group 1 and Group 2)|Study period (Group 1 and Group 2). PH-ECG transmission to a cardiologist's hand-held device was attempted through pre-assigned EMS ambulances equipped with a wireless ECG transmission device in addition to a STEMI code system. In Group 1, this referred to the pilot study at NEMC from June 2003 to May 2005.
89168778|NCT00682526||Post-study period (Group 1)|Post-study period (Group 1). PH-ECG transmission and a STEMI code system implemented after the pilot study period.
89168779|NCT02609295|Placebo Comparator|Placebo|Individuals who consumed 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil daily
89168780|NCT02609295|Experimental|ALA group|Individuals who consumed 1.2 g (two capsules) of perilla oil daily
89168781|NCT04136834|Experimental|Pegtomarginase (PT01)|To determine the MTD of PT01 based on the toxicity observed during Cycle 1 of the Dose Escalation Phase and to investigate the safety and tolerability of PT01 when administered intravenously(IV) to subjects with advanced malignancies
89168782|NCT00694460|Experimental|1|
89168783|NCT00694460|Experimental|2|
89168784|NCT00694460|Experimental|3|
89168785|NCT00694460|Experimental|4|
89168786|NCT00694460|Active Comparator|5|
89168787|NCT04776525|Experimental|Sequential ifosfamide and doxorubicin|Four cycles ifosfamide 9 g/m2 and four cycles doxorubicin 80 mg/m2. Each cycle has a duration of 14 days.
89168788|NCT00689000|Experimental|CHR-2797 (tosedostat)|oral, once daily administration of CHR-2797 to determine safety & anti-disease activity.
89168789|NCT00489541|Experimental|TAXUS Element Stent System|
89168790|NCT00689156|Active Comparator|Regimen 1|Epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times three followed by docetaxel 100 mg/m2 intravenously day 1 every 3 weeks times three
89168791|NCT00689156|Experimental|Regimen 2|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
89168792|NCT00689234|Placebo Comparator|A|"At time of inclusion randomised in the no intervention arm (the subjects will be re-evaluated 6 months later and will get intervention at that time (cross-over protocol)"
89168793|NCT00689234|Active Comparator|B|At time of inclusion the subject get the intervention
89168794|NCT01016821|Other|Oxycodone, labour pain|
89168795|NCT04139174||adolescent group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).~measurements will be done on the radiograph using digital software."
89168796|NCT04139174||adult group|"Panoramic radiographs of finished orthodontic cases will be collected after fulfilling the inclusion and exclusion criteria. Then the collected data will be divided into two groups according to age either adolescent (12-18 years old) or adult group (after 18 years old).~measurements will be done on the radiograph using digital software."
89168797|NCT01011205|Experimental|Dosing Regimen 1|Advagraf + MMF + Corticosteroids (Bolus)
89168798|NCT01011205|Experimental|Dosing Regimen 2|Advagraf + MMF + Basiliximab + Corticosteroids (Bolus)
89168799|NCT01011205|Experimental|Dosing Regimen 3|Advagraf (5 days delay) + MMF + Basiliximab + Corticosteroids (Bolus)
89168800|NCT04143698|Active Comparator|Disposable (single-use) duodenoscope|This group will be using the disposable (single-use) duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
89168801|NCT04143698|Active Comparator|Reusable duodenoscope|This group will be using the reusable duodenoscope during endoscopic retrograde cholangiopancreatography (ERCP).
89168802|NCT00694538|Active Comparator|1|100 patients are being treated with a single laser beam over pain area.
89168803|NCT00694538|Experimental|2|100 patients are being treated with interferential laser from two independent sources
89168804|NCT00809835|No Intervention|Standard Treatment As Usual (TAU)|Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.
89168805|NCT00809835|Experimental|TAU Plus Galantamine|Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
89168806|NCT00809835|Experimental|TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)|TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
89168807|NCT00809835|Experimental|TAU plus CBT plus galantamine|Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.
89168808|NCT00694616|Other|1|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
89168809|NCT00694616|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
89168810|NCT01014559|Active Comparator|Prolonged release tablet|OxyCodone Naloxone controlled release tablet
89168811|NCT01014559|Active Comparator|Tablet|Oxycodone PR Tablets
89168812|NCT00853242|Placebo Comparator|Placebo|Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks.
89168813|NCT00853242|Experimental|Genz-644470 2.4 Grams Per Day (g/day)|Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
89168814|NCT00853242|Experimental|Genz-644470 4.8 g/day|Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
89168815|NCT00853242|Experimental|Genz-644470 7.2 g/day|Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
89168816|NCT00853242|Active Comparator|Sevelamer Carbonate 2.4 g/day|Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
89168817|NCT00853242|Active Comparator|Sevelamer Carbonate 4.8 g/day|Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
89168818|NCT00853242|Active Comparator|Sevelamer Carbonate 7.2 g/day|Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
89168819|NCT04143230|Active Comparator|Extended Screening Tool (EST)|The SIAARTI/NCCN (EST) screening tool is, in fact, an instrument validated by many scientific societies, but it is very articulated and its compilation is too much time-consuming.
89168820|NCT04143230|Experimental|Simplified Screening Tool (SST)|The Simplified Screening Tool (SST) has been created through a statistical process in order to include all the critical variables, with the advantage of being shorter and therefore easier to administer in a routinely use.
89168821|NCT02625818||acute psychiatric condition|
89168822|NCT00689312|Active Comparator|1|
89168823|NCT00689312|Experimental|2|
89168824|NCT00689312|Experimental|3|
89168825|NCT04117386||Primary pterygium group|Participants who was diagnosed with primary pterygium
89168826|NCT04117386||Secondary pterygium group|Participants who was diagnosed with secondary pterygium
89168827|NCT04117386||Healthy participants as control group|Participants who have no pterygium and other inflammation disease in eyes
89168828|NCT02609061|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
89168829|NCT02609061|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
89168830|NCT02609061|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating furcation defect
89168831|NCT04136678|Experimental|treadmill back walking training|15 minutes conventional walking training, 15 minutes of treadmill back walking training, 15-minute treadmill forward walking training
89168832|NCT02608983|Experimental|Treatment 1|
89168833|NCT02608983|Experimental|Treatment 2|
89168834|NCT02608983|Placebo Comparator|Treatment 3|
89168835|NCT00848250|Experimental|ACE inhibitor|Patients already on an ACE inhibitor will continue it until the day of surgery
89168836|NCT00848250|Experimental|No ACE inhibitor|Patients on ACE inhibitors who are randomized to stop their ACE inhibitor 48 hours prior to surgery
89168837|NCT00912626|Experimental|FU-1 feedback|
89168838|NCT00912626|No Intervention|control group|
89168839|NCT04116294|No Intervention|Before|Standard of care for informatic prescription.
89168840|NCT04116294|Active Comparator|After|Computer-assisted prescription for radiological procedure
89168841|NCT00694694|Experimental|1AZ+AQ|Azithromycin + artesunate
89168842|NCT00694694|Active Comparator|2AL|Artemether-lumefantrine
89168843|NCT00682682|Experimental|1|all study participants will have 4 visits: VR alone, VR + opioid, opioid alone, and no VR/opioid
89168844|NCT04136600|Experimental|EGFR antibody arm|Participants received a dose of 500 mg/m2 Cetuximab iv on Day 1 of cycle every 3 weeks, or 400mg Nimotuzumab on Day 1 of cycle, every week, until disease progression. 12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
89168845|NCT04136600|Placebo Comparator|Placebo arm|12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)
89168846|NCT00809757|Experimental|1|90 ug Levalbuterol (2 actuations)
89168847|NCT00809757|Active Comparator|2|0.31 ug Levalbuterol UDV TID
89168848|NCT00809757|Placebo Comparator|3|Placebo
89168849|NCT00594464|Experimental|1|Rotigotine
89168850|NCT00694772|Active Comparator|Electrocautery|
89168851|NCT00694772|Experimental|Coblation|
89168852|NCT00682760|Active Comparator|1|Korean botulinum toxin A treatment
89168853|NCT00682760|Placebo Comparator|2|Botox treatment
89168854|NCT00689468|Placebo Comparator|1|"Osteopathic sham treatment plus placebo Echinacea drops"
89168855|NCT00689468|Active Comparator|2|Active Echinacea drops plus sham osteopathic treatment
89168856|NCT00689468|Active Comparator|3|"Active osteopathic manipulation plus placebo Echinacea drops"
89168857|NCT00689468|Active Comparator|4|Active osteopathic manipulation plus active Echinacea drops.
89168858|NCT00682916|Active Comparator|1|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
89168859|NCT00682916|Placebo Comparator|2|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
89168860|NCT00809445|Experimental|HIV rapid test & counseling|Participants will be offered an oral fluid HIV rapid test (via oral swab) and brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach (Project RESPECT-2 counseling). Prior to receiving testing, study participants must first provide consent for HIV testing. Consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test.
89168861|NCT00809445|Experimental|HIV rapid test and info|Participants will be offered an oral fluid HIV rapid test (via oral swab). Prior to receiving testing, study participants must first provide consent for HIV testing. Again, consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test. Participants will receive rapid HIV testing and test results after signing the consent to be tested. In both Groups 1 and 2, participants who test reactive (preliminary positive) will be counseled on the sexual risk behaviors associated with transmission of HIV and the acquisition of STDs, as is current clinical practice with those testing HIV positive. Confirmed positives will be linked to HIV primary care.
89168862|NCT00809445|Active Comparator|HIV testing referral|Participants randomized to group 3 will receive a referral list for HIV community-testing agencies. Each CTP site will have previously prepared an extensive referral list of testing sites in the surrounding geographic area. By virtue of their status as patients in the CTPs, they will receive whatever HIV testing and HIV education referrals the CTPs normally provide to their patients. This is the standard of care at CTPs that do not provide on-site testing.
89168863|NCT00689546||I/A|All cases of acute viral hepatitis irrespective of type (A, B, E) with underlying Type 2 diabetes mellitus
89168864|NCT00689546||I/B|Age and sex matched non- diabetic patients with acute viral hepatitis (irrespective of type) recruited from all the patients of acute viral hepatitis registered during the time period in which cases were recruited.
89168865|NCT00689546||II/A|All diabetic who have acute icteric viral hepatitis due to HEV infection
89168866|NCT00689546||II/B|Age and sex matched diabetic who have acute icteric viral hepatitis due to hepatiits virus other than HEV.
89168867|NCT00682994|Other|Decision Making|Questionnaire + Interview
89168868|NCT00695006|Sham Comparator|II|Sham Traction
89168869|NCT00695006|Active Comparator|I|Traction
89168870|NCT05326269|Active Comparator|Intervention group|Terbutaline 0.5 mls (0.25 mg) , subcutaneously
89168871|NCT05326269|Placebo Comparator|Control group|Placebo (normal saline) 0.5 mls , subcutaneously
89168872|NCT04665453|Experimental|Melatonin peroral|0,1mg/kg melatonin will be given in the form of a syrup to the participant before EEG and vital functions monitoring
89168873|NCT04665453|Experimental|Dexmedetomidine intranasally|3 mcg/kg of dexmedetomidine in the form of a nasal spray will be given to the participant before EEG and vital functions monitoring
89168874|NCT04665453|Experimental|Dexmedetomidine sublingually|3 mcg/kg of dexmedetomidine will be given to the participant sublingually before EEG and vital functions monitoring
89168875|NCT00695084|Experimental|1|Treatment with Constraint-Induced Movement Therapy
89168876|NCT00695162|Other|1|hearing impaired inpatients
89168877|NCT00695162|Other|2|Non-hearing-impaired inpatients
89168878|NCT00695240|Experimental|Bupiv analgesia|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. The catheter was placed in the operating room with a peel-away trocar and attached to the pump. The trocar was inserted through a 5 mm stab incision made near the superior part of the pubic bone between the genitoinguinal fold and the midline of the symphysis. Once through the incision, the trocar is advanced subcutaneously and made to exit the posterior fourchette just beneath the posterior vaginal mucosa where it is advanced by tenting up the skin.
89168879|NCT00683072||1|
89168880|NCT00683150||Endothelial Function Test|Patients scheduled to have major abdominal or thoracic surgery.
89168881|NCT00689780|Experimental|1|AZD1940 + Placebo
89168882|NCT00689780|Other|2|
89168883|NCT00689858|Experimental|1|Period 1: Cilostazol, Ginkgo biloba Period 2:Cilostazol, placebo
89168884|NCT00689858|Active Comparator|2|Period 1: Cilostazol, placebo Period 2: Cilostazol, Ginkgo biloba
89168885|NCT00695474||A|The cohort consists of type 2 diabetics from the outpatient clinic at Silkeborg Hospital.
89168886|NCT00683228|Other|Counseling|some caregivers will be provided counseling related to the hazards of secondhand smoke exposure
89168887|NCT00695630|Experimental|1|Flumazenil 2mL
89168888|NCT00695630|Placebo Comparator|2|Saline, 2mL SM
89168889|NCT01614899|Experimental|SM-13496 40mg|
89168890|NCT01614899|Experimental|SM-13496 80mg|
89168891|NCT01614899|Placebo Comparator|Placebo|
89168892|NCT00695708|Experimental|BFT|20 schizophrenic patients
89168893|NCT00695708|Active Comparator|CP|19 schizophrenic patients
89168894|NCT00695708|No Intervention|HCG|20 healthy age and sex matched subjects
89168895|NCT00690014|Experimental|A|
89168896|NCT00690092|Active Comparator|1|Volunteers with a history of pulmonary coccidioidomycosis verified by serology and/or histology or mycology.
89168897|NCT00690092|Active Comparator|2|Volunteers without a history of pulmonary coccidioidomycosis confirmed by serology (naive).
89168898|NCT00690092|Active Comparator|3|Volunteers with a history of pulmonary histoplasmosis but no history of coccidioidomycosis confirmed by serology.
89168899|NCT04208399|Experimental|Part A: Group 1|Participants with liver cirrhosis with moderate hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
89168900|NCT04208399|Experimental|Part A: Group 2|Participants with normal liver function with no liver cirrhosis will receive a single oral dose of JNJ-56136379 in fed condition.
89168901|NCT04208399|Experimental|Part B: Group 3 (optional)|Participants with liver cirrhosis with mild hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
89168902|NCT04208399|Experimental|Part B: Group 4 (optional)|Participants with liver cirrhosis with severe hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.
89168903|NCT02624258|Experimental|RNA CART19 cells|CD19 RNA redirected autologous T-cells (RNA CART19 cells)
89168904|NCT04138199||Participants with Human Immunodeficiency Virus-1 Infection|Human Immunodeficiency Virus-1 (HIV-1) infected and clinically stable patients on dual or triple HAART including Kaletra who switched or planned to switch to generic product of lopinavir/ritonavir
89168905|NCT00912392|Experimental|Etoposide-Carboplatin with Endostar|Endostar® 7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
89168906|NCT00912392|Active Comparator|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
89168907|NCT00683462|Placebo Comparator|1|
89168908|NCT00683462|Experimental|2|
89168909|NCT00683462|Experimental|3|
89168910|NCT00695942||1|pregnancy women
89168911|NCT02624024||Acute chest pain or equivalent ischemic symptoms|acute chest pain or equivalent ischemic symptoms suggestive of acute coronary syndromes (ACS) or acute myocardial infarction (MI)
89168912|NCT04135820|Experimental|Fasted|BPI-7711 following a period of fasting
89168913|NCT04135820|Experimental|High-fat meal|BPI-7711 following a high-fat meal.
89168914|NCT04135664|Active Comparator|Patients undergoing adjuvant esophagectomy|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients randomized into undergoing adjvant esophagectomy."
89168915|NCT04135664|Experimental|Patients undergoing adjuvant chemoradiation|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients randomized into undergoing adjvant chemoradiation."
89168916|NCT04135664|Active Comparator|Prospective registry of patients that cannot be randomized|"Patients underwent endoscopic submucosal dissection and diagnosed with pathological-T1b and clinical-N0 squamous cell carcinoma.~Patients cannot be randomized into undergoing adjvant esophagectomy or chemoradiaton.~This arm includes patients undergoing adjuvant esophagectomy; adjuvant chemoradiation and active surveillance."
89168917|NCT00690170|Active Comparator|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotine IV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
89168918|NCT00690170|Placebo Comparator|Placebo Comparator|-Placebo administration: Normal saline (sodium chloride 0.9%)over 95 minutes
89168919|NCT00690170|Active Comparator|Ketamine and Placebo|"Ketamine administration: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes~Placebo administration: Normal saline (sodium chloride 0.9%)over 94 minutes"
89168920|NCT00690170|Active Comparator|Nicotine and Placebo|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg)IV (in the arm), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
89168921|NCT00593918||Toll-like Receptor 4 -2026/GG Genotype|Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection
89168922|NCT00593918||Toll-like Receptor 4 -2026/AG and AA Genotypes|Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection
89168923|NCT02623868|Experimental|Group 1|A-B-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
89168924|NCT02623868|Experimental|Group 2|B-C-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
89168925|NCT02623868|Experimental|Group 3|C-A-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
89168926|NCT02623868|Experimental|Group 4|A-C-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
89168927|NCT02623868|Experimental|Group 5|B-A-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
89168928|NCT02623868|Experimental|Group 6|C-B-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
89168929|NCT00689624|Experimental|1|FOLFOXIRI+Erbitux
89168930|NCT05298800|Experimental|COVID-19 and QIV|
89168931|NCT05298800|Experimental|COVID-19 and PPV23|
89168932|NCT05298800|Experimental|COVID-19|
89168933|NCT05298488|Experimental|Home office for first 4 weeks, and office for the last 4 weeks|Participants will work from home for first 4 weeks, and at the office for the last 4 weeks
89168934|NCT05298488|Active Comparator|Office for first 4 weeks, and home office for the last 4 weeks|Participants will work at the office for the first 4 weeks, and from home during the last 4 weeks
89168935|NCT02621528|Other|CeraFlex occluder|The Lifetech CeraFlex™ study is a triple-arm study.
89168936|NCT02621684|Experimental|Arm 1: Aerobics|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.~Require physical evaluation and orientation to the WellAware gym~12 week walking program at the WellAware Center~required to check in with gym staff to check attendance~advised to walk at own pace for 3 days per week~15 minutes per day for the first 2 weeks~30 minutes per day for the next 2 weeks~50 minutes or more for remaining weeks"
89168937|NCT02621684|Experimental|Arm 2: Resistance training|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.~Require physical evaluation and orientation to the WellAware gym~12 week weight lifting program at WellAware Center~exercise physiologists will work with each patient to develop a custom routine~exercise load will start at 60% of one-repetition maximum and progress from 8 to 12 repetitions~2-4 sets of repetition exercises will be performed to target upper & lower muscle groups~resistance load will be added by 5 pounds when patients can complete more than 12 repetitions"
89168938|NCT02621684|Active Comparator|Arm 3: Usual care|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations."
89168939|NCT02623790|Experimental|Test meal (butter)|Subjects will eat one test meal containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
89168940|NCT02623790|Experimental|Test meal (cheddar cheese)|Subjects will eat one test meal containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
89168941|NCT02623790|Experimental|Test meal (cream cheese)|Subjects will eat one test meal containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
89168942|NCT00696098|Experimental|1|sodium butyrate
89168943|NCT00696098|Placebo Comparator|2|
89168944|NCT02623634||observation|this study measure the cuff leak volume and cuff leak ratio according to the cuff leak test with different positions and waveform,, at the same time observe the patient general condition, vital signs, oxygen saturation, cuff leak test results under different conditions and the breathing machine parameters, the diameter of the airway, the use of sedatives and hormones, after extubation stridor and intubation is happening again, the use of NPPV after extubation, patient outcomes
89168945|NCT02623556|Experimental|TB subjects|"720 cases TB (Tuberculosis) subjects who meet the standard respectively are divided average into two groups through a randomized and blind method.~360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm. 360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h."
89168946|NCT02623556|Experimental|non-TB subjects with lung disease and suspected TB subjects|360 cases non-TB subjects with lung disease and suspected TB subjects,who meet the standard respectively are divided average into different groups through a randomized and blind method. 180 non-TB subjects with lung disease are injected ESAT6-CFP10(10ug/ml) in left arm and TB-PPD in right arm. 180 non-TB subjects with lung disease are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. The study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
89168947|NCT00684008|Experimental|I|"Single arm dose escalation study. Three successive cohorts of 3 patients each. Doses to be evaluated: 10, 20, and 30 mcg/kg/dose for 3 consecutive doses.~CYT107 is a recombinant protein belonging to the class of growth factors known as cytokines.~CYT107 is a heavily glycosylated and sialylated form of recombinant human Interleukin-7.~CYT107 is supplied as a sterile colorless liquid at a concentration of 4 mg/ml."
89168948|NCT00696176|Experimental|A|STAT 3 decoy administration
89168949|NCT05326724|Experimental|Acupuncture|
89168950|NCT02623478|Experimental|Insulin Lispro - Test Formulation|Novel formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
89168951|NCT02623478|Active Comparator|Insulin Lispro - Reference Formulation|Marketed formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
89168952|NCT02623400||Preterm infants and their parents|Preterm infants born before 34 weeks gestational age and/or with a birth weight lower than 1500g and their parents.
89168953|NCT02621450|Placebo Comparator|standart dialysate|dialysate sodium 140 mEq/L
89168954|NCT02621450|Other|low sodium dialysate|dialysate sodium will be reduced from 140 mEq/L to 137 mEq/L
89168955|NCT04139954||Rheumatoid arthritis and Spondyloarthritis|Patients using Biological or Targeted Synthetic DMARDs
89168956|NCT02623088||PAP therapies|Patients with sleep apnea syndrome treated by CPAP after respiratory and vascular assessment and followed 5-7 years, as part of a clinical research.
89168957|NCT04135040|Experimental|Lysine metabolic availability|Lysine metabolism from pure amino acids and cereal foods in children.
89168958|NCT04135430||Survey|Practice of an updated questionnaire at D0, D2 and D7
89168959|NCT00684164|Experimental|1|Subjects in the treatment group will receive standard medical treatment plus Conivaptan administered as a 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
89168960|NCT00684164|Placebo Comparator|2|Subjects in the placebo control group will receive an equivalent volume loading dose of D5 followed by an infusion of D5 in the same manner as the experimental group.
89168961|NCT04135508|Experimental|BAT1406|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
89168962|NCT04135508|Active Comparator|Humira|Adalimumab, 40 mg/0.8 mL/vial, subcutaneously 1 vial every two weeks, up to a maximum of 6 months treatment.
89168963|NCT04135196|Experimental|Low Magnitude|voluntary forearm compression by leaning onto the palm of the hand with low target strain
89168964|NCT04135196|Experimental|High Magnitude|voluntary forearm compression by leaning onto the palm of the hand with high target strain
89168965|NCT04135196|Experimental|Low Rate|"voluntary forearm compression by leaning onto the palm of the hand with low strain rate (task performed slowly and evenly)"
89168966|NCT04135196|Experimental|High Rate|"voluntary forearm compression by leaning onto the palm of the hand with high strain rate (task performed as quickly as possible, with a bump)"
89168967|NCT04135196|No Intervention|Control|observation only
89168968|NCT02621294|Experimental|Measuring protein requirement|Measuring protein requirement of athletes by feeding different amount of protein in the form of amino acid mixture and measuring their oxidation through expired CO2
89168969|NCT04134962||Ankel surgery group|Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.
89168970|NCT04134962||control foot group|"Adult patients for which a Cone Beam under load is prescribed for a preoperative assessment of a foot or ankle surgery or for a follow-up consultation.~Will be retained only results of normal aligment FAO"
89168971|NCT02622932|Experimental|Anlotinib and 14C-labeled Anlotinib|each participant will be given a single dose of 14C-labeled gilteritinib.
89168972|NCT02617238|Active Comparator|PWV group|"Cardiovascular risk management based on PWV will include altogether~the implementation of international guidelines,~the normalisation of blood pressure, and~the normalisation of arterial stiffness"
89168973|NCT02617238|No Intervention|Conventional group|These patients will be treated according to the 2007 (and then 2013) ESH-ESC Guidelines for the management of hypertension
89168974|NCT04135274||Sepsis group|
89168975|NCT04135274||Non Sepsis group|
89168976|NCT02622620||Patients with glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
89168977|NCT02620982|Experimental|ARIES Application|Low intensity Extracorporeal Shockwave Application utilizing the Dornier Aries
89168978|NCT02621138||cerebral palsy|Age 6-12 years Gross Motor Function Classification System I-II
89168979|NCT02621138||control|Age 6-12 years
89168980|NCT02617394|Active Comparator|Control group|
89168981|NCT02617394|Experimental|Study group|
89168982|NCT02622776|Other|Vaginal DNA Collection|Patients with a diagnosis of ovarian cancer or endometrial cancer who have not yet had surgery, chemotherapy or radiation may be able eligible to participate. Patients unaffected by cancer may be able to participate.
89168983|NCT02617316|Other|barefoot first|Ten runners carried on barefoot test first and then in-shoes.
89168984|NCT02617316|Other|in shoes first|Ten runners carried on in-shoes test first and then barefoot.
89168985|NCT02616770|Experimental|S1226 (4%)|S1226 (4%) dosed as single dose for 2 minutes
89168986|NCT02616770|Placebo Comparator|Saline (for 4%)|3 mL saline and medical air as single dose for 2 minutes
89168987|NCT02616770|Experimental|S1226 (8%)|S1226 (8%) dosed as single dose for 2 minutes
89168988|NCT02616770|Placebo Comparator|Saline (for 8 %)|3 mL saline and medical air as single dose for 2 minutes
89168989|NCT02616770|Experimental|S1226 (12%)|S1226 (12%) dosed as single dose for 2 minutes
89168990|NCT02616770|Placebo Comparator|Saline (for 12%)|3 mL saline and medical air as single dose
89168991|NCT00499369|Experimental|Arm I (chemotherapy, cetuximab)|Patients receive single-agent irinotecan hydrochloride IV or FOLFIRI IV. They also receive cetuximab IV over 1-2 hours on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
89168992|NCT00499369|Experimental|Arm II (chemotherapy, cetuximab, bevacizumab)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive bevacizumab IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
89168993|NCT00499369|Experimental|Arm III (closed to accrual as of 4/20/2009)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive a higher dose of bevacizumab (higher than in arm II) IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
89168994|NCT02622464|Experimental|micro injection of SVF in vocal cords|micro injection of Stromal Vascular Fraction extracted from autologous adipose tissue in vocal cords
89168995|NCT02622698|Placebo Comparator|Control|The patients in the control group did not receive any supplementation, and were directed to follow the dietary guidelines of their surgeon.
89168996|NCT02622698|Experimental|Treatment|Patients were instructed to consume one ounce (containing 16 grams of protein) of the supplement three times daily. No other modifications were made to the patient's diet. Patients were provided with a total of 60 doses, which would last 20 days if they consumed each dose as instructed.
89168997|NCT04134806||Young Adults|Neurologically healthy young adults between ages 18 and 40
89168998|NCT04134806||Older Adults|Neurologically healthy older adults between ages 60 and 85
89168999|NCT04134806||Mild Cognitive Impairment/Mild Dementia|Older adults between ages 60 and 85 with Mild Cognitive Impairment or Mild Dementia
89169000|NCT02616692||HCC patients / Cohort 1|Patient preferences associated with oral anti-cancer therapy (Sorafenib), repeated TACE, and HAIC and their perceptions regarding the respective treatment characteristics
89169001|NCT02620592|Active Comparator|ZYDPLA1 tablet|ZYDPLA1 tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
89169002|NCT02620592|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
89169003|NCT02620514|No Intervention|Health-literacy Assessment|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with low adherence will continue to one or more intervention groups that address needs based on the results of the survey.
89169004|NCT02620514|Experimental|Health-literacy Assessment + Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with then complete a 24-week intervention aimed to improve education about inflammatory bowel disease and scheduled nurse phone call reminders.
89169005|NCT02620514|Experimental|Health-literacy Assessment + Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education about IBD.
89169006|NCT02620514|Experimental|Health-literacy Assessment + Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education regarding their medications.
89169007|NCT02620514|Experimental|Health-literacy Assessment + Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive financial support for medications.
89169008|NCT02620670|Active Comparator|Individuals with obesity|Body mass index (BMI) is 30.0 to 39.9 kg / m2 and a waist circumference greater than 80 cm in women and 90 cm for men Physical activity of moderate intensity for 3 days
89169009|NCT02620670|Active Comparator|Individuals with normal weight|Body mass index BMI is 18.5 to 24.9 kg / m2 with lower waist circumference of 80 cm for women and 90 cm for men Physical activity of moderate intensity for 3 days
89169010|NCT02622308|Experimental|single-case design|"The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls:~Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design)."
89169011|NCT02622152|Active Comparator|Right lateral position group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for 30 minutes period on the supine position Repositioning the patients for 30 minutes period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
89169012|NCT02622152|Active Comparator|Routine hospital care group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for two-hours period on supine position Repositioning the patients for two-hours period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
89169013|NCT02622230|Experimental|Mianhuahua Flavonoids Tablets|Mianhuahua Flavonoids Tablets, oral administration
89169014|NCT02622230|Placebo Comparator|Placebo|Placebo, oral administration
89169015|NCT01014637|Active Comparator|Amorolfine 5%|
89169016|NCT01014637|Experimental|RV4104A-cylcopiroxolamine-ciclopirox|
89169017|NCT02616926|Experimental|Hepatic resection|"Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.~Intervention: Hepatic resection"
89169018|NCT02616926|Active Comparator|TACE + RFA|"TACE is performed as a primary treatment for hepatocellular carcinoma. RFA will be performed two weeks later if necessary.~Intervention: TACE; RFA"
89169019|NCT01014715|Other|Single Arm|Phase II-Preoperative Radiation followed by Lumpectomy
89169020|NCT02621996|Experimental|Hammock group|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
89169021|NCT02621996|Active Comparator|control group|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
89169022|NCT00696566|Experimental|A|All subjects will receive Clopidogrel and Rifampicin.
89169023|NCT01017133|Other|Arm I|With 6 weeks prior to surgery, patients undergo fluorine F18 (18F)-EF5 PET at 10 minutes and 90 minutes after injection of 18F-EF5. Patients also undergo fludeoxyglucose F18 (18F-FDG) PET at 1 hour and 3 hours after injection of 18F-FDG.
89169024|NCT04031066|Experimental|Velmanase alfa|
89169025|NCT04031066|Placebo Comparator|placebo|
89169026|NCT01017211|Experimental|auricular acupuncture protocol|
89169027|NCT01017211|Sham Comparator|sham auricular acupuncture|
89169028|NCT01017289|Experimental|Quantum|In this single arm study, the Quantum nailing system will be used in all patients.
89169029|NCT00869258|Experimental|GTX and Radiation Therapy with Gemzar|"Chemotherapy Treatment with Gemcitabine, Docetaxel, and Capecitabine:~A cycle of chemotherapy is made up of 21 days. During each cycle patients will take Xeloda® twice a day for 14 days followed by a rest period of 7 days. On day 4 and 11 (+/- 2 days) of each 21-day cycle patients will also receive Gemzar and Taxotere.~Weekly Radiation Therapy with Low-Dose Gemzar Chemotherapy:~After completing a total of 3 cycles of GTX chemotherapy each patient will receive 5 weeks of standard radiation therapy in combination with low-dose Gemzar chemotherapy."
89169030|NCT01011517|Experimental|grape seed supplement|Nature's Pearl 650 mg, two capsules daily
89169031|NCT01011517|Placebo Comparator|placebo|placebo
89169032|NCT03996811|Experimental|exercise group|exercise education: A 12-week regimen of home-based walking exercises, include moderate intensity for 40 min, three times a week on non-dialysis days. We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the target heart rate, as determined by the Karvonen method, and 12-13 on the RPE.
89169033|NCT03996811|No Intervention|usual-care group|Hospital routine care
89169034|NCT00696644||Patients with severe osteoporosis|Postmenopausal women and men aged > 21 years old affected by severe osteoporosis
89169035|NCT01017367|Experimental|MDX-1100|MDX-1100 10 mg/kg administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
89169036|NCT01017367|Placebo Comparator|Placebo|Placebo (saline) administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
89169037|NCT00696722|Experimental|1|Placebo treatment first, atazanavir treatment second
89169038|NCT00696722|Experimental|2|Atazanavir treatment first, placebo treatment second
89169039|NCT02620436|Experimental|Core Mother Shelter Model|Existing mother shelters will be renovated, and mother shelters will be built at intervention sites, to meet the Core Mother Shelter Model. This model includes ensuring a safe infrastructure with four walls, a roof, doors and windows that lock, a toilet, running water, and beds.
89169040|NCT02620436|No Intervention|Standard of Care|Existing mother shelters with no changes made, except to ensure that they can provide standard of care.
89169041|NCT00696956|Placebo Comparator|A|Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec)
89169042|NCT00696956|Active Comparator|2|Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel)
89169043|NCT02616848|Experimental|Everolimus, Eribulin|
89169044|NCT02621918|Experimental|Progressive Resistance Training (PRT)|For the progressive resistance training we use 11 exercises. The exercises for upper limbs were held in the waiting room before the hemodialysis session. Resistance exercise was carried out in two sets of 15-20 repetitions, the intensity were determined by the method of maximal repetitions, where series were run until exhaustion to momentary exercises (15-20 repetitions) with specific load. The load adjustments or volume were managed when necessary, but necessarily for every 4th week of training. The effort perception should be situated between 12 and 16 on the Borg scale (Borg and Noble, 1974), as proposed by The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995).
89169045|NCT02621918|Experimental|Aerobic Exercise (AER)|Aerobic exercise was conducted with a mini ergometer cycling (Mini Bike E5 Acte Sports) attached to the patient chair. Patients exercised 50-60 minutes of continuous workout with increased load. The workload was adjusted when necessary, according to the perceived effort made by the patient. The scale of perceived exertion, Borg scale (Borg and Noble , 1974), was used in accordance with the proposed By The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995), which defines the values of perceived exertion between 12 and 16.
89169046|NCT02621918|Placebo Comparator|NEPLA|The control group performed active mobilization of members, circumduction of cervical, scapular girdle and extremities, breathing exercises with no loads, set on three to five repetitions only and no stretch exercises. The exercises were performed during the hemodialysis session, three times per week and did not exceed 5 minutes.
89169047|NCT02620124|No Intervention|Natural cycle, control|Treatment cycles with normal luteal support with progesteron
89169048|NCT02620124|Experimental|Natural cycle, intervention|Treatment cycles with normal luteal support with progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days: Intervention is the additional 0.1 mg triptorelin as described in the previous sentence.
89169049|NCT02620124|No Intervention|Hormone replacement cycle, control|Standard hormone replacement cycle with estrogen and progesteron
89169050|NCT02620124|Experimental|Hormone replacement cycle, intervention|Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days
89169051|NCT02617160|Experimental|MD Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
89169052|NCT02617160|Active Comparator|Control Group-Medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
89169053|NCT04134650|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 12 months Linagliptin 2.5mg + metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
89169054|NCT04134650|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 12 months Metformin 1700mg every 24 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
89169055|NCT02621762|Experimental|Mg first|Receives MgCl2 first, MgCl2 and Bicarbonate in second phase
89169056|NCT02621762|Experimental|Bicarbonate first|Receives Bicarbonate first, MgCl2 and Bicarbonate in second phase
89169057|NCT02621840|Experimental|Intervention|Patients in the intervention group will be mandated to complete the PAT with Dr. Koka. After scheduling the surgery with the surgical coordinator, intervention patients will be required to go directly to Dr. Koka's office, to complete all necessary pre-operative steps.
89169058|NCT02621840|No Intervention|Usual Care|Patients in the usual care group will be treated with the standard protocol that is currently utilized in the Wills Eye Hospital Cataract and Primary Eye Care (CPEC) Service. After scheduling the surgery with the surgical coordinator, the patient will be given pre-admission testing (PAT) paperwork to be completed. The patient schedules the PAT on his or her own with the primary care physician.The patient will be given the information for Dr. Koka's cardiology office if he or she has any problem getting the PAT done.
89169059|NCT02620358|Experimental|High Work of Breathing|"If patient has weaning criteria, a Spontaneous Breathing Trial (SBT) with T Tube for 2 hours will be done.~The patient will be extubated after the SBT if he has no criteria of SBT failure."
89169060|NCT02620358|Experimental|Low Work of Breathing|"If patient has weaning criteria a Spontaneous Breathing Trial (SBT) with Pressure Support Ventilation of 8 cmH2O for 30 minutes will be done.~The patient will be extubated after the SBT if he has no criteria of SBT failure."
89169061|NCT00698360||A|MDRD 10-30
89169062|NCT00698360||B|MDRD 30-60
89169063|NCT00698360||C|MDRD 60-80
89169064|NCT00698360||D|MDRD > 80
89169065|NCT02999074|Active Comparator|Resistance exercise|
89169066|NCT02999074|Active Comparator|Aerobic exercise|
89169067|NCT02999074|Other|Waitlist control|
89169068|NCT00693784|Experimental|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
89169069|NCT00693706|Experimental|GSK 1388442A Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of GSK 1388442A vaccine at Day 0. The GSK 1388442A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89169070|NCT00693706|Active Comparator|Fluarix Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of Fluarix® vaccine at Day 0. The Fluarix® vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
89169071|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 1)|Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 13 months), and 1 dose each of MMR and Hib (booster) at 13 months.
89169072|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 2)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months.~This group had an additional blood draw at the time of enrollment."
89169073|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 3)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months of age.~This group had an additional blood draw at 6-7 days after third dose of MenACWY-CRM."
89169074|NCT00746044||1|Healthy volunteers >18y, 20 male, 20 female
89169075|NCT00746200|Experimental|A|
89169076|NCT00746200|Sham Comparator|S|
89169077|NCT00746278|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
89169078|NCT00746278|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
89169079|NCT00746278|Active Comparator|3|Laparoscopic ovarian cystectomy using suture
89169080|NCT00746434|Active Comparator|1|Roflumilast cream 0.5%
89169081|NCT00746434|Placebo Comparator|2|Placebo cream
89169082|NCT02563366|Experimental|MSCs group|Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1*10^6/kg every week for four consecutive doses.
89169083|NCT02563366|Placebo Comparator|Control group|Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses.
89169084|NCT02563132|Experimental|Carbon dioxide insufflation colonoscopy (CO2)|Carbon dioxide during both insertion and withdrawal phase of the colonoscopy.
89169085|NCT02563132|No Intervention|Air insufflation colonoscopy (AI)|Air insufflation during both insertion and withdrawal phase of the colonoscopy.
89169086|NCT02563288|Active Comparator|Esmolol|Esmolol 500mcg/kg before induction in anesthesia following by 300mcg/Kg/min until extubation.
89169087|NCT02563288|Active Comparator|Dexmedetomidine|Dexmedetomidine 1mcg/Kg following by 0.7mcg/Kg/h until end of surgery.
89169088|NCT00711269|Experimental|SM-13496 (lurasidone HCl) 40mg|SM-13496 40 mg was administered orally once daily.
89169089|NCT00711269|Experimental|SM-13496 (lurasidone HCl) 80mg|SM-13496 80mg was administered orally once daily.
89169090|NCT00711269|Placebo Comparator|Placebo|Placebo was administered orally twice daily.
89169091|NCT00711269|Active Comparator|Risperidone|Risperidone was administered orally twice daily.
89169092|NCT01017445|Experimental|Quadricep strengthening exercise|Quadricep strengthening exercise
89169093|NCT01014793||Responders to cabergoline|patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)
89169094|NCT02697461|Experimental|Intrinsic Foot Arm|In arm 1, a randomized control trial will be used in the investigation of validity and reliability comparing multisegmented foot motion, clinical joint physiological and accessory motion, and morphologic foot measurements, and the effect of intrinsic foot strengthening on multisegmented foot function.
89169095|NCT02697461|Experimental|Joint Mobilization Arm|In arm 2, the investigation of group differences in clinical and laboratory measures of multisegmented foot motion and kinetics will use a case control design. A randomized controlled trial will be conducted in the study investigating joint mobilization, with the researcher performing the assessments and the provider performing the treatments blinded to group allocation
89169096|NCT00693472|Experimental|Part 1: Preladenant|Preladenant 25 mg every 12 hours for 13 days
89169097|NCT00693472|Placebo Comparator|Part 1: Placebo|Placebo every 12 hours for 13 days
89169098|NCT00693472|Experimental|Part 2: Preladenant|Preladenant 25 mg every 12 hours for 13 days
89169099|NCT00693472|Active Comparator|Part 2: Standard of Care|Anticholinergic agents or Propranolol as standard-of-care dosing regimen (supplied by the study site)
89169100|NCT02697149||intervention|patients undergoing nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography
89169101|NCT02697149||control|patients undergoing standard endoscopic retrograde cholangiopancreatography
89169102|NCT00622661|Other|1|Normal weight
89169103|NCT00622661|Other|2|Overweight
89169104|NCT00498433|Experimental|Aliskiren|"Part 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase (period 1) consisting of treatment with one tablet of placebo to aliskiren once daily (o.d.). This was followed by a 4 week treatment phase (period 2) consisting of treatment with 300 mg aliskiren o.d..~Part 2: Eligible randomized patients in this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks."
89169105|NCT00498433|Active Comparator|Amlodipine|"Part 1: After aliskiren treatment (period 2), each patient was entered into a second washout period (4 weeks) during which blood pressure was required to be ≤ 140/90 mmHg. If blood pressure exceeded 140/90 mmHg on two consecutive days (home monitoring) and was confirmed at the study center, the patient was entered into the amlodipine treatment period (period 3). In period 3, all patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.~Part 2: Eligible patients randomized to part 2 received amlodipine 5 mg o.d. and aliskiren placebo for 12 weeks"
89169106|NCT00639821||inflammatory bowel disease|Patients with refractory inflammatory bowel disease (ulcerative colitis and Crohn's disease) before and after treatment with infliximab.
89169107|NCT02565160||Septic Arthritis|Patients suspected of having septic arthritis
89169108|NCT02565160||Osteoarthritis|Patients suffering with osteoarthritis undergoing an intervention
89169109|NCT02565160||Joint Revision|Patients who has a prosthetic joint in situ
89169110|NCT02689583|Experimental|Successful treatment|The patients with H. pylori infection have successful treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
89169111|NCT02689583|Experimental|refractory infection|The patients with H. pylori infection have failed treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
89169112|NCT00498355|Experimental|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
89169113|NCT02564302|No Intervention|Control|These patients will not receive a device, but have to fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
89169114|NCT02564302|Experimental|Treatment Group|These patients will receive the device. they are expected to use it for at least 5 minutes per day. Patients in this arm will fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
89169115|NCT04327271|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
89169116|NCT04327271|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
89169117|NCT04539223|Active Comparator|Drug (Evolocumab)|Individuals randomized to this arm will administer Evolocumab subcutaneously (SC) every two weeks (Q2W) for 26 weeks.
89169118|NCT04539223|No Intervention|No Drug (Standard of Care)|Individuals randomized to this arm will not administer a placebo.
89169119|NCT00743080|Experimental|1|Laparoscopic myomectomy and supracervical hysterectomy using GYNECARE MORCELLEX
89169120|NCT00743080|Active Comparator|2|Laparoscopic myomectomy and supracervical hysterectomy using ROTOCUT G1
89169121|NCT03382769|Experimental|Group A (Immediate Cochlear Implantation)|Group A will consist of 30 individuals who are candidates for cochlear implantation. They will be unilaterally implanted immediately after initial study testing has been completed and then be followed for 12 months after device activation.
89169122|NCT03382769|Active Comparator|Group B (Delayed Cochlear Implantation)|Group B will consist of 30 individuals who are candidates for cochlear implantation. They will continue to wear hearing aids after enrolling in the study and then be unilaterally implanted 6 months after enrollment and followed for 6 more months after device activation.
89169123|NCT00746824|Experimental|1|"AM dose: 0.85 mg~PM dose: placebo"
89169124|NCT00746824|Experimental|2|"AM dose: 0.85 mg~PM dose: 0.85 mg"
89169125|NCT00746824|Experimental|3|"AM dose: 2.55 mg~PM dose: placebo"
89169126|NCT00746824|Experimental|4|"AM dose: placebo~PM dose: 2.55 mg"
89169127|NCT00746824|Experimental|5|"AM dose: 2.55 mg~PM dose: 2.55 mg"
89169128|NCT00746824|Experimental|6|"AM dose: placebo~PM dose: placebo"
89169129|NCT01011751|Experimental|Cyproterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
89169130|NCT01011751|Experimental|Medroxyprogesterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
89169131|NCT01011751|Experimental|Venlafaxine|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks.
89169132|NCT02686619|Active Comparator|Mycophenolate Mofetil + Cyclosporine|Participants will receive mycophenoate mofetil, daclizumab, cyclosporine, and corticosteroids (prednisolone) for 3 to 12 months.
89169133|NCT02686619|Experimental|Mycophenolate Mofetil + Sirolimus|Participants will receive mycophenoate mofetil, daclizumab, and corticosteroids (prednisolone) for 3 to 12 months. Participants will also receive cyclosporine which will be replaced with sirolimus at later stage of the study.
89169134|NCT00688636|Active Comparator|1|
89169135|NCT00688636|Placebo Comparator|2|
89169136|NCT00870740|Experimental|Group 1: DAC HYP 150 mg|Participants who received placebo in 205MS201 receive DAC HYP 150 mg subcutaneous (SC) injection every 4 weeks for a total of 13 doses.
89169137|NCT00870740|Experimental|Group 1: DAC HYP 300 mg|Participants who received placebo in 205MS201 receive DAC HYP 300 mg SC injection every 4 weeks for a total of 13 doses.
89169138|NCT00870740|Experimental|Group 2: Washout then DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 150 mg SC every 4 weeks for a total of 8 doses.
89169139|NCT00870740|Experimental|Group 2: DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 receive DAC HYP 150 mg SC every 4 weeks for a total of 13 doses.
89169140|NCT00870740|Experimental|Group 3: Washout then DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 300 mg SC every 4 weeks for a total of 8 doses.
89169141|NCT00870740|Experimental|Group 3: DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 receive DAC HYP 300 mg SC every 4 weeks for a total of 13 doses.
89169142|NCT02563210|Experimental|airway resistance measurement|interruption and plethysmography techniques airway resistance measurement at each routine visit
89169143|NCT01017523|Experimental|1 (Couples)|Diabetes self-management education, telephone support and behavior change for couples.
89169144|NCT01017523|Active Comparator|2 (Individual)|Diabetes self-management education, telephone support and behavior change for individuals.
89169145|NCT01017523|Placebo Comparator|3 (Control)|Diabetes self-management education only.
89169146|NCT02686853|Experimental|Intrathecal administration group|
89169147|NCT02565082|Experimental|Sickle cell disease|This arm will include an approximate number of 50 sickle cell disease patients, homozygous and heterozygous.
89169148|NCT02565082|Other|Control|This arm will include an approximate number of 30 healthy volunteers.
89169149|NCT02689505|Experimental|BI 836880|
89169150|NCT01017679|Experimental|1|Oral Drug gefitinib(Iressa) 500 mg Everyday
89169151|NCT01017679|Active Comparator|2|Oral Drug gefitinib(Iressa) 250 mg Everyday
89169152|NCT00743236|Experimental|Arm I|Patients undergo warm ischemia followed by partial nephrectomy.
89169153|NCT00743236|Experimental|Arm II|Patients undergo cold ischemia followed by partial nephrectomy.
89169154|NCT01017757||Renal transplant patients|
89169155|NCT04187339|Experimental|NGM395 Dose 1|NGM395 Subcutaneous Injection
89169156|NCT04187339|Experimental|NGM395 Dose 2|NGM395 Subcutaneous Injection
89169157|NCT04187339|Experimental|NGM395 Dose 3|NGM395 Subcutaneous Injection
89169158|NCT04187339|Experimental|NGM395 Dose 4|NGM395 Subcutaneous Injection
89169159|NCT04187339|Experimental|NGM395 Dose 5|NGM395 Subcutaneous Injection
89169160|NCT04187339|Experimental|NGM395 Dose 6|NGM395 Subcutaneous Injection
89169161|NCT04187339|Placebo Comparator|Placebo|Placebo
89169162|NCT00746902|Active Comparator|1|Arm 1: Active CPAP, a nasal continuous positive airway pressure
89169163|NCT00746902|Sham Comparator|2|Arm 2 : Sham CPAP :Placebo/CPAP
89169164|NCT01017835||statin treatment, isolated hypertension|treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
89169165|NCT01017835||placebo treatment, isolated hypertension|treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
89169166|NCT04130672|Other|Hot saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 50 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 50 ° C saline irrigation was applied.
89169167|NCT04130672|Other|Cold saline irrigation|. After adenoidectomy, tonsil tampon at room temperature or 22 ° C was placed in the nasopharynx. Five minutes later, the tampon was removed, and 22 ° C saline irrigation was applied.
89169168|NCT02686463|Experimental|the laparoscopy group|Patients who are randomized to the laparoscopy group.
89169169|NCT02686463|Experimental|the laparotomy group|Patients who are randomized to the laparotomy group.
89169170|NCT00869024|Experimental|Stem Cell therapy|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
89169171|NCT00869024|Placebo Comparator|Placebo|Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
89169172|NCT02685449|Placebo Comparator|group A|"On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal.~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
89169173|NCT02685449|Active Comparator|group B|"On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal.~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
89169174|NCT00697034|Experimental|1|Study subjects will be patients with chronic plaque-type psoriasis
89169175|NCT00506779|Experimental|Phase I: Paclitaxel + Imatinib Mesylate|Phase I MTD using oral dose Imatinib Mesylate escalation 400, 500, 600 mg daily; Paclitaxel 175 mg/m^2 every 21 days
89169176|NCT00506779|Experimental|Phase II: Paclitaxel Alone or Pacliataxel + Imatinib Mesylate|"Intended randomization of Paclitaxel alone or Paclitaxel + Imatinib Mesylate; the study was terminated early due to poor enrollment and all patients are no longer being treated or followed. Single treatment arm MTD using oral dose Imatinib Mesylate escalation = 500 mg daily; Paclitaxel 175 mg/m^2 every 21 days~Phase II, (Arm 1) = Paclitaxel 175 mg/m^2 every 21 days Phase II, (Arm 2) Paclitaxel 175 mg/m^2 every 21 days+ Imatinib Mesylate MTD using oral dose Imatinib Mesylate escalation = 500 mg daily"
89169177|NCT02689193||Salmonella|Patients for whom blood cultures grew Salmonella species.
89169178|NCT02689193||No pathogen|Patients for whom blood cultures did not grow a pathogen and no pathogen was detected using other routine care diagnostics (e.g. malaria with the use of a malaria rapid test).
89169179|NCT02689193||Another pathogen|Patients for whom blood cultures grew with another pathogen or a pathogen was detected using other routine care diagnostics (e.g. malaria with the use of malaria rapid test).
89169180|NCT02689193||Healthy controls|Healthy controls. Patients without fever but from whom blood is drawn for another reason (e.g. check of cholesterol).
89169181|NCT02616458|Experimental|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours. The research assistant provided and reviewed proper dosing instructions for acetaminophen and ibuprofen, and provided a prescription for antipyrine/benzocaine analgesic ear drops to each family to use as pain relief if their child did develop ear pain in the subsequent 12 months.
89169182|NCT02616458|Active Comparator|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
89169183|NCT02685371||Breathing effort type|Current known criteria for constrictive pericarditis will be test under: 1- spontaneous breathing 2- Breathing with a negative pressure of -15 to - 30 cm of water 3- Breathing with a negative pressure of more than - 30 cm of water.
89169184|NCT01017913|Active Comparator|Electrotherapy equipment|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms with two channels.
89169185|NCT01017913|Active Comparator|electrotherapy equipment|The CI was adjusted with 4000 HZ bases frequency, modulation frequency range 20 HZ, ∆F10 HZ, slope 1/1 and quadripolar manner.
89169186|NCT01017913|No Intervention|Control|The patients of the Control group stayed without any treatment in the same period
89169187|NCT02619968|Experimental|Experimental group|"Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application.~Application of the tourniquet Will be held in conjunction with exercises for the experimental group.~Tennis ball: will initially be 3 sets, where one series with 10 grips, increasing 5 grips every week, 60 seconds rest every series.~Halter: are performed with load of 1 kg, 2 kg and 3 kg. Handgrip: they will be performed 3 sets of dynamic manual hold exercises in the intensity of 40% of MVC.~Home program: at home will be performed isometric exercises with tennis ball on the same frequency as in performing ambulatory without applying the tensiometer."
89169188|NCT02619968|Sham Comparator|Group control|Will be held the same isometric and isotonic concentric ambulatory and home with the same duration, frequency and intensity, except is not to apply the tourniquet.
89169189|NCT00639977|Sham Comparator|2|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
89169190|NCT00639977|Active Comparator|1|20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming)
89169191|NCT00639977|No Intervention|3|
89169192|NCT04130360|Experimental|Problem-solving|
89169193|NCT04130360|No Intervention|Control|
89169194|NCT01017991|Experimental|Infant formula with probiotic|Infant formula with probiotic for 0 to 12 months of age
89169195|NCT01017991|Placebo Comparator|Standard infant formula|Infant formula for 0 to 12 months of age
89169196|NCT04185233|Experimental|iPad distraction|"Children of this group will receive the iPad when the nurse will prepare the material for the venous track. They will choose a game adapted to their age and will be able to play it during all the procedure time.~Intervention : game on iPad"
89169197|NCT04185233|Active Comparator|Nitrous Oxide|"Children of this group will receive the Nitrous Oxide 3 minutes before the intervention (venous track). They will keep the mask during all the procedure time.~Intervention : Nitrous Oxide"
89169198|NCT00639431|Experimental|1|Direct observation of a sequence of right foot movements performed by the experimenter while visualizing moving the amputated or phantom right foot.
89169199|NCT00639431|Experimental|2|Direct observation of a sequence of left foot movements performed by the experimenter while visualizing moving the amputated or phantom left foot.
89169200|NCT00639431|Experimental|3|Direct observation of a sequence of left and right foot movements performed by the experimenter while visualizing moving the amputated or phantom left and right feet.
89169201|NCT00639431|Experimental|4|Mental visualization with closed eyes of a sequence movements performed with the right amputated or phantom foot.
89169202|NCT00639431|Experimental|5|Mental visualization with closed eyes of a sequence movements performed with the left amputated or phantom foot.
89169203|NCT00639431|Experimental|6|Mental visualization with closed eyes of a sequence movements performed with the left and right amputated or phantom feet.
89169204|NCT04130282|Experimental|Group 1|8 volunteers receiving 3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
89169205|NCT00488293|Experimental|Arm 1|Store and forward teledermatology consult process
89169206|NCT00488293|No Intervention|Arm 2|Conventional consult process
89169207|NCT02614430|Active Comparator|Vocational training|Participants are randomized into the intervention group (training) where they are offered a training course of 4-9 weeks of physical training three times a week with a physiotherapist.
89169208|NCT02614430|No Intervention|Control|Participants are randomized into the control group where they are offered the standard treatment.
89169209|NCT04185077|Experimental|Experimental|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
89169210|NCT04185077|Active Comparator|Control|a bolus dose of 100 U/kg Heparin was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
89169211|NCT04527965|Experimental|Customized diet to reduce liver fat|Ad libitum diet high in plant-derived PUFA and lower in carbohydrates
89169212|NCT04527965|Experimental|Healthy Nordic diet|Ad libitum diet, based on Nordic foods, higher in carbohydrates (high fiber/low GI) and lower in fat but rich in monounsaturated fatty acids (MUFA) and PUFA
89169213|NCT04527965|Active Comparator|Control|Ad libitum diet in accordance with the Nordic Nutrition Recommendations
89169214|NCT01018069|Active Comparator|AEG35156|Patient receive AEG35156 prior to chemotherapy
89169215|NCT01018069|Sham Comparator|Control|Patients receive chemotherapy only
89169216|NCT02686307||ICD Implant|All patients receiving a dual chamber ICD
89169217|NCT00638339||1|critically ill patients undergoing invasive mechanical ventilation in medical ICU and CCU
89169218|NCT00638339||2|critically ill patients undergoing noninvasive mechanical ventilation in medical ICU and CCU
89169219|NCT02686385|Experimental|Prednisolone + N-Acetylcysteine|Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
89169220|NCT02686385|Active Comparator|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
89169221|NCT02686151|Active Comparator|letrozole|2.5mg/tablet(Jiangsu Hengrui Medicine Co., Ltd. products), orally taken 5mg once a day for 5 days
89169222|NCT02686151|Other|Polygeline Injection|500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection，once a day for 2 days
89169223|NCT00868790|Experimental|PLA→MK-3577 QD AM→MK-3577 QD PM→MK-3577 BID (Arm 1)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
89169224|NCT00868790|Experimental|MK-3577 QD AM→PLA→MK-3577 BID→MK-3577 QD PM (Arm 2)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
89169225|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 BID→PLA→MK-3577 QD AM (Arm 3)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed MK- 3577 25 mg BID for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
89169226|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD PM→MK-3577 QD AM→PLA (Arm 4)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
89169227|NCT00868790|Experimental|PLA→MK-3577 BID→MK-3577 QD AM→MK-3577 QD PM (Arm 5)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
89169228|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 QD PM→PLA→MK-3577 BID (Arm 6)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4.
89169229|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 QD AM→MK-3577 BID→PLA (Arm 7)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
89169230|NCT00868790|Experimental|MK-3577 BID→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 8)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
89169231|NCT00868790|Experimental|PLA→MK-3577 QD PM→MK-3577 BID→MK-3577 QD AM (Arm 9)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
89169232|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 BID→MK-3577 QD PM→PLA (Arm 10)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
89169233|NCT00868790|Experimental|MK-3577 QD PM→PLA→MK-3577 QD AM→MK-3577 BID (Arm 11)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
89169234|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD AM→PLA→MK-3577 QD PM (Arm 12)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
89169235|NCT00868790|Experimental|PLA→METF→MK-3577 QD AM→MK-3577 QD PM (Arm 13)|Domiciled participants were to receive oral treatment with dose-matched placebo to metformin (METF) for 4 weeks during Period 1, followed by metformin 1000 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Participants in this arm were administered metformin placebo during Period 1 and active metformin during Period 2.
89169236|NCT00868790|Experimental|METF→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 14)|Domiciled participants were to receive oral treatment with metformin 1000 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to metformin for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4. Participants in this arm were administered active metformin during Period 1 and metformin placebo during Period 2.
89169237|NCT00496483|Active Comparator|LCP-Tacro (tacrolimus)|Experimental: LCP Tacro; investigational product LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
89169238|NCT00697580|No Intervention|1|Control (C)
89169239|NCT00697580|Experimental|2|Nutrition (N)
89169240|NCT00697580|Experimental|3|Strength Training & Nutrition (ST + N)
89169241|NCT00697580|Experimental|4|Circuit Training & Nutrition (CT + N)
89169242|NCT02614352|Experimental|AG1502|
89169243|NCT02614352|Active Comparator|Candesartan + Atorvastatin|
89169244|NCT02616536|Active Comparator|Flipped classroom|The flipped classroom is new pedagogical method, which employs asynchronous video lectures and practice problems as homework and active, group-based problem solving activities in the classroom.
89169245|NCT02616536|Active Comparator|traditional classroom|The classroom lecture is a special form of communication in which voive, gesture. Movements, facial expression and eye contact can either complement or detract from the content. No matter what your topic, your delivery and manner of speaking immeasurably influence your student's' attentiveness and learning.
89169246|NCT02619890||Patients with glioma requiring treatment|Patients with glioma requiring treatment, who undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent
89169247|NCT01018147|Experimental|CT Imaging|Patients undergo 4-D, 4-dimensional computed tomography, CT imaging prior to radiotherapy sessions and once a week at the end of treatment.
89169248|NCT01011985||AVF|Initial access is an AVF
89169249|NCT01011985||AVG|Initial vascular access is an AVG
89169250|NCT01011985||TC|Initial vascular access is a tunneled catheter, with or without a maturing AVF or AVG
89169251|NCT04133246|Other|Group arm|Includes subjects enrolled in focus groups
89169252|NCT04133246|Other|Interview arm|Includes subjects with individual interviews
89169253|NCT01018225|Experimental|darifenacin|
89169254|NCT01018225|Placebo Comparator|Sugar Pill|
89169255|NCT00698438|Active Comparator|a|Implantation of Ex-PRESS mini glaucoma shunt under a scleral flap
89169256|NCT00698438|Active Comparator|b|Trabecolectomy
89169257|NCT03528551|Experimental|N8-GP, once weekly|All participants will receive turoctocog alfa pegol (N8-GP) once weekly.
89169258|NCT03528551|Experimental|N8-GP, twice weekly|All participants will receive N8-GP twice weekly.
89169259|NCT03528551|Experimental|N8-GP, three times weekly|All participants will receive N8-GP three times weekly.
89169260|NCT01018303|Experimental|Antioxidant-enriched multivitamin supplement|
89169261|NCT03996343|Experimental|Endotracheal intubation|
89169262|NCT03996343|Experimental|Laryngeal mask airway|
89169263|NCT00487981|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
89169264|NCT01014949|Other|Control, Diabetes and Metabolic Syndrome|
89169265|NCT02685137|Experimental|Active drug-Stannsoporfin|"Stannsoporfin, single dose 4.5mg/kg administered Intramuscular (parental injection in the thigh) for treatment of jaundice~20 mg/mL 1.5 mL/vial"
89169266|NCT02685137|Sham Comparator|Reference Therapy-Sham|Sham Injection, no injection followed by a Band-Aid to thigh
89169267|NCT01015027|Experimental|Dose 1|(3:1, active:placebo)
89169268|NCT01015027|Experimental|Dose 2|(3:1, active:placebo)
89169269|NCT01015027|Experimental|Dose 3|(3:1, active:placebo)
89169270|NCT01015027|Experimental|Dose 4|(3:1, active:placebo)
89169271|NCT01012063|Experimental|group IE|The group IE received iron sucrose and erythropoietin-β (Epo-β) during the operation
89169272|NCT01012063|Placebo Comparator|group C|The group C received saline as same method.
89169273|NCT04435327||Oxygen therapy|Patients who were hospitalised due to COVID-19 pneumonia and received only oxygen support therapy.
89169274|NCT04435327||Non invasive ventilation (NIV/CPAP)|Patients who were hospitalised due to COVID-19 pneumonia and received non invasive ventilation (NIV/CPAP) as maximum support therapy
89169275|NCT04435327||Invasive ventilation|Patients who were hospitalised due to COVID-19 pneumonia and received invasive mechanical ventilation (IMV)
89169276|NCT04105439||control|healthy subjects who do not have the disease
89169277|NCT04105439||patients with Behçet's disease|subjects who do have the disease ( Behçet's disease )
89169278|NCT02689115||Clinical activity|Patients with rheumatoid arthritis who met the criteria established by the American College of RheumatologyDisease Activity Score 28 (DAS28) > 3.6.
89169279|NCT02689115||Clinical remission|Patients with rheumatoid arthritis with Disease Activity Score 28 (DAS28) < 2.4.
89169280|NCT00861744|Experimental|Priorix 1 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 1) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
89169281|NCT00861744|Experimental|Priorix 2 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 2) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
89169282|NCT00861744|Experimental|Priorix 3 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 3) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
89169283|NCT00861744|Active Comparator|MMR-II Group|Subjects between 12 and 15 months of age at the time of study vaccination who randomly received one dose of one of three different commercially-available lot of M-M-R II (Merck and Co.) vaccine subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
89169284|NCT00638417|Experimental|maximal strength training|maximal dynamic strength training
89169285|NCT00638417|Other|conventional rehabilitation|rehabilitation as usual
89169286|NCT02685059|Experimental|MEDI4736|part 1: MEDI4736 (with half dose as monotherapy for the first two weeks) part 2: MEDI4736 1.5 g total for 20 weeks
89169287|NCT02685059|Placebo Comparator|Placebo|part 1: Placebo (for the first two weeks) part 2: Placebo for 20 weeks
89169288|NCT02685059|Active Comparator|Taxane|Nab-Paclitaxel 125 mg/m² weekly for 12 weeks
89169289|NCT02685059|Active Comparator|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
89169290|NCT02685059|Active Comparator|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
89169291|NCT00640055|Active Comparator|1|Coordinator (non-physician)
89169292|NCT00640055|Placebo Comparator|2|Physician
89169293|NCT02686073||Group A|Underweight participants whose body mass index is less than 18.5 kg/m2
89169294|NCT02686073||Group B|Control group, in which the participants belong to the normal body mass index range , from 18.5 to 29.9 kg/m2
89169295|NCT02686073||Group C|Obese participants whose body mass index is more than or equal to 30 kg/m2.
89169296|NCT00603239|Experimental|Exenatide twice daily (BID)|
89169297|NCT00603239|Placebo Comparator|Placebo|
89169298|NCT00700986|Experimental|1|
89169299|NCT00700986|Placebo Comparator|2|
89169300|NCT04119726|Other|Control Group|The control group will receive a simplified tool including only the education message. The methodology will ensure that potential confounders by differences in nonspecific support and attention could be adjusted. Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behavior. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
89169301|NCT04119726|Experimental|Intervention Group|The intervention group will receive a complete social medial tool (web-based application ) installed on mobile phones including general education about coronary disease、personalized reminders and internet-based counseling. Patients will be followed up for 4/8/12 months after admission through mHealth tools or telephone.
89169302|NCT04119882||Positive for ischaemia|Blood test for 121 patients with confirmed cardiac ischemic event
89169303|NCT04119882||Negative for ischaemia|Blood test for 283 patients with no cardiac ischemic event
89169304|NCT04186715||TOETVA|The demographic data of the patients undergoing TOETVA surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
89169305|NCT04186715||Open thyroidectomy|The demographic data of the patients undergoing open thyroidectomy surgery will be recorded. Then, blood pressure, pulse pressure, pulse oximeter, end-tidal carbon dioxide, right and left cerebral regional oxygen values in the operation room will be recorded at certain intervals. It will also be recorded if complications develop.
89169306|NCT00699114|Placebo Comparator|Placebo|Single dose placebo capsule
89169307|NCT00699114|Active Comparator|Ibuprofen 400 mg|Single dose ibuprofen 400 mg capsule
89169308|NCT00699114|Active Comparator|Ibuprofen 600 mg|Single dose ibuprofen 600 mg capsule
89169309|NCT00699114|Active Comparator|Ibuprofen 800 mg|Single dose ibuprofen 800 mg capsule
89169310|NCT00699114|Active Comparator|Paracetamol 500 mg|Paracetamol 500 mg (acetaminophen) capsule
89169311|NCT00699114|Active Comparator|Paracetamol 1000 mg|Single dose paracetamol 1000 mg (acetaminophen) capsule
89169312|NCT00699114|Active Comparator|Paracetamol 1000 mg + codeine 60 mg|Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule
89169313|NCT00700518|Placebo Comparator|1.|placebo cream applied to 2 adjacent fingers on non-dominant hand one time
89169314|NCT00700518|Active Comparator|2|0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand
89169315|NCT00700518|Active Comparator|3|1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
89169316|NCT00700518|Active Comparator|4|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time
89169317|NCT00700518|Active Comparator|5|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
89169318|NCT00852930|Experimental|laser alone|The intervention was therapist administered low level laser therapy using low level laser, number of sessions based upon patient response
89169319|NCT00852930|Active Comparator|mld alone|The intervention was therapist administered manual lymphatic drainage (mld) using standard massage techniques,number of sessions based upon patient response
89169320|NCT00852930|Experimental|laser and mld combined|The intervention was therapist administered low level laser and mld using low level laser and standard massage techniques, number of sessions based upon patient response
89169321|NCT00852540|Experimental|Retapamulin|
89169322|NCT00852540|Active Comparator|Linezolid|
89169323|NCT00701142|Active Comparator|Haemocomplettan® P|Intravenous infusion during aortic surgery
89169324|NCT00701142|Placebo Comparator|Saline solution|
89169325|NCT00700674||1|Entropy group
89169326|NCT00700674||2|Control
89169327|NCT00861198||ERCP|Patients who have a medical indication for ERCP with cholangioscopy and/or pancreatoscopy and are referred for the procedure as part of their standard medical care will be considered for the study.
89169328|NCT00847704|Experimental|Test treatment group|Device: Assisted movement and enhanced sensation
89169329|NCT02613702|Experimental|Modified Free Gingival Graft|Twenty patients will receive the modified free gingival graft technique at the inferior incisors area. In this technique, the graft is covered by a flap, similarly to what is done in a connective tissue graft surgery.
89169330|NCT02613702|Active Comparator|Original Free Gingival Graft technique|Twenty patients will receive the original technique of free gingival graft at the inferior incisors area.
89169331|NCT00701298|Active Comparator|Group 1 (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose disease is not responding after the first course may crossover to group 2.
89169332|NCT00701298|Experimental|Group 2 (chemotherapy and antineoplastic agent)|Patients receive decitabine as in group 1 and pegylated interferon alfa-2b subcutaneously on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89169333|NCT00860574|Experimental|Treatment (allogeneic transplantation)|CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
89169334|NCT00699270||Biomet Humeral Stems|Biomet Humeral Stems: Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems
89169335|NCT00496015|Experimental|Synflorix I Group|Subjects were vaccinated with 3 primary vaccination doses of Synflorix™ vaccine with prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa along with prophylactic antipyretic treatment.
89169336|NCT00496015|Experimental|Synflorix II Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment
89169337|NCT00496015|Experimental|Synflorix PRE Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (before the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
89169338|NCT00496015|Experimental|Synflorix POST Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (after the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
89169339|NCT00496015|Active Comparator|Mencevax + Infanrix Hexa Group|Age-matched pneumococcal vaccine unprimed group receiving a single dose of Mencevax™ vaccine co-administered with Infanrix™ hexa vaccine.
89169340|NCT01018381|Active Comparator|Conventional Therapy|Conventional therapy is given, including PEIT, TOCE, PEIT + TOCE, TOCE + RFA for hepatocellular carcinoma or Entecavir for hepatitis B virus.
89169341|NCT01018381|Experimental|Conventional Therapy plus MGN-3|
89169342|NCT00487825|Experimental|Canakinumab + Methotrexate|Canakinumab, human anti-interleukin-1beta monoclonal antibody plus Methotrexate (MTX). Intravenous (IV) Infusion of 600mg canakinumab on Day 1, 15 continuing every 4 weeks up to week 26. MTX was given as variable dosing regimen of 7.5 mg-15 mg weekly.
89169343|NCT00487825|Active Comparator|Methotrexate + placebo|Methotrexate (MTX) was given as variable dosing regimen of 7.5 mg-15 mg weekly. Intravenous (IV) Placebo Solution, given in the same mode of administration as the canakinumab solution.
89169344|NCT00487747|Experimental|Peginterferon Alfa-2a|
89169345|NCT00487435|Experimental|001|Tapentadol (CG5503) Extended Release (ER) 100 150 200 250 mg oral tablet twice daily for 52 weeks
89169346|NCT00487279|Experimental|ICD Group|ICD (Implantable Cardioverter Defibrillator)
89169347|NCT00487279|Other|Control Group|Medial Therapy
89169348|NCT04385875|Experimental|Vaccine group|ATI_extension will keep allocation from AELIX-002 for a separate description of the results.
89169349|NCT04385875|Placebo Comparator|Placebo group|ATI_extension will keep allocation from AELIX-002 for a separate description of the results.
89169350|NCT00495625|Experimental|Sunitinib Malate (SUO11248) Treatment|
89169351|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD|
89169352|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD|
89169353|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD|
89169354|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD|
89169355|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD|
89169356|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD|
89169357|NCT00847626|Active Comparator|Chlorthalidone 12.5 mg QD|
89169358|NCT00847626|Active Comparator|Chlorthalidone 25 mg QD|
89169359|NCT00847626|Experimental|Azilsartan medoxomil 20 mg QD|
89169360|NCT00847626|Experimental|Azilsartan medoxomil 40 mg QD|
89169361|NCT00847626|Experimental|Azilsartan medoxomil 80 mg QD|
89169362|NCT04115904|Experimental|Post-endodontic Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg takena week after. Incidence of flare ups after a single vsmultiple visits root canal treatments.
89169363|NCT04115904|Experimental|Acute pain|Acetaminophen 325 mg for Acute pain. Taken secondday after. Incidence of Post operative pain after rootcanal treatment in one vs two visits
89169364|NCT05297994|Experimental|Flu-M|200 volunteers were vaccinated with the Flu-M inactivated split influenza vaccine with a preservative
89169365|NCT05297994|Active Comparator|Vaxigrip|200 volunteers were vaccinated with the Vaxigrip® inactivated split influenza vaccine
89169366|NCT00851682|Other|Radical prostatectomy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo radical prostatectomy and have not received any preoperative treatment for prostate cancer.
89169367|NCT00851682|Other|Brachytherapy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo brachytherapy and have not received any preoperative treatment for prostate cancer.
89169368|NCT04116138|Experimental|Salovum|Salovum®, an egg powder enriched for anti secretory factor.
89169369|NCT04116762|Experimental|Intervention|Placement of TissuePatchDS-P™ at time of operation. No surgical drain is used.
89169370|NCT04116762|Active Comparator|Control|No use of TissuePatchDS-P™. Wound is closed with a surgical drain (Surgeon's choice) in situ.
89169371|NCT00860262|Experimental|telmisartan and amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
89169372|NCT00860262|Active Comparator|amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
89169373|NCT00860262|Active Comparator|telmisartan|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
89169374|NCT00701454||1|Healthy participants (physically and mentally).
89169375|NCT04119492|Experimental|CO-OP Treatment Group|Participants in the treatment group will receive occupational therapy once weekly for 10 weeks using the published protocol for the CO-OP approach.
89169376|NCT04119492|No Intervention|Waitlist Control Group|Participants in the waitlist control group not receive CO-OP intervention during this time. They will receive their CO-OP intervention 12 weeks after their baseline assessment.
89169377|NCT00700830||A|
89169378|NCT02613000||All enrolled patients/Group A|500 consecutive adult patients will be enrolled in Part A (clinical data)
89169379|NCT02613000||Patients with blood and urine sampling/Group B|Patients with informed consent signed (anticipated 200 out of 500 patients) will participate in Part A (clinical data) and B (intestinal-specific biomarkers from blood and urine)
89169380|NCT00860028|Experimental|Extended Varenicline Pretreatment|Arm 1 (Experimental) = 4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
89169381|NCT00860028|Experimental|Short-term Varenicline Pretreatment|Arm 2 (Experimental) = 3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
89169382|NCT00701532|Experimental|1|active
89169383|NCT00701532|Placebo Comparator|2|Placebo
89169384|NCT00859638|Experimental|Intervention Group|Rehabilitation self-management group, on-line self monitoring of physical function, and organizational capacity building.
89169385|NCT00859638|No Intervention|Case matched controls|Usual care in primary health care.
89169386|NCT00700908|Experimental|1|Automated telephone intervention
89169387|NCT00700908|Active Comparator|2|Usual care
89169388|NCT00846846|Experimental|Endeavor® Zotarolimus Eluting Coronary Stent|Endeavor® Zotarolimus Eluting Coronary Stent System
89169389|NCT00701610||1|All infants born in our hospital between August 2007 and August 2009 will participate.
89169390|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 10 mg|
89169391|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 50 mg|
89169392|NCT00863798|Placebo Comparator|Placebo|
89169393|NCT00697658||001|
89169394|NCT00859014|Experimental|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.
89169395|NCT00701688|Experimental|Dose Level 1|Palifermin 40 mcg/kg/day intravenous
89169396|NCT00701688|Experimental|Dose Level 2|Palifermin 60 mcg/kg/day intravenous
89169397|NCT00701688|Experimental|Dose Level 3|Palifermin 90 mcg/kg/day intravenous
89169398|NCT00699426|Active Comparator|Nexium + Yoghurt|
89169399|NCT00699426|Placebo Comparator|Nexium + Placebo|
89169400|NCT00699426|Placebo Comparator|Placebo+ Yoghurt|
89169401|NCT00699426|Placebo Comparator|placebo+placebo|
89169402|NCT00593606|Experimental|Rotigotine|Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.
89169403|NCT04119102|Experimental|Open Label Duobrii|Duobrii QD
89169404|NCT02614118|Active Comparator|Ketorolac tromethanine|10 mg oral Ketorolac tromethanine 45 minutes before root canal treatment
89169405|NCT02614118|Active Comparator|Acetaminphen & Ketorolac tromethamine|1000 mg Acetaminophen and 10 mg Ketorolac tromethamine oral 45 minutes before root canal treatment
89169406|NCT02614118|Placebo Comparator|Placebo|placebo 45 minutes before root canal treatment
89169407|NCT04127942|Experimental|platelet-rich plasma injection|1cc platelet-rich plasma(PRP) injection in the superior temporomandibular disk joint space by ultrasound guidance.
89169408|NCT04127942|Placebo Comparator|normal saline injection|1cc normal saline injection in the superior temporomandibular disk joint space by ultrasound guidance.
89169409|NCT04134416|Experimental|Anodal transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive 10 20-minute sessions while receiving REGIAplus (online). Group 1 will receive active stimulation (anodal stimulation, A-tDCS).The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
89169410|NCT04134416|Sham Comparator|Sham transcranial direct current stimulation|Group 2 will receive sham stimulation (S-tDCS). In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (REGIAplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the assay.
89169411|NCT04134182|Experimental|Nivolumab + Ipilimumab|Patients will receive a combination of ipilimumab, followed by nivolumab for 16 weeks.
89169412|NCT00870584|Experimental|Omalizumab|The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.
89169413|NCT00870584|Placebo Comparator|Placebo|Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol.
89169414|NCT02616224||Participants with unresectable LA/mBC|
89169415|NCT02614508|Experimental|Cohort A (buparlisib, ofatumumab)|Patients receive buparlisib PO QD on days 1-28 and ofatumumab IV on days 1, 8, 15, and 22 during of courses 1-2; and day 1 of courses 4-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89169416|NCT02614508|Experimental|Cohort B (buparlisib, ibrutinib)|Patients receive buparlisib as in Cohort A and ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89169417|NCT02613806|Experimental|D group (dexmedetomidine)|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion with microperfusion pump at the beginning of the surgery,and continued till end of surgery.
89169418|NCT02613806|Active Comparator|C group (saline)|The patients received equal volume normal saline by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
89169419|NCT02616068|Experimental|transdermal patch & placebo|transdermal patch 100 mg once a day for 7 days and placebo (for loxoprofen sodium 60 mg tablet) by mouth, every 8 hours for 7 days
89169420|NCT02616068|Active Comparator|loxoprofen sodium & placebo|loxoprofen sodium 60 mg by mouth, every 8 hours for 7 days and placebo (for transdermal patch 100 mg) once a day for 7 days
89169421|NCT04127084|Experimental|normal albuminuria|baseline urinary albumin creatinine ratio [UACR]< 30 mg/g
89169422|NCT04127084|Experimental|moderately increased albuminuria|baseline UACR 30~300 mg/g
89169423|NCT04127084|Experimental|severely increased albuminuria|baseline UACR>300mg/g
89169424|NCT04127084|No Intervention|blank Comparator|normal participant
89169425|NCT04126928|Other|Participant|Each participant will go through (i) screening using DMFT and PUFA, (ii) orthopantomography assessment using PAI, and (iii) comprehensive clinical examination to derive pulpal and periapical diagnoses
89169426|NCT02615834|No Intervention|Control group|
89169427|NCT02615834|Active Comparator|Study group|
89169428|NCT00870194|Experimental|1|
89169429|NCT00870194|Placebo Comparator|2|
89169430|NCT00690430|Active Comparator|Pasireotide LAR|Patients assigned to pasireotide LAR will receive a 60 mg dose of pasireotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 40 mg is permitted if tolerability issues arise. In addition, after 24 hours of the first LAR injections the patients were permitted to use pasireotide s.c. formulation for breakthrough symptoms as needed.
89169431|NCT00690430|Active Comparator|Octreotide LAR|Patients assigned to octreotide LAR will receive a 40mg dose of octreotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 30 mg is permitted if tolerability issues arise. Patients requiring a dose reduction are to return to the higher dose once the tolerability issue is resolved, if required for efficacy In addition, after 24 hours of the first LAR injections the patients were permitted to use octreotide s.c. formulation for breakthrough symptoms as needed.
89169432|NCT02619656|Experimental|Treatment|"Patients randomized to insufflation with CO2.~Intervention: CO2 Insufflation with CO2Efficient Endoscopic Insufflator on managed flow setting at 3.4 L/min"
89169433|NCT02619656|Active Comparator|Control|"Patients randomized to insufflation with ambient air.~Intervention: Ambient air insufflation with Evis Exera 111 CLV-190 on medium air flow setting 0.68 L/min"
89169434|NCT02619734|No Intervention|Control|Conventional treatment established by the good clinical practice Patients received standard local care dressing method (compresses) to heal leg ulcers
89169435|NCT02619734|Experimental|Stem Cell Injection|Intramuscular implantation of Autologous bone marrow-derived mononuclear cells
89169436|NCT04060186|Active Comparator|Balloninflation Group|Patient who will perform a balloninflation after operation
89169437|NCT04060186|Sham Comparator|Conservative Group|Patient without performing a balloninflation
89169438|NCT03890146||intensive care patients|patient hospitalised in intensive care unit veinous and capillary ponction
89169439|NCT02619500|Experimental|Thrust Manipulation|Subjects in this arm will receive spinal thrust manipulation to both the cervical and thoracic spines.
89169440|NCT02619500|Active Comparator|Non-thrust Mobilizations|Subjects in this arm will receive spinal non-thrust mobilizations to both the cervical and thoracic spines
89169441|NCT04126304||Common cold|A cold is a clinical diagnosis.Complaints may include a stuffy nose, sore throat, cough and headache.Objective signs are rare, but may include fever, enlarged anterior cervical lymph nodes, nasal mucosa and oropharyngeal erythema, and nasal mucus.
89169442|NCT04126304||acute bronchitis|In 2011, the European society of respiratory diseases (ERS) defined acute disease in patients with non-chronic lung disease. Symptoms include cough, with or without expectoration of phlegm, and other symptoms and signs may indicate lower respiratory tract infection and cannot be explained by other diseases (e.g., sinusitis, asthma).The main symptoms of acute bronchitis are cough, may be accompanied by fever, fatigue, asthma and dyspnea.
89169443|NCT04126304||Post-infection cough|The definition in the 2013 guidelines for diagnosis and treatment of chronic cough in Chinese children: cough refers to a recent history of respiratory tract infection;The cough lasted > for 4 weeks, presenting an irritating dry cough or a little white phlegm.Chest x - ray examination showed no abnormality or only increased lung veins.The pulmonary ventilation function was normal, or presented transient high airway response.Coughs are usually self-limited, and other diagnoses should be considered if the cough is more than 8 weeks old.In addition to other causes of chronic cough.
89169444|NCT04126304||community-acquired pneumonia|According to the 2019 guidelines for the diagnosis and treatment of community-acquired pneumonia in children, it is defined as infectious pneumonia developed outside the hospital (community), including pneumonia developed after admission due to infection of pathogens with a clear incubation period outside the hospital (community).
89169445|NCT02677792|Experimental|Behavioral Family Intervention (BFI)|
89169446|NCT00746980|Experimental|Treatment|Subjects receiving drug
89169447|NCT00863330|Experimental|Determine toxicity of treatment regimen.|
89169448|NCT02563054|Active Comparator|5-Fluorouracil + Cisplatin|Participants will receive 5-FU in combination with cisplatin upto disease progression.
89169449|NCT02563054|Experimental|Capecitabine + Cisplatin|Participants will receive capecitabine in combination with cisplatin upto disease progression.
89169450|NCT02614040|Active Comparator|0.9% Saline|Patients in a month randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
89169451|NCT02614040|Active Comparator|Physiologically-balanced|Patients in a month randomized to physiologically-balanced isotonic fluid will receive physiologically-balanced isotonic crystalloid (Plasma-Lyte© A or Lactated Ringer's) whenever isotonic intravenous fluid administration is ordered by the treating provider.
89169452|NCT00698594|Active Comparator|1|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
89169453|NCT00698594|Active Comparator|2|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
89169454|NCT00698594|Placebo Comparator|3|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
89169455|NCT00743470|Experimental|A, B|Group 1 receives regimen A and B. A: Healthy volunteers, receiving one 150 mg rifabutin QD alone. B: Healthy volunteers, receiving 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
89169456|NCT00743470|Experimental|C|Group 2 receives regimen C. C: 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
89169457|NCT02613962|Experimental|relapsed or refractory pediatric tumor|This is a prospective, international, multicentric clinical proof-of-concept study to stratify targeted therapies adapted to molecular profiling of relapsed or refractory pediatric tumors. The molecular screening will be done on a newly biopsied or resected tumor sample obtained at the time of relapse/progression, using high-throughput technologies, primarily WES and RNA Sequencing, and bioinformatics analysis.
89169458|NCT00688324|Experimental|Single Arm|All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.
89169459|NCT02619578|Other|TEAS Group|TEAS consisted of 30 min of stimulation (12-15 mA, 2/100 Hz) at the Hegu (L14) and Neiguan (PC6) before anesthesia. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
89169460|NCT02619578|Other|Con Group|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
89169461|NCT02562820|Experimental|Ketamine|Subjects will receive intravenous infusion of a 0.1, 0.5, 1.0, 2.0 or 4.5 mg/kg dose over the course of 40 minutes
89169462|NCT02562820|Placebo Comparator|Placebo|Subjects will receive an intravenous infusion of normal saline over the course of 40 minutes
89169463|NCT02615912|Other|Surfactant Exposure|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5% Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5% Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5% Silwet* DA-63 (Momentive) 1.5% Sodium lauryl sulfate (Sigma Aldrich) 1.0% Water
89169464|NCT02615756|Experimental|Physical exercise|
89169465|NCT04133090|Active Comparator|Autogenous block bone graft|Surgical site as control group was treated with autogenous block bone graft. Augmentation site was covered with a mixture of particulate allograft and leukocyte and platelet-rich fibrin (L-PRF) membrane.
89169466|NCT04133090|Active Comparator|i-PRF enriched allograft material+screw tent pole technique|Surgical site as test group was treated with injectable platelet rich-fibrin (i-PRF) enriched allograft material. To avoid soft tissue collapse, screws were used. Augmentation site was covered with leukocyte and platelet-rich fibrin (L-PRF) membrane.
89169467|NCT02619422|Other|Intensivo|intensive cardiac rehabilitation program in less time
89169468|NCT02619422|No Intervention|Convencional|standard cardiac rehabilitation program
89169469|NCT04123652|Other|Lidocaine and ketamine infusion|
89169470|NCT00862940|Experimental|Memantine|
89169471|NCT00862940|Placebo Comparator|Placebo|
89169472|NCT04122716|Active Comparator|Liraglutide + exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
89169473|NCT04122716|Other|Liraglutide + non-exercise|"Liraglutide: 3 mg/day sc. The GLP-1 RA, liraglutide (3.0 mg), or placebo, will be administrated once daily as subcutaneous injections in the abdomen or thigh. The starting dose is 0.6 mg with weekly increments of 0.6 mg until 3.0 mg is achieved. The titration procedure will be prolonged for participants who do not tolerate fast up-titration. Participants who do not tolerate the 3.0 mg dose may in special circumstances stay at lower dose (2.4 mg). However, the aim is to reach 3.0 mg for all study participants.~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
89169474|NCT04122716|Other|Placebo + exercise|"Placebo: 3mg/day sc.~Exercise: 150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations."
89169475|NCT04122716|No Intervention|Placebo + non-exercise|"Placebo: 3mg/day sc.~Non-exercise: Participants should stay at same physical activity level (i.e. max. 2 h of vigorous endurance training/week) as when the participant was included in the study."
89169476|NCT00868166|Experimental|Olesoxime|2 Capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzole 50mg bid
89169477|NCT00868166|Placebo Comparator|Placebo Comparator|2 Capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
89169478|NCT00698672|Active Comparator|2|articulation Spectron EF CoCr/ Reflection All-Poly Eto-sterilized
89169479|NCT00698672|Active Comparator|3|articulation Spectron Ef CoCr/ Reflection All-Poly XLPE
89169480|NCT00698672|Active Comparator|4|articulation Spectron EF Oxinium/ Reflection All-Poly Eto-sterilized
89169481|NCT00698672|Active Comparator|5|articulation Spectron EF Oxinium/ Reflection XLPE
89169482|NCT00698672|Active Comparator|1|articulation Charnley/ Ogee
89169483|NCT00858780|Active Comparator|1|50mg once weekly + methotrexate
89169484|NCT00858780|Active Comparator|2|25mg once weekly + methotrexate
89169485|NCT00858780|Placebo Comparator|3|once weekly + methotrexate
89169486|NCT04132856|Experimental|Intervention Group|The Intervention group will receive the services of the Psychosocial Navigator (PSN) monthly for the full 12 months of the study. At baseline, the PSN will provide the health care providers (HCPs) and family with recommendations for mapping and triaging of resources to levels of psychosocial risk (PAT: Universal, Targeted, Clinical) and level of depression and anxiety (mild, moderate, and high mental health problems; as determined by the standardized norms for the measures). This information will be summarized in the Communication Summary Profile and shared with the treating team (oncologist, nurse, and Social Worker, core psychosocial staff involved in the child's care) and family within 48 hours of completion. The PSN will conduct follow-up psychosocial screenings on a monthly basis, using the Distress Thermometer for children and caregivers. Results of the monthly assessments and recommended resources will also be communicated to the caregiver/parent and treating team of the youth.
89169487|NCT04132856|No Intervention|Treatment as Usual Group|Current psychosocial care services will be accessible to Treatment as Usual Group (e.g., social work, child life, psychology, art and music therapy, and psychiatry).
89169488|NCT00698750||Copeland™ Humeral Resurfacing Head|Copeland™ Humeral Resurfacing Head
89169489|NCT02619188||Hyperemesis gravidarum|Hyperemesis gravidarum patients admitted to hospital PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis), Intervention at discharge : PUQE-form, Nutritional form and Blood sampling
89169490|NCT02619188||Control: Healthy pregnant women|Outpatients NOT subjected to severe nausea and emesis (PUQE-score <13). PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis).
89169491|NCT02615678|Experimental|Acupuncture|Acupuncture including scalp needling will be applied to selected points based on literature
89169492|NCT02613234|Experimental|Experimental Group|Active Intervention on brain waves by cathode tDCS
89169493|NCT02613234|Sham Comparator|Control Group|Sham Intervention on brain waves by cathode tDCS
89169494|NCT02619266|Experimental|Acupuncture+Placebo|Acupuncture once daily for 7 days and Placebo tablet by mouth, twice a day for 7 days.
89169495|NCT02619266|Active Comparator|Megestrol Acetate+Sham acupuncture|Megestrol Acetate tablet 160mg by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
89169496|NCT02619266|Placebo Comparator|Placebo+Sham acupuncture|Placebo tablet by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
89169497|NCT00850200|Experimental|Proton Radiation Plan|
89169498|NCT00850200|Active Comparator|Conventional Photon Radiation Plan|
89169499|NCT00850200|Active Comparator|Intensity Modulated Radiation Plan|
89169500|NCT02618954|Other|Study patient|Articular ultrasound at each study follow-up
89169501|NCT02619110|Other|backward walking treadmill training|The intervention group not only received four weeks of conventional physical therapy but also accepted additional four weeks of backward walking treadmill training at the same time
89169502|NCT02619110|Other|conventional physical therapy|The conventional physical therapy training focused on strengthening, postural control, functional mobility and forward gait training program but excluded backward walking training
89169503|NCT02612766|Other|Single Arm|This is a single-arm interventional study, in which each patient gets 50 grams/day of pure, uncontaminated oats
89169504|NCT04122092||MM patients have curative effect at least VGPR|We will detect cfDNA CIN of multiple myeloma patients who have the curative effect at least very good partial response (VGPR) after front line therapy, and then monitoring cfDNA CIN every two treatment cycles or every three months during follow up，the result will be compared with bone marrow aspiration MFC.
89169505|NCT02613156||laparoscopic group|patients in the laparoscopic group underwent laparoscopic resection of recurrent HCC
89169506|NCT02613156||control group|patients in the control group underwent conventional open surgery
89169507|NCT00698906|Experimental|Group A|
89169508|NCT00698906|Experimental|Group B|
89169509|NCT00698906|Experimental|Group C|
89169510|NCT00698906|Experimental|Group D|
89169511|NCT00698906|Experimental|Group E|
89169512|NCT00698906|Active Comparator|Group F|
89169513|NCT04118946|Active Comparator|intravesical instillation|Intravesical instillation of platelet enriched plasma every week for 6 weeks
89169514|NCT04118946|Active Comparator|submucosal injection|submucosal injectionof platelet enriched plasma
89169515|NCT00698984|Active Comparator|1|30 mg BONISTEIN(R) 150 ug Vitamin K1 800 IU Vitamin D3 1000 mg PUFA 500 mg Calcium
89169516|NCT00698984|Placebo Comparator|2|500 mg Calcium
89169517|NCT04116060|Experimental|Nitrate|Dietary nitrate dissolved in water (0,12 mmol sodium-nitrate/kgBW/day) Dietary Supplement: Dietary nitrate 200 ml tab water with 0,12 mmol/kgBW sodium-nitrate
89169518|NCT04116060|Placebo Comparator|Control|Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day) Dietary Supplement: Dietary sodium-chloride 200 ml tab water with 0,12 mmol/kgBW sodium-chloride
89169519|NCT00699062|Placebo Comparator|Placebo pill|The patients allocated into this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator plus placebo for 6 months.
89169520|NCT00699062|Experimental|Singular pill|The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and montelukast for 6 months
89169521|NCT02619032|Active Comparator|Remifentanil|Drug: Remifentanil (Ultiva). Intraoperative intravenous infusion of remifentanil 0.5-1 μg/kg/min for up to 1 h.
89169522|NCT02619032|Active Comparator|Fentanyl|Drug: Fentanyl (FNT). Intraoperative administration of fentanyl given as one single bolus dose of 50 μg at the time of induction of anesthesia.
89169523|NCT00858234|Experimental|Vorinostat + Bortezomib|Participants undergo up to 3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg once daily [QD] on Days 1 through 14) + bortezomib (1.3 mg/m^2 intravenous [IV] on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m^2 IV on Days 1, 4, 8, and 11).
89169524|NCT00697814|Experimental|Clomiphene|Clomiphene 50 mg/day for 12 weeks
89169525|NCT04116450|Other|primary congenital glaucoma|Glaucolight illuminated microcatheter trabeculotomy in primary congenital glaucoma
89169526|NCT00701844|Experimental|Experimental Writing Type 1|
89169527|NCT00701844|Experimental|Experimental Writing type 2|
89169528|NCT00701844|Active Comparator|Control writing type 1|
89169529|NCT00701844|Placebo Comparator|Control writing type 2|
89169530|NCT04115592|Experimental|Liquid oil type 1|Cocoa butter (CB)
89169531|NCT04115592|Experimental|Solid oil type 1|Cocoa butter oleogel (CBOG)
89169532|NCT04115592|Experimental|Liquid oil type 2|Sal seed oil (SL)
89169533|NCT04115592|Experimental|Solid oil type 2|Sal seed oleogel (SLOG)
89169534|NCT00862082|Experimental|PR104 + Sorafenib|PR104 will be administered IV once every four weeks, in addition to 400mg sorafenib PO twice daily
89169535|NCT00692770|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
89169536|NCT00692770|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
89169537|NCT00849108|Experimental|Cohort 1: dose range and dose interval|Patients to receive either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during pharmacological or exercise stress, over a 1-day or 2-day period.
89169538|NCT00849108|Experimental|Cohort 2: Pharm&exercise stress Efficacy|"Patients to receive 2 IV bolus injections of BMS747158:1 at rest and 1 at stress~For the Pharmacologic (Adenosine) Stress:~Doses at rest to range between 2.9 and 3.4 mCi.~Doses under stress to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~Doses at rest were to range between 1.7 and 2.0 mCi.~Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
89169539|NCT00867308|Experimental|Lenalidomide 15 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 15 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
89169540|NCT00867308|Experimental|Lenalidomide 50 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 50 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
89169541|NCT00849186|Experimental|Arm 1|
89169542|NCT04119908|Experimental|Patients with haemorrhagic disease|Patients with von Willebrand disease or Patients with Glanzmann Thrombasthenia
89169543|NCT04119908|Other|Control group|Patients with moderate or severe hemophilia A or women carrying the hemophilia gene
89169544|NCT02613078|Experimental|Gut-Directed Hypnotherapy (GDH)|Gut-Directed Hypnotherapy on a daily basis (20 min each day, at least 4 times/week)
89169545|NCT02613078|Experimental|Probiotic (NS)|Nutritional supplement SymbioLact B once a day diluted in water or tea
89169546|NCT02613078|Active Comparator|Active Controls (AC)|AC group keeps a symptom dairy (self-monitoring)
89169547|NCT02618876|Active Comparator|Nalbuphine group|30 children will be given Caudal Bupivacaine plus Nalbuphine.
89169548|NCT02618876|Other|Control group|30 children will be given Caudal Bupivacaine.
89169549|NCT04132700|Experimental|ICU Patients|Patients admitted to the ICU will be monitored using the Q-NRG for up to 30 mins.
89169550|NCT04120142|Experimental|IMT goup|Inspiratory muscle training + aerobic exercice
89169551|NCT04120142|Active Comparator|Control group|aerobic exercice
89169552|NCT00743548|Active Comparator|1|Interdental brush (IB), the intervention is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
89169553|NCT00743548|Placebo Comparator|2|Dental floss (DF), the positive control, is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
89169554|NCT04132622|Experimental|Experimental therapy group|Besides Traditional therapy，patients in this group will also receive thyroid replacement therapy.
89169555|NCT04132622|Sham Comparator|Traditional therapy group|Patients in Standard therapy group will receive treatments according to guideline worldwide.
89169556|NCT00743626|Other|1|Healthy patients screened for cervical cancer
89169557|NCT02562976||early gastric cancer group|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia in patients with early gastric cancer or high-grade neoplasia(HGN)
89169558|NCT02562976||non-early gastric cancer group|patients diagnosed as non- gastritis, gastritis or low-grade neoplasia (LGN) by pathology were defined as non-EGC group
89169559|NCT04119752|Active Comparator|Curcumin powder|Curcumin powder - 10g
89169560|NCT04119752|Placebo Comparator|Placebo ( curcumin depleted)|Placebo- sucralose -1g
89169561|NCT00747058|Experimental|healthy volunteers|
89169562|NCT00747058|Placebo Comparator|Placebo|
89169563|NCT00866918|Experimental|Arm I (standard risk, combination chemotherapy)|See Detailed Description
89169564|NCT00866918|Experimental|Arm II (high risk, combination chemotherapy)|See Detailed Description.
89169565|NCT03158285|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.
89169566|NCT03158285|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.
89169567|NCT03158285|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.
89169568|NCT00861692|Experimental|Argatroban|
89169569|NCT03157973|Experimental|Education intervention|
89169570|NCT03157973|No Intervention|Standard of Care|
89169571|NCT02684747|Experimental|Treatment - Autologous Transfusion|Participants will be randomized to the treatment group (autologous transfusion)
89169572|NCT02684747|Placebo Comparator|Control - Normal Saline (Placebo)|Participants will either be randomized to the control group (saline transfusion)
89169573|NCT04422821|Experimental|FreeStyle Libre™|FreeStyle Libre™ will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will receive subcutaneous sensor for glucose monitoring (FreeStyle Libre™; Abbott Diabetes Care, Alameda, CA) for 4 weeks.
89169574|NCT04422821|Active Comparator|iXell®|iXell® will comprise 50 pregnant women between 24-28 weeks of gestation, diagnosed with gestational diabetes mellitus, who will monitor glycemia through use of standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) for 4 weeks.
89169575|NCT02685917|Experimental|Microfracture with Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
89169576|NCT02685917|Active Comparator|Microfracture without Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
89169577|NCT02689037|Experimental|stenting+medical treatment|Patients in PTAS+MT group will receive Percutaneous transluminal angioplasty and stenting and medical treatment (aspirin 100mg daily and clopidogrel 75mg daily)
89169578|NCT02689037|Active Comparator|Aspirin plus clopidogrel|Patients in aspirin plus clopidogrel group will receive aspirin 100mg daily and clopidogrel 75mg daily for 90 days.
89169579|NCT04184921||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
89169580|NCT04184921||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
89169581|NCT00602927|Placebo Comparator|Placebo|
89169582|NCT00602927|Active Comparator|Varenicline|
89169583|NCT00639743|Experimental|group A|tenecteplase (group A)
89169584|NCT00639743|Placebo Comparator|group B|placebo ( group B)
89169585|NCT02684513|Active Comparator|Oral Carbohydrate Beverage Group|Subjects assigned to this group will receive 710 mL of a preoperative beverage the evening prior to surgery and 355 mL the morning of surgery.
89169586|NCT02684513|Active Comparator|Rehydration Beverage Group|Subjects assigned to this group will receive 710 mL of re-hydration beverage the evening prior to surgery and 355 mL the morning of surgery.
89169587|NCT02684513|No Intervention|Fasted Controls|Subjects assigned to this group will fast for ≥8 hours prior to surgery.
89169588|NCT02685683|Experimental|GED-0301 Induction (160mg) followed by intermittent 160 mg|"GED-0301 160 mg by mouth (PO) daily (QD) for 12 weeks, followed by alternating GED 0301 160 mg QD for 4 weeks and no IP for 4 week, up to Week 100"
89169589|NCT00602537|Experimental|I|Antidepressant therapy
89169590|NCT00602537|Active Comparator|II|Mood stabilizer therapy
89169591|NCT02685839|Active Comparator|Traditional rehabilitation|"Each subject will do traditional rehabilitation work two times per week and one hour at a time~, lasting 24 weeks."
89169592|NCT02685839|Experimental|Power rehabilitation|Each subject will do Power rehabilitation work with motion tracking and biofeedback recording two times per week and one hour at a time, lasting 24 weeks.
89169593|NCT02688803|Active Comparator|Dose dense AC-P|Dose dense AC-P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
89169594|NCT02688803|Active Comparator|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
89169595|NCT02688803|Active Comparator|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
89169596|NCT00638495|Experimental|1|
89169597|NCT00638495|Placebo Comparator|2|
89169598|NCT03041363|Experimental|Triheptanoin|Dose 1 C7 administered as 40% daily caloric intake. Dose 2. C7 administered as 45% daily caloric intake.
89169599|NCT02688725|Experimental|Ultrasound|post mastectomy ultrasound
89169600|NCT02976935||Healthy Volunteers|Subjects will receive 1L non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath while the MRI scan is performed. Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2:Identical to Study Visit 1 but with the further series of inhalations being up to a maximum of 4 (maximum total exposure to hyperpolarised 129Xenon will be 5L).Optional Study Visit #3: Identical to Study Visit 2 (maximum total exposure to hyperpolarised 129Xenon will be 5L)
89169601|NCT02976935||Chronic Obstructive Pulmonary Disease|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
89169602|NCT00861614|Active Comparator|Ipilimumab|
89169603|NCT00861614|Placebo Comparator|Placebo|
89169604|NCT00485173|Experimental|INFUSE® Bone Graft|In this arm, patients will receive implant with INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate.
89169605|NCT00495469|Experimental|GSK189075|Participants will receive GSK189075 for 12 weeks
89169606|NCT00495469|Placebo Comparator|Placebo|Participants will receive GSK189075 matching Placebo for 12 weeks
89169607|NCT00861380|Experimental|10Pn3+1-6W- 6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
89169608|NCT00861380|Experimental|10Pn2+1-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
89169609|NCT00861380|Active Comparator|Ctrl-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to either a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule), or according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
89169610|NCT00861380|Experimental|10Pn7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
89169611|NCT00861380|Active Comparator|Ctrl7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
89169612|NCT00861380|Experimental|10Pn12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
89169613|NCT00861380|Active Comparator|Ctrl12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
89169614|NCT00495391|Active Comparator|1|Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
89169615|NCT00495391|Placebo Comparator|2|Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
89169616|NCT04378621|Experimental|Pharmacological anti-inflammatory treatment|Use of anti-rheumatic treatment with TNF-α inhibitor (subcutaneous injection given once or twice a week) or JAK inhibitor (per oral tablet once or twice a day)
89169617|NCT04378621|Experimental|Physical hand training|Physical hand training 10 min twice daily while on stable treatment
89169618|NCT00869960|Experimental|Antiretroviral therapy|Healthy volunteers received two doses of Tenofovir, Emtricitabine, Atazanavir and Ritonavir administered twice (on day 6 - 10 and day 20 - 25 after day of Follicular phase); with pharmacokinetic measurements at 6 - 10 days after menses and then again at day 20 - 25 after menses.
89169619|NCT02618486|Experimental|Obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
89169620|NCT02618486|Active Comparator|Non obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
89169621|NCT02615444|Experimental|Beta-glucan enriched oatcake|Oatcakes which have been enriched with beta-glucan. Each participant will consume 5 oatcakes daily in order to ingest 4g of oat-beta glucan.
89169622|NCT02615444|Placebo Comparator|Isocaloric control|Control: Wheat based snack, equicaloric and matched to intervention product for macronutrient content. Contains no oat-beta glucan. Each participant will consume 6.5 Krackawheats daily.
89169623|NCT02618564|Active Comparator|2 TABS QHS|Sennosides 2 tabs, taken two nights before the colonoscopy
89169624|NCT02618564|Active Comparator|3 TABS QHS|Sennosides 3 tabs, taken two nights before the colonoscopy
89169625|NCT02618564|Active Comparator|2 TABS AM|Sennosides 2 tabs, taken the morning before the colonoscopy
89169626|NCT02618564|Active Comparator|3 TABS AM|Sennosides 3 tabs, taken the morning before the colonoscopy
89169627|NCT02618564|Active Comparator|2 TABS AM & QHS|Sennosides 2 tabs taken the morning before and 2 tabs taken the evening before the colonoscopy.
89169628|NCT02615366|Active Comparator|Tranexamic Acid|Tranexamic acid will be provided as an intravenous infusion (1g in 100mL 0.9% NaCl solution [1% TXA] at 5 ml/min) 20 minutes pre-operatively, followed by an additional intravenous dose of the same dosing parameters postoperatively. Oral tablet doses containing 1 g of TXA (2x 500mg tablets) per dose will be administered to the patient to be taken orally by the patient according to a standard regimen; the first tablet dose will be taken on the same day as the surgery, in the evening. The patient will then take one tablet dose three times a day for a total of five days following the surgery (one dose in the morning, one dose mid-day, and one dose in the afternoon) for a 6 day total regimen.
89169629|NCT02615366|Placebo Comparator|Placebo Control|Placebo control will be either 100 ml of 0.9% NaCl solution or tablets of similar appearance containing no medicinal ingredients; placebo will be administered according to the same regimen as the intervention group.
89169630|NCT00699296|Experimental|1|
89169631|NCT00494299|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.
89169632|NCT00494299|Placebo Comparator|Placebo|Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).
89169633|NCT02618330|Experimental|retainer: 0.75-mm-thick film|
89169634|NCT02618330|Experimental|retainer: 1.00-mm-thick film|
89169635|NCT05298176|Experimental|Patients with untreated EGFR positive NSCLC tumors|TKI-naïve advanced NSCLC patients, harboring a non-exon20insertion uncommon EGFR mutation, who are eligible for treatment with afatinib in 1st line
89169636|NCT00593684|Experimental|Algidex patch|Infants in this group received the Algidex patch on top of the line insertion sites of any of the following lines: umbilical arterial line, umbilical venous line, peripheral arterial line, peripheral long line, and central venous line. This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2. Every 7 days, each insertion site was cleansed and then a new patch was placed and covered with a fresh occlusive dressing (Tegaderm, Opsite).
89169637|NCT00593684|No Intervention|Control group|Infants in this group served as the control group and received line-dressing changes every 7 days according to standard hospital protocol specific for the type of line inserted. Insertion sites were covered with only an occlusive dressing (Tegaderm, Opsite).
89169638|NCT02615288|Active Comparator|High Dose Vitamin D3 (10,000 IU daily)|
89169639|NCT02615288|Placebo Comparator|Low Dose Vitamin D3 (1000 IU daily)|
89169640|NCT02618096|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
89169641|NCT02618096|Active Comparator|Oxytocin & Dinoprostone|"Women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
89169642|NCT04134026|Experimental|HIF-PHI|HIF-PHI will be dosed orally three times a week.
89169643|NCT04134026|Active Comparator|Epoetin alfa|Epoetin alfa wull be disoensed per the package insert or the country-specific product labeling.
89169644|NCT02963831|Experimental|Cohort A: ONCOS-102 Dose Escalation|"ONCOS-102, 1 x 10^11 viral particles (VPs) monotherapy for 6 weeks, followed by durvalumab 1500 mg starting on Day 71.~A bolus dose of 300 mg cyclophosphamide (CPO) was administered intravenously (IV) 1 to 3 days before the first infusion of ONCOS-102.~ONCOS-102 was infused intraperitoneally (IP) in a total volume of 500 mL saline (0.9 mg/mL sodium chloride [NaCl] in water for injection) by gravity feed or per institutional procedures for IP infusions. ONCOS-102 was to be administered weekly for a total of 6 weeks, starting on Day 1.~Durvalumab was administered as an intravenous (IV) infusion at a fixed dose of 1500 mg in either 0.9% (w/v) saline or dextrose every 4 weeks (Q4W) for 10 cycles, starting on Day 71.~Optional durvalumab treatment extension beyond the initial 12-cycle treatment period was allowed for subjects who complete the 12-cycle treatment period with Stable Disease or better."
89169645|NCT02963831|Experimental|Cohort B: ONCOS-102 Dose Escalation|"ONCOS-102, 1 x 10^11 VPs + durvalumab 1500 mg starting on Day 15.~A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.~ONCOS-102 was infused IP in a total volume of 500 mL saline (0.9 mg/mL NaCl in water for injection) by gravity feed or per institutional procedures for IP infusions. ONCOS-102 was to be administered weekly for a total of 6 weeks, starting on Day 1.~Durvalumab was administered as an intravenous (IV) infusion at a fixed dose of 1500 mg in either 0.9% (w/v) saline or dextrose Q4W for 12 cycles, starting on Day 15.~Optional durvalumab treatment extension beyond the initial 12-cycle treatment period was allowed for subjects who complete the 12-cycle treatment period with Stable Disease or better."
89169646|NCT02963831|Experimental|Cohort 1: Epithelial Ovarian Cancer|"ONCOS-102, 3 x 10^11 VPs + durvalumab 1500 mg starting on Day 15.~A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.~ONCOS-102 was infused IP in a total volume of 500 mL saline (0.9 mg/mL NaCl in water for injection) by gravity feed or per institutional procedures for IP infusions. ONCOS-102 was to be administered weekly for a total of 6 weeks, starting on Day 1.~Durvalumab was administered as an intravenous (IV) infusion at a fixed dose of 1500 mg in either 0.9% (w/v) saline or dextrose Q4W for 12 cycles, starting on Day 15.~Optional durvalumab treatment extension beyond the initial 12-cycle treatment period was allowed for subjects who complete the 12-cycle treatment period with Stable Disease or better."
89169647|NCT02963831|Experimental|Cohort 2: Metastatic Colorectal Cancer|"ONCOS-102, 3 x 10^11 VPs + durvalumab 1500 mg starting on Day 15.~A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.~ONCOS-102 was infused IP in a total volume of 500 mL saline (0.9 mg/mL NaCl in water for injection) by gravity feed or per institutional procedures for IP infusions. ONCOS-102 was to be administered weekly for a total of 6 weeks, starting on Day 1.~Durvalumab was administered as an intravenous (IV) infusion at a fixed dose of 1500 mg in either 0.9% (w/v) saline or dextrose Q4W for 12 cycles, starting on Day 15.~Optional durvalumab treatment extension beyond the initial 12-cycle treatment period was allowed for subjects who complete the 12-cycle treatment period with Stable Disease or better."
89169648|NCT00859898|Experimental|Dapagliflozin + Metformin XR|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks~Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"
89169649|NCT00859898|Experimental|Dapagliflozin + Placebo|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.~Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."
89169650|NCT00859898|Active Comparator|Metformin XR + Placebo|"Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks~Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"
89169651|NCT02685761|No Intervention|Low Transverse|Patients in this arm will undergo their cesarean section using the standard low transverse skin incision location
89169652|NCT02685761|Experimental|Midline Vertical|Patients in this arm will undergo their cesarean section using a midline vertical skin incision
89169653|NCT02685761|Experimental|High Transverse|Patients in this arm will undergo their cesarean section using a high transverse skin incision, above the pannus
89169654|NCT00640211||PIPET B|Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
89169655|NCT02683967|Active Comparator|Acupuncture|These patients received acupuncture during the follicular development phase and on the day of egg collection.
89169656|NCT02683967|No Intervention|Control|Patients received standard care, no acupuncture.
89169657|NCT00859586|Experimental|Miltenyi Magnetic cell sorter for CD3|"Miltenyi Magnetic cell sorter device will be used for CD3 selection of granulocyte colony stimulating factor mobilized allogeneic PBSCT. In stage 1, subjects will receive 1 x 10 to the eight power CD3 cells/kg. In stage II, the dose of CD3+ cells will be increased to 2 x 10 to the eight power cells/kg.~This phase II clinical trial is designed to evaluate a novel non-myeloablative but highly immunosuppressive disease specific conditioning regimen and infusion of unmanipulated lymphocytes from a haplo-identical familial donor in subjects with relapsed disease following matched sibling stem cell transplantation who are not candidates for alternative treatment options. The clinical trial will evaluate recipient survival at six months post-relapse of disease."
89169658|NCT00638729|Active Comparator|Midazolam|Pre-anesthetic medication with midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
89169659|NCT00638729|Active Comparator|Clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
89169660|NCT00638729|Placebo Comparator|Placebo|Pre-anesthetic medication with an inert tablet, p.o., 60-90 min prior to estimated induction time
89169661|NCT00697892|Experimental|Group A4|healthy volunteers assigned to the efavirenz with artemether/lumefantrine intervention
89169662|NCT00697892|Experimental|Group A3|healthy volunteers assigned to the lopinavir/ritonavir with artemether/lumefantrine intervention
89169663|NCT02683811|Experimental|Intervention group|Diario della Salute (DDS-2), a school-based program aimed to promote psychological well-being and to prevent cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity in preadolescents aged 11-13 years. The program is composed by 5 highly standardised interactive units led by previously trained teachers during school hours (15 hours total). Units focus on emotional and social issues related to adolescent developmental tasks. The goal is to promote the adolescent emotional and social skills.
89169664|NCT02683811|No Intervention|Control group|No intervention aimed at preventing cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity and promoting emotional and social well-being is administered at school by teachers.
89169665|NCT00699452|Active Comparator|1|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
89169666|NCT00699452|Placebo Comparator|2|Placebo
89169667|NCT02683733|Active Comparator|Treatment Arm|"Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:~Starting dose: 50 mg BID of Bio-enhanced Curcumin Soft Gelatin Capsule Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
89169668|NCT02683733|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
89169669|NCT02683655|Experimental|Apatinib 500mg qd p.o.|Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy
89169670|NCT02683655|Experimental|Apatinib 750mg qd p.o.|Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy
89169671|NCT00494221|Active Comparator|FOLFOX + Cediranib 20 mg|FOLFOX + Cediranib 20 mg
89169672|NCT00494221|Active Comparator|FOLFOX + Cediranib 30 mg|FOLFOX + Cediranib 30 mg
89169673|NCT00494221|Placebo Comparator|FOLFOX + Placebo Cediranib|FOLFOX + Placebo Cediranib
89169674|NCT00857948|Experimental|0.15% ivermectin|Participant on 0.15% ivermectin treatment conditioner
89169675|NCT00857948|Experimental|0.25% ivermectin|Participants on 0.25% ivermectin treatment conditioner
89169676|NCT00857948|Experimental|0.50% ivermectin|Participants on 0.50% ivermectin treatment conditioner
89169677|NCT00857948|Placebo Comparator|Placebo|participants on Placebo (Vehicle control)
89169678|NCT02618174|Placebo Comparator|Neutral Control Condition|Message about age of University of Birmingham
89169679|NCT02618174|Placebo Comparator|Food-based Control Condition|Message about variety of vegetables in the world
89169680|NCT02618174|Active Comparator|Health Condition|Message about the health benefits of eating vegetables
89169681|NCT02618174|Active Comparator|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
89169682|NCT02618174|Experimental|Liking Social Norm|Message suggesting most people like eating vegetables
89169683|NCT02618018|Experimental|intraocular lens|AT TORBI 709M toric intraocular lens
89169684|NCT02688491|Experimental|A (Intervention group,sunitinib)|Beginning 4-12 weeks following radical nephrectomy, patients receive sunitinib malate PO QD for 4 weeks
89169685|NCT02688491|No Intervention|B(observation group)|Patients with radical nephrectomy are observed without intervention
89169686|NCT00866606|Experimental|Benefix|Subjects received on-demand treatments with BeneFIX over a 6-month (calendar day) period.
89169687|NCT02615132|Experimental|Treatment Group|The study SLP will instruct the patient to use the ipad apps as intervention for at least one-hour per day, until they are admitted to outpatient SLP services or for a maximum of 8 weeks, whichever comes first. Throughout the telemedicine treatment phase, patients' progress will be monitored remotely by a study SLP through Apps/Skype/Facetime/Telephone consultation on a weekly basis.
89169688|NCT02615132|No Intervention|Control|Patients will be sent home with standard of care.
89169689|NCT02614976|No Intervention|Control|No padding before application of blood pressure cuff
89169690|NCT02614976|Experimental|Padding|Padding before application of blood pressure cuff
89169691|NCT02617940|Experimental|fissure sealant|single placement of resin-based sealant on occlusal surface and oral hygiene orientation
89169692|NCT02617940|Placebo Comparator|oral hygiene orientation|single application of water on occlusal surface and oral hygiene orientation
89169693|NCT00857792|Other|Open Label|
89169694|NCT02613494|Active Comparator|Hyoscine|Hyoscine hydrobromide
89169695|NCT02613494|Active Comparator|Glycopyrrolate|Glycopyrronium bromide
89169696|NCT02613494|Placebo Comparator|Placebo|Placebo
89169697|NCT00699530||Hyperprolactinemia|Patients recently diagnosed with hyperprolactinemia
89169698|NCT04119128|Active Comparator|Active tDCS|Patients in this group will receive 5 active sessions of low-intensity transcranial electrical stimulation for 20 minutes.
89169699|NCT04119128|Sham Comparator|Sham tDCS|Patients in this group will receive 5 sessions of sham transcranial electrical stimulation for 20 minutes.
89169700|NCT02617862|Experimental|PCI imaging system|
89169701|NCT00697970|Experimental|Group A|
89169702|NCT00697970|Experimental|Group B|
89169703|NCT00697970|Experimental|Group C|
89169704|NCT00697970|Experimental|Group D|
89169705|NCT00697970|Experimental|Group E|
89169706|NCT00697970|Active Comparator|Group F|
89169707|NCT02617706|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 - 4 weeks + standard wound care
89169708|NCT02617706|No Intervention|Standard of care|standard wound care for 4 weeks
89169709|NCT00601835|Experimental|Canadian Td Vaccine Group|Participants received Canadian manufactured Td vaccine
89169710|NCT00601835|Active Comparator|United States Td Vaccine Group|Participants received US manufactured Td vaccine
89169711|NCT02617472|Experimental|Pelvic floor exercise|Pelvic floor exerciser, daily use
89169712|NCT00640367|Experimental|IA thrombolysis|IA recombinant tissue plasminogen activator and/or mechanical thrombolysis
89169713|NCT00640367|Active Comparator|IV rtPA|IV recombinant tissue plasminogen activator
89169714|NCT04133714|Experimental|multi-channel tDCS|"In the multi-channel tDCS stimulation group, a 1:4 (anode: cathode) approach was applied, with the central anode placed in the left dorsolateral prefrontal cortex (dlPFC) (reference 10-20 standard lead EEG), and the remaining cathode distributed around the central electrode.~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
89169715|NCT04133714|Experimental|single-channel tDCS|"The anode electrode of the single-channel tDCS stimulation group was placed in the left dlPFC, and the cathode electrode was placed in the right orbital forehead.~The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off)."
89169716|NCT04133714|Sham Comparator|sham stimulation|The shame stimulation group had only 30 seconds of up and down stimulation, with no intermediate stimulation.
89169717|NCT00697424|Experimental|1|All subjects will be placed on continuous positive airway pressure (CPAP) therapy during a full night sleep study or polysomnography (PSG). The subjects will spend 2 hours on sub-therapeutic CPAP 4 cmH2O of pressure and the remainder on there therapeutic pressure. Values reported on the device will be compared to scored values from manual scoring of the sleep study.
89169718|NCT00640445|Experimental|Expressive Writing|Participants assigned to the Expressive Writing (EW) condition will write about their deepest thoughts and feelings associated with their experience transitioning from being a soldier to being a civilian for 20 minutes a day for 4 days within a week.
89169719|NCT00640445|Active Comparator|Control Writing|Those assigned to control writing condition will write factually about the information needs of veterans transitioning from active duty to civilian status for 20 minutes on 4 days within one week.
89169720|NCT00640445|No Intervention|No Writing Control|Treatment As Usual
89169721|NCT02688413|Experimental|MindMotionPRO|MindMotionPRO exercises in addition to standard practice for upper limb rehabilitation
89169722|NCT02688413|Active Comparator|Self-Directed Prescribed Exercises|Self-Directed Prescribed Exercises in addition to standard practice for upper limb rehabilitation
89169723|NCT00697502|Experimental|Group 2: TSER 3R/3R|Cohorts of 3-6 patients in each genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
89169724|NCT00697502|Experimental|Group 1: TSER 2R/2R or 2R/3R|Cohorts of 3-6 patients in this genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
89169725|NCT02617082||partial breast irradiation|
89169726|NCT04118816||Control|Healthy subjects, 7-75 y/o
89169727|NCT04118816||Study|7-75 y/o, diagnosed with Prader-Willi syndrome.
89169728|NCT04183517|Experimental|Fasted|PXS-5382A administered as a single dose in the fasted state
89169729|NCT04183517|Experimental|Fed|PXS-5382A administered as a single dose in the fed state
89169730|NCT04183517|Experimental|Twice daily|PXS-5382A administered twice daily for 5 days in the fed state
89169731|NCT02682797||1|At all study visits a complete ophthalmic examination, visual acuity and refractive error, Spectralis OCT, Cirrus OCT, Topcon OCT, PS-OCT, Optomap Fundus photography will be performed.
89169732|NCT02688335|Experimental|Cloud9 Snoring Treatment|Snoring participants will be instructed to use the device as much as possible for 2 weeks.
89169733|NCT00640913||I|Twenty consecutive patients operated on with low anterior resection of the rectum for cancer with a defunctioning stoma who accept participation.
89169734|NCT02688179||Cardiac surgery patients|
89169735|NCT00857246|Experimental|Induction/ surgery/ chemoRT|"Induction treatment (3 weeks/cycle x 4 cycles): Cisplatin and Irinotecan on days 1 and 8; Cetuximab on days 1, 8, and 15.~Surgery (starts 3-4 weeks after induction treatment).~Chemoradiation treatment (starts 4-6 weeks after surgery):~weeks 1-19: Cetuximab on day 1 of every week; week 1: 5-FU and Leucovorin (LV) x 5 days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU+ LV on days 1-4; week 9: 5-FU+ LV on days 1-3; weeks 14 and 19: 5-FU+LV x 5days"
89169736|NCT02683499|Experimental|Ultrasonic tips|Prepared surfaces will be finished with ultrasonic tips
89169737|NCT02683499|No Intervention|Conventional|Prepared surfaces will be finished with ordinary burs
89169738|NCT04184531||Children with Sensenbrenner Syndrome|Children with Sensenbrenner followed from 2005. Variable phenotype related to the mutation gene will be analysed to determine some possible prognostic factors of the risk of developing end-stage kidney disease.
89169739|NCT04118582||Prospective analisys|"Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).~Evaluation of RMR For the evaluation of the RMR, the values of VO2 and VCO2 will be collected by the indirect calorimetry (IC) method using the Ultima CPX metabolic analyzer (MedGraphics, USA), calibrated with each test."
89169740|NCT02683343||carpal tunnel syndrome|No intervention
89169741|NCT02683343||normals|no intervention
89169742|NCT00699686|Active Comparator|Glargine|During this arm/phase patients take subcutaneous glargine daily for 3 months.
89169743|NCT00699686|Experimental|Detemir|During this arm/phase, patients take insulin Detemir subcutaneously for 3 months.
89169744|NCT02688101|Experimental|DpC|DpC capsules, administered orally
89169745|NCT04184063|Experimental|active treatment with NBMI|
89169746|NCT04184063|Placebo Comparator|Placebo|
89169747|NCT04183985|Experimental|Anatomically aligned total knee arthroplasty|Use anatomically aligned total knee arthroplasty implant (Journey II Bi-cruciate substituting total knee system, JII-BCS, Smith & Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
89169748|NCT04183985|Active Comparator|Conventaional total knee arthroplasty|Use conventional total knee arthroplasty implant (Legion total knee system, Smith & Nephew) in patients undergoing same-day bilateral total knee arthroplasty.
89169749|NCT00640679|Active Comparator|Clopidogrel Tapering|
89169750|NCT00640679|Active Comparator|Abrupt Clopidogrel Interruption|
89169751|NCT02682953|Experimental|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
89169752|NCT02683031|No Intervention|Without Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent conventional ICSI cycle.
89169753|NCT02683031|Experimental|With Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent ICSI cycle combined with artificial oocyte activation using Ca2+ ionophore.
89169754|NCT04183907|No Intervention|Control group|The control group completes three questionnaires in months 1, 3 and 6, including questions on health behaviours, workaholism and work outcomes.
89169755|NCT04183907|Experimental|Transform|Intervention (see next page)
89169756|NCT04184141|Experimental|alprazolam|
89169757|NCT04184141|Experimental|hydroxyzine|
89169758|NCT04184141|Placebo Comparator|control|
89169759|NCT02682407|Experimental|OMS721 (narsoplimab)|Administration of OMS721 (narsoplimab)
89169760|NCT02682251|Experimental|Heart Failure Patients with CRT-CIED|PHR Messaging to notify patient of device transmitted information (i.e. percentage LV pacing)
89169761|NCT02682329|Active Comparator|CP 10% + HP 40%|Carbamide Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. CP at home and HP at office
89169762|NCT02682329|Active Comparator|CP 15% + HP 40%|Carbamide Peroxide 15% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
89169763|NCT02682329|Active Comparator|CP 20% + HP 40%|Carbamide Peroxide 20% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
89169764|NCT02682329|Active Comparator|HP 10% + HP 40%|Hydrogen Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. HP at Home and HP at office
89169765|NCT00640991|No Intervention|Control|Patients assigned to the control arm will receive usual care for AMI, according to local practice of each participating centre.
89169766|NCT00640991|Experimental|Intervention|The experimental arm will have an IV infusion of glulisine insulin started directly after randomization for at least 24 hours and for as long as CCU-level care is required, and the insulin infusion will be adjusted to achieve and maintain a target glucose range of 5.0-6.6 mmol/L (90-118 mg/dL). Once transferred to the ward, patients in the experimental arm will switch to glargine insulin and will continue this treatment for the remainder of their hospitalization and after hospital discharge, for a total duration of 30 days post randomization.
89169767|NCT00640757|Active Comparator|Low Methionine 1|Methionine deficient diet
89169768|NCT00640757|Placebo Comparator|Placebo 2|Placebo comparator methionine complete diet
89169769|NCT00638807|Experimental|A|
89169770|NCT00638807|Placebo Comparator|B|
89169771|NCT00856856|Experimental|Absorb stent|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
89169772|NCT00782327|Experimental|1|Losartan
89169773|NCT00782327|Placebo Comparator|2|Placebo
89169774|NCT00559091|Experimental|I|Ribavirin
89169775|NCT00641615|Experimental|Phase 1|
89169776|NCT04108949|Experimental|Tuning in to Kids|Eight weekly two-hour sessions delivered in groups of up to six parents.
89169777|NCT04108949|Active Comparator|Treatment as usual|Treatment as usual, may consist of any psychosocial intervention the therapist sees fit, which is the type of intervention the participants ordinarily receives in the participating clinics. No limit on number of sessions or format of delivery.
89169778|NCT00493285|Active Comparator|1|MEDI-534 at 10^4 TCID50 at 0, 2, and 4 months (Nasal spray)
89169779|NCT00493285|Active Comparator|2|MEDI-534 at 10^5 TCID50 at 0, 2, and 4 months (Nasal Spray)
89169780|NCT00493285|Active Comparator|3|MEDI-534 at 10^6 TCID50 at 0, 2, and 4 months (Nasal Spray)
89169781|NCT05664035||Case group|18 to 65 year old patients with a history of recurrent bacterial infections of upper and/or lower respiratory tract for at least 2 years
89169782|NCT04182581|Experimental|CAR-T treatment group|The patients will receive one dose of BCMA/CD19 dual-target CAR-T. BCMA/CD19 dual-target CAR-T dosage ranges from 5×10^4 to 3×10^5 CAR+T/Kg.
89169783|NCT02682173|Active Comparator|Laparoscopic gastric bypass|MR Abdomen in morbidly obese patients receiving gastric bypass
89169784|NCT02682173|Active Comparator|Laparoscopic sleeve gastrectomy|MR Abdomen morbidly obese patients receiving sleeve gastrectomy
89169785|NCT02682017|Placebo Comparator|Treatment 1|Pork meat from pigs feed with a standard feed
89169786|NCT02682017|Experimental|Treatment 2|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix
89169787|NCT01015105||patients with hip fracture|
89169788|NCT04033835|Experimental|MBT-I|12 sessions of MBT
89169789|NCT04033835|Active Comparator|Waiting list control|Treatment as usual
89169790|NCT00856778|Other|Virtue® Male Sling|Subjects implanted with Virtue® Male Sling
89169791|NCT02682095||Patients: achieved BP control|Patients who have achieved blood pressure control (≤140/90 mmHg)
89169792|NCT02682095||Patients: not achieved BP control|Patients who have not achieved blood pressure control (>140/90 mmHg)
89169793|NCT02682095||Individual interviews|Hypertensive patients who have considered changing lifestyle regarding one or more of the areas of tobacco, alcohol, diet, physical activity or stress.
89169794|NCT02682095||Focus-group interviews|Hypertensive patients
89169795|NCT02680925|Placebo Comparator|Conventional ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 10 ml/kg without PEEP during two-lung ventilation and TV of 8 ml/kg without PEEP during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
89169796|NCT02680925|Active Comparator|Lung protective ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 6 ml/kg with PEEP 6 cmH2O during two-lung ventilation and TV of 4 ml/kg PEEP 6 cmH2O during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
89169797|NCT05663879|Experimental|ID120040002 A mg|Single dose 8 volunteers will be administered ID120040002 Amg or placebo comparators (ID120040002: placebo = 6:2)
89169798|NCT05663879|Experimental|ID120040002 Bmg|Single dose 8 volunteers will be administered ID120040002 Bmg or placebo comparators (ID120040002: placebo = 6:2)
89169799|NCT05663879|Experimental|ID120040002 Cmg|Single dose 8 volunteers will be administered ID120040002 Cmg or placebo comparators (ID120040002: placebo = 6:2)
89169800|NCT05663879|Experimental|ID120040002 Dmg|"Period1:~Single dose 8 volunteers will be administered ID120040002 Dmg or placebo comparators (ID120040002: placebo = 6:2)~Period2:~Single dose 8 volunteers will be administered ID120040002 Dmg or placebo comparators (ID120040002: placebo = 6:2)"
89169801|NCT05663879|Experimental|ID120040002 Emg|Single dose 8 volunteers will be administered ID120040002 Emg or placebo comparators (ID120040002: placebo = 6:2)
89169802|NCT05663879|Experimental|ID120040002 Fmg|Multiple dose 10 volunteers will be administered ID120040004 F mg or placebo comparators (ID120040002: placebo: 8:2)
89169803|NCT05663879|Experimental|ID120040002 Gmg|Multiple dose 10 volunteers will be administered ID120040004 G mg or placebo comparators (ID120040002: placebo: 8:2)
89169804|NCT05663879|Experimental|ID120040002 Hmg|Multiple dose 10 volunteers will be administered ID120040004 H mg or placebo comparators (ID120040002: placebo: 8:2)
89169805|NCT05663879|Experimental|ID120040002 Img|Multiple dose 10 volunteers will be administered ID120040004 I mg or placebo comparators (ID120040002: placebo: 8:2)
89169806|NCT05663879|Active Comparator|Compound-X Jmg|Multiple dose 8 volunteers will be administered compound-X J mg
89169807|NCT02680769|Experimental|Magnesium|300 mg of citrate Mg/daily
89169808|NCT02680769|Placebo Comparator|Placebo|placebo group
89169809|NCT04049903|Experimental|MP0310 Part A|Enrollment will follow a standard 3 + 3 dose escalation design. Sequential Cohorts of patients will be dosed until the MTD or unacceptable toxicity is reached. Up to 12 additional patients in total may be included at selected dose levels (up to 3).
89169810|NCT04049903|Experimental|MP0310 Part B|weekly schedule, at least 3 and up to 24 patients evaluable for DLT assessment will be enrolled (1 to 4 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)).
89169811|NCT04049903|Experimental|MP0310 Part C|q3w schedule implementing B-cell depletion, at least 3 and up to 12 patients evaluable for DLT assessment will be enrolled (1 to 2 cohorts with 3 to 6 patients each (3 initial plus up to 3 backfill patients)).
89169812|NCT05664503|No Intervention|Booklet|Control-Classical patient education before the operation, the patient is educated with the classical method brochure.
89169813|NCT05664503|Experimental|STOMA-M|Patients are educated with the mobil aplikasyon method.
89169814|NCT02687945|Active Comparator|Outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of outpatient physiotherapy with 2-3 weekly sessions
89169815|NCT02687945|Active Comparator|No outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of self-guided physiotherapy exercises
89169816|NCT02687789|Experimental|Medical Device: WO3191|The vaginal suppository is used for the reduction and/or inhibition of vaginal biofilms that were shown to be related to recurrent bacterial vaginosis.
89169817|NCT02687789|Active Comparator|Medical Device: Vagisan® Lactic Acid|It is used for the maintenance and restoration of a natural pH level in the vagina. The acidification of the vaginal milieu with lactic acid promotes the growth of typical vaginal flora (lactic acid bacteria) and is unfavourable for the growth of pathogens in the vagina. Vagisan® Lactic Acid is used in the post-treatment of bacterial vaginosis.
89169818|NCT05664347|Active Comparator|Control|Standard verbal teach to goal inhaler technique education
89169819|NCT05664347|Active Comparator|Intervention|Video based teach to goal inhaler technique education
89169820|NCT05663723|Active Comparator|Intervention group with the IV and V LED board|Time of Applications will for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
89169821|NCT05663723|Active Comparator|Intervention group with the IV, V and Violet LED board|Time of Applications will be for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
89169822|NCT05663723|Placebo Comparator|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application. Women will receive a booklet with guidelines for the correct use of the LED board and will be instructed to continue their usual physical activities and mark the daily frequency of application of the LED board
89169823|NCT02680535|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to ultrasound-guided laser irradiation using a FDA cleared laser and an interstitial optical fiber.
89169824|NCT02680691|Experimental|Robot, then conventional training|Robot assisted gait training 4 weeks after conventional gait training
89169825|NCT02680691|Active Comparator|Conventional, then robot training|Conventional gait training 4 weeks after robot assisted gait training
89169826|NCT02680613|Experimental|Motivational SMS|This arm will receive 15 motivational SMS about cervical cancer and screening.
89169827|NCT02680613|Experimental|Travel Voucher|This arm will receive a voucher covering return transport from the screening clinic. This arm will also receive identical 15 motivational SMS about cervical cancer and screening as the Motivational SMS arm.
89169828|NCT02680613|No Intervention|Control|This arm will receive standard sensitization during study period (church announcements, screening promotion by key community leaders and posters in community, as well as sensitization by the research assistants conducting the door-to-door household recruitment) during the study and follow-up period. They will also receive one SMS message with the location of screening services during the study period. At the conclusion of the study, participants in the arm will receive identical motivational SMS as the other two arms.
89169829|NCT00603473|Experimental|gabapentin|
89169830|NCT02688023|Experimental|single-arm Irinotecan-Oxaliplatin-5-Fluorouracil/leucovorin|Irinotecan,oxaliplatin and 5-fluorouracil/leucovorin(5-fluorouracil/leucovorin can be substituted with Capecitabine or S-1)
89169831|NCT02680223|Active Comparator|Precision tinted lenses|Precision tinted lenses will be provided for one month.
89169832|NCT02680223|Sham Comparator|Non-beneficial tinted lenses|Tinted lenses at a colour different from but not easily distinguishable from the precision tinted will be provided for one month.
89169833|NCT00910013|Experimental|Ropivacaine + femoral block|After the surgery is proceeded and after the closure of the joint capsule, 20 cc of ropivacaine 0.5% is inserted intra-articular through a catheter.
89169834|NCT04182503||Beijing|
89169835|NCT04182503||Guangzhou|
89169836|NCT04182503||Jinan|
89169837|NCT04182503||Nanjing|
89169838|NCT04182503||Hangzhou|
89169839|NCT04182503||Wuhan|
89169840|NCT04182503||Zunyi|
89169841|NCT04182503||Xiangyang|
89169842|NCT04182503||Nantong|
89169843|NCT04182503||Suizhou|
89169844|NCT04182503||Huangshi|
89169845|NCT04182503||Changzhou|
89169846|NCT04182503||Suqian|
89169847|NCT04182503||Shiyan|
89169848|NCT04182503||Xiaogan|
89169849|NCT04182503||Huanggang|
89169850|NCT00486889|Experimental|Alglucosidase Alfa|Participants received alglucosidase alfa 20 milligrams per kilogram (mg/kg) body weight as intravenous infusion every 2 weeks and were followed for 10 years or up to discontinuation from study treatment due to any reason.
89169851|NCT04182191|Experimental|Interventional group|89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
89169852|NCT02680379|Experimental|Minocycline, then Minocycline/Lovastatin|Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.
89169853|NCT02680379|Experimental|Lovastatin, then Minocycline/Lovastatin|Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months
89169854|NCT03996421|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
89169855|NCT03996421|Experimental|ferrous fumarate + 15 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 15 g GOS
89169856|NCT00641693|Experimental|1|Nasal Spray
89169857|NCT00641693|Placebo Comparator|2|
89169858|NCT04183361||Patients with noise exposure and salivary cortisone|"male and female~ages 19-35~exposure to noise level ≥ 85 dB (A) per week at the workplace~work in noise from 1 to 16 years~workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)~unilaterally or bilaterally normal otoscopic findings~unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
89169859|NCT04183361||Patients without noise exposure and salivary cortisone|"male and female~ages 19-35~no exposure to noise level ≥ 85 dB (A) per week at the workplace~work in noise from 1 to 16 years~workplace not involving exposure to carbon disulfide or a mixture of organic solvents that have toxic effects on the ear (toluene, xylene and styrene)~unilaterally or bilaterally normal otoscopic findings~unilaterally or bilaterally tympanogram: peak pressure value ± 50 daPa at 226 Hz with eardrum mobility of 0.3 to 1.3 mL"
89169860|NCT02681861|Experimental|Part 1: ASP6294 Single Ascending Intravenous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo intravenously. If no dose limiting toxicities are observed escalation to the next higher dose is planned approximately every 3 weeks. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
89169861|NCT02681861|Experimental|Part 2: ASP6294 Single Ascending Subcutaneous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo subcutaneously. The subcutaneous cohorts may be done in parallel with part 1, using doses which have been proven to be safe and tolerable. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
89169862|NCT02687867||Dabigatran|Non-valvular atrial fibrillation patients who were initiated on dabigatran for stroke prevention.
89169863|NCT02687867||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on VKA for stroke prevention.
89169864|NCT02681939|Experimental|Tulsi|One capsule of Tulsi (Ocimum sanctum) orally, every morning and evening in empty stomach for 60 days regularly.
89169865|NCT02681939|No Intervention|No Tulsi|No intervention
89169866|NCT02681783|Active Comparator|neovascular AMD group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
89169867|NCT02681783|Experimental|CSR group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
89169868|NCT02681783|Experimental|iPCV group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
89169869|NCT02681783|No Intervention|cataract patients|Patients diagnosed with cataracts requiring cataract surgery will serve as study controls. No intervention will be applied to these patients.
89169870|NCT00486811|Placebo Comparator|Matching Placebo (twice daily)|The starting dose of placebo was matched with the active treatment arms taken twice daily for the first 3 days. The dose was then increased to match the active treatments for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days as in the active treatment arms. Dose decreases were allowed without time restrictions.
89169871|NCT00486811|Experimental|Tapentadol ER (100 to 250 mg twice daily)|The starting dose was tapentadol ER 50 mg twice daily for 3 days. The dose was then increased to 100 mg tapentadol ER twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
89169872|NCT00486811|Active Comparator|Oxycodone CR (20 to 50 mg twice daily)|The starting dose was oxycodone CR 10 mg twice daily for 3 days. The dose was then increased to 20 mg oxycodone CR twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
89169873|NCT04183127||ACP|ACPs, either qualified or in training, working in the South Yorkshire and Bassetlaw area.
89169874|NCT04060810|Other|grey zone hydrocephalic patients|MR CSF flowmetry CT brain Ventriculoperitoneal shunt
89169875|NCT04182347|Other|People with IDD and caregivers|
89169876|NCT00921700|Experimental|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg
89169877|NCT00921700|Experimental|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg + codeine 60 mg
89169878|NCT00921700|Active Comparator|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg + codeine 60 mg
89169879|NCT00921700|Placebo Comparator|Placebo|Single oral dose of lactose as placebo
89169880|NCT02678195|Experimental|3 days amoxicillin + 2 days placebo|3 days amoxicillin DT + 2 days placebo DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
89169881|NCT02678195|Active Comparator|5 days amoxicillin|5 days amoxicillin DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
89169882|NCT03881566||Immunocompetent sepsis patients|Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
89169883|NCT03881566||Immunocompromised sepsis patients|Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count < 1 × 109/L), exposure to glucocorticoids (> 0.5 mg/kg for > 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
89169884|NCT03881566||Patients without sepsis|Patients who admitted intensive care unit without sepsis
89169885|NCT02681627|Active Comparator|endometrial scratch|Patient will be randomised to the intervention arm which is the luteal phase endometrial scratch
89169886|NCT02681627|Sham Comparator|touching cervix|Patient will have a speculum examination and cleaning of the cervix with cotton tip with saline but no scratch
89169887|NCT03996577|Placebo Comparator|control group|the control group will be given the same volume of saline as the experimental group
89169888|NCT03996577|Experimental|Experimental: lidocaine group|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
89169889|NCT02681705|Experimental|Study Treatment|All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with Temozolomide. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as Temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
89169890|NCT00921622|Active Comparator|Vitamin D|1000 IU twice daily for up to 10 days
89169891|NCT00921622|Active Comparator|Vitamin C|500 mg twice daily for up to 10 days
89169892|NCT02681471|Active Comparator|Monopolar TURP|Patients in Group M (Monopolar) were used monopolar resectoscope (Karl Storz, Tottling, Germany) and 5% Mannitol as an irrigation fluid.
89169893|NCT02681471|Active Comparator|Bipolar TURP|Patients in Group B (Bipolar) were used bipolar resectoscope TURis (OLYMPUS, Tokyo, Japan) and 0,9% Sodium chloride as an irrigation fluid.
89169894|NCT00747292|Active Comparator|Epidural|Epidural
89169895|NCT00747292|Active Comparator|2|Spinal
89169896|NCT00747292|Active Comparator|3|Patients in this limb receive a PCA
89169897|NCT00642395|Experimental|1|bortézomib
89169898|NCT00747370|Other|1|16 healthy volunteers with no complaints of urinary symptoms and without urogenital prolapse of more than first degree.
89169899|NCT00747370|Other|2|Forty two stress urinary incontinence patients without prior urogenital prolapse or incontinence operation and without genital prolapse more than first degree
89169900|NCT00747370|Other|3|16 genital prolapse women without prior prolapse operations or any symptoms of incontinence
89169901|NCT02679989|Experimental|Intermittent Energy Restriction|Weight loss intervention: Intermittent Energy Restriction
89169902|NCT02679989|Active Comparator|Continuous Energy Restriction|Weight loss intervention: Continuous Energy Restriction
89169903|NCT01018459|Experimental|Group D: 10^11 vp/mL or placebo|10 subjects will receive 10^11 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
89169904|NCT01018459|Experimental|Group A: 10^9 vp/mL or placebo|10 subjects will receive 10^9 viral particles (vp)/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
89169905|NCT01018459|Experimental|Group B: 10^10 vp/mL or placebo|10 subjects will receive 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
89169906|NCT01018459|Experimental|Group C: 5 x 10^10 vp/mL or placebo|10 subjects will receive 5 x 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
89169907|NCT01018615|Experimental|low dose silymarin and low dose EGCG|
89169908|NCT01018615|Experimental|high dose silymarin and low dose EGCG|
89169909|NCT05663021|Experimental|Ultrasound-Guided Biopsy of Tumor Site during neoadjuvant chemotherapy|For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated CNB (RCNB) was performed after 2-4 cycles of NAC, depending on the total cycles of NAC. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
89169910|NCT02678117|Active Comparator|Pregabalin & placebo|: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.
89169911|NCT02678117|Active Comparator|Magnesium sulphate & Placebo|will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.
89169912|NCT02678117|Active Comparator|Pregabalin & Magnesium sulphate|: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.
89169913|NCT02678117|Placebo Comparator|Placebo|will receive placebo medications at the same time and route of administration of other groups.
89169914|NCT01018849|Active Comparator|Vitamin D (cholecalciferol)|Subjects receive 150,000 IU of Vitamin D3 every 2 months
89169915|NCT01018849|Placebo Comparator|Placebo|Subject will receive a placebo - an exact replica of the Vitamin D3 capsule that does not contain the active ingredient, Vitamin D3
89169916|NCT00743860|Experimental|Single dose|single oral dose
89169917|NCT00743860|Experimental|Repeat Dose|28 day repeat dose
89169918|NCT01018693|Experimental|VAK694 AND Immunotherapy (alutard)|
89169919|NCT01018693|Experimental|: VAK694 placebo AND Immunotherapy (alutard)|
89169920|NCT01018693|Experimental|VAK694 placebo AND Immunotherapy (alutard) placebo|
89169921|NCT00747526|Experimental|Rabeprazole sodium 5 mg|
89169922|NCT00747526|Experimental|Rabeprazole sodium 10 mg|
89169923|NCT01018771|Experimental|Actifuse ABX|Actifuse ABX bone substitute
89169924|NCT01018771|Active Comparator|INFUSE, plus Mastergraft granules|
89169925|NCT01025011||healthy volunteers, anemic patients|healthy volunteers from the eye and gynecology department pregnant patients with anemia
89169926|NCT00747604||Increlex patients|Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.
89169927|NCT02151604|Experimental|129 Xenon MR Imaging|Xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
89169928|NCT00466921|Experimental|Lenalidomide|
89169929|NCT02564770||Rheumatoid arthritis (RA) participants|Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.
89169930|NCT02563912|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
89169931|NCT02563912|Active Comparator|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
89169932|NCT02073292|Experimental|c-RFA|cooled radiofrequency ablation
89169933|NCT02073292|Active Comparator|t-RFA|thermal radiofrequency ablation
89169934|NCT00601523|Active Comparator|Pramipexole|Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily
89169935|NCT00601523|Placebo Comparator|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
89169936|NCT00466687|Experimental|Therapeutic Intervention|"Tarceva and Avastin:~Tarceva: 150mg PO, days 1-28~Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course"
89169937|NCT00747760||1|Extended family members
89169938|NCT00747760||2|Control- subjects from the same town without known thyroid diseases
89169939|NCT01759459|Experimental|Lidocaine|1% Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm
89169940|NCT01759459|Experimental|Buffered Lidocaine|"1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm~Buffered lidocaine is compounded by the following process:~2.3 mLs of 8.4% sodium bicarbonate is added to a vial of 1% lidocaine"
89169941|NCT01759459|Experimental|Bacteriostatic Normal Saline|Bacteriostatic Normal Saline for injection, 0.50 mL administered one time intradermally in peripheral forearm
89169942|NCT02537795||Deep Brain Stimulation Patients|Patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
89169943|NCT02537795||Deep Brain Stimulation Family Members|Family members of patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
89169944|NCT02537795||Anterior Capsulotomy Patients|Patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
89169945|NCT02537795||Anterior Capsulotomy Family Members|Family members of patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
89169946|NCT02562742||SOF+REB|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+REB as part of routine clinical care at a participating clinical site.
89169947|NCT04182971|Active Comparator|Whole fruit|Phase 1 of study is an orange, Phase 2 of study is an apple
89169948|NCT04182971|Active Comparator|Juice|Phase 1 of study is orange juice, Phase 2 of study is apple juice
89169949|NCT04182971|Experimental|Juice plus pomace fiber|Phase 1 is orange juice with added fiber, Phase 2 is apple juice with added fiber
89169950|NCT00305851|Active Comparator|Arm I (counseling)|Patients undergo six 1-hour sessions twice a week for 3 weeks with a trained counselor in which they choose up to 3 books on CD and listen to the book and/or discuss their impressions and thoughts about the contents with the counselor. Patients are provided with a portable CD player to listen to the books during their hospitalization.
89169951|NCT00305851|Experimental|Arm II (counseling and music therapy)|Patients undergo six 1-hour sessions twice a week for 3 weeks with a music therapist, designed specifically for the pre-transplant and acute phase of treatment. Phases of patient participation include song writing, recording the song with a digital accompaniment track, completing a video layout worksheet, taking photos or making drawings for the video, viewing clip art and pictures on a computer, and sharing the final video with family members and hospital staff.
89169952|NCT04183283|Experimental|LY3526318|LY3526318 administered orally in three of four study periods.
89169953|NCT04183283|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
89169954|NCT00744016|Placebo Comparator|2|Placebo
89169955|NCT00744016|Active Comparator|1|Granulated mesalamine
89169956|NCT05664269|Experimental|Canola protein|20g of canola protein
89169957|NCT05664269|Active Comparator|Whey protein|20g of whey protein
89169958|NCT05664269|Sham Comparator|Placebo|Water, matched for taste and volume
89169959|NCT00744094|Placebo Comparator|1|placebo drink
89169960|NCT00744094|Experimental|2|protein drink
89169961|NCT01018927||Additional MRI images|Prospective review of 100 CMR studies performed on multiple myeloma patients referred for cardiac evaluation by MRI. Three additional MRI images will be performed to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
89169962|NCT02677883|Experimental|Arm I: Manometry-guided thoracentesis|Intervention Group - Patients undergo fine needle- aspiration, called therapeutic thoracentesis, to drain fluid accumulated around the lung. Unlike Arm II, the intervention group will have their pleural pressure monitored during the procedure.
89169963|NCT02677883|Active Comparator|Arm II: Symptom-guided thoracentesis|Comparison Group - Patients undergo symptom-guided thoracentesis, the current standard-of-care is to drain fluid until 1) it is all gone or 2) a symptom occurs that indicates the lung may take longer to fully re-expand and drainage should be stopped.
89169964|NCT04182893||Pulmonary nodules population|We will enroll 300 pulmonary nodules penplein this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
89169965|NCT04182893||Healthy population|We will enroll 100 healthy penple in this study. After bronchoscopy, surgical examination or clinical follow-up, pulmonary nodules were finally diagnosed as malignant or benign.
89169966|NCT00641303|Sham Comparator|Arm I (control)|Patients receive 8 weekly sessions of sham acupuncture treatment comprising 20 minutes of a non-penetrating device consisting of a retractable needle and an adhesive tube on the skin using the Park Sham Device (PSD) in 14 non-acupuncture points. Patients may receive 4 free acupuncture sessions (not sham) after the 12 or 24-week follow-up visit.
89169967|NCT00641303|Experimental|Arm II (treatment)|Patients receive 8 weekly sessions of acupuncture treatment comprising 20 minutes of needle insertion in 15 acupuncture points including CV 4, CV 6, CV12 and bilateral LI 4, MH 6, GB 34, ST 36, KI 3, BL 65.
89169968|NCT04182737|Experimental|IgM titer-based treatment|The treatment with IgM preparation will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The calculation of the dose is based on IgM single compartment distribution. The first dose of IgM preparation will be calculated on IgM serum concentration obtained within 24 hours after shock appearance to achieve serum titers above 100mg/dl. In the next days, the daily IgM preparation dose will be assessed individually on the basis of IgM serum titers assessment performed in the morning with the purpose of maintaining IgM serum titers above 100 mg/dl, up to discontinuation of vasoactive drugs or day 7 after enrolment. Daily, the calculated dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg per hour (20mg/kg per hour). IgM preparation will be administered up to the withdrawal of vasoactive drugs with a maximum allowed of 7 days of therapy and a maximum dose of 350mg/Kg/day.
89169969|NCT04182737|Active Comparator|IgM Flat treatment|The IgM treatment will be initiated as soon as possible after randomization (maximum allowed starting time 12h after randomization). The dose of IgM preparation will be 250mg/kg for 3 days, the dose will be administered in 24 hours in continuous infusion with a maximum infusion rate of 0,4 ml/kg (20mg/kg per hour) until reaching 250mg/kg.
89169970|NCT02681393|Experimental|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
89169971|NCT02681393|Active Comparator|Brochure Only|Participants will receive the Aerobic Exercise After Stroke educational brochure only.
89169972|NCT02679599|Other|Cardiac rehabilitation as usual|Participants will receive cardiac rehabilitation as usual (i.e., as offered in the clinical setting).
89169973|NCT02679599|Experimental|Cardiac rehabilitation plus B-MOBILE-CARDIAC smartphone app|Participants will receive cardiac rehabilitation as usual, plus access to the B-MOBILE-CARDIAC smartphone application through 4 weeks post-rehabilitation.
89169974|NCT02537639||Control group|Control group. Standard teaching in transesophageal echocardiography.
89169975|NCT02537639||Intervention group|Intervention group. Additional teaching with a transesophageal echocardiography simulator.
89169976|NCT00641849|Active Comparator|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
89169977|NCT00641849|Active Comparator|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
89169978|NCT05663489||Patients with obsessive-compulsive, social anxiety or panic disorder|Patients with obsessive-compulsive disorder. The MRI substudy will also include patients with social anxiety or panic disorder
89169979|NCT05663489||For MRI substudy: Healthy controls|Healthy controls demographically matched to the patient group on age, sex and years of education
89169980|NCT04181645|Experimental|SHR-120, Paclitaxel-albumin and Gemcitabine|"Subjects receive SHR-1210 200mg (Day 1) and Paclitaxel-albumin 125mg/m2 (Day1 and Day8) and gemcitabine 1000mg/m2 (Day 1 and Day 8) of each 21-day cycle for at most 6 cycles until documented PD or intolerable adverse event or new anti-cancer treatment or loss to follow-up or death.~Subjects receive SHR-1210 200mg (Day1) to maintain after 6 cycles treatment without PD or listed situation to terminate."
89169981|NCT02679833|Placebo Comparator|Placebo|A toothpaste, with the same matrix, all components, and appearance like the active arm but not containing vitamin B12.
89169982|NCT02679833|Active Comparator|Cyanocobalamin|A toothpaste with cyanocobalamin 100 µg cyanocobalamin per 1 g.
89169983|NCT00641927|Experimental|1|Antidepressant
89169984|NCT00641927|Active Comparator|2|Drug
89169985|NCT04033523|Experimental|High intensity-interval training (HIIT)|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
89169986|NCT04033523|No Intervention|normal counterparts|gender-matched normal counterparts (NC) did not receive any form of intervention
89169987|NCT00641459||001|
89169988|NCT02677571|Experimental|PVB|51 patients receiving US guided homolateral paravertebral thoracic block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
89169989|NCT02677571|Experimental|PECS|51 patients receiving US guided pectorals nerve block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
89169990|NCT04182269||Study Group|Multiple Sclerosis Patients
89169991|NCT04182269||Control Group|Healthy Subjects
89169992|NCT02681315|Experimental|6 liter/min group|Infants will be extubated to a HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) at ﬂow rate of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
89169993|NCT02681315|Active Comparator|3 liter/min group|Infants will be extubated to HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) a ﬂow rate of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
89169994|NCT04181567|Experimental|electroconvulsive therapy + agomelatine|electroconvulsive therapy 2 times weekly + agomelatine 50 mg daily
89169995|NCT04181567|Active Comparator|electroconvulsive therapy + placebo|electroconvulsive therapy 2 times weekly + placebo
89169996|NCT02681081|Other|Control|For sessions 2 through 4, maintain normal eating patterns.
89169997|NCT02681081|Active Comparator|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
89169998|NCT02681081|Active Comparator|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
89169999|NCT00642005|Experimental|1|Humidified and warmed carbon dioxide laparoscopic insufflation.
89170000|NCT00642005|Placebo Comparator|2|Cold and dry carbon dioxide laparoscopic insufflation.
89170001|NCT02679521|Active Comparator|rESWT|Radial extracorporeal shock wave therapy (rESWT).
89170002|NCT02679521|Placebo Comparator|Placebo|Placebo treatment.
89170003|NCT00642083|Experimental|1|viabahn stent-graft
89170004|NCT02676011|Active Comparator|Group A|Intramuscular (IM) atropine (0.01 mg/kg) (1 ml) 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
89170005|NCT02676011|Active Comparator|Group B|1 ml normal saline IM 30 minutes before induction of anesthesia, intravenously (IV) atropine (0.01 mg/kg) in 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
89170006|NCT02676011|Active Comparator|Group C|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and 1mg/kg atropine mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
89170007|NCT02676011|Placebo Comparator|Group D|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
89170008|NCT00643253|Experimental|1|Receipt of behavioral interventions to encourage breastfeeding.
89170009|NCT00643253|No Intervention|2|Standard of Care
89170010|NCT02677649|Active Comparator|cranberry|30 grams/day freeze dried whole cranberry powder added to a basal diet comprising meats, dairy products, simple sugars, and stevia
89170011|NCT02677649|Placebo Comparator|placebo|30 grams/day placebo powder [made with maltodextrin (CPC Maltrin M-180), citric acid, artificial cranberry flavor (Lorann oils), fructose, red color (Lorann oils), and grape shade] added to a basal diet comprising meats, dairy products, simple sugars, and stevia
89170012|NCT00465985|Experimental|Part I, Part II-arm1, & Part III|
89170013|NCT00465985|Placebo Comparator|Part II - arm 2|
89170014|NCT00643331|Experimental|1|Exercise performed at the gym and at home
89170015|NCT00643331|No Intervention|2|Usual care no additional exercise
89170016|NCT02679365|Experimental|group a|This arm will have lower segment cesarean section done with double locking technique for closure of Rectus Sheath.
89170017|NCT02679365|Active Comparator|group b|This arm will have lower segment cesarean section done with continuous non-locking technique for closure of rectus sheath.
89170018|NCT01025167|Experimental|Test|Supportan(R) (500 ml)/disease-specific enteral tube feed for oncologic patients with special key substrates
89170019|NCT01025167|Placebo Comparator|Control|Fresubin(R) energy fibre (500 ml)/a nutritionally complete enteral standard feed (isoenergetic)
89170020|NCT02679443|No Intervention|Delayed Arm|Participants are started on folate and vitamin B12 supplementation for 5-7 days prior to initiation of chemotherapy
89170021|NCT02679443|Experimental|Immediate Arm|Participants are started on folate and vitamin B12 supplementation simultaneously with chemotherapy (within 24 hours of initiation of chemotherapy)
89170022|NCT01019005|Experimental|Tibial|
89170023|NCT01019005|Experimental|Wound|
89170024|NCT01019005|No Intervention|Sham|
89170025|NCT05663255||Exposed group|Patients treated with CFTR modulator with at least the discontinuation of one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics) during the year of initiation (A0) of CFTR modulator.
89170026|NCT05663255||Control group|Patients treated with CFTR modulator without any discontinuation of respiratory co-therapy (azithromycin, RhDNase, inhaled antibiotics) during the year of initiation (A0) of CFTR modulator.
89170027|NCT02678975|Active Comparator|Control|Alkylating chemotherapy
89170028|NCT02678975|Experimental|Experimental|Alkylating chemotherapy + disulfiram + copper
89170029|NCT02677415|Other|Local anesthesia|local anesthesia and spontaneous breathing will be maintained.
89170030|NCT02677415|Other|General anesthesia|Intravenous anesthetics and controlled ventilation will be used .
89170031|NCT00454051|Active Comparator|Omalizumab|Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
89170032|NCT00454051|Placebo Comparator|Placebo|Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.
89170033|NCT04181489|Experimental|Sintilimab + R-CHOP|
89170034|NCT02537561|Experimental|Arm 1: Cisplatin, Gemcitabine, Talazoparib Solid Tumors|"Dose levels of the drugs will be dependent on which dose level the participants is enrolled.~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~Cisplatin and gemcitabine will be given for a total of 6 cycles.~Talazoparib may be continued as a single agent maintenance therapy."
89170035|NCT02537561|Experimental|Arm 2: Cisplatin, Gemcitabine, Talazoparib NSCLC|"Dose levels of the drugs will depend on what the MTD is in the dose escalation portion of the study~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~Cisplatin and gemcitabine will be given for a total of 6 cycles.~Talazoparib may be continued as a single agent maintenance therapy."
89170036|NCT04179773||Cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
89170037|NCT04179773||Non-cirrhotic patients|Current care study. Data collection on oncological efficacy (Clinical, biological, imaging) Data collection on hepatology (clinical, biological, imaging)
89170038|NCT02676089|Experimental|CHF 5993 200/6/12.5 µg|"Treatment A:~CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB"
89170039|NCT02676089|Active Comparator|CHF 1535 200/6 µg|"Treatment B:~CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF"
89170040|NCT02676089|Active Comparator|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|"Treatment C (open-label arm):~CHF 1535 200/6 µg: 2 inhalations bid~+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio"
89170041|NCT02679053|Experimental|Exercise (IG)|Aerobic exercise three times per week on indoor bicycles at 60 to 75% of maximal heartrate aiming at a weekly total of 17.5kcal/kg bodyweight for 6 consecutive weeks. The exercise will take place under supervision. At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
89170042|NCT02679053|Placebo Comparator|Control (CG)|Basic stretching and mobilisation program 3 times per week each for approx. 40 minutes, also under supervision for 6 consecutive weeks. At the end of every week physical fitness is evaluated by the queens step test.At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
89170043|NCT02679209|Experimental|Bone allograft|commercially available demineralized bone matrix putty allograft will be used to fill in the defect after opening a periodontal flap
89170044|NCT02679209|Experimental|Amnion chorion membrane|Amnion chorion commercially available allograft bioresorbable membrane as a guided tissue regeneration technique will be used to in the defect after opening a periodontal flap
89170045|NCT02679131|Experimental|Cohort A|Normal Renal function, Belinostat IV, Dose A
89170046|NCT02679131|Experimental|Cohort B|Mild Impairment, Belinostat IV, Dose A
89170047|NCT02679131|Experimental|Cohort C|Moderate Impairment, Belinostat IV, Dose B
89170048|NCT02679131|Experimental|Cohort D|Severe Impairment, Belinostat IV, Dose B
89170049|NCT02675777|Experimental|Quality Improvement Intervention|"Quality improvement intervention: 4 months during which a practice facilitator supports the clinic in implementing routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs (see Intervention) as part of behavioral health integration."
89170050|NCT02675777|No Intervention|Usual Care|Care received after 2/2016 but before active implementation begins, which includes passive access to tools in the EHR and 2 months of preparation in each clinic (team building and local pretesting by a local implementation team supported by the external practice facilitator).
89170051|NCT00484939|Experimental|Bevacizumab + capecitabine|Participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3-week treatment cycle. In addition, participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
89170052|NCT00484939|Active Comparator|Capecitabine|Participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
89170053|NCT02677337|No Intervention|No intervention|
89170054|NCT02677337|Other|Educational Program|chart abstraction will be conducted post education intervention component.
89170055|NCT02677025|Experimental|Young Women's Health CoOp (YWHC)|This is an adapted behavioral intervention for young women in Cape Town South Africa who dropped out of school, who use alcohol and other drugs and are at risk for HIV.
89170056|NCT02677025|Active Comparator|HIV Counseling/Testing|Provide age and gender appropriate standard HIV counseling and testing.
89170057|NCT02675855|Experimental|GrafixPRIME®|GrafixPRIME® is cryopreserved human placental membrane Patients will be fitted with off-loading devices
89170058|NCT02675855|Active Comparator|Active Comparator|Wound cover, Dressing Application Patients will be fitted with off-loading devices
89170059|NCT02675621|Placebo Comparator|Control|Mix 1 flavored still beverage
89170060|NCT02675621|Active Comparator|Phenolic beverage 1|Mix 2 flavored still beverage with a high dose phenolic extract
89170061|NCT02675621|Active Comparator|Phenolic beverage 2|Mix 3 flavored still beverage with a high dose phenolic extract1 and a fruit extract
89170062|NCT02675621|Active Comparator|Phenolic beverage 3|Mix 4 flavored still beverage with a low dose phenolic extract3 and a fruit extract
89170063|NCT05663177||Study arm|Almonertinib plus metronomic oral vinorelbine
89170064|NCT00642551|Active Comparator|MK-7|1 capsule per day existing of 180 µg menaquinone-7
89170065|NCT00642551|Placebo Comparator|Placebo|1 placebo capsule per day for three years
89170066|NCT02678897|No Intervention|Pain management in early pregnancy MTOP|Patients in early pregnancy (pregnancy weeks <9weeks) undergoing medical termination of pregnancy gets Ibuprofen (tbl 600mg 3 times a day) and Paracetamol (tbl 1000mg 3 times a day).
89170067|NCT02678897|Experimental|Patient controlled analgesia (PCA)|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.~Patients get pain medication (Oxynorm) via PCA"
89170068|NCT02678897|Active Comparator|Oxynorm on-demand|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.~Patients get extra pain medication (Oxynorm) on-demad from the nurse."
89170069|NCT04181957|Placebo Comparator|Placebo|Participants receive placebo tablet composed of lactose.
89170070|NCT04181957|Active Comparator|Active|Participants receive a 50mg tablet of lisdexamfetamine dimesylate (LDX) once.
89170071|NCT02678819|Experimental|Digital Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid during anesthesia and intensive care crises management.
89170072|NCT02678819|No Intervention|No digital aid|Anesthesia and intensive care crises managed without any cognitive aid.
89170073|NCT02678663|Experimental|Injection-assisted cold snare polypectomy (I-CSP)|Polyps in this group will be resected with the cold snare technique after pre-lift of the lesion with a submucosal injection of methylene blue-tinted normal saline solution. The polyp and a small rim of normal tissue will be then snared closely and removed in a single piece without the use of electrocautery.
89170074|NCT02678663|Active Comparator|Endoscopic mucosal resection (EMR).|"Polyps in this group will be removed in a single piece by using an inject-and-cut EMR technique. Methylene blue-tinted normal saline solution will be injected into the submucosal space followed by the application of snare cautery for lesion resection."
89170075|NCT00643409|Experimental|1|
89170076|NCT00643409|Experimental|2|
89170077|NCT04180007|Experimental|Neoadjuvant arm|Patients receive Apatinib orally qd up to 12 wk.
89170078|NCT02675309|Experimental|MT-8554, rosuvastatin and simvastatin|Subjects will be administered a single dose of rosuvastatin followed on Day 4 by a single dose of simvastatin. MT-8554 will be administered from Days 6 to 12 with co-administration of rosuvastatin and simvastatin on Days 9 and 12, respectively.
89170079|NCT00453973|Experimental|Maintenance Switch in Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were on dialysis and had been on Epoetin at study entry, and who were switched to peginesatide (NCT00434330). This group is categorized as Maintenance Switch in Dialysis Participants regardless of dialysis status at the start of or during this study."
89170080|NCT00453973|Experimental|Treatment Initiation in Non-Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were not on dialysis and not on erythropoiesis stimulating agents (ESAs), and who received peginesatide (NCT00228436). This group is categorized as Initiation of Treatment in Non-Dialysis Participants regardless of dialysis status at the start of or during this study."
89170081|NCT05662007||Young swimmers group|
89170082|NCT05662007||Healthy Control Group|
89170083|NCT01025245|Experimental|remifentanil, MgSO4|Experimental 1 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and MgSO4 30 mg/kg IV at the induction followed by intraoperative infusion at 10 mg/kg/hr Drug : remifentanil, MgSO4 Experimental 2 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and normal saline Drug : remifentanil Active comparator : Intraoperative remifentanil infusion at 0.05 ㎍/㎏/min and normal saline Drug : remifentanil
89170084|NCT05661929||Users of medical internet resources|This group includes people older 18 years who are looking for medical information at the Internet-resources
89170085|NCT01025323|Active Comparator|Minimal Intervention Group|Participants in this arm receive advice and printed guidelines but no counseling or systematic instruction.
89170086|NCT01025323|Active Comparator|Enhanced Intervention Group|Participants in this group receive advice and the same printed guidelines as the Minimal Intervention Group, together with dietary and physical activity counseling provided by a dietician and/or coordinator, periodic professional reviews of their progress and systematic instruction.
89170087|NCT02677259|Experimental|Estradiol + Standard Luteal Phase Support|"17-beta estradiol 3 mg PO/PV BID from day of oocyte retrieval until 6 weeks gestation~Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation"
89170088|NCT02677259|Active Comparator|Standard Luteal Phase Support|1. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation
89170089|NCT00465361|No Intervention|Baseline Performance|Observation of baseline performance
89170090|NCT00465361|Experimental|Post-intervention Performance|Observation of performance post-intervention
89170091|NCT05484479|Experimental|Exercised group|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will be trained using sixty-minute Baduanjin training/exercise (5 times weekly)
89170092|NCT05484479|No Intervention|control group|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will receive no training
89170093|NCT02677103|Experimental|RSWT group|The RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder. RSWT will be performed once per week, and will be continued for 3 weeks.
89170094|NCT02677103|Experimental|USNP group|All needle punctures will be guided by ultrasound (US). The puncture needle is a 3.8cm 22# needle attached on a 5ml syringe. Before puncture, the skin of the puncture site will be sterilized with better iodine, and the transducer will be covered with a sterilized plastic bag. After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed. The needle tract will be monitored by ultrasound to make sure the needle penetrated through the calcific plaque, but does not penetrate the rotator cuff.
89170095|NCT02677103|Experimental|RSWT plus USNP|In this group, each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs
89170096|NCT00464815|Experimental|Group A|Subjects of 11-17 years of age who will receive GSK134612
89170097|NCT00464815|Active Comparator|Group B|Subjects of 11-17 years of age who will receive MencevaxTM ACWY
89170098|NCT02675387|Active Comparator|Traditional Group|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine
89170099|NCT02675387|Experimental|Buzzy|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine after sensitizing the area with a vibrating device
89170100|NCT00642239|Placebo Comparator|2|Concurrent radiochemotherapy and placebo
89170101|NCT00642239|Experimental|1|concurrent radiochemotherapy and Sodium Glycididazole
89170102|NCT01022437|Experimental|Geranium Oil and component PN-34|
89170103|NCT00642317||Asian Youth and Tobacco Control|Smoking Questionnaire for self-identified Chinese or Vietnamese participants.
89170104|NCT04181021|Experimental|Intervention|Providers and community-based promoters will participate in the VCAT workshop. Providers and community-based promoters will take part in two different workshops at different times.
89170105|NCT04181021|No Intervention|Control|Providers and promoters in the control arm will not be invited to participate in the VCAT workshop.
89170106|NCT02678507||Patients with chronic pain on opioids|
89170107|NCT02676947|Experimental|Open Label|Intravenous Tocilizumab 8mg/kg monthly (up to a maximum dose 800mg) for 6 months
89170108|NCT04180865||Parkinson's disease patients|150 de novo treatment naive Parkinson's disease patients.
89170109|NCT04180865||Healthy control subjects|150 Healthy sex- and age-matched controls, also matched according to presence and severity of constipation, serving as a control group for microbiome composition analyses.
89170110|NCT00464737|Placebo Comparator|Placebo|Placebo
89170111|NCT00464737|Experimental|Rotigotine 4 mg|4 mg/24 hrs
89170112|NCT00464737|Experimental|Rotigotine 8 mg|8 mg/24 hrs
89170113|NCT00642629|Active Comparator|1|STA-5326 mesylate
89170114|NCT00642629|Placebo Comparator|2|Placebo
89170115|NCT02678585|Active Comparator|Nalbuphine|53 patients received intravenous regional lidocaine plus Nalbuphine
89170116|NCT02678585|Other|Control group|53 patients received intravenous regional lidocaine
89170117|NCT04102163||All Participants|Participants diagnosed with CD and CPF from approximately 20 Spanish hospitals, who will initiate medical or surgical treatment for their CPF within the eligibility period from Sep 2020 to Sep 2021, will be observed prospectively for approximately 31 months.
89170118|NCT00453349|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
89170119|NCT00453349|Active Comparator|Levofloxacin plus Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
89170120|NCT02675153|Experimental|Upper gastrointestinal strictures|Patients with upper gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
89170121|NCT02675153|Experimental|Lower gastrointestinal strictures|Patients with lower gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
89170122|NCT04033601|Experimental|non-pharmacological intervention group|
89170123|NCT04033601|Experimental|control group|
89170124|NCT01025401|No Intervention|Motor manifestations during seizures|
89170125|NCT02673437||Rivaroxaban group|Patients who have been prescribed rivaroxaban and antiplatelet therapy for the prevention of atherothrombotic events following ACS.
89170126|NCT02673437||Alternative dual antiplatelet therapy|Patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS
89170127|NCT00642785||1|Patients with active oral or genital HSV skin lesions
89170128|NCT00642785||2|Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment
89170129|NCT00642785||3|Patients with active shingles/zoster
89170130|NCT00642785||4|Patients with post herpetic neuralgia
89170131|NCT02676557||LASIK|
89170132|NCT02676713|Experimental|TCM Sequential Treatment|"After conservative surgery, patients start to take pre-ovulation decoction for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found LUFS or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles.~Pre-ovulation decoction is HuoXueXiaoYi decoction, and post-ovulation decoction is BuShenZhuYun decoction. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.~All drugs are tcm formula granules, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
89170133|NCT02676713|Placebo Comparator|Placebo|"After conservative surgery, patients start to take pre-ovulation decoction(placebo) for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found luteinized unruptured follicle syndrome (LUFS) or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction(placebo) for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.~Pre-ovulation decoction and post-ovulation decoction is placebo, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
89170134|NCT02673593|Placebo Comparator|Placebo|Taken orally as a single dose (Cohorts 1 - 4) Taken orally as a multiple daily dose for 28 days (Cohorts 5 - 7)
89170135|NCT02673593|Experimental|DS102 100mg Single Dose|Taken orally once by Cohort 1
89170136|NCT02673593|Experimental|DS102 500mg Single Dose|Single Dose taken orally on three separate occasions by Cohort 2 (second and third dose assessing food effect)
89170137|NCT02673593|Experimental|DS102 1000mg Single Dose|Taken orally once by Cohort 3
89170138|NCT02673593|Experimental|DS102 2000mg Single Dose|Taken orally once by Cohort 4
89170139|NCT02673593|Experimental|DS102 500mg Multiple Dose|Taken orally once a day for 28 days by Cohort 5
89170140|NCT02673593|Experimental|DS102 1000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 6
89170141|NCT02673593|Experimental|DS102 2000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 7
89170142|NCT04178525|Experimental|Arm A (Experimental group|ChitoCare gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
89170143|NCT04178525|Placebo Comparator|Arm B (Control group)|Placebo gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
89170144|NCT04181099|Other|Zirconia structure|The participants will carry an orthodontic device containing 4 discs of differently structured zirconia and titanium to test the biofilm formation in order to determine the ideal structure for the neck area of zirconia dental implants.
89170145|NCT04178369|Experimental|Experimental-Study Group|In addition to the conservative treatment of the control group, proximal and distal tibiofibular joint manipulations will be applied for 6 weeks.
89170146|NCT04178369|Active Comparator|Control Group|All participants were given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept (conservative treatment) for 5 days a week, 45 minutes each.
89170147|NCT04179617|Experimental|Preferred nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 5% nicotine content pod (their preferred pod)
89170148|NCT04179617|Experimental|Low nicotine content JUUL pod|During one experimental visit, participants will have access to a JUUL loaded with a 3% nicotine content pod (non-preferred pod)
89170149|NCT00464269|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.
89170150|NCT00464269|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
89170151|NCT00464269|Experimental|BRV 20mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.
89170152|NCT00464269|Experimental|BRV 50mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.
89170153|NCT00642863|Experimental|Low birth iron|Infants with low birth iron who receive vitamins A and D + iron
89170154|NCT00642863|Experimental|Marginal birth iron 1|Infants with marginal birth iron randomized to receive vitamins A and D + iron
89170155|NCT00642863|Active Comparator|Marginal birth iron 2|Infants with marginal birth iron randomized to receive vitamins A and D without iron
89170156|NCT00642863|Active Comparator|Normal birth iron|Infants with normal birth iron who receive vitamins A and D without iron
89170157|NCT00642863|Experimental|Combined ID|Marginal-birth-iron vitamins only-treated infants who have IDA at 9 mo.
89170158|NCT00642863|Experimental|Early postnatal IDA|Infants with IDA at 9 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks
89170159|NCT00642863|Experimental|Late postnatal IDA|Infants with IDA at 18 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks. These infants were also not anemic when screened at 9 months.
89170160|NCT02674763|Experimental|Dose Escalation Schedule A|IMGN779 administered on days 1 and 15 of a 28-day cycle
89170161|NCT02674763|Experimental|Dose Escalation Schedule B|IMGN779 administered on days 1, 8, 15 and 22 of a 28-day cycle
89170162|NCT02674763|Experimental|Dose Escalation Schedule C|IMGN779 administered on days 1 and 8 of a 21-day cycle
89170163|NCT02674763|Experimental|Dose Expansion Cohort|Patients with Relapsed AML; IMGN779 administered at dose and schedule selected as the putative RP2D.
89170164|NCT02674997||Study participants|Participants with Hemophila A
89170165|NCT02676635|Experimental|Ergonomics Training Only|Participants in this arm receive Ergonomics training only
89170166|NCT02676635|Experimental|Ergonomics and Safety Voice Training|Participants in this arm receive training on both Ergonomic principles and Safety Voice training
89170167|NCT02676635|No Intervention|Control Group|Participants in this arm will receive no additional Ergonomics or Safety Voice training
89170168|NCT04178291|Experimental|Conventional debridement and air polishing|All participants will receive full mouth EPAP as an adjunct to RSD using ultrasonic scalers and Gracey currettes. The EPAP procedure will be performed using the Air-Flow Master R (EMS) equipment. For supragingival biofilm removal, the Air-Flow handpiece will be used, while the Perio-Flow handpiece with a disposable nozzle will be used for subgingival debridement at sites with PPD ≥ 5mm. No time limit is applicable for supragingival air polishing. However, for subgingival debridement, the nozzle will be inserted for 5 seconds into each pocket, and moved vertically up and down. Gracey currettes will be used at sites with PPD ≥ 5mm.
89170169|NCT04178291|Active Comparator|Conventional debridement|All participants will receive full mouth RSD using ultrasonic scalers and Gracey currettes. Gracey currettes will be used at sites with PPD ≥ 5mm.
89170170|NCT04178681|Experimental|V-A-C|"Order of administration:~100% vegetable fat blend~100% Anhydrous Milk Fat (AMF)~100% Cream (AMF + milk fat globular membranes)"
89170171|NCT04178681|Experimental|V-C-A|"Order of administration:~100% vegetable fat blend~100% Cream (AMF + milk fat globular membranes)~100% Anhydrous Milk Fat (AMF)"
89170172|NCT04178681|Experimental|A-V-C|"Order of administration:~100% Anhydrous Milk Fat (AMF)~100% vegetable fat blend~100% Cream (AMF + milk fat globular membranes)"
89170173|NCT04178681|Experimental|A-C-V|"Order of administration:~100% Anhydrous Milk Fat (AMF)~100% Cream (AMF + milk fat globular membranes)~100% vegetable fat blend"
89170174|NCT04178681|Experimental|C-A-V|"Order of administration:~100% Cream (AMF + milk fat globular membranes)~100% Anhydrous Milk Fat (AMF)~100% vegetable fat blend"
89170175|NCT04178681|Experimental|C-V-A|"Order of administration:~100% Cream (AMF + milk fat globular membranes)~100% vegetable fat blend~100% Anhydrous Milk Fat (AMF)"
89170176|NCT04016675|Experimental|Study Group|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
89170177|NCT04016675|Active Comparator|Control Group|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
89170178|NCT04180631|Experimental|Quantitative ultrasound imaging parameter|Quantitative ultrasound imaging parameter (QUS)
89170179|NCT02673125|Experimental|Double embryo transfer|Patients with both MitoGrade normal and Mitograde elevated PGS normal embryos will have two embryos replaced- one Mitograde normal and one Mitograde elevated.
89170180|NCT00644267|Active Comparator|1|Subjects will use a telemedicine system for blood pressure control
89170181|NCT00644267|No Intervention|2|Patients with hypertension receiving usual care by a primary care physician
89170182|NCT00643643|Experimental|A|
89170183|NCT00643643|Experimental|B|
89170184|NCT00643643|Experimental|C|
89170185|NCT00643643|Experimental|D|
89170186|NCT00643643|Placebo Comparator|E|
89170187|NCT04179227||Observational (focus group)|Participants attend a focus group session and review printed copies of planned posts for the to-be-developed Facebook intervention over 90 minutes to 2 hours.
89170188|NCT04180787|Experimental|Keto Coffee|VPX Bang® Keto Coffee beverage
89170189|NCT04180787|Placebo Comparator|Placebo|Flavor-matched placebo beverage
89170190|NCT02676869|Experimental|IMP321 dose escalation|IMP321 administered fortnightly in addition to SOC pembrolizumab.
89170191|NCT02676245|Experimental|Viewing NBS + DBS Educational Movies|Group A: pregnant women who will view the NBS and residual specimen movies and printed materials during one visit between 30 and 40 weeks gestation.
89170192|NCT02676245|Experimental|Viewing NBS Educational Movie only|Group B: pregnant women who will view the NBS movie only and printed materials at one visit between 30 and 40 weeks. The movies will be presented on a tablet PC.
89170193|NCT02676245|No Intervention|No Educational Interventions|Control Group: pregnant women who will receive no experimental intervention during pregnancy or the postpartum period but will receive whatever information is routinely provided by their OB clinic and/or delivery center.
89170194|NCT02674841|Experimental|Feedback group|Receives live feedback on TUT and pulling force during exercises.
89170195|NCT02674841|Active Comparator|Control group|Receives no feedback on TUT but on pulling force during exercises.
89170196|NCT02673047||Botox®|Patients prescribed botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence associated with neurogenic detrusor overactivity or overactive bladder as per standard of care in clinical practice.
89170197|NCT02672813|Experimental|Pectoral Nerve I and II block|Under Ultrasound guidance, Pectoral nerve I block is given for every breast surgery using 10ml of 0.25 % Ropivacaine ( without added preservatives). Similarly Pectoral nerve II block is also given using 20 ml of 0.25% Ropivacaine ( without added preservative) in same group of patient.
89170198|NCT02672813|No Intervention|No block|Pectoral nerve block is not given in this group of patients undergoing breast surgery
89170199|NCT00643019|Experimental|SAFE Intervention|Behavioral Intervention
89170200|NCT00643019|Other|Control|Sexually Transmitted Infection Risk Reduction Counseling
89170201|NCT00643721||D,FR|Young healthy athletes
89170202|NCT02676167|Other|Intervention|
89170203|NCT02672735|Experimental|Corrective Exercise Program|Participants in the Corrective Exercise Program (CEP) group (n = 28) will be given a four-week corrective exercise programming intervention.
89170204|NCT02672735|No Intervention|Control|The participants in the Control (CON) group (n = 28) will have their four-week corrective exercise programming intervention deferred for 4 weeks, and as such, will serve as the comparative group for the CEP group.
89170205|NCT04178447|Experimental|Group 1: ESRD subjects not on dialysis or severe RI|subjects with eGFR <15 mL/min/1.73 m2) or (eGFR 15 to <30 mL/min/1.73 m2)
89170206|NCT04178447|Experimental|Group 2: normal renal function|subjects with eGFR ≥90 mL/min/1.73 m2
89170207|NCT04178447|Experimental|Group 3: moderate RI|subjects with eGFR 30 to <60 mL/min/1.73 m2
89170208|NCT04178447|Experimental|Group 4: mild RI|subjects with eGFR 60 to <90 mL/min/1.73 m2
89170209|NCT04180553|Experimental|Point-Of-Care Ultrasound Guided Resuscitation|Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission.Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and IVC study performed post-operatively in PACU, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two. Based on ultrasound findings, their fluid resuscitation will be guided to a fluid liberal or fluid restrictive strategy at the time of each assessment.
89170210|NCT04180553|Active Comparator|Usual Care|The comparator arm in this trial is randomization to usual care. Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria
89170211|NCT05277155|Experimental|Intervention Group (BEJO Red Ginger Extract)|84 patients, dosage: BEJO Red Ginger Extract orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)
89170212|NCT05277155|Placebo Comparator|Control Group (Placebo)|84 patients, dosage: Placebo orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)
89170213|NCT02674919|Experimental|Nordic Hamstring|The Nordic Hamstring group performs a progressive strengthening program (Mjolsnes et al., 2004) comprising of the Nordic Hamstring exercise during a period of 10 weeks. The training load increases from one session per week in week 1 to 3 sessions per week in week 3-10. Number of sets and repetitions progressively increase from 2 to 3 and 5 to 12, respectively. The exercise program is performed in the end of a regular football training session.
89170214|NCT02674919|Other|Control|The control group are asked not to perform the exercise or any other specific strength training for the hamstring muscles and to continue to play football as usual.
89170215|NCT05584319|Experimental|Empagliflozin group|Subjects in Empagliflozin group take in 10Mg Empagliflozin per day.
89170216|NCT05584319|No Intervention|Blank control group|Subjects in Blank control group will not receive Empagliflozin or other sglt-2 inhibitors.
89170217|NCT02674607|Experimental|patients|thirty children with beta thalassemia major will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
89170218|NCT02674607|No Intervention|controls|thirty healthy children of matched age and sex
89170219|NCT02676323|Experimental|Treatment|Participants will be given panobinostat in combination with fludarabine and cytarabine. Treatment consists of one course of therapy given over 12 days. Participants will also receive intrathecal triples and leucovorin
89170220|NCT00643799|Experimental|A|
89170221|NCT00643799|Active Comparator|B|
89170222|NCT00643799|Placebo Comparator|C|
89170223|NCT02672891|Experimental|Device|condom balloon catheter which is composed of a latex condom (SURE natural latex condom, Shanghai) and a 16-20 F, 2 ways silicon coated Foley catheter (Egypt). The catheter was introduced inside the condom and tied over tightly several times with a silk suture, to prevent air escape.
89170224|NCT02676401|Experimental|MT-3995 Low|
89170225|NCT02676401|Experimental|MT-3995 Middle|
89170226|NCT02676401|Experimental|MT-3995 High|
89170227|NCT02672969|Experimental|Smoke evacuation uses|Smoke evacuation uses means using RapidVac Smoke Evacuator with electrosurgical unit during coagulation and cutting surgery. (Experimental group)
89170228|NCT02672969|No Intervention|no smoke evacuation uses|No smoke evacuation uses means using only the regular electrosurgical unit during coagulation and cutting surgery. (Control group)
89170229|NCT05348213|Experimental|R-ICE+X|
89170230|NCT02674451|Active Comparator|RIPC|Participants will receive remote ischemic preconditioning within one hour of coronary angiography. This involves blood pressure cuff inflation to 200mmHG for three-5 minute periods, each separated by 5 minute intervals.
89170231|NCT02674451|Sham Comparator|Controls|Participants will have routine blood pressure measurements will be obtained.
89170232|NCT00643877|Experimental|B|PHRAC was performed 7 days before surgery. Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
89170233|NCT00643877|No Intervention|A|Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
89170234|NCT02676479|Experimental|Uterine Lavage Group|"The study will involve up to 30 pairs of male and female sexually intimate partners who are carriers for a genetic disease (e.g Sickle Cell Disease or Thalassemia) and at high risk of transmitting the gene.~The female partner will be superovulated to mature multiple oocytes which can be fertilized, inseminated with her partner's sperm through intra-uterine insemination (IUI). Four to six days after IUI, the female partner will undergo a non-surgical uterine lavage procedure (Previvo Uterine Lavage System™, CA, U.S.A.) to recover preimplantation embryos."
89170235|NCT00643175||1|Osteoporosis in patients with fragility hip fractures.
89170236|NCT02674295|Experimental|Cohort 1|50 milligram (mg) of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration.
89170237|NCT02674295|Experimental|Cohort 2|20 mg of intravenous esketamine in 30 milliliter (mL), fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
89170238|NCT02674373||Localized gastric cancer|resectable tumor receiving a curative intent treatment.
89170239|NCT02674373||advanced gastric cancer|unresectable tumor treated with palliative chemotherapy
89170240|NCT04179071|Experimental|Savolitinib|Subjects will receive single dose of 600mg savolitinib after a high-fat, high-calorie meal.
89170241|NCT04179071|Experimental|Savolitinib + Famotidine|Subjects will receive savolitinib 600mg single dose after high-fat, high-calorie meal and after 1.5 hours (Part A) or 5.5 hours (Part B) of famotidine 40mg dose. Famotidine will be administered after an overnight fast of at least 8 hours with approximately 240 mL of water.
89170242|NCT02672579||Children 4-7 years|Pediatric subjects between the ages of 4 and 7 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
89170243|NCT02672579||Children 8-17 years|Pediatric subjects between the ages of 8 and 17 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
89170244|NCT02672579||Parents|Parents of pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of their child's severity of pruritus.
89170245|NCT02672579||Clinicians|Clinicians treating pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of the child's severity of pruritus.
89170246|NCT02672501|Experimental|anti-CD19-CAR-T cells|patients receive chemotherapy(CF, cyclophosphamide and Fludarabine) on day -6 to day -1, then infusied with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity.
89170247|NCT02673983|Experimental|Patients undergoing endoscopic full-thickness biopsy|
89170248|NCT02675933|No Intervention|Standard of Care|"The control arm participants will receive only a satisfaction survey once disposition is determined by the physician provider. The satisfaction survey will be collected by the research associated and kept in a protected location, along with all other study materials.~All patients will receive standard of care, which at this institution is the help of Child Life Specialists, when they are available and requested by the physician. Physicians will be instructed to request Child Life Specialists with the same discretion as with all patients."
89170249|NCT02675933|Active Comparator|Questionnaire|"Participants who are randomized to the questionnaire arm will receive a patient-centered questionnaire at the beginning of their visit. This single page document will ask questions about their child including, but not limited to, diagnoses, suggestions for distraction, sensory issues that may affect their visit, and method to best administer medications. The research associate will ask them to fill it out to the best of their ability and will collect the questionnaire prior to a physician provider seeing the patient. At least one physician provider must review the questionnaire prior to seeing the patient.~Once disposition is determined, the satisfaction survey will be distributed by the research associate along with an envelope for the parent to seal their survey within."
89170250|NCT02674139|Active Comparator|IUD insertion 6 Weeks after delivery|Subjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later
89170251|NCT02674139|Experimental|Immediate Post-placental insertion|Subjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section.
89170252|NCT00910169||inpatient treatment|naturalistic treatment no modification: observational study
89170253|NCT00484315|Experimental|TAXUS Element|
89170254|NCT00484315|Active Comparator|TAXUS Express|
89170255|NCT02672267|Experimental|Stem Cells|Experimental: Stem Cells ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS Intervention: Biological: Stem cells
89170256|NCT02672267|Placebo Comparator|Placebo|Lactated Ringer's Solution
89170257|NCT04178759|Active Comparator|Control|Patients with benign liver disease, who undergo liver resection
89170258|NCT04178759|Experimental|Experimental|Patients with liver metastases and received chemotherapy, who undergo liver resection
89170259|NCT02671799|Experimental|VenTouch System Implant|The VenTouch System is indicated for patients who have moderately severe or severe functional mitral regurgitation (grade 3 or 4 MR).
89170260|NCT01019083|Placebo Comparator|zinc supplementation-Placebo|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
89170261|NCT01019083|Placebo Comparator|Anti Parasite Drug- Placebo|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
89170262|NCT01019083|Experimental|Effect of Arsenic in Dukoral- Control|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
89170263|NCT01019083|Experimental|zinc supplementation|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
89170264|NCT01019083|Experimental|administration of antiparasitic drugs|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
89170265|NCT01019083|Experimental|Effect of arsenic on Dukoral response|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
89170266|NCT00463801|Experimental|Daptomycin|350 mg of Daptomycin was supplied as sterile lyophilized powder in glass vials. Each vial was to be reconstituted with 7 mL of normal saline or water for injection, to give a 50 mg/mL drug concentration. Daptomycin was to be administered as a 30-minute intravenous infusion, once daily for at least 7 days, at the dose of 4 mg/Kg, up to a maximum of 14 days.
89170267|NCT04016519||Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
89170268|NCT02672345||Sevoflurane Group|Group of patients receiving sevorane during extracorporeal circulation period.
89170269|NCT02672345||Not Sevoflurane Group|Group of patients who did not receive the sevorane during extracorporeal circulation period.
89170270|NCT02537483|Experimental|IDP-120 Gel|IDP-120 Gel, applied topically to the face once daily for 12 weeks.
89170271|NCT02537483|Active Comparator|IDP-120 Component A|IDP-120 Component A, applied topically to the face once daily for 12 weeks
89170272|NCT02537483|Active Comparator|IDP-120 Component B|IDP-120 Component B, applied topically to the face once daily for 12 weeks
89170273|NCT02537483|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, applied topically to the face once daily for 12 weeks
89170274|NCT02537249|Experimental|Dexmedetomidine|
89170275|NCT02537249|Sham Comparator|Saline 0.9%|
89170276|NCT00644111|Placebo Comparator|1|Control group receiving saline placebo through an epidural catheter
89170277|NCT00644111|Active Comparator|2|Experimental group receiving active medication through the epidural catheter
89170278|NCT04016441||Subjects|Subjects who are capable of completing an online, English survey.
89170279|NCT02673827|No Intervention|Group control|Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
89170280|NCT02673827|Experimental|experimental group|"Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation.~They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation."
89170281|NCT00644891|Active Comparator|1|
89170282|NCT00644891|Active Comparator|2|
89170283|NCT02670863|Experimental|Experimental Infant Formula|Experimental Infant Formula containing a prebiotic
89170284|NCT02670863|Active Comparator|Standard Infant Formula|Standard bovine milk-based term infant formula
89170285|NCT04178057|Experimental|GB222 3mg/kg|GB222 3mg/kg
89170286|NCT04178057|Experimental|GB222 5mg/kg|GB222 5mg/kg
89170287|NCT04178057|Experimental|GB222 7.5mg/kg|GB222 7.5mg/kg
89170288|NCT04178057|Experimental|GB222 10mg/kg|GB222 10mg/kg
89170289|NCT02672189|No Intervention|Waiting list control group|Women in the waiting list control group will receive usual care. They will complete questionnaires during a period of 6 months. After completion of the last questionnaire they will be offered the opportunity to follow the EVA-Online program.
89170290|NCT02672189|Experimental|EVA-Online guided group|"The CBT/Relaxation program (EVA-Online) consists of 6 online sessions intended to be completed weekly over a 6 week period. The program comprises the following elements: (1) information and advice about symptoms (e.g., hot flushes, night sweats and sexual functioning); (2) monitoring and modifying precipitants; (3) relaxation and stress reduction; (4) cognitive restructuring of unhelpful thoughts and (5) encouraging helpful behavioral strategies (e.g., pacing activities). Throughout the program women will be asked to spend an hour a week to read the session and fill in the assignments and to spend 30 minutes per day on homework exercises (eg, filling in a hot flush/night sweats diary, practicing relaxation techniques).~Participating women will first undergo a 30 minute phone interview with a trained therapist before they start the online program. The same therapist will provide weekly feedback and support."
89170291|NCT02672189|Experimental|EVA-Online self-management group|The content of the self-management CBT/Relaxation program is the same as the guided version of the program as described above, but without weekly guidance by a trained therapist. The women allocated to the self-management intervention will work through the program independently.
89170292|NCT04177043|Other|Screening|
89170293|NCT04177979|Experimental|Near assisted learning group|Participants in this arm were supervised by the trained peer-instructors.
89170294|NCT04177979|No Intervention|Self directed learning group|Participants in this arm were practicing independently. They were not supervised by any instructors.
89170295|NCT04097249||Healthy subjects|Participants free from any pain specific to the upper limb, chronic pain or other disease.
89170296|NCT04175951|Active Comparator|Tecnis Eyhance|Tecnis Eyhance hydrophobic IOL is a monofocal IOL with added advantage of slightly better unaided intermediate vision at 60 cms.
89170297|NCT04175951|Active Comparator|Rayner RayOne|Rayner Rayone is a monofocal hydrophilic IOL which is not intended to give better unaided or near vision.
89170298|NCT04175795|Experimental|Dashboard group|The intervention group will receive their personal profile via this e-mail along with instructions on goal-setting and tips to improve brain health.
89170299|NCT04175795|No Intervention|No Dashboard group|The control group will receive only the goal-setting instructions and tips.
89170300|NCT04175717|Experimental|physiotherapy-led follow-up programme|
89170301|NCT02671487|Experimental|Mind-Body Skills Groups|Mind-body skills groups will be administered for 2 hours once a week for 10 weeks and then once a month for 10 months.
89170302|NCT02671487|No Intervention|Wait List Control|No intervention will be administered. Students will have the opportunity to receive the intervention at the end of the study.
89170303|NCT04177667|Active Comparator|Proxeed arm|Subjects received 2 packets per day for 6 months of supplement (1000 mg of L-carnitine, 725 mg of fumarate, 500 mg of acetyl-L-carnitine, 1000 mg of fructose, 50 mg of citric acid, 50 µg of selenium, 20 mg of coenzyme Q10, 90 mg of vitamin C, 10 mg of zinc, 200 µg of folic acid and 1.5 µg of vitamin B12)
89170304|NCT04177667|Placebo Comparator|Placebo arm|Subjects received 2 packets per day for 6 months of placebo
89170305|NCT04093661||Children below 1 year|Children <= 1 year for elective surgery
89170306|NCT04177745|Experimental|Hot Application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
89170307|NCT04177745|Experimental|Cold Application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
89170308|NCT04177745|No Intervention|Standard Practice|The standard practice of the clinic was made. Accordingly, the researcher performed the vein assessment after the participants filled out the questionnaire, and then inserted the 20-G catheter into the inner surface of their forearm without any application. Afterwards, she assessed the pain and anxiety levels of the patients twice before and after the catheter insertion procedure.
89170309|NCT02671955|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression. Dose escalation will continue until the maximum tolerated dose is reached.
89170310|NCT02671955|Experimental|Part 2: Biomarker Evaluation|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
89170311|NCT02671955|Experimental|Part 3: Dose Expansion|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
89170312|NCT02671955|Experimental|Part 4: Dose Expansion|Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
89170313|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.003 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
89170314|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.01 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
89170315|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.02 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
89170316|NCT02670785|Placebo Comparator|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
89170317|NCT04096079||OHCA patients|Patients who suffered an out-of-hospital cardiac arrest between 2015 and 2018 in Province of Pavia (Italy), Ticino Region (Switzerland), Wien area (Austria) and Nicosia area (Cyprus) who underwent a coronary angiography.
89170318|NCT04176809|Experimental|Interventional arm|The intervention will consist in an electronic measurement of HRQoL before each consultation with delivery scores to clinicians, who can discuss it with patients and coupled with therapeutic information. Patients will complete the EORTC-Quality of Life Questionnaire (QLQ)-C30 and the EORTC-QLQ-Breast (BR) 23 questionnaires using the CHES software before their consultation, via a touch pad or from their home via a secure web portal. Therapeutic information will consist on workshops on various themes. Only attendance Workshop 1 will be required, other workshops will be optional. The aim of workshop 1 is to inform patients about their ET and treatment benefits. Two additional optional workshops on nutrition (Workshop 2) and fatigue (Workshop 3) will be offered. This workshops will be collective. Every month, a letter encouraging patients to regularly take their medication will be sent. This letter will also include some tips on how to deal with some particular side effects of ET.
89170319|NCT04176809|No Intervention|Control arm|Participants in the control arm will receive standard care. They will not undergo digital HRQoL collection, and therapeutic information workshops will not be proposed.
89170320|NCT04091321||Chronic Headache|Women who endorse chronic headache
89170321|NCT04091321||Chronic Back Pain|Women who endorse chronic back pain
89170322|NCT02670395|Experimental|JNJ-54416076|Participants will receive single dose of JNJ-54416076 (in ascending dose) in Part 1 and 2 doses of JNJ-54416076 (one dose in the fasted state and an identical dose in the fed state) in Part 2. The dose selected for Part 2 will be selected based on the preliminary safety and PK data in Part 1.
89170323|NCT02670395|Experimental|Placebo|Participants will receive single dose of placebo in Part 1.
89170324|NCT02670317|Experimental|G CHOP 21 + Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
89170325|NCT04175561|Experimental|Intervention|Participants in the intervention arm will be given a green prescription (gardening activities).
89170326|NCT04175561|No Intervention|Control|Participants in the control arm will not be given the intervention.
89170327|NCT04033133|Experimental|Multiple Sclerosis|People with MS get tDCS with different intensities.
89170328|NCT04033133|Active Comparator|Healthy Subjects|Healthy subjects get tDCS with different intensities.
89170329|NCT00644501|Experimental|1|
89170330|NCT00644579|Active Comparator|1|bLAC high dose
89170331|NCT00644579|Active Comparator|2|bLAC low dose
89170332|NCT00644579|Placebo Comparator|3|
89170333|NCT02670239||EVLP group|All lungs from brain dead donors that were considered at high-risk for transplantation and underwent EVLP in the Turin lung transplantation program
89170334|NCT02670005||FFR-PCI group|patients with ST-segment elevation myocardial infarction (STEMI) who received fractional flow reserve (FFR)-guided selective percutaneous coronary intervention (PCI)
89170335|NCT02670005||angiography-PCI group|patients with STEMI who received angiography-guided selective PCI
89170336|NCT05143697|Other|Wellness Coaching for Families and Kids|For clinics assigned to mBMI2Kids intervention, Pediatricians will be trained in Motivational Interviewing (MI) and behavioral intervention. Pediatricians will conduct up to 3 sessions with each parent (3 x 10 min) and refer patients electronically to experienced MI-trained lifestyle coaches. With full access to the electronic medical record coaches will call referred families (child's BMI-for-age ≥85th percentile) and deliver a telephonic MI counseling over two years (6 x 45 min) simultaneous with pediatricians. 49 clinics will be selected with 24 participating in the intervention and 25 providing patients with usual care.
89170337|NCT02671565||Hyaluronic acid (HA) injection users|Patients with at least one procedure claim for intra-articular administration of hyaluronic acid (procedure codes: J7320, J7322, J7325, Q4084, J7317, Q4083, J7321, Q4085, J7323, Q4086, J7324, J7327, J7326) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as HA users.
89170338|NCT02671565||Corticosteroids (CS) injections users|Patients with at least one procedure claim for intra-articular administration of corticosteroids (procedure codes: J1020, J1030, J1040, J1094, J1100, J2920, J2930, J0702, J0704, J3300, J3301, J3302, J3303, J1700, J1710, J1720, J2650, J2920, J2930) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as CS users.
89170339|NCT02671565||HA non-users|Patients who do not have any claims for procedural or surgical intervention including HA and CS injections in first 90 days after their first specialist visit will be considered as HA non-users
89170340|NCT02671721|No Intervention|Conventional Strategy|Patients will receive usual and prudent PEEP and tidal volume settings.
89170341|NCT02671721|Experimental|Maximal Compliance Strategy|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
89170342|NCT02671721|Experimental|Transpulmonary Pressure Strategy|Personal PEEP titration using transpulmonary pressures obtained from a naso/orogastric tube containing an esophageal balloon port
89170343|NCT02537093|Active Comparator|Synchronous telepsychiatry (STP)|Control Arm/Synchronous telepsychiatry (STP): After baseline assessment, subjects will be assessed by a psychiatrist using live interactive videoconferencing every 6 months for a 1 year follow up (3 STP assessments: baseline plus 2 assessments). A report with treatment recommendations following American Psychiatric Association guidelines will be sent to the PCP who will be able to have adlib telephone or email consultations with the telepsychiatrist. The telepsychiatrist will have access to all previous clinical information about the patients.
89170344|NCT02537093|Experimental|Asynchronous telepsychiatry (ATP)|Intervention Arm (ATP): All ATP assessments at 6 monthly intervals post baseline will be conducted by an ATP trained clinician. This interview will be video recorded.The ATP clinicians will then fill out a standardized medical template that will be reviewed by a psychiatrist who will provide a written assessment and psychiatric treatment plan. He will have access to any previous assessments and the PCP will also have continuing access to this psychiatrist by phone or email between the 3 consultations.
89235058|NCT05091593|Active Comparator|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
89170345|NCT02671409|Placebo Comparator|Control group|The exercise program will be drawn from the recommendations of the American College of Physicians and the American Pain Society for the treatment of low back pain. The exercise protocol consist of: Strengthening the abdominal muscles and erector spinae: will be three sets of 15 repetitions for each exercise with rest time between 2 minutes series; - Proprioceptive Neuromuscular Facilitation (PNF). The PNF technique will be the contract-relax the hamstrings by 6/2. Stretching the erector muscles of the spine, iliopsos, hamstrings, quadriceps and sural triceps: will be three three repetitions, with 30 seconds support time each stretch and rest time between sets 1 minute.
89170346|NCT02671409|Experimental|MOB Group|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
89170347|NCT05143463|Experimental|Sequential SAD - NS101|A staggered dosing schedule will be used for each dose level administered under fasting conditions.
89170348|NCT05143463|Placebo Comparator|Sequential SAD - NS101 Placebo|Volume of matching placebo will be determined based on subject weight and NS101 concentration per cohort.
89170349|NCT02669771||Enzalutamide group|oral
89170350|NCT02537405|Experimental|BAY59-7939 granule|
89170351|NCT02537405|Active Comparator|BAY59-7939 tablet|
89170352|NCT02668445|Experimental|Low carbohydrate|Subjects will eat a low carbohydrate diet
89170353|NCT02668445|Experimental|High carbohydrate|Subjects will eat a high carbohydrate diet
89170354|NCT02668601||GDM Exposed|Children exposed to gestational diabetes in utero
89170355|NCT02668601||Non-GDM Exposed|Children not exposed to gestational diabetes in utero
89170356|NCT02668367|Active Comparator|BTA-C585 oral capsules|100 mg capsules; Multiple ascending doses (MAD) from 100 mg to 600 mg
89170357|NCT02668367|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
89170358|NCT04175171|Experimental|GB221|Coprelotamab Injection, 8mg/kg, single dose
89170359|NCT04175171|Active Comparator|Herceptin|Trastuzumab Injection, 8mg/kg, single dose
89170360|NCT04175093||Mild persistent asthma|• Group I, patients with mild persistent asthma.
89170361|NCT04175093||Moderate persistent asthma|• Group II, patients with moderate persistent asthma.
89170362|NCT04175093||Severe persistent asthma|• Group III ,patients with severe persistent asthma.
89170363|NCT02669693|Placebo Comparator|bread without olives|Intervention (no olives): Subjects will consume a meal of 109 g white bread and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
89170364|NCT02669693|Active Comparator|bread with olives|Intervention (olives 100 g): Subjects will consume a meal of 109 g white bread, 100 g of olives and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
89170365|NCT04176653|Placebo Comparator|Placebo|
89170366|NCT04176653|Experimental|0.3 mg/kg|
89170367|NCT04176653|Experimental|1.0 mg/kg|
89170368|NCT04176653|Experimental|3.0 mg/kg|
89170369|NCT04176653|Experimental|10.0 mg/kg|
89170370|NCT00645125|Active Comparator|1|
89170371|NCT00645125|Active Comparator|2|
89170372|NCT04175405|Experimental|Right side of the maxilla|The 635-nm laser parameters; dose: 10J per point (20J/cm2), time: 100 sec per point, 2 points (irradiation on a buccal, and a palatal side of the alveolus/implant), the total energy per session 20J.
89170373|NCT04175405|No Intervention|Left side of the maxilla|
89170374|NCT02669459|Active Comparator|LLETZ|LLETZ (Large Loop excision of the transformation zone) treatment conform current guidelines, which is also the current gold standard in the Netherlands
89170375|NCT02669459|Other|Imiquimod 5% cream|intervention group
89170376|NCT04176887|Experimental|Levetiracetam|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
89170377|NCT04176887|Active Comparator|Phenytoin|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
89170378|NCT04174937|Experimental|Potentiator of antibiotics (PA)|Potenciator of antibiotics (PA) , albumin complex of tetraiodid was given per os, single and multiple doses for the different periods (but not exceeding 14 days)
89170379|NCT04174937|Placebo Comparator|Patients taking placebo PA|Placebo without any active pharmaceutical ingredients was given per os dosed for the patients in same periods of time as per experimental group, single and multiple doses for the different periods (but not exceeding 14 days)
89170380|NCT02668523|Experimental|Raindrop|A single arm study to evaluate the effectiveness of a 2mm Raindrop Near Vision Inlay for the treatment of presbyopia in pseudophakic subjects. This corneal inlay is placed under a LASIK flap or in a corneal pocket, and is designed to change the anterior curvature of the cornea, resulting in the ability to reduce spectacle dependency for near and intermediate tasks.
89170381|NCT02667899|Active Comparator|DBS group|Besides routine treatment, Doc patients in this group will accepted deep brain stimulation treatment.
89170382|NCT02667899|Active Comparator|TMS group|Besides routine treatment, Doc patients in this group will accepted transcranial magnetic stimulation treatment.
89170383|NCT02667899|Placebo Comparator|Control group|This Doc patients will accepted routine treatment.
89170384|NCT02667977|Active Comparator|Group 1|These patients will receive Dextrose 5% and 0.9 NS in their maintenance IV fluids
89170385|NCT02667977|Active Comparator|Group 2|These patients will receive Dextrose 5% and 0.45 NS in their maintenance IV fluids
89170386|NCT05276999|Experimental|Echocardiographic Screening of school age children|Echocardiographic screening of school age children in Tororo and Iganga districts in Uganda to measure the prevalence of RHD before and two years after the deployment of an integrated strep infection education and treatment package.
89235059|NCT05089162|Experimental|Patients with chronic HF with reduced ventricular ejection fraction coming for scheduled day|
89170387|NCT05276999|Experimental|Healthcare worker knowledge|Health care worker representatives from 101 facilities (n=101) will participate in primary educational workshops in identifying and treating GAS pharyngitis.
89170388|NCT05276999|Experimental|Health seeking behavior in the community|To increase health seeking behavior for sore throat thorough a multifaceted community awareness campaign that includes school based education, VHT lead education, education of patients seeking evaluation of sore throat at HC, and public service announcements
89170389|NCT00645203|Other|1|
89170390|NCT02669381|Other|Experimental: phenylalanine intake|Dietary supplement: phenylalanine intake
89170391|NCT02669303|Experimental|platelet-rich plasma group|Autologous platelet-rich plasma subacromial injection
89170392|NCT02669303|Active Comparator|Methylprednisolone group|Methylprednisolone subacromial injection
89170393|NCT02671019|Experimental|Internet-based treatment|A five-module Internet-based treatment program for harmful alcohol use (including therapist support) based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
89170394|NCT02671019|Active Comparator|Face-to-face treatment|Same treatment content as in the Internet-based treatment delivered via face-to-face treatment sessions in specialized addiction treatment.
89170395|NCT00645281|Experimental|tolterodine ER group|
89170396|NCT04084925||Diabetics with NAFLD|Diabetics whose abdominal ultrasound showed that they have NAFLD
89170397|NCT04084925||Diabetics without NAFLD|Diabetics whose abdominal ultrasound showed that they do not have NAFLD
89170398|NCT02668835||Cohort 1|Idiopathic Parkinson's Disease as defined by the UK brain bank criteria and history of resting tremor.
89170399|NCT02668835||Cohort 2|Essential Tremor with history of resting tremor. Diagnosis made by a movement disorder specialist
89170400|NCT02668991||Cohort 1|It will consist of planned 100 children and adults with Autism Spectrum Disorder (ASD) aged 6 years and older with no requirements regarding concurrent therapies or treatments.
89170401|NCT02668991||Cohort 2|It will consist of planned 50 children and adults aged 6 and older who, as part of their standard care, happen to be beginning a behavioral intervention within 2 weeks after the baseline visit of the study. This intervention can be an applied behavior analysis (ABA) program or similar or a social skills program or a school-based autism program and must be intended to last at least throughout the duration of the study.
89170402|NCT02668991||Cohort 3|It will consist of planned 30 normally developing children and adults. These participants will only have a single visit wherein they will undergo a single session with the task battery and biosensors. There should be 5 participants aged 6-9 years, 5 aged 10-12 years, 5 aged 13-17 years, and 5 aged 18 years and older. This cohort should approximate the male:female ratio in Cohorts 1 & 2, with approximately 1 female for every 5 males.
89170403|NCT02668757|Other|HeartHab application arm|Patients in the HeartHab application arm will receive the mobile application during study period.
89170404|NCT02668679|Active Comparator|Children and their parents with the presence of Dream Doctors|The DD will use various methods for entertaining the child and alleviate stress . The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
89170405|NCT02668679|Placebo Comparator|Children and their parents without the presence of DD|No DD during the gastroscopy. The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
89170406|NCT02668133|Active Comparator|lipid-based nutrient supplement SQ-LNS|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day) 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution~1 mg isotopically enriched 68Zn intravenously"
89170407|NCT02668133|Experimental|lipid-based nutrient supplement SQ-LNS with phytase|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS added during manufacturing 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution~1 mg isotopically enriched 68Zn intravenously"
89170408|NCT02668055|Experimental|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells in wound, stick with wound edge skin suture, with vaseline gauze bandaging, controlled side not adding slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitutes
89170409|NCT02668211|Other|PROFEMUR Preserve RSA|Single cohort of subjects prospectively implanted with PROFEMUR® Preserve Classic femoral components
89170410|NCT02668913|Experimental|Diagnostic Analysis|This arm will be subject to Caris Molecular profiling.
89170411|NCT04176341|Other|Intervention group|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
89170412|NCT04176341|No Intervention|Control group|chronic pain patient consulting in Lyon University Hospital who will receive usual care.
89170413|NCT02667665||Alzheimer's Disease Dementia|
89170414|NCT02667665||non-Dementia|
89170415|NCT02537171|Active Comparator|Apatinib 750mg group|Apatinib mesylate tablets(ATAN) is taken 750mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.The dose of the study drug may be modified following the occurence of a clinically significant adverse event(AE).
89170416|NCT02537171|Active Comparator|Apatinib 500mg group|Apatinib Mesylate Tablets(ATAN) is taken 500mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.Treatment will be discontinued if the subject is unable to tolerate a daily dose of 500mg.
89170417|NCT00645515|Experimental|Arm A|
89170418|NCT00645515|Active Comparator|Arm B|
89170419|NCT00644735|Experimental|1|Nexium
89170420|NCT00644735|Active Comparator|2|Prevacid
89170421|NCT04175015|Experimental|Experimental|Participants will be randomised to eat an orange coloured smartie©
89170422|NCT04175015|Active Comparator|Control Group|Participants will be randomised to eat a pink coloured smartie ©
89170423|NCT04084613||Patients with uncontrolled severe eosinophilic asthma|Asthmatic patients with peripheral blood eosinophils ≥300 cells/μL at any measurement in the previous year or ≥150 cells/μL in a recent measurement, with poor symptom control and increased number of exacerbations (2 or more) despite optimal treatment with high doses of inhaled corticosteroids and β2 stimulants.
89170424|NCT04176263|Experimental|SBT|The SBT group will receive a 4-week split-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
89170425|NCT04176263|Active Comparator|TBT|The TBT group will receive a 4-week tied-belt treadmill training program consisting of 3 training sessions every week. The training will have a progression of training duration over the four weeks. Participants will start at a total training duration of 30 minutes and this will be increased with 5 minutes every week. The maximal length will be 45 minutes of training. One session including breaks will take approximately 1 hour.
89170426|NCT05069519|Experimental|Facebook Condition|Participants assigned to this intervention will take part in personalized Facebook health education, receive a smartwatch, receive weekly health education, share sentiments on Facebook, and receive personalized feedback.
89170427|NCT05069519|Experimental|Smartwatch Condition|Participants assigned to this intervention will use a Fitbit to track daily physical activity (PA), share PA data remotely, and receive personalized feedback.
89170428|NCT05069519|Experimental|Combined Condition|Participants assigned to this condition will receive both Fitbit and Facebook health education programs, (The Smartwatch and Facebook Conditions). The investigators will also provide weekly personalized feedback, based on PA data and sentiment analysis, that have been developed in prior pilot studies.
89170429|NCT05069519|No Intervention|Attention Control|Participants assigned to the control condition will not receive any intervention. They will receive a Fitbit smartwatch, and continue with their standard care currently done in their life during the intervention period.
89170430|NCT04017299|Active Comparator|Virtual reality with computer graphics|Use of Virtual reality with computer graphics
89170431|NCT04017299|Active Comparator|Virtual reality with real movies|Use of Virtual reality with real movies
89170432|NCT04017299|Active Comparator|Music therapy (dedicated device and music scores)|Use of music therapy (dedicated device and music scores)
89170433|NCT04017299|Other|Usual device (TV radio)|usual distraction : watching TV
89170434|NCT02667743|Experimental|Paclitaxel Micelles for Injection + Cisplatin|"In the First Period, 230 mg/m2 of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.~In the Second Period, 300 mg/㎡ of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device to patients whose minimum neutrophil ≥1.0 × 109 /L and minimum platelet count ≥80 × 109 /L and with no hematologic toxicity of grade II to IV occurred in the First Period. Then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment."
89170435|NCT02667743|Active Comparator|Paclitaxel Injection + Cisplatin|175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.
89170436|NCT04176107|Other|Study group- video+questionnaire|"The study group will be exposed to a video at admission to an elective cesarean delivery. The video will have information regarding the admission, pre-operation preparation and post- operation recovery.~All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate the impact of exposure to informative video before caesarean delivery on anxiety and stress measured by State-Trait Anxiety Inventory (STAI)."
89170437|NCT04176107|No Intervention|Control group- questionnaire only|All patients will answer a questionnaire at admission, before surgery and 24 hours later. the questionnaires will evaluate anxiety and stress measured by State-Trait Anxiety Inventory (STAI) without intervention.
89170438|NCT04173845|Experimental|Tianqi Pingchan Granule group|Tianqi Pingchan Granule were manufactured according to Good Manufacturing Practice (GMP) by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. , granule, twice a day, for six months.
89170439|NCT04173845|Placebo Comparator|Tianqi Pingchan Granule Placebo group|placebo, granule, twice a day, for six months.
89170440|NCT02666651|Experimental|Test group|Administration of oral tolvaptan (15-60mg PO titration) during admission for decompensated heart failure
89170441|NCT02666651|Other|Control group|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority
89170442|NCT02666807|Experimental|Ginger|Ginger (Zingiber officinale Roscoe) 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
89170443|NCT02666807|Placebo Comparator|Placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks Placebo twice daily
89170444|NCT02671175|Active Comparator|dihydroartemisinin-piperaquine|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrollment)
89170445|NCT02671175|Placebo Comparator|dihydroartemisinin-piperaquine Placebo|Placebo comparator (matching tablets containing no active ingredients)
89170446|NCT02666573|Experimental|Photodynamic therapy protocol|In addition to scaling and root debridement, test sites received PDT according to manufacturer's instructions.
89170447|NCT02666573|Other|SRP|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
89170448|NCT00644813||Scapular with glenoid neck fractures|Collect outcome and radiological data on patients with scapular fractures involving the glenoid neck (bone joining the shoulder joint and the scapular body) for a period of 1 year.
89170449|NCT02670941|Experimental|Ginger|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
89170450|NCT02670941|Experimental|Lavender|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
89170451|NCT02670941|Experimental|Orange|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
89170452|NCT02670941|Placebo Comparator|Jojoba|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
89170453|NCT02667041|Experimental|rTMS treatment (Monophasic vs. biphasic)|Safety and efficacy
89170454|NCT02667041|Active Comparator|EEG/ERP biomarkers|Investigation of pre- and post-treatment cognitive biomarkers
89170455|NCT02667041|Active Comparator|Blood biomarkers|Investigation of pre- and post-treatment protein biomarkers
89170456|NCT02671097|Experimental|BAY1841788 (ODM-201) + Rosuvastatin|All subjects will receive a single dose BAY1841788 (ODM-201) (600 mg) followed by multiple doses BAY1841788 (ODM-201) (600 mg BID) as well as 2 times a single dose rosuvastatin (5 mg), once alone and once in combination with BAY1841788 (ODM-201).
89170457|NCT02665169|Experimental|Exercise intervention group|Supervised exercise intervention of 12 months. One Taiji and one gym training per week for first six months followed by 6 months free independent use of municipal facilities, including gym, swimming hall and weight room. Written and oral health counselling provided.
89170458|NCT02665169|Active Comparator|Control group|Control group, without any induced exercise intervention. Written and oral health counselling provided.
89170459|NCT00645983|Experimental|1|Chamomile Extract
89170460|NCT00645983|Placebo Comparator|2|Anxiolytic Therapy
89170461|NCT02667197||Opioid overdose and poisoning|
89170462|NCT02665091|Experimental|Peer Education Group|Group was self compared after the intervention
89170463|NCT05276921||Patient|Postoperative ICU patient
89170464|NCT02665325||TSHsuppressive therapy group|TSH-suppressive therapy group: newly diagnosed differentiated thyroid carcinoma and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
89170465|NCT02665325||Negative control group|Healthy volunteers (normal T3,T4,FT3,FT4,TSH, TG-ab,TPO-ab,TG) are recruited to match the patients with age, gender, education level, ect.
89170466|NCT02665325||Positive control group|Newly diagnosed nodular goiter and undergone thyroidectomy according to the China thyroid association guidelines for the management of thyroid nodule and thyroid cnacer; followed by L-T4 replacement therapy 6/12 months.
89170467|NCT05257421|Experimental|shockwave group|
89170468|NCT05257421|Active Comparator|exercise group|
89170469|NCT05257421|Active Comparator|combined group|
89170470|NCT02665403|Experimental|play intervention|30 minutes of hospital play interventions
89170471|NCT02665403|Placebo Comparator|control|usual care
89170472|NCT00463567|Experimental|Indacaterol 150 µg (Continued Into Stage 2)|"In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
89170473|NCT00463567|Experimental|Indacaterol 300 µg (Continued Into Stage 2)|"In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
89170474|NCT00463567|Active Comparator|Tiotropium 18 µg (Continued Into Stage 2)|"Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
89170475|NCT00463567|Placebo Comparator|Placebo (Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
89170476|NCT00463567|Experimental|Indacaterol 75 µg (Not Continued into Stage 2)|"In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
89170477|NCT00463567|Experimental|Indacaterol 600 µg (Not Continued Into Stage 2)|"In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
89170478|NCT00463567|Active Comparator|Formoterol 12 µg (Not Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
89170479|NCT00646061|Experimental|1|morphine, ketorolac, and buscopan
89170480|NCT00646061|No Intervention|2|morphine and ketorolac
89170481|NCT00646841|Experimental|A|
89170482|NCT02666261||Breast Cancer Pathology Samples|Data on the epidemiology and HER2 testing of breast cancer will be collected from pathology routine diagnostics.
89170483|NCT04173143|Experimental|Group 1|This group will receive Cranio cervical flexion training with pressure biofeedback protocol.
89170484|NCT04173143|Active Comparator|Group 2|This group will receive Cranio cervical flexion training without pressure biofeedback protocol
89170485|NCT00646919||1|All pre-operative pediatric patients in our outpatient clinic
89170486|NCT02665013|Experimental|Tailored|Participants will complete surveys at each intervention time point. Based on survey responses, they will receive vaccine information on the study website tailored to their vaccine concerns and values
89170487|NCT02665013|Placebo Comparator|Untailored|Participants will complete surveys at each intervention time point and receive vaccine information on the study website. The vaccine information will NOT be tailored to their concerns and values.
89170488|NCT02665013|No Intervention|Usual Care|Participants will complete surveys at each intervention time point. They will receive vaccine information sheets that are provided in the well child visits at enrollment in the study.
89170489|NCT01323049|Active Comparator|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia in this group
89170490|NCT01323049|Active Comparator|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia in this group
89170491|NCT00645749|Experimental|Helminth ova|Subjects serving as their own controls (baseline - end-of-treatment) will receive a dose of 2,500 ova, in liquid form, every 2 weeks
89170492|NCT03995797|Active Comparator|Treatment arm|Treatment with erbium YAG laser
89170493|NCT03995797|Placebo Comparator|Sham arm|Sub therapeutic procedure with erbium YAG laser
89170494|NCT04167397|Experimental|Single training|Initial training individually
89170495|NCT04167397|Experimental|Dyad training|Initial training in groups of 2
89170496|NCT04167397|Experimental|Triad training|Initial training in groups of 3
89170497|NCT04167397|Experimental|Tetrad training|Initial training in groups of 4
89170498|NCT00646997||1|Patients with postoperative atrial fibrillation
89170499|NCT00646997||2|Patients without postoperative atrial fibrillation.
89170500|NCT01019161|Experimental|AZD1152|100 mg Lyophile 5 mL Diluent
89170501|NCT01019161|Experimental|C14 AZD1152|AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial.
89170502|NCT04173767|Experimental|HFNC|
89170503|NCT00646217|Experimental|1|SELF CARE Talk
89170504|NCT00646217|No Intervention|2|Comparison Group
89170505|NCT01025557|Experimental|Chocolate milk|
89170506|NCT01025557|Experimental|Milk|
89170507|NCT01025557|Experimental|Infant formula|
89170508|NCT01025557|Experimental|Soy beverage|
89170509|NCT01025557|Experimental|Water|
89170510|NCT00647075|Experimental|1|Yunzhi extract 3.5 g/day
89170511|NCT00647075|Placebo Comparator|2|Placebo
89170512|NCT04172753|Experimental|Rectal and anal cancer|In this arm patients with rectal and anal cancer are recruited.
89170513|NCT04172753|Experimental|Prostate cancer|In this arm patients with prostate cancer are recruited.
89170514|NCT04172753|Experimental|Head and neck cancer|In this arm patients with head and neck cancers are recruited.
89170515|NCT04172753|Experimental|Esophageal cancer|In this arm patients with esophageal cancer are recruited.
89170516|NCT04172753|Experimental|Breast Cancer|In this arm patients with breast cancer are recruited.
89170517|NCT04172753|Experimental|Central nervous system tutors|In this arm patients with tumors of the central nervous system are recruited.
89170518|NCT04172753|Experimental|Palliative treatments|In this arm patients with palliative treatments are recruited.
89170519|NCT04172753|Experimental|Other|In this arm patients with other tumors are recruited.
89170520|NCT04172753|Experimental|Imaging only|In this arm patients receive only imaging on the MR-Linac
89170521|NCT01022515||patients with pheochromocytoma|Patients with pheochromocytoma / paraganglioma are being followed as recommended according to international standards. No intervention is expected except regular measurement of plasma CgA (as usual) and EM66 (research purpose) levels.
89170522|NCT01022515||Patients with essential hypertension|Patients with essential hypertension will be selected as controls. EM66 and CgA plasma levels will be assessed in these patients after having excluded the presence of a pheochromocytoma / paraganglioma with normal urinary metanephrines / normetanephrines excretion levels.
89170523|NCT00484159|Experimental|1|Radiofrequency lumbar facet joint denervation only if positive response to 2 diagnostic facet blocks.
89170524|NCT00484159|Experimental|2|Radiofrequency lumbar facet joint denervation if positive response to single facet joint block.
89170525|NCT00484159|Experimental|3|Radiofrequency lumbar facet denervation without a diagnostic facet block.
89170526|NCT02666417|Active Comparator|MNP+iron and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as FeFum and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
89170527|NCT02666417|Active Comparator|MNP+iron+GOS and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
89170528|NCT04072523||Observational Study Investigational Product NA|Patients : Type 2 Diabetic Patients
89170529|NCT00647153|Experimental|Radiation: iodine I 123 anti-CEA recombinant diabody T84.66|
89170530|NCT00910637|Experimental|Arm 1|
89170531|NCT00462865|Experimental|Gemcitabine and Capecitabine and Avastin|Avastin administered concurrently with chemotherapy (Gemcitabine + Capecitabine) for six cycles followed by single agent Avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
89170532|NCT00647309||1|
89170533|NCT00647309||2|
89170534|NCT02666027|Experimental|FIVA ON|The FIVA will be turned on for cases randomized to an even number. The ON light will be covered by tape. Routine induction and maintenance of anesthesia and rate and manner of delivery of IV fluid will be administered at the discretion by the anesthesiologist. The FIVA monitor will only monitor the first IV fluid bag since the study will be unblinded once the FIVA monitor alarm is triggered. When the IV bag is empty and the FIVA alarm is triggered, the anesthesiologist will turn off the FIVA and change the IV bag. The following will be recorded by the anesthesiologist: Type of surgical procedure; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA during the procedure; VAS assessment of ease of use of the FIVA; Loudness of audial alarm of the FIVA.
89170535|NCT02666027|Placebo Comparator|FIVA OFF|The FIVA will be off for cases randomized to odd numbers. The indicator lights will be covered by tape. Routine induction and maintenance of anesthesia and rate/manner of delivery of IV fluid will be administered at the discretion of the anesthesiologist. The IV bag may run dry with or without being noticed by the anesthesiologist. When they detect the empty bag, it will be changed after the removal of the FIVA. The anesthesiologist will record the presence or absence of air in the IV tubing following the termination of the study. The following will be recorded by the anesthesiologist: Type of surgery; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA device; VAS assessment of ease of use of the FIVA; Assessment of audial alarm of the FIVA.
89170536|NCT01025713|Experimental|1|GS-9411 2.4 mg
89170537|NCT01025713|Experimental|2|GS-9411 4.8 mg
89170538|NCT01025713|Placebo Comparator|Placebo|Placebo
89170539|NCT04173455|Experimental|HZ-A-018|"In the dose-escalation part, the 3+3 design will be applied. If the subject does not have a DLT during the first 28-day cycle, those who with stable or remission of disease may continue to receive treatment until disease progression, intolerable toxicity or the subject no longer benefits.~In the dose-expansion part, HZ-A-018 will be administered for several 28-day cycles until disease progression, intolerable toxicity or the subject no longer benefits."
89235060|NCT05089149|Experimental|Patients with chronic heart failure coming for scheduled day hospitalization|"Clinical examination focusing on congestion~Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone follow-up"
89170540|NCT03839641|Experimental|High Fat Meal First|Arm 1 participants randomized to receive high fat meal first, and low fat meal second
89170541|NCT03839641|Experimental|High Fat Meal Second|Arm 2 participants randomized to receive low fat meal first, and high fat meal second
89170542|NCT02667353|Other|electroconvulsive therapy|only one arm in this study: patients who are treated with electroconvulsive therapy and have been given anesthesia with etomidate and succinylcholine
89170543|NCT00462709|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 7 days.
89170544|NCT02664857|Active Comparator|vitamin D|After per orally vitamin D supplementation during 12 weeks, serum Vitamin D level will evaluate with laboratory testing. 600 IU vitamin D will apply to 30 subject during 12 weeks. At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
89170545|NCT02664857|Sham Comparator|Placebo|Grup P will not take vitamin D during 12 weeks. This group just only will follow by researchers.At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
89170546|NCT01019239|Experimental|Laparoscopic Washout|Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed. Intravenous antibiotics will be continued for a minimum of 72hours and oral antibiotics will be continued for one week. Oral fluids will be commenced on the first postoperative day and diet will be introduced subsequently, depending on clinical status. Early mobilisation will be encouraged.
89170547|NCT01019239|Active Comparator|Conventional Treatment|Operative procedure will be similar to that previously described.Patients randomised to the second arm will undergo standard management (according to local preference) which will consist of Hartmanns Procedure or Primary resection of the diseased segment and anastomosis. Post operative care will be standardised between arms as described in the protocol
89170548|NCT04172519|Experimental|Group A|Patients who before prostate cancer surgery will receive: psychological consultation, nursing consultation, physiotherapy consultation and intervention (4 visits which will be implemented pelvic floor muscle training). Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Then, 6 months after the surgery, there will also be a physiotherapy consultation.
89170549|NCT04172519|Experimental|Group B|Patients who will receive: psychological consultation, nursing consultation, physiotherapy consultation before prostate cancer surgery. Subsequently, patients will have the procedure performed laparoscopic radical prostatectomy, immediately after which they receive psychological consultation, nursing consultation. The physiotherapist consultation will be two weeks after the surgery, during which the physiotherapist will provide an instruction pelvic floor muscle training. Patients do the exercises themselves at home according to the instructions, 3 times a day for 3 months). Physiotherapeutic consultation 6 months after surgery.
89170550|NCT04172519|Experimental|Group C|Patients who will not receive any intervention before prostate cancer surgery. Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Physiotherapeutic consultation 6 months after surgery.
89170551|NCT04172519|No Intervention|Group D|Control group, patients after radical laparoscopic prostatectomy, without additional interventions
89170552|NCT03996031||Study Sample|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests. Following the baseline assessment, participants will engage with the Plan to Thrive app for a 90-day period.
89170553|NCT00646295|Experimental|A|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes
89170554|NCT00647465|Active Comparator|1|IFNalpha 2b
89170555|NCT00647465|Placebo Comparator|2|Placebo
89170556|NCT04172207||Results of study groups.|
89170557|NCT02665793|Experimental|DBPCFC to peanut cookie, then single-dose DBPCFC x 2|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions"
89170558|NCT02665793|Experimental|Single dose DBPCFC x 2, then DBPCFC to peanut cookie|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit"
89170559|NCT02665871|Experimental|one dose of Influenza Vaccine in aged 18 years and older|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 18 years and older
89170560|NCT02665871|Experimental|One dose of Influenza Vaccine in aged 3-17 year|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 3-17 years
89170561|NCT02665871|Placebo Comparator|placebo in aged 18 years and older|placebo in 10 subjects aged 18 years and older on day 0
89170562|NCT02665871|Placebo Comparator|placebo in aged 3-17 years|placebo in 10 subjects aged 3-17 years on day 0
89170563|NCT02664779|Experimental|Arrhythmia diagnosis with the 10 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias.
89170564|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 6 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
89170565|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 4 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
89170566|NCT00647543|Experimental|High Risk|
89170567|NCT00647543|Experimental|Low Risk|
89170568|NCT00647543|Experimental|Medium Risk|
89170569|NCT04172285|Experimental|Physical activity group|
89170570|NCT04172285|Experimental|Physical activity and supplementation group|
89170571|NCT04172285|Experimental|Control group|
89170572|NCT00647621|Experimental|1|Extended Phenytoin Sodium Capsules 100 mg
89170573|NCT00647621|Active Comparator|2|Dilantin® Kapseals® 100 mg
89170574|NCT00461305|Experimental|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
89170575|NCT00461305|Experimental|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
89170576|NCT04172129||NANOS|NANOS™ Neck Preserving Hip Stem
89170577|NCT04172051|Experimental|Experimental Group|"Subjects will be admitted into the Tony Robbins event for free, or receive a voucher for an event in the future. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
89170578|NCT04172051|No Intervention|Control Group|"The control group will be asked to engage in gratitude journaling every day for a month. The control group will NOT attend the event. This exercise will take 10 minutes to complete. The subject will write down three things that went well each day and provide an explanation about why they went well. This will be written down in a journal. The subjects will follow these instructions:~Give the event a title (e.g., co-worker complimented my work on a project)~In the space below, write down exactly what happened in as much detail as possible, including what you did or said, and if other people were involved, what they did or said.~Include how this event made you feel at the time and how this event made you feel later (including now, as you remember it)."
89170579|NCT04172051|Active Comparator|Motivated Experimental Group|"The Motivated Experimental Group (M Experimental) will consist of participants who registered and paid for Tony Robbins Date with Destiny (DWD). They are chosen as the motivated experimental as they will be paying full price for the event. The experimental group will attend the event. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives. After attending the event, the experimental group will be asked to continue practicing Priming  daily for a month. A One-page priming cheat sheet will be given to the subjects in the experimental group."
89170580|NCT04174547||Clonal hematopoiesis (AIM 1)|"The investigators will analyze the genomic features of clonal dominance and ineffective hematopoiesis in elderly subjects enrolled in two population-based studies: Health and Anemia study [Haematologica 2010;95:1849], and Monzino 80-plus study [BMC Neurol.2011;11:54, validation cohort]. Overall in 5000 subjects aged >65y peripheral blood samples (in some cases collected at different time points) will be available for biological investigations."
89170581|NCT04174547||Innovative predictive models in MDS (AIM2)|"The investigators will base on large retrospectove adult MDS population with comprehensive genomic and clinical data available within EuroBloodNet network (data on 3000 patients will be available), to accurately predict clinical outcomes in MDS at individual-patient level.~The investigators plan to define 2 homogenous clinical cohorts (learning and testing cohort at 2:1 ratio) in order to define distinct patterns and genetic groups within MDS and to independently validate their predictive value."
89170582|NCT04174547||Predictive biomarkers in MDS (AIM3)|The investigators will analyze MDS patients enrolled in prospective clinical trials conducted within the EuroBloodNet network. Overall 350 patients treated with azacitidine from prospective studies (VidazaAllotrial, RELAZA02 trial, AZA-Ida study, intensive AZA study) will be available for biological investigations to define biomarkers associated with clinical response. Validation of biomarkers will then be performed in an independent cohort including 320 patients (AZA-PLUS trial). In all these studies, biobanking of bone marrow (BM) and peripheral blood (PB) samples has been systematically performed, providing a unique resource to be investigated within this proposal.
89170583|NCT01022671|Experimental|Belotecan|Single arm
89170584|NCT01022749|Experimental|2|patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
89170585|NCT01022749|Experimental|3|patients with IBD receiving immunosuppressants including TNF blockers (n=100)
89170586|NCT01022749|Experimental|1|patients with IBD not receiving immunosuppressant (n=100)
89170587|NCT01022749|Active Comparator|4|patients with IBD receiving immunosuppressants including TNF blockers (n=20)
89170588|NCT02664623|Experimental|Dietary advice sheet|"Patients in this arm will receive a dietary advice sheet at the beginning of the study.~Intervention: Dietary advice sheet"
89170589|NCT02664623|Experimental|Dietary advice sheet + consults with dietician|"In addition to receiving a dietary advice sheet at the beginning of the study, patients randomized to this arm will have individual consultations with a dietician at inclusion, month 1 and month 3.~Intervention: Dietary advice sheet Intervention: Individual dietary consultations"
89170590|NCT01022827|Experimental|posterior shoulder stiffness massage group|The inclusion criteria of patients with glenohumeral internal rotation limitation and posterior shoulder stiffness were: [1] limitation of internal rotation ROM compared to the sound side; [2] mild glenohumeral joint hypomobility according to joint play assessment; [3] stiffness in the posterior shoulder region.
89170591|NCT01022827|Placebo Comparator|posterior shoulder stiffness placebo group|
89170592|NCT01022905|Experimental|High-risk patients ( 5 cohorts)|
89170593|NCT01022905|Active Comparator|Healthy controls|
89170594|NCT00645905|Active Comparator|A|
89170595|NCT00645905|Placebo Comparator|B|
89170596|NCT00647777|Experimental|1|Olanzapine Tablets 5 mg
89170597|NCT00647777|Active Comparator|2|Zyprexa® Tablets 5 mg
89170598|NCT04173611|Experimental|EXPAREL®|For those subjects randomized to EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1mL (13.3mg) for cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4mL (53.2mg).
89170599|NCT04173611|Active Comparator|Bupivacaine|In each cohort, subjects randomized to the bupivacaine arm will receive 15mg of plain bupivacaine HCL (the equivalent of 13.3mg bupivacaine base) providing a 1:1 reference to the starting dose level chosen for EXPAREL®.
89170600|NCT04173611|Active Comparator|Placebo|Subjects in the placebo arm will receive normal saline intrathecal injection
89170601|NCT02664467|Experimental|Bright light therapy (BLT)|Bright light therapy (10'000 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
89170602|NCT02664467|Placebo Comparator|Placebo dim light|Placebo dim light (50 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
89170603|NCT02665715|Experimental|Low carbohydrate/Standard carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
89170604|NCT02665715|Experimental|Standard carbohydrate/Low carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
89170605|NCT02665637|Active Comparator|CT-P6|Trastuzumab
89170606|NCT02665637|Active Comparator|US-licensed Herceptin|Trastuzumab
89170607|NCT00647855|Experimental|1|Levothyroxine Sodium Tablets 300 μg
89170608|NCT00647855|Active Comparator|2|Synthroid® Tablets 300 μg
89170609|NCT02665559||Hypogonadism group|a cross-sectional and prospective study, in HIV-infected men less than 50 years old, with HIV-RNA ≤ 50 cop/mL under ART who had never presented AIDS
89170610|NCT02666729||AF Ablation Procedure|Patients with AF who are schedule for a first time pulmonary vein isolation (PVI) for AF using the TactiCath catheter. Patients will have four pulmonary veins ablated during procedure. The researcher will perform AF Ablation with contact force information on two veins. The research will perform AF Ablation without contact force information on the other two veins.
89170611|NCT00648011|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
89170612|NCT00648011|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
89170613|NCT04173299||Early Tips|Patients wtih early tips for Acute esophageal variceal bleeding
89170614|NCT04173299||stantard treatment|patients with standard treatment (medical + endoscopic) for Acute esophageal variceal bleeding
89170615|NCT04171973|Other|Driving an electric wheelchair in real condition|In order to be able to evaluate the feasibility of virtual reality driving training, the driving performance will be evaluated on the same 3 standardized circuits: for the control group, 3 circuits of test of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
89170616|NCT04171973|Experimental|Driving an electric wheelchair in virtual condition|In order to be able to evaluate the feasibility of driving training in virtual reality, the driving performance will be evaluated on the same 3 standardized circuits: for the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
89170617|NCT00646529|Experimental|1|budesonide/formoterol
89170618|NCT00646529|Active Comparator|2|budesonide
89170619|NCT00648089|Experimental|1|
89170620|NCT00648089|No Intervention|2|
89170621|NCT00646607|Experimental|A|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 3 months or XELOX (capecitabine and oxaliplatin) for 12 weeks.
89170622|NCT00646607|Active Comparator|B|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 6 months or XELOX (capecitabine and oxaliplatin) for 24 weeks.
89170623|NCT02666885|Experimental|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
89170624|NCT02664389|Experimental|Genetic analysis of patient with early-onset breast cancer|Sequencing of 200 selected genes in patient with early-onset breast cancer without genomic alterations of BRCA1, BRCA2 or TP53
89170625|NCT02664389|Experimental|Genetic analysis of patient with early-onset ovarian cancer|Sequencing of 200 selected genes in patient with early-onset ovarian cancer without genomic alterations of BRCA1, BRCA2
89170626|NCT02664389|Experimental|Genetic analysis of patient with pediatric cancer|Sequencing of 200 selected genes in patient with pediatric cancer without genomic alteration of TP53
89170627|NCT02664389|Experimental|Genetic analysis of patient with early-onset colorectal cancer|Sequencing of 200 selected genes in patient with early-onset colorectal cancer without genomic alteration of APC, MUTYH, SMAD4, BMPR1A, PTEN or STK11 in case of adenomatous polyposis or hamartoma presentation or without genomic alteration of MSH2, MLH1 or MSH6 in case of HNPCC presentation
89170628|NCT02664389|Experimental|Genetic analysis of patient with multiple primary tumors|Sequencing of 200 selected genes in patient with Multiple primary malignant tumors without syndromic presentation
89170629|NCT00856544|Experimental|Active 5 mg|
89170630|NCT00856544|Experimental|Active 10 mg|
89170631|NCT00856544|Placebo Comparator|Placebo Sequence 1|Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
89170632|NCT00856544|Placebo Comparator|Placebo Sequence 2|Placebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.
89170633|NCT02664233|Experimental|Connected group|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
89170634|NCT02664233|No Intervention|Usual diabetes education and care|Participants will receive standard diabetes education and care; each of the recruiting clinics offers diabetes self-management education programs.
89170635|NCT00646685|Other|1|
89170636|NCT00646685|Other|2|
89170637|NCT02663921|Experimental|Healthy volunteers|Healthy volunteers without cutaneous disorders associated with pigmentary changes
89170638|NCT00648245|Experimental|1|
89170639|NCT00648245|Experimental|2|
89170640|NCT00648245|Experimental|3|
89170641|NCT00648245|Placebo Comparator|4|
89170642|NCT00648245|Experimental|5|
89170643|NCT00648323|Experimental|A|
89170644|NCT00648557|Experimental|1|Levothyroxine Sodium Tablets 200 mg
89170645|NCT00648557|Active Comparator|2|Synthroid Tablets 200 mg
89170646|NCT04170569|Experimental|Experimental Group|Yoga program was applied.
89170647|NCT04170569|No Intervention|Control Group|No yoga program.
89170648|NCT00856388|Experimental|Treatment (Reduced intensity allogeneic stem cell transplant)|"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.~Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan."
89170649|NCT00648401|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
89170650|NCT00648401|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
89170651|NCT04132154||No Warming|Patients in this group were treated according to our institution's old protocol and did not receive any warming intervention during the surgical procedure.
89170652|NCT04132154||Active Warming|This group will include the patients treated after the implementation of the S3 Guidelines for prevention of hypothermia. For this purpose convective warming through an underbody blanket was used during the surgical procedure
89170653|NCT02660099|Experimental|Internet-delivered CBT|12 weeks of internet-delivered cognitive behavior therapy provided through a secure internet platform and online clinician contact
89170654|NCT00698048||1|Controls
89170655|NCT00698048||2|Sepsis
89170656|NCT00698048||3|Septic Shock
89170657|NCT02663999|Experimental|diazepam nasal spray (AB)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
89170658|NCT02663999|Experimental|diazepam nasal spray (BA)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
89170659|NCT00648479|Experimental|1|
89170660|NCT00648479|Active Comparator|2|
89170661|NCT04169087||General anesthesia|Patients undergoing general anesthesia
89170662|NCT04171427|Other|Lithium liposome and placebo A|• Group A : 4 patients; Lithium liposome 1 application / day (evening) on target lesions on one side of the body, placebo 1 application / day (evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
89170663|NCT04171427|Other|Lithium liposome and placebo B|Group B : 4 patients; Liposomal Lithium 2 applications / day (morning and evening) on target lesions on one side of the body, placebo 2 applications / day (morning and evening) on contralateral target lesions and excimer lamp on target lesions on the two sides;
89170664|NCT04171427|Other|Lithium liposome and placebo C|Groupe C : 4 patients; Lithium liposome 2 applications / day (morning and evening) on one side, placebo 2 applications / day (morning and evening) on contralateral target lesions.
89170665|NCT04171739|Other|Cohort A|Itraconazole DDI
89170666|NCT04171739|Other|Cohort B|Rifampicin DDI
89170667|NCT02656043|Active Comparator|XPF-005|Active treatment: XPF-005 Gel
89170668|NCT02656043|Placebo Comparator|Vehicle gel|Placebo: XPF-005 Vehicle Gel
89170669|NCT02656277|Experimental|Decision tool|The decision tool includes a questionnaire and statistical model used to determine how patient preference regarding shoulder pain, physical limitations, physical therapy, recovery period, prognosis, and cost impact choice of surgical versus non-surgical intervention.
89170670|NCT02656277|Active Comparator|Information on Shoulder Dislocation|Subjects in this arm will receive the standard of care information available to patients to make this treatment decision.
89170671|NCT02656121|Experimental|Vitamin D|1st subgroup will be tested and treated with vitamin D together with Clomiphene Citrate for induction of ovulation
89170672|NCT02656121|Active Comparator|control|2nd subgroup will be treated with Clomophene Citrate only
89170673|NCT02659865|Placebo Comparator|Part A: Placebo|Single oral dose of placebo administered in one of three study periods
89170674|NCT02659865|Experimental|Part A: LY3039478 new formulation|Escalating single oral dose of LY3039478 administered in two of three study periods
89170675|NCT02659865|Experimental|Part B: LY3039478 original formulation|Single oral dose of LY3039478 administered in one of two study periods
89170676|NCT02659865|Experimental|Part B: LY3039478 new formulation|Single oral dose of LY3039478 administered in one of two study periods
89170677|NCT02656355|No Intervention|Stage 1:Healthy people|To establish baseline and reliability.
89170678|NCT02656355|No Intervention|Stage 2:Healthy people|To establish stage 3 training protocol.
89170679|NCT02656355|No Intervention|Stage 2:PD people|To establish stage 3 training protocol.
89170680|NCT02656355|Experimental|Stage 3:PD APA training group|Weight shift training and APA feedback.
89170681|NCT02656355|Experimental|Stage 3:PD Balance training group|Weight shift training without APA feedback.
89170682|NCT02656355|No Intervention|Stage 3:PD Control group|Control group
89170683|NCT04169555|Experimental|Ultrasound|
89170684|NCT04169555|Other|Standard care|
89170685|NCT02659553||mild steatosis|5% - 30% of hepatocytes have fatty infiltration
89170686|NCT02659553||moderate steatosis|30% - 60% of hepatocytes have fatty infiltration
89170687|NCT02659553||No steatosis|No or less than 5% of hepatocytes have fatty infiltration
89170688|NCT00648713|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
89170689|NCT00648713|Active Comparator|2|Lamisil® Tablets 250 mg
89170690|NCT02659319|Experimental|Family Lifestyle (FL; n = 117)|This arm includes the Family Food & Lifestyle intervention (FL). Parents and children meet for 12 weekly, 90-minute psychoeducational groups in children's schools. They meet separately for 45 minutes and then conjointly for 45 minutes.
89170691|NCT02659319|Experimental|FL + Family Dynamics (FL+FD; n = 88)|This arm includes the Family Food & Lifestyle + Family Dynamics interventions (FL+FD). Parents and children meet separately for the full 90-minute psychoeducation sessions. The first 45 minutes are devoted to the Family Food & Lifestyle intervention and the second 45 minutes to the Family Dynamics intervention.
89170692|NCT02659319|Experimental|FL + Peer Group (FL+PG; n = 124)|This arm includes the Family Food & Lifestyle intervention plus the 12-session, Peer Group intervention.
89170693|NCT02659319|Experimental|FL + FD + Peer Group (FL+FD+PG; n = 130)|This arm includes the Family Food & Lifestyle intervention plus the Family Dynamics Intervention plus the Peer Group intervention.
89170694|NCT02659319|No Intervention|Control (n = 82)|Non-intervention control group
89170695|NCT00649883|Experimental|1|
89170696|NCT00649883|Active Comparator|2|
89170697|NCT00648791|Experimental|1|Finasteride Tablets 5 mg
89170698|NCT00648791|Active Comparator|2|Proscar Tablets 5 mg
89170699|NCT02655809|Other|Physica KR|Patients who have received a Physica KR total knee implant.
89170700|NCT00649181|Experimental|1|Metolazone Tablets 5 mg
89170701|NCT00649181|Active Comparator|2|Zaroloxyn® Tablets 5 mg
89170702|NCT02659475|Experimental|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
89170703|NCT04170257|Experimental|Opportunistic screening cohort|This opportunistic screening cohort is constructed among patients aged 45-69 years who undergo endoscopic examinations at the endoscopy center in any of the five hospitals included in this study. Enrolled participants are requested to complete a computer aided one-on-one questionnaire regarding demographic factors, smoking and alcohol drinking status, dietary habits，digestive tract symptoms and family history of ESCC. Then experienced endoscopists will perform the upper gastrointestinal endoscopic examination for each participant, and the entire esophagus will be visually examined with the white light, NBI and iodine staining endoscopic examination.
89170704|NCT02655731|Other|Treatment|PVI with HeartLight
89170705|NCT02663843|Experimental|i-gel airway|I-gel inserted for the low skill fibreoptic intubation technique
89170706|NCT02663843|Experimental|air-Q airway|Air-Q inserted for the low skill fibreoptic intubation technique
89170707|NCT04444427|Experimental|Part 1: Dose Escalation|Dose escalation cohorts are planned to determine the maximum tolerated dose or recommended phase 2 dose of GLR-2007, as well as expansion cohorts and a Phase 2 cohort.
89170708|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort A|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their non-small cell lung cancer (NSCLC) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
89170709|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort B|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their brain metastases of breast or NSCLC origin will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
89170710|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort C|Participants experiencing their first recurrence glioblastoma multiforme (GBM) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
89170711|NCT02655965|Experimental|Ropivacaine + Clonidine|"A pecs block of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml will be injected to the patients prior surgery. 10 ml of the drug combination will be injected between pectoral muscles and 20 ml of the drug combination will be injected between the muscles pectoralis minor and serratus anterior.~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
89170712|NCT02655965|Placebo Comparator|Sodium Chloride|"A pecs block of Placebo (Sodium Chloride 0.9%) will be injected to the patients prior surgery. 10 ml of the Sodium chloride solution will be injected between pectoral muscles and 20 ml of the Sodium chloride solution will be injected between the muscles pectoralis minor and serratus anterior).~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
89170713|NCT04170179|Experimental|Systemic chemotherapy plus lenvatinib and toripalimab|Systemic chemotherapy of oxaliplatin , fluorouracil, and leucovorin every 3 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab 240mg intravenously every 3 weeks.
89170714|NCT02659163|Experimental|intervention|Intervention subjects will receive feedback on their health behaviors along with clinical recommendations.
89170715|NCT02659163|Active Comparator|control|Control subjects will receive feedback on their health behaviors for self-guided care.
89170716|NCT02655341||Consecutive STEMI Patients|All patients with AMI referred for primary PCI in a single centre
89170717|NCT04170413||CeVUS Urodynamic|patients undergoing urodynamic study with CeVUS
89170718|NCT02655497|Experimental|Cognitive Training|Cognitive training intervention. The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The experimental group will receive real-world strategy training, a cognitive strategy based approach that trains people to improve their level of independence on meaningful activities of daily life with which they are having difficulty.
89170719|NCT02655497|Active Comparator|Psychosocial education|The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The control group will receive brain-health education.
89170720|NCT02655263|No Intervention|Control|12 hours of fasting
89170721|NCT02655263|Experimental|GH infusion|12 hours of fasting
89170722|NCT02655263|Experimental|GH and ketone bodies infusion|12 hours of fasting
89170723|NCT02659085|Active Comparator|Electroconvulsive Therapy (ECT)|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly. Each participating clinic decides for each patient whether the treatment is given uni- or bilateral, as well as the exact stimulation parameters. Choice of anesthetic drug (e.g. thiopental of propofol) and muscle relaxant is done by local anesthesiologist. The procedure differs in no way from how a given patient would have been treated if he or she were not included in the study.
89170724|NCT02659085|Experimental|Ketamine IV Infusion|Ketamin intra venous infusions of racemic ketamine (0.5mg/kg), delivered over a period of 40 minutes thrice weekly, as ECT (Monday, Wednesday and Friday).
89170725|NCT02659007|Experimental|yoga|yoga, 2 times a week for 8 weeks
89170726|NCT04171271|Experimental|Activating kinesthetic motor imagery training|
89170727|NCT04171271|Active Comparator|Relaxing kinesthetic motor imagery training|
89170728|NCT04171271|No Intervention|Control (no specific intervention)|
89170729|NCT04168697|Experimental|Controls|Control subjects undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
89170730|NCT04168697|Experimental|BAD|Patients with bipolar affective disorder (BAD) undergoing an 8-week behavioral modification technique consisting of a combination of breathing exercises, cold exposure and meditation
89170731|NCT04170101|Experimental|a continuous deep NMB (group A)|after 0,6 mg/kg LBW Rocuronium for intubation Rocuronium is given in a continuous infusion starting at 1 mg/kg/h and adapted to keep PTC below 5 and note.
89170732|NCT04170101|Placebo Comparator|non deep NMB (group B)|after 0,6 mg/kg LBW Rocuronium for intubation no extra NMB is given and depth is measured by TOF/PTC to note depth.
89170733|NCT02663375||ACURATE TA™ Transapical Aortic Biorposthesis|Patients implanted with ACURATE TA™ Transapical Aortic Biorposthesis and Delivery System
89170734|NCT02655185||Heart failure|
89170735|NCT04171193|Experimental|ISO|Patients not taking oral medications for depression. They will receive the study intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes.
89170736|NCT04171193|Experimental|ISOAD|Patients in treatment with oral medications for depression, will receive intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes
89170737|NCT04171193|Experimental|ISOPOT|Patients that where from ISO arm, that did not respond to intervention consisting in general anesthesia with the volatile anesthetic gas Isoflurane until burst suppression is detected in electroencephalogram more than 80% of the time for 15 minutes They will now, start taking sertraline as oral medication for depression to asset the enhancement of oral treatment after Isoflurane challenge.
89170738|NCT02663141|Experimental|Losartan|Oral losartan 50 mg daily for 6 months
89170739|NCT02663141|Placebo Comparator|Placebo|Oral placebo daily for 6 months
89170740|NCT04171349|Active Comparator|Group A|Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%
89170741|NCT04171349|Experimental|Group AD|Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg).
89170742|NCT02536547||patients with suspected VAP|"All patients with suspected VAP will be included in the study (new or extension of a radiological image in a patient in mechanical ventilation for at least 48 hours associated with at least two of the following:criteria :~fever ≥38.5 ° C or <36, 5 ° C leukocytosis> 10 * 103 / ml or leukopenia <4 * 103 / ml secretions purulent tracheal reduction in PaO2 / FiO2 <300 or PaO 2 <60 mmHg"
89170743|NCT00650039|Active Comparator|Arm 1|
89170744|NCT00650039|Active Comparator|Arm 2|
89170745|NCT00650039|Placebo Comparator|Arm 3|
89170746|NCT00649259|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
89170747|NCT00649259|Active Comparator|2|Ditropan XL® Tablets 10 mg
89170748|NCT02658695||Group 1|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) <10 mm.
89170749|NCT02658695||Group 2|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) >10 mm.
89170750|NCT02658773|Active Comparator|lidocaine-Prilocaine cream|lidocaine-Prilocaine anesthetic cream placed into their cervix prior to having the IUD inserted
89170751|NCT02658773|Placebo Comparator|placebo cream|an inert placebo cream placed into their cervix
89170752|NCT04170491|No Intervention|control|The standard medical care (Control) group will receive sequential portable EEGs, performed according to clinical demand. These patients usually have 2 recordings of 20-30 minutes each within 24 or 48 hours. The studies include baseline recoding and recording after auditory, tactile and nociceptive stimulation. The EEGs will be visually reviewed and reported within 4 hours after the recording completion by a Consultant Clinical Neurophysiologist or other doctor with equivalent qualifications.
89170753|NCT04170491|Experimental|cEEG|The treatment (cEEG) group will have cEEG applied within 12 hours of RSE diagnosis, which will continue until 24 hours after cessation of clinical and electrical seizure activity. Reactivity testing with auditory, tactile and nociceptive stimulation will be repeated at least once daily. The cEEG will be visually interpreted twice daily by a Consultant Clinical Neurophysiologist and the results will be communicated within two hours of their completion to the treating clinical team.
89170754|NCT02654951|Experimental|Visual + Force Feedback|Participants will complete a set of trials while receiving visual feedback only. After finishing, participants will continue to a new set of trials while receiving force feedback only.
89170755|NCT02654951|Experimental|Force + Visual Feedback|Participants will complete a set of trials while receiving force feedback only. After finishing, participants will continue to a new set of trials while receiving visual feedback only.
89170756|NCT02654873||Benign|Benign pathology specimens with macroscopically
89170757|NCT02654873||Suspicious|Suspicious group includes the conditions such as increasing of the gallbladder wall thickness, having calcifications or polyps in the gallbladder.
89170758|NCT02654873||Malign|Malign group includes the conditions such as detecting mass or irregularities in the gallbladder wall.
89170759|NCT04169945|Experimental|Ultrasonic instrumentation and Air Polishing|All participants will receive full mouth conventional ultrasonic subgingival debridement, followed by air-polishing with erythritol powder which include activating device for 5 seconds of each surface (Petersilka 2003). Subsequently, Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth >4mm. Perio-Flow handpiece with a special disposable nozzle will be used for pocket depth >4mm
89170760|NCT04169945|Active Comparator|Ultrasonic instrumentation|All participants will receive full mouth conventional ultrasonic subgingival debridement only. No time limit (Flemmig 2012), until dental surfaces feel smooth.
89170761|NCT04169867||Healthy Volunteers|This cohort will consist of 1000 healthy volunteers from Poland.
89170762|NCT04169867||Melanoma|This cohort will consist of 160 patients with melanoma.
89170763|NCT02536625||Everolimus|Immunomonitoring
89170764|NCT02662673|Other|Localized prostate cancer, Focal treatment.|
89170765|NCT02662595|No Intervention|Control|
89170766|NCT02662595|Active Comparator|Text message|Subjects in this arm will receive a text message reminder in due time for measles vaccination.
89170767|NCT02662595|Active Comparator|Text message and voice call|Subjects in this arm will receive a voice call in addition to a text message reminder in due time for measles vaccination.
89170768|NCT02654795|Placebo Comparator|Patients without stroke|This group will consists of patients scheduled for atrial fibrillation ablation without history of stroke.
89170769|NCT02654795|Experimental|Patients with history of stroke|This group will consists of patients after ischemic stroke and history of atrial fibrillation.
89170770|NCT04168853|Other|Roller pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Maquet® for the roller pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
89170771|NCT04168853|Other|Centrifugal pump group|CABG was performed under normothermic (36-37°C) cardiopulmonary bypass (CPB). All components of the circuits were coated with phosphorylcholine inert surface (PHISIO, Sorin®). The pump manufacturer is Sorin® for the centrifugal pumps.1.5 cm of ITA distality was sampled before blood flow interruption into the graft and before starting CPB (Time 1) and another segment (1.5 cm) before the last coronary anastomosis during aortic cross clamping (Time 2) (Figure 1). Each arterial segment was cut into three parts: a fresh part for arterial myography bathed and stored in a 50 ml organ bath containing a physiological salt solution (PSS). The other two parts were cooled in liquid nitrogen and stored at -80°C for immunohistochemistry and RT-PCR analysis.
89170772|NCT02662829|Experimental|Community-based intervention (CBI)|"Nurse training and mentorship in TB prevention using clinical algorithm based on national guidelines.~Health education using a treatment literacy curriculum for parents and guardians.~Community outreach by trained village health workers."
89170773|NCT02662829|Active Comparator|Standard of Care (SOC)|At SOC clinics, patients will receive usual care for management of contact tracing, screening, and IPT provision. Childhood TB in Lesotho is managed by nurses in health centers. Per national guidelines, TB patients are asked to bring in child contacts, who are screened using a simple symptom questionnaire. Children who screen negative are assessed for IPT eligibility. Absent contra-indications (eg, active hepatitis, regular alcohol consumption, peripheral neuropathy), nurses counsel children and guardians on IPT benefits, potential side effects, and importance of adherence. Children requiring chest x-rays or gastric lavage and HIV-infected children under age 1 are referred to the hospital. After initiation, patients and guardians return to the clinic monthly for monitoring for side effects, TB symptoms, adherence, and 30-day supply of isoniazid. If adherence problems are noted, the nurse counsels patient and guardian as appropriate.
89170774|NCT02536859|Experimental|IDeg|
89170775|NCT02536859|Active Comparator|IGlar U300|
89170776|NCT02536937|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
89170777|NCT02536937|Experimental|GZ385660 (subjects with mild renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
89170778|NCT02536937|Experimental|GZ385660 (subjects with moderate renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
89170779|NCT02536937|Experimental|GZ385660 (subjects with severe renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
89170780|NCT00649337|Experimental|1|Adjunct screening with sonocine
89170781|NCT02654405|Experimental|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
89170782|NCT02654405|Placebo Comparator|Placebo|Placebo capsule with 2 mg of sodium butyrate for making taste or odor, (9 mg/day)
89170783|NCT04169789|Active Comparator|L. reuteri Low Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E8 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total dose of either 1x10E9 L.reuteri CFU and 400 IU of cholecalciferol per day.
89170784|NCT04169789|Active Comparator|L. reuteri High Dose|Capsules of freeze-dried L. reuteri 6475 of 5x10E9 colony-forming units (CFU) mixed with maltodextrin powder and 200 IU of cholecalciferol, taken twice daily for 24 months, yielding a total daily dose of 1x10E10 L.reuteri CFU and 400 IU of cholecalciferol per day.
89170785|NCT04169789|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 24 months.The placebo product contains 200 IU cholecalciferol per dose, yielding a total dose of cholecalciferol of 400 IU per day.
89170786|NCT00649415|Active Comparator|Arm 1|
89170787|NCT00649415|Active Comparator|Arm 2|
89170788|NCT02658617||patients|20 patients were enrolled. Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire). 1-2 days after the imaging patients started the treatment with duloxetine: 30mg for the first three days, then 60-90mg.
89170789|NCT02658617||healthy controls|Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire).
89170790|NCT04171505||vaccinated women|"Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.~Women who sign informed consent.~Patients with negative results in the first post-surgery control.~Patients who have received HPV vaccination and provide vaccination card."
89170791|NCT04171505||non vaccinated woman|"Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically.~Women who sign informed consent.~Patients with negative results in the first post-surgery control.~Patients who have NOT received HPV vaccination and provide vaccination card."
89170792|NCT00650117|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
89170793|NCT00650117|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
89170794|NCT00650117|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
89170795|NCT00650117|Experimental|4|Duragesic 25 mcg/h + Scotch Duct Tape (3M)
89170796|NCT00650117|Experimental|5|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
89170797|NCT00650117|Experimental|6|Duragesic 25 mcg/h + Microfoam Tape (3M)
89170798|NCT02654249|Other|THD and mucopexy|Patients will undergo to transanal hemorrhoidal dearterialization with mucopexy (THD)‪ under generla anesthesia.
89170799|NCT02654249|Active Comparator|Ligasure hemorroidectomy|Patients will undergo to Ligasure™ hemorroidectomy under generla anesthesia.
89170800|NCT02662751|Active Comparator|Routine Imaging|"Patients randomized to this arm will have routine post-stroke/TIA imaging assessments.~Intervention: Routine Imaging Assessment"
89170801|NCT02662751|Experimental|LDWBA first|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~Intervention: LDWBA first followed by Routine Imaging Assessment if required."
89170802|NCT00648947|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
89170803|NCT00648947|Active Comparator|2|Plavix® Tablets 75 mg
89170804|NCT00649493|Experimental|1|Rabeprazole Sodium Tablets 20 mg
89170805|NCT00649493|Active Comparator|2|Aciphex® Tablets 20 mg
89170806|NCT02654093|Experimental|Group A|A → B → C / A: Cholecalciferol, B: Raloxifene, C: Cholecalciferol+Raloxifene
89170807|NCT02654093|Experimental|Group B|A → C → B
89170808|NCT02654093|Experimental|Group C|B → A → C
89170809|NCT02654093|Experimental|Group D|B → C → A
89170810|NCT02654093|Experimental|Group E|C → A → B
89170811|NCT02654093|Experimental|Group F|C → B → A
89170812|NCT02662439|Experimental|BCM group|The patients are measured by Body Composition Monitor (BCM) and both the patient and the physician know the results and adjust the diuretic therapy accordingly.
89170813|NCT02662439|Placebo Comparator|Control group|The patients are measured by Body Composition Monitor (BCM) but neither the patient nor the physician know the results, the physician adjusts the diuretic therapy as usual, according to the protocols.
89170814|NCT04168619||Transient elastography (TE)|All patients who had MTX taken
89170815|NCT04168619||Two dimensional shear wave elastography (2D SWE)|For patients who has cumulative more than 3.5g methotrexate
89170816|NCT04168619||Liver biopsy|For patients who has cumulative more than 3.5g methotrexate and had 2D SWE done
89170817|NCT00650195|Experimental|1|Metolazone Tablets 10 mg
89170818|NCT00650195|Active Comparator|2|Zaroloxyn® Tablets 10 mg
89170819|NCT04170959|No Intervention|A: Observational arm|Radiotherapy as per standard of care without metformin, no additional biomarkers/imaging will be performed
89170820|NCT04170959|Other|B: Control arm|Radiotherapy as per standard of care without metformin, with additional biomarkers/imaging
89170821|NCT04170959|Active Comparator|C: Interventional arm|Radiotherapy as per standard of care with metformin, with additional biomarkers/imaging
89170822|NCT02662361||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
89170823|NCT02662361||peri-implant disease|The subjects who suffered from peri-implant disease.
89170824|NCT04169399|Experimental|Toripalimab plus SBRT|Participants received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Participants recevied Stereotactic body radiotherapy. Radiotherapy dose was 36 ~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
89170825|NCT00848354|Experimental|Phase 1 Etanercept + methotrexate|Phase 1: Etanercept + methotrexate
89170826|NCT00848354|Active Comparator|Phase 1 Conventional DMARD (SSZ or HCQ) + MTX|Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate
89170827|NCT02614664||Single ventricle|Patients with single ventricle physiology presenting for laparoscopic procedures.
89170828|NCT00848198||Normal|Subjects with no objective signs of Dry Eye Disease
89170829|NCT00848198||Dry Eye Disease|Subjects with objective signs of Dry Eye Disease
89170830|NCT00848120|Experimental|1|
89170831|NCT00600821|Active Comparator|B|Bevacizumab will be administered in combination with carboplatin and paclitaxel.
89170832|NCT00600821|Experimental|A|AG-013736 will be administered in combination with carboplatin and paclitaxel.
89170833|NCT00699764|Experimental|Group A|
89170834|NCT00699764|Placebo Comparator|Group B|
89170835|NCT02658383|Experimental|Cleaner cookstove received after visit 2|This arm receives the cleaner cookstove earlier in the study (after visit 2 which is approximately after 6 months)
89170836|NCT02658383|Experimental|Cleaner cookstove received after visit 4|This arm receives the cleaner cookstove later in the study (thus acting as a control arm until after visit 4 which is after approximately 1 yr and 6 months)
89170837|NCT02653703|Placebo Comparator|Vehicle, topical ethanol 96%|Exposure: 10 % topical trans-cinnamaldehyde [CAS Number: 14371-10-9] Vehicle: 96% ethanol
89170838|NCT02653703|Experimental|Topical L-menthol 40%|Exposure: 10 % trans-cinnamaldehyde [CAS Number: 14371-10-9] Intervention: 40% l-menthol [CAS Number: 2216-51-5] Vehicle: 96% ethanol
89170839|NCT02658305||transoral group|orthognathic patients that were treated with a transoral surgical approach
89170840|NCT02658305||transbuccal group|orthognathic patients that were treated with a transbuccal surgical approach
89170841|NCT04168463|Experimental|Immediate Intervention|This cluster of four homes will receive robot animals immediately at commencement of the eight month trial.
89170842|NCT04168463|Other|Delayed Intervention|This cluster of four homes will receive robot animals four months after commencement of the 8 month trial. The four months without robots will serve as a control period.
89170843|NCT04168541|Active Comparator|Oral Nutrition Supplement A|Product containing calories from carbohydrate, protein, and fat
89170844|NCT04168541|Active Comparator|Oral Nutrition Supplement B|Product containing calories from carbohydrate, protein, and fat
89170845|NCT04168541|Active Comparator|Oral Nutrition Supplement C|Product containing calories from carbohydrate, protein, and fat
89170846|NCT04168541|Active Comparator|Oral Nutrition Supplement D|Product containing calories from carbohydrate, protein, and fat
89170847|NCT04168541|Active Comparator|Oral Nutrition Supplement E|Product containing calories from carbohydrate, protein, and fat
89170848|NCT04168541|Active Comparator|Oral Nutrition Supplement F|Product containing calories from carbohydrate, protein, and fat
89170849|NCT02653781|Experimental|Realistic simulation; Performance|Student participation in the study will happen on demand by enrollment in activities of dialogue-exhibition (workshop) on realistic simulation in the context of patient safety. Check the performance of students in face of simulation workshop for test realistic simulation.
89170850|NCT02653781|Other|theoretical-practical classes|Will be to give a theoretical-practical classes for students of control group the provision of similar opportunities
89170851|NCT00649571|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
89170852|NCT00649571|Active Comparator|2|Adoxa Tablets 100 mg
89170853|NCT02662283|Active Comparator|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
89170854|NCT02662283|Experimental|Reh-acteoside|Oral take reh-acteoside (0.4g bid) for 8 weeks
89170855|NCT02662283|Experimental|Reh-acteoside+Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) and reh-acteoside (0.4g bid) for 8 weeks
89170856|NCT04170803|Experimental|True Dry Needling|"Active duty DoD beneficiaries, with shoulder pain will be recruited from Army Medical Department Center and School (AMEDDC&S) and the Brooke Army Medical Center (BAMC) Outpatient Physical Therapy Clinic who meet inclusion and exclusion criteria. The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the infraspinatus muscle using FDA approved (FDA regulation # 880.5580) disposable 0.25 x 40 mm stainless steel Seirin J-type needles (Seirin, Japan). Each shoulder will undergo this treatment. Each needle insertion will last approximately 2-3 seconds using the sparrow pecking (in and out) technique to the depth of the scapula at 3 locations in the infraspinatus muscle on the affected (painful) side. When detectable, the needle insertion will specifically target palpably painful and/or taut bands of tissue. Immediately after use, all needles will be disposed of in approved sharps containers."
89170857|NCT04170803|Sham Comparator|Sham Dry Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a blunted instrument in a needling guide tube against the skin. The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in previous studies performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants..
89170858|NCT02653937|Experimental|Kampo medicine|7.5g per day of Tsumura's shigyakusan ( Tsumura & Co ) was administered to each of 110 cases.
89170859|NCT02657993|Experimental|Hypnosis|The hypnosis intervention involves three, face-to-face, hypnosis sessions delivered by doctoral-level psychology professionals
89170860|NCT02657993|Active Comparator|Attention Control (Non-Hypnosis)|The attention control intervention is matched to the hypnosis intervention in terms of the amount of professional time received by patients.
89170861|NCT02653547|Experimental|standard multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
89170862|NCT02653547|Experimental|high-frequency multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
89170863|NCT02653547|Experimental|standard multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
89170864|NCT02653547|Experimental|high-frequency multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
89170865|NCT02657759|Experimental|CARDICHOL|Food supplement formula in shape of pill called CARDICHOL. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.
89170866|NCT02657759|Placebo Comparator|Placebo|"placebo with the same characteristics, appearance, packaging, and composition as the active formula, except for active ingredients replaced by dicalcium phosphate and flavouring substances.~2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch."
89170867|NCT02657603|Active Comparator|LAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the adductor canal
89170868|NCT02657603|Active Comparator|SAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the contralateral adductor canal
89170869|NCT02657447|Experimental|Arm 1: Betalutin with lilotomab dose 1|Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing
89170870|NCT02657447|Experimental|Arm 2: Betalutin with lilotomab dose 2|Betalutin 15MBq/kg b.w. with lilotomab pre-dosing
89170871|NCT02657681|Experimental|tSMS|30 min of tSMS, one session per day, for 9 days over 2 weeks
89170872|NCT02657681|Placebo Comparator|sham|30 min of sham, one session per day, for 9 days over 2 weeks
89170873|NCT00649649|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
89170874|NCT00649649|Active Comparator|2|Accupril® Tablets 40 mg
89170875|NCT00592904|Experimental|1|
89170876|NCT02657291|Experimental|Costoclavicular|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the costoclavicular approach
89170877|NCT02657291|Active Comparator|Paracoracoid|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the paracoracoid or standard approach
89170878|NCT02662205|Active Comparator|Traditional Group|Traditional process psychotherapy group
89170879|NCT02662205|Experimental|Yoga Therapy Group|Psychotherapy group integrating yoga and process dialogue
89170880|NCT02662205|Active Comparator|Yoga Class|Yin yoga class
89170881|NCT04118426||Radiotherapy group|Patients receiving radiotherapy after surgery for brain tumor
89170882|NCT04118426||No radiotherapy group|Patients NOT receiving radiotherapy after surgery for brain tumor
89170883|NCT02662127|Experimental|SIGVARIS®. Class 2 - RAL: 23-32|Graduated elastic compression stockings
89170884|NCT00699920|Experimental|1|Coarsucam double-layer artesunate/amiodaquine tablets
89170885|NCT00699920|Active Comparator|2|Coartem (artemether/lumefantrine) fixed-dose combination tablets
89170886|NCT02661893|Experimental|JNJ-42847922 and Rifampin|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ-42847922 on Day 1; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed with one oral dose of rifampin 600 mg (2*300 mg) on Day 5; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed on Day 12, following once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5-12.
89170887|NCT04131608||diabetic foot ulcer (1and2)with iron defic|"50 diabetic patients with diabetic foot ulcer grade (1and2) with iron deficiency anemia will be applied TO~cbc~ferritin~HBA1C~ankle brachial index by duplex"
89170888|NCT04131608||diabetic foot ulcer grade(1and2)without iron deficiency anemia|"50 patients with diabetic foot ulcer grade (1and2) without iron deficiency anemia will be applied to~CBC~Ferritin,~HBA1C~ankle brachial index by duplex"
89170889|NCT04170881||CHILDREN|Children from involved daycares (Paris region)
89170890|NCT04170881||WORKERS|workers in involved daycares (Paris region)
89170891|NCT02653235|Active Comparator|Typhoid vaccination|Salmonella typhi vaccination
89170892|NCT02653235|Placebo Comparator|Placebo|0.9% sodium chloride
89170893|NCT02653469||Augmented ventilation with fluid loading|This is an observational study and as a diagnostic intervention, subjects in the study would receive mechanical ventilation with augmented tidal volume of 12ml/kg for 2min. Augmented ventilation is performed when the patient's PPV is within grey zone (9-13%). The investigators perform this procedure to every patients and do not assigh this intervention to the subjects of the study. Then, 6ml/kg of ballanced crystalloid loading will be infused to every patient.
89170894|NCT00855920|Active Comparator|Placebo (for Rilonacept) and Indomethacin|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 with Indomethacin orally thrice a day (TID) for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
89170895|NCT00855920|Active Comparator|Rilonacept and Indomethacin|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
89170896|NCT00855920|Active Comparator|Rilonacept and Placebo (for Indomethacin)|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Placebo (for Indomethacin) orally TID for 12 days.
89170897|NCT04168307|Experimental|Ankle trainer device|The patients were instructed in the use of a new spring loaded ankle trainer
89170898|NCT04168307|Active Comparator|Conventional physiotherapy|The patients were instructed in passive stretching exercises by the use of a non-elastic band
89170899|NCT02657213|Experimental|Minimed 640G with smartguard activated|"Group SmartGuard On: Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640G insulin pump with SmartGuard activation"
89170900|NCT02657213|Active Comparator|Minimed 640G with smartguard off|"Group SmartGuard Off Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640 insulin pump without SmartGuard activation"
89170901|NCT00649727|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
89170902|NCT00649727|Active Comparator|2|Ditropan XL® Tablets 10 mg
89170903|NCT00650273|Experimental|1|Azithromycin Tablets 600 mg
89170904|NCT00650273|Active Comparator|2|Zithromax® Tablets 600 mg
89170905|NCT00848042|Active Comparator|AuroShell-3.5|Group treated with the lowest treatment level with 4.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 3.5 watts. Device: AuroLase Therapy
89170906|NCT00848042|Active Comparator|AuroShell-4.5|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 4.5 watts. Device: AuroLase Therapy
89170907|NCT00848042|Active Comparator|AuroShell-5.0|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 5.0 watts. Device: AuroLase Therapy
89170908|NCT02657135|Experimental|History of Traumatic Brain Injury|All participants have a history of TBI. At study outcome participants are provided treatment recommendations that are the result of a consensus meeting of all physician investigators. Follow up care is not provided by this clinical trial.
89170909|NCT00698126||A|
89170910|NCT00698126||B|
89170911|NCT02657057|Experimental|Transcutaneous Tibial Nerve Stimulation|TENS SNS therapy is performed as follows; patient is asked to sit with legs slightly bent and an adhesive electrode is attached transcutaneously 5cm cephalic to either the right or left medial malleolus (subject choice). A surface electrode is placed on the medial surface of the ipsilateral calcaneum and both electrodes are connected to a low voltage electronic stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
89170912|NCT02657057|Active Comparator|Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; patient is asked to sit with legs slightly bent. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial surface of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage electrical stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and the subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
89170913|NCT00701012|Experimental|1|low ligation, which the IMA is ligated below the origin of the left colic artery
89170914|NCT00701012|Active Comparator|2|high ligation, which the IMA is ligated at its origin from the aorta
89170915|NCT02661659|Other|Weekly Vaccination|Maintenance multipeptide vaccine (S-588210) administered every week
89170916|NCT02661659|Other|Every other Week Vaccination|Maintenance multipeptide vaccine (S-588210) administered every other week
89170917|NCT04168151|Experimental|hypoxic group|hypoxic patients (hypoxic index less than 250)
89170918|NCT02661425||Standard of Care|
89170919|NCT02661425||EnteraGam|
89170920|NCT02656901|Active Comparator|Auto Total endovenous anesthesia|The closed loop delivering as already approved by ClinicalTrials.gov Identifier: NCT00392158
89170921|NCT02656901|Sham Comparator|Manual Desflurane anesthesia|The anesthesia will be maintained with desflurane to target the BIS of 50.
89170922|NCT02656901|Sham Comparator|Manual sevoflurane anesthesia|The anesthesia will be maintained with sevoflurane to target the BIS of 50.
89170923|NCT02656901|Sham Comparator|Manual total endovenous anestesia|In ManualTIVA group, the anesthesia will be maintained with propofol to target the BIS of 50
89170924|NCT00847886|Experimental|LX3305|Daily oral intake of LX3305 for 14 days.
89170925|NCT00847886|Placebo Comparator|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
89170926|NCT04315649|Experimental|3D movie|3D movie viewing
89170927|NCT02653157||Burn patients with VAT or VAP with MDR-GNB|Adult patients with burn and/or inhalation injury requiring intubation
89170928|NCT00847808|Experimental|1|
89170929|NCT02656979|Other|Blood flow pre&post IOP lowering|After measurement of blood flow with MRI and measurements of ocular parameters the patient receives the IOP lowering eye drop latanoprost once daily in one eye for approximately one week and then the measurements are are repeated in the same manner.
89170930|NCT02656979|No Intervention|Blood flow|The subjects will do blood flow measurements with MRI and measurements of ocular parameters only once. No intervention with IOP lowering drops.
89170931|NCT02656667|Experimental|neuromuscular electrical stimulation|conventional pulmonary rehabilitation including exercise training on treadmill and neuromuscular electrical stimulation with a medical device for quadriceps muscle strengthening
89170932|NCT02656667|Experimental|cycle ergometer training|conventional pulmonary rehabilitation including exercise training on treadmill and quadriceps strenghthening on cycle-ergometer
89170933|NCT04168229|Experimental|ITE Hearing Aid|The subjects will wear the ITE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
89170934|NCT04168229|Active Comparator|BTE Hearing Aid|The subjects will wear the BTE devices in a field test for 10 +/-7 days. At the second and third visits they will perform speech testing in the lab in three randomized conditions (unaided, aided with ITE, and aided with BTE).
89170935|NCT04017455|Experimental|bevacizumab and atezolizumab|1 cycle of bevacizumab monotherapy, followed by 2 cycles of bevacizumab combined with atezolizumab, followed by 1 cycle of atezolizumab monotherapy
89170936|NCT05298020|Experimental|Envafolimab and Endostar plus AG regimen|Envafolimab:400mg,sc,d1,Q4W; Endostar：210mg，CIV72h，d1-3，Q4W； Chemotherapy:AG (nab-paclitaxel:125mg/m2,iv,d1,d8,Q4W；gemcitabine：1000mg/m2, iv,d1,d8，Q4W).
89170937|NCT02536469|Experimental|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
89170938|NCT02661581|Experimental|Peer Support|Peer support intervention group: During the first 3 months of DSME, participants in the DSMS intervention group will be invited to attend 6 lifestyle change sessions delivered a 2-person peer leader team and conducted bi-weekly. Immediately following the 3 months of DSME, participants are invited to attend 9 months of weekly DSMS sessions (60-minutes per session) delivered by a Peer Leader. These sessions are designed to sustain the self-management gains achieved in the 3 months of DSME.
89170939|NCT02661581|No Intervention|Wait-list Control|Immediately following the 6 bi-weekly DSME sessions, participants randomized to the Wait-list control group will have completed their participation in the study.
89170940|NCT02652845|Experimental|Intervention-Wellness Engagement Program|"The group assigned to the intervention arm will receive treatment as described below for a twelve week period:~Weekly lessons related to healthy eating and physical activity Biweekly check-in calls with a trained peer support coach Access to neighborhood wide physical activity and nutritional education events"
89170941|NCT02652845|No Intervention|Delayed treatment control group|The delayed treatment control group will not receive the intervention for measurement purposes; however the intervention as described will be administered to this group upon conclusion of the 12 week period for the intervention group.
89170942|NCT02661347|Active Comparator|Active comparator: tDCS & Risperidone|In the active arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2 milliampere (mA) for 20 minutes, twice a day for five consecutive days, for a total of 10 sessions.
89170943|NCT02661347|Sham Comparator|Sham comparator: tDCS & Risperidone|In the sham arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2mA for 1 minute, twice a day for five consecutive days, for a total of 10 sessions.
89170944|NCT02661269||Septic patients|Septic patients with fluid overload (fluid balance + 4 L)
89170945|NCT02661269||Post-cardiac surgery patients|Patients after cardiac surgery, at arrival on ICU.
89170946|NCT00649805|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
89170947|NCT00649805|Active Comparator|2|Verelan® PM extended-release capsules controlled-onset 300 mg
89170948|NCT02652689|Experimental|Diagnostic ultrasound|Recording Doppler ultrasound signals noninvasively from the right chest wall
89170949|NCT02656589||Herceptin probable sensitive group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable sensitive group
89170950|NCT02656589||Herceptin probable resistant group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable resistant group
89170951|NCT00600353|Experimental|Melphalan, dexamethasone, aprepitant, palonosetron|"Group A: Subjects with Multiple Myeloma~Conditioning regimen, over a 7 day period, includes:~Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion~Group B: Subjects with Lymphoma~Conditioning regimen, over a 7 day period, includes: (BEAC)~BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant"
89170952|NCT02661191|Other|asthma severity and disease exacerbation|intramuscular cholecalciferol 100,000 IU, followed by oral cholecalciferol 5000 IU weekly plus 400 IU daily for one year
89170953|NCT02660879|Placebo Comparator|Written Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given written educational materials, and given 5 minutes to read these materials. They were then re-taped for their inhaler technique.
89170954|NCT02660879|Experimental|Online Video Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given online video education located at use-inhalers.com, and were asked to complete the education (took on average 5 minutes). They were then re-taped for their inhaler technique.
89170955|NCT02660957|Experimental|self-determination smoking cessation|Subjects in the intervention group will be allowed to select their own schedules of quitting after discussing their situation with the counsellor (quit immediately (QI), or quit progressively (QP) with the ultimate goal of completing cessation over an acceptable period). Subjects in the intervention group will receive a self-help quitting leaflet published by the Hong Kong Council on Smoking and Health plus a series of brief interventions using the AWARD model.
89170956|NCT02660957|Placebo Comparator|health life|Subjects in the placebo control group will receive a smoking cessation leaflet published by the Hong Kong Council on Smoking and Health (COSH), as will the intervention group. Moreover, subjects in the placebo control group will undergo a similar schedule of telephone follow-up as those in the intervention group. They will receive a 'placebo' intervention with a 'placebo booster' of the same duration on increasing physical activity and fruit and vegetable intake.
89170957|NCT00691210|Experimental|V/N: Level 1|Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg
89170958|NCT00691210|Experimental|V/N: Level 2|Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg
89170959|NCT00691210|Experimental|V/N: Level 3|Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg
89170960|NCT00691210|Experimental|V/N: Level 4|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg
89170961|NCT00691210|Experimental|V/N: Level 5|Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg
89170962|NCT00691210|Experimental|V/N/E: Level 1|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2
89170963|NCT00691210|Experimental|V/N/E: Level 2|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2
89170964|NCT00691210|Experimental|V/N/E: Level 3|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2
89170965|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
89170966|NCT02536703|Experimental|Lotus Valve System|Transcatheter Aortic Valve Implantation (TAVI) with Lotus Valve System
89170967|NCT02652143|Experimental|sibling oocytes in vivo|randomized oocytes assigned to in vivo culture
89170968|NCT02652143|Active Comparator|sibling oocyte in vitro|randomized oocytes assigned to in vitro culture
89170969|NCT02652065|Active Comparator|Healthy skin|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin.~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
89170970|NCT02652065|Experimental|Psoriasis plaque|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back).~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
89170971|NCT00650429|Experimental|Arm A|
89170972|NCT00691132|Experimental|PEITC - Placebo (short-term trial)|Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
89170973|NCT00691132|Experimental|Placebo - PEITC (short-term trial)|Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
89170974|NCT04262219|Experimental|iShare|Participants will be asked to listen to a podcast intervention.
89170975|NCT02652299||Early Rheumatoid Arthritis group|Following informed written consent, 20 patients with early RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
89170976|NCT02652299||Longstanding Rheumatoid Arthritis group|Following informed written consent, 20 patients with longstanding RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
89170977|NCT02652299||Control group: Synovial tissue and peripheral blood|20 Non-RA patients who are referred to arthroscopy in a joint of the hand at OUH Department of Orthopedics, Section of hand surgery, are asked to participate by the surgeon at the first ambulatory consultation. Following informed written consent, MRI of hand, a blood sample and synovial biopsies, will be used as control for synovial and plasma fibrocyte levels. The synovial biopsies will be obtained during the planned arthroscopy.
89170978|NCT02651909||Rivaroxaban Cohort|Evidence of Rivaroxaban use with-in the last 48hours Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
89170979|NCT02651909||Control cohort not taking Rivaroxaban|Not taking Rivaroxaban - matched to Rivaroxaban group by age gender, type of injury or illness requiring urgent surgery Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
89170980|NCT03887728||Artificial (HRT) Cycles|"Commence estradiol tablets (E2) 4mg from day 2 or 3 of period for 3 days~Increase E2 to 6mg on day 4 of E2 treatment, according to clinician discretion based on endometrial thickness.~Transvaginal scan throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of a dominant follicle on the ovaries.~Serial measurements of serum LH (luteinizing hormone), estradiol and progesterone levels.~Initial progesterone dose of 100mg at 22hrs (vaginal suppository) after ≥ 10 days and ≤ 16 days of estradiol administration when the minimal endometrial thickness achieved is 6mm with a trilaminar appearance.~Subsequently increase progesterone administration to 100mg vaginally three times daily. Continue E2 administration 6mg (3 tablets daily). Embryo transfer is scheduled 5 days following the initial initiation of progesterone"
89170981|NCT03887728||Spontaneous natural cycles|"Day 2 of menses and throughout patients' natural cycle scans to monitor follicular growth.~Measurements of serum LH, estradiol and progesterone levels to determine ovulation.~The LH surge will be considered to have begun when the concentration rises by 180% above the most recent serum value and continues to rise thereafter (Irani et al. 2017, Fatemi et al., 2010).~Day 1 after the LH rise, a decrease in estradiol concentration is identified. Twenty four hours later progesterone concentrations rise with a level of greater than or equal to 1.5nmol /L confirming ovulation (day 0) (Irani et al., 2017; Speroff et al.). This is considered as day 0 with initiation of vaginal progesterone 100mg at 22hrs that night. The following day (day 1) the patient increases progesterone administration to 100mg vaginally 8 hourly and continues until 7 weeks gestation as per clinic protocol. Embryo transfer is scheduled 5 days (day 5) following confirmation of ovulation (day 0)."
89170982|NCT02564458|Experimental|Interval Exercise Training/Motivational Accelerometry (IET/MA)|All patients on the experimental arm receive the intervention of 5-12 weeks of pre-transplant IET, motivational accelerometry via the FitBit Surge, pre- and post-fitness assessments, and periodic quality of life and symptom surveys.
89170983|NCT02564458|No Intervention|Normal Standard of Care (control)|All patients on the control arm participate in the pre- and post-fitness assessment, are given the FitBit Surge without the motivational component, and are also given periodic quality of life and symptom surveys.
89170984|NCT00747994||1|
89170985|NCT02651753|Experimental|A|"Period 1: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.~Period 2: Test drug(CKD-337), 1 capsule administered under fed conditions."
89170986|NCT02651753|Experimental|B|Period 1: Test drug(CKD-337), 1 capsule administered under fed conditions. Period 2: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.
89170987|NCT00855218|Experimental|Sorafenib (Nexavar, BAY43-9006) + TACE|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Patients were then also treated with Transarterial Chemoembolization (TACE) performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of sorafenib, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
89170988|NCT00855218|Placebo Comparator|Placebo + TACE|Placebo was to be orally administered as 2 tablets bid (twice daily). Patients were then also treated with TACE performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of placebo, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
89170989|NCT00748150|Experimental|1|
89170990|NCT00744172|Active Comparator|I|laparoscopy
89170991|NCT00744172|Active Comparator|2|vaginal
89170992|NCT00744172|Active Comparator|3|abdominal
89170993|NCT00650507|Experimental|1|
89170994|NCT00650507|Active Comparator|2|
89170995|NCT00748228|Experimental|A|10 mEq/day dietary sodium
89170996|NCT00748228|Experimental|B|150 mEq/day dietary sodium
89170997|NCT00748228|Experimental|C|300 mEq/day dietary sodium
89170998|NCT02651519|Sham Comparator|Control|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with saline.
89170999|NCT02651519|Experimental|stellate-ganglion block|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with 0.25% ropivacaine hydrochloride.
89171000|NCT00748306|Experimental|GSK2190915|Intervention
89171001|NCT00748306|Placebo Comparator|Placebo|
89171002|NCT02651363||Patients treated with Dolocordralan|
89171003|NCT02651441|Experimental|D-CIK|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines,patients will receive 3 cycles of D-CIK treatment.
89171004|NCT02651441|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
89171005|NCT01063348|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine - 600mg tablets by mouth (dosing 1200mg - 3000mg qd)
89171006|NCT01063348|Placebo Comparator|Placebo|Matching placebo taken daily
89171007|NCT00855062|Active Comparator|Minocycline|Minocycline 100 mg orally every 12 hours
89171008|NCT00855062|Placebo Comparator|Placebo|Placebo minocycline capsules every 12 hours
89171009|NCT00744250|Other|1|"Pre-treatment vs. post-treatment-~In the first phase, before administration of the capsules and liquid diet, baseline gastric and duodenal secretions will be aspirated via the oro-enteric tube. Subjects will get 5 placebo capsules at Time=0 given orally with the liquid Lundh diet. Pancreato-biliary and duodenal secretions in the duodenal region will be aspirated continuously over the first 20 min. Gastric and duodenal fluids will be aspirated from 20-180 min at specified time points. Following a rest of 1 hour, the same process will be repeated with the drug capsules. At the end of the study the catheter will be removed and patient will be offered a meal."
89171010|NCT02651207||local anaesthetic spray group|women will either chose the above, ethyl chloride spray prior to having their contraceptive implant fitted or the below injection. This comes in a canister and a maximum of 5 spray for 5 seconds will be applied topically to the skin at the site of the contraceptive implant insertion
89171011|NCT02651207||local anaesthetic injection group|women will either chose ethyl chloride spray prior to having their contraceptive implant fitted or the injection, subcutaneous 1% lidocaine, usually a dose of about 1-2 mls to the area skin where the contraceptive implant is to be inserted.
89171012|NCT02564536|Experimental|Arm 1: Pacritinib and Decitabine|"Patients will receive one cycle of single agent pacritinib.~Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy.~Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced.~Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle.~Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle.~Patients may continue treatment for up to 12 cycles."
89171013|NCT02651285|Experimental|G-CSF|The embryos obtained with IVF in patients included iin this arm will be incubated after fertilization with medium supplemented with G-CSF
89171014|NCT02651285|Placebo Comparator|CONTROL|The embryos obtained by women undergoing IVF included in this arm will be incubated with a standard medium for IVF, and utilized as control group.
89171015|NCT00854906||Keratometric Tear Breakup Time|These are the study participants whose tear break up times were measured with a keratometer.
89171016|NCT00854906||Fluorescein Break Up Time|These are the study participants whose tear break up times were measured with with fluorescein dye.
89171017|NCT00748384||1|Self trained subjects
89171018|NCT00748384||2|supervised trained subjects
89171019|NCT00748462|Experimental|1|Fractional CO2 laser resurfacing
89171020|NCT00854828|Active Comparator|Surgical Intervention|
89171021|NCT00854828|Active Comparator|Non-Operative Intervention|
89171022|NCT02614820|Experimental|treatment group|inflation of a blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals
89171023|NCT02614820|Other|control group|inflation of a blood pressure cuff on the bilateral thighs to 40 mm Hg for four 5-minute intervals
89171024|NCT00847730|Experimental|VAC GranuFoam Bridge Dressing|This is a medical device foam dressing allowing placement away from wound site. It is designed to simplify the bridging application. It is used in combination with the V.A.C. Negative Pressure Wound Therapy System. For each subject, the dressing was applied in compliance with the IFU for 48-72 hours.
89171025|NCT00600119|Placebo Comparator|A|Placebo
89171026|NCT00600119|Experimental|B|NKTR-118
89171027|NCT02651051|Sham Comparator|High Fat Breakfast Meal|High fat breakfast meal served without addition of whey protein isolate
89171028|NCT02651051|Experimental|High Fat Breakfast Meal + Whey Protein|High fat breakfast meal served with addition of whey protein isolate
89171029|NCT04032821|Experimental|Alkotinib（300mg）First empty stomach, after the meal|Alkotinib（300mg），Subjects need to be fasting overnight for at least 10 hours before being warmed to 240 mL on an empty stomach Water service, lunch 4 hours later, dinner 10 hours later.
89171030|NCT04032821|Experimental|Alkotinib（300mg）After eating first, after fasting|Alkotinib（300mg），Subjects need to be fasting for at least 10 hours overnight, starting 30 min before taking the medication A standard meal (800-1000 CAL) can be taken before taking the medicine, and 240 mL warm water can be taken after the meal Lunch hours later, dinner 10 hours later.
89171031|NCT02650973|Experimental|Sequence A|3 doses of CHS-1701 or Neulasta, random order
89171032|NCT02650973|Experimental|Sequence B|3 doses of CHS-1701 or Neulasta, random order
89171033|NCT02650973|Experimental|Sequence C|3 doses of CHS-1701 or Neulasta, random order
89171034|NCT02660567|Experimental|Amr Maneuver|Active management of third stage plus Amr's maneuver
89171035|NCT02660567|No Intervention|Active management alone|Active management of third stage alone
89171036|NCT00866294|Experimental|paroxetine CR group|controlled-release (CR) of paroxetine 12.5 to 50mg/day
89171037|NCT00866294|Other|paroxetine IR group|Immediate-release (IR) of paroxetine 10 to 40mg/day as a reference arm
89171038|NCT00866294|Placebo Comparator|placebo group|matched placebo to both paroxetine CR and paroxetine IR
89171039|NCT02660333|Placebo Comparator|Placebo|Maltodextrin
89171040|NCT02660333|Active Comparator|Prebiotic|Fructooligosaccharide
89171041|NCT02660333|Active Comparator|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
89171042|NCT00649103|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
89171043|NCT00649103|Active Comparator|2|Accupril® Tablets 40 mg
89171044|NCT04131530||Colon mucosa observed by pCLE|pCLE is used to evaluate the inflammation activity in different parts of the colon mucosa
89171045|NCT02660177|Experimental|metamizole|single IV metamizole (10mg/kg) administration
89171046|NCT00701246|Experimental|I|I Treatment: a daily dose (5 times a week) of either 4,2 mg/kg/day of ferrous sulfate + folic acid (50 mcg)
89171047|NCT00701246|Placebo Comparator|II|II Treatment of anemic children with 4,2 mg/kg/day of ferrous sulfate and folic acid placebo.
89171048|NCT00701246|Experimental|III|Prevention of anemia in non-anemic children ( 5 times a week)- 1,4 mg/kg/day of ferrous sulfate and folic acid
89171049|NCT00701246|Placebo Comparator|IV|1,4 mg/kg/day of ferrous sulfate plus folic acid placebo, five days a week.
89171050|NCT02648711|Experimental|CRLX101 alone|Subjects will receive weekly infusion of CRLX101 alone. Starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2 (or 10 mg/m^2 if 12 mg/m^2 is not well tolerated. No other dose levels will be explored.
89171051|NCT02648711|Experimental|CRLX101 in combination with bevacizumab|Subjects receive weekly infusion of CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg. The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2. No other dose levels will be explored.
89171052|NCT02648711|Experimental|CRLX101 in combination with mFOLFOX6|Subjects receive weekly infusion of CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m^2, leucovorin 400 mg/m^2 and 5FU 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous infusion). The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2.
89171053|NCT00701324|Experimental|Arm A|BI 811283, 24h infusion d1 and d15 every 4 weeks
89171054|NCT00701324|Experimental|Arm B|BI 811283, 24h infusion d1 every 3 weeks
89171055|NCT02648399|Placebo Comparator|control group|only unilateral center lymph node dissection
89171056|NCT02648399|Experimental|experimental group|bilateral center lymph node dissection
89171057|NCT02648555|No Intervention|Standard follow-up (controls)|Given that depressive disorders may increase the risk of spontaneous abortions, antidepressants will be not discontinued. However, expectant mothers on paroxetine or sertraline, which have been reported to increase the incidence of cardiac malformations, will be switched to fluoxetine.
89171058|NCT02648555|Experimental|W+D protocol (lifestyle intervention)|Daily walking and dietary recommendations. Expectant mothers on paroxetine or sertraline will be switched to fluoxetine
89171059|NCT00854360|Experimental|BDP HFA 80 µg/day|During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.
89171060|NCT00854360|Experimental|BDP HFA 160 µg/day|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.
89171061|NCT00854360|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
89171062|NCT00854360|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
89171063|NCT02650661|Experimental|Online program & Health coaching|"This group is provided with Online health management program, Health coaching and Workshop."
89171064|NCT02650661|Experimental|Online program|"This group is provided with Online health management program."
89171065|NCT02650661|Active Comparator|Enhanced Usual Care|"This group is provided with Standard health educational booklet."
89171066|NCT00650351|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
89171067|NCT00650351|Active Comparator|2|Cipro® XR Tablets 1000 mg
89171068|NCT04117880|Experimental|Ataluren|Ataluren Oral suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20 mg/kg in the evening).
89171069|NCT02650739||SS-OCTdetermined group|Eyes with macular hole surgery that the postoperative prone positioning was discontinued after detecting a closure by SS-OCT
89171070|NCT02650739||Control group|Eyes with macular hole surgery that the halting of the prone position was determined by the surgeon
89171071|NCT02648633|Experimental|Nivolumab & Valproate Following G.K.|Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
89171072|NCT00853970|Experimental|Bromfenac ophthalmic solution 0.09%|dosed 1 drop daily in study eye for 2 weeks
89171073|NCT00853970|Placebo Comparator|Placebo|dosed 1 drop daily in study eye for 2 weeks
89171074|NCT04116008|Active Comparator|Erector Spinae Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
89171075|NCT04116008|Active Comparator|Subcostal Abdominis Plane Block|Ultrasound-guided bilateral STAP block performed at end of the surgery with 40 ml of a bupivacaine/prilocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
89171076|NCT02652377|Experimental|EDP-494 SAD Cohorts|EDP-494, oral 50 mg, 100mg, 200mg, 400mg and 800 mg, capsules, once daily in one single administration
89171077|NCT02652377|Experimental|EDP-494 MAD/POC Cohorts|EDP-494, oral 200mg, 400mg and 800 mg, capsules, once daily for 14 days
89171078|NCT02652377|Placebo Comparator|EDP-494 SAD Placebo Cohort|
89171079|NCT02652377|Placebo Comparator|EDP-494 MAD/POC Placebo Cohort|
89171080|NCT02648321|Experimental|Motivational Interviewing|Motivational Interviewing
89171081|NCT02648321|Active Comparator|Health Education|Health Education
89171082|NCT00651287|Active Comparator|quinapril 20 mg|
89171083|NCT00651287|Active Comparator|quinapril 20 mg+hydrochlorothiazide 12.5 mg|
89171084|NCT00651287|Active Comparator|quinapril 40 mg|
89171085|NCT02648243|No Intervention|Control|Patients will receive routine discharge instructions and medication information by the nurses and treating physicians at hospital discharge: Patients will not have any contact with the clinical pharmacists.
89171086|NCT02648243|No Intervention|Pharmacist delivered usual care at discharge|Patients will receive the usual counseling at discharge by the clinical pharmacists.
89171087|NCT02648243|Experimental|structured intervention at discharge and tailored follow up|The pharmacist will deliver a structured personalized discharge intervention in addition to 2 follow-up session (around 30 minutes each session) at 4 weeks of discharge and 8 weeks of discharge.
89171088|NCT00910793|Other|Inuvair|
89171089|NCT02648087|Other|With and without SDB|comparison of patients with and without sleep-disordered breathing
89171090|NCT02647931|Experimental|Voice Therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia patients.
89171091|NCT02647853|Experimental|TAT4 Gel concentration A|TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
89171092|NCT02647853|Experimental|TAT4 Gel concentration B|TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
89171093|NCT02647853|Placebo Comparator|Placebo|Placebo product once daily to 50 cm2 for 14 days.
89171094|NCT02650505|Experimental|LEO 43204|LEO 43204 will be applied topically to the skin under open conditions 10 times
89171095|NCT02650505|Placebo Comparator|LEO 43204 vehicle|LEO 43204 vehicle will be applied topically to the skin under open conditions 10 times
89171096|NCT02650427|Experimental|DPPIV Inhibition|The study will include 3 weeks administration (± 7 days) of sitagliptin as monotherapy (taken orally). The study will use 3 doses: the first five patients will receive 100 mg/day, the next five 200 mg/day and the last five patients 600 mg/day. During this time, arrangements will be made for surgical resection, as per the standard of care treatment of patients. Blood samples will be obtained for immunology studies. The study will end one week after surgery. Patients will continue their treatment for HCC as prescribed by the clinician.
89171097|NCT02650583|Experimental|Supportive care (Enhancing Connections Program)|Patients participate in Enhancing Connections Program comprising of anchoring patients to help their child, adding to listening skills, building on listening skills, being a detective of their child's coping, and celebrating success for 5 sessions. Patients also receive workbook which includes text from the sessions, handouts, and at-home assignments to be completed between sessions.
89171098|NCT02650349|Experimental|spinal cord stimulation|The Vectris® SureScan® MRI lead will be connected to a RestoreSensor® SureScan® MRI neurostimulator.
89171099|NCT00650741||1|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), no repetition of test
89171100|NCT00650741||2|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), Repetition with Nitroglycerin
89171101|NCT00650741||3|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), repetition of test with the Endotect
89171102|NCT00652613|Active Comparator|1|3 dimensional conformal radiotherapy
89171103|NCT00652613|Experimental|2|Intensity Modulated Radiation Therapy (IMRT)
89171104|NCT02644889||Patients advanced NSCLC EGFR mutated|This is an observational study, there is no intervention.
89171105|NCT00651365|Experimental|001|
89171106|NCT04166747|Experimental|Intervention Group|The participants in this group will receive virtual reality based intervention for 15 minutes at a time, twice in a week for six weeks.
89171107|NCT04166747|No Intervention|Control Group|The participants in this group will not receive virtual reality based intervention for six weeks.
89171108|NCT02647775|Other|multi-port VATS|Multi-port VATS is an operative method
89171109|NCT02647775|Other|single-port VATS|Single-port VATS is an operative method
89171110|NCT02644811|Experimental|Group A - Miniscrews|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal). Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with miniscrews (Spider Screw K1 short neck). Miniscrews are placed buccally between the maxillary second premolar and the first molar after topical anesthesia (buccal) and injection (buccal). Miniscrews are placed when space closure starts. Space closure is performed as en masse retraction. Miniscrew are immediately loaded with 150g Nickel Titanium coil springs."
89171111|NCT02644811|Active Comparator|Group B - Molarblock|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal. Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with molarblocks - a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar. Molarblocks are installed from the beginning of leveling and alignment. Space closure is performed as en masse retraction with type one active tie-backs."
89171112|NCT02647463|Experimental|Attachment and Biobehavioral Catch-up|10-session intervention for parents and infants aimed at increasing parents' nurturance and following the lead, and reducing frightening behavior
89171113|NCT02647463|No Intervention|Waitlist Control|Waitlist Control
89171114|NCT00651443|Experimental|1|
89171115|NCT02649881||isolated heart from heart transplantation|
89171116|NCT00650897|Experimental|A|Patients with Diabetes Mellitus and Major Depression
89171117|NCT02644655|Experimental|CD19-specific chimeric antigen receptor|After pretreatment, cluster of differentiation antigen 19 (CD19)-specific chimeric antigen receptor will be transfused.
89171118|NCT02644499|Active Comparator|Combination therapy|Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
89171119|NCT02644499|Active Comparator|Monotherapy|Methotrexate (up to 25 mg once a week) for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
89171120|NCT02649803|Other|community hospital|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the nearest community hospital or Shanghai Children's Medical Center, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children. The patient's caregiver will be instructed to install asthma APP at their smart phone to follow up."
89171121|NCT02647541|Experimental|Nutritional intervention|Consultation with a dietitian, including nutritional recommendations and supplementation.
89171122|NCT02647541|No Intervention|Standard therapy|No specific nutritional recommendations.
89171123|NCT04166825|Active Comparator|Long protocol|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono) and/or urinary human menopausal gonadotropin (menotropin, Menopur®, Ferring GmbH) or mixed recombinant human FSH/LH (Pergoveris®, Merck Serono) with a starting dose of 87.5-250 IE/day
89171124|NCT04166825|Active Comparator|Short protocol|Ovarian hyperstimulation with a GnRH-antagonist consisted of the use of ganirelix (Orgalutran®, MSD) from the 6th day of stimulation until it's end at the daily dose of 0.25 mg
89171125|NCT04166825|Active Comparator|Clomiphene citrate|Ovarian stimulation with clomiphene citrate (Clostilbegyt®, EGIS) 50 mg daily per os form 3rd to 7th day of the cycle
89171126|NCT04166825|Active Comparator|Letrozole|Ovarian stimulation with letrozole (Lametta®, Vipharm) 2.5 mg daily per os form 3rd to 7th day of the cycle
89171127|NCT04166825|Active Comparator|Gonadotropins|Ovarian hyperstimulation started on day 2 or 3 of the cycle with daily subcutaneous injections of recombinant human FSH (follitropin α, Gonal F®, Merck Serono).
89171128|NCT00651521||1|CKD stage 1 patients
89171129|NCT00651521||2|CKD stage 2 patients
89171130|NCT00651521||3|CKD stage 3a patients
89171131|NCT00651521||4|CKD stage 3b patients
89171132|NCT00651521||5|CKD stage 4 patients
89171133|NCT00651521||6|CKD stage 5 patients
89171134|NCT00652769|Active Comparator|B|Control arm: Current practice for diagnosing and staging lung cancer. Most patients with intra-thoracic disease suspected of lung cancer will undergo bronchoscopy (or CT guided biopsy), PET scan and possibly mediastinoscopy.
89171135|NCT00652769|Experimental|A|Active arm: A new pathway for the diagnosis and staging of lung cancer with endobronchial (EBUS) or endoscopic ultrasound (EUS) as a first test. If EBUS or EUS is negative the patient will have PET scan +/- mediastinoscopy.
89171136|NCT02536157|Active Comparator|Dorsal block splint|Thermoplastic splint in 20 degrees flexion applied to the dorsum of the PIPJ.
89171137|NCT02536157|Experimental|Volar gutter splint|Thermoplastic splint in 0 degrees flexion applied to the volar surface of the finger.
89171138|NCT02647697|Experimental|Radiprodil|Subjects will receive a single dose of Radiprodil 30 mg in suspension form, orally via a syringe in the morning of Day 1.
89171139|NCT02647307|Experimental|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg).
89171140|NCT03785327|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
89171141|NCT03785327|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
89171142|NCT03785327|Experimental|Autism Training Program|Training program designed to increase autism understanding followed by behavioral testing Intervention:Training program
89171143|NCT03785327|No Intervention|Social interaction without intervention|Control condition: Behavioral testing without an intervention component
89171144|NCT02649569||Observational (continuous activity monitoring, questionnaires)|Patients wear an activity monitor throughout and up 4 weeks after completion of radiation therapy. Patients who are willing may continue to wear the monitor through routine follow up appointments. Patients also complete questionnaires at evaluations, which take place prior to radiotherapy initiation, weekly during radiotherapy, and then 2 and 4 weeks after the completion of radiotherapy.
89171145|NCT00650975|Active Comparator|ELCA|Laser Thromboablation
89171146|NCT00650975|Active Comparator|PTCA|PTCA (Direct Stenting)
89171147|NCT02649179|Experimental|local infiltration with ropivacaine|patients were to receive 0.75% ropivacaine
89171148|NCT02649179|Placebo Comparator|local infiltration with 0.9% saline|patients were to receive placebo
89171149|NCT02644577|Experimental|metformin group|Metformin 1000mg/day
89171150|NCT02644577|Placebo Comparator|placebo group|starch
89171151|NCT02644421|Experimental|VVZ-149|"The following doses will be administered intravenously:~Loading Dose: 1.8 mg/kg VVZ-149 over 0.5 hours~Maintenance infusion: 1.3 mg/kg/hr VVZ-149 over 7.5 hours"
89171152|NCT02644421|Active Comparator|Lidocaine|"The following doses will be administered intravenously:~Lidocaine 4mg/kg LBM over 0.5 hours~Normal saline over 7.5 hours"
89171153|NCT02644421|Placebo Comparator|Placebo|Normal saline administered intravenously over 8 hours
89171154|NCT02649257|Experimental|MC 6125 AS IOL + CTR|All patients received the same procedure: cataract surgery with phakoemulsification, implantation of a capsular tension ring (CTR13/11) and implantation of an intraocular lens (MC 6125 AS).
89171155|NCT04167449|Active Comparator|Hydroponic Red Ginseng|
89171156|NCT04167449|Active Comparator|Conventional White Ginseng|
89171157|NCT04167449|Placebo Comparator|Placebo|
89171158|NCT02647229|Active Comparator|Isosmotic bowel cleansing preparation|Isosmotic solution ingested prior to colonoscopy
89171159|NCT02647229|Active Comparator|Colonic Hyrdrotherapy|Colonic hydrotherapy is an FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician.2 There
89171160|NCT00651599|Placebo Comparator|Arm 2|
89171161|NCT00651599|Experimental|Arm 1|
89171162|NCT02647151|Active Comparator|METHYLAMINOLEVULINATE HYDROCHLORIDE|METHYLAMINOLEVULINATE HYDROCHLORIDE (MAL)cream 160mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
89171163|NCT02647151|Experimental|AMINOLEVULINIC ACID HYDROCHLORIDE|AMINOLEVULINIC ACID HYDROCHLORIDE (ALA) gel 78mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
89171164|NCT04167293|Experimental|SBRT + PD-1 Arm|Patients assigned to this arm will receive SBRT followed by sintilimab. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks. In the SBRT + PD-1 arm, sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
89171165|NCT04167293|Other|SBRT Arm|Patients assigned to this arm will receive SBRT alone. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
89171166|NCT04166357||Respiratory and autonomic complications of GBS|"Early detection of respiratory failure is among the main challenges raised by the management of GBS. Careful monitoring by an experienced team of nurses and physicians is crucial. The classic signs of respiratory failure occur late, and the early manifestations consist only of tachypnea, tachycardia, air hunger, broken sentences, and a need to pause between sentences; later, use of the accessory respiratory muscles, paradoxical breathing, and orthopnea indicate severe diaphragmatic weakness.~Autonomic dysfunction occurred in the affected patients, including cardiac arrhythmia, hypertension or hypotension, ileus, and urinary retention."
89171167|NCT02536391|Experimental|Sequence 1: Tablet/Capsule/Tablet with food|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
89171168|NCT02536391|Experimental|Sequence 2: Tablet/Tablet with food/Capsule|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib capsule administered after fast.
89171169|NCT02536391|Experimental|Sequence 3: Capsule/Tablet/Tablet with food|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
89171170|NCT02536391|Experimental|Sequence 4: Capsule/Tablet with food/Tablet|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib tablet administered after fast.
89171171|NCT02536391|Experimental|Sequence 5: Tablet with food/Tablet/Capsule|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib capsule administered after fast.
89171172|NCT02536391|Experimental|Sequence 6: Tablet with food/Capsule/Tablet|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after fast.
89171173|NCT02644187|Other|Left side first -Aktilite CL128|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
89171174|NCT02644187|Other|Right side first -Aktilite CL128|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
89171175|NCT02644187|Other|Left side first -BF-RhodoLED|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
89171176|NCT02644187|Other|Right side first -BF-RhodoLED|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
89171177|NCT02536235|Experimental|Intervention: intraoperative topical heat|
89171178|NCT02536235|No Intervention|Control: no intraoperative heat|
89171179|NCT04166279|Experimental|Single rehabilitative Treatment|Patients treated within single rehabilitative protocol
89171180|NCT04166279|Experimental|Group rehabilitative Treatment|Patients treated within group rehabilitative protocol
89171181|NCT04167137|Experimental|Arm 1: SYNB1891 Monotherapy|SYNB1891 is to be administered as an intratumoral injection in up to four 21-day cycles of escalating doses on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-4. The starting dose of SYNB1891 in the first cohort will be 1 × 10^6 live cells and will be increased in approximately 3-fold increments in subsequent cohorts until MTD determination. A de-escalation dose of 3 × 10^5 live cells is available if the starting dose is deemed not tolerable. Patients without progressive disease at the end of cycle 4 may receive additional cycles of SYNB1891 on day 1 of each cycle for up to 24 months after initial dose of study treatment.
89171182|NCT04167137|Experimental|Arm 2: SYNB1891 in Combination with Atezolizumab|Once the MTD has been established in Arm 1, dosing of SYNB1891 will begin in Arm 2 at a 10-fold lower dose than the Arm 1 maximum tolerated dose (MTD) and will be increased in approximately 3-fold increments in subsequent cohorts until recommended Phase 2 dose (RP2D) determination. SYNB1891 is to be administered in the same manner and frequency as Arm 1. Atezolizumab will be administered in accordance with its recommended dose and schedule (1200 mg IV every 3 weeks) on day 1 of each of the 4 planned cycles. On days when atezolizumab and SYNB1891 are both administered, SYNB1891 will be administered first, followed by at least 1 hour of observation prior to the atezolizumab infusion. Combination doses will not be escalated above the SYNB1891 single-agent MTD established in Arm 1. Patients without progressive disease at the end of cycle 4 may receive additional cycles of SYNB1891 and atezolizumab on day 1 of each cycle for up to 24 months after initial dose of study treatment.
89171183|NCT00651677|Active Comparator|HAL Proctectomy|Hand-assisted laparoscopic proctectomy
89171184|NCT00651677|Active Comparator|SL Proctectomy|"straight laparoscopic proctectomy"
89171185|NCT02644031|Experimental|Mtwo rotary system|( continuous rotation system)
89171186|NCT02644031|Experimental|safe-sider rotary system|(reciprocating system)
89171187|NCT02644031|Experimental|hand files|k-files
89171188|NCT02646995|Experimental|Active|modified lipid formulation
89171189|NCT02646995|Active Comparator|Control|fish oil
89171190|NCT00651833|Experimental|1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. Patient will also receive cisplatin, 75 mg/m2 as a 1- to 3-hour infusion on Day 1 of each cycle.
89171191|NCT04167215|Experimental|perforator flap augmentation|Doppler probe is used to locate perforating vessels from the superior gluteal artery. . Flaps or lumbar artery flap will be designed to allow deepithelialization and dissection laterally to medially to identify the perforator . then sketolization is performed A gluteal pocket will then create for the augmentation flaps by undermining in a plane just superficial to the gluteal muscle extending to within 5 cm of the inferior gluteal crease. The deepithelialized flaps will then transpose inferomedially , and tacked to the fascia with several sutures.to be used as autologus buttock augmentation flap
89171192|NCT04167215|Experimental|fat injection|liposuction is performed firstly to parts where excess fat is exist and we will prepare the aspirated fat for injection as a graft in subcutaneous tissue of the buttock regoin
89171193|NCT02649413|Experimental|Early response to prednisone treatment|intervention -children that will have a remission in 8 days (response) will get an adjusted steroids dose treatment.children that have a remission between 9-28 days will get a regular steroid dose.
89171194|NCT04167059|Experimental|Waitlist-Control Group|The 'waitlist control' group will receive the 12-week non-intervention period first, followed by 12 week intervention period.
89171195|NCT04167059|Experimental|Immediate Treatment|The 'immediate treatment' group will receive the 12-week intervention period first, followed by 12 week non-intervention period.
89171196|NCT02643953|No Intervention|Control Group|This arm includes women who are eligible and give birth (including cases of fetal or infant death) in the intervention period in comparative health wards, who will not receive the interventions and who will continue to receive their usual pattern of utilization of maternity care.
89171197|NCT02643953|Experimental|Other|The intervention will need to be multi-faceted, and will consist of provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; conditional cash transfers to promote uptake of services and targeted community health education and advocacy activities
89171198|NCT02643641|Experimental|BM32-3|2 placebo injections will be given followed by 3 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
89171199|NCT02643641|Experimental|BM32-4|1 placebo injections will be given followed by 4 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
89171200|NCT02643641|Experimental|BM32-5|5 injections with 20 micrograms each of BM321, BM322, BM325 and BM326 will be given
89171201|NCT02643641|Placebo Comparator|Placebo|5 placebo injections (alhydrogel only) will be given
89171202|NCT02643563|Experimental|Ropivacaine 0.5%|Low volume (5 ml) Interscalene Block with Ropivacaine 0.5%
89171203|NCT02643563|Active Comparator|Ropivacaine 1%|Low volume (5 ml) Interscalene Block with Ropivacaine 1%
89171204|NCT02643563|Active Comparator|Bupivacaine 0.5% + epinephrine 1:200,000|Low volume (5 ml) Interscalene Block with Bupivacaine 0.5% + epinephrine 1:200,000
89171205|NCT02643797|Experimental|Intervention Group: MA Health Coaching|"Patients in the intervention group will receive the MA Health Coaching intervention during their primary care visits, as well a follow-up calls to encourage/monitor progress and offer support."
89171206|NCT02643797|No Intervention|Usual Care|"Patients in this group will receive treatment as usual during their primary care visits."
89171207|NCT02647073|Experimental|Mobile monitoring device arm|Canary 01 Mobile Vital Signs Monitoring Device
89171208|NCT00651209|Experimental|1|Sub-group 1- continue telbivudine if HBV DNA non-detectable at week 24 Sub-group 2- tenofovir added to telbivudine in patients if HBV DNA detectable at week 24
89171209|NCT00652925|Experimental|High Dose|
89171210|NCT00652925|Experimental|Low Dose|
89171211|NCT00652925|Active Comparator|Naproxen|Control comparator, 15 mg/kg/dy target dose
89171212|NCT00653003|Experimental|A|Subjects received Kali formulated product under fed conditions
89171213|NCT00653003|Active Comparator|B|Subjects received Aventis formulated products under fed conditions
89171214|NCT02646605||patients initiating ART|HIV positive men and women initiating ART
89171215|NCT02646605||patients on established ART|HIV positive men and women on established ART
89171216|NCT02643719|Active Comparator|Topiramate|
89171217|NCT02643719|Active Comparator|Behavioral intervention|
89171218|NCT02643719|Active Comparator|topiramate and behavioral intervention|
89171219|NCT02643719|Active Comparator|Standard of Care|
89171220|NCT02649023||A: Patients with deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a positive finding will be grouped in arm A"
89171221|NCT02649023||B: Patients without deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a negative finding will be grouped in arm B"
89171222|NCT04166201|Other|modified chevrel technique|hernioplasty done with double mesh modification of chevrels technique
89171223|NCT00865904|Placebo Comparator|Placebo|Placebo matched to VX-809 capsule orally once daily for 28 days.
89171224|NCT00865904|Experimental|VX-809, 25 mg|VX-809, 25 milligram (mg) capsule orally once daily for 28 days.
89171225|NCT00865904|Experimental|VX-809, 50 mg|VX-809, 50 mg capsule orally once daily for 28 days.
89171226|NCT00865904|Experimental|VX-809, 100 mg|VX-809, 100 mg capsule orally once daily for 28 days.
89171227|NCT00865904|Experimental|VX-809, 200 mg|VX-809, 200 mg capsule orally once daily for 28 days.
89171228|NCT02648867|Experimental|Patients receiving PushCoach feedback|Patients will receive continuous maternal feedback from the PushCoach device, which includes both audio and visual feedback of fetal head movement during the second stage of labor
89171229|NCT02648867|Active Comparator|Patients blinded to PushCoach feedback|Patients will not receive continuous maternal feedback from the PushCoach device (it will be in place and collect data), but will receive normal feedback from the clinician during the second stage of labor.
89171230|NCT02649101|Experimental|thalidomide plus chemotherapy|thalidomide tablet 100mg qn po
89171231|NCT02649101|Active Comparator|chemotherapy|Physician's choice chemotherapy. No constraints of the choice of chemotherapy drugs and regimens.
89171232|NCT02648945|Active Comparator|high intensity exercise|"high intensity exercise on a treadmill according to Balke's Protocol.~high intensity of exercises for each group of 15 participants were set at 80-85% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax~After rearrangement, it will be:~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
89171233|NCT02648945|Active Comparator|low intensity exercise|"low intensity exercise on a treadmill according to Balke's Protocol. low intensity of exercises for each group of 15 participants were set at 50-55% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax~After rearrangement, it will be:~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
89171234|NCT02613260|No Intervention|Usual Care|Patients in this study arm will receive usual care from their primary care clinic.
89171235|NCT02613260|Experimental|FIT Outreach + Usual Care|Patients in this study arm will receive usual care at their primary care clinic and the intervention.
89171236|NCT04166045|Sham Comparator|Sham|Treatment at the bicep location
89171237|NCT04166045|Active Comparator|Verum|Treatment at the hand location
89171238|NCT00700154|Experimental|Insulin infusion (aspart)|
89171239|NCT00700154|No Intervention|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
89171240|NCT02643485||Study group|Patients undergoing forefoot reconstruction of hallux valgus or hallux rigidus
89171241|NCT02643485||Control group|Healthy volunteers (Students)
89171242|NCT00651989||A|healthy individuals
89171243|NCT02643407|Experimental|Docetaxel plus Nedaplatin|docetaxel 60mg/m2 and nedaplatin 80mg/m2, d1 every 3 weeks
89171244|NCT02643407|Active Comparator|Docetaxel plus Cisplatin|docetaxel 60mg/m2 and cisplatin 75mg/m2, d1 every 3 weeks
89171245|NCT02643329|Experimental|BF-Gliclazide Tablet 80mg|During the study session, healthy male subjects will be administered a single oral dose of BF-Gliclazide Tablet 80 mg after an overnight fast of approximately 10 hours.
89171246|NCT02643329|Active Comparator|Diamicron 80mg Tablet|During the study session, healthy male subjects will be administered a single oral dose of Diamicron 80 mg Tablet after an overnight fast of approximately 10 hours.
89171247|NCT04165655|Experimental|Keep Achieving (KA) group|Participants in the experimental group will take part in a 10-week group based activity programme. The activity programme will consist of 1, 50 minute session each week for the duration of 10-weeks. The activity sessions will include semi-structures free play sessions, sport specific sessions facilitated by local sports teams and swimming sessions.
89171248|NCT04165655|No Intervention|Waitlist control group|Participants in this group will not receive the 10-week group based activity intervention throughout the duration of this study. Participants will be able to participate in the 10-week activity intervention once this research has ended.
89171249|NCT00652067||1|Only one patient is being treated under a single patient IND.
89171250|NCT02643017|Placebo Comparator|normal saline|
89171251|NCT02643017|Experimental|Dex|
89171252|NCT02643173||Volatile|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using volatile anesthetics as maintenance agents.
89171253|NCT02643173||Intravenous|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using intravenous anesthetics as maintenance agents.
89171254|NCT02646215|Active Comparator|Inspiratory muscle training group|Threshold inspiratory muscle training
89171255|NCT02646215|No Intervention|Control group|No training
89171256|NCT02646137|Active Comparator|Transarterial chemoembolization (TACE)|treated by transarterial chemoembolization
89171257|NCT02646137|Experimental|Radiofrequency ablation with TACE|Radiofrequency ablation combined with TACE
89171258|NCT02646137|Experimental|Microwave ablation combined with TACE|Microwave ablation combined with TACE.
89171259|NCT04165421|Experimental|Family intervention group|The intervention starts with a two hour group session for AF-patients and family members designed by the PhD student and the project nurses based on clinical guidelines of AF-management and theory from multifamily group intervention. Project nurses who are also Nurse specialists will facilitate knowledge to patients and family members about AF and how to support self-management in their daily living. Furthermore the (Family focused nursing) FFN intervention will consist of 3 -5 Family Strength Orientated Therapeutic Conversations (FAM-SOTC) accordingly to the needs of patient and the family. The FAM-SOTC conversations will be used as health promoting conversations and a way to enhance family health and psychological resilense
89171260|NCT04165421|No Intervention|Control group|"The control group will receive conventional care and treatment according to guidelines.~Conventional care is characterized by ad hoc management as per usual standards of clinical care (with access to routine medical care, hospital care, and pharmacotherapy)."
89171261|NCT00653081|Active Comparator|A|Supervised Exercises performed at ulleval Hospital for patients with shoulder pain. Dosage: 45 minutes each time, max 2-3 times a week in max 12 weeks
89171262|NCT00653081|Active Comparator|B|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
89171263|NCT00653549|Experimental|A|Subjects received Par formulated product under fasting conditions
89171264|NCT00653549|Active Comparator|B|Subjects received Roche formulated product under fasting conditions
89171265|NCT02642861|Active Comparator|Cyclobenzaprine|Cyclobenzaprine administration for 2 weeks
89171266|NCT02642861|Placebo Comparator|PLacebo|Calcium carbonate for 2 weeks
89171267|NCT02641535|Experimental|research arm|"12 healthy volunteers from the border guard of the police forces will participate in this study. The subjects will undergo 4 experiment days:~Recruitment , medical examination and VO2max test.~Acclimatization day by performing moderate exercise protocol under hot and humid climate.~3.2 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:~Protective garment in current use + NBC mask.~The new BC membrane protective garment + NBC mask"
89171268|NCT02641457|Experimental|Aflibercept x Ranibizumab|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and 12 eyes patients received an intraocular injection of 1.25mg ranibizumab
89171269|NCT02641613|Active Comparator|supraclavicular|patients receive a supraclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
89171270|NCT02641613|Experimental|retroclavicular block|patients receive a retroclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
89171271|NCT04131452||Fresh embryo transfers|those undergoing fresh embryo transfer
89171272|NCT04131452||Frozen embryo transfers|those undergoing frozen embriyo transfer
89171273|NCT02646059|Experimental|Text group|Text messages containing reminds of blood donation information would be sent to donors in this group.
89171274|NCT02646059|Experimental|Telephone group|Investigators would give telephone calls to the donors in this group, ask the reasons why they stopped donating blood.
89171275|NCT02646059|No Intervention|Control group|No intervention will be giving to this group.
89171276|NCT02642939|Experimental|mifepristone|mifepristone 300 mg capsule per day, orally in 28-day cycles
89171277|NCT02642549|Experimental|Girls for Health Intervention (G4H)|G4H will integrate proven girls' education strategies with innovative vocational interventions to build 1350 girls' career aspirations and academic achievement
89171278|NCT02642549|No Intervention|Control Condition|standard of care to support school attendance among girls (i.e., school tracking of attendance and reaching out to truant girls).
89171279|NCT02641301|Experimental|Subjects Roux-en-Y-gastric bypass (RYGB)|Sustained release morphine sulfate, 30 mg
89171280|NCT02641301|Active Comparator|Control volunteers matched with RYGB|Sustained release morphine sulfate, 30 mg
89171281|NCT02642783|Other|Descriptive analysis|panelists were asked to rate different sensory attributes for different laxative bowel cleansing solutions on a 15 cm line scale.
89171282|NCT02642783|Other|Acceptability test|panelists were asked to rate the acceptability of different laxative bowel cleansing solutions using the 9-point hedonic scale.
89171283|NCT04165187|Experimental|BAT+Home exercise program|The patients in this group will participate in BAT for 3 days a week for 6 weeks in addition to home exercise program.
89171284|NCT04165187|Active Comparator|Home exercise program|The patients in the control group will perform home exercise program, two times a day, 7 days a week for 6 weeks.
89171285|NCT02642471|Experimental|Arm 1|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
89171286|NCT02642471|No Intervention|Arm 2|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
89171287|NCT02642471|Experimental|Arm 3|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
89171288|NCT02642471|No Intervention|Arm 4|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
89171289|NCT02640989|Experimental|Group 1|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, Anflu®"
89171290|NCT02640989|Experimental|Group 2|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, VAXIGRIP"
89171291|NCT02640989|Active Comparator|Group 3|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, Fluarix"
89171292|NCT02642705|Experimental|High intensity interval training N|High intensity interval training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing ambient air (normoxia)
89171293|NCT02642705|Experimental|High intensity interval training H|High intensity interval training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing hypoxic air (about 3 500 m of altitude)
89171294|NCT02642705|Active Comparator|Constant load exercise training N|Constant load exercise training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing ambient air (normoxia)
89171295|NCT02642705|Experimental|Constant load exercise training H|Constant load exercise training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing hypoxic air (about 3 500 m of altitude)
89171296|NCT02642705|Experimental|Hypoxic conditioning at rest|Hypoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, hypoxic breathing for one hour (about 4500 m of altitude) while seating quietly
89171297|NCT02642705|Sham Comparator|Normoxic conditioning at rest|Normoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, normoxic breathing for one hour (ambient air) while seating quietly
89171298|NCT00653627|Experimental|A|Study of BCG quantification and immunogenicity 2 weeks after BCG vaccination
89171299|NCT00653627|Experimental|B|Study of BCG quantification and immunogenicity 4 weeks after BCG vaccination
89171300|NCT02645747||Group 1|The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
89171301|NCT00653237|Other|1|crossover trial. insertion of both devices consecutively, computer randomized order
89171302|NCT04165499|Experimental|Combination of Plant Extracts (BSL_EP026)|Volunteers will take 1 capsule twice daily with the combination of the plant extracts (BSL_EP026).
89171303|NCT04165499|Placebo Comparator|Control|Volunteers will take 1 capsule twice daily with maltodextrin.
89171304|NCT00653315|Experimental|A|Subjects received kali product under fasting conditions
89171305|NCT00653315|Active Comparator|B|Subjects received Ortho-Mcneil product under fasting conditions
89171306|NCT00652223|Experimental|1|
89171307|NCT02640833|Experimental|Duvelisib+Venetoclax|
89171308|NCT00653393|Experimental|A|Subjects received Kali product under fasting conditions
89171309|NCT00653393|Active Comparator|B|Subjects received Parnate product under fasting conditions
89171310|NCT02640599|Experimental|Vestibular Rehabilitation + Areobic Exercise|
89171311|NCT02640599|Active Comparator|Vestibular Rehabilitation|
89171312|NCT00599339||Neupro|Neupro at study onset
89171313|NCT00599339||Dopamine Agonist|Other Dopamine-Agonist at study onset
89171314|NCT00599339||L-Dopa|L-Dopa
89171315|NCT00599339||Neupro + L-Dopa|Neupro in combination with L-Dopa at study onset
89171316|NCT00599339||Dopamine Agonist + L-Dopa|Other Dopamine Agonist in combination with L-Dopa at study onset
89171317|NCT02645669|Experimental|Study site|Scaling and Root planing (SRP) was followed by placement of S boulardii-FOS mixture
89171318|NCT02645669|Placebo Comparator|Control site|Only Scaling and Root planing (SRP) was performed
89171319|NCT02645903|Active Comparator|transversus abdominis plane block|"Patients who received a tranversus abdominis plane block with ultrasound after standard general anesthesia represented Group 1.~The tranversus abdominis plane block was performed bilaterally by obtaining an image with real time ultrasound guidance with a 6-13 MHz linear probe.~The block was placed with a 22 G 80 mm needle while obtaining real-time images via an in-plane technique.~Two 20 mL syringes were prepared after preparing a local anesthetic concentration of 1.5 mg/kg of 0.5% bupivacaine to 40 mL with saline. These were administered to the left and right abdominal walls.~Postoperative analgesia was administered through a morphine the patient-controlled analgesia device."
89171320|NCT02645903|Placebo Comparator|nonblocked|Patients who received standard general anesthesia alone made up Group 2. Postoperative analgesia was administered through a morphine the patient-controlled analgesia device.
89171321|NCT02645981|Experimental|Donafenib|Drug:Donafenib; Dose:200mg,bid,po.
89171322|NCT02645981|Active Comparator|Sorafenib(Nexavar)|Drug:Sorafenib; Dose:400mg,bid,po.
89171323|NCT02535767|Experimental|A: 0.40 mg/kg PQ G6PDd|0.40 mg/kg of primaquine (as a single dose) in G6PD-deficient individuals
89171324|NCT02535767|Experimental|B: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
89171325|NCT02535767|Experimental|C: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
89171326|NCT02535767|Experimental|D: PQ G6PDn|A single dose of primaquine in G6PD-normal men, at the highest tolerable dose determined by the DSMB, from previous dose groups.
89171327|NCT02640521|No Intervention|Control Parents|
89171328|NCT02640521|Active Comparator|Treatment Parents|Chart reminders (paper or electronic medical records, depending on clinic wishes) to prompt providers to ask about in home smoking at every medical visit; establishing a New York State Quit line referral system in the pediatric practice; and amending the training curriculum for providers and the patient education materials that are part of a provider toolkit, to focus on the negative impact of second hand smoke (SHS) on their children,and specifically, asthma outcomes.
89171329|NCT04165265|Experimental|Responders and Partial/non-responders|"The definition of responders to glucocorticoids is: Bowel movements ≤ 3/day without blood and normalization of CRP. In the study, this is supported by CC.~The definition of non-responders is: Bowel movements > 8/day or 3-8/day and CRP > 45 mg/l. The decision if the patient is a non-responder is supported by CC.~Questionnaires in CC and FC analysis with CalproSmart are performed every day until discharge or when classified as green in CC. After discharge questionnaires in CC and FC analysis are performed once every week in the following 7 weeks and a final registration at week 52. In case of disease relapse between week 7 and 52 registration in CC and FC analysis are performed on demand. Fecal samples for future use (biobank) and FC Elisa as well as blood samples are done before administration of IFX (week 2 and 6). At follow-up (week 52) it is considered whether the patient underwent colectomy or not."
89171330|NCT02640443|Experimental|Treatment|Treatment with sulfamethoxazole. Subjects will serve as their own control, by using the data from baseline and after treatment stop.
89171331|NCT02640365|Experimental|GROUP A / GROUP B (two differents cohorts)|"GROUP A (Patients with unresectable advanced non-colorectal cancer ) - irinotecan + MM-398 dose escalation (3-18 patients)~Level 1 : initial DOUBLIRI dose 60/90 (0-3 patients)~MM-398 : 60mg/m²~Irinotecan (CPT-11) : 90mg/m²~Level 2: DOUBLIRI dose 80/90 (9 - 18 patients)~MM-398 : 80mg/m²~CPT-11: 90mg/m²~Level 3A: DOUBLIRI dose 60/120 (12-18 patients)~MM-398 : 60mg/m²~CPT-11: 120mg/m²~Level 3B: DOUBLIRI dose : 80/120 (12-18 patients)~MM-398 : 80mg/m²~CPT-11 : 120 mg/m²~GROUP B (Patients with unresectable metastatic colorectal cancer)- LV/5FU-bevacizumab+irinotecan+MM-398 dose Escalation (3-18 patients)~same level as group A + LV/5FU - bevacizumab regimen :~Bevacizumab : 5mg/kg(day (d) 1)~Leucovorin (LV) : 400mg/m² (d1)~5-fluorouracile infusion (5 FU) :2400mg/m² (d1,2)"
89171332|NCT02645591|Experimental|Nerve Sparing RARP + AmnioFix®|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.
89171333|NCT02645591|Active Comparator|Nerve Sparing RARP|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)
89171334|NCT02645513|Experimental|Malaria-only text messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to malaria diagnosis and treatment.
89171335|NCT02645513|Experimental|Malaria, pneumonia, and diarrhea messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to diagnosis and treatment of malaria, pneumonia, and diarrhea
89171336|NCT02645513|Placebo Comparator|Control|No text message reminders to health workers, just the usual health system supports.
89171337|NCT02642003|Experimental|GCSF+SMT|5-day course of GCSF (5 μg/kg/d) plus standard medical therapy for 6 months
89171338|NCT02642003|No Intervention|SMT|
89171339|NCT00653705|Active Comparator|Probiotic|Children given probiotic BB12 enriched yogurt drink.
89171340|NCT00653705|Placebo Comparator|Control|Children given dairy drink.
89171341|NCT02641925|Active Comparator|Omentum preserving|Omentum preserving: The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed.
89171342|NCT02641925|Experimental|Total omentectomy|Total omentectomy: Whole omentum will be removed.
89171343|NCT02640287|Experimental|Waldenström macroglobulinemia|Patients with diagnosis of Waldenström macroglobulinemia
89171344|NCT02640287|Experimental|Others B-cell malignancies|Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma
89171345|NCT02640287|Other|Healthy subjects|Control healthy subjects without B-cell malignancy
89171346|NCT02536001|Other|One mesh Endofast reliant system|Patients with anterior compartment stage III and uterus prolapse grade II will be treated with one mesh - Anterior Endofast reliant system (fixation of posterior arms to the sacrospinous ligament)
89171347|NCT02536001|Other|two meshes Endofast reliant system|intervention: Patients with anterior compartment stage III and uterus prolapse grade II will be treated with 2 meshes: anterior Endofast reliant system mesh to correct the anterior compartment and posterior Endofast reliant system mesh to correct the apical prolapse (fixation to the sacrospinous ligament)
89171348|NCT00653471|Active Comparator|Lean|Lean patients
89171349|NCT00653471|Active Comparator|Obese no OSA|Obese patients without osa
89171350|NCT00653471|Active Comparator|Obese osa|Obese patients with osa
89171351|NCT02641769|Other|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
89171352|NCT02640131|Experimental|BSHR Intervention|"Couples will attend 30-minute clinic consultations with an Urologist and a Sexual Health Counsellor and receive session-specific chapters of the Kindness, Intimacy, Sexuality and Satisfaction manual over the course of the intervention.~The BSHR Intervention involves two complementary components; the bio-medical, and the psychosocial. The bio-medical component for both arms intervention includes an urologist consultation at a pre-operative appointment and 5 f/u appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.~The psychosocial component aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive sexual health counseling and manualized support."
89171353|NCT02640131|Active Comparator|Attention Control|"Survivorship Counseling: Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) and receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You Manual. The bio-medical component is the same in both arms.~The core topics discussed during over 7 counseling sessions include: preparation for immediate post-surgery recovery, Kegel exercises, nutrition and prostate cancer, exercise and prostate cancer, and maintaining healthy lifestyle change."
89171354|NCT00599027|Experimental|Mometasone furoate nasal spray|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
89171355|NCT00599027|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
89171356|NCT02645357|Experimental|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
89171357|NCT02645357|Other|Control group|No on-screen, point-of-care computer reminders on clinical practice.
89171358|NCT03272633|Experimental|Cohort I (initial IHC within 42 days)|Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
89171359|NCT03272633|Experimental|Cohort II (initial IHC within 70 days or after relapse)|Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
89171360|NCT00652379|Experimental|1|Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose
89171361|NCT00652379|Active Comparator|2|Somatostatin analog, unaltered dosage
89171362|NCT00910949||Painfree|Thoracotomy patients without chronic pain
89171363|NCT00910949||With Pain|Thoracotomy patients with chronic pain
89171364|NCT00655187||Group A|Cases
89171365|NCT00655187||Group B|Controls
89171366|NCT02639975|Experimental|100 mg PBF-677|
89171367|NCT02639975|Experimental|200 mg PBF-677|
89171368|NCT02639975|Experimental|400 mg PBF-677|
89171369|NCT02639975|Experimental|600 mg PBF-677|
89171370|NCT02639975|Placebo Comparator|Placebo 100 mg|
89171371|NCT02639975|Placebo Comparator|Placebo 200 mg|
89171372|NCT02639975|Placebo Comparator|Placebo 400 mg|
89171373|NCT02639975|Placebo Comparator|Placebo 600 mg|
89171374|NCT04164797|Experimental|treatment group|endostar : 7.5mg/m2/d,continuous infusion for 5 days in week 1、3、5、7, chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
89171375|NCT04164797|Active Comparator|control group|chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36, carboplatin AUC 2, ivgtt d8, 15, 22, 29, 36 radiotherapy：EBRT，61.2 Gy，1.8Gy/d
89171376|NCT00654017|Placebo Comparator|placebo|
89171377|NCT00654017|Active Comparator|sildenafil|
89171378|NCT02639819|Experimental|Treatment|Study drug
89171379|NCT02645201|Active Comparator|Probiotic|Children in probiotic group will receive chewable tablets containing 4x108 CFU of Gastrus. Subjects will take 1 tablet twice a day for 21 days
89171380|NCT02645201|Placebo Comparator|Placebo|Children in placebo group will receive placebo tablets of similar appearance and taste as Gastrus tablets. Subjects will take 1 placebo tablet twice a day for 21 days
89171381|NCT02645045||Dry eye|Patients with dry eye syndrome
89171382|NCT02645045||normal|Patients without dry eye
89171383|NCT02639741|Active Comparator|Oral Melatonin Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of melatonin (6 mg) or placebo tablet will be given one hour before the start of anesthesia.
89171384|NCT02639741|Active Comparator|Oral Vitamin C Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of vitamin C (2 gr) or placebo tablet will be given one hour before the start of anesthesia.
89171385|NCT02639741|Placebo Comparator|Oral Placebo Tablet|Preoperative single oral dose of placebo tablet will be given one hour before the start of anesthesia.
89171386|NCT04164719|Experimental|Treatment A|TNX-102 SL 2.8 mg, under fasting conditions
89171387|NCT04164719|Experimental|Treatment B|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fasting conditions
89171388|NCT04164719|Experimental|Treatment C|TNX-102 SL 5.6 mg (2 x 2.8 mg sublingual tablets), under fed conditions
89171389|NCT02639663|Experimental|women whom are interested in breastfeeding and have not begun.|"Post-partum primi and multiparous women Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control"
89171390|NCT02639663|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
89171391|NCT00654173|Experimental|1|Rosuvastatin
89171392|NCT00654173|Active Comparator|2|Simvastatin
89171393|NCT00654173|Active Comparator|3|Atorvastatin
89171394|NCT02645435|Active Comparator|Hip direct anterior approach|Patients with hip arthritis
89171395|NCT02645435|Active Comparator|Lateral hip approach|Patients with hip arthritis
89171396|NCT02645279|Active Comparator|oral 30% glucose|oral 30% glucose total 200 mg/kg with 0.5-1 mL increments
89171397|NCT02645279|Active Comparator|IV midazolam|intravenous administration of midazolam 0.1 mg/kg
89171398|NCT02639585|Experimental|Treatment arm|Daclinza and Sunvepra
89171399|NCT04164251|Experimental|Inpatient screening mammography for non-adherent and high risk|All non-adherent women were offered inpatient screening mammography during hospitalization
89171400|NCT04164953|Experimental|Dupuytren's|Surgical intervention as second-line surgery for the treatment of Dupuytren's disease.
89171401|NCT02639195||Treatment, retrospective|Retrospective analysis on patients treated with manual physical therapy in quality of life outcomes as measured by pre and post treatment questionnaires. Chart review.
89171402|NCT02639195||Untreated control|Prospective data collection via questionnaire of subjects with a history of small bowel obstruction in an observational manner. No treatment is performed.
89171403|NCT02881151|Experimental|Treatment|Subjects will be treated with deep brain stimulation throughout the study, with the exception of a brief, 21 day blinded withdrawal phase that will be undertaken to assess for any possible therapeutic effect.
89171404|NCT04164329||Exposed group|The exposed group will be composed by the patients that undergo CRT/ICD implantation (general anesthesia).
89171405|NCT04164329||Not exposed group|The non-exposed group, or control group, will be composed by the patients undergo PM implantation (without anesthesia)
89171406|NCT02800655|Experimental|DHFS with IS-ARV|Digital Health Feedback System (DHFS) with either IS- Odefsey®, IS- Genvoya®, IS-Biktarvy®, IS- Tivicay® and Truvada® or IS- Tivicay® and Descovy ® (IS-co-encapsulated with ingestion sensor) -1 or 2 capsules daily (QD), depending on the treatment regimen, administered orally for 16 weeks.
89171407|NCT04164095|Experimental|lappg|
89171408|NCT04164095|Active Comparator|ladgbi|
89171409|NCT02637869||Control Group - non-intervention|Clinics that did not participate in the APM project
89171410|NCT02637869||Alternative Payment Model -intervention|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
89171411|NCT02639039|Active Comparator|Cortisone Injection|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
89171412|NCT02639039|Active Comparator|Trigger Point Dry Needling|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
89171413|NCT00689728|Experimental|30 milligram (mg) LY2127399|"Double-blind Treatment: 30 mg LY2127399 administered as a single intravenous (IV) infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
89171414|NCT00689728|Experimental|80 mg LY2127399|"Double-blind Treatment: 80 mg LY2127399 administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
89171415|NCT00689728|Placebo Comparator|Placebo|"Double-blind Treatment: Placebo comparator administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on same initial randomized treatment up to Week 24.~Follow-Up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
89171416|NCT02639117|Other|Vismodegib|Vismodegib 150 mgs po qd. Open label.
89171417|NCT04163939|Experimental|Collar|This group will wear a cervical collar for at least 30 minutes per day, 5 out of 7 days of the week
89171418|NCT04163939|Placebo Comparator|Control|This group will not wear the cervical collar
89171419|NCT00655265|Experimental|Colesevelam hydrochloride film-coated tablets|
89171420|NCT00655265|Placebo Comparator|Placebo|
89171421|NCT04163861||1|"31 patients diagnosed as heart failure with preserved ejection fraction per ESC guidelines 2016 on the basis of history, clinical examination and investigations presenting to the department of cardiology, BSMMU were selected inclusion criteria~Patients with regional wall motion abnormality in 2D echocardiography.~Patients with moderate to severe valvular heart diseases.~Patients with prosthetic valves and pacemakers.~Patients with congenital heart diseases.~Patients currently having arrhythmia such as atrial fibrillation on ECG screening during enrollment of patient.~Patients with poor echo window.~Patients who were not interested to take part in the study."
89171422|NCT04163861||2|31 normal healthy control subjects of similar age and sex of HFpEF subjects were taken. Normal echocardiograms will be defined as normal LV size and geometry, normal LVEF >55%). patients are free from cardiovascular diseases.
89171423|NCT02638961|Placebo Comparator|Standard treatment|Only standard medical treatment
89171424|NCT02638961|Active Comparator|IMT group|Standard medical treatment associated to Inspiratory muscle training
89171425|NCT02638961|Active Comparator|FES group|Standard medical treatment associated to functional electrostimulation of both legs for 45 minutes a day, 2 days per week for a total of 12 weeks.
89171426|NCT02638961|Active Comparator|IMT+FES group|Standard medical treatment associated to combination of inspiratory muscle training and functional electrostimulation of both legs
89171427|NCT02562586|Active Comparator|Closed Suction Drainage System|Group 1: patients undergoing total hip replacement received a Closed Suction Drainage System for 24 hours after the surgical procedure
89171428|NCT02562586|No Intervention|No Closed Suction Drainage System|Group 2: patients undergoing total hip replacement have not received a Closed Suction Drainage System after the surgical procedure
89171429|NCT02562664|Active Comparator|CC with placebo|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with placebo tablets taken twice daily continuously for three cycles.
89171430|NCT02562664|Active Comparator|CC plus Metformin|received t100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with plus Metformin 500 mg twice daily continuously for three cycles.
89171431|NCT02635919|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
89171432|NCT02635919|No Intervention|Control|Smokers in this group will not be given the mSMART application.
89171433|NCT02564614|Experimental|RO7070179|Participants will receive RO7070179, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in Week 1 of Cycle 1 on Day 1 and Day 4. If a dose-limiting toxicity (DLT) occurs in more than 33% of participants at any time, the dose will be reduced to 10 mg/kg/week. The dose will be further reduced to 6 mg/kg/week if more than 33% of treated participants have a DLT.
89171434|NCT04164017|Experimental|EUS-guided FNB with syringe suction|
89171435|NCT04164017|Active Comparator|EUS-guided FNB without syringe suction|
89171436|NCT04060576|Experimental|Group A treated with a 16-gauge needle|Group A is intervened on the gastrocnemius muscle with a 16-gauge needle.
89171437|NCT04060576|Experimental|Group B treated with a 25-gauge needle|Group B is intervened on the gastrocnemius muscle with a 25-gauge needle.
89171438|NCT04060576|Experimental|Group C treated with a 32-gauge needle|Group C is intervened on the gastrocnemius muscle with a 32-gauge needle.
89171439|NCT02635763|Other|PNBs1|Femoral nerve and the lateral cutaneous nerve block combined with general anesthesia
89171440|NCT02635763|Other|PNBs2|Lumbar plexus and sacral plexus nerve block combined with general anesthesia
89171441|NCT04060498|Experimental|Mindfulness intervention|This arm consists of seven weekly-session mindfulness-based intervention for psychosis (MBI-p). The MBI-p is a protocol-based, low intensity intervention developed to help patients achieve a greater sense of peace and calmness, and facilitates participants in handling everyday stress and conflicts.
89171442|NCT04060498|Placebo Comparator|Psychoeducation intervention|This arm consists of seven weekly-sessions of psychoeducation. Topics to be discussed in the sessions include the signs and symptoms of psychosis, aetiology of psychosis, as well as pharmacological and non-pharmacological interventions.
89171443|NCT00654407|Experimental|1|Rosuvastatin
89171444|NCT00654407|Active Comparator|2|Atorvastatin
89171445|NCT00654407|Active Comparator|3|Simvastatin
89171446|NCT00691054|Experimental|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4.
89171447|NCT00748696|No Intervention|1|No intervention
89171448|NCT00748696|Experimental|2|patient receiving oral nutrition supplement
89171449|NCT00748696|Experimental|3|resistance training
89171450|NCT00748696|Experimental|4|patients receiving resistance training and oral nutritional supplement
89171451|NCT02563756|Experimental|UKA, unicompartmental knee replacement|Procedure: Participants are operated with a mobile bearing medial unicompartmental knee arthroplasty (Oxford). They are followed with CT, functional tests and PROM, compared with those operated with TKA.
89171452|NCT02563756|Experimental|TKA, total knee replacement|Procedure: Participants are operated with a cruciate retaining conventional tricompartmental prosthesis (PFC). They are followed with CT, functional tests and PROM, compared with those operated with UKA.
89171453|NCT00598871|Placebo Comparator|2|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of eyedrops to the affected eye, identical to the active drug but with no thymosin beta 4 (0.00% thymosin beta 4, w/w), 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
89171454|NCT00598871|Active Comparator|1|There are 2 groups: active drug and placebo. The patients in the active comparator arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
89171455|NCT00744406|Experimental|1|
89171456|NCT00744406|Experimental|2|
89171457|NCT00744406|Experimental|3|
89171458|NCT00748774||MDASI-BT|MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) questionnaire given to patients with a primary brain tumor and their caregivers.
89171459|NCT00748930||Cohort 1|Subjects previously enrolled in the ATTRACT trial from three Canadian sites.
89171460|NCT00741520|Placebo Comparator|1|Control group
89171461|NCT00741520|Active Comparator|2|CPAP
89171462|NCT00744562|Experimental|Open-label OMP-21M18|
89171463|NCT00690820|Experimental|A|
89171464|NCT00690820|Placebo Comparator|B|
89171465|NCT00741676|Active Comparator|2|
89171466|NCT00741676|Experimental|1|
89171467|NCT02562508|Experimental|9-17y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
89171468|NCT02562508|Experimental|9-14y (0,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
89171469|NCT02562508|Experimental|18-26y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
89171470|NCT00749008||Term Infants|High risk infants with history of respiratory insufficiency requiring NICU care.
89171471|NCT00749008||Preterm Infants|Infants less than 37 weeks gestational age.
89171472|NCT02562352|Experimental|TAPER program|"The intervention arm is comprised of:~Identification of medications that are appropriate for discontinuation/dose reduction.~Linked pharmacist/family physician consultations with patient to discuss medication discontinuation/dose reduction."
89171473|NCT02562352|No Intervention|Control|Standard of Care as wait list control
89171474|NCT00749086|Experimental|2|balloon kyphoplasty
89171475|NCT00749086|Active Comparator|1|vertebroplasty
89171476|NCT00689338|Experimental|Treatment Group|Option to treat with oral azole therapy following treatment with anidulafungin
89171477|NCT00749242|Other|1|conventional orthopedic brace with antalgic treatment
89171478|NCT00749242|Other|2|balloon kyphoplasty introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
89171479|NCT00686998|Experimental|AZD2624|AZD2624 40 mg
89171480|NCT00686998|Other|Olanzapine|Olanzapine 15 mg
89171481|NCT00686998|Placebo Comparator|Placebo|Matching Placebo
89171482|NCT00744640|Experimental|single|single arm study with triple combination chemotherapy
89171483|NCT00749320|Other|ASL MRI|ASL MRI performed at different time intervals on participants receiving sunitnib or pazopanib for treating RCC
89171484|NCT00848718|Experimental|MK-2206 + carboplatin + paclitaxel|MK-2206 combined with carboplatin and paclitaxel
89171485|NCT00848718|Experimental|MK-2206 + docetaxel|MK-2206 combined with docetaxel plus pretreatment with a corticosteroid
89171486|NCT00848718|Experimental|MK-2206 + erlotinib|MK-2206 combined with erlotinib
89171487|NCT02612844|Experimental|NNC0143-0406|
89171488|NCT02612844|Active Comparator|Insulin Aspart|
89171489|NCT00883337|Experimental|Teriflunomide 7 mg / 14 mg|Teriflunomide 7 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
89171490|NCT00883337|Experimental|Teriflunomide 14 mg / 14 mg|Teriflunomide 14 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extension treatment period).
89171491|NCT00883337|Active Comparator|IFN-β-1a / 14 mg|Interferon β-1a 3 times a week (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
89171492|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 1)|
89171493|NCT00838110|Placebo Comparator|Placebo TID (Cohort 1)|
89171494|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 2)|
89171495|NCT00838110|Placebo Comparator|Placebo TID (Cohort 2)|
89171496|NCT04163783|Experimental|Arm A|Subjects will be administered a single oral dose of 320 mg of [14C]-BGB-3111
89171497|NCT00654485|Experimental|1|Rosuvastatin
89171498|NCT00654485|Active Comparator|2|Atorvastatin
89171499|NCT00655343|Experimental|ATG-F|"ATG-Fresenius S (20 mg/kg body weight at days -3 to -1 (total dose: 60 mg/kg)~cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
89171500|NCT00655343|No Intervention|non-ATG-F|"cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
89171501|NCT04162379|Other|Prospective quizi-pre-post oral predensolone|single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mgs for 3 successive dosing every 4th day then stop the drug totally).
89171502|NCT02637791|Experimental|Intervention|The virtual glove in their homes for a period of 8 weeks and advised to try to build up to using the system for a maximum of 20 minutes 3 times a day for 8 weeks.
89171503|NCT02637791|No Intervention|Control|Usual care
89171504|NCT02637635|Experimental|Breast reconstruction with implant|The patients will undergo breast reconstruction with an expander prosthesis.
89171505|NCT02637635|Experimental|Autologous fat transplantation|The patients will undergo lipofilling as a pre-treatment before they will undergo breast reconstruction with an expander prosthesis.
89171506|NCT00837876|Experimental|Treatment|Sorafenib + Erlotinib
89171507|NCT00655421|Experimental|Unaided|Unaided Visual Inspection of the Oral Cavity
89171508|NCT00655421|Experimental|VelScope|VelScope assisted examination of the oral cavity
89171509|NCT00655421|Experimental|Toluidine|Examination of oral cavity after the local application of Toluidine Blue dye
89171510|NCT00911027|Experimental|SonoVue guided biopsy|
89171511|NCT00911027|Other|Systematic biopsy|
89171512|NCT00707070|Experimental|1|efalizumab 1 mg/kg/week subcutaneous plus acitretin 0.4 mg/kg/day oral
89171513|NCT00707070|Placebo Comparator|2|efalizumab 1 mg/Kg/week subcutaneous plus oral placebo
89171514|NCT04115670|Experimental|specific intervention (experimental)|Specific intervention (experimental). The intervention group will carry out 3 sessions of specific pain education + 15 sessions of physical training.
89171515|NCT04115670|Active Comparator|control group (no intervention)|NO intervention
89171516|NCT02638727|Active Comparator|Drug Arm|This group treat with L-Citrulline (3 grams per day)
89171517|NCT02638727|Placebo Comparator|Placebo Arm|this group treat with placebi every day
89171518|NCT00686920|Experimental|Rifaximin|Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.
89171519|NCT02562118|Experimental|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by Letrozole 2.5mg daily + lenvatinib x 12 weeks (for Part A) or continuous till progression or intolerability (Part B)
89171520|NCT00741754|Experimental|I, II|compare the amount of salivary flow of the same patient at different times.
89171521|NCT00741832|Experimental|I|Patients breath while a conical positive expiratory pressure device during exercises
89171522|NCT00741832|Active Comparator|C|Patients (normal) breath during exercise
89171523|NCT00845832|Experimental|1|
89171524|NCT00845832|Active Comparator|2|
89171525|NCT02562274|Placebo Comparator|Placebo group|Subjects are received the placebo product which has same color and smell look like the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) treatments once daily for 8 weeks
89171526|NCT02562274|Active Comparator|MP 50 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 50 mg/day treatments once daily for 8 weeks
89171527|NCT02562274|Active Comparator|MP 1500 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 1500 mg/day treatments once daily for 8 weeks
89171528|NCT00703482|Placebo Comparator|1|
89171529|NCT00703482|Active Comparator|2|
89171530|NCT00703482|Active Comparator|3|
89171531|NCT00703482|Experimental|4|
89171532|NCT00703482|Experimental|5|
89171533|NCT00703482|Experimental|6|
89171534|NCT00703482|Experimental|7|
89171535|NCT02562196|Experimental|optimized protocol chosen|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
89171536|NCT02562196|Sham Comparator|sham tDCS|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
89171537|NCT00885755|Experimental|1|
89171538|NCT00749554|Active Comparator|Disc biacuplasty|
89171539|NCT00749554|Placebo Comparator|Sham treatment.|
89171540|NCT00749710|Active Comparator|1|immediate operation - ORIF - of hip fracture in patient treated with clopidogrel
89171541|NCT00749710|Active Comparator|2|ORIF - surgical treatment patients not on antiaggregant therapy
89171542|NCT00913302|Experimental|Training|cardiovascular training
89171543|NCT04058548|Experimental|6MWT and STS|All participates will receive 6MWT and STS test
89171544|NCT00749866|Active Comparator|1|Nebulised Gentamicin
89171545|NCT00749866|Placebo Comparator|2|Nebulised 0.9% Saline
89171546|NCT00655577|No Intervention|2|Control group
89171547|NCT00655577|Experimental|1|Exercise group
89171548|NCT04058236|Experimental|human albumin 5%|10 patients with pancreatic cancer will receive human albumin 5% in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
89171549|NCT04058236|Active Comparator|gelofusine|10 patients with pancreatic cancer will receive gelofusine in a restrictive goal directed fluid regime preoperatively for the first 24 hours.
89171550|NCT02638649||subjects who call 911 for dyspnea|All subjects who call 9-1-1 for difficulty breathing will have the potential to be enrolled in the study.
89171551|NCT00742066|Experimental|I|Irbesartan
89171552|NCT00742066|Active Comparator|II|Felodipine
89171553|NCT00742066|Placebo Comparator|III|Placebo
89171554|NCT02635529|Active Comparator|OFD + DFDBA|Intrabony defects treatment was carried out with OFD + DFDBA
89171555|NCT02635529|Active Comparator|OFD+DFDBA+AM|Intrabony defects treatment was carried out with OFD + DFDBA+ AM
89171556|NCT00837486|Active Comparator|Active Group - Active Stimulation|Receive active stimulation with Reclaim™ DBS System
89171557|NCT00837486|Sham Comparator|Control Group - Sham Stimulation|Receive sham stimulation with Reclaim™ DBS System
89171558|NCT00922818||Radical perineal prostatectomy patients|Radical perineal prostatectomy patients
89171559|NCT00742144|Experimental|ofatumumab|Japanese patients with CD20 positive follicular lymphoma or chronic lymphocytic leukemia
89171560|NCT00742222|Other|single arm, treatment with FDA cleared technology|Patients who have early stage breast cancer, and are candidate for intracavitary accelerated partial breast irradiation may be considered for this study.
89171561|NCT00845676|Experimental|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a + Ribavirin
89171562|NCT00707148|Active Comparator|Group 2: Control|16 pregnant women to receive: antepartum: saline; postpartum; Tdap vaccine.
89171563|NCT00707148|Experimental|Group 1: Intervention|32 pregnant women to receive: antepartum: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) vaccine; postpartum: saline.
89171564|NCT00707148|Active Comparator|Group 3: Control|32 non-pregnant women to receive a single dose of Tdap vaccine.
89171565|NCT00742300|Experimental|A|Treatment Group
89171566|NCT02611908|Experimental|ibrutinib +obinutuzumab|
89171567|NCT00742378||C|Normal controls
89171568|NCT00742378||G|Glaucoma
89171569|NCT00702000||1.|Those with ICU-acquired weakness
89171570|NCT02561884|Experimental|AB|Olostar Tab. followed by Olmetec and Crestor
89171571|NCT02561884|Experimental|BA|Olmetec and Crestor followed by Olostar Tab.
89171572|NCT00703560||1|HIV and HCV genotype 1 coinfected (any race)
89171573|NCT00703560||2|HCV genotype 1 (any race)
89171574|NCT00655655|Experimental|Arm I|See Detailed Description
89171575|NCT00845520|Experimental|Lens implantation +1.00 diopter (D) postop target|Lens implant power calculated for postoperative MRSE target of +1.00 D
89171576|NCT00845520|Experimental|Lens implantation -1.00 D postop target|Lens implant power calculated for postoperative MRSE target of -1.00 D
89171577|NCT00845520|Experimental|Lens implantation 0.00 D postop target|Lens implant power calculated for postoperative MRSE target of 0.00 D
89171578|NCT02638571|Sham Comparator|Usual education|Households in the control clusters (kebeles) will receive usual nutrition education from Health extension workers, about complementary foods, over 9 months.
89171579|NCT02638571|Experimental|Enhanced Education|Additional education sessions from Health extension workers (HEWs) trained on use of pulses for complementary foods (CF). HEWs provide nutrition education programs and counseling about pulse-cereal mix complementary foods, over 9 months.
89171580|NCT00844896|Active Comparator|DEF-only|Distress Emotional Support and Family Assessment Treatment
89171581|NCT00844896|Experimental|DEF + COPE|Distress Emotional Support and Family Assessment Treatment and Creating Opportunities for Parent Empowerment Treatment
89171582|NCT00911105||Patients with multiple myeloma|Patients with multiple myeloma receiving second line therapy or higher.
89171583|NCT00654719|Active Comparator|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
89171584|NCT00654719|Placebo Comparator|Placebo|
89171585|NCT00654797|Experimental|eProtocol|
89171586|NCT00707226||1|15 patients with primary open angle glaucoma
89171587|NCT00707226||2|15 age matched healthy subjects
89171588|NCT00837330|Experimental|Ranibizumab 0.5 mg/ 0.05 cc|Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
89171589|NCT00837330|Experimental|Ranibizumab 0.3 mg/ 0.05 cc|Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab
89171590|NCT00703638|Experimental|Sorafenib/Pemetrexed/Cisplatin|Patients receiving a dose escalation scheme of daily oral sorafenib (200 mg or 400 mg bid) when given in combination with fixed dose intravenous pemetrexed and cisplatin for the treatment of solid tumors.
89171591|NCT00837096|Experimental|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distrubtes negative pressre across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
89171592|NCT00837096|Active Comparator|Moist Wound Therapy (MWT)|t wound therapy (MWT) is a widely used treatment modality that demonstrates benefit through the facilitation of a moist wound environment, which is known to promote faster relative wound healing compared to wounds exposed to air.
89171593|NCT00703794||AXIUM Coils|
89171594|NCT00885677|Active Comparator|Study Group|Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
89171595|NCT00885677|No Intervention|Control Group|Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.
89171596|NCT02637479|Experimental|Pituitary radiosurgery group|Subjects will receive a pituitary radiosurgery by GammaKnife® during a brief hospitalization associated with standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
89171597|NCT02637479|Active Comparator|Control group|Subject will receive standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
89171598|NCT04162301|Experimental|CS3002 CDK4/6 inhibitor|
89171599|NCT02637401||Therapy group|Dialectical behaviour therapy: a psychological therpay involving 16 group sessions plus approximately 5 individual meetings over 4 months.
89171600|NCT00885365|Experimental|Bramitob|tobramycin / Bramitob administered 300mg twice a day for 4 weeks
89171601|NCT00885365|Active Comparator|TOBI|tobramycin / TOBI administered 300mg twice a day for 4 weeks
89171602|NCT00827112|Experimental|Arm A|maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir (Reyataz) in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir (Prezista)/ritonavir (Norvir)((800/100 mg) QD or lopinavir/ritonavir (Kaletra, Aluvia)(400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir (Prezista)/ritonavir (Norvir) or lopinavir/ritonavir (Kaletra, Aluvia)(, then the subject must be discontinued from the study.
89171603|NCT00827112|Experimental|Arm B|"emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD~Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir/ritonavir (800/100 mg) QD or lopinavir/ritonavir (400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir/ritonavir or lopinavir/ritonavir, then the subject must be discontinued from the study."
89171604|NCT00689104|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets and matching tolterodine slow release (SR) placebo capsules orally once a day for 12 weeks.
89171605|NCT00689104|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
89171606|NCT00689104|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
89171607|NCT00689104|Active Comparator|Tolterodine SR 4 mg|Participants received tolterodine SR 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 weeks.
89171608|NCT02635217|Experimental|Group A1|EGD performed before the Colonoscopy with Carbon Dioxide insufflation.
89171609|NCT02635217|Experimental|Group A2|EGD performed before the Colonoscopy with room air insufflation.
89171610|NCT02635217|Experimental|Group B1|Colonoscopy performed before the EGD with Carbon Dioxide insufflation.
89171611|NCT02635217|Experimental|Group B2|Colonoscopy performed before the EGD with room air insufflation.
89171612|NCT00702078|Other|usual care|follow-up according to todays best practice.
89171613|NCT00702078|Experimental|cooperation|Follow-up from the hospital and the primary healthcare in cooperation
89171614|NCT00702156|Experimental|1|Bisoprolol
89171615|NCT00702156|Placebo Comparator|2|Identical appearance matching placebo
89171616|NCT00707382|Other|Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1) the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment in accordance with the current guidelines from Sct. Hans hospital. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described in the clinical guidelines."
89171617|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
89171618|NCT00707382|No Intervention|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
89171619|NCT02638415|Experimental|HVPG group|HVPG-guided therapy
89171620|NCT02638415|Other|non-HVPG group|routine therapy
89171621|NCT00703872|Experimental|1|Oral HDV-Interferon
89171622|NCT00703872|Experimental|2|Injectable HDV-Interferon + ribavarin
89171623|NCT00703950|Experimental|A,1|Cup feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
89171624|NCT00703950|Active Comparator|A,2|bottle feeding - conventional method Bottle feeding is the conventional method to feed preterm infant before breastfeeding or to substitute breastfeeding. We are using this method in the control group.
89171625|NCT00702312|Experimental|Study group|Study group that will attend low-salt educational community programme
89171626|NCT00702312|No Intervention|Control group|Subjects in this arm will have routine medical and dietetic treatment for low-salt reduction.
89171627|NCT00742456|Experimental|I|Glucose
89171628|NCT00742456|Placebo Comparator|II|Placebo
89171629|NCT00707460|Active Comparator|1|Please, see design section for details.
89171630|NCT00707460|Experimental|2|"Traditional Diet~Please, see design section for details."
89171631|NCT00707460|Experimental|3|"Healthy Store-bought Diet~Please, see design section for details."
89171632|NCT00689026|Experimental|Experimental|The lubiprostone group will receive an additional two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
89171633|NCT00689026|Active Comparator|Control|All patients in the study will receive a standard oral dosing of 4L Polyethylene glycol with electrolytes colonoscopy preparation the day prior to their scheduled colonoscopy.
89171634|NCT02612376||AD, DS, Mild Cognitive Impairment|Persons with age-related Mild Cognitive Impairment (MCI) or Alzheimer Disease (AD) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria. Individuals with Down Syndrome (DS) according to clinical diagnosis, with cognitive ability sufficient to follow directions.
89171635|NCT02612376||Healthy Controls|"Non-DS community-dwelling controls~Non-pregnant mothers and fathers of DS individuals (controls)~An Informant (study partner) available to complete functional interviews/survey measures annually."
89171636|NCT04058002|Experimental|Experimental|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.
89171637|NCT04058002|Active Comparator|Control group|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.
89171638|NCT00598559|Experimental|1 g IV Acetaminophen|1 g q6h IV Acetaminophen
89171639|NCT00598559|Experimental|650 mg IV Acetaminophen|650 mg q4h IV Acetaminophen
89171640|NCT00598559|Other|Standard of Care|The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
89171641|NCT00686686|Experimental|Infliximab 5 mg/kg|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
89171642|NCT02637167|Active Comparator|Rifaximin|Rifaximin: one tablet (550 mg) morning and evening for three months
89171643|NCT02637167|Active Comparator|Saccharomyces boulardii|S. boulardii: two capsules (500 mg) morning and evening for three months
89171644|NCT02637167|No Intervention|Control group|The third group receives no intervention
89171649|NCT04164485|Experimental|Functional collagen scaffold transplantation|
89171650|NCT04164485|Experimental|Autologous adipose cell transplantation|
89171651|NCT00750022|Experimental|E1|
89171652|NCT00750022|Active Comparator|A1|
89171653|NCT02638181|Experimental|trabeculectomy|
89171654|NCT02561728|Experimental|Plagiocephaly|Children with a misshaped head due to positioning. This is also known as flat head. Children with plagiocephaly will be treated with either the Hangar Helmet or the P-Pod helmet.
89171655|NCT02561728|Experimental|Craniosynostosis|Craniosynostosis occurs when one or multiple sutures fuse too early. Several sutures may be fused alone or in combination. An open or endoscopic surgical procedure to open the suture(s) is necessary to allow for normal brain growth and development. After surgery a cranial remolding helmet is used to direct skull growth. Children with craniosynostosis will be treated with either the Hangar Helmet or the P-Pod helmet
89171656|NCT00750100|Active Comparator|A|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins.
89171657|NCT00750100|Experimental|B|Patients are undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.
89171658|NCT00655031|Experimental|1|Pomegranate concentrate (POMx)
89171659|NCT00655031|Placebo Comparator|2|Fruit flavored juice low in antioxidants
89171660|NCT00655109|Active Comparator|1|Olopatadine
89171661|NCT00655109|Active Comparator|2|Fluticasone
89171662|NCT00655109|Placebo Comparator|3|Placebo nasal spray
89171663|NCT00655109|Placebo Comparator|4|Placebo Eyedrops
89171664|NCT00656045|Experimental|A|Arm A focuses on increasing the participant's physical activity level.
89171665|NCT00656045|Experimental|B|Arm B focuses on decreasing the amount of time the participant spends watching Television.
89171666|NCT02637089||PD-non-MCI|Patients with Parkinson's disease, no mild cognitive impairment
89171667|NCT02637089||PD-MCI|Patients with Parkinson's disease with mild cognitive impairment
89171668|NCT02637089||MCI (non-PD-MCI)|Patients with mild cognitive impairment, no Parkinson's disease
89171669|NCT02637089||HC (non-PD-non-MCI)|Healthy Controls (age-matched to patients)
89171670|NCT02632877|Experimental|Pirfenidone with MODD|"Active ingredients: Pirfenidone 8% with modified oxide diallyl disulfide (MODD) 0.016%.~Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every eight hours for 6 months."
89171671|NCT02632877|Active Comparator|Ketanserin|"Active ingredients: Ketanserin 2%. Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 months."
89171672|NCT04163705||Gram negative|"The presence of one or more positive samples will be considered positive blood cultures.~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
89171673|NCT04163705||Gram positive|"The presence of one or more positive samples will be considered positive blood cultures.~Patients with severe sepsis will be enrolled prospectively and consecutively. Some of the blood used for blood culture samples will be processed for the study (sample 0). The plasma will be stored at -80 ° for later analysis. A routine clinical and laboratory database will be completed.~Only patients who have positive blood cultures will be randomized according to their result in: sepsis by Gram positive or Gram negative."
89171674|NCT00656123|Experimental|CY and colon GVAX|
89171675|NCT04032431|Experimental|Telerehab VR intervention|The telerehab VR intervention consists of a custom-made software running on a computer connected with a commercial VR device (i.e. Oculus Rift). PwMS will be requested to reproduce several ADLs from the three main areas of self-care, dressing and meal preparation. The user can physically see his/her hands within the virtual scenario and, during the exercise, the hand coordinates are continuously recorded. Thus, data on 3D trajectory, speed, accuracy on target placement and movement smoothness, will be accessible. They will be stored in the PC and also be remotely sent to the clinical center for further analysis/processing. Both target position and task complexity will define the exercise difficulty, which can be modified automatically, on the basis of the previous performance or manually modified by the user
89171676|NCT04032431|Active Comparator|Conventional therapy|Conventional therapy will focus on task-related upper-limb treatments while in a sitting or prone position, representing the standard care in MS. Several manual techniques, therapy tools and objects of ADL will be allowed during treatment. No restrictions will be placed on the material used (ie, ADL, reaching and grasping material). Use of additional electrical or mechanical therapy devices (ie, support arm systems, splints) will be avoided. The interventions will be conducted on a one-on-one basis in the physiotherapy or occupational therapy department of each participating center. Training and therapy content will be tailored to each participant's preferences, the agreed movement aims and the motor function level of each MS patient.
89171677|NCT04163471||VasoStat|Randomized to use of VasoStat radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
89171678|NCT04163471||TR Band|Randomized to use of TR Band radial mechanical compression for hemostasis device following sheath removal after transradial access for arterial catheterization procedures.
89171679|NCT00657449|Active Comparator|Arm 1|
89171680|NCT00657449|Active Comparator|Arm 2|
89171681|NCT04160195|Active Comparator|1/Conditioning chemotherapy plus Chimeric Antigen Receptors (CAR) T-cells dose escalation|All participants will be receiving escalating dose of Anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) CAR T cells/kg + conditioning chemotherapy
89171682|NCT04160195|Active Comparator|2/Conditioning chemotherapy plus Chimeric Antigen Receptors (CAR) T-cells expansion phase|Maximum tolerated dose (MTD) dose of Anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) CAR T cells/kg + Conditioning chemotherapy
89171683|NCT04159883|Experimental|app|For the App group, we installed the app from the store in their smart phone or tablets, made their account using the same email they use in their smart phone store. the participant was informed if they cannot follow the animated image in the app, they can re-launch the program and start to follow.
89171684|NCT04159883|Active Comparator|paper|For the paper group, the participants were provided with a hard copy of the exercise program; we gave one paper of all nine exercises.
89171685|NCT00911261|Experimental|Single Arm|
89171686|NCT00686374|Experimental|Any adalimumab|Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.
89171687|NCT00750178|Experimental|A|MK0683
89171688|NCT04159961|Experimental|GroupA|Inject the Drug into submental fat and abdominal fat via subcutaneous
89171689|NCT04159961|Experimental|GroupB|Inject the Drug into submental fat and abdominal fat via subcutaneous
89171690|NCT04159961|Experimental|GroupC|Inject the Drug into submental fat and abdominal fat via subcutaneous
89171691|NCT00750256|Experimental|Cohorts|This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
89171692|NCT00750334|Experimental|Part A|clofarabine Dose Escalation
89171693|NCT00750334|Experimental|Part B|Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.
89171694|NCT00750412|Experimental|TeenScreen|
89171695|NCT00750412|No Intervention|Treatment As Usual|
89171696|NCT04056832|Experimental|Single Strip Pericardium|Aortic Valve Replacement using single strip of patient's autologous pericardium
89171697|NCT04056832|Active Comparator|Mechanical Prosthetic Valve|Aortic Valve Replacement using mechanical prosthetic valve
89171698|NCT02561416|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) The MBSR consists in eight 2-h group sessions and an all-day mindfulness retreat, and offers intensive and structured training in mindfulness meditation to help patients to relate to their physical and psychological conditions in more accepting and nonjudgmental ways. Participants will be encouraged to engage in home mindfulness practices. Sessions will be lead by 4 MBSR accredited instructors.
89171699|NCT02561416|Active Comparator|Psycho-educational Program|Psycho-educational Program (FibroQol) It consists of eight 2-h group sessions including information about FMS (4 sessions) based on a consensus document of the Health Department of Catalonia + autogenic relaxation (4 sessions).
89171700|NCT02561416|Other|Treatment As Usual|Treatment As Usual.
89171701|NCT00571948|Active Comparator|Babyfood with usual meat content and corn oil|Infants in the control group received vegetable-potato-meat-meals as part of complementary food containing common amounts of meat and corn oil marketed in Germany.
89171702|NCT00571948|Experimental|more meat and a vegetable oil rich in omega-3 fatty acids|Infants in the intervention group received vegetable-potato-meat-meals as part of complementary food containing higher amounts of meat than the control group and rapeseed oil instead of corn oil.
89171703|NCT04054726|Experimental|Real tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
89171704|NCT04054726|Sham Comparator|Sham tPCS|Patients of degenerative ataxia will be randomly allocated into both the arms. Sham tPCS arm will receive sham tPCS. Then they will be crossed over to Real tPCS arm.
89171705|NCT00752284|Experimental|A|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
89171706|NCT00752284|Active Comparator|B|"Control Group:~total excision of lower wisdom tooth"
89171707|NCT00752362|Active Comparator|1|Percutaneous coronary intervention with bare metal stent
89171708|NCT00752362|Experimental|2|Percutaneous coronary intervention with paclitaxel-eluting stent
89171709|NCT00752362|Experimental|3|Percutaneous coronary intervention with sirolimus-eluting stent
89171710|NCT04054258|Experimental|App support programme group|In addition to the usual care, the participant and one family member will receive a CHD app and a briefing from a trained research nurse (A). The reason to invite an additional family member to install the app is to ensure that he/she can be informed automatically when the patient presses an icon during a chest pain attack. The patient may be too stressed during an angina attack and may not be able to follow the 'Things to Do List' quickly. In addition, automatic reminders of the individual's medication times and follow-up times will be pre-set in the app for individual use.
89171711|NCT04054258|Active Comparator|Telephone support group|In addition to the above usual care, bi-weekly 20-minute telephone follow-ups will be provided by a trained research nurse (B) for up to 3 months. Patients can ask about related health problems if any. The nurse will address their problem by providing advice or referring them to the ED follow-up clinic. The team has set up a telephone advice guide to support the research nurse in giving phone advice.
89171712|NCT00684424||Outpatients with epilepsy|
89171713|NCT00750568||Group 1|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages 2 years to 6 years"
89171714|NCT00750568||Group 2|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages greater than 6 years to 12 years"
89171715|NCT00750568||Group 3|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages greater than 12 years to 18 years"
89171716|NCT00745186|Active Comparator|1|Glucagen
89171717|NCT00745186|Experimental|2|Mayne Glucagon
89171718|NCT02635451||study group|Study group included 20 pregnant women with PPROM and fulfilled the inclusion and exclusion criteria.
89171719|NCT02635451||control group|Control group also included 20 pregnant women without PPROM following every recorded case of PPROM and matched for gestational age.
89171720|NCT00750646||A|Subject's adherence to prescribed therapy will be monitored with an electronic compliance device.
89171721|NCT04056364||Asthma|Asthma patients will be diagnosed according to a clinical history of wheezing, cough, chest tightness or shortness of breath, as well as the presence of BHR (cumulative dose caus¬ing a 20% decrease in FEV1), based on the GINA guidelines. None of them had a history of COPD, or previous doctor-diagnosed ACO. All subjects had not used any oral or/and inhaled corticosteroid (ICS) in the previous 12 weeks. The included patients with asthma had initial diagnosis and were under uncontrolled stage.
89171722|NCT04056364||COPD|COPD patients were diagnosed according to the GOLD criterion, which included a post-bronchodilator spirometry to confirm airflow obstruction (FEV1 to forced vital capacity ratio [FEV1/FVC] ,70%), in a clinical context (dyspnea, chronic cough or sputum production, and a history of expo¬sure to risk factors for the disease). They had received a COPD diagnosis at least 1 year before the study. None of them had a history of asthma. All subjects had not used any oral or/and ICS in the previous 4 weeks. The included COPD patients had exacerbations. The GOLD stage of COPD was defined according to the 2019 recommendations of GOLD.
89171723|NCT04056364||ACO|ACO will be diagnosed by two steps: the first step is the identification of a history of chronic airway disease, i.e., chronic or recurrent cough, sputum production, wheezing, or repeated acute lower respiratory tract infections. In the second step, the features of asthma and those of COPD that best describe the patients
89171724|NCT00750724|Placebo Comparator|B|2 ml of Normal saline intraarticular injection to the knee joint weekly for 5 weeks
89171725|NCT00750724|Experimental|A|2 ml of 25 mg sodium hyaluronate intraarticular injection to the knee joint weekly for 5 weeks
89171726|NCT00685750|Other|ME1|Patients with cutaneous metastatic melanoma receiving dacarbazine or temozolomide as first line treatment
89171727|NCT00685750|Other|ME2|Patients with cutaneous metastatic melanoma receiving first line treatment other than dacarbazine or temozolomide only
89171728|NCT00685750|Other|ME3|Patients with cutaneous metastatic melanoma receiving any second-or higherline chemotherapy treatment
89171729|NCT00685750|Other|ME4|Patients with cutaneous metastatic melanoma receiving local irradiation of cutaneous/subcutaneous tumor lesions
89171730|NCT00685750|Other|ME5|Patients with cutaneous metastatic melanoma receiving local imiquimod
89171731|NCT00685750|Other|NSC|Non-small cell lung cancer patients
89171732|NCT00685750|Other|ME6|Patients with cutaneous metastatic melanoma receiving ipilimumab
89171733|NCT02561104|Experimental|LenSx|Laser-assisted cataract surgery performed using the LenSx femtosecond laser.
89171734|NCT02561104|Experimental|Phaco|Traditional manual phacoemulsification cataract surgery
89171735|NCT00752596|Experimental|1|1 tablet of 125 mg/day of azimilide 2HCl, oral
89171736|NCT00745264|Experimental|2|400 mg Ketoprofen from Diractin to 4 joints
89171737|NCT00745264|Experimental|3|100 and 400 mg Ketoprofen used concomittant with heat
89171738|NCT00745264|Experimental|4|100 and 400 mg Ketoprofen concomittant with moderate exercise
89171739|NCT00745264|Experimental|1|100 mg ketoprofen to 2 joints
89171740|NCT00752674|Experimental|1|Neuromuscular balance
89171741|NCT00750802|Experimental|1|
89171742|NCT00750802|Experimental|2|
89171743|NCT00750802|Active Comparator|3|
89171744|NCT00750802|Placebo Comparator|4|
89171745|NCT00750958|No Intervention|1|ED patients that are not monitored with conventional therapy.
89171746|NCT00745342|Experimental|Teamwork Group|Families randomized to the Teamwork Group received the behavioral family teamwork intervention.
89171747|NCT00745342|No Intervention|Standard Care|Families in the Standard Care group received standard diabetes care and equal attention from study staff between visits to schedule appointments and encourage regular diabetes follow-up care.
89171748|NCT02563444|Experimental|Ultrasound fusion guiding system|
89171749|NCT00751192|Experimental|A|
89171750|NCT00751192|Active Comparator|B|
89171751|NCT00751582|Experimental|2|Food supplementation and nutrition education
89171752|NCT00751582|Experimental|1|Nutrition Education only
89171753|NCT00576628|Experimental|C.E.R.A|Participants received methoxy polyethylene glycol-epoetin beta (Continuous Erythropoietin Receptor Activator [C.E.R.A]) subcutaneously every four weeks for 44 weeks. The participants received initial dose of 1.2 microgram per kilogram (mcg/kg) of C.E.R.A. Once the Hemoglobin (Hb) concentration was attained within the target range of 11.0 and 13.0 gram per deciliter (g/dL), the dose was adjusted to maintain the Hb concentration within the target range.
89171754|NCT02561650|Experimental|COV155|
89171755|NCT00752830|Experimental|1|AZD0328 administration during fasting condition
89171756|NCT00752830|Experimental|2|AZD0328 administration after food intake
89171757|NCT00683878|Experimental|Arm 1|
89171758|NCT00683878|Experimental|Arm 2|
89171759|NCT00683878|Placebo Comparator|Arm 3|
89171760|NCT00884741|Active Comparator|Arm I (radiation therapy, temozolomide, placebo)|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks and receive temozolomide PO QD for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive placebo IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemotherapy and radiation therapy and continuing until the completion of temozolomide.
89171761|NCT00884741|Experimental|Arm II (radiation therapy, temozolomide, bevacizumab)|Patients undergo radiation therapy and receive temozolomide as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemoradiotherapy and continuing until the completion of adjuvant temozolomide.
89171762|NCT00656279|Experimental|1|Intensive dietary phosphorus education
89171763|NCT00656279|No Intervention|2|Standard dietary education consists of the dietitian assessing laboratory values and dietary intake and providing dietary education for abnormal values using handouts developed for specific nutrients.
89171764|NCT02632799|Experimental|NHF small cannula|NHF 8 L/min (Airvo2) , Smaller cannula (neonatal, yellow)
89171765|NCT02632799|Experimental|NHF big cannula|NHF 8 L/min (Airvo2) , Bigger cannula (neonatal, purple)
89171766|NCT02632799|Experimental|Mask CPAP|CPAP 5cm H2O
89171767|NCT02632799|No Intervention|no intervention|control
89171768|NCT00657527|Experimental|1|Rosuvastatin
89171769|NCT00657527|No Intervention|2|Diet
89171770|NCT04159649|Experimental|letrozole, gonadotropins and fixed GnRH antagonist|letrozole (2.5 mg) will be given from the second day of the cycle and for 5 days, gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF (interventional group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
89171771|NCT04159649|Active Comparator|gonadotropins and fixed GnRH antagonist (control group).|gonadotropins will be given from the third day of the cycle and GnRH antagonist will be added from the six day of the cycle for controlled ovarian stimulation in IVF(control group). Participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
89171772|NCT00880763|Experimental|Vaniprevir 200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
89171773|NCT00880763|Experimental|Vaniprevir 600 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 300 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
89171774|NCT00880763|Experimental|Vaniprevir 1200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 600 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
89171775|NCT00880763|Placebo Comparator|Placebo + peg-IFN + ribavirin|Participants will receive placebo twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
89171776|NCT00657683|Experimental|1|
89171777|NCT00657683|Placebo Comparator|2|
89171778|NCT04159727|Experimental|IBD or PD patients|20 patients suffering from IBD 10 patients suffering from PD
89171779|NCT04159727|Active Comparator|Asymptomatic subjects|30 asymptomatic subjects matched to patients on age, sexe and BMI
89171780|NCT00884273|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
89171781|NCT00884273|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.~On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin."
89171782|NCT00657761|Placebo Comparator|Placebo|Saline solution 0.9% sc/12h for 7 days
89171783|NCT00657761|Experimental|Enfuvirtide|Enfuvirtide 90 mg/12h sc for 7 days
89171784|NCT04159493|Placebo Comparator|Placebo|"Subjects will be randomized to placebo.~Placebo, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
89171785|NCT04159493|Active Comparator|Ovestin|"Subjects will be randomized or assigned to varying doses of Ovestin (500, 50, 25, 12.5, 10, 5, 2.5, 0.5, 0.25 mcg) as determined by the dose de-escalation constraints specified in the protocol.~Active, Vaginal Application 0.5 to 2 g administered daily for the 1st 14 days, then twice weekly for following 10 weeks"
89171786|NCT00657839|Experimental|Arm 1|
89171787|NCT00657839|Placebo Comparator|Arm 2|
89171788|NCT00884117||Participants Infected with Influenza|Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled and followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. Participants may receive treatment including oseltamivir, other treatment/medication, or no treatment.
89171789|NCT04159181|Experimental|Day A|After an overnight fast participants will receive an oral solution of lactulose (20g lactulose/200mL water).
89171790|NCT04159181|Experimental|Day B|After an overnight fast participants will drink 200mL of water
89171791|NCT04159181|Experimental|Day C|After an overnight fast and an evacuation of the colonic content, participants will receive an oral solution of lactulose (20g lactulose/200mL water).
89171792|NCT00884039|Active Comparator|30 mg anecortave acetate|
89171793|NCT00884039|Active Comparator|15 mg anecortave acetate|
89171794|NCT00657995|Experimental|2|Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.
89171795|NCT02636621|Active Comparator|Brazilian Dental Appliance|The device increases the volume of the airway by mandibular traction.
89171796|NCT02636621|Placebo Comparator|Placebo|Oral device that does not change the volume of the airway
89171797|NCT02632565|Active Comparator|intra-articular 0.5% lidocaine|intra-articular 7 mL 0.5% lidocaine injection for 3 times with one week intervals
89171798|NCT02632565|Active Comparator|intra-articular saline|intra-articular 7 mL saline injection for 3 times with one week intervals
89171799|NCT04158947|Experimental|T-DM1 + Afatinib|"Trastuzumab emtansine (T-DM1) : 3.6 mg/kg IV Day 1 every 21 days.~Afatinib: the highest dose of Afatinib with T-DM1 found in Phase I, po every day"
89171800|NCT04158947|Active Comparator|T-DM1|Trastuzumab emtansine (T-DM1) :3.6 mg/kg IV Day 1 every 21 days.
89171801|NCT02632643|Experimental|lifestyle counseling|
89171802|NCT00835770|Experimental|BG00012 plus placebo|In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
89171803|NCT00835770|Experimental|BG00012|In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.
89171804|NCT00658073|Active Comparator|A|Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.
89171805|NCT00658073|Active Comparator|B|Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.
89171806|NCT00658073|Active Comparator|C|Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A.
89171807|NCT04163237|Experimental|PD-1 & Sorafenib|
89171808|NCT04163237|Other|Sorafenib|
89171809|NCT04159259|Experimental|Diet intervention|All participants will stay weight stable while undergoing 3 phases of a dietary intervention
89171810|NCT00658229|Experimental|Strength training group|A four months strength training program during androgen deprivation therapy for prostate cancer patietns.
89171811|NCT00658229|No Intervention|Control group|Patients in the control group are not discouraged from performing normal activities. They are however asked not to start a strength training program or increase their activity level in the same period as the experimental group is performing their strength training program. We will offer the control group a modified strength training program after the post-intervention assessment.
89171812|NCT02636543||Group 2a-patient|75 patients who attended a genetic counselling consultation.
89171813|NCT02636543||Group 2a-public|75 persons belonging to general population.
89171814|NCT02636543||Group 2b-patient|75 patients who attended a genetic counselling consultation (those patients are different than patients from group 2a-).
89171815|NCT02636543||Group 2b-public|75 persons belonging to general population (those persons are different than patients from group 2a).
89171816|NCT02636543||Group 2b-professional|75 genetic professionals.
89171817|NCT00880685|Experimental|Memantine|Memantine 10-30mg
89171818|NCT00913146||index|child with fever and a negative malaria RDT
89171819|NCT00913146||control|apparently healthy child with a negative RDT
89171820|NCT02636465||obese healthy adults|persons with BMI> 30 kg/m2
89171821|NCT02636465||obese COPD patients|COPD-patients (GOLD I-IV Group A-D) with BMI> 30 kg/m2
89171822|NCT02636465||OHS-patients|patients with defined OHS: BMI>30 kg/m2 and sleep related breathing disease, no COPD
89171823|NCT00658307|Experimental|1|
89171824|NCT00658307|Experimental|2|
89171825|NCT00658307|Sham Comparator|3|
89171826|NCT00835380|Experimental|1|VAQTA™
89171827|NCT02612298|Experimental|arotinolol|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks
89171828|NCT02612298|Active Comparator|Metoprolol|Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.
89171829|NCT00880607|Active Comparator|Intrathecal morphine|Receives a single dose of intrathecal morphine
89171830|NCT00880607|Experimental|Extended Release Epidural Morphine|Receives DepoDur extended release epidural morphine for pain management
89171831|NCT04158791||EMM-I|Group with an intact IS/OS junction
89171832|NCT04158791||EMM-D|Group with a disrupted IS/OS junction
89171833|NCT00656435|Experimental|A|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
89171834|NCT00656435|No Intervention|B|Patients will not receive bevacizumab pretreatment
89171835|NCT02636231|Active Comparator|IMRT and concurrent Endostar|"IMRT and concurrent Endostar (Endostatins) to treat locally recurrent NPC patients; Endostar is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.~IMRT is to give GTV 60Gy in 27 fractions."
89171836|NCT02636231|Experimental|IMRT alone|IMRT alone to treat locally recurrent NPC patients. IMRT is to give GTV 60Gy in 27 fractions.
89171837|NCT02632487|Active Comparator|Exercise|This group will receive 8 weeks of center-based exercise followed by recommendations to remain physically active.
89171838|NCT02632487|Experimental|Exercise + Non-Exercise Physical Activity (NEPA)|This group will receive 8 weeks of center-based exercise combined with behavioral counseling and a technology intervention designed to increase daily Exercise + Non-Exercise Physical Activity (NEPA).
89171839|NCT02636309|No Intervention|control group|control group only filled up the questionnaires. They didn't receive intervention
89171840|NCT02636309|Experimental|intervention group|physical therapy at work
89171841|NCT00835068||BeneFIX|
89171842|NCT00658463|Experimental|1|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
89171843|NCT00658463|Placebo Comparator|2|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
89171844|NCT00658853|Active Comparator|1|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a 5% graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
89171845|NCT00658853|Active Comparator|2|4 times 4 minutes interval training in hyperoxia - 100% oxygen
89171846|NCT00658853|Active Comparator|3|One leg at a time training 4 times 4 minutes interval training using cycling ergometer
89171847|NCT00658931|Experimental|Treatment|
89171848|NCT00834912|Experimental|1: Tramadol HCl (Confab Laboratories) fasting|
89171849|NCT00834912|Experimental|2: Tramadol HCl (Confab Laboratories) fed|
89171850|NCT00834912|Experimental|3: Tramadol HCl (Trillium Healthcare) fasting|
89171851|NCT02535689|Active Comparator|1|ARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
89171852|NCT02535689|Active Comparator|2|ARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
89171853|NCT02535689|Placebo Comparator|3|ARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily.
89171854|NCT02632331|Experimental|Fasted dosing preceding group|
89171855|NCT02632331|Experimental|Fed dosing preceding group|
89171856|NCT00707538|Experimental|1|
89171857|NCT04162535|Experimental|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
89171858|NCT04162535|Experimental|Total intravenous anesthesia|Patients will receive a general anesthesia with Propofol as anesthetic agent
89171859|NCT04162535|Experimental|Total intravenous anesthesia and Lidocaine|Patients will receive a general anesthesia with Propofol as anesthetic agent and will also receive a fully lidocaine infusion according to the lidocaine protocol
89171860|NCT04162535|No Intervention|Placebo|10 presumed healthy volunteers that have donated 10 ml of venous blood for serum comparison
89171861|NCT05472324|Placebo Comparator|Placebo|Placebo, subcutaneous administration, 4 weeks as a treatment cycle.
89171862|NCT05472324|Experimental|TQC2731 injection 70 mg|TQC2731 injection 70 mg, subcutaneous administration, 4 weeks as a treatment cycle.
89171863|NCT05472324|Experimental|TQC2731 injection 210 mg|TQC2731 injection 210 mg, subcutaneous administration, 4 weeks as a treatment cycle.
89171864|NCT05472324|Experimental|TQC2731 injection 420 mg|TQC2731 injection 420 mg, subcutaneous administration, 4 weeks as a treatment cycle.
89171865|NCT02632019|Active Comparator|gemcitabine|Gemcitabine treatments will be performed once a week with a total of six times
89171866|NCT02632019|Experimental|Dendritic cell-precision T cell for neo-antigen|Dendritic cell-precision T cell for neo-antigen (DC-PNAT) combined with gemcitabine treatment: Gemcitabine: once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: once per 3 weeks with a total of three periods.
89171867|NCT00707616||A|Subjects without type 2 diabetes living in Olmsted County, MN
89171868|NCT00659009|Active Comparator|1|Barometric pressure equivalent to sea level (760 mm Hg).
89171869|NCT00659009|Experimental|2|Barometric pressure equivalent to 6000 feet (609 mm Hg)
89171870|NCT00659009|Experimental|3|Barometric pressure equivalent to 8000 feet (565 mm Hg).
89171871|NCT00659087|Experimental|Femoral Block|Those receiving femoral block in addition to usual pain management
89171872|NCT00659087|Active Comparator|Usual Care|Those receiving only usual pain management without a femoral block
89171873|NCT00659243|Experimental|rhBSSL|
89171874|NCT00659243|Placebo Comparator|Placebo|
89171875|NCT00883493|Experimental|Quetiapin fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
89171876|NCT00883493|Experimental|Quetiapin fumarate XR+Lithium carbonate|Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
89171877|NCT00659321|Active Comparator|1|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
89171878|NCT00659321|Placebo Comparator|2|16 weeks treatment with placebo
89171879|NCT02636153|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
89171880|NCT02636153|Experimental|Restricted Phosphorus Diet|Diet containing 500mg of phosphorus per day
89171881|NCT04158479||Pulmonary Support|ECMO support for acute respiratory failure, ARDS
89171882|NCT04158479||Cardiac Support|ECMO support for heart failure, cardiogenic shock
89171883|NCT04158479||Extracorporeal Cardiopulmonary Resuscitation|ECMO support for cardia arrest
89171884|NCT02636075||Upper 1/3 of thyroid tissue|
89171885|NCT02636075||Middle 1/3 of thyroid tissue|
89171886|NCT02636075||Lower 1/3 of thyroid tissue|
89171887|NCT02636075||Below thyroid tissue|
89171888|NCT04032353|Other|Medical Consortium|subjects involved in medical consortium for screening upper gastrointestinal canccers(MCSC)
89171889|NCT00659477|Experimental|single arm|
89171890|NCT00911339|Active Comparator|Atorvastatin 10 mg|
89171891|NCT00911339|Active Comparator|Atorvastatin 80 mg|
89171892|NCT05863208|Active Comparator|Artificial Intelligence-assisted Colonoscopy with Endocuff Vision|Use artificial intelligence-assisted colonoscopy with Endocuff Vision
89171893|NCT05863208|Active Comparator|Artificial Intelligence-assisted Colonoscopy|Use artificial intelligence-assisted colonoscopy alone
89171894|NCT05863208|Sham Comparator|Standard colonoscopy|Use standard colonoscopy without artificial intelligence-assisted colonoscopy or Endocuff Vision
89171895|NCT05863195|Experimental|Arm A (HAI, floxuridine, standard chemotherapy)|Patients undergo surgery to place the HAI pump, followed by SPECT/CT on study. Patients then receive floxuridine via the HAI pump on study. Patients also receive one of the following standard chemotherapy regimens per the treating physician: FOLFOX, FOLFIRI, or OX/IRI with or without cetuximab IV and/or panitumumab IV on study. Patients also undergo CT scans throughout the trial.
89171896|NCT05863195|Active Comparator|Arm B (standard chemotherapy)|Patients receive one of the following standard chemotherapy regimens per the treating physician: FOLFOXIRI, FOLFOX, FOLFIRI, or OX/IRI with or without cetuximab IV, panitumumab IV, and/or bevacizumab IV on study. Patients also undergo CT scans throughout the trial.
89171897|NCT05863169|Experimental|dlPFC fNIRS-Feedback|Feedback of oxygenation in 4 DLPFC channels
89171898|NCT05863169|Experimental|IFG fNIRS-Feedback|Feedback of oxygenation in 4 IFG channels
89171899|NCT05863169|Active Comparator|Control fNIRS-Feedback|Feedback of oxygenation in 4 control channels over temporal areas (unrelated to cognitive control or ADHD)
89171900|NCT05863156|Experimental|intervention 1|electro fetal monitoring
89171901|NCT05863156|Experimental|intervention 2|electro fetal monitoring
89171902|NCT05863156|Experimental|control group|electro fetal monitoring
89171903|NCT05863091|Experimental|A group of patients undergoing pulmonary function tests|Patients undergoing pulmonary function tests with spontaneous breathing
89171904|NCT05863091|Experimental|A group of patients on ventilators in an intensive care unit|Among patients who are on a ventilator, those on the Richmond agitation sedation scale -4 to -5 and who do not breathe spontaneously
89171905|NCT05863078||Group following the Menus of Change diet|
89171906|NCT05863078||Group not following the menus of Change diet|
89171907|NCT05863065|Experimental|Personalized Virtual Reality exposure|Participants are exposed to a personalized, relaxing VR scenario administered by the Oculus Quest 2 tool.
89171908|NCT05863013|No Intervention|Health education and home care|They will receive standard care: a therapeutic education session on admission, plus daily in-house early postoperative rehabilitation, delivered by a physiotherapist. The therapeutic educational session will involve counseling and self-care management, aiming to prepare patients for the postoperative period, emphasizing breathing exercises and sputum clearance techniques, pain control strategies and self-care. It will consist of smoking cessation education, respiratory retraining (pursed-lip breathing, diaphragmatic breathing, and segmental breathing), and secretion clearance training (coughing exercise, huffing, assisted coughing, and postural drainage).
89171909|NCT05863013|Experimental|Pulmonary rehabilitation|They will receive standard care described (AP) plus perioperative PR, with 20 preoperative and 60 postoperative sessions. The preoperative sessions will be held 2X/week, in addition to the home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall, and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and inspiratory muscles training and home will last for 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at an intensity of 60-80% of maximum HR. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
89171910|NCT05863000||Patients in Region H|The health care system in Region H consists of 10 hospitals, including Region H's Psychiatry which consists of 11 centers. The hospitals annually have around 3 million visits from outpatients
89171911|NCT05862974|Experimental|LPM3480392 X1mg|8 subjects will receive LPM3480392 X1mg and 2 receive placebo
89171912|NCT05862974|Experimental|LPM3480392 X2mg|8 subjects will receive LPM3480392 X2 mg and 2 receive placebo
89171913|NCT05862974|Experimental|LPM3480392 X3mg|8 subjects will receive LPM3480392 X3mg and 2 receive placebo
89171914|NCT05862974|Experimental|LPM3480392 X4mg|8 subjects will receive LPM3480392 X4mg and 2 receive placebo
89171915|NCT05862974|Experimental|LPM3480392 X5mg|8 subjects will receive LPM3480392 X5mg and 2 receive placebo
89171916|NCT05862974|Experimental|LPM3480392 X6mg|8 subjects will receive LPM3480392 X6mg and 2 receive placebo
89171917|NCT05862974|Experimental|LPM3480392 X7mg|8 subjects will receive LPM3480392 X7mg and 2 receive placebo
89171918|NCT05862974|Experimental|LPM3480392 X8mg|8 subjects will receive LPM3480392 X8mg and 2 receive placebo
89171919|NCT05862948|Experimental|CADe Colonoscopy|Colonoscopy with the help of CADe system (ENDO-Aid)
89171920|NCT05862948|No Intervention|Conventional Colonoscopy|Standard Colonoscopy with white light
89171921|NCT05862922||lumbosacral plexus block group|
89171922|NCT05862922||sacral plexus + suprainguinal fascia iliaca plane block group|
89171923|NCT05862896||Control|Healthy, age and sex matched controls
89171924|NCT05862896||Long Covid|Patients with breathlessness (defined as self-reported modified Borg Scale score of 2 or more when walking on flat ground for 100 metres) that has continued or developed and persists more than 4 weeks after acute COVID 19 i.e., related to 'long COVID' (covid confirmed by photographic evidence of positive lateral flow/NHS application, EMIS records or hospital lab data).
89171925|NCT05862883|Experimental|Target group|201 children 6-18 years old with mild to moderate COVID-19, who were taking Rutan.
89171926|NCT05862883|Other|control group|100 children 6-18 years old with mild to moderate COVID-19, who were not taking Rutan.
89171927|NCT05862831|Experimental|PM1003|PM1003 0.02mg/kg-10mg/kg
89171928|NCT05862818|Experimental|Day shift protocol with diet A|Day shift protocol with diet A condition. Since this is a single-blind study, the details of the meal conditions cannot be released during the recruitment stage but will be made public once enrollment closes.
89171929|NCT05862818|Experimental|Day shift protocol with diet B|Day shift protocol with diet B condition. Since this is a single-blind study, the details of the meal conditions cannot be released during the recruitment stage but will be made public once enrollment closes.
89171930|NCT05862818|Experimental|Night shift protocol with diet A|Night shift protocol with diet A condition. Since this is a single-blind study, the details of the meal conditions cannot be released during the recruitment stage but will be made public once enrollment closes.
89171931|NCT05862818|Experimental|Night shift protocol with diet B|Night shift protocol with diet B condition. Since this is a single-blind study, the details of the meal conditions cannot be released during the recruitment stage but will be made public once enrollment closes.
89171932|NCT05862805|Active Comparator|Heavy Menstrual Bleeding|Participants with heavy menstrual bleeding will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
89171933|NCT05862805|Active Comparator|Regular Mensural Bleeding|Participants with normal menstrual bleeding will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
89171934|NCT05862779|Placebo Comparator|Placebo Group|Group supplemented with maltodextrin (40g/day) and corn oil (4g/day). All groups will undergo a training program with strength exercises for 12 weeks
89171935|NCT05862779|Experimental|Whey Protein + Placebo|Group supplemented with isolated whey protein (40g/day) and corn oil (4g/day). All groups will undergo a training program with strength exercises for 12 weeks.
89171936|NCT05862779|Experimental|Omega 3 + Placebo|Group supplemented with omega-3 (4g/day) and maltodextrin (40g/day). All groups will undergo a training program with strength exercises for 12 weeks.
89171937|NCT05862779|Experimental|Omega 3 + Whey Protein|Group supplemented with omega-3 (4g/day) and whey protein (40g/day). All groups will undergo a training program with strength exercises for 12 weeks.
89171938|NCT05862753|Experimental|Etomidate 0,2 mg/kg|8 patients recruited, to receive an injection of bolus of Etomidate at dosage 0,2 mg/kg,
89171939|NCT05862753|Experimental|Etomidate 0,3 mg/kg|10 patients recruited, to receive an injection of bolus of Etomidate at dosage 0,3 mg/kg
89171940|NCT05862740|Experimental|Laparoscopic debulking surgery - LDS|Primary debulking surgery or Interval debulking surgery performed by laparoscopy (P-LDS and I-LDS)
89171941|NCT05862740|Active Comparator|Debulking surgery - DS|Primary debulking surgery or Interval debulking surgery performed by/converted to laparotomy (PDS and IDS)
89171942|NCT05862714|Active Comparator|Group A Fluconazole|Oral fluconazole (400 mg stat) given to patients.
89171943|NCT05862714|Active Comparator|Group B Itraconazole|Oral Itraconazole (1000 mg stat) given to patients.
89171944|NCT05862701|Active Comparator|Permethrin|Group A treated with application of topical 5% permethrin cream twice with one week interval. Follow-up at 1, 2 and 4 weeks
89171945|NCT05862701|Active Comparator|Sulfur|Group B treated with 10% sulfur ointment for two or three weeks. Follow-up at 1, 2 and 4 weeks
89171946|NCT05862662||Children in MOVE Program|Children 5-12 years old who participated in the MOVE program for at least 12 continuous months prior to March 1, 2020 and again for at least 12 continuous months after August 2021.
89171947|NCT05862662||Adults in MOVE Program|Adults 22-65 years old who participated in the MOVE program for at least 12 continuous months prior to March 1, 2020 and again for at least 12 continuous months after August 2021.
89171948|NCT05862610|Experimental|Trilaciclib plus chemotherapy (Trilaciclib+AC-T)|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
89171949|NCT05862610|Experimental|Chemotherapy (AC-T)|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
89171950|NCT05862597||Health Status|Normal examination in recent six months and not fit inclusion criteria of suboptimal health status.
89171951|NCT05862597||Post-Covid syndrome|(A) Age between 20-70 years old, male or female. (B) Have a history of Covid-19 infection. (C) It has been 3 months since the day when the rapid screening test was negative. Antigen positive turn to negative (D) At least one symptom that cannot be explained by other diagnoses and lasts for at least 2 months after being infected with Covid-19.
89171952|NCT05862532|Experimental|Welsh Herbal tea with Senna|Welsh Herbal tea with green tea and Senna
89171953|NCT05862532|Experimental|Welsh Herbal tea with rhubarb root|Welsh Herbal tea with green tea and rhubarb root
89171954|NCT05862532|Active Comparator|Green tea|Dartmoor green tea
89171955|NCT05862519|Experimental|Intervention Group|"Participants will begin taking the Reset supplement for 5 days. Then there will be a 2-day break with no products taken (wash out period).~Participants will then begin taking the following 2 supplements: Stay Ready Fiber and libido with a partial overlap of products.~Stay Ready Fiber will be taken from day 7 through 21, three capsules will be taken twice daily in the morning and afternoon.~Libido will be taken from day 7 through 28, 2 capsules will be taken daily, preferably with a meal.~Participants will then begin taking the Testosterone supplement. Testosterone will be taken from day 28 through to 84, 2 capsules will be taken daily, preferably with a meal."
89171956|NCT05862480|Active Comparator|Hypochlorous Acid Group (HClO)|Patients received one nasal spray in each nasal nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
89171957|NCT05862480|Placebo Comparator|Placebo Group|Patients received one nasal spray in each nasal nostril/3 hours and two oral sprays/3 hours by a Placebo for 5 days .
89171958|NCT05862441|Experimental|AV2-SA|100% AV2 (v/v) - 17% SA (w/v) treatment one drop daily and 10% AV2 (v/v) spray one puff weekly
89171959|NCT05862441|Active Comparator|SA|100% d-carvone (v/v) - 17% SA (w/v) treatment one drop daily and 10% d-carvone (v/v) spray one puff weekly
89171960|NCT05862428|Experimental|Rectal misoprostol|This group received misoprostol transrectally before surgery 1 hour
89171961|NCT05862428|No Intervention|Control group|This group not received any drugs before surgery
89171962|NCT05862415|Active Comparator|strength+aerobic group (SAG)|"All training sessions began with a 5- to 7-minute warm- up (consisting low-intensity walking and running, and dynamic mobility exercises) and active recovery of 4- to 5-minute (based on stretching and relaxation exercises). Sessions lasted approximately 50 minutes (warm-up and cold down included), with an overall weekly volume of 105-120 minutes.~The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The resistance training program was performed using the circuit training method in which two or three sets were performed. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc."
89171963|NCT05862415|Experimental|aerobic+strength group (ASG)|Similar to the active comparator group, but the order of the training reverse.
89171964|NCT05862402|Experimental|Intervention group|Dose antibiotics adjusted by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
89171965|NCT05862402|No Intervention|Control group|Dose antibiotics from standard care
89171966|NCT05862350|Experimental|Aromatherapy inhalation with lavender essential oil|Patients in this group will receive aromatherapy inhalation with lavender essential oil for 28 days , and their sleep quality, anxiety and fatigue will be evaluated at baseline, the 7th day, and 28th day.
89171967|NCT05862350|Placebo Comparator|Aromatherapy inhalation with coconut essential oil|Patients in this group will receive aromatherapy inhalation with coconut essential oil for 28 days , and their sleep quality, anxiety and fatigue will be evaluated at baseline, the 7th day, and 28th day.
89171968|NCT05862337|Experimental|Anlotinib hydrochloride capsules + Penpulimab injection|Anlotinib hydrochloride capsules + Penpulimab injection, 21 days as a treatment cycle.
89171969|NCT05862337|Placebo Comparator|Anlotinib hydrochloride capsules -matching placebo+ Penpulimab injection -matching placebo|Anlotinib hydrochloride capsules -matching placebo+ penpulimab injection -matching placebo, 21 days as a treatment cycle.
89171970|NCT05862311|Experimental|systemically healthy and periodontitis|
89171971|NCT05862311|Experimental|type 2 diabetes and periodontitis|
89171972|NCT05862246||Children with pain|"These are children referred with fot and leg pain. Following outcomes will be measured on all included children:~Silvferskiölds test Height Weight Gender Age PROM child: Oxford Ankle and Foot Questionnaire for children PROM parent: Oxford Ankle and Foot Questionnaire for parents FPS pain scoring over 1 week"
89171973|NCT05862246||Control group children without pain|"Following outcomes will be measured on all included children in control group:~Silvferskiölds test Height Weight Gender Age"
89171974|NCT05862220||D-Dimer group|A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
89171975|NCT05862220||CTPA group|CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.
89171976|NCT05862181||HEPA-HAIC group|HEPA-HAIC group is composed of advanced HCC patients treated with HepaSphere DEB-TACE combined with HAIC as the interventional therapy
89171977|NCT05862181||HAIC group|HAIC group is composed of advanced HCC patients treated with only HAIC as the interventional therapy
89171978|NCT05862129||observation group|This group will collect rectal secretions and stool samples and pus samples from patients with perianal abscess before treatment, and collect rectal secretions and stool samples from patients again 2 months after treatment according to the diagnosis and treatment guidelines.
89171979|NCT05862129||control group|This group collected rectal secretions and stool specimens from a healthy population.
89171980|NCT05862116||Patients with chronic non-specific low back pain|Patients with chronic non-specific low back pain.
89171981|NCT05862103||optimized group|the patients received at least one optimized treatment
89171982|NCT05862103||un-optimized group|the patients didn't receive optimized treatment
89171983|NCT05862090|Experimental|Arm 1 (First RLD2301, then RLD2301+RLD2007)|Period1 : RLD2301 Period2 : RLD2301 + RLD2007
89171984|NCT05862090|Experimental|Arm 2 (First RLD2007, then RLD2301+RLD2007)|Period1 : RLD2007 Period2 : RLD2301 + RLD2007
89171985|NCT05861908|Experimental|Body Bulk-Fill|20 cavity class II restored with Body bulk-fill Resin composite
89171986|NCT05861908|Experimental|preheated Bulk-Fill|20 cavity class II restored with preheated bulk-fill Resin composite
89171987|NCT05861908|Experimental|Injectable Bulk-Fill|20 cavity class II restored with injectable bulk-fill Resin composite
89171988|NCT05861908|Experimental|Sonic-Fill|20 cavity class II restored with sonic-fill bulk-fill Resin composite
89171989|NCT05861882||handball player|"To be a licensed handball athlete~Not having undergone a surgical operation involving the musculoskeletal system in the last six months~Not having any obstacle to perform the tests to be performed within the study~Volunteering to participate in the study"
89171990|NCT05861882||sedantary young people|-being a volunteer
89171991|NCT05861869||PLA2R-induced membranous nephropathy group|"Pathological examination showed that patients with membranous nephropathy were positive for PLA2R by immunohistochemistry, and the symptoms were not completely relieved; (24 h urine protein quantification<0.3g or urine protein /creatinine (uPCR)<300mg /g is regarded as complete remission)~In patients with nephrotic syndrome (serum albumin ≤ 30.0g /L, clinical manifestations show moderate to large amount of proteinuria (urine protein>3.5g /L or urine protein /creatinine ratio ≥ 3500mg /g), and their serum anti PLA2R antibody detection shows positive."
89171992|NCT05861869||Secondary membranous nephropathy group|"Patients in nephrology department who have ruled out primary membranous nephropathy.~the patient has the remaining serum samples of normal test, and the serum volume of the sample is not less than 1ml."
89171993|NCT05861817|Experimental|Study group|The participants were treated using LLLT (904nm and 2.5 J/ sinus) for one month
89171994|NCT05861817|Sham Comparator|Control group|using LLLT without output adjustment of the parameters
89171995|NCT05861791|Experimental|opioid group|IV-PCA consisted of fentanyl
89171996|NCT05861791|Active Comparator|non-opioid group|IV-PCA consisted of ketorolac and nefopam
89171997|NCT05861752||Clinical cohort|"Patients seeking treatment with Paraphilic disorders, compulsive sexual behavior disorder and/or sexsomnia. These will be explored separately within each condition.~For procedures, see the Detailed description heading"
89171998|NCT05861752||Healthy controls|"Sex- and age-matched controls will be recruited through special research units, and through advertising on e.g. in newspapers, websites and on social media.~If the person gives written consent, a structured medical assessment is carried out including assessment of psychiatric co-morbidity and medical history.~The control person will then answer the same questionnaires as the research subjects in the clinical population. They also will be tested regarding impulsivity and provide blood samples."
89171999|NCT05861739|Experimental|Intervention group|Endometriosis Self Care Support Program (Endometriosis Training and Motivational Interview) will be applied to the women in the intervention group.
89172000|NCT05861739|No Intervention|Control group|Women in the control group will receive standard treatment. Training and motivational interviewing will not be applied.
89172001|NCT05861726|Active Comparator|Exercising Group|"The exercising group shall have pre-intervention assessment of executive brain functions vide Stroop test, Trail making test & N-Back task/2-Back by using online psytoolkit followed by intervention.~The intervention for the group being acute aerobic exercise, which will comprise of 30 minutes of treadmill walking at 60-65% of Heart Rate max with continuous recording of heart rate and ECG via Biopac MP36 Student Lab system.~This will be followed by post-intervention assessment of executive brain functions vide Stroop test, Trail making test & N-Back task/2-Back by using online psytoolkit."
89172002|NCT05861726|Placebo Comparator|Control Group|"The control group will also have pre-intervention assessment of executive brain functions vide Stroop test, Trail making test & N-Back task/2-Back by using online psytoolkit.~The control group will undergo NO EXERCISE intervention. They will sit idly in laboratory for 30 minutes with continuous recording of heart rate and ECG via Biopac system.~The executive brain functions of the control group will be re-assessed vide Stroop test, Trail making test & N-Back task/2-Back by using online psytoolkit."
89172003|NCT05861713|Experimental|Hydrating cream group|The subjects will be instructed to apply the Hydrating Cream to the more severely affected side as the experimental group (e.g., the more severely injured left or right hand of tug-of-war athletes). At the same time, the other limb will be regarded as the control group. The study lasted for two weeks, and after two weeks, the experimental and control groups were switched, with the entire observation process lasting four weeks.
89172004|NCT05861687|Experimental|Esomeprazole in combination with Amoxicillin and Clarithromycin|Esomeprazole : once a day per oral; 0.4 mg/kg Amoxicillin: thrice a day per oral; 25 mg/kg Clarithromycin: twice a day per-oral; 7.5 mg/kg
89235061|NCT05073081|Experimental|Prehabilitation|The 8-week prehabilitation program will be delivered online using synchronous and asynchronous sessions delivered by either a physiotherapist, chiropractor or kinesiologist. There will be 4 individual exercises sessions delivered synchronously using Zoom or Physitrack in which motivational interviewing and graded activity exercises will be conducted. Participants will also be asked to exercise at least 3 times a week using the asynchronous exercise videos. The exercises will be individualized on participants functional ability and personal goals identified at baseline, with a focus on muscle strengthening, stretching, improving spinal flexibility and stability. There will be a booster session at 6-weeks post-op. Participants will also undergo 5 group educational sessions, which will provide information regarding: goal setting, pain education, self-management, pacing, post-operative expectations, exercise recommendations, and information regarding their upcoming surgery.
89235062|NCT05073081|Active Comparator|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice. This generally consists of one session with an anesthesiologist, a nurse and access to our online videos.
89235063|NCT05061966|Active Comparator|Online Resource website|The comparator is a website that includes a list of freely available web-based resources for sexual and gender minority youth.
89235064|NCT05061966|Experimental|immi|The intervention is a novel and scalable web application designed to provide sexual and gender minority youth with tools for affirming their identity and coping with minority stress.
89235065|NCT05037734|Active Comparator|Robotic-Assisted UKA|Randomized participant will receive UKA via the ROSA Partial Knee System.
89235066|NCT05037734|Active Comparator|Traditional/Conventional UKA|Randomized participant will receive the UKA via Conventional/Traditional UKA Methods.
89235067|NCT05027815|Experimental|cePolyTregs 100 x10^6 cells Open Label|single dose of 100 x 10^6 cells by IV infusion
89235068|NCT05027815|Experimental|cePolyTregs 200 x10^6 cells Open Label|single dose of 200 x 10^6 cells by IV infusion
89235069|NCT05027815|Experimental|cePolyTregs 400 x10^6 cells Open Label|single dose of 400 x 10^6 cells by IV infusion
89235070|NCT05003856|Experimental|Treatment (RFA)|Patients undergo ultrasound guided RFA over 1-2 hours.
89235071|NCT04998370||Study cohort|The study population consists of patients admitted to an academic tertiary care center due to an aneurysmal subarachnoid hemorrhage. The primary objective of the study focuses on patients included with external ventricular drain (EVD), while secondary objectives consider patients with both EVD and lumbar drain (LD) as well as patients without any drainage system.
89235072|NCT04957758|Active Comparator|OC-01 (varenicline) nasal spray, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
89235073|NCT04957758|Placebo Comparator|Placebo (vehicle control) nasal spray|Placebo (vehicle control) nasal spray
89235074|NCT04951154||Participants with Suspected Lung Cancer|Eligible participants with suspected lung cancer will be enrolled and undergo diagnostic and research bronchoscopic biopsies and research blood sample collection for biomarker analysis. Those participants who proceed to surgical resection will have additional research samples taken from the resected tumor and additional research blood samples drawn for biomarker analyses at the resection visit and at the post-operative follow up visit. Participants will then be followed clinically for two years for evidence of recurrence or until participants with confirmed lung cancer recurrence, whichever occurs earlier.
89235075|NCT04947176|Active Comparator|Active|200mg of pentadecanoic acid (C15:0) supplementation in capsules form
89235076|NCT04947176|Placebo Comparator|Placebo|Matching placebo in capsules form
89235077|NCT04940000|Experimental|Patient with T3-T4 ORL cancer, relevant to surgery and/or radiotherapy and/or chemotherapy.|
89235078|NCT04920045|Active Comparator|Liberal Transfusion Arm|Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb>9g/dL, and this will be maintained throughout their hospitalization.
89235079|NCT04920045|Active Comparator|Restrictive Transfusion Arm|Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.
89235080|NCT04919967|Experimental|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course an also receive support through the Virtual Implementation Protocol.
89235081|NCT04919967|Active Comparator|E-learning/toolkit alone|Participants assigned to the e-learning/toolkit alone group will only complete the e-learning course/receive the e-learning toolkit.
89235082|NCT04919967|No Intervention|Treatment as usual|Participants assigned to this group will not be provided any additional training or implementation assistance. They will be able to take trainings outside of study protocol if they would otherwise plan or want to do so. They will be offered the study-specific training and implementation assistance after they have completed the final study assessments.
89235083|NCT04907201||Patients|A group pf 30 patients with lower limb spasticity who are already candidate for cryoneurotomy will be invited to have an extra electrophysiological test for participation in this study. The test will be done for both limbs for a better comparison.
89235084|NCT04907201||Healthy participants|A group of 30 healthy participants will be invited as a control group, and they will have a single session of electrodiagnostic test for their lower limb in dominant side.
89235085|NCT04899934|Experimental|Mobile and technology assisted aftercare|participants randomized to this condition will receive up to 26 sessions with a community support specialist aftercare provider and 6 months of access to behavioral health mobile applications.
89235086|NCT04899934|Active Comparator|Treatment as usual (TAU)|Participants randomized to this condition receive standard treatment services available to persons discharging from a CSU.
89235087|NCT04868110|No Intervention|Usual Care|Women in the usual care group, will received standard care from the obstetrician.
89235088|NCT04868110|Experimental|High fiber|Women in high fiber group will receive education on consuming a high fiber diet, including weekly lessons and daily snacks.
89172005|NCT05861687|Active Comparator|Lansoprazole in combination with Amoxicillin and Clarithromycin|Lansoprazole: once a day per oral; 15 mg if body weight < 30 kg and 30 mg if body weight > 30 kg Amoxicillin: thrice a day per oral; 25 mg/kg Clarithromycin: twice a day per-oral; 7.5 mg/kg
89172006|NCT05861648|Experimental|Drug group 1|Dietary Supplement: Folic acid 2.5 mg/day
89172007|NCT05861648|Placebo Comparator|Control group 2|Dietary Supplement: Placebo
89172008|NCT05861635|Experimental|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
89172009|NCT05861622|Experimental|Novel moisturizer|Subjects will apply the test product twice daily, both in the morning and the evening.
89172010|NCT05861609|Active Comparator|No pain medication tapering (usual care)|Usual care
89172011|NCT05861609|Active Comparator|Standardized pain medication tapering|Standardized pain medication tapering
89172012|NCT05861609|Active Comparator|Personalized pain medication tapering|Personalized pain medication tapering
89172013|NCT05861596|Experimental|Group A|Conscript 10 individuals, every individual will receive 20 mins of repetitive transcranial magnetic stimulation and 30 min NMES combined with conventional swallowing therapy, 5 times per week, lasting for 2 weeks.
89172014|NCT05861596|Sham Comparator|Group B|Conscript 10 individuals, every individual will receive sham repetitive transcranial magnetic stimulation and 30 min NMES combined with conventional swallowing therapy, 5 times per week, lasting for 2 weeks.
89172015|NCT05861557|Experimental|Experimental arm|Toripalimab + SBRT radiotherapy
89172016|NCT05861544|Experimental|Experimental group|Patients under medication for addiction treatment (MAT) that are active members of the Greek Organization Against Drugs (OKANA) therapeutic units will be recruited for this investigation. The participants will be stratified into two subgroups, i.e., methadone maintenance treatment (MMT) and buprenorphine maintenance treatment (BMT), according to the maintenance treatment program they attend. Pomegranate juice, which is the examined nutritional intervention, will be administered to the participants of both MMT and BMT subgroups of the experimental group. The juice will be administered to the patients at the following dosage: 250 ml/day, seven days/week, for four months.
89172017|NCT05861544|No Intervention|Control group|Patients under medication for addiction treatment (MAT) that are active members of the Greek Organization Against Drugs (OKANA) therapeutic units under methadone or buprenorphine treatment. The participants will be stratified into two subgroups, i.e., methadone maintenance treatment (MMT) and buprenorphine maintenance treatment (BMT), according to the maintenance treatment program they attend. The patients of the control group (both MMT and BMT subgroups) will not consume any similar beverage as a placebo due to the objective difficulties of making one that will be identical to the fresh pomegranate juice.
89172018|NCT05861531|Experimental|Oromotor stimulation with reading curriculum|"1. Obtain baseline LENA recording 2. Review language curriculum and provide LENA linguistic feedback 3. LENA recording every 2 weeks until 36 weeks corrected 4. Review age-appropriate language curriculum and provide LENA linguistic feedback from prior weeks 5. NTrainer Pacifier System prior to oromotor stimulation at approximately 33 weeks corrected 6. The day following pre-oromotor stimulation NTrainer Pacifier System session, will conduct 10-15 minute oromotor stimulation behind curtain prior to a feeding time for 10 total days over a 2 week period 7. NTrianer Pacifier System post oromotor stimulation at approximately 35 weeks corrected 8. Final LENA feedback and PTSD screen~Assessments: 1. PSS:NICU at 36 weeks corrected 2. PPQ screen at 7, 12, and 24 months corrected 3. Child Behavior Checklist at 24 months corrected 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months"
89172019|NCT05861531|Active Comparator|Standard care with reading curriculum|"1. Obtain baseline LENA recording 2. Review language curriculum and provide LENA linguistic feedback 3. LENA recording every 2 weeks until 36 weeks corrected 4. Review age-appropriate language curriculum and provide LENA linguistic feedback from prior weeks 5. NTrainer Pacifier System prior to oromotor stimulation at approximately 33 weeks corrected 6. The day following pre no oromotor stimulation NTrainer Pacifier System session, will have no oromotor stimulation occur behind curtain for 10-15 minutes prior to a feeding time for 10 total days over a 2 week period 7. NTrainer Pacifier System post no oromotor stimulation at approximately 35 weeks corrected 8. Final LENA feedback and PTSD screen~Assessments: 1. PSS:NICU at 36 weeks corrected 2. PPQ screen at 7, 12, and 24 months corrected 3. Child Behavior Checklist at 24 months corrected 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months"
89172020|NCT05861518|Experimental|Group 1|.Participants, who had been receiving treatment for FMS for at least six months at the physical therapy and rehabilitation outpatient clinic .Participants continued their current drug treatment. In the hypnosis group, the patients were given 3 hypnosis sessions once a week. in groups of 3, each standardized for approximately 30 minutes.
89172021|NCT05861518|No Intervention|Group 2|.Participants, who had been receiving treatment for FMS for at least six months at the physical therapy and rehabilitation outpatient clinic .Participants continued their current drug treatment.
89172022|NCT05861505|Active Comparator|Upfront repeat local treatment|
89172023|NCT05861505|Experimental|Neoadjuvant systemic therapy followed by repeat local treatment|
89172024|NCT05861492|Active Comparator|FDDA Group|Fatigue anamnesis was done with the help of the Fatigue Differential Diagnosis Aid.
89172025|NCT05861492|No Intervention|Non-FDDA group|Fatigue anamnesis was done without the help of the Fatigue Differential Diagnosis Aid.
89172026|NCT05859971|Experimental|Sentinel Lymph Node (SLN) mapping|SLN mapping and biopsy will be performed using technetium-99m sulfur colloid and isosulfan blue dye, as well as ICG-fluorescent imaging.
89172027|NCT05859685|Experimental|Experimental group|"The patients included in the experimental group will undergo the following manual therapy techniques:~Talar dorsal sliding technique. A dorsal mobilization of the talus will be performed, with the patient in the supine position and dorsiflexion of the ankle, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
89172028|NCT05859685|Placebo Comparator|Control group|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
89172029|NCT05859659||Molecular pathology of glioma positive|
89172030|NCT05859659||Molecular pathology of glioma negative|
89172031|NCT05859503||Perclose-Proglide system|
89172032|NCT05859503||Figure-of-8|
89172033|NCT05859256|Experimental|Experimental group|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
89172034|NCT05859256|Placebo Comparator|Control group|The subjects included in the control group will perform the same procedures, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
89172035|NCT05858931||CSD patients|All women suffered from abnormal uterine bleeding and were evaluated in a standardized way with hysteroscopy before vaginal surgery.
89172036|NCT05855031|Experimental|Intervention|An invitation to a liver stiffness measurement (Transient Elastography), to blood sampling and a leaflet on alcohol-related disease.
89172037|NCT05855031|No Intervention|Control|An invitation to screening by blood sampling with Fib-4
89172038|NCT05853991|Experimental|Therapeutic touch|The intervention will be based on 2 phases: 1) assessment to identify areas following the NAME procedure, 2) treatment to improve the function of the area identified
89172039|NCT05853991|Active Comparator|Affective touch|Participants will receive an affective touch intervention following the standardised procedure for affective touch
89172040|NCT05853991|Placebo Comparator|Static touch|Participants will receive a static touch intervention following the standardised procedure for static touch
89172041|NCT05852561|Active Comparator|Group Superficial+Deep Serratus Anterior Plan Block|Superficial+Deep Serratus Anterior Plan Block after Video-Assisted Thoracic Surgery
89172042|NCT05852561|Active Comparator|Group Deep Serratus Anterior Plan Block|Deep Serratus Anterior Plan Block after Video-Assisted Thoracic Surgery
89172043|NCT05852509|Experimental|TPA4You group|Participants in the TPA4You group will be given an overview of the TPA4You program and PA exercise safety instructions. HF-FCPs will receive 28 PA sessions delivered by the coach over 12 weeks. The coached sessions will taper from 3 days/week (weeks 1-4) to 2 days/week (weeks 5-12) but exercise on 3 days/week will be recommended throughout. Participants will receive tailored motivational text messages every other day to encourage daily exercise and wearing the Fitbit.
89172044|NCT05852509|Other|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
89172045|NCT05844865|Other|Subjects with Gastrointestinal Peritoneal Carcinomatosis|Subjects with gastrointestinal (GI) peritoneal carcinomatosis who are undergoing planned standard of care (SOC) surgical procedures. Biospecimens such as blood, peritoneal wash fluid and tumor samples will be obtained.
89172046|NCT05842993|Experimental|Hydrogen inhalation|Patients receive hydrogen inhalation.
89172047|NCT05842993|Placebo Comparator|Placebo|Patients receive placebo.
89172048|NCT05842941|Experimental|DNL343|
89172049|NCT05842941|Placebo Comparator|Matching Placebo|
89172050|NCT05826639||Temperature-sensitive RFA prior to biliary stenting|Data will be collected on subjects undergoing endoscopic retrograde cholangiopancreatography (ERCP) with temperature-sensitive RFA prior to biliary stenting for treatment of malignant biliary strictures as part of clinical care.
89172051|NCT05826639||Non-RFA biliary stenting for malignant biliary obstruction|Retrospective participants that have undergone non-RFA biliary stenting for malignant biliary obstruction from a historical cohort will serve as controls.
89172052|NCT05825768|Active Comparator|MRI-group|This group of patients are allocated to a supplementary preoperative breast Magnetic Resonance Imaging (MRI) in addition to standard preoperative breast imaging (ultrasound and mammography).
89172053|NCT05825768|Other|Control group|This groups of patients are allocated to receive standard preoperative breast imaging only (ultrasound and mammography).
89172054|NCT05819684|Experimental|Part 1: Dose escalation|
89172055|NCT05819684|Experimental|Part 2: PK expansion|
89172056|NCT05819684|Experimental|Part 3: efficacy expansion|
89172057|NCT05817370|Experimental|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
89172058|NCT05817370|No Intervention|Standard Screening and treatment of HSIL|The standard screening and treatment of HSIL outlined by the International Anal Neoplasia Society
89172059|NCT05809310|Experimental|Interventional group|Percutaneous intervention for PA stenosis
89172060|NCT05809310|No Intervention|Control group|Conservative management (percutaneous intervention for PA stenosis 6 months postponed)
89172061|NCT05808673|Experimental|Post-change CMAB807X|120 mg Subcutaneous injection around belly button
89172062|NCT05808673|Other|Pre-change CMAB807X|120 mg Subcutaneous injection around belly button
89172063|NCT05808673|Active Comparator|Xgeva®|120 mg Subcutaneous injection around belly button
89172064|NCT05806411||Patients|Patients with calcific aortic sclerosis (stage III and IV) that are going to be treated with traditional surgery according to International Guidelines will be enrolled as cases.
89172065|NCT05806411||Controls|Patients that will undergo a cardiac transplantation (for nonvalvular cardiac disease) or patients with aortic valve insufficiency will be enrolled as controls
89172066|NCT05793372||patients with Alzheimer's Disease|Patients with Alzheimer's disease
89172067|NCT05785182||Open Fracture|High energy open fracture.
89172068|NCT05785182||Infected Fracture|Infected open or closed fracture.
89172069|NCT05776420|Experimental|Food voucher|
89172070|NCT05776420|No Intervention|Control|
89172071|NCT05775003|Placebo Comparator|Placebo|Resistant starch
89172072|NCT05775003|Experimental|500 mg BAIBA supplementation|500 mg BAIBA supplementation
89172073|NCT05775003|Experimental|500 mg BAIBA supplementation + 40 mg Grains of Paradise|500 mg BAIBA supplementation + 40 mg Grains of Paradise
89172074|NCT05773326|Experimental|Single infusion of Temsirolimus|Single infusion of Temsirolimus via super-selective intra-arterial infusion or IV
89172075|NCT05766475|Active Comparator|In-Person Delivery of Group Preventative Intervention (ROSE)|The Reach Out, Stay Strong, Essentials for New Mothers Program (ROSE), is an established Interpersonal Therapy (IPT)-oriented group intervention for postpartum depression. ROSE is a brief (5-session) program and its content addresses social support, role transition to motherhood, communication skills, and psychoeducation on PPD. ROSE consists of four 90-minute, weekly in person group sessions and one individual booster session. The first four sessions of ROSE will be delivered in groups of 6 to 20, and conducted in both English and Spanish. For the in-person groups, transportation via Uber will be provided to Denver Health Medical Center to reduce barriers to attendance.
89172076|NCT05766475|Experimental|Virtual Delivery of Group Preventative Intervention (ROSE)|In parallel to ROSE delivered in person, virtual ROSE consists of four 90-minute, weekly group sessions conducted via Zoom and one individual booster session.
89172077|NCT05765071|Active Comparator|Treatment|Botulinum toxin (Botox) injection
89172078|NCT05765071|Placebo Comparator|Control|Normal saline injection
89172079|NCT05744232|Experimental|Intervention- Low calorie diet/ Total diet replacement|Participants in the intervention group will be offered a dietitian-delivered intervention over 6 months, similar to the NHS pilot of low calorie diets for type 2 diabetes remission. The intervention starts with 12 weeks of low-energy total diet replacement (approx. 860 kcal/day) in a nutritionally replete package of soups, shakes, and bars. It continues with stepped food reintroduction (maximum 6 weeks) as a low-calorie, nutrient-rich diet personalised to the individual participant circumstances and preferences, and weight maintenance (6 weeks).
89172080|NCT05744232|Other|Control- usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded. Participants will be offered an invitation to a 30-45' 1:1 session with the research dietitian at the end of the study to provide help and signposting as required for the management of their diabetes.
89172081|NCT05736159||3 years old age group|Children from 2 years 10 months 16 days to 3 years 2 months 29 days
89172082|NCT05736159||3.6 years old age group|Children from 3 years 3 months to 3 years 8 months 29 days
89172083|NCT05736159||4 years old age group|Children from 3 years 9 months to 4 years 2 months 29 days
89172084|NCT05736159||4.6 years old age group|Children from 4 years 3 months to 4 years 8 months 29 days
89172085|NCT05736159||5 years old age group|Children from 4 years 9 months to 5 years 2 months 29 days
89172086|NCT05736159||5.6 years old age group|Children from 5 years 3 months to 5 years 8 months 29 days
89172087|NCT05736159||6 years old age group|Children from 5 years 9 months to 6 years 2 months 29 days
89172088|NCT05736159||6.6 years old age group|Children from 6 years 3 months to 6 years 8 months 29 days
89172089|NCT05736159||7 years old age group|Children from 6 years 9 months to 7 years 5 months 29 days
89172090|NCT05736159||8 years old age group|Children from 7 years 6 months to 8 years 5 months 29 days
89172091|NCT05718180|Experimental|Supine|Measures are performed first in the supine position and then in a flexible sacrum position
89172092|NCT05718180|Active Comparator|Flexible|Measures are performed first in a kneeling squat position and then in the supine position
89172093|NCT05718141|Experimental|Intervention: COMET-GB|Online single session intervention via qualtrics (any internet connected device) based on cognitive and behavioural principles.
89172094|NCT05718141|No Intervention|Waiting List Control|Participants in the control arm will be provided with information about sources of wellbeing support they can access and will also be asked to fill out additional questionnaires at baseline, which will act as a control for time spent completing online activities. These measures are a Symptom Importance Rating Questionnaire, the Chalder Fatigue Questionnaire [32], Pittsburgh Sleep Quality Index [33], Snaith-Hamilton Pleasure Scale [34], Fatigue Associated with Depression Scale [35]. These will not be completed by the intervention group nor reported as main outcomes on the RCT itself, but will be used in separate observational projects.
89172095|NCT05716542|Experimental|Physical Activity Intervention|"Participants will complete a primarily home-based PA intervention, with the goal of safely increasing their steps/day by incorporating moderate-to-vigorous physical activity (MVPA)~Participants will receive Fitbits with heart rate capabilities to support maintenance of the prescribed intensity during home exercise sessions and participants' self-monitoring of daily steps.~Participants will strategize aerobic MVPA behaviors with the intervention PT to identify preferable and enjoyable PA modalities (e.g., walking, cycling), while also identifying alternative options to allow for flexibility if life- or cancer-specific barriers arise~During the first Zoom coaching session, the intervention PT will train participants on using the Fitbit and completing home exercise logs. The PT will continue to meet with participants to support exercise maintenance, review home exercise sessions, strategize new exercises, and troubleshoot emerging chemotherapy-related health declines."
89172096|NCT05716542|No Intervention|Usual care, wait-list control condition|-Participants in the control group will proceed with their treatment regimen as prescribed by their oncologist(s). To prevent drop out and high attrition rates as well as promote healthy behavior, control group participants will receive a Fitbit at the initial set-up meeting to wear during chemotherapy, as well as an individualized home exercise program and up to two Zoom coaching sessions with a PT after chemotherapy completion.
89172097|NCT05713695|Experimental|Full MISSION|Participants assigned to this condition will receive full MISSION services. MISSION services include 6-months of integrated mental health and substance use treatment and treatment planning with the MISSION Case Manager (13 session curriculum) and Peer Support Specialist (11 session curriculum). Content of these sessions will be directed using the MISSION Treatment Manual and Consumer Workbooks. MISSION teams will also provide linkages and supports to treatment services within the participant's community throughout the duration of the study.
89172098|NCT05713695|Active Comparator|Linkage Only Delivered by a Peer Specialist|Our Linkage only arm delivered by a Peer Specialist will act as the comparison group to the MISSION arm. Participants randomized to the linkage only arm will receive 6-months of linkage care from a Peer Specialist. The Peer Specialist will provide informal treatment planning as well as linkages and support to community services, but will not provide integrated dual disorders treatment, nor will this arm utilize any MISSION materials or offer Peer led groups.
89172099|NCT05705921|Active Comparator|Standard treatment|moderately hypofractionated radiotherapy 62 Gy in 20 fractions of 3.1 Gy
89172100|NCT05705921|Experimental|Experimental treatment|SBRT 5x7Gy with an iso-toxic integrated focal boost up to 50 Gy (Hypo-FLAME) in 15 days (2 fractions per week)
89172101|NCT05696730|Experimental|Communication intervention about sexuality in people with COPD|Communication intervention. Individual counselling to improve holistic well-being by addressing sexuality and to increase adherence for long-term physical activity given the correlation with sexual activity.
89172102|NCT05696730|No Intervention|30 minutes counselling and intervention material per request after the RCT|Usual care. Participants will have the possibility to receive a brief version of the intervention on request (30 minutes counselling and intervention material) at the end of the 3-months follow-up assessment visit.
89172103|NCT05686681|Experimental|Brief Behavioral Activation for Improving Social Connectedness|Active, 6 session Brief Behavioral Activation for Improving Social Connectedness
89172104|NCT05685108|Active Comparator|Group 1|"In Subgroup 1, individuals will receive pulsed ultrasound with a mechanical index of 0.6 and 1.4 delivered to the splenic hilum.~In Subgroup 2, individuals will receive pulsed ultrasound with a mechanical index of 1.0 and 1.8 delivered to the splenic hilum. The two doses will be administered in separate visits with min. 14 days between each stimulation.~In both Subgroups, the two doses will be administered in separate visits with min. 14 days between each stimulation."
89172105|NCT05685108|Active Comparator|Group 2|Individuals will receive pulsed ultrasound with a mechanical index of 1.4 delivered to the splenic hilum and the cervical vagus nerve. The two doses will be administered in separate visits with min. 14 days between each stimulation.
89172106|NCT05646368|Experimental|Formulation #1 of a multivitamin/mineral supplement|Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
89172107|NCT05646368|Active Comparator|Formulation #2 of a multivitamin/mineral supplement|Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
89172108|NCT05618379||DMT Treated Participants|Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 60 months and the available data is collected retrospectively.
89172109|NCT05618379||Untreated Participants|Participants with SMA who received no treatment will be followed prospectively for up to 60 months.
89172110|NCT05614661|Experimental|Mom Power|Mom Power is an evidence-based 13-session psychosocial mother-child group intervention that improves sensitive caregiving, parental stress, and depression
89172111|NCT05614661|Sham Comparator|Control|Controls participants for the intervention receive 10 weekly mailings, with content relevant for the postpartum period (i.e., information on baby sleep, developmental milestones, box breathing and other self-care/coping strategies, fun games to play with a baby, and community resources, and general parenting); plus 10 brief check-in phone calls verifying that material was received, and additional longer phone calls to assess any imminent family needs and provide resources as needed/requested.
89172112|NCT05604066|Experimental|Patients with myofascial-related pain diseases|Subjects diagnosed with myofascial-related pain disease will receive the research MRI imaging including MR elastography and MRI structural imaging.
89172113|NCT05604066|Experimental|Healthy controls without myofascial-related pain diseases|Subjects without myofascial-related pain disease will receive the research MRI imaging including MR elastography and MRI structural imaging.
89172114|NCT05582850|Experimental|DT-9081|Capsule, 25 mg, 50 mg and 100 mg
89172115|NCT05541055|Experimental|Digital CBT-I|Digitally-delivered CBT for insomnia accessed via web and/or mobile app
89172116|NCT05541055|Active Comparator|Sleep hygiene education|This group will receive access to sleep hygiene education delivered via digital written materials
89172117|NCT05527678||5 years ICU survivors|Survivors 5 years after ICU and who participated in the Promorea1 study will be contacted to assess their quality of life.
89172118|NCT05496166|Experimental|surgery group|SHR-1316+chemotherapy+surgery
89172119|NCT05496166|Active Comparator|radiotherapy group|SHR-1316+chemotherapy+radiotherapy
89172120|NCT05491642|Experimental|Up-titration Scheme 1|Participants will receive 12 days treatment in total.
89172121|NCT05491642|Experimental|Up-titration Scheme 2|Participants will receive 12 days treatment in total.
89172122|NCT05491642|Experimental|Up-titration Scheme 3|Participants will receive 12 days treatment in total.
89172123|NCT05489185|Placebo Comparator|Extracapsular fracture with intravenous contraindication (control).|Physiological saline
89172124|NCT05489185|Experimental|Extracapsular fracture with intravenous contraindication (experimental).|Amchafibrin
89172125|NCT05489185|Placebo Comparator|Extracapsular fracture without intravenous contraindication (control).|Physiological saline
89172126|NCT05489185|Experimental|Extracapsular fracture without intravenous contraindication (experimental).|Amchafibrin
89172127|NCT05489185|Placebo Comparator|Intracapsular fracture with intravenous contraindication (control).|Physiological saline
89172128|NCT05489185|Experimental|Intracapsular fracture with intravenous contraindication (experimental).|Amchafibrin
89172129|NCT05489185|Active Comparator|Intracapsular fracture without intravenous contraindication (control).|Physiological saline
89172130|NCT05489185|Experimental|Intracapsular fracture without intravenous contraindication (experimental).|Amchafibrin
89172131|NCT05469581|Experimental|Intervention group|"Interventions to be administered:~A set of preventive interventions to improve adherence in vulnerable elderly people (We will not administer any medications in the research):~reviewing the list of medications, delivery of an ordered list of medications and checking medication regimen understanding;~delivering a leaflet on the correct/safe taking of medication, discussion, explanation, and verification of understanding of the content;~a counseling about the importance of adherence;~handing over the medication dispenser (if the elderly person does not have one yet),~delivering of a personal medication card, which shows the timeline of taking prescribed medication."
89172132|NCT05469581|No Intervention|Control group|"Interventions to be administered:~- review of the list of medication, delivery of an ordered list of medication, and counseling"
89172133|NCT05465304||Control group|control group, included pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments (progesterone) for prolongation of pregnancy.
89172134|NCT05465304||Azithromycin group|the first test group, involved pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin for 5 days every month
89172135|NCT05465304||Azithromycin plus Clindamycin group|the second test group in which the pregnant women administerated Azithromycin and clindamycin (Dalacin®) vaginal gel 5 times per month.
89172136|NCT05453370|Experimental|CALMA app|the arm will receive CALMA app and continue with the usual treatment in a mental health service of a public hospital during the 3 months of the study. In the first interview, the CALMA application will be downloaded to the participant's smartphone. In each follow-up interview (30-days and 60-days), the use of the app will be reinforced.
89172137|NCT05453370|Other|Treatment As Usual (TAU)|the arm will not receive the app and will continue with the usual treatment in a mental health service of a public hospital during the 3 months of the study.
89172138|NCT05442333|Active Comparator|preoperative radiotherapy|The patients which will receive preoperative radiotherapy
89172139|NCT05442333|Active Comparator|postoperative radiotherapy|The patients which will receive postoperative radiotherapy
89172140|NCT05440240|Active Comparator|Corticosteroid injection|Percutaneous needle fasciotomy with corticosteroid injection
89172141|NCT05440240|Placebo Comparator|Saline injection|Percutaneous needle fasciotomy with saline injection
89172142|NCT05412524|Experimental|Reading|Mother and, if desired, mother's partner will read to infant for at least 15 minutes per week, but will be encouraged to read to infant as much as possible. Saliva will be collected from infants and parents for OXTRm assay at pre-specified time points, and at these time point parents will also complete standardized questionnaires including PSS-NICU, PROMIS depression, and PROMIS anxiety to assess parental mood and stress. Reading time will be measured with a reading log provided to the parents, as well as with a commercially-available LENA device to measure word count.
89172143|NCT05412251|No Intervention|contrl|provide an irregular nutrition counselling to case by nutritionist
89172144|NCT05412251|Experimental|intervention|Multi-domain intervention included exercise,cognitive training and diet education was conducted for five hours per week in the first month, second month and third month.
89172145|NCT05391633|Placebo Comparator|Placebo|Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), infants randomized to the non-intervention arm will be played a blank recording of approximately 60 minutes duration, once every 24 hours for a 2-week (14 day) period.
89172146|NCT05391633|Experimental|Recorded Voice Exposure|Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), infants randomized to the intervention arm will be played a recording of their mother's voice with approximately 60 minutes of scripted content, once per 24 hours for a 2-week (14 day) intervention period. (Mothers will be recorded reading a children's book and the recording will be looped to create the 60 minutes of content).
89172147|NCT05375266||Study Cohort|The study cohort consist of patients with newly diagnosed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, paranasal sinuses or larynx in stage UICC (Union internationale contre le cancer) II-IVB
89172148|NCT05375266||Control Group|The control group consists of patients with no current diagnoses of cancer undergoing surgery at the participating medical center
89172149|NCT05370313|Experimental|Cigarette smokers - Tobacco Parity|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Tobacco Parity Tax Condition described in the intervention section.
89172150|NCT05370313|Experimental|Cigarette smokers - Nicotine-Content|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Nicotine-Content Tax Condition described in the intervention section.
89172151|NCT05370313|Experimental|Cigarette smokers - Harm-Reduction|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the Harm-ReductionTax Condition described in the intervention section.
89172152|NCT05370313|Experimental|Cigarette smokers - Modified Risk Tobacco Products (MRTP)|Exclusive cigarette smokers will be recruited and will be exposed to the control condition and the MRTP Tax Condition described in the intervention section.
89172153|NCT05366075|Experimental|Intervention 1 (simple exercise program)|The intervention will include up to four sessions per day. It consists of sit-to stand exercises and walking along the corridor of the ward (for those who can walk).
89172154|NCT05366075|Experimental|Intervention 2 (comprehensive exercise program)|This intervention consists of two daily sessions (morning and afternoon). The morning session includes individualized supervised progressive resistance, balance, and walking training exercises, tailored to each participant's capacity. The resistance training includes using weight cuffs, involving mainly lower-extremity muscles. Balance and gait exercises includes different exercises such as line walking, stepping practice, and walking with small obstacles. The evening session consists of functional exercises using light loads, such as knee extension and flexion, hand training with a ball, and daily walking exercises (for those who can walk).
89172155|NCT05366075|No Intervention|Control group|The control group will receive usual care, which may include physical rehabilitation when needed.
89172156|NCT05357768||retrospective cohort|"Patients with undifferentiated round cell sarcomas treated from 01 January 1983 to April 2019 will be included.~For retrospective analysis, it is expected to include about 200 patients."
89172157|NCT05357768||prospective cohort|prospective patients with undifferentiated round cell sarcomas will be included in the study. For prospective study, it is expect to include 60 patients.
89172158|NCT05344885|Active Comparator|DPT-standard|A standard digital parent training intervention
89172159|NCT05344885|Experimental|DPT-Enhanced|Enhanced digital parent training intervention
89172160|NCT05332236||Community sample|Adolescents (10-18 years) and their parents, recruited via schools or online sampling, from the general population
89172161|NCT05332236||At-risk sample|Parents seeking parenting advice in information centres/helplines.
89172162|NCT05332236||Clinical sample|Children and parents are recruited among in- and outpatients at the Clinic for Child and Adolescent Psychiatry of the University Medical Center Hamburg-Eppendorf
89172163|NCT05324449|Other|treatment arm|open label treatment intervention
89172164|NCT05315440|Active Comparator|control group|"The treatment of control group will be organized according to the classic protocol currently in use in our Institute which consists of:~30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation."
89172165|NCT05315440|Experimental|experimental group|30 minutes of passive and active assisted mobilization guided by the therapist associated with instrument assisted soft tissue mobilization, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
89172166|NCT05304871|Placebo Comparator|placebo|patients receive saline infusion prior to port placement
89172167|NCT05304871|Experimental|antibiotic|patients receive antibiotic (Cefazolin 2 g) infusion prior to port placement
89172168|NCT05297604|Active Comparator|Non-Invasive Intravascular Laser Irradiation Of Blood Group|Participants in this group will receive low-intensity laser that is attached to a bracelet that has been developed so that the light beam is transported transcutaneously over the radial artery.
89172169|NCT05297604|Placebo Comparator|Placebo group|Participants will be treated in the same way as the active group. The person in charge of the ILIB application will simulate the irradiation with the equipment kept off, so that the participant does not identify the group to which he belongs, and the device activation sound (beep) will be turned on at the time of application.
89172170|NCT05297604|No Intervention|Control group|Composed of individuals who will not receive any type of intervention.
89172171|NCT05293314||Patients with bronchiectasis|Diagnosis of bronchiectasis was performed using chest HRCT scans in suspected patients with coughing and expectoration, or long durations of haemoptysis. High-resolution images were obtained during full inspiration at 1-mm collimation and 10-mm intervals from the apex to the base of the lungs. The presence of bronchiectasis was confirmed based on the following criteria: 1) lack of tapering in the bronchi; 2) dilation of the bronchi where the internal diameter was larger than that of the adjacent pulmonary artery; or 3) visualisation of the peripheral bronchi within 1 cm of the costal pleural surface or the adjacent mediastinal pleural surface.
89172172|NCT05293314||Healthy control group|Control group is healthy participants.
89172173|NCT05281978|Experimental|Decrease Sedentary Time + Increase MVPA|Participants in this group will receive a 12-week, social cognitive theory-based intervention targetting reduction of daily sedentary time. This information will be delivered to them in the form of Zoom workshops, a program workbook, personalized step count goals, and a private social media page. The aim of this component will be to have participants displace their daily sedentary time with light-intensity physical activity, such as casual walking. The second component of this intervention will be increasing participants' weekly MVPA engagement. Participants will participate in 1 live, virtual aerobics-based exercise class per week and complete 2 additional sessions on their own time. Participants will build up to exercising 150 minutes/week (the federal physical activity recommendations).
89172174|NCT05281978|Active Comparator|Increase MVPA only|Participants in this group will only receive the MVPA-promoting component (which will be the same delivery as the intervention group). Participants in this arm will participate in 1 live, virtual aerobics-based exercise class per week (held separately from the intervention group) and will complete 2 additional exercise classes on their own time. Participants will build up to exercising 150 minutes/week (the federal physical activity recommendations).
89172175|NCT05281406|Experimental|Osimertinib in combination with platinum-based chemotherapy|all patients received a platinum-based chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed) for a maximum of 4 cycles (q3w) in combination with 80 mg Osimertinib daily
89172176|NCT05277350|Active Comparator|Cohort 1|6 participants on SNIPR001 (Dose 1 BID for 7 days) and 2 participants on placebo
89172177|NCT05277350|Active Comparator|Cohort 2|6 participants on SNIPR001 (Dose 2 BID for 7 days) and 2 participants on placebo
89172178|NCT05277350|Active Comparator|Cohort 3|12 participants on SNIPR001 (Dose 3 BID for 7 days) and 8 participants on placebo
89172179|NCT05275582|Experimental|CARE-PACT|Brief (5 minute) meeting between the PACT medical provider and a behavioral health educator (in person or virtual using VA's VVC system) -followed by- 30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app 2 optional 15-minute phone calls with behavioral health educator
89172180|NCT05275582|Experimental|CARE-PCMHI|30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app 2 optional 15-minute phone calls with behavioral health educator
89172181|NCT05262712|Experimental|Stimulation|During motor training participants in the stimulation arm receive vitro-tactile feedback applied to the feet when touching an object as measured by force-sensing resistors mounted to the sole of the feet.
89172182|NCT05262712|Placebo Comparator|Control|The control group receives the same motor training with the same derives (force-sensing resistors, vibro-tactile stimulators) mounted to the feet but receives no stimulation.
89172183|NCT05256888|Experimental|Time-restricted eating|Participants will self-select a 10-hour window in which to consume all food and beverages (with the exception of black coffee and unsweetened tea in the mornings; water is okay at all times). Participants will also receive weekly tips to encourage a healthy lifestyle in cancer survivorship.
89172184|NCT05256888|Other|Control|Participants will receive weekly tips to encourage healthy lifestyle behaviors in cancer survivorship.
89235089|NCT04854967|Experimental|De-implementation Intervention|"The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an unlearning component targeting provider and patient education and 3) a substitution component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing)."
89172185|NCT05255562|Active Comparator|Combined Serratus Anterior Plane Block|In patients who are planned to have combined deep and superficial serratus anterior plane block, following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 15 ml 0.25% bupivacaine will be injected into the area. Then, with the same needle, will be returned 1-2 cm from the deep serratus anterior area to the superficial serratus anterior area above the serratus anterior muscle and injected 2 ml normal saline for hydrodissection. Finally, 15 ml of 0.25% bupivacaine will be injected for the superficial serratus anterior block into the interfacial area.
89172186|NCT05255562|Active Comparator|Thoracic Paravertebral Block|In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.
89172187|NCT05250414|Other|Study Procedure|
89172188|NCT05236075|Experimental|patients with polysomnography diagnostic of obstructive sleep disorders moderate to severe|
89172189|NCT05233722|Placebo Comparator|Post-exercise insulin sensitivity following placebo administration|Young healthy males will ingest placebo (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.
89172190|NCT05233722|Experimental|Post-exercise insulin sensitivity following Rapamycin administration|Young healthy males will ingest Rapamycin (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.
89172191|NCT05233592||T1D Patients Using CGM|Type 1 Diabetes patients using CGM who have received COVID-19 vaccine booster shot (first or second)
89172192|NCT05221892|Experimental|Test combination|Gamma-aminobutyric acid tartrate 100mg, glutamic acid 100mg, dibasic calcium phosphate 50mg, thiamine nitrate 25mg, pyridoxine hydrochloride 10mg and cyanocobalamin 5mcg
89172193|NCT05221892|Active Comparator|Comparative medication|Ginger extract 160mg (8mg gingerols)
89172194|NCT05216172|Experimental|AZD1656|AZD1656 100mg BD for 3 months
89172195|NCT05216172|Placebo Comparator|placebo|placebo 100mg BD for 3 months
89172196|NCT05215847|Experimental|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
89172197|NCT05197348|Experimental|Meaning-Centered Group Psychotherapy (MCP).|The intervention lasts two months and includes eight sessions that follow a two-hour group format on a weekly basis. The investigators will follow the manualized MCP for patients with advanced cancer.
89172198|NCT05197348|Active Comparator|Cognitive Behavioral Psychotherapy (CBT).|The intervention lasts two months and includes eight sessions that follow a two-hour group format on a weekly basis, with the following sessions. The investigators will follow the manualized CBT or patients with advanced cancer.
89172199|NCT05194306|Experimental|Perla® Cold Preservation solution|Perla® is a Cold Preservation Solution, with purpose to wash out, preserve during transport liver and kidney grafts in optimal conditions from the donor to the recipient.
89172200|NCT05136105|Experimental|Preventive Narrative Exposure Therapy (PreNET) family intervention|"The intervention group receives treatment as usual in the first aid center for survivors of sexual abuse. This includes medical and judicial assistance if necessary. Furthermore, they receive the psychological family focused intervention.~The intervention consists of a total of three sessions with the aim of reestablishing and validating the relationship between sexually abused children and their parents. The intervention focuses on psychoeducation regarding shame and other trauma related disorders. Further, the acknowledgement of shame and embarrassment as well as parental skills are intended to be improved."
89172201|NCT05136105|No Intervention|No Intervention group|The control group will receive only the assessments, and treatment as usual in a first aid center for survivors of sexual abuse. This includes usually a brief assessment of what happened as well as medical and judicial assistance if necessary.
89172202|NCT05128019|Experimental|Intervention|50 GPs will recruit 10 patients each from their daily practice, to take part in the study. They will offer the patients a session of unspecified length or number of consultations, to follow the conversation tool ICIT
89172203|NCT05128019|No Intervention|Control|50 GPs will recruit 10 patients each from their daily practice, to take part in the study. They will however, only receive standard routine care and follow-up by their GP.
89172204|NCT05107869|Active Comparator|Medium Chain Fatty Acid High Fat Meal|This arm will assess the effect of increased plasma ceramide on peripheral microvascular function after consuming a medium chain fatty acid high fat meal.
89172205|NCT05107869|Experimental|Long Chain Fatty Acid High Fat Meal|This arm will assess the effect of increased plasma ceramide on peripheral microvascular function after consuming a long chain fatty acid high fat meal.
89172206|NCT05096234|Experimental|[18F]F-AraG PET|"Subjects will undergo PET imaging at the following time points:~Baseline, prior to lymphodepleting chemotherapy: [18F]F-AraGPET/CT, followed the next day by FDG-PET/CT~At peak CAR expansion: Day 4 (± 2 days) post-CAR infusion:~[18F]F-AraG PET~At Day +28 (± 4 days) post-CAR infusion: FDG-PET/CT Subjects will have a paired biopsy after each imaging time point, if possible. Subjects will be followed for safety of [18F]F-AraG for 30 days after last dose"
89172207|NCT05081804|No Intervention|Non-diabetic Control|Patients without diabetes. No intervention will be administered - standard care.
89172208|NCT05081804|Experimental|Non-diabetic CHO Drink|Patients without diabetes. Commercially available preoperative carbohydrate drink will be administered two hours prior to cesarean section.
89172209|NCT05081804|No Intervention|Diabetic Control|Patients with diabetes. No intervention will be administered - standard care.
89172210|NCT05081804|Experimental|Diabetic CHO Drink|Patients with diabetes. Commercially available preoperative carbohydrate drink will be administered two hours prior to cesarean section.
89172211|NCT05045794|Experimental|Hypothermic oxygenated perfusion (HOPE)|Ex-vivo donor liver preservation using static cold storage followed by HOPE using the VitaSmart Liver Machine
89172212|NCT05045794|Other|Static cold storage|Ex-vivo donor liver preservation using static cold storage only
89235090|NCT04854967|No Intervention|Usual Care|The patient receives usual care from their assigned clinical provider.
89172213|NCT05044936|Experimental|Training|Visit 1: sign consent form, pregnancy tests for females, resting blood pressure, height/weight, body composition, and VO2max test. Visit 2: 1-repetition maximum (RM) test and protocol familiarization. Visit 3: perform a muscle-damaging exercise protocol. Pre-exercise soreness and blood samples will be collected. After, they will perform the pre-exercise testing to assess baselines levels of power and sprint times. Upon completion, they will undergo the muscle-damaging exercise protocol. Post-exercise blood samples and soreness will be collected. The participant will then be given either placebo or CBD cream to rub into their quadriceps. Visit 4 & 5: collect blood samples and soreness scale measurements. Participants will then be given the same treatment (placebo or CBD cream) as they had on visit 3. Visit 6 will be similar to visit 3, except the participant will be given the opposite treatment (placebo or CBD cream). Visits 7 & 8 will be similar to visits 4 & 5, respectively.
89172214|NCT05021900|Experimental|Tenalisib 800 mg BID|
89172215|NCT05021900|Experimental|Tenalisib 1200 mg BID|
89172216|NCT05014646|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89172217|NCT04995666|Experimental|Hearing Aid|Participants will wear Phonak rechargeable Audeo hearing aids
89172218|NCT04971954|Experimental|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
89172219|NCT04971954|Placebo Comparator|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
89172220|NCT04969471|Experimental|Thrombectomy Arm|enVast stent deployed at occlusion site as first measure to obtain reperfusion and withdraw the clot
89172221|NCT04969471|Experimental|Conventional Treatment Arm|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
89172222|NCT04942340|Active Comparator|Phase 1: Atipamezole & caffeine's in a 1:1 ratio|Is this arm, subjects will be randomized to IV administration of Atipamezole & caffeine's in a 1:1 ratio
89172223|NCT04942340|Placebo Comparator|Phase 1: Precedex & Saline in a 1:1 ratio|Is this arm, subjects will be randomized to receive IV administration of Precedex & Saline in a 1:1 ratio
89172224|NCT04932525|Experimental|solid tumor or hematological malignancy|
89172225|NCT04909723|Placebo Comparator|Stage 1 placebo arm|
89172226|NCT04909723|Experimental|Stage 1 NB1000S 10^9 CFU one time on Day 1|
89172227|NCT04909723|Experimental|Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 0.5g/day|
89172228|NCT04909723|Experimental|Stage 1 NB1000S 10^9 CFU one time on Day 1 and NB2000P 10g/day|
89172229|NCT04909723|Experimental|(Optional) Stage 1 variable doses of NB1000S and NB2000P at varying dosing regimens.|Adaptive trial design supports the enrollment of additional arms with variable doses of NB1000S, NB2000P, at varying frequencies of NB1000S and NB2000P administrations.
89172230|NCT04909723|Experimental|Stage 1 NB2000P at a dose to be determined|
89172231|NCT04909723|Experimental|Stage 2 NOV-001 at dose determined in Stage 1|In Stage 2, subjects will be randomized (3:1, NOV-001:placebo) to receive NOV-001 (consisting of NB1000S and NB2000P at a dose and regimen determined in Stage 1) for 28 days.
89172232|NCT04909723|Placebo Comparator|Stage 2 placebo arm|In Stage 2, subjects will be randomized (3:1, NOV-001:placebo) to receive placebo for 28 days.
89172233|NCT04905654|Active Comparator|Levcromakalim|
89172234|NCT04905654|Placebo Comparator|Saline|
89172235|NCT04890483|Experimental|Intervention|The ARD patients with post-acute COVID-19 will receive tDCS sessions for one week.
89172236|NCT04887922|No Intervention|Pre-Surgery: No Incentive Spirometry (IS)|-Will not receive a incentive spirometer prior to surgery
89172237|NCT04887922|Experimental|Pre-Surgery: Standard Incentive Spirometry (IS)|"Will receive a conventional spirometer prior to surgery~Will be asked to perform spirometry 30 times per day."
89172238|NCT04887922|Experimental|Pre-Surgery: Digital Incentive Spirometry (IS) + Text Message|"Will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~Will be asked to perform spirometry 10 times per hour, every hour while awake, every day for at least 7 days prior to surgery. Absence of spirometry for 24 hours will trigger a text message reminder to encourage compliance with IS."
89172239|NCT04887922|Active Comparator|Post-Surgery: Standard Incentive Spirometry (IS)|"After surgery, the participants will receive a conventional spirometer.~Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~The conventional spirometer will be equipped with an accelerometer that will allow the research team to determine whether the spirometer moves throughout the patients' postoperative stay (as a proxy for IS use)"
89172240|NCT04887922|Experimental|Post-Surgery: Digital Incentive Spirometry (IS) + Text Message|"After surgery, the participants will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~Will receive text reminders to perform spirometry if they do not perform spirometry in a 24-hour period."
89172241|NCT04878406|Experimental|1.7 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 1.7 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
89172242|NCT04878406|Placebo Comparator|Placebo (1.7 mg NNC0480-03899) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
89172243|NCT04878406|Experimental|8.6 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 8.6 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
89172244|NCT04878406|Placebo Comparator|Placebo (8.6 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
89172245|NCT04878406|Experimental|30 mg NNC0480-0389 + 0.5 mg Semaglutide|Participants will be co-administered single doses of 30 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.
89172246|NCT04878406|Placebo Comparator|Placebo (30 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)|Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.
89172247|NCT04877730|Experimental|FCL (Fully Closed Loop)|Closed-loop control without meal anticipation module without meal bolus
89172248|NCT04877730|Experimental|FCL+ (Fully Closed Loop with meal anticipation)|Closed-loop control with meal anticipation module without meal bolus
89172249|NCT04877730|Experimental|HCL (Hybrid Closed Loop)|Closed-loop control without meal anticipation module with meal bolus
89172250|NCT04868305|Active Comparator|Intramedullary nail|Intramedullary nail with proximal lagscrew and distal locking screw(s)
89172251|NCT04868305|Active Comparator|Hip arthroplasty|Hemiarthroplasty (HA) or Total hip arthroplasty (THA). A cemented dual-mobility cup will be utilized in THA. Addition of cerclage/trochanter claw plate to fixate trochanter major will be used when suitable.
89172252|NCT04857398|Experimental|Insulin icodec|The participants will receive an individualised weekly dose of subcutaneously (s.c.) insulin icodec for 6 weeks
89172253|NCT04814407||Lung cancer patients|Patients age over 20, with suspected or confirmed diagnosis of lung cancer.
89172254|NCT04814407||Indeterminate subjects|Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
89172255|NCT04814407||Control subjects|Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
89172256|NCT04812548|Experimental|sabatolimab + azacitidine + venetoclax|"Part 1: Safety run-in consists of 2 subsequent cohorts of a lower dose (cohort 1) and s higher dose (cohort 2) of sabatolimab in combination with fixed dose of venetoclax and azacitidine. Cohort 2 will be open only after the review of safety data from cohort 1 indicates the regimen is safe. If the regimen using sabatolimab at the lower dose is not safe, the study will be stopped. Subsequently, if the review of safety data from participants enrolled in cohort 2 indicates that the regimen is safe, then Part 2 will be opened. Otherwise, if the regimen at the higher dose is not safe, the study will be also stopped.~Part 2: Expansion will enroll additional participants to further investigate the regimen including sabatolimab at the higher dose, azacitidine and venetoclax. Participants data from Part 1 and Part 2 treated with the higher dose will be combined to determine the complete remission rate."
89172257|NCT04803773|Experimental|Experimental Arm|
89172258|NCT04794075|Experimental|Experimental group with the therapeutic education and nursing support program|In addition to the conventional oncology follow-up, patients will participate in an initial educational assessments day.
89172259|NCT04794075|No Intervention|Control group|Patients will have the conventional oncology follow-up.
89172260|NCT04783181|Experimental|Dose Level 1|BBP-631 lowest dose, administered once, intravenously (IV)
89172261|NCT04783181|Experimental|Dose Level 2|BBP-631 middle dose, administered once, IV
89172262|NCT04783181|Experimental|Dose Level 3|BBP-631, high dose, administered once, IV
89172263|NCT04783181|Experimental|Dose Level 4|BBP-631, highest dose, administered once, IV
89172264|NCT04771403|Experimental|FMPD AP system|Participants will use the FMPD AP system for automated insulin delivery for a 76 hour study visit.
89172265|NCT04771403|Experimental|MPC AP System|Participants will use the MPC AP system for automated insulin delivery for a 76 hour study visit.
89172266|NCT04771403|Experimental|Dexcom G6 Training Arm|Participants will use the Dexcom G6 CGM system within the MPC AP system to generate sensor glucose data during a 7 day period.
89172267|NCT04749004|Experimental|Intervention Group|"Tracking of steps by means of a fitness tracker~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)~Setting-up of a commitment contract on the individual's goal of monthly steps taken~Provision of financial incentives upon achievement of one's goal of steps taken~Provision of nudges (reminders)"
89172268|NCT04749004|No Intervention|Control Group|"Tracking of steps by means of a fitness tracker~For the economic experiments on time and risk preferences monetary rewards are used with the amount depending on the decisions of the participants.~Participants collect points for transmitting informations about the amount of steps taken on the basis of which they get a small reward (e.g., a skiing ticket)~To keep incentives constant the control group will also receive the flat payment of €10 to disentangle the effects between the contract and financial incentives."
89172269|NCT04704284|Experimental|ZTE MRI Imaging|Pediatric patients that have gotten a clinically indicated CT within a 6 week time period will receive a Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)
89172270|NCT04702022|Other|Humoral Arm|"The renal biopsy shows signs of humoral rejection: the patient is excluded from the study and is treated as usual on the basis of the histological results."
89172271|NCT04702022|Other|"Highly Metabolic patients"|"The renal biopsy does not show signs of humoral rejection but the 18FDG PET / CT shows a high metabolic activity of the graft (> 2.4): the patient is treated as usual on the basis of histological findings."
89172272|NCT04702022|Other|" Low metabolic patients"|The renal biopsy does not show signs of humoral rejection and the 18FDG PET / CT shows a weak metabolic activity of the graft (<2.4): the immunosuppressive treatment is gradually weaned off corticosteroids.
89172273|NCT04698525|Active Comparator|Valproate group|This is a well know antiepileptic drug with efficacy as a preventive tic treatment in episodic migraine
89172274|NCT04698525|Active Comparator|Memantine|This is a possible preventive treatment in episodic migraine
89172275|NCT04680845|Experimental|Self-affirmation|"Participants will be asked to complete a standard questionnaire including:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will… …think about the things I value about myself~remember things that I have succeeded in~think about what I stand for~think about things that are important to me~If…______________________________________________________________________"
89172276|NCT04680845|No Intervention|Control|Participants will be asked to complete a standard questionnaire.
89235091|NCT04848636||Healthy Controls|"Age greater than or equal to 18 years~lack of kidney disease, cardiovascular disease, diabetes, liver cirrhosis and peripheral edema"
89235092|NCT04848636||Chronic Kidney Disease Patients|"Age greater than or equal to 18 years~evidence of kidney disease persisting > 3 months and no indications to start dialysis"
89172277|NCT04678635|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with cathode will be positioned at contralateral to the dominant limb and the anode charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. The stimulation will happen simultaneously to aerobic exercises for 20 minutes. Total number of stimulation associated with aerobic exercise sessions: 10
89172278|NCT04678635|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session. However, the patients will do aerobic exercises for 20 minutes. Total number of sham-stimulation associated with aerobic exercise sessions: 10
89172279|NCT04672538|Experimental|Low transition to High Vt protocol|This arm of the study will begin with lower tidal volumes at higher respiratory rates for initial hemodynamic measurements. They will then be transitioned to the higher tidal volume at lower respiratory rate condition for repeat hemodynamic measurement.
89172280|NCT04672538|Experimental|High transition to Low Vt protocol|This arm of the study will begin with higher tidal volumes at lower respiratory rates for initial hemodynamic measurements. They will then be transitioned to the lower tidal volume at higher respiratory rate condition for repeat hemodynamic measurement.
89172281|NCT04670627||Seasonal Allergic Rhinitics|"Non-smoking males and females aged 18-70 years, inclusive with history of Seasonal Allergic Rhinitis defined by:~Sensitization to at least one seasonal aeroallergen via skin prick testing (wheal =3 mm than negative control), AND History of physician-diagnosed seasonal allergic rhinitis, OR Symptoms consistent with seasonal allergic rhinitis, such as runny nose, nasal congestion, sneezing, or nasal pruritis."
89172282|NCT04670627||Control|Non-smoking males and females aged 18-70 years, inclusive with no history of physician-diagnosed allergic rhinitis and no history of seasonal runny nose, nasal congestion, sneezing or nasal pruritis. Negative results to a panel of aeroallergens via skin prick testing.
89172283|NCT04667104|Experimental|Treatment Period (TP) 1 (JNJ-73763989 + Nucleos(t)ide Analog)+ TP 2 (TP 1+PegIFN-alpha2a)|Participants will receive combination treatment with JNJ-73763989+ nucleos(t)ide analog (NA) for 12 weeks during Treatment Period 1 and the participants who meet the eligibility criteria for PegIFN-alpha2a at Week 12 will receive combination treatment with JNJ-73763989 + NA plus PegIFN-α2a for 12 weeks during Treatment Period 2.
89172284|NCT04659369|Experimental|CMAB819|CMAB819 480 mg intravenous (IV) solution for Injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
89172285|NCT04659369|Active Comparator|Nivolumab|Nivolumab 480 mg intravenous (IV) solution for injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent, or the study ends or up to 4 doses in subjects without disease progression, whichever occurs earlier. After completing 4 doses of Nivolumab therapy, administer of CMAB819 480 mg intravenous (IV) solution for injection every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
89172286|NCT04651439|Experimental|FILGRASTIM|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + ZARZIO@ (30 MU/0,5mL and/or 48 MU/0,5mL - solution of 20 ml diluted in GLUCOSE 5%) administrated by IV or subcutaneous route over a period of 5 consecutive days (1 injection per day during 30 minutes)
89172287|NCT04651439|Placebo Comparator|PLACEBO|Standard symptomatic treatment of the SJS/NET (until the reepidermization of the patient) + 20 ml GLUCOSE 5% administrated by IV route over a period of 5 consecutive days (1 injection per day during 30 minutes)
89172288|NCT04649801|No Intervention|conventional|
89172289|NCT04649801|Active Comparator|interventional|
89172290|NCT04641663|Experimental|100 RDD|100% of recommended daily dose (RDD) of the MORNING tablet dose (5 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
89172291|NCT04641663|Experimental|80 RDD|80% of recommended daily dose of the MORNING tablet dose (4 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
89172292|NCT04641663|Experimental|60 RDD|60% of recommended daily dose of the MORNING tablet dose (3 tablets), all groups will receive the full recommended dose for both EVENING (3 tablets) and OMEGA (2 softgels) doses.
89172293|NCT04635774|Active Comparator|Treatment Group|The treatment group will receive 40 IU via four activations of an intranasal spray.
89172294|NCT04635774|Placebo Comparator|Placebo Group|The placebo group will receive four activations of an intranasal spray containing placebo (normal saline).
89172295|NCT04634799|Active Comparator|TM5614|TM5614 30 mg tablets. 6 tablets (180 mg) taken by mouth, once daily for up to 7 days
89172296|NCT04634799|Placebo Comparator|Placebo|Placebo tablets. 6 tablets taken by mouth, once daily for up to 7 days
89172297|NCT04622930|Experimental|Experimental: Smartphone-delivered CBT for SAD|12-week Smartphone delivered CBT for SAD.
89172298|NCT04622930|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for SAD following the 12-week waitlist control).
89172299|NCT04603365|Experimental|Treatment (pamiparib, temozolomide)|Patients receive PO BID on days 1-28 and temozolomide PO QD on days 1-7. Cycles repeat every 28 days for up to 36 months in the absence of disease progression or unacceptable toxicity.
89172300|NCT04591912|Experimental|mind. body. voice.|The 10-week mind. body. voice. program.
89172301|NCT04591912|No Intervention|Control|Assessment-only control
89172302|NCT04591873||Critical patients in the emergency department|
89172303|NCT04587089|Experimental|Non-instrumental Endodontic Treatment (NIET) + Guedes-Pinto Paste Group|In this group, the canals will not be instrumented and the filling will be performed with Guedes-Pinto paste.
89172304|NCT04587089|Experimental|Non-instrumental Endodontic Treatment (NIET) + CTZ Paste Group|In this group, the canals will not be instrumented and the filling will be performed with CTZ paste (Chlorophenicol, Tetracycline and Zinc Oxide and Eugenol).
89172305|NCT04565015|Experimental|GC5107|Immune Globulin Intravenous (Human), 10% Liquid
89172306|NCT04560660|Experimental|Ketamine and prolonged exposure (PE)|Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
89172307|NCT04560660|Placebo Comparator|Midazolam and prolonged exposure (PE)|Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
89172308|NCT04556526|Experimental|Group A: Ad26.ZEBOV, MVA-BN-Filo|Participants will receive intramuscular (IM) injection (0.5 milliliter [mL]) of Adenovirus serotype 26 encoding the ebola virus mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5*10^10 viral particle(s) [vp]) on Day 1, followed by modified vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1*10^8 infectious unit(s) [Inf U]) on Day 57.
89172309|NCT04556526|Other|Group B: No vaccination during pregnancy|Participants (pregnant women) in control Group B will not receive any vaccination during pregnancy. However, women in this group will receive the 2-dose vaccination regimen at the earliest 6 weeks after delivery/termination of pregnancy that is Dose 1 of Ad26.ZEBOV vaccine (0.5 mL) (5*10^10 vp) on Day 1 by IM injection followed by 0.5 mL of MVA-BN-Filo (1*10^8 Inf U) vaccine by IM injection 56 days after Dose 1.
89172310|NCT04551638||Online Videogame Players|One cohort of healthy young adults players of online video games.
89172311|NCT04517916||Zephyr Valve treatment|Patients undergoing the Zephyr Valve treatment for emphysema/COPD
89172312|NCT04510675|Experimental|Test Article (Omeza Collagen Matrix)|"Repetitive and continuous patch applications of the test article to the same test sites on the back approximately 48 hours on weekdays and for approximately 72-hour periods over weekends over 3 weeks, for a total of 9 induction applications. During a subsequent challenge phase 10-17 days after the induction phase, the test article and negative control will be applied for 48 hours.~Each subject will receive both the test article and negative control at the same time."
89172313|NCT04510675|Experimental|Negative Control (0.9% aqueous sodium chloride)|"Repetitive and continuous patch applications of the negative control to the same test sites on the back approximately 48 hours on weekdays and for approximately 72-hour periods over weekends over 3 weeks, for a total of 9 induction applications. During a subsequent challenge phase 10-17 days after the induction phase, the test article and negative control will be applied for 48 hours.~Each subject will receive both the test article and negative control at the same time."
89172314|NCT04493957|Experimental|educational intervention|"Patients and caregivers included in the ACCOMPAGNE Education Program group will benefit from seven group workshops spread over three half-days (once a week over 3 consecutive weeks), animated in pairs, each lasting approximately one and a half hours. and using educational pedagogical methods."
89172315|NCT04493957|Active Comparator|Control group|"Patients and caregivers included in the Control group will receive the usual recommendations for driving, issued by their referring doctor in memory consultation during the diagnostic announcement process or during the follow-up of their illness."
89172316|NCT04478617|Experimental|Metronidazole|
89172317|NCT04478617|No Intervention|Control|
89172318|NCT04462289|No Intervention|Usual Care|Randomly assigned sample who will receive usual care for tobacco cessation treatment
89172319|NCT04462289|Experimental|Proactive Outreach|Randomly assigned sample who will receive a proactive offer of tobacco treatment with connection to motivational texting program.
89172320|NCT04452292|Active Comparator|No TP53/Rb1 Co-Mutation|HG-LCNEC tumor lacking the TP53/Rb1 co-mutation (non-small cell-like).
89172321|NCT04452292|Experimental|TP53/Rb1 Co-Mutation Present|HG-LCNEC tumor with the TP53/Rb1 co-mutation.
89172322|NCT04432064|Experimental|Phase 3 Active TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation. Participants will receive stimulation for 60 minutes on one day.
89172323|NCT04432064|Sham Comparator|Phase 3 Sham TI-NDBS|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds.
89172324|NCT04432064|Active Comparator|Phase 4 Traditional tDCS|Participants assigned to this condition will receive traditional transcranial direct current stimulation for 60 minutes for 5 days.
89172325|NCT04432064|Experimental|Phase 4 TI-NDBS|Participants assigned to this condition will receive active temporal interference non-invasive deep brain stimulation for 60 minutes for 5 days and will be compared to sham stimulation and tDCS.
89172326|NCT04432064|Sham Comparator|Phase 4 Sham stimulation|Participants assigned to this condition will receive sham temporal interference non-invasive deep brain stimulation, in which they will have electrodes attached to the scalp but the device is only turned on for a few seconds. Participants will be in the scanner for 60 minutes for 5 days. This will be used as the control condition and compared with TI-NDBS and tDCS.
89172327|NCT04431999|Experimental|Whole blood group|Damage control resuscitation for trauma care using whole blood.
89172328|NCT04431999|Active Comparator|Fractionated blood products group|Damage control resuscitation for trauma care using component therapy.
89172329|NCT04424966|Experimental|Arm 1|"Phase 0: 125 mg of infigratinib administered orally for 7 days prior to surgical resection.~Expansion Cohort: 125 mg of infigratinib administered orally for 21 days of a 28-day treatment cycles."
89172330|NCT04401605|Experimental|Fermented Food-Supplemented Diet|Patients in this arm will supplement their regular diet by an increasing number of daily servings of fermented food over a period of 10 weeks.
89172331|NCT04401605|Placebo Comparator|Regular Diet Control Arm|Patients in this arm will continue their regular diet throughout the 10 weeks of study with a maximum of 1 serving of fermented foods per day.
89172332|NCT04397159|Experimental|Combination Exercise|Flywheel resistance exercise plus aerobic exercise
89172333|NCT04397159|No Intervention|Standard-of-care|Participants will maintain standard-of-care and current activity levels during the course of the study.
89172334|NCT04361045|Experimental|Intervention Condition|Participants in this condition were delivered 8 weeks of online intervention modules and then were invited to complete a posttest survey.
89172335|NCT04361045|No Intervention|Waitlist Condition|Participants in this condition received no intervention content nor communications for 8 weeks and then were invited to complete a posttest survey.
89172336|NCT04358276|Experimental|Group I (PAE)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months.
89172337|NCT04358276|Experimental|Group II (PAE, physician)|Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit.
89172338|NCT04358276|Experimental|Group III (PAE, physician, dermatoscope)|"Participants receive a study packet on skin cancer. Participants also receive text messages once every 3 weeks for 9 months. Participants' physician receives a letter that describes the educational intervention and encourages them to do a skin examination at next patient visit. Physicians also receive a free dermatoscope with instructions for uploading images of suspect lesions and attend a 30-minute online course comprising additional descriptions of dermoscopic images for skin cancers and mimickers common in hematopoietic stem cell transplantation patients, along with clear instructions for using a dermatoscope and steps to integrate dermoscopy into their practice."
89172340|NCT04336683|Other|Patient|Patients undergoing gynecological brachytherapy, will be imaged with a 3D ultrasound medical device for the purpose of efficacy testing.
89172341|NCT04301271|Experimental|Simvastatin|Simvastatin and Escitalopram
89172342|NCT04301271|Placebo Comparator|Placebo|Placebo and Escitalopram
89172343|NCT04287218|Experimental|TG-iConquerFear|The participant is guided through the web-based sessions by minimum weekly contact with an experienced therapist (estimated ½ hour/week for 10 weeks). The therapist will motivate, answer questions and give feedback on written material and exercises.
89172344|NCT04287218|Active Comparator|Augmented treatment as usual|"The control group is described as augmented treatment as usual (aTAU), since the diagnostic telephone interview exceeds standard treatment. Further more, the participants will be referred to a website with a non-guided, publicly available E-learning program in cancer rehabilitation hosted by the Region of Central Jutland (livogkraeft.rm.dk). In addition to written material the website includes self-help instructions for meditation."
89172345|NCT04269655|Experimental|Intervention CB CGM|On CB CGM patients, CGM data will also be transmitted from the bedside smartphone to the Digital Dashboard. The Digital Dashboard will integrate CGM data for CB CGM's participants for presentation via two views: (1) Real-Time Management and (2) Clinical Optimization. Telemetry technicians to conduct site-based monitoring, and the Diabetes APN will conduct remote management of patients at the site from a central, Scripps Diabetes Hub, per below. (Note, as CGMs are not FDA-approved for in-hospital glucose management, CB CGM participants will also have their glucose monitored via the hospital's standard POC testing protocol described for UC).
89172346|NCT04269655|No Intervention|Usual Care|For UC, CGM data will be blinded to the care team and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours for patients who are not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring: UC (and intervention) participants' glucose levels will be managed using the glucose management protocol and the Diabetes APN will assess UC participants' POC data documented in the EMR from the previous 24-48 hours and make recommendations for changes to the basal/bolus regimen to improve glucose management.
89172347|NCT04229134|Other|Pilot Arm: Project CONNECT|8-week home based reciprocal peer support pain self-management program for chronic musculoskeletal pain
89172348|NCT04228783|Experimental|Active Vaccine: Group 1 (Ad26.ZEBOV-Lot A, MVA-BN-Filo-Lot 1)|Participants will receive Intramuscular injection (0.5 milliliter [mL]) of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 (5*10^10 viral particle(s) [vp], Lot A) on Day 1, followed by Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) as Dose 2 (1*10^8 infectious unit(s) [Inf U], Lot 1) on Day 57.
89172349|NCT04228783|Experimental|Active Vaccine: Group 2 (Ad26.ZEBOV-Lot B, MVA-BN-Filo-Lot 2)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot B) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 2) on Day 57.
89172350|NCT04228783|Experimental|Active Vaccine: Group 3 (Ad26.ZEBOV-Lot C, MVA-BN-Filo-Lot 3)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, Lot C) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, Lot 3) on Day 57.
89172351|NCT04228783|Placebo Comparator|Control Vaccine: Group 4 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9 percent [%] saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57.
89172352|NCT04228783|Experimental|Booster Cohort: Group 5 (Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV)|Participants will receive Intramuscular injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5*10^10 vp, a single Lot) on Day 1, followed by MVA-BN-Filo as Dose 2 (1*10^8 Inf U, a single Lot) on Day 57 and a booster dose of Ad26.ZEBOV (at a dose of 5*10^10 vp, a single Lot) 4 months after Dose 2 (on Day 177).
89172353|NCT04228783|Placebo Comparator|Booster Cohort: Group 6 (Placebo)|Participants will receive Intramuscular injection (0.5 mL) of placebo (0.9% saline) matching to Ad26.ZEBOV as Dose 1 on Day 1, followed by placebo matching to MVA-BN-Filo as Dose 2 on Day 57 and a booster dose of matching placebo on Day 177.
89172354|NCT04188119|Experimental|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
89172355|NCT04188119|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
89172356|NCT04183218||Observational (cardiac monitoring)|Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.
89172357|NCT04170023|Experimental|Open-label ALXN2050 Monotherapy|"Experimental: Open-label ALXN2050 Monotherapy ALXN2050 orally administered~Group 1: Patients with PNH who are treatment naïve~Group 2: Patient with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months, who continue to experience anemia and reticulocytes above the upper limit of normal (ULN)~Group 3: Patients with PNH who have received danicopan monotherapy during study ACH471-103"
89172358|NCT04138394|Experimental|Vitamin C|Patients will receive intravenous vitamin C at 50mg/kg every 6 hours for 96 hours
89172359|NCT04138394|Placebo Comparator|Control group|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
89235093|NCT04848636||Hemodialysis Patients|"Age greater than or equal to 18 years~more than 3 months duration of therapy"
89172360|NCT04129931|Experimental|Medium Chain Triglycerides (MCT)|Participants in this arm will receive Medium Chain Triglycerides (MCT) powder packets (10 g each) at each treatment visit at any point in the study. Participants will mix 1-2 packets of MCT supplement powder into liquids or semi-solid food and ingest 3 times a day during the 16-week treatment period. Participants will be randomized to the treatment sequence and will receive either the active MCT or the matching placebo first or vice versa.
89172361|NCT04129931|Experimental|Clazakizumab|Participants randomized to this arm will receive a 12.5 mg dose of Clazakizumab via a subcutaneous injection at every study visit, every 4 weeks, during the 16-week treatment period at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Clazakizumab or the matching placebo first or vice versa.
89172362|NCT04129931|Experimental|Broncho-Vaxom|Participants randomized to this arm will receive 7 mg of Broncho-Vaxom once a day on an empty stomach for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Broncho-Vaxom or the matching placebo first or vice versa.
89172363|NCT04129931|Experimental|Imatinib|At any point in the study, participants randomized to this arm will take two 100 mg Imatinib tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Participants will then take four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Participants will be randomized to the treatment sequence and will receive either the active Imatinib or the matching placebo first or vice versa.
89172364|NCT04129931|Experimental|Cavosonstat|Participants randomized to this arm will take one 50 mg Cavosonstat capsule orally twice a day for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Cavosonstat or the matching placebo first or vice versa.
89172365|NCT04103814|Active Comparator|Mg-CBDa cream|Subjects in this group will receive the active Mg-CBDa (magnesium-cannabidiolic acid) for topical treatment of hallux valgus or hallux rigidus.
89172366|NCT04103814|Placebo Comparator|Placebo cream|Subjects in this group will receive the inactive CBD cream for topical treatment of hallux valgus or hallux rigidus. The ingredients of the placebo cream are: butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), and food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
89172367|NCT04097067|Experimental|Treatment (low-dose radiation therapy)|"Patients undergo low-dose radiation therapy with daily 2 Gy ad 20 Gy (ISRT with IMRT & IGRT).~Blood draw for biomarker-analysis (at baseline visit/ after 4 Gy/ after 10 Gy / after 20 Gy RT/ at 3 and 6 months after RT)"
89172368|NCT04096430|Experimental|ENGAGE approach (child-oriented goal-setting)|Therapists will receive training on our principles-based goal setting approach and strategies in the goal setting toolbox. Training will include an overview of tools and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS) and the Pediatric Activity Card Sort (PACS). In addition, we will provide training on Goal Attainment Scaling and administration of the Canadian Occupational Performance Measure (COPM). We will introduce simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
89172369|NCT04096430|No Intervention|Usual care|The control group will comprise of usual care.
89172370|NCT04042610|Experimental|Intervention: electronic prompt to interrupt sitting time|The intervention will consist of two components: education and an electronic prompt via the iOS application Stand Up and notification through the Amzafit BIP device. The Stand-Up application will generate a prompt every hour during the workday to interrupt sitting time and encourage 2 minutes of physical activity. The intervention group participants will be given verbal and written educational materials on the health benefits of incorporating physical activity throughout their workday as well as the health risks of a sedentary lifestyle. Suggestions and demonstrations of physical activity will be given including but not limited to: use a restroom further away from their workstation, take a brief walk around the office, walk-in place, stretch. In addition, they will record their steps via the Amazfit BIP device and submit their daily step counts for weeks: 1,2,4, 6 and 8.
89172371|NCT04042610|No Intervention|Control Group|The control group will be given an Amazfit BIP device to record their steps. They will submit their daily steps counts for weeks: 1,2,4, 6 and 8.
89172372|NCT04027075|Experimental|Intervention|This group will be asked to use the Rewire app daily in the month following the baseline assessment. This group will also receive services as usual from the Department of Youth Services.
89172373|NCT04027075|No Intervention|Services as usual|This group will receive services as usual from the Department of Youth Services.
89172374|NCT04016285|Experimental|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
89172375|NCT04016285|Active Comparator|Standard of Care: Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
89172376|NCT04007770|Experimental|Acupuncture|
89172377|NCT04007770|Sham Comparator|Sham Acupuncture (SA)|
89172378|NCT04007770|Other|Wait-List Control|This arm is Closed to accrual.
89172379|NCT03977662|Experimental|PTG with adult pancreatic islet co-transplantation|People with Type 1 (c-peptide negative) diabetes with stable kidney or liver allografts on chronic immunosuppression who receive study intervention, which is co-transplantation of allogeneic parathyroid (PTG) with adult pancreatic islets in people with Type 1 diabetes in the intramuscular (IM) site
89172380|NCT03977363||Anticoagulated patients|Patients receiving anticoagulation treatment
89172381|NCT03973502|Experimental|18F-DOPA PET|PET/CT
89172382|NCT03950674|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression (up to 35 treatment administrations; up to approximately 2 years).
89172383|NCT03950674|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression (up to 35 treatment administrations; up to approximately 2 years).
89172384|NCT03949972||A - Pediatric Cohort|Pediatric patients until 18 years of age presenting with or diagnosed with idiopathic nephrotic syndrome or a biopsy-proven diagnosis of MCD or FSGS.
89172385|NCT03949972||B -Adult Cohort|Adult patients 18 years and above with a biopsy-proven diagnosis of primary or secondary FSGS or MCD.
89172386|NCT03911661|Active Comparator|Standard Management|The standard management phase will be historical and consist of warfarin management during the 12-months prior to signing informed consent.
89172387|NCT03911661|Experimental|Fearon Algorithm (FA) Anticoagulation Management Service|Once study patients have received an approved FA report, the FA AMS phase of the study will commence. An investigator will communicate the new warfarin tablet size, if necessary, and use the FA report to determine warfarin doses for the patient.
89172388|NCT03911661|Experimental|Fearon Algorithm (FA) Patient Self Management|At the conclusion of the six-month FA anticoagulation management service phase, patients will be trained to use the FA for patient self management (PSM) and after successfully demonstrating the ability to engage in PSM the FA PSM phase of the study will commence.
89172389|NCT03909477||Cannabis Smoker|Participants in this group will be current or former cannabis smokers
89172390|NCT03898856|Experimental|Crofelemer and Diagnostic tests for cause of chronic diarrhea|125 mg tablets taken by mouth twice daily for 28 days
89172391|NCT03874923|Active Comparator|250 mL of fluid challenge|
89172392|NCT03874923|Experimental|500 mL of fluid challenge|
89172393|NCT03872414|Experimental|Healthy Younger Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
89172394|NCT03872414|Experimental|Healthy Older Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
89172395|NCT03872414|Experimental|Parkinson Disease Group|Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
89172396|NCT03872414|Active Comparator|Control Group|Participants will receive rt-fMRI training to increase primary auditory cortex activation.
89172401|NCT03837041|Active Comparator|Reconditioning Proprioception group|Training Proprioception 1 hour for 2 day a week
89172402|NCT03837041|No Intervention|Control group|
89172403|NCT03836755|Other|METACOS|Required to do some motor tasks during static and dynamic RSA
89172404|NCT03826147|Active Comparator|Nitrate-rich beetroot juice|Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.
89172405|NCT03826147|Placebo Comparator|Nitrate-depleted beetroot juice|Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
89172406|NCT03803618||Confirmed dengue case|Dengue cases who are 9-14 years old during the dengue mass vaccination program in Cebu with <5 days history of fever, admitted in the participating hospitals with dengue virus confirmation by RT-PCR
89172407|NCT03803618||Control|Age and sex matched neighborhood controls
89172408|NCT03782623||Intensive care patients after elective open aortic surgery|
89172409|NCT03782623||Intensive care patients after bilateral lung transplantation|
89172410|NCT03782623||Anesthetic intensive care patients, unplanned admission|
89172411|NCT03749538|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: three times, once per day.
89172412|NCT03749538|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session.
89172413|NCT03711604|Experimental|Tenalisib|Participants receive Tenalisib (RP6530) BID Orally
89172414|NCT03708627|Experimental|Bimatoprost in more proptotic eye|Patients instill Bimatoprost in their more proptotic eye one nightly
89172415|NCT03708627|No Intervention|Control|Bimatoprost is not instilled in the patient's fellow eye
89172416|NCT03702621|Active Comparator|Liposomal Bupivacaine|"LB (Liposomal Bupivacaine) group - This group will be receiving 20 mL EXPAREL (266mg) and 40 mL of 0.125% bupivacaine in total, 30ml on each side.~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
89172417|NCT03702621|Active Comparator|Standard Bupivacaine|"SB (Standard Bupivacaine) group - This group will be receiving 60 mL of 0.25% bupivacaine in total, 30 mL on each side.~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
89172418|NCT03691441|Experimental|Resection/adjuvant radio(-chemo)therapy|"Transoral surgical resection within 4 weeks after randomization~Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization~6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery"
89172419|NCT03691441|Active Comparator|Adjuvant radio(-chemo)therapy/salvage neck dissection|"6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization~70-72 Gy, SIB possible~Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33~+/- Salvage neck dissection 12±2 weeks after treatment"
89172420|NCT03688295|Other|experimental group|no antibiotherapy post surgery for complicated acute appendicitis (CAA)
89172421|NCT03688295|Active Comparator|control group|antibiotherapy post surgery for complicated acute appendicitis (CAA)
89172422|NCT03677544||no intraoperative FS examination|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation. procedures were performed between 1980 and 2013
89172423|NCT03677544||intraoperative FS examination|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation procedures were performed between 2001 and 2013
89172424|NCT03655665|Experimental|Treatment Ear|Participants will serve their own control. Participants will receive 3 drops of ofloxacin otic solution intra- and post-operatively 3 times per day for 3 days in ONE ear. Ear sidedness will be randomized by participant.
89172425|NCT03655665|No Intervention|No Intervention|Participants will serve their own control. Participants will receive no intervention in the ear contralateral to the treated ear. Ear sidedness will be randomized by participant.
89172426|NCT03641690||27 case|Twenty-seven patients were admitted to the ICU with severe pneumonia and with a high probability of viral infection or a previously confirmed diagnosis received Empirical antimicrobial therapy
89172427|NCT03641690||70 control|70 healthy subjects (HS) among blood donors attending the Regional Center for Blood Transfusion (Lille, France).
89172428|NCT03633370|No Intervention|Control Group|Usual management of patients according to international guidelines. Protocols of call acceptance, phone advice and sending of emergency services are not modified
89172429|NCT03633370|Other|Test Group|"Multifaceted intervention~Training using distance learning for medical regulation assistants to recognise cardiac arrest on phone~Activation of the location-software application to send bystanders on cardiac arrest location before the arrival of emergency medical services (EMS)~Motivation feed-back Volunteers will received feed-back regarding CPR initiated before EMS arrival and survival"
89172430|NCT03625752|Active Comparator|Active Comparator: Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
89172431|NCT03625752|Sham Comparator|Sham|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
89172432|NCT03604627|Other|Patients treated for cancer during childhood or adolescence|Patients over the age of 18 treated during childhood or adolescence for cancer with irradiation affecting the heart area (≥20% of ≥5Gy heart volume) and / or anthracyclines (≥ 300mg/m^²)
89172433|NCT03577990|Experimental|Interactive Technology Enhanced Coaching (ITEC)|Fitbit Plus monitoring will include BP, weight measurements, daily food intake, self-report medication-taking, and physical activity plus weekly Interactive Technology-Enhanced Coaching (ITEC) for 3 months, then biweekly ITEC for 3 months, followed by another 3 months with no coaching to assess for sustainability.
89172434|NCT03577990|Active Comparator|Interactive Technology-No Coaching (IT)|Participants will receive usual care for 3 months followed by 6 months of only Fitbit Plus monitoring (with no ITEC) of BP, weight measurements, daily food intake, self-report medication-taking, and physical activity to be used for comparative data with the treatment arm.
89172435|NCT03565497|Placebo Comparator|Wellness Education Control Condition|The wellness education control condition (CC) is modeled after that used in our studies of exercise for smoking cessation, but delivered in an individual format. Content focuses on discussions of a variety of healthy lifestyle topics, such as healthy eating, time management, recommended health screenings, and cancer and cardiovascular prevention. Content is delivered using a combination of lectures, videos, handouts, and discussions while allowing participants to set their own realistic wellness goals, which they can gradually incorporate into their lives.
89172436|NCT03565497|Experimental|Mindfulness Training (MT)|Mindfulness training will be adapted for 6 individual sessions;elements include: (1) a body scan designed to teach participants to pay attention to specific parts of their bodies as a strategy to increase attentional capacities/reduce habitual mind-wandering; (2) non-judgmental awareness, and (3) 'awareness of breath' meditation, with an additional focus on helping participants become more aware of the present moment and refrain from habitually engaging in self-related pre-occupations concerning the future or the past.
89172437|NCT03565497|Experimental|Mindfulness Training Plus IE (MT+IE)|This condition will mirror the MT condition for the first 4 individual sessions, then for the final 2 individual sessions, MT will be rehearsed under conditions of sensations of anxiety/tension induced by interoceptive exposure procedures (IE).
89172438|NCT03519581|Active Comparator|Micropulse Laser Treatment|"Subjects assigned to the micropulse laser arm of the trial will undergo the following procedures:~Confirmation of the subject's identity and eye to be treated~Subject's eye will be dilated~Subject will be positioned at the slit lamp for treatment~Application of subthreshold micropulse laser using the Iridex IQ577 laser unit. (intermittent pulsed energy) in a 7 X 7 grid pattern surrounding the fovea."
89172439|NCT03519581|Placebo Comparator|Sham Treatment|"Subjects assigned to the sham arm of the trial will undergo the following procedures:~Confirmation of the subject's identity and eye to be treated~Subject's eye will be dilated~Subject will be positioned at the slit lamp for treatment~No Actual laser treatment will occur"
89172440|NCT03516656|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively and transitioned to a weight-based dose by their surgeons. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
89172441|NCT03516656|Active Comparator|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged
89172442|NCT03515603|Active Comparator|microsurgical technique|
89172443|NCT03515603|Active Comparator|endoscopic technique|
89172444|NCT03479905|Sham Comparator|Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 36%
89172445|NCT03479905|Sham Comparator|Face mask group|A standard face mask will be used at 8L/minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 60%.
89172446|NCT03479905|Experimental|High Floow Oxygen delivery|Oxygen will be delivered by using high flow nasal cannula
89172447|NCT03478462|Experimental|CLR 131|CLR 131 intravenous administration
89172448|NCT03476226|Experimental|Group 1|"The research team will provide the intervention to subjects. Intervention: The nursing-driven Cognitive Dysfunction Coping Strategy Teaching Sheet and provide education as to its use.~QOL survey administered"
89172449|NCT03476226|No Intervention|Group 2|Provide current standard of education for cognitive dysfunction. QOL survey administered
89172450|NCT03465254||Cohort|Recruited members of the cohort are children aged 9-14 years old and eligible to receive the dengue vaccine at the time of the initiation of community-based dengue immunization program of the Department of Health.
89172451|NCT03458884|Experimental|Cardiorespiratory interval training|Cardiorespiratory interval training program on ergometer cycle, 30-40 minutes, 3 days a week for 8 weeks.
89172452|NCT03458884|No Intervention|Usual care|Usual ESD care including information about post-stroke fatigue, support and practical advice about how to identify and manage fatigue symptoms in daily tasks, such as the adaptation and prioritization of activities, physical activity and rest.
89172453|NCT03416270|Experimental|Ertuglifozin Treatment Arm|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks
89172454|NCT03416270|Placebo Comparator|Placebo Arm|Placebo Matching Ertugliflozin Tablet for 12 weeks
89172455|NCT03362931|Experimental|XEN45 Glaucoma Treatment System (hereafter referred to as XEN)|XEN45 unilaterally implanted in the study eye
89172456|NCT03360019|Active Comparator|Residents in memory care or skilled nursing Facility|
89172457|NCT03360019|Active Comparator|Resident in independent living setting|
89172458|NCT03360019|Other|Care Partners|
89172459|NCT03282097|Experimental|Mammogram decision aid|Will be mailed the DECAD decision aid before their next PCP visit in order to better inform their decision to continue or stop mammography.
89172460|NCT03282097|Active Comparator|Home safety guide|The home safety guide is a two-page paper pamphlet developed by the American Geriatrics Society Foundation for Health in Aging. It provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards. We selected the home safety guide to account for the attention given to the intervention group but not to provide information that would bias the control group away from talking about mammography with the patient's PCP.
89172461|NCT03245008|Experimental|MT-5547 dosing regimen 1|MT-5547 Subcutaneous (SC) dosing regimen 1. Naproxen-matching placebo oral after Week 16.
89172462|NCT03245008|Experimental|MT-5547 dosing regimen 2|MT-5547 SC dosing regimen 2. Naproxen-matching placebo oral after Week 16.
89172463|NCT03245008|Placebo Comparator|MT-5547-matching placebo|MT-5547-matching placebo SC dosing. Naproxen oral after Week 16.
89172464|NCT03203473|Experimental|Overall cohort: Initial Primary Treatment with Nivolumab (induction phase)|"Therapy with nivolumab IV every 2 weeks~Serial imaging assessments every 8 weeks~After confirmatory scans, patients are assigned to Arm A or Arm B."
89172465|NCT03203473|Experimental|Arm A: Observation Arm (for patients with persistent response to induction nivolumab)|"Patients with persistent response (complete or partial response) to induction nivolumab are assigned to Arm A (Observation Arm).~Patients discontinued nivolumab after allocation to Arm A.~Serial imaging assessments every 8 weeks.~If scans persistently show PR/CR, patients remained on observation.~If progressive disease develops, therapy with nivolumab (480 mg IV every 4 weeks) will be resumed.~If there is subsequent progression on nivolumab monotherapy, ipilimumab (1 mg/kg IV every 3 weeks x 2 doses) is added.~If progression after nivolumab + ipilimumab, therapy discontinued. If SD/PR/CR, nivolumab is continued until progression."
89172466|NCT03203473|Experimental|Arm B: Nivolumab+Ipilimumab then nivolumab alone (for patients with SD/PD to induction nivolumab)|"Patients with confirmed SD/PD to induction nivolumab are allocated to Arm B (Combination Therapy Arm).~In combination therapy, patients received nivolumab 3 mg/kg and ipilimumab 1 mg/kg intravenously every 3 weeks for two doses.~After then nivolumab will be continued at 480 mg IV every 4 weeks until disease progression.~Arm B patients undergo imaging at 12 weeks and then every 8 weeks."
89172467|NCT03201094|No Intervention|Standard of Care|Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.
89172468|NCT03201094|Experimental|HPRO + NMES|Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.
89172469|NCT03201094|Experimental|NMES only|Patients will undergo two 30 minute NMES sessions per day during study period.
89172470|NCT03201094|Experimental|HPRO only|Patients will receive HPRO three times daily during study period
89172471|NCT03185208|Experimental|Lithium carbonate|Lithium carbonate will be initiated at 150 mg per day and increased based on blood levels until a steady blood level between 0.6 and 0.8 meq/L is achieved. Participants will continue at the dose achieved for 2 years with quarterly monitoring.
89172472|NCT03185208|Placebo Comparator|placebo|Matching placebo will be initiated and increased based on pretend blood levels. Participants will take placebo for 2 years with quarterly monitoring.
89172473|NCT03158051|Experimental|Intervention|Telephone health coaching, home blood pressure monitoring, individualized goal setting, and tailored educational materials
89172474|NCT03158051|No Intervention|Usual clinical care|Usual care arm participants will receive routine hypertension clinical care per their primary care provider.
89172475|NCT03140644|Experimental|Patients with thoracic sarcoidosis|Patients routinely followed-up for thoracic sarcoidosis with a CT scan indicated in the follow-up
89172476|NCT03117179|Other|Patient with an interview|
89172477|NCT03117179|Other|Patient without an interview|
89172478|NCT03115567|No Intervention|Control|Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
89172479|NCT03115567|Experimental|Triamcinolone|Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.
89172480|NCT03114930|Other|Standard output|
89172481|NCT03114930|Other|Non standard output|
89172482|NCT03103698|Other|Monitoring of perioperative analgesia by the ANI device|
89172483|NCT03103698|Other|conventional monitoring based on hemodynamic variations.|
89172484|NCT03092180||Idiopathic inflammatory myopathies 1|Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset
89172485|NCT03092180||Idiopathic inflammatory myopathies 2|Intravenous infusion with methyprednisolone at disease onset
89172486|NCT02982902|Experimental|CMV specific adoptive t-cells|This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.
89172487|NCT02976636|Active Comparator|Family-based behavioral therapy (FBT)|Family-based behavioral therapy for pediatric weight loss
89172488|NCT02976636|Experimental|Parenting training and FBT|Family-based behavioral therapy for pediatric weight loss + parenting training to enhance outcomes
89172489|NCT02964559|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89172490|NCT02893293|Active Comparator|Ferumoxytol-enhanced MRI|Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
89172491|NCT02893293|Sham Comparator|Non-ferumoxytol enhanced MRI|Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.
89172492|NCT02725905|Experimental|Multi-Modal Education (MME)|1) The MME is a three year multi-modal educational intervention including a series of interactive learning components and interventions focused on integrated weight management counseling. Prior to its launch, each component of the curriculum will be refined using a school participatory approach to help ensure feasibility and acceptability.
89172493|NCT02725905|Active Comparator|Traditional Education (TE)|2) The TE arm of the study includes the school's current curriculum which may include topics related to the treatment of weight management and obesity.
89172494|NCT02691923|Active Comparator|Fluorescein|Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
89172495|NCT02691923|Experimental|Fluorescein + ALA|"Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.~ALA administered orally at 20mg/kg approximately 3 hours before surgery."
89172496|NCT02600507|Experimental|Lumateperone 28 mg (ITI-007 40 mg tosylate)|Lumateperone 28 mg (ITI-007 40 mg tosylate) administered orally as capsules once daily for 6 weeks
89172497|NCT02600507|Experimental|Lumateperone 42 mg (ITI-007 60 mg tosylate)|Lumateperone 42 mg (ITI-007 60 mg tosylate) administered orally as capsules once daily for 6 weeks
89172498|NCT02600507|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
89172499|NCT02578680|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
89172500|NCT02578680|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. With Amendment 10 (effective date: 23-Dec-2019), all participants will discontinue saline placebo. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.
89172501|NCT02464072|Experimental|Subtotal Parathyroidectomy|Patients will be submitted to subtotal parathyroidectomy. The intention is to leave a parathyroid remanent equivalent to two normal parathyroid glands in situ. The type of the operation is the intervention. No drugs or devices are tested.
89172502|NCT02464072|Active Comparator|Total Parathyroidectomy + 45 autografts|Patients will be submitted to a total parathyroidectomy and 45 fragments of parathyroid tissue are grafted in the forearm. This is the current standard treatment at the institution for severe secondary hyperparathyroidism.The type of operation is the intervention itself. No new device or drug is involved.
89172503|NCT02464072|Experimental|Total Parathyroidectomy + 90 autografts|Patients will be submitted to a total parathyroidectomy and 90 fragments of parathyroid tissue are grafted in the forearm. The type of operation is the intervention. No new device or drug is involved. .
89172504|NCT02459171||Participants|"Subjects who meet eligibility requirements and consent to participate.~Interventions: Blood sample, nasal wash, throat swab, questionnaire"
89172505|NCT02385266|Experimental|D-Cycloserine and Acetominophen|D-cycloserine 200mg/bid and Acetaminophen prn
89172506|NCT02385266|Placebo Comparator|Placebo and Acetominophen|Placebo capsules (lactose)/bid and Acetaminophen prn
89172507|NCT02381106||Women with preeclampsia|Women delivered by cesarian section and with preeclampsia
89172508|NCT02381106||Women with dysfunctional labor|Women delivered with cesarian section due to dtsfunctional labor
89172509|NCT02381106||Women with cesarian section due to maternal request|Women with cesarian section due to maternal request
89172510|NCT02381106||Women with preamture labor|Women with pemature labor undergoing cesarian section
89172511|NCT02379988|Experimental|Verify radiation dose to heart and lung|Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT. Inspiratory gated breath-hold will be used. Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold. The cardiac and lung doses will be determined. At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
89172512|NCT02351765|Experimental|Acelarin & Cisplatin|"The maximum tolerated dose (MTD) of Acelarin in combination with 25mg/m2 Cisplatin will be determined.~The starting dose will be 625mg/m2 Acelarin which will be escalated to 725mg/m2 if the criteria for dose escalation is met (i.e. the proportion of dose limiting toxicities is acceptable as detailed in the protocol). Escalation will continue in accordance with the protocol up to a maximum of 925mg/m2. Only if the MTD is exceeded at the starting dose level (at least 2 of 3 participants or at least 2 of 6 participants have DLT at the first dose level) will there be a de-escalation to 500mg."
89172513|NCT02263300||Supine- Supine|Group A (supine-supine) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global rating scale and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the SUPINE then UPRIGHT position. At the end of one week,the same medical student will then perform the intubation with the mannequin in both positions.
89172514|NCT02263300||Upright-upright|Group B (upright-upright) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the UPRIGHT then SUPINE position.At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
89172515|NCT02263300||Supine -upright|Group C( supine -upright) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the UPRIGHT then SUPINE position. At the end of one week, The same medical student will then perform the intubation with the mannequin in both positions.
89172516|NCT02263300||Upright - supine|Group D( upright - supine) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the SUPINE then UPRIGHT position. At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
89172517|NCT02251431|Experimental|Exenatide-extended release|Exenatide-extended release (BYDUREON™) 2 mg subcutaneously once per week x 38 weeks
89172518|NCT02251431|Placebo Comparator|Placebo|Matching placebo subcutaneously once per week x 38 weeks
89172519|NCT02191488|Experimental|Experimental: 5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
89172520|NCT02006069|Experimental|MPP ON|MPP ON: feature is enabled
89172521|NCT02006069|No Intervention|MPP OFF|MPP OFF: feature not enabled
89172522|NCT01985867|Experimental|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 8×10^8 colony forming units (CFU), twice daily, orally for 4 weeks
89172523|NCT01985867|Placebo Comparator|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
89172524|NCT01837745|Active Comparator|Ablation group|"Administration of 1.1 GBq of I131 is given after the second intramuscular injections of rhTSH (0.9 mg). A whole body scan (WBS) is performed 2 to 5 days after the administration or I131 with determination of the neck uptake.~Follow-up consists in:~10 (+/- 2 months) after randomization: neck ultrasound + a serum Tg measurement after rhTSH stimulation~2 years (+/- 2 months) after randomization: serum Tg measurement under LT4 treatment (Tg/LT4)~3 years (+/- 2 months) after randomization: neck ultrasound and a serum Tg/LT4~4 years (+/- 2 months) after randomization: a serum Tg/LT4~5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
89172525|NCT01837745|Experimental|Follow up group|Patients randomized in the follow up group neither received 131I nor rhTSH. Patients will undergo the same followup procedures as patients randomized to the ablation group, except that at 10 months after randomization, Tg will be measured under LT4 treatment and not after rhTSH stimulation.
89172526|NCT01495234|Experimental|Cohort 1|Each patient will receive 15mg of rhBMP-2 in rhBMP-2/BCP device and implant unilaterally during a posterolateral spinal fusion procedure. The contralateral side was fused using standard fusion techniques with autograft bone.
89172527|NCT01495234|Experimental|Cohort 2|Each patient will receive 20mg of rhBMP-2 in rhBMP-2/BCP device and implant bilaterally.
89172528|NCT01494493|Experimental|rhBMP-2/ACS|
89172529|NCT01494493|Active Comparator|Autogenous Bone|
89172530|NCT01494454|Experimental|rhBMP-2/BCP|
89172531|NCT01494454|Active Comparator|Autograft|
89172532|NCT01494441|Experimental|rhBMP-2/BCP|
89172533|NCT01494441|Experimental|rhBMP-2/BCP/TSRH® Spinal System|
89172534|NCT01494441|Active Comparator|Autograft/TSRH® Spinal System|
89172535|NCT01494428|Experimental|rhBMP-2/ACS|
89172536|NCT01494428|Active Comparator|Autogenous Bone|
89172537|NCT01491542|Experimental|rhBMP-2 / ACS|
89172538|NCT01491542|Active Comparator|Autogenous bone|
89172539|NCT01491464|Experimental|rhBMP-2/ACS|
89172540|NCT01491464|Active Comparator|Autogenous bone|
89172541|NCT01491451|Experimental|rhBMP-2/ACS|
89172542|NCT01491451|Active Comparator|Autogenous bone|
89172543|NCT01491425|Experimental|rhBMP-2/ACS|
89172544|NCT01491425|Active Comparator|Autogenous Bone|The control group of patients from another study (Protocol ID: C-9702 Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic DDD).
89172545|NCT01491399|Experimental|INFUSE™ Bone Graft/CORNERSTONE-SR™|
89172546|NCT01491399|Active Comparator|Autogenous bone/CORNERSTONE-SR™|
89172547|NCT01491386|Experimental|rhBMP-2/ACS|
89172548|NCT01491386|Active Comparator|Autogenous Bone|
89172549|NCT01367002|Active Comparator|Carboplatin/Paclitaxel|Chemotherapy
89172550|NCT01367002|Experimental|Trastuzumab|Monoclonal antibody
89172551|NCT01124214|No Intervention|High Resolution endoscopy (HRE)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN
89172552|NCT01124214|Active Comparator|Endomicroscopy (EM)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN and endomicroscopy esophageal evaluation
89172553|NCT00858273|Active Comparator|Antioxidant Supplement|Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg
89172554|NCT00858273|Placebo Comparator|Placebo|
89172555|NCT00624234|Experimental|NF-Tutoring Program 1|Tutoring Program I
89172556|NCT00624234|Experimental|NF-Tutoring Program 2|Tutoring Program II
89172557|NCT00624234|No Intervention|Typically Developing Readers|Control group
89172558|NCT00624234|Experimental|IRD-Tutoring Program 1|Tutoring Program I
89172559|NCT00624234|Experimental|IRD-Tutoring Program 2|Tutoring Program II
89172560|NCT00624234|No Intervention|Waitlist Control|Intervention Control Group (RD)
89172561|NCT04158167|Other|oxytocin|All subjects will receive both oxytocin and placebo in a counterbalanced design
89172562|NCT00659555|Experimental|Treatment A receivers|Subjects received pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution in Period 1
89172563|NCT00659555|Experimental|Treatment B receivers|Subjects received ketoconazole, daily 400 mg oral dose on Days 1 to 8; pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution on Day 5 in Period 2
89172564|NCT02635997||patients on antiresorptive therapy|Ibandronate 150 mg per month + Vitamine D 400-800 IU and Calcium 500-1000 mg per day
89172565|NCT00659867|Experimental|A|Chromoscopy-guided endomicroscopy with targeted biopsies
89172566|NCT00659867|Active Comparator|B|Standard endoscopy with random and targeted biopsies
89172567|NCT00660101|Experimental|1|5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
89172568|NCT00660101|Experimental|2|2.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
89172569|NCT00660101|Experimental|3|0.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
89172570|NCT02635607|Other|Fixed Protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start fixedly on stimulation Day 5. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
89172571|NCT02635607|Other|Flexible protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start flexibly by the promissory criterion in the flexible group. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
89172572|NCT04156841||performed SLNB using a single mapping agent|
89172573|NCT04156841||performed SLNB by combination of blue dye and radiotracer|
89172574|NCT04156841||underwent SLN surgery receiving neoadjuvant chemotherapy|
89172575|NCT04156841||underwent SLN surgery not receiving neoadjuvant chemotherapy|
89172576|NCT00660257|Experimental|No.1: 1.25 ug|
89172577|NCT00660257|Experimental|No.2: 2.5 ug|
89172578|NCT00660257|Experimental|No.3: 5.0 ug|
89172579|NCT00660257|Experimental|No. 4: 10 ug|
89172580|NCT00844428|Experimental|Eculizumab|
89172581|NCT00660335|Experimental|1|
89172582|NCT00660413|Experimental|AMG|Acceleromygraphy monitoring
89172583|NCT00660413|Active Comparator|MMG|Mechanomyography monitoring
89172584|NCT04156685|Experimental|PartA, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
89172585|NCT04156685|Experimental|PartA, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
89172586|NCT04156685|Experimental|PartB, Treatment-1|Period 1 : Reference drug Period 2 : Test drug
89172587|NCT04156685|Experimental|PartB, Treatment-2|Period 1 : Test drug Period 2 : Reference drug
89172588|NCT00707772|Active Comparator|1|Genotype 2 or 3 in Hemophilic Patients with HCV
89172589|NCT00707772|Active Comparator|2|Other Genotypes (except 2 or 3) in Hemophilic Patients with HCV
89172590|NCT00660491|No Intervention|1|Control
89172591|NCT00660491|No Intervention|2|moderate exercise training group
89172592|NCT00660491|Experimental|3|high intensity exercise group
89172593|NCT02611284|Experimental|Treatment Cohort (LISA)|All preterm infants born at < 32 WG between October 2013 and November 2014 who met inclusion criteria were managed by the new LISA technique.
89172594|NCT02611284|Other|Historical Cohort (INSURE)|The control group was collected from the period immediately before the study's initiation (from Jun 2012 to September 2013). This cohort was comprised of preterm infants of less than 32 WG who met the inclusion criteria.
89172595|NCT00660569||1|Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA
89172596|NCT02535377||High cryoresistance|High resistance to sperm cryopreservation (decreased sperm motility <20%)
89172597|NCT02535377||Low cryoresistance|Low resistance to sperm cryopreservation (decreased sperm motility >20%)
89172598|NCT00834834|Active Comparator|Fluoxetine|Participants will receive fluoxetine with clinical management, which may involve switching medication to citalopram, another SSRI.
89172599|NCT00834834|Active Comparator|Dialectical behavior therapy|Participants will receive dialectical behavioral therapy (DBT).
89172600|NCT02631863|Experimental|ALA|Patients will receive 3 topical treatments of aminolaevulinic acid 500mg
89172601|NCT02631863|Placebo Comparator|Placebo|Patients will receive 3 topical treatments of placebo 500mg
89172602|NCT00834366|Experimental|Tramadol HCl 200 mg Film-coated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
89172603|NCT00834366|Experimental|Tramadol HCl 200 mg Uncoated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
89172604|NCT04157933|Experimental|A-1a|Part A, Arm 1 (active), Dose 1 (009-A1)
89172605|NCT04157933|Experimental|A-2a|Part A, Arm 2 (active), Dose 2 (009-A2)
89172606|NCT04157933|Experimental|A-3a|Part A, Arm 3 (active), Dose 3 (009-A3)
89172607|NCT04157933|Placebo Comparator|A-0p|Part A, placebo comparator in all 3 arms, placebo dose (009-A0)
89172608|NCT04157933|Experimental|B-1 (009-B3 -> 009-B0)|Crossover (active to placebo)
89172609|NCT04157933|Experimental|B-1 (009-B0 -> 009-B3)|Crossover (placebo to active)
89172610|NCT02631785|Experimental|Anxious group|Youth diagnosed with anxiety disorder will receive Cognitive Behavioral Therapy for reducing anxiety symptoms.
89172611|NCT02631785|No Intervention|Control group|Healthy youth will be recruited for comparison but their participant in the study will not include intervention.
89172612|NCT00704574||A|
89172613|NCT04157777|Experimental|massage|Among women who applied to Maternity Hospital 350 pregnant women were assigned to massage group. Participants in massage group filled out an information form including socio-demographic characteristics. Perineum massage with olive oil in the second period of delivery was performed to massage group.In massage group when they progressed to full dilatation of the cervix, the midwife inserted two fingers inside vagina and using a sweeping motion gently stretched the perineum with lubricant 5 up to 10 minutes, in and between mother's pushing in the second stage of labour.
89172614|NCT04157777|Experimental|control|Among women who applied to Maternity Hospital 350 pregnant women were assigned to control group. Participants in control group filled out an information form including socio-demographic characteristics.And, no other interventions except for applications performed routinely in the delivery room were done.In control group just Ritgen Maneuver was applied. At last, we com-pared the rate of intact perineum, episiotomy and laceration, mean duration of the second stage of labor and Apgar score in 1 and 5 minutes be-tween two groups.
89172615|NCT04156529|Experimental|ESU position|Firstly, the semi-elevated supine position was given to participants during tube feeding
89172616|NCT04156529|Experimental|ESRL position|Firstly, the semi-elevated right lateral position was given to participants during tube feeding
89172617|NCT00660647|Experimental|methotrexate + adalimumab|Methotrexate and intraarticular triamcinolone hexacetonide plus adalimumab.
89172618|NCT00660647|Placebo Comparator|methotrexate + placebo|Methotrexate and intraarticular triamcinolone hexacetonide and placebo
89172619|NCT02632097|Experimental|Histoacryl|Intervention: Lichtenstein Hernioplasty with Histoacryl™(cyanoacrylate glue 0.5 ml) for mesh fixation (Optilene™ mesh 60 g/m2 (B. Braun))
89172620|NCT02632097|Experimental|Suture|Intervention: Lichtenstein Hernioplasty with Sutures (polypropylene 2/0) to fix the Optilene™ mesh 60 g/m2 (B. Braun)
89172621|NCT04156451|Active Comparator|Central Venous Pressure 8 - 10 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 8-12 mmHg is reached
89172622|NCT04156451|Experimental|Central Venous Pressure 0 - 4 mmHg|Furosemide deresuscitation or crystalloid loading until the CVP target 0-4 mmHg is reached
89172623|NCT00660725|Other|Vandetanib/GEMOX|All subjects receive the same combination study drug and follow the same study schedule. As a phase 1 study, only the doses will vary between subjects.
89172624|NCT00844194|Other|DPNP with depression (1)|Patients that have diabetic polyneuropathy and depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
89172625|NCT00844194|Other|DPNP with depression (2)|Patients that have diabetic polyneuropathy and depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
89172626|NCT00844194|Other|DPNP without depression (1)|Patients that have diabetic polyneuropathy and no depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
89172627|NCT00844194|Other|DPNP without depression (2)|Patients that have diabetic polyneuropathy and no depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
89172628|NCT02632253|Active Comparator|Moderate intensity continuous exercise|"Patients perform two weekly supervised MICE session on a cycling ergometer per week plus one self monitored 30-60 min MICE training of choice at home.~MICE is performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down)."
89172629|NCT02632253|Experimental|High intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min.~Additionally patients perform one self monitored 30-60 min MICE training of choice per week at home."
89172630|NCT04157387|Experimental|Cyriax inferior capsular stretching + Manual Therapy|"Cyriax inferior capsular stretching~+ Electrotherapy Manual therapy : Kaltenborn grade 1 and 2 Mobilization~Active ROM exercises :~Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction"
89172631|NCT04157387|Active Comparator|Manual Therapy|Analgesic short-wave diathermy Manual Therapy: Kalternbon grade 1 and 2 Mobilization :, Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction.
89172632|NCT00660803||1|Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
89172633|NCT04157543|Experimental|electroacupuncture|electroacupuncture at points after surgery
89172634|NCT04157543|Sham Comparator|electroacupuncture non-point|electroacupuncture at non-points after surgery
89172635|NCT04157543|No Intervention|Control group|only injection painkiller were used before surgery
89172636|NCT00661115|Experimental|Arm 1|
89172637|NCT00661115|Placebo Comparator|Arm 2|
89172638|NCT04157699|Experimental|QL-007 100 mg QD + TDF|QL-007 tablet 100 mg QD was combined with TDF tablet 300mg
89172639|NCT04157699|Experimental|QL-007 200 mg QD + TDF|QL-007 tablets 200 mg QD were combined with TDF tablet 300mg
89172640|NCT04157699|Experimental|QL-007 400 mg QD+ TDF|QL-007 tablets 400 mg QD were combined with TDF tablet 300mg
89172641|NCT04157699|Experimental|QL-007 200 mg BID+ TDF|QL007 tablets 200 mg BID were combined with TDF tablet 300mg
89172642|NCT04157699|Active Comparator|TDF monotherapy|TDF tablet 300mg
89172643|NCT00665717|Active Comparator|A|Pravastatin 40 mg QD for 4 days
89172644|NCT00665717|Active Comparator|B|Raltegravir 400mg BD for 4 days
89172645|NCT00665717|Experimental|C|Interaction between pravastatin and raltegravir
89172646|NCT02611596|Experimental|Ranolazine|Subjects will take one 500mg tablet twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
89172647|NCT02611596|Placebo Comparator|Placebo|Subjects will take one placebo tablet (identical to the 500mg Ranolazine tablet) twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
89172648|NCT00661349|Active Comparator|1|Nevirapine
89172649|NCT00661349|Experimental|2|Lopinavir/ritonavir
89172650|NCT00702858|Active Comparator|1|Blue Citrus either months 1-3 or 4-6
89172651|NCT00702858|Placebo Comparator|2|Placebo
89172652|NCT00665795||1Patients with Graves´orbitophathy.|Patients with Graves´orbitophathy.
89172653|NCT00665795||2 Patients with detected DON|Patients with Graves´orbitophaty and detected dysthyroid optic neuropathy (DON)
89172654|NCT00704652||A|Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
89172655|NCT00704652||B|Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.
89172656|NCT04156607|Experimental|Kinesio taping group (KT)|"Kinesio taping applied to plantar soles of these children with Down Syndrome. Epidermis-Dermis-Fascia technique was used for providing sensory input from soles.~The application was performed on both feet."
89172657|NCT04156607|Sham Comparator|Sham taping group (ST)|A random taping was performed using Kinesio tape but without using Kinesiotaping techniques for sham taping. The application was performed on both feet
89172658|NCT04156607|No Intervention|Healty control group|This group took no intervention but all balance assessments once.
89172659|NCT02631005|Experimental|Walk With Ease Participants|"Participants will receive a copy of the Walk With Ease workbook. This workbook provides guidance on walking safety and on how to start and maintain a regular walking program. It is designed to help participants increase their physical activity over a six-week period. Participants will complete self-reported outcomes questionnaires before and after completion of the program."
89172660|NCT00826176|Experimental|Sugammadex in Caucasian Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Caucasian subjects living in Europe.
89172661|NCT00826176|Experimental|Sugammadex in Chinese Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Chinese subjects living in China.
89172662|NCT00665873|Active Comparator|A|Antibiotics
89172663|NCT00665873|Active Comparator|B|No Antibiotics
89172664|NCT05297916|Active Comparator|delayed enteral feeding|delayed enteral feeding
89172665|NCT05297916|Active Comparator|early enteral feeding|early enteral feeding
89172666|NCT04156061|No Intervention|ASSIGN score|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.~Patients randomised to standard care with ASSIGN score alone (n=200) will be invited back approximately 6 months after baseline assessment. The detailed questionnaire, breath test, blood pressure monitoring, and 2-week activity monitor will be repeated. Bloods will be retaken to look at change in lipid levels and HbA1c where appropriate - no more than 30mls will be required."
89172667|NCT04156061|Active Comparator|CTCA - visual report|"Those in the CTCA group will be further randomised into review with or without CT images.~The review WITH images (VISUAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
89172668|NCT04156061|Active Comparator|CTCA - verbal report|"The baseline assessment will be completed on the same day as consent is gained. Every patients will complete a comprehensive assessment including questionnaires and objective assessments.~Those in the CTCA group will be further randomised into review with or without CT images.~The review WITHOUT images (VERBAL REPORT N=100) group will have results delivered by the principal investigator (a trained Cardiology Registrar) to ensure a standardised approach to relaying information. These results will be preliminary and focused only on whether the patient has evidence of coronary disease or not. A full report describing the extent of coronary disease, other cardiac problems and incidental findings will follow as per the SCOT-HEART-2 protocol. Patients will be made aware that the presented findings are a focused preliminary report and that a more detailed formal report will follow."
89172669|NCT00707850|Experimental|1|Thalassemic Patients with HCV
89172670|NCT00665951|Active Comparator|A|Kaletra tablets
89172671|NCT00665951|Experimental|B|Lopimune granules
89172672|NCT00665951|Experimental|C|Lopimune tablets
89172673|NCT02631707|No Intervention|Control Standard Protein Diet|Control Arm Ministry of Health guidelines percentage energy from carbohydrate (50-55%), protein (10-15%) and fat (30%).
89172674|NCT02631707|Experimental|Intervention High Protein Diet|Intervention Arm Percentage energy from carbohydrate (40%), protein (30%) and fat (30%).
89172675|NCT02631161|Experimental|EQUIA forte|Dental non-carious cervical restorations are being restored with a glass hybrid restorative system (Medical product: EQUIA forte).
89172676|NCT02631161|Active Comparator|Filtek Supreme XT/Clearfil SE Bond|Dental non-carious cervical restorations are being restored with a composite resin based material/Adhesive combination (Medical product: Filtek Supreme XT/Clearfil SE Bond).
89172677|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (high GI)|Subjects will consume meals which are high glycemic index for breakfast (Honey stars cereal), lunch (glutinous rice meal) and snack (white bread and jam) in the whole body calorimeter. A take-away high glycemic index dinner will be provided.
89172678|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (low GI)|Subjects will consume meals which are low glycemic index for breakfast (All bran cereal), lunch (basmati rice meal) and snack (multigrain bread and sugar-free jam) in the whole body calorimeter. A take-away low glycemic index dinner will be provided.
89172679|NCT00661739|Experimental|Singular Arm|Bendamustine treatment
89172680|NCT00878969|Active Comparator|Valsartan|80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
89172681|NCT00878969|Active Comparator|Ramipril|2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
89172682|NCT00878969|Placebo Comparator|Placebo|matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months
89172683|NCT02630849|Experimental|IMF group|intercostal muscle flap and pericostal no-compression suture of the intercostal space
89172684|NCT02630849|Active Comparator|IINB group|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
89172685|NCT02630927|Placebo Comparator|Part 1 Single-Ascending (SAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. A single dose of AG-519 will be administered by mouth (orally).
89172686|NCT02630927|Placebo Comparator|Part 2 Multiple-Ascending (MAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
89172687|NCT02630927|Experimental|Part 3 Bioavailability & Food Effect|The dose to be assessed in Part 3 will be selected based on emerging safety, tolerability and PK/PD data from preceding cohorts in Part 1 and Part 2, which will be reviewed during a dose decision meeting.
89172688|NCT02630927|Experimental|Experimental Part 4 (Subjects of Japanese Origin)|Two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3
89172689|NCT02630927|Experimental|Experimental Part 5 Open-label Multiple-Ascending (MAD)|Up to two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
89172690|NCT00843726|Experimental|Arm I|Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
89172691|NCT00843726|Experimental|Arm II|Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
89172692|NCT00661817|Active Comparator|1|Participants in this group will receive usual medical care and reading materials on weight loss.
89172693|NCT00661817|Experimental|2|Participants in this group will take part in the lifestyle modification program.
89172694|NCT02630771||PDAP only|Persistent dentoalveolar pain disorder patients who do not fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
89172695|NCT02630771||PDAP + TMD|Persistent dentoalveolar pain disorder patients who also fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
89172696|NCT02630771||Painfree controls|Painfree subjects. Pressure pain threshold before/during conditioned pain modulation.
89172697|NCT00843492|Active Comparator|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
89172698|NCT00843492|Experimental|Fondaparinux|After randomization (Day 1), subjects will receive subcutaneously, once daily, fondaparinux 2.5 mg (1.5 mg in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
89172699|NCT02631629|Placebo Comparator|Non-fortified foods SA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of South Asian (SA) origin
89172700|NCT02631629|Placebo Comparator|Non-fortified foods CA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of Caucasian (CA) origin
89172701|NCT02631629|Active Comparator|Vitamin D fortified foods SA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of South Asian (SA) origin
89172702|NCT02631629|Active Comparator|Vitamin D fortified foods CA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of Caucasian (CA) origin
89172703|NCT04156139|Active Comparator|Control group|NPPV treatment for patients will be performed for patients immediately after extubation in control group.
89172704|NCT04156139|Experimental|intervention group|HFNC treatment will be performed for patients immediately after extubation in the intervention group.
89172705|NCT00666185|Experimental|1|
89172706|NCT00666185|Active Comparator|2|
89172707|NCT00833976|Experimental|open-label Lovaza (omega-3 fatty acids)|4g per day (4g once a day or 2g two times a day) for 16 weeks
89172708|NCT00913224|Experimental|1|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
89172709|NCT00913224|Active Comparator|2|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)
89172710|NCT00666341|Placebo Comparator|Placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
89172711|NCT00666341|Experimental|20 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
89172712|NCT00666341|Experimental|40 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
89172713|NCT00666341|Experimental|80 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
89172714|NCT00666341|Experimental|120 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
89172715|NCT04154657|Experimental|biventricular conductance catheter|patients with indication for invasive assessment receive right and left heart catheter and parallel biventricular conductance catheter at rest and stress
89172716|NCT00833898|No Intervention|Caregiver Control|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
89172717|NCT00833898|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), which included one-on-one psychoeducation, stress management intervention, with paced respiration.
89172718|NCT00661973|Experimental|overall|
89172719|NCT00666575|Experimental|Gabapentin|
89172720|NCT00666575|Placebo Comparator|Placebo|
89172721|NCT00662051||OCP Users|
89172722|NCT00662051||Non-users of OCPs|
89172723|NCT00707928|Active Comparator|1|1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.
89172724|NCT00707928|Placebo Comparator|2|2=placebo with the same volume as NTG 100-200 microgram of IV.
89172725|NCT00662285|Other|A: Niferex|100 mg Fe++
89172726|NCT00666809|Active Comparator|Arm 1|
89172727|NCT00666809|Placebo Comparator|Arm 2|
89172728|NCT00666887|Active Comparator|Minocycline|Minocycline 100 mg oral for up to 24 months
89172729|NCT00666887|Placebo Comparator|Placebo|Lactose Monohydrate NF (Spray-dried) 235 mg/cap Magnesium Stearate NF 1 mg/cap Croscarmellose Sodium NF 4 mg/cap Stearic Acid 10 mg/cap Placebo CAP Lt orange OP-Purple OP (APO 100)
89172730|NCT02631473|Active Comparator|1st Stage-Group A|"Day 1: 50 mg NANO-efavirenz single dose~Days 4-21: 50 mg NANO-efavirenz OD (once daily)"
89172731|NCT02631473|Active Comparator|1st Stage-Group B|"Days 1-7: 400mg NANO-lopinavir BID (twice daily)~Days 8-21: Wash-out period~Days: 22-28: 200mg NANO-lopinavir BID plus 100mg Ritonavir (Norvir) BID"
89172732|NCT02631473|Active Comparator|2nd Stage-Group A-Group 1-Dose level 1|"21 Days: 300mg NANO-efavirenz OD~4 weeks: Wash-out period~21 days: 600mg Sustiva OD"
89172733|NCT02631473|Active Comparator|2nd Stage-Group A-Group 2-Dose level 2|"21 Days: 200mg NANO-efavirenz OD~4 weeks: Wash-out period~21 days: 400mg Sustiva OD"
89172734|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 1|"7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD~2 weeks: Wash-out period~7 days: NANO-lopinavir (200mg +/- ritonavir®)"
89172735|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 2|"7 days: NANO-lopinavir (200mg +/- ritonavir Norvir)~2 weeks: Wash-out period~7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD"
89172736|NCT00825162|Experimental|Cohort A|Participants aged 6 months to less than 3 years
89172737|NCT00825162|Experimental|Cohort B|Participants aged 3 years to less than 9 years
89172738|NCT00825162|Experimental|Cohort C|Participants aged 9 years to less than 18 years
89172739|NCT00662441|Experimental|Arm 1|
89172740|NCT04154501|Placebo Comparator|Cohort 1 Placebo|Oral Placebo Capsule
89172741|NCT04154501|Experimental|Cohort 1 Drug|25 mg Oral Capsule
89172742|NCT04154501|Placebo Comparator|Cohort 2 Placebo|Oral Placebo Capsule
89172743|NCT04154501|Experimental|Cohort 2 Drug|50 mg Oral Capsule
89172744|NCT04154501|Placebo Comparator|Cohort 3 Placebo|Oral Placebo Capsule
89172745|NCT04154501|Experimental|Cohort 3 Drug|100 mg Oral Capsule
89172746|NCT04154501|Placebo Comparator|Cohort 4 Placebo|Oral Placebo Capsule
89172747|NCT04154501|Experimental|Cohort 4 Drug|300 mg Oral Capsule
89172748|NCT04154501|Placebo Comparator|Cohort 5 Placebo|Oral Placebo Capsule
89172749|NCT04154501|Experimental|Cohort 5 Drug|450 mg Oral Capsule
89172750|NCT04154501|Placebo Comparator|Cohort 6 Placebo|Oral Placebo Capsule
89172751|NCT04154501|Experimental|Cohort 6 Drug|600 mg Oral Capsule
89172752|NCT04154501|Placebo Comparator|Cohort 7 Placebo|Oral Placebo Capsule
89172753|NCT04154501|Experimental|Cohort 7 Drug|800 mg Oral Capsule
89172754|NCT04154501|Placebo Comparator|Cohort 9 Placebo|Oral Placebo Capsule
89172755|NCT04154501|Experimental|Cohort 9 Drug|1000 mg Oral Capsule
89172756|NCT04154501|Experimental|Cohort 8 Fasted|Participant will take 300 mg Oral Capsule in a fasting state, and then fed state.
89172757|NCT04154501|Experimental|Cohort 8 Fed|Participant will take 300 mg Oral Capsule in a fed state, and then fasting state.
89172758|NCT00708006|Experimental|1|HGS1029
89172759|NCT00911573|Experimental|A|Tigecycline
89172760|NCT00911573|Active Comparator|B|Clindamycin (or Vancomycin if needed)
89172761|NCT04155827|Experimental|SIT for males|
89172762|NCT04155827|Experimental|SIT for females|
89172763|NCT02630381|Experimental|Shock wave arm|Unfocused extracorporeal shock wave therapy will be applied on the distal radius on one site when the patient is receiving general anaesthesia for surgery on the lower extremity or spine.
89172764|NCT02630381|No Intervention|Contra-lateral arm|The distal radius and/or wrist that did not receive UESWT will not be treated
89172765|NCT00667433|Other|Single Arm|Single arm where subjects will receive Raltegravir 400 mg BID along with Truvada once a day for 104 weeks
89172766|NCT00667667|Active Comparator|1|vertical vibration device (using Vibrafit whole body vibration platforms)
89172767|NCT00667667|Active Comparator|2|side-alternating vibration device (using Board 3000 whole body vibration platforms)
89172768|NCT00667667|Sham Comparator|3|wellness-control group
89172769|NCT00662519|Experimental|Neulasta|Subjects will receive Neulasta subcutaneously every 2 weeks for 12 weeks (6 doses). In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
89172770|NCT00662519|Placebo Comparator|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
89172771|NCT00662753|Active Comparator|home monitoring|home blood pressure monitor
89172772|NCT00662753|Experimental|monitor & phone call|home blood pressure monitor + phone calls
89172773|NCT00667979|Experimental|Arm 1|
89172774|NCT00667979|Placebo Comparator|Arm 2|
89172775|NCT00668057|Experimental|Arm 1|
89172776|NCT00668057|Experimental|Arm 2|
89172777|NCT00668057|Experimental|Arm 3|
89172778|NCT00668057|Placebo Comparator|Arm 4|
89172779|NCT00668057|Placebo Comparator|Arm 5|
89172780|NCT00668057|Placebo Comparator|Arm 6|
89172781|NCT00668135|Experimental|Arm 1|
89172782|NCT00668135|Placebo Comparator|Arm 2|
89172783|NCT04155905|Active Comparator|group A fistulotomy group|35 patients with simple anal fistula subjected to fistulotomy
89172784|NCT04155905|Active Comparator|group B marsupialization group|35 patients with simple anal fistula subjected to fistulotomy and marsupialization of fistulotomy wound
89172785|NCT02630303|Experimental|LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
89172786|NCT02630303|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
89172787|NCT00668291||CNC|Primary pigmented nodular adrenocortical disease (PPNAD) and the Carney complex (CNC)
89172788|NCT00668291||MC-L|cardiac myxoma or isolated lentiginosis
89172789|NCT04155983|Active Comparator|High ACB|In the pre-operative cohort, the adductor canal block is administered by anesthesia staff immediately prior to patient transport to the operating room. The thigh is prepped with cholorhexidine at the midpoint between the anterior superior iliac spine and the patella and sterile drapes are applied. An ultrasound probe is then used to localize the adductor canal and confirm that the femoral artery, femoral vein and saphenous nerve can be visualized deep to the sartorious. The probe is moved proximally or distally until the neurovascular bundle is centered under the sartorius. A 20cc syringe with a blunt tip 1.5in 18ga needle is then used to inject 15cc of 0.5% ropivocaine. Following this, the wound is prepped and draped in usual sterile fashion for the arthroplasty procedure.
89172790|NCT04155983|Active Comparator|Low ACB|Surgeon Administered Group In the intra-operative cohort, the block will be administered after the final components are in place and cement debris is removed. The knee joint is irrigated with dilute hibiclens or betadine followed by pulsatile lavage per institutional protocol. A blunt tip 1.5in 18ga needle was then used to administer 15cc of 0.5% ropivocaine.. The location of the saphenous nerve as it exits the adductor canal will be estimated to be 1.5x the TEA proximal to the medial epicondyle in men and 1.3x the TEA proximal in women as described by Kavolus et al. The 60cc of the anesthetic will then injected through the vastus medialis musculature in a field extending from 1cm proximal to one cm distal to the assumed location of the nerve with the needle directed in from 20° to 45° medial. The wound is then irrigated pulsatile lavage one final time and closed in layered fashion.
89172791|NCT00668369|Experimental|1|Liver transplant recipients with HCV infection fulfilling inclusion criteria.
89172792|NCT02631317||rt-PA|patients treated with rt-PA, followed strategies were used: advance hospital notification by EMS, stroke team notification, key performance indicators feedback form, standard informed consent procedures, performance of thrombolysis at CT-room.
89172793|NCT00668447|Experimental|1|Soy protein and isoflavone tablets
89172794|NCT00668447|Active Comparator|2|Soy protein and placebo tablets
89172795|NCT00668447|Active Comparator|3|control protein and Isoflavone tablets
89172796|NCT00668447|Placebo Comparator|4|control protein and placebo tablets
89172797|NCT00668603|Experimental|2|Postmenopausal women with severe vasomotor symptoms
89172798|NCT00668603|Experimental|1|Postmenopausal women without vasomotor symptoms
89172799|NCT00662987|Placebo Comparator|Group B|Received 3 days of amoxicillin followed by 4 days of placebo
89172800|NCT00662987|Active Comparator|Group A|Received 7 days of amoxicillin
89172801|NCT00663065|Experimental|arm 1|
89172802|NCT00663143||Stromal Cell Sample|
89172803|NCT00668681|Active Comparator|Endorefix|Evaluation of EndoRefix Endovascular Delivery System and Staple
89172804|NCT00668759|Experimental|1|"Vernakalant Injection:~In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes."
89172805|NCT00668759|Active Comparator|2|"Amiodarone Injection:~In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF."
89172806|NCT02630225|Experimental|Intervention|"Participants in this arm will receive three intervention services in addition to treatment as usual services:~A brief intervention including a feedback session utilizing principles of Motivational Interviewing (MI).~Extended outreach services (6 months) using the Critical Time Intervention (CTI) approach.~Multi-agency attention."
89172807|NCT02630225|Other|Treatment as Usual|Participants in this arm will receive the usual care offered to victims of gun shot wounds.
89172808|NCT02631395|Other|Training group|Six teams, consisting of 13 to 25 players each, were randomized into two groups throughout their competition season; the training Group (intervention Group) and the Control Group.The intervention group completed strength training exercises Three times a week the Whole competition season.
89172809|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
89172810|NCT00668915||A|Primary arthroplasty
89172811|NCT00663221|Placebo Comparator|1|
89172812|NCT00663221|Experimental|2|
89172813|NCT00824850|Experimental|1|Subjects received Prevnar in study D118-P8
89172814|NCT00824850|Experimental|2|Subjects received MnCC in study D118-P8
89172815|NCT00668993|Experimental|A, B|A is treatment group B is waitlist group
89172816|NCT00596687|Experimental|1|Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG > 140
89172817|NCT00596687|Active Comparator|2|Sliding scale regular insulin four-times daily achs.
89172818|NCT02631239|Active Comparator|MESA|Methotrexate, etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
89172819|NCT02631239|Experimental|ESA|Etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
89172820|NCT00663299|Other|Trufill Detachable Coil System|There is only one treatment arm in the registry and it is all patients receiving treatment with Trufill Detachable Coil System. The use of bare platinum coils for the endovascular occlusion of cerebral aneurysms.
89172821|NCT04056767||Imaginal PE|
89172822|NCT04056767||Writing PE|
89172823|NCT00669149|Experimental|1|group without anticoagulant therapy
89172824|NCT00669149|Active Comparator|2|group with heparin
89172825|NCT00669149|Active Comparator|3|group with enoxaparin
89172826|NCT00669149|Active Comparator|4|group with bivalirudin
89172827|NCT00669227|Active Comparator|1|autologous stem cells, Ficoll preparation, intracoronary administration at the same day of bone marrow cell aspiration
89172828|NCT00669227|Placebo Comparator|2|placebo is visually indistinguishable from verum due to integration of autologous erythrocytes, intracoronary administration the same day of bone marrow aspiration
89172829|NCT04032275||Untreated chronic HBV infected person group|Enrolled in the Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Department of Liver Histology, Department of Hepatology, Chronic HBV HBV infection.
89172830|NCT00669305||Cohort 1|Human participants affected with sickle cell disease or thalassemia will donate bone marrow for use in experimental models
89172831|NCT00663455|Other|A|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
89172832|NCT00663455|No Intervention|B|Standard CSA-dosing without reduction. Therapy control by C2-monitoring.
89172833|NCT00663533|No Intervention|Device study only.|
89172834|NCT00669695|Placebo Comparator|Stat/CPAP|Atorvastatin and CPAP treatments
89172835|NCT00669695|Placebo Comparator|Stat/sham CPAP|Atorvastatin and sham CPAP treatments
89172836|NCT00669695|Sham Comparator|Placebo/CPAP|Placebo and CPAP treatments
89172837|NCT00669695|Active Comparator|Placebo/sham CPAP|Placebo and sham CPAP treatments
89172838|NCT00663689|Experimental|1|non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity
89172839|NCT00669773|Experimental|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
89172840|NCT00669773|Experimental|Docetaxel|
89172841|NCT00824616|Placebo Comparator|Placebo|Participants receiving placebo tablets three times daily plus insulin injection once daily
89172842|NCT00824616|Experimental|MK-0941|Participants receiving MK-0941 tablets three times daily plus insulin injection once daily
89172843|NCT04155671|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
89172844|NCT04155671|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
89172845|NCT00669929||1|patients visited to Severance hospital
89172846|NCT00669929||2|patients visited to Youngdong Severance hospital
89172847|NCT00669929||3|patients visited to Wonju Christian hospital
89172848|NCT05443620|Active Comparator|High Load|Participants will be standing with a heavy weight vest (11 percent of body weight).
89172849|NCT05443620|Placebo Comparator|No Load|Participants will be sitting.
89172850|NCT00663845|Experimental|Arm 1|
89172851|NCT00663845|Placebo Comparator|Arm 2|
89172852|NCT00708240|Experimental|Escitalopram|
89172853|NCT04155515|Other|Non-cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
89172854|NCT04155515|Other|Cirrhotic, HCV genotype 1 infected subjects|Subjects will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.
89172855|NCT00664001|Placebo Comparator|Control|Placebo tablet
89172856|NCT00664001|Active Comparator|Intervention|Anti-oxidant supplementation
89172857|NCT00670163|Experimental|1|Participating community will provide Comunidades Positivas plus enhanced partner therapy.
89172858|NCT00670163|Experimental|2|Participating community will provide enhanced partner therapy alone.
89172859|NCT00670163|Experimental|3|Participating community will provide Comunidades Positivas alone.
89172860|NCT00670163|Active Comparator|4|Participating community will provide standard of care.
89172861|NCT00664079||1|Patients who are receiving vasoactive medications and/or are mechanically ventilated.
89172862|NCT00824382|Experimental|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation
89172863|NCT00824382|Experimental|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation
89172864|NCT00824382|Placebo Comparator|Placebo|2 puffs
89172865|NCT00824382|Experimental|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation
89172866|NCT00670319|Experimental|1|Raloxifene HCL 60 mg orally once a day
89172867|NCT00670319|Experimental|2|Raloxifene HCL 120 mg orally once a day
89172868|NCT00670319|Placebo Comparator|3|
89172869|NCT00664157|Other|2|40 patients with an idiopathic Parkinson's disease and 40 healthy paired volunteers (control group)
89172870|NCT00670397|Experimental|Treatment (PDT)|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light treatment to the tumor bed on day 2. Treatment may repeat every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89172871|NCT00708318|Experimental|A, B, C|
89172872|NCT05532540||Liver transplant recipients|All adults enlisted for liver transplantation at Copenhagen University Hospital - Rigshospitalet (N = around 60 per year) will be invited to participate regardless of indication for liver transplantation. These participants are expected to undergo a liver transplantation and will continue in the study after the procedure.
89172873|NCT00670475|Active Comparator|P (Pircoxicam Group)|in this arm 100 patients with osteoarthritis of knee will receive piroxicam gel in blinded 60 grams tubes,they will be instructed to use 1 gram of piroxicam gel (with inserted dispensing device) three times in a day on the affected knee.
89172874|NCT00670475|Experimental|O (olive oil group)|in this arm 100 patients with osteoarthritis of knee will receive virgin olive oil in blinded 60 grams tubes,they will be instructed to use 1 gram of olive oil (with inserted dispensing device) three times in a day on the affected knee.
89172875|NCT00704886|No Intervention|1|verbal
89172876|NCT00704886|Experimental|2|video
89172877|NCT04154033|No Intervention|Arm A: Circadian Rhythm of Itch|For the study arm A, to evaluate circadian rhythm of itching, patients will record for 7 days 6 times daily in a booklet the itch intensity on a visual analog scale (VAS) scale. These time points for itch intensity recording will be hours after time of awakening (AW), so they will be AW+2h, AW+4h, AW+6h, AW+8h, AW+10h, AW+12h. Patients are to document all their pruritus attacks at these time points. On day 8 the investigators will collect suction blisters (4-5 10mm blisters) at these 6 time points from unaffected skin on the trunk. For this purpose, the investigators will use the commercially available 47mm orifice plate (Electronic Diversities, Finksburg MD, USA) with 4-5 x10mm openings for each time point and use the 4-5 1mm blister roofs for harvesting.
89172878|NCT04154033|Experimental|Arm B: Topical Naltrexone Cream|Patients will start with placebo in week 2 and move on to naltrexone treatment in week 3. There will be a wash-in phase during week 1. Following week 2 and week 3, at visits 3 and 4, patients will be asked for the area where they are experiencing most intense itch and the investigators will take suction blisters from that area before any treatment. They will be told to bring the medication they have been using and they will apply this topically. After an hour, another suction blister will be taken from the same area. This will ensure the study is still blinded as neither the physician or the participant will know whether the medication was a placebo or not. Participants may apply their topical treatment as often as he wishes.
89172879|NCT04154033|Placebo Comparator|Arm C: Placebo Cream|Patients will start with naltrexone treatment in week 2 and move on to placebo treatment in week 3. Other than this, all procedures will be the same as in study arm B.
89172880|NCT05530356||Lean Controls (previously enrolled in the Renal HEIR Study)|
89172881|NCT05530356||Obese Youth without Type 2 Diabetes (previously enrolled in the Renal HEIR Study)|
89172882|NCT05530356||Obese Youth with Type 2 Diabetes (previously enrolled in the Renal HEIR Study)|
89172883|NCT00664313|Experimental|1|Linezolid 600 mg po QD
89172884|NCT00664313|Placebo Comparator|2|Placebo
89172885|NCT00670553|Experimental|LBH589|
89172886|NCT00664391|Experimental|1|
89172887|NCT00833040|Experimental|Titration of sufentanil, the DBL sufentanil & PBO|"During the Titration Phase, patients titrated to the effective dosage of sublingual sufentanil NanoTab™(20, 30, 40, 60 or 80 mcg). One sublingual sufentanil NanoTab™ was taken as needed for breakthrough pain.~During the Double-Blind Phase, patients were then randomized to one of six treatment sequences, each of which included seven active doses of sublingual sufentanil (dosage determined in Titration Phase) and three placebo doses taken in random order. One NanoTab™ was taken as needed for breakthrough pain."
89172888|NCT02629913|Experimental|Intervention|mementor somnium
89172889|NCT02629913|Other|Waitlist|
89172890|NCT02629835|Active Comparator|Intravenous dexamethasone 8 mg|patients receiving intravenous 8 mg of dexamethasone in parallel to ultrasound guided axillary nerve block with a standardized local anesthetic solution
89172891|NCT02629835|Active Comparator|Perineural dexamethasone 8 mg|patient receiving perineural 8 mg of dexamethasone in a mixture with a standardized local anesthetic solution for ultrasound guided axillary block
89172892|NCT00664469|Experimental|EZE+statin|ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
89172893|NCT00664469|Active Comparator|Stat2|patients on statins has their dose doubled for 6 weeks followed by another 6 weeks in which ezetimibe is added or the statin dose is doubled again.
89172894|NCT00664547|No Intervention|C|
89172895|NCT00664547|Active Comparator|DWL|Diet Weight Loss
89172896|NCT00664547|Active Comparator|EWL|Exercise Weight Loss
89172897|NCT00664547|Active Comparator|EWS|Exercise without weight loss
89172898|NCT02629757|Experimental|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles.
89172899|NCT00843024|Experimental|Sumatriptan and Naproxen 1|Sumatriptan succinate and naproxen sodium combination 10mg/60mg
89172900|NCT00843024|Experimental|Sumatriptan and Naproxen 2|Sumatriptan succinate and naproxen sodium combination 30mg/180mg
89172901|NCT00843024|Experimental|Sumatriptan and Naproxen 3|Sumatriptan succinate and naproxen sodium combination 85mg/500mg
89172902|NCT00843024|Placebo Comparator|Placebo|Placebo to match
89235094|NCT04844580|Placebo Comparator|Standard Treatment + Placebo|Standard medical treatment, as deemed appropriate by physicians, is going to be according to the Turkish Republic COVID-19 (SARS-CoV-2 INFECTION) ADULT PATIENT TREATMENT GUIDELINES published by the Ministry of Health, General Directorate of Public Health. The management of all additional complications and / or symptoms that develop in patients will be managed in the same way as specified in these guidelines. If these guidelines are changed by the Turkish Republic Ministry of Health General Directorate of Public Health, a protocol amendment will be planned. The necessary changes within the scope of urgent security measures will be reflected in the standard treatment in accordance with the necessary regulations.
89235095|NCT04844580|Experimental|Standard Treatment + Inhaled Aviptadil|In addition to the standard medical treatment mentioned above, patients randomized to this arm will be given Inhaled Aviptadil 2 times a day, 30 minutes apart. Aviptadil treatment is aimed to be a minimum of 7 days and a maximum of 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. The dose of inhaled Aviptadil was determined by evaluating the results of the Phase 1 and Phase 2 studies.
89235096|NCT04827134|Experimental|Cohort 1: TRIUMEQ Fed followed by TRIUMEQ Fasted|Participants received TRIUMEQ (dolutegravir [DTG] 5 milligram [mg]/abacavir [ABC] 60 mg/lamivudine [3TC] 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment A) in treatment period 1 followed by TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment B) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
89235097|NCT04827134|Experimental|Cohort 1: TRIUMEQ Fasted followed by TRIUMEQ Fed|Participants received TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment B) in treatment period 1 followed by TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment A) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
89235098|NCT04827134|Experimental|Cohort 2: DOVATO Fed followed by DOVATO Fasted|Participants received DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment C) in treatment period 1 followed by DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment D) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
89235099|NCT04827134|Experimental|Cohort 2: DOVATO Fasted followed by DOVATO Fed|Participants received DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion under fasted conditions (Treatment D) in treatment period 1 followed by DOVATO (DTG 5 mg/3TC 30 mg), dispersible tablets administered as a dispersion immediately after a high calorie meal (under fed condition) (Treatment C) in treatment period 2. The treatment periods were separated by a washout period of about 7 days. All participants were followed-up for 7 to 14 days of last dose in treatment period 2.
89235100|NCT04826276|Experimental|All Subjects|"for the abstinence intervention, 12+ hours after smoking will be assessed before assessments following smoking as normal~For the satiated intervention, smoking as normal will be assessed first before assessments following 12+ hours of abstinence from smoking"
89235101|NCT04818593|Experimental|ZyMot Separation|Treatment
89235102|NCT04818593|Active Comparator|Density Gradient Centrifugation|Control
89235103|NCT04811079|Experimental|Spectacle Filter Sequence 1|(419nm, 437nm, 373nm, 456nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 1.
89235104|NCT04811079|Experimental|Spectacle Filter Sequence 2|(437nm, 456nm, 419nm, 476nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 2.
89235105|NCT04811079|Experimental|Spectacle Filter Sequence 3|(456nm, 476nm, 437nm, 373nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 3.
89235106|NCT04811079|Experimental|Spectacle Filter Sequence 4|(476nm, 373nm, 456nm, 419nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 4.
89235107|NCT04811079|Experimental|Spectacle Filter Sequence 5|(373nm, 419nm, 476nm, 437nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 5.
89235108|NCT04811079|Experimental|Spectacle Filter Sequence 6|(476nm, 456nm, 373nm, 437nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 6.
89235109|NCT04811079|Experimental|Spectacle Filter Sequence 7|(373nm, 476nm, 419nm, 456nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 7.
89235110|NCT04811079|Experimental|Spectacle Filter Sequence 8|(419nm, 373nm, 437nm, 476nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 8.
89235111|NCT04811079|Experimental|Spectacle Filter Sequence 9|(437nm, 419nm, 456nm, 373nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 9.
89235112|NCT04811079|Experimental|Spectacle Filter Sequence 10|(456nm, 437nm, 476nm, 419nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 10.
89235113|NCT04804943|Experimental|NOA-001 group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
89235114|NCT04804943|No Intervention|Standard treatment group (ARDS caused by Non-COVID-19 cohort)|Patients will receive the standard therapy.
89235115|NCT04804943|Experimental|NOA-001 group (ARDS caused by COVID-19 cohort)|Patients will receive the standard and NOA-001 therapy.
89235116|NCT04793516|Experimental|VR-based spatial retraining|Game-like therapy activities will be taken place in a virtual environment, provided through an immersive head-mounted display.
89235117|NCT04736953|Active Comparator|Sirolimus|Sirolimus 1 to 2 mg bid
89235118|NCT04736953|Placebo Comparator|Placebo|Placebo 1 to 2 mg bid
89235119|NCT04707911|Experimental|Vaping Intervention|The vaping intervention will be implemented on Instagram. Participants in the treatment condition will be assigned to groups on Instagram, where they will receive up to 3 posts per day for 30 days. Groups are facilitated by a trained Guide, working with the Principal Investigator, Co-Investigators and a Pediatrician on demand if additional expertise or clinical advice is needed. Participants will be educated about signs of nicotine dependence and if they express interest in pharmacotherapy will be encouraged to access this through their personal healthcare providers. The Instagram groups will provide educational and social support, troubleshooting and advice about nicotine replacement therapy (NRT) or other forms of treatment.
89235120|NCT04707911|No Intervention|Control Condition|Participants in the control condition will be directed to the Truth Initiative e-cigarette texting quit program. This innovative and free text message program was created with input from teens, college students and young adults who have attempted to, or successfully, quit e-cigarettes using text coaching methods
89235121|NCT04685421|Experimental|Liposomal Bupivacaine PK|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
89235122|NCT04683042|Active Comparator|TENS with PT|TENS with PT group: The TENS with PT group will receive usual PT care and following enrollment, during the second PT visit, participants will receive TENS units and instruction on use of the TENS units. TENS will be applied to the upper and lower back with butterfly electrodes using the following parameters: mixed frequency (2-125Hz), strong but comfortable intensity, variable pulse duration from 100-250 microseconds. TENS to be applied when the patient is active and doing exercises at home and during PT sessions for 30 minutes at least 2 hours per day. The TENS with PT group will complete TENS use to the end of the study at 6 months.
89235123|NCT04683042|Other|No TENS with PT|The No TENS group will receive usual PT care until the primary endpoint timeframe of 60 days. After completion of the research homework at 60 days, TENS units will be mailed to the participants and a study team member will complete virtual TENS instruction. The no TENS group will complete TENS to the end of the study at 6 months.
89235124|NCT04680975|Experimental|Belumosudil|Participants received belumosudil 200 mg tablet orally PO, BID for 52 weeks.
89235125|NCT04680455|Experimental|Intervention|Participants in the intervention group were asked to exercise three times per week while performing four basic bodyweight exercises in a circuit manner for 12 weeks while supervised online via the Microsoft TEAMs platform. Participants were eased into the program by completing 120 minutes of exercise in week one, 150 minutes in week two, and 180 minutes in the following weeks. Participants were supervised 3X/week for the first four weeks, then 2X/week for the next four weeks and 1X/week for the remaining four weeks. At each session, participants performed the four prescribed exercises (squats, tricep dips, lunges, and push-ups) for 45 seconds each, then switched immediately (15 seconds) to the next exercise followed by one minute of rest at the end of each circuit. Following this exercise program, men living with obesity were able to reach moderate intensity.
89235126|NCT04680455|No Intervention|Control|Participants allocated to the control group received an online exercise resource for a 12-week workout plan covering fitness components required to reach both components of the weekly physical activity guidelines on their own. It was recommended that they do a minimum of 150 minutes of moderate to vigorous aerobic activities and two sessions of muscle-strengthening activities using an online program. No supervision was offered and no contact was permitted between the research team and participants from this group.
89235127|NCT04673786|Experimental|CT-P43|All patients who were initially randomized to the CT-P43 group on Day 1 (Week 0) will continue their treatment with CT-P43 until Week 40.
89235128|NCT04673786|Active Comparator|Stelara|Patients who were initially randomized to Stelara group on Day 1 (Week 0) will be randomized again in a ratio of 1:1 to either continue Stelara or undergo transition to CT-P43 prior to dosing at Week 16. Thereafter, patients will continue their treatment until Week 40.
89235129|NCT04672798|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinical trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
89235130|NCT04672798|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive treatment from their mental health clinician which may include safety planning.
89235131|NCT04666792|Other|PrEP for HIV-1 uninfected for women accessing family planning|Women accessing family planning will be assessed for HIV risk and PrEP eligibility. If eligible and willing to initiate PrEP, they will be provided PrEP in accordance with national guidelines as part of their standard of care at the family planning clinic.
89235132|NCT04647929|Experimental|PRESERFLO MicroShunt|Patients will undergo Santen PRESERFLO MicroShunt implantation with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
89235133|NCT04647929|Active Comparator|Trabeculectomy|Patients will undergo trabeculectomy with intraoperative use of Mitomycin C 0.2mg/ml for 2 minutes.
89235134|NCT04611399|Experimental|Virtual Reality (VR) Group|"The treatment for the participants allocated to the VR Group consists of three home-sessions of approximately 30 minutes each, conducted over one week. In each session, participants will be asked to try for about 15 minutes MIND-VR. Subsequently, they will try the virtual relaxation content The Secret Garden."
89235135|NCT04611399|Active Comparator|Control (CR) Group|The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
89235136|NCT04605978|Experimental|S95011 concentrate for solution for infusion|S95011 is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
89235137|NCT04605978|Placebo Comparator|S95011 Placebo concentrate for solution for infusion|S95011 placebo is administrated by one IV infusion every 2 weeks for the first month and then every 3 weeks.
89235138|NCT04602533|Experimental|Durvalumab|"Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy)~Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities."
89235139|NCT04602533|Other|standard of care|"Induction phase: Radiochemotherapy according to guideline~Maintenance: Standard of care"
89235140|NCT04597671|Experimental|Arm A|Durvalumab with low-dose PCI
89235141|NCT04597671|Active Comparator|Arm B|Durvalumab with observation
89235142|NCT04584320||Premature neonates with necrotizing enterocolitis|
89235143|NCT04584320||Premature neonates without necrotizing enterocolitis|
89235144|NCT04583969|Experimental|Remdesivir + Lenzilumab|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 600-mg IV lenzilumab infusion every 8 hours starting on Day 1 for a total of 3 doses. N=275.
89235145|NCT04583969|Active Comparator|Remdesivir + Placebo|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 600-mg IV lenzilumab placebo infusion every 8 hours starting on Day 1 for a total of 3 doses. N=275.
89235146|NCT04575857||Statin arm|To receive pill packet with atorvastatin (40mg/day) which will be taken nightly.
89235147|NCT04575857||Placebo arm|To receive pill packet with placebo which will be taken nightly
89235148|NCT04569708|Experimental|Children and adolescents with epilepsy and controls|Closed loop auditory stimulation during nap
89235149|NCT04561115|Active Comparator|Gamunex-C|Participants received Gamunex-C by means of an infusion pump at a dose of 200 to 800 mg/kg per infusion at an infusion rate of 1 mg/kg/min or up to 8 mg/kg/min depending on participant tolerance. The participant's usual mg/kg dose (given on either a 3 or 4 week repeating schedule) was the same mg/kg dose and schedule that the participant was receiving prior to entering screening. This mg/kg dose and schedule were used throughout the study duration. Gamunex-C was administered every 3 weeks (±4 days) or 4 weeks (±4 days), depending on the participant's prior IVIG dosing schedule. The duration of Gamunex-C treatment included the Gamunex-C PK Phase (up to 4 weeks) plus the additional Gamunex-C Run-in Phase (up to 4.5 months) for participants not receiving Gamunex-C or not on a stable dose of Gamunex-C upon entering the trial. The approximate maximum duration was up to 6 months.
89235150|NCT04561115|Experimental|IVIG-PEG|Participants received IVIG-PEG by means of an infusion pump at a dose of 200 to 800 mg/kg per infusion at an infusion rate of 1 mg/kg/min or up to 8 mg/kg/min depending on participant tolerance. IVIG-PEG was administered every 3 weeks (±4 days) or 4 weeks (±4 days), depending on the participant's prior IVIG dosing schedule. The duration of IVIG-PEG treatment included the IVIG-PEG Treatment Phase (up to 4.5 months) and the IVIG-PEG PK Phase (up to 4 weeks), for an approximate maximum of up to 6 months.
89235151|NCT04549779|Experimental|Group I (low volume)|patients will receive 5 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
89235152|NCT04549779|Experimental|Group II (intermediate volume)|patients will receive 10 ml levobupivacaine 0.25% in ultrasound-guided interscalene brachial plexus block
89235153|NCT04549779|Experimental|Group III (high volume)|patients will receive 15 ml levobupivacaine 0.25% ultrasound-guided interscalene brachial plexus block.
89235154|NCT04509245|Experimental|Effects of a digitally assisted lifestyle intervention|Testing the effects of a low-calorie diet in connection with app-based digital education and behavioral change program on glucose metabolism and disease management.
89235155|NCT04502706|Experimental|GS-0189 (Monotherapy Dose Escalation, MDE)|Relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) participants will receive GS-0189 doses of 10, 30, or 100 mg every 2 weeks.
89235156|NCT04502706|Experimental|GS-0189 + Rituximab (Combination Dose Escalation, CDE)|R/R NHL participants will receive GS-0189 doses of 100, 300, 1000, 2000, and 3000 mg in combination with rituximab at 375 mg/m^2.
89235157|NCT04502706|Experimental|GS-0189 + Rituximab (Pharmacokinetic (PK) Evaluation)|R/R NHL participants will receive GS-0189 dose of up to 30 mg followed by the highest designated safe dose from the Combination Dose Escalation cohort (CDE) in combination with rituximab at 375 mg/m^2.
89235158|NCT04502706|Experimental|GS-0189 + Rituximab (Alternate Schedule Evaluation, ASE)|R/R NHL participants will receive GS-0189 every 4 weeks in combination with rituximab 375 mg/m^2. The GS-0189 dose will be determined based on the totality of safety, PK, and pharmacodynamic (PD) data from the preceding cohorts.
89235159|NCT04502706|Experimental|GS-0189 + Rituximab (DLBCL Expansion)|Diffuse large B-cell lymphoma (DLBCL) participants will receive GS-0189 in combination with rituximab 375 mg/m^2. The GS-0189 dose will be determined based on the totality of safety, PK, and PD data from the preceding cohorts.
89235160|NCT04477564||Unprovoked proximal deep vein thrombosis|
89235161|NCT04477564||Provoked distal deep vein thrombosis|
89235162|NCT04477564||age-matched control group with no history of vein thrombosis|
89235163|NCT04468776|Active Comparator|Medication (zolpidem or trazodone)|Zolpidem or trazodone, as prescribed by physician
89235164|NCT04468776|Active Comparator|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|Internet-based CBT-I program
89235165|NCT04468776|Experimental|Combination|Medication (zolpidem or trazodone) as prescribed by physician and Internet-based CBT-I program
89235166|NCT04416269|Experimental|Oral Anti-diabetes Drugs (OADs) alone|OADs will be continued at same outpatient dosage unless contraindicated
89235167|NCT04416269|Active Comparator|Basal bolus insulin|Basal insulin with glargine or detemir and rapid-acting insulin (lispro/aspart) will be used as per the hospital formulary. OADs and non-insulin injectable antidiabetic medication will be discontinued on admission.
89235168|NCT04400292|Experimental|SLN mapping by NIR with ICG|Patients will undergo ICG injection and NIR imaging for lymphatic mapping. Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy. The SLN biopsy procedure will be performed as described below. Although NIR with ICG is used to assess conduit perfusion in all esophagectomies performed at MSK, its use for lymphatic mapping is considered experimental in esophageal cancer.
89235169|NCT04398017|Active Comparator|Standard support|
89235170|NCT04398017|Experimental|Hypnosis|
89235171|NCT04394351|Experimental|Part A - High Dose|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
89235172|NCT04394351|Experimental|Part A - Low Dose|Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
89235173|NCT04394351|Experimental|Part B - High Dose|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
89235174|NCT04394351|Experimental|Part B - Low Dose|Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
89235175|NCT04394351|Experimental|Part C - High Dose|Part C consists of up to 108-week open-label extension period. All patients will receive higher exposure dupilumab subcutaneous (SC) administration at tiered dosing regimens based on body weight. No matching placebo administered in Part C.
89235176|NCT04374461|Experimental|mechanically ventilated &/or managed in a critical-care|"This arm is closed to accrual as of September 2020. Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.~Patients will receive treatment for a maximum of 3 weeks or until one of the following:~Arm A:~Transfer out of the critical-care unit~Extubation~Toxicity~Death"
89235177|NCT04374461|Experimental|non-mechanically ventilated, non-critical-care|"Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician.~Patients will receive treatment for a maximum of 3 weeks or until one of the following:~Arm B:~Discharge from hospital~Admission to a critical-care unit~Intubation~Toxicity~Death"
89235178|NCT04371432||Sample Group 1 (NIHCC)|Existing NIH Clinical Center patients/participants tested positive for SARS-CoV-2 invited to participate by their NIH study team
89235179|NCT04371432||Sample Group 2 (OMS &amp; Field)|Recruited through NIH OMS, referred by collaborators or who self-refer, tested positive for SARS-CoV-2 (and selected relatives of participants irrespective of infection status)
89235180|NCT04366258|Experimental|Patients with MDD|Participants will undergo 4 Transcranial Photobiomodulation (t-PBM) treatment visits and receive 1 irradiance dose per visit. The order of dose administration is randomized so patients receive each irradiance dose (50 mW/cm2; 300 mW/cm2; 770 mW/cm2), as well as a sham dose (0 mW/cm2), once over the 4 treatment visits.
89235181|NCT04343443|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
89235182|NCT04343430|Other|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary , peritoneal , jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
89235183|NCT04333420|Experimental|Phase II: IFX-1 + BSC|Phase II study part: IFX-1: 800mg intravenously administered, BSC: Best supportive care
89235184|NCT04333420|Other|Phase II: BSC|Phase II study part: BSC: Best supportive care
89235185|NCT04333420|Experimental|Phase III: IFX-1 + SOC|Phase III study part: IFX-1: 800mg intravenously administered, SOC: Standard of care
89235186|NCT04333420|Placebo Comparator|Phase III: Placebo + SOC|Phase III study part: Placebo: placebo infusion intravenously administered, SOC: Standard of care
89235187|NCT04332692|Experimental|Patients hospitalized for acute heart failure|"Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination focusing on congestion~Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds~Blood sample retrieved for biological assessment and biobanking~Telephone follow-up"
89235188|NCT04291131||Veterans with COPD|Veterans with COPD who will participate in a physical activity intervention or exercise program
89235189|NCT04268485||IPF patients|Patients with an MDT diagnosis of idiopathic pulmonary fibrosis. Patients will be observed over a 12 month period and have serial serum samples taken for KL-6 level.
89235190|NCT04247165|Experimental|Experimental|"Nivolumab 3 mg/kg will be given on day 1 (± 2 days) of each 28-day treatment cycle until the progression of disease, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given once only on day 1 cycle 1. Nivolumab will be administered as an IV infusion over 30 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Pre-medication for chemotherapy (based on standard-of-care and local institutional standards) and chemotherapy will then be administered after a further 30 minutes rest period.~The recommended dose of nab-paclitaxel is 100 mg/m2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8, and 15 of each 28-day cycle. Gemcitabine 800 mg/m2 will be administered over 30 to 40 minutes immediately after nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle."
89235191|NCT04234867|Experimental|Dapagliflozin - Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of 250µg ACTH (Synacthen)
89235192|NCT04234867|Experimental|Dapagliflozin and Placebo Stress|Administration of 10mg dapagliflozin oral for 5 days and one i.v. administration of Placebo matching Synacthen
89235193|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of 250µg ACTH (Synacthen)
89172903|NCT04154813|Experimental|Topiramate group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is topiramate group.During this group the initial dose of 25mg/day is rapidly increased to the target dose (100mg/day) or below the maximum tolerable dose if the patient can tolerate it.
89172904|NCT04154813|Experimental|Fluoxetine+DBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+DBT group. Group cognitive behavioral therapy was performed while fluoxetine was maintained. Target dose of fluoxetine is 60mg/day.Treatment was divided into three stages: the initial stage, the main stage and the end stage. The treatment was conducted once a week for a total of 12 times, followed by maintenance treatment for 6 months.
89172905|NCT04154813|Experimental|Fluoxetine+CBT group|If fluoxetine doesn't work after 3 months, randomly assigned to 3 groups, one group is fluoxetine+CBT group.Target dose of fluoxetine is 60mg/day. DBT therapy was performed while the original fluoxetine dose was maintained.The core treatment stage was 1 time per week, 12 times in total, and 6 months of maintenance treatment followed.
89172906|NCT00664703|Experimental|Lobeline 7.5 mg|Sublingual tablet
89172907|NCT00664703|Experimental|Lobeline 15 mg|Sublingual tablet
89172908|NCT00664703|Experimental|Lobeline 30 mg|Sublingual tablet
89172909|NCT00664703|Active Comparator|Methylphenidate HCl 15 mg|Capsule
89172910|NCT00664703|Active Comparator|Methylphenidate HCl 30 mg|Capsule
89172911|NCT00664703|Placebo Comparator|Lobeline 0 mg (placebo)|Sublingual tablet
89172912|NCT00664703|Placebo Comparator|Methylphenidate HCl 0 mg (placebo)|Capsule
89172913|NCT00670787|Active Comparator|Combination pill|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
89172914|NCT00670787|No Intervention|Control group|combination therapy of angiotensin receptor antagonists (losartan potassium 50mg, candesartan 8mg, valsartan 80mg, telmisartan 40mg or olmesartan 20mg) and thiazide or thiazide-like diuretics (hydrochlorothiazide 6.25-12.5mg, trichlormethiazide 0.5-1.0mg, indapamide 0.5-1.0mg or chlorthalidone 6.25-12.5mg)
89172915|NCT04154969|Experimental|intervention|daily physiotherapy session as part of the rehab plan, which includes 10 minutes of vestibular exercize.
89172916|NCT04154969|Active Comparator|control|daily physiotherapy session as part of the rehab plan
89172917|NCT00670865|Experimental|eDischarge|The eDischarge arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use the electronic discharge summary program.
89172918|NCT00670865|No Intervention|Traditional|"The traditional arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use traditional, dictated discharge summaries."
89172919|NCT00670943||A|Patients with stable CAD with scheduled discontinuation of clopidogrel
89172920|NCT00670943||B|Patients with stable CAD not taking clopidogrel
89172921|NCT00832650|Experimental|Fesoterodine|Tablets
89172922|NCT00832650|Placebo Comparator|Placebo|Tablets
89172923|NCT00832650|Active Comparator|Solifenacin|Tablets
89172924|NCT00708396|Experimental|Patients|Patients which diagnosed as OCD and schizophrenia
89172925|NCT00671021||1|Patients suffering from stable CAD, on chronic ASA therapy
89172926|NCT04153799|Experimental|EGFR CAR-T|Group: 3 dose levels
89172927|NCT00671099|Experimental|1|Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid
89172928|NCT00671099|Placebo Comparator|2|Placebo
89172929|NCT00665093||A|
89172930|NCT00665093||B|
89172931|NCT00595517|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
89172932|NCT00671255|Experimental|Ramelteon 4 mg QD|
89172933|NCT00671255|Experimental|Ramelteon 8 mg QD|
89172934|NCT00671255|Placebo Comparator|Placebo|
89172935|NCT00911651|Active Comparator|salbutamol|6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD
89172936|NCT00911651|Active Comparator|ipratropium bromide|COPD patients GOLD stage II and III
89172937|NCT00665249|Active Comparator|Full Motivational Interviewing|"This condition consisted of all the standard elements of MI, both the non-directive and directive strategies (Miller & Rollnick, 2002). Rogerian elements, such as warmth, egalitarianism, genuineness, and a client-centered approach to the therapeutic relationship, are commonly referred to as MI Spirit (Moyers, Martin, Manual, Hendricksen, & Miller, 2005). MI is comprised of MI spirit and includes specific directive strategies geared to focus the client toward targeted behavior change, such as confidence and importance rulers, visualization of behavior change, or a decisional balance. The directive elements of MI are those that selectively reinforce positive change talk or enhance discrepancy between a client's wish to change and stay with the status quo."
89172938|NCT00665249|Active Comparator|No Intervention: Self Change|Participants in this condition were not assigned to treatment, but were asked to attempt to change on their own during the 8-week follow-up period. SC participants were told that research had shown that some individuals could reduce their drinking without professional help; that participating in the IVR might facilitate their efforts; and that they would be offered professional treatment at the end of the 8-week period. As noted in the Introduction, SC was selected rather than a traditional wait-list control because the aim of the study was to decompose MI into its 3 hypothesized components that include self-change.
89172939|NCT00665249|Active Comparator|Spirit-Only Motivational Interviewing|While this condition retained the Rogerian elements to MI, directive elements were excluded. For example, SOMI consisted of the non-directive elements including therapist stance (warmth, genuineness, egalitarianism), emphasis on client responsibility to change, extensive use of reflective listening skills (e.g., open-ended questions, simple reflections), and avoidance of MI-inconsistent behaviors (advise, confront, take expert role, interpretation). Reflective listening was focused on the whole experience of the client and the client's affect, and targeting a particular behavior or eliciting change talk about drinking was proscribed. Furthermore, tools utilized frequently in MI to develop discrepancy, such as amplified or double-sided reflections, were proscribed.
89172940|NCT00665327|Experimental|Arm 1|
89172941|NCT00665327|Active Comparator|Arm 2|
89172942|NCT00671333|Active Comparator|1|(LRTI) Ligament reconstruction and tendon interposition
89172943|NCT00671333|Active Comparator|2|Ascension PyroDisk
89172944|NCT00823836|Experimental|ropinirolePR-PR group|
89172945|NCT00823836|Active Comparator|ropiniroleIR-PR group|
89235194|NCT04234867|Placebo Comparator|Placebo Dapagliflozin and Placebo Stress|Administration of placebo oral for 5 days identical to dapagliflozin and one i.v. administration of Placebo matching Synacthen
89235195|NCT04219280|Active Comparator|Quillivant XR|Once-daily, long-lasting MPH solution with the following dosing schedules: 7.5mg/15mg/22.5mg/30mg for children 20-25kg 10mg/20mg/30mg/40mg for children 26-30kg 10mg/22mg/34mg/46mg for children > 30 mg
89235196|NCT04219280|Placebo Comparator|Placebo|Liquid-based suspension to match the color and banana-flavor of Quillivant XR.
89235197|NCT04186637|Experimental|Dose escalation and expansion|ALPN-202
89235198|NCT04177693|Experimental|EGCG daily alone.|EGCG daily alone. 800mg
89235199|NCT04177693|Experimental|EGCG with clomiphene citrate|EGCG 800 mg daily with clomiphene citrate 100mg for 5 days.
89235200|NCT04177693|Experimental|EGCG with letrozole|EGCG 800mg daily with letrozole 5mg for 5 days.
89235201|NCT04169009|Active Comparator|ZVL >5 years previously|Participants have received Zostavax (ZVL) at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
89235202|NCT04169009|Active Comparator|ZVL 6-12 months previously|Participants who received ZVL 6-12 months previously will be administered an intradermal dose of vOka varicella zoster virus (ZVL) in non-dominant deltoid.
89235203|NCT04169009|Active Comparator|No previous ZVL|Participants who've never received a shingles vaccine will be given the 2 standard doses of RZV. Six months later they will be given the intradermal dose of vOka varicella zoster virus (ZVL) in the non-dominant deltoid.
89235204|NCT04169009|Active Comparator|SRX >5 years previously|Participants have received Shingrix at least 5 years previously. Will be administered intradermal vOka varicella zoster virus (ZVL) in non-dominant deltoid. A skin biopsy will be performed at the injection site on 20 subjects.
89235205|NCT04146064||Validation cohort: NSCLC|"Patients with advanced/metastatic NSCLC planned for IO-treatment in one of the following categories~Pembrolizumab monotherapy first-line~Pembrolizumab or nivolumab monotherapy in second or later line"
89235206|NCT04146064||Cohort 1: NSCLC|Patients with advanced/metastatic NSCLC planned for Pembrolizumab-chemotherapy combination therapy first-line
89235207|NCT04146064||Cohort 2: Melanoma|"Patients with advanced/metastatic melanoma planned for IO-treatment in one of the following categories~Nivolumab/ipilimumab combination treatment 1L~Pembrolizumab or nivolumab monotherapy treatment 1L~Ipilimumab monotherapy 2L"
89235208|NCT04146064||Cohort 3: Mixed solid tumor cohort|Patients with advanced/metastatic solid tumors such as Head&Neck tumors, kidney cancer and urothelial cancer planned for IO-treatment
89235209|NCT04146064||Cohort 4: NSCLC|Patients with advanced/metastatic NSCLC planned for treatment with Chemotherapy-only (either platinum-based combination treatment or docetaxel monotherapy)
89235210|NCT04129229|Experimental|LTR Treatment|Eligible subjects will undergo insertion of the LTR device in their tongue. Initiation of treatment will occur 7 days post insertion procedure and will be monitored over the course of 1 year.
89235211|NCT04118387|Active Comparator|acetazolamide|To determine the effect of dampening chemoreceptor sensitivity AND decreasing plant gain. The investigators hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to PAP plus each intervention alone or placebo in reducing CAHI and the CO2 reserve during sleep in Veterans with CSA.
89235212|NCT04118387|Active Comparator|zolpidem|To determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. The investigators hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in Veterans with CSA compared to PAP plus placebo.
89235213|NCT04118387|Active Comparator|buspirone|To determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. The investigators hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with CSA compared to PAP plus placebo.
89235214|NCT04118179||Suspected Sepsis Group|Participants suspected of potential to develop sepsis recruited at the emergency department.
89235215|NCT04118179||Surgical Group|Participants undergoing non-emergency scheduled surgery, including ear/nose and throat cases, orthopaedic surgery of the major joints including hip, knee, ankle, shoulder, and wrist.
89235216|NCT04118179||Healthy Group|Healthy participants
89235217|NCT04105335|Experimental|Cohort 1 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 70mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
89235218|NCT04105335|Experimental|Cohort 2 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 98mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
89235219|NCT04105335|Experimental|Cohort 3 MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA 130mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
89235220|NCT04105335|Experimental|Expansion Cohort MTL-CEBPA in combination with pembrolizumab|MTL-CEBPA RP2D administered once every 3 weeks on Day 1 of every 3 week cycle. Pembrolizumab 200mg administered once 3 weeks on Day 8 of every 3 week cycle.
89235221|NCT04087538||Patients treated using troponin T|
89235222|NCT04087538||Patients treated using troponin I|
89235223|NCT04072952|Experimental|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
89235224|NCT04072952|Experimental|ARV-471 and palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days.
89235225|NCT04071470|Active Comparator|Standard of Care|Standard of care for pregnant women at risk of HIV seroconversion includes couples counseling and access to PrEP (women) and ART (men)
89235226|NCT04071470|Experimental|Storytelling Intervention|Participants in this group will receive the same services as those in the SOC but will also be provided three storytelling sessions for themselves and their families as a way to educate and de-stigmatize PrEP services.
89235227|NCT04040049|Experimental|FLT190|FLT190 is a recombinant adeno- associated viral (AAV) vector. Administered by a single intravenous infusion.
89235228|NCT04021784|Experimental|Spring Distraction System (SDS)|The SDS will be placed and fits around a standard rod of 5.5mm.
89172946|NCT00671411|Experimental|1|Patients entering into this protocol will also have a preoperative renal contrast enhanced US for this research study. Renal mass US contrast enhancement results will be compared with surgical pathological findings to determine if contrast enhancement patterns of the renal masses correlate with benign and malignant histopathology, and/or malignant histologic subtype.
89172947|NCT04154735|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with fludarabine, cyclophosphamide, mesna, and alemtuzumab. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant until engraftment. Rifaximin and tacrolimus will be administered for 6 and 12 months, respectively, beginning one day before the infusion of stem cells.
89172948|NCT00665405||PN|Control - Induced or natural labor under anesthesia
89172949|NCT00665405||PC|Case - Cesarean section under anesthesia
89172950|NCT00665483|Experimental|1|Skin Prick Test
89172951|NCT00705042|Experimental|A|25 mg
89172952|NCT00705042|Experimental|B|50 mg
89172953|NCT04030806|Experimental|Intervention group|"All patients will perform 60 minutes of intervention, twice a week, for six weeks. During the intervention, the patient will be positioned seated in a chair with a table in front of him and a mirror (50cm x 50cm) will be placed vertically between his upper extremity.~The patient's paretic upper extremity will be positioned behind the mirror, allowing only the movements of his healthy upper extremity to be visualized. The reflective side of the mirror will be facing the healthy upper extremity , the patient will perform the exercises observing the movements of his healthy upper extremity through the reflection produced by the mirror, interpreting as the movement of his paretic member."
89172954|NCT04030806|Sham Comparator|Control group|All patients will perform 60 minutes of intervention, twice a week, for six weeks. The mirror will be placed in the same position as the intervention group. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm. In the control group, the patients will be submitted to the same bimanual activities of the intervention group, but without the reflecting side of the mirror. Thus, the nonreflective side of the mirror will be facing the healthy arm, the patient will perform the same exercises visualizing only the movement of the healthy member.
89172955|NCT00879437|Experimental|valproic acid and radiation, followed by valproic acid and bevacizumab|radiation phase (week 1-6): daily valproic acid and radiation, for approximately 6 weeks post-radiation phase (week 7-10): valproic acid daily maintenance phase (starting week 11): daily valproic acid, and bevacizumab once every 2 weeks; to continue for a maximum duration of 2 years
89172956|NCT00665639|Experimental|1|Daily dose
89172957|NCT00665639|Active Comparator|2|
89172958|NCT00665639|Experimental|3|Every other day dose, alternating with placebo
89172959|NCT00671567|Experimental|Ramelteon 8 mg QD|
89172960|NCT00671567|Experimental|Ramelteon 16 mg QD|
89172961|NCT00671567|Placebo Comparator|Placebo|
89172962|NCT04153253|Active Comparator|Group I|Intravitreal injection of Aflibercept followed by panretinal photocoagulation.
89172963|NCT04153253|Active Comparator|Group II: Early vitrectomy.|Early vitrectomy.
89172964|NCT00671645|Experimental|1|
89172965|NCT00675857|Placebo Comparator|A|
89172966|NCT00675857|Active Comparator|B|
89172967|NCT02629601|Experimental|Active Rewards|Participant will receive the standard active rewards incentives.
89172968|NCT02629601|Active Comparator|Active Rewards Doubled|Participant will receive the standard active rewards doubled in magnitude.
89172969|NCT02629601|Active Comparator|Active Rewards & Lottery 1|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward.
89172970|NCT02629601|Active Comparator|Active Rewards & Lottery 1 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward. Includes broadcasting winners (number) each week.
89172971|NCT02629601|Active Comparator|Active Rewards & Lottery 2 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 2 with a 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward. Includes broadcasting winners (number) each week.
89172972|NCT00675935|Experimental|1|One high-risk medical unit at each hospital will be randomly assigned to receive the fall prevention toolkit
89172973|NCT00675935|No Intervention|2|One high-risk medical unit at each hospital will be randomly assigned to receive usual care as it relates to fall prevention; i.e., receives no intervention.
89172974|NCT02629523|Experimental|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
89172975|NCT02629679||Males nonathletes|Boys non-involved in organized sport and exercising
89172976|NCT02629679||Females nonathletes|Girls non-involved in organized sport and exercising
89172977|NCT02629679||Males athletes|Athletic boys (involved in sports)
89172978|NCT02629679||Females athletes|Athletic girls (involved in sports)
89172979|NCT00676169||Observational|Pa negative or concurrently enrolled in the EPIC Clinical Trial
89172980|NCT04152005||Control|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
89172981|NCT04152005||Periodontitis|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
89172982|NCT04152005||Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
89172983|NCT04152005||Periodontitis+Cardiovascular|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
89172984|NCT00676247||preterm|Very-low-birth-weight preterm infants with brain lesion
89172985|NCT00676247||full-term|Healthy fullterm infants
89172986|NCT00671801|Experimental|Irinotecan + Lenalidomide|Irinotecan 200 mg/m^2 intravenous once every 2 weeks on days 1 and 15; Lenalidomide orally 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
89172987|NCT04153331|Experimental|Patients admitted to emergency department with medical cause|Patient included in emergency with a nasal swab
89235229|NCT04021784|Experimental|Necker Enfants Malade OSTeosynthesis (NEMOST)|The NEMOST is a one-way-rod that uses a ratchet type of locking mechanism. Both NEMOST devices should be placed in parallel, on the two fixator rods that are connected with a cross connector
89235230|NCT04006522|Experimental|Cohort 1|Patients with Localized RCC prior to nephrectomy.
89235231|NCT04006522|Experimental|Cohort 2|Patients with Unresectable/Metastatic RCC prior to treatment with an immune checkpoint inhibitor.
89235232|NCT03961061|Active Comparator|Brenner FIT (Standard Care)|Adolescents will participate in Brenner Families in Training along with their caregiver. They will receive all components of standard Brenner FIT treatments.
89235233|NCT03961061|Experimental|Brenner mFIT (standard care plus mobile health components)|"Adolescents will participate in Brenner Families in Training along with their caregiver.~Brenner mFIT (Families in Training + mobile health) includes all components of the standard Brenner FIT"
89235234|NCT03922048|Experimental|Cohort 1 Part A: HTX-011|Adolescents ≥12 to <17 years of age. A single dose of HTX-011 via instillation into the surgical site.
89235235|NCT03922048|Active Comparator|Cohort 1 Part A: bupivacaine HCl|Adolescents ≥12 to <17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site.
89235236|NCT03922048|Experimental|Cohort 1 Part B: HTX-011|Adolescents ≥12 to <17 years of age. Dose to be determined from Cohort 1 Part A.
89235237|NCT03922048|Active Comparator|Cohort 1 Part B: bupivacaine HCl|Adolescents ≥12 to <17 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
89235238|NCT03922048|Experimental|Cohort 2 Part A: HTX-011|Children ≥6 to <12 years of age. Dose to be determined from Cohort 1.
89235239|NCT03922048|Active Comparator|Cohort 2 Part A: bupivacaine HCl|Children ≥6 to <12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
89235240|NCT03922048|Experimental|Cohort 2 Part B: HTX-011|Children ≥6 to <12 years of age. Dose to be determined from Cohort 1.
89235241|NCT03922048|Active Comparator|Cohort 2 Part B: bupivacaine HCl|Children ≥6 to <12 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
89235242|NCT03922048|Experimental|Cohort 3: HTX-011|Children ≥3 to <6 years of age. Dose to be determined from Cohorts 1 and 2.
89235243|NCT03922048|Active Comparator|Cohort 3: bupivacaine HCl|Children ≥3 to <6 years of age. A single dose of bupivacaine HCl 0.25% (without epinephrine) via injection into the surgical site
89235244|NCT03891667|Experimental|8 Week Disulfiram|Patients in this group receive disulfiram for 8 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg for week 3, and 500 mg daily for week 4 to week 8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
89235245|NCT03891667|Active Comparator|4 Week Disulfiram|Patients in this group receive disulfiram for 4 weeks followed by placebo capsules for 4 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg during week 3, and 500 mg daily during week 4. Placebo capsules are given during weeks 5-8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
89235246|NCT03871855|Experimental|A:SHR-1702 Dose Escalation|SHR-1702 given intravenously (IV).
89235247|NCT03871855|Experimental|B:SHR-1702 Dose Expansion|SHR-1702 given intravenously (IV).
89235248|NCT03871855|Experimental|C:SHR-1702 and Camrelizumab Dose Escalation|SHR-1702 and Camrelizumab given intravenously (IV).
89235249|NCT03871855|Experimental|D:SHR-1702 and Camrelizumab Dose Expansion|SHR-1702 and Camrelizumab given intravenously (IV).
89235250|NCT03866174|Experimental|Psilocybin|Participants will receive a single 25 mg dose of psilocybin along with the Set and Setting (SaS) protocol. Psilocybin is administered orally as a capsule and taken with water.
89235251|NCT03866174|Active Comparator|Niacin|Participants will receive a single 100 mg dose of niacin along with the Set and Setting (SaS) protocol. Niacin is administered orally as a capsule and taken with water.
89235252|NCT03859869|Experimental|Resected Participants Receiving Low Dose (12,000/6,000 units lipase) Pancrelipase|Resected participants (surgery to remove pancreatic cancer) will first be given low dose pancrelipase. Low dose is defined as 12,000 USP units (lipase) with meals and 6000 U with snacks. At Weeks 1, 5, or 9, participants will be evaluated, and those who meet criteria for dose increase will be given high dose pancrelipase. High dose is defined as 72,000 U with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding.
89235253|NCT03859869|Experimental|Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase|Resected participants (surgery to remove pancreatic cancer) will receive and continue on high dose pancrelipase throughout the study. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding.
89235254|NCT03859869|Experimental|Non-Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase|Non-resected participants (those who did not have surgery to remove pancreatic cancer) will receive high dose pancrelipase throughout the study in an open-label cohort. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks.
89235255|NCT03822910||Healthy Controls|Matched Healthy Controls
89235256|NCT03822910||Firt Episode Psychosis (FEP)|subjects before and after antipsychotic treatment
89235257|NCT03799458|Active Comparator|Active Stimulation|Active HD-tDCS will be delivered while subjects perform sensory training tasks.
89235258|NCT03799458|Sham Comparator|Sham Stimulation|Sham HD-tDCS will be delivered while subjects perform sensory training tasks.
89235259|NCT03799458|No Intervention|Imaging Only|40 subjects will undergo initial testing only as a healthy control group.
89235260|NCT03763565||Vaccinated group|Thai women who received at least one dose HPV vaccination at least 5 years ago, either by Bivalent or Quadrivalent HPV vaccines when they were 20-45 years old
89235261|NCT03763565||Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
89235262|NCT03740204|Experimental|17-β estradiol with cyclic progesterone|
89235263|NCT03740204|Placebo Comparator|Placebo|
89235264|NCT03735563|Experimental|Ketamine|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
89235265|NCT03735563|Experimental|Fentanyl|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
89235266|NCT03717402|Other|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
89235267|NCT03715153|Experimental|BUMETANIDE (S95008) followed by Open-Label S95008|Participants will receive S95008 for 6 months, 26 weeks, and then they will begin an open-label 6 month treatment period with S95008.
89235268|NCT03715153|Placebo Comparator|PLACEBO followed by Open-Label S95008|Participants will receive placebo for 6 months, 26 weeks, and then they will begin an open-label 6 month treatment period with S95008.
89235269|NCT03685773|Experimental|MRI: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
89235270|NCT03685773|Placebo Comparator|MRI: Non-diabetic transplant (Placebo)|Taste-matched placebo for diazoxide
89235271|NCT03685773|Experimental|MRI: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg)
89235272|NCT03685773|Placebo Comparator|MRI: T2D transplant (Placebo)|Taste-matched placebo for diazoxide
89235273|NCT03685773|Experimental|Clamp: Non-diabetic transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
89235274|NCT03685773|Placebo Comparator|Clamp: Non-diabetic transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
89235275|NCT03685773|Experimental|Clamp: T2D transplant (Diazoxide)|Diazoxide (up to 7 mg/kg) before pancreatic clamp study
89235276|NCT03685773|Placebo Comparator|Clamp: T2D transplant (Placebo)|Taste-matched placebo (for diazoxide) before pancreatic clamp study
89235277|NCT03685773|Experimental|Clamp: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg) before pancreatic clamp study
89235278|NCT03685773|Experimental|Clamp: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide) before pancreatic clamp study
89235279|NCT03685773|Experimental|MRI: T2D transplant (Diazoxide + Nicotinic Acid)|Nicotinic acid infusion and diazoxide (up to 7 mg/kg)
89235280|NCT03685773|Experimental|MRI: T2D transplant (Placebo + Nicotinic Acid)|Nicotinic acid infusion and placebo (for diazoxide)
89235281|NCT03683277|Experimental|Ixazomib/Pomalidomide/Dexamethasone|"Single arm treatment organized in 2 separate phases~Induction phase : association of Ixazomib, Pomalidomide & Dexamethasone (IPD) 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years or Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Maintenance phase : association of Ixazomib and Pomalidomide (IP) 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
89235282|NCT03665207|Experimental|Tight glucose control|Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.
89235283|NCT03665207|Active Comparator|Liberal glucose control|Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.
89235284|NCT03660683|Experimental|Group A Dapa|Dapagliflozin 10 mg + Saxagliptin Placebo
89235285|NCT03660683|Active Comparator|Group B DapaSaxa|Dapagliflozin 10mg + Saxagliptin 5mg
89235286|NCT03660683|Placebo Comparator|Placebo|Placebo Oral Tablet
89235287|NCT03566511|Experimental|Healthy (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Healthy participants will receive diazoxide between MRI scans.
89235288|NCT03566511|Placebo Comparator|Healthy (Placebo)|Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
89235289|NCT03566511|Experimental|T2D (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
89235290|NCT03566511|Placebo Comparator|T2D (Placebo)|Taste-matched placebo. T2D participants will receive placebo between MRI scans.
89235291|NCT03525262|No Intervention|SAbR WITHOUT Neurovascular sparing|"GTV represents MR defined dominant radiographic disease, if identifiable.~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.~PTV1_30Gy will not be used or created on this arm~PTV2_SAbR40Gy OR PTV2_SAbR45Gy will be generated by a 3mm expansion on the CTV. PTV2_SAbR will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
89235292|NCT03525262|Experimental|SAbR WITH Neurovascular sparing|"GTV represents MR defined dominant radiographic disease, if identifiable.~CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.~PTV1_30Gy represents a 3mm expansion on the CTV, excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).~PTV2_SAbR40Gy OR PTV2_SAbR45Gy will be generated by subtracting a 5mm expansion around the neurovascular elements to be spared (at least one side, left or right) from PTV1. These neurovascular structures consist of the neurovascular bundle, penile bulb, and internal pudendal arteries (see 4.1.5.2.16). PTV2 will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy)."
89235293|NCT03494179|Experimental|High Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
89172988|NCT00676325|Active Comparator|1|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction were eligible for participation.traditional colporrhaphy in this group.
89172989|NCT00676325|Active Comparator|2|The NAZCA TC™ POP REPAIR SYSTEM (polypropylene mesh repair),promedon™ , cordoba, argentina, is used to repair anterior vaginal prolapse by a transobturator and pre pubic approach . Helical needles are used to anchor graft to the pelvic sidewall at two points transobturator, the other two arms pre pubic needles is used. We designed this randomized control trial to compare the anatomic success rates, effect on quality of life and sexual symptom scores, and rates of adverse events of the procedure with polypropylene mesh with that of anterior colporrhaphy, with planned follow-up of 1 years.
89172990|NCT00676481|Active Comparator|1|Phase III participants who are educated about risk of HIV infection before receiving a rapid HIV test
89172991|NCT00676481|No Intervention|2|Phase III participants who are not educated about risk of HIV infection before receiving a rapid HIV test
89172992|NCT00671957||Patients undergoing gastric bypass|"Patients undergoing gastric bypass surgery and who are participants in Longitudinal Assessment of Bariatric Surgery (LABS-2).~Inclusion Criteria:~No acute illnesses~Weight less than 227 kg (limit of Bod Pod and Treadmill)~Able to walk at 2.4 mph for 15 minutes (needed for the energy expenditure testing)~No tobacco use~Ability to stop alcohol consumption during test phases~For female subjects; no plans for pregnancy in 24 months and menstrual cycles of 21-35 days~No history of eating disorder~No history of current substance abuse~No history of chest pain or shortness of breath at rest or on exertion.~Negative pregnancy in women."
89172993|NCT00672035|Experimental|1|7.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
89172994|NCT00672035|Experimental|2|7.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
89172995|NCT00672035|Experimental|3|22.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
89172996|NCT00672035|Experimental|4|22.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
89172997|NCT00672035|Experimental|5|37.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
89172998|NCT00672035|Experimental|6|37.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
89172999|NCT00672035|Experimental|7|50µg LT Dose placed at the Deltoid on Day 0 and Day 21
89173000|NCT00672035|Experimental|8|50µg LT Dose placed at the Lower Back on Day 0 and Day 21
89173001|NCT00672035|Placebo Comparator|9|Placebo (0µg LT) placed at the Deltoid on Day 0 and Day 21
89173002|NCT00672035|Placebo Comparator|10|Placebo (0µg LT) placed at the Lower Back on Day 0 and Day 21
89173003|NCT00676559|Experimental|Group 1|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
89173004|NCT00676559|Experimental|Group 2|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
89173005|NCT00676559|Experimental|Group 3|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks in combination with ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
89173006|NCT00672113|Experimental|Arm 1|
89173007|NCT00672113|Active Comparator|Arm 2|
89173008|NCT00676637||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
89173009|NCT00672269||1|Families with carcinoid in multiple family members
89173010|NCT00877799|Experimental|CR845|CR845 administered as a single 15-min i.v. infusion at doses of 0.008 or 0.024 mg/kg on the day after surgery (Cohort 1), or at a dose of 0.040 mg/kg immediately after surgery (Cohort 2)
89173011|NCT00877799|Placebo Comparator|Placebo|Matched placebo administered as a single 15-min i.v. infusion on the day after surgery (Cohort 1), or the immediately after surgery (Cohort 2)
89173012|NCT00672347|Active Comparator|B|compare caudal anesthesia with bupivacaine alone or in addition to morphine, clonidine or both
89173013|NCT00672347|Active Comparator|C|compare caudal anesthesia with bupivacaine plus clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or morphine plus clonidine
89173014|NCT00672347|Active Comparator|M|compare caudal anesthesia with bupivacaine plus morphine with caudal anesthesia with bupivacaine alone or in addition to clonidine or morphine plus clonidine
89173015|NCT00672347|Active Comparator|CM|compares caudal anesthesia with bupivacaine, morphine and clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or clonidine
89173016|NCT00676871|Experimental|1|MEDI-538
89173017|NCT00676871|Experimental|2|MEDI-538
89173018|NCT00676871|Experimental|3|MEDI-538
89173019|NCT00676871|Experimental|4|MEDI-538
89173020|NCT00676871|Experimental|5|MEDI-538
89173021|NCT00676871|Experimental|6|MEDI-538
89173022|NCT00676871|Experimental|7|MEDI-538
89173023|NCT00676949|Experimental|1|cyclophosphamide dose escalation, level 1:150mg/m2,level 2: 300mg/m2, level 3: 300mg/m2x2, with 5 kinds o tumor specific antigen peptides followed by low dose IL-2, 6 patients will be enrolled for each level.
89173024|NCT00672503||1|Patients who acquired a CA-UTI in the PICU between 2004-2007.
89173025|NCT00672503||2|Patients who did not acquire a CA-UTI while hospitalized in the PICU but had an indwelling urinary catheter between 2004-2007.
89173026|NCT00672503||A|Nurses currently employed in the PICU at Children's Mercy Hospital.
89173027|NCT00672503||a|Root Cause Analysis on all patients who acquired a CA-UTI during 2009.
89173028|NCT00677027|Experimental|1|
89173029|NCT00677027|Placebo Comparator|2|
89173030|NCT00672581|Experimental|1|Control (healthy volunteers)
89173031|NCT00672581|Experimental|2|Mild Hepatic Impairment
89173032|NCT00672581|Experimental|3|Moderate Hepatic Impairment
89173033|NCT00672581|Experimental|4|Severe Hepatic Impairment
89173034|NCT00595127|Experimental|1|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m^2 of unlabeled 8H9.
89173035|NCT00672659|Active Comparator|1|Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
89173036|NCT00672659|Placebo Comparator|2|Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
89173037|NCT00677183||SN###.#1|All children in this cohort will have biopsy-proven NASH.
89173038|NCT00677183||SN###.#2|This cohort will be parents (mother and father when possible) of child subjects with biopsy-proven NASH.
89173039|NCT00877487|Experimental|SPD489|
89173040|NCT00877487|Placebo Comparator|Placebo|
89173041|NCT02629211|Experimental|NaviAid™ AB|NaviAid™ AB device procedure
89173042|NCT00677261|Experimental|1|
89173043|NCT00677261|Experimental|2|
89173044|NCT00677261|Sham Comparator|3|
89173045|NCT00912119|Experimental|Group A|Group A - Low Dose
89173046|NCT00912119|Experimental|Group B|Group B - Intermediate Dose
89173047|NCT00912119|Experimental|Group C|Group C - High Dose
89173048|NCT00912119|Experimental|Group D|Group D - Extra Low
89173049|NCT02629289|Other|Treatment A|HSP-130, 6 mg, single subcutaneous (SC) injection in the deltoid region
89173050|NCT02629289|Other|Treatment B|US-approved Neulasta, 6 mg, single SC injection in the deltoid region
89173051|NCT02629289|Other|Treatment C|EU-approved Neulasta, 6 mg, single SC injection in the deltoid region
89173052|NCT00677339|Active Comparator|1|Active L-arginine plus active vitamin D
89173053|NCT00677339|Active Comparator|2|Placebo L-arginine plus active Vitamin D
89173054|NCT00677339|Active Comparator|3|Active L-arginine plus placebo vitamin D
89173055|NCT00677339|Placebo Comparator|4|placebo L-arginine plus placebo vitamin D
89173056|NCT00672893||Observation|Patients who present to the clinic with airway obstruction and who are designated to undergo intervention
89173057|NCT00672971|Experimental|1|4% dimethicone foam
89173058|NCT00672971|Active Comparator|2|1% permethrin
89173059|NCT00673205|Placebo Comparator|A|
89173060|NCT00673205|Active Comparator|B|
89173061|NCT00673283|Experimental|A|
89173062|NCT00677495|Experimental|Gluten-free diet|Gluten-free diet
89173063|NCT00677573|Active Comparator|UrFSH|
89173064|NCT00677651||1|Five caucasian women
89173065|NCT00677651||2|Five caucasian men
89173066|NCT02628431||General anesthesia|Patients that will recieve general anesthesia for elective surgery
89173067|NCT02628431||Regional or neuraxial anesthesia|Patients that will revieve regional or neuraxial anesthesia for elective surgery
89173068|NCT00677729|Active Comparator|1|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline (NaCl)
89173069|NCT00677729|Placebo Comparator|2|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl)
89173070|NCT02629055|Experimental|Respiratory EMG|Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
89173071|NCT02629055|No Intervention|Care as usual|NIV will be initiated according to standard care protocol.
89173072|NCT02628509||cardiac devices|patients receiving mechanical circulatory support patients undergoing transaortic valve replacement
89173073|NCT02635295|Experimental|Mobile cooperation|Nursing student - nurse teacher mobile cooperation during the clinical practicum.
89173074|NCT02635295|No Intervention|Standard cooperation|Nursing student - nurse teacher standard cooperation during the clinical practicum.
89173075|NCT02635139|Experimental|Breakfast Skipping|Effect of breakfast skipping on metabolism
89173076|NCT02635139|Experimental|Dinner Skipping|Effect of dinner skipping on metabolism
89173077|NCT00673517||1|Patients randomized to high frequency oscillation
89173078|NCT00673517||2|Patients randomized to conventional lung protective ventilation
89173079|NCT02628353|Placebo Comparator|Placebo|control group
89173080|NCT02628353|Experimental|Phenolic compound|treated group
89173081|NCT02628197|Active Comparator|CONTROL GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.Scaling and root planing was not done in this group.
89173082|NCT02628197|Active Comparator|TEST GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received scaling and root planing along with calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.
89173083|NCT00673751|Placebo Comparator|2|subcutaneous isotonic saline
89173084|NCT00673751|Active Comparator|1|subcutaneous GLP-2
89173085|NCT00911885|Experimental|High Fiber Diet|A single dietary change condition that focuses exclusively on increasing fiber.
89173086|NCT00911885|Active Comparator|AHA Diet|The AHA Diet is the current recommendation for patients with the metabolic syndrome.
89173087|NCT00677963|Other|1|Patients with symptomatic 70-99% carotid stenosis who are operated on.
89173088|NCT00673829|Experimental|Phase Ia|
89173089|NCT00673829|Experimental|Phase Ib: Control|
89173090|NCT02628119|Experimental|Intra-procedural access flow|"Management of access dysfunction based on intra-procedure access flow monitoring.~Criteria for target access flow:~Within 90% of baseline access flow if known 180% increase from pre-intervention flow if access flow not known 600ml/min for thrombosed grafts and 500 ml/min for thrombosed arteriovenous fistula in case baseline access flow not known"
89173091|NCT02628119|Active Comparator|Standard Angioplasty|Intervention based on current standards of care i.e. 2 dimensional angiographic views.
89173092|NCT04152629|Experimental|FOQUEST adults|adult (≥18 years or older) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg, or 100 mg/day)
89173093|NCT04152629|Active Comparator|VYVANSE adults|adult (≥18 years or older) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
89173094|NCT04152629|Experimental|FOQUEST pediatric|pediatric (6 to 17 years old) patients with ADHD receiving FOQUEST (controlled-release methylphenidate 25 mg, 35 mg, 45 mg, 55 mg or 70 mg/day)
89173095|NCT04152629|Active Comparator|VYVANSE pediatric|pediatric (6 to 17 years old) patients with ADHD receiving VYVANSE (lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg/day)
89173096|NCT02628977|Experimental|OSA Health Education & Support Group|Participants randomly assigned to the intervention arm will receive OSA health education and social support from a trained Peer educator.
89173097|NCT02628977|Active Comparator|Attention Control Group|Participants in the attention control group will receive standard sleep literature, providing information about Obstructive Sleep Apnea and access to available sleep services.
89173098|NCT04152707|Experimental|Splendor X|
89173099|NCT00673907|Sham Comparator|1|Clean air
89173100|NCT00673907|Experimental|2|Wood smoke particle concentration of 200 ug/m3
89173101|NCT00673907|Experimental|3|Wood smoke particle concentration of 400 ug/m3
89173102|NCT02535299|Experimental|insulin|basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.
89173103|NCT00673985|Active Comparator|1|"PTA Only: Active Comparator~Percutaneous transluminal angioplasty (PTA) alone"
89173104|NCT00673985|Experimental|2|"Test Arm: Experimental~The main objective of this study is to assess the safety and effectiveness of the Edwards Lifesciences LifeStent nitinol self expandable stent device and its delivery system in the treatment of occlusive superficial femoral artery (SFA) disease."
89173105|NCT02628041|Active Comparator|Permanent Iodine-125 seed implant|Prostate brachytherapy using Iodine-125 seed implant to a prescription dose of 144 Gy delivered to the Target volume defined as Clinical Target volume (CTV)+ 0-3 mm margin.
89173106|NCT02628041|Experimental|High-dose-Rate Prostate brachytherapy|"Prostate brachytherapy implant using Iridium-192 to a prescription dose of 19 Gy delivered to the CTV in one fraction. Greater than 95% coverage of the CTV with the prescription dose is considered per protocol, 90-95% coverage is considered a minor deviation and, < 90% coverage is considered a major deviation.~Attempts should be made to achieve these other dosimetric values:~D90: 105-115%~V150 ≤ 35%~V200 ≤ 12%"
89173107|NCT00674063|Experimental|1|Dose regimen 1
89173108|NCT00674063|Experimental|2|Dose regimen 2
89173109|NCT04151459|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy on severe obesity PCOS patients
89173110|NCT00674141|Other|1|only one experimental treated group
89173111|NCT00678197|Experimental|A|
89173112|NCT00678197|Experimental|B|
89173113|NCT00678197|No Intervention|C|
89173114|NCT00678275|Other|A|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, RECEIVING ATG in conditioning regimen
89173115|NCT00678275|Other|B|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, NOT RECEIVING ATG in conditioning regimen
89173116|NCT00878501|Experimental|AZD1386, 90 mg|
89173117|NCT00878501|Experimental|AZD1386, 30 mg|
89173118|NCT00878501|Placebo Comparator|Placebo|
89173119|NCT00678353||1|Follow-up to S01-01US, conducted to expand information
89173120|NCT00674375|Experimental|1|Primary care clinicians (physicians, nurse practitioners, and physician assistants) randomized to the intervention arm will receive electronic alerts within the electronic medical record system during office visits with patients complaining of chest pain.
89173121|NCT00674375|No Intervention|2|Primary care clinicians randomized to the 'no intervention' arm will evaluate and treat patients complaining of chest pain without the aid of electronic risk alerts.
89173122|NCT04162145|Active Comparator|Active Device|Patients in the Active Device arm will receive placement of an active BRIDGE device.
89173123|NCT04162145|Sham Comparator|Sham Device|Patients in the Sham Device arm will receive placement of an inactive, or sham, BRIDGE device. The inactive device will be identical in appearance to the active device but will have no electrical current.
89173124|NCT02627885|Active Comparator|ICBT|Internet-based CBT for Parkinsons Disease with therapist contact added to standard medical treatment
89173125|NCT02627885|Other|SMT|Standard Medical Treatment for Parkinsons Disease only
89173126|NCT00674453|Experimental|Lasofoxifene 0.25 mg/d|
89173127|NCT00674453|Placebo Comparator|Placebo|
89173128|NCT02634671|Other|22Q11|24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
89173129|NCT02634671|Other|SCHIZOPHRENIA|24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
89173130|NCT02627807|Experimental|Individualized CTV|Patients receive IMRT using individualized CTV based on disease extension risk atlas and computer-aided delineation. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
89173131|NCT02627807|Active Comparator|Traditional CTV|Patients receive IMRT using traditional CTV. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
89173132|NCT00674531|Other|1|Enterovirus RNA analysis
89173133|NCT00678431|Placebo Comparator|Arm 1|Liquid placebo
89173134|NCT00678431|Experimental|Arm 2|Liquid Resveratrol with Glucose, and Malate
89173135|NCT00678509|Experimental|A|
89173136|NCT00674687|Placebo Comparator|Sequence 1|
89173137|NCT00674687|Experimental|Sequence 2|
89173138|NCT02628821||Preterm Infants treated with non-invasive ventilation|"Preterm Infants of less than 32 weeks of Gestational age treated with synchronized non-invasive ventilation (SNIPPV) to prevent intubation or extubation failure based in a prospective protocol:~nCPAP failure: Preterm infants supported with nCPAP that meet intubation criteria if they are in a stable situation.~Electively For extubation:~Preterm infants in which nCPAP extubation has previously failed or Prolonged mechanical ventilation (more than 15 days) with high respiratory parameters (PMAP > 10 cmH2O and FiO2>35%)."
89173139|NCT02634749|Experimental|Nordic diet|The participant in the Nordic diet group will experience three interventions: a) a systematic introduction of taste portions, b) Protein reduced complementary foods (milk cereal drinks, porridge and baby milk with reduced protein content), and c) homemade and industry manufactured main meals with a predominance of Nordic ingredients.
89235294|NCT03494179|Experimental|Low Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
89173140|NCT02634749|No Intervention|Regular diet|The participants will be given the current advice on infant feeding issued by the Swedish National Food Agency. They will also be given regular, commercially available milk cereal drinks, porridge, baby milk and industry manufactured main meals. No advice or recipes on meals will be given apart from the current recommendations.
89173141|NCT00656747|Active Comparator|Arm 2|
89173142|NCT00656747|Experimental|Arm 1|
89173143|NCT04152317|Experimental|Misoprostol 200mcg|In this group, the participants will receive 200mcg of misoprostol, single dose, via the vaginal route.
89173144|NCT04152317|Active Comparator|Misoprostol 800mcg|In this group, the participants will receive 800mcg of misoprostol, single dose, via the vaginal route.
89173145|NCT02628665|Experimental|24 to 48 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 24 to 48 hours: The injection of photosensitizer(photofrin) 24 to 48 hours light irradiation power.~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
89173146|NCT02628665|Active Comparator|48 to 72 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 48 to 72 hours: The injection of photosensitizer(photofrin) 48 to 72 hours light irradiation power.~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
89173147|NCT00674843|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
89173148|NCT00678977|Experimental|Arm A|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, and 1000 mg/m2 gemcitabine. Intermediate dose levels may also be explored. Intravenous gemcitabine will be given on Day 1 and 8 of Cycle 1 and each subsequent cycle.~Cohort expansion phase - patients will receive gemcitabine alone, at the OTR dose starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR beginning on Day 2 Cycle 1 after the last blood sample for gemcitabine analysis is collected, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib. On Day 1 of Cycle 2 patients will receive the simultaneous administration of gemcitabine and pazopanib"
89173149|NCT00678977|Experimental|Arm B|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, 1000 mg/m2 gemcitabine and 60 mg/m2 cisplatin. Doses of gemcitabine may range from 600 to 1250 mg/m2. Doses of cisplatin may range from 60 to 80 mg/m2. Intermediate dose levels may also be explored. Pazopanib administered starting on Day 1 of Cycle 1, gemcitabine co-administration on Day 1 and 8, and cisplatin on Day 1 in each 21-day cycle.~Cohort expansion - patients will receive gemcitabine and cisplatin alone, at the OTR doses, starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR dose beginning on Day 2 of Cycle 1, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib"
89173150|NCT00674921|Placebo Comparator|1|It will comprise patients randomized to receive the placebo (stop cotrimoxazole prophylaxis) at CD4 counts of 200 or more but less than 350 cells/ul as they continue with HAART. Patients will be followed until they achieve a CD4 count of 350 cells/ul.
89173151|NCT00674921|Active Comparator|2|It will comprise patients randomized to continue with cotrimoxazole prophylaxis and HAART at CD4 counts of 200 or more but less than 350 cells/ul. These patients will be followed until they achieve a CD4 count of 350 cells/ul and above, at which point they will be considered for the second randomization.
89173152|NCT00674921|Placebo Comparator|A|This arm will comprise patients who have achieved a CD4 count of 350 or more cells/ul either at the beginning of the study or once they have reached this threshold at the end of follow up in arms 1 and 2. They (including those previously in Arm 1) will receive the placebo (stop cotrimoxazole prophylaxis) after the second randomization but continue with HAART.
89173153|NCT00674921|Active Comparator|B|It will comprise patients randomized to continue or start with cotrimoxazole prophylaxis and HAART at CD4 of 350 or more cells/ul after second randomization. Some of them will have used cotrimoxazole prophylaxis whilst they were in arm 2 and others in arm 1 will restart cotrimoxazole prophylaxis at this stage.
89173154|NCT00674999|Experimental|1|Amnion with processing procedures involving the use of trypsin-Edetic Acid(EDTA)
89173155|NCT00674999|Experimental|2|Amnion with processing procedures involving the use of Dispase II
89173156|NCT00674999|Active Comparator|3|Prepared Antibiotic ointment Polysporin, Bacitracin and Mycostatin
89173157|NCT00882713|Experimental|C.E.R.A.|Eligible participants will be administered continuous erythropoietin receptor activator (C.E.R.A.[Mircera]) intravenously (IV) every 4 weeks for 44 weeks. The starting dose of 120, 200, or 360 micrograms (mcg) will be based on the dose of epoetin alfa or beta administered in the week preceding the switch to C.E.R.A. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin (Hb) within a range of +/- 1.0 grams per deciliter (g/dL) of the reference hemoglobin (Hb) concentration and between 10.50 and 12.50 g/dL.
89173158|NCT02627729|Active Comparator|Linear cutter-Circular stapler J pouch|J pouch anal anastomosis after laparoscopic low anterior resection
89173159|NCT02627729|Active Comparator|Circular stapler Side-to-end anastomosis|side to end coloanal anastomosis after laparoscopic low anterior resection
89173160|NCT04162223|Experimental|Subcutaneous Fat Vaccine Injection|Subcutaneous fat Hepatitis B vaccine injections on Days 0, 28, and 180.
89173161|NCT04162223|Experimental|Intramuscular Vaccine Injection|Intramuscular Hepatitis B vaccine injections on Days 0, 28, and 180.
89173162|NCT04151381|Placebo Comparator|the control group|the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .
89173163|NCT04151381|Active Comparator|Amiophylline (2mg)|Aminophylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia
89235295|NCT03472404|Experimental|Intervention Group|Internal Brace augmented ankle Ligament reconstruction
89235296|NCT03472404|Active Comparator|Control Group|Brostrom-Gould ankle Ligament reconstruction
89235297|NCT03464136|Experimental|Group 1 (Ustekinumab)|Participants will receive intravenous (IV) infusion of ustekinumab (approximately 6 milligram/kilogram [mg/kg]) and 4 subcutaneous (SC) injections of placebo for adalimumab at Week 0, followed by 2 SC injections of placebo at Week 2. From Week 4 to Week 56, participants will self-administer one SC injection of ustekinumab 90 milligram (mg) every 8 weeks (q8w) starting at Week 8 and placebo adalimumab at the other designated every 2 weeks (q2w) dosing intervals.
89235298|NCT03464136|Active Comparator|Group 2 (Adalimumab)|Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.
89235299|NCT03427450||Healthy Volunteers (Controls)|A control population of healthy volunteers (HVs) consisting of women with no prior/current history of cancer and no known history of breast disease (the information obtained from the HVs may be 'self-reports', as complete medical records may not be available at the enrolling site for these control subjects), and with a broadly similar age range to the cancer patient study population. All eligible and consenting subjects will have blood draw.
89235300|NCT03427450||MBC Patients (Cancers)|Women with either newly diagnosed metastatic breast cancer who are about to start a new line of therapy of any type for the treatment and/or management of their disease or those with currently progressive or recurrent disease (as determined by any means) will be eligible for enrollment into the cancer population. All eligible and consenting subjects will have blood draw.
89235301|NCT03382587||Aflibercept|Treatment-naive wet age-related macular degeneration patients under routine intravitreal aflibercept treatment in a treat-and-extend scheme
89235302|NCT03325972|Experimental|IV dexmedetomidine|Dexmedetomidine is an alpha-2-adrenergic agonist. It is commonly used for sedation and as an adjunct to general anesthetics.
89235303|NCT03325972|Placebo Comparator|Placebo|saline placebo
89235304|NCT03261362|Placebo Comparator|Amino acid powder with all amino acids|amino acid powder 80 g oral Administration 1 week
89235305|NCT03261362|Active Comparator|Amino acid powder without BCAAs-reduced intake|Branched-chain amino acids reduced intake - amino acid powder lacking BCAAs 80 g oral Administration 1 week -
89235306|NCT03247712|Experimental|Treatment Cohort 1|Nivolumab administration (3 doses) and radiation (5 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
89235307|NCT03247712|Experimental|Treatment Cohort 2|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
89235308|NCT03247712|Experimental|Treatment Cohort 3|Radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
89235309|NCT03247712|Experimental|Treatment Cohort 4|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
89235310|NCT03235076|Experimental|Subjects with mild renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
89235311|NCT03235076|Experimental|Subjects with moderate renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
89235312|NCT03235076|Experimental|Subjects with severe renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
89235313|NCT03235076|Experimental|Matched healthy subject group|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
89235314|NCT03208049|Experimental|Sleep Restriction Therapy|Sleep Restriction Therapy (SR). The initial Time in Bed (TIB) prescription is calculated on the average total sleep time (TST) reported in the baseline sleep logs. After one week, depending on subject's daily sleep logs and adherence to treatment, the therapist suggests a new TIB prescription. Napping is neither prescribed nor proscribed. However, if subjects find themselves having difficulty staying awake during the day, they are advised to take a brief (15 to 30 minutes) nap to ensure their safety.
89235315|NCT03208049|Experimental|Cognitive Therapy|Cognitive Therapy (CT). The CT treatment module is designed to meet three general goals: 1) identify dysfunctional sleep cognitions, 2) challenge their validity, and 3) replace them with more adaptive substitutes. Several specific techniques designed to meet these goals are discussed in materials distributed to subjects. Similar to SR, subjects in CT are provided with information about relevant elements of the science of sleep and healthy sleep practices.
89235316|NCT03196518|Experimental|PET Imaging With 18F-TFB|The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
89235317|NCT03104699|Experimental|Monotherapy|Dose of 3 mg/kg IV every 2 weeks for up to 24 months.
89235318|NCT03048825|Experimental|Colchicine + Spironolactone +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
89235319|NCT03048825|Experimental|Spironolactone +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
89235320|NCT03048825|Experimental|Colchicine +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
89173164|NCT04151381|Active Comparator|Aminophylline(4mg)|Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.
89173165|NCT04151537|Active Comparator|Intervention|The intervention group is provided with a PA tracker that enables self-monitoring of PA and are instructed to obtain a personalized PA goal on a weekly basis.
89173166|NCT04151537|Active Comparator|Control|The control group is recommended to follow national PA guidelines, which can be considered as the 'intervention' offered to the public.
89173167|NCT00675077|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
89173168|NCT00809133|Experimental|Part A|BIBW2992 + Paclitaxel
89173169|NCT00809133|Experimental|Part B|BIBW2992 + Paclitaxel + Bevacizumab
89173170|NCT00809133|Experimental|Part C|BIBW2992 + Carboplatin
89173171|NCT00809133|Experimental|Part D|BIBW2992 +Paclitaxel + Carboplatin
89173172|NCT00679133|Experimental|1|
89173173|NCT04151771|Experimental|LL-BFRT group|Participants randomised into intervention group are attending pulmonary rehabilitation in which strengthening exercises of the lower limb are performed using LL-BFRT.
89173174|NCT04151771|Active Comparator|Usual pulmonary rehabilitation group|Participants randomised into control group are attending usual pulmonary rehabilitation as established.
89173175|NCT00675155|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
89173176|NCT02634593|No Intervention|Control|Control
89173177|NCT02634593|Active Comparator|Low glycemin load snacks|Low glycemic load snacks, consumed during specific times
89173178|NCT00912275|Experimental|Lapatinib plus Oral Vinorelbine|Oral vinorelbine on day 1 and day 8 q3w plus lapatinib 1000mg/day.
89173179|NCT00675233|Experimental|Treatment PDT|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.
89173180|NCT04151303||Cerclage 1|Time to delivery after cerclage removal Between 36-36.6 weeks' gestation - group 1
89173181|NCT04151303||Cerclage 2|Time to delivery after cerclage removal Between 37-37.6 weeks' gestation - group 2
89173182|NCT04151303||Cerclage 3|Between 38-38.6 weeks' gestation - group 3
89173183|NCT04151303||Cerclage 4|Time to delivery after cerclage removal Beyond 39 weeks' gestation - group 4
89173184|NCT04152395||Metabolic group|Patients with metabolic syndrome undergoing EVAR
89173185|NCT04152395||Control group|Patients without metabolic syndrome undergoing EVAR
89173186|NCT02608749|Experimental|IC|Integrated care (IC)
89173187|NCT02608749|Experimental|LEE|Lower extremity exercise (LEE)
89173188|NCT02608749|Experimental|HC|Home care (HC)
89173189|NCT00675311|Active Comparator|DM-Standard|The conventional disease management group will receive management under the site's usual program offering, which includes, but is not limited to, compliance with the prescribed treatment regimens, dietary management, exercise programs, and other measures recommended by the American Diabetes Association (ADA) and the Association of American Endocrinologists (AACE).
89173190|NCT00675311|Active Comparator|DM-Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology that includes mobile phone client software with web-based companion software, Bluetooth glucose meter cradle, and web-based clinical management software for the clinical management team. The core of the system is the patient's cell phone which is used as an input device and which enables patients to maintain an electronic diary of information such as meal times, blood glucose, insulin use, weight, blood pressure, and exercise. The device is customizable to collect only the information relevant to the patient with diabetes and their healthcare provider. The patient with diabetes enters diary information on his or her mobile phone. No immediate or real-time information is provided to patients as part of this study.
89173191|NCT00882557|Experimental|A|9 mg/kg of daptomycin administered during the last 30 minutes of a hemodialysis session.
89173192|NCT00882557|Experimental|B|Post dialysis dosing
89173193|NCT02627573|Experimental|Thymoglobulin|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
89173194|NCT02627573|Experimental|PTCy|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
89173195|NCT00656825|Active Comparator|Panel I|The first 12 subjects will be selected and ranodmized in order to receive the first treatment dose of 100 μg/mL or placebo in a 8:4 ratio
89173196|NCT00656825|Active Comparator|Panel II|The second 12 subjects will be selected and randomized in order to receive the second treatment dose of 200 μg/mL or placebo in a 8:4 ratio
89173197|NCT00656825|Active Comparator|Panel III|The third 12 subjects will be selected and randomized in order to receive the third treatment dose of 300 μg/mL or placebo in a 8:4 ratio
89173198|NCT00656825|Placebo Comparator|Placebo|Patients from each panel will be given placebo in a 4:8 ratio.
89173199|NCT00675389|Experimental|A|Peer Health Workers Intervention
89173200|NCT00675389|Experimental|B|Peer Health Workers and Mobile Phone Intervention
89173201|NCT00675389|No Intervention|C|Control
89173202|NCT00675467||Group 1|Early cancer group-children ages 10-13 years
89173203|NCT00675467||Group 2|Early cancer group-children ages 14 to 18 years
89173204|NCT00675467||Group 3|Early cancer group-parents of patients ages 10-18 years
89173205|NCT00675467||Group 4|Advanced cancer group-children ages 10-13 years
89173206|NCT00675467||Group 5|Advanced cancer group-children ages 14-18 years
89173207|NCT00675467||Group 6|Advanced cancer group-parents of children ages 10-18 years
89173208|NCT00675467||Group 7|End of life group - parents of children ages birth to 18 years of age at time of death
89173209|NCT00679445|Experimental|A|Device: NeoVista Ophthalmic System A single procedure using the NeoVista Ophthalmic System plus an injection of Lucentis.
89173210|NCT00675545|Experimental|docetaxel and prednisolone|"Patients in study will receive both chemotherapeutic agents on day 1 and day 8 of every 21-day cycle as described below:~Docetaxel 30 mg/m2 over 1 hour IV infusion, followed by~Carboplatin (AUC 2) over 1 hour IV infusion~Additonal medication required: IV Dexamethasone 10 mg followed by PO dexamethasone 4 mg 8 hourly x 4 doses, starting 12 hours after starting iv docetaxel."
89173211|NCT00679523|Experimental|Group 1|AN2690 Solution, 5.0%
89173212|NCT00679523|Experimental|Group 2|AN2690 Solution, 7.5%
89173213|NCT00675701|Placebo Comparator|A|Placebo by mouth
89173214|NCT00675701|Experimental|B|lixivaptan
89173215|NCT00675701|Active Comparator|C|moxifloxacin
89173216|NCT00808899|Experimental|1|Fixed doses of IV temsirolimus concomitantly with two courses of fixed dosages of irinotecan, 2 days off, repeated daily 5 times.If initial dosages are not tolerable, subsequent patients will be given a reduced dosage of temsirolimus with irinotecan.If this dosage combination is not tolerable,irinotecan dosage will be decreased.If this dosage combination is not tolerable.Further enrollment to initial six week treatment will be terminated.Second course of irinotecan will begin on day 22, response will be determined after six weeks. Resection of primary tumor will be attempted after initial therapy.Following initial treatment children will undergo alternating courses of induction chemotherapy with cyclophosphamide,doxorubicin,etoposide,topotecan, and cisplatin.First cohort of 17 patients will receive Block 2 with temsirolimus for all three courses, weekly 2 times.If this is not tolerated subsequent patients will receive Block 2 chemotherapy with reduced dosages of temsirolimus.
89173217|NCT00808665|Experimental|Dexmedetomidine|At the beginning of spinal surgery, patients will receive 1 hour dexmedetomidine intravenous bolus of 0.7 mcg/kg, followed by infusion of dexmedetomidine at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of dexmedetomidine at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
89173218|NCT00808665|Placebo Comparator|Saline|Since this is a blinded study, at the beginning of spinal surgery, patients will receive a 1 hour 0.9% saline intravenous bolus at a rate and volume commensurate with a 0.7 mcg/kg/hour bolus of dexmedetomidine. Similarly, this will be followed with a saline infusion at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of saline at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
89173219|NCT04586517|Experimental|Intervention group|Participants will receive supervised heavy-load resistance training twice a week during treatment with chemotherapy (approximately 16-weeks). After end of chemotherapy, participants will be encouraged to continue the training program and are provided with 12-month membership at a local gym.
89173220|NCT04586517|Active Comparator|Control group|Participants will be encouraged to continue with their usual activities during chemotherapy and not start resistance training (approximately 16-weeks). After end of chemotherapy participants will be offered to attend a 2-week introduction to the strength-training program and provided with a 12-month membership at a local gym.
89173221|NCT04576533|Experimental|walk out from operating room|patients will return to the ward after surgery by walking
89173222|NCT04576533|No Intervention|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
89173223|NCT00808509|Active Comparator|Adalimumab + MTX|Participants continued treatment with adalimumab 40 mg subcutaneously every other week plus methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
89173224|NCT00808509|Experimental|Methotrexate|Participants discontinued adalimumab and continued to receive methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. Participants with a significant increase in RA disease activity were re-instituted to adalimumab 40 mg every other week (rescue arm). After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
89173225|NCT05754723|Experimental|e-Psychotherapy|Participants in the treatment group will receive access to the hub's services which begin with six weeks of online psychoeducation. Participants will be recruited through on-campus flyers, advertisements and wellness-center announcements, media advertisements, expert end-user referrals, and self-referrals. Participants will be excluded if they have active psychosis, acute mania, and/or active suicidal or homicidal ideation, and have received psychoeducation or psychotherapy like that offered by our proposed hub in the past six months. Participants with high disorder severity will be referred to other community resources determined by clinicians and therapists on the research team.
89173226|NCT05754723|No Intervention|Treatment as Usual|TAU will consist of medications, regular physician or clinician visits, referrals or consultations that are conducted outside of the current research study.
89173227|NCT05754645||110 women|60 women with a BMI between 18,5-25 kg/m2, of which 10 preconceptional 60 women with a BMI > 30 kg/m2, of which 10 preconceptional
89173228|NCT02608827|Active Comparator|Slow breathing group (GRL)|After randomization and have done aerobic exercise, patients allocated in this arm of the study, using the device-guided breathing - Slow breathing group (GRL), for 15 minutes during the experimental session.
89173229|NCT02608827|Placebo Comparator|Music group (GC)|After randomization and have done aerobic exercise, patients allocated in this study arm will hear slow music - Music group (GC), for 15 minutes during the experimental session.
89173230|NCT02608593||Implant reconstruction with Strattice|Women having immediate breast reconstruction with partial or total Strattice cover
89173231|NCT02608593||Implant reconstruction without Strattice|Women having immediate implant based breast reconstruction where no Strattice has been used
89173232|NCT02627651|Experimental|brain injury|children post brain injury
89173233|NCT02627651|Active Comparator|controls|children typically developed age matched
89173234|NCT04305951|No Intervention|Routine care group|Subjects assigned to this group will continue their routine care without receiving any acupuncture and acupressure treatment during the study period. The routine care may include physiotherapy and intellectual activities. Post-trial treatment of either CAT, CAE, or CAT+CAE will be offered to serve as a compensation for their participation.
89173235|NCT04305951|Active Comparator|CAT group|Subjects assigned to comprehensive acupuncture therapy (CAT) group will receive CAT treatment in addition to routine care.
89235321|NCT03048825|Placebo Comparator|Placebo +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
89235322|NCT03039413|Experimental|Diagnostic (Copper Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT after 60 minutes. Patients then undergo standard of care cystectomy and/or biopsy 1 to 4 weeks later.
89235323|NCT03026790|Active Comparator|Telecare collaborative management (TCM)|Uses medication management approach delivered by a clinical pharmacist care manager with a collaborating physician to address common barriers to effective pain medication management in primary care.
89235324|NCT03026790|Active Comparator|Integrated pain team (IPT)|Uses a biopsychosocial management approach delivered by a multidisciplinary team that emphasizes non-pharmacological pain management options.
89235325|NCT03026790|Active Comparator|Standard taper options|The standard taper options arm uses patient education and shared decision-making to guide opioid medication management.
89235326|NCT03026790|Active Comparator|Expanded taper options|The expanded taper options arm uses patient education and shared decision-making to guide opioid medication management and includes the additional option of rotation to buprenorphine-naloxone.
89235327|NCT03020823|Experimental|SCB01A alone|intra-subject dose escalation starting from 12 mg/m2, then to18 mg/m2, and finally to 24 mg/m2 if no DLT
89235328|NCT02995538||Neurogenetic Patients|The Neurogenetics Clinic, which started in 2016, provides clinical care for undiagnosed patients with complex neurological disorders in which a genetic etiology is considered and for children with diagnosed rare neurogenetic disorders - provide pre test counseling, diagnostic services for the undiagnosed patients and long-term management of patients with a wide range of diagnosed genetic disorders of the nervous system.
89235329|NCT02969369|Experimental|SEP-363856|SEP-363856 (25, 50, or 75mg/day), once daily
89235330|NCT02969369|Placebo Comparator|Placebo Capsule|Placebo once daily
89235331|NCT02948036|Experimental|MMT|Mobile-device, plasticity-based adaptive cognitive treatment
89173236|NCT04305951|Active Comparator|CAE group|Subjects assigned to 'Comfy Acupressure for the Elderly (CAE)' group will receive CAE in addition to routine care.
89173237|NCT04305951|Active Comparator|CAT + CAE group|Subjects assigned to CAT+CAE group will receive CAT+CAE in addition to routine care.
89235332|NCT02777879||Chronic Obstructive Pulmonary Disease (COPD)|Case of early COPD (GOLD 1-2, FEV1/FVC<70 and FEV1>50%)
89173238|NCT00807885|Experimental|Tegaderm-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with Tegaderm
89173239|NCT00807885|Experimental|Tape-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with a tape double chevron
89235333|NCT02777879||Control|No obstruction (FEV1/FVC<70). Controls will be recruited after each case and will be matched by: age (±5 year), 2) gender, 3) smoking (±5 pack-year) and 4) BMI (±5).
89235334|NCT02761499||Total Hip Arthroplasty|The United Hip System consist of several components, and for this clinical evaluation it includes the U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem.
89235335|NCT02703246|Active Comparator|abdominal morcellation|Women randomized to this group will undergo abdominal morcellation.
89235336|NCT02703246|Active Comparator|vaginal morcellation|Women randomized to this group will undergo vaginal morcellation.
89173240|NCT00807885|Experimental|Tegaderm-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with Tegaderm
89173241|NCT00807885|Experimental|Tape-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with a tape double chevron
89235337|NCT02664610|No Intervention|No text messages, hypertensive|Participants who have high blood pressure, who are randomized to health information (do not receive text messages).
89235338|NCT02664610|Experimental|Text messages, hypertensive|Participants who have high blood pressure, who are randomized to receive text messages.
89235339|NCT02637973|Experimental|Empagliflozin|Empagliflozin, film-tablet, 25mg once daily
89235340|NCT02637973|Placebo Comparator|Placebo|Placebo, once daily
89235341|NCT02583269|Experimental|Arm 1 (muscadine grape skin extract) 1 pill 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
89235342|NCT02583269|Experimental|Arm 2 (muscadine grape skin extract) 2 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
89235343|NCT02583269|Experimental|Arm 3 (muscadine grape skin extract) 3 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
89235344|NCT02583269|Experimental|Arm 4 (muscadine grape skin extract) 4 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
89235345|NCT02583269|Experimental|Arm 5 muscadine grape skin extract) 5 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
89235346|NCT02546921|Experimental|MOv18 IgE Cohort 1|
89235347|NCT02546921|Experimental|MOv18 IgE Cohort 2|
89235348|NCT02546921|Experimental|MOv18 IgE Cohort 3|
89235349|NCT02546921|Experimental|MOv18 IgE Cohort 4|
89235350|NCT02546921|Experimental|MOv18 IgE Cohort 5|
89235351|NCT02546921|Experimental|MOv18 IgE Cohort 6|
89235352|NCT02546921|Experimental|MOv18 IgE Cohort 7|
89235353|NCT02527681|Experimental|Ceftobiprole|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
89235354|NCT02516696|Experimental|BiRD treatment regimen|Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
89235355|NCT02516696|Active Comparator|Rd treatment regimen|Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.
89235356|NCT02513329|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with 10 mL .5 % bupivacaine.
89235357|NCT02513329|Sham Comparator|Saline|Saline injection (.9 normal saline) 5 ml.
89235358|NCT02425826|Experimental|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
89235359|NCT02425826|Placebo Comparator|Placebo|Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
89235360|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 10 mg|Participants will continue with their current treatment regimen (10 milligram [mg] of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 10 milligram (mg) of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
89235361|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 25 mg|Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
89235362|NCT02406027|Placebo Comparator|Double-blind Treatment Phase: Placebo|Participants will continue with their current treatment regimen established in the parent study of JNJ-54861911. Participants will receive placebo matching to JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
89235363|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 5 mg|Participants who were receiving JNJ-54861911, 10 mg and placebo in the DB treatment phase, will receive the 5 mg JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in Open-label phase.
89235364|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 25 mg|Participants who were receiving JNJ-54861911, 25 mg in the DB treatment phase, will continue to receive the same regimen in open-label treatment phase. Participants who were receiving placebo in the DB treatment phase will be randomly assigned to receive 25 mg of JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in the open-label treatment phase.
89235365|NCT02384434|Other|Low Level Laser Therapy|Non-invasive, cold laser output treatment.
89235366|NCT02255357|Placebo Comparator|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
89235367|NCT02255357|Active Comparator|Intranasal Syntocinon|Intranasal Oxytocin 24 IU per day.
89235368|NCT02217943|Active Comparator|Roux-en-Y gastric bypass|Subjects who receive a Roux-en-Y gastric bypass
89235369|NCT02217943|Active Comparator|Sleeve Gastrectomy|Subjects who receive a sleeve gastrectomy
89235370|NCT02211131|Other|Surgery|Surgical resection of melanoma tumor lesion(s)
89235371|NCT02211131|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec for 6 doses followed by surgical resection of melanoma tumor lesion(s).
89235372|NCT02134587|Other|Subjects post educational intervention|Multifaceted educational intervention in pharmacovigilance
89235373|NCT02072772|Experimental|Positively Smoke Free group treatment|"Eight 90 minute group sessions (6-8 HIV-infected smokers per group) led by a pair of trained group leaders: a professional with psychology or social work training and a peer HIV-infected ex-smoker with tobacco treatment training.~All subjects will be offered a 3 month supply of nicotine patches"
89235374|NCT02072772|Active Comparator|Standard care|Brief (<5 minutes) advice to quit Offer of nicotine patches Self-help brochure
89235375|NCT02057107|Other|SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel|Previously Treated With Cetuximab - Group A; No Previous Cetuximab - Group C
89235376|NCT02057107|Other|SBRT + Cetuximab followed by Cetuximab|Previously Treated with Cetuximab - Group B; No Previous Cetuximab - Group D
89235377|NCT01752920|Experimental|Low Dose Group|Patients who received derazantinib orally at dose levels from 25 mg every other day (QOD) - 200 mg daily (QD) on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
89235378|NCT01752920|Experimental|Middle Dose Group|Patients who received derazantinib orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
89235379|NCT01752920|Experimental|High Dose Group|Patients who received derazantinib orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
89235380|NCT01752920|Experimental|Expanded Cohort Group|Patients who received derazantinib orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
89235381|NCT01479075|Experimental|intranasal insulin in patients|intranasal insulin is applied to diabetic patients under fasting conditions
89235382|NCT01479075|Experimental|intransal insulin in study participants|intranasal insulin is applied to healthy patients under fasting conditions
89235383|NCT01479075|Placebo Comparator|placebo in patients|placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions
89235384|NCT01479075|Experimental|placebo in study participants|placebo spray is applied intranasally in healthy participants under fasting conditions
89173242|NCT00807885|Experimental|Tegaderm-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with Tegaderm
89173243|NCT00807885|Experimental|Tape-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with a tape double chevron
89235385|NCT01479075|Experimental|taNVS|Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants
89235386|NCT01479075|Placebo Comparator|Sham stimulation|Sham stimulation in the ear lobe is applied for 14 min in healthy participants
89235387|NCT01409330|Experimental|hypocaloric diet containing increased fibers and coffee|In the intervention group the patients are allowed to eat only white meat and fish. They also need to increase their daily fiber intake to 50grams and drink 5 cups of coffee a day.
89235388|NCT01409330|Active Comparator|hypocaloric diet containing red meat|control group (n=20): diet according to the ADA/EASD guidelines (50% carbohydrates, 20% proteins, 30% fat). In the control group the patients should eat 150 grams of red meat a day and are not allowed to consume alcohol, coffee and whole grains.
89235389|NCT01397279|Active Comparator|Botnia clamp|hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
89235390|NCT01397279|Active Comparator|hyperinsulinemic euglycemic clamp|hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
89235391|NCT01327105|Experimental|TVU|
89235392|NCT01134172||Breast cancer survivors|Women being treated for stage I-III breast cancer who were employed prior to this diagnosis will be recruited in their physicians' offices.
89235393|NCT01134172||Comparison group|Peer controls will be nominated by participants in the breast cancer survivor group or recruited by community outreach and matched for age, language, and ethnicity. This cohort is no longer recruiting.
89235394|NCT01082679|Other|methadone via specialty care|
89173244|NCT00807885|Experimental|Tegaderm-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with Tegaderm
89235395|NCT01082679|Other|Suboxone via specialty care|
89235396|NCT01082679|Other|Suboxone via primary care|
89235397|NCT00976963|Active Comparator|TMP/SMX|Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab; 800mg/160mg BID x 3 days
89235398|NCT00976963|Experimental|Fosfomycin|3g sachet single dose
89235399|NCT00958633|Active Comparator|8 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s)and will be randomized to one of two treatment arms for up to 52 weeks:~Group 1 patients randomized to the 8 week arm will discontinue antidepressant treatment after 8 weeks, as recommended in current clinical practice guidelines. The antidepressant will be tapered in a double-blind manner beginning at 6 weeks, and will be substituted with placebo by 8 weeks.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
89235400|NCT00958633|Active Comparator|52 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s) and will be randomized to one of two treatment arms for up to 52 weeks:~Group 2 patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
89235401|NCT00911560|Experimental|vaccine group one|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a inimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to in Group 1 will receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
89235402|NCT00911560|Experimental|vaccine group two|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to Group 2 will receive oral β glucan (40 mg/kg/day) starting week 1 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
89235403|NCT00911560|Experimental|vaccine group three|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Group 3 will include patients who have previously received vaccine and oral β glucanglucan. Patients in this group will not be randomized using the MSK CRDB system. They will be treated as patients in Group 1 and receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination . They will not be eligible for primary endpoint.
89235404|NCT00902590||1|Patients with urothelial cancer
89173245|NCT00807885|Experimental|Tape-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with a tape double chevron
89173246|NCT00807885|Experimental|SC button with 27 ga X 9 mm needle|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a button-type subcutaneous delivery system (with a 27-gauge, 9 mm long metal needle)
89173247|NCT00807573|Experimental|Paclitaxel, Bevacizumab & Pemetrexed|During each 28-day cycle, paclitaxel, pemetrexed and bevacizumab will be given intravenously on days 1 and 15. Paclitaxel will be administered at 90mg/m^2 over 60 minutes on days 1 and 15. Pemetrexed 500mg/m^2 will be administered over 10 minutes on days 1 and 15. Bevacizumab will be given at 10mg/kg over 20 minutes on days 1 and 15
89173248|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Gem|
89173249|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Vin|
89173250|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Gem|
89173251|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Vin|
89173252|NCT00842712|Experimental|Randomized part: Cil (Once Weekly) + Cetuximab + Chemotherapy|
89173253|NCT00842712|Experimental|Randomized part: Cil (Twice Weekly) + Cetuximab + Chemotherapy|
89173254|NCT00842712|Active Comparator|Randomized part: Cetuximab + Chemotherapy|
89173255|NCT00705120|Other|1|
89173256|NCT00705120|Other|2|
89173257|NCT00708474|Experimental|OsseoFit™|Treatment of bone graft site with OsseoFit™ Porous Tissue Matrix™.
89173258|NCT00708474|No Intervention|Open|Treatment of bone graft site without OsseoFit™ Porous Tissue Matrix™.
89173259|NCT00842244|Experimental|A|
89173260|NCT00832416|Experimental|1 Tramadol Once A Day 100mg|
89173261|NCT00832416|Experimental|2: Tramadol Once A Day 200mg|
89173262|NCT00832416|Experimental|3: Tramadol Once A Day 300mg|
89173263|NCT00832416|Experimental|4: Placebo|
89173264|NCT00705198||Newly diagnosed patients|Patients treated with temozolomide for newly diagnosed malignant glioma
89173265|NCT00705198||Relapsed patients|Patients treated with temozolomide for relapsed malignant glioma
89173266|NCT00705198||Newly diagnosed anaplastic astrocytoma patients|Patients treated with temozolomide for newly diagnosed anaplastic astrocytoma
89173267|NCT00708630|Experimental|1|Provision of extended symptom side effects information
89173268|NCT00708630|No Intervention|2|Standard information on side effects
89173269|NCT00702936|Active Comparator|R|Twenty-five patients assigned to ramipril 5 mg daily
89173270|NCT00702936|Active Comparator|T|Twenty-five patients assigned to Telmisartan 80 mg daily
89173271|NCT00705276|Experimental|I|
89173272|NCT00841776|Active Comparator|Duac gel|Clindamycin and benzoyl peroxide gel
89173273|NCT00841776|Active Comparator|Ziana gel|Clindamycin and tretinoin gel
89173274|NCT00683800|Experimental|1|desvenlafaxine succinate (DVS) SR
89173275|NCT00683800|Placebo Comparator|2|Placebo
89173276|NCT00683644|Experimental|1 - zinc placebo|Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months. Washout 1 month. Placebo oral capsule taken once a day for 4 months.
89173277|NCT00683644|Experimental|2 - placebo zinc|Placebo oral capsule taken once a day for 4 months. Washout 1 month. Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months.
89173278|NCT00745576|Experimental|1|
89173279|NCT00753064|Active Comparator|AScVS|a clinical scoring system for dose requirement for AScVS is evolved based on sweating, pulse rate, respiratory rate, blood pressure, CNS effects and presence of priapism. Computed doses were given according to clinical grading as intravenous bolus slowly.
89173280|NCT00753064|Active Comparator|Prazosin.|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
89173281|NCT00753064|Active Comparator|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin (500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
89173282|NCT00751738|Experimental|1|125 mg azimilide
89173283|NCT00751816||Supportive Care|head and neck cancer survivors who are undergoing chemotherapy and radiation therapy
89173284|NCT00685360|Experimental|Delamanid 100 mg BID + OBR|"Participants received delamanid 100 milligrams (mg) (two 50 mg tablets), orally, BID with two matching placebo tablets plus optimized background regimen (OBR) for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on World Health Organization (WHO) guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
89173285|NCT00685360|Experimental|Delamanid 200 mg BID + OBR|"Participants received delamanid 200 mg (four 50 mg tablets), orally, BID plus OBR for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
89173286|NCT00685360|Placebo Comparator|Placebo + OBR|"Participants received four placebo tablets matching 50-mg tablets of delamanid, orally, BID plus OBR for 56 consecutive days (from Day 1 to Day 56).~Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment, in conjunction with national TB program guidelines in each country."
89173287|NCT04060264|Experimental|BCD-148|"14 participants in BCD-148 group. During the main period (first 27 weeks), test product BCD-148 will be administered as 25- to 45-minute intravenous infusions.~After Week 27 BCD-148 900 mg will be administered biweekly as maintenance therapy."
89173288|NCT04060264|Active Comparator|Soliris|"14 participants in Soliris group. During the main period (first 27 weeks), Soliris® will be administered as 25- to 45-minute intravenous infusions.~After Week 27, patients be switched to BCD-148 900 mg biweekly as maintenance therapy."
89173289|NCT00684814|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered after an overnight fast of at least 10 hours.
89235405|NCT00902590||2|unrelated adults accompanying patients to clinic
89235406|NCT00748254||Rheumatoid Arthritis|Patients who have active disease affecting the joints in the hand will have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound
89173290|NCT00684814|Experimental|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered after an overnight fast of at least 10 hours.
89173291|NCT00576472|Experimental|Treatment|
89235407|NCT00748254||Normal controls|Healthy volunteers who do not have arthritis will also have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound on the joints of their hand
89235408|NCT00622583||Observation Group|Subjects who meet the inclusion/exclusion criteria who have had a hernia repair.
89235409|NCT00591981||Primary|All patients 70 years old and above scheduled for a thoracic oncologic surgery (typically esophageal or lung cancer) will be approached for entry into this study
89235410|NCT00393783|Experimental|1|HER2 ECD DNA.
89235411|NCT00074269|Experimental|treatment|
89173292|NCT00823212|Active Comparator|PROMUS|Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent
89173293|NCT00823212|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
89173294|NCT00807495|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).
89173295|NCT02561494|Placebo Comparator|Control|Intravenous normal saline 2 ml is given slowly as a placebo before the anesthesia induction and after finishing anesthesia.
89235412|NCT00423735|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
89235413|NCT00626327|Experimental|MenACWY-CRM+ MMRV|
89235414|NCT00626327|Active Comparator|MMRV|
89235415|NCT00626327|Experimental|MenACWY-CRM|
89235416|NCT01032213|Placebo Comparator|group C|control group
89235417|NCT01032213|Experimental|group M|magnesium group
89235418|NCT00357994|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
89173296|NCT02561494|Experimental|Nefopam|Intravenous nefopam 20 mg is given slowly before the anesthesia induction and after finishing anesthesia.
89173297|NCT00745732|Experimental|Radiation Therapy + ZD6474|"Radiation Therapy - Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.~ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth."
89235419|NCT00357994|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
89235420|NCT00823433|Experimental|Oral Penicillin|2 grams of oral penicillin V given within 4 hours of delivery
89173298|NCT05958693||Patients detected with Plasmodium falciparum (Artemether-lumefantrine)|Patients with mono-infection of Plasmodium falciparum with 1,000-100,000 asexual forms per µl
89173299|NCT05958680|Experimental|ASDactive|Theoretically derived behaviour change intervention aimed at promoting habitual physical activity uptake
89235421|NCT00423657|Experimental|Ceftaroline fosamil for Injection|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
89235422|NCT00423657|Active Comparator|IV Vancomycin plus IV Aztreonam|Vancomycin 1 g administered over 60 minutes every 12 hours followed by aztreonam 1 g administered over 60 minutes every 12 hours.
89235423|NCT00831155|Active Comparator|1|Extinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date.
89173300|NCT05958667|Experimental|Quitxt bilingual text messaging and chat|"Culturally and linguistically tailored, bilingual text messaging or chat mobile app.~Our text messaging or chat intervention will include messaging options in which users can text or message a code when they are craving a cigarette or at risk of relapse and immediately receive text or social media messages to help them avoid smoking. The social media content also will include opportunities for users to repeatedly visit key content pages and receive immediate support when experiencing cravings, stress, bad mood, or when feeling at risk of smoking."
89235424|NCT00831155|No Intervention|2|Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date.
89235425|NCT00827021|Experimental|ESAs 1 low dose|
89235426|NCT00827021|Active Comparator|ESAs 2 high dose|
89235427|NCT02533414|Experimental|UAS (+)|RIRS with UAS: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
89235428|NCT02533414|Active Comparator|UAS (-)|RIRS without UAS: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
89235429|NCT01029015||Group 1 -OAB|Subjects with overactive bladder (OAB)
89235430|NCT01029015||Group 2 - Insomnia|Subjects with insomnia
89235431|NCT01029015||Group 3 - Normal|Normal Subjects
89235432|NCT01050712|Experimental|Carbon Monoxide|
89235433|NCT01050712|Placebo Comparator|Synthetic Air|
89235434|NCT02550119|Experimental|Arm I (aprepitant, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
89235435|NCT02550119|Placebo Comparator|Arm II (placebo, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.
89235436|NCT02549495||Patients with Diabetes or Hypertension|All patients in the seven study communities will receive the community health worker intervention provided by CES, as it is incorporated into the standard of care. However, they will receive the intervention at different points in time depending on which community they lived in, as community health worker programs can only be started at every-three-month intervals
89235437|NCT02548403|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
89235438|NCT02548403|Active Comparator|PEG-Asc with simethicone|group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
89235439|NCT00823511||Female Partners|Female partners of HIM Study participants
89235440|NCT00823589|Experimental|pathological group|pathological group
89235441|NCT00823589|Experimental|healthy aged|healthy aged
89235442|NCT00367432|Experimental|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
89235443|NCT01086670|Other|1|Subjects will be randomly assigned to use one of two novel lower extremity exercise devices: a motor-assisted cycle or an elliptical trainer.
89235444|NCT01053052|Experimental|Sonography with FemVue vs. HSG|FemVue sonography and HSG
89235445|NCT01050868|Experimental|Single Arm|
89235446|NCT00623363|Active Comparator|piclozotan|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of piclozotan administered at a plasma level of 30 ng/mL over 2 inpatient days.
89235447|NCT00623363|Placebo Comparator|0.9 % sodium chloride (normal saline)|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of 0.9 % sodium chloride (normal saline) administered at a plasma level of 30 ng/mL over 2 inpatient days.
89235448|NCT00827177|Experimental|ARQ 197 in combination with sorafenib|
89235449|NCT00823667|Active Comparator|Phase 1 Usual care|
89235450|NCT00823667|Active Comparator|Phase 2 Intervention|
89235451|NCT00423267|Experimental|Posaconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months.
89235452|NCT00423267|Active Comparator|Fluconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months. Fluconazole treatment or placebo only occurred during Period A.
89235453|NCT02549261|Experimental|the tolerance trial of treatment|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
89235454|NCT02549261|Experimental|A|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
89235455|NCT02549261|Placebo Comparator|B|chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
89235456|NCT01032369|Experimental|CBT|with behavioral intervention-CBT.
89235457|NCT01032369|Other|Without CBT|Without behavioral intervention-CBT
89235458|NCT00823745|Experimental|1|[14C]-PF-00868554
89235459|NCT00626093|Other|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|Patients in the study who received a Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for it. It's a single arm study in which patients underwent defibrillation threshold (DFT) testing at implant and 6 months.
89235460|NCT00357760|Experimental|Arm A (higher dose of VEGF Trap)|Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89235461|NCT00357760|Experimental|Arm B (lower dose of VEGF Trap)|Patients receive a lower dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, the dose of ziv-aflibercept (VEGF Trap) may be escalated to the higher dose in Arm A.
89235462|NCT02548013|Experimental|Home management|outpatient management patients if stable will be discharged to continue treatment at home
89235463|NCT02548013|Active Comparator|hospital management|Inpatient management patients will continue there treatment in hospital till delivery
89235464|NCT01049230|Experimental|Proton beam radiation|Radiation therapy with proton beam
89235465|NCT00622739|Active Comparator|ziprasidone rapid dose|Rapid Dose Titration Group
89235466|NCT00622739|Active Comparator|ziprasidone slow dose|Slow Dose Titration Group
89235467|NCT03742336|Experimental|Arm 1|Single dose of dabigatran on Day 1 of Period 1 and Single dose of dabigatran + PF-04965842 on Day 1 of Period 2.
89235468|NCT03742336|Experimental|Arm 2|Single dose of dabigatran + PF-04965842 on Day 1 of Period 1 and Single dose of dabigatran on Day 1 of Period 2.
89235469|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_24 Weeks|Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
89235470|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_24 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
89235471|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_48 Weeks|Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
89235472|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_48 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
89235473|NCT00824057|Experimental|1|
89235474|NCT01053130|Experimental|weight loss surgery|laparoscopic sleeve gastrectomy
89235475|NCT01053130|Active Comparator|Lifestyle Intervention|Diet and exercise with or without pharmacotherapy
89235476|NCT02534272||Symptomatic subjects|Subjects with intestinal symptoms
89235477|NCT02534272||Asymptomatic subjects|Subjects without intestinal symptoms
89235478|NCT00574145|Experimental|Radiotherapy/Supportive Care (A)|Patients receive radiotherapy and healing touch therapy from a healing touch therapist once a week for the duration of their radiotherapy
89235479|NCT00574145|Sham Comparator|Control ARM (B)|Patients receive radiotherapy and sham healing touch therapy from a sham healing touch therapist once a week for the duration of their therapy
89235480|NCT01053208|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
89235481|NCT01053208|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
89173301|NCT05958667|Other|Usual care|Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit (www.yesquit.org) available to smokers seeking help quitting. The abbreviated text messaging will include general information on smoking harms and benefits of cessation, and baseline data collection and follow-up assessments.
89173302|NCT05958654|Experimental|with DETECT-RPC screening tool|
89173303|NCT05958654|No Intervention|without DETECT-RPC screening tool|
89173304|NCT05958641||Investigation Team|Questionnaires assessed adolescents aged 14-35 years old (including 14,25 years old) who agreed to participate in the study
89173305|NCT05958602|Experimental|Technology|The interventional group will receive a standard, evidence-based DSMES curriculum and supplemental diabetes education-related technology to assess an improvement in participation, retention, engagement, and clinical outcomes (HbA1C).
89173306|NCT05958602|Active Comparator|Standard DSMES Only|The control group will receive a standard, evidence-based DSMES curriculum only to assess an improvement in participation, retention, engagement and clinical outcomes (HbA1C)
89173307|NCT05958602|Active Comparator|Traditional DSMES Recruitment Methods|The traditional DSMES recruitment method participants will be recruited using traditional methods such as flyers, word of mouth, and media ads to assess the effectiveness of traditional methods on recruiting and enrollment into to pharmacist-led DSMES programs.
89235482|NCT00831467|Experimental|CV9103|CV9103 is applied intradermally into the thigh and upper arm of either side of the body at week 1, week 3, week 7, week 15, week 23
89235483|NCT00423189|Active Comparator|Ranibizumab only|drug - intravitreal ranibizumab
89235484|NCT00423189|Experimental|40% fluence PDT/procedure|40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
89235485|NCT00423189|Experimental|20% fluence photodynamic therapy|20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
89235486|NCT03991858|Other|Phone follow-up|Phone follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
89235487|NCT03991858|Experimental|Telerehabilitation follow-up|Telerehabilitation follow-up initiated by the health care professional one month after the initial evaluation at the external rehabilitation clinic.
89235488|NCT00831545|Experimental|Subjects with melanoma|
89235489|NCT00831545|Experimental|Subjects with breast cancer|
89235490|NCT00831545|Experimental|Subjects with non-small cell lung cancer|
89235491|NCT01034865||HCC PTS|Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
89235492|NCT01034865||LD|Patients with chronic liver disease without evidence of HCC
89235493|NCT01051024|Experimental|A|Diamel
89235494|NCT01051024|Placebo Comparator|B|Placebo
89235495|NCT02549417|Experimental|KHK7580|
89235496|NCT00824135|Experimental|1|
89235497|NCT00422799|Experimental|bortezomib and rituximab|bortezomib and rituximab
89235498|NCT00827333|No Intervention|Phase I-Usual Care|
89235499|NCT00827333|Active Comparator|Phase 2 - Intervention|
89235500|NCT00827411|Experimental|1: Monitoring Arm|"First randomization:~Monitoring Arm: dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay (VerifyNow)."
89235501|NCT00827411|Active Comparator|2: Conventional Arm|"First randomization:~Conventional Arm: fixed dose regiment of both aspirin and clopidogrel in all patients following DES implantation according to international guidelines"
89235502|NCT00827411|Experimental|3: Pursuit Arm|"Second randomization after one year of follow-up:~Pursuit Arm: Pursuit of a dual oral antiplatelet therapy (aspirin and clopidogrel) beyond one year"
89235503|NCT00827411|Active Comparator|4: Interruption Arm|"Second randomization after one year of follow-up:~Interruption Arm: Interruption of clopidogrel therapy."
89235504|NCT00435045|Active Comparator|atorvastatin arm|atorvastatin + placebo
89235505|NCT00435045|Experimental|Lovaza arm|Lovaza + atorvastatin
89235506|NCT01029171|Experimental|1|OEP (Otago Exercise Program; home-based balance and strength retraining program)
89235507|NCT01029171|Active Comparator|2|CON (control; usual care)
89235508|NCT00441129|Active Comparator|Conventional insulin pump therapy|Conventional insulin pump therapy or continuous subcutaneous insulin infusion (CSII)
89235509|NCT00441129|Experimental|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
89235510|NCT01029249||ACTG A5257 participants|Participants in this study will also be enrolled in ACTG A5257.
89235511|NCT00622505|Experimental|Zoledronic acid|Participants received 4 milligrams (mg) or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes, every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine N-telopeptide of type 1 collagen (NTx) measurement (greater than or equal to [≥] 50 nanomoles per millimoles [nmol/mmol] creatinine or <50 nmol/mmol creatinine, respectively).
89235512|NCT02550275|Other|presymptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) < 5
89235513|NCT02550275|Other|symptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) > 5
89235514|NCT02550275|Other|controls|unaffected patient with Huntington's disease
89235515|NCT02549183|Active Comparator|Arm 1|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to A KHz
89235516|NCT02549183|Active Comparator|Arm 2|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to B KHz
89235517|NCT02549183|Active Comparator|Arm 3|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to C KHz
89173308|NCT05958602|Experimental|CHW-Led DSMES Recruitment Methods|The CHW-led DSMES recruitment model participants will be recruited utilizing a CHW-led, multidirectional recruitment process involving community health workers (CHWs), primary care physicians, and community pharmacists to assess the effectiveness of a multidirectional recruitment process into pharmacist-led DSMES programs.
88804643|NCT02774954|Active Comparator|Nutrition|The nutrition equal attention control intervention is a single-session, 60- minute Information-Motivation-Behavioral (IMB) skills-based intervention addressing healthy eating. The healthy eating intervention uses a one-on-one guided conversation between the interventionist and the participant. The intervention addresses (1) information about current eating patterns and recommendations for healthy alternatives (20 minutes), (2) motivations for improving healthy eating by providing feedback to participants on personal responsibility, a menu of alternative change options, a decision balance exercise, and eating goal setting (10 minutes), and (3) Behavioral Self-Management Component (30 minutes) that covers eating scenarios, participant responses, and healthy alternatives to the scenario and the participants feedback.
89173309|NCT05958589|Experimental|General anesthesia + caudal block|General anesthesia with intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg), in combination with a single shot caudal block with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).
89173310|NCT05958589|Active Comparator|General anesthesia|General anesthesia with intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg)
89173311|NCT05958563|Experimental|CPAP group|Continuous positive airway pressure (CPAP) for one year
89173312|NCT05958563|No Intervention|Control group|No CPAP treatment
89173313|NCT05958550||Hypothermia group|
89173314|NCT05958550||Non-hypothermia group|
89173315|NCT05958498|Active Comparator|Group I|who will receive intrusive arches after leveling and alignment assisted with i-PRF according to standardized protocol
89173316|NCT05958498|Active Comparator|Group II|Will includes 9 patients who will receive intrusive utility arches after leveling and alignment assisted with (MOPs) according to standardized protocol.
89173317|NCT05958459|Experimental|study group|The individuals in the study group will perform home-based eye exercises for at least 1 session (~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.
89173318|NCT05958459|Experimental|control group|The control group, on the other hand, will not perform any exercise, but will only be evaluated.
89173319|NCT05958446||Pregnant women with SSA Auto Ab|All patients over the age of 18, who will sign the informed consent for participation in the study, characterized by the positivity of autoantibodies against Ro/SSA who will become pregnant during the enrollment period.
89173320|NCT05958420||Group 1|Patients with liver failure
89173321|NCT05958420||Group 2|Healthy donors
89173322|NCT05958394|Experimental|Treatment|This arm will receive the intervention. This intervention is access to the SkillFlix for Parents Microskills video library, about 60 minute in duration. The library includes a curriculum covering skills such as seizing teachable moments, talking about identities, and using a conversation tone.
89173323|NCT05958394|No Intervention|Control|During the intervention period arm 2 will receive written conversation guides for the assigned conversations. This arm will receive the intervention upon completion of follow-up study activities.
89173324|NCT05958329|Experimental|HRV Biofeedback|5 minute daily sessions of HRV biofeedback
89173325|NCT05958277|Experimental|Vitamin B3|Vitamin B3 group
89173326|NCT05958277|Experimental|Vitamin B12 group|Vitamin B12 group
89173327|NCT05958238|Experimental|AR/VR group|Students in EG recieved a 2-hour AR/VR training for elderly oral healthcare at 2-week and 4-week follow-ups.
89173328|NCT05958238|Active Comparator|Traditional teaching group|Students in the CG received thirty minutes oral care training class with same teaching content in AR/VR-based training system by well-trained oral hygienist.
89173329|NCT05958212|Experimental|Intervention Group|Participants in the intervention group will receive a weekly gait training program at PolyU in addition to conventional treatment at Outpatient Patient Department (OPD) of The Hong Kong Buddhist Hospital twice per week for 4 consecutive weeks. Gait training program at PolyU is a supervised rehabilitation program performed on the dual-belt treadmill.
89173330|NCT05958212|Active Comparator|Control Group|Participants in control group will only receive conventional treatment at Outpatient Patient Department (OPD) of BH twice per week for 4 consecutive weeks.
89173331|NCT05958186||Children group|Ages≤18
89173332|NCT05958186||Adults group|Ages>18
89173333|NCT05958173|Active Comparator|Capsaicin|Natural TRPV1 agonist at a concentration of 10mcM. Posology: 10 mL every 8h for 6 month.
89173334|NCT05958173|Active Comparator|Piperine|Natural TRPA1/V1 agonist at a concentration of 150mcM. Posology: 10 mL every 8h for 6 month.
89173335|NCT05958173|Placebo Comparator|Placebo|Deionized water + the same preservatives as in the active treatments
89173336|NCT05958160|Experimental|Modified Atkins Diet Arm|Modified Atkins diet will be added to the ongoing anti-seizure medication regimen
89173337|NCT05958160|Active Comparator|Topiramate arm|Topiramate will be added to the ongoing anti-seizure medication regimen
89173338|NCT05958108|No Intervention|Control group|Primary care centers allocated to the Control Group will continue with healthcare as usual. They will receive the intervention at the end of the trial, once all post-intervention data has been collected (waitlist approach). Although audits will be conducted in this group, the centers in this group will not have access to the feedback reports or any other information with the results from the audits.
89235518|NCT02549183|Active Comparator|Arm 4|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to D KHz
89235519|NCT02550353|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery
89235520|NCT02550353|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the femtosecond laser-assisted laser in situ keratomileusis surgery.
89235521|NCT00827489|Experimental|HTC-867|
89235522|NCT00827489|Placebo Comparator|Placebo|
89235523|NCT00831857||Group A|Treatment with sunitinib.
89235524|NCT00831857||Group B|Treatment with bevacizumab and interferon
89235525|NCT00824447|Placebo Comparator|Placebo control|Placebo control
89235526|NCT00824447|Active Comparator|Grass pollen extract, twice weekly|Grass pollen extract, 9,500 BU, given twice weekly
89235527|NCT00824447|Active Comparator|Grass pollen extract daily|Grass pollen extract, 9,500 BU, given daily
89235528|NCT00824447|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen extract, 19,000 BU, given daily
89235529|NCT02548169|Active Comparator|Group 1|Group 1 will consist of patients with resectable, borderline resectable or locally advanced pancreatic cancer. Group 1 will receive DC Vaccine + Standard of Care Chemotherapy.
89235530|NCT02548169|Active Comparator|Group 2|Group 2 will consist of patients with metastatic pancreatic cancer, newly diagnosed/untreated metastatic pancreatic cancer, or metastatic pancreatic cancer who have undergone prior neo-adjuvant therapy. Group 2 will receive DC Vaccine + Standard of Care Chemotherapy.
89235531|NCT00831935||Depressed|Depressed individuals, as identified by their referring physician.
89235532|NCT00831935||Non-depressed|Non-depressed individuals, confirmed to be non-depressed by the Centers for Epidemiological Studies Depression Scale (CES-D).
89235533|NCT00824603||primary care provider|attending insulin CME Training
89235534|NCT04043429|Experimental|Vision Restoration Training (VRT)|home-based rehabilitation program which applies intense light stimulation via a PC-monitor to areas of residual vision with a duration of 1 hour daily/six days a week, subjects are asked to respond via button press upon appearance of light stimuli without eye movements
89235535|NCT04043429|Active Comparator|Vision Exploration Training (VET)|home-based rehabilitation program to train eye movements upon visual stimuli presented via a PC-monitor with a duration of 1 hour daily/six days a week, subjects are asked to shift their gaze towards targets and respond via button press upon detection of targets
89235536|NCT04043819|Experimental|PSC-01|All study participants will receive intraarticular injection of the investigational biological product, PSC-01.
89235537|NCT04016987|Experimental|Automated, Individualized Education|Subjects will be given instructions to install the patient-end App, which includes the following functions: diabetes education, patient-doctor communication, diabetes diary, peer support, reminder for blood sugar test and related abnormal results. They receive push notifications that provides recommended education materials which meet the needs of the patient by considering his/her baseline diabetes-related knowledge.
89235538|NCT04016987|No Intervention|Routine care|Subjects only receive the education provided by health-care professionals in the outpatient department
89235539|NCT00827645||Uterine artery embolization|Women with symptomatic uterine fibroids scheduled for uterine artery embolization
89235540|NCT00824681|Experimental|1|Sound Of Family Together (S.O.F.T.) Music Program
89235541|NCT00824681|Active Comparator|2|Non-Therapy Related Activities (NTRA)
89235542|NCT00832013|Active Comparator|1|"Propofol 1 % at a dose of 4mg/kg will be administered intravenously via a standard Medex Protégé® 3010 (Medex-A Furon. Healthcare Company, Duluth, GA, USA) infusion pump at a constant rate determined by the randomization schedule. Fresh gas flow will be maintained at 6 l/min throughout the induction procedure with the FiO2 increased to 0.5. Full cardiovascular, respiratory and EEG monitoring will continue during induction of anesthesia.~Once the loading dose of propofol has been delivered the propofol infusion will be maintained at a rate of 200mcg/kg/min or as determined by the attending anesthesiologist whilst the end-point respiratory responses are observed."
89235543|NCT00832013|Active Comparator|2|Same procedure as above. These subjects will be stratified by age and randomized, using the Biased Coin Design (BCD) principle to determine the infusion rate of propofol for delivery of the induction dose.
89235544|NCT00824759|Placebo Comparator|placebo|
89235545|NCT00824759|Active Comparator|oxygen|
89235546|NCT00832169|Experimental|1|
89235547|NCT00827723||Alcoholic|Alcoholic cirrhotic patient with resectable hepatocellular carcinoma
89235548|NCT00827723||Viral|Viral cirrhotic patient with resectable hepatocellular carcinoma
89235549|NCT00824837|Experimental|A|New larger pore membrane
89235550|NCT00824837|Active Comparator|B|Standard haemodialysis membrane
89235551|NCT00832403||polytetrafluoroethylene|
89235552|NCT02550041|Other|Cystic fibrosis|
89235553|NCT00832481|Active Comparator|Repaglinide,tablet|
89235554|NCT00832481|Active Comparator|Metformin, tablet|
89235555|NCT04044287|Active Comparator|Intervention|200 micrograms of Misoprostol applied sublingually together with standard parenteral oxytocic therapy
89235556|NCT04044287|Placebo Comparator|Placebo|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy micrograms of misoprostol
89235557|NCT00827801||Group 1|MDASI-HF questionnaire provided to Doctor for symptom management.
89235558|NCT00827801||Group 2|MDASI-HF questionnaire collected not provided to Doctor.
89235559|NCT02549729|No Intervention|Control|Control group not using hormonal replacement therapy will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and up to 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
89235560|NCT02549729|Experimental|Exercise|Experimental group not using hormonal replacement therapy will receive supervised pelvic floor muscle training.
89235561|NCT02549729|No Intervention|Hormone Therapy|Experimental group using hormonal replacement therapy will not receive supervised pelvic floor muscle training.
89235562|NCT02549729|Experimental|Exercise and Hormone Therapy|Experimental group using hormonal replacement therapy will receive supervised pelvic floor muscle training.
89235563|NCT00827879|Experimental|Strength at Home Couples Group|PTSD-Focused Cognitive Behavioral Therapy for Couples
89235564|NCT00827879|Placebo Comparator|Supportive Group Therapy|Supportive therapy for couples
89235565|NCT00832559|Experimental|CVA21|CVA21
89235566|NCT02549807||Children muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
89235567|NCT02549807||Adolescent muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured ((muscle elasticity measure)
89235568|NCT02549807||Adult muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
89235569|NCT00357370|Experimental|Cohort 1|20 mg
89235570|NCT00357370|Experimental|Cohort 2 - Arm 1|10 mg
89235571|NCT00357370|Experimental|Cohort 2 - Arm 2|20 mg
89235572|NCT00357370|Placebo Comparator|Cohort 2 - Arm 3|
89235573|NCT00832715|Experimental|EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA)
89235574|NCT00825071|Active Comparator|Group D|Dexamethasone group : This group received 8 mg dexamethasone
89235575|NCT00825071|Active Comparator|Group O|Ondansetron Group: received 4 mg ondansetron
89235576|NCT00825071|Placebo Comparator|Group P|(Group P) received normal saline (Placebo)
89235577|NCT00827957|Active Comparator|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
89235578|NCT00827957|Active Comparator|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
89235579|NCT03987724|Experimental|Experimental group|The experiment consists of a supine bicycle exercise in a positron emission tomography (PET) scanner. Each subject will perform the experiment as well as serve as their own control (tumor blood flow at rest vs. blood flow during exercise).
89235580|NCT00574847|Experimental|Escitalopram|Escitalopram treatment
89235581|NCT00574847|Placebo Comparator|Placebo|Placebo
89235582|NCT00348790|Experimental|Vatalanib|"Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.~Patients who are responding may remain on study treatment for 12 months."
89235583|NCT00828035|Other|1, REL|rel group : patients with light endoscopic robot
89235584|NCT00828035|Active Comparator|2, AO|AO group : Patients with surgery assistant
89235585|NCT00825149|Experimental|A: R/R FL: Obinutuzumab Low Dose + CHOP|Participants with Relapsed/Refractory (R/R) FL will receive obinutuzumab 400 milligrams (mg) intravenous (IV) infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 milligrams per square-meter (mg/m^2), vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
89235586|NCT00825149|Experimental|B: R/R FL: Obinutuzumab High Dose + CHOP|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
89235587|NCT00825149|Experimental|C: R/R FL: Obinutuzumab Low Dose + FC|Participants with R/R FL will receive obinutuzumab 400 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
89235588|NCT00825149|Experimental|D: R/R FL: Obinutuzumab High Dose + FC|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 4 weeks on Days 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
89235589|NCT00825149|Experimental|E: First-Line FL: Obinutuzumab + Bendamustine|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Bendamustine 90 mg/m^2 IV infusion on Days 2 and 3 of Cycle 1 and every 4 weeks on Days 1 and 2 of each subsequent cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
89235590|NCT00825149|Experimental|F: First-Line FL: Obinutuzumab + CHOP|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
89235591|NCT00825383|Active Comparator|1|High Fiber Diet
89235592|NCT00825383|Active Comparator|2|Moderate Fiber Diet
89235593|NCT00360490|Experimental|Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
89235594|NCT00360490|Active Comparator|Medroxyprogesterone acetate (MPA)|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
89235595|NCT02549105|Active Comparator|EMLA CREAM|EMLA CREAM 5 mg TOPICAL APPLICATION FOR CS WOUND AND ASSESSMENT FOR POST OPERATIVE PAIN IN FIRST 6 HOURS
89235596|NCT02549105|Active Comparator|LIDOCAINE INFILTERATION|LIDOCAINE 1 % 20 ml INFILTERATION FOR WOUND AND ASSESSMENT OF POST OPERATIVE PAIN IN FIRST 6 HOURS
89235597|NCT00828269|No Intervention|1|Liver tissue biopsy
89235598|NCT00825461||1|Anorexia with tube feeding
89235599|NCT00825461||2|Anorexia without tube feeding
89235600|NCT00825461||3|Control
89235601|NCT00833183|Active Comparator|25 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
89235602|NCT00833183|Active Comparator|37 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
89235603|NCT00833183|Active Comparator|25 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
89235604|NCT00833183|Active Comparator|37 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
89235605|NCT00624377||COPD patients|
89235606|NCT02549963|Experimental|WATCHMAN LAA Occlusion Device|Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.
89235607|NCT02549963|Active Comparator|Rivaroxaban|Subjects assigned to receive the Rivaroxaban therapy.
89235608|NCT00624065|Experimental|carvedilol CR + lisinopril|
89235609|NCT00624065|Active Comparator|lisinopril + placebo|
89235610|NCT00360412|Experimental|E2007|During the first two weeks of the study, Patients received 1 x 2mg E2007 tablet. At the week 2 visit, patients who tolerated the 2 mg/day dose were up-titrated to receive 4mg/day (2 x 2 mg E2007 tablets). Patients not tolerating the 4 mg dose were allowed to down titrate to 2 mg. Patients who did not tolerate the 2 mg dose were withdrawn from the study. Patients returned at week 4, if their tolerance to the 4 mg/day dose was acceptable they remained on this dose for the maintenance phase of the study. If at any time their tolerance declined, they were to return for an unscheduled visit and the daily dose was reduced to 2 mg. If at any stage, 2 mg day wass not tolerated, the patient was withdrawn from the study.
89235611|NCT00623831|Experimental|Cohort 1|Subjects received MBV at a starting dose of 250 EU (dose level 1) twice weekly, with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed. The maximum possible dose to be investigated was 547,000 EU (dose level 8).
89235612|NCT00623831|Experimental|Cohort 2|Subjects received MBV twice weekly at the fixed dose (60,800 EU [dose level 6]) that was determined to be the pyrogenic dose level in Cohort 1.
89235613|NCT00833339|Experimental|1|mifepristone
89235614|NCT00833339|Placebo Comparator|2|
89235615|NCT02549885|Experimental|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
89235616|NCT02549885|Experimental|Static stretching|Static stretching of neck muscles.
89235617|NCT00825617|Experimental|HRT|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
89235618|NCT00825695|Active Comparator|flavanol-rich cocoa|
89235619|NCT00825695|Placebo Comparator|flavanol-poor cocoa|
89235620|NCT00833573||1|For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.
89235621|NCT00833573||2|For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.
89235622|NCT00360334|Experimental|1|
89235623|NCT00360334|Active Comparator|2|
89235624|NCT00422097|Experimental|Ixabepilone, 5 mg/d|If none of first 3 participants experiences a dose-limiting toxicity (DLT) during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the maximum tolerated dose (MTD). If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
89173339|NCT05958108|Experimental|SinergiAPS intervention group|"SinergiAPS is an assessment and monitoring tool designed to support primary healthcare centers to identify potential problems and areas for improvement related to patient safety based on information provided by their own patients. This intervention consists of three main elements:~Patient safety audit of healthcare centers: Patient safety is evaluated from the perspective of patients using the validated PREOS-PC questionnaire.~Feedback of results to healthcare centers: SinergiAPS automatically generates a report with the audit results. This feedback report is specific to each healthcare center and includes a comparison with other participating centers to facilitate benchmarking.~Design of action plans: The centers design patient safety improvement plans based on the problems identified in their center's result report. For this purpose, the SinergiAPS web tool provides resources, training materials, and recommendations on how to improve patient safety in primary care."
89173340|NCT05958095|Experimental|MamaLift Plus|Principles of Cognitive Behavioral Therapy used to treat PPD with App
89173341|NCT05958095|Sham Comparator|Digital Sham App|Content on general mental health and wellbeing topics delivered with sham App
89173342|NCT05958069|Experimental|minocycline|Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
89173343|NCT05958004||Benign Prostatic Hyperplasia|Participants who are suspected of prostate cancer due to elevated PSA but have not received any treatment and eventually confirmed benign prostatic hyperplasia after biopsies
89173344|NCT05958004||Prostate Cancer|Participants who are suspected of prostate cancer due to elevated PSA but have not received any treatment and eventually confirmed prostate cancer after biopsies
89173345|NCT05957991||Met -lifestyle intervention|Girls with overweight and early puberty aged 8-9 years Treatment with metformin without lifestyle intervention (diet, training)
89173346|NCT05957991||Met + lifestyle intervention|Girls with overweight and early puberty aged 8-9 years Treatment with metformin with lifestyle intervention (diet, training)
89173347|NCT05957991||Placebo-lifestyle intervention|Girls with overweight and early puberty aged 8-9 years Treatment with placebo without lifestyle intervention (diet, training)
89173348|NCT05957991||Placebo+lifestyle intervention|Girls with overweight and early puberty aged 8-9 years Treatment with placebo with lifestyle intervention (diet, training)
89173349|NCT05957939|Experimental|a case study with TNBC or ER positive , PR positive HER2 negative ,|researchers will study a case with metastatic breast cancer stage 4 and the source of nutrition either glucose source as energy fuel of cells or another nutrition ( alkaline glucosodiene)
89173350|NCT05957913|Experimental|Treatment arm|After a one-month baseline period where patients will not take any study drug, all patients will receive Truvada (tenofovir/emtricitabine) for three months. The study drug will be Truvada (tenofovir/emtricitabine), an antiviral drug that is approved by the Food & Drug Administration (FDA) for the treatment of chronic hepatitis B virus and for the treatment and prevention of human immunodeficiency virus (HIV) infection. The study drug will be administered at the standard dose used for the treatment and prevention of HIV (300mg tenofovir disoproxil fumarate, 200mg emtricitabine). Since extensive safety and tolerability data already exists for this standard dose, the selection of this dose also allows us to use existing data to inform strategies for safety and tolerability monitoring to minimize risk, as detailed in the study design.
89173351|NCT05957887|Active Comparator|Dapagliflozin use in diabetic patients with anterior STEMI|
89173352|NCT05957887|No Intervention|diabetic patients with anterior STEMI without Dapagliflozin|
89173353|NCT05957887|Active Comparator|Dapagliflozin use in non-diabetic patients with anterior STEMI|
89173354|NCT05957887|No Intervention|Non-diabetic patients with anterior STEMI without Dapagliflozin|
89173355|NCT05957861|Experimental|web-based exercise|Participants will receive web-based aerobic exercise (AE) training three times per week for 16 weeks.
89173356|NCT05957861|No Intervention|control group|control group without any intervention.
89173357|NCT05957835|Experimental|BR-HIGH|Participants will ingest an elevated dose of nitrate 2.5 hours prior to exercise.
89173358|NCT05957835|Experimental|BR-MOD|Participants will ingest a moderate dose of nitrate 2.5 hours prior to exercise.
89173359|NCT05957835|Experimental|BR-LOW|Participants will ingest a low dose of nitrate 2.5 hours prior to exercise.
89173360|NCT05957835|Placebo Comparator|PL|Participants will ingest a negligible amount of nitrate 2.5 hours prior to exercise.
89173361|NCT05957796|Active Comparator|Regular eye shield after surgery|Alcon eye shield after surgery
89173362|NCT05957796|Experimental|Novel prototype eye shield after surgery|Novel prototype eye shield after surgery
89173363|NCT05957783||Group 1|Preoperative patient group with diplegic or hemiplegic cerebral palsy
89173364|NCT05957783||Group 2|Postoperative patient group with diplegic or hemiplegic cerebral palsy
89173365|NCT05957783||Control group|5-15 age healthy children.
89173366|NCT05957744||Group with colorectal cancer and malnutrition|
89173367|NCT05957744||Group with colorectal cancer without malnutrition|
89173368|NCT05957705|Active Comparator|Bilateral Sinus Augmentation|Split-mouth bilateral sinus augmentation of xenogeneic bone graft associated or not with platelet-rich fibrin produced by horizontal centrifugation.
89173369|NCT05957705|Active Comparator|Early dental implant placement by Guided Surgery|
89173370|NCT05957705|Active Comparator|Dental implants reopening surgery for implant load|
89173371|NCT05957666|Experimental|oral misoprostol|oral misoprostol will be given in a dose of 50microgram and repeated after 6 hours if required.Maximum 2 doses will be given
89173372|NCT05957666|Active Comparator|vaginal misoprostol|vaginal misoprostol will be given in a dose of 50 microgram and repeated after 6 hours if required.Maximum 2 doses will be given
89173373|NCT05957653|Experimental|Lidocaine + sufentanil intervention group|
89173374|NCT05957653|Placebo Comparator|Saline control group|
89173375|NCT05957640|Experimental|Yttrium-90 carbon microspheres|Single dose of yttrium-90 carbon microspheres injection. Patients will be assessed by SPECT-CT imaging within 24 hours for yttrium-90 distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.Six Patients will be tested for the radioactivity of yttrium-90 in blood, urine, and feces (if available).
89173376|NCT05957614|Experimental|Traditional Rehabilitation Protocol|
89173377|NCT05957614|Active Comparator|Acupuncture-assisted Rehabilitation Protocol|
89173378|NCT05957601||Women with pelvic floor dysfunction or healthy|All women who met the inclusion criteria, whether pelvic floor dysfunction or healthy, were included. If necessary, grouping can be done during statistics.
89173379|NCT05957588|Experimental|Proning group|COVID-19 hypoxemic patients that receive standard of care AND participate in self-proning following the research protocol.
89173380|NCT05957588|Other|Control group|COVID-19 hypoxemic patients that receive standard of care.
89173381|NCT05957562|Active Comparator|EA/TOF primary repair with Azygos vein preservation|primary esophagoesophagostomy with azygous vein preservation technique and will be done for 32 neonates with EA/TOF amenable for primary repair
89173382|NCT05957562|Active Comparator|EA/TOF primary repair with Azygos vein sacrifice (disconnection)|primary esophagoesophagostomy with azygous vein disconnection ordinary technique and will be done for 32 neonates with EA/TOF suitable for primary repair
89173383|NCT05957549|Experimental|Speech Sounds|Participants listen to speech sounds while the investigators measure electrical and hemodynamic changes in the brain.
89173384|NCT05957523|Experimental|Healthy population|Subjects aged 18 to 45 years and in good health agree to participate in the clinical trial and sign an informed consent form.
89173385|NCT05957471|Experimental|BC3195 treatment group.|BC3195 via intravenous(IV).
89173386|NCT05957458|Experimental|Moderate irradiance of PBM therapy to myopia|The PBM therapy irradiance is about 0.60mW. It is asked subjects to look at the light binocularly with fusion through the pupils with natural pupils. The distance between the light and the pupils is about 5~10cm. The treatment of each session is 3 minutes and twice daily administration while the interval time between two session is equal or larger than 4 hours with twice daily administration.
89173387|NCT05957458|Sham Comparator|Extra low irradiance PBM therapy group|The PBM therapy irradiance is about 0.37mW. It is asked subjects to look at the light binocularly with fusion through the pupils with natural pupils. The distance between the light and the pupils is about 5~10cm. The treatment of each session is 3 minutes and twice daily administration while the interval time between two session is equal or larger than 4 hours with twice daily administration.
89173388|NCT05957458|Experimental|high lever PBM therapy group|The PBM therapy irradiance is about 1.20mW. It is asked subjects to look at the light binocularly with fusion through the pupils with natural pupils. The distance between the light and the pupils is about 5~10cm. The treatment of each session is 3 minutes and twice daily administration while the interval time between two session is equal or larger than 4 hours with twice daily administration.
89173389|NCT05957458|No Intervention|Control|Without PBM therapy group.
89173390|NCT05957419|Experimental|Hypertrophic Obstructive Cardiomyopathy|Transapical beating-heart septal myectomy for the patient with hypertrophic obstructive cardiomyopathy.
89173391|NCT05957380|Experimental|Treatment group|
89173392|NCT05957380|Experimental|Reference group|
89173393|NCT05957341|Experimental|active rTMS: 20min inter-session interval|Three sessions of active rTMS would be delivered, with 1800 pulse/session and 20 min inter-session intervals.
89173394|NCT05957341|Active Comparator|active rTMS: 50min inter-session interval|Three sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
89173395|NCT05957341|Sham Comparator|sham rTMS: 20min inter-session interval|Three sessions of sham rTMS would be delivered, with 1800 pulse/session and 20 min inter-session intervals.
89173396|NCT05957341|Sham Comparator|sham rTMS: 50min inter-session interval|Three sessions of sham rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
89173397|NCT05957328|Active Comparator|liposomal iron group|The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
89173398|NCT05957328|Active Comparator|ferrous ascorbate group|The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
89173399|NCT05957315|Experimental|Mobile Cardiac Outpatient Telemetry Device (MCOT)|These participants will be randomized into receiving the Philips/BioTel MCOT device in addition to usual care.
89173400|NCT05957315|No Intervention|Standard Treatment Group|These participants will be randomized into only receiving usual care and will not receive the MCOT device.
89173401|NCT05957302|Active Comparator|Ketamine group|bolus of sedation for resuming sedation after sedation vacation
89173402|NCT05957302|Active Comparator|Fentanyl group|bolus of sedation for resuming sedation after sedation vacation
89173403|NCT05957263|Experimental|Biofeedback training and Osteopathy procedure|"the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. During biofeedback-assisted pelvic floor muscle exercises, the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscles.~The osteopathy techniques involved a combination of myofascial, visceral, and articular techniques aimed at restoring and rebalancing internal tensions and improving visceral mobility."
89173404|NCT05957263|Active Comparator|Biofeedback training|he biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. During biofeedback-assisted pelvic floor muscle exercises, the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscles.
89173405|NCT05957263|Active Comparator|Osteopathy procedure|The osteopathy techniques involved a combination of myofascial, visceral, and articular techniques aimed at restoring and rebalancing internal tensions and improving visceral mobility.
89173406|NCT05957250|Experimental|[68Ga]Ga-FAPI-46 PET/CT|Depending on study fase: injection(s) with [68Ga]Ga-FAPI-46 for one or two [68Ga]Ga-FAPI-46 PET/CT scan(s)
89173407|NCT05957237||Subjects hospitalised with non-surgical complications after bariatric surgery (case)|
89173408|NCT05957237||Subjects with bariatric surgery without nonsurgical complications (control)|
89173409|NCT05957237||Subjects with obesity (control)|
89173410|NCT05957224|Experimental|Shake 1 then Shake 2|Participants will consume 1 bottle of shake 1 and take their normal morning medications. After this 3ml blood samples will be taken via the cannula at 30mins, 60mins and 120 mins post meal. During the waiting period between phlebotomy, a sensory analysis questionnaire which asks participants to rate the taste, appearance, texture and smell of the product. After a 1-week washout period, the entire protocol will be repeated using Shake 2.
89173411|NCT05957224|Experimental|Shake 2 then Shake 1|Participants will consume 1 bottle of Shake 2 and take their normal morning medications. After this 3ml blood samples will be taken via the cannula at 30mins, 60mins and 120 mins post meal. During the waiting period between phlebotomy, a sensory analysis questionnaire which asks participants to rate the taste, appearance, texture and smell of the product. After a 1-week washout period, the entire protocol will be repeated using Shake 1.
89173412|NCT05957172||Active Treatment|Subjects assigned to wear the FDA-cleared AMS device for 30-60 days Sequential enrollment to avoid preferential selection Investigator blinded to the AMS data
89173413|NCT05957146||Chronic hemodialysis patients|Adult patients treated with routine hemodialysis 3x/week during at least 3 months
89173414|NCT05957133|Active Comparator|Multicomponent exercise group without action observation (MTG)|"The main part of the multicomponent exercise program integrates different exercise modalities: Aerobic, mobility, strength, balance and coordination exercises, playful activities or games are also included with some activities aimed at working on cognitive functions to reinforce the overall effects of the program, such as games with colors, numbers, letters, right-left laterality, memory, etc.~The progression of the different models is as follows:~E. Aerobic: Start with continuous work, then intervallic, and decrease rest times in intervallic work.~E. Strength: Increase sets, repetitions and decrease rest time. Balance: start with static and evolve with blindfolds, perturbations, dynamic balance, etc.~Coordination, and cognitive games will also become more complicated, with more complicated and faster decision making."
89173415|NCT05957133|Experimental|Multicomponent exercise group associated to action observation (AOG)|"It is the same intervention as the other group with the addition of the observation of actions thanks to the fact that the physiotherapist carries out the exercises with them at all times.~The main part of the multicomponent exercise program integrates different exercise modalities: Aerobic, mobility, strength, balance and coordination exercises, playful activities or games are also included with some activities aimed at working on cognitive functions to reinforce the overall effects of the program, such as games with colors, numbers, letters, right-left laterality, memory, etc.~The progression of the exercises will be the same as in the other group."
89173416|NCT05957120||Patients on local therapy|20 patients on local antipsoriatic therapy (either corticosteroid cream/ointment, calcipotriol or combination (corticosteroid and calcipotriol); duration of treatment varies in cohort of patients
89173417|NCT05957120||Patients on methotrexate|20 patients on methotrexate with dosage adjusted by weight; duration of treatment varies in cohort of patients
89173418|NCT05957120||Patients on biologic therapy with anti-tumor necrosis factor-alpha|20 patients on adalimumab - 40 mg every two weeks (or 40 mg weekly if the response was previously insufficient); duration of treatment varies in cohort of patients
89173419|NCT05957120||Patients on biologic therapy with anti-interleukin-17|20 patients on secukinumab - 300 mg monthly (or 300 mg every two weeks if the response was previously insufficient); duration of treatment varies in cohort of patients
89173420|NCT05957120||Patients on biologic therapy with anti-interleukin-23|20 patients on guselkumab - 100 mg every 8 weeks; duration of treatment varies in cohort of patients
89173421|NCT05957120||Controls|20 subjects who are age-matched
89173422|NCT05957094|Placebo Comparator|Placebo visit|Participants will then undergo pre-intervention testing, with at least 20 minutes of rest between each. Once these tests are complete, the participant will ingest a placebo (sugar pill) that is identical in appearance to the drug condition. Three hours after placebo ingestion all tests will be conducted again. Participants will remain in the lab and will be free to read or work during this resting 3 hour period. This will conclude this experimental visit.
89173423|NCT05957094|Active Comparator|SSRI visit|Participants will then undergo pre-intervention testing, with at least 20 minutes of rest between each. Once these tests are complete, the participant will ingest citalopram (40 mg) Then three hours later all tests will be conducted again. Participants will remain in the lab and will be free to read or work during this resting 3 hour period. This will conclude this experimental visit.
89173424|NCT05957068|Experimental|Exercise|The exercise intervention group will undergo an aerobic exercise and strength training programme, comprising 3 sessions per week, spanning 24 weeks (total: 3x24=72 sessions).
89173425|NCT05957068|Experimental|Control|The usual care group.
89173426|NCT05957029|Experimental|Nuera Tight RF System|Subjects will receive an RF treatment session on the periorbital area and cheeks with a frequency of 1 and 4 MHz. Each subject will be treated on one side of the face using a 10 mm capacitive electrode, and on the other side using a 20 mm capacitive electrode. The target temperature will be set at 42 C.
89173427|NCT05956977|Experimental|prospective arm|Use of 3D ultrasound intraoperative before intraoperative MRI
89173428|NCT05956977|No Intervention|retrospective matched pair arm|no use of intraoperative ultrasound before intraoperative MRI
89173429|NCT05956925|No Intervention|Control|Following the educational session, the control group participants' BP, ASA24® Dietary Assessment Tool (ASA24; sodium intake), and pre-test knowledge on HTN will be obtained (using Qualitrics). Four weeks later, the participants were scheduled for a follow-up meeting to collect each participant's BP, ASA24, and post-test knowledge on HTN (using Qualitrics).
89173430|NCT05956925|Experimental|MOBILE Intervention Group|Intervention participants were required to take daily BP, provide their motivation level, and send them to the research assistant to receive the appropriate text messages.
89173431|NCT05956873||RTAAA patients treated with REVAR|Included population were consecutive patients presented with evidence of active bleeding (frank ruptures), or without active bleeding but with periaortic structures infiltration/hematoma (contained rupture); undergoing urgent/emergent endovascular RTAAA (Crawford's extend I-IV + suprarenal AAA) repair within the first 24 hours, requiring a proximal landing zone above the celiac trunk with off-the-shelf, F/B-EVAR, PMEG and PG.
89173432|NCT05956691|Experimental|Investigation|"Dosing Instructions~Brush teeth with water (no toothpaste).~Scrub tongue with warm, wet, washcloth from the back to the front until most of the white/yellow biofilm on the tongue is gone.~Gargle and swish hot (optimal 120°F) water for 10-20 seconds. Spit out and repeat gargling over the next 5 minutes. The tongue should be red and without any biofilm. If it is not, repeat Step 2, and gargle once more.~Self-administer one lozenge. Let the lozenge slowly melt in the mouth. Do not chew or swallow whole. This may take up to 60 minutes. Discard if it is not fully dissolved after 60 minutes.~Wash the washcloth to be ready before next use."
89173433|NCT05956691|Active Comparator|Control|"Dosing Instructions~Microwave: heat the product in 5 second increments until soft. (Caution: more than 10 seconds of microwaving the product may cause it to burn).~Cut: cut the product into smaller pieces~Swallow: swallow without chewing the pieces with warm water while they are still warm. It can be swallowed over time or at once."
89173434|NCT05954364||Psoriatic Arthritis|Patients with a rheumatologist-confirmed diagnosis of psoriatic arthritis who are initiating advanced therapy for peripheral musculoskeletal manifestations of psoriatic arthritis
89173435|NCT05954338|Experimental|Intervention: DWC202307 + DWJ1543|
89173436|NCT05954338|Experimental|Intervention: DWC202307 + DWC202216|
89173437|NCT05954273||Sinus membrane perforation|Sinus membrane perforation incidences to measure the perforation rate.
89173438|NCT05954273||Alveolar bone height below the maxillary sinus floor|Pre-sinus augmentation alveolar bone ridge height.
89173439|NCT05954273||Maxillary sinus augementation level|Vertical graft height in the maxillary sinus.
89173440|NCT05954273||Implants length and width|Placed implants length and width
89173441|NCT05954247|Experimental|Intervention: DWJ1543|
89173442|NCT05954247|Experimental|Intervention: DWC202216|
89173443|NCT05951712|Placebo Comparator|No Intervention|"In this arm, the participants will receive placebo ( 100 ml water) 10-30 minutes before the procedure under the supervision of a trained nurse. All patients will be given standard recommendations before the procedure: at least 8 hours of liquid and solid fasting.~During endoscopy, mucosal visibility will be evaluated in 6 segments (gastric antrum, lower gastric body, upper gastric body, fundus, first and second part of duodenum), using a scale ranging from 1 to 4 points: (1) no adherent mucus in the gastric mucosa examined; (2) a small amount of mucus in the gastric mucosa examined that does not hinder vision; (3) a large amount of mucus in the gastric mucosa examination, which can be washed thoroughly with <50 mL of water; (4) a large amount of mucus in the gastric mucosa examined which requires ≥50 mL of water for washing."
89173444|NCT05951712|Experimental|Simethicone 150 mg|"In this arm, the participants will receive 150 mg simethicone dissolved in 100 ml water 10-30 minutes before the procedure under the supervision of a trained nurse.All patients will be given standard recommendations before the procedure: at least 8 hours of liquid and solid fasting.~During endoscopy, mucosal visibility will be evaluated in 6 segments (gastric antrum, lower gastric body, upper gastric body, fundus, first and second part of duodenum), using a scale ranging from 1 to 4 points:(1) no adherent mucus in the gastric mucosa examined; (2) a small amount of mucus in the gastric mucosa examined that does not hinder vision; (3) a large amount of mucus in the gastric mucosa examination, which can be washed thoroughly with <50 mL of water; (4) a large amount of mucus in the gastric mucosa examined which requires ≥50 mL of water for washing."
89173445|NCT05951712|Experimental|N Acetyl cysteine 600 mg|"In this arm the participants will receive 600 mg N-acetyl cysteine dissolved in 100 ml water 10-30 minutes before the procedure under the supervision of a trained nurse.All patients will be given standard recommendations before the procedure: at least 8 hours of liquid and solid fasting.~During endoscopy, mucosal visibility will be evaluated in 6 segments(gastric antrum, lower gastric body, upper gastric body, fundus, first and second part of duodenum), using a scale ranging from 1 to 4 points:(1) no adherent mucus in the gastric mucosa examined; (2) a small amount of mucus in the gastric mucosa examined that does not hinder vision; (3) a large amount of mucus in the gastric mucosa examination, which can be washed thoroughly with <50 mL of water; (4) a large amount of mucus in the gastric mucosa examined which requires ≥50 mL of water for washing."
89173446|NCT05951712|Experimental|Simethicone (150 mg) plus N Acetyl cysteine 600 mg combination|"In this arm, the participants will receive 150 mg simethicone and N-acetyl cysteine dissolved in 100 ml water 10-30 minutes before the procedure under the supervision of a trained nurse.All patients will be given standard recommendations before the procedure: at least 8 hours of liquid and solid fasting.~During endoscopy, mucosal visibility will be evaluated in 6 segments (gastric antrum, lower gastric body, upper gastric body, fundus, first and second part of duodenum), using a scale ranging from 1 to 4 points:(1) no adherent mucus in the gastric mucosa examined; (2) a small amount of mucus in the gastric mucosa examined that does not hinder vision; (3) a large amount of mucus in the gastric mucosa examination, which can be washed thoroughly with <50 mL of water; (4) a large amount of mucus in the gastric mucosa examined which requires ≥50 mL of water for washing."
89173447|NCT05951595|Experimental|Artemether-Lumefantrine-Amodiaquine (ALAQ)|TACT group
89173448|NCT05951595|Active Comparator|Artemether-Lumefantrine (AL)|ACT 1 group
89173449|NCT05951595|Active Comparator|Artesunate-Amodiaquine (ASAQ)|ACT 2 group
89173450|NCT05950425|Experimental|Experimental I group (video training + standard training)|This group will be trained with the aspiration training video shot by the researcher on the model. The video content will include the introduction of the materials used in the aspiration application, how to maintain sterility, the position to be given to the child during aspiration, and the sterile aspiration on the model. After obtaining the consent of the mothers in Experiment I group who participated in the study and were assigned by randomization method, they will be taken to the day room of the service and the training video will be watched on the computer. After the end of the video, if they have any questions, they will be answered and they will be taken to their child's intensive care room after wearing the equipment (bonnet, shoe covers, apron, mask) necessary for the standard education and providing hand hygiene.
89173451|NCT05950425|Experimental|Experimental II group (education booklet training + standard training)|Aspiration training will be given to this group with a picture training booklet. The training booklet includes the purpose of aspiration, the materials to be used, the position to be given to the child during aspiration, the preservation of sterility, and the application of aspiration. Expert opinion will be taken for the training booklet to be used. After obtaining the consent of the mothers in the Experimental II group, who participated in the study and were assigned with the randomization method, they will be taken to the day room of the service and aspiration training will be given with a picture training booklet. After the training, the questions of the mothers will be answered. At the end of the illustrated training booklet training, mothers will be put in the necessary equipment (bone cap, shoe covers, apron, mask) for standard practice training and hand hygiene will be provided and they will be taken to the intensive care environment to their children's rooms.
89173452|NCT05950425|No Intervention|Control group|The routine standard training given to this group in aspiration training will be used. In this training, one-to-one telling and showing are available. After obtaining the consent of the mothers in the control group who participated in the study and were assigned by randomization method, the necessary equipment (bone cap, shoe covers, apron, mask) will be put on and hand hygiene will be provided and they will be taken to the intensive care unit. After the mother is taken to the room where the child is staying, the equipment and apparatus connected to her child (monitor, infusion pump, NG probe, foley catheter, endotracheal tube, tracheostomy, etc.) will be introduced, equipment used in the treatment process of her child (mechanical ventilator, oxygen valve, aspirator, ambu, aspiration). probe, etc.) will be introduced and physical contact with the child will be supported and ensured.
89173453|NCT05929157|Active Comparator|Artesunate-pyronaridine intravenous|
89173454|NCT05929157|Active Comparator|Artesunate-pyronaridine intramuscular|
89173455|NCT05905432|Experimental|Dosage A1|n=2 will receive a dose of 20 mcg UF6b (A1), n=9 will receive 20 mcg AnAPN1: GLA-LSQ (5 mcg GLA/2 mcg LSQ) (A2)
89173456|NCT05905432|Experimental|Dosage B1|n=2 will receive 50 mcg UF6b (B1), n=9 will receive 50 mcg UF6b: GLA- LSQ (12.5 mcg GLA/5 mcg LSQ) (B2)
89173457|NCT05905432|Experimental|Dosage C1|n=2 will receive 100 mcg UF6b (C1); n=9 will receive 100 mcg UF6b: GLA- LSQ (25 mcg GLA/10 mcg LSQ) (C2)
89173458|NCT05881616||GDM group|Pregnant women aged 20-40 with positive oral glucose tolerance test (OGTT) results at 24-28 weeks.
89173459|NCT05881616||non-GDM group|Pregnant women aged 20-40 with negative OGTT results at 24-28 weeks.
89173460|NCT05881616||Control group|Healthy non-pregnant women aged 20-40.
89173461|NCT05880251|Experimental|Intervention Group|Intervention group receives peripheral stimulation with realtime operant conditioning feedback training.
89173462|NCT05880251|Experimental|Control Group|Control group receives peripheral stimulation but without operant conditioning feedback.
89173463|NCT05879471|Experimental|68Ga-NY104 PET/CT|Each patient will receive one dose of 68Ga-NY104 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.
89173464|NCT05874466||Pediatric patients, 16-37 months of age, recruited through pediatric medical clinics|Consecutive pediatric participants will be recruited and enrolled via > 6 participating sites comprised of pediatric medical clinics (e.g., primary care and family medicine clinics) that are part of the broader Duke University Health System (DUHS) located in North Carolina. Enrollment will proceed until the targets of N = 150 participants diagnosed with autism spectrum disorder and N = 200 without autism are reached.
89173465|NCT05864651|Experimental|Tele-exercise program group|"Provide the following programs:~tele-exercise program: 5 times per week, 30 minute/session~conventional fencing exercise: 5 times per week, 30 minute/session"
89173466|NCT05864651|Active Comparator|Control group|"Provide the following programs:~1) conventional fencing exercise: 5 times per week, 30 minute/session"
89173467|NCT05861167|Experimental|SIIT group|
89173468|NCT05861167|No Intervention|Non-intensive induction therapy group|
89173469|NCT05828459|Experimental|OT-A201 monotherapy|OT-A201 administered by IV infusion on a weekly (qw) basis. An alternative dosing schedule of every 2 weeks (q2w) may be implemented based on the clinical safety and laboratory data.
89173470|NCT05828459|Experimental|OT-A201 in combination with iMiD|OT-A201 in combination with lenalidomide or pomalidomide at the approved dose
89173471|NCT05828459|Experimental|OT-A201 in combination with a specific agent|OT-A201 in combination with late stage approved treatment (combination to be defined by a protocol amendment)
89173472|NCT05828459|Experimental|OT-A201 in combination with bevacizumab|OT-A201 in combination with bevacizumab at the approved dose
89173473|NCT05828459|Experimental|OT-A201 in combination with paclitaxel|OT-A201 in combination with paclitaxel at the approved dose
89173474|NCT05824845||ARC Study Cohort|
89173475|NCT05822102||People with Cystic Fibrosis who are taking ETI that has reached a steady state dosing level.|Blood samples will be collected from people with CF who are taking ETI at a continuous dosing regimen for a minimum of 14 days.
89173476|NCT05817071|Active Comparator|Arthroscopic massive Rotator Cuff Tears Repair without using long head of biceps tendon augmentation|Arthroscopic repair either complete or partial with medialization or not by anchors without using proximal part of long head of biceps tendon) ( single row or double row )(partial or complete anatomical)
89173477|NCT05817071|Experimental|Arthroscopic Massive Rotator Cuff Tears Repair With biceps Augmentation|• Single or double row repair technique by Rotator Cuff(RC) anchors. Biceps augmentation will be done via release and mobilize the Long Head of Biceps Tendon from bicipital groove. then the proximal part of long head of biceps tendon will be lateralized towards greater tuberosity crossing the gap by passing 1 limb of the RC anchor using suture passer (scorpion or lasso loop) and the other limb of the same anchor was passed through torn cuff. a horizontal limb of distal part biceps tendon was interpositioned between the Rotator Cuff Tears And humeral head, aiding in biological healing and strengthening poor quality rotator cuff tendons
89173478|NCT05809895|Experimental|Arm A: ociperlimab+tislelizumab+chemotherapy (PD-L1 CPS ≥ 10)|Participants with a PD-L1 CPS ≥ 10 will receive after randomization ociperlimab + tislelizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
89173479|NCT05809895|Active Comparator|Arm B: placebo + pembrolizumab + chemotherapy (PD-L1 CPS ≥ 10)|Participants with a PD-L1 CPS ≥ 10 will receive after randomization placebo + pembrolizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
89173480|NCT05809895|Active Comparator|Arm C: placebo + tislelizumab + chemotherapy (PD-L1 CPS ≥ 10)|Participants with a PD-L1 CPS ≥ 10 will receive after randomization placebo + tislelizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
89173481|NCT05809895|Other|Arm D: ociperlimab + tislelizumab + chemotherapy (PD-L1 CPS score ≥ 1 to < 10)|Exploratory arm: Participants with a PD-L1 CPS ≥ 1 to < 10 will receive ociperlimab + tislelizumab + chemotherapy. The choice of one of three chemotherapy options is at the discretion of the investigator provided that it is either: (1) paclitaxel, (2) nab-paclitaxel, or (3) gemcitabine plus carboplatin.
89173482|NCT05804786||single group|Patients with peripheral pulmonary lesions which require histological differentiation because of the possibility of malignancy, and a biopsy can be attempted through 3D electromagnetic navigation bronchoscopy
89173483|NCT05794724||Clinical T1N0M0 lung adenocarcinoma patients eligible for surgery.|
89173484|NCT05794711||Clinical T1N0M0 lung adenocarcinoma patients eligible for surgery.|
89173485|NCT05794698||Study group|Clinical T1N0M0 lung adenocarcinoma patients eligible for surgery.
89173486|NCT05791162|Other|IgA nephropathy in follow-up (arm 1)|Diagnosis of IgA nephropathy from 2009, with a minimum follow-up for nephropathy of 5 years
89173487|NCT05791162|Other|Newly diagnosed IgA nephropathy (arm 2)|Diagnosis of IgA nephropathy during the study period
89173488|NCT05791162|Other|CD163s control (arm 3)|Diagnosis of Lupus or ANCA-associated vasculitis or polycystic kidney disease
89173489|NCT05791097|Experimental|Arm A: Ociperlimab + tislelizumab + chemotherapy|Participants will receive ociperlimab in combination with tislelizumab and platinum-based doublet chemotherapy
89173490|NCT05791097|Active Comparator|Arm B: Placebo + pembrolizumab + chemotherapy|Participants will receive ociperlimab placebo in combination with pembrolizumab and platinum-based doublet chemotherapy
89173491|NCT05791097|Placebo Comparator|Arm C: Placebo + tislelizumab + chemotherapy|Participants will receive ociperlimab placebo in combination with tislelizumab and platinum-based doublet chemotherapy
89173492|NCT05783349|Other|Women treated in the Medically Assisted Procreation (MAP) center of Nice|
89173493|NCT05778721||adult patients with a diagnosis of idiopathic hypersomnia|adult patients with a diagnosis of idiopathic hypersomnia according to the International Classification of Sleep Disorders (ICSD 3) criteria and the performance of a 48-hour polysomnography at the Sleep Laboratory, between 2004 and today.
89173494|NCT05768906||Life-sustaining therapies limitation decision situations - observation only|For each participating center, consecutive inclusion of the first 10 life-sustaining therapies limitation decision situations from the study start date over a maximum of 12 months. Data collection for these patients especialy information concerning disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians.
89173495|NCT05763680||Infants suspect of neonatal sepsis (early and late onset) up to 90 days postnatally|Infants who are suspect of sepsis, either based on risk factors for infection or on clinical assessment. No restrictions in terms of gestational age
89173496|NCT05754294||Coronary arteries bypass grafting with conventional cardiopulmonary bypass (cCPB)|(n=20) patients, were allocated for Conventional Cardiopulmonary Bypass (cCPB)
89173497|NCT05754294||Coronary arteries bypass grafting with Minimally invasive extracorporeal circulation (MiECC)|(n=20) patients, were allocated for Minimal invasive Extracorporeal Circulation (MiECC) type III.
89173498|NCT05754294||Minimally invasive mitral valve repair (MIMVR) with CPB time (< 60 min.)|(n=20) patients, were allocated for Minimally invasive mitral valve repair (MIMVR) with CPB time (< 60 min.)
89173499|NCT05754294||Minimally invasive mitral valve repair (MIMVR) with CPB time (>100 min.)|n=20) patients, were allocated for Minimally invasive mitral valve repair (MIMVR) with CPB time (> 100 min.)
89173500|NCT05736289||Percutaneous mitral valve repair|Patients undergoing percutaneous mitral valve repair under general anesthesia for mitral valve regurgitation.
89173501|NCT05736289||Surgical mitral valve repair or replacement|Patients undergoing surgical mitral valve repair or replacement for mitral valve regurgitation.
89173502|NCT05709223|Experimental|Participants receiving both Categorical Loudness Scaling Based Fitting and behavioural fitting.|Participants will receive a categorical loudness scaling based fitting (Interventional) and behavioural fitting with 4 weeks experience of both MAPS
89173503|NCT05705908|No Intervention|Control Group - No foot bath|"24 hours after surgery - did not give foot bath to patients~Pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
89173504|NCT05705908|Experimental|Experimental Group- Hot Foot Bath 1|"Post operative 24th hour - 48 th hour - 72 nd hour - gave patients hot foot bath~Patient was seated in an upright position.~FM 4020 Grundig brand footbath device was used for the Hot Foot Bath.~It was filled with 40 degrees water, 20 cm (4 lt. of water)~Soaked in hot water up to the ankles~The foot bath was continued for 20 minutes with the feet in the device.~After 20 minutes, the patient's feet were dried with a towel.~After the foot bath pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
89173505|NCT05705908|Experimental|Experimental Group- Hot Foot Bath 2|"Post operative 24th hour - 48 th hour - 72 nd hour - gave patients hot foot bath with Lavender Essential Oil~Patient was seated in an upright position.~FM 4020 Grundig brand footbath device was used for the Hot Foot Bath.~It was filled with 40 degrees water, 20 cm (4 lt. of water)~Soaked in hot water up to the ankles~The foot bath with Lavender Essential Oil was continued for 20 minutes with the feet in the device.~After 20 minutes, the patient's feet were dried with a towel.~After the foot bath with Lavender Essential Oil pain was evaluated with VAS scale. Post-operative 24th hour, 28th hour, 32nd hour, 36th hour, 40th hour, 44th hour, 48th hour, 52nd hour, 56th hour, 58th hour, 62nd Hour, 64th Hour., 68th Hour, 72nd Hour~Sleep Questionnaire was administered at 08:00-09:00 in the morning when the patient woke up; 24th hour, 48 th hour, 72 th hour."
89173506|NCT05690425|Experimental|BC3402 treatment group|BC3402 as a single agent via intravenous infusion once every 3-weeks
89173507|NCT05677893|Experimental|Investigational drug|Eligible participants will be assigned to receive 0.3-1.2 mg/kg single or multiple doses of the investigational drug.
89173508|NCT05677893|Placebo Comparator|Placebo|Eligible participants will be assigned to single or multiple doses of the placebo.
89173509|NCT05664659|Active Comparator|Oxytocin+Misoprostol|Patients in this group will receive 600 micrograms misoprostol rectally immediately before sterilization plus 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution immediately after delivery of the fetus.
89173510|NCT05664659|Experimental|Carbetocin|Patients in this group will receive 100ug Carbetocin by slow IV infusion (over one minute) intra-operative immediately after delivery of the fetus.
89173511|NCT05661370|Active Comparator|Intervention|Access to educational mobile application for 8 days, diagnosing 500 digital patient-cases.
89173512|NCT05661370|No Intervention|Control|Control group receiving no intervention, continuing daily practice.
89173513|NCT05626478|Active Comparator|Arm 1 - Cataract surgery gtt regimen per SOC|Following cataract surgery (without Dextenza 0.4mg insert) patients will receive: Prednisolone Acetate 1% QID X 2 Weeks, then BID x 2 weeks and stop / Prolensa 0.07% QD X 4 Weeks and stop.
89173514|NCT05626478|Experimental|Arm 2 - Cataract surgery with Dextenza and less frequency of gtt regimen|Following cataract surgery with DEXTENZA 0.4mg insert, patients will receive: Prolensa 0.07% QD X 4 Weeks and stop
89173515|NCT05625113|Experimental|neuroprosthesis|This is a prospective, monocentric, real-life, feasibility case series, succeeding to the PREHENS-STROKE study, aimed at assessing the feasibility, acceptability, tolerance, efficacy and organizational impact of the use of a gripping neuroprosthesis at home (innovative medical device) in a population of vascular hemiparetic patients. The study consists of an initial phase of inclusion and evaluation (T1 and T2), an intermediate phase (T3 to T9) of learning and use of the gripping neuroprosthesis at home by the patient and a final phase (T10 and T11) of evaluation of the impact of the use of the neuroprosthesis. Each patient is their own control (self-matching).
89173516|NCT05616884|Experimental|Cementless|Cementless fixation partial knee replacement
89173517|NCT05616884|Active Comparator|Cemented|Cemented fixation partial knee replacement
89173518|NCT05604001|Experimental|Symptomatic submucosal myoma|patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy with laser ablation of the myoma.
89173519|NCT05600309|Experimental|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.
89173520|NCT05600309|Active Comparator|Standard of Care (Regorafenib or TAS-102)|Participants will receive 160 mg regorafenib orally daily on Days 1-21 of each 28-day cycle. Participants will also receive 35 mg/m^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day treatment cycle.
89173521|NCT05578079|No Intervention|Control group|No music will be played to the control group.
89173522|NCT05578079|Active Comparator|Intervention 1|"The Intervention-1 group will listen to the music which determined by the researchers by examining the literature (DOI: 10.4274/jpr.24892). The music which determined by the researchers is The art of fugue by Johann Sebastian Bach."
89173523|NCT05578079|Active Comparator|Intervention 2|The Intervention-2 group will listen to lullaby.
89173524|NCT05574114|Experimental|Radiation Therapy Before CAR T Cell Therapy|For the purposes of this protocol, day 0 will be considered the date of planned CAR T infusion. BRT Part I (intervention is 9 fractions of 3 Gy to a total dose of 27 Gy). Post-BRT Phase I re- evaluation period: Following delivery of the first 9- fractions of BRT, patients will have a period for recovery, and undergo protocol-mandated reassessment (e.g., PET scan and biopsy). Patients will receive standard of care lymphodepleting chemotherapy. Substitutions to the lymphodepleting regimen will be permitted at the discretion of the treating investigator. Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy). Day -1: No protocol scheduled treatment interventions. Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product, as an inpatient or outpatient, at the discretion of the treating investigator.
89173525|NCT05569694|Experimental|Women in the Community|Movement-Based pelvic health education
89173526|NCT05560490|Experimental|FibroFix Cartilage P Implant + Drill set|Participants that have been implanted with FibroFix Cartilage P Implant using the FibroFix Drill Set
89173527|NCT05531214|Experimental|Intervention|Patients randomized based on their primary care clinician to a co-localized care with a telemedicine-based cardiorenal multidisciplinary team (cardiologist, nephrologist, and research coordinators) providing guidance and recommendations to the primary care clinician.
89173528|NCT05531214|No Intervention|Control|"Patients randomized to the control group will proceed with usual care with a primary care clinician making referrals to a cardiologist or nephrologist for-cause as determined by the primary care clinician, to ultimately assess the rates of improvement in the implementation of GDMT."
89173529|NCT05489627|Experimental|Main arm of the study|"Medial knee instabilities will be addressed in this arm. Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with D concomitant ACL QTB reconstruction and MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well.~17 patients will be included in this arm - this number was calculated and rounded up as a mean of number patients from studies of Alm et al. 2021 (17 patients in ACLR+MCLR group), Lee et al. 2020 (10 patients in ACLR+MCLR group), Kitamura et al. 2013 (16 patients in ACLR+MCLR group), LaPrade et al. 2012 (8 patients in ACLR+MCLR group), Lind et al. 2009 (34 patients in ACLR+MCLR group) and Kim et al. 2008 (12 patients in ACLR+MCLR group). All above referenced studies apart from the study of LaPrade et al. were retrospective."
89173530|NCT05488795|Other|Suite TB-HBPM pre intervention|Each suite/cluster throughout the institution will begin in the baseline usual care phase in the first year.
89173531|NCT05488795|Other|Suite TB-HBPM throughout intervention implementation|Each suite will be randomized to implement the TB-HBPM program during one of three wedges separated by six months between each, 1.5 years later.
89173532|NCT05488795|Other|Suite TB-HBPM post intervention implementation|Post implementation phase of the suites 2 years after introduction of intervention.
89173533|NCT05481645|Experimental|Group one|"First-line treatment: TQB2450 injection 1200mg,d1/Q3W+Carboplatin Injection, AUC=5 mg/ml.min,d1/Q3W + Paclitaxel Injection 175mg/m2,d1/Q3W;6-8 cycles;~Maintenance treatment: TQB2450 injection, 1200mg，d1/Q3W"
89173534|NCT05481645|Experimental|Group two|First-line treatment: TQB2450 Injection 1200mg, d1/Q3W + Anlotinib Hydrochloride Capsules 8mg/qd, d8-21/Q3W + Carboplatin Injection AUC=5 mg/ml.min, d1/Q3W + Paclitaxel Injection 175mg/m2, d1/Q3W ; 6-8 cycles; Maintenance treatment: TQB2450 injection+ Anlotinib Hydrochloride Capsules 8mg/qd, d8-21/Q3W
89173535|NCT05481645|Experimental|Group three|"First-line treatment stage:~TQB2450 injection 1200mg, d1/Q3W + anlotinib hydrochloride capsules 8mg/qd, d8-21/Q3W+ chemotherapy（① Doxorubicin Hydrochloride Injection 60mg/㎡，d1/Q3W; or ② Gemcitabine Hydrochloride Injection 900mg/㎡, d1, d8/Q3W+ Docetaxel Injection 75mg/㎡, d8/Q3W）; 6-8 cycles;~Maintenance phase:~TQB2450 injection 1200mg, d1/Q3W+ Anlotinib hydrochloride capsules 10mg/qd, d8-21/Q3W"
89173536|NCT05425498|Experimental|Physical Activity Program Group|In the physical activity group, In the physical activity group, a 12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model. Assessments will perform just before starting to study, at the end of 12 weeks (just after the physical activity program), and the end of 24 weeks.
89173537|NCT05425498|No Intervention|Control group|In the control group, information about physical activity will be given without applying the physical activity program. Control group's assessments will be performed when they are included in the study, at the end of 12 weeks and 24 weeks.
89173538|NCT05410925|Experimental|r-SAK group|intravenous injection of single-bolus 5 mg r-SAK in 3 min
89173539|NCT05410925|Placebo Comparator|placebo group|intravenous injection of placebo in 3 min
89173540|NCT05410457||thrombolysis group|Inclusion criteria: a) age ≥18 years; B) hospital admission for acute ischemic stroke; C) the time from onset to admission ≤ 4.5 hours; D) received intravenous thrombolysis; E) signed informed consent.
89173541|NCT05410457||thrombectomy group|Inclusion criteria: a) age ≥18 years; B) hospital admission for acute ischemic stroke; C) the time from onset to admission ≤ 24 hours; D) vascular assessment by CTA or multimodal MRI; E) received thrombectomy; F) signed informed consent.
89173542|NCT05410457||stent group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) vascular assessment by CTA or multimodal MRI; D) received stent implantation ; E) Signed informed consent.
89173543|NCT05410457||regular treatment group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) received regular medical treatment; D) signed informed consent.
89173544|NCT05410457||young stroke group|Inclusion criteria: a) age between 18 and 50 years of age (45/55Y); B) hospital admission due to ischemic stroke; C) received CT or MRI imaging assessment; D) signed informed consent.
89173545|NCT05410457||unexplained stroke group|Inclusion criteria: a) age ≥18 years; B) hospital admission due to ischemic stroke; C) Received CT or MRI imaging assessment; D)TOAST was classified as unknown cause type (including two or more causes and no cause was found by auxiliary examination); E) signed informed consent.
89173546|NCT05397652|Experimental|Tranexamic acid injectable product|Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously
89173547|NCT05397652|Placebo Comparator|Placebo|Patients from the control group will receive 10 minutes before the procedure 100 ml sterile saline intravenously
89173548|NCT05397405|Experimental|Intervention group|Blood Lipid management with atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
89173549|NCT05397405|No Intervention|Control group|Blood Lipid management with atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg for 6-12 months
89173550|NCT05385341|Experimental|Telerehabilitation (Tele RCV)|Experimental group (Tele-RCV): the treatment will consist of 20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training (the first session in center to form the patient) associated with 8 educative sessions.
89173551|NCT05385341|Active Comparator|Rehabilitation (RCV)|Group control (RCV) : 20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.
89173552|NCT05368077|Experimental|35 Pediatric Obstructive Sleep Apnea|"The investigators will also determine whether brain tissue changes, reduced CBF, and altered neural responses to cognitive challenge reverse, and cognition and mood signs improve after standard surgical procedure adenotonsillectomy for breathing condition at 6 months in pediatric OSA."
89173553|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg as the low dose group.
89173554|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg as the middle dose group.
89173555|NCT05345522|Experimental|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg as the high dose group.
89173556|NCT05342584|Experimental|Venetoclax plus 7+3|see detailed description
89173557|NCT05340504|Experimental|Group A: NAC, then Placebo Oral Capsule|Group A will receive NAC 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive Placebo Oral Capsule 2 times a day for 14 days and have another MRI exam on day 14.
89173558|NCT05340504|Experimental|Group B: Placebo Oral Capsule, then NAC|Group A will receive Placebo Oral Capsule 2 times a day for a total of 14 days. On Day 14 they will have a Magnetic Resonance Imaging (MRI) exam. They will then have a 14 day washout period. They will then receive NAC 2 times a day for 14 days and have another MRI exam on day 14.
89173559|NCT05338658|Experimental|Peptide Alarm Therapy + Pembrolizumab|"Participants receive pembrolizumab 200 mg every 3 weeks (Dose Finding Component) or a disease appropriate PD1/PD-L1 inhibitor (Dose Expansion Component) for 2 treatment courses per standard of care.~The first dose of PAT is given on Day 1 and on Day 3 (36 to 48 hours after the 1st PAT dose)~A second course of the PD1/PD-L1 inhibitor is given per standard of care on Day 22 (Cycle 2 Day 1)."
89173560|NCT05333549|Experimental|Usual care plus istradefylline|Participants will receive usual care, and in addition, will be asked to take istradefylline daily for 26 weeks.
89173561|NCT05323084|Experimental|Dietary supplement|Green tea extract 5 grams, Chicory extract 1gram and collagen peptides 5 grams in 60ml with sugar, erythritol and 2% potassium sorbate and 1% flavor
89173562|NCT05323084|Placebo Comparator|Placebo|60ml of water, sugar, erythritol, 2% potassium sorbate, and 1% flavor
89173563|NCT05319652|Experimental|Pain self-management program|Participants log in to the online program and develop practical strategies to manage CNCP.
89173564|NCT05308693|No Intervention|Control-Classical patient education|Before the operation, the stoma area is marked, the patient is educated with the classical method brochure
89173565|NCT05308693|Experimental|Experimental-Patient Compatible Stoma Educational Material|The stoma area is marked before the operation; A brochure is given to the patient. Practical training is given on the patient's own body with patient-compatible stoma training material.
89173566|NCT05303363||VV-ECMO|Critically ill patients with a suspected indication for VV-ECMO. ECMO will be provided according to local guidelines. In the Amsterdam UMC, location AMC, next to VV-ECMO, veno-arterial (VA-ECMO) is also provided. For this study, only patients on VV-ECMO will be included.
89173567|NCT05296954|Experimental|Group 1|Tachycardia
89173568|NCT05296954|Active Comparator|Group 2|Without tachycardia
89173569|NCT05295615|Experimental|Active ECHS AD device|Experimental intervention arm
89173570|NCT05295615|Sham Comparator|Sham ECHS AD device|Sham intervention arm
89173571|NCT05278715|Experimental|optic pathway glioma|
89173572|NCT05262738|Experimental|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects in this arm will be randomized to the 50 micrograms of vaginal misoprostol (intervention) group, they will be admitted to labor and delivery and undergo placement of 50 micrograms of intravaginal misoprostol every 4 hours for cervical ripening.
89173573|NCT05262738|Active Comparator|25 Micrograms Vaginal Misoprostol (Control)|Subjects in this arm will be randomized to the 25 micrograms of vaginal misoprostol (control) group, they will be admitted to labor and delivery and undergo placement of 25 micrograms of intravaginal misoprostol every 4 hours for cervical ripening.
89173574|NCT05257681|Experimental|Fissure completion and adhesiolysis arm|Patients will undergo a VATS or robotic interlobar lung fissure completion with pleural adhesiolysis. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
89173575|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg single dose usage
89173576|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg single dose usage
89173577|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg single dose usage
89173578|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg single dose usage
89173579|NCT05256719|Experimental|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg single dose usage
89173580|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
89173581|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg, i.v. single dose usage.
89173582|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
89173583|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
89173584|NCT05256719|Placebo Comparator|Placebo Group:Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
89173585|NCT05242445|Experimental|Cohort 1: Cetrelimab or Placebo (Dose 1)|Participants will receive cetrelimab Dose 1 or placebo via subcutaneous (SC) injection on Day 1.
89173586|NCT05242445|Experimental|Cohort 2 (Optional): Cetrelimab or Placebo (Dose 2)|Participants will receive cetrelimab Dose 2 or placebo administered via an Intravenous (IV) infusion on Day 1 based on the data review of previous cohort(s) (safety and tolerability data through at least 6 weeks postdose as well as pharmacokinetic (PK) and receptor occupancy (RO) data through at least day 4 postdose).
89173587|NCT05242445|Experimental|Cohort 3 (Optional): Cetrelimab or Placebo|Participant will receive cetrelimab or placebo via SC injection based on the data review of previous cohort(s) (safety and tolerability data through at least 6 weeks postdose as well as PK and RO data through at least day 4 postdose).
89173588|NCT05242445|Experimental|Cohort 4 (Optional): Cetrelimab or Placebo|Participant will receive cetrelimab or placebo via SC injection based on the data review of previous cohorts (safety and tolerability data through at least 6 weeks postdose as well as PK and RO data through at least day 4 postdose).
89173589|NCT05229835|Experimental|Time restricted eating|Tasks for participants are to fast for 14 h during the day and eat 10h during 12 weeks period
89173590|NCT05229835|Experimental|Time restricted eating combined with exercise|Tasks for participants are to fast for 14 h during the day and eat 10h during 12 weeks period combined with aerobic exercise 3 times a week.
89173591|NCT05229835|Experimental|Exercise|Tasks for participants are to perform aerobic exercise 3 times a week.
89173592|NCT05229835|No Intervention|Control|Tasks for participants are keeping their daily habits
89173593|NCT05213351|Experimental|Graded Motor İmagery|Graded Motor İmagery (GMI) group will receive a treatment protocol consisting of Graded Motor Imagery, cold therapy, traditional exercises and home exercises.
89173594|NCT05213351|Active Comparator|Exercise|Exercise group will receive training involves mobilizations, stretching, specific exercises for the frozen shoulder.
89173595|NCT05206396||TIL in breast cancer patients who completed neoadjuvant therapy|"Tumour infiltrating lymphocytes will be examined on pre-existing histopathologic samples.~Data will be extracted from the files of the patients including:~Demographic data, clinicopathologic data, pathologic complete response, and date of last follow up."
89173596|NCT05189249||Case|Patients who have undergone repeat revascularization within 5 years of undergoing index PCI at Aga Khan University Hospital Karachi.
89173597|NCT05189249||Control|Patients who have not undergone repeat revascularization within 5 years of undergoing index PCI at Aga Khan University Hospital Karachi.
89173598|NCT05179044|Experimental|Guardian knee brace group|Patients undergoing elective Total knee arthroplasty (TKA) by surgeons from NYU Langone with the presence of a pre-operative knee flexion contracture greater than 5 degrees and willingness to participate in our institution's outpatient rehabilitation and physical therapy. Those randomized to this group will be fitted with a Guardian Rehabilitator Brace.
89173599|NCT05179044|No Intervention|No Guardian brace used group|Patients undergoing elective Total knee arthroplasty (TKA) by surgeons from NYU Langone with the presence of a pre-operative knee flexion contracture greater than 5 degrees and willingness to participate in our institution's outpatient rehabilitation and physical therapy as part of standard of care.
89173600|NCT05163626|Experimental|Combined aerobic exercise and cognitive training program|
89173601|NCT05163626|No Intervention|Standard health counseling at baseline|
89173602|NCT05163210|Experimental|AO+VR|Participants of the experimental group will undergo a treatment based on observation of actions followed by their immediate reproduction in VR (AO+VR treatment).
89173603|NCT05163210|Placebo Comparator|CO+VR|Participants randomly assigned to the control group will receive an equal number of rehabilitation sessions, as the experimental group. Differently from the latter, patients of the control group will be required to observe videos depicting naturalistic scenes, without motor contents, for 1.5 min. Then, they will receive a motor training in the VR environment, performing the same type of exercises included in the above-described experimental treatment, prompted by the verbal instructions of an expert therapist.
89173604|NCT05152901|Active Comparator|EpiPen ®.|Dosage Form- Intra muscularly (IM), Dosage- 0.3mg, Dosage Frequency and Duration- Single dose of 0.3mg epinephrine via IM on day, Visit 2.
89173605|NCT05152901|Experimental|Epinephrine (0.3mg)|Dosage Form- Inhaled, Dosage- 0.3mg, Dosage Frequency and Duration- Single dose of 0.3mg epinephrine via inhalation on day 2 of Visit 2.
89173606|NCT05152901|Experimental|Epinephrine (1.3mg)|Dosage Form- Inhaled, Dosage- 1.3mg, Dosage Frequency and Duration- Single dose of 1.3mg epinephrine via inhalation on Visit 3.
89173607|NCT05152901|Experimental|Epinephrine (4mg)|Dosage Form- Inhaled, Dosage-4mg, Dosage Frequency and Duration- Single dose of 4mg epinephrine via inhalation on Visit 4.
89173608|NCT05147935|Experimental|Specialist Palliative Care|All patients will be assigned to receive the intervention, consisting of two outpatient palliative care visits at Vanderbilt University Medical Center (VUMC).
89173609|NCT05126303|Experimental|RMC-035|"RMC-035 is a concentrate (6.0 mg/mL) for solution for infusion for IV administration.~Dosing will be based on renal function at Day -1: Subjects with eGFR ≥60 mL/min/1.73m2 will receive 1.3 mg/kg (per dose) for the first and second dose, followed by 0.65 mg/kg (per dose) for the third, fourth and fifth dose, while subjects with eGFR >30 and <60 mL/min/1.73m2 will receive 0.65 mg/kg (per dose) for all five doses Dosing occurs at time 0 and then after 6, 12, 24 and 48 hours."
89173610|NCT05126303|Placebo Comparator|Placebo|Identical to RMC-035 arm except that the placebo contains no active ingredient.
89173611|NCT05089747||Adult with solid cancer. No intervention.|
89173612|NCT05078580|Experimental|Healthy participants|Iptacopan 200 mg single dose
89173613|NCT05078580|Experimental|Mild hepatic impairment patients|Iptacopan 200 mg single dose
89173614|NCT05078580|Experimental|Moderate hepatic impairment patients|Iptacopan 200 mg single dose
89173615|NCT05078580|Experimental|Severe hepatic impairment patients|Iptacopan 200 mg single dose
89173616|NCT05074550|Experimental|PPMX-T003|This drug should be administered within 48 hours after the phlebotomy. In addition, as a dose escalation design, 4 doses of 0.25 mg/kg, 0.4 mg/kg, 0.64 mg/kg, and 1 mg/kg are administered to the same subject, when the next phlebotomy required during observation period after the 1st administration.
89173617|NCT05074433|Experimental|casirivimab+imdevimab Initial + Q4W|Initial subcutaneous (SC) dose, then SC dose every 4 weeks (Q4W)
89173618|NCT05074433|Experimental|casirivimab+imdevimab Q4W|SC dose Q4W
89173619|NCT05074433|Experimental|casirivimab+imdevimab Q12W|SC dose every 12 weeks (Q12W)
89173620|NCT05074433|Placebo Comparator|Placebo|SC dose Q4W
89173621|NCT05064319|Experimental|Group A - Gabapentin|
89173622|NCT05064319|Placebo Comparator|Group B - Placebo|
89173623|NCT05047406|Experimental|Probiotic|2 oral mini-bottles daily of Bacillus clausii probiotic liquid containing 2 billion spores/bottle for 2 weeks before living donor liver transplantation surgery In addition, patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
89173624|NCT05047406|No Intervention|Control (No Probiotic)|patients will receive standard of care regarding immunosuppressants and antibiotic prophylaxis
89173625|NCT05045430|Experimental|Assigned Intervention|Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silver II Non-Woven Dressing
89173626|NCT05026957|Active Comparator|Control group|Participating in regular cardiac rehabilitation
89173627|NCT05026957|Experimental|Intervention|Participating in regular cardiac rehabilitation + using the shared-decision making application
89173628|NCT05021367|Experimental|TQB3823 tablets|Subjects receive TQB3823 in the first cycle for a total of 28 days , a single dose on Day 1. Day 2 to Day 7 are the elution period, and the continuous doses are from Day 8 to Day 21. From the second cycle, continuous treatment for 28 days is as a treatment cycle.
89173629|NCT05010564|Experimental|Autologous TRICAR-ALL T-Cells and lymphodepletion chemotherapy|Three dose levels will be evaluated. The TRICAR-ALL T-cells will be administered after lymphodepletion chemotherapy with Cyclophosphamide and fludarabine.
89173630|NCT05006482|Active Comparator|Arm I (usual care)|Patients receive routine survivorship follow-up care at their doctor's office for 5 visits over 12 months. Caregivers will be followed for 3 visits over 6 months.
89173631|NCT05006482|Experimental|Arm II (GEMS intervention)|Patients and caregivers participate in GEMS consultation over 1 hour that includes discussion of results and recommendations from geriatric assessment. Patients also participate in survivorship health education sessions over 75 minutes twice weekly for 4 weeks. Patients also participate in EXCAP program, which includes daily walking and resistance exercises.
89173632|NCT04999488|Placebo Comparator|Older adults with sarcopenia (placebo)|
89173633|NCT04999488|Active Comparator|Older adults with sarcopenia (drug)|
89173634|NCT04987671|Experimental|Treatment with AMX0035|Two sequential study period. In Period 1, subject receive AMX0035 daily for approximately 14 days. In Period 2, subjects receive AMX0035 twice a day, morning and evening, for up to 25 days.
89173635|NCT04985630|Experimental|Mitopure Challenge to assess blood levels of Urolithin A after dietary and Mitopure intake|Mitopure challenge with diet (Pomegranate juice- Before) followed by Mitopure supplementation (After) to compare levels in blood spots of UA-Glucuronide (in ng/mL)
89173636|NCT04952571|Experimental|GBM at first relapse|
89173637|NCT04952571|Experimental|GBM at second relapse|
89173638|NCT04946071|No Intervention|Control|Period in which each group will not receive the arts-based HIV stigma intervention.
89173639|NCT04946071|Experimental|Group 1|"Arts-based HIV stigma intervention for three 8-week periods (24 weeks). The intervention will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
89173640|NCT04946071|Experimental|Group 2|"Arts-based HIV stigma intervention for two 8-week periods (16 weeks). Each intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
89173641|NCT04946071|Experimental|Group 3|"Arts-based HIV stigma intervention for one 8-week period. The intervention period will begin with 5 weeks of two 2 interrelated activities: 1) Transformative educational activities that will engage learners in problem-based discussions; 2) Arts-based activities that will focus on addressing the problem through finding solutions and encouraging action will be accomplished by learning traditional Ugandan songs, dance, told and acted stories, proverbs and sayings that incorporate empowering messages and moral teachings connected with self and community, respect for self, peers and authority, and responsibility for others. These activities will be followed by 3 weeks of a participatory theatre intervention (PTI) developed by students that will summarize the learnings and cultural traditions from the weekly sessions."
89173642|NCT04945733|Experimental|Amivantamab: Gastric Cancer (GC) Cohorts|Participants in Phase 2a GC cohorts will receive intravenous (IV) infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight less than (<) 80 kilograms (kg) will receive IV infusion of amivantamab 1,050 milligrams (mg) and participants with body weight greater than or equal to (>=) 80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle), followed by additional dosing based on body weight if recommended by clinical trial management team (CTMT) (amivantamab 1750 mg for body weight <80 kg and 2100 mg for body weight >=80 kg as IV infusion) every 2 weeks on Days 1 and 15 of 28 day cycle. Phase 2b GC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
89173643|NCT04945733|Experimental|Amivantamab: Esophageal Cancer (EC) Cohorts|Participants in Phase 2a EC cohorts will receive IV infusion of weight-based dose of amivantamab in 28-day cycles. Participants with body weight <80 kg will receive IV infusion of amivantamab 1,050 mg and participants with body weight >=80 kg will receive IV infusion of amivantamab 1,400 mg once weekly in Cycle 1 and then every 2 weeks in subsequent cycles (on Days 1 and 15 of each cycle) followed by additional dosing based on body weight if recommended by CTMT (amivantamab 1750 mg for body weight <80 kg and 2100 mg for body weight >=80 kg as IV infusion) every 2 weeks on Days 1 and 15 of 28 day cycle. Phase 2b EC expansion cohorts will be initiated if activity is observed within Phase 2a cohorts.
89173644|NCT04940390|Experimental|STS101|STS101 (dihydroergotamine nasal powder)
89173645|NCT04940390|Experimental|STS101 Placebo|STS101 Placebo
89173646|NCT04939142|Experimental|SVd (Selinexor+Bortezomib+dexamethasone)|Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.
89173647|NCT04939142|Experimental|Vd(Bortezomib+dexamethasone)|Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.
89173648|NCT04922021|Experimental|LEO 138559|Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
89173649|NCT04922021|Placebo Comparator|Placebo|Participants will receive injections of placebo from Week 0 (baseline) to Week 16 (end of treatment).
89173650|NCT04901507|Experimental|The Voutia System|The Voutia System oral irrigation device
89173651|NCT04876365||All Participants|All participants diagnosed with severe hemophilia A previous received prophylaxis regimen for Standard Half-life/Extended Half-life Factor VIII (SHL/EHL-FVIII) products will be compared to after the participants switched to regular prophylaxis with Adynovate with at least 6 months follow up.
89173652|NCT04848025|Experimental|3D customized airway stents|
89173653|NCT04844463|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive a single ascending oral dose of JNJ-68179280 or placebo capsules under fasted condition (Cohort 1, 2 and 5) and under fasted-fed condition (either Cohort 3 or 4) on Day 1. In 1 of the study cohorts 3 or 4, participants will also receive study intervention on Day 8 under fed condition. One additional optional Cohort 6 may be dosed to assess the safety and pharmacokinetics (PK) of an alternate dose of formulation A under fasted condition.
89173654|NCT04844463|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive multiple ascending oral doses of JNJ-68179280 or placebo capsules once daily in Cohort 1 through 4 or twice daily in Cohort 5 (optional) on Days 1 through 14 under fasted or fed condition.
89173655|NCT04844463|Experimental|Part 3: Multiple Dose Alternative Formulation (Optional)|Participants will receive multiple oral doses of an alternative JNJ-68179280 formulation once daily in Cohort 1 and Cohort 2 (optional) on Days 1 through 14 under fasted or fed condition. Doses in Part 3 will depend on the safety, tolerability, PK and pharmacodynamics data from Part 1 and Part 2.
89173656|NCT04819542|Experimental|drain + compression bandage|
89173657|NCT04819542|Active Comparator|drain without compression bandage|
89173658|NCT04805970||Patients with and without diabetes who were previously diagnosed with COVID-19|
89173659|NCT04804384|Experimental|Experimental|
89173660|NCT04801108|No Intervention|Medical management group|COPD patients with severe emphysema and incomplete lobar fissures will be placed on maximal medical therapy for 3 months. At the end of this 3 month period, patients will fill in an additional set of quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. New pulmonary function testing will be performed and crossover to the intervention group will be offered.
89173661|NCT04801108|Experimental|Intervention group|COPD patients with severe emphysema and incomplete lobar fissures will undergo video-assisted thoracic surgery fissure completion and valves placement. After a 3 month follow-up period, patients will fill additional quality of life questionnaires including the St.George Respiratory Questionnaire, COPD Assessment tool, and the modified medical research council dyspnea scale. Pulmonary function testing and a high-resolution CT scan will be performed at the end of the 3-month postoperative follow-up.
89173662|NCT04801108|Experimental|Crossover group|Subjects allocated to the medical management group will be offered to crossover after the 3 months follow-up period. The same procedure as in the intervention group will be performed. Follow-up after surgery will be the same as in the intervention group.
89173663|NCT04775147|Experimental|Intervention group|Achieving SBP level of <120mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.
89173664|NCT04775147|No Intervention|Control group|Maintaining SBP level of <140mmHg within 1 hour after successful recanalization, and maintaining this level at least 72 hours.
89173665|NCT04770337|Sham Comparator|Sham treatment|Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.
89173666|NCT04770337|Experimental|STARSTIM device treatment|Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.
89173667|NCT04757168|Experimental|NOGA TM probe|
89173668|NCT04742998||Patients treated for an oral or oropharyngeal tumor for at least 6 months|Patients treated for an oral or oropharyngeal tumor for at least 6 months
89173669|NCT04722354|Active Comparator|ABA group|95 ug 2x/day for 14 days
89173670|NCT04722354|Placebo Comparator|Placebo group|Corn Starch 300 mg for 14 days
89173671|NCT04717141|Experimental|Biomecanical evaluation of the selective nerve block effects|"D0 :~Information, collection of consent, inclusion,~Clinical and instrumental evaluation,~Realization of the selective nerve block,~Post-selective nerve block clinical and instrumental re-evaluation,~Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation."
89173672|NCT04709419|Experimental|Celliant Sock|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction. Celliant® fibers are comprised of a proprietary blend of infrared (IR) emitting ceramic materials mixed with polyethylene terephthalate (PET). The proprietary blend consists of the following components: alumina oxide; silicon dioxide; and titanium dioxide. The Celliant fibers are woven or knitted into yarn and used to manufacture the Celliant Sock. The Celliant Sock content will be 82% Celliant polyester, 13% Nylon and 5% Spandex. Celliant fibers absorb energy (heat) generated by the wearer's body by radiation, convection and conduction, and also from the environment, and re emit the energy as infrared radiation back into the wearer's body."
89173673|NCT04709419|Sham Comparator|Control Sock|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
89173674|NCT04688554||Refractory Obsessive Compulsive Disorder|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical capsulotomy
89173675|NCT04688554||Refractory Pain|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
89173676|NCT04688554||Refractory Tremor|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical thalamotomy
89173677|NCT04688554||Refractory Depression|fMRI, DTI, behavioral, psychological, and disease-specific changes following radiosugical cingulotomy
89173678|NCT04659421|Experimental|Low-grade gliomas|Treated with Recombinant human endostatin, Carboplatin, and Vincristine
89173679|NCT04636684|Experimental|patients undergoing surgical valve replacement for degenerative aortic stenosis|
89173680|NCT04614948|Experimental|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants who have not yet received second vaccination will receive second dose of Ad26.COV2.S vaccine on Day 57, if applicable and newly enrolled participants will either receive IM injection of one dose of Ad26.COV2.S vaccine on Day 1 or two doses of Ad26.COV2.S vaccine on Day 1 and Day 57. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
89173681|NCT04614948|Placebo Comparator|Placebo|Participants will receive IM injection of placebo on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants initially receiving placebo will be offered to receive IM injection of a single dose of Ad26.COV2.S vaccine. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
89173682|NCT04614064|Experimental|COPD patients|As per inclusion and exclusion criteria for COPD patients
89173683|NCT04614064|Experimental|Healthy volunteers|As per inclusion and exclusion criteria for healthy volunteers
89173684|NCT04607954|Experimental|Treatment (durvalumab, lurbinectedin)|Patients receive durvalumab IV over 60 minutes on day 1 and lurbinectedin IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89173685|NCT04594096|Experimental|Immediate Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.~Patients enrolled on the immediate arm will start the intervention (telehealth visits) in Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will resume clinical care as usual."
89173686|NCT04594096|Experimental|Delayed Intervention Arm|"Observation periods will be from 4 days post last administration of chemotherapy until the next chemotherapy administration.~All patients will undergo an initial observation period that will span two chemotherapy cycles and will be receiving clinical care as usual determined by the primary oncology team.~Patients enrolled on the delayed arm will receive clinical care as usual during Time Period 2 (following chemotherapy cycles 3 and 4). During Time Period 3 (following chemotherapy cycles 5 and 6), this arm will start the intervention (telehealth visits)."
89173687|NCT04585841|Experimental|Intervention group|Cancer patients receiving cannabidiol
89173688|NCT04585841|No Intervention|Control group|Cancer patients not receiving cannabidiol
89173689|NCT04572022|Experimental|Intervention group rehabilitation teaching video instructions|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions module.
89173690|NCT04572022|No Intervention|Control group|Control group receive proximal humerus fracture standard care only.
89173691|NCT04557020|Experimental|Arm A|IC with anti-PD1 mab+CCRT+anti-PD1 mab
89173692|NCT04557020|Active Comparator|Arm B|IC+CCRT
89173693|NCT04555551|Experimental|Targeted MCARH109 CAR Modified T cells|Patients will undergo leukapheresis of peripheral blood for further T cell enrichment; activation and genetic modification using a lentiviral vector encoding a GPRC5D targeted CAR (MCARH109). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. These modified T cell infusions will be administered 2-7 days following completion of conditioning chemotherapy.
89173694|NCT04543786|Experimental|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation on lower back for 30-60 minutes for 5 consecutive days.
89173695|NCT04521140|Experimental|PKP with Dextenza (study)|"Patients undergoing PKP will receive Dextenza insert with:~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
89173696|NCT04521140|Other|PKP without Dextenza (Controlled)|"Patients undergoing PKP will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
89173697|NCT04521140|Experimental|DSEK with Dextenza (study)|"Patients undergoing DSEK will receive Dextenza insert with:~topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
89173698|NCT04521140|Other|DSEK without Dextenza (Controlled)|"Patients undergoing DSEK will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
89173699|NCT04521140|Experimental|DMEK with Dextenza (study)|"will receive Dextenza insert with: topical prednisolone acetate 1% 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
89173700|NCT04521140|Other|DMEK without Dextenza (Controlled)|"Patients undergoing DMEK will receive:~topical prednisolone acetate 1% every two hours (6X /day) for 2 weeks, 4 times a day for 1 month, 3 times a day for one month, 2 times a day for one month, once a day for one month, then Lotemax once a day thereafter.~PolymyxinB/Trimethoprim or Vigamox / Moxifloxacin 4 times a day for 2 weeks"
89173701|NCT04519658|Experimental|CIN-107 0.5mg|Subjects received CIN-107 0.5 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
89173702|NCT04519658|Experimental|CIN-107 1mg|Subjects received CIN-107 1 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
89173703|NCT04519658|Experimental|CIN-107 2mg|Subjects received CIN-107 2 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
89173704|NCT04519658|Placebo Comparator|Placebo|Subjects received placebo tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
89173705|NCT04511572|No Intervention|Standard Care: burr hole surgery|Patients who have had burr hole evacuation for symptomatic chronic subdural hematomas will be followed in the outpatient clinic after hospital discharge at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
89173706|NCT04511572|Active Comparator|embolisation middle meningeal artery|Besides standard treatment those patient who are allotted to the intervention group will receive embolization of the middle meningeal artery until 72 hours after burr hole evacuation. After hospital discharge follow-up is at 8, 16 and 24 weeks with a follow-up CT-scan of the head in addition to assessment of mRS, MOCA, mNIHSS, Markwalder score, SF-36, EQ-5D-5L, ALDS, iMCQ and iPCQ.
89173707|NCT04507178|No Intervention|prophylactic dose LMWH|Patients assigned to the control group will receive standard care according to current protocol with a prophylactic dose of LMWH (nadroparin once daily 2850 AxaIE subcutaneously) starting within 24 hours after coiling, continued until discharge or when mobilized for at least six hours a day.
89173708|NCT04507178|Active Comparator|therapeutic dose LMWH|In the intervention group, the standard prophylactic dose will be replaced by a higher dose of LMWH (nadroparin; twice daily 5700 IE) starting within 24 hours after coiling and continued for 21 days after initial SAH. After this, patients will continue with standard care (prophylactic dose until discharge or when mobilized for more than six hours per day).
89173709|NCT04497259|Experimental|Interventional|Patients in the teleconsultation arm will benefit from a tele-evaluation (a questionnaire filled through a chatbot link) and teleconsultation (skype-like connection) at 6 and 9 months after surgery.
89173710|NCT04497259|Experimental|Control|Patients in the consultation arm will benefit from a tele-evaluation (a questionnaire filled at home after the file was sent by secured mail) and a classical face to face consultation at 6 and 9 months after surgery.
89173711|NCT04496674|Experimental|Treatment with bispecific Ab CC-1|administration of bispecific PSAMxCD3 Ab CC-1.
89173712|NCT04495699||Observation|Patients who elect to have observation of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
89173713|NCT04495699||Stone treated|Patients who elect to have intervention of their asymptomatic stones as part of usual care will be followed. Note that there is no randomization, the decision to treat or not treat a stone is made in the usual clinical fashion by the patient in consultation with their surgeon.
89173714|NCT04495660|Experimental|Severe/profoundly deaf children 10-24 months old|The cohort 1 includes patients aged 10-24 months old about to be implanted
89173715|NCT04495660|Experimental|Severe/profoundly deaf children 3-7 years old|The cohort 2 includes 3-7 years old cochlear implanted patients (implanted before 24 months of age)
89173716|NCT04495660|Other|Normally hearing children 10-24 months old|The cohort 1 includes patients aged 10-24 months matched in age and sex with normally hearing children
89173717|NCT04495660|Other|Normally hearing children 3-7 years old|The cohort 2 includes 3-7 years old matched in sex and age with cochlear implanted patients
89173718|NCT04474717|Other|The natural history of COPD|Monitoring risk factors, chronic respiratory symptoms and respiratory function in the natural history of chronic obstructive pulmonary disease
89173719|NCT04474717|Experimental|Study of systemic inflammation and molecular mechanisms|Study of systemic inflammation and molecular mechanisms underlying the comorbid course of COPD and atherosclerosis
89173720|NCT04474717|Other|Exhaled breath condensate|A study of the clinical and biochemical COPD phenotype with systemic inflammation and comorbidity
89173721|NCT04456140|Experimental|Prevention (pre-genetic test counseling, genetic testing)|Patients watch a pre-recorded genetic counseling video and those who consent to genetic testing undergo collection of blood samples. Patients also complete surveys over 5-15 minutes each prior to receiving their genetic test results and following the receipt of genetic test results.
89173722|NCT04449861|Experimental|Durvalumab plus 4-6 cycles chemotherapy|Participants will receive treatment with durvalumab + etoposide and either cisplatin or carboplatin (EP) for 4 to 6 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy (EP) and will continue to be administered as monotherapy every 4 weeks (Q4W) post-chemotherapy until progressive disease (PD). Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab.
89173723|NCT04426812||MTurk sample|Data collected from a sample of participants in an online convenience platform called MTurk who self-identify as having chronic pain.
89173724|NCT04426812||KnowledgePanel|Data collected from a sample of panel members in an online representative panel called KnowledgePanel who self-identify as having chronic pain.
89173725|NCT04425967|Active Comparator|25x2Gy|the conventional schedule of 25 x 2 Gy, once daily fractionation in a five-week OTT
89173726|NCT04425967|Experimental|14x3Gy|the study schedule of 14 x 3 Gy, once daily fractionation in a three-week overall treatment time
89173727|NCT04405765|Active Comparator|Lyopreserved Stravix|Treated with NPWT and lyopreserved Stravix
89173728|NCT04405765|Active Comparator|Cryopreserved Stravix|Treated with NPWT and cryopreserved Stravix
89173729|NCT04405050|Active Comparator|Restrata|Treated with Restrata
89173730|NCT04405050|Active Comparator|NPWT|Treated with NPWT (Negative Pressure Wound Therapy)
89173731|NCT04392375|Active Comparator|Nifedipine 30MG|Oral administration of 30mg Nifedipine XL q24 hours until delivery
89173732|NCT04392375|Placebo Comparator|Placebo|Matching placebo group q24hrs until delivery
89173733|NCT04375748||Patients treated for symptoms of acute myocarditis.|Patients treated in intensive coronary care unit (ICCU) or intensive care unit (ICU), in one of the participating hospitals, for symptoms of acute myocarditis confirmed by a myocardial MRI and/or a CT scan and/or a myocardial biopsy.
89173734|NCT04362540||Pregnant women with GDM|Ultrasound liver scan in addition to routine foetal assessment (antenatal) Metabolic profile blood tests, Oral Glucose Tolerance Test, ELF blood test, repeat liver ultrasound scan and MRI scan (post partum)
89173735|NCT04318002|Experimental|Group 1A|Volunteers (aged 18-45 years) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 2
89173736|NCT04318002|Experimental|Group 1B|Volunteers (aged 18-45 years) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
89173737|NCT04318002|Experimental|Group 2A|Volunteers (aged 5-17 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 2.
89173738|NCT04318002|Experimental|Group 2B|Volunteers (aged 5-17 months) of low malaria exposure status will receive 3 doses of 10µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 6.
89173739|NCT04318002|Experimental|Group 2C|Volunteers (aged 5-17 months) of low malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
89173740|NCT04318002|Experimental|Group 2D|Volunteers (aged 5-17 months) of high malaria exposure status will receive 2 doses of 50µg RH5.1 /50µg Matrix-M intramuscularly at months 0, 1 and 1 dose of 10µg RH5.1 /50µg Matrix-M at month 6.
89173741|NCT04314570|Experimental|Ropivacaine Treatment|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Ropivacaine through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
89173742|NCT04314570|Placebo Comparator|Saline Control|After the patient has been consented for a post-operative nerve block, physicians will provide a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
89173743|NCT04278573|Experimental|Vitamin D3 Treatment Group|Subjects will receive a Vitamin D3 injection into their wart
89173744|NCT04278573|Placebo Comparator|Placebo Group|Subjects will receive a placebo injection into their wart
89173745|NCT04267003|Experimental|DLPFC Stimulation + Task|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during cognitive task completion.
89173746|NCT04267003|Experimental|DLPFC Stimulation + Rest|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex during rest.
89173747|NCT04267003|Sham Comparator|Sham Stimulation + Task|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during cognitive task completion.
89173748|NCT04267003|Sham Comparator|Sham Stimulation + Rest|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation, during rest.
89173749|NCT04233580|Active Comparator|Weekly AmnioEXCEL+ group|AmnioEXCEL+ will be applied weekly at study visits
89173750|NCT04233580|Active Comparator|PRN AmnioEXCEL+ group|AmnioEXCEL+ will be applied maximum every 2 weeks (PRN, in the case that the wound requires debridement at a visit not intended for AE+ application, the wound will be treated as SOC)
89173751|NCT04201197|Active Comparator|Inje Cocktail|Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)
89173752|NCT04201197|Experimental|Inje Cocktail + THC extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 20mg THC
89173753|NCT04201197|Experimental|Inje Cocktail + THC/CBD extract|Single oral administration of Inje Cocktail + brownie infused with cannabis extract containing 20mg THC and 640mg CBD
89173754|NCT04193670|Experimental|Atopic dermatitis classical form|15 patients
89173755|NCT04193670|Experimental|Atopic dermatitis with atopic prurigo type|10 patients
89173756|NCT04174443|Experimental|Pulsed radiofrequency + Continuous radiofrequency|
89173757|NCT04174443|Active Comparator|Pulsed radiofrequency|
89173758|NCT04156191|Experimental|ARQ-151 cream 0.15% or 0.05%|Open-label study of 0.15% or 0.05% active concentration
89173759|NCT04128306|Experimental|Patient group|"A total of 120 patients with brain tumors will be divided into our two groups, divided as follows:~In the group Pre-Per, 20 patients will be included by localization of electrical stimulation (60 patients in total). A patient who would be stimulable in two different areas could be included in two different groups.~In the group Pre-End, the subjects will be distributed by localization of the brain tumor, by lobe. A total of 20 participants will be included per lobe, corresponding to the frontal, temporal or parietal lobes (as a reminder, a tumor in the occipital lobe is an exclusion criterion), for a total of 60 participants"
89173760|NCT04128306|Active Comparator|Control group|A maximum of 120 healthy matched sex and age subjects with patients will also be included
89173761|NCT04107740|Experimental|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
89173762|NCT04107740|Placebo Comparator|Placebo (0mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
89173763|NCT04085315|Experimental|Dose Escalation (Closed to Enrollment)|Patients will continue to receive osimertinib 80 mg PO daily as part of standard of care therapy during screening and study treatments. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose will be 30 mg twice daily (dose level 1). All patients at a given dose level must complete the DLT period before any additional cohorts can be opened.
89173764|NCT04085315|Experimental|Dose Expansion: Cohort A|Stage IV EGFR-mutant NSCLC currently receiving and progressing on osimertinib who have received no more than one additional line of systemic cancer therapy other than osimertinib (e.g., chemotherapy +/- immunotherapy, amivantamab +/- Lazertinib) for metastatic disease. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
89173765|NCT04085315|Experimental|Dose Expansion: Cohort B|Stage IV EGFR-mutant NSCLC patients who are currently receiving first line osimertinib treatment and have received at least 3 months, but no more than 6 months, of osimertinib with a best response of PR or SD. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
89173766|NCT04067960|Experimental|Screening (pharmacogenomics testing)|Patients undergo one-time collection of saliva sample for pharmacogenomics testing. Patients also complete quality of life assessment at baseline and at 3 months after pharmacogenomics testing.
89173767|NCT04038190|Experimental|Behavioral Activation Course|Behavioral activation course condition administered in a college freshman orientation seminar
89173768|NCT04038190|No Intervention|Standard Orientation Course|Standard freshman orientation seminar course condition
89173769|NCT04028050|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants will receive intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min), followed by intravenous infusion of etoposide 100 milligrams per square meter (mg/m^2) on days 1 through 3 of each cycle during the induction phase (21-day cycle for four/six cycles). On Days 2 and 3, participants will receive etoposide alone. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks until PD, unacceptable toxicity, loss of clinical benefit or study termination by the Sponsor.
89173770|NCT04016805|Experimental|ublituximab + umbralisib + ibrutinib|Participants were administered with ublituximab, 900 milligrams (mg), intravenous (IV) infusion once every cycle through cycle 6, then every three cycles upto 24 cycles; umbralisib, 800 mg, oral tablet, daily through Cycles 1-24; ibrutinib oral tablet daily (1 Cycle = 28 days).
89173771|NCT04016805|Experimental|ublituximab + umbralisib + venetoclax|Participants were administered with ublituximab, 900 milligrams (mg), intravenous (IV) infusion once every cycle through cycle 6, then every three cycles upto 24 cycles; umbralisib, 800 mg, oral tablet, daily through Cycles 1-24; venetoclax oral tablet daily (1 Cycle = 28 days).
89173772|NCT04016805|Experimental|ublituximab + umbralisib + acalabrutinib|Participants were administered with ublituximab, 900 milligrams (mg), intravenous (IV) infusion once every cycle through cycle 6, then every three cycles upto 24 cycles; umbralisib, 800 mg, oral tablet, daily through Cycles 1-24; acalabrutinib oral capsule every 12 hours (1 Cycle = 28 days).
89173773|NCT04002986|Experimental|Women at intermediate/high risk of breast cancer|Women age 35 years old identified at intermediate/high risk of breast cancer will receive genetic testing
89173774|NCT03982199|Experimental|Group 1: RSV Vaccine|Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. Participants will then be divided into revaccination subcohorts: 1A, 1B, and 1C to receive revaccination with Ad26.RSV.preF based vaccine at 1 year, 2 years, and 3 years respectively after the first vaccination.
89173775|NCT03982199|Placebo Comparator|Group 2: Placebo|Participants will receive a single IM injection of placebo control on Day 1. Participants will then be divided into revaccination subcohorts 2A, 2B, and 2C, and will first receive Ad26.RSV.preF based vaccine at years 1, 2, and 3. In subcohorts 2A and 2B, participants will receive a revaccination one year later with either Ad26.RSV.preF based vaccine, study vaccine A or study vaccine B.
89173776|NCT03979508|Experimental|Cohort A Group 1; Cohort B Group 3 (surgery)|Patients undergo standard of care surgical resection.
89173777|NCT03979508|Experimental|Cohort A Group 2; Cohort B Group 4 (abemaciclib, surgery)|Patients receive abemaciclib PO BID on days 1-14 or days 1-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical resection no later than 12 weeks after the last dose of neoadjuvant chemotherapy.
89235625|NCT00422097|Experimental|Ixabepilone, 10 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
89235626|NCT00422097|Experimental|Ixabepilone, 15 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
89235627|NCT00422097|Experimental|Ixabepilone, 20 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
89235628|NCT00422097|Experimental|Ixabepilone, 25 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
89235629|NCT00422097|Experimental|Ixabepilone, 30 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
89235630|NCT00422097|Experimental|Ixabepilone, 25 mg, with famotidine|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive famotidine, 40 mg on Day 1.
89235631|NCT00422097|Experimental|Ixabepilone, 25 mg, with food|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive a low-fat meal on Day 1.
89235632|NCT02534194||Newborn Infant|Newborn babies (within 7 days of birth) born between 23-42 weeks.
89235633|NCT01051102|Experimental|IDegAsp|
89235634|NCT01051102|Active Comparator|BIAsp 30|
89235635|NCT01053364|Experimental|Implant|
89235636|NCT01029327||Healthy subjects|
89235637|NCT00348556|Experimental|Nesiritide|Subjects received an intrarenal infusion of nesiritide at 0.005 microgram/kg/min for 6 hours, 0.01 microgram/kg/min for 6 hours, 0.02 microgram/kg/min for 6 hours, and 0.03 microgram/kg/min for 6 hours.
89235638|NCT00434967|No Intervention|4|Placebo
89235639|NCT00434967|Active Comparator|2|Candesartan cilexetil
89235640|NCT00434967|Active Comparator|3|Hydrochlorothiazide (HCT)
89235641|NCT00434967|Experimental|1|Candesartan cilexetil + Hydrochlorothiazide Combination
89173778|NCT03971955||Adult Onset Autoimmune Diabetes/Latent Autoimmune Diabetes|
89173779|NCT03971955||Type 2 Diabetes|
89173780|NCT03971955||Type 1 Diabetes|
89173781|NCT03971955||Healthy Normal Volunteers (HNV)|
89173782|NCT03969199|Experimental|MANNA Food Delivery Service|MANNA will deliver meals to patients randomized to the intervention arm of the study every week on the same day for 90 days. Each delivery will include: 7 breakfast meals, 7 lunch meals, 7 dinner entrees, health desserts, and fresh fruit. Meals will be delivered frozen and can be stored in a freezer until ready to eat. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
89173783|NCT03969199|No Intervention|Standard of Care Counseling|Patients randomized to the control arm will receive standard or care dietary counseling from either their physician or a dietician. Patients will be followed for 180 days and will be assessed for their salt affinity and urine sodium at 3 separate time points throughout the study: baseline, 90 days, and 180 days.
89173784|NCT03959358|Experimental|Lenalidomide|"Participants will only receive lenalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.~Participants will first be given a low dose of lenalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with lenalidomide at."
89173785|NCT03959358|Experimental|Pomalidomide|"Participants will only receive pomalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.~Participants will first be given a low dose of pomalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with pomalidomide at."
89173786|NCT03958240|Other|Patient with local and/or metastatic solid malignant tumor|Patient receiving an anticancer treatment in the context of their standard care.
89173787|NCT03902431|No Intervention|Control|CVD risk prior to the patient and clinician training
89173788|NCT03902431|Experimental|Training|CVD risk after the patient and clinician training
89173789|NCT03855787|Active Comparator|Ureteral stent group|A ureteral stent will be placed after ureteroscopy.
89173790|NCT03855787|Active Comparator|No ureteral stent group|A ureteral stent will not be placed after ureteroscopy.
89173791|NCT03828448|Experimental|Ublituximab + Umbralisib|Participants were administered ublituximab, 900 milligrams (mg), intravenous (IV) infusion through Cycles 1-6, Cycles 9 and 12. Participants also received umbralisib, 800 mg, oral tablet, daily through Cycles 1-24. 1 Cycle = 28 days.
89173792|NCT03821922||pregnancy-induced pregnancy|Those women (subjects) with pregnancy-induced pregnancy.
89173793|NCT03821922||Control|Those healthy pregnant women
89173794|NCT03793127|Other|Young group|20-40 years of age
89173795|NCT03793127|Other|Old group|60-80 years of age
89173796|NCT03787511|Other|Diabetic patients with chronic cough|Diabetic patients with chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
89173797|NCT03787511|Other|Diabetic patients without chronic cough|Diabetic patients without chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
89173798|NCT03783572|Experimental|Stroke patients|40 stroke patients : Injection of the TBA and the investigator will compare the measure of spastic cocontraction index (ICCS) during different movement before versus 4 weeks after injection of TBA : Clinical evaluation and Instrumental evaluation TBA injections are performed as part of routine care
89173799|NCT03783572|Active Comparator|Control Group|The control group : Clinical evaluation consists in the search for criteria of non-inclusion and manual laterality score The will ha an Instrumental review just like the patient : concomitant evaluation of the 3D kinematics of the dominant upper limb, EMG of the triceps brachii muscles, biceps brachii, brachio-radial, brachial; associated with EEG recording, during active extension and elbow flexion movements, of the dominant upper extremity, at spontaneous and maximal speed Clinical evaluation
89173800|NCT03762954||Research Subjects|All adults aged 60 years or older scheduled to undergo outpatient ERCP and/or EUS at Vanderbilt University Medical Center (VUMC) will be invited to participate in the study. Invited patients who consent to participate as study subjects will undergo neurocognitive and functional assessment pre-procedure and at 90 days post-procedure.
89173801|NCT03744559|Experimental|R-E (Retrieval Extinction) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a lab-based smoking-related cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the R-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
89173802|NCT03744559|Experimental|R-E (Retrieval Extinction) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a smoking-related cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
89173803|NCT03744559|Other|NR-E (No R-E) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a lab-based non-smoking or neutral cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the NR-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
89235642|NCT00833651||tacrolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
89235643|NCT00833651||sirolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
89235644|NCT00833651||Healthy controls|Age, gender- and race-matched individuals, not on immunosuppressive medications
89235645|NCT00825773|Active Comparator|Excel|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
89235646|NCT00825773|Sham Comparator|Cypher|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
89235647|NCT00833729|Experimental|etanercept|Single armed study
89235648|NCT00837239|Experimental|Gemcitabine + HuaChanSu|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off + HuaChanSu 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
89235649|NCT00837239|Experimental|Gemcitabine + Placebo|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle) + Placebo 500 ml saline only administered as a 2 hour infusion by central line.
89235650|NCT00833807|Experimental|Nab-paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
89235651|NCT00833885|Other|1|Control
89235652|NCT00833885|Other|2|Masks
89235653|NCT00833885|Other|3|Masks and Hygiene
89235654|NCT00833963||Participants Treated With Trastuzumab|Participants who are being treated with trastuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
89235655|NCT00833963||Participants Treated With Trastuzumab and Pertuzumab|Participants who are being treated with the combination of trastuzumab and pertuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
89235656|NCT00833963||Participants Treated With Ado-Trastuzumab Emtansine|Participants who are being treated with ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
89235657|NCT00837317|Experimental|1|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
89235658|NCT00828425||1|Diabetic patients with retinopathy
89235659|NCT00837395||premenstual asthma|women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period
89235660|NCT04043897|Experimental|Drug|Patients will receive open-label rifaximin 550mg tid x 4 weeks.
89235661|NCT00356590|Other|1|
89235662|NCT04043663|Experimental|Virtual reality program group|Virtual reality program based on a virtual reality guided tour registered in the investigator's pediatric OR setting before surgery.
89235663|NCT04043663|Active Comparator|control group|standard perioperative care without virtual reality program
89235664|NCT00837551|Placebo Comparator|1 Placebo cream|0% cream 12 patients
89235665|NCT00837551|Active Comparator|2. Cream|0.5% WBI-1001 cream 12 patients
89235666|NCT00837551|Active Comparator|3. Cream|1.0% WBI-1001 cream 12 patients
89235667|NCT00834353||Pulmonary tuberculosis patients|Freshly diagnosed pulmonary tuberculosis patients who are started with antituberculosis drugs
89235668|NCT03987334|Experimental|Experimental Group (VRT)|Subjects in the experimental group (VRT) will undergo 30 minutes of motor control exercises using a virtual reality-based sensorimotor rehabilitation provided using the Virtual Reality Rehabilitation System (VRRS) of Khymeia Group. The equipment includes a computer workstation connected to a 6 degrees of freedom (DOF) motion-tracking system (Polhemus G4, Vermont, US), a high-resolution LCD displaying the virtual scenarios on a large screen and a software processing the motion data coming: from the receiver of the sensors end-effectors placed on the sternum and on the head through a helmet. The system has been found to reliably record head position and cervical range of motion among asymptomatic people as well as persistent neck pain patients. The VRRS allows the participant to perform the requested motor tasks, while the movement of the system's end-effector is simultaneously represented in a virtual scenario.
89235669|NCT03987334|Active Comparator|Control Group (CT)|Control group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
89235670|NCT02548871|Experimental|Teen Outreach Program|Teen Outreach Program
89235671|NCT02548871|No Intervention|Comparison|Business as usual
89235672|NCT03987256|Experimental|ECRB needling with adjuvant PRP infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy~Second step: one single tendon needling with PRP"
89235673|NCT03987256|Active Comparator|ECRB needling with adjuvant NaCl 0.9% infiltration|"First step: rehabilitation protocol during 3 months including focal shockwave therapy~Second step: one single tendon needling with Saline solution"
89235674|NCT00828503|Active Comparator|1 Certican + Valganciclovir|Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression
89235675|NCT00828503|Active Comparator|2 Valganciclovir alone|Valganciclovir will be added alone.
89235676|NCT03990220||Treatment|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of yoghurt containing Lactobacillus rhamnosus, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
89235677|NCT03990220||Control|500 children, 3-6 years old attending pre-primary school in Southwest Uganda, who recently decided to start the consumption of milk, 100 ml per day, on any school day (i.e. monday - friday with the exception of school holidays).
89235678|NCT03990376|Other|Blood volume assessment with Blood Volume Analyzer|Injections of 1 mL of I-131-labeled serum albumin based on each patient's height and weight - 1 pre-surgical and 1 post-surgical
89173804|NCT03744559|Other|NR-E (No R-E) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a non-smoking or neutral cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
89173805|NCT03742440|Other|GrafixPL PRIME|Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
89173806|NCT03737929|Experimental|Hybrid ablation procedure|In the hybrid ablation procedure, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure.
89173807|NCT03737929|Active Comparator|Percutaneous endocardial catheter ablation procedure|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint).
89173808|NCT03714308||Patients with nAMD_Treatment-naive (anti-VEGF naive)|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
89173809|NCT03714308||Patients with nAMD_Pre-treated with IVT-AFL|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
89173810|NCT03714308||Patients with nAMD_Pre-treated with any anti-VEGF|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
89173811|NCT03713125|Active Comparator|Reading Tutoring Intervention|20 hours of one-on-one reading tutoring administered over 6 weeks
89173812|NCT03713125|No Intervention|Business as Usual|Instruction as usual within schools
89173813|NCT03702270|Experimental|Penicillin Allergic Floor Patients- Experimental|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
89173814|NCT03702270|No Intervention|Penicillin Allergic Floor Patients- Control|Patients will receive current standard of care for penicillin allergy, which typically involves physician judgement on challenges versus consultation of allergy service.
89173815|NCT03580369|Experimental|Ligelizumab 120 mg|Ligelizumab 120 mg arm: 1 injection of 1.0 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
89173816|NCT03580369|Experimental|Ligelizumab 72 mg|Ligelizumab 72 mg arm: 1 injection of 0.6 mL ligelizumab + 1 injection of 1.0 mL ligelizumab placebo q4w
89173817|NCT03580369|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg arm: 2 injections of 1.2 mL omalizumab q4w
89173818|NCT03580369|Placebo Comparator|Placebo|Placebo-ligelizumab arm: 2 injections of 1.0mL of ligelizumab placebo from Week 0 through Week 20; 1 injection of 1.0mL of ligelizumab 120 mg + 1 injection of 1.0 mL ligelizumab placebo from Week 24 through Week 48
89173819|NCT03554083|Experimental|Arm A - CLOSED (vemurafenib, cobimetinib, atezolizumab)|"Patients receive vemurafenib PO BID on days 1-28 and cobimetinib PO QD on days 1-21. Patients also receive atezolizumab intravenously (IV) over 30-60 minutes on days 1 and 15 of cycles 2 and 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
89173820|NCT03554083|Experimental|Arm B - CLOSED (cobimetinib, atezolizumab)|Patients receive cobimetinib as in Arm A and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89173821|NCT03554083|Experimental|Arm C (atezolizumab, tiragolumab)|Patients with BRAF wild-type or BRAF mutant melanoma receive atezolizumab IV over 30-60 minutes and tiragolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89173822|NCT03503773|Experimental|Treatment Arm:|Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
89173823|NCT03503773|Sham Comparator|Sham Control Arm|Only renal angiography performed
89173824|NCT03479476|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
89173825|NCT03479476|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
89173826|NCT03407066||In-person|200 in-person healthy volunteers
89173827|NCT03407066||On-line|10,000 on-line healthy volunteers
89173828|NCT03396224||Patients who received the Avenir® Cemented Hip Stem|Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
89235679|NCT00834509||Obstructive Sleep Apnea (OSA)|OSA participants will be treated with a CPAP/APAP treatment, per standard clinical care.
89235680|NCT00834509||Control|Control participants will not receive APAP/CPAP treatment, if not diagnosed with OSA.
89235681|NCT01051180||Doppler|Those patients where the doppler was randomised to be on
89235682|NCT01051180||Non doppler patients|those with no doppler guidance
89235683|NCT04322825|Experimental|intervention|24 weeks of TENS
89235684|NCT03990142|Experimental|Group 1: patients without intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients without intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
89235685|NCT03990142|Experimental|Group 2: patients with intradialytic hypotension|The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients with intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.
89235686|NCT00834665|Experimental|hTERT/GM-CSF+PCV, T cell infusion|ARM A = hTERT/GM-CSF+PCV, T cell infusion
89235687|NCT00834665|Experimental|GM-CSF+PCV, T cell infusion,GM-CSF+PVC|ARM B GM-CSF+PCV, T cell infusion,GM-CSF+PVC
89235688|NCT01055860||Robotic sacral colpopexy|Our study population will be women who underwent Robotic assisted laparoscopic sacral colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapse using a synthetic polypropylene mesh.
89235689|NCT02548247|Experimental|Orafti® Inulin|Daily consumption of 12g Orafti® Inulin (3x 4g/d) over a period of 4 weeks
89235690|NCT02548247|Placebo Comparator|Placebo|Daily consumption of 12g/ Maltodextrin (3x 4g/d) over a period of 4 weeks
89235691|NCT01055938|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
89235692|NCT01055938|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
89235693|NCT00837785|Experimental|1|240 mg (two 120 mg capsules) twice a day
89235694|NCT00837785|Experimental|2|240 mg (two 120 mg capsules) three times a day
89235695|NCT00356278|Experimental|A|Participants will receive VRE therapy and D-cycloserine
89235696|NCT00356278|Active Comparator|B|Participants will receive VRE therapy and alprazolam
89235697|NCT00356278|Placebo Comparator|C|Participants will receive VRE therapy and placebo
89235698|NCT00837863|Experimental|1|ALTU-238
89173829|NCT03358706|Experimental|Crohn's Disease or Ulcerative Colitis Participants: Ustekinumab + Probe Cocktail|Participants will receive a single Intravenous (IV) infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8 and a ustekinumab 90 milligram (mg) maintenance dose via subcutaneous (SC) route on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator. The probe cocktail (2 milligram [mg] of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) will be administered orally on Days 1, 22, and 113.
89235699|NCT00837863|Experimental|2|ALTU-238
89235700|NCT00837863|Experimental|3|ALTU-238
89235701|NCT00837863|Active Comparator|4|Nutropin AQ
89235702|NCT00834821|Experimental|1|Participants will undergo the Child Life and Attention Skills (CLAS) Program.
89235703|NCT00834821|Active Comparator|2|Participants will undergo parent focused training (PFT).
89235704|NCT00834821|No Intervention|3|Participants will receive a list of referrals for clinical services as needed, including professional organizations, support groups, and the community mental health system.
89235705|NCT03991780|Experimental|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib (tablet taken orally) twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
89235706|NCT02547389|Active Comparator|Intervention Group (IG)|IG additionally received community health programs with health workers(intensive education, consultation services, maintenance of anepilepsy tracking card, and repeated reminders).
89235707|NCT02547389|Other|Control Group (CG)|Patients in the CG were supplied with only printed epilepsy educational module
89235708|NCT01051336|Experimental|TARIS Placebo|
89235709|NCT01051336|Sham Comparator|Sham Procedure|
89235710|NCT00837941|Experimental|1|sequence 1 - Pregabalin, Duloxetine hydrochloride, Diphenhydramine hydrochloride
89235711|NCT00837941|Experimental|2|sequence 2 - Duloxetine hydrochloride, Pregabalin, Diphenhydramine hydrochloride
89235712|NCT00837941|Experimental|3|sequence 3 - Diphenhydramine hydrochloride, Duloxetine hydrochloride, Pregabalin
89235713|NCT00837941|Experimental|4|sequence 4 - Pregabalin, Diphenhydramine hydrochloride, Duloxetine hydrochloride
89235714|NCT00837941|Experimental|5|sequence 5 - Duloxetine hydrochloride, Diphenhydramine hydrochloride, Pregabalin
89235715|NCT00837941|Experimental|6|sequence 6 - Diphenhydramine hydrochloride, Pregabalin, Duloxetine hydrochloride
89235716|NCT01053442|Experimental|NaFeEDTA|The maize porridge is fortified with 2.5mg iron as NaFeEDTA
89235717|NCT01053442|Active Comparator|FeSO4|The maize porridge is fortified with 2.5 mg iron as ferrous sulphate plus ascorbic acid.
89235718|NCT00828659|Placebo Comparator|Placebo|
89235719|NCT00828659|Active Comparator|Active Comparator #1|
89235720|NCT00828659|Active Comparator|Active Comparator #2|
89235721|NCT00828659|Active Comparator|Active Comparator #3|
89235722|NCT00828659|Experimental|Lorcaserin Dose #1|
89235723|NCT00828659|Experimental|Lorcaserin Dose #2|
89235724|NCT00828659|Experimental|Lorcaserin Dose #3|
89235725|NCT02547545||All|The side effects after chemotherapy were observed for all patients. Potential risk factors would be explored for the side effects such as chemotherapy realted vomit.
89235726|NCT00356200|Experimental|Fluphenazine treated|Treated with fluphenazine
89235727|NCT00356200|Placebo Comparator|Placebo|Treated with Placebo
89235728|NCT04044053|Experimental|Relative Bioavailability|Each participant will receive 400 mg IR, 400 mg MR, and 50 mg MR in the fed state, and 400 mg MR in the fasted state
89235729|NCT04044053|Experimental|Fasted State|Comparison of 400 mg MR in fed and fasted states
89235730|NCT00835289|Placebo Comparator|Placebo (corn oil)|Each participant will be taking 3 capsules of a matching placebo (corn oil).
89173830|NCT03358706|Experimental|Healthy Participants: Probe Cocktail|Participants will receive the probe cocktail (2 mg of midazolam, 10 mg of warfarin plus 10 mg of vitamin K, 20 mg of omeprazole, 30 mg dextromethorphan, and 100 mg of caffeine) orally on Day 1.
89173831|NCT03338920|Experimental|Sumatriptan nasal powder|Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).
89173832|NCT03338920|Placebo Comparator|Placebo|Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.
89173833|NCT03331289|Placebo Comparator|Placebo|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
89173834|NCT03331289|Active Comparator|Exenatide|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
89173835|NCT03331289|Active Comparator|Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
89173836|NCT03331289|Active Comparator|Exenatide and Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
89173837|NCT03280303||non-interventional study|This prospective, observational study will be conducted according to each site's routine clinical practice.
89173838|NCT03215810|Experimental|TIL+ Nivolumab|Tumor-infiltrating Lymphocyte Therapy (TIL) + Nivolumab Treatment Plan: Tumor harvest, Tumor-infiltrating Lymphocytes growth, 4 cycles of nivolumab, cytoreductive chemotherapy with cyclophosphamide and fludarabine, TIL infusion, Interleukin-2 treatment.
89173839|NCT03208478|Active Comparator|Adductor Canal Nerve Block group|Adductor Canal perineural catheter placement. Adductor Canal continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed in the adductor canal. A Nimbus pump (Infutronix) will be delivering the medication.
89173840|NCT03208478|Active Comparator|Femoral Nerve Block group|Femoral Nerve perineural catheter placement. Femoral continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed near the femoral nerve. A Nimbus pump (Infutronix) will be delivering the medication.
89173841|NCT03177018|Experimental|Patients with Cardiomyocytes collection|Patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment
89173842|NCT03169257|Experimental|OB|Obese subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years. OB subjects will undergo for 12 months an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes.
89173843|NCT03169257|No Intervention|NW|Normal weight subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years and age, sex and pubertal status matched with the OB group
89173844|NCT03167671|Active Comparator|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy.
89173845|NCT03167671|Experimental|AposTherapy|Treatment with at home AposTherapy with daily use of the shoe.
89173846|NCT03154255|Experimental|Mediterranean Style-Diet Group|"These subjects will receive a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
89173847|NCT03154255|No Intervention|Standard Diet Group|These subjects will receive Standard Diet according to routine care and practice. The standard diet will be distributed with 55-60% of carbohydrates (45-50% complex and no more than 10% refined and processed sugars), 25-30% lipids and 15% proteins, and will be performedin accordance with the calories of an isocaloric balanced diet calculated throughout the Italian LARN Guidelines for age and gender (Società Italiana di Nutrizione Umana, 2014), inspired to Mediterranean pyramid.
89173848|NCT03102554|Experimental|Genetic Testing|Subjects will provide a DNA sample, which will be screened for variants in genes related to DSD/hypospadias. Probands/parents who wish to receive results of genetic testing related to DSD/hypospadias will receive these results directly from the research study. Parents who receive results of genetic testing for probands 17 years old or younger will complete questionnaires at the time of enrollment, right after receiving genetic results, and 3 months after receiving genetic results.
89173849|NCT03092531|Experimental|Positive STEPS|"Step 1) all participants randomized to the experimental condition will receive low-intensity, daily two-way SMS texts of personalized reminders to take medications as prescribed (social-cognitive cues). If a participants demonstrates >90% adherence they will remain on step one. Participants who continue to have difficulty adhering to their HIV medications at one month after baseline or anytime up to the end of month three (weeks five through twelve) will progress to Step 2) Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes."
89173850|NCT03092531|No Intervention|Standard of Care|The standard health services offered at each site (e.g., mental health services, case management) and a brief adherence educational session. This will consist of a review of medications and recommended dosing (i.e., to understand regimen), adherence expectations, toxicity expectations and medication misperceptions.The participant will then view a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication effectiveness.
89173851|NCT03032627|Other|Cardiac surgery|Subjects will be recruited by a coordinator through electronic medical record (EMR) searches to identify those undergoing left ventricle assist device (LVAD) implantation and explantation, heart transplant, valve replacement or repair, endomyocardial biopsy during catheterization, and arterial bypass surgery. Prior to the procedure, potential subjects will be informed about the clinical study and if interested, they will be consented.
89173852|NCT02999269|Experimental|600 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
89173853|NCT02999269|Experimental|700 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
89173854|NCT02999269|Active Comparator|800 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
89173855|NCT02977468|Experimental|Single Arm open label|"Participants receive 'Merck 3475 Pembrolizumab' by vein one to two times before Intraoperative radiation therapy (IORT).~The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial."
89173856|NCT02955355|Experimental|HYQVIA|Subjects will continue to receive HYQVIA/HyQvia infusions every 2, or 3, or 4 weeks (±3 days) following the same dose and dosing regimen of the Phase 3 pivotal study (Study 161403).
89173857|NCT02910895|Other|single arm|single tumor biopsy
89173858|NCT02891538|Experimental|epigallocatechin gallate (EGCG)|Patients randomized to the EGCG arm, will start EGCG within 4-12 weeks of surgery and take EGCG 450 mg PO twice a day.
89173859|NCT02891538|No Intervention|Observation Only|Standard of care surgical resection followed by standard of care colonoscopy at year.
89173860|NCT02728635|Active Comparator|Group A- Women- Healthy 'pears'|This group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.78 or less.
89173861|NCT02728635|Active Comparator|Group B- Women- Healthy 'apples'|The group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.85 or more.
89173862|NCT02728635|Active Comparator|Group C- Men- Healthy 'apples'|The group will consist of men with a BMI between 23 and 35 kg/m2.
89173863|NCT02676206|Experimental|Music intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. Classical music will be played until the subject is fully awake.
89173864|NCT02676206|No Intervention|Non intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. No music will be played. The headphones will be removed when the subject is fully awake.
89173865|NCT02672332|Experimental|SB204 4%|SB204 4% topically once daily
89173866|NCT02672332|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
89173867|NCT02667444|Experimental|SB204 4%|SB204 4% topically once daily
89173868|NCT02667444|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
89173869|NCT02646384|Experimental|Ovarian tissue cryopreservation|Children faced with a fertility threatening diagnosis or treatment plan will be offered ovarian tissue cryopreservation, particularly if pre menarchal and without other options to preserve fertility. Although considered experimental, there are over 120 live births worldwide using this technique
89173870|NCT02634710|Experimental|Hypofractionated Radiation Therapy|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
89173871|NCT02632656||Patients with congestive heart failure|Patients with congestive heart failure (CHF) who are followed in the hospital or clinic setting, with optimization of medical therapy
89173872|NCT02565628|Experimental|PF-06669571|Once daily (QD) for 7 days
89173873|NCT02565628|Placebo Comparator|Placebo|QD for 7 days
89173874|NCT02540993|Experimental|Finerenone (BAY94-8862)|Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy
89173875|NCT02540993|Placebo Comparator|Placebo|Participants received matching placebo once daily in addition to standard of care therapy
89173876|NCT02519621|Active Comparator|NPWT PRO without irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
89173877|NCT02519621|Active Comparator|NPWT PRO with Irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
89173878|NCT02519621|Active Comparator|KCI Ulta NPWT|KCI Ulta NPWT without irrigation.
89173879|NCT02501538|Experimental|Transcutaneous O2 device|Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.
89173880|NCT02486640||Betaferon|
89173881|NCT02463500||DFU with/without osteomyelitis|Patients of the investigators. Male and female, age 18 and older (up to age 89), of any race or ethnicities, who have diabetes (Type I or II) and a foot ulceration.
89173882|NCT02463487|Active Comparator|Cardinal Pro + Irrigation (NPWTi)|Negative Pressure Wound Therapy with Irrigation: Quantum™ +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan® Intervention is receiving the Cardinal Vac with Irrigation
89173883|NCT02463487|Active Comparator|Cardinal Pro (NPWT) Therapy|Negative Pressure Wound Therapy without Irrigation: Quantum™ (NPWT) -Negative Pressure Wound Therapy (without Prontosan®) Intervention is receiving the Cardinal Vac without Irrigation
89173884|NCT02449239|Experimental|Vicinium|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
89173885|NCT02330991|Experimental|Arm1 ,one-week on/one-week off regimen|One-week on/one-week off regimen is administered for 12 cycles of 28 days. Arm 1 receives temozolomide 150 mg/m2 daily during days 1 to 7 and 15 to 21 of each cycle.Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
89173886|NCT02330991|Experimental|Arm 2,continuous dose-intense regimen|Continuous dose-intense regimen is administered for 12 cycles of 28 days .Arm 2 receives temozolomide 50mg/m2 daily during days 1 to 28 of each cycle. Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
89173887|NCT02106858||Group 1|Patients treated by Physician with Stivarga under approved local prescriptions
89173888|NCT01582737||Group 1|Patients treated with Xarelto for the purpose of prevention of ischemic stroke and systemic embolism
89173889|NCT01463891||Eribulin Mesylate|
89173890|NCT01321567||Rabeprazole Sodium|
89173891|NCT01292928|Experimental|Stent|Stent implantation into SFA/PPA
89173892|NCT01290445||Exposed|Infants exposed in utero to varenicline
89173893|NCT01290445||Unexposed|infants exposed in utero to cigarette smoke from maternal smoking
89173894|NCT01290445||Reference|infants not exposed in utero to either varenicline or cigarette smoke from maternal smoking
89173895|NCT01251718||Donepezil Hydrochloride|
89173896|NCT01194817|Other|Cemented fixation|Nexgen High-Flexion Knee Replacement System using Cemented Fixation
89173897|NCT01194817|Other|Cementless fixation|Nexgen High-Flexion Knee Replacement System using Cementless Fixation
89173898|NCT00925431|Experimental|Lifestyle Modification|Behavioral: cognitive-motivational enhancement to lifestyle management plus nutritional education.
89173899|NCT00925431|Active Comparator|Supportive education|General fibromyalgia education plus nutritional education.
89173900|NCT00664456|Active Comparator|AHT group|Randomized patients undergo 3-month neoadjuvant therapy (NHT)within 14 days and receive 9-month adjuvant therapy (AHT) following after Iodine I-125 implantation (TPPB).
89173901|NCT00664456|Active Comparator|Non-AHT group|Rondomized patients undergo 3-month neoadjuvant therapy (NHT) within 14 days and receive Iodine I-125 implantation therapy (TPPB). 40 weeks observation is followed under no further treatment.
89173902|NCT00581828|Experimental|1|Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).
89173903|NCT00380861|Active Comparator|PFC Sigma RP-F|PFC® Sigma™ RP-F knee implant is a posterior stabilized cemented component cemented that is implanted with a standard posterior stabilized surgical technique.
89173904|NCT00380861|Active Comparator|PFC Sigma RP|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System has a special insert that helps the knee move more like it did before the knee replacement.
89173905|NCT00220337|Experimental|Lacosamide (LCM)|Open label active treatment
89173906|NCT02608125|Experimental|PRN1371|Drug: PRN1371
89173907|NCT05421156||Subtotal Laparoscopic Hysterectomy|Women who underwent subtotal laparoscopic hysterectomy
89173908|NCT05421156||Total Laparoscopic Hysterectomy|Women who underwent total laparoscopic hysterectomy
89173909|NCT00745810||1|sequential changes before and after cardiopulmonary bypass including ROS, antioxidant status, leukocyte elastase, complements, inflammatory cytokines
89173910|NCT00823134|Other|AL + polysomnography|Participant wears an Apnea Link sleep apnoea screening device during the polysomnography to detect apnoeas (obstructive, central).
89173911|NCT00745888||1|age > 18 y/o Patients admitted to surgical ICU
89173912|NCT00755872|Experimental|1|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
89173913|NCT00755872|Experimental|2|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
89173914|NCT00755872|Experimental|3|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
89173915|NCT00755872|Experimental|4|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
89173916|NCT00755950|Experimental|1|280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
89173917|NCT00755950|Placebo Comparator|3|Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
89173918|NCT00755950|Experimental|2.|420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
89173919|NCT00756028|Experimental|1|Patients receiving short protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-antagonist (Orgalutran®: Ganirelix)
89173920|NCT00756028|Active Comparator|2|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®: Nafarelin)
89173921|NCT02560948|Placebo Comparator|Placebo|
89173922|NCT02560948|Experimental|gpASIT+TM|
89173923|NCT02560090|Placebo Comparator|Control Group|Survey assessments as well as collection of medical records and billing information.
89173924|NCT02560090|Active Comparator|Telephonic Nurse Intervention|Survey assessments as well as collection of medical records and billing information. A nurse will communicate with participants via telephone to support diabetes self-management practices.
89173925|NCT02560090|Active Comparator|In-person Community Health Worker Intervention|Survey assessments as well as collection of medical records and billing information. A community health worker will work with participants in person to support diabetes self-management practices.
89173926|NCT00831792|Experimental|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day). Following an initial 4-week cycle at a starting dose of 400 mg 5 days- on and 2 days off, TKI258 may be escalated to 500 mg/day 5 days-on/2 days off if no significant Grade3/4 AEs or laboratory abnormalities are observed.
89173927|NCT00705354|Active Comparator|1|Control group undergoing standard ESS will have a saline soaked Nasopore sponge placed during surgery and will receive routine oral antibiotics post-operatively
89173928|NCT00705354|Experimental|2|Treatment group undergoing ESS will have Nasopore sponge soaked with Bacitracin, but will not receive oral antibiotics post-operatively
89173929|NCT00575380|Active Comparator|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days
89173930|NCT00575380|Active Comparator|Vigamox Eye Drops|One drop three times a day for seven days
89173931|NCT00840996|Placebo Comparator|Placebo|Perioperative placebo IV infusion besides the standard anesthesia care, including general anesthesia and postoperative patient controlled analgesia.
89173932|NCT00840996|Active Comparator|Lidocaine|Perioperative intravenous lidocaine infusion besides the standard anesthesia care, including general anesthesia plus and post operative patient controlled analgesia.
89173933|NCT02559934|Experimental|SR-T100 gel|A single dose of 0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract) in 25 cm2 skin area covered by an occlusive dressing at least 20 hours a day and will be given once daily for sixteen consecutive weeks.
89235731|NCT00835289|Experimental|PUFA (Omax3)|Omax3[TM] (Cenestra Health), or dietary supplement: n-3 polyunsaturated fatty acids, is a 1 gram softgel capsule containing 94.5% omega-3 fatty acids. Each participant will be taking 3 capsules of Omax3[TM].
89235732|NCT00838019|Experimental|Cord blood|
89235733|NCT02548091|Active Comparator|Preventive non invasive ventilation|Patients will receive the non invasive ventilation (NIV) systematically during the whole procedure of pulmonary angioplasty, and then systematically in post procedure period, 1 hour every 4 hours, during the whole hospitalization in post anesthesia care unit (PACU).
89235734|NCT02548091|Other|Non invasive ventilation on demand|Patients will not receive the NIV during the procedure of pulmonary angioplasty; in case of respiratory decompensation in post procedure period they will receive NIV during the whole hospitalization in PACU according to the following criteria: paradoxical breathing, respiratory rate above 25/minutes, a ratio of arterial oxygen pressure to fraction of inspired oxygen values (PaO2/FiO2) below 200.
89235735|NCT00828737|Experimental|Arm 1|
89235736|NCT00356122|Experimental|Docetaxel/Oxaliplatin/Bevacizumab|Participants with advanced, recurrent, or metastatic Non Small Cell Lung Cancer (NSCLC), treated with the combination of docetaxel, followed by oxaliplatin, and then bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.
89235737|NCT01056094|Active Comparator|20mg Lutein|Dietary Supplement: 20mg Lutein; daily supplementation 12 week
89235738|NCT01056094|Active Comparator|10mg Lutein|Dietary Supplement: 10mg Lutein; daily supplementation 12 week
89235739|NCT01056094|Placebo Comparator|0mg Lutein|Dietary Supplement: 0mg Lutein; daily supplementation 12 week
89235740|NCT00838175||1|All pts. who have undergone percutaneous intervention who received a suture-mediated closure of the venous access site will be screened for eligibility for this research trial.
89235741|NCT03989908|Experimental|Co-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the same direction in the production of the microfluidic noodle.
89235742|NCT03989908|Experimental|Counter-flow alginate/SPI food gel|Direction of flow in alginate and SPI are in the opposite direction in the production of the microfluidic noodle.
89235743|NCT03989908|Placebo Comparator|Mee Sua|Mee Sua is used as a control to compare the outcome due to its similarity in textural properties
89235744|NCT01053520|Experimental|Sequence I|
89235745|NCT01053520|Experimental|Sequence II|
89235746|NCT01053520|Experimental|Sequence III|
89235747|NCT00835445||1|Asthmatics with polyps
89235748|NCT00835445||2|Non-asthmatics with polyps
89235749|NCT00838253|Experimental|1|
89235750|NCT00838253|Experimental|2|
89235751|NCT00838253|Experimental|3|
89235752|NCT00838253|Placebo Comparator|4|
89235753|NCT00347932|Experimental|ISV-403|0.6% ISV-403 ophthalmic suspension
89235754|NCT00347932|Placebo Comparator|Vehicle|Vehicle of ISV-403 ophthalmic suspension
89235755|NCT00835523||OHSS risk|
89235756|NCT03990688|Experimental|AK3280 (Cohort 1)|Subjects in Cohort 1 are administered with an oral dose of 100 mg AK3280 b.i.d from Day 1 to Day 14.
89235757|NCT03990688|Experimental|AK3280 (Cohort 2)|Subjects in Cohort 2 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 2 will be based on the emerging data from previous cohort.
89235758|NCT03990688|Experimental|AK3280 (Cohort 3)|Subjects in Cohort 3 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 3 will be based on the emerging data from previous cohorts.
89235759|NCT03990688|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose cohort.
89235760|NCT00838409||1|
89235761|NCT02548793|Active Comparator|VSI Kit|Education: CPR Training using the CPR Anytime VSI Kit Individuals will learn chest-compression only CPR (no rescue breaths) using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
89235762|NCT02548793|Experimental|Mobile Application|Education: CPR Training via Mobile App Individuals will learn chest-compression only CPR (no rescue breaths) using a newly developed mobile training application.
89235763|NCT00835757||1|Diabetic peripheral neuropathy
89235764|NCT00835757||2|Healthy controls
89235765|NCT02547701|Experimental|P-3058|
89235766|NCT00828971|Experimental|Arm 1|
89235767|NCT00828971|Active Comparator|Arm 2|
89235768|NCT02548637|Experimental|Acupuncture Therapy|Based on the Traditional Chinese Medicine theory, investigators will use the systemic treatment methods (full body treatment with the joint specifications). Every patient will receive the standard protocols of these points uniformly regardless of their symptoms. The only variable will be the location of placement of the four electrodes (two positive charges and two negative charges) to the needle points at the most painful joints bilaterally. Needles will be in place a total of 45 minutes per session. The Thermal Design Power (TDP) infrared heat lamp will be applied concurrently to the most painful joint(s) for the entire 45 minutes. Acupuncture will be administered twice a week for 6 weeks, then once a week for an additional 4 weeks.
89235769|NCT00835835|Placebo Comparator|Control group|The placebo group did not receive treatment during the matched period yet did undergo all assessments. The MS Placebo group received equal treatment following the study intervention period.
89235770|NCT00835835|Experimental|Combination Treadmill training group|Subjects randomized to Combination therapy received 20 minutes of Lokomat assisted treadmill training followed by up to 20 minutes of BWS treadmill training (without robotic assistance) twice a week.
89235771|NCT00528996|Placebo Comparator|Placebo|Matching Placebo
89235772|NCT00528996|Experimental|BEA 2180 BR low dose|Low dose
89235773|NCT00528996|Experimental|BEA 2180 BR medium dose|Medium dose
89235774|NCT00528996|Experimental|BEA 2180 BR high dose|High dose
89235775|NCT00528996|Experimental|Tiotropium Bromide|Tiotropium Bromide
89235776|NCT00838487|Active Comparator|condroflex and exercise|assent arm
89235777|NCT00838487|Placebo Comparator|sugar pill and exercise|sugar pill arm
89235778|NCT00838643||Allogeneic pts|Adult allogeneic HSCT recipients
89235779|NCT00838877|Experimental|1|
89235780|NCT00836147|Placebo Comparator|1|250 ng dose
89235781|NCT00836147|Active Comparator|2|250 ng dose
89235782|NCT05732922|No Intervention|Control|Participants will be receiving their standard medical care.
89235783|NCT05732922|Active Comparator|Intervention|Participants will be receiving the intervention on top of their standard medical care.
89235784|NCT03878160|Other|Women and Men, <2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS within the past 2 years and have elevated depression symptoms.
89235785|NCT03878160|Other|Women and Men, >2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS greater than 2 years ago and have elevated depression symptoms.
89235786|NCT03878160|Other|Women and Men, Lifetime History of ACS, Individual Interview|Individual interviews for women and men who have experienced an ACS at some point in their life and do not have elevated depression symptoms.
89235787|NCT02534116|Experimental|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will have incisional vacuum-assisted closure (VAC) therapy performed.
89235788|NCT02534116|Active Comparator|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision.
89235789|NCT03987490|Experimental|Parents of Girls|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
89235790|NCT03987490|Experimental|Parents of Boys|Parents of 11-to-12-year-old girls who did not have records of the HPV vaccine in the EHR or Medicaid claims.
89235791|NCT01008072||without buprenorphine preparation|
89235792|NCT01008072||with buprenorphine preparation|
89235793|NCT00623597|Experimental|1|
89235794|NCT05732844|Experimental|Intervention group with Enna pelvic ball|This group will receive instructions on how to carry out PFMT daily at home, and indications for the placement of Enna pelvic ball vaginal spheres daily.
89235795|NCT05732844|Active Comparator|Control group|This group will receive instructions on how to carry out PFMT daily at home.
89235796|NCT01053676|Experimental|Arm 1|
89235797|NCT01053676|Active Comparator|Arm 2|
89235798|NCT05732766|Experimental|Group-I (Age: ≥18)|Group-I (Age: ≥18) In this group, a total of 600 participants aged ≥18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
89173934|NCT00756184|Active Comparator|A|Intervention will consist of intensive teaching on the nature of glaucoma, value of IOP control, need to adhere to medical therapy and counseling on the proper use of travoprost eye drops.
89235799|NCT05732766|Experimental|Group-II (Age: ≥5 to <18)|Group-II (Age: ≥5 to <18): In this group, a total of 600 participants aged ≥5 to <18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
89235800|NCT05732766|Experimental|Group-III (Age: ≥1 to <5)|Group-III (Age: ≥1 to <5): In this group, a total of 600 participants aged ≥1 to <5 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14
89235801|NCT01056172|Active Comparator|A. 24 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 24 weeks in patients with RVR.
89235802|NCT01056172|Experimental|B. 16 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 16 weeks in patients with RVR.
89235803|NCT05732688|Experimental|Pharmacoscopy|Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds
89235804|NCT00838955|Experimental|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
89235805|NCT00347776|Active Comparator|Control|topical tetracycline
89235806|NCT00347776|Active Comparator|Intervention 1|oral azithromycin, single 1g dose to subject
89235807|NCT00347776|Active Comparator|Intervention 2|single oral azithromycin dose to subject and immediate family members
89235808|NCT00839033|Experimental|1|patients treated with standard treatment and a mechanical insufflation-exsufflation
89235809|NCT00839033|Active Comparator|2|Patients with standard treatment and standard respiratory physiotherapy
89235810|NCT00829127|Experimental|1|
89235811|NCT00829127|Placebo Comparator|2|
89235812|NCT02533882|Experimental|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors.
89235813|NCT02533882|Active Comparator|Adapted Yoga|Yoga classes will consist of postures adapted by qualified yoga instructors who have extensive experience in disability.
89235814|NCT02533882|No Intervention|Waitlist Control|This group will receive biweekly newsletters on a variety of topics. At the end of this trial, they will receive a home based intervention.
89235815|NCT00836225|Experimental|A|50 mg ISIS 388626 vs Placebo, s.c. injection
89235816|NCT00836225|Experimental|B|100 mg ISIS 388626 vs Placebo, s.c. injection
89235817|NCT00836225|Experimental|C|200 mg ISIS 388626 vs Placebo, s.c. injection
89235818|NCT00836225|Experimental|D|400 mg ISIS 388626 vs Placebo, s.c. injection
89235819|NCT00836225|Experimental|AA|50 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
89235820|NCT00836225|Experimental|BB|100 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
89235821|NCT00836225|Experimental|AAA|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
89235822|NCT00836225|Experimental|BBB|100 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
89235823|NCT00836225|Experimental|CCC|200 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
89235824|NCT00836225|Experimental|FFF|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
89235825|NCT03987178|Experimental|Head Dunk|Subjects who are assigned to be in this arm are asked to sit in a hot tub for 15 minutes and instructed to submerge his or her head in the hot tub at least once and at least up to the eyebrows during his or her time in the hot tub.
89235826|NCT03987178|Placebo Comparator|No Head Dunk|Subjects assigned to this arm are asked to sit in a hot tub for 15 minutes but to keep his or her chin above water during the entire time.
89235827|NCT00839111|Experimental|A|Sorafenib plus FOLFIRI regimen
89235828|NCT01053832|Other|Ventricular Pace Suppression- ON|
89235829|NCT01053832|Other|Ventricular Pace Suppression- OFF|
89173935|NCT00756184|Placebo Comparator|B|"Intervention with travoprost therapy and TDA monitoring. Patients of this arm will also be prescribed travoprost and will be followed up in a standard clinical fashion. This group will receive a comparable amount of personal physician attention, but will not be given adherence, or glaucoma education and will not be told that their adherence will be monitored. Their attention placebo intervention will discuss the importance and techniques of good eye health (sunglasses, vitamins, cataract development, etc but no details, or discussion of either glaucoma or adherence) will insure that the study results are not a result of a change in physician attention to a patient, per se, rather than adherence training."
89173936|NCT00756340|Experimental|1|"Dose Level 0, Bevacizumab IV every 2 weeks 8 mg/kg, Everolimus 4 mg/m^2~Dose Level 1 (starting dose), Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 4 mg/m^2~Dose Level 2, Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 5 mg/m^2"
89173937|NCT00705510|Active Comparator|A|
89173938|NCT00705510|Placebo Comparator|B|
89173939|NCT05434780|Active Comparator|(Intervention 1 or group A)|Facilitatory kinesiology taping on calf muscles
89173940|NCT05434780|Experimental|(Intervention 2 or group B)|Inhibitory kinesiology taping on calf Muscles combined with Facilitatory kinesiology taping on Tibialis Anterior
89173941|NCT00680914|Experimental|Synflorix Group|Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
89173942|NCT00680914|Active Comparator|Prevenar Group|Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
89173943|NCT00680836|Active Comparator|Treatment Group|These patients have IBS and are receiving the rifaximin.
89173944|NCT00680836|Placebo Comparator|Placebo group|These patients have IBS and are receiving the placebo.
89173945|NCT02560168|Experimental|Coronary artery disease|Patients scheduled for computed tomographic coronary angiography (CTA)
89173946|NCT00754000||Cohort 1|All patients in study
89173947|NCT00754078|Other|1|anal cancer patients treated with tomotherapy and chemotherapy
89173948|NCT00757120||1|This group will include current and former smokers who have emphysema.
89173949|NCT00757120||2|This group will include current and former smokers who do not have emphysema.
89173950|NCT05428306|Experimental|Group A: Ibuprofen/ Acetaminophen in fixed dose|Pharmaceutical Form: Tablet Formula: Ibuprofen 200 mg/ Acetaminophen 500 mg Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
89173951|NCT05428306|Active Comparator|Group B: Ibuprofen|Pharmaceutical Form: tablets Dosage: 400 mg (1 tablet) Administration way: oral
89173952|NCT05428306|Active Comparator|Group C: Acetaminophen|Pharmaceutical Form: Tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
89173953|NCT05424796|Experimental|Group 1: Physiological saline (Control group) (n=30)|In this group, hemostasis was achieved by checking the saline soaked cotton pellet placed over canal orifices and into the pulp chamber at 2-minute intervals.
89173954|NCT05424796|Experimental|Group 2: Hemostasis and cavity disinfection with NaOCl (n=30)|In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices and into the pulp chamber to achieve complete hemostasis.
89173955|NCT05424796|Experimental|Group 3: Hemostasis and cavity disinfection with KTP laser (n=30)|In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy). After initial hemorrhage control, complete hemostasis was achieved by exposure to a KTP laser (532 nm wavelength) in noncontact mode at 1.5 W of power with a pulse mode (Ton 100 ms, Toff 100 ms) for 2 s. The diameter of optical fiber was 300 μm. Laser application was repeated 3 times if required. After bleeding control was achieved, cavity disinfection was performed by laser application with a noncontact circular movement for 5 s using 1 W power and 300 nm tip.
89173956|NCT00757198|Experimental|1|remifentanil o.1 mcg/kg/min
89173957|NCT00757198|Active Comparator|2|remifentanil 0.3 mcg/kg/min
89173958|NCT00757276||1|"All patients > 18 years who are tested for the diagnosis of DI because of a history of polyuria (> 40 ml/kg per 24 hours) in the presence of polydipsia Patients with known DI will be contacted whether they agree to participate in the study and to undergo again a water deprivation test to measure copeptin to confirm the diagnosis.~The investigators hypothesize that basal copeptin levels can reliably differentiate between the 5 groups(central, nephrogenic, psychogenic and partial forms) with a sensitivity and specificity >80%."
89173959|NCT00757354|Experimental|Metal on Metal cementless hip|Metal on Metal cementless hip arthroplasty
89173960|NCT00757510||Congenital heart disease|All subjects will have known or suspected congenital heart disease
89173961|NCT05418322|Other|Verbal Oral Hygiene Intervention|Each participant will be given oral hygiene instruction verbally by a clinician face to face.
89173962|NCT05418322|Other|Video-assisted Oral Hygiene Intervention|Each participant will be required to watch a pre-recorded oral hygiene instruction video via a tablet in a separate room away from the clinician
89173963|NCT00757744|Experimental|A|Methadone maintenance treatment with Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
89173964|NCT00757744|Active Comparator|B|Methadone maintenance treatment with standard drug counseling
89173965|NCT04052074|Experimental|Intervention group. Music in palliative patient|Listening to pre-recorded and selected music preferred by the patient, half an hour for 7 days.
89173966|NCT04052074|Sham Comparator|Palliative patient.|Basic therapeutic education repetition performed to all patients through earphones, half, an hour for 7 days.
89173967|NCT04052074|Experimental|Carer music.|Listening to pre-recorded and selected music preferred by the carer, half an hour for 7 days.
89173968|NCT04052074|Sham Comparator|Carer.|Basic therapeutic education repetition performed to all carer through earphones, half an hour for 7 days.
89173969|NCT04052308|Active Comparator|Control group|"Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team.~They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end fo the study; The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end fo the study; Answer EQ-5D-5L at baseline and at the end fo the study."
89235830|NCT00836303|No Intervention|Control|Patients of physicians randomly assigned to the control group received usual care
89173970|NCT04052308|Experimental|Continuous group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill at 60% of reserve heart rate), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
89173971|NCT04052308|Experimental|Interval group|Two days of lectures about knee OA, but will also come to the hospital after the first class to consult about nutritional habits to be improved; therapy session with the psychologists, sessions with the physical therapy team; sessions with the physical educators team. The supervised exercise sessions will consist of 10 min of warm-up stretching exercises, 40 min of treadmill (40 min on treadmill with alternating intensity between 50% and 80%) of HR, resulting in an average load of 60% ((50% 2) + 80% 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises. They will be submitted to 24-hour ambulatory blood pressure monitoring (ABPM) at baseline and at the end of the study. The arterial stiffness and endothelial reactivity will be assessed by measurement of the carotid-femoral pulse wave velocity by means of a non-invasive automatic device at baseline and at the end of the study.
89173972|NCT00679432|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
89173973|NCT00679432|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
89173974|NCT00679432|Placebo Comparator|3: Placebo|Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
89173975|NCT00679432|Active Comparator|4: Asacol® 400 mg|Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
89173976|NCT02561260||autoimmune encephalitis|
89173977|NCT02561260||unknowm encephalitis|
89173978|NCT02561260||other encephalopathy|
89173979|NCT02560870|Active Comparator|Aloe Vera mouthwash|mouthwash (Aleo Vera)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
89173980|NCT02560870|Active Comparator|Chlorhexidine mouthwash|mouthwash (Chlorhexidine )10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
89173981|NCT00679354|Experimental|Treatment (cilengitide)|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89173982|NCT02559700|Experimental|Brain training programme|Participants will complete a package of online brain training games focusing on reasoning and problem solving. The intervention will be accessed via a computer. There is no minimum or maximum dosage but participants will be recommended to complete the intervention five times a week. The package takes approximately 10 minutes to complete, depending on individual performance.
89173983|NCT02560792|Experimental|Positive Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to positive affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to positive feelings.
89173984|NCT02560792|Experimental|Negative Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to negative affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to negative feelings.
89173985|NCT02560792|Experimental|Control Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise - affect was not mentioned.
89173986|NCT04050826|Experimental|Dermal Pharmacokinetic study|"Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dOFM after topical application of three lidocaine/prilocaine products in 20 participants.~After baseline sampling (1 hour pre-dose) the three lidocaine/prilocaine products will be applied and removed after 3 hours. ISF and blood sampling will be continued for a duration of 12 hours post-dose. Additionally different physical parameters (e.g. TEWL) will be measured."
89173987|NCT00757900|Active Comparator|1|To receive a sub-unit influenza vaccine
89173988|NCT00757900|No Intervention|2|
89173989|NCT00757978|Placebo Comparator|1|Clozapine plus placebo
89173990|NCT00757978|Active Comparator|2|Clozapine plus memantine
89173991|NCT00754702|Experimental|1|Vinorelbine metronomic/Lapatinib
89173992|NCT00822900|Experimental|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone will be combined with a 20% Intralipid mixture for infusion.
89235831|NCT00836303|Experimental|Intervention Group|This group will receive the behavioral intervention.
89173993|NCT00822900|Placebo Comparator|Placebo|"Placebo stock solution was the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid was based on the same mg/kg/hr volume that would be required if PROG had been in the vial. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid was administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table was used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The placebo will be combined with a 20% Intralipid mixture for infusion."
89173994|NCT00682786|Experimental|Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
89173995|NCT00682786|Experimental|Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Irinotecan 50 mg/m2 IV weekly for 5 doses.~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
89173996|NCT00840450|Experimental|Paclitaxel + Imatinib Mesylate (Gleevec)|
89173997|NCT00754858|Experimental|belotecan and Cisplatin|belotecan 0.5 mg/m2 and Cisplatin 60mg/m2
89173998|NCT05402748|Experimental|exosome cases|The patients whose fistula is treated by exosome (40 patients).
89173999|NCT05402748|Placebo Comparator|Controls|The patients whose fistula is treated with conventional treatment plan (40 patients).
89174000|NCT00755014|Experimental|2|Forty subjects are randomized to a group (n=20) that consumed red wine (100 ml) or a group (n=20) that consumed beer (250 ml) daily for 3 weeks
89174001|NCT00705588|Experimental|1|Patients treated with epoprostenol (Flolan) will be given tadalafil (Cialis).
89174002|NCT00705588|Experimental|2|Patients receiving iloprost (Ventavis) will receive vardenafil (Levitra)
89174003|NCT00755092|Active Comparator|1|Doula for Nulliparous women
89174004|NCT00755092|Active Comparator|2|Doula for Multiparous women
89174005|NCT00705744|Experimental|I|
89174006|NCT00755170|Experimental|1|Vinorelbine metronomic + bevacizumab
89174007|NCT00705822|Experimental|1|Docetaxel + Estramustine + Hydrocortisone
89174008|NCT00705822|Active Comparator|2|Docetaxel + Prednisone
89174009|NCT00755248||1|Pts undergoing CABG or OPCAB
89174010|NCT00840294|No Intervention|Observation|Observation only for 2 weeks
89174011|NCT00840294|Active Comparator|Antibiotic|Ciprofloxacin 500 mg twice daily for 2 weeks
89174012|NCT02561026|Experimental|FP Transfusion|patients randomized to receive frozen plasma transfusions
89174013|NCT02561026|No Intervention|no FP Transfusion|patients not receiving frozen plasma transfusions
89174014|NCT04030884|Experimental|Intervention Lap.Chol.|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a laparoscopic cholecystectomy.
89174015|NCT04030884|No Intervention|Control Lap.Chol.|The participants received standard care for their laparoscopic cholecystectomy.
89174016|NCT04030884|Experimental|Intervention Thyroidectomy|Honey and water mixture was ingested up to two hours preoperatively by the participants who were going to have a thyroidectomy.
89174017|NCT04030884|No Intervention|Control Thyroidectomy|The participants received standard care for their thyroidectomy.
89174018|NCT00755404|Active Comparator|A|
89174019|NCT00755404|Experimental|B|
89174020|NCT00703170|Experimental|Dose Level 1 (original)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 30 mg/m2 once every 4 weeks"
89174021|NCT00703170|Experimental|Dose Level 1 (revised)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
89174022|NCT00703170|Experimental|Dose Level 2|"Temsirolimus IV 25 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
89174023|NCT02612142|Experimental|aerobic exercise (AE)|Intervention type: Behavioral. Intervention name: Aerobic exercise Intervention description: 10 days of daily aerobic exercise (brisk walking, jogging); duration: 30 minutes per session; intensity: 65%-75% of age-predicted maximal heart rate. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
89174024|NCT02612142|Sham Comparator|stretching exercise (ST)|Intervention type: Behavioral. Intervention name: Stretching exercise Intervention description: 10 days of daily stretching exercise; duration: 30 minutes per session. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
89174025|NCT02612142|No Intervention|no intervention (NI)|No behavioral intervention. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
89174026|NCT00758134|Experimental|A|Trastuzumab 6 mg/Kg
89174027|NCT02560636|Experimental|Dose level 1a|Radiotherapy: 24Gy in 6f Pembrolizumab: 100mg
89174028|NCT02560636|Experimental|Dose level 1b|Radiotherapy: 24Gy in 6f Pembrolizumab: 200mg
89174029|NCT02560636|Experimental|Dose level 2a|Radiotherapy: 24Gy in 4f Pembrolizumab: 100mg
89174030|NCT02560636|Experimental|Dose level 2b|Radiotherapy: 24Gy in 4f Pembrolizumab: 200mg
89174031|NCT02560636|Experimental|Dose level 3a|Radiotherapy: 30Gy in 5f Pembrolizumab: 200mg
89174032|NCT00758212|Experimental|A|The experimental group will consist of HIV/AIDS patients(approx.50) who volunteer to receive a reduced dose Influenza vaccine using mesotherapy as a mode of injecting the vaccine intradermally.
89174033|NCT00680368||Residents and Attending Physicians|This group contains the residents and the attending physicians who consented to participate in the study. They participated in a survey administered by a research assistant. Both physician resident and attending physicians were administered the survey twice within 24-hours and their test-retest responses were compared for reliability. Responses to attending and resident physicians covering the care for the patient and clinical care encounter were compared for accuracy.
89174034|NCT02560480||groin injury (group A)|magnetic resonance imaging performed in all athletes with acute or subacute groin injury
89174035|NCT02560480||control (group B)|magnetic resonance imaging performed in selected asymptomatic control athletes
89174036|NCT00680056|Active Comparator|1|Formoterol plus Placebo (Tiotropium)
89174037|NCT00680056|Experimental|2|Formoterol plus Tiotropium
89174038|NCT00758368|Experimental|Ambulatory Pump|Participants will receive apomorphine via a pump. Participants in the Continuous Delivery Arm will self-administer apomorphine continuously (12-14 hours a day) using a portable pump.
89174039|NCT00758368|Active Comparator|Subcutaneous Injections|Participants will receive apomorphine via an injection pen. Participants in the Intermittent Delivery Arm will self-administer apomorphine at intervals, via a injection, using pen injector.
89174040|NCT02560402||Patients with sepsis or trauma|Adult patients, admitted to the intensive or medium care unit with sepsis or trauma
89174041|NCT00755482|Active Comparator|1|Subjects were given Aquamin F
89174042|NCT00755482|Placebo Comparator|2|Subjects were given a maltodextran placebo
89174043|NCT00755638|Experimental|single|8 subjects (6 active and 2 placebo)
89174044|NCT05435794||Patient treated with CPAP|
89174045|NCT05435794||Patient treated with MAD|
89174046|NCT02560246||Preterm Labor|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
89174047|NCT02560246||Term Labor|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
89174048|NCT05435560|Experimental|Dexmedetomidine|During the imaging scan subjects will receive an initial 1µg/kg bolus of dexmedetomidine up to a maximum dose of 80 µg, infused through IV over 10 minutes. After the bolus has been administered, a constant infusion of up to 0.6 µg/kg/hr (0.01 µg/kg/min) of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
89174049|NCT05435560|Placebo Comparator|Saline|A saline infusion will be used as a placebo comparator for the dexmedetomidine infusion. It will be administered in the same manner and dosages as the dexmedetomidine.
89174050|NCT00680992|Experimental|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
89174051|NCT02559154|Experimental|modified BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received regimen with bortezomib (1.6mg/㎡) as an intravenous bolus once weekly on day 1, 8 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
89174052|NCT02559154|Active Comparator|conventional BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received bortezomib (1.3mg/㎡) administration twice weekly on day 1,4, 8,11 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
89174053|NCT03798964||Elective term cesarean|Low-risk women undergoing elective term cesarean section
89174054|NCT03798964||Term vaginal delivery|Low-risk women undergoing term vaginal delivery
89174055|NCT03798964||Preterm vaginal delivery|Women undergoing preterm vaginal delivery
89174056|NCT05435248|Experimental|HS-10375|"Experimental: HS-10375（Phase 1a：Dose Escalation） Subjects with advanced or metastatic NSCLC will be enrolled in dose escalation cohorts. Dose escalation of HS-10375 will be done to determine maximum tolerated dose.~Experimental: HS-10375（Phase 1b：Dose Expansion） Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced or metastatic NSCLC having a EGFR C797S mutation.~Experimental: HS-10375（Phase 2） Subjects with locally advanced or metastatic EGFR C797S mutant NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10375 as monotherapy."
89174057|NCT02559076|Experimental|Ten Steps Leaflet|Ten steps leaflet advice for healthy lifestyle
89174058|NCT02559076|No Intervention|Usual care|Usual care given
89174059|NCT00805389|Experimental|GSK223192A 1 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
89174060|NCT00805389|Experimental|GSK223192A 2 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
89174061|NCT00805389|Experimental|GSK223192A 3 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
89174062|NCT00805389|Experimental|Fendrix Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
89174063|NCT00805389|Active Comparator|Engerix-B Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
89174064|NCT00678886|Experimental|otelixizumab|otelixizumab
89174065|NCT00678886|Placebo Comparator|placebo|Placebo
89174066|NCT04016103|Experimental|MY01 Device|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
89174067|NCT05747001||Cohort 1|Cohort of patients suffering from epilepsy with Focal Onset Seizure (FOS) and enrolled into the Early Access Program (EAP) in Germany, France and UK
89174068|NCT00914199|Experimental|Kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent using kissing balloon dilatation
89174069|NCT00914199|Experimental|No kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent and not using kissing balloon postdilatation
89174070|NCT02607969|Experimental|seen once every six weeks|Parents will be educated about home program and they will be asked to control once every six weeks.
89174071|NCT02607969|Experimental|seen once a week.|Parents will be educated about home program and they will be asked to control once a week.
89174072|NCT02608047||dengue patients|Dengue patients confirmed by Non-structural protein and RNA
89174073|NCT02608047||Healthy controls|Healthy population without any diseases
89174074|NCT00804843|Experimental|Statin 80 mg + Niacin extended-release (ER)|Participants in Russia and Brasil will receive 80 mg Simvastatin + niacin. All other participants will receive 80 mg Atorvastatin + niacin.
89174075|NCT00804843|Active Comparator|Statin 10 mg|Participants in Russia and Brasil will receive 10 mg Simvastatin. All other participants will receive 10 mg Atorvastatin.
89174076|NCT00822120|Experimental|HIV Positive, PET Positive: BEACOPP standard|Etoposide 100 mg/m2 IV Days 1, 2, 3 Dox 25 mg/m2 IV Day 1 Cyclo 650mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 Q 21 Days x 6 cycles
89174077|NCT00822120|Experimental|HIV Negative, PET Positive: BEACOPP escalated|Etoposide 200 mg/m2 IV Days 1, 2, 3 Dox 35 mg/m2 IV Day 1 Cyclo 1,250 mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 G-CSF 5mcg/kg/day SQ Days 8-14 Q 21 Days x 6 cycles
89174078|NCT00822120|Active Comparator|HIV Positive, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
89174079|NCT00822120|Active Comparator|HIV Negative, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
89174080|NCT00804687|Experimental|JNJ-39220675 then Pseudoephedrine then Placebo|Single-dose of JNJ-39220675 will be administered as 1 milliliter (ml) of 10 milligram/milliliter (mg/ml) solution orally along with placebo tablet in first treatment period; after that in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 milligram (mg) pseudoephedrine tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
89174081|NCT00804687|Experimental|JNJ-39220675 then Placebo then Pseudoephedrine|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
89174082|NCT00804687|Experimental|Placebo then JNJ-39220675 then Pseudoephedrine|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
89174083|NCT00804687|Experimental|Placebo then Pseudoephedrine then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
89174084|NCT00804687|Experimental|Pseudoephedrine then JNJ-39220675 then Placebo|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
89174085|NCT00804687|Experimental|Pseudoephedrine then Placebo then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
89174086|NCT00678652|Experimental|10 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 10 μg with Adjuvant
89174087|NCT00678652|Experimental|25 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 25 μg with Adjuvant
89174088|NCT00678652|Experimental|50 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 50 μg with Adjuvant
89235832|NCT01008228|Active Comparator|tube thoracic drainage|drainage performed with tube drainage CH 16 or ch 20
89235833|NCT01008228|Experimental|exsufflation|exsufflation with a specific thoracentesis system
88804644|NCT02639442|Experimental|ClearRing™|subjects will undergo general/spinal/local block anesthesia and cystoscopy and/or x-ray evaluation. One to three implants will be transplanted into the patient prostate, followed by cystoscopy for results evaluation
89174089|NCT00678652|Experimental|75 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 75 μg with Adjuvant
89174090|NCT05740605|Experimental|HABIT-ILE therapy at home without a HABIT-ILE follow-up at home|2 weeks of HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy at home followed by 9 weeks of usual care
89174091|NCT05740605|Experimental|HABIT-ILE therapy at home with a HABIT-ILE follow-up at home|2 weeks of HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy at home followed by 9 weeks of HABIT-ILE follow-up at home
89174092|NCT05740605|Active Comparator|Classic HABIT-ILE therapy without follow-up HABIT-ILE at home|2 weeks of classic HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy on site followed by 9 weeks of usual care
89174093|NCT05740605|Active Comparator|Classic HABIT-ILE therapy with follow-up HABIT-ILE at home|2 weeks of classic HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) therapy on site followed by 9 weeks of HABIT-ILE follow-up at home
89174094|NCT02607657|Experimental|Eplerenone 25 mg|Eplerenone 25 mg Tablet Oral Once daily
89174095|NCT02607657|Experimental|Eplerenone 50 mg|Eplerenone 50 mg Tablet Oral Once daily
89174096|NCT02607657|Experimental|Eplerenone 100 mg|Eplerenone 100 mg (2 tablets of 50 mg) Tablet Oral Once daily
89174097|NCT02607657|Experimental|Eplerenone 50 mg x 2|Eplerenone 50 mg Tablet Oral Twice daily
89174098|NCT02607657|Experimental|Eplerenone 25 mg x 2|Eplerenone 25 mg Tablet Oral Twice daily
89174099|NCT03658642|Experimental|Clinical Decision Support for BUP|The Clinical Decision Support (CDS) will be available for clinician use for Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) with referral for ongoing medication assisted treatment (MAT) if: ED chief complaint or urine drug screen indicate opioid use. The clinician will then be prompted to complete DSM-5 checklist for OUD. If DSM-5 OUD Score>5 and urine drug screen is positive for opioids, then the clinician is prompted to complete COWS scale. If COWS score >12, then the clinician is prompted to order BUP. Regardless of COWS score, the clinician will be prompted to schedule an MAT appointment with BUP provider. The CDS will interface with outside MAT facilities so that making an appointment is easy and to capture data on whether an appointment has been scheduled.
89174100|NCT03658642|No Intervention|Usual Care|The CDS will not be activated and patients will receive care as usual.
89174101|NCT04015947|Experimental|Active treatment|This is an open label, single-institution pilot study to evaluate local response to split-thickness skin grafts from a matched bone marrow donor to chronic GVHD-affected skin in a hematopoietic stem cell transplant patient.
89174102|NCT04921228|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback training will be administered via a smartphone app (Optimal HRV) that reads the participants' pulse rate through a Bluetooth connected photoplethysmography (PPG) sensor attached to the finger or thumb.
89174103|NCT00840060|Experimental|AMALS|Addressing multiple aspects of language simultaneously
89174104|NCT00840060|Experimental|DTA|Discrete Trial Approach
89174105|NCT00574912|Experimental|Placebo then Insulin Glargine|"Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.~Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)"
89174106|NCT00922896|Experimental|GPE|Gemcitabine-Cisplatin-Erlotinib
89174107|NCT00674128|Experimental|Adhesive|Cyanoacrylate tissue adhesive.
89174108|NCT00674128|Active Comparator|Suture|Polyglactin 910 suture.
89174109|NCT00760942|Active Comparator|1|Liquid human milk fortifier
89174110|NCT00760942|Active Comparator|2|Powdered human milk fortifier
89174111|NCT00761020|Experimental|Mefloquine|Mefloquine 250 mg orally daily x 3 days beginning 2 days prior to challenge and then weekly for 4 weeks post challenge.
89174112|NCT00761020|Sham Comparator|Control|
89174113|NCT00804141|Experimental|MOA-728 12 mg QD|Participants will receive MOA-728 12 milligrams (mg) SC once daily (QD) for 48 weeks. Dosing could be adjusted to an as needed (PRN) basis with a minimum 1 dose per week and maximum 1 dose per day.
89174114|NCT04049032||In-Person Participants|This group received perinatal OUD treatment in-person.
89174115|NCT04049032||Telemedicine Participants|This group received perinatal OUD treatment via telemedicine.
89174116|NCT00761098|Active Comparator|1|Standard Care (albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
89174117|NCT00761098|Experimental|2|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
89174118|NCT03556137|Experimental|Pain Patients|Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a [18F]FTC-146 PET/MRI scan.
89174119|NCT03556137|Experimental|Healthy Volunteers|Individuals who do not have pain and undergo a [18F]FTC-146 PET/MRI scan.
89174120|NCT00677092|Experimental|Imatinib Mesylate (IM) Treatment|Imatinib mesylate 400 milligrams (mg) orally once daily for 4 months. Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.
89174121|NCT02607579|Active Comparator|Ropivacaine|This group is given an adductor canal block with Ropivacaine which is the previous gold standard medication.
89174122|NCT02607579|Experimental|Exparel|This group is given an adductor canal block with Exparel which is believed to last longer and provide a better pain relief post-operatively.
89174123|NCT03539367|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89174124|NCT03539367|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89174125|NCT00677014|Active Comparator|Echo optimized AV delay|Echo optimized AV delay
89174126|NCT00677014|Active Comparator|Algorithm optimized AV delay|Algorithm optimized AV delay
89174127|NCT00677014|Active Comparator|Fixed AV Delay|Fixed AV Delay
89174128|NCT03591640|Active Comparator|Pregnant with hemoglobinopathy|Standard of care with blood test before active labor
89235834|NCT00836381|Experimental|Tolterodine ER|Tolterodine ER 4mg once daily
89235835|NCT00836381|Placebo Comparator|Placebo|Placebo once daily
89235836|NCT02533336|Experimental|DL+LLINs|DL treated with abamectin and fenpyroximate
89174129|NCT03591640|Active Comparator|Pregnant without known hemoglobinopathy|Standard of care with blood test before active labor
89174130|NCT02607267||laparoscopic Roux en Y Gastric Bypass|patients undergoing LRYGB, being the first surgical treatment for severe obesity
89174131|NCT02607267||laparoscopic Sleeve Gastrectomy|patients undergoing LSG, being the first surgical treatment for severe obesity
89174132|NCT04048954||APPLITABAC arm|Use of a smartphone application on screening for complications related to tabagism
89174133|NCT04847986|Experimental|acceptance and commitment therapy (ACT) group|8 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
89174134|NCT04847986|Sham Comparator|Control group|care as usual with psychoeducation materials provided
89174135|NCT03416361|Experimental|Vitamin D|4000IU Vitamin D3 as two 50mcg tablets per day
89174136|NCT03416361|Placebo Comparator|Control|Placebo - two chewable blackcurrant flavoured tablets per day
89174137|NCT04049968|Experimental|Experimental group|Patients in the experimental group were individually assessed by a mobile health application (APP).
89174138|NCT04049968|Active Comparator|Control group|Patients in the control group were individually assessed by a traditional routine health care and instruction.
89235837|NCT02533336|No Intervention|LLINs|LLINs only
89235838|NCT00836459|No Intervention|Control|
89235839|NCT00836459|Experimental|Mini Booster|
89174139|NCT00761332||Teriparatide|Patients treated with teriparatide
89174140|NCT00761332||Antiresorptive|Patients treated with antiresorptive therapy
89174141|NCT03356925|No Intervention|Centralised Xpert®Ultra testing|Patients are selected to receive the standard of care for TB diagnosis at a centralised laboratory facility
89174142|NCT03356925|Active Comparator|Xpert Ultra Point of Care testing|Patients are selected to receive the point of care for TB diagnosis at the clinic facility they are visiting
89174143|NCT03321201|Experimental|Cauterization|
89174144|NCT03321201|Active Comparator|Fibrin glue|
89174145|NCT00839436|Experimental|3 microgram/kg CYT107|3 microgram/kg CYT107
89174146|NCT00839436|Experimental|10 microgram/kg CYT107|10 microgram/kg CYT107
89174147|NCT00839436|Experimental|20 microgram/kg CYT107|20 microgram/kg CYT107
89174148|NCT00761410|Other|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
88804645|NCT02583113||Total and Unicompartment Knee Replacement|
89174149|NCT04049188|Experimental|Single-Fraction Palliative RT|Single-Fraction Palliative Radiation Therapy Adminstration
89174150|NCT02607345|Active Comparator|Glucomedics®|25gr Glucomedics®
89174151|NCT02607345|Experimental|Zusto®|25gr Zusto®
89174152|NCT00709020|Experimental|White Button Mushroom Extract|
89174153|NCT03388762|Active Comparator|GlucoSupreme™ Herbal|Each daily serving of four GlucoSupreme™ Herbal tablets includes extracts from: cinnamon bark (Cinnamomum cassia) 500 mg, banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid) 200 mg, kudzu root (Pueraria lobata standardized to 40% isoflavones) 200 mg, fenugreek seed (Trigonella foenum-graceum standardized to contain 60% saponins) 200 mg, and gymnema leaf (Gymnema sylvestre standardized to contain 25% gymnemic acid). Additionally, American ginseng root (Panax quinquefolius standardized to contain 5% ginsenosides) 200 mg, and berberine HCl derived from bark (Berberis aristata) 500 mg. Other ingredients include Cellulose (capsule), microcrystalline cellulose, silicon dioxide, and vegetable stearate.
89174154|NCT03388762|Placebo Comparator|Control|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
89174155|NCT02612220|Experimental|Experimental Group|Complete hemostasis will be achieved using BioFoam® Surgical Matrix
89174156|NCT02612220|Active Comparator|Control Group|Complete hemostasis will be achieved without the use of topical agents, using conservative hemostasis
89174157|NCT04627246|Experimental|PEP-DC + Nivolumab + SOC|PEP-DC: Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides Nivolumab SOC: Standard of Care Chemotherapy
89174158|NCT00761488|Experimental|1|AcrySof® Toric IOL
89174159|NCT00761566|Experimental|1|
89174160|NCT00761566|Experimental|2|
89174161|NCT00761644|Experimental|Doxil, Bevacizumab + Temsirolimus|"Doxil day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.~Bevacizumab day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.~Temsirolimus days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes."
89174162|NCT04049812|Active Comparator|Pulsed electromagnetic field (PEMF) treatment Group|Group received routine hot pack, Transcutaneous electrical nerve stimulation (TENS) and PEMF treatment.
89174163|NCT04049812|Sham Comparator|Sham PEMF treatment Group|Group received routine hot pack, TENS and sham PEMF treatment.
89174164|NCT04049734|Active Comparator|patients received the oral losartan|50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis
89174165|NCT04049734|No Intervention|patients didn't receive the oral losartan|50 patients with obstructive jaundice indicated for ERCP and didn't receive any prophylactic drugs
89174166|NCT04617418||subjects with refractory focal epilepsy with a seizure frequency|The investigators will include 100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month, and ask them to keep a seizure diary and use the TapCounter app for three months.
89174167|NCT02559388|Active Comparator|montelukast|montelukast 10 milligram, daily for 30 days
89174168|NCT02559388|Placebo Comparator|placebo|Placebo one tablet for 30 days
89174169|NCT03168256|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
89174170|NCT03168256|Experimental|CF101 3mg|CF101 3mg, orally q12 hours
89174171|NCT03168256|Active Comparator|Apremilast 30mg|Apremilast 30mg, orally q12 hours
89174172|NCT03168256|Placebo Comparator|Placebo|Placebo control , orally q12 hours
89235840|NCT00836459|Experimental|Full Booster|
89235841|NCT03991390|Experimental|Core stability and feedback visual laser exercises|"Two complementary protocols for the treatment of balance after stroke in patients with pusher syndrome were designed, including multidimensional physiotherapy exercises. Both protocols differentiate 3 levels of difficulty: Second level requires maintenance of balance sitting 5, if the patient does not succeed, stays in level 1. To move to L3 patients must stay seated 10''. Each exercise is repeated 5 times, always considering patients' levels of fatigue and safety.~Visual feedback with laser (Motion Guidance Clinical Kit, approved for therapeutic use): Through visual aid, patients' verticality is achieved by encouraging their active participation in correcting the imbalance while performing the exercises.~Core stability: The exercises have to be adapted for the pusher patient avoiding overuse of the less affected side of the body, and strengthening the muscles that stabilize the trunk."
89235842|NCT03991390|Active Comparator|Control stroke|Rehabilitation program is based on a comprehensive approach, where the patient follows a personalized plan of exercises according to the deficits, the previous situation and personal concerns.
89235843|NCT00829361|Other|Telemedicine|
89235844|NCT03829228|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks.
89235845|NCT01008306||Renal transplanted children and young adults|"Renal transplanted children and adolescents (2-18yrs) transplanted between 1993-2006.~Renal transplanted young adults aged 20-35 yrs old, transplanted from 1983 onwards."
89235846|NCT01053910|Experimental|Ramipril|Duration of treatment: 2 months 7 first days: 1.25mg once daily in patients with stable heart failure and 7 days 2.5mg once daily or 14 first days:2.5mg once daily in patients without heart failure for 14 more days:5mg once daily maintenance therapy for 1 month: 10 mg (5mg, 2 tablets)
89235847|NCT00829517|Active Comparator|STI kiosk|computer-assisted provision of screening for chlamydia
89235848|NCT00829517|Experimental|contraceptive kiosk|computer-assisted provision of hormonal contraception
88804646|NCT02552511||Exposure|Perinatal factors exposure
88804647|NCT02551081||Birth Defects|Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
88804648|NCT02544100||Database Entry / Biospecimen Collection|Systematic Medical information of infants born with severe encephalopathy entered into database. In addition, Blood, urine, CFS samples will be collected.
89235849|NCT03987412|Experimental|Behavioral intervention|Pregnant women randomized to the behavioral intervention group will recieve a face-to-face education about the risks of GDM at their local rearch centers. Then they will be provided with a mobile APP incorporating nutrition, exercise and phycological support. They will also have regular prenatal care in their local hospitals.
89235850|NCT03987412|No Intervention|Control group|Pregnant women randomized to the control group only have regular prenatal care in their local hospitals.
89235851|NCT00839267||Unstable|Patient with acute myocardial infarction plus severe hemodynamical instability. It means, on mechanical ventilation and catecholamine support
88804649|NCT02457845|Experimental|HSV G207|"Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI. If G207 is safe in the first two cohorts of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor defined by MRI followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.~Intervention: Biological: G207"
88804650|NCT02399813|Experimental|Axalimogene filolisbac|Participants received intravenous (IV) infusion of axalimogene filolisbac administered over 60 minutes every 3 weeks at a dose of 1 x 10^9 colony forming units (cfu) for up to 2 years or until a discontinuation criterion was met (documented progression, unacceptable adverse events, withdrawn due to investigator's discretion, participant withdraws consent, pregnancy or noncompliance with study procedures or treatments). A treatment cycle was defined as 9 weeks in duration.
88804651|NCT02362802|Active Comparator|Antitachycardia Pacing|Implantable cardioverter defibrillator placement with Antitachycardia Pacing. Apart from that usual standard of care.
88804652|NCT02362802|No Intervention|No Antitachycardia Pacing|"Implantable cardioverter defibrillator placement without Antitachycardia Pacing.~Apart from that usual standard of care."
88804653|NCT02341924|Experimental|Portfolio of functional foods|"A portfolio of functional foods provided as packaged shelf-stable food products (Step One Treatment) which will include foods such as oatmeal, pancakes, cranberry bars, chocolate bars, smoothies, and a sprinkle offering which can be added to almost any food to enhance its nutritional impact.~All products are interchangeable in terms of their nutrients of interest and contain a minimum of 5 g of fibre, 1800 mg of omega-3 fatty acids, 1000 mg of phytosterols and 1800 µmol antioxidants per serving. Calorie counts range from 110-190 kcal per serving."
88804654|NCT02341924|Placebo Comparator|Control foods|Control products will be like-items drawn from the general grocery marketplace. Test and control products will be packaged and coded identically.
88804655|NCT02291055|Experimental|Part A Escalation (Cervical): 1×10^9 CFU ADXS11-001/ 3 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 3 milligrams per kilogram (mg/kg) intravenous (IV) infusion every 2 weeks (Q2W) at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion every 4 weeks (Q4W) at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
88804656|NCT02291055|Experimental|Part A Escalation (Cervical and Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with cervical cancer and SCCHN received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
88804657|NCT02291055|Experimental|Part A Expansion (Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with SCCHN received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
89235852|NCT00839267||Stable|Patients with myocardial infarction hemodynamically completely (Killip I)stable.
89174173|NCT00761722|Experimental|Arm 1|"subcutaneous and oral azacitidine~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle."
89174174|NCT00761722|Experimental|Arm 2|"Oral Azacitidine~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
89174175|NCT00761878|Active Comparator|Skin treatment|
89174176|NCT04507906|Other|Nivolumab + Anlotinib Arm|
89174177|NCT04471636|Experimental|Telemedicine Care|Patients receive assessment at baseline and at 30 day follow up. Patient receive a smart watch capeable of recording SpO2, ECG, and heart rate. Patients also receive access to 24/7 medical hotline for telemedical care. All public services of the health care system remain available.
89174178|NCT04471636|No Intervention|Control|Patients receive assessment at baseline and at 30 day follow up. Patient have access to all services of the health care system, but do not receive a smart watch or medical hotline access.
89174179|NCT00762112|Experimental|TAK-559 32 mg QD|
89174180|NCT00762190|Experimental|TAK-559 32 mg QD + Insulin|
89174181|NCT00762190|Active Comparator|Insulin|
89174182|NCT00762346|Experimental|1|
89174183|NCT04375930|Experimental|Experimental|The patient will be trained with STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION. The patient will be follow up at 2nd, 6th and 12th weeks.
89174184|NCT04375930|Active Comparator|control|The patient will be trained only skills and discharge education. The patient will be follow up at 2nd, 6th and 12th weeks.
89174185|NCT00762658|Experimental|1|AN2728 Ointment, 5%
89174186|NCT00762658|Experimental|2|AN2728 Ointment, 2%
89174187|NCT00762658|Experimental|3|AN2728 Ointment, 0.5%
89174188|NCT00762658|Placebo Comparator|4|AN2728 Ointment Vehicle
89174189|NCT00762658|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
89174190|NCT00762658|Active Comparator|6|Protopic® Ointment (tacrolimus 0.1 %)
89174191|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 5 mg QD|
89174192|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 40 mg QD|
89174193|NCT00762736|Active Comparator|Pioglitazone 15 mg QD|
89174194|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 5 mg QD|
89174195|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 40 mg QD|
89174196|NCT00762736|Active Comparator|Pioglitazone 45 mg QD|
89174197|NCT00762814|Experimental|Parkinson subjects with freezing|"Each subject will have been diagnosed with Parkinson disease and will serve as his/her own control. Inclusion criteria: history of consistent freezing with ambulation in a straight line and/or when turning, normal central and peripheral neurological function, at least grade 4 strength and normal joint ranges of motion in both legs, normal somatosensory function in the feet (joint position sense), except for their neurological diagnosis and use of levodopa, each must have had clear benefit from levodopa for at least some of his/her PD symptoms, and all subjects with PD must be able to walk independently for 10 feet.~Exclusion criteria include: serious medical problem that would impair the ability to undergo testing, use of neuroleptic or other dopamine-blocking drug, use of drugs that might affect balance, history or evidence of other neurological deficit that could interfere, such as previous stroke or muscle disease, or participants who are unable to provide informed consent."
89174198|NCT02915224||Obinutuzumab|Participants will receive obinutuzumab as per Summary of Product Characteristics in daily practice along with chlorambucil for 24 months.
89174199|NCT02813824|Active Comparator|Aspirin300|Acetylsalicylic acid 300 mg tablet by mouth, daily dose during 4 years
89174200|NCT02813824|Placebo Comparator|Placebo300|Placebo (like Acetylsalicylic acid 300 mg) tablet by mouth, daily dose during 4 years
89174201|NCT02813824|Active Comparator|Aspirin100|Acetylsalicylic acid 100 mg tablet by mouth, daily dose during 4 years
89174202|NCT02813824|Placebo Comparator|Placebo100|Placebo (like Acetylsalicylic acid 100 mg) tablet by mouth, daily dose during 4 years
89174203|NCT00675766||Group 1|HIV-positive adults 50 and older/ HIV-positive adults 18-40 years old
89174204|NCT00675766||Group 2|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
89174205|NCT00675766||Group 3|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
89174206|NCT00675766||Group 4|HIV-negative controls 18-40 years old
89174207|NCT05306782|Experimental|Transcranial Random Noise Stimulation|Transcranial Random Noise Stimulation (1.5 mA, High Frequency) administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
89174208|NCT05306782|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (1.5 mA, anodal) administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
89174209|NCT05306782|Sham Comparator|Sham Direct Current/Random Noise Stimulation|Sham stimulation administered by using surface scalp electrodes (20 minutes, initial part of the session) in correspondence of associative motor regions, during speech therapy sessions (45 minutes).
89174210|NCT02669680|Experimental|G-CSF + Standard therapy|Standard care of acute-on-chronic liver failure and application of G-CSF
89174211|NCT02669680|Active Comparator|Standard therapy|Standard care of acute-on-chronic liver failure
89174212|NCT00673894|Experimental|Glutamine+Sitagliptin|Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin
89174213|NCT00673894|Placebo Comparator|Glutamine+Placebo|Glutamine 30 g/d (15 g with breakfast and dinner) + placebo
89174214|NCT00763126|Active Comparator|Spouse present,|
89174215|NCT00763126|Active Comparator|spouse absent|
89174216|NCT00763204|Experimental|1|AN2728 Cream, 2%
89174217|NCT00763204|Experimental|2|AN2728 Cream, 1%
89174218|NCT00763204|Experimental|3|AN2728 Cream, 0.3%
89174219|NCT00763204|Placebo Comparator|4|AN2728 Cream Vehicle
89174220|NCT00763204|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
89235853|NCT00829595|Experimental|1|IBD, on both an anti-TNF agent and an immunomodulator
89235854|NCT00829595|Experimental|2|IBD, not on any immunosuppressive medications
89235855|NCT00829595|Active Comparator|3|Healthy, non-IBD, not on immunosuppressive medications (control arm)
89235856|NCT01008384|No Intervention|placebo|
89235857|NCT01008384|Experimental|Vitamin D3|Vitamin D3 given for 8 weeks
89235858|NCT00836771|Placebo Comparator|Materna infant formula 1|milk based infant formula powder
89235859|NCT00836771|Experimental|Materna infant formula 2|Probiotic supplemented infant formula
89235860|NCT00836771|Experimental|Materna infant formula 3|Prebiotic supplemented infant formula
89235861|NCT00836771|Experimental|Materna infant formula 4|Prebiotic+ Probiotic supplemented infant formula
89235862|NCT00836771|Other|Human milk|Human Milk
89235863|NCT02547155|Experimental|Spinal anesthesia|Subjects randomized to spinal anesthesia will receive Bupivacaine 0.75%, 8-12.5 mg dose depending on estimated duration of surgery and anesthesiologist decision. In addition to spinal anesthesia, these subjects will possibly have concurrent administration of fentanyl, midazolam, and propofol so that they are mildy sedated or sleeping.
89235864|NCT02547155|Active Comparator|General anesthesia|Subjects randomized to general anesthesia will receive propofol induction, in combination with a muscle relaxant and inhalational gas per anesthesia standard of care at our institution
89235865|NCT00836849|Experimental|1|
89235866|NCT00836849|Active Comparator|2|
89235867|NCT03999294|No Intervention|Control Group|
89235868|NCT03999294|Experimental|Experimental Group|
89235869|NCT00829751|Active Comparator|ReNu Multiplus|Purevision lenses will be soaked in ReNu Multiplus
89235870|NCT00829751|Active Comparator|OptiFree RePlenish|PureVision lenses will be soaked in OptiFree RePlenish
89235871|NCT00839501|Experimental|1|Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.
89235872|NCT04859712||Trial group: 45 patients with lumbar disc herniation|"The Pulse Detection System of Sound Waves  was used to collect three parts and five layers of pulsed sound waves from the hands of 45 patients with lumbar disc herniation."
89235873|NCT04859712||Control group :45 relatively healthy people|"The Pulse Detection System of Sound Waves  was used to collect the three-parts and five-layers pulse sound waves of the hands of 45 relatively healthy people."
89235874|NCT00837005||1|Patients with suspected CAD
89235875|NCT00837005||2|Patients with known CAD and suspected ischemia.
89235876|NCT00839579|Experimental|4x4min|4x4minutes interval group
89235877|NCT00839579|Experimental|1x4min|
89235878|NCT00829907|Experimental|1|Orm-12741
89235879|NCT00529542|Experimental|Atorvastatin|
89235880|NCT00529542|Placebo Comparator|Placebo|
89235881|NCT04043741|Experimental|Dry Needling|Dry needling (04 Sessions) and exercises
89235882|NCT04043741|Active Comparator|Sustain Pressure|sustained pressure and Exercises
89235883|NCT00621959|Placebo Comparator|Placebo|Matched placebo tablets once daily
89235884|NCT00621959|Experimental|LCTZ|5 mg levocetirizine dihydrochloride tablet
89235885|NCT05702736|Experimental|Intervention group|Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to intervention group as a pre-test. Inaddition to the Standard treatment, the intervention group received a logotherapy-based intervention. Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to intervention group as a post test and follow up test.
89235886|NCT05702736|No Intervention|Control group|Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to control group as a pre-test. The control group received only standard treatment. Beck Depression Inventory, Psychache Scale, Meaning of Life Questionnaire was applied to control group as a post test and follow up test.
89235887|NCT00839657|Experimental|1|Genotype-guided dosing algorithm for warfarin
89235888|NCT00839657|Active Comparator|2|Clinical-guided dosing algorithm for warfarin
89235889|NCT00839735||COPD|Chronic obstructive pulmonary disease
89235890|NCT00839735||Asthma|
89235891|NCT00839735||Healthy controls|
89235892|NCT05261568|Experimental|experimental group|"The first application is carried out by a researcher close to the polyclinic with care and demonstration.~The application will be suggested by hanging it from side to side in sitting position. They will be informed about the same application conditions in their own practice at home.~The program, which will last for 6 weeks, will continue from the home environment after a video surveillance observed by the beneficiary.~Periods of entry and exit times thanks to the mobile program. It will be done over the phone by the people who will come for 6 weeks. history book, lack of tools, etc. a website will be searched. Adhering to application products through study. A total of 42 sessions for 6 weeks, 7 days a week. About 30min. It is used to benefit from training to benefit from sustained progression. Apart from that, he can enjoy wearing it by dressing casually and casually."
89235893|NCT05261568|No Intervention|control gruop|"The control group did not receive any intervention other than their own treatment during the study.~will not be applied. Progressive relaxation exercise application to the individuals included in the control group personal information form, Pittsburgh sleep quality index, fatigue severity scale will be applied as test-post-test."
89235894|NCT02547857||Cohort 1|All women who undergo pelvic US in the ED, assuming they meet inclusion/exclusion criteria
89235895|NCT03999528||study group|RA Patients
89235896|NCT03999528||control group|normal control
89235897|NCT00839813|Experimental|Yoga|10 week trauma-sensitive yoga classes
89235898|NCT00839813|No Intervention|Women's Health Education|10 weeks of women's health education classes as an attentional control group
89235899|NCT00839891|Placebo Comparator|3|"Group 1: 56 subjects to receive active study drug (VI-0521) at steady state, PHEN/TPM 7.5/46 (a potential therapeutic dose), escalating to PHEN/TPM 22.5/138 (a supra-therapeutic dose);~Group 2: 28 subjects to receive placebo preceded by a single oral dose of moxifloxacin on Day 2;~Group 3: 28 subjects to receive placebo followed by a single oral dose of moxifloxacin on Day 24;"
89235900|NCT00830141||1|50 children with GH deficiency
89235901|NCT00830141||2|50 children with ISS
89235902|NCT00830141||3|50 children with FTT
89174221|NCT02558140|Experimental|Part 1: Dose Escalation|All participants will be given RO6874813 as a single low dose of 0.5 milligrams per kilogram (mg/kg) via intravenous (IV) infusion in a 7-day pharmacokinetic (PK) run-in period (Cycle 0). This is followed by dose escalation (Cycle 1) for which participants will receive escalating doses of RO6874813 (starting dose = 1 mg/kg) via IV infusion every week (qw) or every 2 weeks (Q2W) for 28 to 42 days to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
89235903|NCT00830141||4|50 children with obesity
89235904|NCT00830141||5|50 children without short stature or obesity will serve as controls
89235905|NCT00839969|Sham Comparator|Cystoscopy alone|Women in this arm will undergo saline cystoscopy under general anaesthesia only.
89174222|NCT02558140|Experimental|Part 2: Tumor Biopsy and Imaging|The first 15 participants with fibroblast activation protein-alpha positive (FAP+) tumors will be treated at the RP2D and dosing schedule as determined in Part 1, and will undergo paired tumor biopsies for biomarker assessments. Up to 5 participants with FAP+ tumors will undergo baseline and on-treatment tumor biopsies for biomarker assessments at a dose below the RP2D. The dose for these participants can be escalated to RP2D after 4 weeks of treatment and upon completion of biomarker assessment.
89235906|NCT00839969|Active Comparator|Cystoscopy and urethral dilatation|Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
89235907|NCT00830297|Active Comparator|1 Insulatard (long-acting insulin)|
89235908|NCT00830297|Active Comparator|2 Conventional treatment|
89235909|NCT03877224|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
89235910|NCT03877224|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
89235911|NCT00843557||all ICU admissions|patients admitted to the ICU for greater then 72hrs
89235912|NCT00840125|Experimental|1|docetaxel + erlotinib
89235913|NCT02548481||BESTA scale|BESTA scale is administered at T0, T1 (3 months) and T2 (1 year)
89235914|NCT00840359|Experimental|1 PDT|Leishmania lesion
89235915|NCT00840359|Active Comparator|Cryo|Leishmania lesion
89235916|NCT00830453|Experimental|Hyperbaric oxygen|Hyperbaric oxygen, 1.5 atmospheres absolute, 60 minutes door-to-door, 60 daily sessions.
89235917|NCT04016597||Lung diffusing capacity measurements|Participants perform single-breath lung diffusing capacity measurements in random order during one study visit.
89235918|NCT00528606|Experimental|AA4500 0.58 mg|
89235919|NCT00528606|Placebo Comparator|Placebo|
89235920|NCT00843869||Chronic Rhinosinusitis|Participants with chronic rhinosinusitis
89235921|NCT00840515||Emulsion|
89235922|NCT00830531|Experimental|1|Standard phenobarbital combined with either 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the status of the dose escalation design.
89235923|NCT00830531|Placebo Comparator|2|Standard phenobarbital therapy combined with normal saline as placebo for bumetanide
89235924|NCT05014542|Experimental|Acupuncture Group|Participants in Acupuncture group will get acupuncture treatments to their symptomatic knee/knees according to the study protocol. Acupuncture will be provided to participants in three cycles, each three weeks duration, with frequency three times weekly. Period between the cycles is three weeks long. Participants will get acupuncture as adjunctive therapy to conventional medical treatment (analgesic therapy) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
89235925|NCT05014542|Active Comparator|Control Group|Participants in Control group will get their standard conventional treatment (analgesics) which dose could vary according to participant symptoms intensity. Participants and investigator are not blinded for treatment type.
89235926|NCT00840593|Active Comparator|1. Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
89235927|NCT00840593|Active Comparator|2 Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
89235928|NCT04925622||Control|No symptoms of neurological condition
89235929|NCT04925622||Parkinson's disease|Parkinson's disease diagnosis
89235930|NCT04925622||Non-PD Movement disorder|Non-PD with other movement disorder such as progressive supranuclear palsy, multiple system atrophy, essential tremor, corticobasal degeneration, vascular Parkinsonism, or Parkinsonian syndromes
89235931|NCT00621257|Active Comparator|Treatment A|2,000 IU/day of ergocalciferol orally for 6 weeks (control arm)
89235932|NCT00621257|Experimental|Treatment B|2,000 IU/day of cholecalciferol orally for 6 weeks
89235933|NCT00621257|Experimental|Treatment C|50,000 IU of ergocalciferol once a week orally for 6 weeks
89235934|NCT00621257|Active Comparator|Maintenance A|400 IU/day of ergocalciferol orally over 2 years (control arm)
89235935|NCT00621257|Experimental|Maintenance B|2,000 IU/day of ergocalciferol orally from November 1 to April 30, and 1,000 IU/day of ergocalciferol orally for the remainder of the year over 2 years
89235936|NCT00528840|Experimental|AA4500 0.58 mg|
89235937|NCT02547077|Experimental|Wound Closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
89235938|NCT02547077|Active Comparator|Wound Closure with 5-0 Fast Absorbing Gut|One side of the patient's wound defect will be assigned to wound closure with 5-0 fast absorbing gut sutures.
89235939|NCT00840671|Experimental|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
89235940|NCT00840671|Placebo Comparator|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
89235941|NCT00851123|Experimental|1. Modified Constraint-Induced Movement therapy|Modified Constraint-Induced Movement Therapy at the rehabilitation unit or in an outpatient clinic.
89235942|NCT00851123|Experimental|2.Task-specific bimanual training|Task-specific bimanual training at the rehabilitation unit or in an outpatient clinic.
89174223|NCT02558140|Experimental|Part 3: Preliminary Efficacy Assessment|Participants with locally advanced or metastatic non-resectable FAP+ sarcoma will be treated with RO6874813 at the RP2D and as per schedule determined upon completion of Part 1. Participants continuing treatment with RO6874813 beyond 36 weeks will enter the extension phase of Part 3 and will be monitored for disease status and clinical safety per routine standard of care.
89174224|NCT02558218|Active Comparator|Systane ultra group|Participants in this group were administered systane ultra quid (Alcon, Fort Worth) for two months postoperatively), additionally to tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.
89174225|NCT02558218|Active Comparator|Control group|Participants in this group were administered the standard postoperative medication [tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.]
89174226|NCT00763438|Experimental|Sertindole|
89235943|NCT05691114|Experimental|hAESCs treatment|"hAESCs will be administration through Ommaya reservoir implanted into the lateral ventricle.~The tolerability, safety, and efficacy will be examined of 4 monthly doses of hAESCs for 3 months followed by 2 doses every 3 months in dose escalation through 3 cohorts.~Dose A (5×10^7 cells/dose)~Dose B (1.0×10^8 cells/dose)~Dose C (1.5×10^8 cells/dose)."
89235944|NCT00840905||1|HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
89235945|NCT00840905||2|A cohort of HIV seropositive women from Gabarone Botswana
89235946|NCT00840905||3|A cohort of HIV seropositive women from Rio De Janeiro Brasil
89235947|NCT02545985|Experimental|Prolim stent implantation|In patients with symptomatic coronary artery disease Prolim stent was implanted in coronary arteries
89235948|NCT00851201|Active Comparator|Standard Intervention|
89235949|NCT00851201|Experimental|Intensive lifestyle|
89235950|NCT00844025|Experimental|Pharmacist intervention|Patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medication review, medication reconciliation, patient education and recommended actions.
89235951|NCT00844025|No Intervention|Usual care|Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist and nurse.
89235952|NCT02546531|Experimental|Dose escalation (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
89235953|NCT02546531|Experimental|Dose expansion (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
89235954|NCT00840983|No Intervention|1-Immediate Cord Clamping|infants received the routine care of immediate clamping of the umbilical cord
89235955|NCT00840983|Experimental|2-Delayed Cord Clamping|after birth, cord clamping was delayed 30 to 45 seconds while infant was held lower than the level of the placenta.
89174227|NCT00763516|Experimental|Proton radiation and chemotherapy|"Proton radiation~Capecitabine chemotherapy on radiation days~Surgery~Gemcitabine chemotherapy"
89174228|NCT02558842|Experimental|Education Strategy|Educational Strategy and Oversight Distance
89235956|NCT05205720|Experimental|NB group|"Celiac plexus block (CPB) was added to the postoperative analgesia plan.~CPB: the target nerve is located in the retroperitoneal space, embedded in the fat in front of the aorta, and distributed in a network along the anterolateral wall of the aorta, just at the beginning of the celiac trunk. During direct vision (anterior) block, first expose the upper edge of the pancreas, palpate the abdominal aorta and abdominal trunk, and palpate the pulsation of the common hepatic artery and splenic artery at the level of the abdominal trunk. Use a 25g 6cm puncture needle with an extension tube and a syringe pumped back by an assistant to form a negative pressure, then the needle is inserted into the fat on both sides of the abdominal aorta. If there is no blood or fluid outflow, slowly inject 10ml of 0.5% ropivacaine each side. After pulling out the needle, observe whether there is damage and bleeding. If necessary, use low-energy electrocoagulation to stop bleeding."
89174229|NCT02558842|No Intervention|Routine|Routine hospital assistance
89174230|NCT02158000|Active Comparator|Group A|In group A , 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles are allocated to receive one tab / 8 hs of Diosmin ( 500mg) beginning from the day of ovum retrieval and for 3 days (till the day of embro trasfer) in addition to aspiration of the fluid by an IUI catheter.
89174231|NCT02158000|No Intervention|Group B|In group B (control group) 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles, no thing will be done
89174232|NCT01027078||OSA|patients diagnosed with obstructive sleep apnea who do not have existing cardiovascular disease
89174233|NCT01027078||control|patients without obstructive sleep apnea who are matched in weight and age to the OSA patients
89174234|NCT00674986|Other|Active Control Group (ACG)|Participants in the Active Control Group received enhanced standard of care (more frequent clinic visits, free blood glucose meters and strips and point-of-care Hemoglobin A1c (HbA1c) test) for management of their Type 2 diabetes.
89235957|NCT05205720|No Intervention|GC group|The same analgesic plan as the experimental group, except that CPB is not performed.
89235958|NCT00844103|Experimental|1|
89235959|NCT00844103|Placebo Comparator|2|
89235960|NCT00841061|Active Comparator|Cereal L|Rice cereal with electrolytic iron
89174235|NCT00674986|Experimental|Structured Testing Group (STG)|Participants in the Structured Testing Group in addition to enhanced standard of care for the treatment of their Type 2 diabetes used the ACCU-CHEK® 360° View blood glucose analysis system (Tool) to monitor glucose levels at least quarterly.
89174236|NCT02559232||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fibrillation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
89235961|NCT00841061|Active Comparator|Cereal M|Rice cereal with ferrous fumarate
89174237|NCT00758446|Experimental|A|BLX-028914 50 mg
89174238|NCT00758446|Experimental|B|BLX-028914 15 mg
89174239|NCT00758446|Placebo Comparator|C|Placebo
89174240|NCT00763594|Active Comparator|IPT|Interpersonal Psychotherapy for Major Depressive Disorder
89174241|NCT00763594|Experimental|BRT|Brief Relational Therapy adapted for treatment of Major Depressive Disorder
89174242|NCT00763672|Other|A|sFlt-1 status known
89174243|NCT00763672|Other|B|sFlt-1 status unknown
89174244|NCT00764842||CLP Hip|
89174245|NCT02558062|Experimental|BAC ONE administration|All participants in this clinical study will be dosed on one occasion with BAC ONE. The final dosage will be 80 µg (± 25%).
89174246|NCT00673660||Statins|Patients with dyslipidemia who are taking or planning to take a statin treatment (Atorvastatin, Fluvastatin, Prevastatin, Rosuvastatin, Simvastatin or generics).
89174247|NCT00763906|Placebo Comparator|1|Patients were assigned to norepinephrine infused at the clinician's discretion.
89174248|NCT00763906|Active Comparator|2|Patients were assigned to norepinephrine infused under computerized fuzzy logic control.
89174249|NCT00763984|Active Comparator|1 Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT
89174250|NCT00763984|Experimental|2 Bladder Health Class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
89174251|NCT00764062|Experimental|1|7-day amoxicillin treatment (1g per os twice daily)
89174252|NCT00764062|Active Comparator|2|3-day amoxicillin (1g per os twice daily) + 4-day placebo treatment (1g per os twice daily)
89174253|NCT00758992||Immunodeficient mice|Please see the Study Description for complete information.
89174254|NCT00759070|Active Comparator|1|Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)
89174255|NCT00759070|Active Comparator|2|Tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir (LPV/RTV)
89174256|NCT00764140||2|Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls
89174257|NCT00764140||1|Patients with hepatocellular carcinoma and Healthy controls
89174258|NCT00672958|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.
89174259|NCT00672958|Experimental|Vortioxetine|Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.
89174260|NCT00764218|Experimental|SAS+HTA+|Obstructive sleep apnea syndrome and hypertension
89174261|NCT00764218|Experimental|SAS+HTA-|non hypertensive patients with obstructive sleep apnea syndrome
89174262|NCT00764218|Experimental|SAS-HTA+|hypertensive patients without obstructive sleep apnea syndrome
89174263|NCT00764218|Experimental|SAS-HTA-|non hypertensive patients without obstructive sleep apnea syndrome
89174264|NCT00764296||no treatment|The information obtained by the evaluation of both acute and chronic wounds is pivotal to truly understanding the intercellular tactics used by wound biofilms which work to disrupt host tissue and to evade the host's immune system.
89174265|NCT00764374|Experimental|1|
89174266|NCT00672646|Experimental|AZD1386|
89174267|NCT00672646|Active Comparator|Naproxen|
89174268|NCT00672646|Placebo Comparator|Placebo|Placebo matching AZD1386
89174269|NCT04048798|Active Comparator|Oxygen therapy via HFNC|Patients who will be applied high frequency nasal cannula before and after surgery
89174270|NCT04048798|Active Comparator|Oxygen therapy via face mask|Patients who will be applied O2 via face mask before and after surgery
89174271|NCT00764530|Experimental|Investigational|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell.
89174272|NCT00764530|Active Comparator|Control Device|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head.
89174273|NCT00764998|Active Comparator|Fluviral|
89174274|NCT00764998|Placebo Comparator|placebo|
89174275|NCT00764608||No Treatment|
89174276|NCT00759382||I|Patients with non-small cell lung carcinoma treated with curative intent
89174277|NCT00759460|Experimental|1|
89174278|NCT00759460|Active Comparator|2|
89174279|NCT00759538||1|lung transplant patients performing a three week lasting rehabilitation program
89174280|NCT00765154|Active Comparator|Group 1|Immediate switch from NNRTI/PI to DRV/r
89174281|NCT00765154|Active Comparator|Group 2|Switch after 10 weeks from NNRTI/PI to DRV/r
89174282|NCT00759616|Experimental|1|
89174283|NCT00764686|Experimental|1|Low disease severity group
89174284|NCT00764686|Experimental|2|Higher disease severity group
89174285|NCT00764764|Active Comparator|I|Group I - Shoulder treatment only
89174286|NCT00764764|Experimental|II|Cervical and shoulder treatment
89174287|NCT00672490|Experimental|1|Quetiapine Fumarate - tablets
89174288|NCT00672490|Experimental|2|Quetiapine Fumarate - tablets and Lithium
89174289|NCT04048096|Placebo Comparator|Placebo|4g/day of mixed vegetable oil supplements
89174290|NCT04048096|Experimental|Krill|4g/day krill oil
89174291|NCT00922012|Experimental|Electromagnetic stimulation|Electromagnetic stimulation therapy
89235962|NCT03999060|Experimental|Electric Stimulation|
89235963|NCT00844181||0|white women
89235964|NCT00844181||1|Black women
89174292|NCT00759850|Active Comparator|A|Patient with ST elevation myocardial infarction randomly assigned to receive a Bare Metal Stent n=90)
89235965|NCT04042805|Experimental|Sintilimab Plus Lenvatinib|Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day (QD) plus sintilimab 200 mg intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89235966|NCT05643846|Active Comparator|(Group 1) will receive the intervention 'Bupivacaine at concentration of 0.125%, dose of 0.2 ml/kg'.|(Group 1) will receive bilateral QLB procedure with the intervention 'Bupivacaine local anesthetic drug at concentration of 0.125% concentration, at a dose of 0.2 ml/kg'.
89235967|NCT05643846|Active Comparator|(Group 2) will receive the intervention 'Bupivacaine concentration of 0.25%, dose of 0.2 ml/kg'.|(Group 2) will receive bilateral QLB procedure with the intervention 'Bupivacaine local anesthetic drug at a concentration of 0.25% concentration, at a dose of 0.2 ml/kg'.
89235968|NCT00841139|Experimental|Perhexiline|perhexiline 100mg bd for 1 month duration
89235969|NCT00841139|Placebo Comparator|Placebo|placebo one tablet bd for 1 month duration
89235970|NCT00841217|Placebo Comparator|1|placebo group
89235971|NCT00841217|Active Comparator|2|GW501516, 2.5mg
89235972|NCT00841295|Experimental|Carnitine|Intervention 'Parenteral L-carnitine supplementation' Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
89235973|NCT00841295|Placebo Comparator|Controle|Intervention 'Parenteral supplementation with sterile water'
89235974|NCT00851435|Experimental|KBPA-101, a monoclonal antibody|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
89235975|NCT00844259||Research Group|15 children with Down syndrome, observed in two interaction conditions: playing with their therapist (A) and playing with their caregiver (B).
89235976|NCT00844337|Active Comparator|1|One study arm will receive injectable gentamicin once daily and oral amoxicillin twice daily for seven days by comparison to other study arms.
89235977|NCT00844337|Active Comparator|2|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days
89235978|NCT00844337|Active Comparator|3|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days (COMPARISON ARM)
89235979|NCT00841373|Active Comparator|1|Panretinal Photocoagulation
89235980|NCT00841373|Active Comparator|2|Ranibizumab Supplementing Panretinal Laser Photocoagulation
89235981|NCT00844493|Experimental|H10407 challenge 1|7 or 8 logs of E. coli strain H10407 with CeraVacx buffer
89235982|NCT00844493|Experimental|H10407 challenge 2|7 or 8 logs of E. coli strain H10407 with bicarbonate buffer
89235983|NCT00844493|Experimental|H10407 challenge 3|6 logs of E. coli H10407 with bicarbonate buffer
89174293|NCT00759850|Experimental|B|Patient with ST elevation myocardial infarction randomly assigned to receive a Paclitaxel Eluting Stent (n=90)
89174294|NCT00759850|Experimental|C|Patient with ST elevation myocardial infarction randomly assigned to receive a Sirolimus Eluting Stent (n=90)
89174295|NCT02557984|Placebo Comparator|Placebo|Placebo Pill
89174296|NCT02557984|Experimental|Amisulpride|400 mg Amisulpride (Solian®)
89174297|NCT02557984|Experimental|Naltrexone|50 mg Naltrexone (Naltrexin®)
89235984|NCT00844493|Experimental|H10407 challenge 4|5 logs of E. coli H10407 with bicarbonate buffer
89235985|NCT00851513|Experimental|Group B|local anesthetics (lidocaine) associated with local steroids (depo-medrol)
89235986|NCT00851513|Experimental|Group C|local anesthetics (lidocaine) associated with local steroids (depomedrol) and important volumes of physiological serum
89235987|NCT00851513|Active Comparator|Group A|only local anesthetic (lidocaine)
89235988|NCT00841607|Experimental|Pancreaticojejunostomy|Pancreaticojejunostomy reconstruction used following Whipple surgery.
89235989|NCT00841607|Active Comparator|Pancreaticogastomy|Pancreaticogastomy reconstruction used following Whipple surgery.
89235990|NCT00844571||E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
89235991|NCT00844571||control group|
89235992|NCT00841841|Experimental|Dipyrone|"Analgesic affectiveness using Dipyrone (500mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
89235993|NCT00841841|Experimental|Acetaminophen|"Analgesic affectiveness using Acetaminophen (750mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
89235994|NCT02545751|Experimental|SBRT and Thymalfasin arm|SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
89235995|NCT00841919|Active Comparator|2|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
89235996|NCT00841919|Experimental|1|"The study group will receive Insulin Glargine as basal insulin and bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff"
88804658|NCT02291055|Experimental|Part B Expansion (Cervical): 10 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
89174298|NCT00759928|Experimental|Erlotinib/Sorafenib|Patients will receive erlotinib 150 mg once daily by mouth and sorafenib 400 mg twice daily by mouth. The study will begin with a 2-week run-in period (which will begin on Day 14 of the study, and continue through Day 1 of the study), in which erlotinib will be dosed alone at 150 mg once daily. Patients will continue taking erlotinib as a single agent at 150 mg once daily through Day 1. After the 2-week run-in period, patients will receive continuous dosing of both agents (erlotinib 150 mg once daily and sorafenib 400 mg twice daily) in cycles of 28 days each. Toxicity will be assessed every cycle (every 4 weeks) for all patients. Because this is not an efficacy study, restaging tumor measurements will be at the discretion of the physician every 8 weeks during treatment. Patients with objective response or stable disease will continue therapy; patients with disease progression or unacceptable toxicity will be discontinued from the study.
89174299|NCT00760162||HSCB, Brooklyn, NY|State University of New York Brooklyn, NY 11203
89174300|NCT00760162||2. Nephrology Associates,|Scarborough, ON CANADA, LI H IC5
89174301|NCT00760162||3.New York Harbor VA Medical Center|NYU School of Medicine New York, NY.10010
89174302|NCT00760162||4.Hospital Juarez De Mexico|Madero, Mexico, D.FC.P. 07760
89174303|NCT00760162||5. Hospital Italiano de Buenos Aires|Buenos Aires, Argentina.
89174304|NCT00760162||6. National Hospital|Abuja, Nigeria
89174305|NCT00670930|Active Comparator|omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single use, 5 ml vial that was designed to deliver 150 mg of omalizumab for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The dose administered was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and the number of injections and injection volume was determined using protocol-specified dosing tables. Omalizumab 75 to 375 mg was administered SQ every 2 or 4 weeks depending on the dose for the 78 weeks duration of double-blinded treatment.
89174306|NCT00670930|Placebo Comparator|Placebo|Omalizumab matching placebo was supplied as lyophilized, sterile powder in a single-use, 5 ml vial that was designed to deliver omalizumab matching placebo for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The number of injections and injection volume was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and was determined using protocol-specified dosing tables. Placebo was administered SQ every 2 or 4 weeks for the 78 weeks duration of double-blinded treatment.
89174307|NCT00670540||1|patients with suspected Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
89174308|NCT00770458||Pregnant women|Pregnant women that will undergo standard of care procedures to evaluate fetus for Down Syndrome
89174309|NCT00591786|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
89174310|NCT00591786|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
89174311|NCT00591786|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
89174312|NCT00591786|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
89174313|NCT00591786|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.8 mg/kg sugammadex was administered IV.
89174314|NCT00591786|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
89174315|NCT00591786|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
89174316|NCT00591786|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
89174317|NCT00591786|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
89174318|NCT00591786|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
89174319|NCT00770536|Experimental|Part 1|In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy [(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)].
89174320|NCT00770536|Experimental|Part 2|The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1
89174321|NCT00770614|Active Comparator|1|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
89174322|NCT00770614|Active Comparator|2|Isotonic Saline (0.9% sodium chloride) 1 mL/kg/h for 12 hours after the procedure
89174323|NCT00770614|Placebo Comparator|3|Placebo
89174324|NCT00765544|Experimental|Arm 1|Anklebot
89174325|NCT00765544|Experimental|Arm 2|Body-weight supported treadmill training
89174326|NCT00765544|Experimental|Arm 3|Combination therapy (Anklebot and BWSTT)
89174327|NCT04048174|Sham Comparator|Saline irrigation|"Each participant performed nasal saline irrigation at 2 periods:~Day -14 to Day 0~Day 14 to Day 28"
89174328|NCT04048174|Experimental|Probiotic lactococcus lactis W136 irrigation|Each participant performed Probiotic lactococcus lactis W136 nasal irrigation from Day 0 to D14
89174329|NCT00770926|Experimental|Program immediately|Receives the lifestyle program as soon as possible after randomization
89174330|NCT00770926|No Intervention|Wait list control|Wait one year and at the end of the year, is offered the option of participating in the program
89174331|NCT00771004|Experimental|Pioglitazone 30 mg to 45 mg QD|
89174332|NCT00771004|Placebo Comparator|Placebo QD|
89174333|NCT00765622||G2|G2 = control group (no incontinence)
89174334|NCT00765622||G1|G1 = urinary incontinence
89174335|NCT00760240||Glaucoma patients|This is a group of patients with restricted visual fields or ETDRS visual acuity of 20/60 or worse
89174336|NCT00760240||Retina patients|A group of patients with retinal pathology(ARMD, CME, diabetic retinopathy) contributing to their decreased vision.
89174337|NCT00674362|Experimental|Certolizumab pegol 200 mg (CDP870)|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
89174338|NCT00674362|Placebo Comparator|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
89174339|NCT00820950|Experimental|Cohort A: INCB018424 Ruxolitinib 0.5%|INCB018424 Ruxolitinib 0.5% vs vehicle applied once daily for 28 days
89174340|NCT00820950|Experimental|Cohort B: INCB018424 Ruxolitinib 1.0%|INCB018424 Ruxolitinib 1.0% vs vehicle applied once daily for 28 days
89174341|NCT00820950|Experimental|Cohort C: INCB018424 Ruxolitinib 1.5%|INCB018424 Ruxolitinib 1.5% vs vehicle applied twice for 28 days
89174342|NCT00820950|Experimental|Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene|INCB018424 up to 1.5% versus Dovonex® calcipotriene 0.005% cream applied BID for 28 days
89174343|NCT00820950|Experimental|Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate|INCB018424 up to 1.5% versus Diprolene ® AF betamethasone dipropionate 0.05% cream applied twice a day for 28 days
89174344|NCT00765934|Other|Rapydan|Internal control. Blood from both arms will be drawn. Only one arm of the subject is treated with Rapydan.
89174345|NCT04049344|Experimental|Combination of decitabine with oxaliplatin treatment|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
89174346|NCT00709176|Experimental|Brief|Dyads randomized to BRIEF arm received the Brief FOCUS Program (two home visits and one phone call by a trained nurse) in addition to standard clinical care.
89174347|NCT00709176|Experimental|Extensive|Dyads randomized to EXTENSIVE arm received the Extensive FOCUS Program (4 home visits and two phone calls by a trained nurse) in addition to standard clinical care.
89174348|NCT00709176|No Intervention|Control|Dyads randomized to CONTROL arm continued with standard clinical care.
89174349|NCT00670306|Experimental|Cetrorelix 78 mg|Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.
89174350|NCT00703248|Experimental|1|
89174351|NCT00703248|No Intervention|2|
89174352|NCT00709254|Active Comparator|Treatment Group A|Subjects received an i.v. dose of fentanyl (200 µg)
89174353|NCT00709254|Experimental|Treatment Group B|Subjects received a single dose of 3 mL AeroLEF (500 µg/1 mL)
89174354|NCT00709254|Experimental|Treatment Group C|Subjects received multiple doses of 3 mL AeroLEF (500 µg/1 mL) every 12 hours for a total of five doses over a 3 days
89174355|NCT00766012|Experimental|1|4 dose panels receiving a specified volume of AZD2066 oral solution once daily for 11 days
89174356|NCT00766012|Placebo Comparator|2|Included in each dose panel
89174357|NCT04048018||Active Tuberculosis Patient|
89174358|NCT04048018||High risk for LTBI Participant|
89174359|NCT04048018||Low risk for prior TB infection Participant|
89174360|NCT04048018||NTM patient|
89174361|NCT04048018||Precision patient|
89174362|NCT02558608|Experimental|WR AND DIPL|patients undergo wedge resection and dissection the inferior pulmonary ligament by thoracoscopic surgery or video assisted thoracoscopic surgery
89174363|NCT02558608|Active Comparator|WR|patients undergo wedge resection by thoracoscopic surgery or video assisted thoracoscopic surgery without dissection the inferior pulmonary ligament
89174364|NCT00672256|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
89174365|NCT02558686|Experimental|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
89174366|NCT02558686|Sham Comparator|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
89174367|NCT02558686|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
89174368|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
89174369|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant
89174370|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant + Rituximab|BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
89174371|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant|BEAM + Rituximab Followed by Stem Cell Transplant
89174372|NCT00766168|Active Comparator|Control|FluoroPerm 30 RGP lens daily wear
89174373|NCT00766168|Experimental|HDS HI 1.54|New rigid gas permeable contact lens material material
89174374|NCT02557828|Active Comparator|palpation|participants who are randomized to have radial arterial cannulation via palpation technique
89174375|NCT02557828|Active Comparator|ultrasound|participants who are randomized to have radial arterial cannulation via a new ultrasound technique
89174376|NCT00760396|Experimental|Group 1|40mg QD dose group
89174377|NCT00760396|Experimental|Group 2|100mg QD dose group
89174378|NCT00760396|Experimental|Group 3|200mg QD dose group
89174379|NCT00760396|Experimental|Group 4|200mg BID dose group
89174380|NCT00760630|Experimental|CDP LFC|all patients will have this calculation based upon diagnostic parameters with IVUS and FFR and/or CFR
89174381|NCT00771394|Placebo Comparator|1. Tamsulosin alone|
89174382|NCT00771394|Experimental|2. Tamsulosin + solifenacin (low dose)|
89174383|NCT00771394|Active Comparator|3. Tamsulosin + solifenacin (high dose)|
89174384|NCT00670228|Active Comparator|Intensive Insulin Therapy (IIT)|In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.
89174385|NCT00670228|Active Comparator|Standard Glycemic Care (SGC)|"In SGC arm subjects assigned to standard of care received subcutaneous regular insulin per sliding scale."
89174386|NCT02557360|Experimental|S-adenosyl-L-methionine|Patients with primary biliary cirrhosis will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
89174387|NCT00771628|Experimental|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
89174388|NCT00771628|Active Comparator|2 Malleable|
89174389|NCT00766246|Experimental|First-line|Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
89174390|NCT00766246|Experimental|Maintenance|Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
89174391|NCT00766402|Experimental|Tramadol/Acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
89174392|NCT00766402|Active Comparator|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
89174393|NCT00771706|Experimental|Proton Pump Inhibitor|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
89174394|NCT00771706|Placebo Comparator|Sugar Pill|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough
89174395|NCT00771784||1|Short term endotracheal intubation.
89174396|NCT00771784||2|Long term endotracheal intubation.
89174397|NCT00771862|Placebo Comparator|1. standard care|1 day of perineural ropivacaine 0.2% infusion followed by 4-5 days of normal saline infusion.
89174398|NCT00771862|Active Comparator|2: experimental care|4-5 days of perineural ropivacaine 0.4% infusion.
89174399|NCT00771940|Active Comparator|Ghrelin|
89174400|NCT00772096|Experimental|Verum|
89174401|NCT00772096|No Intervention|No treatment|
89174402|NCT00760708||undergoing persantine stress test|
89174403|NCT00760786|Active Comparator|1|Intensive lipid lowering plus Omega3-fatty acid
89174404|NCT00760786|Active Comparator|2|Moderate lipid lowering plus Omega3-fatty acid
89174405|NCT00760786|Active Comparator|3|Intensive lipid lowering plus placebo
89174406|NCT00760786|Active Comparator|4|Moderate lipid lowering plus placebo
89174407|NCT00760864|Experimental|TAK-715 25 mg BID|
89174408|NCT00760864|Experimental|TAK-715 50 mg BID|
89174409|NCT00760864|Experimental|TAK-715 100 mg BID|
89174410|NCT00760864|Active Comparator|Methotrexate|
89174411|NCT00766480|Experimental|Regimen 1|Patients receive low-dose cisplatin IV on days 1 and 29 and low-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy on days 1-4 and 29-32. Patients undergo salvage surgery if needed.
89174412|NCT00766480|Experimental|Regimen 2|Patients receive high-dose cisplatin IV on days 1 and 29 and high-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy and salvage surgery as in regimen 1.
89174413|NCT00766558||1 Disclosure|Traumatic writing prompts provided. Participant is assigned a potential stress-producing topic for written disclosure.
89174414|NCT00766558||2 control|Received nontraumatic writing prompts. Participant assigned a non-stressful writing condition
89174415|NCT00772174|Experimental|Pioglitazone + Metformin|
89174416|NCT00772174|Active Comparator|Metformin|
89174417|NCT00772252||1|patient with hepatic failure undergoing liver support treatment in surgical intensive care unit
89174418|NCT02557282||Predicate software|Olea Sphere PACS with CT Perfusion Module
89174419|NCT02557282||Investigational software|Vue PACS 12.1.5 Computed Tomography (CT) Perfusion
89174420|NCT00766714|Experimental|1|Cook K-SOFT-5100 catheter
89174421|NCT00766714|Active Comparator|2|Frydman classical catheter
89174422|NCT00772408||TB|patients with pulmonary TB
89174423|NCT00772408||control|healthy controls
89174424|NCT00772486|Experimental|Experimental: ISF35 and FCR|ISF35 and FCR
89174425|NCT00766792|Experimental|1|Nocturnal dialysis
89174426|NCT00766792|Active Comparator|2|Standard dialysis
89174427|NCT00772564|Experimental|Atorvastatin 80 mg|
89174428|NCT00772564|Experimental|Atorvastatin 10 mg|
89174429|NCT00766870|Experimental|1|
89174430|NCT00766870|Experimental|2|
89174431|NCT00766870|Experimental|3|
89174432|NCT00766870|Other|4|
89174433|NCT00766870|Placebo Comparator|5|
89174434|NCT00775216|No Intervention|Standard care|Standard behavioral counseling
89174435|NCT00775216|Experimental|Intervention|"Behavioral counseling intervention augmented with an interactive health promotion telephone helpline"
89174436|NCT00766948||No Treatment|
89174437|NCT00775294|Experimental|maraviroc|Single arm trial looking at the pharmacokinetics of maraviroc in healthy volunteers.
89174438|NCT00772876|Experimental|P1446A-05|Single arm of the study drug. This being a dose escalation study, patient will receive a dose depending on the stage of the trial.
89174439|NCT00767026|Experimental|1|
89174440|NCT00767026|Active Comparator|2|
89174441|NCT00570778|Experimental|indacaterol/glycopyrrolate 300/50 μg|One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
89174442|NCT00570778|Active Comparator|indacaterol 600 μg|Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
89174443|NCT00570778|Active Comparator|indacaterol 300 μg|One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
89174444|NCT00570778|Placebo Comparator|placebo|Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
89174445|NCT00775372|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
89174446|NCT00775372|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
89174447|NCT00668746|Experimental|Minocycline HCl microspheres|Minocycline HCl microspheres
89174448|NCT00668746|No Intervention|No drug intervention|No drug intervention
89174449|NCT00767182||Pregnant patients with VPP antecedent|Pregnancy women consulting for an scan during their 12th week of amenorrhea at the University Hospital of Saint Etienne will be studied in this clinical trial. They have an history of VPP (Vascular Placental Pathology). They will have to give a blood sample.
89174450|NCT04047940|Experimental|LY900020 Formulation 1|LY900020 Formulation 1 administered orally
89174451|NCT04047940|Experimental|LY900020 Formulation 2|LY900020 Formulation 2 administered orally
89174452|NCT04047940|Experimental|LY900020 Formulation 3|LY900020 Formulation 3 administered orally
89174453|NCT04047940|Active Comparator|Reference Drugs|Metformin XR, atorvastatin, and valsartan administered orally
89174454|NCT00773110|Experimental|1 Albumin|Priming of the cardiopulmonary bypass circuit with 20% human albumin solution prior to surgery
89174455|NCT00773110|Placebo Comparator|2 Gelofusin|Priming of the cardiopulmonary bypass circuit with gelofusin prior to surgery
89174456|NCT00773188|Experimental|1|
89174457|NCT00767260|Experimental|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
89174458|NCT00767260|Experimental|BM-MNC|Autologous Bone Marrow mononuclear cell Infusion
89174459|NCT00767260|Experimental|HOT|hyperbaric oxygen therapy
89174460|NCT00767260|Active Comparator|Control|stand medical therapy (enhanced hemoglucose monitor, health and diet counseling and insulin injection)
89174461|NCT02557126|Experimental|URC102|URC102
89174462|NCT02557126|Placebo Comparator|Placebo|Placebo
89174463|NCT00767494|Experimental|1|Travoprost/Brinzolamide AM, Vehicle PM
89174464|NCT00767494|Experimental|2|Travoprost/Brinzolamide PM, Vehicle AM
89174465|NCT00767494|Active Comparator|3|AZOPT AM and PM
89174466|NCT00767494|Active Comparator|4|TRAVATAN PM, Vehicle AM
89174467|NCT00773500||1|Providers adopting electronic prescribing in New York City, New York
89174468|NCT00773500||2|Providers adopting electronic prescribing in the Taconic region of New York
89174469|NCT00773578||1|atopic asthmatic children exposed to environmental tobacco smoke
89174470|NCT00773578||2|atopic asthmatic children unexposed to environmental tobacco smoke
89174471|NCT02557204|Active Comparator|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
89174472|NCT02557204|Experimental|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
89174473|NCT02557204|Experimental|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
89174474|NCT02557204|Experimental|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
89174475|NCT00773656||1|patients treated for a prostate adenocarcinoma
89174476|NCT00775762|Active Comparator|aspirin|
89174477|NCT00775762|Active Comparator|clopidogrel|
89174478|NCT00775762|Active Comparator|clopidogrel plus aspirin|
89174479|NCT00775840|Experimental|Candesartan QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
89174480|NCT00775840|Placebo Comparator|Placebo QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
89174481|NCT00775918|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
89174482|NCT00775918|Active Comparator|2|Adoxa ® 100 mg tablets of Bradley Pharmaceuticals Inc
89174483|NCT00878189|Experimental|1|
89174484|NCT00775996|Experimental|1|15 mg clorazepate dipotassium tablets of ranbaxy
89174485|NCT00775996|Active Comparator|2|(TranxeneeT-Tab®) 15 mg clorazepate dipotassium tablets
89174486|NCT00773812|Experimental|Active Mecamylamine|There will be 12 children in this arm. These children will receive the active medication (mecamylamine).
89174487|NCT00773812|Placebo Comparator|Placebo|There will be 8 children in this arm. These children will receive placebo instead of the active medication.
89174488|NCT00773890|Experimental|TRF-1101|Daily treatment with TRF-1101
89174489|NCT00773890|Placebo Comparator|Placebo|Daily treatment with placebo
89174490|NCT00767728|Active Comparator|1|Mesalamine pellets
89174491|NCT00767728|Placebo Comparator|2|Placebo
89174492|NCT00774124|Experimental|1 Telemedicine|Usual care plus telemonitoring
89174493|NCT00774124|Active Comparator|2 Standard of Care|Standard of care - women will monitor and record blood glucose levels four times a day.
89174494|NCT00776074|Experimental|Leuprorelin (GF)|
89174495|NCT00776074|Experimental|Leuprorelin (GC)|
89174496|NCT02628587|Experimental|Generic clopidogrel|Patients are assigned to take generic clopidogrel
89174497|NCT02628587|Active Comparator|Patent clopidogrel|Patients are assigned to take patent clopidogrel (Plavix)
89174498|NCT04162457|Experimental|Stevia beverage|Participants receive 4 study beverages in the 4 imaging sessions in randomised and counterbalanced order.
89174499|NCT04162457|Experimental|Glucose beverage|330 ml of water with glucose (equal sweetness with the stevia beverage)
89174500|NCT04162457|Experimental|Maltodextrin beverage|330 ml of water with maltodextrin (equal amount of calories as the glucose beverage)
89174501|NCT04162457|Placebo Comparator|Water|330 ml water
89174502|NCT02634437|Experimental|Normal Renal Function|Ulipristal acetate, 10 mg, oral administration
89174503|NCT02634437|Experimental|Moderate Renal Impairment|Ulipristal acetate, 10 mg, oral administration
89174504|NCT02634437|Experimental|Severe Renal Impairment|Ulipristal acetate, 10 mg, oral administration
89174505|NCT00668200|Other|zoledronic acid|5 mg of Reclast (ZOL446, zoledronic acid) injection in 100 mL ready to infuse solution administered intravenously via a vented line. The infusion time was to be not less than 15 minutes given over a constant infusion rate.
89174506|NCT00675779|Experimental|2|oral contraceptive + atorvastatin
89174507|NCT00675779|Active Comparator|1|oral contraceptive
89174508|NCT00774280|No Intervention|ArmI(BuCy)|"Intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4~Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2"
89174509|NCT00774280|No Intervention|Arm II (BuFlu)|"Intravenous busulfan 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4.~Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2"
89174510|NCT04151147|Experimental|CGF application in the extraction socket|Partially impacted third molar was extracted with the help of straight elevator and third molar forceps. After extraction, any remains of the dental follicle were removed and the extraction sockets were irrigated with 60 mL of sterile saline. CGF fibrin gel was then randomly placed into one socket and wound closure was completed with silk suture.
89174511|NCT04151147|Experimental|non-CGF application in the extraction socket|Opposite side of the patient was considered as the control. After extraction of the third molar, dental follicle were removed and to prevent the flap laceration, bone contouring was also performed under sterile saline irrigation. Finally, wound closure was completed with silk suture.
89174512|NCT00774358|Experimental|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
89174513|NCT02627417|Experimental|Dapsone: (Disulone®)|Dapsone: Disulone® given orally at 100 mg per day
89174514|NCT02627417|Active Comparator|"Prednisone (Cortancyl®) alone and standard of care"|"Prednisone (Cortancyl®) alone at 1 mg/kg for 3 weeks followed by monitoring and standard of care (control arm)"
89174515|NCT00774436|Experimental|Patients scheduled to receive Focal Cryotherapy|After enrollment, patients will undergo a repeat transrectal ultrasound- guided prostate biopsy (minimum of 12 cores) to confirm the low-risk nature of their cancer. For study purposes, patients must meet the original entry crieteria on this repeat biopsy. If the patient meets the repeat-biopsy enrollment criteria, they will be treated with focal cryotherapy, meaning cryoablation of the regions of the prostate containing cancer. Efficacy is defined as all negative biopsy cores at the site of the focal ablation on a repeat transrectal biopsy 6 months after cryoablation. At baseline (prior to the re-staging biopsy), 3 months after focal cryotherapy, and at 6 months after focal cryotherapy (prior to the repeat prostate biopsy used to define efficacy), the patient will complete quality of life questionnaires as standard for all patients in the Urology Service.
89235997|NCT00851669|Experimental|IPT|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
89235998|NCT00851669|Active Comparator|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
89235999|NCT04214327|Active Comparator|Strengthening Families Program Online eLearning Game|This arm of the study receives a 10-session online family-based intervention with separate, but intersecting, tracks for parents and youth. Each lesson contains 3 mini-lessons per week and includes behavioral skills training and interactive multimedia lessons with video vignettes that target parenting skills, family cohesion, organization, communication, social skills, and drug prevention for youth. The youth track is highly gamified to stimulate engagement and reinforce the core active ingredients. There are self-correcting quizzes to assess learning, and process evaluation to determine program fidelity and engagement. There are learning theory instructional design elements with scaffolding, stealth learning, and theoretical principles of social learning, social interactional, and family systems theory. There is a highly animated game families can play upon successful completion of each lesson, using game points they earned through quizzes and practices. There is a 3-month follow-up.
89236000|NCT04214327|Active Comparator|SFP Home-use DVD/video series|"This arm of the study receives an 11-session home-use DVD or coupon code for viewing the SFP videos online at home that contains the same SFP skills and lesson content as the online condition. However, the lesson material is not animated and involves simply viewing the videos at home. This arm represents an attention-control condition as the requirements of participation and exposure to the intervention will match the online condition, as participants use the Internet or a DVD player to view lesson material in a self-paced format. There are no differences in recruitment for this condition; all assignment to experimental conditions is based on their recruiter's location using a randomized control trial design. Participants in this condition will be provided a hyperlink URL to answer pre- and posttest assessments and at the 3-month follow-up. Process evaluation materials will be delivered via a hyperlink to a commercial survey vendor during the trial and at the conclusion."
89236001|NCT04214327|Active Comparator|Wait-Listed Control|"This arm of the study receives no active intervention for the initial intervention period of 11 weeks; however, following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention. During the initial trial of 11 weeks, participants in this condition receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. The intent of these weekly emails is to stimulate continued participation and reduce attrition.~Individual families will be randomly assigned to one of the three interventions with a computerized random number generator."
89236002|NCT04214327|No Intervention|SFP Group Norms|This arm of the study provides a means to conduct a non-inferiority trial contrasting the active intervention conditions (SFP Online and Home-use DVD/videos) to the traditional 14-session in-person group-delivery format, which serves as a benchmark of effectiveness for SFP. There is no data collection as the Group Norms are part of an existing database of families that already took SFP classes. All effect size comparisons are conducted using secondary data analysis. The expected margin of equivalence is set at 10% so that any condition that exceeds another in the magnitude of effect size is considered as 'good as' the comparison condition. All effect sizes will be adjusted for demographic and site-specific factors to control for clustering and within-site contextual factors that can influence program outcomes.
89236003|NCT00851981|Placebo Comparator|1|
89236004|NCT00851981|Active Comparator|SAMe|
89236005|NCT00852059|Experimental|Immediate release|Treatment with immediate release (IR) methylphenidate (Medikinet®) in the morning and 3-4 h later (twice a day)
89236006|NCT00852059|Active Comparator|Extended release|Treatment with extended release (ER) methylphenidate (Medikinet reatard®) applied with breakfast(once daily)
89236007|NCT00844727|Active Comparator|1|Rofexocib 25 mg OD, 1 year treatment
89236008|NCT00844727|Placebo Comparator|2|Placebo
89236009|NCT00844961|Experimental|Internet CBT|10 weeks of internet delivered cognitive behaviour therapy
89236010|NCT00844961|No Intervention|Waiting list|Waiting list which is offered treatment after completion of post intervention assessments
89236011|NCT00845117|Experimental|Limbal Stem Cell Transplant|The cornea is debrided of all superficial fibrovascular tissue and the cultivated stem cell graft is glued onto the cornea.
89236012|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 750 milligram (mg) orally administered every 8 hours (hr) for 12 weeks, in combination with standard treatment composed of pegylated interferon (Peg-IFN)-alfa-2a solution for subcutaneous injection at the dose of 180 microgram per week (mcg/week) and ribavirin (RBV) oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
89236013|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 750 mg orally administered every 8 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kilogram/week (mcg/kg/week) and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
89236014|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2a solution for subcutaneous injection at the dose of 180 mcg/week and RBV oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
89236015|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kg/week and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
89236016|NCT00620555|Experimental|gabapentin|
89236017|NCT00845273||Pegaptanib sodium|Patients administered Pegaptanib sodium.
89236018|NCT00845351|Experimental|Bexarotene|Bexarotene 300 mg/m2/day times 5 days
89236019|NCT00529386|Experimental|Botox|300 IU botox
89236020|NCT02546141|Active Comparator|skimmed milk (UHT)|portion size that contains 25 g of protein, oral, single administration
89236021|NCT02546141|Active Comparator|skimmed milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
89236022|NCT02546141|Active Comparator|skimmed yoghurt|portion size that contains 25 g of protein, oral, single administration
89174516|NCT02556892|Experimental|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
89174517|NCT00774514|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
89174518|NCT00774514|Experimental|NO2 exposure|1 hour exposure to nitrogen dioxide at 4ppm during intermittent exercise
89174519|NCT00679679|Experimental|Metformin|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
89174520|NCT00679679|Placebo Comparator|Placebo|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
89174521|NCT00774592|Experimental|1|Focus on Youth in the Caribbean (FOYC) plus Caribbean Informed Parents and Children Together (CImPACT)
89174522|NCT00774592|Experimental|2|FOYC plus Goal For It (GFI)
89174523|NCT00774592|Active Comparator|3|Wonderous Wetlands plus GFI
89174524|NCT00774592|Experimental|Grade 10-BFOOY+CImPACT|Youth receives HIV intervention; parents receive parental monitoring intervention
89174525|NCT00774592|Experimental|Grade 10 BFOOY+GFI|Youth receive HIV prevention intervention and parents receive attention control intervention on career planning
89174526|NCT00774592|Experimental|BFOOYand no parent intervention|Youth receive HIV prevention intervention; parents receive no intervention
89174527|NCT00774592|Placebo Comparator|Health and FAmily life|Youth receive standard of care (current curriculum); parents receive no intervention
89174528|NCT00838578|Experimental|KRN330 + Irinotecan|open label, single arm
89174529|NCT00774826|Experimental|1|R-CVP x 3; Restaging if> RP then R-CVP x 5
89174530|NCT00774826|Experimental|2|R-CHOP x 3; Restaging if > RP then R-CHOP x 3 plus 2 Rituximab
89174531|NCT00774826|Experimental|3|R-FM x 3; Restaging if > RP then R-FM x 3 plus 2 Rituximab
89174532|NCT00656981|Experimental|Arm 1|
89174533|NCT00656981|Placebo Comparator|Arm 2|
89174534|NCT02634515|Experimental|Julphar Insulin R|Julphar Insulin R, soluble human insulin, biosimilar, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
89174535|NCT02634515|Active Comparator|Huminsulin® Normal|Huminsulin® Normal, soluble human insulin, reference, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
89174536|NCT00705900|Experimental|1|LCD Solution: 2 applications / day
89174537|NCT00705900|Active Comparator|2|Calcipotriol cream: 2 applications / day
89174538|NCT00679835|Experimental|Group 1|8 mg/kg over a one hour infusion
89174539|NCT00679835|Experimental|Group 2|10mg/kg over a one or two hour infusion
89174540|NCT00829296|Experimental|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
89174541|NCT00829296|Active Comparator|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
89174542|NCT00774982|Experimental|1 6MP Test Formulation|1 x 40 mg Oral Tablet, 6 MP Delayed Release Test Formulation, for targeted ileal delivery
89174543|NCT00774982|Active Comparator|2. 6MP Reference Formulation|2 x 50 mg oral tablet, PURINETHOL
89174544|NCT00881621|Experimental|Lapatinib and Capecitabine|Treatment
89174545|NCT02634281|Experimental|group A|Subjects in Group A will receive varenicline for six weeks .During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
89174546|NCT02634281|Active Comparator|group B|group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
89174547|NCT00818766|Active Comparator|Antibiotic|Participants received intravenous (IV) cefazolin or vancomycin (for participants allergic to cephalosporin) immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
89174548|NCT00818766|Placebo Comparator|Placebo|Participants received IV placebo-matching antibiotics immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
89174549|NCT00779272||1|Without preoperative chemotherapy
89174550|NCT00779272||2|With preoperative chemotherapy
89174551|NCT00779350|Experimental|1|sertraline 100 mg tablets of ranbaxy
89174552|NCT00779350|Active Comparator|2|Zoloft® 100 mg tablets
89174553|NCT00680537|No Intervention|1|Control group
89174554|NCT00680537|Experimental|2|Exercise group
89174555|NCT00705978|Experimental|1|
89174556|NCT00705978|Placebo Comparator|2|
89174557|NCT04150835|Experimental|Xingnaojing|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
89174558|NCT04150835|Placebo Comparator|Placebo|Subjects will receive intravenously administered Xingnaojing placebo, combined with guidelines-based standard care.
89174559|NCT00667888|Active Comparator|Intensity Modulated Radiotherapy (IMRT)|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
89174560|NCT00667888|Experimental|Hypofractionated Intensity Modulated Radiotherapy (HIMRT)|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
89174561|NCT00680615|Experimental|Usual Care|
89174562|NCT00680615|Experimental|Enhanced|
89174563|NCT02556970|Experimental|Single-port surgery|"After induction of anaesthesia and lung isolation, a single intercostal incision will be placed laterally. This will usually be anterior to the border of the latissimus dorsi muscle, and in the 4th-7th space as appropriate to the planned surgery.~A soft tissue wound protector can be used to protect the wound edges, but rigid intercostal retraction is not permitted. All instruments will be placed via this incision."
89174564|NCT02556970|Active Comparator|Multiple port surgery|Patients in this arm will have 3 separate incisions placed to site the camera and other instruments. This will involve three separate incisions.
89174565|NCT00594815|Experimental|1|
89174566|NCT00776542|Experimental|1|Minocycline 100 mg tablets of ranbaxy
89174567|NCT00776542|Active Comparator|2|Minocin 100mg tablets
89236023|NCT02546141|Active Comparator|full-fat milk (UHT)|portion size that contains 25 g of protein, oral, single administration
89174568|NCT04150679|Active Comparator|group I retrospective non access loop|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy without access loop
89174569|NCT04150679|Active Comparator|GROUP II access loop group|patients with iatrogenic bile duct injuries, cases treated with hepaticojejunostomy with duodenojejunostomy access loop
89174570|NCT00776620|Experimental|1|Glimepiride 1 MG Tablets of Ranbaxy
89174571|NCT00776620|Active Comparator|2|AMARYL® 1 mg tablets
89174572|NCT00680693|Experimental|1|Mindfulness-based stress management 8-week program
89174573|NCT00680693|Active Comparator|2|Psycho-educational support group for women with IBS
89174574|NCT00776698|Experimental|1|
89174575|NCT04161833|Experimental|OPERA|Women receiving adjuvant aromates-inhibitor with arhtralgia grade ≥ 1 (CTACAE 4.03)
89174576|NCT00680147|Experimental|Brief HPV vaccine informational intervention|Because we anticipated that knowledge and awareness of the HPV vaccine would be low in our study population, our CASI survey included a brief, informational overview of key facts concerning HPV vaccination prior to assessing vaccine acceptance, perceived barriers to vaccination, and intentions to vaccinate. The overview lasted approximately 3 minutes and consisted of a brief overview of key HPV vaccination facts that were presented visually (on the computer screen) and read aloud using a digital recording. HPV and vaccine knowledge, awareness, and attitudes items were administered prior to participants hearing the informational overview.
89174577|NCT02634047|Active Comparator|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
89174578|NCT02634047|Experimental|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
89174579|NCT00680849||1|Treatment condition from first study. This is a follow-up study.
89174580|NCT00680849||2|Control condition from first study.
89174581|NCT00680303|Experimental|1|The child will receive the Lidcombe Program 2x per week
89174582|NCT00680303|Experimental|2|The child will receive the Lidcombe Program once every 2 weeks (fortnightly visits)
89174583|NCT00680303|Other|3|The child will receive the standard Lidcombe Program once per week (control)
89174584|NCT04150757|No Intervention|Standard Analgesia|"Patients receiving no intervention will receive no intranasal ketamine while awaiting intravenous line placement for parenteral pain control."
89174585|NCT04150757|Active Comparator|Intranasal Ketamine + Standard Analgesia|Enrolled patients will receive one dose of Intranasal Ketamine dosed at 1mg/kg (Ketamine 500mg/10 mL solution) after triage while waiting for IV placement (max 50mg).
89174586|NCT04150211|Active Comparator|Exten(d)|Subjects have to take Exten(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
89174587|NCT04150211|Placebo Comparator|Placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks.
89174588|NCT04150367||Study group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive intravenous treatment with Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
89174589|NCT04150367||Control group|Patients with first diagnosed widespread destructive pulmonary tuberculosis with bacterial excretion, who receive oral forms of Isoniazid, Rifampicin, Ethambutol first two months of intensive phase of tuberculosis treatment. Then group receives oral treatment of tuberculosis according to the known scheme.
89174590|NCT02627339||Healthy controls|Healthy controls age 10 to 90 years
89174591|NCT02634203|Experimental|Balloon Pulmonary Angioplasty (BPA)|Non-operable patients with CTEPH allocated to BPA arm
89174592|NCT02634203|Active Comparator|Riociguat|Non-operable patients with CTEPH allocated to Riociguat arm
89174593|NCT00680381|Active Comparator|1|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly therapist phone calls for eight weeks.
89174594|NCT00680381|Active Comparator|2|Following 12 weeks of FFT, weekly one-hour group therapy for eight weeks
89174595|NCT00680381|Active Comparator|3|Following 12 weeks of FFT, an eight-week, customized series of therapist visits with the adolescent, family, teachers, coaches and others who can support the adolescent's reduced level of drug use.
89174596|NCT04161521|Other|Placenta Accreta patients|of 60 pregnant female diagnosed as placenta previa accreta recuirted from Obstetrics and Gynecology Department , Menoufia University Hospital.
89174597|NCT00681005|Active Comparator|Rabeprazole|Rabeprazole 1 # qd
89174598|NCT00681005|Active Comparator|pantoprazole|Pantoprazole 1# qd
89174599|NCT04150055|Experimental|Intervention|Everyone in the study will get Mindfulness Coach and an orientation session. Mindfulness Coach is a self-guided mHealth intervention designed to help individuals learn MT, an evidence-based treatment to enhance health, wellness and mental health. The intervention will be introduced during 1 in-person session by a trained research assistant with 1-2 booster instructional phone call at 7 and 14-days to ensure that the participant knows how and is encouraged to use the app. The participant will also be provided with a laminated card that provides the basic instructions. We will encourage the participant to use Mindfulness Coach weekly for 8 weeks, or more if desired, as this treatment dose is commensurate with most in-person MT psychotherapy treatment protocols.
89174600|NCT00681161|Other|A|
89174601|NCT00912353|Experimental|AZD7268|
89174602|NCT00912353|Placebo Comparator|Placebo|
89174603|NCT02633969|Experimental|Indomethacin Capsules low dose|Indomethacin Capsules low dose twice daily for up to three days
89174604|NCT02633969|Experimental|Indomethacin Capsules high dose|Indomethacin Capsules high dose twice daily for up to three days
89174605|NCT00684827|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose"
89174606|NCT00684827|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose.
89174607|NCT04149119|Experimental|Intervention arm|ATSB+LLINs+Standard Care for Malaria case management
89174608|NCT04149119|No Intervention|Standard arm or arm 2|LLINs+Standard Care for MalarIA case management
89174609|NCT00820170|Experimental|dasatinib and paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.~The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel."
89174610|NCT00681239|Experimental|A|Patients will receive the modified Atkins diet in combination with a 10 oz KetoCal shake for the first month. The second month no shake will be given. Results at 1 month will be compared to 2 months, as well as to historical controls with the modified Atkins diet.
89174611|NCT02627027|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)
89174612|NCT02627027|Experimental|TR group|T: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)
89174613|NCT00681317|Experimental|1|
89174614|NCT00913536|Experimental|Cone beam CT in Bladder Cancer|
89174615|NCT00685061|Experimental|A|Thymoglobulin Induction
89174616|NCT00685061|Experimental|B|Campath-1H Induction
89174617|NCT00685061|Experimental|C|Daclizumab Induction
89174618|NCT02633813|Experimental|Naftifine hydrochloride 2%|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
89174619|NCT02633813|Active Comparator|Naftin® 2% (Naftifine hydrochloride 2%)|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
89174620|NCT02633813|Placebo Comparator|Placebo vehicle cream.|A thin layer of sufficient quantity of vehicle cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
89174621|NCT02626247|Active Comparator|Vitamin A + Long chain PUFA|The test product is a food supplement containing Vitamin A + Long chain Poly Unsaturated Fatty Acids (PUFA). It is presented as a hard shell capsule containing lipophylic nutrients.
89174622|NCT02626247|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
89174623|NCT02627105|Experimental|Beef group|Subjects in this group are asked to consume 4 or more servings of beef per week and to exclude all other red meats from their diet for the 6 month study.
89174624|NCT02627105|Other|Non-beef group|Subjects in this group are asked to avoid all red meats from their diet for the 6 month study.
89174625|NCT02626403|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (bilateral fronto-parietal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
89174626|NCT02626403|Sham Comparator|sham tDCS|Patients will receive sham tDCS (15 second of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
89174627|NCT02611440|Experimental|Pharmacist Intervention|It will be a semi -structured interviews with patient and pharmacist over various time after the stroke (at Month0, M3, M6, M9) combined with patient's therapeutic follow-up from various healthcare professionals.
89174628|NCT02611440|No Intervention|Control|No pharmacist intervention planned.
89174629|NCT00828984|Experimental|Arm A (high-dose PEG 3350)|Patients receive high-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
89174630|NCT00828984|Experimental|Arm B (low-dose polyethylene glycol)|Patients receive low-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
89174631|NCT00828984|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
89174632|NCT05758584|Experimental|Group 1|Vibrating tourniquet group
89174633|NCT05758584|Experimental|Group 2|Distraction cards group
89174634|NCT05758584|No Intervention|Group 3|Control group
89174635|NCT00828750|Experimental|Treatment|Eltrombopag oral tablets once daily
89174636|NCT05758740|Experimental|E-health enhanced behavioural change intervention|The investigators will administer e-health behavioural change techniques (e.g., automated advice, tele-counselling, digital-tailored advice) on top of the conventional behavioural change techniques (e.g., information provision, goal setting) via digital devices (i.e., smartphone) to promote moderate-to-vigorous physical activity of the participants.
89174637|NCT05758740|Active Comparator|Conventional behavioural change intervention|The investigators will administer conventional behavioural change techniques (e.g., information provision, goal setting) via conventional methods (i.e., face-to-face meetings) to promote moderate-to-vigorous physical activity of the participants.
89174638|NCT05306808|Experimental|center-based exercise|Participants in intervention group will attend a program combining 24 sessions of physiotherapy and 10 sessions of educational class over 12 weeks.
89174639|NCT05306808|No Intervention|exercise on his/her own|Participants in control group will be asked to exercise on their own, they will only attend 10 sessions of educational class over 12 weeks.
89174640|NCT04030494|Other|Blood pressure (BP)|Group for the validation of blood pressure measurement by the device
89174641|NCT04030494|Other|Atrial fibrillation (AF)|Group for the validation of detection of AF by the device
89174642|NCT04030494|Other|Valvular heart disease (VHD)|Group for the validation of detection of VHD by the device
89236024|NCT02546141|Active Comparator|non-homogenized full-fat milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
89236025|NCT02546141|Active Comparator|full-fat cheese (semi-matured)|portion size that contains 25 g of protein, oral, single administration
89236026|NCT02546141|Active Comparator|whey protein|portion size that contains 25 g of protein, oral, single administration
89236027|NCT02546141|Active Comparator|micellar casein|portion size that contains 25 g of protein, oral, single administration
89236028|NCT05213286|Other|Patients referred for assessment of ASD, non-ASD psychiatric patients and control group|All three groups will be tested with RAADS-R-DK and ZAQ. The results from these diagnostic tests will be compared to gold standard clinical assessments in specialized multidisciplinary teams
89236029|NCT00845585|Active Comparator|Owniflow II|
89236030|NCT00845585|Active Comparator|PTFE|
89236031|NCT03875118|Experimental|The intervention group|Subjects in the intervention group received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
89236032|NCT03875118|Active Comparator|The control group|Subjects in the control group also received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
89236033|NCT00845819|Active Comparator|EGF|rhEGF + povidone iodine, chlorhexidine, & nystatin
89236034|NCT00845819|Placebo Comparator|Placebo|Placebo + povidone iodine, chlorhexidine, & nystatin
89236035|NCT02546843|Experimental|Group A|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid sequence induction).~maintaining the depth of neuromuscular blockade - rocuronium: the appropriate depth of the block will be maintained with repeated boluses of rocuronium 0.3 mg/kg according to TOF 0, PTC 0-1.~Specific Neuromuscular Blockade reversal will be performed with Sugammadex intravenously. The proper dosage of sugammadex will depend on the depth of the blockade:at TOF -1-2 (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered"
89236036|NCT02546843|Active Comparator|Group B|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with cisatracurium 0.15mg/kg intravenously.~Maintaining the depth of neuromuscular blockade - cisatracurium:the appropriate depth of the block will be maintained with repeated boluses of cisatracurium 0.03 mg/kg - according to TOF maintaining of muscular relaxation TOF 1.~Nonspecific Neuromuscular Blockade reversal will be performed with neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously, the reversal will be applicated in case of TOF 1 or higher."
89236037|NCT00842387||1|Patients with symptoms suggestive of GERD, managed according to a new structured and implemented pathway
89236038|NCT00842387||2|Patients with symptoms suggestive of GERD, managed according to usual clinical practice.
89236039|NCT00529308|Active Comparator|Active|
89236040|NCT00529308|Sham Comparator|Sham|
89236041|NCT03999840|Experimental|IMP|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
89236042|NCT03999840|Placebo Comparator|Placebo|Cemdisiran (600 mg) or placebo will be administered subcutaneously every four weeks up to week 32 (end of the Core Study).
89236043|NCT05000424|Experimental|Intervention|Participants in this group will receive a fragrant plant based massage oil with the addition of clary sage essential oil. The massage oil will be massaged into the upper thighs daily for the duration of the third trimester.
89236044|NCT05000424|Placebo Comparator|Control|Participants in this group will receive a fragrant plant based massage oil. The massage oil will be massaged into the upper thighs daily for the duration of the third trimester.
89236045|NCT03875508|Experimental|Risankizumab|Risankizumab solution (150 mg/mL) for injection; self-administered subcutaneously via a pre-filled autoinjector at Weeks 0, 4, 16, and 28
89236046|NCT03998982|Active Comparator|glycyrrhetinic acid Combining HD-DXM|Compound glycyrrhizin tablets 75mg three times per day, 1 month, and HD-DXM (orally at 40 mg daily for 4d )
89236047|NCT03998982|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
89236048|NCT04991766|Experimental|[¹⁴C]-LY3484356 (Part 1)|Single dose of [¹⁴C]-LY3484356 administered orally.
89236049|NCT04991766|Experimental|LY3484356 + [¹⁴C]-LY3484356 (Part 2)|Single dose of LY3484356 administered orally followed by Single dose of [¹⁴C]-LY3484356 administered intravenously (IV).
89236050|NCT00620321|Experimental|LY2181308 sodium, idarubicin, cytarabine|
89236051|NCT00848159||1|Group 1 was composed of six women with a densitometric diagnosis of osteoporosis in column (DP =- 2.70 to -4.97), with an average weight of 57.5 (+6.9) kg, mean height of 1 , 4 (+ 0.07) my body mass index (BMI) of 26.1 (+1.8) Kg/m2
89236052|NCT00848159||2|Group 2 consists of six women with a densitometric diagnosis of osteopenia in column (DP =- 1.07 to -2.09), with an average weight of 62.1 (+9.9) kg, mean height of 1, 5 (+0.03) I BMI 25.3 (3.3) kg/m2, both compared with young adults
89236053|NCT00848471|Experimental|1|Quark RMR calorimeter (Cosmed)
89236054|NCT00848471|Active Comparator|2|Deltatrac II (GE health Care Clinical Systems)
89236055|NCT00852215|Active Comparator|1|Taxus stent group
89236056|NCT00852215|Active Comparator|2|Vision stent group
89236057|NCT00852293||study group|Patients with liver disease followed at the liver unit at Hadassah Medical Center.
89236058|NCT00621023|Experimental|1|Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid for MDS
89236059|NCT02546687||Canidate for elective esophagectomy|Venous blood sampling from gastric tube during elective esophagectomy
89236060|NCT00842465||1|benign breast diseases
89236061|NCT00842465||2|breast cancer
89236062|NCT00842465||3|control
89236063|NCT00848627||Males|60 years of age or older Smokers or history of smoking
89236064|NCT00842621||1|Pediatric participants with severe sickle cell disease (HbSS or Hb S/β°-thalassemia) who are not receiving treatment, e.g., hydroxyurea or chronic transfusions
89174643|NCT00667810|Experimental|Bapineuzumab 0.5 mg/kg|
89174644|NCT00667810|Experimental|Bapineuzumab 1.0 mg/kg|
89174645|NCT00667810|Placebo Comparator|Placebo|
89174646|NCT00819390|Experimental|A: Chloroquine then Placebo for Off-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
89174647|NCT00819390|Experimental|B: Placebo then Chloroquine for Off-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
89174648|NCT00819390|Experimental|C: Chloroquine then Placebo for On-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
89174649|NCT00819390|Experimental|D: Placebo then Chloroquine for On-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
89174650|NCT00876395|Experimental|Everolimus + Paclitaxel + Trastuzumab|Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
89174651|NCT00876395|Placebo Comparator|Placebo + Paclitaxel + Trastuzumab|Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
89174652|NCT05758662||Intra-annular|Patients with an intra-annular Sapien TAVI prosthesis
89174653|NCT05758662||Supra-annular|Patients with a supra-annular CoreValve Evolut TAVI prosthesis
89174654|NCT00776932||Knee OA|Those over the age of 50 who have frequent pain in their knee that has lasted for at least six months.
89174655|NCT02633657|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
89174656|NCT02626169|Active Comparator|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
89174657|NCT02626169|Active Comparator|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
89174658|NCT00685217|Experimental|TVT Secur surgical device|Single incision tape device
89174659|NCT00685217|Active Comparator|TVT surgical device|Usual care retropubic tape device
89174660|NCT04139915|Experimental|10 mg daily RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 16 weeks
89174661|NCT04139915|Placebo Comparator|Placebo|Oral matching placebo once daily for 16 weeks
89174662|NCT04148183|Experimental|Metformin Group|Metformin (850 mg/day) treatment was administered for 8 weeks
89174663|NCT04148183|Experimental|Rosiglitazone Group|Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
89174664|NCT04148183|Placebo Comparator|Placebo Group|Placebo treatment was administered for 8 weeks
89174665|NCT00681395|Experimental|1|ABT-143 capsules 20/135 mg
89174666|NCT00681395|Active Comparator|2|ABT-335 135mg and rosuvastatin 20mg
89174667|NCT00681395|Experimental|3|ABT-143 capsules 5/45mg
89174668|NCT00681395|Active Comparator|4|ABT-335 45mg and rosuvastatin 5mg
89174669|NCT02633579|Active Comparator|Erythromycin lactobionate|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
89174670|NCT02633579|Active Comparator|Erythromycin lactobionate with atropine|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min
89174671|NCT02633579|Placebo Comparator|Atropine|"Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min.~Infusion of saline as a placebo for erythromycin was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %"
89174672|NCT02633579|Placebo Comparator|Placebo|Infusion of saline was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; also placebo for atropine was given as an i.v. bolus of saline followed by a continuous infusion over 30 min
89174673|NCT00685529|Active Comparator|A|12 µg of racemic formoterol fumarate BID
89174674|NCT00685529|Experimental|B|15 µg of nebulized arformoterol tartrate inhalation solution BID
89174675|NCT00685529|Active Comparator|C|24 µg of racemic formoterol fumarate BID
89174676|NCT02633345|Experimental|Probiotic|The probiotic tablets contain Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2 at a dose of 1 * 109 CFU/tablet. The participants will take two tablets a day for four weeks.
89174677|NCT02633345|Placebo Comparator|Control|Placebo tablets. The participants will take two tablets a day for four weeks.
89174678|NCT00594659|Active Comparator|1|Therapist delivered cognitive behavioral treatment
89174679|NCT00594659|Experimental|2|Computerized Cognitive Behavioral treatment
89174680|NCT00594659|Active Comparator|3|Motivational enhancement therapy
89174681|NCT00685607|Experimental|1|loperamide-simethicone
89174682|NCT00685607|Placebo Comparator|2|matching placebo
89174683|NCT00681551|Active Comparator|Arm 1|
89174684|NCT00681551|Experimental|Arm 2|
89174685|NCT00912431|Experimental|1|
89174686|NCT00912431|Placebo Comparator|2|
89174687|NCT04161365|Experimental|Urethral stricture patients|Patients suffering from urethral stricture are treated with direct visual internal urethrotomy (DVIU). Free fat graft is gathered from the abdominal subcutaneous fat. Fat graft is prepared and injected to the stricture site.
89174688|NCT00657059|Active Comparator|Pred group|Pred Group: Prednisone treatment Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.
89174689|NCT00657059|Active Comparator|MMF Group|MMF Group: MMF treatment Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month.
89236065|NCT00842621||2|Pediatric participants with other forms of SCD or severe sickle cell disease patients (HbSS or Hb S/β°-thalassemia) being treated with hydroxyurea or chronic transfusions
89236066|NCT00842621||3|Pediatric and adult participants with other non-sickling hematological disorders
89236067|NCT04042883|Active Comparator|ANH|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
89236068|NCT04042883|No Intervention|Control|No intervention
89236069|NCT00848705|Active Comparator|Measurement Only|
89236070|NCT00848705|Experimental|Internet Intervention|
89236071|NCT00842699||1|patients receiving IL-2 receptor antagonist (Simulect) as induction treatment
89236072|NCT00842699||2|patients receiving Thymoglobulin as induction treatment
89236073|NCT00848861|Active Comparator|1 propofol|
89236074|NCT00848861|Active Comparator|2 midazolam plus meperidine|
89236075|NCT00852371|Active Comparator|Combination of Amodiaquine +sulfadoxine-pyrimethamine|Combination of Amodiaquine (Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
89236076|NCT00852371|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets targeting a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively, given in 3 equally divided daily doses to the nearest ¼ tablet)
89236077|NCT00852371|Placebo Comparator|Placebo|Placebo (had no active ingredients, produced by Cosmos Limited, Nairobi, Kenya)
89236078|NCT00852371|Active Comparator|Sulfadoxine-pyrimethamine alone|sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
89236079|NCT00842777|Experimental|Parent group treatment|Manualized group treatment of parents. Allocation of 4-6 parental couples of children with similar age.
89236080|NCT00842777|Active Comparator|Parent self-help groups|Professionals initiate and organize the self-help groups initially. The groups will not receive any teaching or counseling concerning eating and physical activity.
89236081|NCT00842855||1|274 GERD patients, partial responders to PPI treatment
89236082|NCT00528372|Experimental|Group 1: Dapagliflozin, 2.5 mg AM|Participants with hemoglobin A1c (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks.
89236083|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks.
89236084|NCT00528372|Experimental|Group 1: Dapagliflozin 2.5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each evening for up to 102 weeks.
89236085|NCT00528372|Experimental|Group 1: Dapagliflozin, 5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each evening for up to 102 weeks.
89236086|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each evening for up to 102 weeks.
89236087|NCT00528372|Experimental|Group 2: Dapagliflozin, 5 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
89236088|NCT00528372|Experimental|Group 2: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
89236089|NCT00528372|Experimental|Group 1: Dapagliflozin placebo AM & PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin placebo once each morning and evening for up to 102 weeks.
89236090|NCT00528372|Experimental|Group 1: Dapaglifozon, 5 mg AM|Participants with (HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
89236091|NCT01564680|Experimental|Lornoxicam|Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
89236092|NCT01564680|Placebo Comparator|Control|Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
89236093|NCT01564680|Experimental|Paracetamol|1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively
89236094|NCT01564836|Experimental|Imatinib treatment discontinuing|
89236095|NCT00527982|Experimental|Celecoxib treatment|600 mg orally (PO) daily
89236096|NCT00527982|No Intervention|No treatment|
89236097|NCT04121286|Experimental|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
89236098|NCT00527904|Experimental|PN 400 (VIMOVO)|500 mg delayed release naproxen/20 mg immediate release esomeprazole
89236099|NCT00619619|Experimental|A|
89236100|NCT00852449|Experimental|restrictive fluid|Restrictive fluid administration: 6 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
89236101|NCT00852449|Experimental|liberal fluid|Liberal fluid administration: 12 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
89236102|NCT00848939|Experimental|treprostinil diethanolamine|
89236103|NCT00842933|Experimental|Experimental group|Corticosteroids discontinued 24 hours after cessation of vasopressor therapy or 7 days, which ever comes first.
89236104|NCT00842933|Active Comparator|Standard of care group|Standard corticosteroid therapy given for 7 days as treatment for adrenal insufficiency during septic shock.
89236105|NCT00849095|Experimental|as needed medication|patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
89236106|NCT00849095|Active Comparator|guideline treatment|bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
89236107|NCT00527826|Active Comparator|arm 1|
89236108|NCT00527826|Active Comparator|arm 2|
89236109|NCT00843011|Experimental|Arm 1|Orvepitant 60 mg
89236110|NCT00849329|Experimental|Period 1|1250mg lapatinib once daily in the morning
89174690|NCT00657059|Active Comparator|Pred plus MMF Group|"Pred plus MMF Group: Prednisone plus MMF treatment. Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.~Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month."
89174691|NCT00667732|Active Comparator|1|Participants will receive exenatide as part of their diabetes treatment
89174692|NCT00667732|Placebo Comparator|2|Participants will receive placebo rather than exenatide as part of their diabetes treatment
89174693|NCT04161209|Experimental|Drug: Citalopram|20mg oral dose of citalopram (tablet encapsulated in opaque capsule)
89174694|NCT04161209|Placebo Comparator|Placebo|Lactose placebo (tablet encapsulated in opaque capsule)
89174695|NCT00767962|Other|1|talc pleurodesis under medical thoracoscopy
89174696|NCT00767962|Other|2|pleurodesis under video-assisted thoracoscopy surgery
89174697|NCT04161053|Active Comparator|Rifaximin|550 mg Rifaximin tablets twice daily for six months.
89174698|NCT04161053|Experimental|Nitazoxanide|500 mg Nitazoxanide tablets twice daily for six months.
89174699|NCT00777010|Active Comparator|Healthy high carbohydrate diet|Participants will follow a typical, higher carbohydrate dietary intervention with emphasis on lower glycemic carbohydrate foods and monounsaturated fatty acid consumption
89174700|NCT00777010|Experimental|Carbohydrate restricted, ketogenic diet|Paricipants will follow a carbohydrate restricted dietary intervention designed to induce ketone metabolism
89174701|NCT00681707||1|Hypertension patients recovering from stroke
89174702|NCT00685841|Experimental|A|Arformoterol 50 mcg QD and placebo MDI
89174703|NCT00685841|Experimental|B|Arformoterol 25 mcg BID and placebo MDI
89174704|NCT00685841|Experimental|C|Arformoterol 15 mcg BID and placebo MDI
89174705|NCT00685841|Active Comparator|D|Salmeterol MDI 42 mcg BID and placebo inhalation solution
89174706|NCT00685841|Placebo Comparator|E|Placebo BID MDI and inhalation solution
89174707|NCT04145609|Experimental|Intensified care|Experimental: Multidisciplinary team (MDT) care + Acute kidney disease (AKD) clinic Participants randomized to this arm will receive multidisciplinary team (MDT) care by a specialized medical team which is composed of nephrologist, pharmacist and dietitian. Besides intensified care, participants of this arm receive evaluation of biochemical and physiological renal function more frequently. In order to provide seamless care of this group, post-discharge acute kidney disease (AKD) clinic will also be arranged for them. Clinic visits consist of evaluation of renal function, reconciliation of medication and steering necessity of renal replacement therapy.
89174708|NCT04145609|No Intervention|Usual care|No intervention: Usual care Participants randomized to this arm will receive usual care according to the medical decisions of principal care physician. Nephrologist consultation and nephrology outpatient clinic follow-up will be allowed. However, this group of patient will not have access to MDT care and AKD clinic.
89174709|NCT00681785|Active Comparator|A|5000IE dalteparine
89174710|NCT00681785|Placebo Comparator|B|NaCL 0.9%
89174711|NCT04139759|Experimental|hand massage group|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
89174712|NCT04139759|Experimental|Foot massages group|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
89174713|NCT04139759|No Intervention|control group|The patients in the control group (n = 28) were not administered except nursing interventions in the HD unit.
89174714|NCT00671788|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89174715|NCT02626481|Experimental|Daratumumab + Dexamethasone|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
89174716|NCT00779818|Experimental|Group 1|Treatment by electrical acupuncture
89174717|NCT00779818|Experimental|Group 2|Treatment by laser
89174718|NCT00777166|Active Comparator|1|oxytocin 5 units
89174719|NCT00777166|Active Comparator|2|oxytocin, 10 units
89174720|NCT00681941|Experimental|1|Sevelamer Carbonate Tablets Dosed Three Times A Day
89174721|NCT02557906|Experimental|Implant and Surgimend|Breast reconstruction surgery with an implant and an ADM (Surgimend)
89174722|NCT02557906|Active Comparator|Autologous tissue|Breast reconstruction surgery with autologous tissue
89174723|NCT02557906|Active Comparator|Implant + dermal sling/LD flap|Breast reconstruction surgery using a dermal sling or a latissimus dorsi (LD)flap
89174724|NCT03874702||Ischemic stroke patients with <4.5 hours of onset .|analysis of the computed tomography without contrast and detection of early changes, scoring with ASPECTS score and integration to the machine learning data base.
89174725|NCT00657137|Experimental|A|apricoxib + lapatinib + capecitabine
89174726|NCT00657137|Placebo Comparator|B|placebo + lapatinib + capecitabine
89174727|NCT00777244|No Intervention|Follow-up|Arm B
89174728|NCT00777244|Experimental|Mitotane|Arm A
89174729|NCT04160819|Experimental|individualized nutritional intervention programs (iNIPs)|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs. Anthropometry (i.e., body mass index, limb circumference, and subcutaneous fat thickness), blood parameters (i.e., albumin and total lymphocyte count), hospital stay, Mini-Nutritional Assessment-Short Form (MNA-SF) score, target daily calorie intake, total calorie intake adherence rate, and three-major-nutrient intake were assessed during hospitalization and 3 and 6 months after discharge. Both groups received regular follow-up through phone calls. Furthermore, the rate of readmission resulting from pneumonia was recorded after discharge.
89174730|NCT04160819|No Intervention|standard care (SC) group|SC group was only provided standard nutritional supplements according to the Kaohsiung Chang Gung Memorial Hospital Nutrition Department, and patients' family members were not provided dietary advice.
89174731|NCT04160897||ETV cohort|CHB patients with entecavir naive treatment
89174732|NCT04160897||TDF cohort|CHB patients with naive tenofovir disopropyl naive treatment
89236111|NCT00849329|Experimental|Period 2|1250mg lapatinib once daily in the morning in combination with esomeprazole 40mg once daily at bedtime.
89236112|NCT02545829|Experimental|Sequence 1|HGP1406 → HIP1302
89236113|NCT02545829|Experimental|Sequence 2|HIP1302 → HGP1406
89174733|NCT00777322|Experimental|Interventional study|Patients with known keratoconus or pellucid marginal degeneration will be invited to join the study. The study is partly a continuation in the management of patients who have had previous keratophakia, who will have near-normal or supra-physiological levels of corneal thickness. It is also intended for patients with relatively mild keratoconus who have sufficient corneal thickness to allow a limited laser ablation whilst still leaving a residual stromal bed of at least 350μ.
89174734|NCT00682019|Experimental|Arm 1|
89174735|NCT00682019|Placebo Comparator|Arm 2|
89174736|NCT00682097|Experimental|1|
89174737|NCT00682097|Experimental|2|
89174738|NCT00682097|Experimental|3|
89174739|NCT00682097|Experimental|4|
89174740|NCT00682097|Experimental|5|
89174741|NCT00682097|Experimental|6|
89174742|NCT00682097|Experimental|7|
89174743|NCT02556268|Experimental|Riociguat and ATRIPLA|
89174744|NCT02556268|Experimental|Riociguat and COMPLERA|
89174745|NCT02556268|Experimental|Riociguat and STRIBILD|
89174746|NCT02556268|Experimental|Riociguat and TRIUMEQ|
89174747|NCT02556268|Experimental|Riociguat and antiretroviral protease inhibitor with TRIUMEQ|
89174748|NCT00682175||Observation|Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.
89174749|NCT00780052|Experimental|1|c-myb AS ODN as a 24-hour continuous infusion over 7 days
89174750|NCT00780130||Group 1|male & female college students ages 20 to 50, asymptomatic normals
89174751|NCT02626637|Experimental|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
89174752|NCT00780286|Experimental|1|
89174753|NCT00780286|Active Comparator|2|
89174754|NCT00875615|Experimental|Cisplatin or Carboplatin + Sorafenib|
89174755|NCT00768352|Other|Education Intervention|
89174756|NCT00780520|Experimental|1|
89174757|NCT00780520|Placebo Comparator|2|
89174758|NCT00682409|Other|1|Analysis of the value of the imaging of distribution and the late sequence to differentiate the cholesteatoma of the fibrosis in the follow-up operating post at the child
89174759|NCT00777400|Experimental|1|Efalizumab will be started on Day 0 until the end of the study at Week 24. At the end of the first week, after efalizumab is started, cyclosporine or tacrolimus will be decreased by 50% and at 2 weeks the dose of cyclosporine or tacrolimus will be completely discontinued. At 12 weeks Cellcept or myfortic will be discontinued and the patient will be converted to sirolimus for the remainder of the study.
89174760|NCT04143737|Other|Intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
89174761|NCT04143737|No Intervention|Control|22 women participated in the control group. They were recruited from a community center in the old city of Jerusalem and did not receive any intervention. Baseline data was collected.
89174762|NCT00768508|Experimental|Ondansetron|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy
89174763|NCT00768508|Experimental|Naltrexone|Naltrexone 50 mg/day + Cognitive Behavioral Therapy
89174764|NCT00768508|Experimental|Ondansetron + Naltrexone|Ondansetron 4 ug/kg b.i.d. + Naltrexone 50 mg/day + Cognitive Behavioral Therapy
89174765|NCT00768508|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
89174766|NCT00682487||1|patients admitted to the cardiology department with acute Myocardial infarction.
89174767|NCT00682487||2|patients admitted to an internal medicine department due to reasons other than an acute thrombotic event
89174768|NCT04143425||Received bevacizumab treatment|Recurrent glioblastoma patients with received anti-angiogenic treatment
89174769|NCT00780598|Experimental|Tosedostat|oral, once daily administration of tosedostat to evaluate its efficacy, safety and tolerability
89174770|NCT00780754|Experimental|dutasteride|treatment group
89174771|NCT00780754|Active Comparator|watchful waiting strategy|
89174772|NCT00768586||1|Extreme premature infants under the 28th week of gestation.
89174773|NCT02633423|Experimental|PEEP and CPAP|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
89174774|NCT02633423|Experimental|ZEEP and CPAP|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
89174775|NCT02633423|Experimental|PEEP and NO VM|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
89174776|NCT02633423|Placebo Comparator|ZEEP and NO VM|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
89174777|NCT00780832|Active Comparator|1|Caffeine reduction through diet and beverage counselling
89174778|NCT00780832|Active Comparator|2|Anticholinergic medication
89174779|NCT00597701|Active Comparator|Baclofen|Standard benzodiazepine therapy plus baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
89174780|NCT00597701|Placebo Comparator|Placebo|Standard benzodiazepine therapy plus placebo every eight hous as inpatients for 72 hours or until discharge if less than 72 hours.
89174781|NCT02556658|Experimental|Smartpilot View group|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
89174782|NCT02556658|Active Comparator|Control group|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
89174783|NCT02632955|Experimental|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
89174784|NCT02632955|Sham Comparator|Regular Angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
89174785|NCT04048486||CAPA-IVM|Live babies born from CAPA-IVM
89174786|NCT04048486||IVF/ICSI|Live babies born from IVF/ICSI
89174787|NCT04048486||Natural conception|Live babies born from natural conception
89174788|NCT04160273|Experimental|Diagnosis and follow-up arm|"Patients are informed during the 9th month pregnancy consultation consultation at Angers University Hospital by the midwife or obstetrician in charge of the consultation. They are included in the 48 hours following the delivery after their hospitalization in the maternity ward.~During hospitalization, socio-demographic and medical data are collected and the IDP scale is completed before returning home.~Follow-up at one month and one year is carried out by the investigators by means of a telephone call during which the patient answers the PCL-S questionnaire. Also collected during this call are information on the physical and mental state of the patient, the state of health of her newborn and the progress of the return home.~Patients are considered at high risk of PTSD if they have a PCL-S score ≥ 44 at 1 month. A consultation with a psychiatrist is offered to these patients at risk of PTSD in order to make the diagnosis and offer them appropriate care if necessary."
89174789|NCT04048720|Experimental|Family Nurture Intervention (FNI)|FNI sessions will be held once a week in the afternoon for eight weeks. Participants will take part in FNI group therapy with their child alongside other mother-child pairs. One to two staff members will lead FNI sessions.
89174790|NCT00657293|Sham Comparator|C|In an attempt to make the groups comparable in terms of attention, the control group will receive a sham.
89174791|NCT00657293|Active Comparator|ATP|Patients will undergo a specific arm training program (ATP).
89174792|NCT02535455|Experimental|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
89174793|NCT02556034||Disease evaluation|Rheumatoid arthritis evaluations.
89174794|NCT04031573|Experimental|Ivabradine (Low)|
89174795|NCT04031573|Experimental|Ivabradine (High)|
89174796|NCT04031573|Placebo Comparator|Control|
89174797|NCT00682721|Active Comparator|2|Valacyclovir 1 gm daily x number of days active in the study
89174798|NCT00682721|Placebo Comparator|1|
89174799|NCT00671554|Experimental|Melaxin and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration
89174800|NCT00686465|Other|PET/CT scan|PET/CT scan
89174801|NCT00781066|Experimental|1|Controlled cord traction (CCT)
89174802|NCT00781066|Active Comparator|2|No CCT
89174803|NCT02626091|Experimental|Perfusion evaluation of anastomosis|During left-sided colonic resections, anastomosis perfusion will be estimated by the visual appreciation of the surgeon and the ICG fluorescence-based enhanced reality. These two approaches will be compared.
89174804|NCT00781144||1|first year osteopathic students
89174805|NCT00781144||2|fourth and fifth year osteopathic students
89174806|NCT00781144||3|experienced osteopathic clinicians
89174807|NCT00682877||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
89174808|NCT00682877||Gastroparesis|Subjects with documented gastroparesis
89174809|NCT02556814|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
89174810|NCT02556814|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
89174811|NCT00682955|Active Comparator|B|This group has been given Zinc Sulphate in Suspension Form.
89174812|NCT00682955|Active Comparator|A|This group has been given Tablets of Zinc Sulphate.
89174813|NCT00683033|Active Comparator|A|Brief counseling based on public health service guidelines.
89174814|NCT00683033|Experimental|B|Brief counseling based on public health service guidelines for quitting smoking plus prize-based contingency management
89174815|NCT04142879||Non-Interventional Centers|"Cohort A: Viz Subjects Initially Presenting to a Non-Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a non- interventional center.~Cohort B: Subjects Initially Presenting to a Non-Interventional Center The standard of care group will be comprised of subjects randomized to not have Viz notification and who initially present to a non-interventional center."
89174816|NCT04142879||Interventional Centers|"Cohort C: Viz Subjects Initially Presenting to an Interventional Center The group will be comprised of subjects randomized to Viz and who initially present to a interventional center.~Cohort D: Subjects Initially Presenting to a Interventional Center The standard of group will be comprised of subjects randomized to not have Viz notification and who initially present to an interventional center."
89174817|NCT00683111|Active Comparator|1|oral esomeprazole 20 mg daily
89174818|NCT00683111|Active Comparator|2|oral famotidine 40mg daily
89174819|NCT04138901|Experimental|Group T|Patients receiving bilateral subcostal TAP block.
89236114|NCT02545595|Experimental|Sugammadex 1mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
89236115|NCT02545595|Experimental|Sugammadex 2mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
89236116|NCT02545595|Experimental|Sugammadex 4mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
89236117|NCT00843089|No Intervention|1|Standard care
89236118|NCT00843089|Experimental|2|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
89236119|NCT00843245||heart failure|Heart failure attending a HF clinic with or without clinical decompensation
89236120|NCT00849407||1|melanoma patients
89236121|NCT00849407||2|controls
89236122|NCT00849563|Active Comparator|SRA+genetic test|patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
89236123|NCT00849563|No Intervention|SRA only|Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
89236124|NCT00849563|No Intervention|no testing control|Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only
89236125|NCT05027178|Experimental|Chiropractic care for Ischemic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
89236126|NCT05027178|Experimental|Chiropractic care for Hemorrhagic Stroke Patients|12 weeks of full spine chiropractic care will be provided to patient. Patients may be asked to present one- two times per week.
89236127|NCT04840212|Experimental|Study Group|Patients currently hospitalized in multiple service lines (surgical intensive care unite [SICU], surgical progressive care unit [SPCU], burns, trauma, plastics, general surgery, orthopedics, surgical specialties, and inpatient rehabilitation) will be included. Lavender-Sandalwood scented aromatherapy sticker will be used throughout the patient hospital stay.
89236128|NCT04840212|No Intervention|Control Group|The historical control group will be comprised of hospitalized patients in multiple service lines from the previous year with the same time period, demographic characteristics, service line, and relevant clinical information.
89236129|NCT00849641||1|patients with decompensated liver cirrhosis admitted to the medical ICU
89236130|NCT00849641||2|critically ill patients without liver cirrhosis, matched to group 1
89236131|NCT00849641||3|healthy control group
89236132|NCT01564992||Parkinson disease|Identification of genes
89236133|NCT00855491|Experimental|1. MYOPIA|axial length > 26.00 mm
89236134|NCT00855491|Active Comparator|2. Emmetropia|emmetropic eyes- eyes with an axial length of 21.00 to 23.99 mm
89236135|NCT00849719|Experimental|1|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient.
89236136|NCT00849719|Active Comparator|2|Patients in this arm will be administered with only boluses of 1.5 mg/bolus of MO, by request.
89236137|NCT04832256||High Flow anesthesia|administered 4 L/min fresh gas flow during general anesthesia
89236138|NCT04832256||Low Flow Anesthesia|administered 1 L/min fresh gas flow during general anesthesia
89236139|NCT02546219||Adults with EoE|Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
89236140|NCT01565070|Active Comparator|Biofreeze|
89236141|NCT01565070|Placebo Comparator|Placebo|Use of placebo ointment
89236142|NCT00849953||FinESS Treatment|Subjects undergoing treatment with the FinESS Sinus Treatment System
89236143|NCT00527748|No Intervention|Standard of care|Patient ankle range of motion will be assessed at clinic visit. No stretching exercises with the device, but will be provided standard care through physiotherapist in acute cases, and no stretching exercises for chronic patients. Reassessment will be done at six weeks and 10 weeks.
89236144|NCT00527748|Experimental|Non-Measuring Ankle Exerciser|Subjects will train using only one combination of movement, dorsiflexion with inversion. This is done by manipulating the ring so that the medial and anterior ropes are taut. Subject will start with 3 minute warm-up. Subject will then manipulate the ring so that the foot moves into dorsiflexion with inversion until a point of tolerable discomfort is felt; subject will hold this position for 30 seconds. Stretch will be repeated 10 times, each day, for six weeks. Reassessment will be done at six weeks and 10 weeks.
89236145|NCT00852605|No Intervention|Oxygen|Conventional Treatment including Oxygen-support
89236146|NCT00852605|Experimental|NIV|Conventional Treatment plus intermittent Non-Invasive-Ventilation
89236147|NCT00619385|Experimental|Proellex 100 mg|Proellex 100 mg daily for 7 days
89236148|NCT00619385|Experimental|Proellex 150 mg|Proellex 150 mg daily for 7 days
89236149|NCT00619385|Experimental|Proellex 200 mg|Proellex 200 mg daily for 7 days
89236150|NCT00855569||1|Each donor site will act as it own control - both dressings will be applied to the donor site and assessments will be made
89236151|NCT00852683|Active Comparator|A|
89236152|NCT00852683|Placebo Comparator|B|
89236153|NCT04103255|Experimental|High frequency and intensive prevention|"High frequency and intensive prevention program~Tai Chi~CogniFit (cognitive training)~SpeechCare (speech training)"
89236154|NCT04103255|Active Comparator|Control group (CogniPlus)|Computer-assisted cognitive training program
89236155|NCT00619307|Active Comparator|Transition with prophylactic ibuprofen|
89236156|NCT00619307|Active Comparator|Transition with PRN ibuprofen|
89236157|NCT00850187|Experimental|Bone marrow mesenchymal stem cells|
89236158|NCT00923897|Experimental|RT for Liver Mets and HCC|
89236159|NCT00855881|Experimental|Treatment arm|Treated with tegafur-uracil for 1 year
89236160|NCT00850265|Experimental|Spacer|Extrafine formoterol plus beclomethasone with spacer
89236161|NCT00850265|No Intervention|No Spacer|Extrafine formoterol plus beclomethasone without spacer
89236162|NCT00619229|Experimental|Alprostadil|Alprostadil
89236163|NCT00619229|Placebo Comparator|Placebo|Placebo
89236164|NCT02544971|Experimental|NF-N group|Neurofeedback in a neutral context
89236165|NCT02544971|Active Comparator|NF-T group|Neurofeedback in a trauma-related context
89174820|NCT04138901|No Intervention|Group C|Patients not receiving bilateral subcostal TAP block.
89174821|NCT04138745||Control|Historical control patients that are matched to the surgery type
89174822|NCT04138745||Experimental|After the practice change of TTP was initiated, the future pediatric patients were put into a database.
89174823|NCT00690287|Experimental|Part A, arm 1|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food
89174824|NCT00690287|Experimental|Part A, arm 2|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food
89174825|NCT00690287|Experimental|Part B, arm1, 2, and 3|"AZD6370 dose x mg o.d.~dose x/2 mg b.i.d.~dose x/4 mg q.i.d."
89174826|NCT00690287|Experimental|Part B, arm 4|4) Placebo
89174827|NCT00922649|Other|A|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of ≥ 2 OAs
89174828|NCT00922649|Other|B|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of basal insulin ± OAs
89174829|NCT00922649|Other|C|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen basal-bolus insulin ± OAs
89174830|NCT04142411|Experimental|Insulin and Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin and 20 mg of Sodium Hyaluronate
89174831|NCT04142411|Active Comparator|Insulin Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 10 IU of crystalline insulin
89174832|NCT04142411|Active Comparator|Sodium Hyaluronate Ultrasound guided injection|Subjects will receive Ultrasound guided injection of 20 mg of Sodium Hyaluronate
89174833|NCT00667576|Experimental|Paricalcitol 2 µg ± 1 µg|Paricalcitol initial dosage 2 micrograms (µg) with incremental adjustment of 1 µg
89174834|NCT00667576|Experimental|Paricalcitol 2 µg ± 2 µg|Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg
89174835|NCT00667576|Experimental|Paricalcitol 4 µg ± 1 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg
89174836|NCT00667576|Experimental|Paricalcitol 4 µg ± 2 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg
89174837|NCT00667576|Other|Maxacalcitol 5 or 10 µg ± 2.5 µg|Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg
89174838|NCT04141787|Active Comparator|Ceftriaxone|Ceftriaxone 2g IV q24hvia Gravity (or q12h in the case of CNS infections) Duration dependent on site of infection, determined by treating infectious diseases (ID) clinicians based on accepted clinical guidelines.
89174839|NCT04141787|Active Comparator|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Usual Antibiotics to treat methicillin-susceptible Staphylococcal infections~Cloxacillin 2g IV q4h via Pump (dose adjusted for renal function)~Cefazolin 2g IV q8h via Preloaded Syringe (dose adjusted for renal function)~Daptomycin 6-10mg/kg IV daily via Gravity (dose will be determined based on the severity of infection as per discretion of the ID clinician and in accordance with most recent evidence)~Duration dependent on site of infection, determined by treating infectious diseases clinicians based on accepted clinical guidelines."
89174840|NCT02557594|Experimental|Viread → DA-2802|"Viread 300mg(Tenofovir disoproxil fumarate)~DA-2802 319mg(Tenofovir disoproxil orotate)"
89174841|NCT02557594|Experimental|DA-2802 → Viread|"Viread 300mg(Tenofovir disoproxil fumarate)~DA-2802 319mg(Tenofovir disoproxil orotate)"
89174842|NCT00687011|Experimental|Palonosetron-dexamethasone|
89174843|NCT00777868|Experimental|1|
89174844|NCT00777868|Experimental|2|
89174845|NCT00777868|Experimental|3|
89174846|NCT00777868|Placebo Comparator|4|
89174847|NCT00687089||Subutex group|People who used opiates and willing to start with subutex treatment
89174848|NCT00683267|Experimental|1|Study treatment, 4975, is instilled directly into surgical site
89174849|NCT00683267|Placebo Comparator|2|Placebo is instilled directly into surgical site
89174850|NCT00683345|Active Comparator|Anakinra|Anakinra self-administered s.c. in a dose of 100mg daily
89174851|NCT00683345|Placebo Comparator|Placebo|Placebo self-adminsitered s.c in a dose 0.67ml daily
89174852|NCT04138667|Experimental|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema who will undergo complex decongestive therapy
89174853|NCT00687245|Experimental|1|esomeprazole magnesium 5 mg, weight 8 kg to < 20kg
89174854|NCT00687245|Experimental|2|esomeprazole magnesium 10 mg, weight 8 kg to < 20kg
89174855|NCT00687245|Experimental|3|esomeprazole magnesium 10 mg, weight > 20 kg
89174856|NCT00687245|Experimental|4|esomeprazole magnesium 20 mg, weight > 20 kg
89174857|NCT00690521|Active Comparator|1|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
89174858|NCT00690521|Active Comparator|2|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
89174859|NCT00683501|Experimental|1|dosage X mg BID
89174860|NCT00683501|Experimental|2|dosage Y mg BID
89174861|NCT00683501|Experimental|3|dosage Z mg BID
89174862|NCT00683501|Experimental|4|dosage 2Z mg BID
89174863|NCT00683501|Placebo Comparator|5|Placebo BID
89236166|NCT02544971|Active Comparator|Control group|Treatment as usual
89236167|NCT02545439|Experimental|ALKS 5461|Sublingual tablet
89236168|NCT00619151|Active Comparator|1|CarboMedics Supra-annular Top Hat Valve
89236169|NCT00619151|Active Comparator|2|St. Jude Medical Regent Valve
89236170|NCT02546297|Active Comparator|ICS/LABA Group|Symbicort，Inhalation，Individualized medication，12 months.
89174864|NCT02625701|Experimental|Goal-Directed-Therapy (GDT)|"Besides the basal infusion of crystalloids at 3-6 ml/kg/h, colloids (200 ml) or crystalloids (200 ml) are given over 10 min in the presence of signs of absolute/relative hypovolemia as detected by a fall in cardiac output/stroke volume (CO/SV) or if Pressure Pulse Variation (PVV) or Stroke Volume Variation (SVV) exceeds 10-12%, particularly in the presence. Fluid filling is interrupted when SV fail to increase > 10% (or PVV/SVV =< 10%) Otherwise, vasopressors can be used to achieve appropriate mean arterial pressure (MAP>70 mmHg, within ±20% of baseline).~Blood losses are replaced with colloids (1:1) or crystalloids (2:1)."
89174865|NCT02625701|Active Comparator|Restrictive strategy|"Crystalloids are given at a fixed rate of 3-6 ml/kg/h. Otherwise, vasopressors can be used to achieve appropriate MAP (>70 mmHg, within ±20% of baseline).~Blood losses are replaced with colloids (1:1) or crystalloids (2:1). Clinicians in charge of the patients are free to use hemodynamic parameters such as PVV or SVV, always attempting to limit the amount of fluid infusion and to maintain normovolemia"
89174866|NCT00683579||1|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are initiating HAART with possibility of de-intensification (early treatment).
89174867|NCT00683579||2|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are not initiating treatment.
89174868|NCT00683579||3|Participants with CD4+ T cells < 350 cells/mm3 who are initiating treatment.
89174869|NCT00683579||4|Participants with CD4+ T cells < 350 cells/mm3 who are not initiating treatment.
89174870|NCT00666718|Active Comparator|Glargine|Glargine plus Insulin Lispro (2-3 injections)
89174871|NCT00666718|Experimental|ILPS|Insulin Lispro Protamine Suspension (ILPS) plus Insulin Lispro (2-3 injections)
89174872|NCT00683735|Active Comparator|Treatment A|sitagliptin and placebo
89174873|NCT00683735|Active Comparator|Treatment B|placebo and metformin
89174874|NCT00683735|Active Comparator|Treatment C|sitagliptin and metformin
89174875|NCT00683735|Placebo Comparator|Treatment D|placebo
89174876|NCT02625467|Experimental|Penetrating keratoplasty|Conventional penetrating keratoplasty technique
89174877|NCT02625467|Experimental|PALK|Pachymetry and Excimer laser assisted lamellar keratoplasty
89174878|NCT04139681|Experimental|A. Vogels Sore Throat Lozenges|Each patients receives 1 glass containing 20 A.Vogel Sore Throat lozenges at inclusion visit 1. They first suck under supervision in the study centre one Vogel Sore Throat lozenge and document every 15 minutes the pain 90 minutes. Patients will receive the rest of the bottle still containing 19 Vogel Sore Throat lozenges and have to take them for 4 days (5 lozenges per day, throughout the day) and record tonsillitis pain.
89174879|NCT04047394|Experimental|PEGylated recombinant candida urate oxidase|Participants will be administered with 2mg, 3mg, 4.5mg, 6mg, 8mg, 10mg once by Intravenous injection. Subjects will be followed for 56 days.
89174880|NCT00683813|No Intervention|UC|usual care
89174881|NCT00683813|Experimental|vCRP|
89174882|NCT00687479||1-NGT|normal glucose tolerance
89174883|NCT00687479||2-GDM|Gestational Diabetes mellitus
89174884|NCT00687479||3.GIGT|Gestational Impaired glucose tolerance
89174885|NCT02625779|Active Comparator|Valproate and Placebo|Valproate: 300mg/day for 8 weeks Placebo: for 8 weeks
89174886|NCT02625779|Experimental|Valproate and Cytidine-containing Drug|Valproate: 300mg/day for 8 weeks Cytidine-containing Drug: 2g/day for 8 weeks
89174887|NCT02625779|Experimental|Valproate and Creatine-containing Drug|Valproate: 300mg/day for 8 weeks Creatine-containing Drug: 3g/day for the first week 5g/day for week 2-8
89174888|NCT00667420|Experimental|EOXP chemotherapy|open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle
89174889|NCT04141319|Experimental|The ketorolac group|Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
89174890|NCT04141319|Active Comparator|The control group|In the control group, preoperative peri-incisional scalp infiltration will be performed using 30ml of 60 mg ropivacaine and 0.1mg epinephrine.
89174891|NCT00683969|Experimental|1|
89174892|NCT00683969|Placebo Comparator|2|
89174893|NCT00778024|Experimental|1|fluoxetine HCL 40 mg capsules of ranbaxy
89174894|NCT00778024|Active Comparator|2|PROZAC® 40 mg capsules
89174895|NCT00853658|Experimental|Combination Aliskiren / Enalapril|Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.
89174896|NCT00853658|Experimental|Aliskiren|Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.
89174897|NCT00853658|Active Comparator|Enalapril|Enalapril monotherapy -10 mg film-coated tablet and administered orally.
89174898|NCT02625857|Experimental|Dose Cohort 1A and 1B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
89174899|NCT02625857|Experimental|Dose Cohort 2A and 2B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
89174900|NCT00781300|Active Comparator|Loteprednol|
89174901|NCT00781300|Active Comparator|Dexamethasone|
89174902|NCT04140851|Experimental|overweight/obesity diet intervention group|Dietary fiber intervention
89174903|NCT04140851|Placebo Comparator|overweight/obese normal diet group|Normal diet
89174904|NCT04140851|No Intervention|healthy control group|Healthy people
89174905|NCT00781378|Active Comparator|Group 1|rt-PA 100 mg continuous intravenous infusion for 2 hours
89174906|NCT00781378|Experimental|group 2|rt-PA 50 mg continuous intravenous infusion for 2 hours
89174907|NCT00687791|Experimental|1|20 enrolled patients will be chosen according to the enrollment acceptance criteria. The evidence for the determination of enrolled patients shall be recorded, reviewed and approved. 2> Phacotrabeculectomy is performed.3> After completing phacotrabeculectomy, implant/place ologen™ Collagen Matrix on top of the scleral flap under the conjunctiva. For every inspection and observation, the detailed description and/or inspection data shall be recorded. If any unwanted adverse event is observed during inspection and observation, it shall be recorded and be reported to the investigation conductor.
89174908|NCT00687869|Experimental|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
89174909|NCT00687869|Active Comparator|usual care|Usual stroke aftercare plus patient-information-notes
89174910|NCT00684125|Experimental|1|mediastinal drainage will be accomplished using a 28F or 32F chest tube in the anterior mediastinum and a 19F Blake drain located in the posterior pericardial cavity.
89174911|NCT00684125|Active Comparator|2|mediastinal drainage will be accomplished using two 28F or 32F chest tubes located in the anterior mediastinum.
89174912|NCT02625389|Experimental|Embolization with Lipiodol Ultra Fluid and glue|
89174913|NCT00687947|Experimental|1|MA-patients
89174914|NCT00687947|Experimental|2|FHM-patients
89174915|NCT00687947|Active Comparator|3|Healthy controls
89174916|NCT00688025||1|Insomniacs: Individuals reporting difficulty falling asleep or staying asleep within the past month for more than 3 days per week. Individuals much also meet screening criteria based on an overnight polysomnograph of latency to persistent sleep >20 minutes and/or >60 minutes of wake after sleep onset.
89174917|NCT00688025||2|Controls: Individuals reporting no difficulty falling asleep or staying asleep and objective sleep measures based on an overnight polysomnograph of latency to persistent sleep <20 minutes and/or <60 minutes of wake after sleep onset.
89174918|NCT00666562|Placebo Comparator|Arm I (placebo)|Patients receive six oral placebo capsules once daily for 14-28 days.
89174919|NCT00666562|Experimental|Arm II (polyphenon E, placebo)|Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
89174920|NCT00666562|Experimental|Arm III (polyphenon E, trans-urethral resection or cystectomy)|Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
89174921|NCT00684281|Other|1|Subject control
89174922|NCT00684281|Experimental|2|40 patients before hand include in a program
89174923|NCT00769054|Active Comparator|1|Local Infiltration with Ropivacaine
89174924|NCT00769054|Placebo Comparator|2|Local Infiltration with Placebo
89174925|NCT04138979||Control group|20 healthy volunteers were included in the healthy control group
89174926|NCT04138979||Disease group|First chemotherapy for breast cancer
89174927|NCT00694265||1|Surgical treatment
89174928|NCT00694265||2|Conservative treatment
89174929|NCT04016129|Experimental|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
89174930|NCT00666328|Experimental|clevidipine|This will be a single-arm study with no reference therapy.
89174931|NCT00694343|Experimental|Group A|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
89174932|NCT00694343|Active Comparator|Group B|1000 mL Ringer's Lactate solution
89174933|NCT00781534|Active Comparator|1. Ginseng|Ginseng group
89174934|NCT00781534|Active Comparator|2. Ginsenosdie RE|Ginsenoside RE (a metabolite of ginseng) group
89174935|NCT00781534|Placebo Comparator|3. Placebo|"placebo (sugar pill) group"
89174936|NCT00688337||1|Patients with newly diagnosed breast cancer. Clinically nodal negative.
89174937|NCT00778180|Experimental|1|furosemide 80 mg tablets of Ranbaxy
89174938|NCT00778180|Active Comparator|2|Lasix® (furosemide) 80 mg tablets
89174939|NCT00781690|Experimental|1|Treatment with Evodial with reduction of heparin across study period
89174940|NCT04136795||Conventional surgery|Patients having had esophageal atresia (type III, long gap excluded) repair by conventional surgery (right thoracotomy) or patients having had minimally invasive surgery converted to thoracotomy between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
89174941|NCT04136795||Minimally invasive surgery|Patients having had esophageal atresia (type III, long gap excluded) repair through minimally invasive surgery between the 1st of january 2008 and the 31st of December 2013 and registered on the national esophageal atresia registry (CRACMO, Lille university hospital)
89174942|NCT00694421||1|"adults who participate in study, Social and Psychological Risks for Infectious Disease here at Children's Hospital of Pittsburgh"
89174943|NCT00694421||2|"children 2-6 years who participate in Role of Virus and Genetic Susceptibility study here at Children's Hospital of Pittsburgh"
89174944|NCT00769210|Experimental|A|
89174945|NCT00690911|Experimental|1|open label adalimumab 40mg
89174946|NCT00781846|Experimental|1|30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
89174947|NCT00781846|Experimental|2|40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
89174948|NCT00781846|Experimental|3|40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks
89174949|NCT00853580|Placebo Comparator|2|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
89174950|NCT00853580|Experimental|1|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
89174951|NCT00781924||biopsy|
89174952|NCT00782002|Experimental|IMC-18F1|
89174953|NCT00688493|Experimental|20 mg single dose of dapagliflozin|20 mg dapagliflozin
89174954|NCT00688493|Experimental|150 mg single dose of dapagliflozin2|150 mg dapagliflozin
89174955|NCT00688493|Active Comparator|400 mg single dose of moxifloxacin|Moxifloxacin
89174956|NCT00688493|Placebo Comparator|Placebo|Placebo
89236171|NCT02546297|Active Comparator|LAMA Group|Tiotropium Bromide，Inhalation,Individualized medication，12 months.
89236172|NCT02546297|Active Comparator|LAMA+LABA Group|Tiotropium Bromide, Symbicort, Inhalation, Individualized medication, 12 months.
89236173|NCT00618995|Experimental|A|Arm A: ER niacin/laropiprant + Placebo to laropiprant
89236174|NCT00618995|Experimental|B|Arm B: ER niacin + Placebo to laropiprant
89236175|NCT00618995|Experimental|C|Arm C: laropiprant + Placebo to ER Niacin/laropiprant
89236176|NCT00618995|Placebo Comparator|D|Arm D: Placebo
89236177|NCT03685344|Experimental|ADCT-402|"Dose escalation phase: Ascending doses of Loncastuximab tesirine will be administered using a traditional 3+3 design. Dose level 1: 90 µg/kg, every 3 weeks (Q3W). Dose level 2: 120 µg/kg, Q3W. Dose level 3: 150 µg/kg, Q3W. Loncastuximab tesirine will be given for 2 doses, 3 weeks apart.~Dose expansion phase: Loncastuximab tesirine will be administered at the recommended dose determined in the dose escalation phase. Durvalumab will also be administered at a dose of 1500 mg once every 4 weeks (Q4W) throughout the dose escalation phase and dose expansion phase."
89236178|NCT00850811|Experimental|1|
89236179|NCT00856115||African American Female|
89236180|NCT00856115||African American Male|
89236181|NCT00856115||Caucasian Female|
89236182|NCT00856115||Caucasian Male|
89236183|NCT00856271|Experimental|1|olmesartan medoxomil
89236184|NCT00856271|Active Comparator|2|losartan potassium
89236185|NCT00856427|Experimental|Diagnostic|Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
89236186|NCT00856505|Experimental|Everolimus and mycophenolate sodium|Combination of experimental immunosuppressants for GvHD prophylaxis
89236187|NCT02544893|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block
89236188|NCT02544893|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block
89236189|NCT02544893|Active Comparator|serum phsyologic|0,9% 21 ml serum physiologic
89236190|NCT02546063|Other|GoCARB app|Smartphone app
89236191|NCT02546063|No Intervention|Conventional carbohydrate estimating methods|Individual usual carbohydrate estimation methods (weighing, experience, carbohydrate exchange tables etc.).
89236192|NCT00520572|Active Comparator|1|Etanercept 50mg, subcutaneous, once weekly
89236193|NCT00520572|Experimental|2|50mg oral, once daily
89236194|NCT00520572|Experimental|3|100 mg oral, once daily
89236195|NCT00520572|Experimental|4|200 mg oral, once daily
89236196|NCT00520572|Experimental|5|400mg once, daily
89236197|NCT00520572|Placebo Comparator|6|oral, once daily
89236198|NCT00573833|Experimental|HDR Brachytherapy|9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
89236199|NCT00853463|No Intervention|No Alert|The responsible physician of a patient randomized to the control arm will not be contacted regarding the increased VTE risk of the patient.
89236200|NCT00853463|Other|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
89236201|NCT00853541||heart failure with renal impairment|Heart Failure patients with renal impairment
89236202|NCT00853619|Experimental|Services Demo at PHS and RI|Service based CDS intervention at PHS.
89236203|NCT00853619|Active Comparator|Normal CDS interventions at PHS and RI|Normal CDS intervention at both PHS and RI hospitals
89236204|NCT00853697|Experimental|testosterone with the 5α-reductase inhibitor dutast|This trial is a multi-center, open-label, phase II trial of the combination of exogenous testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride in patients with castration-resistant metastatic prostate cancer.
89236205|NCT00856817|Experimental|1|L-arginine treatment first, heme arginate treatment second
89236206|NCT00856817|Experimental|2|Heme arginate treatment first, L-arginine treatment second
89236207|NCT00520494|Experimental|Vivaglobin|Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.
89236208|NCT04041635|Experimental|Stimuli Reduction|This group will receive reduced visual and auditory stimuli in addition to usual care during venipuncture. Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
89236209|NCT04041635|Active Comparator|Usual Care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
89236210|NCT00853775||African American Families|Families with 2 parents and 2 children - no intervention, observational study
89236211|NCT00853775||Caucasian Families|Families with 2 parents and 2 children - no intervention, observational study
89236212|NCT00861419|Experimental|D|3 mg/kg AMG 386 IV (QW) / 125 mg AMG 706 PO (QD)
89236213|NCT00861419|Experimental|A|3 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
89236214|NCT00861419|Experimental|B|3 mg/kg AMG 386 IV (QW) / 75 mg AMG 706 PO (QD)
89236215|NCT00861419|Experimental|E|3 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
89236216|NCT00861419|Experimental|H|10 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
89236217|NCT00861419|Experimental|G|3 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
89236218|NCT00861419|Experimental|C|10 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
89236219|NCT00861419|Experimental|F|10 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
89236220|NCT00527514|Experimental|1|
89236221|NCT00861497|Experimental|Bifeprunox|
89236222|NCT00857051|Experimental|1|A 22 minute DVD that discusses common stressor in the early postpartum.
89236223|NCT00857051|Experimental|2|A 24 hour hotline available for the first 3 months postpartum.
89174957|NCT00778414|Experimental|1|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension of ranbaxy
89174958|NCT00778414|Active Comparator|2|Augmentin ES - 600
89174959|NCT00688571|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RV-PV conduit.
89174960|NCT00778492||No Treatment|Patients with the history of ingestion of aspirin and/or ADP receptor antagonist (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.
89174961|NCT00694499||Observation|Patients with blunt liver injury
89174962|NCT00865514|Experimental|Haplotypes and DCA metabolism|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
89174963|NCT02556580|Active Comparator|Conscious healthy volunteers|Intervention: intravenious infusion Drug: albumin 20%
89174964|NCT02556580|Experimental|Surgery under general anesthesia|Intervention: intravenious infusion Drug: albumin 20%
89174965|NCT02556580|Experimental|Post-surgical inflammation|Intervention: intravenious infusion Drug: albumin 20%
89174966|NCT00688649|Active Comparator|1|Standard ONS
89174967|NCT00688649|Active Comparator|2|High Energy ONS
89174968|NCT04136717|Other|COPD patients|Patients with acute exacerbation of COPD and respiratory acidosis under oxygen therapy.
89174969|NCT04136717|Other|Bariatric surgery patients|Obese patients after gastric surgery under CPAP.
89174970|NCT00782080|Experimental|Sedariston|Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks in children (6-11): 1 - 0 -1 In Adolescents (12-17 years) two capsules (size 1) twice daily: 2 - 0 - 2.
89174971|NCT00782080|Placebo Comparator|Placebo campsule|Placebo provided by the company given orally in capsules (size 1 )twice daily
89174972|NCT00769288|Experimental|I|Patients will receive a 1-hour infusion of FAU on days 1-5.
89174973|NCT00688727|Experimental|1|Cognitive behavioural Therapy
89174974|NCT00688727|Active Comparator|2|Standard Care
89174975|NCT00700232||1|Normal multiparous pregnant women without intrahepatic cholestasis of pregnancy (control group)
89174976|NCT04136561|Experimental|CVC and Midline Catheter|Existing standard of care CVC. Midline catheter placed within 24 hours of CVC placement.
89174977|NCT04136561|No Intervention|CVC|Standard of care CVC: case-matched controls using baseline data.
89174978|NCT00912938|Experimental|Zoledronic acid|Patients with advanced breast cancer with radiographic confirmation of bone metastases. This arm will be receiving zoledronic acid administration. The primary endpoint is to find the correlation between bone turnover markers and the frequency of skeletal-related-events for one year. Skeletal related events are defined as pathologic fractures, the need for radiation therapy, orthopaedic surgery, hypercalcemia of malignancy and spinal cord compression. A total of 237 patients will be included.
89174979|NCT00912665|Experimental|Healthy Volunteer|
89174980|NCT00782236|Active Comparator|Straumann BoneCeramic|In the test group, the subjects will receive the Bone Graft Material Straumann BoneCeramic in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
89174981|NCT00782236|Active Comparator|Freeze Dried Allograft Bone|In the control group, the subjects will receive Bone Graft Material Freeze Dried Allograft Bone in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
89174982|NCT00913016||letrozole (Femara)|
89174983|NCT00782314||1|patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month
89174984|NCT00782314||2|patients with SMART treatment with Symbicort Turbuhaler for at least 1 month
89174985|NCT00688805|Experimental|Arm 1|
89174986|NCT00688805|Placebo Comparator|Arm 2|
89174987|NCT00701480|Experimental|1|skin cleanser contained Hibiscus sabdariffa
89174988|NCT00701480|Active Comparator|2|marketed skin cleanser
89174989|NCT04136639|Experimental|Miswak|Miswak sticks used twice daily, every 12 hours, for three months.
89174990|NCT04136639|Experimental|Grape Seed Extract|Grape seed extract 6.5% mouthwash used twice daily, every 12 hours, for three months.
89174991|NCT04136639|Active Comparator|Fluoride Mouthwash|0.05% fluoride mouthwash used twice daily, every 12 hours, for three months.
89174992|NCT02613026|Experimental|Combined therapy group|pirarubicin 50mg/m2, iv, d1; docetaxel 75mg/m2, div, d1. 21 days were a cycle of treatment, with a total of 4-8 cycles.
89174993|NCT02613026|Experimental|Sequential therapy group|cyclophosphamide 600mg/m2, iv, d1; Pirarubicin 60mg/m2, iv, d1, 21 days were a cycle of treatment, with a total of 4 cycles. Then followed by Docetaxel 75- 100mg/m2, div, d1, 21 days were a cycle of treatment, with a total of 4 cycles.
89174994|NCT00778570||ASA|Participants treated for Excimer laser vision correction using Advanced Surface Ablation (ASA).
89174995|NCT00778570||LASIK|Participants treated for Excimer laser vision correction using Laser-Assisted In Situ Keratomileusis (LASIK)
89174996|NCT04136483|Experimental|CBT-I|
89174997|NCT00769366|Experimental|Psychotherapy|Psychotherapy and medical therapy
89174998|NCT00769366|Active Comparator|Control|Optimal medical therapy
89174999|NCT02614742|Active Comparator|SFX-01|300mg bid for up to 28 days.
89175000|NCT02614742|Placebo Comparator|Placebo|300mg placebo bid for up to 28 days
89175001|NCT00778726|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets of Ranbaxy
89175002|NCT00778726|Active Comparator|2|Lotensin® HCT tablets
89175003|NCT00688883|Experimental|Arm 1|
89175004|NCT00769522|Experimental|FCR|
89175005|NCT00769522|Experimental|BR|
89175006|NCT04138511|Experimental|Experimental group (ECOFISIO)|Ecofisio Group received the ECOFISIO mobile application after students had received theoretical-practical lessons about ultrasound skills in sports pathologies areas, to study the subject.
89175007|NCT04138511|No Intervention|Control Group|Students received theoretical-practical lessons about ultrasound skills in sports pathologies areas and used traditional study models, to study the subject
89175008|NCT00688961|No Intervention|1|Baseline
89175009|NCT00688961|Experimental|2|Aspirin (1 day after a single, 625 mg dose)
89236224|NCT00857051|Experimental|3|Both the film and the hotline will be given to this arm.
89175010|NCT00688961|Experimental|3|Omacor
89175011|NCT00688961|Experimental|4|Omacor plus aspirin
89175012|NCT04138355|Experimental|Extracorporeal shock wave therapy group|. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
89175013|NCT04138355|No Intervention|conventional manual therapy|the same shock wave equipment used in the experimental group was used with a sham adapter that had the same shape but emitted no energy.
89175014|NCT00778804|Experimental|telemedicine|Web-based monitoring in addition to usual clincial care with quarterly visits
89175015|NCT00778804|No Intervention|Control|Ususal care with quarterly visits
89175016|NCT00689039|Experimental|A|AZD1305 ER tablet
89175017|NCT00689039|Placebo Comparator|B|Placebo tablet
89175018|NCT00782470||Group 1|
89175019|NCT00782470||Group 2|
89175020|NCT00782470||Group 3|
89175021|NCT00865280|Experimental|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet, 300 mg (2 x 150 mg tablets)
89175022|NCT00865280|Active Comparator|Linezolid|Gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; Gram negative treatment: moxifloxacin 400 mg tablet and moxifloxacin 400 mg IV infusion solution
89175023|NCT04136327|Experimental|GLPG1972 oral and [14C]-GLPG1972 IV|GLPG1972 film-coated tablet followed by [14C]-GLPG1972 solution for infusion
89175024|NCT04136327|Experimental|[14C]-GLPG1972 oral solution|[14C]-GLPG1972 oral solution
89175025|NCT00782548|Active Comparator|1|Test product A (1 x 30 mg KADIAN)
89175026|NCT00782548|Active Comparator|2|Reference product B (1 x 30 mg Avinza)
89175027|NCT00689195|Experimental|C|Curcumin
89175028|NCT00689195|Experimental|A|Ashwagandha extract
89175029|NCT00782704||1|questionnair for Patients
89175030|NCT00782704||2|questionnaire for Nurses
89175031|NCT00782704||3|questionnaire for Physicians
89175032|NCT00769678|Active Comparator|Stimulation of diaphragm|
89175033|NCT00694811|Experimental|A|1 week of re-feeding
89175034|NCT00694811|Experimental|B|6 weeks of re-feeding
89175035|NCT00778882|Experimental|VM106|
89175036|NCT00865124|Experimental|Spironolactone (mineralocorticoid receptor [MR] blockade)|
89175037|NCT00865124|Active Comparator|Hydrochlorothiazide + potassium|
89175038|NCT00865124|Placebo Comparator|Placebo capsule|
89175039|NCT00769756||2|"Financial incentive~For the parents the financial incentive was 5 euros for every kilogram of weight-loss. For children the weight loss was calculated differently, taking into account the individual need of each child to lose weight. Children with a body mass index between the 90th and 97th age-adjusted BMI-percentile were asked to maintain their weight, and were paid in dependence on how well they managed to achieve this goal. Children with age-adjusted BMI-percentiles between 97 and 99, or above the 99th age-adjusted BMI-percentile received 5 euros per weight losses of respectively 500 g or 1 kg."
89175040|NCT00769756||1|The telemedical equipment consisted of a weighing scale for each family, an accelerometer for each participant, and a Homebox for each family which received the data from the scale and the accelerometers via bluetooth and transfered them via a telephone link to a server in Munich.
89175041|NCT00769756||3|The basic diet for all participants was supported by a list giving the calorie contents of a large variety of food-stuffs. The dual diet group received a second list giving the glycemic index (GI) for a large variety of carbohy-drates. Emphasis was placed on a preference for low-GI carbohydrates but not on avoidance of carbohydrates as required by the Atkins diet.
89175042|NCT00782860||unsuccessful termination|unsuccessful termination of early pregnancy failure with Misoprostol
89175043|NCT00782860||successful termination|successful termination of early pregnancy failure with Misoprostol
89175044|NCT02556346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
89175045|NCT02556346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
89175046|NCT02556346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
89175047|NCT02556346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
89175048|NCT02556346|Experimental|MT-3724 Phase 1b|MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
89175049|NCT00871715|Experimental|ASAP|A focused, intense, evidence-based, upper extremity rehabilitation program, administered during the early post-acute outpatient interval. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence.
89175050|NCT00871715|Active Comparator|DEUCC|Dose-equivalent usual and customary arm therapy administered early post-acutely in the outpatient setting. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
89175051|NCT00871715|Other|UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group with treatment dose administered in accordance with usual and customary practices.
89175052|NCT00694889|Active Comparator|1|Participants will use commercially available computer games.
89175053|NCT00694889|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
89175054|NCT00694889|Active Comparator|3|Healthy participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
89175055|NCT00691067|Experimental|Mifepristone|600mg of Mifepristone
89175056|NCT00691067|Placebo Comparator|Placebos|Placebo
89175057|NCT04139291|Experimental|Patients with post-mastectomy lymphedema|Patients with breast cancer related lymphedema
89175058|NCT00691145|Experimental|1|
89175059|NCT00694967|Active Comparator|1|McDonald cerclage
89175060|NCT00694967|Active Comparator|2|17 hydroxyprogesterone caproate
89175061|NCT04136249|No Intervention|Control chimiotherapeutic arm|Standard care as comparaison procedure that includes chemotherapy
89175062|NCT04136249|Experimental|Physical over-activity|The procedure under study which includes a re-training mixing EMS and EXC with a nutrition adapted to the needs related to the physical over-activity following the chemotherapy
89175063|NCT00695045|Experimental|1|patients in this group got 100mcg of intrathecal morphine.
89175064|NCT00695045|Experimental|2|patients in this group got 200 mcg intrathecal morphine
89175065|NCT00695045|Experimental|3|patients in this group given 300 mcg intrathecal morphine.
89175066|NCT02624453|Experimental|IMMY LFA positive patients|HIV positive patients who will be positive for cryptococcal antigen (by the IMMY LFA test) would be consented for lumbar puncture in search of cryptococcal meningitis (CM). If CM is not confirmed, they would be prescribed pre-emptive fluconazole based therapy at 800mg/day for two weeks (placed on antiretroviral therapy two weeks after screening for cryptococcal antigen), then 400mg/day for 8 weeks and thereafter 200mg/day until CD4 counts increases beyond 200cells/ml. (CM confirmed cases will be referred to the ACTA trial ISRCTN45035509)
89175067|NCT02624453|Active Comparator|IMMY LFA negative patients|HIV positive patient who will be negative for cryptococcal antigen (by the IMMY LFA test) would not be consented for lumbar puncture, will be placed immediately on antiretroviral therapy immediately after screening for cryptococcal antigen and would not be placed on fluconazole pre-emptive therapy.
89175068|NCT00819234|Placebo Comparator|1|
89175069|NCT00819234|Experimental|2|Pramlintide and 1.25mg Metreleptin
89175070|NCT00819234|Experimental|3|Pramlintide and 2.5mg Metreleptin
89175071|NCT00819234|Experimental|4|Pramlintide and 5.0mg Metreleptin
89175072|NCT00695123||Only 1 participant group (cohort)|The subject may have a blood disorder, may be a stem cell transplant donor, or may be a healthy volunteer.
89175073|NCT00689507|Experimental|Dose Escalation Phase(Part A):|1,10, 30, 100 or 300 mg of LY2127399 IV on day 1 of specific 21 day cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each 21 day cycle
89175074|NCT00689507|Experimental|Dose Confirmation Phase (Part B1):|Dose determined by PK/PD modeling, LY2127399 IV on day 2 of Cycle 1 and on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each cycle
89175075|NCT00689507|Experimental|Dose Confirmation Phase (Part B2):|Dose determined by PK/PD modeling, LY2127399 IV on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of specific cycles
89175076|NCT00695201|Experimental|1|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
89175077|NCT00695201|Experimental|2|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
89175078|NCT02625311|Experimental|MIS|Minimal invasive surgery for placement total knee prosthesis
89175079|NCT02625311|Active Comparator|conventional approach|"conventional open surgery for placement total knee prosthesis."
89175080|NCT00689585|Placebo Comparator|1|
89175081|NCT00689585|Experimental|2|
89175082|NCT04136093|Experimental|the MED|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the MED group
89175083|NCT04136093|Experimental|the DASH|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the DASH group
89175084|NCT04136093|Experimental|The control group|The 50 postmenopausal women who in phase I will lose ≥10% of initial body weight will be randomly assigned to the control group.
89175085|NCT00782938||low SAA|
89175086|NCT00782938||high SAA|
89175087|NCT00769834||CKD|The cohort comprises of patients who are diagnosed to have chronic kidney disease as defined by the K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease-2002.
89175088|NCT00769912|Experimental|1|50% N2O- 50%O2 mixture administration during the intervention
89175089|NCT00769912|Placebo Comparator|2|Placebo (air) during the intervention
89175090|NCT00783016|Experimental|Morphine|
89175091|NCT00783016|No Intervention|Placebo|
89175092|NCT02556502|Experimental|FDG PET positive or negative|
89175093|NCT00778960|Experimental|Slow Breathing Group|
89175094|NCT00778960|Experimental|Meditation Group|
89175095|NCT00778960|Experimental|Meditation and Slow Breathing Group|
89175096|NCT00778960|Placebo Comparator|Sitting Quietly Group|
89175097|NCT00769990|Experimental|Genistein|Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
89175098|NCT00784420|Active Comparator|UK-453,061|
89175099|NCT00784420|Active Comparator|Raltegravir|
89175100|NCT00784420|Experimental|UK-453,061 plus Raltegravir|
89175101|NCT02555800|Experimental|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
89175102|NCT02555800|Experimental|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
89236225|NCT00857051|No Intervention|4|A CD of children's music will be given to mothers in this arm.
89175103|NCT02555800|Placebo Comparator|Saline|Patients will receive 3 intralesional injections of 3.5 mL of saline solution every 3 to 6 weeks in a submucosal plane after surgical debulking.
89175104|NCT00783172|Experimental|OGF & Gemcitabine|Opioid Growth factor 250 ug/kg IV once a week. Gemcitabine 1000 mg/m2 weekly for 7 out of 8 weeks induction then every 3 out of 4 week cycles.
89175105|NCT00770068||Experimental group|All participants testing positive for tree and ragweed pollen allergies, as determined by levels of immunoglobulin E (IgE) antibodies
89175106|NCT00770068||Control group|All participants testing negative for tree and ragweed pollen allergies, as determined by levels of IgE antibodies
89175107|NCT00783250|Experimental|Salbutamol+Tiotropium|Salbutamol will be given at the dose of 400 micrograms and Tiotropium at the dose of 18 micrograms
89175108|NCT00783250|Placebo Comparator|placebo + Tiotropium|Placebo using MDI + administration of Tiotropium after 20 minutes
89175109|NCT00783328|Experimental|1|Open label single arm trial
89175110|NCT02555644|Experimental|Prexasertib + Cisplatin + Radiation Therapy (Part A)|"Prexasertib administered intravenously (IV) every 14 days over an approximately 49-day treatment period.~Cisplatin administered IV every 7 days over an approximately 49-day treatment period.~Intensity modulated radiation therapy administered 5 days per week over an approximately 49-day treatment period.~Participants may remain on treatment until completion of the treatment period."
89175111|NCT02555644|Experimental|Prexasertib + Cetuximab + Radiation Therapy (Part B)|"Prexasertib administered IV every 14 days over an approximately 56-day treatment period.~Cetuximab administered IV every 7 days over an approximately 56-day treatment period.~Intensity modulated radiation therapy administered 5 days per week over an approximately 56-day treatment period (starting at Week 2).~Participants may remain on treatment until completion of the treatment period."
89175112|NCT00871403|Experimental|Arm 1|Investigational treatment (pazopanib and pemetrexed)
89175113|NCT00871403|Active Comparator|Arm 2|Standard treatment (pemetrexed and cisplatin)
89175114|NCT00689663|Active Comparator|1|Dissection staring at the triangle of calots. Dissection with electrocautery.
89175115|NCT00689663|Active Comparator|2|Dissection as fundus first with electrocautery.
89175116|NCT00689663|Active Comparator|3|Dissection as fundus first with ultrasonic dissection.
89175117|NCT00695513|Experimental|I|BENEO synergy1
89175118|NCT00691379|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
89175119|NCT00689741|Experimental|A|
89175120|NCT00689741|Placebo Comparator|B|
89175121|NCT00695591||1SevereRLD,NMD|Patients with FEV1<40%
89175122|NCT00695591||2VerySevereRLD,NMD|FEV1<30%
89175123|NCT00695591||3NINV|FEV1<25%,on non invasive ventilation
89175124|NCT00695591||ModerateRLD,NMD|Patients with FEV1 40-50% of predicted
89175125|NCT02624531|Other|fertility-sparing surgery|NACT with Taxane combined with cisplatin and Fertility-sparing Treatment Strategy
89175126|NCT00689897|Experimental|1|In acupuncture treatment, immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation, the needles are retained for 30 minutes.
89175127|NCT00689897|Active Comparator|2|In acupuncture treatment, immediately after insertion of a needle, it is NOT manually rotated backwards or forwards to induce the DeQi sensation, and retained for 30 minutes.
89175128|NCT00691457|Experimental|1|Opti-Free contact lens solution
89175129|NCT00691457|Active Comparator|2|ReNu Multiplus contact lens solution
89175130|NCT00691457|Active Comparator|3|Clear Care contact lens solution
89175131|NCT00695747|No Intervention|1|Standard 1 site Procedure using a fornix based incision, performed superiorly
89175132|NCT00695747|Experimental|2|2 Site Combined Procedure
89175133|NCT00690053|Experimental|1|
89175134|NCT00695825|Experimental|A1|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
89175135|NCT00695825|Experimental|A2|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
89175136|NCT00690131|Experimental|1|
89175137|NCT00690131|No Intervention|2|
89175138|NCT04136015||Dasatinib group|
89175139|NCT04136015||Imatinib group|
89175140|NCT02624063|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 60 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
89175141|NCT02624063|Experimental|Simeprevir + Sofosbuvir|Simeprevir 150 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
89175142|NCT05298683|Experimental|Single-Arm|"Eligible patients will initially receive six 28-day cycles of isatuximab, pomalidomide, and low-dose dexamethasone. Patients will be allowed to continue treatment until disease progression, death, unacceptable AEs, lost to follow-up, or consent withdrawal.~Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion.~Pomalidomide will be given at 4 mg orally(PO) on Days 1-21 of each cycle.~Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV on days 1, 8, 15, and 22 in each cycle.~Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.~Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.~Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion."
89175143|NCT02624297|No Intervention|Control Group|Healthy control group for comparisons with coronary artery disease groups.
89175144|NCT02624297|No Intervention|CAD without OSA - Control|Clinical follow-up.
89175145|NCT02624297|Experimental|CAD without OSA - Intervention|Aerobic exercise training.
89175146|NCT02624297|No Intervention|CAD with OSA - Control|Clinical follow-up.
89175147|NCT02624297|Experimental|CAD with OSA - Intervention|Aerobic exercise training.
89175148|NCT02624219|Experimental|Group 1|N = 55 receive 7.5 mcg A/H5N8 + AS03 on Day 1, 22
89175149|NCT02624219|Experimental|Group 2|N = 55 receive 7.5 mcg A/H5N8 + MF59 on Day 1, 22
89175150|NCT02624219|Experimental|Group 3|N = 55 receive 15 mcg A/H5N8 unadjuvanted on Day 1, 22
89175151|NCT02624219|Experimental|Group 4|N = 55 receive 15 mcg A/H5N8 + AS03 on Day 1, 22
89175152|NCT02624219|Experimental|Group 5|N = 55 receive 15 mcg A/H5N8 + MF59 on Day 1, 22
89175153|NCT02623907||AS group|Severe AS patients, without severe AR
89175154|NCT02623907||AR|Severe AR patients, without severe AS
89175155|NCT00853112|Experimental|PF-00489791 1 mg|
89175156|NCT00853112|Experimental|PF-00489791 2 mg|
89175157|NCT00853112|Experimental|PF-00489791 4 mg|
89175158|NCT00853112|Experimental|PF-00489791 10 mg|
89175159|NCT00853112|Experimental|PF-00489791 20 mg|
89175160|NCT00853112|Placebo Comparator|Placebo|
89175161|NCT00853112|Active Comparator|Sildenafil|Observational comparator arm
89175162|NCT02624141|Experimental|Epoetin Beta 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks.
89175163|NCT00691613|Experimental|1|EPO
89175164|NCT00691613|Placebo Comparator|2|NaCl
89175165|NCT00691691|Experimental|1|Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
89175166|NCT05298527|Experimental|Intervention Group|In this study, the purpose of the study was explained to the women from intervention group and their partners by visiting them in their home. Personal Information Form (PIF), Pittsburgh Sleep Quality Index (PSQI), Menopause Symptoms Rating Scale (MSRS) and Marital Adjustment Scale (MAS) were filled by the women and MAS was filled by their partners. Firstly, back massage was taught to the partners of women in the intervention group. The massage was made half an hour before the women's sleep time for a total of 15 minutes. Partners were ensured to apply this massage twice a week for four weeks. The intervention group was called by telephone every week to ensure continuity of the study. By visiting those at their homes again at the end of the fourth week, PSQI, MSRS, and MAS were filled by the women and MAS was filled by their husbands for the last time.
89175167|NCT05298527|No Intervention|Control Group|In this study, the purpose of the study was explained to the women from control group and their partners by visiting them in their home. Their signatures indicating that they agreed to participate in the study were obtained after having them read the informed consent form. Personal Information Form (PIF), Pittsburgh Sleep Quality Index (PSQI), Menopause Symptoms Rating Scale (MSRS) and Marital Adjustment Scale (MAS) were filled by the women and MAS was filled by their partners. No application was made to the couples in the control group. By visiting those at their homes again at the end of the fourth week, PSQI, MSRS, and MAS were filled by the women and MAS was filled by their husbands for the last time. Back massage training was given to the partners of the women in the control group at the end of the fourth week.
89175168|NCT00691769||I|CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.
89175169|NCT00691769||II|patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.
89175170|NCT00691769||III|Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.
89175171|NCT04135625|Active Comparator|Full Intervention|The full intervention group will receive three egg laying chickens that will be presented as a gift to the child by their religious leader (imam or priest) during a gifting ceremony, as well as Integrated nutrition and agricultural (INA) education training sessions.
89175172|NCT04135625|Active Comparator|Education Only|The education only intervention group will receive 3 chickens given in manner similar to animal distribution programs and the INA training sessions.
89175173|NCT04135625|No Intervention|Control|The control group will receive no chickens gifted and no INA training sessions.
89175174|NCT04135235||TAF group|take propofol fumarate for Maternal and child blockade treatment
89175175|NCT04135235||TDF group|take difenofurate fumarate for Maternal and child blockade treatment
89175176|NCT00460603|Active Comparator|B|bevacizumab 5 mg/kg every 2 weeks + FOLFOX
89175177|NCT00460603|Experimental|C|AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX
89175178|NCT00460603|Experimental|A|AG-013736 5 mg bid starting dose + FOLFOX
89175179|NCT00696059|Other|1|Open-label, one arm only. All patients receiving active drug according to recommendations (adalimumab (Humira) 40 mg subcutaneously every other week).
89175180|NCT04131218|Experimental|Obese group|n=8, 25≤BMI≤39.9kg/m²
89175181|NCT04131218|Experimental|Morbidly obese group|n=8, BMI≥40kg/m²
89175182|NCT00700388|Experimental|1|TPEP added to conventional manually assisted breathing techniques (MABT)
89175183|NCT00700388|Active Comparator|2|Manually assisted breathing techniques (MABT) alone
89175184|NCT02625155|Other|Standard of Care (SOC Arm)|Standard of Care UDT
89175185|NCT02625155|Other|Selective PGx Testing (Test Arm)|Standard of Care UDT with selective PGx testing
89175186|NCT00700466||1|Patients with hypertension and/or tachycardia prior to induction of anesthesia requiring i.v. beta-blockade for treatment of raised hemodynamic
89175187|NCT00700466||2|Patients with normal hemodynamic values prior to induction of anesthesia not requiring treatment
89175188|NCT00691847||1|Bilateral post refractive procedure
89175189|NCT00698282|Experimental|1|
89175190|NCT00698282|Experimental|2|
89175191|NCT00698282|Placebo Comparator|3|
89175192|NCT02621645|Experimental|Early intervention|Intervention between 12.0 and 14.0 weeks. Early selective reduction of TRAP mass.
89175193|NCT02621645|Active Comparator|Late intervention|Intervention between 16.0 and 19.0 weeks. Late selective reduction of TRAP mass. This is the standard timing of the intervention. One of two possible techniques for late reduction is chosen by the treating physician.
89175194|NCT04117022|Experimental|supplemented arm|Each subject will receive DVS formula, 2 softgels per day for 6 months.
89175195|NCT00700544|Active Comparator|B|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~maintenance therapy every 3 months = 6 courses of reinduction with :~-idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
89175196|NCT00700544|Experimental|A|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~maintenance therapy every 3 months = 6 courses of reinduction with :~idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)~10 to 20 mg (according to body weigh) of norethandrolone daily~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
89175197|NCT02612792|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
89175198|NCT02612792|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
89175199|NCT02612792|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin for treating furcation defect
89175200|NCT04138121|Experimental|Ultrasound|Ultrasound measurements of the cricothyroid membrane.
89175201|NCT00662038|Experimental|Treatment|pirfenidone
89175202|NCT00701792|Active Comparator|1|surgery : liver transplantation
89175203|NCT00701792|Active Comparator|2|standard care for liver disease
89175204|NCT02621567|Experimental|Bright Light Therapy Group|Participants in this group will receive bright light therapy lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
89175205|NCT02621567|Placebo Comparator|Dim Light Group|Participants in this group will receive modified dim lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
89175206|NCT00784498|Active Comparator|midazolam/ketamine|Patients with orthopedic injuries requiring painful manipulation
89175207|NCT00784498|Active Comparator|propofol|Patients with orthopedic injuries requiring painful manipulation
89175208|NCT01022983|Active Comparator|Levosimendan|
89175209|NCT01022983|Placebo Comparator|Povidon, waterfree etanol, glucosis 5%|
89175210|NCT00912860|Experimental|1|serum-free avonex given IM
89175211|NCT02621333|Experimental|CIK combined chemotherapy group|autologous CIK combined chemotherapy group Drugs: platinum combined doublets; After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-indued killer cells are transfused into the vein of patients in one hour.
89175212|NCT02621333|Active Comparator|chemotherapy group|platinum combined doublets Drugs: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/ m2，D1-3 or carboplatin AUC=5, D1.
89175213|NCT00784576||Cardiac surgery patients|Individuals consecutively scheduled for cardiac surgery
89175214|NCT04116086|Other|PSMA PET-CT exam|Ga 68 -PSMA PET/CT scanning will be performed using a combined PET/CT protocol with a 16-detector-row helical CT scanner (Philips Gemini GXL). This scanner allows simultaneous acquisition of up to 45 transaxial PET images with interslice spacing of 5 mm in one bed position and provides an image from the vertex to the thigh in about 10 bed positions. The use of (68)Ga-PSMA HBED-CC results in a relatively low radiation exposure, delivering organ doses that are comparable to those of other (68)Ga-labelled PSMA-inhibitors used for PET-imaging. Total effective dose is lower than for other PET-agents used for prostate cancer imaging (e.g. (11) C- and (18) F-Choline).
89175215|NCT02623673||bevacizumab plus dexamethasone 0.7mg|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg
89175216|NCT05021536|Placebo Comparator|Placebo|Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
89175217|NCT05021536|Experimental|AMX0035|Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
89175218|NCT00701870|Experimental|ezatiostat hydrochloride (Telintra®)|Chemotherapy with docetaxel and carboplatin followed by Telintra until ANC recovery
89175219|NCT00701870|No Intervention|No Intervention|Chemotherapy with docetaxel and carboplatin alone
89175220|NCT00696839|No Intervention|1|Usual care (adherence education)
89175221|NCT00696839|Experimental|2|Usual care and Cognitive Behavioral Therapy sessions
89175222|NCT00691925||1|bilateral post refractive surgery subject
89175223|NCT02625077|Experimental|Laparoscopic valvuloplasty|Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
89175224|NCT02625077|Active Comparator|Laparoscopic Toupet fundoplication|Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
89175225|NCT00784732|Experimental|1|
89175226|NCT00784732|Experimental|2|
89175227|NCT00784732|Active Comparator|3|
89175228|NCT00459979|Experimental|Sunitinib|
89175229|NCT04117256|Active Comparator|Transcranial Stimulation|Transcranial stimulation on the primary motor cortex (M1) with anode located on the point C3 (10/20 EEG system), and the cathode on contralateral supraorbital zone.
89175230|NCT04117256|Active Comparator|Suboccipital Stimulation|Suboccipital stimulation with anode located at the upper cervical level and cathode was placed on the lateral part of right shoulder.
89175231|NCT02621411||Substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are found current use of the certain substance(s).
89175232|NCT02621411||Non-substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are not found use of any substance.
89175233|NCT00783484|Experimental|Cohort 1|PF-03716539 crossover, single dose escalation (doses subject to change).
89175234|NCT00783484|Experimental|Cohort 2|PF-03716539 crossover, single dose escalation (doses subject to change).
89175235|NCT00783484|Experimental|Cohort 3|Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
89175236|NCT00783484|Experimental|Cohort 4|Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
89175237|NCT00783484|Experimental|Cohort 5|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
89175238|NCT00783484|Experimental|Cohort 6|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).
89175239|NCT00706290|Experimental|Intervention - CBT|Participants randomized to the intervention group received cognitive behavioral therapy (CBT) for anxiety after completing a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. After completing the CBT intervention, consisting of 6-7 sessions over the course of 2-3 months, participants completed a post-intervention assessment identical to the baseline.
89236226|NCT03998826|Experimental|Piroxicam drug|20 mg piroxicam
89236227|NCT03998826|Placebo Comparator|Placebo|placebo
89175240|NCT00706290|No Intervention|Routine Care Control|Participants randomized to the control condition completed a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. They then received routine medical care. After 2 months and after completing the post clinical assessment identical to the baseline, they were offered the opportunity to receive the CBT intervention for free. This ensured that all participants ultimately received cognitive-behavioral therapy if desired, while permitting an examination of the effect size for the intervention compared to routine care.
89175241|NCT00700700|Active Comparator|CRT-ON/CRT-OFF|Group initially randomized to CRT-ON, then cross-over to CRT-OFF
89175242|NCT00700700|Active Comparator|CRT-OFF/CRT-ON|Group initially randomized to CRT-OFF, then cross-over to CRT-ON
89175243|NCT04130750|Active Comparator|treatment of physician's choice|Patients in this arm will receive neoadjuvant chemotherapy according physician's choice.
89175244|NCT04130750|Experimental|treatment of drug screening|Patients in this arm will receive neoadjuvant chemotherapy according results of drug screening vitro.
89175245|NCT00783562|Experimental|1|
89175246|NCT00783562|Active Comparator|2|
89175247|NCT00783640|Experimental|1|Lactic Acid
89175248|NCT00851786|Experimental|1|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of ZOSTAVAX (Zoster Vaccine Live) at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted.
89175249|NCT00851786|Placebo Comparator|2|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of placebo at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted
89175250|NCT00665626|Experimental|Arm 1|Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day
89175251|NCT00665626|Placebo Comparator|Arm 2|Placebo, orally, twice-a-day
89175252|NCT04116944|Experimental|Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults with analogue-Generalized Anxiety Disorder
89175253|NCT04116944|Other|Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
89175254|NCT04116944|Experimental|Non-Analogue-Generalized Anxiety Disorder Resistance Training|Resistance exercise training among young adults without analogue-Generalized Anxiety Disorder
89175255|NCT04116944|Other|Non-Analogue-Generalized Anxiety Disorder Wait-List|8-week wait-list control condition among young adults with analogue-Generalized Anxiety Disorder
89175256|NCT00828672|Active Comparator|AXE (ARM 1)|Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
89175257|NCT00828672|Active Comparator|AX (ARM 2)|Bevacizumab and Capecitabine concurrently with radiotherapy
89175258|NCT04130984|Experimental|Group IO|Intraosseous assess will be established in group IO, using EZ-IO for drug or fuild resuscitation. Proximal tibia is the insertion site,locating at 1 cm medial tibial tuberosity. IO access should be retained for less than 1 day, and venous access should be established as soon as possible after winning rescue time to continue treatment. Other treatment measures refer to 2015 AHA guidelines.
89175259|NCT04130984|No Intervention|Group IV|Intravenous access will be established in group IV, choosing any available peripheral venous for the administration of drugs or fluids.The antecubital vein is the preferred choice. If failed, the next catheterization plan will be determined by the physician in charge of the scene.Other treatment measures also refer to 2015 AHA guidelines.
89175260|NCT02612870|Active Comparator|Sienna+ retro and Technetium 1|"Sienna+® is administered retro-mamillary 1 day before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
89175261|NCT02612870|Active Comparator|Sienna+ peri and Technetium 1|"Sienna+® is administered peri-tumorally 1 day before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
89175262|NCT02612870|Active Comparator|Sienna+ retro 4-6 and Technetium 1|"Sienna+® is administered retro-mamillary 4-6 days before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
89175263|NCT02612870|Active Comparator|Sienna+ peri 4-6 and Technetium 1|"Sienna+® is administered peri-tumorally 4-6 days before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
89175264|NCT00784888||Aromatase inhibitors|Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment
89175265|NCT00706368|Experimental|1|Participants in this group will perform self-tests for the first half of the study and will have clinical examinations for the second half of the study
89175266|NCT00706368|Experimental|2|Participants in this group will have clinical examinations for the first half of the study and will perform self-tests for the second half of the study
89175267|NCT00873119|Experimental|Arm A - BelCaP|Group A: belinostat 1000 mg/m² administered as a 30 minute IV infusion once daily on days 1, 2 and 3, with at least 18 hours between infusions, followed by belinostat 2000 mg administered orally once daily on days 4 and 5, every 3-weeks, in combination with paclitaxel 175 mg/m² administered as an IV infusion following the infusion of belinostat on cycle day 3, and carboplatin (AUC 6) administered as a 30-60 minute IV infusion directly after the paclitaxel administration on cycle day 3.
89175268|NCT00873119|Active Comparator|Arm B - CaP|Group B: paclitaxel 175 mg/m² administered as an IV infusion directly followed by carboplatin (AUC 6) administered as a 30-60 minute IV infusion on cycle day 1 of a 3-weekly cycle.
89175269|NCT00706602||1|Swiss COPD cohort
89175270|NCT00706602||2|Dutch COPD cohort
89175271|NCT00661726|Experimental|1|Participants will receive injected decitabine for 12 weeks.
89175272|NCT00865046|Experimental|PST + PST boosters|PST once a week for 10 weeks, then tapering over 6 months
89175273|NCT00865046|Active Comparator|PST + control-PST boosters|PST once a week for 10 weeks, then control-PST tapering over 6 months
89175274|NCT00865046|Placebo Comparator|Control-PST|control-PST for 10 weeks
89175275|NCT00706680|Experimental|1|All subjects meeting the entry criteria will be treated with the study immunosuppressive protocol.
89175276|NCT02624999|Experimental|Immunotherapy|Subjects in this arm will receive immunotherapy (AlloVax™: CRCL + AlloStim™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks
89175277|NCT02624999|Active Comparator|Standard chemotherapy|Subjects in this arm will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV 5FU on days 1-4 of the cycle
89175278|NCT02612480|Experimental|Ticagrelor and acetylsalicylic acid|7 day treatment with ticagrelor 2x90mg after a loading dose of 180 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg.
89175279|NCT02612480|Active Comparator|Clopidogrel and acetylsalicylic acid|7 day treatment with clopidogrel x75 mg after a loading dose of 300 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
89175280|NCT02612480|Placebo Comparator|Placebo and acetylsalicylic acid|7 day treatment with placebo and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
89175281|NCT02612480|Placebo Comparator|Placebo|7 day treatment with 2 placebos
89175282|NCT00784966|Active Comparator|1|Two weeks etanercept post islet transplant
89175283|NCT00784966|Active Comparator|2|Two months etanercept treatment post islet transplant
89175284|NCT00828516|Experimental|Usual treatment plus acupuncture|Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by 6 treatments (Series 2) if participant wishes to continue treatment
89175285|NCT02623595|Experimental|SBRT+GM-CSF|Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in a cycle of 21 days.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
89175286|NCT04135001|Experimental|HBM Training|
89175287|NCT04135001|Placebo Comparator|Placebo Training|
89175288|NCT00665392|Experimental|cetuximab|Cetuximab by intravenous (IV) infusion over 1-2 h on day
89175289|NCT00851630|Experimental|Early|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 2 weeks after commencing antituberculous therapy
89175290|NCT00851630|Experimental|Delayed|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 8 weeks after commencing antituberculous therapy
89175291|NCT04130594|Experimental|phase 1, vaccine half dose|half dose of BVRS-GamVac vaccine single administration
89175292|NCT04130594|Experimental|phase 1, vaccine full dose|full dose of BVRS-GamVac vaccine single administration
89175293|NCT04130594|Experimental|phase 2, vaccine selected dose|selected dose of BVRS-GamVac vaccine single administration
89175294|NCT04130594|Placebo Comparator|phase 2, placebo|placebo single administration
89175295|NCT04135157|Experimental|PECS II or ESP|PECS II or ESP block are performed 30 minutes before general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
89175296|NCT04135157|Active Comparator|Control|In the control group, patients will have only general anesthesia. PCA is used for all the patients in the first 24 hours postoperatively.
89175297|NCT00784108|Other|Diagnostic tool|Modulated Imaging measure effect of Photodynamic therapy treatment
89175298|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
89175299|NCT00459667|Experimental|IFNB-1b 500 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 500 mcg administered s.c. every other day (double blind)
89175300|NCT00459667|Experimental|IFNB-1b 250 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day (double blind)
89175301|NCT00459667|Experimental|IFNB-1b 250 mcg*|"Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day~*(Subjects who were administered Copaxone and subjects who had prematurely discontinued medication during BEYOND study.)"
89175302|NCT02621255|Active Comparator|General anesthesia|General Anesthesia: Effect of general anesthesia will compare with regional anesthesia without use of nonsteroid antiinflammatory drug usage. Propofol 2mg/kg and rocuronium will be administered to patients for anesthesia induction. Anesthesia maintenance will ensure with sevoflurane %2 and N2O/O2 %50/50 mixture.
89175303|NCT02621255|Active Comparator|bupivacaine|Regional Anesthesia: Effect of regional anesthesia will compare with general anesthesia without use of nonsteroid antiinflammatory drug usage. Combined epidural-spinal anesthesia will be performed to patients. %5 bupivacain and 20µg fentanyl will apply for spinal anesthesia. Anesthesia maintenance will ensure with bupivacain.
89175304|NCT04047238|Experimental|Intervention Group|Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving Reminiscence Therapy or to a control group receiving treatment as usual. Participants in the intervention group will participate in two Reminiscence Therapy sessions per week for 3 months besides their treatment as usual. The sessions will be based on the Book of Past and Present and they will follow the same protocol in every participant institution.
89175305|NCT04047238|No Intervention|Control Group|Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.
89175306|NCT00828204|Experimental|Avonex Single-Use Autoinjector|"Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes.~In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks."
89175307|NCT00696215|Placebo Comparator|1|
89175308|NCT00696215|Active Comparator|2|Rasagiline
89175309|NCT00784186|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
89236228|NCT00857129|No Intervention|1|Low risk women with expected normal birth are being Randomized to The Midwife-led Unit, with low amount of intervention, No epidural is offered, no medical augmentation available, unless for the active phase of the second stage. If extended surveillance is necessary or if the birth no longer is considered to be normal and needs to be taken over by a doctor, the woman will be transferred to either the Normal Unit or the Special Unit
89236229|NCT00857129|Experimental|2|Low-risk women are randomised to this Low-risk maternal unit, The Normal Unit.The unit is organised for low-risk women with expected normal birth. The unit has access to extended surveillance, epidural and operative vaginal deliveries. If extended surveillance is necessary for a woman randomised to this unit, she does not have to be transferred to a higher level of care. Instrumental vaginal deliveries can be carried out at this unit.
89236230|NCT00857129|Experimental|3|Women with expected normal births are being randomised to this Special birth unit designed to take care of women before, under and after birth. The Special Unit cares for women with extended need for surveillance, but does also handle low-risk women.
89236231|NCT02383602||Retention strategies|In addition to telephone call(s) made within 1 week prior to scheduled visit, participants will receive at least biweekly communications from the study staff in order to establish and maintain a good relationship between participants and study sites. These communications will make use of various social networking tools (for example, Grindr, LINE and/or WhatsApp and/or SMS and/or Facebook and/or electronic mail).
89236232|NCT00853853|Active Comparator|1. EnSeal Device|The EnSeal device cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding. The device is able to seal blood vessels up to 7mm and hemorrhoidal vessels are much smaller than this size.
89236233|NCT00853853|Active Comparator|2. Ferguson Hemorrhoidectomy|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced.
89236234|NCT04607538||Patellar dislocation, but no trochlear dysplasia|This group consist of patients in age from 15-20 years old in the Faroe Islands, who experience patellar dislocation, but do not have femoral trochlear dysplasia measured on MRI or X-ray
89236235|NCT04607538||Patiens with patellar dislocation and trochlear dysplasia|This group consists of patients in the age from 15-20 years old in the Faroe Islands, who have experience one or more patellar dislocations and have femoral trochlear dysplasia measured on MRI or X-ray
89236236|NCT04607538||Patients with other knee injury|This group consists of patients in the age from 15-20 years old in the Faroe Islands, who have had an ACL-rupture or an meniscus injury.
89236237|NCT00857363||Constipated|Adult subjects with functional constipation as define by Rome II criteria
89236238|NCT00853931|Experimental|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
89236239|NCT00854009|Experimental|1|BLI-489
89236240|NCT00854009|Placebo Comparator|2|Placebo
89236241|NCT03998592|Experimental|Low-dose vaccine|
89236242|NCT03998592|Experimental|Mid-dose vaccine|
89236243|NCT03998592|Experimental|High-dose vaccine|
89236244|NCT03998592|Placebo Comparator|Placebo|
89236245|NCT00861731|Active Comparator|1|hypolipidemic treatment
89236246|NCT00861731|Sham Comparator|2|hypolipidemic treatment
89236247|NCT00861731|Sham Comparator|3|hypolipidemic treatment
89236248|NCT02544659|Experimental|pamidronate disodium|the patients will be administered intravenous pamidronate disodium
89236249|NCT00861887|Active Comparator|Vancomycin|Vancomycin 125 mg every 6 hours x 4 weeks
89236250|NCT00861887|Placebo Comparator|Placebo|Vancomycin 125 mg every 6 hours x 2 weeks, followed by placebo every 6 hours x 2 weeks
89236251|NCT00857441|Experimental|1|Use of Dior balloon and implant of Liberté Bare Metal Stent
89236252|NCT00857441|Active Comparator|2|Use of standard balloon and implant of Liberté Bare Metal Stent
89236253|NCT00857441|Active Comparator|3|Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent
89236254|NCT00857519|Experimental|Chemotherapy|Chemotherapy using Melphalan, Carboplatin.
89236255|NCT00618449|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with 1 gm oral dose of Azithromycin; receive a second 1 gm oral dose of Azithromycin at Day 30; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
89236256|NCT00618449|Active Comparator|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); be treated at Day 30 with the WHO standard of care for trachoma - 1 gm oral dose of Azithromycin; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
89236257|NCT00857597|Experimental|EsophyX|
89236258|NCT00857597|Active Comparator|Proton Pump Inhibitors|
89236259|NCT00857675|Experimental|Adefovir Dipivoxil|ADV 10mg tablets once daily
89236260|NCT00857675|Placebo Comparator|Adefovir Dipivoxil matched placebo|Adefovir Dipivoxil matched placebo one tablet once daily
89236261|NCT00861965|Experimental|Treatment|AlloStim-8
89236262|NCT00857753|Experimental|1|Fentanyl patch 25 ug/hr Sandoz
89236263|NCT00857753|Active Comparator|2|Duragesic Patch 25 ug/hr
89236264|NCT00854321||patients with active RA|drug, follow-up
89236265|NCT03684642|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide subcutaneous (SC) injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 4 mg once weekly for the treatment duration.
89236266|NCT03684642|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 6 mg once weekly for the treatment duration.
89175310|NCT00784186|Experimental|misoprostol|800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
89175311|NCT02611986|Experimental|McGrath MAC|tracheal intubation using the McGrath MAC
89175312|NCT02611986|Experimental|Macintosh Laryngoscope|tracheal intubation using the Macintosh Laryngoscope
89175313|NCT02621177|Experimental|NBP607|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
89175314|NCT02621177|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
89175315|NCT04116554|Active Comparator|intervention group (A)|which will have an ultrasound-guided bilateral transversus thoracic muscle plane (TTP) block by injection of 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side.
89175316|NCT04116554|Sham Comparator|control group (B)|which will have sham block bilaterally by injection of 20 ml of 0.9%saline will be injected on each side.
89175317|NCT00459355|Experimental|Home Safety Toolkit|Intervention group receives home safety tool-kit with education and self-efficacy materials to promote competence to make home safety modifications.
89175318|NCT00459355|No Intervention|Conventional Safety Checklist|Comparison group received a conventional home safety checklist
89175319|NCT00700856|Experimental|1|metformin 2000 mg + pioglitazone 15-45 mg
89175320|NCT00700856|Active Comparator|2|metformin 2000 mg + glibenclamide 5-15 mg or metformin 2000 mg + gliclazide 30-120 mg or metformin 2000 mg + glimepiride 2-6 mg
89175321|NCT00790114|Experimental|1|
89175322|NCT01023139|No Intervention|Standard of care (SOC)|No intervention following phase 1 of the study is done during this 2nd phase. Participants will have their height and weights examined at 3 month and 6 month following end of phase 1. During these two visits, they will receive counseling from the physician regarding food choices and exercise maintenance.
89175323|NCT01023139|Experimental|Continuing Behavioral Therapy (CoBT)|This arm follows the end of the phase 1 which incorporates behavioral therapy, nutrition counseling and pharmacotherapy with Sibutramine while medically supervised. Participants randomized to this arm no longer receive medication and will receive behavioral therapy once a month and then evaluated at 3 months and six months for weight loss maintenance.
89175324|NCT02555176|Experimental|Low Carbohydrate Diet|Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).
89175325|NCT00784342||Stable|Patients who are stable have not had a COPD exacerbation in the past 2 months.
89175326|NCT00784342||Exacerbation|Patients with an exacerbation have been diagnosed and started on treatment for an exacerbation within the past 3 days.
89175327|NCT00790348||1|Patients who on Januvia
89175328|NCT00790348||2|Patients on Janumet (Combination of Januvia and Metformin)
89175329|NCT00790348||3|Patients on Metformin
89175330|NCT00459043|Active Comparator|1|Docetaxel Alone
89175331|NCT00459043|Active Comparator|2|Docetaxel with ZD6474
89175332|NCT00795262|Placebo Comparator|placebo comparator|Quinapril 40 mg (Accupril)plus placebo will be given for 8 weeks.
89175333|NCT00795262|Active Comparator|Active comparator|Quinapril 40 mg plus Alpha Lipoic Acid (ALA)on vascular effects of patients with diabetes and hypertension
89175334|NCT01322893||Blood sampling.|Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
89175335|NCT00785200|Experimental|Chlorhexidine|Approximately 500 detainees housed in approximately 23 detention tanks will be enrolled and receive 2% chlorhexidine-soaked disposable wash cloths (Sage Products, Inc.) to clean their skin on Mondays, Wednesdays, and Fridays for 6 months. Newly arrived detainees in the tanks will be offered enrollment in the study on a biweekly schedule.
89175336|NCT00785200|Placebo Comparator|Water|Approximately 500 detainees in approximately 23 detention tanks will receive water-soaked wash cloths to clean their skin each Monday, Wednesday, and Friday for a 6-month period. If detainees newly arrive to these study tanks, they will be offered enrollment on a biweekly schedule.
89175337|NCT00785200|No Intervention|Usual care|Approximately 500 detainees in approximately 23 detention tanks will be enrolled. These detainees will not receive any intervention. They will be followed for 6 months, and newly arrived detainees will be offered enrollment on a biweekly schedule.
89175338|NCT01023373|Experimental|B:PTRS|B: the same medical therapy, as previously described in group A, associated with PTRS
89175339|NCT01023373|Active Comparator|A:medical therapy|hypotensive drugs, statins and antiplatelet therapy
89175340|NCT00785278||1|Able-bodied participants: Able-bodied individuals will be asked to propel a wheelchair at a self-selected speed for a period of time during which data will be collected on their propulsion biomechanics. It is assumed, for the purpose of the study, that un-learned able-bodied individuals learning to propel a wheelchair reflect newly injured individuals who are just getting accustomed to a new chair.
89175341|NCT00785278||2|Participants with paraplegia: Individuals who are at least 1-year post injury and have used a manual wheelchair as their primary means of locomotion during this time, will be assumed to be, for the purpose of this study, experienced wheelchair users.
89175342|NCT00817206|Experimental|LCP-Tacro|LCP-Tacro tablets™, once daily (LifeCycle Pharma A/S, Hoersholm DK)
89175343|NCT00817206|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
89175344|NCT01023529||Prostate cancer|Patients with incurable prostate cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
89175345|NCT01023529||Rectal Cancer|Patients with incurable rectal cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
89175346|NCT00790504||1 study group|Women with multiple gestations recruited from the prenatal care or high risk pregnancy units
89175347|NCT00790504||2 control group|Women with singleton gestation recruited from the prenatal care or high risk pregnancy units
89175348|NCT02611518|Experimental|Panel 1|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 17.
89175349|NCT02611518|Experimental|Panel 2|Participant will be administered a single oral dose of metformin 500-mg on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 16.
89175350|NCT01023607|Active Comparator|Group A:|Atorvastatin 20mg
89175351|NCT01023607|Experimental|Group B:|Atorvastatin 60mg
89175352|NCT01023607|Active Comparator|Group C:|Rosuvastatin 10mg
89175353|NCT00706758|Active Comparator|1|Structured patients group intervention - IBS school
89175354|NCT00706758|Active Comparator|2|Written information - IBS-guidebook
89175355|NCT02609412|Experimental|Static compression of LMTRP|static compression of most sensitive LMTRP with the foam roll for 90 seconds
89175356|NCT02609412|Experimental|Dynamic self-myofascial release of calf|dynamic self-myofascial release rolling back and forth on the entire calf for 90 seconds with the foam roll
89175357|NCT02609412|Placebo Comparator|Placebo laser acupuncture of LMTRP|placebo laser acupuncture applied on most sensitive LMTRP of the calf, light and acoustic sounds provided, but laser remains switched off, 90 seconds
89175358|NCT00665002|Experimental|WT-1 Analog Peptide Vaccine|Participants received 6 bi-weekly vaccinations over 10 weeks. WT-1 vaccine was given with Montanide. Participants also received an injection of Sargramostim (GM-CSF) two days before each vaccination and again on the day of the WT-1 injection at the same spot.
89175359|NCT05757024|Experimental|experimental group|study group receive high power laser therapy in combination with conventional tempromandibular joint exercises.
89175360|NCT05757024|Active Comparator|control group|control group receive traditional tempromadibular joint exercises.
89175361|NCT02554240|Experimental|DA-5202 High dose|- DA-5202 20mg
89175362|NCT02554240|Experimental|DA-5202 Low dose|- DA-5202 10mg
89175363|NCT02554240|Active Comparator|Na Hyaluronate 20mg|Na Hyaluronate 20mg
89175364|NCT05756868|Experimental|Time restricted feeding|The participants in the intervention group will receive a time restricted feeding intervention (first meal at 10:00, last meal at 18:00) for 6 weeks. Meals of the participants are planned as 8 hours of eating and 16 hours of fasting.
89175365|NCT05756868|No Intervention|Control|Participants in the control group will not receive any dietary intervention. All participants were asked to continue in the same way they were fed before starting the study throughout the study.
89175366|NCT02611050|Experimental|Option Grid|Patients randomized to the Option Grid arm will receive the Multi-vessel Coronary Artery Disease Option Grid at the time of enrollment. The treating physician will then discuss the patient diagnosis and treatment choice reviewing the Option Grid within the conversation to facilitate patient understanding and shared decision making
89175367|NCT02611050|Other|Usual Care|Patients randomized to usual care will discuss the patient diagnosis and treatment options typical to the physician's routine care.
89175368|NCT03847987|Experimental|Part 1|Participants will receive 4 single oral doses of RO7017773 under either fed or fasted conditions, one of which will be a taste assessment. There will be a 7-10 day washout period between doses.
89175369|NCT03847987|Experimental|Part 2|Participants will receive 2 single oral doses of RO7017773, either sweetened/flavored, or unflavored and dispersed in juice. There will be a 7-10 day washout period between doses.
89175370|NCT00660010|Experimental|1|
89175371|NCT04015908|Experimental|multi-modal|"3 Different Non-opioid pain medication taken every 6 hours~Celecoxib 100mg~Acetaminophen 325mg~Pregabalin 50 mg~Plus, for breakthrough pain~oxycodone 5-10 mg will be taken every 4 hours as needed for pain."
89175372|NCT04015908|Active Comparator|Control|7 day supply of Percocet (oxycodone 5mg/acetaminophen 325 mg) to be taken 1-2 by mouth every 4 hours as needed for pain.
89175373|NCT00790816|Experimental|Group 1|Study Drug
89175374|NCT00790816|Experimental|Group 2|Study Drug
89175375|NCT04853316||Case: Exposed (SARS-CoV-2 positive)|Participants found positive by SARS-CoV-2 testing.
89175376|NCT04853316||Control: Unexposed (SARS-CoV-2 negative)|Participants found negative by SARS-CoV-2 testing.
89175377|NCT00873041|Experimental|5 mg/kg/day deferasirox|Participants received a starting dose of 5 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
89175378|NCT00873041|Experimental|10 mg/kg/day deferasirox|Participants received a starting dose of 10 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
89175379|NCT00873041|Placebo Comparator|5 mg/kg/day placebo|Placebo tablet matching 5 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
89175380|NCT00873041|Placebo Comparator|10 mg/kg/day placebo|Placebo tablet matching 10 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
89175381|NCT00795496||AD patients|AD patients who fulfill the inclusion criteria for the study
89175382|NCT00795574|Experimental|infliximab|Double blind placebo cross-over
89175383|NCT00795574|Placebo Comparator|Placebo|Double blind placebo controlled cross-over
89175384|NCT05206864|Experimental|SBD111|
89175385|NCT05206864|Placebo Comparator|Placebo|
89175386|NCT02620943||Exposed Group|Pregnant mothers reporting inadequate (<4) dietary diversity during pregnancy
89175387|NCT02620943||Unexposed group|Pregnant mothers reporting adequate (>=4) dietary diversity during pregnancy
89175388|NCT02609256|Experimental|Stereotactic infarct tissue aspiration|Patients receive the stereotactic infarct tissue aspiration 24-48 hours after cerebral infarction beside medical therapy.
89175389|NCT02609256|Sham Comparator|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc;
89175390|NCT00785434|Experimental|Active|Active escitalopram
89236267|NCT03684642|Active Comparator|Dulaglutide 1.5 mg|Participants received Dulaglutide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 0.75 mg once weekly and increased after 2 weeks to 1.5 mg once weekly for the treatment duration.
89236268|NCT00857831|Experimental|Arm 1|Vitamin D & Calcium supplementation in FES
89236269|NCT00862043|Experimental|Sildenafil Citrate|Sildenafil Citrate 40 mg t.i.d. oral
89236270|NCT00862043|Placebo Comparator|Placebo|Sildenafil-matched oral placebo 40 mg t.i.d
89236271|NCT00519636|Active Comparator|FFNS, FPNS|fluticasone furoate nasal spray, fluticasone propionate nasal spray
89236272|NCT00519636|Active Comparator|FPNS, FFNS|fluticasone propionate nasal spray, fluticasone furoate nasal spray
89236273|NCT00519636|Placebo Comparator|placebo FFNS, placebo FPNS|placebo nasal spray matching fluticasone furoate nasal spray, placebo nasal spray matching fluticasone propionate nasal spray
89236274|NCT00519636|Placebo Comparator|placebo FPNS, placebo FFNS|placebo nasal spray matching fluticasone propionate nasal spray, placebo nasal spray matching fluticasone furoate nasal spray
89236275|NCT00857909|Active Comparator|Randomisation 1|Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
89236276|NCT00857909|Active Comparator|Randomisation 2|Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
89236277|NCT00857909|Placebo Comparator|Placebo|calcium tablet
89236278|NCT00857987|Experimental|1|Guaifenesin, doxylamine succinate and hydrochloride etafedrine syrup
89236279|NCT00857987|Placebo Comparator|2|Vehicle
89175391|NCT02620709|Experimental|Hula intervention|"Participants randomized to the intervention arm will receive the 6-month KaHOLO Program within 1 week of baseline data collection. The first 3 months of the KaHOLO was designed and standardized as a culturally-based PA, which includes 12 weeks of hula lessons. These hula lessons consist of two 60 minute classes per week over 12 weeks. Each hula lesson will consist of 15 participants, providing with the opportunity to engage in social support network.~The last three months of the program will be reduced to once a week sessions. One week will consist of hula lessons for 60 minutes. The remaining 3 weeks will consist of the intervention group meeting for 45 minutes with the community-peer educator."
89236280|NCT03998514|Experimental|Group A1 single ascending dose (SAD)|CB4211 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
89236281|NCT03998514|Experimental|Group A2 SAD|CB4211 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
89236282|NCT03998514|Experimental|Group A3 SAD|CB4211 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
89236283|NCT03998514|Experimental|Group A4 SAD|CB4211 Dose 4 (N=1) Placebo (N=1) Subcutaneous injection
89236284|NCT03998514|Experimental|Group A5 SAD|CB4211 Dose 5 (N=6) Placebo (N=2) Subcutaneous injection
89236285|NCT03998514|Experimental|Group A6 SAD|CB4211 Dose 6 (N=6) Placebo (N=2) Subcutaneous injection
89236286|NCT03998514|Experimental|Group B1 multiple ascending dose (MAD)|CB4211 Dose to be determined (TBD) (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
89236287|NCT03998514|Experimental|Group B2 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
89236288|NCT03998514|Experimental|Group B3 MAD|CB4211 Dose TBD (N=6) Placebo (N=2) Subcutaneous injection once daily for 7 days
89236289|NCT03998514|Experimental|Part C|CB4211 Dose TBD (N=10) Placebo (N=10) Subcutaneous injection once daily for 28 days
89236290|NCT00858065|Active Comparator|RCT FM|Random control trial- Family Matters. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Family Matters program.
89236291|NCT00858065|Active Comparator|Choice SFP|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Strengthening Families Program (SFP).
89236292|NCT00858065|Active Comparator|RCT SFP|Random control trial- Strengthening Families Program. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Strengthening Families Program.
89236293|NCT00858065|No Intervention|RCT Control|Random control trial- Control Group. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to the control group and received no prevention program. However, this group and all groups received an informational pamphlet about youth alcohol and other drug use.
89236294|NCT00858065|Active Comparator|Choice FM|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Family Matters (FM) program.
89236295|NCT00854555|Experimental|robot|30 persons with incomplete SCI who live within driving distance to Oslo and who meet the inclusion/exclusion criteria will be selected for randomization to robotic assisted training or control (conventional treatment). Intervention consists of locomotor training with robot for 60 days during 6 months period in an out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
89236296|NCT00854555|Experimental|manual assistance|30 persons with incomplete SCI who live outside driving distance to Oslo and who meet inclusion/exclusion criteria will be selected for manually assisted training in Tromsø or control (conventional treatment). Intervention consists of 60 days locomotor training with manual assistance during 6 months period in an in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
89236297|NCT00854633|Experimental|1|Talactoferrin
89236298|NCT00854633|Placebo Comparator|2|Placebo
89236299|NCT00618371|Experimental|Raltegravir intensification|Patients will be administered raltegravir 400 mg orally twice daily in addition to antiretroviral therapy
89236300|NCT00858299|Experimental|valsartan|
89236301|NCT00526890|Experimental|CPSR|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation
89236302|NCT04041167|Active Comparator|Alpha lipoic acid|All patients will be assigned intravenous alpha lipoic acid 600mg within 24 hours of symptom onset. Patients will receive intravenous alpha lipoic acid 600mg/day for one week, followed by an oral pill of alpha lipoic acid 600mg/day for three months.
89236303|NCT04041167|Placebo Comparator|Normal saline|All patients will receive intravenous normal saline within 24 hours of symptom onset.
89236304|NCT03998124|Experimental|Peer-led intervention|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
89175392|NCT02620709|No Intervention|Wait-List Control|After baseline data collection and education, participants randomized to the wait-list control arm will not receive the KaHOLO Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not receive the intervention for 6 months until after the intervention arm is completed and their 6 month follow-up data collection is completed. They will not receive any other intervention from us during the 6 month period but they will be instructed to continue with their routine medical care as usual.
89175393|NCT00785590|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
89175394|NCT00458341|Experimental|Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg|During Cycle 1, participants will receive ataluren at 4 mg/kg in the morning, 4 mg/kg at midday, and 8 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 10, 10, and 20 mg/kg) for Cycle 2.
89175395|NCT00458341|Experimental|Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg|During Cycle 1, participants will receive ataluren at 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 4, 4, and 8 mg/kg) for Cycle 2.
89175396|NCT00692081|Experimental|A|8 group sessions social competence training (CBT)
89175397|NCT00692081|Active Comparator|B|special vocational training as usual
89175398|NCT02610894|Experimental|mHealth application|Participants will be provided an iPad Mini tablet computer loaded with an mHealth application (PoCAH) to provide enhanced post-operative pain care management. The app will utilize algorithms tailored to the patient's needs and symptoms in an attempt to reduce poor outcomes related to post-operative pain management.
89175399|NCT02610894|Active Comparator|Control Group|Participants will be provided an iPad Mini tablet computer loaded with a PDF of the As usual standard discharge and care instructions for post-operative pain care management.
89175400|NCT00790894|Active Comparator|1|
89175401|NCT00790894|Experimental|2|
89175402|NCT02623127|Experimental|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment.
89175403|NCT05263492|Experimental|Pembrolizumab & Lenvatinib|Lenvatinib, 20 mg administered orally (PO) once daily (QD) during each 21-day cycle, and Pembrolizumab, 200 mg administered by intravenous (IV) infusion on day 1 of each 21-day cycle.
89175404|NCT04134611|Active Comparator|Knee arthroscopy with Hyaluronic acid injection|Those patients who received hyaluronic acid injection
89175405|NCT04134611|Active Comparator|Knee arthroscopy without Hyaluronic acid injection|Knee arthroscopy who did not Hyaluronic acid injection
89175406|NCT02620631|Placebo Comparator|Placebo|Subjects receive intrathecal injection of saline at time of spinal anesthesia
89175407|NCT02620631|Experimental|Morphine|Subjects receive intrathecal injection of morphine sulfate 0.2mg at time of spinal anesthesia
89175408|NCT00816036|No Intervention|Arm 1|Baseline Period
89175409|NCT00816036|Experimental|Arm 2|Intervention Period
89175410|NCT00795652|Experimental|Distance Treatment|50% randomized to receive Distance Treatment for postpartum depression
89175411|NCT00795652|No Intervention|Usual Care Services|50% randomized to receive usual care services for postpartum depression
89175412|NCT02622971|Active Comparator|PBMT and Cryotherapy|Volunteers allocated in this group received phototherapy (PBMT - applied in six points of quadriceps) and cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
89175413|NCT02622971|Active Comparator|Cryotherapy and PBMT|Volunteers allocated in this group received cryotherapy (20 minutes in PRICE protocol) and phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
89175414|NCT02622971|Active Comparator|PBMT (active phototherapy)|Volunteers allocated in this group received active phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
89175415|NCT02622971|Placebo Comparator|PBMT (placebo phototherapy)|Volunteers allocated in this group received placebo phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. The placebo PBMT device was identical to the active devices and displayed the same settings and emitted the same sound regardless of the comparator.
89175416|NCT02622971|Active Comparator|Cryotherapy|Volunteers allocated in this group cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. Two flexible ice packs filled with ice cubes and water (with a volume of 1.15 liters each) were used in order to cover the entire quadriceps. Rubber belts were used to apply compression and to affix the packs tightly to the volunteers' quadriceps.
89175417|NCT00795730|Placebo Comparator|placebo|
89175418|NCT00795730|Experimental|NSA-789|
89175419|NCT04030572|Experimental|Clonidine Pill|One week period of clonidine, 0.1 mg tabs, one by mouth daily at bedtime
89175420|NCT00795808|Experimental|BMI > 32|Women with BMI > 32
89175421|NCT00795808|Experimental|BMI </= 32|Women with BMI </= 32
89175422|NCT04135781|Experimental|AS|Arm A：nab paclitaxel （120mg/m2；iv；d1，8）+S-1 （<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）Q3W；up to eight cycles
89175423|NCT04135781|Active Comparator|XELOX|Arm B：Capetabine（1000 mg/m2 po, d1-14 bid ）+ Oxaliplatin（130mg/m2 , iv, d1）Q3W；up to eight cycles
89175424|NCT04046692||children in hospital school in contact with outside school|children experience school's lesson with the hospital teacher in the school's room or into their bedrooms and the investigator give before/after the lesson 2 questionnaire (PANAS-C and PH-C) and the VAS to evaluate the aim's study. Then, the investigator asks the children to make 2 paintings: one about the hospital school experience (what is for him/her the hospital school) and one about the outside school (what he/she do/did outside during school).
89175425|NCT04046692||children in hospital school NOT in contact with outside school|"it's the same of the previous group (children experiencing hospital school still in contact with outside school); the only difference of this group is that children are not in contact with the outside school."
89175426|NCT04046692||hospital teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
89175427|NCT04046692||outside teachers|teachers have to answer to some questions (qualitative interview) and fill in CEESQ schedule
89175428|NCT04046692||Parents|parents have to answer some questions (qualitative interview)
89175429|NCT05758350|Experimental|Iowa Oral Performance Instrument (IOPI) training group|Including conventional speech therapy (tongue range of motion and strength, oral diet suggestion, masseter muscle strengthening) and home- IOPI based resistance training
89175430|NCT05758350|No Intervention|controlled group|Including conventional speech therapy (tongue range of motion and strength, oral diet suggestion, masseter muscle strengthening) only
89236305|NCT03998124|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
89175431|NCT00795964|Experimental|1|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
89175432|NCT00795964|Active Comparator|2|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
89175433|NCT04135313|Experimental|Neoadjuvant chemotherapy|Patients receive 2 cycles of induction CapOx (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy, followed by chemoradiotherapy (54 Gy in 2 Gy fractions with concomitant capecitabine 825 mg/m2 per os bid on radiation days), then 2 cycles of consolidation CapOx chemotherapy, surgery (10-12 weeks following chemoradiotherapy) and 2 cycles of adjuvant CapOx chemotherapy
89175434|NCT04135313|Active Comparator|Chemoradiotherpy|Patients receive 54 Gy pelvic chemoradiotherapy in 2 Gy fractions with capecitabine 825 mg/m2 bid per os on radiation days and then surgery following 10-12 weeks. After surgery patients receive 6 cycles of adjuvant CapOx chemotherapy.
89175435|NCT00785746|Experimental|core|strength training of the core muscles.
89175436|NCT00785746|No Intervention|stretch and strength|This program consists of general stretching exercises and peripheral muscle strengthening exercises with a special emphasis on strengthening the upper extremity muscles because of their importance for ADL but not necessarily balance.
89175437|NCT05262972|Experimental|Group I|The subject will obtain a conservative treatment for this type of pathology consisting of the development of a personalized plantar orthosis
89175438|NCT05262972|Experimental|Group II|The subjects belonging to this group, in addition to providing their corresponding personalized plantar orthosis, will receive a complementary treatment consisting of the application of ultrasound-guided percutaneous electrolysis
89175439|NCT00785824||1 A-A Breastfeeding Mothers|Group 1: Postpartum African-American breastfeeding women at 6-8 weeks post childbirth, and again at 12-14 weeks post childbirth
89175440|NCT00785824||2 - AA Bottlefeeding Mothers|Group 2: Postpartum African-American bottlefeeding women at 6-8 weeks post childbirth and again at 12-14 weeks post childbirth.
89175441|NCT00785824||3 - AA Normal Controls|Group 3: Normal African-American non-pregnant controls who are age-matched to Group 1
89175442|NCT00692159|Experimental|1|Dose finding single arm
89175443|NCT00692315|Experimental|Methyl B12|Subcutaneous injection of 75 micrograms/Kg
89175444|NCT00692315|Experimental|Folinic Acid|400 micrograms orally twice a day
89175445|NCT02609022|Experimental|CV-MG01|The therapeutic vaccine candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
89175446|NCT02609022|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
89175447|NCT02623049||octogenarians patients - Apixaban|octogenarians patients who will be treated with Apixaban
89175448|NCT02623049||younger than 70 years patients - Apixaba|younger than 70 years patients who will be treated with Apixaba
89175449|NCT02623049||octogenarians patients - Rivaroxaban|octogenarians patients who will be treated with Rivaroxaban
89175450|NCT02623049||younger than 70 years patients - Rivaroxaban|younger than 70 years patients who will be treated with Rivaroxaban
89175451|NCT02623049||octogenarians patients - Dabigatran|octogenarians patients who will be treated with Dabigatran
89175452|NCT02623049||younger than 70 years patients - Dabigatran|younger than 70 years patients who will be treated with Dabigatran
89175453|NCT02608944|Experimental|MRI perfusion vs. PET Imaging perfusion|Adenosine Regadenoson O-15 labeled radioactive water MRI PET Imaging
89175454|NCT00696917|Active Comparator|Group A|Three doses according to 0, 1, 6-month schedule
89175455|NCT00696917|Experimental|Group B|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
89175456|NCT00696917|Experimental|Group C|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
89175457|NCT00696917|Experimental|Group D|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
89175458|NCT00913614|Experimental|Age Group 6-11 year old - Dose level 1|
89175459|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 2|
89175460|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 3|
89175461|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 1|
89175462|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 2|
89175463|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 3|
89175464|NCT05756478|Other|Medication Review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria) .
89175465|NCT04032756||Group 1|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced Tofacitinib therapy (n=360). Previous treatment(s) with biologics or immunosuppressants is (are) permitted. About 20-30% of the Tofacitinib patients will biologic-naiv.
89175466|NCT04032756||Group 2|UC-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy (n=120). Previous treatment(s) with biologics or immunosuppressants is (are) allowed.
89175467|NCT00664534|Active Comparator|Glargine|Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)
89175468|NCT00664534|Experimental|Premixed Insulin Lispro|Premixed Insulin Lispro (mid-mixture or low-mixture) 1,2 or 3 injections plus OAMs
89175469|NCT00594035|Experimental|1|Spinal Sealant
89175470|NCT00594035|Active Comparator|2|Standard of care
89175471|NCT02620475|Active Comparator|Gold standard of care|The usual gold standard of wound treatment to prevent scarring is to cover the incision with a self adhesive gauze type dressing (Mepore) covered by paper tape.
89175472|NCT02620475|Experimental|SutureSafe dressings|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
89175473|NCT00913848|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
89175474|NCT00913848|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
89175475|NCT00790972|Placebo Comparator|2|Identical-appearing placebo
89175476|NCT00790972|Active Comparator|1|two sprays in each nostril three times daily for one week
89175477|NCT00796042|Active Comparator|1|Usual Care
89175478|NCT00796042|Experimental|2|Individualized, Community-based, Pressure management and Mobility program:
89175479|NCT04135469|Active Comparator|Referral for tax preparation|Participants will be given contact information on financial services, including all the free tax preparation services in the city, including Boston Medical Center.
89175480|NCT04135469|Experimental|BMC tax preparation|A navigator will help the participants with using free tax preparation services located at Boston Medical Center or a service located elsewhere in the city.
89175481|NCT04135391|Experimental|Pre- and Post- exercise training effects|All recruited subjects received aerobic exercise training (HIIT or MICT). VO2peak, cardiac output (CO), bilateral frontal cortex blood volume (∆[THb]), oxyhemoglobin (∆[O2Hb]) and deoxyhemoglobin (∆[HHb]), ventilation efficiency, serum brain-derived neurotrophic factor (BDNF) levels, cognitive and life quality questionnaire, percentage of neuroblastic cell bearing neurites (% neurites), and cell fluorescent staining were examined before and after interventions.
89175482|NCT02620163|Experimental|YH22162|YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
89175483|NCT02620163|Active Comparator|telmisartan/amlodipine|Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
89175484|NCT02620241|Other|sitting position|infants are in a sitting position for 20 minutes
89175485|NCT02622893|Active Comparator|Transperitoneal laparoscopic nephrectomy|Patients in this group underwent transperitoneal laparoscopic nephrectomy in 45-60º modified flank position after receiving epidural catheter in the sitting position before the surgery.
89175486|NCT02622893|Active Comparator|Retroperitoneal laparoscopic nephrectomy|Patients in this group underwent retroperitoneal laparoscopic nephrectomy in lateral decubitis position after receiving epidural catheter in the sitting position before the surgery.
89175487|NCT05758116|Experimental|Consolidation Tislelizumab|Patients completed radiotherapy alone or sequential chemoradiation with 42 days received consolidation Tislelizumab 200mg every 3 weeks for 12 months.
89175488|NCT00912821|Active Comparator|8 L dialysate|8 L peritoneal dialysis solution
89175489|NCT00912821|Experimental|6 L dialysate|6 L peritoneal dialysis solution
89175490|NCT00692393|Active Comparator|1|Surgery : Hartmann intervention
89175491|NCT00692393|Experimental|2|Surgery : primary resection with anastomosis with protective stoma
89175492|NCT05758038||group 1|Patients with benign thyroid nodules undergo RFA
89175493|NCT05758038||group 2|Patients with benign thyroid nodule undergo MWA
89175494|NCT00922727|Active Comparator|L. reuteri|Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract microflora and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938.
89175495|NCT00922727|Placebo Comparator|Sunflower Oil|Placebo will be the equivalent number of drops of suspended sunflower oil (without LR), provided by Biogaia.
89175496|NCT00570310|Active Comparator|A|Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
89175497|NCT00570310|Placebo Comparator|B|Patients in Group B will be treated with placebo.
89175498|NCT00696995||A|
89175499|NCT02620085||Graves' disease|Patient had been diagnosed of Graves' disease and now under euthyroid status
89175500|NCT02610738|Experimental|Junior KICk-OFF education programme|Participants will attend an age appropriate self management programme (Junior KICk-OFF) designed to improve their knowledge and understanding of type 1 diabetes
89175501|NCT02555020|Experimental|Allocated to MN NPO group,|"Patients was administered in hospital~Randomization~Patient was allocated to MN group~Patients were NPO from mid night (MN) to Surgery"
89175502|NCT02555020|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital~Randomization~Patient was allocated to Placebo group~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
89175503|NCT02555020|Active Comparator|Allocated to Carbohydrated group|"Patients was administered in hospital~Randomization~Patient was allocated to Carbohydrated group~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
89175504|NCT00796198|Active Comparator|Xalatan+Cosopt|Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)
89175505|NCT00796198|Active Comparator|Xalatan|when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)
89175506|NCT00692549|Experimental|Ultrasound|use of ultrasound
89175507|NCT00692549|No Intervention|no ultrasound|no ultrasound
89175508|NCT00791050|Experimental|1 Thermo|
89175509|NCT00791050|No Intervention|2 Control|
89175510|NCT02622503||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis receiving rituximab will be observed for treatment responses.
89175511|NCT00791206|Experimental|1|
89175512|NCT00791206|Other|2|
89175513|NCT05326685|Experimental|Intervention|video with korotkoff sounds
89175514|NCT05326685|No Intervention|Control|standart practice
89175515|NCT00814710|Experimental|Synflorix & Tritanrix-HebB/Hib Group|Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
89175516|NCT00814710|Active Comparator|Hiberix group & Tritanrix-HebB Group|Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
89175517|NCT00796354|Active Comparator|NRL920|
89175518|NCT00796354|Placebo Comparator|Placebo|
89175519|NCT04026204||Coronary cannulation after TAVR|Coronary ostia cannulation after TAVR
89175520|NCT02555566|Experimental|Kidney transplant recipients|"blood sampling is done for determination of EPHX Lys55Arg and other polymorphisms status in Kidney transplant recipients.~flow-mediated distal stimulation of the forearm radial artery by cutaneous heating is assessed for evaluation of EEts level in Kidney transplant recipients."
89175521|NCT05757960|Experimental|Physiotherapy|Using a strictly defined physiotherapy protocol, the effects on temporomandibular dysfunctions are studied.
89175522|NCT00871169|Experimental|Irinotecan, oxaliplatin, and cetuximab|The goal is to administer at least 4 cycles to each patient, but treatment may stop earlier if the treating physician deems stopping to be in the best interest of the patient. Repeated treatment may be given to patients who benefit (either complete or partial response or stabilization of disease)
89175523|NCT02610114|Experimental|Z-Score and computer algorithm|
89175524|NCT02610114|Active Comparator|Z-Score|
89175525|NCT00791362|Other|improvement programme CVD|
89175526|NCT00791362|Other|improvement programme other conditions|
89175527|NCT00814632|Experimental|Study Drug CC 10004|Study drug CC-10004 20mg taken orally twice a day.
89175528|NCT00786136|Experimental|1|perioperative rosuvastatin administration for at least 5 dosages
89175529|NCT00786136|Placebo Comparator|control|blank control of perioperative statin administration
89175530|NCT02622737|Experimental|Functional Training|Functional exercise training program
89175531|NCT02622737|Experimental|Stationary Bike|Stationary bike training program
89175532|NCT02622737|Experimental|Exergaming|Virtual Reality Exposure Therapy
89175533|NCT02622815||Healthy blood donors|10,000 highly controlled blood donors in the age range 30-70 years
89175534|NCT02622815||Moli-sani subjects|A sample of 1,000 tumor cases have been identified so far and samples from these participants will be analyzed compared to 1,000 controls from randomly extracted from the Moli-sani cohort (parent cohort).
89175535|NCT02622815||Cancer patients|4,000 Patients with breast, lung, and gastrointestinal tumors.
89175536|NCT00796588|No Intervention|Control group|Patients undergoing liver surgery without the designated intervention
89175537|NCT00796588|Other|RIPC|application of pneumatic tourniquet in patients undergoing liver surgery
89175538|NCT02554942|Experimental|Epoetin beta|Participants will receive weekly SC injection of epoetin beta (450 international units per kilogram [IU/kg]) for 16 weeks.
89175539|NCT00786214|Experimental|Acupuncture|Patients given acupuncture treatment
89175540|NCT00786214|Sham Comparator|Sham acupuncture|Patients given sham acupuncture treatment
89175541|NCT02619773|Experimental|Mupirocin dressing|"Mupirocin + island dressing applied to surgical incision until postoperative day 5.~Intervention: mupirocin ointment applied to extrication incision."
89175542|NCT02619773|No Intervention|Island dressing|Island dressing applied to surgical incision until postoperative day 2. This arm will not undergo any intervention.
89175543|NCT00791440|Experimental|1|Up to 26 sessions (over a 30 week period) of weekly, individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
89175544|NCT00791440|Active Comparator|2|30 weeks of standard psychiatric treatment.
89175545|NCT02622659|Experimental|Fuganlin Oral Liquid|"Fuganlin Oral Liquid:oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day~Xiaoer Jiebiao Oral Liquid placebo:oral~1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day"
89175546|NCT02622659|Active Comparator|Xiaoer Jiebiao Oral Liquid|"Xiaoer Jiebiao Oral Liquid:oral~1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day~Fuganlin Oral Liquid placebo:oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
89175547|NCT02555488|Experimental|2|in the second group diode laser (810 nm, 1.2 W, 30 s) was irradiated. Then second samples were taken from all canals.
89175548|NCT02555488|Experimental|1|In the first group Photodynamic therapy (PDT) with Methylene blue and diode laser (810 nm, 0.2 W, 40 second) was done
89175549|NCT02554864|Active Comparator|Adductor Canal Block- Injection -Site A|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site A - after the sartorius muscle crosses over the femoral artery
89175550|NCT02554864|Active Comparator|Adductor Canal Block - Injection -Site B|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site B - before the sartorius muscle crosses over the femoral artery
89175551|NCT02554864|Active Comparator|Adductor Canal Block -Injection -Site C|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site C - as the sartorius muscle crosses over the femoral artery
89175552|NCT04134377|Experimental|Protein Food Snack|Provide a high protein food snack the first 2 weeks of each month for 6 months. Each participant will receive an 8 ounce food snack after dialysis for a total of 6 food snacks for each month.
89175553|NCT02622425|Active Comparator|PD01|Carotenoid-producing Bacillus strain PD01
89175554|NCT02622425|Placebo Comparator|Placebo|Maltodextrin
89175555|NCT00786292|Other|Noisy PSV|Assisted mechanical ventilation with noisy PSV
89175556|NCT00786292|Other|PSV|Assisted mechanical ventilation with PSV
89175557|NCT00851318|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
89175558|NCT00851318|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
89175559|NCT00696527||1|
89175560|NCT00791596|Experimental|1|The first Arm received the intervention between baseline and the first follow-up, whereas the second Arm was the Control group
89175561|NCT00791596|Experimental|2|The second Arm received the intervention between the third and the fourth follow-up, whereas the first Arm was the Control group
89175562|NCT00791752|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
89175563|NCT00791752|Placebo Comparator|2|Placebo
89175564|NCT00786370|Active Comparator|Propofol|
89175565|NCT00786370|Experimental|Dexmedetomidine|
89175566|NCT02624609|Placebo Comparator|Control without pomegranate juice|Control meal will be white bread and a glass of water containing the same amounts of sugars naturally present in the pomegranate juice.
89175567|NCT02624609|Experimental|Test with pomegranate juice|Test meal will be white bread with a glass of pomegranate juice
89175568|NCT00796900|Experimental|Dantrolene|
89175569|NCT00796900|Placebo Comparator|Placebo|
89175570|NCT02619461|Experimental|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes.
89175571|NCT02619461|No Intervention|Control|Resting
89175572|NCT00791830|Active Comparator|Irbesartan|
89175573|NCT00791830|Placebo Comparator|Placebo|
89175574|NCT04137809|Experimental|Robot Group|1-arm study where eligible volunteers will undergo robotic testing for safety, comfort, and fit.
89175575|NCT00786448||Group 1|
89175576|NCT00692705|Other|1|Alzheimer's Disease (AD) patients
89175577|NCT00692705|Other|2|Healthy volunteers
89175578|NCT00791986|No Intervention|control|The patients in this control group do not conduct any breathing training.
89175579|NCT00791986|Experimental|ULB|The patients conduct controlled slow breathing training using the WPTB device without inspiratory resistance.
89175580|NCT00791986|Experimental|LB|The patients breath in against resistance using WPTB device.
89175581|NCT04137653|Experimental|nab-Paclitaxel group|749 patients will be assigned into nab-Paclitaxel group.
89175582|NCT04137653|Active Comparator|paclitaxel group|749 patients will be assigned into paclitaxel group
89175583|NCT00786604||1|Those with a cervical spinal cord injury
89175584|NCT00786604||2|Those with a thoracic spinal cord injury
89175585|NCT00786604||3|Healthy, control group
89175586|NCT04137497||Patients with disorders of consciousness|
89175587|NCT04137497||Patients with unresponsive wakefulness syndrome|
89175588|NCT04137497||Patients with minimally conscious state|
89175589|NCT00797056|Experimental|G-CSF|
89175590|NCT00797056|Placebo Comparator|Placebo|
89175591|NCT02622269|Experimental|Patient-regulated compression|Patient-regulated compression device
89175592|NCT02622269|Active Comparator|Standard compression|Standard compression device
89175593|NCT00797134||DR|Diabetic Retinopathy
89175594|NCT02554162|Active Comparator|Extruded wholegrain rye flakes|Rye products with varying structures
89175595|NCT02554162|Active Comparator|Extruded wholegrain rye puffs|Rye products with varying structures
89175596|NCT02554162|Active Comparator|Fresh wholegrain rye bread|Rye products with varying structures
89175597|NCT02554162|Active Comparator|Wholegrain rye beverage|Rye products with varying structures
89175598|NCT02554162|Active Comparator|Fresh wheat bread|Rye products with varying structures
89175599|NCT00792064||1|Kidney-Tx-recipients
89175600|NCT00792064||2|Liver-Tx-recipients
89175601|NCT00792064||3|Heart-Tx-recipients
89175602|NCT00792064||4|Lung-Tx-recipients
89175603|NCT00593957|Experimental|DM1( 0.25 mg/kg /day)|Dextromethorphan 0.25 mg/kg per day
89175604|NCT00593957|Experimental|DM2 (2.5 mg/kg/day)|Dextromethorphan 2.5 mg/kg/day
89175605|NCT00593957|Experimental|DM3 (5mg/kg/day)|Dextromethorphan 5mg/kg/day
89175606|NCT00797290||Photon/Proton Radiation Therapy|Photon/Proton Radiation Therapy
89175607|NCT00697151|Active Comparator|Warfarin|Warfarin (target International Normalized Ratio: 1.4 to 2.8) plus placebo aspirin
89175608|NCT00697151|Active Comparator|Aspirin|Aspirin 325 mg plus placebo warfarin
89175609|NCT04046770|Experimental|Double-Chamber Syringe|Intravenous administration of drugs and flushing with the Double-Chamber Syringe
89175610|NCT04046770|Active Comparator|Classical Syringes|Intravenous administration of drugs and flushing with the classical syringe
89175611|NCT00697229|Experimental|Group A|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
89175612|NCT00697229|Experimental|Group B|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
89175613|NCT00697229|Experimental|Group C|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
89175614|NCT00697229|Experimental|Group D|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
89175615|NCT00697229|Experimental|Group E|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
89175616|NCT00697229|Experimental|Group F|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
89175617|NCT00697229|Experimental|Group G|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
89175618|NCT00697229|Experimental|Group H|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
89175619|NCT00792220|Experimental|MSU|
89175620|NCT00792220|Active Comparator|OCCM|
89175621|NCT00797368|Experimental|Manual Therapy and Exercise|Manual Therapy and Exercise
89175622|NCT00797368|Active Comparator|Home Exercise|Home Exercise
89236306|NCT00858377|Experimental|Arm 1- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 3 cohorts of 14 subjects each. One taxane-resistant tumor type will be evaluated in each cohort.
89236307|NCT00858377|Experimental|Arm 1- Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD) of AMG 900 and if necessary, the MTD with prophylactic GCSF support (MTD-G).
89236308|NCT03864900|Experimental|The intervention group|The medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
89236309|NCT03864900|No Intervention|The control group|Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health.
89236310|NCT00854711|Experimental|nitric oxide|inhaled nitric oxide 80 ppm and oxygen
89236311|NCT00854711|Placebo Comparator|standart of care|no intervention
89236312|NCT00858455|Experimental|Healthy Volunteers|4 period cross over
89236313|NCT00862355|Experimental|1|SPARC147609
89236314|NCT00862355|Active Comparator|2|Reference147609
89236315|NCT02544737|Experimental|Apatinib arm|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
89236316|NCT00858533|Other|workplace health advice|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances.
89236317|NCT00858533|No Intervention|GP sickness absence consultation|Routine general practitioner care for workplace sickness absence.
89236318|NCT00526656|Experimental|sunitinib malate|Drug
89236319|NCT04042649|No Intervention|pre-intervention|Critically ill patients didn't provide environmental intervention (help sleep cycle, provide comfortable environment)
89236320|NCT04042649|Experimental|post-intervention|After providing environmental intervention for critically ill patients
89236321|NCT00854789|Experimental|Vaccine|HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
89236322|NCT00854789|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.
89236323|NCT00858767|Active Comparator|1|2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
89236324|NCT00858767|Active Comparator|2|2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
89236325|NCT00858767|Active Comparator|3|2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
89236326|NCT00617903|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
89236327|NCT00617903|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
89236328|NCT00526110|Experimental|5-Fluorouracil + Docetaxel + Oxaliplatin|5-Fluorouracil 2.2 Gm/m^2 intravenously (IV) over 48 hours on Day 1. Docetaxel 20 mg/m^2 IV over 60 minutes. Oxaliplatin 85 mg/m^2 IV over 120 minutes on Day 1.
89236329|NCT02544581||Mandated impaired professionals|Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
89236330|NCT02544581||Non-mandated adults|A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
89236331|NCT00859001|Experimental|FM+R|4 cycles of FM+R plus Zevalin
89236332|NCT00862511|Experimental|Coated Total Knee Arthroplasty|allergy coated TKA
89236333|NCT00862511|Active Comparator|Standard Total Knee Arthroplasty|normal TKA
89236334|NCT00854867|Experimental|Whole brain radiotherapy (WBRT) with concomitant Depocyte|Subjects will receive a total of 38.4 Gray (Gy) WBRT given over 4 weeks. Subjects will receive 3 GyWBRT on Days 1 and 2 and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 3 (or Day 4 or 5) of Week 1, i.e. the third day of radiotherapy treatment when the dosage is reduced to 1.8 Gy. The second dose will be administered on Day 17(+2 days); the third dose will be administered on Day 31 (+2 days); the fourth dose will be administered on Day 45 (+2 days) to complete the induction phase of the protocol. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
89236335|NCT00854867|Active Comparator|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|Subjects will receive a total of 38.4 Gy WBRT given over 4 weeks. Subjects will receive 3 Gy (WBRT on Day 1 and Day 2) and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 29 (+2 days); the second dose will be administered on Day 43(+2 days); the third dose will be administered on Day 57 (+2 days); the fourth dose will be administered on Day 71 (+2 days) to complete the induction phase of the protocol. DepoCyte should never be administered more frequently than every 14th day. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
89236336|NCT00859079|Active Comparator|GLP-1|Intravenously administered GLP-1
89236337|NCT00859079|Active Comparator|Insulin intravenously|Insulin intravenously according to the Munich registry
89236338|NCT02544425|Experimental|VIDL+ASCT|"VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase~Peripheral blood stem cell mobilization:Etoposide~Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide"
89236339|NCT03889548|Experimental|Mental Imagery|
89236340|NCT03889548|No Intervention|Control|
89175623|NCT02619539||Trauma patients|All patients having / suspected to have severe trauma injuries admitted to participating centers.
89175624|NCT00797446||Photon/Proton Radiation Therapy|Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.
89175625|NCT02621957|Experimental|Female Healthy Volunteers|Healthy volunteer female subjects of non-childbearing potential will be administered pravastatin once on Day 1 during Period 1 (Day -1 to Day 4). During Period 2 (Days 5-28) GDC-0810 will be administered daily on Days 5-8. Pravastatin will be co-administered on Day 7.
89175626|NCT00870233||GYN pts undergoing surgery|This study will assess patient use of WEBCORE, an online system designed for cancer patients to self-record toxicity-related symptoms based on NCI Common Terminology Criteria for Adverse Events and global quality of life (QoL) by European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).
89175627|NCT00696683||A|Patients from the identified scorpion envenomation cases, who met inclusion/exclusion criteria.
89175628|NCT00851084|Active Comparator|mFOLFOX6 only|modified FOLFOX6 chemotherapy regimen
89175629|NCT00851084|Experimental|mFOLFOX6 + aflibercept|modified FOLFOX6 chemotherapy regimen in combination with aflibercept
89175630|NCT04137419|Experimental|ProlacSan|Patient will get ProlacSan lozenges after nonsurgical treatment of periodontitis.
89175631|NCT04137419|Placebo Comparator|Placebo|Patients will get placebo lozenges after nonsurgical periodontal treatment
89175632|NCT02619695|Experimental|Ketoprofen|Interventional arm: ketoprofen gel 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
89175633|NCT02619695|Placebo Comparator|Placebo|Placebo arm: placebo gel form of ketoprofen
89175634|NCT00701948||A-1|Proven nosocomial bacterial infection (NBI)
89175635|NCT00701948||A-2|Possible NBI
89175636|NCT00701948||B-1|Absence of NBI
89175637|NCT00701948||B-2|Probable absence of NBI
89175638|NCT02621879|Experimental|Bilateral Gluteal Advancement Flap|Advancement of both gluteal muscles to the midline after release incisions in their fascia.
89175639|NCT02619383|Experimental|HBOT|All patients were treated with 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
89175640|NCT02621801|Experimental|Intervention|Stress Management and Resiliency Training for Residents (SMART-R)
89175641|NCT02621801|Active Comparator|Waitlist Control|The control group will receive the same intervention (SMART-R) after the experimental group.
89175642|NCT02617199|Experimental|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
89175643|NCT02617199|Active Comparator|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
89175644|NCT02617433|Experimental|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours.
89175645|NCT02619227|Experimental|Immediate treatment|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
89175646|NCT02619227|No Intervention|Delayed treatment|Participants will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
89175647|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 10 mg|
89175648|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 14 mg|
89175649|NCT00845858|Placebo Comparator|Placebo Nasal Spray|
89175650|NCT02617043|Experimental|HF-WBI|Hypofractionated whole breast irradiation for early breast cancer with prescription dose 40Gy in 15 fractions in 3 weeks. Tumor bed is simultaneously integrated boosted to 48Gy.
89175651|NCT02616809|Experimental|Sitting|Participants will sit continuously for 8 hours in a simulated office environment
89175652|NCT02616809|Experimental|slow cycling|Participants will cycle at regular hourly intervals during an 8-hr simulated office environment
89175653|NCT02616809|Experimental|standing|Participants will change posture (from sitting to standing) during hourly intervals for an 8-hr period in a simulated office environment
89175654|NCT02616809|Experimental|slow walking|Participants will transition from sitting to slow walking on a treadmill desk at regular hourly intervals during an 8-hr period in a simulated office environment
89175655|NCT02616653|Active Comparator|Sitting followed by lateral position|First half of participants will be assigned to have their L3-L4 intervertebral space located first in the sitting position followed by the lateral position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
89175656|NCT02616653|Active Comparator|Lateral followed by sitting position|Second half of participants will be assigned to have their L3-L4 intervertebral space located first in the lateral position followed by the sitting position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
89175657|NCT02619149|Active Comparator|Intervention|Piperacillin-tazobactam combination product
89175658|NCT02619149|Placebo Comparator|Control|Saline solution
89175659|NCT04134065|Placebo Comparator|Control group|The physical properties such as appearance, size, color, dosage form, weight, taste and odor of placebo should be as much as possible as the test drug, but should not contain the Vitamin D (such as tablets containing lactose).
89175660|NCT04134065|Experimental|Vitamin D group|Liquid cholecalciferol supplementation (OsteVit DTM, Key Pharmaceuticals, Macquarie Park, NSW, Australia), supplied in 50 mL bottles (5000 units in 1 mL)
89175661|NCT02616731|Active Comparator|Tranexamic acid|
89175662|NCT02616731|Active Comparator|Diosmin|
89175663|NCT00850460|Placebo Comparator|Placebo|Lactose placebo pill
89175664|NCT00850460|Active Comparator|Statins|Statin medications
89175665|NCT00661492|Experimental|Arm 1|Erbitux (cetuximab) and Novantrone (mitoxantrone)
89175666|NCT00661492|Experimental|Arm 2|Novantrone (mitoxantrone)
89175667|NCT04116632|Experimental|BMS-963272 or Placebo once daily (QD)|
89175668|NCT04116632|Experimental|BMS-963272 or Placebo every 12 hours (Q12H)|
89175669|NCT04116632|Experimental|BMS-963272 or Placebo every 8 hours (Q8H)|
89175670|NCT02619071|Experimental|Refractory or relapsed acute myeloid leukemia|
89175671|NCT00693095|Experimental|1|CMV-ALT + CMV-DCs
89175672|NCT00693095|Experimental|2|CMV-ALT + Saline
89175673|NCT02619305|Experimental|Immediate treatment|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
89175674|NCT02619305|No Intervention|Delayed treatment|Participants will be social network ties of women receiving no intervention but who will be placed on a waitlist to receive the intervention after a 12-month delay.
89175675|NCT00850070|Experimental|sapropterin, 100 mg capsules|Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
89175676|NCT00850070|Placebo Comparator|Placebo, matching active drug|The placebo was supplied as a 100 mg tablet, and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
89175677|NCT00797524||DR|Diabetic Retinopathy
89175678|NCT00797524||ARMD|Age-Related Macular Degeneration
89175679|NCT00797524||ME|Macular Edema
89175680|NCT00797602||Proton Radiation|
89175681|NCT04134143|Experimental|Cohort 1: One Application|Participants enrolled in Cohort 1 received one application of experimental skin tissue during the first part of this trial (NCT02657876)
89175682|NCT04134143|Experimental|Cohort 2: Up to Five Applications|Participants enrolled in Cohort 2 may receive up to 5 applications of experimental skin tissue as required for wound healing
89175683|NCT04134143|Experimental|Cohort 3: Up to Ten Applications|Participants enrolled in Cohort 3 may receive up to 10 applications of experimental skin tissue as required for wound healing
89175684|NCT00693251|Experimental|bifurcation stent technique|crush technique
89175685|NCT00693251|Active Comparator|bifurcation stent techniqe|provisional T stenting
89175686|NCT00797680|Experimental|72 hours hypothermia|72 hours hypothermia
89175687|NCT00797680|Experimental|24 hours hypothermia|24 hours hypothermia
89175688|NCT02618837|Active Comparator|Downstream strategy arm|downstream administration strategy of P2Y12 receptor blockers (prasugrel or ticagrelor)
89175689|NCT02618837|Active Comparator|Upstream strategy arm|upstream administration strategy (ticagrelor only)
89175690|NCT00792376|Experimental|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
89175691|NCT00792376|Active Comparator|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
89175692|NCT00592358|Experimental|1|
89175693|NCT00814320|Experimental|1|Efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
89175694|NCT00814320|Experimental|2|Pharmacokinetics of intravenous (IV) infusions of immune globulin intravenous (IGIV), 10% and efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
89175695|NCT00787072|Experimental|1|
89175696|NCT00787072|Placebo Comparator|2|
89175697|NCT04030988|Active Comparator|Active|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
89175698|NCT04030988|Placebo Comparator|Placebo|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
89175699|NCT00792454|Experimental|exercise training/renal rehabilitation|Experimental arm will undergo 12 weeks of training in exercise, meditation, and nutrition education.
89175700|NCT00792454|No Intervention|control|Control co-hort will receive usual chronic kidney disease care and no exercise, meditation or dietary education intervention.
89175701|NCT00703352|Active Comparator|1|Eplerenone
89175702|NCT00703352|Placebo Comparator|2|Placebo
89175703|NCT05326607|Other|First Arm|
89175704|NCT05326607|Other|Second Arm|
89175705|NCT00797758|Experimental|1|Umbilical cord blood transplantation after reduced intensity conditioning
89175706|NCT02618525|Active Comparator|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
89175707|NCT02618525|Active Comparator|Jaw thrust maneuver|Jaw thrust maneuver is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
89175708|NCT00703430|Experimental|1|Memantine
89175709|NCT00797836|Experimental|Quantiferon Gold|
89175710|NCT04046380||normal lungs|
89175711|NCT04046380||Acute respiratory distress syndrome (ARDS) group|
89175712|NCT02618447|Experimental|Arm 1: 4D phase contrast MR scan|"Each patient will undergo a total of 3 MRI/MRA scans (lasting 30-60 minutes):~Scan 1: Baseline (pre-portal vein embolization (PRE))~Scan 2: Early after PVE (within 48 hours)~Scan 3: Late after PVE (at 3-8 weeks).~Scans 1 and 3: routine liver MR sequences with/without contrast (Gadoxetic acid, Eovist) and 4D phase contrast of the portal venous system. The 4D phase contrast sequence will be repeated twice at each time point, adding about 15-30 minutes to each scan.~Scan 2: 4D phase contrast sequences and imaging for localization."
89175713|NCT00693407|Experimental|1, FD patients|Eighty male and female FD patients according to Rome III criteria (Drossman, 2006), aged 18 to 70 years, will be recruited from primary and secondary care via advertisements and our referral networks
89175714|NCT00693407|Experimental|2,Healthy controls|Forty male and female healthy volunteers, aged 18 to 70 years without any gastrointestinal pathology or history of significant abdominal pain, bowel disorders, bloating or discomfort during the last 3 months will be recruited.
89236341|NCT03846635||Patients with Suspected Cellulitis|"Patients who undergo an infectious diseases consultation for suspected cellulitis of the upper or lower limbs are eligible to be enrolled. Patients who consent to participation will have chart data extracted and undergo a skin surface temperature measurement of the affected area and surrounding skin using a commercially available infrared thermometer. The dimensions of suspected cellulitis are also measured.~Patients with cellulitis admitted to hospital undergo daily measurements of temperature and dimensions. These patients are also asked standardized questions about their symptoms based on the patient global impression of improvement scale."
89236342|NCT04130633|Placebo Comparator|Placebo|Placebo (5mL distilled water)
89236343|NCT04130633|Experimental|Vaporized high THC alone|25mg of vaporized pure THC
89236344|NCT04130633|Experimental|Vaporized low alpha-pinene|0.5mg of vaporized alpha-pinene
89236345|NCT04130633|Experimental|Vaporized high alpha-pinene|5mg of vaporized alpha-pinene
89236346|NCT04130633|Experimental|Vaporized high THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 25mg vaporized THC
89236347|NCT04130633|Experimental|Vaporized high THC and high alpha-pinene|5mg of vaporized alpha-pinene with 25mg vaporized THC
89236348|NCT04130633|Experimental|Vaporized low THC alone|10mg of vaporized pure THC
89236349|NCT04130633|Experimental|Vaporized low THC and low alpha-pinene|0.5mg of vaporized alpha-pinene with 10mg vaporized THC
89236350|NCT04130633|Experimental|Vaporized low THC and high alpha-pinene|5mg of vaporized alpha-pinene with 10mg vaporized THC
89236351|NCT00859157||Group 1|Patients undergo standard mastectomy.
89236352|NCT00859157||Group 2|Patients undergo tumescent mastectomy.
89236353|NCT00512148|Experimental|1|Receipt of autologous neo-bladder construct consisting of a device regenerated in the laboratory from the patient's own muscle and urothelial cells
89236354|NCT00859235|Active Comparator|1|
89236355|NCT00859235|Placebo Comparator|2. Plain water|
89236356|NCT04523688|Experimental|Experimental treatment|"Induction phase: 4 weekly doses of dendritic cell vaccine (10x10exp6 cells) intradermally administered (weeks 1-4).~Maintenance phase: 28 days cycles with vaccine administration (start on week 7) and adjuvant temozolomide (150-200mg/m2/day) assumed orally from day 1 to 5 q28 (start on week 5). The combined maintenance treatment will continue until disease progression, unacceptable toxicity or withdrawal of consent by the patient, or up to a maximum of 1 year of treatments.~After disease progression or the end of maintenance phase, is foreseen a one-year follow-up phase for each subject."
89236357|NCT00855023||Asymptomatic Volunteers|healthy volunteer athletes and excluded those who had any of the following criteria: 1) counter-indications to magnetic resonance imaging (e.g., pregnancy or postsurgical hardware [plates, screws, aneurysm clip, implanted cardiac pacemaker, etc.]); (2) relevant medical problems (e.g., connective tissue problems, paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.); (3) clinical signs of an impairment or abnormality in the knee (e.g., abnormal range of motion, muscle weakness, or malalignment); (4) injury to the knee that required medical attention; (5) previous surgery on the knee; or (6) current pain in the knee.
89236358|NCT00862667|Experimental|Treatment A|PF-00241939 300ug using Inhaler A
89236359|NCT00862667|Active Comparator|Treatment B|PF-00241939 300ug using Inhaler B
89236360|NCT00862667|Active Comparator|Treatment C|PF-00241939 300ug using Inhaler C
89236361|NCT02544347|Other|diabetes mellitus group|gingival crevicular fluid was collected
89236362|NCT02544347|Other|Control group|gingival crevicular fluid was collected
89236363|NCT02544347|Other|diabetics with chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
89236364|NCT02544347|Other|chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
89236365|NCT00859391||1 - Active|This group received gluten pre-treated with ALV003
89236366|NCT00859391||2 - Placebo|This group received Gluten pre-treated with placebo.
89236367|NCT04041713|Active Comparator|Rett T|Rett T is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
89236368|NCT04041713|Placebo Comparator|Placebo|Placebo is a powder for oral suspension. Dosage is dependent on weight. For participants weighing <30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in approximately 125 mL of water. For participants weighing ≥30 kg, a 8 g dose (i.e., two 4 g sachets) is intended to be administered orally once a day after dissolving in approximately 250 mL of water.
89236369|NCT00859625|Experimental|1|Nurse participation during colonoscope withdrawal
89236370|NCT00859625|No Intervention|2|usual colonoscopy practice
89236371|NCT00511836|Experimental|VIVITROL 380 mg|
89236372|NCT00511836|Placebo Comparator|Placebo|
89236373|NCT04041245||CSAP group|This group will include 40 patients with chronic stable angina pectoris (CSAP).
89236374|NCT04041245||Healthy group|This group will include 40 healthy volunteers.
89236375|NCT00859703|Placebo Comparator|2|"Patients receive placebo 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
89236376|NCT00859703|Active Comparator|1|"Patients receive risedronate 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
89236377|NCT03998436|Active Comparator|Galnobax® 14% gel plus SoC|Galnobax 14% gel along with Standard of Care (SoC) will be administered twice daily (150 subjects)
89236378|NCT03998436|Sham Comparator|SoC Only|Only Standard of Care will be administered twice daily (150 subjects)
89236379|NCT03998436|Placebo Comparator|Vehicle plus SoC|Vehicle gel along with Standard of Care (SoC) will be administered twice daily (50 subjects)
89236380|NCT00855101|Experimental|voriconazole|
89236381|NCT00573755|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89236382|NCT00573755|Active Comparator|Arm II|Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89236383|NCT02545361|Experimental|KAHR002|premedication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2µg/kg KAHR-102 subcutaneous (SC) injection
89175715|NCT00797914||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
89175716|NCT02616341|Experimental|Team ERP (T-ERP) Intervention|The ERP team intervention (T-ERP) consists of 25 sessions over 20 weeks with four components: (a) 3-4 pretherapy individual session with therapist, (b) 12 weekly group sessions (90-mins) led by a therapist and, (c) 10 individual coaching sessions with a case manager during weeks 2-11 of the group, and (d) 2 booster group sessions to reinforce relapse prevention
89175717|NCT02616341|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes standard community treatment consisting of a personalized treatment plan and assistance with treatment referrals to available community resources
89175718|NCT00787306|Experimental|Multi-faceted Cardiovascular Decision Support|Risk factor active surveillance, multi-disciplinary disease management and decision aid intervention
89175719|NCT00787306|Other|Control Usual Care|Usual care in a wait-list control arm that receives the experimental intervention after 6 months.
89175720|NCT02618681||AMI with earlobe crease|To observe the prognosis for AMI with earlobe crease
89175721|NCT02618681||AMI without earlobe crease|To observe the prognosis for AMI without earlobe crease
89175722|NCT00792532||iMRI|
89175723|NCT02618603|Experimental|BoNT-A treatment group|Ultrasound guided sub-acromial bursa injection with BoNT-A (100 u);
89175724|NCT02618603|Active Comparator|Triamcinolone acetonide treatment group|Ultrasound guided sub-acromial bursa injection with Triamcinolone acetonide (40mg)+1% Lidocaine 2 ml;
89175725|NCT02616497|Active Comparator|Aspirin|100mg/day
89175726|NCT02616497|Active Comparator|Triflusal|300mg twice or 600mg once daily
89175727|NCT00570232|Other|Tarceva|All patients will be prescribed erlotinib 150mg daily
89175728|NCT05755854|Experimental|Patients with recurrent hematologic tumors after allogeneic hematopoietic stem cell transplantation|A conditional chemotherapy regimen of fludarabine and cyclophosphamide will be administered, zoredronic acid depending on the patient's status, followed by investigational therapy, allogeneic γ9δ2 T Cells
89175729|NCT04133129|Experimental|LV-High Intensity Interval Training|2 x 4 minutes at 85%-95% of Heart rate max.
89175730|NCT04133129|Experimental|Moderate Intensity Continuous Training|1 x 45 minutes at 65%-75% of Heart rate max.
89175731|NCT04133129|No Intervention|Control Group|They will not be prescribed any training and will be asked to continue with their normal lifestyle.
89175732|NCT00787384|Experimental|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.
89175733|NCT02616419|Experimental|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
89175734|NCT02616419|Active Comparator|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
89175735|NCT00797992|Experimental|1|Myopic eyes with retinal neovascularization
89175736|NCT02618369|Other|MR-HIFU treatment|"The interventional radiologist will locate the target lesion and mark the volume to be treated using MRI images.~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan."
89175737|NCT04137341|Experimental|Tablet A|A single oral 300-mg dose of GLPG1972 in fasted state
89175738|NCT04137341|Experimental|Tablet B|A single oral 300-mg dose of GLPG1972 in fasted state
89175739|NCT04137341|Experimental|Tablet C|A single oral 300-mg dose of GLPG1972 in fasted state
89175740|NCT04137341|Experimental|Food effect|selected tablet B or C under fed conditions
89175741|NCT00798070|Experimental|Arm A: dtEC→dtT|Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week
89175742|NCT00798070|Active Comparator|Arm B: FEC→T|Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel
89175743|NCT02618291|Experimental|Active Geriatric Evaluation (AGE tool)|The Active Geriatric Evaluation is a comprehensive assessment and management tool consisting of a 20-minute clinical screening instrument (Brief Assessment Tool, BAT) to identify 8 geriatric syndromes, and complementary diagnostic evaluations and propositions of management & treatment for each syndrome.
89175744|NCT02618291|Active Comparator|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
89175745|NCT00693563|No Intervention|Control Group|The Control Group will receive usual care following discharge from the inpatient rehabilitation unit.
89175746|NCT00693563|Experimental|Treatment Group|Scheduled Telephone Intervention
89175747|NCT00809328|Experimental|Azithromycin|Azithromycin switch therapy (switch from intravenous to oral)
89175748|NCT00868517|Experimental|True Group Auricular Acupuncture|Received true group auricular acupuncture twice weekly for a period of two months.
89175749|NCT00868517|Sham Comparator|Sham Group Auricular Acupuncture|Received sham group auricular acupuncture twice weekly for a period of two months.
89175750|NCT00868517|Other|Wait-List Control Group|Served as wait list control. Did not receive any acupuncture during the study period.
89175751|NCT00798148|Experimental|MIBG|
89236384|NCT02544191|Experimental|GnRHa/ hCG/ hMG|3.6mg GnRHa (Goserelin, AstraZeneca UK Limited) every 28days for 5 months. After 2 months from the first Goserelin injection, all subjects were treated with hCG (Pregnyl, N.V. Organon Oss,Holland ) at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG (Urofollitropin for Injection, Livzon Pharm Group Inc., China) at a dose of 150 IU every 3 days for 2 months.
89236385|NCT00524316|Experimental|Sunitinib|oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
89236386|NCT00860093|Experimental|1|MPC-5971
89236387|NCT00860093|Placebo Comparator|2|placebo identical in appearance to study drug
89236388|NCT00862901|Experimental|1|100 J / cm2 over 24 hours
89236389|NCT00862901|Experimental|2|200 J / cm2 over 24 hours
89236390|NCT00862901|Experimental|3|400 J / cm2 over 24 hours
89236391|NCT00862901|Experimental|4|800 J / cm2 over 24 hours
89236392|NCT01320072||Aspirin-sensitive asthmatics|asthma patients with aspirin allergy
89236393|NCT01320072||aspirin-tolerant asthmatics|asthma patients without aspirin allergy
89236394|NCT00855257|Experimental|1|treatment by acid nicotinique
89236395|NCT00855257|Placebo Comparator|2|Treatment by placebo
89236396|NCT03861936|Experimental|BOTOX® 72U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 72 units (U) total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
89236397|NCT03861936|Experimental|BOTOX® 48U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
89236398|NCT03861936|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1.
89236399|NCT02544269|Experimental|Lumbosacral plexus blockade|Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
89236400|NCT02544269|Active Comparator|Continuous spinal anesthesia|Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
89236401|NCT00434577|Experimental|GSK1437173A _LD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) low dose (LD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by intramuscular injection (IM) in the upper deltoid site of the left arm.
89236402|NCT00434577|Experimental|GSK1437173A _MD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) medium dose (MD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
89236403|NCT00434577|Experimental|GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
89236404|NCT00434577|Placebo Comparator|Placebo + GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received a 1st dose of saline solution and a 2nd dose of GSK1437173A high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
89236405|NCT00434577|Active Comparator|GSK1437173A_MODIFIED GROUP|Healthy male or female subjects aged 60 years or older, who received 2 doses of GSK1437173A modified formulation vaccine reconstituted with saline solution, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
89236406|NCT04042181|Placebo Comparator|Placebo|
89236407|NCT04042181|Active Comparator|Bifidobacterium longum|
89236408|NCT00860327||Newborns|Newborns with hypoplastic left heart syndrome who are receiving a right ventricle to pulmonary artery shunt as first stage palliation.
89236409|NCT00860327||Infants|Infants who are undergoing complete repair for tetralogy of Fallot or similar pathology.
89236410|NCT00865085|Experimental|A|Citalopram HBr 40 mg tablets, single dose
89236411|NCT00865085|Active Comparator|B|CelexaTM 40 mg tablets, single dose
89236412|NCT00860483|No Intervention|observational|This is an observational study. no intervention occurs in subjects. their performance in a laparoscopic trainer is observed and correlated with brain activity
89236413|NCT00434421|Experimental|German Cockroach Allergen Dosing Group|Glycerinated German Cockroach Allergenic Extract
89236414|NCT00421707|Experimental|GW876008|GW876008
89236415|NCT00421707|Placebo Comparator|Placebo|Placebo
89236416|NCT00796068|Experimental|Arm I (low risk for graft failure)|"Patients receive a conditioning regimen comprising fludarabine phosphate IV over 1 hour QD on days -6 to -2 and treosulfan IV over 120 minutes on days - 6 to -4. Patients undergo TBI on day -1. Patients then undergo donor UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour or PO 2-3 times daily on days -3 to 100, followed by a taper in the absence of GVHD. Patients also receive mycophenolate mofetil IV 3 times daily on days 0 to 40, followed by a taper in the absence of GVHD."
89236417|NCT00796068|Experimental|Arm II (high risk for graft failure)|Patients receive a conditioning regimen, TBI, donor UCBT, GVHD prophylaxis, and mycophenolate mofetil as in Arm I.
89236418|NCT01029483|Experimental|Low carbohydrate diet|6 week ad libitum low carbohydrate diet; research diet provided at 120% of estimated energy requirement for weight maintenance; carbohydrate intake limited to 28g/d
89236419|NCT01029483|Active Comparator|High Carbohydrate Diet-ad libitum|High complex carbohydrate diet (55% carbohydrate, 18% protein, 27% fat. 120% of estimated energy needs for weight maintenance provided, participants allowed to eat as much or as little as desired to satisfy appetite
89236420|NCT01029483|Active Comparator|High Carbohydrate Diet-Energy-matched|High carbohydrate diet (55% carbohydrate, 18% protein and 27% fat). Energy intake restricted to ~68% of energy needs for weight maintenance. Participants required to eat all food provided and nothing else
89236421|NCT03798288|Experimental|Usual care + selfBACK|"The selfBACK system constitutes a data-driven decision support system that uses case-based reasoning to capture and reuse participant cases to suggest the most suitable self-management plan for participants. The system is an intelligent system delivering self-management plans tailored to individual participant characteristics. Information about participant characteristics is collected via a (baseline) questionnaire, weekly self-reports via the app on symptom progression etc., and a wristband that detect daily number of steps. The weekly plans are presented in an app to participants.~The weekly plan includes three categories of content;~information/education~recommended daily number of steps~recommended strength and flexibility exercises"
89236422|NCT03798288|Active Comparator|Usual care|Any diagnostic or treatment-related pathway (e.g. receive information, advice or treatment) as instructed by their health care professional. Patients are allowed to seek care, treatment or help elsewhere as normal.
89236423|NCT00518622|Experimental|1|25 mg b.i.d. MK7009
89236424|NCT00518622|Experimental|2|75 mg b.i.d. MK7009
89236425|NCT00518622|Experimental|3|250 mg b.i.d. MK7009
89236426|NCT00518622|Experimental|4|500 mg b.i.d. MK7009
89236427|NCT00518622|Experimental|5|700 mg b.i.d. MK7009
89236428|NCT00518622|Experimental|6|125 mg q.d. MK7009
89236429|NCT00518622|Experimental|7|600 mg q.d. MK7009
89236430|NCT00518622|Experimental|8|Placebo
89236431|NCT04732182|Experimental|Standard of care medication for early Alzheimer's disease and BrightGo device cognitive training|Participants randomized to the experimental group will have standard of care and 8 weeks of experimental computer-based therapy on the device. Then they will cross over in the control arm. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
89236432|NCT04732182|Other|Standard of care medication for early Alzheimer's disease|Wait list controls will have standard of care only, before they cross over into the experimental group for BrightGo therapy. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
89236433|NCT01009476||001|
89236434|NCT01009476||002|
89236435|NCT00517296|Experimental|Adalimumab with EUS guided therapy|Patients will be randomized to adalimumab treatment with EUS guided therapy decisions. Colorectal surgeon will have access to EUS data prior to EUA with possible seton placement.
89236436|NCT00517296|Active Comparator|Adalimumab|Patients will be randomized to adalimumab treatment. Colorectal surgeon will not have access to EUS data prior to EUA with possible seton placement.
89236437|NCT00516906|Placebo Comparator|Transparent Adhesive Dressing|Standard of Care Non-Antimicrobial Transparent Adhesive Dressing
89236438|NCT00516906|Experimental|CHG antimicrobial transparent dressing|Chlorhexidine gluconate antimicrobial transparent adhesive dressing
89236439|NCT01565304|Experimental|POWER Through Choices|10-session group-based sexual education curriculum
89236440|NCT01565304|No Intervention|Usual services|No intervention
89236441|NCT00523848|Experimental|Arm 1|Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
89236442|NCT04711200|Experimental|Adipose derived stromal cells intravenously injected|
89236443|NCT00617669|Active Comparator|Placebo + Docetaxel|placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
89236444|NCT00617669|Experimental|ZD4054 + Docetaxel|ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
89236445|NCT00863135|Experimental|Continuous Positive Airway Pressure|nocturnal continuous positive airways pressure
89236446|NCT00863135|Other|Control|Waiting list,3 months without any change in their treatment, come into the CPAP procedure after that time
89236447|NCT04018157|Active Comparator|ketodex|ketamine dexmedetomidine mixture
89236448|NCT04018157|Active Comparator|ketofol|ketamine propofol mixture
89236449|NCT04018157|Placebo Comparator|placebo|normal saline
89236450|NCT00860561||1|Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2 or more prior hormone therapies, or were intolerant to prior hormone therapy and have no endocrine therapeutic options.
89236451|NCT00865241|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
89236452|NCT00865241|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
89236453|NCT00863213|Experimental|Atrial Fibrillation Ablation|
89236454|NCT00863213|Active Comparator|Drug therapy|
89236455|NCT00860639|Active Comparator|gemtuzumab ozogamycin|Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course.
89236456|NCT00860639|No Intervention|without Mylotarg|
89236457|NCT01565226||Open|open, observational study
89236458|NCT00860717|Active Comparator|1|Subjects from the arm number 1 received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
89236459|NCT00860717|Experimental|2|Subjects from the arm number 2 received low level laser therapy 3 times per week for 12 weeks, in addition to the same treatment as patients from the arm number 1.
89236460|NCT03660540|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
89236461|NCT03660540|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
89236462|NCT00863291|Active Comparator|1|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
89236463|NCT00863291|Placebo Comparator|2|Placebo given in a manner similar to he active comparator
89236464|NCT04689282|Experimental|Intranasal M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). M2 were generated in vitro from peripheral blood of a parent during 7 days. Cell-free culture medium, containing M2-BFs, was collected, and aliquots of 2 mL/vial were cryopreserved.~30 children with speech disorders will receive their first doses (n=2-3) of M2-BFs in Clinic and wait 2 hrs to determine any short-time adverse effects of inhaled dose. The subsequent course of intranasal inhalations (once a day up to 30 days) performed as outpatient treatment."
89236465|NCT00860873|Experimental|Test 1|Oral Powder EMS
89236466|NCT00860873|Experimental|Test 2|Hard Capsules EMS
89236467|NCT00860873|Active Comparator|Comparator 1|Oral Powder Zodiac
89236468|NCT00860873|Active Comparator|Comparator 2|Hard capsules - Zodiac
89236469|NCT00865319|Experimental|99 m Tc-EC-DG|99m Tc-Ec-DG injection followed by SPECT/CT imaging (range 20-30 mCi) 1mg EC-DG
89236470|NCT00865319|Active Comparator|18F-FDG|18 F FDG injection followed by PET/CT imaging
89236471|NCT00861029|Experimental|Pazopanib|Subjects will receive pazopanib during study
89236472|NCT00861029|Other|Placebo|Placebo as a comparator to pazopanib
89236473|NCT00865397||A|
89236474|NCT00510510|Experimental|NVA237 100 µg|
89236475|NCT00510510|Experimental|NVA237 200 µg|
89236476|NCT00510510|Placebo Comparator|Placebo|
89236477|NCT00863525|Experimental|1|Odanacatib
89236478|NCT00863525|Placebo Comparator|2|Placebo
89236479|NCT01009632|Experimental|Voice rest|
89236480|NCT01009632|Experimental|Resonant voice exercise|
89236481|NCT01009632|Experimental|Spontaneous speech|
89236482|NCT00863603|No Intervention|1|No exposure to supplemental oxygen
89236483|NCT00863603|Other|Oxygen, treatment, supplement|6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement
89236484|NCT00865475|No Intervention|TZV (Trizivir)|Keeping on TZV in patients with viral suppression
89236485|NCT00865475|Experimental|2|Switching to LPV/r monotherapy
89236486|NCT04685694|No Intervention|Expectant|No medication is assigned.
89236487|NCT04685694|Experimental|Medical|SL 800 mcg Misoprostol
89236488|NCT00870311|Experimental|Blinded Lithium|Bipolar Disorder patients
89236489|NCT01564602|Experimental|single port laparoscopic surgery|2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders
89236490|NCT03567486||Tuberculum sellae meningiomas|Adult patient suffering from tuberculum sellae meningiomas with surgical treatment
89236491|NCT03560388|No Intervention|Control|Control group include participants randomly allocated to supportive care (with no added integrative care or acupuncture)
89236492|NCT03560388|Experimental|Touch/relaxation|Touch/relaxation treatment (pre-operative)
89236493|NCT03560388|Experimental|Acupuncture and touch/relaxation|Acupuncture (intra operative) and touch-relaxation treatment (pre-operative)
89236494|NCT00865631|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
89236495|NCT00865631|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
89236496|NCT00863759|Active Comparator|1|Patients will receive an aspheric intraocular lenses (IOL) Akreos AO in the right eye and an spheric IOL Akreos Fit in the left eye, during cataract surgery.
89236497|NCT00863759|Active Comparator|2|Patients will receive an spheric intraocular lens (IOL) Akreos Fit in the right eye and an aspheric IOL Akreos AO in the left eye, during cataract surgery.
89236498|NCT00863837|Active Comparator|Arm A|add pantoloc to reduce ulcer bleeding after banding ligation
89236499|NCT00863837|Placebo Comparator|Arm B: ligation + terlipressin 1mg q6h|Arm B, intervention: ligation + terlipressin 1mg q6h
89236500|NCT01009866|Experimental|MR1-1|All subjects are enrolled onto this arm. All subjects will receive MR1-1.
89236501|NCT00863915|Experimental|A|Ramipril10 mg Capsules, single dose
89236502|NCT00863915|Active Comparator|B|Atlace® 10 mg capsules, single dose
89236503|NCT01009944|Experimental|Lisinopril, Atenolol|
89236504|NCT01010022|Experimental|1|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
89236505|NCT01010022|Active Comparator|2|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
89236506|NCT04672746|Experimental|Brief MI interaction via instant communication|The interaction communication using brief motivational interviewing will be applied via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
89236507|NCT04672746|Placebo Comparator|General health information|"The subjects will receive general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
89236508|NCT00864071|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
89236509|NCT00864071|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
89236510|NCT00870701|Experimental|Absence of Radiotherapy|No Radiotherapy; Simple monitoring without active treatment
89236511|NCT00870701|Active Comparator|Radiotherapy|Radiotherapy
89236512|NCT00864149|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
89236513|NCT00864149|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
89236514|NCT01010100|Experimental|Arm 1|
89236515|NCT01010100|Placebo Comparator|Arm 2|
89236516|NCT00865787||Olive Oil A|
89236517|NCT00865787||Olive Oil B|
89236518|NCT00870779|Experimental|5-aminolevulinic acid|
89236519|NCT04201470|Experimental|MS patients|Patients with atypical MS identified in our cohort
89236520|NCT04201470|Active Comparator|Controls|
89236521|NCT01010178|Experimental|Macrolid, Theophylline, Corticosteroids|Approved drug in this setting
89236522|NCT04196634||People on sick leave|People on sick leave due to musculoskeletal conditions for at least 4 weeks.
89236523|NCT03998904|Experimental|Muscle preservation|Muscle preservation for hamsting graft
89236524|NCT03998904|Active Comparator|None preservation|No muscle preservation for hamstring graft
89236525|NCT01010256||Subjects diagnosed with CMML|Subjects ages 18 and older with a CMML diagnosis based on the WHO 2009 criteria, and who have signed an informed consent are eligible to participate in the study population of this clinical trial. A total of 12 patients will be consented.
89236526|NCT01010256||Control Group|The control group will consist of subjects ages 18 years or older who are healthy (i.e. no hematologic disorders) and have signed an informed consent. A total of 10 healthy control subjects will be consented.
89236527|NCT01010334|Active Comparator|Arm 1|Standard of Care Treatment
89236528|NCT01010334|Experimental|Arm 2|Treatment Arm of a separate protocol (physician discretion)
89236529|NCT04643418|Experimental|MPB-1734, single arm, dose escalation|intravenous, once per 3 weeks, starting at 10 mg/m˄2
89236530|NCT00617591|Experimental|Induction and Maintenance Therapy|"Induction Phase Followed by Maintenance Therapy.~Patients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.~At the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.~Dd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description."
89236531|NCT00870857||1|Subjects will be 300 HIV+ subjects and 300 HIV- controls selected by random sampling stratified by age and smoking history. Subjects will be recruited from the University of Pittsburgh and the University of Washington (UW) MACS sites. The University of California San Francisco (UCSF) will serve as the recruiting center for the WIHS cohort
89236532|NCT00865865|Other|1|Conventional total knee arthroplasty
89236533|NCT00865865|Active Comparator|2|Computer aided total knee arthroplasty
89236534|NCT00864305|Experimental|A|Gabapentin 400 mg capsules
89236535|NCT00864305|Active Comparator|B|Neurontin 400 mg capsules
89236536|NCT00870935|Active Comparator|Balloon catheter|Hysterosalpingography using intrauterine Balloon catheter
89236537|NCT00870935|Active Comparator|Cervical vacuum cup|Hysterosalpingography using cervical vacuum cup
89236538|NCT00870935|Experimental|Operator choice|Hysterosalpingography is performed using either balloon catheter or cervical vacuum cup on the basis of the operator's choice
89236539|NCT00864461||Case|Patients with clinical and cytogenetics diagnosis of Down syndrome, between 7 - 24 years old.
89236540|NCT00864461||Control|Siblings of the same gender of the case, between 7-24 years old.
89236541|NCT00510276|Experimental|Atomoxetine|
89236542|NCT00510276|Placebo Comparator|Placebo|
89236543|NCT00871091|Experimental|1|CAD/CAM group, customized archwires
89236544|NCT00871091|Active Comparator|2|prefabricated archwires (superelastic)
89236545|NCT00871091|Active Comparator|3|prefabricated archwires with manual adjustments
89236546|NCT00864617|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
89236547|NCT00864617|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
89236548|NCT00865943|Experimental|A|Citalopram HBr eq. 10 mg tablets, single dose
89236549|NCT00865943|Active Comparator|B|CELEXATM 10 mg tablets, single dose
89236550|NCT00866021|Experimental|1|Lopinavir/ritonavir (LPV/r) as single antiretroviral administered concomitantly with peg-interferon and ribavirin
89236551|NCT00866021|Active Comparator|2|Lopinavir/ritonavir (LPV/r) with 2 NRTIs, administered concomitantly with peg-interferon and ribavirin
89236552|NCT00866099|No Intervention|"Normal Care"|Primary care practices randomly allocated will be given a summary of the NICE/SCIE dementia guidelines (2006) and offered workshop training and software at the end of the study.
89236553|NCT00866099|Experimental|Training|Practices randomly allocated to the intervention arm will be asked to participate in tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
89236554|NCT00864695||Surgical patients|Individuals who were hospitalized in the Botucatu Medical School Hospital to undergo surgery under anesthesia administered by the Anesthesiology Service of BMS Department of Anesthesiology.
89236555|NCT00871247|Experimental|A|Finasteride 5 mg single dose tablet, single dose
89236556|NCT00871247|Active Comparator|B|Proscar® 5 mg Tablet, single dose
89236557|NCT01010412|Experimental|Ultrasound|Ultrasound guided nerve localization through direct visualization of the nerves and surrounding structures.
89236558|NCT01010412|Active Comparator|Nerve Stimulation|Standard of Care
89236559|NCT04137120||Patients_Ocular disease|Adult patients treated for wet age-related macular degeneration (wAMD), or diabetic macular edema (DME), or macular edema secondary to central retinal vein occlusion (CRVO), or macular edema secondary to branch retinal vein occlusion (BRVO) or myopic choroidal neovascularization (mCNV) in routine clinical practice in Mexico (overall cohort)
89236560|NCT00616655|Active Comparator|1|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
89236561|NCT00616655|Active Comparator|2|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
89236562|NCT00616655|Placebo Comparator|3|Placebo total daily dose 0.9 mg
89236563|NCT00510198|Active Comparator|Control Arm 1: SOC and CC with OptiVol|Standard of Care and Cardiac Compass with OptiVol as the Control. Intervention is standard of care, such as symptom assessment with the addition of viewing Cardiac Compass trends and the OptiVol diagnostic.
89236564|NCT00510198|Active Comparator|Control Arm 2: SOC|Intervention is Standard of Care alone, such as assessment of symptoms, only. Device trending information, but OptiVol is not allowed.
89236565|NCT01010490|Experimental|Torsional ultrasound|Torsional ultrasound with the INFINITI phacoemulsification system (Alcon Lab, USA)
89236566|NCT01010490|Active Comparator|Longitudinal ultrasound (INFINITI)|Longitudinal ultrasound with the INFINITI phacomachine (Alcon Lab, USA)
89236567|NCT01010490|Active Comparator|Longitudinal ultrasound (LEGACY)|Longitudinal ultrasound with the LEGACY phacomachine (Alcon Lab, USA)
89236568|NCT00871559|Experimental|Q2W|REGN421 (SAR153192) taken once every two weeks (Q2W)
89236569|NCT05227859|Experimental|Piezocision therapy|In this group of patients, the canine will be retracted in association with piezocision.
89236570|NCT05227859|Experimental|Low-level laser therapy|In this group of patients, the canine will be retracted in association with LLLT.
89236571|NCT05227859|Active Comparator|Conventional treatment|In this group of patients, the canine will be retracted conventionally without any acceleration intervention.
89236572|NCT05227781|Experimental|L-Citrulline|L-Citrulline: 10 grams/day
89236573|NCT05227781|Placebo Comparator|Placebo|Maltodextrin: 10 grams/day
89236574|NCT05227469|Experimental|Skeletal class II twinblock + myofunctional therapy|Myofunctional exercises will be prescribed in addition to the standart twin block therapy. Movements will be taught to this group, for which we have prescribed the exercises. It will be ensured that the exercises are done more properly and regularly by taking video recordings every other day from the group that does the exercises twice a day. Incorrect exercises will be corrected by providing feedback.
89236575|NCT05227469|No Intervention|Control|Standard twin block therapy will be used for Class II patients. Patients will be informed that they are involved in a study that follows growth and development, and they will receive feedback on whether they use their devices properly, but no myofunctional exercise.
89236576|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Negative|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
89236577|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Positive|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
89236578|NCT04039997|Experimental|Chest compression without cpr feedback device|teaching resuscitation without application of cpr feedback device
89236579|NCT04039997|Experimental|Chest compression with cpr feedback device|teaching resuscitation with application of CPRMeter - cpr feedback device
89236580|NCT04040855|Experimental|Intervention|Patients in the intervention groups received multi-professional medication reviews. A nurse performed a symptom evaluation, a pharmacist assessed the drug list and made adjustment suggestions and finally a physician took action and performed medication changes.
89236581|NCT04040855|No Intervention|Control|Patients were treated according to the usual routine.
89236582|NCT05227625|Experimental|Body dissatisfaction management group|ACT-inspired group for the management of body dissatisfaction
89236583|NCT05227625|Active Comparator|relaxation group|standardized relaxation program
89236584|NCT00864929||1|Appropriate antimicrobial treatment
89236585|NCT00864929||2|Inappropriate antimicrobial treatment
89236586|NCT00871793|Active Comparator|1|Occupational therapy
89236587|NCT00871793|No Intervention|2|watchful waiting
89236588|NCT00871949|Experimental|Cohort 1, Sequence 1|Period 1- Placebo Period 2- 100 mg Period 3- 300 mg
89236589|NCT00871949|Experimental|Cohort 1, Sequence 2|Period 1- 35 mg Period 2- Placebo Period 3- 300 mg
89236590|NCT00871949|Experimental|Cohort 1, Sequence 3|Period 1- 35 mg Period 2- 100 mg Period 3- Placebo
89236591|NCT00871949|Experimental|Cohort 2, Sequence 1|Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
89236592|NCT00871949|Experimental|Cohort 2, Sequence 2|Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
89236593|NCT00871949|Experimental|Cohort 2, Sequence 3|Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)
89236594|NCT00865007|Experimental|Monotherapy group|Lopinavir/ritonavir (LPV/r).
89236595|NCT00865007|Active Comparator|Triple arm|Lopinavir/ritonavir (LPV/r)+ ABC/3TC
89236596|NCT00866489|No Intervention|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
89236597|NCT00866489|Experimental|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
89236598|NCT00872105|Other|Non-operative treatment|The first treatment strategy will involve conservative (nonoperative) management of the clavicle fracture.
89236599|NCT00872105|Active Comparator|Operative treatment|The second treatment strategy will involve operative fixation (i.e. ORIF) of the fracture with a plate and screws.
89236600|NCT00876083||Group 1|
89236601|NCT00872261||Proxy microbicide product|Use of vaginal lubricant as a proxy microbicide gel; use of multivitamin as proxy pre-exposure prophylaxis (PrEP) product
89236602|NCT00866567||1|Premature infants of less than 28 weeks of gestational age
89236603|NCT00866567||2|Premature infants of more than 28 weeks and less than 32 weeks of gestational age
89236604|NCT00866567||3|Term newborns
89236605|NCT00866567||4|Adults
89236606|NCT05225909||Patients who Undergo ERCP procedure with aScope|This will be patients who undergo ERCP procedure using aScope.
89236607|NCT00876161|Experimental|DAS181|
89236608|NCT00876161|Placebo Comparator|Lactose|
89236609|NCT00872417|Experimental|Treatment-naive|To explore the efficiency and safety of generic antiretroviral drugs for 520 treatment-naive HIV/AIDS patients
89236610|NCT00872417|No Intervention|TREATMENT-EXPERIENCED|To explore the long term ARV of treatment-experienced patients who have no sign of drug resistance; to explore the long term efficiency and safety and drug sife effects of ARV in HIV/AIDS patients. These patients have taken ARV for approximately 3 years already.
89236611|NCT00872417|Experimental|drug resistance|To explore the second line drugs for those drug resistance patients
89236612|NCT00872573|Other|C-Stem™ AMT Femoral Component|
89236613|NCT00876317|Active Comparator|1|Etoricoxib 60 mg per oz for 14 days
89236614|NCT00876317|Active Comparator|2|Etoricoxib 90 mg per oz for 14 days
89236615|NCT00866645|Experimental|1|Intramuscular Levosulpiride
89236616|NCT00866645|Active Comparator|2|Intramuscular Haloperidol
89236617|NCT00872651|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
89236618|NCT00872651|Active Comparator|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
89236619|NCT00866801||Healthy|Healthy subjects scheduled for general anesthesia
89236620|NCT00866801||Healthy with thoracic epidural anelgesia|Healthy subjects scheduled for general anesthesia and thoracic epidural analgesia
89236621|NCT00866801||Diabetes|Subjects with diabetes scheduled for general anesthesia
89175752|NCT00787462|Active Comparator|Active|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
89175753|NCT00787462|Placebo Comparator|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
89175754|NCT02618135|Experimental|Intervention Group|10 child participants in the intervention group will take part in a total of 24 sessions spread over an 8-week period, and a final follow-up review 1 month after the completion of the training session. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy.
89175755|NCT02618135|Other|Control Group|10 child participants in the control group will not receive BCI training during the first 8 weeks of their study participation; they will act as controls. At week 9, subjects in this group will go through the BCI training similar to the intervention group. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy. They will take part in a total of 24 sessions spread over an 8-week period, followed by a final follow-up review 1 month after the completion of the training sessions.
89175756|NCT00792766|Experimental|RAD001|
89175757|NCT02617979|Experimental|Arm 1: SAFECARE at Home|"Patients randomized to the intervention arm will be assigned a username and password to access a SAFECARE at Home account via the internet. They will also be emailed a link to the site with their username and password.~The investigators have worked directly with SAFECARE at Home to create customized lessons for patients undergoing pancreatectomy. These lessons are comprehensive and encompass preoperative preparation as well as postoperative recovery and care. This includes videos, printed material, web-based material, and modules that focus on the pre-treatment, treatment, and follow-up care of patients undergoing surgery for pancreatic cancer.~All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients."
89175758|NCT02617979|No Intervention|Arm 2: Standard of Care|-All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients.
89175759|NCT00787540||I|Coronary Slow Flow Patients
89175760|NCT00787540||II|Coronary Artery Occlusion Patients
89175761|NCT02616107|Experimental|Intervention|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the intervention group and will receive the booklet, Managing Cancer Care: A Caregiver's Guide (MCC-CG) (N=18)
89175762|NCT02616107|Active Comparator|Control|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the control group and will receive the Symptom Management Toolkit (N=17)
89175763|NCT00787696|Experimental|Skills Training|intervention group received information, motivation and skills training: condom application, assertive communication & problem solving
89175764|NCT00787696|Active Comparator|Health Education|Comparsion group received information and motivation
89175765|NCT00798382|Experimental|1: Soy formula|experimental soy formula #1
89175766|NCT00798382|Active Comparator|2: Soy Formula|Commercially available soy formula
89175767|NCT00798382|Experimental|3: Soy formula|experimental soy formula #2
89175768|NCT00868439|Active Comparator|patiromer|
89175769|NCT00868439|Placebo Comparator|placebo|
89175770|NCT00798460|Active Comparator|Lamivudine plus adefovir|
89175771|NCT00798460|Active Comparator|Clevudine plus adefovir|
89175772|NCT00798538|Active Comparator|Integrated|Provision of buprenorphine induction and management, substance abuse counseling and HIV care at one clinic.
89175773|NCT00798538|Placebo Comparator|Non-integrated|Buprenorphine induction, substance abuse counseling and HIV care will be managed at multiple locations, respectively: the Community Health Care Van, the Yale AIDS Program, and individuals' HIV clinics.
89175774|NCT02615873|Experimental|AP CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
89175775|NCT00814164|Experimental|Clorafarbine with daunorubicin|Patients receive clofarabine IV over 1 hour on days 1-5 and daunorubicin hydrochloride IV over 5 minutes on days 1, 3, and 5.
89175776|NCT02609334|Placebo Comparator|Placebo|Matching placebo tables are given as a single dose
89175777|NCT02609334|Active Comparator|CRD007 Low dose|"Low dose of CRD007 (pemirolast sodium) given as a single dose"
89175778|NCT02609334|Active Comparator|CRD007 High dose|"High dose CRD007 (pemirolast sodium) given as a single dose"
89175779|NCT00693641|Active Comparator|1|"Safe Sea™ jellyfish sting inhibitor (barrier, or repellent) lotion"
89175780|NCT00693641|Placebo Comparator|2|Regular sun lotion
89175781|NCT00659230|Placebo Comparator|Placebo|Arm 1
89175782|NCT00659230|Active Comparator|Nepicastat|Arm 2
89236622|NCT00866801||Diabetes with autonomic neuropathy|Subjects with diabetes and cardiovascular autonomic neuropathy scheduled for general anesthesia
89236623|NCT00872807|Experimental|Group intervention|Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality. They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
89236624|NCT00872807|Active Comparator|Individual intervention|Lifestyle counseling for each separate family practiced by single health professionals both in hospital and municipality. A more conventional model.
89236625|NCT00876473||1|Acute Respiratory Failure patients
89236626|NCT00876551|Experimental|E-V.A.C.|Patients that are treated with E-V.A.C.
89236627|NCT00872963||RABIES VACCINE|Those subjects who received the active comparator
89236628|NCT00872963||RTS,S/AS01E|The subjects who received investigational product
89236629|NCT05193539|Experimental|Augmented reality and virtual reality rehabilitation|This group underwent augmented reality and virtual reality rehabilitation for 60 minutes per session, 5 days per week for 2 weeks.
89236630|NCT05193539|Active Comparator|Conventional occupational therapy|This group underwent conventional occutational therapy for 60 minutes per session, 5 days per week for 2 weeks.
89236631|NCT00617357|Experimental|1|Strattice Reconstructive Tissue Matrix
89236632|NCT05168501|Experimental|Lead-In|Multiple rebreathing procedures using methodology developed by Duffin (referred to as Duffin's rebreathing procedure) will be conducted under hyperoxic and hypoxic conditions over the course of a day to confirm feasibility and gather reproducibility data using the procedure.
89236633|NCT04039685|Experimental|Aerobic exercise group|
89236634|NCT04039685|Experimental|Resistance exercise group|
89236635|NCT04039685|Experimental|Combined (aerobic+resistance) exercise group|
89236636|NCT04039685|No Intervention|Non-exercise group|
89236637|NCT00876707|Active Comparator|Tecnis|
89236638|NCT00876707|Active Comparator|ReSTOR|
89236639|NCT00876707|Active Comparator|ReZoom|
89236640|NCT00876785|Active Comparator|1|Reference wheat bread breakfast
89236641|NCT00876785|Experimental|2|Rye bread breakfast
89236642|NCT03838757||Patients|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
89236643|NCT03838757||Healthy controls|Maximal exercise capacity was assessed using cardiopulmonary exercise testing (CPET), exercise capacity six minute walk test, physical activity multi-sensor activity monitor, pulmonary function spirometry, respiratory muscle strength mouth pressure device, peripheral muscle strength hand held dynamometer, dyspnea Modified Medical Research Council Dyspnea Scale (MMRC), fatigue Fatigue Severity Scale, quality of life The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and Functional Assessment of Cancer Therapy - Lung cancer quality of life questionnaire (FACT-L), depression Montgomery Asberg Depression scale, sleep of quality Pittsburgh Sleep Quality index and cough using Leicester Cough Questionnaire were evaluated.
89236644|NCT04040543|Experimental|Daily|Daily supplementation with product containing markers
89236645|NCT04040543|Experimental|Intermittent|Daily supplementation with either the product containing markers or the product not containing markers
89236646|NCT04040543|Placebo Comparator|Control|Daily supplementation with product not containing markers
89236647|NCT00873197|Experimental|Sancuso® patch/IV granisetron|Subjects will receive 1 Sancuso® patch worn for 7 days (168 hours). Immediately after the patch has been applied on Day 1, IV granisetron will be administered over 30 seconds. Following patch removal at 168 hours, a new patch will be immediately applied to the opposite arm and will remain in place for a further 7 days (168 to 336 hours).
89236648|NCT00873353|Experimental|Unique arm|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
89236649|NCT00876941|Experimental|Standard Brief Intervention|
89236650|NCT00876941|Experimental|Enhanced Brief Intervention|
89236651|NCT00876941|Active Comparator|Control|
89236652|NCT00877097|Experimental|1|Clodronate 800 mg / day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
89236653|NCT00877097|Placebo Comparator|2|Placebo 2 tablets/ day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
89236654|NCT00877097|Active Comparator|3|Clodronate 800 mg / day for five years.
89236655|NCT00873431|Experimental|IC47 30 mcg|30 mcg with Alum
89236656|NCT00873431|Experimental|IC47 30 mcg w/o|30 mcg without Alum
89236657|NCT00873431|Experimental|IC47 150 mcg|150 mcg with Alum
89236658|NCT00873431|Experimental|IC47 150 mcg w/o|150 mcg without Alum
89236659|NCT00877175|Experimental|1|Lower conjunctival fornix packing arm. For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix.
89236660|NCT00877175|Active Comparator|2|Conventional instillation arm. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
89236661|NCT00867347|Active Comparator|Arm I|"Patients undergo a radical cystectomy, including pelvic lymphadenectomy,~between 4 and 6 weeks after initiating course 4 of chemotherapy."
89236662|NCT00867347|Experimental|Arm II|Patients with no visible residual tumor (cT0 or pT0) or residual but superficial tumor (pTa, pT1) undergo radiotherapy beginning within 4-6 weeks of day 1 of course 4 and continuing for 6.5 weeks.
89236663|NCT00420927|Experimental|ADA+MTX/PBO+MTX (Arm 1)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
89236664|NCT00420927|Experimental|ADA+MTX/ADA+MTX (Arm2)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
89236665|NCT00420927|Experimental|ADA+MTX/OL ADA+MTX (Arm 3)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
89236666|NCT00420927|Experimental|PBO+MTX/PBO+MTX (Arm 4)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
89236667|NCT00420927|Experimental|PBO+MTX/OL ADA+MTX (Arm 5)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.
89236668|NCT00573443|Experimental|DM 30 mg/Q 10 mg|AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
89236669|NCT00573443|Experimental|DM 20 mg/ Q 10 mg|AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
89236670|NCT00573443|Placebo Comparator|Placebo|Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks
89236671|NCT01029561|Active Comparator|CPAP and diet|The patients with severe OSA (AHI>=30) who do not fulfill the specific exclusion criteria wil be randomized. In the CPAP and diet arm, patients wil receive Continuous Positive air pressure therapy and the regular dietary treatment.
89236672|NCT01029561|Active Comparator|Diet|The diet arm wil receive the Conventional diet treatment that usually receive the patients included in the Bariatric Surgery Program
89236673|NCT05225831|Experimental|SL19+22 CAR-T|Eligible patients will be treated with SL19+22 CAR-T.
89236674|NCT00873509|Experimental|1|Buspirone 2.5 mg
89236675|NCT00873509|Experimental|2|Buspirone 5.0 mg
89236676|NCT00873509|Placebo Comparator|3|Placebo match
89236677|NCT00873587|Other|Inspiration|
89236678|NCT00873587|Other|Expiration|
89236679|NCT00867425|Experimental|Intervention|
89236680|NCT00877253|Experimental|Dose Level One|
89236681|NCT00877253|Experimental|Dose Level Two|
89236682|NCT00877253|Experimental|Dose Level Three|
89236683|NCT05225753||patients treated with Affixus Zimmer-Biomet|
89236684|NCT05225753||patients treated with EBA2 Citieffe|
89236685|NCT05225753||patients treated with Proximal Femoral Nail Antirotation Synthes|
89236686|NCT00877331|Experimental|1|Brief intervention using motivational interviewing. One in-person session (30-45 minutes) with a brief phone follow-up one week later.
89236687|NCT00877331|No Intervention|2|Enhanced care as usual.
89236688|NCT00867581||1|chronic-stage patients after infarction in the territory of unilateral middle cerebral artery
89236689|NCT00867581||2|age, sex and risk factor matched volunteers without ischemic stroke
89236690|NCT00873665|Experimental|Aerobic exercise|"To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.~The test of the arm effect of incidence of ED will be made with the Wald chi-square test from the logistic regression model. A dichotomous variable indicating whether the patient received PDE-5 inhibitor therapy will be used as a covariate in the model. The arm effect will be summarized by giving arm-specific covariate-adjusted proportions and their 80% confidence intervals, and the p-value."
89236691|NCT00873665|Other|Wait-list control|"To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.~For the analyses of arm differences in erectile dysfunction (IIEF) score, sexual functioning, urinary incontinence, and QOL, the primary endpoints will be the change across time in these continuous variables. Specifically, change across time for LTF patients will be imputed to be zero for all these analyses."
89236692|NCT00877409|Active Comparator|Acnase|
89236693|NCT00877409|Placebo Comparator|Vehicle|
89236694|NCT00873743||1|60 women after elective cesarian section
89236695|NCT00873743||2|60 women after elective cesarian section
89236696|NCT00873899||Remote Arm|The patients in Remote arm will receive a Medtronic CareLink Monitor to perform remote interrogation and transmission of ICD data. The remote arm ICD will be programmed to transmit over the CareLink Network.
89236697|NCT00873899||Implantable defibrillator patients|Heart failure patients implanted with a wireless-transmission-enabled ICD.
89236698|NCT00873977|Active Comparator|C-flex|
89236699|NCT00873977|Active Comparator|A-flex|
89236700|NCT00873977|No Intervention|Auto-CPAP|
89236701|NCT00874133|Active Comparator|Motillium|20 mg motilium thrice daily for 12 weeks.
89236702|NCT00874133|Active Comparator|Acupuncture|Acupuncture treatment.
89236703|NCT00867737|Experimental|Advair 115/21 MDI|Advair HFA 115/21 MDI Intervention = initiate intervention after screening
89236704|NCT00867737|Active Comparator|2 = Symbicort 160/4.5|Symbicort initiated after screening
89236705|NCT00874211||Observation|Patients will be observed and will undergo assessment of therapy complications.
89236706|NCT00877643|Experimental|Upstream rhythm control|
89236707|NCT00877643|Active Comparator|Conventional rhythm control|
89236708|NCT00874289||Acute heart failure patients|
89236709|NCT00874289||Chronic heart failure patients|
89236710|NCT04040465|Active Comparator|Normal Weight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
89236711|NCT04040465|Active Comparator|Normal Weight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
89236712|NCT04040465|Active Comparator|Normal Weight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
89236713|NCT04040465|Active Comparator|Overweight/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
89236714|NCT04040465|Active Comparator|Overweight/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
89236715|NCT04040465|Active Comparator|Overweight/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
89236716|NCT04040465|Active Comparator|Obese/Low Dose Aspirin|BMI 22-25 kg/m^2 & receiving 81mg Aspirin daily for 2 weeks
89236717|NCT04040465|Active Comparator|Obese/Normal Dose Aspirin|BMI 25-30 kg/m^2 & receiving 325mg Aspirin daily for 2 weeks
89236718|NCT04040465|Active Comparator|Obese/High Dose Aspirin|BMI > 30 kg/m^2 & receiving 500mg Aspirin daily for 2 weeks
89236719|NCT00874445||ICD shocks programmed to Tuned Waveform|ICD shocks programmed to Tuned Waveform
89236720|NCT00874445||ICD shocks programmed to Fixed Tilt Waveform|ICD shocks programmed to Fixed Tilt Waveform
89236721|NCT00420849|Experimental|Lenalidomide plus Dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
89236722|NCT00617279|Active Comparator|GORE PROPATEN Vascular Graft:|
89236723|NCT00617279|Active Comparator|Disadvantaged Autologous Vein Graft|
89236724|NCT00877721|Experimental|balance treatment|
89236725|NCT00874523|Active Comparator|Arm A|
89236726|NCT00874523|Active Comparator|Arm B|
89236727|NCT00874601|Experimental|valsartan group|The valsartan group will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
89236728|NCT00874601|No Intervention|control group|Patients on control group will not receive any other antihypertensive medication for first 7 days after stroke onset. However, rescue therapy with antihypertensive agents can be permitted for episodes with severely elevated blood pressures during acute periods.
89236729|NCT00874679||Group 1|
89236730|NCT00420381|Experimental|A|
89236731|NCT01032681|Experimental|Group 1|Dose escalation of EMD 521873 monotheraphy 3 doses per cycle
89236732|NCT01032681|Experimental|Group 2|Low dose CPA + Dose escalation of EMD 521873 three doses per cycle
89236733|NCT01032681|Experimental|Group 3|Dose escalation of EMD 521873 monotheraphy 1 dose per cycle
89236734|NCT00867893||DA group|RLS patients started treatment on dopamine agonists within the past year
89236735|NCT00867893||NonDA|RLS patients started treatment on medication other than dopamine agonists within the past year
89236736|NCT00617201|Experimental|1|Atomoxetine
89236737|NCT00617201|Placebo Comparator|2|Matched Placebo
89236738|NCT00420303|Experimental|A|
89236739|NCT00420303|Placebo Comparator|B|
89236740|NCT00617123|Experimental|Vorapaxar|Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year
89236741|NCT00617123|Placebo Comparator|Placebo|Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year
89236742|NCT00877955|Active Comparator|alprazolam sublingual tablet reference|
89236743|NCT00877955|Experimental|alprazolam sublingual tablet test|
89236744|NCT00419757|Active Comparator|Symbicort|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
89236745|NCT00419757|Active Comparator|Budesonide|budesonide HFA pMDI 160 μg x 2 actuations twice daily
89236746|NCT00874913|Experimental|Laser Doppler Flowmetry|
89236747|NCT00878033||1|Diabetic Dialysis Patients
89236748|NCT00878033||2|Non-Diabetic Dialysis Patients
89236749|NCT00878033||3|Healthy Controls
89236750|NCT00878111|Experimental|A: escalating dose levels of NGR-hTNF|NGR-hTNF administered at high doses
89236751|NCT00867971||RGH treated|
89236752|NCT00867971||Starting treatment with RGH|
89236753|NCT00434109|Experimental|Sunitinib Malate and Hepatic Artery Embolizations|Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations.
89236754|NCT00875069|Experimental|ethanol|
89236755|NCT00875069|Placebo Comparator|placebo|
89236756|NCT01029639|No Intervention|Treatment|Diabetic patients will complete hypoglycemia unawareness questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on low blood sugar incidences reported by subjects requiring heath care intervention other than by the subject themselves.
89236757|NCT01029639|Experimental|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
89236758|NCT00875147||with bevacizumab|Neoadjuvant chemotherapy with bevacizumab
89236759|NCT00875147||without Bevacizumab|Neoadjuvant chemotherapy without Bevacizumab
89236760|NCT01566513|No Intervention|Treatment as usual|
89236761|NCT01566513|Experimental|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
89236762|NCT01566513|Experimental|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
89236763|NCT01566513|Experimental|Peer Case Manager|If a participant is randomized into this condition, they are offered the chance to work with a Case Manager, who is trained in strengths-based case management.
89236764|NCT05226845|Experimental|exercise to improve the neck strength in neck pain chosen by the therapist|
89236765|NCT05226845|Experimental|exercise to improve the neck strength in neck pain chosen by the patient|
89236766|NCT00875225|Active Comparator|Control DVD|Control DVD with usual care information
89236767|NCT00875225|Active Comparator|Intervention DVD|Intervention group will receive DVD with patient stories and information from health care professionals
89236768|NCT01034943|Active Comparator|External fixation|Operation with external fixation and optional addition of k-wire
89236769|NCT01034943|Active Comparator|Volar plate|Operation with Synthes volar two column plate (TCP)
89236770|NCT00433329|Experimental|Bosentan|Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
89236771|NCT01035021|Active Comparator|group N|Anesthesia is induced with propofol and remifentanil and LMA is inserted by the standard technique according to eht manufacturer's instruction. Rocuronium is administered for the operation.
89175783|NCT04133831|No Intervention|Condition 1: Combined only|Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals.
89175784|NCT04133831|Experimental|Condition 2: Combined plus Total|Participants randomized to Condition 2 will view combined transplant survival and total survival outcome information when making a choice between the two hospitals.
89175785|NCT04133831|Experimental|Condition 3: Stratified only|Participants randomized to Condition 3 will view only stratified transplant survival outcome information when making a choice between the two hospitals.
89175786|NCT04133831|Experimental|Condition 4: Stratified plus Total|Participants randomized to Condition 4 will view stratified transplant survival and total survival outcome information when making a choice between the two hospitals.
89175787|NCT04133831|Experimental|Condition 5: Total only|Participants randomized to Condition 5 will view only total survival outcome information when making a choice between the two hospitals.
89175788|NCT00693797||I, observation|patients with aortic stenosis
89175789|NCT00693797||II, observation|patients with aortic stenosis
89175790|NCT00792844|Experimental|Bio-K capsule|1 capsule of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for duration of antibiotic therapy and 7 days after or until discharge, whichever comes first
89175791|NCT00792844|Active Comparator|Bio-K liquid|98 g of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever comes first
89175792|NCT00792844|No Intervention|no Bio-K|No lactobacillus product - standard infection control procedures (i.e. handwashing, etc.)
89175793|NCT02615795|No Intervention|Control|Best practice
89175794|NCT02615795|Experimental|Intervention|Best practice + Tele Monitoring of physiological parameters (heart frequence, oxygen saturation, weight, FEV1), and answers to disease specific questions, using Tunstall monitoring device.
89175795|NCT00809094|Placebo Comparator|Placebo|Placebo was administered oral tablet TID for 24 weeks.
89175796|NCT00809094|Active Comparator|N-Acetylcysteine|Participants received 900 mg of oral N-acetylcysteine TID for 24 weeks.
89175797|NCT00658996|Experimental|SofLens DD Toric|Bausch & Lomb SofLens Daily Disposable Toric Contact Lens
89175798|NCT00658996|Active Comparator|Ciba Vision Toric Lens|Ciba Vision Focus Dailies Toric Contact Lens
89175799|NCT02615639|Experimental|HPDC-T cells & entecavir|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks , and entecavir(ETV) 0.5mg tablet by mouth, every night.
89175800|NCT02615639|Active Comparator|entecavir|entecavir 0.5mg tablet by mouth, every night.
89175801|NCT02615639|Experimental|HPDC-T cells & IFN-a-2a|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
89175802|NCT02615639|Active Comparator|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
89175803|NCT02615639|Experimental|HPDC-T cells & Telbivudine|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and Telbivudine 600mg tablet by mouth, every night.
89175804|NCT02615639|Active Comparator|Telbivudine|Telbivudine 600mg tablet by mouth, every night.
89175805|NCT00798616|Placebo Comparator|Responders/Placebo|Albuterol responders being given placebo
89175806|NCT00798616|Active Comparator|Responders/Steroids|albuterol responders being given steroids
89175807|NCT00798616|Placebo Comparator|Non-responders/placebo|non-albuterol responders being given placebo
89175808|NCT00798616|Active Comparator|non-responders/steroids|non-albuterol responders being given steroids
89175809|NCT02618057|Experimental|Steroid|Prednisolone, 1.0 mg/kg/day, PO, for 5 days Levofloxacin, 10mg/kg/day, IV, for 5days
89175810|NCT02618057|Active Comparator|Control|Levofloxacin, 10mg/kg/day, IV, for 5days
89175811|NCT02617823|No Intervention|semi-recumbent|rutine positioning at the hospital today
89175812|NCT02617823|Experimental|lateral position|experimental position to be evaluated against rutine
89175813|NCT00867815|Other|Arm 1|
89175814|NCT04030728||Group 1: Standardized coaching arm|Patients in this group receive a continuous standardized MOATT based patient education and coaching and optional eMBSR (electronic Mindfulness-Based Stress Reduction) within the first 24 weeks of Abemaciclib treatment.
89175815|NCT04030728||Group 2: Coaching according to local practice|Patients in this group receive a patient management according local routine.
89175816|NCT00922168||Cardiac Surgeries: CABG, valve replacements|
89175817|NCT04137029|Experimental|smoking|Healthy smoking volunteers
89175818|NCT04137029|Experimental|non-smoking|Healthy non-smoking volunteers
89175819|NCT00452413|Experimental|Enzastaurin and erlotinib combination therapy|"Enzastaurin:~Phase 1, Dose Level 1: 500 milligram (mg) oral loading dose Day 1, 250 mg oral, daily Day 2-28, 28-day cycle until disease progression~Phase 1, Dose Level 2: 1125 mg oral loading dose Day 1, 500 mg oral, daily until disease progression~Phase 2: Dose determined from Phase 1, oral, daily, 28-day cycles until disease progression~Erlotinib:~• 150 mg, oral, daily, 28-day cycles until disease progression"
89175820|NCT00793000|Experimental|Cohort 1|
89175821|NCT00793000|Experimental|Cohort 2|
89175822|NCT00793000|Experimental|Cohort 3|
89175823|NCT00793000|Experimental|Cohort 4|
89175824|NCT00793000|Experimental|Cohort 5|
89175825|NCT00793000|Experimental|Cohort 6|
89175826|NCT00793000|Experimental|Cohort 7|
89175827|NCT00793000|Experimental|Cohort 8|Japanese volunteers, low dose previously tested (based on PK)
89175828|NCT00793000|Experimental|Cohort 9|Japanese volunteers, intermediate dose previously tested (based on PK)
89175829|NCT00793000|Experimental|Cohort 10|Japanese volunteers, high dose previously tested (based on safety)
89175830|NCT05091450|Experimental|Couple-based I-BMS intervention for infertility|The I-BMS intervention will be conducted face-to-face and in group format. It comprises four 3-hour sessions within one month. Two registered social workers who are professionally trained on I-BMS intervention model will deliver the intervention.
89175831|NCT05091450|Other|Waitlist control|Couples allocated in the waitlist control group will begin the I-BMS intervention (same as the intervention group) after completing the 1-month follow-up assessment.
89175832|NCT04134533||Oral Feeding Group|Children with cerebral palsy who fed orally according to the Functional Oral Intake Scale
89175833|NCT04134533||Non-Oral Feeding Group|Children with cerebral palsy who fed non-orally according to the Functional Oral Intake Scale.
89175834|NCT00798772|Experimental|A: Broad spectrum micronutrients|"The experimental treatment medications (micronutrients and antioxidants) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
89175835|NCT00798772|Active Comparator|B: Identical appearing multivitamins|"The active comparator/control medications (identical appearing RDA multivitamins and minerals) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
89175836|NCT00867503|Experimental|bendamustine|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
89175837|NCT05055648|Active Comparator|Photon Arm|Standard arm with neoadjuvant chemoradiotherapy (nCXT) with photons
89175838|NCT05055648|Experimental|Proton Arm|Experimental arm with neoadjuvant chemoradiotherapy (nCPT) with protons
89175839|NCT04134299|Experimental|AXA4010|AXA4010
89175840|NCT00793156|Placebo Comparator|Placebo|Patients will be randomized into Placebo group
89175841|NCT00793156|Active Comparator|2|2.5 µg group randomized
89175842|NCT00793156|Active Comparator|3|5.0 µg group randomized
89175843|NCT04132739|No Intervention|Control|
89175844|NCT04132739|Experimental|Exercise only|
89175845|NCT04132739|Experimental|Diet only|
89175846|NCT04132739|Experimental|Diet + Exercise|
89175847|NCT00798850|Active Comparator|PTA|
89175848|NCT00798850|Active Comparator|SEP|
89175849|NCT00798850|Active Comparator|PTA+SEP|
89175850|NCT05757726|Experimental|Interventional Arm|
89175851|NCT02613104|Experimental|Sad to Happy|emotion recognition modification - sad>happy
89175852|NCT02613104|Placebo Comparator|Sad control|emotion recognition modification - sad>happy control
89175853|NCT02613104|Experimental|Angry to Happy|emotion recognition modification - angry>happy
89175854|NCT02613104|Placebo Comparator|Angry control|emotion recognition modification - angry>happy control
89175855|NCT02615561|Experimental|Phase 1 (Cure phase)|Efficacy and safety of the medical device Bepanthen Itch Relief Cream in children´s mild AD (responders will enter study phase 2)
89175856|NCT02615561|Experimental|Phase 2 (Care phase) / Arm 1|Efficacy and safety of the new cosmetic Bepanthen test product in maintaining healthy skin in the remission phase after cure of children´s mild AD
89175857|NCT02615561|Active Comparator|Phase 2 (Care phase) / Arm 2|Efficacy and safety of Stelatopia (cosmetic comparator) in maintaining healthy skin in the remission phase after cure of children´s mild AD
89175858|NCT00799006|Placebo Comparator|Placebo|
89175859|NCT00799006|Experimental|PF-04620110|
89175860|NCT00693953||1|Year one
89175861|NCT00693953||2|Year two
89175862|NCT00793234|Experimental|1|0.3 mg/kg TB-402
89175863|NCT00793234|Experimental|2|0.6 mg/kg TB-402
89175864|NCT00793234|Experimental|3|1.2 mg/kg TB-402
89175865|NCT00793234|Active Comparator|4|
89175866|NCT04571112|Experimental|NBM ON|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.~The NBM ON arm will have constant NBM stimulation for 8 weeks."
89175867|NCT04571112|Sham Comparator|NBM OFF|"The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over.~The NBM OFF arm will have NBM stimulation turned off for 8 weeks."
89175868|NCT04133597|Experimental|Interventional|Two experimental steps: baseline skin conductance measurements (step 1, three minutes) and measurements of SC after social media stimulation with Line messages or calls (step 2, three minutes). With a 5-minute rest period after these two steps completed, then each participant fill out questionnaires for assessing anxiety and problematic smartphone use.
89175869|NCT00697775|Experimental|Group A|HBV-MPL Formulation A at months 0 and 6
89175870|NCT00697775|Experimental|Group B|HBV-MPL Formulation B at months 0 and 6
89175871|NCT00697775|Experimental|Group C|HBV-MPL Formulation A at month 0 and Engerix™-B at month 6
89175872|NCT00697775|Active Comparator|Group D|Engerix™-B at months 0, 1, 6
89175873|NCT00799084|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
89175874|NCT00799084|Experimental|AVR|Receives symptom management assistance from an Automated telephone system
89175875|NCT02609958|Experimental|Treatment Arm A|Varlitinib (ASLAN001) tablets
89175876|NCT04133051|Active Comparator|Quadratus Lumborum Block|17 cases will be subjected to bilateral Ultrasound-guided Quadratus lumborum block through bilateral catheter insertion for perioperative analgesia.
89175877|NCT04133051|Active Comparator|Epidural Analgesia|17 cases will be subjected to epidural catheter insertion for perioperative analgesia (as a control group).
89175878|NCT00788242|Experimental|1|Administration of glucose-insulin-potassium
89175879|NCT00788242|Placebo Comparator|2|
89175880|NCT05039970|Experimental|Experimental Arm - WellQuest™ Users|Participants in National DPP groups randomized to the experimental arm will be instructed by lifestyle coaches to download the WellQuest™ game application and will receive instructions on how to use the game throughout the LCP.
89175881|NCT05039970|No Intervention|Control Arm|Participants in National DPP groups randomized to the control arm will proceed with their routine National DPP participation.
89175882|NCT00694031|Active Comparator|A|Hemodialysis
89175883|NCT00694031|Experimental|B|On-line hemodiafiltration
89175884|NCT02609802|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
89175885|NCT02609802|Experimental|Desflurane|Anesthesia was maintained with desflurane.
89175886|NCT02617745|Experimental|Stupp protocol|Blood assessment of the platelet level every week during the radiotherapy phase and every cycle during the chemotherapy
89175887|NCT02609646||linezolid|patients treated with linezolid
89175888|NCT02609646||meropenem|patients treated with meropenem
89175889|NCT02609646||piperacillin/tazobactam|patients treated with piperacillin/tazobactam
89175890|NCT02609646||vancomycin|patients treated with vancomycin
89175891|NCT02610504|Experimental|Durolane 3ml|Single intra-articular injection into shoulder
89175892|NCT04136873|Active Comparator|Part A: 5 mg QD CVL-231|Oral Dose
89175893|NCT04136873|Placebo Comparator|Part A: 5 mg QD Placebo|Matching Placebo; Oral Dose
89175894|NCT04136873|Active Comparator|Part A: 10 mg QD CVL-231|Oral Dose
89175895|NCT04136873|Placebo Comparator|Part A: 10 mg QD Placebo|Matching Placebo; Oral Dose
89175896|NCT04136873|Active Comparator|Part A: 20 mg QD CVL-231|Oral Dose
89175897|NCT04136873|Placebo Comparator|Part A: 20 mg QD Placebo|Matching Placebo; Oral Dose
89175898|NCT04136873|Active Comparator|Part A: 5-10-20 mg BID CVL-231|Oral Dose
89175899|NCT04136873|Placebo Comparator|Part A: 5-10-20 mg BID Placebo|Matching Placebo; Oral Dose
89175900|NCT04136873|Active Comparator|Part A: 30 mg QD CVL-231|Oral Dose
89175901|NCT04136873|Placebo Comparator|Part A: 30 mg QD Placebo|Matching Placebo; Oral Dose
89175902|NCT04136873|Active Comparator|Part B 30 mg QD CVL-231|Oral Dose
89175903|NCT04136873|Placebo Comparator|Part B 30 mg QD Placebo|Matching Placebo; Oral Dose
89175904|NCT04136873|Active Comparator|Part B 20 mg BID CVL-231|Oral Dose
89175905|NCT04136873|Placebo Comparator|Part B 20 mg BID Placebo|
89175906|NCT04132583|Experimental|First Deflox®, Then Cataflam DD®|Participants received single oral dose of Deflox® 50 milligrams (mg) tablet in Treatment Period 1 followed by a single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between the Treatment Periods 1 and 2.
89175907|NCT04132583|Experimental|First Cataflam DD®, Then Deflox®|Participants received single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 1 followed by single oral dose of Deflox® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between Treatment Periods 1 and 2.
89175908|NCT05754762|Experimental|Age range of 18 to 40 years olds|Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
89175909|NCT05754762|Experimental|Age range of 41 to 55 years olds|Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
89175910|NCT05754762|Experimental|Age range of 56 to 70 years olds|Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
89175911|NCT02608866|Experimental|SF-SSRS|Single-Fraction (SF) Stereotactic Spine Radiosurgery
89175912|NCT02608866|Experimental|MF-SSRS|Multiple-Fraction (MF) Stereotactic Spine Radiosurgery
89175913|NCT05326152|Experimental|IntralesionaL Hepatitis B vaccine|0.2 ml of hepatitis B vaccine injected in the largest wart and repeated every 2 weeks till clearance of warts or for a maximum of 5 sessions
89175914|NCT05326152|Experimental|Intramuscular Hepatitis B vaccine|"0.5 ml injected in the deltoid muscle for those who were younger than 19 years at the time of study and 1 ml for those who were 20 years and older at the time of study.~Three injections were done at 0, 1, and 4 months."
89175915|NCT05326152|Placebo Comparator|Intralesional saline|0.2 ml of saline injected in the largest wart and repeated every 2 weeks till clearance of warts or for a maximum of 5 sessions
89175916|NCT00914004|Experimental|1|Desipramine HCl 50 mg Tablets Cord Laboratories
89175917|NCT00914004|Active Comparator|2|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
89175918|NCT00867113|Experimental|Imatinib|All subjects received in tablet form imatinib (STI571) 400 mg once daily.
89175919|NCT02610270|Experimental|2 Gums|Athletes that continued their usual training and diet, who took 2 gums of omega 3 (DHA 760 mg) during the experimental period.
89175920|NCT02610270|Experimental|3 Gums|Athletes that continued their usual training and diet, who took 3 gums of omega 3 (DHA 1140 mg) during the experimental period.
89175921|NCT02610270|No Intervention|Control|Athletes and coaches that continued their usual training and diet, but did not take any supplements during the experimental period.
89175922|NCT02608710|Experimental|Single Dose|Single dose of RDEA3170 4.5 mg, RDEA3170 6 mg or RDEA3170 12 mg on Days 1, 5 and 9.
89175923|NCT02608710|Experimental|Multiple Dose|RDEA3170 12 mg once daily (qd)
89175924|NCT02608710|Experimental|Single Dose Food Effect|Since dose of RDEA3170 6 mg administered in fed or fasted state on Day 1 and Day 8.
89175925|NCT02615483|Experimental|Web-based platform|Access to a web-based platform
89175926|NCT02615483|No Intervention|Control|Conventional
89175927|NCT04030260|Experimental|Regorafenib and PD-1 antibody in Combination with Radiotherapy|
89175928|NCT00697385|Experimental|TA|on treatment
89175929|NCT04133753|Experimental|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
89175930|NCT04133753|No Intervention|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
89175931|NCT00451555|Experimental|Enzastaurin + Fulvestrant|"Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.~Participants received enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 250 mg orally (BID) twice daily in a 28-day cycle.~Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter."
89175932|NCT00451555|Placebo Comparator|Fulvestrant + Placebo|Participants received fulvestrant: 500 mg, IM, day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression. Then, participants received placebo, oral, daily.
89175933|NCT00808236|Experimental|RhinoChill|Intra-arrest cooling with the RhinoChill during advanced cardiac life support
89175934|NCT00808236|Other|Control|Advanced cardiac life support, only
89175935|NCT00867035|Active Comparator|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions from investigator: twice a day a tongue scraper was used with 4 or more strokes, followed by 20ml of 0.12% chlorhexidine gluconate mouthwash used for 30 sec, for one week.
89175936|NCT00867035|Experimental|Chlorine dioxide and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.1% stabilized chlor8ine dioxide rinse for 30sec, for one week.
89175937|NCT05012748|Experimental|Ketogenic diet|The participants are instructed to follow a ketogenic diet consisting of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant.
89175938|NCT05012748|No Intervention|Normal western diet|The participants are instructed to follow a normal western diet without emphasising any particular macronutrient.
89175939|NCT05298839||COVID-19|
89175940|NCT05298839||Non COVID-19|
89175941|NCT02617121|Active Comparator|Gabapentin|oral gabapentin 300 mg 1 hours before induction of anesthesia
89175942|NCT02617121|Active Comparator|ramosetron|ramosetron 0.3 mg iv at end of surgery
89175943|NCT02617121|Active Comparator|Gabapentin and ramosetron|oral gabapentin 300 mg 1 hours before induction of anesthesia ramosetron 0.3 mg iv at end of surgery
89175944|NCT05005572|Experimental|Treatment|
89175945|NCT05005572|No Intervention|Control|
89175946|NCT00663208|Active Comparator|Group 1|"Daclatasvir (1 mg), once daily~or~Matching Placebo, once daily"
89175947|NCT00663208|Active Comparator|Group 2|"Daclatasvir (10 mg), once daily~or~Matching Placebo, once daily"
89175948|NCT00663208|Active Comparator|Group 3|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
89175949|NCT00663208|Active Comparator|Group 4|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
89175950|NCT00663208|Active Comparator|Group 5|"Group 5: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
89175951|NCT00663208|Active Comparator|Group 6|"Group 6: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
89175952|NCT02609490|Experimental|Treatment-Azilsartan|Azilsartan tabelts
89175953|NCT02609490|Active Comparator|Positive Control-olmesartan medoxomil|olmesartan medoxomil tablets
89175954|NCT00810810|Active Comparator|1|Blood components with no additional treatment
89175955|NCT00810810|Experimental|2|Blood components leukoreduced
89175956|NCT00810810|Experimental|3|Blood components leukoreduced and irradiated
89175957|NCT04025190||Allogeneic Transplant|All patients seen in the UNC Bone Marrow Transplant clinic who are candidates for allogeneic transplantation attending their pre-admission visit were approached to offer study participation. Study participation included completion of surveys over a time period up to 60 days after their transplant.
89175958|NCT00661258|Experimental|Intervention|The intervention group patients were given their electronic drug monitoring feedback data at each monthly visit. The study coordinator would quickly calculate whether the patient's adherence was below 95% in the previous month. If so, that patient was flagged for enhanced counseling with a clinic doctor and this counseling was based on a printout containing the electronic drug monitoring data.
89175959|NCT00661258|No Intervention|Comparison|"The comparison group patients were not given the data from the electronic data monitoring feedback data. Instead, they filled out a self report form that all patients fill out. If they indicated in this report that their adherence in the previous was less than 95%, then they were flagged for enhanced counseling with a doctor. This counseling was based on the patient's self report. Thus both groups received enhanced counseling if they indicated poor adherence, but only the intervention group were given their electronic data output."
89175960|NCT02610348|Experimental|Group A|Toddlers vaccinated with Hexaxim®/Hexyon®/Hexacima® in study A3L12
89175961|NCT02610348|Experimental|Group B|Toddlers vaccinated with Infanrix hexa® in study A3L12
89175962|NCT05757336|Experimental|combined treatment group|"Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab GC regimen: up to the results of safety run-in stage~Dose A: gemcitabine 1000mg/m2, paclitaxel for injection (albumin-bound) 125mg/m2 iv Q3W~Dose B: gemcitabine 800mg/m2, paclitaxel for injection (albumin-bound) 100mg/m2 iv Q3W~Sintilimab: 200mg, iv, d1, q3w Bevacizumab: 7.5mg/kg, d1, q3w"
89175963|NCT02610036||neuropathic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
89175964|NCT02610036||neuroischemic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
89175965|NCT00871871|Experimental|Part I, Placebo-HCTZ|Placebo in Period 1 followed by HCTZ in Period 2
89175966|NCT00871871|Experimental|Part I, HCTZ-Placebo|HCTZ in Period 1, followed by placebo in Period 2
89175967|NCT00871871|Experimental|Part II, Placebo-ISMN|Placebo in Period 1, followed by ISMN in Period 2
89175968|NCT00871871|Experimental|Part II, ISMN-Placebo|ISMN in Period 1, followed by placebo in Period 2
89175969|NCT02608788|Active Comparator|S.L.® & Difflam Forte ®|"1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg and 3.0 mg/ml Benzydamine ,Difflam Forte ® 5.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
89175970|NCT02608788|Placebo Comparator|placebo ( for Acular® )|placebo(distilled water)spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
89175971|NCT02608788|Active Comparator|Acular® & S.L.®|"5％ Ketorolac Tromethamine , Acular® 8.0 mg and 1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
89175972|NCT02608788|Experimental|Difflam Forte ® & Acular®|"3.0 mg/ml Benzydamine , Difflam Forte ® 5.0 mg and 5％ Ketorolac Tromethamine Acular® 8.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
89175973|NCT05754372||Hyperammonaemia|
89175974|NCT04132349|Experimental|Ullipristal Acetate|Women with symptomatic uterine fibroids will be treated with 5 mg UPA / day in 3 months
89175975|NCT00913926||Group 1|
89175976|NCT02617355|Other|Prototype vs Covidien magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs Covidien magnetic drape
89175977|NCT02617355|Other|Prototype vs 4 commercial drapes|"New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs 4 commercially available magnetic drapes:~Green Covidien Magnetic Drape Jac-Cell Medic Reusable Magnetic Pad DeRoyal Magnetic Pad size 10 x 16 DeRoyal Magnetic Pad size 20 x 16"
89175978|NCT02615405|Experimental|EPA|3.5 g/day in Studies 1 & 2
89175979|NCT02615405|Active Comparator|DHA|1.75 g/day in Studies 1 & 2
89175980|NCT02615405|Placebo Comparator|Placebo capsules|oleic oil in Study 1
89175981|NCT04130789||patients with sepsis (cases)|patients who developed or were admitted with sepsis to the ICU (cases)
89175982|NCT04130789||patients without sepsis (controls)|patients who did not develop sepsis (controls).
89175983|NCT00849680|Placebo Comparator|Placebo|Participants receiving 1.0 ml of placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine or the placebo to the MRKAd5 HIV-1 gag vaccine injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26 or a 2-dose regimen at Day 1 and Week 26 or Day 1 and Week 4.
89175984|NCT00849680|Experimental|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Participants receiving 1.0 ml of the Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
89175985|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
89175986|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
89175987|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
89175988|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
89175989|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26, or in a 2-dose regimen at Day 1 and Week 4 (with no vaccine administered at Week 26) or Day 1 and Week 26 (with placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine administered at Week 4)
89175990|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
89175991|NCT00810342|Experimental|1- physical activity tailored|Tailored telephone counseling about how to become more physically active and goal setting. Email feedback on physical activity progress. Website listing resources new mothers can use to become more active.
89175992|NCT00810342|Active Comparator|2 - physical activity standard|Standard Website resources / information on physical activity
89175993|NCT04130945|Active Comparator|group 1|patients with erector spine plane block
89175994|NCT04130945|No Intervention|group 2|patients without erector spine plane block
89175995|NCT00849524|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
89175996|NCT00808080|Experimental|Biologic|AML_CTL cells
89175997|NCT00866723|Experimental|bevacizumab|Bevacizumab was administered at 15 mg/kg intravenously every 3 weeks. Treatment continued until disease progression or unacceptable toxicity.
89175998|NCT00697853|Active Comparator|Group A|
89175999|NCT00697853|Experimental|Group B|
89176000|NCT00697853|Experimental|Group C|
89176001|NCT00697853|Experimental|Group D|
89176002|NCT00697853|Experimental|Group E|
89176003|NCT02615327|Experimental|Active Treatment 1|8g Polydextrose
89176004|NCT02615327|Experimental|Active Treatment 2|12 g Polydextrose
89176005|NCT02615327|Experimental|Active Treatment 3|16 g Polydextrose
89176006|NCT02615327|Placebo Comparator|Placebo|0 g Polydextrose
89176007|NCT02613455|Active Comparator|Kenalog (triamcinolone )|Patients assigned to the corticosteroid arm will receive an intratendinous injection of 1cc Kenalog-40 (triamcinolone-40mg) + 2cc lidocaine 1% by an attending orthopaedic hand surgeon in clinic. They will be provided a home stretching regimen for lateral epicondylitis. They will be discouraged from using nonsteroidal anti-inflammatory drugs . No additional physical or occupational therapy will prescribed.
89176008|NCT02613455|Active Comparator|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either Walter Reed National Military Medical Center (WRNMMC) or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24 kilovolts, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
89176009|NCT00849212|Experimental|1|
89176010|NCT04119011|Experimental|Probiotic|Probiotic in powder form containing lactobacillus and bifidobacterium strains, sugar, milk powder and flavoring, taken 2 sachets daily for 3 months
89176011|NCT04119011|Placebo Comparator|Placebo|Placebo in powder form containing sugar, milk powder, flavoring, taken 2 sachets daily for 3 months
89176012|NCT00703586|Experimental|1|"ARM A:~Intensification with maraviroc for 24 weeks at one of the following doses:~150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~600 mg orally BID when coadministered with efavirenz or nevirapine"
89176013|NCT00703586|Active Comparator|2|"ARM B~Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc~Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc."
89176014|NCT04130399|Experimental|Preoperative Chemotherapy + SBRT|"Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines.~After 6 cycles of neoadjuvant therapy are completed, patients will undergo imaging with pancreatic protocol CT and PET-MRI to assess disease status . Patients without evidence of disease progression at the end of 6 cycles of neoadjuvant treatment will proceed to SBRT followed by surgical resection.~Following surgery, patients will receive an additional 6 cycles of FOLFIRINOX chemotherapy."
89176015|NCT00810264||Data Collection Group|
89176016|NCT00849056|Placebo Comparator|placebo + pioglitazone (with or without metformin)|Placebo albiglutide weekly injection + pioglitazone (with or without metformin)
89176017|NCT00849056|Experimental|albiglutide + pioglitazone (with or without metformin)|albiglutide weekly injection + pioglitazone (with or without meformin)
89176018|NCT02612948|No Intervention|Standard Care|Standard care for delerium
89176019|NCT02612948|Active Comparator|Quetiapine|Quetiapine therapy was initiated at 12.5 mg twice daily a. After thefirst dose of quetiapine 12.5 mg, the regimen could then be adjusted by the rounding surgeon. If the surgeon felt benefit from receiving a higher dose of quetiapine the dose could then be increased. Quetiapine was discontinued if adverse events (torsades de pointes or other ventricular tachycardias) occurred. All patients receiving at least one dose of quetiapine were included in the final intention-to-treat analyses. All prescribing decisions were left to the discretion of the rounding surgeon and were not mandated as part of the study.
89176020|NCT00706862|Experimental|1|Talactoferrin, Carboplatin, Paclitaxel
89176021|NCT00706862|Placebo Comparator|2|Placebo, Carboplatin, Paclitaxel
89176022|NCT00707018|Experimental|External rotation shoulder sling|External rotation shoulder sling
89176023|NCT00707018|Active Comparator|Internal rotation shoulder sling|Internal rotation shoulder sling
89176024|NCT00913406|Experimental|1|Experimental=Standard formula with lutein added to the formula
89176025|NCT00913406|Active Comparator|2|Active Comparator=Standard formula
89176026|NCT00913094||ICG|Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.
89176027|NCT02612714|Other|medication status|Rosuvastatin 5 mg qd for 6 months, Quitted rosuvastatin for 6 months, Re-administrated rosuvastatin for 6 months
89176028|NCT02612636|Active Comparator|ear plug and eye mask|"The patients will not receive the intervention in the first night (N1) from 9 pm to 6 am~The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.~The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.~The patients will receive the intervention (eye mask and ear plug) in the fourth night (N4) from 9 pm to 6 am."
89176029|NCT02612636|No Intervention|control|The researcher will assess and observe the patients who are receiving the routine hospital nursing care during the four nights.
89176030|NCT02612558|Experimental|Fostamatinib 150 mg|Fostamatinib 150 mg bid (morning and evening) over the course of 24 weeks
89176031|NCT00702026|Experimental|1|
89176032|NCT00702026|Placebo Comparator|2|
89176033|NCT02612402|Experimental|Learning algorithm|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT the Patients will receive daily messages, a learning algorithm will study the exercise response to each type of message and personalize the best message sequence for each patient.
89176034|NCT02612402|Active Comparator|control|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT THE Patients will receive a weekly reminder to exercise.
89176035|NCT00837434|Experimental|Etanercept|Participants receive a subcutaneous injection of etanercept once every week for 24 weeks
89176036|NCT00837434|Experimental|Adalimumab|Participants receive a subcutaneous injection of adalimumab once every 2 weeks for 24 weeks
89176037|NCT00703742|Experimental|A,1|A: Escitalopram, 20 mg/day,8weeks
89176038|NCT00702182|Experimental|Conventional Vinorelbine, Erlotinib|Escalating doses of vinorelbine on Day 1 and Day 8 of 21 Day cycle; Erlotinib 100 mg OD
89176039|NCT00702182|Experimental|Metronomic Vinorelbine, Erlotinib|Escalating doses of vinorelbine TIW; erlotinib 100 mg OD
89176040|NCT00702416|Experimental|US Group|In this group, the continuous block will be performed under real-time ultrasound (US) guidance.
89176041|NCT00702416|Active Comparator|ENS Group|In this group, the continuous block will be performed with an electrical nerve stimulation (ENS) technique.
89176042|NCT00827918|Experimental|MK-8998|MK-8998, 6 mg twice a day (BID) for Days 1 to 7, and 8 mg BID thereafter for a 4-week total treatment period
89176043|NCT00827918|Active Comparator|Olanzapine|Olanzapine, 5 mg BID for Day 1 to 7, and 15 mg (5 mg in the morning and 10 mg in the evening) thereafter for a 4-week total treatment period
89176044|NCT00827918|Placebo Comparator|Placebo|Placebo Comparator to MK-8998 or olanzapine
89176045|NCT00813150|Experimental|Vd (bortezomib + dexamethasone)|"Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days~1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle."
89176046|NCT00813150|Active Comparator|Vcd (bortezomib + low-dose dexamethasone + cyclophosphamide)|Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle and single oral doses of 50 mg cyclophosphamide on a once daily basis from Day 1, Cycle 1 continuously until Day 21, Cycle 8.
89176047|NCT02609568||Control Group 1|Children with non-trauma complaints
89176048|NCT02609568||Control Group 2|Children with non TBI and musculoskeletal trauma
89176049|NCT02609568||Cases|Children admitted to hospital with moderate/severe isolatedTBI
89176050|NCT00807846|Experimental|Celecoxib|
89176051|NCT00807846|Experimental|Naproxen|
89176052|NCT05754138||study population|The study population will consist of patients with an implanted S-ICD as their first implanted device, who continue to exercise regularly and actively participate in competitive or recreational sports with a sport-intensity above a predefined level
89176053|NCT00810108|Experimental|Whole Then Crushed Tablets|These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.
89176054|NCT00810108|Experimental|Crushed Then Whole Tablets|These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.
89176055|NCT05297370|Other|Mixed and Match|Participants can choose to receive their own smoking cessation treatment options from our menu.
89176056|NCT05297370|Other|Control|Participants will receive a self-help quitting leaflet
89176057|NCT00827606|Experimental|Atorvastatin|All subjects will be treated with atorvastatin
89176058|NCT04892082|Experimental|Mindful Moment|Mothers who present parenting stress equal or above 41 score on PSS will receive a web-based intervention to reduce parenting stress (the Mindful Moment program).
89176059|NCT04892082|Active Comparator|Control|All mothers who present parenting stress will have access to Mindful Moment intervention. The control group only receive the intervention at the end of the intervention group.
89176060|NCT04016220|Experimental|Budesonide group|The experimental group received a first nebulization of 5 mg of terbutaline(solution of 5mg/ 2 ml ) in association with 0.5 mg of ipratropium bromide (solution of 0.5 mg/ 2 ml) and 0.5 mg of budesonide (solution of 0.5 mg/2 ml) followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min. All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
89176061|NCT04016220|Placebo Comparator|normal saline|The control group received a nebulization of 2 ml normal saline at baseline, 20, 40, 60 and 120 min as placebo comparator in association with nebulized terbutaline . All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer.
89176062|NCT00663052|Experimental|Group A|A
89176063|NCT00663052|Experimental|Group B|B
89176064|NCT05599880|Experimental|Treatment|Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
89176065|NCT00707252|Experimental|Phase I/II|Phase I: Polyphenon E + Erlotinib - Polyphenon E 200, 400 and 800 mg/day dose levels evaluated in a step-wise manner with Erlotinib 150 mg/day to establish Maximum Tolerated Dose (MTD) of Polyphenon E. Phase II consists of MTD of Polyphenon E established in Phase I, administered alone for two weeks and thereafter together with Erlotinib 150 mg/day.
89176066|NCT00826748|Experimental|Treated Smokers|The treatment with inhaled beclomethasone will be administered to this cohort from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days.
89176067|NCT00826748|No Intervention|Non-Treated Smokers|This cohort will act as control and include healthy smokers who receive no treatment.
89176068|NCT00826748|No Intervention|Non-Smokers|This cohort will act as control and include healthy non-smokers who receive no treatment.
89176069|NCT00922844|Active Comparator|Sevoflurane|Administration of the volatile anesthetic Sevoflurane.
89176070|NCT00922844|Active Comparator|Isoflurane|Administration of the volatile anesthetic Isoflurane.
89176071|NCT00707330|Experimental|1|Subjects randomised to this arm will first be treated with Clarithromycin for a week, then have a 2-week washout, and finally one week of no treatment
89176072|NCT00707330|Active Comparator|2|Subjects randomised to this arm will first receive one week of no treatment, then have a 2-week washout, and finally be treated with Clarithromycin for a week
89176073|NCT00806988|Active Comparator|Mitral Valve Repair|Participants will undergo CABG and a mitral valve repair procedure.
89176074|NCT00806988|Active Comparator|CABG|Participants will undergo CABG.
89176075|NCT05749770||COVID-19|Patients affected with SARs-CoV-2 infection and hospitalized in the COVID wards of Auxologico
89176076|NCT05749770||CONTROLS|440 NON-COVID subjects collected retrospectively at other collaborating centers) University of Siena, Campus Biomedico Rome, University of Catania, San Giovanni Rotondo)
89176077|NCT00788320|Placebo Comparator|Placebo|Placebo three times a week for 8 weeks
89176078|NCT00788320|Experimental|Cholecalciferol|Vitamin D3 50,000 IU three times a week for 8 weeks
89176079|NCT00799162||Women with a scheduled cesarean section|
89176080|NCT00807144|Experimental|Prolonged-Release Tacrolimus|Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy
89176081|NCT00807144|Active Comparator|Standard-Release tacrolimus|Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy
89176082|NCT02553850||Ibandronate|Patients receiving ibandronate will be evaluated for bone turnover markers for 12 months. Ibandronate is not an investigational medicinal product (IMP) in this study.
89176083|NCT00799240|Active Comparator|Arm A Pemetrexed Cisplatin|Arm A: Pemetrexed, cisplatin: pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days. Patients will be treated for a maximum of 6 cycles.
89176084|NCT00799240|Experimental|Arm B Permetrexed, Cisplatin, MK-0646|Pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days in combination with MK-0646 given IV, 10 mg/Kg, Days 1, 8 and 15 weekly
89176085|NCT02555410||Brain Sentinel Seizure Detection and Warning System|To test the usability of the Brain Sentinel Seizure Detection and Warning System(also known as the SPEAC system) in a patient home setting.
89176086|NCT02555332||Women underwent screening for thyroid function|All these women underwent screening for thyroid function (TSH,FT4,TPOAb) at the first antenatal visit and the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The correlation between the combination of TSH level and TPOAb status and the risk of Gestational Diabetes Mellitus was analyzed.
89236772|NCT01035021|Active Comparator|group R|Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.
89236773|NCT01035177||Control|Women without hip fracture, matched on age to the cases
89236774|NCT01035177||Patient|Female patients aged 60 and older with hip fracture
89236775|NCT00616421|Experimental|MenACWY-CRM (1 dose)|1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
89176087|NCT00793390||inflammatory breast cancer cases|inflammatory breast cancer cases
89176088|NCT00793390||non-inflammotory breast cancer cases|non-inflammatory breast cancer cases
89176089|NCT00793390||visitor controls without cancer|visitor controls without breast cancer- those visiting cancer patients
89176090|NCT00591006|Experimental|Four Treatments Per Participant|This study has one arm due to a crossover design. All 17 subjects received 4 treatments: placebo then placebo, phenytoin then placebo, placebo then hydrocortisone, and phenytoin then hydrocortisone. Each treatment was randomly assigned and had a unique sequence out of 24 possible sequences.
89176091|NCT00788398|Active Comparator|Saline, gravity flow|
89176092|NCT00788398|Active Comparator|Saline, Low Pressure|
89176093|NCT00788398|Active Comparator|Saline, High Pressure|
89176094|NCT00788398|Active Comparator|Soap, Gravity Flow|
89176095|NCT00788398|Active Comparator|Soap, low pressure|
89176096|NCT00788398|Active Comparator|Soap, high pressure|
89176097|NCT02606916|Experimental|SMART & S-1/DDP|Patients in experimental group receive daily simultaneous modulated accelerated radiotherapy combined with DDP and S-1.
89176098|NCT00788476||Childhood Cancer Survivors|
89176099|NCT00788476||Primary Caregivers|
89176100|NCT02554084|Experimental|Dry Eye Disease|Optical Coherence Tomography
89176101|NCT02554084|Active Comparator|Normals|Optical Coherence Tomography
89176102|NCT05715918|Experimental|Vaccine|"Group 1 - 150 volunteers, Vaccine 0.5 ml, 21 days interval, post-vaccination observation period of 21 days.~An additional objective of the study is to evaluate the safety, immunogenicity and efficacy of the CoviVac vaccine in the period from 21 days to 24 weeks after the second vaccination in comparison with placebo throughout the study."
89176103|NCT05715918|Placebo Comparator|Placebo|"No active ingredient in the placebo~Group 2 - 150 volunteers, Placebo 0.5 ml, 21 days interval, post-vaccination observation period of 21 days.~An additional objective of the study is to evaluate the safety, immunogenicity and efficacy of the CoviVac vaccine in the period from 21 days to 24 weeks after the second vaccination in comparison with placebo throughout the study."
89176104|NCT02554552|Experimental|YY1201 2ml|YY1201 2ml
89176105|NCT02554552|Experimental|YY1201 3ml|YY1201 3ml
89176106|NCT02554552|Placebo Comparator|Placebo 2ml|Phosphate buffered saline 2ml
89176107|NCT02554552|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
89176108|NCT03764124||Kidney recipients|Kidney recipients aged over 18 and of all sexes recruited between 2007 and 2020 from the Centre Hospitalier Universitaire de Liege, who have e-GFR follow-up and data from protocol and for cause biopsies available at 1-year post transplant. PET/CT imaging will be performed with patient's approval for protocol and per cause biopsies we performed. Data will be collected in the follow up such as clinical, biological and histological data.
89176109|NCT00788554|Active Comparator|1|
89176110|NCT00788554|Active Comparator|2|
89176111|NCT00844844|Experimental|Eculizumab|
89176112|NCT05748054|Active Comparator|Study group|Children who receive a single application of 38% SDF
89176113|NCT05748054|No Intervention|Control group|Children do not receive any intervention
89176114|NCT00660790||Patients with Type 2 Diabetes|diabetic subjects, above targets
89176115|NCT00702572|Experimental|1|Phase I dose escalating scheme
89176116|NCT00702572|Experimental|2|Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.
89176117|NCT00913172||Intervention group|Directly Observed Treatment under Health Extension Workers
89176118|NCT00913172||Control group|Directly observed treatment under general health workers
89176119|NCT00788632|Experimental|educational materials|Patient educational DVD and brochure
89176120|NCT00788632|Other|physician education|Physician web modules
89176121|NCT00788632|Experimental|System intervention|Self-referral letter with toll-free number provided
89176122|NCT00793468|Placebo Comparator|Placebo Arm|Subjects in placebo arm will be taking placebo once daily for 12 weeks from week 5 to 16.
89176123|NCT00793468|Experimental|GSK598809 Arm|Subjects in GSK598809 arm will be taking GSK598809 once daily for 12 weeks from weeks 5 to 16.
89176124|NCT00836810|Experimental|Timed Release Tablet Prednisone|12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
89176125|NCT00836810|Active Comparator|Standard Prednisolone|12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
89176126|NCT00788788|Active Comparator|1|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
89176127|NCT00788788|Active Comparator|2|Study subjects where breathing Heliox with a fraction of Helium of 50% followed by 75% and 25% with larger external resistor in comparison to medical air
89176128|NCT00788788|Active Comparator|3|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
89176129|NCT00658684|Experimental|Fesoterodine fumarate|
89236776|NCT00616421|Active Comparator|Licensed polysaccharide vaccine|1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
89236777|NCT00616421|Experimental|MenACWY-CRM (2 doses)|2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.
89236778|NCT00868049||1|Obese subjects
89236779|NCT00868049||2|Normal-weight subjects
89236780|NCT00875303|Placebo Comparator|Control|Routine primary care.
89236781|NCT00875303|Experimental|Multimedia intervention|
89236782|NCT05226767|Active Comparator|Active Arm|Patients who receive treatment with the NLC-V research product depending on the weight of the patients, as follows - Patients weighing less than 70 kg will receive 2 capsules, 4 times a day (80 mg in total per day) Patients weighing between 70 kg and 100 Kg will receive 3 capsules, 4 times a day (a total of 120 mg per day). Patients weighing over 100 kg will receive 4 capsules, 4 times a day (a total of 160 mg per day). NLC-V capsules Will be taken during days 1-10 for the patient's hospitalization NLC-V capsules will be taken during days 1-10 for the patient's hospitalization
89236783|NCT05226767|Placebo Comparator|Placebo|Patients who receive placebo in addition to the usual treatment for COVID-19. The placebo consists of the same solvent, but without the active ingredients of NLC-V. Placebo will be given to patients in the same manner and with the same frequency as NLC-V
89236784|NCT00878267||Interview|
89236785|NCT00878345|Active Comparator|1|Dexmedetomidine sedation protocol
89236786|NCT00878345|Active Comparator|2|Pentobarbital sedation protocol
89236787|NCT00433017|Experimental|Verteporfin + Ranibizumab|Verteporfin (6 mg/m^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
89236788|NCT00433017|Active Comparator|Ranibizumab Monotherapy|Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
89236789|NCT01035411|Experimental|1|AZD9668 2X30mg tablet
89236790|NCT03726671|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89236791|NCT03726671|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89236792|NCT03726671|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89236793|NCT03726671|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89236794|NCT03726671|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89236795|NCT03726671|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
89236796|NCT01030029|Active Comparator|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
89236797|NCT01030029|Placebo Comparator|pstim device without acupuncture|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
89236798|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD|
89236799|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD + Added Therapy|
89236800|NCT00868205|Experimental|low coffee dose|3 cups of coffee daily for 8 weeks
89236801|NCT00868205|Experimental|high coffee dose|5 cups of coffee daily for eight weeks
89236802|NCT00868205|No Intervention|Control|Consumption of water instead of coffee daily for eight weeks
89236803|NCT05202197||Experimental|Alzheimer´s patients
89236804|NCT05195879|Experimental|XTR004|Single dose 6.0-8.0 mCi intravenous injection of XTR004 and investigation of XTR004 (MPI radiotracer).
89236805|NCT00868361|Experimental|Slow and rapid N-acetyl transferase genotypes|
89236806|NCT04039373|Experimental|Treatment Arm|
89236807|NCT00615719||ED patients undergoing coronary CTA|Emergency Department patients suspected of having acute coronary syndrome undergoing Coronary Computed Tomographic angiography.
89236808|NCT00875537|Active Comparator|Capsaicin oral gel 0.01%|
89236809|NCT00875537|Active Comparator|Capsaicin oral gel 0.025%|
89176130|NCT04046146|Experimental|NIR-ICG MRL|We may ask healthy subjects to return for up to four injection sessions for the study. The first injection session will consist of intradermal injection of ICG into the webspaces of the hand as done in our previous studies followed by NIR camera imaging. The second session will consist of intradermal gadolinium injection and intravenous (IV) iron contrast agent followed by MRI imaging approximately 1 week after the first session. The third session will occur at minimum eight weeks later and entail intra-articular ICG injection in order to evaluate drainage via the lymphatics. The MCP joints will be identified in the non-dominant hand and injected with ICG. Approximately one week later, the fourth session will compromise of intra-articular gadolinium injection and IV iron contrast to confirm lymphatic drainage. The MCP joints of the non-dominant hand will again be identified and injected with gadolinium.
89176131|NCT00800098|Placebo Comparator|Placebo|Placebo cream matched on consistency, color, and smell
89176132|NCT00800098|Active Comparator|Active|AARP active arthritis cream
89176133|NCT00788866|Experimental|Pomegranate juice|This arm with receive 8oz of pomegranate juice per day.
89176134|NCT00788866|Placebo Comparator|Placebo|This group will take 8oz of placebo juice that lacks pomegranate daily
89176135|NCT00800332|Experimental|1|
89176136|NCT00800332|Experimental|2|
89176137|NCT00800332|Placebo Comparator|3|
89176138|NCT00660400|Experimental|Combined Therapy|5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).
89176139|NCT00800410|No Intervention|Information on community resources|Participants received information about free and publicly available community resources on healthy lifestyle activities
89176140|NCT00800410|Experimental|Community Health Worker services|
89176141|NCT00788944|Other|1|
89176142|NCT00793702|Experimental|A|two injections 0.01 µg rdESAT-6 + rCFP-10 (6 weeks interval)
89176143|NCT00793702|Experimental|B|two injections 0.01 µg rdESAT-6 + rCFP-10 (12 weeks interval)
89176144|NCT00793702|Experimental|C|two injections 0.1 µg rdESAT-6 + rCFP-10 (6 weeks interval)
89176145|NCT00793702|Experimental|D|two injections 0.1 µg rdESAT-6 + rCFP-10 (12 weeks interval)
89176146|NCT00793702|Experimental|E|one injection 1.0 µg rdESAT-6 + rCFP-10
89176147|NCT00826514|Experimental|Tanezumab|
89176148|NCT00826514|Placebo Comparator|Placebo|
89176149|NCT00800566|Experimental|Oral Clofarabine|
89176150|NCT00793858|Active Comparator|1|placebo in left nostril, isotonic ciclesonide in right
89176151|NCT00793858|Active Comparator|2|hypotonic ciclesonide in left nostril, placebo in right
89176152|NCT00793858|Active Comparator|3|hypotonic ciclesonide in right and left nostrils
89176153|NCT00793858|Active Comparator|4|isotonic ciclesonide in both right and left nostrils
89176154|NCT00793858|Placebo Comparator|6|placebo in both right and left nostrils
89176155|NCT00793858|Active Comparator|5|isotonic ciclesonide in left nostril and hypotonic ciclesonide in right
89176156|NCT00800644||Evaluation Group|Bone Mineral Density Test + MRI or CT + Blood Test
89176157|NCT00800722|Experimental|Treatment of Port Wine Stain|Rapamycin Treatment of Port Wine Stain
89176158|NCT00789022||1|40 subjects in a First Psychotic Episode
89176159|NCT00789022||2|20 First Degree relatives
89176160|NCT00789022||3|20 Healthy subjects
89176161|NCT00789100||1|Group provided with home-based monitor
89176162|NCT00789100||2|Group receives no home-based monitor
89176163|NCT04046458|Experimental|EHR Alert|Physician teams will observe the EHR alert as they perform their clinical duties in the EHR.
89176164|NCT04046458|Placebo Comparator|No Alert|Physician teams will perform their clinical duties in the EHR as usual, with no visible alert.
89176165|NCT00789178||patients with fibromyalgia|
89176166|NCT00789178||patients with active RA|
89176167|NCT00826280|Placebo Comparator|Placebo plus Regadenoson|Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection
89176168|NCT00826280|Experimental|Caffeine 200 mg plus Regadenoson|One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection
89176169|NCT00826280|Experimental|Caffeine 400 mg plus Regadenoson|Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection
89176170|NCT00794014|Experimental|Conservative strategy|
89176171|NCT00794014|Experimental|Aggressive strategy|
89176172|NCT00800800|Active Comparator|1|Rosuvastatin 40 mg
89176173|NCT00800800|Placebo Comparator|2|placebo
89176174|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, every other week|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.
89176175|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.
89176176|NCT00864851|Active Comparator|Replagal 0.4 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.
89176177|NCT00794092|Experimental|Sinerem|MRI scanning of patients with AAA before and 24hrs +/- 4hrs after administration of Sinerem
89176178|NCT04030754|Experimental|amniotic membrane group|amniotic dressing will be applied to these patients
89176179|NCT04030754|Experimental|duoderm group|duoderm dressing will be applied to these patients as intervention
89176180|NCT00789412||Expected ICU|Patients with expected postoperative admission to the ICU. Baseline measurement of SSI. Exploration prior to weaning.
89176181|NCT00789412||Unexpected ICU|Patients with unexpected stay at the ICU. No baseline measurement of SSI. Exploration in 'steady state' of analgosedation.
89176182|NCT00800956|Experimental|Single oral dose of [14C]-esreboxetine|
89176183|NCT00857207|Experimental|Arm 1: Treatment Goal Management Training|Treatment Goal Management Training
89176184|NCT00857207|No Intervention|Arm 2: Control-Brain Health Workshop|Control-Brain Health Workshop
89176185|NCT00801034|Placebo Comparator|1|Calcium tablets
89176186|NCT00801034|Active Comparator|2|Potassium tablets
89176187|NCT04130477|Experimental|Clear aligners with tunnel attachment|Participants will receive traditional clear aligner therapy with virtual set up and will be supplemented by virtually planned tunnel attachments which will be threaded by a light Nickel-Titanium wire
89176188|NCT04130477|Active Comparator|Clear aligners|Participants will receive traditional clear aligner therapy with virtual set up
89176189|NCT00794326|Experimental|PDsol 12|Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
89176190|NCT00794326|Active Comparator|Gambrosol trio 40|Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
89176191|NCT00836498|Experimental|Part I, RotaTeq|3 doses of RotaTeq
89176192|NCT00836498|Placebo Comparator|Part I, placebo|3 doses of placebo
89176193|NCT00836498|Experimental|Part II, RotaTeq|3 doses of RotaTeq
89176194|NCT00836498|Experimental|Part II, RotaTeq and placebo|1 dose of RotaTeq and 2 doses of placebo
89176195|NCT00836498|Placebo Comparator|Part II, placebo|3 doses of placebo
89176196|NCT04132037||patient with multiple sclerosis|At each visit, inclusion, 6 weeks, 6 months, 12 months, and 24 months, the clinical and urinary data will be recorded and the ISC frequency , ISC discontinuation and adherence scale will be evaluated
89176197|NCT00801112||1|PD patients with residual renal function >200ml with BIA monitor.
89176198|NCT00801112||2|PD patients with residual renal function <200ml with BIA monitor.
89176199|NCT00801112||3|PD patients with residual renal function >200ml without BIA monitor
89176200|NCT00801112||4|PD patients with residual renal function <200ml without BIA monitor
89176201|NCT02615015||ST elevation myocardial infarction patient cohort|Patients who suffered from ST elevation myocardial infarction since 2006, referred to the General Hospital of Vienna and received primary percutaneous coronary intervention.
89176202|NCT02615015||Healthy proband cohort|Age matched healthy individuals who voluntarily participate in the study.
89176203|NCT00801190|Active Comparator|HES (130/0.4)|33 ml/kg i.v. HES (130/0.4)
89176204|NCT00801190|Placebo Comparator|Ringer's Lactate|33 ml/kg i.v. Rigner's Lactate
89176205|NCT00702728|Experimental|1|Furosemide and matched saline hydration by RenalGuard system
89176206|NCT00702728|Active Comparator|2|Standard IV saline infusion
89176207|NCT00801268|Active Comparator|emodin|
89176208|NCT00801268|Experimental|Triptolide Woldifii|TW60mg/d
89176209|NCT02611622|Active Comparator|Arm 1: Control|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~Participants in the control group will proceed to filling out Demographic Survey and Patient Satisfaction Survey~Once completed, they will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist"
89176210|NCT02611622|Experimental|Arm 2: LUMA ENT™|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~Participants in the intervention group will proceed to viewing the LUMA ENT™ videos pertinent to their thyroid condition using either of the two iPADS (the videos should not last longer than 10 minutes)~Once video viewing is complete, participants will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist, especially as relates to questions that arise as a result of viewing the video~Subsequently, the participants will proceed to filling out Demographic Survey and Patient Satisfaction Survey"
89176211|NCT02614937|Experimental|Squalamine and ranibizumab to Week 10|"All eyes received an initial 10 week mandatory loading period of topical Squalamine Lactate Ophthalmic Solution, 0.2% therapy.~All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6.~Randomize at Week 10 to 2 different groups - Squalamine and No Squalamine, continue PRN ranibizumab in both groups"
89176212|NCT02614937|Experimental|Continue Squalamine, ranibizumab PRN|Continue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
89176213|NCT02614937|Experimental|Stop Squalamine, ranibizumab PRN|Discontinue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
89176214|NCT00707564|Experimental|1|HemCon Dental Dressing
89176215|NCT00707564|Active Comparator|2|Gauze with pressure
89176216|NCT00697931|Experimental|Group A|
89176217|NCT00697931|Active Comparator|Group B|
89176218|NCT00707642|Experimental|1|Low Dose WN-80E API (5 µg) + Alhydrogel (3.5 mg)
89176219|NCT00707642|Experimental|2|Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)
89176220|NCT00707642|Experimental|3|High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)
89176221|NCT00707642|Experimental|4|High Dose WN-80E API (50 µg), no adjuvant
89176222|NCT00789568|Experimental|Sapropterin Dihydrochloride 100mg/kg and placebo Moxifloxacin|A single dose of 100mg/kg of Sapropterin Dihydrochloride taken along with placebo Moxifloxacin.
89176223|NCT00789568|Experimental|Sapropterin Dihydrochloride 20mg/kg and placebo Moxifloxacin|A single dose of 20mg/kg of Sapropterin Dihydrochloride taken along with a placebo Moxifloxacin.
89176224|NCT00789568|Active Comparator|Sapropterin Dihydrochloride placebo and Moxifloxacin|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with 400mg of Moxifloxacin.
89176225|NCT00789568|Placebo Comparator|Sapropterin Dihydrocholide placebo and Moxifloxacin placebo|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with placebo of Moxifloxacin.
89176226|NCT00789646|Experimental|NSS/Lidocaine|First injection: Normal saline Second injection: 2% Lidocaine without adrenaline
89176227|NCT00789646|Experimental|Lidocaine/NSS|First injection: 2% Lidocaine without adrenaline Second injection: Normal saline
89176228|NCT02554006|Other|good clinical practice|all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process
89176229|NCT02554006|Experimental|bundle group|patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)
89176230|NCT00801424|Experimental|standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
89176231|NCT00856973|Experimental|Low dose eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
89176232|NCT00856973|Experimental|High dose eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
89176233|NCT00856973|Placebo Comparator|Placebo|Placebo 6-17 years
89176234|NCT00801502|Other|Control|No change in diet
89176235|NCT00801502|Active Comparator|Oily fish|Two portions of salmon per week from week 20 of pregnancy until giving birth
89176236|NCT00801580|Experimental|1|The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C [cytarabine]).
89176237|NCT00699569|Experimental|1|Patients receiving active investigational product
89176238|NCT00699569|Placebo Comparator|2|Patients receiving Placebo
89176239|NCT00794716|Experimental|NRL972|
89176240|NCT04132271|Experimental|Personalized diet|Personalized diet during the swallowing rehabilitation
89176241|NCT04132271|Active Comparator|Control|Nutritional recommendations during the swallowing rehabilitation
89176242|NCT00794872||1|Patients with stage 3 CKD
89176243|NCT00794872||2|Patients with stage 4 CKD
89176244|NCT00794872||3|Patients without evidence for CDK
89176245|NCT02553382|Experimental|Dietary, Herbal|
89176246|NCT02553382|Placebo Comparator|Positive Control|
89176247|NCT00844532|Experimental|Absolute Pro™ Peripheral Self-Expanding Stent System|Arm includes both Absolute Pro™ and Absolute Pro™ Long Lesion (LL) Peripheral Self-Expanding Stent Systems
89176248|NCT00805194|Experimental|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
89176249|NCT00805194|Placebo Comparator|Placebo plus docetaxel|Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
89176250|NCT00836186|Other|Radiation therapy|Women with non-metastatic breast cancer status post lumpectomy to negative margins and who are receiving whole breast irradiation as per standard treatment plan.
89176251|NCT00657046|Active Comparator|1|Droxidopa at 400 mg (2 capsules each containing 200 mg droxidopa plus one capsule with Placebo)
89176252|NCT00657046|Active Comparator|2|Droxidopa at 600 mg (3 capsules each containing 200 mg droxidopa)
89176253|NCT00657046|Placebo Comparator|3|Placebo (3 capsules with mannitol substituted for droxidopa)
89176254|NCT00707720|Experimental|TERIS procedure|TERIS procedure for the treatment of obesity
89176255|NCT00707798|Experimental|Formulation 1|
89176256|NCT00707798|Experimental|Formulation 2|
89176257|NCT00707798|Experimental|Formulation 3|
89176258|NCT00707798|Experimental|Formulation 4|
89176259|NCT00707798|Experimental|Formulation 5|
89176260|NCT00707798|Experimental|Formulation 6|
89176261|NCT00707798|Active Comparator|23 valent pneumococcal vaccine|
89176262|NCT00805714||Acute myocardial infarction|AMI patients who are in need to be treated by statins
89176263|NCT00704054|Experimental|1|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
89176264|NCT00801736|Experimental|Platinum Arm|Cisplatin (IMP) / Pemetrexed (IMP)
89176265|NCT00801736|Experimental|Non Platinum Arm|Paclitaxel (IMP) / Pemetrexed (IMP)
89176266|NCT00856661|Experimental|Desmoteplase|
89176267|NCT00856661|Placebo Comparator|Placebo|
89176268|NCT02606994|Experimental|Oral Defense Toothpaste|The experimental group will brush with Oral Defense Toothpaste three times per day during the study
89176269|NCT02606994|Placebo Comparator|Crest Toothpaste/Magic Mouth Rinse|The placebo group will brush with Crest Toothpaste three times per day during the study. Participants in the placebo comparator group who require additional management of their oral mucositis pain will be provided Magic Mouth Rinse.
89176270|NCT00844376|Other|Test|Extemporaneous preparation suspension Atorvastatin prototype formulation
89176271|NCT00844376|Other|Reference|Commercial atorvastatin tablet (Lipitor®)
89176272|NCT04046302|Experimental|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
89176273|NCT04046302|Placebo Comparator|placebo|one tablet of placebo self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
89176274|NCT00914394|Active Comparator|NG-monomethyl-L-arginine (L-NMMA)|
89176275|NCT00914394|Active Comparator|Phenylephrine|
89176276|NCT00914394|Placebo Comparator|Physiological saline solution|
89176277|NCT04045678|Experimental|LY03003|
89176278|NCT04045678|Placebo Comparator|Placebo|
89176279|NCT00704210|Sham Comparator|B|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
89176280|NCT00704210|Experimental|A|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
89176281|NCT00801814|Placebo Comparator|1|White Bread
89176282|NCT00801814|Placebo Comparator|2|White Bread and Margarine Control
89176283|NCT00801814|Placebo Comparator|3|Glucose drink control
89176284|NCT00801814|Experimental|4|"White bread and margarine~or~Glucose drink"
89176285|NCT00801814|Experimental|5|"White bread and margarine~or~Glucose drink"
89176286|NCT00801814|Experimental|6|"White bread and margarine~or~Glucose drink"
89176287|NCT00698399||1|Live Donor
89176288|NCT00698399||2|Cadaveric Donor
89176289|NCT00658606|Active Comparator|Alefacept alone|15 mg alefacept intramuscularly (IM) once weekly for 12 weeks
89176290|NCT00658606|Experimental|Alefacept + nbUVB|15 mg alefacept intramuscularly once weekly and narrow band Ultraviolet B (nbUVB) phototherapy 3 times per week for 12 weeks
89176291|NCT03872440||EGFR T790M patients|EGFR T790M patients who have progressed on osimertinib or other third generation (mutant selective) EGFR TKI therapy
89176292|NCT03872440||EGFR exon 19 del or L858R patients|EGFR exon 19 del or L858R patients who have progressed on first line osimertinib
89176293|NCT03872440||Exon 20 insertion mutations patients|Patients with Exon 20 insertion mutations (n=10; regardless of drug therapy). Includes EGFR Exon 20 and up to two HER2 Exon20 patients
89176294|NCT00795106|Active Comparator|Capsaicin patch|Patches will contain capsaicin 0.1% (500 mcg)
89176295|NCT00795106|Placebo Comparator|Placebo patch|Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing.
89176296|NCT00809302|Experimental|1|aplindore 2 mg MR total daily dose
89176297|NCT00809302|Experimental|2|aplindore 6 mg MR total daily dose
89176298|NCT00809302|Experimental|3|aplindore 12 mg MR total daily dose
89176299|NCT00809302|Placebo Comparator|4|Placebo
89176300|NCT00589290|Experimental|Belinostat Treatment|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
89176301|NCT00801970|Experimental|1 - Pregnant - Tokophobic|Psychoanalysis treatment.
89176302|NCT00801970|Experimental|2 - Pregnant - Tokophobic|Cognitive-Behavioral treatment.
89176303|NCT00801970|Experimental|3 - Non-pregnant - Tokophobic|Group Therapy
89176304|NCT00801970|No Intervention|4 - Control|Pregnant and non-pregnant non-tokophobic women will answer questionnaires. Won't receive therapy.
89176305|NCT00802048|Experimental|1|48h postoperative infusion of ropivacaine
89176306|NCT00802048|Placebo Comparator|2|48h postoperative infusion of NaCl.
89176307|NCT00802126|Experimental|Bevacizumab and verteporfin|
89176308|NCT02552680|Experimental|Exercise + guideline|Participants will participate in eight meetings consisting of exercise and guidelines on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
89176309|NCT02552680|Active Comparator|brochure|Participants will receive a manual-brochure - containing information about general health.
89176310|NCT00809380|Experimental|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
89176311|NCT00809380|Active Comparator|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
89176312|NCT04820374|No Intervention|traditional extubation indications and traditional restoration indoor requirements|
89176313|NCT04820374|Experimental|Extubate the tube according to the pupil index and leave the recovery room|
89176314|NCT00843518|Experimental|LY451395|3 milligram (mg) LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
89176315|NCT00843518|Placebo Comparator|Placebo|Placebo orally twice daily for 12 weeks
89176316|NCT02552524|Experimental|rTMS active then rTMS placebo|"A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo (rTMS active then rTMS placebo).~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit."
89176317|NCT02552524|Experimental|rTMS placebo then rTMS active|"A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS active at the frequency of 10 Hz (rTMS placebo then rTMS active).~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit"
89176318|NCT00809536|Other|Cohort 1|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
89176319|NCT00809536|Other|Cohort 2|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
89176320|NCT00809692|Active Comparator|1|50 subjects with allergic disease receiving histamine challenges by the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
89176321|NCT00809692|Experimental|2|150 additional subjects with allergic disease; undergo genotyping; laser Dopper assessment
89176322|NCT00843284||Patients with neuropathic pain|
89176323|NCT02972892|Experimental|Et Control|Subjects, meeting the American Society of Anesthesiologists status classification system 1-3, to undergo a surgical procedure with inhaled anesthesia using the investigational Et Control option intervention. For Subjects under the Et Control option, the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the well being of the subject.
89176324|NCT02972892|Active Comparator|Control Arm|Subjects, meeting the American Society of Anesthesiologists status classification system 1-3, to undergo a surgical procedure with inhaled anesthesia using conventional fresh gas intervention. For subjects under the conventional option, the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature.
89176325|NCT00802282|Experimental|1|First of 5 groups, as described in the protocol and to which volunteers are blinded
89176326|NCT00802282|Experimental|2|Second of 5 groups, as described in the protocol and to which volunteers are blinded
89176327|NCT00802282|Experimental|3|Third of 5 groups, as described in the protocol and to which volunteers are blinded
89176328|NCT00802282|Experimental|4|Fourth of 5 groups, as described in the protocol and to which volunteers are blinded
89176329|NCT00802282|Experimental|5|Fifth of 5 groups as described in the protocol and to which volunteers are blinded
89176330|NCT00802516|Placebo Comparator|1. placebo|placebo margarine
89176331|NCT00802516|Experimental|2. stanol ester|margarine with plant stanol ester
89176332|NCT00802516|Experimental|3. sterol ester|margarine with plant sterol ester
89176333|NCT02606760|Experimental|P-3073|P-3073
89176334|NCT02606760|Placebo Comparator|vehicle of P-3073|vehicle of P-3073
89176335|NCT03871270||Participants|Those with severe chronic illnesses, which included but were not limited to various forms of advanced cancer, blood dyscrasias, graft vs. host disease, and rare genetic conditions.
89176336|NCT00652834|Other|kidney recipients with GI symptoms|This was a four-week study designed to investigate GI mucosal lesions by SBCE in kidney transplant recipients who were using MMF, and to examine the changes in clinical symptoms and intestinal mucosa lesions 30 days after switching over from MMF to EC-MPS. The patient was switched from MMF to EC-MPS (Myfortic) on the equimola basis.
89176337|NCT02553148||Argentina|One of the 23 countries studied
89176338|NCT02553148||Armenia|One of the 23 countries studied
89176339|NCT02553148||Australia|One of the 23 countries studied
89176340|NCT02553148||Brazil|One of the 23 countries studied
89176341|NCT02553148||China|One of the 23 countries studied
89176342|NCT02553148||Egypt|One of the 23 countries studied
89176343|NCT02553148||Ethiopia|One of the 23 countries studied
89176344|NCT02553148||Germany|One of the 23 countries studied
89176345|NCT02553148||India|One of the 23 countries studied
89176346|NCT02553148||Indonesia|One of the 23 countries studied
89176347|NCT02553148||Jordan|One of the 23 countries studied
89176348|NCT02553148||Kenya|One of the 23 countries studied
89176349|NCT02553148||Kyrgyzstan|One of the 23 countries studied
89176350|NCT02553148||Malaysia|One of the 23 countries studied
89176351|NCT02553148||Malawi|One of the 23 countries studied
89176352|NCT02553148||Mexico|One of the 23 countries studied
89176353|NCT02553148||Russia|One of the 23 countries studied
89176354|NCT02553148||Serbia|One of the 23 countries studied
89176355|NCT02553148||South Africa|One of the 23 countries studied
89176356|NCT02553148||Tajikistan|One of the 23 countries studied
89176357|NCT02553148||United Kingdom|One of the 23 countries studied
89176358|NCT02553148||United States|One of the 23 countries studied
89176359|NCT02553148||Zimbabwe|One of the 23 countries studied
89176360|NCT00825812|Experimental|Sugammadex in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
89176361|NCT00825812|Active Comparator|Neostigmine in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
89176362|NCT00825812|Experimental|Sugammadex in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
89176363|NCT00825812|Active Comparator|Neostigmine in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
89176364|NCT00802594|Experimental|DB289|
89176365|NCT02606682|Experimental|NPT200-11 - Cohort 1, Dose 1|Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
89176366|NCT02606682|Experimental|NPT200-11 - Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
89176367|NCT02606682|Experimental|NPT200-11 - Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
89176368|NCT02606682|Experimental|NPT200-11 - Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
89176369|NCT02606682|Experimental|NPT200-11 - Cohort 5 ,Dose 5|Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
89176370|NCT02606682|Experimental|NPT200-11 -Cohort 6, Dose 6|Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
89176371|NCT02606682|Experimental|NPT200-11 - Cohort 7, Dose 7|Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
89176372|NCT00707876|Experimental|1|Dose 1 versus non-contrast MRA
89176373|NCT00707876|Experimental|2|Dose 2 versus non-contrast MRA
89176374|NCT00707876|Experimental|3|Dose 3 versus non-contrast MRA
89176375|NCT00809770|Experimental|1|Contingency management
89176376|NCT00809770|Other|2|Non Contingent Control Condition
89176377|NCT00810004|Experimental|Ferinject|Intravenous infusion of iron
89176378|NCT00810004|Placebo Comparator|Placebo|NaCL 0,9%
89176379|NCT05746962|Active Comparator|Group that does not use the scopeguide screen|The control group should remove the looping of colonoscope by looking at the general colonoscopy screen The control group cannot use scopeguide screen Scopeguide screen is blinded by an opaque wrapping paper
89176380|NCT05746962|Experimental|Group using the scopeguide screen|The experimental group uses a general endoscopic image during colonoscopic insertion The experimental group should remove the looping of colonoscope by looking at the scopeguide screen
89176381|NCT00802750|Experimental|A|
89176382|NCT00802750|Experimental|B|
89176383|NCT00802828|Active Comparator|Test Product|
89176384|NCT00802828|Active Comparator|Reference Product|
89176385|NCT00824720|Experimental|High Dose Device|device worn continuously for 14 days
89176386|NCT00824720|Experimental|Low Dose Device|device worn continuously for 14 days
89176387|NCT00824720|Placebo Comparator|Placebo Device|device worn continuously for 14 days
89176388|NCT00802906|Active Comparator|1|1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
89176389|NCT00802906|Active Comparator|2|initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
89176390|NCT00802906|No Intervention|3|control
89176391|NCT03723486||Roux-en-Y gastric bypass surgery (RYGB)|Morbidly obese patients undergoing gastric bypass surgery
89176392|NCT00803140|Active Comparator|Cautery Arm|Cautery to make skin incision
89176393|NCT00803140|Active Comparator|Scalpel Incision|Scalpel to make skin incision
89176394|NCT00803218||Cohort Group 1|Subjects number 1 to 26
89176395|NCT00803218||Cohort Group 2|Subjects number 27 to 56
89176396|NCT00803296||Obese patients with type 2 diabetes|Patients with type 2 diabetes and BMI>33
89176397|NCT00803296||Obese subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BMI>33
89176398|NCT00803296||Lean subjects with type 2 diabetes|Patients with type 2 diabetes and BM<25
89176399|NCT00803296||Lean subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BM<25
89176400|NCT03704064|Experimental|Stigma + BWL Intervention|Participants in this group will receive the standard behavioral weight loss (BWL) program, which will be combined with a stigma-reduction intervention (more details provided in the Intervention section). All group meetings will be 90 minutes. Beginning at week 5, the 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the monthly and every-other-month weight loss maintenance sessions from weeks 21-72, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically with physical activity.
89176401|NCT03704064|Active Comparator|Standard BWL Intervention|Participants in this group will be provided with 20 weekly behavioral weight loss (BWL) session (described in more detail in the Intervention section), followed by 6 monthly weight loss maintenance sessions and 3 every-other-month sessions (for a total of 29 visits over 72 weeks). All group meetings will be 90 minutes. Beginning at week 5, BWL content in these sessions will last 60 minutes, with an additional 30 minutes devoted to discussing recipes and food preparation.
89176402|NCT00824564|Experimental|A|Tranexamic Acid plus standard of care
89176403|NCT00824564|Other|B|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss.
89176404|NCT00803374|Experimental|0.1 mg/kg|
89176405|NCT00803374|Experimental|0.3 mg/kg|
89176406|NCT00803374|Experimental|1.0 mg/kg|
89176407|NCT00803374|Experimental|3.0 mg/kg|
89176408|NCT00803374|Experimental|10 mg/kg|
89176409|NCT00803530|Experimental|1|"Loading phase (week 1): ATO 0.3 mg/Kg/die for 5 consecutive days.~Subsequent phase (from week 2 to week 16): ATO 0.25 mg/kg twice a week (day 2 and 5 of every week).~Ascorbic acid 1000 mg IV within 30 minutes after each arsenic trioxide infusion for 16 consecutive weeks."
89176410|NCT00803608|Active Comparator|02|Current standard of care insole
89176411|NCT00803608|Experimental|01|TrueContour® insole
89176412|NCT00708188|Experimental|Multidetector raw CT|
89176413|NCT00803764|Active Comparator|Test Product|
89176414|NCT00803764|Active Comparator|Reference Product|
89176415|NCT02611310||Participants with HER2-positive unresectable LA/mBC|
89176416|NCT02553694|Experimental|Enhanced education and Enhanced follow up|Subjects will watch a short video and will be contacted by an MD by phone
89176417|NCT02553694|Active Comparator|Usual education and Usual follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and will be contacted by a sleep center staff member by phone
89176418|NCT02553694|Experimental|Enhanced education and Usual follow up|Subjects will watch a short video immediately prior to the initiation of the in-laboratory polysomnogram and will be contacted by sleep center non-MD staff member by phone
89176419|NCT02553694|Experimental|Usual education with Enhanced follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and contacted by an MD by phone
89176420|NCT00704366|Experimental|1|AZD0530
89176421|NCT00708266|Placebo Comparator|V2|28 hours continuous saline venous infusion.
89176422|NCT00708266|Experimental|V3|28 hours continuous lipid-heparin venous infusion.
89176423|NCT03700554|Experimental|Pleuralvent™|Patients treated with Pleuralvent™ device
89176424|NCT03700554|Active Comparator|Chest tube|Patients treated with Chest tube
89176425|NCT00922246|No Intervention|control group|Conscript used their own ankle boots instead of custom made insoles.
89176426|NCT00922246|Experimental|shoe insoles|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length. The insole was strong enough to fill the arch area thus providing support to the mid foot. It also influences the position of the foot. The insoles were individually customized by heating the polyethylene in form of individual foot with standing and walking in them. The conscripts were advised to use these insoles in their ankle boot.
89176427|NCT00803920||Exenatide|
89176428|NCT00803920||Exenatide LAR|
89176429|NCT00658528|Experimental|1|
89176430|NCT00658528|Active Comparator|2|
89176431|NCT02872974||Exposed|Offspring of woman with GDM
89176432|NCT02872974||Not exposed|Offspring of woman without GDM
89176433|NCT00806104|Experimental|1|Fructo-oligosaccharides
89176434|NCT00806104|Placebo Comparator|2|Maltodextrins
89176435|NCT00806182||Pediatric case-controls|These are children who underwent lumbar puncture and blood drawing for diagnostic testing for non-inflammatory neurological or non-neurological disorders, and whose samples were retrieved from the clinical lab under a linked Institutional Review Board (IRB) protocol.
89176436|NCT00806182||Pediatric OMS|These are patients treated by the P.I. based on clinical decision making, not a clinical trial (this is an observational study). The types of treatments are varied, and, on the initial evaluation, the patients may be untreated or already tried on various immunotherapies. They range from monotherapy with steroids, ACTH, or IVIg, to disease modifying agents, such as rituximab, cyclophosphamide, and other chemotherapy, typically adjunctively or as combination therapy.
89236810|NCT00875693|Experimental|Arm A dose of CPX - 351|Dose level 1A: 60 units/m2 days -28, -26 and -24 Dose level 2A: 80 units/m2 days -28, -26 and -24 Dose level 3A: 100 units/m2 days -28, -26 and -24 Dose level 4A: 120 units/m2 days -28, -26 and -24 Dose level 5A: 140 units/m2 days -28, -26 and -24 Dose level 6A: 160 units/m2 days -28, -26 and -24
89236811|NCT00875693|Experimental|Arm B dose of CPX-351|Dose level 1B: 60 units/m2 days -21, -19 and -17 Dose level 2B: 80 units/m2 days -21, -19 and -17 Dose level 3B: 100 units/m2 days -21, -19 and -17 Dose level 4B: 120 units/m2 days -21, -19 and -17 Dose level 5B: 140 units/m2 days -21, -19 and -17
89236812|NCT00878579|Experimental|PDS System|
89236813|NCT00878579|Active Comparator|Fusion|
89236814|NCT00875771|Experimental|1|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks"
89236815|NCT00875849|Experimental|Cetuximab|
89236816|NCT00868595|Experimental|Dose escalation|"Cohort 1: BPX-101, 4 x 10*6 cells administered every other week for 6 cycles Cohort 2: BPX-101, 12.5 x 10*6 cells administered every other week for 6 cycles Cohort 3: BPX-101, 25 x 10*6 cells administered every other week for 6 cycles Cohort 4: BPX-101, 25 x 10*6 cells administered every 4 weeks for 3 cycles~At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, will be administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours."
89236817|NCT00875927|Active Comparator|1 - control|candy not including scraping microcapsules
89236818|NCT00875927|Active Comparator|2 - Scraping|candy including scraping TCP microcapsules
89236819|NCT00875927|Active Comparator|3 - Scraping plus Propolis|candy including scraping Propolis microcapsules
89236820|NCT00875927|Active Comparator|4 - Scraping plus Zinc|candy including scraping Zinc microcapsules
89236821|NCT00875927|Active Comparator|5 - Scraping plus Propolis and Zinc|candy including scraping Propolis and Zinc microcapsules
89236822|NCT00878657|Experimental|Radiotherapy plus gemcitabine|"Drug: gemcitabine hydrochloride~Radiation: intensity-modulated radiation therapy"
89236823|NCT00876005|Active Comparator|1|80% oxygen during cesarean section
89236824|NCT00876005|Active Comparator|2|30% oxygen during cesarean section
89236825|NCT00868673|Active Comparator|Low fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities, defined as: Diabetes (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~They will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and rest energy (without exercise).~This group will be assigned to a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of less than 20 grams/day fructose diet levels.~Total Time of intervention 6 weeks for each patient"
89236826|NCT00868673|Active Comparator|Normal fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities; defined as: Diabetes Mellitus (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet (of 15% proteins, 30% lipids and 55% carbohydrates); calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise).~This group will receive a controlled fructose diet between 50 and 70 grams/day of fructose intake.~Total time of intervention:6 weeks for each patient"
89236827|NCT00879593|Experimental|PtcCO2|
89236828|NCT00879671|Active Comparator|1|Lutamax
89236829|NCT00879671|Placebo Comparator|2|Placebo
89236830|NCT00868829|Experimental|Firebird2|
89236831|NCT00868907|Experimental|Treatment A|35 mg risedronate DR tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
89236832|NCT00868907|Experimental|Treatment B|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
89236833|NCT00868907|Active Comparator|Treatment C|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
89236834|NCT00868985|Experimental|PEG 3350 plus electrolytes|Patients were dosed with PEG 3350 with electrolytes
89236835|NCT00868985|Experimental|PEG 3350 without electrolytes|Patients were dosed with PEG 3350 without electrolytes
89236836|NCT00869063|Experimental|Diclofenac Sodium Patch|
89236837|NCT00869063|Placebo Comparator|Placebo Patch|
89176437|NCT00806338|Experimental|Trodusquemine (MSI-1436) 3mg/m2|
89176438|NCT00806338|Experimental|Trodusquemine (MSI-1436) 6mg/m2|
89176439|NCT00806338|Experimental|Trodusquemine (MSI-1436) 10mg/m2|
89176440|NCT00806338|Placebo Comparator|Placebo|
89176441|NCT04017052|Other|Booster vaccination|Intervention = one i. m. TBE booster vaccination (FSME-Immun) at visit 1.
89176442|NCT00806572|Experimental|Treatment|
89176443|NCT00806572|No Intervention|Control|
89176444|NCT00856583|Experimental|Sertindole|Normally in the range of 4 to 20 mg/day
89176445|NCT00856583|Active Comparator|Risperidone|Normally in the range of 2 to 8 mg/day
89176446|NCT00856349||Analysis cohort|Enrolled subjects who met study eligibility criteria and contributed data toward study endpoints.
89176447|NCT00803244|Experimental|300 IR|300 IR grass pollen allergen extract tablet
89176448|NCT00803244|Placebo Comparator|Placebo|Placebo tablet
89176449|NCT02608632|Experimental|Group 1 (RDN guided by HFS)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access. After that high-frequency stimulation (HFS) was used before the initial and after each radiofrequency (RF) delivery within the renal artery. RDN was considered to have been achieved when the sudden increase of blood pressure (> 15 mm Hg from invasive arterial monitoring) was eliminated in response to HFS.~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery."
89236838|NCT00869219|Active Comparator|Nevanac|
89236839|NCT00869219|Active Comparator|Acular LS|
89236840|NCT00878735|Experimental|1|Zen meditation
89176450|NCT02608632|Active Comparator|Group 2 (RDN as standard procedure)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access.~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery. High-frequency stimulation (HFS) was performed before and after RDN to just to verify the response of BP"
89176451|NCT02614313|Active Comparator|Fructose double-blind|Fructose during breath test, double-blind 35g
89176452|NCT02614313|Active Comparator|Fructose open|Fructose during breath test, open 35g
89176453|NCT02614313|Placebo Comparator|Sweet placebo double-blind|Assugrin during breath test double-blind
89176454|NCT02614313|Placebo Comparator|Neutral placebo double-blind|Water during breath test double-blind
89176455|NCT02614391|Experimental|Active distraction using a tablet|Children were admitted in a comfortable room with a parent and started to play with a videogame suitable for their age three minutes before procedure. They continued to play the videogame during venipuncture. The use of a computer tablet permitted to play with one hand only.
89176456|NCT02614391|Active Comparator|Passive distracion|Children were admitted in a comfortable room with a parent and received various kinds of passive distractions: nurses singing a song, reading a book, blowing bubbles and playing a puppet show. The technique that most engaged the child, was continued during procedure.
89176457|NCT04131803|Experimental|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
89176458|NCT04131803|Experimental|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
89176459|NCT02608008||Data analysis transfemoral aortic valve implantation|Periinterventional data analysis during structural heart procedures like transfemoral aortic valve implantation with and without the use of EchoNavigator System Release II.
89176460|NCT02608008||Data analysis MitraClip|Periinterventional data analysis during structural heart procedures like MitraClip Implantations with and without the use of EchoNavigator System Release II.
89176461|NCT02608008||Data analysis PFO|Periinterventional data analysis during structural heart procedures like PFO implantations with and without the use of EchoNavigator System Release II.
89176462|NCT02608008||Data analysis ASD|Periinterventional data analysis during structural heart procedures like ASD implantations with and without the use of EchoNavigator System Release II.
89176463|NCT02608086|Other|Control|"Flyer What can I do facing a crisis?"
89176464|NCT02608086|Experimental|Psychological First Aid|"Psychological First Aid according to an adapted protocol based on the WHO PFA Operation Guide 2012 Brochure Network and Services Flyer What can I do facing a crisis?."
89176465|NCT02607852|Other|Arm A|Patients between the ages of 5-18 years. They will complete the 5-18 version of the BOQ on iPads or through the HTTPS Tonic link.
89176466|NCT02607852|Other|Arm B|Patients between the ages of 0-4 years. They will complete the 0-4 version of the BOQ and appropriate Pediatric Symptom Checklists (i.e. baby or preschool) on iPads or through the HTTPS Tonic link.
89176467|NCT04018326||Compliant patients|The compliant patient was defined as a patient who did not miss any follow-up visit until the end of the study period.
89176468|NCT04018326||Loss to follow-up (LTFU)|LTFU was defined as missing any follow-up visit for any interval exceeding 6 months provided that patients eventually resumed care before the end of the study period (time zero was defined as the date of the missed follow-up visit).
89176469|NCT05753358|Experimental|Needs Assessment and Total Worker Health Program|The initial phase was a needs assessment for wildland firefighters across segments and geographic locations to identify and prioritize program components. During the first phase, we recruited firefighters and collected baseline data in order to assess their needs using surveys for quantitative data and interviews and focus groups for qualitative data. The total worker health program includes 14, 30-minute modules on health topics highlighted during the needs assessment phase. Participants completed the program either individually or as part of a group.
89176470|NCT04014972||Patients with Myocardial Infarction|
89176471|NCT05753280|Experimental|treatment group|pegylated interferon 180ug/week and oral vitamin D3 800IU/day for no longer than 48 weeks
89176472|NCT05753280|No Intervention|control group|pegylated interferon 180ug/week for no longer than 48 weeks
89176473|NCT02606370|Experimental|Unstable shoes|Wearing unstable shoes during 1 month
89176474|NCT02606370|No Intervention|Control Group|Not Wearing unstable shoes
89176475|NCT02606214|Experimental|Dose Level 1: 50 mg TBA-354|50 mg TBA-354 for 14 days (two 25 mg once daily)
89176476|NCT02606214|Placebo Comparator|Dose Level 1: Placebo|Placebo cohort for Dose Level 1
89176477|NCT02606214|Experimental|Dose Level 2: 100 mg TBA-354|100 mg TBA-354 for 14 days (one 100 mg tablet once daily)
89176478|NCT02606214|Placebo Comparator|Dose Level 2: Placebo|Placebo cohort for Dose Level 2
89176479|NCT02606214|Experimental|Dose Level 3: 200 mg TBA-354|200 mg TBA-354 for 14 days (two 100 mg once daily)
89176480|NCT02606214|Placebo Comparator|Dose Level 3: Placebo|Placebo cohort for Dose Level 3
89176481|NCT02606214|Experimental|Dose Formulation Comparison Cohort|"All subjects in this cohort will receive two doses of the active drug. The first dose in three subjects will be a 100 mg TBA-354 tablet, followed 14 days later by a 100 mg dose of the TBA-354 suspension formulation. The first dose in the other three subjects will be 100 mgs of the TBA-354 suspension formulation, followed 14 days later by a 100 mg TBA-354 tablet dose. Placebo formulations will not be used in the dose formulation comparison cohort.~Each dose will be administered orally with 200 ml of water after a minimum 8 hour overnight fast. Food will be given two hours after each dose."
89176482|NCT00804570|Experimental|LY2196044|
89176483|NCT00804570|Placebo Comparator|Placebo|
89176484|NCT05753124||Pregnant women with obesity/GDM/T2DM|Pregnant women with obesity/GDM/T2DM
89176485|NCT05753124||Pregnant women with obesity/GDM/T2DM- Controls|Pregnant women with normal BMI/ no GDM orT2DM
89176486|NCT05753124||Post-bariatric pregnant women|Pregnant women with previous bariatric surgery
89236841|NCT00878735|No Intervention|2|No meditation (no intervention; keep regular activities) or a resting group (this group stays at the same place of the retreat group, but only to rest)
89236842|NCT00878813||1|All consecutive stroke patients undergoing acute intra-arterial revascularisation therapy
89236843|NCT00878813||2|All consecutive stroke patients undergoing acute intra-venous revascularisation therapy
89236844|NCT00878813||3|All consecutive stroke patients treated conservatively
89236845|NCT00878813||4|All consecutive TIA patients
89236846|NCT00878891|Active Comparator|1. Conventional glucose monitoring|Discontinuous glucose monitoring - GlucoDay Device with Continue record blinded
89236847|NCT00878891|Experimental|2. Conventional glucose monitoring + Glucoday|Continuous glucose monitoring - GlucoDay device with Continue record displayed
89236848|NCT00418665|Active Comparator|750 mcg AMG 531|750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
89236849|NCT00418665|Placebo Comparator|Placebo Part B|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
89236850|NCT00418665|Placebo Comparator|Placebo Part A|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
89236851|NCT00418665|Active Comparator|500 mcg AMG 531|500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
89236852|NCT00418665|Active Comparator|750 mcg AMG531 Part B|750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
89236853|NCT03994965|Experimental|Patients|"40 antipsychotic-free, first-episode schizophrenia spectrum patients will receive 6 weeks of treatment with a selective serotonin 2A Receptor (2AR) blockade.~Before initiation of treatment patients will undergo: positron emission tomography (PET) imaging of the serotonin 2AR binding potential using the radioligand [¹¹C]Cimbi-36; magnetic resonance spectroscopy (MRS) of cerebral glutamate levels; structural Magnetic Resonance Imaging (MRI), including diffusion tensor imaging (DTI); cognitive and psychopathological examinations; Electrocardiography (ECG), and blood sampling for genetic- and metabolic analyses.~(Full description will be updated on approval)."
89236854|NCT04648059||Lupus nephritis +ve|This group consists of patients with Lupus nephritis
89236855|NCT04648059||Lupus nephritis -ve|This group consist of patients with SLE without Lupus nephritis
89236856|NCT01952067|Experimental|line-to-line reaming|Corail cemented femoral stem using line-to-line reaming and cementing technique, 28mm Alumine Biolox forte femoral head, Marathon cup
89236857|NCT01952067|Active Comparator|standard over-reaming|Corail cemented femoral stem using standard over-reaming with 2 broach sizes, 28mm Alumine Biolox forte femoral head, Marathon cup
89236858|NCT00432237|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
89236859|NCT00432237|Experimental|MK0974 150 mg|MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
89236860|NCT00432237|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
89236861|NCT00432237|Placebo Comparator|Placebo|Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack
89236862|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236863|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/27 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236864|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236865|NCT00531284|Experimental|Phase 2 Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236866|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 36 mg/m²|Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236867|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 45 mg/m²|Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236868|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236869|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89176487|NCT05753124||Pregnant no bariatric women- Controls|"There will be two control groups of women with no previous bariatric surgery:~1. Pregnant women with booking BMI similar to the booking BMI of the post-bariatric ones and 2. Pregnant women with booking BMI similar to the pre-surgery BMI of the post-bariatric ones."
89176488|NCT02606292|Experimental|Arm 1: PAE assessment|-The PAE-EUS assessment will be performed in the operating room by the after induction of general anesthesia and following strict sterile technique while the patient is being positioned and prepped for esophageal surgery.
89176489|NCT00824408|Experimental|BI 6727 +pemetrexed|BI 6727 plus 500 mg/^m2 pemetrexed i.v. on day 1 of 21 day cycle
89176490|NCT00824408|Active Comparator|pemetrexed|500 mg/m^2 i.v. on day 1 of a 21 day cycle
89176491|NCT02611700|Experimental|experimental group|Nimotuzumab+TP(paclitaxel+cisplatin)
89176492|NCT02611700|Placebo Comparator|control group|Placebo + TP(paclitaxel+cisplatin)
89176493|NCT05429840|Experimental|Part 1 MT1980|
89176494|NCT05429840|Placebo Comparator|Part 1 Placebo|
89176495|NCT05429840|Experimental|Part 2 MT1980 Dose Level 1|
89176496|NCT05429840|Experimental|Part 2 MT1980 Dose Level 2|
89176497|NCT05429840|Placebo Comparator|Part 2 Placebo|
89176498|NCT00708344|Active Comparator|Group 1|Usual elective titration regimen
89176499|NCT00708344|Active Comparator|Group 2|Active elective titration regimen
89176500|NCT00866333|Experimental|Entinostat|"Regimen determined by protocol version.~Regimen 1: entinostat 10 mg (two 5 mg tablets) orally, once every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.~Regimen 2: entinostat 10 mg (two 5 mg tablets) orally on Day 1, increased to 15 mg (three 5 mg tablets) beginning on Day 15 of Cycle 1 for participants who had not experienced treatment-related adverse events with severity grade ≥2 (moderate), then continue 15 mg every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.~Regimen 3: entinostat 15 mg (three 5 mg tablets), orally, once weekly for 3 weeks followed by a 1-week break in a 4-week (28-day) cycle until disease progression or unacceptable toxicity."
89176501|NCT00699725||1|NSAID patients with risk factors treated with gastroprotective drugs
89176502|NCT00834080|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
89176503|NCT00823472|Experimental|Start rFSH cycle day 2|
89176504|NCT00823472|Experimental|Start rFSH on cycle day 5|
89176505|NCT04131569||ESBL-E fecal carriers|Patients with a positive ESBL-E fecal carriage according to routine screening
89176506|NCT04131569||non ESBL-E fecal carriers|Patients without positive ESBL-E fecal carriage according to routine screening
89176507|NCT04118699|Experimental|Rifaximin|Two tablets of the investigational product per dosing (400 mg of rifaximin) are orally administered 3 times daily for 4 weeks.
89176508|NCT04118699|Placebo Comparator|Placebo|Two tablets of the placebo are orally administered 3 times daily for 4 weeks.
89176509|NCT00856193|Placebo Comparator|Placebo then NVA237 50μg|Placebo 50 μg capsules followed by NVA237 50 μg capsules for inhalation once daily with Concept 1 device.
89176510|NCT00856193|Experimental|NVA237 50μg then placebo|NVA237 50 μg capsules followed by matching placebo 50 μg capsules for inhalation once daily with Concept 1 device.
89176511|NCT00698087|Experimental|Group A|
89176512|NCT00698087|Active Comparator|Group B|
89176513|NCT00698087|Experimental|Group C|
89176514|NCT04130087|Experimental|Selegiline Group|27 healthy participants who will be administered a single 10mg tablet of selegiline hydrochloride.
89176515|NCT04130087|Placebo Comparator|Placebo Group|27 healthy participants who will be administered a single lactose tablet (placebo)
89176516|NCT00652366|Active Comparator|Gemcitabine, Erlotinib Standard Dose|Participants received erlotinib, 100 milligrams (mg), orally (PO), once daily until disease progression or unacceptable toxicity. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
89176517|NCT00652366|Experimental|Gemcitabine, Erlotinib Escalating Dose|Participants received erlotinib, beginning at 150 mg/day, PO, once daily, and increasing in increments of 50 mg every 2 weeks up to a maximum of 250 mg/day, until development of a grade 2 rash, or occurrence of other, non-rash, dose-limiting toxicity; treatment was continued until disease progression, unacceptable toxicity, death or withdrawal. Participants also received gemcitabine, 1000 mg/m^2, IV, on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
89176518|NCT00841568|Experimental|1|
89176519|NCT00855959|Experimental|1|Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily
89176520|NCT00855959|Experimental|2|Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)
89176521|NCT00704600|Experimental|nelfinavir|see intervention
89176522|NCT00699881|Experimental|A|administer cetuximab in combination with modified FOLFIRI
89176523|NCT00708578|Active Comparator|1|Administration of 4 mg of Glimepiride with Insulin Glargine
89176524|NCT00708578|Active Comparator|2|Administration of 1500 mg of Metformin with Insulin Glargine
89176525|NCT00708578|Experimental|3|Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine
89176526|NCT04130009|Active Comparator|TKA with tourniquet|This group was treated by TKA with the use of tourniquet
89176527|NCT04130009|Active Comparator|TKA without tourniquet|This group was treated by TKA without tourniquet
89176528|NCT00806650||Blood draw for diagnosis testing|
89176529|NCT00841100|Experimental|Acute 24 Hour Component|Participants will receive one dose of Kuvan 20 mg/kg on Day 1 and assessed for Acute 24 hour Kuvan response.
89176530|NCT00841100|Experimental|Phase 1 Group|After completion of acute 24 hour component, participants can enroll in Phase 1 and will receive Kuvan 20 mg/kg by mouth once daily for 28 consecutive days
89176531|NCT00841100|Experimental|Phase 2 Group|Participants in Phase 1 that was not responsive will continue on to the Phase 2 of the study. Positive response is defined as a decrease of blood phenylalanine of 30% or greater from baseline taken from morning blood serum. The Phase 2 component of the study will be a 2 week period of dietary restriction.
89236870|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236871|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/36 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236872|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236873|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236874|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236875|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236876|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236877|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/45 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236878|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/56 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
89236879|NCT01005446||RSP Device|Post Market Study
89236880|NCT00531206||All participants|
89236881|NCT00994994|Active Comparator|Tranexamic acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit.
89236882|NCT00994994|Placebo Comparator|Placebo|same volume of normal saline was given.
89236883|NCT04000022||Non-Treatment Resistant Patients|
89236884|NCT04000022||Treatment-Resistant Patients|The group of patients from NCT03944213
89236885|NCT00999752|Active Comparator|Arm A|Nebivolol to reach blood pressure control
89236886|NCT00999752|Active Comparator|Arm B|Hydrochlorothiazide for blood pressure control
89236887|NCT00530816|Experimental|Carfilzomib|"Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.~Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles."
89236888|NCT01005836|Experimental|Cognitive-behavioral therapy: Anxiety|CBT for child anxiety. Coping Cat.
89236889|NCT01005836|Other|Usual care: Anxiety|Usual clinic care
89236890|NCT01005836|Experimental|Cognitive behavioral therapy: depression|CBT for youth depression. The Primary and Secondary Control Enhancement Training protocol.
89236891|NCT01005836|Other|Usual care: Depression|Usual clinic care for depression
89236892|NCT01005992|Experimental|Laser treated scar|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
89236893|NCT01005992|Active Comparator|Standard scar management|The standard scar management arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
89236894|NCT01008800|Experimental|Center-Based classroom intervention|Four days a week for 2.5 hours a day the child will participate in a classroom with peers in an attempt to increase social communication, language abilities, and other skills. Parents will also receive education sessions 1-3 times per month for 1-2 hours each. Treatment will last for 6 months.
89236895|NCT01008800|Active Comparator|Parent Training|Parents are taught strategies on how to interact with their children to increase their skills. Parent training sessions are given 2 times a month at our center and once a month at home for 60-90 minutes each. Treatment will last for 6 months.
89236896|NCT01006070||Patients with existing spinal fractures|Myeloma patients with documented x-ray evidence of spinal fractures.
89236897|NCT01006070||Patients without spinal fractures|Myeloma patients with bony disease in the spine without existing fractures.
89236898|NCT05092802|Experimental|HLX208|
89236899|NCT00615017|Experimental|AZD9773 cohort 1 (50 units/kg)|AZD9773: single infusion of 50 units/kg
89236900|NCT00615017|Experimental|AZD9773 cohort 2 (250 units/kg)|AZD9773: single infusion of 250 units/kg
89236901|NCT00615017|Experimental|AZD9773 cohort 3 (250/50 units/kg)|AZD9773: loading infusion of 250 units/kg then 9 maintenance doses of 50 units/kg q12hrs
89236902|NCT00615017|Experimental|AZD9773 cohort 4 (500/100 units/kg)|AZD9773: loading infusion of 500 units/kg then 9 maintenance doses of 100 units/kg q12hrs
89236903|NCT00615017|Experimental|AZD9773 cohort 5 (750/250 units/kg)|AZD9773: loading infusion of 750 units/kg then 9 maintenance doses of 250 units/kg q12hrs
89236904|NCT00615017|Placebo Comparator|Placebo|Placebo
89236905|NCT05236244|Experimental|İntervention group|Diaphragmatic breathing exercises: First Evaluation + (1 week break) + Motor imagery protocol + Second Evaluation + 8 weeks of diaphragmatic breathing exercises +Third Evaluation +(1 week interval) + Motor imagery protocol + Fourth Evaluation
89236906|NCT05236244|No Intervention|Control Group|First Evaluation + (1 week break) + Motor imagery protocol + Second Evaluation + 8 weeks break +Third Evaluation +(1 week interval) + Motor imagery protocol + Fourth Evaluation
89236907|NCT01006148|Experimental|Bone substitute|Enrollees will receive Allogenix Plus(TM), a demineralized bone matrix, to fill in calvarial gaps after cranial vault remodeling and fronto-orbital advancement.
89236908|NCT01006226|Experimental|64Cu-ATSM PET|
89236909|NCT00879047|Experimental|HIV+, Ritonavir-regimen|10 subjects will be HIV+ and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
89236910|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Ritonavir-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
89236911|NCT00879047|Experimental|HIV+, Efavirenz-regimen|10 subjects will be HIV+ and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
89236912|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Efavirenz-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
89236913|NCT00879047|Experimental|Maraviroc in Healthy Subjects|10 healthy subjects will begin receiving maraviroc, and their PK interactions with alcohol/placebo will be evaluated.
89236914|NCT01008956|Experimental|Single Group|Subjects enrolled in this group will be stratified by age (18 to 40 years and 41 to 64 years)
89236915|NCT03742700|Experimental|T-smokers|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
89236916|NCT03742700|Experimental|E-smokers|E-smokers were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
89236917|NCT03742700|Experimental|T/E-smokers|T/E-smokers (dual users) were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
89236918|NCT03742700|Placebo Comparator|Control subjects|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
89236919|NCT00879749|Placebo Comparator|Saline|
89236920|NCT00879749|Experimental|Nexvax2|
89236921|NCT01006382||Adolescents and young adults with food allergy|Adolescents aged 13-21 years with a diagnosis of food allergy
89236922|NCT00869297|Active Comparator|Control|
89236923|NCT00869297|Experimental|Intervention|These patients receive fluid boluses based on measurements from the FloTrac
89236924|NCT00999986|No Intervention|placebo|
89236925|NCT00999986|Active Comparator|cyclophosphamide|
89236926|NCT05226611|Experimental|Tender point treatment with Counterstrain|A tender point was located in the upper trapezius region of the test subject and treated with counterstrain. The side with the highest initial pain level was used as the treatment side. Pain level was measured before and after treatment. The MyotonPRO was also used to measure physiologic parameters of the muscle before and after treatment.
89236927|NCT05178758|Experimental|Virtual Reality (VR) Rehabilitation Training|Patients in the VR group will receive VR rehabilitation training in the hospital. The content of the training is the same as the control group. The only difference is that participants in the intervention group will use VR as a training platform. The VR system will include the training materials and tasks required for the patients to perform in the 3D environment. Demographic, clinical data and treatment costs will be collected before and after the rehabilitation training.
89236928|NCT05178758|No Intervention|Control - Conventional Rehabilitation Training|Patients in the control group will receive conventional rehabilitation training currently provided in the hospital. An instructor will assign each participant for training. Demographic, clinical data, and treatment costs will be collected before and after completing the rehabilitation training
89236929|NCT01009112|Experimental|CBT for Insomnia|"Patients change their sleep times and habits in order to reduce alertness and over thinking when they are trying to sleep. This helps them learn how to sleep overnight in one solid block of time"
89236930|NCT01009112|Experimental|Imagery Rehearsal Therapy|"Patients rescript the narrative of a nightmare to eliminate the distressing elements and create a new pleasant dream scene. They then rehearse this scene in their imagination at least twice each day. This reduces the frequency and intensity of the target nightmare and often reduces other nightmares, too."
89236931|NCT01009112|Experimental|Prolonged Exposure|This behavioral treatment for PTSD involves 1) systematic and repeated exposure to objects and situations that are avoided due to trauma-related distress, 2) prolonged, repeated recounting of trauma memories through visualization, and 3)therapist-guided discussions of thoughts and emotions related to the exposure exercises. The goals of PE are to reduce the anxiety and distress elicited by trauma-related memories and situations, show patients these memories and situations are distinct from the trauma, and teach patients they can tolerate the distress caused by these memories and situations.
89236932|NCT01009112|Active Comparator|Suportive Care Therapy|This is an active therapy where the focus of the intervention is on helping patients better understand their emotional response to their PTSD and sleep symptoms.
89236933|NCT01000142|No Intervention|Treatment as Usual Control Group|
89176532|NCT00841100|Experimental|Phase 3 Group|Participants in Phase 2 that achieves a fasting blood phenylalanine of less than 600 umol/l after 2 week dietary restriction will be retreated with Kuvan 20 mg/kg by mouth once daily for a period of 28 consecutive days.
89176533|NCT02614157|Experimental|LLND+TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo lateral lymph node dissection and total mesorectal excision(LLND+TME)
89176534|NCT02614157|No Intervention|TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo total mesorectal excision (TME)solely, without LLND
89176535|NCT02552992|Experimental|Yoga Classes|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
89176536|NCT02552992|Active Comparator|Self-Directed Mind-Body Program|Study Participants will receive: The Back Pain Helpbook, a mind-body self-care program for better living.
89176537|NCT00704678|Experimental|1|1g bid
89176538|NCT00704678|Active Comparator|2|0.8 g tid
89176539|NCT00704678|Experimental|3|1.5 g tid
89176540|NCT00704678|Active Comparator|4|1.6 g tid
89176541|NCT00804076|Experimental|NP2|Intradermal injection
89176542|NCT00698165||Patients|1200 adults with mild to severe Alzheimer's disease
89176543|NCT00698165||Caregivers|1200 informal caregivers
89176544|NCT00703040||Component 1|Existing linkage to care protocols will be obtained from the 15 sites. This component does not involve study subjects.
89176545|NCT00703040||Component 2|Person-to-person or telephone interviews with ATN clinical site staff and staff from their community partners will be audio-taped.
89176546|NCT00703040||Component 3|Notes from direct observation of the linkage to medical care process within sites will be taken.
89176547|NCT00810160|Active Comparator|1|Permeate
89176548|NCT00810160|Active Comparator|2|GOS
89176549|NCT00810160|Active Comparator|3|Bifidobacterium infantis
89176550|NCT00810160|Active Comparator|4|Bifidobacterium animalis
89176551|NCT00708656|Experimental|1: once daily|Three 800mg tablets of mesalazine (Asacol®) in the morning
89176552|NCT00708656|Active Comparator|2: tds|Mesalazine (Asacol®) 800mg given three times daily
89176553|NCT00806728|Experimental|1|MEDI-507
89176554|NCT00806728|Experimental|2|MEDI-507
89176555|NCT04118543|Experimental|Intervention Group|The intervention group will take part in three 1-hour targeted moderate-to-vigorous physical activity (MVPA) gym-based group exercise sessions per week for eight weeks with individualised prescriptions.
89176556|NCT04118543|Sham Comparator|Sham-Exercise Group|The shame-exercise group will complete three sham exercise group sessions per week for eight weeks (including stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group).
89176557|NCT00913328|Active Comparator|Montelukast|Oral montelukast 10 mg once daily for 12 weeks
89176558|NCT00913328|Placebo Comparator|Placebo|Oral placebo once daily for 12 weeks
89176559|NCT00651820|Experimental|Collagenase Santyl Rate of Wound Closure|Dermatome-induced skin wounds treated with drug active (collagenase).
89176560|NCT00651820|Placebo Comparator|Vehicle Rate of Wound Closure|Dermatome-induced skin wounds treated with Vehicle alone.
89176561|NCT02612168|Experimental|All patients|Each patient will have any pigmented lesions (PLs) which are due to be biopsied, two PLs not due for biopsy and one patch of healthy skin photographed. Each will be photographed using three cameras: A standard DSLR and two smartphones with a dermoscopic lens attachment. Photographic images will be analysed by Melanoma Image Analysis Algorithm (MIAA)
89176562|NCT04017208|Experimental|ASP2713|Participants will receive a single dose of ASP2713. Up to 8 dose levels will be administered in the study.
89176563|NCT04017208|Placebo Comparator|Placebo|Participants will receive a single dose of placebo.
89176564|NCT00804232|Experimental|1|effects on child health of family-based home care compared to traditional hospital-based care,
89176565|NCT00804232|Experimental|2|effects on child health of family-based psychological treatment compared to traditional hospital-based treatment
89176566|NCT00866177|Experimental|Arm I|Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89176567|NCT00804310|Experimental|Lapatinib and Ixabepilone|
89176568|NCT04131101|Experimental|Community Organizing|All tenants in three TCHC buildings will be invited to participate in a survey on their building conditions at baseline, 6 months and 12 months. Once baseline data collection is complete, there will be a community organizing campaign involving tenants to advocate for improved building conditions.
89176569|NCT00833924|Other|1|Treatment with Endovascular Graft
89176570|NCT04131257|Experimental|Continuum of care|Trained diabetes nurses will provide continuum of care to the participants that includes: conducting community awareness campaigns, screening programs, linkage to clinical care, community follow-up counseling and support for individuals with diabetes, and prevention programs for individuals with pre-diabetes.
89176571|NCT04131257|Active Comparator|Usual care|The control group will receive usual diabetic care without the nurse coordination and supervision as in the intervention group.
89176572|NCT02614235|Experimental|Pocket-ECG III System|After signing written informed consent, a Pocket-ECG III® system will be given to the patient. All participants will be monitored by the Pocket-ECG® system until a diagnosis is achieved or for a maximum of two months (whatever it happens first). Everyday daily reports sent via e-mail by the manufacturer company (MEDICALgorithmics© S.A.) will be reviewed by the investigator team; in case of a diagnosis event (according to prespecified diagnostic criteria from the European Society of Cardiology), appropriate treatment will be applied.
89176573|NCT02614235|Active Comparator|Conventional Holter|Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered.
89176574|NCT00840086|Experimental|rFVIII|
89176575|NCT04118777|Active Comparator|0.2 % Ropivacaine|An ON-Q pain pump will be placed into the pelvic cavity and 0.2% Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr.
89176576|NCT04118777|Placebo Comparator|Saline|An ON-Q pain pump will be placed into the pelvic cavity and saline will be continuously administered intraperitoneally at a rate of 6 mL/hr
89176577|NCT04129385|No Intervention|Group S|Control group (Group S: 54 patients); this group will undergo the standard laparoscopic procedure (the procedure is done in Trendelenburg position). While in Trendelenburg position and prior to wound closure and with laparoscopic port valves open, the patient's abdomen will be passively deflated. The patients will be placed in supine head up position in the post anesthesia care unit (PACU).
89176578|NCT04129385|Experimental|Group T|Intervention group (Group T: 54 patients); the patients will be subject to the same maneuver as in arm 1 prior to wound closure but will be positioned in a 20 degree Trendelenburg position once fully awake and cooperative in the PACU and will remain in this position for the first 24 hours post operatively, even after they are transferred to their rooms on the American University of Beirut Medical Center (AUBMC) floors. The maximum time allowed in a straight-up position will be three 15-minute intervals over a 24-hour period (the first interval being a clear fluids intake at 12 hours postoperatively).
89176579|NCT00708812|Active Comparator|The control group|paclitaxel-carboplatin
89176580|NCT00708812|Experimental|The treatment group|paclitaxel-carboplatin plus Endostar
89176581|NCT04127747|Active Comparator|Standard dose group|
89176582|NCT04127747|Experimental|Individualized dose group|
89176583|NCT00822926|Experimental|Placebo then Botox|Injection 1: Saline- Subcutaneous injection of saline into scar tissue Injection 2: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
89176584|NCT00822926|Experimental|Botox then Placebo|Injection 1: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue Injection 2: Saline- Subcutaneous injection of saline into scar tissue
89176585|NCT00698555|Experimental|Group A|
89176586|NCT00698555|Experimental|Group B|
89176587|NCT00698555|Experimental|Group C|
89176588|NCT00698555|Experimental|Group D|
89176589|NCT00698555|Experimental|Group E|
89176590|NCT00698555|Active Comparator|Group F|
89176591|NCT00822770|Experimental|Phase I|ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
89176592|NCT00822770|Experimental|Phase II|ATG + MTD Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
89176593|NCT02611388|Experimental|2/10HZ TEAS pretreatment|Patients were given 30min of 2/10HZ TEAS before anesthesia
89176594|NCT02611388|Experimental|10/50HZ TEAS pretreatment|Patients were given 30min of 10/50HZ TEAS before anesthesia
89176595|NCT02611388|Sham Comparator|fake stimulation|Patients were only attached electrodes without electric current
89176596|NCT00822692|Active Comparator|Bactrim DS|Trim/sulfa (800/160) two tablets orally (PO) twice a day (BID) x 7 days
89176597|NCT00822692|Placebo Comparator|matched placebo|matched placebo 2 pills orally (PO) twice a day (BID) x 7 days
89176598|NCT02612012||Axillary radiotherapy|
89176599|NCT03260127|Experimental|CEFT-CPT|Computerized executive function training plus Cognitive Processing Therapy for PTSD
89176600|NCT03260127|Active Comparator|WT-CPT|Word game training plus Cognitive Processing Therapy for PTSD
89176601|NCT02607111|Experimental|open label|Dalteparin injected as a bolus into the arterial port of the hemodialysis machine every dialysis session for four weeks
89176602|NCT00703196|Experimental|Arm I|Patients receive oral folic acid pill once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
89176603|NCT00703196|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
89176604|NCT02611856||monochorial-biamniotic pregnancies|
89176605|NCT00913250|Experimental|Sequence 1|Serum containing Avonex followed by serum free Avonex
89176606|NCT00913250|Experimental|Sequence 2|Serum free Avonex followed by serum containing Avonex
89176607|NCT04016571||Adults with Cystic Fibrosis|"All Adults with a confirmed diagnosis of Cystic Fibrosis being admitted for Intra-Venous Antibiotic Treatment of a Pulmonary Exacerbation~This study is observational so no intervention will be carried out."
89176608|NCT02608554|Experimental|Taichi|The 24 forms of simplified TCC recommended as the popular health sport by the General Administration of Sport of China were applied.
89176609|NCT02608554|Active Comparator|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise.
89176610|NCT02612246|Experimental|GLPG1972 single dose|Single oral dose of GLPG1972 solution - ascending doses
89176611|NCT02612246|Placebo Comparator|Placebo single dose|Single oral dose of placebo solution
89176612|NCT02612246|Experimental|GLPG1972 multiple doses|Multiple oral doses of GLPG1972 solution - ascending doses
89176613|NCT02612246|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo solution
89176614|NCT00914277|Experimental|Sequence 1|"Period 1: placebo~Period 2: sildenafil~Period 3: SAR407899 dose level 2~Period 4: SAR407899 dose level 1"
89176615|NCT00914277|Experimental|Sequence 2|"Period 1: sildenafil~Period 2: SAR407899 dose level 1~Period 3: placebo~Period 4: SAR407899 dose level 2"
89176616|NCT00914277|Experimental|Sequence 3|"Period 1: SAR407899 dose level 1~Period 2: SAR407899 dose level 2~Period 3: sildenafil~Period 4: placebo"
89176617|NCT00914277|Experimental|Sequence 4|"Period 1: SAR407899 dose level 2~Period 2: placebo~Period 3: SAR407899 dose level 1~Period 4: sildenafil"
89176618|NCT00708968|Experimental|FOCUS Intervention|Dyads randomized to this arm received the FOCUS Program, 3 home visits and 2 phone calls by trained nurses.
89176619|NCT00708968|No Intervention|Standard Care|
89176620|NCT00704756||Arm 1|Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice in Belgium.
89176621|NCT00806442|Experimental|1: Borage Seed Oil and Echium Seed Oil|Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
89176622|NCT00806442|Placebo Comparator|2: Placebo Comparator|Placebo comparator: 9 g/day corn oil
89176623|NCT02606955|Experimental|BIA REST|BIA DW assessment
89176624|NCT00821678|Experimental|Arm 1 Telemedicine Outreach for PTSD|Telemedicine-Based Collaborative Care
89176625|NCT00821678|No Intervention|Arm 2 Treatment as usual|Usual Care
89176626|NCT04112121|Experimental|Patients Meeting the Chaplain at the Bedside|First meeting with the chaplain, coupled with biblical readings at the bedside.
89176627|NCT04112121|Experimental|Patients Meeting the Chaplain at the Chapel|First meeting with the chaplain, coupled with biblical readings at the hospital's chapel
89176628|NCT04112121|No Intervention|Patients Not Meeting the Chaplain|In the control group we enrolled patients whose diagnoses and number of days in the hospital was similar to the intervention groups (covariate-adaptive, blocked, stratified randomization method).
89176629|NCT02608242|Experimental|YH22189|YH22189 FDC tablet of Yuhan Corporation
89176630|NCT02608242|Active Comparator|Twynsta 80/10mg|Telmisartan/Amlodipine 80/10mg (FDC)
89176631|NCT02608242|Active Comparator|Crestor 20mg|Rosuvastatin 20mg
89176632|NCT04111653|Experimental|Single arm|Healthy volunteers
89176633|NCT02607696|Experimental|Zolpidem 1.75 mg|Zolpidem Hemitartarate 1.75 mg Orodispersible Tablets Once daily
89176634|NCT02607696|Experimental|Zolpidem 3.50 mg|Zolpidem Hemitartarate 3.50 mg Orodispersible Tablets Once daily
89176635|NCT00915057|Experimental|NRL972|Single 2mg intravenous dose of NRL972, administered on up to seven occasions
89176636|NCT03556722|Active Comparator|repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Coil given on left dorsolateral prefrontal cortex for five sessions.
89176637|NCT03556722|Sham Comparator|Sham repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Sham Coil given on left dorsolateral prefrontal cortex for five sessions.
89176638|NCT00839852|Experimental|Cariprazine 1.5mg|Participants received cariprazine 1.5 mg capsule once, twice or three times a day depending on their response and tolerability
89176639|NCT02604849||Received therapy desconolizacion against Klebsiella pneumoniae|
89176640|NCT02604849||Patients who do not receive the therapy|
89176641|NCT00704834||1|Normal Controls
89176642|NCT00704834||2|Patients with a clinically isolated syndrome (CIS)
89176643|NCT00704834||3|Patients with relapsing, remitting Multiple Sclerosis (RRMS) who are not on treatment
89176644|NCT00704834||4|Patients with Chronic Progressive Multiple Sclerosis who are not on treatment
89176645|NCT00709046|Experimental|1|High dose pantoprazole infusion
89176646|NCT00709046|Active Comparator|2|standard dose pantoprazole infusion
89176647|NCT00833690|Placebo Comparator|[A:]|Placebo to produce no urate elevation
89176648|NCT00833690|Experimental|[B:]|"Inosine to produce a mild urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL"
89176649|NCT00833690|Experimental|[C.]|"Inosine to produce a moderate urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL"
89176650|NCT00820898|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89176651|NCT05370092|Active Comparator|Control group|"Patients assigned to this group will receive a session of manual therapy and therapeutic exercise. The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).~The therapeutic exercise session participants will perform 2 exercises for 4 weeks 3 days per week. The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase. Each exercise will be performed in 3 series of 15 repetitions, with 1 minute rest between series, the exercise session will follow the TM and will last approximately 15-20 minutes."
89176652|NCT05370092|Experimental|Intervention group|"Participants in this group will receive 4 sessions (once a week during their respective treatment session) of percutaneous electrolysis guided by MUSCULO-SKELETAL ECOGRAPHY, by a physiotherapist with extensive clinical experience in this therapeutic approach. The technique will be applied using a specifically developed and medically certified device (EPI Advanced Medicine®, Barcelona, Spain. EPI®). The galvanic current will be applied using acupuncture needles. In the present study, a 0.30*25 mm needle (Agupunt, Barcelona, Spain) will be used, with an intensity of 2 mA for a total of 3-5 seconds and 3-5 impacts on the liquid content (TTP tenosynovitis) and 2 mA for a total of 3 seconds and 2-3 impacts if in the tendon (intrasubstance). The technique shall be applied under ultrasound guidance.~The needle shall be introduced at an angle of 80° in a short-axis cross-section to the skin, with the tip of the needle directed towards the posterior tibial tendon."
89176653|NCT00865709|Experimental|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
89176654|NCT00865709|Placebo Comparator|Matching placebo + mFOLFOX6|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
89176655|NCT00839306|Experimental|1|
89176656|NCT00839306|Active Comparator|2|
89176657|NCT02612090|Active Comparator|Active Treatment Beverage|Strawberry
89176658|NCT02612090|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
89176659|NCT00698243|Experimental|Schedule 1|Once daily for 3 days every 7 days
89176660|NCT00698243|Experimental|Schedule 2|Once weekly
89176661|NCT00698243|Experimental|Schedule 3|Once daily
89176662|NCT04131335|Experimental|Experimental Arm|Experimental arm receives lubricant eye-drops (phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vitamins A and E (AEONTM Repair) to be administered four times a day for 6 weeks following cataract surgery (in addition to the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks).
89176663|NCT04131335|Active Comparator|Control Arm|The control arm group receive the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks after cataract surgery.
89176664|NCT04131023|Experimental|Metabolic Tracking|Metabolism (indirect calorimetry) tracking was performed
89176665|NCT04131023|No Intervention|Standard Care|Metabolic (indirect calorimetry tracking was not performed
89176666|NCT00839072|Experimental|Trazodone Contramid OAD|
89176667|NCT00839072|Active Comparator|Desyrel|
89176668|NCT02613845||Cardiac surgery|Study subjects are all patients who underwent cardiac surgery with cardiopulmonary bypass at the University Hospital Basel during the year 2013.
89176669|NCT04118465|Active Comparator|ECV with Full urinary bladder|ECV with Full urinary bladder
89176670|NCT04118465|Active Comparator|ECV with empty urinary bladder|ECV with empty urinary bladder
89176671|NCT00704990|Experimental|A|All study participants take part in the experimental arm
89176672|NCT00855803|Experimental|Radiation followed by Vertebroplasty|"Intervention:~This study is one arm. All patients will undergo radiotherapy followed by vertebroplasty. Patients who had prior radiotherapy will undergo 5 fractions of stereotactic body radiotherapy (SBRT) over 30-90 minutes each. Patients has no prior radiotherapy will undergo 1 fraction of SBRT over 30-90 minutes. The full patient population will then undergo vertebroplasty*.~*Vertebroplasty may not be possible for certain patients due to tumor location or safety. In such cases, patients will omit the vertebroplasty but receive all other protocol care and follow-up."
89176673|NCT02613923|Experimental|GO! To Sleep|Participants in the intervention group will be provided with a code and website address to participate in this program. This program includes reminder emails and is 6 weeks in duration. Participants will be given a blood draw to measure biomarkers.
89176674|NCT02613923|Active Comparator|informational control|Participants in the control group will receive weekly emails with sleep information and the health benefits of sleep for 6 weeks.Participants will be given a blood draw to measure biomarkers.
89176675|NCT02614001|Experimental|inspiratory muscle training, stroke rehabilitation|Inspiratory muscle training with a pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) will be start at a resistance equal to 30% of their MIP or at a load which patient can tolerate, and then the loading will be gradually increased 2cm H2O per week or as symptom tolerated and according to the RPE scale. Each patient will receive regular post-stroke rehabilitation program.
89176676|NCT02614001|Other|control group|stroke rehabilitation.
89176677|NCT02607774|Experimental|Secukinumab|Secukinumab over 24 weeks
89176678|NCT00838916|Experimental|albiglutide weekly injection|albiglutide weekly subcutaneous injection
89176679|NCT00838916|Active Comparator|insulin glargine|insulin glargine daily injection
89176680|NCT00703274|Experimental|Navigation Group|Participants enrolled in this group will receive education concerning primary and secondary PROTECT DC goals. Primary PROTECT DC goals adhere to the following medication directives: 1) Anti-hypertensive, 2) Lipid Lowering, 3) Anti-Coagulant, and 4) Anti-Diabetic. PROTECT DC secondary goals include the following behaviors 1) Smoking Cessation, 2) Consuming an AHA Diet, 3) Regular Exercise, and 4) Knowledge of Stroke Risk and Warning Signs. Participants will also receive assistance with overcoming resource-related barriers to the PROTECT DC goals.
89176681|NCT00703274|No Intervention|Control Group|Participants enrolled in this group will receive periodic follow up through mailings, phone calls etc to ensure availability for 1 year assessment.
89176682|NCT00838682|Experimental|rabeprazole sodium|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
89176683|NCT00838682|Active Comparator|Omeprazole|Intravenous Omeprazole 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
89176684|NCT02612324|Experimental|Pono Choices|Pono Choices: A Culturally Responsive Teen Pregnancy and STI Prevention Program for Middle School Youth in Hawaii. The program includes 9.5 hours of scripted lessons or modules.
89176685|NCT02612324|Active Comparator|Business as Usual|Middle school sexual health content or programs chosen by control group schools.
89176686|NCT00913484|Experimental|Disulfiram|Disulfiram 250 mg per day
89176687|NCT00913484|Placebo Comparator|Placebo|Placebo
89176688|NCT00709280|Experimental|Active treatment group|7% Hypertonic Saline administered via inhalation twice daily for 48 ± 4 weeks
89176689|NCT00709280|Active Comparator|Control group|0.9% Isotonic Saline administered via inhalation twice daily for 48 ± 4 weeks
89176690|NCT00820040|Experimental|Permacol|
89176691|NCT00709358|Active Comparator|2|Detection by blood culture
89176692|NCT00709358|Experimental|1|Test LightCycler SeptiFast® (Roche)
89176693|NCT00705302|Experimental|patient education including self-help|Patients in the arm will participate in a three months patient education and exercise program including a self-help group in 3 months of time.
89176694|NCT00705302|Active Comparator|patient education|Patients in arm 2 will participate in the same patient education and exercise program as arm 1, but without an additional self-help group.
89176695|NCT05320952|Experimental|working sleep apnea patients|50 sleep apnea patients with mild to moderate sleep apnea using WellO2 device for three months
89176696|NCT00803712|Experimental|Cinacalcet Group|Cinacalcet plus low dose active Vitamin D (if prescribed)
89176697|NCT00803712|Active Comparator|Control Group|Flexible active vitamin D dosing
89176698|NCT00591344|Active Comparator|Progressive resistance training|Subjects will perform between 60 and 90 minutes of progressive resistance training two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
89176699|NCT00591344|Active Comparator|Modified Fitness Counts|Subjects will perform between 60 and 90 minutes of modified Fitness Counts two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
89176700|NCT05758610|Experimental|ETH-155008|"Dose level: 20mg/day, 40mg/day, 60mg/day, 80mg/day, 100mg/day. Each dose level will recruit 1-6 subjects, taking ETH-155008 tablets once daily.~Intervention: Drug: ETH-155008"
89176701|NCT05757050|Experimental|"Re-Focus Tablets Verum"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
89176702|NCT05757050|Placebo Comparator|"Re-Focus Tablets Placebo"|The placebo will be a matched control
89176703|NCT00803634|Experimental|Clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was administered intravenously via a single dedicated line to all patients randomized to the clevidipine arm. Clevidipine was infused at an initial rate of 2 mg/h for the first 3 minutes. If blood pressure was not in the target range at 3 minutes, clevidipine was titrated to effect thereafter by doubling the dose every 3 min, per physician discretion and as tolerated by the patient until the desired effect until the SBP target range was attained. Once target range was achieved, the infusion rate could be increased or decreased as needed to maintain blood pressure for minimum of 30 minutes and a maximum duration of 96 hours. The minimum infusion rate was 1 mg/h and maximum infusion rate was 32 mg/h.
89176704|NCT00803634|Active Comparator|Standard of Care IV antihypertensive|For patients randomized to standard of care (SOC) IV antihypertensive treatment, a continuous infusion of an intravenous antihypertensive agent represented standard of care. The selection of treatment was at the discretion of the investigator. The infusion was to be administered according to the institution's treatment practice.
89176705|NCT00838526|Experimental|1|
89176706|NCT00838526|Active Comparator|2|
89176707|NCT02611934|Experimental|Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
89176708|NCT02611934|No Intervention|no-Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
89176709|NCT00914472|Experimental|Test|Heparin - Hipolabor
89176710|NCT00914472|Active Comparator|Ative comparator|Heparin - APP
89176711|NCT02611466|Experimental|ASP7962|Participants receive 100 mg of ASP7962 orally twice daily for 4 weeks.
89176712|NCT02611466|Active Comparator|Naproxen|Participants receive 500 mg of naproxen orally twice daily for 4 weeks.
89176713|NCT02611466|Placebo Comparator|Placebo|Participants receive placebo orally twice daily for a period of 4 weeks.
89176714|NCT02688270|Experimental|Treatment Sequence A|Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream
89176715|NCT02688270|Experimental|Treatment Sequence B|Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vehicle cream, Vascana® (0.9% nitroglycerin cream)
89176716|NCT02688270|Experimental|Treatment Sequence C|Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream)
89176717|NCT02688270|Experimental|Treatment Sequence D|Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vascana® (0.9% nitroglycerin cream), Vehicle cream
89176718|NCT02610920|Experimental|Iron-tracer Injection and Biopsy|Single injection of 30mg of iron sucrose followed by axillary ultrasound-guided biopsy of lymph node within 2 hours.
89176719|NCT00913562|Active Comparator|Patients with diabetes|Rosuvastatin
89176720|NCT00913562|Active Comparator|Patients with glaucoma|Rosuvastatin
89176721|NCT00913562|Placebo Comparator|Control patients with diabetes|Placebo
89176722|NCT00913562|Placebo Comparator|Control patients with glaucoma|Placebo
89176723|NCT02661204||Population A|Consecutive women in the age range 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2, referring to our department for breast evaluation with ultrasound, will be invited to participate to the study. During the interview, before imaging examination, women will be questioned about family history as well as other relevant personal information (e.g. previous surgery or biopsy for benign breast disease).
89176724|NCT02661204||Population B|Consecutive women with a new breast cancer diagnosis and undergoing pre-operative MRI examination for local staging will be invited to participate to the study. ABUS will be performed within two weeks before the scheduled surgery.
89176725|NCT02661204||Population C|Consecutive women with BI-RADS 3 and 4 lesions detected in a routine breast imaging examination will be invited to participate to the study. ABUS will be performed just after the routine HH-US examination.
89176726|NCT02661204||Population D|Consecutive women undergoing breast MRI examination for the evaluation of breast implants integrity will be invited to participate to the study. ABUS will be performed just after the breast MRI.
89176727|NCT04010136|No Intervention|Control group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will be given no intervention
89176728|NCT04010136|Experimental|Identification tool group|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive access to the Identification tool Supportive and Palliative Care Indicators Tool (SPICT-PT) with a brief training on how to use it.
89176729|NCT04010136|Experimental|Standard Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training according to the Center Healthcare Administrative Region standard model of training.
89176730|NCT04010136|Experimental|Clinical cases based Palliative Care Training|GPs (fellows and specialists) from Center Healthcare Administrative Region that will receive palliative care training using a clinical cases based model.
89176731|NCT00818246|Sham Comparator|Sham light|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with a Sham light on the experimental periorbital area
89176732|NCT00818246|Experimental|LED-treated|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with 660 nm Light emitting diode (LED) on the experimental periorbital area
89176733|NCT00705380|Experimental|1|Participants will receive cognitive behavioral therapy with panic control treatment.
89176734|NCT00705380|Active Comparator|2|Participants will receive cognitive behavioral therapy with panic control treatment after a 12-week waitlist period.
89176735|NCT00818168||Infliximab|Subjects with ankylosing spondylitis who were treated with infliximab. The dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)
89176736|NCT02607540|Experimental|Two cycles PF-radiotherapy|"2 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.~radiotherapy： 50Gy，2 Gy/d，5d/w."
89176737|NCT02607540|Active Comparator|Four cycles PF-radiotherapy|"4 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29, 57, 85；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50Gy，2 Gy/d，5d/w."
89176738|NCT02608398||overweight children at weight-loss camp|This is an observational study there is no intervention. The investigators will carry out metabolic profiling on a cohort of overweight or obese children who are attending a commercial weight loss camp for 2-5 weeks.
89176739|NCT00817778|Experimental|AZD1656|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
89176740|NCT00817778|Placebo Comparator|Placebo|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
89176741|NCT05758532|Active Comparator|C.C. : Both MMR doses given on current schedule (9 months and 12 months)|"Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at:~9 months (= current Swiss schedule)~12 months, concomitant with other vaccines (= current Swiss schedule)"
89176742|NCT05758532|Experimental|M.C. : 1st MMR on modified schedule (6 months) and 2nd MMR on current schedule (12 months)|"Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at:~6 months (= modified schedule)~12 months, concomitant with other vaccines (= current Swiss schedule)"
89176743|NCT05758532|Experimental|C. M. : 1st MMR on current schedule (9 months) and 2nd MMR on modified schedule (13 months)|"Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at:~9 months (= current Swiss schedule)~13 months, distant from other vaccines (= modified schedule)"
89176744|NCT05758532|Experimental|M.M. : Both MMR doses given on modified schedule (6 months and 13 months)|"Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at:~6 months (= modified schedule)~13 months, distant from other vaccines (= modified schedule)"
89176745|NCT00705458|Experimental|CTA|Initial EKG-gated computed tomography angiography of the coronary arteries
89176746|NCT00705458|Active Comparator|MPI|Initial nuclear stress myocardial perfusion imaging
89176747|NCT00813098|Experimental|High dose|A high dose of LX1031; daily oral intake for 28 days
89176748|NCT00813098|Experimental|Low Dose|A low dose of LX1031; daily oral intake for 28 days
89176749|NCT00813098|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake
89176750|NCT00705692|Experimental|Levamisole|Two 50 mg levamisole tablets daily, six days before and six days after Td vaccination.
89176751|NCT00705692|Placebo Comparator|Placebo|Two placebo tablets daily, six days before and six days after Td vaccination.
89176752|NCT05758454|Other|Oral health information|Intervention in form of a health/dental health information translated into different native language will be provided for the intervention group
89176753|NCT00705770|Placebo Comparator|1|Placebo treatment with vehicle
89176754|NCT00705770|Experimental|2|Low dose of study medication
89176755|NCT00705770|Experimental|3|Middle dose of study medication
89176756|NCT00705770|Experimental|4|High dose of study medication
89176757|NCT00705848||1|10 patients with tracheobronchomalacia
89176758|NCT00705848||2|10 patients with tracheal stenosis
89176759|NCT00705848||3|10 patients with normal airways (no known airway diseases)
89176760|NCT02609906|Other|PhilosTM with augmentation (Depuy-Synthes)|The intervention group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)
89176761|NCT02609906|Other|MultiLoc®-Nail (Depuy-Synthes)|The comparison group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
89176762|NCT00796653|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
89176763|NCT00796653|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
89176764|NCT00796653|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
89176765|NCT00796653|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
89176766|NCT00806286|Experimental|CS-7017 with Paclitaxel and Carboplatin|
89176767|NCT00806286|Placebo Comparator|Paclitaxel and Carboplatin|
89176768|NCT03537924|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89176769|NCT03537924|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89176770|NCT02607384|Experimental|Vision problems|Children with refractive error will be prescribed eyeglass wearing, and children with convergence insufficiency will be given orthoptic exercises. Children with any other vision problem will be given a specialist referral to a pediatric eye specialist.
89176771|NCT02605980||Male|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
89176772|NCT02605980||Female|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
89176773|NCT00590538|Active Comparator|Phenylbutyrate|"The standard oral adult dose is 20 g/day for 4 days.~Every participant will receive Genistein during the NPD."
89176774|NCT00590538|Placebo Comparator|Placebo|The placebo is given to match the active comparator for 4 days. Every participant will receive Genistein.
89176775|NCT02608320|Experimental|Treatment Sequence (ACB) Position (RLR)|Participants will receive treatment A (Duragesic 12.5 microgram per hour [mcg/h]) applied to right paraspinal side in period 1, then treatment C (aged JNJ- 35685-AAA-G016 12.5 mcg/h) applied to left paraspinal side in period 2 and then treatment B (New JNJ-35685- AAA-G016 12.5 mcg/h) applied to right paraspinal side in period 3.
89176776|NCT02608320|Experimental|Treatment Sequence (BAC) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
89176777|NCT02608320|Experimental|Treatment Sequence (CBA) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
89236934|NCT01000142|Sham Comparator|Light Touch Group|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
89236935|NCT01000142|Experimental|Standard OMT Group|
89236936|NCT01000220|Active Comparator|Omeprazole|
89236937|NCT01000220|Placebo Comparator|placebo|
89236938|NCT01006460|Experimental|Adapt 232|
89176778|NCT02608320|Experimental|Treatment Sequence (BCA) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment C applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
89176779|NCT02608320|Experimental|Treatment Sequence (CAB) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment B applied to right paraspinal side in period 3.
89236939|NCT01006460|Experimental|Arctic root group|
89176780|NCT02608320|Experimental|Treatment Sequence (ABC) Position (RLR)|Participants will receive treatment A applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
89176781|NCT02608320|Experimental|Treatment Sequence (ACB) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
89176782|NCT02608320|Experimental|Treatment Sequence (BAC) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
89236940|NCT01006460|Active Comparator|Ginseng group|
89236941|NCT01006460|Placebo Comparator|Placebo group|
89236942|NCT01006694|Active Comparator|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
89236943|NCT01006694|Experimental|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
89236944|NCT01006772|No Intervention|Control Group|Control group patients receive usual clinical practice provided by Stroke Unit at Stobhill Hospital in Glasgow. They receive physiotherapy and early mobilisation as deemed appropriate to treat their oown impairments.
89236945|NCT01006772|Experimental|Experimental group|Intervention Group patients receive custom made solid ankle foot orthosis (AFO)treatment.
89236946|NCT04000100|Placebo Comparator|Control group|This group received supraclavicular block using 25mL of 0. 5% bupivacaine and 1 mL normal saline
89236947|NCT04000100|Active Comparator|Neostigmine group|This group received 25 mL 0. 5% bupivacaine and 1 mL neostigmine (0.5 mg)
89236948|NCT01000298|Placebo Comparator|Placebo|
89236949|NCT01000298|Experimental|Amoxicillin|
89236950|NCT01000298|Experimental|cefdinir|cefdinir
89236951|NCT00614939|Experimental|Saxa|Saxagliptin
89236952|NCT00614939|No Intervention|Placebo|Placebo to match
89176783|NCT02608320|Experimental|Treatment Sequence (CBA) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
89176784|NCT02608320|Experimental|Treatment Sequence (BCA) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
89236953|NCT01006928||Mothers|Mother of infants in NICU
89236954|NCT00869453||1|Healthy volunteers
89236955|NCT01007006|Experimental|TMRDU|Telepharmacy Robotic Medicine Delivery Unit (TMRDU) group will receive TMRDU plus medication management
89236956|NCT01007006|No Intervention|Control|Control arm will receive only medication management, no TMRDU.
89236957|NCT00879827|Experimental|Single Group|
89236958|NCT03842111||Region XI Head Start children and families|children (1049) parents (1049) classrooms/teachers (73) program directors (21) center directors (36)
89236959|NCT01007084|Experimental|Propranolol|
89236960|NCT01007084|Placebo Comparator|Sugar pill|
89236961|NCT01000532||Pacemaker therapy|
89236962|NCT00879203||Type 1 Diabetes (T1DM)|Youth and young adults with T1DM
89236963|NCT00879203||Non diabetic siblings|Non diabetic, young siblings of T1DM participants
89236964|NCT00879281|No Intervention|1 Care as usual|Regular care
89236965|NCT00879281|Experimental|2 Intervention|"Regular Care + individualized written action plan to enhance self-mananagement and early detection/treatment of an exacerbation."
89236966|NCT04040309|Experimental|Plasma rich in growth factors group|Group of patients who will receive 1 ml of PRGF 2nd fractions injections into their trigger points in the masseter muscle.
89236967|NCT04040309|Active Comparator|Lidocaine group|Group of patients who will receive 1 ml 2% Lidocaine injections into the myofascial trigger point in the masseter muscle.
89236968|NCT00869531|Experimental|WW|wholegrain wheat
89236969|NCT00869531|Active Comparator|RW|refined wheat
89236970|NCT01000688|Experimental|vildagliptin treatment first, acarbose treatment second|
89236971|NCT01000688|Experimental|acarbose treatment first, vildagliptin treatment second|
89236972|NCT00879905|Experimental|once weekly dosing schedule|
89236973|NCT00879905|Experimental|twice weekly dosing schedule|
89236974|NCT01007240|Experimental|soft liner with nano particles|the obturators of this patients will be relined with soft liner, with incorporated nano particles. after a week, the soft liner will be taken off, and will be checked for bacterial adhesion.
89236975|NCT00879983|Other|Group 1|Will accept azithromycin ER first, after at least 14 days washout, then accept azithromycin tablet.
89236976|NCT00879983|Other|Group 2|Will accept azithromycin tablet first, after at least 14 days washout, then accept azithromycin ER .
89176785|NCT02608320|Experimental|Treatment Sequence (CAB) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
89176786|NCT02608320|Experimental|Treatment Sequence (ABC) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
89176787|NCT02608320|Experimental|Treatment Sequence (DFE) Position (RLR)|Participants will receive treatment D (Duragesic 100 mcg/h) applied to right paraspinal side in period 1, then treatment F (aged JNJ-35685-AAA-G021 100 mcg/h) applied to left paraspinal side in period 2 and then treatment E (new JNJ-35685-AAA-G021 100 mcg/h) applied to right paraspinal side in period 3.
88804659|NCT02291055|Experimental|Part B Expansion (Cervical): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736|Participants with cervical cancer received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
88804660|NCT02277080||Opioid group|These patients should have been treated only with one opioid (morphine, oxycodone, fentanyl, methadone, hydromorphone, tapentadol or tramadol) for more than one month
89176788|NCT02608320|Experimental|Treatment Sequence (EDF) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
89176789|NCT02608320|Experimental|Treatment Sequence (FED) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
89176790|NCT02608320|Experimental|Treatment Sequence (EFD) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment F applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
89176791|NCT02608320|Experimental|Treatment Sequence (FDE) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment E applied to right paraspinal side in period 3.
89176792|NCT02608320|Experimental|Treatment Sequence (DEF) Position (RLR)|Participants will receive treatment D applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
89176793|NCT02608320|Experimental|Treatment Sequence (DFE) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
89176794|NCT02608320|Experimental|Treatment Sequence (EDF) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
89176795|NCT02608320|Experimental|Treatment Sequence (FED) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
89176796|NCT02608320|Experimental|Treatment Sequence (EFD) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
89176797|NCT02608320|Experimental|Treatment Sequence (FDE) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
89176798|NCT02608320|Experimental|Treatment Sequence (DEF) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
89176799|NCT04111887|Experimental|Change Ahead|Each of the 6 weekly 1-hour sessions begins with a voluntary commitment to actively participate and to try something new in the upcoming week; includes a section devoted to selecting and publicly committing to one change focused on reducing negative/increasing positive cognitions and one change focused on increasing pleasant activities; and ends with home practice assignments. Additional exercises designed to increase dissonance induction include (a) group discussions for changing conditions, (b) roleplays to generate quick comebacks to written negative thoughts provided by other group members, (c) in-session writing exercises on the benefits of doing fun activities, (d) discussion of methods for creating internal and external accountability for positive change, (e) home practice assignment of engaging in actions to help someone else' mood, (f) writing a letter to my future self about positive intentions, and (g) providing positive feedback to other group members at the last session.
89176800|NCT04111887|Active Comparator|Blues Program|The 6 weekly 1-hour sessions begin with a review of concepts and (after Session 1) review of past home practice assignments; all sessions conclude with home practice assignments. Each session has a portion devoted to thought identification/recording and cognitive restructuring and a portion devoted to increased involvement in pleasant activities. We use motivational enhancement exercises to maximize willingness to use the new skills, behavioral techniques to reinforce use of the new skills, and group activities to foster feelings of group cohesion.
89176801|NCT04111887|Placebo Comparator|Brochure control|"NIMH brochure that describes major depression and recommends treatment for depressed youth (Let's Talk About Depression NIH Pub. 01-4162), as well as information about local treatment options."
89176802|NCT04111575|Experimental|music therapy group 1|The mothers in the experimental group 1 received music therapy for 30 minutes a day.They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
89176803|NCT04111575|Experimental|music therapy group 2|The mothers in the experimental group 1 received music therapy for 30 minutes twice a day. They listened music for two consecutive days, considering the first day after the C-section as the beginning day.
88804661|NCT02277080||Control group|Chronic non-cancer pain patients not treated with analgesics
89176804|NCT04111575|No Intervention|control group|the control group were made to rest in bed for 30 minutes a day for two consecutive days, considering the first day after the C-section as the beginning day.
89176805|NCT05728788||Patients treated with antineoplastic agents|50 patients treated with antineoplastic agents will be enrolled.
88804662|NCT02112864|Experimental|dexamethasone 10 mg|Dexamethasone 10 mg will be given as a single-dose, pre incision, intravenously
89176806|NCT02604927|Placebo Comparator|Placebo|800 mg of dextrose, four times per day, during 28 days.
89176807|NCT02604927|Experimental|Beta-alanine|800 mg of beta-alanine, four times per day, during 28 days.
89176808|NCT00914082|Experimental|antenatal classes in self hypnosis|3 antenatal classes in self hypnosis. 3 audio compact discs for homework in self hypnosis and 1 audio compact disc for birth
89176809|NCT00914082|Active Comparator|relaxation and awareness|3 antenatal classes including training in relaxation methods and mindfulness.3 audio compact discs for homework and 1 for birth.
89176810|NCT00914082|Other|Control|Only receive ordinary antenatal care and no additional interventions
89176811|NCT04111341|Experimental|TCM Gan-Lu-Yin (GLY)|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
89176812|NCT04111341|Placebo Comparator|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
89176813|NCT00914238|Experimental|5 year|5 years OPUS treatment
89176814|NCT00914238|Active Comparator|2 years of OPUS treatment|2 years OPUS treatment and 3 years of treatment as usual
89176815|NCT05681832|Experimental|Intervention group|
89176816|NCT05681832|No Intervention|Control group|
89176817|NCT04110951|Experimental|Pranayama group|Kapalbhati, Ujjayi and Anuloma-Viloma pranayama techniques were applied to the experimental group. Within this scope, a three days of applied training program was prepared and a guide involving the steps of Pranayama breathing technique was formed. The patients in of pranayama group were trained by the researcher who had yoga trainer certificate. After completing three days of training and observations regarding their accomplishment of applications properly, a pranayama breathing technique video showing how the pranayama breathing technique is done with its details was downloaded to their smartphones and a guide including the application steps was distributed to the patients. The patients were required to apply pranayama technique, in company with the video, 20 min every day and a month in total.
89176818|NCT04110951|Active Comparator|Relaxation group|As there was not placebo breathing control treatment appropriate to yoga breathing technique, relaxation technique was decided to apply in the second group to equalize psychological effects of the treatment. Progressive relaxation technique was taught to the relaxation group during the same training span.A three days of applied training program and Relaxation Technique Application Guide, including steps of progressive relaxation technique, were prepared within this scope. After completing three days of training and observations regarding their accomplishment of applications properly, a relaxing music to listen during applications and a training video involving progressive relaxation directives were downloaded to smartphones of the patients. Also, Relaxation Technique Application Guide involving application steps were distributed to the patients. The patients were required to apply relaxation technique, in company with the video, 20 min every day and a month in total.
89176819|NCT00914550||Procalcitonin level, caregiver informed|Procalcitonin level for patients with lung infiltrates:caregivers know/ do not know results
89176820|NCT02608164|Active Comparator|Vitamin D oral spray solution|An oral spray solution containing 3000IU (75micrograms) vitamin D3 per spray
89176821|NCT02608164|Active Comparator|Vitamin D capsules|A capsule containing 3000IU (75micrograms) vitamin D3 per capsule
89176822|NCT02606058|No Intervention|Early cord clamping (Control Arm)|Immediate cord clamping (< 10 seconds after birth). The cord is clamped 6 cm from the umbilicus within ten seconds of delivery of the baby.
89176823|NCT02606058|Experimental|Deferred cord clamping|Deferred cord clamping. Investigator/Research personnel holds the baby as low as possible below the level of the introitus or placenta for 60 seconds and not to exceed 80 seconds, then clamps the cord about 6 cm from the umbilicus.
89176824|NCT02604693||Chronic Beryllium Disease|Those that have been diagnosed with the disease. No interventions will be administered.
89176825|NCT02604693||Beryllium Sensitization|Those that have been diagnosed with beryllium sensitization and do not have chronic beryllium disease. No interventions will be administered.
89176826|NCT02604693||normal controls|Those that do not have chronic beryllium disease or beryllium sensitization. No interventions will be administered
89176827|NCT00915135|Experimental|Ramelteon QD and Placebo QD (25 possible combinations total)|
89176828|NCT02607462|Experimental|PRP|Platelet-rich plasma taken made from centrifuged venous blood.
89176829|NCT02607462|Placebo Comparator|Saline|Sodium chloride 0.9% used as placebo.
89176830|NCT00796419|Experimental|1|Intravenous 5% human albumin
89176831|NCT00796419|Experimental|2|Intravenous 6% hetastarch
89176832|NCT04110873|Experimental|Antroquinonol capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
89176833|NCT04110873|Experimental|Antroquinonol capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
89176834|NCT04110873|Placebo Comparator|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
89176835|NCT04110717|Experimental|Active Device Group|25 subjects randomised to receive active device use plus lifestyle intervention for 3 months.
89176836|NCT04110717|Placebo Comparator|Control Device Group|25 subjects randomised to receive control device use plus lifestyle intervention for 3 months.
89176837|NCT02604615|Experimental|Capecitabine-oxaliplatin 2 cycles|oxaliplatin：65mg/m2,d1,8,22,29,I.V; capecitabine: 625mg/m2, bid d1-5; q1w, po,5 weeks in total; radiotherapy:50Gy,2 Gy/d,5d/w.
89176838|NCT02604615|Active Comparator|Capecitabine-oxaliplatin 4 cycles|oxaliplatin:65mg/m2,d1,8,22, 29,43,50,64,71,I.V; capecitabine:625mg/m2,bid d1-5; q1w, po,10 weeks in total; radiotherapy:50Gy ,2 Gy/d,5d/w.
89176839|NCT04110639|Active Comparator|Validation Group|A validation group of 10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
89176840|NCT04110639|Experimental|Study Group|A study group of 20 patients with displaced femoral neck fracture patients (Garden 2-4) treated with open or closed reduction and internal fixation
89176871|NCT02604225|Experimental|Penthrox|Methoxyflurane
89176872|NCT02604225|Placebo Comparator|Placebo|Saline 0.9%
89176841|NCT00796107|Experimental|R1507 in Combination With Letrozole|Participants received a full daily dose of 2.5 mg of orally administered Letrozole along with 16 mg/kg of intravenous R1507 administered q3w, and observed for dose limiting toxicity for the first 2 cycles of treatment.
89176842|NCT00795951|Experimental|TRUE Test panels 1.1, 2.1, 3.1|All subjects were patched with 3 T.R.U.E. Test panels containing 28 allergens and 1 negative control.
89176843|NCT04110483|Active Comparator|TURBT|A step-by-step resection of a tumor. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
89236977|NCT01007318|Active Comparator|Single port|Single port through the transumbilical incision was made by wound retractor combined with surgical glove and then 3 trocal was inserted to the finger part of the surgical glove. Laparoscopic instrument was working through the single port and resected appendix removed through it.
89236978|NCT01007318|Active Comparator|3 port|3 port laparoscopic appendectomy was done by conventional method
89236979|NCT00869687|Other|Poly-L-Lactic Acid Injection|
89236980|NCT00869765|Experimental|tDCS and D-CYC|Major Depression tDCS and D-cyc
89236981|NCT00530504|Experimental|Device|Device
89236982|NCT00869843|Other|Single group|
89236983|NCT03999632|Experimental|Mankai Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group A (Wolffia Globosa) will be allowed to have two meals a day and one protein shake (Wolffia Globosa) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Wolffia Globosa) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
89236984|NCT03999632|No Intervention|Control Group|The pre-operative liquid diet will be started two weeks before surgery date for both groups. During the first week patients in group B (Control) will be allowed to have two meals a day and one protein shake (Control) of 16 oz. Each meal will consist of 3-5 oz of lean protein (Chicken, turkey or fish) and one cup of vegetables or salad. During the second week, patients will drink one protein shake of 16 oz (Control) as a meal replacement, three times per day and will not be allowed to eat solid food. Patients will also be allowed to Drink clear liquids in between protein shakes.
89176844|NCT04110483|Experimental|Tm-fiber ERBT|A circumferential incision around the tumor is made in the visually intact bladder mucosa. After that, the incision is continued deeper into the muscular layer. Than the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers.
89176845|NCT04110561|Other|Spinal Cord Injury patients with motor complete paralysis|
89176846|NCT00795717|Active Comparator|Lovaza|Lovaza, dietary counseling
89176847|NCT00795717|Placebo Comparator|Placebo|Placebo, dietary counseling
89176848|NCT00805740|Experimental|Anidulafungin arm|
89176849|NCT00805740|Experimental|Caspofungin arm|
89176850|NCT05613075|Active Comparator|tooth extraction and socket preservation with demineralized tooth graft|
89236985|NCT01000766||Acute drug-induced liver injury|
89236986|NCT00879515||1|Males and females with fragile X syndrome, ages 5 to 25 years old
89176851|NCT05613075|Experimental|tooth extraction and socket preservation with demineralized tooth graft and hyaluronic acid|
89176852|NCT00915213||Repeat Prostate Biopsy|Men who undergo repeat prostate biopsy
89176853|NCT04110015||Neurology patients|Any patients with neurological disorders
89176854|NCT04110015||Glaucoma patients|Any patients with chronic open angle and chronic angle closure glaucoma of all stages
89176855|NCT04110015||Retina patients|Any patients with known retinal conditions
89176856|NCT02605902|Active Comparator|iCBIT|internet-delivered Comprehensive Behavioral Intervention for Tics (iCBIT) consisting of psychoeducation, habit reversal training (HRT), function-based assessment and intervention, and relaxation training
89176857|NCT02605902|Placebo Comparator|Control intervention/reference test|internet-delivered psychoeducation and relaxation training.
89176858|NCT02605902|Active Comparator|face-to-face CBIT-treatment|face-to-face CBIT-treatment
89176859|NCT01227876|Experimental|Test|Ster ® (prednisolone 1% ophthalmic suspension - União Química)
89176860|NCT01227876|Active Comparator|Comparator|Pred Fort ® (prednisolone 1% ophthalmic suspension - Allergan)
89176861|NCT00795639|Experimental|Sitaxsentan|Monotherapy
89176862|NCT00795639|Placebo Comparator|Sitaxsentan Placebo|Monotherapy
89176863|NCT05297292|Active Comparator|Lucentis-0.5mg（Q4w）|It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 0.5mg.
89176864|NCT05297292|Experimental|MW02-1.0mg（Q4w）|It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 1.0mg.
89176865|NCT05297292|Experimental|MW02-1.5mg（Q4w）|It is administered once every 4 weeks for 48 weeks. Intravitreal injection was used, and the dose was 1.5mg.
89176866|NCT05297292|Experimental|MW02（Q8w）|It is administered once every 4 weeks for 3 consecutive times, and then once every 8 weeks for 48 weeks.
89176867|NCT05674734|Experimental|4FM/AT|4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU (Treatment-As-Usual) module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at Institute of Psychiatry and Neurology (IPiN) Mental Health Centre for Mokotów and IPiN.
89176868|NCT05674734|No Intervention|4FM/TAU|Treatment As Usual - 12 group therapy meetings at Day Care Units at IPIN and IPIN Mental Health Centre for Mokotów.
89176869|NCT05612373|Experimental|"Control condition with waiting for you message"|This control condition will use the text message that the investigators found to be the best performing in their last mega-study of vaccine text messages to recommend a COVID vaccination.
89176870|NCT05612373|Experimental|Message offering free round trip ride to the pharmacy|This condition will use a text message offering a free round trip ride to the pharmacy to get a COVID vaccination.
89236987|NCT00879515||2|Males and females with the FMR1 premutation, ages 5 to 25 year old
89236988|NCT00879515||3|Males and females with Down syndrome, ages 5 to 25 years old
89236989|NCT00879515||4|Males and females with normal development, ages 5 to 25 years old
89236990|NCT00880295|Active Comparator|endoscopic surgery|
89236991|NCT00880295|Active Comparator|open surgery|
89236992|NCT00880373|Active Comparator|1|Diamorphine or Morphine by PCA and oral ibuprofen
89236993|NCT00880373|Placebo Comparator|2|Diamorphine or Morphine by PCA and oral placebo
89236994|NCT01007630|Active Comparator|Rasagiline|0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
89236995|NCT01007630|Placebo Comparator|Placebo|0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)
89236996|NCT05883384||patient with cow milk protein allergy|apply CoMiSS on patient suspected to have cow milk protein allergy.
89236997|NCT05883332|Experimental|SANO (1), Oxygen (2)|"All participants will receive self-administered nitrous oxide (SANO) at a range of 25-50% immediately before and during catheter placements. At this time, a participant-preferred level of SANO will be determined.~At the start of the first UDS run, SANO will continue at the participant-preferred level that was determined during catheter placement, ensuring that the patient is relaxed but still conversant through the procedure.~At the end of the first UDS run, SANO will be turned down to 0%. Participants will then receive 100% oxygen at 10 liters/minute for the duration of their second UDS run."
89236998|NCT05883332|Experimental|Oxygen (1), SANO (2)|"All participants will receive self-administered nitrous oxide (SANO) at a range of 25-50% immediately before and during catheter placements. At this time, a participant-preferred level of SANO will be determined.~After catheter placement, SANO will be turned down to 0%. Participants will receive 100% oxygen at 10 liters/minute for the duration of their first UDS run.~At the end of the first UDS run, SANO will start at the participant-preferred level that was determined during catheter placement, ensuring that the patient is relaxed but still conversant through the procedure. SANO will be given for the duration of their second UDS run."
89236999|NCT05883306|Experimental|[14C]LXI-15028(n=6-8)|Subjects will receive a single oral dose of [14C]LXI-15028 suspension under the fasted state .
89237000|NCT05883293|Experimental|Experimental group|"Case Inclusion Criteria:~Patients who sign the informed consent form.~Age 30~80 years old, gender is not limited.~Clinical diagnosis basis for idiopathic pulmonary fibrosis (IPF) in patients with IPF with obvious IPF symptoms, signs, HRCT abnormalities, diagnosed as IPF as prescribed by this protocol, DLCO < 40% of the predictive value, and the existing treatment regimen is ineffective or does not accept the existing treatment regimen:"
89237001|NCT05883280|Experimental|Binaural beats group|Starting 30 minutes before the end of the surgery, a continuous pure tone binaural beat is delivered through headphones to the pediatric patient, with a frequency of 432 Hz in the left ear and 420 Hz in the right ear.
89237002|NCT05883280|No Intervention|Silence group|The headphones are placed on the pediatric patient, but there is no sound in the audio file being played.
89237003|NCT05883254||Control group|Normal individuals
89237004|NCT05883254||thalassemia intermedia patients and sickle cell disease patients|"Inclusion criteria~Patients with sickle cell anemia and β-thalassemia intermedia.~Patients are of both sexes (males and females) at any age.~Exclusion criteria:~Patients with any other type of haemolytic anaemias.~Patients on Hydroxyurea therapy."
89237005|NCT05883215||Female Patients Diagnosed with Fibromyalgia Syndrome|Female patients who give consent to participate and are diagnosed with fibromyalgia syndrome.
89237006|NCT05883189||Group1: non-pregancy health women.|
89237007|NCT05883189||Group 2:Pregancy health women.|
89237008|NCT05883189||Group 3: Diagnosed Antiphospholipid syndrome patients|
89237009|NCT05883176|Experimental|B-TACE|TACE Combined With Bevacizumab Biosimilar
89237010|NCT05883098|Experimental|SUPRA SDRM|"The subject will receive wound standard of care that will include Supra SDRM as an active synthetic wound closure matrix, covered with a non-adherent dressing plus an appropriate outer dressing to maintain moisture balance, then wrapped with stretch gauze and self-adherent wrap. Supra SDRM will be applied weekly, and the exterior dressings will be redressed as necessary.~Supra SDRM is FDA-cleared (K090160, K170213) for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. It is commercialized as a single dermal substitute matrix for wound management. No preparation of SUPRA SDRM matrix is necessary. When applied to the wound SUPRA SDRM adheres well to the wound bed without the need for direct fixation. SUPRA SDRM becomes translucent after the application allowing healthcare professionals to easily assess the wound healing. SUPRA SDRM® is available in multiple sizes and can be trimmed to meet the patient's needs."
89237011|NCT05883098|Active Comparator|Fibracol Plus|"The subject will receive wound standard of care that will include Fibracol Plus collagen dressing as an active synthetic wound closure matrix, covered with a non-adherent dressing plus an appropriate outer dressing to maintain moisture balance, then wrapped with stretch gauze and self-adherent wrap. Fibracol Plus collagen dressing will be applied weekly, and the exterior dressings will be redressed as necessary.~FIBRACOL™ Plus Collagen Wound Dressing with Alginate dressing contains more than just pure collagen. It's a soft, absorbent, and conformable wound dressing, composed of 90% collagen and 10% calcium alginate. In the presence of wound fluid, FIBRACOL™ Plus Dressing helps maintain a physiologically moist microenvironment at the wound surface. This environment supports granulation tissue formation, epithelialization and rapid wound healing."
89237012|NCT05883085|Other|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
89237013|NCT05883059|Experimental|robot group|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Routine rehabilitation therapy includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, and functional electrical stimulation.
89237014|NCT05883059|Active Comparator|control group|Routine rehabilitation therapy includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, and functional electrical stimulation.
89237015|NCT05883046|Other|Baseline|The control measurement was made as a baseline measurement without supplementation
89237016|NCT05883046|Placebo Comparator|Placebo|During Placebo conditions, participants consumed 20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey).
89237017|NCT05883046|Experimental|Caffeine|For Caffeine conditions, participants consumed 6 mg/kg of caffeine, obtained from dosing the content of 200 mg capsules (Nature's Supreme® Caffeine)
89237018|NCT05883046|Experimental|NaHCO3|As for NaHCO3 conditions, participants consumed 0.3 g/kg of sodium bicarbonate (Alfasol®, Kimbiotek, Turkey) dissolved in water
89237019|NCT05883046|Experimental|Combined|For the combined condition, (Caf+NaHCO3), 6 mg/kg of caffeine and 0.3 g/kg of sodium bicarbonate per kilogram of body weight of participants were consumed, after being dissolved together in water
89237020|NCT05883033|Experimental|Vacuum Assisted Closure device|Vacuum Assisted Closure device for healing enhancement
89237021|NCT05883033|Experimental|Conventional dressing|Unprocessed Honey, malysia glycerine and betadine ointment
89237022|NCT05883020|Sham Comparator|Standard physical therapy program|all participants will receive strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait, and balance training. The duration of each session will be 1 hour, 3 times per week for 4 weeks.
89237023|NCT05883020|Active Comparator|Radial shockwave therapy (rSWT)|One session per week of rSWT will be applied using shockwave device. The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
89237024|NCT05882994|Experimental|rom exercise|In this study, ROM exercises will be applied by the researcher 2 days a week for 12 weeks to the intervention group separated by simple randomization method.In this study, considering the existing literature, it was planned to apply the exercise to the patients twice a week, for 12 weeks, with 5 minutes of warm-up, 15 minutes of rom exercises , and 5 minutes of cooling down . Range of motion exercises include wrist rotation (clockwise and counterclockwise), wrist flexion and extension. elbow joint full flexion and extension; rotating ankles (clockwise and counterclockwise); and full flexion and extension of the ankles will be performed. Each movement will be made 20 rounds per minute. The researcher will have the patients perform rom exercises and supervise them during the exercise .
89237025|NCT05882994|No Intervention|control group|Patients in the control group will receive routine care during hemodialysis.At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks.
89237026|NCT05882968||H. Pylori in CKD patients|100 0f patients with H.pylori with ckd according to GFR more than 60 according to kdigo guide lines
89237027|NCT05882968||H.pylori in normal renal function|100 of patients with H.pylori with normal renal function according to GFR less than 60 according to kdigo guide lines
89237028|NCT05882955|Experimental|Dietary app 1|Dietary app recommends high iron or iron focused recipes
89237029|NCT05882955|Sham Comparator|Dietary app 2|Dietary app recommends standard iron recipes
89237030|NCT05882955|Experimental|Hydroponic unit 1|Growing vitamin B12 biofortified plants in a hydroponic unit
89237031|NCT05882955|No Intervention|Hydroponic unit 2|No hydroponic unit given to participants
89237032|NCT05882942|Experimental|Placebo|Participants will be supplemented with a placebo.
89237033|NCT05882942|Experimental|Matcha green tea|Participants will be supplemented with Matcha green tea.
89237034|NCT05882890|Experimental|cranoisacraltherapy receivers|"The participants will receive 5 x one hour treatment of craniosacral therapy. One treatment per week in five weeks. The treatment will follow the protocol avenue of expression end step 2c and 2c in Ten step protocol . They will, if possible be instructed in fascial self treatment for maximum 5 minutes a day. Before treatment the participants fulfill the questionnaire  Xerostomia questionnaire after 3 months - a danish standardized questionnaire of xerostomia used of hospitals. They will fulfill this questionnaire again after ending their 5 treatment sessions, and again 6 months later as a follow up. They will also fulfill a diary with any side effects experienced during the treatment period. I will take their full history the first time we meet I journal my treatment after every treatment session, and journal which effects (positive and negative) the participant has noticed."
89237035|NCT05882864|Active Comparator|Topical 6-Gingerol Group|Group I Will include 14 patients receiving topical ginger extract 1% four times per day (after every meal and before going to bed) for eight weeks (Zakaria et al., 2020).
89237036|NCT05882864|Active Comparator|Topical Steroid Group|"Group II Will include 14 patients receiving topical steroid (triamcinolone acetonide 0.1%) four times per day for eight weeks (Laeijendecker et al., 2006)~In the fourth and eighth weeks, topical anti-fungal will be applied by a third-party medical personnel to avoid 2ry candidiasis for this group."
89237037|NCT05882851||grup 1|Those who recover after vaginitis treatment
89237038|NCT05882851||grup 2|those who were resistant to treatment
89237039|NCT05882838||Patients admitted to the physical medicine and rehabilitation outpatient clinic.|Patients admitted to the physical medicine and rehabilitation outpatient clinic and gave consent to participate.
89237040|NCT05882825||Patients admitted to the physical medicine and rehabilitation outpatient clinic.|Patients admitted to the physical medicine and rehabilitation outpatient clinic and gave consent to participate.
89237041|NCT05882799|Active Comparator|Ultrasound-guided dry needling group|Patients in this group will receive dry needling for piriformis syndrome under real-time ultrasound guidance.
89237042|NCT05882799|Active Comparator|Blinded dry needling group|Patients in this group will receive dry needling for piriformis syndrome without ultrasound guidance.
89237043|NCT05882786|Active Comparator|The corticosteroid (Triamcinolone Acetonide) injection group|Participants in this group will receive a single subacromial injection of 40mg triamcinolone acetonide.
89237044|NCT05882786|Active Comparator|Tendon dry needling group|Participants in this group will receive a total of 3 sessions of dry needling treatment to the supraspinatus, infraspinatus, and subscapularis muscle tendons.
89237045|NCT05882682||Consumers of cereal products|Caregivers with children under 5 years of age who are consumer of cereal products in the Eldoret area.
89237046|NCT05882630|Experimental|Surufatinib Combined With Serplulimab and EC Chemotherapy|
89237047|NCT05882591|Experimental|Main arm of the study|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
89237048|NCT05882578|Experimental|Intervention Group|Patients will be assessed and screened prior the intervention. After the physical assestment they will attend 2 days a week for the supervised, and controlled sessions of physical exercise, performed in the nature (Retiro park in Madrid). To meassure the intensity of the program, they will use the 1-10 Borg ratio of perceived exertion (RPE).
89237049|NCT05882578|Active Comparator|Control Group|Patients will be asked to mantain an active lifestyle, performing physical activity regularly.
89237050|NCT05882539||endotracheal tube material|One group of patients used a spring-loaded endotracheal tube and the other group used a PVC tube.
89237051|NCT05882539||Bite block Material|One group of patients used hard bite block and the other group used soft bite block
89237052|NCT05882539||Moisture of oral mucosa|One group of patients had moist oral mucosa after entering the ward and the other group had dry oral mucosa.
89237053|NCT05882539||serum albumin level|One group of patients had normal serum albumin level at the first blood sample analysis after tracheal intubation and the other group was abnormal.
89237054|NCT05882539||mean arterial pressure level|One group of patients had normal mean arterial pressure leve after entering the ward and the other group was abnormal.
89237055|NCT05882539||blood lactate level|One group of patients had normal blood lactate levels at the first blood sample analysis after tracheal intubation and the other group was abnormal.
89237056|NCT05882539||constraint|One group of patients was constrained during follow-up and the other group was not constrained.
89237057|NCT05882539||sedation|One group of patients was sedated during follow-up and the other group was not sedated.
89237058|NCT05882539||prone position|One group of patients had a prone position performed during follow-up and the other group did not.
89237059|NCT05882539||Duration of tracheal intubation|Dichotomous grouping of the duration of tracheal intubation according to the results of the study.
89237060|NCT05882526|Active Comparator|Evaluation of elastomeric power chain for orthodontic maxillary canine retraction|20 Orthodontic patient treated by for elastomeric power chain canine retraction split mouth.
89237061|NCT05882526|Active Comparator|Evaluation of T loop for orthodontic maxillary canine retraction|20 Orthodontic patient treated by T loop for canine retraction split mouth
89237062|NCT05882513|Experimental|Lung cancer group|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1.~Preoperative neoadjuvant therapy for 2-4 cycles, one cycle every 21 days. Surgical resection of lung cancer will be arranged about 4-8 weeks after the last cycle of neoadjuvant therapy."
89237063|NCT05882500||Pancreatits|Patients with pancreatitis based ont the Atlanta criteria
89237064|NCT05882487|Experimental|KL002 injection solution|single dose, neurosurgically infused, bilaterally into the striatum
89237065|NCT05882474||baseline group|PaCO2 35~40mmHg
89237066|NCT05882474||High-CO2 group|PACO2 increases by 5-10mmHg compared to baseline value and >40mmHg
89237067|NCT05882461|Experimental|Those receiving the 90Second Caregiver health letter|The 90Second Caregiver health letter is a weekly online publication that addresses topics relevant for caregivers. It combines scientifically-valid, evidence-based information with actionable tips to improve caregiver self efficacy and well-being. Participant in this group will receive a 90Second Caregiver health letter every week, via email.
89237068|NCT05882461|No Intervention|The usual care control group|Participants that are randomized to be in the usual care control group will continue on as participants in the Caring Forward Trials within Cohort Study (i.e. filling out questionnaires every 6-months). Participants will continue to participate in the Caring Forward Study until completion in March 2022.
89237069|NCT05882435|No Intervention|Usual Organization|X-rays are done in the radiology department and the images are made available to emergency physicians without waiting for the radiologist's report, which is usually done on a delayed basis.
89237070|NCT05882435|Other|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
89237071|NCT05882409|Experimental|Education group|In the experimental groups the education whose content (definition and importance of violence and conflict, violence against women, the cycle of violence, who is at risk for violence, characteristics of perpetrators and the victims of violence, types of violence against women, consequences of violence and conflict on individuals, legal aspects of violence, positive coping with violence and conflict, empowering women against violence, conflict resolution) was prepared by the researcher in line with the adult education principles and pertinent literature was given in the school prepared for education beforehand. In accordance with the adult education principles, the students were educated in groups of 12-15 people. During the education, methods such as narration, discussion, question-answer, brainstorming, problem solving and summarizing, data shows, brochures, posters and visual materials were used. The duration of the education lasted 30-40 minutes.
89237072|NCT05882409|No Intervention|Standard of care Group|The control group did not receive any treatment.
89237073|NCT05882396|Active Comparator|Rood's approach group|Thirty colorectal cancer patients have oxaliplatin-induced peripheral neuropathy.
89237074|NCT05882396|Active Comparator|Traditional physical therapy program group|Thirty colorectal cancer patients have oxaliplatin-induced peripheral neuropathy.
89237075|NCT05882383||Control Group|unifected with SARS-CoV-2 during follow-up
89237076|NCT05882383||Group A|uninfected at the first visit, have been infected at the second visit
89237077|NCT05882383||group B|have been infected at twice visit
89237078|NCT05882331|Experimental|Extracorporeal photopheresis arm|Patients will receive extracorporeal photopheresis on this arm, in conjucntion to standard COVID-19 treatments (remdesivir, dexamethasone, IL-6- and/or JAK-inhibition).
89237079|NCT05882292|Experimental|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal [should be within 1 hour post-meal (fed state)] at approximately the same time each day in a 21-day cycle.
89237080|NCT05882266|Experimental|Treatment|Receive standard dietary therapy and plant-based omega-3 supplemental beverage consumed once daily during breakfast.
89237081|NCT05882266|Placebo Comparator|Control|Receive only standard dietary therapy
89237082|NCT05882227|Experimental|Video|"patients will watch a video with discharge information taken from the document Optimized hip replacement recovery program; information for patients, family members or caregivers."
89237083|NCT05882227|Active Comparator|Traditional information|"patients will receive discharge information will be provided through the document entitled Optimized Hip Replacement Recovery Program; Information for Patients, Family or Caregivers."
89237084|NCT05882201|Placebo Comparator|Control group|Control group
89237085|NCT05882201|Experimental|Group FICB|✓ Group FICB; (30 patients) Fascia Iliaca compartment block group.
89237086|NCT05882201|Experimental|Group FNB|✓ Group FNB; (30 patients) Femoral nerve block group.
89237087|NCT05882175||OHI+ patients|Adult patients with hematologic malignancies that have sCD25>3,900 U/mL and ferritin >1,000 ng/mL
89237088|NCT05882175||OHI- patients|Adult patients with hematologic malignancies, with sCD25>3,900 U/mL and/or ferritin < 1,000 ng/mL
89237089|NCT05882136||Patients with acute intermittent porphyria (AIP)|Patients aged 18-65 (men and women) with acute intermittent porphyria and at least one episode of exacerbation of this disease requiring admission to the hospital
89237090|NCT05882136||Control group|People recruited from the general population and matched by age, sex and body mass index.
89237091|NCT05882123||Comparison of clinical data between AIS patients in CMB and non-CMB groups|
89237092|NCT05882123||without CMBs; with CMBs|
89237093|NCT05882123||male; female|
89237094|NCT05882019|Other|Breast Exam with Bexa|Bexa exam to be performed on participants already scheduled for either screening or diagnostic mammography.
89237095|NCT05881980|Experimental|Group T1|Terbinafine 250 mg/day will be given in this group
89237096|NCT05881980|Experimental|Group I1|Itraconazole 200 mg/day will be given in this group
89237097|NCT05881980|Experimental|Group T+I|Terbinafine 250 mg + Itraconazole 200 mg/day will be given in this group
89237098|NCT05881980|Experimental|Group T2|Terbinafine 500 mg/day in two divided doses will be given in this group
89237099|NCT05881980|Experimental|Group I2|Itraconazole 400 mg/day in two divided doses will be given in this group
89237100|NCT05881967||Uterine sarcoma|Participants were enrolled for the first treatment of uterine sarcoma or secondary operation for recurrence fo uterine sarcoma.
89237101|NCT05881967||Uterine fibroid|Participants were enrolled for surgery of uterine fibroids.
89237102|NCT05881941|Experimental|using a soundproof nebulizer with a music and a funny mask added|Experimental group 1: using a soundproof nebulizer with a music and a funny mask added
89237103|NCT05881941|Experimental|using a silent nebulizer with no extra attachments|Experimental group 2: using a silent nebulizer with no extra attachments
89237104|NCT05881941|Experimental|using a routinely employed nebulizer|Control group: using a routinely employed nebulizer
89237105|NCT05881902|Experimental|İntervention 1: Cancer awareness training based on the Health Belief Model|"Awareness training based on the Health Belief Model will be given to the participants in the Intervention 1 group during home visits in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made."
89237106|NCT05881902|Experimental|İntervention 2: Standart cancer education|Participants in the Intervention 2 group will be provided with the standard training applied at KETEM by the Ministry of Health on female cancers, which are frequently seen in physical women, during home visits. The training will be held in the form of power-point presentation, question and answer. For 3 months, intervention 2 groups will be applied to reinforce their awareness in standard education (sms reminder).
89237107|NCT05881889|Experimental|repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses). receive 4 week rTMS treatment.
89237108|NCT05881889|Sham Comparator|sham stimulation|For patients in the sham group, we will apply rTMS over the DLPFS in sham modality.
89237109|NCT05881876||burn groups|Inclusion criteria were as follows: male or female patients between 18 and 75 years of age, partial or full-thickness burns that healed spontaneously or required skin grafting, and limited joint ROM in the upper extremities caused by burns.
89237110|NCT05881824|No Intervention|standard care group (SCG)|The SCG received oral healthy lifestyle advice and counseling on physical activity and sleep habits
89237111|NCT05881824|Active Comparator|Mediterranean diet group (MDG)|The MDG was additionally subjected to a 6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet.
89237112|NCT05881785|Experimental|Treatment group 1|GR1501 low dose
89237113|NCT05881785|Experimental|Treatment group 2|GR1501 high dose
89237114|NCT05881785|Placebo Comparator|treatment group 3|placebo
89237115|NCT05881746|Experimental|anatomical resection group|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) is defined as the resection of one or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination thereof.
89237116|NCT05881746|Active Comparator|nonanatomical resection group|nonanatomical resection (NAR), also called as wedge resection, is defined as the resection of the tumor with a margin of normal parenchyma regardless of the hepatic anatomy.
89237117|NCT05881655|Experimental|Study Group 1|With 1.2mW lighting power of red light at wavelenth of 650nm and wearing H.A.L.T lens to control myopia.
89237118|NCT05881655|Experimental|Study Group 2|With 0.6mW lighting power of red light at wavelenth of 650nm and wearing H.A.L.T lens to control myopia.
89237119|NCT05881655|Placebo Comparator|Control Group|Wearing H.A.L.T lens to control myopia only.
89237120|NCT05881642|Experimental|Prostate and seminal-sparing Cystectomy|Patients undergoing transurethral resection and enucleation of the prostate before robot-assisted cystectomy
89237121|NCT05881642|Placebo Comparator|Conventional Radical Cystoprostatectomy|Patients undergoing conventional robot-assisted radical cystoprostatectomy
89237122|NCT05881629|Experimental|Side-lying peanut ball group|Participants randomized to this group will be asked to adopt a side-lying, lateral position on the ipsilateral side of the fetal spine. A peanut ball will be positioned between the participant's legs while in this position. They will be asked to maintain this position for 60 minutes.
89237123|NCT05881629|Placebo Comparator|Control group|Participants randomized to this group will be able to adopt any position of their choosing during the 60-minute study period. They will not be able to use a peanut ball during this time.
89237124|NCT05881577||Cases|The primary study population will consist of subjects with AR
89237125|NCT05881577||Matched controls|children with no history of AR
89237126|NCT05881577||Sibling controls|siblings of the subjects in the case group with no history of AR
89237127|NCT05881525|Experimental|dose escalation|"This study uses the 3+3 dose escalation method. The initial dose is Dose 1, the maximum dose that patients can tolerate is determined as the phase II recommended dose (RPIID), and at least 6 patients are receiving RPIID treatment. If patients develop intolerance in Dose 1 (≥3 subjects with DLT), then the subsequent enrolled patients will receive Dose -1 infusion.~Interventions:~Biological: TCR-T cells Drug: IL-2 Drug: Fludarabine Drug: Cyclophosphamide Drug: Nab-Paclitaxel"
89237128|NCT05881512|Experimental|TUAS|Transcutaneous upper airway stimulation
89237129|NCT05881434|Experimental|Expectations Questionnaire|Provision of expectations questionnaire and associated instructions to patient.
89237130|NCT05881434|No Intervention|Control|Usual care (no expectations questionnaire or further instruction)
89237131|NCT05881330|Experimental|ArtiAid® group|Each pre-filled syringe contains 10 mg/ml (1.0%) sodium hyaluronate, subjects received one injection per week for five weeks.
89237132|NCT05881317|Experimental|ArtiAid® Plus group|Each pre-filled syringe contains 15 mg/ml (1.5%) sodium hyaluronate, subjects received one injection per week for three weeks.
89237133|NCT05881187|Active Comparator|groupA (control group)|will include 20 eyes of 20 patients with infectious keratitis who will receive antimicrobial therapy.
89237134|NCT05881187|Active Comparator|group B|will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated cross-linking Protocol-1 (9 mW/cm2 for 10 minutes to achieve 5.4 J/cm2) followed by antimicrobial therapy
89237135|NCT05881187|Active Comparator|group C|will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated crosslinking Protocol-2 (18 mW/cm2 for 7 minutes to achieve 7.2 J/cm2) followed by antimicrobial therapy
89237136|NCT05881122|Experimental|Mad Dog Dietary Consultation Intervention group|The intervention group received recipes for an anti-inflammatory diet and the 2-part consultation. The consultation consisted of a home-visit that included cooking and accessible kitchen equipment demonstrations, and an accompanied trip to the grocery store.
89237137|NCT05881122|No Intervention|Control group|The controls received the recipes only.
89237138|NCT05881070|Experimental|Mobile health self-management|
89237139|NCT05881018|Experimental|Low glycaemic index|
89237140|NCT05881018|Experimental|Low glycaemic index with physical activity units|
89237141|NCT05881018|Experimental|High glycaemic index|
89237142|NCT05881018|Experimental|High glycaemic index with physical activity units|
89237143|NCT05880979|Experimental|Intervention (Engaging Together for Healthy Relationships)|Providers and families in the intervention arm will receive the ETHR program which includes a clinician training, provider scripts, resource guides, a comprehensive website, and warm referral processes.
89237144|NCT05880979|Active Comparator|Control (Receipt of regular well-child care)|Providers and families in the control arm will receive regular well-child care. All providers in the control arm will have access to ETHR after the pilot trial is over
89237145|NCT05880927|Experimental|Pyrotinib 400mg/day|High risk HER2 positive patients receive pyrotinib 400mg/day for half or one year
89237146|NCT05880745|Experimental|patient group|Patients with MS
89237147|NCT05880745|Experimental|healthy group|age-gender matched healthy persons
89237148|NCT05880732|Experimental|Group I|The study group (Group I) was given 50 mg/kg MgSO4 in 250 ml of isotonic 30 minutes before induction,
89237149|NCT05880732|Placebo Comparator|Group II|the control group (Group II) was given only 250 ml of normal saline isotonic solution 30 minutes before induction,
89237150|NCT05880719|Experimental|Computer-assisted music remediation groupe|All participants benefit from 10 sessions of computer-assisted music remediation.These 10 sessions are spread over 3 month every Week.
89237151|NCT05880693|Experimental|group 1|"The first group (group 1): (n= 28): Received a loading dose of dexmedetomidine 1 μg/kg in a normal saline 0.9% solution of 100 ml 10 minutes before anesthesia induction and then a 0.4 ug/kg/h via syringe infusion pump during the time of surgery.~."
89237152|NCT05880693|Experimental|group 2|The second group (group 2): (n= 28): Received magnesium sulfate 30 mg/kg as a loading dose in a saline 0.9% solution of 100 ml infusion through the syringe pump10 minutes before anesthesia induction and then a 10 mg/kg/h via syringe infusion pump during the time of surgery
89237153|NCT05880654|Active Comparator|Systemically healthy periodontitis|Non Surgical Periodontal therapy ( Scaling & Root planning)
89237154|NCT05880654|Active Comparator|Diabetic & Periodontitis|Non surgical periodontal therapy ( scaling & root planning)
89237155|NCT05880654|No Intervention|Control|Healthy group with neither Diabetes nor Periodontitis
89237156|NCT05880589|Experimental|Milk secretory supplement|Milk secretory supplement composes of fenugreek, banana flower, ginger extract, docosahexaenoic acid, iron, folate, and iodine.
89237157|NCT05880589|Placebo Comparator|Placebo group|Placebo is tablet without fenugreek, banana flower, ginger extract, docosahexaenoic acid, iron, folate, and iodine.
89237158|NCT05880563|Experimental|ALS patients|ALS patients will get two imaging sessions with [18F]RoSMA-18-d6 PET/CT and MRI-scans one year apart
89237159|NCT05880563|Experimental|Healthy volunteers|Healthy volunteers will get only one pair of [18F]RoSMA-18-d6 PET/CT and MRI scans
89237160|NCT05880550|Experimental|study group|
89237161|NCT05880550|Active Comparator|control group|
89237162|NCT05880511|Sham Comparator|Group A (Sham)|Participants in group A will take part in 2-4 weeks of treatment with 3-5 sessions per week. Each session will involve both sham repetitive transcranial magnetic stimulation (rTMS) and augmented reality sensorimotor training. Sham repetitive transcranial magnetic stimulation (rTMS) will be delivered at 10 Hz, 2000 pulses targeting the hand representation of the left primary motor cortex. Participants will hear and experience the clicking but will not be provided with any stimulation. Sham rTMS will take approximately 11.5 minutes. Immediately following sham rTMS, participants will perform augmented reality sensorimotor training. Participants will perform 20 minutes of sensorimotor training.
89237163|NCT05880511|Experimental|Group B (Active)|Participants in group B will take part in 2-4 weeks of treatment with 3-5 sessions per week. Each session will involve both real repetitive transcranial magnetic stimulation (rTMS) and augmented reality. Repetitive transcranial magnetic stimulation (rTMS) will be delivered at 10 Hz, 2000 pulses targeting the hand representation of the left primary motor cortex. rTMS will take approximately 11.5 minutes. Immediately following rTMS, participants will perform augmented reality sensorimotor training. Participants will perform 20 minutes of sensorimotor training.
89237164|NCT05880498|Experimental|Mindfulness Intervention|"6 week smartphone-based self-guided mindfulness training using a customized version of the Healthy Minds app.~Participants were instructed to listen to at least one activity per day for 5 days per week, for 6 weeks. Activities that were part of the structured curriculum consisted of alternating mindfulness didactic 'lessons' (each up to 7 minutes in length) and mindfulness 'practices' (either 10 minutes or 15 minutes in length- as chosen by the participant)."
89237165|NCT05880498|No Intervention|Wait-List Control (WLC)|No intervention was administered during the 6-week wait list control period.
89237166|NCT05880472|Experimental|Intervention arm|Single or multiple injections of holmium-166 microspheres (up to 150 Gy) in a single session. Intervention is not repeated.
89237167|NCT05880433||Before Eye drop instillation|For pupil dilatation, one drop of 2.5% phenylephrine hydrochloride and 0.5% tropicamide was instilled three times at 5 minute intervals, 1 hour before the exam. All infants were fed 1 hour before instillation of drops and infants were swaddled before the procedure.
89237168|NCT05880433||After Eye drop instillation|The same participiants investigated after eye drop instillation
89237169|NCT05880407|Active Comparator|standard treatment|SERI osteotomy
89237170|NCT05880407|Experimental|experimental treatment|percutaneous osteotomy according to Chevron
89237171|NCT05880381|Experimental|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
89237172|NCT05880381|Other|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
89237173|NCT05880342|Other|Mental fatigue group|
89237174|NCT05880342|Other|Physical fatigue group|
89237175|NCT05880342|Other|Combined group|
89237176|NCT05880316|Experimental|Intermittent Fasting Group|IF regime: 3 fasting day: 4 non-fasting day. On fasting day - allows to eat restricted calorie diet (up to 70% total daily calorie intake) for 8 hours.
89237177|NCT05880316|No Intervention|Non-Fasting Group|Usual care. Not allowed to fast
89237178|NCT05880290|Experimental|gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful|
89237179|NCT05880277|Experimental|Jumping|Female jumping collegiate athletes
89237180|NCT05880186|Experimental|Caffeine intake|"Test in the morning~A dose of 3 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test.~Test in the evening~A dose of 3 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test."
89237181|NCT05880186|Placebo Comparator|Placebo intake|"Test in the morning~A dose of 3 mg/kg of placebo (Cellulose, Guinama, Valencia, Spain) was ingested before the beginning of each test.~Test in the evening~A dose of 3 mg/kg of placebo (Cellulose, Guinama, Valencia, Spain) was ingested before the beginning of each test"
89237182|NCT05880173|Other|Diagnostic FIB4|Only one arm because diagnostic study evaluating blood test using elastometry and liver biopsy as reference
89237183|NCT05880121||systemic lupus erythematosus|Patients with SLE according to the 1997 ACR, 2012 SLICC or 2019 EULAR/ACR criteria will undergo MRI along with neuropsychological tests, rheumatological evaluation and blood sample collection at baseline and after at least 12 months or during a new neuropsychiatric manifestation. In case of existing MRI with compatible features, they will be used as baseline studies.
89237184|NCT05880121||healthy controls|Subjects with Charlson's Comorbidity Index=0 with no ongoing chronic therapy and no history of immune-mediated disease will undergo a single MRI study, along with neuropsychological tests and blood sample collection. In case of existing MRI with compatible features, no additional studies will be performed in this cohort.
89237185|NCT05880082|Experimental|tislelizumab, Q3W with TP regimen|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
89237186|NCT05880069||Drug-resistant pathogen|"Individuals of all ages with the target pathogen, resistance phenotype, and infection site combinations as follows:~P. aeruginosa, carbapenems resistant: BSI~A. baumannii, carbapenems resistant: BSI~E. coli, 3rd generation cephalosporins resistant: BSI and UTI~K. pneumoniae, 3rd generation cephalosporins resistant: BSI~K. pneumoniae, carbapenems resistant: BSI~S. aureus, methicillin resistant: BSI, pneumonia, SSI and SSTI~E faecium, vancomycin resistant: BSI~Enterobacterales, 3rd generation cephalosporins resistant: BSI"
89237187|NCT05880069||Drug-susceptible pathogen|"Individuals of all ages with the target pathogen, susceptible phenotype, and infection site combinations as follows:~P. aeruginosa, carbapenems susceptible: BSI~A. baumannii, carbapenems susceptible: BSI~E. coli, 3rd generation cephalosporins susceptible: BSI and UTI~K. pneumoniae, 3rd generation cephalosporins susceptible: BSI~K. pneumoniae, carbapenems susceptible: BSI~S. aureus, methicillin susceptible: BSI, pneumonia, SSI and SSTI~E faecium, vancomycin susceptible: BSI~Enterobacterales, 3rd generation cephalosporins susceptible: BSI"
89237188|NCT05880069||No infection|Individuals of all ages without the infection under study
89237189|NCT05880030|Active Comparator|Vitamin D|Vigantol 10 000 IU/day (20 droplets) two weeks supplementation (vitamin D3)
89237190|NCT05880030|Placebo Comparator|Control|sunflower oil, (20 droplets) two weeks supplementation.
89237191|NCT05880017|Active Comparator|Modified Group|A total of 20 patients undergoing lumber spine surgery receiving modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.
89237192|NCT05880017|Active Comparator|Conventional Group|A total of 20 patients undergoing lumber spine surgery receiving conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.
89237193|NCT05880017|Active Comparator|Morphine Group|A total of 20 patients undergoing lumber spine surgery receiving morphine for peritoperative analgesia (control group).
89237194|NCT05879965||mpox patients|mpox cohort diagnosed and confirmed by PCR at the Institute of Tropical Medicine (ITM) in Antwerp during the recent mpox outbreak May-October 2022, 95 consented patients for follow-up
89237195|NCT05879965||Smallpox vaccine recipients|sub-group 1: 100 participants routinely vaccinated with two subcutaneous 3rd generation smallpox vaccines sub-group 2: 100 participants routinely vaccinated with two intradermal 3rd generation smallpox vaccines
89237196|NCT05879965||Healthy controls|50 controls recruited during HIV-PrEP consultation (no former mpox infection, no smallpox vaccination)
89237197|NCT05879900|Experimental|Intervention Group - IG|The intervention group will have in their Physical Education classes the inclusion of functional physical exercises lasting approximately 15 minutes at the beginning of the classes. After the intervention, the classes will continue according their previously planned contents. Classes take place twice a week, on non-consecutive days. In this way, the intervention program will take place over 12 weeks, totaling 24 sessions distributed in 24 classes. The exercises will be performed with natural body movements such as running, jumping, jumping, pulling, crouching, turning and pushing in order to develop Physical Fitness. During the intervention program period there will be an increase in intensities and complexity going through processes that follow the initial, intermediate and final preparation and progression.
89237198|NCT05879900|Active Comparator|Comparator Group - CG|The comparator group wil keep performing the Physical Education classes according their previously planned contents.
89237199|NCT05879848|Experimental|Experimental analgesic treatment (VR)|Achieved active labor and regular contractions (>= 4 contractions in 10 minutes), patients are given the virtual reality scenario synchronized with the uterine contractions , and no other alternative analgesia is provided, except for the midwife's support.
89237200|NCT05879848|No Intervention|Standard Care (non-VR)|Patients in active labour. undergo standard care (only midwife's support, no analgesia)
89237201|NCT05879809|Experimental|The clinical response of the MT|To assess the efficacy of music therapy of MT group compared to control group in depressive symptoms.
89237202|NCT05879809|Experimental|The alterations of acoustic features in the MT|To understand the possible biological mechanism underlying the efficacy of music therapy by analyzing alterations of acoustic features.
89237203|NCT05879809|Experimental|The alterations of neuroimaging features in the MT|To investigate potential neurobiological mechanisms underlying the effectiveness of music therapy by analyzing alterations in neuroimaging features.
89237204|NCT05879796||envafolimab combined with endostar and concurrent chemoradiotherapy|Concurrent Chemoradiation； Envafulimab,150mg, subcutaneous, QW. Maintenance therapy until disease progression, or intolerable toxicity, or up to 1 year; Endostar, administered at a dose of 75 mg/day, QW, was administered by intravenous pump on day 1 of each cycle, and the first dose was administered on the first day of radiotherapy, 6 cycles in total.
89237205|NCT05879796||concurrent chemoradiotherapy|"Concurrent Chemoradiation:~Cisplatin 40 mg/m2, day1, 7 days as a cycle, 6 cycles in total; External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25- 28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
89237206|NCT05879783|Experimental|Probe-based confocal laser endomicroscopy biopsy|In this study , pCLE-based optical biopsy will be successively performed for peritoneal nodules in colorectal cancer patients during surgical operation.
89237207|NCT05879770||Wire group|Patients who underwent Shouldice inguinal hernia repair using wire.
89237208|NCT05879770||prolene group|Patients who underwent Shouldice inguinal hernia repair using prolene.
89237209|NCT05879705|Experimental|An OT-ParentShip intervention|Each family will participate in a series of 11 individual weekly sessions of 90 minutes each and another session after three months from the end of the intervention.
89237210|NCT05879705|Other|A psycho-educational intervention group.|Each family will receive a general, psycho-educational, video-based intervention. The program includes 6 videos with an average length of 20 minutes each.The participants are asked to watch the video according to the order once every two weeks.
89237211|NCT05879627|Experimental|Cohort 1|BAT8007 for Injection 0.6 mg/kg (frequency: Q2W)
89237212|NCT05879627|Experimental|Cohort 2|BAT8007 for Injection 1.5mg/kg (frequency: Q2W)
89237213|NCT05879627|Experimental|Cohort 3|BAT8007 for Injection 3.0mg/kg (frequency: Q2W)
89237214|NCT05879627|Experimental|Cohort 4|BAT8007 for Injection 4.5mg/kg (frequency: Q2W)
89237215|NCT05879627|Experimental|Cohort 5|BAT8007 for Injection 6.0mg/kg (frequency: Q2W)
89237216|NCT05879627|Experimental|Cohort 6|BAT8007 for Injection 8.0mg/kg (frequency: Q2W)
89237217|NCT05879627|Experimental|Cohort 7|BAT8007 for Injection 10.0mg/kg (frequency: Q2W)
89237218|NCT05879601|Other|control group- immediate retainer delivery|Retainer will be given to the patients immediately [ Just after debonding]
89237219|NCT05879601|Active Comparator|experimental group- delayed retainer delivery|Retainer will be given to the patient 24 hours post debonding.
89237220|NCT05879588|Other|control group-immediate retainer delivery|Retainer will be given to the patients immediately [Just after debonding].
89237221|NCT05879588|Active Comparator|experimental group-delayed retainer delivery|Retainer will be delivered to the patients 3 days post debonding.
89237222|NCT05879562|Experimental|MoCA-Xpresso first|Participants in the study will complete the MoCA-Xpresso test before the digital-MoCA classic test.
89237223|NCT05879562|Experimental|MoCA-Xpresso second|Participants in the study will complete the digital-MoCA classic test before the MoCA-Xpresso test.
89237224|NCT05879536||TRON (Tramadol-Ondansetron)|Women who receive an infusion of tramadol-ondansetron from the end of the cesarean section and for the following 24 h. The infusion (TRON) is composed of 300 mg of tramadol and 12 mg of ondansetron dissolved in 250 ml of 0.9% saline, which is routinely programmed at 11 ml/h until the content is exhausted (approximately 23 hours).
89237225|NCT05879536||AL-EPI (Local anesthetics via epidural)|Women who maintain the epidural catheter as the main measure of analgesia for 24 h. The epidural catheter after caesarean section is programmed with a 0.2% ropivacaine PCA (Patient controlled analgesia) pump at 7 ml/h with 7 ml on-demand boluses, with block every 20 min.
89237226|NCT05879406|Active Comparator|VitaMedica® Clear Skin Formula capsules|Storage Instructions: Store in a cool, dry place. Contents: 60 Capsules Directions for Use: As a dietary supplement, take two capsules with food. Caution: Do not take if safety seal on bottle is broken. KEEP OUT OF REACH OF CHILDREN.
89237227|NCT05879406|Placebo Comparator|Placebo Capsules|Storage Instructions: Store in a cool, dry place. Contents: 60 Capsules Directions for Use: As a dietary supplement, take two capsules with food. Caution: Do not take if safety seal on bottle is broken. KEEP OUT OF REACH OF CHILDREN.
89237228|NCT05879380||Suspicion of pulmonary embolism|The group suspected of a pulmonary embolism will receive standard care, consisting of the CTPA to see wether they have a pulmonary embolism or not. Additional to this imaging they will receive a MRPA.
89237229|NCT05879354|Experimental|Active Cycle Of Breathing Techniques Group|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
89237230|NCT05879354|No Intervention|Control group|No intervention will be given to the patients in the control group.
89237231|NCT05879315|Other|risk stratification of fall in patients waiting for hip and knee surgery|
89237232|NCT05879302|Experimental|Shared Decision Making Intervention|Receives the Shared Decision Making Intervention
89237233|NCT05879302|No Intervention|Usual Care|Receives Usual Care, eg. usual patient education and counseling for kidney transplant candidates.
89237234|NCT05879289|Experimental|Clinical Trial|36 participants using the product for 90 days. Aims to evaluate the clinical, subjective and instrumental usage
89237235|NCT05879276|Experimental|Empaglifozin in addition to standard management|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks
89237236|NCT05879276|No Intervention|Standard management|Patients in cardiogenic shock receiving a standard management. SGLT2 inhibitor, which are now standard of care in chronic heart failure, in the strict respect of their indications, could be prescribed in the standard management group after hospitalization discharge.
89237237|NCT05879263|Experimental|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
89237238|NCT05879263|Active Comparator|CONTINUOUS ENTERAL NUTRITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
89237239|NCT05879237|Active Comparator|Triple therapy therapy and vitamin D3|Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus the standard triple therapy of H pylori (double antibiotics and proton pump inhibitor)
89237240|NCT05879237|Active Comparator|Triple therapy only|Standard triple therapy of H pylori
89237241|NCT05879211|No Intervention|Control|Usual care
89237242|NCT05879211|Experimental|Intervention|Feedback to provider regarding frequency and quality of communication
89237243|NCT05879172|Active Comparator|traditional anastomotic device|
89237244|NCT05879172|Experimental|electric tubular anastomotic device|
89237245|NCT05879133|Experimental|Group 1 (Behavioral)|"Participants are randomly assigned a study group, pariticipants will be given the following:~A Fitbit to wear every day during the study. A Fitbit is a physical activity tracking device that will help measure your physical activity. Participants will also receive a Fitbit Aria weight scale. Participants need to create a Fitbit account on the Fitbit website, which will allow participants to track your physical activity and log your diet information and weight. A member of the study team will call you or help you in-person (if you are in the clinic) to help set up the Fitbit and scale.~Resistance bands with an instructional video on how to use them.~Educational materials, such as handouts about diabetes prevention, as well as written/verbal/video instructions on setting up the Fitbit and scale. This will also include information about online safety/privacy."
89237246|NCT05879133|Experimental|Group 2 (Waitlist)|"Participants are randomly assigned a study group, pariticipants will be given the following:~A Fitbit to wear every day during the study. A Fitbit is a physical activity tracking device that will help measure your physical activity. Participants will also receive a Fitbit Aria weight scale. Participants need to create a Fitbit account on the Fitbit website, which will allow participants to track your physical activity and log your diet information and weight. A member of the study team will call you or help you in-person (if you are in the clinic) to help set up the Fitbit and scale.~Resistance bands with an instructional video on how to use them.~Educational materials, such as handouts about diabetes prevention, as well as written/verbal/video instructions on setting up the Fitbit and scale. This will also include information about online safety/privacy."
89237247|NCT05879068|Experimental|PM8002+Paclitaxel|Subjects will be administered with PM8002 plus Paclitaxel via intravenously (IV) Q3W for 5 cycles, followed by PM8002 until disease progression or intolerable toxicity for a maximum of 2 years.
89237248|NCT05879055|Experimental|PM8002+FOLFIRI|Subjects will be administered with PM8002 plus FOLFIRI via intravenously (IV) Q2W until disease progression or intolerable toxicity for a maximum of 2 years.
89237249|NCT05878977|Other|Immune checkpoint inhibitors|
89237250|NCT05878834|Experimental|Beta-glucan supplement group|Beta-glucan supplement capsule composes of beta-glucan 250 mg, broccoli 75 mg, quercetin 50 mg.
89237251|NCT05878834|Placebo Comparator|Placebo group|Placebo capsule is empty capsule.
89237252|NCT05878756|Experimental|Functional strength training|With conventional therapy,the ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball preform from the patient 5 days per week for 4 weeks.
89237253|NCT05878756|Active Comparator|Conventional therapy|passive and active range of motion exercises,Stretching and strengthening exercise 5 days per week for 4 weeks.
89237254|NCT05878535|Active Comparator|The Metformin Group (MG)|"The group (n=385) will receive metformin oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation.~• Drug: metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.~Other Name: Glucophage."
89237255|NCT05878535|Placebo Comparator|The Placebo Control Group (PCG)|"The group (n=385) will receive placebo oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation.~• Drug: Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. Other Name: Placebo"
89237256|NCT05877833||Vibrancy|Healthy adults
89237257|NCT05877651|Experimental|MASCT-I injection|MASCT-I injection
89237258|NCT05877443||Respiratory support by an open system|
89237259|NCT05877443||Respiratory support by non-invasive mechanical ventilation|
89237260|NCT05877443||Respiratory support by invasive mechanical ventilation|
89237261|NCT05876247||Individuals treated for oral cancer|Dutch native speakers (18+) who will undergo surgical treatment for a T1 or T2 tumour on the tongue.
89237262|NCT05876247||Control speakers|Dutch native speakers (18+) without self-reported speech problems.
89237263|NCT05876117||Claustrophobic adult patients|Claustrophobic adult patients who are undergoing MRI scan as part of chronic pain management.
89237264|NCT05876104||Adult chronic pain patients|Adult chronic pain patients who harass pain clinic staff
89237265|NCT05875506|Experimental|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728)
89237266|NCT05875506|Experimental|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA)
89237267|NCT05875506|Active Comparator|Alveogyl paste|Alveogyl paste ( Septodont, inc, france)
89237268|NCT05875350|Experimental|Intraligamental local anesthetic injection|
89237269|NCT05875350|No Intervention|Buccal infiltration local anesthetic injection|
89237270|NCT05874947||Dental Cast Digitization techniques:(CBCT 3D model scanning module )|Scanning the plaster model using CBCT 3d model scanning module to generate a digital model
89237271|NCT05874947||Dental Cast Digitization techniques :Desktop Optical 3D Scanner|Scanning the plaster model using Desktop Optical 3D Scanner to generate a digital model
89237272|NCT05874947||plaster cast|linear measurments on the plaster cast as the gold standard (using the digital caliper )
89237273|NCT05871086|Experimental|Coenzyme Q10 Group|Patients will receive their JIA standard treatment plus 100 mg Coenzyme Q10 capsules daily for 3 months.
89237274|NCT05871086|Placebo Comparator|Control Group|Patients will receive their standard JIA treatment plus placebo
89237275|NCT05870215||Exacerbation patients|Age ≥12 years old with physician-diagnosed asthma since >6 months experiencing an asthma attack with a patient and/or physician decision to initiate a burst of systemic corticosteroids (but not yet started), assessed within 24 hours on weekdays after a screening telephone call.
89237276|NCT05870215||Healty controls|Age ≥12 years, non-atopic, non-smoking, with normal spirometry and no history of lung disease.
89237277|NCT05867901||patients cohort|As an one-arm observational clinical trial, we have only one patients cohort.
89237278|NCT05864755|Experimental|HAIC+Durvalumab+Tremelimumab+Bevacizumab|
89237279|NCT05864404|Experimental|remimazolam-remifentanil (RR group)|
89237280|NCT05864404|Active Comparator|dexmedetomidine-remifentanil (DR group)|
89237281|NCT05863637|Experimental|Treated|Participants are their own controls when they are on the waiting list before treatment, and they will later be treated with the ISTDP.
89237282|NCT05862454||Adult chronic pain patients|Cohort of adult chronic pain patients, undergoing interventional injection therapy for pain management at a Canadian pain clinic
89237283|NCT05859243|Experimental|Traditional concurrent training|The subjects will perform two concurrent training sessions, of approximately one hour per week. Composed of strength exercises and aerobic exercise (walking outdoors and/or treadmill).
89237284|NCT05859243|Experimental|Concurrent training consisting of strength training combined with dance classes|The subjects will perform two concurrent training sessions associated with dance classes, of approximately one hour per week. Composed of strength exercises and dance classes.
89237285|NCT05859243|No Intervention|Control|Subjects will be instructed to maintain their usual routine during the study period.
89237286|NCT05856981|Experimental|Monotherapy dose escalation, IV, Q3W, multiple dose levels|ADU-1805 monotherapy dose escalation
89237287|NCT05856981|Experimental|Combination dose escalation, IV, Q3W, multiple dose levels, pembrolizumab at fixed dose|ADU-1805 plus pembrolizumab dose escalation
89237288|NCT05850572|Experimental|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
89237289|NCT05850572|Placebo Comparator|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
89237290|NCT05849532|Experimental|Home-training with functional electrical stimulation|This study employs a single group pre-post design to determine the feasibility, safety and efficacy of a 12-week of home-based combined FES and task-specific training program. Also, this study will test the effect of the same intervention on gait, mobility and balance in adults with chronic stroke.
89237291|NCT05849103|Active Comparator|A) Standard BP Control, Clinician Monitoring|Target blood pressure will be less than 150/100. Participants will be instructed to check their blood pressures twice a day for two weeks and daily for weeks 3-6 after delivery and report abnormal blood pressures or symptoms to their obstetric clinicians. Additional postpartum visits beyond the blood pressure check will be directed by their obstetric clinician.
89237292|NCT05849103|Active Comparator|B) Tight BP Control, Clinician Monitoring|Target blood pressure will be less than 140/90. Participants will be instructed to check their blood pressures twice a day for two weeks and daily for weeks 3-6 after delivery and report abnormal blood pressures or symptoms to their obstetric clinicians. Additional postpartum visits beyond the blood pressure check will be directed by their obstetric clinician.
89237293|NCT05849103|Active Comparator|C) Standard BP Control, Care Navigation|Target blood pressure will be less than 150/100. Participants will check blood pressures twice daily for 14 days and daily for weeks 3-6. A nurse navigator will review their blood pressures M-F for Weeks 1-2 and weekly for weeks 3-6 and will provide feedback on blood pressure values and recommend initiating or escalating medications as needed. The nurse navigator will communicate progress to the participant's clinicians and will remind the participant of their appointments. The nurse navigator will facilitate a visit around 3 months with a primary care clinician or a cardiologist for hypertension follow up.
89237294|NCT05849103|Active Comparator|D) Tight BP Control, Care Navigation|Target blood pressure will be less than 140/90. Participants will check blood pressures twice daily for 14 days and daily for weeks 3-6. A nurse navigator will review their blood pressures M-F for Weeks 1-2 and weekly for weeks 3-6 and will provide feedback on blood pressure values and recommend initiating or escalating medications as needed. The nurse navigator will communicate progress to the participant's clinicians and will remind the participant of their appointments. The nurse navigator will facilitate a visit around 3 months with a primary care clinician or a cardiologist for hypertension follow up.
89237295|NCT05847985|No Intervention|Differences between LBDs patients and HC in regulation of language functions|In this study, 25 LBDs patients and 25 HC will undergo neuropsychological assessment, speech and writing recording, and MRI (structural T1 sequences, sentence comprehension fMRI task, neuromelanin-sensitive MRI sequence, and resting state measurement). The HC group will be matched to the LBDs patients with MCI for gender and age.
89237296|NCT05847985|Experimental|Long-term effects of repeated sessions of home-based tDCS delivered via telepractice|The investigators will use a parallel-group, double-blinded, randomized, sham-stimulation-controlled design. Forty LBDs patients will be randomized into two parallel groups, n = 20 subjects in each arm. For the active group, the investigators will use the stimulation protocol with the anode over the left IFG (cathode over the right supraorbital area, 2mA, 20 minutes). Participants will undergo a baseline assessment (A0, as described in arm 1); 10 stimulation sessions (in a two-week period); a follow-up assessment immediately after tDCS treatment (A1), and follow-up assessments 8 weeks (A2) after the baseline assessment. Each assessment will consist of a brief neuropsychological assessment, speech and writing recording and MRI scanning.
89237297|NCT05847790|Experimental|Remote NST|
89237298|NCT05847790|Active Comparator|In-clinic NST - Standard of Care|
89237299|NCT05846906|Experimental|Sildenafil and clomiphene citrate|Oral Clomiphene citrate (Tecnovula®) 50 mg was taken twice daily by the experimental group from day 2 through day 7 of the cycle, and oral sildenafil (Respatio® 20mg for 5 days) was taken from the last day of menstruation until reaching ovulation.
89237300|NCT05846906|Other|clomiphene citrate alone|Oral Clomiphene citrate (Tecnovula®) 50 mg was taken twice daily by the control group from day 2 through day 7 of the cycle in addition to a placebo tablet.
89237301|NCT05845320||Obese|BMI>30
89237302|NCT05845320||Non-obesse|BMI<25
89237303|NCT05844462|Experimental|Experimental arm|Oral Tadalafil 40 mg or Tadalafil 20 mg [(mild or moderate chronic renal failure or liver cirrhosis (Child-Pugh A or B)].
89237304|NCT05844462|Placebo Comparator|Control arm|Oral Placebo 40 mg or Placebo 20 mg [(mild or moderate chronic renal failure or liver cirrhosis (Child-Pugh A or B)].
89237305|NCT05844111|Experimental|[14C] radiolabeled BGB-11417|Participants will receive a single dose of [14C]-BGB-11417
89237306|NCT05839210|Experimental|LIFE-L Group|Participants already undergoing chemotherapy treatment as per standard of care for 6 cycles will meet weekly via phone for 30-45 minutes with a health coach that will provide education on a Mediterranean diet and an exercise program.
89237307|NCT05839210|Other|Control Group|Participants in this group already undergoing 6 cycles of chemotherapy will receive study materials and two 30-45 minutes health coaching sessions four weeks post- intervention.
89237308|NCT05838807|Experimental|Group A: Thermal Ultrasound Group|
89237309|NCT05838807|Experimental|Group B: Pulsed Ultrasound Group:|
89237310|NCT05838807|Experimental|Group C: Combination Group|
89237311|NCT05838807|Placebo Comparator|Group D: Placebo Group|
89237312|NCT05837234|Experimental|ULF SCS|Participants with chronic low back pain that is refractory to conservative care will undergo temporary trial stimulation with the ULF SCS system. Those receiving at least 50% pain relief of their chronic back pain will be eligible for a permanent device implant and followed for 12 months.
89237313|NCT05835245|Experimental|Cryoablation combined with Sintilimab and Lenvatinib|Cryoablation treatment starts at day 0. Sintilimab and Lenvatinib will be initiated on day 1 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89237314|NCT05827276|Experimental|Usage of Life Story Questionnaire|This group will receive 6 weeks of physical therapy treatment as usual with the usage of the Life story questionnaire.
89237315|NCT05827276|No Intervention|No usage of Life Story Questionnaire|This group will receive 6 weeks of physical therapy treatment as usual with no usage of the Life Story Questionnaire.
89237316|NCT05826327|Experimental|Esketamine Group|The epidural analgesic drug mix for labour analgesia is ropivacaine 0.08mg/mL compounded with esketamine 0.3mg/mL.
89237317|NCT05826327|Placebo Comparator|Control Group|The epidural analgesic drug mix for labour analgesia is ropivacaine 0.08mg/mL compounded with sufentanil 0.3ug/mL.
89237318|NCT05823116|Active Comparator|Vancomycin continuous infusion|Continuous infusion of Vancomycin
89237319|NCT05823116|Active Comparator|Vancomycin intermittent infusion|Intermittent infusion of vancomycin
89237320|NCT05817721||PPI-group|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necroses (WON) upon acute pancreatitis (AP) and were prescribed proton pump inhibitors (PPI) concomitantly
89237321|NCT05817721||Non-PPI-group|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necroses (WON) upon acute pancreatitis (AP) and were not prescribed proton pump inhibitors (PPI) concomitantly
89237322|NCT05814991||Patients undergoing bimaxillary osteotomy under general anesthesia|
89237323|NCT05814367|Experimental|Test/Control|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (test then control). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated.
89237324|NCT05814367|Experimental|Control/Test|Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (control then test). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated.
89237325|NCT05800730|Experimental|refined carbohydrate breakfast (Breakfast A)|white bread (50g) + milk powder (25g)
89237326|NCT05800730|Experimental|whole grain breakfast (Breakfast B)|plain oats (35g) + milk powder (25g)
89237327|NCT05800730|Experimental|Energy-restricted diet|
89237328|NCT05800730|Experimental|time-restricted diet|
89237329|NCT05796479|Experimental|Group 1 (Part1)|Participants will receive a single SC dose of amlitelimab DP1 on Day 1.
89237330|NCT05796479|Experimental|Group 2 (Part 2)|Participants will receive a single SC dose of amlitelimab DP1 on Day 1.
89237331|NCT05796479|Experimental|Group 3 (Part 2)|Participants will receive a single SC dose of amlitelimab DP2 on Day 1.
89237332|NCT05794399|Experimental|Rivaroxaban|In this arm, the patients with post-myocardial infarction and left ventricular thrombus will be treated with Rivaroxaban 20mg or 15mg as indicated.
89237333|NCT05794399|Active Comparator|Warfarin|In this arm, the patients with post-myocardial infarction and left ventricular thrombus will be treated with warfarin with a dose adjusted with the International Normalised ratio range of 2.0 to 3.0.
89237334|NCT05789563|Experimental|First smartwatch model|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, SpO2 measurements will be taken by hand from the watch and the pulse oximeter simultaneously.
89237335|NCT05789563|Experimental|Second smartwatch model|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, SpO2 measurements will be taken by hand from the watch and the pulse oximeter simultaneously.
89237336|NCT05789563|Experimental|Third smartwatch model|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, SpO2 measurements will be taken by hand from the watch and the pulse oximeter simultaneously.
89237337|NCT05789433|Sham Comparator|Attention control|Static stretching
89237338|NCT05789433|Experimental|Aerobic exercise|Aerobic exercise at a dose of 225 minutes per week
89237339|NCT05788510||Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
89237340|NCT05783973||bile group|bile samples from 20 resectable BTC patients with 520 Panel sequencing (bile10000X)
89237341|NCT05783973||Tissue group|tissue samples from 20 resectable BTC patients with 520 Panel sequencing (tissue1000X)
89237342|NCT05783973||Plasma group|plasma samples from 20 resectable BTC patients with 520 Panel sequencing (plasma 10000X)
89237343|NCT05780203|Experimental|One session exposure treatment + active Cognitive Bias Modification training|The exposure treatment will be administered at the tower of the German Mining museum. The day after the exposure session, patients will complete the CBM training in the lab of the Mental Health and Research Center of Ruhr University Bochum.
89237344|NCT05780203|Sham Comparator|One session exposure treatment + sham Cognitive Bias Modification training|The exposure treatment will be administered at the tower of the German Mining museum. The day after the exposure session, patients will complete the sham CBM training in the lab of the Mental Health and Research Center of Ruhr University Bochum.
89237345|NCT05764395|Experimental|Treatment (Rigosertib, pembrolizumab)|Patients receive rigosertib PO plus pembrolizumab IV throughout the study. Patients undergo CT or MRI and blood sample collection at screening and on study, and may also undergo tissue biopsy at screening and on study.
89237346|NCT05763186|Experimental|Sampling|"On the PiccLine: a collection of 6 consecutive heparinized tubes with 3.5ml gel corresponding to the usual purge volume~In the periphery : one 3.5ml heparin-gel tube as a reference."
89237347|NCT05763186|Experimental|Sampling and rinsing|"On the PiccLine: a 10 ml pre-rinsing with 0.9% NaCl and then a sampling of 6 consecutive heparinized tubes with 3.5ml gel corresponding to the usual purge volume.~In the periphery: one 3.5 ml heparin-gel tube as a reference."
89237348|NCT05758571|Experimental|EGCG（Epigallocatechin-3-gallate ）|Epigallocatechin-3-gallate (EGCG) (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day. From the beginning of the diagnosis and 7 days after the signing of the informed consent form, the medication can be continued according to the wishes of the patients, but the total medication time is not more than 14 days.
89237349|NCT05756842|Experimental|Honey-based gel consumption|A honey-based gel will be administered to participants in this arm.
89237350|NCT05755113|Experimental|Single Arm, Open Label|Single or multiple Intratumoural injections of tigilanol tiglate at up to a fixed dose of 3.6 mg/m2 (Body Surface Area [BSA]) per treatment.
89237351|NCT05753462|Experimental|Phase 1|Participants will receive single escalating doses of 2, 4, 6, 10, 16 and 25 mg/kg by intravenous infusion of SQY51 every 2 weeks.
89237352|NCT05753462|Experimental|Phase 2a - Treatment arm (Dose 1)|Non randomized participants will receive by IV dose 1 of SQY51 in 4 blocks of 4-weeks.
89237353|NCT05753462|Experimental|Phase 2a - Treatment arm (Dose 2)|Non randomized participants will receive by IV dose 2 of SQY51 in 4 blocks of 4-weeks.
89237354|NCT05753462|Experimental|Phase 2a - Treatment arm (Dose 3)|Non randomized participants will receive by IV dose 3 of SQY51 in 4 blocks of 4-weeks.
89237355|NCT05737264||TAVR group|The group that undergoes transcatheter aortic valve replacement
89237356|NCT05735262|Experimental|DLPFC group|Active iTBS will be delivered to the left DLPFC.
89237357|NCT05735262|Experimental|DMPFC group|Active iTBS will be delivered to the left DMPFC.
89237358|NCT05735262|Sham Comparator|Sham to DLPFC group|Sham iTBS will be delivered to left DLPFC.
89237359|NCT05735262|Sham Comparator|Sham to DMPFC group|Sham iTBS will be delivered to left DMPFC.
89237360|NCT05735171|Active Comparator|Conventional gross total resection surgery|Retrospective cohort of patients who underwent conventional surgery between 2018 and 2021. Confirmed gross total resection (removal of 100 % of contrast-enhancing tumor).
89237361|NCT05735171|Experimental|AI-guided resection|Tailored supramarginal surgery guided by AI-based recurrence probability maps. Aim of supramarginal resection, where the high-risk of recurrence areas identified by the AI-based model are subsidiary to be removed as safe locations for the patient.
89237362|NCT05733273|Active Comparator|Nordic Hamstring exercise program|Participants are required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
89237363|NCT05733273|Experimental|Single leg hamstring bridge exercise program|The single-leg hamstring bridge is performed with the athlete lying on the ground with one heel supported by their partner, the hip in approximately 45° and the knee in approximately 20° of flexion. The participants cross their arms across the chest and push down through the heel to lift their buttocks off the ground. The participant should allow their buttocks to touch the ground momentarily and then the hip should be extended to 0°.
89237364|NCT05733273|Experimental|Razor curl|Participants are required to kneel on a gym mat and flex their hips and knees to approximately 90 degrees. They then allow their body to descend towards the ground by extending at the knees and hip simultaneously. When they can no longer lower themselves as such, they are instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touches the ground they are instructed to immediately return to the starting position by pushing up with their hands
89237365|NCT05727371|Experimental|RegenMatrix-PRP-XLHA|Patients randomized in this group will receive a single injection of a combination of platelet-rich plasma plus cross-linked hyaluronic acid, prepared with the medical device RegenMatrix.
89237366|NCT05727371|Active Comparator|Hylan G-F 20|Patients randomized in this group will receive a single injection of cross-linked hyaluronic acid Hylan G-F 20 (Synvisc-One®).
89237367|NCT05727371|Placebo Comparator|Placebo|Patients randomized in this group will receive a single injection of saline solution (0.9% NaCl)
89237368|NCT05714306|Experimental|Arm A - PEP-DC1 + low dose cyclophosphamide|In arm A, patients will receive PEP-DC1 vaccine in combination with low dose cyclophosphamide.
89237369|NCT05714306|Experimental|Arm B - OC-DC + low dose cyclophosphamide followed by PEP-DC2 + low dose cyclophosphamide|In arm B, patients will receive first, the OC-DC vaccine in combination with low dose cyclophosphamide, then PEP-DC2 vaccine in combination with low dose cyclophosphamide. Finally, patients will be vaccinated with the personalized PEP-DC2 to continue maintenance vaccination.
89237370|NCT05706259|Active Comparator|Soft gelatin vit D supplement|In this arm subjects will receive a weekly single dose 200000 IU soft gelatin capsule of vitamin D3 for 3-weeks
89237371|NCT05706259|Experimental|Orodispersible vit D supplement|In this arm subjects will receive a weekly single dose 200000 IU orodispersible (sachet) vitamin D3 for 3-weeks
89237372|NCT05704374|Experimental|Fibromyalgia group|"In the first phase of the experiment, the effect of sympathetic tone change on T- and H-reflexes will be evaluated.~In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to these patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes."
89237373|NCT05704374|Other|Healthy control group|The effect of sympathetic tone changes on T- and H-reflexes will be evaluated in healthy cases.
89237374|NCT05704192||Clinically significant portal hypertension (CSPH) group|A CT-based HVPG Score, whose computed formula was: 17.37-4.91*ln(Liver/Spleen volume ratio) +3.8[If presence of peri-hepatic ascites],was used to diagnose CSPH (HVPG>10mmHg) with a cut-off value 11.606.
89237375|NCT05704192||non-CSPH group|A CT-based HVPG Score, whose computed formula was: 17.37-4.91*ln(Liver/Spleen volume ratio) +3.8[If presence of peri-hepatic ascites],was used to diagnose CSPH (HVPG>10mmHg) with a cut-off value 11.606.
89237376|NCT05703750||CEPH group|CEPH was defined when at least one following factor was present: 1) esophageal/gastric varices on upper endoscopy or CT imaging, 2) ascites requiring diuretic treatment, 3) splenomegaly (largest diameter on CT >12 cm) with a low platelet count (<100,000/mm3).
89237377|NCT05703750||non-CEPH group|Non-CEPH was defined when none of the following factor was present: 1) esophageal/gastric varices on upper endoscopy or CT imaging, 2) ascites requiring diuretic treatment, 3) splenomegaly (largest diameter on CT >12 cm) with a low platelet count (<100,000/mm3).
89237378|NCT05703724|Other|Subjects|A fundus picture will be acquired without pupil dilation. This examination will be followed by an intra-ocular pressure measurement. The results will be discussed with the participating subject by the present physician. For each subject, both eyes will be evaluated. In case of suspected glaucoma, the subject will be referred to an ophthalmologist for further evaluation.
89237379|NCT05701709|Experimental|SHR-A2102|
89237380|NCT05696171|Active Comparator|Manual insertion|Manual insertion of the cochlear implant
89237381|NCT05696171|Experimental|Robotized insertion|Robotic insertion of the cochlear implant
89237382|NCT05690256|Experimental|Intervention|Resilience Clinic
89237383|NCT05690256|Active Comparator|Control|Enhanced pediatric primary care
89237384|NCT05680558|Experimental|UVA Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis System|TREATMENT with THERAKOS® CELLEX Photopheresis System on two consecutive days every 2 weeks for the first 3 months; then once per month for following 9 months.
89237385|NCT05679180|Experimental|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
89237386|NCT05678127|Experimental|Patients with unilateral ACNES|
89237387|NCT05668728|Active Comparator|Group 1|Dry needling + standard exercise program with 4 sessions of stick and pull out method at 1 week intervals
89237388|NCT05668728|Active Comparator|Group 2|Dry needling + standard exercise program with 4 sessions of turn-and-wait method at 1-week intervals
89237389|NCT05668728|Active Comparator|Group 3|Dry needling + standard exercise program with 4 sessions of stick and turn and wait method 1-week intervals
89237390|NCT05667324|Experimental|Group 1: Ropivacaine plus Dexamethasone|The group 1 injection procedure will be performed as follows: after preparation of the skin using appropriate skin preparation solution and using aseptic technique, a small-gauge spinal needle will be advanced into the pterygopalatine fossa under ultrasound guidance. Once the needle is properly positioned, 0.5% ropivacaine will be administered at a dose of 20 mg plus 4 mg dexamethasone and the needle will be removed. This procedure will be performed bilaterally
89237391|NCT05667324|Active Comparator|Group 2: Placebo plus Dexamethasone|In group 2 the same procedure will be performed, but the injectate will consist of 5 mL of a balanced crystalloid intravenous solution (4 ml of normal saline) plus 4 mg dexamethasone (each side). This procedure will be performed bilaterally.
89237392|NCT05663242|Experimental|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
89237393|NCT05663242|Experimental|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
89237394|NCT05661851|Experimental|Investigational product|Eligible subjects will be randomly assigned the investigational product to be used in both eyes for the duration of the study.
89237395|NCT05661851|Active Comparator|Control product|Eligible subjects will be randomly assigned the control product to be used in both eyes for the duration of the study
89237396|NCT05656521|Experimental|'005 Treatment Arm|'005 IV 20 mg + Standard of care
89237397|NCT05656521|Active Comparator|Dexamethasone Treatment Arm|Dexamethasone 6 mg + Standard of care
89237398|NCT05650086||Cohort 1: Biopsy|Subjects who are scheduled for biopsy will be enrolled.
89237399|NCT05650086||Cohort 2: Screening mammogram|Patients who underwent screening mammogram will be enrolled.
89237400|NCT05650086||Cohort 3: Diganostic mammogram|Subjects scheduled for diagnostic mammogram will be enrolled.
89237401|NCT05650086||Cohort 4: Prior history of lympectomy, routine mammogram|Subjects with prior history of lumpectomy scheduled for their routine mammogram will be enrolled.
89237402|NCT05646511|Active Comparator|Control arm SCRT+CAPOX|The standard-of-care group receives short-course radiation therapy (5 × 5 Gy) followed by six cycles of CAPOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, q3wks).
89237403|NCT05646511|Experimental|Experimental arm SCRT+CAPOXIRI|The standard-of-care group receives short-course radiation therapy (5 × 5 Gy) followed by six cycles of CAPOX (capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, q3wks).
89237404|NCT05644041|Experimental|Gemcitabine induction|Patients will receive Gemcitabine once weekly for 6 weeks.
89237405|NCT05641207|Experimental|Experimental device RheOx™ with the RheOx™ Catheter was only used in the trial|All of participants who signed the ICF and meet all of inclution and exclution criterias will be enrolled to experimental arm.
89237406|NCT05633992|Experimental|V116 Treatment|Participants receive a single intramuscular (IM) injection of V116 on Day 1.
89237407|NCT05633992|Active Comparator|PPSV23 Treatment|Participants receive a single IM injection of PPSV23 on Day 1.
89237408|NCT05630430|Experimental|Volar Carbon Plate Effects on Procedure Time|Carbon alloy plates, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line
89237409|NCT05630430|Active Comparator|Titanium Alloy Plates Group|Titanium alloy plates are frequently used materials in our current orthopedic surgery practices. The main goal during surgical treatment is to obtain an accurate and acceptable bone alignment. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery.
89237410|NCT05628623|Active Comparator|Arm A: Cytarabine|"Patients will participate for 2 cycles. Each cycle is 28 days.~For Core Binding Factor (CBF) leukemia patients: Cytarabine 3000 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference)~For non-Core Binding Factor (CBF) leukemia patients: Cytarabine 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference)"
89237411|NCT05628623|Experimental|Arm B: Cytarabine + Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~For Core Binding Factor (CBF) leukemia patients: Cytarabine 3000 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference) followed by Venetoclax 100 mg daily Day 1 through Day 8~For non-Core Binding Factor (CBF) leukemia patients: Cytarabine 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 either on Days 1, 3, and 5 OR Days 1, 2, and 3 (per institutional preference) followed by Venetoclax 100 mg daily Day 1 through Day 8"
89237412|NCT05628623|Experimental|Arm C: Daunorubicin + Cytarabine Liposome+ Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3 with Venetoclax 400 mg orally once daily on Days 1-14"
89237413|NCT05628623|Experimental|Arm D: Azacitidine + Venetoclax|"Patients will participate for 2 cycles. Each cycle is 28 days.~Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference) with Venetoclax 400 mg orally once daily on Days 1-28"
89237414|NCT05622006|Experimental|Control condition|Control condition: Sitting from 8 am until 3pm.
89237415|NCT05622006|Experimental|Condition 1|Condition 1: 35 minutes of treadmill walking followed by sitting until hour 7 is reached
89237416|NCT05622006|Experimental|Condition 2|Condition 2: 2.5 minutes of treadmill walking for every 30 minutes until hour 7 is reached.
89237417|NCT05622006|Experimental|Condition 3|Condition 3: 5 minutes of treadmill walking every 60 minutes, until hour 7 is reached.
89237418|NCT05616923|Experimental|Trametinib|Cheek describing the active compound (topical cream containing 0.1 mg/g trametinib)
89237419|NCT05616923|Placebo Comparator|Vehicle|Cheek receiving cream without active compound (topical cream lacking active ingredient)
89237420|NCT05614921|Active Comparator|External oblique intercostal plane block|Ultrasound-guided External oblique intercostal plane block before surgery
89237421|NCT05614921|Active Comparator|Wound infiltration|Wound infiltration to trocar sites before surgery
89237422|NCT05612932|Other|control group-immediate retainer delivery|Retainer will be given to the patients immediately [Just after debonding].
89237423|NCT05612932|Active Comparator|experimental group- delayed retainer delivery|Retainer will be delivered to the patients 7 days post debonding.
89237424|NCT05608200|Experimental|Len-Sin-TACE|Lenvatinib, Sintilimab Plus TACE
89237425|NCT05608200|Active Comparator|Len-TACE|Lenvatinib Plus TACE
89237426|NCT05606692|Active Comparator|Sevoflurane group|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
89237427|NCT05606692|Experimental|Propofol group|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
89237428|NCT05606614|Experimental|Cohort 1|Dose Level 1
89237429|NCT05606614|Experimental|Cohort 2|Dose Level 2
89237430|NCT05602688|Experimental|Supplement Group|This arm will receive oral 200 mg Lemon Balm supplement tablet two times a day for three-weeks.
89237431|NCT05602688|Active Comparator|Control group|This arm will receive an oral matched placebo tablet two times a day for three-weeks.
89237432|NCT05601336|Active Comparator|metformin monotherapy|Glucophage 1000 once daily
89237433|NCT05601336|Active Comparator|Dapagliflozin monotherapy .|Farxiga once per day
89237434|NCT05601336|Active Comparator|metformin and dapagliflozin combined therapy|Xigduo once daily
89237435|NCT05601336|No Intervention|control group.|placebo
89237436|NCT05599243|Experimental|experimental drug|0.15% w/w dutasteride topical O/W emulsion.
89237437|NCT05599243|Placebo Comparator|Placebo|vehicle (excipients)
89237438|NCT05597228|Experimental|Behavioral: Cognitive-Behavioral Stress Management and Health Education|Weekly video conference groups led by a trained facilitator
89237439|NCT05594264|Experimental|Web-based Storytelling|Participants will participate in a 6-week web-based storytelling study.
89237440|NCT05592210||Questionnaires assessed Parents of preterm infants|"Inclusion criteria for parents~Parents of hospitalized preterm infants with a gestational age of less than 37 weeks;~Both parents are at least 18 years old;~Able to read and communicate in Chinese, able to complete the questionnaire independently or with the help of the investigator;~Inclusion criteria for infant~Gestational age less than 37 weeks;~admitted to the NU or NICU and discharged after treatment;"
89237441|NCT05587855|Experimental|eCulinary Medicine Group (E-group)|The intervention group will receive weekly cooking demonstrations and education videos via electronic links to use herbs and spices to increase vegetables and reduce sodium in the diet over six weeks
89237442|NCT05587855|No Intervention|Control Group (C-group)|The control group participants will receive usual care from their physician's clinic and the recipes but without the eCulinary intervention over 6 weeks.
89237443|NCT05556889|Experimental|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
89237444|NCT05556889|Other|Traditional auriculotemporal nerve blockade|The traditional method of auriculotemporal nerve block is to inject the needle 1~1.5 cm vertically at the level of tragus and posterior of superficial temporal artery, and inject 2-3 ml of local anesthetics after pumping back without blood
89237445|NCT05545501|Placebo Comparator|No Salt, No β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
89237446|NCT05545501|Active Comparator|High Salt, No β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
89237447|NCT05545501|Experimental|High Salt, High β-OHB|Participants will consume the supplemental intervention for 10 days. On day 10 participants will arrive at the laboratory where the investigators will assess resting blood pressure, arterial stiffness, endothelial function, renal blood flow, and submaximal exercise blood pressure reactivity. Blood will be collected to investigate inflammatory and immune responses to the dietary conditions. Starting on day 9, participants will undergo ambulatory blood pressure monitoring and 24-hour urine collection.
89237448|NCT05540405|Experimental|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
89237449|NCT05540405|Experimental|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
89237450|NCT05540405|Placebo Comparator|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
89290221|NCT03934476|Experimental|Exercise HIIT (High-Intensity Interval Training)|"Exercise intervention:~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:~Cycle 1~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)~Cycle 2~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)~Cycle 3~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
89237451|NCT05530772|Experimental|Immediate endoscopic Necrosectomy|"The subject will have endoscopic necrosectomy at the time of the EUS-guided transmural stent placement.~The necrotic collection is identified with endoscopic ultrasonography (EUS). Transmural placement of stent under EUS guidance is performed. The type of stent is at the discretion of endoscopist. It could be either lumen apposing metallic stent or double pigtail plastic stent. Immediately after stent placement, the cystoenterostomy track is dilated with a 15 mm through the scope (TTS) balloon. Then, direct endoscopic necrosectomy is performed with CO2 insufflation. The duration of necrosectomy will be 30 to 90 minutes. If complete clearance of the cavity is achieved before 30 minutes, the duration of necrosectomy may be less than 30 minutes in the given session. Also, if any complication occurs during necrosectomy, appropriate management will be done, and the procedure may be concluded earlier."
89237452|NCT05530772|Active Comparator|On-demand endoscopic necrosectomy|The subject will have EUS-guided transmural drainage of the necrotic collection The necrotic collection is identified with endoscopic ultrasonography (EUS). Transmural placement of stent under EUS guidance is performed. The type of stent is at the discretion of endoscopist. It could be either lumen apposing metallic stent or double pigtail plastic stent. In this group, endoscopic necrosectomy is not performed at the time of index procedure. Such patients may undergo endoscopic necrosectomy during follow up if clinically indicated.
89237453|NCT05525312|Other|"Standard protective ventilation"|Patients receiving a positive-end expiratory pressure (PEEP) of 5 cmH2O
89237454|NCT05525312|Experimental|"Open lung protective ventilation protocol"|Patients with a titrated positive-end expiratory pressure (PEEP) corresponding to the best lung compliance calculated with transpulmonary pressure.
89237455|NCT05504278|Experimental|IBI351 in combination with Sintilimab and pemetrexed|
89237456|NCT05504278|Experimental|IBI351 in combination with Sintilimab pemetrexed and cis-platinum/carboplatin|
89237457|NCT05504278|Experimental|IBI351 monotherapy|
89237458|NCT05504278|Experimental|IBI351 in combination with Sintilimab|
89237459|NCT05500963|Experimental|Effective dose|• The effective dose of TENS will be set at an intensity to elicit slight contractions in each target muscle, as we have done previously. It will be delivered as 5-Hz bursts (7 pulses at 100 Hz/burst) and applied during the light exercises. The applied current (<20 mA) will differ slightly for each of the four muscle groups and will be determined while the person is standing. The current will be set at the beginning of every treatment session for both groups of participants.
89237460|NCT05500963|Sham Comparator|Sham dose|• The current intensity for the sham dose will be set at sensory threshold, which will be less than that used for the effective dose. After beginning each exercise set, the current for the sham dose will decay to 0 mA within 30 s. In a preliminary study that included a sham dose of TENS, we found that only two of the experienced dancers in the sham group detected the gradual decline in TENS current from its initial value slightly above motor threshold when performing prescribed exercises.
89237461|NCT05492214|Experimental|Delay 30s group|Cord clamping will be delayed at 30 seconds after delivery.
89237462|NCT05492214|Experimental|Delay 60s group|Cord clamping will be delayed at 60 seconds after delivery.
89237463|NCT05492214|Experimental|Delay 90s group|Cord clamping will be delayed at 90 seconds after delivery.
89237464|NCT05492214|No Intervention|Control group|Cord clamping will be immediate (within 15 seconds) after delivery, in accordance with the standard practice in the study sites
89237465|NCT05490134|Experimental|ABVN Only Stimulation|30 minutes of ABVN Only stimulation (15Hz stimulation of cymba conchae).
89237466|NCT05490134|Experimental|ATN Only Stimulation|30 minutes of ATNS Only stimulation (100Hz stimulation adjacently anterior to the tragus)
89237467|NCT05490134|Experimental|Combination (ABVN + ATN) Stimulation|30 minutes of Combo stimulation (stimulation of both the 15Hz cymba conchae and 100HZ adjacently anterior to the tragus)
89237468|NCT05490134|Experimental|Sham Stimulation|30 minutes of Sham (15Hz stimulation of the earlobe)
89237469|NCT05486260|Experimental|Group A|Pills with 300 mg of DMB equivalent to 5,5 mg of the miraculin glycoprotein
89237470|NCT05486260|Experimental|Group B|Pills with 150 mg of DMB equivalent to 2,8 mg of miraculin glycoprotein + 150g of freeze-dried strawberry
89237471|NCT05486260|Placebo Comparator|Group C|Pills with 300 mg of strawberry lyophilisate
89237472|NCT05483270|Active Comparator|Immediate FET group|Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.
89237473|NCT05483270|Experimental|Postponed FET group|Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval.
89237474|NCT05476458||Red Dichromatic Imaging|Per-oral endoscopic myotomy will be performed using novel Evis X1 endoscopy(Olympus corporation, Tokyo, Japan) system. RDI mode 1 and Mode 2 will be used during the procedure. Submucosal bleb will be created by injecting mixture of indigo carmine and normal saline. RDI mode 2 will be used for submucosal injection and Mucosal incision. RDI Mode 2 helps in detection of deep mucosal or submucosal vessels which are the major cause of bleeding. Submucosal dissection and myotomy will be performed under white light. However when there is bleeding, RDI mode 1 will be used for the detection of bleeding point. Bleeding will be controlled with spray coagulation or using Coagrasper. Hemostasis treatment will be performed by switching to RDI only at the time of bleeding during the procedure.
89237475|NCT05476458||White light imaging|Per-oral endoscopic myotomy will be performed using CV-190 Gastroscope (Olympus corporation, Tokyo, Japan). White light imaging is used during entire procedure. Submucosal bleb will be created by injecting mixture of indigo carmine and normal saline. Initial submucosal injection and Mucosal incision will be performed under white light. RDI Entry point bleed and ease of entry into the tunnel will be marked by trainee at the end of the procedure. Submucosal dissection and myotomy will be performed under white light. When there is bleeding, bleeding point is identified with white light and hemostasis is achieved
89237476|NCT05475613|Experimental|Downstaging group|Eligible patients (See inclusion and exclusion criteria) will undergo downstaging treatment containing Anti-PD-1 inhibitor (tislelizumab, pembrolizumab, nivolumab et al). Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously. Other combination regimens, such as locoregional therapies and targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers. Patients that have reached the Criteria for Successful Downstage within 12 cycles of downstaging treatment will proceed to the observation phase, while those who fail to meet the Criteria for Successful Downstage after the maximum length of downstaging procedures will drop out from the study.
89237477|NCT05463198|Experimental|Blood Loss|
89237478|NCT05462795||Indeterminate pulmonary nodule study cohort|Patients undergoing a biopsy of an indeterminate lung nodule by surgical excision, bronchoscopic biopsy or Interventional Radiology directed biopsy
89237479|NCT05462795||Known lung cancer for surgical resection study cohort|Patients with known non-small cell lung cancer who will have surgical resection for treatment
89237480|NCT05462795||Healthy volunteer cohort|Healthy volunteers with a) no current diagnosis of cancer; b) no history of cancer over the last 5 years; and c) no existing known benign lung disease that is currently requiring treatment with medication.
89237481|NCT05462795||Benign lung disease cohort|"Patients with the following categories of benign lung disease:~COPD/emphysema~Granulomatous infection~Interstitial lung disease including pulmonary fibrosis and interstitial lung disease."
89237482|NCT05440201|Experimental|First test session|For each patient, the anticoagulant Clexane 50IE/kg is administered in the venous line of the dialysis circuit once blood is detected by the dialysis machine.
89237483|NCT05440201|Experimental|Second test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
89237484|NCT05440201|Experimental|Third test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
89237485|NCT05440201|Experimental|Fourth test session|The dosis of Clexane is lowered or increased by 50%, depending on the results of the fiber patency and clotting characteristics of the previous session.
89237486|NCT05426785|Active Comparator|Treatment Group(Early Multiple ATP Group)|Set to perform multiple ATP early
89237487|NCT05426785|Active Comparator|Control Group|"Set the extended detection time for the conventional ATP (Refer to the settings of Delayed Therapy-arm C in Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy (MADIT-RIT) study)"
89237488|NCT05418049|Experimental|All Study Participants|Participants received, in random order, a single dose of placebo, baclofen, roflumilast or memantine with a two-week washout period between doses.
89237489|NCT05414019|Active Comparator|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
89237490|NCT05414019|Active Comparator|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
89237491|NCT05414019|Active Comparator|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire.
89237492|NCT05409534|Active Comparator|Backward Walking|Participants who walk backward gait in the form of exercise program
89237493|NCT05409534|Active Comparator|Forward Walking|Participants who walk forward gait in the form of home program
89237494|NCT05409378|Experimental|The HLT® Meridian® TAVR Valve|Transcatheter aortic valve replacement with the HLT Meridian TAVR Valve
89237495|NCT05406193|Experimental|Intervention (CIM2)|An extended overview consultation, lasting 45 minutes, with the general practitioner, the patient (and maybe a relative), and the care coordinator. An individual care plan is developed, covering planned activities in the three sectors (general practice, municipality, and hospital) that will take place within the 12-month intervention period. General practice coordinates the planned patient care between general practice, the municipality, and the hospital, and follow-up on the execution of planned healthcare activities. The individual care plan is shared electronically with the healthcare center in the municipality and with the outpatient clinics using the standard IT-communication tool provided by MedCom and a routinely used national standard in general practice, hospitals, and municipalities.
89237496|NCT05406193|No Intervention|Usual care|Patients with a general practitioner allocated to the control group will receive usual care.
89237497|NCT05404529|Experimental|Moderate Hepatic Function|Participants will receive a single dose of tavapadon, 0.5 milligrams (mg) or 0.25 mg tablet based on tolerability, on Day 1.
89237498|NCT05404529|Experimental|Mild Hepatic Function|Participants will receive a single dose of tavapadon, 0.5 mg or 0.25 mg tablet based on tolerability, on Day 1.
89237499|NCT05404529|Experimental|Normal Hepatic Function|Participants will receive a single dose of tavapadon, 0.5 mg or 0.25 mg tablet based on tolerability, on Day 1.
89237500|NCT05403554|Experimental|NI-1801|
89237501|NCT05398237|Experimental|TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light|We have one arm, which consists of participants with a broad range of sun damage on the forearm. Based on the standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36), we will include mild (N=12), moderate (N=12), and severely (N=12) sun damaged skin.
89237502|NCT05395442|Experimental|Experimental Group|Web-supported diabetic foot care training based on health belief model
89237503|NCT05395442|No Intervention|Control Group|No action will be taken.
89237504|NCT05393986|Experimental|Experimental: CAR-CLDN18.2 T-Cells (CT048)|The subjects will be initially enrolled in the lymphodepletion cohort. Subsequent subjects will be enrolled in the non-lymphodepletion cohort after reviewing the data in the lymphodepletion cohort.
89237505|NCT05393518|Experimental|Drug resistant epilepsy with GAD|Patients suffering from drug-resistant epilepsy and generalized anxiety disorders (GAD),explored by intracranial EEG (seteroelectroencephalography - SEEG) in Hospital
89237506|NCT05393518|Active Comparator|Drug resistant epilepsy without GAD|Patients suffering from drug-resistant epilepsy without generalized anxiety disorders (GAD),explored by intracranial EEG (seteroelectroencephalography - SEEG) in Hospital
89237507|NCT05391477|No Intervention|Human optical diagnosis (HOD)|The examinator will provide a HOD for every lesion (regardless of their size) found during the examination (adenoma vs non-adenoma) following one of the available validated classifications (NICE, JNET, BASIC). He/she will also give a level of confidence in his/her diagnosis (high/low confidence). However, only diminutive lesions will be considered when analyzing the main outcome. The time to get a HOD will be recorded. An in situ surveillance interval will be provided if possible.
89237508|NCT05391477|Experimental|Artificial intelligence optical diagnosis (AIOD):|GI-Genius will provide an artificial intelligence diagnosis (AIOD) for every lesion detected (adenoma vs non-adenoma). Only diminutive lesions will be considered for the analysis of the main outcome. However, data on larger lesions will be recorded to describe GI-Genius´ performance in detail (secondary outcome). The time to get an AIOD will be recorded. An in situ surveillance interval will be provided if possible
89237509|NCT05380076|Experimental|Mindfulness|Mindfulness meditation video before the circuit
89237510|NCT05380076|Experimental|Mobilization of inner resources|Standardised video before the circuit
89237511|NCT05380076|Experimental|Biofeedback|Cardiac biofeedback before the circuit
89237512|NCT05380076|Sham Comparator|Control|Standardised video before the circuit
89237513|NCT05376241||Women with negative reactions to mammography evidence|Recruit up to 40 women from the Ipsos survey who agreed to be contact for a follow-up phone interview. The Investigator will specifically recruit women who expressed negative reactions to mammography evidence, so the team may assess how to improve the mammography decision aid using insights from those who were negatively affected.
89237514|NCT05369676|Experimental|SSD8432 dose 1|SSD8432 dose 1/ritonavir or placebo
89237515|NCT05369676|Experimental|SSD8432 dose 2|SSD8432 dose 2/ritonavir or placebo
89237516|NCT05364372|Active Comparator|Attention control|Dyads will receive mailed print education materials regarding healthy lifestyle (nutrition and physical activity) disseminated by ACS and NCI. They will also receive 12 weekly phone calls to assess post-treatment related symptoms.
89237517|NCT05364372|Experimental|Symptom management and lifestyle intervention|Dyads will receive 12 weekly telephone-based coaching sessions, a participant educational handbook, and a pedometer for self-monitoring physical activity.
89237518|NCT05363176|Experimental|CBT for Treatment Seeking|CBT delivered over the course of 1, ~45 minute session delivered via telehealth.
89237519|NCT05363176|Active Comparator|Pain Treatment Education|Pain treatment education is delivered over the course of 1, ~45 minute session delivered via telehealth
89237520|NCT05360498|Experimental|Intervention Arm|Adaptive Need-based Sequence
89237521|NCT05360498|Active Comparator|Attention control|"This group will be participants that were randomized to the Attention control arm and will not receive the SMSH + TIP-C adaptive intervention."
89237522|NCT06014970|Experimental|Health and Wellness Curriculum|Trained instructors will provide the Health and Wellness Curriculum at the Ravenswood City schools. Each school receiving the curriculum will have a dedicated space and receive a 30 minute class twice a week. Through group discussion, nutrition and character education, and breathing exercises, students will receive instruction to focus their attention, calm their minds, reduce stress, and think before reacting.
89237523|NCT06014970|No Intervention|Control|All control participants go through the same assessment procedures as the experimental group without any intervention.
89237524|NCT06014892|Experimental|Intervention|"The intervention group will receive:~A Snoo smart sleep bassinet~A Willow wearable breast pump~Access to Maven Clinic for 24/7 on-demand perinatal care~A faculty mentor in their own department"
89237525|NCT06014892|No Intervention|Control|"The control arm will receive:~Current standard in the residency training program."
89237526|NCT06014879|Other|Teen Videos|All participants in the teen video phase of this project will make brief videos about living well with type 1 diabetes. Guidance will be provided about requirements for the videos. Participants may make up to 4 brief videos. The videos will be used in the upcoming clinical trial of the new behavioral intervention.
89237527|NCT06014840|Active Comparator|Early diagnosis and treatment of COPD or Asthma|Treatment strategy using evidence-based guidelines for asthma or COPD provided to participant on the day of randomization
89237528|NCT06014840|Other|Delayed diagnosis and treatment of COPD or Asthma|Treatment strategy using evidence-based guidelines for asthma or COPD provided to participant at 12 weeks.
89237529|NCT06014749||Patient under serratus intercostal plane block|patients who will undergo a modified bilateral ultrasound-guided BRILMA block (SIPB) using a high-frequency linear probe (6-15 Hz) and 80 mm needle.
89237530|NCT06014749||patient under epidural analgesia|patients who undergo Epidural Analgesia prior to General Anesthesia and fentanyl 1 mcg/kg approx according to characteristics and needs and upon arrival at the URPA is connected to the PC Levobupi 0.125% at 6 ml / h + rescue boluses of Levobupi 0.125% 4 ml if needed in the 1st hours.
89237531|NCT06014736|Experimental|XJ101 for Injection|XJ101 via intravenous(IV).
89237532|NCT06014736|Placebo Comparator|Placebo|Placebo via intravenous(IV).
89237533|NCT06014710|Experimental|Experimental arm|Patients with swallowing disorders and healthy volunteers
89237534|NCT06014684|Experimental|AM exercise|HIIT program performed between 07:00-09:00 AM
89237535|NCT06014684|Experimental|PM exercise|HIIT program performed between 15:00-17:00 PM
89237536|NCT06014671|Experimental|Intervention group|intervention group were took interpersonal psychotherapy
89237537|NCT06014671|Experimental|Control group|control group didn't took interpersonal psychotherapy
89237538|NCT06014645|Experimental|Intervention Group|The study group will be given a core stabilization program in addition to the training. This program will include reeducation isometric contraction exercises for transversus obdominus, oblique abdominals, multifidus lumborum muscles and strengthening stretching exercises for other extremities. These interventions will be sent to the patients via telerehabitation method and the patients will always have access to the programs and training. In addition, both groups will be told that they can contact the researcher upon request.
89237539|NCT06014645|Active Comparator|Control Group|The control group will receive post-operative cognitive training and will be encouraged to move as described by Moseley et al., 2004.
89237540|NCT06014632|Experimental|Intervention Group|The study group will be given motor control exercises in addition to the program given to the control group. It will include exercise therapy aimed at improving the motor control of the lumbar spine. These applications will be applied to the patients face-to-face in a clinical setting 2 days a week for 12 weeks. In addition, both groups will be told that they can contact the researcher upon request.
89237541|NCT06014632|Active Comparator|Control Group|The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
89237542|NCT06014619||Mohs Micrographic Surgery|Patients treated with Mohs Micrographic Surgery in the dermatology department of Maastricht University Medical Center +, Maastricht, the Netherlands
89237543|NCT06014619||Slow Mohs|Patients treated with Slow Mohs in the dermatology department of Maastricht University Medical Center +, Maastricht, the Netherlands
89237544|NCT06014606|Placebo Comparator|HV/Placebo|Oral placebo (tablet)
89237545|NCT06014606|Active Comparator|HV/Haloperidol|2mg (oral)
89237546|NCT06014606|Active Comparator|HV/Propranolol|40mg (oral)
89237547|NCT06014528|Experimental|Experimental Arm|IN10018+PLD
89237548|NCT06014528|Placebo Comparator|Control Arm|Placebo of IN10018+PLD
89237549|NCT06014476||Experimental Group|Caregivers of patients with disorders of consciousness, including Coma, Unresponsive Wakefulness Syndrome (UWS), and Minimally Consciousness State (MCS). And caregivers of patients emerge from the minimally conscious state (EMCS)
89237550|NCT06014476||Control group|caregivers of patients with other disease
89237551|NCT06014450|Experimental|PCI arm|"72 stage IV NSCLC patients were randomly enrolled in the group. And all required to have a baseline negative MRI scan for central nervous system (CNS) disease.~For patients with positive TKI detection, TKI combined with concurrent radiotherapy DT60-70Gy for the primary tumor. Imaging reexamination 2 months after TKI treatment confirmed the efficacy of CR, PR, and SD; meanwhile, reexamination of head MR Examination confirmed no intracranial metastasis, and PCI was performed DT 30Gy/10f.~For patients with negative TKI detection, the treatment mode was platinum-based regimen chemotherapy combined with concurrent radiotherapy for DT60-70Gy for the primary tumor. Imaging reexamination after 2 cycles of chemotherapy confirmed the efficacy of CR, PR, and SD, and skull MR Examination confirmed that there was no intracranial metastasis. PCI DT: 30Gy/10f.Systematic imaging examinations in the first month following systemic treatment, every 3 months in 2 years, and every 6 months in 5 years."
89237552|NCT06014450|Placebo Comparator|observation arm|"72 stage IV NSCLC enrolled in the observation group. And all required to have a baseline negative magnetic resonance imaging (MRI) scan for central nervous system (CNS) disease. For patients with positive TKI detection, TKI combined with concurrent radiotherapy DT60-70Gy for the primary tumor.~For patients with negative TKI detection, the treatment mode was platinum-based regimen chemotherapy combined with concurrent radiotherapy for DT60-70Gy for the primary tumor. Imaging reexamination after 2 cycles of chemotherapy confirmed the efficacy of CR, PR, and SD, and skull MR Examination confirmed that there was no intracranial metastasis. then observation. Systematic imaging examinations in the first month following systemic treatment, every 3 months in 2 years, and every 6 months in 5 years."
89237553|NCT06014437|Experimental|PLCL/Fg|Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
89237554|NCT06014437|Active Comparator|control group|Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds.
89237555|NCT06014398|Experimental|Study investigation|All enrolled patients will undergo standardised pituitary hormone assessments.
89237556|NCT06014320||ESLD|All participants recruited will belong to this group. These participants will all have end stage liver disease and be listed for liver transplant with an accepted organ offer.
89237557|NCT06014281|Experimental|Meditation group|"Baseline to week 8:~Subjects will be trained to meditate for 10 minutes daily, and several measures (questionnaires, cognitive tests, and physiological measurements) will be obtained to assess the efficacy of daily meditation practice on mental health and well being. Focused-attention meditation technique will be used to train participants. Specifically the SOS meditation technique will be employed.~Week 8 to week 16:~Subjects will self report if they choose to continue SOS meditation and several measures (questionnaires, cognitive tests, and physiological measurements) will be obtained to assess the impact of continued meditation practice on mental health and well being."
89237558|NCT06014281|Experimental|Waitlist control|"Baseline to week 8:~Subjects will be place in a control group which receives no intervention. However, several measures (questionnaires, cognitive tests, and physiological measurements) will be obtained to assess baseline mental health and well being scores.~Week 8 to week 16:~Subjects will be trained to meditate for 10 minutes daily, and several measures (questionnaires, cognitive tests, and physiological measurements) will be obtained to assess the efficacy of daily meditation practice on mental health and well being. Focused-attention meditation technique will be used to train participants. Specifically the SOS meditation technique will be employed."
89237559|NCT06014216|Experimental|Patients allocated ice lollies to treat post-operative thirst|Ice lollies consisted of a flavoured ice popsicle (blackcurrant) provided through hospital catering. Participants were allocated a single ice popsicle with thirst scores recored pre and post intervention.
89237560|NCT06014216|Other|Patients allocated water as control comparison|Water is a routine treatment for post-operative thirst and therefore used a control to compare our intervention against.
89237562|NCT06014190|Experimental|Cohort 1 at 4.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 1 of phase 2a will be randomly assigned to receive HS-20089 at 4.8 mg/kg or 5.8 mg/kg.
89237563|NCT06014190|Experimental|Cohort 1 at 5.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 1 of phase 2a will be randomly assigned to receive HS-20089 at 4.8 mg/kg or 5.8 mg/kg.
89237564|NCT06014190|Experimental|Cohort 2 at 5.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 2 of phase 2a will receive HS-20089 at 5.8 mg/kg.
89237565|NCT06014190|Experimental|Cohort 3 at 5.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 3 of phase 2a will receive HS-20089 at 5.8 mg/kg.
89237566|NCT06014190|Experimental|Cohort 4 at 5.8 mg/kg of HS-20089 (Phase 2a)|Patients in cohort 4 of phase 2a will receive HS-20089 at 5.8 mg/kg.
89237567|NCT06014190|Experimental|Recommended dose of HS-20089 (Phase 2b)|Patients of phase 2b will receive HS-20089 at recommended dose.
89237568|NCT06014151||The candidate to gamete donation|All candidate to gamete donation at the CECOS centers in France
89237569|NCT06014034|Experimental|Study group|Programmed Weaning From Noninvasive Mechanical Ventilation
89237570|NCT06014034|No Intervention|Control group|this is the traditional withdrawal unit (the attending physician will decide the NIV regimen according to the condition).
89237571|NCT06013956|Experimental|eiDBS suppression|Closed-loop evoked interference DBS that suppresses beta oscillations.
89237572|NCT06013956|No Intervention|Off DBS|Off-stimulation and off-medication
89237573|NCT06013956|Experimental|eiDBS amplification|Closed-loop evoked interference DBS that amplifies beta oscillations.
89237574|NCT06013956|Experimental|Levodopa medication|On-medication, off-stimulation
89237575|NCT06013904|Active Comparator|Usual difficult PIV placement personnel|Patients randomized to this arm will follow the usual protocol for difficult IV placement (ultrasound-trained nurses) in the pediatric ED.
89237576|NCT06013904|Experimental|US-trained PEM Fellows|Patients randomized to this arm will have a trained PEM fellow place the difficult PIV in the pediatric ED.
89237577|NCT06013787|Experimental|Intervention Group|"In the communities randomized into the intervention arm, the pregnant women who enrolled in the study received a month long prenatal health education intervention called Nuestras Historias, a digital story curriculum. This video-based curriculum was delivered by by community health workers during their normal home visits and group visits."
89237578|NCT06013787|No Intervention|Control Group|In the communities randomized to the control arm, the pregnant women who enrolled in study had normal visits and group visits with community health workers and received standard prenatal health education, but with no video intervention.
89237579|NCT06013774|Experimental|Hybrid imaging during the pre-treatment procedure of radioembolization|Hybrid imaging will be performed on patients undergoing the pre-treatment procedure of radioembolization
89237580|NCT06013761|Active Comparator|IF 16:8|12 weeks intermittent fasting according to the 16:8 method (IF 16:8)
89237581|NCT06013761|Experimental|IF MCT 16:8|12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8)
89237582|NCT06013735|Active Comparator|sodium fluoride solution|children will rinse with sodium fluoride solution mouth rinse (0.2%).
89237583|NCT06013735|Active Comparator|guava leaves|children will rinse with guava leaves aqueous extract mouth rinse (0.5%).
89237584|NCT06013735|Active Comparator|pomegranate peel|children will rinse with pomegranate peel aqueous extract mouth rinse (0.5%).
89237585|NCT06013735|Placebo Comparator|Control|children will rinse with distilled water
89237586|NCT06013696|Active Comparator|Pediatric UC subjects treated with 5ASA compunds|Each subject will provide a fresh urine sample in an empty sterile plastic cup. Urinalysis will be performed to check for macro- or micro-hematuria or signs of infection. We will take 10mL of the urine sample and add 1mL of transparent (colorless) household bleach (≤5% sodium hypochlorite). The color of the urine before and 5 minutes after adding the bleach will be recorded.
89237587|NCT06013696|Placebo Comparator|Pediatric UC subjects not treated with 5ASA compunds (any other treatments is allowed)|Each subject will provide a fresh urine sample in an empty sterile plastic cup. Urinalysis will be performed to check for macro- or micro-hematuria or signs of infection. We will take 10mL of the urine sample and add 1mL of transparent (colorless) household bleach (≤5% sodium hypochlorite). The color of the urine before and 5 minutes after adding the bleach will be recorded.
89237588|NCT06013670|Experimental|Endoscopy+NSBBs treatment group|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure>90mmHg and heart rate>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
89237589|NCT06013670|Experimental|TIPS treatment group|Patients receives TIPS for the prevention of variceal bleeding
89237590|NCT06013657||Liver resection|Patients undergoing liver resection due to hepatocellular carcinoma from 2010 to 2021 in RSCM, Jakarta, an academic tertiary-level national referral hospital in Indonesia.
89237591|NCT06013644|Active Comparator|Acupuncture needle (study group A)|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
89237592|NCT06013644|Active Comparator|Dry needle (study group B)|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
89237593|NCT06013644|Active Comparator|Botox injection (study group C)|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
89237594|NCT06013631|Experimental|Phantom Exercises|"The phantom exercises involved visualizing and then trying to perform the movements of the phantom limb.~Place the limb at the angle at which they were sensing their phantom limb.~Put their healthy limb in the identical spot as they perceived their phantom limb.~Move their two limbs in opposition to one another.~Go back to where they started. The movements included ankle inversion and eversion, flexion and extension, and adduction and abduction with toe flexion and extension, respectively.~Once the patient is at ease, movements like hip or knee flexion/extension are performed until the PLP is gone.~Phantom exercises will be performed as many times as possible in a single session up to 15 times until the PLP fully subsided."
89237595|NCT06013631|Active Comparator|Prosthesis Training|Training for prostheses at the appropriate amputation level will be provided. Conventional gait training protocols include Tandem walk, within parallel bar, controlled environment, full length Mirror on one side, weight shifting, shifting onto the Prosthetic Side, Pelvic rotation, Stepping on multiple heights and positions, Tandem walk, within parallel bar, and weight shifting. Gait training will last six weeks in total.
89237596|NCT06013605|Experimental|Intervention Group|Participants did walking exercise and usual care (leg straightening)
89237597|NCT06013605|Experimental|Control Group|Participants did usual care (leg straightening)
89237598|NCT06013566||Baseline|This cohort contains individuals tested at baseline, usually in the pre-season of their sporting season
89237599|NCT06013566||Concussed|This cohort contains individuals who have had a concussion, diagnosed by a doctor.
89237600|NCT06013566||Suspected Concussion|This cohort contains individuals suspected of having a concussion, but were cleared by a medical professional and do not have a concussion.
89237601|NCT06013553|Active Comparator|control group|Standard physiotherapy (1st Group): It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
89237602|NCT06013553|Experimental|Experimental: Aerobic Exercises group|Aerobic exercise will be given with bicycle ergometer in addition to Standard physiotherapy (It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises)
89237603|NCT06013540|Experimental|Group A TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|
89237604|NCT06013540|Experimental|Group B Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|
89237605|NCT06013527|Experimental|Physical Therapy Intervention|The intervention group will receive a structured exercise program which will run for 2 months and a follow-up will be done after 3 months.
89237606|NCT06013527|No Intervention|Control Group|This group will continue with their routine life and will receive standard care given by the hospital.
89237607|NCT06013514||Smooth Silicone Breast Implant|
89237608|NCT06013488|Experimental|Intervention Arm|Participants (health workers) allocated to this arm continue to receive the traditional weekly supervision delivered by their supervisor, assigned by the health system, in a face-to-face mode in groups of 1:20 (1 supervisor for a group of ~20 health workers). In addition, participants receive a 5-day residential coaching workshop involving character-strengths based strategies to reduce work-stress, followed by supplemental 8- to 10-week remote telephonic coaching support, after the workshop when they resume work (and experience stressors). The weekly coaching support calls typically last for 30-45 minutes and are delivered by an assigned intervention coach (by the study team) to the health worker (1:1).
89237609|NCT06013488|Active Comparator|Control Arm|Participants (health workers) allocated to this arm receive the traditional weekly supervision delivered by their supervisor, assigned by the health system, in a face-to-face mode in groups of 1:20 (1 supervisor for a group of ~20 health workers).
89237610|NCT06013436||Experimental group|Autologous serum tears, twelve times daily（per hour）, 12weeks. 0.05% cyclosporin eye drop, twice times daily, 12weeks.
89237611|NCT06013410|Experimental|IBS group|patients diagnosed with IBS according to clinical presentations
89237612|NCT06013410|No Intervention|Healthy control group|healthy control group
89237613|NCT06013397|Experimental|self pre-and post-control|It is a self pre- and post-control, which compares the outcomes of the ketogenic diet with the status that did not receive ketogenic treatment
89237614|NCT06013371|Experimental|PF-07038124|PF-07038124 0.02% ointment once daily for 8 weeks
89237615|NCT06013371|Placebo Comparator|Placebo|Placebo Ointment
89237616|NCT06013332|Experimental|Group 1|right face will be injected with PBF PLLA microsphere, and left face with Sculptra®
89237617|NCT06013332|Experimental|Group 2|right face will be injected with Sculptra® and left face with PBF PLLA microsphere
89237618|NCT06013293|Experimental|Zinc oxide eugenol based sealer|Root canal treatment will be performed in posterior teeth.In this group the root canal will be dried with paper points and obturated with using gutta-percha cones and zinc oxide eugenol sealer. Coronal access cavities will be restored with direct composite restorations using dentinal adhesives and universal composite resin . Postoperative VAS scores will be recorded after 24 h and 48 h to determine their post-operative pain.
89237619|NCT06013293|Active Comparator|Resin based sealer|Root canal treatment will be performed in posterior teeth.In this group the root canal will be dried with paper points and obturated with using gutta-percha cones and resin based sealer. Coronal access cavities will be restored with direct composite restorations using dentinal adhesives and universal composite resin . Postoperative VAS scores will be recorded after 24 h and 48 h to determine their post-operative pain.
89237620|NCT06013215|Experimental|Cochlear implant users with Neuro Zti array|Post-lingually cochlear implant users with 12 months of auditory experience Modifications of pulse parameters to determine the charge integration efficiency which is related with neuron survival population
89237621|NCT06013189||Group 1|Sweep Gas Flow did not changed (1.35 L/m2/min)
89237622|NCT06013189||Group 2|Sweep Gas Flow decreased during rewarming (1.2 L/m2/min)
89237623|NCT06013189||Group 3|Sweep Gas Flow decreased during rewarming (1 L/m2/min)
89237624|NCT06013150|Experimental|Epinephrine|"Dosage Level:~Part 1 of the study: Participants across cohort 1 to 3 will receive a single dose of either 1mg or 1.3mg or 1.5mg respectively of epinephrine or placebo via DMC-IHI device.~Part 2 of the study: This is an open label where participants will receive multiple doses of inhaled epinephrine via DMC-IHI across 5 cohorts the highest tolerated dose based on safety, PK, PD data from Part 1 of the study on.~Dosage form: Single-use capsule based dry powder inhaler or EpiPen® IM~Route of administraion: Inhalation (Part 1 and Part 2) and Intramuscular (Part 2)"
89237625|NCT06013150|Placebo Comparator|Placebo|"Drug: Placebo~Participants will receive matching placebo across the Part 1 of the study."
89237626|NCT06013098|Experimental|Experimental: 30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 minuets. After successful anesthesia induction, FiO2 will be adjusted to 60% in one lung ventilation and 30% FIO2 in both lungs ventilation, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cm H2O, RR: 1:2. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected for blood gas analysis. Patients in both groups will be extubation the operating room and then sent to the PACU. patients should transfer to 60% Oxygen group if intraoperative oxygen saturation less than 85%.
89237627|NCT06013098|Placebo Comparator|Experimental: 60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 minutes. After successful anesthesia induction, FiO2 will be adjusted to 100% in one lung ventilation and 60% FIO2 in both lungs ventilation, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cm H2O, RR: 1:2. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected for blood gas analysis. Patients in both groups will be extubation the operating room and then sent to the PACU.
89237628|NCT06013085|Experimental|cognitive behavioral therapy|6 weeks cognitive-behavioral therapy for insomnia
89237629|NCT06013085|No Intervention|treat as usual|provide usual care
89237630|NCT06013046|Active Comparator|Intensity-controlled physical activity training (IPAT)|A group provided education on physical activity recommendations for people with disabilities, access to a community-based accessible gym, and an intensity-controlled 14-week one-on-one supervised physical activity training intervention.
89237631|NCT06013046|Placebo Comparator|Education and Access (EA)|A group provided education on physical activity recommendations for people with disabilities and access to a community-based accessible gym in order to independently complete a 14-week physical activity program.
89237632|NCT06013007|Experimental|JINS approach|The JINS approach is described as inflating a stent balloon with nominal-pressure without decay for at least 30 seconds.
89237633|NCT06012994||GAS|
89237634|NCT06012994||Control|
89237635|NCT06012968||GAS|
89237636|NCT06012968||Control|
89237637|NCT06012955||TCI group|patients receiving general anesthesia using target-controlled infusion delivery system
89237638|NCT06012955||MCI group|patients receiving general anesthesia using conventional manual controlled infusion delivery
89237639|NCT06012903||Parents|
89237640|NCT06012903||Children|
89237641|NCT06012903||Teachers|
89237642|NCT06012890||Automatic acquisition|Clinical MRI planning performed automatically by an AI-based software
89237643|NCT06012890||Manual Acquisition|Clinical MRI planning performed manually by a specialized radiology technician
89237644|NCT06012877|Experimental|Intervention Group|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
89237645|NCT06012877|No Intervention|Control group|Participants in this group continued with normal activities at school and at home, just like the intervention group, so that the only difference between the two groups was taking part in the intervention. Once the post-study data had been collected from all participants, the participant in the control group also took part in the intervention, a few days later.
89237646|NCT06012864|Experimental|modified supine PNL|patients doing FFMS PNL
89237647|NCT06012864|Experimental|prone PNL|patients doing prone PNL
89237648|NCT06012838|Experimental|cause classification of OHCA protocol|The cause classification of OHCA protocol was developed by an expert cardiac arrest committee. A lecture concerning the Utstein's template, the epidemiology of cardiac arrest and the CCCA protocol was addressed to the participants.
89237649|NCT06009172|Experimental|APA group|
88804663|NCT02112864|Placebo Comparator|normal saline|Patients in this group will receive 2.5 mL of normal saline intravenously, pre-incision
88804664|NCT01981837|Experimental|ALN-TTRSC (revusiran)|
89237650|NCT06009172|No Intervention|Control group|
89237651|NCT06009133||Conservative Treatment Group|"Micronized purified flavonoid fraction, which is routinely used within indications in hemorrhoidal disease and recommended in ESCP and ASCRS guidelines, and licensed for use in hemorrhoidal disease by the Ministry of Health in our country, was given 2 g/day for one month.~Also, Conservative methods (fiber foods, warm shower, regulation of toilet habits, laxatives and nonsteroidal anti-inflammatory drugs) were recommended."
89237652|NCT06009133||Surgical Treatment Group|While the patient was in the Jack-knife position, both hips were pulled laterally with tapes, appropriate visualization was obtained, the external thrombosed pack was excised under local anesthesia, and the wound was left to heal with secondary intention.Conservative methods were recommended in the surgical group as well as in the medical group.
89237653|NCT06008210|Experimental|Intervention Group|Decision Support Intervention
89237654|NCT06008210|Active Comparator|Control Group|Health coaching
89237655|NCT06007612|Experimental|Behavioral: Context Sensitivity in Emotion Regulation|
89237656|NCT05997316|Experimental|Time restricted eating|Participants will engage in a 12-week time restricted fasting intervention. Each week, participants will work with a clinical psychologist to modify the timing of their eating behaviors to adhere to a 16-hour fast, 2-3 days per week.
89237657|NCT05997004|Placebo Comparator|Control|31 participants received 1ml of Normal Saline
89237658|NCT05997004|Experimental|Glyco|31 participants received 1ml (0.2mg) of Glycopyrrolate
89237659|NCT05995301|Experimental|Group I|Transversus Abdominis Plane block
89237660|NCT05995301|Experimental|Group II|Local infiltration
88804665|NCT01897558|Active Comparator|Ventricular pacemaker electrode|receives an active fixation ventricular pacemaker electrode
89237661|NCT05993832|Experimental|Referential cues to object|Each object pair that is presented to the child is accompanied by 1) gaze only (3 trials); 2) novel label only (3 trials); or 3) conflicting gaze and novel label (3 trials)
89237662|NCT05876299|Active Comparator|Low-Fat Pork|This condition will consist of consuming 90.2 g of low-fat (4.90% crude fat) ground pork.
89237663|NCT05876299|Experimental|High-Fat Pork|This condition will consist of consuming 109.6 g of high-fat (18.84% crude fat) ground pork.
89237664|NCT05876299|Placebo Comparator|Carbohydrate Control|This condition will consist of a carbohydrate beverage.
89237665|NCT05868044|Experimental|PRIMUS|PRIMUS PNS System
89237666|NCT05858632|Experimental|Guselkumab treatment|Guselkumab treatment for ~ 9 months
89237667|NCT05843890|Experimental|Structured and tailored PainGuide|
89237668|NCT05843890|Active Comparator|Standard PainGuide|
89237669|NCT05814783|Experimental|Integrated digital CBTI|Therapists will be trained to integrate digital CBTI alongside routine psychotherapy. Patients will receive integrated digital CBTI
89237670|NCT05786794|Experimental|Rural Clinic Hearing Healthcare Patient Navigation Program|This arm will involve pilot testing of the Patient Navigation Program with adults in rural primary care clinics
89237671|NCT05785637||Initiation a non-invasive ventilation at night|Neuromuscular patients with chronic respiratory failure who initiate a non-invasive ventilation at night.
89237672|NCT05785546||development cohort|Neuromuscular diseases
89237673|NCT05785546||validation cohort|Neuromuscular diseases
89237674|NCT05783388||HIV-1 positive persons|
89237675|NCT05774600|Experimental|SSW Works|SSW Works, is a virtual learning environment (VLE) for automated, comprehensive, on-demand, tailored distribution of the SSW program to private and public employers with outdoor workers. It will be delivered in both English and Spanish to managers and employees who work outdoors to reduce risk for skin cancer.
89237676|NCT05774600|Active Comparator|Minimal Information Control|Workplaces randomized to the control condition will receive a set of printed materials on occupational sun safety (1 mailing per year) as an attention control. These will include posters on personal protection and skin cancer incidence, risk assessment brochure, American Academy of Dermatology SPOT bookmark showing the ABCDEs of melanoma and skin self-examination, and a sun safety tip card from OSHA.
89237677|NCT05759442|Active Comparator|Metformin|Tablet Metformin HCl 500 mg per oral twice daily for 12 weeks
89237678|NCT05759442|Active Comparator|Apple cider vinegar|Apple Cider Vinegar 15ml per day diluted in 200 ml of water for 12 weeks
89237679|NCT05728346|Experimental|single-arm|
89237680|NCT05728138|Experimental|CMAP Plus FEP|Participants with First episode of psychosis, Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT)
89237681|NCT05728138|No Intervention|treatment as usual|Participants in this group will continue their routine treatment as prescribed by their responsible clinician. In Pakistan TAU mostly comprise of antipsychotics with few patients having access to psychological therapies. Research staff will record the nature and intensity of the TAU for each participant
89237682|NCT05720832|Experimental|Prostate Cancer Patients and their Supporters|"The WINGS smartphone application is being tested on prostate cancer patients for the first time in this pilot study. It provides easy access to prostate cancer-related information and simplifies networking with supporters, such as family and friends. The WINGS smartphone application can be easily downloaded to a personal smartphone via Google Play or the App Store and can be used at any time from home or on the go.~In addition, the WINGS smartphone application also provides supporters, such as family members and friends of prostate cancer patients with easy access to prostate cancer-related information. Moreover, it helps them to support prostate cancer patients by facilitating joint activities, tailored to the needs of the patient."
89237683|NCT05701670|Experimental|Intervention|"The Purrble intervention takes the form of an interactive plush toy, designed to be handed over to the student and support in-the-moment soothing -- see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)~The Single Session Intervention has been co-produced with university students and clinical experts (Prof Jessica Schleider and Prof James Gross), combining the theories of emotion regulation with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~Initial guided reflection exercise~Short interactive psychoeducation~Personalised action plan~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
89237684|NCT05701670|No Intervention|Control|Wait-list control (access to services as usual)
89237685|NCT05694052|Experimental|Multifaceted Intervention|"Lighting: a multi-channel LED Spectrum will be implemented. The spectral output covers the wavelength range from 420 nm to 730 nm. All active channels are mixed, providing a smooth (uniform in color) light with a Lambertian pattern profile.~Noise: the auditory masking system will provide a continuous background digitally generated broadband pink noise. The sound system will be placed near the head of the bed. This will be started (at 62 DB sound level) each night for 8 hours.~Nocturnal patient care activities: night-time patient care activities will be re-organized to minimize interruptions. The medication administration schedule will be organized, and the vital signs monitoring will be done continuously by medical devices without requiring to disturb the patient. Hygiene, comfort, and elective activities will be scheduled for the daytime. Emergency interventions will not be limited."
89237686|NCT05694052|No Intervention|Standard Care|"Lighting: standard lighting system currently installed in the ICU rooms provides a fix light of 300 to 400 lux during daytime, and 0 to 30 lux during night-time. Controls depends on staff to switched on and off.~Noise: The rooms do not have noise isolation and there is no protocol for reducing environmental noise. In our ICU, isolated measurements reported mean average values of 60 dB during daytime and 50 dB during nighttime, with frequent peaks over 80 to 90 dB.~Nocturnal patient care activities: There is no specific protocol for patient care activities during the night. The activities (schedules of drug administration and intravenous infusions, non-urgent examinations, and non-urgent procedures) are organized during the morning by the patient's nurse according to their own clinical criteria. Hygiene and comfort activities are carried out in standard schedules according to the rules of the ICU. Drug administration, examinations and urgent procedures are performed when necessary."
89237687|NCT05681936||Cross-sectional study: healthy controls|
89237688|NCT05681936||Cross-sectional study: chronic traumatic SCI patients|
89237689|NCT05681936||Cross-sectional study: non-traumatic SCI patients with degenerative spondylotic myelopathy|
89237690|NCT05681936||Longitudinal study: healthy controls|
89237691|NCT05681936||Longitudinal study: acute traumatic SCI patients (< 2 months after SCI)|
89237692|NCT05681936||Longitudinal study: patients with neurogenic lower urinary tract dysfunction|
89237693|NCT05661721|Other|"Intervention first, control after (Sweet then salty)"|"This arm will be divided into the following periods:~Run-in period: 7 days without any licorice intake Intervention period: 14 days with sweet licorice intake First wash-out period: 14 days without any licorice intake Control period: 14 days with salty licorice intake Second wash-out period: 14 days without any licorice intake."
89237694|NCT05661721|Other|"Control first, intervention after (Salty then sweet)"|"This arm will be divided into the following periods:~Run-in period: 7 days without any licorice intake Control period: 14 days with salty licorice intake First wash-out period: 14 days without any licorice intake Intervention period: 14 days with sweet licorice intake Second wash-out period: 14 days without any licorice intake."
89237695|NCT05654597||Participants aged 40 or more, without diagnosis of COPD or asthma|Men and women attending aged 40 or more, without previous diagnosis of chronic obstructive pulmonary disease or asthma.
89237696|NCT05639088|Experimental|Group A: SHIFT2|"Adolescents and young adults will engage in routine medical visits and attend 6 sessions (1x/month) focused on transition preparation and diabetes management with a transition coach and will receive bi-weekly messages during these 6-months that encourage self-management behaviors.~Parents will attend 2 sessions (month 1 and 6) with a transition coach and will receive materials, complementing their child's lesson, 1x/month for months 2-5 that focus on transition their role and supporting their child's diabetes management."
89237697|NCT05639088|Placebo Comparator|Group B: TAU+/Control|Participants will engage in routine medical visits and will receive education materials monthly (1x/month) regarding healthcare transition and diabetes management.
89237698|NCT05632497||Anorexia patients|Hospitalized anorexia patients with body mass index < 15.
89237699|NCT05632497||Healthy controls|Health volunteers: 18 years or older with body mass index between 18.5 and 25.
89237700|NCT05631886|Experimental|TP53-EphA-2-CAR-DC plus anti-PD-1 antibody/anti-CTLA4 antibody|"In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and TP53-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.~In the boost phase, TP53-EphA-2-CAR-DC vaccine is infused one dose every 8 weeks since Week 5.~Anti-PD-1 antibody and anti-CTLA4 antibody are administered 2 days after the first dose of TP53-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 3 weeks afterwards for four doses, followed by anti-PD-1 antibody once every 3 weeks, until:~1. Unacceptable toxicity occurred or disease progression; or 2. Reactive T cells are undetected repeatedly after the last vaccine dose; or 3. Vaccine exhaustion."
89237701|NCT05601752|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
89237702|NCT05601752|Experimental|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|
89237703|NCT05600621|Experimental|Condition 1: Components 1, 2,3 and 4|"Participants will be assigned to receive all of the four intervention programs:~Financial Literacy Training (FLT) Workshops~Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
89237704|NCT05600621|Experimental|Condition 2: Components 1, 2 and 3|"Financial Literacy Training (FLT) Workshops~Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
89237705|NCT05600621|Experimental|Condition 3: Components 1, 2 and 4|"Financial Literacy Training (FLT) Workshops~Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
89237706|NCT05600621|Experimental|Condition 4: Components 1 and 2|"Financial Literacy Training (FLT) Workshops~Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)"
89237707|NCT05600621|Experimental|Condition 5: Components 1,3 and 4|"1.Financial Literacy Training (FLT) Workshops~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
89237708|NCT05600621|Experimental|Condition 6: Components 1 and 3|"1.Financial Literacy Training (FLT) Workshops~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
89237709|NCT05600621|Experimental|Condition 7: Components 1 and 4|"1.Financial Literacy Training (FLT) Workshops~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
89237710|NCT05600621|Experimental|Condition 8: Components 1|1.Financial Literacy Training (FLT) Workshops
89237711|NCT05600621|Experimental|Condition 9: Components 2,3 and 4|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
89237712|NCT05600621|Experimental|Condition 10: Components 2 and 3|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)"
89237713|NCT05600621|Experimental|Condition 11: Components 2 and 4|"2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
89237714|NCT05600621|Experimental|Condition 12: Components 2|2.Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)
89237715|NCT05600621|Experimental|Condition 13: Components 3 and 4|"3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)~4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV."
89237716|NCT05600621|Experimental|Condition 14: Components 3|3.A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon)
89237717|NCT05600621|Experimental|Condition 15: Components 4|4.Engagement with HIV treatment-experienced role models who share lived experiences of HIV.
89237718|NCT05600621|Experimental|Condition 16: No Components|Participants not assigned to any of the 4 components
89237719|NCT05576454|Experimental|BAT2606 Injection|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
89237720|NCT05576454|Active Comparator|Mepolizumab Injection (EU-licensed Nucala®)|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
89237721|NCT05576454|Active Comparator|Mepolizumab Injection (US-licensed Nucala®)|PFS, Strength: 100 mg/1 mL, 100 mg, Subcutaneous injection.
89237722|NCT05565794|Experimental|Pemigatinib|Intake of 13.5 mg pemigatinib once daily per oral
89237723|NCT05557747|Experimental|Group A:cervicothoracic junction mobilization|Group A: patients will receive cervicothoracic junction mobilization and conventional physical therapy program for 3 sessions/week over 4 weeks periods
89237724|NCT05557747|Experimental|Group B:autogenic muscle Energy Technique|Group B: will receive autogenic muscle Energy Technique and conventional physical therapy program for 3 sessions/week over 4 weeks periods.
89237725|NCT05557747|Active Comparator|Group C:conventional physical therapy|Group C: will receive conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods.
89237726|NCT05528835||Group A|Women with history of previous one Caesarean section
89237727|NCT05528835||Group B|Women with history of previous normal vaginal delivery.
89237728|NCT05521399||Aim#1 Development|Developing dedicated multiparametric cardiac MRI protocols that account for a wide range of body sizes and patient physiology (e.g., heart rates, breathing patterns) of heart transplant recipients, is critical for the wide age range in HTx from pediatric to adult. Second, to facilitate clinical translation and multi-site portability of the often time-consuming data analysis. Methodology, to be employed and developed artificial intelligence (AI) deep learning concepts to enable automated cardiac MRI analysis across large cohorts. The hypothesis to be tested is that automated AI analysis can detect altered cardiac MRI metrics with improved efficiency and reduced inter-rater variability
89237729|NCT05521399||Aim#2 Cardiac MRI in Pediatric HTx & Donor-Recipient Mismatch|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children. The anticipated enrollment of n=80 (20 per year) pediatric HTx patients (<21 years) in years 2-5 at Lurie Children's Hospital. Inclusion criteria include a clinically indicated routine cardiac MRI for HTx graft surveillance. The hypothesis to be tested is that cardiac MRI measures can inform pediatric donor selection by providing important new data on the impact of donor-recipient mismatch (e.g. age, sex, heart size, etc.) on changes in tissue and function of the transplanted heart.
89237730|NCT05521399||Aim#3 Longitudinal patient outcome study|"The study will research the diagnostic value of cardiac MRI to improve the monitoring of heart transplant recipients for the major complications of acute cardiac rejection (ACR) and cardiac allograft vasculopathy (CAV). The anticipated follow-up enrollment of a total of 80 HTx patients during years 2-5 with a minimum of 5-year follow-up (20 HTx patients/year returning for HTx surveillance, baseline MRI scan was performed during the initial funding period. To clarify, our aim isn't to perfectly match donor-recipient but rather to study the clinical implications of mismatch and to help define the threshold for too much mismatch. In other words, today human beings sometimes don't accept a heart if the mismatch will be too great, this is sometimes hard to do and literature is scarce, especially in terms of functional rather than anatomic implications. Our goal is that this study could better inform these decisions."
89237731|NCT05501847|No Intervention|Patient with ventricular hypertrophy|Screening for cardiac amyloidosis in a patient with heart failure and ventricular hypertrophy is performed as part of routine care according to a standardised care protocol that follows the Gullimor algorithm.
89237732|NCT05501847|Experimental|Patient with no ventricular hypertrophy|"In the context of TEAM-HF research, the heart failure patient without ventricular hypertrophy will undergo a bone scan.~If the diagnosis of amyloidosis is most often suspected on the electrocardiogram and cardiac echography, only cardiac MRI or bone scan with diphosphonates (for transthyretin amyloidosis) can make the diagnosis."
89237733|NCT05463237||Pregnant women with gestational diabetes(n:87)|Visceral adipokine level will be examined in pregnant women with gestational diabetes.
89237734|NCT05463237||Control group pregnant (n:87)|Visceral adipokine level will be examined in pregnant women with normal pregnant .
89237735|NCT05454267||Healthy Volunteer Group|Participants who have never smoked or vaped
89237736|NCT05454267||High Frequency Vaping Group|Participants who vape >20 days per month.
89237737|NCT05454267||Low-Frequency Vaping Group|Participants who vape < 20 days per month
89237738|NCT05453864|Experimental|CMAP Plus TFCBT|This intervention is a manual-assisted intervention, which will include two existing culturally adapted psychological interventions 1) Culturally Adapted Manual Assisted Psychological (CMAP), 2) Self-help manual for trauma - BASID Ki Kahani. Both interventions are based on the principles of Cognitive behavioural therapy (CBT).
89237739|NCT05453864|No Intervention|Treatment As Usual (TAU)|This will be already receiving local medical, psychiatric and primary care services providing standard routine care to the participants.
89237740|NCT05447546|Active Comparator|1 mg HT-6184 QD|Cohort 1 - 6 subjects x 1 mg HT-6184 QD on Day 1
89237741|NCT05447546|Placebo Comparator|1 mg Placebo QD|Cohort 1 - 2 subjects x placebo, QD on Day 1
89237742|NCT05447546|Active Comparator|2 mg HT-6184 QD|Cohort 2 - 6 subjects x 2 mg HT-6184 QD on Day 1
89237743|NCT05447546|Placebo Comparator|2 mg Placebo QD|Cohort 2 - 2 subjects x placebo, QD on Day 1
89237744|NCT05447546|Active Comparator|3 mg HT-6184 QD|Cohort 3 - 6 subjects x 3 mg HT-6184 QD on Day 1
89237745|NCT05447546|Placebo Comparator|3 mg Placebo QD|Cohort 3 - 2 subjects x placebo, QD on Day 1
89237746|NCT05447546|Active Comparator|4 mg HT-6184 QD|Cohort 4 - 6 subjects x 4 mg HT-6184 QD on Day 1
89237747|NCT05447546|Placebo Comparator|4 mg Placebo QD|Cohort 4 - 2 subjects x placebo, QD on Day 1
89237748|NCT05447546|Active Comparator|1 mg HT-6184 QD x 2 weeks|Cohort 5 - 6 subjects x 1 mg HT-6184 QD on Day 1-5, 8-12
89237749|NCT05447546|Placebo Comparator|1 mg Placebo QD x 2 weeks|Cohort 5 - 2 subjects x 1 mg placebo, QD on Day 1-5, 8-12
89237750|NCT05447546|Active Comparator|2 mg HT-6184 QD x 2 weeks|Cohort 6 - 6 subjects x 2 mg HT-6184 QD on Day 1-5, 8-12
89237751|NCT05447546|Placebo Comparator|2 mg Placebo QD x 2 weeks|Cohort 6 - 2 subjects x 2 mg placebo, QD on Day 1-5, 8-12
89237752|NCT05447546|Active Comparator|3 mg HT-6184 QD x 2 weeks|Cohort 7 - 6 subjects x 3 mg HT-6184 QD on Day 1-5, 8-12
89237753|NCT05447546|Placebo Comparator|3 mg Placebo QD x 2 weeks|Cohort 7 - 2 subjects x 3 mg placebo, QD on Day 1-5, 8-12
89237754|NCT05447546|Active Comparator|4 mg HT-6184 QD x 2 weeks|Cohort 8 - 6 subjects x 4 mg HT-6184 QD on Day 1-5, 8-12
89237755|NCT05447546|Placebo Comparator|4 mg Placebo QD x 2 weeks|Cohort 8 - 2 subjects x 4 mg placebo, QD on Day 1-5, 8-12
89237756|NCT05431374|Experimental|Measurement Based Care MBC|patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient.
89237757|NCT05431374|Active Comparator|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
89237758|NCT05415683||Diabetic Foot Ulcer (DFU) Group|Patients with DFUs undergoing 30 day standard wound care (SWC) therapy as part of their standard of care
89237759|NCT05411029||Healthy Somali Americans|Somali Americans with no known history of hypertension, diabetes, or sleep disorders will have a 24 hour blood pressure monitoring and polysomnography.
89237760|NCT05407194|Experimental|Supplement + progressive tendon loading therapy|The intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C, in comparison to a placebo supplement consisting of maltodextrin. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.
89237761|NCT05407194|Placebo Comparator|Placebo + progressive tendon loading therapy|The placebo consists of maltodextrin. In comparison the intervention consists of a nutritional supplement with 10g hydrolysed collagen and 40 mg vitamin C. All participants in both groups will receive education, load management advices and a criteria-based PTLE consisting of 4 stages within the limits of pain during 24-weeks. This (training) intervention has recently been proven to be superior to eccentric training. Participants will be randomly assigned to receive either the nutritional supplement collagen/vitamin C (intervention) or a placebo supplement.
89237762|NCT05405374|Active Comparator|OSTEOAMP|OSTEOAMP SELECT Fibers as an autograft substitute in lumbar interbody fusion procedures
89237763|NCT05405374|Active Comparator|Infuse|The Infuse Bone Graft as an autograft substitute in lumbar interbody fusion procedures
89237764|NCT05400564|Experimental|FCU Online + Coach|Parents in this arm will receive access to the FCU app and telehealth coaching/ support provided by a trained mental health provider. The FCU app includes a brief 5-minute assessment, feedback on parents' responses, and online tools to support parenting in areas that were identified as challenges by the assessment. These tools include videos, animated videos, parenting tips, and interactives to help practice parenting skills. Telehealth coaching sessions will focus on Healthy Behaviors, Positive Parenting, Rules and Consequences, School Support, and Communication.
89237765|NCT05400564|No Intervention|Control|Parents in this arm will receive school support as usual.
89237766|NCT05396443|Experimental|Intervention|Adolescent participants receive 12 week telehealth lifestyle program consisting of a Wellness session, Cooking Experience, and Dance Classes. Caregiver participants are encouraged to participate in the program.
89237767|NCT05396443|Experimental|Intervention-Caregiver|Caregiver of adolescents randomized to the Intervention group are encouraged to participate in the program.
89237768|NCT05363020|Experimental|S-Adenosyl-L-Methionine (SAMe)|Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
89237769|NCT05363020|Placebo Comparator|Placebo|Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
89237770|NCT05346796|No Intervention|Control|Group that will receive written survivorship care information.
89237771|NCT05346796|Experimental|Intervention|Group that will be provided access to the survivorship care plan-personal health record tool.
89237772|NCT05332600|Experimental|pre and post fatigue assessment|assessment pre and post fatigue protocol
89237773|NCT05327543|Experimental|Iyengar yoga|Intervention group 1 receives an Iyengar yoga intervention in a group setting, based on the internationally renowned yoga school of B.K.S. Iyengar, which in the context of this study primarily includes physical and relaxation exercises.
89237774|NCT05327543|Experimental|Meditative yoga|Intervention group 2 receives an Integrative yoga intervention including physical and meditation exercises as well as ideologically neutral explanations of the ethical aspects of Yoga.
89237775|NCT05327543|No Intervention|Waitlist Control Group|Group 3 consists of a waitlist control group. Participants will be offered the opportunity to attend a yoga intervention after 4 months. The patients in this waiting list control group are allowed to choose the yoga course after 4 months.
89237776|NCT05306912|Experimental|blood sampling|blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma
89237777|NCT05298878|Experimental|Virtual home-based rehabilitation plus usual outpatient care|An 8-week home-based virtual rehabilitation program consisting of exercises and education plus usual care.
89237778|NCT05298878|No Intervention|Usual outpatient care|The control group will receive usual outpatient care which consists of any medical outpatient follow-up visits. The participants will receive a set of written generic instructions on how to manage symptoms and engage in physical activity after critical illness.
89237779|NCT05262855|Experimental|68Ga-FAPI-46 PET/CT|Patients receive [68Ga]FAPI-46 intravenously followed by PET/CT 15-25 minutes later
89237780|NCT05238324|Experimental|HMI-203 Low Dose Level Cohort 1|
89237781|NCT05238324|Experimental|HMI-203 Intermediate Dose Level Cohort 2|
89237782|NCT05238324|Experimental|HMI-203 High Dose Level Cohort 3|
89237783|NCT05233228|Experimental|Automated Treatment|Consists of all SC components plus a fully automated smartphone-based treatment program that involves interactive and personalized proactive messages, images, or videos.
89237784|NCT05233228|Active Comparator|Standard Care|Consists of brief advice to quit smoking delivered by research staff, self-help written materials, and a 2-week supply of nicotine replacement therapy (transdermal patches).
89237785|NCT05220371|Experimental|Collagen|15g of collagen peptides ingested daily
89237786|NCT05220371|Placebo Comparator|Placebo|15g of Placebo ingested daily
89237787|NCT05209438|Active Comparator|Cereset Research|This will be the active intervention arm using 6 Cereset (CR) sessions and participants will continue current care.
89237788|NCT05209438|Sham Comparator|Control|Participants will have 6 CR sessions of sham control tones and also continue their current care.
89237789|NCT05193916|Experimental|Chiglitazar low dose|3 tablets of drug and 1 tablet of placebo p.o. per day
89237790|NCT05193916|Experimental|Chiglitazar high dose|4 tablets p.o. per day
89237791|NCT05193916|Placebo Comparator|control group|4 placebo tablets p.o. per day
89237792|NCT05136053|Experimental|Part A: Lu AG22515|Participants will receive a single intravenous (IV) infusion of Lu AG22515.
88804666|NCT01897558|Active Comparator|Passive fixation ventricular pacemaker electrode|receives a passive fixation ventricular pacemaker electrode
89237793|NCT05136053|Placebo Comparator|Part A: Placebo|Participants will receive a single IV infusion of placebo matching to Lu AG22515.
89237794|NCT05136053|Experimental|Part B: Lu AG22515 and Immune System Activator|Participants will receive a single IV infusion of Lu AG22515 and a subcutaneous (SC) injection of immune system activator 14 days prior to and 14 days following the start of Lu AG22515 IV infusion.
89237795|NCT05136053|Placebo Comparator|Part B: Placebo and Immune System Activator|Participants will receive a single IV infusion of placebo matching to Lu AG22515 and an SC injection of immune system activator 14 days prior to and 14 days following the start of placebo IV infusion.
89237796|NCT05136053|Experimental|Part C: Lu AG22515|Participants will receive a single intravenous (IV) infusion of Lu AG22515.
89237797|NCT05136053|Placebo Comparator|Part C: Placebo|Participants will receive a single IV infusion of placebo matching to Lu AG22515.
89237798|NCT05131672|Experimental|Operative reduction w/ fixation|open reduction and internal fixation (ORIF)
89237799|NCT05131672|Active Comparator|Non-operative immobilization|immobilization in a cast without reduction
89237800|NCT05127057|Experimental|PRIME Parkinson Care|PRIME Parkinson Care is a multi-component model of care comprising individual components: a) Case management b) Empowerment of patients and care givers c) Empowerment of healthcare professionals d) IT infrastructure.
89237801|NCT05127057|Placebo Comparator|Usual care|
89237802|NCT05119712|Active Comparator|Placebo to Drug|Subjects will begin treatment on placebo then crossover to study drug.
89237803|NCT05119712|Active Comparator|Drug to Placebo|Subjects will begin treatment on study drug then crossover to placebo.
88804667|NCT01847625||Physicians experienced in lead extraction|Physicians experienced in lead extraction
89237804|NCT05119582|Experimental|TOOsonix System ONE-M|Cutaneous neurofibromas will be treated by high intensity focused ultrasound.
89237805|NCT05104047|Active Comparator|Traditional Moxibustion|Participants receive Active Traditional Moxibustion - a protocol aimed at reducing neuropathic pain/discomfort.
89237806|NCT05104047|Active Comparator|Smokeless Moxibustion|Participants receive Active Smokeless Moxibustion - a protocol aimed at reducing neuropathic pain/discomfort.
88804668|NCT01267500|Experimental|Non-surgical therapy|patching or fusion exercises
88804669|NCT01237457|Experimental|Treatment|Patients with somatostatin receptor-expressing neuroendocrine neoplasms will receive up to 200 mCi of 177Lu-DOTATATE every 6-11 weeks, preferably 6-9 weeks to a cumulative dose of 800 mCi.
88804670|NCT00756353||Wave 1|
88804671|NCT00756353||Wave 2|
88804672|NCT00723697||Patients|Patients addicted to opiates and requiring replacement treatment. Patients in this non-interventional study were prescribed treatment as per usual clinical practice.
88804673|NCT00684073|Experimental|Subutex®/Suboxone®|Subutex® for first two days of study followed by Suboxone® for last 3 days of study
88804674|NCT00603109|Experimental|I|Subjects receive rimonabant 20 mg per day PO
88804675|NCT00603109|Placebo Comparator|II|Subjects take placebo capsule one a day PO
88804676|NCT00199030|Experimental|Arm A|In Arm A, patients with refractory relapse receive a 2 week treatment with MabCampath followed by remission evaluation. In case of insufficient response, treatment with cladribine is added.
89237807|NCT05104047|Placebo Comparator|Placebo Moxibustion Control|"Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not.~Note. All participants randomized to the Control will be offered active protocol moxibustion treatments, at no cost, at the end of their study participation."
89237808|NCT05104047|No Intervention|Waitlist Control|"WaitList (Control) No treatment. Subjects receive all aspects of study participation with the exception of exposure to Moxibustion.~Note. All participants randomized to the Control will be offered active protocol moxibustion treatments, at no cost, at the end of their study participation."
89237809|NCT05101629|Experimental|Pembrolizumab Lenvatinib|Single arm with Pembrolizumab 200 mg over 30 minutes IV infusion on Day 1 every 3 weeks until disease progression or inacceptable toxicity or end of study treatment. Lenvatinib 8 mg for a body weight < 60 kg and 12 mg for a body weight ≥ 60 kg orally continuously once daily, starting on Day 1 of every 3 week cycle until disease progression or inacceptable toxicity or end of study treatment.
89237810|NCT05080179|Experimental|Self-Benefit/Social Norm|"As part of their email, they read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
89237811|NCT05080179|Experimental|Self-Benefit/No Social Norm|"As part of their email, they read, It can help you determine where and when to get testing, and how to get care if you need it. They did not read any information about the number of Pennsylvanians who downloaded the app."
89237812|NCT05080179|Experimental|Other Benefit/Social Norm|"As part of their email, they read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
89237813|NCT05080179|Experimental|Other Benefit/No Social Norm|"As part of their email, they read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They did not read any information about the number of Pennsylvanians who downloaded the app."
89237814|NCT05067075|Experimental|Blinded CGM|Blinded continuous glucose monitor Dexcom G6Pro
89237815|NCT05042609|Experimental|TRS01|
89237816|NCT05042609|Active Comparator|Active comparator|
89237817|NCT05036720|Experimental|LTP+Dads|Participants in this arm will be offered the LTP+Dads intervention. The intervention will be delivered by trained Community Health Workers (CHWs). This will be co-facilitated by LTP+ master trainers.
89237818|NCT05036720|Other|Wait-list control:|Participants in this arm will be offered the intervention once the LTP+ arm have completed their outcome assessment. For example, in each Union Council (UC) once the LTP+ arm has completed the intervention and 4th month outcome assessment the wait-list control group in the same UC will be offered the intervention.
89237819|NCT05036720|Other|Optional mothers component|To facilitate changes in co-parenting and optimize impact on child development, the partners of fathers who participate will be offered optional LTP+ group sessions running parallel to LTP+Dads.
89237820|NCT05025345|Experimental|Study Lens|Tecnis Eyhance
89237821|NCT05025345|Active Comparator|Control Lens|Tecnis 1 piece IOL (Intraocular lens)
89237822|NCT04985344|Experimental|Propranolol|Patient will receive oral propranolol
89237823|NCT04985344|Placebo Comparator|Placebo|Patient will receive oral placebo
89237824|NCT04974970|Experimental|Peanut allergenic extract|injected peanut extract.
89237825|NCT04946370|Experimental|Pembrolizumab + 225Ac-J591 + ARPI|Patients will receive one dose of 225Ac-J591 (single dose, either 65 or 90 Kbq/kg) in combination with pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule, examples of ARPI include enzalutamide and apalutamide).
89237826|NCT04946370|Experimental|Pembrolizumab + ARPI|Patients will receive pembrolizumab (400mg every 6 weeks) and ARPI (standard dose schedule) without 225Ac-J591.
89237827|NCT04941001|Active Comparator|Healthcare professional using ReferID Tool in primary care|The asthma review will be undertaken by a healthcare professional with the use of the ReferID tool in primary care
89237828|NCT04941001|No Intervention|Usual care in primary care|A cohort of patients will be recruited who continue to receive usual care in primary care
89237829|NCT04924569||Standard of Care|Individuals using an intermittent catheter to void urine through the urethra. Participants use their currently prescribed intermittent catheter per their clinician's standard of care.
89237830|NCT04920695|Placebo Comparator|Placebo Control|Inhaled medical grade normoxic gas (FiO2 = 0.21; DIN 02238755 Air Liquid Healthcare, Montreal, Quebec, Canada).
89237831|NCT04920695|Active Comparator|Inhaled Nitric Oxide|Inhaled 40 ppm nitric oxide from a KINOX™ gas cylinder system (Air Liquid Healthcare, Montreal, Quebec, Canada; Control # 198879, DIN 02451328).
89237832|NCT04918290|Experimental|Tegaderm Left|After general anesthesia is administered, Tegaderm will be placed on the left eye and Transpore will be placed on the right eye
89237833|NCT04918290|Experimental|Transpore Right|After general anesthesia is administered, Transpore will be placed on the right eye and Tegaderm will be placed on the left eye.
89237834|NCT04902417|No Intervention|Low Dairy Habitual Diet|Participants will follow their usual diet for 6-weeks, which includes low dairy consumption as screened for with the inclusion criteria.
89237835|NCT04902417|Experimental|High Dairy Diet|Participants will be provided with 3 servings of dairy per day to replace other foods within their diet (preventing weight gain over the intervention period) for 6-weeks
89237836|NCT04820400|Experimental|VR-360 group (VR-group)|Patients will watch a VR-360 distraction video during dressing change. The patient will be asked or helped to wear the HMD write in full at the onset of a procedure and watch the VR-360 video during the dressing change procedure. When experiencing pain, the patient may indicate the need for further analgesic medication during the procedure, the patient will be asked to push a button in their hand that will trigger a light-based signal for the nurse to provide further analgesic medication. Should their hands both be involved in the burn injury, the patient will indicate the same verbally.
89237837|NCT04820400|No Intervention|Control Group (standard treatment)|The patients will receive standard treatment and will be instructed to use the same button to indicate their pain.
89237838|NCT04809207|Experimental|CF Wellness Program|Participants will receive CF Wellness Program sessions.
89237839|NCT04785066|Experimental|Study treatment|Administration of dornase alfa during intervention of thrombectomy
89237840|NCT04778579|Experimental|ARI-0001|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
89237841|NCT04776356||QuickFix Small Staple|The QuickFix Small Staple will be used for an Akin osteotomy to correct hallux valgus interphalangeus.
89237842|NCT04751435|Experimental|Breast,Ovarian, Prostate & Pancreatic Cancer|"There is no treatment or intervention for Phase 1 of this study. Participants will be asked to participate in a cognitive interview.~This section will be amended to include the Phase 2 intervention information once the Phase 1 portion of the study is complete. The Phase 1 materials developed, and results obtained, will directly be part of and inform the intervention for Phase 2."
89237843|NCT04744402|Experimental|CartiLife®|Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
89237844|NCT04737629|Experimental|Expectancy and Water Condition|
89237845|NCT04737629|Experimental|No Expectancy and Water Condition|
89237846|NCT04737629|Experimental|No Water Condition|
89237847|NCT04725721|Experimental|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
89237848|NCT04725721|Active Comparator|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
89237849|NCT04720664|Experimental|oral SM-88|SM-88 taken with three conditioning agents: methoxsalen, phenytoin, and sirolimus
89237850|NCT04718168|Experimental|Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial|
89237851|NCT04718168|Experimental|Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial|
89237852|NCT04718168|Experimental|Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial|
89237853|NCT04718168|Experimental|Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial|
89237854|NCT04711343|Experimental|BAT2306 injection|150mg /1ml; subcutaneous injection
89237855|NCT04711343|Active Comparator|Cosentyx (US-licensed)|150mg /1ml; subcutaneous injection
89237856|NCT04711343|Active Comparator|Cosentyx (EU-licensed)|150mg /1ml; subcutaneous injection
89237857|NCT04683653|Experimental|Hypofractionated Radiation Treatment (Dose-Finding Arm)|All study participants in this arm will receive hypofractionated whole pelvic radiation treatment for a shortened time period of 3-5 weeks. The goal of this arm is to establish a safe and tolerable dose of shortened (hypofractionated) pelvic radiation treatment for study participants. Once a safe and tolerable dose is established for this shortened form of radiation treatment, participants who meet criteria for the second phase of this study will participate in an expansion cohort that will explore the efficacy (how effective shortened/hypofractionated radiation treatment is for treating endometrial cancer).
89237858|NCT04683653|Experimental|Expansion Cohort (Efficacy Arm)|"Participants in this arm will test how effective hypofractionated/shortened whole radiation treatment is (efficacy) at the dose established in the first phase of this study by following up with their doctors to report their current health status and symptoms during clinical visits. Participants will return for routine clinical follow-up approximately 1 month following radiation, then at 3 months following radiation, then every 3 months for the next 2 years following treatment."
89237859|NCT04654949|Experimental|Horticultural Therapy|The Horticultural Therapy group receives 30 minutes of horticultural therapy activities using mobile horticulture kits conducted by therapists or therapy assistants to engage participants at their bedside.
89237860|NCT04654949|No Intervention|Existing Care|The existing Care group receives 30 minutes of routine ward-based engagement leisure activities (e.g. watching television, reading newspapers, etc).
89237861|NCT04646707|Experimental|Study group|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
89237862|NCT04646707|Placebo Comparator|Placebo Group|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
89237863|NCT04646694|Experimental|Study Group 1|Patient will receive Ketamine at a dose of 30 mg every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Ketamine for three days or nine doses total.
89237864|NCT04646694|Placebo Comparator|Study group 2|Patient will receive Placebo at a matching dose every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Placebo for three days or nine doses total.
89237865|NCT04636879|Experimental|• Group 1. Positive expectation|"Dry needling is a very effective tool used in the treatment of nonspecific neck pain, which we hope will reduce your neck pain."
89237866|NCT04636879|Active Comparator|• Group 2. Neutral Expectation|"Dry needling is an indicated tool used in the treatment of nonspecific neck pain, but its efficacy is unknown."
89237867|NCT04636879|Active Comparator|• Group 3. Negative Expectation|"Dry needling is not a very effective treatment tool for nonspecific neck pain, so we expect your neck pain to increase a bit."
89237868|NCT04629950|Experimental|Rimegepant|Participants receive a rimegepant 75 mg tablet orally every other day for 16 weeks.
89237869|NCT04629950|Placebo Comparator|Placebo|Participants receive a placebo tablet matching rimegepant orally every other day for 16 weeks.
89237870|NCT04612400|Experimental|Low|Low dose (6.3g) EAA/whey protein supplement
89237871|NCT04612400|Experimental|High|High dose (12.6g) EAA/whey protein supplement
89237872|NCT04595370|Experimental|AZD9977 Dose A + dapagliflozin 10 mg|Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.
89237873|NCT04595370|Experimental|AZD9977 Dose B + dapagliflozin 10 mg|Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.
89237874|NCT04595370|Experimental|AZD9977 Dose C + dapagliflozin 10 mg|Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.
89237875|NCT04595370|Experimental|Dapagliflozin 10 mg|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
89237876|NCT04554966|Experimental|Part A: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.
89237877|NCT04554966|Experimental|Part A: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.
89237878|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.
89237879|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A|Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.
89237880|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.
89237881|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B|Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.
89237882|NCT04554966|Experimental|Part B: Subcutaneous Cohort: ABBV-382|Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.
89237883|NCT04543942|Experimental|Males|Participants in this group will be adult male heavy drinkers.
89237884|NCT04543942|Experimental|Females|Participants in this group will be adult female heavy drinkers. Data will be segregated by menstrual cycle phase - the late follicular or mid-luteal phase.
89237885|NCT04523714|Active Comparator|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
89237886|NCT04523714|Active Comparator|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills (no usual care services restricted)
89237887|NCT04523714|No Intervention|Usual Care plus information|Receipt of a bound copy of the 2020 edition of the American Chronic Pain Association Resource Guide to Chronic Pain Management and any pharmacologic and nonpharmacologic treatments available to them without restriction
89237888|NCT04511455|Experimental|Experimental|"Cabozantinib peroral 60 mg/day~A stepwise dose de-escalation schedule on individual level is available for patients with lower tolerability against cabozantinib.~The study treatment will be limited to a maximum of 12 months (including interruptions)."
89237889|NCT04506567|Experimental|Dose- Fractionated Cohort|Patients will receive a single cycle of 225Ac-J591, administered as a fractionated dose on days 1 and 15. This is a dose-escalation design, with up to 4 dosing cohorts.
89237890|NCT04506567|Experimental|Multiple Dose Cohort|Patients will receive 225Ac-J591 every 6 weeks, with up to 4 doses. Some patients will be enrolled in a dose-escalation design, with up to 3 dosing cohorts. Additional patients will be enrolled at 2 lower dosing-cohorts.
89237891|NCT04467866|Experimental|ROC-Stand(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
89237892|NCT04467866|Experimental|ROC-Stand(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training.
89237893|NCT04467866|Active Comparator|Control(Mild) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as mild motor delay. The other occupational therapist will be responsible for regular therapy.
89237894|NCT04467866|Active Comparator|Control(Mod) group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as moderate motor delay. The other occupational therapist will be responsible for regular therapy.
89237895|NCT04456478|Active Comparator|pH 7.38 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.38 ± 0.02
89237896|NCT04456478|Experimental|pH 7.22 ± 0.02|IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the culture of the oocytes and embryos in the culture medium with a pH at 7.22 ± 0.02
89237897|NCT04427228|Experimental|Arm A|
89237898|NCT04427228|Active Comparator|ARM B|
89237899|NCT04406818|Active Comparator|Healthy Control|
89237900|NCT04406818|Active Comparator|Sickle Cell Anemia|
89237901|NCT04404660|Experimental|AUTO1|
89237902|NCT04393623|Experimental|Cognitive Reappraisal Microintervention|"The CR microintervention (session 1) is drawn from Barlow & colleagues empirically supported treatment for emotional disorders (the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders). The microintervention consist of four sections: (1) Introduction to cognitive appraisal; (2) Introducing the idea of thinking traps that prevent reappraisal and maintain negative emotion; (3) Describing cognitive reappraisal as a strategy that can help the participant get out of such thinking traps; (4) Providing an example of this process (situation> negative appraisal > negative emotion > thinking trap > opportunity for cognitive reappraisal) and have participants provide a personalized example."
89237903|NCT04393623|Active Comparator|Psychoeducation (Control)|The manualized psychoeducational control module, serving as an attentional control, is derived from two sources: 1. The first session of the Women's Health Education Manual, which provides psychoeducation about the basic body systems and their function, with focus on components of the immune system and 2. Fact sheets published by the American College of Obstetricians and Gynecologists(ACOG), providing female-specific facts about cancer and heart health. None of this psychoeducation discusses potential relevancy of alcohol use, nor will any behavior changes be suggested during the control microintervention.
89237904|NCT04371198|Experimental|Organoid|
89237905|NCT04361708|Experimental|High Risk UGT1A1 genotype|
89237906|NCT04361708|Experimental|Intermediate Risk UGT1A1 genotype|
89237907|NCT04361708|Experimental|Low Risk UGT1A1 genotype|
89237908|NCT04345146|Experimental|FSRT & Bevacizumab|Patients will receive Bevacizumab before and after FSRT: daily FSRT(40Gy in 10 fractions or 30Gy in 5 fractions) to the brain metastases with Bevacizumab(7.5mg/kg, q3w, IV)
89237909|NCT04339543|Other|Longitudinal assessment|Participants will take part in a baseline study session, followed by a year of weekly reports of their number of near falls and falls. The same participants will repeat the same study session six months and twelve months after the baseline session.
89237910|NCT04336098|Experimental|Monotherapy Dose Escalation|The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of SRF617 as monotherapy in up to 36 patients with advanced solid tumors.
89237911|NCT04336098|Experimental|Monotherapy Tumor Biopsy Expansion|The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy in up to 20 patients at cleared and recommended phase 2 dose levels.
89237912|NCT04336098|Experimental|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel Dose Escalation|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with gemcitabine + albumin-bound paclitaxel in patients with locally advanced or metastatic solid tumors.
89237913|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Escalation|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with pembrolizumab (Keytruda®) in patients with locally advanced or metastatic solid tumors.
89237914|NCT04336098|Experimental|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel Dose Expansion|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 10 additional patients with advanced pancreatic ductal adenocarcinoma (PDAC) to further evaluate safety with SRF617 and gemcitabine + albumin-bound paclitaxel combination therapy.
89237915|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Expansion GC/GEJ|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 28 additional patients with 2 anti-PD-(L) 1 naive HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma to further evaluate safety with SRF617 and pembrolizumab combination therapy.
89237916|NCT04336098|Experimental|SRF617 + Pembrolizumab + Gemcitabine + Albumin-bound Paclitaxel Quadruplet Dose Expansion|Enrollment at the recommended phase 2 combination dose established in the combination dose escalation arms (if recommended phase 2 combination doses differ, the lower of the starting 2 doses will be used) may be expanded to include up to approximately 30 additional patients with advanced 1L PDAC.
89237917|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab Dose Expansion anti-PD-L1 GC/GEJ, PD-L1+ NSCLC|Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 29 additional patients with anti-PD-(L) 1 relapsed/refractory PD-L1+ HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma or advanced PD-L1+ NSCLC to further evaluate safety with SRF617 and pembrolizumab combination therapy.
89237918|NCT04316494|Experimental|Hydroxychloroquine|"Patients will be receive 400mg of Hydroxychloroquine (2 x 200mg) to take daily for 52 weeks. Hydroxychloroquine will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
89237919|NCT04316494|Placebo Comparator|Placebo|"Patients will be receive 400mg of Placebo (2 x 200mg) to take daily for 52 weeks. Placebo will be started at a dose of 200mg an up-titrated after the first week to a maximum daily dose of 400mg.~Patients weighing <50kg, or those patients with an eGFR of 30-50mL/min, will receive a reduced dose of 200mg daily."
89237920|NCT04309981|Experimental|ARI0002h|Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory region and signal-transduction CD3z that has been humanized
89237921|NCT04288154|Experimental|EMS Group - Experimental|EMS device will be turned on during exercise for this group.
89237922|NCT04288154|Placebo Comparator|EMS Group - Control|EMS device will be turned off during exercise for this group.
89237923|NCT04287569|Experimental|video recording of endoscopy|Record of sequences of video-endoscopy and the reflectance of light through fibroscopy
89237924|NCT04286594|Experimental|CBD|0.5ml of sublingual CBD solution (30mg/ml) administered twice daily for six weeks.
89237925|NCT04280497|Experimental|Biomarker CIRCI neg: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
89237926|NCT04280497|Placebo Comparator|Biomarker CIRCI neg: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
89237927|NCT04280497|Experimental|Biomarker endocan: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
89237928|NCT04280497|Placebo Comparator|Biomarker endocan: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
89237929|NCT04280497|Experimental|Biomarker GILZ: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
89237930|NCT04280497|Placebo Comparator|Biomarker GILZ: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
89237931|NCT04280497|Experimental|Biomarker CPD: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
89237932|NCT04280497|Placebo Comparator|Biomarker CPD: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
89237933|NCT04280497|Experimental|Biomarker Transcriptomic SRS: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
89237934|NCT04280497|Placebo Comparator|Biomarker Transcriptomic SRS: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
89237935|NCT04280497|Experimental|Biomarker Endotype B: Corticosteroid arm|Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.
89237936|NCT04280497|Placebo Comparator|Biomarker Endotype B: Placebo arm|Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.
89237937|NCT04258579|Experimental|Video PROTECT|Participants will receive PROTECT therapy once a week for 9 weeks.
89237938|NCT04231734|Experimental|All Subjects|Low tumor burden, treatment-naïve MCL
89237939|NCT04230967|Experimental|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit InspireTM devices will be set to this goal and notifications will be given on the device for the participants meeting their goals. Upon enrollment, they will be given a pamphlet with instructions to ambulate out of the room at least once per day with a goal of 2,000 steps daily and their Fitbits will be pre-programmed with this goal. Study staff will also remind participants to ambulate via email, text or in-person if they are not meeting their goal of 2,000 steps per day.
89237940|NCT04230967|Active Comparator|Routine Care|Participants in the routine care arm will be allowed ad lib activity but no encouragement to walk will be given. They will not have any goals set on their Fitbits. Upon enrollment, they will be given pamphlets with no instruction on whether or not to ambulate and their Fitbits will be pre-programmed to have no goal.
89237941|NCT04203381|Other|Transgender Participant|Transgender children at Tanner stage II or early Tanner stage III between the ages of 9 and 14. Must be a current patient at a gender patient and within 6 weeks of initiating pubertal blockade treatment
89237942|NCT04203381|No Intervention|Cisgender Control Participant|Cisgender children Tanner II or early Tanner III between 9 and 14 matched by race, age, and BMI.
89237943|NCT04178434|Active Comparator|Internet-based CBT intervention|A nine step internet-based intervention with focus on stress and anxiety
89237944|NCT04178434|No Intervention|Treatment as usual|Regular follow-up with two doctor and one nurse appointment
89237945|NCT04133909|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously once every 4 weeks over a treatment period of at least 52 weeks up to a maximum of 104 weeks.
89237946|NCT04133909|Experimental|Mepolizumab|Participants will receive mepolizumab subcutaneously once every 4 weeks over a treatment period of at least 52 weeks up to a maximum of 104 weeks.
89237947|NCT04124848||Somali Descent|Study participants who are of Somali origin.
89237948|NCT04124848||Non-Somali Descent|Study participants who are not of Somali origin.
89237949|NCT04069052|Experimental|Inhaled Nitric Oxide|Inhaled nitric oxide administered throughout 4 min exercise protocol at 800 ppm.
89237950|NCT04069052|Placebo Comparator|Placebo|Inhaled room air administered throughout 4 min exercise protocol at FiO2 = 0.21.
89237951|NCT04045470|Experimental|Initial Cohort|"Patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma~Mandatory skin biopsy for corollary studies will be obtained~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)"
89237952|NCT04045470|Experimental|Expansion Cohort|"Only patients with plaque or tumor skin lesions of cutaneous T cell lymphoma or peripheral T cell lymphoma who plan to start systemic therapy as part of standard of care~Mandatory skin biopsy for corollary studies will be obtained~Patients will undergo percutaneous placement of four total microdevice(s) into two skin lesions (2 MD per skin lesion)~Participants will receive standard of care therapy and clinical course followed~Participants will undergo standard of care therapy as previously determined by treating oncologist and/or dermatologist prior to enrollment to study~Participants will not be assigned any treatment intervention"
89237953|NCT04013256|Experimental|Dermal Exposure to Thirdhand Cigarette Smoke|Participants will wear clothing that has been exposed to cigarette smoke, for 3 hours while breathing filtered, temperature and humidity controlled air.
89237954|NCT04013256|Active Comparator|Inhalational Exposure to Thirdhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 22 hours, for 3 hours while wearing clean clothing.
89237955|NCT04013256|Active Comparator|Inhalational Exposure to Secondhand Cigarette Smoke|Participants will breathe cigarette smoke aerosol that has been aged for 30 minutes, for 3 hours while wearing clean clothing.
89237956|NCT04013256|Sham Comparator|Clean Air Exposure|Participants will breathe filtered, temperature and humidity controlled air while wearing clean clothing for 3 hours.
89237957|NCT03974620|Experimental|Individual Placement and Support (IPS)|IPS is a vocational support program to facilitate return to employment in individuals with severe and enduring mental illnesses.
89237958|NCT03974620|Experimental|Cognitive Remediation Therapy (CRT)|CRT will be delivered twice weekly individual computerised CRT with therapist input. This therapy will be delivered by a CRT trained assistant psychologist.
89237959|NCT03974620|Experimental|IPS and CRT|A combination of IPS and CRT will be provided to participants in this arm.
89237960|NCT03974620|No Intervention|Treatment as usual|Continued input as normal with treating psychiatrist.
89237961|NCT03963414|Experimental|Cohort 1|Durvalumab 1500 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab maintenance monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after Cycle 4.
89237962|NCT03963414|Experimental|Cohort 2|Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after the last infusion of the combination.
89237963|NCT03955666|Experimental|Cohort A (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
89237964|NCT03955666|Experimental|Cohort B (PRV-3279 or placebo)|Sterile solution for intravenous administration, 3 doses, every 2 weeks
89237965|NCT03952520|Active Comparator|Standard Approach (SA)|The Standard Approach is a one-size-fits-all multifaceted implementation strategy that was systematically developed using Intervention Mapping.
89237966|NCT03952520|Experimental|Tailored Approach (TA)|The Tailored Approach includes an implementation strategy that will be tailored to match site-specific barriers to implementation of SNaP at that site.
89237967|NCT03945214|Experimental|Meditation group|Participants in the meditation intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks.
89237968|NCT03945214|Experimental|Healthy eating group|Participants in the healthy eating group will be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
89237969|NCT03945214|Experimental|Mediation + Healthy eating group|Participants in the meditation + healthy eating intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks. They will also be required to attend an in-person 50-minute counseling session geared towards developing goals to improve eating behavior, along with three 10-minute booster phone calls at weeks 1, 4, and 8. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks.
89237970|NCT03945214|No Intervention|Waitlist control condition|Waitlist control group participants will continue their normal activities and not add any form of mediation during the study period.
89237971|NCT03931538|Active Comparator|Culture Only|Physician receives only culture result
89237972|NCT03931538|Active Comparator|Guidance 4.0 PCR test only|Physician receives Guidance report only
89237973|NCT03931538|Active Comparator|Culture and Guidance 4.0 PCR test Group|Physician receives both results, gets Culture report immediately before Guidance
89237974|NCT03931538|Active Comparator|Guidance 4.0 PCR test and culture group|Physician receives both results, gets Guidance report immediately before culture
89237975|NCT03929159||Group A (biospecimen collection)|Patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized.
89237976|NCT03929159||Group B (biospecimen collection)|Patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.
88804677|NCT00199030|Experimental|Arm B|In Arm B, patients with molecular relapse (minimal residual disease) receive a 4 week treatment with MabCampath followed by remission evaluation.
89237977|NCT03922646|Experimental|NEAT Active Experimental Group|People in the active group will receive NEAT intervention
89237978|NCT03922646|Active Comparator|Control Group|People in the control group will receive non-essential regularly-scheduled programming (active control) coinciding with the same timeframe
89237979|NCT03867955||Patients who have a neurosurgical intervention|Patients who have a neurosurgical intervention will be included. They will have a collection of datas.
89237980|NCT03861390|Active Comparator|Prednisone, then Placebo|
89237981|NCT03861390|Placebo Comparator|Placebo, then Prednisone|
89237982|NCT03829683|Active Comparator|Vitamin C infusion (ascorbic acid)|Vitamin C 200mg/kg/24hours administered in four doses per day (given every 6 hours)
89237983|NCT03829683|Placebo Comparator|Placebo|Dextrose 5% in water 50 milliliters (mL) administered intravenously every 6 hours
89237984|NCT03810456|Active Comparator|iCBT|Patients in this arm will receive transdiagnostic CBT delivered in an intensive format over one weekend.
89237985|NCT03810456|Active Comparator|sCBT|Patients in this arm will receive transdiagnostic CBT delivered in a standard weekly format for 12 weeks.
89237986|NCT03810456|No Intervention|TAU|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual.
89237987|NCT03737331|Experimental|Fractal visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be fractal (i.e., pink noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
89237988|NCT03737331|Active Comparator|Periodic visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be periodic (i.e., invariant). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
89237989|NCT03737331|Sham Comparator|Random visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be random (i.e., white noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
89237990|NCT03737331|No Intervention|Control|Natural walking.
89237991|NCT03715179||Standard of Care|Individuals living with an ostomy and their caregivers. Participants use their own ostomy pouching systems per their clinician's standard of care
89237992|NCT03566732||Bereaved relatives|Bereaved relatives after cancer deaths in hospitals
89237993|NCT03530696|Experimental|T-DM1 with palbociclib|T-DM1 is given intravenously every 21 days (day 1 of each cycle) Palbociclib is administered orally on days 5-18 of each cycle
89237994|NCT03522961|Active Comparator|Nitrofurantoin prophylaxis/Placebo|Subjects will receive Nitrofurantoin 100mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to Placebo capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
89237995|NCT03522961|Active Comparator|Cranberry capsules|Subjects will receive TheraCran® One Cranberry 36mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to another bottle of TheraCran® One Cranberry 36mg capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
89237996|NCT03514888|Experimental|HIPEC after Radical Cystectomy|After completion of radical cystectomy, HIPEC will be administered using closed abdomen technique for a duration of 60 minutes.
89237998|NCT03360396|Experimental|Endobronchial Coils|Treatment with PneumRx Endobronchial Coil System
89237999|NCT03360396|No Intervention|Control|Medically-managed control group
89238000|NCT03353415|Other|Masked CGM Wear (Phase 1)|Each participant will wear the Dexcom CGM for two sequential phases. During the first phase, participants will not be able to read the sensor glucose levels (masked).
88804678|NCT00198978|Experimental|Interventional arm|
88804679|NCT00109395|Active Comparator|Lorazepam Intermittent bolus|lorazepam administered by intermittent bolus
89238001|NCT03353415|Experimental|Unmasked CGM Wear (Phase 2)|In the second phase, participants will be able to read the sensor glucose levels (unmasked). Frequency of hypoglycemia will be compared between the two phases of the study.
89238002|NCT03198351||Cohort I|Pregnant women with a confirmed diagnosis of multiple sclerosis (MS) and teriflunomide exposure during the current pregnancy
89238003|NCT03198351||Cohort II|Pregnant women with MS not exposed to teriflunomide during the current pregnancy
89238004|NCT03198351||Cohort III|Healthy pregnant women who do not have a known diagnosis of MS and have no known exposure to a known human teratogen
89238005|NCT03198351||"Registry group (not eligible for cohorts)"|Women who contact the OTIS registry study staff and who do not meet the criteria for the prospective study, for example, at time of contacting the study, having known prenatal diagnosis of congenital defect, or gestation weeks greater than 20 following a first trimester teriflunomide exposure, etc.; these participants will not be included in the primary analysis for the cohort study.
89238006|NCT03160040||Minocycline IV|Participants who received 2 doses over 48 hours if given once daily or 4 doses over 48 hours if given twice daily of minocycline intravenous (IV) as monotherapy, with or without transition to oral minocycline.
89238007|NCT03144583|Experimental|Adult differentiated autologous T-cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
89238008|NCT03107182|Experimental|Induction Chemotherapy|"All enrolled patients will receive three 21-day cycles of chemotherapy consisting of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total), carboplatin (AUC 5 on day 1; 3 doses total), and nivolumab (360 mg on days 1; 3 doses total). Growth factor support will be provided using G-CSF administered on days 16-18.~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy."
89238009|NCT03107182|Experimental|Single Modality De-escalation Arm (SDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. De-intensified adjuvant RT will be given for adverse pathologic features. Patients may refuse TORS treatment.~Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 G."
89238010|NCT03107182|Experimental|Intermediate De-escalation Arm (IDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients who have low risk disease with <50% but ≥30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 45 Gy (3 cycles).~Patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles)."
89238011|NCT03107182|Experimental|Regular Dose Arm (RDA)|"Following the induction treatments (carboplatin, nab-paclitaxel, and nivolumab), patients will be assessed based on response to chemotherapy and high or low risk status.~Patients who have low risk disease and <30% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX (paclitaxel, 5-FU, hydroxyurea, dexamethasone, famotidine, and diphenhydramine) to 75 Gy (5 cycles).~Patients who have high risk disease and <50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).~Any patient who has progressive disease will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
89238012|NCT03069495||Healthy Control Adult Subjects|Healthy adult subjects between the ages of 19-50 years will be enrolled.
89238013|NCT03069495||Asthmatic Adult Subjects|Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
89238014|NCT03069495||Chronic Urticaria Adult Subjects|Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.
89238015|NCT02982070|Experimental|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
89238016|NCT02982070|No Intervention|College as Usual|no training provided
89238017|NCT02833701|Experimental|Treatment (bevacizumab and ascorbic acid)|Patients receive ascorbic acid IV over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89238018|NCT02767999|Experimental|Fluoxetine|One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI
89238019|NCT02767999|Placebo Comparator|Placebo|The other group will take a cellulose placebo per day from D0 to D90 and have fMRI
89238020|NCT02675465|Experimental|ATB200|In Stage 1, safety, tolerability, and PK will be evaluated following sequential single ascending doses of intravenously infused ATB200 for 3 dosing periods.
89238021|NCT02675465|Experimental|ATB200 + AT2221|In Stage 2, safety, tolerability, and PK will be evaluated following single- and multiple-ascending dose combinations of ATB200 co-administered with AT2221 (Miglustat) In Stage 3, long term safety and efficacy will be assessed following 24 month treatment of ATB200 co-administered with AT2221 (Miglustat)
89238022|NCT02670707|Experimental|"Cytarabine (experimental) arm"|On this arm, patients will receive single therapy with cytarabine.
89238023|NCT02670707|Active Comparator|"Vinblastine/prednisone (standard) arm"|On this arm, patients will receive standard-of-care therapy with vinblastine and prednisone.
89238024|NCT02658890|Experimental|Combination Therapy (Dose Escalation)|BMS 986205 + Nivolumab specified dose at specified intervals.
89238025|NCT02658890|Experimental|Combination Therapy (Dose Expansion)|BMS 986205 + Nivolumab specified dose at specified intervals.
89238026|NCT02658890|Experimental|Combination Therapy 2 (Dose Expansion)|BMS 986205 + both Nivolumab and ipilimumab specified dose at specified intervals
89238027|NCT02597062|Experimental|Carfilzomib plus cyclophosphamide plus dexamethasone|20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg
89238028|NCT02567292|No Intervention|Retrospective Control Group|Approximately 150 patients with congenital gastrointestinal disorders who were treated in the neonatal intensive care unit (NICU) at Children's Healthcare of Atlanta-Egleston and other participating institutions from 2012 to 2015, who had non-human milk (HM) diets will be identified as retrospective controls using the electronic medical records system.
89238029|NCT02567292|Experimental|Exclusive Human Milk Diet Group|A minimum of 150 patients with CGD admitted to participating NICUs who meet inclusion criteria and provide informed consent will be enrolled in the prospective arm of the study. These patients will be fed an EHMD comprised of mother's own milk (MOM) or pasteurized donor human milk (DM). Fortification will be provided with human milk derived human milk fortifier, either a human milk-based fortifier (Prolact+ H2MF®) for infants born at less than 37 weeks GA or <2,200g birth weight or the term-equivalent version (PBCLN-002) formulated for infants >37 weeks and/or >2,200g at birth. Infants will receive this EHMD until they have achieved full enteral feedings for 7 days with bowel in continuity
89238030|NCT02509221||Less than 30 minutes|
89238031|NCT02509221||30-60 minutes|
89238032|NCT02509221||More than 60 minutes|
89238033|NCT02484417|Experimental|Cohort 1: RSV A2 10^5 PFU/dose|Challenge 4 subjects with low dose and proceed to larger cohort after safety review.
89238034|NCT02484417|Experimental|Cohort 2: RSV A2 10^5 PFU/dose|Challenge 12 subjects with the low dose and proceed to high dose after safety review.
89238035|NCT02484417|Experimental|Cohort 3: RSV A2 10^6.3 PFU/dose|Challenge 12 subjects with the high dose
89238036|NCT02451982|Experimental|Arm A: CY/GVAX alone|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
89238037|NCT02451982|Experimental|Arm B: CY/GVAX with nivolumab|Patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide and nivolumab IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide, nivolumab, and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive nivolumab every 4 weeks for another 6 treatments as well as cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
89238038|NCT02451982|Experimental|Arm C: CY/GVAX with nivolumab and urelumab|Patients receive low-dose cyclophosphamide, nivolumab, and urelumab on day 0 and GVAX pancreatic cancer vaccine on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide, nivolumab, and urelumab on day 0 and the vaccine on day 1. Beginning approximately 28 days after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide, nivolumab, and urelumab on day 0 and GVAX on day 1. Treatment with cyclophosphamide, nivolumab, urelumab, and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive nivolumab and urelumab every 4 weeks for another 6 treatments as well as cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
89238039|NCT02451982|Experimental|Arm D: BMS-986253 and Nivolumab|Patients receive BMS-986253 and nivolumab on day 0 (Cycle 1), 15 days prior to surgery. 6-10 weeks after surgery, patients receive Cycle 2, with nivolumab on day 0 and BMS-986253 on days 0 and 14. Patients then receive standard adjuvant chemoradiotherapy. Approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive 4 additional 28-day cycles of immunotherapy, with Nivolumab on Day 0 and BMS-986253 on Days 0 and 14. Patients will then enter the extended treatment phase where they will receive nivolumab alone every 4 weeks for another 6 treatments.
89238040|NCT02235623|Other|Stage 1- Single-stage Fowler-Stephens orchidopexy (FSO)|Stage 1 single surgery to clip the vessels to the testis, divide the spermatic vessels and bring the testis into the scrotum.
89238041|NCT02235623|Other|Stage 2- Two-stage Fowler-Stephens orchidopexy (FSO)|Stage 2 2 surgeries: 1st surgery-Clip vessels to testis. 2nd surgery done 6-12 months later, divide the spermatic vessels and bring the testis into the scrotum.
89238042|NCT02153684||Mild COPD, symptomatic|Smokers fitting GOLD 1B criteria for COPD
89238043|NCT02153684||Mild COPD, asymptomatic|Smokers fitting GOLD 1A criteria for COPD
89238044|NCT02153684||Symptomatic smokers, at risk for COPD|Smokers who do not meet spirometric criteria for COPD
89238045|NCT02153684||Healthy, non-smoking controls|Non-smokers, matched to smoking groups for age (>40 yrs of age) and gender
89238046|NCT02122185|Experimental|Metformin plus chemotherapy|Patients receive metformin hydrochloride PO BID and standard chemotherapy for 6 -8 cycles. Treatment with metformin hydrochloride continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
89238047|NCT02122185|Placebo Comparator|Placebo plus chemotherapy|Patients receive placebo PO BID and standard chemotherapy for 6 -8 cycles. Treatment with placebo continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
89238048|NCT02041663|Experimental|Population|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
89238049|NCT01830621|Active Comparator|BBI608|BBI608 480 mg two times daily (960 mg total daily dose)+ Best Supportive Care
89238050|NCT01830621|Placebo Comparator|Placebo|Placebo two times daily + Best Supportive Care
89238051|NCT01528852|Experimental|CHX Cord application|Chlorhexidine cord application for 10 days
89238052|NCT01528852|Active Comparator|Control|Same liquid as intervention without the chlorhexidine used for cord cleaning for 10 days once daily
89238053|NCT01528852|No Intervention|Dry Cord care|Use current recommended keep cord dry
89238054|NCT01248585|Active Comparator|Dexamethasone|2 x 4 mg dexamethasone tablets taken once daily for 5 days
89238055|NCT01248585|Placebo Comparator|Placebo|2 placebo tablets taken once daily for 5 days
89238056|NCT00993655|Active Comparator|IV carboplatin + IV paclitaxel|ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles
89238057|NCT00993655|Active Comparator|IP cisplatin + IV/IP paclitaxel|ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-FEB-03)
89238058|NCT00993655|Active Comparator|IP carboplatin + IV/IP paclitaxel|ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles
89238059|NCT00251251|Active Comparator|1. Optimal Medical therapy plus ICD|
89238060|NCT00251251|Active Comparator|2. Optimal Medical Therapy plus CRT/ICD|
89238061|NCT05350800|Experimental|BMS-986369, Part 1 dose escalation|
89238062|NCT05350800|Experimental|BMS-986369 under fasted conditions, Part 2 Food effect|
89238063|NCT05350800|Experimental|BMS-986369 under fed conditions, Part 2 Food effect|
89238064|NCT05346653|Active Comparator|SGLT2i|Participants will be treated with a SGLT2i during their ICU stay. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
89238065|NCT05346653|Active Comparator|No SGLT2i|Participants will not be treated with a SGLT2i during their ICU stay. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
89238067|NCT05335863|Experimental|Experimental|Ingestion of FontActiv® DiaBest high protein/hypercaloric
89238068|NCT05335863|Placebo Comparator|Control|Ingestion of glucose standard solution
89238069|NCT05331105|Experimental|HL-085|HL-085 9mg BID
89238070|NCT05322694||Acute respiratory infections|"Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both.~Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient."
89238071|NCT05322694||Acute infectious diarrhea|"Participants will be recruited according to their symptoms when presenting to the emergency room. They can be included either in the acute respiratory infection group or acute infectious diarrhea group or both.~Immediately after triage, eligible patients will be approached by research personnel (nurse or other professional authorized to perform the sampling and techniques required for the study) and enrolled after consent has been obtained. Once the study procedures are completed, participants will follow the care pathway that they would normally follow without the research project. The results of the clinical decision rule (molecular test and risk stratification tool) will not be disclosed to the treating team or the patient."
89238072|NCT05316493|Experimental|overweight MA+ILI|enrolled overweight (24kg/m2≤BMI<28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management
89238073|NCT05316493|Experimental|overweight LNG-IUS+ILI|enrolled overweight (24kg/m2≤BMI<28kg/m2) patients will be treated with LNG-IUS plus weight management
89238074|NCT05316493|Experimental|obese MA+ILI|enrolled obese (BMI≥28kg/m2) patients will receive megestrol acetate 160mg po qd plus weight management
89238075|NCT05316493|Experimental|obese LNG-IUS+ILI|enrolled obese (BMI≥28kg/m2) patients will be treated with LNG-IUS plus weight management
89238076|NCT05316467|Experimental|overweight 24kg/m2≤BMI<28kg/m2|MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management
89238077|NCT05316467|Experimental|BMI≥28kg/m2|MA+ weight management enrolled patients will receive megestrol acetate 160mg po qd plus weight management
89238078|NCT05308459|Experimental|Step 1: Allocated to start the Data Health VET intervention phase January 2022|Participants receive the Data Health VET intervention in all its steps starting in January 2022
89238079|NCT05308459|Experimental|Step 2: Allocated to start the Data Health VET intervention phase August, 2022|Participants receive the Data Health VET intervention in all its steps starting in August 2022
89238080|NCT05307575||Post-COVID syndrome (PCS) Severe COVID-19|Severe COVID-19 with PCS with cognitive complains
89238081|NCT05307575||Post-COVID syndrome (PCS) Mild COVID-19|Mild COVID-19 with PCS with cognitive complains
89238082|NCT05307575||Controls|Healthy adult controls
89238083|NCT05307549||Post-COVID patients|Adults survivors from severe COVID-19
89238084|NCT05307549||Controls|Healthy adult controls
89238085|NCT05306652|Experimental|A - Home based supervised physical exercise|patients will have a home-based physical activity prescription
89238086|NCT05306652|Active Comparator|B- Unsupervised physical exercise|patients will receive a physical activity counselling, without a real prescription and supervision
89238087|NCT05305677|Experimental|NMN intervention|8 weeks of NMN
89238088|NCT05305677|Placebo Comparator|Placebo|8 weeks of NMN-free placebo
89238089|NCT05304949||Lucentis|Patients prescribed with Lucentis
89238090|NCT05302245||Caregivers of ABI survivors|Unpaid caregivers of acquired brain injury survivors living in Nova Scotia
89238091|NCT05294341|Active Comparator|Drug 1|"Half of the subjects will be assigned 0.35mg norethindrone pills daily for 7 days.~The other half of the subjects will be 5mg norethindrone acetate pills daily for 7 days."
89238092|NCT05294341|Active Comparator|Drug 2|"Half of the subjects will be assigned 5mg norethindrone acetate pills daily for 7 days.~The other half of the subjects will be 0.35mg norethindrone pills daily for 7 days."
89238093|NCT05293964|Experimental|SIM0270|Phase Ia SIM0270 monotherapy dose escalation and expansion
89238094|NCT05293964|Experimental|SIM0270+palbociclib|Phase Ib SIM0270 with palbociclib dose escalation and expansion
89238095|NCT05293964|Experimental|SIM0270+everolimus|Phase Ib SIM0270 with everolimus dose escalation and expansion
89238096|NCT05293743|Active Comparator|Straight bar|This group will continue using the straight bar as part of their brace, per their current treatment.
89238097|NCT05293743|Experimental|Dynamic bar|This group will use the novel dynamic bar for 30 days instead of their standard straight bar.
89238098|NCT05292144||Coronary Artery Disease (CAD)|
89238099|NCT05291637||Medical management cohort|Patients who have undergone medical management stroke treatment from 1/01/2003 to 01/01/2022; this could include intravenous thrombolysis.
89238100|NCT05291637||EVT management cohort|Patients who have undergone EVT stroke treatment from 01/01/2015 to 01/01/2022
89238101|NCT05290207||Newly diagnosed male obese patients with type 2 diabetes|
89238102|NCT05290207||Newly diagnosed male non-obese patients with type 2 diabetes|
89238103|NCT05290207||Newly diagnosed male patients with type 1 diabetes|
89238104|NCT05290207||Healthy, non-obese men|
89238105|NCT05278624|Active Comparator|Active plus vehicle arm|Subjects will be dispensed a tube containing roflumilast and vehicle in topical formulation
89238106|NCT05278624|Placebo Comparator|Vehicle arm|Subjects will be dispensed a tube containing vehicle only in a topical formulation
89238107|NCT05271240|Experimental|SIACI of Bevacizumab (Avastin) with Temozolomide and Radiation|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation
89238108|NCT05271240|Active Comparator|Standard of care Temozolomide and Radiation|Standard of care Temozolomide and Radiation
89238109|NCT05268042|Experimental|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
89238110|NCT05268042|Active Comparator|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
89238111|NCT05264883|Experimental|Venetoclax combined with Decitabine/Azacitidine and Aclarubicin|"Venetoclax (Ven): oral once daily (100 mg d1, 200 mg d2, 400 mg d3-28);~Decitabine (DAC): 20mg/m2 intravenous for 1 hour daily (d1 to d5);~Azacitidine (AZA): 75mg/m2 subcutaneous at two different sites daily (d1 to d7);(Choose decitabine or azacitidine according to the patient's wishes)~Aclarubicin (Acla): 10mg/m2 intravenous daily (d1 to d3);"
89238112|NCT05264883|Active Comparator|Venetoclax combined with Decitabine/Azacitidine|"Venetoclax (Ven): oral once daily (100 mg d1, 200 mg d2, 400 mg d3-28);~Decitabine (DAC): 20mg/m2 intravenous for 1 hour daily (d1 to d5);~Azacitidine (AZA): 75mg/m2 subcutaneous at two different sites daily (d1 to d7);(Choose decitabine or azacitidine according to the patient's wishes)"
89238113|NCT05263453|Experimental|HL-085+Vemurafenib|HL-085 12mg BID+Vemurafenib 720mg BID combination therapy
89238114|NCT05257343|Placebo Comparator|Placebo|Daily dose (10 mL) of a visually identical liquid placebo supplement to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
89238115|NCT05257343|Experimental|Blood Builder Treatment|Daily dose (10 mL) of liquid iron supplement (Blood Builder®) formulation to be ingested on an empty stomach no sooner than 3 hours after consuming a meal.
89238116|NCT05249400|Experimental|Off-site assistance group|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom. The trainer was not allowed to enter the procedure room and touch the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. Then the trainer would then take over and continue with the cannulation.
89238117|NCT05249400|No Intervention|On-site assistance group|The trainer supervised the trainee's cannulation operation in the procedure room. The trainer was allowed to provide unlimited verbal instructions to the trainee on-site. The trainer was not allowed to touch the endoscope or accessories until the trainee ask for help or failed to achieve deep biliary cannulation. The trainer would halt and correct the trainee's inappropriate maneuvers immediately to avoid unnecessary papillary trauma and potential complications. Then the trainer would then take over and continue with the cannulation.
89238118|NCT05245669|Experimental|ENZ215|ENZ215 Injection:- 60 mg Denosumab (ENZ215) will be administered subcutaneously on day 1.
89238119|NCT05245669|Active Comparator|EU Sourced Prolia|EU sourced Prolia Injection:- 60 mg Denosumab (EU sourced Prolia) will be administered subcutaneously on day 1.
89238120|NCT05245669|Active Comparator|US Sourced Prolia|US sourced Prolia Injection:- 60 mg Denosumab (US sourced Prolia) will be administered subcutaneously on day 1.
89238121|NCT05243316|Active Comparator|Patients with clamping of the chest tube|Patients with 6hour clamping prior to removal
89238122|NCT05243316|Sham Comparator|Patients without clamping of the chest tube|Patients will have chest tube removed immediately
89238123|NCT05233332|Experimental|phase IIa: HL-085 in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085
89238124|NCT05233332|Experimental|phase IIa: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
89238125|NCT05233332|Experimental|phase IIa: HL-085+Vemurafenib in Subjects With RAS or other BRAF-Mutated or MEK1/2-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
89238126|NCT05233332|Experimental|phase IIb: HL-085+Vemurafenib in Subjects With BRAF V600E-Mutated CRC|12mg BID HL-085+720mg BID Vemurafenib
89238127|NCT05232084|Active Comparator|Group 30 = 30 ml of Erector spinae plane block group|In group 30 ml, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
89238128|NCT05232084|Active Comparator|Group 20 = 20 ml of Erector spinae plane block group|In group ESPB, ESPB will be performed with patients in the lateral decubitus position while the surgical site up. US probe will be placed 2-3 cm lateral to the T4 transvers process. The block needle will be inserted cranio-caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
89238129|NCT05229783|Experimental|Electronic chromoendoscopy|High-resolution endoscopy combined with virtual chromoendocopy to detect esophageal displasic lesions
89238130|NCT05229783|Active Comparator|White light endoscopy with Seattle protocol|White light endoscopy to detect esophageal displasic lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
89238131|NCT05224622|Experimental|Drive In|Drive In attendees will undergo one breath sampling.
89238132|NCT05224622|Experimental|Healthy|Healthy attendees will undergo two successive breath sampling.
89238133|NCT05224622|Experimental|Corona Department|Healthy attendees will undergo five successive breath sampling.
89238134|NCT05218902||Retrospectively enrolled cohort|Participants who initiate Azacitidine (AZA) before enrollment
89238135|NCT05218902||Prospectively enrolled cohort|Participants who initiate AZA initiation at enrollment
89238136|NCT05218863||Confirmed AMI|Patients in whom diagnosis of acute mesenteric ischaemia (AMI) was confirmed. For these patients full data collection is required, including 1-year outcome. Maximum 500 patients in this group.
89238137|NCT05218863||AMI suspected but not confirmed|"Patients in whom acute mesenteric ischaemia (AMI) was suspected but not confirmed. For these patients minimal data will be collected, only hospital survival as outcome.~Maximum 2000 patients in this group."
89238138|NCT05217303|Experimental|HL-085|12 mg BID HL-085
89238139|NCT05204537||Patients who developed in-hospital COVID-19 thoracic complications, surgically managed.|"The study population consists of patients who have been surgically treated for COVID-19 thoracic complications.~Thoracic complications have been defined as any condition involving the thorax, directly or indirectly consequence of COVID-19, including either pathologies strictly related to the infection, or iatrogenic effects of therapeutic attempts to treat it. Since the wide span of diagnosis, the novelty of this pathology and the different protocols adopted by participating centers, it is not possible to identify common criteria for surgical indications. A wide variety of pleuro/parenchimal surgical procedures are included. Patients undergone chest tube placement alone are not included in the study."
89238140|NCT05195619|Experimental|Cohort 1|metastatic NSCLC of any histology without any actionable oncogenic driver treated by SOC. Maintenance treatment with pemetrexed and/or maintenance/continuation of pembrolizumab, nivolumab or atezolizumab is allowed.
89238141|NCT05195619|Experimental|Cohort 2|metastatic NSCLC with actionable oncogenic driver such as EGFR mutation, ROS-1 or ALK rearrangement, currently receiving osimertinib, alectinib, lorlatinib or crizotinib as per SOC in each disease entity.
89238142|NCT05181475|Experimental|Sodium Oligomannate Capsules (GV-971)|The recommended dose regimen for subjects: GV-971 450 mg (3 capsules) per dose, bid, po. in morning and evening
89238143|NCT05180669|Experimental|OARSCM|OARSCM (n = 51) patients will receive the same TAU procedures described above. They will also earn chances for prizes, with the same targeted behaviors, escalation of chances for prizes for each targeted behavior in a row, and reset criteria described. Briefly, for scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with documentation of each targeted behavior in a row up to a maximum of 10 draws/targeted behavior. With 38 targeted behaviors (schedule MOUD intake, complete intake, 12 opioid-negative urine toxicology/week over 12 weeks plus bonuses for cocaine-negative tests, and 12 group/individual therapy/week over 12 weeks), patients can earn up to 252 chances for prizes during the 12-week RCT.
89238144|NCT05180669|Sham Comparator|TAU with MyMAT|TAU (n = 51) In the acute care setting, the Behavioral Health Service provides SBIRT for substance use disorders, including OUD. They provide SBIRT as part of TAU, including a warm handoff to an outpatient MOUD treatment with a scheduled outpatient appointment, optimally within 48 hours of the ED visit. TAU outpatient suboxone treatment consists of urine toxicology screening, group/individual therapy, and MOUD prescription continent on drug-negative urine toxicology. Treatment visits are typically weekly in weeks 1-4 and then taper over time, to every other week in weeks 5-8, and monthly in weeks 9-12 and after. Nonadherence can lead to increased frequency/intensity of therapy and urine toxicology until the patient stabilizes. If increased frequency/intensity is unsuccessful, patients may be referred to detoxification and subsequently re-admitted to outpatient care when appropriate. Patients will receive MyMAT a mobile application with educational content regarding MOUD treatment.
89238145|NCT05164419||Wide margin|Patients who underwent surgery with a final pathologic margin of more than 5mm.
89238146|NCT05164419||Close margin|Patients who underwent surgery with a final pathologic margin of less than 5mm
89238147|NCT05164406||With blood salvage|Patients undergoing oncologic liver surgery with systematic use of blood salvage therapy
89238148|NCT05164406||Without blood salvage|Patients undergoing oncologic liver surgery without any blood salvage therapy
89238149|NCT05159362|Experimental|OARSCM|After successful completion of usability testing (Patients: n=12, Providers: n=4), a proof-of-concept field test was completed. OARSCM patients (n = 11) received TAU procedures during enrollment (SBIRT for opioid use disorder and a warm handoff to outpatient MOUD treatment). TAU outpatient MOUD treatment consists of urine toxicology (Utox) screening, group/individual therapy, and MOUD prescription. Treatment visits are typically weekly in weeks 1-4 and taper over time. Patients earned chances for prizes, for targeted behaviors, which escalated for each targeted behavior in a row, with reset criteria. For scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with each targeted behavior in a row up to a max of 10 draws/targeted behavior. There are 18 targeted behaviors during the 4-week field test (schedule intake, complete intake, 4 opioid-negative Utox/week plus bonuses for cocaine-negative Utox, and 4 therapy/week).
89238150|NCT05152459|Experimental|Treatment (tazemetostat, umbralisib, ublituximab)|Patients receive ublituximab IV on days 1, 8, and 15 of cycle 1, day 1 of cycle 2-6, and day 1 of every 3 cycles thereafter. Patients also receive tazemetostat PO BID umbralisib by PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
89238151|NCT05151887|Experimental|Meat meal|Minced beef, potato, string beans, apple sauce, and herb butter
89238152|NCT05151887|Experimental|Plant meal|Quinoa, soy beans, chickpeas, broad beans, and soy sauce
89238153|NCT05151315|Active Comparator|Evolution Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the Evolution Total Knee System
89238154|NCT05151315|Experimental|Evolution with NitrX Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the NitrX Evolution Total Knee System which has the specialized protective coating
89238155|NCT05142618|Active Comparator|Standard Post-operative Instructions|Participants in the control group will be told upon post-operative discharge that they should follow the post-operative instructions.
89238156|NCT05142618|Experimental|Supervised Physical Therapy|Participants in the physical therapy group will be scheduled for visits to the physical therapy clinic beginning two weeks after surgery, and will undergo supervised physical therapy treatments approximately twice per week for eight weeks according to a standardized evidence-based post-operative abdominal core surgery rehabilitation program.
89238157|NCT05139914|Experimental|Dapagliflozin then Placebo|Participants in this arm will receive dapagliflozin and then placebo with a 2 week wash out period in between.
89238158|NCT05139914|Placebo Comparator|Placebo then dapagliflozin|Participants in this arm will receive placebo and then dapagliflozin with a 2 week wash out period in between.
89238159|NCT05138835|Active Comparator|Group 1|Subjects will receive BTX in the glabella and forehead regions, using a traditional injection technique commonly utilized in aesthetic medicine. The traditional injection technique will deposit the neurotoxin into the targeted muscles; with up to 24 units being injected into the forehead and 20 units in the glabella.
89238160|NCT05138835|Experimental|Group 2|Subjects will receive the traditional, deep injection technique, in addition to a superficial intradermal injection technique, which uses micro-aliquots of toxin. The superficial technique will deposit 0.1 units of toxin at 5mm intervals, at the level of the deep dermis.
89238161|NCT05132231||Brodalumab initiator|Eligible adult participants who are enrolling into the SILIQ (brodalumab) Patient Support Program (PSP) and initiating brodalumab as per routine care.
89238162|NCT05132231||Matched cohort|Participants treated with other therapies, with similar characteristics as the subgroup (participants who can be linked to an administrative health services database) of brodalumab treated participants such as age, gender/sex, comorbidities, and prior biologic experience.
89238163|NCT05130853|Experimental|SoCIAL Group|Subjects will conduct SoCIAL programme once a week, for a total of 10 weeks. Every session consists of two different modules: 1) a training programme that helps patients recognize emotions and important social signals (such as facial expressions and prosody) and develop strategy focused on the Theory of Mind; 2) a training in narrative enhancement. Time of administration for both modules is 30 minutes; the operator, however, can choose to focus the session on one module rather than the other, based on the subject's specific needs.
89238164|NCT05130853|Active Comparator|Control Group - Treatment-as-usual (TAU)|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study (10 weeks). TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
89238165|NCT05121545|Other|Pro-GRID treatment Arm|Patients enrolled in this study will receive spatially-fractionated radiotherapy or GRID-therapy, which involves delivering a one-time treatment of high dose radiation to small amounts of tumor in a manner that creates alternating regions of high and low dose radiation within the tumor. Patients will receive 2 (lowest dose) to 18 Gy (highest dose) in a single fraction.
89238166|NCT05112497||Crohn's Disease|"Pregnant CD patients~Newborn of pregnant CD patients~Father of the newborn~Non-pregnant CD women"
89238167|NCT05112497||Healthy Control|"Pregnant women without CD~Newborn of pregnant women without CD~Father of the newborn"
89238168|NCT05100056||HL Participants: BV Salvage Pre-ASCT|Participants diagnosed with HL who undergone or undergoing pre-ASCT BV salvage and continue with post-ASCT treatment will be observed prospectively over 24-month period after treatment cessation.
89238169|NCT05100056||HL Participants: BV Consolidation Treatment Post-ASCT|Participants diagnosed with HL who undergone or undergoing post-ASCT BV consolidation treatment will be observed prospectively over 24-month period after treatment cessation.
89238170|NCT05099107|Active Comparator|Treatment|congenital myopathy patients in this group will receive daily oral salbutamol, three times daily.
89238171|NCT05099107|No Intervention|Non treatment|Congenital myopathy patients in this group will not receive any salbutamol nor placebo.
89238172|NCT05093634|Experimental|POMC or PCSK1 variant|1:1 Randomization
89238173|NCT05093634|Experimental|LEPR variant|1:1 Randomization
89238174|NCT05093634|Experimental|NCOA1 (SRC1) variant|1:1 Randomization
89238175|NCT05093634|Experimental|SH2B1 variant|1:1 Randomization
89238176|NCT05091645||Hip fracture_GFI|Greek patients with hip fracture assessed for frailty syndrome with the adapted for the greek population GFI questionnaire
89238177|NCT05077423|Experimental|Subcutaneous administration of CD33*CD3 BsAb up to 12 cycles|Subcutaneous administration of CD33*CD3 BsAb up to 12 cycles
89238178|NCT05077371|Experimental|Experimental group 1|newly diagnosed breast cancer patients receiving the peer support program at the beginning of their medical treatment.
89238179|NCT05077371|Experimental|Experimental group 2|newly diagnosed breast cancer patients receiving the social peer support program at the end of their medical treatment.
89238180|NCT05062772||Glioblastoma|
89238181|NCT05058040|Experimental|GV-971|The recommended dose regimen for subjects: GV-971 450 mg (3 capsules) per dose, bid, po. in morning and evening
89238182|NCT05057923|Experimental|generation of neutralizing antibody for unvaccinated participants|participants received vaccine 1 capsule of 1×10^10 CFU of B. subtilis spore at day 0, 14, and 28 respectively.
89238183|NCT05057923|Experimental|neutralizing antibody booster for vaccinated participants|participants after 4-month vaccinated with Sinovac received 1 capsule of 1×10^11 CFU of B. subtilis spore
89238184|NCT05046002||Prospective (cases)|Patients who develop new symptoms of suspected myocarditis/pericarditis within 42 days of receiving a COVID-19 vaccination. The clinical symptoms include chest pain, pressure, or discomfort; dyspnea, shortness of breath, or pain with breathing; palpitations; diaphoresis or sudden death. The symptoms can also be non-specific, including fatigue, abdominal pain, dizziness or syncope, edema, cough or irritability, vomiting, poor feeding, tachypnea or lethargy in young children
89238185|NCT05046002||Prospective (Control Positive)|Family members/relatives who have been vaccinated in a similar timeframe with the participant and had similar reactions
89238186|NCT05046002||Prospective (Control Negative)|"Family members/relatives who have been vaccinated in a similar timeframe with the participants but did not experience myocarditis side-effects.~If a relative is not available, then a voluntary control who has received the same COVID-19 vaccine in a similar time frame can be recruited."
89238187|NCT05046002||Retrospective|Identified patients, previously diagnosed with the condition, at participating centers
89238188|NCT05035810|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
89238189|NCT05035810|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
89238190|NCT05035810|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
89238191|NCT05035810|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
89238192|NCT05030090|Active Comparator|Control group|"Consulted by the dietitian using communication software (Line) or telephone.~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~The nutrition care plan period will be three months."
89238193|NCT05030090|Experimental|Nutrition care plan group A|"Consulted by the dietitian using communication software (Line) or telephone.~Implement a daily diet with a concentrated high-calorie and high-protein liquid supplement~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~3.The nutrition care plan period will be three months."
89238194|NCT05030090|Experimental|Nutrition care plan group B|"Consulted by the dietitian using communication software (Line) or telephone.~Implement a daily diet with a concentrated high-calorie and high-protein liquid supplement and powdered supplement 1 and nutritional products and powdered supplement 2~At 0.5, 1, 1.5, 2, 2.5, and 3 months will track the biochemical data, assess nutritional status and quality of life.~The nutrition care plan period will be three months."
89238195|NCT05003726|Experimental|Non-pharmacological group including KM|Non-pharmacological treatment including Korean medicine will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
89238196|NCT05003726|Active Comparator|Pharmacological group|Pharmacological treatment will be implemented to the participants for total 8 weeks. This is a pragmatic clinical trial, and the specific intervention will be determined according to the physician's choice. intervention data will be recorded in the case report form.
89238197|NCT04998786|Experimental|assessment of treatment Ixazomib, dexamethasone, iberdomide|Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression
89238198|NCT04998500|Experimental|GH intervention - control intervention|Participants will receive daily subcutaneous injections of growth hormone for 7 days. Approximately 1-4 months later, the participants will receive daily subcutaneous injections of control intervention for 7 days consisting of saline and GH receptor blockade (Pegvisomant).
89238199|NCT04998500|Experimental|Control intervention - GH intervention|Participants will receive daily subcutaneous injections of control intervention for 7 days consisting of saline and GH receptor blockade (Pegvisomant). Approximately 1-4 months later, the participants will receive daily subcutaneous injections of growth hormone for 7 days.
89238200|NCT04988399|Experimental|Reiki Recipients|The Practitioner enters a gassho (two hands coming together at the heart) meditative state with the Distance Symbol. Reiji-ho - moving the joined hands until the thumbs touch the space between the brows. Going into a relaxed state by using a breathing technique. Say the person's name three times. Proceed with byosen (method using the sensitivity in the hands to treat those areas in need of Reiki) scanning technique. Chiryo (standard session visualizing all hand positions) for 5 minutes each: Jawbone-Back of the head-Throat-Lungs-Area of participant's concern-Stomach-Intestines-Kidneys-Spinal cord. At the end of the session, visualize towards the participant's feet to help integrate the healing. Visualize brushing the Biomagnetic field around the participant's body from head to feet. Inform the participant that the session has been completed. Include time to rest quietly for a few minutes. Encourage participant to sip water (if they prefer) and ask them about their experience.
89238201|NCT04983225|Experimental|1×10^6 cells/site group|Human Dental Pulp Stem Cells Injection: 1×10^6 cells/periodontal defect site.
89238202|NCT04983225|Experimental|5×10^6 cells/site group|Human Dental Pulp Stem Cells Injection: 5×10^6 cells/periodontal defect site.
89238203|NCT04983225|Experimental|1×10^7 cells/site group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site.
89238204|NCT04983225|Experimental|2×10^7 cells/two sites group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site, two locations in total, and the total cell injection volume is 2 × 10^7 cells/2 periodontal defect sites.
89238205|NCT04983225|Experimental|3~4×10^7 cells/three or four sites group|Human Dental Pulp Stem Cells Injection: 1×10^7 cells/periodontal defect site, three or four locations in total, and the total cell injection volume is 3 × 10^7 to 4 × 10^7 cells/3 to 4 periodontal defect sites.
89238206|NCT04983225|Placebo Comparator|Saline solution group|Saline solution: 0.6mL/periodontal defect site.
89238207|NCT04976569|Experimental|DBS Regulation Group|All participants will receive STN-DBS sleep regulation.
89238208|NCT04975191|Other|Resources Program (RP)|
89238209|NCT04975191|Active Comparator|Personalized Feedback Program (PFP)|
89238210|NCT04975191|Active Comparator|Brief motivational intervention (BMI)|
89238211|NCT04975191|Active Comparator|Combined PFP+BMI|
89238212|NCT04964089|Experimental|KSI-301 (Treatment Group A)|Intravitreal injection of KSI-301 (5 mg) at Day 1 once every 4 weeks via intravitreal injection through Week 44.
89238213|NCT04964089|Active Comparator|Aflibercept (Treatment Group B)|Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 3 monthly doses followed by intravitreal injection of aflibercept (2 mg) once every 8 weeks from Week 16 to Week 44. Sham injections will be administered at each monthly visit where an active treatment is not administered.
89238214|NCT04963075|Experimental|Unilaterally blind Subjects will be exposed to visual-auditory stimulation|The over-arching objective is to evaluate the functional recovery of vision in hemianopic patients engaged with a multisensory training paradigm. Unilaterally blind participants will participate in weekly training sessions in which they are exposed to high-density spatiotemporally congruent and consistent visual-auditory stimulation. The participants will be tested on a battery of visual tasks probing different levels of function in different environments in a longitudinal study to track recovery.
89238215|NCT04961957|Active Comparator|Waterproof padding|Waterproof, short leg walking cast for 3-7 weeks
89238216|NCT04961957|Active Comparator|Non-waterproof padding|Non-waterproof, short leg walking cast for 3-7 weeks
89238217|NCT04959383|Experimental|Low complexity Exergame balance training group|Wobble board based exergame balance training, the game complexity will be low for this group.
89238218|NCT04959383|Experimental|Moderate complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be moderate for this group.
89238219|NCT04959383|Experimental|High complexity exergame balance training group|Wobble board based exergame balance training, game complexity will be high for this group.
89238220|NCT04959383|Active Comparator|Control group|Wii fit based Exergame training on a stable surface
89238221|NCT04943432|Experimental|People who inject drugs|People who inject drugs recruited from a needle exchange program who will participate in a psychosocial intervention
89238222|NCT04943094||TURBT alone|Patients treated with TURBT without adjuvant instillation therapy
89238223|NCT04943094||TURBT and mitomycin C|Patients treated with TURBT followed by six adjuvant instillations with mitomycin C
89238224|NCT04943094||TURBT and bacillus Calmette-Guerin|Patients treated with TURBT followed by six adjuvant instillations with BCG
89238225|NCT04941807|Experimental|Platelet-rich plasma|The proximal nail fold is cleansed with alcohol and platelet-rich plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
89238226|NCT04941807|Placebo Comparator|Platelet-poor plasma|The proximal nail fold is cleansed with alcohol and platelet-poor plasma obtained from the patient is injected using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
89238227|NCT04931355|Experimental|Acupuncture treatment group|Method: Acupuncture at Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi. The acupuncture treatment starts on the 5th day of the menstrual cycle and lasts to the days before IVF-ET
89238228|NCT04931355|Active Comparator|Western medicine group|The western medicine group will be treated with conventional western medicine
89238229|NCT04924374|Experimental|anti PD1 therapy plus Microbiota Transplant|"Active arm: Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (>30g/day).~anti PD1 therapy every 2-3 weeks"
89238230|NCT04924374|Active Comparator|anti PD1 therapy|Control arm: no intervention before anti PD1 therapy
89238231|NCT04918147|Experimental|Cohort 1a: Elotuzumab-One-Month Regimen (Open-Label) + Pred Taper|"Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, and the prescribed 10-week prednisone taper.~Elotuzumab: 10 mg/kg administered once weekly, intravenously for 4 doses, per protocol.~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs)."
89238232|NCT04918147|Experimental|Cohort 1b: Elotuzumab-Twelve-Month Regimen (Open-Label) + Pred Taper|"Per protocol: Six participants will receive elotuzumab over a 48 week period, dose of 10mg/kg IV x 1, at baseline, then at weeks 8, 16, 24, 32 and 40 (for a total of 6 doses), with the prescribed 10-week prednisone taper.~Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol.~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs)."
89238233|NCT04918147|Experimental|Cohort 2: Arm A- Elotuzumab (Randomized) + Pred Taper|"Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized).~Assuming no safety signal for Cohort 1, forty-two participants will receive elotuzumab per the regimen prescribed above in Part 1B, with the prescribed 10-week prednisone taper.~Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol.~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that is taken daily by mouth, per protocol. Dosage in milligrams (mgs)."
89238234|NCT04918147|Placebo Comparator|Cohort 2: Arm B-Placebo (Randomized) + Pred Taper|"Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized).~Twenty-one participants will receive placebo for elotuzumab on day 0, then weeks 8, 16, 24, 32 and 40, and the prescribed 10-week prednisone taper.~Placebo for elotuzumab: Administered on same schedule as elotuzumab described in Cohort 2 Arm A: intravenously, per protocol.~Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 taken daily by mouth, per protocol. Dosage in milligrams (mgs)."
89238235|NCT04914182|Experimental|LASER|In the intervention group, the laser will be applied to the points of the edges of the lesion, with a distance of one centimeter between them. The laser will be applied in a punctual way, in points on the edges of the lesion site, with a distance of one centimeter between them. This application will take place three times: six hours after delivery, 24 and 48 hours after delivery.
89238236|NCT04914182|Sham Comparator|CONTROL|In the control group, the sham laser will be applied the exact same way as the real laser, to the points of the edges of the lesion, with a distance of one centimeter between them. The sham laser will be applied in a punctual way, in points on the edges of the lesion site, with a distance of one centimeter between them. This application will take place three times: six hours after delivery, 24 and 48 hours after delivery.
89238237|NCT04912531|No Intervention|Usual Care Arm|No intervention will be given to patients in the usual care arm.
89238238|NCT04912531|Experimental|Virtual Reality and Olfactory Stimuli Arm|Patients will undergo a virtual reality and olfactory stimuli therapy session at their appointment where they receive their pulmonary function test, 90 minutes before surgery, and each day they recover in the hospital. In addition, patients will receive nighttime olfactory stimulation using a bedside olfaction device.
89238239|NCT04902625|Active Comparator|Naltrexone-Bupropion combination|The patients in this arm will receive 2 tablets of naltrexone-bupropion 8/90mg 2 times daily in combination with the Back On Track module.
89238240|NCT04902625|No Intervention|Control|The patients is this arm will only participate in the Back On Track module and will not receive any investigational or placebo product.
89238241|NCT04888117||Laparoscopic cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a laparoscopic cholecystectomy.
89238242|NCT04888117||Robotic-assisted cholecystectomy|Subject has a diagnosis of acute cholecystitis and is admitted through the ER for a robotic-assisted cholecystectomy.
89238243|NCT04885985|Experimental|DEB catheter|Use DEB catheter to treat the stenosis or occlusion in below popliteal artery of experimental arm
89238244|NCT04884737|No Intervention|Pre-Intervention|Pre-Intervention Group participants will have 6 visits. During the pre-intervention baseline (3 months) participants will undergo visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, conducted by the research staff: 1.) consent and preoperative, 2.) immediately following surgery in the Post Anesthesia Recovery (PAR) Unit, 3.) on transfer to the floor unit, 4.) post-operative day 1, 5.) post-operative day 3 and 6.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 40 minutes.
89238245|NCT04884737|Experimental|Intervention|Intervention Group participants will have 7 visits. During intervention (3 months) research staff will conduct the visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, and place the MBF dressings to the face (chin, cheeks, forehead), chest and iliac crest: 1.consent and preoperative, 2. MBF dressing placement, 3.) immediately following surgery in the PAR unit with the MBF dressings removed , 4.) on transfer to the floor unit, 5.) post-operative day 1, 6.) post operative day 3 and 7.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 55 minutes.
89238246|NCT04892303|Other|High-risk thyroid cancer patients|All study patients will have histologically confirmed recurrence of thyroid cancer that is incompletely responsive to initial surgery.
89238247|NCT04879537|No Intervention|Control|Participants in this group are routinely treated.
89238248|NCT04879537|Active Comparator|Telemedical support|Participants in this group are routinely treated with additional telemedical support and the use of the early warning system.
89238249|NCT04861077|Experimental|Breast [18F]FMISO-PET with contrast-enhanced magnetic resonance (MR)|"The patient will have a plastic peripheral intravenous catheter placed in the arm for administration of 10 millicuries (mCi)/10milliliters (mL) [18F]FMISO (≤ 15 µg/injected dose) followed by an uptake of 120 minutes.~The injection will be infused nominally over one minute followed by a saline flush. After uptake, the patient will be scanned on the PET/MR for 60 minutes and will receive a contrast injection of gadoteridol during the dynamic sequence of the exam. The patient can be scanned on the PET/CT if the PET/MR is unavailable. During this study patients will be scheduled for up to 3 imaging visits. The first imaging visit will be at baseline prior to starting immunotherapy and is required for study eligibility. If for some reason the patient cannot complete the remaining 2 imaging visits, only one additional imaging visit during the identified times is necessary to remain eligible."
89238250|NCT04848792|Experimental|SFN supplement|The oral sulforaphane supplement is a myrosinase-active whole broccoli sprout material (EnduraCell Bioactive, Cell-Logic, Queensland, AU) containing 14 mg SFN per capsule. Three capsules will be consumed 90 min prior to the start of the acute exercise trial. The dose of 3 capsules is equivalent to approximately 220 µmol of SFN, which is comparable to that of other studies using broccoli sprout extracts and the recommended single dose.
89238251|NCT04848792|Placebo Comparator|Placebo|Placebo capsules provided by Cell-Logic.
89238252|NCT04843306|Experimental|ABC technique plus biofeedback|Patients will utilize biophysical feedback and coaching during the planning and treatment sessions for radiotherapy to help patients with the ABC technique.
89238253|NCT04843306|Active Comparator|Standard of care ABC technique.|Patients will standard of care instructions for using the ABC technique during the planning and treatment sessions for radiotherapy.
89238254|NCT04833075|Other|Single arm|additional blood sampling (single arm)
89238255|NCT04808206||Obese patients eligible for laparoscopic bariatric surgery|
89238256|NCT04805775|Experimental|Desflurane Inhalation Group|Anesthesia maintenance: Desflurane inhalation (MAC 1.0-1.2) Sufentanil 0.3-0.5 μg / (kg·h) Cisatracurium 1-3 μg / (kg·min)
89238257|NCT04805775|Active Comparator|Propofol Group|Anesthesia maintenance: Propofol TCI: 3-4ug / ml Sufentanil 0.3-0.5 μg / (kg·h) Cisatracurium 1-3 μg / (kg·min)
89238258|NCT04800744|Experimental|Lavender Peppermint Elequil Aromatab|Participants will have a lavender peppermint elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new treatment elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
89238259|NCT04800744|Active Comparator|Sweet Almond Oil Elequil Aromatab|Participants will have a sweet almond oil active comparator elequil aromatab applied in same day admissions area at least 1 hour prior to the start of unilateral hip replacement. Thereafter, the participant will apply a new active comparator elequil aromatab at 24 hrs, 36 hrs, 48 hrs, and 60 hrs post-operative.
89238260|NCT04798534|Experimental|Intervention group|CHW in the intervention arm will receive intervention through a combination of in-person training sessions and internet support. MMT patients in the intervention arm can use a specially designed online platform to communicate with their CHW.
89238261|NCT04798534|No Intervention|Control group|The control group CHW will perform business as usual. Both control group CHW and MMT patients do not have access to the online platform.
89238262|NCT04795817||Single arm|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA
89238263|NCT04758702|Experimental|GROUP 1|L-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
89238264|NCT04758702|Experimental|GROUP 2|H-PRF membranes will be placed on the palatal donor site to help stabilizing the blood clot and release of growth factors that help in deceasing the discomfort wound healing.
89238265|NCT04758702|Experimental|GROUP 3|A surgical stent will be delivered to cover the surgical site and apply pressure on the wound site.
89238266|NCT04755647|Experimental|Nitric Oxide-Releasing Solution (NORS)|Five litre foot bath delivery NORS
89238267|NCT04755647|Placebo Comparator|Saline|Five litre foot bath delivery NORS
89238268|NCT04739423|Experimental|CST-103/CST-107 to Placebo|Subjects will receive daily doses of CST-103 co-administered with CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by matching placebo for CST-103 and matching placebo for CST-107 for 14 days.
89238269|NCT04739423|Experimental|Placebo to CST-103/CST-107|Subjects will receive daily doses of matching placebo for CST-103 co-administered with matching placebo for CST-107 for 14 days, followed by a washout period of no drug for 14 days, followed by daily doses of CST-103 co-administered with CST-107 for 14 days.
89238270|NCT04730557|Experimental|Weight-Loss|Participants in the weight-loss intervention arm of the study will be enrolled in an individualized 6-month intervention designed to achieve a 10% reduction of body weight relative to baseline. Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine [29]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Intervention activities include individual diet counseling, group support, goal setting, self-monitoring, stress management, and problem solving. Weekly group support and education sessions, along with daily food journaling and weekly weigh-ins, are recognized approaches for successful weight loss [30-32]. Once the weight loss goal is achieved, diets will be liberalized for weight maintenance.
89238271|NCT04730557|No Intervention|Wellness Education|Control participants will be counseled to maintain their baseline body weight and level of physical activity. They will report weights weekly and if their weight deviates from baseline they will be asked to keep daily food logs and counseled to return calorie intakes to weight maintenance level. To document diet intakes/adherence, 3-day food records will be collected at months 0, 3, and 6 and analyzed for calorie and nutrient composition. Participants will be encouraged not to change their physical activity levels from baseline and their activity will be monitored by Actigraph activity monitors worn in 7-day periods at months 0, 3, and 6. In addition, each participant will be invited to enter the weight loss intervention after completion of the health education control course.
89238272|NCT04704570|Experimental|Treatment Group|Remotely Exercises 3 times a week, 8 weeks remotely (with video) spinal stabilization exercises
89238273|NCT04704570|Other|Control Group|Face to Face Exercises 3 times a week, 8 weeks face to face (in clinic) spinal stabilization exercises
89238274|NCT04704570|Other|Remotely assessment Group-Face to Face Assessment Group|First, a remote evaluation and then a face to face evaluation will be made.
89238275|NCT04704570|Other|Face to Face Assessment Group-Remotely assessment Group|First, a facet o face evaluation and then a remote evaluation will be made.
89238276|NCT04698356|Experimental|Validation of auditory-cognitive training paradigm|In order to provide maximal speech-in-noise training benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate the translated and adjusted sentences (based on the Nottingham UK PLUS training paradigm), the adaptive procedure, and the short-term memory component, in young, normal-hearing adults (18-30 years). Based on the results of this pilot study, the investigators can further optimize the sentences and procedures to be used during the training paradigm for older adults.
89238277|NCT04697264|Experimental|Patients with endometrial cancer|"Potential participants will be identified in the Royal Surrey NHS Foundation trust - either seen here or referred here and receiving her treatment here for diagnosed endometrial cancer.~Patients diagnosed with endometrial cancer will be identified through the Gynaecological Oncology Multi-Disciplinary Team meeting or by the Gynaecological Oncology or Medical Oncology teams.~Blood sample will be collected on the day of the surgery when they are in the theatres and then repeated on day 1 post-operative in gynaecology ward and at 3/6 months post-surgery follow-up in clinic.~For the women undergoing chemotherapy, blood sample will be procured prior to commencing chemotherapy and after 3rd (with the blood test before the fourth cycle of chemotherapy) and 6th cycles of chemotherapy."
89238278|NCT04696432|Experimental|Prizloncabtagene autoleucel|Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion.
89238279|NCT04661748|Active Comparator|Intervention arm|Active alarms
89238280|NCT04661748|No Intervention|no intervention|No alarms
89238281|NCT04661501|Active Comparator|AlloDerm group|Device for immediate implant based breast reconstruction.
89238282|NCT04661501|Active Comparator|AlloMax group|Device for immediate implant based breast reconstruction.
89238283|NCT04661501|Active Comparator|DermACELL group|Device for immediate implant based breast reconstruction.
89238284|NCT04661501|Active Comparator|Flex HD group|Device for immediate implant based breast reconstruction.
89238285|NCT04652609|Experimental|PRESIONA|An adapted therapeutic exercise program using blood flow restriction cuff perfomed during chemotherapy treatment. 24-36 sessions of 1 hour multimodal components: aerobic, strength and fascial release exercises. Frequency will be adapted to the recovery status of each patient.
89238286|NCT04652609|No Intervention|Control group|Patients undergoing usual medical treatment
89238287|NCT04648046|Experimental|Low Dose CAR-T Cells Only|Participants will NOT undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
89238288|NCT04648046|Experimental|Conditioning + Low Dose CAR-T Cells|Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
89238289|NCT04648046|Experimental|Conditioning + High Dose CAR-T Cells|Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 1 x 10^6 cells/kg LVgp120duoCAR-T cells will be infused into the participant. ART will be interrupted immediately after infusion.
89238290|NCT04648020|Placebo Comparator|Placebo|Placebo Mucoadhesive Buccal Tablet given daily during chemoradiotherapy
89238291|NCT04648020|Experimental|Clonidine HCl Mucoadhesive Buccal Tablet (MBT)|Clonidine HCl MBT given daily during chemoradiotherapy
89238292|NCT04637113||All patients admitted to the PICU meeting eligible criteria|This is a non-interventional study.
89238293|NCT04623398|Experimental|Lithium|"Li+ is an FDA (NDA: 016834) and ANSM (AMM 3400931376339) approved drug. There are two lithium salts that are marketed in France, Teralithe LI (cp 250mg) and Teralithe LP (cp 400mg).~The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials."
89238294|NCT04623398|Placebo Comparator|Placebo|"Capsules containing lactose monohydrate in all points resembling the capsules of active ingredients.~Capsules of pla62.5 mg, pla125 mg and pla250 mg (pla=placebo)"
89238295|NCT04617756|Experimental|Durvalumab+Gemcitabine/Cisplatin or with Gemcitabine/Carboplatin|This is a single arm including 2 different cohorts : Cohort 1 includes patients on 40mg/ML Gemcitabine/50mg Cisplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles and Cohort 2 includes patients on 40mg/ML Gemcitabine/450mg Carboplatin used in combination with 50 mg/mL of intravenous Durvalumab (laboratory code MEDI 4736) every 3 weeks for a total of 4 cycles..
89238296|NCT04615650|Active Comparator|Surgical treatment|Patients randomised to operative treatment will have their surgery performed by an orthopaedic surgeon or by orthopaedic trainees under the supervision of a consultant, when fit for surgery. The surgical technique and choice of implants will be decided by the surgeon in order to closely resemble everyday clinical practice. The syndesmosis must be reduced (closed or open) and fixed. Postoperatively, the patients will be treated with an ankle orthosis for six weeks with weight-bearing as tolerated.
89238297|NCT04615650|Experimental|Non-surgical treatment|Patients randomised to non-operative treatment are treated with an ankle orthosis for six weeks with weight-bearing as tolerated. Other types of casts can be used if preferred by the treating orthopaedic surgeon, but the cast must allow full weight-bearing and must prevent equinus position.
89238298|NCT04614194|Experimental|Arm A: Abemaciclib + Letrozole|Patient will take twice daily abemaciclib and daily letrozole (Arm A) for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
89238299|NCT04614194|Experimental|Arm B: Letrozole|Patient will take daily letrozole only (Arm B) according to treatment arm for 2 weeks prior to your planned standard treatment for breast cancer. In addition to tests and procedures that are part of your standard care, you will have a biopsy and blood draw for study purposes prior to starting study treatment.
89238300|NCT04604431|Experimental|Intervention (CDS Tool Integrated)|Pediatric clinicians in this arm will receive the iREACH CDS tool and education on the PPA Guidelines to support adherence to the Guidelines.
89238301|NCT04604431|No Intervention|Control (No CDS Tool Integrated)|No study procedures will be implemented in the control practices, and their pediatric clinicians will not receive extra PPA Guidelines education, nor will any EHR modifications be made in their practices to support adherence to PPA Guidelines.
89238302|NCT04603313||Experimental group|12 departments in mainland France covered by the tele-advice system open to general practitioners
89238303|NCT04603313||Control group|84 departments in mainland France not covered by the tele-advice system.
89238304|NCT04602962||Fertility preservation performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
89238305|NCT04602962||Fertility preservation not performed|subgroup analysis by cause of infertility, clinical characteristics, biochemical markers
89238306|NCT04594824||Term neonates|
89238307|NCT04594824||Preterm neonates|
89238308|NCT04593654||low dose thromboprophylaxis|Daily dose of 2500-4500 IU tinzaparin or 2500-5000 IU dalteparin
89238309|NCT04593654||medium dose thromboprophylaxis|Daily dose of >4500 IU but <175 IU/kg of body weight tinzaparin or >5000 IU but <200 IU/kg of body weight dalteparin
89238310|NCT04593654||high dose thromboprophylaxis|Daily dose of ≥ 175 IU/kg of body weight tinzaparin or ≥200 IU/kg of body weight dalteparin
89238311|NCT04589247||Patients with cancer treated with definitive-intent radiotherapy|Histologically confirmed loco-regional to advanced primary cancer, including but not limited to lung cancer, esophageal, or gastro-intestinal cancers at risk of developing radiotherapy-related toxicity.
89238312|NCT04585893|Experimental|Single Arm Rituximab|"The safety and efficacy of first-line rituximab will be assessed through a risk-stratified rituximab-based Multicentric Castleman disease (MCD) The planned sample size is 27 adult patients accrued at a rate of 10 patients annually.~High-risk patients (defined as patients with ECOG performance status >2 or hemoglobin <8 g/dL) will receive four weekly doses of rituximab (375 mg/m2) and etoposide (100 mg/m2).~Low-risk patients will receive the same dose of rituximab (four weekly doses at 375 mg/m2) alone."
89238313|NCT04583124|Experimental|ATENTO-B|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed before the begining of medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
89238314|NCT04583124|Active Comparator|ATENTO-T|"A multimodal program based on adapted therapeutic exercise and vagal activation techniques performed throughout medical treatment for breast cancer. It consits of 18 sessions to perform aerobic and strength exercises (90' approximately plus myofascial stretching and breathing exercises (20'). Frequency of sessions will be adapted to the recovery of each patients (by heart rate variability parameters and patient perception).~ATENTO is divided in two parts: a) general phase: aimed to improve the overall physical health condition and to correctly learn the execution of each exercise (2 weeks); and b) specific phase: aimed to neurotoxicity prevention."
89238315|NCT04581603|Active Comparator|MED + CBT-I|This arm will consist of patients treated with topiramate, naltrexone, or topiramate + naltrexone on a clinical basis for 6 weeks and then randomized to Cognitive Behavioral Therapy for Insomnia (CBT-I). They will be continued on MED for the next 8 weeks of CBT-I treatment.
89238316|NCT04581603|Placebo Comparator|MED + SHE|This arm will consist of patients treated with topiramate, naltrexone, or topiramate + naltrexone for 6 weeks on a clinical basis for 6 weeks and then randomized to Sleep Hygiene Education (SHE). They will be continued on MED for the next 8 weeks of SHE treatment.
89238317|NCT04576819||Sepsis cohort|"Inclusion criteria~Patients meeting the Sepsis-3 definition of sepsis or septic shock (the sequential organ failure assessment (SOFA) score will be used for organ failure assessment for Sepsis-3 criteria)~Treatment with an institutional, evidence-based guideline management bundle for sepsis~Within 24 hrs of sepsis recognition~Exclusion criteria:~alternative/confounding diagnosis causing shock (e.g., myocardial infarction or pulmonary embolus),~uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),~advanced directives limiting resuscitative efforts,~organ transplant recipient on immunosuppressive agents,~known pregnancy,~inability to obtain informed consent,~HIV/AIDS with CD4 count < 200,~absolute neutrophil count < 500"
89238318|NCT04573517|Experimental|Early amniotomy|Subjects randomized to this arm will undergo amniotomy within 2 hours of removal of Foley balloon.
89238319|NCT04573517|Active Comparator|Delayed amniotomy|Subjects randomized to this arm will undergo amniotomy at least 4 hours after removal of Foley balloon.
89238320|NCT04565535|Experimental|Intervention arm|Liver donors undergoing lifestyle optimisation
89238321|NCT04565535|No Intervention|Control arm|Liver donors who continue normal lifestyle.
89238322|NCT04558346|Placebo Comparator|Placebo|"Placebo (40ug/kg) will be self-administered twice daily for 14 days.~ONLY THE PART B (ACUTE) SUBJECTS WILL BE RANDOMIZED AND MAY RECEIVE PLACEBO."
89238323|NCT04558346|Experimental|Ghrelin (OXE-103)|"OXE-103 (40ug/kg) will be self-administered twice daily for 14 days.~PART A (POST-ACUTE) SUBJECTS WILL BE OFFERED EXPERIMENTAL TREATMENT WITHOUT RANDOMIZATION.~PART B (ACUTE) SUBJECTS WILL BE DOUBLE-BLIND RANDOMIZED TO EXPERIMENTAL OR PLACEBO TREATMENT."
89238324|NCT04547946||dabrafenib + trametinib|Patients administered dabrafenib and trametinib
89238325|NCT04542889|Experimental|Absolute coronary resistances and IMR after angioplasty|Patients with STEMI by acute occlusion of a large caliber coronary artery that had been admitted to hospital less than 12 hours and revascularized by primary angioplasty with good final result.
89238326|NCT04535700|Experimental|pioglitazone|
89238327|NCT04535700|Other|Standard of care treatment|
89238328|NCT04515498||CloudCath System|Patients with End Stage Renal Disease (ESRD) currently using home peritoneal dialysis
89238329|NCT04492020|Experimental|Treatment Sequence A|Participants randomized to Treatment Sequence A will receive placebo to treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying prodrome event
89238330|NCT04492020|Experimental|Treatment Sequence B|Participants randomized to Treatment Sequence B will receive ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second qualifying prodrome event
89238331|NCT04491591|Experimental|BREASTChoice|"After consent, the participant will be randomized~Depending on the clinic work-flow, the patient will be sent the link to the BREASTChoice tool by email or MyChart message~1) prior to their visit with the surgeon;~2) at the time of their visit with the surgeon;~3) after the surgeon appointment~Will receive an online survey to complete after viewing the BREASTChoice tool assessing socio-demographics, knowledge, health literacy, decisional conflict, patient engagement, health-related quality of life, preferred decision role, and usability of the website.~Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
89238332|NCT04491591|Active Comparator|Attention Control Website|"After consent, the participant will be randomized~Depending on the clinic work-flow, the patient will be sent the link to the website by email or MyChart message~1) prior to their visit with the surgeon;~2) at the time of their visit with the surgeon;~3) after the surgeon appointment~Will receive an online survey to complete after viewing the website assessing socio-demographics, knowledge, preferences, health literacy, decisional conflict, measure of patient engagement, health-related quality of life, preferred decision role, consult time, and usability of the website.~Will pull from the electronic medical record breast cancer diagnosis stage, previous breast cancer surgery and participants' reconstruction decision after enrollment."
89238333|NCT04491591|Experimental|Clinicians|"Will receive a brief virtual training on how BREASTChoice functions and the features, including placement of the patient tool summary in the electronic health record~Will complete pre-post trial survey about shared decision making"
89238334|NCT04479943|No Intervention|Pre-intervention/control|160-200 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6 months prior to implementation of the unit-based MOVIN intervention.
89238335|NCT04479943|Experimental|Post-intervention|160-200 older adult patients (age 65 or older) will be recruited on four units across two hospitals (two units per hospital) over 6 months after MOVIN has been implemented on the unit.
89238336|NCT04479735|Experimental|VR goggle with venipuncture|Virtual reality goggles SamsungGearVR supplied by KindVR will be placed on patients at least 2 min prior to venipuncture. All patients will also receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture.
89238337|NCT04479735|No Intervention|no VR goggle with venipuncture|Patients will receive Lidocaine 2.5%/Prilocaine 2.5% cream at least 60 min prior to venipuncture but NO virtual reality goggles.
89238338|NCT04449328|Experimental|Patient with first stroke causing hemiplegic|"Patient with first stroke causing hemiplegic will be included.~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:~Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))~Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
89238339|NCT04449328|Sham Comparator|healthy subjects|"Healthy subjects will be included.~They will have Computerized Mirror Therapy (CMT) associated at tendon vibration:~Visit 1: wrist flexion (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of extension+vibration(incongruence))~Visit 2 (1 week later): wrist extension (right and left arms) with 5 randomized experimental conditions (vision+vibration, vision alone, vibration alone, static image+vibration, vision of flexion+vibration (incongruence)) These conditions will be recording by the Kinovea software, which allows the measurement of angles and amplitudes."
89238340|NCT04445597|Other|COVID-19 positive or negative patients|Hospitalised patients with or without COVID-19 (with or without olfactory dysfunctions)
89238341|NCT04439669|Active Comparator|Starts with active stimulation|"Active nrTMS is given to S2 at the right side (10 sessions in a three week period). Thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to M1 contralateral to the side of pain. After 5 stimulation sessions the response is evaluated. If pain is still ≥510, the investigators change the target to the S2 on the left side for five sessions. If there is response with pain relief, a maintenance therapy with this target is offered for 6 months with gradually reducing stimulation sessions."
89238342|NCT04439669|Placebo Comparator|Starts with sham stimulation|"Sham nrTMS will be targeted to the S2 on the right side, but using a sham box/coil. Stimulation period is similar than for the active comparator. Similarly, thereafter, a new, open label phase will start if the average pain at 3 month follow-up is ≥5/10. Then, the nrTMS will be targeted to S2 at the right side. After 5 stimulation sessions the response is evaluated. If pain is still ≥5/10, the investigators change the target to M1 on the contralateral side of the pain and furthermore to S2 at the left side after 5 stimulation sessions, if pain is still ≥5/10."
89238343|NCT04437225|Experimental|Constant Infusion of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 5:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 7:30 am for the carbon 13 glycolate infusion which will occur at a constant rate for 10 hours, following a priming dose. From 7:30 am to 5:30 pm, urine collections will occur hourly, and from 8:30 am to 5:30 pm, IV blood collections will occur every half hour. Subjects will receive a meal at 5:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
89238344|NCT04437225|Experimental|Single Intravenous Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. An intravenous (IV) catheter will be placed in a vein on the back of the hand at 8:30 am for a single dose of carbon-13 glycolate to be administered. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, IV blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
89238345|NCT04437225|Experimental|Single Oral Dose of 13C2-Glycolate|Subjects will consume a controlled diet for 5 days total. On Days 3 and 4, subjects will collect 24 hour urines. On Day 5, they will come to the Clinical Research Unit (CRU) in the fasted state for a visit lasting from 7:00 am to 2:30 pm. At 8:30 am, subjects will ingest the carbon-13 glycolate, dissolved in to 50 ml (about 1/4 cup) of water. From 7:30 am to 2:30 pm, urine collections will occur hourly. At 8:30 am, intravenous (IV) blood samples will be taken every fifteen minutes until 9:30 am, every half hour from 9:30 am to 10:30 am, and then finally hourly from 10:30 am to 2:30 pm . Subjects will receive a meal at 2:30 pm, thus concluding the CRU visit. At home, subjects will collect timed urine until the next morning to be returned to the CRU.
89238346|NCT04429555|Experimental|MN-166 (ibudilast)|MN-166 capsules, 50 mg twice daily, for 7 days.
89238347|NCT04429555|Placebo Comparator|Placebo|Placebo capsules, 50 mg twice daily, for 7 days.
89238348|NCT04419597|Experimental|HEMOPATCH Collagen Patch and PEG Haemostatic Sealant|Two units of the large patch are applied as reinforcement of the primary dural seal (HEMOPATCH 4,5x9cm, 1506253).
89238349|NCT04419597|Active Comparator|Standard of care treatment|Usual clinical practice techniques for reinforcing primary dural closure.
89238350|NCT04409444||Data (main study)|This study group is for any individual that attends and has a lung health check. The data collected for this study group is to evaluate the uptake and performance of a community-based lung health check / lung screening programme.
89238351|NCT04409444||Biomarker (sub-study)|This sub-study is for participants that are determined to require a CT scan through their lung health check and have also signed up to the data part of the study. This part of the study is to evaluate the potential for biomarkers to improve the early detection of lung cancer.
89238352|NCT04408131|Experimental|Homeless people|Blood sample
89238353|NCT04400474|Experimental|Cabozantinib 40 mg + Atezolizumab 1200 mg|"Cabozantinib 40 mg tablets, oral administration, once daily, continuously.~Atezolizumab 1200 mg administered intravenously, every three weeks (cycle)."
89238354|NCT04398238||Pre-PBM|patients screened for surgery before the implementation of PBM program: pre-operative evaluation and treatment according to usual care
89238355|NCT04398238||post-PBM|patients screened for surgery after the implementation of PBM program (3 months allowed for training/optimization): all patients with pre-operative hemoglobin < 13g/dl undergo screening for causes and treatment as needed.
89238356|NCT04387318|Experimental|Multimodal training|"IMT + NMES + Pulmonary Rehabilitation~IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
89238357|NCT04387318|Experimental|IMT + Pulmonary Rehabilitation|"IMT will be performed using a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
89238358|NCT04387318|Experimental|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil).~Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise."
89238359|NCT04387318|Placebo Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation: The physical training part of pulmonary rehabilitation will consist of aerobic and resistance exercise.
89238360|NCT04383158|Active Comparator|PRGF extraction sockets (Test)|Immediately after dental extraction, the socket will be filled with Plasma Rich in Growth Factors (ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16))
89238361|NCT04383158|No Intervention|Unassisted extraction sockets (Control)|Dental extraction sockets to be left to heal spontaneously unassisted.
89238362|NCT04382911|Experimental|18F-fluoroestradiol PET / MRI|All enrolled subjects will receive the tracer and then have a PET/MRI scan.
89238363|NCT04376229||Cancer patients receiving proton radiation therapy|Registry of cancer patients who receive proton radiation therapy to track disease and toxicity outcomes.
89238364|NCT04364386|Experimental|InPress|Treatment with InPress Device for Postpartum Hemorrhage
89238365|NCT04362618|Experimental|Muscle Strengthening Training (MST)-group|Subjects allocated to the MST group (n=30) will perform a muscle strengthening training program of 12 weeks.
89238366|NCT04362618|Experimental|Behavioral Graded Activity (BGA)-group|Subjects allocated to the BGA group (n=30) will perform a rehabilitation program according to the principles of behavioural graded activity for a period of 12 weeks.
89238367|NCT04362618|No Intervention|Control group|Subjects allocated to the control group (n=30) have to maintain their current life-style and treatment (if any) and to refrain from other new interventions during 24 weeks.
89238368|NCT04360564||Recurrent pregnancy loss|All women with >/=2 pregnancy loss before 20 weeks gestational age
89238369|NCT04360564||Primary recurrent pregnancy loss|Primary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age before the first birth
89238370|NCT04360564||Secondary recurrent pregnancy loss|Secondary RPL is defined by those with >/=2 pregnancy loss before 20 weeks gestational age occurring after the first birth
89238371|NCT04360564||No history of recurrent pregnancy loss|Those with 0 or 1 previous spontaneous pregnancy loss.
89238372|NCT04336527|Experimental|Home Treatment with Peer Support|Patients receive a peer supported home treatment, i.e. treatment by a home treatment/crisis resolution team with a peer support worker.
89238373|NCT04336527|Active Comparator|Home Treatment without Peer Support|Patients receive conventional home treatment by a home treatment/crisis resolution team without contacts to a peer support worker.
89238374|NCT04327284|Experimental|test group|The test group will receive immediate molar implant placement in fresh extraction socket with nonocclusal loading immediate provisionalization (Straumann BLX 6.5mm).
89238375|NCT04327284|Active Comparator|Control group|The control group will receive delayed molar implant placement at least 12 weeks post molar extraction with nonocclusal loading immediate provisionalization (Straumann BLX 5.0mm).
89238376|NCT04327115|Other|Arm 1|"(C-I-I-I) : the centers apply the Control strategy in Period 1 and then apply the Intervention strategy in Periods 2 to 4."
89238377|NCT04327115|Other|Arm 2|"(C-C-I-I) : the centers apply the Control strategy in periods 1 and 2 and then apply the Intervention strategy in periods 3 and 4."
89238378|NCT04327115|Other|Arm 3|"(C-C-C-I) : the centers apply the Control strategy in periods 1, 2 and 3 and then apply the Intervention strategy for period 4."
89238379|NCT04319627|Experimental|Rosuvastatin|Participants randomized to the experimental arm will take one rosuvastatin 20 mg tablet by mouth every day for the duration of their participation in the study.
89238380|NCT04319627|Placebo Comparator|Placebo|Participants randomized to the control arm will take one placebo tablet by mouth every day for the duration of their participation in the study.
89238381|NCT04308395|Experimental|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
89238382|NCT04305613||Cohort|Patients with locally advanced non-small cell lung cancer
89238383|NCT04305496|Experimental|Capivasertib + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
89238384|NCT04305496|Placebo Comparator|Placebo + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
89238385|NCT04287192|No Intervention|Control|Control: Control participants will complete surveys at 4 time points (baseline, 1-2 weeks, 3 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, and assess their quality of life. Aside from completion of these surveys, no changes to their usual care will occur.
89238386|NCT04287192|Experimental|(Digital Bridge intervention)|"Experimental (Digital Bridge intervention) participants will complete surveys at 4 time points (baseline, 1-2 weeks, 3 month and 6 months after discharge). The surveys will capture data on demographics, assess their transition quality, self-reported costs, assess their quality of life, and goal attainment.~One to two days before discharge, patients will work with their team to develop the PODS in Care Connector. Once the PODS is created, the patient and hospital provider will be prompted to set transition goals using the ePRO tool."
89238387|NCT04281017|Experimental|TIVA anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, intravenous infusion of propofol, lidocaine, ketamine or narcotic as deemed appropriate by anesthesiologist. There will be no inhalation anesthetic used. Ventilation with oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During surgery, mechanical ventilation using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
89238388|NCT04281017|Active Comparator|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, the depth of anesthesia will be maintained at a minimum alveolar concentration of 1 to 1.25 using isoflurane in oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During the surgery, subjects will be mechanically ventilated using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
89238389|NCT04280003|Experimental|Treatment group|15 patients will receive intravenous alogenic adipose tissue-derived stem cells in a single dose of one million cells per kg.
89238390|NCT04280003|Placebo Comparator|Placebo group|15 patients will receive a single intravenous placebo solution with the same appearance as the treatment group.
89238391|NCT04275791|Experimental|hierarchized|Structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
89238392|NCT04275791|No Intervention|all-or-nothing|Structured regional health organization, composed of non-hierarchical trauma centers at different levels according to their capacity to receive severe trauma victims (all-or-nothing type).
89238393|NCT04267185|Experimental|Immediate Intervention|PwMS-CG dyads will receive six group telerehabilitation sessions (~60 min each) every other week for a period of 12 weeks. This will be interspersed with brief one-on-one support telephone calls in the weeks that group sessions do not occur. All participants will be taught techniques for monitoring PA behaviour, setting personalized goals to increase PA and reduce sedentary time, and strategies for overcoming challenges to PA participation. Make-up sessions will be offered to those who miss group sessions. The one-on-one support telephone calls will serve to reinforce the information provided during the group sessions, monitor safety and troubleshoot any issues with intervention content.
89238394|NCT04267185|No Intervention|Delayed Control|The delayed control group will not receive the intervention during the study period. Participants assigned to the control group will be offered the intervention once the study is completed.
89238395|NCT04265768|Placebo Comparator|No Soft tissue augmentation surgery|No soft tissue augmentation concomitant to implant placement. Negative control group.
89238396|NCT04265768|Experimental|Soft tissue augmentation surgery with Fibro-Gide|"Soft tissue augmentation concomitant to implant placement with a porcine, volume-stable cross-linked collagen matrix (Fibro-Gide, Geistlich Pharma AG, Wolhusen, Switzerland).~Test group."
89238397|NCT04265768|Active Comparator|Soft tissue augmentation surgery with patient's CTG|"Soft tissue augmentation concomitant to implant placement with a connective tissue graft (CTG) taken from the patient's palate or retromolar area.~Positive control group."
89238398|NCT04261036|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1g of vitamin C for 14 days.
89238399|NCT04261036|Placebo Comparator|Women on a placebo regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take placebo for 14 days
89238400|NCT04255407|Experimental|I-ONE® group|"I-ONE® therapy will be initiated in the 15 days preceding the ACL reconstruction surgery and in the first 60 days following the surgery.~Paracetamol 1000 mg will be supplied to both groups, to be taken for pain control as per normal clinical practice."
89238401|NCT04255407|Placebo Comparator|Control group|Patients will not be treated with I-ONE®. Pain will be treated with common NSAID and Paracetamol.
89238402|NCT04254861|Experimental|Simplified Papilla Preservation Flap (SPPF) and PRGF|
89238403|NCT04254861|Active Comparator|Simplified Papilla Preservation Flap (SPPF) and GTR|
89238404|NCT04247451|Experimental|Interventional group|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using BIA (Nutrilab Akern) and REE using indirect calorimetry (Cosmed Q NRG) will be analyzed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
89238405|NCT04244929|Experimental|PCL removal|Patients will undergo surgery by sacrificing the PCL
89238406|NCT04244929|Active Comparator|PCL preservation|Patients will undergo surgery with retaining the PCL
89238407|NCT04219956|Experimental|Polyamine deficient diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
89238408|NCT04219956|No Intervention|Control|Usual Diet plus two snacks
89238409|NCT04155190|Experimental|Patidegib Topical Gel, 2%|Participants will be randomized (1:1) to receive Patidegib Topical Gel, 2% for 9 months
89238410|NCT04155190|Active Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized (1:1) to receive Patidegib Topical Gel, Vehicle for 9 months
89238411|NCT04129164|Experimental|VIB4920 Dose 1 in Population 1|Participants in population 1 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
89238412|NCT04129164|Placebo Comparator|Placebo in Population 1|Participants in population 1 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
89238413|NCT04129164|Experimental|VIB4920 Dose 1 in Population 2|Participants in population 2 will receive IV VIB4920 Dose 1 in Stage I and placebo matched to VIB4920 in Stage II.
89238414|NCT04129164|Placebo Comparator|Placebo in Population 2|Participants in population 2 will receive IV placebo matched to VIB4920 in Stage I and IV VIB4920 Dose 1 in Stage II.
89238415|NCT04095832||Parturients with preeclampsia|Parturients who were diagnosed with preeclampsia
89238416|NCT04095832||Healthy parturients|Healthy full-term parturients
89238417|NCT04087629|Experimental|CTCL group|Patients with CTCL being treated with mechlorethamine gel will receive StrataCTX® gel.
89238418|NCT04087629|Experimental|Skin Toxicity group|Patients with skin toxicity secondary to chemo/immunotherapy will receive StrataCTX® gel.
89238419|NCT04083365|Experimental|CAPECITABINE + concomitant RT + Durvalumab|After careful staging, patients will be initiated to a standard concomitant chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks and 5040 cGy radiotherapy for 5 days per week for 5 weeks. At the end of treatment patients will undergo a lesion biopsy. One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations. From week 9 to 10 after neoadjuvant therapy will be performed re-staging with CT and MRI scan. Surgery will be performed at week 10-12 from the end of CT/RT and the surgical piece will be analyzed
88804680|NCT00109395|Active Comparator|lorazepam continuous infusion|lorazepam administered by continuous infusion
89238420|NCT04072575|Experimental|Paliperidone Palmitate 6 month(PP6M)|"Participants who enter the this open-label extension study immediately after completing Double-blind Phase Study R092670PSY3015 (previous study) will receive Paliperidone Palmitate 6 month (PP6M) intramuscular (IM) injections, dose will be selected based on the unblinded dose level (moderate or higher) that the participant received during previous study. Participants in the moderate dose level will receive PP6M Dose 1 and higher dose level will receive PP6M Dose 2 during the open-label extension. The PP6M dose level may be adjusted (to Dose 1 or Dose 2) for every 6 month at Visits 3, 5, and 7, based on clinical judgment. Participants who enter this open-label extension study later (up to 3 months after they complete previous study) and were on a moderate or higher dose of PP3M (350 or 525 mg eq.) or PP1M (100 or 150 mg eq.) will receive initial dose of PP6M IM injection (Dose 1 or Dose 2) for every 6 months."
89238421|NCT04072068|Experimental|Edoxaban|edoxaban 60 mg daily
89238422|NCT04071847||Deep brain stimulation|Subjects implanted with an Abbott DBS system
89238423|NCT04037358|Experimental|Radium-223 and SABR|First radium-223 infusion will be within two weeks of SABR
89238424|NCT04037358|Active Comparator|SABR|SABR(1-5 fractions) will be administered for all men
89238425|NCT04030130|Experimental|NDURE|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system-(care coordination), interpersonal-(social support), and individual- (health belief model [HBM]; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, enhance HNSCC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months). The three in-person NDURE navigation sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit, time points chosen to facilitate case identification and coordination across key care transitions.
89238426|NCT04030130|No Intervention|Usual Care|UC consists of discussions about the indications, risks/benefits/alternative, Guidelines, timing, and logistical details of adjuvant therapy. These discussions will be administered according to practice patterns of the involved providers.
89238427|NCT04019327|Experimental|Metastatic Castration Resistant Prostate Cancer|Participants have Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
89238428|NCT04014413|Experimental|Crohn's disease|Fecal Microbiota Transplant will be performed.
89238429|NCT04014413|Experimental|Ulcerative colitis|Fecal Microbiota Transplant will be performed.
89238430|NCT04014413|Experimental|Celiac disease|Fecal Microbiota Transplant will be performed.
89238431|NCT04014413|Experimental|Irritable bowel syndrome|Fecal Microbiota Transplant will be performed.
89238432|NCT04014413|Experimental|Functional dyspepsia|Fecal Microbiota Transplant will be performed.
89238433|NCT04014413|Experimental|Constipation|Fecal Microbiota Transplant will be performed.
89238434|NCT04014413|Experimental|Metabolic disease (diabetes mellitus or obesity)|Fecal Microbiota Transplant will be performed.
89238435|NCT04014413|Experimental|Multidrug-resistant infection|Fecal Microbiota Transplant will be performed.
89238436|NCT04014413|Experimental|Hepatic encephalopathy|Fecal Microbiota Transplant will be performed.
89238437|NCT04014413|Experimental|Multiple sclerosis|Fecal Microbiota Transplant will be performed.
89238438|NCT04014413|Experimental|Pseudo-obstruction|Fecal Microbiota Transplant will be performed.
89238439|NCT04014413|Experimental|CRE infection|Fecal Microbiota Transplant will be performed.
89238440|NCT04014413|Experimental|VRE infection|Fecal Microbiota Transplant will be performed.
89238441|NCT04014413|Experimental|Multiple organ dysfunction|Fecal Microbiota Transplant will be performed.
89238442|NCT04014413|Experimental|Dysbiotic bowel syndrome|Fecal Microbiota Transplant will be performed.
89238443|NCT04014413|Experimental|MRSA enteritis|Fecal Microbiota Transplant will be performed.
89238444|NCT04014413|Experimental|Pseudomembranous enteritis|Fecal Microbiota Transplant will be performed.
89238445|NCT04014413|Experimental|Alopecia|Fecal Microbiota Transplant will be performed.
89238446|NCT04014413|Experimental|Autism|Fecal Microbiota Transplant will be performed.
89238447|NCT04014413|Experimental|Graft-versus-host disease|Fecal Microbiota Transplant will be performed.
89238448|NCT04014413|Experimental|Idiopathic thrombocytopenic purpura|Fecal Microbiota Transplant will be performed.
89238449|NCT04014413|Experimental|Atopy or allergy|Fecal Microbiota Transplant will be performed.
89238450|NCT04014413|Experimental|Liver disease|Fecal Microbiota Transplant will be performed.
89238451|NCT04014413|Experimental|Alcohol dependence|Fecal Microbiota Transplant will be performed.
89238452|NCT04014413|Experimental|Antibiotic-associated diarrhea|Fecal Microbiota Transplant will be performed.
89238453|NCT03991052|Active Comparator|EV1000 monitor|MAP management will be done as usual (adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
89238454|NCT03991052|Experimental|EV1000 monitor + closed-loop system|Fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
89238455|NCT03985046|Experimental|Sintilimab plus chemotherapy|
89238456|NCT03983369|Experimental|"preventive treatment with LLLT (Laser group)"|
89238457|NCT03983369|Placebo Comparator|control group with a placebo intervention|
89238458|NCT03973151|Experimental|HL-085|HL-085 will be administered as BID with specified dose.
89238459|NCT03970655|Experimental|Group 1|a single injection into the LEFT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine or Ropivacaine with epinephrine 1:200.000 with the addition of 4 milligrams of dexamethasone (1ml) and a single injection into the RIGHT pterygopalatine fossa fo 4 milliliters of 0.5% Bupivacaine or Ropivacaine without epinephrine with the addition of 4 milligrams of dexamethasone (1mL) after the induction of general anesthesia. (total volume 5 ml per side)
88804681|NCT00109395|Active Comparator|midazolam continous infusion|midazolam administered by continous infusion
89238460|NCT03970655|Experimental|Group 2|a single injection into the LEFT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine or Ropivacaine without epinephrine with the addition of 4 milligrams of dexamethasone (1ml) and a single injection into the RIGHT pterygopalatine fossa of 4 milliliters of 0.5% Bupivacaine or Ropivacaine with epinephrine 1:200.00 with the addition of 4 milligrams of dexamethasone (1mL) after the induction of general anesthesia. (total volume 5 ml per side).
89238461|NCT03963388|Experimental|Intervention group|Speech therapy, right after T0 (baseline measurement).
89238462|NCT03963388|No Intervention|Control group|Patients will be on a waiting list for 8 weeks. After the primary endpoint (T1), patients will receive speech therapy.
89238463|NCT03962868|Experimental|Endoscopic submucosal dissection (ESD)|
89238464|NCT03962868|Active Comparator|Endoscopic Mucosal Resection (WF-piece meal EMR)|
89238465|NCT03952351|Experimental|CTCA with standard care|Patients will be referred for CT Coronary Angiography, ideally within 2 weeks of randomisation
89238466|NCT03952351|No Intervention|Standard care|
89238467|NCT03944538|Experimental|Lifestyle Physical Activity|"The primary content of the website will be delivered through interactive video courses. The courses will be released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~The website Tracker feature will allow for tracking of daily step counts as well as setting goals and monitoring progress.~The one-on-one video chats will be conducted face to face through Zoom and will be semi-scripted. The chats will consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral changes based on social cognitive theory and current website content. The chats will occur at the same frequency as the video course release. For the second 6 months of the study, participants will be asked to maintain their usual activities."
89238468|NCT03944538|Active Comparator|General Wellness|The general wellness condition will focus on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the National Multiple Sclerosis Society. The delivery of the Internet materials and chat sessions will occur on the same schedule and frequency as the intervention condition, and will have a comparable time commitment. This condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. For the second 6 months of the study, participants will be asked to maintain their usual activities.
89238469|NCT03927066|Experimental|Healthy Volunteer|All Volunteers will be studied at rest and during experimental condition (lower body negative pressure)
89238470|NCT03916627|Experimental|Cohort A1|Cemiplimab prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
89238471|NCT03916627|Experimental|Cohort A2|Cemiplimab and platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
89238472|NCT03916627|Experimental|Cohort A3|Platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) Not open for accrual
89238473|NCT03916627|Experimental|Cohort B|Cemiplimab prior to surgery; cemiplimab post surgery (HCC)
89238474|NCT03916627|Experimental|Cohort C|Cemiplimab prior to surgery; standard of care radiation and/or chemotherapy followed by cemiplimab post surgery (HNSCC) Not open for accrual
89238475|NCT03916627|Experimental|Cohort B2|SBRT 8 Gy X 3 fractions followed by cemiplimab prior to surgery; cemiplimab post surgery (HCC)
89238476|NCT03916627|Experimental|Cohort B3|Cemiplimab and fianlimab before and after surgery (HCC)
89238477|NCT03912064|Experimental|CD25/Treg-depleted DLI + Ipilimumab|"Ipilimumab is administered intravenously every 12 weeks~Patients will receive a defined dose of CD25hi Treg depleted DLI intravenously"
89238478|NCT03911869|Experimental|Standard Dose Arm|"Patients in the standard-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.~450 mg encorafenib orally once a day (QD)~45 mg binimetinib orally twice a day (BID)~Patients who are able to tolerate the standard dose during the first 4 weeks of treatment (Cycle 1) should be dose-escalated to 600 mg encorafenib QD plus 45 mg binimetinib BID provided they meet protocol-defined criteria."
89238479|NCT03911869|Experimental|High Dose Arm|"Patients in the high-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.~300 mg encorafenib orally twice a day (BID)~45 mg binimetinib orally twice a day (BID)"
89238480|NCT03911453|Experimental|Treatment (rucaparib)|"Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of programmed cell death-1 with ligand (PD-L1) by immunohistochemistry (IHC)~. Starting Dose 600 mg twice daily Dose Level -1 500 mg twice daily Dose Level -2 400 mg twice daily Dose Level -3 300 mg twice daily"
89238481|NCT03897088|Experimental|Tildrakizumab|
89238482|NCT03897088|Placebo Comparator|Placebo|
89238483|NCT03897088|No Intervention|PART 3: Observational Safety Follow-up|The subjects will not receive study treatment during the follow-up period
89238484|NCT03873272|Active Comparator|Cryotherapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
89238485|NCT03873272|Active Comparator|Compression Therapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
89238486|NCT03873272|Placebo Comparator|Control arm (Loose glove/sock)|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
89238487|NCT03865290|Experimental|Healthy Control Ondansetron 8 mg|Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
89238488|NCT03865290|Experimental|Diabetic (DM) gastroenteropathy Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
89238489|NCT03865290|Experimental|Non-ulcer dyspepsia (NUD) Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
89238490|NCT03865290|Placebo Comparator|Healthy Control Placebo|Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
89238491|NCT03865290|Placebo Comparator|Diabetic (DM) gastroenteropathy Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.~Oral matched placebo administered three times a day for weeks 3-6"
89238492|NCT03865290|Placebo Comparator|Non-ulcer dyspepsia (NUD) Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.~Oral matched placebo administered three times a day for weeks 3-6"
89238493|NCT03843242|Experimental|Pacemaker with Fixed long AV delay|"Patients who meet the inclusion criteria and is implanted with a Biotronik Enitra 8 DR-T pacemaker are eligible.~The pacemaker was programmed with a long and fixed atrioventricular interval for the first 3 months.~Definition of fixed AV delay (than intrinsic AV conduction) • If P-wave exists: intrinsic AV conduction time = As ~ Vs interval in the marker channel sensed AV delay = intrinsic AV conduction time + 20 msec paced AV delay = sensed AV delay + 30 msec • If no P-wave exits: intrinsic AV conduction time = Ap ~ Vs interval in the marker channel paced AV delay = intrinsic AV conduction time + 20 msec sensed AV delay = paced AV delay - 30 msec • If the intrinsic AV conduction time is ≥ 300ms, make paced/sensed AV delay 350/320 msec"
89238494|NCT03843242|Experimental|Pacemaker with VpS® algorithm on|Vp Suppression ON algorithm: This feature promotes the intrinsic AV conduction by only pacing the ventricle when intrinsic conduction becomes unstable or disappears. Depending on the presence or absence of AV conduction, the feature is implemented either in the ventricular pacing suppression state ADI(R), which promotes the intrinsic conduction, or in the DDD(R) ventricular pacing state Vp DDD(R), which provides ventricular pacing. Automatic switching capabilities between those two states promotethe intrinsic conduction as much as possible without harming the patient. Scheduled Vs searching tests look for intrinsic conduction using an extended AV delay of 450ms.
89238495|NCT03843242|Experimental|Pacemaker with IRSplus algorithm on|IRS plus algorithm: This algorithm incorporates two different functions: the first is scan hysteresis, which better enables the heart to pace on its own by periodically extending the search time for its natural pacing stimulus (the intrinsic AV conduction) over six consecutive atrial cycles. The second is the repetitive hysteresis, which recognizes when the heart is not pacing on its own (a consistent loss of intrinsic AV conduction lasting for six consecutive atrial cycles) and switches the mode of the device from extended to basic atrioventricular (AV) delay.
89238496|NCT03840291|Experimental|Edoxaban treatment|"Men or women aged ≥ 20 years with NVAF patients who has LAA thrombi documented by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication are eligible.~Patients in this group are taking Lixiana® (Edoxaban) 60mg for resolution of left atrial appendage thrombi~Reduced (30mg) dose is administered in patients with one or more of the following clinical factors:~Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min)~Low body weight ≤ 60 kg~Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin,dronedarone, erythromycin, or ketoconazole."
89238497|NCT03837626|Placebo Comparator|Placebo|6 months of daily placebo
89238498|NCT03837626|Experimental|Amiloride|6 months of amiloride (max dose 5 mg) treatment
89238499|NCT03787966|Experimental|ATOPE-B|An adapted therapeutic exercise program performed before medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
89238500|NCT03787966|Active Comparator|ATOPE-I|An adapted therapeutic exercise program performed during medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
89238501|NCT03787771||FMT recipents|Subject who has received or planning to receive FMT or other gut-related microbiota products in routine clinical practice or research
89238502|NCT03787771||FMT donors|Subject who has donated stool or planning to donate stool for FMT or production of other gut-related microbiota products in routine clinical practice or research.
89238503|NCT03781219|Experimental|HL-085 plus Vemurafenib|HL-085 will be administered as BID with specified dose. And the Vemurafenib will be taken as the instruction in the label ( 960 mg, BID)
89238504|NCT03773237|Active Comparator|SMOFLipid|SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.
89238505|NCT03773237|Active Comparator|IntraLipid|Intralipid is a lipid emulsion that contains soybean oil
89238506|NCT03759912||PVI using Ultra-High-Resolution Mapping|The paroxysmal atrial fibrillation patients who received pulmonary vein antral catheter ablation for electrical isolation of pulmonary veins using ultra-high-resolution mapping system (Rhythmia High Density mapping system).
89238507|NCT03733080||1|ages 18 and older
89238508|NCT03731715|Experimental|Cohort I|Subjects ≥18 years of age. Carisbamate, 200 mg, will be administered on Day 1 and 2 of the single-dose period. Carisbamate will be administered at 100 mg twice daily (BID) during the multiple-dose period.
89238509|NCT03731715|Experimental|Cohort II|Subjects 12 to <18 years of age. Carisbamate, 140 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 70 mg twice daily (BID) during the multiple-dose period.
89238510|NCT03731715|Experimental|Cohort III|Subjects 6 to <12 years of age. Carisbamate, 60 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 30 mg twice daily (BID) during the multiple-dose period.
89238511|NCT03731715|Experimental|Cohort IV|Subjects 2 to <6 years of age. The starting doses for the single dose and multiple-dose periods will be based on the PK and safety results of the first 3 cohorts.
89238512|NCT03700684|Experimental|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.
89238513|NCT03700684|Experimental|SpeechVive|Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.
89238514|NCT03700684|Active Comparator|Control|Persons with Parkinsons disease do not receive voice intervention
89238515|NCT03694808|Active Comparator|Fluad Vaccine|A single adjuvanted dose (AD) intramuscular injection
89238516|NCT03694808|Active Comparator|Fluzone Vaccine|A single high dose (HD) intramuscular injection
89238517|NCT03691792|Experimental|Cognitive-Behavioral Therapy (CBT-SAD)|12 1.5-hour group sessions at a rate of 2 sessions per week over 8 weeks.
89238518|NCT03691792|Active Comparator|Light Therapy|6 weeks of daily light therapy at home, using a 10,000-lux light box beginning at 30 minutes upon waking, with dose subsequently adjusted per treatment algorithm.
89238519|NCT03690206|Experimental|Glepaglutide SC injections twice weekly|Intervention: Glepaglutide
89238520|NCT03690206|Experimental|Glepaglutide SC injections once weekly and placebo once weekly|Intervention: Glepaglutide
89238521|NCT03690206|Placebo Comparator|Placebo SC injections twice weekly|Intervention: Placebo
89238522|NCT03659539|Active Comparator|CLADS group|Anesthesia will be induced with propofol administered using automated closed loop anesthesia delivery system (CLADS) which will be set to deliver Propofol. A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anesthesia maintenance will be done with propofol, with its administration controlled with CLADS tuned to consistent anesthetic depth (BIS-50) feedback from the patients.
89238523|NCT03659539|Active Comparator|Desflurane group|Anesthesia will be induced with propofol administered using automated closed loop anesthesia delivery system (CLADS) which will be set to deliver Propofol. A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
89238524|NCT03659136|Experimental|Xentuzumab/everolimus/exemestane|
89238525|NCT03659136|Placebo Comparator|Placebo/everolimus/exemestane|
89238526|NCT03629418|Experimental|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started at the beginning of anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher during surgery.
89238527|NCT03629418|Active Comparator|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
89238528|NCT03615469|Active Comparator|Neuromusclar electrical stimulation|"NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time."
89238529|NCT03615469|Sham Comparator|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation
89238530|NCT03607474||Couple (Patients and caregivers)|"Patient in remission of hypercortisolism Caregivers will be the spouse or, failing that, a person close to the patient, who has been in regular contact with the patient since taking care of him.~Questionnaires of life quality for patients Questionnaires of life quality for caregivers"
89238531|NCT03606213|Placebo Comparator|Cohort A - Arm 1|Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12
89238532|NCT03606213|Active Comparator|Cohort A - Arm 2|Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
89238533|NCT03606213|Active Comparator|Cohort A - Arm 3|Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
89238534|NCT03606213|Active Comparator|Cohort B - Arm 1|A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.
89238535|NCT03603002|Experimental|Stage I NSCLC with SABR Therapy|Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.
89238536|NCT03596476|Experimental|Patients with persistent GERD|Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI
89238537|NCT03586739|Experimental|"Covered stents strategy"|
89238538|NCT03586739|Active Comparator|"Bare metal stents strategy"|
89238539|NCT03555669|No Intervention|Screening Phase (Pre) Group|"Patients who screen positive on the PHQ-9 for depression during the pre period will comprise the comparison group. Participants will receive standard of care depression treatment at the providers discretion."
89238540|NCT03555669|Experimental|Treatment Phase (Post) Group|"Patients who screen positive during on the PHQ-9 for depression during the post period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score."
89238541|NCT03553212|Experimental|High dose external beam Radiotherapy|Image-guided tomotherapy
89238542|NCT03514108|Active Comparator|Hydralazine Isosorbide Dinitrate|"Tablet BiDil (Hydralazine 37.5 mg/ isosorbide dinitrate (ISDN) 20 mg) 2 tablets x 3 daily.~Average treatment period 4 years."
89238543|NCT03514108|Placebo Comparator|Placebo (Hydralazine Isosorbide Dinitrate)|Tablet Placebo 2 tablets x 3 daily. Average treatment period 4 years.
89238544|NCT03514108|Active Comparator|Metformin|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
89238545|NCT03514108|Placebo Comparator|Placebo (Metformin)|Tablet Placebo 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
89238546|NCT03482791|Experimental|Arm 1: Resectable (proton beam therapy)|"Proton beam therapy: total dose of 50 or 50.4 Gy~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision~Surgery should ideally be performed no later than 8 to 10 weeks after completing chemoradiation~Patient-reported outcome measures (PROs) performed at several time points"
89238547|NCT03482791|Experimental|Arm 2: Unresectable (proton beam therapy)|"Proton beam therapy: total dose of 59.4 or 60 Gy~Standard of care chemotherapy - the clinical trial doesn't dictate anything about the chemotherapy given, it is the treating physician's decision~Patient-reported outcome measures (PROs) performed at several time points"
89238548|NCT03479541|Experimental|Physical Therapy (Early)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
89238549|NCT03479541|Experimental|Physical Therapy (Standard of Care)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
89238550|NCT03469362|Experimental|Extracorporeal Urinary Diversion (ECD)|Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
89238551|NCT03469362|Experimental|Intracorporal Urinary Diversion (ICD)|Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
89238552|NCT03419325|Experimental|HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of both high on-treatment platelet reactivity (HTPR) and CYP2C19 loss-of-function (LOF) alleles:~An alternative therapy with either prasugrel or ticagrelor (in line with specific contraindications and precautions for each agent) will be strongly recommended for HPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
89238553|NCT03419325|Experimental|HTPR/no-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of HTPR, but no CYP2C19 LOF allele found:~An alternative therapy should be considered for HTPR/no-LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
89238554|NCT03419325|Experimental|no-HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of a CYP2C19 LOF allele, but no HTPR:~An alternative therapy should be considered for no-HTPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
89238555|NCT03419325|Experimental|No-HTPR/No-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Absence of both HTPR and CYP2C19 LOF alleles:~Maintaining clopidogrel for no-HPR/no-LOF patients. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
89238556|NCT03418792|Experimental|Parotid-Sparing Head & Neck Radiation|Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) who will be treated with parotid-sparing head & neck radiation. MRI Sialograms will be obtained to identify salivary ductal structures and stem cells to be spared during treatment.
89238557|NCT03411408|Experimental|HBO and RT|Hyperbaric oxygenation therapy and Accelerated Hypofractionated intensity - modulated radiotherapy
89238558|NCT03406741|Experimental|Child with Hirschsprung's disease|Neuropsychological assessment at elementary school
89238559|NCT03390036|Experimental|Cingal|Cingal is a combination product consisting of 88 milligrams of crosslinked HA (hyaluronic acid) with 18 milligrams of TH (triamcinolone hexacetonide) in a 4 milliliter (mL) intra-articular injection.
89238560|NCT03390036|Active Comparator|Monovisc|Monovisc is a device that consists of 88 milligrams of cross-linked HA (hyaluronic acid) in a 4 milliliter (mL) intra-articular injection.
89238561|NCT03390036|Active Comparator|Triamcinolone Hexacetonide (TH)|Triamcinolone hexacetonide (TH) is a corticosteroid supplied in a 20 milligram per 1 milliliter (20 mg/mL) intra-articular injection.
89238562|NCT03389685|Experimental|Platelet Rich Plasma|Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system.
89238563|NCT03389685|Placebo Comparator|Saline Placebo|Unmarked syringe with 5 ml of saline
89238564|NCT03386383|Experimental|Intervention|Participants will receive an initial individual session, physical activity tracker, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group immediately after baseline assessments.
89238565|NCT03386383|No Intervention|Wait List Control|Participants will receive a physical activity tracker and be advised to maintain their current activity. After 3 months, participants will receive an initial individual session, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group.
89238566|NCT03385798|Active Comparator|Endo-GIA|
89238567|NCT03385798|Experimental|Endo-wrist|
89238568|NCT03379506|Experimental|EBR/GZR|Pediatric participants receive EBR/GZR as either FDC tablets or oral granules once daily for 12 weeks. A 24-week follow-up period will follow the 12-week treatment regimen.
89238569|NCT03377517|Experimental|ResearchTreatment Plan|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
89238570|NCT03375788|Experimental|Tesamorelin|tesamorelin (brand name Egrifta) 2mg daily given subcutaneously
89238571|NCT03375788|Placebo Comparator|Placebo|identical placebo given subcutaneously daily
89238572|NCT03368079|Experimental|Negative Pressure Suction Device|
89238573|NCT03360539|Experimental|Treatment-NFP|NFP is a prenatal and infancy home visiting program for low-income, first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, helping the mother-to-be make informed choices. The nurses continue visiting regularly until the child is two years old.
89238574|NCT03360539|No Intervention|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
89238575|NCT03341949|Experimental|Patient with chronic kidney disease|Determination of the Cluster of Differentiation 146 (CD146)
89238576|NCT03341936|Experimental|Nivolumab+Lirilumab|"The drugs will be administered intravenously. A single dose of Nivolumab and Lirilumab will be administered prior Salvage surgical resection.~In Cycle 1-3: Nivolumab will be administered on Days 1 and 15 and lirilumab will be administered on Day 1 of each 28 day long cycle~In Cycle 4-6 and beyond: Nivolumab and lirilumab will be administered on Day 1 of each 28 day long cycle."
89238577|NCT03328702|Experimental|Continue Positive Airway Pressure|Continue Positive Airway Pressure during VFSE
89238578|NCT03311412|Experimental|Sym021 Dose Level 1|Part 1, Sym021 monotherapy dose level 1
89238579|NCT03311412|Experimental|Sym021 Dose Level 2|Part 1, Sym021 monotherapy dose level 2
88804682|NCT01215643|Experimental|ALV 1000 mg|Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
89238580|NCT03311412|Experimental|Sym021 Dose Level 3|Part 1, Sym021 monotherapy dose level 3
89238581|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 1|Part 2, Arm A: Sym021 RP2D in combination with dose level 1 of Sym022
89238582|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 2|Part 2, Arm A: Sym021 RP2D in combination with dose level 2 of Sym022
89238583|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 3|Part 2, Arm A: Sym021 RP2D in combination with dose level 3 of Sym022
89238584|NCT03311412|Experimental|Arm A: Sym021+Sym022 Dose Level 4|Part 2, Arm A: Sym021 RP2D in combination with dose level 4 of Sym022
89238585|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 1|Part 2, Arm B: Sym021 RP2D in combination with dose level 1 of Sym023
89238586|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 2|Part 2, Arm B: Sym021 RP2D in combination with dose level 2 of Sym023
89238587|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 3|Part 2, Arm B: Sym021 RP2D in combination with dose level 3 of Sym023
89238588|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 4|Part 2, Arm B: Sym021 RP2D in combination with dose level 4 of Sym023
89238589|NCT03311412|Experimental|Arm B: Sym021+Sym023 Dose Level 5|Part 2, Arm B: Sym021 RP2D in combination with dose level 5 of Sym023
89238590|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 1|Part 3, Sym021 in combination with Sym022 and Sym023
89238591|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 2|Part 3, Sym021 in combination with Sym022 and Sym023
89238592|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 3|Part 3, Sym021 in combination with Sym022 and Sym023
89238593|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 4|Part 3, Sym021 in combination with Sym022 and Sym023
89238594|NCT03311412|Experimental|Sym021+Sym022+Sym023 Dose Level 5|Part 3, Sym021 in combination with Sym022 and Sym023
89238595|NCT03310528||Obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
89238596|NCT03310528||Did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
89238597|NCT03310528||Trauma - obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
89238598|NCT03310528||Trauma - did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
89238599|NCT03306446|Experimental|Adalimumab in monotherapy|Start Adalimumab in monotherapy at 160 mg at inclusion, 80 mg on 2nd week and 40 mg/week each other week over 12 months.
89238600|NCT03292133|Experimental|EGF816 + Gefitinib|"All patients will receive gefitinib orally once daily~EGF816 will be administered orally once daily~Participant will be requested to maintain a medication diary of each dose of medication"
89238601|NCT03289728|Experimental|Strategy guided by ischemia imaging|"Non-invasive imaging (SPECT or DSE) will be performed. High-risk Patients judged to high risk by imaging (according to ESC guidelines (5)) will undergo coronary angiography aimed at myocardial revascularization and have optimal medical treatment, according to ESC guidelines.~- Low or intermediate risk patients will receive optimal medical treatment."
89238602|NCT03289728|Active Comparator|Systematic coronary angioplasty|Patients will routinely undergo invasive coronary angiography aimed at myocardial revascularization.
89238603|NCT03284203|Experimental|SpiroPD|Participants in the intervention arm will be given a handheld spirometry device to take home and use daily for 30 consecutive days.
89238604|NCT03275740|Experimental|PF-06755347 intravenous healthy participant|intravenous administration
89238605|NCT03275740|Placebo Comparator|Placebo intravenous healthy participant|intravenous administration
89238606|NCT03275740|Experimental|PF-06755347 subcutaneous healthy participant|subcutaneous administration
89238607|NCT03275740|Placebo Comparator|Placebo subcutaneous healthy participant|subcutaneous administration
89238608|NCT03275740|Experimental|PF-06755347 subcutaneous ITP|subcutaneous
89238609|NCT03275415|Active Comparator|Experimental|Curosurf + budesonide
89238610|NCT03275415|Placebo Comparator|Placebo|Curosurf + saline
89238611|NCT03269227|Experimental|Accelerated hypofractionation with Tomotherapy|"Tomotherapy Treatment Planning System (TPS) will be used for treatment plannings.~Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for Gross Tumor Volume (GTV)."
89238612|NCT03233724|Experimental|1/Dose Escalation|Decitabine (DAC)-Tetrahydrouridine (THU) + pembrolizumab at escalating doses
89238613|NCT03233724|Experimental|2/Dose Expansion|Decitabine (DAC)-Tetrahydrouridine (THU) + pembrolizumab at the dose established in Arm 1
89238614|NCT03230734|Experimental|Treatment Arm A|radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)
89238615|NCT03230734|Experimental|Treatment Arm B|docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)
89238616|NCT03229408|Experimental|Salsalate-Treated Lean PCOS without IR|n=15
89238617|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS without IR|n=15
89238618|NCT03229408|Experimental|Salsalate-Treated Lean PCOS with IR|n=15
89238619|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS with IR|n=15
89238620|NCT03229408|Experimental|Salsalate-Treated Obese PCOS|n=15
89238621|NCT03229408|Placebo Comparator|Placebo-Treated Obese PCOS|n=15
89238622|NCT03223922|Experimental|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy|Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
89238623|NCT03209050|Other|Central Venous Access Placement|Central venous access placement
89238624|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Healthy Volunteers|"Arm1: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the lungs in the FOV is followed by two vertex-to-thigh PET/CT scans.~NOTE: If the patient cannot tolerate lying down for an extended period of time at the time of imaging, the patient may be switched to scanning protocol Option B, which does not include an initial 60-minute dynamic PET/CT scan.~IPF Patients will have a repeat [18F]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan (within 12-24 months post initial scan for previously scanned IPF patients if they are willing to be re-consented)."
89238625|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in PSC Patients|"Arm 2: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the liver in the FOV is followed by two vertex-to-thigh PET/CT scans.~Patients will have the option for a repeat [18F]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan."
89238626|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients|Arm 3: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. One vertex-to-thigh PET/CT scans to the center of the lung in the FOV will follow approximately 60 min post-injection.
89238627|NCT03176420|Experimental|Interventional arm|Endovascular treatment of occluded carotids
89238628|NCT03176420|No Intervention|medical arm|maximal medical therapy of occluded carotids
89238629|NCT03157713|Experimental|Goal-Directed|Patients will receive enhanced usual care and also be informed that they will receive goal-directed financial incentives.
89238630|NCT03157713|Experimental|Outcome-Based|Patients will receive enhanced usual care and be informed that they will receive outcome-based financial incentives for significant weight losses.
89238631|NCT03157713|Other|Control-Enhanced Usual Care|Patients will only receive enhanced usual care.
89238632|NCT03146962|Experimental|All Subjects|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
89238633|NCT03140865||Cognitively Normal|This group will include 300 healthy volunteers with no apparent memory problems. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
89238634|NCT03140865||Mild Cognitive Impairment|This group will include 400 volunteers who have mild memory problems that are observed during cognitive testing. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
89238635|NCT03140865||Alzheimer's disease|This group will include 150 volunteers with mild stage Alzheimer's disease dementia. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend visits to complete study interviews.
89238636|NCT03125564|Experimental|Fecal Microbiota Transplantation|FMT infusion and Fecal and Mucosal Microbiota Assessment
89238637|NCT03125564|Sham Comparator|Sham infusion|Infusion with sham and Fecal and Mucosal Microbiota Assessment
89238638|NCT03085810|Experimental|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) as two 300-milligram (mg) infusions (infusion length=2.5 hours) on Days 1 and 15, followed by one 600-mg infusion dose every 24 weeks (+/- 14 days) for a maximum of 8 doses throughout the 192 weeks treatment period.
89238639|NCT03085810|Active Comparator|Substudy Group 1|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 3.5 hours every 24 weeks for the remainder of the study duration
89238640|NCT03085810|Experimental|Substudy Group 2|At week 24 of the main study, eligible participants will be randomized to receive 600 mg ocrelizumab infused over approximately 2 hours followed by sodium chloride given as a slow infusion over the remaining 1.5 hours to mimic the standard-length infusion (3.5 hour) every 24 weeks for the remainder of the study duration
89238641|NCT03078452|Experimental|Arm I (biopsy using power drill)|Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
89238642|NCT03078452|Active Comparator|Arm II (biopsy using Jamshidi needle)|Patients undergo bone marrow biopsy using the traditional Jamshidi needle. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
89238643|NCT03056872||AUD only|AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
89238644|NCT03056872||AnxD+AUD-Cognitive Behavioral Therapy (CBT)|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
89238645|NCT03056872||AnxD+AUD- No CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
89238646|NCT03056872||Healthy Controls|Community sample
89238647|NCT03043794|Experimental|SBRT to the breast then surgery|Stereotactic Body Radiation of 21 gy followed by standard of care surgery
89238648|NCT03030443||Oral Sedation|"Patients in this group will receive a standard procedure first trimester abortion using oral sedation for pain management following the clinic's protocol.~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
89238649|NCT03030443||Nitrous Oxide|"Patients in this group will receive a standard procedure first trimester abortion using titrated nitrous oxide for pain management following the clinic's protocol.~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
89238650|NCT03026283||1: HeartFlow CT-FFR Arm|All patients who consent will receive HeartFlow CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
89238651|NCT02998268|Other|Cohort 1|"Subjects in Cohort 1 receive conventional induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
89238652|NCT02998268|Experimental|Cohort 2|"Subjects in Cohort 2 receive pembrolizumab along with induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
89238653|NCT02993900|Experimental|Image-Guided Brachytherapy|Magnetic Resonance Imaging (MRI) guided brachytherapy Procedure: Image-Guided Brachytherapy
89238654|NCT02948452||Anorexia|fMRI: reward task, anxiety provocation
89238655|NCT02948452||Mild anxiety comparison group|fMRI: reward task, anxiety provocation
89238656|NCT02915367|Experimental|SMS Reminders|Participants will receive regular SMS reminders regarding PrEP. All participants will receive adherence monitoring through a WisePill device.
89238657|NCT02915367|No Intervention|No Reminders|Participants will not receive SMS reminders. All participants will receive adherence monitoring through a WisePill device.
89238658|NCT02871882|Active Comparator|Ox bile extract|Ox bile extract 500 mg tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
89238659|NCT02871882|Placebo Comparator|Placebo|Matching placebo tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
89238660|NCT02843087||NW vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238661|NCT02843087||NW C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238662|NCT02843087||Ob vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238663|NCT02843087||Ob C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238664|NCT02843087||GDM vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238665|NCT02843087||GDM C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238666|NCT02843087||T2D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238667|NCT02843087||T2D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238668|NCT02843087||T1D vaginal deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238669|NCT02843087||T1D C-section deliveries|Normal weight (NW; pre-pregnant BMI <25.0 kg/m2), obese (Ob; pre-pregnant BMI >30.0 kg/m2), gestational diabetes (GDM), Type 2 diabetes (T2D), and Type 1 diabetes mothers during the 3rd trimester (34-36 weeks) of pregnancy that will be followed -along with their respective offspring- through the first 12 months of life will be recruited from the University of Florida (UF) Health Shands Hospital. Stool, saliva, blood, vaginal swab, human milk, urine, body composition and clinical variables will be collected from mother and infant at 34-36 weeks of gestation (mom only), 2-weeks, 2-months, and 1-year at the UF Clinical Research Center. Infant body composition is the primary outcome and will be monitored via anthropometry.
89238670|NCT02838680|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
89238671|NCT02824276|Experimental|Oral Opioid Medication|The primary study medication will be oxycodone, with morphine sulfate immediate release (MSIR) as a backup in case of side effects
89238672|NCT02824276|Placebo Comparator|Placebo Treatment|Placebo medications will be encapsulated in an opaque blinding capsule to ensure adequate blinding of study medications
89238673|NCT02813135|Experimental|Arm A. Ribociclib + Topotecan and Temozolomide|Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Ribociclib capsules or oral solution orally QD from Day 6 to 20 of a 28 day cycle.
89238674|NCT02813135|Experimental|Arm B. Ribociclib + Everolimus|Ribociclib capsules or oral solution orally QD for 21 days of each 28 day cycle; Everolimus orodispersible tablets orally QD for 28 days.
89238675|NCT02813135|Experimental|ARM C. Adavosertib + Carboplatin|Adavosertib capsules orally BID 3 days on / 4 days off in week 1; Carboplatin iv QD AUC 5 on Day 1 of a 21 day cycle.
89238676|NCT02813135|Experimental|Arm D. Olaparib + Irinotecan|Olaparib tablets orally BID on Day 1-10 of a 21 day cycle Irinotecan iv QD on Day 4-8 of a 21 day cycle.
89238677|NCT02813135|Experimental|Arm E. Vistusertib single agent|Vistusertib tablets orally BID 2 days on/5 days off per week of a 28 day cycle.
89238678|NCT02813135|Experimental|Arm F. Vistusertib + Topotecan and Temozolomide|Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Vistusertib tablets orally BID 3 days on/4 days off per week of a 28 day cycle.
89238679|NCT02813135|Experimental|Arm G. Nivolumab + Cyclophosphamide +/- Radiotherapy|Nivolumab iv QD every 2 weeks of a 28 day cycle (Days 1 and 15); Cyclophosphamide tablets or oral solution orally BID, 1 week on/1 week off; Palliative irradiation/radiofrequency/cryotherapy starting 2 weeks after the first nivolumab injection.
89238680|NCT02813135|Experimental|Arm H. Selumetinib + Vistusertib|Selumetinib capsules twice daily on a continous administration. Vistusertib orally twice daily on an intermittent schedule : 2 days on / 5 days off per week of a 28 day cycle.
89238681|NCT02813135|Experimental|Arm I. Enasidenib|Enasidenib tablets or sprinkle solution orally on a continuous dosing once daily (QD) per 28 day cycle.
89238682|NCT02813135|Experimental|Arm J. Lirilumab + Nivolumab|Nivolumab iv QD on Day 1 and 15 of a 28 day cycle; Lirilumab iv QD on Day 1 of a 28 day cycle
89238683|NCT02813135|Experimental|Arm K. Fadraciclib (CYC065) + Temozolomide|Fadraciclib iv QD on Day 1 (+/- 15) of a 28 day cycle Temozolomide capsules orally QD on Day 1-5 of a 28 day cycle
89238684|NCT02813135|Experimental|Arm L. Fadraciclib (CYC065) + Cytarabine|Fadraciclib iv QD on Day 1 (+/- 15) of a 28 day cycle Cytarabine iv or sc on Day 2-5 and Day 8-11 of a 28 day cycle
89238685|NCT02813135|Experimental|Arm M. Ribociclib + Everolimus +/- Dexamethasone|"Ribociclib capsules or tablets orally QD on Day 1-21 of a 28 day cycle. Everolimus dispersible tablets orally QD on a continuous dosing per 28 day cycle.~For patients with leukemia and lymphoma:~Dexamethasone orally or iv on Day 1-7 of each 28 day cycle. For patients with ALL, AML and Non-Hodgkin Lymphoma (NHL), Intrathecal chemotherapy will be administered additionally as per standard practice depending on CNS status."
89238686|NCT02813135|Experimental|Arm N. Ceralasertib (AZD6738) + Olaparib|Olaparib tablets orally BID per 28 days Ceralasertib tablets QD or BID per 28 day cycle
89238687|NCT02813135|Experimental|Arm O. Futibatinib (TAS-120)|Futibatinib tablets orally on a continuous dosing QD per 28 day cycle
89238688|NCT02813135|Experimental|Arm P. Capmatinib (INC280) + Everolimus|Capmatinib tablets orally on a continuous dosing BID per 28 day cycle. Everolimus dispersible tablets orally QD on a continuous dosing per 28 day cycle.
89238689|NCT02812537||patients with conduct disorders|Girls and boys having less than 16 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
89238690|NCT02809196|Active Comparator|1: Tailored, friend and mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Friend and mother are invited to participate."
89238691|NCT02809196|Active Comparator|2: Standardized, friend and mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Friend and mother are invited to participate."
89238692|NCT02809196|Active Comparator|3:Tailored, friend and not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Friend is invited to participate but not mother."
89238693|NCT02809196|Active Comparator|4: Standardized, friend and not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Friend is invited to participate but not mother."
89238694|NCT02809196|Active Comparator|5:Tailored, mother and not friend|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Mother is invited to participate but not friend."
89238695|NCT02809196|Active Comparator|6: Standardized, mother and not friend|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Mother is invited to participate but not friend."
89238696|NCT02809196|Active Comparator|7:Tailored, not friend, not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Neither friend nor mother is invited to participate."
89238697|NCT02809196|Active Comparator|8: Standardized, not friend, not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Neither friend nor mother is invited to participate."
89238698|NCT02809196|Other|9: No SMS program|Control Group; no SMS-based educational program
89238699|NCT02800512|Active Comparator|Sacrocolpopexy|Robotic sacrocolpopexy
89238700|NCT02800512|Active Comparator|HUSLS|Vaginal high uterosacral ligament suspension
89238701|NCT02799823|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
89238702|NCT02732288|Experimental|Melatonin, brain injured patients|Melatonin 3mg, orally, at 8pm, daily for 3 months
89238703|NCT02732288|Experimental|Healthy volunteers|Melatonin 3mg, orally, at 8pm
89238704|NCT02712515||Essential tremor|Participants in this group will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
89238705|NCT02712515||Parkinson's disease and dystonia|Participants in this group with Parkinson's disease and/or dystonia will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
89238706|NCT02687958|Experimental|A Everolimus 10mg (every cycle) until PD|Patients with stable disease, partial response or complete response after 4- 6 cycles of induction chemotherapy with Cisplatin or Carboplatin plus Etoposide or alternative first line chemotherapy according with local practice will receive maintenance therapy with Everolimus 10mg every cycle (28days) until PD or unacceptable toxicity.
89238707|NCT02687958|No Intervention|B Observational|Patients in this arm will meet observation criteria
89238708|NCT02657863||Healthy volunteer|Normal volunteers will be enrolled and informed consent obtained per study guidelines as described. Urine and plasma will be collected from each of 30 subjects with no prior history of prostate or other cancers.
89238709|NCT02657863||Prostate cancer patients being treat with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 25 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to the onset of therapy.
89238710|NCT02657863||Prostate cancer patients being treated with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 5 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to initiation of androgen deprivation (week 0), again prior to initiation of radiotherapy (week 8), at the end of radiation therapy (week 16) and at 6 months and 12 months after the conclusion of radiation therapy.
89238711|NCT02623712|Active Comparator|More Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
89238712|NCT02623712|Active Comparator|Less Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
89238713|NCT02593565||Intervention|Woman, 18 years of age or older, currently pregnant, and have a diagnosis of vasculitis.
89238714|NCT02586090|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
89238715|NCT02586090|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
89238716|NCT02503228||MOPS|Transplanted tissue preserved using the MOPS method and obtained from one AATB-approved tissue bank
89238717|NCT02503228||Standard Preservation|Transplanted tissue preserved using standard preservation methods and obtained from one of three AATB-approved tissue banks
89238718|NCT02487524|Other|Nerve resection with pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
89238719|NCT02487524|Other|Nerve resection without pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
89238720|NCT02487524|Other|No nerve resection but pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
89238721|NCT02478710|Placebo Comparator|Aerosolized Placebo|Placebo tobramycin 0.5 mL 0.9% normal saline q.12h. Placebo vancomycin 0.5 mL 0.9% normal saline q.8h.
89238722|NCT02478710|Experimental|Aerosolized Tobramycin or Vancomycin|Aerosolized tobramycin 300 mg diluted in 5 mL 0.9% normal saline q.12h. Aerosolized vancomycin 125 mg diluted in 5 mL 0.9% normal saline q.8h.
89238723|NCT02476279|Experimental|Indomethacin alone|Indomethacin 100 mg rectally immediately after ERCP
89238724|NCT02476279|Active Comparator|Indomethacin+pancreatic stent|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
89238725|NCT02455505||Risk Screening tool & Cognitive Interview|
89238726|NCT02432482|Active Comparator|Standard care|Brief advice to quit (less than 5 minutes) Self-help brochure Offer of nicotine patches
89238727|NCT02432482|Experimental|mobile Positively Smoke Free (mPSF)|"mPSF: a targeted, intensive behavioral cessation intervention for PLWH smokers~offer of nicotine patches"
89238728|NCT02425865|Other|open-label, uncontrolled trial|All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if > 80 kg
89238729|NCT02425852|Active Comparator|Combination therapy arm|Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.
89238730|NCT02425852|Active Comparator|Azathioprine arm|"Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.~In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake."
89238731|NCT02333188|Experimental|Treatment (FOLFIRABRAX)|Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation IV over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
89238732|NCT02330601|No Intervention|control group|The papilla orifice could be enlarged by asphincterotomeif necessary. The stones were retrieved by a basket or a retrieval balloon
89238733|NCT02330601|Other|EPLBD group|a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
89238734|NCT02296528|Other|Swallowing Expansion Device|Titanium swallowing expansion device
89238735|NCT02259413|Experimental|Exercise Rehabilitation|"Participants will receive baseline exercise counselling as per Standard Care group. Participants will then participate in a 26-week exercise rehabilitation program incorporating 3 components:~One-to-one self-management/resistance education once per week during the first 4 weeks of intervention. Participants will subsequently receive resistance training material to allow for home exercise for the remaining 22 weeks of the intervention.~Intradialytic aerobic exercise on a cycle ergometer 3 times weekly for 26 weeks at their usual hemodialysis sessions.~Four additional one-to-one standardized education sessions will be completed during the intervention period."
89238736|NCT02259413|No Intervention|Standard Care|Participants will receive one exercise counseling session as part of their baseline assessment. Participants in the control group will not undergo any other exercise counseling or formal exercise intervention, but will not be prohibited from participating in exercise outside of the study protocol.
89238737|NCT02242760|Experimental|SB204 2% Twice daily|Twice daily SB204 2%
89238738|NCT02242760|Experimental|SB204 4% daily|Once daily SB204 4%
89238739|NCT02242760|Placebo Comparator|Vehicle Gel Daily|Vehicle Gel Daily
89238740|NCT02242760|Placebo Comparator|Vehicle Gel Twice Daily|Twice daily Vehicle Gel
89238741|NCT02242760|Experimental|SB204 4% Twice Daily|Twice daily SB204 4%
89238742|NCT02203695|Experimental|SRT plus Enzalutamide|Arm 2 (experimental): (SRT) Salvage radiation therapy (Three dimensional conformal radiation therapy (3D-CRT)/IMRT [Intensity-modulated radiation therapy]) 66.6-70.2 Gy as 1.8 Gy M-F for 37-39 fx PLUS Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
89238743|NCT02203695|Placebo Comparator|SRT plus placebo|Arm 1 (control): Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT (Intensity-modulated radiation therapy)) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx PLUS Placebo PO daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
89238744|NCT02195050||Therapeutic target arm|Statin treated patients with and without raised triglycerides who do not have diabetes or dysglycemia. Statin treated patients with type 2 diabetes.Statin treated patients with CKD stages 4 and 5 (eGFR ≤30mL/min).
89238745|NCT02195050||Nerve function arm|Patients with severe hypertriglyceridaemia (fasting TG > 5.5mmol/l.) are recruited for nerve function assessment and corneal confocal microscopy.
89238746|NCT02195050||Genetic screening arm|For LAL deficiency screening, patients will be recruited over a 5 year period with a documented triglyceride level of more than 10 mmol/l at any time, low HDLC, raised ALT, combined hyperlipidaemia, or non-alcoholic fatty liver disease. Patients recruited from Manchester will be offered additional genetic testing for familial hypercholesterolaemia.
89238747|NCT02177578|Experimental|Temozolomide plus radiation therapy to the tumor and SVZ|"Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy of radiation therapy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series and FLAIR series, plus the bilateral subventricular zone Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed, areas of contrast enhancement on T1 post gadolinium series MRI plus the ipsilateral subventricular zone Will be prescribed to 14 Gy in 2 Gy fractions"
89238748|NCT02177578|Active Comparator|Temozolomide and neural progenitor cell sparing radiation|"Patients will receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI abnormalities based on T1 post gadolinium series and FLAIR series.~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series.~Will be prescribed to 14 Gy in 2 Gy fractions"
89238749|NCT02177227|Experimental|Total Knee Arthroplasty with PSI|Total Knee Replacement with the use of the Attune TruMatch (TM) Patient-Specific Instrumentation
89238750|NCT02177227|No Intervention|Total Knee Replacement|Total Knee Replacement, as per Standard of Care
89238751|NCT02138448|Experimental|Intervention practices|Intervention practices will implement an interactive preventive health record in addition to their standard personal health record functionality.
89238752|NCT02138448|No Intervention|Control practices|Control practices will continue to field their existing personal health record
89238753|NCT02109705||Alzheimer's Disease|
89238754|NCT02109705||other Dementia|
89238755|NCT02109705||cognitive healthy|
89238756|NCT01994954|No Intervention|Arm A:Standard therapy|Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Polysomnograms will be utilized prior to final discontinuation of oxygen. RHO will only be utilized on the night prior to and during the polysomnogram to compare these two modalities.
89238757|NCT01994954|Experimental|Arm B:RHO|"Infants will have the same monthly clinic assessments as in Arm A, but also will utilize RHO to potentially increase, decrease or maintain oxygen between monthly visits.~Parents will transmit a minimum of 4 days of stored RHO data (min 8 hrs per day) every 4-7 days. Changes in oxygen needs will be made based on standardized objective criteria. To determine discontinuation of oxygen, RHO will be utilized instead of polysomnography."
89238758|NCT01973881||T1 weighted MRI (magnetic resonance imaging)|For the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis. Quantitative MRI parameters for diffusion of water and/or fat content in bone marrow will determine extent of disease in patients with myelofibrosis, and changes in these parameters will predict response to therapy. To investigate this hypothesis, the researchers will perform this pilot clinical study of diffusion and fat content (T1 weighted imaging) in patients before and during treatment for myelofibrosis. The researchers expect to identify MRI parameters that determine the extent and severity of bone marrow disease in these patients and determine response to therapy at earlier time points than currently used clinical parameters.
89238759|NCT01958840|Experimental|Behavioral Activation Treatment for Depression|Behavioral Activation Condition - 10 sessions
89238760|NCT01958840|Active Comparator|Supportive Counseling|Supportive Counseling Condition - 10 sessions
89238761|NCT01892709|Experimental|Hydromorphone|"All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, Do you want more pain medicine? This question will be asked 30 minutes after they answered no or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers yes. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period."
89238762|NCT01873755|Experimental|asthma physical activity intervention|two schools will receive intervention
89238763|NCT01858597|Other|gestational diabetes mellitus|Those women (subjects) with gestational diabetes mellitus
89238764|NCT01858597|Other|control|Those healthy pregnant women
89238765|NCT01806571|Experimental|Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)|"INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on days 1-3, cytarabine IV continuously on days 1-7, and nilotinib PO BID on days 4-14. Patients achieving CR or CRi proceed to consolidation therapy. Patients not achieving a significant decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive another course of induction therapy.~CONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1, 3, and 5, and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every 84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
89238766|NCT01741311|Experimental|3H+ Group|3H+ (Holistic for HIV) group patients will receive the standard of drug treatment care (i.e., methadone maintenance treatment and case management) plus four weekly 60-minute HIV risk reduction groups, and a 60-minute booster session at 12 weeks, led by two facilitators trained and supervised by a licensed clinical psychologist. 3H+ is an HIV risk reduction and ART adherence intervention that provides coping skills training and is delivered in a group modality, addressing high risk drug- and sex-related HIV risk behaviors and ART adherence for opioid-dependent individuals living with HIV.
88804683|NCT01215643|Experimental|ALV 600 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
89238767|NCT01741311|Active Comparator|HHRP+ Group|HHRP+ (Holistic Health Recovery Program) is comprised of 12 two-hour weekly manual-guided group sessions with comprehensive HIV risk reduction content that addresses the medical, emotional, and spiritual needs of opioid-dependent individuals living with HIV. Each session is designed to last 2 hours and is co-facilitated by two trained facilitators, who address potential motivational conflicts of HIV+ individuals by providing them with self-protective as well as altruistic reasons for examining and changing their HIV risk behaviors and improving adherence behavior. Material is presented using cognitive remediation strategies.
89238768|NCT01705899|Experimental|Subjects with preserved kidney function|Subjects with preserved renal function that have not previously received a kidney transplant will be treated with Human Pancreatic Islets (in the form of islets alone - IA).
89238769|NCT01705899|Experimental|Subjects with prior kidney transplant|Subjects with renal failure secondary to diabetes who have received a prior kidney transplant at least 6 months previously and have stable renal function on a steroid-free immunosuppressive regimen will receive Human Pancreatic Islets (in the form of islets after kidney - IAK).
89238770|NCT01701154||Pompe|Adults and children with Pompe disease.
89238771|NCT01658917||Primary|Patients greater than or equal to 18 years of age who have premalignant, primary or metastatic solid tumors based upon either radiographic or biochemical testing, or histological/cytological analysis
89238772|NCT01651910||Controlled Pain|Participants who have controlled pain; requiring regular painkillers which are maintaining the pain as none - mild with no breakthrough pain episodes.
89238773|NCT01651910||Uncontrolled Pain|Participants who have uncontrolled pain; pain that is moderate to severe whether on painkillers or not
89238774|NCT01651910||Breakthrough pain|Participants who have breakthrough pain; pain that is controlled but the patient has episodes when the pain intermittently 'flares up'.
89238775|NCT01642641|Active Comparator|Non-surgical subgingival debridement|
89238776|NCT01642641|Active Comparator|Simplified Papilla Preservation Flap|
89238777|NCT01642641|Active Comparator|Resective Flap with Osseous Recontouring|
89238778|NCT01639196|Experimental|Self-compassion writing|
89238779|NCT01639196|Active Comparator|Self-efficacy writing|
89238780|NCT01633177|Active Comparator|Vitamin D and Omega-3|
89238781|NCT01633177|Active Comparator|Vitamin D and Omega-3 placebo|
89238782|NCT01633177|Active Comparator|Vitamin D placebo and Omega-3|
89238783|NCT01633177|Placebo Comparator|Vitamin D placebo and Omega-3 placebo|
89238784|NCT01607008|Other|MRI imaging|Use of MRI imaging in conjunction with standard radiation treatment
89238785|NCT01517451|Experimental|Radiation with Androgen Deprivation Therapy (ADT)|This will be a Phase I/II study evaluating the effectiveness and toxicity of a combined regimen of 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions) with androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT (stereotactic body radiation therapy). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens.
89238786|NCT01415817|No Intervention|Baseline Data collection|
89238787|NCT01415817|Experimental|Randomization and Training Arm|
89238788|NCT01336855||HIV Positive|HIV-1 positive subjects
89238789|NCT01336855||HIV negative subjects|HIV-1 seronegative control group
89238790|NCT01290835|Experimental|Stereotactic radiotherapy|Accelerated stereotactic radiotherapy as an adjuvant treatment for early stage breast cancer.
89238791|NCT01204216|Active Comparator|Aim 1|Subjects in this arm will be 10 people without diabetes as well as 10 people with diabetes and stable glycemic control. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
89238792|NCT01204216|Active Comparator|Aim 2|For Aim 2, 10 additional subjects with diabetes in poor glycemic control will be studied initially and then again in improved glycemic control after at least 8 months (with up to 5 additional subjects entered as needed to ensure 10 completed paired studies) to assess the potential role of MRBC variation in the discordances seen between HbA1c and blood glucose testing. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
89238793|NCT01202305||HIV negative|
89238794|NCT01202305||HIV positive|
89238795|NCT01161199||Untreated non-controllers|
89238796|NCT01161199||Elite controllers|
89238797|NCT01161199||HAART-suppressed|
89238798|NCT01107015|No Intervention|Group 1: Usual Care|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
89238799|NCT01107015|Active Comparator|Group 2: patient intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback
89238800|NCT01107015|Active Comparator|Group 3: patient-physician intervention|Home diabetes monitoring by patient using mobile phone to communicate and receive feedback; Physician can access unanalyzed information from the patient's electronic logbook
89238801|NCT01107015|Active Comparator|Group 4: data analyzed intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback; Physician can access raw and analyzed patient data; Physician receives report summary and treatment recommendations
89238802|NCT01104350|Experimental|Radiotherapy and Concurrent Gemcitabine Chemotherapy|This is a Phase I dose-escalation study examining the safety and tolerability of intensity modulated external radiation therapy using image-guidance in combination with gemcitabine chemotherapy as an alternative to radical cystectomy.
89238803|NCT01100892|No Intervention|Control group|Observation only. Does not receive once-daily insulin detemir.
89238804|NCT01100892|Experimental|Once-daily insulin detemir|Once-daily insulin detemir
89238805|NCT01025089|Experimental|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
89238806|NCT00999037|Experimental|Renvela|Daily renvela with meals for 12 weeks
89238807|NCT00999037|Placebo Comparator|placebo|
89238808|NCT00921856|No Intervention|CAD|Patients admitted with suspicion of CAD and proof of CAD after coronary angiography.
89238809|NCT00921856|Experimental|No-CAD|Patients admitted with suspicion of CAD but without proof of CAD after coronary angiography will undergo intracoronary acetylcholine provocation test.
89238810|NCT00833664|Experimental|Terbinafine|Terbinafine 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
89238811|NCT00833664|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
89238812|NCT00745355||1|new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion
89238813|NCT00696111|Experimental|1A|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive estrogen plus placebo for another 6 weeks.
89238814|NCT00696111|Experimental|1B|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive progesterone plus placebo for another 6 weeks.
89238815|NCT00696111|Experimental|3|Randomized to receive CPAP (continuous positive airway pressure) treatment for 6 weeks.
89238816|NCT00380367|Experimental|Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)|Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.
89238817|NCT00243776||Cardiac Tissue|Cardiac tissue and cells will be obtained from participants undergoing cardiac surgical repair
89238818|NCT00199862|Experimental|Radio-labeled huA33 Antibody|"Patients will receive a single I-V infusion of 4mCi-10mCi/10mg 124I-huA33 in 5-30 mL of 5% human serum albumin (HAS) in normal saline, over 5 minutes-4 hours. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and ex-vivo quantitation of tumor uptake .~Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV, on and before or after PET scanning on subsequent days.~Surgery (or biopsy) will be scheduled to occur 8- 10 days after administration of 124I-huA33. The 8-10 day imaging session will be scheduled for the morning of surgery or biopsy, approximately 1-6 hours before the procedure."
89238819|NCT00179387|Active Comparator|1|Psycho-educational / Stress Management group
89238820|NCT00179387|Active Comparator|2|Spiritual-Existential Support Group
89238821|NCT00179348|Experimental|Group I (yoga-based rehabilitation program)|Participants undergo a yoga-based rehabilitation program up to 5 days a week for 1.5 hours and practice at home at least once daily for 12 weeks.
89238822|NCT00179348|Active Comparator|Group II (standard care/control)|After a 3 month wait period, participants undergo a yoga-based rehabilitation program as in Group I.
89238823|NCT00128310|Active Comparator|Arm A: Vinorelbine|Arm A: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8.
89238824|NCT00128310|Experimental|Arm B: Vinorelbine and Gemcitabine|Arm B: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8. Gemcitabine will be administered following vinorelbine at a dose of 1200 mg/m2 as an intravenous infusion over 30 minutes.
89238825|NCT00870077|Experimental|1|
89238826|NCT04782401|Active Comparator|Genicular Nerve Block|
89238827|NCT04782401|Active Comparator|Physical Therapy|
89238828|NCT01007708|Experimental|IDP-108|
89238829|NCT01007708|Placebo Comparator|Vehicle|
89238830|NCT00885443|Active Comparator|1|
89238831|NCT00885443|Active Comparator|2|
89238832|NCT00882947||Group 1|
89238833|NCT00531050|Experimental|Part 1: Sequence A, Part 2: Sequence A|"Part 1: Sequence 'A' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus dry powder inhaler (DPI). Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'A' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
89238834|NCT00531050|Experimental|Part 1 : Sequence B, Part 2: Sequence B|"Part 1: Sequence 'B' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'B' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
89238835|NCT00531050|Experimental|Part 1: Sequence C, Part 2: Sequence C|"Part 1: Sequence 'C' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus DPI. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'C' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device . In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
89238836|NCT00531050|Experimental|Part 1; Sequence D, Part 2: Sequence D|"Part 1: Sequence 'D' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'D' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
89238837|NCT00531050|Experimental|Part 1: Sequence E, Part 2: Sequence E|"Part 1: Sequence 'E' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'E' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
89238838|NCT00531050|Experimental|Part 1: Sequence F, Part 2: Sequence F|"Part 1: Sequence 'F' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'F' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
89238839|NCT05231018|Experimental|Psychotherapy|The population of interest includes COVID-19 patients previously or currently hospitalized at the Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, according to inclusion and exclusion criteria.
89238840|NCT00530348|Experimental|Alemtuzumab|
89238841|NCT00530348|Active Comparator|Interferon Beta-1a|
89238842|NCT01001312|Experimental|Daxor Blood Volume Analysis|Subjects in this treatment arm will receive guideline recommended treatment based on direct blood volume measurement for assessment of volume status.
89238843|NCT01001312|Active Comparator|Clinical volume status assessment|Subjects in this treatment arm will receive guideline recommended treatment based on clinical assessment of volume status.
89238844|NCT03886220|Experimental|Elagolix 150 mg|Elagolix 150 mg once daily (QD)
89238845|NCT03886220|Experimental|Placebo|Placebo QD
89238846|NCT01007864|Experimental|piribedil|
89238847|NCT01007864|Active Comparator|pramipexole or ropinirole|
89238848|NCT05111366|Experimental|TQB2450 injection combined with Anlotinib hydrochloride capsules|
89238849|NCT01008020|No Intervention|Dietary supplement: placebo|
89238850|NCT01008020|Active Comparator|Tea catechin extracts|
89238851|NCT01008098|Experimental|PTSD group|
89238852|NCT00530270|Active Comparator|Dexamethasone|
89238853|NCT00530270|Placebo Comparator|Placebo|
89238854|NCT01008254|Experimental|Musical prompt|
89238855|NCT01008254|Active Comparator|Delayed musical prompt|
89238856|NCT01008254|No Intervention|No musical prompt|
89238857|NCT01008332|Experimental|Cohort 1|ToleroMune HDM, subjects to receive either active or placebo comparator
89238858|NCT01008332|Experimental|Cohort 2|ToleroMune HDM, subjects to receive either active or placebo comparator
89238859|NCT01008332|Experimental|Cohort 3|ToleroMune HDM, subjects to receive either active or placebo comparator
89238860|NCT01008332|Experimental|Cohort 4|ToleroMune HDM, subjects to receive either active or placebo comparator
89238861|NCT01008332|Experimental|Cohort 5|Toleromune HDM, subjects to receive either active or placebo comparator
89238862|NCT01008488|Active Comparator|Antibiotic|
89238863|NCT01008488|No Intervention|No antibiotic|
89238864|NCT01001468|Experimental|VB-201 20 mg|
89238865|NCT01001468|Experimental|VB-201 80 mg|
89238866|NCT01001468|Placebo Comparator|Placebo|Single daily dose of oral placebo
89238867|NCT01001624|Experimental|A|Melanil facial cream
89238868|NCT01001624|Active Comparator|B|Hydroquinone 2% cream
89238869|NCT01001780|Experimental|Pentostatin, Cyclophosphamide, Rituximab|
89238870|NCT01001858|Active Comparator|Domiciliary group|In this group OSA diagnosis was performed at patient's home by mean of non-attended RP. All follow-up visits were conducted by a trained nurse in patient's home.
89238871|NCT01001858|Active Comparator|Hospital Group|In this group diagnosis was made by in-hospital PSG. Follow-up was performed at hospital by a specialist Physician
89238872|NCT01001858|Active Comparator|Mixed Group|In this group diagnosis was made by home RP, and follow-up at hospital
89238873|NCT01008566|Experimental|Treatment (cixutumumab, sorafenib tosylate)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22 and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89238874|NCT01008644|Experimental|Saline|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min.
89238875|NCT01008644|Experimental|Water|The subjects will drink tap water for 2 hours, the volume calculated as 20ml/kg/hour
88804684|NCT01215643|Experimental|ALV 800 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
89238876|NCT05593406|Experimental|Vibration Group|The intervention-vibration group, in addition to the conventional physical therapy- NDT they received, were also included in mechanical vibration.
89238877|NCT05593406|Active Comparator|Control Group|The Control group received only conventional physical therapy- NDT.
89238878|NCT01001936|Experimental|1|
89238879|NCT03885596|Experimental|CA-008 Cohort 1|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block."
89238880|NCT03885596|Experimental|CA-008 Cohort 2|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
89238881|NCT03885596|Experimental|CA-008 Cohort 3|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
89238882|NCT03885596|Active Comparator|Exparel|"106 mg [8 mL of the 133 mg/10 mL suspension] only~All subjects received monitored anesthesia care (MAC) and a Mayo block."
89238883|NCT05733338|Active Comparator|IH group|Participants will receive 10 times intermittent hypoxia (oxygen concentration: 13%) intervention before exposure to acute hypoxia environment.
89238884|NCT05733338|Sham Comparator|Control group|Participants will receive 10 times sham-hypoxia (oxygen concentration: 21%) intervention in 5 days before exposure to acute hypoxia environment.
89238885|NCT01002092|Active Comparator|Chemotherapy|
89238886|NCT01002092|Experimental|Endostar plus Chemotherapy|
89238887|NCT05567510|Experimental|BMS-986369|
89238888|NCT03999866|Active Comparator|satisfaction of instructor|visual analogy scale of the satisfaction of the instructor was recorded
89238889|NCT03999866|Active Comparator|satisfaction of the patient|visual analogy scale of the satisfaction of the patient was recorded
89238890|NCT03999866|Active Comparator|duration of view|duration of the visualization the vocal cords was recorded
89238891|NCT01002326|Experimental|Cognitive-Behavioral Therapy|
89238892|NCT01002404|Active Comparator|angled tipped guide wire|angled tipped guide wire used to deep biliary cannulation
89238893|NCT01002404|Active Comparator|straight tipped guidewire|straight guide wire used to deep biliary cannulation
89238894|NCT01002560||Malignant melanoma tumour tissue|
89238895|NCT01002560||Benign pigmented lesions & other skin cancers|Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
89238896|NCT05733026||1|Breast cancer patients who developed cardiotoxic side effects in response to Doxorubicin treatment
89238897|NCT05733026||2|Breast cancer patients who did not develope cardiotoxic side effects in response to Doxorubicin treatment
89238898|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 1|Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m^2) IV through 500 mg/m^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
89238899|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 2|Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
89238900|NCT05467280|Experimental|Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars, and challenges.
89238901|NCT05467280|No Intervention|Control|They will not carry out any type of intervention, they will only be monitored during the 6 months
89238902|NCT04976660|Experimental|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-4 is determined
89238903|NCT01002638|Experimental|Occlusive Dressing|
89238904|NCT01002638|Active Comparator|Surgery|
89238905|NCT03878108|Active Comparator|LCHF diet then LFHC diet|Low carbohydrate, high fat (LCHF) diet then low fat, high carbohydrate diet (LFHC) diet
89238906|NCT03878108|Active Comparator|LFHC diet then LCHF diet|Low fat, high carbohydrate diet (LFHC) diet then low carbohydrate, high fat (LCHF) diet
89238907|NCT01002794|Experimental|Arthroscopic partial meniscectomy|Standard arthroscopic partial meniscectomy - NGD 1
89238908|NCT01002794|Experimental|Exercise Therapy|Supervised neuromuscular- and strength training
89238909|NCT03999398||No-touch|"Participants that operated at the time of the coronary artery bypass grafting with a no-touch venous graft."
89238910|NCT03999398||Conventional|"Participants that operated at the time of the coronary artery bypass grafting with a conventional venous graft."
89238911|NCT00529958|Active Comparator|Patellar Tendon (PT)|ACL reconstruction using a patellar tendon autograft
89238912|NCT00529958|Active Comparator|Hamstring (HT)|ACL reconstruction using a quadruple-strand semitendinosus/gracilis (hamstring) tendon single-bundle autograft
89238913|NCT00529958|Active Comparator|Double-Bundle (DB)|ACL reconstruction using a semitendinosus/gracilis (hamstring) tendon double-bundle autograft
89238914|NCT00529802|Experimental|Everolimus (RAD001) 10mg daily|All patients were to receive 10mg everolimus (RAD001) daily.
89238915|NCT03742622|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions
89238916|NCT01003340|Experimental|Wee Wheezers asthma education|6 lesson asthma education delivered at home by Community Health Workers
89238917|NCT04928456|Experimental|OMT Intervention Arm|"OMT will include:~Myofascial release of the thoracic inlet: gentle pressure applied to shoulders and neck to move the tissue in different directions with a gentle motion.~Pectoral traction: The armpit will be contacted with the finger pads of the doctor and each side will be gently grasped and have a slow pulling force applied towards the shoulders.~Diaphragm release with MFR: The doctor will touch below the ribs on each side and will apply gentle pressure and move the tissue from side to side.~Splenic pump: below the ribs on the left hand-side, the doctor will apply pressure and release pressure several times to create a vibration over the area just below the ribs.~Thoracic pump: The doctor will place their hands over the chest wall on each side and will apply pressure and release pressure several times to generate a pumping action of about 100 times in one minute.~Treatment will last 5 minutes with each technique lasting 1 minute."
89238918|NCT04928456|No Intervention|Control|Participants in the control group will undergo the same assessments as the OMT intervention arm and will receive their vaccinations, but will not receive any OMT.
89238919|NCT00528866|Experimental|Androgen suppression + RT + docetaxel|LHRH agonist and oral antiandrogen (flutamide or bicalutamide), radiation therapy (RT), and docetaxel
89238920|NCT03999008|Active Comparator|Budesonide|"Oral viscous budesonide will be given in apple sauce according to body weight at inclusion:~< 10 kg: 250 mcg BID in 5 ml apple sauce 10 kg to <15 kg: 500 mcg BID in 5 ml apple sauce >15 kg: 1000 mcg BID in 5 ml apple sauce"
89238921|NCT03999008|Placebo Comparator|Placebo|Placebo: 5 ml apple sauce BID plus 1 mL saline
89238922|NCT01003574|Other|Control Arm|Control arm will receive standard care for risk of cardiac sequelae - a mailed, tailored (neither generic nor targeted) print summary of individualized information about the survivor's treatment, late effects risks, and recommended follow-up and lifestyle modifications.
89238923|NCT01003574|Other|Test Arm|Test arm will receive standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
89238924|NCT01003652||Harmonic Focus /conventional haemostasis|
89238925|NCT01003652||Harmonic Focus|
89238926|NCT01003652||new surgical device|
89238927|NCT01003652||Harmonic Focus / conventional haemostasis|Harmonic Focus group refers to the use of ultracision shears for haemostasis and conventional haemostasis group refers to the tie-and-clamp technique in total thyroidectomy
89238928|NCT01003730|Active Comparator|1|High tidal volume (15mL/kg PBW0 with low PEEP (3cm H2O
89238929|NCT01003730|Active Comparator|2|Low tidal volume (6mL/kg PBW) and high PEEP (3cm H2O)
89238930|NCT01003730|Active Comparator|3|low tidal volume (6mL/kg PBW) and high PEEP (10cm H2O)
89238931|NCT04000490||patient with a chest pain|adult patient with a chest pain calling for urgency center
89238932|NCT01003808|Experimental|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
89238933|NCT04932746|Experimental|The dexmedetomidine group:|"An initial dose of 1 mcg / kg 1 dexmedetomidine will be given 10 minutes after the start of anesthesia infusion within 10 minutes, after which the dexmedetomidine infusion is maintained at a dose of 0.4 mcg / kg / hour.~The injection will be stopped before the skin is closed."
89238934|NCT04932746|Experimental|The Placebo group (the control group):|After the same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol.
89238935|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (DB)|In double-blind (DB) Week 1, participants receive cetuximab 400 mg/m^2 intravenously (IV) loading dose and irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV one time each week (Q1W) maintenance dose, irinotecan IV Q1W and DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
89238936|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)|In the open-label (OL) portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W + irinotecan Q1W at their pre-study dosage + OL dalotuzumab (loading dose of 15 mg/kg IV followed by a maintenance dose of 7.5 mg/kg 2 weeks later) to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
89238937|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (OL)|In the OL portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W+ irinotecan Q1W at their pre-study dosage + OL dalotuzumab 10 mg/kg IV Q1W to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
89238938|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
89238939|NCT00614393|Active Comparator|Placebo + Cetuximab + Irinotecan (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB normal saline (placebo) IV Q1W for up to 32 months of treatment.
89238940|NCT00885521|Experimental|Exercise|8 week, twice weekly exercise program with both endurance and upper and lower limb strength training
89238941|NCT00885521|No Intervention|2|No exercise, twice weekly phone calls
89238942|NCT00880529|Experimental|ON-Q|Subcutaneous bupivicaine administration and IV opioid medication if necessary
89238943|NCT00880529|Active Comparator|IV opioids alone|Standard therapy with IV opioid administration
89238944|NCT00883025||1|OSAS patients
89238945|NCT00883025||2|no OSAS Patient
89238946|NCT00880841||no treatment|phase 1a study for healthy normals
89238947|NCT04503863|Experimental|Experimental 1|Single administration of middle dose NPC-22
89238948|NCT04503863|Experimental|Experimental 2|Single administration of high dose NPC-22
89238949|NCT04503863|Placebo Comparator|Experimental 3|Single administration of placebo dose NPC-22
89238950|NCT00883259|Experimental|Experimental|Metformin treatment
89238951|NCT00883259|Placebo Comparator|Placebo|Placebo tablets
89238952|NCT00885599|Experimental|PERIORINSE|naturopathic remedy
89238953|NCT00885599|Active Comparator|CPC|Cepacol, standard anti-bacterial mouthwash
89238954|NCT00885599|Active Comparator|Listerine|standard anti-bacterial mouthwash
89238955|NCT00885599|Placebo Comparator|placebo|colored water
89238956|NCT00881075|Experimental|SeeMore(TM)|intravenous imaging agent for enhanced magnetic resonance imaging.
89238957|NCT04366115|Active Comparator|AVM0703 COVID-19 ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
89238958|NCT04366115|Placebo Comparator|Placebo COVID-19 ARDS - placebo|Matching placebo
89238959|NCT04366115|Active Comparator|AVM0703 Influenza ARDS - active|Supra-pharmacologic dexamethasone sodium phosphate
89238960|NCT04366115|Placebo Comparator|AVM0703 Influenza ARDS - placebo|Matching placebo
89238961|NCT04712747||Cases - patients with stroke|Ophthalmological examinations : At the inclusion visit and 3 months after their stroke Blood pressure measurement at rest : At the inclusion visit
89238962|NCT04712747||Controls - Individuals with no history of stroke|Ophthalmological examinations : At the inclusion visit Blood pressure measurement at rest : At the inclusion visit
89238963|NCT04038125|Other|Ozurdex Implant|Intravitreal injection of Ozurdex implant
89238964|NCT00881153|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
89238965|NCT00881153|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
89238966|NCT00885833|Experimental|Fludarabine|
89238967|NCT00612677|Experimental|Premetrexed and Oxaliplatin|Patients will be treated with oxaliplatin 120 mg/m^2 i.v. over 2 hours and pemetrexed 500 mg/m^2 i.v. over 10 minutes on Day 1 of a 21day cycle. Cycles of treatment will be repeated every 3 weeks. Folic acid and B12 supplementation is obligatory.
89238968|NCT04038749|Experimental|Pharmaceutical method- Bromocriptine|
89238969|NCT04038749|Experimental|Pharmaceutical method- Cabergoline|
89238970|NCT04038749|Other|Without medications that inhibit lactation|
89238971|NCT00883571|Active Comparator|house advancement flap|house advancement flap
89238972|NCT00883571|Active Comparator|Rhomboid flap|rhomboid flapa was incised in the ischiorectal fossa. Without undermining of its fatty base, the flap was then mobilized into the anal canal so that the tip could be sutured to the top of the strictured area using Vicryl 3/0 sutures
89238973|NCT00883571|Active Comparator|Y-V anoplasty|Y-V anoplasty
89238974|NCT00881231|Experimental|1|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
89238975|NCT00881231|Active Comparator|2|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
89238976|NCT00613925|Active Comparator|Pipelle Group|Women were randomized to have an endometrial biopsy collected using Pipelle de Cornier instrument.
89238977|NCT00613925|Active Comparator|Explora group|Women were randomized to have an endometrial biopsy collected using Explora curette instrument.
89238978|NCT00881309|Experimental|immunosuppressor|
89238979|NCT00885911||Extraglottic device|The laryngeal mask airway (LMA) used during pediatric anesthesia for routine and difficult airway management.
89238980|NCT00883649|Placebo Comparator|1|
89238981|NCT00883649|Active Comparator|2|
89238982|NCT00883727|Experimental|stem cells|
89238983|NCT00883727|Placebo Comparator|Placebo|
89238984|NCT00883805||Metal-on-Metal Articulations|Subjects will be people who have had metal-on-metal total hip arthroplasties
89238985|NCT00883805||Ceramic-on-Metal Articulations|Subjects will be people who have had ceramic-on-metal total hip arthroplasties
89238986|NCT00881387|Experimental|Group 1 (eligible for SCT)|Patients receive rituximab IV, vinorelbine ditartrate IV over 6-10 minutes, and gemcitabine hydrochloride IV over 30 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) or partial response (PR) undergo SCT.
89238987|NCT00881387|Experimental|Group 2 (ineligible for SCT)|Patients receive rituximab, vinorelbine ditartrate, gemcitabine hydrochloride, and pegfilgrastim as in group 1. Patients with CR, PR, or stable disease after 3 courses continue to receive therapy in the absence of disease progression or unacceptable toxicity.
89238988|NCT00883883|Experimental|1|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
89238989|NCT00883883|Active Comparator|2|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
89238990|NCT00883961|Experimental|Supervised exercise|
89238991|NCT00883961|No Intervention|Control group|The patients will not carry out a structured exercise program.
89238992|NCT00885989|Experimental|1|
89238993|NCT00885989|Placebo Comparator|2|
89238994|NCT00886067|Experimental|2-[18F]-F-A85380|Single microdose
89238995|NCT00886067|Experimental|AZD1446|Single oral administration
89238996|NCT00881543|Placebo Comparator|1|This arm will begin taking the placebo by a month, after a month will be tested the diets (the same caloric amount with different composition on fat, protein and carbohydrates)making curves of insulin, glucagon, C peptide and glp 1 and lipid when diets are tested (three acute tests with diets). After that, the patient will begin the drug by month (Januvia, 100 mg a day)and repeat all the three curves using the prepared diets to compare with the first month.
89238997|NCT00881543|Active Comparator|2|Since the beginning they will use the drug. Then will make the three tests and after will stop the drug by 1 month and come back to do the tests. We objective to demonstrate the washout of the drug clinically.
89238998|NCT00881699|Experimental|1|Participants will complete HIV risk reduction group meetings.
89238999|NCT00881699|Active Comparator|2|Participants will complete health promotion group meetings.
89239000|NCT04638569|Active Comparator|Ultrasound-guided obturator nerve block group|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle.
89239001|NCT04638569|Active Comparator|obtutaror nerve block with anatomical landmarks|In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL.
89239002|NCT04124861|Experimental|Drug free|"Arm A: Drug free Glucocorticoid（GC）is tapered and stopped in 8 weeks(GCs at a dose of ≤ 2.5 mg of prednisone or equivalent for treatment of adrenal insufficiency) .~Immunosuppressant is also tapered and discontinues in 8 weeks."
89239003|NCT04124861|Experimental|IS monotherapy|Arm B: Immunosuppressant only Glucocorticoid（GC）is tapered and stopped in 8 weeks. The same type and dosage of immunosuppressive agent before admission, including Mycophenolate mate(<= 1g/d) or Leflunomide (<=20mg/d) or Methotrexate (<=15mg/w) or Azathioprine (<=100mg/d)
89239004|NCT04124861|Experimental|GC combined with IS|Arm C: GC+Immunosuppressant Both Glucocorticoid(GC) (no more than 7.5mg/d) and immunosuppressant are kept as maintaining dose.
89239005|NCT00881777|Experimental|RF Heating + CABG|Radiofrequency heating of the myocardial infarct scar plus Coronary Artery Bypass Grafting (CABG) surgery
89239006|NCT00881777|Active Comparator|CABG Alone|Coronary Artery Bypass Grafting (CABG) surgery only, without radiofrequency heating of the myocardial infarct scar
89239007|NCT02542475|Experimental|Mood Improvement|Mood change with daily Low Field Magnetic Stimulation in participants suffering from affective disorders and/or anxiety
89239008|NCT00881855|Experimental|1|Cefprozil 500 mg Tablets (Sandoz, GmbH)
89239009|NCT00881855|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
89239010|NCT04015115|Experimental|Youth Opioid Recovery Support service model|The components of the Youth Opioid Recovery Support service model includes 1) home-delivery of standard-of-care medication and individual/family counseling services; 2) assertive outreach efforts by the treatment team; and 3) contingency management incentives upon receipt of medication treatment.
89239011|NCT00881933|Experimental|Fludarabine|
89239012|NCT03940547|Experimental|Experimental - provision of flour|This arm will receive infant and young child feeding education performed by community health workers and very-low aflatoxin (AF) pre-blended porridge flour, ratio 4:1 maize to groundnut. Provision of this pre-blended flour will be 50 grams/day for 6-8 month olds, 60/day grams for 9-11 months and 75 grams/day for 12-18 month olds (with 10-15 grams added per day to account for any loss). Participants will also receive 1 kg of low-AF groundnut flour each month for 6-18 month olds. Finally, participants will receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
89239013|NCT03940547|Active Comparator|Control - promotion of flour|This arm will receive infant and young child feeding education performed by community health workers and promotion of porridge made from maize and groundnut to match what is provided to the intervention arm. Participants will also receive a thermos flask to hygienically store porridge and a plastic scoop to measure appropriate amount of porridge flour each day.
89239014|NCT04459637||Asymptomatic group|Definition of asymptomatic disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
89239015|NCT04459637||Mild group|Definition of mild disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
89239016|NCT04459637||general-type group|Definition of general-type disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
89239017|NCT04459637||severe group|Definition of severe disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
89239018|NCT04459637||critical group|Definition of critical disease:refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 7)
89239019|NCT00882011||Arm 1|Adult patients with T-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or intensive chemotherapy followed by transplant.
89239020|NCT00884195|Experimental|1|Gratitude Journaling
89239021|NCT00884195|Placebo Comparator|2|Neutral Journaling
89239022|NCT00886223|Experimental|1|
89239023|NCT00882089|Experimental|1|A Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial irradiation begins.
89239024|NCT02543645|Experimental|Varlilumab and Atezolizumab|
89239025|NCT02543411|Experimental|Lidocaine group|Administration of lidocaine 1%
89239026|NCT02543411|Placebo Comparator|Control group|Administration of normal saline
89239027|NCT02543489|Other|Flex IM Rod|
89239028|NCT00882167||1|Patients with laparotomy in history
89239029|NCT00882245|Placebo Comparator|Vehicle ointment|
89239030|NCT00882245|Experimental|SRD441 Ointment|
89239031|NCT02541929|Experimental|DHA|DHA (2grams/day) for 26 weeks
89239032|NCT02541929|Placebo Comparator|placebo|placebo (4 capsules per day) for 26 weeks
89239033|NCT00882323|Experimental|Fludarabine|
89239034|NCT00884429|Active Comparator|1- Conventional Chest Physiotherapy|Percussion , thorax compression and Postural Drainage/suction if necessary
89239035|NCT00884429|Active Comparator|2- Chest physiotherapy- Actual techniques|slow prolonged expiration and clearance rhinopharynx and suction if necessary
89239036|NCT00884429|Active Comparator|3- Airway Suction|Suction superior airways. Only in admission.
89239037|NCT02543333||Asthma|Patients attending outpatient clinic as part of their clinical care who have FEV1 less than 80% of predicted and are referred by their clinician for a bronchodilator test
89239038|NCT02543333||Acute Asthma|Inpatients admitted for an acute asthma exacerbation
89239039|NCT02543333||Normal|Participants with no current or previous diagnosis of a respiratory condition
89239040|NCT00882401|Active Comparator|Ergocalciferol (oral)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
89239041|NCT00882401|Placebo Comparator|Placebo|Matching placebo at same dose schedule as ergocalciferol
89239042|NCT00886457|Experimental|Decitabine plus PEG Interferon-alfa 2B|3.7 mg/m**2 decitabine plus 0, 0.5, 1.5, 3, or 6 mcg/kg PET-Intron
89239043|NCT04038671|Experimental|Activated Carbon Dressing|A low-adherent, comprised of 100% pure activated carbon and also conforms to body contours to maintain contact with the incision surface. The dressing may be used either dry or moistened with sterilized water over dry or discharging, partial and full thickness wounds.
89239044|NCT04038671|Active Comparator|Knitted Cellulose Acetate Mesh|a non-adhering dressing, comprised of a knitted cellulose acetate mesh impregnated with a specially-formulated petrolatum emulsion.
89239045|NCT04038671|Active Comparator|Antimicrobial Alginate Dressing with Silver|a non-adherent antimicrobial alginate dressing with silver
89239046|NCT02543177|Experimental|group A|direct coronary angiography
89239047|NCT02543177|Experimental|group B|direct coronary angiography plus ischemic precondition
89239048|NCT02543177|Experimental|group C|delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
89239049|NCT02543177|Experimental|group D|delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography
89239050|NCT02543099|Experimental|policosanol|Patients will receive policosanol 20mg daily until the end of the trial.
89239051|NCT02543099|Placebo Comparator|placebo|Patients will receive placebo 20mg daily until the end of the trial;
89239052|NCT00882635|Experimental|Enoxaparin|
89239053|NCT00882635|Active Comparator|Unfractionated heparin|
89239054|NCT02543021|Active Comparator|Conventional chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
89239055|NCT02543021|Experimental|Virtual chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy
89239056|NCT02541539|Active Comparator|Lactobacillus casei Zhang|Intervention consists of daily administration of 2g probiotic Lactobacillus casei Zhang, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 months.
89239057|NCT02541539|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 months.
89239058|NCT00886847|Experimental|EBUS FNA vs FNC|
89239059|NCT00888641|No Intervention|Normothermia|After arterial clamping, no ice slush will be used
89239060|NCT00888641|Experimental|Hypothermia|After arterial clamping, the kidney will be surrounded in ice slush for 10 minutes
89239061|NCT00609947|Experimental|Endeavor Zotarolimus-Eluting Coronary Stent|Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
89239062|NCT00609869|Experimental|Lenalidomide and Rituximab|"28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.~Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.~Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15."
89239063|NCT00529568|Experimental|eltrombopag|active treatment arm
89239064|NCT00529568|Placebo Comparator|placebo|placebo control arm
89239065|NCT00888719|Experimental|CWP-0403 50mg|
89239066|NCT00888719|Experimental|CWP-0403 100mg|
89239067|NCT00888719|Placebo Comparator|placebo|
89239068|NCT04037111|Experimental|drug treatment and active VNS|At the same time, actice VNS, escitalopram oxalate tablets were treated for 2 months.
89239069|NCT04037111|Sham Comparator|drug treatment and sham VNS|It received oxacillin oxalate tablets and sham VNS for 2 months.
89239070|NCT04037111|Other|drug treatment|The dose of escitalopram oxalate tablets was maintained at 10-20mg/ day without VNS stimulation.
89239071|NCT00886925|Active Comparator|Albumin|
89239072|NCT00886925|Placebo Comparator|Saline|
89239073|NCT02542709|Active Comparator|Active transcranial magnetic stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
89239074|NCT02542709|Sham Comparator|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
89239075|NCT00888797|Active Comparator|1|Perioperative Propranolol and Etodolac
89239076|NCT00888797|Placebo Comparator|2|Placebo
89239077|NCT00888875|Experimental|1|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
89239078|NCT00888875|Active Comparator|2|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
89239079|NCT00884663|Experimental|1 Candesartan|
89239080|NCT00884663|Active Comparator|2 propranolol|
89239081|NCT00884663|Placebo Comparator|3 Placebo|
89239082|NCT02542553|Experimental|Bilateral BAL|Bronchoscopies are performed in strict accordance with consensus guidelines. The left or right lung is examined with a flexible fiberoptic bronchoscope. If localized infiltrates are present on the chest radiograph, the tip of the scope is wedged into a subsegment of the area displaying the most marked opacity. In the presence of diffuse opacity or when no clear roentgenographic abnormalities are observed, the tip is positioned in the lingula or right middle lobe. Five 20-ml aliquots of sterile normal saline are then injected and reaspirated with a syringe. Bronchoscopy is then repeated in the same manner in the contralateral lung with a second, sterile bronchoscope of the same brand and model.
89239083|NCT00887003|Experimental|LV/LD 1|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
89239084|NCT00887003|Experimental|LV/HD 2|Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
89239085|NCT00887003|Experimental|HV/LD 3|High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
89239086|NCT00887003|Experimental|HV/HD 4|High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
89239087|NCT00887081|Experimental|Interferon and Ribavirin|Patients with hemoglobinopathy will receive Interferon and Ribavirin
89239088|NCT03998696|Active Comparator|Weekly Cisplatin|Inj. Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.
89239089|NCT03998696|Experimental|Three weekly Cisplatin|Inj. Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.
89239090|NCT00888953|Experimental|Intervention|Residents living in nursing homes allocated to intervention group. Assessment of risk factors. Implementation of a multifactorial tailored program to prevent falls.
89239091|NCT00888953|Other|Control|Residents living in nursing homes allocated to control group. Assessment of risk factors. Receive the usual attention.
89239092|NCT00889031||No Treatment|
89239093|NCT05710952|Other|Braces|Patients will receive an orthodontic treatment with fixed braces for 12 to 24 months
89239094|NCT04017923||20-29 age group|
89239095|NCT04017923||30-39 age group|
89239096|NCT04017923||40-64 age group|
89239097|NCT04017923||65 and older age group|
89239098|NCT02542787|Experimental|Active|VSN16R (Canbex name for molecule) oral capsules, 50mg-400mg daily or twice daily, total exposure 26 days
89239099|NCT02542787|Placebo Comparator|Placebo|Placebo capsules, 50mg-400mg daily or twice daily, total exposure 26 days
89239100|NCT04847882||Cystic fibrosis, children from 6 to 17.|This group is made up of children with cystic fibrosis followed at the Strasbourg pediatrics CRCM, aged from 6 to 17 years old, not hospitalized at the time of inclusion, without any other criterion prejudging the seriousness of the pathology.
89239101|NCT04847882||Control group, children from 6 to 17.|"This group is the control group. It is made up of children consulting in pediatric surgical emergencies, aged 6 to 17 years. Surgical emergencies were chosen because it is a point of consultation, rather accidental, where sleep has often not been impacted in the previous months and where the frequency of chronic pathology is not higher than the general population.~An other criteria is that these children are accompanied by at least one of their parents and that they can read and understand French well."
89239102|NCT03999086||Control Group|Traditional evaluation/standard-of-care evaluation of patients undergoing multi-level spinal fusion surgery. These patients will receive point-of-care laboratory testing.
89239103|NCT03999086||Intervention arm|Utilization of TEG for decision-making regarding intra-operative transfusion in major spinal reconstruction surgery.
89239104|NCT00611975|Experimental|A|Participants will receive treatment with fluoxetine for 2 months
89239105|NCT00611975|Experimental|B|Participants will receive treatment with bupropion for 2 months
89239106|NCT00889109||1|Open Capsular Shift
89239107|NCT00889109||2|Arthroscopic Bankart Repair
89239108|NCT00889109||3|Healthy controls
89239109|NCT04895306|Experimental|Testosterone|Weekly intramuscular administration at a dose of 3 mg
89239110|NCT04895306|Placebo Comparator|Placebo|Weekly intramuscular administration of placebo
89239111|NCT02542241|Experimental|Sodium Chloride [3%]|
89239112|NCT02542241|Active Comparator|Sodium Chloride [0.9%]|
89239113|NCT04037891|Experimental|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in an open-label manner at intervals of 1 week and will have weekly clinic visits until Day 14, after which the visit will be every two weeks. When the first 3 patients have completed two weeks of treatment and the safety and tolerability data has been reviewed by the PI and an independent clinician, provided the data is favourable the randomisation process will begin (Part 2). The first 3 patients will continue treatment for a total of 8 weeks and will be assessed throughout the trial by the Principal Investigator according to the Schedule of Events Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
89239114|NCT04037891|Placebo Comparator|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
89239115|NCT00887237|Experimental|TRIV|Cardiac resynchronization with triple site ventricular stimulation (2 RV leads and 1 LV lead)
89239116|NCT00887237|Active Comparator|BIV|Conventional cardiac resynchronization
89239117|NCT05007158||pocket infection|Patients with isolated pocket infection were diagnosed in the presence of local signs of inflammation (one or more of erythema, pain, warmth, swelling, induration, tenderness, or fluctuation), wound dehiscence, hardware protrusion or pus discharge at the pocket in the absence of systemic findings.
89239118|NCT05007158||CIED systemic infection|Patient s with a CIED systemic infection, diagnosed as the presence of pocket infection accompanied by bacteraemia or echocardiographic finding suggestive of infective endocarditis, but not fulfilling the Duke criteria.
89239119|NCT05007158||Lead-associated infective endocarditis|Patients with infective endocarditis, diagnosed according to modified Duke criteria
89239120|NCT05007158||control group|CIED Patients presenting for elective device exchange or planned lead revision between without local or systemic infections were selected as controls
89239121|NCT02541695|Active Comparator|1E10 CFU Escherichia coli (E. coli)|"1E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
89239122|NCT02541695|Experimental|5E10 CFU Escherichia coli (E. coli)|"5E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 5E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
89239123|NCT00889343|Experimental|1|
89239124|NCT00889343|Placebo Comparator|2|
89239125|NCT00884819|Experimental|1|fenofibrate 200mg/daily for 6 months
89239126|NCT00884819|Placebo Comparator|2|Placebo match for 6 months
89239127|NCT05229302|Experimental|Intervention|Secondary students with suicidal ideation participating in the intervention (Reframe-IT). The students will be referred to Primary care where they will be assessed by a physician who will determine if the adolescent could enter into the National Depression Treatment Program for people aged 15 and above, which is organized as a step care treatment
89239128|NCT05229302|Active Comparator|Control|Secondary students referred to Primary care where they will be assessed by a physician who will determine if the adolescent could enter into the National Depression Treatment Program for people aged 15 and above, which is organized as a step care treatment.
89239129|NCT04846946|No Intervention|Control|Time attention control condition.
89239130|NCT04846946|Experimental|Intervention, Module 1 - Knowledge|20-minute module that aims to improve HIV prevention knowledge.
89239131|NCT04846946|Experimental|Intervention, Module 1 - Stigma|20-minute module that aims to reduce SGM- and HIV- related stigma.
89239132|NCT04846946|Experimental|Intervention, Module 1 - Prevention|20-minute module that aims to promote HIV prevention strategies including testing and PrEP.
89239133|NCT00573131|Experimental|Group 1|OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
89239134|NCT00573131|Active Comparator|Group 2|Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
89239135|NCT01565018|Experimental|Treatment A - Treatment B|"Treatment A: Test; drug product PR 2.2.1~Treatment B: Reference; drug product PR 2.1.4~Sequence of two single applications of Rotigotine transdermal patches (PR 2.2.1 first) for 24 hours separated by a Washout Period of 5 days."
89239136|NCT01565018|Experimental|Treatment B - Treatment A|"Treatment B: Reference; drug product PR 2.1.4~Treatment A: Test; drug product PR 2.2.1~Sequence of two single applications of Rotigotine transdermal patches (PR 2.1.4 first) for 24 hours separated by a Washout Period of 5 days."
89239137|NCT01565096|Experimental|Vildagliptin plus Metformin|Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily
89239138|NCT01565096|Active Comparator|Glimepirid plus Metformin|Metformin (1000 mg BID) + Glimepiride (individual dosage)
89239139|NCT00887393|Other|Low carbohydrate|Low carbohydrate pre-bariatric surgery diet
89239140|NCT00887393|Other|Low fat|Low fat pre-bariatric surgery diet
89239141|NCT00889499|Placebo Comparator|Crossover study|Crossover study
89239142|NCT00889499|Placebo Comparator|2|Crossover Study
89239143|NCT00889499|Placebo Comparator|3|Crossover Study
89239144|NCT00889655|Active Comparator|Golytely|216 patients at random will provided a prescription for the standard 4 L golytely preparation as the bowel cleanser for their colonoscopy
89239145|NCT00889655|Experimental|MiraLax|216 patients will be randomized to take 238 gm of miralax mixed with 64 oz of gatorade for their bowel cleanser
89239146|NCT05002946|Experimental|A: SP-104 Fasting|Oral administration of SP-104 under fasting conditions
89239147|NCT05002946|Experimental|B: SP-104 Under Fed Conditions|Oral administration of SP-104 under fed conditions
89239148|NCT05002946|Active Comparator|Naltrexone Hydrochloride Tablets Fasting|Oral administration of Naltrexone Hydrochloride Tablets, 50 mg USP under fasting
89239149|NCT00521144|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive obatoclax mesylate IV over 3 hours on day 1 OR days 1 and 3 and topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
89239150|NCT00520676|Experimental|pemetrexed plus carboplatin|"Drug: pemetrexed 500 milligrams per square meter (mg/m^2), intravenous (IV), every (q) 21 days x 6 cycles maximum~Drug: carboplatin Area Under the Curve (AUC) 5 milligram*minute/milliLiter (mg*min/mL), IV, q 21 days x 6 cycles maximum"
89239151|NCT00520676|Active Comparator|docetaxel plus carboplatin|"Drug: docetaxel 75 mg/m^2, IV, q 21 days x 6 cycles maximum~Drug: carboplatin AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum"
89239152|NCT03998852|Experimental|Molecular imaging|Positron Emission Tomography (PET) molecular imaging of dopaminergic and cholinergic systems using two radiotracers
89239153|NCT04063748|Experimental|Experimental|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
89239154|NCT04063748|Other|Placebo|CI-users: Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, and the fifth session is an in-training test session (DTT and phoneme discrimination).
89239155|NCT04063748|Placebo Comparator|Passive Control|HA users: Participants do not receive an intervention.
89239156|NCT00610649|Experimental|Part 1: Block A MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 16 days.
89239157|NCT00610649|Placebo Comparator|Part 1: Block A Placebo|Participants receive placebo BID for a total of 16 days.
89239158|NCT00610649|Experimental|Part 1: Block B MK-8777|Participants receive MK-8777 initiated at 200 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 13 days.
89239159|NCT00610649|Placebo Comparator|Part 1: Block B Placebo|Participants receive placebo BID for a total of 13 days.
89239160|NCT00610649|Experimental|Part 1: Block C MK-8777|Participants receive MK-8777 initiated at 300 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 10 days.
89239161|NCT00610649|Placebo Comparator|Part 1: Block C Placebo|Participants receive placebo BID for a total of 10 days.
89239162|NCT00610649|Experimental|Part 1: Block D MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum dose determined by the results of Block A. Participants receive MK-8777 for a total of 13 days.
89239163|NCT00610649|Placebo Comparator|Part 1: Block D Placebo|Participants receive placebo BID for a total of 13 days.
89239164|NCT00610649|Experimental|Part 2: MK-8777 200 mg|Participants receive MK-8777 100 mg BID for 27 days followed by one day of 100 mg QD. Participants receive MK-8777 for a total of 28 days.
89239165|NCT00610649|Experimental|Part 2: MK-8777 800 mg|Participants receive MK-8777 200 mg BID for 3 days followed by 400 mg BID for 24 days followed by one day of 400 mg QD. Participants receive MK-8777 for a total of 28 days.
89239166|NCT00610649|Placebo Comparator|Part 2: Placebo|Participants receive placebo BID for 27 days followed by one day of placebo QD. Participants receive placebo for 28 days.
89239167|NCT02542085|Active Comparator|laparoscopic repair|patients who are randomized to have a laparoscopic mesh repair
89239168|NCT02542085|Active Comparator|hybrid repair|patients who are randomized to have a laparoscopic mesh repair and fascial closure
89239169|NCT00885053|Experimental|Fish oil|
89239170|NCT00885053|Placebo Comparator|Olive oil|
89239171|NCT00887627|Experimental|1. Mild Renal Function Impaired Subjects|
89239172|NCT00887627|Experimental|2. Moderate Renal Function Impaired Subjects|
89239173|NCT00887627|Experimental|3. Subjects with Normal Renal Function|
89239174|NCT04037579||Down Syndrome Cordoba Association|The participant will answer a questionnaire related to social skills and physical activity
89239175|NCT04037579||Down Syndrome Granada Association|The participant will answer a questionnaire related to social skills and physical activity
89239176|NCT04037579||Down Syndrome Malaga Association|The participant will answer a questionnaire related to social skills and physical activity
89239177|NCT04037579||Observers in Cordoba|Observers from Cordoba, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
89239178|NCT04037579||Observers in Granada|Observers from Granada, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
89239179|NCT04037579||Observers in Malaga|Observers from Malaga, Spain who know Down Syndrome people well (at least for six months) will answer a questionnaire related to their social skills and physical activity
89239180|NCT00887705|No Intervention|1: Standard rehabilitation programme|
89239181|NCT00887705|Experimental|2. Additional ADL training|
89239182|NCT00885209||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
89239183|NCT00890123|Active Comparator|Omegaven|Patients in this arm will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively.
89239184|NCT00890123|No Intervention|Without Omegaven|Patients will not receive IV Omega 3 fatty acids
89239185|NCT00885287|Active Comparator|HIV-positives on ARVs receiving AL for malaria|HIV-positive patients on first-line ARVs receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
89239186|NCT00885287|Active Comparator|HIV-positives receiving AL for malaria|HIV-positive patients not receiving antiretrovirals but receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
89239187|NCT00885287|Active Comparator|HIV-negatives receiving AL for malaria|HIV-negative patients receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
89239188|NCT00923429|Active Comparator|S-A|
89239189|NCT00923429|Active Comparator|S-A+stretch|
89239190|NCT00923429|Experimental|S-A+stretch+manther|
89239191|NCT00923429|Experimental|S-A+stretch+manther+sterinject|
89239192|NCT02542007|Experimental|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
89239193|NCT02542007|Active Comparator|Nano Polymer-free sirolimus-eluting stent system|The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
89239194|NCT00887861|Experimental|BGG492|
89239195|NCT00887861|Placebo Comparator|Placebo|
89239196|NCT04037267|Experimental|Endoscopic Treatment|Endoscopy was performed using a rigid endoscope. The hematoma was removed by a technique using irrigation and aspiration. The ventricular drainage catheter was placed on the surgical side. Six hours after surgery, we administered 20,000 U urokinase with 5 ml saline every 8 hours through the catheter and the catheter was closed for 1 hour to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
89239197|NCT04037267|Active Comparator|EVD Treatment|The surgeons used a soft catheter to puncture in depth of about 5 cm. The next step was to fix the drainage catheter. Postoperative CT was done immediately to confirm positioning of the soft catheter and stability of the hematoma. Six hours or more after catheter placement, we administered 20,000 U urokinase with 5 ml saline every 8 hours and the catheter was closed for 1 h to allow drug-clot interaction and then reopened to allow for gravitational drainage. Subsequent CT scans were done for any safety concern or every 24 hours. Administration of urokinase was stopped when the CT scans showed that the circulation of cerebrospinal fluid is unobstructed. When CT scans showed that the intracerebral hematoma was significantly reduced and the circulation of cerebrospinal fluid is unobstructed, the catheter could be clamped for 24 h. If there was no acute intracranial pressure increase, the catheter could then be removed.
89239198|NCT02541617|Active Comparator|Movement Disorder Center|Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
89239199|NCT02541617|Experimental|Programming by community Neurologist|Device programming, Deep Brain Stimulator will be programmed by community Neurologist
89239200|NCT00890279|Experimental|Cilnidipine|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.
89239201|NCT00890279|Active Comparator|Imidapril|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
89239202|NCT00888017||PPI group|This group of infants have received treatment with a PPI as ordered by their neonatologist during their hospital stay.
89239203|NCT00888017||non-PPI group|These infants did not receive PPIs during their hospital stay.
89239204|NCT00892619|Experimental|ILM forceps|Using ILM forceps to initiate and complete peel
89239205|NCT00892619|Active Comparator|Other|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
89239206|NCT00890357||Triptan User|
89239207|NCT00890357||Triptan Discontinued|
89239208|NCT00608543|Other|Aripiprazole augmentation|This is a single arm trial in which all participants recieved open label aripiprazole augmentation of their current escitalopram, citalopram or sertraline treatment.
89239209|NCT02541383|Other|Arm A Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
89239210|NCT02541383|Experimental|Arm B Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
89239211|NCT02541383|No Intervention|Arm A Part 2|Observation
89239212|NCT02541383|Experimental|Arm B Part 2|daratumumab
89239213|NCT04036643|Experimental|patient with rectal cancer|Patient with rectal cancer treated by neoadjuvant chemo-radiation therapy with clinical complete response
89239214|NCT04036487|Experimental|IH group|Inhalation anesthesia will be given during transaxillary endoscopic breast augmentation.
89239215|NCT04036487|Active Comparator|TIVA group|Total intravenous anesthesia will be given during transaxillary endoscopic breast augmentation.
89239216|NCT04036565||The experimental group|The first post-test measurements were taken right after the participants completed the sunlight therapy (two to four weeks after the start of the intervention), and the second post-test measurements were taken one month after the intervention was completed (six to eight weeks after the start of the intervention).
89239217|NCT04036565||The control group|Standard care.The first and second post-test measurements were taken two and six weeks, respectively, after they started receiving standard care.
89239218|NCT02541149||Group 1:|Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
89239219|NCT02541149||Group 2|Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
89239220|NCT02541149||Group 3|Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
89239221|NCT05278793|Experimental|Intermittent|This group will receive ferrous fumarate 200mg intermittent three times a week on alternate days.
89239222|NCT05278793|Active Comparator|Daily|This group will receive ferrous fumarate 200mg once daily.
89239223|NCT00892853|Other|Bone Density Scanning|To acquire high resolution images of the bones and aid in determining bone density.
89239224|NCT00890669|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
89239225|NCT05278325|Experimental|Telephone Intervention|Two planned phone call by health care professionals after 8 and 16 weeks adjusting acute and preventive treatment
89239226|NCT05278325|No Intervention|Business as usual|No planned phone calls
89239227|NCT04037657|Experimental|HSK3486|0.288 mg/kg ，0.432 mg/kg ，0.540 mg/kg ，0.648 mg/kg，0.810 mg/kg There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
89239228|NCT04037657|Active Comparator|Propofol|2.5 mg propofol
89239229|NCT04037345|Experimental|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
89239230|NCT04037345|Experimental|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
89239231|NCT04037345|Experimental|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)
89239232|NCT00893009|Placebo Comparator|Placebo|
89239233|NCT00893009|Active Comparator|Theophylline|100 twice a day
89239234|NCT00888095|Experimental|1|caudal Zona incerta (cZI)
89239235|NCT00888095|Experimental|2|Nucleus subthalamicus (STN)
89239236|NCT00890747|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89239237|NCT00890903||NSCLC|Patients with advanced non-small cell lung cancer
89239238|NCT00890903||MBC|Female patients with metastatic, Anthracycline-resistent breast cancer
89239239|NCT00891059||Placebo Diskus Inhaler|
89239240|NCT00888251||Comprehensive weight management program|
89239241|NCT00893087|Active Comparator|1|Flow triggering
89239242|NCT00893087|Active Comparator|2|Pressure triggering
89239243|NCT00893087|Active Comparator|3|NAVA triggering
89239244|NCT04017845|Active Comparator|Household-Open Invitation (HOI)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
89239245|NCT04017845|Active Comparator|Recommendation By Physician (RBP)|Precolonoscopy cleansing regimen and referral to conventional colonoscopy is based on Positive FIT (level ≥75ng/ml) in any of the two collected samples. Histopathological examinations of screen-detected lesions are reported and lesion with the worst prognosis is indicated as the final colonoscopic outcome used for evaluation purposes. Screenees with intermediate and high risk polyp were referred to a follow-up surveillance programme.Treatments were initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment for anal fissure, and tribenoside 400 mg + lidocaine 40 mg suppositories for hemorrhoids. Positive FIT results in participants who were identified with no adenomas, advance adenomas, or adenocarcinomas are considered False-positive FIT (FP-FIT) results.
89239246|NCT00893165||hemodialysis patients|chronic hemodialysis patients with elevated inflammation markers
89239247|NCT02541773||Chronic Heart Failure Patients|Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder
89239248|NCT00891137|Experimental|Group A|Low dose, single donor CLT-008 (human myeloid progenitor cells)
89239249|NCT00891137|Experimental|Group B|Low dose, multiple donor CLT-008 (human myeloid progenitor cells)
89239250|NCT00891137|Experimental|Group C|Intermediate dose, multiple donor CLT-008 (human myeloid progenitor cells)
89239251|NCT00891137|Experimental|Group D|High dose, multiple donor CLT-008 (human myeloid progenitor cells)
89239252|NCT00520130|Experimental|A - Tacrolimus, methotrexate, sirolimus (TMS) Arm|TMS Arm
89239253|NCT00520130|Experimental|B - Cyclosporine (AC) Arm|AC Arm
89239254|NCT00519896|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis therapy)|Patients receive sunitinib malate PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
89239255|NCT03998384|Active Comparator|group of autoserum|One of two eyes of one patient which is assessed to have more serious retinal atrophy will receive the retrobulbar injection of autoserum.
89239256|NCT03998384|Placebo Comparator|group of placebo|The other eye which is assessed to have milder retinal atrophy will receive the retrobulbar injection of saline solution.
89239257|NCT03941600|Active Comparator|Community-based Exercise Intervention group (CBEI)|A group performing a 12-week guided exercise program at an accessible community health and wellness center
89239258|NCT03941600|Placebo Comparator|Exercise Education Control group (EEG)|A group receiving educational information about physical activity and exercise at home and then self-direction a 12-week exercise program on their own.
89239259|NCT00527618|Active Comparator|Standard-dose acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
89239260|NCT00527618|Experimental|High-dose valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
89239261|NCT04622072|Experimental|Experimental group|For dose escalation phase, subjects are enrolled for different doses of the experimental drug.
89239262|NCT00527072|Experimental|001|infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
89239263|NCT00526994|Experimental|Screened|Screened w/4 questions on intimate partner violence; if positive, receives referral information
89239264|NCT00526994|Active Comparator|Universal education|all participants receive partner violence referral information
89239265|NCT00526994|No Intervention|Control|no screen and no referral
89239266|NCT04743128|No Intervention|Control group|The control group received written recommendations to exercise three times per week, for a period of 12 weeks but they did not attend the training sessions.
89239267|NCT04743128|Experimental|Exercise group|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
89239268|NCT00519428|Experimental|escitalopram + bupropion|escitalopram plus bupropion extra long (XL) as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)
89239269|NCT00519428|Active Comparator|escitalopram|escitalopram monotherapy
89239270|NCT00519428|Active Comparator|bupropion|bupropion extra long (XL) monotherapy
89239271|NCT00432159|Experimental|1-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level of the cervical spine, C3 to C7 inclusive.
89239272|NCT00432159|Active Comparator|1-level ACDF with plate|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at a single level of the cervical spine, C3 to C7 inclusive.
89239273|NCT00432159|Experimental|2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at two adjacent levels of the cervical spine, C3 to C7 inclusive.
89239274|NCT00432159|Active Comparator|2-level ACDF|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at two adjacent levels of the cervical spine, C3 to C7 inclusive.
89239275|NCT00432159|Experimental|Training: 1 & 2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level or multiple levels of the cervical spine, C3 to C7 inclusive. Training cohort.
89239276|NCT00519194|Experimental|Epicor Cardiac Ablation|
89239277|NCT02363660|Experimental|Arm I|will receive standard dose (0.5mL) delivered by standard intramuscular injection using a needle and syringe.
89239278|NCT02363660|Experimental|Arm II|will receive standard dose (0.5mL) delivered by intramuscular injection using the Pharmajet needle-free Stratis device.
89239279|NCT02363660|Experimental|Arm III|will receive a reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device
89239280|NCT00431847||Group 1|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war aggressively treated with regional anesthesia for pain control.
89239281|NCT00431847||Group 2|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war receiving standard treatment for pain control.
89239282|NCT00431067|Experimental|BIBW 2992|BIBW 2992 (Afatinib) once daily until progression
89239283|NCT01030107||Children with Insufficient Sleep|Children who sleep approximately 9-10 hours/night
89239284|NCT01030185|Experimental|NovaShunt's Automated Fluid Shunt|The Automated Fluid Shunt (AFS) Device
89239285|NCT01035489|Active Comparator|CRT; RV apical lead placement|Right ventricular apical lead placement in CRT
89239286|NCT01035489|Active Comparator|CRT; RV high posterior septum|High posterior septal lead placement in CRT
89239287|NCT01030263|Experimental|CEM|Biopsies obtained with fluorescence-aided confocal endomicroscopy.
89239288|NCT01030263|Other|RFQ|Random four-quadrant biopsies.
89239289|NCT01035567|Active Comparator|Hybrid revascularization|
89239290|NCT01035567|Active Comparator|Coronary Artery Bypass Grafting|
89239291|NCT00430989|Other|70% Nitrous Oxide|General anaesthesia using 70% Nitrous Oxide with fraction of inspired oxygen at 30%
89239292|NCT00430989|Other|No Nitrous Oxide|General anaesthesia not containing Nitrous oxide with fraction of inspired oxygen at 30%
89239293|NCT01035645|Experimental|GSK1070806 or placebo|This is a single dose escalating study. On enrolment into the study, each subject will be assigned to a group. These groups will be aligned to specific dose levels of GSK1070806. All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline). The randomisation is generated by GSK prior to study start.
89239294|NCT00430755|Other|Inpatients of hospital|"All patients who were admitted to the departments of nephrology or cardiology in a tertiary hospital in Germany.~The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
89239295|NCT00518882|Experimental|Liraglutide|Liraglutide 1.8 mg once daily + subject's own OAD treatment
89239296|NCT00518882|Active Comparator|Exenatide|Exenatide 10 mcg twice daily + subject's own OAD treatment
89239297|NCT00518336|Experimental|Cervarix Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
89239298|NCT00518336|Placebo Comparator|Placebo Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
89239299|NCT00518180|Experimental|MenACWY + Tdap + HPV|Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
89239300|NCT00518180|Experimental|MenACWY →Tdap → HPV|Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
89239301|NCT00518180|Experimental|Tdap →MenACWY → HPV|Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8
89239302|NCT00525902|Experimental|Adalimumab|
89239303|NCT02260778|Experimental|Phase I Intervention|The learning collaborative as designed will be delivered to this arm during phase I, which will last a period of approximately 9 months. After the 9 months, there will be passive follow-up of this arm to see if outcomes following the first 9 months are sustained.
89239304|NCT02260778|No Intervention|Phase II Intervention|This arm will serve as a control for the Phase I intervention arm during the first 9 months of the study for primary analysis. After the first 9 months, the Phase II intervention arm will receive the learning collaborative during the following 9 months.
89239305|NCT00525590|Experimental|1|
89239306|NCT00430677|Experimental|Abatacept 30 mg/kg+Corticosteroids+MMF|Short-term Period
89239307|NCT00430677|Experimental|Abatacept 10 mg/kg+Corticosteroids+MMF|Short-term Period
89239308|NCT00430677|Experimental|Placebo+Corticosteroids+MMF|Short-term Period
89239309|NCT00430677|Experimental|Abatacept 10mg/kg|Long-term Extension Period
89239310|NCT02631759|Experimental|Lévétiracetam|52 patients will be recruited over 2 years in the experimental group
89239311|NCT02631759|Placebo Comparator|Placebo|52 patients will be recruited over 2 years in the control group
89239312|NCT01035801|Experimental|IN105|Prandial Oral Insulin
89239313|NCT01035801|Active Comparator|Insulin Lispro Injection|
89239314|NCT00525512|Experimental|tiotropium 18mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
89239315|NCT00525512|Placebo Comparator|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
89239316|NCT03998306|Experimental|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive probiotic lozenge before falling asleep for12 weeks. They will receive hygienic and dietetic instructions. examination will be conducted before study and after 12 weeks.
89239317|NCT03998306|Sham Comparator|CONTROL|no intervention
89239320|NCT00517634|Experimental|Sequence 1: FP, SFC, Placebo|Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
89239321|NCT00517634|Experimental|Sequence 2: Placebo, SFC, FP|Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
89239322|NCT00517634|Experimental|Sequence 3: SFC, FP, Placebo|Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
89239323|NCT00517634|Experimental|Sequence 4: SFC, Placebo, FP|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
89239324|NCT00517634|Experimental|Sequence 5: FP, Placebo, SFC|Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
89239325|NCT00517634|Experimental|Sequence 6: Placebo, FP, SFC|Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
89239326|NCT01565174||High activity COMT|Carriers of high activity COMT158Val allele who are expected to show higher THC-induced meso-limbic DA release
89239327|NCT01565174||Low activity COMT|Carriers of low activity COMT 158Met homozygotes are expected to release low amount of dopamine after smoking a cigarette with THC
89239328|NCT02167490|Active Comparator|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
89239329|NCT02167490|No Intervention|Arm 2: observation|No axillary staging
89239330|NCT03683576|Placebo Comparator|Placebo|Placebo once per day (QD) for 24 weeks
89239331|NCT03683576|Experimental|GB001 20 mg|GB001 20 mg QD for 24 weeks
89239332|NCT03683576|Experimental|GB001 40 mg|GB001 40 mg QD for 24 weeks
89239333|NCT03683576|Experimental|GB001 60 mg|GB001 60 mg QD for 24 weeks
89239334|NCT03863834|Experimental|Treatment arm|Subjects receive the RFAL treatment
89239335|NCT03998150|Active Comparator|HoLEP holmium laser enucleation of the prostate|holmium laser enucleation of the prostate
89239336|NCT03998150|Active Comparator|BPEP bipolar plasmakinetic enucleation of the prostate|bipolar plasmakinetic enucleation of the prostate
89239337|NCT03656666|Active Comparator|Apremilast|"Week 0-24: 21 patients will receive apremilast oral tablets with initial standard titration of dose day 1-6 followed by standard dose of 30 mg apremilast b.i.d.~Initial titration:~Day 1: 10 mg in morning. Day 2: 10 mg in morning and 10 mg in evening. Day 3: 10 mg in morning and 20 mg in evening. Day 4: 20 mg in morning and 20 mg in evening. Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter: 30 mg twice daily."
89239338|NCT03656666|Placebo Comparator|Placebo + Apremilast|Week 0-24: 21 patients will receive matching placebo oral tablets, with initial titration.
89239339|NCT00430521|Experimental|GSK1562902A V/I/6 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
89239340|NCT00430521|Experimental|GSK1562902A V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
89239341|NCT00430521|Experimental|GSK1562902A 2V/I/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.
89239342|NCT00430521|Experimental|GSK1562902A 2V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
89239343|NCT00430521|Experimental|GSK1562902A V/I/12 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
89239344|NCT00430521|Experimental|GSK1562902A V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
89239345|NCT00430521|Experimental|GSK1562902A 2V/I/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
89239346|NCT00430521|Experimental|GSK1562902A 2V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
89239347|NCT02616627||chronic dialysis|Patient enrolled at the National Taiwan University Hospital Jinshan branch
89239348|NCT01036035|Active Comparator|Treatment B|Study drug
89239349|NCT01036035|Active Comparator|Treatment D|Study drug
89239350|NCT01036035|Placebo Comparator|Treatment E|Placebo
89239351|NCT01036035|Active Comparator|Treatment A|Study Drug
89239352|NCT01036035|Active Comparator|Treatment C|Study Drug
89239353|NCT01323699|Experimental|Behavioral Therapy|
89239354|NCT01036659|Active Comparator|Ecallantide in conjunction with Conventional Therapy|
89239355|NCT01036659|Placebo Comparator|Conventional therapy and placebo|
89239356|NCT01036659|No Intervention|Historical Evaluation|
89239357|NCT01033149|Other|N-acetylcysteine|open label N-acetylcysteine, flexible dose
89239358|NCT00429663|Other|IM Nails|Reamed, Interlocking Intramedullary Nail - Randomized treatment
89239359|NCT00429663|Other|Plate Fixation|Locking Periarticular Plate - Randomized Treatment
89239360|NCT00429585|Other|Randomized Treatment - Nail|Randomized Treatment - Nail
89239361|NCT00429585|Other|Randomized Treatment - Plate|Randomized Treatment - Plate
89239362|NCT06051344|Experimental|A, case group|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
89239363|NCT06051344|Experimental|B, control group|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
89239364|NCT06051292|Experimental|Fast decremental|fast decremental catheter volume titration will be applied
89239365|NCT06051292|Active Comparator|Conventional|conventional catheter volume titration will be applied
89239366|NCT06051266|Experimental|Dynamic navigation|
89239367|NCT06051266|Active Comparator|Static template|
89239368|NCT06051240|Experimental|Lithium|Lithionit 42 mg (lithium sulphate, 6 mmol), start dose 1x1, then slow dose escalation using therapeutic drug monitoring (TDI) to establish a target serum level of 0.5-1.0 mmol/liter.
89239369|NCT06051240|Placebo Comparator|Placebo|Identical looking placebo (white round tablet, 10 mm diameter) will be dose escalated and monitored the same way as lithium, with sham values guiding the dosing.
89239370|NCT06051201|Experimental|Shared-Decision-Making group|
89239371|NCT06051201|Experimental|Physician decision group|
89239372|NCT06051175|Experimental|Sensory attributes perception - bitter taste|"During the experiment individuals will be exposed to caffeine solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
89239373|NCT06051175|Experimental|Sensory attributes perception - salty taste|"Individuals will be exposed to sodium chloride solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
89239374|NCT06051175|Experimental|Sensory attributes perception - sweet taste|"Individuals will be exposed to sucrose solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
89239375|NCT06051175|Experimental|Sensory attributes perception - acid taste|"Individuals will be exposed to citric acid solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
89239376|NCT06051175|Experimental|Sensory attributes perception - umami taste|"Individuals will be exposed to sodium glutamate monohydrate solution, identifying the sensory attributes and basic flavours. Between the tastings of the different foodstuffs, neutralisation phases will occur, where participants will receive a neutral food stimulus. The judgement will be self-reported by the participants after contact with the food.~While the study is taking place, physiological and neurophysiological data will be collected from participants: brain activity (EEG); cardiac activity (ECG); electrodermal activity (galvanic skin response); and facial mimicry via video analysis and eye tracking. These data will be analysed using physiological data analysis software. All participant data will be recorded using coding, ensuring anonymity and confidentiality."
89239377|NCT06051136|Experimental|Early pulmonary rehabilitation (RP)|RP immediately after enrollment.
89239378|NCT06051136|Experimental|Delayed pulmonary rehabilitation (RP)|RP after 3 months after enrollment.
89239379|NCT06051097||OSA with metabolic syndrome|sleep study
89239380|NCT06051097||OSA without metabolic syndrome|sleep study
89239381|NCT06051084|Experimental|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
89239382|NCT06051084|Active Comparator|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
89239383|NCT06051071|Experimental|Treatment|tDCS stimulation arm
89239384|NCT06051032|Experimental|Balloon thrombectomy|Patients diagnosed with arteriovenous fistula (AVF) thrombosis and deemed eligible for endovascular treatment will undergo balloon thrombectomy.
89239385|NCT06051032|Experimental|Thromboaspiration system|Patients diagnosed with arteriovenous fistula (AVF) thrombosis and deemed eligible for endovascular treatment will undergo the thromboaspiration system.
89239386|NCT06051019|Experimental|Aerobic training (FIRST), then balance training (SECOND)|Crossover trial: aerobic training (first treatment), then balance training (second treatment).
89239387|NCT06051019|Experimental|Balance training (FIRST), then aerobic training (SECOND)|Crossover trial: balance training (first treatment), then aerobic training (second treatment).
89239388|NCT06050993||Cirrhotic patients|Patients known to have a cirrhosis, with an invasive procedure scheduled at the Paul Brousse hospital
89239389|NCT06050993||Non-cirrhotic patients|Patients without cirrhosis, with an invasive procedure scheduled at the Paul Brousse hospital
89239390|NCT06050980|Experimental|Phase Ia(Part A): HSK40118 as monotherapy|Phase 1a(Part A): dose escalation of HSK40118 as monotherapy at various dose levels
89239391|NCT06050980|Experimental|Phase Ia(Part B): HSK40118 as monotherapy|Phase 1a(Part B): dose extention of HSK40118 as monotherapy at certain dose levels
89239392|NCT06050980|Experimental|Phase Ib: HSK40118 as monotherapy|Phase 1b: dose expansion for HSK40118 as monotherapy at a dose determined during Phase 1 in patients with previous treatment with 3rd-generation EGFR-TKI
89239393|NCT06050967|Experimental|individualized treatment plan with random dosage and time of administration|Baseline clinical and laboratory parameters acquired at the screening included: a physical examination, complete blood count (CBC), Lyso-GB1 , and a 36-item short-form survey (SF-36) for quality-of-life examination. Once providing informed consent, the Altus Care™ application was installed on the patient's cellular phone. In coordination with the patient's treating physician and the home treating nurse5 , an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks ERT dosages and timing frames for its administration. Per protocol, the patient's monthly dose wasn't changed, but each dose and the timing of administration was changed randomly using the app.
89239394|NCT06050902|No Intervention|Standard ultrasound guidance for subclavian venipuncture|62 patients undergoing the usual standard ultrasound guidance technique for subclavian venipuncture
89239395|NCT06050902|Experimental|Subclavian venipuncture using the needle-steering device|62 patients undergoing subclavian venipuncture using the needle-steering device
89239396|NCT06050863|Experimental|Group I - Silk Fibroin|test group 1 is treated with silk fibroin
89239397|NCT06050863|Active Comparator|Group II -Chlorhexidine|test group 2 is treated with chlorhexidine
89239398|NCT06050863|Experimental|Group III - Combination of Fibroin and Chlorhexidine|test group 3 is treated with combination of silk fibroin and chlorhexidine
89239399|NCT06050772|Experimental|STUDY GROUP|Groups who will receive virtual reality reminiscence versus traditional reminiscence therapy to determine its effect on cognitive function and psychological wellbeing.
89239400|NCT06050772|No Intervention|Control group|Groups who will not receive any intervention
89239401|NCT06050720|Other|Sleep disorder patients|The study participants have been referred by a clinician to the sleep clinic for diagnosis of a sleep disorder, possibly sleep apnoea.
89239402|NCT06050655|Experimental|Adults with Angle Class I malocclusion|"Adults older than 18 years old~About to undergo orthodontic treatment"
89239403|NCT06050642|No Intervention|Control arm (Standard Care)|these patients will continue with their current home support provider's standard care
89239404|NCT06050642|Experimental|Interventional arm (Enhanced Care)|these patients will be prescribed the enhanced care model to replace the standard care provided by their current home support provider. Patients are informed that they can return to standard care at the end of the study period (1 year), or at any time if they wish to leave the study.
89239405|NCT06050629||forme fruste keratoconus|1) no other eye abnormalities except myopia and astigmatism; 2) transparent cornea; 3) no positive signs of keratoconus on slit lamp examination or morphology examination (excluding the appearance of keratoconus as described above, and simultaneously satisfying A0B0C0D0, Index of Surface variance (ISV) < 30, and Keratoconus Index (KI) < 1.07); and 4) Belin/Ambrósio enhanced ectasia total derivation value(BAD-D)≤1.6
89239406|NCT06050629||Clinical keratoconus|46.5 D ≤ Mean K <52 D; 55≤ ISV<200; and 1.10 ≤ KI <1.50
89239407|NCT06050629||severe keratoconus|Mean K ≥ 52D; ISV≥ 200; and KI≥ 1.50
89239408|NCT06050629||normal eye|one eye of healthy participants before refractive surgery were randomly selected. Comprehensive ophthalmic examinations were performed before surgery, which confirmed that the cornea was clear and normal in shape. For this group, there was no family history of keratoconus, no other diseases except ametropia, and no corneal dilatation one year after surgery.
89239409|NCT06050603|Experimental|Experimental_Aim1: Healthy Volunteers|All participants will receive all conditions and the order of all conditions will be counterbalanced across participants. Statistical comparisons will be within-subjects.
89239410|NCT06050590|Experimental|NeuroGlove Treatment Arm|Study participants undergoing treatment using the NeuroGlove.
89239411|NCT06050577|Experimental|oral Semaglutide/Rybelsus|oral Semaglutide 7-14 mg (or highest tolerated dose) once daily for 52 weeks (incl. titration)
89239412|NCT06050577|Placebo Comparator|oral Placebo|oral Placebo 7-14 mg (or highest tolerated dose) once daily for 52 weeks (incl. titration)
89239413|NCT06050551|Experimental|14-Fr pigtail catheter after uniportal VATS|smaller catheter used after uniportal VATS
89239414|NCT06050551|Other|20-Fr chest tube after uniportal VATS|routine management after uniportal VATS
89239415|NCT06050538|Active Comparator|Transabdominal preperitoneal (TAPP)|patients with recurrent inguinal hernia who had Transabdominal preperitoneal (TAPP) approach
89239416|NCT06050538|Active Comparator|Total extraperitoneal (TEP) approach|patients with recurrent inguinal hernia who had Total extraperitoneal (TEP) approach
89239417|NCT06050486|Experimental|Arm 1: Intervention|Participants in Arm 1 receive a psychological intervention (MBT-C).
89239418|NCT06180772|No Intervention|Control|Continue normal activities
89239419|NCT06180772|Experimental|3/wk|Use FIT FIRST 3 times pr. week
89239420|NCT06180772|Experimental|1.5/wk|Use FIT FIRST 1.5 times pr. week
89239421|NCT06180759|Experimental|Intravenous infusion of DMT|Participants will be administered intravenous DMT.
89239422|NCT06180759|Active Comparator|Intravenous infusion of ketamine|Participants will be administered intravenous racemic ketamine.
89239423|NCT06180759|Placebo Comparator|Intravenous infusion of placebo|Participants will be administered intravenous lacebo (saline infusion).
89239424|NCT06180746|Experimental|ECEMSo intervention|This group is composed of health mediators, the people living in informal housing they support and stakeholders. The ECEMSo intervention will be implemented in this group
89239425|NCT06180746|No Intervention|Group 2 : No intervention|This group is composed of health mediators, the people living in informal housing they support and stakeholders. The ECEMSo intervention will not be implemented in this group.
89239426|NCT06180746|No Intervention|Group 3 : No intervention|This group is composed of health workers, social workers, the people living in informal housing they support and stakeholders. The ECEMSo intervention will be implemented in this group.
89239427|NCT06180733|Experimental|Primary MMRd endometrial cancer patients|
89239428|NCT06180720|Experimental|Test (T)-Reference (R)|In this trial, 36 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group A: Test (T)-Reference (R), The washout period (dosing interval) between doses will be at least 2 days. After fasting for at least 10 hours.
89239429|NCT06180720|Experimental|Reference (R)-Test (T)|In this trial, 36 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group B: Reference (R)-Test (T), The washout period (dosing interval) between doses will be at least 2 days. After fasting for at least 10 hours.
89239430|NCT06180707|Experimental|gel of pregabalin|The experimental 10% pregabalin gel (GPG) will be applied to the buccal surfaces of the central and lateral incisors, canines and upper and lower premolars, with an active microbrush, for 10 minutes. Subsequently, all groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whiteness HP, FGM). Sensitivity assessment will be carried out using a form consisting of a visual analogue scale (VAS), patients will be instructed to record tooth sensitivity daily, during the 21 days of follow-up. To measure color, the VITA Easyshade spectrophotometer (VITA, Germany) will be used at two times: baseline (Ti) and one week after the 3rd bleaching session (Tf).
89239431|NCT06180707|Active Comparator|gel with 5% potassium nitrate and 2% sodium fluoride|The gel with 5% potassium nitrate and 2% sodium fluoride (NKFG) will be applied to the buccal surfaces of the central and lateral incisors, canines and upper and lower premolars, with a microbrush actively, for 10 minutes. Subsequently, all groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whiteness HP, FGM). Sensitivity assessment will be carried out using a form consisting of a visual analogue scale (VAS), patients will be instructed to record tooth sensitivity daily, during the 21 days of follow-up. To measure color, the VITA Easyshade spectrophotometer (VITA, Germany) will be used at two times: baseline (Ti) and one week after the 3rd bleaching session (Tf).
89239432|NCT06180707|Placebo Comparator|placebo gel (carbopol 1%)|The placebo gel (PG) will be applied to the buccal surfaces of the central and lateral incisors, canines and upper and lower premolars, with a microbrush actively, for 10 minutes. Subsequently, all groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whiteness HP, FGM). Sensitivity assessment will be carried out using a form consisting of a visual analogue scale (VAS), patients will be instructed to record tooth sensitivity daily, during the 21 days of follow-up. To measure color, the VITA Easyshade spectrophotometer (VITA, Germany)) will be used at two times: baseline (Ti) and one week after the 3rd bleaching session (Tf).
89239433|NCT06180681|Active Comparator|Standard Collaborative Life Skills Program Implementation|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
89239434|NCT06180681|Experimental|Team-Enhanced Collaborative Life Skills Program Implementation|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
89239435|NCT06180668||Trauma Laparotomy Patients|Patients of all ages who present to hospital with a blunt or penetrating injury and undergo a trauma laparotomy within 5 days of presentation to the treating centre
89239436|NCT06180642||Women after breast cancer with UL dysfunctions|
89239437|NCT06180642||Women after breast cancer without UL dysfunctions|
89239438|NCT06180642||Healthy volunteers|age- and gender-matched control group
89239439|NCT06180629|Experimental|Music Consert|During the chemotherapy sessions, the patients in the experimental group listened to music for 20-25 minutes, once a week for a total of 4 weeks, by choosing a music genre decided by the patient himself/herself from 3 music genres selected by the researcher based on scientific content and expert opinion.
89239440|NCT06180629|Active Comparator|control group|The control group continued their normal treatment routine. No application was performed. Only pre-test and post-tests were applied.
89239441|NCT06180577||Adolescent Nerivio Users|Adolescent with migraine who used Nerivio at least once
89239442|NCT06180564|Experimental|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature >3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
89239443|NCT06180564|No Intervention|Conventional without Infra-red thermography|Resection margin determined by conventional visual and palpatory method
89239444|NCT06180512|Experimental|Beta Alanine high dose|Consumption for 1 day.
89239445|NCT06180512|Experimental|Beta Alanine low dose|Consumption for 1 day.
89239446|NCT06180512|Placebo Comparator|Control group|Consumption for 1 day.
89239447|NCT06180434||Proton group|Patients with grade 2 and 3 IDHmt glioma treated with proton therapy in Holland PTC, Maastro and UMC Groningen.
89239448|NCT06180434||Photon group|Patients with grade 2 and 3 IDHmt glioma treated with photon therapy in Erasmus MC, Haaglanden MC, LUMC, Amsterdam UMC, Verbeeten Institute, Maastro, UMC Groningen, and Leuven University Hospital.
89239449|NCT06180421||PolG|Genetically confirmed PoLG patients 16 years or older
89239450|NCT06180421||PMM|Genetically confirmed Primary Mitochondrial Myopathy patients 16 years or older
89239451|NCT06180408|Experimental|manual therapy for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
89239452|NCT06180408|Experimental|lumbar stabilization exercise|core training and myofascial release therapy
89239453|NCT06180369|Other|GC Fuji Triage ® GC America Inc., Alsip, Illinois )|Fissure sealant application with GC Fuji Triage (GC America Inc., Alsip, Illinois )
89239454|NCT06180369|Other|BeutiSealant (Shofu, Kyoto, Japonya)|Fissure sealant application with BeutiSealant (Shofu, Kyoto, Japonya)
89239455|NCT06180317|Experimental|Virtual reality group|Virtual reality to be applied to women undergoing endometrial biopsy.
89239456|NCT06180317|No Intervention|Control group|Participants in this group will consist of people who do not routinely do any practive on their own to reduce anxiety and pain during endometrial biopsy.
89239457|NCT06180304|Experimental|Indoor training group|Exercise group in a gym.
89239458|NCT06180304|Experimental|outdoor training group|Exercise group in an outdoor space.
89239459|NCT06180304|No Intervention|Control group|No exercise group.
89239460|NCT06180291|Experimental|Intervention group|PRECOP group: screening and early treatment. CAMSP (Centre d'Action Médico-Sociale Précoce) orientation upon discharge from neonatology for immediate follow-up according to PRECOP protocol: early multidisciplinary care, with targeted objectives according to the child's needs.
89239461|NCT06180291|No Intervention|Control group|Standard of care group: in the control centers, care includes specialized consultations organized by the perinatal network with a hospital and/or community pediatrician belonging to the network until the child is 2 years old. Cerebral palsy screening is based on clinical examination.
89239462|NCT06180278|Other|Participants with NMOSD exposed to inebilizumab|Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
89239463|NCT06180265|Other|septic shock patients|Septic shock patients undergoing major abdominal surgery treated with polymyxin-B
89239464|NCT06180239||Single Segmentectomy group|patients underwent single segment resection,
89239465|NCT06180239||Lobectomy group|Patients underwent lobectomy
89239466|NCT06180239||Multiple segmentectomy group|patients underwent multiple segments resection,
89239467|NCT06180187|Active Comparator|Osseo-densification group|
89239468|NCT06180187|Active Comparator|Electrical mallet group|
89239469|NCT06180135|No Intervention|Control Group|"The patients in this group will rest their bowel movements after starting oral intake at the 6th hour postoperatively. The time of first degassing and the time of first discharge will be recorded by asking verbally.~Only evaluation will be made at 6. hours after surgery without intervention in the control group."
89239470|NCT06180135|Active Comparator|TURKISH COFFEE DRINKING GROUP - TURKISH COFFEE DRINK|"Turkish coffee group after the patients in start oral intake at the 6th hour after the surgery, 7 gr of Turkish coffee in 75 ml of water will be boiled with water at 50-60°C, prepared by the researcher and given to the patients to drink. Bowel movements will be rested before and after the intake of Turkish coffee. The time of first degassing and the time of first discharge will be recorded by asking verbally.~Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 6th hour after the surgery and the gıs functıons and healıng qualıty will be evaluated."
89239471|NCT06180135|Active Comparator|FENNEL TEA DRINKING GROUP- FENNEL TEA DRINK|"fennal tea group after the patients in start oral intake at the 6th hour postoperatively, 150 ml of boiled water at 100˚C will be added to 2 g of fennel seeds, and then infused for 5-10 minutes, they will be given to the patients to drink. Bowel movements will be rested before and after fennel tea intake. The time of first degassing and the time of first discharge will be recorded by asking verbally.~Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 6th hour after the surgery and the gıs functıons and healıng qualıty will be evaluated."
89239472|NCT06180109|Experimental|Empagliflozin film coated tablets|Empagliflozin 25 mg film coated tablets
89239473|NCT06180109|Active Comparator|Jardiance film-coated tablets|Jardiance (Empagliflozin) 25 mg film-coated tablets
89239474|NCT06180070|Experimental|Ibuprofen/ Paracetamol tablets|Ibuprofen/ Paracetamol tablets (200mg Ibuprofen/ 500mg Paracetamol)
89239475|NCT06180070|Active Comparator|Nuromol® tablets|Nuromol® tablets (200mg Ibuprofen/ 500mg Paracetamol)
89239476|NCT06180031|No Intervention|Group C (control)|will have Peng block using 20mg bupivacaine 0.25%
89239477|NCT06180031|Active Comparator|Group M|will have PENG block with 2mg magnesium sulphate 10% as an adjuvant to 20mg of bupivacaine 0.25%
89239478|NCT06180018|Experimental|cases|Using interrupted sutures
89239479|NCT06179953|Experimental|Experimental group with social robot|"The emotional skills protocol aims to achieve the following objectives:~Acquisition of appropriate emotional skills and understanding of emotions;~Construction of functional thoughts related to emotions;~Enhancement of interpersonal and social skills. It is aimed at a sample of children diagnosed with high-functioning autism spectrum disorder (ASD) between the ages of 5 and 10. The experimental group will carry out training through the use of social robots. The robot provides instructions and if the child requests it, it gives prompts."
89239480|NCT06179953|Other|Control group without social robot|"The emotional skills protocol aims to achieve the following objectives:~Acquisition of appropriate emotional skills and understanding of emotions; Construction of functional thoughts related to emotions;~Enhancement of interpersonal and social skills. It is aimed at a sample of children diagnosed with high-functioning autism spectrum disorder (ASD) between the ages of 5 and 10. Control group which will be conducted through traditional therapy. The therapist provides instructions, and if the child has difficulty responding, he gives prompts."
89239481|NCT06179940|Experimental|Food selectivity group (1) in pairs|15 Children in the experimental group who will undergo the treatment perform the procedure in pairs.
89239482|NCT06179940|Experimental|Food selectivity Group (2) in individual mode|15 Children in the comparator group who will undergo the treatment perform the procedure in individual mode.
89239483|NCT06179927|Experimental|QT robot treatment|Twenty children from the experimental group will undergo the treatment using QT Robot and the tablet.
89239484|NCT06179927|Experimental|Traditional treatment|Twenty children belonging to the control group will be subjected to the same training but in a traditional way, that is, by presenting image stimuli in a paper format.
89239485|NCT06179914||Adolescence and Youth with cancer|Participants were diagnosed with cancer before 18 years old and aged between 10 and 24 years
89239486|NCT06179836||good prognosis group|
89239487|NCT06179836||poor prognosis group|
89239488|NCT06179823||DOAC direct oral anticoagulants|pregnant women exposed to doac
89239489|NCT06179823||VKA vitamin K antagonist|pregnant women exposed to vitamin K antagonist
89239490|NCT06179823||Heparin|pregnant women exposed to Heparin
89239491|NCT06179810|Experimental|Baduanjin exercise in addition to medical treatment|30 patients with metabolic syndrome do baduanjin exercise in addition to traditional medical treatment
89239492|NCT06179810|Experimental|Traditional medical treatment|30 patients with metabolic syndrome taking traditional medical treatment
89239493|NCT06179797|Sham Comparator|sham|BP cuff bilateral arm compression to 50 mmHg.
89239494|NCT06179797|Active Comparator|dose 1|BP cuff bilateral arm compression to 50 mmHg above systolic BP for 2.5 minutes on/off for 4 cycles every other day.
89239495|NCT06179797|Active Comparator|dose 2|BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off for 4 cycles every other day.
89239496|NCT06179797|Active Comparator|dose 3|BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off once daily.
89239497|NCT06179797|Active Comparator|dose 4|BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off twice daily.
89239498|NCT06179784|Experimental|Exposure in vivo|The goal of the exposure in vivo treatment module is the correction of irrational, fearful beliefs regarding movements, a reduction of avoidance behaviours and hence a facilitation of activity levels. This will be done by carrying out feared, avoided movements and seeking out avoided situations and places. Exemplary units are the development of a movement hierarchy and protocols for exposure exercises.
89239499|NCT06179784|Experimental|Relaxation|Goal of the relaxation treatment module is the reduction of stress and tension, which will be achieved applying relaxation techniques such as Progressive Muscle Relaxation (PMR), breathing techniques, and imaginary methods.
89239500|NCT06179784|Experimental|Activity and Rest|The treatment module activity and rest is based on pacing and pursues the goal to balance active and resting phases. For overly active patients, the module will consist of implementing breaks and resting phases, while for overly resting patients the module will consist of graduated activity build-up. Acitivity protocols, plans, and exercises will be used.
89239501|NCT06179784|Experimental|Cognitive Coping with Pain|Goal of the treatment module cognitive coping with pain is the reduction of rigid, dysfunctional thought patterns by flexibilising them and implement functional thought patterns instead. It includes classical methods such as cognitive restructuring as well as meta-cognitive or defusion techniques.
89239502|NCT06179784|Experimental|Attention Control|The goal of the treatment module attention control is to enable patients to willingly draw their attention towards other entities as their pain or perceive their pain in a non-judgmental way, thus improve their coping strategies and enhance functioning levels. Exemplary units are the anti-pain diary or the distraction alphabet.
89239503|NCT06179784|Experimental|Activating Resources|The goal of the activating resources module is relief and a balance between unpleasant perceptions as pain and pleasent experiences. This will be achieved by reactivating lost resources and implementing new ones, e.g. social networks or hobbies. Exemplary units are the positive diary or focusing on healthy bodyparts.
89239504|NCT06179784|Experimental|Acceptance|Goal of the acceptance module is the flexibilisation of thought patterns by regaining mental resources through givign up inner resistance against the pain. Patients will be supported in developing an accepting attitude towards their suffering using working units like the monster by the wayside or concluding a peace treaty with oneself.
89239505|NCT06179784|Experimental|Values and Values-based Action|Goal of the treatment module values and values-based action is enhancing satisfaction with life and regaining action control. Patients will learn about their personal values and how they can align their actions with them. Exemplary units are sorting values, a value diary, or looking back on one's life.
89239506|NCT06179784|Experimental|Sleep|Goal of the treatment module sleep is enhancing the subjective sleep quality and increase the feeling of recovery. Patients will learn about sleep hygiene, stimulus control, and imaginary techniques such as the inner feel-good place.
89239507|NCT06179784|Experimental|Selfcompassion|Goal of the selfcompassion treatment module is the development of a benevolent, loving, and kind attitude towards oneself and one's suffering in order to enhance wellbeing and feelings of self-worth. Exemplary units are the selfcompassion break, writing a letter to oneself, or changing perspective.
89239508|NCT06179771|Active Comparator|Interventional|Patients assigned to interventional arm will receive treatment with a cytokine adsorption device (HA 380) within 72 hours of being admitted to ICU. This is in addition to standard evidence based ICU care. Each patient will receive 2 treatments each lasting a maximum of 6 hours in a 24 hour period.
89239509|NCT06179771|No Intervention|Standard care|Patients assigned to the standard care arm would receive evidence based standard ICU care.
89239510|NCT06179758|Experimental|open-label interventional arm|
89239511|NCT06179745|Experimental|Brain-computer interface (BCI)|"In the BCI arm, FES stimulation and orthosis triggering are only initiated when the BCI infers on line (in real time) the presence of adequate SMRs or ERD/ERS within the epoch. That is, there is precise contingency between the efferent motor command and the afferent feedback induced by BCI-driven actuators (the patient feels he/she can move his upper limb when he wants to do it)."
89239512|NCT06179745|Sham Comparator|Sham-Brain-computer interface (Sham-BCI)|"In the Sham-BCI group, any EEG signals encoding motor intention of the patient are ignored. FES/orthosis triggering is decided at random, by playing back the data of a randomly selected run of a previously recruited participant. Hence, in the Sham-BCI arm, there is no guaranteed contingency between the efferent motor command and the afferent feedback induced by the FES and the orthosis, although it can still happen by coincidence."
89239513|NCT06179732|No Intervention|Control|"Information and Education Campaigns (IEC) campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home).~Epidemiological surveillance: test and treat malaria cases in children 6 - 10 years of age"
89239514|NCT06179732|Experimental|Mesh|"Information and Education Campaigns (IEC) campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home).~Epidemiological surveillance: test and treat malaria cases in children 6 - 10 years of age~Mesh product distributed to households"
89239515|NCT06179719|Experimental|Healthy controls|
89239516|NCT06179680||Alzheimer's Disease Group|"Description: Individuals diagnosed with Alzheimer's disease. Inclusion Criteria: Participants meeting established criteria for Alzheimer's disease diagnosis, which may include cognitive and memory deficits along with functional impairment.~Exclusion Criteria: Exclusion of participants with significant comorbidities that could affect cognitive function and those with other forms of dementia."
89239517|NCT06179680||Amnestic Mild Cognitive Impairment (aMCI) Group|"Description: Individuals diagnosed with amnestic mild cognitive impairment. Inclusion Criteria: Participants displaying cognitive decline beyond what is expected for their age but not meeting criteria for a diagnosis of Alzheimer's disease.~Exclusion Criteria: Exclusion of participants with other neurological conditions that might mimic or contribute to cognitive impairment."
89239518|NCT06179680||Control Group (Healthy Controls)|"Description: Individuals without cognitive impairment or neurological disorders.~Inclusion Criteria: Participants with normal cognitive function for their age, absence of memory complaints, and no history of neurological or psychiatric disorders.~Exclusion Criteria: Exclusion of individuals with any cognitive impairment, psychiatric disorders, or significant medical conditions affecting cognition."
89239519|NCT06179667|Experimental|Intervention Group|Caregivers will be encouraged to use the mobile application every day during the implementation period of the study (two months).
89239520|NCT06179667|No Intervention|Control Group|No treatment will be performed on individuals in the control group.
89239521|NCT06179654|Experimental|Preoperative PFPT|This group of patients will be instructed to start pelvic floor physical therapy 1 month before surgery.
89239522|NCT06179654|No Intervention|Postoperative PFPT|This group of patients will be instructed to start pelvic floor physical therapy after surgery (standard of care).
89239523|NCT06179615|Other|complete denture with prefabricated artificial teeth|complete denture constructed with prefabricated artificial teeth and inserted in the patient mouth to be used for 3, 6 months
89239524|NCT06179615|Other|complete denture with CAD\CAM milled artificial teeth|complete denture constructed with CAD\CAM Milled artificial teeth and inserted in the patient mouth to be used for 3, 6 months
89239525|NCT06179589|Experimental|VS002A|Advanced Amino acid-based ORS: VS002A Traditional oral rehydration solutions (ORS) contain sugars which stimulate intestinal sodium and water absorption through a variety of mechanisms. However, it has been under-appreciated that traditional ORS possess no anti-diarrheal functions and may exacerbate infectious diarrheal secretions.
89239526|NCT06179589|Active Comparator|WHO-ORS|WHO-ORS usually used worldwide in the treatment of diarrhoea.
89239527|NCT06179576|Experimental|EHS-CTB Hybrid|Dyads in the EHS-CTB hybrid condition will receive 6 individual sessions of CTB conducted by trained facilitators. The first session would be at the center, the 2nd through 5th would be remote, and 6th would be at the EHS center as a group session with other families. Sessions will occur approximately one to two weeks apart, allowing for program completion within 10 weeks. During the first in-person session, families will receive tablets with data plans and with the Zoom. They will receive a welcome pack that includes baby gifts that are used to support each session.
89239528|NCT06179576|No Intervention|EHS-CTB Digital Only|Dyads in the EHS-CTB digital only group will receive EHS early education, as well as EHS home visitation, and will have access to the CTB content via text messages, but will receive no CTB sessions. Digital content includes videos of Baby Elmo and his father and suggested activities.
89239529|NCT06179563|No Intervention|Standard telemonitoring|Patients will be monitored according to a fixed telemonitoring schedule at their treating hospitals, based on the patient's medication type and in adherence to national and international guidelines.
89239530|NCT06179563|Experimental|On-Demand Telemonitoring|Patients will have the flexibility to use the telemonitoring application at their own discretion
89239531|NCT06179537|Experimental|Cohort 1|10 Japanese and 8 Caucasian subjects. 8 out of 10 Japanese subjects will receive BLU-5937 Dose A and 2 will receive placebo. All Caucasian subjects will receive BLU-5937 Dose A.
89239532|NCT06179537|Experimental|Cohort 2|8 Japanese subjects. 6 out of 8 will receive BLU-5937 Dose B and 2 will receive placebo.
89239533|NCT06179537|Experimental|Cohort 3|8 Japanese subjects. 6 out of 8 will receive BLU-5937 Dose C and 2 will receive placebo.
89239534|NCT06179524|Experimental|CAR-T-19 cells|CAR-T-19 cells injection: 1.5 x10^6 cells/kg（range 0.5-1.5×10^6 cells/kg）
89239535|NCT06179485||Comparator: Ketamine Group|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation.
89239536|NCT06179485||Comparator: Etomidate Group|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation.
89239537|NCT06178276||A2 level|Level of oral comprehension in italian language
89239538|NCT06178276||B2 level|Level of oral comprehension in italian language
89239539|NCT06176612|Experimental|Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent total hip replacement|
89239540|NCT06176066|No Intervention|Standard of Care|Standard of care glioblastoma resection with standard of care adjuvant therapy (temozolomide + radiation therapy)
89239541|NCT06176066|Experimental|CEST Resection|CEST MRI Based Resection of glioblastoma with standard of care adjuvant therpay (temozolomide + radiation therapy)
89239542|NCT06175494|Experimental|Experimental group|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
89239543|NCT06175494|Active Comparator|Control group|Recombinant COVID-19 Variant Vaccine（ Sf9 Cell）
89239544|NCT06175494|Placebo Comparator|Placebo control group|Placebo control
89239545|NCT06174519||Study group|For this clinical investigation, the clinical data for 325 subjects were used to demonstrate the non-inferiority of iAST® application in comparison with physician prescription. In any case, the data retrospectively analyzed for these 325 subjects were simulated using the iAST® application, in such a way that the same subjects were considered case and control at the same time.
89239546|NCT06173661|Active Comparator|Patients receiving active medication|These patients will receive 675 mg of fremanezumab for two total doses administered 3 months apart.
89239547|NCT06173661|Placebo Comparator|Patients receiving placebo|These patients will receive placebo injections for two total doses administered 3 months apart.
89239548|NCT06173219|Experimental|treatment group|The subjects will receive the combination therapy of SBRT, LDRT, PD-1/L1 inhibitor and GMCSF. The specific treatment regimen is as follows: (1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
89239549|NCT06172790|Experimental|Training Group|"The training group will undergo the Otago Exercise Program (OEP) in a hospital setting, supervised by a physiotherapist, with sessions lasting 60 minutes each, three days a week for a duration of 8 weeks.~Following the initial assessment, a patient education session will be conducted to provide information about the pathophysiology of the disease and the benefits of physical activity."
89239550|NCT06172790|No Intervention|Control Group|Any intervention will not be performed. After the initial assessment, a patient education session will be conducted to provide information on the pathophysiology of the disease and the benefits of physical activity.
89239551|NCT06169280|Experimental|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
89239552|NCT06169280|Experimental|NSC-CRAd-S-pk7 + N-acetylcysteine amide (NACA)|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with 1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses. In addition, N-acetylcysteine amide (NACA) 600 mg oral, is taken daily from registration to just prior to dose 2 of NSC-CRAd-S-pk7.
89239553|NCT06167694|Experimental|Treatment group A|
89239554|NCT06167668||combined group|
89239555|NCT06167668||traditional group|
89239556|NCT06166290|Experimental|CO2 LASER Vaporization Group|
89239557|NCT06166290|Active Comparator|Electrosurgical Fulguration Group|
89239558|NCT06164847|Experimental|AERO Program|"Before their first physiotherapy appointment, patients will be asked to respond to four specific questions to guide the treatment (see link below).~After this, they will receive usual physiotherapy care and a HEP for managing osteoporosis. The number of exercises given for the HEP should minimally be three to maximum six, performed at least three days per week for 12 weeks (time of the final assessment).~After providing the HEP, patients in the intervention group are asked questions which explore their subjective abilities of the COM-B Model (capability, opportunity, or motivation) of undertaking the exercise program. Based on these answers and with the help of further discussions with the patient, the physiotherapist makes an assessment and decides which domains of the COM-B model might be useful to target. In the following 30 minutes PT-sessions, the therapist suggests one or more specific actions to enhance adherence. The participants must attend at least 4 out of 6 sessions."
89239559|NCT06164847|Active Comparator|Standard care|"The control group will receive six PT sessions as standard care. The first session is 60 minutes and the following sessions are 30 minutes. In regular clinical practice, standard care for people with osteoporosis includes measures such as home exercise programs, mobilizations, soft tissue techniques, or training with gym equipment. The HEP in the control group is based on the physical assessment of the physical therapist. The therapists in the control group do not have any restrictions for the exercises chosen. The participants must attend at least 4 out of 6 sessions of the control program."
89239560|NCT06164821|Experimental|luspatercept arm|Luspatercept was given once subcutaneously every 3 weeks for 24 weeks in the treatment period, . Luspatercept was started at 1·0 mg/kg with titration up to 1·25 mg/kg, or reduction in the event of toxicity or excessive haemoglobin concentration increase.. During the treatment, the hemoglobin of patients before each injection of luspatercept should be monitored, and the common adverse reactions (AE) should be monitored. According to the judgment and practice of clinicians, the best supportive treatment, including blood transfusion, iron chelation therapy, and anti-infection treatment, should be provided for patients receiving luspatercept treatment. If the patient has blood transfusion, it is necessary to obtain the blood transfusion record from the hospital system.Concomitant use of iron chelating agents was also recorded.
89239561|NCT06164782||General Pupulation of China|General Pupulation of China
89239562|NCT06158841|Experimental|ABBV-383|Participants will receive ABBV-383 as a monotherapy.
89239563|NCT06158841|Experimental|Standard Available Therapy (SAT)|Participants will receive SAT, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. SAT choices are carfilzomib + dexamethasone (Kd), elotuzumab + pomalidomide + dexamethasone (EloPd), selinexor + bortezomib + dexamethasone (SVd).
89239564|NCT06157736||Cases|Children with newly diagnosed T1D
89239565|NCT06157736||Controls|Healthy siblings of cases
89239566|NCT06150170|Experimental|Group 1|This group includes patients with grade 1 and grade 2 knee osteoarthritis.
89239567|NCT06150170|Experimental|Group 2|This group includes patients with grade 3 and grade 4 osteoarthritis.
89239570|NCT06131593|Experimental|Group TAPB-D (n=25)|Patients in this group will receive TAPB with dexamethasone as an adjuvant to local anesthetic.
89239571|NCT06131593|Active Comparator|Group TAPB-M (n=25)|Patients in this group will receive TAPB with methylprednisolone as an adjuvant to local anesthetic.
89239572|NCT06127368|Experimental|GB-5001A|GB-5001 Suspension for IM/SC injection at three doses(low, intermediate, high) The cohort is determined through random allocation.
89239573|NCT06127368|Experimental|GB-5001D|GB-5001 Suspension for SC injection at three doses(low, intermediate, high) The cohort is determined through random allocation.
89239574|NCT06127368|Active Comparator|Oral cohort|Aricept® tablet. The cohort is determined through random allocation.
89239575|NCT06126926|Experimental|Intervention arm|32-week group therapy
89239576|NCT06126926|Active Comparator|Control group|Treatment as Usual
89239579|NCT06123858||NASH with fibrosis|NASH patients with fibrosis receiving routine treatment
89239580|NCT06117202|Experimental|music therapy|The patients involved in the study will be randomly divided into two groups. One group will be provided with a set of headphones that completely cover the ears and will be played their selected music from a predetermined album for 20 minutes before the procedure. The music will continue to be played through the headphones during the procedure.
89239581|NCT06117202|No Intervention|control group|The control group will be taken to the operating room with standard anesthesia care protocol.
89239582|NCT06107738|Experimental|Iberdomide and Daratumumab|
89239583|NCT06104605|Experimental|Implementation|Implementation will be deployed at the CHC, PCP, and patient level.
89239584|NCT06104605|No Intervention|Standard of care|Usual patient care without deployment of intervention.
89239585|NCT06095973|Experimental|GB-6002|GB-6002 for subcutaneous (SC) injection at three doses(low, intermediate, high)
89239586|NCT06095973|Placebo Comparator|Placebo|Placebo for subcutaneous (SC) injection at three doses(low, intermediate, high)
89239587|NCT06095973|Active Comparator|Naropin injection(Ropivacaine hydrochloride)|Naropin injection(Ropivacaine hydrochloride), single dose
89239588|NCT06091007|Active Comparator|200 mg Magnesium|Participant will take 200 mg of magnesium citrate daily for 4 weeks
89239589|NCT06091007|Active Comparator|400 mg Magnesium|Participant will take 400 mg of magnesium citrate daily for 4 weeks
89239590|NCT06086093|Placebo Comparator|placebo|Take 1 sachet(5g) 4 times daily.
89239591|NCT06086093|Experimental|RespireAid|Take 1 sachet(5g) 4 times daily.
89239592|NCT06085664|Experimental|REGN5678 (anti-PSMAxCD28)|"Participants will receive REGN5678 by vein over about 2 hours the first time you receive it.~Participants will be admitted to the hospital, where participants will be monitored for side effects. Other doses may be given over 30-90 minutes depending on how you handle the dose.~Participants will receive REGN5678 weekly for 6 weeks."
89239593|NCT06083571|Experimental|Intranasal Patients|Intranasal ketorolac (1 spray (15.75mg) if 15kg-29.9kg and 2 sprays (31.5mg) if 30kg or heavier and oral adjuncts oral Prochlorperazine (Between 15-25 kg: dose of 2.5 mg; 26-50 kg: dose of 5 mg; > 50 kg: dose of 10 mg, single maximum dose 10 mg) and oral Diphenhydramine (Between 15-25 kg: dose of 12.5 mg; 26-50 kg: dose of 25 mg; > 50 kg: dose of 50 mg, single maximum dose 50mg)
89239594|NCT06083571|Active Comparator|Intravenous Patients|IV ketorolac (0.5 mg/kg, maximum single dose of 30 mg) with oral adjuncts oral Prochlorperazine (Between 15-25 kg: dose of 2.5 mg; 26-50 kg: dose of 5 mg; > 50 kg: dose of 10 mg, single maximum dose 10 mg) and oral Diphenhydramine (Between 15-25 kg: dose of 12.5 mg; 26-50 kg: dose of 25 mg; > 50 kg: dose of 50 mg, single maximum dose 50mg)
89239595|NCT06077695|Experimental|4 weeks phase A arm|"Phase A = Randomised duration of this phase : 4 weeks. each therapeutic therapeutic education sessions last 90 minutes.~Phase B = therapeutic education with tDCS for 4 weeks~Phase C = Cognitive remediation with tDCS for 4 weeks : Eight specific working memory remediation sessions will be carried out. These will be provided by a neuropsychologist. All cognitive remediation sessions will be individual, biweekly, lasting 1 hour 10 minutes for 4 weeks, for a total duration of 9 hours 20 minutes.~Phase D = follow-up"
89239596|NCT06077695|Experimental|5 weeks phase A arm|"Phase A = therapeutic education. Randomised duration of this phase : 5 weeks. each therapeutic therapeutic education sessions last 90 minutes.~Phase B = therapeutic education with tDCS for 4 weeks~Phase C = Cognitive remediation with tDCS for 4 weeks : Eight specific working memory remediation sessions will be carried out. These will be provided by a neuropsychologist. All cognitive remediation sessions will be individual, biweekly, lasting 1 hour 10 minutes for 4 weeks, for a total duration of 9 hours 20 minutes.~Phase D = follow-up"
89239597|NCT06077695|Experimental|6 weeks phase A arm|"Phase A = therapeutic education. Randomised duration of this phase : 6 weeks. each therapeutic therapeutic education sessions last 90 minutes.~Phase B = therapeutic education with tDCS for 4 weeks~Phase C = Cognitive remediation with tDCS for 4 weeks : Eight specific working memory remediation sessions will be carried out. These will be provided by a neuropsychologist. All cognitive remediation sessions will be individual, biweekly, lasting 1 hour 10 minutes for 4 weeks, for a total duration of 9 hours 20 minutes.~Phase D = follow-up"
89239598|NCT06068933|Experimental|Phase 2A -MCI Pilot Trial Immediate Treatment Group|Immediate treatment with K-HEARS intervention
89239599|NCT06068933|Placebo Comparator|Phase 2A -MCI Pilot Trial Delayed Treatment Group|6-month delayed treatment with K-HEARS intervention
89239600|NCT06068933|Other|Phase 2B -KA Older Adult Focused Trial (non-randomized)|Immediate treatment with K-HEARS intervention
89239601|NCT06064968|Experimental|intervention group|"In intervention group, researcher will explain the patient about the intermittent catheterization technique and give the practical demonstration for better patient understanding and make correction in patient's technique of intermittent bladder catheterization.~Patient will be followed from the day of recruitment in the study after every 02 weeks by the researcher for 2 successive months.~In every follow up session, assessment of the urinary complaints via AUA scoring, review of patient's technique of urethral catheterization in intervention group, and each patient's adherence to the intermittent bladder catheterization (IBC) will be noted"
89239602|NCT06064968|Active Comparator|Control group|In control group already diagnosed cases of urethral stenosis who have undergone urethral dilatation will be followed fortnightly for AUA symptoms scoring for urinary complaints and urethral catheterization with nelton 14 Fr to exclude urethral stricture recurrence.
89239603|NCT06061536|Experimental|Group A：Lipovirtide 10mg+3TC+TDF|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）
89239604|NCT06061536|Experimental|Group B：Lipovirtide 40mg+3TC+TDF|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）
89239605|NCT06061536|Experimental|Group C：Lipovirtide 60mg+3TC+TDF|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）
89239606|NCT06061536|Experimental|Group D：DTG +3TC + TDF|DTG +3TC + TDF（once daily）
89239607|NCT06060587|Experimental|Triplet Arm|"Abiraterone+Docetaxel+ADT~Abiraterone Abiraterone acetate will be four (250 mg) tablets (total dose/day 1000 mg). Abiraterone administration is per a 12-week cycle.~Abiraterone must be taken with prednisone. Prednisone will be provided as 5 mg tablets.~Docetaxel Docetaxel on day 1 of each 21-day cycle, 75 mg/m2 via IV. Dexamethasone will be self-administered by the patient at 16 mg per day for 3 days starting 1 day prior to docetaxel infusion.~ADT Patients may be started on an LHRH agonist or antagonist , the selection of the agent is left to the treating investigator for ADT."
89239608|NCT06060587|Active Comparator|Doublet Arm|"Abiraterone+ADT~Abiraterone Abiraterone acetate will be four (250 mg) tablets (total dose/day 1000 mg). Abiraterone administration is per a 12-week cycle.~Treatment of abiraterone should start ≤14 days after patient randomization.~Abiraterone must be taken with prednisone. Prednisone will be provided as 5 mg tablets.~Docetaxel Docetaxel on day 1 of each 21-day cycle, 75 mg/m2 via IV. Prior to docetaxel, dexamethasone administration is recommended as discussed, but can be adjusted or altered per the treating investigator's discretion. Dexamethasone will be self-administered by the patient at 16 mg per day for 3 days starting 1 day prior to docetaxel infusion."
89239609|NCT06059352||ASD+ CAPD|This group includes children and adolescence with ASD who also have CAPD. No intervention will be applied to this group.
89239610|NCT06059352||ASD- CAPD|This group includes children and adolescence with ASD who are not affected by CAPD. No intervention will be applied to this group.
89239611|NCT06053684|Active Comparator|Standard Non-Invasive Mechanical Servo Ventilation Arm|This arm will utilize a standard mode of non-invasive ventilation within protocol parameters.
89239612|NCT06053684|Experimental|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation Arm|This arm with utilize a NAVA mode of non-invasive ventilation within protocol parameters.
89239613|NCT06041373||Paroxysmal Atrial Fibrillation Patients|
89239614|NCT06040502|Experimental|The DICE Approach|Training of clinic staff to work with caregivers in the approach.
89239615|NCT06037863|Active Comparator|Arm I (bladder filling, CT, radiation)|Patients perform SOC bladder filling and then undergo CT and radiation therapy in 5-39 fractions at the discretion of the treating clinician on study.
89239616|NCT06037863|Experimental|Arm II (bladder emptying, CT, radiation)|Patients perform bladder emptying and then undergo CT and radiation therapy in 5-39 fractions at the discretion of the treating clinician on study.
89239617|NCT06032338|Other|"Control C"|"Usual care : Screening test (Fecal immunochemical test - FIT) delivery and reminders will be carried out in accordance with the Colorectal cancer population-based organised screening program (CRC-PBOSP) specifications at the time of the study.~This arm is suitable for both the first screening round in 50-51 years old population, and for the subsequent screening rounds."
89239618|NCT06032338|Experimental|"Intervention B1"|"FIT mailed at home within the CRC screening invitation without prior information letter.~This arm is suitable for both the first screening round in 50-51 years old population, and for the subsequent screening rounds."
89239619|NCT06032338|Experimental|"Intervention B2"|"FIT mailed at home within the CRC screening invitation with prior information letter.~This arm is suitable for the first screening round in 50-51 years old population only."
89239620|NCT06027229|Experimental|Participants who have had Solid Organ Transplants|Male and females aged 18 to 85 who are solid organ transplant recipients and receive the study intervention.
89239621|NCT06027229|Experimental|Participants with IBD|Male and females aged 18 to 85 who have IBD and receive the study intervention.
89239622|NCT06026033||Patients scheduled for general anesthesia|Patients scheduled for elective general anesthesia will be included, if accepts and signs the informed consent. The inhalational anesthetic should be desflurane. No other inhalational agent should be used during the induction of anesthesia. The inspiratory and expiratory concentration of any inhalational agent should be zero before the induction of anesthesia.
89239623|NCT06024902||childhood asthma|Subjects with confirmed diagnosis of asthma without other lung disease followed for collection of demographic and clinical data.
89239624|NCT06023953||Migraine with aura (MWA)|Patients with migraine who used the Nerivio device at least once and reported having aura in at least one treatment
89239625|NCT06023953||Migraine without aura (MWoA )|Patients with migraine who used the Nerivio device at least once and never reported having aura in any of their treatments
89239626|NCT06020846|Experimental|Soleus Pushup Exercise group A|soleus push up exercise
89239627|NCT06020846|Active Comparator|Treadmill group 2|treadmill walk
89239628|NCT06019819|Active Comparator|control group A|
89239629|NCT06019819|Experimental|Postural correction exercises group B|
89239630|NCT06017297|Experimental|Durvalumab and Tremelimumab plus gemcitabine/cisplatin|Durvalumab and tremelimumab plus gemcitabine/cisplatin combination therapy. If the tumor is evaluated to be resectable after Cycle 4 (C4), then the patient may proceed with surgical tumor resection. If the tumor is deemed unresectable after C4, then the patient will proceed with Cycle 5-8 followed by reevaluation for surgical resection.
89239631|NCT06016764|Experimental|Individuals with a diagnosis of autism|Individuals with an autism diagnosis
89239632|NCT06016582|Other|Patients benefiting from the virtual reality hypnosis headset during frozen embryo transfer|"The study will involve women, aged between 18 and 45, receiving care within the Reproductive Medicine Department at the Mother-Child-Woman Hospital in Lyon, as part of an assisted reproduction journey, and for whom a frozen embryo transfer is planned. The patients should have previously undergone an embryo transfer to be familiar with the medical procedure to be performed. Their partner must have planned to be present during the FET, in order to comply to identity vigilance regulations.~The study will be proposed to them during the consultation scheduled for the dispensing of their prescriptions in preparation for the transfer. If the patient agrees to participate, she will then use a virtual reality hypnosis headset during her frozen embryo transfer."
89239633|NCT06015672|Active Comparator|TMS to premotor cortex|Participants receive TMS at premotor cortex
89239634|NCT06015672|Active Comparator|TMS to primary somatosensory cortex|Participants received TMS sessions at primary somatosensory cortex
89239635|NCT06015672|Sham Comparator|TMS at low amplitude to primary somatosensory cortex|Participants receive TMS at a cortical target at smaller amplitude
89239636|NCT06015646|Experimental|Lifestyle Coaching and Educational Handout|Lifestyle coach-led 30-minute focused, personalized session in addition to educational handout containing lifestyle tips for fatigue mitigation in night shift workers, which will be given to all participants at the beginning of the study.
89239637|NCT06015646|Active Comparator|Educational Handout Control|An educational handout containing lifestyle tips for fatigue mitigation in night shift workers will be given to all participants at the beginning of the study. Personalized coaching will not be offered to participants in this arm.
89239638|NCT06009081|Experimental|postural exercise|An 8-week home exercise program consisting of neck exercises was applied for group 1. The exercise program was carried out three times a week for eight weeks.
89239639|NCT06009081|Active Comparator|aerobic exercise|An 8-week walking program was planned for Group 2 using pedometer feedback as a motivational tool.
89239640|NCT06006507|Active Comparator|control group|no exercise will be given
89239641|NCT06006507|Experimental|exercise group|exercise training will be given and they will be asked to exercise regularly.
89239642|NCT06006494|Active Comparator|aerobic group|only a separate aerobic exercise will be given
89239643|NCT06006494|Experimental|resistant group|aerobic and resistance exercises will be given
89239644|NCT06006494|Experimental|yoga group|aerobic exercises will be given and yoga will be done
89239645|NCT06006351|Active Comparator|control|classical physiotherapy protocol will be applied.
89239646|NCT06006351|Experimental|Massage|In addition to the classical physiotherapy protocol, a Hypervolt Device will be applied.
89239647|NCT06004427|Active Comparator|control group|regular diet program
89239648|NCT06004427|Experimental|exercise group|resistance exercise program
89239649|NCT06003894|Active Comparator|kegel group|Participants will only practice kegel exercises.
89239650|NCT06003894|Experimental|diaphragm group|In addition to kegel exercises, 360 degree expanded diaphragm breathing training will be given to the participants.
89239651|NCT06003868|Active Comparator|control group|Physiotherapy will be applied for 8 weeks, 2 days a week, as one session per day (45 minutes).
89239652|NCT06003868|Experimental|hippotherapy group|"Physiotherapy will be applied for 8 weeks, 2 days a week, one session a day (45 minutes). In addition, the patients will be placed on the simulator and the starting position will be taught. your simulator They will be warned before and during the application to maintain the starting position throughout their movements.~pattern and will be run in the 1st stage of the 3-stage speed level."
89239653|NCT06002633|Active Comparator|Alcohol|Participants will drink beverages containing alcohol.
89239654|NCT06002633|Placebo Comparator|Placebo|Participants will drink beverages containing a very low dose of alcohol (placebo condition).
89239655|NCT05998057|Active Comparator|control group|The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
89239656|NCT05998057|Experimental|exercise group|The neuromuscular training program has been adapted to ice hockey players. The content of the program includes core stabilization, balance and plyometric exercises. The session duration was set to be approximately 60-90 minutes. An average session is 15 minutes of warm-up, followed by 30-40 minutes. continued with neuromuscular training program, 15 min. It was ended with cooling and stretching exercises. Since all exercises are done with body weight, no extra equipment is needed.
89239657|NCT05996731|Active Comparator|Healthy subjects|Five healthy donors will be asked to participate in the study to set up the condition for isolation and culture of skin-derived fibroblasts and to establish the RNA-Seq conditions and profile.
89239658|NCT05996731|Experimental|Validation cohort|To develop a diagnostic pipeline for isolation and sequencing of mRNA from cultured skin fibroblasts, 10 adult patients with known genetic defects affecting RNA levels and/or splicing will be enrolled, as positive controls.
89239659|NCT05996731|Experimental|Discovery cohort|"The second group, the discovery cohort, will be composed of 30 undiagnosed symptomatic patients with clinical suspicion of a genetic disease (both children and adults with onset in infancy or early adulthood) referred to the Clinical Research Center for Rare Diseases Aldo e Cele Daccò, and for which WES analyses did not reveal any causative genetic alteration. To this end, the investigators plan to recruit around 60 patients, their available parents and/or their available informative relatives who will undergo WES, if not previously done. On the basis of literature and their experience, the investigators expect that WES will be resolutive in 40-50% of cases. Consequently, investigators hypothesize to identify 30 patients with a negative WES who will enter the discovery RNA-Seq cohort."
89239660|NCT05985122|Experimental|Patients|"Patients diagnosed with C3G (15 positive and 15 negative for C3NEF) at Centro Daccò, will be identified between those who provided consent to store their samples in the certified biobank (UNI EN ISO 9001:2015; certification n° 6121) of Centro Daccò (Centro di Risorse Biologiche Mario Negri - Biobanca Malattie Rare e Renali) and to share them with external laboratories."
89239661|NCT05985122|Active Comparator|Healthy controls|"Healthy donors will be identified between those who provided consent to store their samples in the certified biobank (UNI EN ISO 9001:2015; certification n° 6121) of Centro Daccò (Centro di Risorse Biologiche Mario Negri - Biobanca Malattie Rare e Renali). Subject that meet the inclusion/exclusion criteria and for which there is no enough material stored in our biobank, will be recontacted by the investigators of Centro Daccò and, if agree, will be asked for serum sampling after informed consent signature."
89239662|NCT05980507|Experimental|ICI201|
89239663|NCT05976230||Entresto|Patients administered Entresto by prescription
89239664|NCT05974722|Other|Mesh-based crural reinforcement|Patient will receive Ovitex mesh to reinforce the crural repair
89239665|NCT05974722|Other|Pledgeted suture-based crural reinforcement|Patient will receive pledgeted sutures to reinforce the crural repair
89239666|NCT05968326|Experimental|Arm 1: Autogene Cevumeran + Atezolizumab + mFOLFIRINOX|Participants will receive autogene cevumeran, atezolizumab and mFOLFIRINOX.
89239667|NCT05968326|Active Comparator|Arm 2: mFOLFIRINOX|Participants will receive mFOLFIRINOX.
89239668|NCT05966584|Experimental|Benralizumab and PI3K inhibition (alpelisib)|Patients will receive fulvestrant or AIs and PI3K inhibition (alpelisib) per SOC (fulvestrant on days 1, 15, 29 and monthly thereafter; Ais on a daily continuous basis). Participants will receive one injection of benralizumab 30mg subcutaneously on day -1.
89239669|NCT05966272|Experimental|Treatment group A|HRS9531 injection dose level 1
89239670|NCT05966272|Experimental|Treatment group B|HRS9531 injection dose level 2
89239671|NCT05966272|Experimental|Treatment group C|HRS9531 injection dose level 3
89239672|NCT05966272|Experimental|Treatment group D|HRS9531 injection dose level 4
89239673|NCT05966272|Placebo Comparator|Treatment group E|HRS9531 injection Placebo dose level 1
89239674|NCT05966272|Placebo Comparator|Treatment group F|HRS9531 injection Placebo dose level 2
89239675|NCT05966272|Placebo Comparator|Treatment group G|HRS9531 injection Placebo dose level 3
89239676|NCT05966272|Placebo Comparator|Treatment group H|HRS9531 injection Placebo dose level 4
89239677|NCT05964504||Initial Cohort|Up to 12 participants at each evaluation timepoint (approximately every 3-6 months to follow standard of care visits) will have up to 40 mL of blood drawn and distributed into 8 cell-free DNA Streck tubes, for plasma isolation, cell free DNA extraction, and ctDNA analysis. Blood for ctDNA analysis will be collected within +/- 14 days of whole body imaging studies which will occur when patients are scheduled for standard of care whole body imaging.
89239678|NCT05962164|Experimental|Passive Heat Therapy|Patients with COPD assigned to passive heat therapy will have their lower legs immersed in a circulating hot water (~42°C) footbath for 45 min per session.
89239679|NCT05962164|Sham Comparator|Sham Immersion|Patients with COPD assigned to the sham condition will have their lower legs immersed in a circulating thermoneutral (~36°C) footbath for 45 min per session.
89239680|NCT05960604||Low cardiac reserve/efficiency|Patients who were identified as having low cardiac reserve and efficiency, based on PRAM parameters.
89239681|NCT05960604||Normal cardiac reserve/efficiency|Patients who were identified as having normal cardiac reserve and efficiency, based on PRAM parameters.
89239682|NCT05940974||Shoulder arthroplasty|All adult patients undergoing primary total shoulder replacement surgery at the Traumatology, Orthopedics and Joint Pathology Clinic of the I.M. Sechenov First Moscow State Medical University (Sechenov University) who meet the inclusion criteria (described below) will be included.
89239683|NCT05933824|Experimental|PartA:Dose level(5mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
89239684|NCT05933824|Experimental|PartA:Dose level(10mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
89239685|NCT05933824|Experimental|PartA:Dose level(20mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
89239686|NCT05933824|Experimental|PartA:Dose level(40mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
89239687|NCT05933824|Experimental|PartA:Dose level(80mg)|Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
89239688|NCT05933824|Experimental|PartB:Dose level(5mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
89239689|NCT05933824|Experimental|PartB:Dose level(10mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
89239690|NCT05933824|Experimental|PartB:Dose level(20mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
89239691|NCT05933824|Experimental|PartB:Dose level(40mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
89239692|NCT05933824|Experimental|PartB:Dose level(80mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
89239693|NCT05933824|Experimental|PartB:Dose level(160mg)|Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
89239694|NCT05921981|Experimental|Multisensorial Stimulation Group|The group to which multi-sensory stimulation will be applied during the retinopathy examination.
89239695|NCT05921981|Active Comparator|White Noise Group|The group to which White Noise will be applied during the retinopathy examination.
89239696|NCT05921981|No Intervention|Control Group|The group that will receive routine care during the retinopathy examination
89239697|NCT05921253|Placebo Comparator|Self administration of Low Level Tragus Stimulation (LLTS; Placebo)|PARASYM neuromodulation device will be placed in a pre-determined position of one ear for 1 hour every day for 14 days.
89239698|NCT05921253|Experimental|Self administration of LLTS|PARASYM neuromodulation device will be placed in a pre-determined position (different from that of the placebo) of one ear for 1 hour every day for 14 days.
89239699|NCT05904886|Experimental|Atezolizumab + Bevacizumab + Tiragolumab|Atezolizumab plus bevacizumab plus tiragolumab will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89239700|NCT05904886|Placebo Comparator|Atezolizumab + Bevacizumab + Placebo|Atezolizumab, bevacizumab plus placebo will be administered every 3 weeks (Q3W) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89239701|NCT05900479|Experimental|PTSD Service Dog|
89239702|NCT05900479|No Intervention|Usual Care|
89239703|NCT05896748|Experimental|Participants receiving CAB LA + RPV LA|Participants will receive SC abdominal injection of CAB LA and RPV LA on Day 1 of every 4 weeks for a total of 12 weeks during the SC abdominal injection phase and will return to the clinic 4 weeks later to receive their first IM gluteal injections (at Week 12) of CAB LA and RPV LA during the return to gluteal injection phase. Subsequent gluteal injection with CAB LA and RPV LA will occur 4 weeks later for 4 weeks later at Week 16.
89239704|NCT05888532|Experimental|Cohort A: 64Cu-GRIP B, Metastatic GU malignancies|Participants with metastatic GU malignancy (renal, urothelial, or prostate) (3 males, 3 females), dosimetry calculation will be performed by obtaining whole body (vertex to thighs) PET images up to five time points from 0.5 to 24 hours post 64Cu-GRIP B injections. An additional intravenous line will be placed in the contra-lateral arm to collect blood for this group.
89239705|NCT05888532|Experimental|Cohort B: 64Cu-GRIP B, RCC and UC participants|Participants with renal cell and urothelial carcinoma will have longitudinal imaging performed prior to treatment outside of this study with anti-programmed death-1 (PD-1)/anti-PD-1 ligand 1 (PD-L1) blockade (with or without concomitant anti-CTLA4 treatment), after 8 weeks of checkpoint blockade, and again at the time of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
89239706|NCT05888532|Experimental|Cohort C: 64Cu-GRIP B, mCRPC participants|Participants with metastatic castration resistant prostate cancer (mCRPC)) will have longitudinal imaging performed prior to treatment outside of this study, 8 weeks following initiation of treatment outside of this study, and at the time of disease progression by Prostate Cancer Working Group 3 (PCWG3) criteria.
89239707|NCT05888532|Experimental|Cohort D: 64Cu-GRIP B, Advanced malignancies|participants with solid tumor malignancies will have longitudinal imaging performed prior to treatment outside of this study, 8 weeks following initiation of treatment, and the opportunity to have an optional scan at the time of progression.
89239708|NCT05876767|Experimental|SAR444336|SAR444336
89239709|NCT05876767|Placebo Comparator|Placebo|placebo
89239710|NCT05870098|Other|All participants|"All participants will receive:~Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
89239711|NCT05868525|Active Comparator|Oral Daily Aspirin 81 mg|
89239712|NCT05868525|Active Comparator|Oral Daily Aspirin 325 mg|
89239713|NCT05856695|Experimental|Carboplatin + Paclitaxel + Durvalumab|Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
89239714|NCT05847140||Evusheld exposed pregnancies|A pregnancy is considered exposed to EVUSHELD if 1 of 2 conditions are met: (1) EVUSHELD was received during the 36-week period [reflective of roughly 3 half-lives of EVUSHELD] prior to LMP, or (2) EVUSHELD was received on/after LMP during the exposure ascertainment period, which will vary based on the outcome of interest.
89239715|NCT05840354|Active Comparator|active repetitive transcranial magnetic stimulation + steroid joint injection|"Active transcranial stimulation will be delivered for a total of 11 sessions. Each session will consist of 40 trains of 5s delivered at 10 Hz, at an intensity of 85% of the resting motor threshold for the first dorsal interosseous muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session).~The steroid joint injection will be given 1-4 week before rTMS begins. A dose of 0.5mL of 40mg/mL triamcinolone and 0.5mL of 2% lidocaine will be given per joint via spinal needle. The treatment team will determine how many joints will be injected based on their standard clinical assessment. Usually, about 2-4 joints are injected depending on a person's pain presentation. Standard practice is to place the needle in the region of the steroid joint opening, resulting in a peri- +/- intra-articular infusion of the injectate. This project will utilize standard clinical practice without modification."
89239716|NCT05840354|Sham Comparator|sham repetitive transcranial magnetic stimulation + steroid joint injection|"The sham repetitive transcranial magnetic stimulation coil will be delivered using a sham coil of identical colour, size, and shape as the active rTMS coil. The sham coil uses a magnetic shield that blocks the magnetic field from being delivered to the scalp while producing a similar auditory click during discharge. All other aspects of the rTMS protocol will be identical between the active and sham conditions.~The steroid joint injection will be given 1-4 week before sham rTMS begins and will also follow the same protocol as the active rTMS group."
89239717|NCT05838781|No Intervention|General/control|Standard of care.
89239718|NCT05838781|Experimental|General/intervention|Standard of care plus 14-days continuous ECG monitoring using an ECG patch.
89239719|NCT05838781|Experimental|Risk prediction model/control|Standard of care.
89239720|NCT05838781|Experimental|Risk prediction model/intervention|Standard of care plus 14-days continuous ECG monitoring using an ECG patch.
89239721|NCT05836688|Experimental|Goal-Focused Emotion-Regulation Therapy (GET)|A novel behavioral intervention to enhance self-regulation through improved goal navigation skills, improved sense of purpose, and better ability to regulate emotional responses in young adults with testicular cancer.
89239722|NCT05836688|Active Comparator|Individual Supportive Listening|Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience.
89239723|NCT05830409|Experimental|Multisensorial Stimulation Group|Preterm newborns who will receive multisensory stimulation during the eye examination.
89239724|NCT05830409|No Intervention|Control Group|Preterm newborns who will receive routine care during the eye examination
89239725|NCT05822921|Experimental|In-person Psychoeducation|
89239726|NCT05822921|Experimental|Telehealth Psychoeducation|
89239727|NCT05822921|Active Comparator|Psychoeducation as Usual|
89239728|NCT05817656|Experimental|Intervention group|After polypectomy with a suitable method, either cold snare polypectomy, hot snare polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection, we will monitor if immediate polypectomy bleeding occurs. If immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine, heater probe coagulation, and/or hemoclipping. If there is no immediate bleeding, we will apply prophylactic clipping in high-risk patients with polyp size ≥ 1cm. After then, we will spray 3g of sucralfate powder through colonoscopy precisely on the polypectomy wound in the intervention group.
89239729|NCT05817656|No Intervention|Control group|After polypectomy with a suitable method, either cold snare polypectomy, hot snare polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection, we will monitor if immediate polypectomy bleeding occurs. If immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine, heater probe coagulation, and/or hemoclipping. If there is no immediate bleeding, we will apply prophylactic clipping in high-risk patients with polyp size ≥ 1cm.
89239730|NCT05817539|Experimental|Corrective strategy|In the experimental group, all patients will have a UFnet settled (2 ml/kg/h ) in order to reach the patient baseline body weight.
89239731|NCT05817539|Other|Stabilizing strategy|In the control group, all patients will have a UFnet 2 ml settled (0 to 1 ml/kg/h) in order to stabilize the patient body weight.
89239732|NCT05802914|Experimental|Exosuit|Exosuit refers to a soft active back exosuit. Participants in the exosuit arm will be fitted to a personal back exosuit device. Participants will be trained on how to use the device (retrieval, donning, powering up, mode switching, and doffing). Participants will be instructed to use the device at work, emphasizing they wear it whenever it seems practical (e.g. lifting) for as long as it remains comfortable. Associates from Verve Motion will check in with exosuit participants to address comfort issues and help participants integrate the exosuit into their workday.
89239733|NCT05802914|No Intervention|Control|Control participants will not be assigned a back exosuit. Participants in the control group will perform workplace tasks as normal, completing study surveys at baseline and monthly for 4 months that are identical to exosuit group.
89239740|NCT05796518|Experimental|PREVENT - Cardiovascular Health Assessment Tool|An adapted version of the PREVENT tool for endometrial cancer survivors will be used collect data during routine follow-up care for endometrial cancer that will yield a cardiovascular health score based on the Simple 7 risk factors (current smoking habits, body mass index, physical activity, diet, cholesterol, blood pressure and fasting plasma glucose).
89239741|NCT05794191||Persons living with HIV (PLWH)|Adults with HIV
89239742|NCT05763576|Experimental|RO7565020|
89239743|NCT05763576|Placebo Comparator|Placebo|
89239744|NCT05761158||patient|patients answer the same questionnaire whether they have frontal alopecia or lichen planus pilaris
89239745|NCT05757817|Experimental|Patient with an ORL Cancer|
89239746|NCT05756179|Active Comparator|Intervention group|Diosmin 450 mg and Hesperidin 50 mg Combination /tablet/ twice daily for 3 months + Conventional Therapy (Methotrexate)
89239747|NCT05756179|No Intervention|Control group|Conventional Therapy (Methotrexate) only
89239748|NCT05755139|Experimental|IPL with smart diagnostic handpiece|"Standard IPL module which has FDA clearance (K083733) for a wide range of indications including vascular and pigmented lesions. The Universal IPL handpiece (HP) operates at a spectrum of 400-1,200 nm with 7 different cut-off filters and 2 different notch filters that can be easily inserted into the handpiece to treat different conditions.~The SMART Camera is a novel add-on skin diagnostic (SD) tool. The SD module includes a proprietary spectral camera embedded in a handpiece, and proprietary computer vision-based algorithms designed to process the spectral information and to determine the skin attributes and optimal treatment IPL preset."
89239749|NCT05752201|Experimental|Gamma variant vaccine (Phase 2 and Phase 3)|Participants will be included in this group during phase 2 and phase 3. All participants will receive one dose of gamma variant vaccine and one dose of placebo 28 days apart, in a crossover design.
89239750|NCT05752201|Experimental|Omicron variant vaccine (Phase 3)|Participants will be included in this group during phase 3. All participants will receive one dose of omicron variant vaccine and one dose of placebo 28 days apart, in a crossover design.
89239751|NCT05752201|Experimental|Bivalent vaccine (gamma and omicron variants) (Phase 3)|Participants will be included in this group only during phase 3. All participants will receive one dose of bivalent gamma omicron vaccine and one dose of placebo 28 days apart, in a crossover design.
89239752|NCT05749393|Experimental|Low-dose group|The initial dose was 50U/kg intravenous injection, and the dosage was halved by intravenous injection every 1 hour to the minimum 1000u/h. The medication will be discontinued at the end of the procedure.
89239753|NCT05749393|Experimental|High-dose group|The initial dose was 70U/kg intravenous injection, and the dosage was halved by intravenous injection every 1 hour to the minimum 1000u/h. The medication will be discontinued at the end of the procedure.
89239754|NCT05733390|Experimental|JZP541|Participants who will be randomized to receive JZP541.
89239755|NCT05733390|Placebo Comparator|Placebo|Participants who will be randomized to receive placebo.
89239756|NCT05717738||TACE-Len-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus lenvatinib (Len) and anti-PD-1 antibody as conversion therapy for downstaging.
89239757|NCT05717738||TACE-A-T cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus bevacizumab (A) and atezolizumab (T) as conversion therapy for downstaging.
89239758|NCT05717738||TACE-B-S cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus bevacizumab biosimilar (Byvasda, B) and Sintilimab (Tyvyt, S) antibody as conversion therapy for downstaging.
89239759|NCT05717738||TACE-Apa-C cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus Apatinib (Apa) and Camrelizumab (C) antibody as conversion therapy for downstaging.
89239760|NCT05717738||TACE-Sor-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus sorafenib (Sor) and anti-PD-1 antibody as conversion therapy for downstaging.
89239761|NCT05717738||TACE-Don-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus donafenib (Don) and anti-PD-1 antibody as conversion therapy for downstaging.
89239762|NCT05717738||TACE-Reg-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined TACE plus regorafenib (Reg) and anti-PD-1 antibody as conversion therapy for downstaging.
89239763|NCT05715086|Active Comparator|Group A (Upfront ureteroscopy)|
89239764|NCT05715086|No Intervention|Group B (Observation/delayed ureteroscopy)|
89239765|NCT05713994||HAIC-A-T cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus bevacizumab (A) and atezolizumab (T) as conversion therapy for downstaging.
89239766|NCT05713994||HAIC-Len-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus lenvatinib (Len) and anti-PD-1 antibody as conversion therapy for downstaging.
89239767|NCT05713994||HAIC-B-S cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus bevacizumab biosimilar (Byvasda, B) and Sintilimab (Tyvyt, S) antibody as conversion therapy for downstaging.
89239768|NCT05713994||HAIC-Apa-C cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus Apatinib (Apa) and Camrelizumab (C) antibody as conversion therapy for downstaging.
89239769|NCT05713994||HAIC-Sor-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus sorafenib (Sor) and anti-PD-1 antibody as conversion therapy for downstaging.
89239770|NCT05713994||HAIC-Don-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus donafenib (Don) and anti-PD-1 antibody as conversion therapy for downstaging.
89239771|NCT05713994||HAIC-Reg-ICI cohort|Patients with advanced hepatocellular carcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus regorafenib (Reg) and anti-PD-1 antibody as conversion therapy for downstaging.
89239772|NCT05709860|No Intervention|Usual Care|Usual care includes: 1) no specific materials to promote PrEP knowledge or uptake among women in primary care, and 2) variable physician counseling on PrEP among women with increased vulnerability to HIV.
89239773|NCT05709860|Active Comparator|The EMC2 PrEP Strategy|The EMC2 PrEP Strategy will utilize health information and consumer technologies to automatically deposit an interactive PrEP educational material into the patient portal of women with clinically indicated increased vulnerability to HIV. The material will: 1) promote PrEP knowledge, and 2) prompt discrete scheduling of a dedicated PrEP visit among those interested.
89239774|NCT05703399||Observational (biospecimen collection, questionnaire)|Patients undergo collection of blood samples and complete questionnaires throughout the study. Patients may also undergo the collection of tissue samples throughout the study.
89239775|NCT05702138|Active Comparator|Conventional Gait and Balance Training (CGBT)|The current approach for walking retraining, Conventional Gait and Balance Training (CGBT) focuses on walking training in a variety of conditions, obstacle management training, functional independence training, strength training, and standing dynamic balance training.
89239776|NCT05702138|Experimental|High Intensity Step Training (HIST)|High Intensity Step Training (HIST) focuses on the repetition of stepping at higher cardiovascular intensities and yielding a greater number of steps per training session.
89239777|NCT05702138|Experimental|High Intensity Step Training with Virtual Reality (HISTVR)|The third arm combines virtual reality with HIST, designed to increase cortical excitability while concurrently activating the neuromuscular system.
89239778|NCT05695573||Controlgroup|25 healthy volunteer as a control
89239779|NCT05695573||diabetic patients with normoalbuminuria|Consisted of 25 type 2 diabetic patients with normoalbuminuria (levels <30 mg/g creatinine)
89239780|NCT05695573||diabetic patients with microalbuminuria|Consisted of 25 type 2 diabetic patients with microalbuminuria (between 30-300 mg/g creatinine).
89239781|NCT05695573||diabetic patients with macrolbuminuria|Consisted of 25 type 2 diabetic patients with macroalbuminuria (levels >300 mg/g creatinine)
89239782|NCT05674487|Experimental|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
89239783|NCT05674487|Active Comparator|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
89239784|NCT05660330|Experimental|Holistic semi-tailormade well-being (intervention) group|They receive the holistic semi-tailormade intervention, consisting of training and workshops in three well-being domains: psychosocial, ergonomic and lifestyle. In addition to this intervention, they still receive their standard interventions
89239785|NCT05660330|No Intervention|Standard well-being (control) group|At first, they receive standard well-being interventions. After six or twelve months, this group can participate in the holistic semi-tailormade well-being intervention.
89239786|NCT05656508|Experimental|25 µg of antigen|Volunteers will receive 2 doses of ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2) of 25 µg of antigen, separated by 28 days
89239787|NCT05656508|Experimental|50 µg of antigen|Volunteers will receive 2 doses of ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2) of 50 µg of antigen, separated by 28 days
89239788|NCT05651594|Experimental|Treatment (mFOLFOX6, pembrolizumab, propranolol)|Patients receive mFOLFOX6 (leucovorin IV, oxaliplatin IV, and fluorouracil IV), pembrolizumab IV, and propranolol PO on study. Patients also undergo tumor biopsy during screening and CT scans and collection of blood samples during screening and on study.
89239789|NCT05645432|Experimental|Brexanolone|Participants will receive a continuous, 6-hour IV infusion of Brexanolone on Day 1 of the Treatment Period.
89239790|NCT05642988||Adult patients being discharged from hospital following intra-abdominal or pelvic surgery|Patient compliance with wearable biosensor monitoring after major intracavity surgery. The remote monitoring is made up of a wearable biosensor and a data-enabled relay device which will detect vital sign observations (ECG, heart rate, temperature and respiratory rate) and a health status assessment questionnaire.
89239791|NCT05641987|Experimental|Educator Well-being Program|Staff at participating schools will experience the Educator Well-being Program process and complete pre- and post-intervention survey.
89239792|NCT05641987|Active Comparator|Delayed Intervention|Status quo program remains in place with new ongoing data collection, then experimental intervention as above.
89239793|NCT05636124|Experimental|Kaneka i-ED coil|Patients in the experimental arm will be treated according to the standard of care for endovascular aneurysm coiling, with no procedural modifications related to the use of the experimental device.
89239794|NCT05636124|No Intervention|Matched patients who underwent intracranial aneurysm embolization|The comparator arm will be comprised of propensity matched patients who underwent intracranial aneurysm embolization as part of the FEAT Trial (NCT01655784).
89239795|NCT05631041|No Intervention|Control group|Group I (Control group ; n=32) which will receive FOLFIRI regimen (5-flourouracil, leucovorin, irinotecan) or XELIRI (Capecitabine and irinotecan) with or without target therapy (Bevacizumab).
89239796|NCT05631041|Active Comparator|Silymarin group|Group II: (Silymarin group ; n=32) which will receive FOLFIRI regimen (5-flourouracil, leucovorin, irinotecan) or XELIRI (Capecitabine and irinotecan) with or without target therapy (Bevacizumab). plus silymarin 140 mg once daily.
89239797|NCT05630690|Experimental|IPL with smart diagnostic handpiece|"Standard IPL module which has FDA clearance (K083733) for a wide range of indications including vascular and pigmented lesions. The Universal IPL handpiece (HP) operates at a spectrum of 400-1,200 nm with 7 different cut-off filters and 2 different notch filters that can be easily inserted into the handpiece to treat different conditions.~The SMART Camera is a novel add-on skin diagnostic (SD) tool. The SD module includes a proprietary spectral camera embedded in a handpiece, and proprietary computer vision-based algorithms designed to process the spectral information and to determine the skin attributes and optimal treatment IPL preset."
89239798|NCT05616221|Experimental|AP-PA02|Anti-pseudomonal bacteriophage
89239799|NCT05616221|Placebo Comparator|Placebo|Inactive isotonic solution
89239800|NCT05612490||Critically ill patients undergoing RRT|Patients admitted to participating ICU and receiving renal replacement therapy.
89239801|NCT05610735|Experimental|Combination of DOXIL and Ashwagandha|"The study contains two parts. In part 1 (Phase I), 18 patients with recurrent ovarian cancer will be recruited and administered IV with liposomal doxorubicin (DOXIL) 40 mg/m2 on day 1 of 28 days cycle for 4 cycles. Ashwagandha will be administered on daily basis for 2 years. Three doses of Ashwagandha (2 g, 4 g or 8.0 g) will be administered orally with water every day for two years to evaluate a tolerable dose of Ashwagandha. Six patients will be recruited for each dose.~In part 2 Phase II), 54 additional patients with recurrent ovarian cancer will be recruited and administered with DOXIL IV (40 mg/m2) and maximum tolerable dose of Ashwagandha (determined from part 1) in the form tables orally with water on daily basis for two years. The survival rate (SR), complete response (CR) and partial response (PR) will be evaluated."
89239802|NCT05597917|Active Comparator|Arm 1: Standard chemotherapy with trabectidin (in-label)|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
89239803|NCT05597917|Experimental|Arm 2: tTF-NGR added to standard trabectedin|Patients will receive standard trabectedin according to arm 1 plus the safe dose according to safety run-in part of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days, q d 22 x until disease progression or contraindications against further application.
89239804|NCT05595577|Experimental|Physical Activity Intervention|Participants will have the ability to attend one to two training sessions per week and 1-2 sessions per week at home (the 4th level of our multi-level intervention) or the location site using the Trainerize application to deliver the exercise prescription.
89239805|NCT05595577|Experimental|Healthy Living Intervention (Control Arm)|Participants randomized to the control arm will participate in organized health workshops. Each session will last 60 minutes and will be offered on location and virtually (e.g., Zoom) over 6 months. Participants will meet once a week for the first 4 weeks, biweekly for 3 months, and once a month for the last 2 months for a total of 12 sessions.
89239806|NCT05590078|Other|Control group|General routine care. This group will undergo to ambulatory surgery without preoperative virtual reality session. Will be applied the usual treatment to reduce preoperative anxiety.
89239807|NCT05590078|Experimental|Virtual reality group|Virtual Reality. This group will undergo to 20 min virtual reality before ambulatory surgery. In addition to virtual reality session, will be applied the usual treatment to reduce preoperative anxiety, after virtual reality, if necessary.
89239808|NCT05589610|Experimental|EQ101|EQ101 weekly
89239809|NCT05580991|Experimental|CAN1012|CAN1012 intratumoral injection given alone
89239810|NCT05571488||Healthcare professionals|All type of healthcare professionals (HCPs), working in a variety of settings and across Switzerland
89239811|NCT05571488||Informal caregivers|All type of informal caregivers (ICs), assisting a person for health reasons across Switzerland
89239812|NCT05570565|Experimental|Erector spinae plane group|"The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear ultrasound transducer will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 20 mL of local anesthestic mixture of 0.25% bupivacaine and 1%lidocaine adrenaline (1;200000) will be injected. The procedure will be repeated following the same steps on the other side.~The surgical intervention will be then allowed 20 minutes after finishing the block procedure"
89239813|NCT05570565|Active Comparator|local field block|For the preincisional local field block, a 23-gauge needle is used to infiltrate 20mL of local anesthestic mixture of 0.25% bupivacaine and 1%lidocaine adrenaline (1;200000) will be injected in the subcutaneous space and in the paravertebral muscles on each side of the spinous processes of the presumed surgical approach.
89239814|NCT05566756||Ofatumumab|Patients prescribed with ofatumumab
89239815|NCT05553223|Experimental|Microdoses of Activity|5-min bouts of walking will break up 3 hours of sitting at minutes 30, 90 and 150.
89239816|NCT05553223|No Intervention|Control|Prolonged sitting (3 hours)
89239817|NCT05549635||Patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP)|"The overall inclusion criteria of patients in the HP cohort are:~Diagnosis of HP at an MDT conference according to the current international guidelines~Age of 18 years or older~The patients must be capable of giving informed consent"
89239818|NCT05548907|Experimental|Sleep restriction treatment|In this condition participants receive a behavioral sleep restriction intervention for six weeks
89239819|NCT05548907|Placebo Comparator|Sleep monitoring|In this control condition people fill out a sleep diary for six weeks
89239820|NCT05533112|No Intervention|Control|Control Group, no Intervention received
89239821|NCT05533112|Experimental|Preop Stimulation|Binaural Beat Stimulation preoperatively
89239822|NCT05533112|Experimental|Postop Stimulation|Binaural Beat Stimulation postoperatively
89239823|NCT05533112|Experimental|Pre- & Postop Stimulation|Binaural Beat Stimulation pre- and postoperatively
89239824|NCT05527379|Experimental|CIP procedure under virtual reality|CIP procedure under virtual reality
89239825|NCT05517044|Experimental|Preacclimatization group|The participants assigned to the preacclimatization group will undergo a defined preacclimatization program by sleeping in a nitrogen concentration tent prior to an expedition to high altitude.
89239826|NCT05517044|No Intervention|Control group|The participants assigned to the control group sleep in their regular environment without use of a nitrogen concentration tent prior to an expedition to a high altitude expedition.
89239827|NCT05516563|Active Comparator|EDucation and eXercise intervention (EDX)|EDX-Ireland will involve 6 face-to-face education and exercise sessions on a individualised basis with a physiotherapist, delivered over eight weeks. This will be supplemented by a home based exercise programme.
89239828|NCT05516563|No Intervention|Usual Care|"Participants will continue to follow what they have done so far for their hip pain, or what their doctor has suggested/prescribed. If a participant is referred to physiotherapy as part of the usual care treatment, waiting time will be recorded.~Participants will receive a written information leaflet on the pathology of gluteal tendinopathy and general advice on symptom management."
89239829|NCT05513534|Experimental|Standard Hatha Yoga|A yoga program adapted for those with PD will be used in the current study. It will be conducted over a 16-week period and consists of twice-weekly sessions lasting approximately one hour. The program will be based on principles of Hatha yoga which incorporate longer holds and deep breathing. Each session will include a warm-up, three yoga flows, a balance training section, and a cooldown phase. The first four weeks will emphasize proper alignment, breathing, and technique. Additionally, the classes will be led by a certified yoga instructor and include multiple on-site assistants to ensure a safe training environment. Participants will also be provided with assistive devices (i.e. chairs, yoga blocks, and blankets) if they are required.
89239830|NCT05513534|Experimental|Power Resisatnce Training|: A high-velocity resistance (power) will be conducted over a 16-week period and consists of twice-weekly sessions lasting approximately one hour. Each training session will begin with a brief warm-up. Each session will consist of three sets of 10 repetitions each with 1.5 to 2- to minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds. Exercise order will be randomized during each session and upper and lower body exercises will be alternated whenever possible.
89239831|NCT05513261|Other|Control arm: High definition colonoscopy|Diagnostic test: Standard colonoscopy
89239832|NCT05513261|Experimental|PolyDeep assisted high definition colonoscopy|Diagnostic test: PolyDeep
89239833|NCT05505214|Experimental|Bacterial decolonization|Validated decolonization regimen
89239834|NCT05505214|Experimental|Topical corticosteroid|Mometasone furoate 0.1% cream
89239835|NCT05505214|Experimental|Combination|Validated decolonization regimen and mometasone furoate 0.1% cream
89239836|NCT05495386|Experimental|Hyposafe H02 Device|Hyposafe H02 Device will be used in the study
89239837|NCT05493670||DBS-STN|The DBS-STN group will consist of individuals with Parkinson's disease who have already elected to undergo deep brain stimulation surgery.
89239838|NCT05493670||Control|The control group will consist of individuals with Parkinson's disease who are not undergoing deep brain stimulation placement. No interventions will be completed with the control group.
89239839|NCT05493566|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients will be treated with pembrolizumab 200 mg IV once every 3 weeks in combination with IL-2 given at 5 million IU subcutaneously twice daily for 3 weeks (5 days on, 2 days off each week, first dose in clinic and subsequent doses at home). IL-2 will be given only for the three weeks, after which pembrolizumab will be continued as monotherapy at either 200 mg every 3 weeks or 400 mg every 6 weeks.
89239840|NCT05492513|Experimental|Grade 1 CI Therapy + Sensory Components|All participants will receive the Grade 1 CI Therapy + Sensory Components administered over a two-week period of time.
89239841|NCT05488678|Experimental|Group 1 - Control|Healthy control participants will be matched by gender, age, and BMI to participants with renal impairment
89239842|NCT05488678|Experimental|Group 2 - Mild Renal Impairment|Mild Renal Impairment
89239843|NCT05488678|Experimental|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
89239844|NCT05488678|Experimental|Group 4 - Severe Renal Impairment|Severe Renal Impairment
89239845|NCT05488678|Experimental|Group 5 - End Stage Renal Disease|End Stage Renal Disease undergoing chronic intermittent hemodialysis
89239846|NCT05487248|Experimental|Unresectable locally advanced or metastatic colorectal cancer patients|"● Samples collection:~Collection of blood samples 6 x 9 ml at day 1~Collection of blood samples 4 x 9 ml at day 15 and day 29~Collection of blood samples 4 x 9 ml at week 8 or 12 and every 8 or 12 weeks thereafter (+/- 7 days) until evidence of progressive disease by RECIST 1.1 (according to local assessment)"
89239847|NCT05482802|Active Comparator|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short-lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
89239848|NCT05482802|Placebo Comparator|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
89239849|NCT05481879|Experimental|Placebo-Controlled MAD Period: DYNE-101|Participants will be randomized to receive ascending doses of DYNE-101, once every 4 weeks (Q4W) or once every 8 weeks (Q8W) for up to 24 weeks.
89239850|NCT05481879|Placebo Comparator|Placebo-Controlled MAD Period: Placebo|Participants will be randomized to receive DYNE-101 matching placebo, Q4W or Q8W for up to 24 weeks.
89239851|NCT05481879|Experimental|Treatment Period: DYNE-101|"Participants who receive DYNE-101 in Placebo-Controlled Period will continue to receive DYNE-101, Q4W or Q8W for up to 24 weeks.~Participants who receive placebo in Placebo-Controlled Period will receive DYNE-101, Q4W or Q8W for up to 24 weeks."
89239852|NCT05481879|Experimental|Long-Term Extension Period: DYNE-101|Participants will receive DYNE-101, Q4W or Q8W for up to 96 weeks.
89239853|NCT05469945||Observational cohort|Patients diagnosed with curable gynaecologic cancer and accepting to participate before start of any gyneco-oncologic treatment.
89239854|NCT05469945||Interventional subgroup|Patients in the observational cohort, who develop early stage lymphedema (ISL stage 0-1): they will enter a randomized non-blinded interventional subgroup, comparing standard of care preventive measures only or in combination with compressive garments (compression class II)
89239855|NCT05468359|Other|Treatment|All participants will receive Atezolizumab, Bevacizumab,Sorafenib and cyclophosphamide until maximum tolerated dose is reached.Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.
89239856|NCT05467150|Experimental|Probiotic Supplement|Participants (mothers) randomized to this arm will take one Culturelle® Digestive Daily Probiotic Capsule per day from study enrollment through the first postpartum month. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG
89239857|NCT05467150|No Intervention|No intervention|Participants (mothers) randomized to this arm will agree to continue not taking any over the counter probiotic supplements from study enrollment through the first postpartum month.
89239858|NCT05462613|Experimental|Experimental|Regorafenib + metronomic Capecitabine + metronomic Cyclophosphamide + low-dose Aspirin followed by second line of chemotherapy (Bevacizumab + FOLFOX or FOLFIRI)
89239859|NCT05462613|Active Comparator|Control|Second line of chemotherapy (Bevacizumab + FOLFOX or FOLFIRI)
89239860|NCT05452668|Experimental|Group I|Seventeen patients will receive treatment using the red wavelength (660 nm) to provide biostimulation. Plus the current protocol (antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file.
89239861|NCT05452668|Experimental|Group II|Seventeen patients will receive treatment using the infrared wavelength (970 nm) to provide biosstimulation. plus the current protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file.
89239862|NCT05452668|Sham Comparator|Group III|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
89239863|NCT05444257|Experimental|VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA once daily.
89239864|NCT05407363|Experimental|ABB and ATG with simultaneous implant placement|Using ABB with ATG to fill the gap around simultaneously placed dental implants
89239865|NCT05407363|Experimental|XBB and ATG with simultaneous implant placement|Using XBB with ATG to fill the gap around simultaneously placed dental implants
89239866|NCT05407363|Active Comparator|ABB and ABG with immediate implant|Using ABB with ABG to fill the gap around immediately placed dental implants
89239867|NCT05392946|Experimental|Treatment (iberdomide, bortezomib, dexamethasone, daratumumab)|"INDUCTION PHASE: Patients receive iberdomide PO QD on days 1-21, bortezomib SC on days, 1, 8, 15, and 22, and dexamethasone PO on days 1, 8, 15, 22. Patients also receive daratumumab SC on days 1, 8, 15, 22 of cycles 1 and 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.~CYCLES 13-36 CYCLES: Patients receive iberdomide PO QD on days 1-21. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity."
89239868|NCT05378737|Experimental|A/1.2mg/kg|Drug：BAT8006 for Injection, 1.2mg/kg, Q3W（Dose escalation study）
89239869|NCT05378737|Experimental|B/2.4mg/kg|Drug：BAT8006 for Injection, 2.4mg/kg, Q3W（Dose escalation study）
89239870|NCT05378737|Experimental|C/ 3.0mg/kg|Drug：BAT8006 for Injection, 3.0mg/kg, Q3W（Dose escalation study）
89239871|NCT05378737|Experimental|D/ 3.6mg/kg|Drug：BAT8006 for Injection, 3.6mg/kg, Q3W（Dose escalation study）
89239872|NCT05378737|Experimental|93mg/m^2 or 84mg/m^2|Drug：BAT8006 for Injection, 93mg/m^2 or 84mg/m^2, Q3W（Dose extension study）
89239873|NCT05372497|Experimental|Conventional physiotherapy plus central nervous system focused treatment group (CP+CNS group)|For the patients participating in the study, a protocol focused on the central nervous system and aimed at reducing hypersensitivity was applied with pain, graded sensory discrimination and graded motor imagery (GMI) training in addition to conventional physiotherapy. Graded sensory dicrimination training includes localization training level 1, localization training level 2 and graphesthesia training. GMI training includes right/left discrimination training, visual imagery, isometric and functional exercises, and mirror therapy. The treatment was applied in 20 sessions, for 45-60 minutes, 5 days a week.
89239874|NCT05372497|Active Comparator|Conventional Physiotherapy Group (CP Group)|In the conventional physiotherapy group of the study, in addition to physiotherapy modalities for 20 sessions, 5 days a week, for 45-60 minutes each session, 5 days a week, electrotherapy, scapular mobilization, passive stretching, stick exercises, finger ladder exercises, pendulum exercises and shoulder flexion, extension, abduction, internal rotation, external rotation strengthening exercises were applied.
89239875|NCT05370391|Experimental|Comprehensive Behavioral Intervention for Tics (CBIT)|"Experimental: Comprehensive Behavioral Intervention for Tics (CBIT) Group~Participants in this group will receive the CBIT intervention for up to 6 weeks."
89239876|NCT05368402|Experimental|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg b.i.d. for 7 cycles of 14 days with an interval of 14 days off, for a total duration of 26 weeks.
89239877|NCT05368402|Placebo Comparator|Placebo|Matching placebo will be administered with the same treatment schedule of the IMP.
89239878|NCT05360329|Experimental|Mild to moderate knee osteoarthritis (Kellgren Lawrence Score 1-3)|Geniculate artery embolization will be performed in all eligible participants.
89239879|NCT05354544|Experimental|SVF for treating scarred vocal folds|Subject identified with scarred vocal folds will have autologous adipose derived SVF harvested and applied to scarred vocal folds.
89239880|NCT05350930||R-CHOP or G-CHOP chemotherapy|Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy
89239881|NCT05337696|Experimental|Participants with vertebral compression fractures|Participants with vertebral compression fractures who have failed conservative care strategies.
89239882|NCT05320445|Experimental|Supportive-expressive group therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
89239883|NCT05320445|No Intervention|Treatment as usual|The treatment as usual group will receive standard care only (which may include an individual psychiatric consultation).
89239884|NCT05314400|Active Comparator|Full Protocol|Routine Primovist MRI
89239885|NCT05314400|Experimental|Abbreviated Protocol|Shortened Primovist MRI
89239886|NCT05309655|Experimental|Near-Complete Estrogen Deprivation Therapy Participants|Participants will receive cardiac imaging stress tests as well as study laboratory tests to monitor for changes in heart as well 30-day at the end of the study along with annual long-term follow up to 5 years from baseline imaging.
89239887|NCT05305794|Experimental|Semaglutide|
89239888|NCT05305794|Active Comparator|Control|
89239889|NCT05300724||Intermediate AMD|Participants with iAMD will be evaluated for the progression of iAMD to more advanced atrophic AMD stages, such as nascent geographic atrophy (nGA) or incomplete retinal pigment epithelium and outer retinal atrophy (iRORA), and subsequently from nGA or iRORA to complete retinal pigment epithelium (cRORA) and outer retinal atrophy or geographic atrophy (GA), on Day 1 and thereafter every 12 weeks up to the end of the Observation Period, approximately 3 years.
89239890|NCT05300152|Experimental|ACTIVA BioACTIVE Base/Liner|is a BioACTIVE glass-incorporated light-curable pulp capping material also known as light-cured resin-modified calcium silicate
89239891|NCT05300152|Active Comparator|Mineral trioxide aggregate (MTA)|is a bioactive materials containing calcium silicate
89239892|NCT05296668|Experimental|Cuffed ETT group|(group C) to receive a cuffed ETT for airway management.
89239893|NCT05296668|Active Comparator|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
89239894|NCT05292131|Experimental|Test|Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-2mL presentation (test).
89239895|NCT05292131|Other|Reference|Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-1x2mL presentation (reference).
89239896|NCT05281718|Experimental|Patient Group|In vitro spiking experiments will be realized in plasmas from patients with severe haemophilia A on emicizumab using increasing concentrations of factor IX (rFIX), Activated prothrombin complex (aPCC) and recombinant VIIa (rFVIIa).
89239897|NCT05281601|Experimental|AZD7442|All participants will receive a single dose of AZD7442 on Day 1, either IM (AZD8895 followed by AZD1061) or IV (AZD8895 + AZD1061 concurrently).
89239898|NCT05251285||Prophylactic Nipple-Sparing Mastectomy|
88804685|NCT01215643|Experimental|ALV 600 mg+PEG|Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
89239899|NCT05233891||Breast reconstruction after breast cancer|Women who have had/have breast cancer and will have/have had a breast reconstruction.
89239900|NCT05233891||Breast reduction|Women who have had/will have a breast reduction due to breast hypertrophy.
89239901|NCT05216224|Experimental|ATI-450|ATI-450 50mg oral tablet BID
89239902|NCT05216224|Experimental|Placebo|Placebo oral tablet BID
89239903|NCT05191238|Experimental|Participants consented for IUD removal|Participants will be shown an educational video about IUD self-removal and simulation models. After the video, participants will be given the choice to either attempt IUD self-removal or to have their provider perform standard removal. If a participant elects to attempt self-removal and fails, their provider will offer standard removal.
89239904|NCT05160025|Other|Virtual Reality Bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
89239905|NCT05155423||group 1|patient using mask for immobilization
89239906|NCT05155423||group 2|patients using Elekta BodyFix
89239907|NCT05151731|Experimental|Arm A: 0.25 mg Vamikibart Q8W|Participants will receive vamikibart 0.25 milligrams (mg), by intravitreal (IVT) injection, on Day 1 and every 8th week (Q8W), up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
89239908|NCT05151731|Experimental|Arm B: 1.0 mg Vamikibart Q8W|Participants will receive vamikibart 1.0 mg, by IVT injection, on Day 1 and Q8W, up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
89239909|NCT05151731|Experimental|Arm C: 1.0 mg Vamikibart Q4W|Participants will receive vamikibart 1.0 mg, by IVT injection, on Day 1 and every 4th week (Q4W), up to Week 44 for a total of 12 injections.
89239910|NCT05151731|Active Comparator|Arm D: 0.5 mg Ranibizumab Q4W|Participants will receive ranibizumab 0.5 mg, by IVT injection, on Day 1 and Q4W, up to Week 44 for a total of 12 injections.
89239911|NCT05143476||Observational group|Follow-up visits will be conducted at 4-6, 7-9, 12-16 and 26-32 weeks, from time of fracture. A participant's doctor will perform routine examination of fracture healing. The assessment will include evaluation of gross fracture site motion and presence or absence of radiographic healing, including a mRUST score.
89239912|NCT05141721|Experimental|Vaccine Arm|After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and after completing vaccine production screening, patients will receive a total of 6 administrations of GRT-C901/GRT-R902 plus ipilimumab co-administered only with the first dose of GRT-C901 and GRT-R902. All patients will receive atezolizumab in addition to maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.
89239913|NCT05141721|Active Comparator|Control Arm|After receiving up to 24 weeks induction therapy with a fluoropyrimidine/oxaliplatin/bevacizumab (with or without irinotecan), per standard of care and undergoing vaccine production screening, patients will receive maintenance therapy of a fluoropyrimidine and bevacizumab according to standard of care.
89239914|NCT05138068|Experimental|MDMA-assisted psychotherapy|Two sessions of manualized MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose 1.5 to 2 hours later. MDMA sessions are preceded by 3 non-drug preparatory psychotherapy sessions and followed by 3 integrative non-drug psychotherapy sessions.
89239915|NCT05138068|Other|Delayed treatment|Participants randomly assigned to the delayed treatment control condition will wait 16 weeks and then receive MDMA-assisted therapy protocol described in the experimental arm of the study.
89239916|NCT05126901|Experimental|1 month to 2 year old subjects (infants)|"Subjects aged 1 month to less than 2 years will enter a Pre-assignment phase: baseline urine samples are collected and subjects will take a single dose of 0.1 ml/kg ferric maltol suspension. Further 3 samples up to 12h will be taken.~Subjects showing evidence of absorption, metabolism and elimination of maltol will enter the treatment phase and be assigned to the ferric maltol arm.~The first 6 subjects screened will perform the pre-assignment PK phase. After review by the investigator, and medical monitors , if Maltol Glucuronide is shown to be adequately eliminated, timepoint 20-24 hrs (+ 4hrs) will not be performed on subsequent subjects.~Subjects will be assigned to receive ferric maltol oral suspension and start the 0.1 ml/kg BID dose on V2 and continue for 7-10 days. On V3 they will perform the same PK assessments as on Pre-assignment PK visit."
89239917|NCT05126901|Experimental|2 to 17 year old subjects - Ferric Maltol|"Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid.~The first 12 subjects randomised to ferric maltol in each age sub-group (2 - 9 yrs, 10 - 17 yrs respectively) will enter a PK phase with 2 PK days.~Following PK Day 2 subjects will continue until Week 12. Once the 18 subjects in each age subgroup have finished their PK visits, they will continue until week 12.~Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID.~Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period."
89239918|NCT05126901|Active Comparator|2 to 17 year old subjects - Ferrous Sulfate|"Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid.~Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID.~Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period."
89239919|NCT05119569|Experimental|Fenebrutinib|Participants will receive oral fenebrutinib.
89239920|NCT05119569|Placebo Comparator|Placebo|Participants will receive oral placebo.
89239921|NCT05096728||Once daily Nifedipine XL 60mg|Participants will receive Nifedipine XL once daily 60 mg for 48 hours.
89239922|NCT05096728||Twice daily Nifedipine XL 30mg|Participants will receive Nifedipine XL twice daily 30 mg for 48 hours.
89239923|NCT05094154|Active Comparator|anti-pseudomonal cephalosporin|Participants in the anti-pseudomonal cephalosporin arm will receive at least one dose of an anti-pseudomonal cephalosporin.
89239924|NCT05094154|Active Comparator|anti-pseudomonal penicillin|Participants in the anti-pseudomonal penicillin arm will receive at least one dose of an anti-pseudomonal penicillin.
89239925|NCT05094141|No Intervention|Non-VR (Virtual reality)|The patient is not assigned to play the VR game. mYPAS scoring for port access is done.
89239926|NCT05094141|Experimental|VR (Virtual Reality)|The patient is assigned to play the VR game for 15 minutes prior to actual port access procedure start. mYPAS scoring while playing VR device for Port access
89239927|NCT05076149|Experimental|VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
89239928|NCT05076149|Active Comparator|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
89239929|NCT05069610|Experimental|Standard of care + AD17002 (3 weekly doses)|Received 3 weekly doses of AD17002 20 μg/dose of AD17002 by intranasal route
89239930|NCT05069610|Placebo Comparator|Standard of care + Placebo (3 weekly doses)|Received 3 weekly doses of Placebo Formulation buffer by the intranasal route
89239931|NCT05069610|Experimental|Standard of care + AD17002 (3 doses in 5 days)|Received 3 doses of AD17002 in 5 days 20 μg/dose of AD17002 by the intranasal route on days 1, 3, and 5
89239932|NCT05069610|Placebo Comparator|Standard of care + Placebo (3 doses in 5 days)|Received 3 doses of Placebo in 5 days Formulation buffer by the ntranasal route on days 1, 3, and 5
89239933|NCT05066880|Experimental|Yoga|Participants allocated to the yoga group will receive the yoga-based intervention through an internet-based video conference remotely in real-time. Each class will accommodate a maximum of 5 subjects. A qualified physiotherapist who was a certificated yoga instructor will teach in these classrooms. The 8-week exercise intervention consists of three times per week sessions of yoga.
89239934|NCT05066880|Experimental|Aerobic exercise|Participants of the aerobic exercise group will be requested to perform unsupervised aerobic training in the home environment (e.g., at home, park, backyard, or in the local gym). The 8-week exercise intervention consists of three times per week sessions of aerobic exercise. Training will consist of a 10-min warm-up period, aerobic activity, and 5-min cool-down period.
89239935|NCT05066880|No Intervention|Wait-list|Participants in the wait-list group will be advised to continue their habitual physical activity next to usual medical care. A yoga or aerobic exercise program of 8 weeks will be offered after the ending of the study period.
89239936|NCT05056857||Observational (biospecimen collection, medical chart review)|Patients undergo collection of blood samples and their medical charts are reviewed.
89239937|NCT05048953||MRC GROUP|All newly admitted patients (shifted to ICU within 48 h of hospital admission), aged ≥ 16 years and expected to stay in ICU or critical care areas for 7 days will be included in the study after excluding those who fulfill excluding criterial. In all the participants, muscle strength will be assessed at day 1, day 4 and day 7, if the patients are awake as assessed by Richmond Agitation Sedation Scale (RASS) (19) between -1 and 1, and cooperative (20) assessed by being able to follow at least 3 out of 5 verbal commands with facial muscles (scored by the Score of 5 Questions). Assessment will be done by an ICU physician blinded to the result of ultrasound. The MRC score will be used for assessment of strength in the following six muscle groups bilaterally: wrist dorsiflexors, elbow flexors, shoulder abductors, hip flexors, knee extensors and ankle dorsiflexors. ICU-AW will be defined as MRC sum score < 48, in accordance with the international consensus statement.(1)
89239938|NCT05048953||Muscle ultrasound measurements (the index test)|"Muscle ultrasound will be performed by an ICU faculty or a DM resident of Critical care medicine (who has an experience of at least 25 muscle ultrasonography with at least 10 muscle ultrasonography performed under supervision) (21) and will be blinded to the result of MRC score of the patient. Muscle ultrasound images on day 1, day 4 and day 7 will be obtained in the participants.~The following parameters will be measured by muscle ultrasound~Muscle thickness~Muscle echogenicity~Muscle fasciculations Muscle thick"
89239939|NCT05036096|Experimental|CBBCT Imaging Screening Patients|Patient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of screening mammography.
89239940|NCT05036096|Experimental|CBBCT Imaging Diagnostic Patients|Patient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of diagnostic mammography.
89239941|NCT05035368|Experimental|Ladarixin - placebo|"In this arm the treatment sequence is ladarixin 400 mg twice-a-day, followed by placebo, as adjunctive therapy to insulin in overweight, IR, T1D patients.~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Ladarixin 24 weeks, washout 21 days, Placebo 24 weeks)."
89239942|NCT05035368|Experimental|Placebo - Ladarixin|"In this arm the treatment sequence is placebo followed by ladarixin 400 mg twice-a-day, as adjunctive therapy to insulin in overweight, IR, T1D patients.~IMP will be administered for 24 weeks in each treatment period with a 21-day washout between the two periods. (Placebo 24 weeks, washout 21 days, Ladarixin 24 weeks)."
89239943|NCT05030766|Experimental|MT plus NRT Group|Participants who receive the Mindfulness Training (MT) intervention for 4 weeks in addition to 6 weeks of Nicotine Replacement Therapy (NRT).These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
89239944|NCT05030766|Experimental|CM plus NRT Group|Participants who receive the Contingency Management (CM) intervention for 4 weeks in addition to 6 weeks of NRT. These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
89239945|NCT05030766|Experimental|MT plus NRT with additional CM Group|Participants who received the MT intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional CM intervention for another 4 weeks.
89239946|NCT05030766|Experimental|CM plus NRT with additional MT Group|Participants who received the CM intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional MT intervention for another 4 weeks.
89239947|NCT05010785|Experimental|alveolar ridge splitting with GBR and i-PRF|alveolar ridge splitting in combination with the use of GBR with i-PRF (sticky bone) with immediate implant placement
89239948|NCT05010785|Active Comparator|alveolar ridge splitting with GBR|alveolar ridge splitting in combination with the use of GBR without i-PRF (sticky bone) with immediate implant placement
89239949|NCT04998721|Experimental|Maternal Infant Dyadic Care|Perinatal collaborative care and Promoting First Relationships-Brief
89239950|NCT04998721|Active Comparator|Control|Perinatal collaborative care only
89239951|NCT04991116|Experimental|TILD q12 weeks|
89239952|NCT04987112|Experimental|CAN1012 single agent|CAN1012 intratumoral injection given alone
89239953|NCT04975555|Experimental|Siltuximab|Patients who experience CRS/ICANS will receive this treatment
89239954|NCT04963166||12-17 years of age|12-17 years of age
89239955|NCT04963166||2-6 years of age|2-6 years of age
89239956|NCT04963166||7-11 years of age|7-11 years of age
89239957|NCT04925479|Experimental|Asciminib|"This arm consists of 2 groups:~The pediatric formulation group where the dose is based on body weight (1.3mg/kg)~The adult formulation group where participants will receive a flat dose of 40mg BID"
89239958|NCT04915950|Experimental|Temanogrel (Stage A Dose 1)|
89239959|NCT04915950|Experimental|Temanogrel (Stage A Dose 2)|
89239960|NCT04915950|Placebo Comparator|Placebo (Stage A)|
89239961|NCT04915950|Experimental|Temanogrel (Stage B Dose 1)|
89239962|NCT04915950|Experimental|Temanogrel (Stage B Dose 2)|
89239963|NCT04915950|Placebo Comparator|Placebo (Stage B)|
89239964|NCT04899271|Experimental|Ladarixin|The treatment group will receive 400 mg b.i.d. for 13 cycles of 14 days on/14 days off)
89239965|NCT04899271|Placebo Comparator|Placebo|The control group will receive matched placebo
89239966|NCT04897347|Experimental|Robotic Trunk-Support-Trainer (TruST)|Postural-reaching control intervention with TruST
89239967|NCT04897347|Active Comparator|Static Trunk Support|Postural-reaching control intervention with Rigid Trunk Support
89239968|NCT04894370|Experimental|Experimental|"Phase 1: Radiotherapy (8 Gy on target lesions)~Phase 2: Combination immunotherapy and mDCF regimen mDCF regimen every 2 weeks for 8 cycles~Docetaxel (40 mg/m², day 1),~Cisplatin (40 mg/m², day 1)~5-FU (1200 mg/m²/day for 2 days) Spartalizumab: 400 mg intravenous will be administrated every 4 weeks~Phase 3 : Multimodal treatment of residual disease The multimodal treatment is recommended in oligometastatic anal cancer. The support by ablative treatment (surgery, hypofractionnated radiotherapy or by radiofrequency) improve survival.~In absence of progression disease:~Ablative treatment: surgery, hypofractionnated radiotherapy or by radiofrequency of residual metastases~and Chemo-radiotherapy (CRT) for local disease~Phase 4: Maintenance treatment with Spartalizumab 400 mg intravenous every 4 weeks for 12 months from enrolment maximum"
89239969|NCT04889469||Breast hypertrophy operated|Women who have had a breast reduction in the public health care system
89239970|NCT04889469||Breast hypertrophy controls|Women with symptoms of breast hypertrophy, who do not fulfill the requirements to have a breast reduction in the public health care system
89239971|NCT04889469||Augmented controls|Patients who have breast hypertrophy due to cosmetic breast augmentation
89239972|NCT04889469||The general public|Random sample of the general public
89239973|NCT04884750|Experimental|High engagement mechanisms, tailed content|During this time the investigators will conduct a 2x2 factorial RCT (with the individual the unit of random assignment and measurement) to assess the impact of two app design features on engagement and outcomes: (1) the investigators will manipulate engagement mechanisms (ENGAGEMENT), including reminder notifications and trust-building dialogue by the ECA and, (2) independently manipulate cultural tailoring of vaccination promotion counseling language used by the agent (TAILORING) to either adaptive religiosity (tailored) or secular (non-tailored). The investigators' primary hypotheses are that participants with have significantly greater vaccination completion rates in the high engagement and tailored conditions at 6 months (H1) and 12 months (H2) compared to other conditions.
89239974|NCT04884750|Experimental|Low engagement mechanisms, tailed content|manipulate low engagement mechanisms while provide adaptive religiosity (tailored) content
89239975|NCT04884750|Experimental|High engagement mechanism, non-tailed content|manipulate high engagement mechanisms while provide secular (non-tailored) content
89239976|NCT04884750|Experimental|Low engagement mechanism, non-tailed content|manipulate low engagement mechanisms and provide secular (non-tailored) content
89239977|NCT04873869|Placebo Comparator|Placebo|Participants will receive matching placebo for up to 18 weeks.
89239978|NCT04873869|Experimental|NBI-921352|In the first 6 weeks participants will receive increasing doses of NBI-921352 (Titration Period) based on weight, followed by 10 weeks of treatment at their final tolerated dose (Maintenance Period) and 2 weeks of treatment with decreasing doses (Taper Period).
89239979|NCT04870034|Experimental|Treatment (palbociclib, binimetinib)|Patients receive palbociclib PO QD and binimetinib PO BID for 14 days in the absence of disease progression or unacceptable toxicity. Within 1 week after last dose of study medication, patients undergo surgery.
89239980|NCT04862689|Experimental|Experimental|Adult subjects clinically indicated for non-emergent percutaneous coronary intervention (PCI) as a stand-alone procedure or following non-emergent diagnostic angiography performed during the same procedure that, in the physician's estimation, requires prolonged balloon inflation with distal perfusion.
89239981|NCT04849169|Experimental|Experimental Arm|Adult subjects who experience a perforation of a coronary vessel during percutaneous coronary intervention (PCI) and require management of hemorrhage until a definitive treatment is determined.
89239982|NCT04845945||PCV15 only|Draw blood for ELISA and OPA, then administer PCV15
89239983|NCT04845945||PPS23 only|Draw blood for ELISA and OPA, then administer PPS23
89239984|NCT04845945||PCV15 and PPS23|Draw blood for Administer PPS23 then draw blood again ELISA and OPA, then administer PCV15
89239985|NCT04845178|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - intramuscular injections into specified muscles.
89239986|NCT04845178|Experimental|ABP-450 - High Dose|ABP-450 High Dose - intramuscular injections into specified muscles.
89239987|NCT04845178|Placebo Comparator|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur) intramuscular injections into specified muscles.
89239988|NCT04837248|Active Comparator|Group 1. Conventional treatment|Patients will be treated with a physiotherapy programme without digital support.
89239989|NCT04837248|Experimental|Group 2. Experimental treatment.|Patients will be treated using a digitally supported physiotherapy programme.
89239990|NCT04817241|Experimental|Arm I (decitabine and cedazuridine, venetoclax)|Patients receive ASTX727 PO QD at the recommended phase II dose and venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
89239991|NCT04817241|Active Comparator|Arm II (cytarabine, daunorubicin)|Patients receive cytarabine IV over 24 hours on days 1-7 of each cycle and daunorubicin IV over 10-30 minutes on days 1-3 of each cycle. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy throughout the trial.
89239992|NCT04817241|Experimental|Phase Ib (decitabine and cedazuridine, venetoclax)|Patients receive ASTX727 PO QD on days 1-4 or 1-5 of each cycle and venetoclax PO QD on days 1-28 or days 1-21 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and biopsy and collection of blood samples throughout the trial.
89239993|NCT04806347|Experimental|Treatment arm|Participants will undergo a conditioning regimen, specific for the original disease, After that peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCRαβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems will be administered intravenously on Day 0 to all participants.
89239994|NCT04792385|Experimental|E4/DRSP 15/3 mg|Single treatment arm will receive E4/DRSP 15/3 mg
89239995|NCT04791579|Active Comparator|Treatment Arm|Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure
89239996|NCT04791579|Placebo Comparator|Placebo Arm|Placebo pill PO every 12 hrs for 3 days following the procedure
89239997|NCT04781530|Experimental|Intervention (Device)|"Diagnostic Test: BioFire~A molecular rapid syndromic testing platform, using the following panel:~BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus) In addition to standard of care"
89239998|NCT04781530|No Intervention|Control (Standard of Care)|Standard of Care
89239999|NCT04768777|Experimental|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
89240000|NCT04768777|No Intervention|waitlist control condition|Participants will have 16-weeks of no intervention or interaction.
89240001|NCT04762953|Experimental|SingleArm: Systemic therapy and IP Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis|Patients will receive sequential intraperitoneal paclitaxel along with intravenous paclitaxel, 5-FU, and leucovorin on Days 1 and 8 of every 21 day cycle for 3 months.
89240002|NCT04735978|Experimental|Dose escalation of RP3 - superficial and/or deep/visceral tumors|Dose escalation of RP3 alone in 2 cohorts with intratumoral (IT) injections including use of imaging guided injection for deep tumors.
89240003|NCT04735978|Experimental|Dose combination of RP3 and anti-PD1 therapy - superficial and/or deep/visceral tumors|Dose combination of RP3 and anti-PD1 therapy. IT injections of RP3 including use of imaging guided injection for deep tumors.
89240004|NCT04735978|Experimental|Seronegative cohort|Doses of RP3 (IT) in HSV seronegative participants.
89240005|NCT04732546||patients with a mullerian variation|
89240006|NCT04719988|Experimental|Experimental|"Induction treatment~Modified DCF: every 2 weeks for 8 cycles Docetaxel (40 mg/m², day 1), Cisplatin (40 mg/m², day 1) , 5-FU (1200 mg/m²/day for 2 days)~Ezabenlimab: 240 mg intravenous, every 3 weeks for 3 cycles~In case of tumor response:~Two additional cycles of mDCF and one additional cycle of Ezabenlimab (Q3W).~Hypofractionated radiotherapy~Ezabenlimab: 240 mg intravenous, every 3 weeks for 7 cycles~In absence of tumor response:~o Chemoradiotherapy (Intensity-Modulated Radiation Therapy [IMRT]) treatment: Chemoradiotherapy using IMRT will begin 3-4 weeks following the last cycle of induction phase, in the absence of toxicities of grade 1 and/or management of toxicities. It will last 7 weeks and will consist of:~• Standard dose of 45 Gy in 25 fractions over 5 weeks followed by a sequential boost of 14.4 Gy in 8 sessions,~Concomitantly given with:~Capecitabine (825 mg/m²/orally twice daily) from Monday to Friday,~Mitomycin C (10 mg/m² Day 1)"
89240007|NCT04700072|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab and quavonlimab) intravenously (IV) plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
89240008|NCT04700072|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
89240009|NCT04696653|Other|Comprehensive unit based safety (CUSP) intervention arm|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
89240010|NCT04678154|Active Comparator|Control|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
89240011|NCT04678154|Experimental|Treatment|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
89240013|NCT04627818||patients with a mullerian variation|
89240014|NCT04619472|Experimental|Radiofrequency Ablation (RFA)|The subjects will first undergo interventional bronchoscopy to reach the target lesion through the bronchial pathway. Then the lung lesions will be treated with radiofrequency ablation using the pulmonary radiofrequency ablation system and the disposable pulmonary radiofrequency ablation catheter.
89240015|NCT04597008|Active Comparator|Control|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed immediately before wound closure.
89240016|NCT04597008|Experimental|Treatment|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed immediately before wound closure.
89240017|NCT04591392|Experimental|Device|ASD closure with the reSept ASD Occluder
89240018|NCT04581681|Experimental|Group CBT for Perinatal Anxiety|Using cognitive-behavioural therapy principles, this group therapy is intended to treat perinatal anxiety.
89240019|NCT04581681|Active Comparator|Waitlist Control|This is a control condition in which patients are randomly assigned to the waitlist control condition before receiving the treatment.
89240020|NCT04579237||1/All Subjects|Data will be derived from primary studies on all subjects.
89240021|NCT04568902|Experimental|Dose Escalation Part: H3B-6545 300 mg|Participants will receive H3B-6545 300 milligram (mg) tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
89240022|NCT04568902|Experimental|Dose Escalation Part: H3B-6545 450 mg|Participants will receive H3B-6545 450 mg tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
89240023|NCT04568902|Experimental|Antihistamine Prophylactic Administration Part|Participants will receive prophylactic treatment with non-sedating systemic antihistamine, orally, once from Cycle 1 Day 1 until Cycle 1 Day 28, followed by H3B-6545 450 mg tablets, orally, once daily in 28 days cycle until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
89240024|NCT04568902|Experimental|Randomization Part|Participants will be randomized in 1:1 ratio to receive H3B-6545 450 mg, tablets, orally, once daily in 28 days cycle either with non-sedating systemic antihistamine prophylactic administration from Day 1 until Day 28 of Cycle 1 OR without antihistamine prophylactic administration until disease progression, violation of study requirements, unable to continue study based on investigator opinion or withdrawal of consent.
89240025|NCT04550923|Experimental|Investigational device (non-rigid) group|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device.
89240026|NCT04550923|Active Comparator|Control device (rigid) group|Use rigid (PEEK) interbody fusion device .
89240027|NCT04550442|Experimental|Treatment (venetoclax, azacitidine)|Patients receive venetoclax PO daily on days 1-14 and azacitidine IV over 15 minutes or SC on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
89240028|NCT04548999|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
89240029|NCT04548999|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
89240030|NCT04547907|Experimental|nab-PHP|Albumin binding paclitaxel + trastuzumab+ patuzumab
89240031|NCT04547907|Active Comparator|TCbHP|Docetaxel + carboplatin + trastuzumab + patuzumab
89240032|NCT04534218|Experimental|Experimental|"REGORAFENIB:~For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle.~METRONOMIC CHEMOTHERAPIES:~Capecitabine: 625mg/m²/orally twice daily continuously for 6 months~Cyclophosphamide: 50 mg per os, daily, for 6 months~ASPIRIN:~75 mg orally and daily until progression"
89240033|NCT04533763|Experimental|Mindful Living (ML)|Mindful Living Intervention A 10-week group-based and web-delivered psychosocial intervention targeting key concerns of ovarian cancer survivors.
89240034|NCT04533763|Active Comparator|Healthy Lifestyles (HL)|Healthy Lifestyle Intervention A 10-week group-based and web-delivered intervention providing information on health promotion for ovarian cancer survivors.
89240035|NCT04530448|Active Comparator|Standard of Care|Standard of Care treatment
89240036|NCT04530448|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
89240037|NCT04511078|Experimental|Panitumumab-IRDye800|50 mg infusion of panitumumab-IRDye800 given over 60 minutes
89240038|NCT04503018||Interviewed -implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
89240039|NCT04503018||Questionnaires - implant loss|Patients who have had immediate breast reconstruction and lost the implant due to for example infection.
89240040|NCT04503018||Questionnaires - controls|Patients who have had immediate breast reconstruction without complications
89240041|NCT04495452||Study Participants|"We will be enrolling 200 participants, this will provide a large enough sampling to assure there are at least 25 patients with significant respiratory depression and 25 with insignificant respiratory depression.~The genetic data from participants with the most respiratory depression defined as having a 20-40% decrease from initial respiratory parameters will be compared with genetic data from participants with the least respiratory depression defined as having no change or less than 10% decrease from initial respiratory parameters."
89240042|NCT04476030|Active Comparator|Placebo + Assigned ADT|Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.
89240043|NCT04476030|Experimental|SAGE-217 + Assigned ADT|Participants received SAGE-217, 50 milligrams (mg), orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.
89240044|NCT04462042|Active Comparator|Photon radiotherapy|Conventional photon radiation is delivered by volumetric arc therapy/intensity modulated radiotherapy/helical tomotherapy using simultaneous integrated boost (SIB) technique. The total dose to the primary tumour target and node metastases >2 cm is 57.5 Gy in 27 fractions, one fraction/day, five fractions/week during 5.5 weeks. Node metastases up to 2 cm will receive 50.5 Gy in 27 fractions. Elective lymph nodes will receive a total dose of 41.6 Gy.
89240045|NCT04462042|Experimental|Proton radiotherapy|Proton radiation is delivered by spot scanning. Proton plans will be produced by single field optimisation/single field uniform dose or multifield optimisation/intensity modulated proton therapy using simultaneous integrated boost (SIB) technique. The total dose to the primary tumour target and node metastases >2 cm is 57.5 Gy(RBE) in 27 fractions, one fraction/day, five fractions/week during 5.5 weeks. Node metastases up to 2 cm will receive 50.5 Gy(RBE) in 27 fractions. Elective lymph nodes will receive a total dose of 41.6 Gy(RBE).
89240046|NCT04458831||Cohort 1|Patients with multiple myeloma (MM) and are considered as RRMM according to the International Myeloma Working Group (IMWG) criteria
89240047|NCT04450316|Active Comparator|Low-dose naltrexone|4.5mg of naltrexone to be taken one hour prior to bedtime nightly for 8 weeks.
89240048|NCT04450316|Placebo Comparator|Placebo|Placebo tablet (sugar-pill) to be taken one hour prior to bedtime nightly for 8 weeks.
89240049|NCT04447820|Experimental|K-877-ER Dose A|K-877-ER dose A administered once daily
89240050|NCT04447820|Experimental|K-877-ER Dose B|K-877-ER dose B administered once daily
89240051|NCT04447820|Experimental|K-877-IR|K-877-IR administered twice daily.
89240052|NCT04443062|Experimental|Interventional arm: 177Lu-PSMA radioligand therapy|2 (+2) cycles of 7.4 GBq 177Lu-PSMA 6 weeks in between
89240053|NCT04443062|No Intervention|Standard of care|Deferred androgen deprivation therapy. However, the control arm can receive the study drug (177Lu-PSMA) in case of disease progression (defined in the study protocol).
89240054|NCT04442711||PFBIO-EXA|All patients recruited for PFBIO-EXA from the original PFBIO cohort are included into the cohort.
89240055|NCT04438213|Experimental|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
89240056|NCT04438213|Experimental|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
89240057|NCT04438213|Placebo Comparator|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
89240058|NCT04402957|Placebo Comparator|Placebo|100 mL drug-free IV saline infusion over 2 hours daily
89240059|NCT04402957|Experimental|LSALT|100 mL of 5 mg IV LSALT peptide infusion over 2 hours daily
89240060|NCT04395989|Experimental|LAR-HER2mut|If patients were LAR subtype with HER2 gene activated mutation
88804686|NCT01215643|Active Comparator|PEG+RBV|Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.
88804687|NCT00004144|Experimental|bryostatin 1 & gemcitabine hydrochloride|
89240061|NCT04395989|Experimental|LAR-PI3K/AKTmut|If patients were LAR subtype without HER2 gene activated mutation, but had PI3K/AKT/mTOR pathway mutation
89240062|NCT04395989|Experimental|IM|If patients were IM subtype (CD8 positive T cell more than 10%)
89240063|NCT04395989|Experimental|BLIS/MES-PI3K/AKTWT|If patients were BLIS subtype or MES subtype without PI3K/AKT/mTOR pathway activation
89240064|NCT04395989|Experimental|MES-PI3K/AKTmut|If patients were MES subtype and had PI3K/AKT/mTOR pathway activation
89240065|NCT04382612|Other|HARPOON MVRS|Subjects who were treated with the HARPOON MVRS.
89240066|NCT04360941|Experimental|Two-part phase 1b trial of induction palbociclib with avelumab|"Recruitment to Part A will be conducted at the Royal Marsden Hospital only. Up to 18 patients will be recruited for dose escalation of palbociclib in combination with fixed dose avelumab.~Part B will recruit at up to 8 high volume centres. Up to 27 patients will be recruited to treatment with the maximum tolerated dose and schedule established in part A. In Part B of the study, additional selection by triple negative histology and positive androgen receptor status will define the study population."
89240067|NCT04357275||ICU admissions due to COVID-19|
89240068|NCT04303858|Experimental|Eciskafusp Alfa as a Single Agent|Part 1: Dose-escalation of eciskafusp alfa as a single agent. eciskafusp alfa will be either an intravenous administration (IV) or subcutaneous administration (SC) in multiple-ascending doses.
89240069|NCT04303858|Experimental|Eciskafusp Alfa in Combination with Atezolizumab|Part 2: Dose-escalation of eciskafusp alfa in combination with atezolizumab.
89240070|NCT04303858|Experimental|Eciskafusp Alfa as a Single Agent and/or with Atezolizumab|Part 3: Extension of eciskafusp alfa as a single agent and/or in combination with atezolizumab.
89240071|NCT04282785||Cohort of patients with severe infections|Patients with severe infections admitted to the Uppsala University Hospital and gets treated with either Piperacillin-Tazobactam, Meropenem or Cefotaxim
89240072|NCT04273555|Experimental|[18F]-Fluorodeoxyglucose (FDG) PET/ MRI|
89240073|NCT04258722|Experimental|Trainee + Teleneonatologist|Trainee, teleneonatologist, nurse, and respiratory therapist will perform resuscitation
89240074|NCT04258722|Active Comparator|Trainee|Trainee, nurse, and respiratory therapist will perform resuscitation.
89240075|NCT04239794|Active Comparator|Inhalation anesthesia|Patients are anesthetized with sevoflurane and remifentanil infusion for maintenance of anesthesia during the surgery
89240076|NCT04239794|Experimental|Total intravenous anesthesia|Patients are anesthetized with target-controlled intravenous infusion of propofol and remifentanil infusion for maintenance of anesthesia during the surgery
89240077|NCT04222556|Experimental|Thiwáhe Gluwáš'akapi|"Weeks 1-7: Weekly in-person 2.5 hour family sessions 30 minute family meal 1 hour separate youth and adult sessions~1 hour family session"
89240078|NCT04222556|Active Comparator|Woyute Waśte|"Respect for community and cultural values regarding research protocols precluded use of a randomized controlled design with a control group receiving no intervention, so we identified a cost-effective comparison condition program to offer value to study participants. A focus on healthy eating and exercise was of interest to community partners and not expected to directly confound the primary outcomes of the TG program (substance use and suicide risk).~Week 1 in-person 2.5 hour family session 30 minute family meal 2 hour interactive family session (3 stations) Weeks 2-7: text messages with program content and questions"
89240079|NCT04220229|Experimental|Treatment (cabozantinib S-malate, radiation therapy)|Patients receive cabozantinib S-malate PO QD on days 1-21. Cycles repeat every 21 days until the completion of radiation therapy in the absence of disease progression or unacceptable toxicity. Beginning cycle 1 day 8, patients also undergo standard of care radiation therapy for 5-6 weeks.
89240080|NCT04200911|Experimental|RAPA intervention|Sirolimus 1mg orally once a day for 8 weeks
89240081|NCT04164472|Experimental|Friend to Friend with Coaching|Program for relationally aggressive girls and their classmates delivered by school personnel who have been coached by study team.
89240082|NCT04164472|No Intervention|Control|Referral to school counselor as needed as per standard practice.
89240083|NCT04158687|Placebo Comparator|Placebo|Participants received CTP-692 matched-placebo powder for oral solution, once daily (QD) for up to 12 weeks.
89240084|NCT04158687|Experimental|CTP-692 1 gram QD|Participants received CTP-692 1 gram powder for oral solution, QD for up to 12 weeks.
89240085|NCT04158687|Experimental|CTP-692 2 grams QD|Participants received CTP-692 2 grams powder for oral solution, QD for up to 12 weeks.
89240086|NCT04158687|Experimental|CTP-692 4 grams QD|Participants received CTP-692 4 grams powder for oral solution, QD for up to 12 weeks.
89240087|NCT04155125|Experimental|efepoetin alfa|"Route of administration: Subcutaneous Injection.~The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period."
89240088|NCT04155125|Placebo Comparator|Mircera|"Route of administration: Subcutaneous Injection.~The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL."
89240089|NCT04153864|Experimental|Non-specialist|Trained non-mental health providers (e.g., nurses or midwives) with general healthcare professional skills (as assessed during recruitment) with no previous experience delivering psychological treatments implementing a brief, manualized behavioral activation treatment
89240090|NCT04153864|Active Comparator|Specialist|Psychiatrists, psychologists and social workers with experience in treating perinatal mental illness and a minimum of 5 years of experience delivering psychological treatments delivering a brief, manualized behavioral activation treatment
89240091|NCT04153864|Experimental|Telemedicine|A brief, manualized behavioral activation treatment delivered over Zoom™ in Toronto, via Webex™ in Chapel Hill, and via Zoom™ in NorthShore
89240092|NCT04153864|Active Comparator|In-Person|A brief, manualized behavioral activation treatment delivered in-person held at participating clinical care sites within UToronto, UNC and NorthShore
89240093|NCT04142905||Patients With Asthma|Subjects with sleep disordered breathing with asthma
89240094|NCT04142905||Patients Without Asthma|Subjects with sleep disordered breathing without asthma
89240095|NCT04127032|Experimental|Tailored ICBT for PSP|Therapist-guided, Internet-delivered cognitive behavioral therapy tailored specifically for Canadian public safety personnel.
89240096|NCT04123418|Experimental|WVT078 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
89240097|NCT04123418|Experimental|WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
89240098|NCT04098276|Experimental|Online weWomen Intervention|For first stage randomization, women in the intervention group receive the online safety planning intervention informed by culturally specific danger assessment (DA) tool.
89240099|NCT04098276|No Intervention|Online usual care or no treatment control|Women in the control group receive the non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
89240100|NCT04098276|Experimental|WeWomen Plus Text messaging only|For second stage randomization, the text messaging intervention will follow-up with non-responder group of immigrant women (those who did not improve in intervention or control arms above) on their enactment of tailored (tailored to the DA Score and priorities) safety plan provided in the online weWomen intervention or non-tailored (standard list of resources) safety recommendations provided in the usual care control arm
89240101|NCT04098276|Experimental|WeWomen Plus Text messaging and phone|Second stage randomization will involve both text (described above) and phone calls for non-responder group of women in intervention or control arm. The phone calls will draw from motivational interviewing adapted for abused women, solution focused therapy and a strengths perspective to discuss women's safety concerns and other needs, and strategies to strengthen social support networks
89240102|NCT04090749|Experimental|Open Label Group|In this arm, 5 participants will be enrolled in the intervention without blinding or randomization. The intervention and study delivery will be improved based on findings from this arm.
89240103|NCT04090749|Other|Waitlist Control|The waitlist control group (n=20) will be provided written materials with community resources for caregivers during the first 16 weeks, then the intervention will begin.
89240104|NCT04090749|Experimental|Immediate Intervention|The immediate intervention group (n=20) will receive the intervention during weeks 0-16. There will be assessment at week 32 to examine maintenance on primary and secondary outcomes.
89240105|NCT04076059|Experimental|Enzalutamide Plus Androgen Deprivation Therapy (ADT) (Double Blind Phase)|Participants received enzalutamide 160 mg capsules, orally once daily if tolerable, and continued ADT until radiographic disease progression was documented or until they started another investigational agent or new therapy for treatment of prostate cancer. Participants were to remain on study treatment until confirmed radiographic disease progression. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment.
89240106|NCT04076059|Placebo Comparator|Placebo Plus ADT (Double Blind Phase)|"Participants received enzalutamide-matching placebo capsules, orally once daily and continued ADT until radiographic disease progression was documented or until they started another investigational agent or new therapy for treatment of prostate cancer. Participants were to remain on study treatment until confirmed radiographic disease progression. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment."
89240107|NCT04076059|Experimental|Enzalutamide Plus ADT (Open-Label Phase)|Participants who received placebo in double-blind phase and remaind on study treatment until confirmed radiographic disease progression received enzalutamide and continued ADT in open-label phase. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment.
89240108|NCT04047420|Experimental|Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Insert|On the first dosing visit (Visit 3), participants will receive a single TAF/EVG Insert for rectal administration. On the second dosing visit (Visit 7), after a washout period of at least 7 days, participants will receive two TAF/EVG Inserts for rectal administration. Each participant will be on study for approximately 6-13 weeks.
89240109|NCT04026516|Experimental|CAVA Dizziness Trial Arm|All trial participants are within this arm. All participants will wear the CAVA device for 30 days and follow the same procedures throughout the trial.
89240110|NCT04014647||Event-free|Patients who have had no negative events (as described in group 2)
89240111|NCT04014647||Negative event|"Group 2 - patients with one or more of the following negative events post-operatively:~Whether the patient has been prescribed inotropic support~Wound infection by assessing use of antibiotics.~Length of stay in hospital >1 week~Reduced renal function assessed by having any AKI alert during hospital stay~Cardiac event within 31 days following surgery~Death within 31 days following surgery"
89240112|NCT04006457|Experimental|Treatment sequence 1|"Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 tablet or capsule given QD for 59 months.~Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 56 visit of the main B7981032 study."
89240113|NCT04006457|Experimental|Treatment sequence 2|"Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 tablet or capsule given QD for 59 months.~Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 56 visit of the main B7981032 study."
89240114|NCT03973814|Active Comparator|Prior to Thermax Warming|Baseline temperature
89240115|NCT03973814|Active Comparator|During warming|Temperature during Thermax warming
89240116|NCT03973814|Active Comparator|Post warming|Temperature after cessation of Thermax warming
89240117|NCT03958045|Experimental|Patients with Stage IV SCLC|Patients with extensive stage (IV) SCLC (small cell lung cancer)
89240118|NCT03952065|Experimental|PD1/PDL1/CTLA4 inhibitors infusion via neck artery|Interventional technique is used to localize neck artery to infuse the inhibitors directly into tumor.
89240119|NCT03952065|Experimental|PD1/PDL1/CTLA4 inhibitors infusion via peripheral vein|Routine peripheral vein infusion of PD1/PDL1/CTLA4 inhibitors is performed.
89240120|NCT03952065|Experimental|PD1/PDL1/CTLA4 inhibitors infusion via intra-tumor penetration|Interventional technique is used to intra-tumor injection of the inhibitors directly into tumor.
89240121|NCT03911271|Experimental|Loading dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
89240122|NCT03911271|Experimental|Low dose|"In phase 1 (treatment phase), the participants (n=50) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
89240123|NCT03911271|Placebo Comparator|Placebo|"In phase 1 (treatment phase), the participants (n=50) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.~In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months."
89240124|NCT03910465||1/Cohort 1|Subjects with confirmed chordoma.
89240125|NCT03904134|Other|Donor Search Prognosis: MUD Very Likely|Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a >90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.
89240126|NCT03904134|Other|Donor Search Prognosis: MUD Very Unlikely|Patients who are Very Unlikely to find a MUD, defined as having a <10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
89240127|NCT03904134|Other|Donor Search Prognosis: MUD Less Likely|Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.
89240128|NCT03885024|Active Comparator|Retention Video|"Participants the peer-driven retention arm will receive video-based and in-person training from Retention Specialists on how to encourage study retention. Participants will watch a 7 minute video that standardizes retention messages. A brief face-to-face conversation with the Retention Specialist follows the video viewing to answer questions and reinforce video messages. At the end of the training, participants receive information about their recruit(s) who consented to release their information to their recruiters. Peers remind their enrolled study buddy to attend their scheduled follow up assessments. Participants meet with a study Retention Specialist by phone or in person, at 3 and 9 months after enrollment to answer questions about peer retention strategies and remind participants of their peers' contact information and follow-up schedules."
89240129|NCT03885024|No Intervention|Standard Retention Strategy|Control arm: At NROI enrollment, all participants provide detailed information to assist with retention and/or contact for future research, and contact information for up to three people who should know how to reach the participant if contact information changes. Participants randomized to receive the standard retention strategy are contacted at the mid-point of each follow-up interval (i.e., at 3-month post enrollment and 9-months post-enrollment) to update locator information and remind them about their follow-up appointment date. Study associates contact the participant using their contact information and, if not successful, will try to reach one of their contacts in the locator form.
89240130|NCT03868475|Experimental|Vacuum-assisted percutaneous excision|"Patients will undergo vacuum-assisted percutaneous excision (VAPE). The intervention group will have post-procedure imaging the same day to confirm complete excision.~The intervention group will then have imaging at 6, 12, and 24 months as per the radiology algorithms for following suspicious lesions (BIRADS 3 category). If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The intervention group will also be seen in clinic at 1 month with no imaging and then at 6, 12, and 24 months to correspond to the imaging visits."
89240131|NCT03868475|Active Comparator|Open surgical excision|"Patients will undergo standard open surgical excision.~The control group will then have follow up imaging at 12 and 24 months as per the usual radiology algorithms following excision of a lesion. If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The control group will also be seen in clinic at 1 month with no imaging and then at 12 and 24 months to correspond to the imaging visits."
89240132|NCT03847766|Experimental|PRO-based follow-up|Patients will receive a questionnaire every 3 months. The PRO questionnaire is used as decision aid together with other available clinical data to decide whether the patient needs a visit or not. Hence, patients only visit the outpatient clinic if there is a clinical need or a patient's wish. The actual response for each questionnaire automatically results in a colour code (green, yellow or red). A red or yellow response indicates that the patient needs to be contacted. A green colour indicates no need for a visit. Based on an overview of the questionnaire and the patient's blood samples a physician decides whether this patient should have a telephone consultation or the patient needs to be seen in the clinic.
89240133|NCT03847766|Experimental|PRO-based telephone consultations|Patients receive an electronic questionnaire every 3 months prior to a scheduled telephone consultation.The PRO questionnaire is used as dialogue support during the telephone consultation. The actual response for each item automatically results in a colour code (green, yellow or red). A red response indicates that the patient has a problem; a yellow colour indicates a potential problem, while a green colour indicates no problems.
89240134|NCT03847766|No Intervention|Usual outpatient follow-up visits|Patients in the control group will continue to have usual scheduled outpatient follow-up visits at the hospital initiated by the physician every 3 months. These patients do not use the clinical PRO questionnaire, but complete the research questionnaires.
89240135|NCT03844048|Experimental|Venetoclax|Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.
89240136|NCT03808584|No Intervention|Control group|The patients in the control group will receive standard physiotherapy and will be instructed to limit core muscle activity and weight bearing according to their pain symptomatology. Standard physiotherapy for all hospitalised patients includes early mobilization and exercises to prevent thrombosis and pulmonary complications (atelectasis, pneumonia, diaphragmatic deconditioning), balance training and endurance and exercise training
89240137|NCT03808584|Experimental|Intervention group|The patients in the intervention group will be given exercises to perform postoperatively.They will be instructed by a physiotherapist in how to perform the four specific exercises targeting core muscles. The patient will perform these exercises daily during hospitalization under the supervision of the physiotherapist and then at home for two months after the operation. The intensity of the exercises will be adjusted daily to the physical capabilities of the patient. They will also benefit from standard physiotherapy as described above.
89240138|NCT03806179|Experimental|10 MBq/kg Betalutin with rituximab treatment|10 MBq/kg Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
89240139|NCT03806179|Experimental|15 MBq/kg Betalutin with rituximab treatment|15 MBq/kg Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
89240140|NCT03789084|Experimental|Cognitive-Behavioral Therapy|Brief Cognitive-Behavioral Therapy for Health Anxiety
89240141|NCT03789084|Other|Referral to mental health provider|Provider makes referral to a mental health provider
89240142|NCT03788213|Active Comparator|3 week RT|Adjuvant Radiotherapy delivered over 3 weeks
89240143|NCT03788213|Experimental|1 Week RT|Adjuvant Radiotherapy delivered over 1 week
89240144|NCT03783624|Experimental|Hypnosis|"This represents 6 individual script-based sessions lasting 1h, distributed over 8 weeks, administered by a certified expert in therapeutic hypnosis. A set of standardized recordings are provided to use at home for self-hypnosis. Suggestions address deep relaxation, sensory substitution or transformation, pain intensity reduction, decreased pain unpleasantness and intensity, sense of control. A brief example of such suggestions: in this deeply relaxed state, you can imagine that your feet are covered in anesthetic… a deep layer of a powerful anesthetic medication, creating protective, soothing socks with which you can walk again…."
89240145|NCT03783624|Placebo Comparator|Open Label placebo|This consists in information provided with a placebo pill. Patients are asked to take the placebo pills as a self-healing ritual. The information relies on 4 points of explanation, i.e. (1) the placebo effect can be powerful, (2) the body automatically can respond to taking placebo pills like Pavlov dogs who salivated when they heard a bell, (3) a positive attitude can be helpful but is not necessary, and (4) taking the pills faithfully for the full duration of treatment is critical.
89240146|NCT03783624|No Intervention|Usual care|Patients continue with their usual treatments
89240147|NCT03759587|Experimental|Niraparib 300 mg|Niraparib 300 mg, capsules, orally, once daily on Days 1 to 28 of each 28-day treatment cycle (up to 51 cycles).
88804688|NCT01261819|Experimental|transurethral laparoscope|These patients had cystoscopy performed with the transurethral laparoscope.
89240148|NCT03752684|Experimental|Low Oxalate Diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a low oxalate diet to determine baseline oxalate values in urine .~Subjects will be colonized with Oxalobacter formigenes (Intervention). Following colonization with Oxalobacter formigenes, urinary oxalate will be measured to determine the impact of colonization."
89240149|NCT03752684|Experimental|Moderately high oxalate/low calcium diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a moderately high oxalate/ low calcium oxalate diet to enhance dietary oxalate absorption.~Subjects will be colonized with Oxalobacter formigenes(Intervention). Following colonization with Oxalobacter formigenes, urinary oxalate will be measured to determine the impact of colonization."
89240150|NCT03752684|Experimental|Oxalobacter formigenes|Subjects will ingest a live preparation of O.formigenes
89240151|NCT03748953|Experimental|Ixazomib|"Ixazomib 3 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 1 through Cycle 4, during which if the participants have tolerated the initial dose, the dose may be escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of every 28-day cycle for Cycle 5 through Cycle 26, or until documented PD or intolerable toxicity, whichever occurs first.~Participants who received placebo-matching capsules before unblinding and have not yet experienced disease progression will have the opportunity to cross over to ixazomib maintenance."
89240152|NCT03746431|Experimental|[225Ac]-FPI-1434 Single-Dose Escalation|
89240153|NCT03746431|Experimental|[225Ac]-FPI-1434 Multi-Dose Escalation|[225Ac]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).
89240154|NCT03746431|Experimental|FPI-1175 Cold Antibody|
89240155|NCT03746431|Experimental|[225Ac]-FPI-1434 Multi-Dose|Phase 2 Tumour Cohort - Head & Neck Squamous Cell Carcinoma (HNSCC), Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative, Adrenocortical Carcinoma (ACC), Uveal Melanoma, [225Ac]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).
89240156|NCT03737851|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
89240157|NCT03737851|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
89240158|NCT03737851|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
89240159|NCT03737149|Experimental|mymobility with Apple Watch|Post-operative mobile application-guided education and exercise paired with accurate and sensitive activity monitoring.
89240160|NCT03737149|No Intervention|Standard of Care Physical Therapy|Standard of care patient education and post-operative physical therapy, as determined by local site guidelines and care pathways.
89240161|NCT03733496||Participants from VY-AADC01 clinical studies:|Participants who have completed participation in VY-AADC01 clinical studies (PD-1101 or PD-1102) will be invited to participate in this extension study
89240162|NCT03730194|Experimental|Melatonin Only|"In stage 1, participants in this arm will take 3 mg of melatonin 30 minutes before bedtime for 4 weeks.~In stage 2, responders to melatonin will take 3 mg of melatonin 30 minutes before bedtime for an additional 4 weeks (repeat stage 1, for a total of 8 weeks)."
89240163|NCT03730194|Experimental|The Bedtime Bank Only|"In stage 1, participants in this arm will utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks.~In stage 2, responders to The Bedtime Bank will utilize The Bedtime Bank, a behavioral sleep intervention for an additional 4 weeks (repeat stage 1, for a total of 8 weeks)."
89240164|NCT03730194|Experimental|Melatonin than Bedtime Bank|"In stage 1, participants in this arm will take 3 mg of melatonin 30 minutes before bedtime for 4 weeks.~In stage 2, non-responders to melatonin will utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks."
89240165|NCT03730194|Experimental|Melatonin than Melatonin+Bedtime Bank Combo|"In stage 1, participants in this arm will take 3 mg of melatonin 30 minutes before bedtime for 4 weeks.~In stage 2, non-responders to melatonin will take 3 mg of melatonin 30 minutes before bedtime for an additional 4 weeks (repeat stage 1, for a total of 8 weeks) AND utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks."
89240166|NCT03730194|Experimental|Bedtime Bank than Melatonin|"In stage 1, participants in this arm will utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks.~In stage 2, non-responders to The Bedtime Bank will take 3 mg of melatonin 30 minutes before bedtime for 4 weeks."
89240167|NCT03730194|Experimental|Bedtime Bank than Bedtime Bank+Melatonin Combo|"In stage 1, participants in this arm will utilize The Bedtime Bank, a behavioral sleep intervention, for 4 weeks.~In stage 2, non-responders to The Bedtime Bank will utilize The Bedtime Bank, a behavioral sleep intervention for an additional 4 weeks (repeat stage 1, for a total of 8 weeks) AND take 3 mg of melatonin 30 minutes before bedtime for 4 weeks."
89240168|NCT03723551|Experimental|Afabicin|"In Part A, afabicin will be given intravenous (IV) at a dose 160 milligrams (mg) twice daily (BID) for a minimum of 1 day (2 doses) and up to a maximum of 14 days (2 weeks), followed by a switch to oral Afabicin at a dose of 240 mg BID for the remaining treatment duration.~In Part B, participants will be administered with open label afabicin IV at a dose of 55 mg BID for a minimum of 1 day (2 doses) and up to a maximum of 14 days (2 weeks) followed by a switch to oral afabicin at a dose of 80 mg BID for the remaining treatment duration. In certain study conditions a higher dosing regimen of afabicin might be used: afabicin intravenous (IV) at a dose of 80 mg BID for a minimum of 1 day (2 doses) and up to a maximum of 14 days (2 weeks) followed by a switch to oral afabicin at a dose of 120 mg BID for the remaining treatment duration."
89240169|NCT03723551|Active Comparator|Standard of Care (SOC) (Parts A and B)|Participants will be administered with SOC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.
89240170|NCT03689699|Experimental|Arm A: Nivolumab alone|Men with hormone-sensitive prostate cancer will receive Nivolumab alone every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + Degarelix every 4 weeks for 16 weeks (4 doses).
89240171|NCT03689699|Experimental|Arm B: Nivolumab plus BMS-986253|Men with hormone-sensitive prostate cancer will receive Nivolumab plus BMS-986253 every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + BMS-986253 + Degarelix every 4 weeks for 16 weeks (4 doses).
89240172|NCT03669497|Experimental|Hypo fractionated radiotherapy|Hypo fractionated whole breast radiotherapy with simultaneous integrated boost to the tumour
89240173|NCT03655886|Experimental|Radical prostatectomy|
89240174|NCT03655886|Experimental|Radiotherapy|
89240175|NCT03655678|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
89240176|NCT03653507|Experimental|Arm A (zolbetuximab plus CAPOX)|Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 followed by a lower dose in subsequent cycles every 3 weeks. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
89240177|NCT03653507|Placebo Comparator|Arm B (Placebo plus CAPOX)|Participants will receive placebo starting at Cycle 1 Day 1 and every 3 weeks thereafter. Additionally, participants will receive CAPOX (capecitabine/oxaliplatin) treatment until IRC confirmed disease progression or a total of 8 treatments (each cycle is defined as 3 weeks = approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive capecitabine twice daily on days 1 through 14 of each cycle at the investigator's discretion until the subject meets study treatment discontinuation criteria.
89240178|NCT03568890|Active Comparator|Anticoagulation therapy|Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 60 days.
89240179|NCT03568890|Active Comparator|Antiplatelet therapy|Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 60 days.
89240180|NCT03562364|No Intervention|Standard of Care|The standard of care group will remain non-weight bearing for 10-12 weeks following definitive fixation and receive physical therapy in accordance with standard practice at the treating center.
89240181|NCT03562364|Experimental|Early Advanced Weight Bearing (EAWB)|The Early Advanced Weight Bearing (EAWB) group will receive early weight-bearing treatment using the antigravity AlterG treadmill. These sessions will begin 14-28 days following definitive fixation and last for a total of 10 weeks
89240182|NCT03559400|Experimental|gentamicin injection at fracture site|Subjects with an open tibia fracture who receive gentamicin in saline solution administered after closure at the time of initial debridement.
89240183|NCT03559400|Placebo Comparator|placebo saline injection at fracture site|Subjects with an open tibia fracture who receive placebo saline solution administered after closure at the time of initial debridement.
89240184|NCT03530683|Experimental|maplirpacept (PF-07901801) Monotherapy|"In the phase 1a dose- escalation part for single-agent maplirpacept (PF-07901801), participants with Relapsing or Refractory (R/R) lymphoma will be enrolled in sequential dose cohorts to receive maplirpacept (PF-07901801) QW to characterize safety, tolerability, and PK; to determine the Maximum Tolerated Dose (MTD) or P1b Starting Dose (a dose lower than or equal to the single-agent MTD), and to gain preliminary evidence of antitumor activity.~In addition, participants with R/R Lymphoma may also be enrolled in a cohort to receive maplirpacept (PF-07901801) Q2W and a cohort to receive maplirpacept (PF-07901801) Q3W to characterize safety, tolerability, and PK; to determine the MTD; and to gain preliminary evidence of antitumor activity."
89240185|NCT03530683|Experimental|Cohort A: maplirpacept (PF-07901801) + Azacitidine|"Cohort A1: participants with newly diagnosed TP53-mutated Acute Myelocytic Leukemia (AML) will be treated with maplirpacept (PF-07901801) QW + azacitidine.~Cohort A2: participants with newly diagnosed TP53-mutated AML will be treated with maplirpacept (PF-07901801) QW + azacitidine."
89240186|NCT03530683|Experimental|Cohort B: maplirpacept (PF-07901801) + Azacitidine and Venetoclax|"Cohort B1: elderly or unfit participants with newly diagnosed TP53-wildtype AML will be treated with maplirpacept (PF-07901801) QW + azacitidine and venetoclax~Cohort B2: elderly or unfit participants with newly diagnosed TP53-wildtype AML will be treated with maplirpacept (PF-07901801) QW + azacitidine and venetoclax."
89240187|NCT03530683|Experimental|Cohort D1 and D2: maplirpacept (PF-07901801) + an anti-CD20 targeting agent|"Cohort D1: participants with Relapsing or Recurrent (R/R) CD20+ Diffuse Large B Cell Lymphoma (DLBCL) will be treated with maplirpacept (PF-07901801) QW, then an increased dose Q3W + an anti-CD20 targeting agent.~Cohort D2: participants with R/R CD20+ DLBCL will be treated with maplirpacept (PF-07901801) dosed QW for 4 weeks, then an increased dose Q3W + an anti-CD20 targeting agent."
89240188|NCT03530683|Experimental|Cohort E1 and E2: single agent maplirpacept (PF-07901801)|"Cohort E1: participants with Relapsing or Recurrent (R/R) Multiple Myeloma (MM) will be treated with single agent maplirpacept (PF-07901801) QW.~Cohort E2: participants with R/R MM will be treated with single agent maplirpacept (PF-07901801) increased dose QW."
89240189|NCT03530683|Experimental|Cohort F1, F2 and F3: maplirpacept (PF-07901801) + isatuximab, carfilzomib and dexamethasone|"Cohort F1: participants with Relapsing or Recurrent (R/R) Multiple Myeloma (MM) will be treated with increasing doses of maplirpacept (PF-07901801) + isatuximab, carfilzomib and dexamethasone.~Cohort F2: participants with R/R MM will be treated with maplirpacept (PF-07901801) QW + isatuximab, carfilzomib and dexamethasone.~Cohort F3: participants with R/R MM will be treated with maplirpacept (PF-07901801) increased dose QW + isatuximab, carfilzomib and dexamethasone."
89240190|NCT03530683|Experimental|Cohort C1, C2 and C3: maplirpacept (PF-07901801) + Carfilzomib and Dexamethasone|"Cohort C1: participants with Relapsing or Refractory (R/R) Multiple Myeloma (MM) will be treated with maplirpacept (PF-07901801) QW~+ carfilzomib and dexamethasone.~Cohort C2: participants with R/R MM will be treated with maplirpacept (PF-07901801) QW + carfilzomib and dexamethasone.~Cohort C3: participants with R/R MM will be treated with maplirpacept (PF-07901801) Q2W + carfilzomib and dexamethasone."
89240191|NCT03518853|Experimental|Short-course Radiation Therapy|Short-course Hypofractionated Once-weekly Radiation Therapy: 35Gy in 5 fractions delivered once a week.
89240192|NCT03513484|Experimental|Treatment (nintedanib, azacitidine)|Participants receive nintedanib PO BID on days 1-28 and azacitidine IV or SC on days 1-7. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, participants may discontinue treatment, receive nintedanib every 4-8 weeks, or receive nintedanib and azacitidine every 4-8 weeks.
89240193|NCT03499678||Lung Cancer|Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)
89240194|NCT03499678||Control|Age and sex matched control individuals
89240195|NCT03495674|Experimental|Group I (FITBIT, cycling)|Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.
89240196|NCT03495674|Active Comparator|Group II (FITBIT, information)|Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.
89240197|NCT03494803||Control|
89240198|NCT03494803||Prostate Cancer|
89240199|NCT03483012|Experimental|Atezolizumab + Stereotactic radiosurgery (SRS)|"Atezolizumab administered intravenously once every 3 weeks~Stereotactic radiosurgery (SRS) begin within 14 days after brain MRI obtained"
89240200|NCT03455673||Atrial fibrillation|ATE score will be determined for patients hospitalized for ablation of atrial fibrillation or symptomatic left atrial tachycardia
89240201|NCT03440970|Experimental|Lysine Chloride|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
89240202|NCT03440970|Placebo Comparator|Placebo|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
89240203|NCT03379649|Experimental|PRP|Patient with recurrent implantation failure who receives intrauterine infusion of platelet rich plasma
89240204|NCT03379649|Placebo Comparator|Placebo|Patient with recurrent implantation failure who receives intrauterine infusion of embryo culture media
89240205|NCT03368950|Experimental|Intervention|Participants in this arm are invited to undertake an 8-week online mindfulness course
89240206|NCT03368950|Active Comparator|Wait list|Participants in this arm are informed they are on a wait list and are required to wait 8 weeks, before being invited to take part in the intervention itself (an 8-week online mindfulness course).
89240207|NCT03363893|Experimental|Module 1 Part A Multiple ascending dose cohort|Participants with advanced solid tumours receive CT7001 (samuraciclib) as oral monotherapy, in ascending dose cohorts, to identify the maximum tolerated dose (MTD), minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D).
89240208|NCT03363893|Experimental|Module 1 Part B-2 Castrate resistant prostate Cancer (CRPC) Expansion|Participants with castrate resistant prostate cancer will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
89240209|NCT03363893|Experimental|Module 1 Part B-1 Triple-negative breast cancer (TNBC) Expansion|Participants with locally advanced or metastatic triple-negative breast cancer (TNBC) will receive CT7001(samuraciclib) as oral monotherapy at the dose, frequency and schedule recommended from Module 1 Part A.
89240210|NCT03363893|Experimental|Module 2 Part A|Participants with locally advanced or metastatic HR+ve and HER2-ve breast cancer will receive CT7001 (samuraciclib) at the dose, frequency and schedule recommended from Module 1 part A and will receive Fulvestrant solution in pre-filled syringe for intramuscular (IM) injection
89240211|NCT03363893|Experimental|Module 4|Participants with advanced solid tumours will receive CT7001(samuraciclib) oral monotherapy in a randomized, balanced, single-dose, two-treatment (fed v fasting), two-period, two-sequence crossover study followed by once daily continuous dosing.
89240212|NCT03363893|Experimental|Module 1 Part A Paired Biopsy Breast Cancer Expansion Cohort|Participants with locally advanced or metastatic breast cancer will receive CT7001 (samuraciclib) as oral monotherapy at the minimally biologically active dose (MBAD) and recommended dose for Phase II testing (RP2D).
89240213|NCT03339128|Experimental|Eluxadoline 25mg|Eluxadoline 25mg, oral administration, twice daily
89240214|NCT03339128|Experimental|Eluxadoline 50mg|Eluxadoline 50mg, oral administration, twice daily
89240215|NCT03339128|Experimental|Eluxadoline 100mg|Eluxadoline 100mg, oral administration, twice daily
89240216|NCT03339128|Experimental|Placebo|Dose-matched placebo, oral administration, twice daily
89240217|NCT03325088|Other|Severe Asthma|patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment
89240218|NCT03325088|Other|Mild to moderate Asthma|patients affected with untreated mild to moderate asthma
89240219|NCT03325088|Other|Controlled Sample|smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor
89240220|NCT03251599|Sham Comparator|Glyceryl trinitrate 0.2|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.2 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
89240221|NCT03251599|Active Comparator|Glyceryl trinitrate 0.5|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.5 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
89240222|NCT03241056|Experimental|CBT for Maladaptive Beliefs about Memory|Using cognitive-behavioural therapy principles, this therapy is intended to examine and change maladaptive beliefs about memory as they pertain to compulsive checking.
89240223|NCT03241056|Active Comparator|Treatment as Usual|This is a control treatment, Treatment as Usual (TAU), which is what patients or community members would otherwise normally receive.
89240224|NCT03231709|Experimental|Trelagliptin 100 mg + Alogliptin 25 mg|Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks.
89240225|NCT03231709|Experimental|Alogliptin 25 mg + Trelagliptin 100 mg|Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks.
89240226|NCT03199651|Active Comparator|Arm I (UC)|Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
89240227|NCT03199651|Experimental|Arm II (AGIT/DS)|Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
89240228|NCT03199469|Experimental|Lower Dose|"1.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.~1.3 x10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time."
89240229|NCT03199469|Experimental|Higher Dose|"3.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.~3.5 x 10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time"
89240230|NCT03199469|No Intervention|Delayed-Treatment Control|Delayed-Treatment Control subjects will generally have the same assessments as treated subjects. After the follow up period, eligible delayed-treatment control subjects will be dosed with AT132 and initiate the same post-dose procedures as subjects who received AT132.
89240231|NCT03180502|Active Comparator|Arm I (photon-based IMRT, temozolomide)|Patients undergo photon-based IMRT QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
89240232|NCT03180502|Experimental|Arm II (proton beam radiation therapy, temozolomide)|Patients undergo proton beam radiation therapy QD, 5 days a week for 6 weeks for a total of 30 fractions. Beginning 4 weeks after completion of radiation therapy, patients receive standard of care temozolomide for 5 days. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression of unacceptable toxicity.
89240233|NCT03138863|Experimental|FETO Group|Participants undergoing fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
89240234|NCT03121248|Experimental|WBI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed
89240235|NCT03121248|Active Comparator|WBI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed
89240236|NCT03121248|Experimental|WBI - observational - 5|WBI 5 fractions SIB 5 fractions if needed
89240237|NCT03121248|Active Comparator|WBI - observational - 15|WBI 15 fractions SIB 15 fractions if needed
89240238|NCT03121248|Experimental|WBI + LNI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
89240239|NCT03121248|Active Comparator|WBI + LNI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
89240240|NCT03121248|Experimental|WBI with LNI - observational - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
89240241|NCT03121248|Active Comparator|WBI with LNI - observational - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
89240242|NCT03121248|Experimental|thoracic wall irradiation (TWI) +/- LNI - observational - 5|TWI 5 fractions SIB 5 fractions if needed LNI 5 fractions
89240243|NCT03121248|Active Comparator|TWI +/- LNI - observational - 15|TWI 15 fractions SIB 15 fractions if needed LNI 15 fractions
89240244|NCT03117972|Experimental|Arm A : FOLFOXIRI - bevacizumab|FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities
89240245|NCT03117972|Active Comparator|Arm B: FOLFOX or FOLFIRI - bevacizumab|FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities
89240246|NCT03108066|Experimental|PT2385 Tablets|Twenty-five patients will be enrolled in each stage of a two-stage design
89240247|NCT03054896|Experimental|VR-EPOCH|"Standard chemotherapy regimen, DA-EPOCH-R, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~Chemotherapy cycles will be administered approximately every 3 weeks~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
89240248|NCT03054896|Experimental|VR-CHOP|"Standard chemotherapy regimen, R-CHOP, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~Chemotherapy cycles will be administered approximately every 3 weeks~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
89240249|NCT03053193||MammaPrint and BluePrint testing|All patients will receive MammaPrint and BluePrint testing using the full-genome testing data chip. Treatment will be at the discretion of the physician while adhering to NCCN guidelines.
89240250|NCT03043573|Experimental|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
89240251|NCT03043573|Active Comparator|Supportive Therapy|Supportive Therapy focuses on: 1. Facilitating expression of affect; 2. Conveying to the patient that he or she is understood; 3. Offering empathy; and 4. Highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
89240252|NCT03028337|Experimental|Spine Radiosurgery - 1 Dose|Participants receive spine radiosurgery in a single large dose.
89240253|NCT03028337|Active Comparator|Spine Radiosurgery - 3 Doses|Participants receive spine radiosurgery over 3 smaller doses.
89240254|NCT03014479|Experimental|Trelagliptin|Trelagliptin 100 mg, orally, once weekly for up to 12 weeks. Trelagliptin 50 mg, orally, once weekly for up to 12 weeks in patients with moderate renal impairment.
89240255|NCT03014479|Active Comparator|Daily DPP-4 inhibitors|An inhibitor orally administered at the dosage and administration in the package inserts for each drug, for up to 12 weeks.
89240256|NCT02937818|Experimental|ARM A|
89240257|NCT02937818|Experimental|ARM B|
89240258|NCT02937818|Experimental|ARM C|
89240259|NCT02927691|Experimental|Immediate Treatment|Participants will begin treatment immediately following baseline testing.
89240260|NCT02927691|Other|Delayed Treatment|Following baseline testing, participants will receive no treatment for five weeks, then begin treatment immediately following a second baseline testing session.
89240261|NCT02916511|Experimental|Chemo-radiation group|"A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5"
89240262|NCT02872805|Active Comparator|PEPFAR Enhanced Standard of Care (PESCA)|This arm reflects an enhanced standard of care comparison group for PEPFAR supported sites. We will provide standardized materials to be used by current clinical staff to help support whatever the site specific activities are related to transition from pediatric to adult medical care
89240263|NCT02872805|Experimental|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
89240264|NCT02864394|Experimental|Pembrolizumab|Participants with NSCLC receive pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
89240265|NCT02864394|Experimental|Docetaxel|Participants with NSCLC receive Docetaxel 75 mg/m^2 IV over 1 hour Q3W until disease progression, toxicity, investigator's decision to discontinue, or consent withdrawal.
89240266|NCT02836418|Experimental|ATYR1940|Participants will receive ATYR1940 up to 3.0 milligrams per kilograms (mg/kg) intravenous (IV) infusion once weekly until approval of ATYR1940, discontinuation of its development, the study was closed by the Sponsor, or a criterion for study drug discontinuation (up to 34 weeks).
89240267|NCT02823860|Other|Biospecimens and Quality of Life (QoL)|Only if patient's consent is obtained, biospecimens, including tumor and/or peripheral blood are collected.
89240268|NCT02773849|Experimental|ADSTILADRIN|Intravesical administration of ADSTILADRIN into the bladder
89240269|NCT02727270||Parkinson's - High Stress *FULL NOT RECRUITING|Parkinson's disease patients with self-reported high strain/stress.
89240270|NCT02727270||Parkinson's - Low Stress *FULL NOT RECRUITING|Parkinson's disease patients with self-reported low strain/stress.
89240271|NCT02727270||Controls - High Stress *FULL NOT RECRUITING|Healthy controls (no neurological disease) with self-reported high strain/stress.
89240272|NCT02727270||Controls - Low Stress *FULL NOT RECRUITING|Healthy controls (no neurological disease) with self-reported low strain/stress.
89240273|NCT02727270||Huntington's - High Stress *FULL NOT RECRUITING|Huntington's disease patients and/or Huntington's disease gene carriers with self-reported high strain/stress.
89240274|NCT02727270||Huntington's - Low Stress *FULL NOT RECRUITING|Huntington's disease patients and/or Huntington's disease gene carriers with self-reported low strain/stress.
89240275|NCT02727270||Parkinson's Disease - ReEnrollment (COVID-19) *FULL NOT RECRUITING|Parkinson's disease patients that had previously completed the study.
89240276|NCT02684006|Experimental|Avelumab in combination with axitinib|Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
89240277|NCT02684006|Active Comparator|Sunitinib|Sunitinib given at 50 mg PO QD on schedule 4/2
89240278|NCT02654990|Experimental|Arm A - 20mg PAN TIW|20mg panobinostat three times a week, 2 weeks on/1 week of in combination with s.c. bortezomib and p.o. dexamethasone
89240279|NCT02654990|Experimental|Arm B - 20mg PAN BIW|20mg panobinostat twice a week, 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
89240280|NCT02654990|Experimental|Arm C - 10mg PAN TIW|10mg panobinostat three times a week 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
89240281|NCT02606422|Experimental|Active HD-tDCS plus Speech-Language Therapy|Active HD-tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min.
89240282|NCT02606422|Sham Comparator|Sham plus Speech-Language Therapy|Sham HD-tDCS will be applied at the beginning of 45min speech-language therapy session.
89240283|NCT02583672|Experimental|N-acetylcysteine|The first 10 GD1 subjects will take 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days. An interim analysis will be performed to determine if this dose produces changes in systemic redox status and brain glutathione (GSH) levels. If no signal of a significant change is observed, the remaining 20 subjects will receive up to 3600 mg NAC orally twice a day (7200 mg/day).
89240284|NCT02542839|Experimental|Real rTMS Stimulation|Repetitive TMS will be delivered over each cerebellar hemisphere, using a NeuroStar TMS therapy system. The coil will be positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. The coil position will be marked on the skin. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. Constant coil position will be continuously monitored during the experiment. A similar protocol will be observed for the contralateral cerebellum. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
89240285|NCT02542839|Sham Comparator|Sham rTMS Stimulation|Patients will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham NeuroStar TMS therapy system coil which produces discharge noise and vibration without stimulating the cerebral cortex. This technique has been suggested to provide more effective blinding compared to other methods use in previous controlled studies. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
89240289|NCT02491528|Experimental|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
89240290|NCT02491528|Active Comparator|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
89240291|NCT02464878|Other|Main study treatment|
89240292|NCT02399995||patients following hepatectomy|
89240293|NCT02372097|Experimental|Group A|Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
89240294|NCT02372097|Experimental|Group B|Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.
89240295|NCT02309151|Experimental|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
89240296|NCT02309151|No Intervention|Not immediate coronary angiography|Coronary angiography with possible coronary intervention may be performed at the discretion of the interventional cardiologist and should preferably not be performed until three days after the cardiac arrest. This strategy is in accordance with standard practice.
89240297|NCT02212860|Experimental|Single Fraction|Stereotactic neoadjuvant ablative radiation give in one single dose of 21 Gy. Lumpectomy to follow within 14-20 from radiation treatment date.
89240298|NCT02212860|Experimental|Three Fractions|Stereotactic neoadjuvant ablative radiation give in three doses of 10 Gy (30 Gy given in 3 fractions, one treatment every second business day). Lumpectomy to follow within 14-20 days from last radiation treatment.
89240299|NCT02162810|Active Comparator|oral steroids|Systemic high-dose steroids (30 mg/kg methylprednisolone) have been shown in a randomized, double-blind, placebo-controlled trial in humans not to negatively impact wound infection or dehiscence rates, instead benefitting patients in the postoperative period in ways such as decreasing pain. An acute course of oral systemic steroids has been routinely used in patients under the age of 12 with asthma exacerbations (liquid prednisolone at 1-2 mg/kg/day in 1-2 divided doses for up to 10 days, although usually given for 5 days, which is at least 19 times less than the dose proven to be safe in the randomized controlled trial mentioned above) and proven to be safe without adverse effects. Effect of prednisolone on the systemic response and wound healing after colonic surgery.
89240300|NCT02162810|Placebo Comparator|placebo-controlled|Simple Syrup will be used as the placebo
88804689|NCT01261819|Active Comparator|Traditional cystoscopy|"These patients had cystoscopy performed with the traditional cystoscope, which is considered to be the gold standard."
88804690|NCT00004156|Experimental|Vaccine: MUC1-KLH vaccine/QS21|Patients receive glycosylated MUC-1 antigen containing MUC-1(106) or MUC-1(33) with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, and 19 for a total of 5 vaccinations. Patients are followed every 3 months.
89240301|NCT02122107||breast cancer survivors who had received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
89240302|NCT02122107||breast cancer survivors who had not received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
89240303|NCT02122107||non-cancer controls matched by age,education, and race|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
89240304|NCT01709435|Experimental|Treatment (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89240305|NCT01585480|Experimental|weight gain prevention intervention|
89240306|NCT01585480|No Intervention|No treatment comparison group|
89240307|NCT01571895|Experimental|DF2156A 150 mg|150 mg capsule twice a day (every 12 h) for a maximum of 14 days
89240308|NCT01358877|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m^2 + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).
88804691|NCT01262131|Active Comparator|Resonator Protocol A|
88804692|NCT01262131|Active Comparator|Resonator Protocol B|Application of magnetic fields using the Resonator device Protocol B
88804693|NCT01262131|Placebo Comparator|Inactive Resonator|
88804694|NCT00004162|Experimental|Dose group 1 - dose 1 of Doxorubicin HCL Liposome|Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
89240309|NCT01358877|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram [mg/kg] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m^2) + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin AUC 6 (up to 900 milligrams [mg]).
89240310|NCT00643279|Experimental|CHRONICLE|Subjects randomized to the CHRONICLE group were managed using data from an implantable hemodynamic monitoring (IHM) device, including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The Chronicle IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
89240311|NCT00643279|Placebo Comparator|CONTROL|Subjects randomized to the CONTROL group implanted with the Chronicle implantable hemodynamic monitoring (IHM) device, but the intracardiac diagnostic information was blinded to both the patient and the physician during the randomized period of the study. Subjects were managed conventionally with standard of care. Physicians and patients have access to the intracardiac data after the randomized period of the study is over, at 6 months.
89240312|NCT00633087|Experimental|2-deoxyglucose|
89240313|NCT00182728|Experimental|Intraoperative Radiation Arm|Intraoperative radiotherapy (radiation therapy) during surgery for tumor excision.
89240314|NCT00176631|Experimental|licorice root extract and docetaxel|
89240315|NCT00002965|Experimental|Arm 1: Benign Meningiomas|INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
89240316|NCT00002965|Experimental|Arm 2: Other Pathologies|INF alpha as subcutaneous injection Monday to Friday for 8 weeks.
89240317|NCT06050473|Active Comparator|Supraclavicular nerve-sacrificing procedure|Surgeon will not attempt to identify the supraclavicular nerve branches.
89240318|NCT06050473|Active Comparator|Supraclavicular nerve-preserving procedure|Surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
89240319|NCT06050460|Experimental|SA55 injection|Cohort 1: 150mg; Cohort 2: 300mg; Cohort3: 600 mg; Cohort4: 900 mg
89240320|NCT06050460|Placebo Comparator|Placebo for SA55 injection|Cohort 1: 0mg; Cohort 2: 0mg; Cohort3: 0mg; Cohort4: 0mg
89240321|NCT06050447||Patients with right-sided colon cancer|Tumors located anywhere from the cecum to the proximal transverse colon.
89240322|NCT06050447||Patients with left-sided colon cancer|Tumors located anywhere from the distal transverse colon to the rectosigmoid junction
89240323|NCT06050447||Patients with rectal cancer|Tumors located in rectosigmoid junction and in the rectum with/without the external sphincter or the levator muscles invasion
89240324|NCT06050447||Patients with right- and left-sided colon cancer (primary multiple cancer)|Patients with primary multiple cancer tumors
89240325|NCT06050421|Other|Treatment as Usual (TAU)|The TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
89240326|NCT06050421|Experimental|TAU + Radically Open Dialectical Behaviour Therapy (RO-DBT)|2. TAU + skills of the RO-DBT: In this treatment branch, a RO-DBT skills training therapy will be added to TAU. Treatment and therapists: RO DBT skills training consists of a 30-week intervention program in which a set of skills specifically designed to treat overcontrol are taught on an ongoing basis. The duration of each session is 2 hours. Table X provides an overall summary of each skill training session content. Detailed and extensive information about the treatment can be found elsewhere [24], [34]. Three clinical psychologists and one psychiatrist will conduct the treatment, all of whom have undergone extensive training in RO DBT. A maximum of two therapists will be in charge of each session, and the same two therapists will go throughout each group intervention. The team will be supervised by an approved RO DBT supervisor to improve therapeutic skills and ensure adherence to the protocol.
89240327|NCT06050421|Other|Healty controls|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
89240328|NCT06050408|Experimental|Acute stroke group|Patients receive treatment 6-12 weeks after stroke.
89240329|NCT06050408|Experimental|Subacute stroke group|Patients receive treatment 16-20 weeks after stroke.
89240330|NCT06050408|Experimental|Chronic stroke group|Patients receive treatment 52+ weeks after stroke.
89240331|NCT06050382|Experimental|WOMEN WITH TENSION-TYPE HEADACHE|"The tension headache group consists of 22 women aged 20-45 years.The inclusion criteria were determined as follows being between the ages of 20 and 45, having a diagnosis of TTH or migraine according to the International Classification of Headache Disorders (ICHD-II)(1), and expressing voluntary willingness to participate in this study.~The exclusion criteria for the study included having any pathology involving the cervical region such as disc herniation, radiculopathy, a history of surgery, tumor, or cyst, having received any form of physical therapy targeting the cervical region within the past 3 months, being pregnant or in the menopausal phase; not participating in at least 15% of the training sessions, having a mental disorder (being diagnosed with depression or using antidepressant medication), having a chronic, neurological, or rheumatic disorder; suffering from sinusitis, and being on continuous prophylactic medication for migraines"
89240332|NCT06050382|Experimental|WOMEN WITH MIGRAINE|"The Migraine group consists of 22 women aged 20-45 years.The inclusion criteria were determined as follows being between the ages of 20 and 45, having a diagnosis of TTH or migraine according to the International Classification of Headache Disorders (ICHD-II)(1), and expressing voluntary willingness to participate in this study.~The exclusion criteria for the study included having any pathology involving the cervical region such as disc herniation, radiculopathy, a history of surgery, tumor, or cyst, having received any form of physical therapy targeting the cervical region within the past 3 months, being pregnant or in the menopausal phase; not participating in at least 15% of the training sessions, having a mental disorder (being diagnosed with depression or using antidepressant medication), having a chronic, neurological, or rheumatic disorder; suffering from sinusitis, and being on continuous prophylactic medication for migraines"
89240333|NCT06050343|Experimental|Rinsulin® R|Single subcutaneous administration of Insulin at a dose 0.3 IU / kg
89240334|NCT06050343|Active Comparator|Humulin® Regular|Single subcutaneous administration of Insulin at a dose 0.3 IU / kg
89240335|NCT06050330|Active Comparator|cases group|patients with psoriasis
89240336|NCT06050330|Active Comparator|control group|Healthy
89240337|NCT06050317|Experimental|Sintilimab Plus Chemotherapy and Radiotherapy|Sintilimab Plus mFFN and Radiation
89240338|NCT06050304||Crack-cocaine Use Disorder users|Observation of behaviour in ecological conditions in patients with crack-cocaine dependence
89240339|NCT06050239|Experimental|Radioligand Therapy|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
89240340|NCT06050226|Experimental|Arm1：low MY008211A dose|Participants will receive low MY008211A dose orally b.i.d
89240341|NCT06050226|Experimental|Arm2：high MY008211A dose|Participants will receive high MY008211A dose orally b.i.d
89240342|NCT06050213|Active Comparator|three implant group|Maxillary overdenture retained by 3 unsplinted implants in midline and canines regions.
89240343|NCT06050213|Active Comparator|five implant group|Maxillary overdenture retained by 5 unsplinted implants in midline, canines and molar regions.
89240344|NCT06050213|Active Comparator|four implant group|Maxillary overdenture retained by 4 unsplinted implants in canines and molar regions.
89240345|NCT06050200|Active Comparator|PVE|Portal Vein Embolisation Patients in this group will undergo embolisation of branch of portal vein (interventional radiological procedure)
89240346|NCT06050200|Active Comparator|LVD|Liver Venous Deprivation Patients in this group will undergo simultaneous embolization of branch of the portal vein and one or two hepatic veins (interventional radiological procedure)
89240347|NCT06050200|Experimental|ALPPS|Associating Liver Partition and Portal vein Ligation for Staged hepatectomy: Patients in this group will undergo surgical ligation of portal vein branch with partial liver transection (surgical procedure)
89240348|NCT06050174|Experimental|Azadirachta Indica|Azadirachta Indica (neem) gel are locally delivered to deepest part of the periodontal pocket by syringe with blunted tip gently and removed slowly in order not to harm the tissue for group 1 patients after phase 1 therapy by two weeks.
89240349|NCT06050174|Placebo Comparator|Non Surgical Periodontal Therapy|The patients will receive full mouth one stage debridement using ultrasonic scalers, manual scalers and curettes with oral hygiene instructions and education.
89240350|NCT06050161|Experimental|Artisential laparoscopic instrument|Artisential laparoscopic instrument use for suturing during minimally invasive gynecologic surgery
89240351|NCT06050161|Active Comparator|Conventional laparoscopic instrument|"Conventional (straight stick) laparoscopic instrument use for suturing during minimally invasive gynecologic surgery"
89240352|NCT06050161|Active Comparator|Robotic instrument|Robotic instrument use for suturing during minimally invasive gynecologic surgery
89240353|NCT06050148|Experimental|Feacal microbial transplantation (FMT)|
89240354|NCT06050148|Placebo Comparator|Placebo transplantation (PT), transplantation with coloured 0,9% NaCl-solution|
89240355|NCT06050096||DCB group|CTO patients treated by DCB
89240356|NCT06050044|Experimental|Group A (hyperbaric bupivacaine)|Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution.
89240357|NCT06050044|Experimental|Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)|Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution.
89240358|NCT06050018|Experimental|YesMilkdiet|After one week baseline, the participants will be assigned to YesMilkdiet consuming milk and dairy products for 4 weeks
89240359|NCT06050018|Active Comparator|NoMilkdiet|After one week baseline, the participants will be assigned to NoMilkdiet consuming another source of protein and without milk or dairy products for 4 weeks
89240360|NCT06050005|Experimental|Experimental - rehabilitation activity|All participants will be included in this arm.
89240361|NCT06049992|Active Comparator|Lumenless lead|Left bundle branch stimulation using leads without internal lumen (Lumenless; Medtronic Selectsecure 3830, Minneapolis, USA).
89240362|NCT06049992|Active Comparator|Stylet-driven lead|Left bundle branch pacing using leads with internal lumen and retractable helix (Tendril STS 2088TC, Abbott, Inc., USA; Solia S60, Biotronik, SE & Co., KG, Germany; Ingevity +, Boston Scientific, Marlborough, MA, USA).
89240363|NCT06049979||AGI group|critical ill patient with AGIUS score>2
89240364|NCT06049979||non-AGI group|critical ill patient with AGIUS score 0~2
89240365|NCT06049966|Experimental|Arm A|Carboplatin 5 AUC D1 plus Etoposide 100mg/m2 D1-D3 plus Atezolizumab 1200 mg, Q21, 4 Cycles and then maintenance Atezolizumab 1200 mg Q21
89240366|NCT06049966|Active Comparator|Arm B|Carboplatin 5 AUC D1 plus Etoposide 100mg/m2 D1-D3, 4 Cycles and then observation
89240367|NCT06049914|Experimental|Experimental group|"Exercise interventions~Visiting the primary clinic twice a week and exercising at home once a week for a total of 6 weeks during the introductory and expanding period, and then visiting the primary clinic once a week and exercising at home twice a week for 6 weeks during the maintenance period~For exercise intervention, the researcher visits the primary clinic and conducts it face-to-face~Flexibility and strength Exercises: Up to 4 group exercises under the guidance of researchers, up to 40 minutes scheduled~Nutritional interventions~Evaluate nutritional status through Mini Nutritional Assessment(MNA) survey at the time of Visit 1~Supplementary protein products are provided only for the malnourished group and at risk group with a MNA score of 23.5 or lower~Supplementary protein products: 'Mediwell', healthy five-grain flavor, liquid 150 ml, 150 kcal, 20g carbohydrates, 2g sugars, 8g protein, 5g fat"
89240368|NCT06049914|No Intervention|Control group|"Control group: Providing only video and educational materials without intervention (12 weeks)~Videos and educational materials are provided to both the experimental group and the control group for home exercise.~Subjects write flexibility exercises, strength exercises, aerobic exercises, and meal diaries at home."
89240369|NCT06049901|No Intervention|Control Group|This group will include 30 patients who will be scheduled to receive 6 cycles of 5-Fluorouracil and Oxaliplatin- based regimens every 2 weeks for 3 months.
89240370|NCT06049901|Active Comparator|Nitazoxanide Group|This group will include 30 patients who will be scheduled to receive 6 cycles of 5-Fluorouracil and Oxaliplatin- based regimens every 2 weeks plus nitazoxanide (500 mg orally twice daily) for 3 months.
89240371|NCT06049888|No Intervention|Naturalistic Social Media|In this control condition, participants will have no study-imposed restrictions on social media use.
89240372|NCT06049888|Experimental|Restricted Social Media|Participants will have social media apps on their phones blocked for three months.
89240373|NCT06049875||Home Hospitalization|Patients who arrived at the emergency department and were discharged to home hospitalization or were hospitalized for a day and discharged to comprehensive home hospitalization under the management of a remote internist and a nurse who will make home visits on a daily basis.
89240374|NCT06049875||Internal Ward Hospitalization|Patients who arrived at the emergency department and received a regular treatment.
89240375|NCT06049862|Experimental|MariTensi app and usual care|Patients use the MaRitensi application to manage their hypertension by utilizing various menus in the application and continue receiving treatment as usual for 12 weeks.
89240376|NCT06049862|No Intervention|Usual care|The patient was not given the MaRitensi application and only received treatment as usual.
89240377|NCT06049823|Experimental|Test1|half- (bottom 50% of socket filled with gelatin sponge and the top 50% of the socket filled with deproteinized bovine bone mineral mixed with collagen (DBBM-C)) then covered with a collagen membrane in tooth sockets
89240378|NCT06049823|Experimental|Test2|half- (bottom 50% of socket filled with gelatin sponge and the top 50% of the socket filled with deproteinized bovine bone mineral mixed with collagen (DBBM-C)) then covered with a nonresorbable membrane in tooth sockets
89240379|NCT06049823|Experimental|Control|full-grafting (DBBM-C+ Collagen membrane) in tooth sockets
89240380|NCT06049784|Experimental|Visual Biofeedback using self operated home ultrasound device|"Sonographic fetal weight and biophysical profiles will be done at the hospital clinic. A single ultrasound biofeedback session using trans-perineal Ultrasound (TPU) will guide maternal pushing. The process includes (a) Ultrasound assessing fetal head descent with the screen facing the provider, measuring the angle of progression (AOP); (b) Explaining anatomical landmarks to the patient; (c) Repeat AOP measurement with the screen facing the patient for biofeedback; (d) Reassess with the screen turned away.~Participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home, ideally twice a week, up to 4 times. Session records will be sent electronically to the sonographer for assessment and feedback.~All groups will complete questionnaires three times: (1) baseline, (2) about two weeks later (after home biofeedback training), and (3) six to eight weeks postpartum."
89240381|NCT06049784|Active Comparator|Visual biofeedback at the Hospital|"A sonographic fetal weight estimate and biophysical profile will occur at the hospital clinic for all patients. A single ultrasound-based biofeedback session will employ TPU for maternal pushing guidance. This process involves (a) Assessing fetal head descent with ultrasound to measure the angle of progression (AOP) during rest and pushing; (b) Explaining anatomical landmarks to the patient; (c) Repeating the AOP measurement as biofeedback; (d) Reassessing with the screen turned away.~Participants will complete questionnaires three times: (1) baseline, (2) two weeks later, and (3) six to eight weeks postpartum."
89240382|NCT06049784|No Intervention|Control / Standard care - Obstetrical ultrasound only|"A sonographic estimated fetal weight and biophysical profile will be performed in the hospital.~The participant will fill in questionnaires at three time points: (1) at baseline, before the ultrasound examination; (2) about two weeks later (i.e., after completing the self-operated visual biofeedback training at home, or at an equivalent time for the other two groups); (3) six to eight weeks postpartum."
89240383|NCT06049771|Experimental|Intervention group|Patients who were infected caused by CRE bloodstream infection and were treated with tigecycline. Blood samples were collected.
89240384|NCT06049758|Active Comparator|Laparoscopic hemicolectomy with Complete Mesocolic Excision|Patients will have laparoscopic hemicolectomy with Complete Mesocolic Excision, D3 lymph node dissection.
89240385|NCT06049758|Active Comparator|Conventional laparoscopic right hemicolectomy|Patients will have conventional laparoscopic right hemicolectomy with D2 lymph node dissection.
89240386|NCT06049745|No Intervention|hysteroscopic myomectomy without misoprostol|Patients undergoing hysteroscopic myomectomy that will be randomized to no intervention before the procedure.
89240387|NCT06049745|Experimental|Misoprostol group|Patients undergoing hysteroscopic myomectomy will be randomized to 400 mcg of misoprostol sublingual before the procedure.
89240389|NCT06049706|Experimental|Active Priming (TMSr)|"To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
89240390|NCT06049706|Sham Comparator|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
89240391|NCT06049667|Experimental|NTQ2494|For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).
89240392|NCT06049641||13 to 15 Year-Old|"Normotensive (Normal BP): SBP and/or DBP values below the 90th percentile for teens of the same age and sex.~Prehypertensive (High-normal BP): SBP and/or DBP values at or above the 90th percentile and/or below the 95th percentile for for teens of the same age and sex.~Hypertensive: SBP and/or DBP values at or above the 95th percentile for teens of the same age and sex."
89240393|NCT06049641||16 to 19 Year-Old|"Normotensive (Normal BP): SBP <130 mmHg and/or DBP <85 mm Hg.~Prehypertensive (High-normal BP): SBP 130 to 139 mmHg and/or DBP 85 to 89 mm Hg.~Hypertensive: SBP ≥140 mm Hg and/or DBP ≥90 mmHg."
89240394|NCT06049628|Experimental|FIFA 11+ group|The experimental group will apply FIFA 11+ training 3 times a week for 9 weeks.
89240395|NCT06049628|Active Comparator|control group|The control group members will be advised to continue their routine warm-up program 3 times a week for 9 weeks.
89240396|NCT06049550||mild thicknening of Bowman's Capsule|
89240397|NCT06049550||severe thickening of Bowman's Capsule|
89240398|NCT06049511|Experimental|intervention group|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved oral care, teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education.
89240399|NCT06049511|Other|control group|The control group consisted of a total of 30 patients who met the selection criteria, willingly participated in the study, and were randomly assigned based on a predetermined randomization list. In the control group, the investigator did not administer any specific oral care intervention. Instead, the patients received standard nursing care provided at the clinic to prevent oral mucositis. Moreover, all patients in the control group were given the same mouthwashes (Benzydamine and Mycostatin) as those in the treatment group. However, the frequency and timing of oral care varied among the nurses in the clinic due to differences in work load and individual experience.
89240400|NCT06049498|Experimental|Mongolian Medicine ZhenBao Pills group|Experimental group
89240401|NCT06049498|Placebo Comparator|Mongolian Medicine ZhenBao Pills Placebo-controlled group|Placebo-controlled group
89240402|NCT06049433|Other|Choice 1|Options; On-Demand (OD) alone or On-Demand (OD) with a facilitated discussion board (DB)
89240403|NCT06049433|Other|Choice 2|"Options:~On-Demand (OD) + Discussion board (DB) or OD + Video Conference (VC)"
89240404|NCT06049433|Other|Choice 3|Options; Om-Demand (OD) or On-Demand (OD) + Video Conference (VC)
89240405|NCT06049407|Experimental|Experimental: Intervention group|
89240406|NCT06049407|No Intervention|No Intervention: Control group|
89240407|NCT06049381||Patients receive LY007 CD20 CAR-T|
89240408|NCT06049381||Patients receive commerial CD19 CAR-T in China|
89240409|NCT06049368|Experimental|68Ga-P16-093|Within 1 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-P16-093.
89240410|NCT06049355|Experimental|Arm I (Exercise Together exercise program)|Patients and partners undergo Exercising Together exercise program during radiation therapy on study. Patients also undergo collection of blood samples throughout the trial.
89240411|NCT06049355|Active Comparator|Arm II (educational material)|Patients and partners receive educational materials specific to exercise. Patients also undergo collection of blood samples throughout the trial.
89240412|NCT06049225|Experimental|Experimental: High-Tech Intervention Group|Those in the high-tech intervention group will receive 6 months of active intervention (up to 60 minutes weekly health coaching calls and content delivery) and technology access.
89240413|NCT06049225|Experimental|Experimental: Low-Tech Intervention Group|Those in low-tech group will receive 6 months of one weekly coaching calls (last up to 60 minutes) and one weekly email
89240414|NCT06049225|Active Comparator|Active Comparator: Attention Control Group|The control group will be used to provide an untreated comparison for the intervention groups and will not receive MNT or technology support. Participants in the control arm will only get a baseline and post-intervention testing.
89240415|NCT06049186|Experimental|CRD group|Patients in the calorie-restricted diet (CRD) group will have strict calorie-restriction diets for 8 weeks and then weight stability for 4 weeks.
89240416|NCT06049186|Active Comparator|Control group|Patients in the control group will receive regular diets and metformin 1500 mg daily for 12 weeks. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
89240417|NCT06049173|Experimental|novel recruitment maneuver therapy|The use of abdominal compression cardiopulmonary resuscitation apparatus for new recruitment maneuver therapy: the use of autonomous ventilation mode (PSV or CPAP) during mechanical ventilation, followed by abdominal compression recruitment maneuver therapy, the number of times of each compression is 5-10, each time the duration of 30 to 40s, and then adjust to the previous breathing pattern.
89240418|NCT06049173|No Intervention|control group|The automatic ventilation mode (PSV or CPAP) is used during mechanical ventilation, with the pressure support set to 0 cmH2O and the positive end-expiratory pressure set to 30 to 45 cmH2O for 30 to 40s, and then adjusted to the previous breathing pattern.
89240419|NCT06048874|Experimental|FNB|sono-guided injection with 20ml ropivacaine
89240420|NCT06048874|Placebo Comparator|no FNB|sono-guided injection with 20ml 0.9% saline
89240421|NCT06048848|Experimental|FNB|sono-guided injection with 20ml ropivacaine
89240422|NCT06048848|Placebo Comparator|no FNB|sono-guided injection with 20ml 0.9% saline
89240423|NCT06048640|Placebo Comparator|Placebo|100 mg of placebo (cellulose)
89240424|NCT06048640|Active Comparator|Active|100 mg of Dynamine (methylliberine)
89240425|NCT06048341|Experimental|FNB|sono-guided femoral nerve injection with 20ml ropivacaine
89240426|NCT06048341|Placebo Comparator|No FNB|sono-guided femoral nerve injection with 20ml 0.9% saline
89240427|NCT06047639||Bone Anchored Hearing Implants(BAHI) Patient|Patients with chronic otitis media whose hearing could not corrected with surgery and also could not use conventional and got bone-anchored hearing implants as a standard of care were included.
89240428|NCT06046092|Experimental|Vaccinated|Participants will be allocated to one of 3 dose groups, each receiving two intradermal (i.d.) vaccinations with 0.12 mg, 0.60 mg, or 3.00 mg of H7HLAII, respectively.
89240429|NCT06045884|Experimental|FNB|sono-guided femoral nerve injection with 20ml ropivacaine
89240430|NCT06045884|Placebo Comparator|No FNB|sono-guided femoral nerve injection with 20ml 0.9% saline
89240431|NCT06045442|Experimental|Intervention|3 months intradialytic exercise intervention: 30 minutes of endurance training at the dialysis unit with a dialysis training device, twice a week.
89240432|NCT06045442|Active Comparator|Control|Usual Care
89240433|NCT06044805|Experimental|Therapeutic Efficacy of Chloroquine Plus Primaquine|"An invivo single arm trial. Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1(10mg/kg) and 2 (5mg/kg). Total dose, 25 mg base/kg.~Primaquine - it was given once a day (0.25 mg/kg) for fourteen days, starting on day 0 of CQ treatment. Total dose, 3.5mg/kg.~The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
89240434|NCT06044779|Active Comparator|Transversus Abdominis Plane (TAP) Anesthestic Block|Ultrasound-guided TAP block is done using 20 mL of 0.25% Bupivacaine administered at the lateral abdominal wall between the costal margin and the iliac crest
89240435|NCT06044779|Active Comparator|Erector Spinae Plane (ESP) Anesthetic Block|Ultrasound-guided ESP block is done using 20 mL of 0.25% Bupivacaine administered at the tip of the transverse process at the T9 level
89240436|NCT06043895|Experimental|EpiFaith CV|The conducting physicians in this group will use EpiFaith CV to localize the central vein and assess if there is arterial puncture
89240437|NCT06043895|Active Comparator|Conventional|The conducting physicians in this group will use Raulerson syringe to localize the central vein and assess if there is arterial puncture
89240438|NCT06043882||the relation between COVID-19 infection and the development of sarcoidosis .|All patients were subjected to the following : history taking , clinical examination , radiological assessment by CT chest , fiberoptic bronchoscopy where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination and if the patient had past history of COVID-19 infection with previous positive RT-PCR.
89240439|NCT06043128||Group with High Body Control|This group consists of stroke patients who received 23 or close to 23 points on the trunk impairment scale. In these patients, muscle stiffness, awareness of the sense of balance and position, quality of life will be evaluated and their relationships will be examined.
89240440|NCT06043128||Group with Low Body Control|This group consists of stroke patients who received 0 points or close to 0 points from the trunk impairment scale. In these patients, muscle stiffness, awareness of the sense of balance and position, quality of life will be evaluated and their relationships will be examined.
89240441|NCT06042127|Experimental|Per-oral endoscopic myotomy with fundoplication|The detail of the procedure has been reported in the literature. After completion of myotomy as per conventional anterior POEM, a serosal incision would be made at the level of the GE junction below the diaphragmatic crus. The peritoneal cavity would then be entered and the anterior gastric wall could be identified. A detachable endoloop would be introduced alongside the endoscope with the guidance of endoscopic clip. Three to four clips would be applied to the anterior gastric fundus while additional 3-4 clips would be applied to the edge of the submucosal tunnel, all anchoring to the endoloop. Upon tightening of the endoloop the anterior fundus would be approximated to the esophagogastric junction and thus completing the partial anterior fundoplication. Abdominal paracentesis to treat capnoperitoneum would be performed as required based on patient's clinical condition.
89240442|NCT06042127|Active Comparator|Conventional POEM|Conventional per-oral endoscopic myotomy An anterior POEM would be performed per usual manner described in the literature. The procedure would be performed under general anaesthesia by expert endoscopists with at least 50 case experience of conventional POEM and 5 cases experience of POEM-F. The requirement of POEM experience is based on a recent multicenter study of learning curve by Fujiyoshi Y, et al. The procedure would follow the current recommendations from expert panel in reducing GER, including avoidance of excessive gastric myotomy and preservation of the sling fibers are the gastric cardia. The length of the esophageal and gastric myotomy is standardized at 5cm and 2cm respectively
89240443|NCT06041776|Experimental|Befotertinib + Icotinib placebo|Befotertinib (75 mg or 100 mg orally, once daily) and Icotinib placebo(125 mg orally, three times daily)，in accordance with the randomization schedule
89240444|NCT06041776|Active Comparator|Icotinib + Befotertinib placebo|Icotinib (125 mg orally, three times daily) and Befotertinib placebo (75 mg or 100 mg orally, once daily)，in accordance with the randomization schedule
89240445|NCT06040060|Active Comparator|Preemptive Ketamine|Preemptive administration of Ketamine 0.5 mg/kgBB intravenously, given 10 minutes prior to incision
89240446|NCT06040060|Placebo Comparator|Placebo|Placebo administration of 10 mL NaCl 0,9% intravenously, given 10 minutes prior to incision
89240447|NCT06040034|Active Comparator|Continuous Lidocaine Intravenous Infusion|Patients were given a loading dose of 1.5 mg/kgBW intravenous lidocaine for 10 minutes before induction of anesthesia using a syringe pump, followed by continuous intravenous administration of 1.5 mg/kgBW/hour lidocaine until 30 minutes before the end of the surgery (when the skin is being sutured by the surgeon) using a syringe pump. Continuous administration of lidocaine was prepared by the research team as 10 cc of 20 mg/cc lidocaine in a 10 cc syringe and 10 cc of 0.9% NaCl in a 10 cc syringe.
89240448|NCT06040034|Active Comparator|Bolus Lidocaine Intravenous|Patients were given a loading dose of 1.5 mg/kgBW intravenous lidocaine for 10 minutes before induction of anesthesia using a syringe pump, followed by intravenous infusion of saline with the same volume until 30 minutes before the end of the surgery (when the skin is being sutured by the surgeon) using syringe pump.
89240449|NCT06038981|No Intervention|Control Group (CG).|no tranexamic acid administration.
89240450|NCT06038981|Experimental|TXA group.|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced.
89240451|NCT06022185|Experimental|Experimental group|Web Based E-Health Literacy, Digital Literacy and Healthy Lifestyle Behaviors Training
89240452|NCT06022185|No Intervention|Control Group|No action will be taken.
89240453|NCT06022172|Experimental|Experimental group|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.
89240454|NCT06022172|No Intervention|CONTROL GROUP|no action will be taken
89240455|NCT06015737|Experimental|Anifrolumab|The participants will receive dose A of anifrolumab as a SC injection from Week 0/Day 1 upto and including week 51.
89240456|NCT06015737|Placebo Comparator|Placebo|The participant will receive placebo as a SC injection from Week 0/Day 1 to Week 23. From Week 24 the participants will receive dose A of anifrolumab up to and including Week 51.
89240457|NCT06015087|Experimental|Intervention group|
89240458|NCT06015087|No Intervention|Control group|
89240459|NCT06010823|Experimental|Intervention|All the participants allocated to this group will undergo rehabilitation according to each medical center's standard rehabilitation practice. In addition, the participants will receive 12 therapy sessions incorporating error enhancement (3 session a week, for a period of 4 weeks), lasting approximately 25-30 minutes each.
89240460|NCT06010823|No Intervention|Control|All participants allocated to this study group will undergo rehabilitation according to each medical center's standard rehabilitation practice.
89240461|NCT06004700|Experimental|Mobile Application|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive the EHR integrated app and follow a 12-month interrupted time series analysis (ITSA) design.~n = 200"
89240462|NCT06004700|No Intervention|Controls|"This arm of the study will contain half the study population after randomization. The participants in this arm will be from the same rheumatologists as the experimental participants and will be used as concurrent controls by accessing their data on visits from the EHR during the same time period.~n = 200"
89240463|NCT05998005|Experimental|Initial training group|Participants who are initially trained in the First Face training program
89240464|NCT05998005|Other|Waitlist-control group|Participants who are trained in the First Face training program 6 months after the initial training group
89240465|NCT05990400|Experimental|Combination of minoxidil 5% topical and finasteride 0,1% topical group|Combination of minoxidil 5% solutio and finasteride 0,1% solutio which has administered topically
89240466|NCT05990400|Active Comparator|Minoxidil 5% topical group|Minoxidil 5% solutio which has administered topically
89240467|NCT05987605|Experimental|1A46 Drug Substance|One cycle is defined as 21 days. Patients will be scheduled to receive weekly infusions of 1A46 for the first cycle and then for the remaining 15 cycles of the study, patients will receive a single infusion of 1A46 per cycle (Q3W)
89240468|NCT05985200|Experimental|BI 3032950: Dose group 1|
89240469|NCT05985200|Experimental|BI 3032950: Dose group 2|
89240470|NCT05985200|Experimental|BI 3032950: Dose group 3|
89240471|NCT05985200|Experimental|BI 3032950: Dose group 4|
89240472|NCT05985200|Placebo Comparator|Placebo|
89240473|NCT05976711||Surveillance|20 AAA patients will undergo two MRI scans with a half year interval to assess a possible correlation between MRI derived biomarkers and the clinical standard to assess aneurysm progression (maximum AAA diameter).
89240474|NCT05976711||EVAR planning|10 patients will undergo magnetic resonance angiography next to the standard of CT angiography (CTA). It is investigated whether EVAR planning is feasible based on MRA and if or how measurements between MRA and CTA differ.
89240475|NCT05976711||EVAR follow-up|30 AAA patients who underwent EVAR will be included in three groups: 10 patients with ten complication free years after EVAR or sac regression, 10 patients with endoleak type I and 10 patients with endoleak type II. It is investigated whether MRI can provide extra information for the detection of endoleaks after EVAR.
89240476|NCT05973669|Experimental|Remote cochlear implant support|Participants will use MED-EL Remote Care to test their hearing and device functionality. Participants and clinicians will complete user feedback surveys regarding their experience and time/cost-savings.
89240477|NCT05964218|Experimental|Food-Body-Mind Intervention|Guided by the Actor-Partner Interdependence Model, the Allostatic Load Model, and the Transactional Theory of Stress and Coping, the proposed 16-week Food-Body-Mind intervention includes: 1) a school-based mindfulness component delivered to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises); 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a school learning and home practice connection component to improve caregiver-preschooler relationships.
89240478|NCT05964218|No Intervention|Usual Care Control|"Like those in the intervention group, preschoolers assigned to the control group will receive usual Head Start activities during the intervention period. After the 12-month follow-up data collection from both intervention and control participants in each year, each control family will receive all intervention supplies including the Tasty Healthy Cookbook, MyPlate plates, and a breathing ball, as well as the program manual on how to use the intervention supplies. These intervention supplies will be distributed to control families at the end of in-person data collection appointments. Moreover, a virtual caregiver meeting on mindful eating, movement, and parenting will be provided to all caregivers who are interested."
89240479|NCT05960812|Active Comparator|group 1 (patient treated by skillful neglect with biceps tenotomy)|neglect of upper border subscapularis tear and doing biceps tenotomy
89240480|NCT05960812|Active Comparator|group 2 (patient treated by arthroscopic repair with biceps tenotomy)|repair of upper border subscapularis tear and doing biceps tenotomy
89240481|NCT05951660|Experimental|INT1: Only patients are educated|
89240482|NCT05951660|Experimental|INT2: Only Healthcare Professionals are educated|
89240483|NCT05951660|Experimental|INT3: Both patients and Healthcare Professionals are educated|
89240484|NCT05951660|No Intervention|Control|
89240485|NCT05951179|Experimental|TARA-002|TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
89240486|NCT05941052|Experimental|Evaluation of various novel TB triage and diagnostic tests|For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB. The investigators aim to enroll 450 participants per year at each of three enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.
89240487|NCT05934240|Active Comparator|Experimental group|Diaphragmatic mobilization, toracic mobilization and manipulation
89240488|NCT05934240|Placebo Comparator|Control group|Placebo mobilization and manipulation
89240489|NCT05932368||patients undergoing open heart surgery|"Patients who underwent open heart surgery at Istanbul University, Istanbul Medical Faculty, Department of Cardiovascular Surgery between 2018 and 2022, and whose data required for the study are complete in their discharge file.~The inclusion criteria of the files were: the patient was between the ages of 25-70, had undergone open heart surgery, was included in a phase 1 cardiac rehabilitation program, and had a preoperative ejection fraction of over 40%. Files of patients who do not meet the inclusion criteria and do not give the necessary permission to use their data will not be included in the study."
89240490|NCT05928078|No Intervention|Control|Participants will develop their usual activity
89240491|NCT05928078|Experimental|Intervention|Participants will use the e-Health platform
89240492|NCT05926193|Experimental|Nutrition Workshops|
89240493|NCT05926193|No Intervention|No Workshops|
89240494|NCT05925322|Experimental|"Engage & Connect Psychotherapy"|"Engage & Connect is a remotely-delivered psychotherapy, aimed to increase engagement in rewarding social activities and in turn, reduce suicidality. In Engage & Connect, depressed middle-aged and older adults with suicidal ideation work with a therapist to develop action plans to pursue rewarding social activities of their choice."
89240495|NCT05925322|Active Comparator|Symptom Review and Psychoeducation (SRP)|In this intervention, the therapist will review the participant's symptoms and provide literature-based clinical explanations and clarifications about the symptoms, the course, and the causes of depression and aging processes. In SRP, the therapist reviews the depressed individual's symptoms, and level of information on depression, identifies misconceptions, and guides selection of educational material which could benefit the patient.
89240496|NCT05922618|Experimental|I-ONE group|The group will undergo home biophysical treatment with I-ONE® therapy (experimental group) for 4 hours/day for 60 days. Patients will follow standard rehabilitation treatment: patients will perform active and active-assisted range of motion (ROM) recovery exercises and stretching exercises for 30 minutes per day, for 6 weeks.
89240497|NCT05922618|No Intervention|Exercise group|The group, not subjected to biophysical therapy, will be controls. Patients will follow standard rehabilitation treatment: patients will perform active and active-assisted ROM recovery exercises and stretching exercises for 30 minutes per day, for 6 weeks.
89240498|NCT05897983|Experimental|Rocabado exercises plus TENS|Rocabado exercises plus TENS and traditional exercises For 8 weeks,Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises are done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
89240499|NCT05897983|Experimental|Rocabado exercises|Rocabado exercises part (1): 6×6×6 exercises are (1).The rest position of the tongue , (2). Shoulder retraction exercises, (3). Stabilized head flexion ,( 4). The axial extension of the neck , (5).Control of TMJ rotation , (6).Rhythmic stabilization technique . part (2): Joint mobilization) includes Distraction given with anterior glide, with anterior and lateral glide right/left & Lateral glide without distraction. Plus Traditional exercises.
89240500|NCT05897983|Experimental|Transcutaneous electrical nerve stimulation device|TENS is used, frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds. TENS electrodes are placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the upper back ,The TENS will be applied for 20 min 3 sessions/week for 8 weeks. Plus Traditional exercises.
89240501|NCT05892081|No Intervention|Control group|The control group received the usual care of the unit.
89240502|NCT05892081|Experimental|Colloid group|Received cold cream three times a day on the rash area while diaper changing by the researcher plus the usual care
89240503|NCT05892081|Experimental|Colloid oatmeal group|Received colloid oatmeal cream three times a day on the rash area while diaper changing by the researcher plus the usual care
89240504|NCT05891860|Experimental|Intervention|Study participants will be present during daily ICU team rounds by secure video conference.
89240505|NCT05876611||Using the new type of self stabilizing atlantoaxial fusion cage|Use the new type of self stabilizing atlantoaxial fusion cage to treat atlantoaxial dislocation.
89240506|NCT05876611||Using other fusion systems|Use screw and plate system or other existing models of fusion cages.
89240507|NCT05875636||Patients taking a GLP-1 agonist medication|Participants meeting all inclusion/exclusion criteria who are taking a GLP-1 agonist medication
89240508|NCT05875636||Controls|Participants meeting all inclusion/exclusion criteria and are NOT taking a GLP-1 agonist medication.
89240509|NCT05869721|Experimental|Yoga group|Participants will receive yoga programme over a period of eight weeks
89240510|NCT05869721|No Intervention|Control group|The participants in the control group will receive usual care, and complete all assessments on the same timeline as the intervention group. They will be offered yoga programme at the completion of the final measurement.
89240511|NCT05861856|Active Comparator|Virtual reality group|Virtual reality supported core stabilization exercises will be performed.
89240512|NCT05861856|Active Comparator|Manual therapy group|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
89240513|NCT05861856|Active Comparator|Combine group|Both virtual reality supported core stabilization exercises and manual therapy techniques will be applied.
89240514|NCT05859100|Experimental|Early Intervention|Participants are expected to begin intervention immediately after the completion of treatment for a period of 8 weeks.
89240515|NCT05859100|Other|Delayed Intervention|Participants are expected to begin intervention 4 weeks after the completion of the treatment, for a period of 4 weeks (weeks 5-8).
89240516|NCT05855577|Experimental|Terazosine|Pharmacological Treatment of Pakinson's disease patients using Terazosin 2 mg
89240517|NCT05855577|Placebo Comparator|placebo T|Pharmacological Treatment of Parkinson's disease patients using Placebo
89240518|NCT05855577|Experimental|Lisosan-G (Nutritional Supplement)|Treatment of Parkinson's disease patients using Lisosan-G
89240519|NCT05855577|Placebo Comparator|Lisosan_G Placebo|Treatment of Parkinson's disease patients using Lisosan-G
89240520|NCT05832112|Experimental|Out of the Cage Robotic Lobectomy|Consented patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, except for the incisions, that will consist in 1 to 4 subcostal ports, based on the patient and case characteristics.
89240524|NCT05829330|Active Comparator|Outpatient|Outpatient initiation of non-invasive mechanical ventilation
89240525|NCT05829330|Placebo Comparator|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
89240526|NCT05816031||Ketogenic diet|Patients scheduled to right laparoscopic adrenalectomy and belonging to the case arm, will be administered a standard 21 days ketogenic diet before surgery. Ketogenic diet is based on a standard diet plus a ketogenic product to be taken once daily for 21 days. In both groups patients will undergo abdominal ultrasound before surgery.
89240527|NCT05816031||No ketogenic diet|Ketogenic diet will not be prescribed to patients belonging to control group.
89240528|NCT05809453|Experimental|Cocaine|Prior to entering the warm environmental conditions the participant will receive cocaine intranasally at a dose no higher than 3 mg per kilogram body mass. This dose will be given only once.
89240529|NCT05809453|Placebo Comparator|Lidocaine|Prior to entering the warm environmental conditions the participant will receive lidocaine intranasally at a dose no higher than 3 mg per kilogram body mass. This dose will be given only once.
89240530|NCT05809219|No Intervention|Control group|Participants maintain usual diet and physical activity without any intervention
89240531|NCT05809219|Experimental|1 hour combined intervention ( Exercise and nutrition)|During intervention period, participants have 3 times exercise program per week. Each program is 30 minutes of resistance exercise and aerobic exercise. Participants take oral supplement (103 kcal and 8.4 g of protein) in 1 to 2 hours after exercise program.
89240532|NCT05809219|Experimental|3 hours combined intervention ( Exercise and nutrition)|"The only one different between 1 hour combined intervention and this intervention is the time interval between exercise and nutrition. The time interval of 1 hour combined intervention is 1 to 2 hour, and this intervention is 2.5-4 hours. Other procedure is totally the same."
89240533|NCT05809219|Experimental|Nutrition intervention|"Participants only take oral supplement. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
89240534|NCT05808530|Experimental|Intervention arm|It is te intervention grup.
89240535|NCT05808530|No Intervention|no intervention arm|It is the non intervention group.
89240536|NCT05803889||EC + Tax group|For the EC + Taxol arm, patients will have five visits during (neo)adjuvant chemotherapy: before the start of chemotherapy (evaluation 1), before the second EC administration (evaluation 2), before the third EC administration (evaluation 3), at the end of EC sessions and before the start of Tax (evaluation 4), and at the end of Tax administration (end of chemotherapy) (evaluation 5).
89240537|NCT05803889||Trastuzumab group|Patients in the Trastuzumab arm will be assessed only once at the end of treatment (on the same evaluation as the CE + Tax arm) to allow comparison with the fifth evaluation in the CE + Tax arm.
89240538|NCT05778448|Experimental|BCI-FES-VR|Participants look at an external screen displaying the VR avatar participant's arms while performing wrist dorsiflexion MI in random order (left or right). The BCI system detects the ERD of the motor area corresponding to correct MI. Then, visual feedback with the VR and motor-tactile feedback with the discharge of the FES is delivered. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
89240539|NCT05778448|Active Comparator|BCI-FES|Same procedure as arm 1 (BCI-FES-VR), but the difference is that the participant's hands replace the VR system. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
89240540|NCT05778448|Active Comparator|BCI-VR|Same procedure as arm 1 (BCI-FES-VR), but the FES is removed. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval. Each session requires 240 MI trials with a training duration of 10 sessions in a 3-week interval.
89240541|NCT05773703|Experimental|Trillium Compound Alone|Single dose of PSMA-Targeted [In-111]-Labeled Trillium Compound
89240542|NCT05773703|Experimental|Trillium Compound + Single Dose PTI-122|Single dose of PSMA-Targeted [In-111]-Labeled Trillium Compound plus single dose of PTI-122 at 5, 10 or 15 mg
89240543|NCT05773703|Experimental|Trillium Compound + Multiple Dose PTI-122|Single dose of PSMA-Targeted [In-111]-Labeled Trillium Compound plus two doses of PTI-122 at the preferred dose level
89240544|NCT05772520|Experimental|Cohort 1|TLL018 tables, 10 mg 1piece,BID
89240545|NCT05772520|Experimental|Cohort 2|TLL018 tables, 20 mg 1piece,BID
89240546|NCT05772520|Experimental|Cohort 3|TLL018 tables, 40 mg 1piece,BID
89240547|NCT05772520|Placebo Comparator|Cohort 4|placebo, 1piece,BID
89240548|NCT05771545||Pre-Innovation (Usual Care)|Patients evaluated in the psychiatric emergency department for possible involuntary admission during the year prior to the innovation in care. During this period, the attending psychiatrist was required to physically come to the hospital to examine the patient.
89240549|NCT05771545||Innovation (Tele-Psychiatry)|Patients evaluated in the psychiatric emergency department for possible involuntary admission during the innovation period. Instead of physically coming to the hospital, the attending physician will evaluate the patient via video-link, which will be facilitated by the on-site psychiatric resident.
89240550|NCT05768789|Experimental|Buoy Electrolyte Drops|The goal is to give 600mg of Na+ over 4 hours while measuring urine output over 6 hours. The recommended Buoy dosage is ⅓ tsp in 237 ml of water (50mg Na+) multiple times a day (Table 1). Therefore, to safely achieve a total dose 600mg Na+ (6-fold increase from single dose) we will use 4 tsps (18 ml) of Buoy diluted in 1 L of water.
89240551|NCT05768789|Experimental|Nuun Electrolyte Tablet|The goal is to give a one-time dose of Nuun (600mg Na+) at the start of the trial, diluted in 1L water to be consumed within 30 min (similar to prior published data, Pence 2020).
89240552|NCT05768789|Placebo Comparator|Water|Participants will ingest the same quantity of water (1 L) at a rate of 6.25% of the calculated amount of water every 15 min for 4 hours.
89240553|NCT05760742|Placebo Comparator|Placebo group|2 capsules of Maltodextrin per day
89240554|NCT05760742|Experimental|MicAlgae100|2 capsules per day containing 100mg of microalgae based ingredient
89240555|NCT05760742|Experimental|MicAlgae250|2 capsules per day containing 250mg of microalgae based ingredient
89240556|NCT05760742|Experimental|MicAlgae500|2 capsules per day containing 500mg of microalgae based ingredient
89240557|NCT05756686|Experimental|Breathing Group 1|Arm 1 will receive an 8-week remotely delivered intervention that consists of a set of breathing practices through 60-minute weekly virtual group sessions (1day/week) with a 20-minute daily home sessions (in between weekly sessions; 6 days/week).
89240558|NCT05756686|Active Comparator|Breathing Group 2|Arm 2 will receive an 8-week remotely delivered intervention that consists of slow breathing practices through 60-minute weekly virtual group sessions (1day/week) with a 20-minute daily home sessions (in between weekly sessions; 6 days/week).
89240559|NCT05749419||study group and control group|"Study group - children with chronic diseases, disabilities, or congenital anomalies.~Control group - their siblings."
89240560|NCT05731934|Experimental|HX301|Study treatment: during each cycle (28 days), HX301 is dosed QD for 3 weeks (21 days) followed by 1 week (7 days) off therapy.
89240561|NCT05730972|Experimental|true TEAS|"A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral Jiaji acupoint group (EX-B2) or the ipsilateral limb acupoint group(Hegu (LI4) - Waiguan (TE5), or Zusanli (ST36) - Sanyinjiao (SP6)), so as contralateral side.~A single TEAS treatment takes 30 min. TEAS specific parameters were dilatation wave 2Hz and stimulus current intensity in degrees as tolerated by the patient.~7 days was considered as 1 session. Self-controlled treatment refers to not setting an upper limit on the number of treatment times, but must have met at least 3 days or 5 times of TEAS treatment within each session.~A total of 4 sessions of treatment were administered."
89240562|NCT05730972|Sham Comparator|sham TEAS|Each step of the sham TEAS operation is the same as the TEAS group. A total of 4 sessions of treatment were administered. 10 free TEAS treatments will be given after the trial.
89240563|NCT05726825|Experimental|Therapeutic Plasma Exchange (TPE)|"1 x TPE with donor Fresh Frozen Plasma (FFPs) (1.2 x individual plasma volume) within the first 6 hrs after randomization.~A second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min within 24 hours after the first intervention."
89240564|NCT05726825|No Intervention|Standard of Care (SOC)|Non-interventional standard of care
89240565|NCT05724511|Experimental|Intervention|
89240566|NCT05724511|No Intervention|Control|
89240567|NCT05723549|Experimental|group1|Period1 : HCP1803-3
89240568|NCT05723549|Active Comparator|group2|Period1 : RLD2002, HCP1904-1
89240569|NCT05706610|Experimental|Tailored Program|8-week tailored program including 4 coach visits and 4 bi-weekly text check-ins
89240570|NCT05706610|Other|Feedback Program|8-week feedback program including 8 weekly texts
89240571|NCT05694819|Experimental|Darolutamide monotherapy|Targeted patients: 24
89240572|NCT05694819|Experimental|Darolutamide plus Goserelin|Targeted patients: 32
89240573|NCT05668988|Experimental|DZD9008|
89240574|NCT05668988|Active Comparator|Platinum-based Chemotherapy|
89240575|NCT05647213|Experimental|Treated|Subjects in Treated arm will receive one dose of Investigational Product. Within this arm are three dose levels. Dose level selection will be determined by product availability subjects have available product and when they can be treated. Dose levels will escalate in order of treatment date.
89240576|NCT05647213|No Intervention|Control|Subjects who enroll but do not receive Investigational Product will be placed in the control arm.
89240577|NCT05643105||Colon cancer patients with intestinal anastomosis|There is a single cohort of patients, the one operated on for colon cancer with intestinal continuity construction through an anastomosis without derivative stoma construction of any kind.
89240580|NCT05635591|Experimental|KSD-101|
89240581|NCT05628883|Experimental|Infusion of TBio-4101 TIL|"TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product: participants tumor tissue is surgically removed and immune T-cells are taken out of the tumor and multiplied, or grown, in the laboratory. TIL product infused intravenously over 20 to 30 minutes within 2 to 4 days after the last dose of fludarabine~Participants will also receive:~Cyclophosphamide dose 60 mg/kg/day for 2 days administered IV in 250 mL dextrose 5% in water infused simultaneously with Mesna 15 mg/kg/day delivered over 1 hour per day for 2 days. Fludarabine 25 mg/m2/day is delivered by intravenous piggyback daily over 15-30 minutes for 5 days.~Interleukin-2 (IL-2)- will be given to participants through IV after they receive the infusion of the TIL. IL-2 is administered at a dose of 600,000 IU/kg (based on actual body weight) IV every 8-12 hours beginning within 24 hours of TIL infusion for a maximum of 6 doses."
89240582|NCT05623137|Experimental|Acu-TENS+SHP|The 120z Dual-Channel TENS Unit (ECS300A; Neurotrac, Verity Medical LTD, Ireland) will be used to stimulate the selected acupoints. The electrode will be placed over the acupoints and connected to the TENS stimulator. The stimulation frequency will be set at 100 Hz with a pulse width of 0.2 ms. Participants will also receive a set of instructions relating to SHP. SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. Participants will be instructed to read the guide after the baseline assessment (T0).
89240583|NCT05623137|Sham Comparator|Sham Acu-TENS+SHP|Participants will receive similar treatment as Acu-TENS groups via identical-looking TENS devices with the electrical circuit disconnected.Participants will also receive a set of instructions relating to SHP. SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. Participants will be instructed to read the guide after the baseline assessment (T0).
89240584|NCT05616247|Experimental|ECALC|Cognitive Behavioral Program to Change Expectancy Processes
89240585|NCT05616247|Experimental|ECALC Plus Weekly Boosters|Cognitive Behavioral Program to Change Expectancy Processes with Weekly Booster Content Delivered by Mobile Device
89240586|NCT05616247|No Intervention|Control|Control Group Presentation on Body Image
89240587|NCT05607043|Other|SARS-CoV-2 testing|There is only one arm in this study- the study is a non-randomized pilot. All the subjects will be tested for SARS CoV 2 viral infection as described.
89240588|NCT05591833|Active Comparator|SASI|
89240589|NCT05591833|Experimental|SAS-J|
89240590|NCT05590455|Experimental|Adalimumab arm|"Standard TBM treatment~Adalimumab 40 mg: one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids"
89240591|NCT05590455|No Intervention|Control arm|- Standard TBM
89240592|NCT05589116|Experimental|Intervention group|Participants given immediate access to two-week, online compassionate imagery course.
89240593|NCT05589116|No Intervention|Wait-list control group|Participants will not access intervention during 10-week study period (access will be given to online compassionate imagery course after all outcome measures have been completed).
89240594|NCT05582876|Active Comparator|Group 1- patient of middle and high risk of prostate cancer|Patients with diagnosis or high probability of prostate cancer medium and high risk according to ISUP for which implementation is planned radical treatment [i.e. PSA≥10 ng / ml or GS ≥ 7 (ISUP ≥2) or ≥cT2b].
89240595|NCT05582876|Active Comparator|Group 2- patient after radical treatment, at relapse biochemical|Prostate cancer patients after radical treatment, with recurrence biochemical tests according to the criteria of the European Society of Urology (EAU, European Association of Urology) [at least double measurement PSA ≥0.2 ng / ml not earlier than 6-13 weeks after radical prostatectomy or PSA≥0.1 with PSAdt (PSA doubling time) <3 months or increase in PSA after radical radiotherapy> 2 ng / ml above PSAnadir - the lowest PSA value found after the test treatment] for whom further treatment is planned and the test result imaging / molecular imaging may alter the therapeutic decision
89240596|NCT05580003|Experimental|PF-07817883 Dose 1 in PART-1|
89240597|NCT05580003|Experimental|PF-07817883 Dose 2 in PART-1|
89240598|NCT05580003|Experimental|PF-07817883 Dose 3 in PART-1|
89240599|NCT05580003|Experimental|PF-07817883 Dose 4 in PART-1|
89240600|NCT05580003|Experimental|PF-07817883 Dose 5 in PART-1|Optional dose levels
89240601|NCT05580003|Experimental|PF-07817883 Dose 6 in PART-1|Optional dose levels
89240602|NCT05580003|Placebo Comparator|Placebo in PART-1|A single dose of placebo
89240603|NCT05580003|Experimental|PF-07817883 DR1 in PART-2|DR=Dosing regimen; twice a day
89240604|NCT05580003|Experimental|PF-07817883 DR2 in PART-2|
89240605|NCT05580003|Experimental|PF-07817883 DR3 in PART-2|Optional dosing regimen
89240606|NCT05580003|Experimental|PF-07817883 DR4 in PART-2|Optional dosing regimen
89240607|NCT05580003|Experimental|PF-07817883 in Japanese in PART-2|Optional dosing regimen to be studied in Japanese population
89240608|NCT05580003|Experimental|PF-07817883 in Chinese in PART-2|Optional dosing regimen to be studied in Chinese population
89240609|NCT05580003|Placebo Comparator|Placebo in PART-2|
89240610|NCT05580003|Experimental|PF-07817883 Suspension Fasted in PART-3|PART-3 is optional
89240611|NCT05580003|Experimental|PF-07817883 FORM-1 Fasted in PART-3|First solid oral formulation (FORM1)
89240612|NCT05580003|Experimental|PF-07817883 FORM-2 Fasted in PART-3|Second solid oral formulations (FORM-2) is optional
89240613|NCT05580003|Experimental|PF-07817883 FORM-1 Fed in PART-3|
89240614|NCT05580003|Experimental|PF-07817883 FORM-2 Fed in PART-3|
89240615|NCT05580003|Experimental|PF-07817883 in PART-4|PART-4 is optional
89240616|NCT05580003|Experimental|Midazolam 5 mg in PART-5|Single dose of 5 mg alone
89240617|NCT05580003|Experimental|Midazolam 5 mg with PF-07817883 in PART-5|Single dose of 5 mg on Day 10 with multiple doses (twice a day) of PF-07817883
89240618|NCT05580003|Experimental|PF-07817883 in PART-6|A single dose at supratherapeutic exposure administered as divided doses (1h apart)
89240619|NCT05580003|Placebo Comparator|Placebo in PART-6|A single dose of placebo administered as divided doses (1h apart)
89240620|NCT05580003|Active Comparator|Moxifloxacin 400 mg in PART-6 (open label)|Moxifloxacin 400 mg at 0h followed by placebo at 1h
89240621|NCT05578742|Experimental|Strategy A: PEEP 15 cmH2O → PEEP 5 cmH2O|
89240622|NCT05578742|Active Comparator|Strategy B: PEEP 5 cmH2O → PEEP 15 cmH2O|
89240623|NCT05574790||Admitted|We will include patients who had been admitted by meeting Ollero et al categories in hospitalization ward
89240624|NCT05572229|Experimental|Tec-Dara|For patients assigned to cohort A (Tec-Dara) patients will receive Tec-Dara until documented PD or unacceptable toxicity
89240625|NCT05572229|Experimental|Tec-Len|For patients assigned to cohort B (Tec-Len) patients will receive Tec-Len until documented PD or unacceptable toxicity
89240626|NCT05569408||EVUSHELD Arm|Individuals given EVUSHELD for prophylaxis
89240627|NCT05569408||Concurrent Control Arms|Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD
89240628|NCT05567679|Experimental|Tazemetostat|Tazemetostat 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
89240629|NCT05563818||Arabic-speaking individuals with schizophrenia|Approximately 56-60 Arabic-speaking individuals with a DSM-5 diagnosis of schizophrenia
89240630|NCT05552781|Experimental|20 mg QD, oral|H002 20mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89240631|NCT05552781|Experimental|40 mg QD, oral|H002 40mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89240632|NCT05552781|Experimental|80 mg QD, oral|H002 80mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89240633|NCT05552781|Experimental|150 mg QD, ora|H002 150mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89240634|NCT05552781|Experimental|250 mg QD, oral|H002 250mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89240635|NCT05552781|Experimental|350 mg QD, oral|H002 350mg QD, orally administered in fasting state, receive a single dose of H002 orally, followed by a 4-day washout period. Then, the same dose of H002 will be administered QD until disease progression or not tolerated.
89240636|NCT05548543|Experimental|Sequence 1|Period 1: RLD2202 +RLD2203 Period 2: HCP2202 Period 3: RLD2202 +RLD2203 Period 4: HCP2202
89240637|NCT05548543|Experimental|Sequence 2|Period 1: HCP2202 Period 2: RLD2202 +RLD2203 Period 3: HCP2202 Period 4: RLD2202 +RLD2203
89240638|NCT05548387|Experimental|Sequence 1|Period 1: RLD2202 +RLD2203 Period 2: HCP2202 Period 3: RLD2202 +RLD2203 Period 4: HCP2202
89240639|NCT05548387|Experimental|Sequence 2|Period 1: HCP2202 Period 2: RLD2202 +RLD2203 Period 3: HCP2202 Period 4: RLD2202 +RLD2203
89240640|NCT05512234|Experimental|L. reuteri|5 drops administered once daily for 21 days
89240641|NCT05512234|Placebo Comparator|Placebo|5 drops administered once daily for 21 days
89240642|NCT05508152|Sham Comparator|Wound irrigation with saline|After the closure of the aponeurosis, and before the closure of the skin, the subcutaneous layer of the wound will be rinsed with a determined volume (depending on the diameter of the incision) of a saline solution. Then, a gauze soaked with the same solution will be placed in the wound for 3 minutes.
89240643|NCT05508152|Experimental|Wound irrigation with antibiotic|After the closure of the aponeurosis, and before the closure of the skin, the subcutaneous layer of the wound will be rinsed with a determined volume (depending on the diameter of the incision) of amoxicillin-clavulanate in saline solution. Then, a gauze soaked with the same solution will be placed in the wound for 3 minutes.
89240644|NCT05500378|Other|neck extension group|Neck extension group
89240645|NCT05492565||Men who have sex with men|Men who have sex with men at substantial risk for HIV infection due to high-risk sexual habits
89240646|NCT05492565||Transgender women|Transgender women at substantial risk for HIV infection due to high-risk sexual habits
89240647|NCT05492565||Sex workers|Sex workers at substantial risk for HIV infection due to high-risk sexual habits
89240648|NCT05492565||HIV-uninfected people at substantial risk for HIV infection (other)|All HIV-uninfected people at substantial risk for HIV infection due to any other reason, including having an HIV-positive life partnerwith an HIV-positive life partner
89240649|NCT05486104|Experimental|Hemay005 45 mg BID group|3 tablets of Hemay005 (15mg/tablet) and 1 tablet of Hemay005 placebo will be orally administered twice daily.
89240650|NCT05486104|Experimental|Hemay005 60 mg BID group|4 tablets of Hemay005 (15mg/tablet) will be orally administered twice daily.
89240651|NCT05486104|Placebo Comparator|Hemay005 placebo BID group|4 tablets of Hemay005 placebo will be orally administered twice daily.
89240652|NCT05485168|Experimental|Sequential Variety, Small Portion|3 different foods served in a small portion in 3 successive courses
89240653|NCT05485168|Experimental|Sequential Variety, Large Portion|3 different foods served in a large portion in 3 successive courses
89240654|NCT05485168|Experimental|Single-Food, Small Portion|1 food served in a small portion in 3 successive courses
89240655|NCT05485168|Experimental|Single-Food, Large Portion|1 food served in a large portion in 3 successive courses
89240656|NCT05481411|Experimental|Single Dose Olpasiran Hepatic Impairment|Participants will be enrolled in 1 of 3 hepatic impairment groups based on their hepatic impairment status, as determined by Child-Pugh classification. All participants will receive a single dose of olpasiran on Day 1.
89240657|NCT05481411|Experimental|Single Dose Olpasiran Normal Hepatic Function|Participants with normal hepatic function will be enrolled and will receive a single dose of olpasiran on Day 1.
89240658|NCT05481307|Experimental|Fixed Sequence|Period 1: RLD2202, Period 2 : RLD2203 -> RLD2202+RLD2203
89240659|NCT05477511||Mother|Chinese mother in Hong Kong who had been assessed in HAPO follow-up study when their children was at either 7 or 11-14 years of age
89240660|NCT05477511||18 years old child of the enrolled mother|Children who had been assessed in HAPO follow-up study at either 7 or 11-14 years of age
89240661|NCT05454514|Other|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
89240662|NCT05452174|Experimental|Mirtazapine Treatment Arm|Subjects will be administered the initial dose of mirtazapine, with dosage progressively increased over the course of the study. The initial dose of mirtazapine is 15 mg tablet, once per day. The dose will be increased weekly as tolerated up to 45 mg per day. The dose will be increased by 15 mg each week if the lower dose is tolerated without significant side effects. That is to say, the subject will take 15 mg/day every day for the first week, 30 mg/day every day for the second week, and 45 mg/day every day for the third week, with the option of the subject continuing the medication for the remainder of the pregnancy. If subjects choose to discontinue the mirtazapine, there will be a tapering regimen: if a patient is taking 45 mg at the end of week 3, they will begin a taper (by week) of 30 to 15 to 7.5 to 0 mg. If they relapse or has discontinuation symptoms, the previous effective dose will be given. They may attempt to taper again with the same approach.
89240663|NCT05448547|Experimental|immediate curative therapy|Patients randomized to the intervention arm will receive immediate curative therapy in the form of either radiotherapy to the prostate in combination with hormone therapy (ADT or monotherapy) or surgery (radical prostatectomy). Standard treatment in this arm is radiotherapy + hormone therapy. Surgery is reserved for patients with strong preferences against radiotherapy.
89240664|NCT05448547|Active Comparator|initial observation/ hormone therapy|Patients in this arm will either be observed (with localized high-risk prostate cancer) or receive hormone therapy (locally advanced prostate cancer; ADT or monotherapy). Further local or systemic therapy is given at doctor's discretion triggered by local or/ and systemic progression.
89240665|NCT05446779||Sudden death|Unexpected witnessed death occurring within an hour of the onset of symptoms in a person with or without previously known cardiac disease without an extra-cardiac cause, or unexpected unwitnessed death without extra-cardiac cause occurring in the previous 24 hours
89240666|NCT05446779||Control|Death because of an exogenic reason for sudden death such as trauma or suicide as a control group i.e. non-disease-induced sudden death
89240667|NCT05442645||Participants with AD|Male or female, 18 years or older at the baseline visit initiated treatment with dupilumab for AD, who are eligible for dupilumab reimbursement according to the country-specific prescribing information
89240668|NCT05434702||Young adult cancer survivors|Adolescent and young adult cancer survivors
89240669|NCT05431166|Experimental|Immediate Treatment Group|8 weeks of Yoga Classes during first 8 weeks of study
89240670|NCT05431166|Active Comparator|Waitlist Control|8 weeks of Yoga Classes during second 8 weeks of study
89240671|NCT05423197|Active Comparator|panitumumab 30 mg|Subjects will be given a 30mg of panitumumab
89240672|NCT05423197|Experimental|89Zr-panitumumab IV|Subjects will be given 89Zr-panitumumab IV
89240673|NCT05411471|Experimental|Arm 1 (1 dose Omicron Vaccine arm, mRNA vaccine group)|75 participants who have completed two/three doses of mRNA vaccine (prior to this study) will receive one dose COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain(1200 SOU).
89240674|NCT05411471|Experimental|Arm 2 (2 doses Omicron Vaccine arm, mRNA vaccine group)|75 participants who have completed two/three doses of mRNA vaccine (prior to this study) will receive two doses COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (0,28 days)(1200 SOU).
89240675|NCT05411471|Experimental|Arm 3 (1 dose Omicron Vaccine arm, CoronaVac® group)|75 participants who have completed two/three doses of CoronaVac®(prior to this study) will receive one dose COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (1200 SOU).
89240676|NCT05411471|Experimental|Arm 4 (2 doses Omicron Vaccine arm, CoronaVac® group)|75 participants who have completed two/three doses of CoronaVac®(prior to this study) will receive two doses COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain (0,28 days)(1200 SOU).
89240677|NCT05399693||Patients with Platelet Transfusion Refractoriness|
89240678|NCT05399693||Patients without Platelet Transfusion Refractoriness|
89240679|NCT05399498|Experimental|Experimental: Psilocybin|Single 25 mg capsule oral dose of psilocybin
89240680|NCT05389826|Experimental|mHealth App group|Patients will be followed with the developed mobile web app,
89240681|NCT05389826|No Intervention|Control|Patients will be treated according to the current clinical practice.
89240682|NCT05377008|Experimental|Intervention|Parents in the intervention arm will receive one single-session intervention one month after completion of baseline measures. They will also complete a feasibility exit interview one month after completion of their data collection period (i.e., at 7 months).
89240683|NCT05377008|No Intervention|Control|Families in the control arm will complete measures at the exact same timepoints as those in the intervention arm but will not receive the single session intervention and will not complete the feasibility exit interview. They will receive the same information as the intervention arm via an education manual at the completion of their data collection period.
89240684|NCT05371860|Experimental|Omit breast radiation|
89240685|NCT05349591|No Intervention|Control|The Participants in this arm receive islet transplant only and no cePolyTregs.
89240686|NCT05349591|Experimental|Treatment|Participants will receive cePolyTregs (target 400-1600 million, with a minimal acceptable dose of 100 million) two weeks post islet transplant and will be followed for 1 year after cePolyTregs infusion to assess the safety and preliminary efficacy of cePolyTregs therapy.
89240687|NCT05342441|Experimental|QT-graft|Quadriceps tendon autograft (n=50)
89240688|NCT05342441|Experimental|St/Gr-graft|Semitendinosus/gracilis autograft (n=50)
89240689|NCT05342441|Experimental|BPTB-graft|Patella tendon autograft (n=50)
89240690|NCT05342428|Experimental|Cohort 1|TLL018 tablets, 1piece,BID
89240691|NCT05342428|Experimental|Cohort 2|TLL018 tablets, 2pieces, BID
89240692|NCT05342428|Experimental|Cohort 3|TLL018 tablets, 3pieces, BID
89240693|NCT05342428|Placebo Comparator|Cohort 4|TLL018 placeboes, 3pieces, BID
89240694|NCT05335083|Experimental|CPAP on condition|Participants in this arm will begin by using their CPAP as per usual for 2 weeks. Then they will undergo 2 weeks of CPAP withdrawal and stop using their CPAP machine.
89240695|NCT05335083|Experimental|CPAP off condition|Participants in this arm will withdraw from their regular CPAP use for 2 weeks. They will then resume their CPAP use for 2 weeks as usual.
89240696|NCT05323812|Experimental|TW001|
89240697|NCT05323812|Placebo Comparator|Placebo|
89240698|NCT05323110|Experimental|Part A - Cohort 1A|Single dose cohort
89240699|NCT05323110|Experimental|Part A - Cohort 2A|Single dose cohort
89240700|NCT05323110|Experimental|Part A - Cohort 3A|Single dose cohort
89240701|NCT05323110|Experimental|Part A - Cohort 4A|Single dose cohort
89240702|NCT05323110|Experimental|Part A - Cohort 5A|Single dose cohort
89240703|NCT05323110|Experimental|Part A - Cohort 6A|Single dose cohort
89240704|NCT05323110|Experimental|Part A - Cohort 7A|Single dose cohort
89240705|NCT05323110|Experimental|Part A - Cohort 8A|Single dose cohort
89240706|NCT05323110|Experimental|Part B - Cohort 1B|Multiple dose cohort
89240707|NCT05323110|Experimental|Part B - Cohort 2B|Multiple dose cohort
89240708|NCT05323110|Experimental|Part A - Cohort 3B|Multiple dose cohort
89240709|NCT05301062||Radium-223 dichloride treatment|Castration-resistant prostate cancer (CRPC) patients with bone metastases for whom a decision has been made independently by the treating physician and the patient to treat with Radium-223.
89240710|NCT05294159||Clinic-based PLH on CAB+RPV LA|All PWH participants will begin injections in the clinic setting in Phase 1. During Phase 1, PWH participants are screened and consented to participate in the study. During the screening phase, potential participants will be asked to identify their preferred location for phase 2 (decentralised site) and the reason for their preference. At the time of consent, patients will select their injection setting for Phase 2. Patients can select their preferred choice of setting until the 50 in-clinic numbers and 100 decentralised site places have been reached. After this, PWH participants will be allocated to the setting yet to reach its cap. In Phase 2, PWH participants will either continue to receive injection in clinic or receive injections from community nurses or clinic nurses at decentralised sites.
89240711|NCT05294159||Community-based PLH on CAB+RPV LA|All PWH participants will begin injections in the clinic setting in Phase 1. During Phase 1, PWH participants are screened and consented to participate in the study. During the screening phase, potential participants will be asked to identify their preferred location for phase 2 (decentralised site) and the reason for their preference. At the time of consent, patients will select their injection setting for Phase 2. Patients can select their preferred choice of setting until the 50 in-clinic numbers and 100 decentralised site places have been reached. After this, PWH participants will be allocated to the setting yet to reach its cap. In Phase 2, PWH participants will either continue to receive injection in clinic or receive injections from community nurses or clinic nurses at decentralised sites.
89240712|NCT05269303|Experimental|Intervention group|Participants will receive a 3-month Live With Wearable Monitoring Device program.
89240713|NCT05269303|No Intervention|Control group|Usual care. As with the participants in the intervention group, those in the control group can utilize the features in the Wearable Monitoring Device.
89240714|NCT05257928|Experimental|CARE-CITE GAIT Carepartner|This study arm consists of carepartners (CP) receiving the CARE-CITE Gait intervention. Over a period of one month, alongside the stroke survivor, the CP will receive 2 two-hour home-based therapy visits with a licensed physical therapist to develop therapy goals related to gait, mobility and balance and develop a home exercise plan to improve function. The CP will receive two additional phone calls to discuss the online CARE-CITE educational modules.
89240715|NCT05257928|Experimental|CARE-CITE GAIT Stroke Survivor|This study arm consists of stroke survivors (SS) of carepartners receiving the CARE-CITE Gait intervention. Over a period of one month, along with the CP, the SS will receive 2 two-hour home-based therapy visits with a licensed physical therapist to develop therapy goals related to gait, mobility and balance and develop a home exercise plan to improve function.
89240716|NCT05254236|Experimental|Medium-dose arm|75 participants vaccinated two doses of mRNA vaccine(prior to this study) will be given one dose booster immunization using medium-dose COVID-19 Vaccine (Vero Cell), Inactivated
89240717|NCT05254236|Experimental|High-dose arm|75 participants vaccinated two doses of mRNA vaccine(prior to this study) will be given one dose booster immunization using high-dose COVID-19 Vaccine (Vero Cell), Inactivated
89240718|NCT05243810|Experimental|Intervention|A prospective, single-arm, repeated measures feasibility study will be coordinated on the use of EPC Silver Wound Gel in patients with diabetic foot ulcers and localized infections within an outpatient clinical setting, to determine the safety of EPC Silver Wound Gel on diabetic foot ulcerations and impact on wound infection classification, wound ecology, and immunological biomarkers, in conjunction with the standard of care, to clarify parameters for a potential future study.
89240719|NCT05242042|Experimental|Arm 1|
89240720|NCT05242042|Placebo Comparator|Arm 2|
89240721|NCT05232942||Studied group|The study population will consist of patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (galcanezumab, fremanezumab or eptinezumab) or else its receptor (erenumab), with positive response, and discontinue the treatment.
89240722|NCT05217147||Patient group|60 patients with laryngeal carcinoma
89240723|NCT05217147||Control group|20 healthy age- and sex- matched controls
89240724|NCT05216081|Experimental|Elder adults in emergency department setting with cognitive impairment|Elder mistreatment in an Emergency Department setting with cognitive impairment.
89240725|NCT05199129|Experimental|HCP1904-3|
89240726|NCT05199129|Active Comparator|RLD2001-1|
89240727|NCT05197699||DMT-Treated Participants|MS participants who are receiving DMTs will be enrolled.
89240728|NCT05197699||Untreated Participants|MS participants who are receiving no DMT treatment or receiving only symptomatic treatment will be enrolled.
89240729|NCT05194202|Experimental|ED-HEART (Intervention Arm)|All adolescents take a baseline survey in the Emergency Department (ED), receive Emergency Department Healthcare Education Assessment and Response for Teen Relationships (ED HEART) by a trained health educator, complete an exit survey while in the ED, complete a 6-week check-in to confirm contact information and aid retention, and complete a 12-week follow up survey.
89240730|NCT05194202|No Intervention|Enhanced Standard Care (Control Arm)|All adolescents take a baseline survey in the Emergency Department (ED), receive enhanced standard care (i.e., standard care + teen resource list), complete a 6-week check in to confirm contact information and aid retention, and complete a 12-week follow up survey.
89240731|NCT05179616||Heart Failure Patients|Patients suffering from symptoms of right heart failure due to high-grade tricuspid regurgitation
89240732|NCT05175014|Experimental|Single full dose of PCV 10|27 clusters randomized to receive a vaccination campaign with the full dose.
89240733|NCT05175014|Experimental|Single fractional dose of PCV10 (1/5)|27 clusters randomized to receive a vaccination campaign with the fractional dose (1/5).
89240734|NCT05175014|No Intervention|Control Group|9 clusters randomized to the control arm.
89240735|NCT05165823|Experimental|Sodium restriction|
89240736|NCT05165823|No Intervention|Usual diet|
89240737|NCT05159245|Experimental|Alectinib|For patients with a molecular tumor profile that can potentially be targeted by alectinib.
89240738|NCT05159245|Experimental|Cobimetinib|For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.
89240739|NCT05159245|Experimental|Vismodegib|For patients with a molecular tumor profile that can potentially be targeted by vismodegib.
89240740|NCT05159245|Experimental|Trastuzumab+Pertuzumab|For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.
89240741|NCT05159245|Experimental|Entrectinib|For patients with a molecular tumor profile that can potentially be targeted by entrectinib.
89240742|NCT05159245|Experimental|Atezolizumab|For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.
89240743|NCT05159245|Experimental|Vemurafenib|For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.
89240744|NCT05159245|Experimental|Regorafenib|For patients with a molecular tumor profile that can potentially be targeted by regorafenib.
89240745|NCT05159245|Experimental|Apalutamide|For patients with a molecular tumor profile that can potentially be targeted by apalutamide.
89240746|NCT05159245|Experimental|Abemaciclib|For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.
89240747|NCT05159245|Experimental|Selpercatinib|For patients with a molecular tumor profile that can potentially be targeted by selpercatinib.
89240748|NCT05159245|Experimental|Dabrafenib|For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.
89240749|NCT05159245|Experimental|Trametinib|For patients with a molecular tumor profile that can potentially be targeted by trametinib.
89240750|NCT05159245|Experimental|Dabrafenib+Trametinib|For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.
89240751|NCT05159245|Experimental|Pralsetinib|For patients with a molecular tumor profile that can potentially be targeted by pralsetinib.
89240752|NCT05155995|Experimental|Sequence 1|"Period 1: Fasted state + RLD2007 +RLD2008 + RLD2102~Period 2: Fasted state + HCP2001"
89240753|NCT05155995|Experimental|Sequence 2|"Period 1: Fasted state + HCP2001~Period 2: Fasted state + RLD2007 +RLD2008 + RLD2102"
89240754|NCT05155995|Experimental|Sequence 3|"Period 1: High fat diet + RLD2007 +RLD2008 + RLD2102~Period 2: High fat diet + HCP2001"
89240755|NCT05155995|Experimental|Sequence 4|"Period 1: High fat diet + HCP2001~Period 2: High fat diet + RLD2007 +RLD2008 + RLD2102"
89240756|NCT05142371|Experimental|Arm A (home-based exercise program)|Patients undergo home-based exercise program 3 times per week for 8 weeks. Patients complete questionnaires at baseline (before 1 week) and at weeks 9 and 17.
89240757|NCT05142371|Active Comparator|Arm B (current activities)|Patients complete questionnaires at baseline and at week 9 and 17. Patients continue maintaining current activities of daily living and do not participate in any exercise program. Patients may then participate in home-based exercise program 3 times per week for 8 weeks.
89240758|NCT05116995|Active Comparator|Rivaroxaban first|Patients will be treated with rivaroxaban 2.5 mg twice a day for one week then on Day 21, will be treated with ticagrelor 60 mg twice a day for one week.
89240759|NCT05116995|Active Comparator|Ticagrelor first|Patients will be treated with ticagrelor 60 mg twice a day for one week then on Day 21, will be treated with rivaroxaban 2.5 mg twice a day for one week.
89240760|NCT05105776|No Intervention|Physiotherapy only|
89240761|NCT05105776|Experimental|Active galvanic stimulation (GVS; week 1) to sham GVS (week 2)|Physiotherapy + translingual neurostimulation provided throughout
89240762|NCT05105776|Experimental|Sham GVS (week 1) to active GVS (week 2)|Physiotherapy + translingual neurostimulation provided throughout
89240763|NCT05105776|Experimental|Active GVS throughout weeks 1 + 2|Physiotherapy + translingual neurostimulation provided throughout
89240764|NCT05097885|Experimental|Sub Acute (12 week) Whole Body Training|
89240765|NCT05095857|Active Comparator|S-ketamine|S-ketamine is given as a continuous infusion started at a dose of 2.0 mg/kg/hour. The infusion rate will be re-evaluated after 24 hours, where (1) the infusion will be stopped if 24 hours ensue without SDs, (2) maintained at 2.0 mg/kg/hour if the 24-hour incidence of SDs decreases below the rate of the previous 24 hours but SD is not totally abolished, or (3) increased to 3.0 mg/kg/hour if the incidence of SD is at or above the rate of the previous 24 hours. If the infusion rate has been increased to 3.0 mg/kg/hour, the rate will be returned to 2.0 mg/kg/hour if 24 consecutive hours of ECoG show no SD.
89240766|NCT05095857|Placebo Comparator|Isotonic saline|Isotonic saline is given as placebo. It will be given as a continuous infusion started at a dose corresponding to a dose of S-ketamine of 2.0 mg/kg/hour, and follow the criteria for increasing/decreasing infusion rates as S-ketamine. The infusion rate is read from a table listing different infusion rates (ml/hour) based on participant weight and if the treatment tier corresponds to a S-ketamine dose of 2 or 3 mg/kg/hour.
89240767|NCT05094817||Access to Computer|Participants completing the BHA should be at least somewhat comfortable or very comfortable with using a computer and mouse and should use a computer at least once a week.
89240768|NCT05094817||No Access to Computer|Since participants in previous studies on cognitive screening are usually more educated individuals with higher income, participants who do not have proficiency/or access to a computer will be asked to complete some questionnaires to determine any sociodemographic or baseline differences between patients who are able to complete BHA vs. those who are not able to complete BHA.
89240769|NCT05086380|Experimental|FND Patients Experimental|Group of patients with functional neurological disorders
89240770|NCT05086380|Active Comparator|Organic controls|Group of patients with organic neurological disorders
89240771|NCT05086380|Active Comparator|Healthy controls|Group of healthy controls
89240772|NCT05086380|Active Comparator|FND Patients Comparator|Group of patients with functional neurological disorders
89240773|NCT05078398|Experimental|POINT-B|Patients will receive perioperative counseling on opioid consumption following breast surgery, both preoperatively and postoperatively. Upon discharge, patients will be asked whether they would like to be discharged with narcotic pain medication or not.
89240774|NCT05078398|Active Comparator|Usual Care|Patients will receive equivalent of 5 tabs of Norco 5/325 mg upon discharge routinely
89240775|NCT05056623|Experimental|Dyadic pain management program|The DPM is an 8-week group-based program. The DPM included 4 weeks of center-based, face-to-face activities and 4 weeks digital-based activities delivered via a WhatsApp group.
89240776|NCT05056623|Other|Usual care and pain management pamphlet|The participants in the control group will receive the usual care and a pain management pamphlet.
89240777|NCT05053113|Experimental|Group 1 (phone call, FitBit, newsletter, accelerometer)|Participants receive phone calls over 30-45 minutes each from a health coach weekly during month 1, twice monthly during months 2-4, and monthly during months 5-6 for a total of 12 phone calls that focus on identifying needs, practicing autonomy supportive behaviors, and the development of a mutual support plan. Participants also engage in at least one physical activity per week with their partner and monitor their own and each other's activity using a FitBit. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days. Participants also receive an electronic newsletter twice monthly during months 1-3 and monthly during months 4-6 that provides educational physical activity-related information and tips for overcoming barriers to physical activity.
89240778|NCT05053113|Active Comparator|Group 2A (phone call, FitBit, newsletter, accelerometer)|Participants receive phone calls from a health coach as in Intervention I that focus on providing support for behavioral skills, including monitoring physical activity, goal-setting, and problem-solving to overcome barriers to physical activity. Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 that provides educational physical activity-related information and tips for overcoming barriers to physical activity. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
89240779|NCT05053113|Active Comparator|Group 2B (FitBit, newsletter, accelerometer)|Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 to share basic health education related to physical activity and provide support for engagement. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
89240780|NCT05041842|Experimental|Tucatinib plus systemic treatment with or without hormone therapy|Addition of tucatinib to the systemic treatment (pertuzumab and trastuzumab) with or without hormone therapy.
89240781|NCT05039541|Experimental|ESRD Patients|ESDR Patients will wear the Alio Device over their vascular access for either I) the duration of their dialysis session in clinic or II) for a 90 day period.
89240782|NCT05018728|Experimental|Voxelotor|Children with sickle cell anemia taking voxelotor for 12 weeks.
89240783|NCT04995913|Experimental|Computer-based (PC) online CBT program (Web version of the EASE Online Program)|The Web version of the EASE Online Program delivers the online CBT program through the Program website. It includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy.
89240784|NCT04995913|Experimental|Smartphone-based (App) online CBT program (App version of the EASE Online Program)|The App version of the EASE Online Program delivers the online CBT program through a smartphone application. The program content and system functions are the same as those of the Web version.
89240785|NCT04995913|Other|Waitlist control group|The Waitlist control group will receive the service of the Web version of the EASE Online Program after the two experimental groups completed the service.
89240786|NCT04995835|Experimental|Cefiderocol|Participants will receive four to six doses of Cefiderocol as per current prescribing information based on calculated creatinine clearance.
89240787|NCT04983511|Experimental|Electrical Epidural Stimulation Test (EST)|Postpartum women are given EST to predict epidural catheter reactivation for their subsequent procedures (i.e. tubal ligation).
89240788|NCT04973683|Experimental|Treatment (AL101)|Patients receive AL101 IV over 60 minutes QW for 6-8 weeks in the absence of disease progression or unacceptable toxicity. Within 24-72 hours after the last infusion of AL101, patients undergo surgery per standard of care. Patients may continue AL101 after surgery at the discretion of the study doctor.
89240789|NCT04962594|Experimental|Experimental formulas (EF) group|Starter infant formula, follow-up infant formula and growing-up milk (partially hydrolyzed bovine whey protein) supplemented with pre- and probiotic(s)
89240790|NCT04962594|Active Comparator|Control formulas (CF) group|Starter infant formula, follow-up infant formula and growing-up milk (partially hydrolyzed bovine whey protein) not supplemented
89240791|NCT04962594|Active Comparator|Breastfed (BF) group|Breast milk
89240792|NCT04949750|Experimental|Paper based cognitive training|Patients with Alzheimer's disease in the early stage receive 12 weeks paper based cognitive training and standard care (medication)
89240793|NCT04949750|No Intervention|Control group|Patients with Alzheimer's disease in the early stage only receive standard care (medication)
89240794|NCT04949243||People who use the self administered SARs-CoV-2 antigen testing kits|
89240795|NCT04929275|Other|Enhanced recovery program|
89240796|NCT04929184|Experimental|Adults who stutter (AWS)|Participants will have 2 visits.
89240797|NCT04929184|Other|Healthy Adults|Participants will have 2 visits.
89240798|NCT04929184|Experimental|Children who Stutter|Participants will have 1 visit.
89240799|NCT04929184|Other|Healthy Children|Participants will have 1 visit.
89240800|NCT04918121|Experimental|Yutiq|A sustained-release steroid insert (Yutiq) will be implanted along with a glaucoma drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery.
89240801|NCT04918121|No Intervention|Control|Non-study eye will not receive the Yutiq insert
89240802|NCT04894084|Experimental|Test product|Subjects are requested to use the test device (supporting product) beneath their ostomy baseplate. Subjects may change their appliance as they wish, either they may change due to a notification from the app and/or follow their change routine.
89240803|NCT04893330||patients|children under 8 months of age at inclusion, with a diagnosis or strong suspicion of APLV
89240804|NCT04884685|Experimental|Experimental Group|Participant will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.
89240805|NCT04884685|Placebo Comparator|Control Group|Placebo will receive two doses of placebo. The placebo will given by intramuscular injection on day 0 and day 28.
89240806|NCT04881812|Experimental|Drug-coated balloon|Patients will receive stenting of the actual CTO body with additional DCB treatment of the residual disease of the coronary artery.
89240807|NCT04881812|Active Comparator|Drug-eluting stent|Patients will receive complete stenting of the CTO body and residual disease of the coronary artery.
89240808|NCT04881526|Active Comparator|Ketone ester drink|
89240809|NCT04881526|Placebo Comparator|Placebo drink|
89240810|NCT04880226|Other|Healthy Volunteers|Imaging of healthy volunteers would performed to optimize image parameters (contrast, SNR) prior to clinical imaging of actual patients receiving treatment.
89240811|NCT04880226|Experimental|Patients receiving MRI-guided procedures|As described in the study protocol this imaging would be performed to evaluate a given sequence for potential benefit during MR-guided interventions.
89240812|NCT04857944|Experimental|Personalised exercise group program + fitness tracker + app with motivational messages (A)|After study entry and baseline assessments, subjects will attend the one-month IDEA group sessions aimed at promoting physical activity and exercise. Participants randomly assigned to this study arm will use the smart band and the app with the motivation set enabled, allowing participants to receive the messages according to their compliance and adherence to the personalised prescriptions. After group sessions (week 4), study subjects will start receiving motivational messages up until the end of the trial (8 consecutive months).
89240813|NCT04857944|Experimental|Personalised exercise group program + fitness tracker + app without motivational messages (B)|Subjects will follow the same procedure as intervention A, with the difference that the app will have the motivation set disabled, therefore participants will not receive any messages regarding their compliance. After group sessions, study subjects will be expected to continue using the smart band and app up until the end of the trial (8 consecutive months).
89240814|NCT04857944|Sham Comparator|Fitness tracker + app without motivational messages (CG)|After study entry and baseline assessments, all patients assigned to the control group will receive both the app and the smart band, but the motivation set will be disabled. Study subjects will be expected to use the smart band and app up until the end of the trial.
89240815|NCT04831918|Experimental|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of the Mueller cemented cup as acetabular component.
89240816|NCT04830449|Experimental|HCP1904-2|
89240817|NCT04830449|Active Comparator|RLD2001-2|
89240818|NCT04820907|Experimental|HCP1904-1|
89240819|NCT04820907|Active Comparator|RLD2001-1|
89240820|NCT04801446|Active Comparator|Transcranial Direct Current Stimulation|
89240821|NCT04801446|Sham Comparator|Sham Stimulation|
89240822|NCT04791514|Experimental|Treprostinil Palmitil Inhalation Powder|Participant received a single dose of TPIP 112.5 micrograms (μg) via oral inhalation on Day 1. The participant then entered into a 16-week Extended Use Treatment (EUT) Period during which TPIP, administered via oral inhalation, was titrated up to a mean daily dose of 320 μg.
89240823|NCT04789096|Experimental|TUGETHER Treatment|"Participants will receive:~Tucatinib (oral) at a dose of 300 mg BD on day 1-21 of each 21-day cycle~Pembrolizumab will be administered at a dose of 200 mg IV on day 1 of each 21 day cycle~Trastuzumab will be given as a loading dose of 8 mg/kg IV (if loading required, otherwise 6 mg/kg) on day 1 followed by 6 mg/kg on day 1 of each 21 day cycle.~Participants registered to PD-L1 negative/unknown cohort prior to Protocol Amendment 2 received Capecitabine 1000 mg/m^2 day 1-14 of each 21 day cycle."
89240824|NCT04782986|Experimental|Pan-intestinal capsule endoscopy|PillCam Crohn's capsule protocol
89240825|NCT04782986|Active Comparator|Conventional colonoscopy|Same-day colonoscopy under propofol sedation
89240826|NCT04780503||Intubation Group/ Non-Intubation Group|Intubation group: Patients who failed noninvasive mechanical ventilation and who underwent endotracheal intubation Non-Intubation Group: Patients whose noninvasive mechanical ventilation is successful and endotracheal intubation is not applied
89240827|NCT04780503||Dying patients / Surviving patients|Dying patients :Patients with in-hospital mortality presenting with acute respiratory failure Surviving patients: Patients presenting and surviving due to acute respiratory failure
89240828|NCT04776239|Experimental|Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group|Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).
89240829|NCT04776239|Experimental|Group 2: Placebo Group|Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.
89240830|NCT04769037|Active Comparator|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
89240831|NCT04769037|Placebo Comparator|Placebo|Lactose identical in appearance and taste to the active supplement
89240832|NCT04768127|Experimental|Early aftercare (intervention group 1)|Patients in this group will begin the ACHT program immediately after their bariatric metabolic operation. 3 weeks post surgery, they will attend the initial examination and meet their case manager. The obesity guide will then set up an electronic case file for the patient and introduce the patient to the obesity app. Through the next 18 months the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 2 patients visit a sports physician who assesses their mobility and physical capacity to compile a personal training plan, which will be uploaded onto the patient's case file and thus be available to the patient via the app. In months 3,6,9.12 and 18, patients will attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined by a physician and receive tailored dietary advice from a nutritional advisor. In month 18 patients revisit the surgical centre for the follow-up examination
89240833|NCT04768127|Experimental|Mid-term to long-term aftercare (intervention group 2)|Patients in this group first visit the study center 18 months after their bariatric surgery for the initial examination and start the program in month 19 post-op. At the center, they will meet their obesity guide who will set up an electronic case file for the patient and introduce the patient to the obesity app. Throughout the next 18 months, the obesity guide will monitor the patient's therapeutic success and adherence to the therapeutic goals. In month 19 post-surgery, patients visit a sports physician who assesses their mobility and devises a personal training plan. This plan will be uploaded onto the patient's case file and made available to the patient via the app. In months 19,21,24, 30 and 36, patients attend their aftercare appointments at specially trained ACHT physicians, where they will be physically examined and receive tailored dietary advice. In month 36, patients will be reexamined at the study center.
89240834|NCT04768127|No Intervention|control group 1 (early aftercare)|"Analogous to intervention group I, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination (18 months after the operation) at the obesity centre.~If interested, patients in this group can be included in intervention group II until the required number of cases (140 patients) has been reached."
89240835|NCT04768127|No Intervention|control group 2 (mid-term to long-term aftercare)|Analogous to intervention group II, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination at the study center 36 months after the operation.
89240836|NCT04720755|Experimental|Treatment|Participants will receive twice-weekly Li-ESWT treatments of 0.2mJ/mm² over 3 treatment sites along the dorsal penile shaft (distal, mid-shaft, proximal), 1500 shocks per treatment (500 shocks per treatment site) for a total of 3000 shocks per week, for 6 weeks (total of 18,000 shocks)
89240837|NCT04697004|Experimental|SMR Stemless Reverse|
89240838|NCT04697004|Active Comparator|SMR Reverse Shoulder System|
89240839|NCT04656730|Experimental|Study 1: Experimental: Study 2: Experimental|Iberogast® (STW5) or Iberogast® N (STW5-II) 20 drops TID per 14 days
89240840|NCT04656730|Placebo Comparator|Study 1: Comparator Study 2: Comparator|Placebo 20 drops TID per 14 days
89240841|NCT04649034||86 patients ischemic DCM|A cohort of 86 patients with ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
89240842|NCT04649034||86 patients non ischemic DCM|A cohort of 86 patients with non-ischemic dilated cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 45%
89240843|NCT04649034||86 patients hypertrophic cardiomyopathy|A cohort of 86 patients with hypertrophic cardiomyopathy in sinus rhythm and ejection fraction (EF) of LV less than 55% or with an apical aneurism diagnosed in an image test
89240844|NCT04626466||Non-metastatic prostate, rectum, canal, endometrium, cervix or vaginal cancer Radiotherapy treatment|
89240845|NCT04616495||Liver transplanted patients|
89240846|NCT04614129|Experimental|Low-Dose CT|Low Dose CT Scan of the Chest
89240847|NCT04611867|Experimental|Intervention Arm|"The intervention will be comprised of providing patients with supportive application with integrated PRO consisting of:~Weekly self-reporting of PRO-CTCAE with integrated preparation questionnaire available for staff~Daily monitoring of self-reporting by study staff~Intervention if required based on self-reporting~Reports to oncologists (at consultation)~Information module about treatment, side effects and contact information"
89240848|NCT04611867|No Intervention|Standard Arm|"Standard care for patients will be included in no-intervention arm will consist of the standard procedures at Herlev Hospital, Department of Oncology for monitoring and documenting symptoms, which will be typical of oncology practice. Symptoms will be discussed and documented in the medical record during clinical encounters between patients and their oncologists. Patients will be encouraged to initiate telephone contact between visits for concerning symptoms, i.e. call early and often."
89240849|NCT04598451|Experimental|efgartigimod PH20 SC|patients receiving efgartigimod PH20 SC on top of prednisone
89240850|NCT04598451|Experimental|placebo|patients receiving placebo on top of prednisone
89240851|NCT04596410|Experimental|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
89240852|NCT04596410|Active Comparator|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every day
89240853|NCT04565041|Experimental|Social Support|
89240854|NCT04564976|Experimental|Social Support|
89240855|NCT04561466|Experimental|treatment group|"14 adult patients in whom the diagnosis of LHON obtained on anamnestic, clinical and ancillary testing / laboratory data. LHON should have occurred for less than 5 years and must be genetically proved with a 3460 or 11778 mitochondrial DNA mutation. Given the mode of transmission, genetic research may have been carried out in a maternal relative.~Befizal® 200 mg will be tested for one year"
89240856|NCT04553523|Experimental|Hydrus Microstent|Hydrus Microstent implanted in the eye immediately following cataract surgery and placement of a monofocal intraocular lens (IOL)
89240857|NCT04553263|Experimental|Contrave|Participants will receive daily weight loss medication, Contrave, at a dose of 360 mg (Naltrexone HCl 32mg, Bupropion HCl 360mg). The dose will be titrated: 8 mg/90 mg on Week 1, 16 mg/180 mg on Week 2, 24 mg/270 mg on Week 3 and 32 mg/360 mg on Week 4. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone.
89240858|NCT04553263|Experimental|Bupropion|Participants will receive daily extended-release oral bupropion (Wellbutrin XL) at a dose of 450 mg. The dose will be titrated: 150 mg on Days 1 and 2, 300 mg on Days 3 and 4, and 450 mg on Day 5. Dosing will continue for a total of 4 weeks during inpatient treatment, and thereafter for another month, with compliance monitored by smartphone. A reduction to 300 mg will permitted to alleviate medication-related adverse effects if they occur.
89240859|NCT04553263|No Intervention|Treatment As Usual|Participants will complete inpatient treatment as usual and will not receive any medication. This arm serves as a TAU control to compare outcomes versus Bupropion and Contrave arms.
89240860|NCT04550221|Experimental|Intervention|The Shauriana intervention is aimed at promoting sexual health and preventing HIV through a comprehensive prevention toolbox including PrEP. Components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions.
89240861|NCT04550221|Active Comparator|Standard care|Standard care includes clinic-based HIV counseling and testing, screening for symptoms of sexually transmitted infections (STI), and individual counseling about HIV prevention methods. Standard of care counseling for HIV prevention in Kenya includes general information about HIV transmission and discussions of risk reduction including condom use. PrEP counseling sessions focus on PrEP knowledge, adherence tips, and strategies to address adherence barriers.
89240862|NCT04549688|Experimental|Focal therapy|
89240863|NCT04542707|Active Comparator|Joint manipulation|Grade V-Thrust manipulation with audible sound and without audible sounds of T7, MTP 2 and MCP2 joints.
89240864|NCT04542707|Active Comparator|Exercise|Aerobic, anaerobic, and yoga exercises
89240865|NCT04542707|Active Comparator|Soft tissue massage|Instrument assisted soft tissue massage
89240866|NCT04535076|Experimental|Transcatheter Aortic Valve Implantation|
89240867|NCT04535076|Active Comparator|Surgical Aortic Valve Replacement|
89240868|NCT04534738|Experimental|Mediterranean Diet|Participants in the Mediterranean Diet arm are asked to follow a Mediterranean Diet for 8 weeks. The diet is ad libitum. A combination of fresh, frozen, and shelf-stable meals are provided for the first 4 weeks. Also during the first 4 weeks, participants receive an education session to discuss how to effectively implement a Mediterranean Diet into their daily routine.
89240869|NCT04534738|No Intervention|Usual care|Participants in the usual care are will complete all the same study assessments as those in the intervention group. They will not receive any specific dietary advice, but they will be permitted to seek dietary advice outside the study. Data from this group are indispensable in understanding the nutritional habits and preferences of patients undergoing chemotherapy, and these data will be used to optimize nutritional interventions in future studies. At the end of the 8-week intervention, the participants in the usual care group will be provided the intervention materials gratis, including one-week of Mediterranean Diet food and education materials.
89240870|NCT04525365|Experimental|Pleural aspiration|Pleural aspiration under sedation
89240871|NCT04525365|Active Comparator|Closed Thoracostomy|Actual management
89240872|NCT04525157|Experimental|Afamelanotide and NB-UVB|Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
89240873|NCT04525157|Placebo Comparator|Placebo and NB-UVB|Participants received Placebo implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
89240874|NCT04525157|Experimental|Single-Arm, Open Label Group|"The study design was modified into a single-arm, open label study with only one treatment group receiving afamelanotide implants plus NB-UVB light.~Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0)."
89240875|NCT04515004|Experimental|Intervention|All qualified participants meeting entry criteria that are enrolled will receive 2-3 weeks of oral LP treatment.
89240876|NCT04514107|Active Comparator|Control|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD). n=1740
89240877|NCT04514107|Experimental|Intervention|29 school-based clusters of healthy individuals, age 6-11, exposed to standard vector control efforts recommended by the Brazilian National Dengue Control Program (PNCD) and Wolbachia-infected Aedes aegypti (wMel) mosquitoes. n=1740
89240878|NCT04509011|Experimental|Fluobeam® LX|Fluobeam® LX is used to detect autofluorescens and identify and evaluate parathyroid glands
89240879|NCT04509011|No Intervention|Control|In the control group, the parathyroid glands are identified and evaluated by eye (ocular examination).
89240880|NCT04503694|Experimental|Single arm|"Induction treatment: treatment with nivolumab (240 mg intravenously on day 1 and 15) and regorafenib (80 mg/day orally from day 1 to 14)~Standard SCRT: consists of 25 Gy delivered in 5 fractions (from day 22 to 26)~Consolidation treatment: treatment with nivolumab (240 mg intravenously on day 29, 43 and 57) and regorafenib (80 mg/day orally from day 29 to 49)~Surgery: Surgical resection will be performed according to the principles of TME (between day 74 and 87, i.e., between 7 to 8 weeks after completion of SCRT). As an alternative to surgery, subjects who achieve cCR can be offered a watch & wait approach.~Adjuvant chemotherapy: Administration of adjuvant chemotherapy will be left to the discretion of the treating physician The study also includes translational procedures (collection of tumour biopsies, blood and stool samples at pre-specified time points) for exploratory molecular and immune contexture analyses. These are mandatory for all study subjects."
89240881|NCT04493151|Experimental|Imipenem-Cilastatin-Relebactam|Participants will receive a four to six doses of intravenous imipenem-cilastatin-relebactam as per current prescribing information based on estimated creatinine clearance.
89240882|NCT04463992|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: proactive symptom assessments for patients for up to 12-months.
89240883|NCT04463992|Active Comparator|Behavioral:Program participants|The control group arm will receive usual care as provided by their local oncologists.
89240884|NCT04454476|Experimental|Trametinib treatment|
89240885|NCT04452461|Other|Single Arm Intervention|"Chemotherapy: 6 cycles (three months) of IV combination chemotherapy with mFOLFIRINOX on day 1 followed by one week of rest (14-day cycle). Alternatively, patients will receive three months of gemcitabine / nab-paclitaxel.~Re-staging CT scan with Carbohydrate Antigen (CA) 19-9 serum test.~Staging laparoscopy to rule out occult metastatic disease is optional based on surgeon's preference.~5. Pancreatectomy 4 weeks following the last day of Chemotherapy as per standard of care.~6. Adjuvant chemotherapy: as per standard of care. 7. Clinical assessment and CT scan with CA 19-9 serum test at 4-month intervals until identification of cancer recurrence.~8. Follow up of patients after 2 years every six months for up to 5 years following the initiation of treatment will be performed off-protocol as per standard of care."
89240886|NCT04448249|Experimental|Interventional group|The interventional group keeps a traditional follow up (day hospitalization then consultation with a MD within two to twelve months) but also meets an APN between the day hospitalization and the MD consultation, within one to six months
89240887|NCT04448249|No Intervention|Control group|The control group of patients keeps a traditional follow-up: day hospitalization then consultation with a MD within two to twelve months
89240888|NCT04424667|Active Comparator|Holder pasteurization|Donor milk pasteurized by Holder method (62.5ºC, 30 minutes)
89240889|NCT04424667|Experimental|HTST pasteurization|Donor milk pasteurized by High Temperature Short Time (HTST) method (72ºC, 15 seconds)
89240890|NCT04417829||Only one arm (intervention=TAVI)|There is not control group/arm for comparison.
89240891|NCT04389242|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
89240892|NCT04389242|Experimental|app-based cognitive behavioral intervention|"Application-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, one face-to-face session and one telephone follow-up with a certified CBT therapist."
89240893|NCT04389242|Other|Wait-list control group|No intervention will be provided when the experimental groups are receiving services, but the access to the App-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
89240894|NCT04388800|Experimental|web-based cognitive behavioral intervention|"The web-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist."
89240895|NCT04388800|Experimental|app-based cognitive behavioral intervention|"App-based cognitive behavioral intervention program The App-based program is consisted of 8 online modules, forum, internal messaging, reminder, online assessment and online booking. Each online module contains mood check, animation briefing and debriefing, case demonstration videos, session review and exercise.~Blended mode is adopted to deliver service, which includes the online program, two face-to-face session and 2 telephone follow-ups with a clinical psychologist"
89240896|NCT04388800|No Intervention|Wait-list control group|No intervention will be provided when the experimental group is receiving services, but the access to the app-based program will be delivered to the wait-list control group after the two experimental groups complete the service.
89240897|NCT04382963|Other|High Risk- intense coaching|"age ≥ 55 with MORE than three of the following risk factors:~History of TIA/Stroke~History of Coronary Artery disease~History of Hypertension and/or current elevated blood pressure~History of Diabetes~Current smoker~BMI ≥30"
89240898|NCT04382963|Other|High Risk - standard care|"age ≥ 55 with MORE than three of the following risk factors:~History of TIA/Stroke~History of Coronary Artery disease~History of Hypertension and/or current elevated blood pressure~History of Diabetes~Current smoker~BMI ≥30"
89240899|NCT04382963|Other|Low risk - control|"age ≥ 55 with LESS than three of the following risk factors:~History of TIA/Stroke~History of Coronary Artery disease~History of Hypertension and/or current elevated blood pressure~History of Diabetes~Current smoker~BMI ≥30"
89240900|NCT04378335|Experimental|one arm|oral disorder
89240901|NCT04373902|Experimental|Physiological-based cord clamping|In PBCC, the Concord will be placed next to the bed of the mother and all equipment will be checked before the second stage of labour has started. The infant will be placed on the platform of the Concord immediately after birth, avoiding any traction or pressure on the cord and avoiding heat loss by radiation heating. The umbilical cord will not be clamped until the infant is considered respiratory stable, which is defined as the presence of a heart rate >100 bpm and preductal oxygen saturation >85%, while using an fraction of inspired oxygen (FiO2) of <0.5. The minimum and maximum times of cord clamping are three and ten minutes after birth, respectively. Oxytocin administration will be postponed until after cord clamping if there are no obstetric concerns. At any time, the attending neonatologist and obstetrician can decide that PBCC should not be performed or be interrupted. In that case, the infant can be placed on the standard resuscitation table for (further) stabilisation.
89240902|NCT04373902|No Intervention|Immediate cord clamping|In the immediate cord clamping group, the cord will be clamped immediately after birth. The infant will then be transferred to the standard neonatal resuscitation table. After cord clamping, all infants will be managed according to the standardised neonatal management protocol for infants with a CDH, which is a consensus of current clinical guidelines by the CDH EURO consortium.
89240903|NCT04373278||description of infection of free fibula flap reconstruction|
89240904|NCT04301323|Experimental|BHVI1|BHVI1 eye drops
89240905|NCT04301323|Experimental|BHVI2|BHVI2 eye drops
89240906|NCT04301323|Experimental|BHVI3|Combination of BHVI1 and BHVI2 eye drops
89240907|NCT04301323|No Intervention|Non-randomized control group|a separate control group including 105 children enrolled and followed with only single-vision spectacles.
89240908|NCT04280471|Experimental|Treatment (OpenBiome FMT capsule DE)|Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days. One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules. If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days.
89240909|NCT04278404||Children and young adults who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care OR are SARS-CoV-2 positive.
89240910|NCT04275999|Other|Control Group|In the control group, all subjects will receive ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea. Subjects will not receive any follow-up intervention from the study team.
89240911|NCT04275999|Experimental|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their use ivermectin generated by Causa Research; in addition to receiving ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
89240912|NCT04275999|Experimental|GPSkin group|The GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin once daily. Subjects also are receiving the ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
89240913|NCT04243759|Experimental|Control App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
89240914|NCT04243759|Experimental|Standard App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
89240915|NCT04243759|Experimental|Experimental, Feedback App Group|Young Adult Drinkers will be randomized to 1 of the 3 app conditions (Control App Version; Standard App Version; Experimental, Feedback App Version). The apps will be tested both during a laboratory alcohol drinking session and a 4-week period outside the lab in which they can use this technology in actual drinking situations. For the 4-week period outside the lab, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.
89240916|NCT04193176|Experimental|Gefapixant|Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
89240917|NCT04193176|Placebo Comparator|Placebo|Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.
89240918|NCT04190485|Experimental|Placebo and GMNL-143 Probiotic Toothpastes|Subjects will receive placebo and GMNL-143 probiotic toothpastes.
89240919|NCT04190485|Experimental|Placebo and GMNL-464 Probiotic Toothpastes|Subjects will receive placebo and GMNL-464 probiotic toothpastes.
89240920|NCT04174703|Experimental|Self-compassionate letter-writing intervention|An online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks
89240921|NCT04174703|No Intervention|Control condition|
89240922|NCT04166071|Active Comparator|Naltrexone|
89240923|NCT04166071|Placebo Comparator|Placebo|
89240924|NCT04164277|Experimental|Intervention|"The 16-week intervention includes three components:~Caregiver Component. Facebook-based program including four new habit-formation tasks/week, and 3 face-to-face or virtual caregiver meetings: MSU research staff will lead the meetings at Head Start centers (weeks 1, 8, & 16) to connect caregivers to each other, offer health information, and discuss behavioral change strategies.~Caregiver-Preschooler Learning. Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent privately to each caregiver , and caregivers will be asked to respond to the letters.~Center-based Preschooler Component. Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators."
89240925|NCT04164277|No Intervention|Control|Control group will receive usual Head Start activities during intervention period. After post-intervention data collection, each control caregiver will receive all intervention supplies and a mini program including a face-to-face or virtual caregiver meeting and 1-week preschooler program. The caregiver meeting will cover contents on alternative cooking ingredients, food labels, and portion sizes.
89240926|NCT04142619|Experimental|Dose Escalation|Several tested doses of UCARTCS1A until the Maximum Tolerated Dose (MTD) is identified.
89240927|NCT06083285||Control group|
89240928|NCT06083285||Observation group|
89240929|NCT06083155||Normal CFT results: no coronary vasomotor dysfunction|Collection of data on anginal complaints, use of medication and major adverse cardiac events (MACE) by means of online patient questionnaires
89240930|NCT06083155||Abnormal CFT results: coronary vasomotor dysfunction|Comparison of patient reported outcomes of different endotype groups Collection of data on anginal complaints, use of medication and MACE by means of online patient questionnaires
89240931|NCT06083129|Active Comparator|Anti-T lymphocyte globulin (ATLG)|
89240932|NCT06083129|Active Comparator|Anti Thymocyte Globulins (ATG)|
89240933|NCT06083116|Experimental|healthy subjects|
89240934|NCT06083090|Experimental|Yogatherapy|Randomization of 36 patients in the yogatherapy group.
89240935|NCT06083090|Active Comparator|Physiotherapy|Randomization of 36 patients in the physiotherapy group.
89240936|NCT06083077|Experimental|Infant < 6 months with severe bronchiolitis|"Infant will be recorded successively in 6 conditions (10 min each) :~Without chest wall strapping at PEEP 0 and PEEP 7~With chest wall strapping at PEEP 0 and PEEP 7~again without chest wall strapping at PEEP 0 and PEEP 7."
89240937|NCT06083025|Experimental|CleaRing device for cataract patients|"All subjects who meet eligibility requirements will be asked to participate. Subjects will be considered enrolled into the study after:~A signed Informed Consent has been obtained.~The subject has met all of the inclusion and none of the exclusion criteria.~The ability of the subject to safely undergo cataract surgery under local anesthesia was confirmed by the investigator, according to standard procedure of the medical center."
89240938|NCT06082973|Experimental|Dual-hormone configuration system (insulin and glucagon)|12-hour inpatient study that will include an unannounced 30-min aerobic exercise session and a meal challenge. Automated insulin and glucagon delivery will be performed using a dual-hormone configuration system for glucose control .
89240939|NCT06082973|Active Comparator|Single-hormone configuration (insulin) with carbohydrate recommendations system|12-hour inpatient study that will include an unannounced 30-min aerobic exercise session and a meal challenge. Automated insulin delivery will be performed using a single-hormone configuration system with carbohydrate recommendations if needed for glucose control .
89240940|NCT06082934|Experimental|OVD regimen of Olverembatinib plus venetoclax and dexamethasone|Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
89240941|NCT06082869|Experimental|Experimental|Protegera™ toothpaste (NaF), brushing twice daily for one minute
89240942|NCT06082869|Active Comparator|Control|Crest™ Cavity Protection toothpaste (NaF), brushing twice daily for one minute
89240943|NCT06082791||COPD|
89240944|NCT06082791||other respiratory disease without COPD|
89240945|NCT06082791||healthy people without respiratory disease|
89240946|NCT06082674|Experimental|Vayu CPAP Group|The patients will be hooked to VAYu bCPAP
89240947|NCT06082674|Active Comparator|Mechanical Ventilator Driven CPAP|Patients will be hooked to Mechanical Ventilator Driven CPAP
89240948|NCT06082648|Sham Comparator|Sham Stimultion Group|Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
89240949|NCT06082648|Active Comparator|Pre-ileostomy-closure Stimultion Group|Patients on the Pre-ileostomy-closure group will be interfered with stimulation 3 weeks before the procedure of ileostomy closure.
89240950|NCT06082648|Active Comparator|Post-ileostomy-closure Stimultion Group|Patients on the Post-ileostomy-closure group will be interfered with stimulation 3 weeks after the procedure of ileostomy closure.
89240951|NCT06082635|Experimental|TGRX-326|Subjects to be treated with the investigational drug TGRX-326 at 60 mg once day in 28-day cycles.
89240952|NCT06082635|Active Comparator|Crizotinib|Subjects to be treated with the active control drug crizotinib at 250 mg twice day in 28-day cycles.
89240953|NCT06082622|Experimental|NEW PROTOCOL|Using the triple therapy protocol for management of FC
89240954|NCT06082622|Experimental|CONVENTIONAL|Using the conventional laxative therapy with rehabilitation (two axis) only
89240955|NCT06082609|Active Comparator|• Group 1 (Functional relining of processed RPD base at insertion)|"After try in, a record base will be attached to the minor connectors and metal frameworks using 3D printed master cast.~Registration of jaw relation.~Mounting of master casts on articulator.~Setting of artificial teeth according to lingualized occlusion principles.~Try in of RPD.~Flasking of RPD to obtain mandibular distal extension removable partial dentures.~The finished removable partial denture is relined using the functional relining impression technique."
89240956|NCT06082609|Active Comparator|• Group 2 (Digitally obtained altered cast );|"Construction of custom tray on metal frame work.~Border molding of custom tray.~Selective pressure impression technique will be made.~Digital altered cast will be done according to J. Wu, Y. Cheng~3D printing of altered master cast that will be used for completing the construction of RPD with the same steps of group (A) but without relining.~Finally the occlusion of dentures in the two groups will be verified before delivery."
89240957|NCT06082596|Experimental|Monotherapy group 1(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 10mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
89240958|NCT06082596|Experimental|Monotherapy group 2(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 15mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
89240959|NCT06082596|Experimental|Monotherapy group 3(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 22.5mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
89240960|NCT06082596|Experimental|Monotherapy group 4(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 33.75mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
89240961|NCT06082596|Experimental|Monotherapy group 5(Dose escalation phase)|BEBT-908 for injection， dosage form ：Injection； specification: 25 mg , administration method: 45mg/m2，intravenous drip, firstly the subjects were given a single dose and observed for 6 days. At the end of the observation period, if the subjects were tolerant to a single dose and safe, they would receive the same dose for a cycle (21 days), giving the drug three times a week for 2 weeks and stopping the drug for 1 week. A total of 21 days is a cycle.
89240962|NCT06082596|Experimental|Monotherapy group 6（Dose expansion phase）|BEBT-908 for injection ，dosage form ：Injection ；specification: 25mg , administration method: 15mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle, until the disease progressed or withdrew.
89240963|NCT06082596|Experimental|Monotherapy group 7（Dose expansion phase）|BEBT-908 for injection ，dosage form ：Injection ；specification: 25mg , administration method: 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle, until the disease progressed or withdrew.
89240964|NCT06082583|Active Comparator|Tibetan Medicine Group|
89240965|NCT06082583|Experimental|Tibetan Medicine-Remote Ischemic Conditioning Group|
89240966|NCT06082570|Experimental|All the subjects enrolled will receive the experimental intervention, c610 injection|
89240967|NCT06082557|Experimental|All the subjects enrolled will receive the experimental intervention, T60c injection|
89240968|NCT06082531|No Intervention|Preoperative|
89240969|NCT06082531|Experimental|postoperative (6 weeks)|The patients were injected with PRP.
89240970|NCT06082531|Experimental|postoperative (3 months)|The patients were injected with PRP.
89240971|NCT06082453|Experimental|Molecular testing for detection of T. pallidum and use of CDC guidelines for diagnosis of syphilis|
89240972|NCT06082427|Experimental|VRH|"VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system called  IPNEO  and designed by the society Cayceo (Montpellier, France, https://cayceo.fr/). The device display an enchanted environment movie based on hypnosis induction and suggestions (relaxation, comfort, and safety)."
89240973|NCT06082427|No Intervention|Control|Usual care
89240974|NCT06082414||<28 weeks and <1000 grams|By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.
89240975|NCT06082414||<28 weeks and ≥1000 grams|By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.
89240976|NCT06082414||≥28 weeks and <1000 grams|By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.
89240977|NCT06082401|Experimental|Treatment Group|EVLP + HDF
89240978|NCT06082401|Active Comparator|Control Group|EVLP
89240979|NCT06082388|Active Comparator|Atropine|Patients in whom during electrophysiological study atropine will be used. I.v. bolus of 0.01 mg/kg b.w. will be administered to reach the increase of heart rate of 25% or up to 130/min. If necessary, dose will be increased every 5 minutes until mention above parameters are achieved. Maximum dose will be 0.4 mg/kg b.w.
89240980|NCT06082388|Active Comparator|Isoprenaline|Patients in whom during electrophysiological study isoprenaline will be used. Continuous i.v. infusion of 0.01 mcg/kg b.w./min will be administered to reach the increase of heart rate of 25% or up to 130/min. If necessary, dose will be doubled every 5 minutes until mention above parameters are achieved. Maximum dose will be 20 mcg/min.
89240981|NCT06082375|Experimental|Vitamin D|"Individually adapted to each participant based on BMI, dose of vitamin D3 in drops.~BMI 19-25 - 4000 IU~BMI 25-29,9- 6000 IU~BMI >30- 8000 IU"
89240982|NCT06082375|Placebo Comparator|Placebo|The placebo group will receive drops containing vegetable oil in the same bottles as vitamin D3.
89240983|NCT06082362||Infertile men|Men with infertility
89240984|NCT06082362||Fertile men|Fertile men
89240985|NCT06082362||Oncologic patients|Patients with kidney, bladder, chest, or pancreas tumors
89240986|NCT06082336|Experimental|Single arm|This study is single arm.
89240987|NCT06082323|Experimental|Single Ascending Dose (SAD) and Food Effect (FE) Study|Part 1 is a double-blinded, randomized, placebo-controlled, SAD, sequential group study in 48 adult HVs, divided into 6 cohorts of 8 HVs each and a single arm, for food effect (FE) study. Within each cohort, 6 HVs will be randomized to receive LT-002-158 and 2 HVs will be randomized to receive placebo.
89240988|NCT06082323|Experimental|Multiple Ascending Doses (MAD) Study|Part 2 is a double-blinded, randomized, placebo-controlled, MAD sequential group study in 30 adult HVs, divided into 3 cohorts of 10 adult HVs in each cohort. This MAD study will evaluate 3 dose levels of LT-002-158 once daily for consecutive 14 days. Thirty healthy volunteers will be enrolled into 3 cohorts and within each cohort, 8 HVs will be randomized to receive LT-002-158 and 2 HVs receiving placebo.
89240989|NCT06082297|Experimental|Single arm where repeated measures where performed in 15 participants.|Each of the 15 participants in the arm was, in addition to the resting state (no intervention), exposed to 10 different interventions repeated after each other to enable repeated measures of the outcomes.
89240990|NCT06082284||Patients who come to the hospital for treatment|Patients attending the outpatient/emergency/inpatient department of Zhujiang Hospital over 18 years old.
89240991|NCT06082245|Active Comparator|TLIP Group|Patients were anesthetized before surgery using TLIP lumbar block (L3) under ultrasound with 20ml of ropivacaine 0.25% anesthetic on each side. After that, the patient was given general anesthesia for surgery
89240992|NCT06082245|Active Comparator|ESP Group|Patients were anesthetized before surgery with lumbar (L3) ESP block method under ultrasound with 20ml of Ropivacaine 0.25% anesthetic on each side. After that, the patient was given general anesthesia for surgery.
89240993|NCT06082245|Experimental|Control Group|Patients received general anesthesia, then the incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery
89240994|NCT06082180|Experimental|test group|prophylactic central neck dissection
89240995|NCT06082180|No Intervention|control group|no central neck dissection
89240996|NCT06082128|No Intervention|Usual care|Dyads in the control group will receive usual care only. Usual advanced cancer care is known to be heterogeneous. It is expected usual care to include care from specialists, doctors, nurses or other health care professionals that patients usually engage with.
89240997|NCT06082128|Experimental|FOCUSau|Dyads in the FOCUSau arm will receive the web-based FOCUSau program in addition to usual care.
89240998|NCT06082115|Experimental|Selected Physical and Occupational Therapy Program|Unilateral cerebral palsy children will receive selected physical and occupational therapy program for 1 hour. The duration of treatment will be 3 times/week for 12 weeks.
89240999|NCT06082115|Experimental|Mirror Therapy|Unilateral cerebral palsy children will receive selected physical and occupational therapy program for 1 hour in addition to mirror therapy for 30 minutes. The duration of treatment will be 3 times/week for 12 weeks.
89241000|NCT06082115|Experimental|Task Oriented Training|Unilateral cerebral palsy children will receive selected physical and occupational therapy program for 1 hour in addition to task oriented training for 30 minutes. The duration of treatment will be 3 times/week for 12 weeks.
89241001|NCT06082089|Experimental|Postdivorce Intervention Program|The experimental arm will receive the 5- or 6-session online group intervention program developed for divorced women.
89241002|NCT06082089|No Intervention|Wait List and Delayed Intervention|In this arm, participants in the wait list control group will complete outcome measures without the intervention program being implemented. After the post intervention assessments are completed, this group will receive either the online intervention program or booklets including detailed information about the program, depending on their preference.
89241003|NCT06082076|Active Comparator|Group D (dexmedetomidine group)|
89241004|NCT06082076|Active Comparator|Group K (ketamine group)|
89241005|NCT06082076|Placebo Comparator|Group C (control group)|
89241006|NCT06082063|Active Comparator|Multifactorial intervention group|The multifactorial intervention will be determined by the risk profile and risk markers of each individual and the participants will be allocated to Semaglutide, sotagliflozin or finerenone. The intervention will also comprise more ambitious treatment targets for blood pressure and lipid levels. In addition, all participants will take aspirin 75 mg OD.
89241007|NCT06082063|No Intervention|Standard intervention group|During the whole study period the standard intervention shall be done according to current Danish and international (ADA/EASD) guidelines. This will address similar risk factors as in the intensive group, but to a less ambitious treatment target for blood pressure and lipid lowering and will not include the use of SGTL2i, finerenone or GLP-1RA, unless these drug classes become recommended in future versions of guidelines.
89241008|NCT06082050|Experimental|YOLT-201|Phase 1a, which includes three dose cohorts (0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg) with a sample size of 1-2 subjects per cohort, aims to determine the optimal biologically active dose (OBD) of YOLT-201. Phase 1b will enroll an additional 8 subjects at the OBD to evaluate its safety and preliminary efficacy further
89241009|NCT06082024||delirium|Patients present with delirium within 7 days after general anesthesia
89241010|NCT06082024||non delirium|The patient did not develop delirium for 7 days after general anesthesia
89241011|NCT06082011||RWS study for SP Gynecological Surgeries|da Vinci SP Surgical System(SP1098)
89241012|NCT06081985|Active Comparator|Active TMS|Deep TMS to the left dorsolateral prefrontal cortex with double-cone coil
89241013|NCT06081985|Sham Comparator|Sham TMS|Sham TMS to the left dorsolateral prefrontal cortex with sham coil
89241014|NCT06081959|Experimental|SKB264 for injection|
89241015|NCT06081959|Active Comparator|Treatment of Physician's Choice|Eribulin, capecitabine, gemcitabine or vinorelbine will be administered and managed according to the investigator's clinical judgment, guided by clinical practice.
89241016|NCT06081933|Experimental|intranasal dexmedetomidine|Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline
89241017|NCT06081933|Experimental|intravenous dexmedetomidine|patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.
89241018|NCT06081868|Experimental|Toothbrush/toothpaste/fluoride varnish|Children will be instructed to use toothbrush/toothpaste/fluoride varnish.
89241019|NCT06081868|Experimental|Education on nutrition/oral hygiene|Children receive individual education on nutrition/oral hygiene.
89241020|NCT06081855||Repaired TOF|
89241021|NCT06081855||Unrepaired TOF|
89241022|NCT06081842|Active Comparator|Arm 1. Routine care|Routine contraceptive counseling and routine method availability
89241023|NCT06081842|Experimental|Arm 2. Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
89241024|NCT06081842|Experimental|Arm 3. Expanded methods|Routine care with the contraceptive counseling package combined with wider method availability as recommended by national policies.
89241025|NCT06081803|Experimental|Evolocumab group|Evolocumab 420mg subcutaneous injection before primary PCI
89241026|NCT06081803|No Intervention|Control group|without Evolocumab 420mg before primary PCI
89241027|NCT06081777||Arms1：For stage III NSCLC patients who underwent complete resection.|"Immunotherapy alone or chemotherapy combined with immunotherapy. Collect patients' baseline puncture tissues, peripheral blood samples from multiple nodes after new adjuvant treatment, surgery (if any), adjuvant treatment, and follow-up, and carry out for 1021-MRD analysis through tumor-informed personalized monitoring MRD test kit.~Assigned Interventions：1021-MRD analysis"
89241028|NCT06081777||Arms 2：For stage III NSCLC patients who underwent concurrent radio-chemotherapy.|"Immunotherapy alone or chemotherapy combined with immunotherapy. Collect patients' baseline puncture tissues, peripheral blood samples from multiple nodes after new adjuvant treatment, surgery, adjuvant treatment, and follow-up, and carry out for 1021-MRD analysis through tumor-informed personalized monitoring MRD test kit.~Assigned Interventions：1021-MRD analysis"
89241029|NCT06081764|Experimental|Otago Exercise Program|They participated the Otago Exercise Program, which last 3 days a week and an average of 30 minutes per day for 12 weeks in total. In addition, they did moderate-intensity walking exercise for 30 minutes a day, 2 days a week.
89241030|NCT06081764|No Intervention|Control Group|No program were applied to the participants in the control group.
89241031|NCT06081751|Experimental|İntervention Group|"Children in the intervention group will play traditional games for 60 minutes, 3 days a week for 8 weeks. The program to be implemented is as follows;~Week 1 (Day 1 - I Sell Oil, I Sell Honey game, Day 2 - Snatch game, Day 3 - Corner Snatch Game) Week 2 (Day 1 - Handkerchief game, Day 2 - My Fire game, 3 Day 2 - Kurt Baba Game) Week 3 (Day 1 - Chubby game, Day 2 - Jump rope game, Day 3 - Mouse game in the middle) Week 4 (Day 1 - Rook dodgeball game, Day 2 - Stop game, Day 3 - Old cushion mouse game) Week 5 (Day 1 - I Sell Oil, I Sell Honey game, Day 2 - Snatch game, Day 3 - Corner Catch Game) Week 6 (Day 1 - Handkerchief grabbing game, Day 2 - My Fire game, Day 3 - Daddy Wolf Game) Week 7 (Day 1 - Chubby game, Day 2 - Jumping rope game, Day 3 - Mouse game in the middle) Week 8 ( Day 1 - Dodgeball game, Day 2 - Stopping game, Day 3 - Old matte mouse game)"
89241032|NCT06081751|Active Comparator|Control Group|no intervention will be made
89241033|NCT06081738|Active Comparator|Neostigmine Group|
89241034|NCT06081738|Active Comparator|Sugammadex Group|
89241035|NCT06081712|Experimental|Multiple Ascending Doses Cohort 1|TNP-2198 Capsules 200mg, BID, for 14days
89241036|NCT06081712|Experimental|Multiple Ascending Doses Cohort 2|TNP-2198 Capsules 400mg,BID, for 14days
89241037|NCT06081712|Experimental|Multiple Ascending Doses Cohort 3|TNP-2198 Capsules 600mg,BID, for 14days
89241038|NCT06081699|Experimental|Single Ascending Doses Cohort 1|TNP-2198 Capsules 50mg
89241039|NCT06081699|Experimental|Single Ascending Doses Cohort 2|TNP-2198 Capsules 100mg
89241040|NCT06081699|Experimental|Single Ascending Doses Cohort 3|TNP-2198 Capsules 200mg
89241041|NCT06081699|Experimental|Single Ascending Doses Cohort 4|TNP-2198 Capsules 400mg
89241042|NCT06081699|Experimental|Single Ascending Doses Cohort 5|TNP-2198 Capsules 600mg
89241043|NCT06081699|Experimental|Single Ascending Doses Cohort 6|TNP-2198 Capsules 800mg
89241044|NCT06081699|Experimental|Single Ascending Doses Cohort 7|TNP-2198 Capsules 1000mg
89241045|NCT06081699|Experimental|Food Effect Cohort 8|TNP-2198 Capsules 200mg
89241046|NCT06081699|Placebo Comparator|Placebo Cohort 9|Placebo
89241047|NCT06081686|Experimental|Phase I:[177Lu]Lu-XT033 Injection|During dose verification phase,Patients received [177Lu]Lu-XT033 Injection 1.11Gbq（30mCi）/1.85Gbq（50mCi）intravenously every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
89241048|NCT06081686|Experimental|Phase II:[177Lu]Lu-XT033 Injection|During dose expansion phase,patients received [177Lu]Lu-XT033 Injection at R2PD based on phase I.
89241049|NCT06081673|Experimental|Penpulimab combined with cisplatin and albumin-paclitaxel neoadjuvant therapy|"Penpulimab injection combined with cis-platinum and albumin-bound paclitaxel before surgery, 21 days as a treatment cycle.~Adjuvant therapy was started within 6 weeks after surgery：Patients who achieved MPR after surgery were randomized 1:1 with standard adjuvant therapy(RT alone or combined with cisplatin) and Alternative adjuvant therapy(RT alone or combined with Penpulimab).~Non-MPR patients receive standard adjuvant therapy"
89241050|NCT06081660|Active Comparator|ACP education|"ACP education consisting of~a brief social work screening,~an educational pamphlet,~advance directive forms (in English and Spanish), and~community resource materials (i.e., handout)"
89241051|NCT06081660|Experimental|ACP education plus counseling|"ACP education plus counseling consisting of~a brief social work screening,~an educational pamphlet,~advance directive forms (in English and Spanish), and~community resource materials (i.e., handout);~motivational interviewing~decisional support, and~patient navigation to address barriers"
89241052|NCT06081647|Experimental|the COMBO Endoscopy Oropharyngeal Airway Group|In this group, patients use the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
89241053|NCT06081647|Active Comparator|Regular Nasal Cannula Group|In this group, patients use the regular nasal cannula for oxygenation.
89241054|NCT06081634|Active Comparator|Enhancing cognitive reserve|After the baseline assessment, subjects will be randomly assigned by non-research staff, following the balanced clocks method, to receive a psychological intervention for the improvement of cognitive reserve (N=60) or to the group receiving TAU only (N=60). All assessments will be common to both groups. The experimental group will receive an intervention consisting of 12 weekly sessions of approximately 60 minutes duration. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Patients will also receive pharmacological follow-up in each center. A psychologist blind to the results of the assessment will provide the therapeutic approach for the improvement of cognitive reserve.
89241055|NCT06081634|Placebo Comparator|Placebo group|This group will receive only pharmacological treatment supervised by the Psychiatrists of each Unit.
89241056|NCT06081621|Experimental|REGEND001|
89241057|NCT06081621|Placebo Comparator|Placebo|
89241058|NCT06081595|Experimental|Fluzoparib+Apatinib combination|
89241059|NCT06081582|Experimental|Toripalimab plus Cetuximab，chemotherapy group|"All subjects received 2-cycle conversion therapy with the PD-1 inhibitor toripalimab combined with cetuximab, cisplatin, and 5-FU~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W；Cisplatin: 25mg/m2, Day1-3, Q3W；5-FU: 1000mg/m2, Day1-3, Q3W Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week"
89241060|NCT06081569||Alzheimer's disease|the diagnosis of AD is according to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD.
89241061|NCT06081569||Mild cognitive impairment|the diagnosis of MCI refers to the criteria defined by Peterson in 2004.
89241062|NCT06081569||Control|participants who are age-matched with AD and MCI participants, without cognitive impairment.
89241063|NCT06081556||Group A|the difference between mean gestational sac diameter and crown-rump length （mGSD-CRL） ≥ 10mm
89241064|NCT06081556||Group B|10 mm < mGSD-CRL ≤ 15 mm
89241065|NCT06081556||Group C|mGSD-CRL >15 mm
89241066|NCT06081543|Experimental|Ketogenic Diet|This arm will be provided food to induce a state of nutritional ketosis in each person as defined as blood Beta-hydroxybutyrate (3-OHB) ≥0.5 millimoles (mM), which will require most participants to consume <50 g/day carbohydrate and 1.5g/kg reference weight protein. Fat will comprise the remaining calories with an emphasis on monounsaturated and saturated sources from whole foods.
89241067|NCT06081543|Experimental|Low-fat mixed Diet|This arm will be provided food consisting of ~25% fat, and the remaining calories from carbohydrate (~55% after accounting for protein at ~20%).
89241068|NCT06081517||Black patients with advanced cancer|
89241069|NCT06081517||Non Black patients with advanced cancer|
89241070|NCT06081504|Experimental|Wii fit exercises group|Fifteen patients will be engaged in the Wii Fit exercises program for 30 minutes in addition to the standard physical therapy program, 3 sessions a week for 12 weeks.
89241071|NCT06081504|Experimental|Pilates exercises group|Fifteen patients will be engaged in the Pilates exercises program for 30 minutes in addition to the standard physical therapy program, 3 sessions a week for 12 weeks.
89241072|NCT06081504|Active Comparator|Standard physical therapy group|Fifteen patients will be engaged in the Standard physical therapy program (lower limb stretching and strengthening exercises and deep friction massage) for 45 minutes, 3 sessions a week for 12 weeks.
89241073|NCT06081478|Experimental|CD19/CD22 CAR-T group|Patients would receive autologous CAR-T cell therapy targeting both CD19 and CD22. The dosage for CD19-CAR-T cell was 2×10e6/kg and CD22-CAR-T cell was 1×10e6/kg. Both CAR-T cells were infused at the same day.
89241074|NCT06081387|Experimental|Training and Vitamin D supplementation|Subjects in the vitamin D and resistance training group will take oral capsules containing 5,000 international units of vitamin D every two weeks for four months. The tablets will be taken with 250 ml of water at lunch. Sarcoplasm stimulating training system will be used. This program will run for 15 weeks and three sessions a week. This exercise plan is designed in three 5-week periods. In the first week, the movements are as follows: 4 sets of eight repetitions with 20 seconds interval of rest between sets will be performed, with 60% of maximum repetitions. In the second week, with increasing intensity, the exercise will be performed with 60% 1RM. The third week, each movement will be performed in 5 sets with 6 repetitions with 20 seconds of rest between Hursts as an interval with 60% of maximum repetitions.
89241075|NCT06081387|Placebo Comparator|Training with placebo|Sarcoplasm stimulating training system will be performed. This program will run for 15 weeks and three sessions a week. This exercise plan is designed in three 5-week periods. In the first week, the movements are as follows: 4 sets of eight repetitions with 20 seconds interval of rest between sets will be performed, with 60% of maximum repetitions. In the second week, with increasing intensity, the exercise will be performed with 60% 1RM. The third week, each movement will be performed in 5 sets with 6 repetitions with 20 seconds of rest between Hursts as an interval with 60% of maximum repetitions. This time, instead of taking a vitamin D capsule, capsules made of paraffin oil will be offered. Capsules designed as a placebo will be indistinguishable in shape and colour from vitamin D capsules. The tablets will be taken with 250 ml of water at lunch.
89241076|NCT06081387|Experimental|Vitamin D supplementation|In this group, no exercise program will be performed. They will take oral capsules containing 5,000 international units of vitamin D every two weeks for four months. The tablets will be taken with 250 ml of water at lunch.
89241077|NCT06081387|Placebo Comparator|Placebo|The control group will only take the placebo capsule: capsules made of paraffin oil will be offered. Capsules designed as a placebo will be indistinguishable in shape and colour from vitamin D capsules. The tablets will be taken with 250 ml of water at lunch.
89241078|NCT06081374|Experimental|simulation intervention|simulation will be implemented.
89241079|NCT06081374|Active Comparator|education implication|education will be implemented.
89241080|NCT06081374|No Intervention|control group|no intervention will be made.
89241081|NCT06081322|Experimental|Phase Ia: Dose escalation|To determine the therapeutic dose of 177Lu-EB-FAPI using a 3 + 3 dose-escalation mode
89241082|NCT06081322|Experimental|Phase Ib: Dose expansion-pancreatic cancer cohort|In pancreatic cancer cohort, patients will receive the first phase determined dose of 177Lu-EB-FAPI every 4 weeks, and each patient will receive no more than 4 cycles.
89241083|NCT06081322|Experimental|Phase Ib: Dose expansion-cholangiocarcinoma cohort|In cholangiocarcinoma cohort, patients will receive the first phase determined dose of 177Lu-EB-FAPI every 4 weeks, and each patient will receive no more than 4 cycles.
89241084|NCT06081296|Experimental|Control group|Alveolus closure with total flap elevation and simple suture
89241085|NCT06081296|Active Comparator|Group Free Gingival Mixed Graft|Closure of the alveolus without flap elevation, and placement of a mixed free gingival tissue graft (epithelialized in the central region and de-epithelialized (2 mm) in the vestibulolingual edges
89241086|NCT06081296|Active Comparator|Bone + Mixed Free Gum Graft Group|Socket closure without flap elevation, placement of lyophilized bone graft and socket sealing with mixed free gingival tissue graft (as previously described)
89241087|NCT06081296|Active Comparator|Bone + Titanium Seal Group|Socket closure without flap elevation, placement of lyophilized bone graft, socket sealing by installing a non-absorbable titanium membrane.
89241088|NCT06081218|Experimental|Chronic cannabis users|
89241089|NCT06081218|Sham Comparator|Healthy subjects|
89241090|NCT06081192|Experimental|One-piece titanium-zirconium mini implants|Six one-piece titanium-zirconium mini implants (Straumann® Mini Implant System, Institut Straumann AG, Switzerland) in the edentulous maxilla, using a partially-guided insertion protocol.
89241091|NCT06081140|Experimental|Supplementation|Participants were enrolled at baseline where all outcome measures were collected. Once baseline visit was complete, participants started with the supplementation of Hemp Oil Complex by Standard Process. After 10 days, outcome measures were collected.
89241092|NCT06080672|Experimental|Group 1 (dental examination-training-tooth brushing)|Students, whose first records (plaque index, gingival index) are taken after the examination by the periodontology specialist, will be taught how to brush their teeth with the Modified Bass Technique and how to use dental floss/interdental brush. Students will then be asked to brush their teeth.
89241093|NCT06080672|Experimental|Group 2 (dental examination-training-plaque disclosing-tooth brushing)|The students, whose initial records (plaque index, gingival index) are taken after the examination by the periodontology specialist, will be taught how to brush their teeth with the Modified Bass Technique and how to use dental floss/interdental brush. After staining the teeth with a plaque disclosing agent, they will be shown in the mirror. Then the students will then be asked to brush their teeth.
89241094|NCT06079840|Experimental|MBSR-AAC app|Participants will receive the MBSR-AAC app for 8-weeks.
89241095|NCT06079840|Active Comparator|Comparison|Participants will receive information regarding caregiver services and resources for 8-weeks.
89241096|NCT06078384|Experimental|Cohort 1-Pembrolizumab plus Paclitaxel|Pembrolizumab will be administered at a fixed dose of 200 mg every 3 weeks (Q3W), with a total of 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles
89241097|NCT06078384|No Intervention|Cohort 2-Observation|No treatment will be administered, patients will undergo standard surveillance every 6 months according to local practice.
89241098|NCT06078358|Experimental|Resistance exercise training|Participants undergo 8 weeks (3 days/week) of resistance exercise training.
89241099|NCT06078358|No Intervention|Control|Participants do not perform 8 weeks of resistance exercise training.
89241100|NCT06078215|No Intervention|Thrombolysis and/or mechanical thrombectomy|patients included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy - comparator
89241101|NCT06078215|Experimental|Cerebrolysin|patients included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy and treated with Cerebrolysin
89241102|NCT06078215|No Intervention|No reperfusion therapy / no cerebrolysin|patients not referred to reperfusion therapy nor Cerebrolysin
89241103|NCT06077903|Experimental|GT101 treatment group|Autologous tumor infiltrating lymphocyte injection
89241104|NCT06076408|Experimental|SNAGS with Pilates|Sustained Natural Apophyseal glides and Pilates Exercises
89241105|NCT06076408|Active Comparator|SNAGS|Sustained Natural Apophyseal glides
89241106|NCT06076356|Active Comparator|Group A|Foam Rolling Group
89241107|NCT06076356|Active Comparator|Group B|Kinesio Taping Group
89241108|NCT06071702|Experimental|IoNIR Ridaforolimus-Eluting Coronary Stent|IoNIR Ridaforolimus-Eluting Coronary Stent System
89241109|NCT06071195||Prostate Cancer Patients|"Patients will undergo a combined whole-body MRI + multiparametric prostate MRI examination along with routine staging examinations (PET, CT / bone scintigraphy).~Reporting will be performed without and with reference to the whole-body MRI examination. Differences in the resulting staging and in management recommendations based on the two reportings will be recorded."
89241110|NCT06071065|Active Comparator|Basic|"Basic intervention included the usual counselling by a clinical pharmacist e.g.~Patients Education~Pharmacist counseling regarding their disease type and severity~Pharmacist counseling (15- to 20-minute sessions) on the proper use of medication~Pharmacist counseling regarding the importance of their therapy (treatment)~Labeling of medication packs to assist pill sorting. Labels included instructions on dose and frequency/ timing of medication doses~Optimizing therapy monitoring~Prescription information quality (incomplete prescription)~wrong dose~wrong frequency etc."
89241111|NCT06071065|Experimental|Advanced|"In addition to Basic Intervention:~Preventing drug interactions :~• Detection or assessment of potential DDIs by a pharmacist prior to the start of treatment and recommendations for their management.~Patient Education regarding Medications :~Pharmacist counseling (15- to 20-minute sessions) on the proper use of medication.~Pharmacist counseling on the safe use of medication (self-medication or over-the-counter [OTC] medicines)~Preventing an adverse drug event~• Monitoring, and prompt detection of adverse drug events (ADEs)~Education on lifestyle modifications~Education on lifestyle e.g. regarding exercise~Renal diet plan will be given to patients~Renal Dose Adjustments :~Detection or assessment of potential nephrotoxic drugs by a pharmacist prior to start of treatment and recommendations for their renal dose adjustment."
89241112|NCT06069973||Delayed cerebral ischemia|Definition by Vergouwen et al. Verified by computed tomography
89241113|NCT06069973||Non-delayed cerebral ischemia|No signs of cerebral ischemia clinically or by computed tomography.
89241114|NCT06066411|Experimental|Massage Ball Group|A massage ball will be applied to the patients' hands and feet for 20 minutes.
89241115|NCT06066411|No Intervention|Control Group|No application will be made to this group by the researcher.
89241116|NCT06065514||Patients Group|The study plans to include 120 consecutive patients above 18 years old presenting with STEMI, NSTEMI, or UA and referred for coronary angiography.
89241117|NCT06065514||Control Group|60 patients will consist of the control group. The patient and control group will be matched at baseline by equating certain clinical characteristics of interest between the exposed and unexposed groups. The control group will consist of individuals to whom the obstructive coronary artery disease would be ruled out either by invasive or non-invasive coronary angiography or by myocardium perfusion SPECT or stress echocardiography.
89241118|NCT06063941|Active Comparator|1% iodine solution arm|Esophageal chromoendoscopy will be performed with a 15 ml volume of 1% Lugol iodine solution.
89241119|NCT06063941|Experimental|5% iodine solution arm|Esophageal chromoendoscopy will be performed with a 3 ml volume of 5% iodine stock solution.
89241120|NCT06054984|Experimental|TCR-T Cells Injection（GB3010 Cells Injection）|This study was designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of TCRT cell injection (GB3010) in patients with advanced pancreatic cancer by intravenous injection. The target population is patients with advanced pancreatic cancer who lack effective treatment methods, so that the benefits of patients participating in clinical trials will outweigh the risks.
89241121|NCT06054308|Experimental|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
89241122|NCT06052462|Experimental|[14C]-LY3556050|Single dose of [¹⁴C]-LY3556050 administered orally
89241123|NCT06051669||iLivTouch then FibroScan|"Subjects in the Group iLivTouch then FibroScan will be measured using iLivTouch first and then FibroScan based on the randomization result."
89241124|NCT06051669||FibroScan then iLivTouch|"Subjects in the Group FibroScan then iLivTouch will be measured using FibroScan first and then iLivTouch based on the randomization result."
89241125|NCT06047938||carotid intima thickness measurment|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
89241126|NCT06047704||All participants-cross sectional|All participants received the same data collection protocol. No intervention
89241127|NCT06045104|Active Comparator|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
89241128|NCT06045104|Experimental|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
89241129|NCT06036082|Experimental|Conventional physical therapy group|It consisted of 20 children received conventional physical therapy program
89241130|NCT06036082|Experimental|isokinetic training group|It consisted of 20 children received conventional physical therapy program and isokinetic training
89241131|NCT06036082|Experimental|Treadmill training group|It consisted of 20 children received conventional physical therapy program and treadmill training
89241132|NCT06036069|Experimental|Conventional physical therapy group|It consisted of 20 children received conventional physical therapy
89241133|NCT06036069|Experimental|Core stability exercises group|It consisted of 20 children received conventional physical therapy and core stability exercises
89241134|NCT06036069|Experimental|Whole body vibration|It consisted of 20 children received conventional physical therapy and whole body vibration exercises
89241135|NCT06034288|Experimental|Xeomin|100units xeomin dilated in 10mL injectable saline will be injected into the detrusor muscle to a depth of 3mm at 20 sites at 0.5mL volume each
89241136|NCT06034288|Active Comparator|Botox|100units Botox dilated in 10mL injectable saline will be injected into the detrusor muscle to a depth of 3mm at 20 sites at 0.5mL volume each
89241137|NCT06012175|Experimental|Oral melatonin supplementation|Participants in the intervention arm will receive one 3 mg melatonin tablet every night before going to bed
89241138|NCT06012175|Placebo Comparator|Placebo|The control group will receive an identical-looking inert placebo tablet every night before going to bed
89241139|NCT06008938||HEMGENIX|Patients with hemophilia B treated with HEMGENIX in countries where HEMGENIX is approved for commercial use.
89241140|NCT06008938||FIX Prophylaxis|Patients with hemophilia B on FIX prophylaxis and enrolled in American Thrombosis and Hemostasis Network (ATHN) Transcends (A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders) Hemophilia Cohort, or a similar registry.
89241141|NCT06003348|Active Comparator|Potassium Citrate (Urocit®-K)|Potassium Citrate KCit 10 mEq 2 tabs, twice daily and Placebo 1 tab, twice daily Total Daily Dose: Citrate 40 mEq/d
89241142|NCT06003348|Experimental|Super CitriMax; OHCit-standard dose|Super CitriMax 7 mEq 3 tabs, twice daily Total Daily Dose: OHCit 42 mEq/d
89241143|NCT06003348|Experimental|Super CitriMax; OHCit-low dose|Super CitriMax 7 mEq 2 tabs, twice daily And Placebo 1 tab, twice daily Total Daily Dose: OHCit 28 mEq/d
89241144|NCT06003348|Placebo Comparator|Placebo|Placebo 3 tablets twice daily Total Daily Dose: None
89241145|NCT06000891|Active Comparator|ZP7570|ZP7570 for subcutaneous once-weekly injection.
89241146|NCT06000891|Placebo Comparator|Placebo|Placebo for subcutaneous once-weekly injection. Corresponding volume matching active treatment
89241147|NCT05998070|Experimental|Training group|Hip strengthening exercises will be performed in the training group.
89241148|NCT05998070|No Intervention|Control group|The control group will continue their training and matches.
89241149|NCT05998044|Active Comparator|control group|Before starting the study for the Control Group, the participants were informed about the research and their consent will be obtained. Afterwards, evaluation surveys will be applied. They will be asked not to participate in any regular exercise for 8 weeks. At the end of 8 weeks, re-evaluation surveys will be applied.
89241150|NCT05998044|Experimental|pilates group|After people fill out the evaluation questionnaires, they will watch the video recording of pilates based exercises via the link sent to them via Google Drive, and they will be applied twice a week for 8 weeks. All exercises in the video recording will be explained in written, applied and verbal form by the physiotherapist, and they will be asked to practice. Every week, feedback will be received from people that they have done the exercises via their contact numbers. The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). Participants will be asked to open the video recording each time they exercise and follow them to do the exercises. At the end of 8 weeks, re-evaluation surveys will be applied.
89241151|NCT05994638|Experimental|Aerosol for use in the oral cavity|Group of 10 patients with head and neck cancer who have undergone radiotherapy
89241152|NCT05988047||Patients with AML|Peripheral blood will be taken at the timepoint of primary diagnosis and analyzed for CMTM6 expression and T cell activation
89241153|NCT05988047||Healthy controls|Peripheral blood will be taken analyzed for CMTM6 expression and T cell activation
89241154|NCT05979233|Active Comparator|staged managment|ERCP then interval laparoscopic cholecystectomy
89241155|NCT05979233|Experimental|one session ERCP then LC|one session ERCP then LC
89241156|NCT05979233|Experimental|one session LC then ERCP|one session LC then ERCP
89241157|NCT05975021|Experimental|Istaroxime|Istaroxime delivered as an IV infusion via a syringe pump. Dosage regime is 1.0 µg/kg/min for 6 hours, 1.0 or 0.5 µg/kg/min for 18 hours, 0.5 µg/kg/min for 24 hours. Total duration 48 hours.
89241158|NCT05975021|Placebo Comparator|Placebo|Placebo (lactose) delivered as an IV infusion via a syringe pump. Total duration 48 hours.
89241159|NCT05967520|Experimental|JMKX000189 - higher dose|Randomized 16 patients will be received JMKX000189 at a higher dose in oral continuously from Week 0 to Week 12 in addition to SOC.
89241160|NCT05967520|Experimental|JMKX000189 - lower dose|Randomized 16 patients will be received JMKX000189 at a lower dose in oral continuously from Week 0 to Week 12 in addition to SOC.
89241161|NCT05967520|Placebo Comparator|Placebo|Randomized 16 patients will be received Placebo in oral continuously from Week 0 to Week 12 in addition to SOC.
89241162|NCT05960734||Samples group|Samples collected regarding the online information about incontinence after cancer surgery.
89241163|NCT05948644|Experimental|TPN171H|TPN171H is received 2.5mg QD for 2 consecutive weeks, then 5 mg QD for 14 consecutive weeks. If the dose is well-tolerated,TPN171H is up-titrated to 10mg QD , which will last for up to 2 years.
89241164|NCT05947162|Experimental|smoking cessation combining with nicotine cue extinction training|Participants should stop smoking after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
89241165|NCT05947162|Placebo Comparator|smoking cessation combining with neutral cue extinction training|Participants should stop smoking after 18:00 the night before the test, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.
89241166|NCT05947162|Experimental|smoking cessation combining with fasting and nicotine cue extinction training|Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts are repeatedly presented with nicotine cue picture stimuli for extinction training, which lasts for 25 minutes.
89241167|NCT05947162|Placebo Comparator|smoking cessation combining with fasting and neutral cue extinction training|Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
89241168|NCT05947162|Sham Comparator|smoking cessation combining with early lifting of fast and nicotine cue extinction training|Participants should stop smoking and eating food after 18:00 the night before the test. After breakfast at 8:00 in the morning, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.
89241169|NCT05947162|No Intervention|healthy control|Non-smoker healthy subjects matched with the smoking group in terms of age, gender, education level, etc. were used as the control group. Those healthy participants will finish fMRI scanning task.
89241170|NCT05945680|Placebo Comparator|Placebo|Normal saline for intravenous administration.
89241171|NCT05945680|Active Comparator|Tranexamic acid|Tranexamic Acid for intravenous administration.
89241172|NCT05943795|Experimental|Experimental group|Participants receive SI-B001 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89241173|NCT05943795|Experimental|Control group|Participants receive Docetaxel as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
89241174|NCT05941728|Experimental|Avocado|The experimental treatment will contain an avocado. Avocados will be consumed daily for 4 weeks.
89241175|NCT05941728|Active Comparator|Fiber + Oil|The active comparator will have a snack that mimics the fiber and fatty acid composition found in avocados and will be consumed daily for 4 weeks.
89241176|NCT05941728|Sham Comparator|Standard American Diet|The sham comparator contains foods and beverages of a standard American diet and will be consumed daily for 4 weeks.
89241177|NCT05938959|Active Comparator|Sham group|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% Normal Saline
89241178|NCT05938959|Active Comparator|ESPB group|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
89241179|NCT05937230||Drug-coated balloon|Paclitaxel coated balloon
89241180|NCT05937230||Drug-eluting stent|Second-generation eluting stents
89241181|NCT05932615|Experimental|Navitor Transcatheter Aortic Valve Implantation (TAVI) System|TAVI with Abbott Navitor Transcatheter Aortic Valve Implantation (TAVI) System
89241182|NCT05932615|Active Comparator|Any Commercially Available Transcatheter Aortic Valve System (CAV)|TAVI with any FDA approved commercially available Transcatheter Aortic Valve System (CAV)
89241183|NCT05932459|Experimental|BA Study|18 subjects were randomly divided into two sequences, TR and RT, with 9 subjects in each sequence, and were given in fasted condition once per period. In the first period of TR sequence, 100mg Deuremidevir Hydrobromide dry suspension was taken, and in the second period, 100 mg Deuremidevir Hydrobromide tablets were taken. In the first period of RT sequence, 100mg Deuremidevir Hydrobromide tablets were taken, and 100mg Deuremidevir Hydrobromide dry suspension was taken in the second period.
89241184|NCT05932459|Experimental|FE Study|12 subjects were randomly divided into two sequences, sequence 1 and sequence 2. There were 6 subjects in each sequence, and one dose per period. Sequence 1: Take Deuremidevir Hydrobromide dry suspension in fasted condition in period 1, and take Deuremidevir Hydrobromide dry suspension after taking infant formula for 10 minutes in period 2; Sequence 2: Take Deuremidevir Hydrobromide dry suspension after taking infant formula for 10 minutes in period 1, and take Deuremidevir Hydrobromide dry suspension in fasted condition in period 2.
89241185|NCT05932459|Experimental|PK Study|Fasting; PK study form is dry suspension, the doses are 25 mg, 100 mg, 300 mg, taken orally once in fasted condition. 8 subjects in 25 mg group; The 100 mg group used the data of 18 subjects with dry suspension in BA study, while the 300 mg group used the fasting condition data of 12 subjects with dry suspension in FE study.
89241186|NCT05914649|Experimental|1500mL Normal Saline|1500mL of normal saline infused intravenously.
89241187|NCT05914649|Placebo Comparator|50mL Normal Saline|50mL of normal saline infused intravenously.
89241188|NCT05914090|Experimental|Intervention group|
89241189|NCT05914090|No Intervention|Control group|
89241190|NCT05903209||Software diagnosis|Software diagnosis with gold standard of 3 doctors' interpretation.
89241191|NCT05899595|Experimental|Personalized training group with the fatigue status (PERSO)|The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises.
89241192|NCT05899595|Active Comparator|Traditional training group following the recommendations (RECO)|The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.
89241193|NCT05894876||Good responders|Participants on previous treatment with growth hormone will have one study visit for taking a non-invasive biological sample. Good responders are defined as participants with a change in height Standard Deviation Score (SDS) more than (>) 1.0, corresponding to >85th percentile.
89241194|NCT05894876||Poor responders|Participants on previous treatment with growth hormone will have one study visit for taking a non-invasive biological sample. Poor responders are defined as participants with a change in height SDS less than (<) 0.4, corresponding to <15th percentile.
89241195|NCT05892835|Other|educative intervention|A 2-hour training workshop was carried out where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Mannequin for CPR practices Little Anne QCPR. Laerdal) and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
89241196|NCT05880849|Experimental|Choline|2.2 g of choline, given as choline bitartrate, for a total of 180 days.
89241197|NCT05878015|Experimental|IV Acetaminophen Group|Subjects presented to emergency department (ED) and diagnosed with small bowel obstruction which receive IV acetaminophen
89241198|NCT05878015|No Intervention|Usual Care Group|Subjects presented to emergency department (ED) and diagnosed with small bowel obstruction will receive intravenous opioids per their provider's choice as standard of care.
89241199|NCT05872477|Experimental|Group treatment|There will be 2 arms with intra individual comparison. After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
89241200|NCT05872477|Placebo Comparator|group placebo|"Each grafted side of the body will be randomly assigned to receive twice daily application of placebo cream (Group B).~After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months."
89241201|NCT05867875|Experimental|Experimental group (ORI)|ORI and SpO2 monitoring values during preoxygenation of patients will be provided to investigator to determine anaesthesia induction initiation. Anesthesic induction is provided after 30 secondes at ORI > 0.6 and at least 2 min 30 of preoxygenation (so globaly 3 minutes of preoxygenation)
89241202|NCT05867875|Other|Standard of care (SoC) group|Only SpO2 values during preoxygenation of patients will be provided to investigator to determine anaesthesia induction initiation. Anesthesic induction is provided at least 3 min of preoxygenation
89241203|NCT05854602|No Intervention|Condition 1: 000|Families in this condition will not receive any of the intervention components during study period (T0-T2, T2-T4, T4-T6). Target n = 35.
89241204|NCT05854602|Experimental|Condition 2: 0A0|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241205|NCT05854602|Experimental|Condition 3: 00A|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
89241206|NCT05854602|Experimental|Condition 4: 0AB|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
89241207|NCT05854602|Experimental|Condition 5: 0AC|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
89241208|NCT05854602|Experimental|Condition 6: 0B0|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241209|NCT05854602|Experimental|Condition 7: 00B|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
89241210|NCT05854602|Experimental|Condition 8: 0BA|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
89241211|NCT05854602|Experimental|Condition 9: 0BC|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
89241212|NCT05854602|Experimental|Condition 10: 0C0|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241213|NCT05854602|Experimental|Condition 11: 00C|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
89241214|NCT05854602|Experimental|Condition 12: 0CA|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
89241215|NCT05854602|Experimental|Condition 13: 0CB|This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
89241216|NCT05854602|Experimental|Condition 14: A00|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241217|NCT05854602|Experimental|Condition 15: A0B|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
89241218|NCT05854602|Experimental|Condition 16: A0C|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
89241219|NCT05854602|Experimental|Condition 17: AB0|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241220|NCT05854602|Experimental|Condition 18: ABC|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
89241221|NCT05854602|Experimental|Condition 19: AC0|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241222|NCT05854602|Experimental|Condition 20: ACB|This intervention condition received Component A from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
89241223|NCT05854602|Experimental|Condition 21: B00|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241224|NCT05854602|Experimental|Condition 22: B0A|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
89241225|NCT05854602|Experimental|Condition 23: B0C|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
89241226|NCT05854602|Experimental|Condition 24: BA0|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241227|NCT05854602|Experimental|Condition 25: BAC|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component C from T4 to two weeks later (T6). Target n = 7.
89241228|NCT05854602|Experimental|Condition 26: BC0|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241229|NCT05854602|Experimental|Condition 27: BCA|This intervention condition received Component B from baseline (T0) to the second measurement point two weeks later (T2), Component C from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
89241230|NCT05854602|Experimental|Condition 28: C00|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241231|NCT05854602|Experimental|Condition 29: C0A|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
89241232|NCT05854602|Experimental|Condition 30: C0B|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), no intervention from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
89241233|NCT05854602|Experimental|Condition 31: CA0|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241234|NCT05854602|Experimental|Condition 32: CAB|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
89241235|NCT05854602|Experimental|Condition 33: CB0|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and no intervention from T4 to two weeks later (T6). Target n = 7.
89241236|NCT05854602|Experimental|Condition 34: CBA|This intervention condition received Component C from baseline (T0) to the second measurement point two weeks later (T2), Component B from T2 to two weeks later (T4), and Component A from T4 to two weeks later (T6). Target n = 7.
89241237|NCT05844657||Individuals with Meniere's disease|Voluntary Meniere's patients aged 18-65 years, not in the relapse period, who met the inclusion criteria
89241238|NCT05844657||Healthy individuals without Meniere's disease|Volunteer healthy individuals aged 18-65 years without dizziness who met the inclusion criteria
89241239|NCT05838755|Experimental|GSK3858279 Dose 1|Participants will receive GSK3858279 dose 1.
89241240|NCT05838755|Experimental|GSK3858279 Dose 2|Participants will receive GSK3858279 dose 2.
89241241|NCT05838755|Placebo Comparator|Placebo|Participants will receive placebo.
89241242|NCT05838313|Experimental|Decision Support Tool|Participants will interact with the decision support tool prior to making their decision regarding whether to have an induction of labor without a medical indication
89241243|NCT05821465||HeartWatch vs. Event Recorder|All patient-tagged (symptomatic) events recorded by the HeartWatch, and reference devices (Event Recorder) and all non-normal clinically significant rhythm auto-triggered and recorded events will be adjudicated and classified using literature-based definitions.
89241244|NCT05821465||HeartWatch vs. Holter|All patient-tagged (symptomatic) events recorded by the HeartWatch, and reference devices (Holter) and all non-normal clinically significant rhythm auto-triggered and recorded events will be adjudicated and classified using literature-based definitions.
89241245|NCT05816226|Experimental|Hydrocortisone topical|2.5% hydrocortisone cream
89241246|NCT05816226|Active Comparator|Diclofenac topical|1% diclofenac cream
89241247|NCT05793801|Active Comparator|Control group|Patients receiving normal management with dressings changed once a week according to the SF2H recommendations.
89241248|NCT05793801|Experimental|Experimental group|Patients whose dressings are changed every other day.
89241249|NCT05792956|Experimental|Mobile Application group|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
89241250|NCT05792956|No Intervention|Control group|To the control group, the routine protocol in the clinic (Bladder training is given by the nurses after the women apply. They come to deliver the bladder diary given after the bladder training in the 3rd and 6th months. According to the results of the bladder diary, the nurses provide counseling for the problems detected regarding the symptoms they experience). After the first interview, they will be asked to fill in the required scales one day in the 3rd and 6th months.
89241251|NCT05787483|Experimental|MindUP group|Teachers in the MindUP group will deliver the program lessons twice a week for 30 minutes (1 hour per week) for 12 weeks. Based on previous studies, 12 weeks should be sufficient to cover the content from the 17 lessons.
89241252|NCT05787483|Active Comparator|active control group|business as usual; regular wellness or SEL classes
89241253|NCT05771779|Experimental|Arm A: Oral Cholera Vaccine (OCV) only|Based on randomization (n= 413) Potential participants will be vaccinated with OCV on Day 0 and Day 28. Two doses of MR vaccine will be given on day 56 and day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28, Day 56, Day 84 and Day 264 . All details will be recorded in the eCRF.
89241254|NCT05771779|Experimental|Arm B: Typhoid Conjugate Vaccine (TCV) only|Based on randomization (n= 314) Potential participants will be vaccinated with TCV on Day 0 and two doses of MR vaccine will be given on Day 56 and Day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28, Day 84 and Day 264 . All details will be recorded in the eCRF.
89241255|NCT05771779|Experimental|Arm C: Measles and Rubella (MR) only|Based on randomization (n= 250) Potential participants will be vaccinated with MR on Day 0 and Day 180. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 and Day 208 . All details will be recorded in the eCRF.
89241256|NCT05771779|Experimental|Arm D: Co-administration of Measles and Rubella (MR) and Typhoid Conjugate Vaccine (TCV)|Based on randomization (n= 314) Potential participants will be vaccinated with TCV on Day 0 and two doses of MR vaccine will be given on Day 0 and Day 180 . A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 and Day 208 . All details will be recorded in the eCRF.
89241257|NCT05771779|Experimental|Arm E: Co-administration of Measles and Rubella (MR) and Oral Cholera Vaccine (OCV)|Based on randomization (n= 413) Potential participants will be vaccinated with OCV on Day 0 and Day 28 . Two doses of MR vaccine will be given on Day 0 and Day 180 . A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 , Day 56 and Day 208 . All details will be recorded in the eCRF.
89241258|NCT05771779|Experimental|Arm F: Co-administration of Typhoid Conjugate Vaccine (TCV) and Oral Cholera Vaccine (OCV)|Based on randomization (n= 413) Potential participants will be vaccinated with TCV on Day 0 . Two doses of OCV vaccine will be given on Day 0 and Day 28. Also two doses of MR vaccine will be given on Day 56 and Day 236. A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 , Day 56 , Day 84 and Day 264 . All details will be recorded in the eCRF.
89241259|NCT05753670|Experimental|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
89241260|NCT05753670|Placebo Comparator|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
89241261|NCT05746468|Experimental|Intervention group|The intervention group will receive a combination of (1) a time-based system-triggered EMI, which will collect participants' sources and status of depression, anxiety and depression in daily life and provide instructions (audios and videos) on mindfulness practice, and (2) a longitudinal survey in parents of children with ASD. The participants will first complete a baseline questionnaire, and then participate in EMI via a smartphone application (App) for 8 consecutive weeks and receive the exercise prompts daily. The EMI will include questions of the self-reported feelings of depression, anxiety and depression. After the 8-week EMI, the participants will be invited to complete a post-experimental survey with similar questions in the baseline questionnaire. Two months after completing the EMI, participants will be contacted to complete a telephone follow-up survey with similar questions in the baseline questionnaire.
89241262|NCT05746468|Active Comparator|Control group|The control group will receive the longitudinal survey exactly the same as the intervention group and 8-week mindfulness-based short-messages sent by the research team on a daily basis. The messages will contain instructions of mindfulness-based practice which will be the same as the intervention group.
89241263|NCT05744765|Experimental|Breathing exercises|First evaluation - breathing exercises (1 session) - second evaluation - breathing exercises (11 sessions) - third evaluation
89241264|NCT05744765|No Intervention|No exercise|First evaluation - no intervention (1 session) - second evaluation - no intervention (11 sessions) - third evaluation
89241265|NCT05742698|Active Comparator|Nabilone|"Weeks 1-2 Nabilone and placebo will be taken orally by the patient as per the schedule provided by the research team. All patients will start with one 0.5mg capsule per day, taken before bed for the first week and then increase administration to the 1mg capsule taken before bed for the second week.~Weeks 3-4 Two weeks after the start of the trial patients and study partners will attend an in person or remote Interim Assessment. If remission is not achieved and no clinically significant adverse drug reactions are reported then the dose schedule will increase to 2 capsules per day (2mg/day), 1 capsule in the morning and 1 before bed.~Weeks 5-6 Four weeks after the start of the trial there will be a second in person or remote Interim Assessment identical to the first. If remission of agitation has not been achieved and no adverse drug reactions are reported the dose schedule will increase to 4 tablets per day (4mg/day), with 2 tablets in the morning and 2 before bed."
89241266|NCT05742698|Placebo Comparator|Placebo|"Weeks 1 and 2 Participants will receive one capsule per day to be taken orally before bedtime.~Weeks 3-4 Participants will receive 2 capsules per day, one in the morning and one before bedtime.~Weeks 5-6 Participants will receive 2 capsules per day, one in the morning and one before bedtime.~The placebo dosing regimen is designed to be as similar as possible to the nabilone dosing regime, including using identical capsules."
89241267|NCT05731960|Experimental|Dexamethasone (Group SD)|10 mg IV dexamethasone x1
89241268|NCT05731960|Active Comparator|Metoclopramide (Group SM)|10 mg IV metoclopramide x1
89241269|NCT05723679|Experimental|HeO2 gas mixture, then Room air gas mixture|Participant will be randomized to each intervention on separate days (Study visit 3 and 4) in this cross-over trial. Participants that receive HeO2 first will then receive the room air gas mixture. At least 24 hours will separate each visit.
89241270|NCT05723679|Experimental|Room air gas mixture, then HeO2 gas mixture|Participant will be randomized to each intervention on separate days (Study visit 3 and 4) in this cross-over trial. Participants that receive Room air first will then receive the HeO2 mixture. At least 24 hours will separate each visit.
89241271|NCT05714696|Experimental|Weight discrimination experience|"Participants in the experimental condition will:~Learn that their group mates are biased against overweight people (i.e., they have negative attitudes toward people with higher body weight),~Receive feedback about their personal attributes that is consistent with negative weight-based stereotypes (e.g., lacking self-discipline), and~Not be selected as a partner for the remaining lab tasks (i.e., this experience may prompt feelings of social exclusion)."
89241272|NCT05714696|Active Comparator|Control experience|"Participants in the control condition will:~Learn that their group mates are very accepting of overweight people (i.e., they have positive attitudes toward people with higher body weight),~Receive positive feedback about their personal attributes that is not consistent with negative weight-based stereotypes, and~Will be told that one of their group members had to leave early for an emergency so the pairs cannot be assembled as usual (i.e., this experience should not prompt feelings of social exclusion)."
89241273|NCT05705739|Experimental|Retrolaminar plane block|
89241274|NCT05705739|Experimental|ESPB|
89241275|NCT05688436||Diroximel Fumarate (DRF)|Pregnant women with MS who were exposed to DRF.
89241276|NCT05688436||Non-DRF|Pregnant women with MS who were exposed to disease-modifying therapies (DMTs) other than DRF.
89241277|NCT05688436||Non-DMT|Pregnant women with MS who were not exposed to DMTs.
89241278|NCT05685758|Experimental|Intervention group|Individuals with Major Depressive Disorder who have access to an FTP-based mobile phone application for eight weeks.
89241279|NCT05685758|No Intervention|Control group|Individuals with Major Depressive Disorder who are on an 8-week waitlist (delayed intervention) before being offered to use the app. During the eight weeks, they will be subjected to the same questionnaires and assessments as the intervention arm.
89241280|NCT05679622|Experimental|FMT group|In the refractory ulcerative colitis group, our study is aims to explore repeated and multiple FMTs plus PEN in the treatment of refractory pediatric UC;
89241281|NCT05676450|Other|cell-free DNA (cfDNA) samples|"cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.~Blood will be drawn 3 times (by vein)"
89241282|NCT05654259||obese women with normal gestational weight gain|obese women (body mass index ≥30 kg/m2) with weight gain 5-9 kg
89241283|NCT05654259||obese women excessive gestational weight gain|obese women (body mass index ≥30 kg/m2) with weight gain >9 kg
89241284|NCT05654259||non-obese women with normal gestational weight gain|non-obese women (body mass index 18.5-24.9 kg/m2) with weight gain 11.5-16 kg
89241285|NCT05654259||non-obese women with excessive weight gain|non-obese women (body mass index 18.5-24.9 kg/m2) with weight gain >16 kg
89241286|NCT05654259||obese women with OSA|obese women (body mass index ≥30 kg/m2) with Obstructive Sleep Apnea (OSA) (Apnea and Hypopnea Index (AHI) ≥5 events/hr
89241287|NCT05654259||obese women without OSA|obese women (body mass index ≥30 kg/m2) without Obstructive Sleep Apnea (OSA) (AHI <5 events/ hr)
89241288|NCT05654259||non-obese women without OSA|non-obese women without OSA (AHI <5 events/ hr)
89241289|NCT05650606|Experimental|High Intensity Gait Training|"HIGT will be performed 4-6 times per week in place of conventional physical therapy. The patient's heart rate(HR)and blood pressure(BP) will be measured throughout each session. If the HR or BP is out of the acceptable range, patients will undergo standard physical therapy for that session, and the medical team will be contacted.~Target HR zones will be calculated with the Karvonen formula. The first session goal is to reach a target HR range that is 50-60% of heart rate reserve. The goal for subsequent sessions is to reach 70-80% of heart rate reserve. Rate of perceived exertion (RPE) will also be utilized.~The primary therapist will design an individualized HIGT treatment program with a combination of speed dependent treadmill activities, activity-based treadmill activities, stair training, and over ground activities.~The patient will be reminded during each session to ask for a rest as needed. Standing rests are preferred over sitting rests, but either may be utilized."
89241290|NCT05650606|Active Comparator|Conventional|The conventional physical therapy sessions are what a patient would normally receive during their rehabilitation. Physical therapy sessions are usually 60-90 minutes per day for 5 days each week, and possibly one 30-minute session on a 6th day. Physical therapy sessions are focused on gait, balance, and strengthening activities to address goals related to functional mobility. Clinicians administering therapy to patients in this arm will not be given instructions on the types of therapies they administer; however, they will not be permitted to do HIGT with patients. Therapists will be permitted to use other devices such as Ekso exoskeleton, Lite Gait, Rifton Tram Body Weight Support Devices, and Electrical Stimulation devices including the XCITE and RT300.
89241291|NCT05637515|Active Comparator|Humira continuously|"Subjects receive Humira continuously both during Run-in period and Randomized interchangeable treatment period.~Run-in Period:~Subjects will receive Humira (initial dose of 80 mg [2 × 40 mg]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Randomized interchangeable treatment period:~Subjects continue to receive Humira (40 mg every other week) until Week 26"
89241292|NCT05637515|Experimental|Repeated switches Humira - Hulio|"Subjects will receive Humira in Run-in period & undergo repeated switches between Humira Hulio during randomized interchangeable treatment period~Randomized interchangeable treatment period:~Subjects undergo repeated switches between Humira and Hulio between week 12 to week 26.~Hulio (40 mg every other week) at Week 12 and Week 14~Humira (40 mg every other week) at Week 16 and Week 18, and~Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
89241293|NCT05635162|No Intervention|Arm A: Control|Active observation
89241294|NCT05635162|Experimental|Arm B: Experimental|Time limited Zanubrutinib-R 6 x 28 day cycles
89241295|NCT05620264||Keratitis Group|Patients with clinically suspected bacterial or fungal keratitis
89241296|NCT05614544|Experimental|Treatment A: HSK3486 dose 1|Treatment A: HSK3486 dose 1 (IV bolus over 30 seconds [+5 seconds] from a syringe; dose to be determined in Part 1)
89241297|NCT05614544|Experimental|Treatment B: HSK3486 dose 2|Treatment B: HSK3486 dose 2 (IV bolus over 30 seconds [+5 seconds] from a syringe; dose to be determined in Part 1)
89241298|NCT05614544|Active Comparator|Treatment C: Propofol|Treatment C: Propofol (IV bolus over 30 seconds [+5 seconds] from a syringe; dose to be determined in Part 1)
89241299|NCT05614544|Placebo Comparator|Treatment D: Placebo|Treatment D: Placebo (Treatment A matched) (IV bolus over 30 seconds [+5 seconds] from a syringe)
89241300|NCT05547412||Cohort X|Phase 0 will include up to 20 subjects in Cohort X (TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
89241301|NCT05547412||Cohort Y|Phase 0 will include up to 20 subjects in Cohort Y (No TCD). This phase is for training and feasibility purposes only and data collected will not be used in the final analysis.
89241302|NCT05547412||Cohort A|Both Phase 1 and Phase 2 of the study will enroll Cohort A (LVO TCD). Cohort A will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
89241303|NCT05547412||Cohort B|Both Phase 1 and Phase 2 of the study will enroll Cohort B (Non-LVO TCD). Cohort B will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
89241304|NCT05547412||Cohort C|Both Phase 1 and Phase 2 of the study will enroll Cohort C (LVO No-TCD). Cohort C will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
89241305|NCT05547412||Cohort D|Both Phase 1 and Phase 2 of the study will enroll Cohort D (Non-LVO No-TCD). Cohort D will enroll 54 subjects in Phase 1 and 156 subjects in Phase 2
89241306|NCT05544903||Mortality, ICU admission, or rapid response team activation|Carotid flow patterns and velocity time integral values, as determined by FloPatch.
89241307|NCT05544903||No mortality, ICU admission, or rapid response team activation|Carotid flow patterns and velocity time integral values, as determined by FloPatch.
89241308|NCT05533372|Experimental|IA-14069 MAD|Subjects will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 10 days.
89241309|NCT05533372|Experimental|IA-14069 DDI|"Subjects will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 10 days.~On day 11, subjects will be adminiatrated oral dose of IA-14069 or matching placebo with methotrexate.~On day 21, subjects will be administrated methotrexate alone."
89241310|NCT05533372|Experimental|IA-14069 MAD RA patients|"Patients will be administrated multiple oral doses of IA-14069 at three ascending dose levels or matching placebo for 28 days.~Patients will be on a stable dose of methotrexate throughout the study period."
89241311|NCT05527938|Experimental|web-based intervention|"Establishing management teams.~Establishment of a nursing intervention team.~Daily uploading of health intervention records~Regularly delivering related health knowledge.~Home visiting~Psychological guidance."
89241312|NCT05527938|No Intervention|the control group|"1. Routine care.At each visit to the hospital, in this time, the child and his parents are given health education on diet and exercise booklets, and the parents supervise the child's daily life.~The team members will review the child's condition every month for feedback."
89241313|NCT05525078|Experimental|Switch Group|Participants in the Switch group will receive a 5-week supply of e-cigarettes.
89241314|NCT05525078|Active Comparator|Meds Group|Participants in the Meds Group will receive a 5-week supply of combination nicotine replacement therapy (transdermal nicotine patch and short-acting nicotine lozenge).
89241315|NCT05519007|Experimental|The Next Science treatment|The surgical site will be irrigated with NS prior to closure, which will be suctioned at the end of the treatment time
89241316|NCT05519007|Active Comparator|Standard of Care|Saline irrigation
89241317|NCT05498038|No Intervention|Healthy Control Service Members|Non-concussed, age-matched SM will serve as a healthy control group (HC) for comparing CSM to normal physiology and to control for the effect of time and of aerobic exercise. They will not be given intervention.
89241318|NCT05498038|No Intervention|Concussed Service Members PRA|CSM allocated to this group will complete PRA protocols/ will receive treatment as usual.
89241319|NCT05498038|Experimental|Concussed Service Members PRA+Exercise|CSM allocated to this group will complete PRA protocols/ will receive treatment as usual and will receive an exercise program in addition to PRA.
89241320|NCT05493657|Active Comparator|Aspirin group|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
89241321|NCT05493657|Experimental|Clopidogrel group|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
89241322|NCT05476094|Experimental|Experimental: AYP-101 1|0.2 mL injections, 1.0 cm apart, up to 10.0 ml, Single administration
89241323|NCT05476094|Experimental|Experimental: AYP-101 2|0.2 mL injections, 1.0 cm apart, up to 10.0 ml, Single administration
89241324|NCT05476094|Placebo Comparator|Placebo|0.2 mL injections, 1.0 cm apart, up to 10.0 ml, Single administration
89241325|NCT05466916|Experimental|Exercise and diet education and instruction|The intervention will be 12 weeks in duration. The five intervention components (e.g., educational sessions and instructional sessions) will be supervised. Research staff will conduct the intervention. Participants will be instructed to gradually aim for 30 minutes of physical activity for five days per week by Week 12 Participants will also aim for improved healthy dietary practices including > 200 grams/day (g/d) of fruits and vegetables, > 15 g/d of fiber (whole grains and beans), < 250 g/d of sugar-sweetened drinks and lower percent of total kcal from fast foods18 by Week 12. Sessions will be about 35- to 50-minutes in duration and be structured as follows: (a) review of previous session and an opportunity to ask questions (~5 minutes); (b) presentation of content (20- to 30-minutes); (c) opportunity for questions (~5 minutes); and (d) preview of next sessions and research activity reminders (2- to 3-minutes).
89241326|NCT05440058||BIS Monitoring|Subjects will have BIS sensors applied to forehead
89241327|NCT05439902|Experimental|Tamsulosin|
89241328|NCT05439902|Placebo Comparator|Placebo|
89241329|NCT05439148|Experimental|OPC-61815|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day
89241330|NCT05424757||Children who are taking PEG 3350|"Children less than 17 years old who have taken PEG 3350 daily for at least 30 days.~Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day.~Preference will be given to children taking at least 17 grams/day.~Notes:~Only children who are already taking PEG 3350 as part of their current medical regimen will be included. Changes to medical therapy are not recommended as part of this study.~Children in three subgroups will be enrolled:~Children with no known bowel or nervous system disease or neuropsychiatric symptoms.~Children with bowel problems that might increase intestinal permeability.~Children with neurologic disease or with neuropsychiatric disorders or symptoms."
89241331|NCT05424757||Children who are not taking PEG 3350|"Children less than 17 years old who have NOT taken PEG 3350 for at least 30 days.~Children in three subgroups will be included:~Children with no known bowel or nervous system disease or neuropsychiatric symptoms.~Children with bowel problems that might increase intestinal permeability.~Children with neurologic disease or with neuropsychiatric disorders or symptoms."
89241332|NCT05422599|Experimental|Lemon balm|300mg Lemon balm and Maltodextrin
89241333|NCT05422599|Placebo Comparator|Placebo|Placebo
89241334|NCT05419427|Experimental|Denosumab Solution for injection in single use prefilled syringe 60 mg permL|Unit Dose Strength 60 mg per mL,Dosage Level 60 mg once every 6 months, Route of Administration-Subcutaneous injection
89241335|NCT05419427|Active Comparator|Prolia® Solution for injection in single use prefilled syringe 60 mg per mL|Unit Dose Strength 60 mg per mL,Dosage Level 60 mg once every 6 months,Route of Administration-Subcutaneous injection
89241336|NCT05414305|Other|Heparin & Alkalinized Lidocaine Bladder Instillation|Six weekly bladder instillations, each instillation consisting of 40,000 IU Heparin, 200mg lidocaine, 2ml 8.4% sodium bicarbonate, sterile water for a total volume 50 milliliters (mL).
89241337|NCT05412290|Experimental|Consolidation Mosunetuzumab|Mosunetuzumab is a CD3xCD20 bispecific antibody administered intravenously in the consolidation setting after autologous stem cell transplant (autoSCT). Mosunetuzumab will be given in a step-up dosing schedule beginning on Day 49 after autoSCT on C1D1, C1D8, C1D15, and then Day 1 of all cycles thereafter. Patients will undergo PET-CT restaging around Day 100 post-autoSCT (approximately Cycle 3) and patients in complete response will continue mosunetuzumab for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients not in complete response will discontinue treatment and enter follow-up. All cycles are planned to be 21 days.
89241338|NCT05384834|Experimental|AYA participants|AYA participants will complete a brief initial survey consisting of demographic information and the Visual Analog Scale (VAS) and the #HerHeart tool in clinic. AYA participants will the rate the usability of the #HerHeart tool using the Website Analysis and Measurement Inventory (WAMMI), the likelihood they would recommend the app to their friends, and the likelihood of behavior change. AYA participants will then be offered the opportunity to continue into the 3-month intervention phase.
89241339|NCT05362929|Experimental|Hybrid Fractional laser - SOC|23 participants with fitzpatrick skin type IV-V will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.
89241340|NCT05362929|Experimental|Hybrid Fractional laser- Non- SOC|23 participants with Fitzpatrick skin type I-III will be in this arm. At the first visit, participants will undergo informed consent, education about the procedure, education about proper sun-care, and will be provided sunscreen. Participants will be prescribed a prescription of hydroquinone or a retinol to prevent hyperpigmentation, per standard of care. If participants choose to take this they will wait one month of taking the prescription and then begin treatment sessions. If not, participants can begin treatment sessions right away. Treatment consists of 3 laser sessions with the Sciton Halo hybrid fractional laser. Session amount depends on the degree of improvement. At each session before and after images will be collected. At each session participants will fill out the dermatology quality of life survey as well as a patient satisfaction survey.
89241341|NCT05356897|Experimental|Treatment (tucatinib, trastuzumab, TAS-102)|Patients receive tucatinib PO BID, trastuzumab IV over 30-90 minutes on days 1 and 15, and TAS-102 PO BID on days 1-5 and 8-12. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89241342|NCT05346757|Other|miRFec test|The miRFec test corresponds to the combination of fecal hemoglobin concentration and fecal miRNA expression
89241343|NCT05345041|Experimental|Keep it Movin'|
89241344|NCT05345041|Active Comparator|Go 4 Life Self Guided Education|
89241345|NCT05337930|Other|Intervention arm|Study participants will use the Happyr Health app, a mobile application to support CYP with primary headaches in coping with chronic pain, for eight weeks. For this study, a research version of the app will be provided via Google Play Store Testing Tracks and Apple TestFlight. In the app, a storyline and gamification elements engage CYP in filling out their headache diary and a regular mood diary.
89241346|NCT05329935||Main cohort|All eligible patients
89241347|NCT05329935||Secondary cohort|All eligible patients who survived 1 year post treatment
89241348|NCT05320887|Experimental|Normal Nicotine Content Vape with all flavor e-liquids|Normal Nicotine Content Vape with all flavor e-liquids
89241349|NCT05320887|Experimental|Normal nicotine content vape with tobacco e-liquids|Normal nicotine content vape with tobacco e-liquids
89241350|NCT05320887|Experimental|Low nicotine content vape with all flavor e-liquids|Low nicotine content vape with all flavor e-liquids
89241351|NCT05320887|Experimental|Low nicotine content vape with tobacco e-liquids|Low nicotine content vape with tobacco e-liquids
89241352|NCT05312177||DS with CAVSD Repair|Children ages 5 through 12 years with Down syndrome who had Complete atrioventricular septal defect (CAVSD) repair in the first year of life and their parent(s) will be administered the Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), Peabody Picture Vocabulary Test, Fifth Edition (PPVT-5), Expressive Vocabulary Test, Third Edition (EVT-3), Leiter International Performance Scale, Third Edition (Leiter-3), Vineland-3 Q-global Comprehensive Report (Vineland-3) ,Social Communication Questionnaire, Current version (SCQ), Aberrant Behavior Checklist, Second Edition, (ABC-2) and Repetitive Behavior Scale, Revised (RBS-R)
89241353|NCT05312177||DS without major CHD|Children ages 5 through 12 years with Down syndrome without major Congenital Heart Disease(CHD) and their parent(s) will be administered the Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), Peabody Picture Vocabulary Test, Fifth Edition (PPVT-5), Expressive Vocabulary Test, Third Edition (EVT-3), Leiter International Performance Scale, Third Edition (Leiter-3), Vineland-3 Q-global Comprehensive Report (Vineland-3) ,Social Communication Questionnaire, Current version (SCQ), Aberrant Behavior Checklist, Second Edition, (ABC-2) and Repetitive Behavior Scale, Revised (RBS-R)
89241354|NCT05311956|Experimental|Experimental|Patients will receive tDCS delivered over the motor cortex, at an intensity of 2mA, delivered for 20 minutes 5 times each week over eight consecutive weeks (40 applications in total).
89241355|NCT05311956|Sham Comparator|Sham Comparator|Sham treatment will consist of 30 seconds of the direct current at 2mA and 0 current for the remaining time of the 20-minute application 5 times per week over eight consecutive weeks (40 applications in total).
89241356|NCT05304962|Experimental|Arm A|RGT-419B given alone as monotherapy
89241357|NCT05304962|Experimental|Arm B|RGT-419B in combination with Hormonal Therapy
89241358|NCT05298371||Patients with adolescent idiopathic scoliosis|"Patients with AIS applying to Bandırma Onyedi Eylül University Physiotherapy and Rehabilitation Department will be included in this study.~Individuals diagnosed with AIS, whose Cobb angle is between 20º -50º, who do not have any chronic disease requiring neurological or psychiatric medication, and who volunteered to participate in the study will be included. Individuals with any contraindications for exercise, previous spinal surgery, 6 or more curvature of the thoracic apex, mental problems, non-idiopathic scoliosis but with different causes will be excluded from the study."
89241359|NCT05294016|Other|Patient group|
89241360|NCT05294016|Other|Control group|
89241361|NCT05275907|Active Comparator|A first, then B|6 weeks of drug A followed by a 2-week washout period completed with 6 weeks of drug B
89241362|NCT05275907|Active Comparator|B first, then A|6 weeks of drug B followed by a 2-week washout period completed with 6 weeks of drug A
89241363|NCT05274048|Experimental|Neratinib plus TDxD|Neratinib oral daily days 1-21 plus TDxD on day 1 administered intravenously of a 21 day treatment cycle.
89241364|NCT05269316|Experimental|IMP9064 Monotherapy|Dose-escalation IMP9064 administered orally on empty stomach once/twice daily
89241365|NCT05265429||Data/Biospecimen Collection|Tumor and saliva specimens from participants with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosed at age 45 or younger
89241366|NCT05250843|Experimental|TACE/HAIC and Lenvatinib and PD-1(Sintilimab) before liver resection|For patients staged BCLC B/C,TACE/HAIC combined with Lenvatinib and Sintilimab will be conducted as neoadiuvent therapy before liver resection
89241367|NCT05250843|Active Comparator|Direct surgery group|After being diagnosed with hepatocellular carcinoma, surgery will be immediately performed.
89241368|NCT05230043||Suicide Attempters using Violent Means|A violent suicidal act is any suicidal act conducted with any means except for medication overdose or superficial wrist cutting.
89241369|NCT05230043||Patient Control|
89241370|NCT05230043||Healthy Controls|
89241371|NCT05230043||Suicide Attempters not using Violent Means|
89241372|NCT05223725|Experimental|dose escalation|initial phase, increasing dose
89241373|NCT05223725|Experimental|low dose|second phase, fixed dose 5x10(11) vp
89241374|NCT05223725|Experimental|high dose|second phase, fixed dose 2x10(12) vp
89241375|NCT05223725|No Intervention|control|second phase, blinded, randomized with no intervention delivered but with testing and monitoring.
89241376|NCT05205343||Standard of Care|"questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery.~The questionnaire will ask about your health, appetite, and quality of life. It should take about 3-5 minutes to complete."
89241377|NCT05205343||Control group|"questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery.~The questionnaire will ask about your health, appetite, and quality of life. It should take about 3-5 minutes to complete."
89241378|NCT05197842|Experimental|Group A|BDB-001 injection low dose plus reduced dose glucocorticoids in combination with cyclophosphamide
89241379|NCT05197842|Experimental|Group B|BDB-001 injection high dose plus reduced dose glucocorticoids in combination with cyclophosphamide
89241380|NCT05197842|Active Comparator|Group C|Standard dose glucocorticoids in combination with cyclophosphamide
89241381|NCT05197842|Experimental|Group D|BDB-001 injection low dose in combination with cyclophosphamide
89241382|NCT05197842|Experimental|Group E|BDB-001 injection high dose in combination with cyclophosphamide
89241383|NCT05176145|Other|single arm|Only one arm. The urine collection from each patient will be used for VisioCyt® test and conventional cytology
89241384|NCT05152940|Active Comparator|Ertugliflozin then Placebo|Treatment with Ertugliflozin for one month, washout period for one month, and then with Placebo for one month
89241385|NCT05152940|Active Comparator|Placebo|Treatment with matching placebo for one month, washout period for one month, and then Ertugliflozin for one month
89241386|NCT05131087|Experimental|Cadence|Cadence procedure
89241387|NCT05107219|Experimental|Arm I (plecanatide, EGD)|Patients receive a single dose of plecanatide (3 mg) PO 60-120 minutes prior to standard of care EGD with biopsy and luminal fluid collection.
89241388|NCT05107219|Experimental|Arm II (linaclotide, EGD)|Patients receive a single dose of linaclotide (145 mcg) PO 60-120 minutes prior to standard of care EGD with biopsy and luminal fluid collection.
89241389|NCT05107219|Active Comparator|Arm III (EGD)|Patients undergo standard of care EGD with biopsy and luminal fluid collection.
89241390|NCT05101486|Experimental|Group 1: Ad26.RSV.PreF-based Vaccine|Participants will receive a single intramuscular (IM) injection of Ad26.RSV.PreF-based vaccine on Day 1 (non-aged lot).
89241391|NCT05101486|Experimental|Group 2: Ad26.RSV.PreF-based Vaccine|Participants will receive a single IM injection of Ad26.RSV.PreF-based vaccine on Day 1 (aged lot 1).
89241392|NCT05101486|Experimental|Group 3: Ad26.RSV.PreF-based Vaccine|Participants will receive a single IM injection of Ad26.RSV.PreF-based vaccine on Day 1 (aged lot 2).
89241393|NCT05100706|Experimental|Continuous adductor canal block (CACB)|Will receive an infusion of 0.2% ropivacaine 5mL/h through adductor canal catheter.
89241394|NCT05100706|Placebo Comparator|Sham continuous adductor canal block (ShACB).|Will receive an infusion of NaCl 0.9% 5mL/h through adductor canal catheter.
89241395|NCT05091372|Experimental|Belantamab mafodotin|belantamab mafodotin by vein over about 30 minutes on Day 1 of each cycle
89241396|NCT05091372|Experimental|Lenalidomide|lenalidomide by mouth every day of each cycle
89241397|NCT05089474|Experimental|Streamline|Streamline Surgical System
89241398|NCT05087563|Experimental|Neurolens|Our proprietary contoured prism lens design, commercially known as neurolens.
89241399|NCT05087563|Placebo Comparator|Control lens|A simple refractive error correction lens
89241400|NCT05083585|Experimental|Group 1: Phase 3 Clinical Trial Material (CTM)|Participants will receive a single intramuscular (IM) injection of adenovirus serotype 26 (Ad26). respiratory syncytial virus (RSV). prefusion conformation-stabilized F protein (preF)-based vaccine on Day 1, which is a Phase 3 CTM.
89241401|NCT05083585|Experimental|Group 2: Phase 2b CTM|Participants will receive a single IM injection of Ad26.RSV.preF-based vaccine on Day 1, which is a Phase 2b CTM.
89241402|NCT05081219|Experimental|Intranasal Insulin and Empagliflozin Placebo|"40 IU of intranasal insulin administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily~Placebo capsules taken by mouth 30 minutes before breakfast once daily"
89241403|NCT05081219|Experimental|Empagliflozin and Intranasal Insulin Placebo|"Empagliflozin 10 mg capsules taken by mouth 30 minutes before breakfast once daily~40 IU of intranasal insulin diluent (placebo) administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily"
89241404|NCT05081219|Experimental|Intranasal Insulin and Empagliflozin|"40 IU of intranasal insulin administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily~Empagliflozin 10 mg capsules taken by mouth 30 minutes before breakfast once daily"
89241405|NCT05081219|Placebo Comparator|Placebo|"40 IU of intranasal insulin diluent (placebo) administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily~Placebo capsules taken by mouth 30 minutes before breakfast once daily"
89241406|NCT05071313|Experimental|Group 1: Coadministration (CoAd) Group|Participants will receive Ad26.RSV.preF-based vaccine and quadrivalent high dose influenza vaccine concomitantly on Day 1 and placebo on Day 29.
89241407|NCT05071313|Experimental|Group 2: Control Group|Participants will receive placebo and quadrivalent high-dose influenza vaccine on Day 1 and Ad26.RSV.preF-based vaccine on Day 29.
89241408|NCT05048797|Experimental|Arm 1|Trastuzumab Deruxtecan (T-DXd)
89241409|NCT05048797|Active Comparator|Arm 2|Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)
89241410|NCT05019729|Experimental|Group 1: L9LS (1 mg/kg IV)|L9LS (1 mg/kg) administered by intravenous (IV) infusion (Day 0)
89241411|NCT05019729|Experimental|Group 2: L9LS (5 mg/kg IV)|L9LS (5 mg/kg) administered by IV infusion (Day 0)
89241412|NCT05019729|Experimental|Group 3: L9LS (5 mg/kg SC)|L9LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
89241413|NCT05019729|Experimental|Group 4: L9LS (20 mg/kg IV)|L9LS (20 mg/kg) administered by IV infusion (Day 0)
89241414|NCT05019729|Other|Group 5: CHMI Controls|Control participants who did not receive L9LS and were enrolled to complete the controlled human malaria infection (CHMI)
89241415|NCT05019729|Experimental|Group 6: L9LS (5 mg/kg IM)|L9LS (5 mg/kg) administered by intramuscular (IM) injection (Day 0)
89241416|NCT05007080|Experimental|Group 1: Ad26.COV2.S Dose Level 1 (Lower Volume): 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 1 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
89241417|NCT05007080|Experimental|Group 2: Ad26.COV2.S Dose Level 2: 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 2 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
89241418|NCT05007080|Experimental|Group 3: Ad26.COV2.S Dose Level 3: 1-Dose Regimen|Participants will receive 1-dose of Ad26.COV2.S at dose level 3 on Day 1 and placebo on Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination. Participants will receive booster vaccination at dose level 1 on Day 184.
89241419|NCT05007080|Experimental|Group 4: Ad26.COV2.S Dose Level 1: 2-Dose Regimen|Participants will receive 2-dose of Ad26.COV2.S at dose level 1 on Day 1 and 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
89241420|NCT05007080|Experimental|Group 5: Ad26.COV2.S Dose Level 2: 2-Dose Regimen|Participants will receive 2-doses of Ad26.COV2.S at dose level 2 on Day 1 and Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
89241421|NCT05007080|Experimental|Group 6: Ad26.COV2.S Dose Level 3: 2-Dose Regimen|Participants will receive 2-doses of Ad26.COV2.S at dose level 3 on Day 1 and Day 57. Participants will be unblinded to the primary vaccination regimen at 6 months after the first vaccination.
89241424|NCT04891406|Other|ABCDE|"Subjects use product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes on Day 1, then switch to use product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 min on Day 2, then product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 min on Day 3, then D (nicotine pouch, 10.6 mg/pouch) on Day 4 and finally E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette), smoked in approximately 5 minutes with puffs taken at regular intervals approximately 30 seconds apart, on Day 5.~Subjects can use their assigned product ad libitum on each study day, after all study assessments are performed, until 10pm. A washout period of product abstinence is observed between products, overnight."
89241425|NCT04891406|Other|BCDEA|Same as previous arm but in a different randomization order.
89241426|NCT04891406|Other|CDEAB|Same as previous arm but in a different randomization order.
89241427|NCT04891406|Other|DEABC|Same as previous arm but in a different randomization order.
89241428|NCT04891406|Other|EABCD|Same as previous arm but in a different randomization order.
89241429|NCT04890236|Experimental|Treatment (duvelisib)|Patients receive duvelisib PO BID for 2 weeks prior to collection of CAR-T cells in the absence of disease progression or unacceptable toxicity. Patients then receive tisagenlecleucel via infusion.
89241430|NCT04885998|Experimental|Phase 1: Dose Exploration|The recommended phase 2 target dose (RP2D) of tarlatamab in combination with AMG 404 will be estimated using a modified toxicity probability interval (mTPI-2) design. A combination RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an maximum tolerated dose (MTD).
89241431|NCT04885998|Experimental|Phase 2: Dose Expansion|Participants will receive the RP2D of tarlatamab in combination with AMG 404 identified in Phase 1 (dose exploration) of the study.
89241432|NCT04825873||Cohort 1|Prospective observation of participants with non-small cell lung cancer (NSCLC)
89241433|NCT04825873||Cohort 2|Prospective observation of participants with squamous cell carcinoma of head and neck (SCCHN)
89241434|NCT04825873||Cohort 3|Retrospective observation of participants with NSCLC
89241435|NCT04825873||Cohort 4|Retrospective observation of participants with SCCHN
89241436|NCT04817462||Liver Biopsy|All patients undergo a liver biopsy only
89241437|NCT04799171|Active Comparator|Young Adults (Age group 18-39)|31P-Magnetic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
89241438|NCT04799171|Active Comparator|Middle Aged Adults (Age group 40-59)|31P-Magnetic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
89241439|NCT04799171|Active Comparator|Old Adults (Age group >60)|31P-Magnetic Resonance Spectroscopy exam on one thigh to measure mitochondrial capacity non-invasively after exercise training.
89241440|NCT04764799||Patients that need emergency rapid sequence inductions|"Patients of all ages who need emergency rapid sequence inductions due to their medical condition performed by the staff of the Department of Anaesthesiology and Pain Medicine at the Bern University Hospital.~We defined emergency as a non scheduled intervention with immediate (or maximum up to 6 hours after announcement) need of general anaesthesia (e.g. trauma patients with need for emergency surgery) and therefore appropriate fastening is not possible."
89241441|NCT04764799||Patients that need scheduled rapid sequence inductions|"Patients of all ages who need scheduled rapid sequence inductions due to their medical condition performed by the staff of the Department of Anaesthesiology and Pain Medicine at the Bern University Hospital.~Patients of this cohort have a scheduled intervention and therefore can fasten meals for at least 6 hours before induction of general anaesthesia."
89241442|NCT04747054|Experimental|Radiotherapy added to systemic treatment|"Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.~Loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) with 54 Gy/18 fractions in the head and neck region.~If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will start from cycle 3 or 4 of pembrolizumab (after radiotherapy administration) and will combine carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles"
89241443|NCT04747054|Active Comparator|Systemic treatment|"Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.~If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles"
89241444|NCT04740515|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
89241445|NCT04740515|No Intervention|usual care only|Patients were provided with usual care.
89241446|NCT04728854||Adult bullous pemphigoid patients|Patients with diagnosis of bullous pemphigoid will participate in monitoring with face to face assessment and remote telehealth visits with store and forward images captured.
89241447|NCT04692181|Placebo Comparator|Placebo + IV Meropenem|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Meropenem (MER)
89241448|NCT04692181|Active Comparator|SYN-004 + IV Meropenem|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Meropenem (MER)
89241449|NCT04692181|Placebo Comparator|Placebo + IV Piperacillin/Tazobactam|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Piperacillin/Tazobactam (PIP/TAZO)
89241450|NCT04692181|Active Comparator|SYN-004 + IV Piperacillin/Tazobactam|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Piperacillin/Tazobactam (PIP/TAZO)
89241451|NCT04692181|Placebo Comparator|Placebo + IV Cefepime|Placebo, oral administration, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Cefepime (FEP)
89241452|NCT04692181|Active Comparator|SYN-004 + Cefepime|SYN-004, oral administration, 150mg, 4 times per day (q6h), beginning on day +1 after HCT until 72-hours after completion of IV Cefepime (FEP)
89241453|NCT04643574|Experimental|NeoTIL-ACT + LDI|Non-myeloablative lymphodepleting chemotherapy (fludarabine and cyclophosphamide), Low Dose Irradiation (LDI), ex vivo expanded Tumor Infiltrating Lymphocyte (TIL), enriched for tumor antigen specificity (NeoTIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2).
89241454|NCT04642105|Experimental|Hospital-based study|The investigators will select 15 patients with refractory focal epilepsy who are admitted to the videoEEG room for longterm videoEEG recording as part of a presurgical evaluation. The Sensor-Dot and Plug 'n Patch recordings will be compared with the gold-standard videoEEG recordings.
89241455|NCT04642105|Experimental|Home-based study|The investigators will select 30 patients with refractory focal epilepsy, 15 patients with refractory idiopathic generalized epilepsy and 15 patients with frequent tonic-clonic seizures, i.e. a group at increased risk for sudden unexpected death in epilepsy (SUDEP).
89241456|NCT04623047||Adults 18 years of age and up|The study will recruit any adult over the age of 18 years.
89241457|NCT04589663|Experimental|MF followed by QMF149|Single inhaled dose of mometasone furoate on Day 1 delivered via TH inhaler followed by 4-7 days of washout. On Day 6-9, single inhaled dose of QMF149 delivered via C1 inhaler.
89241458|NCT04562233|Experimental|Intervention arm|Participants will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer. Once a week, the exercise trainer and participant will each log on to Zoom from their locations to begin the supervised exercise session. The exercise trainer will record all sessions. Sessions will be 30 to 45 minutes long and be structured as follows: review of previous session and an opportunity to ask questions; 5-minute warm-up; 20- to 25-minute workout; 5- to10-minute cool down and reminder of next session and/or data collection time period. Supervised sessions will be scheduled once a week over the 12-week intervention. Participants will be expected to complete their resistance-based physical activity program for an additional 1-2 days a week as per the intervention schedule to meet as physical activity guidelines. The exercise trainer will track participant attendance. During the session, participants must have another person in the same location in case of an emergency.
89241459|NCT04562233|Other|Control Arm|"The attention control arm will include a printed, individualized resistance-based physical activity program.~Participants randomized to the control arm will be given a printed or digital individualized, resistance-based physical activity program and told to aim to for three exercise sessions per week. Control participants will follow the same measurement schedule as intervention participants."
89241460|NCT04551560|Other|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
89241461|NCT04549662|Experimental|Group A|Powdered formula containing whey protein and arginine (Active A) and lipid bolus containing omega 3 fatty acids. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
89241462|NCT04549662|Active Comparator|Group B|Powdered formula containing whey protein and arginine (Active A) and placebo oil. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
89241463|NCT04549662|Placebo Comparator|Comparator|Powdered formula containing whey protein (Active B) and placebo oil. Participants will mix the powder (Active B) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
89241464|NCT04544475|Experimental|Investigational|
89241465|NCT04544475|Active Comparator|Standard of Care|
89241466|NCT04507438|Experimental|Donepezil treatment group|Administration of 5mg or 10 mg of donepezil daily
89241467|NCT04507438|Placebo Comparator|Control group|Administration of placebo
89241468|NCT04459273|Experimental|Basic science (68GA-FAPI-46 PET/CT)|Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable).
89241469|NCT04457973|Experimental|Active tDCS|
89241470|NCT04457973|Placebo Comparator|Sham tDCS|
89241471|NCT04457232|Experimental|Basic Science (68Ga-FAPi-46 PET/CT)|Patients receive 68Ga-FAPi-46 IV and undergo PET/CT imaging over 20-50 minutes.
89241472|NCT04441775||All patients for enrollment and analysis|Patients previously treated with RT for prostate cancer who are now being enrolled into this study for data analysis and incorporation into Artificial Intelligence (AI) models
89241473|NCT04381897|Experimental|Group A: NAC 1800mg then Placebo|NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks, followed by a 2-week wash-out period, followed by NAC Placebo-matching solution, orally every 8 hours, for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
89241474|NCT04381897|Experimental|Group B: Placebo then NAC 1800mg|NAC Placebo-matching solution, orally every 8 hours, for 8 weeks, followed by a 2-week wash-out period, followed by NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day.
89241475|NCT04362501|Experimental|dupilumab treatment group|dupilumab treatment group
89241476|NCT04362501|Placebo Comparator|placebo group|placebo group
89241477|NCT04360213||Children with Asthma|"Patients ages 1 to 17 years old~Patients in the Emergency Department or admitted to the hospital for asthma exacerbation."
89241478|NCT04360213||Children with allergy|"Patients ages 1 to 17 years old~Patients scheduled to do an oral food challenge"
89241479|NCT04330690|Experimental|Artesunate|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
89241480|NCT04330690|Experimental|Imatinib|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
89241481|NCT04330690|Experimental|Infliximab|Subjects will be randomized Artesunate vs Imatinib vs Infliximab vs standard of care
89241482|NCT04330690|Experimental|Dexamethasone|Subjects will be randomized between Dexamethasone vs standard of care.
89241483|NCT04330690|Experimental|LSALT Peptide|Subjects will be randomized between LSALT vs standard of care.
89241484|NCT04330690|No Intervention|Control (Standard Care)|This arm will receive standard supportive care guidelines for COVID-19. It is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
89241485|NCT04304872|Experimental|Gamification Intervention|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day, they are told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who receives a weekly email with the participant's progress. The study group will hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, the study group will have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
89241486|NCT04304872|Experimental|Loss-Framed Financial Incentive Intervention|Participants are informed that each week that $14 is placed in a virtual account for them. Each day, the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
89241487|NCT04304872|Experimental|Gamification and Loss-Framed Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
89241488|NCT04280757||Arm 1|Biopsied ICSI embryos
89241489|NCT04280757||Arm 2|Non biopsied ICSI embryos
89241490|NCT04280757||Arm 3|Natural pregnancy embryos
89241491|NCT04276064|Experimental|Patients with insomnia|Patients with insomnia disorder according to DSM-5 criteria
89241492|NCT04276064|Experimental|Healthy controls|Healthy controls
89241493|NCT04268199|Other|Self Injection of Bortezomib|Subcutaneous self administration of bortezomib
89241494|NCT04255303|Experimental|iCPR group|Clinic personnel (Providers and Nurses) will receive online training that includes: 1) an overview of the project; 2) iCPR workflows including triage; 3) CPR component review and risk categories; 4) history and physical examination components of the CPRs. The online training will be followed by in-person training to reinforce the online training and teach additional skills. In-person training sessions led by study team will last approximately 60 minutes, and consist of four basic components: 1) a review of the iCPR ARI protocol and tools; 2) on-screen walk-throughs of common scenarios employing the new tools; 3) physical examination technique practice with simulated patients; A 60-minute in-person follow-up nurse training will take place 4-6 weeks after implementation of the intervention.
89241495|NCT04255303|No Intervention|Control no intervention group|standard care will continue as usual.
89241496|NCT04252794|Experimental|Patients who undergo GIM|If inclusion criteria are met, after randomisation, these group of patients will undergo splenic artery ligation (graft inflow modulation)
89241497|NCT04252794|Active Comparator|No splenic artery ligation|If inclusion criteria are met, after randomisation, these group of patients will not undergo splenic artery ligation (graft inflow modulation)
89241498|NCT04223310|Experimental|Virtual AAD TEST group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Preselect drug with optimal antiarrhythmic effects in the patient.~Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
89241499|NCT04223310|Active Comparator|Empirical AAD group|"Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~Drug selection should be decided according to the guidelines.~A follow-up of rhythm follow-up has to be conducted according to the above study design."
89241500|NCT04198116|Experimental|Varenicline + Guanfacine ER|Varenicline (2mg/day) + Guanfacine extended release (6mg/day ER). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Guanfacine ER (6mg/day) administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM for both medications.
89241501|NCT04198116|Active Comparator|Varenicline|Varenicline (2mg/day). Varenicline (2mg/day) administered orally twice a day at 8:00 AM and 8:00 PM while titrating to full dose. Titration schedule: Days 1-9 0mg/day; 0mg/dose, Days 10-12 0.5mg/day; 0.5mg/dose 8:00 PM, Days 13-15 1mg/day; 0.5mg/dose, Days 16-21 2mg/day; 1mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
89241502|NCT04172844|Experimental|Pevonedistat Dose Escalation|This study uses a varied 3 + 3 design. Three patients will be started at a dose of 10 mg/m^2 days 1, 3 and 5. If no DLTs are observed in the first 3 participants, then a new cohort will be enrolled at the next planned dose level of 15 mg/m^2 days 1, 3 and 5. If two out of three subjects experience a DLT, then they will de-escalate one dose level. If one subject in three experiences a DLT, then expand up to three subjects at 20 mg/m^2 day 1, 3 and 5. If two out of six subjects experience a DLT, de-escalate one level. All subjects will receive Azacitidine and Venetoclax at the indicated dosages and timing.
89241503|NCT04172844|Experimental|Dose Expansion Phase|Patients will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase.
89241504|NCT04147494|Experimental|Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)|Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable). Patients may also receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on a separate day (for volunteer patients only, PSMA PET/CT is optional and not required).
89241505|NCT04144413|Experimental|Period 1 Open-label Ikervis|Period 1 for all patients: IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Baseline for the first 12 months of treatment.
89241506|NCT04144413|Experimental|Period 2 Masked Ikervis|"Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.~IKERVIS® (1mg/ml CsA). Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
89241507|NCT04144413|Other|Period 2 Masked Vehicle|"Other: Vehicle Comparator. Period 2 for markedly improved patients at Month 12 only, and double-masked fashion.~Vehicle. Instillation of one drop in each affected eye, once daily at bedtime. From Month 12 to Month 36."
89241508|NCT04124939|Active Comparator|10 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 10 cc of sterile saline for the purpose of 10 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
89241509|NCT04124939|Active Comparator|20 Botox Injections|100 units of Botox® (onabotulinumtoxinA) will be combined with 20 cc of sterile saline for the purpose of 20 injections. The bladder will be instilled with 2% lidocaine solution through a catheter for at least 5 minutes prior to the procedure. Cystoscopy with either a rigid or flexible cystoscope (per surgeon preference) will be performed using sterile technique. The Botox® will be injected in a grid like pattern avoiding the trigone.
89241510|NCT04078698|Experimental|Treatment with the IgG immunoadsorber GLOBAFFIN®|Treatment with the IgG immunoadsorber GLOBAFFIN® in clinical routine according to their intended use.
89241511|NCT04047251|Experimental|Cohort 1: Treatment at Dose Level 1|FF-10850 Topotecan Liposome Injection, Dose Level 1 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
89241512|NCT04047251|Experimental|Cohort 2: Treatment at Dose Level 2|FF-10850 Topotecan Liposome Injection, Dose Level 2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
89241513|NCT04047251|Experimental|Cohort 3: Treatment at Dose Level 3|FF-10850 Topotecan Liposome Injection, Dose Level 3 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
89241514|NCT04047251|Experimental|Cohort E1: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with advanced ovarian cancer: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
89241515|NCT04047251|Experimental|Cohort E5: Treatment at Recommended Phase 2 Dose (RP2D)|For patients with advanced Merkel cell carcinoma: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
89241516|NCT04045613|Experimental|Substudy 1: Derazantinib 300 mg once daily|Patients with urothelial cancer were treated with derazantinib 300 mg once daily
89241517|NCT04045613|Experimental|Substudy 2 (Dose-Level 1): Derazantinib 200 mg once daily + atezolizumab 1200 mg|Patients with any solid tumors were treated with derazantinib 200 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as intravenous (IV) infusion
89241518|NCT04045613|Experimental|Substudy 2 (Dose-Level 2): Derazantinib 300 mg once daily + atezolizumab 1200 mg|Patients with any solid tumors were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion
89241519|NCT04045613|Experimental|Substudy 3: Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Patients with urothelial cancer were treated with derazantinib 200 mg twice daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion
89241520|NCT04045613|Experimental|Substudy 4 (Cohort 4a):Derazantinib 300 mg once daily|Patients with FGFR inhibitor resistant urothelial cancer were treated with derazantinib 300 mg once daily
89241521|NCT04045613|Experimental|Substudy 4 (Cohort 4b):Derazantinib 300 mg once daily + atezolizumab 1200 mg|Patients with urothelial cancer were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion
89241522|NCT04045613|Experimental|Substudy 5: Derazantinib 200 mg twice daily|Patients with urothelial cancer were treated with derazantinib 200 mg twice daily
89241523|NCT04042831|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial, and collection of blood and tissue samples on study.
89241524|NCT03964207|Experimental|(T1): 5μg tiotropium Respimat®, then (T2): 18μg tiotropium Handihaler®|"From Day 1 of Period 1 participants received Test treatment (T1): tiotropium Respimat® (Spiriva® Respimat®) 5 microgram (μg) once daily for a duration of 4 weeks, given as 2.5μg per puff, two puffs (2.5μg per puff) inhalation solution of tiotropium, orally via Respimat®.~From Day 1 of Period 2 participants received comparator treatment(T2): tiotropium Handihaler® (Spiriva®) 18μg once daily for a duration of 4 weeks, inhalation powder tiotropium with 1 Handihaler® device."
89241525|NCT03964207|Experimental|(T2): 18μg tiotropium Handihaler®, then (T1): 5μg tiotropium Respimat®|"From Day 1 of Period 1 participants received comparator treatment (T2): tiotropium Handihaler® (Spiriva®) 18 microgram (μg) once daily for a duration of 4 weeks, inhalation powder tiotropium with 1 Handihaler® device.~From Day 1 of Period 2 participants received Test treatment (T1): tiotropium Respimat® (Spiriva® Respimat®) 5 microgram (μg) once daily for a duration of 4 weeks, given as 2.5μg per puff, two puffs (2.5μg per puff) inhalation solution of tiotropium, orally via Respimat®."
89241526|NCT03947255|Experimental|Brentuximab vedotin|
89241527|NCT03930147|Experimental|Passive phase, Pressure-Control Ventilation / ASV order|90 minutes of Pressure-Control Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Control Ventilation mode at the end of the intervention.
89241528|NCT03930147|Experimental|Passive phase, ASV / Pressure-Control Ventilation order|90 minutes of ASV, change to Pressure-Control Ventilation mode with 15 to 30 minutes of washout, 90 minutes of Pressure-Control Ventilation.
89241529|NCT03930147|Experimental|Active phase, Pressure-Support / ASV order|90 minutes of Pressure-Support Ventilation, change to ASV mode with 15 to 30 minutes of washout, 90 minutes of ASV. Return to Pressure-Support Ventilation at the end of the intervention.
89241530|NCT03930147|Experimental|Active phase, ASV / Pressure-Support order|90 minutes of ASV, change to Pressure-Support Ventilation with 15 to 30 minutes of washout, 90 minutes of Pressure-Support Ventilation.
89241531|NCT03929757|Experimental|Arm 1: Ad26.ZEBOV, MVA-BN-Filo|Participants will be administered 0.5 mL of Ad26.ZEBOV vaccine (5*10^10 viral particles [vp]) on Day 1 by intramuscular (IM) injection followed by 0.5 mL of MVA-BN-Filo (1*10^8 infectious units [Inf U]) vaccine by IM injection on Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit. Upon completion of the main study, participants in the extension phase who were originally randomized to the control arm will receive the same vaccine regimen as the participants in the Ad26.ZEBOV, MVA-BN-Filo arm of the main study.
89241532|NCT03929757|Active Comparator|Arm 2: MenACWY|Participants will be administered 0.5 mL of MenACWY vaccine by IM injection on Day 1 and Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit.
89241533|NCT03845829|Experimental|Patients with TBAD treated with TEVAR|In situ laser assisted fenestration for the left subclavian artery during the TEVAR procedure for TBAD.
89241534|NCT03789786||Cases (+SDR)|Patients with cerebral palsy that underwent an SDR
89241535|NCT03789786||Controls (-SDR)|Matched patients with cerebral palsy but did not undergo an SDR
89241536|NCT03770858||Crisaborole and wearable sensor|Subjects will apply topical crisaborole twice daily to the affected atopic dermatitis areas for three weeks.
89241537|NCT03754803||Treatment naïve subjects with HIV infection|Treatment naïve HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included
89241538|NCT03754803||Pre-treated subjects with HIV infection|Pre-treated HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included.
89241539|NCT03748823|Experimental|Ravulizumab SC Treatment Group|"In the Randomized Treatment Period, participants will receive an IV loading dose of ravulizumab on Day 1 followed by SC maintenance doses of ravulizumab administered via the ravulizumab OBDS on Day 15 and every week (qw) thereafter for a total of 10 weeks of study treatment.~In the Extension Period, ravulizumab SC will be administered via the ravulizumab OBDS from Day 71 qw through Day 1274."
89241540|NCT03748823|Active Comparator|Ravulizumab IV Treatment Group|"In the Randomized Treatment Period, participants will receive an IV loading dose of ravulizumab on Day 1 followed by IV maintenance doses of ravulizumab on Day 15.~In the Extension Period, ravulizumab SC will be administered via the ravulizumab OBDS from Day 71 qw through Day 1274."
89241541|NCT03741400|Experimental|Standard Occupational Therapy + Smart Glove|Subjects randomized to this arm will be expected to use the Neofect Rapael Smart Glove for a minimum of 20-30 minutes per day, 5 days per week, in addition to prescribed occupational therapy.
89241542|NCT03741400|No Intervention|Standard Occupational Therapy|Subjects in the control arm will undergo standard of care occupational therapy as prescribed by their care team.
89241543|NCT03716167|Experimental|Laser Treatment|Summus Laser treatment with infrared light
89241544|NCT03716167|Sham Comparator|Sham treatment|Sham Summus Laser treatment with no infrared light
89241545|NCT03690154|Experimental|FN-1501|
89241546|NCT03665831|Experimental|Active H1 Coil deep rTMS active treatment|
89241547|NCT03622606|Experimental|Acute and subacute phase of right stroke|"The intervention will be the passation of Right Language Screening Test (R-LAST).~Patients in acute phase of right hemispheric stroke will be used for the internal validation and the integrated reliability of the Right Language screening test.~Patients in subacute phase of right hemispheric stroke will be used for the external validation of the Right Language screening test."
89241548|NCT03617497|Active Comparator|Healthy control participants|Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography
89241549|NCT03617497|Active Comparator|Alzheimer disease|Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography
89241550|NCT03617497|Experimental|Alzheimer disease with high seizure risk|Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography
89241551|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 3 mg/mL|AXR-159 Low Dose
89241552|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 30 mg/mL|AXR-159 Mid Dose
89241553|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 50 mg/mL|AXR-159 High Dose
89241554|NCT03598699|Placebo Comparator|AXR-159 Ophthalmic Solution Vehicle|Control Group
89241555|NCT03573089|Active Comparator|Liberal phosphate target|Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
89241556|NCT03573089|Experimental|Intensive phosphate target|Intensive serum phosphate target of ≤1.50 mmol/L.
89241557|NCT03565913|Experimental|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
89241558|NCT03565913|Active Comparator|CaAcS|Patients in the CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate) per day.
89241559|NCT03548558|Experimental|"Arm 1 (group sessions)"|Group meetings only (16 total)
89241560|NCT03548558|Experimental|"Arm 2 (group+home sessions)"|Mixed group meetings with a limited number of individual home visits (12 group meetings + 4 home visits)
89241561|NCT03548558|No Intervention|Arm 3|This arm will serve as the control group to identify the effects of a parenting intervention and the most effective mode of delivery, as well as the sustained impacts from the intervention
89241562|NCT03548558|Experimental|Arm B (Booster villages)|In one half of Arm 1 and Arm 2 villages above, after the end of the main intensive intervention, extended light-touch group booster sessions held every other month over two years between the two follow-up surveys will be held
89241563|NCT03548558|Other|Arm A (Non-booster villages)|In the other half of Arm 1 and Arm 2 villages, no boosters will be held during phase 2
89241564|NCT03548558|Experimental|Arm X: Fathers invited|During phase 1, fathers were invited to attend sessions in half of Arms 1 and 2 villages.
89241565|NCT03548558|Other|Arm Y: Fathers not invited|During phase 1, fathers were not invited in the other half of Arms 1 and 2 villages.
89241566|NCT03535883||patients taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).
89241567|NCT03535883||patients not taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC).
89241568|NCT03523156|Active Comparator|Azithromycin mass treatment|Persons living in regions randomized to this arm will receive mass drug administration (MDA) of azithromycin per the current annual MDA schedule.
89241569|NCT03523156|Experimental|Azithromycin mass treatment plus targeted treatment|In addition to azithromycin administration per the current annual MDA schedule, children in regions randomized to this arm will receive azithromycin targeted treatment.
89241570|NCT03517657|Experimental|Bilateral motor priming + Task specific training (BMP + TST)|A combination of bilateral motor priming (BMP) plus task specific training (TST) for 30 hours over 5 weeks.
89241571|NCT03517657|Active Comparator|Control Priming + TST (CP + TST)|The control priming is transcutaneous electric stimulation (TENS) set at a low threshold followed by the same task specific training protocol for 30 hours over 5 weeks.
89241572|NCT03503058|Experimental|Group 1|N=124 will receive PfSPZ Vaccine; three doses of 9x10^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given on day 1, 8 and 29.
89241573|NCT03503058|Placebo Comparator|Group 2|N=62 will receive normal saline; three doses of NS administered by DVI given on day 1, 8 and 29.
89241574|NCT03503058|Experimental|Group 3|"N=124 will receive PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis; three doses of 2x10^5 PfSPZ of PfSPZ Challenge administered by DVI on day 1, 29 and 57, with weekly CQ.~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
89241575|NCT03503058|Placebo Comparator|Group 4|"N=62 will receive normal; three doses of NS administered by DVI given on day 1, 29 and 57, with weekly CQ.~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
89241576|NCT03502993||BIVA studies - children with fever and/or suspected infection|A minimum of 3,000 children will be recruited to the BIVA-ED (Biomarker Validation in Emergency Department) study, in order to capture sufficient children with confirmed bacterial infection. Additional children with less common febrile illnesses will also be recruited: 500 critically ill (BIVA-PIC); 200 at high-risk of bacterial illness through primary or secondary immunodeficiency (BIVA-HR); 150 with an inflammatory diagnosis, whose initial presentation is difficult to discriminate from bacterial infection (BIVA-INF). Samples collected from recruits in the BIVA studies will be used for the validation of biomarkers (clinical, proteomic and transcriptomic biomarkers) for diagnosis of febrile illness, including markers of bacterial and viral infection (confirmed by culture and/or molecular microbiology) and inflammatory conditions.
89241577|NCT03502993||BIVA studies - control children without fever or suspicion of infection|Afebrile children <18 years (16 years depending in the setting) of age who are having blood tests for reasons other than for investigation of infectious or inflammatory illness or whom parents give consent for bloods taken for research purposes. Controls may have a range of clinical presentations including co-morbidities without infection. One set of samples will be taken from controls, no follow up data or samples taken.
89241578|NCT03459534|Experimental|Radotinib HCl|"Enrolled subjects will continue to administer Radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.~Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg."
89241579|NCT03456817|Experimental|Treatment Arm - High dose ATG, Low dose CSA|High dose ATG will be infused on days -4, -3, -2, -1 and 0. Before each infusion of ATG (thymoglobulin), patient will receive medications preventing side effects from the ATG, including diphenhydramine (Benadryl), an antipyretic (ibuprofen or acetaminophen) and methylprednisolone (Solumedrol). The high dose ATG will be given into patient's vein via central venous catheter. Each infusion of ATG will take 4-8 hours. CSA (cyclosporine A) will be given from day 21. Standard dose methotrexate will be given.
89241580|NCT03456817|Other|Control Arm - Standard of care|Low dose ATG (thymoglobulin) will be infused on days -2, -1 and 0, and CSA (cyclosporine A) will be given from day -1 through day 84. Standard dose methotrexate will also be given.
89241581|NCT03435705|Experimental|intervention arm|maintaining of occupational therapy for a 4 months period
89241582|NCT03435705|No Intervention|control arm|usual care after the end of the recommended initial program
89241583|NCT03428633|Active Comparator|Group A|Thoracic paravertebral block using ropivacaine
89241584|NCT03428633|Active Comparator|Group B|Morphine IV
89241585|NCT03419832|Experimental|NEAT Form|Study participants will be randomized to the NEAT form and the materials that accompany it (also detailing the ARIC study).
89241586|NCT03419832|Active Comparator|Standard Form|Study participants will be randomized to the traditional standard consent form (detailing the ARIC study).
89241587|NCT03367247|Experimental|Bolster|"Bolster provides participants with longitudinal nursing support across care settings,~A smartphone-based symptom management app,~A print and web-based symptom management toolkit,~Advance care planning to ensure that the patient receives care that is congruent with her informed preferences~BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks~Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice"
89241588|NCT03367247|Other|Enhanced Discharge Planning (EDP)|"Medication education,~Self-management strategies for symptoms,~Skills training,~A list of red flag symptoms and numbers for who to call"
89241589|NCT03364673|Experimental|Fitness Tracker + Social Incentive Intervention|Participants will enroll with a teammate (i.e. family or friend) and collaborate together. Teams will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive a social incentive intervention.
89241590|NCT03330405|Experimental|Dose Level 0 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
89241591|NCT03330405|Experimental|Dose Level -1 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
89241592|NCT03330405|Experimental|Dose Level -2 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
89241593|NCT03330405|Experimental|A1. NSCLC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241594|NCT03330405|Experimental|A2. NSCLC PD-L1 Resistant DDR+ Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241595|NCT03330405|Experimental|B1. TNBC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241596|NCT03330405|Experimental|B2. HR+BC DDR Defect +Assay Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241597|NCT03330405|Experimental|C1. Ovarian CA Recurrent Plat-Sensitive Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241598|NCT03330405|Experimental|C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241599|NCT03330405|Experimental|D.Urothelial CA Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241600|NCT03330405|Experimental|E1. CRPC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241601|NCT03330405|Experimental|E2. CRPC DDR Defect +Assay Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241602|NCT03330405|Experimental|F: Advanced Solid Tumors with BRCA or ATM defect Phase 2|"Drug: Avelumab~Drug: Talazoparib"
89241603|NCT03222869||Laryngotracheal Stenosis|Patients with laryngotracheal stenosis will have pressure sensors placed proximal and distal to the stenosis. Pressure and air flow will be measured
89241604|NCT03176927|Experimental|Gastroparesis|"magnetogastrogram~Diabetes with and without gastroparesis ; Idiopathic gastroparesis"
89241605|NCT03176927|Experimental|Gastrectomy|"magnetogastrogram~Total or partial gastrectomy group"
89241606|NCT03176927|Experimental|Functional dyspepsia|"magnetogastrogram~Children with functional dyspepsia"
89241607|NCT03176927|Experimental|Chronic nausea|"magnetogastrogram~Children with chronic nausea"
89241608|NCT03176927|Experimental|Control participants|"magnetogastrogram~Group without any gastrointestinal diseases."
89241609|NCT03164928|Other|Placebo|SC Q6M placebo
89241610|NCT03164928|Experimental|Denosumab|1 mg/kg BW (up to a maximum of 60 mg) SC Q6M
89241611|NCT03153280|Experimental|Lithium, Oxaliplatin & Capecitabine|Target serum concentrations of escalating doses of lithium (0.6, 0.9, 1.26 or 1.4 mmol/L) in combination standard chemotherapy - oxaliplatin and capecitabine.
89241612|NCT03150797|Experimental|Melatonin 3mg|Melatonin 3mg
89241613|NCT03150797|Experimental|Melatonin 6mg|Melatonin 6mg
89241614|NCT03150797|Placebo Comparator|Placebo oral capsule|Placebo
89241615|NCT03096418|Experimental|Weekly Paclitaxel|"Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle.~Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery."
89241616|NCT03074513|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab and bevacizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89241617|NCT03070106|No Intervention|Usual Care|usual care delivered by an endocrinologist
89241618|NCT03070106|Active Comparator|Functional Medicine + Usual Care|Functional Medicine in addition to usual care delivered by an endocrinologist
89241619|NCT03054909|Experimental|Arm 1: ALT-803 subcutaneous only|
89241620|NCT03054909|Experimental|Arm 2: ALT-803 intraperitoneal and subcutaneous|
89241621|NCT03044392|Active Comparator|Next Bolus Interval 15 minutes|Next Bolus Interval 15 minutes
89241622|NCT03044392|Active Comparator|Next Bolus Interval 30 minutes|Next Bolus Interval 30 minutes
89241623|NCT03044392|Active Comparator|Next Bolus Interval 45 minutes|Next Bolus Interval 45 minutes
89241624|NCT03014414|Experimental|Fun First|If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
89241625|NCT03014414|Active Comparator|Weight Watchers|If randomized to the 12-month Weight Watchers program, participants are provided with study-paid access to weekly ongoing Weight Watchers meetings led by peer meeting leaders for 12 months at Weight Watchers locations convenient to participants as well as study-paid access to Weight Watchers personalized online tools. [The study and investigative team have no financial relationship with Weight Watchers].
89241626|NCT02835443|Experimental|Electrical Stimulation|This is a single arm study and all subjects will receive electrical stimulation.
89241627|NCT02817698|Experimental|Drug of dependence|There is only one arm to the study. All subjects will receive their drug of dependence in this study. Nicotine dependent subjects will receive tobacco cigarettes, cannabis dependent subjects will receive cannabis cigarettes, and cocaine dependent subjects will receive IV cocaine.
89241628|NCT02756897|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after cycle 27 may continue treatment with ibrutinib.
89241629|NCT02754830|Experimental|LY3303560|Single IV infusion 7 milligram (mg), 21 mg, 70 mg, 210 mg, 700 mg, 1400 mg, 2800 mg, and 5600 mg of LY3303560 on Day 1 in healthy participants.
89241630|NCT02754830|Placebo Comparator|Saline Solution|Single IV infusion of saline solution to match LY3303560 on Day 1 in healthy participants.
89241631|NCT02754830|Experimental|LY3303560 Subcutaneous (SC)|Single SC injection of 210 mg LY3303560 on Day 1 in healthy participants.
89241632|NCT02732171|Other|Screening Bone Marrow Aspirate|All patients will undergo screening bone marrow aspirate to test for disseminated tumor cells (DTCs) by immunohistochemistry. The bone marrow sample is also used for other research tests.
89241633|NCT02683239|Experimental|Fasinumab dosing regimen 1|
89241634|NCT02683239|Experimental|Fasinumab dosing regimen 2|
89241635|NCT02683239|Experimental|Placebo|
89241636|NCT02608411|Experimental|ARQ-197|ARQ-197 360 mg twice/day by mouth (PO), with meals, continuously as maintenance treatment until disease progression or unacceptable toxicity.
89241637|NCT02551237|Active Comparator|Radiochemotherapy|"Patients who will be treated with~radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks associated with~oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
89241638|NCT02551237|Experimental|Radiotherapy|"Patients who will be treated with radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm) without chemotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
89241639|NCT02437214|Experimental|Use of music for anxiety in children|Children in the Exp group received the usual medical care in combination with the intervention. The intervention was started by the patients nurse without the knowledge of the research associate. In the intervention group, music was played until the CT scan was completed.
89241640|NCT02437214|No Intervention|Control|Children in the Con group received the usual medical care without listening to the music intervention.
89241641|NCT02407808|Active Comparator|THC|Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.
89241642|NCT02407808|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
89241643|NCT02299921||Adult ICU patients with respiratory problem|Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs.
89241644|NCT02299921||Intubated Adult ICU patients with respiratory failure|A subset of subjects, adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation.
89241645|NCT02228343|Experimental|Ayurveda|Ayurvedic therapy
89241646|NCT02097134|Experimental|Treatment (melphalan)|Patients receive melphalan IA on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89241647|NCT01961375||Group 1|BAY 86-5028; Levonorgestrel- Intra Uterine System
89241648|NCT01954992|Experimental|glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle
89241649|NCT01954992|Active Comparator|5-FU|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
89241650|NCT01946854|Other|Observation Arm|Patients observed for 6 months, then will receive chemotherapy for 6 months.
89241651|NCT01946854|Active Comparator|Chemotherapy Group|Patients receive chemotherapy for 6 months, then observed for 6 months. The exact type of fluoropyrimidine-based chemotherapy is not mandated and final treatment decisions will be left to the medical oncologist who is administering the chemotherapy. All chemotherapy adjustments will be done by the treating medical oncologist according to standard of care.
89241652|NCT01927744|Experimental|Chemotherapy + Erlotinib|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus Erlotinib 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
89241653|NCT01927744|Experimental|Chemotherapy + Placebo|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus placebo 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
89241654|NCT01891981|Experimental|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
89241655|NCT01859130|Other|Persona TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
89241656|NCT01750892|Active Comparator|Group 1: Control|Group 1 will be the control group. They will complete questionnaires but will otherwise receive usual care from their Primary Care Provider (PCP). At the end of the study period they will be given the Study Materials for participating.
89241657|NCT01750892|Experimental|Group 3: Group Intervention|Group 3 (Group Intervention) will receive the Study Materials at the beginning of the study and will also be invited to attend two REACH for Independence group sessions.
89241658|NCT01750892|Experimental|Group 4: Full Intervention|Group 4 (Full Intervention) will receive the Study Materials at the beginning of the study, will be invited to attend the REACH for Independence group sessions, and will be invited to a Transition Consult with an MD and social worker.
89241659|NCT01750892|Experimental|Group 2: Basic Intervention|Group 2 (Basic Intervention) will receive the Study Materials at the beginning of the study but will otherwise continue with their usual PCP care.
89241660|NCT01742039||b-blocker|
89241661|NCT01742039||amiodarone|
89241662|NCT01742039||atrial pacing|
89241663|NCT01742039||amiodarone plus atrial pacing|
89241664|NCT01628536|Experimental|Black cohosh|
89241665|NCT01534299||Renal Denervation Treatment|All patients treated with renal denervation procedure will be enrolled as part of this single arm registry
89241666|NCT01335308|Active Comparator|Standard Care with Education Materials|Measure height and weight only. usual care
89241667|NCT01335308|Experimental|Moderate Dose Motivational Interviewing|MI delivered by PCP, 4 sessions
89241668|NCT01335308|Experimental|Higher Dose Motivational Interviewing|MI delivered by PCP, 4 sessions plus MI delivered by RD, 6 sessions
89241669|NCT01174043|Experimental|Erlotinib|
89241670|NCT00954226|Experimental|Arm I (standard-dose erlotinib hydrochloride)|Patients receive standard-dose erlotinib hydrochloride PO QD for 2-3 weeks (up to 8 weeks if surgery is delayed).
89241671|NCT00954226|Experimental|Arm II (high-dose erlotinib hydrochloride)|Patients receive high-dose erlotinib hydrochloride PO QD for 2-3 weeks (2-8 weeks for current smokers or up to 8 weeks if surgery is delayed).
89241672|NCT00494728|Other|CBASP + ST|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) + Smoking Cessation Treatment (ST)
89241673|NCT00494728|Other|ST|Smoking Cessation Treatment (ST)
89241674|NCT00488072|Experimental|Mirtazapine|Mirtazapine 15 mg by mouth (PO) daily for 15 days; Day 22-29, increased to 30 mg PO daily.
89241675|NCT00488072|Placebo Comparator|Placebo|One placebo tablet by mouth daily.
89241676|NCT00329043|Experimental|Sunitinib + Hormonal Ablation Before Prostatectomy|Sunitinib Malate 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles. LHRH Agonist intramuscular injection either monthly for 3 months or in a single 3-month dose. Radical prostatectomy after completion of Sunitinib and LHRH agonist.
89241677|NCT00254384|Experimental|Treatment (docetaxel, cisplatin, erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning within 90 days following definitive surgical resection, patients receive erlotinib hydrochloride PO daily for up to 1 year.
89241678|NCT00253318|Experimental|RAD001 + Docetaxel|RAD001 30 mg orally on Days 1 and 8. Docetaxel 40 mg/m^2 intravenous (IV) over 1 hour on Day 1. Dexamethasone 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
89241679|NCT00081874|Experimental|RAD001|"Phase I: Participants initially treated with 5 mg RAD001 by mouth daily for 28 days.~Phase II: The MTD (either 5mg or 10mg) administered daily until intolerance or failure or lack of response after 4 cycles of therapy. For assessment purposes, each cycle will comprise a 28-day period."
89241680|NCT04119674|Experimental|single-arm|single-arm Drug: Anlotinib Drug: Temozolomide Radiotherapy:Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
89241681|NCT04109365|Experimental|Electrical Epidural Stimulation Test (EST)|Laboring women are given EST test initially before local anesthetic is administered and 1 hour post-anesthetic in order to measure sensory and motor responses.
89241682|NCT04089566|Experimental|28/28 Milligram (mg) Safety Group|Part A: Participants with later-onset SMA will receive loading doses of 28 mg of nusinersen intrathecally on Days 1, 15 and 29 followed by maintenance doses of 28 mg on Days 149 and 269.
89241683|NCT04089566|Active Comparator|12/12 mg Randomized Control Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 12 mg of nusinersen intrathecally on Days 1, 15, 29, and 64 followed by maintenance doses of 12 mg on Days 183 and 279. Sham procedure will be administered on Day 135.
89241684|NCT04089566|Experimental|50/28 mg Randomized Treatment Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 50 mg of nusinersen intrathecally on Days 1 and 15 followed by maintenance doses of 28 mg on Days 135 and 279. Sham procedure will be administered on Days 29, 64 and 183.
89241685|NCT04089566|Experimental|12/50/28 mg Titration Group|Part C: Participants who have been receiving the approved dose of 12 mg for at least 1 year prior to entry, will receive a single bolus dose of 50 mg of nusinersen intrathecally on Day 1 (4 months after their most recent maintenance dose of 12 mg) followed by maintenance doses of 28 mg on Days 121 and 241.
89241686|NCT04050982|Experimental|Pilot Testing|Patients interface with the digital application, providing feedback on usability and satisfaction.
89241687|NCT04050982|Active Comparator|AF CARE plus Usual Care|Patients will interface with the digital application.
89241688|NCT04050982|Active Comparator|Usual Care then AF Care|After a 6 month period of usual care only, patients will interface with the digital application.
89241689|NCT04032847|Experimental|Cohort A|Following lymphodepletion, infusion of cell therapy product ATL001.
89241690|NCT04032847|Experimental|Cohort B|Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor.
89241691|NCT04031430|Experimental|telemonitoring group (TM)|telemonitoring group (TM)
89241692|NCT04031430|Active Comparator|Patient self-monitoring group (PSM)|Patient self-monitoring group (PSM)
89241693|NCT04031430|No Intervention|control group (CC)|No intervention
89241694|NCT04031430|Experimental|CAPROM - Group 1|pregnant women randomly assigned to the TM group of PREMOM II
89241695|NCT04031430|Experimental|CAPROM - Group 2|pregnant women followed-up via TM group as part of their usual care
89241696|NCT04013126|Experimental|endometriosis|Women who undergoing surgery for removal of endometriosis implants
89241697|NCT04013126|Active Comparator|non-endometriosis|Women who undergoing surgery for removal of benign masses in the pelvis
89241698|NCT03990571|Experimental|Treatment (axitinib, avelumab)|Patients receive axitinib PO BID on days 1-28 and avelumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89241699|NCT03948139|Other|Functional Bracing Group|In a presented abstract, the functional brace group has been to shown equivalent outcomes to the hip spica cast. Subject will be administered the functional brace without going to the operating room to be put under full anesthesia. Most cases will not require any sedation in this group (in some cases, light sedation may be needed). Brace will be used for up to 8 weeks post-administration, until adequate callous formation is confirmed.
89241700|NCT03948139|Other|Spica Cast Group|If subject is randomized into the hip spica cast group, subject will proceed to the operating room and be given general anesthesia to administer the spica cast. Cast will be used for up to 8 weeks, until adequate callous formation is confirmed.
89241701|NCT03944434|Experimental|single arm|"patients will receive anastrozole tablets (1 mg once daily) or letrozole tablets (2.5 mg once daily) + ribociclib tablets (600 mg day 1 to 21 in a 28 day cycle). Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, physician's decision, patient's refusal/consent withdrawal, or lost to follow-up.~A LHRH agonist (triptorelin 3,75 mg or leuprolide 3,75 mg or goserelin 3,6 mg, as injectable intramuscular (i.m.) or subcutaneous (s.c.) implant every 28 days) will be used in men."
89241702|NCT03905265|Experimental|Moxidectin 2 mg|Moxidectin 2 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
89241703|NCT03905265|Experimental|Moxidectin 8 mg|Moxidectin 8 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
89241704|NCT03905265|Experimental|Moxidectin 20 mg|Moxidectin 20 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
89241705|NCT03905265|Experimental|Moxidectin 36 mg|Moxidectin 36 mg will be administered as a single dose. Each subject will receive the same number of tablets made up of moxidectin 2 mg tablets and placebo tablets to maintain the blind.
89241706|NCT03899350||Spontaneous Supratentorial Intracerebral Haemorrhage|Participants with spontaneous supratentorial intracerebral haemorrhage.
89241707|NCT03899350||Spontaneous Intracerebellar Hemorrhage|Participants with spontaneous intracerebellar hemorrhage.
89241708|NCT03898596|Other|ECG Monitoring|ECG readings will be collected for neonatal patients who require or currently have UVC
89241709|NCT03869476|Experimental|BioscoreSMP cohort|
89241710|NCT03859752|Experimental|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
89241711|NCT03852784||Bone and joint infection with Streptococcus peumoniae|Patients having had an osteoarticular infection with Streptococcus peumoniae
89241712|NCT03850860||empirical antibotherapy currently used|patients having had a vancomycin and piperacillin-tazobactam combination as empirical antibiotherapy
89241713|NCT03850860||another empirical antibotherapy|patients having had a vancomycin and cefepime combination as empirical antibiotherapy
89241714|NCT03848845|Experimental|Part 1: Dose escalation|Subjects will receive belantamab mafodotin at escalating doses of 2.5 milligrams per kilograms (mg/kg) and 3.4 mg/kg along with 200 mg pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day cycle to establish RP2D. There will be maximum of 35 cycles of combination treatment.
89241715|NCT03848845|Experimental|Part 2: Expansion cohort|Subjects will receive belantamab mafodotin at RP2D along with 200 mg pembrolizumab via IV infusion on Day 1 of each 21-day cycle. There will be maximum of 35 cycles of combination treatment.
89241716|NCT03827434|Active Comparator|Continuous glucose Monitoring and Clarity|Patients with DM2 and abnormal glycemic control followed by Continuous glucose Monitoring, using Clarity software
89241717|NCT03827434|Placebo Comparator|Point of Care Fingerstick Glucose values|Patients with DM2 and abnormal glycemic control followed by Point of Care Fingerstick Glucose values
89241718|NCT03781440|Experimental|Bilateral ESP catheter with Lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
89241719|NCT03781440|Placebo Comparator|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
89241720|NCT03771989|Active Comparator|Intervention|Patients are treated with an intra articular injection with autologous, micro-fragmented adipose tissue.
89241721|NCT03771989|Placebo Comparator|Control|Patients are treated with an intra articular injection with saline (placebo).
89241722|NCT03762044|Experimental|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|10 sessions of 30 minutes, twice a week in a total 5 week period of Activity-oriented Proprioceptive Antiedema Therapy (TAPA in Spanish)
89241723|NCT03762044|Active Comparator|Complete Decongestive Therapy (CDT)|10 sessions of 30 minutes, twice a week in a total 5 week period of complete decongestive therapy (CDT).
89241724|NCT03742037|Experimental|Cenerimod 0.5 mg|Participants will receive cenerimod 0.5 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 0.5 mg for a further 6 months and end study treatment at the Month 12 visit.
89241725|NCT03742037|Experimental|Cenerimod 1 mg|Participants will receive cenerimod 1 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 1 mg for a further 6 months and end study treatment at the Month 12 visit.
89241726|NCT03742037|Experimental|Cenerimod 2 mg|Participants will receive cenerimod 2 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 2 mg for a further 6 months and end study treatment at the Month 12 visit.
89241727|NCT03742037|Experimental|Cenerimod 2 mg (Ex-4mg)|Half the participants that complete treatment with cenerimod 4 mg in Treatment Period 1 will be re-randomized to cenerimod 2 mg once daily in addition to background SLE therapy during Treatment Period 2. Participants will receive cenerimod 2 mg for 6 months and end study treatment at the Month 12 visit.
89241728|NCT03742037|Placebo Comparator|Placebo (Ex-4mg)|Half the participants that complete treatment with cenerimod 4 mg in Treatment Period 1 will be re-randomized to placebo (matching cenerimod) once daily in addition to background SLE therapy during Treatment Period 2. Participants will receive cenerimod 2 mg for 6 months and end study treatment at the Month 12 visit.
89241729|NCT03742037|Experimental|Cenerimod 4 mg|"Participants will received cenerimod 4 mg once daily in addition to background SLE therapy for up to 6 months in Treatment Period 1. The participants randomized to the 4 mg treatment who were still on treatment at Month 6 were re-randomized in a 1:1 ratio to placebo or cenerimod 2 mg to enter Treatment Period 2. The participants who did not complete 6 months of cenerimod 4 mg treatment will be analyzed in the Non Re-randomized (Ex-4mg) treatment group."
89241730|NCT03742037|Placebo Comparator|Placebo|Participants will receive placebo (matching cenerimod) once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with placebo (matching cenerimod) for a further 6 months and end study treatment at the Month 12 visit.
89241731|NCT03714815|Experimental|Open-label treatment period|oral administration of 10 mg macitentan once daily
89241732|NCT03713229||HIV-infected men who have sex with men|HIV-infected male patients who refer to conducting sexual risk practices that enable HPV transmission
89241733|NCT03713229||HIV-infected men|HIV-infected male patients who neglect conducting sexual risk practices that enable HPV transmission
89241734|NCT03713229||HIV-infected women|HIV-infected female patients disregarding sexual risk practices
89241735|NCT03712943|Experimental|Regorafenib and Nivolumab Combination - Escalation|Dose Escalation: To find the dose of regorafenib that can be safely given with nivolumab in patients with advanced, refractory colorectal cancers.
89241736|NCT03712943|Experimental|Regorafenib and Nivolumab Combination - Expansion|Dose Expansion: To find the effect on tumor of the combination of regorafenib and nivolumab.
89241737|NCT03710915|Experimental|HG146 capsule treat multiple myeloma|"Experimental: 5/10/15/20 mg HG146 capsule 5 mg starting dose taken orally on Day 1, 3, 5, 7, 9, 11, 13 of each cycle, and off drug for 8 days (3 weeks).~Intervention: Drug: HG146 capsule"
89241738|NCT03707938|Experimental|Treatment (brigatinib, LCT)|Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89241739|NCT03686488|Experimental|TAS 102 and Ramucirumab|TAS 102 (Lonsurf) and Ramucirumab 10 MG/ML Intravenous Solution (CYRAMZA) administered concurrently.
89241740|NCT03640312|Experimental|QUARTET LDQT|Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
89241741|NCT03640312|Active Comparator|Candesartan|Patients randomized to the comparison arm will take a once daily 8mg candesartan.
89241742|NCT03625388|Other|Dasatinib 50 mg|Dasatinib 50 mg orally once daily
89241743|NCT03625388|Other|Dasatinib 100 mg|Dasatinib 100 mg orally once daily
89241744|NCT03622879|Experimental|MT + TENS|The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
89241745|NCT03622879|Placebo Comparator|Placebo-MT+TENS|In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
89241746|NCT03622879|Placebo Comparator|MT+placebo-TENS|In the MT+placebo-TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group. The only difference is that placebo stimulation will be applied to the paretic limb from identical-looking TENS devices with the electrical circuit disconnected inside. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
89241747|NCT03622879|Sham Comparator|control training|All subjects will perform 60 minutes of lower limb task-oriented training only.
89241748|NCT03614962|Experimental|Warmth + TENS group|All participants will be offered a hat device that elicits warmth and TENS.
89241749|NCT03614962|Active Comparator|Warmth + placebo-TENS group|All participants will be offered a hat device that elicits warmth and placebo-TENS.
89241750|NCT03614962|Active Comparator|Warmth group|All participants will be offered a hat device that elicits warmth only.
89241751|NCT03614962|Active Comparator|TENS group|All participants will be offered a hat device that elicits TENS only.
89241752|NCT03614962|Sham Comparator|control group|All participants will be offered a hat device that without warmth or TENS output.
89241753|NCT03580213|Experimental|Hand therapy MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living."
89241754|NCT03580213|Experimental|Hand therapy PIPJ affected|"40 participants With Dupuytren's contracture with the proximal interphalangeal joint involved, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living. Possible additional splint and exercises specifically for the PIPJ extension."
89241755|NCT03580213|No Intervention|Control group MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
89241756|NCT03580213|No Intervention|Control group PIPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
89241757|NCT03570827|Experimental|Group I (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy over 15-30 minutes every other day over 2 weeks, for 5 treatments.
89241758|NCT03570827|Experimental|Group II (radiation therapy, androgen suppression therapy)|Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
89241759|NCT03570827|Experimental|Group III (radiation therapy, androgen suppression therapy)|Participants receive androgen suppression therapy as Group II for up to 18 months (at the discretion of the treating physician), then undergo hypofractionated radiation therapy over 15-30 minutes every other day over 1-2 weeks, for 1-5 treatments.
89241760|NCT03404310|Experimental|Treatment|Zinc Sulfate 220mg twice daily for three months.
89241761|NCT03404310|Placebo Comparator|Placebo|Gelatin Placebo tablet twice daily for three months.
89241762|NCT03399721|Active Comparator|Chordate S101 Active|Active treatment With Device Chordate S101
89241763|NCT03399721|Placebo Comparator|Chordate S101 Placebo|Placebo treatment With Device Chordate S101
89241764|NCT03387553|Active Comparator|Lead In Phase - Arm A|Arm A: One Dendritic Cell Vaccine (DC1) per week x 3 weeks.
89241765|NCT03387553|Active Comparator|Lead In Phase - Arm B|Arm B: Two DC1 vaccinations per week (given 3 days apart i.e., Mon and Thurs or Tues and Friday) x 3 weeks.
89241766|NCT03387553|Experimental|Expansion Phase|DC1 vaccinations according to optimal vaccination schedule. Participants will receive a booster intranodal study vaccine at week 25 prior to receiving surgery. Participants will then undergo definitive curative surgery following completion of the neoadjuvant therapy, additional adjuvant locoregional/systemic therapy (as deemed appropriate by their treating physicians).
89241767|NCT03367533|Experimental|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
89241768|NCT03367533|Placebo Comparator|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
89241769|NCT03299088|Experimental|Arm A (trametinib, pembrolizumab)|Patients receive trametinib PO daily. Beginning on day 1 of course 2, patients also receive pembrolizumab IV over 30 minutes. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89241770|NCT03299088|Experimental|Arm B (pembrolizumab, trametinib)|Patients receive pembrolizumab IV over 30 minutes on day 1. Beginning on day 1 of course 2, patients also receive trametinib PO daily. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89241771|NCT03272464|Experimental|Trametinib + Dabrafenib + INCB039110|"Dabrafenib is administered orally every 12 hours~Trametinib is administered orally once a day~INCB039110 is administered orally once a day"
89241772|NCT03263481|Experimental|ERCP with inadvertent pancreatic cannulation|Subjects undergoing ERCP for a biliary indication in which inadvertent pancreatic cannulation occurs will undergo intraductal secretin testing per the study protocol.
89241773|NCT03155737|Experimental|Self-acupressure Training|Subjects in the self-administered acupressure exercise group will receive two 1.5 hours acupressure training sessions. The training will be conducted in a group format with 4-7 subjects per group. Each subject will then receive a handout and an acupressure log. The handout includes a picture-illustrating acupressure step-by-step protocol. They will be told to perform the self-acupressure twice per day for 6 weeks.
89241774|NCT03155737|Active Comparator|Knee Health Education|Subjects in the health education control group will receive knowledge related to knee OA. The health education will be conducted in a talk format for 1.5 hours for two sessions.
89241775|NCT03128151||Study group|Intraoperative neuromuscular monitoring and pharmacological reversion according to data sheet
89241776|NCT03128151||Control group|Treated according to usual clinical practice
89241777|NCT03115632||Obese asthmatic & lean asthmatic|men and women with asthma and either obese or lean BMI
89241778|NCT03115632||Obese non-asthmatic & lean non-asthmatic|men and women without asthma and either obese or lean BMI
89241779|NCT03115632||Asthmatic undergoing bariatric surgery|Obese asthmatic men and women undergoing bariatric surgery
89241780|NCT03115632||Non-asthmatic undergoing bariatric surgery|Obese men and women undergoing bariatric surgery
89241781|NCT03082248|Other|Physical Therapy Group|10-week supervised physiotherapeutic intervention; all patients will receive educational leaflets and folders for maintenance and adherence to the treatment program.
89241782|NCT03082248|Other|Spinal Surgery Group|Surgical procedures and techniques specific for the low back region, previously discussed and agreed upon among surgeons according to patients description.
89241783|NCT03079011|Experimental|A- palbociclib + AI|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
89241784|NCT03079011|Experimental|B- Palbociclib + fulvestrant|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
89241785|NCT03079011|Experimental|Selection - Palbociclib + AI|All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
89241786|NCT03038828|Experimental|Arm A|Cohort A - 200IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off two weeks, then repeat 200IU 5 days/week x 2 weeks.
89241787|NCT03038828|Experimental|Arm B|Arm B - 400IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off 2 weeks, 400IU 5 days/week x 2 weeks.
89241788|NCT02964624|Other|Rehabilitation|The rehabilitation protocol will consist of three exercise session/week for eight weeks
89241789|NCT02866383|Experimental|Nivolumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT and then every 2 weeks (q2w), for a maximum of 52 weeks
89241790|NCT02866383|Experimental|Nivolumab & Ipilimumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT. Thirty minutes after the completion of nivolumab infusion patients will receive ipilimumab 1 mg/kg over 90 minutes IV as an IV infusion. Nivolumab will be given every 2 weeks (q2w) and ipilimumab every 6 weeks (q6w), respectively for a maximum of 52 weeks
89241791|NCT02841215|Experimental|Oral ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
89241792|NCT02841215|Active Comparator|Oral ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
89241793|NCT02804542||Fascia Iliaca Block Cohort|Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED.
89241794|NCT02804542||Retrospective Control Cohort|No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care).
89241795|NCT02798601|Experimental|Hypernatremia|Serum sodium between 150 - 155 milliequivalent/L. 7,5% sodium chloride (2 ml/kg every 4 hours), with controls of serum sodium every 4 hours, to achieve a goal of serum sodium between 150 - 155 milliequivalent/L. If after 4 doses of 7.5% sodium chloride the serum sodium is below the target, a bolus of 1 ml/kg of 12% sodium chloride will be used every 4 hours. The goal of serum sodium will be maintained for 48 hours.
89241796|NCT02798601|No Intervention|Normonatremia|Serum sodium between 135 - 145 milliequivalent/L. Mannitol 100 ml every 4 hours for the first three days; 80 ml every 4 hours the fourth day; 60 ml every 4 hours the fifth day and 40 ml every 4 hours the sixth day and then stopping. The mannitol protocol will be interrupted at any moment if serum sodium is below 135, the systolic blood pressure is below 90 mmHg or the patient has signs of hypovolemia. In this case, 2 ml/kg of 3% sodium chloride every 4 hours will be used until the target of serum sodium is achieved and both, normovolemic state and blood pressure are restored. In addition, the mannitol protocol will be suspended when serum osmolality is above 320.
89241797|NCT02793466|Experimental|Durvalumab; MEDI4736|Open label
89241798|NCT02767557|Experimental|Tocilizumab & Gemcitabine and nab-Paclitaxel|"Tocilizumab:~8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.~Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
89241799|NCT02767557|Active Comparator|Gemcitabine and nab-Paclitaxel|"Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
89241800|NCT02736383||Tranexamic Acid|Patients that receive 2 gm TXA during surgery
89241801|NCT02736383||No Tranexamic Acid|Patients that receive no TXA during surgery
89241802|NCT02594917||Test Group|The study population will include ten patients (ages 18-60 yrs) with confirmed mutations of the iron-sulfur cluster biogenesis complex of proteins and experiencing dyspnea, heart failure, or exercise intolerance.
89241803|NCT02594917||Control Group|It will also include ten additional patients (ages 18-60 yrs) who are unaffected first-degree family members of the above subjects.
89241804|NCT02463708||BHL COTP Caregivers|Caregivers participate in the BHL COTP, which provides support, education, and care management services from a Behavioral Health Provider (BHP) in addition to the Telehealth Education Program (TEP), a manualized program that consists of various modules that seek to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
89241805|NCT02461368|Experimental|anterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
89241806|NCT02461368|Active Comparator|posterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
89241807|NCT02400190|Experimental|Endocrine therapy alone|Patients receive endocrine therapy alone without radiotherapy
89241808|NCT02373072|Experimental|Cohort 1|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
89241809|NCT02373072|Experimental|Cohort 2|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
89241810|NCT02285140|Experimental|Cefazolin monotherapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
89241811|NCT02285140|Experimental|Cefazolin monotherapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
89241812|NCT02285140|Experimental|Combination therapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
89241813|NCT02285140|Experimental|Combination therapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
89241814|NCT02254278|Experimental|IMRT 6 weeks + cisplatin|IMRT 6 weeks with concurrent cisplatin
89241815|NCT02254278|Experimental|IMRT 5 weeks|IMRT 5 weeks
89241816|NCT02174549|Experimental|Tirapazamine|Intra-arterial administration with tirapazamine before embolization to evaluate the response in metastatic liver lesions of NET
89241817|NCT02145000|Experimental|Rotavirus vaccine (BRV-PV)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine (BRV-PV) contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is in lyophilized form and supplied with 2.5 ml of citrate bicarbonate buffer that is added for reconstitution just before oral administration.
89241818|NCT02145000|Placebo Comparator|Placebo|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
89241819|NCT02059499|Experimental|Arm A (imiquimod)|Patients apply imiquimod intra-anally QD for 16 weeks.
89241820|NCT02059499|Experimental|Arm B (fluorouracil)|Patients apply fluorouracil intra-anally BID on days 1-5. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
89241821|NCT02059499|No Intervention|Arm C (observation)|Patients receive no treatment. Patients who still have HSIL at week 20 and who agree to randomization may cross-over to Arm A or B.
89241822|NCT01998841|Experimental|Mutation Carriers: Crenezumab|"Study Period A: Participants will receive Crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: Participants will be offered the opportunity to continue to receive blinded study drug until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
89241823|NCT01998841|Placebo Comparator|Mutation Carriers: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: All mutation carriers entering Study Period B will, receive Crenezumab until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued."
89241824|NCT01998841|Placebo Comparator|Non-carriers of Mutation: Placebo|"Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.~Study Period B: All non-mutation carriers entering Study Period B will continue to receive Placebo, until the results of the study are known and post trial access to Crenezumab is started or development of Crenezumab is discontinued."
89241825|NCT01864850|Active Comparator|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
89241826|NCT01864850|Experimental|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
89241827|NCT01607879|Experimental|Standard of care ADT + (HMB + AG)|Standard of care androgen deprivation therapy plus the nutritional supplement HMB + arginine + glutamine (AG)
89241828|NCT01607879|Active Comparator|Standard of care ADT|Standard of care androgen deprivation therapy
89241829|NCT01561612|Experimental|Intervention|Breastfeeding promotion according to World Health Organization's Baby Friendly Hospital Initiative
89241830|NCT01561612|No Intervention|Control|Usual care
89241831|NCT01336933|Experimental|Treatment|"A Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) B Treatment: Pralatrexate (P)~A cycles (CEOP) of the treatment regimen are 14 days, followed by  B cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses.~Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation."
89241832|NCT01107522|Experimental|Arm A|Single Agent CTO
89241833|NCT01107522|Experimental|Arm B|Combination CTO and Temodar®
89241834|NCT01107522|Experimental|Arm C|Combination CTO, Temodar®, Radiation therapy
89241835|NCT01087619|No Intervention|Follow-up|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are followed only
89241836|NCT01087619|Experimental|Surgery|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are treated with parathyroid surgery
89241837|NCT00756379|Experimental|Intensive lifestyle modification|P.E.T. guided comprehensive therapy program. The study intervention is Comprehensive therapy program for risk factor modification. The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by primary physician. No experimental medications or procedures will be used.
89241838|NCT00756379|No Intervention|Current standard of care|Current standard of care medical management as provided by primary physician.
89241839|NCT00352027|Experimental|All Participants|Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
89241840|NCT00285259|Experimental|VCL-CB01|
89241841|NCT00285259|Placebo Comparator|Placebo|PBS
89241842|NCT00262470|Experimental|1|Acetazolamide
89241843|NCT00262470|Experimental|2|Atomoxetine
89241844|NCT00262470|Experimental|3|NO Drug
89241845|NCT00262470|Experimental|4|Clonidine
89241846|NCT00262470|Experimental|5|Entacapone
89241847|NCT00262470|Experimental|6|Indomethacin
89241848|NCT00262470|Experimental|7|Isosorbide Dinitrate
89241849|NCT00262470|Experimental|8|Mecamylamine
89241850|NCT00262470|Experimental|9|Memantine
89241851|NCT00262470|Experimental|10|Melatonin
89241852|NCT00262470|Experimental|11|Midodrine
89241853|NCT00262470|Experimental|12|Modafinil
89241854|NCT00262470|Experimental|13|Octreotide
89241855|NCT00262470|Placebo Comparator|14|Placebo (lactose tablet)
89241856|NCT00262470|Experimental|15|Propranolol
89241857|NCT00262470|Experimental|16|Sertraline
89241858|NCT00262470|Experimental|17|Normal Saline (0.9%) 1 liter
89241859|NCT00262470|Experimental|18|Drinking Water
89241860|NCT00262470|Experimental|19|Dead Space Breathing Device
89241861|NCT00262470|Experimental|Abdominal Binder|Abdominal binder with inflatable pressure over abdomen
89241862|NCT00082641|Experimental|Arm I|Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).
89241863|NCT00082641|Experimental|Arm II|Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.
89241864|NCT00440271|Other|Standard of Care (SoC)|Standard of Care (SOC) Arm = Tipranavir/ritonavir (TPV/r) capsules taken orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR). No TPV/r dose changes were permitted.
89241865|NCT00440271|Other|Therapeutic Drug Monitoring (TDM)|Therapeutic Drug Monitoring (TDM) Arm = Patients began by receiving standard of care (SOC) tipranavir/ritonavir (TPV/r) capsules orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR) followed, if needed, by TPV or ritonavir (RTV) dose adjustments at Week 4, 6, 10, 14, 18, 22, 26 and 30 based on viral response, phenotypic inhibitory quotient (IQ), and TPV trough concentrations.
89241866|NCT00346216|Experimental|celecoxib|subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
89241867|NCT00346216|Active Comparator|ibuprofen|subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
89241868|NCT00346216|Active Comparator|naproxen|subject receives naproxen and dummy (placebo) celecoxib and ibuprofen
89241869|NCT04740242||Cohort of exposed patients (Group 1)|All patients admitted for decompensated HF and presenting MA at the time of admission
89241870|NCT04740242||Cohort of unexposed patients (Group 2)|All patients admitted for decompensated HF and who do NOT present MA at the time of admission
89241871|NCT01030419|Experimental|FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
89241872|NCT01030419|Placebo Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 12-month follow-up testing.
89241873|NCT01325116|Active Comparator|Control|Usual post-STEMI care
89241874|NCT01325116|Experimental|Intervention|Recurrent, personalized, educational reminders sent via post on behalf of the interventional cardiologist to the patient and their family physician urging long-term adherence to secondary prevention medications post-STEMI. A copy of the letter will be provided to the patient to take to their pharmacist.
89241875|NCT01051648|Experimental|Triamcinolone acetenoide|Intra ocular injection of triamcinolone acetonide to visualize vitreous strands in the anterior chamber of the eye in complicated cataract surgery
89241876|NCT00417963|Experimental|stent placement in the carotid artery|placement of a bare metal stent for treatment of carotid artery stenosis
89241877|NCT00429273|Active Comparator|Group 1: Guan-Guan+Placebo|weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
89241878|NCT00429273|Active Comparator|Group 2: Placebo-Placebo+DMPH|weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
89241879|NCT00429273|Experimental|Group 3: Guan-Guan+DMPH (Comb)|weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH
89241880|NCT00359632|Experimental|Linezolid|Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
89241881|NCT00359632|Active Comparator|Matched control|Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid. Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
89241882|NCT01324960|Experimental|Ceplene® / IL2 + Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene (EpiCept Corporation, Tarrytown, NY) at 0.5 mg subcutaneous twice daily and human recombinant IL-2 (aldesleukin; Novartis) 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
89241883|NCT01324960|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
89241884|NCT00417885|Experimental|A|sunitinib + exemestane
89241885|NCT01056250|Other|SILS cholangiography|Performing cholangiography in all patients undergoing SILS cholecystectomy.
89241886|NCT03989596|Experimental|Radiotherapy with hyperthermia|10x 3.25 Gy + hyperthermia + surgery or radiotherapy boost (4x 4 Gy + hyperthermia)
89241887|NCT01036893|No Intervention|oral contraceptives without prucalopride|
89241888|NCT01036893|Active Comparator|oral contraceptives with prucalopride|prucalopride
89241889|NCT01056406|No Intervention|Control Group|Overweight and obese pregnant women who are randomly assigned to the control group will receive the current standard of optimal care in addition to 1 nutrition education session with the study nutritionist (a registered dietitian) at 6-16 weeks gestation.
89241890|NCT01056406|Experimental|Nutrition Education Group|Overweight and obese pregnant women randomly assigned to the nutrition education group, in addition to the current standard of optimal care, will receive twice monthly interaction with the study nutritionist (a registered dietitian) from 6-16 weeks gestation through 6 months postpartum.
89241891|NCT01856439|Other|Long term follow up|Long term follow up of patient's who received ProSavin in previous study
89241892|NCT01051726|Experimental|Aromatherapy group 1|Participants will be given essential oil consisting of (Peppermint, Lavender, Clary Sage and Frankincense) together with a swab to put the oil on.
89241893|NCT01051726|Placebo Comparator|Control group 2|Participants receive a bottle of non essential oil and a swab.
89241894|NCT01051726|No Intervention|Control group 3|Standard maternity care to measure baseline.
89241895|NCT04488770|Experimental|Part 1 (SAD) Cohort 1:Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 50 milligram (mg), 150 mg and 250 mg orally on Day 1 of period 1, 2 and 3 respectively. Period 4 will be conducted to assess food effect based on the observed human PK.
89241896|NCT04488770|Placebo Comparator|Part 1 (SAD),Cohort 1:Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 2 and 3. Period 4 will be conducted to assess food effect based on the observed human PK.
89241897|NCT04488770|Experimental|Part 1 (SAD),Cohort 2: Participants receiving GSK3882347|In this single ascending dose phase, participants will receive GSK3882347 500 mg, 15 mg and 900 mg orally on Day 1 of period 1, 3 and 2 respectively.
89241898|NCT04488770|Placebo Comparator|Part 1 (SAD),Cohort 2: Participants receiving Placebo|In this single ascending dose phase, participants will receive matching Placebo orally on Day 1 of period 1, 3 and 2.
89241899|NCT04488770|Experimental|Part 2 (MAD),Cohort 3: Participants receiving GSK3882347 50mg|In this multiple ascending dose phase, participants will receive GSK3882347 50 mg orally on Day 1 to Day 7 of the study. The dose to be administered may be changed based on clinical safety, tolerability and PK findings in Part 1.
89241900|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 3: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
89241901|NCT04488770|Experimental|Part 2 (MAD),Cohort 4: Participants receiving GSK3882347 150mg|GSK3882347 150 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
89241902|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 4: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
89241903|NCT04488770|Experimental|Part 2(MAD),Cohort 5: Participants receiving GSK3882347 500mg|GSK3882347 500 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
89241904|NCT04488770|Placebo Comparator|Part 2 (MAD),Cohort 5: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
89241905|NCT04488770|Experimental|Part 2(MAD),Cohort 6: Participants receiving GSK3882347 900mg|GSK3882347 900 mg will be administered orally to the participants on Day 1 to day 7 of the study. This is a projected dose. The dose administered in Part 2, Cohort 6 will be based on PK/PD results from preceding dosing cohorts.
89241906|NCT04488770|Placebo Comparator|Part 2(MAD),Cohort 6: Participants receiving Placebo|In this multiple ascending dose phase, participants will receive matching Placebo orally on Day 1 to Day 7 of the study.
89241907|NCT00525044|Placebo Comparator|Control|
89241908|NCT00525044|Experimental|Ambroxol|
89241909|NCT00355342|Experimental|Salmeterol 50 mcg BID|Participants randomized to this arm received salmeterol 50 microgram (mcg), formulated with lactose via the DISKUS™ inhaler one inhalation twice daily (BID) one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication. DISCUS is registered trademark product of GlaxoSmithKline.
89241910|NCT00355342|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication.
89241911|NCT03573362|Experimental|Vizishot Flexneedle 19G|Mediastinal and hilar lymph node sampling using the Vizishot Flexneedle19G EBUS-TBNA needle
89241912|NCT03573362|Active Comparator|Vizishot 22G|Mediastinal and hilar lymph node sampling using a standard Vizishot 22G EBUS-TBNA needle
89241913|NCT01051804|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
89241914|NCT01051804|Active Comparator|Optive|Optive Lubricant Eye Drops
89241915|NCT01051882|Experimental|MSC-NTF cells IM|Intramuscular administration in early stage patients
89241916|NCT01051882|Experimental|MSC-NTF cells IT|Intrathecal administration in progressive stage patients
89241917|NCT01573754|Experimental|Hydroxychloroquine|Low-dose hydroxychloroquine 100 mg by mouth twice weekly
89241918|NCT01573754|Active Comparator|Phlebotomy|Phlebotomy 450 mL biweekly
89241919|NCT03989674|No Intervention|White bread|
89241920|NCT03989674|Experimental|Anthocyanin-fortified bread (2% w/w)|
89241921|NCT03989674|Experimental|Anthocyanin-fortified bread (4% w/w)|
89241922|NCT03986788|Other|Weightlessness|Weightlessness measurements during flight
89241923|NCT03989830|Experimental|Second-line chemotherapy combined with Endostar|Second-line chemotherapy+Endostar
89241924|NCT03989518|Experimental|Simple stimuli|Two perceptually simple stimuli are used during all experimental phases (geometrical figures).
89241925|NCT03989518|Experimental|Complex stimuli|Two complex stimuli are used in all experimental phases. Stimuli consist of photographs of real objects of the same size and shape as the simple stimuli, but include perceptually more complex patterns, details and colors.
89241926|NCT03989284|Experimental|Peer counseling group|Peer counselors performed 1-hour home visits weekly to their assigned clients for three months.
89241927|NCT03989284|Experimental|Social engagement group|Senior citizens joined 3-hour weekly social events held at the OSCA Center for three months.
89241928|NCT03989284|Experimental|Combination group|Senior citizens in this group underwent both peer counseling and social engagement interventions mentioned above.
89241929|NCT03989284|No Intervention|Control group|Senior citizens in this group had access to usual or standard care from health and aged care services that were usually available.
89241930|NCT00355264|Experimental|Single Arm on Active Drug|"5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels~Outcomes were also evaluated by the subject's type of BH4 deficiency either defects in the genes encoding the enzymes involved in biosynthesis or defects in the genes encoding the enzymes involved in recycling."
89241931|NCT02533648|Experimental|Allopurinol|Allopurinol, experimental arms, type 2 diabetes subjects receive 2 capsules of allopurinol 150 mg daily for 3 month
89241932|NCT02533648|Placebo Comparator|Placebo|Placebo, type 2 diabetes subjects receive 2 capsules of lactose (placebo) daily for 3 month
89241933|NCT01056796|Experimental|CAR™ 27|Any patient with a diagnosis of colorectal cancer that has been previously radiated to the pelvic area (6-8 weeks prior to surgery) and that is electively scheduled for an open or laparoscopic total mesorectal excision (TME) and low anterior resection surgery (< 10cm from the anal verge) which requires the creation of an anastomosis, will be offered participation in this study.
89241934|NCT02533492|Active Comparator|Vicryl|Vicryl suture for wound closure after total knee replacement
89241935|NCT02533492|Experimental|vicryl plus|Vicryl plus suture for wound closure after total knee replacement
89241936|NCT01056874|Active Comparator|Digoxin|
89241937|NCT01056874|Experimental|Digoxin + Maraviroc|
89241938|NCT01056952|Experimental|Optiflow then CPAP|Standard low flow oxygen therapy then High flow oxygen nasal therapy (Optiflow)then Continuous positive airway pressure (CPAP)
89241939|NCT01056952|Experimental|CPAP then Optiflow|Standard low flow oxygen therapy then Continuous positive airway pressure (CPAP)then High flow oxygen nasal therapy (Optiflow)
89241940|NCT00355030|Experimental|1|
89241941|NCT00355030|Experimental|2|
89241942|NCT01057030|Active Comparator|A1 (BMS-708163)|Healthy Japanese Subjects
89241943|NCT01057030|Placebo Comparator|A2 (Placebo)|Healthy Japanese Subjects
89241944|NCT01057030|Active Comparator|B1 (BMS-708163)|Healthy Non-Japanese Subjects
89241945|NCT01057030|Placebo Comparator|B2 (Placebo)|Healthy Non-Japanese Subjects
89241946|NCT03991546|Experimental|Acceptance and Commitment Therapy|Subjects randomizing into this arm received the study intervention that consisted of twice-daily, AM and PM, text messages starting on postoperative day one and ending on postoperative day fourteen. Subjects were only required to read these messages, which utilized the principles of Acceptance and Commitment therapy.
89241947|NCT03991546|No Intervention|Control group|Subjects randomizing into this arm did not receive the text message study intervention.
89241948|NCT03986632|Experimental|Tundra gifts program|
89241949|NCT03986632|No Intervention|Comparison|
89241950|NCT03989128||Observational (survey)|Participants complete a survey over 5-10 minutes
89241951|NCT01057108|Active Comparator|ESRD: FOSTRAP Chewing Gum|
89241952|NCT01057108|Active Comparator|CKD: FOSTRAP Chewing Gum|
89241953|NCT01057108|Placebo Comparator|ESRD Matching Placebo|
89241954|NCT01057108|Placebo Comparator|CKD Matching Placebo|
89241955|NCT01057186||hereditary hypophosphatemia|Norwegian patients with hereditary hypophosphatemia.
89241956|NCT01057186||Hereditary hyperphosphatemia|Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
89241957|NCT03986476|Experimental|Lactobacillus reuteri strain 1|Probiotic compound
89241958|NCT03986476|Experimental|Lactobacillus reuteri strain 2|Probiotic compound
89241959|NCT03986476|Placebo Comparator|Placebo|Placebo
89241960|NCT01057264|Experimental|HAI Abraxane + Gemcitabine + Bevacizumab|HAI (hepatic arterial infusions) Abraxane with Gemcitabine + Bevacizumab
89241961|NCT03991312|Experimental|Part 1|"Period 1: Day 1, participants will receive 20 milligrams (mg) of mitapivat sulfate.~Period 2: Day 1 to Day 9, participants will receive 200 mg of itraconazole, once daily and 20 mg of mitapivat sulfate on Day 5."
89241962|NCT03991312|Experimental|Part 2|"Period 1: Day 1, participants will receive 50 milligrams (mg) of mitapivat sulfate.~Period 2: Day 1 to Day 12, participants will receive 600 mg of rifampin, once daily and 50 mg of mitapivat sulfate on Day 8."
89241963|NCT03988972|Experimental|diathermy group|"Diathermy incisions will be carried out using monopolar blade pen electrode, set on cutting mode and delivering a 35 continuous current. Electrosurgical cutting was performed without pressure or mechanical displacement.~'Bleeders' will be controlled by using diathermy, on coagulating mode, and will be applied to a hemostat on the vessels"
89241964|NCT03988972|Active Comparator|scalpel group|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
89241965|NCT01057342|Experimental|Paclitaxel, Carboplatin, ASA404|
89241966|NCT01054534|Other|Placement of interstim lead|Placement of interstim lead using US image fusion technology
89241967|NCT01057420|Other|Inhalation of 80% Oxygen|Inhalation of 80% Oxygen by nonrebreathing reservoir face masks for 4 hours
89241968|NCT01054690|Experimental|Silver alloyed urinary catheter|
89241969|NCT01054690|Placebo Comparator|Silicone urinary catheter|
89241970|NCT01057498|Experimental|1a - RNS60 in Healthy Subjects|Single dose administration of nebulized RNS60 testing for bronchoconstriction in healthy human subjects.
89241971|NCT01057498|Experimental|1b: RNS60 in Mild Asthmatics|Single-dose administration of nebulized RNS60 testing for bronchoconstriction in mild asthmatics.
89241972|NCT01057498|Experimental|2e: RNS60 in mild-to-moderate asthmatics|RNS60 in mild-to-moderate asthmatics who are not currently taking a chronic asthma medication.
89241973|NCT03742258|Experimental|Treatment (R-CHOP, TAK-659)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in course 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
89241974|NCT01057576|Experimental|PMI 5011|An experimental group randomized to PMI 5011
89241975|NCT01057576|Placebo Comparator|Placebo|Placebo
89241976|NCT00354172|Experimental|Treated Patients|All patients receiving treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.
89241977|NCT03986242|Experimental|static stretchin|Static extremity muscles of the lower extremities, including: gluteal muscles (major muscle group: gluteus maximus), anterior thigh muscles (strand rectus, medial femoral muscle, lateral femoral muscle, medial femoral muscle), posterior thigh muscles (main muscle) Group: semimembranosus, semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). 4 groups per muscle group, 30 seconds/group
89241978|NCT03986242|Experimental|non- vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each leg of each pair performs 30 seconds/group for a total of 4 groups for a total time of 20 minutes.
89241979|NCT03986242|Experimental|Vibration rolling|Lower limb part. Such as: gluteal muscle (main muscle group: gluteus maximus), anterior thigh muscle group (straight rectus, medial femoral muscle, lateral femoral muscle, femoral intermediate muscle), posterior thigh muscle group (main muscle group: semimembranosus, Semitendinosus, biceps femoris), anterior muscles of the calf (anterior tibialis anterior muscle, extensor muscle), and posterior muscles of the calf (gastrocnemius, soleus muscle). Each muscle group of each foot performs 30 seconds/group, a total of 4 groups, the vibration frequency is 28 Hz, and the total time is 20 minutes.
89241980|NCT00345592|Experimental|Device managed arm|Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.
89241981|NCT00345592|Active Comparator|Traditional arm|Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.
89241982|NCT01052506|Placebo Comparator|Placebo|Single dose of saline solution (8 cohorts IV; 1 cohort SC)
89241983|NCT01052506|Experimental|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)
89241984|NCT03988816|Experimental|Roflumilast|Roflumilast tablets will be supplied at a concentration of 500 mcg. Each tablet contains 500mcg of the active ingredient in addition to the excipients: lactose monohydrate, corn starch, povidone and magnesium stearate. The coating contains hypromellose, macrogol, titanium dioxide, yellow iron oxide. Patients should take 1 tablet once daily, before, during or after meals, at the same time each day.
89241985|NCT03988816|Placebo Comparator|Placebo (control)|Roflumilast placebo-containing tablets will look similar to active roflumilast tablets and will be supplied to patients in packs identical to those of the active drug.
89241986|NCT00353704|Active Comparator|Pregabalin|150 mg Pregabalin per orally about one hour before surgery
89241987|NCT00353704|Placebo Comparator|Placebo|One capsule of saccharose (placebo) was administered orally about one hour before surgery.
89241988|NCT03742180|Experimental|intranasal dexmedetomidine|this group is planned for intranasal dexmedetomidine
89241989|NCT03742180|Active Comparator|sublingual ketorolac|this group is planned for sublingual ketorolac
89241990|NCT00512252|Experimental|Phase I Dose Escalation|"AMD3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 1 AMD3100 dose = 80 mcg/kg/d~Dose Level 2 AMD3100 dose = 160 mcg/kg/d"
89241991|NCT00512252|Experimental|Phase II Dose Treatment|"AMD 3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)"
89241992|NCT03988894|No Intervention|Control: Usual Care|All participants will (a) receive a general hypertension health education booklet from the Heart and Stroke Foundation of Ontario;(b) be encouraged to see their family physicians or primary health care providers regarding their blood pressure status; those who do not have a primary health care provider will be referred to a walk-in clinic or a community health centre; and (c) have access to family physicians, tele-health, emergency care, hospital and other health care facilities in the Greater Toronto Area as required.
89241993|NCT03988894|Active Comparator|Intervention: mDASHNa-CC app use|In addition to usual care, those participants randomized to the intervention group will be offered use of the app.Then, they will load the app in their smartphones and be requested to review educational contents, conduct dietary self-assessment, and monitor blood pressure for 8 weeks.By the end of eight weeks post randomization, seniors will be prompted by phone using an audible alert to complete the app Evaluation Questionnaire on the smartphone, which ascertains likes and dislikes with the app.
89241994|NCT00516386|Experimental|Insulin like growth factor- 1 (IGF-1)|Adolescent girls with AN meeting inclusion criteria were administered recombinant human (rh) rhIGF-1 at a dose of 35-40 mcg/k twice daily by subcutaneous injections for a 7-10 day period.
89241995|NCT00524420|Experimental|Active rTMS|Active rTMS involves administration of real rTMS to the patient.
89241996|NCT00524420|Sham Comparator|Sham rTMS|Sham rTMS is a placebo or inactive form of rTMS for study control and comparison purposes.
89241997|NCT04782518||Participants with PD|Adults with Parkinson Disease. This is an observational study without an intervention.
89241998|NCT00512096|Experimental|Cisplatin + Ifosfamide + Paclitaxel|Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1
89241999|NCT01565252|No Intervention|Stage 1|"Dietary regimens:~Stage1 - all participants (N=20) in first stage will receive two regular (high n-6 PUFA) hard-boiled eggs/day at breakfast for a three weeks period for each participant."
89242000|NCT01565252|Experimental|Stage 2|Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.
89242001|NCT04462796|Experimental|Magnesium Citrate|Magnesium Citrate given orally taken once daily for 8 weeks
89242002|NCT00524030|Experimental|1|
89242003|NCT00524030|Experimental|2|
89242004|NCT00523718|Experimental|riluzole|Patients randomized to this arm will receive riluzole augmentation, at a standard, fixed dose (50 mg bid), in addition to the medication regimen they are on at enrollment
89242005|NCT00523718|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from riluzole, in addition to the medication regimen they are on at study enrollment.
89242006|NCT00523640|Experimental|I|"Combination of gemcitabine, capecitabine, and bevacizumab~gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle"
89242007|NCT00345358|Active Comparator|Synflorix <6M Group|This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of Synflorix™ vaccine co-administered with Infanrix™ IPV/Hib at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (Synflorix™) or the left (Infanrix™ IPV/Hib ) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
89242008|NCT00345358|Experimental|Synflorix 7-11M Group|This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
89242009|NCT00345358|Experimental|Synflorix 12-23M Group|This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose 2 months later. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
89242010|NCT00345358|Experimental|Synflorix >=24M Group|This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of Synflorix™. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
89242011|NCT03869684|Experimental|MT-0814 High dose|
89242012|NCT03869684|Experimental|MT-0814 Low dose|MT-0814 plus placebo
89242013|NCT03869684|Placebo Comparator|Placebo|
89242014|NCT01058746|Active Comparator|pts undergoing pancreatic resection Restrictive arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from 8am to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. After randomization occurs, those patients randomized to the Restricted Arm will continue to receive Normosol or equivalent solution at 6ml/kg/operative hour.
89242015|NCT01058746|Active Comparator|pts undergoing pancreatic resection Liberal arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from midnight to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. Those patients randomized to the Liberal Arm will receive an additional Normosol bolus or equivalent solution equal to (another) 1.5 ml/kg/fasted hour IV (to bring the total to 2 ml/kg/fasted hour) plus an additional bolus of Normosol or equivalent solution 6ml/kg/operative hour to bring the hourly rate to 12ml/kg/operative hour with a maximum of 1000 ml/operative hour.
89242016|NCT00516074|Experimental|Exenatide Arm|This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
89242017|NCT00516074|Placebo Comparator|Placebo Arm|This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
89242018|NCT01054924||U.S. CRC screening population|
89242019|NCT01057654|Experimental|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
89242020|NCT01057654|Active Comparator|Pravastatin|Pravastatin 40 mg per day
89242021|NCT00515294|Experimental|1Caffeinated Alcoholic Beer|Caffeinated Alcoholic beer
89242022|NCT00515294|Active Comparator|2Non-Caffeinated Alcoholic Beer|Non-Caffeinated Alcoholic beer
89242023|NCT00515294|Active Comparator|3Caffeinated Non-Alcoholic Beer|Caffeinated Non-Alcoholic Beer
89242024|NCT00515294|Placebo Comparator|4Non-Caffeinated, Non-Alcoholic Beer|Non-Caffeinated, Non-Alcoholic Beer
89242025|NCT00345046|Active Comparator|Pred Forte 1%|Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
89242026|NCT00345046|Active Comparator|EconoPred Plus 1%|EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
89242027|NCT00345046|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
89242028|NCT01055002|Active Comparator|Artemether/lumefantrine tablets|Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
89242029|NCT01055002|Active Comparator|Atovaquone/Proguanil HCl tablets|Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8
89242030|NCT00515216|Experimental|Oxaliplatin/Leucovorin/5-FU|"Good risk patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks."
89242031|NCT00522626||Observational|Opioid exposed pregnancies
89242032|NCT00440193|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
89242033|NCT00440193|Active Comparator|Enoxaparin/VKA|Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
89242034|NCT00511472|Experimental|MK-0941|
89242035|NCT00511472|Placebo Comparator|Placebo|
89242036|NCT01033305|Placebo Comparator|Placebo|
89242037|NCT01033305|Experimental|CyCol™|
89242038|NCT01037049|No Intervention|Group 1|Patients who have surgery at 6 weeks after radiotherapy/chemoradiotherapy
89242039|NCT01037049|Experimental|Group 2|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
89242040|NCT00514904|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89242041|NCT00514904|Active Comparator|Mencevax ACWY Group|Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.
89242042|NCT00440115|Experimental|High intensity disease management|High intensity disease management, free nicotine replacement therapy or bupropion
89242043|NCT00440115|Experimental|Low intensity disease management|Low intensity disease management, free nicotine replacement therapy or bupropion
89242044|NCT00440115|Other|Comparison group|Comparison group, free nicotine replacement therapy or bupropion
89242045|NCT04384328|Experimental|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
89242046|NCT04384328|No Intervention|Standard Care|Standard follow-up within the RPSOF-ASNR network, without systematic speech therapy sessions.
89242047|NCT01037205|Active Comparator|DAS181 High Dose|DAS181 Dry Powder 10 mg qd x 3 days
89242048|NCT01037205|Active Comparator|DAS181 Low Dose|DAS181 Dry Powder 10 mg Day 1 Lactose Placebo Day 2 and Day 3
89242049|NCT01037205|Placebo Comparator|Lactose Placebo|Lactose (Respitose ML006 (DMV-Fonterra)) 1 capsule qd x 3 days
89242050|NCT00440037|Experimental|AMG 531|
89242051|NCT01037283|Other|Interpersonal and Social Rhythm Therapy|All participants receive eight sessions of Interpersonal and Social Rhythm Therapy.
89242052|NCT03198962||Groups A|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-negative participants will be actively offered to visit the clinic for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or STI services and encouraged to visit the clinic outside of the scheduled visits for these services whenever they feel needed. Adherence to PrEP, PEP, STI treatment will be evaluated in those who are prescribed these medications. Among HIV seroconverters, drug use patterns will be longitudinally monitored prior to and after HIV diagnosis. HIV seroconverters at month 6 or month 12 will be transferred to groups C, D dependent on drug use history.
89242053|NCT03198962||Groups C|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
89242054|NCT03198962||Group B|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
89242055|NCT03198962||Group D|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
89242056|NCT01033461|Experimental|calcium and probiotic|intervention
89242057|NCT01033461|Experimental|probiotic|intervention
89242058|NCT01033461|Placebo Comparator|placebo|placebo, no intervention
89242059|NCT01786785||Stroke Patients|Subjects between 2 and 17 years of age with a confirmed arterial ischemic stroke.
89242060|NCT01786785||Controls|Age and Gender Matched Controls
89242061|NCT01033539|Active Comparator|Placebo control|Placebo control without probiotics ATCC PTA 4659
89242062|NCT01033539|Active Comparator|ATCC PTA 4659 Low dose|
89242063|NCT01033539|Active Comparator|ATCC PTA 4659 high dose|
89242064|NCT01037439|Active Comparator|Conventional ASV|Current adaptive servoventilation therapy algorithm for non invasive ventilation treatment of Cheyne-Stokes Respiration.
89242065|NCT01037439|Experimental|Modified ASV|Modified adaptive servoventilation algorithm for improved treatment of nocturnal breathing disorders
89242066|NCT01033617|Placebo Comparator|Placebo|Saline solution with autologous plasma.
89242067|NCT01033617|Experimental|CD133+ stem cells|Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.
89242068|NCT02562963|Experimental|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment. Intervention: Biological: NKT cell
89242069|NCT02561559||Lung metastasis from soft-tissue sarcoma|Lung metastases from soft-tissue sarcoma
89242070|NCT03055611||Haemophilia A patients|Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
89242071|NCT03055611||Haemophilia B patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
89242072|NCT01030731|Experimental|Ceftobiprole (end-stage renal disease subjects).|Ceftobiprole 250mg single dose over 2 hours.
89242073|NCT01030731|Active Comparator|Ceftobiprole (healthy subjects)|Ceftobiprole 250 mg single dose over 2 hours.
89242074|NCT00417027|Active Comparator|2.5 mL bolused every 15 minutes|
89242075|NCT00417027|Active Comparator|5ml bolused every 30 minutes|
89242076|NCT00417027|Active Comparator|10ml bolused every 60 minutes|
89242077|NCT00416949|Experimental|Patient-specific 3D-RD Dosimetry|Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.
89242078|NCT03993483|Experimental|Higher Load|One arm and one leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
89242079|NCT03993483|Experimental|Lower Load|The other arm and leg were randomized (based on limb dominance) to perform unilateral biceps curls (arm) and knee extensions (leg) with relatively higher loads (80 % of their one-repetition maximum).
89242080|NCT00416715|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
89242081|NCT01037517|Active Comparator|Successful Mobilizers|Successful Mobilizers are defined as having a peripheral blood CD34 > 10X106/L.
89242082|NCT01037517|Experimental|Poor Mobilizers|Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood [CD34] ≤ 10 X106/L
89242083|NCT03928665||Control group|
89242084|NCT03928665||Sleep apnea using CEPAP|
89242085|NCT03928665||Sleep apnea not using CEPAP|
89242086|NCT03928665||Glaucoma control group|
89242087|NCT01323933|Experimental|AB0024|"The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK.~The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in <33% of patients enrolled from Part A."
89242088|NCT00406029|Experimental|Preladenant 1 mg BID|Participants received preladenant 1 mg twice daily (BID) during the 12-week treatment period.
89242089|NCT00406029|Experimental|Preladenant 2 mg BID|Participants received preladenant 2 mg BID during the 12-week treatment period.
89242090|NCT00406029|Experimental|Preladenant 5 mg BID|Participants received preladenant 5 mg BID during the 12-week treatment period.
89242091|NCT00406029|Experimental|Preladenant 10 mg BID|Participants received preladenant 10 mg BID during the 12-week treatment period.
89242092|NCT00406029|Placebo Comparator|Placebo BID|Participants received preladenant matching placebo BID during the 12-week treatment period.
89242093|NCT00514514|Active Comparator|CNI standard regimen|Myfortic, Sandimmun Optoral and corticosteroids
89242094|NCT00514514|Experimental|CNI free regimen|"CNI free regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids"
89242095|NCT00514514|Active Comparator|CNI low regimen|"CNI low regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids"
89242096|NCT00405639|Active Comparator|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
89242097|NCT00405639|Placebo Comparator|Placebo|Subjects randomized to this arm will receive self administered SQ placebo (normal saline) injections to match those of the study drug group. That is, first dose on Day 1, second dose 12 hours after the first dose, third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
89242098|NCT03993795|Experimental|A19010-W, B19010-F Use Group|Use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
89242099|NCT03993795|Experimental|B19010-F, A19010-W Use Group|Use of product B19010-F exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-W exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
89242100|NCT01030809|No Intervention|Usual Care practice|Patients managed according to usual care practices
89242101|NCT01030809|Active Comparator|Treatment Algorithm|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
89242102|NCT00439725|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 20 mg oral tablet once daily
89242103|NCT00439725|Placebo Comparator|Placebo|Participants were to receive matching placebo oral tablet once daily
89242104|NCT00521586|Other|1|arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
89242105|NCT00521586|Other|2|arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5
89242106|NCT00515502|Active Comparator|Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: umeclidinium bromide (UMEC) 250 micrograms (µg), UMEC 500 µg, Tiotropium 18 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
89242107|NCT00515502|Active Comparator|Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
89242108|NCT00515502|Active Comparator|Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242109|NCT00515502|Active Comparator|Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, placebo and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242110|NCT00515502|Active Comparator|Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242111|NCT00515502|Active Comparator|Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242112|NCT00515502|Active Comparator|Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, Tiotropium 18 µg, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242113|NCT00515502|Active Comparator|Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, placebo, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242114|NCT00515502|Active Comparator|Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
89242115|NCT00515502|Active Comparator|Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, placebo and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242116|NCT00515502|Active Comparator|Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242117|NCT00515502|Active Comparator|Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and Tiotropium 18 µg. Treatment periods were seperated by a washout period of at least 14 days.
89242118|NCT03997734|Experimental|Treatment A-AB001|Apply 1 patch of AB001 patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1. Subjects who received the AB001 patch in period 1 will then receive a single oral capsule of active ingredient on Day 20 in period 2.
89242119|NCT03997734|Experimental|Treatment B-AB001|Apply 2 patches of AB001 patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
89242120|NCT03997734|Active Comparator|Treatment C|Apply 1 patch of positive comparative patch on the lower back of the subjects on either side of the spine without occlusion for 48 hours on Day 1 and then one patch every two days from Days 8 to 20.
89242121|NCT03997734|Placebo Comparator|Treatment A-Placebo|Apply 1 patch of placebo patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1.
89242122|NCT03997734|Placebo Comparator|Treatment B-Placebo|Apply 2 patches of placebo patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.
89242123|NCT03997890|Experimental|Symfony group|The subjects who underwent cataract surgery with binocular implantation of either Symfony or Symfony toric IOLs
89242124|NCT03997344|Experimental|Nature hiking|Group hikes in a natural setting (e.g., park, wilderness area)
89242125|NCT03997344|Active Comparator|Urban hikes|Group hikes in a urban setting (e.g., downtown area)
89242126|NCT01010646|Experimental|GP1N IFN alfa-2bXL 27 MUI + Ribavirin|IFN alfa-2bXL 27 MUI, powder and solvent for solution injection
89242127|NCT01010646|Experimental|GP2N IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI, powder and solvent for solution injection
89242128|NCT01010646|Active Comparator|GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections
89242129|NCT00439647|Experimental|Zoledronic Acid|5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
89242130|NCT00439647|Placebo Comparator|Placebo|100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
89242131|NCT00515112|Experimental|A|Twenty subjects will receive testosterone gel
89242132|NCT00515112|Placebo Comparator|B|Twenty subjects will receive the placebo
89242133|NCT03034785|No Intervention|Group 1|Term
89242134|NCT03034785|No Intervention|Group 2|Preterm
89242135|NCT03034785|Experimental|Group 3|Term
89242136|NCT03034785|Experimental|Group 4|Preterm
89242137|NCT01030887|Active Comparator|Exercise Programme|This will consist of an 8-week exercise programme, performed twice per week.
89242138|NCT01030887|Placebo Comparator|Usual Care|Standard practice including opportunistic exercise advice and patients' self-directed physical activity
89242139|NCT03742557|Active Comparator|Ketamine|"Ketamine 50 MG/ML - at a dose of 0.5 mg/kg IV diluted in 100cc of saline solution 0.9% over 40 minutes.~The intervention will be done twice weekly for 8 weeks."
89242140|NCT03742557|Placebo Comparator|Placebo|Saline solution 0.9% over 40 minutes. The intervention will be done twice weekly for 2 weeks, and then patients will receive intervention with ketamine as described above in the Active Comparator.
89242141|NCT01324011|Experimental|Family-based intervention|Special intervention (20 weekly group-based sessions) to be compared with a delayed intervention control group.
89242142|NCT01324011|Other|Delayed intervention controls|The delayed intervention controls will continue with usual care (if patients with diabetes)and at the end of the experimental period (6 months), they will receive a 6-session weight loss intervention delivered over a 2 month period.
89242143|NCT03906279||Myopic participants|
89242144|NCT03906279||Emmetropic participants|
89242145|NCT03906279||Hyperopic participants|
89242146|NCT01324089|Active Comparator|Arm 1|Resveratrol 2.5 grams x 1 dose
89242147|NCT01324089|Experimental|Arm 2|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
89242148|NCT01324089|Other|Arm 3|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
89242149|NCT00404547|Active Comparator|Alvesco|Alvesco 320mcg / Alvesco 640mcg
89242150|NCT00404547|Active Comparator|Usual Care|
89242151|NCT01588977||All-Inside TightRope technique|
88804695|NCT00004162|Experimental|Dose group 2 - dose 2 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
89242152|NCT01588977||ACL reconstruction with TLS system|
88804696|NCT00004162|Experimental|Dose Group 3 - dose 3 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
89242153|NCT01588977||Hamstring Tendon Graft Reconstruction of the ACL|
89242154|NCT00515034|Experimental|001|Doripenem 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
89242155|NCT00515034|Active Comparator|002|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
89242156|NCT00515034|Experimental|003|Doripenem 1 gram infused over 4 hours at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
89242157|NCT00515034|Active Comparator|004|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
89242158|NCT01012518|Active Comparator|Conventional PCT|PCT performed without video guidance, as conventionally performed
89242159|NCT01012518|Experimental|Video-assisted PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
89242160|NCT00404235|Experimental|paclitaxel + carboplatin|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) IV over 30 minutes followed by carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected periodically to evaluate secreted protein acidic and rich in cysteine (SPARC) content of tumor tissue by immunohistochemistry and to explore the impact of therapy on immune homeostasis. Samples are also analyzed by immunoenzyme techniques for angiogenesis markers.~After completion of study treatment, patients are followed periodically for up to 2 years."
89242161|NCT00404079|Experimental|Glucosamine Sulphate|
89242162|NCT00404079|Placebo Comparator|Placebo|
89242163|NCT00403845|Experimental|Placebo-indacaterol 150μg-indacaterol 300μg-indacaterol 600μg|In treatment period, 1 patients received 2 placebo capsules; in treatment period 2, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4, patients received 2 indacaterol 300 μg capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89242164|NCT00403845|Experimental|Indacaterol 150μg-indacaterol 600μg-placebo-indacaterol 300μg|In treatment period 1, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 indacaterol 300 μg capsules; in treatment period 3, patients received 2 placebo capsules; and in treatment period 4, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89242165|NCT00403845|Experimental|Indacaterol 300μg-placebo-indacaterol 600μg-indacaterol 150μg|In treatment period 1, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 placebo capsules; in treatment period 3, patients received 2 indacaterol 300 μg capsules; and in treatment period 4, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89242166|NCT00403845|Experimental|Indacaterol 600μg-indacaterol 300μg-indacaterol 150μg-placebo|In treatment period 1, patients received 2 indacaterol 300 μg capsules; in treatment period 2, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4 patients received 2 placebo capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
89242167|NCT00509262|Experimental|Sitagliptin|Sitagliptin + Placebo for Glipizide
89242168|NCT00509262|Active Comparator|Glipizide|Glipizide + Placebo for Sitagliptin
89242169|NCT00607997|Experimental|All Study Patients|"Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15~Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8~Schedule C: 72 mg/m2 on Days 1 and 4, or~Schedule C: 90 mg/m2 on Days 1 and 4"
89242170|NCT00509106|Experimental|Ceftaroline fosamil for injection|Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
89242171|NCT00509106|Active Comparator|IV Ceftriaxone|Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).
89242172|NCT03997656|Experimental|MyDipp|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program. Each lesson will take 30 to 60 minutes to complete. The lesson will be considered complete if the participants clicked through all of the pages and answered multiple choice questions to indicate engagement and understanding.
89242173|NCT03997656|Other|Control|Participants in the control group (usual care) will receive standard health education from primary care providers in the clinic. In addition, they also will be provided with pamphlets and booklets about various health topics. They will be given a diary to record their weights, diet, physical activities and blood test result.
89242174|NCT00607919|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
89242175|NCT00607919|Placebo Comparator|Placebo|Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.
89242176|NCT00344968|Experimental|1|
89242177|NCT00344968|Experimental|2|
89242178|NCT00344968|Sham Comparator|3|
89242179|NCT02541461|Other|Non-Obese|Patients who underwent laparoscopic gastrectomy and with BMI < 25 kg/m2
89242180|NCT02541461|Other|Obese|Patients who underwent laparoscopic gastrectomy and with BMI ≥ 25 kg/m2
89242181|NCT00509028|Experimental|BUD - Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
89242182|NCT00509028|Active Comparator|CONV - Conventional Asthma Therapy|Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
89242183|NCT00893243||1Tears Again/Control|
89242184|NCT00893243||2Opticol/Control|
89242185|NCT00893243||3Optive/Control|
89242186|NCT00893243||4Tears Again/Opticol|
89242187|NCT00893243||5Tears Again/Optive|
89242188|NCT00893243||6Opticol/Optive|
89242189|NCT01055080|Placebo Comparator|Cow's milk formula|
89242190|NCT01055080|Active Comparator|Bovine insulin-free whey based formula|
89242191|NCT01055080|Active Comparator|Whey-based hydrolysed formula|
89242192|NCT00893321|Other|Inferior Oblique Muscle Recession and Myectomy|
89242193|NCT01012752|Active Comparator|modified allergen extract|
89242194|NCT01012752|Placebo Comparator|Placebo|
89242195|NCT00352846|Experimental|Vitamin D + Calcium Carbonate|Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
89242196|NCT00352846|Experimental|Vitamin D + Calcium Carbonate + Zoledronic Acid|Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m^2 intravenous at baseline and 6 months.
89242197|NCT00508872|Experimental|FOLFOX-B|FOLFOX-B: 5-Fluorouracil 400 mg/m^2 IV + Bevacizumab 5 mg/kg IV + Leucovorin 400 mg/m^2 IV + Oxaliplatin 85 mg/m^2 IV
89242198|NCT00508482|Experimental|deep needling group|Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
89242199|NCT00508482|Active Comparator|lactulose group|Lactulose Oral Solution was taken orally at the dose of 20~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
89242200|NCT00508482|Active Comparator|shallow needling group|Bilateral ST25, the same acupoints as deep needling group, were used. After skin disinfection, needles of the size of 0.30×25mm penetrated the skin uprightly for about 5~9mm into the fat layer without manipulation. The usage of EA apparatus and treatment course were the same as deep needling group.
89242201|NCT00344500|No Intervention|Usual Care|Usual Care
89242202|NCT00344500|Active Comparator|Lifestyle Balance|Behavioral Weight Loss Program
89242203|NCT00344032|Experimental|Cervarix|Subjects who received 3 doses of HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) (at 0, 1, 6 months).
89242204|NCT00344032|Placebo Comparator|Placebo|Subjects who received 3 doses of Placebo (at 0, 1, 6 months).
89242205|NCT01057732||primary hyperparathyroidism|patients with primary hyperparathyroidism
89242206|NCT01057732||controls|subjects without primary hyperparathyroidism
89242207|NCT00607373|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
89242208|NCT00607373|Placebo Comparator|Placebo|Participants received placebo as a subcutaneous injection once a week for 26 weeks.
89242209|NCT00508404|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.
89242210|NCT00888407|Experimental|HBV Screening|Small group educational session with HBV screening resources provided.
89242211|NCT00888407|Sham Comparator|Nutrition|Small group educational discussion, diet & nutrition resources provided.
89242212|NCT00352690|Other|Cohort 1 (first 12 eligible patients)|"Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
89242213|NCT00352690|Experimental|Cohort 2 (remaining patients)|"Paclitaxel poliglumex 175 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
89242214|NCT00888485|Experimental|Behavioral intervention|Group exposed to behavioral intervention program
89242215|NCT00888485|Active Comparator|Standard treatment|
89242216|NCT00895505|Active Comparator|oral anticoagulants|Experimental intervention: Extension of OAT in VTE patients showing high plasma levels of D-Dimer after end of routine secondary prophylaxis.
89242217|NCT00895505|No Intervention|2|Control: Withdrawal of OAT in VTE patients after end of routine secondary prophylaxis and receiving low molecular weight heparin in risk situations.
89242218|NCT03988738|Experimental|Intervention|Participants will receive messages regarding blood donation promotion and campaigns through social media once or twice a week for six months.
89242219|NCT03988738|Sham Comparator|Control|Participants will receive a message regarding blood donation at the beginning of the study through social media. After four months they will receive another message including information about upcoming blood donation campaigns.
89242220|NCT03268824||Children / adolescents with drug-resistant focal epilepsy|
89242221|NCT03268824||Children / adolescents without drug-resistant focal epilepsy|
89242222|NCT03249012|Experimental|Empiric calcium and calcitriol repletion group|All patients in this group will receive post-operative calcium carbonate and calcitriol.
89242223|NCT03249012|Experimental|PTH based repletion group|Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
89242224|NCT01565460||pancreatic/biliary strictures|Sample Collection: Patients with pancreatic/biliary stricture undergoing intervention will have samples of brushings and bile taken during the procedure.
89242225|NCT03194880||HIV testing|At each visit, the DIC HIV testing algorithm will be performed, and additionally, HIV testing by the Anonymous Clinic Algorithm, the Alere™ HIV Combo and the Alere™ q HIV-1/2 Detect. The latter two tests will be performed at the DICs. In case of an invalid result for the Alere™ HIV Combo or the Alere™ q HIV-1/2 Detect, the test will be repeated. If the repeated test is invalid after the second attempt, it is recorded as 'invalid result'.
89242226|NCT01010724|Experimental|bIAP|Dosage 200 IU bIAP/kg: 1000 IU prior to anaesthesia administered as a bolus followed by intravenous continuous infusion of 5,6 IU/kg/hr for approximately 36 hours.
89242227|NCT01010724|Placebo Comparator|Placebo|
89242228|NCT00609245|Experimental|Placebo then Valproic Acid (VPA)|all patients will have placebo on day 1 and VPA infusion on day 2
89242229|NCT01010802|Experimental|Erythropoietin|"There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin."
89242230|NCT04036253|Active Comparator|Eprex/Erypo|"Receive EPREX/ ERYPO® subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
89242231|NCT04036253|Experimental|Hemax PFS|"receive HEMAX® PFS subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.~There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks."
89242232|NCT00343642|Experimental|Active Fructo-oligosaccharide|"Subjects received an active fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.~The fructo-oligosaccharide supplement was administered orally in a powder form two teaspoons daily."
89242233|NCT00343642|Placebo Comparator|Placebo Fructo-oligosaccharide|Subjects received a placebo fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.
89242234|NCT00343642|Active Comparator|Dietary Therapy|Subjects received a placebo fructo-oligosaccharide supplement and a restrictive anti-inflammatory diet developed by the research team.
89242235|NCT00893555|Active Comparator|control|Voriconazole dosing based on SPC
89242236|NCT00893555|Experimental|TDM|Voriconazole serum concentration based dosing
89242237|NCT02541071|Experimental|Yohimbine and Stress Film|Administration of 10mg yohimbine before the trauma film.
89242238|NCT02541071|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
89242239|NCT02541071|Experimental|Clonidine and Stress Film|Administration of 0.15mg clonidine before the trauma film.
89242240|NCT01058824|Active Comparator|Lincomycin - Active Comparative - Hard Gelatin Capsule|
89242241|NCT01058824|Experimental|Lincomycin - Study Drug - Hard Gelatin Capsule|
89242242|NCT01325038|Active Comparator|extra protein supplement|isometric training with addition of extra protein
89242243|NCT01325038|Active Comparator|extra food supplement|isometric exercise with addition of extra food and calories: one fast food meal/day
89242244|NCT03988660||Healthy controls|Healthy individuals
89242245|NCT03988660||Histologically confirmed appendicitis|Patients who have diagnosis of appendicitis on histology
89242246|NCT03988660||Histologically normal appendix|Patients who have diagnosis of a normal appendix on histology
89242247|NCT03988660||Alternative diagnosis group|Patients who diagnosed with a condition other than appendicitis
89242248|NCT03986320|Experimental|Keeogo™ Dermoskeleton|Keeogo™ Dermoskeleton is a low-profile, assistive exoskeleton (or 'dermoskeleton') that orthotically fits to the lower limbs. Keeogo™ is worn on the user's lower body using a belt and contact areas attached around the thighs and calves.
89242249|NCT03986398|Experimental|Prophylactic efficacy of Urell®|Prophylactic efficacy of Urell® on urinary tract infections in patients with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty
89242250|NCT03988348|Experimental|study group|infraumbilical transverse incision will be done
89242251|NCT03988348|Active Comparator|control group|Direct intraumbilical transverse incision will be done
89242252|NCT03988582|Experimental|HCT (hematopoietic cell transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
89242253|NCT03988582|Experimental|SOT (solid organ transplant) recipients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
89242254|NCT03988582|Experimental|Other immune competent or immune compromised patients|EBV-CTLs will be administered in cycles lasting 5 weeks (35 days). During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period. Each dose, or the cumulative three doses can be within 20% of the targeted dose.Treatment will continue until maximal response, unacceptable toxicity, or failure of EBV-CTLs (progression of disease after three cycles of cells or 6 months of therapy without response).
89242255|NCT01058902|Placebo Comparator|Negative control|Not on aspirin pre operatively, but refuse to enter trial or have a contraindication to aspirin
89242256|NCT01058902|Experimental|Aspirin treatment|group randomised to aspirin
89242257|NCT01058902|Experimental|No aspirin treatment|Randomised to no aspirin
89242258|NCT01058902|Active Comparator|Positive control|Already on aspirin. just observational limb
89242259|NCT01055158|Experimental|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes.
89242260|NCT01055158|Active Comparator|Control|Enhanced Usual Care
89242261|NCT01055236|Placebo Comparator|hydroxyzine|
89242262|NCT01055236|Placebo Comparator|placebo|starch tablet
89242263|NCT04036955|Experimental|intervention group|"The INFOSA-DEM programme consists of five, 90-minute informational/training sessions delivered consecutively over one week. Morning or afternoon groups are offered depending on the caregiver's availability. Programme content was developed for use in small groups of 6-8 caregivers. Topics covered in the sessions include basic concepts in dementia and specific issues such as nutrition, rest, medication, physical and cognitive changes, management of behavioural symptoms, affective problems in the patient and informal caregiver, verbal and non-verbal communication techniques, caregiver self-care and information on available resources and community services.~The sessions are conducted using audio-visual material to facilitate understanding of the content and to encourage active participation among caregivers when talking about their experiences."
89242264|NCT04036955|No Intervention|usual care|Caregivers in the Group control received usual care in the centres where the follow-up was carried out. This consisted of annual or quarterly consultations with a health professional (GP, geriatrician or neurologist) and, depending on the health centre, a nurse and social worker.Currently, there is no homogenous protocol for all care centres for the patient with high levels of cognitive impairment and dependency.
89242265|NCT00895973|Experimental|Stirrups delivery|Mom will be assigned to deliver with legs positioned in stirrups
89242266|NCT00895973|Experimental|Bed delivery|Mom will be assigned to deliver with the legs positioned in bed in the supine position
89242267|NCT00896129||Study population|
89242268|NCT00606281|Experimental|1|
89242269|NCT00606281|Placebo Comparator|2|
89242270|NCT00506142|Experimental|Cohort 1|Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
89242271|NCT00506142|Experimental|Cohort 2|Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
89242272|NCT00891605|Experimental|Paclitaxel and ABT-263|
89242273|NCT00891683|Placebo Comparator|Placebo|4 Capsules of Placebo
89242274|NCT00891683|Active Comparator|100 mg|One 100 mg capsule and 3 placebo capsules of AEG33773
89242275|NCT00891683|Active Comparator|200 mg|Two 100 mg capsules and two placebo capsules
89242276|NCT00891683|Active Comparator|400 mg|Four 100 mg AEG33773 capsules
89242277|NCT00893711|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops of a commercially available oil suspension, 30 min before feeding, once a day for 30 days.
89242278|NCT00893711|Placebo Comparator|Placebo|Placebo is administered in V drops once a day for 30 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
89242279|NCT00893711|Active Comparator|L.reuteri + vit D|L. reuteri DSM 17938 (10^8 CFU) plus vitamin D3 (400 UI) five drops/day for 3 months
89242280|NCT00893711|Placebo Comparator|Vit D Placebo|vitamin D3 (400 UI) five drops/day for 3 months
89242281|NCT00514020|Experimental|Treatment|
89242282|NCT03560531|Experimental|ZN-c5 monotherapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 as well as expansion cohorts and a Phase 2 cohort.
89242283|NCT03560531|Experimental|ZN-c5 + palbociclib combination therapy|Dose escalation cohorts are planned to determine maximum tolerated dose(MTD) or recommended phase 2 dose (RP2D) of ZN-c5 in combination with palbociclib as well as a Phase 2 cohort.
89242284|NCT00513708|No Intervention|Treatment As Usual (TAU)|"Treatment as Usual (TAU): Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during medically managed inpatient detoxification."
89242285|NCT00513708|Experimental|Motivational Enhancement Therapy (MET)|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Motivational Enhancement Therapy (MET) session delivered by a trained professional."
89242286|NCT00513708|Experimental|Peer-delivered Twelve Step Facilitation|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Peer-delivered Twelve Step Facilitation (P-TSF)session delivered by individuals from a common self-help program."
89242287|NCT00896207|Experimental|Arm I|Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories) meal, and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
89242288|NCT00896207|Experimental|Arm II|Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
89242289|NCT00896207|Experimental|Arm III|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.
89242290|NCT00896207|Experimental|Arm IV|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
89242291|NCT00896207|Experimental|Arm V|Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
89242292|NCT00896207|Experimental|Arm VI|Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.
89242293|NCT00896285|Active Comparator|1|
89242294|NCT00896285|Active Comparator|2|
89242295|NCT00896285|Active Comparator|3|
89242296|NCT00896285|Active Comparator|4|
89242297|NCT00891761|Active Comparator|Active Comparator|Patients receive IV casopitant (active), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
89242298|NCT00891761|Placebo Comparator|Placebo Comparator|Patients receive IV casopitant (placebo), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
89242299|NCT01012830|Experimental|Huperzine A|200 micrograms (mcg) of HuperzineA taken twice daily.
89242300|NCT04036175|Other|Group 1|Standard oxygen - High-Flow Nasal Oxygen - Non-invasive ventilation - Standard Oxygen (20 minutes for each condition)
89242301|NCT04036175|Other|Group 2|Standard oxygen - Non-invasive ventilation - High-Flow Nasal Oxygen - Standard Oxygen (20 minutes for each condition)
89242302|NCT02540603|Experimental|Full Face Mask|F&P Jupiter Full Face Mask with Headgear
89242303|NCT00513474|Experimental|Rasburicase Group|Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.
89242304|NCT00513474|Other|Control Group|Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.
89242305|NCT00891917|Placebo Comparator|Syrup|identical placebo formulation to be administered twice a day.
89242306|NCT00891917|Active Comparator|Ubiquinol-10 Syrup|CoQ (LiQ-NOL®) 10.0 mg/kg/d to be administered twice a day
89242307|NCT00893867|Experimental|DP-b99|
89242308|NCT00893867|Placebo Comparator|Mannitol|
89242309|NCT01010958|Experimental|Valproate|Valproic Acid taken orally, daily to reach serum levels between 50 to 100 µg/mL.
89242310|NCT00896597|Experimental|NRL972|A single dose of 2 mg NRL972 will be administered on four occasions over a period of up to 6 weeks.
89242311|NCT00505752|Experimental|AS900672-Enriched 50 mcg|
89242312|NCT00505752|Experimental|AS900672-Enriched 100 mcg|
89242313|NCT00505752|Experimental|AS900672-Enriched 150 mcg|
89242314|NCT00505752|Active Comparator|Follitropin alfa 150 IU|
89242315|NCT01011036|Other|1|
89242316|NCT01011036|Other|2|
89242317|NCT01011036|Other|3|
89242318|NCT03601637|Experimental|Part A: LUM/IVA|Participants weighing 7 to less than (<)10 kilograms (kg) at screening received LUM 75 milligrams (mg)/IVA 94 mg fixed-dose combination (FDC) every 12 hours (q12h) and those weighing 10 to <14 kg at screening received LUM 100 mg/IVA 125 mg q12h for 15 days. Participants weighing greater than or equal to (>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 15 days.
89242319|NCT03601637|Experimental|Part B: LUM/IVA|Participants weighing 7 to <9 kg at screening received LUM 75 mg/IVA 94 mg FDC q12h and those weighing 9 to <14 kg received LUM 100 mg/IVA 125 mg q12h for 24 weeks. Participants weighing >=14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 24 weeks. Doses were adjusted upwards for changes in weight.
89242320|NCT00896675||patients treated with EGFR inhibitors and/or VEGF inhibitor|
89242321|NCT00896675||NOT treated with EGFR inhibitors and/or VEGF inhibitor|
89242322|NCT00893945|Experimental|DC/AAT vaccine|Intradermal injection of 3 Autologous dendritic cell vaccines (DC/AAT, DC/AAT-flu, DC/KLH) that have been co-cultured with autologous apoptotic tumor specimens.
89242323|NCT00894023|Experimental|Abciximab|IC bolus of abciximab
89242324|NCT00894023|Active Comparator|IV Abciximab|IV abciximab + infusion
89242325|NCT00892073|Experimental|Diazoxide and Metformin Therapy|
89242326|NCT00894101|Experimental|[F-18] FLT and FDG|
89242327|NCT00896753||patients with metastatic colon cancer|
89242328|NCT00896831|Active Comparator|L-ornithine-L-aspartate|5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days
89242329|NCT00896831|Placebo Comparator|placebo|5 g (1 sachet) of placebo comparator three times per day for 60 days
89242330|NCT04017689||Verbal Information Group|Verbal Information
89242331|NCT04017689||Photo Group|Information by photos
89242332|NCT04017689||Video Group|Information by video
89242333|NCT02541227||Cerebrolysin group|Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
89242334|NCT02541227||Control group|Patients who are not treated with Cerebrolysin; treatment follows local clinical practice
89242335|NCT00896987|Experimental|1|lamotrigine
89242336|NCT00896987|Active Comparator|2|carbamazepine
89242337|NCT04035863|Experimental|PBM + physiotherapy exercises|"will be submitted to active PBM and physiotherapeutic exercises.~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated at the lesion level with a wavelength of 808 nm, 25 J per point for 12 sessions. The same laser device (Laser DMC Therapy EC).~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
89242338|NCT04035863|Sham Comparator|SHAM PBM + physiotherapy exercises|"will be submitted to sham PBM and physiotherapeutic exercises.~For irradiation sham, the individuals will be positioned comfortably in lateral decubitus on the examining table. The same laser device (Laser DMC Therapy EC) will be used but the device will emit sound but not light.~Physical therapy will occur twice per week after PBM for six weeks. Static balance exercises will be performed with the feet together and tandem on a variety of different surfaces (hard surface, foam rubber and carpets with different textures) and sensory inputs (eyes open and closed). Dynamic balance exercises will involve walking forward and backward on firm and foam surfaces and circumventing obstacles. Muscle strengthening exercises, squatting and changing postural positions will also be performed. All activities will be in the form of play to maintain the children's interest"
89242339|NCT00343252|Experimental|Teriparatide|Teriparatide 20 micrograms (ug)/day, subcutaneous, 18 months plus once weekly oral placebo
89242340|NCT00343252|Active Comparator|Risedronate|Risedronate 35 milligrams (mg)/once weekly, oral, 18 months plus daily subcutaneous injection placebo
89242341|NCT00892229|Active Comparator|Buccal Misoprostol|Group one: 50 patients with first trimester missed abortion received buccal misoprostol
89242342|NCT00892229|Active Comparator|Vaginal Misoprostol|Group two: 5 patients received vaginal misoprostol
89242343|NCT00892229|Active Comparator|Buccal and Vaginal Misoprostol|"50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects.~Each group was randomly allocated (1,3,5,... for the buccal group & 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol."
89242344|NCT00894335||1|Pheochromocytoma
89242345|NCT00894335||2|Conn-Syndrome
89242346|NCT00894335||3|Cushing disease
89242347|NCT00894335||4|Metastasis
89242348|NCT00894335||5|Non-functional tumor
89242349|NCT00897221|Experimental|Dose 1|Deferiprone oral solution 20 mg/kg/day
89242350|NCT00897221|Experimental|Dose 2|Deferiprone oral solution 40 mg/kg/day
89242351|NCT02540525|Experimental|Single incision mini-sling|Experimental group: surgery to treat stress urinary incontinence with the Ophira mini sling systemt®
89242352|NCT02540525|Active Comparator|Transobturator sling|Control group: surgery to treat stress urinary incontinence with the Unitape T Plus®.
89242353|NCT00342628|Experimental|Vi-rEPA plus DTP|Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months
89242354|NCT00342628|Active Comparator|Hib-TT plus DTP|Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months
89242355|NCT00342628|Active Comparator|EPI|DTP at 2,4 and 6 months
89242356|NCT00897377|Experimental|Total resection with early radiation|Total resected LGGs treated with early radiation
89242357|NCT00897377|No Intervention|Total resection without radiation|Total resected LGGs treated without radiation
89242358|NCT00897377|Experimental|Residual LGGs with radiation|Residual LGGs treated with early radiation
89242359|NCT00897377|Experimental|Residual LGGs with chemo|Residual LGGS treated with temozolomide
89242360|NCT00505284|Placebo Comparator|Placebo|
89242361|NCT00505284|Active Comparator|Perampanel 2mg|
89242362|NCT00505284|Active Comparator|Perampanel 4mg|
89242363|NCT00505284|Active Comparator|Perampanel 6mg|
89242364|NCT00505284|Active Comparator|Perampanel 8mg|
89242365|NCT00894569|Active Comparator|A|6 cycles of carboplatin/paclitaxel
89242366|NCT00894569|Experimental|B|carboplatin/paclitaxel plus cetuximab until disease progression
89242367|NCT00337168|Experimental|Induc, ReInduc, Consol, clofarabine, cytarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
89242368|NCT00892385|Experimental|Non-CNS Disease|A traditional 3 + 3 dose escalation design will be implemented. Successive cohorts of participants (3 participants/cohort) will be entered sequentially to each dose level. If 0/3 participants at a dose level experience dose limiting toxicity (DLT) new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 2 or more experience DLT in the first cycle, no further participants are started at that dose and the MTD is the highest dose level in which <2 (of 6) participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if a DLT has not been observed.
89242369|NCT00892385|Experimental|CNS Disease|A traditional 3 + 3 dose escalation design with successive cohorts of 3 participants will be entered sequentially to each dose level. If 0/3 participants experience DLT, new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 1/3 participants experience a non-CNS DLT in Cohort B dose level 6, dose escalation will continue to dose level 7, as 3 subjects have already been treated in Cohort A dose level 6 and 7 subjects in Cohort A dose level 7, none of whom experienced non-CNS toxicities. If 2 or more experience DLT in cycle 1, no more participants are started at that dose and the MTD is the highest dose where <2/6 participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if no DLT has been observed.
89242370|NCT01011114|Active Comparator|Cincalcet|cinacalcet will be titrated as needed to achieve serum phosphorus of > 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mg/l.
89242371|NCT01011114|Placebo Comparator|Control|"subjects will receive placebo pill titrated as needed to achieve phosphorus > 2.5 mg/dl.~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mEq/l."
89242372|NCT01011192||ke0 of 0.26 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 0.26 min-1 (Asena PK® - Cardinal Health)
89242373|NCT01011192||ke0 of 1.21 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 1.21 min-1 (Primea Orchestra® - Fresenius-Kabi basis)
89242374|NCT00606905|Active Comparator|1|IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution
89242375|NCT00606905|Placebo Comparator|2|normal saline
89242376|NCT01055392|Experimental|Lithium|Patients received low doses of lithium salts (from 150 mg to 450 mg of lithium salts daily) to achieve sub-therapeutic lithium levels (target serum lithium level of 0,25 - 0,5 mEq/L). Lithium doses were administered twice a day. Lithium doses were titrated to achieve the target serum lithium levels within the first two weeks after study recruitment. After achieving the target serum lithium level, lithium salts doses remained stable until the end of the study.
89242377|NCT01055392|Placebo Comparator|Placebo|Identical placebo tablets were administered twice-a-day for two years.
89242378|NCT03063762|Experimental|Escalation Part (Arm A): Atezolizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has complete response (CR), treatment may be discontinued and reintroduced if progressive disease (PD), for a maximum duration of 24 months.
89242379|NCT03063762|Experimental|Escalation Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab and bevacizumab until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
89242380|NCT03063762|Experimental|Extension Part (Arm A): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
89242381|NCT03063762|Experimental|Extension Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
89242382|NCT03063762|Experimental|Extension Part (Arm C): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
89242383|NCT03063762|Experimental|Extension Part (Arm D): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: Arm D is closed for future enrollment"
89242384|NCT03985228|Experimental|Fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks.
89242385|NCT03985228|Placebo Comparator|Placebo milk|The subjects assumed daily 250 ml of placebo milk for 12 weeks.
89242386|NCT01058980|Active Comparator|Dormant PV conduction|"After PVI, dormant conduction will be evaluated using intravenous adenosine. If dormant conduction is present, the patients will be randomized to two parallel groups:~Group 1: No additional ablation~Group 2: Additional ablation until elimination of dormant conduction."
89242387|NCT01058980|Active Comparator|No dormant PV conduction|If no dormant conduction is documented, patients will be selected in a random fashion to be included in a registry (follow-up as planned for group 1 and 2 above). The registry group will allow for further assessment of the role of dormant conduction as a predictor of AF recurrence by comparing the success rate after ablation in patients without dormant conduction with those of Group 1 and 2.
89242388|NCT00894725|Experimental|LPS|laparoscopic left colonic resection
89242389|NCT00894725|Active Comparator|Open|open left colonic resection
89242390|NCT05278637|Active Comparator|Aspirin 81mg/day, Aspirin 325mg/day, Aspirin washout, Ticagrelor 90mg BID|
89242391|NCT05278637|Active Comparator|Aspirin 325mg/day, Aspirin 81mg/day, Aspirin washout, Ticagrelor 90mg BID|
89242392|NCT05278637|Active Comparator|Ticagrelor 90mg BID|
89242393|NCT00900965|Active Comparator|Electroacupuncture treatment|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
89242394|NCT00900965|Sham Comparator|Sham acupunture treatment|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
89242395|NCT00901043|Experimental|Walnut supplementation|Eight weeks with walnut supplementation to an ad lib diet
89242396|NCT00901043|Active Comparator|Ad lib diet|Eight weeks ad lib diet without walnut supplementation
89242397|NCT00901121|Experimental|BoneCeramic|Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).
89242398|NCT00901121|Active Comparator|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
89242399|NCT04017377|Experimental|Chemotherapy+ Radiation therapy|"Chemotherapy: Patients firstly receive an escalating dose of weekly Nab-paclitaxel starting at 10 mg/m^2 up to 70 mg/m^2, Patients secondly receive weekly cisplatin (40 mg/m^2). Treatment repeats every week until the disease recurrence or unacceptable toxicity, death or begin a novel therapeutic. Concurrent chemotherapy is a weekly regimen during radiotherapy. Patients will complete at least 4 cycles of concurrent chemoradiotherapy, until the maximal tolerated dose (MTD) appeared.~Radiation therapy: Patients also receive pelvic radiation therapy once daily (Monday-Friday) for a total of 28 fractions and intracavitary brachytherapy twice a week for a total 5 fractions. Complete radiotherapy within 55 days."
89242400|NCT02539901||12-30 months-old deaf children|Children with deafness of bilateral deep perception had : Evaluation of the detection of non-linguistic sounds, Early Social Communication Scale (ECSP) and psychomotor infancy development scale or Lézine Brunet-Revised scale
89242401|NCT02539901||6-9 years-old deaf children|"Free hearing test categorization and NEPSY (two domains: memory and learning and attention and executive functions) in 6-9 years-old deaf child cohort with deafness of bilateral deep perception and carrying a cochlear implant"
89242402|NCT02539901||12-30 months-old normal hearing children|Evaluation of the detection of non-linguistic sounds in 12-30 months-old normal hearing child cohort
89242403|NCT02539901||6-9 years-old normal hearing children|'Free hearing test categorization' in 6-9 years-old normal hearing child cohort
89242404|NCT00894881||1 group|patients before colonoscopy
89242405|NCT00901277|No Intervention|Control|Usual Care
89242406|NCT00901277|Experimental|Web Intervention|Web-based: interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
89242407|NCT00901277|Experimental|Nurse Intervention|Nurse: an interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
89242408|NCT04035785|Experimental|Kangfu anti-inflammatory suppository|"Kangfu Xiaoyan Suppository was used for 21 days, while levofloxacin + metronidazole for 10 days, levofloxacin + metronidazole for 4 days.~One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity.~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
89242409|NCT04035785|Placebo Comparator|antibiotics alone group|"One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gram-negative bacteria. Bacterial activity.~Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc."
89242410|NCT00898079||Observational|Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
89242411|NCT04035707|Experimental|anaesthesia with rocuronium|rocuronium is used during anaesthesia
89242412|NCT04035707|Experimental|anaesthesia without rocuronium|during anaesthesia rocuronium is not used
89242413|NCT00901433||A|Usability study of the Personal Wheezometer
89242414|NCT02539745||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
89242415|NCT02539745||randomly age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
89242416|NCT00894959|Experimental|1|Heparin Sodium Blausiegel 1
89242417|NCT00894959|Experimental|Active Comparator|heparin sodium - APP 5.000 USP
89242418|NCT04035395|Experimental|Intervention|Participants randomized to the intervention group will receive the SyV 2.0 program, which in addition to standard diabetes management services of SyV 1.0 services, could include MTM services, care coordination by a team of behavioral health care providers, and/or referrals to community-based lifestyle programs, as determined by their tailored care plan. The participant will be seen by evaluation staff to complete baseline assessment for the study. Then, an individualized care plan will be developed by SyV 1.0 interdisciplinary staff and reviewed by the chronic care case management team. The care plan will include information on additional services provided by UTHealth such as, but not limited to, behavioral health services, or pharmacy services. Each participant will receive an individualized care plan and when applicable, referrals to community-based programs. Evaluation staff and CHWs will make follow-up appointments for the participant depending on their care plan.
89242419|NCT04035395|No Intervention|Control|Participants randomized to the usual care group will receive the SyV 1.0 program which includes community based program referrals (excluding intervention programs) and home-based visits from CHWs. These participants will also receive the standard follow-up from UTHealth staff such as a phone call, an information session as per their treatment plan, and /or a onetime mailing of information about the importance of following their treatment plan. Before implementation begins, additional details about standard care will be ascertained from partner organizations to better understand how these differ from the treatment conditions of the intervention group. Once the participant completes 12 months in the study, 2.0 services will be initiated.
89242420|NCT00901589|Active Comparator|Premenopausal women-fishoil|
89242421|NCT00901589|Placebo Comparator|Premenopausal-placebo|
89242422|NCT00901589|Active Comparator|Postmenopausal women-fishoil|
89242423|NCT00901589|Placebo Comparator|Postmenopausal-placebo|
89242424|NCT04035083|Experimental|Laser activated irrigation|Laser activated irrigation of sodium hypochlorite using a 980 nm diode laser device
89242425|NCT04035083|Active Comparator|Passive ultrasonic irrigation|passive ultrasonic irrigation of sodium hypochlorite using an ultrasonic laser device
89242426|NCT00895115|Sham Comparator|Arm I|Patients receive no supplementation.
89242427|NCT00895115|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 1 week.
89242428|NCT00895115|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 2 weeks.
89242429|NCT02540759|Placebo Comparator|High oleic sunflower oil (HOSO)|10 ml HOSO/day in a single dose, 28 days
89242430|NCT02540759|Experimental|High dose Buglossoides oil|10 ml Buglossoides oil/day in a single dose, 28 days
89242431|NCT02540759|Experimental|Medium dose Buglossoides oil|6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
89242432|NCT02540759|Experimental|Low dose Buglossoides oil|3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
89242433|NCT00901745|Experimental|Infusion of apelin|Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
89242434|NCT00901745|Active Comparator|Sodium nitroprusside infusion|Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
89242435|NCT02540837|Experimental|Bupivacaine|Obturator nerve block
89242436|NCT02540837|Placebo Comparator|Saline|Saline is injected as a placebo
89242437|NCT00898391||Ancillary-Correlative|Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
89242438|NCT00901823|Experimental|Sequence 1|Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
89242439|NCT00901823|Experimental|Sequence 2|Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
89242440|NCT00606593|Experimental|ABECD|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242441|NCT00606593|Experimental|BCADE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242442|NCT00606593|Experimental|CDBEA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242443|NCT00606593|Experimental|DECAB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242444|NCT00606593|Experimental|EADBC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242445|NCT00606593|Experimental|DCEBA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242446|NCT00606593|Experimental|EDACB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242447|NCT00606593|Experimental|AEBDC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242448|NCT00606593|Experimental|BACED|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242449|NCT00606593|Experimental|CBDAE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
89242450|NCT00902057|Active Comparator|desmopressin 1.5|
89242451|NCT00902057|Active Comparator|desmopressin 3|
89242452|NCT00902057|Active Comparator|desmopressin 15|
89242453|NCT00902057|Placebo Comparator|placebo|
89242454|NCT00895349|Experimental|1|CT Abdomen and Pelvis + whole body PET-CT
89242455|NCT00895349|Active Comparator|2|CT Abdomen and Pelvis
89242456|NCT00898547||Group 1|Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
89242457|NCT04035941|Experimental|Feasibility|The cycle training intervention group
89242458|NCT00902135||Group 1|
89242459|NCT00902135||Group 2|
89242460|NCT00902135||Group 3|
89242461|NCT00895427||1|Male ages 45-54, without diabetes, CAC score from 0 to >1000
89242462|NCT00895427||2|Male ages 55-64, without diabetes, CAC score from 0 to >1000
89242463|NCT00895427||3|Male ages 65+, without diabetes, CAC score from 0 to >1000
89242464|NCT00895427||4|Male ages 45-54, with diabetes and CAC score from 0 to >1000
89242465|NCT00895427||5|Male ages 55-64, with diabetes, CAC score from 0 to >1000
89242466|NCT00895427||6|Male ages 65+, with diabetes, CAC score from 0 to >1000
89242467|NCT00895427||7|Female ages 50-59, without diabetes, CAC score from 0 to >1000
89242468|NCT00895427||8|Females ages 60-69, without diabetes and CAC score from 0 to >1000
89242469|NCT00895427||9|Females ages 70 +, without diabetes, CAC score from 0 to >1000
89242470|NCT00895427||10|Female ages 50- 59, with diabetes, CAC score from 0 to >1000
89242471|NCT00895427||11|Female ages 60-69, with diabetes, CAC score from 0 to >1000
89242472|NCT00895427||12|Female age 70+, with diabetes, CAC score from 0 to >1000
89242473|NCT02539589|Experimental|Becoming a Responsible Teen (BART)|Becoming a Responsible Teen (BART) is the treatment condition. BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk.
89242474|NCT02539589|Active Comparator|Healthy Living|Healthy Living is the control counterfactual condition. It is a knowledge-based intervention that aims to impact nutrition, healthy eating, body image, and exercise.
89242475|NCT00902213|No Intervention|Minimal movement|Minimal movement group with usual care non-intervention.
89242476|NCT00902213|Active Comparator|Physical Therapy|
89242477|NCT02540369||BAY86-5321- with wAMD|Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
89242478|NCT02540369||BAY86-5321 - with DME|Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients
89242479|NCT00902369|Experimental|AK106-001616|
89242480|NCT00902369|Placebo Comparator|Placebo|Part1: AK106-001616 and Placebo
89242481|NCT00902369|Active Comparator|Active comparator|Part2: AK106-001616 and Active comparator
89242482|NCT02540135|Experimental|Arm A|Flourescein plus intraoperative MRI
89242483|NCT02540135|Active Comparator|Arm B|intraoperative MRI alone
89242484|NCT00905879||Group 1|
89242485|NCT02539433|Experimental|F-18-F-DOPA i.v.|F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
89242486|NCT00605267|Active Comparator|1|Tamoxifen
89242487|NCT00605267|Experimental|2|Anastrazole (Arimidex)
89242488|NCT00898781||Metastatic Breast Cancer|
89242489|NCT00898781||Metastatic Ovarian Cancer|
89242490|NCT00898781||Metastatic Pancreatic Cancer|
89242491|NCT00898781||Metastatic Colon Cancer|
89242492|NCT00898781||Stage 3 Ovarian Cancer|
89242493|NCT00898781||Locally Advanced Pancreatic Cancer|
89242494|NCT02539355|Active Comparator|Diet A|Standard Healthy Diet (Diet A)
89242495|NCT02539355|Experimental|Diet B|Alternative Test Diet (Diet B)
89242496|NCT00902525|Experimental|90Y-Ibritumomab Tiuxetan double dose|90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3
89242497|NCT00898859||1|Healthy, non-smoking
89242498|NCT00898859||2|healthy, ex-smoking
89242499|NCT00898859||3|healthy, current-smokers
89242500|NCT00898859||4|COPD, ex-smokers
89242501|NCT00898859||5|COPD, smokers
89242502|NCT00902603||1|Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.
89242503|NCT00902681|Other|Reference|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Zwickau
89242504|NCT00902681|Other|Test|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Vega Baja (Test)
89242505|NCT00906113|Experimental|Intra-arterial melphalan|The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma
89242506|NCT00906191|Experimental|1|Single oral dose
89242507|NCT00902759|No Intervention|Usual Care Group|"Participants randomized to the usual care group will be encouraged to return to their usual or pre-surgical levels of activity. Usual care of post-surgical PC and peri-ampullary patients typically includes encouragement to walk and be active as they can be by the surgeons, surgical nurses and the nurse practitioners. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry. The usual care group will perform a baseline walk. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry nor will they will a telephone call every month. Repeat questionnaires will be performed at 6 months."
89242508|NCT00902759|Experimental|Walking Program|Participants in the intervention arm will participate in a walking program consisting of a 6 week graduated walking program. There are three phases to the walking program, Phase 1 is Warm-up, Phase 2 is Brisk Walking and Phase 3 is Cool Down. Phase 1 is the same for all 6 weeks, and consists of a slow 5 minute walk. In Months 1 and 2, Phase 2 is a 10 minute brisk walk. In Months 3 and 4, Phase 2 is a 20 minute brisk walk. In Months 5 and 6, Phase 2 is a 25 - 30 minute brisk walk. Phase 3 is the same for all 6 weeks and consists of a 5 minute rest/cool down period.
89242509|NCT04035317|Experimental|Aesculus hippocastanum|Patients will receive extract of Aesculus hippocastanum
89242510|NCT04035317|Placebo Comparator|Placebo|Patients will receive placebo
89242511|NCT00902837|Active Comparator|oxycodone Tablet|OxyCodone Prolonged release tablets
89242512|NCT00902837|Experimental|oxycodone naloxone tablet|Oxycodone naloxone prolonged release tablets (OXN)
89242513|NCT00605813||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
89242514|NCT00899093||Ancillary-Correlative (serum collection for YKL-40 and CA125)|Patients undergo collection of serum samples for analysis of YKL-40 via ELISA and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
89242515|NCT00906269|Active Comparator|1|
89242516|NCT00906269|Sham Comparator|2|
89242517|NCT02538653|Experimental|Sandwich biscuits high in SDS|50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.
89242518|NCT02538653|Active Comparator|Co-extruded cereals low in SDS|48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.
89242519|NCT00902915|Experimental|Lenalidomide - Dexamethasone|
89242520|NCT02538575|Experimental|6-minute walk test|
89242521|NCT02540057|Active Comparator|Flexor carpi radialis|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the flexor carpi radialis tendon.
89242522|NCT02540057|Active Comparator|Abductor pollicis longus|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the abductor pollicis longus tendon.
89242523|NCT00902993|Experimental|1|Part A single and multiple dose and part B fractionated dose
89242524|NCT00902993|Placebo Comparator|2|
89242525|NCT00922415||cases|patients at least 18 years of age, with confirmed Crohn's disease undergoing intestinal resection for complicated Crohn's disease
89242526|NCT00604721|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive a single dose of selumetinib on day 1 and undergo blood collection for PK sampling pre-dose (within 30 min of dosing), 15 and 30 minutes and 1, 2, 4, 8, 12, 24 and 48 hours post-dose. Beginning 48 hours after the initial dose and continuing until day 21, patients receive oral selumetinib twice daily. Patients also undergo blood collection for PK sampling on day 15 of course 1. In all subsequent courses, patients receive selumetinib on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89242527|NCT04034771|Experimental|propofol and melatonin|propofol iv infusion and melatonin 10 mg tablet through a nasogastric tube, once at admission.
89242528|NCT04034771|Active Comparator|propofol and placebo|propofol iv infusion and a placebo tablets through a nasogastric tube once at admission
89242529|NCT00906581|Experimental|Behavioral|Behavioral
89242530|NCT00906581|No Intervention|Waitlist control|Waitlist control
89242531|NCT00899483|Active Comparator|1|Administered with glucose potassium insulin solution to achieve euglycaemia 4.0-6.0 mmol/L
89242532|NCT00899483|No Intervention|2|Normal departmental practice using dextrose insulin infusion
89242533|NCT02539121|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman. After that, the needle is covered with a opaque plastic cup and the cup is fixed with the adhesive tape.
89242534|NCT02539121|Placebo Comparator|Control|In the control group the puncture of the Ren Mai 6 is not performed, the acupuncturist disinfects the abdominal area with antiseptic and put the needle in the area of Ren Mai 6 without puncturing, after that, the needle is fixed but not punctured, and it is covered with a opaque plastic cup fixed with adhesive tape, guaranteeing that neither the mother nor the midwife responsible of measuring the variables can identify the assigned group.
89242535|NCT02539199|Active Comparator|Misoprostol modified-release pessary|
89242536|NCT02539199|Active Comparator|Misoprostol, per-oral tablets|
89242537|NCT00903149||MITP exposure or not|Mothers of children born preterm and term.
89242538|NCT00903227|Experimental|Low Dose|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg) and 1 puff of inhaled Placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
89242539|NCT00903227|Experimental|Combined|One puff of inhaled fluticasone propionate Evohaler pMDI 50 µg twice a day (Total daily FP dose 100 µg) and 1 puffs of Placebo twice a day with intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).
89242540|NCT00903227|Experimental|High dose|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg) and 1 puff of inhaled placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
89242541|NCT00605657|Experimental|Valproic acid|Single arm study involving oral administration of valproic acid and monitoring of its efficacy by CT scans done before and after the intervention. Blood samples were also obtained to monitor safety labs and biomarkers.
89242542|NCT00906659||diabetic macular edema|type 2 patients who had been treated with selective photocoagulation for clinically significant macular edema
89242543|NCT04034849|Experimental|Test group|Low-Level Laser Therapy was applied in the test group with a Diode Laser Fox (A.R.C. Laser, Italy) using these parameters: a wavelength of 810 nm, a power of 0.6 W, a power density of 1.2 W/cm2, a beam area of 0.08 cm2 and an energy of 6 J with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
89242544|NCT04034849|Placebo Comparator|Placebo group|Low-Level Laser Therapy was applied in the placebo group with a Diode Laser Fox (A.R.C. Laser, Italy) turned off with an application time per point of 10 seconds in 56 points (3 in the vestibular mucosa of the 4 quadrants, 6 in each of the two buccal mucosa, 6 in the hard palate, 4 in each lateral of the tongue, 6 in the dorsum of the tongue and 4 sublingual points) with a distance between points of 2mm. It was applied, therefore, a dose of 12 J/cm2 in a continuous mode in a total of 10 sessions, 2 sessions per week for 5 weeks.
89242545|NCT00903305|Experimental|Group II (SNIP)|Patients undergo SNIP comprising four visits over 2 months and four monthly telephone calls from the APN. The APN will provide 24 hour access during the study. Patients complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
89242546|NCT00903305|Active Comparator|Group I (usual care intervention)|Patients undergo usual care and complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
89242547|NCT02539043|Active Comparator|Focused ultrasound cavitation: Lipofocus|The first group will receive only the application of focused ultrasound cavitation.
89242548|NCT02539043|Active Comparator|Focused ultrasound and drainage: Lipofocus|The second group will receive focused ultrasound cavitation followed by stereodynamic drainage.
89242549|NCT00903461|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Subjects will receive a total of up to 7 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive a total EGFR AS dose of 1.92 milligrams in 1.78 milliliters on each weekly treatment. This dose may be delivered equally in the same tumor site per weekly session, the primary tumor or cervical lymph nodes.
89242550|NCT00604565|Experimental|SFP dialysate|dialysate with added soluble ferric pyrophosphate (SFP)
89242551|NCT00604565|Placebo Comparator|standard dialysate|standard dialysate without soluble ferric pyrophosphate (SFP)
89242552|NCT00899951||Cohort 1|receiving fentaly citrate
89242553|NCT02539979|Active Comparator|IV Paracetamol|Patients will receive 1gram of IV paracetamol mixed in 100ml infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
89242554|NCT02539979|Placebo Comparator|IV Placebo (Normal Saline)|Patients will receive 100ml of normal saline infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
89242555|NCT00906737|Experimental|Ankle-Bot Training|Subjects in this group receive focused ankle training using the ankle-bot device.
89242556|NCT00906737|Active Comparator|Conventional Therapy|Subjects in this group will receive conventional focused ankle physical therapy.
89242557|NCT00906737|No Intervention|Control|Subjects in this group will not receive treatment; they will continue their usual care.
89242558|NCT00906893|Experimental|1|
89242559|NCT05277701|Experimental|Lazertinib|
89242560|NCT00900653|Experimental|Gynoflor|
89242561|NCT00900653|No Intervention|Control|
89242562|NCT00605345|Experimental|CERA Treatment Once Monthly|
89242563|NCT00605345|Active Comparator|Darbepoetin Alfa Once Biweekly|
89242564|NCT00903851|Experimental|(1) Lidoderm|(1)Commercially available Lidoderm® (lidocaine patch 5%), up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain
89242565|NCT00900887|Active Comparator|Ketorolac|ocular topic ketorolac used 3 times a day for a week after the selective photocoagulation
89242566|NCT00900887|Active Comparator|Nepafenac|ocular topic nepafenac 3 times a day during one week after selective photocoagulation
89242567|NCT00900887|Placebo Comparator|Polietilenglicol 400, propilenglicol|ocular lubricant drops 3 times a day for a week after selective photocoagulation
89242568|NCT02539277|Experimental|Treatment group|Jinyebaidu granule, blunt, 10g / time, three times a day; Fufangshuanghua granule placebo, blunt, 6g / time, 4 times a day.
89242569|NCT02539277|Active Comparator|Control group|Fufangshuanghua granule, blunt, 6g / time, 4 times a day; Jinyebaidu granule placebo, blunt, 10g / times, three times a day.
89242570|NCT00904085|Active Comparator|Oxymorphone|
89242571|NCT00904085|Placebo Comparator|Placebo|
89242572|NCT00908453|Experimental|15mg/kg of loading dose|
89242573|NCT00908453|Experimental|18mg/kg of loading dose|
89242574|NCT00908453|Experimental|22.5mg/kg of loading dose|
89242575|NCT00907049||Subacute neck pain; chronic neck pain|Patients with subacute or chronic neck pain seen in the Primary Care Centers participating in the study.
89242576|NCT02538497|Experimental|NBO plus routine care|The Newborn Behavioral Observation
89242577|NCT02538497|Other|Routine care|
89242578|NCT04034537|Experimental|cPSTA GROUP|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo cardiac Phase Space Tomography Analysis (cPSTA) signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
89242579|NCT00907127|Active Comparator|Mediterranean Diet and Exercise|Mediterranean Diet and Exercise
89242580|NCT02538731|Other|Dilation-assisted group|Dilation-assisted group:Dilation-assisted stone extraction
89242581|NCT02538731|Other|laser lithotripsy group|laser lithotripsy group:laser lithotripsy
89242582|NCT00908531|Active Comparator|Postoperative letrozole|Definitive surgery without preoperative AI treatment
89242583|NCT00908531|Experimental|Preoperative letrozole|Treatment with letrozole for 4 months before definitive surgery.
89242584|NCT00908609||1|Patients who undergo routine ultrasound guided biopsy will be studied by optical imaging technique.
89242585|NCT00908609||2|Patients who have advanced breast cancers and are under neoadjuvant chemotherapy treatment will be studied by optical technique.
89242586|NCT02538263|Experimental|Volume-targeted noninvasive ventilation|For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
89242587|NCT02538263|No Intervention|Pressure-limited noninvasive ventilation|For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
89242588|NCT00904319|Experimental|Aquatic|Aquatic Power Training
89242589|NCT00604175|Experimental|Stratum A|Participants with screening CD4 count >350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
89242590|NCT00604175|Experimental|Stratum B|Participants with screening CD4 count >200 to <=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
89242591|NCT00604175|Experimental|Stratum C|Participants with screening CD4 count <=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
89242592|NCT00605189|Active Comparator|VAC NPWT|
89242593|NCT00605189|Active Comparator|Gauze-Based NPWT|
89242594|NCT00605189|Active Comparator|Moist Wound Therapy|
89242595|NCT00904397|Experimental|Lidoderm|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back
89242596|NCT00904397|Active Comparator|Celecoxib|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
89242597|NCT02538887||Radio Frequency Surgical Detection|
89242598|NCT00907205|Experimental|SF1126|Twice weekly IV infusion
89242599|NCT00908765|Active Comparator|Aerobe Interval Training|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
89242600|NCT00908765|Active Comparator|Moderate Continous Training|Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
89242601|NCT00903071|Active Comparator|REAL PPL|REAL+PPL profiles PCP performance using real electronic medical record derived data to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
89242602|NCT00903071|Active Comparator|SIM PPL|SIM+PPL, profiles PCP performance using simulated cases to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
89242603|NCT00903071|No Intervention|Control|No intervention -control group
89242604|NCT00908843|Experimental|(I) BICARBONATE INTRAVENOUS INFUSION|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
89242605|NCT00908843|Active Comparator|(II) ORAL SODIUM SOLUTION|Oral hydration with Sodium solution (Casen solution of rehydratation) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
89242606|NCT00904475|Experimental|1- Lidoderm®|Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
89242607|NCT00904475|Placebo Comparator|2-Placebo|Matching placebo, up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
89242608|NCT00908921|Experimental|1|"The treatment period is 16 weeks with 5 visits: at weeks 2, 4, 8, 12, 16. At every visit if Fasting Blood Glucose (FBG) >7.0mmol/L the Glimepiride dosage is increased from 1mg to 2mg or 2mg to 4mg.~At every visit if FBG<3.9mmol/L the Glimepiride dosage is decreased from 4mg to 2mg or 2mg to 1mg.~Patients who have been on 4mg for 4 weeks and FBG>11.0mmol/L at visit, another treatment can be added at the physician's discretion."
89242609|NCT00904631|Experimental|Treatment|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
89242610|NCT00908999||Controls|The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender). These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.
89242611|NCT00908999||amnestic Mild Cognitive Impairment|Participants who have expressed interest to take part in the study. A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled. The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.
89242612|NCT00908999||Alzheimer's disease|Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria. An additional criterion is a MMSE score between 16 and 27. All AD patients must have capacity to provide informed consent as judged by the referring physician.
89242613|NCT00909077|Active Comparator|1|Combination therapy with Dexamethasone and Rituximab
89242614|NCT00909077|Active Comparator|2|Dexamethasone as monotherapy
89242615|NCT00904709|Experimental|Tranexamic acid, Menorrhagia, Bleeding|Tranexamic acid with titrated doses. All women with menorrhagia will take .
89242616|NCT05277389|Sham Comparator|Control|Individuals in this group will practice object manipulation tasks without the START (Startle Adjuvant Rehabilitation Therapy) intervention
89242617|NCT05277389|Experimental|START|Individuals in this group with practice object manipulation tasks with the START condition (startling acoustic stimuli applied during 33% of trials)
89242618|NCT00340834|Experimental|Fingolimod 1.25 mg|
89242619|NCT00340834|Experimental|Fingolimod 0.5 mg|
89242620|NCT00340834|Active Comparator|Interferon β-1a 30 µg|
89242621|NCT03986554|Other|Randomization Visit A|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Each sequence will be use VFSS to visualize swallows.
89242622|NCT03986554|Other|Randomization Visit B|Participants enrolled in this arm will consume 300ml of water over 60 minutes. Each session will consist of 30 swallows broken into three 10-swallow sequences of 10ml of water. Sequences 1 and 3 will use videofluoroscopy only, while sequence 2 will use VFSS with simultaneous pharyngeal high resolution manometry in order to visualize swallows.
89242623|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel
89242624|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Half Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength)
89242625|NCT01057966|Experimental|ICAPS AREDS coated tablets - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets
89242626|NCT01058044|Experimental|adherence assessment group|evaluation of adherence using MEMS
89242627|NCT01058122||Patients on the ward|
89242628|NCT00603941|Experimental|Cohort 1; 0.15 mg CS-7017|Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 [Dose Level 1a] or 175 [Dose Level 1b] mg/m^2 intravenous (IV) paclitaxel once every 3 weeks.
89242629|NCT00603941|Experimental|Cohort 2; 0.30 mg CS-7017|Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
89242630|NCT00603941|Experimental|Cohort 3; 0.50 mg CS-7017|Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
89242631|NCT00340678|Experimental|Normoalbuminuria Losartan|Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
89242632|NCT00340678|Placebo Comparator|Normoalbuminuria Placebo|Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.
89242633|NCT00340678|Experimental|Microalbuminuria Losartan|Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
89242634|NCT00340678|Placebo Comparator|Microalbuminuria Placebo|Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.
89242635|NCT01055470|Active Comparator|Diclofenac|Tab.Diclofenac 50 mg ,Orally, 12 hrly in morning and in evening after taking food for 3 months.
89242636|NCT01055470|Experimental|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
89242637|NCT00904787|Experimental|1|
89242638|NCT02533102|Experimental|Part A: E7050 100 mg tablet under fasted conditions|Participants will receive a single tablet containing 100 mg E7050 following an overnight fast.
89242639|NCT02533102|Experimental|Part A: E7050 100 mg tablet with low-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard low-fat meal.
89242640|NCT02533102|Experimental|Part A: E7050 100 mg tablet with high-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard high-fat meal.
89242641|NCT02533102|Experimental|Part B: E7050 200 mg tablet under fasted conditions|Participants will receive a single dose of 200 mg (two 100 mg tablets) of E7050 under fasted conditions.
89242642|NCT02533102|Experimental|Part B: E7050 400 mg tablet under fasted conditions|Participants will receive a single dose of 400 mg (four 100 mg tablets) of E7050 under fasted conditions.
89242643|NCT02533024|Experimental|Group Cohort|All subjects will have nerve conduction studies (Electromyography/EMG) pre-operatively, monitored intra-operatively and immediately post-operative.
89242644|NCT05277311|Experimental|LongShengZhi capsule|Experimental group
89242645|NCT05277311|Placebo Comparator|LongShengZhi capsule placebo|Placebo group
89242646|NCT03986008|Experimental|Benaglutide|Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.
89242647|NCT03986008|Active Comparator|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day.
89242648|NCT00909233||Group 1|
89242649|NCT03985774||Patients requiring carotid revascularization|Symptomatic patients, male or female, with atherosclerotic extracranial internal carotid stenosis (ICA) with or without involvement of the contiguous common artery (CCA), that require carotid revascularization.
89242650|NCT00904865|Other|1|SPA cholecystectomy
89242651|NCT00904865|Other|2|laparoscopic cholecystectomy
89242652|NCT03986086|Experimental|MPH966|Participants receive MPH966 at RP2D tablet orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
89242653|NCT03986086|Placebo Comparator|Placebo|Participants receive MPH placebo tablet matching MPH966 orally twice daily from the start of conditioning chemotherapy through 45 days post transplant.
89242654|NCT03313895|Active Comparator|Cycling Only|Moderate-intensity cycling, 3 times a week for 6 months, supervised by an exercise specialist
89242655|NCT03313895|Active Comparator|Cognitive Training Only|Computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
89242656|NCT03313895|Experimental|ACT|Moderate-intensity cycling followed by computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
89242657|NCT03313895|Sham Comparator|Stretching and Mental Stimulation Activities|Stretching and mental stimulation activities, 3 times a week for 6 months, supervised by a specialist
89242658|NCT01058200|Active Comparator|vacuum extractor 'iCUP'|new vacuum extractor: sterile disposable plastic cup
89242659|NCT01058200|Sham Comparator|reference vacuum extractor|reference cup of the obstetrical ward: metallic cup
89242660|NCT00909311|Active Comparator|1|Non-fasting
89242661|NCT00909311|Active Comparator|2|Fasting
89242662|NCT00907595|Active Comparator|Ramelteon|Subjects randomized to Ramelteon
89242663|NCT00907595|Placebo Comparator|Placebo|Subjects randomized to placebo
89242664|NCT00907673|Active Comparator|Patient condition pre-implant|
89242665|NCT00907751|Experimental|1|Microangiopathic hemolytic anemia (< 12 g/dL) with thrombocytopenia (<50 G/L)
89242666|NCT00909467||myeloproliferative, -dysplastic disease|
89242667|NCT00905333|Other|Single-arm|3 treatments, 6 sequences, 3 periods, cross-over, single dose arm (Willians' Plan)
89242668|NCT00907829|Active Comparator|Arm 1|persons with severe hand impairment following hemiparetic stroke
89242669|NCT00907829|Active Comparator|Arm 2|persons with severe hand impairment following hemiparetic stroke
89242670|NCT00905411|No Intervention|Attention Control / Usual Care|
89242671|NCT00905411|Experimental|Intervention|
89242672|NCT00336544|Experimental|Cethromycin|
89242673|NCT00336544|Active Comparator|Clarithromycin|
89242674|NCT01059058|Active Comparator|Test Group A: MI Paste Plus Group|
89242675|NCT01059058|Active Comparator|Test Group B: Fluoride Varnish Group|
89242676|NCT01059058|Placebo Comparator|Control Group|
89242677|NCT00605033|Active Comparator|Suboxone|Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
89242678|NCT00605033|Active Comparator|Subutex|Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
89242679|NCT03988114|Experimental|Abemaciclib + NSAI|Abemaciclib given orally and nonsteroidal aromatase inhibitor (NSAI) of physician's choice (anastrazole or letrozole) given orally.
89242680|NCT00905723|Experimental|Estrogen|Women randomized to this group will receive daily pills containing 1 mg of estradiol
89242681|NCT00905723|Experimental|Isoflavone|Women randomized to this group will receive daily pills of 150 mg isoflavone
89242682|NCT00905723|Placebo Comparator|Placebo|Women randomized to this group will be administered daily placebo pills
89242683|NCT04034069|Experimental|cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of priming iTBS protocol (cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
89242684|NCT04034069|Active Comparator|Sham cTBS + iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of non-primed, standard iTBS (sham cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
89242685|NCT04034069|Sham Comparator|Sham cTBS + sham iTBS, in addition to robot-assisted training|Participants will receive 10-session intervention of sham stimulation (sham cTBS followed by sham iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
89242686|NCT03987646|Experimental|xenograft cortical flexible sheet|a-traumatic tooth removal , socket lavage and curettage, performing a vestibular access horizontal incision corresponding to the socket 3-4 mm apically from the muccogingival junction , a tunnel is then created from the socket office and extended apically till it connects with the vestibular access incision, a computer guided surgical template is then used to deliver the implant in its optimal position, a slowly resorbable membrane shield is then introduced through the tunnel and stabilized with a membrane tac , it is a sturdy fixable membrane barrier placed above the labial plate
89242687|NCT00907985|Experimental|Treatment sequence A|Subjects on sequence A will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
89242688|NCT00907985|Experimental|Treatment sequence B|Subjects on sequence B will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
89242689|NCT00907985|Experimental|Treatment sequence C|Subjects on sequence C will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
89242690|NCT00907985|Experimental|Treatment sequence D|Subjects on sequence D will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
89242691|NCT00907985|Experimental|Treatment sequence E|Subjects on sequence E will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
89242692|NCT00907985|Experimental|Treatment sequence F|Subjects on sequence F will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
89242693|NCT00907985|Experimental|Treatment sequence G|Subjects on sequence G will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
89242694|NCT00907985|Experimental|Treatment sequence H|Subjects on sequence H will receive single dose of placebo part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
89242695|NCT00907985|Experimental|Treatment sequence I|Subjects on sequence I will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
89242696|NCT00907985|Experimental|Treatment sequence J|Subjects on sequence J will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
89242697|NCT00907985|Experimental|Treatment sequence K|Subjects on sequence K will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
89242698|NCT00907985|Experimental|Treatment sequence L|Subjects on sequence L will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
89242699|NCT00907985|Experimental|Treatment sequence M|Subjects on sequence M will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
89242700|NCT00907985|Experimental|Treatment sequence N|Subjects on sequence N will receive single dose of vofopitant 10 milligrams capsule in part 1, placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
89242701|NCT00907985|Experimental|Treatment sequence O|Subjects on sequence O will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
89242702|NCT00907985|Experimental|Treatment sequence P|Subjects on sequence P will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
89242703|NCT00907985|Experimental|Treatment sequence Q|Subjects on sequence Q will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
89242704|NCT00907985|Experimental|Treatment sequence R|Subjects on sequence R will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
89242705|NCT00907985|Experimental|Treatment sequence S|Subjects on sequence S will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
89242706|NCT00907985|Experimental|Treatment sequence T|Subjects on sequence T will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
89242707|NCT01055548||Parents of babies born before 33 weeks gestation|
89242708|NCT03987880|Active Comparator|4.0 mm zone|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea. The area consist of three rings with a central 2-mm zone that is left untreated. The energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2-mm from the corneal centre. Pulsed UV-light, 1s on / 1s off; 30mW. For myopia of less than 0.75D, 10 J/cm2 is used, for higher levels of myopia 15J/cm2 is used.
89242709|NCT03987880|Experimental|3.5 mm zone|PiXL treatment with UV irradiation in a central ring-shaped 3.5-mm zone of the cornea, with a central 1.5 mm zone that is left untreated. The illumination area consists of three rings, where the outer and inner ring are thinner than the middle ring. The maximum energy is distributed in the middle ring. Pulsed UV-light, 0.5s on / 1s off; 45mW. For myopia of less than 0.75D, a maximum of 10 J/cm2 is used, for higher levels of myopia a maximum of 15J/cm2 is used.
89242710|NCT01325194|Experimental|CNS prophylaxis|
89242711|NCT00908063|Experimental|Oxycyte|"Single intravenous infusion of Oxycyte (Perfluoro(t-butylcyclohexane) Intravenous Emulsion 60% w/v)~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
89242712|NCT00908063|Placebo Comparator|Normal Saline|"Single intravenous infusion of Normal Saline~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
89242713|NCT00909701|Experimental|Test|PreOP Booster (Fresenius Kabi, Bad Homburg, Germany)
89242714|NCT00909701|Active Comparator|Comparator|PreOP (Nutricia Clinical Care, Trowbridge, UK)
89242715|NCT01058278|Active Comparator|Prednisone acetate 1%|A topic cortisone-based treatment
89242716|NCT01058278|Active Comparator|diclofenac 0.1%|an non-steroidal anti-inflammatory drug
89242717|NCT01058278|Placebo Comparator|Artificial Tears|Pharmasciences DIN: 02229570
89242718|NCT00905801|Other|Arm A CT Perfusion|"Arm A Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~CTP imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Subject will stand up and walk around, and then lay back down~CT Perfusion imaging: Second single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from their clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
89242719|NCT00905801|Other|Arm B CT Perfusion|"Arm B Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~- CT Perfusion imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
89242720|NCT00908219|Experimental|Bevacizumab IV|All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study.
89242721|NCT00927173|Sham Comparator|Sham|Sham treatment
89242722|NCT00927173|Active Comparator|Active|Active Deep Transcranial Magnetic Stimulation treatment
89242723|NCT02538185|Placebo Comparator|Vaccine injected ID with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with vaccine (0.1mL);~Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL)."
89242724|NCT02538185|Active Comparator|Vaccine injected ID with NanoJect device (DebioJect™)|"Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL)."
89242725|NCT02538185|Placebo Comparator|Vaccine injected IM with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL)."
89242726|NCT00927329|Experimental|dust mite|
89242727|NCT00931541|Experimental|A|AZD6088 oral solution
89242728|NCT00931541|Experimental|B|Placebo oral solution
89242729|NCT00927407|Experimental|Malathion gel 0.05%|Malathion gel 0.5% topical treatment for head lice
89242730|NCT00927407|Active Comparator|Malathion lotion 0.5%|Malathion lotion 0.5% treatment for head lice
89242731|NCT00339040|Active Comparator|Arm A: QHPV|QHPV at week 0, 8, 24, 96.
89242732|NCT00339040|Other|Arm B: Placebo/QHPV|Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.
89242733|NCT03743519|Placebo Comparator|Placebo|
89242734|NCT03743519|Experimental|Cherry juice|
89242735|NCT04015193||Full responders|Full responders: no signs or symptoms of Raynaud's phenomenon (RP) in Raynaud condition score, no RP during cooling-recovery experiment.
89242736|NCT04015193||Partial responders|Partial responders: at least 25% reduction in Raynaud condition score and finger ischemia time during cooling and recovery.
89242737|NCT04015193||Non-responders|Non-responders: no or less than 25% reduction in Raynaud condition score and/or finger ischemia time during cooling and recovery.
89242738|NCT01061086||1|Patients over 18 years old admitted to the hospital with Acute Coronary Syndrome.
89242739|NCT00931697|Experimental|AD 452 (+) mefloquine|
89242740|NCT00931697|Active Comparator|Racemic mefloquine|
89242741|NCT00931697|Placebo Comparator|Placebo|
89242742|NCT00927797|Experimental|Immunochemotherapy, Maintencance|
89242743|NCT00338962|Active Comparator|Paroxetine and naltrexone|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
89242744|NCT00338962|Active Comparator|paroxetine and placebo|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day.
89242745|NCT00338962|Active Comparator|Desipramine and naltrexone|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
89242746|NCT00338962|Active Comparator|Desipramine and placebo|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day.
89242747|NCT00931775|Placebo Comparator|Citalopram + placebo|Citalopram 20 mg/day t.i.d
89242748|NCT00931775|Experimental|Citalopram + pindolol|Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.
89242749|NCT00927875|Experimental|All Subjects|
89242750|NCT00924599|Experimental|Intervention Group-English|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
89242751|NCT00924599|Experimental|Intervention Group-Spanish|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
89242752|NCT00924599|Active Comparator|Lifestyle education-English|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
89242753|NCT00924599|Active Comparator|Lifestyle education-Spanish|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
89242754|NCT00924677|Sham Comparator|lidocaine|Local injection with lidocaine through the RF cannula without activation of RF generator.
89242755|NCT00924677|Active Comparator|lidocaine, radiofrequency current|After lidocaine injection through the RF cannula, the temperature of the electrode tip was raised to 70℃ for 90 seconds by RF generator.
89242756|NCT00568061|Experimental|Inhaled Nitric Oxide|Inhaled Nitric oxide administered at 80 parts per million (ppm)
89242757|NCT00568061|Placebo Comparator|Placebo|Inhaled nitrogen gas (Placebo) administered at 80 ppm
89242758|NCT00931853|Experimental|SENNA + CASSIA (Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
89242759|NCT00931931|Experimental|HSV1716 - Intratumoral route|Research participants with localized disease receiving HSV1716 as an intratumoral injection
89242760|NCT00931931|Experimental|HSV1716 - intravenous|Research participants with metastatic disease receiving HSV1716 intravenously
89242761|NCT03547427|Experimental|Insulin hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
89242762|NCT03547427|Active Comparator|Insulin hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone') and receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
89242763|NCT03547427|Experimental|Exercise hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
89242764|NCT03547427|Active Comparator|Exercise hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia' ). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
89242765|NCT00932009||Human papillomavirus|Tanzanian men with HPV and Tanzanian men without
89242766|NCT00932087||type 2 diabetics with metabolic syndrome|
89242767|NCT00932087||metabolic syndrome without diabetes|
89242768|NCT00932087||type 1 diabetes|
89242769|NCT00932087||control|
89242770|NCT00928109|Experimental|Cognitive Behavioral Couples Therapy (CBCT)|CBCT is a 20-week program consisting of 1-hour sessions between a couple and a therapist. In this program, couples learn about ways to communicate about their relationship in the context of experiencing anorexia nervosa. CBCT focuses on couple-specific skills such as communication and targets relationship domains such as exercise, body image and sexuality, eating together as a couple, and broader relationship concerns outside of anorexia nervosa.
89242771|NCT00928109|Active Comparator|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
89242772|NCT00928343|Experimental|GLPG0187|Single dose
89242773|NCT00928343|Placebo Comparator|Placebo|
89242774|NCT00338884|Experimental|SUNITINIB MALATE.|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
89242775|NCT00338806|Experimental|Interpersonal Psychotherapy-Prevention|Participants will receive interpersonal psychotherapy for prevention with adolescents
89242776|NCT00338806|Active Comparator|Educational and Clinical Monitoring|Participants will receive educational clinical monitoring
89242777|NCT03038100|Experimental|Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.
89242778|NCT03038100|Placebo Comparator|Placebo With Paclitaxel, Carboplatin and Bevacizumab|Participants in the primary tumor-reductive surgery group will receive paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group will receive paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants will start maintenance therapy of bevacizumab and placebo for additional 16 cycles.
89242779|NCT00338728|Experimental|Treatment (imatinib mesylate, letrozole)|Participants receive imatinib mesylate PO BID and letrozole PO QD for 8 weeks in the absence of disease progression or unacceptable toxicity.
89242780|NCT01061164||HIV-infected infants, children, and adolescents|Infants, children, and adolescents with HIV infection who have participated in PACTG 219C and/or select IMPAACT studies.
89242781|NCT01059136|Experimental|1:Spironolactone|Aldosterone blockade on top of standard therapy
89242782|NCT01059136|No Intervention|2:Standard therapy|Standard therapy
89242783|NCT01061242|No Intervention|Baseline|Post-Intensive Care Unit (ICU) neurocognitive testing and sleep survey performed on patients exposed to ad-lib Medical ICU environment.
89242784|NCT01061242|Experimental|Sleep Promotion Group|Post-ICU neurocognitive testing and sleep survey performed on patients exposed to interventions in the pre-existing MICU sleep quality improvement project.
89242785|NCT03985618|Active Comparator|Randomized Caesarean section|Randomized to planned pre-labour Caesarean section
89242786|NCT03985618|Active Comparator|Randomized Induction of Labour|Randomized to planned induction of labour
89242787|NCT03985618|Active Comparator|Preference Caesarean section|Preference for planned pre-labour Caesarean section
89242788|NCT03985618|Active Comparator|Preference Induction of Labour|Preference for planned Induction of Labour
89242789|NCT03983278|Experimental|School Model|School Model (n=47 schools): Vision screening will be carried out by the vision screeners; refraction will be done at the schools by refractionists, and children who need them will be given free spectacles at the school within two weeks.
89242790|NCT03983278|Experimental|Referral Model|Referral Model (47 schools): Vision screening carried out by the vision screeners, and children are referred to nearby Vision Center/ secondary center for refraction and delivery of free spectacles. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary.
89242791|NCT03983278|Experimental|Referral Model + Cost Recovery|"Referral Model + Cost Recovery (47 schools): Vision screening carried out by the vision screeners; children referred to Vision Center for refraction and delivery of spectacles with an option to purchase upgrade spectacles (which was shown to be appealing to families in the recent PRICE study. These spectacles have scratch-proof coatings and designs selected to appeal to local children. Teachers will contact families not presenting for follow-up care and for spectacle compliance through SMS, phone call and notations in the school diary."
89242792|NCT00336856|Experimental|IRINOTECAN AND CETUXIMAB|Cetuximab will be administered at the dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks, IV over 2 hours at an infusion rate not to exceed 5 ml/min. Followed immediately by Irinotecan administered at a dose of 180 mg/m2 IV over 60 minutes every two weeks.
89242793|NCT02532868|Experimental|MK-0457|Participants received MK-0457 at assigned dose as a continuous intravenous infusion (CIV) over 24 hours; one group of participants also received MK-0457 100 mg capsules, orally, prior to the CIV.
89242794|NCT01059370|Experimental|Autonomic dysrefleksia|Autonomic dysreflexia in SCI when emptying bowels or filling bladder
89242795|NCT00566501|Experimental|Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).
89242796|NCT00566501|Experimental|Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).
89242797|NCT02997462||Heart Failure|"Heart Failure patients admitted to the ICU or Heart Failure Service.~No changes in service-directed plan of care for patients."
89242798|NCT02997462||Healthy Control|Healthy, age-matched controls.
89242799|NCT00504894|Placebo Comparator|Placebo|Placebo given in low dose to gauge subject's responses to visual stimuli.
89242800|NCT00504894|Active Comparator|Propofol|Propofol given at 0.90 μgml-1 to gauge subject's responses to visual stimuli.
89242801|NCT00504894|Active Comparator|Thiopental|Thiopental given at 3.0 μgml-1 to gauge subject's responses to visual stimuli.
89242802|NCT03743441|Active Comparator|Exercise + Cryotherapy + LLLT|
89242803|NCT03743441|Sham Comparator|Exercise + Cryotherapy + Sham LLLT|
89242804|NCT01011270||Back pain|The aim of this study was to investigate the effect of rehabilitation of the dynamic ;(RDM) in balance and balance of industrial operators. The sample consisted of industrial operators, individuals with low back pain, referred to the industry of Physical Therapy
89242805|NCT01011270||Balance|the treatment with RDM reflected in significant improvement in back pain and postural balance of industrial operators.
89242806|NCT00928577||ACAM2000 Smallpox Vaccine Group|Participants are vaccinia vaccine-naive and have received ACAM2000 Smallpox vaccine as part of their Service Member readiness process.
89242807|NCT00928577||Other vaccinia vaccine Group|Participants did not receive ACAM2000 Smallpox vaccine as part of their Service Member readiness process because they are still protected by previous vaccinia vaccination or are ineligible for current ACAM2000 vaccination either because of recency of prior vaccinia vaccination or for reasons solely attributable to conditions or characteristics of their contacts (such as a healthy soldier who is married to someone with a contraindicated condition).
89242808|NCT01011348|Other|Placebo vs Q10 100mg vs Q10 300mg|
89242809|NCT01011348|Other|Q10 100mg vs Placebo vs Q10 300mg|
89242810|NCT01011348|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
89242811|NCT01011348|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
89242812|NCT00924911|Experimental|Part 1|A 4 way crossover of three GSK1322322 tablet formulations and GSK1322322 powder in bottle
89242813|NCT00924911|Experimental|Part 2|A 3 way crossover of a GSK1322322 tablet with a high fat meal, with Ranitidine, and with Ranitidine and Vitamin C.
89242814|NCT00928655|Experimental|acetazolamide|combination of acetazolamide and nocturnal continuous positive airway pressure ventilation
89242815|NCT00928655|Placebo Comparator|placebo capsules|combination of placebo and nocturnal continuous positive airway pressure ventilation
89242816|NCT03743363|Experimental|Exergame 3/week|The group does active training for 8 weeks after not training.
89242817|NCT03743363|Experimental|Exergame 2/week|The group does active training for 8 weeks after not training.
89242818|NCT03743363|Experimental|Healthy control / Exergame 1/week|In the first 8 week-long only control group, The group will do 1 training/week for the next 8 weeks.
89242819|NCT01011426|Active Comparator|Bisacodyl|
89242820|NCT01011426|Placebo Comparator|empty opague capsule|
89242821|NCT00925067|Experimental|lightweight TiMesh|
89242822|NCT00925067|Experimental|lightweight VyproII|
89242823|NCT00925067|Experimental|Heavyweight Marlex|
89242824|NCT00932555||Group 1|
89242825|NCT00928733|Experimental|alcohol|Intraduodenal infusion of ethanol
89242826|NCT00928733|Other|Ethanol|
89242827|NCT00928733|Experimental|Placebo|Intraduodenal infusion of tap water
89242828|NCT01012908|Experimental|Norzyme|Pancreatic Enzymes - Norzyme (Bergamo)
89242829|NCT01012908|Active Comparator|Creon (Solvay)|Pancreatic Enzymes - Creon (Solvay)
89242830|NCT00932711|Experimental|Educational intervention|Subjects in this group will receive educational brochures about management of COPD
89242831|NCT04014959|Experimental|All Participants|All participants follow the same procedures.
89242832|NCT01012986||2nd Grade|students of 2nd grade
89242833|NCT01012986||4th Grade|students of 4th Grade
89242834|NCT01011582||Novel H1N1 influenza|
89242835|NCT01011582||Seasonal influenza|
89242836|NCT00513240|Experimental|EPO group|Patients randomized to receive the 3 doses of erythropoetin.
89242837|NCT00513240|Placebo Comparator|Control group.|Patients randomized to receive 3 doses of normal saline control.
89242838|NCT00925145||1|
89242839|NCT00928811|Other|Control|Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.
89242840|NCT00928811|Experimental|Simulect|"Simulect (basiliximab) intravenously day of transplant and day 4.~Chronic Simulect (basiliximab) administration monthly for one year duration.~Concomitant decrease in Prograf administration."
89242841|NCT00932867||Group 1|
89242842|NCT00928967||Group 1|
89242843|NCT00932945|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Treatment duration: 21 consecutive days
89242844|NCT00504426|Placebo Comparator|1|
89242845|NCT00504426|Active Comparator|2|
89242846|NCT00504426|Active Comparator|3|
89242847|NCT00504426|Active Comparator|4|
89242848|NCT00933023|Experimental|Mild steroid|1%hydrocortisone for 8 weeks
89242849|NCT00933023|Experimental|Potent Steroid|
89242850|NCT00933101||HgbA1c <8|Adolescents with HgbA1c < or equal to 8% for the previous 12 months
89242851|NCT00933101||HgbA1c >10|Adolescents with HgbA1c > or equal to 10% for previous 12 months
89242852|NCT00933179|Experimental|Arm 1|
89242853|NCT00933179|Active Comparator|Arm 2|
89242854|NCT00925223||irritable bowel syndrome|patients with diarrhea-predominant IBS will be enrolled in this group.
89242855|NCT00925223||control group|patients with colon cancer or colon polyp will be enrolled as control group.
89242856|NCT00504348|Experimental|Prospective investigation group|Tacrolimus treatment is to be initiated at the starting dose of 0.075mg/kg/day, adjusted to maintain its whole blood trough levels between 5 and 10 ng/mL for 52 weeks. All patients are to receive glucocorticoids with the starting doses equivalent to between 0.6 and 1.0 mg/kg/day of prednisolone which are to be continued for the first 28 days after which be subsequently tapered according to a predefined guideline. Up to two courses of pulse intravenous glucocorticoid therapy are allowed during that period.
89242857|NCT00929123|Experimental|neural mobilization|manual therapy technique known to directly stress the median nerve
89242858|NCT00929123|Placebo Comparator|sham neural mobilization|manual therapy technique known to directly stress the median nerve without any stimulation.
89242859|NCT00929123|Active Comparator|Healthy Controls|People without carpal tunnel syndrome for comparison
89242860|NCT00507546|Experimental|Ramelteon then placebo|8 mg nightly ramelteon for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of nightly placebo (cross-over)
89242861|NCT00507546|Experimental|Placebo then ramelteon|placebo nightly for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of 8 mg nightly ramelteon (cross-over)
89242862|NCT00925457||001|Current Domperidone Current domperidone at any dose regardless of proton pump inhibitor status
89242863|NCT00925457||002|Current proton pump inhibitor (PPI) Current PPI and not current dapoxetine
89242864|NCT00925457||003|No Intervention Neither current domperidone nor current PPI
89242865|NCT04522674|Experimental|Autologous platelet rich plasma|0.5 mL of activated autologous PRP will be injected by fluoroscopic guidance into the affected lumbar facet joint (s) depending on the number of affected levels. A max of 4 joints will be injected per patient.
89242866|NCT00933257|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
89242867|NCT04015271|Experimental|Action Observation + Repetitive Task Practice|Action Observation (AO) therapy regimen will include watching a 6 minute video of another person completing a specified functional task (Putting on a shirt, pick up a sandwich and bring to mouth, eat food with a spoon, or cut meat with knife and fork). Subjects will be instructed to carefully watch the AO video and prepare to physically perform the task immediately after observing the video. The Repetitive Task Practice (RTP) therapy regimen emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task that is matched to the AO recording. The AO + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
89242868|NCT04015271|Placebo Comparator|Placebo Video + Repetitive Task Practice|The control placebo videos (PV) will be 6 minutes, and will include a series of changing static images without animals, human beings, or sound (i.e. pictures of buildings, trees, cruise ships, mountains, beach umbrellas, beds, and tables). A Repetitive Task Practice (RTP) therapy regimen will be completed immediately after observing the PV, which emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task. These tasks include putting on a shirt, picking up a sandwich and bringing it to mouth, eating food with a spoon, or cutting meat with knife and fork. The PV + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
89242869|NCT00925613|No Intervention|Control|The double lumen tube is kept until extubation; there is no exchange with any tracheal tube or LMA.
89242870|NCT00925613|Active Comparator|Proseal|The double lumen tube is exchanged with a Proseal (LMA) before emergence according to the study protocol.
89242871|NCT00925613|Active Comparator|Tracheal tube|The double lumen tube is exchanged with a tracheal tube before emergence according to the study protocol.
89242872|NCT00929279|Active Comparator|Abciximab bolus plus infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen.
89242873|NCT00929279|Experimental|bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
89242874|NCT00567593|Other|Rosiglitazone|Rosiglitazone; 8mg tablet once a day for 14 days
89242875|NCT00335764|Experimental|Group 1|Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
89242876|NCT00335764|Experimental|Group 2|Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
89242877|NCT00335764|Experimental|Group 3|Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.
89242878|NCT03743285|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
89242879|NCT00933413|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Application of Lactic acid during 21 consecutive days
89242880|NCT03981562|Experimental|1000 IU Vitamin D|
89242881|NCT03981562|Experimental|4000 IU Vitamin D|
89242882|NCT03981562|Placebo Comparator|Placebo|
89242883|NCT03981484|Experimental|PCC|single dose of 4-Factor PCC in addition to standard resuscitation methods
89242884|NCT03981484|Active Comparator|Standard of Care|standard resuscitation methods only
89242885|NCT03983200|Sham Comparator|Control group|Mecobalamine 0.5mg, tid
89242886|NCT03983200|Experimental|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min,bid + Mecobalamine 0.5mg, tid
89242887|NCT00567359|Experimental|Erlotinib|
89242888|NCT01063582||fighter pilots f-16|This group is made up of pilots from the F-16 Venezuelan military air force stationed in the Base Vicente Landaeta Gil de Barquisimeto, Lara State.
89242889|NCT01063582||aircraft maintenance personnel f-16|Staff responsible for the preparation of aircraft for the flight and maintenance in the hangar at the airbase Vicente Landaeta Gil de Barquisimeto, Lara. Venezuela
89242890|NCT04014725|Experimental|Eligible patients for AI test|
89242891|NCT01063660|Experimental|Treosulfan|Patients with acute myeloid leukaemia (AML) according to WHO classification (> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with < 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation
89242892|NCT00933569|Experimental|Dermacyd Silver Floral (Lactic Acid)|Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days
89242893|NCT00929435||MRSA surveillance|Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.
89242894|NCT00925847|Experimental|1|
89242895|NCT00492726|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
89242896|NCT00492726|Active Comparator|Ertapenem|Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
89242897|NCT00925925||Normal Birth Weight (NBW)|Term, healthy infants born at normal birth weights
89242898|NCT00925925||Low Birth Weight (LBW)|Infants born at > or equal to 34 0/7 weeks with a birth weight at < or equal to 10% for gestational age at birth (Small for Gestational Age, SGA)
89242899|NCT00933647|Experimental|Yerba Mate Tea|Subjects will drink 1000ml/day of yerba mate tea for 8 weeks.
89242900|NCT00933647|Active Comparator|Green Tea|Subjects will drink 1000ml/day of green tea for 8 weeks.
89242901|NCT00933647|Placebo Comparator|Apple Tea|Subjects will drink 1000ml/day of apple tea for 8 weeks.
89242902|NCT00933725|Experimental|TCM intervention|Particle of compound Chinese herbs and TCM emotion treatment and tablet placebo of Tibolone
89242903|NCT00933725|Active Comparator|Western intervention|Tibolone and supportive psychotherapy and Particle placebo of compound Chinese herbs
89242904|NCT00309946|Experimental|Treatment (enzyme inhibitor therapy)|Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
89242905|NCT00492648|Experimental|GSK1437173A 18-30 Years Old Group|Subjects aged 18 to 30 years old receiving 2 doses GSK1437173A vaccine in the primary study.
89242906|NCT00492648|Experimental|GSK1437173A 50-70 Years Old Group|Subjects aged 50 to 70 years old receiving 2 doses GSK1437173A vaccine in the primary study.
89242907|NCT00929591|Active Comparator|tamoxifen for five years|tamoxifen for five years
89242908|NCT00929591|Experimental|CAF followed by tamoxifen for five years|intermittent CAF X 6 courses followed by tamoxifen for five years
89242909|NCT00929591|Experimental|CAF with concurrent tamoxifen for five years|intermittent CAF X 6 courses with concurrent tamoxifen for five years
89242910|NCT01063738|Active Comparator|ICU Recovery Manual & placebo supplement|Patients will receive the standard self-directed rehabilitation package and a placebo nutritional supplement
89242911|NCT01063738|Experimental|ICU recovery manual & amino acid (AA) supplement|Patients will receive the standard self-directed rehabilitation package with the essential amino acid supplement
89242912|NCT01063738|Experimental|PEPSE & placebo supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the placebo nutritional supplement
89242913|NCT01063738|Experimental|PEPSE & AA supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the essential amino acid nutritional supplement
89242914|NCT00929747|Active Comparator|Toric IOL|AcrySof IQ Toric IOL
89242915|NCT00929747|Active Comparator|Limbal Relaxing Incision|AcrySof IQ with Limbal Relaxing Incision
89242916|NCT03997500|Placebo Comparator|Normal saline|Simultaneous with subarachnoid block, a bolus of normal saline was given followed by normal saline infusion
89242917|NCT03997500|Experimental|Norepinephrine|Simultaneous with subarachnoid block, a bolus of norepinephrine was given followed by norepinephrine infusion
89242918|NCT00933881||Gestational Diabetes Mellitus (GDM)|
89242919|NCT01013064|Experimental|Cohort1|
89242920|NCT01013064|Experimental|Cohort2|
89242921|NCT01013064|Experimental|Cohort3|
89242922|NCT01013064|Experimental|Cohort4|
89242923|NCT01013064|Experimental|Cohort5|
89242924|NCT01013064|Experimental|Cohort6|
89242925|NCT00933959|Experimental|Mind-Body Bridging Program|"Subjects will undergo two approximately 1.5 hr training sessions using MBBP spaced one week apart at the VASLCHCS. Each training session will comprise a number of objectives:~Session 1:~The patient will discover the underlying cause of the insomnia.~The patient will learn how to use easy to apply tools to quieten the mind to sleep soundly.~Session 2:~The patient will learn how to reduce daytime stress.~The patient will experience a greater sense of self.~To be maximally effective, the participant should master these objectives and practice MBBP on a daily basis. Bridging and all the other MBBP techniques can be implemented at any time throughout the day and right up to the onset of sleep."
89242926|NCT00933959|Active Comparator|Sleep Hygiene|Participants in the sleep hygiene arm will receive a 1 hr class directing them to the importance of following a list of up to 15 points (tips) for getting to sleep. These points include: limiting alcohol and caffeine intake before bed, using the bed only for sleeping, and having regular bedtimes. Once the instructor has gone over this list and has described in detail each of the 15 points, the class will have an opportunity to ask questions. The participant will be encouraged to learn and practice the objectives of the sleep hygiene class on a daily basis.
89242927|NCT01011660|Active Comparator|A,1,IV|A means active; 1 means Amlodipine+Amiloride Compound; IV means phase IV
89242928|NCT01011660|Active Comparator|A,2,IV|A means active; 2 means Amlodipine+Telmisartan; IV means phase IV
89242929|NCT01011660|Active Comparator|A,3,IV|A means active; 3 means Amlodipine+Amiloride Compound with or no Simvastatin; IV means phase IV
89242930|NCT01011660|Active Comparator|A,4,IV|A means active; 4 means Amlodipine+Telmisartan with or no Simvastatin; IV means phase IV
89242931|NCT04014881|Experimental|CD123+ Acute Myeloid Leukemia|Patients will receive CD123-targeted CAR-T cells in the dose-climbing trial. Each dose group has 3 patients and the the maximum dose can be extended.
89242932|NCT04015505|Experimental|Intervention|Participants will receive 5 sessions of a psychological (talking therapy) intervention based on the wisdom enhancement 'timeline technique' within cognitive behavioural therapy for older adults.
89242933|NCT01015248|Experimental|Rituximab and Bendamustine|
89242934|NCT00926081|No Intervention|Best medical treatment|Patients with peripheral artery disease receiving best medical treatment only
89242935|NCT00926081|Active Comparator|Supervised exercise training|Patients with peripheral artery disease receiving best medical treatment plus supervised exercise training
89242936|NCT00929825|Experimental|Elastomers|Patients will use hyperboloid as mechanical salivary stimuli. Patients will chew hyperboloid 3 times a day
89242937|NCT00929825|Experimental|TENS|TENS is a eletric stimuli that will be use in the skin near to parotid glands. Patients will receive TENS treatment as eletric salivary stimuli. Patients will receive TENS stimuli once a day for 15 days
89242938|NCT00929825|Experimental|Elastomers+TENS|Patients will receive TENS plus hyperboloid as eletric and mechanical treatment for salivary stimuli
89242939|NCT00929825|No Intervention|No therapy (control)|Patients will not receive intervention
89242940|NCT01013142|Experimental|MN-221|
89242941|NCT01013142|Placebo Comparator|MN-221 Placebo|
89242942|NCT00934037|Other|Combined CT Angiography and Myocardial Perfusion|Single Arm study. All patients underwent combined CT Angiography and Myocardial Perfusion.
89242943|NCT01013220|Experimental|Depression Product Detailing|Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org
89242944|NCT01013220|Placebo Comparator|Depression HEDIS Detailing|Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive
89242945|NCT04014569|Experimental|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA algorithm
89242946|NCT00506922|Experimental|No Pentostatin|Group 1: No Pentostatin
89242947|NCT00506922|Experimental|Pentostatin 0.5|Group 2: Pentostatin 0.5 mg/m^2
89242948|NCT00506922|Experimental|Pentostatin 1|Group 3: Pentostatin 1 mg/m^2
89242949|NCT00506922|Experimental|Pentostatin 1.5|Group 4: Pentostatin 1.5 mg/m^2
89242950|NCT00506922|Experimental|Pentostatin 2|Group 5: Pentostatin 2 mg/m^2
89242951|NCT00929903|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89242952|NCT01013298|Experimental|Video-guided PCT|Patients that will be extubated and re-intubated with the ETT-TVT, and monitored throughout intubation and PCT
89242953|NCT00934193|Active Comparator|Gabapentin|
89242954|NCT00934193|Placebo Comparator|Placebo|
89242955|NCT01013376|Experimental|Active|Topical administration of MC-1101
89242956|NCT01013376|Placebo Comparator|Vehicle|Vehicle
89242957|NCT00926159||ICD eligible|Patients with Ejection Fraction (EF) of 35% or less as determined by cardiac echocardiogram or cardiac nuclear scan.
89242958|NCT01011972|Experimental|XMT-1107|Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
89242959|NCT04014491|Experimental|Scapula control exercise|Subjects will perform three exercises with EMG biofeedback and verbal cues. Three exercises are elevation in scapular plane, sidelying external rotation and dynamic hug plus
89242960|NCT04014491|Experimental|Scapula strengthening exercise|The subjects in the scapular strengthening group will be asked to perform the three exercises the same as scapula control exercise group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
89242961|NCT04014491|Other|Healthy subject group|Healthy subjects will be included to compare the differences in corticospinal system between healthy subjects and subjects with shoulder impingement syndrome, so this group will not receive any treatment.
89242962|NCT01012050|Experimental|NV Group|Performed nebulization coupled with noninvasive ventilation
89242963|NCT01012050|Active Comparator|NEB group|Performed nebulization alone.
89242964|NCT00930137|Experimental|High dairy trans fat|a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal)
89242965|NCT00930137|Active Comparator|Low dairy trans fat diet|a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)
89242966|NCT01015404|Experimental|Experimental H|high volume (0.6mL、0.3% Trafermin)
89242967|NCT01015404|Experimental|Experimental L|low volume (0.2mL、0.3% Trafermin)
89242968|NCT00934271||Fractionated stereotactic radiotherapy|patients with active acromegaly
89242969|NCT00934349||Patient|Native to the Comoro Archipelago (Grande Comore, Mayotte, Anjouan, Mohéli) fulfilling the clinical definition of the dry beriberi.
89242970|NCT00934349||Control|Native to the Comoro Archipelago, living in the same household as the patient, sharing the same meals. Free from beriberi and with normal neurological examination.
89242971|NCT00492024|Experimental|Moxifloxacin 400 mg|Moxifloxacin 400mg once daily for 5 days
89242972|NCT00492024|Placebo Comparator|Placebo|Matching placebo for 5 days
89242973|NCT00934427|Active Comparator|Vascana|
89242974|NCT00934427|Placebo Comparator|Vehicle|
89242975|NCT00926315|Experimental|calcitriol|calcitriol supplementation (0.25 mcg 2x/d)
89242976|NCT01013454|Experimental|Varenicline transdermal delivery system|
89242977|NCT00930215|Experimental|D961H 40 mg gelatin capsule|2 way crossover
89242978|NCT00930215|Experimental|D961H 40 mg HPMC capsule|2 way crossover
89242979|NCT00926471|Experimental|Cognitive Behavioral Therapy (CBT) Program|Participants will receive a treatment program involving CBT plus adjunctive group counseling and parent training.
89242980|NCT00926471|No Intervention|Wait list control|Participants will be placed on a 12-week wait list with no active treatment
89242981|NCT00491556|Experimental|Experimental Arm|Subjects in the experimental group will begin HAART consisting of TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
89242982|NCT00491556|Other|Standard Care Arm|Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
89242983|NCT04015037|Experimental|Group A|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
89242984|NCT04015037|Experimental|Group B|The participants will be with age greater than 20 old, be in either the menacme (not pregnant). They will have complaints about sexual activity, an active sex life, and body mass index (BMI) equal to or less than 30. Through these criteria of inclusion and exclusion
89242985|NCT00926549|Experimental|spectral domain-OCT|Spectral domain-OCT scanning performed.
89242986|NCT00926627|Placebo Comparator|Placebo|placebo b.i.d.
89242987|NCT00926627|Experimental|Bosentan|62.5 mg/125 mg bosentan b.i.d.
89242988|NCT00934583|Experimental|Image and Mood (IaM) program|Participants will participate in the IaM program.
89242989|NCT00934583|No Intervention|Wait-list control|Participants will be placed on a wait list until after participants in the IaM group have completed all assessments. After that, these participants will be offered the option to complete the IaM program.
89242990|NCT00934739|No Intervention|Control|Standard postoperative concurrent chemoradiotherapy
89242991|NCT00934739|Experimental|Thalidomide, Celebrex|Adjuvant anti-angiogenesis therapy
89242992|NCT00934739|Active Comparator|Cyclophosphamide, Dexamethasone|Adjuvant anti-angiogenesis therapy
89242993|NCT01015482|Experimental|Remifentanil|Remifentanil Infusion
89242994|NCT01015482|Active Comparator|Midazolam|Active Placebo
89242995|NCT03760679|Active Comparator|Laryngeal mask Supreme|Device: Laryngeal mask Supreme
89242996|NCT03760679|Experimental|i-gel|Device: i-gel
89242997|NCT00934817|Experimental|TR sequential group|Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
89242998|NCT00934817|Active Comparator|RT sequential group|Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
89242999|NCT01013532|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
89243000|NCT01013532|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
89243001|NCT01013532|Experimental|Cilostazol|cilostazol plus placebo of aspirin
89243002|NCT01013532|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
89243003|NCT01012206|No Intervention|Control group|Children in control group obtained no lifestyle counseling (intervention).
89243004|NCT01012206|Active Comparator|Intervention group|Children in the intervention group and their parents were given lifestyle counseling and participated in an intervention program regarding food habits and physical activity.
89243005|NCT00926705|Active Comparator|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
89243006|NCT00926705|Experimental|Dexmedetomidine and Fentanyl|This group received a combination of Dexmedetomidine (1 ug/kg) and Fentanyl (1.79 ug/kg). Total number of patients in this group 24.
89243007|NCT00930449|Experimental|Cogmed Working Memory Training Program|
89243008|NCT00930449|Active Comparator|Academy of Math® program|
89243009|NCT00930449|Active Comparator|Special Education/Individualized Tutoring|
89243010|NCT00506454|Active Comparator|Lipidose|Dosage of 1.5 mL/kg of Lipidose over a 2-hour period.
89243011|NCT00506454|Placebo Comparator|Placebo|Dosage of 1.5 mL/kg of Placebo over a 2-hour period.
89243012|NCT03415139||Arm 1 for MRD HCT Recipients|Patients undergo an Oral Glucose Tolerance Test (OGTT) and 1 hyperglycemic clamp will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
89243013|NCT03415139||Arm 2 for MRD HCT Recipients|Patients undergo 2 Oral Glucose Tolerance Test (OGTTs) (with and without GLP-1 analogue) will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
89243014|NCT01012284|Experimental|Panel A|8 patients with moderate hepatic impairment classified as moderate as per the Child Pugh Classification.
89243015|NCT01012284|Experimental|Panel B|8 healthy participants who will match to patients with hepatic impairment in Panel A with regards to sex, age (more or less to 5 years), and body mass index.
89243016|NCT00934973|Active Comparator|mebeverine + no website|Mebeverine 135mg tds for 6 weeks
89243017|NCT00934973|Active Comparator|methylcellulose + no website|methylcellulose 3 tablets twice a day for 6 weeks
89243018|NCT00934973|Placebo Comparator|placebo + no website|placebo tablets
89243019|NCT00934973|Active Comparator|mebeverine + CBT website minimal support|mebeverine 135mg tds and access to website
89243020|NCT00934973|Active Comparator|methylcellulose + CBT website|methylellulose 3 tablets twice a day and access to website
89243021|NCT00934973|Placebo Comparator|placebo + CBT website minimal support|placebo tablets and access to website
89243022|NCT00934973|Active Comparator|mebeverine + CBT website with support|mebeverine 135mg tds and access to website with nurse support session
89243023|NCT00934973|Active Comparator|methylcellulose + CBT website support|methylcellulose 3 tablets twice a day and access to website with nurse support
89243024|NCT00934973|Placebo Comparator|placebo + CBT website with support|placebo tablets and access to website with nurse support
89243025|NCT00485472|Experimental|Lacosamide|lacosamide (LCM)
89243026|NCT00485472|Placebo Comparator|Placebo|Placebo
89243027|NCT00930605|Experimental|Alemtuzumab combination with CHOP and ESHAP|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5. CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
89243028|NCT01018836|Experimental|Riluzole; Radiation Therapy|
89243029|NCT00935051|Experimental|Arm 1|There is only one group of patients. Thus there is only one arm. Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. A numeric photograph of the wound will be taken at week 0, week 4 and week 12.
89243030|NCT04015661|Experimental|Nab-paclitaxel+Nedaplatin|induction chemotherapy by nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
89243031|NCT04015661|Active Comparator|Paclitaxel+Nedaplatin|induction chemotherapy by paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
89243032|NCT00491400|Active Comparator|Fenofibrate First|Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
89243033|NCT00491400|Active Comparator|Atorvastatin First|Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second
89243034|NCT04015583|Experimental|exergaming group|"The exergaming group (EXG) performed exercise using Exerheart® devices (D&J Humancare, Busan, South Korea) composed of a running/jumping mat [730(W) × 730(D) × 130(H)] and a tablet PC on a stand (can be adjusted to any height between 70 and 155 cm) (Supplemental Figure 1A). Exerheart® is an exergaming developed for in-situ running along with the video game called Alchemist's Treasure (D&J Humancare, Busan, South Korea). To play this game, the subject has to run or jump on a spot on the mat to move a virtual avatar on the screen of the tablet PC to the front, back, left, and right along with music. The subject can control the speed of avatar movement by running or jumping speed on the mat."
89243035|NCT04015583|Active Comparator|treadmill exercise group|The treadmill exercise group (TEG) performed exercise using commercial treadmills (MOTUS, Gyeonggi-do, South Korea). Each subject walked or ran on the treadmill at a comfortable speed.
89243036|NCT00491322|Experimental|Ergocalciferol group|Ergocalciferol 50000 international units once a week for 12 weeks
89243037|NCT00491322|Placebo Comparator|Ergocalciferol Placebo group|Matching placebo once a week for 12 weeks
89243038|NCT00930683|Other|1|MEDI-546
89243039|NCT00930683|Other|2|MEDI-546
89243040|NCT00930683|Other|3|MEDI-546
89243041|NCT00930683|Other|4|MEDI-546
89243042|NCT00930683|Other|5|MEDI-546
89243043|NCT00930683|Other|6|MEDI-546
89243044|NCT00930683|Other|7|MEDI-546
89243045|NCT00930683|Other|8|MEDI-546
89243046|NCT00930683|Other|9|MEDI-546
89243047|NCT00926861||Dry AMD|male or female persons aged over 50 years with dry age-related macular degeneration
89243048|NCT00935129|Experimental|OmniPod system|At this arm patients will be treated with the OmniPod system for 12 weeks
89243049|NCT00935129|Active Comparator|patient's conventional pump|At this arm patients will be treated with their conventional pump for 12 weeks
89243050|NCT00930839||Controls|Normal, healthy controls, males and females, ages 30-80
89243051|NCT00935207||Pediatric Pain Diary|Patients will be give a pain diary to complete.
89243052|NCT01013610|Active Comparator|Multiple Dose|
89243053|NCT01013610|Placebo Comparator|Placebo|
89243054|NCT00926939|Experimental|Abstinence Contingent (AC)|This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
89243055|NCT00926939|Experimental|Submission Contingent (SC)|This group receives vouchers for submitting videos of their CO breath test.
89243056|NCT01015716|Active Comparator|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
89243057|NCT01015716|Experimental|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
89243058|NCT00927017|Active Comparator|Liquorice 66 g/day|Liquorice given 66 grams per day for two weeks
89243059|NCT00927017|Active Comparator|Liquorice 102 g/day|Liquorice given 102 grams per day for two weeks
89243060|NCT03997032|Experimental|Patients with Diabetes|Patients with Type 1 or Type 2 Diabetes
89243061|NCT00930917|Experimental|cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
89243062|NCT00930917|Active Comparator|wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
89243063|NCT00930917|Other|conventional group|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
89243064|NCT01015794|Experimental|Adrenergic agonist|
89243065|NCT01015872|Experimental|CPAP|the subjects introduced with CPAP treatment
89243066|NCT00935363|Experimental|glyburide + fluconazole|
89243067|NCT00935363|Experimental|glyburide + rifampin|
89243068|NCT00935363|Active Comparator|glyburide|
89243069|NCT00935363|Experimental|glyburide + fluconazole + rifampin|
89243070|NCT00930995|Active Comparator|A|
89243071|NCT00930995|Placebo Comparator|B|
89243072|NCT00935441|Experimental|Telemonitoring|Case management with home telemonitoring for blood sugar and blood pressure plus home HbA1c measurement
89243073|NCT00935441|Active Comparator|Usual case management|Case management
89243074|NCT01015950|Experimental|Pumpy'Sup|Lipid-based nutrient supplement
89243075|NCT01015950|Experimental|SCSB|Processed, fortified, cereal-based food blend (SCSB for malnourished children)
89243076|NCT01015950|Experimental|Misola|Locally processed, fortified food blend (Misola)
89243077|NCT01015950|Active Comparator|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, oil) and a multiple micronutrient powder (Mix-Me) are provided to simulate the currently recommended enhanced home-prepared rehabilitation food mixture (farines enrchies) according to the national Mali CMAM protocol."
89243078|NCT00931073|Experimental|Period 1|
89243079|NCT00931073|Experimental|Period 2|
89243080|NCT00931073|Experimental|Period 3|
89243081|NCT01016028||Questionnaire + Sensory Tests + Interview|
89243082|NCT00935597|Experimental|Group 1|Patients with Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion
89243083|NCT00935597|Experimental|Group 2|Patients with greater than Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion in conjunction with donor lymphocyte infusion (DLI)
89243084|NCT00931151|Experimental|Casein|Protein source in the high fat meal is casein
89243085|NCT00931151|Experimental|Milk soluble protein|Protein source in the high fat meal are milk soluble protein
89243086|NCT00931151|Experimental|Alpha lactalbumin|Protein source in the high fat meal is alpha-lactalbumin
89243087|NCT00936689|Sham Comparator|Traditional TACE|Chemoembolization by standard technique: epirubicin (maximum dose of 75 mg) conjugated with an oil-based contrast medium (Lipiodol) at the maximum dose of 15 ml + gelatin sponge particles(particles of transient embolization material, required to obstruct the treated vessel).
89243088|NCT00936689|Active Comparator|TACE with microsphere|
89243089|NCT01018914|Active Comparator|Prograf with Myfortic|
89243090|NCT01018914|Experimental|Advagraf with Myfortic|
89243091|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh A|
89243092|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh B|
89243093|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh C|
89243094|NCT01019070|Active Comparator|BMS-650032 in Healthy Subjects|
89243095|NCT00936767|Experimental|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
89243096|NCT00936767|Active Comparator|Artesunate/Mefloquine (MAS3)|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
89243097|NCT00931229|Experimental|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines.
89243098|NCT01019226||cardiac MRI|Ischemic cardiomyopathy, non ischemic cardiomyopathy, myocarditis, cardiomyopathy
89243099|NCT00936845||Females with Hemophilia|Females with severe or moderate Hemophilia A or B.
89243100|NCT01013688|Experimental|left atrial RF ablation groups|Excised the left atrial appendage Encircling the left pulmonary veins and an extension to the posterior mitral valve annulus From the left atrial appendage to the left superior pulmonary vein A connecting line between both islands of pulmonary veins From the middle of the mitral valve ablation line down towards the base of the atria ligament of Marshall
89243101|NCT01013688|Experimental|Bi-atrial radiofrequency ablation group|In the basis of left atrial group,excised the right atrial appendage; from the amputated right atrial appendage towards the inferior vena cava; from the midterm of interatrial septum to the AV groove; ablation between the superior and inferior caval cannulation sites; radiofrequency ablation for Waterston's groove
89243102|NCT01013688|No Intervention|Amiodarone group|No radiofrequency ablation procedure during the valve surgery; Amiodarone 200 mg/day for 12 months after surgery
89243103|NCT00936923|Active Comparator|furosemide1|Patients will take furosemide 60mg per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
89243104|NCT00936923|Active Comparator|furosemide 2|Patients will take 120mg furosemide per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
89243105|NCT00936923|No Intervention|control|Patients in control group will not take furosemide
89243106|NCT01019382|Experimental|All patients|All patients entering the trial
89243107|NCT04014023|Experimental|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
89243108|NCT04014023|Experimental|DWP16001 Bmg|DWP16001 Bmg, Tablets, Orally, Once daily
89243109|NCT04014023|Experimental|DWP16001 Cmg|DWP16001 Cmg, Tablets, Orally, Once daily
89243110|NCT04014023|Placebo Comparator|Placebo|Placebo, Tablets, Orally, Once daily
89243111|NCT03997188|Experimental|Hepilor arm|patients received ZLC solution. The prescribed dose was 10 ml, in the morning and evening, between meals.
89243112|NCT03997188|Placebo Comparator|Placebo arm|Patients received a placebo solution. The prescribed dose was 10 ml, in the morning and evening, between meals
89243113|NCT00935675|Active Comparator|Antidepressant treatment|
89243114|NCT00935675|Placebo Comparator|Placebo|
89243115|NCT01016184|Active Comparator|vitamin D|
89243116|NCT01016184|Active Comparator|placebo|
89243117|NCT00502320|Experimental|Ramelteon|8 mg
89243118|NCT00502320|Placebo Comparator|Placebo|
89243119|NCT02567825|Active Comparator|Surgical Management|Tympanostomy Tube Placement Topical antimicrobial treatment of acute otitis media episodes with ofloxacin drops
89243120|NCT02567825|Other|Non-Surgical Management|Antimicrobial treatment of acute otitis media episodes with amoxicillin-clavulanate and/or ceftriaxone
89243121|NCT00490776|Experimental|Panobinostat 20 mg|Participants received panobinostat, 20 milligrams (mg), capsules, orally, thrice weekly on alternate Days 1, 3, and 5 per week of a 28-day treatment cycle until unacceptable toxicity, disease progression, and/or physician's discretion to discontinue the treatment.
89243122|NCT00935753|Experimental|Kuvan|10mg/kg Kuvan for 5 days followed by 20mg/kg Kuvan for a total of 60 days
89243123|NCT00935831|Experimental|Subjects with renal impairment, non-dialysis|Subjects with moderate to severe renal impairment equivalent to National Kidney Foundation Kidney Disease Outcomes Quality Initiative stage 3 and stage 4 who are not undergoing dialysis will be included. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
89243124|NCT00935831|Experimental|Healthy volunteers|Healthy subjects will be matched to the moderate and severe renally impaired subjects for gender, age, and BMI. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
89243125|NCT00935831|Experimental|Hemodialysis dependent subjects|The arm will consist of subjects with severe renal impairment (end-stage renal failure) who have been on stable hemodialysis treatment scheduled three times per week. Subjects will receive single oral doses of 150 mg GSK1278863A in each of 2 dosing periods in an open-label, fixed sequence. GSK1278863A will be administered just prior to receiving scheduled hemodialysis in Dosing Period 1. In Dosing Period 2, subjects will receive a single oral dose of GSK1278863 the morning after completion of a scheduled hemodialysis session.
89243126|NCT00566735|Placebo Comparator|1|
88804697|NCT00004162|Experimental|Dose group 4 - dose 4 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
88804698|NCT00004162|Experimental|Dose group 5 - dose 5 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
89243127|NCT00566735|Active Comparator|2, Galantamine|
89243128|NCT03653273|Experimental|DMT withdrawal|DMT will be immediately stopped after randomization.These patients will be followed for 2 years.
89243129|NCT03653273|Active Comparator|DMT continuation|The previously established therapy will be continued at the same dose during two years.
89243130|NCT00936143|Experimental|infliximab|200mg infliximab inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
89243131|NCT04013633|Experimental|Lifesaver virtual reality (VR) training|Training using the Lifesaver VR application. Lifesaver VR is an interactive game that can be played on smartphones allowing users to 'resuscitate' a victim of cardiac arrest, while wearing VR-goggles showing a filmed CPR-scenario
89243132|NCT04013633|Active Comparator|Face-to-face training|A short face-to-face CPR training based on international guidelines provided by certified instructors
89243133|NCT00566111|Active Comparator|A|
89243134|NCT00566111|Placebo Comparator|P|
89243135|NCT00937313||Champagne wine|
89243136|NCT00937313||Placebo|alcohol with sparkling mineral water
89243137|NCT00514046|Experimental|Vandetanib|Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 150 mg/m^2/day.
89243138|NCT00937469|Experimental|Social sk. tr., parent tr.,standard tr.|
89243139|NCT00937469|Active Comparator|Standard treatment|
89243140|NCT04014101|Experimental|SHR-1210+ apatinib|SHR-1210 was administered intravenously (without prophylaxis) at a fixed dose of 200 mg for 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 2 years; Apatinib was taken orally after meals, once a day, for continuous medication, and 1 cycle every 4 weeks.
89243141|NCT04014257|Experimental|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A(TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
89243142|NCT04618250|Experimental|Coordinated, co-produced health care|
89243143|NCT04618250|No Intervention|Care as usual|Care as usual
89243144|NCT04264052||CBE & MRI|Forty healthy volunteers split in different age ranges (20-30 years n=10, 30-40 years n=10, 40-50 years n=10 and 50-60 years n=10) will undergo two airway assessments at rest and during exercise. The exercise assessments will be a continuous bronchoscopy during exercise (CBE-1st visit) and magnetic resonance imaging (MRI-2nd visit) separated by at least three days to ensure for a sufficient cardiorespiratory and musculoskeletal recovery.
89243145|NCT00564629|Experimental|IV acetaminophen plus oral placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive 1 g of acetaminophen in 100 ml of intravenous solution and oral placebo.
89243146|NCT00564629|Active Comparator|Oral acetaminophen plus IV placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive oral acetaminophen 1 g plus 100 ml of intravenous placebo solution.
89243147|NCT00564395|Experimental|Insulin Detemir+RAI, then Insulin Detemir and RAI separately|Participants first received, Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for 10 days. Then they received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for the next 10 days.
89243148|NCT00564395|Active Comparator|Insulin Detemir and RAI separately, then Insulin Detemir+RAI|Participants first received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for 10 days. Then they received Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for the next 10 days.
89243149|NCT00940199||Standard of Care|I:Application of L-M-X topical anesthetic cream 4% to the breast within one hour of sub-areaolar injection of 4 ml 99mTc-sulfur colloid (1 mCi in normal saline)
89243150|NCT00940199||1 mCi in sodium bicarbonate|II. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate)
89243151|NCT00940199||1 mCi in 1% Lidocaine|III. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in 1% Lidocaine)
89243152|NCT00940199||1 mCi in sodium bicarbonate + 1% Lidocaine|IV. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate + 1% Lidocaine)
89243153|NCT00937703|Placebo Comparator|Group1: Control group|face to face visit à T4mounths
89243154|NCT00937703|Active Comparator|Group2: IVS Group|face to face visit at T4mounths plus telephone visits each 2 weeks
89243155|NCT00937703|Active Comparator|Group3: PDAphone group|PDA system face to face visit at T4mounths plus telephone visits each 2 weeks
89243156|NCT00939419|Other|Health worker TB care group|
89243157|NCT00939419|Other|Community health worker TB care group|
89243158|NCT00939419|Other|Self-administered treatment group|
88804699|NCT00004162|Experimental|Dose group 6 - dose 6 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
88804700|NCT00004162|Experimental|Dose group 7 - dose 7 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
88804701|NCT00004162|Experimental|MTD group|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
89243159|NCT04013243|Active Comparator|Magnesium Sulfate group|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
89243160|NCT04013243|Placebo Comparator|Placebo group|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
89243161|NCT00940277|Experimental|Enhanced Couples Group|Enhanced Couples Group: consists of eight 90-minute sessions, conducted weekly. ECG has a didactic educational content presented by the group leader or practice of specific relationship communication, relationship support, and couple-focused stress management. ECG participants are also given instruction about what types of behaviors are unsupportive and training in how to not behave in an unsupportive manner.
89243162|NCT00940277|Experimental|Support Group|Support Group: 8 weekly 90-minute group counseling sessions. Using a standard approach to supportive therapy, the group interventionists will focus on encouraging participants to share their experiences with cancer, express their emotions related to the experience, voice problems they have in coping with the cancer, and offer support and advice to other members of the group. The co-facilitators will facilitate expression of affect and the sharing of the group's common issues related to cancer. Each session has a broad topic for discussion. Topics include communication with health care providers, issues related to occupational life, and coping with medical procedures and treatment. No formal or didactic information will be provided.
89243163|NCT03160547|Active Comparator|Usual Protein/Amino Acid Group|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
89243164|NCT03160547|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
89243165|NCT00938093|Active Comparator|Cognitive-behavioral therapy|cognitive-behavioral therapy
89243166|NCT00938093|Placebo Comparator|Enhanced usual care|enhanced usual care
89243167|NCT00938171|Active Comparator|local anesthesia|local anesthesia with propofol sedation Target-controlled infusion (TCI) system will be used to maintain proper sedation level)
89243168|NCT00938171|Active Comparator|General anesthesia|Patients receiving general anesthesia
89243169|NCT00938249|Experimental|Monascus Garlic Fermented Extract|
89243170|NCT00938249|Placebo Comparator|Placebo|
89243171|NCT00940355|Experimental|Intervention pulmonary nurse|group III: intervention conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, increasing motivation to engage in additional treatment, and improving health status.
89243172|NCT00940355|No Intervention|Usual care|group II: usual care as delivered by the outpatient clinic.
89243173|NCT00940433|Active Comparator|open properitoneal|patients undergoing open properitoneal hernia repair
89243174|NCT00940433|Active Comparator|Lechtenstien repair|Patients undergoing Lechtestien hernia repair
89243175|NCT00940433|Active Comparator|Laparoscopic transperitoneal repair|Patients undergoing TAPP repair
89243176|NCT00940433|Active Comparator|Lap totally extraperitoneal approach|Patients undergoing TEP approach
89243177|NCT00502242|Active Comparator|A|Capsule - initial treatment is 5 mg (active)- oral - once per day
89243178|NCT00502242|Placebo Comparator|B|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
89243179|NCT00938405|Experimental|Colesevelam HCl|Beginning at Visit 1, two weeks after screening, subjects in the active treatment group will take 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
89243180|NCT00938405|Placebo Comparator|Comparison group|Beginning at Visit 1, two weeks after screening, subjects in the comparison group will be administered placebo, taking 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
89243181|NCT00938483|Experimental|Extensively hydrolyzed infant formula|New extensively hydrolyzed formula, NPS-202
89243182|NCT00938483|Active Comparator|Infant formula - Extensively hydrolyzed Nutramigen Lipil|Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)
89243183|NCT00938561||With and without Chronic Kidney Disease|A cohort of 10 patients subjects with and without kidney disease exhibiting a broad range of age and kidney function
89243184|NCT03045653|Experimental|treatment arm|receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
89243185|NCT03972137|Experimental|Heart Rate Variability Biofeedback-Smoking Cessation Therapy|All participants in this open trial received individualized cognitive-behavioral smoking cessation treatment (SCT), up to 8 weeks of the transdermal nicotine patch (NRT) and individualized heart rate variability biofeedback (HRVB).
89243186|NCT00940511|Experimental|Coordinated care|Individuals will be passively enrolled in Medicaid managed care. Those who do not opt out of managed care will be provided with care coordination.
89243187|NCT00940511|No Intervention|Usual care|The usual care group will remain in fee-for-service Medicaid and receive services normally available through that system.
89243188|NCT00490698|Experimental|Zoledronate + Atorvastatin|Zoledronate 4 mg intravenous (IV) once every 4 Weeks + Atorvastatin 20 mg orally (PO) daily
89243189|NCT04492254|Experimental|Enoxaparin|(40 mg o/d if < 100 kg, 40 mg b/d if ≥ 100 kg)
89243190|NCT04492254|No Intervention|Current standard of care (no enoxaparin)|Standard of care
89243191|NCT01013766|Other|AM/PM/BID|Subjects will receive a dose of 100mg in the AM on Day 1, followed by a dose of 100mg in the PM on Day 4, and a dose of 50mg BID on Day 6.
89243192|NCT01013766|Other|PM/AM/BID|Subjects will receive a dose of 100mg in the PM on Day 1, followed by a dose of 100mg in the AM on Day 4, followed by 50mg BID on Day 6.
89243193|NCT01013922||No treatment|Patients with a smoking history of 15 pack years or more.
89243194|NCT00939575||Preeclampsia|Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of gestation in a previously normotensive woman, a diastolic blood pressure > 90 mmHg recorded twice at least four hours apart or > 110 mmHg, with proteinuria > 300 mg/24h or > 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to SOGC consensus ).
89243195|NCT00939575||control|Women will be matched to women with pre-eclampsia according to gestational age at diagnosis of preeclampsia, maternal age (in stratum of 5 years), gender, ethnicity (4 categories: Caucasian, black, Asian and other) and body mass index (5 classes: <20, 20-25, 26-30, 31-35 and <35). Patients of this group should be at low risk of obstetric complications at recruitment and planning to deliver at the CHUS.
89243196|NCT03855228|Experimental|MFNS 200 µg + Loratadine 10 mg|Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.
89243197|NCT03855228|Active Comparator|MFNS 200 µg|Daily administration of 200 µg of MFNS plus oral placebo tablet.
89243198|NCT03855228|Active Comparator|Loratadine 10 mg|Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.
89243199|NCT03855228|Placebo Comparator|Placebo|Daily administration of placebo nasal spray plus oral placebo tablet.
89243200|NCT04013165|Active Comparator|Active control|Usual care of the Community Mental Health Service
89243201|NCT04013165|Experimental|Village-based intervention|Individual-based case management + group-based program
89243202|NCT04013477|Experimental|Cohort1|"drug : DA-5207 80mg/40cm²~placebo : 40cm²"
89243203|NCT04013477|Experimental|Cohort2|"drug : DA-5207 120mg/60cm²~placebo : 60cm²"
89243204|NCT04013477|Experimental|Cohort3|"drug : DA-5207 160mg/80cm²~placebo : 80cm²"
89243205|NCT04013477|Active Comparator|Cohort4|drug : Aricept
89243206|NCT00511238|Experimental|carfilzomib (A0)|
89243207|NCT00511238|Experimental|carfilzomib (A1)|
89243208|NCT00940667|Experimental|amlodipine/losartan 5/50mg|
89243209|NCT00940667|Active Comparator|amlodipine 5mg|
89243210|NCT04013087|Experimental|Test Formula|Feihe Stage 1 infant formula
89243211|NCT04013087|Active Comparator|Control formula|A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used)
89243212|NCT04013087|Other|Breast feeding|Breast fed of human milk
89243213|NCT01019772|Experimental|LBVH0101|
89243214|NCT01019772|Active Comparator|Hiberix|
89243215|NCT00940745|Experimental|Stereotactic Aspiration and Thrombolysis|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
89243216|NCT00940745|Active Comparator|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
89243217|NCT01014000|Active Comparator|Empirical|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
89243218|NCT01014000|Experimental|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
89243219|NCT00513500|Experimental|1|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.
89243220|NCT00513500|Active Comparator|2|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility
89243221|NCT03969719|Placebo Comparator|Placebo|Palacebo
89243222|NCT03969719|Experimental|Low Dose|150 mg
89243223|NCT03969719|Experimental|High Dose|300 mg
89243224|NCT03998072|Experimental|Intervention|
89243225|NCT03998072|No Intervention|Treatment as usual (waiting list control)|
89243226|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole -STD|Standard therapy of DEC (300mg) and albendazole (400mg) yearly
89243227|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole- HD1|High dose of DEC (300mg) and albendazole (800mg) yearly
89243228|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole-HD2|High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)
89243229|NCT02550197|Experimental|QIV Group|Subjects will receive one dose of the Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation
89243230|NCT02550197|Active Comparator|TIV Group|Subjects will receive one dose of the Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
89243231|NCT01009424|Experimental|1|R7103 (dose 1) followed by placebo or placebo followed by R7103 (dose 1)
89243232|NCT01009424|Experimental|2|R7103 (dose 2) followed by placebo or placebo followed by R7103 (dose 2)
89243233|NCT01009424|Experimental|3|R7103 (dose 3) followed by placebo or placebo followed by R7103 (dose 3)
89243234|NCT01009424|Experimental|4|R7103 (dose 4) followed by placebo or placebo followed by R7103 (dose 4)
89243235|NCT01009424|Experimental|5|R7103 (dose 5) followed by placebo or placebo followed by R7103 (dose 5)
89243236|NCT01009424|Experimental|6|R7103 (dose 6) followed by placebo or placebo followed by R7103 (dose 6)
89243237|NCT00938795|Other|Uncertainty Management Intervention|The Uncertainty Management Intervention will consist of six 30-minute phone calls with a study educator to discuss issues of psychological distress, uncertainty management, symptom control, self efficacy for symptom management, and quality of life.
89243238|NCT00938795|Other|Comparison Conditions for Liver Disease|Six 30-minute telephone calls that provide structured education about liver disease.
89243239|NCT00939887|Experimental|Treatment|
89243240|NCT00938873||Mindfulness Based Cognitive Therapy|The present study will use participants who have experienced more than three episodes of depression as judged by South London and Maudsley NHS Trust. No restrictions are placed in terms of participants' use of antidepressant medication. Participants will be 18 to 65 years old and would have participated in an MBCT course run by South London and Maudsley NHS Trust.
88804702|NCT01262599|Sham Comparator|Sham PEMF Device|Patients will receive inactive device
89243241|NCT04012541|Experimental|treatment group|"post-myocardial infarction management~basic periodontal examinations~active dental procedure"
89243242|NCT04012541|Active Comparator|control group|"post-myocardial infarction management~basic periodontal examinations"
89243243|NCT02877134|Experimental|Part I : Placebo|Participants will receive placebo Subcutaneously (SC) at Weeks 0, 2, 4, 6, 8, and 10. From Week 12 Placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) or CDAI <150) will continue to receive placebo SC injections every 2 weeks from Week 12 through Week 22. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 400 mg SC at Week 12 and then JNJ-64304500 200 mg every two weeks from Week 14 through Week 22.
89243244|NCT02877134|Experimental|Part I : JNJ-64304500|Participants will receive JNJ-64304500 400 milligram (mg) SC at Week 0 then 200 mg SC every two weeks through Week 22.
89243245|NCT02877134|Experimental|Part II : Placebo|"Placebo SC at Weeks 0, 2, 4, and 8. From Week 12, placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in CDAI or CDAI <150) will continue to receive placebo at Weeks 12, 14, 16, and 20. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 150 mg SC at Week 12 and then JNJ-64304500 75 mg at Weeks 14, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive placebo up to 52 weeks (for a total of up to 72 weeks of placebo in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ- 64304500. Participants receiving placebo during the LTE will stop receiving placebo."
89243246|NCT02877134|Experimental|Part II : JNJ-64304500 High Dose|"JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 high dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
89243247|NCT02877134|Experimental|Part II : JNJ-64304500 Middle Dose|"JNJ-64304500 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 middle dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
89243248|NCT02877134|Experimental|Part II : JNJ-64304500 Low Dose|"JNJ-64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 low dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
89243249|NCT02877134|Experimental|Part II : Ustekinumab|"Participants will receive tiered doses of Ustekinumab 260 mg (weight <=55 kg), Ustekinumab 390 mg (weight >55 kg and <=85 kg), Ustekinumab 520 mg (weight >85 kg) intravenously at Week 0 followed by 90 mg subcutaneously at Weeks 8 and 16. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive Ustekinumab up to 52 weeks (for a total of up to 72 weeks of Ustekinumab in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving Ustekinumab during the LTE will stop receiving study drug and will have a final safety follow-up visit after the last dose of study drug. However, participants receiving Ustekinumab in countries where Ustekinumab is not commercially available or approved for adult Crohn's disease were continued to receive Ustekinumab in the LTE."
89243250|NCT00563381|Active Comparator|Tiotropium + Placebo|patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily
88804703|NCT01262599|Active Comparator|PEMF Device|Patients will receive Ivivi Torino II PEMF Device
88804704|NCT01262755||African Americans|Consists of 450 African Americans living in the zip code surrounding Temple Hospital between the ages of 18 and 80.
88804705|NCT00004984|Experimental|Parenteral Insulin|High risk participants randomized to intervention
89243251|NCT00563381|Active Comparator|Salmeterol + Placebo|patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily
89243252|NCT00512798|Experimental|Phase I|
89243253|NCT00512798|Experimental|Phase II|
89243254|NCT03998930|Experimental|brain injuried patients|"Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R),~15-minute break between the two evaluations.~Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task (imagine moving the right or left wrist)."
89243255|NCT00940043||Rupture of fetal membranes|women with rupture of fetal membranes before onset of labor
89243256|NCT03743207|Experimental|Room temperature|All of the infants in neonatal intensive care units are used to be fed with milk at 22-24°C which is close to room temperature.
89243257|NCT03743207|Experimental|Warmer temperature|The investigators decided to feed the infants in this group with warmer milk at to examine the effects of feeding temperature.
89243258|NCT00940121|Experimental|1. mirabegron, low dose|Oral mirabegron 25 mg
89243259|NCT00940121|Experimental|2. mirabegron, middle dose|Oral mirabegron 50 mg
89243260|NCT00940121|Experimental|3. mirabegron, higher dose|Oral mirabegron 100 mg
89243261|NCT00565721|Experimental|Fluciclatide Injection - (AH111585 (F18))|Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide.
89243262|NCT00940979|No Intervention|No use of integuseal|
89243263|NCT00940979|Experimental|Use of Integuseal|Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.
89243264|NCT00938951|Experimental|Systane® Ultra|Systane® Ultra
89243265|NCT04012619|Experimental|Anlotinib Hydrochloride Combined With AP|Patients receive pemetrexed (500mg/m2) with cisplatin (75mg/m2)/carboplatin (area under the curve 5) once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14 of a 21-day cycle. Anlotinib with AP will be administrated up to 4 cycles followed by maintenance treatment with anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle until disease progression or treatment intolerance.
89243266|NCT00561977|Active Comparator|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
89243267|NCT00561977|Active Comparator|Low Saturated Fat|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal per day.
89243268|NCT00561977|Active Comparator|Combination Diet|Combination low saturated fat (≤7% of total calories);high fiber (>30g fiber per day) -500 kcal from RMR, not less than 1200 kcal/day.
89243269|NCT00941057|Experimental|Estradiol + dienogest + levomefolate|Treatment A
89243270|NCT00941057|Active Comparator|Estradiol + dienogest|Treatment B
89243271|NCT00941057|Active Comparator|Levomefolate|Treatment C
89243272|NCT00561821|Experimental|Esmirtazapine 0.5 mg|one placebo tablet daily for 14 days, followed by one 0.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
89243273|NCT00561821|Experimental|Esmirtazapine 1.5 mg|one placebo tablet daily for 14 days, followed by one 1.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
89243274|NCT00561821|Experimental|Esmirtazapine 3.0 mg|one placebo tablet daily for 14 days, followed by one 3.0 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
88804706|NCT00004984|Active Comparator|Close Observation|High risk participants randomized to observation
88804707|NCT00004984|Experimental|Oral Insulin|Intermediate risk participants randomized to intervention
89243275|NCT00561821|Placebo Comparator|Placebo|one placebo tablet daily for 14 days, followed by one placebo tablet daily for 16 days, and then one placebo tablet daily for 7 days
89243276|NCT00558701|Active Comparator|Microcurrent Stimulator + Silverlon|Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
89243277|NCT00558701|Sham Comparator|Silverlon alone|Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
89243278|NCT03684044|Experimental|Baloxavir Marboxil|"Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
89243279|NCT03684044|Placebo Comparator|Placebo|"Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
89243280|NCT01009502|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
89243281|NCT00510692|Experimental|2g/day Eicosapentanoic Acid (EPA)|"Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.~Endoscopy and biopsies taken as described under intervention."
89243282|NCT00510692|Placebo Comparator|Placebo|Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.
89243283|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA high dose|
89243284|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA low dose|
89243285|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA high dose|
89243286|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA low dose|
89243287|NCT00522548|Active Comparator|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) at a target dose of 720 mg orally twice daily for 6 months after transplant.
89243288|NCT00522548|Active Comparator|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent manufactured by Sandoz, at a target dose of 1000 mg orally twice daily for 6 months after transplant.
89243289|NCT00522392|Experimental|Arm A (VRD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.
89243290|NCT00522392|Active Comparator|Arm B (VD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.
89243291|NCT04346264||General Cohort|Population general cohort from the Austrian LEAD Study
89243292|NCT01061320|Active Comparator|alpha tocopherol|
89243293|NCT01061320|Placebo Comparator|placebo|
89243294|NCT01061398|Experimental|Cardiac CT Arm|Patients referred for stress imaging due to complaints consistent with possible angina, randomized to receive an additional cardiac CT scan.
89243295|NCT01061398|Active Comparator|No CT Arm|Patients with symptoms consistent with possible angina, randomized to receive the type of stress imaging test ordered by their physician.
89243296|NCT01565408|Experimental|NNC0114-0006|
89243297|NCT01565408|Placebo Comparator|Placebo|
89243298|NCT03985306|Experimental|Feasibility trial group|Every trial patient will receive the intervention (the inforatio technique) that is intended for the definitive randomized clinical trial.
89243299|NCT01012544|Active Comparator|stent thrombosis patients|Patients with a history of a stent thrombosis
89243300|NCT01012544|Active Comparator|Patients without a history of a stent thrombosis|Patients without a history of stent thrombosis
89243301|NCT01012700|No Intervention|intranasal or IV|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
89243302|NCT01012700|Active Comparator|Hiltonol (poly ICLC)|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
89243303|NCT01012778|Experimental|Climbup ADHD and Dyslexia Program|"Open label - intervention with pre and post parameters collected~Intervention: Yoga, Meditation, Play therapy for children with ADHD and Dyslexia twice a week in classroom with 6 week and 12 month, primary outcomes in terms of Vanderbilt ADHD scores"
89243304|NCT01565486|Other|Ultrasonic coagulation device|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
89243305|NCT01565486|Other|Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
89243306|NCT01565720|Experimental|Group 1|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole low dose once a day (QD) for 11 days
89243307|NCT01565720|Experimental|Group 2|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole high dose once a day (QD) for 11 days
88804708|NCT00004984|Placebo Comparator|Placebo|Intermediate risk participants randomized to placebo
88804709|NCT01284517|Experimental|Lurasidone 20-120 mg flexible dose|
89243308|NCT01565720|Placebo Comparator|Group 3|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 11 days
89243309|NCT01565720|Active Comparator|Group 4|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 10 days and then moxifloxacin on Day 13
89243310|NCT00309244|Experimental|TI + Insulin glargine|Technosphere® Insulin Inhalation Powder + insulin glargine
89243311|NCT00309244|Active Comparator|BPR 70/30|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
88804710|NCT01284517|Placebo Comparator|Placebo|
89243312|NCT00483756|Active Comparator|1|Treatment Arm 1 will also receive standard of care medications
89243313|NCT00483756|Experimental|2|Treatment Arm 2 will also receive standard of care medications
89243314|NCT00483756|Experimental|3|Treatment Arm 3 will also receive standard of care medications
89243315|NCT00309166|Experimental|Cervarix Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
89243316|NCT00309166|Active Comparator|Engerix-B Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Engerix-B™ (HBV) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
89243317|NCT01063816|Experimental|Arm 1|
89243318|NCT00501852|Experimental|NVA237 12.5 µg|12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
89243319|NCT00501852|Experimental|NVA237 25 µg|25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
89243320|NCT00501852|Experimental|NVA237 50 µg|50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
89243321|NCT00501852|Experimental|NVA237 100 µg|100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
89243322|NCT00501852|Placebo Comparator|Placebo|Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
89243323|NCT00501852|Active Comparator|Tiotropium 18 µg|18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
89243324|NCT03981250|No Intervention|Control Group|The control group will be asked to keep their lifestyle behaviour and not increase their physical activity levels during the study period.
89243325|NCT03981250|Experimental|Exercise Group|The exercise group will engage in a home-based resistance exercise intervention for 12 weeks. They will perform 6 exercises, one each day for one minute, for 6 days a week.
89243326|NCT03985462|Experimental|VSEL Max|A total of 300,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a high dose group
89243327|NCT03985462|Experimental|VSEL Medium|A total of 200,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a middle dose group
89243328|NCT03985462|Experimental|VSEL Mini|A total of 100,000 VSEL cells in 5 mL plate-rich plasma are injected into the bilateral fallopian tubes as a low dose group
89243329|NCT03985462|No Intervention|Control|5 mL plate-rich plasma with no cells inside were injected into the bilateral fallopian tubes as a control group
89243330|NCT03983122|Experimental|Study group|Patients who undergo laparoscopic sleeve gastrectomy
89243331|NCT00490542|Placebo Comparator|Placebo arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received sugar pills.
89243332|NCT00490542|Active Comparator|Geodon arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received Geodon.
89243333|NCT03982966|Experimental|Omega 3|Group 1 will be 40 patients that will take Omega 3 fatty acids (fish oil)
89243334|NCT03982966|No Intervention|Control|20 patients will not take omega 3 fatty acids.
89243335|NCT01016418|Experimental|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
89243336|NCT01059604||Pregnant women exposed to sumatriptan, naratriptan, or combo|Women exposed to sumatriptan, naratriptan or the sumatriptan-naproxen combination treatment during pregnancy
89243337|NCT02532634|Experimental|ramosetron, aprepitant, dexamethasone|"Ramosetron 0.3mg IV day1~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
89243338|NCT02532634|Active Comparator|palonosetron, aprepitant, dexamethasone|"Palonosetron 0.25mg IV day1~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
89243339|NCT03981172||Non-obese/HED|Non-obese women given 60 gram portions of high energy density snack foods to consume daily for two weeks.
89243340|NCT03981172||Non-Obese/LED|Non-obese participants that were given 60 gram portions of low energy density foods to consume daily for two weeks.
89243341|NCT03981172||Obese/LED|Obese participants that were given 60 gram portions of low energy density snack foods to consume daily for two weeks.
89243342|NCT03981172||Obese/HED|Obese participants that were given 60 gram portions of high energy density snack foods to consume daily for two weeks.
89243343|NCT00501540|Experimental|Lithium|Lithium carbonate will be dosed on a flat scale of mg/day and not by weight or body surface area (BSA). Lithium carbonate will be provided as a 300mg tablet and will be taken daily without breaks in treatment.
89243344|NCT01014156|Experimental|epoprostenol intraveneously|epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
89243345|NCT00322348|Experimental|ZOLADEX 10.8 mg|ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks
89243346|NCT00322348|Experimental|ZOLADEX 3.6 mg|ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks
89243347|NCT01014234|Experimental|Rapamycin|Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
89243348|NCT01014234|Active Comparator|cyclosporine|Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
89243349|NCT00501228|Experimental|Filgrastim Injections|
89243350|NCT00308620|Experimental|Chloroquine|Chloroquine 205mg or 500mg orally once daily (Results pooled)
89243351|NCT00308620|Placebo Comparator|Placebo|Placebo once daily for 8 weeks
89243352|NCT01014312|Experimental|Depression Care Management (DCM)|Participants will receive Depression Care Management.
89243353|NCT01014312|Active Comparator|Enhanced Care|Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.
89243354|NCT01016496|Experimental|Action observation plus repetition|Observation of actions and repetition of the same actions
89243355|NCT01016496|Active Comparator|repetition only|repetition of gestures
89243356|NCT00492752|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was administered orally at a dose of 400 mg (2 x 200 mg tablets) bid (twice daily); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily (od) and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment.
89243357|NCT00492752|Placebo Comparator|Placebo|Placebo tablets matching in appearance were orally administered bid (twice daily).
89243358|NCT01016574|Other|women with stage I or II breast cancer|
89243359|NCT01009658|Active Comparator|MSG first|
89243360|NCT01009658|Placebo Comparator|NaCl first|
89243361|NCT05113706||Bystander not emotional distressed|If caller is not emotional distressed the first minute of the call
89243362|NCT05113706||Bystander emotional distressed|If caller is emotional distressed the first minute of the call
89243363|NCT00308308|Experimental|1|Technosphere Insulin
89243364|NCT00308308|Active Comparator|2|Rapid-acting analogue insulin plus basal insulin glargine
89243365|NCT00505934|Experimental|Levetiracetam|
89243366|NCT02532790|Experimental|group 1|Prednisone Drug : prednisone 1.5mg/kg/d for 4-6 weeks, then 1.5mg/kg/d qod for 4 weeks, reduce 5mg every 2-4 weeks If the proteinuria decreases by less than 50% after treating for two months, this candidate reaches the ending point.
89243367|NCT02532790|Experimental|group 2|Angiotension converting enzyme inhibitors(ACEI) Drug: lotensin 0.2-0.3mg/kg/d (the maximum dose is 20mg)
89243368|NCT03981406|Experimental|Palliative Care|Palliative care is comprehensive, coordinated interdisciplinary care for patients and families facing a potentially life-threatening illness. This consists of specially trained teams of professionals including physicians, nurses, social workers, and chaplains that provide care and support in inpatient and outpatient settings.
89243369|NCT03981406|Placebo Comparator|Standard of Care|Standard of care for idiopathic pulmonary fibrosis
89243370|NCT00505778|Active Comparator|Mesalamine (Asacol) Once-Daily|an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)
89243371|NCT00505778|Active Comparator|Mesalamine (Asacol) Twice-Daily|an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)
89243372|NCT01061554|Experimental|Gastric stable emulsion|A gastric stable emulsion vehicle for administration of tri-glyceride based omega-3 oils
89243373|NCT01061554|Active Comparator|Soft gel capsule (TG)|Soft gel capsule for administration of tri-glyceride based omega-3 oils
88804711|NCT01216735|Active Comparator|smokers, Fluticasone first, then Placebo|The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) . The subjects and the investigators will be blinded to the random choice of inhaler.
89243374|NCT01061554|Active Comparator|Soft gel capsules (MPL)|Soft gel capsule for administration of marine phospholipids based omega-3 oils
89243375|NCT01063894|Experimental|breakfast cereal|breakfast cereal and milk
89243376|NCT01063894|Placebo Comparator|water|water
89243377|NCT01064050|Experimental|trachea-bronchial stent (Novatech)|
89243378|NCT01064050|No Intervention|control|
89243379|NCT00308074|Experimental|Aripiprazole|aripiprazole monotherapy, begun at 2.5 mg or 5.0 mg based on clinical impression and severity of aggression and agitation. Dose to be adjusted in not more than 5 mg increments, weekly. The lowest effective dose will be used up to a maximum daily dose of 20 mg.
89243380|NCT01059838|Experimental|single subject|
89243381|NCT03997058|No Intervention|Control group|
89243382|NCT03997058|Experimental|Auricular acupoint pressing group|
89243383|NCT03997058|Active Comparator|Oral estazolam group|
89243384|NCT03997058|Active Comparator|Combined treatment group|
89243385|NCT00500760|Experimental|Panitumumab Plus Chemoradiation|Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.
89243386|NCT00500760|Active Comparator|Chemoradiotherapy Alone|Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m^2 on Days 1, 22, and 43.
89243387|NCT00505622|Experimental|E2007|E2007 2 mg (one 2 mg tablet taken daily in the evening), or 4 mg (two 2 mg tablets daily in the evening).
89243388|NCT03852576|Experimental|Esophagus sprayed with KSP/QRH dimer|Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe
89243389|NCT01012856|Active Comparator|Cognitive-Behavioral Therapy for Depression (CBT)|
89243390|NCT01012856|Experimental|Exposure-Based Cognitive Therapy for Depression (EBCT)|
89243391|NCT03851094|No Intervention|Standard of Care (Group A)|Standard of care is dictated by the HME normal practices for new CPAP patients.
89243392|NCT03851094|Experimental|Wellth App (Group B)|Intervention is use of the Wellth app during the initial compliance period.
89243393|NCT01016730|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89243394|NCT00505076|Experimental|MK-0777 8 mg|MK-0777 8 mg tablet by mouth twice daily for 4 weeks
89243395|NCT00505076|Experimental|MK-0777 3 mg|MK-0777 3 mg tablet by mouth twice daily for 4 weeks
89243396|NCT00505076|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 4 weeks
89243397|NCT01012934|Experimental|1|Alendronate Sodium Tablets, 70 mg
89243398|NCT01012934|Active Comparator|2|Fosamax Tablets, 70 mg
89243399|NCT04334330|Experimental|Treatment group|
89243400|NCT01015196|Active Comparator|Idarubicine|
89243401|NCT01015196|Experimental|Daunorubicine|
89243402|NCT01009892|Active Comparator|Codeine Sulfate, 30 mg|tablet
89243403|NCT01009892|Active Comparator|Codeine Sulfate, 60 mg|tablet
89243404|NCT01009892|Active Comparator|Codeine Sulfate, 15 mg|tablet
89243405|NCT00307684|Experimental|001|open label PR OROS methylphenidate Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
89243406|NCT00307684|Experimental|002|double blind PR OROS methylphenidate 18 36 54 72 or 90 mg/day once daily for 4 weeks
89243407|NCT00307684|Placebo Comparator|003|double blind placebo matching placebo tablets once daily for 4 weeks
89243408|NCT00489918|Placebo Comparator|Macroflux® placebo|Macroflux® placebo patch
89243409|NCT00489918|Experimental|Macroflux® 20 mcg|Macroflux® 20 mcg patch
89243410|NCT00489918|Experimental|Macroflux® 30 mcg|Macroflux® 30 mcg patch
89243411|NCT00489918|Experimental|Macroflux® 40 mcg|Macroflux® 40 mcg patch
89243412|NCT00489918|Active Comparator|FORTEO®|FORTEO® 20 mcg injection
89243413|NCT01061788|Experimental|Everolimus, AMG 479, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLC Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
89243414|NCT00307294|Experimental|thalidomide and doxil|Combination of Thalidomide and Doxil
89243415|NCT03981094|Experimental|BMS-986278|
89243416|NCT03981094|Experimental|Pirfenidone|
89243417|NCT03981094|Experimental|BMS-986278 + Pirfenidone|
89243418|NCT01064128|Active Comparator|conventional laparoscopic hysterectomy|Three or four ports conventional laparoscopic hysterectomy
89243419|NCT01064128|Active Comparator|SPA laparoscopic hysterectomy|Single umbilical incision laparoscopic hysterectomy
89243420|NCT03963401|Experimental|PF-06700841 60 mg once daily|PF-06700841 60 mg once daily for 52 weeks
89243421|NCT03963401|Experimental|PF-06700841 30 mg once daily|PF-06700841 30 mg once daily for 52 weeks
89243422|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 60 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
89243423|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 30 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
89243424|NCT03963401|Placebo Comparator|Placebo once daily followed by 60 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
89243425|NCT03963401|Placebo Comparator|Placebo once daily followed by 30 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52
89243426|NCT04410965|Experimental|teriflunomide|daily oral administration of teriflunomide 14 mg for 24 weeks
89243427|NCT04012775|Active Comparator|Insulin Humulin® NPH|Insulin Humulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
89243428|NCT04012775|Experimental|Insulin Rinsulin® NPH|Insulin Rinsulin® NPH twice daily, individually glucose-level based administered doses +/- 1,2 or 3 OADs in stable doses, started before enrollment
89243429|NCT00944723|Experimental|Zinc-fortified bread (10 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month
89243430|NCT00944723|Experimental|Zinc fortified bread (20 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month.
89243431|NCT00944723|Experimental|Zinc supplemented group|Daily consumption of non-fortified bread and daily intake of zinc supplement (10 mg zinc/d)
89243432|NCT00944723|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified bread and a placebo supplement for 1 month.
89243433|NCT00944801|Experimental|Pegylated Liposomal Doxorubicin|Radiotherapy is planned with dedicated computed tomography and three-dimensional planning systems and delivered to the gross tumor volume with a 2 to 3 cm margin for the clinical target volume. After a 4-week break, patients receive adjuvant TMZ 150 to 200 mg/m2 day 1 to 5 in 28 days until tumor progression or up to at least 12 cycles. In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
89243434|NCT00334282|Placebo Comparator|placebo arm|matching placebo (800 mg tablet) once daily
89243435|NCT00334282|Experimental|pazopanib arm|Oral pazopanib tablet 800 mg once daily continuously
89243436|NCT01060228|Other|001|paliperidone ER 1 tablet of 500 mg once daily on Day 1 and Day 15
89243437|NCT01060228|Other|002|divalproex sodium ER 2 tablets of 500 mg once daily from Days 5 through 18
89243438|NCT00306670|Experimental|Rituximab|Patients will receive rituximab.
89243439|NCT00306670|Active Comparator|Oral cyclophosphamide|Patients will receive oral cyclophosphamide.
89243440|NCT00306592|Experimental|Natalizumab|All study participants in 101-MS-322 (NCT00306592) and 101-MS-321 (NCT00297232) received open label 300 mg intravenous (IV) natalizumab 60-minute infusion once every 4 weeks (28 days ±7 days) for up to 48 weeks. After 48 weeks, participants from 101-MS-322 (NCT00306592) entering study 101-MS-321 (NCT 00297232; considered the Long-Term Treatment Period of 101-MS-322) were continued on treatment from Week 52 through Week 480.
89243441|NCT03982732||Women vaccinated at less than 24 weeks|Women receiving a pertussis containing vaccine at less than 24 weeks
89243442|NCT03982732||Women vaccinated at 24-27+6 weeks|Women receiving a pertussis containing vaccine at 24-27+6 weeks
89243443|NCT03982732||Women vaccinated at 28-31+6 weeks|Women receiving a pertussis containing vaccine at 28-31+6 weeks
89243444|NCT01060306||Bare metal stent 1 month|Patients implanted with the bare metal stent Gazelle evaluated for neointimal coverage one month after implantation
89243445|NCT01060306||Biodegradable polymer stent 6 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage after full drug elution and polymer biodegradation (6 months)
89243446|NCT01060306||Biodegradable polymer stent 7 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage one month after full drug elution and polymer biodegradation (7 months)
89243447|NCT02532478||Stoma reversed|Patients whose ileostomy have been closed after laparoscopic low anterior resection
89243448|NCT02532478||Stoma not-reversed|Patients whose ileostomy have not been closed due to some problems
89243449|NCT00321646|Experimental|chemotherapy|docetaxel and bevacizumab prior to prostatectomy
89243450|NCT03982654|Experimental|Bloomlife|
89243451|NCT00403767|Experimental|Rivaroxaban|
89243452|NCT00403767|Active Comparator|Warfarin|
89243453|NCT00492284|Experimental|1/4 Fluence Triple Therapy|Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
89243454|NCT00492284|Experimental|1/2 Fluence Triple Therapy|Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
89243455|NCT00492284|Experimental|1/2 Fluence Double Therapy|Reduced-fluence Visudyne followed by Lucentis double therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
89243456|NCT00492284|Experimental|Ranibizumab|Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter
89243457|NCT01015274||Healthy control male|
89243458|NCT01013012|Active Comparator|Group A|Group A : saline 1 ml + ramosetron 6μg/kg
89243459|NCT01013012|Experimental|Group B|Group B : dexamethasone 4 mg + ramosetron 6μg/kg
89243460|NCT01009970|Experimental|1|R-COMP
89243461|NCT01013090|Active Comparator|Epidural crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
89243462|NCT01013090|Active Comparator|Epidural colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
89243463|NCT01013090|Active Comparator|Spinal crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
88804712|NCT01216735|Placebo Comparator|smokers Placebo first, then Fluticasone|The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
89243464|NCT01013090|Active Comparator|Spinal colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
89243465|NCT01013090|Active Comparator|CSEA crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
89243466|NCT01013090|Active Comparator|CSEA colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
89243467|NCT01015352|Active Comparator|Arm A|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.
89243468|NCT01015352|Active Comparator|Arm B|"Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND~Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)~12 additional maintenance courses are planned in responders"
89243469|NCT01043757|Experimental|Control|1) Control Group. Receives daily step goals via emails and has access to the study website to allow them to track their progress. Eligible for check-in incentives.
89243470|NCT01043757|Experimental|Fixed|"Receives control intervention plus are incentivized to attain their daily step goals through daily lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot. Participants who meet their step goal for the day and who upload their data will be entered into the same lottery each day, where the small jackpot is $10 and the large jackpot is $100."
89243471|NCT01043757|Experimental|Ascending|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot.~Participants can increase their daily jackpots by meeting their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $4 and the large jackpot is $40; if they successfully meet their step goal on the first day of the week, the jackpots for the second day increase to $6/$60, and so on such that if they reach their goals each day, the jackpots on day seven will reach $16/$160."
89243472|NCT01043757|Experimental|Decreasing|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Daily drawing procedure same as Ascending condition; structure of incentives is different: Participants can decrease their daily jackpots by failing to meet their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $16 and the large jackpot is $160; if they successfully meet their step goal on the first day of the week, the jackpots will remain at $16/$160; if they do not meet their goal the jackpots will decrease to $14/$140, and so on such that if they fail to reach their goals each day, the jackpots on day seven will decrease to $4/$40."
89243473|NCT00510458|Other|LFIT™Femoral Heads With X3® Insert|LFIT™ Femoral Heads With X3® Insert
89243474|NCT03563157|Experimental|NANT Colorectal Cancer (CRC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.
89243475|NCT03563157|Active Comparator|Regorafenib|In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.
89243476|NCT01010048|Experimental|progesterone,tamsulosin,propantheline Bromide and nifedipine|different effect of these drugs use to treat urinary calculus after ESWL
89243477|NCT01013168|Experimental|OncoSorb® column|
89243478|NCT01013246|Experimental|Video game play|
89243479|NCT00414765|Experimental|Aldesleukin|All participants were treated with aldesleukin 600,000 international units per kilogram [IU/kg] (0.037 milligram (mg)/kg) administered as a 15-minute intravenous (IV) infusion every 8 hours for a maximum of 14 doses for the first cycle (5-day cycle). Following 9 days of rest from therapy, the cycle was repeated for up to 14 doses (i.e., a total of up to 28 doses), if tolerated.
89243480|NCT03997292||Alteplase group|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion
89243481|NCT03997292||Urokinase group|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously End
88804713|NCT01216735|No Intervention|health non-smokers|The healthy non-smokers will have only visit 1 and no intervention.
88804714|NCT01285843|Active Comparator|Quadra Group|
88804715|NCT01285843|Active Comparator|AMIStem Group|
89243482|NCT01013402|Experimental|volunteers for insulin hypoglycemia test|None of the subjects had diabetes mellitus or any other metabolic diseases. They were not taking any medicine and they did not have anemia or polycythemia. Also none of the patients had any condition causing hypoxia or any compromise in peripheral circulation.
89243483|NCT01013480|Active Comparator|STX209|
89243484|NCT00500682|Placebo Comparator|Placebo|
89243485|NCT00500682|Experimental|AST-120|
89243486|NCT00500370|Experimental|Group A|
89243487|NCT00500370|Placebo Comparator|Group B|
89243488|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4|
89243489|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12|
89243490|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4|
89243491|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12|
89243492|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12|
89243493|NCT03996798|Experimental|Jessa Hospital, Herk-de-Stad|"Back to Work methodology: a revalidation trajectory with standard revalidation therapy in combination with an early focus on back to work, using a Disability Case Manager"
89243494|NCT03996798|No Intervention|Revalidation and MS Clinic Overpelt|"Standard revalidation therapy without explicit focus on back to work"
89243495|NCT03996486|Experimental|Hemophilia|Dose escalation starting with 200 mg of BAY1093884
89243496|NCT01064206||Buerger's disease patients|200 thromboangiitis obliterans patients (Buerger's disease or TAO)
89243497|NCT01064206||Control group|200 atheromatous arteritis patients
89243498|NCT01014468|Active Comparator|Ranibizumab|Intravitreal injection of Ranibizumab (3 monthly injection followed by monthly injections as long as required)
89243499|NCT01014468|Active Comparator|Bevacizumab|Intravitreal injection of Bevacizumab (3 monthly injection followed by monthly injections as long as required)
89243500|NCT03980782|Experimental|Music Intervention|Each participant will receive a 30 minute individual music intervention twice daily.
89243501|NCT03980782|No Intervention|Care as usual|Each participant will receive care as usual.
89243502|NCT00503984|Experimental|Phase 1 - Aza + Doc|Phase 1 Azacitidine (Aza) and Docetaxel (Doc) with dose escalation/de-escalation design, and Prednisone, with growth factor support; GADD45α methylation and expression analysis, with optional growth factor support (pegfilgrastim/filgrastim).
89243503|NCT00503984|Experimental|Phase 2 - Aza + Doc RPTD|Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel; and Prednisone; with optional growth factor support (pegfilgrastim/filgrastim).
89243504|NCT03981016|Experimental|Biological collection|"For the patients include in the study :~blood samples collected at different times : Before surgery and during the post-operative visit and~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
89243505|NCT03996564|Active Comparator|Acupuncture Group|"Battlefield Acupuncture (BFA) has a structured administration sequence that was utilized to limit any variability between investigators administering the treatment. The BFA technique has been suggested that the needles are placed not just in an acupoint but actually acupoint zones. BFA utilizes one to ten (maximum five points per ear) ASP semi-permanent gold needles® placed in one or both ears. The ASP Gold needle® is a sterile device which inserts a small 2 mm needle into the auricle. It is comprised in single-needle applicator ensuring ease of insertion combined with excellent precision. The needles remain in the ear and fall out spontaneously as early as two hours and up to seven days. After administration of the BFA, if subjects felt that their pain was not controlled based on verbal response, rescue medication could be administered to control pain to a tolerable level for discharge."
89243506|NCT03996564|Active Comparator|Standard Care Group|Participants randomized to the standard care group were treated with one, or a combination of selected medications to include oral Acetaminophen 500mg-1000mg, Diclofenac 50mg-75 mg orally, Diazepam 5mg-10 mg intravenous or oral, Hydrocodone 5mg/325mg-10mg/650mg mg oral, or intramuscular Ketorolac 30mg-60 mg, as deemed appropriate by the treating investigator (medical provider). Standard treatment was administered by the investigators based on the patient's presentation and driving status as many of the medications cannot be administered if the subject would operate a vehicle. No standardized algorithm was specified and the route and dose of medications was administered at the provider's discretion. After administration of the traditional standard care medications, if subjects felt their pain was not controlled based on verbal responses, rescue medication would be given to control pain to a more tolerable level for discharge.
89243507|NCT00565409|Active Comparator|1|
89243508|NCT00565409|Active Comparator|2|
89243509|NCT00565409|Placebo Comparator|3|
89243510|NCT03980860|Active Comparator|HIIT (High Intensity Interval Training)|Subjects are undergoing high intensity interval training
89243511|NCT03980860|Active Comparator|Low intensity training long duration|Subjects are undergoing a lower intensity training program for a long duration
89243512|NCT03980860|No Intervention|Control|No exercise program intervention (usual care)
89243513|NCT00394251|Experimental|AC --> ABI-007|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
89243514|NCT00394251|Experimental|AC --> Taxol|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
89243515|NCT02532400|Experimental|Neoadjuvant endocrine therapy|Six months of exemestane or anastrozole plus goserelin.
89243516|NCT02532400|Active Comparator|Neoadjuvant chemotherapy|Six cycles of docetaxel plus epirubicin and cyclophosphamide(TEC).
89243517|NCT03980704|Active Comparator|High Protein|Provision of 400 ml per day of high protein oral nutritional supplements
89243518|NCT03980704|Experimental|Immuno ONS|Provision of 400 ml per day of immunostimulating oral nutritional supplements
89243519|NCT03980548||CABG patients|
89243520|NCT03980548||PAD patients|
89243521|NCT03980548||Healthy volunteers|
89243522|NCT03980548||Patients with CAD|
89243523|NCT00394095|Experimental|Topiramate Group|Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
89243524|NCT00394095|Placebo Comparator|Placebo Group|Sugar pill
89243525|NCT00503906|Experimental|Abraxane, Avastin and Gemcitabine|"Each treatment cycle is 28 days. Participants will be treated until disease progression:~Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
89243526|NCT00305110|Experimental|2 mg IV hydromorphone|2 mg IV hydromorphone administered over 2-3 minutes
89243527|NCT03984760|Experimental|Ferric Citrate Capsule|Ferric Citrate Capsule, product specification: 500 mg/cap, manufactured by Panion & BF Biotech Inc.
89243528|NCT03984760|Active Comparator|Sevelamer Carbonate Tablet|Sevelamer carbonate tablet group, product specification: 800 mg/tablet, manufactured by Genzyme Ireland Limited
89243529|NCT01060462||001|Pts. w/ neutropenic fever associated w/ hematologic malignancy Itraconazole 200 mg twice daily for 2 days for a total of 4 doses then 200 mg once daily for 12 days. After 14 days of IV administration itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
89243530|NCT00491894|Other|Patients with Chronic Drooling|Arm receiving study drug
89243531|NCT01060618|Experimental|Maraviroc + Trofile ESTA®|the patients have the Trofile ESTA® test performed and sent for evaluation. Once the results are obtained (about 1 month later), the patients take the medication Maraviroc during ten days. The viral load assessment throughout the Study help to make a prediction to assess if the patients would have a positive response Vs. CCR5 antagonist of a negative response
89243532|NCT03984604|Active Comparator|CHI-921|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (CHI-921) for 3 weeks, followed by another 3 weeks of treatment at 1.0 mL for and another 3 weeks of treatment at 2.0 mL.
89243533|NCT03984604|Placebo Comparator|Placebo|During the double-blind treatment period (9 weeks), subjects will take 0.5 mL of their randomized treatment (placebo) for 3 weeks, followed by another 3 weeks of placebo treatment at 1.0 mL for and another 3 weeks of placebo treatment at 2.0 mL.
89243534|NCT00491504|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg total dose (2 sprays each nostril)
89243535|NCT00491504|Placebo Comparator|Placebo|Placebo (2 sprays each nostril)
89243536|NCT04326452|Experimental|Enrolled Subjects|The purpose of this study is to compare the use of our bidirectional oxygenation mouthpiece with conventional oxygen support versus conventional oxygen support of any Person Under Investigation for infection by the COVID-19 virus.
89243537|NCT01010438||Adults|Adult patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
89243538|NCT01010438||Children (1-17)|Pediatric patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
89243539|NCT01015508|Other|High predisposition|High predisposition for weight regain
89243540|NCT01015508|Other|low predisposition|low predisposition for weight regain
89243541|NCT01015508|Other|Medium predisposition|Medium predisposition for weight regain
89243542|NCT00500292|Placebo Comparator|1|FOLFOX + Placebo vandetanib
89243543|NCT00500292|Experimental|2|FOLFOX + low dose vandetanib
89243544|NCT00500292|Experimental|3|FOLFOX + high dose vandetanib
89243545|NCT04308044||Chronic MSK Pain|Participants who have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), and psychological state via the completion of questionnaires by the patient.
89243546|NCT04308044||Healthy Control|Participants who do not have chronic musculoskeletal pain.The pain profile of the patient will be assessed, including biological sample analysis (blood), quantitative sensory testing, electroencephalogram (EEG), insole assessment (40 healthy control participants), and psychological state via the completion of questionnaires by the patient.
89243547|NCT01013558|Active Comparator|remifentanil|
89243548|NCT01013558|Placebo Comparator|saline|
89243549|NCT01013636||Anaplasma|
89243550|NCT00499746|Active Comparator|Tramadol|oral dose, once per day
89243551|NCT00499746|Placebo Comparator|Placebo|oral dose, once per day
89243552|NCT00499746|Active Comparator|hydromorphone|oral dose, once per day
89243553|NCT00499746|Active Comparator|methylphenidate|oral dose, once per day
89243554|NCT01010516|Active Comparator|High-dose rosuvastatin|40 mg of rosuvastatin
89243555|NCT01010516|Active Comparator|Stain plus fenofibrate|existing statin plus micronized fenofibrate 200 mg
89243556|NCT01010516|Active Comparator|Statin plus niacin ER/laropiprant|existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
89243557|NCT01020084||Control|Subjects with normal salivary flow rate
89243558|NCT01020084||Hyposalivation|Subjects presenting low salivary flow rate as a side effect of systemic isotretinoin therapy.
89243559|NCT01020162|Active Comparator|Non-surgical|TENS, amitriptyline, gabapentin.
89243560|NCT01020162|Active Comparator|Surgical intervention|Resection of the ilioinguinal nerve
89243561|NCT00489216|Experimental|Efalizumab|All patients on study will receive a total of 8 injections of efalizumab
89243562|NCT01016886|Experimental|1|
89243563|NCT00499590|Active Comparator|A|Lucentis® (0.5mg) every 4 weeks.
89243564|NCT00499590|Experimental|B|Bevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
89243565|NCT00499590|Experimental|C|Bevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
88804716|NCT01263301|Active Comparator|carotid duplex for hemolytic patients wtih SSS|assigned intervention:carotid duplex
89243566|NCT00510146|Experimental|Olanzapine|During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
89243567|NCT00510146|Placebo Comparator|Placebo|Matching placebo administered once daily, by mouth during double-blind treatment.
89243568|NCT00510146|Experimental|Olanzapine (open-label treatment period)|During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
89243569|NCT00480636||One cohort of patients treated with dalteparin.|About 100 patients with deep-vein thrombosis and with or without pulmonary embolism will be included in the study.
89243570|NCT01017198|Experimental|BIIB021 and Food|The food phase will assess the effect of a high fat meal on the pharmacokinetics of BIIB021.
89243571|NCT01017198|Experimental|BIIB021 and Antacid|Antacid phase will assess the effect of an antacid on the pharmacokinetics of BIIB021.
89243572|NCT01013948||N/A (Survey study)|
89243573|NCT00499122|Experimental|NOV-002 and Chemotherapy|"NOV-002:~Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart~Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration~Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections~Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1~Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1~Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1"
89243574|NCT01017276|Experimental|ASP group|
89243575|NCT00393939|Experimental|A|
89243576|NCT00393939|Active Comparator|B|
89243577|NCT00488982|Experimental|Docetaxel + Observation|Intermittent docetaxel/prednisone with no maintenance therapy: Patients will discontinue docetaxel/prednisone and undergo observation until disease progression at which time they will re-initiate docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before subsequent discontinuation of chemotherapy
89243578|NCT00488982|Experimental|Docetaxel + GM-CSF|Intermittent docetaxel/prednisone with maintenance GM-CSF therapy: Patients will discontinue docetaxel/prednisone and will receive maintenance GM-CSF until disease progression at which time, they will discontinue GM-CSF and resume docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before discontinuation of chemotherapy and GM-CSF therapy is re-initiated. GM-CSF dose/schedule will be as previously described (250 mcg/m2 SQ daily, days 15-28 q28 days)
89243579|NCT06314230||Kidney transplant recipients|"Kidney or kidney-pancreas transplant recipients enrolled into the study prospectively. Risk factors recorded, blood/urine/kidney samples analysed and correlated with outcomes.~Non-interventional, observational in nature."
89243580|NCT06314217|Experimental|Open-label prospective device study|Treatment of previously treated patients diagnosed with diabetic macular edema (DME)
89243581|NCT06314191|Experimental|arthrose group|
89243582|NCT06314191|Active Comparator|controle group|
89243583|NCT06314178||Pregnant women between 24-42 weeks of gestation|No interventions
89243584|NCT06314165|Experimental|group practicing music medicine|There will be 2 follow-ups for each group. In the first follow-up for the experimental group, when symptoms begin on the first day of their menstrual period, they will be asked to fill out the Menstruation Symptom Scale and Visual Analogue Scale, and the designated music will be played for 30 minutes. After 30 minutes, he/she will be asked to fill out the same surveys again. In the 2nd follow-up (during the menstrual period one month after the first follow-up), they will be asked to repeat what was done in the 1st follow-up on the first day of their menstrual period.
89243585|NCT06314165|No Intervention|Group where music medicine is not applied|Two follow-ups will be applied to the groups. At the first follow-up for the control group, they will be asked to fill out the Menstruation Symptom Scale and Visual Analog Scale when symptoms begin on the first day of their menstrual period. In the 2nd follow-up (during the menstrual period one month after the first follow-up), they will be asked to repeat what was done in the 1st follow-up on the first day of their menstrual period.
89243586|NCT06314139|Active Comparator|cTBS group|cTBS at 80% action motor threshold (AMT) with 600 pulses over bilateral M1 and cerebellum. Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum.
89243587|NCT06314139|Sham Comparator|sham group|Sham stimulation was performed with the same protocol using an inactive coil to mimic true stimulation sound effects, but does not stimulate the brain or produce neurophysiological changes in cerebello-thalamo-cortical (CTC) connections and eyeblink regulation.
89243588|NCT06314126|Experimental|D-Chiro-Inositol|Patients will receive oral D-Chiro-Inositol.
89243589|NCT06314126|Placebo Comparator|Placebo|Patients will receive oral placebo.
89243590|NCT06314113||Low-grade Cervical Lesions (L-SIL)|Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection
89243591|NCT06314100||THS smokers|Each subject undergoes a routine intraoral examination and anamnesis. Samples of supragingival dental biofilm and saliva are taken for microbiological analysis
89243592|NCT06314100||cigarette smokers|Each subject undergoes a routine intraoral examination and anamnesis. Samples of supragingival dental biofilm and saliva are taken for microbiological analysis
89243593|NCT06314100||nonsmokers|Each subject undergoes a routine intraoral examination and anamnesis. Samples of supragingival dental biofilm and saliva are taken for microbiological analysis
89243594|NCT06314087|Active Comparator|Control arm: Arm #1|
89243595|NCT06314087|Experimental|Experimental arm: Arm #2|Personalized tumor peptide vaccine + conventional treatment including radiotherapy group
89243596|NCT06314074|Experimental|Oscillometric blood pressure monitoring at 2.5-minute intervals|"In patients assigned to oscillometric blood pressure monitoring at 2.5-minute intervals, oscillometric upper-arm cuff blood pressure will be measured and displayed on the patient monitor every 2.5 minutes during surgery.~Blood pressure will additionally measured with BLINDED continuous non-invasive finger-cuff blood pressure monitoring."
89243597|NCT06314074|Active Comparator|Oscillometric blood pressure monitoring at 5-minute intervals|"In patients assigned to oscillometric blood pressure monitoring at 5-minute intervals, oscillometric upper-arm cuff blood pressure will be measured and displayed on the patient monitor every 5 minutes during surgery.~Blood pressure will additionally measured with BLINDED continuous non-invasive finger-cuff blood pressure monitoring."
89243598|NCT06314061|Experimental|Intervention group|Participants in the intervention group will wear the CGM-device Dexcom G7, and real-time alerts on dysglycaemia and rapidly increasing or falling glucose levels will alert the nursing staff.
89243599|NCT06314061|No Intervention|Control group|Participants in the control group will wear a blinded CGM device. The nursing staff will monitor glucose levels with standard care using POC blood glucose measurements.
89243600|NCT06314048|Other|Standard of Care - CGM and RPM|1. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
89243601|NCT06314009||Normal Weight|Body Mass Index (BMI) 18.5-24.9 kg/m^2
89243602|NCT06314009||Obese|Pre-pregnancy Body Mass Index (BMI) ≥ 30.0 kg/m^2
89243603|NCT06313996|Active Comparator|Arm A|"Active Comparators:~R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)~B-R (bendamustine and rituximab)~R2 (rituximab and lenalidomide)"
89243604|NCT06313996|Experimental|Arm B|Lisocabtagene Maraleucel
89243605|NCT06313983|Experimental|Hemay022 and AI|Hemay022 in combination with AI will be taken orally once daily. Planned dose of Hemay022 will be 500mg daily for 21 days.
89243606|NCT06313983|Active Comparator|Lapatinib and Capecitabine|lapatinib in combination with capecitabine will be taken in suitable dose until disease progression or death, etc.
89243607|NCT06313970|Experimental|QL1706+chemotherapy|"QL1706 administered by intravenous infusion, 5 mg/kg, administered once every 3 weeks, every 3 weeks as a cycle; Albumin paclitaxel administered by intravenous infusion, 125 mg/m2, administered on Days 1 and 8, 1 treatment cycle every 3 weeks; Gemcitabine IV infusion over 30 min, 1000 mg/m2, administered on Days 1 and 8, 1 treatment cycle every 3 weeks; On day 1 of each cycle, drugs were administered in the following order: ql1706 → albumin paclitaxel → gemcitabine.~The first dose was administered within 2 days of randomization, and subjects used the study drug until protocol-specified criteria for treatment termination were present."
89243608|NCT06313970|Experimental|QL1706+chemotherapy+ bevacizumab|"QL1706 administered by intravenous infusion, 5 mg/kg, administered once every 3 weeks, every 3 weeks as a cycle; Bevacizumab administered by intravenous infusion, 7.5 mg/kg, administered once every 3 weeks, every 3 weeks as a treatment cycle; Albumin paclitaxel administered by intravenous infusion, 125 mg/m2, administered on Days 1 and 8, 1 treatment cycle every 3 weeks; Gemcitabine IV infusion over 30 min, 1000 mg/m2, administered on Days 1 and 8, 1 treatment cycle every 3 weeks; On day 1 of each cycle, drugs were administered in the following order: ql1706 → bevacizumab → albumin paclitaxel → gemcitabine.~The first dose was administered within 2 days of randomization, and subjects used the study drug until protocol-specified criteria for treatment termination were present."
89243609|NCT06313957|Experimental|Each subject will receive LUCAR-20SP cells|Chimeric antigen receptor T cells LUCAR-20SP cells
89243610|NCT06313944||Patients with Clinical Alzheimer's syndrome treated with TPS|Patients with clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months that have planned treatment with TPS
89243611|NCT06313931|Experimental|Experimental group|Experimental group
89243612|NCT06313931|Active Comparator|Control group|Control group
89243613|NCT06313918|Active Comparator|Standard HIT|Standard 4 x 4 min HIT at treadmill. First 7 min warm-up, then 4 sessions with 4 min walking/running at 80-95% of maximal heart rate, with 3 min of active rest in between. Ending with 5 min of cooling down. Two sessions per week for 26 weeks.
89243614|NCT06313918|Experimental|Short HIT|Short 1 x 4 min HIT at treadmill. Starting with 7 min warm-up walking/running, then 1 session with 4 min walking/running at 80-95% of maximal heart rate, ending with 5 min of cooling down. Two sessions per week for 26 weeks.
89243615|NCT06313905|Experimental|EVADRY|90 Sjogren's syndrom patients with objective xerostomia receiving the EVADRY dietary supplement treatment.
89243616|NCT06313905|Placebo Comparator|PLACEBO|90 Sjogren's syndrom patients with objective xerostomia receiving a placebo.
89243617|NCT06313879|Experimental|trained parent group|The experimental group will be given a total of 6 hours of training for 2 weeks, and they will be asked to fill out the State and Trait Anxiety Scale and the General Self-Efficacy Scale before and after the training. After 3 months of counseling, the scales will be filled in again.
89243618|NCT06313879|No Intervention|uneducated parent group|The control group will be asked to fill out the State and Trait Anxiety Scale and the General Self-Efficacy Scale at the first interview. After 2 weeks, they will be asked to fill out the scales simultaneously with the experimental group, without any training. They will be asked to fill out the Parental Knowledge Test, State and Trait Anxiety Scale, and General Self-Efficacy Scale simultaneously with the experimental group, without any intervention for 3 months.
89243619|NCT06313866|No Intervention|control|Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.
89243620|NCT06313866|Experimental|Electronuchal acupuncture group treatment|Use the neck needle to take the Fengchi and Gongxue on both sides (1.5cm directly below Fengchi point).
89243621|NCT06313866|Experimental|Smell therapy group treatment|The volatile oil of Acorus calamus is packed in the sniffer. Smell at the sniffing end, breathe evenly, 5-10 minutes each time, 3-5 times a day, for a total of 4 weeks of treatment.
89243622|NCT06313866|Experimental|The combined treatment|The electro-neuchal acupuncture combined with sniffing and suction therapy group is treated with sniffing and suction therapy on the basis of electro-neuchal acupuncture treatment.
89243623|NCT06313853|Experimental|COACH-Cog Intervention|Oncology clinician intervention components: 1) a brief training video, 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments. Patient/Care partner dyad intervention components: 1) Communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
89243624|NCT06313853|No Intervention|Usual Care|Usual Care
89243625|NCT06313840||Case group - subjects with central sleep apnea|Patients with moderate to severe CSA defined by an apnea hypopnea index (AHI) ≥ 15 events per hour and a central apnea hypopnea index (CAHI) ≥ 50% of total AHI.
89243626|NCT06313840||Control group - subjects with no sleep disordered breathing|Patients with no SDB defined by an AHI < 5 events per hour.
89243627|NCT06313840||Other SDB group - subjects with other forms of sleep disordered breathing|Patients that do not meet criteria for CSA or no SDB
89243628|NCT06313827|Active Comparator|Control exercise group (CG-1)|Participants will receive their usual physiotherapy treatment.
89243629|NCT06313827|Experimental|Exercise plus monitoring group (TG-2)|Participants will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment.
89243630|NCT06313827|Experimental|Exercise plus monitoring and follow-up group (TGF-3)|Participants will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment, plus telematic control (via 1:1 real-time videoconferencing) of exacerbations with feedback from the physiotherapist.
89243631|NCT06313814|Other|before and after result comparison|we will see if there is an effect after the intervention. we will measure the before and after signs.
89243632|NCT06313801|Active Comparator|Control group|FLOT: Docetaxel 50 mg/m2 intravenously on day 1 + Oxaliplatin 85 mg/m2 intravenously on day 1 + Calcium folinate 200 mg/m2 2-hour intravenous infusion on day 1 + fluorouracil 2600 mg/m2 x intravenous infusion 24-hours (infusion of the same of the total dose of fluorouracil for 48 hours) on day 1. Repeat every 2 weeks. 6 courses.
89243633|NCT06313801|Experimental|Study group|"mFLOT: Oxaliplatin 85 mg/m2 intravenously on day 1 + Calcium folinate 200 mg/m2 2-hour intravenous infusion on day 1 + fluorouracil 2600 mg/m2 x intravenous infusion 24-hours (infusion of the same of the total dose of fluorouracil for 48 hours) on day 1. Repeat every 2 weeks. 6 courses.~+ The drugs for PIPAC - Docetaxel 50 mg/ m2 diluted with saline sodium chloride to a total volume of 200 ml (intraperitoneal pressurized infusion)."
89243634|NCT06313788|Experimental|Possession Group|"Participants will be presented with two leaflets about a branded band-aid, which specify its functions, e.g., stop bleeding, protect wounds and reduce pain. Participants read its analgesic component and mechanism (e.g., reduces pain sensitization of peripheral nerves) to induce a positive expectation that the branded bandage can effectively help them alleviate pain. Next, participants rate their perceived effectiveness of the band-aid and their use intention. In order to mask the purpose of the study, they will also answer other distractor marketing questions, such as to guess the price of the band-aid and their impression on the package design of the band-aid.~Participants in possession group will be told that in order to thank them for doing the marketing interview, as a token of appreciation, they will receive a free band-aid with a customized cartoon of their preference."
89243635|NCT06313788|No Intervention|No Possession Group|Like participants in the possession condition, participants in the no-possession condition will also be first introduced to the function of a branded band-aid using the leaflet advertisement and asked to complete the marketing survey. They will be verbally thanked for their participation to take part in the marketing interview, but they will not be given any first-aid bandage as a souvenir.
89243636|NCT06313775|Active Comparator|Spinal anesthesia|spinal anesthesia : 0.5%hyperbaric bupivacaine 10-15 mg/dose injected at L3-L5
89243637|NCT06313775|Experimental|spermatic cord block|1%Xylocaine with adrenaline (Max 7 mg/kg/dose) divided to inject into each side of the spermatic cord 6-8 ml and infiltration into the scrotal incision area 3-4 ml.
89243638|NCT06313762|Experimental|Intervention Group|
89243639|NCT06313762|Active Comparator|Control Group|
89243640|NCT06313749|Experimental|MIMS® Device/Procedure Arm|Arm which includes subjects undergoing the MIMS® surgical procedure using the proprietary MIMS® device developed by Sanoculis Ltd.
89243641|NCT06313723|Experimental|İntervention group (n:52)|Pregnant women assigned to the intervention group (52) will be listened to podcasts on a Samsung Galaxy J7 Prime brand phone while undergoing a 20-minute NST procedure.Pregnant women in the intervention group will be made to listen to 3 podcasts consisting of 3 modules lasting an average of 5-6 minutes during the Non-Stress Test. After the podcast is prepared, it will be edited in line with expert opinion and its final version will be given.
89243642|NCT06313723|No Intervention|Control group (n:52)|"Pregnant women assigned to the control group were given T.R. treatment within the scope of routine care. The Ministry of Health's Pregnancy and Birth Process booklet will be given and the pregnant woman's questions will be answered on the topics she wants to get information about."
89243643|NCT06313710|No Intervention|control|
89243644|NCT06313710|Experimental|low dose of head down position|-10° Trendelenburg for 30 min
89243645|NCT06313710|Experimental|high dose of head down position|-10° Trendelenburg for 60 min
89243646|NCT06313697|Experimental|Treatment group 1|single dose
89243647|NCT06313697|Experimental|Treatment group 2|single dose
89243648|NCT06313697|Experimental|Treatment group 3|single dose
89243649|NCT06313697|Experimental|Treatment group 4|single dose
89243650|NCT06313697|Experimental|Treatment group 5|single dose
89243651|NCT06313697|Experimental|Treatment group 6|single dose
89243652|NCT06313619|Experimental|Digital Pharmacy Intervention|"A total of 39 pharmacy will be included in the intervention. The digital intervention named SmartAMR will be introduced among them. The participants will install the mobile app and use it to keep record of the antimicrobial sales in a central database."
89243653|NCT06313593|Experimental|Part 1 Dose Escalation - with MF|INCB160058 will be administered at a protocol defined starting regimen to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE[s]). Participants with myelofibrosis (MF) will enroll in this group.
89243654|NCT06313593|Experimental|Part 2 Dose Expansion - with MF|INCB160058 will be administered at the RDE(s) identified during Part 1. Participants with MF will enroll in this group.
89243655|NCT06313567|Experimental|Metronomic capecitabine|Low-dose capecitabine maintenance (650 mg/m2 body surface area twice daily for 1 year) after completion of standard adjuvant chemotherapy,
89243656|NCT06313567|Active Comparator|Standard therapy group|Observation after completion of standard adjuvant chemotherapy,
89243657|NCT06313554|Experimental|Surufatinib Combined With Toripalimab and HAIC|"The first week dose of solantinib was 150mg, the second week and the subsequent cycle was 200 mg once a day (QD) orally, Q3W, and the drug was suspended for one day on the day of HAIC;~Toripalimab: 240mg intravenous infusion d1, Q3W;~HAIC: All patients received HAIC treatment on D1. Hepatic arterial perfusion therapy (HAIC) : a treatment cycle every 3 weeks for 4-6 consecutive cycles:~Surufatinib and Toripalimab were administered continuously until intolerable toxicity, disease progression, withdrawal of informed consent, loss of follow-up, and investigator judgment that medication should be discontinued (whichever occurred first)."
89243658|NCT06313541|Active Comparator|PD-1/PD-L1 inhibitor combined with chemotherapy|
89243659|NCT06313541|Experimental|Treatment response adapted hybrid radiotherapy plus PD-1/PD-L1 inhibitor and chemotherapy|
89243660|NCT06313528|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
89243661|NCT06313528|Placebo Comparator|Placebo|Placebo administered SC
89243662|NCT06313502|Experimental|75gm HDAA + Melphalan 100mg/m2|Subjects will receive HDAA alone (75gm) on day -4, HDAA combined with melphalan 100 mg/m2 on day -1, and ASCT on day 0. Four additional HDAA doses (75gm) will then be administered 3 days apart on D+2, D+5, D+8 and D+11, followed by weekly doses of the corresponding dose of HDAA for four additional weeks. On day, D-1, when both drugs are given, melphalan should be given first
89243663|NCT06313502|Experimental|100gm HDAA + Melphalan 100mg/m2|Subjects will receive HDAA alone (100gm) on day -4, HDAA combined with melphalan 100 mg/m2 on day -1, and ASCT on day 0. Four additional HDAA doses (100gm) will then be administered 3 days apart on D+2, D+5, D+8 and D+11, followed by weekly doses of the corresponding dose of HDAA for four additional weeks. On day, D-1, when both drugs are given, melphalan should be given first
89243664|NCT06313502|Experimental|125gm HDAA + Melphalan 100mg/m2|Subjects will receive HDAA alone (125gm) on day -4, HDAA combined with melphalan 100 mg/m2 on day -1, and ASCT on day 0. Four additional HDAA doses (125gm) will then be administered 3 days apart on D+2, D+5, D+8 and D+11, followed by weekly doses of the corresponding dose of HDAA for four additional weeks. On day, D-1, when both drugs are given, melphalan should be given first
89243665|NCT06313489||Patients with ruptures of Extensor pollicis longus tendon after distal radial fracture|Patients planned for intervention according to the clinical practice. We planned to include all patients that would be treated in out department.
89243666|NCT06313476||Patients|Premenopausal patients with early breast cancer who received chemotherapy (neoadjuvant chemotherapy or adjuvant chemotherapy) and did not use OFS ovarian suppression at the Breast Cancer Center of Sun Yat-sen Memorial Hospital, Sun Yat-sen University
89243667|NCT06313463|Experimental|Camrelizumab group|
89243668|NCT06313463|Placebo Comparator|Placebo group|
89243669|NCT06313437|Experimental|Dose Escalation Revumenib|"Standard 3+3 design for a recommended phase 2 dose of Revumenib per dose-limiting toxicity rules. Cycles are 28 days.~Baseline~Induction Cycle:~Days 1-3: Predetermined dose of Daunorubicin 1x daily~Days 1-7: Predetermined dose of Cytarabine~Days 8-21: Predetermined dose of Midostaurin 2x daily~Days 8-28: Predetermined dose of Revumenib 2x daily~End of Induction visit~Follow-up~Reinduction Cycle: Therapy will be administered in the hospital~Days 1-2: Predetermined dose of Daunorubicin 1x daily~Days 1-5: Predetermined dose of Cytarabine~Days 8-21: Predetermined dose of Midostaurin 2x daily~Days 8-28: Predetermined dose of Revumenib 2x daily~End of reinduction visit~Follow-up~Consolidation Cycle: Therapy will be administered in the hospital~Days 1, 3, and 5: Predetermined dose of Cytarabine~Days 8-21: Predetermined dose of Midostaurin 2x daily~Days 8-28: Predetermined dose of Revumenib 2x daily~End of consolidation visit~Follow up"
89243670|NCT06313437|Experimental|Dose-Expansion Revumenib|"Cycles are 28 days~Baseline visit and assessments~Induction Cycle:~Days 1-3: Predetermined dose of Daunorubicin 1x daily~Days 1-7: Predetermined dose of Cytarabine~Days 8-21: Predetermined dose of Midostaurin 2x daily~Days 8-28: Predetermined dose of Revumenib 2x daily~End of Induction visit~Follow-up~Reinduction Cycle: Therapy will be administered in the hospital~Days 1-2: Predetermined dose of Daunorubicin 1x daily~Days 1-5: Predetermined dose of Cytarabine~Days 8-21: Predetermined dose of Midostaurin 2x daily~Days 8-28: Predetermined dose of Revumenib 2x daily~End of Reinduction visit~Follow-up~Consolidation Cycle: Therapy will be administered in the hospital~Days 1, 3, and 5: Predetermined dose of Cytarabine~Days 8-21: Predetermined dose of Midostaurin 2x daily~Days 8-28: Predetermined dose of Revumenib 2x daily~End of Consolidation visit~Follow up"
89243671|NCT06313385|Experimental|Group 5 mg/mL|This group received 5 mg/mL concentration of Indocyanine Green (Aurogreen®, Aurolab, Tamil Nadu, India). Indocyanine Green (ICG) is being diluted with 5 mL dextrose 5%. The research assistant take 1 mL ICG using 1 mL syringe using filter that originated from the Aurogreen package.
88804717|NCT01263301|Active Comparator|carotid duplex for nonhemolytic patients with SSS|
88804718|NCT01264705|Experimental|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
88804719|NCT01264705|Experimental|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
88804720|NCT01264705|Experimental|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
88804721|NCT01217515|Experimental|Diltiazem hydrochloride 4% cream|2.5 cm Diltiazem hydrochloride 4% cream applied peri-anally three times daily for eight weeks.
89243672|NCT06313385|Active Comparator|Group 2,5 mg/mL|This group received 2,5 mg/mL concentration of Indocyanine Green (Aurogreen®, Aurolab, Tamil Nadu, India). Indocyanine Green (ICG) is being diluted with 5 mL dextrose 5%. The research assistant take 0,5 mL ICG using 1 mL syringe using filter that originated from the Aurogreen package. The ICG in the syringe is added with 0,5 mL Dextrose 5%.
89243673|NCT06313385|Active Comparator|Group 0,5 mg/mL|This group received 2,5 mg/mL concentration of Indocyanine Green (Aurogreen®, Aurolab, Tamil Nadu, India). Indocyanine Green (ICG) is being diluted with 5 mL dextrose 5%. The research assistant take 0,1 mL ICG is taken using 1 mL syringe using filter that originated from the Aurogreen package. The ICG in the syringe is added with 0,9 mL Dextrose 5%.
89243674|NCT06313359||Cancer treatment induced peripheral neuropathy|Individuals with a history of non CNS cancer with cancer treatment induced peripheral neuropathy symptoms.
89243675|NCT06313359||Control group|Age and gender matched individuals without peripheral neuropathy symptoms.
89243676|NCT06313346|Experimental|Probiotic group|Subjects will consume one capsule of probiotic, daily, during 6 weeks.
89243677|NCT06313346|Placebo Comparator|Placebo group|Subjects will consume one capsule of placebo, daily, during 6 weeks.
89243678|NCT06313307|Active Comparator|Thulium 1927nm fractional laser|1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
89243679|NCT06313307|Experimental|Thulium 1927nm fractional laser and topical H2R antagonist|Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene glycol)) was applied immediately after the laser therapy and then topically twice per day in the morning and the evening for 16 weeks.
89243682|NCT06313268||Test group|Bevacizumab (Effivia®)
89243683|NCT06313255||PegIFNα2b|
89243684|NCT06313255||PegIFNα2b+prebiotics|
89243685|NCT06313255||Nucleoside analog|
89243686|NCT06313255||Nucleoside analog+prebiotics|
89243687|NCT06313229|Experimental|Staged implant placement approach|the bone defect was grafted using bone plates buccally and palatally and the defect between plates was grafted by sticky allogenic bone graft. 6 months later the implant was placed in the grafted site.
89243688|NCT06313229|Experimental|Simultaneous implant placement approach|the bone defect was grafted using bone plates buccally and palatally and the defect between plates was grafted by sticky allogenic bone graft combined with simultaneous implant placement.
89243689|NCT06313216|Experimental|Immediate Implant Placement Using duoteck membrane|after insertion of immediate implant, the dehisced bone defect will be grafted Using duoteck membrane
89243690|NCT06313216|Experimental|Immediate Implant Placement autogenous demineralized tooth graft|after insertion of immediate implant, the dehisced bone defect will be grafted Using autogenous demineralized tooth graft
89243691|NCT06313216|Experimental|Immediate Implant Placement with autogenous demineralized tooth graft and tooth plate|after insertion of immediate implant, the dehisced bone defect will be grafted Using autogenous demineralized tooth graft and autogenous demineralized tooth plate
89243692|NCT06313203|Active Comparator|Hepatic artery infusion (HAI) chemotherapy|Liver-directed hepatic arterial chemotherapy delivered through a surgically implanted HAI-pump has been evaluated in several small series and appears to have greater efficacy than systemic therapy alone.
89243693|NCT06313203|Active Comparator|Selective Internal Radiation Therapy (SIRT)|SIRT is approved in Norway, however, usen in a limited degree. Recent research in hepatocellular carcinoma has shown the importance of personalized dosimetry to obtain high tumour radiation dose, while limiting the dose to surrounding liver tissue, yielding improved response and survival (Dosisphere study), It is likely that these findings can be applied also to cholangiocarcinoma.
89243694|NCT06313190|Experimental|Arm A|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week. Then patients in the study group (arm A) will receive sintilimab as adjuvant therapy for up to 6 cycles after the completion of radiotherapy.
89243695|NCT06313190|Active Comparator|Arm B|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week. Then patients in the control group (arm B) will be followed up regularly.
89243696|NCT06313177|Active Comparator|group A|group(A) cases with ankle in neutral position during syndesmosis fixation
89243697|NCT06313177|Active Comparator|group B|group(B) cases with ankle in dorsiflexion position during syndesmosis fixation
89243698|NCT06313164|Experimental|enhanced L-gluthathione group|
89243699|NCT06313164|Placebo Comparator|placebo group|
89243700|NCT06313138|Experimental|Interventional group|"The Individual and Family Enhancement Program Session 1(1st week): Assessment and exchange information and building trusting relationship between researcher and participants; Session 2-3(1st-2nd week): Information sharing based on PITS model (Pathophysiology, Symptoms, or signs) and evaluation participants' understanding based on UPP scale.~Session 4-5(2nd-3rd week): Information sharing based on PITS model (treatment) and health maintenance skills.~Session 6 (3rd week): Information sharing based on PITS model (specifics) and family role in self-management.~Session7(4th week): Evaluation and summary. Session 8(5th week): Assess health literacy and information provision"
89243701|NCT06313138|Other|control group|Community nurses provide usual care
89243702|NCT06313125|Experimental|Foot-ankle exercise group|In the foot-ankle exercise group, three-dimensional foot-ankle extension exercises will be applied in the Proprioceptive Neuromuscular Facilitation (PNF) pattern, in diagonal 1 and 2 directions and short-foot exercise.
89243703|NCT06313125|Active Comparator|Hip exercise group|Clam exercise will be given to this group as a hip abductor and external rotator strengthening exercise. In addition, short-foot exercise will be applied.
89243704|NCT06313125|Active Comparator|Control group|The control group will do only short-foot exercise.
89243705|NCT06313099||All participants will be evaluated|
89243706|NCT06313086|Experimental|DP303c|DP303c injection, 3.0 mg/kg, Q3W.
89243707|NCT06313086|Active Comparator|trastuzumab emtansine|trastuzumab emtansine,3.6 mg/kg, Q3W.
89243708|NCT06313073|Experimental|Neoadjuvant radiotherapy|The patient received synchronous radiotherapy and chemotherapy before surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
89243709|NCT06313073|Active Comparator|Adjuvant radiotherapy|The patient underwent postoperative adjuvant radiotherapy. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
89243710|NCT06313060|Experimental|Intervention group|200 ml of Coca-Cola will be administered and must be ingested within a maximum of 10 minutes
89243711|NCT06313060|No Intervention|Control group|will not receive any type of medication or drink
89243712|NCT06313034|Experimental|experimental group|"Breastfeeding education will be given to mothers in the experimental group in 4 individual and face-to-face sessions based on motivational interviewing technique.~The first session of breastfeeding training based on motivational interviewing technique will be held in the delivery room where the mother is hospitalized before being discharged from the hospital. Other sessions will be held according to the monitoring frequency recommended in the Postnatal Care Management Guide of the Ministry of Health of the Republic of Turkey (2018). These will be done at the health institution where the mother receives service.~Second session; Between the 2th and 5th postpartum day Third session; Between the 13th and 17th postpartum day Fourth session; Between the 30th and 42th postpartum day The duration of each motivational interview is planned to be between 30-40 minutes on average."
89243713|NCT06313034|No Intervention|control group|Before discharge, mothers in the control group will be given routine breastfeeding training by the midwife working in the delivery room in accordance with the mother/baby friendly hospital protocol.
89243714|NCT06313021||stroke group|stroke group
89243715|NCT06312995|Experimental|T3DDY01|Acquired a digital acquisition of the patient's forearm using the Intel RealSense D415. The arm of the patient' is placed on a support to allow the plaster nurse to position of the wrist at the correct angle to treat the fracture. The limb is temporarily immobilised in a plaster cast by the nurses of the practice. The patient is booked for a subsequent outpatient visit (which will be conducted within 72 hours of digital acquisition of the forearm) for the application of the device under investigation. The production of the device through a Stratasys F370 3D printer owned by the Meyer Children's Hospital IRCCS. The material used is ABS (Acrylonitrile butadiene styrene) supplied by Stratasys and specific to the machine. Placement of the device on the patient by the investigating nurses, after removal of the temporary device. Collection of data on the evaluation of study parameters.
89243716|NCT06312995|Active Comparator|PLASTER|Traditional device placement (antibrachio-metacarpal cast). Radiological check at 7 days after trauma to verify the angle of the stumps fracture angle, followed by radiological check at 14 days if necessary . Removal of the plaster cast 30 days after the trauma, radiological check to verify the formation of bone callus, clinical evaluation and data collection at the end of treatment
89243717|NCT06312982|Experimental|Experimental group|The enrolled patients will receive a long course of NCRT (50 Gy / 25f, capecitabine 850-1000 mg / m2, BID, PO, D1-D5, QW) within the first 5 weeks. In regard to tumor immunotherapy, enrolled patients will receive tislelizumab (200 mg, iv) on the first day at week 2,5, and 8 after initiation of radiotherapy. Thereafter, patients will be treated with two 14-day cycles of the CAPOX（Q 3 w; D1 oxaliplatin, 130mg/m2,iv.gtt; D1-D14, capecitabine, 850-1000mg / m2, BID, PO）regimen. Two CAOPX regimens were treated one week apart. Eight to 8-10 weeks after the completion of radiation therapy, patients will undergo multiple examinations, including colonoscopy and MRI. Subsequent treatment options will be determined by each center physician based on their clinical experience.
89243718|NCT06312982|No Intervention|Control group|This group required only 5 weeks of NCRT and two 14-day cycles of the CAPOX （Q 3 w; D1 oxaliplatin, 130mg/m2,iv.gtt; D1-D14, capecitabine, 850-1000mg / m2, BID, PO）regimen.
89243719|NCT06312969|Experimental|Intervention group with video game-based training|"Cognitive training through 3 types of video games:~Serious games or brain-training games.~Exer-gaming~Skill-training games Method of administration~The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern:~Brain-training game: sessions of 7-12 minutes with a frequency of 4 days a week.~Exer-gaming: sessions of 15-20 minutes 2 days a week.~Skill-training games: sessions of 15-20 minutes 2 days a week."
89243720|NCT06312969|No Intervention|Waiting group (no training)|Patients in waiting group will not receive treatment whilst the 3 month period.
89243721|NCT06312943||Patients with various bone and joint diseases|Patients with various bone and joint diseases
89243722|NCT06312917|Experimental|Physical activity group|Exercise intervention According to the guidelines of the American Sports Medicine Association (ACSM) and the National Fitness guidelines of the General Administration of Sport of China
89243723|NCT06312917|No Intervention|control group|Maintain the current state of physical activity, do not do physical activity intervention.
89243724|NCT06312904|Experimental|paravertebral block group|This group of patients will undergo postoperative paravertebral block.
89243725|NCT06312904|Active Comparator|local infiltration group|This group of patients will undergo postoperative local infiltration anesthesia.
89243726|NCT06312891||Conventional anti-inflammatory treatment (control group).|
89243727|NCT06312891||Conventional ttt PLUS Carvedilol.|
89243728|NCT06312891||Conventional ttt PLUS Ivabradine.|
89243729|NCT06312878||Included patients|All patients with interrupted IVC with azygous continuation on CT scan.
89243730|NCT06312865||study group|patients diagnosed with 8 prism diopters or more exodeviation at distant or near fixation, regardless of age or fusion control (including intermittent exotropia, and constant exotropia).
89243731|NCT06312839||Control group|Esophagectomy alone
89243732|NCT06312839||Study Group|Preoperative ischemic conditioning before esophagectomy
89243733|NCT06312826|Active Comparator|US group|Subjects will be evaluated by two rounds of tests with abdominal US for the surveillance of HCC at intervals of 6 months.
89243734|NCT06312826|Experimental|AMRI group|Subjects will be evaluated by two rounds of tests with AMRI for the surveillance of HCC at intervals of 6 months.
89243735|NCT06312813|Experimental|Imipramine and Vehicle|4% imipramine and vehicle are applied on a 2x2cm2 area of the subject's cheek. The imipramine is applied on one side of the subject's face (cheek) and vehicle is applied on the other side.
89243736|NCT06312813|Experimental|Amitriptyline and Vehicle|4% amitriptyline and vehicle are applied on a 2x2cm2 area of the subject's cheek. The amitriptyline is applied on side of the subject's face (cheek) and vehicle is applied on the other side.
89243737|NCT06312800|Experimental|Acamprosate|Commercially available Acamprosate 333 mg tablets will be administered three times daily. Subjects will be started with one tablet with breakfast for 3 days, then one tablet with breakfast and dinner for 3 days, then one tablet 3 times a day for the next 15 days. Intervention order of medication trials will be determined by biostatistician.
89243738|NCT06312800|Active Comparator|Placebo|Placebo tablets are not available from the manufacturer for either of these drugs which are marketed as white tablets about the size of an aspirin tablet. Custom made placebo tablets will be purchased that are about that size. While not ideal , the extent of disguising the drug identity should be adequate with this. The placebo tablets will be administered three times daily. Subjects will be started with one tablet with breakfast for 3 days, then one tablet with breakfast and dinner for 3 days, then one tablet 3 times a day for the next 15 days. Intervention order of medication trials will be determined by biostatistician
89243739|NCT06312800|Experimental|Methazolamide|Commercially available methazolamide 50 mg tablets will be administered three times daily. Subjects will be started with one tablet with breakfast for 3 days, then one tablet with breakfast and dinner for 3 days, then one tablet 3 times a day for the next 15 days. Intervention order of medication trials will be determined by biostatistician
89243740|NCT06312787|Experimental|Sequence 1|Participants will receive a single dose of VX-118 as a suspension in the fasted state in dosing period 1, followed by a single dose of VX-118 as tablets in the fasted state in dosing period 2, followed by a single dose of VX-118 as tablets in the fed state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods.
89243741|NCT06312787|Experimental|Sequence 2|Participants will receive a single dose of VX-118 as tablets in the fasted state in dosing period 1, followed by a single dose of VX-118 as tablets in the fed state in dosing period 2, followed by a single dose of VX-118 as a suspension in the fasted state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods.
89243742|NCT06312787|Experimental|Sequence 3|Participants will receive a single dose of VX-118 as tablets in the fed state in dosing period 1, followed by a single dose of VX-118 as a suspension in the fasted state in dosing period 2, followed by a single dose of VX-118 as tablets in the fasted state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods.
89243743|NCT06312774||Individuals with Chronic Lung Disease|
89243744|NCT06312774||Healthy Controls|
89243745|NCT06312761|Experimental|Arm 1 Oral testosterone undecanoate without Curcumin|Oral testosterone undecanoate 237 mg Day 2
89243746|NCT06312761|Experimental|Arm 2 Oral testosterone undecanoate with Curcumin|Oral testosterone undecanoate 237 mg & Curcumin 630 mg Day 3
89243747|NCT06312761|Other|Relugolix 120 mg single dose|All subjects will received Relugoliz on Day 1
89243748|NCT06312748|Experimental|L-Citrulline, Then Placebo|Participants will receive a 90-day supply of L-Citrulline and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of Placebo and perform baseline and follow-up assessments as above.
89243749|NCT06312748|Experimental|BH4, Then Placebo|Participants will receive a 90-day supply of BH4 and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of Placebo and perform baseline and follow-up assessments as above.
89243750|NCT06312748|Experimental|Atorvastatin, Then Placebo|Participants will receive a 90-day supply of Atorvastatin and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of Placebo and perform baseline and follow-up assessments as above.
89243751|NCT06312748|Experimental|Placebo, Then L-Citrulline|Participants will receive a 90-day supply of Placebo and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of L-Citrulline and perform baseline and follow-up assessments as above.
89243752|NCT06312748|Experimental|Placebo, Then BH4|Participants will receive a 90-day supply of Placebo and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of BH4 and perform baseline and follow-up assessments as above.
89243753|NCT06312748|Experimental|Placebo, Then Atorvastatin|Participants will receive a 90-day supply of Placebo and perform baseline assessments of resting arterial blood pressure, ECT, arterial elasticity/pulse contour analysis, flow-mediated vasodilation and passive limb movement procedures. Participants will return to the laboratory for up to 5 additional study visits (days 10, 20, 30, 60, and 90) and repeat the experimental protocol. After a two-week washout period, participants will receive a 90-day supply of Atorvastatin and perform baseline and follow-up assessments as above.
89243754|NCT06312722|Other|Study Arm|Study consists of a single arm.
89243755|NCT06312696|No Intervention|No treatment group|No Treatment: participants will be placed in a similar position to the other groups for the same duration, but no treatment or touch will be administered.
89243756|NCT06312696|Sham Comparator|Pseudo sham group|Light massage group
89243757|NCT06312696|Experimental|Experimental group|Spinal Manipulative therapy group
89243758|NCT06312670|Experimental|EPI-7386 + Enzalutamide|EPI-7386 at 600 mg twice daily orally with standard of care Enzalutamide at 160 mg, once daily, orally for 36 months of treatment (11 cycles).
89243759|NCT06312657|Experimental|Money-vs-money task|
89243760|NCT06312657|Experimental|Drug-vs-money task|
89243761|NCT06312631|Experimental|Task handover model #1|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 1st model follows the following diagram:~Visit T1 = AB; Visit T2 = AB; Visit T3 = AB"
89243762|NCT06312631|Experimental|Task handover model #2|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 2nd model follows the following diagram:~Visit T1 = BA ; Visit T2 = AB ; Visit T3 = AB"
89243763|NCT06312631|Experimental|Task handover model #3|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 3rd model follows the following diagram:~Visit T1 = AB ; Visit T2 = BA ; Visit T3 = AB"
89243764|NCT06312631|Experimental|Task handover model #4|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 4th model follows the following diagram:~Visit T1 = AB ; Visit T2 = AB ; Visit T3 = BA"
89243765|NCT06312631|Experimental|Task handover model #5|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 5th model follows the following diagram:~Visit T1 = BA ; Visit T2 = BA ; Visit T3 = AB"
89243766|NCT06312631|Experimental|Task handover model #6|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 6th model follows the following diagram:~Visit T1 = BA ; Visit T2 = AB ; Visit T3 = BA"
89243767|NCT06312631|Experimental|Task handover model #7|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 7th model follows the following diagram:~Visit T1 = AB ; Visit T2 = BA ; Visit T3 = BA"
89243768|NCT06312631|Experimental|Task handover model #8|"At each visit, the patient will perform the tasks with the gripping glove (A) or without the gripping glove (B).~The order of administration with then without the glove (AB) or without then with the glove (BA) is drawn at random for each patient.~The 8th model follows the following diagram:~Visit T1 = BA ; Visit T2 = BA ; Visit T3 = BA"
89243769|NCT06312618|Active Comparator|Group 1: Propofol group|
89243770|NCT06312618|Active Comparator|Group 2: Dexmedetomidine group|
89243771|NCT06312605|Active Comparator|Intramucosal vitamin C injection|After surgical gingival depigmentation, injectable vitamin C (Redox C 500 mg) using insulin syringe(29 Gauge 1cc 0.33mm x 8mm 5/16 needle) is applied at gingival sites 0.1 ml for each point that should be 3 mm. The regimen is done once weekly for a month then once a month for additional 5 months.
89243772|NCT06312605|Active Comparator|(Vitamin C topical gel|After surgical gingival depigmentation, patients in this group apply ascorbic acid containing gel prepared by Nawah Scientific Research Center. The micro emulsion was prepared by mixing tween 20 (4.66% w/w) as surfactant and isopropanol (2.3% w/w) as co-surfactant using magnetic stirring then diluted drop-wise with Vitamin C solution in water (10% w/w). The formed micro emulsion was then converted into gel using Poloxamer 407 (20% w/w) that was added at 4°C under continuous magnetic stirring
89243773|NCT06312605|Placebo Comparator|Control group|Surgical gingival depigmentation is carried out for these patients
89243774|NCT06312592|Experimental|Intervention group|Receives the Entrepreneurship School with Gender Lens intervention. Participants receive a general training with six modules focused on business modeling and female empowerment for the participants. It is targeted for women who are forcibly displaced people, including refugees, and who are survivors or at risk of Sexual or Gender Based Violence. Each women entrepreneur, participates in individual mentoring sessions to build their business plan after the training and receives $800 start-up capital for their business plan. For at least a year, entrepreneurs will have a follow-up to promote their business scale up, including how to formalize their business in the market, how to define new strategies, and how to answer to the market's evolving requirements. Additionally, the participants receive an extensive training in gender aspects that have been identified as relevant to promote women's empowerment. The intervention also includes mental health content.
89243775|NCT06312592|No Intervention|Control group|Does not receive the Entrepreneurship School with Gender Lens intervention the Entrepreneurship School with Gender Lens intervention
89243776|NCT06312579|Experimental|12-week home based exercise|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week (Monday, Wednesday and Friday), and strength/balance exercise performed 2 days a week (Tuesday and Thursday).
88804722|NCT01217515|Experimental|Diltiazem hydrochloride 2% cream|2.5 cm of Diltiazem hydrochloride 2% cream applied peri-anally three times daily for eight weeks.
88804723|NCT01217515|Placebo Comparator|Placebo cream|2.5 cm placebo cream applied peri-anally three times daily for eight weeks.
88804724|NCT03009799|Active Comparator|Eye drops containing Iota-Carrageenan|Eye drops 3.2mg/ml
88804725|NCT03009799|Placebo Comparator|Ocular Lubricant Eye Drops|Carmellose 0.5% sterile solution
88804726|NCT00016718|Experimental|Age Group 1: 90 days to < 3 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
88804727|NCT00016718|Experimental|Age Group 2: 3 to 12 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
88804728|NCT00016718|Experimental|Age Group 2: 13 to 21 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
89243777|NCT06312579|Placebo Comparator|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
89243778|NCT06312566|Experimental|Treatment A-B|Study participants randomized to this arm will receive multiple doses of brivaracetam tablet (Treatment A) as reference and multiple doses of brivaracetam dry syrup (Treatment B) as test in the treatment sequence A-B at pre-specified timepoints.
89243779|NCT06312566|Experimental|Treatment B-A|Study participants randomized to this arm will receive multiple doses of brivaracetam tablet (Treatment A) as reference and multiple doses of brivaracetam dry syrup (Treatment B) as test in the treatment sequence B-A at pre-specified timepoints.
89243780|NCT06312527|Experimental|Silicone dressing|Apply silicone dressing after wound completely healed. Changing the dressing sheet every 7 days by Close the silicone cover for 10 weeks.
89243781|NCT06312527|No Intervention|No intervention|Do not apply silicone dressing
89243782|NCT06312514|Experimental|Intervention Arm|Participants will be young gay, bisexual and all other men who have sex men (YGBMSM) and providers from healthcare institutions working with (YGBMSM) who will receive the LAFIYA intervention.
89243783|NCT06312514|Experimental|Waitlist control group.|Control arm for comparison who will receive the intervention after the intervention group
88804729|NCT01897064|Experimental|Aerobic Exercise|Up to 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric treatment.
88804730|NCT01897064|Active Comparator|Standard Psychiatric Treatment|12 weeks of standard psychiatric treatment.
88804731|NCT00005032|Experimental|Arm A|G3139 (3 mg/kg/day continuous IV infusion over 7 days every 21 days), Paclitaxel (150 mg/m2, 3 hr IV infusion on Day 6 of every 21 day cycle)
88804732|NCT00019682|Experimental|Arm I (aldesleukin)|Patients receive aldesleukin IV over 15 minutes every 8 hours for 12 doses. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
89243784|NCT06312501||RPM heart failure patients|Patients that use RPM for the follow-ups of their condition.
89243785|NCT06312501||Real-life heart failure patients recieving conventional care|Patients that do not use any medical devices and/or solutions such as RPM for the follow-ups of their condition.
89243786|NCT06312488|Other|Septic patients|
89243787|NCT06312488|Other|Healthy volunteers|
89243788|NCT06312475|Experimental|Arm 1: KN057 Prophylaxis|Successfully screened participants will be randomly assigned to KN057 Prophylaxis versus No Prophylaxis at a ratio of 2:1. Participants in Arm 1 (KN057 Prophylaxis) will receive KN057 through the main trial (26 weeks) and extension period (26 weeks) for total of approximately 1 year.
89243789|NCT06312475|Experimental|Arm 2: No Prophylaxis|Successfully screened participants will be randomly assigned to KN057 Prophylaxis versus No Prophylaxis at a ratio of 2:1. Participants in Arm 2 (No Prophylaxis) will continue on-demand treatment with their usual bypass agents (rFVIIa or PCC) through the main trial for 26 weeks, in the extension period they will switch to prophylaxis treatment and receive KN057 for 26 weeks.
89243790|NCT06312462|Experimental|A:Intervention group|A group of students who receive schistosomiasis health education intervention led by community health volunteers.
89243791|NCT06312462|No Intervention|B:Control group|A group of students who do not receive schistosomiasis health education intervention led by community health volunteers.
89243792|NCT06312449|Experimental|The experimental group|The second stage of delivery involves using the lateral position with peanut ball
89243793|NCT06312449|Placebo Comparator|Control Group A|The second stage of delivery adopts the lateral position
89243794|NCT06312449|No Intervention|Control Group B|As usual care
89243795|NCT06312436||REBOA group|After allocation, access to a femoral artery is swiftly established by either ultrasound-guided puncture or via surgical cut-down. In parallel major haemorrhage protocol transfusion and further diagnostics are being carried out. Balloon occlusion is then achieved by placing a balloon catheter (ER-REBOA catheter, Prytime Medical®, Boerne, TX, USA) into aortic zone I (supradiaphragmatic) or III (aortic bifurcation) according to clinician decision based on injury pattern. Continuing management, including further computed tomography diagnostics and damage control interventions (operative or angioembolisation) and ongoing transfusions are undertaken according to patient status.
88804733|NCT00019682|Experimental|Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)|Patients receive gp100 antigen emulsified in Montanide ISA-51 SC on day 1. Patients also receive aldesleukin as in Arm I beginning on day 2. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
89243796|NCT06312436||Control group|After allocation, major haemorrhage protocol transfusion and all resuscitative measures except REBOA are performed. Continuing management, including further computed tomography diagnostics and damage control interventions (operative or angioembolisation) and ongoing transfusions are undertaken according to patient status.
88804734|NCT00005578|Experimental|Arm 1|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs.
89243797|NCT06312423|Experimental|Group 1 - 20 mg|Four volunteers will be enrolled (no more than one per day and only after verifying that the preceding volunteer did not show any significant adverse effects) who will be administered the initial dose level (1 x 20 mg of IMT504).
89243798|NCT06312423|Experimental|Group 2 - 60 mg|If no toxicity is detected and there is good tolerance, another 4 patients will be enrolled (no more than one per day and only after verifying that the preceding one did not show significant adverse effects) who will receive treatment with the next dose level (3 x 20 mg of IMT504, one application per day for 3 consecutive days).
89243799|NCT06312423|Experimental|Group 3 - 100 mg|If no toxicity is detected and there is good tolerance, another 4 patients will be enrolled (no more than one per day and only after verifying that the preceding one did not show significant adverse effects) who will receive treatment with the next dose level (5 x 20 mg of IMT504, one application per day for 5 consecutive days).
89243800|NCT06312410|Experimental|VIA Family 2.0|"In the intervention all child-involving elements are adapted to the specific age groups of the children, but everything is built on the same basic multidisciplinary, holistic and cross-sectional team model.~Every family will be affiliated to a case manager, who will coordinate all activities and appointments and be available throughout the intervention period of two years. A range of intervention elements will be offered to the family, depending on age of the child(ren), the family's needs and will always rely on their motivation:~Case-management supporting to reach good family functioning~Family-based psychoeducation~Parents' and children's groups with integrated peer-support~Parenting support and training~Mapping and nurturing of resources in the social network and social counseling~Early assessment of children's possible mental health problems~All elements will be adapted to the age of the children (details available upon request)"
89243801|NCT06312410|Active Comparator|Treatment as usual (TAU)|"TAU varies to some extent in the two regions, but common is that it consists of 2-3 family consultations (family sessions) with the presence of parents and all children above the age of six years.~These consultations will be managed by the Center for Relatives in the North Denmark Region and by the clinical 'child key persons' , who are staff with a special training in children and family impact in all departments of mental health services in the Capital Region.~The child is also referred to participate in a psychoeducational group for same aged children. Children can participate in a group with peers, who have a parent with a mental illness as well. These groups are run by two therapists with many years of experience working with groups like this for different age groups. Participation in groups like this is voluntary, and not all children continue in a group after the family consultations."
89243802|NCT06312397|Active Comparator|Acupressure group|"After coronary angiography, acupressure will be applied for a total of 15 minutes. For the acupressure group, a total of three points will be applied: the heart meridian 7th point (HT7), the large intestine meridian 4th point (LI4), and the stomach meridian 36th point (ST36), which is deemed appropriate in the lower extremity.~The symmetry of the three selected different points will also be applied to the other extremity."
89243803|NCT06312397|Placebo Comparator|Sham acupressure|In the acupressure application applied to the sham group, parallel pressure will be applied to the bone area and points where the HT7, LI4, ST36 meridians do not pass.
89243804|NCT06312397|No Intervention|Control group|With the control group, no intervention was conducted, and only standard care was given.
89243805|NCT06312384|Active Comparator|study|The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane will be applied, in this group 3D surgical template will be applied which consist of a two-piece tooth-supported surgical template will fabricated through 3D printing technology before surgery base on the digital simulation of bone graft contour.
89243806|NCT06312384|Active Comparator|control|The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane will be applied [conventional guided tissue regeneration].
89243807|NCT06312371|Experimental|Intermittent Oro-esophageal Tube Feeding|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups
89243808|NCT06312371|Active Comparator|Nasogastric Tube Feeding|the group was given enteral nutritional support with Nasogastric Tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements.
89243809|NCT06312358|Experimental|Teacher Professional Development Workshop and Coaching|Teachers will participate in a professional development workshop session (approximately 2 hours in duration) followed by 8 weekly coaching sessions (approximately 45-60 minutes in duration). The study team (trained coaches) will utilize the Practice-Based Coaching model (Snyder et al., 2015) to support teachers' use of developmentally appropriate practices in early childhood classrooms. Teachers will be coached to implement strategies that foster responsive and nurturing relationships with young children.
89243810|NCT06312345|Experimental|Experimental: ciprofol|
89243811|NCT06312345|Placebo Comparator|Placebo Comparator: propofol|
89243812|NCT06312332|Experimental|MEDIC site|
89243813|NCT06312293|Experimental|In-Ear stimulation|Participants in this group underwent intra-ear transcutaneous vagus nerve simulation.
89243814|NCT06312293|Experimental|Behind the ear stimulation|Participants in this group underwent transcutaneous vagus nerve simulation behind the ear.
89243815|NCT06312293|Placebo Comparator|In-Ear stimulation (device switched off)|In order to see the placebo effect of in-ear simulation in participants in this group, the electrode was placed inside the ear with the device closed and the results were evaluated.
89243816|NCT06312293|Placebo Comparator|Behind the ear stimulation (device switched off)|In order to see the placebo effect of behind-ear simulation in participants in this group, the electrode was placed inside the ear with the device closed and the results were evaluated.
89243817|NCT06312267|No Intervention|Control Arm|Study participants will undergo surgery using current ERAS protocol standard of care skin cleaning preparation.
89243818|NCT06312267|Experimental|Experimental Arm|Study participants will use Bioelectrical dressing preoperatively and post-operative.
89243819|NCT06312254|Active Comparator|Pharmacological modulation with lidocaine 5%|Experimental investigation of pharmacological modulation of peripheral nerve excitability, which is measured with the human perception threshold tracking method. With this method neurophysiological mechanisms of sensory afferents can be investigated
89243820|NCT06312254|Active Comparator|Pharmacological modulation with Phenytoin 10%|Experimental investigation of pharmacological modulation of peripheral nerve excitability, which is measured with the human perception threshold tracking method. With this method neurophysiological mechanisms of sensory afferents can be investigated
89243821|NCT06312254|Active Comparator|Pharmacological modulation with Mepyramine 2%|Experimental investigation of pharmacological modulation of peripheral nerve excitability, which is measured with the human perception threshold tracking method. With this method neurophysiological mechanisms of sensory afferents can be investigated
89243822|NCT06312254|Placebo Comparator|Control|Experimental investigation of pharmacological modulation of peripheral nerve excitability, which is measured with the human perception threshold tracking method. With this method neurophysiological mechanisms of sensory afferents can be investigated
89243823|NCT06312241|Experimental|Metacognitive Training-Silver BeWell|MCT-Silver BeWell is a cognitive-behavioral therapy based group intervention, which aims to improve insight for and change negative (meta)cognitive beliefs (e.g., negative mental filter), information-processing biases (e.g., mood-congruent memory), unhelpful behaviors (e.g., social withdrawal) and emotion-regulation (ER) strategies (e.g. rumination, avoidance of negative feelings) associated with the onset of depression. The training represents a variant of MCT-Silver for depression in later life developed for older adults without clinical depression.
89243824|NCT06312228|Experimental|Helper Skin Tap Technique Group|Before the vaccine injection, body weight, height and physiological parameters (pulse, blood pressure, SpO2, body temperature) were measured and behavioural pain responses were evaluated by the child, nurse and parent using the Wong-Baker pain scale and fear scale. Slow tapping was performed with rhythmic tapping movements on the left deltoid muscle where the vaccine will be administered to the children. When the needle was to be inserted into the deltoid muscle, the tapping was slightly increased and the needle entry was made with the same movement. After the vaccine injection was given, the needle was rapidly withdrawn from the muscle by increasing the tapping movements while the needle was withdrawn.
89243825|NCT06312228|Experimental|Buzzy Group|Before the vaccine injection, body weight, height and physiological parameters (pulse, blood pressure, SpO2, body temperature) were measured and behavioural pain responses were evaluated by the child, nurse and parent using the Wong-Baker pain scale and fear scale. The ice pack previously removed from the deep freezer was kept at room temperature for 10 minutes and the hole in the ice pack wing was placed on the hook behind the Buzzy®. The Buzzy® was placed on the left arm deltoid muscle and activated and kept for 30 seconds. After 30 seconds, Buzzy® was pulled up 1 centimetre (cm) and the MMR vaccine injection was administered to the area corresponding to the left deltoid muscle. After the vaccine injection, Buzzy® was pulled to the injection site and kept for another 30 seconds.
89243826|NCT06312228|No Intervention|Control Group|Before the vaccine injection, body weight, height and physiological parameters (pulse, blood pressure, SpO2, body temperature) were measured and behavioural pain responses were evaluated by the child, nurse and parent using the Wong-Baker pain scale and fear scale. MMR vaccine injection was routinely administered in the area corresponding to the left deltoid muscle without any intervention or application to the injection site.
89243827|NCT06312215|Experimental|Closed System Peripheral Catheters|After the area where the catheter would be inserted was cleaned with an antiseptic solution and allowed to dry, a closed-system catheter was applied. Closed-system catheters are devices that allow access through needleless mechanisms, protecting the patient from accidental needle puncture injuries. They have mechanisms preventing blood leakage or pathogen entry.
89243828|NCT06312215|No Intervention|Control|After the area where the catheter would be inserted was cleaned with an antiseptic solution and allowed to dry, a catheter was applied.
88804735|NCT00005578|Experimental|Arm 2|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Dexrazoxane hydrochloride on days 0, 1, and 7
88804736|NCT00022490|Experimental|Cytarabine/ Imatinib Mesylate|
89243829|NCT06312189|Experimental|Valbenazine|Capsule, administered orally once daily.
89243830|NCT06312176|Experimental|Arm A: MK-2870|Participants receive 4 mg/kg of MK-2870 once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation.
89243831|NCT06312176|Experimental|Arm B: MK-2870+Pembrolizumab|Participants receive 4 mg/kg of MK-2870 Q2W via IV infusion until progressive disease or discontinuation PLUS 400 mg of pembrolizumab once every 6 weeks (Q6W) via IV infusion for up to 18 administrations (up to ~2 years).
89243832|NCT06312176|Active Comparator|Arm C: Treatment of Physician's Choice (TPC)|At the physician's discretion, participants receive chemotherapy of 80 mg/m^2 of paclitaxel once every week (Q1W) via IV infusion OR 90 mg/m^2 of paclitaxel once every 4 weeks (Q4W) via IV infusion OR 100 mg/m^2 of nab-paclitaxel Q4W via IV infusion OR 1000 mg/m^2 of capecitabine every 3 weeks (Q3W) orally OR 50 mg/m^2 of liposomal doxorubicin once every 4 weeks (Q4W) via IV infusion, until progressive disease or discontinuation.
89243833|NCT06312163||ARM1|The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design)
89243834|NCT06312163||Arm2|The patient's own corneal RGP lens - CE (UKCA) marked class 2 medical devices.
89243835|NCT06312137|Experimental|MK-2870 + Pembrolizumab|Participants will receive pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by MK-2870 4 mg/kg IV infusion every 2 weeks (Q2W) for up to 20 doses (~40 weeks) with pembrolizumab monotherapy 200 mg IV infusion every 6 weeks (Q6W) for up to 7 cycles (~42 weeks).
89243836|NCT06312137|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab 200 mg intravenous (IV) infusion Q3W for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by pembrolizumab monotherapy 200 mg IV infusion Q6W for up to 7 cycles (~42 weeks).
89243837|NCT06312124|Experimental|Participants scheduled for non-gynecologic abdominopelvic surgery|Participants will be aged ≥45 years, have at least 1 fallopian tube, will not desire or plan to have children in the future, and will be scheduled to undergo non-gynecologic abdominopelvic surgery.
89243838|NCT06312111|Experimental|A physically inactive subgroup|Patients who walked <5,000 steps per day during the first two weeks
88804737|NCT00386230|Experimental|1|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Smother-Sinfant)
89243839|NCT06312111|Active Comparator|A physically active subgroup|Patients who walked >5,000 steps per day during the first two weeks
89243840|NCT06312085|Experimental|Endofill arm|Endofill arm- This arm will receive the novel obturation material after root canal preparation and success of root canal treatment will be measured after 12 months
89243841|NCT06312072||MEIRU rural population cohort|"Adults aged >=18 living in MEIRU's rural health demographic surveillance area (Karonga district)~No interventions to be administered; observational study only, with collection of survey data, blood samples and urine samples."
89243842|NCT06312072||MEIRU urban population cohort|"Adults aged >=18 living in MEIRU's urben demographic surveillance area (Lilongwe Area 25)~No interventions to be administered; observational study only, with collection of survey data, blood samples and urine samples."
89243843|NCT06312059|Active Comparator|Market leader- Competitor Cow Milk based infant formula|Intervention with Competitor product currently in market- Control.
89243844|NCT06312059|Experimental|Test product Cow Milk based infant formula|Intervention with Test product product - Test arm.
89243845|NCT06312059|Experimental|Test product Goat Milk based infant formula|Intervention with Test product product - Test arm.
89243846|NCT06312046|Experimental|Balance training intervention group|The program HiBalance-MS is based on scientifically well-established principles of exercise training and postural control. It will be conducted as a progressive individually adjusted group training to challenge the specific balance deficit of every participant. To ensure highly challenging exercises, each task is individually adjusted, e.g., by altering the base of support, increasing speed, restricting vision and varying grade of multitasking. Daily variation in capacity will be rated before each training session and participants will at the end of each session rate the challenging level. The training will be performed in the clinic, at Karolinska University Hospital, for an hour, twice a week for 10 weeks, as a group intervention including 6 to 8 participants and facilitated by two physiotherapists/trainers.
89243847|NCT06312046|No Intervention|No intervention control group|Participants in the control group are encouraged to maintain their normal physical activities and are not restricted from participation in ongoing rehabilitation programs.
89243848|NCT06312033|Experimental|naturally cycling women starting with placebo|naturally cycling women during early follicular phase starting with placebo (order was randomly selected)
89243849|NCT06312033|Experimental|naturally cycling women starting with estradiol|naturally cycling women during early follicular phase starting with estradiol (order was randomly selected)
89243850|NCT06312020|Experimental|HZN-1116 Dose 1 in Population 1|Participants will receive Dose 1 of HZN-1116
89243851|NCT06312020|Experimental|HZN-1116 Dose 2 in Population 1|Participants will receive Dose 2 of HZN-1116
89243852|NCT06312020|Placebo Comparator|Placebo in Population 1|Participants will receive Placebo matched to HZN-1116
88804738|NCT00386230|Experimental|2|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Smother-Linfant)
88804739|NCT00386230|Experimental|3|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Lmother-Sinfant)
88804740|NCT00386230|Active Comparator|4|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Lmother-Linfant). This study arm was the reference regimen.
89243853|NCT06312020|Experimental|HZN-1116 Dose 1 in Population 2|Participants will receive Dose 1 of HZN-1116
89243854|NCT06312020|Experimental|HZN-1116 Dose 2 in Population 2|Participants will receive Dose 2 of HZN-1116
89243855|NCT06312020|Experimental|HZN-1116 Dose 3 in Population 2|Participants will receive Dose 3 of HZN-1116
89243856|NCT06312020|Experimental|HZN-1116 Dose 4 in Population 2|Participants will receive Dose 4 of HZN-1116
89243857|NCT06312020|Placebo Comparator|Placebo in Population 2|Participants will receive Placebo matched to HZN-1116
89243858|NCT06312007|Experimental|Semi-seated position|Semi seated position
89243859|NCT06312007|Experimental|Side Lying position|Side lying position
89243860|NCT06311994|Experimental|Intervention with virtual reality|"Factors that may affect patient compliance with the VR-based intervention method to be applied to patients undergoing knee surgery and the factors that may affect the measurements were evaluated through a literature review and inclusion and exclusion criteria were created."
89243861|NCT06311994|No Intervention|Control|Among the randomized patients, patients included in the control group will be included in the conventional rehabilitation program.
88804741|NCT00097448|Other|1|Nineteen days of oral prednisone
88804742|NCT00097448|Experimental|2|Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks
88804743|NCT00004246|Experimental|RT + Fludarabine|Radiotherapy (RT) on Days 1-5 for 7 weeks + Fludarabine IV, 3-4 hours prior to daily RT, Days 1-5 of weeks 6 and 7 of RT
88804744|NCT00423280|Active Comparator|1|700mg/day 6R-BH4
88804745|NCT00423280|Active Comparator|2|400mg/day 6R-BH4
89243862|NCT06311981|Experimental|Study arm|The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
89243863|NCT06311968|Experimental|Study arm|Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
89243864|NCT06311955|Experimental|Study arm|The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
89243865|NCT06311942|Experimental|Triple adjuvant therapy group|Patients in the triple adjuvant therapy group received HAIC in combination with PD-1 inhibitors and lenvatinib adjuvant therapy.
89243866|NCT06311942|Active Comparator|Dual adjuvant therapy group|Patients in the Dual adjuvant therapy group received PD-1 inhibitors combined lenvatinib adjuvant therapy.
89243867|NCT06311929|Experimental|Combined adjuvant therapy group|Patients in the combined adjuvant therapy group received PD-1 monoclonal antibody with Lenvatinb adjuvant therapy after liver resection.
89243868|NCT06311929|Active Comparator|Monotherapy group|Patients in the monotherapy group received PD-1 monotherapy after liver resection.
89243869|NCT06311916|Experimental|Neoadjuvant therapy group|Patients in the neoadjuvant therapy group received neoadjuvant therapy before undergoing liver resection.
89243870|NCT06311916|Active Comparator|Direct surgical resection group|Patients in the control group undergoing liver resection directly.
89243871|NCT06311903|Experimental|Group I|Patients were received resuscitative fluid [administered at beginning with the arrival of the patient in the emergency department (mean blood pressure >70 mmHg)] followed by low dose of norepinephrine (NE) (0.05-0.2 μg/kg/min).
89243872|NCT06311903|Experimental|Group II|patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received norepinephrine (NE) gradually till reach high dose (≥0.3 μg/kg/min).
89243873|NCT06311890|Experimental|photosensitizer group|Subjects will receive a photodynamic therapy with chlorin-e6 after acne removal surgery.Each subject will receive three treatments, two weeks (±3 days) intervals.
89243874|NCT06311890|Placebo Comparator|photosensitizer-placebo group|Subjects will receive a red light exposure treatment with chlorin-e6 placebo after acne removal surgery.Each subject will receive three treatments, two weeks (±3 days) intervals.
89243875|NCT06311877|Experimental|Experimental group given mBerry tablet|For the experiment group, the clinician will be providing participant with daily 0.4 gram mBerry tablets (total of 112 tablets) to consume twice a day (for two meals) over an 8-week period. The participant will be provided with a log form to track mBerry use for the two meals each day for the 8-week period. They will be requested to bring log to each of the clinical visits which include bi-weekly taste assessments.
89243876|NCT06311877|Active Comparator|Control group not receiving mBerry|The control group will not be given a placebo. The control group will come to clinic for bi-weekly taste assessments.
89243877|NCT06311864||daridorexant|Patients who have been newly prescribed oral tablets of daridorexant 50 mg to treat their insomnia
89243878|NCT06311851|Experimental|Bevacizumab Transarterial Chemoembolization|The procedure commences with local disinfection and anesthesia, followed by a percutaneous right femoral artery puncture, performed using a modified Seldinger technique. A 5-F Simmons Ⅰ catheter was introduced through a vascular sheath and positioned in the common hepatic artery with the guidance of digital subtraction angiography to identify the tumor-supplying vessels. A 2.8-F microcatheter catheter was advanced into the vessel supplying the hepatic tumor. In cases of bilobar disease, the initial treatment focus was on the lobe with the greatest tumor burden, with the contralateral lobe addressed in a subsequent TACE session scheduled 4-6 weeks apart. Bevacizumab 100 mg was injected first followed by an emulsion of chemotherapeutic agents (including Carboplatin 50 mg, Mitomycin 10 mg, and Idarubicin 10 mg) together with iodized oil and gelatin sponge particles. The procedure was monitored under fluoroscopy until arterial flow stasis was achieved.
89243879|NCT06311838|Experimental|Motivational Interviewing/Community Reinforcement Approach + Services as Usual (MI/CRA + SAU)|"The current evidence base recommends integrating treatments targeting both Substance Use Disorder and psychiatric disorders, especially combining Motivational Interviewing with behavioral interventions such as CRA or Cognitive Behaviorial Therapy.~Enhancing intrinsic motivation for behavioral change is the central purpose of motivational interviewing (MI), a clinical method built on the insights and strategies described by Carl Rogers as client-centered therapy. MI is also directive, however, in selectively eliciting and reinforcing client change talk. Typically offered as a brief intervention of 1-2 sessions, MI has a strong record of efficacy in the treatment of alcohol and other drug use disorders, mental health and other problematic behaviors.~The Community Reinforcement Approach (CRA) offers an empirically-based multifaceted approach to substance abuse/mental health treatment that also addresses many of the clinical needs of multi-problem homeless individuals."
89243880|NCT06311838|Experimental|Strengths-Based Outreach and Advocacy + Services As Usual (SBOA +SAU)|"Some research suggests that engagement with an advocate is key to success when linking those experiencing homelessness to available services and supports in the community. The strengths model is based on the premise that the purpose of advocacy is to assist consumers in identifying, securing, and preserving the range of resources, both external and internal, needed to live in a normal, independent way in the community. Strengths-based interventions focus on enhancing well-being and happiness rather than attempting to correct deficits or pathology. The advocate takes responsibility for securing needed services for the youth and remains a support as they traverse the system of care. The focus of the first several weeks of advocacy is on obtaining identification and ensuring basic needs are met (food, safety, medical care, housing, etc.). As basic needs are addressed, youth and advocates focus on other high need areas including education, employment, mental health and substance use."
88804746|NCT00423280|Placebo Comparator|3|Placebo
89243881|NCT06311838|Experimental|Motivational Interviewing/Community Reinforcement Approach (MI/CRA) + SBOA + SAU|This intervention combines all three interventional models: Motivational Interviewing/Community Reinforcement Approach along with Strengths-Based Outreach and Advocacy and the Services as Usual.
89243882|NCT06311838|Active Comparator|Services as Usual (SAU)|All youth will receive services as usual provided by the drop-in center.
89243883|NCT06311825|Experimental|Horticultural Therapy Group (Experimental)|Horticultural therapy will be applied to experimental group.
89243884|NCT06311825|No Intervention|Controls (Control Group)|No intervention will be applied to the control group.
89243885|NCT06311799|No Intervention|Arm 1: Clinic Model|Clinical team gives WIC information only
89243886|NCT06311799|Active Comparator|Arm 2: Clinic-WIC Model|Clinical team connects patient to WIC
89243887|NCT06311799|Active Comparator|Arm 3: Clinic-RDN Model|Clinical team gives WIC information only; connects patient to registered dietitian/nutritionist (RDN)
89243888|NCT06311799|Active Comparator|Arm 4: Clinic-WIC-RDN|Clinical team connects patient to WIC and RDN
89243889|NCT06311786|Experimental|[14C]-BIIB091|Participants will receive a single oral dose of [14C]-BIIB091 on Day 1.
89243890|NCT06311773|Experimental|Treated with Boomerang Catheter|
89243891|NCT06311760|Experimental|AZD0292 Dose 1|Participants will receive single dose of AZD0292 dose 1 as IV infusion on Day 1.
89243892|NCT06311760|Experimental|AZD0292 Dose 2|Participants will receive single dose of AZD0292 dose 2 as IV infusion on Day 1.
89243893|NCT06311760|Experimental|AZD0292 Dose 3|Participants will receive single dose of AZD0292 dose 3 as IV infusion on Day 1.
89243894|NCT06311760|Placebo Comparator|Placebo|Participants will receive matching placebo to AZD0292 as IV infusion on Day 1.
89243895|NCT06311734|Experimental|Part A: SAD in healthy participants|Part A: Single ascending doses of up to 800 mg LW231 tablets in healthy participants.
89243896|NCT06311734|Experimental|Part b: MAD in healthy participants|Part B: Multiple ascending doses of up to 400 mg LW231 tablets in healthy participants. Dosages will be determined from data collected from Part A.
89243897|NCT06311734|Experimental|Part c: MAD in CHB participants (optional)|Part C: Multiple ascending doses of up to 400 mg LW231 tablets in CHB participants. Dosages will be determined from data collected from Part A and Part B.
89243898|NCT06311721|Experimental|ABP 234|Part 1: Participants will receive ABP 234 followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive ABP 234 followed by pemetrexed.
89243899|NCT06311721|Experimental|Pembrolizumab (US)|Part 1: Participants will receive FDA-licensed pembrolizumab followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive FDA-licensed pembrolizumab followed by pemetrexed.
89243900|NCT06311721|Experimental|Pembrolizumab (EU)|Part 1: Participants will receive EU-approved pembrolizumab followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive EU-approved pembrolizumab followed by pemetrexed.
89243901|NCT06311708||Retrospective and Prospective|Patients who meet the eligibility criteria are observed and data collected both prospectively and retrospectively.
89243902|NCT06311695||Contrast Enhanced Mammography|Patients underwent Contrast Enhanced Mammography
89243903|NCT06311682|Experimental|Tralokinumab + TCS for subjects aged 2 to <12 years|Dose and dosing frequency for each subject will depend on the subject's body weight.
89243904|NCT06311682|Experimental|Placebo + TCS for subjects aged 2 to <12 years|Dose and dosing frequency for each subject will depend on the subject's body weight.
88804747|NCT00028262|Experimental|Drug: Cystagon and N-acetylcysteine|
88804748|NCT04771286|Experimental|BI 1015550 (C-14)|
89243905|NCT06311682|Experimental|Tralokinumab + TCS for subjects aged 6 months to <2 years|Dose and dosing frequency for each subject will depend on the subject's body weight.
89243906|NCT06311669|Active Comparator|Isolated iliac vein stenting|
89243907|NCT06311669|Active Comparator|Concomitant iliac vein stenting with pelvic vein embolization|
89243908|NCT06311656|Experimental|LY4100511 (DC-853)|Single and multiple doses of LY4100511 (DC-853) administered orally.
89243909|NCT06311656|Placebo Comparator|Placebo|Placebo administered orally.
89243910|NCT06311643|Experimental|Study group|Postpartum Back Massage is done to puerperal women just after 4 hours of delivery and for 1 month with rate of 3 sessions per week and routine postnatal care
89243911|NCT06311643|No Intervention|Control group|Puerperal women just have routine post natal care for 1 month
89243912|NCT06311617||Healthy Pregnant Patients|Health pregnancies
89243913|NCT06311617||Pregnant Patients with Pre-Existing Diabetes|Patients with pre-existing diabetes who are pregnant
89243914|NCT06311617||Pregnant Patients with Vascular Disease or Risk Factors for Vascular Disease|"Multiple gestations~Preeclampsia or eclampsia~Gestational diabetes~Hypercoagulable state such as disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome."
89243915|NCT06311604|Experimental|ISOFLURANE SEDATION|"Inclusions will have 4 phases according to gradual increased doses of isoflurane (0.3 MAC; 0.5 MAC and 0.7 MAC) Upgrading dose of isoflurane in each phase will be validated by an independent data and safety monitoring committee (DSMC).~Inclusion of 12-15 additional patients will be included at the 0.7 MAC dose, to have 18 patients exposed to 0.7 MAC isoflurane."
89243920|NCT06311565|Experimental|Education|People who have undergone colorectal cancer screening will be given training on colorectal cancer prevention. Training will be carried out face to face and individually. The training will take approximately 25-30 minutes.
89243921|NCT06311565|No Intervention|Control|Individuals in this group will be screened for colorectal cancer. However, this group will not be given any training on cancer prevention.
89243922|NCT06311552||CMR scan on either a 1.5- or 3-Tesla scanner|
89243923|NCT06311539|Experimental|Morning chronotype|Participants who score between 59-70 in the Morningness Eveningness Questionnaire will be assigned to the morning chronotype group.
89243924|NCT06311539|Experimental|Evening chronotype|Participants who score between 16-41 in the Morningness Eveningness Questionnaire will be assigned to the evening chronotype group.
89243925|NCT06311526||Stroke patients suffering a spastic upper limb paresis|
89243926|NCT06311513|Experimental|Investigational Arm|Patients undergoing revision anterior cruciate ligament reconstruction surgery will get an intraoperative injection of concentrated bone marrow aspirate (cBMA).
89243927|NCT06311513|Sham Comparator|Control Arm|Patients undergoing revision anterior cruciate ligament reconstruction surgery will get a sham incision in lieu of bone marrow harvesting.
89243928|NCT06311500|Experimental|Sleep Health Enhancement Intervention|4 weekly visits using Zoom video conferencing consisting of education and strategies to enhance sleep health with each visit lasting about 60 minutes.
89243929|NCT06311500|No Intervention|Wait-List Control Group|People in the wait-list group will continue with their usual activities for 4 weeks and then start the sleep health enhancement intervention.
88804749|NCT02602808||Severe acute pancreatitis group|Severe acute pancreatitis is characterised by persistent organ failure.
88804750|NCT02602808||Moderately severe acute pancreatitis|Moderately severe acute pancreatitis is characterised by the presence of transient organ failure or local or systemic complications in the absence of persistent organ failure.
89243931|NCT06311474|No Intervention|Waitlist Control|Participants randomized to the waitlist control (or delayed treatment) condition will receive written and verbal feedback after the baseline assessment visit. These families will participate in follow-up visits at 3 months, 6 months, and 12 months after the baseline visit. They will receive the same treatment (PCIT) after the 6-month assessment.
89243932|NCT06311474|Experimental|Immediate Treatment|Participants randomized to the immediate treatment condition will receive written and verbal feedback after the baseline assessment visit. These families will begin PCIT shortly after this visit. These families will participate in follow-up visits at 3 and 6 months after the baseline visit.
89243933|NCT06311461|Experimental|Acupuncture|Participants in the acupuncture group will receive a standardized Traditional Chinese Medicine (TCM) point prescription. Acupuncture will be administered 2 times per week for 5 weeks for a total of 10 treatments.
89243934|NCT06311461|Active Comparator|Attention Control Group|The attention control group will view non-pain related TED talk videos over 5 weeks approximately equal to 10 hours of treatment for the acupuncture group.
89243935|NCT06311448||Treated with immunomodulation|Adult patients with COVID-19 ARDS admitted to ICU and requiring mechanical ventilation and receiving standard of care treatment (including steroids) and single-target immunomodulation, for example Toculizimab, Anakinra, etc.
89243936|NCT06311448||Not treated with immunomodulation|Adult patients with COVID-19 ARDS admitted to ICU and requiring mechanical ventilation and receiving standard of care treatment (including steroids).
89243937|NCT06311435|Active Comparator|Participants never infected by SARS-COV-2|Participants with no history of SARS-COV-2 infection. This is a control arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243938|NCT06311435|Active Comparator|Participants with SARS-COV-2 post-infection without long COVID|Participants with a history of SARS-COV-2 infection, but never developed long term sequalae. This is a control arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243939|NCT06311435|Active Comparator|Participants with long COVID and respiratory symptoms|Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with their respiratory system: continued shortness of breath, etc.. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243940|NCT06311435|Active Comparator|Participants with long COVID and neurological symptoms|Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with their neurologic system: brain fog, confusion, etc.. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243941|NCT06311435|Active Comparator|Participants who have long COVID with both respiratory and neurological symptoms|Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with both their respiratory system and their neurologic system. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243942|NCT06311435|Active Comparator|Participants who have other long COVID symptoms|Participants with a history of SARS-COV-2 infection and developed long term sequalae not associated with their respiratory system and their neurologic system. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
88804751|NCT02602808||Mild acute pancreatitis|Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local or systemic complications.
88804752|NCT02602808||post-ERCP pancreatitis|Patients with new onset of epigastric pain, an increase in pancreatic enzymes of at least three times the upper limit of the normal range within 24 hours after ERCP, and hospitalization for at least 2 nights.
89243943|NCT06311435|Active Comparator|Participants with neurological symptoms prior to 1 November 2019|Participants with a history of SARS-COV-2 infection who had neurologic symptoms prior to 1 November 2019. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243944|NCT06311435|Active Comparator|Participants with respiratory symptoms prior to 1 November 2019|Participants with a history of SARS-COV-2 infection who had respiratory symptoms prior to 1 November 2019. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243945|NCT06311435|Active Comparator|Neurological symptoms prior to 1 November 2019 without history of SARS-COV-2 infection|Participants without a history of SARS-COV-2 infection who had neurologic symptoms prior to 1 November 2019. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243946|NCT06311435|Active Comparator|Respiratory symptoms prior to 1 November 2019 without history of SARS-COV-2 infection|Participants without a history of SARS-COV-2 infection who had respiratory symptoms prior to 1 November 2019. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
89243947|NCT06311435|Active Comparator|Participants who do not meet long COVID criteria but are otherwise unclassified|Participants with a history of SARS-COV-2 infection who do not have signs of Long COVID but do not fit into other arms.
89243948|NCT06311396|Experimental|Neuronal micRoscopy for cEll behaVioural Examination and mAnipuLation|validate the ability of a neuronal microscope to decipher the biomechanism at the origin of liver cancer, especially addressing the problem of biological heterogeneity
89243949|NCT06311383||First-line Ribociclib + endocrine therapy|Ribociclib + letrozole, or Ribociclib + anastrozole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
89243950|NCT06311383||First-line endocrine therapy|As of physicians choice
89243951|NCT06311383||First-line chemotherapy|As of physicians choice
89243952|NCT06311370||Children age 4 to 7|Children age 4-7 in therapeutic school, diagnosed with ADHD, Autism monitored with raters and the sensor watch.
89243953|NCT06311357|No Intervention|Control|Nutritional advise
89243954|NCT06311357|Experimental|Intervention|Medical supplement and nutritional advise
89243955|NCT06311344|Other|Biological samples|M. perstans microfilariae and Schistosoma spp eggs, obtained from the routine diagnostic procedures carried out on patients, specifically migrants and travellers, visited in the centres participating to this study
89243956|NCT06311331||Total Talus Replacement|50 subjects receiving the Total Talus Replacement device
89243957|NCT06311318|Experimental|Massage group|Patients in the experimental group received training and guidance from trained investigators regarding post-operative lower eyelid massage.
89243958|NCT06311318|No Intervention|Non-massage group|The control group receiving standard care without post-operative lower eyelid massage.
89243959|NCT06311305|Other|early laparoscopic cholecystectomy after ERCP|we assess the risks and complications of early laparoscopic cholecystectomy after ERCP
89243960|NCT06311292|Experimental|Intrapulmonary Percussive Ventilation for Non-sputum Producer|Unable to produce adequate amount of lower airway bacterial sampling for culture results in last year.
89243961|NCT06311279|Active Comparator|Group A|the first group included patients who will have anterior resection with end-to-end anastomosis
89243962|NCT06311279|Active Comparator|Group B|the second group included patients will have anterior resection with side to end anastomosis.
89243963|NCT06311266|Active Comparator|robotic|In the robotic group the endoscope will be guided with the EndoGuide robotic system
89243964|NCT06311266|Active Comparator|standard freehand|In the standard freehand group the endoscope will be guided freehand throughout the surgery
89243965|NCT06311240||Participant with CKD|Participant with CKD answering the questionnaires
89243966|NCT06311227|Experimental|Treatment (venetoclax)|Patients receive venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and blood sample collection throughout the study. Patients may undergo bone marrow biopsy and/or aspiration on study.
89243967|NCT06311214|Experimental|Cohort A (sacituzumab govitecan)|Patients receive sacituzumab govitecan IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the trial, undergo biopsy after enrollment to cohort but prior to treatment and again on study, and undergo collection of blood samples after enrollment to cohort but prior to treatment. Patients may optionally undergo biopsy at the time of progression and may optionally undergo collection of blood samples on study and at the time of progression.
89243968|NCT06311214|Experimental|Cohort B (enfortumab vedotin)|Patients receive enfortumab vedotin IV over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the trial, undergo biopsy after enrollment to cohort but prior to treatment and again on study, and undergo collection of blood samples after enrollment to cohort but prior to treatment. Patients may optionally undergo biopsy at the time of progression and may optionally undergo collection of blood samples on study and at the time of progression.
89243969|NCT06311214|Experimental|Cohort C (trastuzumab deruxtecan)|Patients receive trastuzumab deruxtecan IV over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the trial, undergo biopsy after enrollment to cohort but prior to treatment and again on study, and undergo collection of blood samples after enrollment to cohort but prior to treatment. Patients also undergo ECHO or MUGA at screening and on study. Patients may optionally undergo biopsy at the time of progression and may optionally undergo collection of blood samples on study and at the time of progression.
89243970|NCT06311214|Other|Screening (record review, IHC assay)|"SCREENING STEP 1: Patients who have previously undergone SOC RNA testing have the results of their SOC RNA testing reviewed. Patients whose tumor expresses an appropriate TOI by RNA testing proceed to screening step 2.~SCREENING STEP 2: Patients have TOI expression testing at the protein level by IHC assay performed on previously collected tissue. Patients with high Trop-2 protein expression are assigned to Cohort A. Patients with high nectin-4 protein expression are assigned to Cohort B. Patients with high HER2 protein expression are assigned to cohort C."
89243971|NCT06311175|Active Comparator|Standard Diet Tracking Prescription|This group will be asked to track their diet using a commercial mobile application every day for the 8 week digital weight loss intervention.
89243972|NCT06311175|Experimental|66% Tracking Prescription|This group will be asked to track their diet for 2 weeks, then they will get a 1 week break, track for 2 more weeks and then get a 1 week break, and then track for 2 weeks during the 8 week digital weight loss intervention.
88804753|NCT00005596|Experimental|Arm I|Patients receive IT methotrexate on day 1 followed by methotrexate IV over 20 minutes followed by methotrexate continuously over 23.6 hrs on wks 7, 10, 13, 16,19, and 22. At 42 hrs after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium every 6 hrs for a total of 3 doses. Patients also receive oral mercaptopurine daily beginning on wk 5 and continuing until the completion of consolidation therapy; oral dexamethasone twice daily on days 1-7 of wks 8 and 17; and vincristine sulfate IV on day 1 of wks 8, 9, 17, and 18.
88804754|NCT00005596|Experimental|Arm II|Patients receive methotrexate IV over 4 hours on weeks 7, 10, 13, 16, 19, and 22. At 42 hours after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium as in arm I. Patients also receive mercaptopurine, dexamethasone, vincristine sulfate, and IT methotrexate as in arm I.
88821559|NCT03535727|Experimental|Phase 1, Cohort 2, Dose level 3|"Gemcitabine: 500 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Nab-paclitaxel:80 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle~Capecitabine:500mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle~Cisplatin:20 mg/m^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle~Irinotecan: 20 mg/m^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle"
89243973|NCT06311175|Experimental|50% Tracking Prescription|This group will be asked to track their diet every other week during the 8 week digital weight loss intervention.
89243974|NCT06311123||patients with active ulcerative colitis|patients with active ulcerative colitis starting ozanimod therapy
89243975|NCT06311110||DCD case group|The case group consists of children with developmental coordination disorder.
89243976|NCT06311110||TDC control group|The control group consists of typically developing children, grade and gender matched with the DCD case group.
89243977|NCT06311084|Experimental|Imaginator - Functional Imagery Training|3 weekly face to face sessions of Functional Imagery Training, followed by 5 fortnightly phone support calls, and the Imaginator app
89243978|NCT06311058|Experimental|Protein Supplement Group|Participants in this group will receive 25g of whey protein isolate twice a day for 12 weeks.
89243979|NCT06311058|Experimental|Protein + Amino Acid Supplement Group|"Protein drink - 25g of whey protein isolate~Amino Acid Blend - 7g of protein (4g Leucine, 1g iso leucine, 1g valine, 1g arginine)~Twice a day for 12 weeks"
89243980|NCT06311058|Placebo Comparator|Placebo Group|"• isocaloric-matched (25g) maltodextrin supplement~Twice a day for 12 weeks"
89243981|NCT06311045|Experimental|NAC|Following run-in PAP therapy per standard clinical care for 12 weeks, participants randomized to the NAC arm will also receive the supplement N-acetylcysteine (NAC) for four weeks while remaining on PAP therapy.
89243982|NCT06311045|Experimental|Placebo|Following run-in PAP therapy per standard clinical care for 12 weeks, participants randomized to the placebo arm will also receive placebo for four weeks while remaining on PAP therapy.
89243983|NCT06311032||Vignettes with Risk Stratification Tool|"Physicians will be posed with a series of three clinical case vignettes. Each vignette describes an IPMN of varying severity, and the physician will be asked determine whether they would continue or discontinue clinical surveillance in each case. Participants in this arm will be provided a risk stratification tool (DART-1) when presented with their clinical case vignettes.~The DART-1 is a 5-question tool which calculates the probability (%) of IPMNs without worrisome features or high-risk stigmata at diagnosis."
89243984|NCT06311032||Vignettes without Risk Stratification Tool|Physicians will be posed with a series of three clinical case vignettes. Each vignette describes an IPMN of varying severity, and the physician will be asked determine whether they would continue or discontinue clinical surveillance in each case. Participants in this arm will be not be provided a risk stratification tool when presented with their clinical case vignettes.
89243985|NCT06311019|No Intervention|1 (Standard care)|In this arm the patients continue to measure blood glucose with fingerprick and use standard insulin pens
89243986|NCT06311019|Active Comparator|2 (CGM and connected pen)|In this arm the patients switch from glucose measurement with fingerprick to continuous glucose monitoring and they switch from standard insulin pen for bolusinsulin to connected pen for bolusinsulin
89243987|NCT06311006||Patients|adult patients for whom FMT for CDI is indicated and planned as part of the routine care (definition of CDI and recurrence according to European recommendations 2014 10)
89243988|NCT06311006||Stool donor|
89243989|NCT06310993|Experimental|Intervention|The exercise programme will include one weekly supervised exercise sessions and one weekly unsupervised exercise session. The frequency will be twice weekly, one supervised and one unsupervised session a week for 12 weeks. The exercises will be of moderate intensity aerobic interval exercise (performing at 60% maximum heart rate) combined with 1-3 sets of 6-12 Repetition Maximum (RM) resistance training. The type of exercise will be aerobic interval exercise (cycling) and Resistance training (3 exercises: chest press, biceps, and leg curl) The timing will be 4 x 4-minute cycling at 60%, max HR with 3 minutes active recovery. 3 sets with 2 minutes per set - around 20 minutes resistance training
89243990|NCT06310980|Experimental|smartpen|patients treated by smartpen, glucose sensor and connected by a digital application
89243991|NCT06310967|Other|Cohort A (0.25 g tablets)|"Cohort A will have 10 eligible patients. 8 subjects will receive the active study drug (IG3018) and 2 shall receive placebo in each dose cohort.~Dose shall be at 0.25 g tablets. Single-dose initial treatment phase: D1~D3. Subject will receive a single dose of IG3018 or the placebo on Day 1. The predetermined information shall be collected in the form of blood and urine samples for PK analyses, whilst efficacy and safety assessment data will be collected within 48 hours after the single dose of study drug administration (IG3018 or placebo).~Maintenance treatment on daily basis phase: 4 weeks. Subjects in this maintenance treatment phase shall receive the study drug IG3018 in twice daily dosing for 28 days from Day 4 to Day 31, and will be given IG3018 once on the morning of D32."
89243992|NCT06310967|Other|Cohort B (0.5 g tablets)|"Cohort B will have 10 eligible patients. 8 subjects will receive the active study drug (IG3018) and 2 shall receive placebo in each dose cohort.~Dose shall be at 0.5 g tablets. Single-dose initial treatment phase: D1~D3. Subject will receive a single dose of IG3018 or the placebo on Day 1. The predetermined information shall be collected in the form of blood and urine samples for PK analyses, whilst efficacy and safety assessment data will be collected within 48 hours after the single dose of study drug administration (IG3018 or placebo).~Maintenance treatment on daily basis phase: 4 weeks. Subjects in this maintenance treatment phase shall receive the study drug IG3018 in twice daily dosing for 28 days from Day 4 to Day 31, and will be given IG3018 once on the morning of D32."
89243993|NCT06310967|Other|Cohort C (1.0 g tablets)|"Cohort C will have 10 eligible patients. 8 subjects will receive the active study drug (IG3018) and 2 shall receive placebo in each dose cohort.~Dose shall be at 1.0 g tablets. Single-dose initial treatment phase: D1~D3. Subject will receive a single dose of IG3018 or the placebo on Day 1. The predetermined information shall be collected in the form of blood and urine samples for PK analyses, whilst efficacy and safety assessment data will be collected within 48 hours after the single dose of study drug administration (IG3018 or placebo).~Maintenance treatment on daily basis phase: 4 weeks. Subjects in this maintenance treatment phase shall receive the study drug IG3018 in twice daily dosing for 28 days from Day 4 to Day 31, and will be given IG3018 once on the morning of D32."
89243994|NCT06310967|Other|Cohort D (0.5 g BID IG3018)|5 to 8 hyperuricemia subjects with advanced CKD will be enrolled in Cohort D and will receive 0.5 g IG3018 twice daily (BID) for 4 weeks.
89243995|NCT06310967|Other|Cohort E (1.0 g BID IG3018)|5 to 8 hyperuricemia subjects with advanced CKD will be enrolled in Cohort E and will receive 1.0 g IG3018 twice daily (BID) for 4 weeks.
89243996|NCT06310954|Experimental|Ketogenic Diet plus Conventional Treatment Group|This arm of the trial explores the efficacy of an early initiation of the ketogenic diet in conjunction with conventional antiepileptic drugs (AEDs) for children with refractory epilepsy. The intervention aims to evaluate the impact on seizure frequency, and inflammatory markers, and identify patient characteristics predicting a better response to the ketogenic diet, to improve overall therapeutic response rates in refractory epilepsy.
89243997|NCT06310954|Placebo Comparator|Control Group: Conventional Treatment Group|Participants in this arm will receive a standard diet without any ketogenic restrictions, alongside conventional antiepileptic drugs. This comparator aims to assess the standard care's efficacy against the experimental intervention, focusing on seizure control, inflammatory markers, and identifying patient characteristics associated with treatment responsiveness.
89243998|NCT06310941|Active Comparator|Standard of Care|Standard of care: Systemic antibiotic therapy according to local protocol and at the discretion of the attending intensivist.
89243999|NCT06310941|Experimental|Mechanical insufflation-exsufflation with hypertonic saline/hyaluronic acid comination|Systemic antibiotic therapy choice according to local protocol and at the discretion of the attending intensivist plus Mechanical insufflation-exsufflation (MI-E sessión tid during the first 48 hours, followed by MI-E if secretions are present or suspected; recommended settings +50 cmH2O/-50 cmH2O) with simultaneous nebulization of hypertonic saline (7%) with hyaluronic acid (0.1%).
89244000|NCT06310941|Experimental|Mechanical insufflation-exsufflation|Systemic antibiotic therapy choice according to local protocol and at the discretion of the attending intensivist plus Mechanical insufflation-exsufflation (MI-E sessión tid during the first 48 hours, followed by MI-E if secretions are present or suspected; recommended settings +50 cmH2O/-50 cmH2O)
89244001|NCT06310928|Experimental|Thermal Blanket Intervention Group|After the informed consent form is signed by the patients, general body warming of the patient will be provided with the hot air blowing system after surgery. In the 30th minute of the active heating method, a thermal blanket will be applied to the treated area (extremity) of the patient. The first 24 hours after the application; Pain will be evaluated every hour for the first 8 hours, every 2 hours for the second 8 hours, every 4 hours for the last 8 hours with the VAS Pain Scale and circulation with the Neurovascular Diagnosis Form. Mobilization of the patient for the first time in the 8th hour and for the second time in the 24th hour will be evaluated with the Patient and Observer Mobility Scale. Pain and neurovascular evaluation will be performed every 12 hours on the second postoperative day. Mobility will be assessed for the third time on the second postoperative day.
89244002|NCT06310928|No Intervention|Control Group|After the informed consent form was signed by the patients who agreed to participate in the study before the application and who met the inclusion criteria, respectively;The vital signs of patients admitted to the intensive care unit after surgery will be stabilized.The patient's general warming of the body will be ensured with the hot air blowing system (Forced-air), which is an active heating method.Afterwards, the treated extremity will be wrapped with cotton alban, which is a routine application.Tests will be performed to the participants in the control group at the same time as in the experimental group.
89244003|NCT06310902||Borderline Resectable Pancreatic Cancer|Cancer tissue specimens can be collected postoperatively following neoadjuvant chemotherapy.
89244004|NCT06310902||Resectable Pancreatic Cancer|Cancer tissue specimens can be directly collected postoperatively
89244009|NCT06310863|Experimental|test group|The test device, LASBEAU Strong, was developed for the purpose of temporary improvement of facial nose and lip wrinkles, which is the same indication as the control device, and has a hyaluronic acid structure similar to that of Restylane® Lyft Lidocaine, and was developed using the same crosslinker, 1,4-butanediol diglycidyl ether. The test device, LASBEAU Strong, has a higher content of hyaluronic acid than the control device, Restylane® Lyft Lidocaine, but the clinical efficacy cannot be evaluated as superior because of the high content of hyaluronic acid. This is because, in addition to the content of hyaluronic acid, differences in the manufacturing process can affect the physicochemical properties and decomposition period.
89244010|NCT06310863|Active Comparator|control group|Restylane® Lyft Lidocaine, a previously licensed product with the same ingredients as the test group, was selected as the control group. Restylane® Lyft Lidocaine is a representative filler formulation that has been recognized for the temporary improvement of facial nose and lip wrinkles, and it was selected as a control group because it is similar to the clinical trial medical device in the test group, and the application site and application method are the same. The control device, Restylane® Lyft Lidocaine, is a product imported and sold by Galderma Korea, which is a bacterial fermentation product and is known as non-animal hyaluronic acid. The purpose of use is to temporarily improve the wrinkles of the nose and lips of the face.
89244011|NCT06310850|Placebo Comparator|Group Placebo|intravenous placebo
89244012|NCT06310850|Active Comparator|Group Ketamine|intravenous ketamine 0.15 mg kg-1
89244013|NCT06310837|Experimental|ADA+MMF group|Adalimumab biosimilars with immunosuppressants therapy
88821560|NCT03535727|Experimental|Phase 2 Dose Expansion (Cohort 1, DL5)|"Gemcitabine:500 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Nab-paclitaxel:125 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle~Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle~Cisplatin:20 mg/m^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle~Irinotecan: 20 mg/m^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle"
89244014|NCT06310837|Active Comparator|Corticosteroids+MMF group|Corticosteroids with immunosuppressive therapy；
89244015|NCT06310811|Experimental|Cell injection|
89244016|NCT06310798|Experimental|Inter-professional team test|Dental hygienists, nursing assistants and older adults participating in new model for oral health planning in ordinary home settings.
89244017|NCT06310798|No Intervention|Oral health planning control|Dental hygienists, nursing assistants and older adults participating in oral health planning in ordinary home settings (business as usual).
89244018|NCT06310785|Experimental|Esketamine group|Esketamine group was induced with esketamine 0.5 mg/kg, propofol 2 mg/kg, and rocuronium bromide 0.9 mg/kg. Anesthesia is maintained with propofol 5 mg/kg/h and esketamine 0.5 mg/kg/h.
89244019|NCT06310785|Active Comparator|opioid group|Anesthesia induction in the opioid group Sufentanil 0.5 ug/kg, propofol 2 mg/kg, rocuronium bromide 0.9 mg/kg. Anesthesia is maintained with propofol 5 mg/kg/h and remifentanil 1 ug/kg/h.
89244020|NCT06310772||Children with CAE or Controls|Pediatric Epilepsy Side Effect Questionnaire Continuous Performance Test Children's Sleep Questionnaire Anxiety/Depression Screening Eye tracking during active tasks- saccade/antisaccade task, and passive tasks
89244021|NCT06310746|Experimental|HLX6018|
89244022|NCT06310746|Placebo Comparator|Placebo|
89244023|NCT06310720|Experimental|Written Discharge Education + Video Education|These patients will view a 12-minute educational video on SMM warning signs, in addition to the written discharge instructions provided by nursing staff. At the completion of the video, they will complete a post-video questionnaire to assess their knowledge on the covered topics.
89244024|NCT06310720|No Intervention|Written Discharge Education|They will receive the written discharge instructions provided by nursing staff and complete the post-discharge instruction questionnaire.
89244025|NCT06310707|Experimental|ePatch® Extended Wear Holter (EWH) Arm|Participants will undergo long-term continuous ambulatory ECG recording of 7-day duration
89244026|NCT06310707|No Intervention|Standard of Care|Participants will undergo 24 hours of continuous ECG recording.
89244027|NCT06310694|Experimental|Intervention Group (Elastane circular dressing on sterile transparent dressing)|"A peripheral intravenous catheter was placed by following all the steps applied to the control group. A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter. There is no need to remove additional circular dressings during intravenous therapy.~The peripheral intravenous catheter was monitored for 72 hours with 8-hour observations. Peripheral intravenous catheter was evaluated for infiltration, phlebitis, pain, obstruction, dressing stability, and leakage."
89244028|NCT06310694|No Intervention|Control group (fixation of PIVC with a sterile transparent dressing)|"Peripheral intravenous catheter application was performed by the researcher in accordance with all steps. In the study, only patients who received a 20-gauge peripheral intravenous catheter were followed. The patient's peripheral intravenous catheter was fixed by the researcher with a sterile transparent dressing.~The peripheral intravenous catheter was monitored for 72 hours with 8-hour observations. Peripheral intravenous catheter was evaluated for infiltration, phlebitis, pain, obstruction, dressing stability, and leakage."
89244029|NCT06310681|Experimental|"Encompass group programme"|
89244030|NCT06310668|Experimental|CBT intervention arm|patients with substance use disorder in the inpatient department of the addiction unit in Mansoura University Hospital who will receive group CBT sessions
89244031|NCT06310668|No Intervention|NON-CBT control arm|age and gender-matched patients with substance use disorder in the outpatient clinics of the addiction unit in Mansoura University Hospital who will not receive group CBT sessions
89244032|NCT06310655|Experimental|Proton Stereotactic Body Radiotherapy (SBRT)|All patients will receive standard of care proton SBRT either daily or every other day for a total of 5 fractions. At the time of each treatment, the initial pre-plan will be generated on the patient and assessed for coverage and safety. An adaptive plan based on the patient's anatomy that day will also be generated and then compared to the initial pre-plan. The optimal treatment plan will be chosen and administered to the patient on that day. This process will be repeated for each fraction for every patient.
89244033|NCT06310642|Experimental|Prochlorperazine 10 mg|Subjects received 10 mg Prochlorperazine one time.
89244034|NCT06310642|Placebo Comparator|Placebo|Subjects received Placebo one time.
89244035|NCT06310629|Active Comparator|High Flow Nasal Cannula|High Flow Nasal Cannula
89244036|NCT06310629|Experimental|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"
89244037|NCT06310616|Experimental|Loestrin + VH4524184|Eligible participants entering a run-in period of 21 days (Days -28 through -8) will receive Loestrin (EE and NEA) to stabilize on the combined OCs containing EE and NEA to synchronize the menstrual cycles of multiple participants. Participants completing the run-in period will enter Treatment Period 1 and will be administered Loestrin once daily from Days 1 to 10. On Day 11, participants will enter Treatment Period 2 and will be administered Loestrin + VH4524184 once daily from Days 11 to 20.
89244038|NCT06310603|Experimental|Low-Processed Food Group|
89244039|NCT06310603|No Intervention|Typical Diet Group|
89244040|NCT06310590|Experimental|NRT6003 Injection|"Patients will be administered a single dose of NRT6003 Injection, and then they will be assessed by SPECT-CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.~Nine Patients will be tested for the radioactivity of Yttrium-90 in blood, urine, and feces (if available)."
89244041|NCT06310577|Experimental|Leak free bronchoscope adapter|"As a standard part of procedure, bronchoscopy will be performed using the standard commercial adapter. Following the standard bronchoscope adapter use, leak-free bronchoscope adapter will be tested to compare the amount, and quality of air leaked between thestandard commercial adapter and the leak-free adapter."
89244042|NCT06310564|Experimental|stereotactic ablative radiotherapy (SABR)|SABR to all the active sites of disease (1-3 oligometastases). 3D-CRT, IMRT and VMAT techniques are allowed, but IMRT and VMAT are strongly suggested.
89244043|NCT06310564|No Intervention|no SABR|no SABR
89244044|NCT06310551|Experimental|Formulation A SC Group|Participants receive a Formulation A starting dose of VH4524184 LAI subcutaneously (SC).
89244045|NCT06310551|Experimental|Formulation B SC Group|Participants receive a Formulation B starting dose of VH4524184 LAI subcutaneously.
89244046|NCT06310551|Experimental|Formulation C SC Group|Participants receive a Formulation C starting dose of VH4524184 LAI subcutaneously. This intervention is optional and initiated only if Formulation B is poorly tolerated.
89244047|NCT06310551|Experimental|Formulation A IM Group|Participants receive a Formulation A starting dose of VH4524184 LAI intramuscularly (IM).
89244048|NCT06310551|Experimental|Multiple doses Group|VH4524184 LAI formulations administered SC or IM as single doses that achieve adequate PK exposure targets, may be evaluated for safety and tolerability as multiple doses.
89244049|NCT06310538|Experimental|Kou Sha group|Generally, the Kou Sha therapy group needs to kou sha 2-3 times, and after each kou sha, it is necessary to rest for 1 week or all the shas in the part fade before they can be kou sha again. The duration of treatment is 1 menstrual cycle.
89244050|NCT06310538|Active Comparator|Control group|The control group is treated with conventional Western medicine, and according to the patient's condition, Chinese patent medicine treatment, psychological counseling and lifestyle adjustment are carried out. The duration of treatment is 1 menstrual cycle. Stop all medications during menstruation. During this period, avoid excessive fatigue and mental stimulation, and avoid spicy and irritating foods
89244051|NCT06310512|Experimental|Intervention group|Intervention group patients will undergo structured drug treatment management at their first visit. During on-site follow-up at 1, 3, and 6 months, as well as telephone follow-up at the second week, 2 and 4 months, the patient's condition will be evaluated, corresponding information will be collected, and possible intervention measures will be taken for the patient.
89244052|NCT06310512|No Intervention|Non-Intervention group|For non intervention group patients, pharmacists evaluate the patient's condition and collect corresponding information at the first visit and on-site follow-up at 1, 3, and 6 months, explain the dosage and dosage of drugs to the patient, and remind them of medication contraindications. Necessary intervention measures are taken at the 6th month.
89244053|NCT06310499||Primary fatal drowning|These patients are registered in the Danish Register of Causes of Death, with drowning as an underlying cause of death in the death certificate.
89244054|NCT06310499||Secondary fatal drowning|These patients are registered in the Danish Register of Causes of Death, with drowning as a contributory cause of death or drowning not registered in the death certificate.
89244055|NCT06310486||Fatal drowning|These patients experienced a drowning incident and died within 30 days after the incident because of their submersion injury.
88821561|NCT03515174|Experimental|Interventional Program|Patients will participate in a structured supportive care program.
89244056|NCT06310486||Non-fatal drowning|These patients experienced a drowning incident and survived until 30 days after the incident.
89244057|NCT06310473|Experimental|Cadonilimab Plus Chemotherapy|"Neoadjuvant Immunotherapy and Chemotherapy：Cadonilimab+Oxaliplatin+Capecitabine, every 3 weeks for 3 cycles;~Adjuvant chemotherapy： Oxaliplatin+Capecitabine, every 3 weeks for 3-5 cycles;"
89244058|NCT06310447||Students|Students of the physiotherapy and rehabilitation department in Istanbul constitute the population of the research.
89244059|NCT06310408|Experimental|nasal mask|Give noninvasif respiratory support with interface nasal mask
89244060|NCT06310408|Active Comparator|nasal prong|Give noninvasif respiratory support with interface nasal prong
89244061|NCT06310369|Experimental|RT arm|Radiation therapy will be given covering the whole bladder over 4 weeks. The use of a radiosensitizing agent is mandatory.
89244062|NCT06310317|Experimental|experimental group|15 children belonging to the experimental group will undergo the treatment carries out the procedure by means of stimuli presented with technologies supports
89244063|NCT06310317|Other|control group|15 children belonging to the control group will undergo the treatment by performing the procedure with images printed on laminated A4 sheets.
89244064|NCT06310304|Experimental|Cohort 1: Dose Treatment A|Ruxolitinib IR will be administered at protocol defined dose.
89244065|NCT06310304|Experimental|Cohort 1: Dose Treatment B|Ruxolitinib XR will be administered at protocol defined dose.
89244066|NCT06310304|Experimental|Cohort 2: Dose Treatment A|Ruxolitinib IR will be administered at protocol defined dose.
89244067|NCT06310304|Experimental|Cohort 2: Dose Treatment B|Ruxolitinib XR will be administered at protocol defined dose.
89244068|NCT06310291|Placebo Comparator|Matched Placebo (SAD)|2 placebo comparators; 1 for each part of the study
89244069|NCT06310291|Experimental|VTP-1000 Dose 1 (SAD)|3 dose levels in SAD and MAD parts of trial
89244070|NCT06310291|Experimental|VTP-1000 Dose 2 (SAD)|3 dose levels in SAD and MAD parts of trial
89244071|NCT06310291|Experimental|VTP-1000 Dose 3 (SAD)|3 dose levels in SAD and MAD parts of trial
89244072|NCT06310291|Placebo Comparator|Matched Placebo (MAD)|2 placebo comparators; 1 for each part of the study
89244073|NCT06310291|Experimental|VTP-1000 Dose 1 (MAD)|3 dose levels in SAD and MAD parts of trial
89244074|NCT06310291|Experimental|VTP-1000 Dose 2 (MAD)|3 dose levels in SAD and MAD parts of trial
89244075|NCT06310291|Experimental|VTP-1000 Dose 3 (MAD)|3 dose levels in SAD and MAD parts of trial
89244076|NCT06310278||Normal-hearing|
89244077|NCT06310239||Study subjects|Individuals with a limb amputation who are undergoing an osseointegration surgery
89244078|NCT06310226|Experimental|Responders to spinal cord stimulation|Patients with chronic low back pain, with >50% pain reduction in response to spinal cord stimulation
89244079|NCT06310226|Experimental|Non-responders to spinal cord stimulation|Patients with chronic low back pain, with minimal to no pain reduction in response to spinal cord stimulation
89244080|NCT06310213|Active Comparator|Aim 1 Control|Intervention at single time point not to interfere with standard of care procedures
89244081|NCT06310213|Experimental|Aim 1 Hydrocephalus|Intervention at single time point during standard of care hydrocephalus evaluation (anterior fontanelle assessment and measurement of head circumference), unless further assigned to supplemental arm following standard of care surgical procedure
89244082|NCT06310213|Experimental|Aim 2 Hydrocephalus, Shunt surgery|Intervention pre- and post-operatively
89244083|NCT06310213|Experimental|Aim 3 Hydrocephalus, EVD ICP monitor|Intervention during standard of care monitoring of EVD ICP reading(s)/hydrocephalus evaluation (anterior fontanelle assessment and measurement of head circumference)
89244084|NCT06310213|Experimental|Aim 4 Hydrocephalus, Reservoir surgery|Intervention pre- and post- ventricular reservoir tap(s)
89244085|NCT06310200|Experimental|Intervention Arm|Subjects will receive 1 mL of 4% lidocaine (0.5mL in each nostril) administered by intranasal atomization or 0.9% normal saline administered by intranasal atomization.
89244086|NCT06310200|Placebo Comparator|Placebo Arm|Subjects will receive normal saline placebo mixed with an edible bittering agent added to blind the participant from recognizing the taste of the lidocaine containing solution.
89244087|NCT06310187|Experimental|High Oxidant Unflavored Little Cigar - Group A|
89244088|NCT06310187|Experimental|Low Oxidant Unflavored Little Cigar - Group B|
89244089|NCT06310187|Experimental|High Oxidant Flavored Little Cigar - Group C|
89244090|NCT06310187|Experimental|Low Oxidant Flavored Little Cigar - Group D|
89244091|NCT06310187|Other|Usual Cigarette - Group E|Control Condition - this is the subject's normal cigarette/cigar
89244092|NCT06310187|Sham Comparator|Unlit Little Cigar - Group F|
89244093|NCT06310135|Experimental|Unfiltered Monocular|Unfiltered monocular with the non-dominant eye occluded.
89244094|NCT06310135|Experimental|Filtered Binocular|Filtered binocular with both eyes filtered.
89244095|NCT06310135|Experimental|Filtered Monocular|Filtered monocular with non-dominant eye filtered, the other non-filtered.
89244096|NCT06310135|Experimental|Unfiltered Binocular|Unfiltered binocular - neither eye will be filtered.
89244097|NCT06310135|Placebo Comparator|Dim Light Control|Dim light with no filters.
89244098|NCT06310122|Experimental|Group (A) treatment group|Group (A) will receive extracorporeal shockwave therapy and (Ultrasound, stretching and strengthening exercises)
89244099|NCT06310122|Experimental|Group (B) traditional group|Group (B) will receive (Ultrasound, stretching and strengthening exercises)
89244100|NCT06310109|Experimental|PICU diary|"The PICU diary arm, will receive a PICU diary at the patient bedside."
89244101|NCT06310109|No Intervention|Control arm|The control arm will receive standard care (no PICU diary).
89244102|NCT06310096|Active Comparator|TLF fascial stretching exercise|The study group received a 4-week TLF fascial stretching exercise (10 times per day) in addition to the conventional physiotherapy program, while the control group only received a conventional physiotherapy program
89244103|NCT06310096|Active Comparator|conventional physiotherapy program|The study group received a 4-week TLF fascial stretching exercise (10 times per day) in addition to the conventional physiotherapy program, while the control group only received a conventional physiotherapy program.
89244104|NCT06310083|Active Comparator|Submucosal Rescetion Turbinoplasty|participants in this group were applied for Endoscopic submucosal resection Turbinoplasty
89244105|NCT06310083|Placebo Comparator|Partial Inferior Turbinectomy|participants in this group were applied for Partial Inferior Turbinectomy
89244106|NCT06310018|Experimental|Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis|10 patients with bilateral PE will be treated with ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours) followed by 50 patients (total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system
89244107|NCT06309953|Experimental|Miebo treatment|
89244108|NCT06309563|Active Comparator|Aminoacids|Patients with obesity treated with essential aminoacids (EAA-AC)
89244109|NCT06309563|Placebo Comparator|Control|Patients with obesity treated with placebo
89244110|NCT06309316|Experimental|Person-centred care (PCC)|"Intervention PCC:~In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. The primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.~Usual care:~Patients with GD have regular meetings with the endocrinologist during the treatment with anti-thyroid drugs and leave blod sampels. Many patients are on sick leave in the beginning of treatment. If questions occur between meetings, patients contact a service centre and get feed-back from the nurse or physician on duty at Sahlgrenska University Hospital in Gothenburg."
89244111|NCT06309316|No Intervention|Usual care|"Usual care:~Patients with GD have regular meetings with the endocrinologist during the treatment with anti-thyroid drugs and leave blod sampels. Many patients are on sick leave in the beginning of treatment. If questions occur between meetings, patients contact a service centre and get feed-back from the nurse or physician on duty at Sahlgrenska University Hospital in Gothenburg."
89244112|NCT06309290|Experimental|Prehabilitation intervention program|All volunteers be subjected to 16 - 20 weeks of full body resistance exercise training (2 times per week. However, usual care program.
89244113|NCT06309290|Active Comparator|Usual Care Program|All volunteers be subjected usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).
89244114|NCT06308900|Experimental|Experimental|Physitherapy students
89244115|NCT06308809|Experimental|PNF training group|The experimental group will undergo 60 minutes of PNF training.
89244116|NCT06308809|Other|Control training group|The control group will follow the curriculum standards set by the Sports University.
89244117|NCT06308796|Experimental|CaP + Fluoride|Irradiated head and neck cancer patients receiving topical CaP mousse to be applied at home (once a day for the first 3 months, then once a day for one week per month as maintenance), besides topical fluoride (F) in form of professional varnishes (every 6 months) and home products (once a day oral rinse with F mouthwash; three times a day toothpaste with brushing).
89244118|NCT06308796|No Intervention|Only fluoride|Irradiated head and neck cancer patients receiving only topical fluoride (F) in form of professional varnishes (every 6 months) and home products (once a day oral rinse with F mouthwash; three times a day toothpaste with brushing). Topical fluoride is included in the standard of care, according to national and international guidelines.
89244119|NCT06308757|Experimental|VLCKD arm|"The VLCKD dietary intervention consists of five phases:~Ketogenic Low-Calorie Period (2 months):~Phase 1 (30 days - Visits 1-3): Ketogenic diet with low-fat content, 600 kcal/day.~Phase 2 (15 days - Visit 5): 660 kcal/day.~Phase 3 (15 days - Visit 5): 730 kcal/day~Low-Calorie Period (2 months):~Phase 4 (30 days - Visits 6-7): Hypocaloric diet with the reintroduction of different foods, 1,050 kcal/day.~- Phase 5 (30 days - Visits 7-8): 1,400 kcal/day.~During these phases, the patient will receive nutritional supplementation with vitamins, trace elements, and omega-3 fatty acids. Throughout the very low-calorie ketogenic period, the patient will have three interim dietetic consultations (Visits 2-4) and a medical visit (Visit 5). During the low-calorie period, the patient will receive alternating two dietetic consultations (Visits 6 and 7) and one medical visit every 30 days (Visit 8)."
89244120|NCT06308757|Active Comparator|Control LCD arm|"The control LCD arm consists of a diet with natural low-calorie foods (1200-1500 kcal/day or a reduction of 500-1000 kcal/day compared to baseline) and a low glycemic index based on the Mediterranean Diet model, following the most recent guidelines on MAFLD/NAFLD. Similar to the VLCKD arm, for the entire duration of the dietetic treatment, the patient will alternately receive dietetic consultations and medical visits.~At the end of the dietary intervention, patients from both study arms will continue with a controlled, low glycemic index diet tailored to the patient's basal metabolic rate (BMR) (estimated with bioimpedance assessment) for an additional six months.~Both study arms will follow a physical activity schedule and will have psychological-motivational support."
89244121|NCT06308744|Experimental|Mindfulness conditions|Participants will engage in a 15-minute mindfulness meditation session. Within this framework, four distinct experimental conditions will be introduced, each showcasing a unique mindfulness exercise: Body Scan, Mindful Breathing, Mindful Walking, and Loving-Kindness Meditation. The audio tracks of the mindfulness experimental conditions is embedded in the Qualtrics survey.
89244122|NCT06308744|Active Comparator|Listening of a story|Participants in the active control condition listened to a 15-minute story. The audio track of the control condition is embedded in the Qualtrics survey.
89244123|NCT06308718||Patients enrolled in the FBX-101-LTFU study|The participants will be followed for 36 months after they have concluded their participation in the interventional trial. They will complete 5 scheduled visits with assessments as specified in the schedule of assessments, to collect data for safety and additional signs of efficacy for FBX-101. Those patients enrolled from any other early terminated trial, will first complete pending evaluations from that trial.
89244124|NCT06308419|Experimental|Gemcitabine + Nab-sirolimus|Participants found to be eligible to take part in this study, participants will be assigned to a dose level of gemcitabine and nab-sirolimus based on when participants join this study.
89244125|NCT06308146|Experimental|Probiotic, Bacillus subtilis|Bacillus subtilis ATCC 122264; One capsule per day with a larger meal; providing 5 billion CFU for 8 weeks.
89244126|NCT06308146|Placebo Comparator|Placebo|Placebo; matched the test product in colour, size, smell and texture and contained only the excipients (maltodextrin and hydroxypropylmethylcellulose); one capsule per day with a larger meal, for 8 weeks.
89244127|NCT06307860||P group|Perform pulsed field ablation surgery after meeting the inclusion criteria
89244128|NCT06307860||R group|Perform radiofrequency ablation surgery after meeting the inclusion criteria
89244129|NCT06307704|Experimental|US - PEEP group|Lung Ultrasound - guided Positive End Expiratory Pressure group
89244130|NCT06307704|Active Comparator|Standard group|Standard Ventilation group
89244131|NCT06307002|No Intervention|Control Arm|The control group will receive SOC counseling, defined as the current practice at our partner institutions. Patients presenting for contraceptive counseling are given informational pamphlets and have the option to review additional materials posted on the clinic walls and on a rotating slide deck on a digital screen. During their counseling session with a provider, they review eligible methods and can make a decision about whether or not to adopt a method, and to select and initiate the contraception of their choice.
89244132|NCT06307002|Experimental|WMM Arm|The intervention group will be provided with a tablet loaded with the WMM game which will be played in the waiting room prior to their visit. They will then receive SOC counseling, defined as the current practice at our partner institutions. Patients presenting for contraceptive counseling are given informational pamphlets and have the option to review additional materials posted on the clinic walls and on a rotating slide deck on a digital screen. During their counseling session with a provider, they review eligible methods and can make a decision about whether or not to adopt a method, and to select and initiate the contraception of their choice.
89244133|NCT06306950|Experimental|Near infrared spectroscopy neuromonitor|Patients were assigned into active treatment (intervention) with cerebral oximetry monitoring using Near infrared spectroscopy monitoring (NIRS) bilaterally (Root; Prime Medical Corporation, MASIMO, USA). After cleansing the adjacent skin area with alcohol, an adhesive optode pad was placed over each frontal to temporal area. Resting baseline rSO2 values were obtained after waiting at least 1 minute after the placement of the sensors. Once values had stabilized, the screen was electronically blinded, and the time monitoring and baseline parameters were recorded by taking the data frequency of 1 minute, 3 minutes after the start recording. For the intervention group, an alarm threshold at 55% of the resting baseline rSO2 value was established. Continuous rSO2 values were stored on a floppy disk with a 15-second update for the duration of the perioperative period.
89244134|NCT06306950|No Intervention|No neuromonitor|For usual care patients, the best clinical practices aim at maintaining hemoglobin (Hb) levels greater than 7 g/dl, blood glucose within the institutional normal range of 80-180 mg/dl, and mean arterial pressure (MAP) of 65 mmHg in the ICU and were monitored for invasive arterial blood pressure, peripheral O2 saturation (SpO2), and electrocardiograms. Sedative and paralysis agents were given; keep the Richmond Agitation Sedation Scale (RASS) less than -3 and the Bispectral Index (BIS) 40-60 monitoring based on bedside intensivist judgment, including fentanyl, propofol, midazolam, and cisatracurium. Patients were mechanically ventilated using a volume-control ventilation mode with a tidal volume of 8 ml/kg, a respiratory rate adjusted to maintain normocapnia, an inspired oxygen fraction adjusted to maintain SpO2 above 95%, and an inspiratory/expiratory ratio of 1:2.
89244135|NCT06306924||Palliative radiation therapy|Subjects who are with metastatic cancer receive palliative radiation therapy.
89244136|NCT06306807|Experimental|Experimental Group|Participants in the experimental group underwent the exercise program including active cervical range of motion, strengthening, and posture correction exercises for 6 weeks, 3 days a week, once a day for 10 repetitions. Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Strengthening exercises were planned for weak, lengthened, inhibited muscles. Ergonomic modifications while using a smartphone were taught. Additionally, participants in the experimental group were included in a PNF exercise program to be applied by a physiotherapist 3 days a week for 6 weeks. The contract-relax technique for the neck extension pattern and the replication technique for the scapular posterior elevation pattern were used.
89244137|NCT06306807|Active Comparator|Control Group|Participants in the experimental group underwent the exercise program including active cervical range of motion, strengthening, and posture correction exercises for 6 weeks, 3 days a week, once a day for 10 repetitions. Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Strengthening exercises were planned for weak, lengthened, inhibited muscles. Ergonomic modifications while using a smartphone were taught.
89244138|NCT06306391|Experimental|Intravenous naloxone|
89244139|NCT06306391|Experimental|Intranasal naloxone|
89244140|NCT06306326|Experimental|3D Facial Scanning for Evaluating Autologous Fat Grafting in Craniofacial Deformities|By performing autologous fat grafting surgery on 100 patients with craniofacial deformities that meet the research criteria, 3dMD technology will be used for facial three-dimensional scanning preoperatively, immediately postoperatively, and at six months postoperatively to obtain facial volume data. Then, through precise data analysis, we will calculate the fat absorption rate and study the effects of individual factors on treatment outcomes through correlation regression analysis.
89244141|NCT06305988|Experimental|intervention group（Transcranial direct current stimulation）|tDCS group participants will receive tDCS intervention stimulation for 1 week (1.5mA, 20min/ time, twice a day)
89244142|NCT06305988|Placebo Comparator|control group（Sham Transcranial direct current stimulation）|Placebo comparator group subjects will receive similar sites and the same frequency of spurials (0mA, 20min/ time, twice daily) for 1 week
89244143|NCT06305936|Experimental|Intervention group|As part of the 4-week intervention in the feasibility study, the intervention group will receive 1) Educational materials (videos) 2) Participation in a cooking workshop with introduction to PBD meals, including recipes, and 3) Daily delivered PBD dinner meal during the four weeks.
89244144|NCT06305936|No Intervention|Control group|The control group will be asked to maintain habitual diet and lifestyle. In addition, they will follow the same outcome assessments as the intervention group.
89244145|NCT06305624|Experimental|Connections App|The Connections app is based on principles of effective care for substance use disorders, such as sustained duration, peer support, improving coping skills in high-risk situations, assertive outreach, self- monitoring, prompts, and action planning. The theoretical foundation of CHESS Health is self-determination theory, which holds that an individual's adaptive functioning can be improved if the patient feels (1) competent, (2) related to others, and (3) internally motivated rather than coerced in one's actions.
89244146|NCT06305624|No Intervention|Treatment as Usual|
89244147|NCT06305520|Experimental|Investigational Medical Device|Application of the investigational medical device (SkinPlus-HYAL Implant Lidocaine)
89244148|NCT06305520|Active Comparator|Active Comparator Medical Device|Application of the control device (RESTYLANE Lidocaine)
89244149|NCT06305403||1|Patients with sepsis who develop AKI
89244150|NCT06305403||2|Patients with sepsis who not develop AKI
89244151|NCT06305208||Primary bariatric endoscopic procedures|
89244152|NCT06305208||Revisional bariatric endoscopic procedures|
89244153|NCT06305208||Primary metabolic endoscopic procedures|
89244154|NCT06305182|Experimental|Metreleptin|"25 patients will receive a daily subcutaneous injection of metreleptin for 14 days.~The dose starts with 0.4 ml daily, and gradually increases until 1.8 ml; until 1.2 ml in male patients daily."
89244155|NCT06305182|Placebo Comparator|Placebo|25 patients will receive a daily subcutaneous injection of inactive substance (placebo) for 14 days. To ensure blinding, the dosing scheme of placebo will have the identical volume to the dosing scheme of metreleptin (verum).
89244156|NCT06304909|Experimental|Dexmedetomidine group will receive 0.5 mcg/kg|
89244157|NCT06304909|Experimental|Dexamethasone group will receive 8mg/kg|
89244158|NCT06304909|Experimental|Control group will receive equivalent volume of saline 0.9%.|
89244159|NCT06304870|Placebo Comparator|Rehabilitation therapy+Placebo Glossopharyngeal Nerve Block|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy and placebo nerve block.
89244160|NCT06304870|Experimental|Rehabilitation therapy+Glossopharyngeal Nerve Block|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
89244161|NCT06304831|Experimental|Intervention|The intervention group will receive biweekly updates about quality ratings of recently visited health care providers for children by everyone enrolled in the study.
89244162|NCT06304831|No Intervention|Control|The control group will not receive any information about health care providers for children.
89244163|NCT06304818|Experimental|SCTB14|SCTB14 of different doses,IV,every 3 weeks
89244164|NCT06304142|Experimental|Rehabilitation therapy+Stellate ganglion block|The study lasts 10 days for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.
89244165|NCT06304142|Placebo Comparator|Rehabilitation therapy+placebo block|The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. This group will be additionally provided with placebo block without any drugs.
89244166|NCT06304116|Experimental|Rehabilitation therapy+Stellate ganglion block|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Based on the invention above, the patients in the observation group were provided with stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)"
89244167|NCT06304116|Placebo Comparator|Rehabilitation therapy+Placebo|The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
89244168|NCT06304103|Experimental|AND017 capsules 4 mg|
89244169|NCT06304103|Experimental|AND017 capsules 12 mg|
89244170|NCT06304103|Experimental|AND017 capsules 30 mg|
89244171|NCT06304090|Experimental|routine rehabilitation treatment+Stellate ganglion block|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The experimental group was given Stellate Ganglion Block.
89244172|NCT06304090|Placebo Comparator|routine rehabilitation treatment+Placebo|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
89244173|NCT06303947|Experimental|Intermittent Oro-esophageal Tube+comprehensive rehabilitation therapy|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding"
89244174|NCT06303947|Active Comparator|Nasogastric Tube+comprehensive rehabilitation therapy|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines."
89244175|NCT06303908|Experimental|The Simple Gymnastics Training group|The observation group is the only group.The elderly individuals will be arranged to undergo a continuous three-week (21 days) duration of Simple Gymnastics Training, with weekends off and training conducted only on weekdays, two sessions per day, each lasting 30 minutes. Each training session will be conducted approximately at 9.00 a.m. Apart from this,we require participants to only engage in daily activities and avoid strenuous and dangerous behaviors
89244176|NCT06303882|Experimental|Computer-assisted Cognitive Function Training+routine rehabilitation treatment|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment. The experimental group additionally underwent computer-assisted cognitive training, which generated training content of corresponding difficulty based on the patient's cognitive impairment assessment results. The training was conducted seven days a week, once a day, for a duration of 30-45 minutes per session.
89244177|NCT06303882|Active Comparator|routine rehabilitation treatment+conventional cognitive training|In this study, each patient received a continuous 15-day treatment. During the treatment, both groups of patients received routine rehabilitation treatment.The control group was given conventional cognitive training.
89244178|NCT06303128|Experimental|One-dose group|Patients assigned to this group will receive a liquid placebo followed by full-dose liquid amoxicillin 250mg PO thirty minutes later.
89244179|NCT06303128|Active Comparator|Graded, two-dose group|Patients assigned to this group will receive liquid amoxicillin (25% of 250mg dose), followed by liquid amoxicillin 187.5mg PO (75% of 250mg dose) thirty minutes later.
89244180|NCT06303115|Active Comparator|Nicotine Pouch P1312914, 4 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
88821562|NCT03515174|Active Comparator|Control Group|Patients in the control group will receive usual care.
89244181|NCT06303115|Active Comparator|Nicotine Pouch P1312915, 8 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
89244182|NCT06303115|Active Comparator|Nicotine Pouch P1013215, 8 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
89244183|NCT06303115|Active Comparator|Nicotine Pouch P1013218, 10 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
89244184|NCT06303115|Active Comparator|Nicotine Pouch P1012919, 12 mg nicotine|Subjects will be switched to exclusive use of their assigned pouch flavor and strength.
89244185|NCT06303115|Other|Smoking Abstinence|Subjects will not use any tobacco or nicotine containing products.
89244186|NCT06303115|Other|Continued UB cigarette smoking|Subjects will continue use of their Usual Brand Cigarettes.
89244187|NCT06302751|Experimental|Care 4 Today ® (Johnson and Johnson) mobile app|Patients will undergo standard perioperative management. Additionally, patients will use the Care 4 Today ® (Johnson and Johnson) mobile app for remote monitoring from the preoperative assessment day to 30 days after surgery. The Care 4 Today Care ® (Johnson and Johnson) mobile app will include daily reminds for preoperative recommendations adherence (water intake, medications adherence, mobilization, smoking quit...) and postoperative monitoring of symptoms (fever, pain, and mood deflections).
88804755|NCT00005596|Experimental|Arm III|Patients receive methotrexate IV as in arm I on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; pegaspargase IM on day 2, 3, OR 4 of wk 16; oral mercaptopurine daily on wks 5-13, and from wk 24 until the completion of consolidation therapy. Patients also receive IT methotrexate as in arm I on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone 2x daily on weeks 8, 16-18, and 28 for a total of 35 days; vincristine sulfate IV on day 1 of wks 8, 9, 16, 17, 18, 28, and 29; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV over 30 minutes on day 1 of week 20; cytarabine IV or subcutaneously daily on days 2-5 of wks 20 and 21; and oral thioguanine daily on wks 20-21.
88821563|NCT03514368|Other|Patients treated with immune checkpoint blockade|
88821564|NCT03507855|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
89244188|NCT06302751|No Intervention|Standard perioperative management|The historic cohort include patients who underwent standard perioperative management from March 2020 to April 2023.
89244189|NCT06302647||Questionnaire for subjects|Questionnaire will be provided to general subjects anonymously to gain knowledge on their willigness to use a platform to look for early phase clinical trials.
89244190|NCT06302647||Questionnaire for pharma/biotech industry|Questionnaire will be provided to Pharma/biotech industry anonymously to gain knowledge on their willigness to use a platform to promote the recruitment in early phase clinical trials.
89244191|NCT06302647||Questionnaire for doctors|Questionnaire will be provided to Pharma/biotech industry anonymously to gain knowledge on their willigness to use a platform to have information and promote the recruitment in early phase clinical trials.
89244192|NCT06302634||Center-Based Cardio-Oncology Rehabilitation (CBCORe)|Therapeutic exercise program supervised by a physiotherapist. 2 days/week, duration 1h, in the Cardiac Rehabilitation ward.
89244193|NCT06302634||Home-Based Cardio-Oncology Rehabilitation (HBCORe)|Recommendation of physical exercise and motivational interview through telephone follow-up every 2 weeks by the physiotherapist.
89244194|NCT06301087||users|users of the web-application
89244195|NCT06300125||Cryoablation|Percutaneous Cryoablation of Breast Cancer
89244196|NCT06299579|Experimental|GD-11 for injection test group|"GD-11 for injection, freeze-dried powder, 80mg, 160mg/dose Before the test drug is used, from the specification of 100 ml saline infusion bag, use a sterile syringe to extract about 15 ml saline into the test drug, by the oscillator or artificial vibration for about 5min, completely dissolved and then injected back to the administration of the infusion bag with a sterile syringe, gently shaking and mixing, and then intravenously titrated for 30min ± 10min.~The first dose should be completed as soon as possible after randomization; the second dose should not be less than 6 hours from the start of the first dose, but not more than 12 + 1h; each subsequent dose interval of 12 ± 1h (calculated using the fixed time of administration as the baseline point and each dose should not be less than 6 hours from the start of the last dose); 10 consecutive days of treatment, a total of 20 times."
89244197|NCT06299579|Placebo Comparator|Placebo control group|"Placebo, freeze-dried powder, 80mg, 160mg/dose Before the test drug is used, from the specification of 100 ml saline infusion bag, use a sterile syringe to extract about 15 ml saline into the test drug, by the oscillator or artificial vibration for about 5min, completely dissolved and then injected back to the administration of the infusion bag with a sterile syringe, gently shaking and mixing, and then intravenously titrated for 30min ± 10min.~The first dose should be completed as soon as possible after randomization; the second dose should not be less than 6 hours from the start of the first dose, but not more than 12 + 1h; each subsequent dose interval of 12 ± 1h (calculated using the fixed time of administration as the baseline point and each dose should not be less than 6 hours from the start of the last dose); 10 consecutive days of treatment, a total of 20 times."
89244198|NCT06299280|Experimental|dual-task group|Cognitive tasks will be given simultaneously while students exercise in physical education class.
89244199|NCT06299280|Experimental|single-task group|Students exercise in physical education class.
89244200|NCT06298747||Selective cervical nerve root pulsed radiofrequency|A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root with a current of 1.0-1.2 V at a frequency of 2 Hz for 4 minutes at 42 °C.
89244201|NCT06298487|Other|PTE group|Group composed of patients who have already taken part in at least 3 Patient Therapeutic Education (PTE) workshops at the Maison de Prévention de la Santé et d'Accompagnement Therapeutique (MPSAT)
89244202|NCT06298487|Other|Control group|Group made up of patients on the waiting list for Patient Therapeutic Education (PTE) workshops at the Maison de Prévention de la Santé et d'Accompagnement Thérapeutique (MPSAT)
89244203|NCT06298227|Active Comparator|Group ESPB = Erector spinae plane block group|ESPB will be performed
89244204|NCT06298227|Active Comparator|Group QLB = Quadratus lumborum block group|QLB will be performed
89244205|NCT06297798|Experimental|Telerehabilitation Group|"In the telerehabilitation group, posture and stabilization exercises will be performed using Whatsapp and Zoom applications for 40 minutes, 5 days a week. Exercises will be applied for 10 weeks.~Posture and Stabilization Exercise Program:~Stretching of neck flexor, extensor, and lateral flexor muscles (30 seconds each)~Pectoral muscle stretching (30 seconds, 3 repetitions)~Isometric neck exercises (10 seconds, 10 repetitions)~Rhomboid strengthening exercise (bringing shoulder blades closer together against resistance using a TheraBand) (10 seconds, 10 repetitions)~Stretching of hamstring, lumbar lordosis and gastrocnemius muscles (sitting and standing) (30 seconds, 3 repetitions)~Pelvic posterior tilt exercise (10 seconds, 10 repetitions)~Bridge exercise (20 seconds, 10 repetitions)~Single-leg bridge exercise (Right-Left) (10 seconds, 10 repetitions)~Plank (starting with 60 seconds, increasing by 10 seconds each week)"
89244206|NCT06297798|No Intervention|Control Group|The control group will not be given any exercise program; instead, general posture recommendations will be given.
89244207|NCT06297590|Experimental|LY3954068 (Part A)|Single ascending dose of LY3954068 administered intrathecally (IT)
89244208|NCT06297590|Placebo Comparator|Placebo (Part A)|Single ascending dose of placebo administered IT
89244209|NCT06297590|Experimental|LY3954068 (Optional Part B)|Multiple ascending dose of LY3954068 administered IT
89244210|NCT06297590|Placebo Comparator|Placebo (Optional Part B)|Multiple ascending dose of placebo administered IT
89244211|NCT06296381||Patients in the ICU|The ICU sample will comprised patients of both sexes, aged between 18 and 90 years old, able to do volitional tests and without barriers to the assessment of peripheral muscle strength.
89244212|NCT06296381||Healthy Participants|The healthy sample will comprised volunteers of both sexes, aged between 18 and 90 years old, able to do volitional tests and without barriers to the assessment of peripheral muscle strength.
89244217|NCT06295367|Active Comparator|ARM A (Enhanced usual care)|Patients receive PAF brochure describing financial navigation services.
89244218|NCT06295367|Experimental|ARM B (CostCOM)|Patients receive usual financial care per practice standard of care and CostCOM financial counseling sessions over 1 hour within 30 days after enrollment and at 3, 6 and 12 months.
89244219|NCT06295367|Experimental|Non-patient participants: (interview)|Non-patient participants complete surveys and participant in 1 on 1 in depth semi-structured interview over 20-30 minutes at 15-39 months after first patient enrollment.
89244220|NCT06295263||Parkinson Disease group|100 patients with primary Parkinson's disease were included, mainly from outpatient clinics and wards of the Parkinson's Disease and Movement Disorders Center. Inclusion criteria: patients with primary Parkinson's disease, based on the 2015 MDS Parkinson's disease diagnostic criteria. Exclusion criteria: ① patients suffering from other central nervous system diseases, such as cerebrovascular disease, traumatic brain injury, central system inflammatory diseases, intracranial tumors and postoperative neurosurgery; ② patients with various types of cognitive disorders (MMSE score <24); ③ severe psychiatric disorders that are difficult to cooperate.
89244221|NCT06295263||Alzheimer Disease group|One hundred patients with Alzheimer's disease were included, mainly from geriatric neurology outpatient clinics and wards (F5A & F6A). Inclusion criteria: patients with Alzheimer's disease, meeting the IWG-2 clinical diagnostic criteria as the basis. Exclusion criteria: ① patients suffering from other central nervous system diseases, such as cerebrovascular disease, traumatic brain injury, central system inflammatory diseases, intracranial tumors and postoperative neurosurgery; ② severe psychiatric illnesses that are difficult to cooperate with.
89244222|NCT06295263||Nervous System Diseases group|Neurodegenerative diseases (non-PD non-AD) group 100: source neurology outpatient clinic visits, exclusion criteria: ① patients suffering from other central nervous system diseases, such as cerebrovascular disease, traumatic brain injury, central system inflammatory diseases, intracranial tumors and neurosurgery postoperative; ② severe psychiatric diseases difficult to cooperate with the person.
89244223|NCT06295263||Healthy geriatric group|Healthy elderly control 80 people, from peer attendees and health checkup centers. Inclusion criteria: ① Voluntary participation in this study and signing of informed consent; ② Age and gender matched with the patients in the case group; Exclusion criteria: ① Previous history of chronic diseases related to the study subjects, such as cerebrovascular disease, traumatic brain injury, inflammatory diseases of the central system, intracranial tumors and neurosurgery, etc.; ② Patients with various types of cognitive disorders (MMSE scores <24); ③ Those with poor adherence.
89244224|NCT06295263||Healthy Adults Group|Young healthy controls 80 people, from peer attendees and health screening centers. Inclusion criteria: ① Voluntary participation in the study and signing of informed consent; ② Gender matched with the patients in the case group, age <60 years; Exclusion criteria: ① History of chronic diseases related to the study subjects, such as cerebrovascular disease, traumatic brain injury, inflammatory diseases of the central system, intracranial tumors and neurosurgery, etc.; ② With various types of cognitive disorders (MMSE scores <24); ③ Poor adherence to the study. Poor adherence.
89244225|NCT06294795|Experimental|Toric|A folding hydrophobic acrylic IOLs AcrySof IQ SN60WF and Clareon SY60WF
89244226|NCT06294795|Active Comparator|Non-toric|A folding hydrophobic acrylic IOLs AcrySof IQ Toric SN6ATx and Clareon Toric CNW0Tx
89244227|NCT06294548|Experimental|Phase 1b: Valemetostat + Atezolizumab 1200 mg + Bevacizumab 15 mg/kg|"In Phase 1b patients will receive valemetostat (DS-3201) orally daily at their assigned dose level, plus atezolizumab 1200 mg intravenously (IV) on day 1, and bevacizumab 15 mg/kg IV on day 1 of each cycle.~During Phase 1b, a 3+3 dose escalation design will be utilized to define the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) with starting dose of valemetostat 150mg by mouth daily."
89244228|NCT06294548|Experimental|Phase II: Valemetostat + Atezolizumab 1200 mg + Bevacizumab 15 mg/kg|During Phase II, study participants will receive valemetostat (DS-3201) orally daily at MTD/RP2D, plus atezolizumab 1200 mg intravenously (IV) on day 1, and bevacizumab 15 mg/kg IV on day 1 of each cycle.
89244229|NCT06292390|Experimental|Intervention Group|Pet therapy was applied to the individuals in the intervention group for 6 weeks in addition to their normal routine lives. This therapy was applied every 20 minutes, 2 days a week. Repeated measurements were made before therapy, at the end of therapy and 4 weeks after the end of therapy. The scales were collected by the questionnaire by face-to-face interview method.
89244230|NCT06292390|No Intervention|Control Group|The elderly in this group have not been given any treatment, they have received routine nursing home care and necessary treatments if any. The first evaluation of the elderly in the control group, 6.week and 10.the necessary measurements were made with the scales three times a week in total. The scales were collected by the questionnaire by face-to-face interview method.
89244231|NCT06291714|Active Comparator|Interventional group|GDT-therapy guided hemodynamic management based on Clearsight system
89244232|NCT06291714|No Intervention|Control group|Clearsight-monitor is blinded but records standard hemodynamic care
89244233|NCT06291350||MMPg and periodontitis|15 adult patients with MMPg and periodontitis
89244234|NCT06291350||no MMPg and periodontitis|15 adult patients not suffering from MMPg with periodontitis
89244235|NCT06291350||no MMPg with healthy periodontal conditions|15 adult patients not suffering from MMPg with healthy periodontal conditions
89244236|NCT06290934|Experimental|Part 1A, Part 1B: GS-1427 Dose A|Participants will receive GS-1427 Dose A Day 1 through Week 12 (Part 1A). Participants will be eligible to continue and remain on the same dose of GS-1427 through Week 52 (Part 1B).
89244237|NCT06290934|Experimental|Part 1A, Part 1B: GS-1427 Dose B|Participants will receive GS-1427 Dose B Day 1 through Week 12 (Part 1A). Participants will be eligible to continue and remain on the same dose of GS-1427 through Week 52 (Part 1B).
89244238|NCT06290934|Experimental|Part 1A, Part 1B: GS-1427 Dose C|Participants will receive GS-1427 Dose C Day 1 through Week 12 (Part 1A). Participants will be eligible to continue and remain on the same dose of GS-1427 through Week 52 (Part 1B).
89244239|NCT06290934|Experimental|Part 1A, Placebo; Part 1B, GS-1427|Participants will receive Placebo to match GS-1427 Day 1 through Week 12 (Part 1A). Participants will be eligible to be re-randomized to receive one of the GS-1427 dose A, B, or C treatment after Week 12 through Week 52 (Part 1B).
89244240|NCT06290934|Experimental|Part 2: GS-1427 Monotherapy|Participants will receive GS-1427 (at a dose determined based in Part 1A) Day 1 through Week 12. Participants will be eligible to continue and remain on the same dose of GS-1427 through Week 24.
89244241|NCT06290934|Experimental|Part 2: Ustekinumab Monotherapy|Participants will receive ustekinumab, initial dose determined by body weight: 260 to 520 mg intravenous (IV), then subsequent dose: 90 mg subcutaneous (SC) 8 weeks after the initial IV dose, and every 8 weeks up to week 16 ( total of 2 subcutaneous injections after initial IV ustekinumab). Participants will be eligible to continue and remain on the ustekinumab through Week 24.
89244242|NCT06290934|Experimental|Part 2: GS-1427 + Ustekinumab Combination Therapy|Participants will receive GS-1427 (dose determined based on Part 1A) and ustekinumab, initial dose determined by body weight: 260 to 520 mg IV, then subsequent dose: 90 mg SC 8 weeks after the initial IV dose, and every 8 weeks up to week 16 ( total of 2 subcutaneous injections after initial IV ustekinumab). Participants will be eligible to continue and remain on the same dose of GS-1427 and ustekinumab combination therapy through Week 24.
89244243|NCT06290934|Experimental|Part 2: Open-label GS-1427|Participants who complete Part 2 Week 24, will be eligible to continue and and receive open-label GS-1427 through Week 52 at a dose to be determined in Part 1A.
89244244|NCT06289673|Experimental|Newly diagnosed ALL, LLy, and MPAL patients|"All eligible patients receive the following intervention:~Dexamethasone, Vincristine, Daunorubicin, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)"
89244245|NCT06289621|Experimental|Anxiety Disorders and Post-traumatic Stress Disorder (PTSD) Transdiagnostic Treatment ( FSET)|The anxiety disorders and post-traumatic stress disorder (PTSD) transdiagnostic treatment (FSET) is brief, 5-session, cognitive-behavioral intervention designed to treat symptoms associated with anxiety disorders and PTSD. The treatment is administered by lay providers (e.g., nurses) in primary care clinics in South Africa.
89244246|NCT06289621|Other|Enhanced Standard Care Group|The enhanced standard care group is the condition. Those in the enhanced standard care control group will receive standard care plus referrals. Upon completion of the study, they will be offered the anxiety disorder and post-traumatic stress disorder treatment (FSET).
89244247|NCT06289192|Experimental|Smoking Cessation Intervention|Participants will receive a virtual counselor intervention for smoking cessation, be offered the opportunity to utilize nicotine replacement therapies, participate in shared decision-making around lung cancer screening, and be supported by a community health worker. Participants will be followed for a total of 3 months. Assessments will be conducted at baseline, 1 month, and 3 months.
89244248|NCT06288386|Experimental|Higher filler content composite|Attachments will be performed with a higher filler content flowable composite resin.
89244249|NCT06288386|Active Comparator|Lower filler content composite|Attachments will be performed with a lower filler content flowable composite resin.
89244250|NCT06288347|Experimental|Experimental group|The experimental group used the GGON module for 15 days after the first assessment.
89244251|NCT06288347|Active Comparator|Control group|The control group used the GGON module for 15 days after the second assessment.
89244252|NCT06287762||Centralized|Visits are conducted at the NIH clinical center. All participants are ambulatory.
89244253|NCT06287762||Decentralized|Visits are conducted via telehealth.
89244254|NCT06286540|Experimental|Lymphoblock|Patients from this group received Lymphoblock.
89244255|NCT06286540|Placebo Comparator|Placebo|Patients from this group received placebo.
89244256|NCT06286241||HEPA-filtered room|multiple myeloma patients who received autologous stem cell transplantation were admitted in HEPA-filtered room
89244257|NCT06286241||non-HEPA-filtered room|multiple myeloma patients who received autologous stem cell transplantation were admitted in non-HEPA-filtered room
89244258|NCT06285695|Experimental|Clareon Toric IOL|Clareon Toric IOL implanted in one or both eyes during cataract surgery
89244259|NCT06284954|Experimental|Dose regimen 1|Patients receiving Empasiprubart IV
89244260|NCT06284954|Experimental|Dose regimen 2|Patients receiving Empasiprubart IV
89244261|NCT06284954|Experimental|Dose regimen 3|Patients receiving Empasiprubart IV
89244262|NCT06284954|Placebo Comparator|Dose regimen 4|Patients receiving Placebo IV
89244263|NCT06284473|Experimental|Intranasal Ketamine|Participants assigned to this arm will receive intranasal ketamine administered at 0.7mg/kg along with normal lidocaine local sedation
89244264|NCT06284473|Placebo Comparator|Placebo|Participants assigned to this arm will receive volume-based dose of intranasal saline administered along with normal lidocaine local sedation
89244265|NCT06284122|Experimental|Mosun-Len|Mosunetuzumab + lenalidomide
89244266|NCT06284122|Active Comparator|R-CHOP|Rituximab-CHOP
89244267|NCT06284122|Active Comparator|G-CHOP|Obinutuzumab-CHOP
89244268|NCT06284122|Active Comparator|R-Benda|Rituximab-Bendamustin
89244269|NCT06284122|Active Comparator|G-Benda|Obinutuzumab-Bendamustin
89244270|NCT06281249|Experimental|Intrathecal neuraxial procedure|Participants undergoing surgery, receiving neuraxial intrathecal anesthesia with block placement in part by the investigational device.
89244271|NCT06280859|Experimental|Intervention|Participants in the intervention arm will receive the Hoosier Sport intervention 2-3 times a week (twice in PE class, and once in home room). This will involve learning new sport, exercise, and nutrition knowledge, as well as developing leadership skills.
89244272|NCT06280859|No Intervention|Control|Participants in the control arm will not receive the Hoosier Sport intervention.
89244273|NCT06279312|Placebo Comparator|Placebo drink|consume 1 drink per day for 4 weeks
89244274|NCT06279312|Experimental|Adaptogen Elixir drink|consume 1 drink per day for 4 weeks
89244275|NCT06279247||narcolepsy group|
89244276|NCT06279247||health control group|
89244277|NCT06276452|Experimental|Supporting resilience psychoeducational group|This group-based psychoeducational intervention will take place once weekly for eight weeks and will be centered upon building older adults' knowledge, skills, and motivation to manage chronic disease.
89244278|NCT06275919|Experimental|Arm A (interventional arm)|REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
89244279|NCT06275919|Active Comparator|Arm B (control arm)|Local Standard of Care until disease progression or unacceptable toxicity
89244280|NCT06275724||inclisiran|Patients prescribed with inclisiran
89244281|NCT06274333|Active Comparator|DP group|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg
89244282|NCT06274333|Active Comparator|TP group|Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
89244283|NCT06273891|Active Comparator|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days
89244284|NCT06273891|Active Comparator|Azithromycin|Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days
89244285|NCT06273072|Active Comparator|Metformin hydrochloride extended-release tablets|Metformin hydrochloride extended-release tablets 2000 mg once daily
89244286|NCT06273072|Placebo Comparator|Visually identical placebo tablets|Placebo tablet once daily
89244287|NCT06270810|Experimental|Aerobic Exercise (AeroEx) Group|Participants in this group will do moderate-intensity aerobic training for 4 days a week for 8 weeks.
89244288|NCT06270810|Experimental|Aerobic Exercise+non-Exercise (nE) Physical Activity (AeroEx+nE PA) Group|Participants in this group will increase their non-exercise physical activities and do moderate-intensity aerobic training for four days a week for 8 weeks.
89244289|NCT06269185||Infliximab|Bio-naive patients with ulcerative colitis who starts treatment with infliximab
89244290|NCT06269185||Adalimumab|Bio-naive patients with ulcerative colitis who starts treatment with adalimumab
89244291|NCT06268639|Experimental|Osseodensification in Dental Implant Surgery|The arm involves participants undergoing dental implant surgery with the use of osseodensification drills. This technique is intended to enhance bone density and improve the primary stability of the implants by compacting bone rather than removing it during the osteotomy process. The study aims to assess the impact of osseodensification on bone density at the implant sites, comparing pre-operative and post-operative bone density measurements to evaluate the effectiveness of this intervention.
89244292|NCT06268262||Obesity|Non-intervention
89244293|NCT06268262||Healthy control|Non-intervention
89244296|NCT06265285|Experimental|Health services research (in-clinic and at-home nivolumab)|Patients receive nivolumab SC on day 1 of each cycle. Cycles repeat every 28 days in clinic for 2 cycles, then at home by a HHNP for 4 cycles, followed by either in-clinic or at-home administration for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive in-home visits by a home health nurse and undergo remote patient monitoring including vital sign measurements and condition-specific symptom assessments throughout study.
89244297|NCT06262984|Experimental|Therapeutic Play Group|The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
89244298|NCT06262984|No Intervention|Control Group|Children who choose the control group will be explained the nasopharyngeal swab procedure as routinely performed in the outpatient clinic.The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
89244299|NCT06259058|Experimental|NALIRIFOX + SBRT + NALIRIFOX + Surgery + NALIRIFOX|Patients receive 3 cycles of NALIRIFOX followed by SBRT (30Gy/5Fx). Then undergo surgery and receive 6 cycles of NALIRIFOX after surgery. NALIRIFOX consists of irinotecan liposome injection, oxaliplatin, 5 FU/LV.
89244300|NCT06259058|Active Comparator|NALIRIFOX + Surgery + NALIRIFOX|Patients receive 6 cycles of NALIRIFOX. Then undergo surgery and receive 6 cycles of NALIRIFOX after surgery. NALIRIFOX consists of irinotecan liposome injection, oxaliplatin, 5 FU/LV.
89244301|NCT06256835|Experimental|The experimental group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment.The experimental group was given the Myofascial Release Therapy, five days a week, once a day, for 30-60 minutes each time.
89244302|NCT06256835|Active Comparator|The control group|Study lasts 21 days for each patient. All patients are given rehabilitation treatment, five days a week, once a day, for 30-60 minutes each time.
89244303|NCT06256120|Experimental|R- fluid group|The group to which restrictive fluid replacement will be applied (Group R); 3 ml/kg/hour Ringer lactate (RL) solution will be given.
89244304|NCT06256120|Experimental|L- fluid group|7 ml/kg/hour RL solution will be given to the group that will receive a liberal liquid regimen (Group L).
89244305|NCT06255366|Experimental|Caroxime sodium sulfonate|Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
89244306|NCT06255366|Experimental|Desmopressin|Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
89244307|NCT06255366|Placebo Comparator|0.9% Sodium chloride injection|Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
89244308|NCT06254482|Experimental|PTC518 5 mg|Participants will receive PTC518 5 mg tablets once daily orally for 24 months.
89244309|NCT06254482|Experimental|PTC518 10 mg|Participants will receive PTC518 10 mg tablets once daily orally for 24 months.
89244310|NCT06254482|Experimental|PTC518 20 mg|Participants will receive PTC518 20 mg tablets once daily orally for 24 months.
89244311|NCT06254053|Experimental|Zirconomer Restorative material in primary molar|Arm one zirconomer restorative material (intervention)
89244312|NCT06254053|Active Comparator|Glass Ionomer Cement in primary molar|Arm two Glass Ionomer cement (control)
89244313|NCT06253351||Group1|Patients between 15 and 25 years old with type 1 diabetes and treated by hybrid closed loop
89244314|NCT06252623|Experimental|Drug: Exenatide 2 mg [Bydureon]|Participants will receive once-weekly subcutaneous exenatide (2 mg) injections for 6 weeks.
89244315|NCT06252623|Placebo Comparator|Drug: Placebo|Participants will receive once-weekly subcutaneous saline (i.e., placebo) injections for 6 weeks.
89244316|NCT06251973|Experimental|Participants diagnoses with Esophageal, Gastric, or Gastro-esophageal Junction Cancer|Participants with measurable disease and with evaluable disease as defined by RECIST v1.1 will be enrolled on this study.
89244317|NCT06250582|Experimental|virtual reality therapy, then standard of care|During the intervention phase (A) participants will receive virtual reality therapy during their dialysis sessions over a period of one month. After a washout phase of one week, participants will run through a control phase (B, standard of care) also for a period of one month. Subjects will be randomized to an AB or BA sequence.
89244318|NCT06250582|Experimental|standard of care, then virtual reality therapy|During the control phase (B) participants will be treated according to standard of care over a period of one mont. After a washout phase of one week, participants will run through an intervention phase (A) and will receive virtual reality therapy during their dialysis sessions. Also for a period of one month. Subjects will be randomized to an AB or BA sequence.
89244319|NCT06249815|Active Comparator|Foley catheter + misoprostol|-cervical ripening with transcervical Foley catheter 22 F for 16 hours, then sequentially 25 μg oral misoprostol once every 2 hour.Max 200 μg
89244320|NCT06249815|Active Comparator|misoprostol|25 μg oral misoprostol alone once every 2 hour, Max 200 μg.
89244321|NCT06248255|Experimental|Intervention arm|Single arm study, all participants get pads applied to their forearms
89244322|NCT06247904|Active Comparator|Active rTMS|10 daily sessions of High-frequency Transcranial Magnetic Stimulation (HF-rTMS) applied bilaterally over the hand primary motor area informed by e-field modelling and targeting will be aided by neuronavigation system for precise targeting during each intervention session. Active group will receive HF-rTMS intensity calculated using electric field modelling to create electric field intensity of approximately motor threshold, using the cool-B65 A/P rTMS coil.
89244323|NCT06247904|Sham Comparator|Sham rTMS|10 daily sessions of Sham High-frequency Transcranial Magnetic Stimulation (HF-rTMS) applied bilaterally over the hand primary motor area informed by e-field modelling and targeting will be aided by neuronavigational system for precise targeting during each intervention session Sham group receives no active magnetic stimulation. Cool-B65 A/P rTMS coil will be used to avoid unblinding of administrator and/or study participant.
89244324|NCT06247124|Other|HPV vaccination|Multi-channel campaign to promote HPV vaccination
89244325|NCT06246968|Experimental|Pembrolizumab + Cryoablation|Participants will have a diagnosis of metastatic triple negative breast cancer or locally advanced inoperable triple negative breast cancer. Participants will be randomized 2 (cryoablation arm): 1 (no cryoablation arm).
89244326|NCT06246968|Active Comparator|Pembrolizumab|Participants will have a diagnosis of metastatic triple negative breast cancer or locally advanced inoperable triple negative breast cancer. Participants will be randomized 2 (cryoablation arm): 1 (no cryoablation arm).
89244327|NCT06246747|Experimental|Physical therapy treatment in the clinic + telerehabilitation|Patients performed treatments in the clinic in the presence of their physical therapist (PT) as well as perform remote treatment from their homes. The remote treatment included using video chat with their PT as well as performing PD-specific exercises which were stored in a specific library on the platform.
89244328|NCT06246747|Experimental|TR-only|Patients received treatment at their homes using the TR platform. This included video chat with their clinician as well as performing PD-specific exercises which were stored in a specific library on the platform.
89244329|NCT06246747|Active Comparator|Control group|Patients received treatment in the clinic in the presence of their PT
89244330|NCT06246539|Experimental|Intervention - VR Mindfulness|"The intervention group will be given the VR headset for their unrestricted use over the 12 week intervention period. The VR headset is exceptionally easy and intuitive to use. Each participant will have the choice of 20 locations in which to use the mindfulness-based program. Each of the 20 locations/programs are different. They range in length from 5 minutes (introductory) to 20 minutes."
89244331|NCT06246539|No Intervention|Control|The control arm will not have any intervention. However, at the conclusion of the study, all participants from the Control group will be given the VR intervention
89244332|NCT06245382|Experimental|Goode Health Beverage|Goode Health Beverage that is high in natural ingredients that are high in Polyphenol 3 content and also have anti-inflammatory and antioxidant properties
89244333|NCT06245382|Placebo Comparator|Vanilla Base Blend Beverage|The control beverage is similar but it does not contain the same amount of fiber, anti-inflammatory, and/or antioxidant properties (i.e. mainly smaller or no amounts of flax, ginger, cinnamon, turmeric, berberine bergamot, bilberry, black garlic, and green tea).
89244334|NCT06244771|Experimental|FMC-376|Dose Escalation, Dose Expansion, and Cohort Expansion; Administered for 21-day cycle
89244335|NCT06243094||microbiologically confirmed VAP|patients who meet ATS/IDSA 2005 VAP criteria with microbiological confirmation
89244336|NCT06243094||non microbiologically confirmed VAP|patients who do not meet ATS/IDSA 2005 criteria with microbiological confirmation
89244337|NCT06242522|Other|Female patients with gestational trophoblastic tumour.|Female patients treated in phase II or III clinical trials: TROPHIMMUN and TROPHAMET or who have received AVELUMAB outside the trial for a gestational trophoblastic tumour.
89244338|NCT06242470|Experimental|Cohort 1|
89244339|NCT06242470|Experimental|Cohort 2|
89244340|NCT06242470|Experimental|Cohort 3|
89244341|NCT06242470|Experimental|Cohort 4|
89244342|NCT06242470|Experimental|Cohort 5|
89244343|NCT06242470|Experimental|Cohort 6|
89244344|NCT06242470|Experimental|Expansion cohort 1|
89244345|NCT06242470|Experimental|Expansion cohort 2|
89244346|NCT06242470|Experimental|Expansion cohort 3|
89244347|NCT06242470|Experimental|Expansion cohort 4|
89244348|NCT06242444|Experimental|Experimental Dentifrice|Participants will brush the buccal surfaces of their natural teeth using 1.5+/- 0.1 grams (g) of the experimental dentifrice containing 1150 ppm fluoride and 5 percent (%) potassium nitrate (KNO3) for 25 timed seconds and then swish the resulting dentifrice slurry around the mouth, without further brushing, for a timed period of 95 seconds. Participants will use the dentifrice under supervision of the study staff while the intraoral appliance is in place in Treatment Periods 1 to 3. There will be a washout period of a minimum of 3 days prior to each treatment during which the participants will use their own dentifrice for at least one day, and a 0 ppm fluoride washout dentifrice for two days.
89244349|NCT06242444|Placebo Comparator|Placebo Control Dentifrice|Participants will brush the buccal surfaces of their natural teeth using 1.5+/- 0.1 g of the placebo dentifrice containing 0 ppm fluoride and 5% KNO3 for 25 timed seconds and then swish the resulting dentifrice slurry around the mouth, without further brushing, for a timed period of 95 seconds. Participants will use the dentifrice under supervision of the study staff while the intraoral appliance is in place in Treatment Periods 1 to 3. There will be a washout period of a minimum of 3 days prior to each treatment during which the participants will use their own dentifrice for at least one day, and a 0 ppm fluoride washout dentifrice for two days.
89244350|NCT06242444|Active Comparator|Reference Dentifrice|Participants will brush the buccal surfaces of their natural teeth using 1.5+/- 0.1 g of the reference dentifrice containing 1100 ppm fluoride as stannous fluoride (SnF2) for 25 timed seconds and then swish the resulting dentifrice slurry around the mouth, without further brushing, for a timed period of 95 seconds. Participants will use the dentifrice under supervision of the study staff while the intraoral appliance is in place in Treatment Periods 1 to 3. There will be a washout period of a minimum of 3 days prior to each treatment during which the participants will use their own dentifrice for at least one day, and a 0 ppm fluoride washout dentifrice for two days.
89244351|NCT06241859|Active Comparator|Light sedation according to BIS|Sedation depth will be monitored according to BIS.
89244352|NCT06241859|Sham Comparator|Sedation according to clinical signs|Sedation depth will be monitored according to clinical signs using RASS scale, which aim is -3.
89244353|NCT06240546|Experimental|2 mg/m2|LPM6690176 capsules administered 2 mg/m2 on day 1-5 (qd) every two weeks.
89244354|NCT06240546|Experimental|4 mg/m2|LPM6690176 capsules administered 4 mg/m2 on day 1-5 (qd) every two weeks.
89244355|NCT06240546|Experimental|8 mg/m2|LPM6690176 capsules administered 8 mg/m2 on day 1-5 (qd) every two weeks.
89244356|NCT06240546|Experimental|16 mg/m2|LPM6690176 capsules administered 16 mg/m2 on day 1-5 (qd) every two weeks.
89244357|NCT06240546|Experimental|24 mg/m2|LPM6690176 capsules administered 24 mg/m2 on day 1-5 (qd) every two weeks.
89244358|NCT06240546|Experimental|36 mg/m2|LPM6690176 capsules administered 36 mg/m2 on day 1-5 (qd) every two weeks.
89244359|NCT06240546|Experimental|48 mg/m2|LPM6690176 capsules administered 48 mg/m2 on day 1-5 (qd) every two weeks.
89244360|NCT06235996|Experimental|Music Intervention|A patient is scheduled for an office-based procedure such as a nerve block, epidural steroid injection, etc. Music-of-choice during the office-based procedure intervention is assigned to this group. Music via external speakers played in the procedure room. To ensure acute pain and anxiety control, participants will receive standard analgesic treatment in the beginning of their scheduled interventional procedure. Such treatment includes injection and topical application of lidocaine to induce local anesthesia. Standard of care is applied.
89244361|NCT06235996|Other|Control|A patient is scheduled for an office-based procedure such as a nerve block, epidural steroid injection, etc. No music intervention is assigned to this group. No music at any time during the procedure. To ensure acute pain and anxiety control, participants will receive standard analgesic treatment in the beginning of their scheduled interventional procedure. Such treatment includes injection and topical application of lidocaine to induce local anesthesia. Standard of care is applied.
89244362|NCT06234631|Experimental|Pre - and post-operative CBD|Participants will take 300 milligrams (mg)/day on days 1-36 (150mg twice a day [b.i.d.])
89244363|NCT06234631|Experimental|Pre-operative placebo plus post-operative CBD|Participants will take placebo prior to surgery days 1-7, then days 8-36 participants will take CBD 300 milligrams (150mg twice a day [b.i.d.])
89244364|NCT06234631|Experimental|Pre-operative CBD plus post-operative placebo|Participants will take CBD 300 milligrams (mg) /day prior to surgery on days 1-7 (150mg twice a day [b.i.d.]), then days 8-36 will take placebo twice a day [b.i.d.]
89244365|NCT06234631|Placebo Comparator|Pre- and post-operative placebo|Participants will take placebo on days 1-36 twice a day [b.i.d.]
89244366|NCT06232980|Active Comparator|Anesthesia induction group guided by BIS in geriatric patients.|The BIS index will be evaluated every 30 seconds. The initial dose and infusion rate will be applied as 1.5 mg/kg and 100 mg/min, respectively. In the BIS group, the target index is set between 40-60, and additional doses of 20 mg will be planned every 30 seconds until reaching this target index.
89244367|NCT06232980|Active Comparator|Observer's Alertness/Sedation Score-guided induction group in geriatric patients.|The initial dose will be applied as 1.5 mg/kg, and the infusion rate will be 100 mg/min. An additional 20 mg of propofol will be administered every 30 seconds until the Observer's Assessment of Alertness/Sedation (OAA/S) score reaches 1.
89244368|NCT06232096|Experimental|MBS314|
89244369|NCT06232057|Experimental|Intervention Group|Virtual Reality Application Group
89244370|NCT06232057|No Intervention|Control Group|Control group without any intervention
89244371|NCT06231706|Placebo Comparator|Bread crouton|Control.
89244372|NCT06231706|Experimental|Prebiotic-like nut and seed mix|Intervention treatment.
89244373|NCT06231706|Other|Probiotic capsule|Secondary Intervention treatment.
89244374|NCT06227026|Experimental|Anti-CD19 CAR-T Cell Infusion|
89244375|NCT06226870|Experimental|NSRCT Group|Non-surgical root canal therapy
89244376|NCT06226870|Experimental|VPT Group|vital pulp therapy
89244377|NCT06226870|Experimental|VPT+PRF Group|vital pulp therapy with PRF
89244378|NCT06225973|Experimental|TL-925 Arm|TL-925 will be administered OU BID
89244379|NCT06225973|Placebo Comparator|Vehicle Arm|Vehicle will be administered OU BID
89244380|NCT06225466|Active Comparator|Neuromuscular blockade|"Rocuronium 0.6 mg/kg IV (max 50 mg) intraop with repeated doses of 0.2 mg/kg (max 15 mg) as indicated. Sugammadex 2-4 mg/kg IV at the end of surgery.~SOC drugs:~Midazolam 0.5 mg/kg (max 15 mg) and acetaminophen 15 mg/kg (max 800 mg) PO 20-30 minutes before surgery.~Sevoflurane induction and maintenance of anesthesia~Dexamethasone 0.5 mg/kg IV (max 8 mg) intraop~Dexmedetomidine 0.3 mcg/kg IV (max 12 mcg) intraop~Fentanyl at the discretion of the anesthesiologist. In the post-anesthesia care unit (PACU), fentanyl 0.5 mcg/kg IV (max 25 mcg) for pain score 4 or greater (max 3 doses).~Ondansetron 0.1 mg/kg (max 4 mg) IV intraop~Ibuprofen 10 mg/kg (max 500 mg) PO every 6 hours beginning after surgery and alternating with acetaminophen 15 mg/kg (max 800 mg) every 6 hours.~Device monitoring:~Bispectral index system intraop~TetraGraph neuromuscular transmission monitor intraop~ExSpiron respiratory volume monitor intraop and in PACU"
89244381|NCT06225466|Other|No neuromuscular blockade|"Anesthesia will be administered in a standard fashion. Rocuronium and sugammadex will not be administered.~SOC drugs:~Midazolam 0.5 mg/kg (max 15 mg) and acetaminophen 15 mg/kg (max 800 mg) PO 20-30 minutes before surgery.~Sevoflurane induction and maintenance of anesthesia~Dexamethasone 0.5 mg/kg IV (max 8 mg) intraop~Dexmedetomidine 0.3 mcg/kg IV (max 12 mcg) intraop~Fentanyl at the discretion of the anesthesiologist. In the post-anesthesia care unit (PACU), fentanyl 0.5 mcg/kg IV (max 25 mcg) for pain score 4 or greater (max 3 doses).~Ondansetron 0.1 mg/kg (max 4 mg) IV intraop~Ibuprofen 10 mg/kg (max 500 mg) PO every 6 hours beginning after surgery and alternating with acetaminophen 15 mg/kg (max 800 mg) every 6 hours.~Device monitoring:~Bispectral index system intraop~ExSpiron respiratory volume monitor intraop and in PACU"
89244382|NCT06224543|Active Comparator|Group A (10% dose GV)|Each participant will receive a Standard dose gadobutrol (0.1 mmol/kg) in Period 1 and 10% dose gadobutrol (0.01 mmol/kg) in Period 2. During study Period 1, each participant will receive gadobutrol as a single intravenous (IV) administration at the standard dose for contrast-enhanced MRI followed by study Period 2 where a single IV low dose (10% dose) of gadobutrol will be administered. There will be a washout period of at least 72 hours but less than 15 days between the two periods. The individual study duration will therefore range from 4 to 15 days.
89244383|NCT06224543|Active Comparator|Group B (25% dose GV)|Each participant will receive a Standard dose gadobutrol (0.1 mmol/kg) in Period 1 and Study Period 2: 25% dose gadobutrol (0.025 mmol/kg) in Period 2. During study Period 1, each participant will receive gadobutrol as a single intravenous (IV) administration at the standard dose for contrast-enhanced MRI followed by study Period 2 where a single IV low dose (25% dose) of gadobutrol will be administered. There will be a washout period of at least 72 hours but less than 15 days between the two periods. The individual study duration will therefore range from 4 to 15 days.
89244384|NCT06224348|Experimental|Amlitelimab dose 1|Subcutaneous injection as per protocol
89244385|NCT06224348|Experimental|Amlitelimab dose 2|Subcutaneous injection as per protocol
89244386|NCT06224348|Placebo Comparator|Placebo|Subcutaneous injection as per protocol
89244387|NCT06224205|No Intervention|Annual Well Visit or any other visit to Primary Care Doctor|Annual Well Visit or any other visit to Primary Care Doctor: This is the usual care arm. Electronic Health Record Data for patients from the clinics randomized to usual care will be collected for comparison with the other 2 arms. Patients from these primary care clinics must have had a visit to their doctor either as an annual well visit (AWV) or any other type of visit. These clinics will not have to do anything for the study but run their business as usual without altering anything.
89244388|NCT06224205|Experimental|Passive Digital Marker (PDM)|Passive Digital Marker (PDM): Electronic Health Record Data from those clinics randomized to PDM will be run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset.
89244389|NCT06224205|Active Comparator|Passive Digital Marker (PDM) + Quick Dementia Rating Scale (QDRS)|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
89244390|NCT06223685|Experimental|Probiotic|"Dosage 2x1 capsule per day. 12 weeks~Probiotic, which will contain a combination of four freeze-dried strains of probiotic bacteria in DRcaps enteral capsulesTM . These are capsules that protect the probiotics from the effects of hydrochloric acid in the stomach, as they only dissolve in the intestines. The tested composition of probiotics is on sale in Poland, Italy, Taiwan, among other countries. It has a positive recommendation of the Institute Pomnik-Center for Children's Health No. 16/DJW/2022.~(Lactococcus lactis Rosell® - 1058, Lactobacillus casei Rosell® - 215, Lactobacillus helvetius Rosell® - 52, Bifidobacterium bifidum Rosell® - 71)"
89244391|NCT06223685|Placebo Comparator|Placebo|"Capsules that look identical to the probiotic and contain potato starch and a shell: hydroxypropylmethylcellulose, gellan gum.~Dosage 2x1 capsule per day. 12 weeks"
89244392|NCT06223685|No Intervention|Control group|The control group will consist of healthy subjects (25 subjects) without SIBO (with a negative hydrogen-methane test) and without NAFLD (CAP<248dB/m, TE<6.5kPa).
89244393|NCT06221475|Experimental|Healthy male participants from Netherlands|In Part 1, participants will receive a single dose of 40 mg of BAY2927088 as oral tablets on Study Day 1 approximately 30 min after a light meal, they will then receive a single dose of a microtracer not exceeding 100 ug of [14C]-BAY2927088 and 37 kilo becquerel (kBq) [1000 nano Curie (nCi)] of 14C will be administered intravenously (IV) as a 15 min infusion ending at the expected median time to maximum concentration (tmax) for the tablet (2 hours oral post-dose). After 2 days of washout, participants will move on to Part 2. In Part 2, on Study Day 1 approximately 30 min after a light meal, all enrolled participants will receive a single dose of 40 mg BAY2927088 containing approximately 3.7 MBq (100 µCi) [14C]-BAY 2927088 administered as an oral solution
89244394|NCT06219174|Experimental|Phase 1: Dose Escalation for Pembrolizumab and Difluoromethylornithine (DFMO)|"Difluoromethylornithine (DFMO) + Pembrolizumab Pre-treated or treatment naive advanced or metastatic NSCLC.~The phase I dose escalation will include a fixed dose of Pembrolizumab IV every 3 weeks and escalating doses of DFMO (three dose levels) to determine the maximum tolerated dose (MTD) to be used in the phase II portion of the trial.~DFMO level -1: Dose Level -1: 4500 mg/m2 by mouth (PO) once a day (QD).~DFMO Level 1: (start): 6750 mg/m2 PO QD~Dose Level 2: 9000 mg/m2 PO QD"
89244395|NCT06219174|Active Comparator|Phase II: Pembrolizumab and Difluoromethylornithine (DFMO)|"Difluoromethylornithine (DFMO) + Pembrolizumab~Advanced/metastatic NSCLC who are immunotherapy naïve.~Pembrolizumab IV flat dose every 3 weeks~DFMO dose to be determined (TBD) based on maximum tolerated dose (MTD) and dose limiting toxicities (DLT) in Phase I dose escalation."
89244396|NCT06219122|Experimental|A CAPTS intervention for people with personality disorders.|Experimental: Control Period - Intervention Period Multiple baseline single case experimental design wherein all patients are first assigned to the control condition (or control period) are then assigned to the intervention condition (or intervention period) and finally to the follow-up period (control period). Patients are randomized for the time (t) at which they start with the intervention.
89244397|NCT06218797|Active Comparator|Group C|Control group
89244398|NCT06218797|Active Comparator|Group ND|Nebulisation with dexmedetomidine
89244399|NCT06218290|Experimental|All Patients|All patients with chronic kidney disease with hyperphosphatemia
89244400|NCT06217822|Experimental|Dose escalation of BAY3563254|Participants with advanced mCRPC will receive increased 225Ac-PSMA-Trillium doses in a planned stepwise fashion.
89244401|NCT06217822|Experimental|Dose expansion group A of BAY3563254|Participants with advanced mCRPC treated with 225Ac-PSMA-Trillium, who must have received at least 1 but no more than 2 prior taxane-based chemotherapy regimens. Prior radiopharmaceutical treatment is not permitted.
89244402|NCT06217822|Experimental|Dose expansion group B of BAY3563254|Participants with advanced mCRPC treated with 225Ac-PSMA-Trillium, who must not have received taxane-based chemotherapy since becoming castration resistant. Prior radiopharmaceutical treatment is not permitted.
89244403|NCT06217822|Experimental|Dose expansion group C of BAY3563254|Participants with advanced mCRPC treated with 225Ac-PSMA-Trillium, who must have had prior treatment with 177Lu-PSMA more than 6 weeks before the start of study treatment and at least 1 but no more than 2 taxane regimens (or been deemed ineligible for or refused taxane therapy on consultation with their physician).
89244404|NCT06217822|Experimental|111In-PSMA-Trillium and Tris-POC Imaging|Participants who sign informed consents for both the main study and the optional 111In-PSMA-Trillium and Tris-POC Imaging Substudy. 111In-PSMA-Trillium and Tris-POC Imaging Substudy participants are not eligible for the 225Ac-PSMA-Trillium Imaging and Dosimetry Substudy or for the dense-PK sub-cohort in dose expansion. Each substudy participant will enter the 111In-PSMA-Trillium and Tris-POC Imaging Substudy period after completing a shortened screening period and before starting study treatment with 225Ac-PSMA-Trillium.
89244405|NCT06217822|Experimental|225Ac-PSMA-Trillium Imaging and Dosimetry|The 225Ac-PSMA-Trillium Imaging and Dosimetry Substudy will enroll throughout both dose escalation and dose expansion, starting with the first dose level in dose escalation. The substudy will generally be available at all study sites to participants in the main study.
89244406|NCT06217822|Experimental|HPGe or NaI Whole Body Radioactivity Measurement of 225Ac-PSMA-Trillium|HPGe or NaI measurements of whole-body radioactivity of 225Ac and its daughters as a function of time will be conducted on an optional basis during dose escalation and dose expansion at selected sites to evaluate the clearance of total radioactivity from the body over time. Participants in the 111In-PSMA-Trillium and Tris-POC Imaging Substudy will not be eligible for this HPGe or NaI Whole Body Radioactivity Measurement of 225Ac-PSMA-Trillium Substudy.
89244407|NCT06215755|Experimental|VRG50635|
89244408|NCT06215495|Experimental|reduced CTV (clinical target volume) and PTV (planning target volume)|
89244409|NCT06215495|Active Comparator|EORTC CTV (clinical target volume) and PTV (planning target volume)|
89244410|NCT06215131|Active Comparator|In-person dietary weight loss counseling|The counseling content will be 30 minutes of RDN delivered educational session on energy density and portion sizes then the second 30 minutes being the RDN answering participant questions and providing feedback.
89244411|NCT06215131|Experimental|Virtual reality dietary weight loss counseling|The counseling content will be 30 minutes of virtual reality delivered educational session on energy density and portion sizes with an RDN remotely monitoring then the second 30 minutes being the RDN answering participant questions and providing feedback through synchronous audio/video.
89244412|NCT06212557|Experimental|Active Treatment as Usual plus KIOS App|Treatment as usual in clinics with the use of the KIOS App
89244413|NCT06212557|Sham Comparator|Treatment as Usual plus KIOS education App|Treatment as usual in clinics with the use of the KIOs education App (Sham)
89244414|NCT06210009|Experimental|DASH-Style Diet|For seven days, participants will consume a diet characterized by higher intake of fruits, vegetables, and low-fat dairy, in addition to whole grains, poultry, fish, and nuts, but smaller amounts of red meat, sweets, and sugar-containing beverages.
89244415|NCT06210009|Other|Western-Style Diet|For seven days, participants will consume a diet characterized by characterized by higher intake of red meat, sweets, and items containing added sugar, processed starches, and seed oils, in addition to lower intake of fruits, vegetables, and low-fat dairy.
89244416|NCT06209801|Experimental|Experimental group|Individuals with peripheral nerve injuries
89244417|NCT06209801|Active Comparator|Control group|Healthy individuals
89244420|NCT06207877|Experimental|CagriSema|Participants will receive dose 1 cagrilintide and dose 2 semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) during the maintenance period of 5 weeks.
89244421|NCT06207877|Active Comparator|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously once-weekly for 21 weeks.
89244422|NCT06207370|Active Comparator|Group 1|TQ: 2 x 100 mg TQ tablets orally on Days 1, 2, 3, and 4
89244423|NCT06207370|Placebo Comparator|Group 2|Placebo: 2 x 100 mg placebo tablets orally on Days 1, 2, 3, and 4
89244424|NCT06206837|Experimental|vepdegestrant in combination with PF-07220060|vepdegestrant administered orally once daily (QD) continuously and PF-07220060 administered orally twice daily (BID) continuously on 28-day cycles
89244425|NCT06206759||study group- ICU patients treated with vitamin C|ICU patients treated with vitamin C
89244426|NCT06206759||control group- ICU patients not treated with vitamin C|ICU patients not treated with vitamin C
89244427|NCT06204926||Eyes with SMILE surgeries|Eyes with SMILE surgeries which were performed by surgeons with experiences.
89244428|NCT06203392|Experimental|Very low carbohydrate ketogenic diet for six weeks|
89244429|NCT06203392|Active Comparator|Mediterranean diet for six weeks|
89244430|NCT06203379|Experimental|Neuromuscular Exercise Training|
89244431|NCT06203379|Active Comparator|Exercise Training|
89244432|NCT06202742|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia (CBTI) is non-medical treatment to improve insomnia. CBTI group will attend online meeting, 1 hour weekly for 8 weeks.
89244433|NCT06202742|Active Comparator|Health education|Health education group will attend online meeting, 1 hour weekly for 8 weeks.
89244434|NCT06202066|Experimental|ARM I (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT scans or MRI scans throughout study.
89244435|NCT06202066|Experimental|ARM II (temozolomide, SurVaxM)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days until disease progression or unacceptable toxicity and can be continued at investigators discretion at end of treatment. Patients also receive SurVaxM with Montanide ISA-51 SC and sargramostim SC once every 2 weeks for 4 doses. Patients with clinical benefit after 4 doses of SurVaxM and remain free of tumor progression and unacceptable toxicity may receive 3 additional doses on weeks 24, 36, and 48. Additionally, patients undergo blood sample collection, CT scans or MRI scans throughout study.
89244436|NCT06202066|Experimental|PART 1 (temozolomide, SurVaxM)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity and can be continued at investigators discretion at end of treatment. Patients also receive SurVaxM with montanide ISA-51 SC and sargramostim SC once every 2 weeks for 4 doses. Patients with clinical benefit after 4 doses of SurVaxM and remain free of tumor progression and unacceptable toxicity may receive 3 additional doses on weeks 24, 36, and 48. Additionally, patients undergo blood sample collection, CT scans or MRI scans throughout study.
89244437|NCT06201702|Experimental|Experimental group|Participants in the intervention group will first be pre-tested by filling out the data collection tools, and then they will be informed about 3 mL of pomegranate supplementation three times a day for 10 days during 2 menstrual cycles (between 7 days before and 3 days after the estimated onset of menstruation). The test will be repeated at the end of the 2nd month after the intervention
89244438|NCT06201702|No Intervention|Control group|Participants in the control group will be pre-tested and post-tested after 2 menstrual cycles and at the end of menstrual bleeding. This group will not receive any intervention.
89244439|NCT06199973|Experimental|SHR-A1811|
89244440|NCT06199973|Experimental|physician choiced treatment|include: TAS-102, or Regorafenib, or Fruquintinib
89244441|NCT06199206|Experimental|Intervention Group|Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
89244442|NCT06199206|No Intervention|Control Group|No therapeutic play will be made to children. Children will be verbally informed about the lumbar puncture.
89244443|NCT06197776||chemoradiotherapy combined with immunotherapy|Patients treated with chemoradiotherapy combined with immunotherapy
89244444|NCT06195124|Experimental|RGL-193（low-dose）Treatment group|Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10^11 VG and a bilateral dose of 3.0×10^11 VG.
89244445|NCT06195124|Experimental|RGL-193（high-dose）Treatment group|Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10^11 VG and a bilateral dose of 1.0×10^12 VG.
89244446|NCT06194448|Experimental|Open-Label Osimertinib Induction Treatment|Patients will receive open-label osimertinib induction treatment for 8 weeks (± 1 week window to account for patient variability and CRT scheduling), followed by CRT treatment for 6 weeks (± 1 week) and then osimertinib maintenance treatment until RECIST 1.1-defined radiological progression by investigator unless there is evidence of unacceptable toxicity or if the patient requests to stop the study treatment.
89244447|NCT06194032|Experimental|Treatment Sequence ABCD|Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (ABCD) in a crossover design with a washout period of at least 7 days between each study dose administration.
89244448|NCT06194032|Experimental|Treatment Sequence BDAC|Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (BDAC) in a crossover design with a washout period of at least 7 days between each study dose administration.
89244449|NCT06194032|Experimental|Treatment Sequence CADB|Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (CADB) in a crossover design with a washout period of at least 7 days between each study dose administration.
89244450|NCT06194032|Experimental|Treatment Sequence DCBA|Dummy sequence according to CSP: Participants will receive a single dose of all 4 treatments (DCBA) in a crossover design with a washout period of at least 7 days between each study dose administration.
89244452|NCT06189755||Cases|Moderate-severe OSA (defined as AHI ≥15 events/hour)
89244453|NCT06189755||Controls|No OSA (defined as AHI <5 events/hour)
89244454|NCT06188741|No Intervention|Part 1: WBMRI for NF1 patients with no known PN|To assess the incidence of asymptomatic PN in any location in participants with NF1 and no known PN
89244455|NCT06188741|Experimental|Part 2: Treatment randomization to selumetinib vs observation|To determine if selumetinib treatment prevents PN growth in young participants with asymptomatic tumors in high-risk locations
89244456|NCT06188741|Experimental|Part 3: Part 2 participants with growing or symptomatic PN|To assess the proportion of participants who are able to maintain tumor response after transition to an intermittent dosing schedule
89244457|NCT06188078|Other|Control|Babies in the control group will be fed only breast milk or formula, and a urine bag will be inserted after 10 minutes and they will be expected to urinate. The success of the transaction and the processing time will be recorded.
89244458|NCT06188078|Experimental|The bladder stimulation technique|"Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. A urine bag will be inserted 10 minutes after the feeding.~The newborn will be held under the armpit by the nurse, male infants will be held with their legs hanging down, and female infants will be held in the hip flexion position.~Newborns with spontaneous voiding during the period from the beginning of the investigation procedure to positioning the newborn will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until voiding begins.The success of the transaction and the processing time will be recorded."
89244459|NCT06188078|Experimental|Bath|Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. Babies in the bath group will be given a bath under running water for no longer than 5 minutes before feeding. After the bath, the baby will be fed, and a urine bag will be inserted 10 minutes after the feeding. The success of the transaction and the processing time will be recorded.
89244460|NCT06186700|Active Comparator|Pentoxifylline group|the patient will take 400 mg orally Pentoxifylline 3 tablets per day starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the fourth cycle
89244461|NCT06186700|Placebo Comparator|Control group|the patient will take placebo tablets three times per day, starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the fourth cycle
89244462|NCT06184451|Experimental|Therapeutic exercise and Transcutaneous electrical nerve stimulation|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets. TENS will be applied with a portable device during the therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.
89244463|NCT06184451|Placebo Comparator|Therapeutic exercise and Placebo Transcutaneous electrical nerve stimulation|Participants in the control group will perform the same therapeutic exercise protocol previously reported in the experimental group, associated with placebo TENS. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this.
89244464|NCT06183593|Experimental|Radiofrequency-evoked potentials (RFEPs)|The application of RF stimuli will be carried out using an adapted electrocoagulation device (ECD). These devices have several types of applicators, depending on the type of stimulation to be performed. In the bipolar mode, the applicator consists of a small clamp whose tips constitute the active and return electrodes, and the electric current flows only through the tissue captured between the two tips of the clamp. In the unipolar mode, the active electrode is an interchangeable tip with a variable surface (resembling for example a blade or a needle), and the return electrode is a metal plate in contact with another part of the volunteer's body. In this case, the current also flows from the active electrode to the return electrode, but over a considerably longer path. In both cases the physiological effect is similar: the stimulation elicits superficial, localized and limited heating of the tissue in the vicinity of the active electrode.
89244465|NCT06183593|Experimental|Pinprick evoked potentials|An automatic stimulator with a section of approximately 0.35 mm in diameter and with a blunt tip was developed to apply this type of stimulus. This stimulator has a calibrated spring, which allows force to be gradually applied, while providing a safety margin to avoid accidents during tests. This allows two types of measurements to be made depending on the speed with which the stimulus is applied.
89244469|NCT06179550|Active Comparator|The control group|"Assigned by the random number table. During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient&amp;#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements."
89244470|NCT06179550|Experimental|The observation group|"Assigned by the random number table.During the treatment, all patients were provided with comprehensive rehabilitation therapy as follows:~Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.~The observation group was given enteral nutritional support with IOE according to the following procedure. The feeding content was formulated by the nutritionists based on the patient&amp;#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups"
89244471|NCT06179420||standard IVF regime protocol based on clinician decision|The dosage of gonadotrophin and time of transvaginal ultrasound decided by clinician
89244472|NCT06179420||clinical decision support tool, Opt-IVF for IVF regime protocol|The dosage of gonadotrophin and time of transvaginal ultrasound decided by a clinical decision support tool ( OPt -IVF)
89244473|NCT06177535|Experimental|Kava Group|Subjects will receive Kavalactones for 28 days
89244474|NCT06177535|Placebo Comparator|Placebo Group|Subjects will receive placebo for 28 days
89244475|NCT06177431|Experimental|Monepantel treatment arm|Daily dose of 10 mg/kg body weight (QD)
89244476|NCT06176339|Active Comparator|Pentoxyphyllin group|Patients will undergo a treatment plan determined by the multidisciplinary team. This involves four cycles of intravenous (IV) doxorubicin at a dose of 60 mg/m2 along with IV cyclophosphamide at 600 mg/m2 per cycle. Following this, taxane will be administered. Additionally, patients are prescribed 400 mg pentoxifylline tablets to be taken three times daily.
89244477|NCT06176339|Placebo Comparator|Control group|Patients will undergo a treatment plan determined by the multidisciplinary team. This involves four cycles of intravenous (IV) doxorubicin at a dose of 60 mg/m2 along with IV cyclophosphamide at 600 mg/m2 per cycle. Following this, taxane will be administered. Additionally, patients will take placebo tablets three times daily.
89244478|NCT06175767|Experimental|Screening Phase (Day -28 to Day -1, up to 28 days):|"Screening phase is designed to determine subject's eligibility to proceed to Randomization and the Treatment Phase of the study. During this phase, a series of assessments will be performed to determine subject eligibility as per inclusion and exclusion criteria.~Subjects who meet eligibility criteria, but have some abnormal laboratory values, based on PI review a repeat laboratory sample may be collected. The repeat laboratory reports should be reviewed by the PI to confirm eligibility prior to randomization.~Subjects who fail to meet eligibility criteria during the Screening phase will be considered screen failures and will be exited from the study. Subjects who meet the eligibility criteria will be scheduled for randomization visit."
89244479|NCT06175767|Experimental|Randomization and Double-Blind Treatment Phase (TV0- TV3, 12 weeks):|Subjects who have successfully completed the Screening phase will enter the Randomization and Double-Blind treatment phase of the study. Subjects will take the assigned randomized treatment, MT101-5 at 400 mg, 600 mg or placebo for 12 weeks. MT101-5 and matching placebo are oral tablets that will be taken as six tablets two times a day (b.i.d.) at least 2 hours before or 2 hours after meal in the morning and evening daily during this study.
89244480|NCT06175767|Experimental|Follow-up Phase (FUV, 4 weeks ± 3 days)|The follow-up phase will consist of a follow-up visit at the end of the Double-Blind Treatment phase.
89244481|NCT06169215|Experimental|Arm I (Dara-SVD)|Patients receive daratumumab and hyaluronidase-fihj SC or daratumumab IV on days 1, 8, 15, & 22 for cycles 1-2, then days 1 & 15 for cycles 3-4, and selinexor PO, bortezomib SC, and dexamethasone PO on days 1, 8, 15, & 22 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET, MRI, or CT, and bone marrow biopsy and collection of blood samples during screening and at the end of treatment.
89244482|NCT06169215|Active Comparator|Arm II (Dara-RVD)|Patients receive daratumumab and hyaluronidase-fihj SC or daratumumab IV on days 1, 8, 15, & 22 for cycles 1-2, then days 1 & 15 for cycles 3-4, lenalidomide PO QD on days 1-21 of each cycle, and bortezomib SC and dexamethasone PO on days 1, 8, 15, & 22 of each cycle. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET, MRI, or CT, and bone marrow biopsy and collection of blood samples during screening and at the end of treatment.
89244483|NCT06168695|Experimental|anterior crossbite treatment with evaluation of speech and quality of life|"removable anterior expansion screw is used to correct anterior crossbite~Child Perceptions Questionnaire was used to gauge how the anterior crossbite affected the children's OHRQoL.~children were subjected to the Protocol of speech evaluation"
89244484|NCT06163898|Experimental|Part A|
89244485|NCT06163898|Experimental|Arm B1|
89244486|NCT06163898|Experimental|Arm B2|
89244487|NCT06163898|Experimental|Arm C1|
89244488|NCT06163898|Experimental|Arm C2|
89244489|NCT06163560|Experimental|Babyapp group|This group will be provided access to the app and be asked for their feedback on the performance of the app.
89244490|NCT06163560|Active Comparator|Control group|This group will be given an information pack consisting of a parenting booklet from the Maternal and Child Health Centres (MCHC).
89244491|NCT06162780||TEER group|Severe DMR patients of low to intermediate surgery risk who underwent TEER.
89244492|NCT06162624|Experimental|ACT workbook|
89244493|NCT06162624|Active Comparator|Control workbook|
89244494|NCT06160427|Experimental|CTM Treatment|2.0 cc (cubic centimeter) dose injection of CTM Boost will be administered by injection directly into the rotator cuff using a 20 gauge needle.
89244495|NCT06160427|Active Comparator|PRP Treatment|Each participant randomized to this arm will receive a single injection of Platelet Rich Plasma (PRP).
89244496|NCT06159777|Experimental|Pre-operative|Participants will be instructed to take 17 grams of powder Polyethylene glycol 3350 (PEG) every day starting 3 days prior to scheduled surgery date and continue to take 17 grams of PEG every day for 7 days following the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used.
89244497|NCT06159777|Active Comparator|Post-operative|Participants will be instructed to take 17 grams of powder PEG* every day for 7 days starting the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used.
89244498|NCT06159127|Experimental|SMART@Home|Use of the SMART@Home app for medication and symptom tracking
89244499|NCT06157827|Experimental|LBL-024+Etoposide+Cisplatin/Carboplatin|LBL-024+Etoposide+Cisplatin/Carboplatin Injection , dose A or dose B; Q3w
89244500|NCT06154525|Placebo Comparator|Control Group (CC)|The control group receives RO water with a dosage of 1 ampoule per time, 2 times per day for 28 days.
89244501|NCT06154525|Experimental|Preg-Mom Group (AA)|The Preg-Mom group receives RO water plus B. subtilis, B. clausii, and B. coagulans at 3 billion CFU/5 mL (LiveSpo® Preg-Mom) with a dosage of 1 ampoule per time, 2 times per day for 28 days.
89244502|NCT06154525|Experimental|KIDS Group (BB)|The KIDS group receives RO water plus B. subtilis and B. clausii at 3 billion CFU/5 mL (LiveSpo® KIDS) with a dosage of 1 ampoule per time, 2 times per day for 28 days.
89244503|NCT06154382||group 1: eltroxin administration|patients witn low T4 level who recieved eltroxin in ICU
89244504|NCT06154382||group 2: no eltroxin administration|patients witn low T4 level who did not recieve eltroxin in ICU
89244505|NCT06153004|Experimental|Healthy Activity Program (HAP)|HAP is a brief psychological treatment adapted from behavioral activation therapy, an empirically supported psychological treatment recommended by the World Health Organization.
89244506|NCT06153004|Experimental|Antidepressant medication (ADM)|Fluoxetine is a selective serotonin reuptake inhibitors (SSRIs) and one of the safest medications used to treat depression. It is a routinely used medication and part of the Essential Drug List (EDL) in India.
89244507|NCT06152185|Experimental|Mindfulness Training|Mindfulness intervention involving 28 audio-guided lessons plus daily brief practice prompts. Lessons train meditation techniques for 3 mindfulness skills: concentration, sensory clarity, and equanimity. Practice prompts delivered 3x daily build on the skills trained in each lesson.
89244508|NCT06152185|Active Comparator|Enhanced Usual Care (EUC)|Participants in the EUC condition will have no study requirements during the 4-week intervention period, but they will receive a list of stress management resources upon randomization (websites, books, health tracking apps, and mental health services) with no additional intervention support.
89244509|NCT06151236|Experimental|Neoadjuvant Treatment|"Nivolumab and relatlimab will be administered in a fixed dose combination (FDC). The FDC product contains nivolumab and relatlimab in a protein-mass ratio of 3:1 (nivolumab 240 mg and relatlimab 80 mg): in a 20 mL concentrate solution per single vial. The dose and dosing regimen for this study is nivolumab 480 mg and relatlimab 160 mg - 2 vials per infusion. This was primarily based on the observed benefit/risk profile observed in metastatic melanoma patients from Study CA224-020 pharmacokinetics (PK), pharmacodynamics, and extensive nivolumab monotherapy clinical experience. In addition, the Phase 2/3 Study CA224-047 established this dose as active in unresectable and metastatic melanoma.~This study is open label and single arm, with all patients scheduled to receive two doses of nivolumab and relatlimab FDC prior to surgery on days 1 and 29."
89244510|NCT06150534||Adult Patients with PID|Adult patients with PID who recently started or will soon begin to complete SCIG (HyQvia or Cuvitru) infusions independently will be interviewed before and/or after the use of Alexa Skill.
89244511|NCT06150534||Caregivers of Patients with a Self-reported Diagnosis of PID|Caregivers who recently started or will soon begin infusing SCIG (HyQvia or Cuvitru) for patients with a self-reported diagnosis of PID will be interviewed before and/or after the use of Alexa Skill.
89244512|NCT06150534||Healthcare Professionals (HCPs)|HCPs, specifically, clinical immunologists who prescribe SCIG for the treatment of PID and nurses who have experience administering SCIG will be interviewed after the use of Alexa Skill.
89244513|NCT06149104|Experimental|sacubitril/valsartan|single arm, open label sacubitril/valsartan
89244514|NCT06148779||Joint Academy|
89244515|NCT06148779||BOA|
89244516|NCT06147258|Experimental|Expressive writing|Participation in a 10 weekly virtual expressive writing with 1 session per week
89244517|NCT06147258|No Intervention|Waitlist control|Participation in usual daily activities
89244518|NCT06147063|Experimental|Arm 1: dosage 1 of AZD9838 18 to 64 years of age|Participants will receive 1 intramuscular dose of AZD9838.
89244519|NCT06147063|Experimental|Arm 2: dosage 2 of AZD9838 18 to 64 years of age|Participants will receive 1 intramuscular dose of AZD9838.
89244520|NCT06147063|Active Comparator|Arm 3: licensed mRNA vaccine 18 to 64 years of age|Participants will receive 1 intramuscular dose of the licensed mRNA vaccine.
89244521|NCT06147063|Experimental|Arm 4: dosage 1 of AZD6563 18 to 64 years of age|Participants will receive 1 intramuscular dose of AZD6563.
89244522|NCT06147063|Experimental|Arm 5: dosage 2 of AZD6563 18 to 64 years of age|Participants will receive 1 intramuscular dose of AZD6563.
89244523|NCT06147063|Experimental|Arm 6: dosage 1 of AZD6563 65 years of age and older|Participants will receive 1 intramuscular dose of AZD6563.
89244524|NCT06147063|Experimental|Arm 7: dosage 2 of AZD6563 65 years of age and older|Participants will receive 1 intramuscular dose of AZD6563.
89244525|NCT06147063|Active Comparator|Arm 8: licensed mRNA vaccine 65 years of age and older|Participants will receive 1 intramuscular dose of the licensed mRNA vaccine.
89244526|NCT06144918|Experimental|SBI-100 Ophthalmic Emulsion, 0.5%|All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
89244527|NCT06144918|Placebo Comparator|SBI-100 Ophthalmic Emulsion Placebo|All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
88821565|NCT03507855|Active Comparator|Control|Normal operating room environment.
89244528|NCT06144918|Experimental|SBI-100 Ophthalmic Emulsion, 1%|All patients enrolled into the study will be randomly assigned to an interventional treatment of 0.5% or 1.0% or Placebo, SBI-100 Ophthalmic Emulsion
89244529|NCT06144827|Active Comparator|Multiparametric MRI scan group|Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software.
89244530|NCT06144827|Experimental|Multiparametric MRI scans + HepQuantShunt Test group|Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials.
89244531|NCT06143891|Experimental|Belumosudil|"Participants will receive belumosudil 200 mg tablets Per os(PO) once daily (QD) per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study~note: 200mg two times a day (BID) is used in some cases, when the subject is taking a proton pump inhibitor or a strong CYP3A4 inducer)"
89244532|NCT06143891|Placebo Comparator|Placebo|Participants will receive matching placebo tablets PO QD per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study
89244533|NCT06142539||SDCT group|
89244534|NCT06142539||LDCT group|
89244535|NCT06141824|Experimental|Subject Self-Collection and Specimen Testing|"A subject's participation in this study will consist of one study visit. The subject self-collects a nasal swab sample according to Lucira COVID- 19 & Flu Test instructions and runs test according to QRI.~Following the Lucira COVID-19 & Flu Test self-collection will be an additional swab collection for reference method testing. One (1) additional NS specimen will be collected by the healthcare professional, prepared in Transport Medium, and sent to the reference laboratory."
89244536|NCT06141733||NIRS (Near-infrared spectroscopy) group of the COSGOD III trial|"A multi-center, multi-national randomized-controlled trial was performed in 11 centers in Europe and Canada. Preterm neonates less than 32 weeks gestation were randomly assigned to standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.~In the NIRS-group 252 (82.9%) out of 303 neonates (gestational-age, median (interquartile-range): 28.9 (26.9-30.6) weeks) survived without cerebral injury until term age or discharge. (primary outcome of the COSGOD III trial)"
89244537|NCT06141733||Control group of the COSGOD III trial|"A multi-center, multi-national randomized-controlled trial was performed in 11 centers in Europe and Canada. Preterm neonates less than 32 weeks gestation were randomly assigned to standard care (control-group) during immediate transition (first 15 minutes after birth) and resuscitation.~In the Control-group 238 (78.5%) out of 304 neonates (gestational-age, median (interquartile-range): 28.6 (26.6-30.6) weeks) survived without cerebral injury until term age or discharge. (primary outcome of the COSGOD III trial)"
89244538|NCT06140043|Active Comparator|2D Monitor screen|Patient consultation with 3D models of bone and skin, seen with a monitor screen
89244539|NCT06140043|Experimental|3D AR|Patient consultation with 3D models of bone and skin, seen in augmented reality trough AR glasses
89244540|NCT06139224|Experimental|HIV-infected ART-suppressed individuals with AUD|Only 10 HIV+ ART+,AUD + individuals will be invited to take part in a prebiotic sub study, which they will take a commercially available prebiotic (FOS) for 10 days
89244541|NCT06139224|Experimental|HIV-infected ART-suppressed individuals with no AUD|Only 10 HIV+ ART+,AUD - individuals will be invited to take part in a prebiotic sub study, which they will take a commercially available prebiotic (FOS) for 10 days
89244542|NCT06138743|Experimental|ARO-DM1|ARO-DM1 for Injection
89244543|NCT06138743|Placebo Comparator|Placebo|(0.9% NaCl)
89244544|NCT06138613|Experimental|Tradipitant Dose A|"See Drug"
89244545|NCT06138613|Experimental|Tradipitant Dose B|"See Drug"
89244546|NCT06136650|Experimental|MK-5684 + hormone replacement therapy (HRT)|Participants receive MK-5684 5 mg by oral tablets twice daily (BID) plus dexamethasone 1.5 mg by oral tablets and fludrocortisone acetate 0.1 mg oral tablet once daily (QD) continuously until disease progression. Hydrocortisone 100 mg (oral or intramuscular [IM]) will also be provided to participants for use as rescue medication.
89244547|NCT06136650|Active Comparator|Alternative next generation hormonal agent (NHA)|Participants receive Abiraterone 1000 mg QD by oral tablets plus Prednisone 5 mg BID by oral tablets or Enzalutamide 160 mg QD by oral tablets until disease progression.
89244548|NCT06136624|Experimental|MK-5684|Participants receive MK-5684 5 mg by oral tablets twice daily (bid) plus dexamethasone 1.5 mg by oral tablets once daily (qd) and 0.1 mg fludrocortisone acetate by oral tablet qd until progression. Hydrocortisone 100 mg (oral or intramuscular [IM]) dose will also be provided to participants for use as rescue medication.
89244549|NCT06136624|Active Comparator|Abiraterone Acetate or Enzalutamide|Participants receive abiraterone 1000 mg qd by oral tablets plus prednisone 5 mg bid by oral tablets or enzalutamide 160 mg qd by oral tablets.
89244550|NCT06136234|Experimental|Experimental Condition with intensive assessment|Caring Contacts plus best available resources, with monthly EMAs during study year
89244551|NCT06136234|Active Comparator|Control Condition with intensive assessment|Best available resources, with monthly EMAs during study year
89244552|NCT06136234|Experimental|Experimental Condition without intensive assessment|Caring Contacts plus best available resources, without monthly EMAs during study year
89244553|NCT06133114|Experimental|S arm: Single drug clonazepam|Single drug clonazepam: 1 mg a day (0.5 mg twice a day) with Treatment As Usual (TAU)
89244554|NCT06133114|Experimental|D arm: Two-drug combination clonazepam/olanzapine|Two-drug combination clonazepam/olanzapine: 1 mg a day (0.5 mg twice a day) of Clonazepam plus 2.5 mg a day of Olanzapine with Treatment As Usual (TAU)
89244555|NCT06133114|Experimental|T arm: Three-drug combination clonazepam/olanzapine/buprenorphine|Three-drug combination clonazepam/olanzapine/buprenorphine: 1 mg a day (0.5 mg twice a day) of Clonazepam plus 2.5 mg a day of Olanzapine plus 2mg a day of Buprenorphine with Treatment As Usual (TAU)
89244556|NCT06133114|No Intervention|Control Group|Participants that will not receive an intervention.
88821566|NCT03504553|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
89244557|NCT06133010|Experimental|mRNA-1647|CMV-seronegative and CMV-seropositive participants will receive 3 intramuscular (IM) injections of mRNA-1647 vaccine on Days 1, 29, and 57.
89244558|NCT06133010|Experimental|Placebo|CMV-seronegative and CMV-seropositive participants will receive 3 IM injections of mRNA-1647 vaccine-matching placebo on Days 1, 29, and 57.
89244559|NCT06132490|Experimental|Valveless 12|Patients scheduled for genitourinary or colorectal robotic surgery, valveless insufflators will be used with 12 mmHg intra-abdominal pressure.
89244560|NCT06132490|Experimental|Valveless 8|Patients scheduled for genitourinary or colorectal robotic surgery, valveless insufflators will be used with 8 mmHg intra-abdominal pressure.
89244561|NCT06132126|Experimental|LY3938577 (Part A)|LY3938577 administered Subcutaneously (SC).
89244562|NCT06132126|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
89244563|NCT06132126|Active Comparator|Insulin degludec (Part A)|Insulin degludec administered SC.
89244564|NCT06132126|Experimental|LY3938577 (Part B)|LY3938577 administered SC.
89244565|NCT06132126|Active Comparator|Insulin degludec (Part B)|Insulin degludec administered SC.
89244566|NCT06131983|Experimental|ARO-DUX4|ARO-DUX4 for Injection
89244567|NCT06131983|Placebo Comparator|Placebo|(0.9%NaCl)
89244571|NCT06128837|Experimental|LY01610|Patients will consecutively receive LY01610 on Day 1 q2wk (every two weeks = one treatment cycle)
89244572|NCT06128837|Active Comparator|Topotecan|Patients will consecutively receive Topotecan on Days 1-5 q3wk(every three weeks = one treatment cycle)
89244573|NCT06126861|Experimental|[14C]LP-168|Using 14C-labeled LP-168 as a marker to investigate the absorption characteristic, as well as to evaluate the metabolism and elimination pathways in healthy subjects
89244574|NCT06126276|Active Comparator|Arm I (neratinib maleate)|Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
89244575|NCT06126276|Experimental|Arm II (neratinib maleate, palbociclib)|Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.
89244576|NCT06125067||Control Group (no peripheral block applied)|No peripheral block was applied to this group and it was accepted as the control group. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group
89244577|NCT06125067||Fascia Iliaca Compartment Block Group|Fascia Iliaca Compartment block was applied to this group under ultrasound guidance. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
89244578|NCT06125067||iPACK Block Group|iPACK block was applied to this group under ultrasound guidance. Standard multimodal analgesia and rescue analgesia according to NRS score were applied to each group.
89244579|NCT06123468|Experimental|Sacituzumab-govitecan|Single arm with Sacituzumab-govitecan 10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W). Patients will receive the treatment for a maximum of 12 months.
89244580|NCT06123351|Experimental|Denneroll protocol|orthotic will be placed under participants' neck. Treatment session time begin with 3 minutes then increase of 2-3 minutes until they reach 15 to 20 minutes in each session.
89244581|NCT06123351|Active Comparator|Traditional protocol|consists of one strengthening exercise for 10 repetitions in 3 sets each, and two stretching exercises with a hold for 20-30 seconds.
89244582|NCT06123351|Active Comparator|Dental management|formed soft occlusal splint will be individually designed for the upper arch of each participant.
89244583|NCT06123104|Experimental|Automatic Tourniquet|Automatic pneumatic tourniquet
89244584|NCT06123104|Active Comparator|Combat Application Tourniquet (CAT)|Combat Application Tourniquet Generation 7
89244585|NCT06122610|Experimental|Participants treated with Lutathera|
89244586|NCT06121336||Ischemic Stroke|100 patients admitted to a specialized stroke service because of an acute ischemic stroke due to large- or medium-vessel occlusion within 9 hours of stroke onset. BD-tau levels and other suggested markers of brain injury (e.g.. NfL) will be assessed every hour from admission to 48 hours after onset. Routinely collected clinical data including from neuroimaging will be collected throughout hospitalization. Clinical follow-up will be performed at 3 months.
89244587|NCT06120608|Experimental|Restriction high bioavailability potassium sources|Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.
89244588|NCT06120608|Active Comparator|Control|Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
89244589|NCT06119711||Short stay|Patients admitted to the ICU with a need for mechanical ventilation of less than 48 hours
89244590|NCT06119711||Long stay|Patients admitted to the ICU with a need for mechanical ventilation of 48 hours or more
89244591|NCT06119685|Experimental|Phase 1: Single Agent IDP-023 - Single Dose|NHL or MM patient treated with a single dose of IDP-023 monotherapy
89244592|NCT06119685|Experimental|Phase 1: Single Agent IDP-023 - Multiple Doses|NHL and MM patients treated with multiple doses of IDP-023 monotherapy
89244593|NCT06119685|Experimental|Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2|NHL and MM patients treated with multiple doses of IDP-023 monotherapy
89244594|NCT06119685|Experimental|Phase 2: Combination IDP-023 plus rituximab|NHL patients treated with multiple doses of IDP-023 in combination with rituximab
89244595|NCT06119685|Experimental|Phase 2: Combination IDP-023 plus daratumumab|MM patients treated with multiple doses of IDP-023 in combination with daratumumab
89244596|NCT06117891||Treatment|Patients with a diagnosis of uHCC treated with first-line AB or another approved 1L-IO combo and in whom a decision to treat with a second-line of systemic therapy has been made by the treating physician at the time of study enrollment
89244597|NCT06116097|Experimental|Nutrition education intervention group|Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
89244598|NCT06116097|No Intervention|Control group|Control group has not taken any nutrition education but has been filled all of the questionnaires, acitivity logs and food diaries.
89244599|NCT06115967|Experimental|AZD6912 Dose 1|Participants will receive AZD6912 Dose 1.
89244600|NCT06115967|Experimental|AZD6912 Dose 2|Participants will receive AZD6912 Dose 2.
89244601|NCT06115967|Experimental|AZD6912 Dose 3|Participants will receive AZD6912 Dose 3.
89244602|NCT06115967|Experimental|AZD6912 Dose 4|Participants will receive AZD6912 Dose 4.
89244603|NCT06115967|Experimental|AZD6912 Dose 5|Participants will receive AZD6912 Dose 5.
89244604|NCT06115967|Experimental|AZD6912 Dose 6|Participants will receive AZD6912 Dose 6.
89244605|NCT06115967|Placebo Comparator|Placebo|Participants will receive Placebo.
89244606|NCT06115967|Experimental|AZD6912 additional cohort 1 -including Japanese Participants|Participants will receive AZD6912.
89244607|NCT06115967|Experimental|AZD6912 additional cohort 2 -including Japanese Participants|Participants will receive AZD6912.
89244608|NCT06114745|Experimental|Dose level 1 SHR-1707|SHR-1707 is administered intravenously.
89244609|NCT06114745|Placebo Comparator|Dose level 1 Placebo|Placebo is administered intravenously.
89244610|NCT06114342||HC group|There were 50 healthy control participants in the HC group.
89244611|NCT06114342||MDD group|There were 84 MDD patients in the MDD group. 50 MDD subjects were enrolled at each acupoint for each test.
89244612|NCT06113471|Experimental|Experimental: Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
89244613|NCT06113471|Placebo Comparator|Placebo|Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
89244614|NCT06113445|Experimental|Experimental: Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
89244615|NCT06113445|Placebo Comparator|Placebo|Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
89244616|NCT06113341||IDegLira + Dose Check|Participants will be treated with commercially available Xultophy® (IDegLira) used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
89244617|NCT06112756|Experimental|Elinzanetant arm|Participants will take Elinzanetant
89244618|NCT06112756|Placebo Comparator|Placebo arm|Participants will take elinzanetant matching placebo
89244619|NCT06112158|Experimental|Education Intervention|"The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~While the training program prepared by the researchers was applied to the intervention group, it was planned that no application would be applied to the nonınterventıon group.~In this study, the training period was determined in two ways:~First; In face-to-face training, each training is planned as four sessions of 45 minutes. Each session is planned with a different purpose and application.~Latter; The system will continue to be open during the training provided through web support and face-to-face training, but the system will be closed to access immediately after the face-to-face training is completed."
89244620|NCT06112158|No Intervention|nonıntervention Group|Until the research is finalized, no intervention will be made. After the research is finalized, the system will be opened to the nonınterventıon group and the university in general to contribute to their knowledge and awareness.
89244621|NCT06111872|Experimental|Ketamine - Midazolam arm|Initial IV Ketamine of 0.5mg/kg with IV Midazolam 0.02mg/kg given over 1 minute. If depth of sedation not adequate, to give another bolus of IV ketamine 0.25mg/kg after 2 minutes with IV Midazolam 0.01mg/kg. If depth of sedation not adequate, to give another bolus of IV Ketamine 0.25mg/kg after 2 minutes and IV Midazolam 0.01mg/kg. Failure of sedation: inadequate sedation for the intention to treat: patient will be arranged for MAC (monitored anaesthesia care) with anaesthesia team
89244622|NCT06111872|Active Comparator|Midazolam - Pethidine arm|Initial IV Midazolam 0.05mg/kg given over 1 minute with IV Pethidine 0.7mcg/kg. If depth of sedation not If adequate, to give another bolus of IV Midazolam 0.02mg/kg after 2 minutes and IV Pethidine 0.7mcg/kg. If depth of sedation not adequate, to give another bolus of IV Midazolam 0.02mg/kg after 2 minutes. Failure of sedation: inadequate sedation for the intention to treat: patient will be arranged for MAC (monitored anaesthesia care) with anaesthesia team.
89244623|NCT06111248|No Intervention|Control group|638 patients receiving the usual, standard management for anesthesia when undergoing surgery lasting > 60 min and involving intermediate or major non-cardiac risk.
89244624|NCT06111248|Experimental|Experimental group|638 patients undergoing surgery lasting > 60 min and involving intermediate or major non-cardiac risk who have been managed by staff trained in the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
89244625|NCT06108440|Experimental|action observation training group|Patients in Group A will receive action observation training with conventional treatment.
89244626|NCT06108440|Active Comparator|motor imagery training group|Patients in Group B will receive motor imagery with conventional treatment.
89244627|NCT06108089||patients treated with CRT|Two hypoxia MR scans will be performed, one at pre-treatment and one at 2 weeks into CRT. Patients receive FMISO-PET/CT scans prior to the initiation of CRT.
88821567|NCT03504553|No Intervention|Control|Normal operating room environment.
89244628|NCT06108089||patients treated with primary surgical resection.|Hypoxia MR scan and FMISO-PET/CT scan will be performed prior to the treatment (surgery). Surgical specimen of excised primary tumor will undergo IHC staining.
89244629|NCT06106828|Experimental|Satralizumab|In the Part I period, participants will receive satralizumab every 4 weeks (q4w) followed by proptosis response-based individualized treatment in Part II of the study
89244630|NCT06106828|Placebo Comparator|Placebo|In the part I period, participants will receive placebo every 4 weeks (q4w) followed by proptosis response-based individualized treatment in part II of the study
89244631|NCT06102902|Experimental|Treatment (ZEN003694, cetuximab, encorafenib)|Patients receive ZEN003694 PO QD on days 1-28 of each cycle, cetuximab IV over 120 minutes on days 1 and 15 of each cycle, and encorafenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial. Patients may also undergo biopsy at screening and on study.
89244632|NCT06102005|Experimental|SAR443765 Dose1 interval 1|Participants will receive Dose 1 of SAR443765 (subcutaneous injection) according to established dosing interval 1
89244633|NCT06102005|Experimental|SAR443765 Dose 1 interval 2|Participants will receive Dose 1 of SAR443765 (subcutaneous injection) according to established dosing interval 2
89244634|NCT06102005|Experimental|SAR443765 Dose 2 interval 1|Participants will receive Dose 2 of SAR443765 (subcutaneous injection) according to established dosing interval 1
89244635|NCT06102005|Experimental|SAR443765 Dose 2 interval 2|Participants will receive Dose 2 of SAR443765 (subcutaneous injection) according to established dosing interval 2
89244636|NCT06102005|Placebo Comparator|Placebo|Participants will receive placebo (subcutaneous injection) according to established dosing intervals corresponding to Dose 1 and Dose 2
89244637|NCT06100874|Experimental|Sacituzumab Govitecan + Trastuzumab (or Biosimilar)|"Participants will complete the following:~Baseline visit with assessments.~CT or MRI scans every 9 weeks for 27 weeks and then every 12 weeks.~Echocardiogram or MUGA scan every 12 weeks for 24 weeks and then every 16 weeks.~Cycle 1 through Cycle 2:~Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.~Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.~Cycle 2:~Day 1: Optional tumor biopsy~Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.~Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.~Cycle 3 through End of Treatment:~Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.~Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.~End of treatment:~Follow up visits every 6 months."
89244638|NCT06099782|Experimental|Arm A: MK-3475A SC →Pembrolizumab IV|In the treatment crossover period, participants will receive MK-3475A SC followed by pembrolizumab IV. After completion of the treatment crossover period, participants will enter the treatment continuation period, where they will receive their preferred intervention for up to ~1 year for renal cell carcinoma (RCC) and melanoma and for up to ~2 years for non-small cell lung cancer (NSCLC).
89244639|NCT06099782|Active Comparator|Arm B: Pembrolizumab IV→MK-3475A SC|In the treatment crossover period, participants will receive pembrolizumab IV followed by MK-3475A SC. After completion of the treatment crossover period, participants will enter the treatment continuation period, where they will receive their preferred intervention for up to ~1 year for RCC and melanoma and for up to ~2 years for NSCLC.
89244640|NCT06098144|Experimental|Tobacco Quit-line (TQL) Group|Participants will be referred to the TQL and will be followed up for up to 12 months.
89244641|NCT06098144|Experimental|Brief Behavioral Counseling Group|Participants will receive one brief behavioral counseling session and be followed up for 12 months.
89244642|NCT06098144|Experimental|Intensive Behavioral Counseling Group|Participants will receive four behavioral counseling sessions and be followed up for 12 months.
89244643|NCT06097650|Experimental|cold snare polypectomy|cold snare polypectomy for resection of small pedunculated colorectal polyps
89244644|NCT06097650|Active Comparator|hot snare polypectomy|hot snare polypectomy for resection of small pedunculated colorectal polyps
89244645|NCT06097507|Experimental|Asthma patients|"Low risk educational intervention. The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.~Also 5 selected asthma providers will be asked to fill a questionnaire on their perspectives on the climate impact of inhalers and their approach to inhaler rotation. This may also be supplemented with a phone interview"
89244646|NCT06097494||People with Vitiligo|Children and adults with new onset Vitiligo registered with OPCRD during the study period.
89244647|NCT06097494||People without Vitiligo|Children and adults without Vitiligo registered with OPCRD during the study period
89244648|NCT06094816|Experimental|Salt Resistant Adults|Adults who experience minimal BP change during dietary sodium challenge
89244649|NCT06094816|Experimental|Salt Sensitive|Adults who experience increased BP (mean arterial pressures >5mmHg) during dietary sodium challenge
89244650|NCT06092099|Experimental|Intervention|Subjects wear the sensor part of the Change indicator system during a 15-day period.
89244651|NCT06091813|No Intervention|No Directed Dietary Intervention|Control group without any directed dietary modifications
89244652|NCT06091813|Experimental|Medical Nutrition Therapy|
89244653|NCT06091111|Experimental|Intervention arm|Subjects is randomized to start with either a period of reference product use followed by a cross over to using the study device or the opposite sequence, starting with the study device and then cross over to using the reference device.
89244654|NCT06090539|Experimental|Part A1|Single Agent
89244655|NCT06090539|Experimental|Part A2|Combination Treatment
89244656|NCT06090539|Experimental|Part B1|Single Agent
89244657|NCT06090539|Experimental|Part B2|Combination Treatment
89244658|NCT06090162|Experimental|experimental diagnostic test|Lumbar punction at diagnosis. CSF and blood samples will be assessed by the two diagnostic tests (CSF ctDNA and conventional test (CC/FC))
89244659|NCT06089161|Active Comparator|Standard of Care Group|Participants in this group receive the standard of care treatment for sleep apnea for up to six months.
89244660|NCT06089161|Experimental|Personalized OSA Treatment Group|Participants in this group receive personalized OSA treatment for sleep apnea for up to six months.
89244661|NCT06088199|Experimental|Apremilast|Apremilast will be dosed by participant's body weight and administered twice daily (BID) in the form of oral tablets, approximately 12 hours apart, without restriction of food or drink.
89244662|NCT06087224|Experimental|Teleneonatology group|Study eligible neonates cared for by the community hospital team with telemedicine consultation by a neonatologist from the regional neonatal intensive care unit (NICU).
89244663|NCT06087224|No Intervention|Control group|Study eligible neonates cared for by the community hospital team per the site's usual practice of care.
89244664|NCT06087107|Experimental|High Intensity Spinal Decompression Exercises|Participants in this group will receive high intensity spinal decompression exercises
89244665|NCT06087107|Active Comparator|Eldoa|Participants in this group will receive Eldoa.
89244666|NCT06086340||Palbociclib + AI|Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy in SEER-Medicare
89244667|NCT06086340||AI alone|Adult metastatic breast cancer patients who initiated an aromatase inhibitor (alone) as first line therapy
89244668|NCT06085560|Active Comparator|Usual Care Message|"Participants selecting a colorectal cancer screening will receive usual care from the FQHC."
89244669|NCT06085560|Active Comparator|Implementation Intention Intervention: Standard Message|"Participants selecting a colorectal cancer screening will receive implementation intention messages in addition to the usual care from the FQHC."
89244670|NCT06085560|Experimental|Implementation Intention Intervention: Culturally-Targeted Message|"Participants selecting a colorectal cancer screening will receive culturally-targeted implementation intention messages in addition to the usual care from the FQHC."
89244671|NCT06085547|Active Comparator|White Rural: General|"White rural participants receive general consumption video information about SARS-CoV-2 antibody testing."
89244672|NCT06085547|Experimental|White Rural: Rural-Targeted|White rural participants receive rural-targeted video information about SARS-CoV-2 antibody testing.
89244673|NCT06085066|Active Comparator|Conventional Ultrafiltration alone on Cardiopulmonary bypass|Conventional ultrafiltration was used on a cardiopulmonary bypass procedure for patients who underwent open heart surgery
89244674|NCT06085066|Active Comparator|Conventional Ultrafiltration followed by Modified Ultrafitration on Cardiopulmonary bypass|Modified ultrafiltration was used following the conventional ultrafiltration on cardiopulmonary bypass procedure for patients who underwent open heart surgery
89244675|NCT06084845|Active Comparator|Arm A (chemoradiation)|Patients receive cisplatin or carboplatin IV over 30-60 minutes QW for 6 doses with concurrent IMRT and IGRT five days a week for 30-33 fractions in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, PET-CT, and/or chest x-ray during screening and follow-up. Patients may also undergo blood sample collection during follow-up.
89244676|NCT06084845|Experimental|Arm B (chemoradiation, xevinapant)|Patients receive cisplatin or carboplatin IV over 30-60 minutes QW for 6 doses with concurrent IMRT and IGRT five days a week for 30-33 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive xevinapant PO on days 1-14 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, PET-CT, and/or chest x-ray during screening and follow-up. Patients may also undergo blood sample collection during follow-up.
89244677|NCT06084598|Experimental|BMS-986446|
89244678|NCT06084598|Experimental|Placebo|
89244679|NCT06081361|Experimental|Short-Term Regimen|"Intervention will be determined based on Fluoroquinolones(FQs) resistance.~For those sensitive to FQs: BDQ DLM CZD LFX(MFX) for 6 months~For those resistant to FQs: BDQ DLM CZD CFZ for 6 months"
89244680|NCT06081361|Active Comparator|Standard Regimen|"Intervention will be determined based on Fluoroquinolones(FQs) resistance.~For those sensitive to FQs: BDQ LZD LFX(MFX) CS CFZ regimen for 6 months, then LFX(MFX) CS CFZ for 12 months~For those resistant to FQs: LFX(MFX) will be replaced by Pto, PZA, PAS or EMB"
89244681|NCT06080763||Non-Responders|Individuals who do not respond to physical therapy are determined by the absence of significant improvements, with no change in pain or function exceeding 50%, and with an absolute change of less than 20%.
89244682|NCT06080763||Responders|Individuals who respond to physical therapy are determined by the presence of significant improvements, with changes in pain or function exceeding 50%, and with an absolute change of more than 20%.
89244683|NCT06079918|Active Comparator|MMS with 30 mg iron|MMS with standard UNIMMAP formulation of 15 micronutrients, including 30 mg of iron
89244684|NCT06079918|Experimental|MMS with 45 mg iron|MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients
89244685|NCT06079918|Experimental|MMS with 60 mg iron|MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients
89244686|NCT06079346|Active Comparator|OT-101 + mFOLFIRINOX|OT-101 IV dosed on Days 4-7 plus mFOLFIRINOX (dl-LV 400 mg/m2, irinotecan 180 mg/m2 and oxaliplatin 85 mg/m2 followed by a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycle
89244687|NCT06079346|Placebo Comparator|mFOLFIRINOX Only|mFOLFIRINOX (dl-LV 400 mg/m2, irinotecan 180 mg/m2 and oxaliplatin 85 mg/m2 followed by a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycle
89244688|NCT06077760|Experimental|V940 + Pembrolizumab|Participants will receive 1 mg of V940 via intramuscular (IM) injection once every 3 weeks for up to 9 doses PLUS 400 mg of pembrolizumab via intravenous (IV) infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner.
89244689|NCT06077760|Active Comparator|Placebo + Pembrolizumab|Participants will receive V940-matched placebo via IM injection once every 3 weeks for up to 9 doses PLUS 400 mg of pembrolizumab via IV infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner.
89244690|NCT06077669|Experimental|Methylphenidate - low dose|5 mg of methylphenidate
89244691|NCT06077669|Experimental|Methylphenidate - high dose|10 mg of methylphenidate
89244692|NCT06077669|Placebo Comparator|Placebo|placebo
89244693|NCT06077175|Experimental|intervention group|
89244694|NCT06077175|No Intervention|Control group|
89244695|NCT06074237|Experimental|Interactive Vaccine Education Program for resident providers|Resident providers in pediatric, pediatric/medicine and family medicine clinics will be given interactive educational interventions using online training modules combined with standardized patient encounters to teach and refine vaccine counseling skills
89244696|NCT06074133||Indeterminate Pulmonary Nodules|A combined biomarker model (hs-CYFRA 21-1, radiomics, Mayo) score will be obtained to estimate potential clinical utility compared to the Mayo Model.
89244708|NCT06067568|Experimental|Part 1, Dose A|Participants will receive a single dose of Lutikizumab Dose A.
89244709|NCT06067568|Experimental|Part 1, Dose B|Participants will receive a single dose of Lutikizumab Dose B.
89244710|NCT06067568|Experimental|Part 2|Han Chinese participants will receive a single dose of Lutikizumab.
89244711|NCT06066957|Experimental|Letermovir|"Will include those participants who receive letermovir for CMV prophylaxis as provided through the clinical trial. The exposed group will be ascertained prospectively over a one-year period (the post-intervention period)."
89244719|NCT06059027||Plain Cohort|Plain Community Children
89244720|NCT06059027||Madison Cohort with Asthma|Madison-area Children with Asthma
89244721|NCT06059027||Madison Cohort without Asthma|Madison-area Children without Asthma
89244722|NCT06059027||Madison Cohort with Active Respiratory Illness|Madison-area children with active respiratory illness, with or without asthma
89244723|NCT06058845|Active Comparator|10% Tamarindus indica fruit pulp juice|Participants will follow a daily consumption of 600ml of Tamarindus indica fruit juice containing 10% Tamarindus indica fruit pulp for 30 days
89244724|NCT06058845|Experimental|30% Tamarindus indica fruit pulp juice|Participants will follow a daily consumption of 600ml of Tamarindus indica fruit juice containing 30% Tamarindus indica fruit pulp for 30 days
89244725|NCT06058663|Experimental|Cohort I: (Y90, tremelimumab on day 1, cycle 1, durvalumab)|Patients receive transarterial Y90 radioembolization and tremelimumab IV over 1 hour on day 1 of cycle 1 and durvalumab IV over 1 hour on day 1 of each cycle. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo mapping angiography during screening as well as CT and MRI or PET/CT during screening and on study. Patients also undergo blood sample collection throughout the trial and may undergo tumor biopsy during screening and on study.
89244726|NCT06058663|Experimental|Cohort II: (Y90, tremelimumab on day 14, cycle 1, durvalumab )|Patients receive transarterial Y90 radioembolization on day 1 of cycle 1 and receive tremelimumab IV over 1 hour on day 14 of cycle 1 and durvalumab IV over 1 hour on day 14 of each cycle. Cycles repeat every 42 days for cycle 1 and then every 28 days for cycles 2-24 in the absence of disease progression or unacceptable toxicity. Patients also undergo mapping angiography during screening, as well as CT and MRI or PET/CT during screening and on study. Patients also undergo blood sample collection throughout the trial and may undergo tumor biopsy during screening and on study.
89244727|NCT06058559|Experimental|Sunflower Lecithin|Total 4800 mg sunflower lecithin per day taken in 4 softgel capsules
89244728|NCT06058559|Placebo Comparator|Olive Oil|Total 4000 mg olive oil per day taken in 4 softgel capsules
89244729|NCT06057675|Active Comparator|Control|The control arm will receive the current standard of care. Before incision, local anesthetic (1% lidocaine with 1:100,000 epinephrine) will be injected subcutaneously into the surgical site. The surgical team will inject approximately 0.8mL per square centimeter of the surgical site area (defect area and undermined tissue area).
89244730|NCT06057675|Experimental|Experimental|The experimental arm will receive local anesthetic (1% lidocaine with 1:100,000 epinephrine) and TXA (1g/10mL) in a 9:1 volume ratio. This will be injected subcutaneously into the surgical site. The surgical team will inject approximately 0.8mL per square centimeter of the surgical site area (defect area and undermined tissue area).
89244731|NCT06053580|Experimental|Valsartan|Valsartan 40mg capsule taken twice daily for 24 weeks.
89244732|NCT06053580|Placebo Comparator|Placebo|Placebo capsule taken twice daily for 24 weeks.
89244733|NCT06046859|Experimental|Subjects randomized to get Fluoxetine therapy|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
89244734|NCT06046859|Active Comparator|Subjects randomized to Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
89244735|NCT06046001|Experimental|AirWaze|AirWaze - easy and advanced tools for CBCT guided lung interventions
89244736|NCT06044337|Experimental|BIIB059|Participants will receive BIIB059 subcutaneously, once every 4 weeks up to Week 100.
89244737|NCT06043505|Experimental|Interventional Strategy: STOPFLUID Algorithm|Fluid management is optimised using the specific echographic hemodynamic algorithm ('STOPFLUID') of this study described during the first 4 days of septic shock. Fluid bolus will not be administered in case of increased left ventricle filling pressures; fluid challenge will be performed based on dynamic indices and fluid depletion will be considered on the basis of Lung UltraSound (LUS) assessment.
89244738|NCT06043505|No Intervention|Standard Strategy|Fluid management will be handled according to standard care, without using transthoracic echocardiography (TTE) during the first 4 days of septic shock management. Haemodynamic monitoring including pulmonary artery catheter, transpulmonary thermodilution, or any other device will be left at the physician's discretion. TTE will be allowed in the standard group only for excluding cardiac tamponade in case of clinical suspicion (one or more of the following signs: jugular distension, pulsus paradoxus)
89244739|NCT06043271|Experimental|The EMPOWER Program|The EMPOWER Program (Sung et al., 2021) is a web-based, self-administered SSI for parents that takes about 30 minutes to complete. The SSI includes 5 elements based on the components of CBT.
89244740|NCT06043271|No Intervention|Waitlist as Usual|Participants in the control group will have their children remain on the waitlist until they are assigned to a therapist in the clinic.
89244741|NCT06041204|Active Comparator|Letrozole Group|Participants randomized to letrozole group will take 5mg tablets orally daily for 5 days starting on day 3 of cycle. Dose can be adjusted up to 7.5mg based on ovulation response, maintained for subsequent cycles. Treatment continues for up to 6 ovulatory cycles or until pregnancy occurs. Ovulation assessed by follicular monitoring and progesterone. Compliance monitored by pill counts and diary. Routine antenatal care if pregnant. Adverse effects monitored per guidelines. Participants followed for multiple pregnancies. Tablets taken at same time each day. Maximum treatment period is 6 months.
89244742|NCT06041204|Experimental|Letrozole plus levothyroxine|Participants randomized to this group will take letrozole tablets at same dose and schedule as letrozole only group. In addition, they will take levothyroxine tablets orally once daily. Levothyroxine dose will start at 25mcg and be titrated based on TSH level, with a target TSH in the normal range. Participants will take levothyroxine at approximately same time each day. Letrozole dosing and schedule as described for other group. Treatment continues for up to 6 ovulatory cycles or until pregnancy occurs. Ovulation assessed by follicular monitoring and progesterone. Compliance monitored by pill counts, TSH levels and diary. Routine antenatal care if pregnant. Adverse effects monitored per guidelines. Participants followed for multiple pregnancies. Maximum treatment period is 6 months.
89244743|NCT06039241||AD patients treated with dupilumab|Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their severe AD (6-11 years) or moderate to severe AD (adult and adolescent patients ≥12 years of age) based on the patient's medical requirements and standards of best medical practice.
89244744|NCT06039020||Anti-human thymocyte immunoglobulin, equine|Patients with moderate to severe aplastic anemia who receive ATGAM (Anti-human thymocyte immunoglobulin, equine)
89244745|NCT06038149||Low PH probability|Individuals identified as being of a low risk of pulmonary hypertension on routine echocardiography through existing British Society of Echocardiography/ European Society of Cardiology guidelines will undergo a research echocardiogram on the day of their planned right heart catheter.
89244746|NCT06038149||Intermediate PH probability|Individuals identified as being of an intermediate risk of pulmonary hypertension on routine echocardiography through existing British Society of Echocardiography/ European Society of Cardiology guidelines will undergo a research echocardiogram on the day of their planned right heart catheter.
89244747|NCT06037733|Experimental|CTV-omitted|CTV was omitted for primary tumor radiotherapy for advanced NSCLC who responded to therapy with immunotherapy and chemotherapy.
89244748|NCT06037733|Active Comparator|CTV-delineated|CTV was delineated for primary tumor radiotherapy for advanced NSCLC who responded to induction therapy with immunotherapy and chemotherapy.
89244749|NCT06036134|Experimental|Baseline and Digital Storytelling (DST)|Once participants complete the consent, they will be asked to complete a baseline assessment using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DST arm. The intervention group participants will watch the four selected digital stories about COVID-19 vaccine experiences among Hispanic parents of children. Each story was made with voice, images, and sound (3-5 minutes each). Intervention group participants will complete the Time 2 (T2) online survey immediately after the DST intervention. Two months later, the investigators will contact all participants and ask them to complete another follow-up (T3) assessment of participants' vaccine hesitancy and COVID-19 vaccination behaviors (since T1 and T2).
89244750|NCT06036134|Active Comparator|Baseline and Control|Once participants complete the consent, they will be asked to complete a baseline assessment using the web-based data collection platform, Research Electronic Data Capture before the random assignment to control arm. Control group participants will receive a CDC COVID-19 Vaccine Information Sheet appropriate for their child's age before completing the T2 assessment. Two months later, the investigators will contact all participants and ask them to complete another follow-up (T3) assessment of participants' vaccine hesitancy and COVID-19 vaccination behaviors (since T1 and T2).
89244751|NCT06034860|Experimental|Part A- Dose Escalation Monotherapy|"Part A- Dose escalation of MT-8421 monotherapy in patients with selected advanced solid tumors.~The assigned dose level of MT-8421 will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e. on day 1, day 8, day 15, and day 22 of each 28-day cycle)."
89244752|NCT06034860|Experimental|Part A- Dose Escalation Combination Therapy|"Part A- Dose escalation of MT-8421 in combination with nivolumab in patients with selected advanced solid tumors.~The assigned dose level of MT-8421 will be given as an intravenous (IV) infusion over about 30 minutes prior to the infusion of 480 mg nivolumab. MT-8421 will be given on the same day every week (i.e. on day 1, day 8, day 15, and day 22 of each 28-day cycle). Nivolumab will be given on the first day of each cycle beginning at cycle 2."
89244753|NCT06034860|Experimental|Part B Dose Expansion Monotherapy|"Part B- Dose expansion of MT-8421 monotherapy in patients with selected advanced solid tumors.~Part B monotherapy will include two expansion groups: Group B1 (NSCLC) and group B2 (HCC).~The assigned dose level of MT-8421 determined in Part A will be given as an intravenous (IV) infusion over about 30 minutes on the same day every week (i.e. on day 1, day 8, day 15, and day 22 of each 28-day cycle)."
89244754|NCT06034860|Experimental|Part B Dose Expansion Combination|"Part B- Dose escalation of MT-8421 in combination with nivolumab in patients with selected advanced solid tumors.~Part B combination therapy will include two expansion groups: Group B3 (Melanoma) and Group B4 (RCC).~The assigned dose level of MT-8421 determined in Part A will be given as an intravenous (IV) infusion over about 30 minutes prior to the infusion of 480 mg nivolumab. MT-8421 will be given on the same day every week (i.e. on day 1, day 8, day 15, and day 22 of each 28-day cycle). Nivolumab will be given on the first day of each cycle beginning at cycle 2."
89244757|NCT06033092|Active Comparator|Low dose tamoxifen|Tamoxifen 10 mg (1 tablet) every other day for 6 months.
89244758|NCT06033092|Active Comparator|Low dose tamoxifen + Intermittent Caloric Restriction|Tamoxifen 10 mg (1 tablet) every other day for 6 months + 5:2 diet (5 days/week at regular energy intake+2 days a week at an average 75% energy deficit)
89244759|NCT06033092|Placebo Comparator|Lifestyle intervention|Step counter device
89244760|NCT06033092|Active Comparator|Lifestyle Intervention + Intermittent Caloric Restriction|Step counter device + 5:2 diet (5 days/week at regular energy intake+2 days a week at an average 75% energy deficit)
89244761|NCT06032208|Experimental|Patients receiving Hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regular scheduled dialysis sessions to remove larger middle molecules.
89244762|NCT06032052|Experimental|Metastatic NSCLC patients over 65 years old|In metastatic NSCLC patients over 65 years old, we employed gemcitabine or paclitaxel or vinorelbine plus immunotherapy for squamous cell carcinoma. Paclitaxel or pemetrexed plus immunotherapy are available for non-squamous and non-small cell lung cancer.
89244763|NCT06031363|Active Comparator|Regular dosage group|Give indomethacin suppository 100mg anal plug immediately after operation.
89244764|NCT06031363|Experimental|Low dosage group|Give indomethacin suppository 50mg anal plug immediately after operation.
89244765|NCT06031363|Experimental|High dosage group|Give indomethacin suppository 150mg anal plug immediately after operation.
89244766|NCT06030037|Experimental|R-FMT + pembrolizumab/lenvatinib (Arm A)|"Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity as described).~Lenvatinib will be administered at 20 mg daily.~R-FMT (induction) will be administered at C1D1 and C4D1 via colonoscopy.~R-FMT (maintenance) will be repeated every 9 weeks starting with C4D1 via sigmodoscopy."
89244767|NCT06030037|Active Comparator|pembrolizumab/lenvatinib (Arm B)|"Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity as described).~Lenvatinib will be administered at 20 mg daily."
89244768|NCT06028828|Experimental|Patients with AML, ALL, MDS, CML, NHL, HD, CLL requiring AHSCT|Patients will be treated with allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on their Hematopoietic Cell Transplant - Composite Risk (HCT-CR), age, and Karnofski performance status (KPS).
89244769|NCT06026813||Healthy controls|Patients without diabetes who do not have foot wounds or history of amputation
89244770|NCT06026813||Patients with Diabetic Neuropathy|Patients with diagnosed diabetes and neuropathy who do not have foot wounds or history of amputation.
89244771|NCT06026371|Experimental|Group I (fecal microbiota transplant)|Patients receive fecal microbiota capsules PO QD for 7 days
89244772|NCT06026371|Placebo Comparator|Group II (Placebo)|Patients receive placebo PO QD for 7 days
89244773|NCT06025578|Experimental|BMS-986278 Dose 1|
89244774|NCT06025578|Experimental|BMS-986278 Dose 2|
89244775|NCT06025578|Placebo Comparator|BMS-986278 Placebo|
89244776|NCT06023615|Experimental|Intervention Group|Usual Care + mHealth/Telehealth
89244777|NCT06023615|No Intervention|Control Group|Usual Care + Attention Control
89244778|NCT06023589|Experimental|Tezepelumab|Participants will be receiving tezepelumab subcutaneous injection
89244779|NCT06023589|Placebo Comparator|Placebo|Participants will be receiving placebo through a subcutaneous injection
89244781|NCT06022861|Experimental|LY01015+ Fluorouracil + Cisplatin|
89244782|NCT06022861|Active Comparator|Opdivo® + Fluorouracil + Cisplatin|
89244783|NCT06021288|Experimental|Intervention Group|CRRT will be established with a draining dose (effluent dose) of 10-15ml/kg/h in pursuit of establishing a controlled azotaemia.
89244784|NCT06021288|Active Comparator|Control Group|"Standard of Care:~CRRT will be established with a draining dose (effluent dose) of 25-30ml/kg/h"
89244785|NCT06020430|Experimental|CTV-omitted|CTV was omitted for the radical radiotherapy for locally advanced NSCLC who responded to induction therapy with immunotherapy and chemotherapy.
89244786|NCT06020430|Active Comparator|CTV-delineated|CTV was delineated for the radical radiotherapy for locally advanced NSCLC who responded to induction therapy with immunotherapy and chemotherapy.
89244789|NCT06007053|Experimental|ReACT Intervention|At the end of the baseline visit, half of the participants will be randomized to receive Retraining and Control Therapy (ReACT)
89244790|NCT06007053|Active Comparator|Supportive Therapy|At the end of the baseline visit, half of the participants will be randomized to receive supportive therapy
89244791|NCT06007053|No Intervention|Healthy Control|Healthy controls are ages 12-18 with no significant comorbid medical or mental health conditions. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
89244792|NCT06006559|Experimental|EYU688|EYU688 administered by oral route
89244793|NCT06006559|Placebo Comparator|Placebo|Matching placebo
89244794|NCT06005181|Experimental|Music listening then piano training|Participants will listen to music for 10 minutes per day for 12 weeks. After one week of assessments, participants will practice piano for 10 minutes per day for 12 weeks.
89244795|NCT06005181|Experimental|Piano training then music listening|Participants will practice piano for 10 minutes per day for 12 weeks. After one week of assessments, participants will listen to music for 10 minutes per day for 12 weeks.
89244796|NCT06003712|Experimental|Mindfulness Exercise Group|Subjects will participate in a one-month mindfulness breathing-exercise program
89244797|NCT06003686|Experimental|Paralyzed Veterans of America (PVA) Cardio-Metabolic Disease (CMD) Consumer Guide Group|Hard paper copy of as well as an electronic copy of the guide will be provided to subjects and study staff will provide a general review of the contents of the guide with subjects during their education sessions. Participants will be in this group for 6 months.
89244798|NCT06003686|Active Comparator|WebMD Group|Subjects will be introduced to WebMD and its contents. A brief document will be provided that includes site summary and website. Study staff will provide a very brief overview of the site. Participants will be in this group for 6 months.
89244799|NCT06001372|Experimental|Arm 1|Three 2.5-3 hour Ketamine Assisted Psychotherapy sessions, each 2-7 days apart
89244800|NCT05997290|Experimental|SSA: Group 1|Participants 12 years of age and older, COVID-19 vaccine-experienced will receive 30 µg of BNT162b2 (Omi XBB.1.5) at Visit 1.
89244801|NCT05997290|Experimental|SSB: Group 2|Participants 12 years of age and older who were previously exposed to SARS-CoV-2 and are COVID-19 vaccine-naïve will receive 30 μg of BNT162b2 (Omi XBB.1.5) at Visit 1
89244802|NCT05994521|Active Comparator|ERCP alone|ERCP procedure alone and management of MGOO will be on a wait-and-see approach, using endoscopic interventions performed only if obstruction is clinically diagnosed
89244803|NCT05994521|Experimental|ERCP + ProEUS-GE|ERCP with prophylactic eus-guided gastroenterostomy
89244804|NCT05988645|Experimental|MiWEndo + colonoscope|All patients will be explored with MiWEndo as an accessory to colonoscopy
89244805|NCT05985135|Experimental|Type 1 Diabetes Mellitus (T1DM) Insulin Deprived|Subjects will have their insulin infusions replaced with saline and have blood draws to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
89244806|NCT05985135|Experimental|Type 1 Diabetes Mellitus (T1DM) Insulin Treated|Subjects will continue their baseline insulin infusion while maintaining a target blood glucose range. Blood draws will be obtained to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
89244807|NCT05985135|Experimental|Type 1 Diabetes Mellitus (T1DM) Insulin-Treated with Hyperglycemia|Subjects will be continue their baseline insulin infusion for 2 hours and then receive an intravenous dextrose infusion to maintain elevated blood sugar levels. Blood draws will be obtained to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
89244808|NCT05985135|Other|Non-Diabetic Controls|Subjects will have blood draws to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
89244809|NCT05985135|Experimental|Diabetes after Total Pancreatectomized (DATP) Insulin Treated|Subjects will continue their baseline insulin infusion while maintaining a target blood glucose range. Blood draws will be obtained to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
89244810|NCT05985135|Experimental|Diabetes after Total Pancreatectomized (DATP) Insulin Deprived|Subjects will have their insulin infusions replaced with saline and have blood draws to monitor glucose levels along with a muscle biopsy following consumption of a Jell-O with Amino acids.
89244811|NCT05982730|Experimental|PD - individuals with Parkinson Disease, either male or female|Individuals, aged 50-85, with a clinical diagnosis of idiopathic Parkinson Disease, either male or female, with moderate disease stage presenting balance alterations (Hoehn or Yahr stage III)
89244812|NCT05980754||Healthy group|No intervention
89244813|NCT05980754||pre diabetic patients|No intervention
89244814|NCT05980754||T2DM patients|No intervention
89244815|NCT05980429|Experimental|Music Therapy, Prescribed|During weeks 2-5, participants in the prescribed music group underwent a minimum of 15 minutes (mandatory) of nightly self-administered music intervention immediately before bedtime.
89244816|NCT05980429|Experimental|Music Therapy, Self-selected|During weeks 2-5, participants in the self-selected music group underwent a minimum of 15 minutes (mandatory) of nightly self-administered music intervention immediately before bedtime.
89244817|NCT05980429|No Intervention|No Music Therapy Control|During weeks 2-5, participants in the no-music group continued as usual.
89244818|NCT05979441|Experimental|EFG PH20 SC|participants receiving efgartigimod PH20 SC on top of background treatment
89244819|NCT05976828|Experimental|First Dose Level|Dose Cohort 1: IBRX -042 1e11 virus particles per dose
89244820|NCT05976828|Experimental|Second Dose Level|Dose Cohort 2: IBRX-042 5e11 virus particles per dose
89244821|NCT05976828|Experimental|De-escalation Dose Level|Dose Cohort -1: IBRX-042 5e10 virus particles per dose
89244822|NCT05975073|Experimental|Part 1: Dose Exploration of AMG 193 Combined With IDE397|Participants will receive escalating doses of AMG 193 and IDE397 administered orally (PO) in cycles of 21 days.
89244823|NCT05975073|Experimental|Part 2: Dose Expansion of AMG 193 Combined With IDE397|AMG 193 and IDE397 will be administered PO in cycles of 21 days.
89244824|NCT05970510|Experimental|Toludesvenlafaxine Hydrochloride Sustained-release Tablets 80 mg group|orally once a day
89244825|NCT05970510|Experimental|Toludesvenlafaxine Hydrochloride Sustained-release Tablets 160 mg group|orally once a day
89244826|NCT05970510|Sham Comparator|Placebo|orally once a day
89244827|NCT05967871|Experimental|Fecal Microbiota Transpant|Participants will receive a Fecal Microbiota transplant Infusion via participants' existing enteral feeding tubes or via elective upper endoscopy (with infusion into the duodenum). Most patients with SBS at MCH and HSC have an existing enteral feeding tube (gastrostomy or jejunostomy tube).
89244828|NCT05964712||Population # 1|De novo patients with acromegaly, diagnosed according to Endocrine Society guidelines, aged equal or above 18 years old
89244829|NCT05964712||Population # 2|Acromegalic patients with different disease status (active disease despite ongoing therapies, controlled disease under medical therapy, and disease remission), aged equal or above 18 years old
89244830|NCT05962151|Experimental|NAL ER|NAL ER, tablets, 27 mg QD to BID, 54 mg BID, 108 mg BID
89244831|NCT05962151|Placebo Comparator|Placebo|Placebo, tablets, 0 mg QD to BID, 0 mg BID, 0 mg BID
89244832|NCT05960097|Experimental|Part A, Group A: CV0701 High dose|Participants receive high dose of CV0701.
89244833|NCT05960097|Experimental|Part A, Group B: CV0701 Medium dose|Participants receive medium dose of CV0701.
89244834|NCT05960097|Experimental|Part A, Group C: CV0701 Low dose|Participants receive low dose of CV0701.
89244835|NCT05960097|Experimental|Part A, Group D: CV0601 High dose|Participants receive high dose of CV0601.
89244836|NCT05960097|Active Comparator|Part A, Group E: Control vaccine|Participants receive control vaccine.
89244837|NCT05960097|Experimental|Part B, Condition 1: Baseline-control|Participants receive one dose of CV0801.
89244838|NCT05960097|Experimental|Part B, Condition 2: Intermediate storage|Participants receive one dose of CV0801.
89244839|NCT05960097|Experimental|Part B, Condition 3: Maximum storage conditions|Participants receive one dose of CV0801.
89244840|NCT05956821|Experimental|SIACI of cetuximab and bevacizumab|Participants in this group will receive Cetuximab and Bevacizumab infusion into an artery each month for up to approximately one year.
89244841|NCT05949788||Anemia group|The very low birth weight (VLBW) infants meet the diagnostic criteria of neonatal anemia during hospitalization between January 2020 and January 2023.
89244842|NCT05949788||Control group|The very low birth weight (VLBW) infants are included without anemia during hospitalization between January 2020 and January 2023.
89244843|NCT05947851|Experimental|Nemtabrutinib + Venetoclax|Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 Day 1 (C2D1) up to 2 years post C2D1 or until progressive disease (PD) or discontinuation. A cycle = 4 weeks.
89244844|NCT05947851|Active Comparator|Venetoclax + Rituximab|Participants will receive venetoclax oral tablets at doses from 20 mg up to 400 mg daily starting at C1D1 on 4-week cycles up to 2 years and rituximab or biosimilar at 375 mg/m^2 up to 500 mg/m2 intravenous infusion once per 28-day cycle starting at C2D1, for 6 total cycles. Treatment will continue until progressive disease (PD) or discontinuation.
89244845|NCT05945615|Experimental|Oxymetazoline 0.1% ophthalmic drops|Patients will use once daily in affected eye. Drops are provided in single use vials.
89244846|NCT05945615|Placebo Comparator|Preservative free lubricating drops|Patients will use once daily in affected eye. Drops are provided in single use vials.
89244847|NCT05945537|Experimental|A (INI-822)|Participants will receive INI-822 orally once daily.
89244848|NCT05945537|Placebo Comparator|B (Placebo)|Participants will receive placebo orally once daily.
89244849|NCT05943522||Asciminib|Patients prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice
89244850|NCT05943106|Experimental|Durvalumab + BCG|Participants will receive Durvalumab for 13 cycles every 4 weeks (q4w) for a maximum 12 months. All participants will receive BCG (supplied by the site) intravesically, as induction weekly for 6 weeks. Patients will subsequently receive BCG for maintenance for 3 weekly doses at 3,6,12,18, and up to 24 months, at the physician's discretion.
89244851|NCT05941741|Experimental|Low-dose RT plus ICI|Patients will receive induction chemotherapy plus low-dose radiotherapy and immuce checkpoint inhibitor then followed by concurrent chemoradiotehrapy.
89244852|NCT05941741|Active Comparator|IC+CCRT|Patients will receive induction chemotherapy plus concurrent chemoradiotehrapy.
89244853|NCT05941585|Experimental|mitoxantrone hydrochloride liposome injection combined with of cytarabine|Patients will receive mitoxantrone hydrochloride liposome injection combined with standard-dose of cytarabine.
89244854|NCT05941585|Experimental|mitoxantrone hydrochloride liposome with cytarabine and homoharringtonine|Patients will receive mitoxantrone hydrochloride liposome injection combined with intermediate-dose of cytarabine and homoharringtonine.
89244855|NCT05941585|Experimental|mitoxantrone hydrochloride liposome injection combined with cytarabine and venetoclax|Patients will receive mitoxantrone hydrochloride liposome injection with cytarabine and venetoclax.
89244856|NCT05940324|Experimental|Ketamine + Naltrexone|"OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion. fMRI will be acquired before, during, and after infusion.~Oral naltrexone 50 mg will be administered before the infusion."
89244857|NCT05940324|Placebo Comparator|Ketamine + Placebo|"OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion. fMRI will be acquired before, during, and after infusion.~An oral inactive placebo will be administered before the infusion."
89244858|NCT05940324|No Intervention|Healthy Volunteers|Healthy volunteers will have one fMRI scan visit.
89244859|NCT05939583|Experimental|Treatment Group|The treatment group will receive US, TENS, IR and exercises in addition to shock waves therapy. Patients will receive 3 sessions per week for 4 weeks
89244860|NCT05939583|Experimental|Control Group|Control group will receive US, TENS, IR and exercises. Patients will receive 3 sessions per week for 4 weeks
89244861|NCT05936567|Experimental|Povorcitinib Dose A|Participants will receive dose A of povorcitinib for a 12 week period, followed by dose A for an additional 24 week period.
89244862|NCT05936567|Experimental|Povorcitinib Dose B|Participants will receive dose B of povorcitinib for a 12 week period, followed by dose B for an additional 24 week period.
89244863|NCT05936567|Experimental|Povorcitinib Dose C|Participants will receive dose C of povorcitinib for a 12 week period, followed by dose C for an additional 24 week period.
89244864|NCT05936567|Experimental|Placebo followed by Povorcitinib Dose A, B, or C|Participants will receive placebo for a 12 week period, followed by randomization to either Dose A, Dose B, or Dose C for an additional 24 week period.
89244865|NCT05936359|Experimental|Part 1a Dose Escalation Cohort Disease Group A - with MF|INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles as monotherapy to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE[s]). Participants with myelofibrosis (MF) will enroll in this group.
89244866|NCT05936359|Experimental|Part 1a Dose Escalation Cohort Disease Group A - with ET|INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles as monotherapy to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE[s]). Participants with with essential thrombocythemia (ET) will enroll in this group.
89244867|NCT05936359|Experimental|Part 1a: Dose Escalation Cohort Disease Group B - with TGB-MF SubOpt R|INCA033989 will be administered at a protocol defined starting regimen in 28- day cycles and will allow for the evaluation of INCA033989 in combination with ruxolitinib to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE[s]). Participants with myelofibrosis (MF) exhibiting suboptimal response (SubOpt R) will enroll in this group.
89244868|NCT05936359|Experimental|Part 1b: Dose Expansion - with MF|INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) myelofibrosis MF will enroll in this group.
89244869|NCT05936359|Experimental|Part 1b: Dose Expansion - with TGB-MF SubOpt R|INCA033989 will be administered as an add-on therapy in combination with ruxolitinibat at the RDE(s) identified during Part 1a. Participants with treatment Group B (TGB) MF SubOpt R will enroll in this group.
89244870|NCT05936359|Experimental|Part 1b: Dose Expansion - with ET|INCA033989 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) essential thrombocythemia (ET) will enroll in this group.
89244871|NCT05936359|Experimental|Part 1c: Dose Expansion|INCA033989 will be administered at the dose level found to exhibit an overall positive benefit/risk as monotherapy or as combination therapy with Ruxolitinib. Participants with myelofibrosis (MF) will enroll in this group. The participants enrolled in the monotherapy arm will be offered the option to crossover to combination therapy with ruxolitinib if a suboptimal response to monotherapy is observed after 12 weeks.
89244872|NCT05935280|Placebo Comparator|Room temperature injection|Pain induced by intradermal injection of fluid with room temperature.
89244873|NCT05935280|Placebo Comparator|Cold temperature injection 1|Pain induced by intradermal injection of increasingly cold fluid down to 3°C.
89244874|NCT05935280|Active Comparator|Cold temperature injection with lidocain|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including lidocain (unspecific sodium channel blocker).
89244875|NCT05935280|Placebo Comparator|Cold temperature injection 2|Pain induced by intradermal injection of increasingly cold fluid down to 3°C.
89244876|NCT05935280|Experimental|Cold temperature injection with PF-05105679|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-05105679 (specific TRPM8 antagonist).
89244877|NCT05935280|Experimental|Cold temperature injection with A-967079|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including A-967079 (specific TRPA1 antagonist).
89244878|NCT05935280|Experimental|Cold temperature injection with PF-05089771|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-05089771 (specific Nav1.7 antagonist).
89244879|NCT05935280|Experimental|Cold temperature injection with PF-06305591|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-06305591 (specific Nav1.8 antagonist).
89244880|NCT05935280|Experimental|Cold temperature injection with PF-05105679, A-967079, PF-05089771, PF-06305591|Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-05105679 (TRPM8)-, A-967079 (TRPA1)-, PF-05089771 (Nav1.7)-, PF-06305591 (Nav1.8)- antagonist.
89244881|NCT05933252|Experimental|Augmented reality (AR)|"Augmented reality (AR)~Participants will view the real world through a device's camera and application (app) but adds virtual or digital characters and items to the image"
89244882|NCT05932940|Experimental|GATT group|detection of incidence of Descemet membrane detachment post gonioscopy-assisted transluminal trabeculotomy by anterior segment optical coherence tomography in patients with open angle glaucoma.
89244883|NCT05932225|Experimental|Systane Complete Preservative-Free|1-2 drops in each eye four times a day for 30 days
89244884|NCT05931783|Active Comparator|skeletonized harvesting technique|In skeletonized harvesting technique, only the left internal artery itself is harvested.
89244885|NCT05931783|Active Comparator|pedicled harvesting technique|In pedicled harvesting technique the left internal thoracic artery, it's accompanying veins and parts of the endothoracic fascia is harvested, creating a 1-2 cm broad pedicle.
89244886|NCT05930275||Upadacitinib|Participants will receive upadacitinib as prescribed by their physician according to local label.
89244887|NCT05927350||Survey|Participants will complete a one-time survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
89244888|NCT05925556|Experimental|Communal Coping Intervention|"The intervention consists of a single session brief communal coping intervention followed by 7 days of intervention prompts delivered via text message to help couples generalize what they have learned into their daily life. There are 9 components to the intervention:~establishment of rapport~shared stressor recollection~communal coping education~application of appraisal to diabetes~we-statements to reframe diabetes as shared~facilitated discussion between couple members to identify each person's needs with active listening~collaborative implementation intentions~EMI text messaging for 7 days following intervention"
89244889|NCT05925556|No Intervention|Diabetes Education Attention Control|These participants will receive diabetes education via a 15-20 minute videotape (as well the intervention group)
89244890|NCT05924256|Experimental|Arm 1|This arm for HER2-alteration salivray gland carcinoma.
89244891|NCT05924256|Experimental|Arm 2|This arm for AR-postive salivray gland carcinoma.
89244892|NCT05924256|Experimental|Arm 3|This arm for salivray gland carcinoma without HER-2 alteration or AR-postive.
89244893|NCT05924256|Experimental|Arm 4|This arm for low HER2 expression salivray gland carcinoma.
89244894|NCT05924126||septic patients who recieved appropriate empiric antibiotics|
89244895|NCT05924126||septic patients who recieved inappropriate empiric antibiotics|
89244896|NCT05923099|Experimental|Dose regimen 1|Dose A every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
89244897|NCT05923099|Experimental|Dose regimen 2|Dose B every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
89244898|NCT05923099|Experimental|Dose regimen 3|Dose A every week from Week 0 to Week 3, then dose C every 2 weeks from Week 4 to Week 16
89244899|NCT05923099|Experimental|Dose regimen 4|Dose C every week from Week 0 to Week 3, then dose D every 2 weeks from Week 4 to Week 16
89244900|NCT05923099|Placebo Comparator|Placebo regimen|Placebo every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
89244901|NCT05916157||ABBV-951|Participants will receive ABBV-951 as prescribed by their physician.
89244902|NCT05913037|Experimental|FCN-159|Experimental: FCN-159 Dosage form:tablet Specification: 1mg，4mg Dose: FCN-159 8 mg, orally, once daily Method of administration: Oral
89244903|NCT05913037|Placebo Comparator|placebo|Experimental: placebo Dosage form:tablet Specification: 1mg，4mg Dose: placebo 8 mg, orally, once daily Method of administration: Oral
89244904|NCT05910476|Active Comparator|rosuvastatin/ezetimibe 20/10mg|rosuzet 10/20mg
89244905|NCT05910476|Active Comparator|atorvastatin/ezetimibe 40/10mg|NB zet 10/40mg
89244906|NCT05910164||A) administration starting with prefilled syringe|"- Group A = Phase 1 then phases 2, 3, 4~The study protocol consists of 4 different stages~Phase 1: injection by pre-filled syringe by a state-certified nurse (IDE)~Phase 2: pen injection guided (thanks to the detailed information) by the IDE~Phase 3: injection by pen in autonomy supervised by the IDE (can only interfere in case of non-compliance with the injection protocol) = Learning phase~Phase 4: injection by pen in complete autonomy, patient alone"
89244907|NCT05910164||B) administration starting with prefilled pen|"- Group B = Phase 2, 3, 4 then phase 1~The study protocol consists of 4 different stages~Phase 1: injection by pre-filled syringe by a state-certified nurse (IDE)~Phase 2: pen injection guided (thanks to the detailed information) by the IDE~Phase 3: injection by pen in autonomy supervised by the IDE (can only interfere in case of non-compliance with the injection protocol) = Learning phase~Phase 4: injection by pen in complete autonomy, patient alone"
89244908|NCT05908630||Normothermic drowning patients with OHCA.|First in-hospital temperature measurement (using any probe) within 6 hours after hospital admission ≥35C.
89244909|NCT05908630||Hypothermic drowning patients with OHCA.|First in-hospital temperature measurement (using any probe) within 6 hours after hospital admission <35C.
89244910|NCT05907941|Experimental|ciNPT|
89244911|NCT05907941|Active Comparator|Conventional tape dressings|
89244912|NCT05907304|Experimental|Naporafenib + Trametinib|Naporafenib (ERAS-254) 200 mg twice daily (BID) Trametinib 1 mg once daily (QD)
89244913|NCT05906628|Experimental|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
89244914|NCT05906628|Placebo Comparator|Vehicle|Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
89244915|NCT05904210||Patients treated by SEVENFACT®|"Patients that initiated treatment with SEVENFACT® in real-world clinical care in the USA will be eligible.~Data from eligible patients' medical charts, bleeding diaries, and medication logs will be extracted from the time of initiation of SEVENFACT® treatment and for each bleeding episode and surgery or invasive procedure requiring treatment with SEVENFACT® or for prophylaxis, up until the data collection at the investigational site."
89244916|NCT05902988|Experimental|Dose Escalation: Dose Escalation Cohorts|Subjects will be enrolled at various doses and/or schedules of VLS-1488. These Dose Escalation Cohorts will be utilized to identify the MTD and to select dose levels for Dose Expansion.
89244917|NCT05902988|Experimental|Dose Escalation: Backfill Cohorts|Additional subjects may be enrolled at any dose level that does not meet de-escalation or elimination rules per the BOIN design. These Backfill Cohorts will be utilized to build additional data to support selection of doses and/or tumor types for further study in Dose Expansion.
89244918|NCT05902988|Experimental|Dose Expansion: Exploration Cohorts|Subjects with a selected single tumor type will be randomized 1:1 into Exploration Cohorts at two or more dose levels of interest. A subset of subjects will have additional assessments to examine the potential for VLS-1488 to interact with other drugs and the effect of food on VLS-1488 absorption.
89244919|NCT05902988|Experimental|Dose Expansion: Development Cohorts|Subjects with other tumor types will be enrolled at a single dose level of interest. These Development Cohorts will be utilized to examine the preliminary efficacy of VLS-1488 in various tumor types.
89244920|NCT05899673|Experimental|Fazirsiran 200 mg|Participants who are currently taking part in or who have completed their treatment in parent studies AROAAT2001 (NCT03945292) and AROAAT2002 (NCT03946449) may rollover in this study to receive fazirsiran, 200 milligrams (mg), injection, subcutaneously on Day 1 and once every 12 weeks (Q12W) thereafter for up to 96 weeks or until participant withdraws from the study or the sponsor terminates the study.
89244921|NCT05898867||Responders|"Participants from the trial Reinforcement of Treatment Response in Knee Osteoarthritis: A Randomised Trial will be defined as responders if they belong to the upper quartile of the change to the pain Visual Analogue Scale (VAS) (those who had the greatest positive changes)"
89244922|NCT05898867||Non-responders|"Participants from the trial Reinforcement of Treatment Response in Knee Osteoarthritis: A Randomised Trial will be defined as non-responders if they belong to the lower quartile of the change to the pain Visual Analogue Scale (VAS) (those who had the smallest change)."
89244923|NCT05895474|Experimental|Focused Ultrasound Dose #1|Focused Ultrasound will be administered using high frequency stimulation as condition 1. Stimulation will last 1-10 minutes.
89244924|NCT05895474|Experimental|Focused Ultrasound Dose #2|Focused Ultrasound will be administered using medium frequency stimulation as condition 2. Stimulation will last 1-10 minutes.
89244925|NCT05895474|Experimental|Focused Ultrasound Dose #3|Focused Ultrasound will be administered using low frequency stimulation as condition 4. Stimulation will last 1-10 minutes.
89244926|NCT05895474|Sham Comparator|Focused Ultrasound Dose #4|Focused Ultrasound will be administered using the sham condition.
89244927|NCT05894590||Cohort 1|Participants received 2 doses of mRNA-1273 vaccine approximately 4 weeks apart.
89244928|NCT05894525||Cohort 1|Participants received 2 doses of mRNA-1273 vaccine approximately 4 weeks apart.
89244929|NCT05894499||Cohort 1|Participants received 2 doses of mRNA-1273 vaccine approximately 4 weeks apart.
89244930|NCT05891561|Experimental|Pertuzumab|4 cycles of taxane, Pertuzumab, Trastuzumab
89244931|NCT05891119|Experimental|Rocatinlimab and CYP450 Substrates|"A single oral dose of a CYP450 substrates cocktail which will include caffeine, metoprolol, midazolam, warfarin (with vitamin K), and omeprazole will be administered on Day 1.~A single dose of rocatinlimab will then be administered on Days 8, 22, 36, 64, and 92.~A single oral dose of CYP450 substrates cocktail in combination with a single dose of rocatinlimab will then be administered on Day 120."
89244932|NCT05890742|Experimental|Phase Ib Experimental group|In Phase Ib Experimental group，subjects will receive two cycles of neoadjuvant immunotherapy: the first cycle of IBI310 (1mg/kg) & Sintilimab (200mg) and the second cycle of Sintilimab (200mg) only.Followed by radical surgery for colon cancer.
89244933|NCT05890742|Active Comparator|Phase Ib Control group|In Phase Ib Control group，subjects will receive two cycles of neoadjuvant immunotherapy with 200 mg of sintilimab per cycle, followed by radical surgery for colon cancer.
89244934|NCT05890742|Experimental|Phase III Experimental group|In Phase III Experimental group，subjects will receive two cycles of neoadjuvant immunotherapy: the first cycle of IBI310 (1mg/kg) & Sintilimab (200mg) and the second cycle of Sintilimab (200mg) only. Followed by radical surgery for colon cancer. Adjuvant chemotherapy will be given or not according to the pathological stage after surgery.
89244935|NCT05890742|Active Comparator|Phase III Control group|In Phase III Control group, subjects will receive radical surgery without neoadjuvant therapy. Adjuvant chemotherapy will be given or not according to the pathological stage after surgery.
89244936|NCT05887635|Experimental|Study arm- RF Vapor Ablation arm|This is a single arm study. All enrolled patients will be included in this arm
89244937|NCT05886920|Experimental|D3S-002|Dose Escalation, D3S-002 administered orally.
89244938|NCT05883956|Active Comparator|ABBA|Cycle 1: Oral decitabine/cedazuridine; Cycle 2: Subcutaneous azacitidine; Cycle 3: Subcutaneous azacitidine; Cycle 4: Oral decitabine/cedazuridine
89244939|NCT05883956|Active Comparator|BAAB|Cycle 1: Subcutaneous azacitidine; Cycle 2: Oral decitabine/cedazuridine; Cycle 3: Oral decitabine/cedazuridine; Cycle 4: Subcutaneous azacitidine
89244940|NCT05883111|Other|Trans men and non-binary people with a cervix|Participants will have a clinician-collected cervical screening sample and then collect the following self-samples for research: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection.
89244941|NCT05883111|Experimental|Trans women and non-binary people|Participants will collect the following self-samples for research in the clinic: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection. Participants will collect the following self-samples for research at home: Vaginal swab, Anal swab, and Oral rinse sample for the detection of HPV detection.
89244942|NCT05879822|Experimental|Part 1: INCB099280 Dose 1|Participants will receive INCB099280 dose 1 twice daily (BID) for up to 2 years.
89244943|NCT05879822|Experimental|Part 1: INCB099280 Dose 2|Participants will receive INCB099280 dose 2 twice daily (BID) for up to 2 years.
89244944|NCT05879822|Experimental|Part 1: INCB099280 Dose 3|Participants will receive INCB099280 dose 3 twice daily (BID) for up to 2 years
89244945|NCT05879822|Experimental|Part 2: INCB099280 Dose selected from Part 1|Participants will receive INCB099280 dose selected from Part 1 twice daily (BID) for up to 2 years.
89244946|NCT05874414|Experimental|GNS561+Trametinib|"Phase 1b Dose Finding Patients will receive GNS561 (50mg QD; 100mg QD; 150mg; 200mg QD) and trametinib (2mg QD; 1.5mg QD; 1mg QD) in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD) of the combination.~Experimental:~Phase 2a Patients will receive GNS561 and trametinib at the recommended dose of the combination determined during Phase 1b"
89244947|NCT05873712|Experimental|Treatment (zanubrutinib, liso-cel)|Patients receive zanubrutinib PO, undergo leukaphereis, and receive fludarabine IV, cyclophosphamide IV, and liso-cel IV on study. Patients also undergo BM biopsy and lymph node biopsy at screening and follow up, and undergo collection of blood samples and CT, PET/CT, and/or MRI throughout the trial.
89244948|NCT05873244|Experimental|Experiment arm|"Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~Geptanolimab at 3mg/kg given intravenously every 2 weeks"
89244949|NCT05873244|Other|Control arm|"Clinicians' choice of TKI at corresponding recommended dosage:~Lenvatinib at 8mg daily for patients with body weight <60kg or 12mg daily with body weight ≥ 60kg~Sorafenib at 400mg twice daily"
89244950|NCT05871008|Experimental|IA3-CP with SDoH|Assess IA3-CP with SDoH and provide feedback (provider & patient)
89244951|NCT05871008|Experimental|IA3-CP only|Assess IA3-CP only without added SDoH and provide feedback (provider & patient)
89244952|NCT05871008|No Intervention|Control - usual care|Usual care: Assess IA3-CP without providing the feedback report
89244953|NCT05869851|Experimental|Brace Treatment|Patients randomized to the brace treatment group will be treated with a Pavlik harness for a minimum of six weeks.
89244954|NCT05869851|No Intervention|Active Monitoring|Patients randomized to the control group will undergo observation only.
89244955|NCT05868122|Experimental|Acetaminophen/Naproxen Sodium Fixed Combination|Participants will receive oral doses of two Acetaminophen/Naproxen Sodium Fixed Combination tablets taken with water. Multiple doses will be administered over a 48-hour period.
89244956|NCT05868122|Placebo Comparator|Placebo|Participants will receive oral doses of two placebo tablets taken with water. Multiple doses will be administered over a 48-hour period.
89244958|NCT05862272|Experimental|Relugolix Combination Tablet|Participants will receive relugolix combination therapy orally once daily for 48 months.
89244959|NCT05861999|Experimental|Risdiplam|Participants will receive risdiplam orally once daily for 72 weeks (Treatment Period). The Treatment Period will be followed by a 1-year Treatment Extension Period for a total study duration of 120 weeks (approximately 2.5 years) for each participant enrolled.
89244960|NCT05861453|Experimental|Epeleuton 4g/day|
89244961|NCT05858580|Experimental|Intervention Group|"Intervention participants will receive approximately 25 hours of programming (over a 6-month period) related to the promotion of physical activity and healthy diet through:~16 self-contained, parent-guided activity kits,~9 one-on-one health coach/support sessions in-person or virtual by a trained health coach,~unlimited access to a resource toolbox."
89244962|NCT05858580|No Intervention|Control Group|"Control group programming consists of:~6 parent-guided activity kits focused on STEM activities,~6 monthly check-in calls to support retention.~The investigators will use Home Science Lab STEM kits designed for English- and Spanish-speaking children aged 6-11 years. The STEM kits do not include any physical health content. Kits will be mailed monthly to the participants' home. To maximize retention in the control group, staff will contact participants each month to confirm the kit was received, encourage completion of the kits, ask about their experience, and answer questions."
89244963|NCT05853575|Experimental|Adagrasib 600mg BID|Adagrasib 600mg BID without regard to food
89244964|NCT05853575|Experimental|Adagrasib 400mg BID|Adagrasib 400mg BID with food
89244965|NCT05853042||Cohort|Study population: Prospective, observational cohort study of consecutive patients (goal, 1500 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
89244966|NCT05852132|Experimental|PPV+PRP|PPV was performed for severe non-proliferative diabetic retinopathy with PRP.
89244967|NCT05852132|Active Comparator|Pars plana vitrectomy(PPV)|Vitrectomy was performed for severe non-proliferative diabetic retinopathy, but panretinal photocoagulation(PRP) was not performed
89244968|NCT05852132|Placebo Comparator|Panretinal photocoagulation(PRP)|Only PRP was used for severe non-proliferative diabetic retinopathy.
89244969|NCT05851625|Placebo Comparator|Placebo|The control group was given a placebo press needle acupuncture (using plaster) with standard medical therapy for CINV prevention.
89244970|NCT05851625|Experimental|Acupuncture|The intervention group was given press needle acupuncture with standard medical therapy for CINV prevention.
89244971|NCT05851443|Placebo Comparator|Inhaled Corticoseroid Long Acting Beta-Agonist(ICS-LABA) + placebo|Participants will receive stable background therapy with ICS-LABA in combination with placebo once daily (QD) for 24 weeks during the placebo-controlled period. Participants will be allocated to 1 of 3 doses of povorcitinib during the extension period of 28 weeks
89244972|NCT05851443|Experimental|ICS-LABA + povorcitinib Dose 1|Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 1 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks
89244973|NCT05851443|Experimental|ICS-LABA + povorcitinib Dose 2|Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 2 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks
89244974|NCT05851443|Experimental|ICS-LABA + povorcitinib Dose 3|Participants will receive stable background therapy with ICS-LABA in combination with povorcitinib dose 3 once daily (QD) for 24 weeks during the placebo-controlled period, and Participants will continue to take the same dose of povorcitinib during the extension period of 28 weeks
89244975|NCT05851144|Experimental|Intervention|Intervention arm involves participants to the Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula with multi-prong interventions.
89244976|NCT05851144|No Intervention|Control|Participants in the control group follow regular routine with physical activities, food service, and parental engagment.
89244977|NCT05850546|Experimental|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission. The prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on alternate days for the next 6 weeks; therapy is then discontinued.
89244978|NCT05850546|Other|Routine Therapy|The prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on alternate days for the next 6 weeks; therapy is then discontinued.
89244979|NCT05847998|Experimental|measurement of capillary refill time|measurement in a cohort of ICU adult patients with acute circulatory failure
89244980|NCT05845645|Experimental|Part A|Study participants enrolled and randomized to this arm will receive a single dose of UCB0599 in 3 different formulations according to a pre-specified sequence during both Treatment Periods in the absence of esomeprazole, and the Treatment Periods in the presence of esomeprazole.
89244981|NCT05845645|Experimental|Part B|Study participants enrolled to this arm will receive pre-specified doses of UCB0599 or Placebo in a pre-specified sequence during the Treatment Period.
89244982|NCT05845333||Stimulant Use Severity High|
89244983|NCT05845333||Stimulant Use Severity Medium|
89244984|NCT05845333||Stimulant Use Severity Low|
89244985|NCT05845333||Psychopathic Traits High|
89244986|NCT05845333||Psychopathic Traits Medium|
89244987|NCT05845333||Psychopathic Traits Low|
89244988|NCT05845333||Community (Healthy) Controls|
89244989|NCT05844995|Experimental|Acetaminophen /Naproxen Sodium|Participants with age group 12 to less than (<) 17 years who undergone a non-surgical orthodontic procedure will enroll and receive fixed dose combination of acetaminophen/naproxen sodium tablet orally on baseline (Day 0).
89244990|NCT05844878|Experimental|Dental anxiety management intervention group|in this arm; the patients will under go combination of 2 anxiety management techniques by using of behavioral therapeutic management including; Cognitive behavioral therapy (CBT) by using Distraction technique, and Mindfulness technique by using of relaxation breathing with muscle relaxation, during dental treatment through 30 minutes. then after 3 months those patients will be followed up for re measurement of anxiety level by using the same modified dental anxiety scale questionnaire.
89244991|NCT05844878|No Intervention|control group|in this arm; the patients will under go dental treatment for the same duration as the intervention arm treatment, but without applying the anxiety management techniques. Subsequently, each patient will be followed up after 3 months, similar to the intervention group.
89244992|NCT05844332||LUTATHERA|patients treated with LUTATHERA Injection
89244993|NCT05842954|Experimental|KLU156|KLU156 once daily (QD) for 3 days under fed conditions (light meal).
89244994|NCT05842954|Active Comparator|Coartem|Coartem twice a day (BID) for 3 days under fed conditions.
89244995|NCT05841537||Risankizumab|Participants will receive risankizumab as prescribed by their physician according to local label.
89244996|NCT05841056|Active Comparator|Amiodarone maintenance therapy|Amiodarone 200 mg daily for four weeks
89244997|NCT05841056|No Intervention|No Amiodarone maintenance therapy|No ongoing Amiodarone maintenance therapy for four weeks
89244998|NCT05840224|Experimental|Phase 1a: GS-4528 Monotherapy Dose Escalation|Participants will receive escalating doses of GS-4528 monotherapy to determine the maximum tolerated dose.
89244999|NCT05840224|Experimental|Phase 1a: GS-4528 Monotherapy Dose Expansion|Participants will receive GS-4528 monotherapy at the dose determined in the escalation phase.
89245000|NCT05840224|Experimental|Phase 1b:Dose Escalation of GS-4528 in Combination With Anti-PD-1 Monoclonal Antibody (zimberelimab)|Participants will receive escalating doses of GS-4528 in combination with anti-PD1 monoclonal antibody (zimberelimab) to determine the maximum tolerated dose of GS-4528 as a combination therapy.
89245001|NCT05839951||Cohort R-T|Patients with mCRC who started with regorafenib first, followed by TAS+/-Bev (Bevacizumab) without other therapies in between.
89245002|NCT05839951||Cohort T-R|Patients with mCRC who started with TAS+/-Bev first, followed by regorafenib, without other therapies in between.
89245003|NCT05839951||Cohort TAS+BEV|Patients with mCRC who received combo use of TAS+BEV.
89245004|NCT05838625|Experimental|Digital Therapeutic A|Evaluate the efficacy and safety of digital therapeutic A as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
89245005|NCT05838625|Experimental|Digital Therapeutic B|Evaluate the efficacy and safety of digital therapeutic B as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.
89245006|NCT05838443|Active Comparator|Self-directed mindfulness|
89245007|NCT05838443|Active Comparator|Provider-directed mindfulness|
89245008|NCT05838443|Other|Conventional care|Control Comparator
89245009|NCT05838417||Cohort-1|Individuals who identify as female at birth age 39-49 without a prior breast cancer diagnosis (including DCIS or LCIS) or known BCRA1/2 gene mutations.
89245010|NCT05837936||Total intravenous anesthesia (TIVA)|TIVA is achieved without inhalational agents and may be performed in cases where patients have an intravenous line in place prior to induction of anesthesia
89245011|NCT05837936||Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA is a modification of TIVA in the setting where a patient does not tolerate the insertion of an intravenous line prior to induction of anesthesia. The patient undergoes induction of anesthesia with sevoflurane and transition to Propofol IV anesthesia for maintenance once the intravenous line is in place and discontinues the inhalational agent, sevoflurane.
89245012|NCT05833048|Experimental|Rectus Sheath Block|
89245013|NCT05833048|No Intervention|No block|
89245014|NCT05832450||No intervention|Perioperative data of patient undergoing elective brain tumor resection without requirements of red cell concentrate transfusion.
89245015|NCT05828589|Experimental|Part 1 (Cohort A1): Dose escalation in patients with B-cell non-Hodgkin lymphoma (NHL)|Participants with R/R B-cell NHL (including diffuse large B-cell lymphoma [DLBCL], follicular lymphoma [FL], marginal zone lymphoma [MZL], transformed B-cell NHL (B-NHL), and Richter's transformation to DLBCL) will receive BGB-21447 once a day.
89245016|NCT05828589|Experimental|Part 1 (Cohort B): Dose escalation in R/R CLL/SLL participants with low tumor burden|Participants with relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) will receive BGB-21447 once a day.
89245017|NCT05828589|Experimental|Part 2 (Cohort A2): BGB-21447 Monotherapy Dose Expansion|Participants will receive BGB-21447 with up to two dose levels from Cohort A1 for further evaluation of safety and efficacy.
89245018|NCT05826678|Active Comparator|Participants on CGM|Participants in this group will be offered a CGM device for glucose monitoring, with training and educational materials provided in either English or Chinese, according to the participant's preference.
89245019|NCT05826678|Placebo Comparator|Participants on Finger-stick only|Participants in this group continue standard fingerstick self-monitoring of blood glucose (FSGM) as per standard care protocol. They will also receive educational materials provided in either English or Chinese, according to the participant's preference.
89245020|NCT05822219|Active Comparator|COVID-19 vaccine and booster training|Group training involving COVID-19 vaccine and booster information, including background, development, and myths.
89245021|NCT05822219|Experimental|COVID-19 vaccine and booster training with extra undisclosed component|Group training involving COVID-19 vaccine and booster information, including background, development, and myths. Contains extra training component that is undisclosed until the end of the study so as not to introduce bias.
89245022|NCT05820035|Experimental|Experiment group|Patients treated with PFA catheter.
89245023|NCT05818358|Active Comparator|Black Beans (cooked)|At one of the three visits, participants will consume a ¾ cup of cooked black beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 2 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 3 visits have been completed.
89245024|NCT05818358|Active Comparator|Whole Wheat Grain (cooked)|At one of the three visits, participants will consume a ¾ cup of cooked whole wheat grain. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 2 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 3 visits have been completed.
89245025|NCT05818358|Placebo Comparator|White Rice (cooked)|At one of the three visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 2 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 3 visits have been completed.
89245026|NCT05816395|Experimental|RHH646|RHH646
89245027|NCT05816395|Placebo Comparator|Placebo|RHH646 placebo
89245028|NCT05813327|Experimental|Phase I: ADI-PEG 20 + ifosfamide + radiotherapy|Patients will receive ADI-PEG 20 on Day -7 of Cycle 1 and Days 1, 8, and 15 of each of three 21-day cycles, and ifosfamide per dose escalation/de-escalation schedule on days 1 through 5 of each cycle. Mesna will be given on days 1 through 5 with ifosfamide as supportive care. Patients will also receive radiotherapy (XRT) starting on Week 4.
89245029|NCT05813327|Experimental|Phase II: ADI-PEG 20 + ifosfamide + radiotherapy|Patients will receive ADI-PEG 20 on Day -7 of Cycle 1 and Days 1, 8, and 15 of each of three 21-day cycles, and ifosfamide per the RP2D determined in Phase I of the study on days 1 through 5 of each cycle. Mesna will be given on days 1 through 5 with ifosfamide as supportive care. Patients will also receive radiotherapy (XRT) starting on Week 4.
89245030|NCT05810753|Experimental|SPOONful|Participants will be asked to consume one ONS with their breakfast, and one with their lunch, daily for three weeks.
89245031|NCT05810753|No Intervention|Control|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks without any precise instruction regarding when to consume the ONS during the day (standard care).
89245032|NCT05809934|Experimental|AZD2693 dose 1|Participants will receive AZD2693 dose 1
89245033|NCT05809934|Experimental|AZD2693 dose 2|Participants will receive AZD2693 dose 2
89245034|NCT05809934|Placebo Comparator|Placebo|Participants in this arm will receive placebo
89245035|NCT05809596|Other|Device Group|WATCHMAN FLX Pro LAAC Device Implantation
89245036|NCT05809401|Experimental|PRAGMACOM|An experimental treatment for pragmatic disorders characterized by activities that focus on conversational rules and on understanding figurative language. The treatment is already tested on Schizophrenic patients.
89245037|NCT05809401|Active Comparator|Standard Neuropsychological Treatment|The standard treatment for neuropsychological disorders is administered to RHD, and TBI patients in the IRCCS San Camillo Hospital, which consists mostly of attentional training.
89245038|NCT05804045|Experimental|Part 1/Part 2/Part 3- Pimicotinib(ABSK021)/ Pimicotinib(ABSK021)|Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 and continue on the open-label Pimicotinib(ABSK021) in Part 2 and Part 3.
89245039|NCT05804045|Placebo Comparator|Part 1- Placebo/ Pimicotinib(ABSK021)|Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 and have option to receive the open-label Pimicotinib(ABSK021) in Part 2.
89245040|NCT05803408|Experimental|Early introduction of gluten free oats|Early introduction of oats (starting GF oats immediately after the diagnosis, within 3 months)
89245041|NCT05803408|Active Comparator|Late introduction of gluten free oats|Late introduction of oats (starting GF oats 6 months after diagnosis of celiac disease)
89245042|NCT05801133|Experimental|Pirfenidone combined with radiotherapy|"Pirfenidone: synchronized with RT, 200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months~Radiotherapy: no limitation, TD≥50Gy (BED/ α/β： 10）"
89245043|NCT05791643|Experimental|Real-time intervention for promoting safety plan and coping strategy use|"Momentary surveys in which elevated (non-zero but < 8 out of 10) levels of suicidal intent or high (>= 8 out of 10) suicidal urges are reported will be randomized either to receive a real-time intervention that consists of automated, interactive reminders with suggested strategies for coping with suicidal thoughts or no intervention.~If randomized to receive an intervention, the intervention type will also be randomized (at equal probabilities) to suggest either coping strategies from the participant's personalized safety plan or general common coping strategies."
89245045|NCT05788796|Experimental|Experimental: Experimental group|Experimental:Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid.
89245046|NCT05788796|No Intervention|Assigned Interventions|No Intervention: Control group Pregnant women in the control group will be asked not to make any lifestyle changes and to continue their routine daily lives.
89245047|NCT05785715|Experimental|NX-13 250mg|Subjects will take study drug by ingesting three tablets per day, recommended at the same time daily for consistency. Subjects in a NX-13 group will receive either 250 mg or 750 mg of NX-13 in 3 tablets and subjects in the placebo group will receive matching placebo.
89245048|NCT05785715|Experimental|NX-13 750mg|Subjects will take study drug by ingesting three tablets per day, recommended at the same time daily for consistency. Subjects in a NX-13 group will receive either 250 mg or 750 mg of NX-13 in 3 tablets and subjects in the placebo group will receive matching placebo.
89245049|NCT05785715|Placebo Comparator|NX-13 Placebo|Subjects will take study drug by ingesting three tablets per day, recommended at the same time daily for consistency. Subjects in a NX-13 group will receive either 250 mg or 750 mg of NX-13 in 3 tablets and subjects in the placebo group will receive matching placebo.
89245050|NCT05784922||Digital Outreach: Patient Gateway|"Participants who list Patient Gateway as the preferred mode of contact in the electronic health record (EHR) system. Patient Gateway is an online patient portal that gives patients access to securely message their Mass General Brigham provider, request routine appointments, prescriptions and referral authorizations as well as view test results that were processed at a Mass General Brigham facility. Participants will receive the digital educational lung cancer screening video via their patient gateway account."
89245051|NCT05784922||Digital Outreach: Text|"Participants who list Text as the preferred mode of contact in the electronic health record (EHR) system. Participants will receive the digital educational lung cancer screening video via a text message sent directly to their cell phone."
89245052|NCT05784922||Digital Outreach: Email|"Participants who list Email as the preferred mode of contact in the electronic health record (EHR) system. Participants will receive the digital educational lung cancer screening video directly to the email they have listed."
89245053|NCT05784350|Active Comparator|Intravenous fluid bolus|
89245054|NCT05784350|Active Comparator|Intravenous Ondansetron|
89245055|NCT05784350|No Intervention|No intervention|
89245056|NCT05783570|Experimental|EU307 CAR-T Cell|
89245057|NCT05782777|Experimental|Combination therapy group|Ezetimibe/high-intensity statin combination therapy
89245058|NCT05782777|Active Comparator|Statin monotherapy group|High-intensity statin monotherapy
89245059|NCT05782335||Arm 1: Abatacept Initiator|RA patients of any disease duration, 18 years or older who are starting ABA (either IV or subcutaneous at standard doses) for the first time. Concomitant non-biologic medications (for e.g., standard conventional synthetic (cs)DMARDs, one of which must be MTX as typically used in routine care, or if MTX was not tolerated leflunomide will be acceptable) will be allowed as long as the dose has been stable for at least 3 months.
89245060|NCT05782335||Arm 2: csDMARD/TNFi Treated|RA patients, 18 years or older and on stable doses of conventional DMARDs (MTX with or without hydroxychloroquine, sulfasalazine, with or without leflunomide therapy, where leflunomide therapy can be an alternate to MTX). Patient's disease activity can be controlled or near controlled (CDAI <=12) or active if a recent DMARD or TNFi has been added, though they will have been on MTX at doses of at least 15mg weekly or leflunomide 10 mg or more for 4 weeks or more. A combination of csDMARDs at stable doses for 4 or more weeks with >= MTX 10 mg weekly or ± MTX 10 mg weekly for at least 4 weeks with any dose of a conventional TNF inhibitor (stable dose + TNFi) is permitted.
89245061|NCT05782335||Arm 3. Healthy Controls|Healthy individuals over 18 y.o. without RA, SLE, juvenile arthritis, psoriasis or psoriatic arthritis or other inflammatory auto-immune rheumatic disease, who are receiving care at the HSS or volunteers from the community. Participants will be recruited to serve in the control population for this study. Given that the range of age for most RA patients is between 40-70, we will aim to recruit control volunteers in this age range, ensuring that at least 60% - 70% are female, ensuring an age range and sex that is proportionately similar to the RA population at HSS.
89245062|NCT05780970||Non-targeted individuals|Non-targeted children and caregivers living in the same household as the target parent/adolescent dyad. Non-targeted meaning they did not receive the TEENS+ intervention.
89245063|NCT05779423|Experimental|Ipilimumab + Nivolumab + Cryoablation|"Study will be conducted in two stages:~Stage 1: Will enroll 15 participants, and if 6 or more have clinical benefit, the study will proceed to Stage 2.~Baseline CT scan.~Cycle 1-4: Pre-determined doses of ipilimumab and nivolumab. Medications administered under direction of treating oncologist.~Day 2 - 14: Core Needle Biopsy followed by cryoablation between Cycle 1 - 2~Surveillance CT scan at weeks 8 - 12, weeks 16 - 24.~Follow up for 6 months to assess safety after cryoablation. Participants followed for duration of response.~Stage 2: Will enroll 22 participants~Baseline CT scan.~Cycle 1-4: Pre-determined doses of ipilimumab and nivolumab. Medications administered under direction of treating oncologist.~Day 2- 14: Core Needle Biopsy followed by cryoablation between Cycle 1 - 2.~Surveillance CT scan at weeks 8 - 12, weeks 16 - 24~Follow up period to assess safety 6 months after cryoablation. Patients followed for duration of response."
89245064|NCT05777993|Experimental|Mitapivat|Participants will receive mitapivat of 5, 20 or 50 milligrams (mg), orally, twice daily (BID), based on the last dose received by the participants in the antecedent study. Mitapivat will be administered from Day 1 up to end of treatment period of this study.
89245065|NCT05776914|Experimental|Donor Fecal Microbiota Transplantation Group|Subjects will receive a fecal microbiota transplantation (FMT) using stool from a donor
89245066|NCT05776914|Placebo Comparator|Autologous Fecal Microbiota Transplantation Group|Subjects will receive a fecal microbiota transplantation (FMT) using their own stool
89245067|NCT05775848|Active Comparator|BBP-418|BBP-418 Granules for Oral Solution will be supplied as granules in tri-ply PET/Aluminum/PE sachets for unit dose. The number of sachets to reconstitute will depend on the applicable dose to be delivered, 9 g BID or 12 g BID, as determined by the weight of the participant. The granules will be reconstituted in water for oral administration.
89245068|NCT05775848|Placebo Comparator|Placebo to Match BBP-418|The placebo will be identical to the BBP-418 Granules for Oral Solution in appearance, packaging, labeling, and storage conditions.
89245069|NCT05771480|Experimental|Durvalumab + Gemcitabine based chemotherapy|"Participants will receive durvalumab 1500mg every 3 or 4 weeks, in combination with continuation of all or some of the original background gemcitabine based chemotherapy every 3 or 2 weeks for up to a maximum of 8 cycles of chemotherapy. Durvalumab 1500mg is given as a 60-minute IV infusion in the first cycle (Day 1) and as a 30-minute IV infusion in following cycles.~Upon completing 8 cycles of background gemcitabine-chemotherapy, or after discontinuing any of the combination chemotherapies due to toxicity before completing 8 cycles, participants are eligible to continue receiving durvalumab 1500 mg IV every 4 weeks either alone or in combination with gemcitabine-based chemotherapy (with the exception of paclitaxel), as per investigator's discretion."
89245070|NCT05770609|Experimental|SPH3127 Tablets with Dose A|Oral daily dose of SPH3127 Tablets for up to 8 weeks
89245071|NCT05770609|Experimental|SPH3127 Tablets with Dose B|Oral daily dose of SPH3127 Tablets for up to 8 weeks
89245072|NCT05770609|Placebo Comparator|SPH3127 Tablets placebo|Oral daily dose of SPH3127 Tablets placebo for up to 8 weeks
89245073|NCT05766670|Other|Intramedullary calcium sulfate antibiotic depot prior to Intramedullary nailing (IMN) placement (CS)|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
89245074|NCT05766670|Other|Standard of care intramedullary nail (SN)|Standard of care intramedullary nail
89245075|NCT05764265|Experimental|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 52 weeks
89245076|NCT05764161|Experimental|Ruxolitinib 1.5% Cream|Participants apply ruxolitinib 1.5% cream topically to the affected areas as a thin film BID for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will enter the open label extension (OLE) period for up to 40 weeks.
89245077|NCT05764161|Placebo Comparator|Vehicle Cream|Participants apply ruxolitinib matching vehicle cream topically to the affected areas as a thin film twice daily (BID) for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will enter the open label extension (OLE) period for up to 40 weeks.
89245078|NCT05762159||erector spinae block|Patients receiving erector spinae block for pain management of spinal osteosynthesis. Pupillometer will be realized during analgesia (usual practice).
89245079|NCT05762133|Experimental|ASSET-PPD intervention group|25 parent dyads with a mother who is receiving individual treatment outside of the study and the father is receiving the ASSET-PPD training
89245080|NCT05762133|No Intervention|No additional treatment group|25 parent dyads with a mother who is receiving individual treatment outside of the study and the father is not receiving the ASSET-PPD training
89245081|NCT05760300|Experimental|Group A: Bulevirtide (BLV), Severe Renal Impaired Participants|"Participants with severe renal impairment will receive BLV 2 mg once daily for 6 days.~Following completion and evaluation of pharmacokinetics (PK) and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated."
89245082|NCT05760300|Experimental|Group A: BLV, Normal Renal Function (Matched Control Participants)|"Participants with normal renal function will receive BLV 2 mg once daily for 6 days.~Following completion and evaluation of PK and safety data from all participants in Group A, additional participant groups (Groups B, C, and D) and BLV doses (2 mg or 10 mg) may be initiated."
89245083|NCT05757128|Experimental|treatment arm|The single treatment arm will be administered optimal health program (OHP) intervention.
89245084|NCT05755919|Other|Patients with epilepsy|Epilepsy surgery will be performed as a part of the clinical management of patients with drug-resistant epilepsy.
89245085|NCT05755438|Placebo Comparator|Vehicle Cream BID|Participants apply ruxolitinib matching vehicle cream topically to the affected areas as a thin film twice daily (BID) for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will apply ruxolitinib 1.5% cream topically during the open label extension (OLE) period for up to 40 weeks.
89245086|NCT05755438|Experimental|Ruxolitinib 1.5% Cream|Participants apply ruxolitinib 1.5% cream topically to the affected areas as a thin film BID for 12 weeks during the DBVC period. Participants who have completed the treatment during DBVC period will apply ruxolitinib 1.5% cream the open label extension (OLE) period for up to 40 weeks.
89245087|NCT05752591||Enrolled patients with DM|
89245088|NCT05752552|Experimental|Cohort 1 (starting dose)|Oral administration, once a day for 28 days, in a 4-week cycle
89245089|NCT05752552|Experimental|Cohort 2 (dose level 2)|Oral administration, once a day for 28 days, in a 4-week cycle
89245090|NCT05752552|Experimental|Cohort 3 (dose level 3)|Oral administration, once a day for 28 days, in a 4-week cycle
89245091|NCT05752552|Experimental|Cohort 4 (dose level 4)|Oral administration, once a day for 28 days, in a 4-week cycle
89245092|NCT05752552|Experimental|Cohort 5 (dose level 5)|Oral administration, once a day for 28 days, in a 4-week cycle
89245093|NCT05752552|Experimental|Cohort 6 (dose level 6)|Oral administration, once a day for 28 days, in a 4-week cycle
89245094|NCT05752552|Experimental|Cohort 7 (dose level 7)|Oral administration, once a day for 28 days, in a 4-week cycle
89245095|NCT05749107||Atrial secondary tricuspid regurgitation|Patients with persistent/permanent atrial fibrillation and any degree of isolated tricuspid regurgitation
89245096|NCT05745246|Experimental|Intervention Group|"This arm will receive the online e-health intervention for six months.~The intervention consists of three sections:~a novel health information strategy, 90SecondFire Cancer health letters~a brief on-line course~a problem-solving asynchronous bulletin board to mobilize existing knowledge"
89245097|NCT05745246|No Intervention|waitlist control group|This group will be placed on a waitlist and will receive the online treatment program after six months.
89245098|NCT05742607|Experimental|IPH5201 + durvalumab + standard chemotherapy|"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."
89245099|NCT05742113|Experimental|Triage status red|the relationship between the perfusion index and the emergency triage classification in patients admitted to the emergency department with dyspnea.
89245102|NCT05732402|Experimental|povetacicept 80mg|
89245103|NCT05732402|Experimental|povetacicept 240mg|
89245104|NCT05731128|Experimental|Dupilumab|Initial loading dose followed by regular administration for the duration of the treatment period.
89245105|NCT05731128|Placebo Comparator|Placebo|Initial loading dose followed by regular administration for the duration of the treatment period.
89245106|NCT05731128|Other|Open-label arm (optional)|Regular administration of open label dupilumab
89245107|NCT05728086|Experimental|Group art therapy|Participants randomised to the intervention group receive the group art therapy intervention shortly after baseline assessment. Adherence to the intervention will be checked via an adherence questionnaire completed by therapist delivering the intervention after each session. In addition, 20% of sessions will be observed by an independent researcher for adherence checking.
89245108|NCT05728086|No Intervention|waitlist control group|Participants randomised to the waitlist control group will complete outcomes measures at baseline and at the end of a 6 week waiting period. They will then begin the intervention (1-2 weeks after the intervention group has finished).
89245109|NCT05727800|Experimental|Part A|Participants grouped in different cohorts will receive a single ascending dose of VX-668.
89245110|NCT05727800|Placebo Comparator|Placebo Part A|Participants will be randomized to receive placebo matched to VX-668.
89245111|NCT05727800|Experimental|Part B|Participants grouped in different cohorts will receive multiple doses of VX-668.The dose levels will be determined based on the data from Part A.
89245112|NCT05727800|Placebo Comparator|Placebo Part B|Participants will be randomized to receive placebo matched to VX-668.
89245113|NCT05725057|Active Comparator|AX-158 - (Arm 1)|AX-158 Dosage:5 mg capsules Form: Capsule Frequency - 2 capsules daily taken orally Duration - 28 consecutive days
89245114|NCT05725057|Placebo Comparator|Placebo - (Arm 2)|Placebo Dosage: NA Form: Capsule Frequency: 2 capsules daily taken orally Duration: 28 consecutive days
89245115|NCT05717725|Active Comparator|Pulsed-field ablation arm|Patients will undergo catheter ablation using for atrial fibrillation using pulsed-field energy
89245116|NCT05717725|Sham Comparator|Sham procedure arm|Patients will receive sham procedure (no ablation)
89245117|NCT05717530|Active Comparator|wound site local anesthesic infiltration|at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site
89245118|NCT05717530|Active Comparator|Erector spinae plane block|: Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction
89245119|NCT05717530|No Intervention|Control|There was no intervention.
89245120|NCT05714969|Experimental|TAK-755 Dose 1 in Acute Phase and Dose 2 in Post-acute Phase|TAK-755 Dose 1, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.
89245121|NCT05714969|Experimental|TAK-755 Dose 2 in Both Acute and Post-Acute Phase|TAK-755 Dose 2, IV infusion, in the acute phase until clinical response is achieved. All participants achieving clinical response will receive TAK-755 at Dose 2, for up to 6 weeks during the post-acute phase.
89245122|NCT05712278|Experimental|SAR445419|Treatment consists of chemotherapy with fludarabine 30mg/m2/day and cytarabine 2g/m2/day administered for 5 days (Day -6 to Day -2), followed by 6 doses of SAR445419 given thrice weekly for 2 weeks beginning Day 1.
89245123|NCT05710445|Experimental|Augmented Reality|Subjects in this group will have their intravenous catheter placed while the physician uses a mixed reality headset to view the ultrasound images being used to guide the catheter placement.
89245124|NCT05710445|No Intervention|Control|Subjects in this group will have their intravenous catheter placed using standard of care. The physician will use the monitor on the ultrasound machine only to view the ultrasound images being used to guide the catheter placement.
89245125|NCT05709977|Experimental|Acupuncture arm|Fixed set of acupuncture points
89245126|NCT05709977|Active Comparator|Control (Carelastin®) arm|Carelastin® (1 mg/ml) azelastine nasal spray, 1 spray puff (0.14 ml) per nostril twice daily (totally 0.56 ml per day)
89245127|NCT05705258||Aflibercept treatment|The patients will be included in this study by investigators who are prescribing Aflibercept (AFL) routinely in their clinical practice. The enrollment of each patient in this study is able to accept at latest in 6 months from initiation of treatment.
89245128|NCT05703178|Experimental|Education + Online Pain Coping Skill Training|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects. They will also be given access to an online pain coping skills training program and asked to complete it at home over 8 to 10 weeks. This interactive, web-based program teaches cognitive and behavioral skills that research has shown can reduce pain and pain-related interference with daily activities. The program includes eight sessions that participants will complete at a rate of about 1 per week. Each session takes 35-45 minutes. Participants will be shown how to use the program and can contact the study team if they have any problems with it. Participants who do not have a device capable of accessing the program will be loaned a tablet computer for the study.
89245129|NCT05703178|Active Comparator|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
89245130|NCT05702515||Adult male patients scheduled to receive a PICC insertion|Adult male patients scheduled to receive a PICC insertion using the Vascular Positioning System G4 tip navigation system
89245131|NCT05702060|Experimental|Left distal radial artery approach|Coronary angiography and intervention were performed using the left distal radial artery approach
89245132|NCT05702060|Active Comparator|Right Radial Artery Approach|Coronary angiography and intervention were performed using the Right Radial Artery Approach
89245133|NCT05700565||Steroid-refractory or dependent immune-related adverse events|Immune-related adverse events (irAE) after immune checkpoint inhibitor therapy (PD-1/PD-L1 or PD-1 + CTLA4 blockade) refractory to therapy with corticosteroids or inability to taper corticosteroids to prednisone equivalent <= 5mg
89245134|NCT05699603|Experimental|Prevention (calcipotriene, fluorouracil)|Participants receive calcipotriene plus fluorouracil cream topically BID for 6 consecutive days on study. Participants also undergo skin biopsies throughout the study. Patients who continue to experience AKs at week 8 may receive a second course of calcipotriene plus fluorouracil cream topically BID for 6 consecutive days on study.
89245135|NCT05697783||Methadone-treated group|
89245136|NCT05697783||Fentanyl-patch treated group|
89245137|NCT05696392|Experimental|Treatment Group: Ruxolitinib|ruxolitinib cream 1.5% will be applied twice daily (BID) as a thin film.
89245138|NCT05692427|Other|Cryotherapy|Cryotherapy on granuloma pyogenicum
89245139|NCT05691010|Experimental|Participants with Endometrial Cancer|Participants have stage III endometrial cancer
89245140|NCT05688423|Experimental|SIRI Team|"The study intervention (SIRI Team) consists of a hospital-based multidisciplinary (ID/SUD consult) team that will provide intensive, integrated care for participants' ID and SUD both during the hospital stay and post-discharge for up to four months post-randomization. The SIRI Team will provide low barrier access to medications and harm reduction services for SUD; streamline ID/SUD treatment; provide longitudinal care with familiar providers; leverage different areas of expertise between physicians, advance practice providers, and patient navigators; and create patient-centered treatment plans, tailored to the individual, and informed by each patient's social circumstances, substance use, and personal goals/desires."
89245141|NCT05688423|Active Comparator|Treatment as Usual|Treatment as Usual (TAU) will consist of the current healthcare landscape at each participating hospital site.
89245142|NCT05687539|Experimental|Mastiha water|Patients will receive 10ml of Mastiha water before every meal for one month
89245143|NCT05687539|Experimental|Mastiha capsules|Patients will receive 2 Mastiha capsules (2x350mg) before every meal for one month
89245144|NCT05687539|No Intervention|Control-Mastiha free|Patients will follow a Mastiha free one month period
89245145|NCT05685199||Case Group|Participants with heavy menstrual bleeding (HMB)
89245146|NCT05685199||Control Group|Participants without heavy menstrual bleeding (HMB)
89245147|NCT05685004|Active Comparator|Standard of Care|Subjects will have standard surgery which will be followed approximately 5 weeks later by combined radiotherapy and chemotherapy consisting of temozolomide 75 mg/m2 dosed once daily beginning on the first day of radiotherapy and continuing until the final day of radiotherapy. Subjects will receive adjuvant temozolomide, and proceed with post therapy surveillance.
89245148|NCT05685004|Experimental|Interventional TVI-Brain-1 Autologous Vaccine and activated autologous blood-derived t cells|TVI-Brain-1 immunotherapy is integrated with radiation and temozolomide in the test group in the following manner: 1) Subjects undergo surgical resection of their cancer and are tapered off steroids. 2) Subjects receive the first vaccination of TVI-Brain-1 as soon as the laboratory prepared vaccine is available for use (approximately 7 - 14 days following surgery). 3) Subjects receive a second vaccination 7-10 days later. 4) Subjects are leukapheresed to obtain immune T cells for ex vivo-activation. 5) Subjects' T cells are stored frozen until after chemoradiotherapy is completed. 6) Following chemoradiotherapy Subjects are infused with activated effector T cells followed by a 10-day course of low-dose interleukin 2 (IL-2). 7) Subjects then proceed with post therapy surveillance.
89245149|NCT05684926|Experimental|Experimental Group|The intervention group is a group of asthmatic children aged 6-11 years, determined by randomization. Yoga asana includes pranayama and concentration. It will be held 3 days a week for 12 weeks.
89245150|NCT05684926|No Intervention|Control Group|The control group is a group of asthmatic children aged 6-11 years, determined by randomization method. He will be put on the waiting list and after the second evaluation, yoga exercises will be done for 8 weeks.
89245151|NCT05684328|Experimental|WLI Then NBI Withdrawal Group|After successful intubation of the cecum, carefully inspect the whole colorectal mucosa by white light imaging(WLI) during the first colonoscopy withdraw. Then reinsert to the cecum and withdraw with narrow band imaging(NBI). Stop watch will be utilized to remind endoscopists.
89245152|NCT05684328|Active Comparator|NBI Then WLI Withdrawal Group|After successful intubation of the cecum, carefully inspect the whole colorectal mucosa by narrow band imaging(NBI) during the first colonoscopy withdraw. Then reinsert to the cecum and withdraw with white light imaging(WLI). Stop watch will be utilized to remind endoscopists.
89245153|NCT05683834|Placebo Comparator|Control|The placebo will be delivered intramuscularly into the deltoid muscle at Days 0, 30, and between 60 and 90. Each dose will consist of 0.4mL normal saline.
89245154|NCT05683834|Experimental|Interventional|The gp350-Ferritin vaccine will be delivered intramuscularly into the deltoid muscle at Days 0, 30, and between 60 and 90. Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1 adjuvant.
89245155|NCT05683457|Experimental|mRNA-1647|Participants will receive mRNA-1647 vaccine by intramuscular (IM) injection on Day 42, Day 67, and Day 92, and a booster dose on Day 180.
89245156|NCT05683457|Placebo Comparator|Placebo|Participants will receive mRNA-1647 vaccine matching placebo by IM injection on Day 42, Day 67, and Day 92, and a booster dose on Day 180.
89245157|NCT05682144|Experimental|Autologous Plasmablasts (B cells)|Dose Level: 5 x 10e7 cells/kg on Day 0
89245160|NCT05681624|Other|Oxygen|
89245161|NCT05681624|Active Comparator|Room air|
89245162|NCT05681468|Experimental|KETO-Can|KETO diet supplemented with Canola oil (high in MUFA and omega-3 FA).
89245163|NCT05681468|Experimental|KETO-Sat|KETO diet supplemented with butter, coconut or palm oil (high in SFA).
89245164|NCT05681468|Active Comparator|Low fat diet (LFD)|Low fat diet supplemented with whole grains and other low-fat foods.
89245165|NCT05681026|Experimental|Yoga Sessions|Participants will take part in Yoga of gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
89245166|NCT05680298|Experimental|AD patients|Pediatric patients (≥6 and <12 years of age) with moderate-to-severe AD will receive a SC injection of dupilumab depending on the body weight
89245167|NCT05680298|No Intervention|Healthy volunteers|Except for IMPs administration, skin barrier function assessments for healthy volunteers are conducted at the same time and in the same measurement conditions as for AD patients.
88804756|NCT00005596|Experimental|Arm IV|Patients receive methotrexate IV as in arm II on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; and pegaspargase, mercaptopurine, IT methotrexate, dexamethasone, vincristine sulfate, daunorubicin hydrochloride, cyclophosphamide, cytarabine, and thioguanine as in arm III.
88804757|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days|
89245170|NCT05677711||Ultimaster|Ultimaster stent
89245171|NCT05672199|Placebo Comparator|Placebo|Participants who were receiving the placebo during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive the placebo.
89245172|NCT05672199|Experimental|Efavaleukin Alfa Dose 1 (Low Dose)|Participants who were receiving efavaleukin alfa dose 1 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 1.
89245173|NCT05672199|Experimental|Efavaleukin Alfa Dose 2 (Moderate Dose)|Participants who were receiving efavaleukin alfa dose 2 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 2.
89245174|NCT05672199|Experimental|Efavaleukin Alfa Dose 3 (High Dose)|Participants who were receiving efavaleukin alfa dose 3 during the dose-finding study (study 20170104) that decided to continue onto this long-term extension study will continue to receive efavaleukin alfa dose 3.
89245175|NCT05669846|Experimental|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT along with an intestinal biopsy will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy (Treatment Phase 1) and by a sigmoidoscopy (Treatment Phase 2). FMT will be performed on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.~Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle."
89245178|NCT05668741|Experimental|Single Ascending Dose (SAD)|Participants grouped into different cohorts will receive a single ascending dose of VX-522.
89245179|NCT05668741|Experimental|Multiple Ascending Dose (MAD) Arm 1|Participants grouped into different cohorts will receive multiple ascending doses of VX-522 in treatment arm 1 (T1).
89245180|NCT05668741|Experimental|MAD Arm 2: VX522+ IVA|Following run-in period with ivacaftor (IVA), participants will receive multiple doses of VX-522 with IVA in treatment arm (T2).
89245181|NCT05665595|Experimental|Pembrolizumab/Vibostolimab|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
89245182|NCT05665595|Active Comparator|Pembrolizumab|Adult participants receive 200 mg and adolescent participants ≥40 kg receive 2 mg/kg (up to a max of 200 mg) pembrolizumab via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
89245183|NCT05664841|Experimental|magic trick training|Participation in a 6 weekly virtual magic trick training camp with three lessons per week.
89245184|NCT05664841|No Intervention|waitlist control|Participation in usual daily activities.
89245185|NCT05664126|Experimental|Cohort A|"Cohort A will include haploidentical donor who is identical to the stem cell donor.~The first 5 patients will be enrolled in Cohort A. If safety criteria are met, cohort B will be open for enrollment."
89245186|NCT05664126|Experimental|Cohort B|Cohort B will include haploidentical donor who is different from the stem cell donor
89245187|NCT05663515||Initiators of exenatide|Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide during the study period, 2006 to 2023
89245188|NCT05663515||Initiators of non-GLP-1 RA based glucose lowering drugs|Patients with T2DM, aged 18 years or older, who initiated treatment with non-GLP-1 RA based glucose lowering drugs during the study period, 2006 to 2023
89245189|NCT05663034|Active Comparator|Cognitive behavioral therapy for insomnia (CBT-I)|CBT-I treatment will involve a standardized 6-session blended intervention that combines cognitive and behavioral techniques. The core components include (1) education about sleep and insomnia, stimulus control (SC) and sleep restriction (SRT) (week 1); (2) sleep hygiene education (week 2); and (3) relaxation training, cognitive restructuring (to counter-arousal and address sleep-interfering cognitions), adherence monitoring, and adjusting the recommended sleep-wake schedule (weeks 3 through 6). The final session will also include a review of treatment content and relapse prevention. Common to all sessions is an initial review of participant diary data, charting progress, setting measurable goals, discussing adherence, and reinforcing learned skills.
89245190|NCT05663034|Active Comparator|Mindfulness-based treatment for insomnia (MBTI)|MBTI treatment will involve a standardized 6-session intervention which integrates the mindfulness training and exercises from mindfulness-based stress reduction (MBSR) with behavioral strategies based on sleep restriction therapy and stimulus control delivered within the context of mindfulness principles. Mindfulness principles include: 1) increase awareness of the mental and physical states that promote sleep (i.e., sleepiness), 2) shift sleep-related metacognitions to reduce hyperarousal, and 3) promote a mindful stance to respond when symptoms of insomnia arise. An overview of the treatment program, sleep education, and an introduction to the principles of mindfulness meditation is given (week 1). Then a combination of mindfulness meditations, sleep restriction, and stimulus control is conducted (week 2-6).
89245191|NCT05661643|Experimental|temozolomide treatment|
89245192|NCT05661578|Experimental|Tiragolumab and Atezolizumab IV FDC|Participants will receive tiragolumab and atezolizumab as an intravenous fixed dose combination (IV FDC) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
89245193|NCT05660980|Experimental|Cohort 1|Cohort 1 will receive Once daily oral CAB + oral RPV through the Week 4b visit, followed by intramuscular injection doses of CAB LA + RPV LA every four weeks (Q4W dosing regimen) or every eight weeks (Q8W dosing regimen)
89245194|NCT05660980|Experimental|Cohort 2A|Cohort 2A: Once daily doses of oral CAB + oral RPV through the Week 4b visit, followed by Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.
89245195|NCT05660980|Experimental|Cohort 2B|Cohort 2B: Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.
89245196|NCT05656248|Experimental|CPX-351|"Participants will receive CPX-351 for remission induction, and then will proceed to allogeneic HSCT or other therapies as per institutional practice.~Intrathecal (IT) chemotherapy will be given on Day 1 of each cycle, for all participants, but may be delayed if clinically indicated. IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) according to age are all acceptable."
89245197|NCT05656118||Paclitaxel Coated Balloon|Patients treated with Genoss® DCB in patients with coronary artery in-stent restenosis (ISR)
89245198|NCT05653778|Experimental|Scrambler therapy|"Scrambler Therapy is a non-invasive neuromodulation approach using superficial electrocardiogram (ECG) electrodes in paired channels on the involved dermatomes to send non-pain information along the existing nerve pathways, which can modify peripheral and central sensitization."
89245199|NCT05653778|Active Comparator|TENS treatment|Transcutaneous electrical nerve stimulation (TENS) is a battery-powered device which delivers low-voltage electrical current through superficial electrocardiogram (ECG) electrodes placed on the surface of the skin to provide pain relief.
89245200|NCT05652205|Experimental|Part 1 Linaclotide|Participants will receive linaclotide for 12 weeks.
89245201|NCT05652205|Experimental|Part 1 Placebo|Participants will receive placebo for 12 weeks.
89245202|NCT05652205|Experimental|Part 2 Linaclotide|Participants who completed study intervention in Part 1 of this study or the Phase 2 Study LIN-MD-67 will receive 24 weeks of linaclotide exposure.
89245203|NCT05645731||Lung cancer patient|Lung cancer patients or lung cancer survivors willing to refer close contacts for lung cancer screening
89245204|NCT05645731||Referred participants|Participants referred to the study by close contacts living with lung cancer.
89245205|NCT05644327|Experimental|Cardiovascular training (CT)|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and, through a linear progression, will reach vigorous intensity; then, this intensity will be maintained until the end of the training period. Each session will include five minutes of warm-up and cool-down performed at the beginning and at the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool-down. CT's sessions will last approximately 45 minutes (30 to 50 minutes) and will be interspersed with 48 hours of recovery.
89245206|NCT05644327|Experimental|Resistance training (RT)|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start and end with five-minute of warm-up and cool-down, which will include exercise on a recumbent stepper and stretching, respectively. RT's sessions will last approximately 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
89245207|NCT05644327|Experimental|Multimodal training (MT)|Multimodal training (MT) will combine cardiovascular and resistance training interventions using the modalities described previously, but each component will be shortened to match the overall training duration (i.e., volume) among groups. The first part of each training session will always include three resistance exercises, which will be followed by 15-20 minutes of cardiovascular training performed on the total body recumbent stepper. Periodization will follow the same progression previously described for cardiovascular and resistance training, respectively, reaching vigorous intensity towards the end of the training period. Training sessions will include a five-minute warm-up and cool-down on the total body recumbent stepper. MT's sessions will approximately last 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
89245208|NCT05644327|No Intervention|Control condition (CON; waiting list)|The control condition (CON; waiting list) will receive no intervention (i.e., exercise) but usual care. Participants in the CON will be required to go about their normal life, maintaining their current physical activity levels until the end of the study. Then, they will be offered to join one of the training programs/condition.
89245209|NCT05641974|Experimental|Helpers Stay Quit Training|Research participants randomized to the experimental arm will receive the on-line Helpers Stay Quit training which provides training on how to help others quit smoking.
89245210|NCT05641974|No Intervention|Usual Care|Research participants randomized to the arm without intervention will receive Quitline usual care. They will be contacted for assessment of abstinence at 7 months after enrollment in services. If the participant has relapsed, the Quitline will attempt to re-engage the participant in cessation services (telephone and/or web-based).
89245211|NCT05641077|Experimental|Virtual Visit|Patients randomized to the experimental arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
89245212|NCT05641077|Active Comparator|Office Visit|Patients randomized to the active comparator arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
89245213|NCT05640999|Experimental|Sub-study A: RAINBO BLUE Cohort A1|Observation
89245214|NCT05640999|Experimental|Sub-Study A: RAINBO BLUE Cohort A2 Exploratory|Observation or Adjuvant Radiotherapy
89245215|NCT05640999|Experimental|Sub-Study B: TAPER|Observation or Vaginal Brachytherapy
89245216|NCT05636176|Experimental|Ziltivekimab 15 mg|Participants will receive ziltivekimab 15 milligrams (mg) subcutaneous (s.c.) injection once-monthly and added to standard of care for up to 4 years.
89245217|NCT05636176|Placebo Comparator|Placebo|Participants will receive ziltivekimab placebo subcutaneous (s.c.) injection once-monthly and added to standard of care for up to 4 years.
89245218|NCT05634746|Experimental|APT-1011|APT-1011 3 mg HS
89245219|NCT05634746|Placebo Comparator|Placebo|Placebo HS
89245220|NCT05630040|Experimental|Non-invasive Vagus Nerve Stimulation|Participants in the Non-Invasive Vagus Nerve Stimulation arm will have devices calibrated to a therapeutic setting.
88804758|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days|
89245221|NCT05630040|Sham Comparator|Sham Vagus Nerve Stimulation|"Participants in the sham VNS arm will be asked to use the VNS device daily on a sham setting for six weeks and will be given the opportunity to crossover into the active VNS arm once they have completed the sham arm."
89245222|NCT05629962|Experimental|Bemnifosbuvir (BEM)|
89245223|NCT05629962|Placebo Comparator|Placebo|
89245224|NCT05629390|Experimental|Lotilaner Ophthalmic Solution (TP-03)|Lotilaner Ophthalmic Solution (TP-03)
89245225|NCT05629390|Placebo Comparator|Vehicle Control|Vehicle Control
89245226|NCT05629208|Experimental|Edecesertib|Participants will receive edecesertib 30 mg, once daily starting on Day 1 for up to 12 weeks.
89245227|NCT05629208|Placebo Comparator|Edecesertib Placebo|Participants will receive edecesertib placebo, once daily starting on Day 1 for up to 12 weeks.
89245228|NCT05627258|Experimental|Group 1|5 mg/kg IV single administration
89245229|NCT05627258|Experimental|Group 2|5 mg/kg SC single administration
89245230|NCT05627258|Experimental|Group 3|20 mg/kg IV single administration
89245231|NCT05627258|Experimental|Group 4|40 mg/kg IV single administration
89245232|NCT05627258|Experimental|Group 5|5 mg/kg SC repeat dosing
89245233|NCT05627258|Experimental|Group 6|20 mg/kg IV repeat dosing
89245234|NCT05626803|Experimental|Open Label Sentinel|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (sentinel n=10)
89245235|NCT05626803|Experimental|Medium Dose Arm|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets total dose is 1×10 to the power 11 IU/dose (N=50)
89245236|NCT05626803|Experimental|High Dose Arm|Bivalent GII.4/GI.1 vaccine Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets total dose is 2×10 to the power 11 IU/dose (N=50)
89245237|NCT05626803|Placebo Comparator|Placebo Arm|Placebo tablets (N= 25)
89245238|NCT05621668|Experimental|Part A: Dose Findings (MTD)|The dose of attIL2-T cell therapy the participants will receive will depend on when the participants joined this study. The first group of participants will receive the lowest dose level of attIL2-T cell therapy.
89245239|NCT05621668|Experimental|Part B: Osteosarcoma Dose Expansion|Participants will receive attIL2-T cell therapy at the recommended dose that was found in Phase 1.
89245240|NCT05620836|Experimental|Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 54 weeks.
89245241|NCT05620836|Experimental|Povorcitinib Dose B|Participants will receive Povorcitinib Dose B for 54 weeks.
89245242|NCT05620836|Placebo Comparator|Placebo|Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
89245246|NCT05615233|Experimental|Intervention Group|Patient will use TACAD and the Alzheimer's Association Website
89245247|NCT05615233|Active Comparator|Active Control Group|Patient will use only the Alzheimer's Association Website
89245248|NCT05615220|Experimental|1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl)|Ecopipam 11.2, 22.4, 33.6, 44.8, 67.2 and 89.6 mg tablets (containing 12.5, 25, 37.5, 50, 75 and 100 mg ecopipam HCl, respectively); 1.8 mg/kg/day ecopipam (2 mg/kg/day ecopipam HCl) target dose; oral administration daily in evenings.
89245249|NCT05615220|Placebo Comparator|Placebo during R/WD Phase|Matching Placebo tablets during R/WD period taken orally in the evening.
89245250|NCT05614024|Experimental|Real fNIRS Neurofeedback Arm|Participants assigned to the experimental arm will see their true, real-time brain activation (i.e., active real-time neurofeedback) during the neurofeedback session. This activation will be displayed to the participant as a thermometer that will increase as brain activation in the target region increases.
89245251|NCT05614024|Sham Comparator|Sham-Control fNIRS Neurofeedback Arm|Participants assigned to the sham-control arm will see false feedback (or a fake signal) that is not connected to their right vlPFC activation during the neurofeedback session.
89245252|NCT05612945|Experimental|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. This protocol will elicits moderate-to-severe claudication pain during exertion. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test."
89245253|NCT05612945|Experimental|Low-to-moderate intensity training group (LowMod group)|Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.
89245254|NCT05611983|Active Comparator|Observation fo touch|
89245255|NCT05611983|Active Comparator|Observation of pictures|
89245256|NCT05611983|Active Comparator|Imagery of touch|
89245257|NCT05611983|Active Comparator|Mirror therapy|
89245258|NCT05605093|Experimental|S-217622 plus standard of care (SOC)|Study investigational agent (S-217622) will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.
89245259|NCT05605093|Placebo Comparator|placebo plus standard of care (SOC)|Study investigational placebo (S-217622) will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.
88804759|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days|
89245260|NCT05604560|Experimental|Arm A - Tislelizumab and SX-682|
89245261|NCT05602883|Experimental|Experimental group|Experimental: Experimental group Pregnant women in this group will listen to a music of their choice for 30 minutes before going to bed at night.
89245262|NCT05602883|No Intervention|Control group|Women in the control group will not be interfered with and will be followed in line with the routine follow-up protocol of the clinic.
89245263|NCT05600972|No Intervention|non-FSH priming|Routine CAPA-IVM treatment will be performed. The oocyte retrieval will be performed 2 days after the randomization accordingly to the current routine procedures. An ultrasound scan will be performed to exclude the development of any dominant follicle.
89245264|NCT05600972|Active Comparator|FSH priming|Routine CAPA-IVM treatment will be performed. Patients who are randomized into the FSH priming arm will receive two days of FSH injections of 150 IU/day. Oocyte retrieval will be scheduled at 42 hours after the last FSH injection.
89245265|NCT05600712|Other|single arm|subjects who have redapt sleeved stem implant
89245266|NCT05597605|Experimental|The SHINE SYSTEM|
89245267|NCT05593302|Experimental|Control Period - Intervention Period|Multiple baseline single case experimental design wherein all patients are first assigned to the control condition (or control period) are then assigned to the intervention condition (or intervention period) and finally to the follow-up period (control period). Patients are randomized for the time (t) at which they start with the intervention.
89245268|NCT05589259|Experimental|Axillary Brachial Plexus Block plus Physiotherapy|Participants who are randomized to the experimental group (EXP arm) will receive a single-shot axillary-approach brachial plexus block with 1.5mg/kg (up to 50mg total) bupivacaine 0.25% at the Kingston Health Sciences Centre Chronic Pain Clinic (KHSC-CPC). Prior to treatment, a blinded third party will perform a baseline physical exam. Under the brachial plexus block, the physiotherapist will provide standard of care, including manual therapy. The patient will then complete a 6-week physiotherapy program, including GMI. Following the 6 week program, a blind observer will repeat the physical exam.
89245269|NCT05589259|Active Comparator|Physiotherapy alone|Participants who are randomized to not receive a block (CON arm) will also have a baseline physical exam performed by a blinded third party. Following baseline data collection, the physiotherapist will provide standard of care, including manual therapy. They will then complete a 6-week home exercise program, including GMI. Following the 6 week program, a blinded observer will repeat the physical exam.
89245270|NCT05588128||Cohort 1|Participants with biochemically recurrent prostate cancer
89245271|NCT05584202|Experimental|Part 1: mRNA-1273.214 Dose A|Participants will receive 2 doses of mRNA-1273.214 Dose A by intramuscular (IM) injection approximately 8 weeks apart (Day 1 and Day 57).
89245272|NCT05584202|Experimental|Part 1: mRNA-1273.214 Dose B|Participants will receive 2 doses of mRNA-1273.214 Dose B by IM injection approximately 8 weeks apart (Day 1 and Day 57).
89245273|NCT05584202|Experimental|Part 2: mRNA-1273.214|Participants will receive 2 doses of mRNA-1273.214 by IM injection approximately 8 weeks apart (Day 1 and Day 57).
89245274|NCT05584202|Placebo Comparator|Part 2: Placebo|Participants will receive 2 doses of placebo by IM injection approximately 8 weeks apart (Day 1 and Day 57).
89245275|NCT05584124|Experimental|Real M1 High Frequency rTMS|Participants will be randomly assigned to receive high-frequency repetitive transcranial magnetic stimulation (rTMS) to the top of their head for approximately 40 minutes.
89245276|NCT05584124|Experimental|Real LDLPFC High Frequency rTMS|Participants will be randomly assigned to receive high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left frontal part of their head for approximately 40 minutes.
89245277|NCT05584124|Sham Comparator|Sham rTMS|Participants will be randomly assigned to receive sham/placebo repetitive transcranial magnetic stimulation (rTMS) to the their head for approximately 40 minutes. This is a control condition.
89245278|NCT05583344|Experimental|High Dose GSK4532990|
89245279|NCT05583344|Experimental|Low Dose GSK4532990|
89245280|NCT05583344|Placebo Comparator|Placebo|
89245281|NCT05581498|Experimental|GLAUCOMA|"we will recruit patients with a diagnosis of primary Glaucoma for the experimental group.~Exercise bikes and muscle-strength exercise belts will be used for exercise interventions."
89245282|NCT05581498|Active Comparator|CONTROL|"we will recruit normally sighted older adults for the control group.~Exercise bikes and muscle-strength exercise belts will be used for exercise interventions."
89245283|NCT05580458|Experimental|Shingrix|Shingrix will be administered in two 0.5-mL doses approximately 2 months apart.
89245284|NCT05573295||Children with CLP|
89245285|NCT05573295||Healthy controls with gender-age match|
89245286|NCT05571059|Experimental|Ifetroban Sodium|Drug: Ifetroban Oral capsule, 250 mg, once daily for 12 months
89245287|NCT05571059|Placebo Comparator|Placebo|Drug: Placebo Matching placebo, oral capsule, once daily for 12 months
89245288|NCT05570916|Experimental|Test Article - Zip-stitch Clips|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
89245289|NCT05570916|Other|Reference Group|Will not be comparative against the test article, but will be performed for reference and safety.
89245290|NCT05568797|Experimental|Co-Ad Group|Participants received one dose of FLU-aQIV vaccine and one dose of RSVPreF3 OA vaccine, both doses administered at Day 1, and were followed until end of study.
89245291|NCT05568797|Active Comparator|Control Group|Participants received one dose of FLU-aQIV vaccine at Day 1, followed by one dose of RSVPreF3 OA vaccine at Day 31, and were followed until end of study.
89245292|NCT05567835|Experimental|Arm A: FLOT-TNT ( Investigational Arm)|Arm A is the investigational arm with all 4 cycles of FLOT given as total neoadjuvant chemotherapy prior to surgery. Each cycle is 28 days and consists of 2 chemotherapy sessions given every 14 days. The total number of chemotherapy sessions in Arm A is 8. Every effort will be made to have surgery in week 20 ( -1 to +2 weeks), 4 weeks post C4 on arm A.
89245293|NCT05567835|Experimental|Arm B: FLOT-POP ( Standard Arm)|Arm B us the standard perioperative arm with 2 cycles of pre-operative FLOT ( 4 treatment sessions) and 2 cycles ( 4 treatment sessions) of post-operative FLOT. Post-surgery FLOT will start 4-6 weeks post surgery. Each cycle of chemotherapy consists of 28 days and consists of 2 chemotherapy sessions given every 14 days. The total number of chemotherapy sessions in arm B is 8. Every effort should be done to have surgery done in week 12 ( -1 to +2 weeks) post completion of cycle 2 on ARM B.
89245294|NCT05567172|Experimental|Watchman FLX Pro|
89245295|NCT05566574|Experimental|RP-3500 in Combination With Standard Radiation Therapy|Patients with metastatic cancers with identified mutations in ATM will be enrolled. All patients will receive a standard palliative RT (4Gy x 5 fractions) on Days 1-5 in combination with RP-3500 on Days 1-5. In the first phase of the study, a 3+3 study design will be used to identify a safe dose of RP-3500 (starting at 80 mg QD) in combination with palliative RT.
89245296|NCT05561530|Experimental|ALG-125755|Subcutaneous injections of ALG-125755 in HV or CHB subjects, up to 6 injections over the course of up to 72 weeks
89245297|NCT05561530|Placebo Comparator|Placebo|Subcutaneous injections of placebo in HV or CHB subjects, up to 6 injections over the course of up to 72 weeks
89245298|NCT05557942|Experimental|low dose AV-101|
89245299|NCT05557942|Experimental|medium dose AV-101|
89245300|NCT05557942|Experimental|high dose AV-101|
89245301|NCT05555849||Study group, Newly retired elite athletes|Elite athletes at the time of retirement of professional career. Reinvestigated after three months and thereafter yearly.
89245302|NCT05554939|Experimental|Patients with refractory or relapsed B-cell NHL|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, allogenic targeting CD19 chimeric antigen receptor γδT cells.
89245303|NCT05554367|Experimental|Combination Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)|Patients receive palbociclib PO QD on days 1-21 and binimetinib PO BID on days 1-28 of each cycle. throughout the trial. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 3 years. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
89245304|NCT05554367|Experimental|Monotherapy Cohort 1 (binimetinib)|Patients receive binimetinib PO BID daily, in the absence of disease progression or unacceptable toxicity, for up to 3 years. Patients who experience disease progression may elect to migrate to the combination cohort. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.
89245305|NCT05554094|Experimental|Psilocybin-assisted therapy|Participants will receive two doses of psilocybin, approximately 2 weeks apart, in conjunction with preparatory and post-psilocybin therapy sessions
89245306|NCT05548205|Experimental|Continuous Glucose Monitoring (CGM)|Patients in the CGM group will be instructed to wear a CGM uninterruptedly for 2 weeks duration.
89245307|NCT05548205|Active Comparator|Blood Glucose Monitoring (BGM)|Patients in the BGM group will be instructed to check their blood glucose utilizing fingerstick glucose monitoring multiple times daily depending on their insulin regimen for 2 weeks duration.
89245308|NCT05548062||Hydroxyurea|Patients being treated with hydroxyurea at enrollment and for at least 18 months prior to enrollment. Patients may switch to ruxolitinib treatment during the study in case of inadequate response or intolerance.
89245309|NCT05548062||Ruxolitinib|Patients on treatment with ruxolitinib who started treatment up to 18 months prior to enrollment.
89245310|NCT05546723|Experimental|LMY-920 dose escalation|Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.
89245311|NCT05546671||Strong grippers|
89245312|NCT05546671||Weak grippers|
89245313|NCT05543356|Active Comparator|Monovalent Pfizer-BioNTech(BNT162b2): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Tozinameran - Monovalent Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
89245314|NCT05543356|Active Comparator|Monovalent Moderna(mRNA-1273, Spikevax®): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Elasomeran - Monovalent Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)."
89245315|NCT05543356|Active Comparator|Monovalent Pfizer-BioNTech(BNT162b2): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Tozinameran - Monovalent Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
89245316|NCT05543356|Active Comparator|Monovalent Moderna(mRNA-1273, Spikevax®):AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Elasomeran - Monovalent Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)."
89245317|NCT05543356|Active Comparator|Bivalent Pfizer-BioNTech (BNT162b2 OMI): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Pfizer-BioNTech, BNT162b2 OMI - bivalent Pfizer-BioNTech bivalent COVID-19 vaccine contains ancestral BNT162b2 and Omicron variant BNT162b2 Omi (BA.1). The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
89245318|NCT05543356|Active Comparator|Bivalent Moderna (mRNA-1273.214): Pfizer-BioNTech(BNT162b2)-Pfizer-BioNTech(BNT162b2)|"Participants who received Pfizer-BioNTech(BNT162b2) as primary series and Pfizer-BioNTech(BNT162b2) as first booster will receive a second booster dose of:~Biological/Vaccine: Moderna, mRNA-1273.214 - bivalent The Moderna bivalent vaccine (mRNA-1273.214) encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in RNA-lipid nanoparticles composed of 4 lipids and 1-monomethoxypolyethyleneglycol-2, 3-dimyristylglycerol with polyethylene glycol. 25μg of each mRNA sequence that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 [BA.1])."
89245319|NCT05543356|Active Comparator|Bivalent Pfizer-BioNTech (BNT162b2): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1-S, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Pfizer-BioNTech, BNT162b2 OMI - bivalent Pfizer-BioNTech bivalent COVID-19 vaccine contains ancestral BNT162b2 and Omicron variant BNT162b2 Omi (BA.1). The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA."
89245320|NCT05543356|Active Comparator|Bivalent Moderna (mRNA-1273.214): AstraZeneca(ChAdOx1, Vaxzevria®)-Pfizer-BioNTech(BNT162b2)|"Participants who received AstraZeneca (ChAdOx1-S, or Vaxzevria®) as primary series and Pfizer-BioNTech (BNT162b2) as first booster will received a second booster dose of:~Biological/Vaccine: Moderna, mRNA-1273.214 - bivalent The Moderna bivalent vaccine (mRNA-1273.214) encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in RNA-lipid nanoparticles composed of 4 lipids and 1-monomethoxypolyethyleneglycol-2, 3-dimyristylglycerol with polyethylene glycol. 25μg of each mRNA sequence that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 [BA.1])."
89245321|NCT05539365|Experimental|Treatment (ST-alpha-DC1, pembrolizumab)|Patients undergo leukapheresis over 90 minutes. Patients then receive ST-alpha-DC1 IT on days 1, 8, and 50 in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV on days 8, 29, 50, and 71 in the absence of disease progression or unacceptable toxicity. Patients who are receiving clinical benefit from treatment at the end of day 85, may continue to receive pembrolizumab IV every 3 weeks beyond the 4 study doses. Patients also undergo tumor biopsies on days 1, 8, and 50 and CT scans at baseline and days 50 and 85.
89245322|NCT05534815|No Intervention|Usual Care Control group|Participants in the Usual Care Control group will receive methadone or buprenorphine treatment, counseling, and employment services.
89245323|NCT05534815|Experimental|Initiation Only group|Participants assigned to the Initiation Only group will be able to earn abstinence-contingent stipends for working with the employment specialist for up to 20 hours per week and performance stipends for engaging in job-seeking behaviors. When employed, those participants will be able to earn abstinence-contingent wage supplements for up to 40 hours worked (verified by pay stubs) in a community job. Participants can earn from both Therapeutic Workplace Work Hours and from wage supplements for working in a community job, however, participants will only be able to earn stipends and wage supplements for a maximum total of 40 hours.
89245324|NCT05534815|Experimental|Initiation and Maintenance group|"The Initiation and Maintenance group procedures will receive the same intervention as the Initiation Only participants for 24 weeks (during the Initiation period). Then, Initiation and Maintenance participants will receive a low-magnitude incentive intervention for 52 weeks (the Maintenance period, weeks 25-76) to maintain drug abstinence and employment. The low-magnitude incentive intervention will be identical to the final weeks of the high magnitude incentive intervention, with two important exceptions.~During the low-magnitude intervention, participants will receive money per hour for maintaining drug abstinence and work (stipends for working with the employment specialist and wage supplements for providing pay stubs).~During weeks 25-76, if a participant in the Initiation and Maintenance group provides a drug-positive urine sample or misses a required mandatory sample, the participant will not receive any incentive."
89245325|NCT05533333|Experimental|Self administered dual-task training|"The exercise intervention will continue for 9 months, beginning with 12 weeks of training accompanied by workshops to teach the exercises.~Experimental group: sDTT group participants will be instructed to perform 10 minutes of warm-up, 40 minutes of dual-task training and 10 minutes of cool-down exercises. The size of the workshop will be limited to 10 participants. The sDTT programme includes performing a selection of six cognitive tasks during walking, the sit-to-stand movement, heel and toe raising, stepping, tandem standing and walking and multidirectional reaching tasks. The cognitive tasks will include mental tracking, working memory, auditory cues and verbal fluency tasks. Participants will be given the freedom to mix and match the physical and cognitive tasks to make them more challenging."
89245326|NCT05533333|Active Comparator|Self-administered singletask training|Control group: The self-administered single-task training group will receive 10 minutes of warm-up, 20 minutes of physical tasks (as outlined above) and 20 minutes of cognitive tasks (as outlined above) followed by 10 minutes of cool-down exercises. Participants will be instructed to perform the exercises for the same dosage as the experimental group. After a 6-month follow-up period, the control group will receive two complimentary sessions of self-administered dual-task training.
89245327|NCT05526729||Beovu|Patients prescribed with Beovu for diabetic macular edema
89245328|NCT05525975|No Intervention|Control/Standard of Care|This arm will follow the standard of care practices of the Shoulder Surgery Department at UIHC, and will work as a control group.
89245329|NCT05525975|Experimental|Education Arm|"Participants in this arm will receive at their preoperative work-up visit a brochure and will watch an educational video. Both educational materials (brochure and video) will address information about opioid medications, pain management techniques and properly disposal of any excess opioid medication. In addition, participants receive an envelope in which they will be able to dispose their unused opioid pills. These envelopes will be the same ones used in our pilot study (IRB# 202012142). The disposal method consists of secured, labeled envelopes to dispose of the excess of Opioid medication. These envelopes will be provided by Sharps Compliance, Inc., a company that manages pharmaceutical waste disposal programs for healthcare facilities. Through their TakeAway Medication Recovery System Envelope (USPS) they allow the collection and disposal of controlled substances (Schedules II-IV) and non-controlled medications."
89245330|NCT05524519|Active Comparator|WT group|This group will include 30 patients with MDD. Patients in this group will not receive IA treatment during the study period. When the study is over, they will receive 6 weeks of the same IA treatment as in the CCA group.
89245331|NCT05524519|Experimental|CCA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. LR3, PC6, SP6, and HT7 will be selected for IA.
88804760|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days|
88804761|NCT00005080|Experimental|Nelarabine|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to 8 courses of therapy.
89245332|NCT05524519|Experimental|TSA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. TSA selected in the first part of the study will be stimulated.
89245333|NCT05524519|Experimental|PSA group|This group will include 30 patients with MDD who will be treated with basic treatment and IA. PSA selected in the first part of the study will be stimulated.
89245334|NCT05514444|Experimental|MK-4464|Participants will receive an intravenous (IV) infusion of MK-4464 administered in escalating doses every 3 weeks for up to 35 cycles. Escalation to subsequent MK-4464 doses will be based on safety of previous dose.
89245335|NCT05514444|Experimental|MK-4464 + Pembrolizumab|Participants will receive an IV infusion of MK-4464 administered in escalating doses and a 200 mg IV infusion of Pembrolizumab every 3 weeks for up to 35 cycles. Escalation to subsequent MK-4464 doses will be based on safety of MK-4464 monotherapy arm.
89245336|NCT05514444|Experimental|MK-4464 + Pembrolizumab + Zirconium 89 (89Zr)-MK-4464|Participants will receive an IV infusion of 89Zr-MK-4464 + IV infusion of MK-4464 on Cycle 1 Day 1, followed by an IV infusion of MK-4464 + a 200 mg IV infusion of pembrolizumab starting on Cycle 2 Day 1 and every 3 weeks for up to 35 cycles. Each cycle=3 weeks. MK-4464 doses will be based on safety of MK-4464 monotherapy arm. Participants may receive a 200 mg IV infusion of pembrolizumab on cycle 36.
89245337|NCT05510908||New, primary or recurrent disease|Considering or currently receiving cancer treatment
89245338|NCT05510908||Metastic or locally advanced cancer|This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.
89245339|NCT05510908||Prior cancer|Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.
89245340|NCT05509751|Active Comparator|Intervention group|geriatric assessment (GAM) and remote exercise and education prior to and during curative/adjuvant or first/second line palliative chemotherapy /immunotherapy or targeted therapy
89245341|NCT05509751|No Intervention|Waitlist control group|Wait list, receiving standard of care and option to receive intervention after treatment.
89245342|NCT05499130|Experimental|TEV-48574 Dose A (UC)|Dose regimen A administered by subcutaneous infusion for participants with UC
89245343|NCT05499130|Experimental|TEV-48574 Dose B (UC)|Dose regimen B administered by Subcutaneous infusion for participants with UC
89245344|NCT05499130|Experimental|TEV-48574 Dose A (CD)|Dose regimen A administered by subcutaneous infusion for participants with CD
89245345|NCT05499130|Experimental|TEV-48574 Dose B (CD)|Dose regimen B administered by subcutaneous infusion for participants with CD
89245346|NCT05499130|Placebo Comparator|Placebo UC|Matching Placebo
89245347|NCT05499130|Placebo Comparator|Placebo CD|Matching Placebo
89245348|NCT05497830|No Intervention|Standard care|Routine clinical care. Physicians will actively be asked to self-report their clinical impression of each included patient and policy will be monitored.
89245349|NCT05497830|Experimental|RISKINDEX|Routine clinical care. Physicians will actively be asked to self-report their clinical impression of each included patient and policy will be monitored. In the intervention group, physicians will be presented with the RISKINDEX. Subsequently, self-report will again be initiated to evaluate the physicians' response to the ML score and possible policy changes due to the intervention.
89245350|NCT05497713|No Intervention|Control Condition|No Mindset.
89245351|NCT05497713|Experimental|Egoistic x Proximal|"Mindset: This is my 5-minute exercise."
89245352|NCT05497713|Experimental|Egoistic x Distal|"Mindset: I am doing this for my health."
89245353|NCT05497713|Experimental|Altruistic x Proximal|"Mindset: I am saving one kilo of CO2: "
89245354|NCT05497713|Experimental|Altruistic x Distal|"Mindset: I am doing this to fight climate change."
89245355|NCT05494606||Participants receiving upadacitinib|Participants receiving upadacitinib for moderate to severe Ulcerative colitis (UC) in real-world practice.
89245356|NCT05492578|Experimental|Amlitelimab|Subcutaneous injection Q4W
89245357|NCT05492396||Standard gluteus medius repair|Subjects will all undergo standard gluteus medius repair that includes augmentation with the biointegrative implant.
89245358|NCT05490446|Experimental|Core Period: Phase 2a - AG-946 5 mg|Participants will receive AG-946, 5 milligrams (mg) orally, once daily for up to 16 weeks. At the discretion of the investigator, participants who complete Core Period will be eligible to receive the same dose in Extension Period for up to 156 weeks.
89245359|NCT05490446|Experimental|Double-blind Period: Phase 2b - AG-946 2 mg|Participants will receive AG-946, 2 mg orally, once daily for up to 24 weeks.
89245360|NCT05490446|Experimental|Double-blind Period: Phase 2b - AG-946 3 mg|Participants will receive AG-946, 3 mg orally, once daily for up to 24 weeks.
89245361|NCT05490446|Experimental|Double-blind Period: Phase 2b - AG-946 5 mg|Participants will receive AG-946, 5 mg orally, once daily for up to 24 weeks.
89245362|NCT05490446|Placebo Comparator|Double-blind Period: Phase 2b - Matching-placebo|Participants will receive AG-946-matching placebo orally, once daily for up to 24 weeks.
89245363|NCT05490446|Experimental|Extension Period: AG-946 2 mg|At the discretion of the investigator, participants who received placebo in the Double-blind Period will receive AG-946, 2 mg orally, once daily for up to 156 weeks.
89245364|NCT05490446|Experimental|Extension Period: AG-946 3 mg|At the discretion of the investigator, participants who received placebo in the Double-blind Period will receive AG-946, 3 mg orally, once daily for up to 156 weeks.
89245365|NCT05490446|Experimental|Extension Period: AG-946 5 mg|At the discretion of the investigator, participants who received placebo in the Double-blind Period will receive AG-946, 5 mg orally, once daily for up to 156 weeks.
89245366|NCT05483920|Experimental|One-time educational video|A one-time educational video on best practices for good sleep hygiene
89245367|NCT05483920|Experimental|One-time educational video plus automated text messaging|A one-time educational video on best practices for sleep hygiene plus daily automated text messages to reinforce habit.
89245368|NCT05477953||Pregnant women exposed to nifurtimox|The study will examine the effects of nifurtimox on fetuses, neonates and infants through 12 months of age who were exposed to nifurtimox in utero and maternal complications of pregnancy in women who were exposed to at least one dose of nifurtimox during pregnancy.
89245369|NCT05475483|Experimental|SOM3355 300 mg BID|Administration of SOM3355 in up-titration for 3 weeks up to the maintenance dose of 300 mg BID (twice daily) administered for 7 additional weeks, and down-titration for 2 weeks.
89245370|NCT05475483|Experimental|SOM3355 200 mg BID|Administration of SOM3355 in up-titration for 2 weeks up to the maintenance dose of 200 mg BID (twice daily) administered for 8 additional weeks, and down-titration for 2 weeks.
89245371|NCT05475483|Placebo Comparator|Placebo BID|Administration of matching Placebo BID (twice daily) for 12 weeks.
89245372|NCT05472506|Experimental|Cohort 1|600 mg qd PO IK-175 + nivolumab
89245373|NCT05472506|Experimental|Cohort 2|450 mg q12h PO IK-175 + nivolumab
89245374|NCT05470218|Active Comparator|Standard protein meal|Participants will receive a standard protein meal, containing about 10% of energy as protein
89245375|NCT05470218|Active Comparator|High protein meal|Participants will receive a high protein meal, containing about 50% of energy as protein
89245376|NCT05470218|Active Comparator|Low protein meal + leucine|Participants will receive a standard protein meal, containing about 10% of energy as protein to which leucine has been added to match the total leucine content of the high protein meal
89245377|NCT05469737|Experimental|Part I - Oral-Aza (Dose 1)|
89245378|NCT05469737|Experimental|Part I - Oral-Aza (Dose 2)|
89245379|NCT05469737|Experimental|Part II - Oral-Aza (RP3D)|RP3D: Recommended Phase 3 Dose
89245380|NCT05469737|Experimental|Part II - Placebo|
89245381|NCT05468320|Experimental|Caplacizumab & immunosuppressive therapy without 1st-line TPE|All participants will receive open label caplacizumab daily and immunosuppressive therapy (corticosteroid +/-anti-CD20 therapy antibody [rituximab or biosimilar]) without first line TPE
89245382|NCT05463120||IFED-2|Children who participated in the IFED study as infants (2010-2014) and a parent/guardian will be enrolled in this follow-up study in childhood and followed for at least one year.
89245383|NCT05463081|Experimental|Genitourinary disorder|"Participants with:~stress urinary incontinence,~mixed urinary incontinence with a predominance of the stress component,~genitourinary menopausal syndrome,~dystrophic and atrophic processes in the genital area,~scleroatrophic changes in the urogenital region.~Laser treatment of the vagina, vulva, and paraurethral region with Magic Gyno laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~st Stage - vaginal processing with a conical mirror handpiece,~nd Stage - vaginal processing with a corner mirror handpiece,~d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
89245384|NCT05463081|Experimental|Relaxation of vagina|"Participants with:~prolapse of the genitals I-II degree,~vaginal relaxation syndrome,~postpartum recovery,~sexual dysfunctions,~restoration of tone, turgor and tissue density of the urogenital area (Intimate rejuvenation, correction of age-related changes),~preoperative preparation for genital prolapse surgery and postoperative rehabilitation.~Laser treatment of the vagina, vulva, and paraurethral region with Magic Gyno laser. In total, three procedures will be performed with an interval of 4 weeks.~During the procedure, the following sequence of actions will be performed:~st Stage - vaginal processing with a conical mirror handpiece,~nd Stage - vaginal processing with a corner mirror handpiece,~d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
89245385|NCT05459129|Active Comparator|Atezo + Tira|Participants in the atezolizumab plus tiragolumab arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
89245386|NCT05459129|Experimental|Atezo + Tira + CP|Participants in the atezolizumab plus tiragolumab plus carboplatin plus paclitaxel arm arm will receive treatment for two cycles (6 weeks) until surgery or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
89245387|NCT05458401||Trastuzumab Deruxtecan (T-DXd) Cohort|Patients with advanced/metastatic HER2-positive breast cancer who are receiving treatment (or previously treated) with trastuzumab deruxtecan (T-DXd).
89245388|NCT05457972|Experimental|Vaginal Estrogen|Estradiol 4 mcg vaginal insert, daily for two weeks then twice weekly for ten weeks.
89245389|NCT05457972|Active Comparator|Vaginal Moisturizer|Vaginal moisturizer, daily for two weeks then twice weekly for ten weeks.
89245390|NCT05456425|Placebo Comparator|Vehicle|Emulsion eye drop without drug
89245391|NCT05456425|Experimental|0.1% CBT-001|0.1% CBT-001 emulsion eye drop
89245392|NCT05456425|Experimental|0.2% CBT-001|0.2% CBT-001 emulsion eye drop
89245393|NCT05454891|Experimental|High Fat High Protein (HFHP) Meal- extended then standard insulin bolus arm|Subjects will receive extended meal bolus for breakfast on the first day and standard meal bolus on the second day of the study.
89245394|NCT05454891|Experimental|High Fat High Protein (HFHP) Meal- standard then extended insulin bolus arm|Subjects will receive standard meal bolus for breakfast on the first day and extended meal bolus on the second day.
89245395|NCT05453695|Experimental|Intravenous DNase I|"We will enroll up to 36 Participants; each is receiving repeated unit doses of DNase I, BID, delivered by IV infusion over 3 or 7 consecutive days (12 +/- 1 hour apart) according to the following dose-escalation schedule with up to 6 Participants per dose panel.~Panel 1: 25 µg/kg, BID for 3 days (cumulative dose: 150 µg/kg)~Panel 2: 25 µg/kg, BID for 7 days (cumulative dose: 350 µg/kg)~Panel 3: 125 µg/kg, BID for 3 days (cumulative dose: 750 µg/kg)~Panel 4: 125 µg/kg, BID for 7 days (cumulative dose: 1750 µg/kg)"
89245396|NCT05453695|No Intervention|Control|We will also enroll 12 septic Participants who do not receive intravenous DNase I (as Comparator Group). These patients will be recruited contemporaneously based on the same inclusion and exclusion criteria.
89245397|NCT05452239|Experimental|Eptinezumab|Participants will receive an intravenous (IV) infusion of eptinezumab at Week 0 and Week 12.
89245398|NCT05452239|Placebo Comparator|Placebo|Participants will receive a single IV infusion of matching placebo to eptinezumab at Week 0. Then, all participants will receive a single IV infusion of eptinezumab at Week 12.
89245399|NCT05450692|Experimental|Group A: Ceralasertib plus durvalumab combination therapy|Participants will be administered ceralasertib orally followed by durvalumab administered intravenously.
89245400|NCT05450692|Active Comparator|Group B: Docetaxel monotherapy|Participants will be administered docetaxel (standard of care) administered intravenously.
89245401|NCT05448625||High Ischemic Group|"Acute myocardial infarction (AMI)~≥ 2 stents implanted~bifurcation lesion~Left main lesion~Lesion treated with rotational atherectomy~Chronic total occlusion (CTO) lesion"
89245402|NCT05442047|Experimental|NNC6019-0001, 10 mg/kg|Participants will receive intravenous (i.v.) infusion of 10 milligrams per kilograms (mg/kg) NNC6019-0001 every 4 weeks (Q4W) added to standard of care until week 52.
89245403|NCT05442047|Experimental|NNC6019-0001, 60 mg/kg|Participants will receive i.v. infusion of 60 mg/kg NNC6019-0001 Q4W added to standard of care until week 52.
89245404|NCT05442047|Placebo Comparator|Placebo|Participants will receive i.v. infusion of placebo (NNC6019-0001) Q4W added to standard of care until week 52.
89245405|NCT05441657||dyspnoeic patients with post-acute COVID-19 syndrome|Patients with persisting dyspnoeic symptoms after COVID-19 disease were examined by Electric Impedance Tomography (EIT).
89245406|NCT05441657||control group|Healthy volunteers with no lung disease and non-smokers were voluntarily examined by Electric Impedance Tomography.
89245407|NCT05441540|Experimental|Treatment Group|Device will be fitted and worn up to two hours daily and participants will log changes in symptom intensity before and during device usage
89245408|NCT05433181|Experimental|ACE2 Chewing Gum|
89245409|NCT05433181|Placebo Comparator|Placebo Chewing Gum|
89245410|NCT05432856|Experimental|Time-Restricted Eating and Sedentary Time Reduction|Group 1 (Experimental intervention): Participants assigned to this group will receive standard chemotherapy treatment plus a dietary program, and sedentary time reduction strategies, program and a Fitbit monitor. If you are randomized into this group, you will be asked to follow TRE, will receive nutritional education and individualized recommendations on improving diet quality and healthy eating practices, and given to strategies to work towards reducing sedentary time. These components will be gradually introduced over the 24-week program.
89245411|NCT05432856|No Intervention|Nutrition and Exercise Guidelines|"Group 2 (Non-experimental intervention): Participants randomized to this group will receive standard chemotherapy treatment plus a single, group-based nutrition during cancer class, as well as a copy of Canada's Food Guide, physical activity guidelines, and a Fitbit monitor. You will be asked to only make dietary changes if they are recommended within the class or by your doctor, and to maintain your usual timing and number of meals consumed per day. Throughout the 24-week period, you will receive seven brief phone calls from a study staff member to ask about your symptoms and provide support. After the end of the study, participants in this group will be offered a one-one-one counselling session with a registered dietitian."
89245412|NCT05425576|Experimental|Drug OT-101 plus pembrolizumab|"OT-101 will be administered at a RP2D dose/m2/day for 4 days continuously and 10 days off every two weeks via a portable infusion pump.~Pembrolizumab will be administered with the standard regimen of 400 mg intravenously (IV) every six weeks."
89245413|NCT05424263|Experimental|Acetate|Subjects will be orally supplemented with calcium acetate for 12 weeks. Subjects will be instructed to take a volume of the oral liquid solution that contains 1,334 mg of calcium acetate 3x per day with meals, for a total dose of 4,000 mg/day. Calcium acetate will be compounded by the CU Anschutz Medical Campus Research Pharmacy and dispensed to subjects in 4-week supplies.
89245414|NCT05424263|Placebo Comparator|Placebo|Subjects will be orally supplemented with calcium carbonate for 12 weeks. This placebo has been selected to match any potential effects of calcium and phosphate binding of the calcium acetate, i.e., we will isolate the effects of acetate. Subjects will be instructed to take a volume of the oral liquid solution equal to that of the calcium acetate group 3x per day with meals. To match the amount of elemental calcium between calcium acetate and calcium carbonate, this dose of calcium carbonate will contain 833 mg of calcium carbonate, for a total dose of 2,500 mg/day. Calcium carbonate will be compounded by the CU Anschutz Medical Campus Research Pharmacy, visually identical to calcium acetate including the packaging, and dispensed to subjects in 4-week supplies.
89245415|NCT05415618|Active Comparator|Kontrol group|
89245416|NCT05415618|Experimental|MLD group|
89245417|NCT05415618|Experimental|Nerve gliding group|
89245418|NCT05415267|Active Comparator|Group 1 Arm A|Immediate SARS-CoV-2 booster at week 0 and booster of combined diphtheria toxoid/tetanus toxoid (dT vaccine) at week 24.
89245419|NCT05415267|Active Comparator|Group 1 Arm B|dT vaccine at week 0 and SARS-CoV-2 deferred booster at week 24.
89245420|NCT05415267|Active Comparator|Group 2 Arm C|Immediate SARS-CoV-2 booster at week 0.
89245421|NCT05415267|Active Comparator|Group 2 Arm D|Delayed SARS-CoV-2 booster at week 24
89245422|NCT05411081|Active Comparator|Arm I (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and bone scans throughout the trial. Patients may also undergo collection of blood samples throughout the trial.
89245423|NCT05411081|Experimental|Arm II (cabozantinib S-malate, atezolizumab)|Patients receive cabozantinib S-malate PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and bone scans throughout the trial. Patients may also undergo collection of blood samples throughout the trial.
89245424|NCT05407675|Experimental|Part 1: BMS-986408 Monotherapy|
89245425|NCT05407675|Experimental|Part 2: BMS-986408 in combination with nivolumab|
89245426|NCT05407675|Experimental|Part 2: BMS-986408 in combination with nivolumab and ipilimumab|
88804762|NCT00005086|Experimental|Arm A|Methotrexate will be given as a short infusion (introduced into a vein) for approximately 5 minutes on the first day (day 1). ). A week later (day 8), both methotrexate and docetaxel will be given the same way, but this will take about 1 hour. The first course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks. X-rays or scans will then be performed to determine if your tumor is shrinking. You will then start treatment with gemcitabine and cisplatin. On the first day (day 1), you will receive both cisplatin and gemcitabine into your vein. A week later (day 8), you will receive only gemcitabine as an infusion into your vein over 100 minutes and no additional intravenous fluid will be required on that day. This second course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks.
88804763|NCT00005614|Experimental|Gemcitabine Treatment|Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter.
88804764|NCT00101036|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89245427|NCT05407675|Experimental|Part 2: BMS-986408 in combination with nivolumab and chemotherapy|
89245428|NCT05407675|Experimental|Part 2: BMS-986408 in combination with rabeprazole|
89245429|NCT05407675|Experimental|Part 3: BMS-986408 in combination with nivolumab|
89245430|NCT05407675|Experimental|Part 3: BMS-986408 in combination with nivolumab and chemotherapy|
89245431|NCT05405361|Experimental|Dose regimen 1|ARGX-117/Placebo IV
89245432|NCT05405361|Experimental|Dose regimen 2 or Dose regimen 3|ARGX-117/Placebo IV
89245433|NCT05396859|Experimental|Treatment (ASTX727, entrectinib)|Patients receive entrectinib PO QD on days 1-28 and ASTX727 PO QD on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89245434|NCT05395481|Experimental|LY3849891 (Part A)|Single ascending doses of LY3849891 administered subcutaneously (SC).
89245435|NCT05395481|Experimental|LY3849891 (Part B)|Repeated doses of LY3849891 administered SC.
89245436|NCT05395481|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
89245437|NCT05395481|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
89245438|NCT05395312|Experimental|Blended stepped-care group|Participants in the blended stepped-care group can access the online materials at levels based on their psychological distress through login to the platform of the JCTH+ project. They can choose their preferred online courses by using online course taster. Also, they can join offline programs corresponding to their levels of psychological distress.
89245439|NCT05395312|No Intervention|Waitlist control group|Participants in the waitlist control group will receive their usual treatment and follow their usual practice if any. They will be offered the opportunity to receive the services in the blended stepped-care group after the study has ended.
89245440|NCT05394519|Experimental|CagriSema|Cagrilintide + semaglutide once weekly
89245441|NCT05394519|Placebo Comparator|Placebo|Placebo cagrilintide + semaglutide once weekly
89245442|NCT05381194|Experimental|single arm (investigational arm)|BPaLM
89245443|NCT05380401|Other|DHA/ARA supplement|"DHA/ARA supplement throughout the duration of the protocol, d-on"
89245444|NCT05380401|No Intervention|No DHA/ARA supplement|"no DHA/ARA supplement throughout the duration of the protocol, d-off"
89245445|NCT05380401|Other|DHA/ARA initially then no supplement|"DHA/ARA supplement from enrollment to 31 6/7 weeks post-menstrual age (PMA) then no supplement from 32 to 36 weeks' PMA, x- on/off"
89245446|NCT05380401|Other|No supplement initially then DHA/ARA supplement|"No DHA/ARA supplement till 31 6/7 weeks' then long-chain polyunsaturated fatty acids (LCPUFA) supplement from 32 to 36 weeks PMA, x-off/on"
89245447|NCT05379023|Other|Face-to-face evaluation (FF), TeleNP evaluation|
89245448|NCT05379023|Other|TeleNP evaluation, Face-to-face evaluation (FF)|
89245449|NCT05378399|Experimental|Digital Pills and Beiwe|Participants will take one PrEP digital pill per day, for 60 days total, while using the ID-Cap digital pill system and Beiwe digital phenotyping app.
89245450|NCT05376618||stable COPD|
89245451|NCT05376618||Healthy|
89245452|NCT05372042|Experimental|Loss Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward preventing future losses from trauma exposure, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
89245453|NCT05372042|Experimental|Loss Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward prevent future losses from trauma exposure, and day 3 will have a simple reminder to use the skill.
89245454|NCT05372042|Experimental|Gain Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward future benefits from doing so, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
89245455|NCT05372042|Experimental|Gain Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward future benefits from doing so, and day 3 will have a simple reminder to use the skill.
89245456|NCT05372042|Experimental|No Framing + Growth Mindset|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that has no framing, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
89245457|NCT05372042|Active Comparator|No Framing + Simple Reminder|Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that has no framing, and day 3 will have a simple reminder to use the skill.
89245458|NCT05371977|Experimental|Deep sclerectomy|
89245459|NCT05371977|Active Comparator|Trabeculectomy|
89245460|NCT05371015|Experimental|quadratus lumborum nerve block group with injection of local anesthetic (Ropivacaine)|The subjects would have quadratus lumborum nerve block group with injection of local anesthetic (Ropivacaine) after vaginal delivery.
89245461|NCT05371015|Placebo Comparator|quadratus lumborum nerve block with normal saline|The subjects would have quadratus lumborum nerve block with normal saline after vaginal delivery.
89245462|NCT05369052|Experimental|contezolid acefosamil/contezolid|
89245463|NCT05369052|Active Comparator|linezolid|
89245464|NCT05363904||Atopic Dermatitis (Europe)|
89245465|NCT05363904||Healthy Controls (Europe)|
89245466|NCT05363904||Atopic Dermatitis (Tanzania)|
89245467|NCT05363904||Healthy Controls (Tanzania)|
89245468|NCT05363904||Atopic Dermatitis (Madagascar)|
89245469|NCT05363904||Healthy Controls (Madagascar)|
89245470|NCT05361421|Experimental|Intensive targeting group|Intensive lipid loweroing therapy with LDL-cholesterol goal of <55mg/dL
89245471|NCT05361421|Active Comparator|Conventional therapy group|Initiate and maintain moderate intensity statin therapy
89245472|NCT05359991|Active Comparator|Healthy Controls|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in healthy controls. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~The child will be in a fasted state.~An IV will be placed into the child's arm.~Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
89245473|NCT05359991|Experimental|Children With Documented History of SARS CoV-2 Infection|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with a documented history of SARS CoV-2 Infection. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~The child will be in a fasted state.~An IV will be placed into the child's arm.~Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
89245474|NCT05359991|Experimental|Children With Sickle Cell Disease (SCD)|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Sickle Cell Disease (SCD). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~The child will be in a fasted state.~An IV will be placed into the child's arm.~Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
89245475|NCT05359991|Experimental|Children With Cystic Fibrosis (CF)|"Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Cystic Fibrosis (CF). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur:~The child will be in a fasted state.~An IV will be placed into the child's arm.~Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise."
89245476|NCT05358717|Experimental|PTC518 5 mg|Participants will receive PTC518 5 milligrams (mg) tablets once daily orally for 12 months.
89245477|NCT05358717|Experimental|PTC518 10 mg|Participants will receive PTC518 10 mg tablets once daily orally for 12 months.
89245478|NCT05358717|Experimental|PTC518 20 mg|Participants will receive PTC518 20 mg tablets once daily orally for 12 months.
89245479|NCT05358717|Placebo Comparator|Placebo|Participants will receive placebo matching to PTC518 tablets once daily orally for 12 months.
89245480|NCT05357482|Experimental|briquilimab in stem cell transplant recipients for SCD|Affected SCD and beta-thal subjects will receive briquilimab
89245481|NCT05357482|No Intervention|Stem cell Donors of Recipients undergoing stem cell transplant|Participants donate stem cells for recipient to undergo stem cell transplant
89245482|NCT05353816|Experimental|Corheart 6 LVAS|Corheart 6 Left Ventricular Assist System (Corheart 6 LVAS) to be used on patients with end-stage heart failure.
89245483|NCT05353452|Experimental|Collaborative Care|Participants in this arm will receive 24 weeks of neurology based collaborative care.
89245484|NCT05353452|Active Comparator|Standard of Care (SOC)|Participants in this arm will receive provider-recommended clinic visits, prescriptions, testing, and referrals.
89245485|NCT05350761||Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
89245486|NCT05350761||Field Cohort|includes Proband, Other carriers in family, Family Controls
89245487|NCT05350501|Experimental|Patients With Minimal Residual Disease of Colorectal Cancer|Patients With Circulating Tumor DNA-defined Minimal Residual Disease of Colorectal Cancer Stage II, III, or IV After Completion of Curative Therapy
89245488|NCT05349864|Experimental|PF-07284890 Sequence 1|"PF-07284890 tablet will be taken by mouth in a single dose for Treatment A while fasting.~Five days later PF-07284890 tablet will be taken by mouth for Treatment B after a low fat meal.~Five days later PF-07284890 tablet will be taken by mouth for Treatment C after a high fat meal."
89245489|NCT05349864|Experimental|PF-07284890 Sequence 2|"PF-07284890 tablet will be taken by mouth for Treatment B after a low fat meal.~Five days later PF-07284890 tablet will be taken by mouth in a single dose for Treatment A while fasting.~Five days later PF-07284890 tablet will be taken by mouth for Treatment C after a high fat meal."
89245490|NCT05349721|Experimental|PTC857|"Participants will receive PTC857 during the 24-Week Treatment Period.~Following successful completion of the Treatment Period, participants who enter the Long-term Extension (LTE) Period, will receive open-label PTC857 for 28 weeks. Following completion of the LTE period, participants who enter the Continued LTE Period will receive open-label PTC857 for an additional 108 weeks."
89245491|NCT05349721|Active Comparator|Placebo|"Participants will receive matching placebo during the 24-Week Treatment Period.~Following successful completion of the Treatment Period, participants who enter the LTE Period, will receive open-label PTC857 for 28 weeks. Following completion of the LTE period, participants who enter the Continued LTE Period will receive open-label PTC857 for an additional 108 weeks."
89245492|NCT05348915|Experimental|Inclacumab 30 mg/kg|Inclacumab 30 mg/kg administered intravenously (IV)
89245493|NCT05348577|Experimental|capivasertib + docetaxel|Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.
89245494|NCT05348577|Placebo Comparator|placebo + docetaxel|Participants receive placebo in combination with docetaxel and steroids on a background of ADT.
89245495|NCT05347173|No Intervention|Bupivacaine group (B gp)|Patients will receive 2.5 ml hyperbaric bupivacaine (0.5%) plus 0.5 ml normal saline
89245496|NCT05347173|Active Comparator|Bupivacaine-Dexmedetomidine group (BD gp)|Patients will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus 10 µg Dexmedetomidine in 0.5 mL normal saline
89245497|NCT05347173|Active Comparator|Bupivacaine-Nalbuphine group (BN gp)|Patients will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus 1 mg Nalbuphine in 0.5 mL normal saline
89245498|NCT05346913|Experimental|Caregivers of Persons with Spinal Cord Injury (mTBI)|
89245499|NCT05345457|Experimental|Antibiotics|Patients randomized into the treatment (i.e., antibiotics) arm of the study will be treated with a seven-day course of oral azithromycin and amoxicillin. Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days). Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
89245500|NCT05345457|No Intervention|No antibiotics|Patients randomized into the control (i.e., no antibiotics arm) will be managed according to standard of care practices for previable PPROM desiring of expectant management.
89245501|NCT05341518|Experimental|Subscapularis repair|Patients will undergo standard of care reverse total shoulder arthroplasty with subscapularis repair
89245502|NCT05341518|No Intervention|No repair|Patients will undergo standard of care reverse total shoulder arthroplasty. The subscapularis will not be repaired.
89245503|NCT05339087|Experimental|Riociguat|patients will undergo a titration phase starting with 1mg riociguat oral tablets tid (three times daily) up to a maximum dosage of 2.5mg tid that will be continued for the remainder of the study.
89245504|NCT05339087|Placebo Comparator|Placebo|Placebo tablets with the same treatment regimen (tid) as the verum therapy will be provided. Patients will undergo a sham titration phase with sham doses individually adjusted as in the experimental arm
89245505|NCT05338307|Experimental|BHB supplementation|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol, for a total of 4 weeks.
89245506|NCT05338268|Experimental|CBT for Loneliness|CBT delivered over the course of 8, ~45 minute sessions delivered via telehealth.
89245507|NCT05338268|Active Comparator|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
89245508|NCT05336812|Experimental|Arm I (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 13 and day 1 of cycles 14-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
89245509|NCT05336812|Experimental|Arm II (acalabrutinib, venetoclax)|Patients receive acalabrutinib PO BID on days 1-28. Patients also receive venetoclax PO QD on days 1-28 days of cycles 13-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
89245510|NCT05335317|Experimental|Laser Treatment|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks.~During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
89245511|NCT05335317|Active Comparator|Topical hormone|Local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy, when the suppository will be used of 2 times a week for 1.5-2 months to prevent symptoms.
89245512|NCT05335317|Other|No treatment|Participants without vaginal atrophy (no complaints of vaginal health and a vaginal health index greater than 20) and not receiving any treatment.
89245513|NCT05332769||Infertile women have IVF/ICSI cycle|All Vietnamese infertile women who have IVF/ICSI cycle with at least 8 follicles ≥ 10 mm on ultrasonography at induced ovulation date agreed to freeze-all day 5-6 embryos at IVFMD and IVFMD PN will be enrolled in the study.
89245514|NCT05330429|Experimental|Safety Run-in Cohort: Magrolimab + Bevacizumab + FOLFIRI|Participants will receive magrolimab in de-escalating doses to establish recommended Phase 2 dose (RP2D) in combination with + bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
89245515|NCT05330429|Experimental|Randomized Cohort: Magrolimab + Bevacizumab + FOLFIRI|Participants will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
89245516|NCT05330429|Active Comparator|Randomized Cohort: Bevacizumab + FOLFIRI|Participants will receive bevacizumab (5 mg/kg every 2 weeks) + FOLFIRI (irinotecan 180 mg/m^2 + leucovorin 400 mg/m^2 + fluorouracil 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous on Days 1, 2, 15, and 16 of a 28-Day Cycle).
89245517|NCT05329584|Experimental|Group I|InSpace device + accelerated rehabilitation in a formalized program (FP)
89245518|NCT05329584|Experimental|Group II|InSpace device + accelerated rehabilitation in an at-home program (AHP)
89245519|NCT05329428|Experimental|Vitamin D Supplementation 20 µg/day|Dietary supplements containing 20 µg of vitamin D per day will be provided to study subjects.
89245520|NCT05329428|Experimental|Vitamin D Supplementation 40 µg/day|Dietary supplements containing 40 µg of vitamin D per day will be provided to study subjects.
89245521|NCT05329428|Active Comparator|Usual Antenatal Care|Women randomized to usual antenatal care will receive advise about vitamin D supplementation according to usual antenatal care routines.
89245522|NCT05325073|Other|EPO Arm|
89245523|NCT05324371|Experimental|Device Arm|WATCHMAN FLX™ device implantation
89245524|NCT05321992|No Intervention|Usual Care Community|Participants in this arm will not be given the eCHEC program
89245525|NCT05321992|Active Comparator|eCHEC Community|Participants in this arm will be given the eCHEC program as their intervention
89245526|NCT05321342|Experimental|Intervention group|This group will receive Professional Development and Coaching (CCU)
89245527|NCT05321342|No Intervention|Control group|Business as usual
89245528|NCT05320926|Experimental|Short-term DAPT followed by clopidogrel monotherapy|atients who received zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease at de novo coronary lesion will maintain 1-3 months DAPT. Patients will be randomized to stop aspirin and maintain clopidogrel after DAPT.
89245529|NCT05320926|Active Comparator|Short-term DAPT followed by aspirin monotherapy|Arm Description: Patients who received zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease at de novo coronary lesion will maintain 1-3 months DAPT. Patients will be randomized to stop clopidogrel and maintain aspirin after DAPT.
89245530|NCT05320627|Experimental|Edoxaban treatment|
89245531|NCT05318729|Experimental|Vibration tool|"Use of the vibration tool 3 times per day for 10 minutes for each session Morning, mid-day, and evening.~Volarly for 5 minutes and dorsally for 5 minutes, for a total of 10 minutes during each session:"
89245532|NCT05318729|No Intervention|Control|Standard of care, no vibration tool.
89245533|NCT05318105|Experimental|Aquadex ultrafiltration therapy|
89245534|NCT05318105|Active Comparator|IV loop diuretics|
89245535|NCT05314075|Active Comparator|Upper Body|
89245536|NCT05314075|Active Comparator|Under body|
89245537|NCT05312658|Experimental|Routine external aortic compression|The assistant surgeon or nurse places heel of the hand or fist over the abdominal aorta immediately after the baby is born while the surgeon helps the baby out, the placenta is expulsed or fetched, and the surgeon gains control over bleeding. The compression should be held until controlled bleedning, for example until the first layer of the uterine incision is sutured. Maximum time of aortic compression is 20 minutes, then a 5 minute break is required, after which compression may be reapplied.
89245538|NCT05312658|No Intervention|No external aortic compression|No routine aortic compression. If deemed vital to the mother, aortic compression should be exerted. Aortic compression may be exerted if bleeding exceeds 1000 ml.
89245539|NCT05311826|Active Comparator|STANDARD PHYSIOTHERAPY TREATMENT - CTL GROUP|Patients aged from 12 to 24 years hospitalized for corrective arthrodesis surgery with Adolescent Idiopathic Scoliosis (AIS) diagnosis.
89245540|NCT05311826|Experimental|EXPERIMENTAL diaphragmatic breathing exercise - EXP GROUP|Patients aged from 12 to 24 years hospitalized for corrective arthrodesis surgery with Adolescent Idiopathic Scoliosis (AIS) diagnosis.
89245541|NCT05310019|Experimental|Physiotherapy plus Electroacupuncture Group|The physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
89245542|NCT05310019|Active Comparator|Physiotherapy Group|The physiotherapy protocol will be the same as the active group. Protocol: warm compress with facial thermal blanket (5 min), respiratory muscle mobility training and cervical muscle relaxation (5 min) facial lymphatic drainage (10 min), start of myolyphokinetic exercises for the orbicularis oris, zygomatic major and minor, levator labii superioris and nasal ala, buccinator and platysma (5 min), release of intraoral adhesions (5 min) vacuum therapy at 60 mmHg (5 min), active exercises free of mandibular movements of right and left laterality, protrusion and mandibular opening (5 min), maintenance of mandibular opening with wooden tongue depressors (10 min).
89245543|NCT05308290|Experimental|Blood pressure managed by cerebral autoregulation|In this arm cerebral autoregulation monitoring will be used to determine the lower and upper limits of cerebral autoregulation. Monitoring will continue throughout the surgery. Blood pressure management will be maintained to be within the limits of cerebral autoregulation.
89245544|NCT05308290|Active Comparator|Standard of care blood pressure management|In this arm cerebral autoregulation monitoring will be used for observation. The anesthesia provider will use usual care guidelines for blood pressure management.
89245545|NCT05306054||Intra-Articular Knee Injury|Forty men and women aged 18-45 years old who are 1-7 years following an intra-articular knee injury.
89245546|NCT05306054||Controls|Forty men and women aged 18-45 years old who are matched to the injured group by age, sex and body mass index.
89245547|NCT05305482|Experimental|DCS group|Drug-coated stent group
89245548|NCT05305482|Active Comparator|DES group|Drug-eluting stent group
89245549|NCT05301608|Experimental|Psilocybin First|Psilocybin (10mg) will be administered one time orally as a capsule taken with water. Expected duration of acute effects is approximately 6 hours. After a period of a washout, participants will switch to the placebo intervention.
89245550|NCT05301608|Placebo Comparator|Placebo First|Participants will be administered placebo in a clinical setting. Placebo is administered orally as a capsule taken with water. After a period of a washout, participants will switch to the Psilocybin intervention.
89245551|NCT05298202|Experimental|Capsaicin gel application|Capsaicin gel will be applied to the skin prior to exercise in the heat
89245552|NCT05298202|Placebo Comparator|Hypoallergenic gel application|A hypoallergenic gel will be applied to the skin prior to exercise in the heat
89245553|NCT05294406|Experimental|IPTp-DP|Pregnant women attending routine antenatal care visits in their second and third trimester are given a monthly, presumptive treatment dose of dihydroartemisinin-piperaquine of three tablets daily for three days (9 tablets). The first dose is given by directly observed therapy (DOT), and the remaining doses given to the women to take at home.
89245554|NCT05294289||PROS patients treated with alpelisib|Patients with PROS who receive treatment with alpelisb
89245555|NCT05294289||PROS patients not treated with alpelisib|Patients with PROS who don't receive treatment with apelisib
89245556|NCT05293496|Experimental|Cohort -1|vobramitamab duocarmazine at dose level -1 and lorigerlimab intravenously (IV) every 4 weeks
89245557|NCT05293496|Experimental|Cohort 1|vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks
89245558|NCT05293496|Experimental|Cohort 2|vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks
89245559|NCT05293496|Experimental|Cohort 3|vobramitamab duocarmazine at dose level 2 and lorigerlimab IV every 4 weeks
89245560|NCT05293496|Experimental|Cohort 4|vobramitamab duocarmazine at dose level 3 and lorigerlimab IV every 4 weeks
89245561|NCT05293496|Experimental|Cohort 5|vobramitamab duocarmazine at dose level 4 and lorigerlimab IV every 4 weeks
89245562|NCT05293496|Experimental|Cohort Expansion|maximum tolerated dose of vobramitamab duocarmazine and lorigerlimab IV every 4 weeks
89245563|NCT05289310|Experimental|Normobaric hypoxia (NH)|8 weeks of overnight exposure (8 hrs/night) to NH conditions (~15% oxygen; achieved with nitrogen dilution, equivalent to ~8500 feet elevation) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
89245564|NCT05289310|Sham Comparator|Normobaric normoxia (NN)|8 weeks of overnight exposure (8 hrs/night) to NN conditions (~21% oxygen; sea level) using a commercially available tent and generator system (Hypoxico, Inc., New York, NY).
89245565|NCT05288166|Experimental|Abemaciclib + Abiraterone + Prednisone/Prednisolone|Abemaciclib plus (+) abiraterone + prednisone/prednisolone administered orally.
89245566|NCT05288166|Active Comparator|Placebo + Abiraterone + Prednisone/Prednisolone|Placebo + abiraterone + prednisone/prednisolone administered orally.
89245567|NCT05285839|Experimental|Dupixent and Narrowband UVB|Dupixent and Narrowband UVB
89245568|NCT05285553|Experimental|MiSight 1 day|MiSight 1 day
89245569|NCT05285553|Active Comparator|Proclear 1 day|Proclear 1 day
89245570|NCT05285527|Experimental|MiSight 1 Day|MiSight 1 Day
89245571|NCT05284617|Experimental|Active Treatment: HU6 Planned doses of HU6; N = 31|
89245572|NCT05284617|Placebo Comparator|Placebo Comparator Non-active study drug N = 31|
89245573|NCT05282953|Experimental|Patients with Retinitis Pigmentosa and Choroideremia|
89245574|NCT05280366|Other|Streamline Surgical System|Streamline Surgical System procedure administered
89245575|NCT05280366|Active Comparator|iStent Inject W|iStent Inject W implanted
89245576|NCT05280184|Experimental|Coin2Dose|BEI intervention that also combines automated text message reminders to dose for insulin; will test Contingent and Non-Contingent BEI
89245577|NCT05280184|No Intervention|Standard Care Control|Standard care control group; will not receive automated text message reminders to dose for insulin nor BEI for daily BOLUS scores
89245578|NCT05276453|Experimental|GMove Suit|Participants randomised to a group including normal therapy (physiotherapy) and the use of a lower-limb compression (GMove) Suit. All participants have previously completed normal NHS therapy.
89245579|NCT05276453|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
89245580|NCT05275218|Experimental|Intervention Group|Implementation of the KDIGO bundle for at least 12 hours 1. discontinuation of all nephrotoxic drugs when possible 2. optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring) 3. close monitoring of serum creatinine, fluid balance and urinary output 4. avoidance of hyperglycemia 5. considerations of alternatives to radiocontrast agents 6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period 7. avoidance of hydroxyethyl starch, gelatin, and chlorid-rich solutions
89245581|NCT05275218|No Intervention|Control Group|"Patients in the control group will receive standard of care. According to best clinical practice, this includes the following targets (unless specific individual targets are chosen by treating physician):~mean arterial pressure (MAP): ≥ 65 mmHg~passive leg raising test (PLRT): increase of cardiac output (CO)<10%"
89245582|NCT05269745|Active Comparator|Immobilization group (IG)|One group - immobilization group (IG) - will receive the standard treatment.
89245583|NCT05269745|Experimental|Immobilization/Activity Group (IAG)|The other group - Immobilization/Activity Group (IAG) - will be treated with a new approach.
89245584|NCT05269745|Other|Control Phase|Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned.
89245585|NCT05267626|Experimental|AU-007 Monotherapy|AU-007 (Q2w) will be administered as a monotherapy sequential ascending doses with each Dose Escalation Cohort
89245586|NCT05267626|Experimental|AU-007 combined with an aldesleukin loading dose|AU-007 (Q2w) will be administered at a fixed dose in combination with a single dose of aldesleukin with the initial AU-007 dose. The aldesleukin dose will be escalated with each Dose Escalation Cohort
89245587|NCT05267626|Experimental|AU-007 combined with aldesleukin given concomitantly|AU-007 will be administered at a fixed dose in combination with a aldesleukin, both administered Q2w. The aldesleukin dose will be escalated with each Dose Escalation Cohort
89245588|NCT05267613|Active Comparator|Nexium - high dose|Arm 1 (High dose = Healing dose)
89245589|NCT05267613|Active Comparator|Nexium - Low dose|Arm 2 (Low dose = ½ healing dose)
89245590|NCT05264740|Experimental|Motivational interviewing|
89245591|NCT05264740|Active Comparator|no motivational interviewing|
89245592|NCT05262803|No Intervention|Standard-of-care DAPT|Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and prasugrel or ticagrelor for 6 months followed by ASA monotherapy.
89245593|NCT05262803|Experimental|Genotype-guided DAPT|DAPT according to CYP2C19*2/*3-genotyping for 6 months followed by ASA monotherapy.
89245594|NCT05262803|Experimental|Shorter genotype-guided DAPT|DAPT according to CYP2C19*2/*3-genotyping for 3 months followed by ASA monotherapy.
89245595|NCT05262296||Laparoscopic Surgeon|This cohort of participants will have their procedure completed by a human surgeon.
89245596|NCT05262296||Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System
89245597|NCT05255991|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer QID
89245598|NCT05255991|Experimental|Inhaled Treprostinil|Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
89245599|NCT05254171|Experimental|Experimental Arm|SBP-101 + Nab-paclitaxel and Gemcitabine
89245600|NCT05254171|Placebo Comparator|Control Arm|Placebo + Nab-Paclitaxel and Gemcitabine
89245601|NCT05253768|Experimental|intervention|Patients who receive a fecal microbiota transplantation via a nasointestinal tube.
89245602|NCT05253768|Placebo Comparator|placebo|Patients who receive a placebo FMT via a nasointestinal tube.
89245603|NCT05253586||Laparoscopic Arm|This cohort of participants will have their procedure completed by a human surgeon.
89245604|NCT05253586||Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
89245605|NCT05249634|Experimental|treatment|JATENZO daily for 6 months
89245606|NCT05248191|Experimental|Capsule fecal microbiota material (cap-FMT)|Participants will receive colonoscopy at day 0 and week 8 and receive cap-FMT orally for five days post-colonoscopy. Stool swabs and samples will be collected regularly.
89245607|NCT05248191|Active Comparator|Colonoscopic fecal microbiota material (colo-FMT) plus placebo|Participants will receive colonoscopy at day 0 and week 8 and receive a placebo orally for five days post-colonoscopy. During the first colonoscopy, colo-FMT will be administered. Stool swabs and samples will be collected regularly.
89245608|NCT05247047|Experimental|Device|Clusters in this arm will start using the device and use it for 6 weeks.
89245609|NCT05247047|No Intervention|Control|Clusters in this arm will not receive the device it will continue with usual care with no changes.
89245610|NCT05244928|Experimental|Cluster 1.|The clusters will be formed from two ambulance stations (Approximately 50 participants).
89245611|NCT05244928|Experimental|Cluster 2.|The clusters will be formed from five ambulance stations (Approximately 70 participants).
89245612|NCT05241990|Experimental|Alcohol Stepped Care|Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
89245613|NCT05241379|Experimental|Amber UI Therapy|Participants will undergo surgical implantation of the Amber UI System incorporating 2 electrode leads connected to a single IPG
89245614|NCT05238623||Control cohort|lung-healthy volunteers get a EIT measurement
89245615|NCT05238623||Case cohort|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement
89245616|NCT05235464|Active Comparator|Standard meal|
89245617|NCT05235464|Experimental|High animal protein meal|
89245618|NCT05235464|Experimental|High plant protein meal|
89245619|NCT05235464|Experimental|High plant protein meal with additional leucine|
89245620|NCT05234307|Experimental|Treatment (PBF-1129, nivolumab)|Patients receive PBF-1129 PO QD and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89245621|NCT05232045||Automated urinary output collection system group (tight monitoring of urine output)|
89245622|NCT05232045||Manual urinary output collection system group (routine monitoring of urine output)|
89245623|NCT05231954|No Intervention|Annual Well Visit or any other visit to Primary Care Doctor|Annual Well Visit or any other visit to Primary Care Doctor: This is the usual care arm. Electronic Health Record Data for patients from the clinics randomized to usual care will be collected for comparison with the other 2 arms. Patients from these primary care clinics must have had a visit to their doctor either as an annual well visit (AWV) or any other type of visit. These clinics will not have to do anything for the study but run their business as usual without altering anything.
89245624|NCT05231954|Experimental|Passive Digital Marker (PDM)|Passive Digital Marker (PDM): Electronic Health Record Data from those clinics randomized to PDM will be run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset.
89245625|NCT05231954|Active Comparator|Passive Digital Marker (PDM) + Quick Dementia Rating Scale (QDRS)|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
89245626|NCT05231668|Experimental|SAR439459|Participants will receive a single dose of SAR439459
89245627|NCT05231668|Placebo Comparator|Placebo|Participants will receive a single dose of placebo
89245628|NCT05228275||Observational (survey, biospecimen collection)|Patients receive COVID-19 vaccine per standard of care. Patients also complete a survey at 1 month and undergo collection of blood samples at 1, 3, 6, 12, 18, and 24 months. Patients may complete an additional survey at 1 month after each vaccine boost and undergo collection of blood samples before each vaccine boost, 1 month after each vaccine boost, and at the time of COVID-19 infection.
89245629|NCT05226026|Experimental|NiteCAPP HELPS|4 weeks of online CBT-I (1 session/week for 1 hour), followed by tapered withdrawal and motivational interviewing and check-ins.
89245630|NCT05226026|Other|Treatment as Usual|Continuation of standard treatment for sleep and pain for 4 weeks, followed by tapered withdrawal and motivational interviewing and check-ins.
89245631|NCT05222308|Other|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
89245632|NCT05221840|Experimental|Arm A: Durvalumab and Oleclumab|Durvalumab on Day 1 of each 28-day cycle + Oleclumab on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months
89245633|NCT05221840|Experimental|Arm B: Durvalumab and Monalizumab|Durvalumab + Monalizumab on Day 1 of each 28-day cycle for up to 12 months. Placebo infusion will be administered on Day 15 of cycles 1 and 2 only
89245634|NCT05221840|Active Comparator|Arm C: Durvalumab and Placebo|Durvalumab on Day 1 of each 28-day cycle + Placebo on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months
89245635|NCT05219500|Experimental|FPI-2265|All patients will receive FPI-2265, administered at 8 ± 1-week interval, with the initial activity of 100 kBq/kg (±10%).
89245636|NCT05216835|Experimental|Cohort A: Dose Escalation|Patients with anti-PD-1/PD-L1 exposed r/r cHL will receive AZD7789.
89245637|NCT05216835|Experimental|Cohort B1: Dose Expansion|Patients with anti-PD-1/PD-L1 exposed r/r cHL will receive AZD7789 once the recommended phase 2 dose (RP2D) has been determined.
89245638|NCT05216835|Experimental|Cohort B2: Dose Expansion|Patients with anti-PD-1/PD-L1 naïve r/r cHL will receive AZD7789 once the RP2D has been determined.
89245639|NCT05215496|Experimental|[18F]fluoro-PEG-folate PET/CT scan|Patients with FIGO stage IIIB/IIIC epithelial ovarian cancer, 185 MBq of [18F]fluoro-PEG-folate.
89245640|NCT05215340|Experimental|Pembrolizumab + Datopotamab Deruxtecan (Dato-DXd)|Participants will be randomized to receive 200 mg pembrolizumab followed by 6.0mg/kg Dato-DXd.
89245641|NCT05215340|Active Comparator|Pembrolizumb|Participants will be randomized to receive 200 mg pembrolizumab.
89245644|NCT05203289|Experimental|BI 695501 40 mg/0.4 mL (T)|Participants were subcutaneously injected 40 milligram (mg)/0.4 milliliter (mL) of BI 695501 solution for injection in prefilled syringe (PFS) (Test Treatment (T)).
89245645|NCT05203289|Experimental|BI 695501 40 mg/0.8 mL (R)|Participants were subcutaneously injected 40 milligrams (mg)/0.8 milliliter (mL) of BI 695501 solution for injection in prefilled syringe (PFS) (Reference Treatment (R)).
89245646|NCT05200676||Main group|"All included in the study will offered to participate in:~ePatch-monitoring~Blood pressure measurement~Cardial vagal tone~Questionnaire-assessment"
89245647|NCT05200676||Subgroup|"Part of the study-population will be offered to participate in en examination with a SmartPill. The Smartpill measures pressure, pH, temperature and movement in the gut. These measurements gives an indication of the function of the autonomic nervous system (ANS) of the participant. Although measured in the gut, this is relevant as ANS-dysfunction may cause arrhythmias.~Only a subgroup of the study population will be offered to participate due to the cost of this examination."
89245648|NCT05197465||Patients undergoing major abdominal surgery|The investigators aim to conduct a prospective observational, cohort study including all patients undergoing a major open abdominal surgery.
89245649|NCT05196880||ARM 1|Patients with negative clinical suspicion of Biofilm containing wounds(CSB-).
89245650|NCT05196880||ARM 2|Patients with positive clinical suspicion of Biofilm containing wounds(CSB+)
89245651|NCT05193370|Experimental|angiotensin II (intervention)|For patients randomized to the intervention group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, angiotensin II will be started at a dose of 20 ng/kg/min (recommended starting dose in package insert). Thereafter, angiotensin II and norepinephrine will both be titrated according to the schema in UNM Hospitals Nursing Department Titration Guideline. Angiotensin II treatment will be capped at 72h, at which point (if a second vasopressor is still needed) the patient will be started on an alternative agent.
89245652|NCT05193370|Active Comparator|vasopressin (standard of care)|In patients randomized to the control group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, vasopressin will be used at a fixed dose of 0.04 units/min and norepinephrine will be titrated per usual standard of care (as also outlined in the UNM Hospitals Nursing Department Titration Guideline).
89245653|NCT05185947|Experimental|1/ IP Catheter Placement and Bidirectional Chemotherapy|IP and IV paclitaxel administration with oral nilotinib
89245654|NCT05184894|Experimental|AKI in Care Transitions (ACT) Group|Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will participate in the ACT program which provides standardized education and assists with coordination of follow up care after hospital stay.
89245655|NCT05184894|No Intervention|Usual Care Group|Subjects diagnosed with Acute Kidney Injury (AKI) during their hospital stay will receive standard of care from their inpatient and outpatient care teams.
89245656|NCT05183217|Active Comparator|Online continence promotion program without tailoring|Participants will be allocated to the online continence promotion program without tailoring.
89245657|NCT05183217|Experimental|Online continence promotion program with tailoring|Participants will be allocated to the online continence promotion program with tailoring.
89245658|NCT05182073|Experimental|Regimen A|FT576 single dose monotherapy in subjects with r/r MM
89245659|NCT05182073|Experimental|Regimen A1|FT576 multiple dose monotherapy in subjects with r/r MM
89245660|NCT05182073|Experimental|Regimen B|FT576 single dose in combination with daratumumab in subjects with r/r MM
89245661|NCT05182073|Experimental|Regimen B1|FT576 multiple dose in combination with daratumumab in subjects with r/r MM
89245662|NCT05180084|Experimental|Cognitive Behavior Therapy|Therapist-Guided Internet based Cognitive Behavior Therapy
89245663|NCT05180084|No Intervention|Wait-list control|Wait-list control participants will receive the same treatment at the end of the study period.
89245664|NCT05175105|Experimental|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
89245665|NCT05175105|Placebo Comparator|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
89245666|NCT05175105|Experimental|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the OLE period will first receive blinded mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment before being transitioned to only receive active, open-label drug (mitapivat).
89245667|NCT05174416|Experimental|Mavacamten|Mavacamten Capsules
89245668|NCT05174416|Placebo Comparator|placebo|Matching Placebo Capsules
89245669|NCT05169970|Experimental|Patients with low-intermediate risk Decipher scores|Will receive ultrahypofractionated EBRT to the prostate and seminal vesicles (40Gy in 5 fractions).
89245670|NCT05169970|Experimental|Patients with high risk Decipher scores|Will receive ultrahypofractionated EBRT to the prostate and seminal vesicles (40Gy in 5 fractions) with a boost of up to 45Gy to the dominant intraprostatic lesion as identified on pretreatment MRI plus hypofractionated pelvic EBRT (25Gy in 5 fractions).
89245671|NCT05169385|Experimental|Parent SMART|Parent SMART is a technology-assisted parenting intervention combining an off-the-shelf computer program (Parenting Wisely), up to four telehealth coaching sessions, and access to an app-based networking forum.
89245672|NCT05169385|Active Comparator|Treatment as Usual|The active comparator is defined as residential treatment services as usual.
89245673|NCT05168332|Experimental|Experimental(Group A): patellar taping combined with isometric strength training|The experimental group (Group A): patellar taping with isometric strength training for six weeks.
89245674|NCT05168332|Sham Comparator|Control group (Group B): sham patellar taping combined with isometric strength training.|Control group (Group B): sham patellar taping combined with isometric strength training for six weeks.
89245675|NCT05166356||Patients|A sample of patients who received the NOHARM intervention after their surgery.
89245676|NCT05166356||Care Team Members|Staff members who had patients on the NOHARM intervention
89245677|NCT05162911|Active Comparator|Ask, Advise, Assist (AAA) and Refer.|Patients will receive Ask, Advise, Assist (AAA) and refer to the quitline as the intervention.
89245678|NCT05162911|Active Comparator|AAA plus referral to onsite counselor (Counsel).|Patients will receive Ask, Advise, Assist plus referral to onsite counselor.
89245679|NCT05162911|Active Comparator|AAA+Counsel+N (Nicotine gum).|Patients will receive Ask, Advise, Assist, plus referral to onsite counselor and nicotine gum.
89245680|NCT05158140|Experimental|V110 Concomitant with mRNA-1273 (V110 Concomitant)|Participants received a single 0.5 mL intramuscular (IM) injection of V110 concomitantly with a single 0.25 mL IM injection of mRNA-1273 on Day 1, followed by a single 0.5 mL IM injection of placebo for V110 on Day 30.
89245681|NCT05158140|Experimental|V110 Nonconcomitant with mRNA-1273 (V110 Nonconcomitant)|Participants received a single 0.5 mL IM injection of placebo for V110 on Day 1 concomitantly with a single 0.25 mL IM injection of mRNA-1273, followed by a single 0.5 mL IM injection of V110 on Day 30.
89245682|NCT05158140|Experimental|V114 Concomitant with mRNA-1273 (V114 Concomitant)|Participants received a single 0.5 mL IM injection of V114 concomitantly with a single 0.25 mL IM injection of mRNA-1273 on Day 1, followed by a single 0.5 mL IM injection of placebo for V114 on Day 30.
89245683|NCT05158140|Experimental|V114 Nonconcomitant with mRNA-1273 (V114 Nonconcomitant)|Participants received single 0.5 mL IM injection of placebo for V114 on Day 1 concomitantly with a single 0.25 mL IM injection of mRNA-1273, followed by a single 0.5 mL IM injection of V114 on Day 30.
89245684|NCT05156268|Experimental|Pembrolizumab with Olaparib|Eligible patients will receive olaparib in combination with pembrolizumab. Olaparib will be administered orally at 300 mg every 12 hours. Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
89245685|NCT05148299|Experimental|Pegcetacoplan|
89245686|NCT05144256|Experimental|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 24 weeks in the fixed-dose period.
89245687|NCT05144256|Placebo Comparator|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 24 weeks in the fixed-dose period.
89245688|NCT05144256|Experimental|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the OLE period will first receive blinded mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment before being transitioned to only receive active, open-label drug (mitapivat).
89245689|NCT05140733||Fusion|1 or 2 levels fusion surgery
89245690|NCT05140733||Foraminotomy|1 or 2 levels lumbar foraminotomy
89245691|NCT05140278|Experimental|1-step Artesunate parenteral arm|Argesun (Artesunate 60 mg)
89245692|NCT05140278|Experimental|2-step Artesunate parenteral arm|Artesun (Artesunate 60 mg)
89245693|NCT05139056|Experimental|Treatment (NSC-CRAd-S-pk7)|Patients undergo standard of care surgical resection. Patients then receive NSC-CRAd-S-pk7 intracerebrally over 10 minutes QW for up to 4 doses in the absence of disease progression or unacceptable toxicity.
89245694|NCT05138575|Active Comparator|Empagliflozin + Potassium Chloride (KCl)|"Empagliflozin (10 mg daily) + Potassium Chloride (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
89245695|NCT05138575|Active Comparator|Empagliflozin + Potassium Nitrate (KNO3)|"Empagliflozin (10 mg daily) + Potassium Nitrate (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
89245696|NCT05138575|Placebo Comparator|Potassium Chloride (KCl) + Placebo for Empa|"Potassium Chloride (6 mmol three times daily) + Placebo for Empagliflozin~Placebo arm will be 6 weeks in duration followed by a 2 week washout period."
89245697|NCT05135000|Experimental|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 24 weeks
89245698|NCT05135000|Placebo Comparator|Placebo|Participants will receive LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 24 weeks
89245699|NCT05128513|Experimental|DELP|Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration
89245700|NCT05128513|No Intervention|control group|
89245701|NCT05124132|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) as delivered in the parent study (Protocol ID #201410093) consisted of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content included instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life. For the current study, participants will continue monthly approximately 2.5 hour booster sessions covering similar content for the duration of the study. Participants will be encouraged to maintain daily formal meditative activities at home.
89245702|NCT05124132|Experimental|Exercise|The exercise protocol in the parent study (Protocol ID #201410093) was optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty. It consisted of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months. For the current study, participants will continue monthly approximately 1.5 hour classes focused on functional training for the duration of the study. Participants will be encouraged to continue between-session engagement in aerobic and resistance training activities at home.
89245703|NCT05124132|Experimental|Mindfulness-Based Stress Reduction + Exercise|This condition will receive both MBSR and exercise as described. Participants in this condition will attend monthly sessions with encouragement to complete at-home mindfulness practice as well as at-home exercise for the duration of the study.
89245704|NCT05124132|Active Comparator|Health Education|The health education control condition is based on a chronic disease self-management program developed at Stanford University and was used as an attentional control in the parent study (Protocol ID #201410093). This control intervention was designed to be time-equivalent to MBSR, with 8 weeks of 2.5 hour weekly group classes followed by monthly booster sessions for approximately 15 months. For the current study, participants will continue monthly approximately 1.5 hour sessions covering similar content for the duration of the study.
89245705|NCT05124080|Experimental|Deucravacitinib 6 mg Daily|All participants will receive 6 mg of deucravacitinib daily.
89245706|NCT05120349|Experimental|Osimertinib|Osimertinib 80mg, orally, once daily (Dose may be reduced to 40 mg once daily if required at the discretion of the investigator)
89245707|NCT05120349|Placebo Comparator|Placebo|Matching placebo for osimertinib, orally, once daily
89245708|NCT05119192||Veterans with Dysvascular Lower Limb Amputation|Self-report assessments, performance-based assessments, and optional individual interview with Veterans with dysvascular lower limb amputation.
89245709|NCT05118893||Ablation-based rhythm-control|Ablation-based rhythm-control consisted of pulmonary vein isolation in paroxysmal atrial fibrillation, and additional ablation for persistent atrial fibrillation
89245710|NCT05118893||Rate-control|Rate-control included AV-nodal blocking agents and AV node ablation with permanent pacing
89245711|NCT05114356||Study group|Patients being treated for degenerative disc disease
89245712|NCT05112302||Virtual reality|
89245713|NCT05109754|Experimental|BPAP EFL|"Phase 1: use device for 2 months~Phase 2: use device for 12 months"
89245714|NCT05109208|Experimental|Ultrasound viscoelastography (UVE) in radical proctectomy recovery|Subjects undergoing radical prostatectomy for prostate cancer disease as standard of care will have a ultrasound vibroelastography performed before surgery, 3 months, 6 months and 9 months post-prostatectomy.
89245715|NCT05105971|Experimental|BAT6026 0.01mg/kg|BAT6026 0.01mg/kg,intervenous infusion,sample size 1
89245716|NCT05105971|Experimental|BAT6026 0.03mg/kg|BAT6026 0.03mg/kg,intervenous infusion,sample size 1
89245717|NCT05105971|Experimental|BAT6026 0.1mg/kg|BAT6026 0.1mg/kg,intervenous infusion,sample size 3~6
89245718|NCT05105971|Experimental|BAT6026 0.3mg/kg|BAT6026 0.3mg/kg,intervenous infusion,sample size 3~6
89245719|NCT05105971|Experimental|BAT6026 1mg/kg|BAT6026 1mg/kg,intervenous infusion,sample size 3~6
89245720|NCT05105971|Experimental|BAT6026 3mg/kg|BAT6026 3mg/kg,intervenous infusion,sample size 3~6
89245721|NCT05105971|Experimental|BAT6026 6mg/kg|BAT6026 6mg/kg,intervenous infusion,sample size 3~6
89245722|NCT05105971|Experimental|Amplification group|BAT6026 10mg/kg,intervenous infusion,sample size 3~6
89245723|NCT05105919|Experimental|Aspirin therapy|All participants will be assigned to aspirin therapy. Participants will receive 80 mg of enteric coated aspirin per day for a 7 day period.
89245724|NCT05096429|Experimental|Intervention|Within these cities/towns, the health department will work with stakeholders to prioritize overdose prevention interventions to neighborhoods with the highest probability of future overdose deaths, as predicted by the PROVIDENT model.
89245725|NCT05096429|No Intervention|Control|Cities/towns assigned to the control arm will continue to work with the health department and distribute these interventions at existing resource levels, but without receiving information on predicted probability of overdose risk for specific neighborhoods.
89245726|NCT05094219||Observation group|Patients with a confirmed diagnosis of Parkinson's disease will be followed up for 12 months from the date of enrollment.
89245727|NCT05086224|Other|Hematoma Block|Inject 20 mL of 1% lidocaine without epinephrine into the hematoma site.
89245728|NCT05086224|Other|Bier Block|Intravenous administration a maximum lidocaine dose of 3 mg/kg.
89245729|NCT05084274|Active Comparator|Lifestyle intervention group|12-week lifestyle modification programme through face-to-face lifestyle counseling and physiotherapy combined with a follow-up programme using video consultations and online training sessions
89245730|NCT05084274|No Intervention|Standard-of-care group|No intervention
89245731|NCT05083091|Active Comparator|Monitor & Accept (MA-MBI)|14-day smartphone based mindfulness meditation attention monitoring and acceptance skills training intervention consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
89245732|NCT05083091|Active Comparator|Monitor Only (MO-MBI)|14-day smartphone based mindfulness meditation training intervention consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
89245733|NCT05083091|Active Comparator|Coping Condition (CC)|14-day smartphone based training intervention focused on coping strategies consisting of a 5-minute introductory video, a 20-minute audio-guided lesson, plus daily life homework practice (3-10 minutes) each day.
89245734|NCT05077800|Experimental|Safety Run-In: FOLFIRINOX + 9-ING-41 + Losartan|"The study will begin with a Safety Run-In phase to establish the side effects from the study treatment to its safety before beginning the main part of the study, six (6) participants will receive 1-2 cycles of:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~9-ING-41 on days on days 1, 3, 8, and 11 of every 14-day cycle~Losartan daily of every 14-day cycle."
89245735|NCT05077800|Experimental|FOLFIRNINOX|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy, participants will receive FOLFIRINOX as follows:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~For Maintenance therapy, participants will receive FOLFIRINOX as follows:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX until further disease progression"
89290292|NCT01126242|Experimental|tape|Group I will be treated with non-elastic adhesive tape around the affected ankle, applied by the 'van Unen-technique'. This technique is an alternative for the 'Coumans- technique'. The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity. Taping is a treatment that involves no loss of time, requires no crutches and is not attended with any ultimate impairment of function.
89245736|NCT05077800|Experimental|FOLFIRINOX + Losartan|"The study will be conducted in three parts depending on participant disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Losartan daily up to 12 cycles (24 weeks)~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~Losartan daily until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + Losartan until further disease progression"
89245737|NCT05077800|Experimental|FOLFIRINOX + 9-ING-41|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle up to 12 cycles (24 weeks)~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle up to 12 cycles (24 weeks)~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle up to 12 cycles (24 weeks)~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression~For Complete Therapy Round 2, repeat of initial complete therapy until further disease progression"
89245738|NCT05077800|Experimental|FOLFIRINOX + 9-ING-41 + Losartan|"The study conducted in 3 parts depending on disease progression: Complete Therapy, Maintenance Therapy and Complete Therapy Round 2.~For initial complete therapy:~FOLFIRINOX~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle~Irinotecan portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Oxaliplatin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~Leucovorin portion of FOLFIRINOX on Day 1 of each 14 day study cycle~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle~Losartan daily~For Maintenance therapy:~5Fluorouracil portion of FOLFIRINOX on Days 1-3 of each 14 day study cycle until disease progression~9-ING-41 on days 1, 3, 8, and 11 of every 14-day cycle until disease progression~Losartan daily until disease progression~For Complete Therapy Round 2, participants will repeat initial complete therapy of FOLFIRINOX + 9-ING-41+ Losartan until further disease progression"
89245739|NCT05067842||Locally advanced esophageal or gastroesophageal adenocarcinoma|Subjects with diagnosed locally advanced esophageal or gastroesophageal adenocarcinoma.
89245740|NCT05065658||Critically-ill COVID-19 patients receiving posaconazole prophylaxis|
89245741|NCT05065658||Critically-ill COVID-19 patients without antifungal prophylaxis|
89245744|NCT05057494|Experimental|Arm A: Acalabrutinib plus Venetoclax (AV)|Participants will receive acalabrutinib and venetoclax orally.
89245745|NCT05057494|Experimental|Arm B: Venetoclax plus Obinutuzumab (VO)|Participants will receive Venetoclax orally and Obinutuzumab via IV infusion.
89245746|NCT05055297|Experimental|SELUTION SLR™ DEB 014|
89245747|NCT05055297|Active Comparator|Plain (Uncoated) Balloon Angioplasty (PTA)|
89245748|NCT05054348|Experimental|IO-108 Monotherapy|Treatment of patients with advanced solid tumors with IO-108 monotherapy
89245749|NCT05054348|Experimental|IO-108 + pembrolizumab combination therapy|Treatment of patients with advanced solid tumors with IO-108 in combination with a fixed dose of pembrolizumab
89245750|NCT05054348|Experimental|IO-108 + cemiplimab combination therapy|Treatment of patients with advanced solid tumors with IO-108 in combination with a fixed dose of cemiplimab
89245751|NCT05051722||Cohort 1 - AUB / PMB|Women ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology.
89245752|NCT05051722||Cohort 2 - Biopsy-proven EC or AEH or EIN|Women ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology.
89245753|NCT05051722||Cohort 3 - Cervix pathology|Women ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings.
89245754|NCT05051722||Cohort 4 - Benign Uterine Pathology|Women with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All women enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery.
89245755|NCT05051722||Cohort 5 - Healthy Control Women|Healthy women ≥45 years of age presenting for well-woman exams to serve as a control group. These women will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These women will not have known or clinically-suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions.
89245756|NCT05051722||Cohort 6- Isolated Adnexal Mass Cohort (ovarian or fallopian mass)|Women ≥50 years of age and postmenopausal (12 months since LMP or available blood hormone levels confirming postmenopausal status) and an isolated adnexal mass or isolated bilateral adnexal masses being surgically removed. These patients will have a final diagnosis of any of the following: benign ovarian neoplasm, borderline tumor of the ovary, or clinically early-stage OC.
89245757|NCT05051722||Cohort 7 - OC Cohort - Biopsy proven or clinically suspected ovarian cancer (OC)|Women ≥18 years of age with ovarian cancer (OC) (clinically probable based on distribution of pelvic/abdominal masses on imaging, elevated CA-125, ascites, and/or imaging-guided biopsy proven) presenting for neoadjuvant chemotherapy or primary surgical management (debulking or staging) of their OC. The umbrella of OC also includes fallopian tube cancer and primary peritoneal cancer. All histologies are eligible for enrollment.
89245758|NCT05048251|Experimental|cTBS|continuous TBS to right MFG
89245759|NCT05048251|Experimental|iTBS|intermittent TBS to right MFG
89245760|NCT05048251|Sham Comparator|sham|sham stimulation to right MFG
89245761|NCT05040386|Active Comparator|Usual COPD Care|Participants randomized to this arm will receive the standard of care for COPD.
89245762|NCT05040386|Experimental|Intervention (EPIC plus Usual COPD Care)|Participants randomized to this arm will receive the experimental treatment for COPD (i.e. EPIC plus usual COPD care).
89245765|NCT05038176|Experimental|Active intervention group (AI)|The active intervention group (AI) receiving the active treatment (MANUP intervention) which include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
89245766|NCT05038176|Active Comparator|Delayed intervention group (DI)|"DI participants will only receive motivational text-messages. They will then flip and receive full intervention after the AI group has completed the program."
89245767|NCT05035095|Experimental|Oral semaglutide|Participants will receive once daily semaglutide tables in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68)
89245768|NCT05035095|Placebo Comparator|Oral semaglutide placebo|All participants are given once daily dose for 68 weeks
89245769|NCT05032157|Experimental|Arm 1: LOU064 (blinded)|LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
89245770|NCT05032157|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
89245771|NCT05030584|Active Comparator|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
89245772|NCT05030584|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily.
89245773|NCT05029128|Other|Exercise|All participants engage in exercise training
89245774|NCT05026866|Experimental|Donanemab|Donanemab administered intravenously (IV)
89245775|NCT05026866|Placebo Comparator|Placebo|Placebo is administered intravenously
89245776|NCT05026203|Experimental|Ketamine|
89245777|NCT05026203|Placebo Comparator|Midazolam|
89245778|NCT05025488|Experimental|CALR mutated|peptide-based vaccine in patients with myeloproliferative neoplasm (myelofibrosis and essential thrombocythemia) with CALR mutations
89245779|NCT05024955||Observational (interview, discussion)|Participants attend an interview over 45-60 minutes and/or a focus group over 1.5 to 2 hours.
89245780|NCT05023538|No Intervention|Usual care|No intervention
89245781|NCT05023538|Experimental|Low-volume moderately-intense exercise|exercise at 50-65%VO2peak; 20-30min/training session, 3x/week, 6 months
89245782|NCT05023538|Experimental|High-volume moderately-intense exercise|exercise at 50-65%VO2peak; 20-50min/training session, 3x/week, 6 months
89245783|NCT05023538|Experimental|Low-volume high-intense exercise|exercise at 50-85%VO2peak; 20-30min/training session, 3x/week, 6 months
89245784|NCT05022121|Experimental|Supported Biopsychosocial Self-Management (SBSM)|Supported Biopsychosocial Self-Management (SBSM)
89245785|NCT05022121|Active Comparator|Medical Care|Medical Care
89245786|NCT05021731|Active Comparator|3-month Isoniazid plus Rifampicin|Daily isoniazid 300 mg plus rifampicin 600 mg for three months
89245787|NCT05021731|Experimental|3-month Isoniazid plus Rifapentine|Weekly isoniazid 900 mg plus rifapentine 900 mg for 12 weeks
89245788|NCT05021731|Experimental|4-month Rifampicin|Daily rifampicin 600 mg for four months
89245789|NCT05020184|Active Comparator|Cimetidine|Cimetidine 800mg orally twice daily
89245790|NCT05020184|Placebo Comparator|Placebo|Placebo capsule orally twice daily
89245791|NCT05019144|Active Comparator|Face-to-face arm|Standard face-to-face burn care.
89245792|NCT05019144|Experimental|TOBI arm|A novel smartphone application for burn wound care, called the Telemedicine Optimized Burn Intervention (TOBI), was recently developed to enable burn experts to direct burn wound care while the patient and caregiver are home through text messaging and video-conferencing. The app was designed to bring expert wound care directly to the patient's home to address barriers to healthcare, including high cost burden and time commitment (e.g., geographic limitations, transportation to burn centers, parking, lodging, meals, time away from school and work), particularly for patients/families in rural and medically underserved communities. TOBI is synced with a portal used by providers, as an adjunct to standard therapy. This burn app provides education through frequently asked questions, instructional burn dressing change videos in addition to direct communication between patient and burn expert through store-and-forward pictures and videoconferencing.
89245793|NCT05018091|Active Comparator|Group 1|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
89245794|NCT05018091|Active Comparator|Group 2|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
89245795|NCT05018091|Active Comparator|Group 3|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
89245796|NCT05016141|No Intervention|no intervention|Participants will be observed for 12 months. Participants will use the Health in Motion app to set goals and keep track of their health and health events, including falls. These participants will NOT receive the education modules or the exercise program.
89245797|NCT05016141|Experimental|digital fall prevention program|Participants will complete the Health in Motion digital fall prevention program for 12 months. This program consists of education modules (modified from the Matter of Balance Program) and exercises based on a digital translation of the Otago Exercise Program.
89245798|NCT05012670|Experimental|[14C]-Paxalisib Capsule|Subjects will be dosed on the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects will remain resident in the clinical unit until 168 h post dose (Day 8) and this may be extended up to a maximum of 48 h (i.e., up to Day 10).
89245799|NCT05012072|Experimental|MLI Experimental group|6 group sessions over 6 weeks with pregnant Latinas and African Americans starting at 14-20 weeks to 20-26 weeks in their prenatal care setting.
89245800|NCT05012072|No Intervention|Control usual prenatal care|Only data collection but no intervention
89245801|NCT05011799|Experimental|Arm I (health education)|Participants attend 1-2 monthly peer educator-led education sessions about PCA genetic testing over 3 hours each for 18 months.
89245802|NCT05011799|Active Comparator|Arm II (cancer educational materials)|Participants receive mailed informational materials about PCA risk, family history, and genetic testing.
89245803|NCT05009095|Experimental|The Listening Program® with bone conduction headphones|"The Listening Program ® Spectrum music requires a person listen to psycho-acoustically modified classical music online using specialized Waves ™ headphones. The headphones transmit sound through bone conduction which provides another mode of perceiving sound (https://advancedbrain.com). The Listening Program ® can be carried out in the home environment with either the base schedule, two fifteen minute sessions at least 30 minutes apart, or a condensed schedule for 30 minutes.~Bone conduction allows the listening experience to go deeper into the vestibular system which is purported to reduce stress, help regulate the fight or flight response, and allow the listener to achieve a state of calm and relaxed alertness. This theory is based on the function of the vagus nerve, the 10th cranial nerve, which has branches that extend to the eardrum. Stimulation of the vagus nerve stimulates the parasympathetic nervous system (Allen, 2008)."
89245804|NCT05006079|Placebo Comparator|Placebo drug|Lactose, administered both at 9:30 am and 12:00 pm
89245805|NCT05006079|Active Comparator|Morphine alone|15mg immediate-release oral morphine, administered both at 9:30 am and 12:00 pm
89245806|NCT05006079|Active Comparator|Alprazolam alone|0.25mg oral alprazolam, administered at both 9:30 am and 12:00 pm
89245807|NCT05006079|Active Comparator|Morphine then alprazolam|15mg oral morphine administered at 9:30 am, then 0.25mg oral alprazolam administered at 12:00 pm
89245808|NCT05006079|Active Comparator|Alprazolam then morphine|0.25mg oral alprazolam administered at 9:30 am, then 15mg oral morphine administered at 12:00 pm
89245809|NCT05006079|Active Comparator|Morphine+alprazolam simultaneously|morphine 15mg + 0.25mg alprazolam at 9:30 am, then morphine 15mg + 0.25mg alprazolam at 12:00 pm
89245810|NCT05005416|Experimental|GOALS Intervention|The experimental arm is an 8-week cognitive-behavioral based physical therapy (PT) intervention for chronic spine pain. The manualized intervention utilizes a hybrid tele-rehabilitation delivery model. GOALS comprises an initial in-person evaluation (60 min) by a research physical therapist, followed by 6 remote treatment sessions (30-45 min each) conducted by the same physical therapist once a week by telephone. A second in-person evaluation is conducted at the midpoint of the GOALS intervention to assess progress and advance the participant's home exercise program.
89245811|NCT05005416|Active Comparator|Usual Care Physical Therapy|The control arm is Usual Care physical therapy (PT) at a local Federally Qualified Health Center (FQHC), which offers PT services at 4 outpatient clinics across San Diego county. Participants in the Usual Care group attend an initial PT evaluation at a FQHC Physical Rehabilitation Clinic. The frequency and type of PT intervention are then determined by the treating physical therapist in accordance with standard clinical practice at the FQHC.
89245812|NCT05000294|Experimental|Atezolizumab + Tivozanib|
89245813|NCT04999202|Experimental|Dose escalation of BAY2416964|Six dose levels of BAY 2416964 (as determined in the first in human mono-therapy study of BAY2416964) are planned in combination with standard dose Pembrolizumab.
89245814|NCT04999202|Experimental|Dose expansion of BAY2416964 in tumor type specific cohort|To determine the RP2D of BAY2416964 in combination therapy with pembrolizumab. Participants will be enrolled in up to 3 tumor type-specific cohorts including relapsed/refractory non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and urothelial cancer.
89245815|NCT04996524|Experimental|epidural analgesia group|
89245816|NCT04996524|No Intervention|systemic analgesia group|
89245817|NCT04991935|Experimental|Administration of CC-93538|Participants are administered CC-93538 dose subcutaneously once weekly
89245818|NCT04990869|Experimental|COPD-NR|COPD patients receiving Nicotinamide Riboside
89245819|NCT04990869|Placebo Comparator|COPD-placebo|COPD patients receiving placebo
89245820|NCT04990869|Experimental|Control-NR|Lung-healthy controls receiving Nicotinamide Riboside
89245821|NCT04990869|Placebo Comparator|Control-placebo|Lung-healthy controls receiving placebo
89245822|NCT04989517|Experimental|AT193|Topical applied daily
89245823|NCT04989517|Placebo Comparator|Placebo|Topical applied daily
89245824|NCT04988009||Observational (survey, medical chart review)|Patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively.
89245825|NCT04986800|Experimental|Intervention Group|Participants in the Intervention Group will receive up to 10 sessions of the PROACTIVE Parent intervention.
89245826|NCT04986566|Experimental|Arm I (telemonitoring)|Patients wear a Vivofit 4 daily for 30 days after hospital discharge for steps monitoring, and complete questionnaires over 5-7 minutes about symptoms and quality of life using the Aetonixx app up to 7 days before surgery, before being discharged from the hospital after surgery, and on days 2, 7, 14, 30 after discharge. Patients also complete pulse oximetry, temperature, blood pressure, heart rate, and weight assessment using at-home monitoring devices before surgery, then on days 2, 7, 14, 30 after discharge. Patients assessments are monitored by the surgical team in real-time to identify outcome trends, including onset, worsening/improving measures, and sporadic versus consistent measures.
89245827|NCT04986566|Active Comparator|Arm II (enhanced usual care)|Patients wear a Vivofit 4 for daily steps monitoring, and complete questionnaires over 5-7 minutes about symptoms and quality of life using the Aetonixx app up to 7 days before surgery, before being discharged from the hospital after surgery, and on days 2, 7, 14, 30 after discharge. Patients also complete pulse oximetry, temperature, blood pressure, heart rate, and weight assessment using at-home monitoring devices before surgery, then on days 2, 7, 14, 30 after discharge. Patients use standard procedures for reporting problems.
89245828|NCT04983043|Experimental|Low dose group|Low dose QiShen YiQi Dripping Pills, 3 bags, take orally after meals, 3 times a day
89245829|NCT04983043|Experimental|High dose group|High dose QiShen YiQi Dripping Pills, 3 bags, take orally after meals, 3 times a day
89245830|NCT04983043|Placebo Comparator|Placebo group|QiShen YiQi Dripping Pills placebo, 3 bags, take orally after meals, 3 times a day
89245831|NCT04976127|Experimental|Talineuren dose escalation|14 doses of GM1 Ganglioside 6, 12, 60, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720 mg. Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).
89245832|NCT04976127|Experimental|Talineuren repeated dose|8 repeated doses of GM1 Ganglioside tbd from the escalation dose (maximum suitable dose). Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).
89245833|NCT04976127|Experimental|Talineuren dose consolidation with intrapatient dosing|8 months repeated doses of 720mg GM1 Ganglioside (Amendment 3).
89245834|NCT04970056||Cohort 1|"Individuals without history of PDAC meeting any of the following criteria:~2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.~2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family~BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family~Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+~Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+~Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+"
89245835|NCT04970056||Cohort 2|"Individuals without history of PDAC meeting any of the following criteria:~ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+~2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family~1 FDR with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member"
89245836|NCT04970056||Cohort 3|Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)
89245837|NCT04970056||Cohort 4|Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.
89245838|NCT04970056||Cohort 5|Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.
89245839|NCT04970056||Cohort 6|"Individuals with a personal history of PDAC meeting any of the following criteria:~Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other~Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11~Diagnosed ≤ age 45"
89245840|NCT04970056||Cyst Cohort|Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)
89245841|NCT04964830|Active Comparator|Children with large overjet|Overjet ≥6 mm, planned orthodontic treatment with functional appliance
89245842|NCT04964830|No Intervention|Control group|Neutral occlusion, no indication for orthodontic treatment, no prior orthodontic treatment
89245843|NCT04962919||Public institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
89245844|NCT04962919||Private institution|Castration-resistant metastatic prostate cancer diagnosed between January 2014 and December 2017
89245845|NCT04961840||Cohort 1: Pregnant Women Exposed to Prucalopride|Pregnant women with clinically diagnosis of constipation who have been exposed to prucalopride during pregnancy will be observed.
89245846|NCT04961840||Cohort 2: Pregnant Women Not Exposed to Prucalopride|Pregnant women with clinical diagnosis of constipation who have been exposed to other laxative and not prucalopride constipation drugs during pregnancy will be observed.
89245847|NCT04961840||Cohort 3: Untreated Pregnant Women|Pregnant women with clinical diagnosis of constipation with no recorded prescription dispensed for any constipation drugs during pregnancy will be observed.
89245848|NCT04958785|Experimental|Safety Run-in Cohort 1: Magrolimab + Nab-Paclitaxel or Paclitaxel|"Participants with untreated unresectable, locally advanced or metastatic TNBC whose tumors are not appropriate for immune checkpoint inhibitor therapy will receive the following:~magrolimab in de-escalating doses to establish RP2D~nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days."
89245849|NCT04958785|Experimental|Phase 2 Cohort 1 Arm A: Magrolimab + Nab-Paclitaxel or Paclitaxel|"Participants with mTNBC will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days.~Magrolimab will be continued until development of unacceptable toxicity that cannot be clinically managed by dose or schedule modifications. Nab-paclitaxel or paclitaxel will be continued until development of unacceptable toxicity."
89245850|NCT04958785|Active Comparator|Phase 2 Cohort 1 Arm B: Nab-Paclitaxel or Paclitaxel|"Participants with mTNBC will receive nab-paclitaxel or paclitaxel administered according to local guidelines.~Each cycle is 28 days.~Nab-paclitaxel or paclitaxel will be continued until development of unacceptable toxicity."
89245851|NCT04958785|Experimental|Safety Run-in Cohort 2: Magrolimab + Sacituzumab govitecan|"Participants with unresectable, locally advanced or metastatic TNBC who have received at least 1 and no more than 2 prior lines of treatment in the unresectable, locally advanced or metastatic setting will receive the following:~magrolimab in de-escalating doses to establish RP2D~sacituzumab govitecan on Days 1 and 8~Each cycle is 21 days."
89245852|NCT04958785|Experimental|Phase 2 Cohort 2: Magrolimab + Sacituzumab govitecan|"Participants with mTNBC will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with sacituzumab govitecan on Days 1 and 8. Each cycle is 21 days.~Magrolimab will be continued until development of unacceptable toxicity that cannot be clinically managed by dose or schedule modifications.sacituzumab govitecan will be continued until development of unacceptable toxicity."
89245853|NCT04957277|Experimental|load modulation|Participants will experience different body weight loading conditions - with body weight added by a weighted vest or removed using the ZeroG overhead harness.
89245854|NCT04952532|Other|Cognitive Remediation+Bridging Intervention|This is a pilot study to collect feasibility data on this novel cognitive remediation intervention for Veterans at high risk for suicide. All patients will receive the active intervention.
89245855|NCT04949256|Experimental|Pembrolizumab + Lenvatinib + Chemotherapy|Participants receive pembrolizumab intravenously (IV) plus lenvatinib orally in combination with FP or TP in Part 1, or in combination with investigator's choice of chemotherapy with FP IV or TP IV or oxaliplatin, 5-FU and leucovorin (mFOLFOX6) IV in Part 2. Induction consists of pembrolizumab 400 mg once every 6-weeks (Q6W) for up to ~12 weeks plus lenvatinib 8 mg once daily (QD) for up to ~12 weeks plus chemotherapy with FP (cisplatin 80 mg/m^2 and 5-FU 4000 mg/m^2) or TP (paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2) once every 3 weeks (Q3W) for up to ~12 weeks or mFOLFOX6 (oxaliplatin 85 mg/m^2, 5-FU 400 mg/m^2 followed by 2400 mg/m^2, and leucovorin 400 mg/m^2 [or levoleucovorin 200 mg/m^2] once every 2 weeks [Q2W] for up to ~12 weeks). This is followed by consolidation with pembrolizumab 400 mg Q6W for up to 16 cycles (each cycle = 6 weeks; total pembrolizumab treatment duration is ~2 years) plus lenvatinib 20 mg QD until progressive disease or discontinuation.
89245856|NCT04949256|Active Comparator|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 400 mg IV Q6W for up to 18 cycles (each cycle = 6 weeks; total pembrolizumab treatment duration is ~2 years) in combination with investigator's choice of chemotherapy with FP (cisplatin 80 mg/m^2 IV Q3W for up to 6 administrations [up to ~18 weeks] and 5-FU 4000 mg/m^2 IV Q3W for up to 35 administrations [up to ~2 years]) or TP (paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 Q3W for up 6 administrations [up to ~18 weeks]) or in combination with mFOLFOX6 (oxaliplatin 85 mg/m^2, 5-FU 400 mg/m^2 followed by 2400 mg/m^2 and leucovorin 400 mg/m^2 [or levoleucovorin 200 mg/m^2] IV Q2W for up to 52 administrations [approximately 2 years]), during Part 2.
89245857|NCT04948658||Adolescents with DOR|Adolescents with diminished ovarian reserve (DOR) who respond poorly to ovarian stimulation for egg freezing
89245858|NCT04948658||Adolescents with POI|Adolescent females up to age 21 years old, who have undergone menarche and are subsequently diagnosed with POI and their last menstrual period occurred within 2 years of presentation.
89245859|NCT04948658||Individuals with variations in sex characteristics (or differences in sex development, DSD)|Individuals with variations in sex characteristics (or differences in sex development, DSD) who undergo gonadectomy for clinical indications.
89245860|NCT04948658||Turner Syndrome and galactosemia|Individuals with Turner Syndrome and galactosemia prior to menarche aged 4 years to 12 years who have not demonstrated signs of premature ovarian insufficiency (one FSH>25 IU/L)
89245861|NCT04948658||Turner Syndrome with Y material|Children and adolescents who have Turner syndrome with Y material and undergo prophylactic gonadectomy.
89245862|NCT04947501|Experimental|Participants with newly-diagnosed HR-Neuroblastoma|This pilot study of N9 as induction chemotherapy will enroll 30 patients with newly-diagnosed HR-NB. A first cohort of >1 to 12-year old, and a second cohort of extended age <19 years old. Both cohorts will be analyzed together.
89245863|NCT04936230|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, bone scan and/or PET scan, as well as optional urine and blood sample collection throughout the study.
89245864|NCT04936230|Experimental|Arm B (pembrolizumab, SBRT)|Patients receive pembrolizumab as in Arm A. Patients also undergo SBRT QD every other day for 3 fractions over 2 weeks that must be completed before 12 weeks after the first dose of pembrolizumab in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, bone scan, and/or PET scan, as well as optional urine and blood sample collection throughout the study.
89245865|NCT04930445||Oxbryta Product Registry|
89245866|NCT04925375|Experimental|Abatacept|"Pediatric subjects weighing <50 kg will be placed in an single arm with abatacept with dosing based on weight. Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26.~Pediatric dosing:~Abatacept subcutaneous every week:~10-25 kg: 50 mg; 25-50 kg: 87.5 mg; >50 kg: 125 mg~Adult dosing:~Abatacept: 125 mg subcutaneous every week"
89245867|NCT04925375|Placebo Comparator|Placebo|Pediatric subjects weighing ≥50kg and adult subjects will enter a double blinded, randomization in a 1:2 ratio of subjects to the abatacept treatment group (arm 1) or to the placebo group (arm 2) treated weekly through weekly 26. The composition of the placebo is the same as the active study drug without the abatacept. To maintain the blind, injection volumes will be the same as the active treatment.
89245868|NCT04924803|Experimental|No video condition|Participants in the no video condition will receive weekly text messages designed to increase vaccination among our sample.
89245869|NCT04924803|Experimental|Video text condition|Participants in the video text condition will receive the text messages designed to increase vaccination among our sample, along with links to iteratively developed intervention videos
89245870|NCT04924608|Experimental|Arm A|Selumetinib
89245871|NCT04924608|Placebo Comparator|Arm B|Placebo
89245872|NCT04921722|Experimental|Topical use of sirolimus|Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
89245873|NCT04921722|Active Comparator|Oral use of sirolimus|Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
89245874|NCT04921072|Experimental|CG - Constant practice condition group|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
89245875|NCT04921072|Experimental|VG - Variable practice condition group|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
89245876|NCT04920578|Experimental|Part 1: Single Ascending Dose (SAD) Cohorts (Double-blind)|Healthy male participants will receive JNJ-69095897 or matching placebo orally in Cohorts 1-8.
89245877|NCT04920578|Experimental|Part 2: Single Dose Cohort (Open-label)|Healthy male participants will receive JNJ-69095897 orally in Cohort 9.
89245878|NCT04920578|Experimental|Part 3: Single or Divided Dose Cohort (Double-blind)|Healthy male participants and women of non-childbearing potential (WONCBP) will receive JNJ-69095897 or matching placebo orally in Cohort 10.
89245879|NCT04916470|Experimental|Semaglutide 2.4 mg once weekly (OW)|Participants will receive semaglutide injections for 52 weeks.
89245880|NCT04916470|Placebo Comparator|Semaglutide placebo OW|Participants will receive semaglutide placebo injections for 52 weeks.
89245881|NCT04910022|Experimental|NMS-03305293 +TMZ|"Phase 1 Dose Escalation: All patients will receive NMS-03305293 and temozolomide (TMZ) administered orally (NMS-03305293 once or twice daily on days 1-7 or 28 consecutive days from Day 1 to Day 28; TMZ once daily on days 1-5;) in repeated 4-week cycles aimed at defining the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Doses (RP2Ds) of NMS-03305293 in combination with TMZ. Each cycle is 28 days.~Phase 2: Once the RP2D is defined, the patients will receive TMZ daily on days 1-5 in combination with NMS-03305293 at the RP2D on days 1-7 or on days 1-28 every 28 days.~Backfill cohorts: additional patients may be treated with TMZ daily on days 1-5 and NMS-03305293 at different dose levels/schedules that have been previously assessed and determined to be safe, in order to properly characterize the exposure relationship over a range of doses/schedules. The backfill cohorts may run in parallel."
89245882|NCT04908020||Follow up|"The group is made up by children and adolescents, aged from 9 to 17, who received a cancer diagnosis, who completed oncological treatment and who are included in a clinical follow-up program since less than 3 years.~Furthermore, the study involves one parent for each patient to collect demographics and clinical data."
89245883|NCT04905082|Active Comparator|Arm I (usual care)|Patients receive education pamphlet about WES and have their genomics test results returned by their clinician in a typical manner.
89245884|NCT04905082|Experimental|Arm II (genomics test results, HOPE-Genomics)|Patients receive their genomics test results both from their clinician and from the HOPE-Genomics tool. Patients then view HOPE-Genomics tool over 15-20 minutes after their results are available.
89245885|NCT04905082|Experimental|Arm III (HOPE-Genomics, genomics test results)|Patients view HOPE-Genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. Patients also receive their genomics test results both from their clinician and from the HOPE-Genomics tool.
89245886|NCT04904276||Initiating treatment with fostamatinib as second-line therapy|
89245887|NCT04904276||Treated with fostamatinib for at least 12 weeks as second-line therapy|
89245888|NCT04904081|Experimental|Treatment Arm (Indocyanine Green [ICG])|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
89245889|NCT04904081|No Intervention|Control Arm (Standard Care)|The Standard Care group will have no change to the medical and surgical care they receive while in the hospital. The surgeon will perform the surgery as they normally would outside of this study. This involves a laparoscopic-assisted transanal pullthrough surgery.
89245890|NCT04903626|Experimental|Participants Treated With Glecaprevir/Pibrentasvir for 8 weeks|Participants treated once daily with oral tablets of glecaprevir/pibrentasvir for 8 weeks.
89245891|NCT04903223|No Intervention|Baseline Mevalonate and MRI Imaging|
89245892|NCT04903223|Experimental|Mevalonate Change After Rosuvastatin|
89245895|NCT04901416|Experimental|Experimental Arm|"Lymphodepleting (LD) chemotherapy will be administered daily for 3 days to all subjects prior to DVX201. Lymphodepleting chemotherapy will consist of the following:~Cyclophosphamide 300 mg/m2 IV over 30 to 60 minutes daily x 3 (day -5 to day - 3)~Fludarabine 30 mg/m2 IV over 30 minutes daily x 3 (day -5 to day -3)~Patients will receive DVX201 at one of 3 prespecified doses infused on day 0 and 7 (± 1 day) for 1 cycle."
89245896|NCT04900454|Experimental|DVX201 infusion|"Subjects will enroll and the MTD and/or the recommended phase 2 dose of DVX201 will be determined utilizing a modified 3+3 enrollment schema.~This study will enroll a minimum 3 subjects who each receive a single dose of DVX201 and who are evaluable for toxicities at each dose level. Depending on the occurrence of DLTs and the number of dose levels evaluated, additional subjects may be enrolled (approximately 3-15 additional subjects). All subjects will be followed for 28 days post infusion of DVX201."
89245897|NCT04897568|No Intervention|Control|The control group will consist of each participant and clinic before the intervention (baseline, first 2 months).
89245898|NCT04897568|Active Comparator|Patient decision aid|The intervention group will consist of each participant and clinic once they move to the intervention phase (stepped-wedge design: practices will be randomized into step 1, 2 or 3; for step 1: the intervention will start at 2 months, for step 2: the intervention will start at 4 months, for step 3: the intervention will start at 6 months).
89245899|NCT04897126|Active Comparator|Experimental group|The experimental group was treated with Shexiang Baoxin pill（MUSKARDIA） (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
89245900|NCT04897126|Placebo Comparator|Placebo group|The control group was given placebo（ 4 capsules / day, 3 times / day）on the basis of conventional treatment until the end of follow-up.
89245901|NCT04895748|Experimental|Arm 1 Dose Escalation DFF332|DFF332 Single Agent
89245902|NCT04895748|Experimental|Arm 2 Dose Escalation DFF332 + Everolimus|Combination treatment DFF332 + Everolimus
89245903|NCT04895748|Experimental|Arm 3 Dose Escalation DFF332 + Spartalizumab + Taminadenant|Combination treatment DFF332 + Spartalizumab + Taminadenant
89245904|NCT04895748|Experimental|Arm 1a Dose Expansion DFF332 in ccRCC|DFF332 Single Agent in patients with ccRCC (age 18 years old and above)
89245905|NCT04895748|Experimental|Arm 1b Dose Expansion DFF332 in HIF stabilizing malignancies|DFF332 Single Agent in patients with HIF stabilizing malignancies (age 12 years old and above)
89245906|NCT04895748|Experimental|Arm 2a Dose Expansion DFF332 + Everolimus in ccRCC|Combination treatment DFF332 + Everolimus in patients with ccRCC (age 18 years old and above)
89245907|NCT04895748|Experimental|Arm 3a Dose Expansion DFF332 + Spartalizumab + Taminadenant in ccRCC|Combination treatment DFF332 + Spartalizumab + Taminadenant in patients with ccRCC (age 18 years old and above)
89245908|NCT04893278||Virtual reality|
89245911|NCT04880538||Asymptomatic patients for any motility disorder|Asymptomatic patients for any motility disorder
89245912|NCT04880538||Patients with gastrointestinal dysmotility|Patients with gastrointestinal dysmotility
89245913|NCT04874350|Experimental|LPCN 1148|Oral LPCN 1148 capsules, administered as BID.
89245914|NCT04874350|Placebo Comparator|Placebo|Oral matching placebo capsules, administered as BID.
89245915|NCT04873453|Active Comparator|Full-spectrum Cannabidiol|150mg/day of full-spectrum cannabidiol, containing less than 0.3%THC.
89245916|NCT04873453|Experimental|Broad-spectrum Cannabidiol|150mg/day of broad-spectrum cannabidiol, containing 0%THC.
89245917|NCT04873453|Placebo Comparator|Placebo|150mg/day of hemp-seed oil with no cannabinoids present.
89245918|NCT04872439||Antibody isolation, DNA isolation|Patients with GI dysmotility
89245919|NCT04870047|Experimental|p64 MW HPC Flow Diverter + SAPT|
89245920|NCT04870047|Experimental|p64 MW Flow Diverter + DAPT|
89245921|NCT04867122|Placebo Comparator|Attention Control|"Family caregivers in the attention control study arm will receive three sessions of attention-matched control in addition to the services and support provided as part of usual outpatient palliative care. Attention-matched control will consist of three friendly visits with a trained research staff person."
89245922|NCT04867122|Experimental|Problem Solving Therapy Intervention|Family caregivers in the intervention study arm will participate in three problem-solving therapy sessions with a trained interventionist in addition to receiving the services and support provided as part of usual outpatient palliative care.
89245923|NCT04867122|Other|In-Depth Interviews for non-FCG Stakeholders|Each year of the project, the investigators will recruit 6 key stakeholders to participate in individual interviews focused on potential barriers and facilitators to adoption of the PST intervention into clinical practice for a total of 30 unique stakeholders who will be interviewed over the duration of this 5-year study.
89245924|NCT04864080|Active Comparator|Healthy Comparison Group|Behavioral tasks and surveys online.
89245925|NCT04864080|Experimental|Pain/Depression patients from clinic|MRI, TMS and EEG, and behavioral tasks and surveys online.
89245926|NCT04861714|Active Comparator|Regeneten|Standard subscapularis repair with Regeneten augmentation group
89245927|NCT04861714|Other|Standard repair|Standard subscapularis repair
89245928|NCT04861064|Experimental|Treatment Group|
89245929|NCT04844190|Experimental|Addition of ADM and EndoFLIP to pre-G-POEM evaluation|During the preoperative upper endoscopy, the EndoFLIP catheter is inserted through the mouth with endoscopic guidance and placed through the gastric pylorus. Once deployed, water is sequentially added at set volumes to a balloon that can be used to measure pyloric diameter, cross-sectional area, pressure, and distensibility at set volumes of 30, 40, and 50 mL for at least five seconds. We will record this data for each patient. The EndoFLIP catheter will then be removed. Subsequently, a high resolution ADM catheter will be inserted through the nose and placed through the pylorus to measure baseline intragastric, transpyloric, and intraduodenal pressures. The patient will be observed for up to four hours to assess a migrating motor complex (MMC). After the MMC is observed, the patient will be given a meal and observed for meal response with the manometry catheter. The meal will be water and two pieces of toast/bread. Following the meal, the catheter will be removed.
89245930|NCT04842877|Experimental|Experimental arm|Experimental arm: Valemetostat tosylate (DS-3201b) is given continuously at 200 mg QD.
89245931|NCT04839198|Experimental|Adaptive Treatment plus usual care|
89245932|NCT04839198|Active Comparator|Usual care|
89245933|NCT04835597||Observational (movement assessment, medical data collection)|Patients complete movement assessment 5-15 days prior to the initiation of neoadjuvant chemotherapy and at day 1 of neoadjuvant chemotherapy. Patients' SAE data is collected. Patients are observed during their neoadjuvant chemotherapy for up to 6 months.
89245934|NCT04833894|Experimental|Efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
89245935|NCT04832854|Experimental|Cohort A (PD-L1 High)|"Participants with high programmed death-ligand 1 (PD-L1) expression level will be enrolled in Cohort A and receive neoadjuvant atezolizumab plus tiragolumab for 4 cycles, followed by surgical resection and either adjuvant atezolizumab plus tiragolumab for 16 cycles or adjuvant chemotherapy for 4 cycles at the discretion of the investigator.~Chemotherapy may include:~cisplatin/carboplatin + pemetrexed (for non-squamous only)~carboplatin + gemcitabine (for squamous only)~carboplatin + paclitaxel"
89245936|NCT04832854|Experimental|Cohort B (PD-L1 All Comers)|"All comers, which are participants with any PD-L1 expression level, will be enrolled in Cohort B and receive neoadjuvant atezolizumab plus tiragolumab plus chemotherapy for 4 cycles, followed by surgical resection and adjuvant atezolizumab plus tiragolumab for 16 cycles.~Chemotherapy may include:~cisplatin/carboplatin + pemetrexed (for non-squamous only)~carboplatin + gemcitabine (for squamous only)~carboplatin + paclitaxel"
89245937|NCT04826874|Experimental|Affect Labeling_direct|Randomized to immediate two-week, internet delivered psychoeducative course in affect labeling
89245938|NCT04826874|No Intervention|Wait-list|Randomized to a two-week wait-list control
89245939|NCT04825860|Experimental|SEP-363856 50 mg/day|Subjects randomized to the SEP-363856 50 mg/day group will receive the assigned dose of SEP-363856 50 mg/day throughout the double-blind phase.
89245940|NCT04825860|Experimental|SEP-363856 75 mg/day|Subjects randomized to the SEP-363856 75 mg/day group will receive SEP-363856 50 mg/day on Day 1 through Day 3 and then the assigned dose of SEP-363856 75 mg/day thereafter.
89245941|NCT04825860|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive placebo throughout the double-blind phase.
89245942|NCT04819997|Experimental|Supportive care (videoconference, questionnaire, survey)|Patients participate in 5 videoconference sessions over 30 minutes each over 6 weeks focused on worry management skills, values-based goal setting, and brief mindfulness-based practices, then complete patient workbook activities after each session over 15-20 minutes per day. Patients also complete a survey over 8 minutes at 6 weeks, an exit interview at 7 weeks, and questionnaires over 25 minutes each at baseline, 6 weeks, and 10 weeks.
89245943|NCT04798547|Placebo Comparator|Standard Length Myotomy|Patients randomized to received 8 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
89245944|NCT04798547|Experimental|Short Length Myotomy|Patients randomized to received 4 cm standard length myotomy in Per-Oral Endoscopic Myotomy (POEM) for achalasia
89245945|NCT04794829||Vaccinated|Received influenza and/or SARS-CoV-2 vaccine
89245946|NCT04793958|Experimental|MRTX849 + Cetuximab|
89245947|NCT04793958|Active Comparator|mFOLFOX6 or FOLFIRI|
89245948|NCT04793100|Experimental|Follow-up for 1 year|
89245949|NCT04792268|Experimental|Electronic clinical decision support|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm. An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~Automated electronic decision support will be provided as a combination of visual prompts on the individual patient's dashboard, accessed by clinicians when they view a patient record on the electronic health record supplemented by an email sent to the NHS Trust email account addresses of the participating ward clinician(s).~Alerts will include locally approved guideline-based recommendations for clinician-led monitoring and management of dysglycaemia and known diabetes, tailored to the individual patient based upon reported HbA1c values."
89245950|NCT04792268|No Intervention|Treatment as usual|Clinicians will not have access to eCDSS on wards recruited to this arm and will deliver care as usual.
89245951|NCT04789746|Experimental|Running group|Participants that will join the running program.
89245952|NCT04789408|Experimental|KITE-222|"Dose Escalation: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-222 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-222 to determine the maximum tolerated dose (MTD) of KITE-222.~Dose Expansion: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose (at the MTD determined) of KITE-222."
89245953|NCT04781907|Experimental|Home Expansion Group|Participants in home expansion group will perform the saline injection for their right tissue expander under clinic staff supervision on their 2nd and 3rd expansion. Beginning their 4th expansion, participants will perform saline injection at home prior to their regularly scheduled clinic visit.
89245954|NCT04781907|No Intervention|Control Group|Standard of Care
89245955|NCT04779242|Experimental|Omadacycline|Omadacycline 100 mg IV; Omadacycline 300 mg PO (2 x 150 mg tablets); QD Dosing; 7-10 day duration.
89245956|NCT04779242|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg IV; Moxifloxacin 400 mg tablets; QD Dosing; 7-10 day duration
89245957|NCT04772664|Experimental|Participants with Major Depression receiving a multi-strain probiotic|Participants with Major Depression receiving a multi-strain probiotic
89245958|NCT04772664|Placebo Comparator|Participants mit Major Depression receiving a placebo|Participants mit Major Depression receiving a placebo
89245959|NCT04772664|Experimental|Healthy volunteers receiving a multi-strain probiotic|Healthy volunteers receiving a multi-strain probiotic
89245960|NCT04772664|Placebo Comparator|Healthy volunteers receiving a placebo|Healthy volunteers receiving a placebo
89245961|NCT04770779|Experimental|Mitapivat|"Double-Blind Period: Participants will receive mitapivat 100 milligrams (mg) orally, twice daily (BID) for 48 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
89245962|NCT04770779|Placebo Comparator|Placebo|"Double-Blind Period: Participants will receive placebo matching mitapivat orally, BID for 48 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
89245963|NCT04770753|Experimental|Mitapivat|"Double-blind Period: Participants will receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 24 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
89245964|NCT04770753|Placebo Comparator|Placebo|"Double-blind Period: Participants will receive placebo matching mitapivat, orally, BID for 24 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
89245965|NCT04763356|No Intervention|Usual Care (UC)|The UC group (control) models the current standard of care model. The NTSS-6 will be completed daily by participants using the SCH system. The results will not be reported to their oncology team. Participants will be counseled at study entry to contact their treating care team to manage CIPN symptoms. They will also receive a reminder to do so at the end of each reporting session. UC participants will attend all regular visits with these providers and can receive any type of treatment for their CIPN symptoms. There are no limitations on the therapies that can be prescribed, or the means by which the clinical team communicates with the participant. Treating physicians will be provided with links to the current ASCP and NCCN guidelines but will not be provided with the algorithm as this group is meant to reflect current standard medical practice.
89245966|NCT04763356|Experimental|SCH with NP follow-up (SCH-NP)|Participants will report daily symptom as above. The SCH system will notify the study NP for any of the following symptoms measured by the NTSS6: aching, allodynia, burning, lancinating, numbness, and prickling that are concerning. Participants will receive a NP call back either the same day or the next day, depending on the time they reported their symptoms. The NP will follow a standardized script to elicit details about the CIPN symptoms and recommend and prescribe CIPN treatment per the treatment algorithm.
89245967|NCT04753996||Primary Sclerosing Cholangitis (PSC)|Subjects diagnosed with Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
89245968|NCT04753996||Control (non-PSC)|Subjects without a diagnosis of Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
89245969|NCT04753749|Experimental|Shortened DAPT followed by P2Y12 inhibitor monotherapy|
89245970|NCT04753749|Active Comparator|Dual Antiplatelet Therapy|
89245971|NCT04746157|Experimental|Intervention group|Patients will have a directly contact with the lead nurse by telephone during the study. The referent nurse will provide support and will promote engagement of patient to adequate secondary prevention measures. In addition, she will provide education based on stroke risk and identified vascular risk factors by Stroke Riskometer.
89245972|NCT04746157|No Intervention|Usual care|Usual care
89245973|NCT04745481|Experimental|Trunk stabilization training device|Participants will receive conventional rehabilitation and use trunk stabilization training device 30min each daily, 20 times for 4weeks.
89245974|NCT04745481|Active Comparator|Conventional rehabilitation|Participants will receive conventional rehabilitation 60min daily, 20times for 4weeks.
89245975|NCT04743908|No Intervention|Social Network Strategy (SNS Condition)|"Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. Study staff will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walkthrough and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared."
89245976|NCT04743908|Experimental|Social Network Strategy + Messaging|"Study staff will describe the Social Network Strategy, construct a plan for successfully referring network members into the study, and discuss compensation for the recruitment efforts. Study staff will specifically discuss network members of interest: friend, family, coworker or someone you spend time with on a regular basis. Walk through and scenario play will be strategies to assist with planning regarding: (1) how the conversation will be raised, (2) how potential barriers to testing will be addressed, (3) how the screening by phone or web survey will be conducted, (4) how network members will have the option to bring others into the study visit with them, (5) what information about the study will be shared. Finally, community developed COVID-19 public health messages will be shared in the participant's preferred language."
89245977|NCT04740333||Group A- Normal ICU admission blood glucose level|Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL).
89245978|NCT04740333||Group B- High ICU admission blood glucose level|Patients with admission blood glucose level higher than 180 mg / dL.
89245979|NCT04739072||Ancillary-correlative (biospecimen collection)|Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed.
89245980|NCT04736173|Active Comparator|Arm A - Study Part 1 (Platinum-based Chemotherapy)|Participants will receive carboplatin, pemetrexed, and paclitaxel by intravenous (IV) infusion.
89245981|NCT04736173|Experimental|Arm B - Study Part 1 (Zimberelimab Monotherapy)|Participants will receive zimberelimab monotherapy by IV infusion.
89245982|NCT04736173|Active Comparator|Arm C - Study Part 1 (Domvanalimab + Zimberelimab Combination Therapy)|Participants will receive zimberelimab in combination with AB154 by IV infusion.
89245983|NCT04736173|Experimental|Arm D - Study Part 2 (Domvanalimab + Zimberelimab Combination Therapy)|Participants will receive domvanalimab in combination with zimberelimab by IV infusion.
89245984|NCT04736173|Experimental|Arm E - Study Part 2 (Pembrolizumab)|Participants will receive pembrolizumab by IV infusion.
89245985|NCT04735549|Experimental|Laser Treatment|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks.~During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece."
89245986|NCT04735549|Active Comparator|Topical hormone|Local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy for 12 months to prevent symptoms.
89245987|NCT04735549|Experimental|Laser Treatment + Topical hormone|"Laser treatment of the vagina, vulva, and paraurethral region with a Magic Max laser. In total, three procedures will be performed with an interval of 4-6 weeks. During the procedure, the following sequence of actions will be performed: 1st Stage - vaginal processing with a conical mirror handpiece, 2nd Stage - vaginal processing with a corner mirror handpiece, 3d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece.~At the same time local hormone therapy with estriol. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy for 12 months to prevent symptoms."
89245988|NCT04734652|Experimental|BIC arm|The Intervention Arm ART regimen is a fixed-drug combination of a single tablet co-formulated regimen containing Bictegravir 50mg Emtricitabine 200mg and tenofovir alafenamide 25mg (BIC/FTC/TAF; Biktarvy®) that will be taken twice a day during rifampicin-containing TB treatment and 2 weeks after stopping TB treatment, thereafter the BIC/FTC/TAF single tablet co-formulation will be taken once daily.
89245989|NCT04734652|Active Comparator|DTG Arm|Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg (TLD- fixed-drug combination single tablet) plus Dolutegravir 50mg evening dose during TB treatment and for two weeks after completion of TB treatment, then TLD once daily thereafter- as per Standard of Care (SOC)
89245990|NCT04729907|Experimental|BIIB058 28 mg (Prior Maintenance Dose 28 mg)|Participants who received maintenance dose of 28 milligrams (mg) nusinersen in study 232SM203 (NCT04089566), will receive maintenance dose of 28 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 1921.
89245991|NCT04729907|Experimental|BIIB058 50/28 mg (Prior Maintenance Dose 12 mg)|Participants who received maintenance dose of 12 mg nusinersen in study 232SM203 (NCT04089566), will receive loading dose of 50 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 1921.
89245992|NCT04729751|Experimental|Maralixibat|Participants will receive up to 600 μg/kg twice daily (PFIC) or up to 400 μg/kg once daily (ALGS) over 13 weeks in the core study and for the duration of the Long Term Extension (LTE) where applicable.
89245993|NCT04729348|Experimental|PEMBROLIZUMAB and LENVATINIB|"The research study procedures include screening for eligibility and study treatment, including evaluations and follow up visits.~PEMBROLIZUMAB daily, every 3 weeks~LENVATINIB daily every 3 weeks"
89245994|NCT04728893|Experimental|Nemtabrutinib|Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation.
89245995|NCT04722523|Experimental|Head and Neck Squamous Cell Cancer/HNSCC|Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.
89245996|NCT04704674||0.5 - 5 years|Age bracket for infants/children up to age five years
89245997|NCT04704674||10 - 18 years|Age bracket for children 10 - 18 years
89245998|NCT04704674||19 + years|Age bracket for adults over 19 years
89245999|NCT04704674||5 - 10 years|Age bracket for children ages 5 - 10 years
89246003|NCT04692103|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
89246004|NCT04691271|Experimental|Intervention group|In addition to routine anesthesia management and surgical operations, a stellate ganglion block was performed before induction of anesthesia, and then receive standard care after operation. Related statistical indicators were collected prospectively.
88804765|NCT04770818|Active Comparator|Modified Brostrum procedure|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL (anterior talo-fibular ligament), CFL (calcanealfibular ligament), lateral ankle capsule and extensor retinaculum.
88804766|NCT04770818|Active Comparator|Modified Brostrum procedure with InternalBrace ligament augmentation|Lateral ankle ligament stabilization procedure utilizing two 2.4mm BioComposite SutureTaks to repair the ATFL, CFL, lateral ankle capsule and extensor retinaculum with InternalBrace fixation using a 4.75mm BioComposite SwiveLock.
89246005|NCT04691271|No Intervention|Blank control group|In this study, a blank control was used. Routine anesthesia management and surgical operation were used without any special interventions(only an camouflaging action), and then receive standard care after operation. Only relevant statistical indicators were collected prospectively.
89246006|NCT04690192|Experimental|CNCT19 following ASCT|Participants will receive high-dose chemotherapy followed by stem-cell reinfusion, and a fixed dose of CNCT19 (2×10^6/kg) will be infused in a single-dose on day +2, +3 or +4.
89246007|NCT04688398|Experimental|Seal oil|Daily intake of 15 ml of seal oil containing 534 mg of EPA + 1129 mg of DHA + 530 mg of DPA during 12 weeks
89246008|NCT04688398|Active Comparator|Control|Daily intake of vegetable oil during 12 weeks
89246009|NCT04687969||COHORT A: PROSTATE CANCER PATIENTS|"Primary prostate cancer patients scheduled to undergo radical prostatectomy.~Twenty five (25) prostate cancer patients will undergo two [18F]DCFPyL PET/MRI scans and~Sixty (60) additional prostate cancer patients will undergo one [18F]DCFPyL PET/MRI scan."
89246010|NCT04687969||COHORT B: SOLID TUMOR PATIENTS|"Patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma).~Up to fifty (50) patients will undergo up to three [18F]DCFPyL PET/MRI scans"
89246011|NCT04686305|Experimental|Arm 1A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
89246012|NCT04686305|Experimental|Arm 1B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
89246013|NCT04686305|Experimental|Arm 1C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed (Arm not initiated)
89246014|NCT04686305|Experimental|Arm 1D: T-DXd|T-DXd
89246015|NCT04686305|Experimental|Arm 3A: T-DXd and MEDI5752|Drug: T-DXd and MEDI5752 T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: MEDI5752 MEDI5752: administered as an IV infusion Other Name: Volrustomig
89246016|NCT04686305|Experimental|Arm 3B: T-DXd, MEDI5752 and Carboplatin|Drug: T-DXd, MEDI5752 and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: MEDI5752 MEDI5752: administered as an IV infusion Other Name: Volrustomig Drug: Carboplatin Carboplatin: administered as an IV infusion
89246017|NCT04684485|Placebo Comparator|Placebo of SCD-044 product|Placebo tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
89246018|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 1|SCD-044 Tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
89246019|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 2|SCD-044 Tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
89246020|NCT04684485|Active Comparator|SCD-044 Tablets_Dose 3|SCD-044 Tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
89246021|NCT04680442|Active Comparator|Control Group|Recommendations for continuing or holding trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) for the control group are guided by an adaptation of the 2008 Canadian recommendations.
89246022|NCT04680442|Experimental|Intervention Group|The intervention group will continue to receive trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) in the setting of asymptomatic decline in LVEF up to an LVEF of 40% as outlined in the criteria listed in Table 3. For reasons of practicality, in the intervention group, the first dose of trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) after randomization can be administered up to 3 weeks late. This will allow time for the participant to be reviewed by a cardiologist and to receive ACE-I/angiotensin receptor blocker and/or beta-blocker, and for dose titration.
89246023|NCT04680065|Experimental|Active Treatment|
89246024|NCT04680065|Sham Comparator|Placebo Surgery|
89246025|NCT04672863|No Intervention|Standard of Care Group|Subjects will participate in a standardized Transplant Nutrition class between day 21-40 as per institutional protocol and will be counseled as per the Mayo Clinic standard of care vis a vis dietary intervention, standard aerobic and resistance exercise recommendations (consistent with AASLD guidelines) and other lifestyle interventions.
89246026|NCT04672863|Experimental|Behavioral: Structured Modified Mediterranean Diet|Subjects will participate in a one-on-one counselling session with a dietician, as opposed to attending the standardized Transplant Nutrition class. Counselling will be provided on the elements of the modified Mediterranean diet which emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt, moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats.
89246027|NCT04669262|Experimental|Part 1: BGB-DXP604|Part 1A: Single low dose of BGB-DXP604 or placebo; Part 1B: Single high dose of BGB-DXP604 or placebo
89246028|NCT04669262|Experimental|Part 2 : BGB-DXP604 + BGB-DXP593|Single dose of BGB-DXP593 followed by a single dose of BGB-DXP604 or placebo
89246029|NCT04669171|Experimental|Cohort 1|Safety Lead-In, Dose-Finding, Cohort, with a 3-by-3 design of EO2463 for 6 weeks followed by addition of lenalidomide week 7 and rituximab week 19 (depending on response). Four to 18 evaluable (previously treated) patients with Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) will be Included based on safety findings
89246030|NCT04669171|Experimental|Cohort 2|15 Previously untreated patients with FL Or MZL. Evaluation of EO2463 monotherapy at the established dose in Cohort 1
89246031|NCT04669171|Experimental|Cohort 3|15 Previously untreated patients with FL or MZL. Evaluation of EO2463 at the established dose in cohort 1 as monotherapy for 6 weeks and in combination with rituximab from week 7
89246032|NCT04669171|Experimental|Cohort 4|15 Previously treated patients with FL Or MZL. Evaluation of EO2463 at the established dose in Cohort 1 in combination with lenalidomide and with addition of rituximab from week 19 onwards (depending on response)
89246033|NCT04666740|Experimental|Cohort A: Core HRD|Patients with either pathogenic germline or somatic alterations of 3 core homologous recombination-genes (HR-genes) - (BRCA1/2, or PALB2) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort A.
89246034|NCT04666740|Experimental|Cohort B: Non core HRD|Patients with either pathogenic somatic or germline non-core 14 HR-gene alterations (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RTEL1) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort B.
89246035|NCT04666740|Experimental|Cohort C: Platinum sensitive|Patients without any of the above HR-gene alterations included in Cohort A and B who have platinum-sensitivity, which is defined as a partial response (PR) or complete response (CR) for the best overall response (BOR) during at least 4 months on platinumbased therapy. Variants of unknown significance of candidate HR-genes from Cohort A or B will be eligible for Cohort C if they meet the partial response to platinum criterion.
88804767|NCT00005626|Experimental|Irinotecan Treatment|Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.
88804768|NCT00005092|Experimental|Chemo, RT + PSCT|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation
89246044|NCT04666545|Experimental|Intervention|"This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to help and enable the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation."
89246045|NCT04666545|No Intervention|Usual Care (control)|In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.
89246046|NCT04665388||EBV-related cancer cohort|up to N=30
89246047|NCT04665388||HPV-related cancer cohort|up to N=45
89246048|NCT04665388||HCC cohort|up to N=30
89246049|NCT04665037|Experimental|Panel A: POS IV|Posaconazole 6 mg/kg body weight administered in a single dose by IV infusion on Day 1.
89246050|NCT04665037|Experimental|Panel B: POS IV|Posaconazole 6 mg/kg body weight administered twice daily by IV infusion on Day 1, and then once daily from Day 2 to a maximum 84 days.
89246051|NCT04665037|Experimental|Panel B: POS PFS|Following a minimum of 7 days IV dosing, participants as clinically able will be transitioned from POS IV to POS PFS nominal 6 mg/kg body weight based on weight bands administered on Day 8, once daily to a maximum 84 days.
89246052|NCT04654559|Other|Unobtrusive data collection|
89246053|NCT04647396|Experimental|Intervention group|
89246054|NCT04647396|No Intervention|Control group|
89246055|NCT04645589||Myfortic|Oral administration
89246056|NCT04642469|Experimental|Durvalumab|Intravenous administration of Durvalumab
89246057|NCT04642469|Placebo Comparator|Placebo|Intravenous administration of placebo
88804769|NCT00005632|Experimental|Vaccine|Patients sequentially will receive glycosylated MUC-1-KLH vaccines at 3ug per vaccination.
88804770|NCT00004342||Adult Neutropenic Subject|Adult subjects with diagnosis of severe chronic neutropenia
88804771|NCT00004342||Minor Neutropenic Subject|Children under 18 years of age who are diagnosed with severe chronic neutropenia
89246058|NCT04641416||Noninvasive pump monitoring|All patients with the HeartMate 3 system implanted at the Medical University of Vienna, which are able and willing to understand and sign the informed consent form, and which do not meet any exclusion criteria will be included.
89246059|NCT04638127|Experimental|PREEMIE PROGRESS|PREEMIE PROGRESS is an innovative, video-based intervention that applies evidence-based family management theories to better equip parents to meet the chronic, complex healthcare needs of their preterm infant.
89246060|NCT04638127|Active Comparator|Attention Control|"To maintain their attention, control parents will view Welcome Videos that explain hand hygiene, visitor IDs, parking, etc. on their mobile devices."
89246061|NCT04632927|Experimental|Secukinumab|AIN457
89246062|NCT04632927|Experimental|Ustekinumab|
89246063|NCT04631562|Experimental|ALXN1820|Participants will receive ALXN1820 SC or ALXN1820 IV according to their assigned cohort. ALXN1820 SC will be evaluated in single and multiple ascending doses while ALXN1820 IV will be evaluated in a single dose cohort only.
89246064|NCT04631562|Placebo Comparator|Placebo|Participants will receive Placebo SC or Placebo IV according to their assigned cohort.
89246065|NCT04631523||IGD Group|The eligibility criteria were for IGD group as follows: being male in age between 10-18 years old; having accepted the research on a voluntary basis and signed the informed consent and being diagnosed with IGD according to DSM-5. Healthy adolescents in this study will be referred from a child and adolescent psychiatrist. All the following assessments will be applied this group for one time; Internet Addiction Scale, 9 Hole Peg Test, Ruler Drop Method, assessment of Forward Head Posture, evaluation of Joint Position Error of cervical region.
89246066|NCT04631523||Healthy Group|The eligibility criteria were for healthy group as follows: being male in age between 10-18 years old and having accepted the research on a voluntary basis and signed the informed consent. The adolescents with IGD in this study will be referred from a child and adolescent psychiatrist. All the following assessments will be applied this group for one time; Internet Addiction Scale, 9 Hole Peg Test, Ruler Drop Method, assessment of Forward Head Posture, evaluation of Joint Position Error of cervical region.
89246067|NCT04630756|Experimental|Module 1: Part A and Part B|"Participants will receive intravenous ascending doses of AZD4573 once weekly with oral acalabrutinib twice daily continuously in Part A. For Part A, cohorts 1, 2, and 3 have different target dose levels respectively.~In Part B, participants will receive the RP2D of AZD4573 from Part A."
89246068|NCT04630756|Experimental|Module 2: Part A and Part B|"Participants will receive AZD4573 as monotherapy for Period 1 and AZD4573 + acalabrutinib as combination therapy for Period 2.~Part B of Module 2 will be determined from the data emerging from Part A."
89246069|NCT04623216|Experimental|Sabatolimab 400mg|Safety cohort 1: Participants in this arm will receive sabatolimab 400mg intravenously every 4 weeks.
89246070|NCT04623216|Experimental|Sabatolimab 800mg|Safety cohort 2: Participants in this arm will receive sabatolimab 800mg intravenously every 4 weeks.
89246071|NCT04623216|Experimental|Sabatolimab + Azacitidine|Expansion cohort 3: Participants in this arm will receive sabatolimab at the recommended dose for expansion in combination with azacitidine.
89246072|NCT04623216|Experimental|Sabatolimab|Expansion cohort 4: Participants in this arm will receive sabatolimab at the recommended dose for expansion.
89246073|NCT04623216|Experimental|Sabatolimab (adolescent cohort)|Adolescent safety cohort (cohort 5): ≥12 to < 18 year old adolescent participants in this arm will receive sabatolimab at the recommended dose for expansion.
89246074|NCT04622917|Active Comparator|Methylprednisolone|Depo-Medrol (Methylprednisolone) 40 milligrams/milliliter, 2 milliliters as a single dosage
89246075|NCT04622917|Placebo Comparator|Sodium Chloride (NaCl)|NaCl 0,9 milligrams/milliliter, 2 milliliters as a single dosage
89246076|NCT04617093|Experimental|Total Patient Population|The planned PrismaLung+ treatment period for this study is 24 hours. Neuromuscular blockade and sedation will be required for the first 24 hours of ECCO2R treatment and thereafter, will be used at the discretion of the attending physician. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Blood warming during ECCO2R treatment will occur using the TherMax blood warmer.
89246077|NCT04610346|Other|Immediate|Participants in this group will begin the training protocol immediately (within 1 week) after baseline pre-training evaluation is completed.
89246078|NCT04610346|Other|Delayed|Participants in the delayed arm will participate in two pre-training evaluations, one immediately upon enrollment and one at the end of the delay period immediately before beginning training
89246079|NCT04603495|Experimental|Pelabresib + ruxolitinib|Pelabresib monohydrate tablets + ruxolitinib phosphate tablets
89246080|NCT04603495|Active Comparator|Placebo + ruxolitinib|Matching placebo tablets + ruxolitinib phosphate tablets
89246081|NCT04597307||IN.PACT™ Admiral™ DCB Cohort|De novo patients not previously treated with a DCB who are successfully treated with the IN.PACT™ Admiral™ DCB (ability to cross the target lesion).
89246082|NCT04575948|Experimental|Moringa Oleifera mouth wash|According to part I of the study, we will select the most effective (Non-toxic, anti-bacterial effect) Moringa extract to prepare the mouth wash.
89246083|NCT04575948|Placebo Comparator|Base formula of mouth wash|Base formula of mouthwash
89246084|NCT04575948|Active Comparator|Chlorhexidine|Commercial 0.12% chlorhexidine digluconate mouthwash
89246085|NCT04575025||Tabrecta tablets|Patients administered Tabrecta by prescription
89246086|NCT04571619|Active Comparator|Pain Coping Skills Training|
89246087|NCT04571619|No Intervention|Usual Care|
89246088|NCT04571619|Active Comparator|Buprenorphine|
89246089|NCT04571619|No Intervention|No Buprenorphine|
89246090|NCT04567628||TDM Cohort|Participants diagnosed with inflammatory bowel disease (IBD) (UC or CD) within Takeda Canada Patient Support Program (PSP) group who received treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 along with the biomarker testing and TDM at pre-specified intervals during their treatment were observed retrospectively.
89246091|NCT04567628||Historical Cohort|Participants diagnosed with IBD (UC or CD) within Takeda Canada PSP group who received treatment with vedolizumab 300 mg, infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 but did not undergo biomarker testing or TDM during their treatment were observed retrospectively.
89246092|NCT04567615|Experimental|Arm A : Nivolumab|
89246093|NCT04567615|Experimental|Arm B : Nivolumab + Relatlimab Dose 1|
89246094|NCT04567615|Experimental|Arm C : Nivolumab + Relatlimab Dose 2|
89246095|NCT04567511|Experimental|Single Arm|Patients with mild hemophilia A (without inhibitors) will be treated with prophylactic emicizumab. The clinical hemostatic efficacy and safety will be assessed. Secondary outcomes will assess changes in quality of life and joint health in treated patients.
89246096|NCT04564482|Other|Neoadjuvant Chemoradiotherapy (CRT)|
89246097|NCT04564482|Other|Short-course preoperative radiotherapy (SCPRT)|
89246098|NCT04564482|Other|Neoadjuvant Chemoradiotherapy (CROSS protocol)|
89246099|NCT04564391|Active Comparator|Whey protein group, 60g/day|Three weeks, daily supplementation with 60 g of whey protein
89246100|NCT04564391|Active Comparator|Casein protein group, 60 g/day|Three weeks, daily supplementation with 60 g of casein protein
89246101|NCT04564391|Active Comparator|pea protein group, 60g/day|Three weeks, daily supplementation with 60 g of pea protein
89246102|NCT04564391|Placebo Comparator|placebo arm|Three weeks, daily supplementation with placebo
89246103|NCT04560972|Experimental|Treatment (LB-100, carboplatin, etoposide, atezolizumab)|"INDUCTION: Patients receive LB-100 IV over 15 minutes on days 1 and 3, atezolizumab IV over 30-60 minutes on day 1, carboplatin IV over 30-60 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: After completion of induction therapy, patients receive LB-100 IV over 15 minutes on days 1 and 3 and atezolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89246104|NCT04558879|Experimental|Cardiovascular training|Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and through a linear progression will reach vigorous intensity; then, this intensity will be maintained until the end of the intervention. Each session will include five minutes of warm-up and cool-down performed at the beginning and the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool down. CT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
89246105|NCT04558879|Experimental|Resistance training|Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low-intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start with five-minute of warm-up performed on a recumbent stepper and will end with five-minute of stretching (cool-down). RT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
89246106|NCT04558554|Experimental|Study 1a: Pharmacy-based PrEP delivery Pilot (13 months)|Participants in this study will have the option to initiate and/or refill pre-exposure prophylaxis (PrEP) at 4 retail pharmacies in Kenya.
89246107|NCT04558554|Experimental|Study 1b: Pharmacy-based PrEP delivery Refill (12 months)|Participants in this study (happening concurrently with Study 1a) will have the option to refill PrEP at 4 retail pharmacies in Kenya after having initiated PrEP at one of 2 public clinics.
89246108|NCT04558554|Experimental|Study 1a: Pharmacy-based PrEP delivery Pilot Extension (6 months)|Participants in this study will have the option to initiate and/or refill pre-exposure prophylaxis (PrEP) or initiate PEP at 12 retail pharmacies in Kenya. Additionally, at a subset of 4 pharmacies, participants will have the option to undergo STI testing.
89246109|NCT04545606|Experimental|In-person CBT for insomnia in children with autism|In-person cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted at the Thompson Center. In-person treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
89246110|NCT04545606|Experimental|Remote CBT for insomnia in children with autism|Remote/videoconferenced cognitive-behavioral treatment (CBT) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep concerns based on the clinical interview.
89246111|NCT04545606|Experimental|Remote behavioral SHARE for insomnia in children with autism|Remote/videoconferenced behavioral sleep hygiene and related education (SHARE) for insomnia in children with autism will be conducted from home (families)/Thompson Center (therapist). Remote treatment will consist of four 50-minute, individually administered sessions and four bi-monthly, 20-minute telephone boosters. Using a flexible, case conceptualization approach, the therapist will adapt the treatment to parent and child characteristics (i.e., verbal skills, development) and family situation/dynamics - promoting optimal efficacy and enhancing broad clinical applicability. Module administration order will be tailored to prioritize each child/family's most pressing sleep and related health related concerns/interests.
89246112|NCT04544241|Experimental|Clergy Wives and Widows|We will provide cancer survivorship and caregiving leadership education and activities for African American Clergy Wives and Widows by creating an educational partnership program aimed towards church-based health education on cancer survivorship and caregiving
89246113|NCT04544189|Experimental|Alpelisib+Fulvestrant (randomized cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
89246114|NCT04544189|Placebo Comparator|Placebo+Fulvestrant (randomized cohort)|Placebo (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
89246115|NCT04544189|Experimental|PK cohort (open label cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
89246116|NCT04544007|Experimental|Administer Poly-ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
89246117|NCT04541589|Active Comparator|Arm 1|Arm 1 - Iscalimab Dose 1
89246118|NCT04541589|Active Comparator|Arm 2|Arm 2 - Iscalimab Dose 2 and Placebo
89246119|NCT04541030||GPS Cohort 1|Samples and images from up to 277 evaluable patients diagnosed with NCCN low or intermediate risk prostate cancer, Gleason <= 7, managed with RP, and mpMRI within 6 months prior to prostatectomy
89246120|NCT04536792|Experimental|Part 1: Single Ascending Dose (SAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once on Day 1. AG-946 will be given under fasted or fed conditions.
89246121|NCT04536792|Experimental|Part 2: Multiple Ascending Dose (MAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once daily (QD) for 14 days or using an alternative dosing regimen for up to 28 days under fasted conditions.
89246122|NCT04536792|Experimental|Part 3: Sickle Cell Disease (SCD) Phase|Participants will receive a range of selected ascending doses of AG-946, orally, QD or using an alternative dosing regimen for 28 days.
89246123|NCT04534205|Experimental|Part A (Safety run-In) - BNT113 + Pembrolizumab|Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.
89246124|NCT04534205|Experimental|Part B (Randomized phase) - BNT113 + Pembrolizumab|BNT113 in combination with pembrolizumab.
89246125|NCT04534205|Active Comparator|Part B (Randomized phase) - Pembrolizumab monotherapy|Pembrolizumab monotherapy.
89246126|NCT04533750|Experimental|Treatment (peposertib, IMRT)|Beginning 60-90 minutes before each radiation treatment, patients receive peposertib PO QD and undergo IMRT daily Monday-Friday for 7 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, or 18F-FDG PET/CT during screening and follow-up.
89246127|NCT04529174|Active Comparator|Active HDL supplement|25 subjects (ages 18-85 years old) will receive an active HDL supplement (CardioLux™HDL). They will take 2 capsules twice a day with food for 12 weeks. Total daily dosing is four (4) capsules.
89246128|NCT04529174|Placebo Comparator|Placebo|25 randomly selected subjects (ages 18-85 years old) will receive a matching Placebo. They will take 2 capsules twice each day with food for 12 weeks. Total daily dosing is four (4) capsules.
89246129|NCT04524065|Experimental|Early intervention group|The 14 early rehabilitation sessions(10 physical therapy sessions; 15minutes per session, 4 occupational therapy sessions; 20minutes per session) occurred per week until discharge.
89246130|NCT04524065|No Intervention|Control group|The control group received 2 sessions(physical therapy) per week over a 2-week period for 10 minutes each.
89246131|NCT04523727|Experimental|Ferric citrate|Participants aged 6 to < 17 years will receive ferric citrate for 36 weeks at a starting dose based on body weight categories.
89246132|NCT04504266|No Intervention|Control Arm|Recommendations to follow Mediterranean diet and exercise regularly before surgery.
89246133|NCT04504266|Experimental|Prehab|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
89246134|NCT04498468|Experimental|Treatment Arm|Commercially available Sustained Release Dexamethasone, 0.4 mg intracannalicular insert (DEXTENZA® - Ocular Therapeutix, Bedford, MA)
89246135|NCT04498468|Sham Comparator|Control Arm|Commercially available EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL) (Vera90™ - Elkridge, MD)
89246136|NCT04496960|Placebo Comparator|Placebo group|Receiving placebo
89246137|NCT04496960|Experimental|Subjects with SS|Receiving tofacidinib
89246138|NCT04493164|Experimental|Treatment (CPX-351, ivosidenib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5, and ivosidenib PO QD on days 1-28. Patients who do not achieve complete remission may receive a second cycle of induction therapy in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission proceed to consolidation.~CONSOLIDATION: Patients receive CPX-351 IV over 90 minutes on days 1 and 3, and ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ivosidenib PO QD for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who are experiencing clinical benefit and who have not experienced excessive toxicity after completion of 2 years of maintenance may be eligible to continue therapy after discussion with the principal investigator."
89246139|NCT04488159|Experimental|Immunoscore stratification|"Immunoscore low (I-Low; I0-1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.). Concomitantly, standardised physical excise (stair walking excise twice a week for 12 weeks), which will be monitored by an electronic sports device.~Immunoscore intermediate-high (I-IntHi; I2-3): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)~Immunoscore high (I high; I4): no adjuvant treatment."
89246140|NCT04488159|Active Comparator|TNM stratification|"TNM-based low-risk (pT1, pT2 or pT3 and pN1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.)~TNM-based high-risk (pT4 and/or pN2): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)"
89246141|NCT04478370|Experimental|An. minimus|"This arm will be divided into 2 groups; the low-exposure groups and the high-exposure group.~In the low-exposure group, participants will be exposed to 5 mosquito bites at weekly intervals from day 14 to day 56 (seven challenges with 5 mosquito bites/challenge over six weeks, yielding a total of 35 mosquito bites).~In the high-exposure group, participants will be exposed to 5 mosquito bites on day 14 and then to 50 mosquito bites at weekly intervals from day 21 to day 56 (one challenge with 5 mosquito bites and six challenges with 50 mosquito bites/challenge over 6 weeks, yielding a total of 305 mosquito bites)."
89246142|NCT04478370|Experimental|An. maculatus|Same as above
89246143|NCT04478370|Experimental|An. dirus|Same as above
89246144|NCT04478370|Experimental|Ae. aegypti|Same as above
89246145|NCT04478370|Experimental|Ae. albopictus|Same as above
89246146|NCT04477486|Experimental|Ibrutinib + Venetoclax|Participants will receive Ibrutinib Dose A + Venetoclax in various doses until a target dose is reached, for up to 104 weeks, followed by Ibrutinib monotherapy.
89246147|NCT04469959|Experimental|L-Dopa First / Placebo Second|"STEP 1(3 weeks): Participants initially assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa capsules) at 9am. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa capsules) at 9am and 5pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa capsules) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period before proceeding to Step 2.~Step 2 (3 Weeks): Participants will receive matching placebo capsules daily. Participants take placebo capusles once daily during week 1 (9am), twice daily during week 2 (9am, 5pm), and three times daily during week 3 (9am, 1pm, 5pm) over three weeks. Following post-trial assessments, participants then enter a 1-week taper period and study drug is withdrawn."
89246148|NCT04469959|Placebo Comparator|Placebo First / L-Dopa Second|"Step 1 (3 Weeks): Participants will receive matching placebo capsules daily. Participants take placebo capsules once daily during week 1 (9am), twice daily during week 2 (9am, 5pm), and three times daily during week 3 (9am, 1pm, 5pm) over three weeks. Following post-trial assessments, participants then enter a 1-week taper period before proceeding to Step 2.~Step 2 (3 Weeks): Participants will begin with a Week 1 L-DOPA daily dosage of 150mg, (1.5 25mg carbidopa/100mg levodopa capsules) at 9am. Week 2 will increase to a L-DOPA daily dose of 300mg (1.5 25mg carbidopa/100mg levodopa capsules) at 9am and 5pm, followed by a Week 3 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa capsules) three times daily. After completing post-trial assessments, participants then enter a 1 week taper period and study drug will be discontinued."
89246149|NCT04466371||MIU students and staff members|All students and staff members in MIU
89246150|NCT04453085|Experimental|JR-171|Until the dose determination, subjects will intravenously receive either the low dose or high dose of JR-171 (the same dose as at Week 12 of the JR-171-101 study). Thereafter, all subjects will receive the optimal dose of JR-171 determined based on the results of JR-171-101 study.
89246151|NCT04440280|Active Comparator|NAC 10% group|Subjects in this group will be treated with eye drops containing a 10% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
89246152|NCT04440280|Active Comparator|NAC 20% group|Subjects in this group will be treated with eye drops containing a 20% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
89246153|NCT04440280|Placebo Comparator|Placebo group|Subjects in this group will be treated with a placebo (Visine Tears Dry Eye Relief artificial tears ophthalmic solution.)
89246154|NCT04437511|Experimental|Donanemab|Participants received 700 milligram (mg) Donanemab every 4 weeks (Q4W) x 3 doses, then 1400 mg Q4W given intravenously (IV) for up to 72 weeks
89246155|NCT04437511|Placebo Comparator|Placebo|Participants received placebo given IV.
89246156|NCT04437095|Experimental|PSBPS Audiorecording|Thirty minute daily administration of audio recording containing messages of psychological support based on positive suggestion delivered via headphones
89246157|NCT04437095|No Intervention|Control|Standard of care
89246158|NCT04435600|Experimental|Part 1: Risankizumab Dose A|Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.
89246159|NCT04435600|Experimental|Part 2: Ustekinumab Dose A/B/C then Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Ustekinumab Dose A, Dose B, or Dose C based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Risankizumab Dose A or B based on body weight for 24 weeks."
89246160|NCT04435600|Experimental|Part 2: Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare.~Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4)."
89246161|NCT04435600|Experimental|Part 3: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
89246162|NCT04435600|Experimental|Part 4: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks (Japan only: participants age 12 to less than 18 years will be included).
89246163|NCT04429308|Active Comparator|Photodynamic Therapy|One upper arm will be exposed to blue light therapy
89246164|NCT04429308|Active Comparator|Chemical Peels|One upper arm will be exposed to Jessner's Solution AND 35% Trichloroacetic acid peel
89246165|NCT04426071||SCI, brain injury, stroke Participants|Those 18 years of age and older, diagnosed with a stroke, spinal cord injury (traumatic and non-traumatic), or acquired brain injury (of all severities, including concussion) living in the community will be included. Additionally, only those the cognitive capacity to understand and complete the measures will be included. Those who consent will complete an online survey on enrollment into the study, and subsequently at 3 and 6 months.
89246166|NCT04419779|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with type 2 diabetes on insulin.
89246167|NCT04419779|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes on insulin.
89246168|NCT04414111||Kidney transplant recipient|Kidney transplant recipient
89246169|NCT04411836|No Intervention|Control|Patients are treated with schizontocidal treatment plus low dose PQ (total dose 3.5mg/kg) unsupervised over 14 days (PQ14)
89246170|NCT04411836|Experimental|PQ Intervention|Patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
89246171|NCT04411836|Experimental|TQ Intervention|Patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ)
89246172|NCT04410042|Experimental|Tranexamic Acid|At initiation of surgical preparation, participants randomized to the active treatment arm will receive tranexamic acid 10 mg/kg (max 1 g), given via syringe pump programmed to infuse over 15 minutes. If no unacceptable toxicities occur, a second dose of tranexamic acid IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
89246173|NCT04410042|Placebo Comparator|Placebo|At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
89246174|NCT04408287|Experimental|Intervention|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
89246175|NCT04408092|Experimental|GM-CSF treatment at second-look surgery arm|Newly diagnosed patients with EPN who have a subtotal resection at initial presentation and are without evidence of metastatic tumor will be enrolled in this stratum. Total patient population in this stratum will be 10 patients. It should be noted that prior experience suggests that about 1/3 of newly presenting patients still have residual tumor after the initial surgery
89246176|NCT04408092|Experimental|GM-CSF treatment at recurrence arm.|"EPN patients with a first regional relapse and without evidence of metastatic tumor will be enrolled in this stratum. Total patient population will be 10 patients.~Patients with a first recurrence will have the recurrence confirmed by the local institutional neuro-radiologists. They will have the entire neuro-axis scanned and a spinal tap performed (where safe) to exclude metastatic tumor. They will then receive 5 days of GM-CSF and then proceed to surgery if deemed clinically indicated by the treating physician"
89246177|NCT04401748|Experimental|Arm 1: Venetoclax + Azacitidine (AZA)|Participants will receive venetoclax once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
89246178|NCT04401748|Active Comparator|Arm 2: Placebo + Azacitidine|Participants will receive placebo once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
89246179|NCT04396340|Experimental|Dose Escalation|XMT-1592 is administered in groups of patients who will receive doses that increase over time until the maximum tolerated dose is achieved.
89246180|NCT04396340|Experimental|Confirmation of Dose|New groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose
89246181|NCT04394546|Experimental|Device Group|Randomized to WATCHMAN FLX Left Atrial Appendage Closure Device
89246182|NCT04394546|Active Comparator|Control Group|Randomized to non-vitamin K oral anticoagulant (NOAC)
89246183|NCT04392908||Patients|Pediatric patients from 12 to 17 with cancer diagnosis only taken by Meyer Children's Hospital prior consent. Knowledge of fluent Italian language is required
89246184|NCT04392908||Parents|Parents of pediatric patients prior consent. Knowledge of fluent Italian language is required
89246185|NCT04392908||Medical Staff|Medical staff including doctor, psychologist and nurse
89246186|NCT04381975|Experimental|Move in Mind Program|The Move in Mind Program is a 6-week Rolfing®-based intervention program shortened from ten to six sessions and adapted to a group setting by Rolfing® instructor Monica Canducci.
89246187|NCT04381975|Other|6 Week Waitlist Control|Participants will be crossed over to the Move in Mind program following the 6-week waitlist control. Participants of the waitlist control group will be asked to complete follow-up questionnaires both at the same time as the intervention group (after week six) as well as after their own program.
89246188|NCT04372433|Experimental|Dose Escalation of IO-202|Dose cohorts treated with intravenous (IV) IO-202 monotherapy in ascending doses.
89246189|NCT04372433|Experimental|Dose Escalation of IO-202 Plus Azacitidine|AZA Dose cohorts treated with intravenous (IV) IO-202 in ascending doses plus Azacitidine (IV or SC) on days 1-7 of each 28-day cycle.
89246190|NCT04372433|Experimental|Dose Expansion of IO-202 plus Azacitidine AML|To enroll high LILRB4 expression monocytic AML patients refractory to or relapsed after available therapies known to be active in AML.
89246191|NCT04372433|Experimental|Dose Expansion of IO-202 plus Azacitidine CMML|To enroll hypomethylating-agent naive CMML patients.
89246192|NCT04372433|Experimental|Dose Expansion of IO-202 plus Azacitidine + Venetoclax (Ven)|To enroll newly diagnosed high LILRB4 expression AML patients who are unfit for intensive induction chemotherapy.
89246193|NCT04363684||Longitudinal Arm|Annual clinic visits throughout the length of the study.
89246194|NCT04363684||Biofluid-Focused Arm|Single clinic visit.
89246195|NCT04362475|Active Comparator|Family Youth Intervention (FYI)|The primary objective of FYI is to evaluate the effectiveness of a theory-based, peer-supported family strengthening intervention on the primary outcomes in a sample of 120 parent-child pairs living in resource-poor urban neighborhoods in Birmingham. For FYI, we will utilize community health advisors (CHAs) to implement the intervention. CHAs will be recruited from each FYI neighborhood and will be trained in research ethics. CHAs will assist and support FYI participants in mastering the sequential skills of the 12 modules designed to improve maternal, youth, and family functioning. Additionally, CHAs will provide emotional social support that is helpful, hopeful, and trustful.
89246196|NCT04362475|Active Comparator|ESPI Environment: Social and Physical Intervention (ESPI)|ESPI will enroll 500 community members to examine the effect of blight elimination through lot recovery on primary outcomes of improved social interaction, social cohesion around common neighborhood norms, and collective efficacy to effect change in the neighborhoods . Neighborhood residents will select a cluster of lots (2-3) for lot recovery that are highly visible in the neighborhood (e.g. on a main thoroughfare). The community residents will lead the neighborhood projects. In some cases, neighborhood residents will personally undertake all or part of the greening projects.
89246197|NCT04362475|Other|Wait-List Control|The two communities will get ESPI, upon completion of the study.
89246198|NCT04362475|Active Comparator|FYI and ESPI|Two of the eight neighborhoods will receive both FYI and ESPI intervention.
89246199|NCT04357574||Radiation Oncology Providers|Faculty physicians, residents and advanced practice providers in the Radiation Oncology Department in Duke University Health System (DUHS)
89246200|NCT04354324|Experimental|The test group|Oral administration of 30mci once on an empty stomach.
89246201|NCT04354324|Active Comparator|The control group|Oral administration of 100mci once on an empty stomach.
89246202|NCT04348136|Experimental|JR-141|
89246204|NCT04332653|Experimental|Phase 1b: NT-I7 Dose Escalation|"NT-I7 will be administered on Day 1 of alternate 21 day cycles (Cycle 1, 3, 5 etc.). Dosage will increase until the maximum tolerated dose (MTD) and/or the recommended phase 2 (RP2D) dose is reached.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246205|NCT04332653|Experimental|Phase 2a: CPI Treated Triple Negative Breast Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory triple negative breast cancer (TNBC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246206|NCT04332653|Experimental|Phase 2a: CPI Treated Non-small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory non-small cell lung cancer (NSCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246207|NCT04332653|Experimental|Phase 2a: CPI Treated Small Cell Lung Cancer|"Participants with checkpoint inhibitor (CPI) treated relapsed or refractory small cell lung cancer (SCLC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246208|NCT04332653|Experimental|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246209|NCT04332653|Experimental|Phase 2a: CPI Naïve Pancreatic Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC). Participants will receive the recommended phase 2 dose (RP2D) identified during Phase 1b.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246210|NCT04332653|Experimental|Phase 2a: CPI Naïve Microsatellite Stable Colorectal Cancer, Expansion Cohort|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory microsatellite stable colorectal cancer (MSS-CRC). Participants will receive 1200 µg/kg of NT-I7 and and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246211|NCT04332653|Experimental|Phase 2a: CPI Naïve Pancreatic Cancer, Expansion Cohort|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory pancreatic cancer (PC).Participants will receive 1200 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246212|NCT04332653|Experimental|Biomarker Cohort: CPI Naïve Ovarian Cancer|"Participants with checkpoint inhibitor (CPI) naïve relapsed or refractory ovarian cancer (OC). Participants will receive a starting dose of 960 µg/kg of NT-I7 and a fixed dose of 200 mg of pemprolizumab.~Pembrolizumab will be administered on Day 1 of every 21 day cycle."
89246213|NCT04321330|Experimental|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
89246214|NCT04311671|Experimental|Moxidectin|In onchocerciasis endemic areas: Moxidectin 8 mg per oral on Day 0
89246215|NCT04311671|Active Comparator|Ivermectin|In onchocerciasis endemic areas: Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0
89246216|NCT04311671|Experimental|Moxidectin with concomitant Albendazole|In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Moxidectin 8 mg per oral with concomitant albendazole 400 mg per oral on Day 0
89246217|NCT04311671|Active Comparator|Ivermectin with concomitant Albendazole|In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Ivermectin treatment with approximately 150 microgram/kilogram (μg/kg) per oral determined based on height with concomitant albendazole 400 mg per oral on Day 0
89246218|NCT04310423|Placebo Comparator|Placebo|Matched to endotoxin
89246219|NCT04310423|Experimental|Endotoxin|Bolus dose of endotoxin (0.8 ng/kg)
89246220|NCT04310020|Experimental|Treatment (hypofractionated radiation therapy, atezolizumab)|"RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week over 3 weeks for 15 fractions in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and may undergo MRI throughout the study, as well as blood sample collection on study."
89246221|NCT04305145|Experimental|Infliximab|"Patients randomized to this arm will receive IV infliximab regardless of whether they are hospitalized due to their colitis.~Infliximab: Predetermined dose of intravenous infliximab, up to 3 times over 7 weeks~Crossover for inadequate response: Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm (corticosteroids) at full initial dosing."
89246222|NCT04305145|Experimental|Corticosteroids|"Patients randomized to this arm will receive IV steroids or oral steroids depending on whether the severity of their colitis requires hospitalization (inpatient).~Inpatient: Predetermined intravenous dose of methylprednisolone, 2x daily up until patients can safely be transitioned to an oral prednisone taper~Outpatient: Predetermined oral dose of predisone, daily over 7 weeks~Crossover for inadequate response: Patients who do not respond to initial treatment within 3 days with a decrease in symptoms by one grade, or who do not improve to grade 2 or less symptoms by 5 days will add combination therapy from the other treatment arm (infliximab) at full initial dosing."
89246223|NCT04304820|Experimental|SAA|Subjects with SAA treated with early initiation of oral treatment
89246224|NCT04304651|Active Comparator|Limited cancer screening|Limited screening alone.
89246225|NCT04304651|Experimental|Limited cancer screening + FDG PET/CT|Limited screening + FDG PET/CT
89246226|NCT04303702|Other|Discontinue Oxytocin|
89246227|NCT04303702|Active Comparator|Continue Oxytocin|
89246228|NCT04298229|Active Comparator|Protocolized diuretic therapy|"The patients with diabetes will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.~The initial loop diuretic regimen after enrollment:~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol."
89246229|NCT04298229|Experimental|Protocolized diuretic therapy plus SGLT2 inhibitor therapy|"The patients with diabetes will receive standard of care point of care blood glucose monitoring 4 times daily (before meals and at bedtime) and sliding scale insulin.~The initial loop diuretic regimen after enrollment:~Loop diuretic naïve: If the patient does not take a scheduled loop diuretic as an outpatient, the initial IV loop diuretic dose will be 40mg of furosemide equivalents every 12 hours.~Chronic, oral loop diuretic therapy: If the patient takes a scheduled loop diuretic regimen as an outpatient prior to hospital admission, the initial IV loop diuretic daily dose will be 2 times the total daily home regimen dose. Diuretic therapy will be titrated to goal urine output using a standardized diuretic protocol.~The patient will receive SGLT2 inhibitor therapy with dapagliflozin 10 mg orally once daily until 5 days or hospital discharge."
89246230|NCT04290273|Experimental|Morning exposure in week 1|Participants will have their first week of testing starting in the morning
89246231|NCT04290273|Experimental|Afternoon exposure in week 1|Participants will have their first week of testing starting in the afternoon
89246232|NCT04288271|Experimental|Adherence Intervention|"The objective of the intervention is to improve medication adherence. Patient-participants will use a multi-dose electronic pillbox and adherence tracking website which can provide dose reminders. Patient will form an Adherence Support Team (AST) including the participant, a parent (or other) and the Coach (study coordinator). The Coach will guide the AST to use Action-focused Problem-solving to address personal barriers to adherence. They will then generate concrete if-then plans for how they will behave in a given situation. Intervention participants with excellent adherence will be encouraged to work on building autonomy in medication-taking instead of adherence. Action plans will be able to be modified, if desired, at the 6-week and 10-week check-ins.~HCP-participants at intervention sites will be given the option to login to the adherence tracking website to view the adherence data of their patients. They will also be alerted by study staff to critical non-adherence events."
89246233|NCT04288271|Other|Healthy Living Education Intervention|Patient-participants will receive a healthy living education intervention with the use of an e-pillbox. Contacts with the coach will occur at the same intervals as at adherence intervention sites. Participants will choose one of 3 healthy living topics on which they will receive education in an interactive format. The coach will engage the participant in a semi-scripted conversation on the selected topic. At check-ins, the coach will either continue the conversation on the topic selected at the outset or provide education on another topic. The coach will NOT engage in discussions about adherence and will NOT provide feedback on adherence data.
89246234|NCT04275726|Experimental|Myval THV Series|"Myval THV Series will include Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site.~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
89246235|NCT04275726|Active Comparator|Contemporary Valves|"Sapien THV Series will consist of Sapien 3/Sapien 3 Ultra THVs or any subsequent advanced version commercially available at the study site.~Evolut THV Series will include Evolut R/Evolut PRO THVs or any subsequent advanced version commercially available at the study site.~This treatment arm will be assigned to 384 / 768 subjects enrolled in a study."
89246236|NCT04273360|Active Comparator|Systematic use group|
89246237|NCT04273360|Experimental|Restrictive use group|
89246238|NCT04261894|Experimental|OPTIMIZE|This arm includes implementation of the OPTIMIZE perinatal care checklist with patient navigation support.
89246239|NCT04261894|No Intervention|Standard Care|This arm includes provision of standard perinatal care.
89246240|NCT04261088||Experts in Swiss assisted suicide|Persons in Switzerland who are experts in how assisted suicide is practiced. We will beexamining already collected interviews.
89246241|NCT04260126|Experimental|Pembrolizumab and PDS0101|Pembrolizumab will be administered via IV Infusion followed by subcutaneous injections of PDS0101 five times throughout the course of the study. Pembrolizumab monotherapy will be administered every cycle there is not a combination treatment until disease progression or up to Cycle 35.
89246242|NCT04259762|Experimental|Breast, Colorectal, and Cervical Cancer Screening|The investigators will train Community Health Representatives (CHRs) in interactive group discussions techniques. CHRs will administer 1 session/week, lasting approximately 2 hours, and conducted among 12 men or women ages 21-75 per cluster. The CHRs will distribute the cancer-specific (i.e., breast, colorectal, and cervical) small media during the first session and refer to it during the course of the 4 sessions. During the sessions, the CHRs will function as a facilitator linking information with practical skills. At the end of the 4-week INT, participants will receive a voucher to present to a designated point-person at the health center who would schedule the screening for the age- and gender-specific cancers.
89246243|NCT04259762|No Intervention|Control|Historical control
89246244|NCT04258709|Experimental|Antenatal Milk Expression (AME) Intervention Group|Weekly video interactions (weeks 37-40 of pregnancy) with International Board Certified Lactation Consultants (IBCLCs) to teach and reinforce antenatal milk expression. At-home practice of hand expression and collection of any expressed milk.
89246245|NCT04258709|Active Comparator|Video-based Infant Care Education Control Group|Weekly video education (weeks 37-40 of pregnancy) on various topics related to infant care (e.g., safe sleep, car seat safety, etc.).
89246246|NCT04253691|Experimental|Virtual Reality Based Relaxation Therapy|This is a pilot trial with one treatment condition (VR mediation).
89246247|NCT04251247||Acute aortic dissection|Patients with a diagnosis of acute aortic dissection.
89246248|NCT04251247||Acute pulmonary embolism|Patients with a diagnosis of acute pulmonary embolism
89246249|NCT04251247||Non-cardiac chest pain|Patients with non-cardiac chest pain
89246250|NCT04241185|Experimental|Pembrolizumab + Chemotherapy + Radiotherapy|Participants receive pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
89246251|NCT04241185|Placebo Comparator|Placebo + Chemotherapy + Radiotherapy|Participants receive placebo to pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
89246252|NCT04235335|Other|Wait List Control|Participants receive intervention after 12 week delay
89246253|NCT04232696|Experimental|Neuspera Implantable Sacral Nerve Stimulation System|Implantation of the simulator.
89246254|NCT04230148|Experimental|Egaten|All subjects will receive Egaten as two 10 mg/kg doses given 12 hours apart.
89246255|NCT04218617|Experimental|Arm 1 - Single fraction|sSRS 18 Gy in 1 fraction
89246256|NCT04218617|Active Comparator|Arm 2 - Two fraction|sSRS 24 Gy in 2 fractions
89246257|NCT04213456|Experimental|Nutritional supplementation|Powder added to water,high protein and multi vitamin and minerals
88804772|NCT00004342||Parent of Minor Neutropenic Subjects|Parent of minor subjects (i.e., children under 18 years of age) who are diagnosed with severe chronic neutropenia
88804773|NCT00030992|Experimental|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
88804774|NCT00032630|Other|Arm 1|Coronary artery bypass - on-pump
89246258|NCT04213456|Placebo Comparator|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
89246259|NCT04213053|Other|Concomitant strabismus patients|Horizontal strabismus surgery
89246260|NCT04212052|Experimental|split-course radiotherapy|"The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).~Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment."
89246261|NCT04210115|Experimental|Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy|"Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either:~FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)] 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray [Gy] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR~FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.~All treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year."
89246262|NCT04210115|Placebo Comparator|Placebo+FP or FOLFOX Therapy+Radiotherapy|"Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either:~FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR~FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.~All treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year."
89246263|NCT04200963|Experimental|IK-175 Single Agent Dose Escalation|Approximately 5 dose escalation steps are planned during the Single Agent Treatment dose escalation phase of the study. (COMPLETE)
89246264|NCT04200963|Experimental|IK-175 Single Agent Dose Expansion|A Single Agent Treatment dose expansion phase will be performed in patients with urothelial carcinoma with IK-175 after completion of the dose escalation to confirm the RP2D. (COMPLETE)
89246265|NCT04200963|Experimental|IK-175 and nivolumab Combination Dose Escalation|Approximately 2 dose escalation steps are planned during the Combination Treatment dose escalation phase of the study. (COMPLETE)
89246266|NCT04200963|Experimental|IK-175 and nivolumab Combination Dose Expansion|A Combination Treatment dose expansion phase will be performed in patients with urothelial carcinoma with IK-175 after completion of the dose escalation to confirm the RP2D. (COMPLETE)
88804775|NCT00032630|Other|Arm 2|Coronary artery bypass - off-pump
88804776|NCT00385450|Experimental|Nelfinavir/placebo|
88804777|NCT01217749|Experimental|Group 1|In Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing
88804778|NCT01217749|Experimental|Group 2|In Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)
88804779|NCT01217749|Experimental|Group 3|In Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily
88804780|NCT01217827|Experimental|Clinical Reminder|Reminder of potential candidacy for an implantable cardioverter defibrillator. The reminder is placed in the medical record with copy to the primary provider and any cardiologist managing the patient.
88804781|NCT01217827|No Intervention|Control|This group does not receive an intervention.
88806084|NCT01895738|Experimental|WrapAround Care|Participants randomized to the intervention arm will be met in the emergency department by a support worker who has lived experience. They will start to build a relationship with the participant at that time (i.e. during the teachable moment) and will work with the participant for approximately one year, delivering WrapAround Care. Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
88804782|NCT02197273|Active Comparator|Standard of care analgesia|"Total Hip Arthroplasty (THA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine~Injection into capsular tissue after placement of the acetabular component:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Knee Arthroplasty (TKA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine All patients will receive an adductor canal block of 0.25% Bupivacaine w/epinephrine 30cc~Injection into posterior capsule of the knee:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Shoulder Arthroplasty (TSA):~All patients will receive a standard interscalene block with bupivacaine followed by indwelling catheter insertion with ropivacaine infusion to be left in place for two days."
88804783|NCT02197273|Experimental|Liposomal bupivacaine|"THA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Anterior capsule Inferior capsule Posterior capsule Short external rotator Gluteus maximus Subcutaneous tissue~TKA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Posterior knee capsule Anterior femoral periosteum Anterior tibial periosteum Subcutaneous tissue Pericapsular meniscal tissue~TSA:~All patients will receive a standard interscalene block with bupivacaine PLUS 266 mg of liposomal bupivacaine.~Posterior capsule Rotator cuff Subscapularis Humeral periosteum Subcutaneous tissue Deltopectoral muscle"
88804784|NCT01288027|Experimental|Alglucosidase Alfa|
88804785|NCT01288807|Experimental|Treatment|Titrated Milnacipram doses
88804786|NCT01289275|Experimental|Telephone Counseling|Up to 5 proactive counseling sessions
88804787|NCT01289275|Experimental|Nicotine Patches|8 weeks of nicotine patches
88804788|NCT01289275|Experimental|Telephone Counseling + Patches|5 proactive sessions, 8 weeks patches
88804789|NCT01289275|Active Comparator|Brief hospital counseling|brief in hospital counseling, no proactive sessions or patches
88804790|NCT00004474|Experimental|1|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2 with antithymocyte globulin IV over 4 hours; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
89246267|NCT04186325|No Intervention|Group C|Group C: the regular mechanical ventilation protocol will be followed.
89246268|NCT04186325|Experimental|Group T|Group T: inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
89246269|NCT04184791|Experimental|Deep Brain Stimulation(DBS) OFF Medication|Subthalamic-DBS in the Levodopa OFF state.
89246270|NCT04184791|Experimental|Deep Brain Stimulation(DBS) ON Medication|Subthalamic-DBS in the Levodopa ON state.
89246271|NCT04174196|Experimental|Participants with Plasmacytoma|Participants will have solitary bone plasmacytoma with minimal marrow involvement and participants with relapsed multiple myeloma with plasmacytomas
89246272|NCT04173988|Experimental|alloCART-19|"For the very first patient, the initial dose could be administered via one or three intravenous infusions within 1 to 5 days. Starting from the second patient, the investigator will decide whether to use single or multiple alloCART-19 infusions, based on the treatment experience at previous dose level(s) and the patient's baseline disease burdens.~A lymphodepletion conditioning with cyclophosphamide and fludarabine will be conducted before alloCART-19 infusion."
89246273|NCT04173650|Experimental|AGLE 102|Treatment arm
89246274|NCT04159675||control patients|Patients with idiopathic craniosynostosis
89246275|NCT04159675||HR patients|Patients with craniosynostosis due to HR
89246276|NCT04155216|Experimental|Guided imagery|Relaxation and guided imagery program
89246277|NCT04140487|Experimental|Treatment (azacitidine, venetoclax, gilteritinib)|Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles, and gilteritinib PO QD on days 1-28. Treatment of azacytidine and venetoclax repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Cycles of gilteritinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89246278|NCT04137562|Experimental|ADSTEM Inj.|ADSTEM Inj. hAD-MSC 1.0x10^8 cells
89246279|NCT04137562|Placebo Comparator|Placebo|0.9% Normal Saline Inj.
89246280|NCT04136054|Experimental|Adjusted group CBT-i for Anxiety and Affective disorders|Cognitive Behavioral group intervention for sleep problems in patients with Anxiety and Affective disorders, based on Cognitive Behavioral Therapy for insomnia
89246281|NCT04136054|Active Comparator|Care as usual wait-list control group|Treatment as Usual. (After about five months, participants in this condition are offered the experimental group treatment.)
89246282|NCT04134910|Experimental|Physical therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
89246283|NCT04130542|Experimental|LVGN6051|The dose escalation phase includes 10 dose levels of LVGN6051, and the highest dose is up to 10mg/kg. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
89246284|NCT04123704|Experimental|Sitravatinib|Sitravatinib 120 mg daily
89246285|NCT04104126|Active Comparator|Standard of Care Physical Therapy|Patients with Achilles injury are prescribed PT for their treatment, therefore physical therapy is a standard of care treatment for patients with tendon pathology.
89246286|NCT04104126|Experimental|Blood flow restriction (BFR) therapy|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff.
89246287|NCT04100148|Experimental|SyncAV Arm|Treatment Arm
89246288|NCT04100148|Active Comparator|Fixed AV Delay Arm|Control Arm
89246289|NCT04097145|Experimental|Edwards PASCAL System & OMT|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
89246290|NCT04097145|Active Comparator|Optimal Medical Therapy (OMT)|Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation
89246291|NCT04097145|Experimental|Single-Arm Registry|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization
89246292|NCT04092530|Experimental|Intervention - Aim 2|During the intervention period, staff will capture women during the first well-baby visit (WBV) and offer to have the next visit co-scheduled for infant and contraception care. Appointments are scheduled during the discharge process at the end of each WBV. During the discharge process all women 0-6 months postpartum will be identified by clerical staff through review of each pediatric clinic beforehand and through an electronic flag alert in the infant's electronic medical record. The pre-review of pediatric clinic schedules and the use of the flag will remind staff to offer the mother a co-scheduled visit for newborn and contraceptive care at the time of the next newborn visit.
89246293|NCT04092530|No Intervention|Control - Aim 2|Clinics will schedule postpartum contraception using normal clinic procedures.
89246294|NCT04089358|Active Comparator|Control Group (educational materials, Fitbit)|Participants receive educational materials about physical activity and wear a Fitbit daily for 48 weeks.
89246295|NCT04089358|Experimental|Intervention group (educational materials, goal set, Fitbit)|See outline
89246296|NCT04081883|Experimental|Biosensor algorithm|The biosensor DIABLO algorithm is compared to Continuous Glucose Monitoring Systems (CGMS) utilisation.
89246297|NCT04067661|Experimental|Intervention|Participants and their partners will complete four couples counseling sessions focused on developing and enhancing relationship skills to decrease HIV risk behaviors.
89246298|NCT04067661|Active Comparator|Control|Participants and their partners will receive information and referrals on HIV risk and prevention strategies.
89246299|NCT04067336|Experimental|Phase 1a - Dose Escalation|
89246300|NCT04067336|Experimental|Phase 1b - Dose-Validation Expansion|"Cohort 1: KMT2A-r / NPM1-m patients will receive a dose previously studied in Phase 1a~Cohort 2: KMT2A-r / NPM1-m patients will receive a dose previously studied in Phase 1a"
89246301|NCT04067336|Experimental|Phase 2|NPM1-m patients will receive the recommended phase 2 dose determined in Phase 1
89246302|NCT04066127|Experimental|Non-ischemic heart preservation (NIHP)|Non-ischemic hypothermic perfusion (NIHP): The donor heart is preserved using a portable heart-lung machine. The device perfuse the heart continuously with a a new preservation solution at a temperature of 8°C.
89246303|NCT04066127|Other|Standard cold storage (SCS)|Standard cold static storage (SCS): The donor heart is preserved using a standard crystalloid cardioplegia. The heart is in then storage i a transport box containing ice to keep the temperature around 4-8°C. The device does not perfuse the heart.
89246304|NCT04062448|Experimental|Ibrutinib + Rituximab|Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.
89246305|NCT04057898|Experimental|MN-166|Subjects will take MN-166 10 mg capsules, up to 50 mg twice a day for 12 months.
89246306|NCT04057898|Placebo Comparator|placebo|Subjects will take up to 5 matching placebo capsules twice a day for 12 months.
89246307|NCT04051580|Experimental|Lactated Ringer's solution|For patients randomized to lactated Ringer's solution (study group), lactated Ringer's solution is used as a base solution for del Nido cardioplegia.
89246308|NCT04051580|Active Comparator|PlasmaLyte-A|For patients randomized to PlasmaLyte-A (control group), PlasmaLyte-A (Baxter Healthcare Corporation, Deerfield, IL, USA) is used as a base solution for del Nido cardioplegia.
89246309|NCT04049890||Parents of children with a chronic disease with no siblings|Parents of children suffering from a chronic disease who has no brother or sister over 3 years of age
89246310|NCT04049890||Parents of children with a chronic disease with siblings|Parents of children suffering from a chronic disease who one or more sibling over the age of 3 years old
89246311|NCT04023812||Cohort 1|Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
89246312|NCT04023812||Cohort 2|Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC
89246313|NCT04020224|Experimental|Treatment with pathogen reduced whole blood|Subjects will receive one amustaline/GSH treated whole blood product.
89246314|NCT04020224|Active Comparator|Treatment with Standard of Care|Subjects will receive the Standard of Care (SOC), either one red blood cell (RBC) component or one whole blood product
89246315|NCT04018859|Experimental|Platelet-Rich Plasma|Participants will receive intradermal injections of 2-3mL autologous PRP to eyebrows.Three treatments will be performed 1 month apart.
89246316|NCT04018859|Placebo Comparator|Placebo (sterile saline)|Participants will receive intradermal injections of 2-3mL sterile saline to eyebrows.Three treatments will be performed 1 month apart.
89246317|NCT04008563|Experimental|Bariatric Surgery and Progestin Intrauterine Device|This group will receive a progestin intrauterine device and be offered to undergo bariatric surgery.
89246318|NCT04008563|No Intervention|Progestin Intrauterine Device Alone|This group will receive a progestin intrauterine device alone.
89246319|NCT03999229|Active Comparator|Blood transfusion with SNO agent|"Autologous blood transfusion packed red blood cells (RBCs) while inhaling S-nitrosylating agent (SNO)~A single intra venous blood transfusion of one unit of packed Red Blood Cells (RBCs) will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.~Inhalation of SNO agent, 20-40 parts per million will occur during the transfusion."
89246320|NCT03999229|Placebo Comparator|Normal Saline with SNO agent|"Normal Saline Transfusion while inhaling S-nitrosylating agent (SNO)~A single intra venous infusion of one unit of normal saline, will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.~Inhalation of the SNO agent at 20-40 parts per million, will occur during the transfusion."
89246321|NCT03994367|No Intervention|Standard protein (control)|
89246322|NCT03994367|Experimental|High animal protein isolate|
89246323|NCT03994367|Experimental|High animal protein whole food|
89246324|NCT03994367|Experimental|High plant protein isolate|
89246325|NCT03994367|Experimental|High plant protein whole food|
89246326|NCT03978052|Experimental|EGCG + multimodal intervention|"EGCG + multimodal intervention (n=50) EGCG: (Font-UP, Laboratoires Grand Fontaine), a daily dose of 5-6 mg/kg up to 500 mg/day for 12 months~+ multimodal lifestyle personalized intervention"
89246327|NCT03978052|Placebo Comparator|Placebo + multimodal intervention|"Placebo Font-Up (n=50)~+ multimodal lifestyle personalized intervention"
89246328|NCT03978052|Sham Comparator|Control|Healthy lifestyle recommendations (n=50)
89246329|NCT03977584|Experimental|[^18F]GTP1 in Mutation Carriers: Crenezumab|Mutation-carrying participants receiving crenezumab in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
89246330|NCT03977584|Placebo Comparator|[^18F]GTP1 in Mutation Carriers: Placebo|Mutation-carrying participants receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
89246331|NCT03977584|Placebo Comparator|[^18F]GTP1 in Non-carriers of Mutation: Placebo|Non-carriers of the mutation receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
89246332|NCT03977493|Active Comparator|Xeomin®|Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).
89246333|NCT03977493|Placebo Comparator|Placebo concentrate|Intramuscular Placebo injection under guidance (EMG and/or sonographic monitoring), in each muscle (max. 5 forearm- and/or hand muscles).
89246334|NCT03972488|Experimental|Lutathera plus long-acting octreotide|
89246335|NCT03972488|Active Comparator|high dose long-acting octreotide|
89246337|NCT03968744|Experimental|Safinamide|PO treatment: 2 weeks of treatment at dose 50 mg/day followed by 10 weeks at 100 mg/day
89246338|NCT03962309||Patients in charge of the participating GPs|In the study will be included patients in charge of the participating GPs aged 40-70 years
89246339|NCT03954132||Spiolto® Respimat®|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
89246340|NCT03954132||Triple-Therapy (LAMA/LABA/ICS)|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
89246341|NCT03944772|Experimental|Module 1: Osimertinib + Savolitinib|The patients in this group will receive osimertinib taken in combination with savolitinib
89246342|NCT03944772|Experimental|Module 2: Osimertinib + Gefitinib|The patients in this group will receive osimertinib taken in combination with gefitinib
89246343|NCT03944772|Experimental|Module 3: Osimertinib + Necitumumab|The patients in this group will receive osimertinib taken in combination with necitumumab
89246344|NCT03944772|Experimental|Module 4: Carboplatin + Pemetrexed + Durvalumab)|The patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
89246345|NCT03944772|No Intervention|Observational Cohort: No study drug|"Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice.~With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib."
89246346|NCT03944772|Experimental|Module 5: Osimertinib + Alectinib|The patients in this group will receive osimertinib taken in combination with alectinib
89246347|NCT03944772|Experimental|Module 6: Osimertinib + Selpercatinib|The patients in this group will receive osimertinib taken in combination with selpercatinib
89246348|NCT03944772|Experimental|Module 7: Etoposide + Durvalumab + Carboplatin or Cisplatin|The patients in this group will receive platinum-containing doublet (etoposide + carboplatin or cisplatin) taken in combination with durvalumab.
89246349|NCT03944772|Experimental|Module 8: Osimertinib + Pemetrexed + Carboplatin or Cisplatin.|The patients in this group will receive Osimertinib plus platinum-containing doublet (pemetrexed + carboplatin or cisplatin).
89246350|NCT03944772|Experimental|Module 9: Osimertinib + Selumetinib|The patients in this group will receive osimertinib taken in combination with selumetinib
89246351|NCT03944772|Experimental|Module 10: Osimertinib + datopotamab deruxtecan|The patients in this group will receive osimertinib taken in combination with datopotamab deruxtecan.
89246352|NCT03941730|Experimental|Treatment (estradiol)|Patients receive estradiol PO TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tissue biopsy at the end of cycle 1, collection of blood samples on C1D1, at the end of cycle 1, and at the end of treatment. In addition, patients undergo CT, MRI, or PET scans at baseline, at the end of cycles 2, 4, and 6, and then every 8 weeks until disease progression.
89246353|NCT03932201||Previously treated patient (PTPs) with hemophilia A|Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis)。
89246354|NCT03929601|Active Comparator|Rituximab-pvvr followed by Abatacept|"Rituximab-pvvr will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 0 of the study.~Abatacept will be given by a subcutaneous formulation weekly for 20 months, beginning at Week 16 (Month 4) of the study. Dosing will be determined by weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL)."
89246355|NCT03929601|Placebo Comparator|Rituximab-pvvr followed by Placebo|"Rituximab-pvvr will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 0 of the study.~Placebo will be given by a subcutaneous isotonic saline formulation weekly for 20 months, beginning at Week 16 (Month 4) of the study. Dosing will be match to active comparator, determined by weight: Up to 25 kg: 0.4 mL; 25 to <50 kg rec 0.7 mL, and > 50 kg receive 1.0 mL."
89246357|NCT03924895|Experimental|Arm A: Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.
89246358|NCT03924895|Active Comparator|Arm B: Surgery alone|Participants receive standard of care surgery alone.
89246359|NCT03924895|Experimental|Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery|Participants receive 3 preoperative cycles of enfortumab vedotin + pembrolizumab, followed by standard of care surgery, followed by 6 cycles of postoperative enfortumab vedotin + pembrolizumab, followed by 8 cycles of pembrolizumab alone. Each cycle is 21 days.
89246360|NCT03922334|Experimental|Navigation Group|Women who are randomized into NNM2 will be assigned to a patient navigator. The patient navigator will meet with the patient after delivery occurs for introductions and education. The patient navigator will offer support and resources (transportation, community referrals, support for your mental health, connection to your doctors, etc.). The navigator will also help to schedule postpartum medical appointments, and will remind the patients of these appointments via text, email, or phone calls. The navigator will continue to provide psychosocial support and continued linkage to resources through one-year postpartum.
89246361|NCT03922334|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
89246362|NCT03916029|Active Comparator|Facilitator|120 hours training for local community members delivered on-country face-to-face during 6 4-day weeks and over a 3-6 month period. Certificate II modules in Aboriginal Primary Health Care, ear and hearing health skills development (otoscopy, tympanometry, and hearScreen) and employment as Ear Health Facilitators to the end of the trial.
89246363|NCT03916029|No Intervention|Control|No Facilitator. Brief 6-monthly 2 to 3 hour in-service training via zoom for health professionals.
89246364|NCT03915964|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
89246365|NCT03915964|Experimental|Baricitinib High Dose|Baricitinib administered orally.
89246366|NCT03915964|Active Comparator|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
89246367|NCT03911726|Other|Healthy subjects|30 healthy subjects will undergo a single PET/MR-measurement.
89246368|NCT03911726|Experimental|First-episode, drug-naive patients with schizophrenia|20 first-episode, drug-naive patients with schizophrenia will undergo a single PET/MR-measurement.
89246369|NCT03911726|Experimental|Pretreated chronically ill patients with schizophrenia|90 pretreated chronically ill patients with schizophrenia will undergo a single PET/MR-measurement.
89246370|NCT03911700|Experimental|Phasix™ Mesh|Prophylactic onlay placement of mesh.
89246371|NCT03911700|No Intervention|Primary Suture Closure|Standard Fascial closure.
89246372|NCT03911388|Experimental|HSV G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.
89246373|NCT03907826|Experimental|PD-1 antibody plus chemoradiotherapy|Patients randomized to this arm will receive three cycles of PD-1 antibody (JS001, 240mg every three weeks) combined with GP chemotherapy, then receive IMRT and PD-1 antibody maintenance for eight cycles.
89246374|NCT03907826|Active Comparator|Chemoradiotherapy|Patients randomized to this arm will receive three cycles of GP chemotherapy, then receive IMRT alone.
89246375|NCT03897530|Experimental|Prevention|During the session, participants are presented with randomly ordered conditions: menthol cigarettes and five flavored e-cigarettes (menthol/mint, fruits, sweets, alcohol, snacks/meals), menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes, non-menthol cigarettes and five flavored e-cigarettes, and non-menthol cigarettes and both unflavored and tobacco-flavored e-cigarettes. Participants' visual attention is evaluated by eye-tracking equipment.
89246376|NCT03896659|Experimental|Depressed: Hydrocortisone, then Placebo|"Participants in the depressed' arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
89246377|NCT03896659|Experimental|Depressed: Placebo, then Hydrocortisone|"Participants in the depressed' arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
89246378|NCT03896659|Experimental|Healthy Controls: Hydrocortisone, then Placebo|"Participants in the healthy control arm will receive a Hydrocortisone 160 mg tablet every day for 3 days. After a washout period of 25 days, they then will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days."
89246379|NCT03896659|Experimental|Healthy Controls: Placebo, then Hydrocortisone|"Participants in the healthy control arm will receive a Placebo tablet (matching Hydrocortisone 160 mg tablet) every day for 3 days. After a washout period of 25 days, they then will receive a Hydrocortisone 160 mg tablet every day for 3 days."
89246380|NCT03896516|Experimental|Active Drug|GOAT Inhibitor
88804791|NCT00004474|Experimental|2|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
89246381|NCT03896516|Placebo Comparator|Placebo|Placebo Participants will take GLWL-01 450 mg b.i.d. or matched placebo for up to 16 days
89246382|NCT03896035|No Intervention|Waitlist Control Group|The waitlist control group will continue with management of chronic back pain and depression per usual care. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant. Subjects randomized to the waitlist control group will be offered the same intervention once the active intervention group has completed the active sessions and assessments.
89246383|NCT03896035|Experimental|Behavioral Intervention Group|For participants assigned to the intervention arm, trained health coaches will deliver the intervention via telephone. All participants, regardless of what group they have been assigned to will undergo several outcome assessments (pre-screening, baseline, mid-point, final assessments) conducted by a blinded research assistant.
89246384|NCT03878121|Experimental|A1|Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
89246385|NCT03878121|Experimental|A2|Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
89246386|NCT03878121|Experimental|B1 (exploratory)|Previously vaccinated; Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
89246387|NCT03878121|Experimental|B2 (exploratory)|Previously vaccinated; Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
89246388|NCT03876457|Experimental|Endovascular Thrombectomy plus Medical Management|
89246389|NCT03876457|Active Comparator|Medical Management|
89246390|NCT03875573|Experimental|Chemotherapy and radiotherapy|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy).
89246391|NCT03875573|Experimental|Chemotherapy and pre-operative radiotherapy plus durvalumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w.
89246392|NCT03875573|Experimental|Chemotherapy & pre-op radiotherapy + durvalumab + oleclumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w and the addition of the anti-CD73 antibody oleclumab IV 3000 mg q2w for 4 administrations, followed by q4w for 3 administrations.
89246393|NCT03867175|Experimental|Arm 1 Stereotactic Body Radiation Therapy/Pembrolizumab|3-10 treatments of SBRT/ pembrolizumab IV for 30 minutes every 3-4 weeks for 1 year at doctor's discretion.
89246394|NCT03867175|Experimental|Arm 2 Pembrolizumab Only|Patients receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
89246395|NCT03866239|Experimental|Obinutuzumab Pretreatment (OpT) + Cibisatamab + Atezolizumab|Participants will receive obinutuzumab approximately 2 weeks before receiving atezolizumab and cibisatamab on Day 1 of each treatment cycle (cycle = 21 days).
89246396|NCT03858868|Experimental|Church and park-based intervention|Participants at intervention churches will be offered: texting intervention (messages about physical activity); peer leader training; walking groups; park-based fitness classes; sermons; participation in park advisory board; community advocacy.
89246397|NCT03858868|Other|Publicly available physical activity materials|Participants at control churches will be offered standard health educational materials (brochures, tip sheets, posters) about physical activity.
89246398|NCT03858439|Experimental|Intervention|Single arm study. All participants will receive dietary intervention.
89246399|NCT03856437|Experimental|Gain-framed messages|Participants in this arm receive gain-framed HPV vaccination messages.
89246400|NCT03856437|Experimental|Loss-framed messages|Participants in this arm receive loss-framed HPV vaccination messages.
89246401|NCT03856437|Active Comparator|Control messages|Participants in this arm receive non-framed HPV vaccination messages.
89246402|NCT03853798|Experimental|Cohort 1|"Participants who received placebo in Study AG348-C-006 will enroll in Cohort 1.~Part 1 (Dose Optimization Period, 12 weeks): Participants will begin by receiving 5 milligrams (mg) orally, twice a day. Each participant's dose of AG-348 may be increased to 20 mg twice a day and then to 50 mg twice a day depending on their response to AG-348 and tolerability.~Part 2 (Fixed Dose Period, 12 weeks): Last dose received in Part 1, twice a day.~After completion of Part 2, participants who, in the opinion of the Investigator, have demonstrated clinical benefit from AG-348 treatment will continue AG-348 treatment in the Continued Treatment Period."
89246403|NCT03853798|Experimental|Cohort 2|"Participants who received AG-348 in Study AG348-C-006 will enroll in Cohort 2.~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-006."
89246404|NCT03853798|Experimental|Cohort 3|"Participants who received AG-348 in Study AG348-C-007 will enroll in Cohort 3.~Participants will continue the AG-348 dose regimen they were receiving at the last visit of Study AG348-C-007."
89246405|NCT03852472|Placebo Comparator|Group A|Placebo twice daily (BID) for Period 1 of the study
89246406|NCT03852472|Experimental|Group B|Avacopan 10 mg twice daily (BID) for Period 1+2 of the study
89246407|NCT03852472|Experimental|Group C|Avacopan 30 mg twice daily (BID) for Period 1+2 of the study
89246408|NCT03852472|Experimental|Placebo to Avacopan 10 mg|Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.
89246409|NCT03852472|Experimental|Placebo to Avacopan 30 mg|Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.
89246410|NCT03851796|Active Comparator|TEENS+Parents as Coaches|"Parents are taught strategies to support and facilitate child weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on strategies to facilitate healthy weight management in their child(ren). Topics include role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen. They receive personalized feedback throughout the program.~All adolescents participate in a group-based empirically supported behavioral weight management treatment, that includes dietary and physical activity goals, and instructions to self-monitor key information. Adolescents will receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program."
89246411|NCT03851796|Active Comparator|TEENS+Parent Weight Loss|"Parents are given a weight loss goal of 1-2 lbs/week, and specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program.~All adolescents participate in a group-based empirically supported behavioral weight management treatment, that includes dietary and physical activity goals, and instructions to self-monitor key information. Adolescents receive training in core behavioral weight loss strategies (e.g. goal setting, stimulus control) and techniques to help them achieve these goals. They also receive personalized feedback throughout the program."
89246412|NCT03851614|Experimental|Cohort A|Olaparib (given orally at a dose of 300 mg twice a day) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
89246413|NCT03851614|Experimental|Cohort B|Cediranib (given orally at a dose of 20 mg daily, 5 days on 2 days off) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
89246414|NCT03838601|Experimental|MET-4|Subjects diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) will receive treatment with MET-4 in addition to standard of care CRT. MET-4 is administered orally as an initial daily loading dose over 2 days followed by a daily maintenance dose of MET-4 and will be administered until week 4 of CRT or unacceptable toxicity whichever occurs earlier and in the absence of criteria to discontinue MET-4.
89246415|NCT03833167|Experimental|Pembrolizumab|Participants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.
89246416|NCT03833167|Placebo Comparator|Placebo|Participants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.
89246417|NCT03829332|Experimental|Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
89246418|NCT03829332|Active Comparator|Pembrolizumab + Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
89246419|NCT03823742|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
89246420|NCT03823742|Experimental|Low FODMAP diet|Low FODMAP diet
89246421|NCT03821506|Experimental|Dynamic light|The experimental intervention is the installation of a dynamic LED-light system in 10 separate patient single rooms. The system includes three elements: a window jamb built-in light panel, two ceiling mounted lamps, and a wall mounted lamp. All lamps will have a dynamic, time dependent frequency distribution and intensity of light.
89246422|NCT03821506|Placebo Comparator|Usual care|The usual care is constant standard LED-light with two elements: two ceiling mounted lamps and a wall mounted lamp.
89246423|NCT03819933|Other|Pregnant women and their partners|"For the qualitative arm of this mixed method study, using an exploratory sequential design, investigators will enroll ~ 30 adult pregnant women admitted estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners to participate in a post-counseling semi-structured interview to explore preferred language and approaches, and better inform questionnaire development. Sample size will be up to 30 families, or until thematic saturation is achieved (total up to 60 if all partners agree to participate).~For the quantitative arm of this study, investigators will enroll ~100 adult pregnant women admitted between estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners (up to total ~200 if all partners present and agree to participate)."
89246424|NCT03819933|Other|Counseling MFM and Neonatology providers|Investigators will enroll ~100 counseling Maternal-Fetal Medicine (MFM) specialists and 100 counseling Neonatologists (total ~200 providers), who provided counseling to the enrolled pregnant women between 22 0/7-25 6/7 weeks' estimated gestation for anticipated extremely preterm delivery. This assumes 1 counseling provider from MFM and 1 from Neonatology per pregnant woman, although there could be more if a consult is performed by both an attending physician and a training fellow or practitioner, or less, if a counseling provider declines to participate in the study. There will be anticipated repetition of counseling providers, accounted for in the statistical analysis. Providers will be asked to complete educational interventions to improve counseling at extreme prematurity.
89246425|NCT03819803|Experimental|Steroid refractory GI-aGvHD|"Patients with GI-aGvHD not sufficiently responding to GvHD therapy with corticosteroids.~Intervention: Fecal microbiota transplantation"
89246426|NCT03814746|Experimental|Crizanlizumab (SEG101) at 5.0 mg/kg|Participants received Crizanlizumab (SEG101) at 5.0 mg/kg
89246427|NCT03814746|Experimental|Crizanlizumab (SEG101) at 7.5 mg/kg|Participants received Crizanlizumab (SEG101) at 7.5 mg/kg
89246428|NCT03814746|Placebo Comparator|Placebo|Participants received the placebo drug.
89246429|NCT03810352||Patients with ITP|Patients with primary or secondary immune thrombocytopenia
89246430|NCT03807778|Experimental|Mobocertinib, Phase 1 Part|Mobocertinib 40 milligrams (mg) (as the starting dose), capsules, orally, once daily on Days 1-28 of each 28-day treatment cycle for up to disease progression or intolerable toxicity, or another discontinuation criterion, and increasing until 160 mg, once daily (for up to approximately 10-12 cycles).
89246431|NCT03807778|Experimental|Mobocertinib, Phase 2 Part|Mobocertinib 160 mg, once daily, for up to approximately 10-12 cycles.
89246432|NCT03807492||EMPOWeR Study|This is a cohort study, with initial patient assessments and longitudinal follow-up. Participation of subjects will be indefinite, which will be discussed in the informed consent.
88804792|NCT01289431|Experimental|Mapracorat|
89246433|NCT03789240|Experimental|1|Window of treatment with Copanlisib 60mg via IV for a single 28 day cycle, once weekly for the first 3 weeks and then a 1 week break followed by induction therapy with copanlisib and rituximab. Induction therapy will be 6 cycles (28 days) of: copanlisib dose and administration same as window, rituximab 375mg/m2 via IV, once weekly for the first 4 weeks during cycle 1, subsequent cycles (cycles 2-6), rituximab will be dosed only once on day 1 of the cycle.
89246434|NCT03784521|Experimental|In-line filtration|For patients randomized to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used for all intravenous access during operation and postoperative period in intensive care unit (ICU).
89246435|NCT03784521|Active Comparator|Control|For patients randomized to control group, All intravenous access is managed routinely according to local standard care without filtration during operation and postoperative period in ICU.
89246436|NCT03783143||Clinical Cohort|This study population will consist of patient volunteers that visit one of our clinical sites with an undiagnosed febrile illness.
89246437|NCT03783143||Cross-sectional Cohort|This study population will consist of patient volunteers that visit one of our clinical sites with an undiagnosed febrile illness.
89246438|NCT03782415|Experimental|MN-166 and temozolomide|Part 1: Combination treatment of MN-166 60 mg/day (30 mg twice a day) for 28 days and temozolomide 150 mg/m² on Days 1-5 of 28-day cycle. Part 2: Open-label, fixed-dose MN-166 and temozolomide combination treatment for 6 cycles until disease progression, unacceptable tolerability and/or toxicity or loss of life.
89246439|NCT03779334|Experimental|Open-label Risdiplam|Participants will be enrolled to receive risdiplam orally once daily at a dose selected to achieve the targeted exposure range.
89246440|NCT03771157|Experimental|Shingrix shingles vaccine treatment|On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
89246441|NCT03770429|Experimental|AZD6738|Patients will receive AZD6738 orally on a 28-day cycle
89246442|NCT03761095|Experimental|Unesbulin and Dacarbazine|Participants will receive unesbulin orally twice weekly in combination with dacarbazine IV once every 21 days. The first participant will receive dacarbazine 1000 mg/m^2 IV every 21 days in combination with unesbulin 200 mg tablet orally twice weekly. For subsequent participants, the dose level at which treatment is initiated will be selected based on the TITE-CRM using the most up to date dose DLT information from all participants previously treated. Participants will receive unesbulin 300 mg twice weekly in combination with dacarbazine in the expansion cohort. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
89246443|NCT03756649||Control Group|Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool
89246444|NCT03756649||Inflammatory bowel disease (IBD)|Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool
89246445|NCT03747146|Active Comparator|Continuous Adductor Canal Catheter (ACC)|Patients will receive a combined spinal epidural, PAI, IPACK, and a continuous adductor canal catheter
89246446|NCT03747146|Sham Comparator|Adductor Canal block with sham catheter|Patients will receive a combined spinal epidural, PAI, IPACK, and an adductor canal block. The patient will also receive a sham catheter.
89246447|NCT03746509|Experimental|Low-High Treatment|Participants in the low-high treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
89246448|NCT03746509|Experimental|High-Low Treatment|Participants in the high-low treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency once a week for a duration of 4 weeks (low intensity).
89246449|NCT03746509|Active Comparator|Low-High Comparator|Participants in the low-high comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
89246450|NCT03746509|Active Comparator|High-Low Comparator|Participants in the high-low comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency once a week for a duration of 4 weeks (low intensity).
89246451|NCT03745144|Experimental|Sequence 1: First Cladribine, Then Placebo|"Period 1: Participants received a single once daily dose of Microgynon® tablet from Day 1-8 followed by 5-day once-daily Cladribine 10 to 20 milligram(mg) depending on body weight along with Microgynon® tablet once daily from Day 9-28.~Period 2: Participants received a single once daily dose of Microgynon® tablet from Day 1-8 followed by 5-day once-daily Cladribine matched Placebo along with Microgynon® from Day 9-14. From Day 15-28 participants received once daily Microgynon® along with 5-day once-daily Cladribine 10 to 20 mg depending on body weight."
89246452|NCT03745144|Experimental|Sequence 2: First Placebo, Then Cladribine|"Participants 5-day once daily Period 1: Participants received a single once daily dose of Microgynon® tablet from Day 1-8 followed by 5-day once-daily Cladribine matched Placebo along with Microgynon® tablet once daily from Day 9-28.~Period 2: Participants received a single once daily dose of Microgynon® tablet from Day 1-8 followed by 5-day once-daily Cladribine 10 to 20 mg depending on body weight along with Microgynon® tablet once daily from Day 9-28."
89246453|NCT03745144|Experimental|Microgynon®|Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle.
89246454|NCT03744156|Experimental|Cognitive Behavioral Treatment-Insomnia|Cognitive Behavioral Treatment-Insomnia. 8 Session treatment focusing on behavior and cognitions related to sleep and pain.
89246455|NCT03744156|Experimental|Sleep Hygiene Education|Sleep Hygiene Education. 8 Session treatment focusing on sleep hygiene education.
89246456|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material
89246457|NCT03738397|Experimental|Upadacitinib 30 mg QD|Participants will receive 30 mg upadacitinib orally once a day (QD) up to Week 24 and placebo to dupilumab by subcutaneous injection every other week from Baseline to Week 22.
89246458|NCT03738397|Experimental|Dupilumab 300 mg EOW|Participants will receive a loading dose of 600 mg dupilumab by subcutaneous (SC) injection on Day 1 followed by 300 mg dupilumab SC every other week (EOW) until Week 22 and placebo to upadacitinib orally QD up to Week 24.
89246459|NCT03692052|Experimental|AG-348|Participants with alpha or beta thalassemia received AG-348 50 mg twice daily (BID), orally up to Week 6. Following Week 6, depending on the participants' safety and hemoglobin (Hb) concentrations, they could undergo one potential dose-level increase from 50 to 100 mg BID. After completion of the Core Period of 24 weeks, participants were eligible to continue to receive AG-348 in the Extension Period which is up to 10 years.
89246460|NCT03690661|Experimental|Intervention Video Game|Participants will play the Intervention Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
89246461|NCT03690661|Placebo Comparator|Control Video Game|Participants will play the Control Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
89246462|NCT03686202|Experimental|Group A: Safety Cohort|Subjects with advanced solid tumors already on ICI will receive treatment with MET-4 in addition to SOC ICI. MET-4 is administered orally as an initial daily loading dose (5g) of MET-4 over 2 days followed by a daily maintenance dose (1.5g) of MET-4 and will be continued until unacceptable toxicity, progression of disease
89246463|NCT03686202|Experimental|Group B|Eligible subjects with advanced solid tumors starting ICI will be randomised in a 3:1 ratio stratifying for prior IO exposure, to receive MET-4 together with any approved PD-1/PD-L1 inhibitor as per SOC or control group. There will be a run-in period for subjects in the MET-4 treatment group. Following the run-in period of ICI therapy, subjects will be administered the same MET-4 dose as subjects in group A.
89246464|NCT03686202|Experimental|Group C|In group C, eligible subjects with advanced solid tumors whom are already on ICI with first unconfirmed PD on evaluation scans per investigator's assessment, will be randomised in a 1:1 ratio to receive MET-4 in addition to the PD-1/PD-L1 inhibitor as per SOC or control group. These subjects must be clinically stable and are to be continued on ICI at the discretion of the investigator. There will be no run-in period for this cohort. Subjects will be administered the same MET-4 dose as subjects in groups A and B.
89246465|NCT03686202|Experimental|Group D|In group D, eligible subjects with stage III or resected stage IV melanoma who are to start adjuvant ICI, will be randomized in a 1:1 ratio to receive MET-4 in addition to anti-PD1 antibody +/- anti-CTLA4 antibody as per SOC or control group. Patients will be stratified per BRAF mutation status. Subjects will be administered the same MET-4 dose as subjects in groups A, B and C. MET-4 will be initiated as run-in for a minimum of 1 week, and maximum of 2 weeks before ICI administration. MET-4 will be continued until unacceptable toxicity, confirmed PD by RECIST v1.1 or completion of 1 year of ICI, whichever occurs earlier. Subjects in the control arms of groups B, C and D will be treated with ICI therapy as per institution standard of care without MET-4.
89246466|NCT03657576|Experimental|C134 Treatment|All patients who enroll will receive C134 inoculation into their tumor (one time procedure with 1-5 inoculation sites)
89246467|NCT03656536|Experimental|Pemigatinib|
89246468|NCT03656536|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.
89246469|NCT03652181||CASH (Cavernous Angiomas with Symptomatic Hemorrhage)|The adjudicated definition of CASH (Cavernous Angiomas with Symptomatic Hemorrhage) requires diagnostic evidence of new lesional bleeding or hemorrhagic growth, in association with directly attributable symptoms.
89246470|NCT03650374|Active Comparator|Group 1|standard of care postoperative rehabilitation.
89246471|NCT03650374|Experimental|Group 2|experimental strength training
89246472|NCT03629886|No Intervention|Vacc-039 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received HPV vaccine in HPV-039 study (NCT00779766), underwent cervical sample collection and didn't receive any vaccine in the current study.
89246473|NCT03629886|Experimental|Vacc-092 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received placebo (control group) in HPV-039 study (NCT00779766), were intended to receive HPV vaccine in the current study and were to provide cervical samples before HPV vaccination.
89246474|NCT03617835|Experimental|R - Low dose of BI 655130 Periumbilical|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the periumbilical region following an overnight fast of at least 10 hours.
89246475|NCT03617835|Experimental|T1 - Low dose of BI 655130 Periumbilical (left and right)|Single low dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 1 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
89246476|NCT03617835|Experimental|T2 - Low dose of BI 655130 Thigh|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the thigh region following an overnight fast of at least 10 hours.
89246477|NCT03617835|Experimental|T3 - High dose of BI 655130 Periumbilical (left and right)|Single high dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 2 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
89246478|NCT03617718|Experimental|Cystic Fibrosis|All Cystic Fibrosis participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
89246479|NCT03617718|Experimental|Asthma|All Asthma participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
88804793|NCT01289431|Placebo Comparator|Mapracorat Vehicle|
88804794|NCT01289665|Experimental|Lubricating Gel|
88804795|NCT01289665|Active Comparator|Water|
88804796|NCT00005776|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO)
88804797|NCT00005776|Placebo Comparator|Oxygen|100% oxygen
89246480|NCT03617718|Experimental|Healthy Control|All Healthy Control participants will undergo screening, baseline characterization, a non-invasive challenge test with inhaled alkaline glycine buffer, followed by repeated measurements of airway function and inflammation, and a research bronchoscopy.
89246481|NCT03613116|Experimental|High Dose Vitamin D3|Receives 4000 IU daily Vitamin D3 tablets.
89246482|NCT03613116|Active Comparator|Standard Dose Vitamin D3|Receives 600 IU Vitamin D3 tablets.
89246483|NCT03608033|Experimental|OMS721|Administration of OMS721
89246484|NCT03608033|Placebo Comparator|Placebo|Administration of Vehicle (D5W or Saline Solution)
89246485|NCT03604315|Experimental|Treatment (FDG PET/CT, [18F]FTT PET/CT)|Patients receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo [18F]FTT PET/CT over 1 hour.
89246486|NCT03593018|Experimental|Oral Azacitidine|Oral azacitidine 300mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacitidine 200mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
89246487|NCT03593018|Active Comparator|Investigator's choice therapy|Romidepsin 14mg/m² on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity) or Bendamustine 120mg/m² on days 1 and 2 of a 21-days cycle (during 6 cycles) or Gemcitabine 1200mg/m² on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
89246488|NCT03591575|Experimental|Deferiprone|Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
89246489|NCT03591575|Placebo Comparator|Placebo|Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses
89246490|NCT03582722|Experimental|Orlistat Weight Loss Aid|Participants randomized to take orlistat at the over-the-counter dose for six months. Diet and exercise plus a daily multivitamin will also be recommended and monitored.
89246491|NCT03582722|Placebo Comparator|Placebo|Participants randomized to take a placebo to match orlistat at the over-the-counter dose for six months. Diet and exercise plus a daily multivitamin will also be recommended and monitored.
89246492|NCT03558191|Experimental|SHR-1210 Injection|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes, once every 2 weeks .
89246493|NCT03537690|Experimental|Treatment (FID-007)|Participants receive FID-007 IV over 60 minutes on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89246494|NCT03534245||1|Healthy children aged 2 - 9 years
88804798|NCT01290913|Experimental|omalizumab, oral desensitization|Patients receive omalizumab along with oral peanut desensitization.
89246495|NCT03526991|Experimental|Spinal Cord Stimulation (SCS) Tonic stimulation|Tonic stimulation
89246496|NCT03526991|Experimental|Spinal Cord Stimulation (SCS) Burst stimulation|Burst stimulation.
89246497|NCT03522298|Experimental|Dose Escalation and Expansion Cohorts|"This is an open-label study.~Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort.~The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where <1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD).~In stage 1, dose escalation will occur for QD dosing.~In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first.~Patients will be randomized in a 1:1 ratio to fed or fasted schedules."
89246498|NCT03519308|Experimental|Arm A|
89246499|NCT03519308|Experimental|Arm B|
89246500|NCT03512418|Experimental|PrEPsteps|Participants receive the digital pills with Truvada, plus the PrEPsteps intervention that is programmed at the randomization study visit (Study Visit 2). Participants will use PrEPsteps and the digital pill to measure Truvada adherence for months 1-3.
89246501|NCT03512418|Active Comparator|Control|Participants receive digital pills with Truvada alone. Participants will use digital pills with Truvada for months 1-3.
89246502|NCT03505762|Experimental|Arm I (tailored prednisone dose)|Participants receive rituximab IV, vincristine sulfate IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1. Participants also receive tailored prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89246503|NCT03505762|Active Comparator|Arm II (usual care prednisone dose)|Participants receive rituximab, vincristine sulfate doxorubicin hydrochloride, and cyclophosphamide as in Arm I. Participants also receive usual care prednisone dose PO QD on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89246504|NCT03504956|Other|Healthy Volunteers|"Approximately 100 healthy male/female adult normals or controls will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant."
89246505|NCT03504956|Other|Coronary Artery Disease (CAD) Patients|40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.
89246506|NCT03494777|Experimental|Adherence-based incentivization|"Participants will be eligible for prize drawings at every regular clinic visit based on high adherence as measured by MEMS-caps. In addition there will be an annual prize drawing that is conditional on showing high adherence over the course of the year.~This arm will receive the intervention 'Incentivization based on high adherence' and the intervention 'Annual adherence prize drawing' and (if eligible) the intervention 'Year 2 booster'.~Note: the 70 treatment initiating clients will all be assigned to this arm to receive preliminary data as to whether incentives may work for this group."
89246507|NCT03494777|Experimental|Viral suppression-based incentivization|"Participants will be able to participate in prize drawings at every clinic visit where eligibility will be based on timely drug refills (that coincide with the clinic visits). Participants will also have a chance to enter a prize drawing at the end of every year if they show viral suppression.~This arm will receive the intervention 'Incentivization based on timely clinic visit' and the intervention 'Annual viral suppression-based prize drawing', and (if eligible) the intervention 'Year 2 booster'."
89246508|NCT03494777|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices.
89246509|NCT03490513|Placebo Comparator|Weight loss plus placebo|Participants will take a placebo every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
89246510|NCT03490513|Experimental|Weight loss plus anastrozole|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
89246511|NCT03481738||PKD Diagnosed|Participants diagnosed with PK deficiency by the presence of 2 or more PKLR gene mutations as well as clinical features.
89246512|NCT03473496|Experimental|CART therapy in multiple myeloma|In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
89246513|NCT03463460|Experimental|Treatment (pembrolizumab, sunitinib malate)|Participants receive pembrolizumab IV over 30 minutes on day 1 and sunitinib malate PO daily on days 1-14. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
89246514|NCT03457675|Experimental|Activa PC+S DBS implant for OCD|all subjects will receive surgical implantation of DBS system
89246515|NCT03457675|Experimental|One Month Blinded Discontinuation Period|all subjects will enter a one-month blinded discontinuation period to confirm clinical benefit at the end of Month 8.
89246516|NCT03452774||Study Group|Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).
89246517|NCT03445585||Primary Sclerosing Cholangitis|Patients with a diagnosis of primary sclerosing cholangitis (PSC).
89246518|NCT03445585||Primary Biliary Cirrhosis/Cholangitis|Patients with a diagnosis of primary biliary cirrhosis (PBC).
89246519|NCT03445585||Control group 1|Patients who do not have PBC or PSC but do have another form of chronic liver disease.
89246520|NCT03445585||Control group 2|Patients without liver disease.
89246521|NCT03441061|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 8. Treatment repeats every 21-28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89246522|NCT03419052|Experimental|MINDSpeed Intervention|Consumption of foods high in polyphenols (i.e., MIND foods) AND speed of processing training
89246523|NCT03419052|Active Comparator|MIND food and training control|Consumption of foods high in polyphenols (i.e., MIND foods) AND online (inert) games
89246524|NCT03419052|Active Comparator|Control foods and speed of processing training|Consumption of low polyphenol foods AND speed of processing training
89246525|NCT03419052|Sham Comparator|Double Control|Consumption of low polyphenol foods AND online (inert) games
89246526|NCT03407859|Experimental|Sequential therapy with different CART|Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10^6/Kg transduced CAR T cells at one time.
89246527|NCT03398200|Experimental|Hyperbaric Oxygen Therapy|Subjects on the experimental arm will receive 90 minutes of hyperbaric oxygen therapy approximately six hours prior to hematopoietic stem cell infusion.
89246528|NCT03398200|Active Comparator|No Hyperbaric Oxygen Therapy|Subjects on the reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell infusion.
89246529|NCT03382977|Experimental|Part A Dose Level 1|VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
89246530|NCT03382977|Experimental|Part A Dose Level 2|VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
89246531|NCT03382977|Experimental|Part A Dose Level 3|VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
89246532|NCT03382977|Experimental|Part B GM-CSF Adjuvant|VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 to 0.4 mL volume, given in two to four equal ID injections.
89246533|NCT03382977|Experimental|Part B AS01B Adjuvant|VBI-1901 10 μg HCMV pp65 formulated with AS01B (50 μg of QS-21 and 50 μg of MPL per dose) in 1.0 mL volume, given in one IM injection
89246534|NCT03382977|Experimental|Part C VBI-1901 with GM-CSF Adjuvant|VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal ID injections.
89246535|NCT03382977|Active Comparator|Part C Standard of Care Treatment|Single-agent standard-of-care (SOC) treatment with either carmustine intravenously at a dose of 150 mg/m² or lomustine orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg).
89246536|NCT03382717|Experimental|Excilor Forte|One application of the MD daily (at same time point), preferably after showering/bathing, during the complete study period.
89246537|NCT03382717|Active Comparator|Loceryl 5%|One application per week of the positive control Loceryl 5% during the whole study period.
89246538|NCT03366779|Other|Surgery with 6mm ACD|ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
89246539|NCT03363529|Placebo Comparator|Standard|This study arm utilizes a standard lighting condition in the patient room
89246540|NCT03363529|Experimental|Dynamic|This study arm utilizes a dynamic lighting from special designed lightfixtures in the ceiling and window sill.
89246541|NCT03339843|Experimental|Abemaciclib|"This study contains 2 stages; during the 1st stage, a maximum of 17 patients will be enrolled in each tumour type cohort. After 13 evaluable patients have been enrolled, an interim analysis will be performed. If 3 or more patients are seen to have experienced a treatment success, then the cohort will pass into the 2nd stage in which a maximum of 20 more patients are enrolled. If 2 or less patients are seen to have experienced a treatment success, then that cohort will be closed and will not proceed into the 2nd stage.~Subjects will receive 200 mg of abemaciclib orally, twice a day, during cycles of 28 days each. The subject will undergo: A baseline FDG-PET/CT and a baseline CT scan and A blinded early FDG-PET/CT at D14 +/- 2 days of study treatment.~A treatment success is defined as a patient who has metabolic response according to PERCIST with a response cut off set at 15% at the early FDG-PET/CT and a morphological disease control after 2 cycles measured by RECIST v1.1."
89246542|NCT03331380|Other|Group A|Group A includes 600 healthy adult volunteers of both sexes with-out known cardiovascular disease
89246543|NCT03331380|Other|Group B|Group B includes 500 adult subjects of both sexes with known sta-ble cardiovascular disease including adults with stable coronary artery disease after myocardial infarction; adults with heart failure and reduced left ventricular systolic function; adults with pulmonary artery hypertension; adults with congenital heart disease including cardiac shunts; adults with valvular heart disease including aortic stenosis, mitral regurgitation, and tricuspid regurgitation; and adults with metallic cardiovascular implants (such as coronary and peripheral artery stents) known to be safe for CMR at 1.5T
89246544|NCT03331380|Other|Group C|Group C includes 500 adult subjects of both sexes with known non-cardiovascular disease
89246545|NCT03327623||Hypertrophic Cardiomyopathy (HCM)|Subjects with a diagnosis of Hypertrophic Cardiomyopathy
89246546|NCT03327623||Control|Subjects who are healthy volunteers
89246547|NCT03324100||Allergic Rhinitis Patients|
89246548|NCT03324100||Healthy Controls|
89246549|NCT03321656|Active Comparator|Tacrolimus|0.1 - 0.2 mg/kg/day in 2 divided doses every 12 hours orally
89246550|NCT03321656|Experimental|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
89246554|NCT03299426|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
89246555|NCT03299426|Active Comparator|Meningococcal A Conjugate Vaccine (MCV-A)|Children will receive a single dose of MCV-A administered by the intramuscular route. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
89246556|NCT03298087|Experimental|Experimental Arm|Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.
89246557|NCT03291444|Experimental|CAR-T cells combined with peptide specific dendritic cell|CAR-T cells combined with Eps8 peptide specific dendritic cell,or CAR-T cells combined with WT1 peptide specific dendritic cell
89246558|NCT03291444|Active Comparator|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
89246561|NCT03284034|Active Comparator|Cyrolipolysis|
89246562|NCT03284034|Experimental|Deoxycholic Acid|
89246563|NCT03278873|Experimental|Biological-Low dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single low dose of either AAV - CNGB3 or AAV - CNGA3
89246564|NCT03278873|Experimental|Biological-medium dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single medium dose of either AAV - CNGB3 or AAV - CNGA3
89246565|NCT03278873|Experimental|Biological-high dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single high dose of either AAV - CNGB3 or AAV - CNGA3
89246566|NCT03267030|Experimental|GRASPA|GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.
89246567|NCT03260881|Active Comparator|L-group|• L-group will be started on liraglutide. Liraglutide will be started and administered for from a minimum of 4 weeks up to 12 weeks prior to CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). The dose of 1.8 mg daily will be maintained until the end of the 12-week study. Other and current diabetes treatment will be continued
89246568|NCT03260881|Placebo Comparator|D-group|placebo will be administered in addition to current treatment prior to the CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). D-group will be started on a supervised low calorie diet (LCD) to achieve approximately 5% of weight loss after from a minimum of 4 weeks up to 12 weeks.
89246569|NCT03250247|Experimental|Endovascular Therapy - Intervention|"All subjects (EVT and No-EVT Arms) will receive optimal PTS care. At each Clinical Center, this will be supervised by a physician experienced in managing PTS.~Subjects randomized to EVT will receive the following:~imaging-guided iliac vein stent placement, and~endovenous ablation of refluxing saphenous vein(s), if the patient has truncal reflux and is still symptomatic.~optimal PTS therapy: medical and compression, lifestyle interventions and venous ulcer care"
89246570|NCT03250247|No Intervention|Non-Endovascular Therapy - Control|All subjects will receive optimal PTS care as noted above.
89246571|NCT03245437|Experimental|Oxytocin with SCST|Oxytocin with SCST (active condition)
88804799|NCT01267045|Experimental|Arm 1|Participants in this arm undergo the mindfulness training intervention through taking part in a Mindfulness-Based Stress Reduction course
88804800|NCT01267045|No Intervention|Arm 2|Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)
89246572|NCT03245437|Sham Comparator|Oxytocin with Health Management|Administration of OT with control psychosocial treatment
89246573|NCT03245437|Placebo Comparator|Placebo with SCST|Administration of Placebo with active psychosocial treatment
89246574|NCT03245437|Placebo Comparator|Placebo with HM|Administration of Placebo with control psychosocial treatment
89246575|NCT03235388|Experimental|Intervention|Audit filter implementation in hospital
89246576|NCT03235388|No Intervention|Control|Routine care
89246577|NCT03229057|Active Comparator|OCP + Placebo|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
89246578|NCT03229057|Active Comparator|Metformin + Placebo|Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. Placebo pills will be administered to individuals randomized to metformin only in order to maintain study blinding.
89246579|NCT03229057|Experimental|OCP + Metformin|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg.
89246580|NCT03224052||Patients with falciparum malaria|"Empirical antibiotic therapy with levofloxacin 750mg daily for 48 hours. This will be ceased if there is no laboratory or radiological evidence of infection at 48 hours.Therapy will be modified based on culture results or clinical judgment if cultures are not available.~If patients deteriorate in the first 48 hours on levofloxacin, antibacterial therapy comprising vancomycin (1.5g bd) and meropenem (1g tds) will be substituted for levofloxacin in addition to increasing supportive care as appropriate.~The dosing of all antibiotics will be adjusted according to creatinine clearance."
89246581|NCT03224052||Patients with vivax malaria|No empirical therapy will be commenced in these patients. If there is laboratory or radiological evidence of infection antibacterial therapy will be administered based on culture results or clinical judgment if cultures are not available.
89246582|NCT03214562|Experimental|Treatment (venetoclax, FLAG-IDA)|See detailed description.
89246583|NCT03196024|Experimental|Family-focused intervention arm|Family-focused intervention arm: Educational sessions will be provided to family pairs that include participants who are at-risk for type 2 diabetes or CVD and their co-participating family member.
89246584|NCT03196024|Active Comparator|Individual-focused intervention arm|Individual-focused intervention arm: Educational sessions will be provided to the individual members of the family pairs who are at-risk for type 2 diabetes or CVD.
89246585|NCT03192020|Experimental|Percutaneous needle fasciotomy (PNF)|PNF is a treatment in which the Dupuytren's contracture cord causing the contracture is not excised, but only divided with a hypodermic needle.
89246586|NCT03192020|Experimental|Collagenase clostridium histolyticum (CCH)|Generic name of the drug is collagenase clostridium histolyticum. Dosage form is injectable powder, dosage 0.58 mg and frequency is one injection in four weeks up to three times. One injection is performed normally at least to three different places in the cord.
89246587|NCT03192020|Active Comparator|Limited fasciectomy (LF)|In LF, the thickened part of the palmar fascia causing the contracture is excised through skin incision.
89246588|NCT03176823|Sham Comparator|Control Arm|"Control-arm patients will be treated with standard Best Practice management of traumatic brain injury, with the addition of sham-RIC. The sham intervention will use a purpose-built device which will visually and audibly mimic a functional RIC device, with the key distinction being non-inflation of the arm cuff with resultant non-occlusion and no induced ischemia. To mask patient enrollment, all patients in both study arms will have the arm and RIC device draped in an opaque sheet so that the extremity distal to the RIC device are not visible to medical staff during the period of intervention."
89246589|NCT03176823|Experimental|RIC Arm|The RIC treatment will be applied with a purpose-built commercial RIC device which will aid in standardizing dose and delivery. Therapeutic RIC will be provided by the CellAegis Technologies autoRIC device on an upper extremity. As with the control cohort, this cohort will undergo complete extremity draping.
89246590|NCT03176797|Experimental|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
89246592|NCT03168815|Experimental|High Flow Nasal Cannula (HFNC)|Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
89246593|NCT03168815|Active Comparator|Low Flow Nasal Cannula (LFNC)|Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
89246594|NCT03161522|Experimental|Group I (maintenance chemotherapy)|Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
89246595|NCT03161522|Experimental|Group II (local therapy)|Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
89246596|NCT03131219|Experimental|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing < 20 kg, for a total of 26 weeks of study treatment in the initial Evaluation Period.~After the Initial Evaluation Period, participants rolled over into an Extension Period in which all participant continued their weight-based maintenance dose until the product was registered or approved (in accordance with country specific regulation) or for up to 4.5 years, whichever occurred first."
89246597|NCT03110159|Experimental|Levulan® Kerastick® and blue light illumination|"Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds.~Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years."
89246598|NCT03101891|Experimental|Serial amnioinfusions with isotonic fluid|"There are two interventional arms to the trial. Recruitment in the bilateral renal agenesis arm of the trial was stopped in July 2022 after DSMB review.~Recruitment is ongoing in the non-bilateral renal agenesis, fetal renal failure with anhydramnios arm of the trial. Patients will undergo amnioinfusions with isotonic fluid every 2-12 days.. A spinal needle will be used to perform the infusion. The latest infusions will begin is 26 weeks gestation. Standard postnatal care will occur at a RAFT center."
89246599|NCT03101891|No Intervention|Expectant|Patients will be observed serially by ultrasound, fetal echocardiogram and MRI. Standard postnatal care will occur at a RAFT center.
89246600|NCT03079024|Experimental|Targeted Cognitive Training (TCT)|Neuroadaptive Cognitive Training
89246601|NCT03079024|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
89246602|NCT03079024|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual
89246603|NCT03072238|Active Comparator|Placebo + Abiraterone|Participants received Placebo plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.
89246604|NCT03072238|Experimental|Ipatasertib + Abiraterone|Participants received Ipatasertib plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.
89246605|NCT03065335|Experimental|Metabolites Substudy|Open-label, single dose of 0.5 mg/kg IV ketamine
89246606|NCT03065335|Experimental|Phase I|Medication taper, drug-free period, and baseline assessments
89246607|NCT03065335|Experimental|Phase II, Arm 1|Double-blind, single dose of 0.5 mg/kg IV ketamine
89246608|NCT03065335|Experimental|Phase II, Arm 1b|Double-blind, single dose of 0.5 mg/kg IV ketamine, concurrently with fMRI+EEG or MEG
89246609|NCT03065335|Placebo Comparator|Phase II, Arm 2|Double-blind, single dose of 0.5 mg/kg IV saline
89246610|NCT03065335|Placebo Comparator|Phase II, Arm 2b|Double-blind, single dose of 0.5 mg/kg IV saline, concurrently with fMRI+EEG or MEG.
89246611|NCT03065335|Experimental|Phase III|Double-blind, repeated dose of 0.5 mg/kg or 0.1 mg/kg IV ketamine
89246612|NCT03065335|No Intervention|Phase IV|Follow-up evaluations
89246613|NCT03031730|Experimental|Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)|Patients receive MDM2 Inhibitor KRT-232 PO QD on days 1-7, carfilzomib IV over 10-30 minutes on days 1-2, 8-9, and 15-16 of cycles 1-12 and on days 1-2 and 15-16 of cycles 13-18, lenalidomide PO on days 1-21, and dexamethasone PO or dexamethasone sodium phosphate IV on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity. Patients undergo echocardiography during screening and bone marrow biopsy and aspiration, and blood sample collection throughout the study.
89246614|NCT03030066|Experimental|Experimental Drug DS-1001b|Oral administration
89246615|NCT03029442|Experimental|Denosumab, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
89246616|NCT03029442|Placebo Comparator|Placebo, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
89246617|NCT03029442|Experimental|Denosumab, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
89246618|NCT03029442|Placebo Comparator|Placebo, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
89246619|NCT03024489|Experimental|Palbociclib-Cetuximab-IMRT|"IMRT will be administered 5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.~Cetuximab will be administered 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.~Palbociclib will be administered orally daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49) on 3 dose levels and the MTD."
89246620|NCT03015402|Experimental|Sodium Nitrite|
89246621|NCT03015402|Placebo Comparator|Placebo|
89246622|NCT03012529|Active Comparator|Active drug|Patients receive oral adjunctive rifampin therapy
89246623|NCT03012529|Placebo Comparator|Placebo|Patients receive oral riboflavin
89246624|NCT03000244||1/Patients|Patients who underwent hematopoietic stem cell transplant for any indication (malignant or non-malignant).
89246625|NCT03000244||2/Donors|Related stem cell donors of those in Patients cohort.
89246626|NCT03000244||3/Parents of patients|Parents/guardians of minors enrolled in cohort 1
89246627|NCT02997202|Experimental|Gilteritinib|Participants will take gilteritinib once daily for continuous daily dosing.
89246628|NCT02997202|Placebo Comparator|Placebo|Participants will take placebo once daily for continuous daily dosing.
89246629|NCT02989922|Experimental|SHR-1210 Q2W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
89246630|NCT02989922|Experimental|SHR-1210 Q3W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks
89246631|NCT02981446|Experimental|DE-117 ophthalmic solution|
89246632|NCT02981446|Active Comparator|Latanoprost ophthalmic solution 0.005%|
89246635|NCT02976545|Other|PNES|Psychogenic Non-epileptic Seizures subjects
89246636|NCT02976545|Other|PTSD|Post Traumatic Stress Disorder
89246637|NCT02976545|Other|Healthy controls|Healthy controls
89246638|NCT02948829|Experimental|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).
89246639|NCT02936102|Experimental|FAZ053 single agent|
89246640|NCT02936102|Experimental|FAZ053 + PDR001|
89246641|NCT02928497|Experimental|WATCHMAN (Device)|WATCHMAN LAAC Device implant including modified post-implant drug regimen.
89246642|NCT02928497|Active Comparator|Control|Single antiplatelet therapy or no therapy (Control) at the discretion of the study physician for the duration of the trial.
89246643|NCT02927262|Experimental|Gilteritinib|Participants received gilteritinib 120 mg (three tablets of 40 mg) orally, once daily (QD) for up to 2 years or until a protocol-specified discontinuation criterion was met.
89246644|NCT02927262|Placebo Comparator|Placebo|Participants received gilteritinib matching placebo orally, QD for up to 2 years or until a protocol-specified discontinuation criterion was met.
89246645|NCT02917759||Hepatocellular cancer|Surgical waste tissue will be collected after removal of a liver tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
89246646|NCT02917759||Cholangiocarcinoma|Surgical waste tissue will be collected after removal of a biliary tumor. A blood sample may be collected at the time of labs related to treatment for the diagnosis. An extra sample of biopsy tissue will be collected from participants having a targeted mass biopsy.
89246647|NCT02914314|Experimental|Perampanel up to 12 or 16 mg/day|Pediatric participants, ranging from 1 month to less than 4 years of age, will receive perampanel oral suspension once a day in titration period starting at Week 0 at a dose of 0.50 mg per day (mg/day) titrated up to 4 mg/day (for participants taking non-EIAED) or up to 8 mg/day (for participants taking EIAED). Depending on participants clinical response, tolerability and investigator's decision, dose can be up titrated to 6 mg/day (for participants taking non-EIAED) and up titrated to 8 mg/day (for participants taking EIAED). Dose titration must not exceed 12 mg/day (non-EIAED) and 16 mg/day (EIAED). Participants will continue taking the perampanel oral suspension at dose level achieved at end of titration period through maintenance period of core study and maintenance period of extension phase (Up to Week 52).
89246648|NCT02896582|Experimental|Induction - ASCT - maintenance|Induction : 4 cycles of GA-DHAP every 21 days - Conditioning regimen and ASCT: GA-BEAM + Autologous transplantation - Maintenance : Obinutuzumab every 2 months for 3 years then every month for patients with positive MRD
89246649|NCT02893397|Experimental|Group I (supervised exercise)|Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.
89246650|NCT02893397|Experimental|Group II (fitbit)|Patients wear a fitbit.
89246651|NCT02882620|Experimental|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
89246652|NCT02882620|Experimental|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
89246653|NCT02882620|Experimental|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
89246654|NCT02858323||1|Previously selected HLA-alloimmunized platelet refractory, clinical, patients.
89246658|NCT02846038||Patient|Patients at St. Jude Children's Research Hospital who meet the eligibility criteria and consent to participate.
89246659|NCT02846038||Primary oncologist|Primary pediatric oncologists who meet the eligibility criteria and consent to participate.
89246660|NCT02846038||Parents of patient|Parents of the enrolled patient who meet eligibility criteria and consent to participate.
89246661|NCT02842749|Experimental|everolimus (single arm)|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
89246662|NCT02837237|Experimental|KBP-5074|Single oral dose
89246663|NCT02823002|Experimental|Slow, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
89246664|NCT02823002|Experimental|Rapid, Room Temperature|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
89246665|NCT02823002|Experimental|Slow, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
89246666|NCT02823002|Experimental|Rapid, Warmed|In Part A, subject will be randomized to receive an injection of lidocaine that is slow at room temperature, rapid at room temperature, slow at warm temperature, or rapid at warm temperature.
89246667|NCT02823002|Experimental|Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
89246668|NCT02823002|Placebo Comparator|Non-Buffered|In Part B, subject will be randomized to receive an injection of lidocaine that is buffered or non-buffered.
89246669|NCT02813590||Patients with liver cirrhosis and with SBP|
89246670|NCT02813590||Patients with liver cirrhosis and without SBP|
89246671|NCT02810548|Placebo Comparator|OFD alone|Control group: including 15 defects that will receive open flap debridement (OFD).
89246672|NCT02810548|Active Comparator|PRF + OFD|Test group (1): including 15 defects that will receive platelet rich fibrin (PRF) with open flap debridement (OFD).
89246673|NCT02810548|Active Comparator|Bone + OFD|Test group (2): including 15 defects that will receive nanohydroxyapatite bone graft with open flap debridement OFD).
89246674|NCT02810548|Active Comparator|PRF + Bone + OFD|Test group (3): including 15 defects that will receive nanohydroxyapatite bone graft with platelet rich fibrin (PRF) after open flap debridement (OFD).
89246675|NCT02810405||1/Patient Samples|Patients treated at NCI with available tissue samples.
89246676|NCT02791334|Experimental|LY3300054|LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle.
89246677|NCT02791334|Experimental|LY3300054 + Ramucirumab|LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle.
89246678|NCT02791334|Experimental|Abemaciclib + LY3300054|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
89246679|NCT02791334|Experimental|LY3300054 + Abemaciclib (Concurrent Dosing)|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
89246680|NCT02791334|Experimental|LY3300054 + Abemaciclib|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
89246681|NCT02791334|Experimental|LY3300054 + Merestinib|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
89246682|NCT02791334|Experimental|LY3300054 Expansion (Metastatic Cutaneous Melanoma)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
89246683|NCT02791334|Experimental|LY3300054 Expansion (MSI-H Solid Tumors)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
89246684|NCT02791334|Experimental|: LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
89246685|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H)|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
89246686|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
89246687|NCT02791334|Experimental|LY3300054 + Merestinib (Pancreatic Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
89246688|NCT02772588|Experimental|patients with prostate cancer|Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.
89246689|NCT02766088|Experimental|Total Group|Subjects aged between 6 months and 50 years at the time of enrolment living in geographically-defined communities in Latin America and Southeast Asia. The study population comprised household members and should include between 30% and 50% of adults (aged 18 years or above) per site.The appropriate recruitment strategy was selected by each participating site. Two approaches might be considered: a school-based approach and a community-based approach without school involvement The expected period for recruiting the target sample size was approximately three months.
89246690|NCT02719899||1|Healthy Volunteers
89246691|NCT02706171|Experimental|A: pre-operative|"Radiation- CyberKnife:~35-40 Gy over 5 fractions~Surgery:~Surgical resection of sarcoma"
89246692|NCT02706171|Experimental|B: Post-operative|"Radiation- CyberKnife:~40 Gy over 5 fractions"
89246693|NCT02706171|Experimental|C: Non-resectable|"Radiation- CyberKnife:~50 Gy over 5 fractions"
89246694|NCT02621021|Experimental|1/ACT TIL|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2)
89246695|NCT02621021|Experimental|2/ACT TIL + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young TIL + highdose aldesleukin (IL-2) + pembrolizumab
89246696|NCT02617966||Affected|Participants with retinal disease
89246697|NCT02617966||Unaffected|Healthy volunteers
89246704|NCT02567422|Experimental|Treatment (berzosertib, cisplatin, radiation therapy)|Patients receive berzosertib IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity.
89246705|NCT02537899|Other|Treatment|NeuroAiD
89246706|NCT02525679|Experimental|BI 655130 (spesolimab)|
89246707|NCT02525679|Placebo Comparator|Placebo|
89246708|NCT02506933|Experimental|Arm I (multi-peptide CMV-MVA vaccine)|Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
89246709|NCT02506933|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM on days 28 and 56 post-HCT.
89246710|NCT02503475|Other|Project 1- Real-Time fMRI|"This arm investigates Real-Time fMRI within 4 groups:~Attention Regulation (AR) Group- Experimental Cognitive Regulation (CR) Group- Experimental Sham Group- Sham Comparator Free Strategy Group- Active Comparator"
89246711|NCT02503475|Experimental|Project 2 - CBT/MBSR|"This arm investigates 2 experimental groups:~Cognitive Behavioral Therapy (CBT) Mindfulness Based Stress Reduction (MBSR)"
89246712|NCT02503475|Other|Project 3- Acupuncture|"This arm investigates Acupuncture within 2 groups:~Verum- Experimental Sham- Sham comparator"
89246713|NCT02476916|Experimental|AG-348 50 mg BID|Participants with PK deficiency received AG-348, 50 milligrams (mg), as initial dose, twice daily (BID) for the Core Period (Week 24).
89246714|NCT02476916|Experimental|AG-348 300 mg BID|Participants with PK deficiency received AG-348, 300 mg, as initial dose, BID for the Core Period (Week 24).
89246715|NCT02469714|Experimental|Peer Navigator Intervention|Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
89246716|NCT02469714|No Intervention|Controlled|Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months
89246717|NCT02456233|Active Comparator|Conventional AF Ablation with PVI|These patients will be treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
89246718|NCT02456233|Experimental|FIRM-guided ablation plus PVI|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM). Conventional ablation (PVI) will then be performed as part of the standard of care procedure.
89246719|NCT02427724|Active Comparator|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
89246720|NCT02427724|Active Comparator|lidocaine 7%/tetracaine 7% topical anesthetic|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
89246721|NCT02427724|Placebo Comparator|placebo vehicle|Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
89246722|NCT02378233|Experimental|iodine|"iodine containing multivitamin~150 ug, 1 tablet daily"
89246723|NCT02378233|Placebo Comparator|placebo|placebo, 1 tablet Daily of a non-iodine containing multivitamin
89246724|NCT02345122|Other|Enhanced Usual Care|This group will receive Enhanced Usual Care. The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life . If the subjects primary care provider chooses, they can use this information to construct the subject's treatment plan.
89246725|NCT02345122|Experimental|Intervention: Mental Health Technician|The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life and recommendations for treatment. Over a 3-12 months period, the Intervention group will receive a brief, telephone-based intervention by a Mental Health Technician that will focus on monitoring symptoms, treatment adherence, and providing psychoeducation.
89246726|NCT02322177||1|Participants are women with inborn errors of metabolism who have been pregnant
89246729|NCT02312102|Experimental|Velcade and Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each treatment cycle lasts 28 days (4 weeks). The first two cycles are called the induction cycles. If the participant respond to treatment during the first two cycles, they can continue on to the maintenance cycles.~During the induction and maintenance cycles, patients receive up to the MTD of lenalidomide on days 1-21 days only. During days 22-28 (4th week) there is a rest period.~Bortezomib: During the induction cycles, the medication will be given on days 2, 5, 9, and 12 followed by a 17-day rest period. During the maintenance cycles, bortezomib will be given on days 2, and 5 followed by 23-day rest period."
89246730|NCT02273297||Pregnant women and their offspring|Ethnically diverse pregnant women and their offspring
89246731|NCT02266615||Genetic research in 5 areas.|Cardiogenetics; Intellectual Disability, Multiple Congenital Abnormalities and Rare Diseases; Oncogenetics; Dermatogenetics; Reproductive Genetics.
89246733|NCT02165137||trauma patients|type and severity of patients, circumstances and trauma pre- and post-injury / -quality initiative
89246734|NCT02156115||healthy volunteers|healthy volunteers
89246735|NCT02156115||lymphatic patients|lymphatic patients
89246736|NCT02156115||relatives|relatives
89246737|NCT02156102||Microbiome with active Leg Ulcer|We will recruit and obtain microbiome samples from male or female adult participants with active leg ulcers and sickle cell disease.
89246738|NCT02156102||Microbiome with no active Leg Ulcer|We will recruit and obtain microbiome samples from male or female adult participants without active leg ulcers but do have sickle cell disease.
89246739|NCT02156102||Non-microbiome participants|We will recruit but not obtain microbiome samples from participants with sickle cell disease
89246740|NCT02154035||Group 1|HIV-infected patients on ART with suppressed viral loads, defined as <40 copies per ml over a period of 10-18 months.
89246741|NCT02154035||Group 2|HIV-infected patients on ART with suppressed viral loads, defined as <40 copies per ml over a period of 10-18 months.
89246742|NCT02134054||Biologic|Patients on treatment with biologics (infliximab or adalimumab)
89246743|NCT02108080||Inpatient AUD|This group includes individuals who are in the alcohol use treatment.
89246744|NCT02108080||Outpatient|This group includes individuals who are not seeking treatment for alcohol use disorder.
89246745|NCT02077894||Affected participants|Participants with an eye disease.
89246746|NCT02077894||Unaffected family members|Unaffected family members.
89246747|NCT02068586|Experimental|Sunitinib- (Cohort 1, Arm I)|"Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity~Quality-of-Life Assessment-Ancillary studies~- Laboratory Biomarker Analysis-Correlative studies"
89246748|NCT02068586|Experimental|Valproic acid- (Cohort 1, Arm II)|"Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity~Quality-of-Life Assessment-Ancillary studies~Laboratory Biomarker Analysis-Correlative studies"
89246749|NCT02068586|Experimental|Sunitinib Malate (Cohort 2)|"Patients receive sunitinib malate PO daily for 12 months in the absence of disease progression or unacceptable toxicity~Quality-of-Life Assessment-Ancillary studies~Laboratory Biomarker Analysis-Correlative studies"
89246750|NCT02068586|Active Comparator|Sunitinib Malate + Valproic Acid (Cohort 3)|"Patients receive sunitinib malate PO daily and valproic acid PO daily for 12 months in the absence of disease progression or unacceptable toxicity.~Quality-of-Life Assessment-Ancillary studies~Laboratory Biomarker Analysis-Correlative studies"
89246751|NCT02055183||Participants treated with BAT®|Any patient of any age with a confirmed or suspected exposure to botulinum toxin who were treated with BAT®.
89246752|NCT02023502||stress urinary incontinence|Patients presenting with stress urinary incontinence according to the inclusion and exclusion criteria
89246753|NCT02023502||healthy controls|healthy women with the same inclusion and exclusion criteria as the case group, except for stress urinary incontinence
89246754|NCT02014246||1|Participants with confirmed or suspected movement disorder or dementia diagnosis and their affected and unaffected family members will be potential candidates for the study, well as unrelated, healthy individuals (known as control samples.
89246755|NCT02014246||2|We plan to enroll 12,000 study subjects (10,000 patients, 1,000 asymptomatic family members, 1,000 neurological normal controls) for this study
89246756|NCT02009761|Experimental|BI 655064 120 mg / 180 mg|"The patients were administered 120 mg BI 655064 solution for subcutaneous injection q1w (once a week) subcutaneously for 4 weeks.~Patients who showed an increase in platelet count above or equal to 100 x 10^9/L continued treatment with 120 mg BI 655064 solution for subcutaneous injection q1w for additional 8 weeks, followed by 12 weeks of follow-up.~Patients whose platelet count stayed below 100 x 10^9/L continued treatment for 2 weeks with 180 mg BI 655064 solution for subcutaneous injection q1w followed by 120 mg BI 655064 solution for subcutaneous injection q1w for additional 6 weeks, followed by 12 weeks of follow-up."
89246757|NCT02008786|Experimental|Rosuvastatin, placebo|rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
89246758|NCT02008786|Experimental|Ramipril, placebo|ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo
89246759|NCT01976286|Active Comparator|Salicylic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
89246760|NCT01976286|Active Comparator|Glycolic Acid Peels|Salicylic Acid and Glycolic Acid Chemical Peels are skin treatments used to correct uneven texture and color by removing dead cells from the skin's top layer.
89246761|NCT01969786|Experimental|Corneal ulcer prevention program|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to the corneal ulcer prevention arm will be trained to diagnose and treat corneal abrasions with antifungal (itraconazole) and antibiotic (chloramphenicol) ointments. FCHVs will promote their new services to their communities and encourage villagers who experience ocular trauma to present to them within 24 hours.
89246762|NCT01969786|No Intervention|Control|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to control (no intervention) will not receive additional training and will not undertake a promotional campaign in their communities.
89246763|NCT01952171||Congenital Heart Disease|Congenital Heart Disease
89246764|NCT01915212|Experimental|HSV529|1 x 107 pfu/dose of HSV529 in 10 mM L-histidine buffer containing 50 mM potassium glutamate, 160 mM sodium chloride, and 10% (w/v) sucrose
89246765|NCT01915212|Placebo Comparator|Placebo|Sodium Chloride 0.9%
89246767|NCT01900132|Experimental|1/All Subjects|Healthy Volunteers and patients
89246768|NCT01886066|Experimental|Indocyanine Green|All patients on study will have ICG injection for SLN mapping
89246769|NCT01885689|Experimental|Treatment (clofarabine, melphalan, transplant)|"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure."
89246770|NCT01790152||Ancillary-Correlative (laboratory biomarker analysis)|Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram, collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of life, family history, physical activity, and smoking questionnaires.
89246771|NCT01778543||Coloboma|Participants with Coloboma and their family members.
89246772|NCT01730833|Experimental|Treatment (pertuzumab, trastuzumab, nab-paclitaxel)|Patients receive pertuzumab IV over 30-60 minutes on day 1, trastuzumab IV over 30-90 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89246773|NCT01722344|Experimental|Individual Placement and Support (IPS)|
89246774|NCT01722344|Experimental|IPS plus|Individual Placement and Support plus cognitive remediation and work-related social skills training
89246775|NCT01722344|No Intervention|Standard intervention|
89246776|NCT01703507|Experimental|Arm A (Ipilimumab and Whole Brain Radiation Therapy)|Patients receive ipilimumab IV over 90 minutes once in weeks 1, 4, 7, and 10. Patients also undergo WBRT 5 days a week in weeks 1-2.
89246777|NCT01703507|Experimental|Arm B (Ipilimumab and Stereotactic Radiosurgery)|Patients receive ipilimumab IV over 90 minutes as in Arm A. Patients also undergo SRS on day 1 in week 1.
89246778|NCT01653678|Active Comparator|Vitamin D + fish oil|
89246779|NCT01653678|Active Comparator|Vitamin D + fish oil placebo|
89246780|NCT01653678|Active Comparator|Vitamin D placebo + fish oil|
89246781|NCT01653678|Placebo Comparator|Vitamin D placebo + fish oil placebo|
89246782|NCT01653392||Anthrax Vaccine Adsorbed|Active duty women who received one or more doses of BioThrax while pregnant, with the onset of pregnancy defined as the first day of the last menstrual period, and all live born infants born to women who join the registry.
89246783|NCT01650701|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
89246784|NCT01650701|Active Comparator|Control|• ONE of the following: Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
89246788|NCT01568697||Healthy Volunteers|Healthy volunteers (with/without periodontal disease)
89246789|NCT01568697||Immune deficient patients|Subjects with known genetic immune deficiency
89246790|NCT01568697||Subjects with severe periodontitis of suspected genetic etiology and their family|Subjects with severe periodontitis of suspected genetic etiology and their family members
89246796|NCT01558804||Rapid Strep Positive|Children will be eligible for this study if they are ages 5 to 15 years and have been diagnosed to have acute pharyngitis caused by GAS with a positive Rapid Antigen Detection Test (RADT).
89246797|NCT01555892|Experimental|EBV-specific T cells: A|"Group A: Patients in second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiple relapsed patients in remission who are at a high risk of relapse)** or any patient with primary disease or in first or subsequent remission if immunosuppressive chemotherapy is contraindicated.~Patients will be treated at Dose Level 3. Each patient will receive 2 injections, 14 days apart, according to the following dosing schedule:~Day 0: 1 x 10^8 cells/m2~Day 14: 2 x 10^8 cells/m2~** Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant."
89246798|NCT01555892|Experimental|EBV-specific T cells: B|"Group B: Patients in remission or with minimal residual disease (MRD) status after autologous or syngeneic SCT.~Patients will be treated at Dose Level 3. Each patient will receive 2 injections, 14 days apart, according to the following dosing schedule:~Day 0: 1 x 10^8 cells/m2~Day 14: 2 x 10^8 cells/m2"
89246801|NCT01498276||General population|Members of the general population
89246802|NCT01498276||Members of under-resourced communities|Participants recruited from under-resourced communities in the Washington, DC area AND in the Southeastern US
89246803|NCT01453127|Experimental|Alzheimer's Disease|Alzheimer's Disease
89246804|NCT01453127|Experimental|Dementia with Lewy Bodies|Dementia with Lewy Bodies
89246805|NCT01453127|Experimental|Frontotemporal Dementia|Frontotemporal Dementia
89246806|NCT01453127|Experimental|Parkinson's Disease|Parkinson's Disease
89246807|NCT01453127|Experimental|Corticobasal Degeneration|Corticobasal Degeneration
89246808|NCT01453127|Experimental|Essential Tremor|Essential Tremor
89246809|NCT01453127|Experimental|Mild Cognitive Impairment|Mild Cognitive Impairment
89246810|NCT01453127|Experimental|REM sleep behavior disorder|REM sleep behavior disorder
89246811|NCT01450306|Experimental|D-cycloserine plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus 50 mg oral d-cycloserine administered 1 hr prior to exposure therapy session
89246812|NCT01450306|Placebo Comparator|Placebo plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus oral placebo capsule administered 1 hr prior to exposure therapy session
89246813|NCT01436227|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 4 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may continue pazopanib hydrochloride in the absence of disease progression.
89246814|NCT01434368||children age 8-17 years admitted to pilot brain imaging studies|children age 8-17 years admitted to pilot brain imaging studies
89246815|NCT01434368||healthy adults|healthy adults ages 25 - 35 years at the time of enrollment
89246816|NCT01434368||typically developing children (with evidence of advanced bone age|typically developing children (with evidence of advanced bone age relative to chronologic age); age 8 or ages 12-13
89246817|NCT01434368||typically developing children ages 12/13 17 years|typically developing children ages 12 or 13 - 17 years
89246818|NCT01434368||typically developing children ages 8 17 years|typically developing children ages 8 - 17 years
89246822|NCT01417533||GNE|Patients with a diagnosis of GNE myopathy
89246823|NCT01417533||GNE-Related Diseases|Patient with a GNE related disease
89246824|NCT01417533||non-GNE|Subjects that are a carrier family member or a caregiver of a patient on the study are eligibleto participate.
89246825|NCT01351103|Experimental|LGK974|LGK974
89246826|NCT01351103|Experimental|LGK974 in combination with PDR001|LGK in combination with PDR001
89246827|NCT01329614|Experimental|Nicotine Replacement Therapy, 7mg dose|
89246828|NCT01329614|Experimental|Nicotine Replacement Therapy, 21mg dose|
89246829|NCT01329614|Placebo Comparator|Nicotine Replacement Therapy, Placebo|
89246830|NCT01329614|Experimental|Nicotine Replacement Therapy, 42mg dose|
89246831|NCT01323322||HANDLS|A fixed cohort as an area probability sample of Baltimore City from August 2004 through November 2009.
89246833|NCT01285479||fingolimod|prescribed fingolimod 0.5 mg/day, including generic versions of fingolimod
89246834|NCT01266577|Other|One Arm|Subjects receive the same scan
89246835|NCT01212003||Active TB|subjects with active TB as determined by smear, culture, or biopsy or have appropriately documented clinically suspicious active TB without definitive microbiology confirmation
89246836|NCT01212003||Latent TB|subjects with documented evidence of a positive PPD skin test or Interferon Gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)/CDC guidelines for latent TB
89246837|NCT01202695|Experimental|AVP-21D9|
89246838|NCT01202695|Placebo Comparator|Placebo|
89246839|NCT01200953||Confirmed or suspected exposure|Confirmed or suspected exposure to biodefense select agent, to agent of bioterrorism concern, to naturally-occurring pathogen in the environment, to EID agent, or to an individual
89246840|NCT01200953||Confirmed or suspected infection|Confirmed or suspected infection by biodefense select agent, by agent of bioterrorism concern, by naturally-occurring pathogen in the environment, or by emerging infectious disease agent
89246841|NCT01200953||Healthcare worker or healthy volunteer|Healthcare worker or healthy volunteer involved in simulation drills or exercises evaluating the Clinical Center admission, care, and infection control processes
89246842|NCT01200953||Healthcare worker surveillance|Healthcare worker surveillance of medical staff involved in the medical care of patients in the above 2 categories
89246846|NCT01135394|Experimental|Pioglitazone (Actos)|Participants will have metabolism studies to consist of outpatient X-ray and MR measurements of bone density and body composition, metabolic testing (intravenous glucose tolerance test), and muscle and adipose tissue biopsies. Blood will also be drawn for genetic testing and for microarray studies of leukocytes. Upon completion of the above studies, the participant will begin pioglitazone therapy. Every 4 weeks throughout the drug intervention, glycemic control, lipoprotein profile, and weight will be monitored. After 12 weeks of pioglitazone therapy, the X-ray and MR measurements of body composition, the biopsies, microarray studies for leukocytes and the metabolic tests will be repeated.
89246847|NCT00967785|Active Comparator|Treatment Arm|neutropenia and infections
89246849|NCT00895271||Healthy Volunteers|Up to 50 subjects as healthy controls
89246850|NCT00895271||Immunodeficiency|Up to 150 subjects with poorly defined, rare inherited immunodeficiency or immunodysregulation disorders
89246851|NCT00814827||Group 1|Patients with nontuberculous mycobacteria (NTM) alone.
89246852|NCT00814827||Group 2|Patients with non-NTM opportunistic infection, either with or without concurrent NTM infection.
89246853|NCT00814827||Group 3|Patients with pulmonary mycobacterium tuberculosis (MTB).
89246854|NCT00814827||Group 4|Patients with disseminated mycobacterium tuberculosis (MTB).
89246855|NCT00814827||Group 5|Blood Specimen Donors.
89246856|NCT00799877||1|This registry will evaluate the long-term safety and effectiveness of HUMIRA® as used in routine clinical practice.
89246857|NCT00774254|Experimental|A|
89246858|NCT00708045|Experimental|All patients|All participants enrolled.
89246859|NCT00646022||Arm 1|Participants who undergo extended evaluation for disease at NIH
89246860|NCT00646022||Arm 2|Participants who do not undergo extended screening or evaluation for disease at NIH
89246861|NCT00594672||AREDS participants|Participants who were enrolled in the AREDS or AREDS2 protocol and successfully completed the final AREDS or AREDS2 follow-up visit.
89246862|NCT00568243||Normal Volunteer|Healthy subjects without neurodegenerative diseases
89246863|NCT00568243||Patients|Subjects with neurodegenerative diseases
89246864|NCT00537004||PPA (Primary Progressive Aphasia)|Individuals with primary progressive aphasia
89246865|NCT00537004||Control|Individuals with no diagnosis of any type of dementia
89246866|NCT00450788||Golestan Cohort|Cohort of adults from Golestan region in Iran
89246867|NCT00448253|Experimental|1|Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA. And a Fourth Cohort at 840 units TNA with 2 additional product lots.
89246868|NCT00448253|Placebo Comparator|2|Saline (equal volume to 210 U, 420 U, or 840 U TNA dose)
89246869|NCT00397111||Healthy Volunteer|Healthy Volunteer/control group
89246870|NCT00397111||Major Depressive Disorder|Individuals with Major Depressive Disorder
89246871|NCT00361829||Ecologic/Community|Married women, infants, caregivers, Japanese-American, Argentine-American
89246875|NCT00339924||Physicians|Currently practicing, board certified general internists, both allopathic and osteopathic, whose offices are in the United States.
89246876|NCT00295646|Active Comparator|AZ (Arimidex+Zoledronate)|Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)
89246877|NCT00295646|Active Comparator|TZ (Tamoxifen+Zoledronate)|Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)
89246878|NCT00295646|Active Comparator|AC (Arimidex Control)|Study Drug Arimidex (Anastrozole)
89246879|NCT00295646|Active Comparator|TC (Tamoxifen Control)|Study Drug Nolvadex (Tamoxifen)
89246880|NCT00236925|Active Comparator|Low dose Hydrocortisone|Low Dose Hydrocortisone
89246881|NCT00236925|Placebo Comparator|Placebo|Placebo
89246882|NCT00135200|Experimental|Bexxar therapeutic|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from the subject's body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated based on the scans performed following the dosimetric dose."
89246883|NCT00106925||1|allogeneic stem cell transplant recipients
89246884|NCT00106925||2|Donors
89246885|NCT00102544|Experimental|All cohorts (prostate biopsy percutaneous biopsy and ablation)|This study will consist of comparison of tracked imaging with near-simultaneous actual imaging .
89246889|NCT00071526||Diabetes Type I|Subjects with Type I diabetes mellitus
89246890|NCT00071526||Diabetes Type II|Subjects with Type II diabetes mellitus
89246891|NCT00071526||Healthy Volunteers|Healthy Volunteers
89246892|NCT00060541||Patients|Patients age 4 or older seeking care from, or being referred to the Surgical Neurology Branch for evaluation and management of neurosurgical conditions
89246894|NCT00046202||normal subjects|subjects in whom no disorder of cholesterol is suspected related to affected individuals
89246895|NCT00046202||subjects suspected of cholesterol disorder|subjects in whom a disorder of cholesterol metabolism is suspected
89246896|NCT00039676||Standard|People that have blood or lymph node cancer, or a family history of leukemia or lymphoma.
89246897|NCT00024804||1|Subjects with known or suspected bone disease and disorder of mineral metabolism.
89246898|NCT00024635||Adult Healthy Volunteers|Adult Healthy Volunteers
89246899|NCT00024635||Adult Patients|Adult patients with mood and anxiety disorders
89246900|NCT00024635||Minor Healthy Volunteers|Minor Healthy Volunteers
89246901|NCT00024635||Minor Patients|Minor patients with mood and anxiety disorders
89246902|NCT00024635||Parents of Minor Healthy Volunteers|Parents and guardians of minor healthy volunteers
89246903|NCT00024635||Parents of Minor Patients|Parents and guardians of minor patients with mood and anxiety disorders
89246904|NCT00024622||Healthy volunteers|Healthy volunteers.
89246905|NCT00024622||Patients - Parkinsons|Patients with Parkinsons
89246906|NCT00024622||Patients - schizophrenia spectrum disorders|Patients - schizophrenia spectrum disorders
89246907|NCT00023036||1|Patients with known or suspected nonsyndromic SNHL associated with EVA
89246908|NCT00023036||2|Patients with nonsyndromic EVA
89246909|NCT00023036||3|unaffected siblings and parents of affected family members
89246910|NCT00023036||4|Other unaffected relatives; included if there is more than one sibship with affected family
89246911|NCT00009243||Patients|Patients with acute stroke symptoms
89246913|NCT00001778||healthy volunteers|At least 18 years old and have no history of any medical illness that may confound study results or make participation in this protocol impossible
89246914|NCT00001778||individuals seropositive for HTLV|Positive HTLV-1 ELISA followed by a positive Western Blot
89246915|NCT00001778||individuals with indeterminate HTLV sero-status|Positive HTLV ELISA but a Western Blot that only partially fulfills criteria
89246916|NCT00001539||healthy volunteers|healthy individuals who have never had Lyme disease
89246917|NCT00001539||Lyme arthritis|patients with suspected Lyme arthritis
89246918|NCT00001539||multiple sclerosis controls|patients diagnosed with multiple sclerosis who have never been diagnosed with Lyme disease
89246919|NCT00001539||OspA vaccine|patients who received two doses of the OspA vaccine
89246920|NCT00001539||PTLDS|presumed PTLDS
89246921|NCT00001539||PTLDS for screening|patients suspected of PTLDS for screening
89246922|NCT00001539||recovered controls|patients who were diagnosed with Lyme disease, treated, and fully recovered
89246923|NCT00001539||seropositive controls|patients who are seropositive for Lyme disease, but have no manifestations/symptoms and have never been treated for Lyme disease
89246925|NCT00001355||Healthy Volunteer|Healthy Volunteer to serve as controls
89246926|NCT00001355||Patient|Patients known to have or suspected of having an immune defect significantly or primarily involving the phagocytes
89246927|NCT00001355||Patient Relatives|blood relatives of patients
89246928|NCT00001351||Immediate family members of patients|immediate family members of patients with inflammatory conditions may be evaluated under this protocol
89246929|NCT00001351||Patients|Inflammatory conditions associated with, but not limited, to acute and chronic infections or presumed infections, and congenital or acquired immunologic disorders
89246930|NCT00001316||Individuals with HIV|Individuals with HIV
89246931|NCT00001316||Individuals without HIV|Individuals without HIV
89246936|NCT00001276||Patients with hypoglycemia|Patients with hypoglycemia due to diverse etiologies.
89246937|NCT00001246||1|Our studies include data from typically developing youth, and individuals with a range of psychiatric presentations from behaviorally-defined (e.g. Childhood-Onset Schizophrenia, Autism Spectrum Disorder) as well as genetically-defined (e.g. Sex Chromosome Aneuploidy) groups. Participants span a wide age range (from 3 years of age upwards).
89246938|NCT00001205||1|Male and female subjects aged 3-75 years with likely or definite neurocysticercosis (NCC) diagnosis
89246940|NCT01017354|Experimental|High-dose vitamin D3|monthly high-dose vitamin D3 supplement dose (60'000 IU/month, equivalent to 2000 IU daily)
89246941|NCT01017354|Experimental|standard vitamin D + 25(OH)D|standard vitamin D3 supplement dose combined with 25(OH)D (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg per day)
89246942|NCT01017354|Active Comparator|standard vitamin D|standard vitamin D3 supplement dose (24'000 IU/month, equivalent to 800 IU daily)
89246943|NCT00393861|Experimental|oxaliplatin & bevacizumab|
89246944|NCT01020240|No Intervention|Avaliation|This group will have 15 women in puerperium and will be realize an interview to avalide the cesarean discomforts in immediate puerperium. These dates will be use for elaborate the orientations guide.
89246945|NCT01020240|No Intervention|Orientation|In this group will be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory and in the second post operatory wil be realize a new interview.
89246946|NCT01020240|Experimental|Guide|in This group wiil be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory, will be realize the orientations and the guide will be give, and in the second post operatory will be realize a new interview.
89246947|NCT03993639|Experimental|KRN125|Single SC administration
89246948|NCT01040481||Malabsorptive distal gastric bypass|
89246949|NCT01040559|Experimental|Idarubicin|Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg
89246950|NCT03996954|Active Comparator|Normal ECGs|Patients with normal ECGs
89246951|NCT03996954|Active Comparator|Abnormal ECGs|Patients with different kinds of abnormal heart rhythms will be enrolled in order to compare whether Alivecor can accurately differentiate between these abnormal heart rhythms and normal sinus rhythm/sinus tachycardia. Also, Alivecor diagnostic accuracy in differentiating between different kinds of arrhythmias will be assessed.
89246952|NCT01020396|Experimental|1|Metronidazole Vaginal Gel, 0.75% (Teva Pharmaceuticals, USA)
89246953|NCT01020396|Active Comparator|2|MetroGel-Vaginal® metronidazole vaginal gel, 0.75% (3M Pharmaceuticals)
89246954|NCT01014702|Experimental|Laser Treatment|
89246955|NCT01014702|Active Comparator|Phacoemulsifcation|
89246956|NCT00480324|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
89246957|NCT00480324|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
89246958|NCT00488592|Experimental|PR1/WT1 Vaccine Response in Participants With Low-Risk Myeloid Cancers|"Subjects were given 6 subcutaneous injects of PR1:169-177 in Montanide adjuvant and 6 subcutaneous injections of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
89246959|NCT04244760|Active Comparator|Verbal Patients|
89246960|NCT04244760|Active Comparator|Non-verbal Patients|
89246961|NCT01014780||Normal (non-dry) dry eye subjects|These are healthy individuals, age 18 and above, who do not exhibit dry eyes by signs and symptoms
89246962|NCT01014780||Dry eye subjects|These are subjects, age 18 years and above, who do exhibit signs and symptoms of dry eye.
89246963|NCT00488514|Other|Active Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)
89246964|NCT00320710|Experimental|Zoledronic acid every (q) 4 weeks|Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
89246965|NCT00320710|Experimental|Zoledronic acid q 12 weeks|Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
89246966|NCT00320710|Experimental|Placebo / zoledronic acid|Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.
89246967|NCT00498186|Experimental|Rotigotine|Rotigotine trans-dermal patch
89246968|NCT00333970|Experimental|cognitive remediation|cognitive remediation
89246969|NCT00333970|No Intervention|treatment as usual|treatment as usual
89246970|NCT01017588|Experimental|back exercise|strengthening back exercise
89246971|NCT03984526|Placebo Comparator|Control group|intravenous normal saline pretreatment
89246972|NCT03984526|Experimental|Atropine group|intravenous atropine 0.5mg pretreatment
89246973|NCT03984526|Experimental|Ephedrine group|intravenous ephedrine 8mg pretreatment
89246974|NCT01017666|Experimental|Rosiglitazone 8mg PO|Cohort 1
89246975|NCT01017666|Experimental|Midazolam 2mg PO, Warfarin 25mg PO|Cohort 2
89246976|NCT03984370|Experimental|80 ug of sc dasiglucagon|80 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
89246977|NCT03984370|Experimental|200 ug of sc dasiglucagon|200 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
89246978|NCT03984370|Placebo Comparator|0.4 mL of sc saline (placebo)|0.4 mL fluid (saline/placebo) is injected abdominal subcutaneous postprandial prior to hypoglycemia.
89246979|NCT03984292|Experimental|Mass Learning|Single teaching session of 3 hours shall be provided
89246980|NCT03984292|Experimental|Distributed Learning|Three teaching sessions of 1 hour each shall be provided.
89246981|NCT01064596||blood sample|Patient with 4 blood samples to measure anti-Xa activity
89246982|NCT03980392|Experimental|Facility-based Intervention|A group will consist of 5 or 10 persons depending on the size of the study center. Exercise training will be guided by study exercise therapists at a gym and consist of programs for progressive muscle strength training, aerobic exercise, and exercises to improve postural balance and flexibility using elastic bands, floor plate and chairs (three times per week, 60 min per session).The cognitive training program is a program including tasks to be effective in episodic memory, executive function, attention, working memory, calculation, and visuospatial function (twice per week, 60 min per session). The nutritional intervention is conducted by study nutritionists (three individual sessions and seven group sessions). Management of metabolic and vascular risk factors will include additional meetings with the study nurse (at 0, 4, 8, 16, and 20 weeks), and the study physician (at 0 and 12 weeks). Motivational training is conducted by psychologist (four group session).
89246983|NCT03980392|Experimental|Home-based Intervention|The nutritional intervention, management of metabolic and vascular risk factors, social activity, and motivational training in the home-based intervention are similar to the facility-based intervention. The physical exercise programs consist of one group session (60 min) and two home-based sessions (60 min per session) per week in the first 2 months of the trial. During the remaining months of the 6-month study, participants in the home-based intervention attend a 1-h physical exercise group session per two weeks and two or three exercise sessions (60 min per session) alone at home per week. The cognitive training programs consist of one group session (60 min) and one home-based sessions (60 min per session) per week in the first 2 months of the trial. For the remainder of the 6-month study, participants in the home-based intervention attend a 1-h group cognitive training session per two weeks and one or two cognitive training sessions (60 min per session) alone at home per week.
89246984|NCT03980392|No Intervention|Controls|They are waiting list controls. They will receive the multi-domain intervention after this study.
89246985|NCT03980236|Experimental|Livongo-Insulia Study App Arm|Participants will be asked to use the Livong-Insulia Study App for the 3 month study duration
89246986|NCT00477594|Experimental|Mipomersen 200 mg per week|Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.
89246987|NCT00477594|Experimental|Mipomersen 200 mg every other week|Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.
89246988|NCT00475722|Active Comparator|1 Healthy Eating|Healthy People 2010 Diet using an exchange list
89246989|NCT00475722|Experimental|2 Mediterranean|Mediterranean Diet using an exchange list
89246990|NCT00304954|Active Comparator|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
89246991|NCT00304954|Active Comparator|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
89246992|NCT00304954|Active Comparator|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
89246993|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
89246994|NCT00475176|Experimental|S-Adenosyl Methionine|
89246995|NCT01062022|Active Comparator|Control - Standard of Care|Participation in the study will involve your child completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Your child will be asked to complete the questionnaire during the baseline assessment, and at 6 months, 12 months, and 24 months after the original assessment.
89246996|NCT01062022|Active Comparator|FOCUS-CI|Those participants in the FOCUS-CI intervention will be part of a family skill-building/resiliency training program designed to provide information and skills training in a variety of forms, including clinician-led sessions, handouts, on-line training modules, and individual family care management. Study participation will also involve completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Questionnaires will be completed during the baseline assessment, and at 6 months, 12 months, and 24 months after the baseline assessment.
89246997|NCT01064674||before renal transplantation|Patients with CKD IV° to V° who are actually registering for a renal transplantation in our department.
89246998|NCT01062100|Experimental|nuclear breast imaging|nuclear breast imaging using MBI Gamma camera
89246999|NCT00414609|Experimental|Aliskiren|"Core Study: Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for next 34 weeks orally once daily in the morning.~Extension Study: Patients from both the core arms who completed core study and signed informed consent form were included in this arm of extension study.~Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study."
89247000|NCT00414609|Placebo Comparator|placebo|Core study: placebo for 36 weeks once daily in the morning
89247001|NCT00393705|Experimental|insulin lispro LM + insulin lispro MM|Three times per day subcutaneous injection of insulin lispro mid mixture (MM) with the possibility to change the evening injection of MM to insulin lispro low mixture (LM) if fasting blood glucose target is not achieved.
89247002|NCT00393705|Active Comparator|Insulin Biphasic Aspart 30/70 or Insulin Lispro LM|Twice daily subcutaneous injection of either insulin biphasic aspart 30/70 or insulin lispro low mixture (LM) (continuation of analogue formulation used before study enrollment).
89247003|NCT00303628|Active Comparator|Arm I|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses.
89247004|NCT00303628|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oxaliplatin, leucovorin calcium, and fluorouracil as in arm I.
89247005|NCT00414453|Active Comparator|Lidocaine 5% + placebo patch, ER and placebo pills|5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period
89247006|NCT01040715|Experimental|TNFa Kinoid dose 1|
89247007|NCT01040715|Experimental|TNFa Kinoid dose 2|
89247008|NCT01040715|Experimental|TNFa Kinoid dose 3|
89247009|NCT01037595|Experimental|turmeric|turmeric 500 mg tid orally for 8 weeks
89247010|NCT01037595|Placebo Comparator|plasebo|placebo tid orally for 8 weeks
89247011|NCT01037673|Experimental|PT progressive exercises|A progressive program of movement and strength exercises for the rotator cuff and scapular muscles combined with mobilisation of the joint capsule when needed
89247012|NCT01037673|Active Comparator|Movement exercises neck and shoulder|General movements for the neck and shoulder,
89247013|NCT01040949|Active Comparator|a self help smoking cessation guide|Guia, a culturally relevant self-help smoking cessation guide in Spanish
89247014|NCT01040949|Experimental|couple-based counseling for smoking cessation plus Guia|couple-based counseling for smoking cessation plus Guis, culturally relevant self-help smoking cessation guide for Latinos
89247015|NCT00332488|Experimental|1|Technosphere Insulin
89247016|NCT00332488|Active Comparator|2|Metformin & Secretagogues
89247017|NCT00332488|Experimental|3|Technosphere & Metformin
89247018|NCT00332332|Experimental|etanercept|Open label etanercept 50 mg twice weekly subcutaneously (SC) for 3 months followed by 50 mg twice a week week SC for 9 months, for a total treatment period of 12 months.
89247019|NCT00392925|Experimental|Placebo and Metreleptin|Placebo-pramlintide 600 microliters (µL) twice a day (BID) and metreleptin (recombinant-methionyl human leptin) 5 milligram (mg) BID, 20 weeks
89247020|NCT00392925|Experimental|Pramlintide Acetate and Placebo|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and placebo-metreleptin 1 mL BID, 20 weeks
89247021|NCT00392925|Experimental|Pramlintide Acetate and Metreleptin|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and metreleptin (recombinant-methionyl human leptin) 5 mg BID, 20 weeks
89247022|NCT00392925|Other|Lead-In Period|During the Lead-In Period before a participant was randomized to a study arm, the participant received 180 mcg pramlintide acetate twice a day (BID) for 2 weeks, followed by 360 mcg pramlintide acetate BID for 2 weeks (total of 4 weeks in the Lead-In Period).
89247023|NCT03979846|Experimental|Arm I (usual care, computer-based symptom reporting)|Participants receive usual care for 3 weeks, then use a computer based symptom reporting system for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
89247024|NCT03979846|Experimental|Arm II (computer-based symptom reporting, usual care)|Participants use a computer based symptom reporting system for 3 weeks, then receive usual care for 3 weeks. Caregivers may assist patients in the use of the computer based symptoms reporting system.
89247025|NCT00474786|Experimental|1|
89247026|NCT00474786|Experimental|2|
89247027|NCT00392769|Experimental|Cetuximab|400 mg/m^2 intravenous (IV) over 120 Minutes, followed by weekly infusions at 250 mg/m^2 IV over 60 minutes.
89247028|NCT01041105||Gastric bypass after previous Nissen|
89247029|NCT01041183|Active Comparator|group I|0.3 mg IV ramosetron
89247030|NCT01041183|Active Comparator|group II|0.1 mg oral ramosetron
89247031|NCT01041183|Active Comparator|group III|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
89247032|NCT01041261|No Intervention|Control arm|Subjects will be issued control study product (Carnation Instant Breakfast, no sugar added)
89247033|NCT01041261|Experimental|Treatment arm|Medical food
89247034|NCT03764943|Experimental|Immunonutrition Intervention|Participants will consume 3 'Impact Advanced Recovery' shakes daily for 5 days prior to surgery 2 hours prior to surgery.
89247035|NCT00319696|Experimental|Bosentan|Bosentan 62.5 mg tablets b.i.d. for the first 4 weeks followed by bosentan 125 mg b.i.d. thereafter
89247036|NCT01037751||Interview + Questionnaires|1-on-1 interview + Questionnaires, Part 1 of Study
89247037|NCT01037751||Questionnaires|Questionnaires Only, Part 2 of Study
89247038|NCT00474630|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy
89247039|NCT00474630|Placebo Comparator|Placebo|Placebo with ancillary therapy
89247040|NCT01041339||acute chest pain ST elevation|patients admitted with acute chest pain sharing ST elevation in ER-ECG and elevated troponin
89247041|NCT01041339||controls|asymptomatic patients
89247042|NCT01043835|Experimental|Laparoscopy-assisted gastrectomy|
89247043|NCT01043835|Active Comparator|Open gastrectomy|
89247044|NCT01064752||Minocycline|HIV-1 infected, not on anti-retroviral medication
89247045|NCT01043913|Experimental|Guaraná extract 50mg q12 hours|Guaraná extract pills of 50mg q12 hours for 21 days
89247046|NCT01043913|Placebo Comparator|Placebo 1 tab q12 hours|Placebo pills 1 tab q12 hours for 21 days
89247047|NCT00392379|Experimental|A|4 mg nicotine lozenges for 3 months
89247048|NCT00392379|Placebo Comparator|B|Placebo nicotine lozenges for 3 months
89247049|NCT01037829||Pregnancy women|Comparison of pregnancy outcomes between (Novartis) H1N1 vaccinated women and (Novartis) H1N1 unvaccinated women.
89247050|NCT01038063|Experimental|Artemether-lumefantrine|Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.
89247051|NCT01038063|Active Comparator|Dihydroartemisinin-piperaquine|Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.
89247052|NCT00497874|Experimental|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
89247053|NCT00497874|No Intervention|Usual care|Usual primary care treatment
89247054|NCT01043991|Experimental|EPO|single bolus of EPO, 150 µg
89247055|NCT01043991|Placebo Comparator|Placebo|NaCl
89247056|NCT01044147|Experimental|VLM-S|"Participants in this arm receive standard lifestyle coaching, which is delivered on a specified schedule. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
89247057|NCT01044147|Experimental|VLM-M|"Participants in this arm receive modulated lifestyle coaching, where coaching frequency may be adjusted according to whether the participant is meeting program goals for program use and targeted behaviors. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
89247058|NCT01044147|Active Comparator|OGR|Participants in this arm will receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle, but not personalized lifestyle coaching.
89247059|NCT01020630|Experimental|Sunitinib|25 mg (2 capsules of 12.5 mg) for oral administration
89247060|NCT01020630|Placebo Comparator|Placebo|2 capsules for oral administration
89247061|NCT00403455|Other|Paroxetine Arm|This is a single arm, single site, open-label clinical trial to treat veterans with PTSD. It is a 12-week trial to investigate the efficacy of paroxetine in reducing PTSD symptoms, with the primary outcome measure using CAPS. Genetic information is included to understand why some respond and some do not respond to paroxetine treatment.
89247062|NCT04923282|Active Comparator|Group 1: single 1-hour IV infusion of 0.8 mg/kg recAP or placebo|single 1-hour IV infusion of 0.8 mg/kg recAP or placebo
89247063|NCT04923282|Active Comparator|Group 2: single 1-hour IV infusion of 1.6 mg/kg recAP or placebo|single 1-hour IV infusion of 1.6 mg/kg recAP or placebo
89247064|NCT04923282|Active Comparator|Group 3: single 1-hour IV infusion of 3.2 mg/kg recAP or placebo|single 1-hour IV infusion of 3.2 mg/kg recAP or placebo
89247065|NCT04923282|Active Comparator|Group 4: 1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3|1-hour infusions of 1.6 mg/kg recAP or placebo on Days 1, 2 and 3
89247066|NCT00318370|Experimental|Far Only|Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
89247067|NCT00318370|Experimental|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
89247068|NCT03996408|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89247069|NCT01064908||Carotid endarterectomy|Patients who are undergoing elective carotid endarterectomy under local anaesthesia
89247070|NCT00510068|Experimental|Everolimus 10 mg/day|Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
89247071|NCT00510068|Placebo Comparator|Placebo|Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
89247072|NCT00509600|Experimental|Etanercept|0.8 mg/kg subcutaneously weekly for 90 days
89247073|NCT04485026|Experimental|Local Consolidative Radiation Therapy Arm|Definitive external beam radiation therapy will be delivered to all sites of progressive disease for all patients. The technique used to deliver radiation therapy will be determined by the treating radiation oncologist.
89247074|NCT04485026|Active Comparator|Standard of Care - Control Arm|Second line systemic therapy is at the discretion of the treating medical oncologist.
89247075|NCT01014104|Experimental|Case|Administration of Methylprednisolone
89247076|NCT01014104|Sham Comparator|Control|
89247077|NCT04280042||Thoracoscopic surgical ablation|Participants in CASA AF Trial who underwent thoracoscopic surgical ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
89247078|NCT04280042||Cather ablation|Participants in CASA AF Trial who underwent conventional catheter ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
89247079|NCT00402987|Experimental|celecoxib 50 mg/50 mg|
89247080|NCT00402987|Experimental|celecoxib 100 mg/placebo|
89247081|NCT00402987|Experimental|celecoxib 100 mg/50 mg|
89247082|NCT00402987|Placebo Comparator|Placebo|
89247083|NCT01010594|Active Comparator|Fruit restricted|Type 2 diabetics are advised to restrict their fruit intake to two pieces or less daily.
89247084|NCT01010594|Active Comparator|Fruit ad libitum|Type 2 diabetics are advised to eat at least two pieces of fruits daily
89247085|NCT01015742|Experimental|Experimental|Stem cell Transplant using two unrelated umbilical cord blood units.
89247086|NCT00501644|Experimental|Chemoimmunotherapy|GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days
89247087|NCT03997214|No Intervention|Control group|as usual care
89247088|NCT03997214|Experimental|experimental group|The intervention of inspiratory muscle strength training
89247089|NCT01014182||Early PCI|Routine invasive strategy with early PCI performed in STEMI patients within 24 hours from successful fibrinolysis
89247090|NCT01014182||Standard Therapy|Standard therapy in STEMI patients with fibrinolysis and/or conventional ischaemic-guided therapy.
89247091|NCT01014260|Placebo Comparator|Placebo|placebo
89247092|NCT01014260|Active Comparator|Doxycycline|Doxycycline
89247093|NCT01010672|Experimental|Ridaforolimus 40 mg|
89247094|NCT01014338|Active Comparator|ACE-inhibitor|
89247095|NCT01014338|Placebo Comparator|Sugar Pill|
89247096|NCT01014416|Experimental|Arm 1|Single dose, Tolvaptan 15mg or Placebo/day
89247097|NCT01014416|Experimental|Arm 2|Single dose, Tolvaptan 30mg or Placebo/day
89247098|NCT01014416|Experimental|Arm 3|Single dose, Tolvaptan 60mg or Placebo/day
89247099|NCT00497796|Experimental|1|
89247100|NCT00497796|Active Comparator|2|
89247101|NCT04449822|Active Comparator|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
89247102|NCT04449822|Active Comparator|Colonic stenting|The colonic stent placement
89247103|NCT00496782|Other|Single|
89247104|NCT01020708|Active Comparator|Comparator|Mesalamine enema
89247105|NCT01020708|Experimental|ALTH12-1:4|ALTH12-1:4 experimental treatment dose
89247106|NCT01020708|Experimental|ALTH12-2:4|ALTH12-2:4 experimental treatment dose
89247107|NCT01020864|Experimental|Chemotherapy|"Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.~Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment."
89247108|NCT01020942|Experimental|Pretreatment|
89247109|NCT01020942|No Intervention|Control|
89247110|NCT01017978|Other|MRI Scan|MRI scan of soft tissue tumor
89247111|NCT00402831|Experimental|Intramuscular ProQuad®|Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
89247112|NCT00402831|Active Comparator|Subcutaneous ProQuad®|Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.
89247113|NCT03996642|Other|Patients with Active Cancer|Eligible participants will undergo an unknown number of Avatar-life review sessions depending on acceptability of the intervention to subjects and the capacity of the team to provide the intervention.
89247114|NCT01038141|Active Comparator|Milligan Morgan|
89247115|NCT01038141|Active Comparator|Recto Anal Repair|
89247116|NCT01038219||fever measurements|"1000 estimates and measurements of children's body temperatures will be carried out by parents and nurses in children's emergency and pediatric units as part of the routine work. The estimates and the measurements will be carried out on children who are referred to an emergency unit and who are hospitalized in the pediatric department-- both boys and girls of all ages. A patient might be measured several times.~The measurements will be gathered in the course of one year. Before the routine taking of temperature, the accompanying parent will be asked to estimate the patient's temperature by feeling his forehead (with the back of the hand, the palm, lips). The parent will record his evaluation (without telling the nurse). Afterwards the nurse will do a similar evaluation (excepting the lip test), record it, and then the routine temperature measurement will be taken."
89247117|NCT01014858|Experimental|Donepezil|5mg of Donepezil for the first 8 weeks raising to 10mg thereafter if patient adjusted to 5mg dose. 10mg does continues for the remainder of the study.
89247118|NCT01014858|Placebo Comparator|Placebo|Patient commences medication to match appearance of 5mg donepezil for first 8 weeks then 10mg for the remainder of the study.
89247119|NCT00496626|Experimental|1|V501 (Gardasil®)
89247120|NCT00496626|Placebo Comparator|2|Placebo
89247121|NCT01018212|Experimental|A|Cicatrix cream
89247122|NCT01015014|Active Comparator|AN3365|
89247123|NCT01015014|Placebo Comparator|Saline|
89247124|NCT01018290||Navigated TMS examination|20 patients with brain tumor in the vicinity of the central motor region scheduled for elective surgery will undergo pre-operative Navigated TMS examination to determine the localization of primary motor cortex and motor representation areas of specific muscles
89247125|NCT04052958|Active Comparator|Group 1: Strength Training|Respiratory muscle strength training
89247126|NCT04052958|Active Comparator|Group 2: Endurance Training|Respiratory muscle endurance training
89247127|NCT04052958|No Intervention|Group 3: Control group|no training of respiratory muscles
89247128|NCT00471276|Experimental|1|
89247129|NCT00470262|Other|Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD|Treatment with pioglitazone and fenofibrate in subjects with pre diabetes
89247130|NCT00470262|Other|Fenofibrate 145 mg PO QD|Treatment with fenofibrate in subjects with pre diabetes
89247131|NCT04034862|Experimental|2DR|Switch from 3 drug regimen (DTG+ABC+3TC) to 2 drug regimen (DTG+3TC)
89247132|NCT04034862|No Intervention|3DR|Continued 3 drug regimen treatment (DTG+ABC+3TC)
89247133|NCT00496470|Active Comparator|Symbicort+TIO|Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily
89247134|NCT00496470|Active Comparator|Spiriva® + Placebo Turbuhaler|Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily
89247135|NCT01021176|Placebo Comparator|0mg 0 spray|No Diltiazem
89247136|NCT01021176|Active Comparator|2mg 2 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 2mg/2 spray Diltiazem
89247137|NCT01021176|Active Comparator|4mg 4 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 4mg/4 spray Diltiazem
89247138|NCT01021176|Active Comparator|8mg 8 spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 8mg/8 spray Diltiazem
89247139|NCT00496080|Experimental|DUAO Device|Doppler-guided uterine artery occlusion device (Single-arm study)
89247140|NCT01018368|Experimental|VX-770|
89247141|NCT01018368|Experimental|Rifampin|
89247142|NCT00487578|Active Comparator|A|Naratriptan 2.5 mg tablet bid x 30 days
89247143|NCT00487578|Placebo Comparator|B|placebo matching naratriptan 2.5 mg tablet
89247144|NCT01021410||Acetaminophen Group|Subjects who completed COMIRB 06-1265 and were assigned to the acetaminophen treatment group for that study.
89247145|NCT00495612|Experimental|Omalizumab|Patients received omalizumab via subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. The dose administered and the dosing interval were determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
89247146|NCT00495612|Placebo Comparator|Placebo|Patients received placebo as a subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. Patients received injections at the same time intervals as the omalizumab group.
89247147|NCT01021488|Experimental|Experimental: Rosuvastatin + enoxaparin arm|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
89247148|NCT01021488|Active Comparator|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
89247149|NCT00487188|Experimental|ENF + HAART|Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
89247150|NCT00487188|Active Comparator|HAART|Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.
89247151|NCT00509366|Active Comparator|Cisplatin Sensitive (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Cisplatin day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Cisplatin day 1, Pemetrexed day 1~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin sensitive arm, based on histology (squamous/non-squamous)."
89247152|NCT00509366|Active Comparator|Cisplatin Resistant (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Docetaxel day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Pemetrexed day 1, Gemcitabine days 1 & 8~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin resistant arm, based on histology (squamous/non-squamous)."
89247153|NCT00509366|Active Comparator|Cisplatin Sensitive (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Cisplatin day 1, Gemcitabine days 1 & 8"
89247154|NCT00509366|Active Comparator|Cisplatin Resistant (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Pemetrexed day 1, Gemcitabine days 1 & 8"
89247155|NCT01015898|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
89247156|NCT03997682|Experimental|Hands-Up Program|Participants will be guided through a 45 minutes exercise program, set up as a group exercise class, with program modifications being made for each individual participant. In order to meet the requisite number of participants there will be approximately 4 cohorts of 10 participants. Immediately after the exercise class participants will attend a 30-minute educational session. The educational sessions will cover bone health principles, nutrition for bone health, osteoporosis practice guidelines, ways to self-monitor balance and lower extremity strength, impacts of physical activity, home hazard detection, hazards at work and in the community, postural effects on bone loading and fracture risk, and integrating physical activity in daily life. Nutritional education will emphasize the importance of calcium and vitamin D, sources of both diary and dairy free calcium, vitamin D supplements, the importance of protein, and meat and meat-free sources of protein.
89247157|NCT03997682|No Intervention|Standard Care|The control group will receive usual care after a distal radius fracture. The standard care for a distal radius fracture will receive an assessment related to whether casting or surgery is necessary. The participant may be in a cast for 6 weeks with routine check up and x-rays to monitor the healing, at 3 months, 6 months and 12 months. The participant should receive some physical therapy related to restoring function of the hand and wrist.
89247158|NCT01016054|Experimental|A. PLD plus AGS-8M4|Women with platinum resistent ovarian cancer
89247159|NCT01016054|Experimental|B. Carboplatin and gemcitabine plus AGS-8M4|Women with platinum sensitive ovarian cancer
89247160|NCT00500318|Experimental|Aclidinium|
89247161|NCT00500318|Placebo Comparator|Placebo|
89247162|NCT00508820|Experimental|1|Romiplostim
89247163|NCT00499694|Experimental|Bevacizumab and Satraplatin|"Bevacizumab 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)~Satraplatin 80 mg/m(2), Orally, Days 1-5, every 35 days"
89247164|NCT01014494|Experimental|Active - Adaprev|Adaprev (Class III medical device)
89247165|NCT01014494|No Intervention|Standard Care|No different treatment to normal
89247166|NCT00486954|Experimental|Paclitaxel plus Lapatinib|6 pills of lapatinib at 250 mg each once daily and infusion of paclitaxel at 80 mglm2 weekly
89247167|NCT00486954|Active Comparator|Paclitaxel alone|Infusion of paclitaxel at 80 mglm2 weekly
89247168|NCT00494676|Experimental|Real prism glasses first, then sham|Participants in this arm will receive high power (57 prism diopter) peripheral prism glasses in the first period of the crossover and low power sham peripheral prism glasses in the second period
89247169|NCT00494676|Experimental|Sham prism glasses first, then real|Participants in this arm will receive low power sham peripheral prism glasses in the first period of the crossover and high power (57 prism diopter) peripheral prism glasses in the second period
89247170|NCT00486720|Experimental|1|vorinostat 400 mg
89247171|NCT00486720|Experimental|2|vorinostat 200 mg
89247172|NCT00486330|Other|Buprenorphine plus Tipranavir/Ritonavir|
89247173|NCT01021566|Experimental|Combined hemoperfusion-hemodialysis|On admission thirty patients will receive the combined hemoperfusion-hemodialysis treatment regimen three hours everyday for three days.
89247174|NCT01021566|Active Comparator|Methadone, conventional treatment for opiate detoxification|On admission thirty patients receive the 10-day methadone treatment regimen.
89247175|NCT01021644|Experimental|aerobic exercise-training|
89247176|NCT01021644|Active Comparator|stretch exercise|
89247177|NCT01021722|Experimental|Modified suture technique|Sutured in a modified manner
89247178|NCT01021722|No Intervention|Historical sphincter group|The outcome of historical sphincter tears
89247179|NCT01021722|No Intervention|Normal primaparous deliveries|Normal deliveries
89247180|NCT00486252||This is N/A due to the above description.|This is N/A due to the above description.
89247181|NCT00494442|Experimental|KU-0059436 (AZD2281) 100 mg BID|
89247182|NCT00494442|Experimental|KU-0059436 (AZD2281) 400 mg BID|
89247183|NCT01021800|Experimental|Cell infusion|
89247184|NCT03851016|Experimental|Life Story Book Intervention First, Then Usual Care|Participants first received the Life Story Book Intervention once a week for 3 weeks. After a washout period of 1 week, they then received the Usual Care Intervention for 3 weeks. Posttests were then conducted for 1 week.
89247185|NCT03851016|Experimental|Usual Care First, Then Life Story Book Intervention|Participants first received the Usual Care Intervention for 3 weeks. After a washout period of 1 week, they then received the Life Story Book Intervention once a week for 3 weeks. Posttests were then conducted for 1 week.
89247186|NCT00493974|Active Comparator|Zileuton|Zileuton (Zyflo, 600 mg 4 times a day)
89247187|NCT00493974|Placebo Comparator|Placebo|Placebo
89247188|NCT01018446|Experimental|Busulfan, Pharmacokinetic|To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.
89247189|NCT01018524|Active Comparator|small hernias - suture repair|
89247190|NCT01018524|Active Comparator|small hernias - mesh repair|
89247191|NCT01018524|Active Comparator|large hernias - sublay mesh|
89247192|NCT01018524|Active Comparator|large hernias - onlay mesh|
89247193|NCT01015092||unselected HIV outpatient attendees|All HIV patients attending for general HIV care at 2 London Hospitals
89247194|NCT01018602|Active Comparator|vildagliptin|
89247195|NCT01018602|Placebo Comparator|inactive pill without active agent|participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
89247196|NCT01018758|Experimental|palonosetron|
89247197|NCT00469092|Experimental|BIAsp 30|
89247198|NCT00469092|Active Comparator|Glargine|
89247199|NCT03997110|Active Comparator|Arm A Or Control Arm- Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
89247200|NCT03997110|Experimental|Arm B or Experimental Arm-Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
89247201|NCT00499616|Experimental|Group 2 (chemotherapy, surgery)|2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.
89247202|NCT00499616|Experimental|Group 3 (chemotherapy, surgery)|4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
89247203|NCT00499616|Experimental|Group 4 (chemotherapy, surgery, antineoplastic therapy)|8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients < 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
89247204|NCT00499616|Experimental|Non-intermediate risk enrolled on intermediate risk trial|The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
89247205|NCT01016210|Experimental|60 infertile women|Candidates for IVF-ET treatment
89247206|NCT01016210|No Intervention|control|no treatment
89247207|NCT00402597|Experimental|001|Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
89247208|NCT00402597|Experimental|002|Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
89247209|NCT00402597|Placebo Comparator|003|Placebo 1 placebo tablet twice daily for 6 months.
89247210|NCT00402363|Experimental|omega-3-acid ethyl esters|
89247211|NCT00402363|Placebo Comparator|Placebo|
89247212|NCT00469014|Active Comparator|Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 30 mg/m^2 intravenous (IV) Daily + Fludarabine 30 mg/m^2 IV Daily; + Clofarabine 10 mg/m^2 IV Daily; Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
89247213|NCT00469014|Experimental|Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 20 mg/m^2 IV + Fludarabine 20 mg/m^2 IV Daily + Clofarabine 20 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
89247214|NCT00469014|Experimental|Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 10 mg/m^2 IV Daily + Fludarabine 10 mg/m^2 IV Daily + Clofarabine 30 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
89247215|NCT00469014|Experimental|Arm 4: Busulfan + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 40 mg/m^2 IV Daily + Clofarabine 40 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
89247216|NCT00493038|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days
89247217|NCT00493038|Active Comparator|Amoxicillin/Clavulanate|Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days
89247218|NCT01024998|Experimental|2 x 10^8 vector genomes (vg) AAV2-sFLT01|
89247219|NCT01024998|Experimental|2 x 10^9 vector genomes (vg) AAV2-sFLT01|
89247220|NCT01024998|Experimental|6 x 10^9 vector genomes (vg) AAV2-sFLT01|
89247221|NCT01024998|Experimental|2 x 10^10 vector genomes (vg) AAV2-sFLT01|
89247222|NCT00392223|Experimental|Treatment Group A|
89247223|NCT00392223|Experimental|Treatment Group B|
89247224|NCT00402285|Active Comparator|lycopene supplement|Two 15mg lycopene capsules daily for 3 months.
89247225|NCT00402285|Active Comparator|fish oil supplement|1g fish oil capsule daily for 3 months.
89247226|NCT00402285|Placebo Comparator|placebo|placebos for lycopene and fish oil.
89247227|NCT01038375||Adherence counseling|
89247228|NCT01038375||Usual care|
89247229|NCT01324479|Experimental|INC280|
89247230|NCT00413283|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
89247231|NCT00413283|Experimental|Romiplostim 250 μg|Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
89247232|NCT00413283|Experimental|Romiplostim 500 μg|Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
89247233|NCT00413283|Experimental|Romiplostim 750 μg|Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
89247234|NCT00402051|Experimental|Pemetrexed + Cisplatin|
89247235|NCT00402051|Experimental|Pemetrexed + Carboplatin|
89247236|NCT00468858|Experimental|T-DEN-Post-Transfection F17|Post-Transfection F17, full dose
89247237|NCT00468858|Experimental|T-DEN-Post-Transfection F19|Post-Transfection F19, full dose
89247238|NCT00468858|Placebo Comparator|Placebo|Control
89247239|NCT00401973|Experimental|Olanzapine|olanzapine plus behavioral information
89247240|NCT00401973|Experimental|Olanzapine + Amantadine|Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
89247241|NCT00401973|Experimental|Olanzapine + Metformin|Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information
89247242|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 35 µg|Dietary Supplement: Cholecalciferol (Vitamin D3) 35 µg per day
89247243|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 70 µg|Dietary supplement: Cholecalciferol (Vitamin D3) 70 µg per day
89247244|NCT01038453|Placebo Comparator|placebo|
89247245|NCT00401193|Experimental|1|
89247246|NCT00401193|Experimental|2|
89247247|NCT00401193|Placebo Comparator|3|
89247248|NCT00400569|Experimental|Sunitinib Malate (SU011248) Treatment|Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks
89247249|NCT03993015||Patients attending the Obstetrical Emergency Unit|Patients attending the Obstetrical Emergency Unit of CHU Montpellier during 2018
89247250|NCT01038531|Active Comparator|low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
89247251|NCT01038531|Experimental|APRV|APRV allows spontaneous breathing.
89247252|NCT00413049|Experimental|Valsartan/amlodipine 80/5 mg|
89247253|NCT00413049|Active Comparator|Amlodipine 5 mg|
89247254|NCT03732495|Experimental|Trial arm|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met."
89247255|NCT01041729|Experimental|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
89247256|NCT01041729|Active Comparator|Control|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment"
89247257|NCT01324245|Experimental|Enalapril|2.5 mg every 12 hours for two doses
89247258|NCT00454194|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89247259|NCT00454194|Active Comparator|Arm II|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89247260|NCT00412971|Active Comparator|Hexvix cystoscopy group|
89247261|NCT00412971|Other|White light|Standard White light cystoscopy
89247262|NCT00303472|Experimental|Part A: 300 µg romiplostim|Cohort 1 in Part A, participants received romiplostim 300 µg subcutaneously once weekly for 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
89247263|NCT00303472|Experimental|Part A: 700 µg romiplostim|Cohort 2 in Part A, participants received romiplostim 700 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
89247264|NCT00303472|Experimental|Part A: 1000 µg romiplostim|Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
89247265|NCT00303472|Experimental|Part A: 1500 µg romiplostim|Cohort 4 in Part A, participants received romiplostim 1500 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
89247266|NCT00303472|Experimental|Part B: 750 µg romiplostim SC QW|Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
89247267|NCT00303472|Experimental|Part B: 750 µg romiplostim SC Q2W|Part B participants received romiplostim 750 µg subcutaneously every two weeks (Q2W) for 8 weeks. Participants who complete Part B could continue to receive injections of romiplostim for up to 1 year in the extension treatment phase.
89247268|NCT00303472|Experimental|Part B: 750 µg romiplostim IV Q2W|Part B participants received romiplostim 750 µg intravenously (IV) once every two weeks for 8 weeks. Participants who complete Part B could continue to receive romiplostim for up to 1 year in the extension treatment phase.
89247269|NCT00468546|Placebo Comparator|Placebo Plus Methotrexate|Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
89247270|NCT00468546|Experimental|Rituximab plus Methotrexate|Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
89247271|NCT00303316|Experimental|DTacP IPV HepB PRP-T Combined Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received DTacP-IPV-HepB-PRP-T (primary series) in Study A3L02.
89247272|NCT00303316|Active Comparator|PENTAXIM™ and ENGERIX B® Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received ENGERIX B® and PEDIATRICO in Study A3L02 (Primary series)
89247273|NCT01064986|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
89247274|NCT01064986|Active Comparator|B|IV Endotoxin plus IV hydrocortisone
89247275|NCT00468312|Experimental|Mometasone Furoate Nasal Spray (MFNS)|200 mcg daily
89247276|NCT00468312|Placebo Comparator|Placebo|Two sprays in each nostril in the morning
88804801|NCT00101660|Experimental|Dasatinib, 70 mg twice daily (BID)|Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.
89247277|NCT03980002|Experimental|FCR/BR alternating with ibrutinib|FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy
89247278|NCT03938220||fluid responders|fluid responder if stroke volume increases by > 10% after the fluid challenge
89247279|NCT03938220||fluid non responders|fluid responder if stroke volume increases by <= 10% after the fluid challenge
89247280|NCT00331864|Experimental|Ranibizumab|Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
88804802|NCT01267279|Placebo Comparator|Placebo|
88804803|NCT01267279|Experimental|Zoledronic Acid|
89247281|NCT03984136|Experimental|Intervention group|Men will be required to exchange the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends conditionally.
89247282|NCT03984136|Active Comparator|Control group|Men will share the Center for Disease Control and Prevention certified online HIV results (COHIV) with friends freely without conditional exchange requirement.
89247283|NCT00331630|Experimental|Treatment arm|30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89247284|NCT00331552|Experimental|Arm I|Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
89247285|NCT01062178|Experimental|comparison to biopsy|Comparing contrast enhanced US with biopsy result
89247286|NCT03983746|Experimental|traditional physical therapy program (control group)|fifteen children with DS received a traditional exercises program with instructions to the children for 60 minutes aiming to improve posture control and balance
89247287|NCT03980080|Experimental|OSE-127: Part 1 (SAD), Cohort A & Cohort B|
89247288|NCT03980080|Placebo Comparator|Placebo: Part 1 (SAD), Cohort A & Cohort B|
89247289|NCT03980080|Experimental|OSE-127: Part 2 (MAD)|
89247290|NCT03980080|Placebo Comparator|Placebo: Part 2 (MAD)|
89247291|NCT04320628|Experimental|Experimental|Target ulcer cleansed with NaOCl. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NaOCl.
89247292|NCT04320628|Placebo Comparator|Control|Target ulcer cleansed with NSS. After cleansing the wound a second MiX is performed. The subject is given a four-week supply of NSS.
89247293|NCT01065064|Experimental|RESTOR|Patients with cataract that had phacoemulsification and AcrySof® ReSTOR IOL implantation.
89247294|NCT03983902|Active Comparator|Delayed cord clamping|Delayed cord clamping
89247295|NCT03983902|Active Comparator|Umbilical cord milking|Umbilical cord clamping
89247296|NCT03983902|Active Comparator|Immediate cord clamping|Immediate cord clamping
89247297|NCT00331006|Experimental|Rituximab|Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks
89247298|NCT00302458|Experimental|OROS-MPH + OROS-MPH|OROS-Methylphenidate Will be administered during the first part of the day, and again during the separate part of the day.
89247299|NCT00302458|Experimental|IR MPH + IR MPH|Immediate release methylphenidate will be administered in the first part of the day followed by Immediate release methylphenidate in the second part of the day.
89247300|NCT00302458|Placebo Comparator|Plabebo + Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
89247301|NCT00302458|Experimental|OROS MPH+ IR MPH|Concerta will be administered in the first part of the day, followed by Immediate Release Methylphenidate in the second part of the day.
89247302|NCT00302458|Experimental|IR MPH + OROS MPH|Immediate release Methylphenidate will be administered in the first part of the day, followed by Concerta in the second part of the day
89247303|NCT03982264|Active Comparator|ESD group|In ESD group, enrolled patients will receive the treatment modality of ESD to remove the rectal NET
89247304|NCT03982264|Experimental|EMR-C group|In EMR-C group, enrolled patients will receive the treatment modality of EMR-C to remove the rectal NET
89247305|NCT00391053|Experimental|Study Group 1|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1
89247306|NCT00391053|Experimental|Study Group 2|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2
89247307|NCT00391053|Experimental|Study Group 3|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3
89247308|NCT00391053|Active Comparator|Group 4|Participants will receive the Standard Fluzone® vaccine
89247309|NCT00317044|Experimental|Esomeprazole 40 mg twice daily|
89247310|NCT00317044|Experimental|Esomeprazole 40 mg once daily|
89247311|NCT00317044|Placebo Comparator|Placebo|
89247312|NCT00301834|Experimental|Single arm - conditioning and transplant|Alemtuzumab 0.5 mg/kg (maximum 15 mg) daily for 3 days; Busulfan i.v. every 6 hours from day -9 to day -6 for 16 total doses; Fludarabine phosphate from day -5 for 4 days at 1.3 mg/kg (if patient was less than 12 kg) or 40 mg/m*2 per dose; Cyclosporine continuous infusion 3 mg/kg/Day beginning day -1 for GVHD prophylaxis; Methotrexate at 15 mg/m*2 on day +1, 10 mg/m*2 on days +3, +6, and (only for MUDs) day +11 also for GVHD prophylaxis; Methylprednisolone only as required for GVHD prophylaxis; allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation or peripheral blood stem cell transplantation or umbilical cord blood transplantation.
89247313|NCT00301366|Experimental|Alpha-1 Proteinase Inhibitor (Human), modified process|Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects.
89247314|NCT00330928|Experimental|1|Subjects undergoing elective percutaneous coronary intervention
89247315|NCT01062334|Experimental|Microdialysis|
89247316|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin|Regimen A: docetaxel 75 milligrams per square meter (mg/m^2), intravenous (IV) is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 milligrams (mg) oral (po), twice daily (BID) every day. In Cycle 1, enzastaurin is given as a loading dose of 1125 mg on the day prior to docetaxel and prednisone therapy, followed by enzastaurin 500 mg po, daily (QD) for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
89247317|NCT00466440|Placebo Comparator|docetaxel + prednisone + placebo|Regimen B: docetaxel 75 mg/m^2, IV is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, placebo is given as a loading dose on the day prior to docetaxel and prednisone therapy, followed by po, QD placebo for the remaining Period 2 (chemotherapy) and Period 3 (maintenance), until unblinding.
89247318|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin (modified Regimen A)|Modified Regimen A, including pharmacokinetic (PK) characterization: Participants were treated with a modified investigational regimen with no dose escalation: docetaxel 75 mg/m2, IV was administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, enzastaurin was given as a loading dose of 1125 mg starting on Day 4, followed by enzastaurin 500 mg po, QD for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
89247319|NCT00465972|Placebo Comparator|Placebo|Placebo
89247320|NCT00465972|Active Comparator|2|Doxepin
89247321|NCT00465972|Active Comparator|3|Temazepam
89247322|NCT03926754|Active Comparator|Mirabegron|Active treatment arm (mirabegron)
89247323|NCT03926754|Placebo Comparator|Placebo|Placebo
89247324|NCT00465894|Active Comparator|Extended Release Tolterodine LA|An anti-muscarinic drug that is used for symptomatic treatment of urinary incontinence.
89247325|NCT00465894|Active Comparator|Intra Vaginal Estradiol Cream|For topical application to the vaginal area to treat symptoms of urgency or irritation with urination.
89247326|NCT00330460|Active Comparator|Alendronate|Subjects in this arm will receive active ALN and placebo denosumab
89247327|NCT00330460|Experimental|Denosumab|Subjects in this arm will receive active denosumab and placbo ALN
89247328|NCT03979768|Experimental|Risk Assessment Only pharmacies (RTO-group)|Offered a diabetes risk assessment service without any blood sample testing.
89247329|NCT03979768|Experimental|HbA1c-group /pharmacies|Offered a diabetes risk assessment service including a measurement of Haemoglobin A1c (HbA1c) to the people with a high risk of developing type 2 diabetes on the risk assessment form (The Finnish Diabetes Risc Score (FINDRISC) to those with a western background, and Leicester Risk Assessment (LRA) form for those with a non-western background.
89247330|NCT01062490|Experimental|Treosulfan|Patients with myelodysplastic syndrome, (MDS) according to WHO classification (< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation
89247331|NCT00454116|Placebo Comparator|1|FOLFIRI + placebo vandetanib
89247332|NCT00454116|Experimental|2|FOLFIRI + low dose vandetanib
89247333|NCT00454116|Experimental|3|FOLFIRI + high dose vandetanib
89247334|NCT00465816|Experimental|Nimenrix + Twinrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
89247335|NCT00465816|Active Comparator|Nimenrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0.
89247336|NCT00465816|Active Comparator|Twinrix Group|Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
89247337|NCT00465738|Experimental|incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 5.0 mL resulted in a dose of 20 units per 1.0 mL."
89247338|NCT00465738|Active Comparator|incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 mL sterile of NaCl 0.9% solution without preservatives. Dilution with 2.0 mL resulted in a dose of 50 units per 1.0 mL."
89247339|NCT00400179|Active Comparator|A|In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
89247340|NCT00400179|Active Comparator|B|In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
89247341|NCT00465270|Experimental|Device|AMPLATZER PFO Occluder
89247342|NCT00465270|Active Comparator|Standard or Care - Medical Management|Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.
89247343|NCT00464490|No Intervention|Standard Hospital Ventilation Weaning Protocol|Control. Hospital weaning protocol
89247344|NCT00464490|Experimental|Dexmedetomidine for Extubation|Dexmedomidine infusion to facilitate extubation
89247345|NCT01022034|Active Comparator|Pexy group|This group of patients with full thickness rectal prolapse will receive standard sacral rectopexy with mesh or sutures
89247346|NCT01022034|Sham Comparator|Non-pexy group|These patients will receive full rectal mobilization from the sacrum but without rectopexy
89247347|NCT03849300|No Intervention|Control Group|No exercise intervention
89247348|NCT03849300|Experimental|Aquatic walking exercise group 1|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
89247349|NCT03849300|Experimental|Aquatic walking exercise group 2|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
89247350|NCT03849300|Active Comparator|Land-based walking exercise group|"The land-based walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of low-intensity forward, backward, and lateral side-stepping movements on flat group. The remaining 30 minutes included treadmill walking exercise.~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
89247351|NCT00412893|Experimental|Isavuconazole|Participants received a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they reached a treatment endpoint or for a maximum of 84 days.
89247352|NCT00412893|Active Comparator|Voriconazole|Participants received a loading dose of voriconazole, 6 mg/kg every 12 hours IV for the first 24 hours, followed by a maintenance dose of 4 mg/kg every 12 hours by IV on Day 2. Beginning on Day 3, participants received 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they reached a treatment endpoint or for a maximum of 84 days.
89247353|NCT00412737|Experimental|Oseltamivir|
89247354|NCT00412737|Placebo Comparator|Placebo|
89247355|NCT00508742|Experimental|1|13 valent pneumococcal conjugate vaccine
89247356|NCT00508742|Active Comparator|2|7 valent pneumococcal conjugate vaccine
89247357|NCT01041885|Experimental|INSTRUCT|INSTRUCT scaffold implantation
89247358|NCT01041963|Active Comparator|Enalapril|
89247359|NCT01041963|Active Comparator|Enalapril plus Losartan|
89247360|NCT01041963|Placebo Comparator|Control|Drug: antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Administration of antihypertensive agents will select as follows : CCB→β-blocker→α-blocker-->hydralazine
89247361|NCT01044225|Active Comparator|Cilengitide EMD 121974|A dose of 2000 mg by iv administration 2 weekly.
89247362|NCT01044225|Active Comparator|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
89247363|NCT00848757|Experimental|Intensive Life-Style Counseling|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the Diabetes Prevention Program (DPP) Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
89247364|NCT00848757|No Intervention|Usual Care Control|Women with pre-diabetes randomized to usual care will be offered 30 minute appointments with a medical provider to review their diagnosis, risk for diabetes, and stress the importance of lifestyle changes to prevent diabetes, including weight loss and exercise and setting individual goals for these. Usual care participants will be encouraged to achieve goals equivalent to the ILI group: to reduce their weight by 7%, and to increase their physical activity to approximately 150 minutes moderate intensity exercise per week. They will be offered a consultation with an FHCHC nutritionist to achieve dietary/weight loss objectives. Participants are offered printed educational materials which are language and literacy-appropriate.
89247365|NCT00508274|Experimental|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
89247366|NCT01016288||22 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 22 G needle
89247367|NCT01016288||25 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 25 G needle
89247368|NCT01038999||A HIV1-infected naive patients|
89247369|NCT01038999||B HIV1-infected patients|in 1st line of ARV therapy for at least 12 months
89247370|NCT01038999||C= control Non infected HIV volunters|
89247371|NCT01042041|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C. Chemoembolization repeats once a month for up to 4 procedures in the absence of disease progression or unacceptable toxicity.
89247372|NCT00499460|Other|Arm I|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
89247373|NCT00499460|Other|Arm II|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
89247374|NCT01010828|Active Comparator|Tri-Vector Approach|
89247375|NCT01010828|Experimental|Mini Mid-Vastus Approach|
89247376|NCT00412113|Active Comparator|Norvasc 5 mg|Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
89247377|NCT00412113|Experimental|Caduet 10/20mg|Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
89247378|NCT00412113|Active Comparator|Norvasc 10 mg|Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
89247379|NCT00412113|Experimental|Caduet 5/20mg|Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
89247380|NCT01014650|Placebo Comparator|IV normal saline|Single IV dose of normal saline as a control for safety and tolerability observations
89247381|NCT01014650|Experimental|IV GLYX-13|Single IV dose of GLYX-13
89247382|NCT01014650|Experimental|SC GLYX-13|Single SC dose
89247383|NCT01042119||Botox|patients who received intravesical injections of botulinum neurotoxin type A
89247384|NCT00411645|Experimental|A|
89247385|NCT00411645|Placebo Comparator|B|
89247386|NCT00490724|Experimental|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
89247387|NCT00490724|Experimental|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
89247388|NCT00490724|Experimental|Nesiritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
89247389|NCT01042197|Active Comparator|2|Body surface area: 12 %
89247390|NCT01042197|Active Comparator|1|Body surface area: 6 %
89247391|NCT01042197|Active Comparator|3|Body surface area: 24 %
89247392|NCT01042197|Active Comparator|4|Body surface area: 6 %
89247393|NCT01042197|Active Comparator|5|Body surface area: 12 %
89247394|NCT01042197|Active Comparator|6|Body surface area: 24 %
89247395|NCT01042197|Active Comparator|7|Body surface area: 6 %
89247396|NCT01042197|Active Comparator|8|Body surface area: 12 %
89247397|NCT01042197|Active Comparator|9|Body surface area: 24 %
89247398|NCT01039077|Active Comparator|Single incision laparoscopic gastric banding|Patients in this group will undergo laparoscopic gastric banding through a single periumbilical incision.
89247399|NCT01039077|Active Comparator|Five port laparoscopic gastric banding|Patients in this group will undergo conventional laparoscopic gastric banding using 5 small incisions.
89247400|NCT01039155|Experimental|Treatment (azacitidine, oxaliplatin)|Patients receive azacitidine IV over 15-30 minutes on days 1-5 and oxaliplatin IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89247401|NCT03835221|Experimental|methafilcon A toric / fanfilcon A toric contact lenses|All subjects will first wear methafilcon A toric contact lenses for four (4) weeks of daily wear, then refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
89247402|NCT01039233|Experimental|Bicalutamide 50 mg Tablet|
89247403|NCT01039233|Active Comparator|Casodex® 50 mg Tablet|
89247404|NCT01042275||TOT|transobturator sling, outside-in (TOT)
89247405|NCT01042275||TVT-O|Tension-free transobturator tape, inside-out (TVT-O)
89247406|NCT01042275||IVS|retropubic Intravaginal Sling (IVS)
89247407|NCT01042275||TVT|retropubic tension-free vaginal tape (TVT)
89247408|NCT01042275||REMEEX|Re-adjustable mechanical external sling (REMEEX)
89247409|NCT00398073|Experimental|mouse gp100 DNA via PMED|patients will be randomized to mouse gp100 DNA delivered via gold particles using the PowderMed delivery system (ND10, described above). Two actuations/day will be administered every two weeks for 4 months for a total of 16 actuations. Each actuation consists of 2 μg of plasmid DNA coated onto 1000 μg of gold. The total dose of plasmid DNA given will be 32 μg DNA on 16,000 μg gold.
89247410|NCT00398073|Experimental|mouse gp100 DNA injections intramuscularly|patients will be injected with 1000 μg of mouse gp100 plasmid DNA intramuscularly. Two injections/day will be administered every two weeks for 4 months (4000 ug of mouse gp100 plasmid/month) for 16 vaccinations.
89247411|NCT00490646|Experimental|Arm A|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
89247412|NCT00490646|Active Comparator|Arm B|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
89247413|NCT01039311||Optical Coherence Tomography|Examine OCT images and compare them to conventional biopsies in same subject.
89247414|NCT01039389|Experimental|Collateral promotion; PCI after 6 months|
89247415|NCT01039389|Experimental|Collateral promotion; PCI at baseline|
89247416|NCT04558827|Experimental|Low Carb / Time Restricted Feeding|Participants will eat a low carbohydrate diet (30-60 grams) in a time restricted feeding window (2 meals within 8 hours) daily for the duration of the study (6 months).
89247417|NCT00388947||1|AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)
89247418|NCT03992937|Experimental|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
89247419|NCT03992937|Active Comparator|LNG-IUS|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.
89247420|NCT01039545|Active Comparator|antibiotic|Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
89247421|NCT01039545|Experimental|symptomatic|Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary
89247422|NCT00490568|Experimental|Rosiglitazone XR|Investigational drug
89247423|NCT00561353|Experimental|TMC435 25 mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with peginterferon alpha-2a (PegIFNα-2a) (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 25 mg once daily coadministered with PR for 28 days (Panel B).
89247424|NCT00561353|Experimental|TMC435 75mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily for 21 days with PegIFNα-2a (P) and ribavirin (R) OR TMC435 75 mg once daily coadministered with PR for 28 days (Panel B).
89247425|NCT00561353|Placebo Comparator|Placebo (Cohort 1/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 25/75 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR and Placebo once daily coadministered with PR for 28 days (Panel B).
89247426|NCT00561353|Experimental|TMC435 200 mg (Cohort 2, Panel A and B)|Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 200 mg once daily coadministered with PR for 28 days (Panel B).
89247427|NCT00561353|Placebo Comparator|Placebo (Cohort 2/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR placebo once daily coadministered with PR for 28 days (Panel B).
89247428|NCT00561353|Experimental|TMC435 75 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
89247429|NCT00561353|Experimental|TMC435 150 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
89247430|NCT00561353|Experimental|TMC435 200 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
89247431|NCT00561353|Placebo Comparator|Placebo (Cohort 4/Panel C)|Treatment-experienced non-responders received placebo once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
89247432|NCT00561353|Experimental|TMC435 200 mg (Cohort 5/Panel D)|Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
89247433|NCT03996746||Non-dialysis Group|non-dialysis patients with CKD 2-5
89247434|NCT03996746||Hemodialysis Group|patients with CKD 5 under hemodialysis for more than 3 months
89247435|NCT00944879||HPV vaccine|Those choosing to receive the HPV vaccine
89247436|NCT00944879||no HPV vaccine|Those choosing not to receive the HPV vaccine
89247437|NCT04383587|Other|Serologic Arm|Enrolled participants will have COVID19 IgG antibody testing performed.
89247438|NCT00944957|Experimental|Raltegravir first|Patients treated with Raltegravir for first 2 weeks
89247439|NCT00944957|Experimental|Efavirenz first|Patients treated with Efavirenz for first 2 weeks
89247440|NCT00945113|Experimental|Treatment group|attendance at one-week speech therapy group
89247441|NCT00945347|No Intervention|Baseline|Visit 1
89247442|NCT00945347|Active Comparator|Miglustat|Nasal instillation of Miglustat (visit 2 or 3)
89247443|NCT00945347|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
89247444|NCT00945425|Experimental|1|Low dose or placebo, twice daily
89247445|NCT00945425|Experimental|2|Low dose or placebo, once daily
89247446|NCT00945425|Experimental|3|Middle dose or placebo, twice daily
89247447|NCT00945425|Experimental|4|High dose or placebo, once daily
89247448|NCT00560885|Experimental|AtriCure Bipolar System|The AtriCure Synergy Bipolar Ablation system is used to create lesions outlined in the Maze IV procedure during a concomitant open cardiac surgical procedure.
89247449|NCT00945503|Experimental|GSK1018921|All subjects will received a dose of GSK1018921 and will peforme three PET scans using the ligand [11C]GSK931145, but in order to obtain adequate sampling of the exposure-time-occupancy curves, a range of doses will be evaluated, and the timing of the post-dose scans will differ between subjects.
89247450|NCT00945581|Experimental|AN777|Powder twice a day
89247451|NCT00945581|Placebo Comparator|Placebo powder|Powder twice a day
89247452|NCT00397215|Experimental|GSK1562902A 1 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
89247453|NCT00397215|Experimental|GSK1562902A 2 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A non-adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
89247454|NCT00397215|Experimental|GSK1562902A 3 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
89247455|NCT00397215|Experimental|GSK1562902A 4 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A non-adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
89247456|NCT01042353|Experimental|E test|
89247457|NCT01042353|Active Comparator|standard culture method|
89247458|NCT01042431||Ward population|Patients hospitalized in the Orthopedics B Ward in the Hillel Yaffe Medical Center that choose to participate in the study
89247459|NCT01042587|Active Comparator|bright light|Bright light has been shown to entrain circadian rhythm so our treatment arm will use thirty minutes of early morning exposure to bright blue light for a four week period.
89247460|NCT01042587|Sham Comparator|red light|Low level red light is a weak entrainment stimulus of circadian rhythm. Elders in the control group will be exposed to low level red light as a placebo for thirty minutes daily for four weeks.
89247461|NCT01039701|Experimental|1|AZD1446 60mg once daily + donepezil 10mg
89247462|NCT01039701|Experimental|2|AZD1446 60mg three times daily + donepezil 10mg
89247463|NCT01039701|Experimental|3|AZD1446 30mg three times daily + donepezil 10mg
89247464|NCT01039701|Placebo Comparator|4|placebo + donepezil 10mg
89247465|NCT03742401|Active Comparator|Surgery|Surgery
89247466|NCT03742401|Active Comparator|HIFU (Echopulse)|HIFU (Echopulse)
89247467|NCT00556439|Experimental|A and C|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to abatacept at this point will be in Group A for giant cell arteritis and Group C for Takayasu arteritis.
89247468|NCT00556439|Placebo Comparator|B and D|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to placebo at this point will be in Group B for giant cell arteritis and Group D for Takayasu arteritis.
89247469|NCT04012229||Patients treated by chemotherapy for an early breast cancer|Patients (Women or Men) older than 18 years old, histologically confirmed invasive early breast cancer, treated by neo-adjuvant and/or adjuvant chemotherapy with the first cure of chemotherapy received between January 1st, 2003 and December 31th, 2013 were included.
89247470|NCT00945737|Active Comparator|Soy protein|
89247471|NCT00945737|Placebo Comparator|Milk protein|
89247472|NCT04012307|Other|Sequence AB|20 subjects assigned to the sequence AB will receive a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in Period 1 and a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89247473|NCT04012307|Other|Sequence BA|20 subjects assigned to the sequence BA will receive a single 32 mg dose of the reference product Atacand® PROTECT (1 x 32 mg tablet), marked as B in the sequence, in Period 1 and a single 32 mg dose of the test product Candesartan Cilexetil (1 x 32 mg tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89247474|NCT00939263||1|cohorts 1 (item weighting phase): 100 children with Eosinophilic Esophagitis, 150 adults with Eosinophilic Esophagitis
89247475|NCT00939263||2|cohorts 2 (evaluation phase): 200 children with Eosinophilic Esophagitis, 200 adults with Eosinophilic Esophagitis
89247476|NCT00941213|Active Comparator|Monopolar Electrosurgery|Preparation during the operation with Monopolar Electrosurgery
89247477|NCT00941213|Experimental|Ultrasound scissors|Preparation during the operation with ultrasound scissors
89247478|NCT00387465|Experimental|Phase I - 30mg/m2 Azacitidine|Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
89247479|NCT00387465|Experimental|Phase I - 40mg/m2 Azacitidine|Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
89247480|NCT00387465|Experimental|Phase II Arm|Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89247481|NCT00945971|Experimental|Physical activity|The intervention group will participate in an exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be performed at the start and in the end of this study.
89247482|NCT00941291||vitrectomy in pseudophakic eyes|
89247483|NCT00941291||vitrectomy and cataract:combined procedure|
89247484|NCT00941291||vitrectomy followed by cataract extraction|
89247485|NCT00941291||vitrectomy on phakic eyes|
89247486|NCT01042665||primary open angle glaucoma|"Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) outside normal limits or pattern standard deviation (PSD) outside 95% normal limits were included."
89247487|NCT01042665||Ocular Hypertensive group|Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam
89247488|NCT00949949|Experimental|Cohort I (everolimus and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and everolimus PO once daily or 3 times weekly.
89247489|NCT00949949|Experimental|Cohort II (everolimus, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 1 hour on days 1 and 8 and everolimus PO once daily or 3 times weekly.
89247490|NCT00949949|Experimental|Cohort III (MTD)|Patients receive treatment as in cohort II.
89247491|NCT00941369|Experimental|1|Insulin glargine: Lantus® (100 U/ml) in TactiPen® re-usable pen
89247492|NCT00941369|Active Comparator|2|Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen
89247493|NCT01042743|Experimental|RAP|individuals who underwent robot-assisted surgery for primary right-sied colon cancer
89247494|NCT01042743|Active Comparator|LAP|Individuals who underwent laparoscopic surgery for primary right-side colon cancer
89247495|NCT00941447|Experimental|Self-Regulation|Self Regulation Arm focuses on increasing participants self-monitoring blood glucose (SMBG) AND awareness of self-regulatory approaches to managing diabetes.
89247496|NCT00941447|Experimental|Self-Monitoring|Self-Monitoring Arm focuses on increasing participants self-monitoring blood glucose (SMBG) and providing nutrition education ONLY.
89247497|NCT00946049|Experimental|Vicryl Plus|
89247498|NCT00946049|Active Comparator|Vicryl|
89247499|NCT00946127||Shunt Arm|Ventriculoperitoneal Shunt
89247500|NCT00946127||ETV arm|Endoscopic Third Ventriculostomy
89247501|NCT00946205|Experimental|Laparoscopic anterior mesh rectopexy|
89247502|NCT00946205|Active Comparator|Laparoscopic posterior rectopexy|
89247503|NCT00950027|Experimental|povidone iodine|Povidone iodine
89247504|NCT00950027|Placebo Comparator|placebo|
89247505|NCT00941525|Other|Ocular hypertensives|"This study includes two groups.~Subjects with ocular hypertension and~Controls. Group 2 undergoes only 1 visit (visit 1) without any intervention. Group 1 undergoes visit 1 without intervention. Then they receive treatment (1 eyedrop of latanoprost (0.005%) dosed once a day in both eyes at 8:00pm for a 4-weeks period for 1 month) and undergo the visit 2 under the effect of treatment."
89247506|NCT00456261|Experimental|Cohort A|Cohort A, will receive bevacizumab 10mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over 10 minutes followed by gemcitabine 1500 mg/m2 by vein over 30-60 minutes. This regimen will be given on day 1 and day 15 of each treatment cycle. Each cycle is 28 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 2 weeks as long as their disease does not worsen.
89247507|NCT00456261|Experimental|Cohort B|Cohort B, will receive bevacizumab 15mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over approximately 10 minutes followed by carboplatin AUC=5 by vein over 30-60 minutes. This regimen will be given on day 1 of each treatment cycle. Each cycle is 21 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 3 weeks as long as their disease does not worsen.
89247508|NCT01042821|Active Comparator|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
89247509|NCT01042821|Active Comparator|Group 2|The flap comprised mucosa, submucosa only
89247510|NCT01042899|Experimental|Teen Online Problem Solving (TOPS)|Web intervention
89247511|NCT01042899|Experimental|Teen Online Problem Solving---Teen Only|Web Intervention
89247512|NCT01042899|Active Comparator|Internet Resources Comparison|Web Intervention
89247513|NCT03993405|Active Comparator|Control group:young|Sixty older subjects will be evaluated in this study.
89247514|NCT03993405|Active Comparator|Control Group:Middle-aged|Sixty middle-aged subjects will be evaluated in this study.
89247515|NCT03993405|Experimental|Experimental group:older|Sixty older subjects will be evaluated in this study.
89247516|NCT00386607|Experimental|Core Treatment|Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
89247517|NCT00386607|Experimental|Extension Treatment|"For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.~The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits."
89247518|NCT00410163|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab every 4 weeks in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 500mg
89247519|NCT00410163|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 monthly infusions with ofatumumab in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 1000mg
89247520|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to <36 months|Participants (aged 6 to <36 months) received a 0.25-milliliter (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89247521|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to <9 years|Participants (aged 3 to <9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
89247522|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 3: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
89247523|NCT03617523|Experimental|Flublok Quadrivalent vaccine Group 4: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.
89247524|NCT03617523|Experimental|Fluzone High-Dose vaccine Group 5: >=65 years|Participants (aged >=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
89247525|NCT00409617|Experimental|Open Label|
89247526|NCT00300274|Experimental|everolimus 1.5 mg|Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
89247527|NCT00300274|Experimental|everolimus 3.0 mg|"Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.~Randomization of new patients in this arm was prematurely stopped as of 27 March 2008 due to high mortality rate, as per Data Monitoring Committee."
89247528|NCT00300274|Active Comparator|mycophenolate mofetil|Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.
89247529|NCT01043289|Experimental|Bright light therapy|Early morning white light @ 7,000 lux for 60 minutes daily (4.2 x 10^5 lux-min) for 5 weeks
89247530|NCT01043289|Placebo Comparator|Dim red light|Early morning dim red light @ 70 lux for 60 minutes daily (3.0 x 10^3 lux-min) for 5 weeks
89247531|NCT01043367|Experimental|A|Deprexil
89247532|NCT01043367|Placebo Comparator|B|Placebo
89247533|NCT01043445|Experimental|GPR119 agonist, 2-oleoyl glycerol|2-oleoyl glycerol; 2g. and vehicle
89247534|NCT01043445|Active Comparator|Oleic acid|oleic acid; 3.2g and vehicle
89247535|NCT01043445|Placebo Comparator|Vehicle|5 ml. of glycerol and 5 ml 96% ethanol
89247536|NCT00299728|Experimental|Arm A; 100 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG|100 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
89247537|NCT00299728|Experimental|Arm B; 400 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG|400 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
89247538|NCT03741946|Other|Triangle of Sedillot identification using ultrasonography|USG probe placed upright at the top of triangle of Sedillot at cricoid level
89247539|NCT00396591|Experimental|Aflibercept|Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met
88804804|NCT00005800|Experimental|Dose-Dense Chemotherapy|Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
89247540|NCT00316264|Experimental|Motavizumab followed by Palivizumab|2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)
89247541|NCT00316264|Experimental|Palivizumab followed by motavizumab|2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
89247542|NCT00316264|Experimental|Motavizumab control|5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
89247543|NCT01325272||preterm newborn|
89247544|NCT01325272||term newborn|
89247545|NCT02532946|Experimental|Bedsider counseling group|Women exposed to: Bedsider.org counseling will be offered a computer or tablet at check-in to clinic. The outcome measure is measured at the patient's surgical abortion procedure appointment, or at medical abortion follow-up, which can range up to 10 days after enrollment
89247546|NCT02532946|No Intervention|Routine counseling group|Women were given counseling in the providers' usual practice style. They were given a card with Bedsider.org's web address along with the counseling.
89247547|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (CNTO 328) (Part 1)|In Part 1, mitoxantrone 12 milligram per square meter (mg/m^2) will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kilogram (mg/kg) intravenously as a 2 hour-infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
89247548|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kg intravenously as a 2-hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
89247549|NCT00385827|Active Comparator|Mitoxantrone+Prednisone (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
89247550|NCT00498602|Experimental|1|ACC-001
89247551|NCT00498602|Other|2|QS-21
89247552|NCT00498602|Other|3|Diluent: Phosphate Buffered Saline
89247553|NCT00498602|Experimental|4|ACC-001
89247554|NCT00507728|Experimental|Bupropion|Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).
89247555|NCT00507728|Experimental|Varenicline|Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).
88804805|NCT00386386|Other|1|Subject receives two infusions: One by EASI Access and one by IV access, at different sites
89247556|NCT00507728|Placebo Comparator|Placebo|Placebo by mouth for 12 weeks.
89247557|NCT00498368|Experimental|Rituximab Plus ACE/ARB|Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
89247558|NCT00498368|Active Comparator|ACE/ARB|ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
89247559|NCT04460066|Experimental|PD-L1 group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 4 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
89247560|NCT04460066|Placebo Comparator|placebo group|All patients will receive 4 cycles of placebo ( IV, every 3 weeks) , concurrently with 4 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).
89247561|NCT00385671|Active Comparator|Pregabalin|Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US & Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US & Germany) or 150 mg BID (Canada), PO for 10 weeks.
89247562|NCT00385671|Experimental|Duloxetine|Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.
89247563|NCT00385671|Experimental|Gabapentin + Duloxetine|Stable Gabapentin (GAB) + Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then stable GAB + DLX 60 mg QD, PO for 11 weeks.
89247564|NCT00497198|Experimental|MCI-196|
89247565|NCT00497198|Placebo Comparator|Placebo|
89247566|NCT00496964|Experimental|1|Injection of Botulinum toxin A into vastus lateralis of study limb plus exercise program
89247567|NCT00496964|Placebo Comparator|2|Placebo injection + exercise
89247568|NCT05076578|Experimental|Evaluate the harvesting of micografts in healthy and patients with chronic wounds|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
89247569|NCT01011062|Experimental|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
89247570|NCT01011062|Experimental|Losartan + hyperinsulinaemia|
89247571|NCT01011062|Placebo Comparator|Saline|Infusion of Saline as a volume control intervention
89247572|NCT01016366|Experimental|Lu AA24493|
89247573|NCT01016366|Placebo Comparator|Placebo|
89247574|NCT03996980|Experimental|Custom-made foot orthoses|treatment intervention custom-made polypropylene foot orthoses for a period of 4 weeks
89247575|NCT03996980|Placebo Comparator|Placebo|a flat insole for a period of 4 weeks
89247576|NCT00490490|Experimental|Tositumomab + XRT + KI|Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)
89247577|NCT04431830|Experimental|Meaning-Centered Pain Coping Skills Training|Four, 45-60 minute, videoconference-delivered sessions focus on training participants in cognitive and behavioral skills (e.g., guided imagery) for managing pain.
89247578|NCT04431830|No Intervention|Standard Care|Information and referrals for free services available through the Duke Cancer Patient Support Program.
89247579|NCT04420364|Experimental|Maintenance of Immunosuppression|Maintenance of immunosuppression (defined as no change to pre-admission immunosuppression, or reduction in anti-metabolite by up to 50% (to a minimum of MMF 500 mg per day or azathioprine 50 mg per day)
89247580|NCT04420364|Active Comparator|Reduction of Immunosuppression|Reduction of immunosuppression (defined as anti-metabolite withdrawal plus reduction of tacrolimus or cyclosporin, to a minimum target trough concentration of 3 ng/mL for tacrolimus and 50 ng/mL for cyclosporin).
89247581|NCT01014884|Other|Control Group|The control group will receive usual care as provided by your Health Plan.
89247582|NCT01014884|Other|Intervention group|Additional visits will be conducted by a member of the multidisciplinary team (case manager/nurse, social worker and/or pharmacist that will be either face to face or by telephone.
89247583|NCT01011140||Online Survey|Survey of Palliative care physicians from Latin America and Spain
89247584|NCT01014962|Experimental|Albaconazole 400 mg cohort 1|Albaconazole 400 mg
89247585|NCT01014962|Placebo Comparator|Placebo cohort 1|Placebo once daily
89247586|NCT01014962|Experimental|Albaconozole 400 mg cohort 2|Albaconozole 400 mg every 12 hours
89247587|NCT01014962|Placebo Comparator|Placebo cohort 2|Placebo every 12 hours
89247588|NCT01014962|Experimental|Albaconozole 400 mg cohort 3|Albaconozole 400 mg every 8 hours
89247589|NCT01014962|Placebo Comparator|Placebo cohort 3|Placebo every 8 hours
89247590|NCT05058248|Active Comparator|Pudendal block|Ultrasound-guided bilateral pudendal block at the start of surgery, in gynecological position: injection of 15 mL of 0.475% Naropein in each ischiorectal fossa.
89247591|NCT05058248|Other|the standard method|Operated and anesthetized patients according to the standard method within the department
89247592|NCT05049980|Experimental|Medical treatment|Patients choosing medical treatment with Mifégyne® and MisoOne®
89247593|NCT05049980|Active Comparator|Surgical treatment|Patients choosing surgical treatment by endo-uterine aspiration.
89247594|NCT01039779|Active Comparator|Lower-extremity exercise training|This training will be tailored by physical therapists for each participant. A series of exercises will be applied to increase the stability of the trunk muscles and to strengthen the leg muscles.
89247595|NCT01039779|Active Comparator|Tai chi exercise|Yang-style tai chi with 18 movements will be taught every week over the 6-month intervention period at a subject's residence by tai chi instructors
89247596|NCT01016444||Albuterol responsive|Those who respond clinically to albuterol.
89247597|NCT01016444||Albuterol unresponsive|Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
89247598|NCT01016522|Experimental|KetoCal|KetoCal tube feeding formula
89247599|NCT01015040|Active Comparator|solifenacin succinate tablet (fasting)|
89247600|NCT01015040|Experimental|solifenacin succinate suspension (fasting)|
89247601|NCT01015040|Experimental|solifenacin succinate suspension (fed)|
89247602|NCT04388618||covid19 positive patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested positive
89247603|NCT04388618||covid19 negative patients|participants who present with signs and symptoms suspected for covid19 and swabbed/tested negative
89247604|NCT01039857|Other|Structured solution focused therapy|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy
89247605|NCT01039857|Experimental|Integrative clarification therapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
89247606|NCT00495794|Experimental|Pharmacist management|Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing)
89247607|NCT00495794|No Intervention|Usual care|Eligible patients receive usual care
89247608|NCT01011296|Experimental|Single IV Dose 1|
89247609|NCT01011296|Experimental|Single IV Dose 2|
89247610|NCT01011296|Experimental|Single IV Dose 3|
89247611|NCT00495170|Experimental|Concurrent proton and Chemotherapy|Proton Radiotherapy + Carboplatin + Paclitaxel
89247612|NCT03853148|Active Comparator|Otago|The Otago exercise program consists of the following: 1) A series of warm-up exercises, 2) Select exercises from the 17 Otago exercises which challenge the participant's strength and balance for up to 30 minutes, three times a week, 3) A walking program for up to 30 minutes, three times a week. Each Otago will be tailored for each participant's ability level.
89247613|NCT03853148|Active Comparator|Otago + Gentle yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the Otago+GYYB group each exercise and their perceived benefits.
89247614|NCT03853148|Active Comparator|Otago + GYYB + Behavioral activation|This condition will incorporate Otago and GYYB as above and will also include behavioral activation to address motivation and affect. Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities. Each participant outlines general values and specific behaviors that 'demonstrate' each value, compiling a list of the latter. This list is then used to generate 10 to 20 highly defined values-based, reinforcing activities. Next, this list is combined with the activities outlines in Otago and GYYB and this master list is used to schedule these values-based activities for the next two days.
89247615|NCT03853148|Experimental|Caregiver Gentle yoga & yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the GYYB group each exercise and their perceived benefits.
89247616|NCT01043601|Experimental|Inhaled PT005 7.2 µg|
89247617|NCT01043601|Experimental|Inhaled PT005 9.6 µg|
89247618|NCT01043601|Placebo Comparator|Inhaled Placebo|
89247619|NCT01043601|Active Comparator|Formoterol Fumarate 12 µg (Foradil Aerolizer)|
89247620|NCT01043679|Active Comparator|Seroquel|Efficacy and Safety of Seroquel
89247621|NCT01043679|Active Comparator|Utapine|Efficacy and Safety of Utapine
89247622|NCT01044615||Mild traumatic brain injury patients|Subjects who have a verifiable diagnosis of mild traumatic brain injury sustained within 24 months prior to enrollment
89247623|NCT01044615||Normal Control|Normal, healthy adults with no history of brain injury.
89247624|NCT00408993|Experimental|Duloxetine|60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)
89247625|NCT00408993|Placebo Comparator|Placebo|Placebo every day (QD), by mouth (PO) for 12 weeks
89247626|NCT00395967|Experimental|All Patients|Patients who were predicted to be unable to mobilize a minimum number of cells (≥2*10^6 CD34+ cells/kg) in 3 apheresis days when given granulocyte colony-stimulating factor (G-CSF) alone and who were eligible for autologous peripheral blood stem cell transplantation.
89247627|NCT03993093||HIV with OIs|Treatment naive HIV patients with OIs
89247628|NCT00395733|Experimental|Gadobutrol, then Gadopentate dimeglumine|Period 1: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged; Period 2: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged
89247629|NCT00395733|Experimental|Gadopentate, dimeglumine then Gadobutrol|Period 1: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged; Period 2: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged
89247630|NCT00441987|Experimental|Single Dose of GSI-953|
89247631|NCT00395343|Experimental|1|sitagliptin
89247632|NCT00395343|Placebo Comparator|2|Placebo
89247633|NCT00560573|Experimental|1|
89247634|NCT00950105|Experimental|CPSI-2364 1 mg p.o.|Single dose
89247635|NCT00950105|Experimental|CPSI-2364 10 mg p.o.|single dose
89247636|NCT00950105|Experimental|CPSI-2364 30 mg p.o.|single dose
89247637|NCT00950105|Experimental|CPSI-2364 90 mg|single dose
89247638|NCT00950105|Experimental|CPSI-2364 270 mg p.o.|single dose
89247639|NCT00946283|Experimental|Lactobacillus GG|Open label trial of Culturelle (Lactobacillus GG) administered to patients after engraftment, post allogeneic stem cell transplantation.
89247640|NCT00946361||Diagnostic|
89247641|NCT00941837|Experimental|Olive Oil|
89247642|NCT00941837|Experimental|Coconut oil|
89247643|NCT00941837|Experimental|Palm Olein|
89247644|NCT00946517||Parents|Parents or caregivers of type 1 diabetics
89247645|NCT00946517||Child|Type 1 diabetics
89247646|NCT00950261|Experimental|tri-weekly cisplatin|Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
89247647|NCT00946595|Active Comparator|efavirenz/emtricitabin/tenofovir|
89247648|NCT00946595|Experimental|lopinavir/ritonavir|
89247649|NCT00942071|Experimental|1. MVA-NP+M1 ID|12 volunteers to receive MVA-NP+M1 via ID route
89247650|NCT00942071|Experimental|2. MVA-NP+M1 IM|16 volunteers to receive MVA-NP+M1 via IM route
89247651|NCT00942071|Experimental|3. MVA-NP+M1 IM upper age group|30 volunteers to receive MVA-NP+M1 via IM route
89247652|NCT03961529|Experimental|0.3% OPA-15406 ointment|Twice daily
89247653|NCT03961529|Experimental|1% OPA-15406 ointment|Twice daily
89247654|NCT00494780|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
89247655|NCT00494780|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg
89247656|NCT01011452|Active Comparator|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
89247657|NCT01011452|Placebo Comparator|Placebo|
89247658|NCT00490022|Active Comparator|1|DHT gel (70 mg/day) for one month
89247659|NCT00490022|Placebo Comparator|2|Placebo gel for one month
89247660|NCT01011530|Experimental|MLN4924|MLN4924 via IV infusion
89247661|NCT00493454|Experimental|Ibritumomab tiuxetan + Rituximab|Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.
89247662|NCT00493220|Experimental|HYLENEX SC, Placebo SC, IV|subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
89247663|NCT00493220|Experimental|HYLENEX SC, IV, Placebo SC|subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
89247664|NCT00493220|Experimental|Placebo SC, HYLENEX SC, IV|subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
89247665|NCT00493220|Experimental|Placebo SC, IV, HYLENEX SC|subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
89247666|NCT00493220|Experimental|IV, HYLENEX SC, Placebo SC|IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
89247667|NCT00493220|Experimental|IV, Placebo SC, HYLENEX SC|IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
89247668|NCT00950339|Experimental|4 weeks of omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
89247669|NCT00950339|Experimental|4 weeks of famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
89247670|NCT00950339|Experimental|4 weeks of pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
89247671|NCT00942227|Active Comparator|Extension oriented treatment approach|Extension exercises. Subjects are instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to further increase extension movement and/or reduction of symptoms.
89247672|NCT00942227|Experimental|Mechanical traction plus extension-oriented treatment|Mechanical lumbar traction will be utilized in addition to extension oriented exercises. Subjects are also instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to increase extension movement and/or reduce radicular symptoms.
89247673|NCT01011608|Experimental|Medical Food Supplement|Medical food supplement to be given in divided portions in morning, afternoon and evening
89247674|NCT01011608|Active Comparator|standard hospital food|standard hospital diet
89247675|NCT00950417|Experimental|Esophageal Cancer|
89247676|NCT03996902|Experimental|Tailored intervention|Brief Motivational Smoking Intervention
89247677|NCT03996902|Experimental|Control|Intervention consistent with standard clinical practice (Control)
89247678|NCT00946673|Experimental|vorinostat & stereotactic radiosurgery|
89247679|NCT00394953|Experimental|MIRCERA|Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA [RO0503821]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of <40, 40-80, and >80 mcg, respectively.
89247680|NCT00394953|Active Comparator|Darbepoetin Alfa|Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.
89247681|NCT00946751|Experimental|1|Levetiracetam Tablets, 750 mg (Sandoz Inc.)
89247682|NCT00946751|Active Comparator|2|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
89247683|NCT00485732|Experimental|Cervarix Group|
89247684|NCT00485732|Placebo Comparator|Placebo Group|
89247685|NCT01043055||Breast Cancer Patients|
89247686|NCT01043055||Healthy Control Group|
89247687|NCT00489554|Experimental|Synflorix Vaccine Group|Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
89247688|NCT00408681|Experimental|Arm I|Patients receive oral lithium carbonate once or twice daily. Treatment continues for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
89247689|NCT01040013|Experimental|Laparoscopy|Laparoscopic Left-Sided Colectomy
89247690|NCT01040013|Active Comparator|laparotomy|Laparotomic Left-Sided Colectomy
89247691|NCT00560417|Active Comparator|ILPS|Insulin Lispro Protamine Suspension (ILPS)
89247692|NCT00560417|Active Comparator|Glargine|Insulin Glargine
89247693|NCT01044927|Experimental|Proactive Integrated Care|COPD-specific education, self-management instruction, remote monitoring and enhanced communication with a coordinator
89247694|NCT01044927|Active Comparator|Standard Care Control|No intervention other that measurements taken at 0, 3, 6 and 9 months of the study.
89247695|NCT01040091|Active Comparator|HIV-Infected Participants|HIV-infected participants will receive FTC, TDF, and EFV for 60 days by prescription from their physicians. Participants will receive Truvada (FTC/TDF) and EFV for the first 30 days. After Day 30, participants may switch to the TDF/FTC/EFV co-formulation through Day 60 as directed by their physician.
89247696|NCT01040091|Active Comparator|HIV-Uninfected Participants|HIV-uninfected participants will receive Truvada (FTC/TDF) for 30 days.
89247697|NCT00942383||IOUS-USEI|Receive intraoperative ultrasound (IOUS) using the Siemens Anteras to acquire ultrasound elasticity imaging (USEI) during standard of care surgical radiofrequency ablation and microwave ablation
89247698|NCT00950495|Active Comparator|Mandibular advancement device (MAD)|an MAD is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
89247699|NCT00950495|Active Comparator|nasal CPAP|The device is turned on, and the nasal mask is placed on the nose prior to sleep. After waking up in the morning, the device is turned off and the mask is removed
89247700|NCT00950495|Placebo Comparator|placebo|the placebo appliance is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
89247701|NCT00942461|Active Comparator|Laparoscopic Surgery group|Group of patients that are operated with laparoscopic approach
89247702|NCT00942461|Active Comparator|Open surgery Group|Group of patients operated with open approach
89247703|NCT00946907|Active Comparator|aspirin|
89247704|NCT00946907|Placebo Comparator|placebo|
89247705|NCT00942539|Experimental|Midazolam|Administration of Midazolam prior Lumbar Puncture
89247706|NCT00947063|Experimental|1|Promethazine HCl 50 mg Tablets (Sandoz, Inc)
89247707|NCT00947063|Active Comparator|2|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
89247708|NCT00950573||hemodialysis|patients treated with conventional hemodialysis
89247709|NCT00950573||peritoneal dialysis|patients treated with peritoneal dialysis
89247710|NCT00950573||nocturnal hemodialysis|patients treated with frequent nocturnal hemodialysis
89247711|NCT00950573||kidney transplantation|patients treated with renal transplantation
89247712|NCT00942617|Experimental|40 mg non-enteric coated aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
89247713|NCT00345345|Experimental|Alemtuzumab in patients with T cell large granular lymphocytic leukemia (T-LGL)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
89247714|NCT03968159|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
89247715|NCT03968159|Placebo Comparator|Placebo|Placebo tablets
89247716|NCT01045005|Active Comparator|Type 1 Diabetes|Subjects with type 1 diabetes mellitus who are administered oxygen and carbon dioxide
89247717|NCT01045005|Active Comparator|Control Subjects|Healthy volunteers administered oxygen and carbon dioxide via respiratory apparatus
89247718|NCT00947141|Experimental|Group A|"Group A: (low level infection) has 2 arms:~Start treatment when 2 consecutive levels CMV PCR >200copies / ml~Monitor (Treatment starts when CMV PCR >3,000 copies / ml (current site clinical protocol))"
89247719|NCT00947141|Experimental|Group B|"Group B: (patients receiving pre-emptive therapy) has 2 arms:~Stop treatment when 2 levels CMV PCR <3,000 copies / ml~Monitor (Treatment stops when there are 2 consecutive levels of CMV PCR <200 copies / ml (current site clinical protocol))"
89247720|NCT03966911|Other|Subjects with diabetes wearing Guardian™ Sensor (3)|Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.
89247721|NCT03966365|Experimental|PRO-122|- Dosage: 1 drop every 12 hours, in both eyes
89247722|NCT03966365|Active Comparator|Krytantek Ofteno®|- Dosage: 1 drop every 12 hours, in both eyes
89247723|NCT02007239|Experimental|treatment|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
89247724|NCT00375219|Experimental|omacetaxine|Treatment was the same for all cohorts: induction therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 14 consecutive days every 28 (±3) days for up to 6 cycles. Maintenance therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 7 consecutive days every 28 (±3) days for up to 3 years.
89247725|NCT03965351|Experimental|Probenecid|the study medication (probenecid) as well as a placebo.
89247726|NCT03965351|Placebo Comparator|Placebo|placebo compared to probenecid
89247727|NCT00947375|Experimental|Starch|In these study participants are randomly (by chance) assigned for two treatment arms of a clinical trial.
89247728|NCT00947375|No Intervention|Lifestyle councelling|May be required to comply with US Public Law 110-85, Section 801
89247729|NCT00942695|Other|base|average American diet without pistachios
89247730|NCT00942695|Active Comparator|1.5PD|average American diet plus 1.5 oz per day pistachios
89247731|NCT00942695|Active Comparator|3.0PD|average American diet plus 3.0 oz per day pistachios
89247732|NCT00947453|Experimental|montelukast group|Identified patients with asthma to recieve Montelukast 10 mg (Merck Sharp & Dohme Ltd, Herts, UK) at 0800 am once daily for 8 weeks.
89247733|NCT00554801|Experimental|Blast|The study group includes soldiers who have recently been exposed to a high-explosive blast while stationed in Iraq or Afghanistan. They will be recruited at Walter Reed Army Medical Center, Washington, DC. They will undergo audiological testing.
89247734|NCT00554801|Active Comparator|Control|Control group are subjects matched to the experimental group by age, gender, and hearing loss, but who have not been exposed to a blast. They will undergo the same audiological testing as the experimental group
89247735|NCT00942773|Active Comparator|CYP2C19 extensive metabolizer|
89247736|NCT00942773|Active Comparator|CYP2C19 heterozygous extensive metabolizer|
89247737|NCT00942773|Active Comparator|CYP2C19 poor metabolizer|
89247738|NCT00942929||Adolescents hospitalized for anorexia nervosa|Adolescent 12-18 years old, fulfilling the DSM IV criteria for anorexia nervosa, hospitalized for medical stabilization and/ or initiation of refeeding
89247739|NCT00942929||Controls|Adolescents 12-18 years old without anorexia nervosa hospitalized for reasons other than those involving the respiratory system and with no underlying lung disease
89247740|NCT00947609||HIV-infected and HIV-uninfected children|HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.
89247741|NCT00947687|Experimental|PUR003|
89247742|NCT00947687|Placebo Comparator|Placebo|
89247743|NCT00943007|Active Comparator|Conventional Neuronavigation|Standard form of neuronavigation: based on preoperative MRI without intraoperative correction for brain shift
89247744|NCT00943007|Experimental|Intraoperative MRI|Standard neuronavigation plus intraoperative MRI to correct for brain shift
89247745|NCT00943085|Experimental|Family-focused therapy|Participants will receive family-focused therapy.
89247746|NCT00943085|Active Comparator|Brief educational treatment|Participants will receive one session of diagnostic feedback, recommendations for continued treatment, and crisis intervention as needed.
89247747|NCT04279769|Experimental|Cohort 1|CB-280 twice daily at 50 mg for 14 days
89247748|NCT04279769|Experimental|Cohort 2|CB-280 twice daily at 100 mg for 14 days
89247749|NCT04279769|Experimental|Cohort 3|CB-280 twice daily at 200 mg for 14 days
89247750|NCT04279769|Experimental|Cohort 4|CB-280 twice daily at 400 mg for 14 days
89247751|NCT04279769|Placebo Comparator|Placebo|Placebo twice daily for 14 days
89247752|NCT00374907|Experimental|Saxagliptin (A)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
89247753|NCT00374907|Placebo Comparator|Placebo (ST) / Metformin (LT) (B)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
89247754|NCT00374127|Experimental|marijuana blunt|marijuana blunt (0%, 1.8%, or 3.6% THC)
89247755|NCT00374127|Experimental|marijuana cigarette|marijuana cigarette (0%, 1.8%, or 3.6% THC)
89247756|NCT01040247|Experimental|Day 0 Embryo Transfer|Embryo transfer will be performed on the same day as oocyte aspiration and fertilization
89247757|NCT01040247|Active Comparator|Day 2,3 Embryo Transfer|Embryo Transfer will be performed 2 or 3 days after oocyte aspiration and fertilization
89247758|NCT01045785||aspirin responsive|PFA Col/EPI normal
89247759|NCT01045785||aspirin resistance|PFA Col/epi showed resistance
89247760|NCT01045083|Experimental|1|
89247761|NCT01040325|Experimental|Active|358 subjects receive a two vaccination regimen with an LT patch
89247762|NCT01040325|Placebo Comparator|Placebo|358 subjects receive a two vaccination regimen with placebo patch
89247763|NCT01045239|Experimental|Micropulse 577 nm yellow diode laser|
89247764|NCT01045239|Active Comparator|532 nm green diode laser|
89247765|NCT01045317|Experimental|intravenous or oral administration|
89247766|NCT01045863|Experimental|PART A: Ascending Cohorts|Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)
89247767|NCT01045863|Experimental|PART B: Food effect|Food effect on PF-03382792 PK
89247768|NCT01045863|Experimental|PART C: CSF Cohort|Optional CSF Cohort
89247769|NCT03081585||Healthy Controls|Normal weight, healthy female participants
89247770|NCT00553787|Experimental|VI-0521 Top|high dose experimental treatment
89247771|NCT00553787|Experimental|VI-0521 Mid|mid dose experimental treatment
89247772|NCT00553787|Placebo Comparator|Placebo|Placebo
89247773|NCT00947843|Placebo Comparator|aspirin+placebo|aspirin protect (Bayer) 100mg + placebo clopidogrel 75mg for 1mo
89247774|NCT00947843|Active Comparator|aspirin+pregrel|pregrel is a generic brand name of clopidogrel
89247775|NCT00947843|Active Comparator|Aspirin+Plavix|plavix is a original brand name of clopidogrel
89247776|NCT00943475|Active Comparator|anaesthesia, circumcision|
89247777|NCT00947921|Active Comparator|Plasty|Patients treated with restrictive Annuloplasty
89247778|NCT00947921|Active Comparator|Prosthesis|Patients treated with valve replacement
89247779|NCT00947999||Healthy Control Group|Subjects in particular group will not have a diagnosis of SCI and do not experience chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
89247780|NCT00947999||Subjects with SCI and Chronic Pain|Individuals recruited into this particular group will have a diagnosis of a spinal cord injury and experience pain on a daily basis with an average intensity of 4 out of 10 on a 0-10 scale.
89247781|NCT00947999||Subjects with SCI and No Chronic Pain|Subjects in particular group will have a diagnosis of SCI and not have chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
89247782|NCT00948077|Active Comparator|Treatment A|"Study agents (Rifater+EMB) will be given approximately 45 minutes prior to the breakfast."
89247783|NCT00948077|Experimental|Treatment B|"Study agents (Rifater+EMB) will be given approximately 45 minutes after the breakfast is finished."
89247784|NCT00407745|Placebo Comparator|matched placebo|
89247785|NCT00407745|Experimental|pregabalin|flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period
89247786|NCT00948233||Intervention|Educational video game
89247787|NCT00948233||Standard Care|Pamphlets on stopping tobacco use
89247788|NCT00948467|Experimental|TAK-733|
89247789|NCT03958955|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 6 weeks
89247790|NCT03958955|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 6 weeks
89247791|NCT00951119|Experimental|resperate device|"Resperate© is a device that helps to slow down breathing. This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest. Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©. By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim<10 breathings per minute)."
89247792|NCT00951119|Sham Comparator|control device|Resperate device without slowing of breathing
89247793|NCT00464334|Experimental|Placebo to V950/IMX 0 mcg|Participants receive Placebo to V950/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247794|NCT00464334|Experimental|Placebo to V950/IMX 16 mcg|Participants receive Placebo to V950/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247795|NCT00464334|Experimental|V950 0.5 mcg/IMX 0 mcg|Participants receive V950 0.5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247796|NCT00464334|Experimental|V950 0.5 mcg/IMX 16 mcg|Participants receive V950 0.5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247797|NCT00464334|Experimental|V950 0.5 mcg/IMX 47 mcg|Participants receive V950 0.5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247798|NCT00464334|Experimental|V950 0.5 mcg/IMX 94 mcg|Participants receive V950 0.5 mcg/IMX 94 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247799|NCT00464334|Experimental|V950 5 mcg/IMX 0 mcg|Participants receive V950 5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247800|NCT00464334|Experimental|V950 5 mcg/IMX 16 mcg|Participants receive V950 5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247801|NCT00464334|Experimental|V950 5 mcg/IMX 47 mcg|Participants receive V950 5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247802|NCT00464334|Experimental|V950 50 mcg/IMX 0 mcg|Participants receive V950 50 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247803|NCT00464334|Experimental|V950 50 mcg/IMX 16 mcg|Participants receive V950 50 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
89247804|NCT00951197||elderly subjects retired from agriculture|
89247805|NCT00951353||Pediatric Renal Transplant Recipients|
89247806|NCT00951431|Experimental|PPI|
89247807|NCT00951431|Placebo Comparator|Control|
89247808|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (FOLLICULAR)|Follicular
89247809|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (DLBCL)|Diffuse Large B-cell Lymphoma
89247810|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (REFRACTORY)|Refractory Aggressive NHL
89247811|NCT00951587|Experimental|1|Patients that are indicated for colonoscopy or who are suspected or known to suffer from colonic diseases.
89247812|NCT00943553|Experimental|1|
89247813|NCT00943553|Experimental|2|
89247814|NCT04011917||Caseload group|
89247815|NCT04011917||Prediction group|
89247816|NCT00453180|Experimental|1|Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.
89247817|NCT00453180|Placebo Comparator|2|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
89247818|NCT00943709|Experimental|Arm I|Patients with goal blood glucose 80-14 mg/dL receive the Robert Wood Johnson Hospital IV insulin infusion protocol followed by insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4 weeks.
89247819|NCT00943709|Active Comparator|Arm II|Patients with goal blood glucose < 250 mg/dL are started on subcutaneous insulin sliding scale at the discretion of the treating physician with blood glucose monitoring and adjustment according to the insulin sliding scale.
89247820|NCT00948545||No treatment|Observing individuals pre and post bariatric surgery
89247821|NCT00951743|Experimental|Adaptavir Treatment|MDAPTA (Adaptavir) will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
89247822|NCT00951743|Placebo Comparator|Placebo|Placebo will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
89247823|NCT00464178|Experimental|Bortezomib and bevacizumab|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
89247824|NCT00560105|Active Comparator|Acapella|The Active Comparator is the Acapella, a OPEP device
89247825|NCT00560105|Experimental|Lung Flute|The Active Comparator is the Lung Flute, a new indication of this device
89247826|NCT00467610|Experimental|Panhematin|
89247827|NCT00316186|Experimental|Single arm, open label|
89247828|NCT04011761|Active Comparator|Experimental Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
89247829|NCT04011761|No Intervention|Control Arm|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the control arm will receive treatment prescribed by pediatricians.
89247830|NCT00948623|Experimental|1|
89247831|NCT00948623|Sham Comparator|2|
89247832|NCT01065220|Experimental|hormone treatment for MtF|"cyproterone acetate~estradiol~alpha-5-reductase-inhibitor"
89247833|NCT01065220|Experimental|hormone treatment for FtM|"testosterone undecanoate~lynestrenol"
89247834|NCT00943865|Active Comparator|hypocaloric diet + exercise advice|Group 1 (control: tailored hypocaloric diet and exercise advised): patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant. Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
89247835|NCT00943865|Experimental|pragmatic diet+ pedometer 10000 steps|Group 2 (pragmatic diet + step counter) - Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control. Subjects were provided with pedometers and were instructed to perform at least 10.000 steps daily, diary recorded.
89247836|NCT00943865|Experimental|pragmatic diet + fitness|Group 3 (pragmatic diet + fitness) - They received the same diet intervention (low carbohydrates, high protein and vegetables style diet and favoring daily brazilian cook habits colored handbook) and hand sized portion control instructions of group 2. They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions.
89247837|NCT02532712|Experimental|Single dose group-Group 1-Experimental|Single dose, 500mg of Study drug(EC-18)
89247838|NCT02532712|Placebo Comparator|Single dose group-Group 1-Placebo|Single dose, 500mg of Placebo
89247839|NCT02532712|Experimental|Single dose group-Group 2-Experimental|Single dose, 1000mg of Study drug(EC-18)
89247840|NCT02532712|Placebo Comparator|Single dose group-Group 2-Placebo|Single dose, 1000mg of Placebo
89247841|NCT02532712|Experimental|Single dose group-Group 3-Experimental|Single dose, 2000mg of Study drug (EC-18)
89247842|NCT02532712|Placebo Comparator|Single dose group-Group 3-Placebo|Single dose, 2000mg of Placebo
89247843|NCT02532712|Experimental|Single dose group-Group 4-Experimental|Single dose, 4000mg of Study drug (EC-18)
89247844|NCT02532712|Placebo Comparator|Single dose group-Group 4-Placebo|Single dose, 4000mg of Placebo
89247845|NCT02532712|Experimental|Multiple dose group-Group 1-Experimental|Multiple dose, Study drug(EC-18) 500mg, Once daily, for 14 days
89247846|NCT02532712|Placebo Comparator|Multiple dose group-Group 1-Placebo|Multiple dose, Placebo 500mg, Once daily, for 14 days
89247847|NCT02532712|Experimental|Multiple dose group-Group 2-Experimental|Multiple dose, Study drug(EC-18) 1000mg, Once daily, for 14 days
89247848|NCT02532712|Placebo Comparator|Multiple dose group-Group 2-Placebo|Multiple dose, Placebo 1000mg, Once daily, for 14 days
89247849|NCT02532712|Experimental|Multiple dose group-Group 3-Experimental|Multiple dose, Study drug(EC-18) 2000mg, Once daily, for 14 days
89247850|NCT02532712|Placebo Comparator|Multiple dose group-Group 3-Placebo|Multiple dose, Placebo 2000mg, Once daily, for 14 days
89247851|NCT02532712|Experimental|Multiple dose group-Group 4-Experimental|Multiple dose, Study drug(EC-18) 4000mg, Once daily, for 14 days
89247852|NCT02532712|Placebo Comparator|Multiple dose group-Group 4-Placebo|Multiple dose, Placebo 4000mg, Once daily, for 14 days
89247853|NCT00948701|Experimental|Phone-based PA program (RTR Plus)|"The PA intervention consists of PA counseling, matched to participants' motivational readiness, plus educational materials. RTR volunteers or coaches will be asked to contact participants by telephone once a week for 12 weeks. The purpose of these calls is to build a supportive relationship with the participant, monitor PA participation, identify any health concerns, assist the participant to identify relevant barriers to PA and help her to problem solve to overcome such barriers."
89247854|NCT00948701|Active Comparator|Standard RTR services (RTR)|RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR. The volunteers will also review the educational materials sent to all participants receiving RTR services. This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
89247855|NCT01065298||Group 1:Stem cell Recipient|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4U/Kg for blood glucose control. They will undergo stem cell therapy initialy and G-CSF therapy at 2 months
89247856|NCT01065298||Group-2: Controls|Type 2 Diabetes mellitus patients on full doses of vildagliptin+metformin+pioglitazone and on Insulin >0.4U/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1.
89247857|NCT00943943|Experimental|G-CSF and Plerixafor with Sorafenib|G-CSF 10 mcg/kg adjusted body weight subcutaneous injection. Plerixafor fixed dose of 240 mcg/kg adjusted body weight subcutaneous injection in abdomen. Patients will receive the 1st doses of G-CSF and Plerixafor on day 1. G-CSF and Plerixafor every other day for 7 total doses, repeated every 28 days. Sorafenib starting dose 400 mg twice daily orally after G-CSF/Plerixafor injections.
89247858|NCT00948779|Other|antibiotics|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the use of antibiotics at home.
89247859|NCT00948779|Experimental|the antipyretic therapy|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the antipyretic therapy at home.
89247860|NCT00453102|Experimental|Zevalin + Rituximab|Ibritumomab Tiuxetan (Zevalin) + Rituximab
89247861|NCT00944099|Experimental|Grazing|participants will be given an eating frequency prescription to eat every 2 to 3 hours
89247862|NCT00944099|Experimental|Three Meals|participants will be given an eating frequency prescription of eating 3 meals per day
89247863|NCT00299182|Experimental|1 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
89247864|NCT00299182|Experimental|3 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
89247865|NCT00299182|Experimental|10 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
89247866|NCT00299182|Placebo Comparator|Placebo (Arm A & Arm B) with Chemotherapy|"Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy~Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
89247867|NCT00299182|Experimental|1 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
89247868|NCT00299182|Experimental|3 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
89247869|NCT00299182|Experimental|10 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
89247870|NCT00467142|Experimental|Folfiri and Bevacizumab|"Premedication = Dexchlorpheniramine, 5 mg in slow Direct IntraVeinous (DIV) on D1.~FOLFIRI (simplified LV5FU2 + irinotecan):~Irinotecan (Campto®): 180 mg/m² on D1 by IV infusion in 250 mL of 0.9% saline over 90 minutes.~LV5FU2, in its so-called simplified version, will be administered as follows L-folinic acid, as a 2-hour intravenous infusion, at a dose of 200 mg/m², on Day 1, in 500 mL of 5% glucose solution, concomitantly with the irinotecan infusion via a Y-tube, followed by 5 Fluorouracil (5 FU), intravenous bolus, at a dose of 400 mg/m² on D1, followed by 5 Fluorouracil (5 FU) as a 46-hour continuous infusion at a dose of 2400 mg/m² from D1 to D3, either in 1000 mL of 5% glucose solution, or in an electric syringe or pump dispenser~Bevacizumab (Avastin®): 5 mg/kg IV infusion in 100 mL of 0.9% saline over 90 minutes for the first infusion, then 60 minutes for the second infusion if tolerated, and 30 minutes for subsequent infusions if tolerated."
89247871|NCT00951977||Subjects who have formerly donated a kidney|
89247872|NCT00951977||Matched community control Subjects|
89247873|NCT01065376|Experimental|on the day of hCG|cabergoline administration for 8 days on the day of hCG.
89247874|NCT01065376|Experimental|on the day after oocyte retrieval|cabergoline administration for 8 days on the day after oocyte retrieval
89247875|NCT05300789||pT4 colon cancer patients after curative resection|
89247876|NCT00949091|Experimental|1|
89247877|NCT00553475|Placebo Comparator|Placebo|
89247878|NCT00553475|Experimental|Pregabalin 300 mg/day|
89247879|NCT00553475|Experimental|Pregabalin 600 mg/day|
89247880|NCT00329602|Placebo Comparator|Double-blind for 12 to 26 Weeks|Double-blind (Ropinirole:Placebo) for 12 to 26 weeks
89247881|NCT00329602|Other|Open-label ropinirole for 40-Weeks|Open label ropinirole for 40 weeks
89247882|NCT01060696|Experimental|Hyoscine, Mefenamic acid, Placebo|Blind randomization to three groups. Mefenamic acid group Hyoscine group Placebo group
89247883|NCT01065610|Experimental|Oxytocin|Intranasal Oxytocin, 24 IU
89247884|NCT01065610|Placebo Comparator|Placebo|
89247885|NCT01062646|Experimental|Multimodal music therapy|Multimodal music therapy comprises 16 sessions single music therapy, group music therapy (max. 6 children/group), parent-child sessions, and parent counseling. The manualized treatment integrates music therapy, behavioral interventions, and family-oriented interventions.
89247886|NCT01062646|Active Comparator|community treatment as usual|
89247887|NCT00949169||Carrotid IMT group according to maximal IMT|We defined increased IMT group as whom had maximal IMT ≥ 1.0 mm.
89247888|NCT00313846|Experimental|BTDS|Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
89247889|NCT00313846|Placebo Comparator|Placebo|Placebo to match BTDS 5, 10 or 20 mcg/h
89247890|NCT00949247|Experimental|Docetaxel,Carboplatin,Trastuzumab and Bevacizumab|
89247891|NCT00551135|Experimental|3|
89247892|NCT00551135|Placebo Comparator|4|
89247893|NCT00551135|Experimental|2|
89247894|NCT00551135|Experimental|1|
89247895|NCT00944255||RA with drug|
89247896|NCT00944255||RA without drug|
89247897|NCT00952055||Patients diagnosed with acute coronary syndrome (ACS)|
89247898|NCT00944333|Experimental|Clopidogrel 6|6 month dual antiplatelet therapies in patients after second generation DES implantation
89247899|NCT00944333|Experimental|Clopidogrel 12|12 month dual antiplatelet therapies in patients after second generation DES implantation
89247900|NCT01529801|Experimental|Roughness group A|Osseotite Certain Tapered Group A
89247901|NCT01529801|Experimental|Roughness Group B|Osseotite Certain Tapered Group B
89247902|NCT01529801|Experimental|Roughness Group C|Osseotite Certain Tapered Group C
89247903|NCT00949481|Experimental|Supply|In each country, this arm will be comprised of women attending family planning clinics within the 5 facilities randomized to this group.
89247904|NCT00949481|Experimental|Demand|In each country, this arm will be comprised of women attending immunization clinics within the 5 facilities randomized to this group.
89247905|NCT00949481|No Intervention|Control|In each country, this arm will be comprised of women attending family planning and immunization clinics in 5 facilities randomized to this group.
89247906|NCT04012385|No Intervention|Control|Subjects assigned to control group receives only a booklet including the recommendations for a correct diet by the Italian National Institute for Research on Food and Nutrition (INRAN), presently called (CRA-NUT) .
89247907|NCT04012385|Experimental|Intervention|"Subjects assigned to the intervention group will follow a nutritional pathway based on a Mediterranean diet pattern for 4 months and receive suggestions on the regular practice of physical activity, under the guide of some nutritionists, who will propose individualized diets for each subject.~All subjects of both groups will undergo urologic examination, measurement of weight, height and abdominal circumference, an interview on demographic data and lifestyle variables, and will provide blood and semen samples in fasting conditions, at the enrollment (baseline), at the end of the intervention phase (after 4 months) and at the end of follow-up (after 8 months)."
89247908|NCT00944489||1|Patients with diagnosis of essential hypertension under the criteria established by the Joint National Committee VII (9) and those patients under pharmacological treatment with the same therapeutic regime during at least the last 6 months.
89247909|NCT00956423|Experimental|moderate-intensity exercise training|
89247910|NCT00956423|Active Comparator|low-intensity stretching|
89247911|NCT00949637|Experimental|Scouting curricular implementation|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
89247912|NCT00949637|Active Comparator|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
89247913|NCT00299104|Experimental|Rituximab (0.5 g x 2) + Methotrexate|Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
89247914|NCT00299104|Experimental|Rituximab (1.0 g x 2) + Methotrexate|Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
89247915|NCT00299104|Placebo Comparator|Placebo + Methotrexate|"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.~From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks."
89247916|NCT03979690|Experimental|Subjects Receiving Colonoscopy|Subjects receiving tandem colonoscopies using the NISInspire-C System followed by a Conventional Colonoscopy
89247917|NCT03979456|Active Comparator|6-month dosing interval|This arm is receiving standard dose rituximab 500 mg every 6 months
89247918|NCT03979456|Experimental|12-month dosing interval|This arm is receiving the comparator dose rituximab 500 mg every 12 months
89247919|NCT00313612|Experimental|Treatment (oxaliplatin plus topotecan)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.
89247920|NCT00507416|Experimental|Bortezomib and Dexamethasone (VD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
89247921|NCT00507416|Experimental|Bortezomib, Thalidomide, and Dexamethasone (VTD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .
89247922|NCT00507416|Experimental|Bortezomib, Melphalan and Prednisone (VMP)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
89247923|NCT00489476|Experimental|1.25 mg Staccato Loxapine|1.25 mg ADASUVE, single dose
89247924|NCT00489476|Experimental|2.5 mg Staccato Loxapine|2.5 mg ADASUVE, single dose
89247925|NCT00489476|Experimental|5 mg Staccato Loxapine|5 mg ADASUVE, single dose
89247926|NCT00489476|Experimental|Staccato Placebo|Staccato Placebo, 0 mg
89247927|NCT00550745|Experimental|1|Arm 1: vaccine
89247928|NCT00550745|Placebo Comparator|2|Arm 2: Placebo Comparator
89247929|NCT00956579||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study"
89247930|NCT00956579||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
89247931|NCT00949793|Experimental|All patients|
89247932|NCT00952601|Experimental|Modified Atkins Diet|Patients are started on the modified Atkins diet at 15 grams per day.
89247933|NCT00956735|Experimental|Pistachio Diet|Incorporates 3.0 oz (2 servings) of pistachios into a daily diet
89247934|NCT00956735|No Intervention|Non-Pistachio|Does not incorporate pistachios into a daily diet
89247935|NCT04216043|Experimental|RUSF skimmed milk powder|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
89247936|NCT04216043|Experimental|RUSF milk protein concentrate and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
89247937|NCT04216043|Experimental|RUSF soy protein and whey permeate|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
89247938|NCT04216043|Experimental|RUSF soy and sucrose|RUSF will provide 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child, to feed it in addition to their usual diet, and to use daily portions.
89247939|NCT00956891||group A|autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)
89247940|NCT00956891||group B|only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation.
89247941|NCT00952679|Experimental|experimental arm|
89247942|NCT00952757||1.|Patients diagnosed of schizophrenia or bipolar disorder with APS-related hyperprolactinaemia who have been switched to quetiapine based on the clinician's judgement
89247943|NCT00956969|Experimental|Anger awareness and expression|Training for anger awareness and expression
89247944|NCT00956969|Active Comparator|Relaxation Training|Teach patients relaxation training
89247945|NCT00956969|No Intervention|No-treatment control|Assessment only control condition
89247946|NCT00952835||asthma and rhinitis control|
89247947|NCT00957125|Experimental|Epirubicin Docetaxel Bevacizumab|"Epirubicin and docetaxel i.v. infusion q 3 weeks for 2 cycles.~If complete response this treatment continues for 4 cycles, totally 6 cycles.~If partial response or stable disease, epirubicin and docetaxel and bevacizumab i.v. infusion q 3 weeks for 4 cycles.~If progressive disease after the first 2 cycles individualized treatment."
89247948|NCT04327583|Experimental|Coordinated pharmaceutical path|Patients treated with anti-cancer oral therapy who benefit a specific pharmaceutical follow-up by the healthcare facilities pharmacist and by the dispensary pharmacist
89247949|NCT04327583|No Intervention|Standard of care|Patients treated with anti-cancer oral therapy who who do not benefit from an additional pharmaceutical intervention
89247950|NCT04295837|Experimental|ABLE - A Better everday LifE|A home-based occupational therapy intervention addressing ADL task performance issues among persons living with chronic conditions. The ABLE intervention is occupation-focused and -based, and follows a structured process of assessment, goalsetting, intervention and evaluation.
89247951|NCT04295837|Active Comparator|Usual care|Community-based occupational therapy addressing ADL task performance issues among persons living with chronic conditions
89247952|NCT00957203|Experimental|Istradefylline|
89247953|NCT00952913|Experimental|1|Bosutinib
89247954|NCT00952913|Experimental|2|bosutinib + lansoprazole
89247955|NCT00957281||Asthma|Asthma patients on inhaled corticosteroids
89247956|NCT00957437|Experimental|Part A: 3 way crossover|AZD1305: ER test formulation 1 (w/wo food) and reference formulation
89247957|NCT00957437|Experimental|Part B1: single arm|AZD1305: ER test formulation 1
89247958|NCT00957437|Experimental|Part B2: 3 way crossover|AZD1305: ER test formulation 2 (w/wo food) and reference formulation
89247959|NCT00957749|Experimental|cPMP|
89247960|NCT00953303|Experimental|glucocorticoid|
89247961|NCT00953303|Active Comparator|Standard care|
89247962|NCT05300555|Experimental|Rivaroxaban group|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
89247963|NCT05300555|Experimental|Warfarin group|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
89247964|NCT04010669|Active Comparator|Study group|The study group includes participants who will receive somatostatin postoperatively (after liver resection).
89247965|NCT04010669|Placebo Comparator|Control group|The control group includes participants who will receive placebo (a 24 hours infusion of 1000ml Normal Saline solution 0.9%) postoperatively (after liver resection).
89247966|NCT04010591||UDS group|All enrolled patients with urodynamic study
89247967|NCT04263311|Experimental|Community Health Workers (CHW) treatment group|There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.
89247968|NCT04263311|No Intervention|Control group|There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes
89247969|NCT00957983|Active Comparator|BGC20-1531 200mg|
89247970|NCT00957983|Placebo Comparator|sugar pill|
89247971|NCT00957983|Active Comparator|BGC20-1531 400mg|
89247972|NCT05299463|Other|Exercise|
89247973|NCT00452790|Experimental|A|
89247974|NCT00452790|Active Comparator|B|
89247975|NCT00953381|Experimental|5 mg ilaprazole|
89247976|NCT00953381|Experimental|10 mg ilaprazole|
89247977|NCT00953381|Experimental|20 mg ilaprazole|
89247978|NCT00953381|Active Comparator|20 mg omeprazole|
89247979|NCT05300477|Experimental|Acetazolamide|Acetazolamide (orally) 250 mg twice a day for 3 1/2 days.
89247980|NCT05300477|Experimental|Erythropoietin and Acetazolamide|Erythropoietin (subcutaneously) 50 IU /kg three times a week for 4 weeks. After the 4 week Erythropoietin, acetazolamide (orally) 250 mg twice a day for 3 1/2 days.
89247981|NCT00953537|Other|capecitabine|
89247982|NCT00463788|Experimental|cisplatin and cetuximab|
89247983|NCT00463788|Active Comparator|cisplatin|
89247984|NCT00548249|Placebo Comparator|0 µg iron/dL of dialysate|Placebo 0 micrograms (µg) of iron/ deciliter (dL) of dialysate
89247985|NCT00548249|Experimental|5 µg iron/dL of dialysate|5 micrograms (µg) of iron/ deciliter (dL) of dialysate
89247986|NCT00548249|Experimental|10 µg iron/dL of dialysate|10 micrograms (µg) of iron/ deciliter (dL) of dialysate
89247987|NCT00548249|Experimental|12 µg iron/dL of dialysate|12 micrograms (µg) of iron/ deciliter (dL) of dialysate
89247988|NCT00548249|Experimental|15 µg iron/dL of dialysate|15 micrograms (µg) of iron/ deciliter (dL) of dialysate
89247989|NCT00463476|Experimental|2-year olds|Healthy children 2 years of age (±3 months) who had previously received all vaccinations recommended under the Sri Lankan childhood immunization schedule according to their age. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12 and 13 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
89247990|NCT00463476|Experimental|5-year olds|Healthy children 5 years of age (±3 months) that met all other eligibility criteria. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12, 13, and 24 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
89247991|NCT01025466|Active Comparator|rivastigmine patch monotherapy|
89247992|NCT01025466|Active Comparator|Combination therapy with memantine|
89247993|NCT00958061||Vietnam-Era Women Veterans|For this study we will use a cohort of women who are on a roster of Vietnam Era women veterans (4,644 Vietnam, 1,213 near Vietnam, 5,465 non-Vietnam) previously identified and characterized by a review of their military personnel records and link it to a list of 8,061 women who presumably served in Southeast Asia. This final cohort could potentially contain approximately 14,000 women. After deceased individuals are removed from the active cohort and contact information is updated, we estimate that there could be approximately 10,000 women to whom the informed consent and mailed survey will be initially mailed.
89247994|NCT03910296||Acceptance & Commitment Therapy|"Acceptance & Commitment Therapy (ACT) use acceptance, mindfulness, commitment, and behavior change strategies to increase psychological flexibility.~Each subject will participate for 6 sessions of Acceptance & Commitment Therapy (ACT).~ACT trains patients to reframe their unpleasant, negative, private events while encouraging personal values."
89247995|NCT04857918|Experimental|Social identity informed virtual running group|Participants will join running groups of six people (males and females) for eight weeks. Each running group will be given the group goal/challenge to collectively run/brisk walk the distance across the province of British Columbia (940 km) over the course of the eight week intervention (Estabrooks et al., 2008), and encouraged to complete 150 minutes of moderate-to-vigorous exercise per week. Participants can record other moderate-to-vigorous exercise to contribute to the group goal. Running groups will be created on the fitness application Strava, and participants will record/post their runs on the Strava app so that members of their running group can provide 'kudos' and words of encouragement. Running groups will have a weekly a coffee chat (via Zoom) to socialize and discuss their experiences running/exercising and progress and challenges associated with meeting the group goal. Participants will also be provided running tip videos, phone armbands, and t-shirts with the study logo.
88804806|NCT01268527|Experimental|Cohort 1|Three concentrations of E6201 topical gel (0.03%, 0.1%, and 0.2%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. The 3 concentrations of E6201 gel were dosed first in Cohort 1 to establish the safety and tolerability prior to dosing in Cohort 2.
89247996|NCT04857918|Active Comparator|Attention control group|This group of participants will act as an attention control condition. This group will be asked to download the fitness application Strava to their smartphone, and track all of their runs and walks on Strava. Similar to the intervention group, participants will be provided with phone armbands to carry their phone during a run or walk so they can record the run or walk on Strava, and will be asked to try participating in 150 minutes of moderate-to-vigorous exercise per week.
89247997|NCT01025544|Active Comparator|Arm 1|
89247998|NCT01025544|Active Comparator|Arm 2|
89247999|NCT03839940|Experimental|Group I (dexamethasone)|Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks.
89248000|NCT03839940|Placebo Comparator|Group II (placebo)|Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks.
89248001|NCT01027494||Treatment|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, 4 drops in outer ear canal of infected ear(s) while awake 2 times per day for 7 days
89248002|NCT01027494||Healthy|No intervention
89248003|NCT01027572|Experimental|Thalamic stimulation|Patients in Vegetative or Minimally Conscious State
89248004|NCT03839628|Experimental|Reduced Physical Activity|Participants will reduce their physical activity levels for 2-weeks by approximately 75% of their baseline level of physical activity
89248005|NCT00462462|Experimental|1|Ethanol gel
89248006|NCT00462462|Active Comparator|2|Ethanol solution
89248007|NCT00462384|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
89248008|NCT00462306||Pregnant population|The study group consisted of pregnant women, presenting to Prentice Women's Hospital of Northwestern Memorial Hospital for spontaneous labor, induction of labor, and scheduled cesarean delivery.
89248009|NCT00462306||Non-Pregnant Population|The study group consisted of non-pregnant females, presenting to Northwestern Memorial Hospital for ambulatory surgery
89248010|NCT03776370||Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
89248011|NCT03776370||The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery
89248012|NCT01566474|Experimental|Melatonin + omeprazole|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
89248013|NCT01566474|Active Comparator|omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
89248014|NCT01025778|Experimental|Remission induction and haplo-SCT|Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.
89248015|NCT03576300||control|subjects without dry eye and diabetes
89248016|NCT03576300||patients with diabetes and dry eye|diabetic patients with dry eye
89248017|NCT03576300||diabetics without dry eye syndrome|diabetic patients without dry eye
89248018|NCT03576300||dry eye syndrome patients without diabetes|non-diabetic patients with dry eye
89248019|NCT00443430|Active Comparator|Methotrexate Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone
89248020|NCT00443430|Active Comparator|Methotrexate-Etanercept-Prednisolone Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks
89248021|NCT01022658|Active Comparator|detemir|Insulin detemir at dinner or bedtime
89248022|NCT01022658|Active Comparator|aspart|Insulin aspart before each meal
89248023|NCT01022658|Active Comparator|detemir and aspart|
89248024|NCT01025856|Active Comparator|high fibre/low glycemic index diet - P A|patients will follow for two months a diet high fibre/low glycemic index without physical activity program
89248025|NCT01025856|Active Comparator|Rich in MUFA diet - PA|Patients will follow for two months a rich in MUFA diet without a physical activity program.
89248026|NCT01025856|Active Comparator|high fibre/low glycemic index diet+PA|Patients will follow for two months a high fibre and low glycemic index diet associated with a physical activity program.
89248027|NCT01025856|Active Comparator|Rich in MUFA diet+PA|Patients will follow for 2 months a rich in MUFA diet with a physical activity program.
89248028|NCT01022736|Experimental|gabapentin|patients scheduled for cardiac bypass surgery will be administered gabapentin (600mg, orally). Blood will be drawn and plasma gabapentin levels determined 1 hour before surgery, 10 minutes into surgery, 10 minutes before separation from bypass, 30 minutes following bypass, and then before and 2 hours after each dose of gabapentin.
89248029|NCT01022814||Pregnant woman|
89248030|NCT01025934|Active Comparator|7 days|
89248031|NCT01025934|Active Comparator|20 days|
89248032|NCT01025934|Sham Comparator|sham|
89248033|NCT01022892||Phase 1 - Pilot phase|Total of 10 patients currently undergoing EVAR Surveillance. These 10 patients include 5 patients with endoleak known from a recent CT scan and 5 patients with no endoleak and shrinking aneurysm.
89248034|NCT01022892||Phase 2 - Blinded from CT Scan|This phase of study involves recruitment of 150 patients currently under post-EVAR surveillance. The physicians and ultrasound technologists will be blinded to the result of the CT Scan when performing and interpreting the CUS. The current schedule for EVAR Surveillance will be maintained so that an individual may receive more than one enhanced CT Scan and CUS during the 18 months of the study.
89248035|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training using software packages donated by Posit Science.
89248036|NCT01027962|No Intervention|Control Intervention|Commercially available computer games that do not contain violent stimuli but are appealing to youth between 10 and 19 years of age.
89248037|NCT01027962|No Intervention|Healthy Control Group|No participation in computer activity.
89248038|NCT01026090|Experimental|Dronedarone pre-cardioversion|Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
89248039|NCT01026090|Placebo Comparator|Placebo pre-cardioversion|Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
89248040|NCT01028040|Experimental|AZD3043|
89248041|NCT01028118|Other|Therapy for Women reporting violence|Asking about life experience with violence and Cognitive Behavior Therapy.
89248042|NCT03891654|Experimental|Dynamic Contrast Enhanced Computed Tomography|DCE-CT, also known as perfusion CT, is a functional imaging modality that uses repeated computed tomography imaging after injection of an iodine based contrast agent.
89248043|NCT00460746|Experimental|001|TMC125, Darunavir; RitonavirTMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
89248044|NCT01026246|Experimental|Group B: 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
89248045|NCT01026246|Experimental|Group A: 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
89248046|NCT01026246|Experimental|Group C: 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
89248047|NCT01028196||1 - schizophrenia|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with schizophrenia as they routinely attend the clinic or are examined in hospital in a consecutively manner.
89248048|NCT01028196||2 - recurrent depression|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with recurrent depression as they routinely attend the clinic or are examined in hospital in a consecutively manner.
89248049|NCT01028274|Placebo Comparator|Placebo|
89248050|NCT01028274|Experimental|Investigational Product 1|
89248051|NCT01028274|Experimental|Investigational Product 2|
89248052|NCT00443118|Active Comparator|Neopuff TM with PEEP|Newborns ventilated for neonatal resuscitation using Neopuff TM with PEEP
89248053|NCT00443118|Active Comparator|Self Inflating Bag with PEEP|Newborns ventilated for neonatal resuscitation using Self Inflating Bag with PEEP valve attached
89248054|NCT00443118|Active Comparator|Self Inflating Bag without PEEP|Newborns ventilated for neonatal resuscitationusing Self Inflating Bag without PEEP valve attached
89248055|NCT00460434|Experimental|1|Tension-free Vaginal Tape (TVT) surgery
89248056|NCT00460434|Sham Comparator|2|Sham Tension-free Vaginal Tape (TVT) surgery
89248057|NCT01023048|Experimental|PGD testing|
89248058|NCT01026558|Active Comparator|Ceftobiprole (not morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
89248059|NCT01026558|Experimental|Ceftobiprole (morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
89248060|NCT01023126|No Intervention|EO|Exercise three times a week, one under supervision and two freely chosen by the participant
89248061|NCT01023126|Experimental|EGT|Exercise three times a week, one under supervision and two freely chosen by the participant
89248062|NCT01025700|Experimental|Cesemat|
89248063|NCT01025700|No Intervention|Placebo|
89248064|NCT00373425|Experimental|Erlotinib|Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
89248065|NCT00373425|Placebo Comparator|Placebo|Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
89248066|NCT00459342|Experimental|Arm I|Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
89248067|NCT03510156|Experimental|Treatment|
89248068|NCT03510156|No Intervention|Observation|
89248069|NCT00443040|Placebo Comparator|Placebo|
89248070|NCT00443040|Active Comparator|Asimadoline 1.0 mg|Asimadoline 1.0 mg b.i.d.
89248071|NCT00443040|Active Comparator|Asimadoline 3.0 mg|Asimadoline 3.0 mg b.i.d.
89248072|NCT00442962|Experimental|EFV + FTC/TDF|Participants will efavirenz (600mg in pill form, taken orally, once daily) and emtricitabine/tenofovir disoproxil fumarate (200/300mg in pill form, taken orally, once daily), for 48 weeks
89248073|NCT03995160|Active Comparator|Total knee replacement with use of closed suction drainage|Use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
89248074|NCT03995160|Active Comparator|Total knee replacement without use of closed suction drainage|Without the use of closed suction drainage following total knee replacement in treatment of knee primary osteoarthritis
89248075|NCT01028508|Active Comparator|PHARM|lithium and venlafaxine
89248076|NCT01028508|Experimental|STABLE|ECT + VLF + Li
89248077|NCT01026636|Experimental|Ceftobiprole|Ceftobiprole 7mg/kg - 15mg/kg per day as 2h infusion
89248078|NCT00313300|Active Comparator|A1|
88806085|NCT01895738|No Intervention|Standard of Care|Standard of Care is typically a sheet of community resources potentially handed out by the emergency physician, nurse or social worker.
89248079|NCT00313300|Experimental|A2|
89248080|NCT00313300|Placebo Comparator|A3|
89248081|NCT00313300|Experimental|A4|
89248082|NCT01023282|Experimental|ACR325|
89248083|NCT01023282|Placebo Comparator|Placebo|
89248084|NCT00459186|Experimental|RAD001 Followed by RAD001 + Docetaxel|RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.
89248085|NCT01026714|Experimental|flurbiprofen 50mg po|
89248086|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inducer|
89248087|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inhibitor|
89248088|NCT03996252|Experimental|Combination treatment arm|Combination of calcipotriene 0.005% foam (Sorilux) and Fluorouracil Cream, 5% USP (generic) applied for four consecutive nights for the treatment of scalp actinic keratoses.
89248089|NCT00328510|Experimental|GTC Frame|Participant undergoes SRT using a GTC frame to immobilize the participant's heading during radiation therapy
89248090|NCT00328510|Experimental|BrainLab thermoplastic mask|Participant undergoes SRT using the BrainLab thermoplastic mask to immobilize the participant's head during radiation therapy
89248091|NCT00459108|Experimental|Oral Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89248092|NCT00458484|Experimental|Series 1: Stereotactic radiosurgery|Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy.
89248093|NCT00458484|Experimental|Series 2: Stereotactic radiosurgery|Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each.
89248094|NCT00328198|Experimental|Dose escalation|Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated).
89248095|NCT00328198|Experimental|No escalation|Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered subcutaneously at alternating injection sites 3 times per week for up to 18 weeks.
89248096|NCT01322880|Other|Control Arm|The project, administered by the International Rescue Committee (IRC), involved 25 village savings and loans association (VSLA) groups across the province. The VSLA groups initially formed through local members of the community designated as community based facilitators (CBF).
89248097|NCT01322880|Experimental|Treatment Group|"Half of the VSLA participants were invited to participate in an additional set of discussion groups to be attended along with their spouse. All participants were informed that due to space constraints, only half of the members would be able to attend. In each VSLA, individuals drew numbers from a bag or hat, and those with winning slips were the ones who entered the discussion groups with spouses."
89248098|NCT01028586|Active Comparator|Arm 1|Number of Cycles: until progression or unacceptable toxicity develops.
89248099|NCT01028586|Active Comparator|Arm 2|Number of Cycles: until progression or unacceptable toxicity develops.
89248100|NCT01028586|Placebo Comparator|Arm 3|Placebo
89248101|NCT03457350|Experimental|office hysteroscopy|Office hysteroscopy 30 degrees 2.6 mm telescope with an outer sheath of 3.2 mm (Storz Co., Tutlingen, Germany). Hysteroscopy is performed as usual by proper examination of the vagina and the ectocervix for any abnormality followed by introduction of the hysteroscope into the cervical canal. At this step, the hysteroscopist waits for a while until the distending fluid forms a micro-cavity. At this point, the telescope is advanced with necessary rotatory movements of the 30 degrees telescope guided by the vision of the dark spot which is the internal os. If it is reached, again waiting for some time to allow fluid distension of the internal os area.
89248102|NCT03457350|Experimental|blind cervical probing|Cervical probing is started with a 2 mm probe after grasping the cervix with a multi-tooth tenaculum put anteriorly or posteriorly according to prior transabdominal or transvaginal sonographic examination of the cervical canal. If the probe succeedes to bypass the internal os, a higher caliber probe is used. Thereafter, a uterine sound (4mm = 1.33 Fr) is introduced into the endometrial cavity. Lastly, gentle cervical dilatation up to Hegar's 8 is performed as usual with classic leaving each dilator for 30 seconds inside the internal os. If probes couldn't bypass the internal os, the procedure is considered failed. If the probe enters a cavity other than endometrial cavity, a false passage is considered.
89248103|NCT01065688|Active Comparator|Roux-en Y|Roux-en Y reconstruction after distal gastrectomy
89248104|NCT01065688|Experimental|Billroth-I|Billroth-I reconstruction after distal gastrectomy
89248105|NCT00450450|Experimental|Arm I|Patients undergo filgrastim (G-CSF)-stimulated allogeneic bone marrow transplantation on day 0.
89248106|NCT00450450|Active Comparator|Arm II|Patients undergo conventional allogeneic bone marrow transplantation on day 0.
89248107|NCT03440892||1|
89248108|NCT00442572|Experimental|PEGASYS|Participants received 4 treatment cycles of continuous intermittent treatment with PEGASYS® (Peginterferon alfa-2a) . Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
89248109|NCT00442572|No Intervention|No Intervention|Participants were on non- specific anti-viral treatment.
89248110|NCT04898322|Experimental|2.5mg SY-005|
89248111|NCT04898322|Experimental|5mg SY-005|
89248112|NCT04898322|Experimental|10mg SY-005|
89248113|NCT04898322|Placebo Comparator|Placebo|
89248114|NCT01322958||At Risk of Ectopic Pregnancy|Women who present to the emergency department at UCSF who are at risk of ectopic pregnancy.
89248115|NCT01323036|Experimental|Krill Oil|
89248116|NCT01323036|Experimental|Fish Oil|
89248117|NCT01023360|Experimental|Clopidogrel and proton pump inhibitors|all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
89248118|NCT01023438|Experimental|Assisted uptitration|Uptitration of recommended drugs by primary care physician with specialist support
89248119|NCT01023438|Active Comparator|Usual care|Usual communication strategy from cardiologist to primary care physician
89248120|NCT00442416|Experimental|RO0503821|Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) subcutaneously (SC) every month for eight months (6 months of titration period [TP] and two months of evaluation period [EP] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of >=10.0 gram per decilitre (g/dL) and <=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
89248121|NCT00442416|Active Comparator|Epoetin Alfa|Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.
89248122|NCT01023594|Active Comparator|External stent|Feeding tube insert at pancreatojejunostomy site as a stent. And stent tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall.
89248123|NCT01023594|Active Comparator|Internal stent|short(5cm)internal stent insertion at pancreatojejunostomy site
89248124|NCT00441792|Experimental|Etomidate|
89248125|NCT00441792|Experimental|midazolam|
89248126|NCT00312208|Experimental|1|Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -> T)
89248127|NCT00312208|Experimental|2|Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
89248128|NCT00297778|Experimental|pramipexole|A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.
89248129|NCT00297778|Placebo Comparator|placebo|Placebo (matching) tablets
89248130|NCT03848832|Experimental|5 milligrams per kilogram per day (mg/kg/day) GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution. Taken twice daily (morning and evening).
89248131|NCT03848832|Experimental|15 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
89248132|NCT03848832|Placebo Comparator|Placebo|Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).
89248133|NCT01026480||IPAA Patients|Patients who have had their IPAA procedures performed by Dr. Becker
89248134|NCT00450372|Experimental|ADI-PEG 20|
89248135|NCT00327340|Experimental|OGX-011 / mitoxantrone/prednisone|OGX-011 / mitoxantrone/prednisone: OGX-011 administered in combination with mitoxantrone and prednisone
89248136|NCT00327340|Experimental|OGX-011/docetaxel/prednisone|OGX-011/docetaxel/prednisone: OGX-011 administered in combination with docetaxel and prednisone
89248137|NCT00548093|Experimental|1|descriptive: adenocarcinoma histology
89248138|NCT00548093|Experimental|2|descriptive: non-adenocarcinoma histology
89248139|NCT01062724|No Intervention|Trophamine|This group of neonates will be receive the Trophamine amino acids solution from Pisa laboratories as an active comparator with Primene. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
89248140|NCT01062724|Experimental|Primene 10% from Baxter|This group of neonates will be receive the Primene amino acids solution (10 %) from Baxter laboratories as other active comparator with Trophamine. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
89248141|NCT05299385|Active Comparator|Comparator|"The investigator provide conventional-treatment to subjects when distributing respiratory rehabilitation education leaflets, Investigators explain the leaflets and self-practice until the subjects fully understand them. Compactor conducts respiratory rehabilitation treatment for 12 weeks according to the following procedures at home~☞ The investigator shall contact the subject every two weeks during the respiratory rehabilitation period and encourage them to perform respiratory rehabilitation treatment according to the assigned group. Subjects perform respiratory rehabilitation exercises at home.~They have to visit hospital at 8 weeks (visit 3) and 12 weeks (visit 4) and then examine the factor of the outcome measure following the clinical protocol"
89248142|NCT05299385|Experimental|Experimental treatment|"Subjects install software as a medical device for clinical trials on smart-phones, so that the subject can perform respiratory rehabilitation treatment at home.~Respiratory rehabilitation treatment for 12 weeks~☞ Respiratory rehabilitation treatment using a mobile-based software, consists of aerobic exercise and anaerobic exercise, and the subject performs themselves~They have to visit hospital at 8 weeks (visit 3) and 12 weeks (visit 4) and then examine the factor of the outcome measure following the clinical protocol"
89248143|NCT00958139|Experimental|Permethrin treatment of clothing|0.5% permethrin sprayed one time on uniform shorts, pants, and socks
89248144|NCT00958139|Sham Comparator|Placebo|Water sprayed on uniform shorts, pants, and socks
89248145|NCT00450216|Experimental|1|HZT-501: Ibuprofen 800mg/famotidine 26.6mg
89248146|NCT00450216|Active Comparator|2|Ibuprofen 800mg
89248147|NCT01566006|No Intervention|control group|group receiving the conventional treatment for DN
89248148|NCT01566006|Experimental|cellcept group|additional to the conventional treatment patients will receive cellcept
89248149|NCT01566006|Experimental|carnitine group|aside to the conventional treatment patients will receive carnitine
89248150|NCT01566006|Experimental|PDE5 group|aside to the conventional treatment patients will receive PDE5 inhibitor
89248151|NCT05300165|Other|Normal population|20 participants representing a normal population will include a daily beer in their meals, changing the kind of beer every 2 weeks from alcohol-free lager beer, lager beer, or dark beer.
89248152|NCT00441480|Active Comparator|Plant sterol esters|plant sterols esterified to fish oil fatty acids
89248153|NCT00441480|Placebo Comparator|placebo|Corn oil
89248154|NCT00958451|Active Comparator|Paricalcitol|Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
89248155|NCT00958451|Active Comparator|Ergocalciferol|Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
89248156|NCT03372408||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
89248157|NCT03372174|Experimental|Mechanical ventilation group|patients with mechanical ventilation during cardiopulmonary bypass for cardiac surgery
89248158|NCT03372174|Active Comparator|Control group|patients without mechanical ventilation during cardiopulmonary bypass for cardiac surgery
89248159|NCT05352191|Active Comparator|Beclomethasone|800 ug inhaled once aday for 8 days
89248160|NCT05352191|Placebo Comparator|Placebo|one pill once aday for 8 days
89248161|NCT01028664|Experimental|Glaucoma or ocular hypertension patients|
89248162|NCT00954005|Experimental|Rituximab, Gemcitabine and Oxaliplatin|Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle
89248163|NCT01023750||Fenofibrate|
89248164|NCT05300009|Experimental|topical methotrexate hydrogel 1% coupled with microneedling|patients who will receive topical methotrexate hydrogel 1% coupled with microneedling
89248165|NCT05300009|Active Comparator|cryotherapy|patients who will receive cryotherapy
89248166|NCT05352113|Experimental|acupuncture + SSRIs group|This group will include 40 patients with MDD who will be treated with acupuncture and SSRIs antidepressants. Acupoints related to MDD will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
89248167|NCT05352113|Experimental|acupuncture + placebo group|This group will include 40 patients with MDD who will be treated with acupuncture and a placebo. Acupoints related to MDD will be stimulated. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
89248168|NCT05352113|Experimental|sham acupuncture + SSRIs group|This group will include 40 patients with MDD who will be treated with sham acupuncture and SSRIs antidepressants. The sham acupuncture will be needled on the points 1cm lateral to acupoints. The oral dose of SSRIs antidepressants will be determined by the clinical specialist.
89248169|NCT00547703|Active Comparator|Nortriptyline|Patients in this group will receive Nortriptyline 25mg at night for 8 weeks.
89248170|NCT00547703|Placebo Comparator|Sugar pill|Patients in this group will receive an identical placebo capsule at night for 8 weeks.
89248171|NCT05352035||Prospective cohort|This cohort will enroll a total of 300 patients prospectively
89248172|NCT00297232|Experimental|Natalizumab|300 mg intravenous (IV) infusions once every 4 weeks for up to 480 weeks
89248173|NCT00954083|Experimental|DIR/Floortime intervention|1=DIR/Floortime intervention
89248174|NCT00954083|Active Comparator|routine care|2=routine care
89248175|NCT05351957|Experimental|dry needling|This study has only 1 arm and the control group is their baseline data
89248176|NCT05351645|Active Comparator|Treatment|Participants in the Treatment arm were assigned to read one each day during the two-week trial period. These articles described a personal experience suicide from a first-person perspective, and included positive messages. Before and after reading these articles, participants in the Treatment arm answered brief questions assessing current suicidal thoughts and other constructs. Participants in the Treatment group were administered follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs.
89248177|NCT05351645|No Intervention|Control|Participants in the Control arm answered questionnaires one time per day assessing suicidal thoughts and among other constructs (the same items as the Treatment group) during the two-week trial. Control participants did not receive the positive suicide related stories during the two-week trial period. Participants in the control group completed follow-up questionnaires 14 days after the completion of the trial period to assess suicidal thoughts and other constructs (the same items as the Treatment group). After the follow-up phase was complete, participants in the Control group received the same intervention as those in the Treatment group.
89248178|NCT01062802|Placebo Comparator|Placebo|
89248179|NCT01062802|Active Comparator|Statin group|
89248180|NCT00954161|Experimental|first aid and helping behaviour|The helping behaviour training is given after 24 hours first aid training and aims to sensitise participants towards a helping reaction and teach participants how to deal with barriers to helping
89248181|NCT00954161|Active Comparator|first aid only|This group receives training in first aid only without training in helping behaviour.
89248182|NCT03982108|Experimental|Knotless suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knotless suture-bridge technique.
89248183|NCT03982108|Active Comparator|Knot-tying suture-bridge technique|All participants in this arm will undergo an arthroscopic rotator cuff repair with knot-tying suture-bridge technique.
89248184|NCT00954317|Active Comparator|Low epidural|epidural placed in the lower lumbar vertebral column
89248185|NCT00954317|Experimental|high epidural|high epidural
89248186|NCT03938909||Patients with Multiple Sclerosis|200 patients and 200 control
89248187|NCT03938909||Patients with dementia|100 patients and 100 control
89248188|NCT03938909||Patients with Parkinson's disease|50 patients and 50 control
89248189|NCT03867383|Experimental|Calcium Chloride|"Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
89248190|NCT03867383|Placebo Comparator|Placebo|"Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
89248191|NCT05351567|Experimental|infertility educatıon group|women wıll educate with model about infertility
89248192|NCT05351567|No Intervention|control group (non-education)|Routıne care
89290293|NCT01126242|Active Comparator|Lace-up brace|The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
89248193|NCT03855215|Experimental|Intervention|"The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.~Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.~The healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs will be recommended below in the absence of warning signs of severity:~CRP level < 10 mg/L: no antibiotics are recommended CRP level from 10 mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level > 40 mg/L: antibiotics are recommended."
89248194|NCT03855215|No Intervention|Control|Working as routine
89248195|NCT05351411||combined progressive functional exercise|The initial implementation for the 8-week (3 days per week) combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike. The second part of the combined exercise program, the progressive resistance training program, is designed to be consistent with the resistance training section of the Canadian Physical Activity Guidelines for adults with MS. Each prescribed session consisted of 1-3 sets and 10-15 repetitions of 10 exercises targeting major muscle groups of the upper and lower extremities. The specific exercises prescribed included lunges, chair raises/squats, calf raises, knee flexion, knee extensions, shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, and abdominal curls.
89248196|NCT05351411||Placebo|Participants in the control group maintained their routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
89248197|NCT00954395||1. anticoagulation suspension|eligible patients undergo measurement of residual venous obstruction (RVO) with compression ultrasound (CUS) in case of a previous deep vein thrombosis (DVT) and/or of pulmonary artery pressure (PAP) with echocardiography in case of previous pulmonary embolism (PE). In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is below age and gender cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If all the D-dimer measurements are below the cut-offs, anticoagulation is definitely interrupted and patients are followed-up for two years.
89248198|NCT00954395||2. anticoagulation prolongation|If RVO is greater than 4 mm at CUS of the lower limbs and/or PAP is increased (> 35 mmHg, > 40 mmHg in the elderly or obese), anticoagulation is prolonged for additional 6 months and the measures of RVO and/oR PAP are repeated. In those in whom PAP is altered also after 6 months of additional therapy, anticoagulation is prolonged. In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is above age and gender cut-offs , anticoagulation is prolonged. If D-dimer is below the cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If one of these D-dimer measurement is above the cut-off , anticoagulation is resumed for at least 6 months and patients are re-evaluated.
89248199|NCT05351177|Experimental|High-Intensity Interval Training Group|Participants in the High-Intensity Interval Training (HIIT) group will complete 8 weeks of twice-weekly HIIT of 30 minutes in duration. Heart rate, ratings of perceived exertion, affect and enjoyment will be assessed. This will include a five minute warm-up on a cycle ergometer, followed by 10 x 60 second repetitions on the cycle ergometer interspersed with 60 seconds rest. A five minute cooldown will follow on the cycle ergometer.
89248200|NCT05351177|Experimental|Concurrent Training Group|Participants in the Concurrent Training (CT) group will complete 8 weeks of twice-weekly CT of 30 minutes in duration. Heart rate, ratings of perceived exertion, affect and enjoyment will be assessed. This will include a five minute warm-up on a cycle ergometer, followed by two sets of four then eight repetitions of deadlift, squat, bench press and shoulder press resistance exercises. Thereafter, 5 x 60 second HIIT cycling intervals will be completed on a cycle ergometer, after which a five minute cooldown will ensue.
89248201|NCT00954473||Ancillary-correlative (osteosarcoma genetic risk)|Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.
89248202|NCT03814889|Active Comparator|Vibration pattern 1|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248203|NCT03814889|Active Comparator|Vibration pattern 2|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248204|NCT03814889|Active Comparator|Vibration pattern 3|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248205|NCT03814889|Active Comparator|Vibration pattern 4|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248206|NCT03814889|Active Comparator|Vibration pattern 5|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248207|NCT03814889|Active Comparator|Vibration pattern 6|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248208|NCT03814889|Active Comparator|Vibration pattern 7|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248209|NCT03814889|Active Comparator|Vibration pattern 8|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248210|NCT03814889|Active Comparator|Vibration pattern 9|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248211|NCT03814889|Active Comparator|Vibration pattern 10|Each tactile vibration pattern will consist of a specific vibration frequency, amplitude, and temporal sequence to be specified via pilot studies.
89248212|NCT03814889|Placebo Comparator|No vibration|A light will blink instead of a vibration pattern being displayed.
89248213|NCT03741101|Experimental|single arm study|children treated with trametinib
89248214|NCT05350787|Experimental|ThisCART19A 5×10^6 cells/kg for dose level 1|Patients will receive 5×10^6 cells/kg of ThisCART19A
89248215|NCT05350787|Experimental|ThisCART19A 8×10^6 cells/kg as dose level 2|Patients will receive 8×10^6 cells/kg of ThisCART19A
89248216|NCT05350787|Experimental|ThisCART19A 12×10^6 cells/kg as dose level 3|Patients will receive 12×10^6 cells/kg of ThisCART19A
89248217|NCT03699917||Patients with SVV < 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of less than 12.
89248218|NCT03699917||Patients with SVV > or = 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of greater than or equal to 12.
89248219|NCT00449670|Experimental|H5N1 Adjuvanted Group|Subjects received 2 doses of H5N1 adjuvanted split virus vaccine (lot 1, 2, 3 or 4) containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 during Primary Phase. A subset of these subjects (Boosted sub-cohort) received a single dose of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 during Booster Phase. The remaining subjects (Non-Boosted sub-cohort) received a single booster dose at Month 12 or 36 after initial priming in study 111443 (NCT00652743).
89248220|NCT00449670|Active Comparator|H5N1 Un-adjuvanted Group|Subjects received 2 doses of a H5N1 non-adjuvanted split virus vaccine containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 and two booster doses of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 and Month 6 + 21 days.
89248221|NCT04011449|Experimental|Device Implantation|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
89248222|NCT00954551||All adult patients with SAH in ICU|All adult patients admitted for an expected ICU stay of more than 24 hrs over a 6-month period (tentative) between xx and xx 2009 with a diagnosis of SAH will be prospectively evaluated.
89248223|NCT04010903|Experimental|HEALTHY SUBJECTS|SUBJECTS WITH BMI<27 and HOMA<4
89248224|NCT04010903|Experimental|OVERWEIGHT NON INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA<4
89248225|NCT04010903|Experimental|OVERWEIGHT INSULINRESISTANT PATIENTS|SUBJECTS WITH BMI>27 and HOMA>4
89248226|NCT05350709|Active Comparator|mirror therapy|An exercise program has been prepared for patients for use in mirror therapy. In this exercise program, firstly, joint movements of the hand and fingers (opening and closing the fingers one by one, making a fist, moving the hand to the right and left, turning the wrist) are shown. Then, activities with some small objects used in daily life (squeezing ball, putting clothespins, collecting paper clips from the table, using tongs, turning cards, turning pages) is shown. The patient will repeat the movement for 3 minutes. The patient will hold the affected extremity behind the mirror with the healthy extremity, the patient will look towards the affected side from the mirror and try to do the movements with the affected extremity. . The treatment period will be 20 sessions, 5 days a week, for 4 weeks.The exercises will take 1 hour, including half an hour of mirror therapy and half an hour of conventional exercises.
89248227|NCT05350709|Active Comparator|action observational therapy|An exercise video has been prepared for the patients to watch for the action observation therapy. In this video, first of all, joint movements of the hand and fingers (opening and closing the fingers one by one, making a fist, moving the hand to the right and left, turning the wrist, etc.) are shown. Then, activities with some small objects used in daily life (squeezing ball, putting clothespins, collecting paper clips from the table, using tongs, turning cards, turning pages, etc.). is shown. The patient will first watch the video of each movement, and then repeat the movement for 3 minutes. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks.The exercises will take 1 hour, including half an hour of action observational therapy and half an hour of conventional exercises.
89248228|NCT05350709|Active Comparator|conventional therapy|Conventional therapy includes range of motion exercises, walking and balance exercises. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks. The exercises will last for half an hour daily.
89248229|NCT04010513|Experimental|Hypnosis|
89248230|NCT04010513|Active Comparator|Standard of Care|
89248231|NCT01023828||TOBACCO SMOKING|Group of patients with diagnosis of NSCLC and exposure to tabacco smoking
89248232|NCT01023828||WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to wood smoke
89248233|NCT01023828||TABACCO SMOKING AND WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to tabacco smoking and wood smoke
89248234|NCT01023828||WHITOUT EXPOSURE|Patients whit diagnosis of NSCLC and whitout exposure to risk factor
89248235|NCT05350553||Healthy Control|Patients 45-75 years of age without Type 2 Diabetes and without chronic low back pain.
89248236|NCT05350553||Type 2 Diabetic with Painful Neuropathy|Patients 45-75 years of age with Type 2 Diabetes and experiencing painful neuropathy (painful numbness or tingling in hands and/or feet)
89248237|NCT05350553||Chronic Low Back Pain as a Result of Lumber Disc Aberrancy|Patients 45-75 years of age with chronic low back pain as a direct result of non-operative lumber disc aberrancy (lumbar disc herniation, protrusion, or extrusion).
89248238|NCT01023906||18-49 years|Younger
89248239|NCT01023906||50-85 years|Older
89248240|NCT00954629|Experimental|2PX|Pain medication
89248241|NCT00954629|Placebo Comparator|Placebo|
89248242|NCT03844698||Patients with Sarcoidosis and Cancer|These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report.
89248243|NCT00296374|Experimental|1|Rosuvastatin 10 mg
89248244|NCT00296374|Experimental|2|Rosuvastatin 40 mg
89248245|NCT00296374|Active Comparator|3|Atorvastatin 80 mg
89248246|NCT03839082|Active Comparator|Usual Care then FitBit|This is the waitlist control arm.
89248247|NCT03839082|Experimental|FitBit then Usual Care|Intervention includes education, physical activity, and a nutrition assessment.
89248248|NCT05350475|Experimental|Proton therapy|"Radiation: Proton Therapy 78 Gray (Gy) in 39 fractions with 56 Gy to the Pelvic Lymph Nodes (LN), 5 days a week.~Androgen Deprivation Therapy (ADT) for three years, starting 3 months before Proton Therapy."
89248249|NCT05350475|Active Comparator|Photon Therapy|Radiation: Photon Therapy 78 Gy in 39 fractions with 56 Gy to the pelvic LN, 5 days a week. ADT for three years, starting 3 months before Photon Therapy.
89248250|NCT05350241|Experimental|Split-belt treadmill walking group|Participants in this group performed repeated split-belt treadmill training with an error-augmentation strategy.
89248251|NCT05350241|Active Comparator|Control group|Participants in this group received the standard physical rehabilitation program
89248252|NCT05304923|Experimental|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted for the participants during sedation.
89248253|NCT05304923|Placebo Comparator|nasal cannula oxygen supply|Oxygen supplementation is delivered via a nasal cannula to the participants during sedation.
89248254|NCT01060774|Experimental|Bupivacaine|0.5% bupivacaine/1:200,000 epinephrine
89248255|NCT01060774|Experimental|Lidocaine|2% lidocaine/1:200,000 epinephrine
89248256|NCT04011059|Placebo Comparator|Comparison/control group|Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.
89248257|NCT04011059|Active Comparator|Experimental group|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed.
89248258|NCT00954785|Placebo Comparator|Placebo drug|
89248259|NCT00954785|Experimental|Etoricoxib|
89248260|NCT00954785|Active Comparator|Diclofenac|
89248261|NCT00326950|Experimental|1|
89248262|NCT03981874|Experimental|Telephonic interview|Parents or patients will be contacted by phone in order to precise whether there are persistent sequelae or not
89248263|NCT00548717|Experimental|Siro/MMF|Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
89248264|NCT00548717|Experimental|Siro/MMF/Bort|Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) *added with study reopening in 2012
89248265|NCT00441168|Active Comparator|VAD Treatment|vincristine in combination with adriamycin and dexamethasone
89248266|NCT00441168|Experimental|PAD Treatment|bortezomib in combination with adriamycin and dexamethasone
89248267|NCT00296140|Other|self management of PSD symptoms|
89248268|NCT00296140|Other|screening and treatment of PSD|
89248269|NCT03669432|Experimental|Intensity Modulated radiotherapy|"In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
89248270|NCT03669432|Other|Surgery alone|In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up
89248271|NCT03958331|Active Comparator|Control Group|Automated reminders and individualized adherence feedback reports
89248272|NCT03958331|Experimental|Treatment Group|Automated reminders and individualized adherence feedback reports with social norms comparisons
89248273|NCT01062958||Arm #1 (Test group)|50 subjects administered Neevo® or Neevo®DHA daily
89248274|NCT01062958||Arm #2 (Control group)|50 subjects administered a prenatal vitamin daily
89248275|NCT01566318|Experimental|Problem solving therapy (PST)|6-8 sessions of PST, with booster, delivered over 8 weeks
89248276|NCT01566318|No Intervention|Usual care|Usual agency care, monitored for mental health services
89248277|NCT03956615|Other|Clinically Suspected or Pathologically Confirmed Multiple Myeloma.|Patients with a clinically suspected or pathologically confirmed multiple myeloma.
89248278|NCT01028976|Placebo Comparator|Placebo|Two tablets, daily, for 8 weeks
89248279|NCT01028976|Experimental|Vitamin C|Two tablets, daily, for 8 weeks
89248280|NCT01024140|Experimental|Escitalopram|Flexible dose (5-20mg/day) of escitalopram monotherapy.
89248281|NCT03956225|Experimental|iLux|Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes will be treated.
89248282|NCT03956225|Active Comparator|LipiFlow|Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes will be treated.
89248283|NCT01027026|Experimental|Group 1 Fast Track Group|The patients are discharged the same day after coronary angiography to the refering Hospital
89248284|NCT01027026|Active Comparator|Group 2: Ordinary care|Ordinary Cardiology care in the Intervention hospital
89248285|NCT05178329|Active Comparator|Intervention group|The patients undergoing intervention exercise.
89248286|NCT05178329|Placebo Comparator|Control Group|The patients undergoing the normal exercise program
89248287|NCT02936609||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
89248288|NCT02936609||Medicaid Non-Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
89248289|NCT02776085||Asymptomatic|Group of patients with CSF shunts who are evaluated for a reason other than concern for shunt failure. The optic nerve sheath diameter of these patients will be used as baseline measurements for children with CSF shunts.
88804807|NCT01268527|Experimental|Cohort 2|Three concentrations of E6201 topical gel (0.005%, 0.01%, and 0.05%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. Cohort 2 participants were not dosed until all participants in Cohort 1 completed treatment and safety data were collected and evaluated.
88806086|NCT01896284|Experimental|0.5mg AFLIBERCEPT injection|Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12, patients will receive an additional injection.
89248290|NCT02776085||Symptomatic, Not Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, but either have shunt failure ruled out, or are felt to be safe for discharge to home. They are not admitted to the hospital. The optic nerve sheath diameter of these patients will be measured once in the emergency department.
89248291|NCT02776085||Symptomatic, Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, and then are admitted to the hospital secondary to these concerns. The optic nerve sheath diameter of these patients will be measured once in the emergency department or as close to admission as possible, and then measured again while they are still inpatient, but after they have an intervention performed (medical or surgical) to relieve their shunt malfunction or failure. These patients will have their initial optic nerve sheath diameters compared to the other two populations, but they will also have their initial and final optic nerve sheath diameters compared to each other.
89248292|NCT00457626|Experimental|Valsartan Open Label|Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.
89248293|NCT02748707|Experimental|Arm 1|Celecoxib 200mg twice daily for 21 days
89248294|NCT02748707|Experimental|Arm 2|Erlotinib 150 mg once daily for 21 days
89248295|NCT02748707|Experimental|Arm 3|Celecoxib 200 mg twice daily for 21 days and Erlotinib 150 mg once daily for 21 days
89248296|NCT02748707|Sham Comparator|Arm 4|Control group with no drug
89248297|NCT05177861|Other|Electromyelography|EMG will be performed only once to determine the ulnar nerve entrapment site in patients.
89248298|NCT05175209|Other|Electromyelography|EMG will be performed only once to determine the ulnar nerve entrapment site in patients.
89248299|NCT05131061||unilateral primary aldosteronism(UPA)|PA confirmatory tests was positive; successful intubation (SI ≥ 3) and LI ≥ 4; If LI between 2 and 4, should be combined with contralateral inhibition index < 1 or CT indicate typical adenomas on the dominant side.
89248300|NCT05131061||bilateral adrenal hyperplasia(BAH)|PA confirmatory tests was positive; successful intubation (SI ≥ 3) and LI < 2; or LI between 2 and 4 but does not meet the UPA conditions
89248301|NCT04010279|Active Comparator|spontaneous breathing|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the spontaneous position.
89248302|NCT04010279|Active Comparator|spontaneous breathing with APL 5 cmH2O|volunteers will breath via an anesthesia face mask spontaneously while the APL (airway pressure release valve) valve is on the 5 cmH2O position.
89248303|NCT04010279|Active Comparator|CPAP 5cmH2O PEEP|volunteers will breath via an anesthesia face mask spontaneously on the CPAP mode of the anesthesia workstation with 5 cmH2O PEEP.
89248304|NCT05050487|Experimental|treatment|patient will recieve pericapsular nerve group block
89248305|NCT05050487|Experimental|treatement|patient will receive lumbar erector spinae plane block
89248306|NCT02249975|Experimental|C2 CryoBalloon Focal Ablation System|Cryoballoon ablation will be performed on patients with Barrett's Esophagus.
89248307|NCT01841957|Experimental|ISBCS|Immediate Simultaneous Bilateral Cataract Surgery
89248308|NCT01841957|Active Comparator|DSBCS|Delayed Sequential Bilateral Cataract Surgery
88806087|NCT02536404|Experimental|Etrasimod 2 mg|
88806088|NCT02536404|Active Comparator|Placebo|
88806089|NCT04271618|Active Comparator|Traditional Treatment Arm|Participants in this group will receive conventional rehabilitation program for postural correction 2 hours/3 sessions' weekly/3 successive months.
89248309|NCT05014061|Experimental|Adenosine|Adenosine infusion 70 µg/kg/min initiated prior to revascularization and maintained for 6 hours
89248310|NCT05014061|No Intervention|Controll|Standard of care
89248311|NCT05001503|Experimental|Intervention Group|The clinical team has access to the Stability UO software. All other care is given as standard.
89248312|NCT05001503|No Intervention|Control Group|Standard care given.
89248313|NCT04977245|Experimental|MBSR Intervention|The intervention group will take part in a group-based mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. This MBSR program will have a shortened session length of 1.5 hours compared to the traditional 2 hours, to reduce caregiver burden. Caregivers will be trained in meditation practices, like awareness of one's breath, body scan, and loving kindness meditation. Participants will also learn about mindfulness and stress theory, and have group discussions covering topics such as self-compassion.
89248314|NCT04977245|Active Comparator|Self-Guided Meditation eCourse|Participants in the active control group will participate in a self-guided, online program named GARDEN. The self guided material teaches skills about increasing the daily experience of positive emotion as a mechanism to assist with stress coping. The program consists of eight skills introduced and discussed over an eight week period.
89248315|NCT00373113|Active Comparator|A|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
89248316|NCT00373113|Experimental|B|37.5 mg daily, continuous dosing
89248317|NCT01045941|Experimental|Patients with distal pancreatic cancer|Patients with distal pancreatic cancer amenable to a laparoscopic distal pancreatectomy
89248318|NCT00407511|Experimental|Pregabalin|
89248319|NCT00384189|Active Comparator|Ciclesonide 40 µg|Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
89248320|NCT00384189|Active Comparator|Ciclesonide 80 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
89248321|NCT00384189|Active Comparator|Ciclesonide 160 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
89248322|NCT00384189|Placebo Comparator|Placebo|Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
89248323|NCT00326716|Experimental|Treatment|
89248324|NCT01063192|Active Comparator|Gemcitabine|Arm 1: Gemcitabine alone
89248325|NCT01063192|Active Comparator|GOFL|Arm 2: GOFL (Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
89248326|NCT03983356|Experimental|Group of GPs receiving training|GPs, psychologists and social workers in the intervention regions will receive a training program.
89248327|NCT03983356|No Intervention|Group of GPs receiving no attention|GPs, psychologists and social workers in the control regions will not receive information about the intervention.
89248328|NCT03978910|Experimental|Weigthlessness|during a flight
89248329|NCT01066078||CRT recipients|
89248330|NCT01063426|Experimental|Atorvastatin + enoxaparine arm|High dose atorvastatin arm before index surgery+ conventional enoxaparin
89248331|NCT01063426|Active Comparator|Conventional Enoxaprin|Conventional Enoxaparin before 12hr and on 1-7th day after index surgery
89248332|NCT00548405|Experimental|Alemtuzumab 12 mg|Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
89248333|NCT00548405|Experimental|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
89248334|NCT00548405|Active Comparator|Interferon Beta-1a|Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
89248335|NCT00958529|Experimental|inulin|0, 5, 10 g inulin
89248336|NCT00958607|Active Comparator|Self-Directed Program|
89248337|NCT00958607|Active Comparator|Stroke Support Person|
89248338|NCT00958607|No Intervention|Standard Care|"Participants in this arm receive Standard Care which consists of being given a copy of the Heart& Stroke Foundation's stroke resource titled Let's Talk About Stroke"
89248339|NCT00958685|Experimental|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
89248340|NCT00958685|Experimental|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
89248341|NCT00958763|Experimental|Motivational Interviewing, Single - MIS|
89248342|NCT00958763|Experimental|Motivational Interviewing, Group - MIG|
89248343|NCT00958763|Other|Usual Care Group - UCG|
89248344|NCT00958997||Type 1 diabetic subjects|Patients with Type 1 diabetes who have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician
89248345|NCT00958997||Healthy control subjects|Age-weight-BMI matched to the subjects with type-1 diabetes
89248346|NCT00959075|Experimental|Oral thiamin supplementation|Vitamin B1 (Oral thiamin) 100mg BID for 6 months
89248347|NCT00959075|Placebo Comparator|Sugar pill|oral placebo 1 tablet BID for 6 months
89248348|NCT05299775||HIV infected time|Group are divided by Infected time: 0-2W, 2W-12M, >1Y
89248349|NCT05299775||different constitutions|Group are divided by different constitutions:It includes 9 basic types of constitution, yang deficiency , yin deficiency , qi deficiency , phlegm dampness , damp-heat, blood stasis, special diathesis , qi depression , gentleness constitution .
89248350|NCT00295750|Experimental|degarelix 240/160 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
89248351|NCT00295750|Experimental|degarelix 240/80 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
89248352|NCT00295750|Active Comparator|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.
89248353|NCT04850963|Active Comparator|Group 1 - anodal tDCS|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. For group 1 (anodic tDCS) the anodic electrode (5x5 cm) will be applied to the primary motor area (C3/C4) ipsilateral to the lesion and the reference electrode (6x9 cm) to the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
89290294|NCT01126242|Active Comparator|Semi rigid brace|A semi-rigid brace, the M-step® from Medi®, will be applied. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
89248354|NCT04850963|Active Comparator|Group 2 - tDCS dualsite|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. In group 2 (dualsite tDCS) two active electrodes (5x5 cm) will be used, which will be positioned over the primary motor area (C3/C4) and over the dorsolateral prefrontal cortex (F3 or F4) in the ipsilateral hemisphere. For this stimulation modality, two active electrodes (anodic) and a reference electrode (6x9 cm) will be used on the deltoid muscle region.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
89248355|NCT04850963|Placebo Comparator|Group 3 - tDCS sham|"Participants will receive 10 tDCS sessions, for 20 minutes, on days alternate (3 times a week).~The neurostimulator TCT-Research will be used for stimulation. The electrodes will be positioned according to the international classification system of the electroencephalogram 10/20. For group 3 (simulated tDCS) the positioning of the electrodes will be the same as for group 1, however the device will be configured in sham mode in which the current will cease 30 seconds after the start of stimulation.~Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training. Each task will have a duration of 3 minutes, followed by a rest period of 30s."
89248356|NCT00959153|Experimental|Kidney stones|Kidney stones
89248357|NCT03948581|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
89248358|NCT03948581|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
89248359|NCT00548327|Active Comparator|Atomoxetine|"Atomoxetine 80 mg final dose. Arm lasts 14 days.~Schedule 25 mg Day 1 (or Day 22), 40 mg Day 2-3 (or Days 23-24), 60 mg Days 4-5 (or Days 25-26), 80 mg Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging (MRI) and neuropsychological testing in addition to psychopathology ratings"
89248360|NCT00548327|Placebo Comparator|Placebo|"Placebo administered for 14 days. Schedule Atomoxetine 25 mg Placebo Day 1 (or Day 22), Atomoxetine 40 mg Placebo Day 2-3 (or Days 23-24), Atomoxetine 60 mg Placebo Days 4-5 (or Days 25-26), Atomoxetine 80 mg Placebo Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging and neuropsychological testing in addition to psychopathology ratings"
89248361|NCT00959309|Experimental|Intervention|
89248362|NCT00959309|Active Comparator|Control|
89248363|NCT04720547|Experimental|Zolpidem, then No Treatment|Participants will be administered zolpidem for the first night study, and No Treatment during the second night study.
89248364|NCT04720547|Experimental|No Treatment, then Zolpidem|Participants will be administered zolpidem for the second night study, and No Treatment during the first night study.
89248365|NCT00959387|Experimental|Induction TP chemotherapy followed by CRT|paclitaxel 175mg/m2 as a 3-h infusion on Day 1, and cisplatin 80mg/m2 as a 2-h infusion on Day 1 three weekly followed by concurrent chemoradiotherapy based on cisplatin. All patient were given adequate hydration and antiemetics. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
89248366|NCT00959465|Experimental|Cohort 1/Dose Level A|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
89248367|NCT00959465|Experimental|Cohort 1/Dose B|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
89248368|NCT00959465|Experimental|Cohort 2/Dose C|A second cohort may be enrolled with all subjects in this cohort receiving two vaccinations of Dose C of H1N1 pandemic influenza vaccine at a 21-day interval.
89248369|NCT04718285|Experimental|Montelukast|3x10 mg oral montelukast first day (morning, noon time and evening) and rest of the 13 days 1 x 10 mg montelukast.
89248370|NCT04718285|Experimental|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast at the first day and rest of the 13 days1 x 10 mg, concurrently.
89248371|NCT04718285|Active Comparator|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
89248372|NCT05299619|Experimental|Tixel Group|Tixel treatments in Dry Eye Patients
89248373|NCT00959543|Other|waterpolo players|30 throwing shoulders of waterpolo players
89248374|NCT00959543|Other|controle group|15 healthy patients (non waterpolo players); 30 shoulders
89248375|NCT00959621|Active Comparator|ASA|The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.ASA or placebo were blinded in the two first groups.
89248376|NCT00959621|Active Comparator|Klexane|Clexane (enoxaparine) 40 mg sc
89248377|NCT00959621|Active Comparator|Aspirin and Enoxaparine|
89248378|NCT05299541|Active Comparator|Control|Measurements and questioners
89248379|NCT05299541|Active Comparator|Group A|Receiving Food dish every night for 6 months Measurements and questioners
89248380|NCT05299541|Active Comparator|Group B|Receiving Food dish every night for 6 months, at this group extra attention have given to the dish plating and appearance by professional (BOCUSE), Measurements and questioners
89248381|NCT00959777|Experimental|DA-3031|
89248382|NCT00959777|Active Comparator|filgrastim|
89248383|NCT04450745|Experimental|Exercise in hypoxia|Patients randomized to this arm will have training program in normobaric hypoxic chamber set to contain equivalent to an altitude of 2500 meters above see level( indoor air composition: 15,4% of O2 and 84,7% of N)
89248384|NCT04450745|Experimental|Exercise in normoxia|Patients randomized to this arm will have the same training program in normoxic conditions
89248385|NCT03953183|Other|P3P-1mg|Subjects randomized to exclusive use of P3P-1mg
89248386|NCT03953183|Other|P3P-2mg|Subjects randomized to exclusive use of P3P-2mg
89248387|NCT00959855|Experimental|Pulmonary Rehabilitation|Pulmonary rehabilitation classes based on the British Thoracic Society guidelines will be undertaken for two hours for 16 sessions within an eight week period.
89248388|NCT00959855|No Intervention|Pulmonary Rehabiliation|The control group will be assessed in the same time frame without participating in the rehabilitation class. They will avail of the next available class after the 12 month assessment.
89248389|NCT00961883|Experimental|1|Thirty participants will receive injections in the following order: NYVAC-B for injections one and two, placebo for injection three, and rAd5 for the fourth and final injection. Two participants in this group will receive placebo vaccines only.
89248390|NCT00961883|Experimental|2|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
89248391|NCT00961883|Experimental|3|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
89248392|NCT00961883|Experimental|4|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
89248393|NCT00959933|Experimental|1|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
89248394|NCT00959933|Active Comparator|2|Rebetol 200 Capsules (Schering Corporation, U.S.A.)
89248395|NCT00962117||Obese/Non-obese|
89248396|NCT00960089|Experimental|LIQUICURE|Medical Device
89248397|NCT00960167|Experimental|Dose Level I|42 Gy in 12 fractions.
89248398|NCT00960167|Experimental|Dose Level II|49 Gy in 14 fractions.
89248399|NCT00960167|Experimental|Dose Level III|56 Gy in 16 fractions.
89248400|NCT00960167|Experimental|Dose Level IV|63 Gy in 18 fractions.
89248401|NCT00962195|Experimental|purple sweet potato juice|Daily oral intake of 3x 125 ml of PSP-juice for a period of 8 weeks
89248402|NCT00962195|Placebo Comparator|Control juice|Daily oral intake of 3x 125 ml of control juice for a period of 8 weeks
89248403|NCT00960245|Experimental|1|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
89248404|NCT00960245|Active Comparator|2|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
89248405|NCT00962273|Experimental|Pandemic Stress Vaccine - Interactive|
89248406|NCT00962273|Active Comparator|Pandemic Stress Vaccine - Didactic|
89248407|NCT00962273|No Intervention|Wait list|Some participants are assigned to an eight week waiting condition prior to the course commencing.
89248408|NCT00406653|Experimental|1|"4 arms for induction period~2 arms for maintenance period"
89248409|NCT00406653|Placebo Comparator|2|"4 arms for induction period~2 arms for maintenance period"
89248410|NCT00406653|Other|abatacept|1 arm for open-label extension phase
89248411|NCT03381651|Active Comparator|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 50.4Gy/28F/5.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 6 wks; Surgery: 4-6 weeks after nCRT
89248412|NCT03381651|Active Comparator|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 41.4Gy/23F/4.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 5 wks; Surgery: 4-6 weeks after nCRT
89248413|NCT00547157|Active Comparator|ARM 1 CRT|Cisplatin plus RT
89248414|NCT00547157|Experimental|ARM 2 PRT|Panitumumab plus RT
89248415|NCT00960479|Experimental|1|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
89248416|NCT00960479|Active Comparator|2|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
89248417|NCT00960557|Experimental|Combretastatin A1 Diphosphate|
89248418|NCT00960635|Active Comparator|calcitriol|
89248419|NCT00960635|Placebo Comparator|pill without agent|
89248420|NCT00960713||The RITAI cohort|Every patient treated by rituximab off-label for auto-immune diseases in the public hospitals of the Midi-Pyrénées County (South of France) is eligible for the study, whatever the dose and planned infusions number. The enrolment is definitive when the first rituximab infusion begins. Follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. At each visit, the investigators will record the adverse events that have occurred since the last visit. Serious or unexpected adverse events will be systematically monitored and declared to the Department of Pharmacology Pharmacovigilance unit and to Health Authorities (AFSSAPS). Imputability will be quoted according to the French method. A biological collection will be constituted to allow pharmaco-immunological studies.
89248421|NCT04009889|Active Comparator|verum|probiotic bland with 5 different lactobacilli
89248422|NCT04009889|Placebo Comparator|placebo|Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.
89248423|NCT00962351|Other|Metal-on-Polyethylene|
89248424|NCT00962351|Other|Metal-on-Metal, 28mm femoral head|
89248425|NCT00962351|Other|Metal-on-Metal, 36mm femoral head|
89248426|NCT00960791|Experimental|1|14C-labelled AZD1656
89248427|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
89248428|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 100 mg|
89248429|NCT00384033|Placebo Comparator|Placebo|
89248430|NCT00384033|Other|Duloxetine 60mg|Active control to assess assay sensitivity
89248431|NCT00962663|Experimental|ICA-105665|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
89248432|NCT00962663|Active Comparator|Ibuprofen|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
89248433|NCT00962663|Placebo Comparator|Placebo|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
89248434|NCT00962819||cross-sectional|College-aged students who were immunized with MMR.
89248435|NCT00961025|Placebo Comparator|Placebo|
89248436|NCT00961025|Experimental|DA-1229|DA-1229
89248437|NCT00962897||Surgical Bypass Group|Those patients that underwent bypass of blockage in the thigh with surgery.
89248438|NCT00962897||Stent-graft group|Patients that underwent treatment of blockage in the thigh with balloon angioplasty and stent placement.
89248439|NCT00962975|Experimental|Single Arm|
89248440|NCT01046097||Synflorix Group|Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.
89248441|NCT00961103||SMA II and SMA III|patients with SMA II and SMA III
89248442|NCT01046175|Experimental|Airstacking with manual resuscitator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
89248443|NCT01046175|Active Comparator|Air-stacking with ventilator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a ventilator.
89248444|NCT04009655|Experimental|music therapy|The infant will receive music therapy over 3 consecutive days and will obtain standard care as usual
89248445|NCT04009655|No Intervention|control|The infant does not receive any sound emission because the headphone will be turned off and will obtain standard care as experimental
89248446|NCT00075387|Experimental|Arm I (combination chemotherapy)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
89248447|NCT00075387|Experimental|Arm II (combination chemotherapy, sodium thiosulfate)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
89248448|NCT00963131|Experimental|antioxidant tablets|the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease
89248449|NCT00963131|Placebo Comparator|placebo tablets|the control arm received placebo tablets for 3 months or until the resolution of the disease
89248450|NCT00963209|Experimental|Tamoxifen|
89248451|NCT00963287|Experimental|bascial prescription|Decoction ,two times a day,one bag of decoction one time
89248452|NCT00963287|Placebo Comparator|low does of bascial decoction|Decoction ,two times a day, one bag decoction of one time
89248453|NCT00961337|Experimental|Vaccination township|Shinwu township was randomly designated as intervention township which freely vaccinated on grade 1-4 and 5-9 students.
89248454|NCT00961337|No Intervention|Control townships|Guanyin township was designated as control township which only provide free vaccination on grade 1-4 students.
89248455|NCT00963365|Experimental|AZD6765 oral solution|Active
89248456|NCT00963365|Experimental|AZD6765 IV infusion|Active
89248457|NCT00963365|Placebo Comparator|Placebo to AZD6765 oral solution|Placebo
89248458|NCT00963365|Placebo Comparator|Placebo to AZD6765 IV infusion|Placebo
89248459|NCT00963443|Experimental|Arm 1|
89248460|NCT00963443|Active Comparator|Arm 2|
89248461|NCT00963443|Active Comparator|Arm 3|
89248462|NCT00963443|Placebo Comparator|Arm 4|
89248463|NCT00963755||Primary prostate cancer|Patients referred with a suspicion of prostate cancer based on elevated PSA and rectal examination in whom a prostate biopsy is planned and radical prostatectomy is envisioned in the event of a positive biopsy finding
89248464|NCT00963755||Prostate cancer relapse|Patients previously treated for prostate cancer and being investigated for biochemical relapse, (mostly in the Urology and Radiation Therapy Department, but not exclusively), for whom surgical or radiation therapy is envisioned in the event of a positive FCH-PET finding
89248465|NCT00961493|Experimental|1|
89248466|NCT00961493|Active Comparator|2|
89248467|NCT00961727||PEWS System of Care|
89248468|NCT00963833||Group 1|
89248469|NCT00964067|Active Comparator|Treadmill group|Interval exercise performed on treadmills, supervised
89248470|NCT00964067|Active Comparator|Exercise groups|Supervised and organised in groups of ten
89248471|NCT00964067|Active Comparator|home-based exercise|Interval training at home, free choice of modality
89248472|NCT01563419|No Intervention|Control|dialing up the selected dose of insulin pens without an indicator magnifying window
89248473|NCT01563419|Experimental|Magnifier|dialing up the selected dose of insulin pens clipped on an indicator magnifying window
89248474|NCT00546377|Experimental|Mitoxantrone|
89248475|NCT00964145||Nulliparous female patients|Nulliparous female patients ages 21-70 years old.
89248476|NCT00964301|Experimental|Intervention Group|Participants, caregivers and school nurse will attend telemedicine education sessions at school.
89248477|NCT00964301|Active Comparator|Usual care|Usual care participant will receive routine care from their primary care provider.
89248478|NCT00967967|Other|Mometasone furoate and desloratadine|Mometasone and desloratadine treatment
89248479|NCT00968045|Placebo Comparator|Placebo|100 ml infusion of saline is given during 15 minutes after anesthesia induction before start of surgery.
89248480|NCT00968045|Experimental|Study drug|Fibrinogen 2g in 100 ml sterile water given during 15 minutes after anestesiainduction before surgery start
89248481|NCT00964379|Active Comparator|intraperitoneal colostomy|
89248482|NCT00964379|Active Comparator|extraperitoneal colostomy|
89248483|NCT00964457|Active Comparator|Capecitabine, oxaliplatin|
89248484|NCT00964457|Active Comparator|capecitabine, oxaliplatin and cetuximab|capecitabine, oxaliplatin ane cetuximab
89248485|NCT00964535|Experimental|Budesonide/formoterol Easyhaler|
89248486|NCT00964535|Experimental|Charcoal and Budesonide/formoterol EH|
89248487|NCT00964535|Active Comparator|Symbicort Turbohaler|
89248488|NCT00964535|Active Comparator|Charcoal and Symbicort Turbohaler|
89248489|NCT00968279||Atrial Fibrillation|
89248490|NCT00964691|Active Comparator|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
89248491|NCT00964691|Active Comparator|IPTp with Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
89248492|NCT00964769|Experimental|Pneumococcal polysaccharide vaccine|The immunogenic response to the pneumococcal polysaccharide vaccine was compared between children, adults and elderly.
89248493|NCT00964847|Active Comparator|Blood pressure education/walking program|
89248494|NCT00964847|Active Comparator|Combined intervention|
89248495|NCT00964847|Experimental|Yoga Exercise Program|
89248496|NCT00968357|Experimental|SCV-07|Cohort 1: SCV-07 0.1 mg/kg. Cohort 2: 1.0 mg/kg per day administered SC
89248497|NCT00968435|Experimental|(IMRT) + cisplatin + bevacizumab + cetuximab|This is a single-institution, non-randomized, phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab + cetuximab.
89248498|NCT00965003|Experimental|MRI scan with surface coil|Patients with known laryngeal cancer, with suspected cartilage involvement by conventional computed tomography scanning, who undergo high resolution magnetic resonance imaging enhanced with a surface coil placed over the larynx.
89248499|NCT05253287|No Intervention|Standard Medical treatment|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
89248500|NCT05253287|Experimental|Growth hormone + Standard medical therapy|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
89248501|NCT00968513|Active Comparator|Usual Care|(N=150) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
89248502|NCT00968513|Experimental|Brief Treatment|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization.
89248503|NCT00968513|Experimental|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
89248504|NCT00968591|Experimental|RAD001|
89248505|NCT00968903|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
89248506|NCT00968903|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
89248507|NCT00969059|Placebo Comparator|PLACEBO|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive placebo for 28 days.
89248508|NCT00969059|Experimental|Active|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive 7.5 mg twice daily (bid) GW856553 for 28 days.
89248509|NCT00969137|Active Comparator|Nicotine|Intravenous Nicotine
89248510|NCT00969137|Placebo Comparator|Saline|Saline infusion
89248511|NCT00969215|Experimental|Laser treatment|Half of each subject's scar will be treated with a fractional CO2 laser.
89248512|NCT00969215|No Intervention|No treatment|Half of each subject's scar will not be treated.
89248513|NCT00969371|Experimental|Lenstec Tetraflex IOL implantation|patients in Study arm received TetraFlex Lens
89248514|NCT00969371|Active Comparator|Control IOL|commercially approved PCIOL implanted
89248515|NCT00969449|Experimental|Arm 1|
89248516|NCT00969449|Active Comparator|Arm 2|
89248517|NCT00965393|Placebo Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of placebo (saline).
89248518|NCT00965393|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of bradykinin receptor antagonist (HOE-140).
89248519|NCT00965471|Experimental|managed group|
89248520|NCT00965471|Placebo Comparator|control group|
89248521|NCT00965549|Experimental|Lantus + Apidra basal plus one|"Before randomization (common with arm 2):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day"
89248522|NCT00965549|Active Comparator|NovoMix 30 Biphasic|"Before randomization (common with arm 1):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)"
89248523|NCT00969527|Experimental|A|Oncoxin + Viusid
89248524|NCT00969527|Placebo Comparator|B|
89248525|NCT00969605|Active Comparator|Pressure support ventilation|
89248526|NCT00969605|Active Comparator|Adaptive support ventilation|
89248527|NCT00969683|Active Comparator|Double lumen tube without a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
89248528|NCT00969683|Experimental|Double lumen tube with a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
89248529|NCT00965705|Active Comparator|Guided Self Help|
89248530|NCT00965705|Active Comparator|Cognitive Behavioral Therapy|
89248531|NCT00965705|Active Comparator|Dialectical Behavioral Therapy|
89248532|NCT00965783|Experimental|1|Sleep time restriction
89248533|NCT00965783|Experimental|2|Sleep time extension
89248534|NCT00969839|Experimental|Intramedullary Fixation System|Humeral fractures to be treated with the Intramedullary Fixation System
89248535|NCT00965861||1|The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
89248536|NCT04009187|Active Comparator|Training group|Training group will first receive 30 minutes of education about biomechanically efficient propulsion techniques. They will be tested on this knowledge to make sure participants understand the material. The participant then will be asked to come into the lab for 6 sessions of training, two times per week for three weeks. The training is an hour of the proper wheelchair propulsion techniques broken into 5 parts, 7 minutes each with breaks. Based on the motor learning principles, we gradually increase the components of the training by focusing either hand reaching toward the back of the wheel or hands reaching down toward the axle.
89248537|NCT04009187|Active Comparator|Control group|Control group will first receive 30 minutes of education about the biomechanically efficient propulsion. They will be tested on this knowledge to make sure participants understand the material. No further training will be implemented with this group.
89248538|NCT00969917|Experimental|IPI-504|IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
89248539|NCT05194163|Experimental|10mg MW150 daily|10 mg MW150 daily (1 capsule of 10 mg daily)
89248540|NCT05194163|Placebo Comparator|placebo daily|placebo daily (1 capsule of matched placebo daily)
89248541|NCT00966017||DS|Those with Down syndrome
89248542|NCT00966017||Non-DS|Healthy controls
89248543|NCT00969995||migraine1|50 subjects with migraine without aura
89248544|NCT00969995||migraine 2|50 subjects with migraine with aura
89248545|NCT00969995||tension|50 subjects with tension headache
89248546|NCT00969995||cluster|50 subjects with cluster headache
89248547|NCT00969995||Healthy|50 healthy subjects
89248548|NCT00966095||men scheduled for prostate biopsy|
89248549|NCT00966251|Experimental|CT-011|
89248550|NCT00966329|Experimental|to switch from the NNRTI/PI to maraviroc|to switch from the NNRTI/PI to maraviroc
89248551|NCT00966329|Active Comparator|to continue with the same approach|to continue with the same approach
89248552|NCT00970229|Experimental|Assess [123I]MNI-420 and SPECT Imaging|To assess [123I]MNI-420 and SPECT Imaging in PD, HD subjects and similarly aged healthy subjects.
89248553|NCT00970385|Active Comparator|CHOP 21|"Induction therapy CHOP every 21 days:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
89248554|NCT00970385|Experimental|VIP/ABVD arm|"VIP cycle:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD cycle:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD)."
89248555|NCT00970463||GH|Patients with GHD
89248556|NCT00970463||Pegvisomant and Somatostatin analogues|Acromegaly
89248557|NCT00966407||Healthy Young Adults|College-age (18-35 years) participants recruited from Howard University, East Carolina University, and University of Massachusetts, Amherst, University of Calgary, Winston-Salem University
89248558|NCT00966485|Active Comparator|80 mg ASA dose|6 months post stent on 80 mg ASA
89248559|NCT00966485|Active Comparator|500 mg ASA dose|6 months posr stent on ASA alone
89248560|NCT00966563|Active Comparator|Mangafodipir treatment|Treatment will be undertaken with a ready-to use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml.
89248561|NCT00966563|Placebo Comparator|NaCl 0.9%|
89248562|NCT00970541|Active Comparator|Cinnamon Supplementation|A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E> 20:1) will be consumed before meals, three times per day.
89248563|NCT00970541|Placebo Comparator|Placebo|A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.
89290295|NCT00254501|Active Comparator|Usual Care plus out-of-pocket cost waiver|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
89248564|NCT04083287|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
89248565|NCT04083287|Active Comparator|Group I = ISCB group|In group I, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
89248566|NCT00970619|No Intervention|Conventional anticoagulation therapy|Conservative treatment consists of an initial treatment with therapeutic doses of low molecular weight heparin (LMWH) in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an international normalized ratio (INR) above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 [23], CBO 2008 [24]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
89248567|NCT00970619|Experimental|Ekos Endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
89248568|NCT00970697|Experimental|becaplermin gel|application of a continuous thin layer of becaplermin gel (Regranex Gel®) during 8 weeks. The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment.
89248569|NCT00970697|Active Comparator|Duoderm Hydrogel™|application of a continuous thin layer of hydrogel dressing (Duoderm Hydrogel®), during 8 weeks. Duoderm Hydrogel™ is a sodium carboxymethylcellulose aqueous-based gel, similar in composition to becaplermin excipient.
89248570|NCT00970775|Experimental|1. AZD2423|
89248571|NCT00970775|Placebo Comparator|2. Placebo|
89248572|NCT00967031|Experimental|Lapatinib + capecitabine|lapatinib 1250mg/day + capecitabine 2000mg/m2/day
89248573|NCT00967109|Active Comparator|Allowed drop in hemoglobin to 4,5-5,5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
89248574|NCT00967109|Experimental|Allowed drop in hemoglobin to 5,5-6,5 mmol/L|Transfusion with red blood cells to level between 5.5-6.5 mmol/L
89248575|NCT00545753|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
89248576|NCT00545753|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
89248577|NCT00545753|Active Comparator|C - NIX|NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
89248578|NCT00967187|Experimental|MPC-4326 200 mg BID X 14 Days|
89248579|NCT00967187|Experimental|MPC-4326 300 mg BID X 14 Days.|
89248580|NCT00970931|Placebo Comparator|placebo|
89248581|NCT00970931|Experimental|chlortalidone-amiloride|
89248582|NCT00971009|Experimental|OPPC service|A practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
89248583|NCT00971009|Experimental|WebChoice IHCA|WebChoice is an interactive health communications application (IHCA) that in addition to offer a practice-integrated nurse administered online patient-provider communication (OPPC) service, allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
89248584|NCT00971009|No Intervention|Control group|The control group receives usual care
89248585|NCT00971087|Other|Biopsy|subjects presenting for a breast biopsy procedure, subject will be imaged before her biopsy procedure with the investigational 2D plus 3D mammography system
89248586|NCT00971087|Other|screening|subjects presenting for routine asymptomatic mammograms and will then have an investigational 2D plus 3D mammogram
89248587|NCT00406419|Placebo Comparator|Placebo × 2 IV + MTX|Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
89248588|NCT00406419|Experimental|Ocrelizumab 200 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
89248589|NCT00406419|Placebo Comparator|Ocrelizumab 500 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
89248590|NCT00967265|Experimental|Introduction seminar|Psychoeducation for patients on waiting list
89248591|NCT00967265|Active Comparator|Usual care|Usual care
89248592|NCT00967421|Experimental|BAC 0.5|BAC level 0.5 g/dL (drink + placebo pill)
89248593|NCT00967421|Experimental|BAC 1.0|BAC level 1.0 g/dL (drink + placebo pill)
89248594|NCT00967421|Placebo Comparator|placebo|BAC level 0,0 g/dL (placebo drink+ placebo pill)
89248595|NCT00971165|Active Comparator|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily for 18 months
89248596|NCT00971165|Experimental|losartan|Oral losartan up to 100 mg daily, once a day, for 18 month
88804808|NCT04351789|Experimental|Intervention Group|Patients randomized to the intervention group will receive a minimal psychoeducational intervention just prior to discharge from the hospital. The goal of the intervention is that patients will be prepared and learn to interpret and react to physical and psychological symptoms that are related to recovering from a COVID-19 infection. The intervention is based on psychoeducational theory and consists of both written and verbal information. A manual describing the content and procedures of the intervention will be developed to ensure that the intervention is both replicable and transparent. The intervention has a planned duration of 30 minutes and will be conducted by a designated study affiliated researcher, who has a background in healthcare (i.e. nurse or medical doctor).
89248597|NCT00971399|Experimental|RMS|ramosetron 0.1mg q.d. SL on D1-5
89248598|NCT00971399|Active Comparator|ODS|ondansetron 8mg, b.i.d SL on D1-5
89248599|NCT01049295|Experimental|oil fish pearls|patients with invasive breast cancer who received 640 mg oil fish pearls 3 times a day
89248600|NCT01049295|Placebo Comparator|placebo|patient with invasive breast cancer who received corn oil pearls as placebo 3 times a day
89248601|NCT00973505||CYP19|CYP19 genetic polymorphism
88804809|NCT04351789|No Intervention|Control Group|Standard of Care at discharge of patients with COVID-19 from hospital is to inform the patients whom to contact in case of worsening of the physical condition, such as increasing e.g. shortness of breath, and of precautions regarding further isolation to avoid infection of household and other contacts, if relevant. Information regarding the patient´s psychological condition is not part of a standard conversation at discharge.
89248602|NCT00971477|Experimental|Teledermatology|Online Telemedicine Group
89248603|NCT00971477|Active Comparator|Usual Care|Conventional in-office care
89248604|NCT00971555||Late preterm|Late preterm infants admitted to the NICU
89248605|NCT00973583|Active Comparator|vitamin D|
89248606|NCT00973583|Placebo Comparator|placebo|
89248607|NCT00971711|Experimental|Probiotic|To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).
89248608|NCT04008953||Sixteen patients having end stage renal disease|Intravascular volume assessment in 16 pediatric patients under going renal transplant surgery using ultrasonography, CVP and echocardiography
89248609|NCT00973661|Experimental|Electronic tools|
89248610|NCT00973661|No Intervention|Usual care|
89248611|NCT00972101|Experimental|Regimen 1: No TBI|High Dose Chemotherapy without Total Body Irradiation (TBI)
89248612|NCT00972101|Experimental|Regimen 2: TBI|High Dose Chemotherapy with Total Body Irradiation (TBI)
89248613|NCT00325468|Experimental|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
89248614|NCT00974129||Patients with Infantile Hemangiomas|
89248615|NCT00972257|Active Comparator|Drug: Dorzolamide/Timolol|
89248616|NCT00972257|Active Comparator|Treatment with Brimonidine/Timolol|
89248617|NCT00311584|Experimental|Disease measurable by CT or MRI scan (Irinotecan/Temozolomide)|Measurable by CT scan (Computed Tomography) or MRI scan (Magnetic Resonance Imaging). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89248618|NCT00311584|Experimental|Disease eval by bone marrow or MIBG (Irinotecan/Temozolomide)|Evaluation by bone marrow or MIBG scan (metaiodobenzylguanidine scan, a radiopharmaceutical). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89248619|NCT03021681|Other|COPD group(self control)|Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively
89248620|NCT03992859|Experimental|serratus catheter|Continuous serratus plane block: Ropivacaine 0.2% infusion through a multiple hole catheter (C-Cat Cimpax Denmark)at a fixed dose of 12 ml/h and a multimodal analgesia with acetaminophen and a PCA of morphine
89248621|NCT03992859|No Intervention|standard treatment|Post-operative multimodal analgesia with Acetaminophen and PCA of Morphine
89248622|NCT00383331|Experimental|A|
89248623|NCT00383331|Experimental|B|
89248624|NCT03934541|Experimental|Group 1 (Treatment 1): MPER-656 Liposome Vaccine|Participants will receive 500 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
89248625|NCT03934541|Placebo Comparator|Group 1 (Control 1): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
89248626|NCT03934541|Experimental|Group 2 (Treatment 2): MPER-656 Liposome Vaccine|Participants will receive 2000 mcg of MPER-656 liposomes, admixed with Aluminum Hydroxide Suspension, to be administered as two 0.5 mL doses at Months 0, 2, and 6.
89248627|NCT03934541|Placebo Comparator|Group 2 (Control 2): Placebo for MPER-656 Liposome Vaccine|Participants will receive placebo to be administered as two 0.5 mL doses at Months 0, 2, and 6.
89248628|NCT00325234|Experimental|Pemetrexed/Carboplatin|"Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1.~Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg*min/mL. The cycle of treatment was 21 days."
89248629|NCT00325234|Active Comparator|Gemcitabine/Vinorelbine|Vinorelbine 30 mg/m^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
89248630|NCT01063504|Active Comparator|Teriparatide 20 microgram daily for 2 months|
89248631|NCT01063504|Placebo Comparator|Placebo|
89248632|NCT00366249|Active Comparator|A|
89248633|NCT00366249|Active Comparator|B|
89248634|NCT00325156|Experimental|Group A|
89248635|NCT01066234|Experimental|concurrent chemoradiotherapy|
89248636|NCT01066234|Active Comparator|chemotherapy only|
89248637|NCT03927911|Active Comparator|Open or mini-open surgical technique cohort|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
89248638|NCT03927911|Active Comparator|Tubular or Percutaneous cohort (Minimally Invasive Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
89248639|NCT03927911|Active Comparator|Lumbar decompression without fusion (Outpatient Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
89248640|NCT00383019|Experimental|Xalatan|
89248641|NCT00383019|Experimental|Xalacom|
89248642|NCT01046331||Adult H1N1|Patients admitted to adult ICU with confirmed or suspected H1N1 Influence infection
89248643|NCT01046331||Pediatric H1N1|Patients admitted to pediatric ICU with confirmed or suspected H1N1 Influenza infection
89248644|NCT00310804|Experimental|cTIV_lot 1|
89248645|NCT00310804|Experimental|cTIV_lot 2|
89248646|NCT00310804|Experimental|cTIV_lot 3|
89248647|NCT00310804|Active Comparator|TIV group|
89248648|NCT01066312||Practitioners|Healthcare practitioners who either use, have used or do not use MMT in practice
89248649|NCT01066312||Testees|Healthy adults with no experience with MMT
89248650|NCT01046409||Main vessel, side branch vessel|
89248651|NCT01060852|Experimental|Media Detective|10-lesson elementary school, substance use prevention program developed based upon the Message Interpretation Processing model designed to increase children's critical thinking skills about media messages and reduce intent to use tobacco and alcohol products.
89248652|NCT00590187|Experimental|A sapacitabine|200 mg b.i.d. x 7 days every 3-4 weeks
89248653|NCT00590187|Experimental|B sapacitabine|300 mg b.i.d. x 7 days every 3 - 4 weeks
89248654|NCT00590187|Experimental|C sapacitabine|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
89248655|NCT00590187|Experimental|D sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
89248656|NCT00590187|Experimental|E sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
89248657|NCT00590187|Experimental|F sapacitabine|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
89248658|NCT00590187|Experimental|G sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
89248659|NCT00590187|Experimental|H sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
89248660|NCT00590187|Experimental|I sapacitabine|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
89248661|NCT03978364|Experimental|azacitidine|"azacitidine~azacitidine 75mg/m2，iH，qd， d1-7"
88806090|NCT04271618|Experimental|TheraTogs Undergarment Arm|Participants in this group will receive the same conventional rehabilitation program as in traditional group in addition to wearing of TheraTogs soft orthotic undergarment with strapping system.
89248662|NCT03978364|Active Comparator|azacitidine combined HHT|azacitidine+HHT azacitidine 75mg/m2，iH，qd， d1-7 HHT 3mg/m2,ivdrip qd,d1-3
89248663|NCT01069276||Patients with clinical signs of stroke|Patients with clinical signs of stroke
89248664|NCT03978286|Experimental|Vortioxetine therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received vortioxetine (10 mg/day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
89248665|NCT03978286|Experimental|Sertraline therapy|patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist. The pharmacological management were randomly assigned: these group of patients received sertraline (75 mg / day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
89248666|NCT03826186|Active Comparator|Traditional epidural group|The traditional approach to placing thoracic epidurals by loss-of-resistance technique using a ground glass syringe will be used in this group.
89248667|NCT03826186|Experimental|CompuFlo epidural group|This device (CompuFlo) will aid in correct placement of the epidural by electronically sensing pressure in real time and by providing a numerical value on a read out screen to determine a loss of resistance. There is also an audio signal that signals a loss of resistance.
89248668|NCT01069432||Patients with CLL|Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
89248669|NCT01069432||Normal Volunteers|Normal volunteers who have no history of active or prior hematologic malignancy.
89248670|NCT00382863|Experimental|Treatment|HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)
89248671|NCT00382863|Active Comparator|Control|Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)
89248672|NCT03933449|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to ~2 years). Participants who complete the first course of up to 35 administrations of pembrolizumab (~2 years) but progress after discontinuation, may be eligible for a second course of pembrolizumab at the investigator's discretion, at the same dose and schedule at 200 mg IV on Day 1 of each 3-week cycle for up to 17 cycles (up to ~1 year).
89248673|NCT03933449|Active Comparator|Chemotherapy|Participants receive Investigator's choice of chemotherapy: paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to ~2 years).
89248674|NCT00974285|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
89248675|NCT00974285|Placebo Comparator|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
89248676|NCT03932045|Experimental|SYB Filler (SF-01)|PCL filler
89248677|NCT03932045|Active Comparator|Ellansé M|PCL filler
89248678|NCT00972413|Experimental|Group I|
89248679|NCT00972413|Experimental|Group II|
89248680|NCT00972413|Experimental|Group III|
89248681|NCT00387075|Experimental|[123I]β-CIT and SPECT imaging|To Assess [123I]β-CIT and SPECT imaging
89248682|NCT00974441|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
89248683|NCT00974441|Active Comparator|Depakote®|500 mg Extended Release Tablet
89248684|NCT01049451|Experimental|ACTH IM monthly|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
89248685|NCT01049451|Active Comparator|MP IV monthly|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months.
89248686|NCT00974519|Active Comparator|Fuzheng 3|Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
89248687|NCT00974519|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
89248688|NCT00974519|Placebo Comparator|Placebo|Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
89248689|NCT01049529|Placebo Comparator|Placebo group|This group is receiving sunflower oil (the excipient for DHA)
89248690|NCT01049529|Active Comparator|DHA group|This group is receiving the docosahexaenoic acid (DHA) supplement
89248691|NCT00972491|Other|0 sec, 60 sec, 90 sec|LMA will be inserted at 0, 60, and 90 seconds after eyelash reflex disappears
89248692|NCT01045395|Placebo Comparator|Corn starch, 90mg/d|Corn starch, 90mg/d
89248693|NCT01045395|Experimental|Unique Marine Algae Concentrate (UMAC). 90mg/d|
89248694|NCT01045395|Experimental|Golden brown algae, 90mg/d|
89248695|NCT00972569|Active Comparator|BNP with PDE-V|BNP (Nesiritide) will be infused starting at 0.0025 g/Kg/min IV for 3 hours, if tolerated increased to 0.005 g/kg/min for 45 hours without bolus with PDEV inhibition, they will also receive Sildenafil 12.5 mg at timepoints 0,12, 24 and 36 hours
89248696|NCT00972569|Active Comparator|BNP (Nesiritide) will be infused at 0.005 u/Kg/min IV for 48 h|BNP (Nesiritide) will be infused at 0.025 ug/Kg/min IV for 3 hours then 0.005ug/kg/min 45 hours without bolus. No PDE-V is given.
89248697|NCT00972569|No Intervention|standard care|Patients randomized to this group will continue to receive therapy at the discretion of the heart failure specialist who is managing the patient (with the exception of BNP and low dose dopamine). Blood and Urine will be collected after the patient has been randomized for 48 hours
89248698|NCT01324557|Experimental|CSII|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII)
89248699|NCT01324557|No Intervention|MDI|MDI: Control Optimized subcutaneous insulin by multiple daily injections (MDI)
89248700|NCT00972647|No Intervention|Unguided|Fluoroscopy images taken without laser beam guidance
89248701|NCT00972647|Experimental|Laser guided|Fluoroscopy images taken with laser beam guidance
89248702|NCT00974753|Placebo Comparator|PPV-MP + Placebo (Saline drops)|PPV-MP= pars plana vitrectomy membrane peel
89248703|NCT00974753|Active Comparator|PPV-MP + Ketorolac 0.5%|PPV-MP= pars plana vitrectomy membrane peel
89248704|NCT00974753|Placebo Comparator|PhacoVit-MP + Placebo (Saline drops)|PhacoVit-MP= phacovitrectomy membrane peel
89248705|NCT00974753|Active Comparator|PhacoVit-MP + Ketorolac 0.5%.|PhacoVit-MP= phacovitrectomy membrane peel
89248706|NCT04008719|Other|Patients|Assessments are made by a psychiatrist
89248707|NCT00974831|Experimental|AA Drink|Amino Acid Drink Mixture
89248708|NCT00974831|Placebo Comparator|Glucose drink|
89248709|NCT00972803|Experimental|pistacia Mutica|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
89248710|NCT00972803|Placebo Comparator|placebo|The subjects were asked to use a mouthwash containing Placebo twice a day for 4 days.
89248711|NCT00972803|Active Comparator|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
89248712|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 1: 3 to < 9 Years|Participants aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose of Fluzone Quadrivalent vaccine was administered at Day 28.
89248713|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 2: 18 to < 65 Years|Participants aged 18 to < 65 years received one 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
89248714|NCT02908269|Experimental|Fluzone High-Dose Vaccine Group 3: ≥ 65 Years|Participants aged ≥ 65 years received one 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
89248715|NCT00974909|Active Comparator|Treatment group|Treatment group
89248716|NCT00974909|Sham Comparator|sham group|Sham group
89248717|NCT00974987|Experimental|Treatment group|BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment) and TMZ(temozolomide) treatment
89248718|NCT00975065|Experimental|Galvus group|"the combination of metformin plus Vildagliptin:~vildagliptin 50 mg bid plus metformin 1500mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy."
89248719|NCT00975065|Active Comparator|Diabex group|"metformin alone arm:~metformin 1500mg plus metformin 500mg or 1000mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy"
89248720|NCT00290758|Experimental|Arm I (genistein)|Patients receive oral genistein once daily for up to 6 months.
89248721|NCT00290758|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for up to 6 months.
89248722|NCT00975299|Experimental|Arm 1|
89248723|NCT00975299|Experimental|Arm 2|
89248724|NCT01060930|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust ~ 300 mcg/m3 - during intermittent exercise
89248725|NCT01060930|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
89248726|NCT00973037||CYP2D6|CYP2D6 genotype
89248727|NCT00973115|Experimental|Simvastatin CR 20mg- morning administration|
89248728|NCT00973115|Active Comparator|Simvastatin CR 20mg- evening administration|
89248729|NCT00975377|No Intervention|No hair removal|Patients randomized to the no hair removal cohort will not undergo any preoperative hair removal.
89248730|NCT00975377|Active Comparator|Hair clipping|Patients in the clipping cohort undergo hair removal at the surgical site. Hair removal will occur on the day of surgery immediately prior to the scheduled operation.
89248731|NCT00975455||Subjects with hematuria|
89248732|NCT00973193|Experimental|panitumumab|
89248733|NCT00975533|Experimental|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
89248734|NCT00975533|Active Comparator|Control|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
89248735|NCT00372567|Experimental|A|
89248736|NCT00372567|Active Comparator|B|
89248737|NCT04008251|Experimental|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
89248738|NCT00973271|Experimental|290 mg DCCR|
89248739|NCT00973271|Experimental|435 mg DCCR|
89248740|NCT00973271|Active Comparator|135 mg fenobric acid|
89248741|NCT00973271|Placebo Comparator|Placebo|
89248742|NCT00975767|Experimental|MGCD265+erlotinib|
89248743|NCT00975767|Experimental|MGCD265+docetaxel|
89248744|NCT00975845||BioCleanse Tibialis Tendon Allograft|Tibialis Tendon allograft from donor 18-65 years old
89248745|NCT00365547|Experimental|Patients Treated With Topotecan and Avastin in NSCLC|Weekly topotecan hydrochloride and bi-weekly Avastin (bevacizumab) in patients with non-small cell lung cancer (NSCLC) who have failed prior systemic chemotherapy.
89248746|NCT00545441|Experimental|1|Surgisis® AFP
89248747|NCT00545441|Active Comparator|2|Flap
89248748|NCT03991767|Experimental|period 1|"Period 1: Retrospective period:~Collection of data from the 12 months preceding the start of the research of hospitalized patients:~number of hospitalizations,~number of HIV serologies performed,~number of patients with socio-demographic criteria justifying HIV screening.~Start of research: Implementation of the POP-UP electronic alert~Period 2: Prospective period: 18 months POP-UP opens for patient who meet the eligibility criteria.~Six possibility to answer:~Patient accept to participate: patient is include and receive HIV serology during their hospitalization.~Not time to answer to the alert~Patient already has a serology less than 3 months old~Patient followed for a known HIV infection.~Patient who refused the test~Clinical condition of the patient not allowing his no opposition Only choice 1 include patient The response close the electronic alert, but it re-opens when the medical file is re-consulted (2/ and 6/) or new hospitalization."
89248749|NCT00976001|Other|Follow-up at an out-patient stroke unit|Information, measurement of handicap, further rehabilitation efforts, drug therapy for secondary prevention of stroke.
89248750|NCT00976001|Other|Follow-up with the general practitioner|
89248751|NCT00979589|Active Comparator|Combination Clopidogrel and asprin|
89248752|NCT00979589|Placebo Comparator|Asprin and placebo|
89248753|NCT00294658|Active Comparator|Thymectomy plus prednisone|Procedure: Extended Transsternal Thymectomy plus prednisone treatment
89248754|NCT00294658|Placebo Comparator|Prednisone alone|Drug: prednisone alone protocol
89248755|NCT00979667|Experimental|Oseltamivir|
89248756|NCT00979667|Experimental|Zanamivir|
89248757|NCT00979667|Placebo Comparator|Placebo of Oseltamivir|
89248758|NCT00976079|Experimental|Active TENS|Active TENS therapy for 4 weeks plus standard physical therapy for same time period.
89248759|NCT00976079|Placebo Comparator|Placebo TENS|Placebo TENS for 4 weeks plus standard physical therapy for same time period.
89248760|NCT00976079|No Intervention|Control Group|No TENS, standard physical therapy for 4 weeks.
89248761|NCT03923933|Placebo Comparator|Placebo|This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
89248762|NCT03923933|Experimental|Treatment grup|This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.
89248763|NCT00372489|Experimental|Peginesatide|
89248764|NCT01066468|Experimental|Gleevec/Glivec|
89248765|NCT00979823|Experimental|Early SimCare Diabetes Group|This group will receive an email web-link to 3 simulated learning cases each month for 6 months. After 6 months (18 total learning cases), they will then complete 4 simulated assessment cases, a diabetes knowledge survey, and a satisfaction survey.
89248766|NCT00979823|Active Comparator|Delayed SimCare Diabetes Group|Beginning in the spring of 2011, residents in this group will receive an email web-link to complete 4 simulated assessment cases and a diabetes knowledge survey. They will subsequently be sent 3 learning cases a month for 6 months and a satisfaction survey to complete.
89248767|NCT01581190|Experimental|Bananas versus 6% carbohydrate beverage|
89248768|NCT00976157||Ventilator-associated pneumonia|
89248769|NCT01069744||Control Group|Control group When neonates are considered ready for oral feedings these feedings will be started with the standard oral feeding protocol for the NICU but without the NTrainer stimulation regimen described previously.
89290296|NCT00254501|Experimental|EMPOWER|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
89290297|NCT05045716|Experimental|Lecanemab 10 mg/kg|Participants will receive lecanemab 10 milligram per kilogram (mg/kg), as single dose IV infusion over approximately 1 hour on Day 1.
89248770|NCT01069744||NTrainer System|NTrainer Experimental Group When neonates are considered ready for oral feedings these feedings will be started simultaneously with the NTrainer therapy. Control and experimental interventions will not be initiated until the infant is in an optimal behavioral state, i.e., drowsy to quiet alert (NIDCAP state 3 or 4). Preterm infants in the experimental group will receive alternating 3-minute epochs of patterned oral somatosensory stimulation and null conditions using the NTrainer© during the tube (gavage) feeding session up to 4 times per day.
89248771|NCT00976235|Experimental|IMT|
89248772|NCT03977740|Experimental|chest PNF|"participants received conventional chest physiotherapy along with chest PNF technique 5 days for 1 week.~Chest PNF technique includes oblique downward pressure at the sternum, diagonal pressure at lower rib cage at the supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on the elbow."
89248773|NCT03977740|Active Comparator|Conventional|participants received conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
89248774|NCT00976313||1|male patients
89248775|NCT00976313||2|female patients
89248776|NCT00979979||HCV patients|HCV patients with detectable viremia; all sera are tested both by Abbott RealTime HCV genotype II test and by direct HCV sequencing both at 5'UTR and NS5B
89248777|NCT00979979||Non-HCV patients|Patient without evidence of HCV infection (negative both for anti-HCV and HCV RNA); all sera are both tested by Abbott RealTime HCV genotype II test and by direct HCV sequencing at 5'UTR and NS5B
89248778|NCT00980135|Experimental|Arm 1|
89248779|NCT00980135|Experimental|Arm 2|
89248780|NCT00980135|Other|Arm 3|
89248781|NCT00980213||sunitinib|advanced renal cell cancer patients treated with sunitinib as first-line therapy
89248782|NCT04986527|Active Comparator|24 hours of suction|Subjects with chest tubes kept to -20 cmH2O suction for 24 hours prior to water seal
89248783|NCT04986527|Experimental|48 hours of suction|Subjects with chest tubes kept to -20 cmH2O suction for 48 hours prior to water seal
89248784|NCT00980369||Chronic anal fissures|Group A: with vertical incision Group B: with parallel incision
89248785|NCT00980369||Parallel incision, vertical insicion|
89248786|NCT00980447|Experimental|UMN-0501 45µg|Recombinant H5N1 vaccine 45µg
89248787|NCT00980447|Experimental|UMN-0501 90µg|Recombinant H5N1 vaccine 90µg
89248788|NCT00980447|Experimental|UMN-0501 135µg|Recombinant H5N1 vaccine 135µg
89248789|NCT00976469|Experimental|Dose A (3.75 µg HA antigen, 0.25 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.
89248790|NCT00976469|Experimental|Dose B (7.5µg HA antigen, 0.5 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.
89248791|NCT00372411|Experimental|Arm 1|Robot-Assisted Therapy - MIT-MANUS System
89248792|NCT00372411|Active Comparator|Arm 2|Intensive Comparison Therapy
89248793|NCT00372411|Other|Arm 3|Usual Care
89248794|NCT00980525||IL-1 genotype positive|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
89248795|NCT00980525||IL-1 genotype negative|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
89248796|NCT00976547||Tinnitus patients|Group of 48 tinnitus patients
89248797|NCT00976625|No Intervention|1|Control group without intervention. Treatment group with aortic valve replacement.
89248798|NCT00976625|Other|2|
89248799|NCT00980603|Active Comparator|docetaxel|
89248800|NCT00980603|Experimental|doctaxel plus cisplatin|
89248801|NCT00980603|Experimental|docetaxel plus S-1|
89248802|NCT00955097|Experimental|Definity Contrast Dye|During liver surgery Definity contrast dye will be administered follwed by an ultrasound to better detect liver tumors
89248803|NCT00955175|Experimental|Group 1|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 24 fractions (total of 72 Gy).
89248804|NCT00955175|Experimental|Group 2|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 22 fractions (total of 66 Gy).
89248805|NCT00955175|Experimental|Group 3|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 20 fractions (total of 60 Gy).
89248806|NCT00980759|Experimental|EFI(Extended-Field Irradiation)|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
89248807|NCT00980759|Experimental|Pelvic RT|Pelvic Irradiation with chemotherapy(cisplatin)
89248808|NCT00976859|No Intervention|Waitlist control group|
89248809|NCT00976859|Experimental|Imagery Modification|Via a internet research patients collect data on skin renewal which is discussed afterwards; in a guided imagery modification the patients imagines the process of skin renewal and the building of new skin cells
89248810|NCT04011293|Experimental|A|Single dose of CNCT19
89248811|NCT03958019|Experimental|Intervention Group|12 week multidisciplinary program consisting of; i) supervised and home-based aerobic and resistance training, ii) 1:1 dietary counselling, and iii) group education sessions.
89248812|NCT03958019|No Intervention|Control|Usual care control group
89248813|NCT00372255|Experimental|Influsplit SSW® 2005/2006 6-9 years Group|Subjects aged 6 to 9 years who received 2 doses of Influsplit SSW® 2005/2006 vaccine at an interval of 4 weeks (Day 0 and Day 28 ± 2).
89248814|NCT00372255|Active Comparator|Influsplit SSW® 2005/2006 10-13 years Group|Subjects aged 10 to 13 years who received 1 dose of Influsplit SSW® 2005/2006 vaccine at Day 0.
89248815|NCT00980915||At risk for Acute Lung Injury|"Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI~Cases-High risk patients that do develop Acute Lung Injury"
89248816|NCT00977015|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
89248817|NCT00977015|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
89248818|NCT00274456|Experimental|ABI-007 300 mg/m^2 q3w|ABI-007 300 mg/m^2 administered once every third week (q3w).
89248819|NCT00274456|Experimental|ABI-007 100 mg/m^2 weekly|ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
89248820|NCT00274456|Experimental|ABI-007 150 mg/m^2 weekly|ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
89248821|NCT00274456|Active Comparator|Docetaxel 100 mg/m^2, q3w|Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).
89248822|NCT01045629||SchizoComp|Competence Ability of schizophrenia
89248823|NCT01045629||NonSchizoComp|Competence of Non-schizophrenia
89248824|NCT01049607|Active Comparator|Clamp-Crush technique|
89248825|NCT01049607|Experimental|Stapler hepatectomy|
89248826|NCT00977093|Experimental|Perfusion CMR examination|All patients will undergo perfusion CMR examination, single-photon emission computed tomography, and conventional invasive coronary angiography.
89248827|NCT00977249|Active Comparator|varenicline|"Varenicline for 12 weeks.~The treatment schedule for varenicline is:~Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks"
89248828|NCT00977249|Placebo Comparator|placebo|Placebo for 12 weeks
89248829|NCT00981071||A platoon with TB outbreak|
89248830|NCT01069822|Experimental|1|midazolam + AZD6765 IV solution
89248831|NCT01069822|Active Comparator|2|
89248832|NCT00977327|Other|Intraoperative MR|Use of intraoperative MR during resection of intraaxial tumor, Glioma
89248833|NCT00977327|Other|Intraoperative Ultrasound|Use of intraoperative ultrasound during resection of intraaxial tumor, Glioma
89248834|NCT03977974|Experimental|LY3526318 - Part A|LY3526318 administered orally once.
89248835|NCT03977974|Placebo Comparator|Placebo - Part A|Placebo administered orally once.
89248836|NCT03977974|Experimental|LY3526318 - Part B|LY3526318 administered once orally on consecutive days.
89248837|NCT03977974|Placebo Comparator|Placebo - Part B|Placebo administered once orally on consecutive days.
89248838|NCT00955565|Experimental|Navigated|
89248839|NCT00955565|Active Comparator|Conventional|
89248840|NCT03976180|Active Comparator|standard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care;
89248841|NCT03976180|Experimental|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;
89248842|NCT03976180|Experimental|HFNO with intermediate FiO2 (50%)|HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
89248843|NCT03976180|Experimental|HFNO with high FiO2 (100%)|HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
89248844|NCT01066702|Experimental|NeoCart|Autologous cartilagenous tissue implant
89248845|NCT01066702|Active Comparator|Microfracture|surgical intervention
89248846|NCT00381849|Active Comparator|Cystone then sugar pill|Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
89248847|NCT00381849|Placebo Comparator|Sugar pill then Cystone|Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
89248848|NCT00381849|Experimental|Open-label Cystone|All subjects will receive Cystone for 46 weeks in the open-label period.
89248849|NCT00273052|Experimental|Carvedilol Phosphate modified release formulation|
89248850|NCT00273052|Active Comparator|metoprolol succinate|
89248851|NCT01046721|Active Comparator|Exenatide|subcutaneous administration of Exenatide (0.02ml)
89248852|NCT01046721|Placebo Comparator|0.9% Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
89248853|NCT02808351|Experimental|Berberine|Preoperative berberine 300 mg administration for at least 6 hours before interventional procedure, post-procedure berberine administration 100 mg at 24, 48 hours after procedure.
89248854|NCT02808351|No Intervention|Blank control|Blank control of berberine administration
89248855|NCT02535195|Active Comparator|Ginger|Participants were randomly divided based on age, sex and severity of steatosis in two groups. Randomization lists were computer-generated by a statistician and participants, project managers and employees at the clinic were completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients advised to consume 2 capsules content 500 mg of ginger (made in Green Plants of Life Pharmaceutics Co., Iran) or placebo (starch) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
89248856|NCT02535195|Placebo Comparator|Placebo|2 capsules content 500 mg of placebo(starch) (made in Green Plants of Life Pharmaceutics Co., Iran) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
89248857|NCT01046799|Experimental|Entecavir|
89248858|NCT00290290|Active Comparator|povidone-iodine|preoperative skin preparation with povidone-iodine
89248859|NCT00290290|Experimental|chlorhexidine-alcohol|preoperative skin preparation with scrub and paint technique
89248860|NCT01049685|Active Comparator|Efavirenz Group|Naïve-treatment HIV patients, who started therapy with Efavirenz
89248861|NCT01049685|Active Comparator|Lopinavir/r Group|Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir
89248862|NCT01580943|Active Comparator|Antiplaque Efficacy|"This study was designed as a randomized, two group parallel, double-blind, 3-day non-brushing clinical trial. The sample size (50 participants) was determined using similar studies, making it a convenience sample.~Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds."
89248863|NCT01580943|Active Comparator|Taste and Side Effects|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
89248864|NCT02534961|Active Comparator|prophylactic antibiotics group|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy.
89248865|NCT02534961|No Intervention|on-demand antibiotics group|Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established.
89248866|NCT01046955|Active Comparator|1mg/kg Thymoglobulin|LD kidneys receiving 1mg/kg Thymoglobulin for 7 days starting at the day of surgery.
89248867|NCT01046955|Active Comparator|Campath-1H at 0.3 mg/kg|Recipients of LD kidneys receiving Campath-1H at 0.3 mg/kg once on the day of surgery and again 3 days post-operatively.
89248868|NCT01046955|Active Comparator|Zenapax 1 mg/kg|Recipients of LD kidneys receiving Zenapax 1mg/kg on the day of surgery followed by the same dose every 2 weeks for a total of 5 dosages.
89248869|NCT00272038|Experimental|Tarceva|Tarceva 150 mg QD
89248870|NCT01047033|Active Comparator|Microcredit only|
89248871|NCT01047033|Experimental|Microcredit plus health education|Thirty minutes of a health education module administered to clients by loan officer at their monthly group meetings over the course of 8 months.
89248872|NCT00271024|Experimental|Male Naltrexone|50 mg Naltrexone tablet
89248873|NCT00271024|Experimental|Female Naltrexone|Females receiving either naltrexone (50 mg)
89248874|NCT00271024|Placebo Comparator|Male Placebo|Males receiving Placebo (sugar pill)
89248875|NCT00271024|Placebo Comparator|Female Placebo|Females receiving placebo (sugar pill)
89248876|NCT00545363|Experimental|Bone Marker Feedback (BMF) Participants|"Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants, in this arm, will receive BMF at Month 3. BMF will be given in terms of providing serum carboxy-terminal collagen crosslinks (CTX) level at Month 3. A BMF-form will be provided to the physicians to allow offering the bone marker result in an easy way. Participants will be informed if their results are within or outside of the desired range. In addition, participants will also supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake."
89248877|NCT00545363|Active Comparator|No BMF Participants|Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants will be supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake.
89248878|NCT04011215|Experimental|wool-first (wool X standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing
89248879|NCT04011215|Active Comparator|standard-first (standard X wool)|standard clothing to be worn for 6 weeks followed by 6 weeks of superfine merino wool clothing
89248880|NCT00955643|Experimental|hyperbaric therapy|Hyperbaric therapy by oxygen
89248881|NCT00955643|Experimental|dental scaling and root planing|dental scaling and cleaning
89248882|NCT05059457||Controlled setting: single capillary and pooled capillary and venous blood|Single drop capillary blood, pooled capillary blood, and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a controlled setting.
89248883|NCT05059457||Field setting: single capillary and venous blood|Single drop capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.
89248884|NCT05059457||Field setting: pooled capillary and venous blood|Pooled capillary blood and venous blood will be collected and hemoglobin measured among non-pregnant women age 15-49 and children age 6-59 months in a field setting.
89248885|NCT00977405|No Intervention|Control|Primary closure after standard washing of wound with chlorhexidine solution
89248886|NCT00977405|Experimental|Collatamp G|Primary closure of wound with collatamp G in subcutaneous layer
89248887|NCT00977717||FOLFOX|Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
89248888|NCT00981383|Experimental|Treatment|Omega-3 Fatty Acid Supplement, 1.9 g ω-3 FAs daily
89248889|NCT00981383|Placebo Comparator|Placebo|Matching placebo, less than 0.12 g ω-3 FAs daily
89248890|NCT00977795|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
89248891|NCT00977873|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
89248892|NCT00977873|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
89248893|NCT00977951|Experimental|Intradermal avotermin|
89248894|NCT00977951|Placebo Comparator|Placebo (vehicle)|
89248895|NCT00981539|Active Comparator|treatment : receives pre operative enema|one arm will receive pre operative enema
89248896|NCT00981539|No Intervention|no enema|this group will not receive pre operative enema
89248897|NCT00457392|Experimental|1|
89248898|NCT00457392|Active Comparator|2|
89248899|NCT00545051|Experimental|Ibandronate|Participants received monthly oral ibandronate (150 milligrams [mg]) for 12 months.
89248900|NCT00545051|Placebo Comparator|Placebo|Participants received monthly oral placebo for 12 months.
89248901|NCT00381615|Experimental|rMenB|"Infants received 4 doses of recombinant meningococcal serogroup B (rMenB) vaccine without outer membrane vesicle (OMV-NZ) at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of Diphtheria Tetanus Pertussis-Haemophilus influenzae type b-Inactivated Polio Vaccine (DTaP-Hib-IPV) (at 2, 3, and 4 months) and Heptavalent Pneumococcal Conjugate (PC7) (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and Measles Mumps Rubella (MMR) (at 13 months)."
89248902|NCT00381615|Experimental|rMenB+OMV|"Infants received 4 doses of rMenB vaccine with OMV-NZ at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months)."
89248903|NCT00381615|Experimental|Routine|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine without OMV-NZ at 12 months of age."
89248904|NCT00381615|Experimental|Routine+OMV|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine with OMV-NZ at 12 months of age."
89248905|NCT01029132|Experimental|non-responder group|patients who did not maintained or improved cognitive function
89248906|NCT01029132|Experimental|responder group|patients who maintained or improved cognitive function
89248907|NCT00981695|Experimental|Vaccinees|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
89248908|NCT00981695|No Intervention|Controls|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
89248909|NCT04008017||stable Chronic obstructive pulmonary disease|clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
89248910|NCT04008017||acute exacerbation of Chronic obstructive pulmonary disease|patients developed fever, increased dyspnea and sputum production plus the clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator
89248911|NCT01049763|Experimental|Regimen A|oseltamivir 75 mg single dose
89248912|NCT01049763|Active Comparator|Regimen B|oseltamivir 150 mg single dose
89248913|NCT00981773|Experimental|Immediate switch|"Continue current boosted protease inhibitor~Switch NRTI backbone to maraviroc 150 mg bid"
89248914|NCT00981773|Active Comparator|Continue current antiretroviral therapy|Continue current antiretroviral regimen until week 12 then switch therapy as per arm 1.
89248915|NCT04007549|Experimental|Individual brief motivational intervention|Individual brief motivational intervention (IBMI) on tobacco/alcohol risk reduction for the breast cancer patient; the partner receive e-mail or postal brief advices.
89248916|NCT04007549|Active Comparator|Couple-based brief motivational intervention|Couple-based brief motivational intervention (CBMI) on tobacco/alcohol risk reduction.
89248917|NCT00371865|Active Comparator|Cognitive Behavioral Therapy|8 group-administered sessions of Cognitive-Behavioral Therapy
89248918|NCT00371865|Experimental|Acceptance-Based Therapy|8 group-administered sessions of Acceptance-based therapy
89248919|NCT05057585|Experimental|Exercise group|Each patient in the experimental group was given in-bed exercises for 15 minutes. An anxiety questionnaire was asked to both the experimental and control groups. It was expected that both the experimental and control group patients would be stable in the postoperative period. The same exercises were applied again for 15 minutes to the patients who were stable after the surgery. Then the patients were made to take steps around the bed. Pain levels were measured.
89248920|NCT05057585|No Intervention|No treatment group|Apart from clinical protocols, no application was made in patient follow-up. Anxiety scale was filled and pain level was evaluated. Pain and anxiety scales were refilled within the same period without any application.
89248921|NCT03935867|Experimental|C-PROFET group|Community-dwelling, older adults participating in a home-based program -- C-PROFET, our adaptation of Prevention Of Falls in the Elderly Trial (PROFET).
89248922|NCT01049841|Experimental|perifosine + temsirolimus|This is a single arm, phase I study. Eligible patients will receive a loading dose of oral perifosine on the first day, followed by a maintenance dose starting on the second day until progression. Each patient is assigned to a group according to their body surface area (BSA). Temsirolimus will be combined with perifosine at four dose levels to determine the MTD for the combination therapy. Temsirolimus dosing will start on the same day as the perifosine load.
89248923|NCT00978263|Experimental|Glargine|Initial basal Insulin therapy was according to the dose administrated at bedtime in the last day hospitalization. basal Insulin doses were titrated every 3 days to achieve target FPG values between 80 and 130 mg/dl.
89248924|NCT00978263|Experimental|metformin-based Oral Antidiabetic Drugs|Subject in metformin-based OAD group was visited every two weeks in the first month and the every four weeks for another five months. The subjects will start with Metformin 425mg bid, The dosage was titrated (up to 850mg bid) based on the fasting blood glucose every two weeks. If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.
89248925|NCT00981851|Active Comparator|beta 2 agonist + anticholinergic aerosol|
89248926|NCT00981851|Placebo Comparator|placebo inhalation|
89248927|NCT00978575|Active Comparator|Intravenous iron|
89248928|NCT00978575|Active Comparator|Oral iron|
89248929|NCT00978575|Placebo Comparator|Isotonic Sodium and placebo tablets|
89248930|NCT04007315|Experimental|SaeboGlove Therapy + usual care|Use for 6 weeks - given an individualised self-management training programme involving repetitive grasping and releasing movements.
89248931|NCT04007315|Active Comparator|Usual care|Usual NHS rehabilitation care based on National Clinical Guidelines for 6 weeks + 2 study visits and one study phone call
89248932|NCT00981929|Active Comparator|Tramadol|CYP2D6 metric
89248933|NCT00981929|Active Comparator|Omeprazole, losartan, caffeine|CYP2C19, CYP2C9 and CYP1A2 metrics
88806091|NCT05438160|Other|Schizophrenia treated with digital therapeutics app CT-155|Single group of People with Schizophrenia to be treated with digital therapeutics app CT-155
89248934|NCT00981929|Active Comparator|Tramadol, omeprazole, losartan and caffeine|CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics
89248935|NCT00982085||Soldiers|Soldiers: The soldiers who respond the questionnaires
89248936|NCT00364845|Active Comparator|Darbepoetin alfa|Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
89248937|NCT00364845|Placebo Comparator|Placebo|Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.
89248938|NCT00978653|Experimental|Allopurinol|Hyperuricemic (uric acid (UA)>7 mg/dL), nondiabetic CKD patients without any comorbidity, age<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
89248939|NCT00982241|Active Comparator|normal fluid intake|1500 ml /day (+/- 300 ml) for 2,5 days
89248940|NCT00982241|Active Comparator|high fluid intake|2400 ml/day (+/- 300 ml )for 2,5 days
89248941|NCT00982241|Active Comparator|low fluid intake|fluid intake 900 ml/day (+/- 300ml) for 2,5 days
89248942|NCT00978809|Active Comparator|Semont|BPPV patients treated by Semont maneuver by a physical therapist.
89248943|NCT00978809|No Intervention|control|healthy volunteers.
89248944|NCT00978809|Active Comparator|Epley maneuver|BPPV patients treated with Epley maneuver by a physical therapist.
89248945|NCT00956033||Patients with multiple myeloma|
89248946|NCT00978887|Experimental|A|Retorna (facial cream)
89248947|NCT00978887|Placebo Comparator|B|Placebo (facial cream)
89248948|NCT04891445|Active Comparator|As usual|"Patients will be directly referred to their family doctor with a report on the data obtained in the analysis (presence of HCV and positive viral load), so that they can follow the usual treatment (as usual) in these cases in the Andalusian Health Service.~The usual treatment implies, once the presence of Virus C has been confirmed, referral by the patient's family doctor to the specialized service, in this case the Gastroenterology Service of the referral Hospital, through the usual appointment procedure. Generally the delay in this process is usually approx. 2-3 months for the first appointment."
89248949|NCT04891445|Experimental|Nurse-Navigation Programme|"A Clinical Pathway (CP) of nursing monitoring will be activated, that is, patients will be accompanied throughout the evaluation and treatment process until their complete cure is guaranteed.~CP will include the activation of care in the Gastroenterology Service by the nurse. By requesting a first appointment in the Gastroenterology Service, via email, the nurse will activate the patients' access to this first appointment, which consist in a one-step intervention: liver evaluation analysis on the genotype, determine the most appropriate type of treatment and, dispensing treatment by the Hospital Pharmacy Unit. To guarantee attendance, in all cases the patient will be accompanied, either by a competent available family caregiver, or by the mental health nursing team.~All the intervention will be operationalized through the mentioned CP developed for this purpose, with the participation of those involved."
89248950|NCT04007237|Experimental|Selsun Shampoo (SeS2 shampoo)|Subject were given the SeS2 1.8% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
89248951|NCT04007237|Active Comparator|Ketoconazole shampoo|Subject were given the Ketoconazole 2% shampoo for 2 weeks. They should use it everyday, 10ml each time for 10 minutes. Evaluation was weekly and note for side effects and compliance
89248952|NCT00293722||Patients with Psoriatic Arthritis|
89248953|NCT01070056|Active Comparator|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
89248954|NCT01070056|Experimental|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension (HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
89248955|NCT03976414||eMOM website users|"Any woman who visits the research tab on the eMOM website will see an invitation to participate in a research study about the impact of the website on her bladder and bowel symptoms. Women may use the intervention (the website) regardless of whether they opt to participate in the research study.~The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence."
89248956|NCT00381303|Experimental|001|darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks
89248957|NCT00448812|Experimental|Alair Treatment|Subjects from PREDECESSOR STUDY (NCT00214526) treated with conventional therapy with ICS+LABA (inhaled corticosteroid + long-acting beta-agonist) plus Bronchial Thermoplasty with the Alair System.
89248958|NCT00448812|No Intervention|Control|Control group subjects from PREDECESSOR STUDY (NCT00214526).
89248959|NCT00364689|Experimental|lactulose given with a placebo (sugar pill)|
89248960|NCT00364689|Experimental|lactulose given with rifaximin|
89248961|NCT00364689|Active Comparator|rifaximin given alone|
89248962|NCT00545129|Experimental|Tanezumab 10 mg IV + opioids|
89248963|NCT00545129|Placebo Comparator|Placebo + opioids|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
89248964|NCT05279339|No Intervention|Control|Participants will not perform any exercise
89248965|NCT05279339|Experimental|Exercise|Participants will perform an exercise recommended for preventing neck and shoulder pain
89248966|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
89248967|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
89248968|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
89248969|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
89248970|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 5 μg|100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 5 μg on day 0 and 21.
89248971|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 10 μg|"200 participants: 100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 and 21.~100 elders to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 only."
89248972|NCT00956111|Placebo Comparator|Placebo control|100 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
89248973|NCT00978965||All patients|
89248974|NCT00982475|Active Comparator|PVI with robotic navigation|
89248975|NCT00982475|Placebo Comparator|PVI manually|
89248976|NCT00979433|Experimental|Bubble CPAP|All neonates randomised to bubble CPAP will be put on Bubble CPAP following initial extubation in first week of life.
89248977|NCT00979433|Other|Conventional CPAP|All neonates randomly allocated to conventional/ventilator derived CPAP.
89248978|NCT00982631|Experimental|temsirolimus/PLD|temsirolimus (Torisel) with pegylated liposomal doxorubicin (PLD,Doxil,Caelyx);a dose escalating study in a 3+3 design
89248979|NCT00364611|Experimental|Docetaxel and Bevacizumab|Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
89248980|NCT00364611|Experimental|Docetaxel, Bevacizumab and Trastuzumab|Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
89248981|NCT00979511|Experimental|1 Hi-Calcium milk & exercise|
89248982|NCT00979511|Experimental|2 Hi-calcium milk with passive exercise|
89248983|NCT00979511|Experimental|3Low-Calcium with exercise|
89248984|NCT00979511|Experimental|4 Low-calcium milk with passive exercise|
89248985|NCT00956189|Experimental|Amisulpride|A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.
89248986|NCT00956189|Experimental|Aripiprazole|A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.
89248987|NCT00984581|Experimental|Intradermal avotermin|
89248988|NCT00984581|Placebo Comparator|Placebo|
89248989|NCT00956267|Experimental|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
89248990|NCT00956267|Active Comparator|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
89248991|NCT04007003|Experimental|optimal injection technique|Subjects will be trained on site regarding optimal insulin injection technique, including avoiding injections in lipohypertrophy areas and proper rotation. Furthermore subjects are provided with access codes to watch online training modules on the Becton Dickinson (BD) and Me(TM) platform
89248992|NCT00982709|Active Comparator|Exercise Types|comparing two different exercise programs for PD
89248993|NCT04007081|Experimental|Participants with Xerostomia|Salivary sample collection, quality of life survey, salivary gland imaging, bone marrow aspiration
89248994|NCT00364533|Placebo Comparator|003|Placebo Fixed Dose Matching placebo for 3 days
89248995|NCT00364533|Active Comparator|002|Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days
89248996|NCT00364533|Experimental|001|Tapentadol IR (CG5503) Fixed Dose 50, 75, & 100 mg BID for 3 days
89248997|NCT00364533|Other|004|Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
89248998|NCT00982787|Experimental|1|
89248999|NCT00982787|Placebo Comparator|2|
89249000|NCT00956345|Experimental|25U/kg|
89249001|NCT00956345|Experimental|50U/kg|
89249002|NCT00956345|Experimental|100U/kg|
89249003|NCT01047423|Experimental|Simvastatin|40mg Simvastatin once daily for 12 weeks followed by 4 week washout period followed by placebo for 12 weeks
89249004|NCT01047423|Placebo Comparator|Placebo|Placebo for 12 weeks followed by 4 week washout period followed by 40mg Simvastatin once daily for 12 weeks
89249005|NCT02534805||Patient Buddy|Subjects and caregivers will be given iphones loaded with the App that will be used to enter medications, issues and orientation questions. They will be seen at day 15 and day 30 and will receive a phone call day 7 and day 21 inquiring about issues that would need medical attention
89249006|NCT01047579|Other|Rivastigmine transdermal|
89249007|NCT04006847|Experimental|Eicosapentaenoic Acid (EPA)|"Phase I: TKI with escalating/de-escalating doses of EPA to determine MTD.~Phase I dose levels: Dose Level 1 = EPA 1500 mg orally once per day; Dose Level 2 = EPA 2000 mg orally once per day; Dose Level 3 = EPA 3000 mg orally once per day; Dose Level -1 = EPA 1000 mg orally once per day; Dose Level -2 = EPA 500 mg orally once per day.~Phase II: TKI administered in combination with the recommended Phase II dose of EPA"
89249008|NCT02534727||Sputum and blood participants|These participants will contribute both blood and sputum to the study
89249009|NCT02534727||Sputum only participants|These participants will only contribute sputum to the study
89249010|NCT00984893||Zoledronic acid|
89249011|NCT00984893||Oral Bisphosphonates|
89249012|NCT02502747|Experimental|G-CSF and Myocardial Contrast Echocardiography (MCE)|subcutaneous Granulocyte - Colony Stimulating Factor ( on top of optimal standard of care) and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
89249013|NCT02502747|Active Comparator|Placebo and Myocardial Contrast Echocardiography (MCE)|Patients will be receive optimal standard of care and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
89249014|NCT00983021|Experimental|A|
89249015|NCT00983021|Experimental|B|
89249016|NCT00983021|Active Comparator|C|
89249017|NCT00983021|Experimental|D|
89249018|NCT00984971|Experimental|Tenofovir|
89249019|NCT00984971|Placebo Comparator|HEC Placebo|
89249020|NCT00984971|Other|Open label tenofovir tablet|
89249021|NCT00544817|Experimental|Combination Therapy|"In the combined modality portion of the study, patients were administered:~Radiation Therapy - 2 Gy/fraction, Single daily fractions M-F, to 60 Gy total Temozolomide - 75 mg/m2 by mouth once daily~Patients took a four week break before beginning follow-up systemic therapy:~Temozolomide - 150 mg /m2 by mouth on days 1-5 every 28 days for 6 cycles Sorafenib - 400 mg by mouth twice a day for 6 months"
89249022|NCT04661423|Experimental|Remote Automated Monitoring System|MultiSense® strip will be attached on patient's thorax. The monitoring will last between 5 and 7 days during the post-ICU hospitalization, at rest and during rehabilitation exercises.
89249023|NCT04812899|Experimental|Parents who have a child/adolescent with an eating disorder on waitlist|"Each participant will receive a series of pre-recorded videos and book -(10 videos of about 10 minutes each, along with the book Help Your Teenager Beat an Eating Disorder). This will include content on empowering parents to renourish their child and interrupt binge/purge behaviors."
89249024|NCT04005833||COPD exacerbation|COPD exacerbation, compared according to blood fibrocytes level measured during the suspected exacerbation (Day 1)
89249025|NCT00289978|Experimental|Fingolimod 1.25 mg|
89249026|NCT00289978|Experimental|Fingolimod 0.5 mg|
89249027|NCT00289978|Placebo Comparator|Placebo|
89249028|NCT00983177|Active Comparator|colchicine|
89249029|NCT00983177|Placebo Comparator|Lactose capsule|
89249030|NCT00985283|Experimental|Preventive home visit|receives preventive home visit intervention 4 times over 1 year
89249031|NCT00985283|Active Comparator|comparison group|receives information packets on local services for older adults and health promotion material twice during 1 year
89249032|NCT00983255|Experimental|SAD/ Part A|Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.
89249033|NCT00983255|Experimental|MAD / Part B|Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.
89249034|NCT00983255|Experimental|Bioavailability / Part C|TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.
89249035|NCT00983255|Experimental|Venous Tolerability/ Part D|IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,
89249036|NCT05279261|Experimental|Experimental group|Undergo the axillary approach
89249037|NCT00983333|Experimental|Web-based communication tool for health care professionals|
89249038|NCT00983333|Experimental|Web-based communication training tool for patients|
89249039|NCT00983333|No Intervention|Usual care for patient participants|
89249040|NCT00983411||Healthy and OHS subjects|10 healthy subjects: 20 to 60 years old 10 patients with Obesity hypoventilation syndrome: 20 to 70 years old treated with nocturnal non invasive ventilation for at least three months.
89249041|NCT00988403|Experimental|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
89249042|NCT00988403|Experimental|Fructan - 10 grams|Subjects will consume 10 grams of fructan
89249043|NCT00988403|Experimental|Fructan - 12.5 grams|Subjects will consume 12.5 grams of fructan
89249044|NCT00988403|Experimental|5 grams Fructan|"Experimental - 5 grams Fructan~Subjects will consume 5 grams of Fructan."
89249045|NCT03720821|Experimental|Cognitive Training + fMRI|"Participants will complete Trail Making Test (TMT) A & B (both electronic and paper-pencil), the paper-pencil Color-Word Matching Stroop Test (CWMST), and its electronic version called Color Match, and a computer-based subset of NCPT (Neurocognitive Performance Test). In addition, participants will also complete Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and the Resilience Scale questionnaires at baseline.~Participants will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.~Participants will be asked to undergo 2 functional magnetic resonance imaging (fMRI) sessions. One prior to, and one after the 5-week cognitive training period."
89249046|NCT00983567|Experimental|Teen web|Main web - with all components
89249047|NCT00983567|Active Comparator|Minimal teen web|Teen web minus behavioral components
89249048|NCT00542321|Experimental|Kinetic Therapy Bed|Kinetic Therapy Bed: Continuous automated turning to 45 degrees with head of the bed elevated 30 degrees or more for up to 7 continuous days
89249049|NCT00542321|Active Comparator|Manual Turn|Manual Turn: lateral rotation every 2 hours from back to left to back to right to back, with >/= 45 degree lateral rotation angle and 30 degree head of bed elevation
89249050|NCT00289900|Experimental|MK-0524B 2g/20 mg|Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks
89249051|NCT00289900|Experimental|MK-0524B 2g/40mg|Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks
89249052|NCT00289900|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg, orally, once daily for 12 weeks
89249053|NCT00289900|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg, orally, once daily for 12 weeks
89249054|NCT00289900|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg, orally, once daily for 12 weeks
89249055|NCT00289900|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg, orally, once daily for 12 weeks
89249056|NCT01067014||iO-Flex|
89249057|NCT00543725|Active Comparator|002|efavirenz 600 mg tablet once daily for 96 weeks
89249058|NCT00543725|Experimental|001|TMC278 25 mg tablet once daily for 96 weeks
89249059|NCT00985361|Experimental|Vitamin D 2000 international units daily|
89249060|NCT00985361|Active Comparator|Vitamin C 500mg daily|
89249061|NCT00984035||Prospecitive Analysis|Patients currently receiving cisplatin as treatment for their cancer.
89249062|NCT00984035||Restrospective Analysis|Patients that have previously received cisplatin as treatment for their cancer.
89249063|NCT00269152|Experimental|A: Pemetrexed + Cisplatin|
89249064|NCT00269152|Experimental|B: Pemetrexed + Carboplatin|
89249065|NCT00988715|Experimental|Treatment (PRIT, transplant)|Patients undergo pretargeted radioimmunotherapy comprising a test dose of BC8-SA conjugate IV on day -22 and 111In-DOTA-biotin IV on day -20, followed by a therapy dose of BC8-SA conjugate IV on day -14 and 90Y-DOTA-biotin IV on day -12. Patients receive fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and then peripheral blood stem cell transplant on day 0. Patients with matched related donors receive cyclosporine IV on days -3 to 56 and taper to day 180 and mycophenolate mofetil PO BID on days 0-27. Patients with matched unrelated donors receive cyclosporine IV on days -3 to 100 and taper to day 180 and mycophenolate mofetil PO TID on days 0-40 and taper to day 96.
89249066|NCT01325662||Continuous drip sampling|Sampling at ~0.6 cc / hour (~1.2 cc / 2 hours, or lowest feasible rate given technical requirements and volume requirements for core analytes assays)
89249067|NCT01325662||Intermittent sampling|Sampling at 4 cc every 2 hours (+ 2 cc dead space clearance, total = 6 cc / 2 hours)
89249068|NCT01325740|Active Comparator|STX107 10 mg|
89249069|NCT01325740|Placebo Comparator|Placebo|
89249070|NCT01325740|Active Comparator|STX107 30 mg|
89249071|NCT03975166|Experimental|Test Product|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89249072|NCT03975166|Active Comparator|Reference Product|ADVAIR DISKUS® 100/50
89249073|NCT01067092|Experimental|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
89249074|NCT01067092|Active Comparator|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
89249075|NCT03976024|Experimental|DHBN-FN arm|"Recruitment is planned in traditional hospitalization for DHBN-FN patients. Evaluation of streptococcal carriage by swab, pharyngeal, anal and perineal in patients hospitalized for a DHBN-FN at the end of hospitalization and 1 month after discharge from hospital during the reassessment consultation. Swabs made by the dermatologist.~The carriage of streptococcus in patients living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index"
89249076|NCT03976024|Active Comparator|Control arm (Erysipelas)|"Recruitment is planned in traditional hospitalization for patients with erysipelas.~The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission)."
89249077|NCT01067170|Experimental|Pneumatic compression stockings|
89249078|NCT01325818|Active Comparator|1:pravastatin, 2:rosuvastatin|"Active Comparator Drug:pravastatin~Active Comparator Drug:rosuvastatin"
89249079|NCT00379899|Active Comparator|Control|Standard of care, without use of cinacalcet.
89249080|NCT02535039|Placebo Comparator|Placebo|Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.The same volume of physiological saline will be given.
89249081|NCT02535039|Experimental|Methylprednisolne|in the anaesthesia to 1 mg/kg intravenous methylprednisolone, methylprednisolone continuous use 1 mg/kg * d until the third day after surgery.Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.
89249082|NCT02535117|Experimental|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
89249083|NCT02535117|Active Comparator|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
89249084|NCT00371787|Experimental|soft contact lens|
89249085|NCT00371787|No Intervention|non-lens wear|control group
89249086|NCT00363129|Experimental|Arm I|Patients receive oral vitamin E twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
89249087|NCT00363129|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
89249088|NCT00268996|Experimental|Subjects with ACS and evidence of MN:SB-480848|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
89249089|NCT00268996|Placebo Comparator|Subjects with ACS and evidence of MN: placebo|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
89249090|NCT00268996|Experimental|Non-ACS and ACS subjects without evidence of MN: SB-480848|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
89249091|NCT00268996|Placebo Comparator|Non-ACS and those ACS subjects without evidence of MN: placebo|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
89249092|NCT00371397|Experimental|Hatha yoga classes|Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
89249093|NCT00371397|Sham Comparator|Movement Control|Non-Hatha yoga gentle movement. Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
89249094|NCT00371397|No Intervention|Passive Video Control|Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
89249095|NCT03975244|Experimental|Exercise group|Three months of semi-supervised exercise program in patients awaiting bariatric surgery. Body composition, cardiovascular risk factors, physical fitness, physical activity levels and quality of life will be assessed before and at the end of the study. In addition, surgery time, hospital length of stay and operative complications also will be evaluated.
89249096|NCT03975244|No Intervention|Control group|The control group only will perform the evaluations of the study.
89249097|NCT01067248||COPD, osteoporosis|The subjects are divided into 6 groups of 20 subjects each, I: COPD patients with osteoporosis based on T-score and without vertebral fractures, II: COPD patients with osteoporosis based on T-score and vertebral fractures, III: COPD patients with vertebral fractures and without osteoporosis based on T-score, IV: COPD patients without osteoporosis based on T-score and without vertebral fractures, V: healthy controls with osteoporosis based on T-score and without vertebral fractures, VI: healthy controls without osteoporosis based on T-score and without vertebral fractures.
89249098|NCT03977506|Experimental|Behavoiral|The evaluation will be realized on two different assessment grids during the test on the road
89249099|NCT00289198|Experimental|Fluticasone furoate|Participants were instructed to administer two sprays into each nostril once daily every morning of fluticasone furoate 110 μg
89249100|NCT00289198|Placebo Comparator|Placebo|Participants were instructed to administer two sprays into each nostril once daily every morning of placebo
89249101|NCT01067404||2008-09 study TIV recipients|Infants and toddlers who participated in earlier clinical trial (TITRE) to evaluate dosing (0.25mL versus 0.5mL) of trivalent influenza vaccine (TIV)
89249102|NCT01067482||Glaucoma patients|
89249103|NCT01067482||Glaucoma suspect group|
89249104|NCT01067482||Normal population|
89249105|NCT03741712|Experimental|SHR2554|Participants will receive SHR2554 orally
89249106|NCT03741712|Experimental|SHR2554+SHR3680|Participants will receive SHR2554 combined with SHR3680 orally
89249107|NCT00363051|Experimental|Everolimus 10 mg|"Stratum 1 patients who were not receiving regular Octreotide Depot therapy. These patients were to receive everolimus monotherapy at 10 mg/day.~Stratum 2 patients who were to receive everolimus 10 mg/day in addition to continuing their entry dose of Octreotide Depot therapy.~Patients were instructed to take two 5 mg tablets of everolimus orally with a glass of water, once daily (preferably in the morning). Dosing was strongly recommended to occur at the same time every day."
89249108|NCT00379353|Active Comparator|Group 1: Thalidomide|100 mg capsules orally, once a day for 14 days
89249109|NCT00379353|Placebo Comparator|Group 2: Placebo|Two placebo capsules orally, once a day for 14 days.
89249110|NCT03992391|No Intervention|Qualitative Interviews|Qualitative Interviews with adolescents, their parents and clinicians.
89249111|NCT03992391|Experimental|Open Pilot|Open-label pilot group of adolescents (n=10) in a suicide prevention intensive outpatient program
89249112|NCT03992391|Experimental|Open-label trial|Open-label trial of adolescents (n=40) in a suicide prevention intensive outpatient program
89249113|NCT01047657|Experimental|weight loss|
89249114|NCT01047657|No Intervention|Control|
89249115|NCT01047813||Type 2 diabetes|This group contains 25 participants with type 2 diabetes
89249116|NCT01047813||control group|This group contains 25 participants withput type 2 diabetes. The control group is matched with age, education and lifestyle to the diabetes group.
89249117|NCT00378573|Experimental|docetaxel, gemcitabine and bevacizumab|Single arm treatment with docetaxel, gemcitabine and bevacizumab
89249118|NCT01049997||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
89249119|NCT01581099||Clinical treatment|Diabetic individuals refractory to medical treatment kept under clinical treatment guidelines and lifestyle
89249120|NCT01581099||Surgery|Diabetic individuals refractory to conservative clinical treatment subject to Digestive Adaptations III Surgery.
89249121|NCT01581099||Control|Healthy individuals (normal weight and no cardiovascular risk factors) will be used to evaluate the behavior incretin hormones in healthy individuals, serving as a benchmark to analyze the results obtained in other groups.
89249122|NCT01047891|Experimental|Experimental|
89249123|NCT02534571|Experimental|TC-325|Endoscopic Application of a Hemostatic Powder TC-325, <=150gm , once
89249124|NCT02534571|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clip or4 pulse , once only
89249125|NCT03831945|Active Comparator|Single infusion of VRC01 and 10-1074|Single infusion of 40 mg/kg VRC-HIVMAB060-00-AB (VRC01) in 100 mL of saline and 30 mg/kg of 10-1074 in 250 mL of saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
89249126|NCT03831945|Placebo Comparator|Single infusion of Normal Saline|Single infusion of 100 mL and 250 mL of normal saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
89249127|NCT00457002|Experimental|Arm 1|"While hospitalized, Apixaban plus Placebo~Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC)~After hospital discharge, Apixaban~Apixaban (Tablets, Oral, 2.5 mg)"
89249128|NCT00457002|Active Comparator|Arm 2|"While hospitalized, Enoxaparin plus Placebo~Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral)~After hospital discharge: Placebo~Placebo (Tablets, Oral)"
89249129|NCT00362115|Experimental|Azilsartan Medoxomil 5 mg QD|
89249130|NCT00362115|Experimental|Azilsartan Medoxomil 10 mg QD|
89249131|NCT00362115|Experimental|Azilsartan Medoxomil 20 mg QD|
89249132|NCT00362115|Experimental|Azilsartan Medoxomil 40 mg QD|
89249133|NCT00362115|Experimental|Azilsartan Medoxomil 80 mg QD|
89249134|NCT00362115|Active Comparator|Olmesartan 20 mg QD|
89249135|NCT00362115|Placebo Comparator|Placebo QD|
89249136|NCT00485264|Experimental|Cohort I|"Participants between the ages of 12 and 18 years; receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily."
89249137|NCT00485264|Experimental|Cohort IIA|"Participants between the ages of 6 and 11 years, receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet."
89249138|NCT00485264|Experimental|Cohort IIB|"Participants between the ages of 6 and 11 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
89249139|NCT00485264|Experimental|Cohort III|"Participants between the ages of 2 and 5 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
89249140|NCT00485264|Experimental|Cohort IV|"Participants between the ages of 6 and 23 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
89249141|NCT00485264|Experimental|Cohort V|"Participants between the ages of 4 weeks and 5 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
89249142|NCT00293254|Experimental|1|raltegravir potassium
89249143|NCT00293254|Placebo Comparator|2|Placebo
89249144|NCT01018784|Experimental|MORAb-009|
89249145|NCT01018940||Plavix|
89249146|NCT01018940||Prasugrel|
89249147|NCT01019018|Active Comparator|Stevens cannula|Subtenon with stevens cannula
89249148|NCT01019018|Experimental|Olive tip|Olive tip group
89249149|NCT03977350||Patients over 65 years undergoing heart surgery|Patients over 65 years undergoing heart surgery under anesthesia, EEG monitored
89249150|NCT04498611|Experimental|breast DCIS patients|Breast DCIS patients who diagnosed by tissue biopsy except excisional biopsy before surgery, and who agreed to taking the breast MRI.
89249151|NCT03975010|Experimental|BUP TDS 20 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 20 mg for 3 days.
89249152|NCT03975010|Experimental|BUP TDS 40 mg for 3 days|Subjects will be randomized into the arms, use BUP TDS 40 mg for 3 days.
89249153|NCT03975010|Experimental|BUP TDS 40 mg for 4 day|Subjects will be randomized into the arms, use BUP TDS 40 mg for 4 days.
89249154|NCT01050075|Experimental|Arm I|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
89249155|NCT01050075|Experimental|Arm II|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.
89249156|NCT01070134|Experimental|Mindfulness-based Behavioural Therapy (MIBT)|
89249157|NCT01070134|Active Comparator|PT (psychodynamic therapy)|
89249158|NCT01048047|Experimental|aliskiren/amlodipine|aliskiren, 300 mg/amlodipine 10 mg
89249159|NCT01048047|Active Comparator|amlodipine|amlodipine 10 mg
89249160|NCT01011686|Experimental|ANT-SM|autologous adipose-derived stem cell
89249161|NCT01324635|Experimental|Arm A (panobinostat, multiple fractions of SBRT)|Patients receive panobinostat PO thrice weekly for 2 weeks and undergo 10 fractions of SBRT over 2 weeks (recurrent gliomas) OR 30 fractions of SBRT over 6 weeks (high grade meningiomas).
89249162|NCT01324635|Experimental|Arm B (panobinostat, stereotactic radiosurgery)|Patients receive panobinostat as in Arm A and undergo a single fraction of stereotactic radiosurgery on day 1 of week 1.
89249163|NCT01017068|Experimental|A1 (glaucoma)|
89249164|NCT01017068|Experimental|A2 (glaucoma)|
89249165|NCT01017068|Experimental|A3 (glaucoma)|
89249166|NCT01017068|Experimental|A1 (normals)|
89249167|NCT01017068|Experimental|A2 (normals)|
89249168|NCT01017068|Experimental|A3 (normals)|
89249169|NCT04178564|Experimental|Intervention Group|Intervention group will receive 47 sessions of group CS and participate in 3 evaluation sessions. The CS program will last 1 year and each group CS session will last approximately 60 minutes.
89249170|NCT04170608|Experimental|FARAPULSE Endocardial Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
89249171|NCT00456846|Experimental|ABI-007|100 mg/m^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
89249172|NCT01011764|Active Comparator|SKILLS group|The SKILLS intervention targets a specific set of social skills over 8 bi-weekly sessions. The intervention is delivered to a small group of children with autism at school during lunchtime. The content delivered to the group of young children with autism including lessons developed from a manual by Seattle Children's Hospital Research Foundation. Children are given weekly homework assignments to reinforce the topics discussed in the group sessions.
89249173|NCT01011764|Experimental|ENGAGE group|The ENGAGE intervention targets two social domains, and two learning contexts. The two social domains are peer acceptance and social engagement with peers. The social group will be small and include children with ASD as well as their typical peers. There will be a greater number of typical peers included to model social behaviors and foster friendships. The typical peers will be selected based on results from the friendship survey and teacher nominations. The two learning contexts are direct instruction in a group social skills format during lunchtime and individualized embedded generalization activities in the school day.
89249174|NCT03324282|Experimental|Arm A: GC + avelumab group|
89249175|NCT03324282|Active Comparator|Arm B: GC group|
89249176|NCT00448344|Experimental|Arm 1|Family-supported smoking cessation
89249177|NCT00448344|Other|Arm 2|Standard smoking cessation
89249178|NCT00484094||Rapamune|
89249179|NCT01029288|Active Comparator|Statin Choice Decision Aid|Subjects will receive an intervention of Statin Choice Decision Aid and usual care for antihyperglycemic medication discussion with their clinician.
89249180|NCT01029288|Active Comparator|Diabetes Medication Choice Decision Aid|Subjects will receive an intervention of Diabetes Medication Choice Decision Aid and usual care for lipid therapy medication discussion with their clinician.
89249181|NCT01029444|Experimental|Insulin|Brittle diabetic patients or patients with uncontrolled blood sugars will complete blood sugar diaries weekly and have hemoglobin A1c lab tests performed quarterly to evaluate progress in stabilizing blood sugars.
89249182|NCT01024452|Experimental|DAWN AC|
89249183|NCT01024452|Active Comparator|Hamilton Nomogram|
89249184|NCT03995394|Experimental|Positive Reinforcement Group|"In the intervention group, participants will receive two text messages weekly. The first text message will ask if participants completed the recommended activity. If the participants respond yes, the participant will receive a positive reinforcement response. If the participants respond no, the participant will receive a text message stating, Thank you for your response."
89249185|NCT03995394|No Intervention|Control Group|"For the control group, participants will receive two text messages weekly. The first text message will ask if the participants completed the recommended activity. When the participant responds, the participant will receive a second text message stating, Thanks for your response."
89249186|NCT01029522|Experimental|Lipilou 20mg|
89249187|NCT01029522|Active Comparator|Lipitor 20mg|
89249188|NCT00447876|Experimental|Botulinum type A toxin (Dysport®)|
89249189|NCT00447876|Placebo Comparator|Placebo|
89249190|NCT01029600|Active Comparator|Arthroscopic Capsulotomy|Arthroscopic capsular release
89249191|NCT01029600|Active Comparator|Distention with steroid|Arthrographic distention with contrast, saline, steroid and local anaesthetic
89249192|NCT01565772|Experimental|Radiation, Chemotherapy and Surgery|Proton beam radiation, plus chemotherapy with cisplatin and etoposide, followed by surgery.
89249193|NCT03995550|Experimental|Single ascending dose Cohort A|Single dose of LEO 142397 or placebo.
89249194|NCT03995550|Experimental|Single ascending dose Cohort B|Single dose of LEO 142397 or placebo.
89249195|NCT03995550|Experimental|Single ascending dose Cohort C|2 single doses, separated by a washout of ≥7 days.
89249196|NCT03995550|Experimental|Single ascending dose Cohort D|2 single doses, separated by a washout of ≥7 days.
89249197|NCT03995550|Experimental|Single ascending dose Cohort E|Single dose of LEO 142397 or placebo.
89249198|NCT03995550|Experimental|Single ascending dose Cohort F|Single dose of LEO 142397 or placebo.
89249199|NCT03995550|Experimental|Single ascending dose Cohort G|Single dose of LEO 142397 or placebo.
89249200|NCT03995550|Experimental|Single ascending dose Cohort H|Single dose of LEO 142397 or placebo - tentative, female-only cohort (to be included only if the number of women recruited in the remaining cohorts is insufficient to assess the pharmacokinetics of LEO 142397 in women). Dose level ≥ that in Cohort C and ≤ that in Cohort D.
89249201|NCT03995550|Experimental|Multiple ascending dose Cohort K|Multiple doses of LEO 142397 or placebo.
89249202|NCT03995550|Experimental|Multiple ascending dose Cohort L|Multiple doses of LEO 142397 or placebo.
89249203|NCT03995550|Experimental|Multiple ascending dose Cohort M|Multiple doses of LEO 142397 or placebo.
89249204|NCT03995550|Experimental|Multiple ascending dose Cohort N|Multiple doses of LEO 142397 or placebo.
89249205|NCT03995550|Experimental|Multiple ascending dose Cohort O|Multiple doses of LEO 142397 or placebo.
89249206|NCT03995550|Experimental|Multiple ascending dose Cohort P|Multiple doses of LEO 142397 or placebo in Japanese-only subjects. Same dose level as for Cohort M.
89249207|NCT00456612|Other|Cyberknife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
89249208|NCT00456300|Experimental|Exenatide 1.25 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
89249209|NCT00456300|Experimental|Exenatide 2.5 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
89249210|NCT00456300|Active Comparator|Insulin|Each subject received a baseline study with insulin alone
89249211|NCT00267748|Experimental|C|
89249212|NCT00267748|Experimental|A|
89249213|NCT00267202|Placebo Comparator|Placebo|The dose of placebo was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
89249214|NCT00267202|Experimental|Omalizumab|The dose of omalizumab was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
89249215|NCT01067638|Experimental|tranexamic acid|Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft
89249216|NCT03977116|Experimental|heart failure patients with diabetes treated by SGLT2 drugs|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received SLGT2 therapy.
89249217|NCT03977116|Placebo Comparator|heart failure patients with diabetes treated by placebo|Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received placebo therapy.
89249218|NCT01067794||pemetrexed + platinum|Patients with pemetrexed + platinum doublet, with or without additional targeted agents
89249219|NCT01067794||gemcitabine + platinum|Patients with gemcitabine + platinum doublet, with or without additional targeted agents
89249220|NCT01067794||taxanes + platinum|Patients with taxanes + platinum doublet, with or without additional targeted agents
89249221|NCT01067794||vinorelbine + platinum|Patients with vinorelbine + platinum doublet, with or without additional targeted agents
89249222|NCT01067794||others + platinum|Patients with other platinum-based doublet, with or without additional targeted agents
89249223|NCT00267046|Experimental|Palifermin|"Palifermin + Chemotherapy (Adriamycin (Doxorubicin)+ Ifosfamide (AI) or Adriamycin (Doxorubicin) + Cisplatin (AP) Regimen); Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
89249224|NCT00267046|Placebo Comparator|Placebo|"Placebo + Chemotherapy (AI or AP Regimen);~AI = Doxorubicin (Adriamycin) + Ifosfamide:~A single dose placebo prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.~AP=Doxorubicin (Adriamycin) + Cisplatin:~A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
89249225|NCT00441090|Experimental|Avatrombopag tablets|"2.5, 5, 10 or 20 mg tablets~1 tablet taken orally once daily for 28 days"
89249226|NCT00441090|Placebo Comparator|Placebo tablet|"2.5, 5, 10, or 20 mg tablets~1 tablet taken orally once daily for 28 days"
89249227|NCT03305406||Focus Group Participants|Semi-structured focus groups
89249228|NCT03305406||Interview Participants|One-on-one interviews
89249229|NCT00441012|Experimental|1|Modified process Hib/Hep B vaccine
89249230|NCT00441012|Active Comparator|2|COMVAX™
89249231|NCT01029678|Experimental|experimental|
89249232|NCT01323426|Experimental|periurethral injection|Periurethral injection of autologous muscle fibers
89249233|NCT00286468|Experimental|Alogliptin 12.5 mg QD|
89249234|NCT00286468|Experimental|Alogliptin 25 mg QD|
89249235|NCT00286468|Active Comparator|Placebo|
89249236|NCT00507026|Experimental|A|DIC075V (IV diclofenac)
89249237|NCT00507026|Active Comparator|B|IV Ketorolac
89249238|NCT00507026|Placebo Comparator|C|Placebo
89249239|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 1|For the first 2 weeks, afegostat tartrate was administered orally at a dose of 225 milligrams (mg) once daily (QD) for 7 consecutive days, followed by no study medication for 7 consecutive days. After 2 weeks, participants then took 225 mg afegostat tartrate QD for 3 consecutive days, followed by no study medication for 4 consecutive days. This 3-days-on/4-days-off treatment regimen was followed for 22 weeks.
89249240|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 2|Afegostat tartrate was administered orally at a dose of 225 mg QD for 7 consecutive days, followed by no study medication for 7 consecutive days. This 7-days-on/7-days-off treatment regimen was followed for 24 weeks.
89249241|NCT01029756|Active Comparator|Macintosh Laryngoscope|
89249242|NCT01029756|Active Comparator|Pentax AWS Videolaryngoscope|
89249243|NCT01019174|Active Comparator|oral application|oral application Cyclophosphamide
89249244|NCT01019174|Active Comparator|intravenous application|intravenous application Cyclophosphamide
89249245|NCT03847974|Experimental|LIB003|LIB003
89249246|NCT01011842|Experimental|radiation therapy arm|
89249247|NCT01011920|Experimental|MTX+ AraC|Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
89249248|NCT01011920|Experimental|Ara-C +Rituximab|Arm B Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
89290298|NCT05045716|Experimental|Lecanemab 700 mg|Participants will receive lecanemab 700 milligram (mg), as single fixed dose SC injection in the abdomen on Day 1.
89249249|NCT01011920|Experimental|Ara-C + rituximab+thiotepa|Arm C Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4
89249250|NCT01011920|Experimental|WBRT 36 Gy +/- boost 9 Gy|ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
89249251|NCT01011920|Experimental|BCNU + Thiotepa + APBSCT|Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0
89249252|NCT01017302|Experimental|1|
89249253|NCT01017302|Placebo Comparator|2|
89249254|NCT01017302|Experimental|3|
89249255|NCT01017302|Placebo Comparator|4|
89249256|NCT01019330||Femoral|Subjects receiving femoral artery cardiac catheterization
89249257|NCT01019330||Radial|Subjects receiving radial artery cardiac catheterization
89249258|NCT03976102|Experimental|Arm A: DRL_RI|DRL_RI (rituximab-Dr. Reddy's Lab) for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36
89249259|NCT03976102|Active Comparator|Arm B: MabThera®|MabThera® for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Week 12, 20, 28 and 36.
89249260|NCT00506948|Experimental|Thymoglobulin + Sirolimus + MMF|Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.
89249261|NCT00286234|Placebo Comparator|1|Dual placebo
89249262|NCT00286234|Experimental|2|niaspan
89249263|NCT00286234|Experimental|3|lovaza
89249264|NCT00286234|Experimental|4|combined therapy
89249265|NCT01019408|Active Comparator|CQ25|Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.
89249266|NCT01019408|Active Comparator|CQ40|Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.
89249267|NCT01067950|Experimental|Isolated Pancreas Transplant|
89249268|NCT01067950|Active Comparator|Intensive Insulin Therapy|
89249269|NCT00445848|Experimental|Erlotinib and Bevacizumab|
89249270|NCT01068028|Placebo Comparator|Placebo for ORM-12741|
89249271|NCT01068028|Experimental|ORM-12741|
89249272|NCT00286156|Experimental|1|Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
89249273|NCT00286156|Experimental|2|Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
89249274|NCT00286156|No Intervention|3|Standard Care
89249275|NCT00455520|Placebo Comparator|Placebo|placebo matching placebo twice daily for 12 weeks
89249276|NCT00455520|Experimental|CG5503|CG5503 100, 150, 200, 250mg twice daily given for up to 15 weeks
89249277|NCT03244098|Experimental|Transition Assistance Program (TAP)|
89249278|NCT03244098|No Intervention|Standard of Care|
89249279|NCT00440700|Experimental|Patient-directed music|Patients select preferred music for listening through headphones whenever they like for as long as they like whenever feeling anxious, desire some rest and quiet time, or for listening enjoyment while mechanically ventilated in the ICU.
89249280|NCT00440700|Active Comparator|Headphones|Noise-canceling headphones only (no music) are applied by the patient to block out noise/sound in the ICU whenever desired.
89249281|NCT00440700|Other|Standard of Care|Patients receive usual care for the ICU and are encouraged to self-initiate rest periods twice daily.
89249282|NCT01029834|Experimental|Intervention- Lifestyle family based|Behavioral family based
89249283|NCT01029834|Active Comparator|Information control|Child intervention only
89249284|NCT00284050|Experimental|Ranibizumab 0.3 mg|Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
89249285|NCT00284050|Experimental|Ranibizumab 0.5 mg|Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
89249286|NCT00284050|Sham Comparator|Sham injection|Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
89249287|NCT00293020|Experimental|1|BEMA Fentanyl
89249288|NCT00377637|Experimental|Induction Phase: Mycophenolate mofetil|Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.
89249289|NCT00377637|Active Comparator|Induction Phase: Cyclophosphamide|Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.
89249290|NCT00377637|Experimental|Maintenance Phase: Mycophenolate mofetil|Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.
89249291|NCT00377637|Active Comparator|Maintenance Phase: Azathioprine|Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.
89249292|NCT01050309|Active Comparator|Cervix|
89249293|NCT01050309|Active Comparator|colon|
89249294|NCT01050309|Active Comparator|Intravenous|
89249295|NCT00377403|Experimental|Intervention Arm|Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
89249296|NCT00377403|Placebo Comparator|Symptomatic treatments only|Placebo for 10 days in addition to symptomatic treatments
89249297|NCT00370149|Active Comparator|Antibiotic-impregnated Catheters (M/R)|Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter. The catheters are sized to accommodate children in different size ranges: Cook Inc. Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
89249298|NCT00370149|Placebo Comparator|Non-impregnated Catheter (C/S)|Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
89249299|NCT00292942|Experimental|2 mg/kg Intravenous Artesunate|2 mg/kg of Intravenous artesunate
89249300|NCT00292942|Experimental|4 mg/kg Intravenous Artesunate|4 mg/kg of Intravenous artesunate
89249301|NCT00292942|Experimental|8 mg/kg Intravenous Artesunate|8 mg/kg of Intravenous artesunate
89249302|NCT00292942|Placebo Comparator|Placebo|Mannitol (200 mg/vial) diluted in phosphate buffer and delivered in an equivalent volume by subject's weight as artesunate.
89249303|NCT01068106|Active Comparator|BPLES|Biodegradable polymer limus-eluting stents
89249304|NCT01068106|Active Comparator|PPLES|Permanent polymer limus-eluting stent
89249305|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group A)|Participants with HCV RNA levels greater than (>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (>=) 15 IU/mL at Week 8, and either HCV RNA less than (<) 15 IU/mL or >=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys) 180 micrograms (mcg) subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 milligrams (mg) orally daily for 48 weeks.
89249306|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group B)|Participants with HCV RNA levels >15 IU/mL at Week 4, HCV RNA >=15 IU/mL at Week 8, and either HCV RNA <15 IU/mL or >=2 log10 drop at Week 12, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 72 weeks, and ribavirin 1000 to 1400 mg orally daily for 72 weeks.
89249307|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group C)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 36 weeks, and ribavirin 1000 to 1400 mg orally daily for 36 weeks.
89249308|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group D)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
89249309|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group E)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 24 weeks, and ribavirin 1000 to 1400 mg orally daily for 24 weeks.
89249310|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group F)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
89249311|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group NR)|Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
89249312|NCT00370071|Experimental|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
89249313|NCT00369915|Experimental|Plac/Scop|Placebo then scopolamine
89249314|NCT00369915|Experimental|Scop/Plac|Scopolamine then placebo
89249315|NCT01019564|Experimental|Easy Rub MPS|Complete Easy Rub Formula MPS
89249316|NCT01019564|Active Comparator|Aquify MPS|
89249317|NCT03991845|Experimental|Low dose Vit D|All Patients belonging to arm 1 will be treated with low dose oral Vit D (2000 IU/day) for 12 weeks
89249318|NCT03991845|Active Comparator|High dose Vit D|All patients in this group will be treated with high dose oral Vit D (60,000 IU/week) for 12 weeks
89249319|NCT03991845|No Intervention|Placebo|No Vit D supplementation will be given to patients in this group
89249320|NCT01017380|Experimental|placebo|identical placebo
89249321|NCT00369681|Experimental|R-ABVD|ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m^2 Cycles 2, 4, and 6 Day 1.
89249322|NCT00266812|Experimental|Chemotherapy with temozolomide and radiotherapy|
89249323|NCT00266812|Active Comparator|Radiotherapy alone|
89249324|NCT00488774|Placebo Comparator|Placebo|Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
89249325|NCT00488774|Experimental|Golimumab 1 milligram (mg) per kilogram (kg)|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
89249326|NCT00488774|Experimental|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
89249327|NCT00488774|Experimental|Golimumab 4 mg per kg|Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.
89249328|NCT00361569|Experimental|1|
89249329|NCT00361569|Experimental|2|
89249330|NCT00361569|Placebo Comparator|3|
89249331|NCT00361569|Placebo Comparator|4|
89249332|NCT02158377|Active Comparator|Tapered Screw-vent implants (TSV)|TSV implants to replace missing tooth/teeth
89249333|NCT02158377|Experimental|Trabecular Metal dental implants (TM)|TM dental implants to replace missing tooth/teeth
89249334|NCT01017458|Experimental|1|MK0773 + placebo injection
89249335|NCT01017458|Active Comparator|2|placebo to MK0773 + testosterone injection
89249336|NCT01017458|Placebo Comparator|3|placebo to MK0773 + placebo injection
89249337|NCT02534415|Active Comparator|Periodontal dressing material|Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
89249338|NCT02534415|Experimental|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
89249339|NCT02534415|Experimental|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
89249340|NCT00488618|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
89249341|NCT00488618|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
89249342|NCT01019642|Experimental|Vitamin D|Cholecalciferol, 4,000 IU/d for 6 months
89249343|NCT01019642|Placebo Comparator|Placebo|placebo
89249344|NCT00266656|Experimental|Experimental 1 Control|"No drug administration in B9R-US-GDFG (NCT00406926).~Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given."
89249345|NCT00266656|Experimental|Experimental 2 Humatrope|Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
89249346|NCT00483704|Experimental|Telcagepant 140 mg|Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
89249347|NCT00483704|Experimental|Telcagepant 280 mg|Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
89249348|NCT00483704|Placebo Comparator|Control Group 1|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 4th). Telcagepant 140 mg will be administered for the 3rd migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
89249349|NCT00483704|Placebo Comparator|Control Group 2|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 3rd). Telcagepant 140 mg will be administered for the 4th migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
89249350|NCT00483548|Experimental|Ziprasidone|Active treatment, double-blind, randomized treatment arm
89249351|NCT00483548|Placebo Comparator|Placebo|Inactive, placebo treatment, double-blind, randomized arm
89249352|NCT00445770|Experimental|1|
89249353|NCT00445770|Experimental|2|
89249354|NCT00445770|Active Comparator|3|
89249355|NCT00266032|Experimental|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
89249356|NCT00266032|Experimental|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
89249357|NCT00266032|Active Comparator|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
89249358|NCT01012076|Active Comparator|Active Control|The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning. Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to improve the parent's ability to successfully promote the child's social and emotional competency.
89249359|NCT01012076|Experimental|Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to promote the ability of the parent-child dyad to successfully manage shared toy play.
89249360|NCT01019798|Experimental|open label|
89249361|NCT01012154|Experimental|All patients|
89249362|NCT00483002||Healthy smokers|
89249363|NCT00482612|Experimental|Esmirtazapine 1.5 mg|Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
89249364|NCT00482612|Experimental|Esmirtazapine 3.0 mg|Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
89249365|NCT00482612|Experimental|Esmirtazapine 4.5 mg|Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
89249366|NCT00482612|Placebo Comparator|Placebo|Placebo to esmirtazapine
89249367|NCT00282568|Experimental|Tacrolimus Modified Release|Participants were enrolled into the study on their stable twice-daily (bid) dose of tacrolimus on Day 1 and continued to receive a stable bid dose of tacrolimus through Day 7. Participants then converted to Tacrolimus Modified Release (MR), administered once daily at an equivalent dose to the patient's previous stable total daily dose of tacrolimus. Participants who completed the 4-week pharmacokinetic treatment period with tacrolimus MR could continue receiving tacrolimus MR as part of the extended treatment period of the study. Dose adjustments were allowed in order to maintain tacrolimus trough concentrations within the target range of 5 to 15 ng/mL and for clinical reasons.
89249368|NCT02532322|Experimental|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
89249369|NCT02532322|Placebo Comparator|normal saline|normal saline (placebo control) 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
89249370|NCT00265564|Active Comparator|Seeking Safety|Seeking Safety is a manualized, empirically supported, cognitive behavioral therapy that treats substance use disorders and comorbid PTSD. Participants assigned to the Seeking Safety arm attend two one hour sessions of group therapy for 12 weeks.
89249371|NCT00265564|Active Comparator|Usual Care|Usual Care Condition. Patients randomized to usual care will receive standard outpatient SUD treatment.
89249372|NCT01068184|Experimental|1|
89249373|NCT01068184|Placebo Comparator|2|
89249374|NCT00376623|Experimental|200 milligram (mg) of BI 2536|Day 1
89249375|NCT00376623|Experimental|50 milligram (mg) of BI 2536|Day 1, 2, and 3
89249376|NCT00376623|Experimental|60 milligram (mg) of BI 2536|Day 1, 2, and 3
89249377|NCT01029990|Experimental|Telephone arm|A midwife tries to contact the woman by telephone and offer her an appointment for a PAP-smear
89249378|NCT01029990|Experimental|Self-test arm|
89249379|NCT01029990|No Intervention|Control arm|No intervention other than what is routine in the screening program
89249380|NCT00445692|Experimental|Treatment (clarithromycin, dexamethasone, lenalidomide)|"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.~NOTE: *After one year of treatment, dexamethasone is tapered for an additional 4 weeks."
89249381|NCT01024842|Experimental|Low dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu.
89249382|NCT01024842|Experimental|High dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu.
89249383|NCT01024842|Placebo Comparator|Low dose placebo|Individuals will receive three intramuscular injections of low dose placebo
89249384|NCT01024842|Placebo Comparator|High dose placebo|Individuals will receive three intramuscular injections of high dose placebo
89249385|NCT03824236|Experimental|P-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
89249386|NCT03824236|Experimental|NP-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and not protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
89249387|NCT03824236|No Intervention|InfectivityCtrl group|Healthy subjects, between and including 18 and 55 years of age, who did not receive, in the current study, any immunization but underwent sporozoite challenge.
89249388|NCT01068340||SBO Patients|Patients who develop small bowel obstruction requiring or not surgical intervention
89249389|NCT01068340||No SBO Patients|Patients who do not develop small bowel obstruction
89249390|NCT00282412|Experimental|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA
89249391|NCT03976726||i-gel size #3|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
89249392|NCT03976726||i-gel size #4|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
89249393|NCT03976726||i-gel size #5|Results of benchtop investigations are compared to in patient-used masks. Increasement of weight, volume expansion and decrease of density are measured.
89249394|NCT00282334|Experimental|Home blood pressure telemonitoring|
89249395|NCT00282334|No Intervention|Conventional blood pressure monitoring|
89249396|NCT00282256|Experimental|Tacrolimus MR|Participants continued to receive their stable twice daily dose of tacrolimus twice daily on Day 1 through Day 7 and on Day 8 were converted to tacrolimus modified release (MR) once-daily in the morning for 7 days on a 1:1 (mg:mg) basis for their total daily dose. Patients who completed the 2-week pharmacokinetic treatment period were eligible to continue receiving tacrolimus MR as part of the extension treatment period of the study. The extended treatment period began on Day 15 and consisted of a single dose of tacrolimus MR once every morning through the end of the study.
89249397|NCT00265330|Experimental|Open|
89249398|NCT00292318|Active Comparator|Arm 1|Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
89249399|NCT00292318|Experimental|Arm 2|Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.
89249400|NCT00281632|Experimental|Pazopanib|800 mg GW786034 administered orally on a daily basis.
89249401|NCT00543569|Active Comparator|Tacrolimus/MMF/Basiliximab|Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
89290299|NCT03934008||Historical Control Group|All pediatric patients 0-6 years of age seen in the clinic within one year prior to the start of the intervention period
89249402|NCT00543569|Experimental|Alefacept QW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
89249403|NCT00543569|Experimental|Alefacept QW/Tacrolimus|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
89249404|NCT00543569|Experimental|Alefacept QOW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
89249405|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and chromoendoscopy with Lugol for detection of esophageal lichen.
89249406|NCT01068574||Single Observational Cohort|
89249407|NCT00984191|Experimental|99mTc positive|99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
89249408|NCT00984191|Experimental|99mTc Negative_Neck dissection|99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
89249409|NCT00984191|Experimental|99mTc Negative_No neck dissection|99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
89249410|NCT04773821|Experimental|Experimental Arm|All men patients with low and intermediate risk prostate cancer (ISUP 1 and 2) who has already chosen to undergo focal treatment, in the referral centers and responding to the inclusion criteria will be included after obtaining their writing consent. Follow-up visits are planned at 3, 6,12 and 13 month from the date of the focal treatment consistently with usual care. All patients will have a MpMRI and MpMRI targeted biopsy in the presence of a lesion suggestive of recurrence at 12 months. The subject will be his own control
89249411|NCT00984347|Active Comparator|Oxytocin induction|women in need for induction of labor due to medical indications, will receive continuous IV oxytocin
89249412|NCT00984347|Active Comparator|Breast Stimultion|nipple stimulation with a breast pump, calibrated at the lowest suction strength,operated alternately: 15 min one breast, 15 min second breast, 15 min rest, till appearance of regular uterine contractions (3 contractions in 10 min). the manipulation will continue for 3 hours of regular contractions.
89249413|NCT00984425|Experimental|Lapatinib and Sorafenib 1° level of dose|Lapatinib 750 mg/die + Sorafenib 200 mg bid
89249414|NCT00984425|Experimental|Lapatinib and Sorafenib 2° level of dose|2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
89249415|NCT00984425|Experimental|Lapatinib and Sorafenib 3° level of dose|3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
89249416|NCT00984425|Experimental|Lapatinib and Sorafenib 4° level of dose|4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid
89249417|NCT00984503|Experimental|Intradermal Juvista|
89249418|NCT00984503|Placebo Comparator|Placebo|
89249419|NCT00984503|Experimental|Intradermal and topical Juvista|
89249420|NCT00984503|Placebo Comparator|Intradermal and topical placebo|
89249421|NCT00445458|Experimental|HKI-272 dose level 1|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
89249422|NCT00445458|Experimental|HKI-272 dose level 2|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
89249423|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm A|Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
89249424|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm B|Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
89249425|NCT00986063|Active Comparator|Standard of care|AIDS patients taking care with standard of care
89249426|NCT00986063|Experimental|Genetic test|AIDS patients who required highly active antiretroviral therapy(HAART) whom genotype status will be determined before initiation of HAART
89249427|NCT01030068|Experimental|Yoga|Yoga plus smoking cessation
89249428|NCT01030068|Active Comparator|Wellness|Health & Wellness classes plus smoking cessation therapy
89249429|NCT03914417|Experimental|Imiquimod 3.75% cream|applied topically
89249430|NCT00988871||Liver transplantation (LT) recipients|LT recipients who had both PICC and CICC at the same time according to the LT protocol of our hospital
89249431|NCT00986141||laser trabeculoplasty|Subjects with POAG and on medical treatment who are undergoing SLT
89249432|NCT00986141||Surgery|Glaucoma laser treatment
89249433|NCT05586113|Experimental|10-day treatment group|10-day Tegoprazan bismuth-containing quadruple therapy Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
89249434|NCT05586113|Active Comparator|14-day treatment group|14-day Tegoprazan bismuth-containing quadruple therapy Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
89249435|NCT00986219||Asthma Language between patients and physicians|
89249436|NCT00986297|Other|arm one|IGRT
89249437|NCT00541385|Experimental|PA group|"Oral pyronaridine/artesunate (PA, 60:20mg granules) once a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
89249438|NCT00541385|Active Comparator|AL group|"Oral artemether/lumefantrine (AL, 20:120mg crushed tablets) twice a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
89249439|NCT00988949|Experimental|PF-04455242 18 mg|Subjects in this arm will receive a single 18 mg oral dose of PF-04455242 prior to spiradoline challenge
89249440|NCT00988949|Placebo Comparator|Placebo|Subjects in this arm will receive placebo prior to spiradoline challenge.
89249441|NCT00988949|Experimental|PF-04455242 30 mg|Subjects in this arm will receive a single 30 mg oral dose of PF-04455242 prior to spiradoline challenge.
89249442|NCT04760951|Experimental|TOTUM-070|Experimental active diet supplement TOTUM-070 taken 2 times per day
89249443|NCT04760951|Placebo Comparator|Placebo|Placebo comparator taken 2 times per day
89249444|NCT00989027|No Intervention|No treatment|A control sample from each patient (no uterotonic drug applied) will be measured concurrently with samples treated with various drugs.
89249445|NCT00989027|Active Comparator|Treatment|Samples from each patient will be bathed in solutions containing varying concentrations of either oxytocin, carboprost and ergonovine, and contractility will be measured.
89249446|NCT00265096|Experimental|002|golimumab 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
89249447|NCT00265096|Experimental|001|Placebo; golimumab SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
89249448|NCT00265096|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
89249449|NCT00986375|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
89249450|NCT00986375|Active Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
89249451|NCT00986531|Experimental|1|80 mg AZD8529
89249452|NCT00986531|Placebo Comparator|2|Placebo
89249453|NCT05529329|Active Comparator|Group (Z)|patients received zirconia restorations group
89249454|NCT05529329|Experimental|Group (EC)|patients received IPS E.max Cad restorations group
89249455|NCT01068808||Nonallergic rhinitis|Nonallergic rhinitis (negative skin prick test)
89249456|NCT00986609|Experimental|Arm I|Patients receive MUC-1 peptide vaccine subcutaneously and poly-ICLC vaccine intramuscularly in weeks 0, 4, 8, 12, 52, and 56, in the absence of disease progression or unacceptable toxicity. Patients may receive additional vaccines in weeks 34 and 38 if anti-MUC1 immunity falls below the two-fold enhancement from baseline
89249457|NCT00281320|Experimental|Asenapine 2-10 mg BID|Dose titration from 2 mg to 5 mg to 10 mg twice daily (BID)
89249458|NCT00281320|Experimental|Asenapine 5-10mg BID|Dose titration from 5 mg to 10 mg BID
89249459|NCT00541307|Experimental|GORE VIABHAN Endoprothesis|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
89249460|NCT01068886|No Intervention|no stent|no stent through pancreatic anastomosis
89249461|NCT01068886|Experimental|stent|stent through pancreatic anastomosis
89249462|NCT05502965|Active Comparator|Exclusive Enteral Nutrition(EEN)|Subjects required exclusive enteral nutrition for one month
89249463|NCT05502965|Experimental|Specific Diet+ Partial Enteral Nutrition|Subjects received partial enteral nutrition with remaining energy and nutrients obtained through diet for one month
89249464|NCT03975556|Experimental|Intervention|Intervention group consisting of culturally-appropriate foods and diet advice in an initial individual session followed by daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
89249465|NCT03975556|Active Comparator|Control|Control arm of standard portion-control general nutritional and cooking advice at the initial individual session, followed by text messages for 2 months. A reinforcement phase of 2-months will follow to repeat the education and text messages.
89249466|NCT05499689|Active Comparator|GON block group|30 patients who underwent greater occipital nerve block
89249467|NCT05499689|Active Comparator|Transcutaneous pulsed RF group|30 patients who underwent greater occipital nerve pulsed radiofrequency
89249468|NCT01017614|Experimental|Monofer|"administered as intravenous infusions (A1)~administered as intravenous bolus injections (A2)"
89249469|NCT01017614|Active Comparator|Iron Sulphate|tablets administered orally
89249470|NCT00986687||Vitrified oocytes|
89249471|NCT00986687||Control oocytes|
89249472|NCT01012232|Active Comparator|low volume local anesthetic|bolus injection of local anesthetic in low volume/high concentration (10 mL, 10 mg/mL)
89249473|NCT01012232|Experimental|high volume local anesthetic|bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL)
89249474|NCT03976570|Experimental|Occupational Therapy|Occupational Therapy
89249475|NCT01017692||Lumbar Spinal Stenosis|Subjects who have undergone or will undergo an MRI, with symptoms of LSS
89249476|NCT01071148||Subgroup 1: Age < 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
89249477|NCT01071148||Subgroup 2: 42 > Age ≥ 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
89249478|NCT00541229|Experimental|1|sitagliptin 100 mg
89249479|NCT00541229|Experimental|2|sitagliptin 200 mg
89249480|NCT00541229|Placebo Comparator|3|Placebo
89249481|NCT04006691|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, the maximum dose is 15ml. 3-6 once weekly intravesical instillations for the ablation treatment.
89290300|NCT03934008||Post-Intervention Group|All pediatric patients 0-6 years of age seen in the clinic for one year following the implementation of the motivational interviewed based tool
89249482|NCT00481988|Active Comparator|transcranial direct current stimulation|The active group of patients will receive active Iomed II Phoresor transcranial direct current stimulation for the first two weeks followed by another two weeks of active transcranial direct current stimulation.
89249483|NCT00481988|Sham Comparator|sham tDCS|The patients in the sham arm receive active Iomed II Phoresor transcranial direct current stimulation for the second two weeks of the clinical trial only. For the first two weeks the Iomed II Phoresor constant current generator is turned on for 10 seconds to produce the tingling sensation on the scalp experienced by the patients in the active arm but the generator is then turned off and the patients receive no stimulation for the remainder of the 20 minute session.
89249484|NCT00986765|Experimental|Lovenox® , 4000 UI/day (+ Aspegic®)|Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin), 100 mg)
89249485|NCT00986765|Active Comparator|Aspegic ®, 100 mg/day|Aspegic® (Aspirin),100 mg/day
89249486|NCT00986843|Experimental|HM30181AK tablet + Irinotecan tablets|HM30181AK tablet + Irinotecan tablets
89249487|NCT01012310|Experimental|Cohort 1|
89249488|NCT01012310|Experimental|Cohort 2|
89249489|NCT01012310|Experimental|Cohort 3|
89249490|NCT01012310|Experimental|Cohort 4|
89249491|NCT04118270|Experimental|AFib 2gether(TM) App|Patients with known Atrial Fibrillation will be assigned to download and use an app targeted at determining stroke risk and increasing knowledge of Atrial Fibrillation and stroke risk along with treatment options and will use this information to facilitate a discussion with their cardiovascular provider.
89249492|NCT01019876|Experimental|Fludarabine|
89249493|NCT01019876|Experimental|Cyclohosphamide 200|
89249494|NCT01019876|Experimental|Cyclophosphamide 40|
89249495|NCT01019876|Experimental|Cyclophosphamide 30|
89249496|NCT01017770|Experimental|Artemether -lumefantrine|Experimental Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
89249497|NCT01017770|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
89249498|NCT00493142|Active Comparator|Usual care|Usual care
89249499|NCT00493142|Experimental|Exercise|Exercise
89249500|NCT01017848||Adults, nondiabetics|adults who are nondiabetic, no CKD, no urinary tract infection, no bladder dysfunction
89249501|NCT01017926|Active Comparator|Triazolam Reference Arm|There will be a clearance period of at least 3 days between the two phases of the study.
89249502|NCT01017926|Experimental|Triazolam Trial Arm|
89249503|NCT04005911||Post-Surgical|Patients who underwent surgery and were admitted to the PACU
89249504|NCT00481832|Experimental|T & B Cell Mobilization Auto & Allo HCT|A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.
89249505|NCT00987077|Experimental|Selective Retinatherapy (SRT)|Treatment was performed with the SRT-Laser system (Medical Laser Center Lübeck, Germany), which consists of a Q-switched frequency doubled Nd:YLF laser (527nm), operating with a pulse repetition rate of 100 Hz. The pulse duration (full width at half maximum) was 1.7 µs. The laser energy was transmitted via fiber to a Lumenis slitlamp allowing the application of a fixed spot size diameter of 200 µm in air. A Mainster central field contact lens with a magnification of 1.05 was used for all irradiations. Per foot switch, 30 pulses are emitted, the pulse energy was chosen by the physician up to a maximum of 370 µJ. According to the treatment protocol, prior to each treatment 5 test shots with increasing energy were applied adjacent to the vessel arcades, in each patient in order to determine the appropriate pulse energy for treatment by recording the OA-value.
89249506|NCT00987077|No Intervention|control group|Patients randomized to control group achieve no treatment and are followed up for three months.
89249507|NCT00987077|Experimental|crossover|After 3 months follow up patients of control group with persistence of disease activity were allocated to crossover group and received either SRT. Crossover group was followed up for further 3 months.
89249508|NCT05407415|Experimental|Kardia Mobile Group|"The intervention arm will be given a KardiaMobile device synched to their smartphone at the time of enrollment. They will be instructed on proper device procedure and will use the device with the onset of potential AF-related symptoms or when requested to do so by their healthcare provider.~The device ECG recordings will be transmitted to participants physicians through MyChart who will incorporate this information into the patient's treatment as indicated.~Healthcare utilization will be assessed by having the participants in both groups complete a questionnaire asking how many times they used their KardiaMobile device (if randomized to this group) and how many office appointments, emergency department visits, and hospital admissions they had within that six-month period."
89249509|NCT05407415|No Intervention|Standard of Care Group|"The standard of care group will follow their routine care for their atrial fibrillation.~Healthcare utilization will be assessed by having the participants in both groups complete a questionnaire asking how many times they used their KardiaMobile device (if randomized to this group) and how many office appointments, emergency department visits, and hospital admissions they had within that six-month period."
89249510|NCT04006067|Experimental|Group A|
89249511|NCT04006067|No Intervention|Group B|
89249512|NCT00481676|Experimental|Omalizumab 75-375 mg|Omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
89249513|NCT00481676|Placebo Comparator|Placebo to omalizumab|Placebo to omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
89249514|NCT00987155|Experimental|high intensity interval training|8 weeks of high intensity 4 times 4 interval training at 85-90% of peak heart rate during hybrid cycling
89249515|NCT04004975|Experimental|anlotinib|12 mg daily from day 1 to 14 of a 21-day cycle
89249516|NCT04086992|No Intervention|Control Group|This group will continue to receive standard care for ACTH monitoring and follow-up with includes blood pressure by the patient's PCP while on therapy, a one week nursing follow-up phone call, and a two-week EEG and Neurology appointment.
89249517|NCT04086992|Experimental|Intervention Group|This group will be provided remote monitoring technology where they will be able to monitor blood pressure at home. In addition, they will receive a nurse-led telemedicine visit at one week and three weeks of therapy. Like the control group, they will still receive a two-week EEG and Neurology appointment.
89249518|NCT01020032|Experimental|Music therapy|"Individual receptive music therapy by U sequence method"
89249519|NCT05712473||Cohort 1|Patients who are newly diagnosed with prostate cancer (and have suspected metastases) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET
89249520|NCT05712473||Cohort 2:|Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry
89249521|NCT03976804|Experimental|atherosclerotic cardiovascular event associated with tobacco|
89249522|NCT01022372||control group|
89249523|NCT01022372||endometriosis group|
89249524|NCT01022372||endometrioma group|
89249525|NCT03727919|Experimental|Early Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided within the first 6 weeks post-stroke
89249526|NCT03727919|Experimental|Delayed Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided between week 8 and week 12 post-stroke
89249527|NCT00987233|Experimental|triamcinolone acetonide aqueous nasal spray|
89249528|NCT00987233|Active Comparator|Nasacort® AQ Nasal Spray|
89249529|NCT00987233|Placebo Comparator|Placebo|
89249530|NCT04006301|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors harboring the kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation will receive oral administration of JNJ-74699157. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
89249531|NCT04006301|Experimental|Part 2: Dose Expansion|Two groups of participants with either non-small cell lung cancer or other solid tumors harboring KRAS G12C mutation will receive JNJ-74699157 at RP2D determined in Part 1.
89249532|NCT04715867|Experimental|Test Group for intramuscular route|110 adult participant will get Ravix-VC
89249533|NCT04715867|Active Comparator|Comparator group for intramuscular route|110 adult participant will get Rabipur
89249534|NCT04715867|Experimental|Test Group for Intradermal Route|110 adult participant will get Ravix-VC
89249535|NCT04715867|Active Comparator|Comparator Group for Intradermal Route|110 adult participant will get Rabipur
89249536|NCT04004897|Other|Preeclampsia group|Patients with preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
89249537|NCT04004897|Other|Pregnants without preeclampsia|Pregnant women without preeclampsia will receive optic nerve sheath diameter measurement with a linear ultrasound probe carefully and gently placed on the closed upper eyelids of patients.
89249538|NCT04377503|Experimental|Tocilizumab|Patients will receive Tocilizumab, 8 mg / kg diluted in 100 ml of saline and administered IV for 60 minutes. The dose will be repeated only once 12 hours after the first dose.
89249539|NCT04377503|Active Comparator|Methylprednisolone|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days in two daily doses. Finally 0.5 mg / kg / day for another 7 days.
89249540|NCT00987311|Active Comparator|1-Test product A|1-Dairy product containing probiotics A (test product A)
89249541|NCT00987311|Active Comparator|2-Test product B|2-Dairy product containing probiotics B (test product B)
89249542|NCT00987311|Sham Comparator|3-Control|3-Dairy product without probiotics (control)
89249543|NCT00542789|Placebo Comparator|1|Placebo
89249544|NCT00542789|Experimental|2|Esomeprazole 20 mg
89249545|NCT00464672|Experimental|Influenza virus vaccine|
89249546|NCT00464672|Active Comparator|Comparator influenza vaccine|
89249547|NCT03996434|Experimental|Coasting group|Including 150 patients who will undergo withholding gonadotropin administration for at least 24 hours before triggering ovulation with hCG. GnRH agonist will be continued daily till the day of triggering. E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml, then 5000 IU of hCG will be given.
89249548|NCT03996434|Active Comparator|Antagonist group|"Including 150 patients who will receive GnRH antagonist (subcutaneous injection Cetrorelix acetate 0.25 mg (Cetrotide, Serono, UK)) daily until the day of hCG administration.~GnRH agonist will be discontinued at the start of antagonist administration.~E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml and TVS revealed that follicles diameter is ≥ 18 mm, then 5000 IU of hCG will be given."
89249549|NCT00987701|Active Comparator|Crystalloid resuscitation|Crystalloid (Ringer's lactate) will be delivered before (15min) or after (15min) neuraxial anesthesia
89249550|NCT00987701|Active Comparator|Colloid resuscitation|Colloid (6% hydroxyethyl starch ) will be delivered before (15min) or after (15min) neuraxial anesthesia
89249551|NCT01020266|Active Comparator|Electroacupuncture|
89249552|NCT01020266|Sham Comparator|Control|
89249553|NCT00987779|Experimental|Period I: Tablet(400 mg single dose)|Period I: Tablet in fasting state, Period II: Liquid formulation in fasting state, Period III: Liquid formulation in fed state
89249554|NCT00987779|Experimental|Period I: Liquid formulation(400 mg single dose)|Period I: Liquid formulation in fasting state, Period II: Tablet in fasting state, Period III: Liquid formulation in fed state
89249555|NCT01020344|Active Comparator|Lung volume reduction surgery|This group will receive lung volume reduction surgery
89249556|NCT01020344|No Intervention|No lung volume reduction surgery|This group will not receive LVRS during the 3 months of the study
89249557|NCT00987857|Active Comparator|2 yearly endoscopies|Two years endoscopies
89249558|NCT00987857|Experimental|endoscopy at need|Endoscopy only when patient reports symptoms
89249559|NCT01020422|No Intervention|Breast hypertrophy|Patients with macromastia will be evaluated in regard to sexual function and depression predictors at 3 moments: initial interview, after 3 months and after 6 months
89249560|NCT01020422|Experimental|Reduction Mammaplasty|Breast hypertrophy patients randomized to this group will immediately be scheduled for reduction mammaplasty and will be will be evaluated in regard to sexual function and depression predictors preoperatively and 3 and 6 months postoperatively
89249561|NCT04225286|Experimental|Intranasal human breast milk|"Human breast milk delivered intranasally to preterm infants (<33 weeks gestation at birth, stratified < and ≥28 weeks) with any grade IVH/intraparenchymal hemorrhage/infarction identified on head ultrasound in the first 10 days of life.~Dosing: Escalating dose starting at 0.2mL into one nostril with repeat dose 10-15 minutes later 1-2x daily, depending on availability of fresh HM"
89249562|NCT01018160||001|
89249563|NCT01018238|Placebo Comparator|Placebo arm|
89249564|NCT01018238|Experimental|Cohort 1|
89249565|NCT01018238|Experimental|Cohort 2|
89249566|NCT01018238|Experimental|Cohort 3|
89249567|NCT01018238|Experimental|Cohort 4|
89249568|NCT03996512|Experimental|Post scaphoid fracture with screw fixation|Post surgical rehabilitation using an early active controlled wrist motion rehab protocol that limits the amount of proximal carpal row loading forces
89249569|NCT00473876|Active Comparator|1|Receiving Metformin for 4 months
89249570|NCT00473876|Placebo Comparator|2|Matched Placebo for 4 months
89249571|NCT03996668|No Intervention|Control|Subjects received standard operating room dress including sequential compression devices.
89249572|NCT03996668|Experimental|Experimental|Subjects wore thigh high compression stockings in addition to standard operating room dress including sequential compression devices.
89249573|NCT01020578||Impaired glucose tolerance|Patients diagnosed with impaired glucose tolerance
89249574|NCT01020578||Control|Patients with normal blood glucose
89249575|NCT00463580|Experimental|Infliximab|Participants in this arm will receive an infusion of infliximab.
89249576|NCT00463580|Placebo Comparator|Placebo|Participants in this arm will receive an infusion of normal saline.
89249577|NCT01020656||group 1|patients with no anticoagulants used as the control group
89249578|NCT01020656||group 2|patients treated with anticoagulant therapy (warfarin, fluindone, acenocoumarol)
89249579|NCT01020656||group 3|patients treated with aspirin
89249580|NCT01020656||group 4|patients treated with clopidogrel therapy
89249581|NCT01020656||group 5|patients treated with both anticoagulant and aspirin medications
89249582|NCT01020656||group 6|patients treated with both anticoagulant and clopidogrel medications
89249583|NCT01020656||group 7|patients treated with both aspirin and clopidogrel medications
89249584|NCT01020734|Experimental|transplantation|perform allogeneic HCT for patients with AML in CR1; then analyze various pre-transplantation variable, including donor type, for correlation to outcomes
89249585|NCT01021046|Experimental|GCCT,corneal allograft survival ,DALK|experimental group: deep anterior lamellar keratoplasty using glycerin-cryopreserved corneal tissue
89249586|NCT01021046|Experimental|FCT,corneal allograft survival ,DALK|control group: deep anterior lamellar keratoplasty using fresh corneal tissue
89249587|NCT01021124||QFT (+) vs QFT (-)|
89249588|NCT00540449|Active Comparator|Efavirenz|Efavirenz 600mg once daily for 96 weeks
89249589|NCT00540449|Experimental|TMC278|TMC278 25 mg tablet once daily for 96 weeks
89249590|NCT05712005||Group 1|Study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times. Next, study subjects will complete up to eight additional neuropsychological assessments, intermittently separated followed by the Cognivue Plus test.
89249591|NCT05712005||Group 2|Study subjects will complete up to eight additional neuropsychological assessments, intermittently separated followed by the Cognivue Plus test. Next, study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times.
89249592|NCT05712005||Group 3|Study subjects will complete the Cognivue Plus test followed by completing up to eight additional neuropsychological assessments, intermittently separated. Next, study participants assigned to this group will complete the Cognivue 5-Minute Screening test across three domains including Memory, Visuospatial and Executive Function as well as two performance measures of Reaction Time and Speed Processing along with Normative Ranges 3 times OR study participants assigned to this group will complete the Cognivue 10-Minute Assessment test across six domains including Memory, Visuospatial, Executive Function, Naming/Language, Memory, Delayed Recall and Abstraction, as well as two performance measures of Reaction Time and Speed Processing, along with Normative Ranges 3 times.
89249593|NCT04872023|Experimental|Patients|All patients will have a extra blood sampling before first cycle of treatment and after one cycle. They also have an extra bone marrow sampling after the first cycle of treatment
89249594|NCT05142527|Experimental|High Dose IM injection of active drug or Placebo (Phase 2)|"Subjects will receive a high dose IM injection of either active drug or placebo.~Approximately 300 subjects will receive active drug and approximately 150 subjects will receive placebo in the Phase 2 segment."
89249595|NCT05142527|Experimental|High Dose IM injection of active drug or Placebo (Phase 3)|"Subjects will receive a high dose IM injection of either active drug or placebo.~Approximately 3000 subjects will receive active drug and approximately 1000 subjects will receive placebo in the Phase 3 segment"
89249596|NCT05137769|Experimental|Body Scan|Participants will listen to a 20-minute, audio-guided mindfulness-based body scan exercise.
89249597|NCT04005131|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 10 weeks
89249598|NCT04005131|Active Comparator|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 weeks
89249599|NCT05135117|No Intervention|Control|Passive rest - no intervention provided
89249600|NCT05135117|Active Comparator|Ice towel cooling|About 6-12 cooling periods of ice towel lasting between 5-20 minutes will be done and equally distributed throughout the respective trials. Towels dipped in ice water will be placed on subjects necks during this time.
89249601|NCT05135117|Experimental|NeuroRescue Neck Cooling Collar|About 6-12 cooling periods of neck cooling with the NeuroRescue collar lasting between 5-20 minutes will be done and equally distributed throughout the respective trials.
89249602|NCT03911843|Experimental|CASES|Of eligible subjects, 26/64 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months
89249603|NCT03911843|Active Comparator|CONTROLS|Others 38/64 subjects joined to the study as data contributors, and were entered as controls (CONTR).
89249604|NCT04833335|Experimental|Adults with brain metastases treated with Gamma Knife whose lesions suggest tumor recurrence versus|Inclusion visit, 1 month later, 6 month later
89249605|NCT00361335|Experimental|Group I: 2mg/kg Golimumab + MTX|Intravenous (IV) infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (an additional 2mg/kg IV infusion of golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of subcutaneous (SC) injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive methotrexate (MTX) at the same dose as that before study entry
89249606|NCT00361335|Experimental|Group II: 2mg/kg Golimumab only|IV infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX or switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules
89249607|NCT00361335|Experimental|Group III: 4mg/kg Golimumab + MTX|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter for a minimum of 48 weeks followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive MTX at the same dose as that before study entry.
89249608|NCT00361335|Experimental|Group IV: 4mg/kg Golimumab only|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
89249609|NCT00361335|Placebo Comparator|Group V: IV Placebo + MTX|IV infusions of placebo at Week 0 and Week 12 with early escape (switch to 4mg/kg IV golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (placebo plus golimumab) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition patients will receive MTX at the same dose as that before study entry. Participants still receiving placebo injections at Week 48 are not eligible to enter the Extension Study.
89249610|NCT00264550|Placebo Comparator|Group 1: Placebo + Methotrexate|Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (early escape at Week 16); Methotrexate - 15 to 25mg weekly from Week 0 up to 5 yrs; Golimumab - if early escape, 50mg SC injections every 4 weeks from Week 16 up to 5 years; Golimumab - 50 mg SC injections every 4 weeks from Week 24 up to 5 yrs (unless early escape); Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
88804810|NCT00005812|Experimental|Temozolomide|"Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:~disease progression~intolerable toxicity~complete response - 2 full additional cycles~if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response."
88804811|NCT01270555|Experimental|Bupropion|
89249611|NCT00264550|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Placebo - 7-10 capsules weekly during blinded period (or Week 16 if early escape); Methotrexate - if early escape, 15 to 25mg weekly from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
89249612|NCT00264550|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 up to 5 yrs (unless early escape at Week 16); Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
89249613|NCT00264550|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
88804812|NCT01270711||Cabergoline users|cohort of patients, who are treated with cabergoline during the study period ( from January 1st, 2006 to July 1st 2012)
88804813|NCT01340053|Placebo Comparator|Placebo|Capsule that is identical in size and color to other treatments
88804814|NCT01340053|Experimental|Low Dose|10 mg capsule of tenapanor
88804815|NCT01340053|Experimental|Mid Dose|30 mg capsule of tenapanor
88804816|NCT01340053|Experimental|High Dose|100 mg capsule of tenapanor
88804817|NCT00004660|Experimental|Radiotherapy|
89249614|NCT04271033|Experimental|Carotid Artery Stenting|Consecutive male and female patients older than 18 year with symptomatic and increased-stroke-risk asymptomatic carotid lesions that require revascularization by Neurovascular Team decision.
89249615|NCT01070290|Experimental|1|ARQ 197
89249616|NCT01070290|Active Comparator|2|Investigator's choice of oxaliplatin, capecitabine or irinotecan
89249617|NCT01048203|Experimental|ABR-215050|
89249618|NCT01070368|Experimental|Food challenge, skin test|Skin test by two extract commercial, and in-house extract. and open challenge with wheat (except in patient with history of wheat anaphylaxis: assume as challenge positive)
89249619|NCT01070446|Experimental|1|This study involves children with CF who will take a water soluble vitamin supplement of choline bitartrate, 2 gm per day with meals.
89249620|NCT01070524|Experimental|CHF 5188 pMDI|
89249621|NCT01070524|Active Comparator|Budesonide extrafine pMDI|
89249622|NCT01070524|Active Comparator|Seretide(r) Evohaler(r)|
89249623|NCT01048359|Experimental|Brief Intervention|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk.
89249624|NCT01048359|Active Comparator|Brief advice|This condition of the experiment acts a control and will be a short session in which the therapist will provide brief advice about drug use and give the patient a pamphlet.
89249625|NCT01048359|Experimental|Brief Intervention plus Booster|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk plus a brief phone booster session at 1 month post-intake to review feedback, 2) assess progress, 2) renew motivation to change, and 3) evaluate and affirm commitment to change.
89249626|NCT01071304|Experimental|All Participants|In Part 1, all participants received a single oral dose of 2 mg midazolam on Day -2. On Days 1-5, all participants received daily single oral doses of ridaforolimus 40 mg ( 4 x 10 mg tablets). On Day 5, all participants received a single oral dose of 2 mg midazolam coadministered with the dose of ridaforolimus. Participants had the option to continue into Part 2 of this study.
89249627|NCT01050465|Active Comparator|email|Patients randomized to this arm will receive an email health information prescription.
89249628|NCT01050465|Active Comparator|paper|Patients randomized to this arm will receive a paper health information prescription.
89249629|NCT01069042|Active Comparator|preserved LVEF under ACEi treatment|preserved LVEF under ACEi treatment
89249630|NCT01069042|Experimental|Poor LVEF group|Poor LVEF under ACEi treatment
89249631|NCT00541931|Other|Nonsmoker|Nonsmokers Intervention: Dietary Supplement: LifePak Nano
89249632|NCT00541931|Other|Smoker|Smoker arm Intervention: Dietary Supplement: LifePak Nano
89249633|NCT03976492||Normal group|normal population
89249634|NCT03976492||Brain injury group|patients with traumatic brain injury within 24 hours
89249635|NCT03976492||Non-brain injury group|Non-brain injury group refers to patients with limb injury or systemic injury except brain injury.
89249636|NCT04004663|Experimental|Treatment Sequence 1|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment A); Period 2 (Treatment B); Period 3 (Treatment C); Period 4 (Treatment D).
89249637|NCT04004663|Experimental|Treatment Sequence 2|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment B); Period 2 (Treatment D); Period 3 (Treatment A); Period 4 (Treatment C).
89249638|NCT04004663|Experimental|Treatment Sequence 3|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment C); Period 2 (Treatment A); Period 3 (Treatment D); Period 4 (Treatment B).
89249639|NCT04004663|Experimental|Treatment Sequence 4|Participants will receive a single dose of each formulation of PF-06651600 in each period as follows: Period 1 (Treatment D); Period 2 (Treatment C); Period 3 (Treatment B); Period 4 (Treatment A).
89249640|NCT01581346|Experimental|exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
89249641|NCT04759313|Experimental|Imagenarrative treatment group|INI Sessions: Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
89249642|NCT04759313|Experimental|Wait List Control Group|In weeks 6 through 10, the same program will be delivered to the wait list control group.
89249643|NCT00368979|Active Comparator|Dutasteride|
89249644|NCT00368979|Placebo Comparator|Placebo|
89249645|NCT00264238|Experimental|Memantine open label|All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.
89249646|NCT00540293|Experimental|Treatment group|this patient group consists of dyslipidemia patients with various CVD risk factors
89249647|NCT01070602|Experimental|anterior corneal incision|
89249648|NCT01563653|Experimental|Patients|Women with stress urinary incontinence schelduled for TVT or TOT procedures. See inclusion/exclusion criteria.
89249649|NCT04971941|Active Comparator|DV3 with first LB injection|Use of Dental Vibe with first long buccal block
88804818|NCT00004660|Sham Comparator|Sham treatment|
88804819|NCT01270867|Active Comparator|Merci Retriever|Merci Retriever is the predicate product that received FDA clearance in 2004. Merci Retriever a first generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke.
89249650|NCT04971941|Active Comparator|DV3 with first LB and with IAN|Dental Vibe with first long buccal injection and inferior alveolar block
89249651|NCT04971941|Experimental|DV3 with 2nd LB|Use of DentalVibe with 2nd Long Buccal injection
89249652|NCT04971941|Experimental|DV3 with 2nd LB and IAN|Use of DentalVibe with 2nd long buccal and inferior alveolar nerve block
89249653|NCT04933643||well prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that the stomach is well prepared when GCS ≥ 18
89249654|NCT04933643||inadequate prepared|GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that GCS < 18 is inadequate.
89249655|NCT00359073|Active Comparator|Montelukast|montelukast (10 mg everyday)
89249656|NCT00359073|Placebo Comparator|Placebo|Placebo comparator
89249657|NCT03991143|Experimental|ATH3G10|Phosphorylcholine human monoclonal antibody (ATH3G10)
89249658|NCT03991143|Placebo Comparator|Placebo|Placebo to ATH3G10, 0.9% sodium chloride
89249659|NCT03918239|Experimental|SHP643 Prefilled Syringe (PFS)|Participants will receive 300 milligram (mg) of SHP643 PFS Subcutaneous (SC) injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
89249660|NCT03918239|Experimental|SHP643 Autoinjector (AI)|Participants will receive 300 mg of SHP643 AI SC injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
89249661|NCT04699331|Experimental|Individualized stimulation group|Patients receive five sessions of individualized stimulation obtained from brain image-based transcranial direct stimulation simulation. The simulator generates the electrode's location on the scalp.
89249662|NCT04699331|Active Comparator|Conventional stimulation group|Patients receive five sessions of conventional stimulation with electrodes over C3 and C4 based on the 10-20 system.
89249663|NCT04699331|Sham Comparator|Sham stimulation group|Patients receive five sessions of sham stimulation with electrodes over C3 and C4 based on the 10-20 system.
89249664|NCT00368745|Active Comparator|Pregabalin|Pregabalin treatment for GAD during 6 week taper/discontinuation from alprazolam treatment; followed by 6 weeks pregabalin treatment 'alprazolam free'.
89249665|NCT00368745|Placebo Comparator|Placebo|Placebo treatment of GAD during 6 week taper/discontinuation of alprazolam treatment followed by 6 weeks continuation of placebo treatment 'alprazolam free'.
89249666|NCT04573673|Experimental|PTNS verum|Patients will be treated with transcutaneous tibial neuro-stimulation with one 30-minute session daily for a period of 12 weeks.
89249667|NCT04573673|Sham Comparator|PTNS placebo|Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for 12 weeks (same treatment regimen as the experimental group).
89249668|NCT04188041|No Intervention|Qualitative|"Specific Aim 1: Explore the specific knowledge, attitudinal, and skills gaps to TB infection testing and treatment among primary care team members in RI through qualitative key informant interviews.~In Aim 1, 30 primary care team members from the Brown Family Medicine and Care New England networks will be purposively sampled to undergo key informant interviews regarding TB infection testing and treatment knowledge, attitudinal, and skill gaps. Questions will be asked to ascertain gaps throughout the entire latent TB infection care cascade. The results from Aim 1 will be used to design the survey instrument and the curriculum for an innovative, telementoring program (TB infection ECHO)."
89249669|NCT04188041|Other|Quantitative|Specific Aim 2: Design and evaluate an evidence-based telementoring intervention (ECHO model) that addresses the identified TB infection gaps in Aim 1, and evaluate this model for feasibility as well as its impact on primary care team member knowledge and TB infection testing and treatment in RI. 20 primary care team members will be recruited to participate in a virtual six-month TB infection ECHO course. Participants will complete quantitative surveys before and after the course as well as post-session surveys following each session. Survey questions will assess feasibility measures related to process, resources, and management and impact measures related to learning and performance. Paired data from pre- and post-course surveys will be analyzed accordingly depending on the distribution of results.
89249670|NCT04188041|Other|Retrospective chart review|Pilot a retrospective electronic medical record (EMR) data review to examine RI primary care providers' testing and treatment before and after ECHO implementation and evaluate the model's reach. In Aim 3, data will be retrospectively extracted from two participants' clinics to research RI primary care providers' testing and treatment patterns before and after the ECHO course. The two clinics will be identified once Aim 2 is completed.
89249671|NCT01048437|No Intervention|Standard transplant education|Missouri Kidney Program's standard Patient Education Program (PEP) transplant module.
89249672|NCT01048437|Experimental|Transplant education with video|Explore Transplant transplant module featuring video
89249673|NCT01048437|Experimental|Transplant education with speakers|Explore Transplant transplant module featuring live guest speakers.
89249674|NCT01050699|Experimental|Dexmedetomidine|Dexmedetomidine plus saline
89249675|NCT01050699|Active Comparator|Usual Care|Midazolam and Fentanyl
89249676|NCT00454818|Experimental|MYDICAR Very Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.
89249677|NCT00454818|Experimental|MYDICAR Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
89249678|NCT00454818|Experimental|MYDICAR Mid Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3x10e12 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
89249679|NCT00454818|Experimental|MYDICAR High Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1x10e13 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
89249680|NCT00454818|Placebo Comparator|Placebo infusion|A single dose of placebo (Sodium Chloride Injection, USP) administered by antegrade epicardial coronary artery infusion.
89249681|NCT03668873|Experimental|Sleep Parent Training|The five SPT sessions (each 60-90 minutes in duration) are individually delivered over 10-weeks. In addition to the five sessions, there are three home visits conducted via Express Care Online (HIPAA compliant video-chat). After Session A, session order may be adjusted to address child-specific problems. One-on-one delivery of SPT permits flexibility for child-specific problems within the program.
89249682|NCT03668873|Active Comparator|Sleep Parent Education|SPE consists of five 60-90 minute sessions, delivered individually over 10 weeks. SPE provides useful information to families of young children with ASD and sleep problems. Session A is designed to develop rapport. The sleep hygiene session (Session B) has been modeled from the RUBI manual. The other sessions include a systematic presentation on several relevant topics. An example of a SPE session is provided in the Intervention section. This condition is intended to parallel what would be offered in typical care, but by telehealth, where a parent might be educated about ASD as well as attend an outpatient appointment at a sleep clinic.
89249683|NCT04552457|Experimental|No activity restrictions|
89249684|NCT04552457|Active Comparator|Activity restrictions|
89249685|NCT00445224|Experimental|Hip Progressive Resistive Exercises|Exercises targeting hip musculature such as hip abduction and hip external rotation that was progressed by increased resistance following typical progressive resistive exercise approach.
89249686|NCT00445224|Active Comparator|Quad Progressive Resistive Exercises|Exercises targeting quadriceps musculature such as quadriceps isometric setting, terminal knee extensions, and straight leg raises that was progressed by increased resistance following typical progressive resistive exercise approach..
89249687|NCT02408315|Placebo Comparator|misoprostol/placebo using buccal|Randomized for buccal route of administration/ placebo
89249688|NCT02408315|Placebo Comparator|misoprostol/placebo using vaginal|Randomized for vaginal route of administration/ placebo
89249689|NCT01323114|Active Comparator|Medical Control Group|Control group of patients who will receive conventional medical treatment for type 2 diabetes, along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
89249690|NCT01323114|Experimental|Surgical Treatment Group|Experimental group in which patients will undergo the laparoscopic duodenal bypass procedure along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
89249691|NCT01030146|Other|NeilMed® Sinus Rinse™ System|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
89249692|NCT05711693|Experimental|Technique comparison|All patients will undergo successively LDV heart to carotid PWV and ascending aorta PWV by MRI, for comparison
89249693|NCT04005365|Experimental|Prop+neochemo|
89249694|NCT03994926|Experimental|Experimental|Directed smoking of about 3.6% THC cannabis cigarette
89249695|NCT01027182|No Intervention|Raltegravir|
89249696|NCT00358917|Experimental|LPV/r 800/200 mg QD Tablet|
89249697|NCT00358917|Active Comparator|LPV/r 400/100 mg BID Tablet|
89249698|NCT04571801|Active Comparator|1|Standard diagnostics
89249699|NCT04571801|Experimental|2|Standard diagnostics + NGS
89249700|NCT03990987||Day group|patients in Day group accept operation from 8：00～12：00
89249701|NCT03990987||Night group|patients in Night group accept operation from 18：00～22：00
89249702|NCT01048515|Experimental|Caffeine|
89249703|NCT01048515|Placebo Comparator|Placebo|
89249704|NCT04004195|Experimental|Healthy participants|
89249705|NCT04004195|Experimental|Participants with mild renal impairment|
89249706|NCT04004195|Experimental|Participants with moderate renal impairment|
89249707|NCT04004195|Experimental|Participants with severe renal impairment|
89249708|NCT01050777|Experimental|Liposomal Paromomycin|Liposomes containing 10% Paromomycin
89249709|NCT01050777|Experimental|Liposomal meglumine antimoniate|Liposomes containing meglumine antimonate
89249710|NCT01050777|Placebo Comparator|Placebo|
89249711|NCT04490369||Group 1- short interval|Less than or equal to six minutes between receiving sedation and the start of the procedure
89249712|NCT04490369||Group 2- long interval|Greater than or equal to seven minutes between receiving sedation and the start of the procedure
89249713|NCT04099589|Experimental|MIBC Group|Muscle-invasive bladder cancer of T2-4aN0M0 confirmed by pathology after maximal transurethral resection of bladder tumors. Enrollment of 30 patients.
89249714|NCT04099589|Experimental|UTUC Group|Upper tract urothelial carcinoma of T1-3N0M0 and high grade confirmed by flexible ureteroscope biopsy. Enrollment of 34 patients.
89249715|NCT01563809|Active Comparator|Low androgens FSH+LH|Patients with androgens below threshold receiving FSH+LH for ovarian stimulation
89249716|NCT01563809|Active Comparator|High androgens FSH+LH|Patients with androgens above threshold receiving FSH+LH for ovarian stimulation
89249717|NCT01563809|No Intervention|High androgens FSH alone|
89249718|NCT01563809|No Intervention|Low androgens, FSH alone|
89249719|NCT00264004|Experimental|1|30 mg AZD2171
89249720|NCT00264004|Experimental|2|45 mg AZD2171
89249721|NCT01069198|Experimental|Intervention group|
89249722|NCT01069198|Placebo Comparator|Non-intervention group|Non-intervention group will receive placebo following the same schedule as intervention group.
89249723|NCT00368355|Experimental|CLINIMACS Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
89249724|NCT00368355|Experimental|ISOLEX Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
89249725|NCT01070680|Active Comparator|dexmedetomidine|sedative medicine
89249726|NCT01070680|Placebo Comparator|sodium chloride 0,9%|
89249727|NCT00445146|Experimental|EVG+RTV|"EVG 85 mg or 150 mg + RTV + ARV regimen~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their ARV regimen will receive EVG 85 mg and all other participants will receive EVG 150 mg.~Some participants may receive EVG 300 mg during the course of protocol amendment 2."
89249728|NCT01581736|Experimental|Exercise|Proteomics of muscle after a single bout of exercise compared to baseline with U100 Humulin infusion at rate of 80 milliunits(mU)/m^2 surface area.
89249729|NCT01030224|Experimental|AZD9742 IV Infusion|Active
89249730|NCT01030224|Placebo Comparator|Placebo to AZD9742 IV Infusion|Placebo
89249731|NCT01030302||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
89249732|NCT00368277|Experimental|Aliskiren-based regimen|Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg
89249733|NCT00368277|Active Comparator|Ramipril-based regimen|Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg
89249734|NCT01324713||Males|
89249735|NCT01324713||Females|
89249736|NCT03992547|Experimental|robot assisted gait traing|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 12 weeks.
89249737|NCT00280150|Experimental|Cohort 1|Bevacizumab 10 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
89249738|NCT00280150|Experimental|Cohort 2|Bevacizumab 10 mg + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
89249739|NCT00280150|Experimental|Cohort 3|Bevacizumab + Erlotinib 150 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
89249740|NCT00280150|Experimental|Phase II|Bevacizumab + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
89249741|NCT03990753||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and microbiome/peptidome examination.
89249742|NCT01582126|Experimental|Group balance training early start|
89249743|NCT01582126|Experimental|Group balance training late start|
89249744|NCT03990675|Experimental|FNA, FNB|
89249745|NCT01582360||antiinfectiva: vancomycin|80 patients Completed.
89249746|NCT01582360||antiinfectiva: meropenem|80 patients recruiting
89249747|NCT01582360||antiinfectiva: flukonazol|80 patients
89249748|NCT01582360||antiinfectiva: cefotaxim|80 patients
89249749|NCT01582360||antiinfectiva: benzylpenicilline|80 patients
89249750|NCT01582360||antiinfectiva: tazobactam piperacillin|80 patients recruiting
89249751|NCT01582360||antiinfectiva: cloxacillin|80 patients
89249752|NCT01582360||antiinfectiva: ciprofloxacin|80 patients
89249753|NCT01052571|Active Comparator|Without Steroids|Group I patients receiving lumbar transforaminal epidural injections with an injection of local anesthetic (lidocaine 1% or bupivacaine 0.25%
89249754|NCT01052571|Active Comparator|steroids|Group II patients will receive lumbar transforaminal epidural injections with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
89249755|NCT00279916|Active Comparator|Triamcinolone acetonide|"Triamcinolone acetonide nasal spray; Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms) for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms) for 6 weeks duration."
89249756|NCT00279916|Sham Comparator|Placebo|"Placebo nasal spray; Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily for 6 weeks duration.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily for 6 weeks duration."
89249757|NCT02534337|Experimental|GEMOX|gemcitabine 1000 mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2.
89249758|NCT02534337|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2.
89249759|NCT01052649||Healthy volunteers|
89249760|NCT01325896|Other|All patients are receiving PEG-Intron|
89249761|NCT01050933|Experimental|Carbon Monoxide|Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.
89249762|NCT00358527|Experimental|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray 200 mcg, once daily.
89249763|NCT00358527|Placebo Comparator|Matching placebo nasal spray|
89249764|NCT00251758|Experimental|Dexlansoprazole MR 60 mg QD|
89249765|NCT00251758|Experimental|Dexlansoprazole MR 90 mg QD|
89249766|NCT00251758|Placebo Comparator|Placebo|
89249767|NCT03974776|Experimental|PF-06946860|Single subcutaneous administration of PF-06946860
89249768|NCT03974776|Placebo Comparator|Placebo|Single subcutaneous administration of placebo
89249769|NCT00262834|Experimental|Arm I|Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgery of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.
89249770|NCT05711459|Experimental|Liver Injury Group|The patients have liver injuries caused by antitumor drugs.
89249771|NCT05709665||Out-of-hospital cardiac arrest|Patient characteristics; Rescue time intervals; Time to eCPR Decision during high quality CPR;
89249772|NCT05709665||In-hospital cardiac arrest|Patient characteristics; Emergency team time intervals; Time to eCPR Decision during high quality CPR;
89249773|NCT04417361|Experimental|Galcanezumab|The galcanezumab arm will self-administer a subcutaneous injection of galcanezumab. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of galcanezumab 120 mg. The injections will be with a pre-loaded syringe containing galcanezumab.
89249774|NCT04417361|Placebo Comparator|Placebo|The placebo arm will self-administer a subcutaneous injection of placebo. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will receive an injection of placebo 120 mg. The injections will be with a pre-loaded syringe containing placebo.
89249775|NCT01563887|Experimental|DD.com|Participants in this arm will receive the DiabetesDriving.com internet intervention intended to help reduce their risk of being in a future collision.
89249776|NCT01563887|Experimental|DD.com + MI|Participants will receive the DiabetesDriving Internet intervention and two 60 minute Motivational Interview (MI) sessions over the telephone. The MI sessions will take place once before and once following completion of the Internet intervention. This interview will focus on making explicit individual's ambivalence around changing behavior.
89249777|NCT04386239|Experimental|Covid-19|Patients with documented (chest X-Ray or Computed Tomography scan) Covid-19 (Polymerase Chain Reaction+ swab test) interstitial pneumonia and BCRSS ≥3 and <4 will be requested consent to the study.
89249778|NCT04004585|Experimental|Intervention|This was a single arm study with all participants receiving the same intervention. Participants will receive a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour.
89249779|NCT00541775|Experimental|Sitagliptin|sitagliptin 100 mg
89249780|NCT00541775|Active Comparator|Rosiglitazone|rosiglitazone 8 mg
89249781|NCT00541775|Placebo Comparator|Placebo|placebo
89249782|NCT04004117|Experimental|Fentanyl s/l|Sublingual fentanyl will consist in liquid fentanyl at a concentration of 25 mcg/mL, with preparation by the pharmacist of pre-dosed syringes of 12,5 mcg (0,5 mL).
89249783|NCT04004117|Placebo Comparator|Placebo|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
89249784|NCT01563965|Active Comparator|Conventional preoperative fast|Patients underwent surgery after 8h fast
89249785|NCT01563965|Experimental|Carbohydrate plus protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil).All the patients fasted for solids at least 8 hours from the operation
89249786|NCT00539513|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
89249787|NCT00539513|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
89249788|NCT04506047||Acute Myocardial Infarction|Consecutive patients with acute myocardial infarction
89249790|NCT04003727|Active Comparator|Neutral Position|Head and neck will be on neutral position.
89249791|NCT04003727|Active Comparator|Sniffing Position|Head and neck will be on sniffing position
89249792|NCT04003727|Active Comparator|Head Extension position|Head will be on simple extension position
89249793|NCT04094441|Experimental|additional pulmonary function tests|additional pulmonary function tests
89249794|NCT04003883||Emergency physicians|Emergency physicians doing shifts at the Medical University of Vienna's emergency response car will recieve a thorough cardiac pretesting. During shifts they will be attached to a Holter-ECG to detect changes in ST-T Segment and other ECG changes. Furthermore surrogate parameters of stress will be measured
89249795|NCT00454584|Experimental|CNTO 1275 45 mg|Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
89249796|NCT00454584|Experimental|CNTO 1275 90 mg|Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
89249797|NCT00454584|Active Comparator|Etanercept 50 mg|Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
89249798|NCT03790644|Experimental|exoskeleton assist|walking with assist of a powered exoskeleton
89249799|NCT02555267||Elderly patients with DLBCL|Elderly patients (age>=65 years) with DLBCL treated with R-CHOP chemotherapy
89249800|NCT02540915||All patients 17 years or younger|Standard of Care - Registry. Must have been 11 yrs or under at initial treatment/evaluation.
89249801|NCT04204343|Active Comparator|Caudal Block|US-guided caudal block with 0.7 ml/kg 0.25% Bupivacaine
89249802|NCT04204343|Active Comparator|Erector Spinae Plane Block|US-guided erector spinae plane block with 0.5 ml/kg 0.25% Bupivacaine
89249803|NCT02845271|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
89249804|NCT02845271|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
89249805|NCT00445068|Experimental|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.
89249806|NCT02404337|Experimental|100 mg/kg of Betaine|Dose 1 : 100 mg/kg of Betaine
89249807|NCT02404337|Experimental|250 mg/kg of Betaine|Dose 2 : 250 mg/kg of Betaine
89249808|NCT05361083|Experimental|First-in-man investigastion of [18F]CETO|"15 patients were investigated with PET/CT after injection of 2,5 MBq/kg [18F]CETO. 5 healthy volunteers were investigated twice (Test-retest), with approximately 2 weeks in-between each PET/CT investigation, after injection of 1,3 MBq/kg [18F]CETO. Arterial blood samples were taken as well as urinary sampels.~3 out of 5 healthy volunteers were also investigated twice with PET/CT after injection of 13,2 MBq/kg [15O]water, performed before the [18F]CETO PET/CT."
89249809|NCT02403089||neonates|neonates 24-41 weeks gestational age
89249810|NCT02403089||children|hematopoietic stem cell transplant recipient children (< 18 years old, donor source: cord blood or genoidentical donor)
89249811|NCT00539279|Experimental|Prolonged Exposure Therapy (PE)|Prolonged Exposure Therapy (PE)
89249812|NCT00539279|Active Comparator|Relaxation Training (RT)|Relaxation Training (RT)
89249813|NCT05360147|Placebo Comparator|Placebo|treated with oral antidiabetic drugs alone or combined with insulin, except for glucagon-like peptide type 1 (GLP-1) analogue
89249814|NCT05360147|Active Comparator|Liraglutide|liraglutide started at an initial dose of 0.6 mg/day and a maximum dose of 1.8mg/day, adjusted once a week when hyperglycemia was uncontrolled
89249815|NCT00444912|Experimental|G-CSF plus plerixafor|Participants with CD20- lymphoma
89249816|NCT00444912|Experimental|G-CSF plus plerixafor and rituximab|Participants with CD20+ lymphoma
89249817|NCT00538733|Experimental|T-BiRD Therapy|"All patients were treated with the same regimen, starting with T-BIRD therapy (Cycles 1-4).~After 4 cycles, Patients with disease progression will be taken off study. Patients who achieve maximum response will receive maintenance. Patients who achieve VGPR or PR will be given T-BiRD for 2 cycles (cycles 5-6). After 6 cycles of T-BiRD, Patients who achieve maximum response will receive maintenance; those with disease progression will be taken off study; all other patients will receive BIRD.~Patients who progress on BiRD will reinitiate T-BiRD. If disease progression continues after 2 cycles, patients will be taken off study.~Patients in CR/sCR or that achieve a plateau of disease for > 2 cycles on BiRD or T-BiRD therapy will receive maintenance."
89249818|NCT00444678|Experimental|Cetuximab, Capecitabine and Oxaliplatin|
89249819|NCT00358449|Experimental|Mepolizumab 0.55 mg/kg|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
89249820|NCT00358449|Experimental|Mepolizumab 2.5 mg/kg|Participants received mepolizumab 2.5 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
89249821|NCT00358449|Experimental|Mepolizumab 10 mg/kg|Participants received mepolizumab 10 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
89249822|NCT00539981|Experimental|FluBlok (Lots A, B, C)|Participants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
89249823|NCT00539981|Placebo Comparator|Placebo|Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
89249824|NCT00990041||PBMC|
89249825|NCT00990041||periodontitis|
89249826|NCT00990119|Experimental|High FLow Therapy|Use of High Flow Therapy for support of Respiratory Insufficiency
89249827|NCT00990119|Active Comparator|NiPPV|
89249828|NCT03992157|Experimental|holter-ECG|Implementation of an ECG Holter during hospitalisation patient.
89249829|NCT03992157|No Intervention|Crontrole|No implementation of an ECG Holter
89249830|NCT00990197|Active Comparator|Day 1|Patients randomized to wearing the patch on day 1 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 2.
89249831|NCT00990197|Active Comparator|Day 2|Patients randomized to wearing the patch on day 2 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 1.
89249832|NCT03992079|No Intervention|Control|The control group will receive standard preoperative and postoperative directions, with the anesthesiologist and surgeon's preferences for analgesia during and after surgery.
89249833|NCT03992079|Experimental|Experimental|The experimental group will receive routine directions for surgery and a ReCOVER patient education document on the Enhanced Recovery protocol, with instructions on preoperative preparation, postoperative wound care, pain management, preventing and managing constipation, activity limitations, and return precautions. The information sheet will be provided to patients in clinic and reviewed with a member of the healthcare team to ensure an understanding of the plan.
89249834|NCT01051011|Experimental|1|
89249835|NCT01051011|Experimental|2|
89249836|NCT01051011|Active Comparator|3|
89249837|NCT05359913|Experimental|African American Women|
89249838|NCT05361005|Experimental|Cohort 2mg/kg|All participants (fasted) received either 2 mg/kg of BDB-001 as a single dose or dose-matched placebo.
89249839|NCT05361005|Experimental|Cohort 4mg/kg|All participants (fasted) received either 4 mg/kg of BDB-001 as a single dose or dose-matched placebo.
88804820|NCT01270867|Experimental|Trevo Stentriever|Trevo Retriever is a second generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke. The Trevo Retriever is a type of stent, specifically design to allow for clot integration into the device. The clot in the retriever is then removed and blood flow is restored.
88804821|NCT01271413|Experimental|Adaptive cognitively stimulating activities|
89249840|NCT05361005|Experimental|Cohort 8mg/kg|All participants (fasted) received either 8mg/kg of BDB-001 as a single dose or dose-matched placebo.
89249841|NCT05361005|Experimental|Cohort 4mg/kg multiple doses|All participants (fasted) received either 4 mg/kg of BDB-001 as a multiple doses or doses-matched placebo.
89249842|NCT01324791|Active Comparator|laparoscopic antireflux surgery|
89249843|NCT01324791|Active Comparator|endoscopic full-thickness-gastroplication|
89249844|NCT05360927|Experimental|Cohort 0.3mg/kg|All participants (fasted) received either 0.3 mg/kg of BDB-001 as a single dose or dose-matched placebo.
89249845|NCT05360927|Experimental|Cohort 1mg/kg|All participants (fasted) received either 1 mg/kg of BDB-001 as a single dose or dose-matched placebo.
89249846|NCT05360927|Experimental|Cohort 3mg/kg|All participants (fasted) received either 3 mg/kg of BDB-001 as a single dose or dose-matched placebo.
89249847|NCT05360927|Experimental|Cohort 8mg/kg|All participants (fasted) received either 8 mg/kg of BDB-001 as a single dose or dose-matched placebo.
89249848|NCT05360927|Experimental|Cohort 16mg/kg|All participants (fasted) received either 16 mg/kg of BDB-001 as a single dose or dose-matched placebo.
89249849|NCT05360927|Experimental|Cohort 20mg/kg|All participants (fasted) received either 20 mg/kg of BDB-001 as a single dose or dose-matched placebo.
89249850|NCT01051089|Experimental|Lifestyle modification|supervised exercise with diet education
89249851|NCT01051089|No Intervention|Control|Control (ordinary care with usual education)
89249852|NCT01048749|Active Comparator|aquatic vertical supsension|Spinal height measurement using a stadiometer following aquatic vertical suspension
89249853|NCT01048749|Active Comparator|land-based supine flexion condition|Spine height will be measured with a stadiometer following completion of the supine land-based flexion position.
89249854|NCT01048827|Experimental|experimental|dose-escalation Busulfan
89249855|NCT01302327|Experimental|Exenatide|
89249856|NCT01048983|Other|Questionnaires and Phone Calls|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
89249857|NCT01048983|Active Comparator|Curcumin Only|
89249858|NCT01048983|Active Comparator|Armodafinil Only|
89249859|NCT01048983|Active Comparator|Minocycline Only|
89249860|NCT01048983|Active Comparator|Bupropion Only|
89249861|NCT01048983|Active Comparator|Curcumin + Armodafinil|
89249862|NCT01048983|Active Comparator|Curcumin + Minocycline|
89249863|NCT01048983|Active Comparator|Curcumin + Bupropion|
89249864|NCT01048983|Active Comparator|Armodafinil + Minocycline|
89249865|NCT01048983|Active Comparator|Armodafinil + Bupropion|
89249866|NCT01048983|Active Comparator|Minocycline + Buproprion|
89249867|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline|
89249868|NCT01048983|Active Comparator|Curcumin + Armodafinil + Bupropion|
89249869|NCT01048983|Active Comparator|Curcumin + Minocycline + Bupropion|
89249870|NCT01048983|Active Comparator|Armodafinil + Minocycline + Bupropion|
89249871|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline + Bupropion|
89249872|NCT03929783|Experimental|Diagnostic (CEM)|Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day.
89249873|NCT01052805||harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
89249874|NCT02534181|Active Comparator|Intervention group|"Patients will undergo a caloric management protocol:~Days 1 and 2:~Reduction of caloric intake to 5kcal/kg/day;~Replacement of serum phosforus, potassium and magnesium;~Administration of 100mg intravenous thiamine, vitamins and microelements.~From day 3:~If serum phosphorus < 2.5mg/dL, protocol will be followed according to day 2;~If serum phosphorus > 2.5mg/dL, a gradual increase to target caloric intake will ensue."
89249875|NCT02534181|No Intervention|Control group|"Nutritional management will be followed according to institutional protocol.~Electrolyte replacement will be provided at the clinician's discretion."
89249876|NCT01052883|Experimental|1|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A] then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
89249877|NCT01052883|Experimental|2|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
89249878|NCT01052883|Experimental|3|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C] then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
89249879|NCT01052883|Experimental|4|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
89249880|NCT00990353||Prism adaptation therapy|Patients receive prism adaptation therapy by protocol (Frassinetti et al., 2002)
88804822|NCT01271413|Active Comparator|Non-adaptive cognitively stimulating activities|
89249881|NCT00990353||Bromocriptine pharmacotherapy|Patients receive bromocriptine pharmacotherapy by protocol (Barrett et al., 1999)
89249882|NCT03990441|Experimental|Intervention|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
89249883|NCT03990441|Placebo Comparator|Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
89249884|NCT05359757|Experimental|Naturalistic therapeutic techniques and PECS therapy.|
89249885|NCT05359757|Active Comparator|PECS therapy Only.|
89249886|NCT03990597|Experimental|Supportive care (StrataXRT, placebo)|Beginning first day of CSI proton radiation therapy, caregivers apply StrataXRT gel to half of the patient's forehead and one ear and placebo to the other half of the forehead and the other ear BID until the last day of radiation therapy.
89249887|NCT01340417|Experimental|one label|Measurements of melatonin levels in urine, blood, milk.
89249888|NCT01049061|Experimental|MORAb-003|
89249889|NCT01049139|No Intervention|No Supplemental Information|Participants will be administered a standard HIV vaccine trial consent form but no additional information.
89249890|NCT01049139|Experimental|Supplemental information with 1-sided message|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
89249891|NCT01049139|Experimental|Supplemental information with 2-sided messages|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
89249892|NCT02533947|Experimental|Exercise group|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
89249893|NCT02533947|Other|Control group|A waitlist control group will get the intervention after 7 month of treatment as usual.
89249894|NCT00367341|Other|Escitalopram|
89249895|NCT00367341|Other|Cognitive Behavioral Therapy|
89249896|NCT01052961|No Intervention|Non-intervention arm|patients may receive oseltamivir 75 mg bd for 5 days, decided by the managing physicians
89249897|NCT01052961|Active Comparator|oseltamivir, higher dose|oseltamivir 150 mg bd for 5 days for patients presented within 96 hours from onset
89249898|NCT02534025|Experimental|P group|Elevation of Cuff pressure to 200 mm Hg for 5 minutes four times 5 minutes apart
89249899|NCT02534025|No Intervention|C group|no intervention will be added to routine anesthetic mangement
89249900|NCT00440466|Experimental|001|epoetin alfa Continue pre-study once weekly dose of epoetin alfa for 36 weeks
89249901|NCT00440466|Experimental|003|epoetin alfa Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
89249902|NCT00440466|Experimental|002|epoetin alfa Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
89249903|NCT03992313|Experimental|Facility-based testing intervention|Community Health Workers (CHWs) will provide information inside their groups on the possibility to be tested in health centers for HCV infection. HCV screening will be done using the SD Bioline HCV RDT on a finger stick capillary whole blood. Results will be available in 15 minutes. In case of positive HCV RDT, an immediate blood sample collection will be done in health center and sent to Provincial Hospital to perform HCV RNA using GenXpert viral load assay on plasma. Results will be sent back to the health center that will be in charge to give result to the participant and to refer to care in case of active infection.
89249904|NCT03992313|Experimental|Community-based testing intervention|After a dedicated training, CHWs will do the SD Bioline HCV RDT on a finger stick capillary whole blood directly in the village of participants. In case of positive HCV RDT, 5 blood spots will be collected immediately on DBS and sent to Phnom Penh for HCV RNA extraction and amplification (Omunis). Results will be sent back to the referral health center of each cluster and CHWs will be in charge to give result to the participant and to refer to care in case of active infection.
89249905|NCT01051167|Experimental|Cetuximab + Folfox-6-regime|"Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:~Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h."
89249906|NCT00537485|Experimental|1|
89249907|NCT00537485|Placebo Comparator|2|
89249908|NCT04003571|Experimental|Augmented reality with functional electrical stimulation group|Ten participants in group A will undergo 30 minutes interactive augmented reality with functional electrical stimulation intervention and 30 minutes traditional physiotherapy per day, 3 days a week for 8 weeks.
89249909|NCT04003571|Active Comparator|Traditional physiotherapy group|Ten participants in group B will undergo 30 minutes treadmill and balance training as well as 30 minutes traditional conventional physiotherapy a day, 3 days a week, for 8 weeks.
89249910|NCT00989339|Experimental|Twenty-four Hour TPN and Saline Infusion|Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 month.
89249911|NCT00989417|Active Comparator|CONTROL Group - Without Home Monitoring|Patients receiving the standard of care. Due to safety concerns, the patients are followed every 6 months after a first follow-up, which is performed between 1 and 3 months after implantation.
89249912|NCT00989417|Experimental|ACTIVE GROUP With Home Monitoring|After a first follow-up (between 1 and 3 months after implantation), the patients are followed one time per year. Within this period, the additional ICD follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception, Data/IEGM-online analysis on internet site or patient/physician call.
89249913|NCT00989495|Experimental|Brace - Randomized|Participants were randomized to be braced
89249914|NCT00989495|No Intervention|Observation - Randomized|Participants were randomized to be observed only
89249915|NCT00989495|Experimental|Brace - preference based|Participants chose to be braced
89249916|NCT00989495|No Intervention|Observation - preference-based|Participants chose to be observed only
89249917|NCT00989651|Experimental|Regimen I (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes (beginning in course 2) on day 1. Patients also receive veliparib PO BID on days 1-21. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
89249918|NCT00989651|Experimental|Regimen II (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Patients also receive carboplatin, bevacizumab, and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
89249919|NCT00989651|Experimental|Regimen III (paclitaxel, cisplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1 and IP on day 8, and cisplatin IP on day 1 or 2. Patients also receive bevacizumab and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
89249920|NCT05590559|Active Comparator|paravertebral block|
89249921|NCT05590559|Experimental|Ultrasound-guided erector spinae plane block|
89249922|NCT05359601|Experimental|24-hour|Every 24-hour infusion set replacement
89249923|NCT05359601|Placebo Comparator|96-hour|Every 96-hour infusion set replacement
89249924|NCT00989729|Active Comparator|Methylprednisolone|75 patients will receive a single preoperative dosage of Methylprednisolone
89249925|NCT00989729|Placebo Comparator|Physiological Saline|75 patients will receive a single preoperative dosage of Physiological Saline
89249926|NCT00990431|Active Comparator|Carbon dioxide laser treatment|
89249927|NCT00990431|Active Comparator|Erbium:YAG laser treatment|
89249928|NCT01590095|Active Comparator|Water quality|90 clusters, approx. 720 newborns
89249929|NCT01590095|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
89249930|NCT01590095|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
89249931|NCT01590095|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
89249932|NCT01590095|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
89249933|NCT01590095|Active Comparator|Nutrition + Combined WASH|90 clusters, approx. 720 newborns
89249934|NCT01590095|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
89249935|NCT05359523|Active Comparator|Patients diagnosed with myofascial pain syndrome|Ultrasound measurements will be made while the upper back is at rest and during arm movements.
89249936|NCT05359523|Active Comparator|Healthy volunteers|Ultrasound measurements will be made while the upper back is at rest and during arm movements.
89249937|NCT05590091|Experimental|Experimental group|roup A were given precise dietary guidance and enteral and parenteral nutrition support treatment using only nutrition software. It is recommended that the precise recommended time covers the start of enrollment until 100 days after transplantation
89249938|NCT05590091|No Intervention|The control group|Group B patients were given the routine nutritional support treatment plan commonly used in clinics. Patients in both groups were monitored and followed up at -5d before transplantation and at +6d, +30d, +60d, +100d, +180d, and +360d after transplantation.
89249939|NCT00990587|Experimental|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at escalating doses depending on when they enter into the trial.
89249940|NCT00988793|Active Comparator|Laparoscopic distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
89249941|NCT00988793|Active Comparator|Open distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
89249942|NCT00989885||Obstructive Sleep Apnea|475 patients that sought the CESF to probable diagnosis of some sleep disorder, subsequently diagnosed with Obstructive Sleep Apnea.
89249943|NCT05589779||With cardiovascular disease|Asthma patients with cardiovascular disease
89249944|NCT05589779||Without cardiovascular disease|Asthma patients without cardiovascular disease
89249945|NCT05358275|Experimental|study group|Guided lid surgery is performed to reduce the loss of bone post operative
89249946|NCT05358275|Active Comparator|control group|The patient will receive active ordinary treatment for removal of odontogenic cysts
89249947|NCT00537329|Other|Open|This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.
89249948|NCT00990743|Experimental|SYL040012|
89249949|NCT05358197|Experimental|Control group|
89249950|NCT00990977|No Intervention|controls|assessment only
89249951|NCT00990977|Experimental|cases|MBSR including brief information session and assessments
89249952|NCT04002869||Active TB suspicion|This study will include both adults and children with suspicion of different degrees of severity of active TB (pulmonary and extrapulmonary) to bring the investigator's study population into line with the routine clinical practice and to avoid the spectrum bias
89249953|NCT04002869||Latent TB infection|Individuals with latent TB infection (adults and children), with positive TST and/or IGRAs; without any sign or radiological evidence of TB disease or any clinical picture compatible with the criteria defined in the section TB cases.
89249954|NCT04002869||NTM infection|Adult and pediatric patients with lymphadenopathies caused by NTMs or individuals with chronic respiratory diseases with a NTM microbiologically confirmed by culture isolation.
89249955|NCT04002869||Uninfected control|Both adult and children without active TB and no immunologic evidence of M. tuberculosis infection, with negative TST and/or IGRAs
89249956|NCT04002869||Other respiratory diseases|Subjects with ARIs, and subjects with lung cancer; without any clinical picture compatible with the criteria defined in TB cases section. Patients with ARIs will be identified as individuals with clinical signs, symptoms and radiology of respiratory infections, and microbiological confirmation of non-TB origin. Patients with lung cancer will be identified as those with a high clinical suspicion, a suggestive chest X-ray/computed tomography scan, and a confirmed histopathological/cytological diagnosis
89249957|NCT05358119||Prospective cohort|Patients with long COVID and new-onset musculoskeletal pain
89249958|NCT03897179|Experimental|INVSENSOR00032 and INVSENSOR00033 test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00032 and/or INVSENSOR00033 device.
89249959|NCT03905135|Experimental|1- Experimental Treatment: Dose Escalation|Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at escalating doses of 1, 2, 3 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with avelumab by intravenous (IV) infusion at a dose of 10mg/kg on Day 8 and 22 of each cycle, to determine maximum tolerated dose (MTD)
89249960|NCT03905135|Experimental|2- Experimental Treatment: Dose Expansion|Interleukin-15 (IL-15) by continuous intravenous (civ) infusion at the maximum tolerated dose (MTD) on days 1-5 of cycles 1-6 with avelumab at 10mg/kg on Day 8 and 22 of each cycle
89249961|NCT05589311|Experimental|Intervention group|One-time 2.5-hour virtual lecture on musculoskeletal pain conducted following Transformative Learning principles
89249962|NCT05589311|Active Comparator|Control group|One-time 2.5-hour virtual lecture on musculoskeletal pain conducted using conventional didactic approach
89249963|NCT00991055|Experimental|Pioglitazone|
89249964|NCT00991055|Placebo Comparator|Placebo|
89249965|NCT04002557||Focus group|"This is a qualitative study using focus group discussions with young people aged 12-18 who are receiving consultation summaries.~Patients attending a single diabetes service will be invited to enrol. This service serves a population from a wide geographic area and socio-economic backgrounds.~Interviews will be conducted by a qualitative researcher with relevant experience. They will be held on the day of a participant's clinic appointment within the same hospital or on the day agreed with the participant."
89249966|NCT05589155|No Intervention|Control|
89249967|NCT05589155|Experimental|Healthi|
89249968|NCT00991133|Experimental|Clofarabine|Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal methotrexate, and then entered follow-up. Patients who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and patients who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.
89249969|NCT00991211|Experimental|Bendamustine + Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
89249970|NCT00991211|Active Comparator|CHOP + Rituximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w
89249971|NCT05588921||Aging group|Participants with baseline information, medical history of diseases, and lens photographs
89249972|NCT00357903|Other|1|
89249973|NCT03990519|Experimental|Cohort1: JNJ-2636682/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
89249974|NCT03990519|Experimental|Cohort 2: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo on Day 1.
89249975|NCT03990519|Experimental|Cohort 3: JNJ-26366821/Placebo|Participants will receive single dose of JNJ-26366821 or placebo. The dose of JNJ-26366821 will be selected based on the safety, pharmacodynamics, and pharmacokinetics data from the previous Cohorts 1 and 2.
89249976|NCT01053039|Active Comparator|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
89249977|NCT01053039|Placebo Comparator|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
89249978|NCT01051401|Experimental|Arm I (rosuvastatin)|Patients receive rosuvastatin PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
89249979|NCT01051401|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
89249980|NCT03989973||Cirrhosis patients|Patients were diagnosed by liver biopsy, CT or ultrasound
89249981|NCT01053117|Experimental|Protocolized approach|Protocolized approach to convert catheter to arteriovenous fistula
89249982|NCT01053117|No Intervention|Current Care Model|
89249983|NCT00348933|Experimental|1|Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for 12 months.
89249984|NCT01325103|Experimental|Stem Cell Transplantation|Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation.
89249985|NCT01051479|Experimental|C11-Choline|
89249986|NCT01055691|Experimental|1|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
89249987|NCT01055691|Experimental|2|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
89249988|NCT01055691|Experimental|3|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
89249989|NCT01055691|Experimental|4|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
89249990|NCT02533869|Experimental|Low-dose CT for acute appendicitis|Low-dose computed tomography for diagnosing acute uncomplicated appendicitis Laparoscopic appendectomy
89249991|NCT03896477|Experimental|Pneumosil|Infants received two primary vaccinations with Pneumosil, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
89249992|NCT03896477|Active Comparator|Synflorix|Infants received two primary vaccinations with Synflorix, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
89249993|NCT03896477|Active Comparator|Prevenar 13|Infants received two primary vaccinations with Prevenar 13, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
89249994|NCT00444600|Experimental|0.5mg Ranibizumab plus laser|
89249995|NCT00444600|Experimental|0.5 mg Ranibizumab plus deferred laser|
89249996|NCT00444600|Experimental|4 mg Triamcinolone plus laser|
89249997|NCT00444600|Active Comparator|Sham plus laser|
89249998|NCT00537095|Experimental|vandetanib (ZD6474)|vandetanib (ZD6474) 300 mg per os once daily
89249999|NCT00537095|Placebo Comparator|Placebo|Placebo
89250000|NCT01030380|Experimental|Slendertone Face NMES|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
89250001|NCT01030380|No Intervention|Control Group: No NMES|Control Group: No NMES over the course of 12 weeks.
89250002|NCT00991367|Experimental|A|Cicatrix
89250003|NCT00991367|Placebo Comparator|B|Placebo
89250004|NCT00991445|Active Comparator|Group MIS|Minimal Invasive Surgery
89250005|NCT00991445|Active Comparator|Conventional Exposure|
89250006|NCT00991523|Experimental|sweetened beverage|
89250007|NCT00991523|Placebo Comparator|placebo control|placebo
89250008|NCT00443898|Experimental|1|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks
89250009|NCT00443898|Placebo Comparator|2|vehicle (placebo) applied once daily for 48 weeks
89250010|NCT00443898|Experimental|3|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks
89250011|NCT00443898|Placebo Comparator|4|vehicle (placebo) applied once daily for 24 weeks
89250012|NCT00537017|Experimental|Preladenant 5 mg BID|Preladenant 5 mg twice daily (BID) given open-label for 36 weeks to participants with moderate to severe Parkinson's Disease who are on a long-term and stable L-dopa treatment regimen.
89250013|NCT05358041||Electromagnetic Navigational Fixed Angle Bronchoscopy with CBCT Guidance|Patient is undergoing electromagnetic navigation bronchoscopy using Medtronic super D version 7 EMN system, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
89250014|NCT05358041||Robotic Shape Sensing Bronchoscopy with CBCT Guidance|Patient is undergoing robotic navigation bronchoscopy using IOn robotic platform, peripheral endobronchial ultrasound and Cone Beam CT Guidance using the Philips Azurion 7 C20 FlexMove with Embo Guide and Overlay software to create CT Augmented Fluoroscopy under general anesthesia.
89250015|NCT00348309|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
89250016|NCT00348309|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
89250017|NCT00348309|Placebo Comparator|Arm 3|Placebo
89250018|NCT05581433|Active Comparator|vapocoolan spray applied group before injection|Vapocoolant spray will be applied to patients in this group before intra-articular knee injection.
89250019|NCT05581433|Placebo Comparator|placebospray applied group before injection|Placebo spray will be applied to patients in this group before intra-articular knee injection.
89250020|NCT05581433|No Intervention|No administration group before injection|In this group, no pain reliever application will be made before the application.
89250021|NCT04451837|Active Comparator|semaglutide|Patients randomized to add semaglutide (Ozempic) will receive injection training at the study site and inject 0.25 mg subcutaneously once weekly during the first four weeks, followed by 0.5 mg weekly for the subsequent four weeks and finally 1.0 mg weekly throughout the study.
89250022|NCT04451837|Active Comparator|dapagliflozin|Those randomized to dapagliflozin will receive 10 mg orally once daily in addition to metformin.
89250023|NCT05580497|Experimental|Soft Wearable Robotic Knee System|30 minutes gait training wearing the Soft Wearable Robotic Knee System
89250024|NCT04003337|No Intervention|GROUP A: Morphological embryo selection|Patients enrolled in group A will receive an embryo transfer according to classical morphological criteria.
89250025|NCT04003337|Active Comparator|GROUP B: Morpho-kinetics embryo selection|Patients enrolled in group B will receive an embryo transfer according to new morphokinetics criteria.
89250026|NCT05493683|Experimental|Combination of Disitamab Vedotin and Tislelizumab|Disitamab Vedotin 2.0mg/kg q2w+Tislelizumab 400mg q6w. The treatment of Disitamab Vedotin + Tislelizumab will continue until the tumor progression confirmed by imaging, or up to 2 years, or intolerable toxic reactions, or other conditions determined by the researchers.
89250027|NCT01053195|Experimental|Lifestyle counseling|In the project areas, lifestyle counseling will be given every three months to individuals having prediabetes and every six months to those with normal glucose levels.
89250028|NCT01053195|No Intervention|Control|No intervention activity will be assigned for participants enrolled from the control areas.
89250029|NCT05440487||Iron chelator|Patients prescribed with Iron Chelators
89250030|NCT01053273|Active Comparator|Caudal epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
89250031|NCT01053273|Active Comparator|Percutaneous Adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone
89250032|NCT00440310|Experimental|Litx + Chemotherapy|
89250033|NCT00440310|Active Comparator|Chemotherapy alone|
89250034|NCT01055847|Experimental|AI 75 mg|Aztreonam for Inhalation 75 mg twice daily
89250035|NCT01055847|Experimental|AI 225 mg|Aztreonam for Inhalation 225 mg twice daily
89250036|NCT01055847|Placebo Comparator|Placebo|Placebo
89250037|NCT02533791|Experimental|low dose group|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
89250038|NCT02533791|Experimental|high dose group|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
89250039|NCT02533791|Placebo Comparator|placebo group|placebo
89250040|NCT05394935|Experimental|Polycystic Ovary Syndrome|Women with PCOS
89250041|NCT05394935|Active Comparator|Controls|Healthy, age and BMI matched controls
89250042|NCT01055925|Active Comparator|MPV|
89250043|NCT01055925|Active Comparator|Aquacel|
89250044|NCT00440232|Experimental|Frovatriptan|5.0 mg of Frovatriptan given as single dose
89250045|NCT00440232|Placebo Comparator|placebo|
89250046|NCT01564199|Experimental|Treatment A|Salmeterol/fluticasone propionate with concomitant charcoal
89250047|NCT01564199|Experimental|Treatment B|Salmeterol/fluticasone propionate without concomitant charcoal
89250048|NCT02533323|Experimental|P-Gemox|P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
89250049|NCT02533479|Experimental|Caloric restriction|three alternate days weekly along 4 weeks.
89250050|NCT01031082||HIV-negative Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-negative/ presumed negative subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-negative/ presumed negative subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
89250051|NCT01031082||HIV-positive Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-positive subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-positive subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
89250052|NCT05311553|Experimental|Zona pellucida thinning|thinning will be performed without reaching the inner membrane of the Zona pellucida thickness.
89250053|NCT05311553|Experimental|Zona pellucida drilling|an opening will be made from the outside to the inside of the Zona pellucida.
89250054|NCT01323348|Experimental|Diabetes Educational Intervention|Study participants in the intervention group will receive a diabetes management educational intervention at baseline and at follow-up visits. For those on an annual follow-up schedule, educational intervention will take place at baseline and 12 months. For those whose standard care involves more frequent, than annual, visits the educational intervention will take place no more than once every 12 weeks.
89250055|NCT01323348|No Intervention|Standard Care|Usual care
89250056|NCT05357807|Active Comparator|Standard RYGB|127 patients undergo a standard Roux-en-Y gastric bypass
89250057|NCT05357807|Experimental|Extended Pouch RYGB|127 patients undergo a Roux-en-Y gastric bypass with an extended pouch.
89250058|NCT05357807|Experimental|Banded Extended RYGB|127 patients undergo a Roux-en-Y gastric bypass with a minimizer around the extended pouch.
89250059|NCT02968836|Active Comparator|Active group|Blend of amino acids
89250060|NCT02968836|Placebo Comparator|Placebo group|maltodextrin only
89250061|NCT04003181|Active Comparator|Positive breath test|Patients with a positive breath test are treated with antibiotics.
89250062|NCT04003181|Active Comparator|Positive SeHCAT scan|Patients with a positive SeHCAT scan are treated with a bile acid binder.
89250063|NCT04003181|No Intervention|No intervention|Patients with a normal breath test and a normal SeHCAT scan receive no intervention.
89250064|NCT01031316|Experimental|Nondisclosure|
89250065|NCT01031316|Active Comparator|Disclosure|
89250066|NCT00356889|Experimental|Bevacizumab and Erlotinib Hydrochloride|"Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels."
89250067|NCT04741308|Experimental|CBT group|Patients randomly assigned to CBT group will receive 8 times of CBT treatment during chemotherapy.
89250068|NCT04741308|No Intervention|non-CBT group|"Patients randomly assigned to non-CBT group will receive four sessions of health education in a month after surgery.~Each session will last 1 hour, including lectures and Q&A . The content of each session is different, including: diagnosis and treatment of colorectal cancer, adverse reactions and management of chemotherapy, nutritional support during chemotherapy and physical exercise during chemotherapy."
89250069|NCT03742323|Experimental|Idelalisib|
89250070|NCT04715022|Placebo Comparator|Placebo infusion|Saline will be administered over 2 hours
89250071|NCT04715022|Active Comparator|Ascorbic acid infusion|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the University of Kansas (KU) Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
89250072|NCT05137691|Experimental|Experimental|Adapted NHS weight management 1:1 programme. Low carbohydrate dietary focus, enhanced behaviour change via telehealth, daily step target supported by pedometers
89250073|NCT05137691|Active Comparator|Active comparator NHS 1:1 weight management programme|12 week NHS 1:1 weight management programme
89250074|NCT01031394|Active Comparator|Group 1|1 aerobic and 1 resistance training per week
89250075|NCT01031394|Active Comparator|Group 2|2 aerobic and 2 resistance training each per week
89250076|NCT01031394|Active Comparator|Group 3|3 aerobic and 3 resistance training per week
89250077|NCT01031472|Experimental|Part A|Subjects will be randomized in a three way crossover design to either a single dose of GSK2248761 100mg Gelucire capsule administered with food and a single dose of 100mg of formulation 1 or a single dose of 100mg of formulation 3 administered in the fed and fasted state
89250078|NCT01031472|Experimental|Part B|A total of twelve subjects who complete Part A will participate in Part B. Subjects from Part A will be asked to participate on a first come first serve basis until there are 12 subjects, at which time enrolment to Part B will be closed. Part B will be a 2 way cross over study design. Subjects will be randomized to one of a single dose of GSK2248761 100mg Formulation 2 or 4 (based on the evaluation of Part A data) administered with food or in the fasted state. Subjects in Part B will not receive the reference formulation since they previously received this in Part A
89250079|NCT05091671|Active Comparator|Free From Pain Exercise Programme Variation 1|"Participants will have the initial online consultation and will be provided with the exercise booklet and the 12 information/metaphor leaflets. The ongoing 12 Zoom online sessions are not included in this option. Instead, participants will be asked to independently engage in the exercises within the exercise booklet. They will be advised to either do all 3 sets of exercises 3 times a week or to do the neck and low back exercises twice a week and the Otago exercises 3 times a week. The exercises should take around an hour to complete each day. The ideal plan would be as follows:~Monday - Otago exercises. Tuesday - Neck and Back exercises. Wednesday - Otago exercises. Thursday - Rest day. Friday - Neck and Back exercises. Saturday - Otago exercises. Sunday - Rest day."
89250080|NCT05091671|Experimental|Free From Pain Exercise Programme Variation 2|Participants will have the initial online consultation and will be provided with the exercise booklet and12 information/metaphor leaflets. This variation also includes the online zoom sessions. The online zoom session will involve a short presentation and a group discussion for 15 minutes followed by a 45-minute exercise class which will be delivered by a suitably trained individual. The exercise class will include the exercises from the Otago Exercise programme + the Motor Control Exercises for low back pain + Isometric and strengthening exercise for the neck. Participants assigned to this intervention will also be asked to independently engage in the exercises within the exercise booklet. They will be advised to use the same weekly structure described previously.
89250081|NCT00356811|Experimental|Single arm|Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
89250082|NCT05357339|Experimental|Interventional 20% Albumin|Septic patients requiring a fluid bolus randomised to receive 100ml 20% albumin as boluses until they are stable or no longer require fluid resuscitation.
89250083|NCT05357339|Active Comparator|Control Crystalloid|Septic patients requiring a fluid bolus randomised to receive 250ml boluses of crystalloid fluid until they no longer require fluid resuscitation.
89250084|NCT00439218|Experimental|Subject Enrollments|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
89250085|NCT01056003||all patients admitting endoscopy for EGD|
89250086|NCT02533635|Experimental|A-first intervention|Subjects in Arm A receive Ganoderma tea (30g) daily for 8 weeks initially, followed by 8 weeks no intervention.
89250087|NCT02533635|Experimental|B-second intervention|Subjects in Arm B receive no intervention for 8 weeks initially, followed by receiving Ganoderma tea (30g) daily for 8 weeks .
89250088|NCT01030614|Active Comparator|Dexamethasone group|One hundred five patients were randomized to receive intravenous dexamethasone (8 mg) before laparoscopic cholecystectomy
89250089|NCT01030614|Placebo Comparator|Placebo group|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
89250090|NCT03991689|Experimental|the six weeks solution-focused pain management groups|
89250091|NCT01030692|Placebo Comparator|Placebo|Placebo capsules as control
89250092|NCT01030692|Active Comparator|Rivastigmine 3 mg|Rivastigmine 3 mg
89250093|NCT01030692|Active Comparator|Rivastigmine 6 mg|Rivastigmine 6 mg
89250094|NCT01030692|Active Comparator|Huperzine A 0.4 mg|Huperzine A 0.4 mg
89250095|NCT01030692|Active Comparator|Huperzine A 0.8 mg|Huperzine A 0.8 mg
89250096|NCT01056081|Experimental|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
89250097|NCT04950959||All subjects|Subjects undergoing CT-guided, minimally invasive percutaneous procedures in an interventional radiology setting
89250098|NCT01051713|Experimental|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
89250099|NCT01051713|Experimental|Technology Supported condition|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
89250100|NCT01051713|No Intervention|Self-Guided|Participants in the Self-Guided condition will receive DPP DVDs (3 DVDs and 1 CD) at the beginning of the study. This condition will not receive any direct dietary or physical activity interventions outside of the DVDs. Although Self-Guided participants will be receiving the same 7% weight loss goal as the other two groups, they will not be receiving physical activity or diet goals. The DVDs cover the initial 12-weekly sessions of the DPP, with the sessions portrayed by professional actors. They will also be provided with a supplemental DVD which includes a manual for each of the 12 sessions. They will also be giving the Keeping Track booklets and asked to record their diet and activity daily.
89250101|NCT03138252|Active Comparator|Cervical Ripening Balloon Alone|Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
89250102|NCT03138252|Active Comparator|Cervical Ripening Balloon + Oxytocin|Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
89250103|NCT05021549|Active Comparator|nasal prong.|the apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong.
89250104|NCT05021549|No Intervention|conventional|the conventional preoxygenation group (30 patients)
89250105|NCT04994561|Experimental|Subjects receiving study drugs and nutritional supplements|All eligible and consented subjects will receive study drugs and nutritional supplements as described in the intervention.
89250106|NCT03096366|Experimental|Physical therapy (PT) plus blood flow restriction (BFR)|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion. With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
89250107|NCT03096366|Active Comparator|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
89250108|NCT01030770|Experimental|Arm A (treatment)|Arm A: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls) (Lucentis®)
89250109|NCT01030770|Placebo Comparator|Arm B (control):|Arm B: Single subconjunctival injection of 0.05mls of 0.9% sodium chloride (Minims Saline®)
89250110|NCT04941443|Experimental|Oral methadone|Participants will be given a preemptive analgesic in addition to a standard dose of ibuprofen while undergoing early medication abortion with mifepristone and misoprostol (not provided as part of the study). All participants will also be provided with supplementary non- opioid analgesics to be used at their own discretion during the process.
89250111|NCT01030848||Patients with knee osteoarthritis|
89250112|NCT03994692|Experimental|PEEK eminoplasty|"CT scan with bony window for facial bones and DICOM files on CD .then, Using cad cam software (mimics 15) , the virtual design and surgery will be done.~under general anathesia The TMJ will be exposed using the endural incision line and the articular eminence will be identified then blunt dissection so that the front wall of the articular capsule can be exposed completely.~The patient specific PEEK eminence will be inserted and secured with two to three pre-planed screws .~Functional mandibular movements were reproduced to confirm absence of subluxation and then closure"
89250113|NCT03994692|Active Comparator|autogenous onlay grafting eminoplasty|"under general anesthesia , chin graft was taken Layered Endural approach to TMJ making wedge in eminence by mallet & chisel (green stick fracture), then wedging piece of chin graft to increase the height of the eminence creating an obstacle to treat dislocation by manipulation of patient mandible intra operative.~- Functional mandibular movements were reproduced to confirm absence of subluxation then closure"
89250114|NCT04868981|Experimental|GST-HG141|GST-HG141 tablets at varying dosages by mouth for 28 days
89250115|NCT04868981|Placebo Comparator|Matching Placebo for GST-HG141|Placebos for GST-HG141 tablets at varying dosages by mouth for 28 days
89250116|NCT01030926|Experimental|A1, first period|
89250117|NCT01030926|Active Comparator|A2, second period|
89250118|NCT01030926|Active Comparator|B1, first period|
89250119|NCT01030926|Experimental|B2, second period|
89250120|NCT04822259|Experimental|JOURNEY II BCS TKA|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
89250121|NCT04822259|Experimental|JOURNEY II CR TKA|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
89250122|NCT00535223|Experimental|Group Based Exposure Therapy|"Behavioral:~GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking."
89250123|NCT00535223|Experimental|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus. This lasted for 16 weeks."
89250124|NCT00536939|Experimental|Enzastaurin + Bevacizumab + Paclitaxel|"Participants randomized to this arm (Arm A) will receive enzastaurin, paclitaxel and bevacizumab until disease progression.~Prior to randomization, a safety lead-in will be conducted in 6 participants who will be treated according to Arm A for 2 cycles (1 cycle = 28 days). Only after an acceptable safety analysis of the safety lead-in, will other participants be randomized to Phase 2 (either Arm A or Arm B). In Phase 2, participants from the safety lead-in will continue treatment according to Enzastaurin + Bevacizumab + Paclitaxel (Arm A)."
89250125|NCT00536939|Placebo Comparator|Bevacizumab + Paclitaxel + Placebo|Participants randomized to this arm (Arm B) will receive bevacizumab, paclitaxel and placebo until disease progression.
89250126|NCT04669925||Users of Lombardy Emergency System 2018-2020|Adults (affected or not affected by Covid-19) who asked for assistance to the Lombardy region's emergency system during the pandemic period and the previous two years
89250127|NCT03883217|Experimental|Vibration first then no vibration|A session with PDVibe2 vibration turned on first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned off.
89250128|NCT03883217|Experimental|No vibration first then vibration|A session with PDVibe2 vibration turned off first, followed by (after a 2 week washout period) a session with PDVibe2 vibration turned on.
89250129|NCT00347919|Experimental|monotherapy arm|1500 mg (6 x 250 mg tablets) oral lapatinib once daily
89250130|NCT00347919|Experimental|Cohort 1 combination arm|1000 mg (4 x 250 mg tablets) of oral lapatinib and 400 mg (4 x 100 mg tablets) of oral pazopanib taken together once daily
89250131|NCT00347919|Experimental|Cohort 2 combination arm|1500 mg (6 x 250 mg tablets) of oral lapatinib and 800 mg (1 x 500 mg tablets plus 3 x 100 mg tablets) of oral pazopanib taken together once daily
88804823|NCT03009565||study patients|Study participants will be individuals aged 30-80 arriving to Rabin Medical Center with suspected CAD and able to provide informed consent. Participants will provide medical, lifestyle, and nutritional questionnaires. Blood pressure and heart-rate measurements will be taken during hospitalization as well as blood tests and fecal samples and/or rectal swabs. In order to evaluate and/or treat suspected atherosclerotic disease patients will undergo cardiac CT and/or cardiac catheterization in accordance with the standard of care and based upon the decision of the treating cardiologist. Diagnostics and treatment options will be based only on their medical condition and regardless of the aforementioned study protocol.
89250132|NCT03987321|Experimental|Denali Group|Those who received Denali filter placement
89250133|NCT03987321|Experimental|Celect Group|Those who received Celect filter placement
89250134|NCT01051869|Active Comparator|simple decompression|
89250135|NCT01051869|Active Comparator|anterior subcutaneous transposition|
89250136|NCT03987087|Experimental|Radiotherapy group|Thoracic intensity modulated radiation therapy (IMRT) concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.Cisplatin Thoracenteral infusion chemotherapy。 Thoracic intensity modulated radiation therapy (IMRT) concomitant with Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations.
89250137|NCT03987087|Active Comparator|Chemotherapy group|"EGFR-TKI on paticipants with known sensitive EGFR mutations,Cisplatin Thoracenteral infusion chemotherapy.~Cisplatin Thoracenteral infusion chemotherapy and Systemic chemotherapy on paticipants with known NOT sensitive EGFR mutations."
89250138|NCT03987243|Other|Intervention|Two interventions will be provided. The first intervention is a structured education regarding pressure ulcer prevention through weight shifts at start of study. The second intervention is the use of a mobile seat interface pressure map (IPM), which will occur during two intervention phases.
89250139|NCT00439140|Experimental|botulinum toxin Type A 200U|Botulinum toxin Type A 200U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
89250140|NCT00439140|Experimental|botulinum toxin Type A 300U|Botulinum toxin Type A 300U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 300U injection after a minimum of 12 weeks (if applicable).
89250141|NCT00439140|Other|Placebo/botulinum toxin Type A 200U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
89250142|NCT00439140|Other|Placebo/botulinum toxin Type A 300U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 300U injection (200U after discontinuation of 300U) after a minimum of 12 weeks (if applicable).
89250143|NCT00356421|Active Comparator|Control|
89250144|NCT00356421|Experimental|Experimental|
89290301|NCT01376206||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
89290302|NCT03932058||osteosarcoma|
89290303|NCT03932058||chondrosarcoma|
89290304|NCT03932058||enchondroma|
89250145|NCT01324869|Experimental|Group A|Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
89250146|NCT01324869|Experimental|Group B|Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
89250147|NCT03990129|Other|Study population|All participants
89250148|NCT01051947|Experimental|Nebivolol|Nebivolol therapy for 2-6 weeks depending on blood pressure readings
89250149|NCT01051947|Experimental|Metoprolol|Metoprolol therapy for 2-6 weeks depending on blood pressure readings
89250150|NCT01052025|Experimental|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
89250151|NCT01052025|No Intervention|Placebo|
89250152|NCT00443820|Experimental|1|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
89250153|NCT00443820|Placebo Comparator|2|Vehicle (placebo) for 48 weeks
89250154|NCT00443820|Experimental|3|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
89250155|NCT00443820|Placebo Comparator|4|Vehicle (placebo) for 24 weeks
89250156|NCT00438672|Active Comparator|Dequervains|The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis.
89250157|NCT00438672|Active Comparator|Lateral Epicondylitis|
89250158|NCT00438672|Active Comparator|CMC Arthritis|The CMC Arthritis injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and it was decided that the trial wasn't feasible for this diagnosis.
89250159|NCT01027260|Active Comparator|Itopride 50 mg|
89250160|NCT01027260|Active Comparator|Itopride 100 mg|
89250161|NCT01027260|Placebo Comparator|Placebo|
89250162|NCT01034046|Active Comparator|Insulin Sensitive Study Participants|Insulin sensitive subjects stratified using fasting insulin levels.
89250163|NCT01034046|Active Comparator|Insulin Resistant Study Subjects|Insulin resistant subjects stratified using fasting insulin levels.
89250164|NCT00438360|Active Comparator|Cyclosporine A|Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
89250165|NCT00438360|Placebo Comparator|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
89250166|NCT00536471|Experimental|A|duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
89250167|NCT00536471|Placebo Comparator|B|placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months
89250168|NCT00359619|Active Comparator|Cervarix Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89250169|NCT00359619|Experimental|Cervarix 1 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 1 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89250170|NCT00359619|Experimental|Cervarix 2 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 2 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89250171|NCT00359619|Experimental|Cervarix 3 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 3 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89250172|NCT00359619|Experimental|Cervarix 4 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 4 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89250173|NCT00359619|Experimental|Cervarix 5 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 5 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89250174|NCT00359619|Experimental|Cervarix 6 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 6 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
89250175|NCT00437658|Experimental|Elagolix 75 mg BID|Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
89250176|NCT00437658|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
89250177|NCT00437658|Active Comparator|DMPA-SC|Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12.
89250178|NCT04689516|Experimental|Control Group|will receive a hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively and will stop after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
89250179|NCT04689516|Experimental|The TFC Group|will receive hypervolemic hemodilution with an IV infusion load of 6% HES.The infusion will be started preoperatively . The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before start and after the end of the infusion.
89250180|NCT03808415|Experimental|EMG-driven|The hand training system functions as a biofeedback device which surface electromyography (EMG) sensors are used to capture the user's own muscle signals to activate the system for moving his/her paretic hand.
89250181|NCT03757793||Reliability of NIRS in DIEP flap surgery|In patients who underwent DIEP flap surgery, monitoring of postoperative tissue oxygen saturation of the flap by use of the FORE-SIGHT Elite monitor will be compared to standard of care physical examination.
89250182|NCT04002635|Active Comparator|Hormonal Replacement Therapy|Artificial preparation of the endometrium using estradiol valerate 2mg 3x/day, and vaginal micronized progesterone 2x 400mg/day.
89250183|NCT04002635|Experimental|Letrozole|Using letrozole for ovulation induction before planning the frozen embryo transfer
89250184|NCT01052181|Experimental|Vitamin D supplementation|Cholecalciferol sachets 120,000 IU monthly for 12 months
89250185|NCT01052181|Placebo Comparator|placebo|placebo with same taste, color, odor
89250186|NCT01056237|Experimental|Multi-target therapy|(Tarcrolimus+mycophenolate mofetil)
89250187|NCT01056237|Active Comparator|Azathioprine|Aza
89250188|NCT02533557|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
89250189|NCT02533557|Active Comparator|1P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced with a direction of upward at the same puncture site and penetrated the nerve sheath. If hand muscle twitching is observed at 0.3 mA, LA 15 mL is injected.
89250190|NCT03986775|Active Comparator|citrus drink with isomaltulose|
89250191|NCT03986775|Placebo Comparator|citrus drink with sucrose|
89250192|NCT00356265|Experimental|CKD|
89250193|NCT00356265|Active Comparator|Hypertension group|
89250194|NCT00356265|Active Comparator|Normotensive group|
89250195|NCT01056471|Experimental|Low dose autologous mesenchymal cells|The dose of infused cells is 10e6 cells/Kg
89250196|NCT01056471|Experimental|High dose|The dose of infused cells is 4*10e6 cells/Kg
89250197|NCT01056471|No Intervention|Placebo Control|
89250198|NCT01052259|Experimental|Deoxyspergualin, Treatment,|
89250199|NCT01056549|Experimental|exenatide subcutaneous injection|Study A: lipoprotein turnover following subcutaneous exenatide administration, under conditions of pancreatic clamp. Study B: lipoprotein turnover study following subcutaneous placebo administration, under conditions of pancreatic clamp.
89250200|NCT01052337|Active Comparator|propofol|
89250201|NCT01052337|Active Comparator|sevofluorane|
89250202|NCT00535145|Experimental|001|Treatment as usual (TAU), Paliperidone ERTreatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
89250203|NCT01056627|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
89250204|NCT01056627|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
89250205|NCT03990831|Other|burn injury and normal patient|HbO2 PFC perfusion using fNIRS
89250206|NCT03985995|Active Comparator|CBD 800 mg p.o.|The study Investigational Medical Product (IMP) is a cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration.
89250207|NCT03985995|Placebo Comparator|Placebo p.o.|Participants in the control arm will be receiving a single dose of oral placebo solution 8 ml matched to the active comparator.
89250208|NCT01053585|Active Comparator|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
89250209|NCT01053585|Placebo Comparator|Placebo|Placebo suspension (single dose 90 minutes prior to physiologic measurement)
89250210|NCT03986697|Active Comparator|Bictarvy|Intervention group: those randomised to switch antiretroviral therapy to Bictegravir, Emtricitabine and Tenofovir Alafenamide fixed dose combination.
89250211|NCT03986697|No Intervention|Usual therapy|Control group: those randomised to continue their usual antiretroviral regime
89250212|NCT01564355|Experimental|Systemic Steroid Group|Will receive post-operative oral steroids for 10 days as per usual protocol.
89250213|NCT01564355|Placebo Comparator|Placebo|Will receive placebo pills for 10 days post-operatively
89250214|NCT01056705|Experimental|Cohort 1: Experiment Infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
89250215|NCT01056705|Experimental|Cohort 2: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
89250216|NCT01056705|Experimental|Cohort 3: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
89250217|NCT01056705|Experimental|Cohort 4: Experiment infants|Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
89250218|NCT01056705|Experimental|Cohort 5: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;
89250219|NCT00437268|Experimental|enzastaurin + irinotecan + cetuximab|
89250220|NCT00437268|Active Comparator|irinotecan + cetuximab|
89250221|NCT04002089|Experimental|Cohort 1 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL admixed with bupivacaine.
89250222|NCT04002089|Experimental|Cohort 2 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 133mg of EXPAREL admixed with bupivacaine.
89250223|NCT04002089|Experimental|Cohort 3 - EXPAREL|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 266mg of EXPAREL only
89290305|NCT01073501|Placebo Comparator|Placebo|Placebo versus pregabalin
89250224|NCT04002089|Active Comparator|Cohort 4 - bupivacaine|A total of 10 subjects will be enrolled. Subjects in this cohort will receive 100mg Bupivacaine only.
89250225|NCT01056783|Experimental|OC000459|OC000459 100mg twice daily
89250226|NCT01056783|Placebo Comparator|Placebo|
89250227|NCT04002245|Experimental|Go back|Application of a compress impregnated with alcoholic Betadine® by movement of return
89250228|NCT04002245|Experimental|Technique of snail|Application of a compress impregnated with alcoholic Betadine into a single movement from the center towards the periphery and covering the end surface of followed by spontaneous drying time 30 seconds.
89250229|NCT01056861||Cervical dystonia (torticollis)|Subjects meeting the criteria fot torticollis who are receiving botulinum toxin injections.
89250230|NCT01056861||Control|age matched controls with out cervical dystonia (torticollis)
89250231|NCT05355467|Experimental|Ricovir® group|
89250232|NCT05355467|Other|Historical Control Group|
89250233|NCT04139525|Experimental|unfractionated heparin and 8% trisodium citrate|Unfractionated heparin and 8% trisodium citrate.
89250234|NCT01058733|Other|Internet|New clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
89250235|NCT00437034|Experimental|Treatment (antiangiogenesis therapy)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89250236|NCT01027338|Experimental|Tai Chi Exercise|
89250237|NCT01027338|No Intervention|Usual Care|
89250238|NCT00337467|Experimental|A1|
89250239|NCT01056939|Active Comparator|NAVA|Children randomised in this arm will be treated with neurally adjusted ventilatory assist
89250240|NCT01056939|Active Comparator|Control|Patients randomized to control group will be treated with pressure controlled ventilation (PC) when they are newborns and older children in this group will be treated with pressure regulated volume controlled (PRVC) ventilation.
89250241|NCT03989739||robotic distal pancreatectomy|
89250242|NCT03989739||laparoscopic distal pancreatectomy|
89250243|NCT03985085|Experimental|Intervention arm|
89250244|NCT03778385|Experimental|Isometric Exercise|Submaximal isometric resistance exercise of the arm.
89250245|NCT03778385|Experimental|Dynamic Exercise|Submaximal dynamic resistance exercise of the arm.
89250246|NCT01058889|Experimental|Telemedical device|Patient will receive a blood glucose measurement device and a telemedical device to monitor blood glucose measurements.
89250247|NCT01058889|No Intervention|Treatment as usual|
89250248|NCT00337077|Experimental|Eribulin mesylate|Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89250249|NCT00428220|Experimental|A|"Sunitinib will be administered in a continuous daily dose (oral, once per day). Starting dose will be 37.5 mg daily unless the patient was on a different dose (25 mg or 50 mg daily) on the previous trial. In that case, they will begin treatment on this study at the same dose used at the end of the previous study.~The protocol now allows for patients on dosing regimens other than only continuous dosing (e.g. 4/2, etc.) to be enrolled if eligible."
89250250|NCT01057329||Anorexia nervosa|36 severe AN patients treated with aripiprazole
89250251|NCT01057329||Anorexia|36 severe anorexia nervosa patients treated with olanzapine
89250252|NCT01057329||Attention Deficit Hyperactivity Disorder|30 ADHD patients treated with atomoxetine
88806092|NCT05435820|Experimental|BCW group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: continuous wave iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
89250253|NCT01057329||Depressive disorder|30 depressed patients treated with duloxetine
89250254|NCT01057407|Experimental|ASP group|
89250255|NCT01057407|Active Comparator|Sevelamer group|
89250256|NCT01037478|Experimental|Resminostat (4SC-201)|oral administration
89250257|NCT01057485|Experimental|AF ablation and AV node ablation|Patients will receive the combined procedure of AF ablation as well as AV node ablation
89250258|NCT01057485|Active Comparator|AV node ablation|Patient will receive AV node ablation alone
89250259|NCT03986463||Cohort 1|"Stage III NSCLC as per the American Joint Committee on Cancer 8th edition (AJCC 8th ed.)~Appropriate to undergo concurrent chemotherapy and radiation~Planned radiation dose must be between 54 and 66 Gy~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2~No prior system chemotherapy (induction) for their stage III NSCLC, any adjuvant chemotherapy given for resected disease must have been at least 100 days prior to enrollment"
89250260|NCT03986463||Cohort 2|"Stage IV NSCLC or stage III NSCLC, as per the AJCC 8th ed.~Planning to start systemic cytotoxic chemotherapy, without concurrent radiation~Previous treatment with tyrosine kinase inhibitors or immunotherapy (PD-1, PD-L1, CTLA4 directed antibodies) is allowed as long as no cytotoxic chemotherapy was given concurrently~Previous palliative radiation is permitted, but must have been completed at least at least 21 days prior to the initiation of treatment~Chemotherapy regimen must include a platinum agent plus one of the following doublet agents: etoposide, pemetrexed, paclitaxel, vinorelbine, docetaxel, gemcitabine or vincristine~Day 1 platinum dose must be ≥ carboplatin 1.6 AUC or cisplatin 30 mg/m2~If cytotoxic chemotherapy was previously given for adjuvant or stage III NSCLC it must have been at least 100 days prior to enrollment"
89250261|NCT03986463||Cohort 3|"Patients with advanced NSCLC set to undergo palliative radiation to the primary or regional or distant metastatic lesion(s), including intracranial lesions~Radiation dose scheduling must be 2.5 to 4.0 Gy on days 1 through 3 for extracranial treatment, ideally 40 Gy in 15 fractions, 20 Gy in 5 fractions, or 30 Gy in 10 fractions.~Radiation dose for brain lesions must be 6 to 9 Gy per dose, ideally 30 to 35 Gy in 5 daily fractions or 27 Gy in 3 fractions on alternating days~No plans for concurrent chemotherapy to be given~Five patients in cohort 3 will receive radiation to the primary tumor and five patients will receive radiation to brain lesions"
89250262|NCT03986307|Experimental|Omega-3|Elderly supplemented with omega-3.
89250263|NCT03986307|Placebo Comparator|Placebo|Elderly supplemented with corn oil.
89250264|NCT01058967||major trauma victims|Code 3 patients (highest acuity) admitted to hospital via air ambulance service
89250265|NCT01059045|Experimental|Cryocontact therapy|
89250266|NCT01059045|No Intervention|Control|
89250267|NCT02873975|Experimental|Homologous Repair (HR) Deficiency Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with homologous repair (HR) deficiency on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
89250268|NCT02873975|Experimental|Replicative Stress Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with advanced solid tumors exhibiting replicative stress on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
89250269|NCT02873975|Experimental|CCNE1 Amplification Cohort|Prexasertib (LY2606368) will be administered as an IV infusion in patients with CCNE1 amplification on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
89250270|NCT01054053||1|children born between 06/04/2004 and 17/04/2008 and called to menBvac vaccination and living around Neufchatel en Bray.
89250271|NCT01057563|Active Comparator|BMS group|Patients undergoing PCI with BMS implantation
89250272|NCT01057563|Active Comparator|PRE-DEB group|Patients undergoing PCI with BMS implantation after lesion predilation with DEB
89250273|NCT01057563|Active Comparator|POST-DEB group|Patients undergoing PCI with BMS implantation followed by postdilation with DEB
89250274|NCT00345579|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of Menhibrix vaccine at 12-15 months of age in the study NCT00345683. Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
89250275|NCT00345579|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
89250276|NCT05356559|Active Comparator|Fish protein|
89250277|NCT05356559|Placebo Comparator|Control|
89250278|NCT04002323||HIV-1 ART-Naive|Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)
89250279|NCT04002713||ALT&AMT free flap reconstruction|Patients who underwent ALT or AMT free flap reconstruction after head and neck cancer surgery between March 1, 2008 and February 28, 2017
89250280|NCT05354921|Experimental|Indwelling|Foley catheterization upon admission and removed the morning following surgery.
89250281|NCT05354921|Experimental|Intermittent|Intermittent catheterization when post-void residual volume is greater than 400 mL.
89250282|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach bath|Subjects will complete a total of 5 study visits over 11 days. At visits 1-4, subjects will soak their forearms in either dilute bleach or dilute vinegar for 10 minutes. At all visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected.
89250283|NCT04001855|Experimental|Dilute vinegar vs. dilute bleach gauze soaks|Subjects will complete a total of two study visits over 21 days, and will be instructed to apply gauze soaks daily at home over the 21-day study period. At baseline and 21-day follow-up visits, measurements of skin barrier function will be obtained using non-invasive, commercially-available devices. Non-invasive, non-painful tape stripping samples and skin culture swabs will also be collected. Subjects will also be provided with a non-invasive skin barrier measurement device to take daily recordings at home.
89250284|NCT00335829|Experimental|single arm, received bevacizumab and TACE|
89250285|NCT02533011||24 Hours|HBP lab test performed 24 hours after meeting sepsis inclusion criteria.
89250286|NCT02533011||48 Hours|HBP lab test performed 48 hours after meeting sepsis inclusion criteria.
89250287|NCT02533011||72 Hours|HBP lab test performed 72 hours after meeting sepsis inclusion criteria.
89250288|NCT01057641|Experimental|Spacer|"Implantation of a percutaneously implanted interspinous device (spacer)"
89250289|NCT01057641|Other|physiotherapy|The control group will receive at least physiotherapy and physical therapy (e.g. massage and fango). Under inpatient conditions therapy will last for seven days. After discharge physical therapy has to be continued for 5 weeks. A schedule will ensure the consistency of the physical therapy. The inpatient-treatment can be repeated every 6 months if necessary.
89250290|NCT05262257|Experimental|Lifestyle intervention group|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
89250291|NCT05262257|Experimental|Metformin treatment group|on the basis of lifestyle intervention, patients were given metformin 2-3 times a day (starting with 2times), 0.5g each time.
89250292|NCT05262257|Experimental|Dapagliflozin treatment group|on the basis of lifestyle intervention, patients took Dapagliflozin orally, once a day, 10mg at a time.
89250293|NCT05262257|No Intervention|Healthy control group|no intervention.
89250294|NCT03989817|Active Comparator|VIP|To investigate the role of VIP on cranial hemodynamic and headache in healthy volunteers.
89250295|NCT03989817|Placebo Comparator|Saline|To investigate the role of saline on cranial hemodynamic and headache in healthy volunteers.
89250296|NCT01059123|Experimental|1:Short treatment|amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
89250297|NCT01059123|Active Comparator|2:Usual treatment|amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.
89250298|NCT03986385|Experimental|A(apatinib Xelox)|Preoperative: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 2 cycles
89250299|NCT03986385|Active Comparator|B(Xelox)|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w） Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 6 cycles
89250300|NCT01054287|Experimental|Falls prevention|
88804824|NCT03009565||control|The control group will be selected to represent an age, sex and cardiovascular risk factors -matched group without current CAD. Further exclusion criteria in the control group will be antibiotic consumption in the following 3 months, inflammatory bowel disease, or other significant chronic disease that may influence the microbiota (such as cancer, autoimmune disease, and chronic immunosuppressive treatment). The control group will undergo cardiac CT or coronary angiography according to clinical suspicion in order to rule-out CAD and irrespective of the study protocol.
88804825|NCT01292005|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
88804826|NCT01292005|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
89250301|NCT01054287|Placebo Comparator|Usual care|
89250302|NCT01059279||FMF patients|15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
89250303|NCT01059279||healthy people|Healthy individuals, that participated in the study of Heller Institute of Medical Research.
89250304|NCT03985137||HIV-infected patients|Male patient presenting at a follow-up consultation for HIV infection or following a Sexual Viral Exposure (EVA) accident, pre-exposure prophylaxis (PrEP) or screening for a Sexually Transmitted Infection (IST).
89250305|NCT01057719|Experimental|Physiotherapy in Spain|Daily inpatient physiotherapy for four weeks in a warm climate
89250306|NCT01057719|Experimental|Physiotherapy in Norway|Daily inpatient physiotherapy for four weeks in a cold climate
89250307|NCT00344019|Active Comparator|atorvastatin 80 mg|80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
89250308|NCT00344019|Placebo Comparator|placebo oral tablet|placebo on average of 2-4 hours pre angio/PCI for ACS
89250309|NCT00344019|No Intervention|Screening|Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail
89250310|NCT01054365||Delayed Discharge Group (DDG)|D/C at least 24 hours after procedure or at usual discharge time (n =200)
89250311|NCT01054365||Early Discharge Group (EDG)|D/C 6 hours after procedure if no indication for extended stay after randomization (n=200)
89250312|NCT03985059||Cases|Patients with ischemic stroke or transient ischemic attack who have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
89250313|NCT03985059||Controls|Patients with ischemic stroke or transient ischemic attack who do not have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
89250314|NCT01059591|Experimental|Active|GSK424887 once daily
89250315|NCT01059591|Placebo Comparator|Placebo|Placebo once daily
89250316|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
89250317|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
89250318|NCT00535847|Experimental|Other|"Subjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects <75 kg and 1200 mg/day for subjects weighing >=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 [NCT00535847]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 [NCT00336479], VX05-950-104EU [NCT00372385] or VX06-950-106 [NCT00420784]) were included in Other reporting group."
89250319|NCT03986151|Active Comparator|Conventional radial access|
89250320|NCT03986151|Experimental|Distal radial access|
89250321|NCT01059669||Patients|Patients with suspected Chronic Pancreatitis
89250322|NCT01059669||Control group|Healthy controls
89250323|NCT03606785|Active Comparator|tranexamic acid group|
89250324|NCT03606785|Placebo Comparator|placebo group|
89250325|NCT03587753|Active Comparator|Unsaturated|A test meal containing a unsaturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning.
89250326|NCT03587753|Active Comparator|Saturated|A test meal containing a saturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning
89250327|NCT03441971|Experimental|Single Arm|Participants will receive the device on Day 1.
89250328|NCT00334893|Experimental|Treatment (chemotherapy)|Patients receive eribulin mesylate IV over 15 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89250329|NCT05356169|Experimental|Venetoclax combined with intensive chemotherapy|The experimental group receives two cycles of inducation chemotherapy consisting of venetoclax combined with standard DA 3+7 regimen. After CR/CRi achieved, subjects proceed allo-transplantation or consolidation therapy according to their ELN risks. The consolidation chemotherapy regimen consists of three cycles of intermediate （for age>55 years）or high（for age≤ 55 years） dose cytarabine combined with venetoclax.
89250330|NCT05356169|Active Comparator|Intensive chemotherapy only|The control group receives two cycles of inducation chemotherapy consisting of standard DA 3+7 regimen without venetoclax. After CR/CRi achieved, subjects proceed allo-transplantation or consolidation therapy according to their ELN risks. The consolidation chemotherapy regimen consists of three cycles of intermediate （for age>55 years）or high（for age≤ 55 years） dose cytarabine without venetoclax.
89250331|NCT01057797|Experimental|Upper Body Strength Training with Self-Efficacy|16 weeks of upper body strength training combined with an exercise-specific self-efficacy enhancing intervention
89250332|NCT01057797|Active Comparator|Upper body strength training|16 weeks of upper body strength training with weekly health education sessions
89250333|NCT01057797|Sham Comparator|Chair exercise|16 wks of gentle chair exercise with weekly health education
89250334|NCT01059747||treatment group|
89250335|NCT01057875|Experimental|coffee with caffeine|
89250336|NCT01057875|Placebo Comparator|decaffeinated coffee|Starbuck's Grande Pike Roast Decaf
89250337|NCT05293691|Experimental|Body, Breath & Mind|"The program Body, Breath & Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich & Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
89250338|NCT05293691|Active Comparator|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored.The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
89250339|NCT05293691|Other|Waitlist control group|Participants in the waitlist control group are given access to the Body, Breath & Mind program after eight weeks, provided they have participated in the previous surveys in the form of a diagnostic pre-, peri-, and post-module.
89250340|NCT04001387||Spinal anesthesia|
89250341|NCT00334737|Experimental|Darbepoetin alfa injection|Darbepoetin alfa 10 mics/kg/week subcutaneous injection x 10 weeks or until 35 completed weeks Drug: Darbepoetin alfa Other names: Aranesp Darbe SC injection
89250342|NCT00334737|Active Comparator|erythropoietin alfa injection|Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks Drug: erythropoietin other names: epogen Epo SC injection
88804827|NCT01341067||Basal insulin, approved oral medications|
88804828|NCT01292629|Experimental|Investigational intraocular lens|iSert 251 intraocular lens
89250343|NCT00334737|Placebo Comparator|placebo/control|Sham injection
89250344|NCT01059981||1|Dialysis patients
89250345|NCT01059981||2|Trauma patients
89250346|NCT01059981||3|Patients with carbon monoxide poisoning
89250347|NCT01564433|Experimental|Gait trainer treatment|
89250348|NCT01564433|Active Comparator|Conventional group|
89250349|NCT03986073|Experimental|Low dose group|Subjects in the low dose group administrated one TQ-F3083 capsule 10mg, one TQ-F3083 blank analog capsule and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
89250350|NCT03986073|Experimental|High dose group|Subjects in the high dose group administrated twoTQ-F3083 capsules 20mg and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
89250351|NCT03986073|Active Comparator|Positive drug control group|Subjects in the positive drug control group administrated two TQ-F3083 blank analog capsules and one Linagliptin tablet orally, once daily for 12 weeks.
89250352|NCT03986073|Placebo Comparator|Placebo group|Subjects in the placebo group administrated two TQ-F3083 blank analog capsules and one Linagliptin blank analog tablet orally, once daily for 12 weeks.
88804829|NCT01272583|Other|Sequence A (sitagliptin→placebo)|Cross-over, both arms reveived the same intervention in different order.
88804830|NCT01272583|Other|Sequence B (placebo→sitagliptin)|Cross-over, both arms reveived the same intervention in different order.
88804831|NCT00005446||Postmenopausal women with coronary heart disease|
88804832|NCT00005446||Postmenopausal women without coronary heart disease|Matched in age to the women with heart disease
88804833|NCT01341301|Experimental|Allogeneic HSCT|"CONDITIONING: Patients undergo Total Body Irradiation (TBI) twice daily (BID) on days -10 to -7. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients receive DLI on day -6 and undergo cluster of differentiation 34 (CD34+) selected allogeneic HSCT on day 0~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO on days -1 with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID or PO on days -1 to 28."
89250353|NCT05279729|No Intervention|Control|
89250354|NCT05279729|Experimental|Weight Watchers (WW)|
89250355|NCT05279729|Experimental|Healthi app|
89250356|NCT03989193|Experimental|Computer guided alveolar ridge splitting technique|Computer guided alveolar ridge splitting using piezo electric device and a 3D printed surgical guide. An L shaped splitting pattern with one crestal and one distal cut will be performed.
89250357|NCT01060137|Experimental|001|fentanyl matrix Fentanyl transdermal patch 12 - 25mcg/hr can increase with 12 - 25mcg/h based on pain assessment
89250358|NCT00991913||Delirium|Delirium was determined by CAM-ICU
89250359|NCT00991913||no Delirium|no Delirium was determined by CAM-ICU
89250360|NCT04001153||Upper primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
89250361|NCT04001153||Lower primary first molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
89250362|NCT04001153||Upper primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
89250363|NCT04001153||Lower primary second molar|Children already treatment planned to have a Hall Technique crown placed to manage primary molars carious lesions will have dental impressions taken before the crown placement, immediately after and at 2, 4, 6 and 8 weeks follow-up.
89250364|NCT01057953|No Intervention|Patient|Blood sample for patient included
89250365|NCT01058031|Experimental|Arm 1|MBSR
89250366|NCT03090347|Experimental|High-sugar diet|Participants will be asked to consume a relatively low-fat, high-carbohydrate eucaloric diet enriched in free-sugars (20% total energy).
89250367|NCT03984747||Adult Transplant Patients|Adult subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
89250368|NCT03984747||Pediatric Transplant Patients|Pediatric subjects between ages 2-17 who have undergone at least one organ transplant prior to enrollment and are willing to provide assent/LAR is willing to provide consent.
89250369|NCT03984747||Pregnant Transplant Patients|Pregnant subjects who have undergone at least one organ transplant prior to enrollment and are willing to provide consent.
89250370|NCT01058109|Experimental|calcium group|dietary calcium intake of 1500 mg/d
89250371|NCT01058109|Experimental|calcium-rich diet (1500 mg/d)|calcium intake from food
89250372|NCT03989583||Children's feet temperature|The thermal images were taken from 162 children who were 9- 10 years old in two schools in Mérida (Badajoz), Spain. Their parents or legal guardians were informed and signed an informed consent. All children were taken infrared images, so that skin temperature was evaluated, by dividing the thermograms in regions of interest in dorsal and plantar images of each foot. Shoes were divided into two regions of interest. The measures were taken in two different days: the first day, children wore school footwear and the second sports shoes.
89250373|NCT00427908|Experimental|Group A|All subjects received GSK Biolgicals' meningococcal vaccine 134612.
89250374|NCT00427908|Active Comparator|Group B|Subjects including and above two years of age received Mencevax™ ACWY, subjects below two years of age received Meningitec™.
89250375|NCT00992069|Experimental|TMC207 alone and with EFV|Participants will receive single-dose TMC207 alone and then single-dose TMC207 with EFV.
89250376|NCT01060215|Active Comparator|Infusion|20cc saline infusion into the knee joint
89250377|NCT01060215|No Intervention|No infusion|
89250378|NCT01060293|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
89250379|NCT01060293|Active Comparator|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
89250380|NCT01060293|Active Comparator|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
89250381|NCT03988959|Other|Control|Standard resection
89250382|NCT05343767|Active Comparator|Control Arm 1 Metformin ( 64 patients)|"Metformin 1000 mg tablets were used.~First Dose: One Metformin 1000 mg tablet + Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Second Dose: Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Third Dose: One Metformin 1000 mg tablet + Two Placebo Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~A total dose of 2000 mg was administered per day."
89250383|NCT05343767|Experimental|Experimental Arm 2: Low Dose NW Low-Glu ( 65 patients)|"The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses as follows:~First Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Second Dose: Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Third Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals."
89250384|NCT05343767|Experimental|Experimental Arm 3: High Dose NW Low-Glu ( 69 patients)|"The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses as follows:~First Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Second Dose: Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals.~Third Dose: One Placebo tablet + Two size 0 NW Low-Glu Capsules administered PO on empty stomach with plenty of water 2 hours after meals."
89250385|NCT01054521|Experimental|Temperature-controlled RF (TCRF)|The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
89250386|NCT01054521|Active Comparator|Bipolar RF (BRF)|The bipolar RF (BRF) probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
89250387|NCT00334113|Experimental|Arm 1|Participants in this arm will meet with an exercise physiologist and obtain an exercise prescription for a walking program. In addition, they will recieve an intervention that will be delivered over an automated telephone system (TLC-PED). These automated phone calls with voice response and voice recognition capabilities will occur weekly over a 6 month period. During these calls, participants' physical activity will be monitored, new physical activities goals will be set, information about physical activity and the associated health benefits will be provided, and barriers to physical activity will be explored.
89250388|NCT00334113|No Intervention|Arm 2|"This is the treatment as usual condition. Participants in this condition will also have 2 sessions with an exercise physiologist and will receive an exercise prescription for a home based walking program. The will not receive the automated phone calls each week that are designed to motivate physical activity."
89250389|NCT00992147|Experimental|autologous cultured adipocytes|
89250390|NCT01060449|Other|LV lead low output|"Low output on left ventricular pacing lead.~Intervention: LV stimulus intensity"
89250391|NCT01060449|Other|LV lead high output|"High output on left ventricular lead~Intervention: LV stimulus intensity"
89250392|NCT04001699|Experimental|Intervention|Preoperative assessment conducted by an interprofessional team
89250393|NCT04001699|Active Comparator|Usual care|Usual care
89250394|NCT01054677|Experimental|Educational intervention on antibiotic prescribing|The participants in this group received an educational intervention.
89250395|NCT01054677|No Intervention|No educational intervention|The participants in this group did not receive the educational intervention
89250396|NCT01058187||Control|Marketed cow milk-based infant formula containing DHA and ARA
89250397|NCT01058187||Investigational 1|Cow milk-based infant formula with differing level of ARA from Control formula
89250398|NCT01058187||Investigational 2|Cow milk-based infant formula with a differing level of ARA from Control
89250399|NCT00416598|Experimental|Treatment (chemotherapy, PBSC or bone marrow transplantation)|See Detailed Description.
89250400|NCT00534599|Other|1|Adjunctive Placebo Seroquel XR to anxiety treatment
89250401|NCT00534599|Experimental|2|Adjunctive Seroquel XR to anxiety treatment
89250402|NCT04001465|Active Comparator|Volumetric methacholine challenge|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer
89290306|NCT01073501|Experimental|Pregabalin|Placebo versus pregabalin
89250403|NCT04001465|Active Comparator|Methacholine challenge with spirometer|Methacholine challenge performed per the volumetric method using an Aerogen Solo vibrating mesh nebulizer fitted with an ultrasonic spirometer
89250404|NCT00992381|Experimental|1|PN400
89250405|NCT00992381|Active Comparator|2|Naproxen
89250406|NCT05320913|Experimental|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|Participants receiving pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)
89250407|NCT05320913|Active Comparator|isolated periarticular multimodal drug injection (PMDI)|Arm Description: Participants receiving isolated periarticular multimodal drug injection (PMDI)
89250408|NCT00992537|Experimental|IDeg|
89250409|NCT00992537|Experimental|IDegAsp|
89250410|NCT00992537|Active Comparator|IAsp|
89250411|NCT00992615|Experimental|Arm 20 cores|
89250412|NCT00992615|Active Comparator|arm 12 cores|
89250413|NCT05317715|Other|without device information|this group of patients will complete a questionnaire before receiving information on contraceptive intrauterine devices (copper or hormonal)
89250414|NCT05317715|Other|with device information|This group of patients will receive information about contraceptive intrauterine devices (copper or hormonal) before completing a questionnaire
89250415|NCT00992693|Experimental|Treatment with IV Ribavirin|In this open label treatment study, the investigators intend to treat all subjects who present with a tentative diagnosis of VHF and meet entry criteria with a 10 day course of IV Ribavirin.
89250416|NCT00992771|Experimental|Varneicline|
89250417|NCT00992771|Placebo Comparator|Placebo|
89250418|NCT00992849|Experimental|Bevacizumab|Arm type to experimental based on single group assignment. Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).VEGF is a chemical signal that stimulates the growth of new blood vessels.
89250419|NCT00993005|Experimental|A|Cicatrix
89250420|NCT00993005|Placebo Comparator|B|Placebo
89250421|NCT00993083|Experimental|Vaccinated|14 volunteers (2 in lead safety group and 12 in main study group) to receive MVA-NP+M1 via the IM route. Volunteers will then be challenged with Influenza 30 days post vaccination.
89250422|NCT00993083|No Intervention|Control|12 volunteers who will not receive vaccine but will also be challenged with Influenza on day 30
89250423|NCT04001231|Experimental|Single arm of exenatide once-weekly suspension|Exenatide once-weekly suspension via subcutaneous (SC) injection
89250424|NCT00993161|Experimental|patients|Patients with neuromuscular disorder and controls
89250425|NCT00993161|Experimental|Controls|healthy controls
89250426|NCT01913795|Active Comparator|Environmental Intervention|4 classroom air purifiers and school integrated pest management environmental intervention
89250427|NCT01913795|Placebo Comparator|Sham and Control|4 sham air purifiers and no school integrated pest management environmental intervention
89250428|NCT01913795|Placebo Comparator|Active Air Purifier and Control|4 air purifiers and no school integrated pest management environmental intervention
89250429|NCT01913795|Sham Comparator|Sham and Integrated Pest Management|4 classroom sham air purifiers and school integrated pest management
89250430|NCT00993239|Experimental|Birinapant (TL32711)|
89250431|NCT00993395|Experimental|Peer Mentor Intervention|peer mentor-based disease management focusing on three domains: medical care, recovery, and social stabilization
89250432|NCT04001543|Experimental|Immunomodulating oral supplementation|"The immunomodulating oral supplementation compound (Oral Impact®) contains 334kcal/bag and 18.1g of proteins, as well as immunomodulatory nutrients such as L-Arginine, RNA and omega-3.~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
89250433|NCT04001543|Active Comparator|Sip feed control|"The control has the same formula to that of the Oral Impact®, but not enriched with specific nutrients: it is an isocaloric isonitrogenous control.~Each bag of product containing powder (74g/bag) will be diluted in 250 millilitres of water by the patients and drunk at home. Three doses will be drunk at home by the patients daily, during the 5 days before each chemotherapy cycle."
89250434|NCT03892889|Experimental|Abilify MyCite®|Participants received Abilify MyCite® a combination product of aripiprazole tablet embedded with sensor and wearable patch for 3 months (Months 1 to 3) and continued for an additional 3 months (Months 4 to 6) as per investigators assessment or switch to a standard-of-care treatment of oral atypical antipsychotics or a long acting injectable.
89250435|NCT00995189|Experimental|OFR|Opti-Free RepleniSH contact lens care solution used for 30 days
89250436|NCT00995189|Active Comparator|RNM|ReNu MultiPlus contact lens care solution used for 30 days
89250437|NCT00993551|Experimental|12 month surgery|Infants will receive primary surgery at age 12 months using Sommerlad technique
89250438|NCT00993551|Experimental|6 month surgery|Infants will receive primary surgery at age 6 months using Sommerlad technique.
89250439|NCT00993629|Active Comparator|Arm 1|adjunctive pregnenolone
89250440|NCT00993629|Placebo Comparator|Arm 2|adjunctive placebo
89250441|NCT00993707|Active Comparator|0.01% CTX-100 (formerly ETX-100)|
89250442|NCT00993707|Active Comparator|0.03% CTX-100 (formerly ETX-100)|
89250443|NCT00993707|Placebo Comparator|Placebo|
89250444|NCT01564511|Experimental|Gait trainer treatment|Roboti gait training by mean of Gangtrainer I
89250445|NCT01564511|Sham Comparator|Conventional group|Convetional physical gait training
89250446|NCT00473330|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
89290307|NCT03972059|Experimental|Experimental group|A 12-week high intensity interval circuit training program for weight management in overweight adults.
89250447|NCT00473330|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
89250448|NCT00473330|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
89250449|NCT00416520|Experimental|1|
89250450|NCT00416520|Placebo Comparator|2|
89250451|NCT00416520|Active Comparator|3|
89250452|NCT00533429|Experimental|A|Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin
89250453|NCT00533429|Placebo Comparator|B|Pemetrexed + Carboplatin + Bevacizumab + Placebo
89250454|NCT01034124|Placebo Comparator|Water|
89250455|NCT01034124|Active Comparator|Cranberry juice|
89250456|NCT01034202|Experimental|Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083|
89250457|NCT01034202|Experimental|Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083|
89250458|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.02 mg/kg + placebo|
89250459|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.04 mg/kg + placebo|
89250460|NCT01034202|Experimental|NNC126-0083|
89250461|NCT01034202|Placebo Comparator|Placebo|
89250462|NCT00533273|Experimental|AA4500 0.58 mg|
89250463|NCT00533273|Placebo Comparator|Placebo|
89250464|NCT03891641|Experimental|Treadling Group|Treadling subjects will do so 3x per week (15 min sessions) for 6 weeks.
88804834|NCT01342471|Active Comparator|30-min walk|"Instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Participants were permitted to exercise in one long bout (30 min) or divide the exercise into multiple bouts as long as the bout length was 10 min or greater."
88804835|NCT01342471|Experimental|TV commercial stepping|"Instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Rather than exercising continuously for at least 10-minute bouts, participants performed multiple (~9 or 10), short (~3-5 min) bouts, conveniently incorporated into their daily TV viewing time."
88804836|NCT01273207|Experimental|Inhaled Cyclosporine in HSCT Participants|Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week
88804837|NCT02195713||Test- Accuryn Urine Output Monitor|Accuryn Anti-airlock Drainage System was attached to the Foley catheter and urine output / drainage line pressure was monitored.
88804838|NCT02195713||Control- Critcore Urine Output Monitor|A commercially available urine output monitor (Criticore, Bard Medical) was attached to the Foley catheter and urine output / drainage line pressure was monitored.
88804839|NCT01342549|Active Comparator|Arm 1|sodium valproate
88804840|NCT01342549|Active Comparator|Arm 2|naltrexone
88804841|NCT01343095|No Intervention|Usual Care|Usual Care between 10pm-6am
88804842|NCT01343095|Active Comparator|Earplugs|Application of foam earplugs from 10pm-6am nightly for seven nights or until ICU discharge.
88804843|NCT01343095|Active Comparator|Earplugs and Headphones|Foam Earplugs and Noise canceling headphones applied from 10pm-6am nightly for 7 nights or until ICU discharge.
88804844|NCT01343251||HeRO Graft|patients who are evaluated and receive a HeRO Graft implant for hemodialysis
88804845|NCT01343251||Control|control group of non-HeRO patients who are evaluated but do not receive a HeRO Graft for any reason
88804846|NCT01343485|No Intervention|Control, standard care for HPV vaccine|Study participants in control sites will receive standard care for HPV vaccine administration and follow-up per PPFA protocol
88804847|NCT01343485|Experimental|Intervention, computer reminder system|Study participants in the intervention sites will receive standard care for HPV vaccine administration per PPFA protocol, reminder messages for subsequent vaccination appointments, and real-time determination of financial assistance for HPV vaccine.
89250465|NCT03891641|No Intervention|Control Group|Control Subjects continue their normal daily activities.
89250466|NCT00995267|Experimental|behavioral intervention|Behavioral intervention arm comprises 5 joint parent-child school-based nutritional activities in which nutritional information was combined with Adler's behavioral concepts. and a 5-session parental workshop.
88804848|NCT01345513||Solid Tumor Cancer|
88804849|NCT01294267|Other|Circulatory Support System|Percutaneous use of left ventricular assist device, Impella 2.5 Circulatory Support System to facilitate mapping and ablation of ongoing VT by maintaining near-normal hemodynamics, reducing myocardial workload and preservice organ perfusion.
88804850|NCT01276171|Active Comparator|Ultrasound|Participants will place arterial line using ultrasound technique
88804851|NCT01276171|Active Comparator|Doppler|Participants will place arterial line using doppler technique
88804852|NCT01276171|Active Comparator|Palpation|Participants will place arterial line using palpation technique
89250467|NCT00995267|No Intervention|control arm|
89250468|NCT00339183|Experimental|Panitumumab Plus FOLFIRI|Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
89250469|NCT00339183|Active Comparator|FOLFIRI Alone|Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
89250470|NCT02533245|Experimental|Tx exercise group|"Convenience sample of solid organ transplant recipients (heart, kidney, lung, liver, pancreas, small bowel) participating in the Transplantoux exercise training intervention.~Intervention:~Home-based individualized exercise training program~Supervised group training sessions~Climb of the Mont Ventoux"
89250471|NCT02533245|No Intervention|Tx matched control group|Controls are retrieved from the Leuven University Hospital heart, kidney, lung, liver, pancreas, small bowel transplant database and matched (1:4 matching) based on type of transplant, gender, age and time since transplant.
89250472|NCT02533245|Experimental|Healthy exercise group|"Convenience sample of health care providers (e.g. doctor, paramedic or medical companion involved in care programs for organ Tx) and patient's family members and friends participating in the Transplantoux exercise training intervention.~Intervention:~Supervised group training sessions~Climb of the mont ventoux"
89250473|NCT01060527||IBS-D|
89250474|NCT01060527||IBS-C|
89250475|NCT01060527||Controll|
89250476|NCT01058343|Experimental|IFN-K 1|IFN kinoid dose 1
89250477|NCT01058343|Experimental|IFN-K-2|IFN kinoid dose 2
89250478|NCT01058343|Experimental|IFN-K 3|IFN kinoid dose 3
89250479|NCT01058343|Experimental|IFN-K 4|IFN kinoid dose 4
89250480|NCT01058343|Placebo Comparator|Saline|saline at same dose as IFN K
89250481|NCT01054833|Experimental|Needleless sling|Needleless® sling
89250482|NCT01325025|Other|Patients|Patients with a metachromatic leukodystrophy
89250483|NCT01325025|Other|Control|Epileptic population
89250484|NCT01060605|Experimental|Rapamycin pre transplant|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
89250485|NCT00532883|Placebo Comparator|Placebo Pills and Placebo Liquid|
89250486|NCT00532883|Active Comparator|Hydroxyurea Pills and Placebo Liquid|
89250487|NCT00532883|Active Comparator|Placebo Pills and Magnesium Pidolate Liquid|
89250488|NCT00532883|Active Comparator|Hydroxyurea Pills and Magnesium Pidolate Liquid|
89250489|NCT00993785|Experimental|OTW Catheter System|
89250490|NCT00993863|Placebo Comparator|Placebo|
89250491|NCT00993863|Experimental|ADL5859 30 mg|
89250492|NCT00993863|Experimental|ADL5859 100 mg|
89250493|NCT00993863|Experimental|ADL5859 200 mg|
89250494|NCT00993863|Active Comparator|ibuprofen 400 mg|
89250495|NCT00995423|Active Comparator|CoroflexTM|highly flexible CoroflexTM Please-Stent features
89250496|NCT00995423|Active Comparator|TAXUS|Paclitaxel-eluting stent
89250497|NCT00993941|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
89250498|NCT00993941|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein.
89250499|NCT00995579||Healthy college volunteers|
89250500|NCT00995657|Active Comparator|High dose ICS|Fluticasone Propionate 250mcg bid
89250501|NCT00995657|Active Comparator|Low dose ICS|Fluticasone propionate 50mcg bid
89250502|NCT00994097|Experimental|A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed|NGR-hTNF with cisplatin/gemcitabine regimen in patients with squamous histology or with cisplatin/pemetrexed regimen in patients with nonsquamous histology
89250503|NCT00994097|Active Comparator|B: cisplatin/gemcitabine or cisplatin/pemetrexed|Cisplatin/gemcitabine regimen is administered in patients with squamous histology and cisplatin/pemetrexed regimen is administered in patients with nonsquamous histology
89250504|NCT00995735||Transgastric|Patients submitted to Transgastric NOTES surgery
89250505|NCT00995735||Transvaginal|Patients submitted to Transvaginal surgery
89250506|NCT04000919|Sham Comparator|Effects of single-dose of carbidopa (50mg) on CNS excitability|Participants will visit the lab and on one of four different occasions they will receive carbidopa only (50 mg). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
89250507|NCT04000919|Placebo Comparator|Effects of single-dose placebo on CNS Excitability|Participants will visit the lab and on one of four different occasions and will receive a placebo. Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
89250508|NCT04000919|Active Comparator|Effects of single-dose 5HTP/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive 5HTP combined with carbidopa (50-200mg HTP/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
89250509|NCT04000919|Active Comparator|Effects of single-dose L-DOPA/carbidopa on CNS Excitability|During one of the four occasions participants visit the lab they will receive L-DOPA combined with carbidopa (50-200mg L-DOPA/50mg carbidopa). Neurophysiology outcome measures will be obtained at 30, 60, 90, 120 and 150 min post drug-intake.
89250510|NCT05223881|Experimental|Cystic Fibrosis|Patients who are diagnosed with Cystic Fibrosis.
89250511|NCT05223881|Active Comparator|Healthy Normal|Patients in this arm will be a sibling of patients who have been diagnosed with Cystic Fibrosis.
89250512|NCT00994253|Experimental|Aliskiren|"Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day.~Patients will be assigned to the treatment arm containing aliskiren. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + aliskiren 150-300mg"
89250513|NCT00994253|Active Comparator|Hydrochlorothiazide|"HCTZ will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day.~Patients will be assigned to the treatment arm containing HCTZ. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + HCTZ 12.5-25mg"
89250514|NCT00994331|Active Comparator|Group A-CT Coregistration|5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
89250515|NCT00994331|Active Comparator|Group B-Angiographic|5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
89250516|NCT00994331|Active Comparator|Group C-Standard Angiography|5 subjects with standard angiography in a conventional PCI (Group C)
89250517|NCT00995969|Placebo Comparator|Placebo only|Subjects will apply placebo cream to both target lesions
89250518|NCT00995969|Active Comparator|Active plus placebo|Subjects will apply CT 327 to one target lesion and placebo to the other target lesion
89250519|NCT00994487|Experimental|Breastfed child|Female, normal weight, 3 to 5 year old children, exclusively breastfed from birth to 3 months of age
89250520|NCT00994487|Active Comparator|Bottle Fed Child|Female, normal weight, 3 to 5 year old children, exclusively bottle fed from birth to 3 months of age
89250521|NCT00996359|Experimental|Irradiated allogeneic lymphocytes after Total Body Irradiation|
89250522|NCT00994565|No Intervention|Usual care|
89250523|NCT00994565|Active Comparator|Activity monitoring and distance counseling|
89250524|NCT00354159|Experimental|Treatment Arm|Physicians have access to device-based hemodynamic monitor information to guide patient management
89250525|NCT00354159|Placebo Comparator|Control Arm|Physicians do not have access to device-based hemodynamic monitor information to guide patient management
89250526|NCT00338949|Active Comparator|Control|Participants on risperidone or olanzapine who will remain on risperidone or olanzapine and do not switch to ziprasidone
89250527|NCT00338949|Experimental|Switch|Participants who enter on risperidone or olanzapine and switch to ziprasidone
89250528|NCT01325259|Experimental|Alzheimer's disease|30 patients suffering from Alzheimer's disease
89250529|NCT01325259|Experimental|Mild Cognitive Impairment|20 patients suffering from Mild Cognitive Impairment
89250530|NCT01325259|Experimental|Control|15 subjects with no cognitive impairment
89250531|NCT01058499|Experimental|MBSR|
89250532|NCT03988881||1 PCI Group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with positive dobutamine stress echocardiography and positive Fractional Flow Reserve recieving revascularization (PCI or CABG) Drug: Standard of care after acute myocardial infarction
89250533|NCT03988881||Group 2 OMT group|Patients after acute myocardial infarction and at least one moderate stenosis on the non-culprit vessels with negative dobutamine stress echocardiography and negative Fractional Flow Reserve or the mismatching cases Standard of care after acute myocardial infarction
89250534|NCT03984435||Patients|Patients with a diagnosed malignancy who have been referred for radiotherapy with extended treatment time (>10 minutes)
89250535|NCT03984435||Radiographers|Radiographers from radiotherapy departments in the UK who deliver radiotherapy
89250536|NCT00332709|Experimental|Letrozole|Letrozole orally 2.5 mg/day for 3 years
89250537|NCT00332709|Experimental|Letrozole + Zoledronic Acid|Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion
89250538|NCT03988725|Experimental|Vitamin E intervention|All study participants receive Vitamin E 800 IU once daily for 6 months
89250539|NCT03984279||Sequentiel group (SEQ)|
89250540|NCT03984279||Siral group (SPI)|
89250541|NCT03984123|Other|Double cuff inflation|The first arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end-diastolic volume of left ventricle
89250542|NCT03984123|Other|Single cuff inflation|The second arm utilizes two ischemic stimuli by brachial cuff inflation of both arms at 200 mmHg for 5 minutes, separated by 15 minutes, after a baseline vascular function assessment (T0). Each ischemic stimulus is followed by a vascular function assessment (T1, T2), with a final assessment 25 minutes after the second cuff deflation (T3). All measurements are preceded by a sham conditioning procedure, by way of cuff inflation omission after their placement around the ordinary brachial position. Blood samples are drawn at baseline (T0) and at the termination of each protocol (T3). Follow-up echocardigraphy is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
89250543|NCT03984123|No Intervention|Standard treatment|The third arm utilizes no cuff inflation to cause remote conditioning and serves as control group. Follow up echocardiography is perfomed at 1 and 2 years after inclusion to assess remodelling of left ventricle by measurmemet of left ventricular end-systolic and end diastolic volume of left ventricle
89250544|NCT00332241|Experimental|A1|Active Abilify
89250545|NCT00332241|Placebo Comparator|A2|
89250546|NCT01054989|Active Comparator|Fat intravenously|Intravenous application of fat
89250547|NCT01054989|Active Comparator|Fat orally|Oral fat load
89250548|NCT01054989|Active Comparator|LPS intravenously|Lipopolysaccharide (LPS; US Standard Reference endotoxin)
89250549|NCT01054989|Placebo Comparator|Glycerol intravenously|Intrevenous glycerol infusion
89250550|NCT03985683|Active Comparator|Control group|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
89250551|NCT03985683|Experimental|Experimental (Nutritional Interventional)|In experimental group athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively. Average carbohydrates required for athletes are 6 to 10 gram per kilogram per day. T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test will use as baseline assessment and after 6 days of intervention.
89250552|NCT03983889|Experimental|F|Sedated with intravenous midazolam (0.03mg/kg) and fentanyl (1μg/kg) for induction and maintenance
89250553|NCT03983889|Experimental|DR|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
88804853|NCT01346683|Experimental|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
88804854|NCT01295515|Experimental|Interferon treatment|Interferon treatment The intervention is administration of Pegylated Interferon Alpha 2b (PEGINTRON) weekly for four weeks
88804855|NCT03008941|Experimental|FMT|"Fecal microbiota capsules (provided by Openbiome).~Dosage:~Induction: 10 capsules (single dose)~Maintenance: 5 capsules, weekly, during 7 weeks."
88804856|NCT03008941|Placebo Comparator|Placebo|"Placebo capsules (provided by Openbiome).~Dosage:~Induction: 10 capsules (single dose)~Maintenance: 5 capsules, weekly, during 7 weeks."
88804857|NCT01277341|Experimental|2% Twice a day|Bepotastine Besilate Nasal Spray 2% Twice a day
88804858|NCT01277341|Experimental|3% Twice a day|Bepotastine Besilate Nasal Spray 3% Twice a day
88804859|NCT01277341|Experimental|4% Twice a day|Bepotastine Besilate Nasal Spray 4% Twice a day
88804860|NCT01277341|Placebo Comparator|Placebo|Placebo nasal spray
89250554|NCT03983889|Experimental|DF|Sedated with intravenous midazolam (0.03mg/kg), dexmedetomidine (0.5-1μg/kg for induction+0.5-0.7μg/kg/h for maintenance) and fentanyl (1μg/kg) for induction and maintenance
89250555|NCT03983889|Experimental|PR|Sedated with intravenous midazolam (0.03mg/kg), propofol (plasma concentration 1.0-2.0ng/ml) and remifentanil (plasma concentration 2.0-2.5ng/ml) for induction and maintenance
89250556|NCT00337935|Experimental|Epoetin Alfa|
89250557|NCT00337935|Other|Group 2|Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
89250558|NCT00337779|Active Comparator|glatiramer acetate 40 mg|
89250559|NCT00337779|Active Comparator|glatiramer acetate 20 mg|
89250560|NCT03983811|Experimental|Chemotherapy+Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
89250561|NCT03983811|Placebo Comparator|Chemotherapy+Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
89250562|NCT00352755|Experimental|Peritonectomy + IP5FU + FOLFOX|"Surgical debulking with peritonectomy~IP 5FU 600 mg/m^2 over 30-60 minutes with patient rotating every 15 minutes. Repeated every 2 weeks for a total of 9 cycles.~FOLFOX (oxaliplatin, 5FU, leucovorin) will follow IP therapy. Oxaliplatin 85 mg/m^2 over 2 hours with leucovorin at 400 mg/m^2 and IV 5-FU at 2400 mg/m^2 over 46 hours. Repeated every 2 weeks for a total of 8 cycles."
89250563|NCT00533897|Experimental|Abatacept|
89250564|NCT00533897|Placebo Comparator|Placebo|
89250565|NCT00426660|Experimental|1|
89250566|NCT00426270|Experimental|Octagam 10% 1 g/kg/day|Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.
89250567|NCT00330681|Experimental|1|MCI-186
89250568|NCT00330681|Placebo Comparator|2|Placebo of MCI-186
89250569|NCT01061073|Experimental|Omexel|
89250570|NCT01061073|Active Comparator|spasfon|
89250571|NCT00329901|Experimental|Tdap + MenACWY-CRM|Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
89250572|NCT00329901|Experimental|Tdap + saline|Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
89250573|NCT00329901|Experimental|MenACWY-CRM + saline|Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms
89250574|NCT01061229|Experimental|Homeopathic drug, potency C12|
89250575|NCT01061229|Placebo Comparator|Placebo|
89250576|NCT00436956|Experimental|AZD2171 in Prostate Cancer|Cohort 1 (n=35) received 20 mg AZD2171 (Cediranib) orally daily. Cohort 2 (n=23) received prednisone 10 mg orally daily with 20 mg AZD2171.
89250577|NCT01323504|Experimental|Music therapy group|Local care with music
89250578|NCT01323504|No Intervention|control group|Local care without music
89250579|NCT00329745|Experimental|Rotarix Group|During the primary study (NCT00197210) subjects received two oral doses of Rotarix™ vaccine.
89250580|NCT00329745|Placebo Comparator|Placebo Group|During the primary study (NCT00197210) subjects received two oral doses of placebo.
89250581|NCT01031784|Experimental|Holmium-166 microspheres, intra-arterial|intra-arterial administration of holmium-166 microspheres in the liver
89250582|NCT01031862|Other|Healthy Volunteers|12 healthy volunteers
89250583|NCT01324050|Experimental|Internet-based Psychodynamic Therapy|
89250584|NCT01324050|Active Comparator|Internet-delivered therapist support|
89250585|NCT00436644|Experimental|Lapatinib + Topotecan|Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.
89250586|NCT01037556|Experimental|Arm 1: PR104|
89250587|NCT00324987|Experimental|Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)|Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89250588|NCT00324987|Active Comparator|Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)|Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89250589|NCT00324675|Active Comparator|Rosiglitazone|
89250590|NCT00324675|Placebo Comparator|placebo|
89250591|NCT03988413|Experimental|25mg|Tablets, Oral, 25mg, single dose
89250592|NCT03988413|Experimental|50mg|Tablets, Oral, 50mg, single dose
89250593|NCT03988413|Experimental|100mg|Tablets, Oral, 100mg, single dose
89250594|NCT03988413|Experimental|200mg|Tablets, Oral, 200mg, single dose
89250595|NCT03988413|Experimental|400mg|Tablets, Oral, 400mg, single dose
89250596|NCT03988413|Experimental|800mg|Tablets, Oral, 800mg, single dose
89250597|NCT03988491||End stage renal disease on maintanance hemodialysis|End-stage renal disease due to any etiology on maintenance hemodialysis and consented to participate in the study.
89250598|NCT01055145|Active Comparator|levofloxacin|Levofloxacin 750mg po per day for 3 months
89250599|NCT01055145|Active Comparator|moxifloxacin|Moxifloxacin 400mg po per day for 3 months
89250600|NCT01060683||Group 1: 15 patients|for elective hepatic resection
89250601|NCT01060683||Group 2: 15|for elective hepatic resection
89250602|NCT01060761|Active Comparator|Rehabilitation program|Counselling (supportive conversation with patient and their relatives together) Retreat Weekend (patient and their relatives together)
89250603|NCT01060761|No Intervention|Ususal treatment and support|Usual support and treatment at the hospital, no retreat Weekend.
89250604|NCT01055301|Experimental|treatment|"Ind (1cycle):~bort 1mg/m2 IV/SQ D1,4,8,11 D1-4: thalid 200mg/d & dex 20mg/d PO; cisplatin & dox 10mg/m2/d, cyclophos 400mg/m2/d, etoposide 40mg/m2/d contIV; enoxaparin 40mg/d SQ prn.~PBSC Coll: at recovery per local standard~Bridging (before/between trans/after Cons):~thal 50mg/d D1-21 & dex 20mg D1,8,15 PO~Tandem Trans (x2):~bort 1mg/m2 IV/SQ D-4,-1 D-4to-1: mel 50 mg/m2 IV, thal 200mg/d & dex 40mg/d PO PBSC >/=200x10^6 cells~Cons (1cycle):~same as Ind except cis/dox 7.5mg/m2/d, cyclo 300mg/m2/d, no enox~Maint(</= 3 yrs):~D1,8,15,22:bort 1mg/m2 IV/SQ, dex 20mg/d PO; len 20mg/d PO D1-20"
89250605|NCT01589016||PUL (pregnancy of unknown location),|
89250606|NCT01589016||EP ( ectopic pregnancies P)|
89250607|NCT01589016||IUP-singleton intrauterine pregnancies|
89250608|NCT01055379|Experimental|Rasagiline|
89250609|NCT01055379|Placebo Comparator|Placebo|
89250610|NCT01031940|Active Comparator|macintosh|
89250611|NCT01031940|Active Comparator|C-MAC|
89250612|NCT01031940|Active Comparator|Airtraq|
89250613|NCT03988101|Experimental|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
89250614|NCT03988101|Placebo Comparator|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
89250615|NCT03987945||Left atrial appendage occlusion|Patients with non-valvular atrial fibrillation who have received left atrial appendage occlusion procedure.
89250616|NCT00352365|Experimental|Treatment (lenalidomide)|"INDUCTION THERAPY: Patients receive oral lenalidomide once daily on days 1-14, 1-21, or 1-28 (course 1). Patients undergo bone marrow biopsy on day 28 or 35 to assess treatment efficacy. Patients with stable or improving disease (i.e., a decrease in blast percentage) without progressive disease proceed to maintenance therapy.~MAINTENANCE THERAPY: Beginning within 42 days after completion of induction therapy, patients receive oral lenalidomide once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
89250617|NCT01055535|Experimental|Microplasmin|
89250618|NCT03987867|Experimental|Arm: CIK+PD-1 inhibitor+chemotherapy|"CIK cell, IBI308, Pemetrexed, Liposome paclitaxel, Carboplatin~IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Liposome paclitaxel intravenous infusion 135mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
89250619|NCT00532493|Active Comparator|Prazosin Group|Subjects randomized to this arm will be on prazosin.
89250620|NCT00532493|Placebo Comparator|Placebo Group|Subjects randomized to this arm will be on placebo.
89250621|NCT00994721||pancreatic cancer|resected pancreatic cancer
89250622|NCT00996515|Experimental|Cohort 5|Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18
89250623|NCT00996515|Experimental|Cohort 4|Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18
89250624|NCT00996515|Experimental|Cohort 3|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17
89250625|NCT00996515|Experimental|Cohort 2|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16
89250626|NCT00996515|Experimental|Cohort 1|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15
89250627|NCT00994799||ranibizumab group|patients receiving intravitreal ranibizumab for diabetic macular edema
89250628|NCT00994799||laser|patients receiving macular grid-pattern laser therapy
89250629|NCT00533507|Experimental|Synflorix group|Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.
89250630|NCT04000607|Experimental|Edwards Transcatheter Atrial Shunt System|
89250631|NCT00994877||Septic Patients|
89250632|NCT00994877||Healthy Control|
89250633|NCT00996671|Experimental|Dose Escalation Cohorts|single dose administration escalating doses starting at 20 mg and continue escalation; the highest dose in this study will not exceed the mean Day 1 exposure in male dogs at the NOAEL dose (6 mg/kg/day).
89250634|NCT00996671|Experimental|Food effect Cohort|Dose to be selected based on emerging safety and PK data; subjects will be given FDA standard high fat meal followed by single dose of study drug.
89250635|NCT00996749|Experimental|Treatment (omega-3 fatty acid)|Patients receive long-term omega-3 PUFA supplementation PO.
89250636|NCT00994955|Experimental|selective retina therapy (SRT)|Focal laser treatment with an SRT-Laser which selectively affects the retinal pigment epithelium while sparing the photoreceptor layer.
89250637|NCT03886493|Experimental|Dupixent Subcutaneous (SQ) Injection|Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.
89250638|NCT00352053|Experimental|OBR + Tenofovir DF|Tenofovir DF administered orally, one tablet daily without regard to meals
89250639|NCT00352053|Placebo Comparator|OBR + Tenofovir DF Placebo|Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals
89250640|NCT00995033|Experimental|NicVAX conjugate vaccine|
89250641|NCT00995033|Placebo Comparator|Placebo|Biological
89250642|NCT00996905|No Intervention|Beginner Conventional (BC)|Beginner level (residents) doing epidural insertions the conventional way (ie. no ultrasound scanning)
89250643|NCT00996905|Experimental|Beginner Ultrasound (BU)|Beginner level (residents) doing epidural insertions with the help of ultrasound scanning.
89250644|NCT00996905|No Intervention|Experienced Conventional|Experienced level (fellows) doing epidural insertions the conventional way.
89250645|NCT00996905|Experimental|Experienced Ultrasound|Experienced level (fellows) doing epidural insertions with the help of ultrasound scanning.
89250646|NCT00998855||Adolescents|Post pubertal, sedentary lean and obese Hispanic adolescents
89250647|NCT00997061||HYCAMTIN|
89250648|NCT00351819|Active Comparator|Androgel (testosterone gel)|Testosterone replacement therapy
89250649|NCT00351819|Placebo Comparator|Placebo|Placebo gel
89250650|NCT00998933|Experimental|1|
89250651|NCT00999089|Active Comparator|CCAB|Conventional Coronary Artery Bypass
89250652|NCT00999089|Active Comparator|OPCAB|Off-Pump Coronary Artery Bypass
89250653|NCT00999089|Active Comparator|PACAB|Pump-Assisted Coronary Artery Bypass
89250654|NCT00997295||Heat moisture exchanger (HME)|This group was submitted to general anesthesia with low flow gas and heat moisture exchanger
89250655|NCT00997295||Low flow gas (LFG)|This group was submitted to general anesthesia with only low flow gas
89250656|NCT00997295||Humidity of the respiration|"Heat and moisture group:~The first group (G1)will be submitted to low flow gas anesthesia and heat and moisture exchanger (HME)~Control group:~The second group(G2)Will be submitted to low flow gas anesthesia"
89250657|NCT00997295||HME and LFG|
89250658|NCT00351351|Experimental|A|Cyberwand
89250659|NCT00351351|Active Comparator|B|Currently available lithotripsy technology
89250660|NCT00997451|Experimental|Behavioral Self-Management|Cognitive-behavioral self-management
89250661|NCT00997451|Active Comparator|Symptom Monitoring|
89250662|NCT00997451|No Intervention|Standard Medical Care|
89250663|NCT03983187|No Intervention|Control|
89250664|NCT03983187|Experimental|Rotating Magnetic Therapy group|
89250665|NCT00999245|Other|High Demand / Low Infusion|PCA dosing plan
89250666|NCT00999245|Other|Low Demand / High Infusion|PCA plan for Low Demand / High Infusion
89250667|NCT03983109|Experimental|Detection by EpiFaith syringe with air|
89250668|NCT03983109|Experimental|Detection by EpiFaith syringe with saline|
89250669|NCT00323115|Experimental|Vaccine|
89250670|NCT00322881|Experimental|Carboplatin/Paclitaxel|Patients received chemotherapy on day 1 of a 21 day cycle for 6 cycles. Paclitaxel was given via peripheral or central IV catheter at the dose of 175 mg/m2 over 3 hours. IV carboplatin followed using a dose of Area Under the Curve (AUC) equal to 5 with creatinine clearance based on Jelliffe formula.
89250671|NCT01061307|Experimental|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
89250672|NCT01061463||Exposed group|French coronary interventional cardiologists and cardiologists specializing in cardiac arrhythmias treatments (electrophysiologists), occupationally exposed to X-Rays
89250673|NCT01061463||Unexposed group|French non-interventional cardiologists and non medical workers, not occupationally exposed to X-Rays
89250674|NCT00415194|Experimental|Pemetrexed/Cisplatin|"Pemetrexed 500 milligrams per meter square (mg/m^2) administered intravenously (IV) plus cisplatin 75 mg/m^2 IV on Day 1 every 21 days. Pretreatment, Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment.~Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
89250675|NCT00415194|Placebo Comparator|Placebo/Cisplatin|"Placebo (approximately 100 mL normal saline) administered intravenously (IV) plus cisplatin 75 mg/m^2 on Day 1 every 21 days.~Pretreatment - Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose.~Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
89250676|NCT00436332|Experimental|Erlotinib and Bevacizumab|
89250677|NCT01034436|Placebo Comparator|Low intake of ALA and triacylglycerols|Sunflower oil
89250678|NCT01034436|Experimental|high intake of ALA and triacylglyceroles|Canola and linseed oils
89250679|NCT01034436|Experimental|high intake of ALA and diacylglycerols|Canola and linseed oils
89250680|NCT00532259|Experimental|CT-011|The monoclonal antibody termed CT-011 (currently, pidilizumab).
89250681|NCT00322491|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
89250682|NCT00322491|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
89250683|NCT01034514|Experimental|4DCT arm|Patients breathe in 99mTc-DTPA and then undergo ventilation scans using a SPECT scanner over 2 hours. Patients also receive 99mTc-MAA IV and then undergo perfusion scans using a SPECT scanner over 2 hours. Patients may also undergo a pre- and post-treatment Xe-CT ventilation scan over 15 minutes and a pre-treatment 4D-CT scan over 5-10 minutes.
89250684|NCT00999323||coronary artery disease|patients who have been revascularized by PCI with stent implantation due to an acute coronary syndrome
89250685|NCT03982953||PD patients with STN-DBS|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that are planned to undergo craniectomy with implantation of bilateral DBS electrodes in the subthalamic nucleus
89250686|NCT03982953||Controls - PD patients with medical treatment|Patients with the diagnosis of Levodopa responsive idiopathic Parkinson's Disease that do not undergo DBS for personal reasons or contraindications for this treatment. Age, sex and disease-severity matched with PD patients with STN-DBS.
89250687|NCT00997529|Experimental|1|
89250688|NCT00997607|Experimental|Ebola vaccine only|Participants will receive only the Ebola vaccine or a placebo injection.
89250689|NCT00997607|Experimental|Marburg vaccine only|Participants will receive only the Marburg vaccine or a placebo injection.
89250690|NCT00997607|Experimental|Ebola and Marburg vaccine|Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.
89250691|NCT00322023|Experimental|D-serine 30 mg/kg|D-serine 30 mg/kg
89250692|NCT00322023|Experimental|D-serine 60 mg/kg|D-serine 60 mg/kg
89250693|NCT00322023|Experimental|D-serine 120 mg/kg|D-serine 120 mg/kg
89250694|NCT00997685|Experimental|Capecitabine plus oxaliplatin，mCRC|
89250695|NCT00414960|Experimental|Enzastaurin|Treatment with enzastaurin 500 milligrams (mg) orally (po) once daily (QD) given as 4 tablets (125 mg each).
89250696|NCT00414960|Placebo Comparator|Placebo|Treatment with placebo po QD appearing identical to enzastaurin.
89250697|NCT01061541|Experimental|Group A|
89250698|NCT01061541|Active Comparator|Group B|
89250699|NCT00997763|Active Comparator|XIENCE V|everolimus-eluting stent
89250700|NCT00997763|Active Comparator|CYPHER|Using Cypher stent
89250701|NCT00997841|Active Comparator|POC algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following Point of Care based algorithm
89250702|NCT00997841|Active Comparator|conventional algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following conventional coagulation management algorithm
89250703|NCT00321789|Experimental|Spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse developed a plan to support patient goal achievement.
89250704|NCT00321789|No Intervention|Usual care|Couples assigned to this arm received educational materials at baseline and usual care thereafter, with no contact from the study interventionist.
89250705|NCT00997919|Experimental|A|
89250706|NCT00997919|Experimental|B|
89250707|NCT00414726|Active Comparator|NBO (Normobaric Oxygen)|Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
89250708|NCT00414726|Placebo Comparator|Room Air|Room Air, inhaled at 30-45L/min via a facemask for 8 hours
89250709|NCT00997997||Group 1|
89250710|NCT00998075|Active Comparator|1|Esomeprazole 40 mg/ASA 325 mg Fixed Dose Combination Capsule
89250711|NCT00998075|Active Comparator|2|Esomeprazole Clinical Trial Capsule 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
89250712|NCT00998075|Active Comparator|3|Esomeprazole MUPS Tablet 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
89250713|NCT00998153|Experimental|1|RRFT
89250714|NCT00998153|Active Comparator|2|Usual care
89250715|NCT00531947|Experimental|EMSAM|Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg
89250716|NCT00531947|Placebo Comparator|Placebo|Placebo Selegiline Transdermal System 6, 9 or 12
89250717|NCT00998231|Active Comparator|Major Depressive Episode (MDE)|20 subjects with major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
89250718|NCT00998231|Active Comparator|Control|20 subjects without major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
89250719|NCT00998387||medical ICU|admitted to medical ICU at Seoul National University Hospital longer than 24 hours
89250720|NCT00998465||Obese, hypertension|Obese patients with hypertension and a body mass index 40-50 kg/m2
89250721|NCT00998465||Control|Control subjects without hypertension and body mass index < 30 kg/m2
89250722|NCT00998465||Obese, normotension|Obese patients without hypertension and a BMI between 40-50 kg/m2
89250723|NCT00998543||Smallpox Vaccine (LISTER Strain) Group|Participants were vaccinated with the second-generation smallpox vaccine in Study VVL04 (NCT 00258947).
89250724|NCT00998621||Hepatitis C infection|
89250725|NCT00998621||Hepatitis C + HIV infections|
89250726|NCT00998699|Active Comparator|XOMA 052|
89250727|NCT00998699|Placebo Comparator|Placebo|
89250728|NCT00998777|Experimental|Shoulder Strengthening|The shoulder strengthening program is a 6-week intervention aimed to improve shoulder and scapular stabilizer strength and scapular kinematics. The program includes 10 exercises: shoulder flexion, Ys,Ts,Ws, Throwing Acceleration, Throwing Deceleration, Low Rows, Dynamic Hug, IR @ 90, and ER @ 90. The program also includes 2 stretches: sleeper stretch and corner stretch.
89250729|NCT01003847|Active Comparator|fenofibrate|
89250730|NCT01003847|Active Comparator|fatty acid|drug
89250731|NCT01003847|Active Comparator|Placebo|
89250732|NCT01003925||Usual Care|Patients randomized to the control group will be sent the post-test measures suitably modified to reflect the fact that they did not participate in the conjoint analysis program. Four weeks after the post-test measures are completed, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (same measurements given to treatment group).
89250733|NCT01003925||Conjoint Analysis Group|Patients randomized to the experimental group will meet the research staff to complete the conjoint analysis software and post-test measures. The post-test measures include preparedness for decision-making, personal uncertainty, osteoarthritis knowledge, arthritis self-efficacy, and satisfaction with the results of the conjoint analysis program. The in-person visit takes approximately 60 minutes to complete. Four weeks after the in-person visit, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (i.e. global pain assessment, arthritis self-efficacy, personal uncertainty, and osteoarthritis knowledge).
89250734|NCT00530855|Experimental|Lacosamide|Lacosamide tablets for dosing 100 -800 mg/day
89250735|NCT01004237|Active Comparator|pravastatin|
89250736|NCT01004237|Active Comparator|valsartan|
89250737|NCT01004237|Active Comparator|pravastatin combined with valsartan|
89250738|NCT01004315|Experimental|KUC-7483|
89250739|NCT01004315|Placebo Comparator|Placebo|
89250740|NCT01004315|Active Comparator|Tolterodine|
89250741|NCT05165459|Experimental|Cytori Celution System in Chronic Non-Healing venous Leg Ulcers|On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
89250742|NCT05239637|Experimental|Previous|Heparin stopped before ECMO decannulation
89250743|NCT05239637|Experimental|Afterwards|Heparin reduced after ECMO decannulation
89250744|NCT01004549||Bilateral intraocular lens implantation.|
89250745|NCT01004627|No Intervention|Control group - selective duplex|Patients will receive a duplex ultrasound only if specifically requested following physical examination.
89290308|NCT03972059|No Intervention|Control group|No intervention for 12 weeks, participants perform all tests.
89250746|NCT01004627|Experimental|Obligatory Duplex scan|Patients will receive a duplex ultrasound regardless of clinical findings. Arterial and venous duplex ultrasound examination
89250747|NCT01005017|Active Comparator|Percutanous RF lesioning|Radiofrequent lesioning uses a high frequency alternating current to heat tissues leading to thermal coagulation. It produces predictable and accurate lesions of the splanchnic nerves.
89250748|NCT01005017|No Intervention|Optimal medical treatment|
89250749|NCT01005095|Experimental|High dose vitamin D|800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
89250750|NCT01005095|Active Comparator|Low dose vitamin D|800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
89250751|NCT01005173||Group A|Subjects receiving recommended doses of acetaminophen in the hospital. 140 Subjects
89250752|NCT01005173||Group B|Healthy Volunteers - No acetaminophen exposure within 14 days of enrollment 23 Subjects
89250753|NCT01005173||Group C|Acetaminophen Overdose Subjects - Hospitalized 90 Subjects
89250754|NCT01005485||Group A|Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.
89250755|NCT01005485||Group B|Healthy controls will be recruited from the general medical population, community.
89250756|NCT01005485||Acute Myocardial Infarction|Patients with acute myocardial infarction with or without ST segment deviation.
89250757|NCT01005563|Experimental|Arm 1: Beef/Pork|Participants consuming diet with beef/pork as predominate sources of protein
89250758|NCT01005563|Experimental|Arm 2: Soy/Legumes|Participants consuming diet with soy/legumes as predominate sources of protein
89250759|NCT01005641|Experimental|A|phase II
89250760|NCT01005797|Experimental|Expansion A|Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
89250761|NCT01005797|Experimental|Expansion B|Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
89250762|NCT01005797|Experimental|Expansion C|Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
89250763|NCT01005953||Professionals treating autistic children|Special educators, occupational therapists, speech pathologists, behavior analysts who work with children on the spectrum.
89250764|NCT01005953||Families with autistic children (3-10)|
89250765|NCT01006031|Experimental|PegIFN alfa-2a and Ribavirin|HIV-coinfected patients with compensated cirrhosis by hepatitis C virus, genotype 1 or 4.
89250766|NCT01006187|Active Comparator|Group 1|1 liposomal lidocaine 4% cream .
89250767|NCT01006187|Active Comparator|Group 2|Vapocoolant spray
89250768|NCT01006187|Active Comparator|Group 3|Rubbing adjacent to the injection site
89250769|NCT01006187|Active Comparator|Group 4|Distraction by means of self-selected reading material or internet
89250770|NCT01006343|Experimental|Higher Protein (HP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The HP menus will contain 30% protein, 45% carbohydrate, and 25% fat. Subjects in the HP group will be provided with portioned, cooked and frozen pork products as part of their HP menu plan.
89250771|NCT01006343|Experimental|Lower Protein (LP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The LP group menus will contain 18% protein, 57% carbohydrate, 25% fat. The LP group will follow a lacto-ovo vegetarian menu with no striated tissue foods. Subjects in the LP group will be provided with selected, portioned dairy products.
89250772|NCT00530777|Experimental|1|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
89250773|NCT00530777|Placebo Comparator|2|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
89250774|NCT01006499|Placebo Comparator|Placebo group|Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).
89250775|NCT01006499|Active Comparator|Pentoxifylline group|Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.
89250776|NCT01006499|Active Comparator|Pentaglobin group|Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days
89250777|NCT01006499|Active Comparator|Pentoxifylline plus Pentaglobin group|Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.
89250778|NCT01006577|Other|colon j pouch|Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
89250779|NCT01006577|Experimental|side-to-end anastomosis (STE)|Experimental intervention: Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon is closed with a linear stapler. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
89250780|NCT01006733|Experimental|Target INR 1.8 and Pharmacogenetic|The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
89250781|NCT01006733|Experimental|Target INR 2.5 and Pharmacogenetic|The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
89250782|NCT01006733|Experimental|Target INR 1.8 and Clinical|The target INR is 1.8. Warfarin initiation is via clinical dosing.
89250783|NCT01006733|No Intervention|Target INR 2.5 and Clinical|The target INR is 2.5. Warfarin initiation is via clinical dosing.
89250784|NCT01006811|Experimental|modified Atkins diet|
89250785|NCT01007045||"Clinically likely"|Subjects deemed clinically likely to have DVT based on modified Well's criteria
89250786|NCT01007045||"Clinically unlikely"|Subjects deemed clinically unlikely to have DVT based on modified Well's criteria
89250787|NCT01007201|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|15 μg HA (0.5 mL) per injection, 2 injections 50 children (aged over 3 years old to 6 years old) and 50 children/teenagers (aged over 6 years old to 18 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
89250788|NCT01007201|Experimental|H1N1 vaccine of 7.5 μg HA on Day 0 and 21|7.5 μg HA (0.25 mL) per injection, 2 injections 50 toddlers (aged over 1 year old to 3 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
89250789|NCT03882047|Experimental|Mometasone furoate nasal spray|Participants receive 200 mcg of mometasone furoate nasal spray and fluticasone propionate placebo matching nasal spray once daily.
89250790|NCT03882047|Active Comparator|Fluticasone propionate nasal spray|Participants receive 200 mcg of fluticasone propionate nasal spray and mometasone furoate placebo matching nasal spray once daily.
89250791|NCT03882047|Placebo Comparator|Placebo nasal spray|Participants receive mometasone furoate placebo matching nasal spray and fluticasone propionate placebo matching nasal spray once daily.
89250792|NCT01007279|Active Comparator|CLOPIDOGREL|
89250793|NCT01007279|Experimental|ROSUVASTATIN|
89250794|NCT00530621|Experimental|Pemetrexed + Enzastaurin|
89250795|NCT00530621|Placebo Comparator|Pemetrexed + Placebo|
89250796|NCT01007513||At risk patient for preterm delivery|Patient referred to the MFM clinic for a risk evaluation for preterm delivery.
89250797|NCT00531479|Active Comparator|Voriconazole|Voriconazole monotherapy
89250798|NCT00531479|Experimental|Voriconazole and Anidulafungin|Combination therapy with voriconazole and anidulafungin
89250799|NCT04000451|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
89250800|NCT04000451|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
89250801|NCT03999905|Experimental|Intervention Arm|Online training on Oral anticoagulant counseling.
89250802|NCT03999905|No Intervention|Control Arm|No counseling training
89250803|NCT01007669|Active Comparator|Reference|Health check only
89250804|NCT01007669|Experimental|Intervention|Physical activity and Health check
89250805|NCT00999479|Experimental|Monophasic OCP|Patients randomized to this study arm will receive combined oral contraceptive pills. Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages
89250806|NCT00999479|Placebo Comparator|Placebo|Patients assigned to this arm will use non-hormonal, barrier contraceptives to prevent pregnancy.Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages.
89250807|NCT05121311||Newborns under bilirubin monitoring|Bilirubin monitoring according to standard of care of the participating center
89250808|NCT01007747|Experimental|Geranium oil|
89250809|NCT05114603|Experimental|Dose-escalation stage|Iinvestigate the safety and determine the MTD of HLX208. Two dose levels of 600mg and 900 mg are planned for dose finding.
89250810|NCT05114603|Experimental|Dose-expansion stage|Patients with advanced melanoma will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX208.
89250811|NCT00999557|Experimental|Arm I|Patients apply topical bimatoprost ophthalmic solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
89250812|NCT00999557|Placebo Comparator|Arm II|Patients apply topical placebo solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
89250813|NCT00999635|Experimental|Custom made insole|Custom made functional moulded insole
89250814|NCT00999635|Active Comparator|Prefabricated Insole|Prefabricated accommodative moulded insole
89250815|NCT01007903|No Intervention|Usual Care|
89250816|NCT01007903|Experimental|Tai Chi|
89250817|NCT05260385|Experimental|QD regimen|KC1036 was administered orally in 60 mg once daily, 21 days as a cycle.
89250818|NCT05260385|Experimental|BID regimen|"Dose-Escalation part : KC1036 was administered orally in 20 mg BID, 30 mg BID, or 40 mg BID.~Dose-Expansion part : According to the results of Dose-Escalation, an appropriate BID regimen was selected for Dose-Expansion ."
89250819|NCT01007981||CRT device|Patients with Cardiac Resynchronization Therapy(CRT) device implanted in the last 5 years will be studied by the new echo modality.Study doesn't involve acute device implantation.
89250820|NCT01008137|Experimental|Group 1: Day 0-PANFLU.1; Day 21-ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
89250821|NCT01008137|Experimental|Group 2: Day 0-ANFLU; Day 21-PANFLU.1|50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
89250822|NCT01008137|Experimental|Group 3: Day 0-PANFLU.1+ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
89250823|NCT00999791|Active Comparator|Avastin|
89250824|NCT00999791|Active Comparator|Diclofenac|
89250825|NCT00999869|Experimental|Botulinum toxin A|At first visit, patients will be randomized by blocked randomization into 2 sides of scalp. Experimental side will be injected with botulinum toxin A ( Botox) 2 units per 6.05 cm2 of lesion ( Concentration 2 units of Botox per 0.1 ml of normal saline ).
89250826|NCT00999869|Active Comparator|Triamcinolone acetonide|At visit0, patients will be injection with triamcinolone acetonide concentration at 10 mg/ml on the comparison side
89250827|NCT05103527|Experimental|Non-operated Knee Osteoarthritis|DRG-S for knee osteoarthritis patients with no history of knee surgery
89250828|NCT05103527|Experimental|Surgically Repaired Knee Osteoarthritis|DRG-S for knee osteoarthritis patients with history of surgical repair of the knee
89250829|NCT01000103|Active Comparator|1: Real rTMS treatment|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
89250830|NCT01000103|Sham Comparator|2: Sham rTMS treatment|Simulation of rTMS
89250831|NCT01008215|Experimental|Algorithm|Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.
89250832|NCT01008215|No Intervention|Care as usual|Control group
89250833|NCT01008293|Experimental|VSL#3|
89250834|NCT01008293|Active Comparator|Lactulose|30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
89250835|NCT01000181||Patients undergoing carotid endarterectomy|
89250836|NCT03742661|Experimental|Treatment Group|SPEAC System
89250837|NCT03742661|No Intervention|Standard of Care|Standard of Care
89250838|NCT01008371||Obese|Healthy obese subjects
89250839|NCT01008371||Non-obese|Healthy non-obese subjects
89250840|NCT01000259||Ancillary-Correlative|Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
89250841|NCT01008527|Experimental|Infusion and Peptide Administration|Patients get the study drug Oncovir poly IC:LC with or without CP 870-893. Up to 6 groups of 3 to 10 patients each will be treated in this study. The first group (between 3 and 6 patients) gets peptide vaccine with poly IC:LC. Second, third and fourth groups of 3 to 6 patients receive peptide vaccine with poly IC:LC and the antibody CP 870,893 at increasing doses from 0.01, 0.025 and 0.05 mg/kg. CP 870-893 will be given to 10 patients at a dose of 0.1 mg/kg to patients in the fifth group, and 0.2 mg/kg to the sixth group. The CP 870,893 will be given as an intravenous infusion over 30 minutes and will be given once every 2 weeks for the first 6 infusions. CP-870-893 will then be given every 4 to 6 weeks for 3 injections. The final 3 injections of CP 870,893 will be given every 8 to 12 weeks. These infusions will take place on weeks 1, 3, 5, 7, 9, 11, 17, 21, 25, 33, 41, and 53 for a total of 12 infusions.
89250842|NCT01000415|Experimental|Cisplatin plus gemcitabine|Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation
89250843|NCT05177783|Experimental|Tuune|Participants complete the Tuune contraceptive decision aid health questionnaire.
89250844|NCT05177783|Active Comparator|Control|Participants complete a standard physician intake health questionnaire.
89250845|NCT01000571||H1N1 pandemic influenza vaccine recipient|Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight with underlying conditions of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.Target total accrual of up to 400 children and young adults stratified based on their underlying diagnosis as follows: 150 children or young adults with cancer, 100 with human immunodeficiency virus (HIV), 100 with sickle cell disease, and 50 with receipt of a stem cell transplant more than a year prior to study entry.
89250846|NCT01008683||Stem cell and and heart transplant patients|Stem cell and and heart transplant patients
89250847|NCT01008761|Active Comparator|Zithromax, 100 mgmgs; 5mls suspension|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
89250848|NCT01008761|Placebo Comparator|Suspension placebo,|placebo (suspension produced by CDC Edmonton.) given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days.
89250849|NCT01008917|Experimental|single treatment-non randomized study|Phase I study is to test the safety of the combination of sorafenib with temsirolimus at different dose levels
89250850|NCT01009073|Experimental|Arm A (ABT-263 and erlotinib)|
89250851|NCT01009073|Experimental|Arm B (ABT-263 and irinotecan)|
89250852|NCT01009073|Experimental|Arm C (ABT-263 monotherapy)|
89250853|NCT01001039||control|Patients seen in the Otology clinic who have not had sinus surgery in the past 2 months or a history of sinusitis in the last 6 months.
89250854|NCT01001039||cases|Patients seen in the Rhinology Clinic with a complaint of facial pain. They must have evidence of chronic sinusitis.
89250855|NCT00530075|Experimental|1|Gusperimus
89250856|NCT01008839||Old age group of healthy women|Old women over 70 years old
89250857|NCT01008839||young group of healthy women|aged 25-35 years
89250858|NCT01001117|Experimental|Laser treated|Eye treated with LensAR Laser System
89250859|NCT01001117|Active Comparator|Control Eye|Contralateral eye treated with conventional phaco-emulsification
89250860|NCT01009151|Experimental|Heart Care Self Tracker|Web-based Home Tele-monitoring system
89250861|NCT01009229|Other|1|
89250862|NCT01001273|Experimental|Study Group|Hyperinsulinemic Normoglycemic Clamp will be started at the time of surgery (before incision) and will be continue for 3 days.
89250863|NCT01001273|No Intervention|Control Group|Patients in the control group will receive standard care.
89250864|NCT03999671|Experimental|INSTRUMENT SF 36|Instrument SF36 Spanish version, validated in Spain, translated in several languages and applied to multiple studios in Mexico. The 36 items explore 8 dimensions: the state of physical health, physical function, physical role, body pain, general health, vitality, social function, emotional role and mental health: considering depression, anxiety, self-control, and general well-being.
89250865|NCT03999671|Active Comparator|Checklist|Verify that the interventions of both groups were carried out
89250866|NCT01001507|Experimental|Integrated HIV/FP services|Family planning services are integrated into HIV care and treatment services at this facility.
89250867|NCT01001507|No Intervention|Standard (non-integrated), referral-based, services|Patients from the HIV care and treatment clinic will be referred for family planning services, and will not receive FP services by the HIV care provider
89290309|NCT01222182||Eligible plan beneficiaries on atorvastatin|A group of 225 eligible patients would no longer have atorvastatin covered by their prescription plan and would need to be changed to another equivalent anti-hyperlipidemic agent.
89250868|NCT01001585|Experimental|slow induction with sevoflurane|Only children with a BIS greater than 95 prior to inhalation of sevoflurane will be included in the study. Inductions will be done using a tight fitting mask with continuous monitoring of end tidal gas concentrations. During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached. Inspired sevoflurane will be increased only after end tidal concentration of sevoflurane is constant for at least one minute. Each induction (except for the patients requiring very low doses of sevoflurane) will take approximately 10 minutes.
89250869|NCT01001663|Experimental|FemoSeal®|Closure device for femoral artery access closure
89250870|NCT01001663|Active Comparator|Manual compression|Conventional manual compression
89250871|NCT05734157|Experimental|Everolimus-coated balloon|Treatment of occlusion or stenosis in Superficial Femoral Artery and Proximal Popliteal Artery with drug-coated balloon
89250872|NCT01001819||1|Chronic Rhinosinusitis w/o nasal polyps
89250873|NCT01001819||2|No sinus disease
89250874|NCT01001897|Experimental|misoprostol|400 micrograms of misoprostol inserted buccally or vaginally prior to IUD insertion
89250875|NCT01001897|Placebo Comparator|Placebo|Troches identical to experimental drug inserted buccally or vaginally prior to IUD insertion
89250876|NCT05734079|Active Comparator|Standard of care|Standard of care includes a written paper sheet that summarizes information about the colonoscopy procedure and bowel preparation.
89250877|NCT05734079|Experimental|Standard of care + Video call|The video call will be performed at a designated time with a GE educated nurse. The purpose of the video call is (i) to clarify the patient in person about the colonoscopy procedure (ii) efficiently prepare the patient for bowel preparation by; asking the patient about her/his medical condition, the indication for colonoscopy, medical history, current medical status and medications currently taken. The patient will be inquired, whether she/he went through colonoscopy in the past, what preparation methods were undertaken and what the outcome of the examination was. Based on the information collected during the conversation, the designated nurse performing the interview will tailor the method of bowel preparation for the patient in terms of kind of relaxant, adjustment of medication intake and dietary adjustments before the examination.
89250878|NCT05734079|Experimental|Standard of care + Video call + Educational video film|The video film will explain the colonoscopy procedure and the bowel preparation procedure, in layman's terms and in the patient's preferred language (Hebrew or Arabic).
89250879|NCT01002053||Diabetics with peripheral neuropathy|Patients with diabetes and peripheral neuropathy.
89250880|NCT01002131||Digital Volume tomography|three-dimensional digital imaging using cone beam tomography (CBCT)
89250881|NCT01002209|Sham Comparator|Sham Hyperbaric Oxygen Treatment|
89250882|NCT01002209|Experimental|Hyperbaric oxygen treatment (HBO)|
89250883|NCT05064917||Children with suspected cow's milk allergy|
89250884|NCT05061797|Active Comparator|Active Study Product|An energy beverage formulated to improve the thermogenic (calorie burning) impact in humans via caffeine and ingredients for overall metabolic wellness.
89250885|NCT05061797|Placebo Comparator|Placebo|A carbonated soft-drink with the same appearance, aroma, and flavor as the active study product
89250886|NCT01002365|Active Comparator|Post op care|
89250887|NCT01002365|Active Comparator|Oxygen administration- different %|
89250888|NCT01002443|Active Comparator|H. pylori eradication|
89250889|NCT01002443|Placebo Comparator|placebo|
89250890|NCT01002521||Cases|Persons With Diabetes (PWD) who have current non-healing ulcer(s)
89250891|NCT01002521||Controls|Persons With Diabetes (PWD) with no current ulcers and no history of ulcers
89250892|NCT01002599|Experimental|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
89250893|NCT01002599|Active Comparator|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
89250894|NCT01002677|Experimental|Curriculum|
89250895|NCT01002677|Active Comparator|Self-directed|
89250896|NCT05733299|Active Comparator|Standard Care|
89250897|NCT05733299|Experimental|aflo™ digital respiratory management platform with standard care|The new aflo™ digital respiratory management platform will provide automated inhaler technique direction, with real time quantitative personalised feedback on inhaler technique and timing.
89250898|NCT01002833|Experimental|PfA|Exposure of human volunteers to bites of mosquitoes infected with the A strain of Plasmodium falciparum
89250899|NCT01002833|Experimental|PfB|Exposure of human volunteers to bites of mosquitoes infected with the B strain of Plasmodium falciparum
89250900|NCT01002833|Active Comparator|NF54|Exposure of human volunteers to bites of mosquitoes infected with the NF54 strain of Plasmodium falciparum
89250901|NCT01002911|Experimental|Aggressive Antibiotic therapy|Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.
89250902|NCT01002911|Active Comparator|Conventional Antibiotic Therapy|Preoperative intravenous antibiotics
89250903|NCT05733221|Experimental|3D Model Generated|Patient will undergo an Open Reduction and Internal Fixation preformed by a surgeon who had pre-operative access to a 3D model printed to help pre-bend hardware.
89250904|NCT05733221|No Intervention|Normal Standards of Care without Aide of Model|Patient will undergo standard Open Reduction and Internal Fixation by a surgeon who did not have a pre-operative 3D model.
89250905|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0|"15 μg HA (0.5 mL) per injection, 1 injection~50 adults (aged 18~60 years) were assigned to receive one injection of H1N1 vaccine"
89250906|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|"15 μg HA (0.5 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
89250907|NCT01003145|Experimental|H1N1 vaccine of 30 μg HA on Day 0 and 21|"30 μg HA (1 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
89250908|NCT01003223|Experimental|PKM modeling with graphical report|
89250909|NCT00531011|Active Comparator|XIENCE V|Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)
89250910|NCT00531011|Active Comparator|TAXUS® Liberté™|Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
89250911|NCT05051267|No Intervention|Routine Care Group|Before the application, the families will be informed by the researcher and the 'Informed Consent Form' will be signed. After the heel blood procedure, comfort will be provided with gentle touches. For ethical reasons, routine care will be provided when the baby cries.
89250912|NCT05051267|Experimental|Mothers Embrace|A mothers embrace is one of the earliest and most common care events that mothers offer to their babies. Close physical contact between mother and baby during hugs can reduce stress by facilitating co-regulation of mother and baby. In a study conducted in Turkey, it was stated that holding the baby on the lap for pain relief in painful interventions is a practical and easy method.
89250913|NCT05051267|Experimental|White Noise|Since white noise is a humming and continuous monotonous sound, it is similar to the sound in the womb (Balci, 2006). It will be explained that this sound is very similar to the sound that the baby hears in the mother's womb by making the white noise recordings listen to the mothers who will have their babies listen to white noise. by Orhan Osman; Dr. From the album 'Kolik', which was created by making use of the album 'The Happiest Baby' prepared by Harvery Karp, which consists only of uterus sounds; The song 'Don't Let Your Baby Cry, PT.2' will be played to babies (Karp, 2015). In addition, infants will be excluded from the study even though they meet the criteria, if they are not sedated, the procedure takes more than 2 minutes, the procedure is disrupted because someone enters the room loudly, or the mother changes the baby's position (Karakoç, & Türker, 2014).
89250914|NCT05051267|Experimental|Mother's Voice|Auditory responses, fetal age 26-28. It develops in the auditory cortex and brain stem in weeks (Eskandari, Keshavarz, & Jahdi, 2010). Hearing is one of the first senses a fetus develops and is 24-33. can recognize and remember the mother's voice after weeks (Djordjevic, 2010 ). The fetus memorizes the musical characteristics of the mother's voice, like tone, by listening to it (Arabin, 2002). It is stated that newborns exposed to their own mother's voice have a lower heart rate, higher sucking rate, a more relaxed appearance, and less crying and body movements (Campbell-Yeo, Fernandes, & Johnston, 2011).
89250915|NCT05051267|Experimental|Mothers Embrace and White Noise Applied Group|One minute after the procedure, the baby's pain score will be evaluated. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the white noise will continue to be listened to. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to pre-procedural basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
89250916|NCT05051267|Experimental|Mothers Embrace and Mother's Voice Group|After the procedure, the baby will continue to listen to the baby who is in the mother's arms. One minute after the procedure, the baby's pain score will be evaluated and the HR and O2 values will be noted. After the procedure, until the baby returns to basal values, the mother will be asked to hold her baby and the mother's voice will continue to be listened to. Video and audio recording will continue until the baby's oxygen saturation and heart rate return to basal values. When it returns to basal values, the baby's pain score will be re-evaluated.
89250917|NCT04000295|Experimental|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
89250918|NCT04000295|Active Comparator|Weekly Paclitaxel|Weekly Paclitaxel (80 mg/m2, d1, d8, d15, q3w) until disease progression or intolerable toxicity
89250919|NCT01003457||detrusor overactivity|
89250920|NCT01003535||[123I]5-IA-85380 SPECT|
89250921|NCT01003613|Active Comparator|Tranilast|CAT with FG and Tranilast and MMC 0.02%
89250922|NCT01003613|Placebo Comparator|Control|CAT with FG and MMC 0.02%
89250923|NCT05732597||Patients with ACS and no IRA|Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - no infarct-related artery (IRA) is found
89250924|NCT05732597||Patients with ACS and IRA|Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - an infarct-related artery (IRA) is found
89250925|NCT00529217|Experimental|Open-Label Active rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS)
89250926|NCT05732441|No Intervention|Conventional treatment group|Routine treatment protocol are used base on clinical guidelines
89250927|NCT05732441|Experimental|Conventional treatment group combined with Huange capsule|Based on the clinical guidelines, the routine treatment was used in addition to Huange Capsule.
89250928|NCT05592977|Experimental|Intra-oral Distalizing Appliance|"Two infra zygomatic mini-implants will be placed Bands will be cemented to upper first molars. The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars.~Orthodontic force 300 mg per side Will be delivered by Niti closed coil spring which is attached from infra zygomatic mini screw to the hook soldered to the wire framework."
89250929|NCT00471146|Experimental|A|
89250930|NCT00471146|Active Comparator|B|
89250931|NCT04027556|Experimental|50 keV DLD images of the LBW-based low-dose group|Low CT contrast media dose calculated based on lean body weight and low monoenergetic images of dual-energy CT with deep learning-based denoising
89250932|NCT04027556|Active Comparator|ADMIRE images of the standard-contrast dose group|Standard CT contrast media dose calculated based on total body weight and conventional images with full model-based iterative reconstruction
89250933|NCT01021280||Type II BS|Adolescents and young adults with type II Bartter syndrome
89250934|NCT01021280||Type IV BS|Adolescents and adults with type IV Bartter syndrome
89250935|NCT01021280||Controls|Age and sex- matched controls
89250936|NCT01021358|Experimental|Arm A (ABT-263 and Ketoconozole)|
89250937|NCT00469898|Experimental|Therapeutic Intervention|Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded or is stable, the patient will continue to be followed for efficacy (i.e. until progressive disease)at 8 week intervals. Following the diagnosis of progressive disease, patients will be followed every two months for survival.
89250938|NCT01021436|Experimental|Amikacin inhalation solution|Subjects received 125 mg/mL of aerosolized amikacin via the PDDS clinical device at a nominal dose of 400 mg every 12 h for 7-14 days
89250939|NCT00529763|Experimental|1|
89250940|NCT00486902|Experimental|Ketamine|Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.
89250941|NCT00486902|Placebo Comparator|Placebo|Subjects receive IV Saline 20 mL 5 minutes after infant delivery
89250942|NCT05559125|Experimental|STSA-1002 and STSA-1005 dose level 1|
89250943|NCT05559125|Experimental|STSA-1002 and STSA-1005 dose level 2|
89250944|NCT05559125|Experimental|STSA-1002 and STSA-1005 dose level 3|
89250945|NCT05559125|Experimental|STSA-1002 and STSA-1005 dose level 4|
89250946|NCT05728541|Experimental|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
89250947|NCT04000139|Active Comparator|Standardized anthocyanin rich extract|3 doses of 2x 500mg in capsules daily
89250948|NCT04000139|Placebo Comparator|Placebo|3 doses of 2x 500mg in capsules daily
89250949|NCT05708729|Experimental|Patients with CPSP which is pharmacorefractory and have a good analgesic response to M1-rTMS|"Diagnosed with definite CPSP (Treede-Klit criteria), which is pharmacorefractory (i.e. amitriptyline 75mg/d 4w, lamotrigine 200mg/d 8w and pregabalin 600mg/d resulting in <50% VAS reduction and/or intolerable side-effects).~A good analgesic response to M1-rTMS is defined as: ≥50% mean 10-d VAS reduction immediately following vs. before active M1-rTMS minus mean 10-d VAS reduction immediately following vs. pre sham M1-rTMS. A good analgesic response gives a high positive predictive value for pain reduction by MCS."
89250950|NCT05708729|Experimental|Patients with CPSP which is pharmacorefractory with less analgesic M1-rTMS response|"Diagnosed with definite CPSP (Treede-Klit criteria), which is pharmacorefractory (i.e. amitriptyline 75mg/d 4w, lamotrigine 200mg/d 8w and pregabalin 600mg/d resulting in <50% VAS reduction and/or intolerable side-effects).~Patients with less analgesic M1-rTMS response (n≈20) will be 1:1 randomized to either MCS (≈10) or Vc-DBS (n≈10)."
89250951|NCT03687827|Experimental|Insulin degludec|Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.
89250952|NCT03687827|Active Comparator|Insulin glargine|Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.
89250953|NCT00529529|Experimental|Indacaterol 300 μg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 μg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89250954|NCT00529529|Experimental|Indacaterol 600 μg|Patients received indacaterol 600 μg (2 x 300 μg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 μg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89250955|NCT00529529|Active Comparator|Salmeterol 50 μg|Patients received salmeterol 50 μg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 μg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89250956|NCT05655377|Experimental|At home exercise therapy with FitMi PD|Participants will be instructed to use FitMi PD exercise system for three hours per week over 3-week period.
89250957|NCT04973111|Experimental|CT-868|SC dose of CT-868 Intervention: Drug: CT-868
89250958|NCT04973111|Placebo Comparator|Placebo|SC dose of placebo matching CT-868 dose Intervention: Drug: Placebo
89250959|NCT04973111|Active Comparator|Active Comparator|SC dose of Active Comparator Intervention: Drug: Active Comparator
89250960|NCT00486434|Active Comparator|1|SMC021 Oral Calcitonin, 0.8 mg twice daily during 24 months
89250961|NCT00486434|Placebo Comparator|2|SMC021 Placebo, orally twice daily during 24 months
89250962|NCT04972019|Experimental|Telerehabilitation experimental group|Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals being measured and logged. Data will be uploaded on a secure cloud server to which clinicians will have access.
89250963|NCT04972019|Sham Comparator|Telerehabilitation control group|Participants will perform web-based game play while wearing sham equipment. Duration of sessions will be fixed and frequency of sessions will equal that of the experimental group training. Over the total training the control group will have an equal duration of training with the experimental group.
89250964|NCT00424632|Experimental|Single arm dose escalation|
89250965|NCT00529451|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily
89250966|NCT00529451|Experimental|Aliskiren 150 mg|Aliskiren 150 mg once daily
89250967|NCT00529451|Experimental|Aliskiren 75 mg|Aliskiren 75 mg once daily
89250968|NCT00529451|Active Comparator|Ramipril 5 mg|Ramipril 5 mg once daily
89250969|NCT03876743|Experimental|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
89250970|NCT03876743|Experimental|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
89250971|NCT03876743|Experimental|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
89250972|NCT03876743|Experimental|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
89250973|NCT03999437|Experimental|Treatment # 1|
89250974|NCT03999437|Experimental|Treatment # 2|
89250975|NCT03999437|Placebo Comparator|Placebo Control|
89250976|NCT05311631|Experimental|Intervention|Improved breastfeeding support provided by health visitors supporting families after discharge from maternity ward at hospital. The intervention is implemented into the existing national health visitor program that is offered free of charge to all. The program is accepted by more than 95% of families.
89250977|NCT05311631|No Intervention|Control|Health visitors in the control municipalities will give breastfeeding support according to standard care.
89250978|NCT05637281|Placebo Comparator|convention|patients in convention arm receive conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
89250979|NCT05637281|Experimental|convention + indometacin|Besides the conventional treatment,patients in convention + indometacin arm receive 50-mg indomethacin suppositories at intervals of 12 hours for a total of 6 doses.
89250980|NCT00486278|Experimental|vatreptacog alfa 5 mcg/kg|
89250981|NCT00486278|Experimental|vatreptacog alfa 10 mcg/kg|
89250982|NCT00486278|Experimental|vatreptacog alfa 20 mcg/kg|
89250983|NCT00486278|Experimental|vatreptacog alfa 40 mcg/kg|
89250984|NCT00486278|Experimental|vatreptacog alfa 80 mcg/kg|
89250985|NCT00486278|Experimental|rFVIIa 90 mcg/kg|
89250986|NCT00321711|Active Comparator|Dose level 1 500 AMG 531 (Part A - azacitidine)|500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
89250987|NCT00321711|Active Comparator|Dose level 1 750 AMG 531 (Part B - decitabine)|750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
89250988|NCT00321711|Active Comparator|Dose level 2 750 AMG 531 (Part A - azacitidine)|750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
89250989|NCT00321711|Placebo Comparator|Placebo (Part A - azacitidine)|Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
89250990|NCT00321711|Placebo Comparator|Placebo (Part B - decitabine)|Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
89250991|NCT00486044|Experimental|simvastatin|simvastatin 40 mg nightly for 1 month then 80 mg nightly for 8 months
89250992|NCT00486044|Placebo Comparator|Placebo|Matching placebo tablet nightly for 9 months
89250993|NCT01018472|Experimental|Bifidobacterium infantis|
89250994|NCT01018472|Placebo Comparator|Placebo|
89250995|NCT04193462|Experimental|Post-partum depression- Dyadic psychotherapy|Mothers and infants will be treated with 8 weeks dyadic psychotherapy at their home using video-feedback of mother-infant interaction to discuss main issues in the mother-infant relationship.
89250996|NCT04193462|Active Comparator|Post-partum depression- Psycho-educational therapy|8 weeks of supportive therapy for the mother at her house, involving the baby. Each session will include different aspects of psycho-education regarding development of the baby.
89250997|NCT04193462|No Intervention|Control- Healthy mothers and their babies|No intervention for 8 weeks.
89250998|NCT00351273|Active Comparator|Azithromycin and Rifampin|Participants received Azithromycin and Rifampin
89250999|NCT00351273|Active Comparator|Doxycycline and Rifampin|Participants received Doxycycline and Rifampin
89251000|NCT00351273|Placebo Comparator|received placebo|Participants received placebo
89251001|NCT01018628|Active Comparator|Cohort 1 - Dose Level A (25 mg/day)|Cohort 1 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 25 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 25 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
89251002|NCT01018628|Active Comparator|Cohort 2 - Dose Level B (75 mg/day)|Cohort 2 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 75 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 75 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
89251003|NCT01018628|Active Comparator|Cohort 3 - Dose Level C (250 mg/day)|Cohort 3 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 250 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 250 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
89290310|NCT03633682|Experimental|Engagement Support|In the engagement support group, participants will be sent text messages that will encourage use of the app through tips, reminders, and encouraging messages.
89290311|NCT03633682|Other|No Engagement Support|Participants in this group will receive no text message support.
89290312|NCT02531789||Observation|45 patients receiving elective colorectal surgery
89290313|NCT01126320|Experimental|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
89251004|NCT01018628|Active Comparator|Cohort 4 - Dose Level D (500 mg/day)|Cohort 4 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 500 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 500 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
89251005|NCT01018628|Active Comparator|Cohort 5 - Dose Level E (1000 mg/day)|Cohort 5 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 1000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 1000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
89251006|NCT01018628|Active Comparator|Cohort 6 - Dose Level F (2000 mg/day)|Cohort 6 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 2000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 2000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
89251007|NCT01018628|Active Comparator|Cohort 7 - Dose Level G (3000 mg/day)|Cohort 7 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 3000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 3000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
89251008|NCT01018628|Active Comparator|Cohort 8 - Dose Level H (500 mg/day in fed state)|Cohort 8 will be administered at approximately the same time every dosing day and 30 minutes following the start of consumption of a standardized high-fat meal. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The dose of SRT2379 administered to subjects in the fed state is planned to be 500 mg, however this may be modified upwards or downwards following evaluation of safety and pharmacokinetic data from earlier cohorts. The fed cohort will be the final cohort dosed in the study.
89251009|NCT01018706||STEMI patients treated with PCI|Four hundred patients with STEMI treated with primary PCI or rescue PCI.
89251010|NCT00327717|Experimental|Zonisamide 100 mg tablet|
89251011|NCT00327717|Placebo Comparator|Placebo|
89251012|NCT03917810|Active Comparator|MODSUG|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
89251013|NCT03917810|Experimental|LOWSUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
89251014|NCT03917810|Experimental|LOWCHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
89251015|NCT03995810|Experimental|Carnosine|Carnosine, capsulle, 2 g/day, 8 weeks
89251016|NCT00463346|Experimental|Acamprosate|Acamprosate
89251017|NCT00463346|Placebo Comparator|placebo|placebo
89251018|NCT01025024||POAG group|Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect
89251019|NCT01025024||Normal control|Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease
89251020|NCT01022528|Experimental|Dexamethasone|
89251021|NCT01022528|Placebo Comparator|Saline|
89251022|NCT01025102|Experimental|Naropin 0.1%|
89251023|NCT00462488|Active Comparator|Treatment Schedule A -|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 6 weeks. If free of disease at 12 weeks after the first instillation, the subject enters Maintenance dosing in which 30 mg of Vicinium is administered once per week for 3 weeks followed by 9 weeks of no therapy.~If the subject had histologically confirmed disease that is stage <T2, they repeat the Induction phase dosing. If the subject is free of disease, the subject enters the maintenance dosing phase of every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 51 (end-of-study [EOS])."
89251024|NCT00462488|Active Comparator|Treatment Schedule B|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 12 weeks followed by 1 week of no therapy.~If 13 weeks after the first instillation of Vicinium the subject is free of disease, they have a break from therapy before entering Maintenance dosing in which 30 mg of Vicinium is administered once weekly for 3 weeks followed by 9 weeks of no therapy. If the subject is free of disease, additional maintenance cycle(s) are repeated every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 57 (EOS)."
89251025|NCT01025180|Other|Procalcitonin level|duration of the antibiotic treatment guided by procalcitonin level
89251026|NCT01025180|No Intervention|physician's appreciation|duration of the antibiotic treatment based on physician's appreciation
89290314|NCT01126320|Active Comparator|Control|routine mechanical ventilator
89251027|NCT00454142|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Pharmacological study will be done on Day 1 and Day 28. Computed tomography will be done at baseline and day 28."
89251028|NCT00424476|Placebo Comparator|Placebo|Placebo
89251029|NCT00424476|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
89251030|NCT00424476|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
89251031|NCT03994536|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses (transition coordinators) who meet the participants at three occasions during the study period and participants will be offered to meet peers with type 1 diabetes during an adolescent day.
89251032|NCT03994536|Experimental|Comparison group: Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
89251033|NCT01037634|Experimental|Oseltamivir|Participants will receive Oseltamivir to treat influenza.
89251034|NCT00453986|Experimental|Nimenrix A Group|subjects received 1 dose of Nimenrix™ Lot A at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
89251035|NCT00453986|Experimental|Nimenrix B Group|subjects received 1 dose of Nimenrix™ Lot B at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
89251036|NCT00453986|Experimental|Nimenrix C Group|subjects received 1 dose of Nimenrix™ Lot C at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
89251037|NCT00453986|Active Comparator|Mencevax ACWY Group|subjects received 1 dose of Mencevax™ ACWY vaccine at Month 0. Mencevax™ ACWY vaccine was administered by subcutaneous injection in the non-dominant upper arm.
89251038|NCT00453986|Experimental|Nimenrix+Fluarix Group|subjects received 1 dose of Nimenrix™ Lot A co-administered with Fluarix™ vaccines at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm. Fluarix™ vaccine was administered by intramuscular injection in the deltoid region of the dominant arm.
89251039|NCT01032252|No Intervention|observational|Control group: followed by monthly falls calenders and four testing periods
89251040|NCT01032252|Experimental|Exercise group|16 week intervention, and followed by monthly fall calenders as well as 4 testing periods
89251041|NCT00435942|Experimental|1|Endovascular Treatment arm to be implanted with Relay device
89251042|NCT00435942|Active Comparator|2|Surgical Control, underwent open repair
89251043|NCT01034748|Experimental|1|Single 45 mg oral dose of [14C]PF-00299804
89251044|NCT01034826||life style modification|everyone in this study was advised about their life style, diet, exercise habits.
89251045|NCT01037712|Experimental|ZELITREX|ZELITREX
89251046|NCT01037712|Placebo Comparator|Placebo|placebo
89251047|NCT00453362|Experimental|Erlotinib|"Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity.~After 14 days and after 56 days of treatment with Erlotinib participants underwent FDG-PET and FLT-PET scans."
89251048|NCT00424398|Experimental|Bepreve|Bepotastine Besilate Ophthalmic Solution 1.5%
89251049|NCT00424398|Placebo Comparator|Placebo|sterile ophthalmic solution
89251050|NCT00424398|Experimental|Bepotastine Besilate|sterile ophthalmic solution 1.0%
89251051|NCT01021514||Type 2 DM, Healthy control|Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
89251052|NCT01021514||Type 2 DM, Heatlhy control|
89251053|NCT00461786|Experimental|Pemetrexed|
89251054|NCT01021592||001|
89251055|NCT01021670||001|Dapoxetine hydrochloride One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
89251056|NCT01021670||002|Alternate care/non-dapoxetine hydrochloride treatment(s) As prescribed or directed
89251057|NCT01025258|Active Comparator|frequent clinic visits|
89251058|NCT00435162|Experimental|Low Dose|
89251059|NCT00435162|Experimental|Medium Dose|
89251060|NCT00435162|Experimental|High Dose|
89251061|NCT03836664|Experimental|Group 1: Timolol|Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
89251062|NCT03836664|Placebo Comparator|Group 2: Placebo|Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
89251063|NCT01037868|Experimental|Supportive SMS messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
89251064|NCT01037868|No Intervention|No supportive SMS text message|Patients in the non-intervention group would also receive text messages once every fortnight thanking them for participating in the study and a monthly phone call which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
89251065|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
89251066|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
89251067|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
89251068|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
89251069|NCT00350727|Experimental|Combination|Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.
89251070|NCT01032486||Azilect|Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.
89251071|NCT01032642|Experimental|thin catheter group|group of women where thin catheter will be used for hysterosalpingography
89251072|NCT00434304|Experimental|Ropinirole PR/XR|
89251073|NCT00424008|Experimental|MF/F MDI 200/10 mcg BID|Mometasone furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily.
89251074|NCT00424008|Active Comparator|F/SC DPI 250/50 mcg BID|Fluticasone propionate/salmeterol (F/SC) 250/50 mcg BID
89251075|NCT03994068|Experimental|VIVO mapping pre-procedure|15 patients with structurally normal heart and indication for PVC/VT catheter ablation, who will undergo pre-procedural non invasive mapping with VIVO mapping system.
89251076|NCT00423930|Experimental|IMRT + cisplatin + bevacizumab|This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.
89251077|NCT00423852|Experimental|chemotherapy with Stem Cell Support|This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.
89251078|NCT01037946|No Intervention|Standard Care Arm|Families living with HIV, offered intervention at the end of study (24 months after recruitment)
89251079|NCT01037946|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
89251080|NCT00461708|Experimental|Rash, Grade <2|Participants with a rash graded less than (<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
89251081|NCT00461708|Experimental|Rash, Grade ≥2|Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
89251082|NCT01032720|Experimental|Ultrasound-guided knee CS injection|Ultrasound will be used to image knee joint and guide needle for intra-articular knee CS injection.
89251083|NCT01032720|Sham Comparator|Sham Ultrasound knee CS injection|CS knee injection will be performed in the same method as the US-guided knee injection but the US machine will be turned off.
89251084|NCT00327171|Experimental|Aflibercept 2.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.
89251085|NCT00327171|Experimental|Aflibercept 4.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.
89251086|NCT01038024|Experimental|Antioxidant Supplements|
89251087|NCT03982875|Experimental|SmartBag arm|"The Alfred SmartBag System will be placed on the ostomy site during surgery. The system will be used to wirelessly monitor ostomy function in the hospital setting and the patient will otherwise receive the standard of care. At discharge the patient will continue to use the Alfred SmartBag System and ostomy function will be monitored by the research and clinical teams remotely.~If participant's output is (i) less than 50mL or greater than 1500mL per day or (ii) greater than 1200mL in two days; the mobile app will alert not only the participant but also the clinical staff (nurse).~Participants will also receive support from a 'Patient Coach', a trained health coach who is also an ostomy patient to provide quality of life support."
89251088|NCT03982719|Experimental|Brief protocol|4 intervention sessions with the occupational therapist of 30 minutes duration.
89251089|NCT03982719|Active Comparator|Intense Protocol|6 intervention sessions with the occupational therapist of 60 minutes duration.
89251090|NCT00461630|Experimental|ER niacin/laropiprant|1 g ER niacin plus 20 mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
89251091|NCT00461630|Active Comparator|Placebo|Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
89251092|NCT01061853|Experimental|T|TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE
89251093|NCT01061853|Active Comparator|C|TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL
89251094|NCT03982641||Colon surgery|patients diagnosed with colon cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
89251095|NCT03982641||Rectal surgery|patients diagnosed with rectal cancer, who undergone at least one surgical procedure at one of participating hospitals during the observational period
89251096|NCT00461552|Active Comparator|Leptin|Leptin weight and gender based dose, sub-cutaneous, twice daily. Leptin versus placebo for entire 6 months double-blind.
89251097|NCT00461552|Placebo Comparator|Placebo|Placebo , sub-Q injection twice daily.
89251098|NCT01325415|Experimental|A|NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
89251099|NCT01325415|Experimental|B|NKTR-118 150 mg (6x25 mg tablet)
89251100|NCT01325415|Placebo Comparator|C|NKTR-118 placebo (6x placebo tablets)
89251101|NCT01325415|Active Comparator|D|Moxifloxacin (1 x 400 mg tablet)
89251102|NCT03900806|Experimental|Basic Cognitive Rehabilitation|The basic arm will consist of a brief cognitive training programme without individual guidance throughout the intervention, involving three to five sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks.
89251103|NCT03900806|Experimental|Extensive Cognitive Rehabilitation|The extensive arm will consist of a comprehensive training program, involving five to eight sessions (each approximately 60 minutes in duration), which have to be completed in a period of 12 weeks. After the first session, each further session in the extensive group involves tailored therapy guidance . Cognitive strategy modules will be assigned by the therapist depending on the participants' cognitive profile and personal treatment goals.
89251104|NCT03900806|No Intervention|Waitlist control group|Participants in the waiting list control group will be offered the opportunity to follow the basic cognitive rehabilitation program after completion of the 26-week follow-up measurement.
89251105|NCT03894254|Experimental|Patients with subjective cognitive complaint or neurocognitive|: Real-life cohort patients with subjective cognitive complaint or neurocognitive disorders undergoing medical examination in memory centers, and for whom extensive evaluations will be performed for the study
89251106|NCT03850496|No Intervention|Group A|No device utilised for 6 weeks.
89251107|NCT03850496|Experimental|Group B|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
89251108|NCT03850496|Experimental|Group C|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
89251109|NCT03995888|Experimental|Healthy Volunteers|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
89251110|NCT03995888|Experimental|Patients|Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
89251111|NCT01022606|Other|Patients with walking limitation|Patients with claudication and Walking-Induced Transient Hack (W.I.T.H.) tcpO2 profiles are tested on treadmill with invasive pO2 arterial sampling and body temperature recording
89251112|NCT01022684||Healthy patients|
89251113|NCT01022840|Placebo Comparator|Placebo|Placebo as saline solution
89251114|NCT01022840|Experimental|Low dose|S-Ketamine
89251115|NCT01022840|Active Comparator|High dose|
89251116|NCT01025570|Experimental|Gem/Bos|"Gemcitabine 1000 mg/m2, D1,8,15 of each cycle~Bostutinib 400 mg daily concurrently with Gemcitabine"
89251117|NCT01021826||Hip and knee replacements recipients|Osteoarthritis patients undergoing elective primary hip and knee replacement and being followed-up in this study.
89251118|NCT03983876|Experimental|AVT02 100mg/mL in PFS|Prefilled Syringe Arm
89251119|NCT03983876|Experimental|AVT02 100mg/mL in Autoinjector|Autoinjector Arm
89251120|NCT00327015|Experimental|Saxagliptin and Metformin (A)|PLUS open-label pioglitazone (as needed as rescue medication)
89251121|NCT00327015|Experimental|Saxagliptin and Metformin (B)|PLUS open-label pioglitazone (as needed as rescue medication)
89251122|NCT00327015|Experimental|Saxagliptin and Placebo (C)|PLUS open-label pioglitazone (as needed as rescue medication)
89251123|NCT00327015|Active Comparator|Metformin and Placebo (D)|PLUS open-label pioglitazone (as needed as rescue medication)
89251124|NCT00434148|Experimental|Pasireotide 600 ug|At randomization, participants received 600 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 900ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
89251125|NCT00434148|Experimental|Pasireotide 900 ug|At randomization, participants received 900 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 1200 ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
89251126|NCT03983655|Experimental|Real High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device emits a pulsed magnetic field at an aproximate frequency of 125 hz and an intensity of 10 gauss.
89251127|NCT03983655|Sham Comparator|Sham High Frequency Low Intensity TMS|Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.
89251128|NCT03983499|Experimental|Special Intervention|The special intervention (SI) arm addresses glycemic control, medication adherence, control of modifiable CVD risk factors, health behavior change, and psychosocial and cultural barriers to self-management. The SI arm consists of a collaborative care team approach with four main elements including: 1) Specialized clinical care by a medical provider; 2) Specialized behavioral health care by a behavioral health provider; 3) Group-based chronic disease self-management education by peer-leaders; 4) Intensive, proactive care coordination facilitated by a patient registry and electronic health records.
89251129|NCT03983499|No Intervention|Usual Care|Participants randomized to the Usual Care (UC) arm continue to see their primary care provider and receive referrals to health education. At the discretion of the provider, UC patients are screened and referred to behavioral health (BH) care.
89251130|NCT01063569|Active Comparator|Oral hydrocortisone|
89251131|NCT01063569|Experimental|Continous subcutaneous hydrocortisone infusion|
89251132|NCT00468728|Active Comparator|1|Vancomycin
89251133|NCT00468728|Experimental|2|PAR-101/OPT-80
89251134|NCT01061931|Active Comparator|Arctic Front® catheter|
89251135|NCT01061931|Active Comparator|HD Mesh Ablator® catheter|
89251136|NCT00433914|Experimental|rMenB|6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
89251137|NCT00433914|Experimental|rMenB+OMV|6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
89251138|NCT03983265|Other|computer guided condylar reposition device|surgical procedure : under general anesthesia after BSSO condyle will be repositioned by computer guided repostioning device
89251139|NCT00468650|Active Comparator|Open label|Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.
89251140|NCT00423150|Experimental|Temozolomide|
89251141|NCT01038102|Active Comparator|PUFA diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%)
89251142|NCT01038102|Active Comparator|SFA diet|Diet high in saturated fat (15 E%)
89251143|NCT01038180||pacemaker group|
89251144|NCT00433836|Experimental|Valsartan 80 mg|
89251145|NCT00433836|Experimental|Valsartan 160 mg|
89251146|NCT00433836|Experimental|Valsartan 320 mg|
89251147|NCT00433836|Active Comparator|Enalapril 10 mg|
89251148|NCT00433836|Active Comparator|Enalapril 20 mg|
89251149|NCT00433836|Active Comparator|Enalapril 40 mg|
89251150|NCT01038258|Other|No arms|No arms
89251151|NCT01022918|Experimental|Bevacizumab/Irinoecan|"Neoadjuvant Treatment Patient will receive bevacizumab 10mg/kg plus irinotecan 125mg/m² 4 times every two weeks.~Radiochemotherapy Then they will receive conformational radiotherapy for 6 weeks (30 Gy, 2Gy/fractions) associated with Temodal ( 75mg/m²/day) from first day up to the end of radiotherapy and 4 injections of Avastin (15mg/kg Day 1, day 15, day 29 and day 43).~Adjuvant treatment:~Patients will receive bevacizumab 15mg/kg plus irinotecan 125mg/m² 12 times every two weeks."
89251152|NCT01022918|Active Comparator|Stupp|patient will receive 6 weeks chemotherapy treatment associating conformational 30 Gy (2Gy/ fraction)and Temodal(75mg/m²/day, followed by 6 months adjuvant therapy consisting in 5 days every 28 days of Temodal (150-200mg/m².
89251153|NCT00433446|Experimental|CNTO 328|
89251154|NCT00468104|Active Comparator|Alteplase, Placebo- intapleural instillation|Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
89251155|NCT00468104|Active Comparator|Placebo, Alteplase -2nd arm|If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days
89251156|NCT00326625|Experimental|40 mg glatiramer acetate (GA)|Pre-filled syringe of 40 mg glatiramer acetate (GA) for injection, administered subcutaneously once a day.
89251157|NCT00326625|Placebo Comparator|Placebo|Pre-filled syringe of matching placebo, administered subcutaneously once a day.
89251158|NCT00433290|Experimental|A|
89251159|NCT00433290|Placebo Comparator|B|
89251160|NCT00467870|Experimental|1|750 mg dose of testosterone undecanoate
89251161|NCT00467870|Experimental|2|1000 mg dose testosterone undecanoate
89251162|NCT01021982||Glaucoma|Glaucoma Patients with visual field defects
89251163|NCT01021982||Retinitis Pigmentosa|Retinitis Pigmentosa Patients with visual field defects
89251164|NCT01022060|Experimental|A|Renalof
89251165|NCT01022060|Placebo Comparator|B|Placebo
89251166|NCT00467558|Active Comparator|Naltrexone|Naltrexone 50mg-150mg by mouth per day.
89251167|NCT00467558|Placebo Comparator|Placebo|Placebo pills (1-3 pills daily) depending upon dose prescribed by study physician
89251168|NCT00422292|Experimental|Menactra® at 9 and 12 Months|Participants will received Menactra® vaccination at 9 and 12 months of age.
89251169|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + MMRV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age
89251170|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + PCV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age
89251171|NCT00422292|Active Comparator|MMRV + PCV at 12 Months|Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age
89251172|NCT01038414|Placebo Comparator|Brief-Duration Counseling|3-Month Duration
89251173|NCT01038414|Active Comparator|Moderate Duration Counseling|6-Month Duration
89251174|NCT01038414|Active Comparator|Extended Duration Counseling|12-Month Duration
89251175|NCT00452348|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
89251176|NCT00452348|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
89251177|NCT00452114|Active Comparator|Assignment to In-Exsufflator Cough Assist Device|In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily
89251178|NCT00452114|Active Comparator|Assignment to flutter valve device|flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily
89251179|NCT01323062|Other|Single-arm trial|Single-arm trial
89251180|NCT00320541|Active Comparator|paclitaxel plus bevacizumab (PB)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
89251181|NCT00320541|Experimental|paclitaxel plus bevacizumab plus gemcitabine (PB+G)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
89251182|NCT03982563|Experimental|Growth Mindset|
89251183|NCT03982563|Experimental|Gratitude|
89251184|NCT03982563|Experimental|Behavioral Activation|
89251185|NCT03982563|Sham Comparator|Study Skills|
89251186|NCT00320385|Experimental|Arm 1: Lapatinib plus Trastuzumab|Lapatinib 1000mg once daily in combination with trastuzumab 4mg/kg loading dose followed by 2mg/kg weekly
89251187|NCT00320385|Experimental|Arm 2: Lapatinib|Lapatinib 1500mg once daily
89251188|NCT01063725|Experimental|Femarelle|Women will receive Femarelle twice daily for 12 weeks
89251189|NCT01063725|Placebo Comparator|Placebo|Women will take placebo capsules twice daily for 12 weeks
89251190|NCT00326001|Experimental|Gold tip catheter|Gold tip catheter
89251191|NCT00326001|Active Comparator|Platinum-iridium tip catheter|Platinum-iridium tip catheter
89251192|NCT00309777|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
89251193|NCT00309777|Active Comparator|Simvastatin 20 mg|Simvastatin 20 mg once daily
89251194|NCT00309777|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
89251195|NCT00309777|Active Comparator|Simvastatin 40 mg|Simvastatn 40 mg once daily
89251196|NCT00309387|Experimental|Centrum|multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.
89251197|NCT00309387|Placebo Comparator|placebo|placebo pills. One tablet a day for the whole study duration.
89251198|NCT03982797|Experimental|treated with IMUNO BCG Moreau RJ adjuvant.|
89251199|NCT00325143|Experimental|Infanrix Hexa Group|Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.
89251200|NCT00319839|Experimental|Abraxane plus Cetuximab|Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.
89251201|NCT01062087||Local anesthetic|Women who received local anesthetic during surgery in addition to general anesthesia
89251202|NCT01062087||No local anesthetic|Women who did not receive any local anesthetic during surgery, but did have general anesthesia
89251203|NCT00319449|Experimental|Ezetimibe 10 mg|Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
89251204|NCT00319449|Placebo Comparator|Placebo 10 mg|Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
89251205|NCT00308997|Experimental|1|Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
89251206|NCT00308997|Sham Comparator|2|sham rTMS to Wernicke's area and a right homologous area
89251207|NCT00308685|Experimental|Albuterol-HFA-BAI|ProAir(TM) HFA, Breath Actuated Inhalation Aerosol
89251208|NCT00308685|Placebo Comparator|Placebo-HFA-BAI|Placebo
89251209|NCT01060839|Experimental|Single session counseling|
89251210|NCT01060839|No Intervention|Standard of care|
89251211|NCT03981159|Experimental|Active group (under physical training)|Subjects belonging to this arm underwent physical training for three months, twice per week (60 minutes per session).
89251212|NCT03981159|No Intervention|Passive group (no physical training)|Subjects served as controls.
89251213|NCT03981237|Experimental|Root canal treatment with laser-activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of a pulsed erbium laser. The canals are then dried and obturated.
89251214|NCT03981237|Active Comparator|Root canal treatment with ultrasonically activated irrigation|In these patients, the root canals of the tooth are chemomechanically prepared. After shaping, irrigant activation is performed by means of an ultrasonically driven instrument. The canals are then dried and obturated.
89251215|NCT03982251|Experimental|High frequency whole body vibration|This group will receive a single 8-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
89251216|NCT03982251|Active Comparator|low frequency whole body vibration|This group will receive a single 12-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
89251217|NCT01060995||SmartConsent|Subjects receiving SmartConsent informed consent
89251218|NCT01060995||Standard consent|Subjects receiving standard consent
89251219|NCT00317109|Experimental|AC primed Group|
89251220|NCT00317109|Active Comparator|AC unprimed Group|
89251221|NCT03982329|Active Comparator|nrTMS group|15 minutes low-frequency nrTMS (1 Hz) of the uneffected hemisphere at 7 consecutive days
89251222|NCT03982329|Sham Comparator|sham group|15 minutes sham stimulation of the uneffected hemisphere at 7 consecutive days
89251223|NCT03981081|Experimental|eosinophil-guided group|patients will receive prednisone at a dose of 1mg/kg/day for up to 5 days or during the hospital stay if less than 5 days, only if the eosinophil count is> 2%
89251224|NCT03981081|Active Comparator|control group|a treatment based on prednisone at a daily dose of 1 mg/kg will be routinely administered for a maximum of 5 days, or during the hospital stay, if it is less than 5 days
89251225|NCT03979287|Experimental|IFC and Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour. Participants will receive treatment with Interferential current therapy plus a program of therapeutic exercise focused on the neck region
89251226|NCT03979287|Active Comparator|Therapeutic Exercise Program|Patients will receive 10 sessions for two weeks. The duration of each session will be of approximately one hour.This group will only receive the same therapeutic exercise program.
89251227|NCT01062243|Experimental|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
89251228|NCT03979209|Experimental|Mometasone 1mg|1mg capsule dissolved in 240mg saline solution nasal irrigation
89251229|NCT03979209|Experimental|Mometasone 2mg|2mg capsule dissolved in 240mg saline solution nasal irrigation
89251230|NCT03979209|Experimental|Mometasone 4mg|4mg capsule dissolved in 240mg saline solution nasal irrigation
89251231|NCT00316719|Experimental|Adefovir Dipivoxil (ADV)|
89251232|NCT00316719|Active Comparator|Lamivudine (LAM)|
89251233|NCT03979053||Patients with AIH|60 adult participants will be recruited who are over the age of 18 and are attending a hepatology appointment at KCH NHS FT and are either being investigated for AIH or have confirmed AIH
89251234|NCT01065987|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
89251235|NCT01065987|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
89251236|NCT01062321||Hepatitis-E, Pregnant & Non-pregnant|Pregnant,Acute Viral Hepatitis, Fulminant Hepatic Failure
89251237|NCT01063959|Other|Safety|Chart review will evaluate the safety of the two procedures, incidence of complications operatively, hospital stay, and 6-week post-operative periods.
89251238|NCT01063959|Experimental|Weight Loss|Chart review will evaluate weight loss in subjects during the operative, 6-week post-operative, and follow-up of at least 18 months.
89251239|NCT01063959|Other|Insurance versus Private Pay|An insurance company issues an insurance policy to cover specific complications from the gastric bypass or the sleeve gastrectomy surgery which allows the surgeon to offer a fixed price to the patient. Comparison of surgical complications in subjects paying by insurance versus paying personally for the gastric bypass operation.
89251240|NCT01066065||Raltegravir Cohort|Patients taking RAL 400 mg BID with Truvada
89251241|NCT01066065||Darunavir Cohort|Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada
89251242|NCT03978975|Active Comparator|normal weight women|20 women with a body mass index ranging between 18,5 and 24,9 kg.m2
88804861|NCT01346839|Experimental|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
89251243|NCT03978975|Experimental|overweight women|20 women with a body mass index ranging between 25 and 29,9 kg.m2
89251244|NCT01064115|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
89251245|NCT01064115|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
89251246|NCT00422058|Placebo Comparator|Lira placebo/Lira 2.4 mg/Lira 3.0 mg|Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
89251247|NCT00422058|Experimental|Lira 1.2 mg/Lira 3.0 mg|Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
89251248|NCT00422058|Experimental|Lira 1.8 mg/Lira 3.0 mg|Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
89251249|NCT00422058|Experimental|Lira 2.4 mg/Lira 3.0 mg|Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
89251250|NCT00422058|Experimental|Liraglutide 3.0 mg|Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
89251251|NCT00422058|Active Comparator|Orlistat|Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)
89251252|NCT02720952|Experimental|Infacort|"Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).~The clinically-appropriate dose, based on standard individualised treatment, will be administered, given as a single dose orally. This will usually be equivalent to the previous day's dose."
89251253|NCT00413244|Experimental|Androgel treatment|"Androgel 5 grams~Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
89251254|NCT00413244|Placebo Comparator|Placebo|Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
89251255|NCT01033032|Experimental|Amrubicin Phase I/II|Systemic therapy with amrubicin
89251256|NCT01032876|Experimental|Deep Hypothermic Circulatory Arrest|
89251257|NCT01032876|Experimental|Antegrade Cerebral Perfusion|
89251258|NCT01038492|Experimental|p16 Methylation in Sputum Testing|"Patients tested for smoking-related changes in their breathing~shown a presentation on development of lung cancer~complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic detail~given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~patients are called again at three months and asked about any changes in their attitudes or smoking habits"
89251259|NCT02316522||Group I: T2D nephropathy|Individuals with type 2 diabetes and nephropathy
89251260|NCT02316522||Group II: T2D and no nephropathy|Individuals with type 2 diabetes and no nephropathy
89251261|NCT02316522||Group III: Control, non-diabetic|Non-diabetic individuals with normal kidney function
89251262|NCT02316522||Group IV: Controls, non-diabetic|Non-diabetic individuals with hypertensive nephropathy
89251263|NCT00420420|Experimental|MK0249|
89251264|NCT00420420|Placebo Comparator|placebo|
89251265|NCT01038570|Experimental|Oxytocin|
88806093|NCT05435820|Experimental|BPW-1 group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: pulsed wave, 10 Hz; 50% duty cycle iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
89251266|NCT01038570|Placebo Comparator|Physiological serum|
89251267|NCT00420342|Experimental|0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
89251268|NCT00420342|Experimental|2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
89251269|NCT00420342|Active Comparator|1.5 mg MPA / 0.3 mg CEE (Prempro)|1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
89251270|NCT00432744|Active Comparator|CoenzymeQ10|CoenzymeQ10: patients will be randomized to receive CoenzymeQ10 in either Period #1 (Months 0-6) or Period #2 (Months 7-12).
89251271|NCT00432744|Placebo Comparator|Placebo|Placebo: patients will be randomized to receive placebo either ion Period #1 (months 1-6) or Period #2 (months 7-12).
89251272|NCT01038648|Placebo Comparator|1|Advice life style at baseline only
89251273|NCT01038648|Active Comparator|sitagliptin arm : 2|"100mg/day sitagliptin~advice on life style modification at baseline only"
89251274|NCT00432666|Experimental|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
89251275|NCT00432666|Placebo Comparator|Placebo|
89251276|NCT00451958|Experimental|Degarelix 80 mg / Degarelix 80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
89251277|NCT00451958|Experimental|Degarelix 160 mg / Degarelix 160 mg|"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
89251278|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 80 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
89251279|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 160 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
89251280|NCT01025804||Infants|
89251281|NCT01023152|Experimental|Automated cuff-inflator|
89251282|NCT01025882|Experimental|Regimen 1|Patients undergo a single fraction of margin-intensive stereotactic body radiotherapy (SBRT) on day 1. Patients undergo pancreatoduodenectomy between days 15-43.
89251283|NCT01025882|Experimental|Regimen 2|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients undergo a single fraction of SBRT between days 21-28 followed by pancreatoduodenectomy between days 35-63.
89251284|NCT01025960|Other|Standard Inspection Colonoscopy|The colonoscope will be inserted rapidly to reach the cecum. Inspection of the large bowel will occur during the withdrawal of the colonoscope.
89251285|NCT01025960|Active Comparator|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
89251286|NCT01026116|Active Comparator|EC-wP|epirubicin/cyclophosphamide followed weekly paclitaxel
89251287|NCT01026116|Experimental|EP-wP|epirubicin/paclitaxel followed by weekly paclitaxel
89251288|NCT01026272||healthy subjects|subjects with no sign of inflammatory disease, or diagnosis of MS
89251289|NCT01026272||Patients with MS|
89251290|NCT00432276|Experimental|Alogliptin 25 mg + Pioglitazone 30 mg add-on to Metformin|Alogliptin 25 mg, tablets, orally, once daily; pioglitazone 30 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
89251291|NCT00432276|Active Comparator|Pioglitazone 45 mg add-on to Metformin|Alogliptin placebo-matching tablets, orally, once daily; pioglitazone 45 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
89251292|NCT01022216|Active Comparator|V.A.C.® Therapy|Vacuum Assisted Closure device that utilizes controlled negative pressure
89251293|NCT01022216|Experimental|Procellera™ Wound Dressing with V.A.C.® Therapy|Procellera wound dressing used as a primary contact layer on the wound bed, used in conjunction with NPWT
89251294|NCT01022294|Experimental|Arm 1|Inhalation of nitrousoxide-oxygen during the first experimental session; inhalation of atmospheric air during the second session
89251295|NCT01022294|Experimental|Arm 2|Inhalation of atmospheric air during the first experimental session; inhalation of nitrousoxide-oxygen during the second session
89251296|NCT01027442|Placebo Comparator|Conventional implant placement method|"The patients in ths group will be treated by conventional, free-hand implant placement"
89251297|NCT01027442|Active Comparator|Computer-guidedimplant placement|In this group, the patients will be treated by implants placed via computer generated SLA guides
89251298|NCT01027520|Experimental|Intervention|Application of Coban dressing
89251299|NCT01023230|Experimental|DV-601|
89251300|NCT03993990|Experimental|Experimental group|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation).
89251301|NCT03993990|No Intervention|Control group|Participants will receive routine care of the research setting only. The counseling will be provided if participants request.
89251302|NCT01027676|Experimental|study arm|single arm Gefitinib plus vorinostat
89251303|NCT01027832|No Intervention|Control arm|no intervention
89251304|NCT01027832|Experimental|Experimental arm|antibiotics
89251305|NCT00413010|Placebo Comparator|Arm 2|
89251306|NCT00413010|Experimental|Arm 1|
89251307|NCT00459290|Experimental|Mifepristone 200 mg PO daily|Mifepristone 200 mg PO daily administered on a continuous basis (every 4 weeks is considered one cycle) until disease progression or adverse effects prohibit further therapy.
89251308|NCT00443534|Experimental|1|
89251309|NCT00419952|Experimental|Symbicort|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
89251310|NCT00419952|Experimental|Budesonide|Budesonide HFA pMDI 160 ug x 2 actuations BID
89251311|NCT00443456|Experimental|Single|
89251312|NCT00419562|Experimental|Oral Insulin|7.5 mg oral insulin capsules given before breakfast on a daily basis.
89251313|NCT00419562|Placebo Comparator|Placebo|Placebo capsule designed to match appearance of treatment capsule
89251314|NCT03557294|Experimental|1.0mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; days 4 through 7: 0.5mg, twice daily; days 8 through end of treatment: 1mg, twice daily.
89251315|NCT03557294|Experimental|0.5mg varenicline b.i.d.|Days 1 through 3: 0.5mg, once daily; 0.5 mg b.i.d. dose starting at day 4 through the end of the study
89251316|NCT03557294|Placebo Comparator|0.0mg placebo varenicline b.i.d.|Days 1 through 3: 0.0mg placebo once daily; days 4 through 7: 0.0mg placebo twice daily; days 8 through end of treatment: 0.0 mg placebo twice daily.
89251317|NCT01026350|Experimental|study group|
89251318|NCT01026428|Experimental|Safinamide + Levodopa|
89251319|NCT01026428|Placebo Comparator|Placebo + Levodopa|
89251320|NCT00432042|Experimental|ProQuad® + Infanrix® hexa|Pediatric (12 to 23 months of age) participants received ProQuad® and Infanrix® hexa (booster dose) concomitantly on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
89251321|NCT00432042|Active Comparator|ProQuad®|Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
89251322|NCT00432042|Active Comparator|Infanrix® hexa|Pediatric (12 to 23 months of age) participants received Infanrix® hexa (booster dose) on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
89251323|NCT00308139|Experimental|Exenatide Once Weekly|Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
89251324|NCT00308139|Active Comparator|Exenatide Twice Daily|"subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study.~Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device."
89251325|NCT00459134|Experimental|Arm I: ArginMax|ArginMax® 3 pills twice daily
89251326|NCT00459134|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo 3 pills twice daily
89251327|NCT00459056|Experimental|Carvediolol CR + Lisinopril, then Lisinopril + HCTZ|Subjects were randomly assigned to Carvedilol CR + Lisinopril for three months, then had a washout period of one month, and then were given Lisinopril + HCTZ for the final three months.
89251328|NCT00459056|Active Comparator|Lisinopril + HCTZ, then Carvedilol CR + Lisinopril|Subjects were randomally assigned to Lisinopril + HCTZ for three months, then had a washout period for one month, and then were given Carvedilol CR + Lisinopril for the final three months.
89251329|NCT01062477|Experimental|Study Group 1|Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age.
89251330|NCT01062477|Experimental|Study Group 2|Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age.
89251331|NCT01062477|Active Comparator|Study Group 3|Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age.
89251332|NCT01066221||Clostridium difficile patients|observational study
89251333|NCT00431964|Active Comparator|Active|azithromycin 250 mg tablets
89251334|NCT00431964|Placebo Comparator|Placebo|placebo tablets (matched to active drug in appearance)
89251335|NCT03531476|Experimental|Online chronic pain management program|There is only one arm. Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
89251336|NCT01322906|Other|Group A|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
89251337|NCT01028066|Active Comparator|Traditional|Traditional nutritional counseling
89251338|NCT01028066|Experimental|Behavioral|Dialogic nutritional counseling
89251339|NCT00431496|Experimental|Cinacalcet|Cinacalcet was administered orally at a starting dose of 30 mg/day for 23 weeks. Possible sequential doses during the study were 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet occurred if the intact parathyroid hormone (iPTH) level from the previous study visit was > 31.8 pmol/L (300 pg/mL) unless the participant had either reached the maximum dose (180 mg/day), the serum corrected total calcium was < 2.1 mmol/L (8.4 mg/dL), or the participant experienced an adverse event that precluded a dose increase.
89251340|NCT00316173|Experimental|Single-arm|HYCAMTIN at a dose of 2.0 - 2.5mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1, every 21 days
89251341|NCT00412542|Experimental|Thalidomide + CPT-11|Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.
89251342|NCT00316017|Experimental|1|7.5% hypertonic saline/6% Dextran-70 (HSD)
89251343|NCT00316017|Experimental|2|7.5% hypertonic saline (HS)
89251344|NCT00316017|Placebo Comparator|3|0.9% normal saline
89251345|NCT00451178|Experimental|R-CHOP and Enzastaurin|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
89251346|NCT00451178|Active Comparator|R-CHOP|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
89251347|NCT00450866|Experimental|Epothilone B|
89251348|NCT01322984|Active Comparator|Normal controls|Normal children and youths
89251349|NCT01322984|Experimental|ASD|Children and youths diagnosed with autism spectrum disorder (ASD)
89251350|NCT01026584|Other|drug|
89251351|NCT01026662||Abdominoplasty|Subjects scheduled for abdominoplasty surgery
89251352|NCT01028456|Placebo Comparator|100 lux|100 lux / 30 minutes day
89251353|NCT01028456|Experimental|Light Therapy 10,000 lux|10,000 lux / 30 minutes a day for 3 months
89251354|NCT01023464|Other|Period 1|FID 114657 or SootheXP
89251355|NCT01023464|Other|Period 2|FID 114657 or SootheXP
89251356|NCT01023542|Active Comparator|1|Basiliximab 20 mg day 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low level cyclosporine [start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)] + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx.
89251357|NCT01023542|Active Comparator|2|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + low-level cyclosporine (start within 30 days after LTx; trough level 100-150ng/mL (CsA).
89251358|NCT01023542|Experimental|3|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + everolimus (start within 30 days after LTx; trough-level 6-10 ng/mL).
89251359|NCT01026740|Experimental|001|Ceftobiprole 500 mg, single infusion over 2 hours
89251360|NCT03848312|Experimental|Computerized Cognitive Training|Participants will complete computerized cognitive training.
89251361|NCT03848312|Active Comparator|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities.
89251362|NCT01028534|Active Comparator|ARB plus increased ARB|angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months
89251363|NCT01028534|Active Comparator|ARB plus CCB|angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months
89251364|NCT01028534|Active Comparator|CCB plus ARB|calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months
89251365|NCT03995342|Experimental|exprimental: Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
89251366|NCT03995342|Placebo Comparator|Active comparator: maltodextrin|Placebo (maltodextrin) 15grams after dissolution by mouth， every morning for three months.
89251367|NCT01023698|Experimental|photocoagulation|Laser photocoagulation
89251368|NCT00442598|Experimental|Glufosfamide q21 days|1-hour infusion of glufosfamide at a dose of 5,000 mg/m2 on Day 1 of a 21-day cycle
89251369|NCT00442598|Experimental|Glufosfamide q7 days low|1-hour infusion of glufosfamide at a dose of 1,660 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
89251370|NCT00442598|Experimental|Glufosfamide q7 days high|1-hour infusion of glufosfamide at a dose of 2,500 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
89251371|NCT01028612|Experimental|thermal ablation with external beam radiation|
89251372|NCT00442286|Experimental|On|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
89251373|NCT00442286|Experimental|Off|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
89251374|NCT00441974|Experimental|Single arm adefovir dipivoxil|adefovir dipivoxil once daily orally 10 mg
89251375|NCT01023854|Experimental|Continuous Paravertebral block|Continuous Paravertebral block
89251376|NCT01023854|Placebo Comparator|Placebo|Placebo
89251377|NCT00441584|Experimental|PegIntron plus Rebetol|PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks
89251378|NCT03368534|Experimental|Skin Wound Patients|Patients will receive ART for wound healing and will be followed for 28 days to determine success of the procedure.
89251379|NCT01028690|Active Comparator|Lactobacillus reuteri|L. reuteri is one species of lactobacillus that naturally inhabits the gastrointestinal tract of humans
89251380|NCT01028690|Placebo Comparator|placebo|Placebo will be delivered in a chewable tablet form (1.5g per dose)
89251381|NCT00430716|Experimental|Sildenafil High dose|
89251382|NCT00430716|Experimental|Sildenafil Low dose|
89251383|NCT00430716|Experimental|Sildenafil medium dose|
89251384|NCT00430716|Experimental|Sildenafil - Open label Phase|Open label extension from week 12 to week 24.
89251385|NCT01023932||Auditory Neuropathy Patients|
89251386|NCT01028768|Experimental|Teduglutide|
89251387|NCT02648256|Experimental|Oropharyngeal rinse|"Polymerase Chain Reaction on Oropharyngeal rinse:~Dosage of Pneumocystis jiroveci will be performed on the broncho-alveolar lavage following the usual routine diagnosis.~Polymerase Chain Reaction will be performed on the broncho-alveolar lavage and the oropharyngeal rinse (not communicated to the clinician result) in the same series, in order to compare the results of the fungal quantification."
89251388|NCT01024088||GBS PATIENT|
89251389|NCT01024088||CONTROL|
89251390|NCT01034904||Patients|Patients who have moderate or severe Hemophilia A, living in Canada and who are using Helixate FS either on-demand or prophylaxis
89251391|NCT01038726|Active Comparator|Exercise Training|
89251392|NCT01038726|Active Comparator|Combined Cognitive/Exercise Training|
89251393|NCT01038726|Active Comparator|Cognitive Training|
89251394|NCT01038726|Active Comparator|Combined Low Intensity Training|
89251395|NCT01566552|Other|SINGLE DOSE AMBISOME|
89251396|NCT01028924|Experimental|Teduglutide 5 mg|Treatment A, subcutaneous injection
89251397|NCT01028924|Experimental|Teduglutide 20 mg|Treatment B, subcutaneous injection
89251398|NCT01028924|Placebo Comparator|Placebo|subcutaneous injection
89251399|NCT01028924|Active Comparator|Moxifloxacin|400 mg, oral
89251400|NCT00430638|Experimental|Treatment|Olmesartan medoxomil, plus hydrochlorothiazide, if necessary
89251401|NCT00430638|Placebo Comparator|Placebo|Placebo tablets were taken once daily for 12 weeks
89251402|NCT01029080||Sepsis|All patients with sepsis defined by actually sepsis guidelines
89251403|NCT01566110|Experimental|Diet Intervention Group|
89251404|NCT01566110|No Intervention|Control Group|Subjects assigned to the control group will continue their usual diet. They will receive dietary teaching at each study visit as part of their diabetes management.
89251405|NCT01038882|Active Comparator|Midazolam|The patients of this arma receives midazolam before the flexible bronchoscopy to maintain conscious sedation
89251406|NCT01038882|Placebo Comparator|Physiological serum|
89251407|NCT00430482|Experimental|1|Cognitive Behavioral Therapy
89251408|NCT00430482|Active Comparator|2|Individual Counseling
89251409|NCT00449930|Experimental|1|Drug
89251410|NCT00449930|Active Comparator|2|Active comparator
89251411|NCT01034982|Experimental|1|tosylate salt tablet
89251412|NCT01034982|Experimental|2|free suspension
89251413|NCT01034982|Experimental|3|tosylate salt tablet
89251414|NCT01034982|Experimental|4|free suspension
89251415|NCT01038960|Experimental|Exercise training|training
89251416|NCT01038960|No Intervention|Not training|No organized training
89251417|NCT00449696|Experimental|Gel-200|
89251418|NCT00449696|Placebo Comparator|PBS|
89251419|NCT01024166||Patient|Patient computer system use questionnaire
89251420|NCT01024166||Caregiver|Caregiver computer system use questionnaire
89251421|NCT01024166||Healthcare Provider|Physician and Nurse computer system use questionnaire
89251422|NCT01566188|Experimental|omega-3 from vegetal origin|
89251423|NCT01566188|Placebo Comparator|Placebo|
89251424|NCT01029158|Experimental|1a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
89251425|NCT01029158|Experimental|1b|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
89251426|NCT01029158|Experimental|1c|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
89251427|NCT01029158|Experimental|1d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
89251428|NCT01029158|Experimental|2a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
89251429|NCT01029158|Experimental|2b|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
89251430|NCT01029158|Experimental|2c|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
89251431|NCT01029158|Experimental|2d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose (i.e. two doses in total).
89251432|NCT00441116|Placebo Comparator|Dutasteride|Dutasteride
89251433|NCT01024322||Ciprofloxicine or Vigamox or other.|
89251434|NCT01024322||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
89251435|NCT01024322||Steroid (FML, Pred Forte, Flarex, etc.)|
89251436|NCT03320642|Experimental|Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions|Itacitinib in combination with a CNI-based intervention.
89251437|NCT01029314||Cardiopulmonary bypass surgery|Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).
89251438|NCT01566266|Experimental|Amoxicillin|
89251439|NCT01566266|Placebo Comparator|Placebo capsules|
89251440|NCT01024400|Experimental|vaccine|
89251441|NCT00430248|Experimental|Febuxostat 40 mg QD|
89251442|NCT00430248|Experimental|Febuxostat 80 mg QD|
89251443|NCT00430248|Active Comparator|Allopurinol 200 mg or 300 mg QD|(dependent on renal function)
89251444|NCT00449540|Active Comparator|Active Transcranial Magnetic Stimulation (TMS) Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
89251445|NCT00449540|Sham Comparator|Sham TMS Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
89251446|NCT01029470|Experimental|Luveris|Those subjects who experience hyponresponse to FSH stimulation during mid-follicle phase after pituitary downregulation will receive Luveris 75IU or 150IU IH injection daily till HCG day.
89251447|NCT00411762|Experimental|PHY906 Administration|PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle
89251448|NCT00429858|Experimental|Targeted therapy group|Gemcitabine monotherapy until disease progression, followed by gemcitabine + S-1
89251449|NCT01323738|No Intervention|Treatment as Ususal|Patients participate in the Treatment as Usual including a non-specific information group.
89251450|NCT01323738|Experimental|Psychoeducation|Intervention group
89251451|NCT01035216|Experimental|GNKG168|The starting dose will be 0.25 mg/kg. If the dose is tolerable, subsequent cohorts will be enrolled and treated with 0.5, 0.75, 1.0 and 1.5 mg/kg. If 0.25 mg/kg proves to be intolerable, the dose will be reduced to 0.15 mg/kg.
89251452|NCT01039116|Experimental|Level of intervention intensity|"High Intensity: Behavioral Experimental:Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.~Active Comparator: Low-intensity Participants were provided with educational materials 4 times yearly."
89251453|NCT01035294|Experimental|mindfulness based intervention|
89251454|NCT01035294|Active Comparator|usual care (UC)|
89251455|NCT01035372|Experimental|dried plum|subjects will have 25% by weight (~ 600 kcal if eat 2500 kcal diet) of their usual diet substituted by dried plum powder
89251456|NCT00449150|Experimental|Treatment Group A: CET 78 mg + 78 mg|"Treatment course 1: Cetrorelix 78 mg + 78 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: 26 mg CET(1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
89251457|NCT00449150|Experimental|Treatment Group B: CET 78 mg + 52 mg|"Treatment course 1: Cetrorelix 78 mg + 52 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: Placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
89251458|NCT00449150|Placebo Comparator|Treatment Group C: Placebo|"Treatment course 1:~Week 0: placebo (2 injections)~Week 2: placebo (1 injection)~Treatment course 2:~Week 26: placebo (2 injections)~Week 28: placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
89251459|NCT00428844|Experimental|Daptomycin 6 mg/kg|Daptomycin (6 mg/kg every 24 hours [q24h]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
89251460|NCT00428844|Experimental|Daptomycin 8 mg/kg|Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
89251461|NCT00428844|Active Comparator|Comparator|Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).
89251462|NCT00457418|Experimental|PEG-Intron|"6 ug/kg/week, SC (first 8 weeks)~3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance)"
89251463|NCT01039194|Active Comparator|galantamine 8 mg (ER)|
89251464|NCT01039194|Active Comparator|galantamine 16 mg (ER)|
89251465|NCT01039194|Active Comparator|BMS-708163|
89251466|NCT00449072|Placebo Comparator|Placebo|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of investigational product (IP) with the nasal spray bottle~Placebo in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
89251467|NCT00449072|Active Comparator|TAA-AQ|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of IP with the nasal spray bottle~Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
89251468|NCT00428610|Experimental|LY573636|LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
89251469|NCT02593656|Experimental|High Protein|Ingestion of 2.0 grams of protein per kilogram of body weight per day combined with exercise training
89251470|NCT02593656|Active Comparator|Normal Protein|Ingestion of 1.0 gram of protein per kilogram of body weight per day combined with exercise training
89251471|NCT01033266||CPET CPAP|
89251472|NCT00419094|Experimental|Keppra XR 1000 mg/day|1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
89251473|NCT00419094|Experimental|Keppra XR 2000 mg/day|2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)
89251474|NCT00448916|Experimental|Pregabalin|Orally-administered pregabalin
89251475|NCT00418938|Experimental|Arm A|FOLFIRI + Panitumumab
89251476|NCT00418938|Experimental|Arm B|FOLFIRI + Bevacizumab
89251477|NCT03279224|Active Comparator|Allogenic FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.
89251478|NCT03279224|Placebo Comparator|Autologous FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.
89251479|NCT01039272||oral cancer|patients with oral squamous cell carcinoma
89251480|NCT01039272||control group|healthy patients without any oral pathology
89251481|NCT01029626|Other|Endoscopy|If the Glasgow-Blatchford score is zero, the endoscopy is delayed as an outpatient
89251482|NCT03996122||resistant patients with schizophrenia|Age 18 - 60 years No MRI contraindication
89251483|NCT00448760|Experimental|Neoadjuvant + Adjuvant Chemotherapy|
89251484|NCT00418314|Experimental|QuickOpt (Treatment)|Frequent optimization using QuickOpt to optimize the AV/PV and VV Delays.
89251485|NCT00418314|Active Comparator|Control|Empiric programming or one-time optimization using a non-IEGM method.
89251486|NCT01033344|Placebo Comparator|Placebo|Solution resembling active solution but without peptides
89251487|NCT01033344|Experimental|Group 1|Cat-PAD dose group 1
89251488|NCT01033344|Experimental|Group 2|Cat-PAD Dose group 2
89251489|NCT00448448|Active Comparator|Brace|This study involves full-time, rigid TLSO's only. Braced subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning. Orthotic evaluations are conducted every 6 months as as necessary to maintain brace fit and function.
89251490|NCT00448448|Active Comparator|Observation|Observation. Observed subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning.
88806094|NCT05435820|Experimental|BPW-2 group|"NIR-TLT dose:~i. Treatment site(s): EEG F3 and F4 ii. Temporal format: pulsed wave, 40-50 Hz; 50% duty cycle iii. Average radiance: 350 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 3.6 kJ (1.8 kJ per treatment location)"
89251491|NCT01039506||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 based regimens
89251492|NCT01033500|Experimental|SIK|Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
89251493|NCT01033578|No Intervention|Control|Receive hepatectomy and thrombectomy alone, no postoperative adjuvant treatments
89251494|NCT01033578|Experimental|PVIC Group|Portal Vein Infusion Chemotherapy (PVIC): 5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) was continuously infused into portal vein through tube by a infusion pump implanted in operation. Treatment started 2 weeks after the operation and was repeated every 4 weeks for six cycles.
89251495|NCT01033578|Experimental|TACE Group|Transcatheter Arterial Chemoembolization (TACE): 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
89251496|NCT01033578|Experimental|PVIC+TACE Group|Combination of PVIC and TACE. PVIC started 2 weeks after operation and TACE started 6 weeks after operation. Both PVIC and TACE were repeated at 8 weeks intervals for 3 cycles.
89251497|NCT01035450|Experimental|Everolimus-eluting stent|
89251498|NCT01035450|Active Comparator|Sirolimus-eluting stent|
89251499|NCT01035528|Active Comparator|insulin glargine|antidiabetic treatment with Lantus o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
89251500|NCT01035528|Active Comparator|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
89251501|NCT03994458|Experimental|Experimental|Participants get the full program for 6 weeks.
89251502|NCT03994458|Placebo Comparator|Placebo|Participants get the placebo program for 6 weeks.
89251503|NCT01039662|Experimental|Oolong tea containing L-arabinose and indigestible dextrin|
89251504|NCT01039662|Placebo Comparator|Oolong tea|
89251505|NCT01033656|Experimental|Anakinra|experimental drug of study
89251506|NCT01033656|Active Comparator|comparator|comparators:methotrexate, azathioprine, leflunomide or supfasalazine
89251507|NCT01039740|Experimental|Responders|Reponders is a patients group who showed 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
89251508|NCT01039740|Experimental|Non-responders|Non-responders is a patients group who did not show 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
89251509|NCT01589172||Pediatric Brain Trauma Patients|
89251510|NCT01036308|Experimental|TypTop|Lupinus albus Typ Top (lupin kernel fibre, dietary fibre content: 83%)
89251511|NCT01036308|Experimental|Soy fibre|Glycine max Hefeng (soy fibre; dietary fibre content: 77%)
89251512|NCT01036308|Experimental|Boregine|Lupinus angustifolius Boregine (lupin kernel fibre, dietary fibre content: 87%)
89251513|NCT00405912|Placebo Comparator|Placeo|Placebo pill was identical in appearance to the active medication.
89251514|NCT00405912|Experimental|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tablets, 3 times a day.
89251515|NCT00405912|Experimental|St. John's Wort-1800 mg/day|St. John's Wort - 600 mg 3 times per day
89251516|NCT00448136|Experimental|1|
89251517|NCT00448136|Experimental|2|
89251518|NCT00307437|Placebo Comparator|Group I: Placebo|
89251519|NCT00307437|Experimental|Group II: Ustekinumab 45 mg|
89251520|NCT00307437|Experimental|Group III: Ustekinumab 90 mg|
89251521|NCT03978819||Patients with large CPA tumors|Patients with large cerebellopontine angle tumors (>2 x 2cm) undergoing elective surgery
89251522|NCT00440726|Experimental|Ph 1 Dose Escalation|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.
89251523|NCT00440726|Experimental|Ph 2 Efficacy and Safety|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.
89251524|NCT01029938|Active Comparator|Covered stent|The Willis covered stent specifically designed for intracranial vasculature was developed by our institution and the MicroPort Medical Company (Shanghai, China), and coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
89251525|NCT01029938|Active Comparator|Coil|Coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
89251530|NCT01030016|Experimental|atenolol|subjects received 6 weeks of atenolol
89251531|NCT03995420|Experimental|Virtual Reality Therapy (V-NeST)|Participants in this arm will receive Virtual Reality Therapy (V-NeST) plus treatment as usual (TAU).
89251532|NCT03995420|Other|Treatment as Usual|Participants in this arm will receive treatment as usual (TAU) only.
89251533|NCT03996278||Patients in the Grafalon group|Patients in the Grafalon group (n=150) will be followed prospectively and data prospectively collected thanks to the Astre database
89251534|NCT03996278||Patients in the Thymoglobulin group|Patients in the thymoglobulin group (n=150) will be selected and analyzed retrospectively from the Astre database
89251535|NCT00447590|Experimental|LAP-BAND|All subjects who received the LAP-BAND System.
89251536|NCT01024634|Other|African American Group|A group of young African American males and females
89251537|NCT01024634|Other|Caucasian Group|a group of young Caucasian men and women
89251538|NCT00447278|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
89251539|NCT00447278|Active Comparator|OEST|Other Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
89251540|NCT01030094||Topiramate|Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
89251541|NCT01030094||Carbamazepine|Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
89251542|NCT01030094||Valproic acid|Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
89251543|NCT01030094||Normal Control|Healthy female participants will be observed in Normal control group.
89251544|NCT01565798|Experimental|Copper Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with copper surfaced objects.
89251545|NCT01565798|No Intervention|Standard Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with standard surfaced objects
89251546|NCT01030328|Active Comparator|TriLipix + Atorvastatin|Two tables of TriLipix + Atorvastatin taken once a day by mouth.
89251547|NCT01030328|Placebo Comparator|2|2 sugar pills
89251548|NCT00446966|Experimental|fish oil , corn oil|Highly purified pharmaceutical grade omega three polyunsaturated fatty acids
89251549|NCT00446966|Placebo Comparator|placebo|olive oil
89251550|NCT01565876|Experimental|study|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
89251551|NCT00446654|Experimental|CGC-11047 once every 2 weeks|16.5 mg CGC-11047 as a subconjunctival injection once every two weeks.
89251552|NCT00446654|Experimental|CGC-11047 once every four weeks|16.5 mg CGC-11047 as a subconjunctival injection once every four weeks.
89251553|NCT03162302||Healthy Subjects|Healthy volunteers will undergo 60 minute non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
89251554|NCT03162302||Clinical Patients|Patients in whom an MRI is indicated for their disease condition will undergo the clinical scan, followed by up to 30 minutes non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences. Clinical patients may also elect to undergo a research only scan of approximately one hour.
89251555|NCT00405756|Experimental|MPR+R|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
89251556|NCT00405756|Experimental|MPR+p|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
89251557|NCT00405756|Other|MPp+p|Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
89251558|NCT00456092|Experimental|Apremilast 40 mg QD|"Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks.~The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 40 mg QD thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication."
89251559|NCT00456092|Experimental|Apremilast 20 mg BID|Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
89251560|NCT00456092|Placebo Comparator|Placebo|Participants received matching placebo to apremilast orally BID for 12 weeks during the Treatment Phase. Participants who entered the Extension Phase were re-randomized on Day 85 to receive either 40 mg apremilast QD or 20 mg apremilast BID for 12 weeks.
89251561|NCT01040442|Experimental|vibration stimuli|
89251562|NCT01030562||Alternate Arm|Subjects who meet eligibility requirements but do not fit into any of the primary experimental arms.
89251563|NCT01030562||Control Arm|Subjects with an on-time interval between Dose 1 and 2 and an on-time interval between Dose 2 and 3.
89251564|NCT01030562||Experimental/Primary Arm 1|This primary arm will consist of subjects receiving the second dose on time/third dose substantially late.
89251565|NCT01030562||Experimental/Primary Arm 2|This primary arm will consist of subjects receiving the second dose substantially late/third dose on time.
89251566|NCT01030562||Experimental/Primary Arm 3|This primary arm will consist of subjects receiving the second dose substantially late/third dose substantially late.
89251567|NCT01030640|Placebo Comparator|placebo|formulation without active drug
89251568|NCT01030640|Active Comparator|tanezumab|
89251569|NCT00411450|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until disease progression, intolerability, death, or study withdrawal.
89251570|NCT00404820|Experimental|Zoledronic acid 5 mg|Patients received zoledronic acid 5 mg in 100 ml solution in a 15 minute intravenous (iv) infusion once per year. The peripheral iv infusion was preceded by and followed by a 10 ml normal saline flush of the intravenous line. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
89251571|NCT00404820|Active Comparator|Alendronate 70 mg|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal. Patients were to remain in an upright position for 30 minutes after swallowing the tablet. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
89251572|NCT00417612|Experimental|1|Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
89251573|NCT00417612|Placebo Comparator|2|Participants given placebo capsule to match for comparison
89251574|NCT00446030|Experimental|Stratum 1: TAC + Bevacizumab|"Human epidermal growth factor receptor-2 (HER2) negative participants stratified at registration, were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
89251575|NCT00446030|Experimental|Stratum 2: TCH + Bevacizumab|"HER2 positive participants stratified at registration, were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
89251576|NCT00411216|Experimental|exercises for gaze stabilization|Experimental group performed vestibular adaptation and substitution exercises
89251577|NCT00411216|Placebo Comparator|Control exercises|Saccadic eye movements against a Ganzfeld to prevent retinal slip error signal; no head movements
89251578|NCT03995732|Experimental|40 mg treatment group|PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
89251579|NCT03995732|Experimental|80 mg treatment group|PC-SOD 80 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
89251580|NCT03995732|Experimental|160 mg treatment group|PC-SOD 160 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
89251581|NCT03995732|Placebo Comparator|placebo control group|placebo dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
89251582|NCT01323816||Traditional|ICU staffed by a resident, pulmonary fellow and attending
89251583|NCT01323816||Non-Traditional|ICU staffed by Nurse Practitioners as the direct care deliverer, a pulmonary fellow, and an attending
89251584|NCT01027052|Active Comparator|Hamburger meat patty with Spice Blend|Hamburger meat patty containing spice blend will be consumed on 3 separate occasions
89251585|NCT01027052|Placebo Comparator|Hamburger meat patty with salt|Hamburger meat patty containing salt will be consumed on 3 separate occasions
89251586|NCT00410514|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
89251587|NCT00410514|Experimental|Mirabegron 50 mg|Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
89251588|NCT00410514|Experimental|Mirabegron 100 mg|Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
89251589|NCT03995498|Active Comparator|Individualized carbohydrate intake|"Based on glucose sensor level, carbohydrate (orange juice, Oasis classic) will then be given as follow:~If sensor glucose level is under < 4.5 mmol/L, the camp staff will treat hypoglycemia according to the camp procedure, If sensor glucose level is between 4.5 and 7.0 mol/L, 0.5g of CHO/kg body weight will be given, If sensor glucose level is between 7.1 and 10.0 mmol/L, 0.25g of CHO/kg body weight will be given, If sensor glucose level is between 10.1 and 15.0 mmol/L, no CHO will be given, If sensor glucose level is > 15.1 mmol/L, the camp staff will treat hyperglycemia according to the camp procedure."
89251590|NCT03995498|Active Comparator|Usual camp protocol|As per camp routine care, there will be no mandatory glucose level measurement before the start of physical activity if no symptoms of hypoglycemia or hyperglycemia appear.
89251591|NCT01036854|Experimental|Regime 1|Regime 1 will be orally administered once daily in the morning over 6 consecutive days.
89251592|NCT01036854|Active Comparator|Regime 2|Regime 2 will be orally administered twice daily at 12 hours interval (morning and evening) over 6 consecutive days
89251593|NCT01036854|Active Comparator|Regime 3|Regime 3 will be orally administered three times daily at 8 hour intervals (morning, afternoon, evening) over 6 consecutive days.
89251594|NCT01036854|Experimental|Regime 4|Regime 4- Day 1- a single dose will be given. Day 2- one placebo capsule; Day 3- a single dose will be given . Day 4 & 5- two placebo capsules on each day; Day 6- a single does will be given.
89251595|NCT03843632|Experimental|VARIVAX™|All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.
89251596|NCT01027130||healthy control|240 female subjects without preeclampsia
89251597|NCT01027130||preeclampsia|120 female subjects with preeclampsia
89251598|NCT03994718|Experimental|Music|The musician will either offer music that can either be played for the participant or an instrument so they can experience playing themselves. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. The outpatient music intervention will consist of providing a recording of similar music for the participant to listen to for at least 30 minutes per week, along a with telephone call session with the music therapist.
89251599|NCT03994718|Experimental|Visual art|The creative visual artist will assess interest in spending time using the materials provided. Participants will be offered watercolor painting, drawing, or adult coloring. There will be a guided activity based on their art making preference. A standardized prompt will be utilized for both writing and visual art sessions. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For remote follow-up sessions, participants will be supplied with a small art kit to use at home.
89251600|NCT03994718|Experimental|Creative writing|The writer will ask the participant about their interests and experiences in writing or storytelling. The following options are offered; introduction to journaling, storytelling or writing exercises with prompts to get started, interactive writing or storytelling activities. For participants who are unable to write or prefer not to, the writer can scribe their words on a laptop and print them out. The duration of the intervention will be determined by participant interest and tolerance, but not to exceed 60 minutes. For follow-up sessions, participants will be supplied with a journal.
89251601|NCT00439556|Experimental|Treatment (chemotherapy, transplant, filgrastim, tacrolimus)|See Detailed Description
89251602|NCT00410202|Active Comparator|Entecavir|With the option of adding tenofovir at week 48. (This does not apply to Korea)
89251603|NCT00410202|Active Comparator|Adefovir + Lamivudine|
89251604|NCT00410202|Active Comparator|Entecavir + Adefovir|
89251605|NCT03802058|Experimental|Nab-paclitaxel|Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy
89251606|NCT03893838||Post refractive surgery without HOA|Patients post refractive surgery that do not complain on the high order aberrations such as glare, halo and starburst.
89251607|NCT03893838||Post refractive surgery with HOA|Patients post refractive surgery that do complain on the high order aberrations such as glare, halo and starburst.
89251608|NCT03893838||Post refractive surgery with rainbow HOA|"Patients post refractive surgery that do complain on:~the high order aberrations such as glare, halo and starburst but with the chromatic aureola~difficulties working with LCD projectors, monitors, cell phones and tablets"
89251609|NCT00445328|Active Comparator|B|
89251610|NCT00445328|Experimental|A|
89251611|NCT00455312|Experimental|Patients with DC|Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.
89251612|NCT00455312|Experimental|Patients with SAA|Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.
89251613|NCT01031108|Other|Type 2 Diabetic Group|The Type 2 Diabetic Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
89251614|NCT01031108|Other|Otherwise Healthy Cigarette Smoking Group|The Otherwise Healthy Cigarette Smoking Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
89251615|NCT01031186|Experimental|Cohort 1, Session 1|In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.
89251616|NCT01031186|Experimental|Cohort 1, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.
89251617|NCT01031186|Experimental|Cohort 1, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.
89251618|NCT01031186|Experimental|Cohort 1, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.
89251619|NCT01031186|Experimental|Cohort 1, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.
89251620|NCT01031186|Experimental|Cohort 2, Session 1|In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.
89251621|NCT01031186|Experimental|Cohort 2, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.
89251622|NCT01031186|Experimental|Cohort 2, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.
89251623|NCT01031186|Experimental|Cohort 2, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.
89251624|NCT01031186|Experimental|Cohort 2, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
89251625|NCT01323452||Chronic HBV patients|Patients with chronic hepatitis B Treated for at least 3 months No HIV, HCV or HDV.
89251626|NCT03994640|Experimental|Cannabis cream|Cannabis cream topical skin application in experimental group
89251627|NCT03994640|Placebo Comparator|Placebo cream|Placebo cream topical skin application in control group
89251628|NCT00444626|Experimental|DGE|Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment period were treated with DGE as an open-label treatment.
89251629|NCT00444626|Active Comparator|Restylane|Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.
89251630|NCT01024790|Experimental|Exercise group|
89251631|NCT01024790|No Intervention|Usual care|
89251632|NCT01031264||Social drinkers|
89251633|NCT01024868||TAP block|Patients before undergoing laparoscopic or other abdominal surgery
89251634|NCT04748120|Active Comparator|Operative management|Treatment with surgery
89251635|NCT04748120|Active Comparator|Non-operative management|Treatment with antibiotics
89251636|NCT00404352|Active Comparator|RNF 44 mcg three times weekly|
89251637|NCT00404352|Active Comparator|RNF 44 mcg once weekly and placebo twice weekly for blinding|
89251638|NCT00404352|Placebo Comparator|Placebo three times weekly|
89251639|NCT03994380|Experimental|Intervention|rhDNAse 2.5 mg nebulizer daily for 4 weeks
89251640|NCT00439244|Active Comparator|Zoledronic acid plus teriparatide|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion. Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
89251641|NCT00439244|Experimental|Zoledronic acid|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion.
89251642|NCT00439244|Active Comparator|Placebo zoledronic acid plus teriparatide|Placebo zoledronic acid 100 mL intravenous (i.v.) (once at randomization) plus teriparatide 20 μg (daily subcutaneous injections administered concurrently through 52 weeks). Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
89251643|NCT01031342|Experimental|Early colonoscopy|Colonoscopy performed within 12 hours of presentation
89251644|NCT01031342|Active Comparator|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
89251645|NCT04844762|Active Comparator|usual brand menthol cigarette (UBMC)|Study participant's usual brand menthol cigarette
89251646|NCT04844762|Active Comparator|menthol roll-your-own cigarette (mRYO)|Mentholated pipe tobacco in a roll-your-own cigarette tube
89251647|NCT04844762|Active Comparator|menthol filtered little cigar (mFLC)|The menthol filtered cigar will be Cheyenne (Cheyennecigars.com) Seneca (senecacigars.com)
89251648|NCT04844762|Active Comparator|non-menthol cigarette (nmC)|The non-menthol cigarette will be Newport non-menthol cigarettes.
89251649|NCT03794024||Dorsal Column Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
89251650|NCT03794024||Dorsal Root Ganglion Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Axium Neurostimulator System
89251651|NCT01323296|Active Comparator|Ferumoxytol|Patients will be administered intravenous ferumoxytol 1 - 3 days following myocardial infarction after baseline cardiac magnetic resonance scanning.
89251652|NCT01323296|No Intervention|Control|Subjects who have suffered myocardial infarction will undergo cardiac magnetic resonance imaging at the same time points as those in the 'ferumoxytol' arm but will not receive ferumoxytol or placebo.
89251653|NCT00438464|Experimental|Arm I (Finasteride)|Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
89251654|NCT00438464|Placebo Comparator|Arm II (Placebo)|Placebo once daily for 4-6 weeks, then undergo prostatectomy.
89251655|NCT00437294|Experimental|Capecitabine + Enzastaurin|
89251656|NCT00437294|Placebo Comparator|Capecitabine + Placebo|
89251657|NCT01033760|Experimental|arm 1|darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir
89251658|NCT01033760|Active Comparator|arm 2|darunavir, ritonavir, emtricitabine/tenofovir
89251659|NCT00443846|Experimental|Group 1: Concomitant Administration|Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
89251660|NCT00443846|Active Comparator|Group 2: Sequential Administration|Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.
89251661|NCT01027208|Experimental|Ixabepilone|
89251662|NCT03619772|Experimental|Bilateral|Participants will control game using EMG from both upper limbs.
89251663|NCT03619772|Active Comparator|Unilateral|Participants will control game using the more impaired upper limb.
89251664|NCT01031732|Experimental|Two-incision|MIS-2 THA
89251665|NCT01031732|Experimental|Watson-Jones|MIS-WJ
89251666|NCT01031732|Experimental|MIS-AL|
89251667|NCT01031732|Experimental|MIS-PL|
89251668|NCT02923544|Experimental|total laparoscopic or robotic-assisted hysterectomy|The YUMI manipulator will be placed at the start of each case. During the surgery, the surgeon will track any intraoperative complications. The surgeon fellow will also note the feasibility of placing the uterine manipulator.After surgery, the surgeon will complete the product evaluation form.
89251669|NCT01033838|Active Comparator|laparoscopic-assisted rectosigmoid resection|
89251670|NCT01033838|Experimental|laparoscopic rectosigmoid resection and transrectal retrieval|
89251671|NCT01033994|Experimental|AS902330|
89251672|NCT01033994|Placebo Comparator|Placebo|
89251673|NCT02911610|Experimental|Arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
89251674|NCT02911610|Other|volar plate|surgery of wrist fractures with volar plate
89251675|NCT01031888|Active Comparator|1|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy receiving topical insulin eye drops in addition to conventional postoperative eye drops
89251676|NCT01031888|Active Comparator|2|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving topical insulin eye drops in addition to conventional postoperative eye drops
89251677|NCT01031888|Placebo Comparator|3|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy treated with conventional postoperative eye drops
89251678|NCT01031888|Placebo Comparator|4|corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving conventional postoperative eye drops
89251679|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (DB period)|Participants received cladribine tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 milligram per kilogram (mg/kg) along with interferon (IFN)-beta therapy (Rebif® new formulation [RNF] 44 mcg three times a week, subcutaneously; Avonex® 30 microgram (mcg) every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the Double blind period (DBP) of 96 weeks.
89251680|NCT00436826|Placebo Comparator|Placebo, IFN-beta (DB period)|Participants received matching placebo tablets orally over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the DB period of 96 weeks.
89251681|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the open label (OL) extension (Ext.) period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
89251682|NCT00436826|Placebo Comparator|Placebo, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received placebo initially and completed DB period entered in the OL Ext. period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
89251683|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (Safety follow up)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
89251684|NCT00436826|Placebo Comparator|Placebo, IFN-beta (Safety follow up)|Participants who received placebo initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
89251685|NCT00410124|Experimental|RAD001 +BSC|The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
89251686|NCT00410124|Placebo Comparator|Placebo (plus BSC)|Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
89251687|NCT01036932|Active Comparator|G-CSF group|Patients with Acute on chronic liver failure after baseline investigations for the etiology of the acute event and the underlying chronic disease were given Granulocyte Colony Stimulating Factor therapy for a total duration of one month.
89251688|NCT01036932|Placebo Comparator|Placebo|After baseline characterization and work up for underlying acute and chronic liver disease, patients were given placebo along with the standard therapy
89251689|NCT03889860||Uveitis group|
89251690|NCT03889860||Control group|age and sex matched group to the uveitis group
89251691|NCT00410046|Experimental|Etanercept (ETN)|Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
89251692|NCT00416624|Experimental|Epoetin alfa - 40000 units|40,000 Units
89251693|NCT00416624|Experimental|Epoetin alfa - 80000 units|80,000 Units
89251694|NCT00416624|Experimental|Epoetin alfa - 120000 Units|120,000 Units
89251695|NCT00416624|Experimental|Darbepoetin alfa***|500 mcg
89251696|NCT01037504|Experimental|A|Drug: AZD5423
89251697|NCT01037504|Placebo Comparator|B|Drug: Placebo
89251698|NCT00262600|Active Comparator|Dabigatran dose 2|twice a day
89251699|NCT00262600|Active Comparator|Warfarin|once a day
89251700|NCT00262600|Active Comparator|Dabigatran dose 1|twice a day
89251701|NCT00409578|Placebo Comparator|Placebo|Placebo tablets and capsules
89251702|NCT00409578|Experimental|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
89251703|NCT00409578|Experimental|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.
89251704|NCT00409578|Experimental|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
89251705|NCT03884088|Experimental|Experimental Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
89251706|NCT03884088|Active Comparator|Control Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
89251707|NCT03881436|Experimental|Pelvic MRI|"This arm involves patients undergoing a pelvic MRI.~At the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
89251708|NCT03881436|Experimental|Pelvic surgery|"This arm involves patients undergoing a pelvic surgery and coming for a postoperative MRI. An additional MRI is performed before the surgery and additional sequences are added to the planned postoperative MRI, at the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
89251709|NCT01037322|Active Comparator|cannabidiol in drops|cannabidiol given in drops of olive oil sub lingual 5 mg twice daily
89251710|NCT01037322|Placebo Comparator|placebo in drops|olive oil given in drops sub lingual
89251711|NCT01039818|Active Comparator|Radiodine-200µCi|A subgroup of patients with Graves' Disease and goiter ≥48ml treated with 200µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU, from a randomized controlled trial run at our institution between February 1997 and March 2000, serves as a historical control.
89251712|NCT01039818|Experimental|Radiodine-250µCi|Patients with Graves' Disease and goiter ≥48ml, prospectively assigned to receive 250 µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU.
89251713|NCT01037400||Total Knee Replacement Patients|Forty men and women ages 18-75 undergoing unilateral (n = 20) or bilateral (n = 20) knee replacement surgery with no musculoskeletal injury requiring medical attention in the past 3 months or producing pain in the previous 2 weeks and no inflammatory disease other than osteoarthritis.
89251714|NCT01039896|Experimental|Group1|SLM0807
89251715|NCT01039896|Experimental|Group2|SLM0807 and HKB0701
89251716|NCT00428090|Experimental|Rosiglitazone|XR (extended release) oral tablets
89251717|NCT00428090|Other|Placebo|Placebo (Double-Dummy to Match)
89251718|NCT00416312||Conventional & Patient-Specific Dosimetry|Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
89251719|NCT01031966|Active Comparator|H1N1sw monovalent vaccine|
89251720|NCT01031966|Experimental|Thymosin alpha 1 3.2mg|
89251721|NCT01031966|Experimental|Thymosin alpha 1 6.4 mg|
89251722|NCT00436436|Experimental|O6-benzylguanine & Temozolomide in Glioblastoma|Patients receive O6-benzylguanine intravenous over 1 hour and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89251723|NCT00262522|Experimental|LPV/r 800/200 mg QD Tablet|
89251724|NCT00262522|Experimental|LPV/r 800/200 mg QD SGC (Through Week 8)|
89251725|NCT00262522|Active Comparator|LPV/r 400/100 mg BID Tablet|
89251726|NCT00262522|Active Comparator|LPV/r 400/100 mg BID SGC (Through Week 8)|
89251727|NCT00436280|Experimental|Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)|
89251728|NCT00250588|Experimental|Problem solving + care coordination|Problem solving skills training and asthma care coordination
89251729|NCT00250588|Experimental|Asthma care coordination|Asthma care coordination
89251730|NCT00250588|Active Comparator|Wait-list control|Usual care
89251731|NCT03584958||Ab interno goniotomy surgery|Gonioscopy-assisted transluminal trabeculotomy (GATT) surgery to decrease intraocular pressure.
89251732|NCT03584958||Gelatin stent surgery|Subconjunctival stent (Xen) surgery to decrease intraocular pressure.
89251733|NCT03584958||Suprachoroid stent and cataract surgery|Suprachoroidal stent (Cypass) to decrease intraocular pressure in combination with cataract surgery.
89251734|NCT03584958||Trabeculectomy surgery|Glaucoma filtering surgery to decrease intraocular pressure.
89251735|NCT03584958||Cataract surgery|Cataract surgery with no glaucoma procedure.
89251736|NCT00416078|Experimental|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
89251737|NCT00416078|Active Comparator|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
89251738|NCT01039974|Experimental|Cohorts 1-2|Cohorts 1 and 2 will complete both periods Period 1 GSK962040 single dose Period 2 Ketoconazole repeat dose (10 days), GSK962040 single dose
89251739|NCT01032122|Experimental|rituximab|
89251740|NCT01040676|No Intervention|Control Group|"Patients in this (the control group) will be eligible to receive the intervention (see Intervention Group) after 12 weeks (essentially when the trial is over)."
89251741|NCT01040676|Experimental|Intervention Group|Patients in the intervention group will receive automated telephone calls at regular intervals twice a week. The system will be programmed to call them at these intervals until contact. The ATNS system will solicit information from them in a culture specific manner, inquiring as to what foods they are eating each meal, each day, and each month. The ATNS system will then make proactive suggestions regarding low glycemic index foods, giving encouragement and feedback as appropriate.
89251742|NCT02481674|Experimental|VX15/2503|The study drug VX15/2503 will be administered via monthly intravenous infusions
89251743|NCT02481674|Placebo Comparator|Placebo|A placebo control will be administered via monthly intravenous infusions
89251744|NCT00394524|Experimental|Computer assisted IV insulin infusion|Subjects in this group will receive continuous intravenous (IV) Insulin Infusion using glucommander computer guided system. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
89251745|NCT00394524|Active Comparator|Standard insulin infusion algorithm|Subjects in this group will receive Insulin using Standard insulin infusion algorithm. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
89251746|NCT01032278|Experimental|Cardiac Biomarker Testing|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI), and symptom questionnaires of participants undergoing anthracycline-based chemotherapy.
89251747|NCT00409344|Placebo Comparator|1|Normal Saline
89251748|NCT00409344|Active Comparator|Dexmedetomidine|Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.
89251749|NCT01040754|Active Comparator|Acupuncture|
89251750|NCT01040754|No Intervention|Waitlist Control|
89251751|NCT00415610|Other|Tier 1|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 170 to 200 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
89251752|NCT00415610|Other|Tier 2|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 140 to 170 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
89251753|NCT00415610|Other|Tier 3|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 110 to 140 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
89251754|NCT00394212|Experimental|1|Transoral suturing of the dilated gastrojejunostomy
89251755|NCT00394212|Sham Comparator|2|Sham Endoscopy (suturing not performed)
89251756|NCT01722812|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion on left body side), Cromoglicate (on a lesion on right body side)
89251757|NCT01722812|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion on right body side), Cromoglicate (on a lesion on left body side)
89251758|NCT01323842||rule in renal colic|ED patients with abdominal/flank pain where a diagnosis of renal colic is being considered and undergoing formal imaging while in the ED
89251759|NCT01032356|Experimental|Dynasplint|Patients will be treated with the current standard of care and the Wrist Extension Dynasplint.
89251760|NCT00250432|Active Comparator|1|50 mg intravenous (IV) infusion (diluted with 9% saline) administered daily (following a 70-mg IV loading dose on Day 1), over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
89251761|NCT00250432|Experimental|2|150 mg intravenous (IV) infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
89251762|NCT00250276|Experimental|Cervarix Lot1 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 1 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
89251763|NCT00250276|Experimental|Cervarix Lot2 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 2 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
89251764|NCT00250276|Experimental|Cervarix Lot3 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 3 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
89251765|NCT00250276|Experimental|Cervarix Low Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine manufactured lower scale-80L according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
89251766|NCT02532088|Active Comparator|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 12 months
88806095|NCT05435820|Sham Comparator|SHAM group|"NIR-TLT dose:~i. Treatment site(s): none ii. Temporal format: none iii. Average radiance: 0 mW / cm2 iv. Exposure time: 429 sec. v. Total fluence delivered: 0 kJ"
89251767|NCT02532088|Placebo Comparator|Placebo|Placebo
89251768|NCT00249808|Experimental|Efalizumab|
89251769|NCT00278512|Experimental|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant will be performed on eligible patients
89251770|NCT00278512|Experimental|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed on eligible patients
89251771|NCT03974698|Active Comparator|Anterolateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
89251772|NCT03974698|Active Comparator|Lateral approach|Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
89251773|NCT01072240||Cohort|
89251774|NCT00427934|Placebo Comparator|2|
89251775|NCT00427934|Experimental|1|This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.
89251776|NCT03974542|Experimental|telephone outreach|
89251777|NCT03974542|No Intervention|control|
89290315|NCT03971981|Experimental|100% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
89251778|NCT00435188|Experimental|Arm 1|Behavioral: Multi-component physical activity counseling program A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
89251779|NCT00435188|No Intervention|Arm 2|Usual care
88806096|NCT01478581|Experimental|Cohort 1|PCI-32765 420 mg per day
89251780|NCT00427778|Experimental|Incontinence ring then no intervention|Participants first were fitted with an incontinence ring, which they wore continuously for 4 weeks. The ring wa then removed and a washout period of 2 weeks followed. Then the second 4-week period with no ring was completed.
89251781|NCT00427778|Experimental|No intervention then incontinence ring|Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.
89251782|NCT02848196|Experimental|Stereotactic body radiation therapy|Oligometastatic patients with adrenal gland metastases are treated with high dose of Stereotactic Body Radiation Therapy delivered with VMAT/Rapid Arc technique.
89251783|NCT00427700|Active Comparator|Clomiphene|Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
89251784|NCT00427700|Experimental|Raloxifene|Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
89251785|NCT00409188|Experimental|Tecemotide (L-BLP25)|
89251786|NCT00409188|Placebo Comparator|Placebo|
89251787|NCT00434954|Experimental|Exenatide Twice Daily (BID)|
89251788|NCT00434954|Active Comparator|Premixed Insulin Aspart Twice Daily (BID)|
89251789|NCT00276484|Active Comparator|1|Atorvastatin 80 mg
89251790|NCT00276484|Experimental|2|Atorvastatin 40 mg + ezetimibe 10 mg
89251791|NCT00426842|Experimental|Arm 1|Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.
89251792|NCT00434876|Experimental|1|Quetiapine XR
89251793|NCT00434876|Placebo Comparator|2|Placebo
89251794|NCT01072318|Experimental|Letrozole, DFS|Efficacy evaluation of extended letrozole after 5 year fareston use
89251795|NCT01072474|Experimental|Capnography|Arm with capnographic monitoring
89251796|NCT01072474|Placebo Comparator|Standard|Standard monitoring.
89251797|NCT01072552||Treated|Palivizumab treated
89251798|NCT01072552||Untreated|Palivizumab untreated
89251799|NCT00276094|Experimental|Ospemifene 30 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 30 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
89251800|NCT00276094|Experimental|Ospemifene 60 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
89251801|NCT00276094|Placebo Comparator|Placebo tablets and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of placebo each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
88806097|NCT01478581|Experimental|Cohort 2|PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week
88806098|NCT01478581|Experimental|Cohort 3|PCI-32765 840 mg per day
89251802|NCT03975088|Other|Persistent Diabetic macular edema|Authors defined refractory DME as eyes with persistent DME despite receiving at least 6 monthly Ranibizumab injections of anti VEGF, and then switched to Aflibercept, receiving at least three monthly injections.
89251803|NCT00276016|Experimental|Phenylephrine, Pseudoephedrine, Placebo|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules."
89251804|NCT00276016|Experimental|Pseudoephedrine, Placebo, Phenylephrine|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
89251805|NCT00276016|Experimental|Placebo, Phenylephrine, Pseudoephedrine|"Placebo: Placebo capsules.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
89251806|NCT00276016|Experimental|Phenylephrine, Placebo, Pseudoephedrine|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
89251807|NCT00276016|Experimental|Pseudoephedrine, Phenylephrine, Placebo|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration.~Placebo: Placebo capsules."
89251808|NCT00276016|Experimental|Placebo, Pseudoephedrine, Phenylephrine|"Placebo: Placebo capsules.~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
89251809|NCT00434642|Experimental|Carboplatin and gemcitabine + bevacizumab|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
89290316|NCT03971981|Experimental|22% Xylitol|The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums.
89251810|NCT00434642|Active Comparator|Carboplatin and gemcitabine + placebo|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.
89251811|NCT01032434|Experimental|sertraline|sertraline: 50-200mg/day
89251812|NCT01032512|Experimental|IMMUNE-ENHANCING|"40 patients will be instructed to consume 600 ml of the special immune-enhancing formula plus 20 g glutamine (Supportan R + Glutamine plus R, which contain 900 Kcal and 60 g protein/day, with 24.4 g glutamine, 2,2 g arginine and 4.4 g of omega 3 fatty acids, in a lower volume due to its higher energy density)."
89251813|NCT01032512|Sham Comparator|CONTROL|40 patients that do not agree to participate, do not have enough time before the operation, do not tolerate the product and/or drink less than 100 cc/day.
89251814|NCT00434330|Experimental|Cohort 1, Q4W, SC, No Transition|
89251815|NCT00434330|Experimental|Cohort 2, Q4W, IV, No Transition|
89251816|NCT00434330|Experimental|Cohort 3, Q4W, SC, Transition|
89251817|NCT00434330|Experimental|Cohort 4, Q4W, IV, Transition|
89251818|NCT00434330|Experimental|Cohort 5, Q4W, SC, Transition|
89251819|NCT00434330|Experimental|Cohort 6, Q4W, IV, Transition|
89251820|NCT01588964|Experimental|HIPEC|Surgery plus HIPEC
89251821|NCT00426764|Experimental|Romidepsin|Participants received romidepsin 14 mg/m^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.
89251822|NCT01589042||Above the Knee|Patients treated with the Chocolate balloon for a lesion located above the knee
89251823|NCT01589042||Below the Knee|Patients treated with the Chocolate balloon for a lesion located below the knee
89251824|NCT01032590|Experimental|Arm I|Arm I (12-week Internet-based weight-loss intervention): After a baseline evaluation, subjects will start a 12 week Internet-based weight-loss intervention.
89251825|NCT01032590|Active Comparator|Arm II|Arm II (wait-list control): Patients are instructed to continue their usual dietary and physical activity routines during a 12-week wait period. After the waiting period, patients receive the Internet-based weight-loss intervention for 12 weeks as in arm I.
89251826|NCT01034150|Active Comparator|Somatosensory stimulation|Active group
89251827|NCT01034150|Placebo Comparator|Control group|Placebo stimulation
89251828|NCT01032668|Experimental|high dose clopidogrel|
89251829|NCT01034228|Active Comparator|Isoleucine|Glucose ORS with L-Isoleucine
89251830|NCT01034228|Placebo Comparator|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
89251831|NCT00434252|Placebo Comparator|Carboplatin+Paclitaxel+Placebo|
89251832|NCT00434252|Experimental|Carboplatin+Paclitaxel+Bevacizumab|
89251833|NCT00425750|Experimental|Treatment|"Docetaxel (40 mg/m2) IV Infusion over 30 minutes every 3 weeks (Day 1 and 8 of 21 day cycle)except the first dose is held on Day 1 of Cycle 1.~Bortezomib (1.6mg/m2) IV 3-5 second push every 3 weeks (Day 1 and 8 of 21 day cycle).Bortezomib is given as a single agent only on Day 1 of Cycle 1."
89251834|NCT03994250|Active Comparator|Kinematic Arm|Kinematic Alignment for TKR surgery
89251835|NCT03994250|Placebo Comparator|Control Arm|Mechanical alignment for TKR surgery
89251836|NCT02791802||Group A: Lipoprotein apheresis subjects|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.~Additional lipoprotein apheresis is established following enrolment using the following established systems: Dextran-sulfate adsorption (DSA) from plasma and whole blood, Heparin-induced LDL precipitation apheresis (HELP®), Polyacrylate adsorption from whole blood and simple DFPP (DALI® and Monet®), ApoB100-immunoadsorption (TheraSorbLDL®, Temperature-optimized double filtration plasmapheresis (DFPP)."
89251837|NCT02791802||Group B: Control group|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.~The control group will not undergo a sham apheresis procedure. It is an open trial."
89251838|NCT00414908|Experimental|A|
89251839|NCT00414908|Placebo Comparator|B|
89251840|NCT01037582|Experimental|Trial part 1|
89251841|NCT01037582|Experimental|Trial part 2|
89251842|NCT00242710|Experimental|1|BZA 20mg/CE 0.625
89251843|NCT00242710|Experimental|Arm 2|BZA 20mg/CE 0.45
89251844|NCT00242710|Active Comparator|Arm 3|CE 0.45mg/MPA1.5mg
89251845|NCT00242710|Placebo Comparator|Arm 4|Placebo
89251846|NCT00408876|Experimental|Duloxetine 20 mg|duloxetine 20 mg once a day (QD), by mouth (PO) for 13 weeks
89251847|NCT00408876|Experimental|Duloxetine 60 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 12 weeks
89251848|NCT00408876|Experimental|Duloxetine 120 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 1 week, then duloxetine 120 mg QD, PO for 11 weeks
89251849|NCT00408876|Placebo Comparator|Placebo|placebo once a day (QD), by mouth (PO) for 13 weeks
89251850|NCT00240994|Experimental|Alemtuzumab (Campath)|In this open-label, single-arm trial , participants will be administered a 0.3 mg/kg dose of alemtuzumab (Campath) intravenously one day prior to kidney transplantation and one day post kidney transplantation. Participants will then receive a maintenance immunosuppressive regimen of tacrolimus and mycophenolate mofetil (MMF) for 8 to 12 weeks, followed by sirolimus and MMF until 24 months post transplantation.
89251851|NCT01070836||natalizumab|US participants with relapsing MS receiving commercial natalizumab
89251852|NCT00239590|Experimental|Testosterone|oral testosterone undecanoate, 80mg twice daily (Andriol Testocaps, Organon, The Netherlands) for 8 weeks
89251853|NCT00239590|Placebo Comparator|Placebo|identical to active medication, taken in an identical way to the active arm
89251854|NCT00433160|Experimental|Teriparatide|20 micrograms for 104 weeks
89251855|NCT00433160|Placebo Comparator|Placebo|Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks
89251856|NCT00239356|Experimental|AI|
89251857|NCT03974386|Experimental|Blood Purification|Patients will receive resuscitation and treatment according to current guidelines for septic shock. In addition to standard care, the patients will receive continuous venovenous hemofiltration and adsorption with oXiris blood purification set.
89251858|NCT03974386|No Intervention|Conventional Treatment|Patients will receive standard care, including resuscitation and treatment according to current guidelines for septic shock.
89251859|NCT00393510|Active Comparator|Traditional Chinese Medicine|12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day.
89251860|NCT00393510|Placebo Comparator|Placebo|Placebo was made with starch and colouring materials. Given to patient orally twice a day
89251861|NCT01040910|Active Comparator|cannabis smoking for IBD|patients with active disease receiving active cannabis for smoking
89251862|NCT01040910|Placebo Comparator|patients smoking non active cannabis|patients with active disease receiving cannabis from which active ingredients have been chemically removed
89251863|NCT00425438|Experimental|Mycophenolate Mofetil|Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1, followed by 1.0 g, PO, BID from Weeks 2 through 24, and 0.75 g, PO, BID from Weeks 32 to 48. Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
89251864|NCT00425438|Active Comparator|Cyclophosphamide/Azathioprine|Participants received cyclophosphamide 0.75 grams per square meter (g/m^2), intravenously (IV), every 4 weeks from Weeks 1 through 4, and 0.5 to (-) 1.0 g/m^2, IV, to maintain a minimum white blood cell (WBC) count of greater than or equal to (≥) 2500 per cubic millimeter (mm^3) every 4 weeks from Weeks 5 through 24. Participants also received azathioprine 100 mg, PO, daily for participants with a body weight of 50 to 70 kg and 150 mg, PO, daily for subjects with a body weight of more than 70 kg from Weeks 25 through 48. Participants also received prednisolone 0.75 to 1.0 mg/kg, PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
89251865|NCT01040988||Pacemaker|Patients meeting entry criteria with a pacemaker in place.
89251866|NCT01040988||ICD|Patients meeting entry criteria with an ICD in place.
89251867|NCT01041066|Active Comparator|group L|0.4 mg/kg labetalol
89251868|NCT01041066|Active Comparator|group N|20 ㎍/kg nicardipine
89251869|NCT01323608|Placebo Comparator|Placebo|
89251870|NCT01323608|Experimental|Low Vitamin D Group|Subjects in this group will receive the equivalent of 400 IU/day.
89251871|NCT01323608|Experimental|Intermediate Vitamin D group|
89251872|NCT01323608|Experimental|High Vitamin D Group|
89251873|NCT00275002|Experimental|O6-BG and TMZ|O6-benzylguanine (O6-BG) and temozolomide (TMZ)
89251874|NCT00433004|No Intervention|1|No advance supply of emergency contraception
89251875|NCT00433004|Active Comparator|2|Advance supply of emergency contraception is given
89251876|NCT00238264|Experimental|Treatment (radiotherapy)|Patients undergo reduced-field conformal radiation therapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
89251877|NCT00414596|Experimental|DRX Group|Patients using the device DRX9000™.
89251878|NCT00393042|Experimental|Focalin XR then Adderall XR|Subjects are given the Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week followed by Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week.
89251879|NCT00393042|Experimental|Adderall XR then Focalin XR|Subjects are given the Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week followed by Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week.
89251880|NCT03742362|Experimental|Bone marrow fat fraction by MRI|MRI scans of distal radius will be performed to all participants to monitor the fat fraction in bone marrow
89251881|NCT00392808|Experimental|MENC-CRM/MENC-CRM|Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
89251882|NCT00392808|Experimental|MENC-CRM/MENC-TT|Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
89251883|NCT00392808|Experimental|MENC-TT/MENC-CRM|Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
89251884|NCT00392808|Experimental|MENC-TT/MENC-TT|Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine
89251885|NCT03766464||with sleep bruxism, apnea and DTM|"Patients who will undergo analysis of:~Evaluation of TMD and pain sensitivity Evaluation of SB Evaluation of AB"
89251886|NCT01041144|Experimental|Lifestyle counseling|
89251887|NCT01040286|Experimental|Flurbiprofen Chip|
89251888|NCT01040286|Active Comparator|Chlorhexidine chip|
89251889|NCT01041222|Experimental|Arm 1|0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours
89251890|NCT01041222|Experimental|Arm 2|0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
89251891|NCT01041222|Experimental|Arm 3|1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
89251892|NCT01041222|Experimental|Arm 4|3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours
89251893|NCT01041222|Placebo Comparator|Placebo (phosphate buffered saline)|
89251894|NCT03761550||Stage 2|The Process Implementation Stage
89251895|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 18 to 60 Years|Participants aged 18 to 60 years received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
89251896|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 61 Years or Older|Participants aged 61 years or older received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
89251897|NCT01043796|Experimental|Insecticide treated nets and wall liners|
89251898|NCT01043796|Active Comparator|Insecticide treated nets alone|
89251899|NCT01043952|Active Comparator|Control|"Patients receive general anesthesia with Propofol and Remifentanil following clinical practice.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
89251900|NCT01043952|Experimental|Bispectral Index Monitor|"Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
89251901|NCT03973450||Pituitary tumours|Patients affected by pituitary tumours and followed-up at the Neuroendocrinology Unit over a 5 yrs period (2014-2018)
89251902|NCT00274846|Experimental|Intent-to-Treat|All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10^7/kg.)
89251903|NCT01073722|Active Comparator|Left double lumen tube|Traditionally, single lung ventilation is obtained with a double lumen tube (DLT). In our institution a polyvinyl DLT (Broncho-cath, Mallinckrodt,) without carinal hook, is used. This type of tube exists of a tube with two lumen with two distal cuffs. One lumen (called the bronchial lumen) extends some distance further, has a slight curvature and has a small blue cuff. The other lumen (called the tracheal lumen) has a larger cuff. A DLT tube exists in four sizes and one can choose in a left or a right configuration. Almost always, we use a left sided DLT. A DLT has a much larger diameter than a standard single lumen endotracheal tube
89251904|NCT01073722|Active Comparator|EZ-blocker|The EZ-blocker (EZB) is a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. It is intended for use in combination with a standard single lumen tube. After the EZB is advanced trough the distal end of the single lumen tube, both extensions spread out and find their way in the left and right main stem bronchi. The place where the two extensions are attached to the shaft now rests on the carina. Fiber optic bronchoscopy should be used for proper positioning. After placement of the EZB, one of the cuffs can be inflated to obtain lung separation under direct visual inspection with fiber optic bronchoscopy.
89251905|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 1|Participants will receive the TetraVax-DV admixture 1 vaccine.
89251906|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 2|Participants will receive the TetraVax-DV admixture 2 vaccine.
89251907|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 3|Participants will receive the TetraVax-DV admixture 3 vaccine.
89251908|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 4|Participants will receive the TetraVax-DV admixture 4 vaccine.
89251909|NCT01072786|Placebo Comparator|Placebo|Participants will receive the placebo.
89251910|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 5|Participants will receive the TetraVax-DV admixture 5 vaccine.
89251911|NCT01071460|Other|SFA Stenting|
89251912|NCT03974308|Experimental|Study group 1|Patients with spine osteoarthritis who will be treated in polish spas in Subcarpathian Region. Comprehensive physiotherapy including balneotherapy will be applied.
89251913|NCT03974308|Active Comparator|Study group 2|Patients with spine osteoarthritis who will be treated in outpatient treatment. Comprehensive physiotherapy without balneotherapy will be applied.
89251914|NCT03974308|Other|Control group|Patients with spine osteoarthritis who will not have applied physiotherapy nor balneotherapy.
89251915|NCT03970798|Experimental|KW-6356/Healthy Japanese adult male subjects|Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11
89251916|NCT00237796|Experimental|ARM 1|Cognitive Behavioral Social Skills Training (CBSST)
89251917|NCT00237796|Active Comparator|ARM 2|Goal Focused Supportive Contact (GFSC)
89251918|NCT03970876|Experimental|ATGC-100 (Phase I/II)|ATGC-100 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
89251919|NCT03970876|Active Comparator|Botox® (Phase II)|Botox® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)
89251920|NCT00414440|Experimental|Everolimus|Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day [5 mg b.i.d.]).
89251921|NCT00414440|Placebo Comparator|Placebo|Placebo tablets equivalent to the dosage of everolimus 5 mg/day, divided in 2 equal doses.
89251922|NCT01073800|Active Comparator|atorvastatin 80 mg|active treatment
89251923|NCT01073800|Placebo Comparator|placebo|
89251924|NCT03971032|Other|Women undergoing hysteroscopy|Women presenting with abnormal bleeding, abnormal cervical or uterine findings who have consented to undergo hysteroscopy
89251925|NCT01037660|Experimental|Metformin|Metformin
89251926|NCT01072864|Experimental|5 g of walnuts|
89251927|NCT01072864|Experimental|20 g of walnuts|
89251928|NCT01072864|Experimental|30 g of walnuts|
89251929|NCT01072864|Experimental|40 g of walnuts|
89251930|NCT01032824|Experimental|Intervention|Individual telephone counseling intervention.
89251931|NCT01032824|Other|Group Arm|Attention-matched comparison arm
89251932|NCT01032824|Other|Book Arm|Information-matched control arm.
89251933|NCT01032902||Known HIV positive|Patients from HIV clinics with documented infections
89251934|NCT01032902||High Risk for Infection with HIV|Patients from defined HIV high-risk populations - i.e. intravenous drug users, or patients presenting with symptoms of sexually transmitted disease.
89251935|NCT01032902||Low-Risk for Infection with HIV|"Individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
89251936|NCT01032980||HUMENZA Vaccine Group|Participants vaccinated with HUMENZA according to the recommendations provided in the product leaflet and local recommendations.
89251937|NCT01032980||PANENZA Vaccine Group|Participants vaccinated with PANENZA according to the recommendations provided in the product leaflet and local recommendations.
89251938|NCT00236080|Experimental|1|PROVIGIL 200 mg/day
89251939|NCT00236080|Experimental|2|Armodafinil 250 mg/day
89251940|NCT00236080|Experimental|3|Armodafinil 200 mg/day
89251941|NCT00236080|Experimental|4|Armodafinil 150 mg/day
89251942|NCT00236080|Placebo Comparator|5|Placebo
89251943|NCT01033058|Active Comparator|usual care|
89251944|NCT01033058|Experimental|intensive statin treatment|
89251945|NCT03973138|Experimental|Treatment group|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab under the pro re nata (PRN) treatment regimen.
89251946|NCT01326130|Active Comparator|Chronic care management 1|Content of chronic care model implemented in territory 1 and level of implementation
89251947|NCT01326130|Active Comparator|Chronic care management 2|Content of chronic care model implemented in territory 2 and level of implementation
89251948|NCT01326130|Active Comparator|Chronic care management 3|Content of chronic care model implemented in territory 3 and level of implementation
89251949|NCT01326130|Active Comparator|Chronic care management 4|Content of chronic care model implemented in territory 4 and level of implementation
89251950|NCT01326130|Active Comparator|Chronic care management 5|Content of chronic care model implemented in territory 5 and level of implementation
89251951|NCT01326130|Active Comparator|Chronic care management 6|Content of chronic care model implemented in territory 6 and level of implementation
89251952|NCT03970564||Suspected lung cancer|Suspected and later on confirmed lung cancer with evidence of mediastinal lymphadenopathy on computerised tomography
89251953|NCT00432380|Experimental|PLACEBO-ROTARIX-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Month 1 and Month 2, and a single oral dose of placebo at Day 0. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
89251954|NCT00432380|Experimental|ROTARIX-PLACEBO-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Day 0 and Month 2, and a single oral dose of placebo at Month 1. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
89251955|NCT00432380|Placebo Comparator|PLACEBO GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 3 oral doses of placebo at Day 0, Month 1 and Month 2. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
89251956|NCT03970486|Active Comparator|Needle Manipulation|Participant will receive dry needling intervention with manipulation.
89251957|NCT03970486|Active Comparator|In Situ|Participant will receive dry needling intervention without manipulation.
89251958|NCT03974074|Experimental|Albumin infusion group|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after hepatic resection in 24 h for three days. All patients wil receive furosemide (10 mg, iv) after albumin transfusion. In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
89251959|NCT03974074|No Intervention|Empty control|Conventional liver protection and rehydration therapy.In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).
89251960|NCT01072942|Experimental|Arm 1|
89251961|NCT01072942|Placebo Comparator|Arm 2|
89251962|NCT01582516|Experimental|Delta24-RGD|Intracerebral slow continuous infusion of study drug in increasing dose
89251963|NCT00234052|Experimental|Treatment Arm|Carboplatin + pemetrexed + bevacizumab
89251964|NCT00408408|Active Comparator|Arm 1A: Docetaxel then AC|Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
89251965|NCT00408408|Experimental|Arm 1B Docetaxel + Bev then AC + Bev|Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
88804862|NCT01346839|No Intervention|Usual Care Control|"The usual care at MEDVAMC consists of providers using an advanced EHR and its notification system (the View Alert system) that immediately alerts providers about clinically significant events. The system relies primarily on computerized notification (alerts) displayed prominently through a View Alert window that is displayed in the EHR every time a provider signs on or switches between patient records. The system does not require providers to read alerts, and providers do have an option of ignoring the View Alert window to bypass it. At SWHS there is a navigation program for patients who have received a cancer diagnosis by tissue biopsy. However, currently there is no routine tracking of patients if they do not show for their scheduled appointments and tests at SWHS."
89251966|NCT00408408|Experimental|Arm 2A: Docetaxel + Capecitabine then AC|Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
89251967|NCT00408408|Experimental|Arm 2B: Docetaxel + Cape + Bev then AC + Bev|Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
89251968|NCT00408408|Experimental|Arm 3A: Docetaxel + Gem then AC|Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
89251969|NCT00408408|Experimental|Arm 3B: Docetaxel + Gem + Bev then AC + Bev|Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
89251970|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 5 μg|Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
89251971|NCT00414050|Active Comparator|RECOMBIVAX HB™ Hepatitis B Vaccine|Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
89251972|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 10 μg|Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
89251973|NCT00414050|Active Comparator|ENGERIX-B®|Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.
89251974|NCT03970408||Carpal tunnel syndrome|"Patients with CTS who fulfill the following eligibility criteria:~Inclusion criteria~Females and male patients referred with a CTS diagnosis confirmed by nerve conduction studies and positive Tinel and Phalen tests.~Age ranging from 30-50 years old.~The selected patient will be able to tolerate the entire standard neurodynamic technique.~Exclusion criteria~Symptoms referred to the neck.~Sever CTS~More than 10% limitation of neck flexion, rotation, and side bending ranges.~History of disease, trauma, or surgery to neck, thorax, or upper limbs.~Presence of peripheral neuropathy or cervical radiculopathy.~History of systemic disease associated with neuropathies such as diabetes mellitus, connective tissue diseases, thyroid disease, or obesity."
89251975|NCT03970408||Healthy control|Asymptomatic healthy age-matched control with no symptoms or history of upper quadrant disease, dysfunction, trauma or surgery.
89251976|NCT01034618|Placebo Comparator|Placebo|
89251977|NCT01034618|Experimental|Intact protein|
89251978|NCT01034618|Experimental|Protein hydrolysate|
89251979|NCT01419860|Experimental|Pixel intensity|Pixel intensity of fluorescence signal describing pixel microcirculation of colon
89251980|NCT03973840|Experimental|healthy men treatment arm|Subjects were given 15 doses over 8 days, and then blood was drawn into several types of collection tubes at different storage conditions.
89251981|NCT00413972|Experimental|Vytorin 10/10|Ezetimibe 10 mg with Simvastatin 10 mg
89251982|NCT00413972|Experimental|Vytorin 10/20|Ezetimibe 10 mg with Simvastatin 20 mg
89251983|NCT00413972|Experimental|Vytorin 10/40|Ezetimibe 10 mg with Simvastatin 40 mg
89251984|NCT00413972|Placebo Comparator|Placebo|
89251985|NCT01037738|Active Comparator|ACS - Orthokin|Autologous conditioned serum (ACS) - Orthokin containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF and TGF-ß1, among others) in the liquid blood phase.
89251986|NCT01037738|Placebo Comparator|Placebo|Physiologic solution
89251987|NCT00259012|Active Comparator|Low dose|
89251988|NCT00259012|Active Comparator|High dose|
89251989|NCT01044108|Experimental|Trial, part 1 (males only)|
89251990|NCT01044108|Experimental|Trial, part 2 (males and females)|
89251991|NCT01044186|Experimental|ICL670|
88804863|NCT04769635|Experimental|CPAP ttt|
89251992|NCT03970174|Experimental|Intervention|Two of the 4 Medicine wards will have implemented the care transition module of Care Connector
89251993|NCT03970174|No Intervention|Control|Remaining 2 of 4 Medicine wards will use all other aspects of Care Connector (except for care transition module)
89251994|NCT01041456||complicated and/or failed BPD|
89251995|NCT03993600|Sham Comparator|Healthy volunteers|sweat test and skin biopsy
89251996|NCT03993600|Experimental|Patients with Cystic fibrosis|sweat test and skin biopsy
89251997|NCT03993600|Experimental|Heterozygotes subjects|sweat test and skin biopsy
89251998|NCT00209170|Experimental|Beating the Blues CBT + Escitalopram|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with the selective serotonin reuptake inhibitor (SSRI) antidepressant, escitalopram (10 mg taken orally once or twice daily) for 6 months
89251999|NCT00209170|Active Comparator|Beating the Blues CBT + Placebo|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with placebo (taken orally one to two tablets daily) for 6 months
89252000|NCT01071694||Group 1|
89252001|NCT00413894|Experimental|1|
89252002|NCT03973216|Experimental|A primary care group-based therapeutic yoga program|A primary care care group-based therapeutic yoga program that consists of 9 sessions.
89252003|NCT03970018||Autosomal dominant polycystic kidney disease|Autosomal dominant polycystic kidney disease (ADPKD) patients starting peritoneal dialysis for end stage renal failure will be included in this study.
89252004|NCT03972748|Experimental|Itraconazole|Oral Itraconazole capsules, 200 mg
89252005|NCT01581814|Active Comparator|Metformin|31 subjects were randomized to receive 500 mg Metformin per 3/die
89252006|NCT01581814|Active Comparator|0.03 mg EE plus 3 mg of DRPS|
89252007|NCT01581814|Active Comparator|Metformin plus Yasmin|
89252008|NCT00407550|Experimental|Gemzar x2|Treat subjects with 2 dosings/cycle of Gemzar x6 cycles.
89252009|NCT00407550|Experimental|Gemzar x1|Treat subjects with 1 dosing/cycle of Gemzar x9 cycles.
89252010|NCT00209092|Active Comparator|Sequential Therapy|Docetaxel will be given at 100mg/m^2 intravenous Day 1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).
89252011|NCT00209092|Active Comparator|Concurrent Therapy|Docetaxel will be given at 50mg/m^2 Intravenous Day1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
89252012|NCT03969862||Patient with an allergen-mediated IgE allergy|Patients with a clinical history consistent with an allergen-mediated IgE allergy & with a sensitization demonstrated by a positive Prick-Test for the allergen source tested
89252013|NCT03969862||Patient without an allergen-mediated IgE allergy|Patient without a clinical history compatible with an IgE allergy-mediated allergy and without PT sensitization to be allergen
89252014|NCT03972982|Experimental|Simplified regimen group|Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week，Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.
89252015|NCT03972982|Active Comparator|Routine group|Inpaitent short-term continuous subcutaneous insulin infusion will be administered to maintained euglycemia for 2 weeks, Then subjects will be follow-up routinely.
89252016|NCT00403494|Experimental|Sapropterin dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
89252017|NCT00403494|Placebo Comparator|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
89252018|NCT00403260|Experimental|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
89252019|NCT00403260|Active Comparator|Mefloquine plus artesunate|Mefloquine (250mg tablets) plus artesunate (100mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
89252020|NCT01324362|Active Comparator|Fluticasone propionate|
89252021|NCT01324362|Active Comparator|Fluticasone propionate/salmeterol combination|
89252022|NCT00406848|Experimental|Duloxetine|
89252023|NCT00406848|Placebo Comparator|Placebo|
89252024|NCT00406692|Experimental|Zonisamide|In open-label non-placebo controlled trial subjects are treatment with zonisamide 400 mg during the maintenance phase of this study
89252025|NCT00315705|Experimental|clofarabine, etoposide, cyclophosphamide|"Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m^2, etoposide dosage from 75-100 mg/m^2, cyclophosphamide dosage from 340-440 mg/m^2.~Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m^2, etoposide 100 mg/m^2 and cyclophosphamide 440 mg/m^2 delivered intravenously"
89252026|NCT03982017|Active Comparator|Usual care|Consists of routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
89252027|NCT03982017|Experimental|Application|Participants will be provided a special link to navigate to the online content and resources.
89252028|NCT03982173|Experimental|previously treated patients with solid tumors|previously treated patients with solid tumors harboring a high mutational load.
89252029|NCT01062633|Experimental|A, observation|dietary supplement
89252030|NCT01062633|Experimental|B|dietary supplement
89252031|NCT01062633|Experimental|C|dietary supplement
89252032|NCT00307125|Experimental|Pilot Phase-Rituximab plus immunosuppression|"Enrollment into a Stage 2 pilot treatment study will occur after Stage 1. Adult Rituximab Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Rituximab Dosing (Subjects <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
89252033|NCT00307125|Placebo Comparator|Pilot Phase-Placebo plus immunosuppression|"Adult Placebo Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Placebo Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
89252034|NCT01066299|Experimental|oxitocin nasal spray|oxytocin nasal spray
89252035|NCT01066299|Placebo Comparator|placebo|inactive nasal spray
89252036|NCT00307047|Experimental|XIENCE V®|
89252037|NCT00307047|Active Comparator|TAXUS™ EXPRESS2™|
89252038|NCT01066377|Experimental|Prebiotic and probiotic mix|Prebiotic: 8g/day, will be selected on the basis of ability to promote optimal growth and survival of the probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested). Probiotic: 10^8 - 10^9 live bacteria/day, bifidobacterium longum bv. infantis CCUG52486.
89252039|NCT01066377|Placebo Comparator|Maltodextrin/milk powder|
89252040|NCT00306891|Experimental|Cediranib 45 mg Fed|Part A: Cediranib 45 mg Fed State
89252041|NCT00306891|Experimental|Cediranib 45 mg Fasted|Part A: Cediranib 45 mg Fasted State
89252042|NCT00306891|Experimental|Cediranib 45 mg Fixed Dose|Part B: Cediranib 45 mg Fixed Dose
89252043|NCT00306891|Experimental|Cediranib 30 - 90 mg Dose Escalation|Part B: Cediranib 30 - 90 mg Dose Escalation
89252044|NCT00314145|Experimental|ChimeriVax™-JE|Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
89252045|NCT00314145|Active Comparator|JE-VAX®|Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.
89252046|NCT00313911|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
89252047|NCT00313911|Active Comparator|Group 2: Tritanrix-Hep B/Hib™+OPV|
89252048|NCT03980847|Active Comparator|Alendronate 20 mg with bone graft|after tooth extraction, put teh Alendronate 20mg with bone graft within teh tooth socket
89252049|NCT03980847|Active Comparator|bone graft alone|after tooth extraction, put the bone graft within the tooth socket
89252050|NCT03978195|Experimental|Treatment|
89252051|NCT03978195|No Intervention|Control|
88804864|NCT04351477|Experimental|Massage chair group|Use mechanical massage chair for 20 minutes/1 session, 3 sessions/week, for 3 weeks
89252052|NCT00391872|Active Comparator|Clopidogrel|Oral treatment
89252053|NCT00391872|Experimental|Ticagrelor|Oral treatment
89252054|NCT01040364||Interna hernia after primary gastric bypass|
89252055|NCT00391170|Experimental|Dexamethasone oral rinse in stem cell transplant participants|Dexamethasone 0.01% (0.5mg/5 mL) oral rinse solution in post allogeneic hematopoietic stem cell transplant participants. Rinse oral cavity three times daily for two minutes with ten milliliters then expectorate. Complete for three months duration.
89252056|NCT00391170|Placebo Comparator|Placebo oral rinse in stem cell transplant participants|Placebo oral rinse in post allogeneic hematopoietic stem cell transplant participants. Rinse oral cavity three times daily for two minutes with ten milliliters then expectorate. Complete for three months duration.
89252057|NCT00402324|Experimental|1|olanzapine and divalproex
89252058|NCT00402324|Placebo Comparator|2|placebo and divalproex
89252059|NCT00294723|Experimental|Lira 1.8|Liraglutide 1.8 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.8 mg once daily in the extension periods (weeks 52-195).
89252060|NCT00294723|Experimental|Lira 1.2|Liraglutide 1.2 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.2 mg once daily in the extension periods (weeks 52-195).
89252061|NCT00294723|Active Comparator|Glimepiride - 1|Glimepiride 8 mg once daily + liraglutide placebo 200 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
89252062|NCT00294723|Active Comparator|Glimepiride - 2|Glimepiride 8 mg once daily + liraglutide placebo 300 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
89252063|NCT00402246|Experimental|Remote Arm|Remote Management
89252064|NCT00402246|Active Comparator|In-office Arm|In-Office Care
89252065|NCT00375492|Experimental|Group A|
89252066|NCT00375492|Placebo Comparator|Group B|
89252067|NCT00306189|Active Comparator|100 mg AMG 162|
89252068|NCT00306189|Active Comparator|60 mg AMG 162|
89252069|NCT00306189|Placebo Comparator|Placebo|
89252070|NCT00306189|Active Comparator|14 mg AMG 162|
89252071|NCT00312897|Placebo Comparator|corn oil|as stated
89252072|NCT00312897|Experimental|Omega 3 Fatty Acids|as stated
89252073|NCT00312663|Experimental|10ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
89252074|NCT00312663|Experimental|50ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
89252075|NCT02532699|Active Comparator|AC mycelia|Subjects receive three capsules per day containing either 420 mg of AC mycelia.
89252076|NCT02532699|Placebo Comparator|Placebo|Subjects receive three capsules per day containing starch placebo of similar appearance.
89252077|NCT00294645|Active Comparator|Control|Transtelephonic monitoring at 2 month intervals
89252078|NCT00294645|Active Comparator|Remote|Medtronic CareLink® Network remote pacemaker interrogation at 3 month intervals
89252079|NCT00305877|Experimental|Arm I (cetuximab, gemcitabine, capecitabine, radiation)|Patients receive cetuximab IV over 60-120 minutes on day 1, once weekly, in weeks 1-24; gemcitabine hydrochloride IV over 30 minutes on day 1, once weekly, in weeks 1-3, 13-15, 17-19, and 21-23; oral capecitabine twice daily on days 1-5, 5 days a week, in weeks 5-10. Patients also undergo radiotherapy once daily, 5 days a week, beginning in week 5 and continuing for approximately 5½ weeks (25 fractions).
89252080|NCT00305877|Experimental|Arm II (bevacizumab, gemcitabine, capecitabine, radiation)|Patients receive bevacizumab IV over 60-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23. Patients also receive gemcitabine hydrochloride and capecitabine and undergo radiotherapy as in arm I.
89252081|NCT01064193|Experimental|group 1 : IVF with biopsy|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation plus local injury to the endometrium of patients one menstrual cycle before the IVF
89252082|NCT01064193|Active Comparator|group 2|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation alone
89252083|NCT03978273|Experimental|Night-time brace + virtual-brace|Patients are conventionally treated with night-time brace. Additionally, they use the new developped virtual-brace (MD).
89252084|NCT03978273|Active Comparator|Night-time brace only|Patients are conventionally treated with night-time brace only.
89252085|NCT03981315||Lithogenic bile in symptomatic patient|Patients who are performed a cholecystectomy as a treatment of their gallbladder disease
89252086|NCT03981315||Lithogenic bile in asymptomatic patient|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) and gall stones are found
89252087|NCT03981315||Non-lithogenic bile|Patients who are performed a cholecystectomy for another reason (cancer, organ donation) without gall stones
89252088|NCT01062711|Other|Control group 0 g protein|Control group in which a placebo drink containing no protein is given following unilateral knee extension exercise
89252089|NCT01062711|Experimental|10g whey|10g whey protein given following unilateral knee extension exercise
89252090|NCT01062711|Experimental|20g whey|20g whey protein given following unilateral knee extension exercise
89252091|NCT01062711|Experimental|30g whey|30g whey protein given following unilateral knee extension exercise
89252092|NCT01062711|Experimental|40g whey|40g whey protein given following unilateral knee extension exercise
89252093|NCT01062711|Experimental|20g soy|20g soy protein given following unilateral knee extension exercise
89252094|NCT01062711|Experimental|40g soy|40g soy protein given following unilateral knee extension exercise
89252095|NCT00312195|Experimental|BTDS (5, 10 or 20)|Buprenorphine transdermal patch
89252096|NCT00312195|Placebo Comparator|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch
89252097|NCT01062789|Other|Use of an optical breath-hold control device|This is a feasibility study that will use this new device in place of a different bellows-based breath-hold control device for a series patients undergoing CT-guided lung biopsy. The new belt will be used in all patients in our study.
89252098|NCT01066533|Experimental|Mineral Trioxide Aggregate(MTA)|MTA is a proper material for direct pulp capping,treatment of tooth perforations,root end filling.It is a safe and biocompatible material,which can induce cementum formation on root surface.In direct pulp capping, MTA can induce dentinal bridge formation on the expose surface to preserve pulp vitality.Although MTA has superior biocompatibility compared with the conventional materials,it has a delayed setting time, poor handling characteristics and off-white color
89252099|NCT01066533|Experimental|NEC cement|NEC cement is a proper material for direct pulp capping and treatment of tooth perforation. It is a new dental material that combines reasonable biocompatibility of MTA with appropriate setting time,handling characteristics,chemical properties and color.Like MTA, NEC cement can induce dentinal bridge formation in direct pulp capping to preserve pulp vitality.
89252100|NCT01062867|Experimental|ORG25435|Infusion of intravenous anaesthetic agent to induce anaesthesia
89252101|NCT02532777|Experimental|Prednisone & Cyclophosphamide|"Drug: prednisone & cyclophosphamide & Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
89252102|NCT02532777|Experimental|Prednisone & Mycophenolate mofetil|"Drug: prednisone & mycophenolate mofetil & Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
89252103|NCT02532777|Experimental|Prednisone & Leflunomide|"Drug: prednisone & leflunomide & Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.~Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
89252104|NCT03977805|Experimental|Hetrombopag Olamine|Hetrombopag Olamine (5 mg, 100 uCi)
89252105|NCT01062945|Placebo Comparator|Placebo|
89252106|NCT01062945|Active Comparator|Doxazosin|
89252107|NCT01063023|Active Comparator|Arm A - Ortho Tri-Cyclen®|1 to 28 days
89252108|NCT01063023|Active Comparator|Arm B - Ortho Tri-Cyclen®|29 to 56 days
89252109|NCT01063023|Active Comparator|Arm C - Ortho Tri-Cyclen® + BMS-650032|"Ortho Tri-Cyclen®: 57 to 77 days~BMS-650032: 68 to 77 days"
89252110|NCT01063101|Experimental|BAX 513|Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)
89252111|NCT01063101|Placebo Comparator|Capsule (cellulose)|Capsule - one of 5 dose levels (per randomization) - BID
89252112|NCT00305253|No Intervention|Pre-Intervention|The Pre-Intervention Phase served as the Control / Baseline group.
89252113|NCT00305253|Experimental|Post-Intervention|Intervention used in this phase and outcomes compared to the Pre-Intervention phase.
89252114|NCT01066611|Active Comparator|1|CAL-263
89252115|NCT01066611|Placebo Comparator|2|Placebo
89252116|NCT01066689|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
89252117|NCT01066689|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
89252118|NCT03980691|Experimental|Chidamide combined with CAR-T or TCR-T cell therapy|Receiving chidamide combined with CAR-T or TCR-T cell therapy based on based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections.
89252119|NCT03980691|No Intervention|without intervention|Not receiving chidamide combined with CAR-T or TCR-T cell therapy but continuing cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART, without active HCV or HBV infection or opportunistic infections.
89252120|NCT00293709||Patients with Psoriatic Arthritis|
89252121|NCT01063257|Experimental|Cohort A|Clofarabine treatment at D1-D5
89252122|NCT01063257|Experimental|Cohort B|Clofarabine treatment at D1, D3, D5, D8, D10
89252123|NCT03977649|Experimental|erenumab|monthly subcutaneous erenumab 140 mg for 12 weeks
89252124|NCT03977649|Placebo Comparator|placebo|monthly subcutaneous masked placebo for 12 weeks.
89252125|NCT01066767|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets Dr. Reddy's Laboratories Limited
89252126|NCT01066767|Active Comparator|Allegra|Allegra Tablets 180 mg Aventis Pharmaceuticals Inc.,
89252127|NCT01063413||Coleman Afterschool Program|Children enrolled in a community center-based after-school program.
89252128|NCT01063413||YMCA Fun Company|Children enrolled in a school-based after-school program.
89252129|NCT03980613||Spontaneous subarachnoid haemorrhage|Patients with verified spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
89252130|NCT03980613||Controls|Patients without spontaneous subarachnoid haemorrhage that have called the emergency medical service Copenhagen.
89252131|NCT03980379|Experimental|experimental group|304 injection.WILL be administered single dose IV in the patients with CD20 positive B cell NHL
89252132|NCT03980379|Active Comparator|control group|Rituximab will be administered single dose IV in the patients with CD20 positive B cell NHL.
89252133|NCT01064271|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
89252134|NCT01064271|Active Comparator|Risperdal®|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
89252135|NCT01066845||Patients prescribed Adcirca|all patients prescribed Adcirca during study period
89252136|NCT01064349||Breast cancer patients with brain metastases|Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
89252137|NCT00311181|Experimental|2.5/3.5/4.5 ms defibrillation waveform|
89252138|NCT01063491|Experimental|Early graft angiography after coronary artery bypass surgery|Treatment of any bypass graft abnormalities that are discovered will be performed if needed
89252139|NCT01063491|No Intervention|No early angiography after coronary artery bypass surgery|
89252140|NCT00293397|Experimental|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|Patients undergo DEB-TACE procedures utilizing LC Beads, polyvinyl alcohol microspheres with diameters of 100-300um or 300-500um, which are loaded with 100mg of doxorubicin hydrochloride and mixed with an equal volume of nonionic contrast media.
89252141|NCT03981627|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation
89252142|NCT03981627|Active Comparator|NovoRapid®|Subcutaneous injection of insulin aspart
89252143|NCT01064427||Chemotherapy group|Breast cancer patients treated by adjuvant chemotherapy after their surgery. The time points of data collection are before the start of the first, second, fourth and sixth cycle of chemotherapy. If patients are treated by radiotherapy after the chemotherapy, there are 2 measurements points pre- and post radiotherapy.The others measurement points are at 12,18 and 24 months after surgery.
89252144|NCT01064427||No chemotherapy group|Breast cancer patients no treated by adjuvant chemotherapy after their surgery. For patients treated by radiotherapy after surgery, there are 2 measurement points pre- and post radiotherapy. The others measurement points are at 4,6,7,8,12,18 and 24 months after surgery.
89252145|NCT01067001||2 Way Crossover|2 Way Crossover bioequivalence study
89252146|NCT01067001||Subjects will be randomly divided in to 2 groups.|A total of 18 normal, healthy, adult, human subjects will be enrolled in the study.
89252147|NCT01064505|Experimental|QPI-1007|
89252148|NCT01069263|Active Comparator|Intravesical DMSO instillation|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
89252149|NCT01069263|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
89252150|NCT01067079||Arm 1|
89252151|NCT01069497|Experimental|Intervention Nursing Homes|Comprising 24 nursing homes implementing a specific infection prevention program
89252152|NCT01069497|No Intervention|Usual care Nursing Homes|
89252153|NCT01064583|Experimental|flavanol rich cocoa drink (596mg)|dissolved in water, twice daily intervention
89252154|NCT01064583|Experimental|flavanol poor cocoa drink ( 13mg)|dissolved in water, twice daily intervention
89252155|NCT01067235|Experimental|BF2.649 + Modafinil placebo|
89252156|NCT01067235|Experimental|BF2.649 + Modafinil|
89252157|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (1mg), CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89252158|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (2mg), CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89252159|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (3mg), CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89252160|NCT01067313|Experimental|Dialyzer Ultraflux EMiC2|Dialyzer Ultraflux EMiC2 used in Continuous Hemodialysis
89252161|NCT01067313|Active Comparator|Dialyzer Ultraflux AV1000S|Dialyzer Ultraflux AV1000S used in continuous Hemofiltration
89252162|NCT00290745|Experimental|tamoxifen or letrozole|tamoxifen or letrozole work in treating women with ductal carcinoma in situ
89252163|NCT01069653|Experimental|CDCA1-KIF20A-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89252164|NCT01069653|Experimental|CDCA1-KIF20A-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89252165|NCT01069653|Experimental|CDCA1-KIF20A-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89252166|NCT03980223|Experimental|Doxy PEP|Doxycycline 200mg in addition to standard of care STI testing and treatment
89252167|NCT03980223|No Intervention|Control|The control arm will consist of standard of care STI testing and treatment
89252168|NCT01067391|Active Comparator|tadalafil 20 mg|Oral study medication to be administered once to each participant
89252169|NCT01067391|Placebo Comparator|placebo|oral study medication to be administered once to each study participant
89252170|NCT00402168|Experimental|A: Belatacept|
89252171|NCT00402168|Active Comparator|B: calcineurin inhibitor (CNI)-based immunosuppressive regimen|
89252172|NCT01064661|Active Comparator|Blend probiotic of L-NCFM and B-LBi07|Blend probiotic pills of L-NCFM and B-LBi07 BID (2x10^10 cfu total bacteria per day)
89252173|NCT01064661|Active Comparator|Single probiotic of L-NCFM alone|Single probiotic pills of L-NCFM alone BID (2x10^10 cfu total bacteria per day)
89252174|NCT00290589|Experimental|Intramuscular methylprednisolone acetate|Methylprednisolone acetate 160mg intramuscular injection
89252175|NCT00290589|Placebo Comparator|Placebo|Placebo intramuscular injection
89252176|NCT01069731||Infants born at 30 to 36 weeks gestation|Infants will be considered eligible if they are born at 30 to 36 weeks gestation and have no exclusion criteria.
89252177|NCT01067547|Experimental|iron sulfate|Oral iron sulfate 300mg tid
89252178|NCT01067547|Active Comparator|intravenous iron sulfate|intravenous iron sulfate 300 mg
89252179|NCT00290511|Experimental|R-FIND + Zevalin|Fludarabine 25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4. Mitoxantrone 10 mg/m^2 IV over 5-30 minutes on Day 2. Rituximab 375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total). Zevalin 0.3 mCi/kg IV after 4 cycles of R-FND. Dexamethasone 20 mg by mouth (PO) or IV daily on Days 2-6.
89252180|NCT00290433|Experimental|HCVIDDOXIL Regimen|"Cycle 1: Cyclophosphamide by vein two times a day on Days 1,2, and 3. Mesna by vein nonstop over Days 1 through 3. Pegylated liposomal doxorubicin by vein over 1 hour on Day 2. Vincristine by vein on Days 4 and 11. Dexamethasone by mouth on Days 1 through 4 and 11 through 14.~Cycle 2: Methotrexate by vein over 2 hours on Day 1 and over 22 hours on day 1. Cytarabine by vein twice a day on Days 2 and 3."
89252181|NCT04323033|Experimental|PERS stent|20 Patients will receive PERS stent
89252182|NCT04323033|Active Comparator|NEPTUN C stent|20 Patients will receive NEPTUN C stent
89252183|NCT00304083|Experimental|Chemotherapy and local control by radiotherapy and surgery|Patients receive doxorubicin hydrochloride and ifosfamide (IA) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients then receive etoposide and ifosfamide (IE) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course. After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy. Some patients may then undergo surgery.
89252184|NCT00304083|Experimental|Chemotherapy and local control by surgery|Patients receive 2 courses of IA followed by 2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery. After recovery from surgery, patients receive 2 more courses of IA followed by 2 more courses of IE in the absence of disease progression or unacceptable toxicity.
89252185|NCT00293241|Other|MVP ON|Managed Ventricular Pacing programmed on
89252186|NCT00293241|Other|MVP OFF|Managed Ventricular Pacing programmed off: conventional pacing
89252187|NCT01069809|Experimental|AGS-004|HIV-1 Immune Therapy
89252188|NCT01069809|Placebo Comparator|Inactive Injection|Inactive Placebo Injection
89252189|NCT01067625|Experimental|TOGA subjects|
89252190|NCT03977103|Experimental|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
89252191|NCT01069887||adult with hematological malignancies|
89252192|NCT01069887||pediatrics with hematological malignancies|
89252193|NCT01069887||pediatrics receiving stem cell transplant|
89252194|NCT01069887||adult receiving stem cell transplant|
89252195|NCT01069965|Experimental|6. BGP-15|400 mg BGP-15 + Placebo
89252196|NCT01069965|Experimental|5. BGP-15|200 mg BGP-15 BID
89252197|NCT01069965|Experimental|4. BGP-15|200 mg BGP-15 + Placebo
89252198|NCT01069965|Experimental|3. BGP-15|Two 50 mg BGP-15 capsules by mouth in the morning; and two 50 mg BGP-15 capsules by mouth in the evening
89252199|NCT01069965|Experimental|2. BGP-15|100 mg BGP-15 + placebo
89252200|NCT01069965|Experimental|1. Placebo|Placebo BID
89252201|NCT03979833||1|Individuals currently living, over the age of 18 years and known carriers of a pathogenic variant in the VHL gene.
89252202|NCT03977415||RA with no ILD|"Subjects diagnosed with RA less then 2 years and without a diagnosis of ILD, will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.~Study Assessments Include:~Medical history and Physical exams~Quality of Life Questionnaires~Collection of Sputum and Blood~Radiology (HRCT)~Lung Function Test"
89252203|NCT03977415||RA with ILD|"Patients diagnosed with RA less than 2 years, and clinically diagnosed with interstitial lung disease (ILD), will complete 5 in-person study visits. Visits will be performed every 6 months for 18 months.~Study Assessments Include:~Medical history and Physical exams~Quality of Life Questionnaires~Collection of Sputum and Blood~Radiology (HRCT)~Lung Function Test~Spirometry"
89252204|NCT01067703|Active Comparator|RIPC|
89252205|NCT01067703|Sham Comparator|CONTROL|
89252206|NCT01064895||Active Cohort|Patients receiving the Benephit device and targeted renal therapy.
89252207|NCT00391092|Experimental|1|
89252208|NCT00391092|Active Comparator|2|
89252209|NCT00374868|Experimental|Pemetrexed + Cisplatin|
89252210|NCT01044342|Experimental|A|Single dose of AZD1446 10 mg
89252211|NCT01044342|Experimental|B|Single dose of AZD1446 80 mg
89252212|NCT01044342|Active Comparator|C|Single Dose of Donepezil 5 mg
89252213|NCT01044342|Placebo Comparator|D|Single dose of placebo to match AZD1446
89252214|NCT00374556|Experimental|Eszopiclone|Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks
89252215|NCT00374556|Placebo Comparator|Placebo|3mg placebo capsule, once daily at bedtime for 12 weeks
89252216|NCT00290355|Experimental|GSK 249553 Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of GSK 249553 vaccine, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
89252217|NCT00290355|Placebo Comparator|Placebo Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of placebo, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
89252218|NCT01064973|Experimental|STX209|STX209 (arbaclofen)
89252219|NCT03741855|Experimental|Remote-Monitoring Program|Cloud Dx kit with remote-monitoring
89252220|NCT03741855|Experimental|Self-Monitoring Program|Cloud Dx kit with self-monitoring
89252221|NCT03741855|No Intervention|Standard of Care|Participants will not be provided with the Cloud DX kit or an action plan
89252222|NCT00374322|Placebo Comparator|Placebo|6 tablets daily for 12 months
89252223|NCT00374322|Experimental|Lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
89252224|NCT00303459|Experimental|A|Bosentan
89252225|NCT00303459|Placebo Comparator|B|Placebo
89252226|NCT01070121||RA patients/participants|
89252227|NCT00289887|Experimental|1|Losartan
89252228|NCT00289887|Placebo Comparator|2|Placebo
89252229|NCT01325649||advanced rectal cancer|Patients with carcinoma of the middle rectum with positive mrCRM (≤ 1 mm), with cT3 low rectal carcinoma, and with cT4 Tumors Arm 1 Long course radiochemotherapy before total mesorectal excision Arm 2 total mesorectal excision without radiochemotherapy
89252230|NCT00303069|Experimental|V710 5 μg|V710 S. aureus vaccine
89252231|NCT00303069|Experimental|V710 30 μg|V710 S. aureus vaccine
89252232|NCT00303069|Experimental|V710 90 μg|V710 S. aureus vaccine
89252233|NCT00303069|Placebo Comparator|Placebo|Placebo
89252234|NCT01325727|Experimental|Brief computerized feedback|Brief computerized feedback
89252235|NCT01325727|Active Comparator|Resources only|
89252236|NCT01068015|Experimental|Intervention|This arm receives free circumcision service, POL intervention, intensive HIV counseling and intensive condom promotion.
89252237|NCT01068015|No Intervention|usual|This arm receives no extra HIV prevention services.
89252238|NCT00401544|Experimental|Darbepoetin alfa 300 μg plus IV Iron|Darbepoetin alfa 300 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
89252239|NCT00401544|Experimental|Darbepoetin alfa 300 μg|Darbepoetin alfa 300 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
89252240|NCT00401544|Experimental|Darbepoetin alfa 500 μg|Darbepoetin alfa 500 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
89252241|NCT00401544|Active Comparator|Darbepoetin alfa 500 μg plus IV Iron|Darbepoetin alfa 500 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
89252242|NCT01044420|Experimental|mFOLFIRI|
89252243|NCT00289731|Experimental|Twinrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received combined Twinrix™ (720/20) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule.
89252244|NCT00289731|Active Comparator|Engerix-B+Havrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of Engerix™-B (20 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Havrix™ (1440 EL.U) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
89252245|NCT00289731|Active Comparator|HB VAX PRO+Vaqta Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of HB VAX PRO™ (10 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Vaqta™ (50 IU) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
89252246|NCT00289185|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of the RTS,S/AS02D vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
89252247|NCT00289185|Active Comparator|Engerix-B Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh..
89252248|NCT03980067|Experimental|Virtual Reality Group|The children in the experimental group will receive the standard of care (access to in room activity including television (TV) distraction if desired, parent support and distraction at bedside, and quiet time) in addition to our intervention, an interactive virtual reality game, played for a minimum of 5 minutes prior to procedural sedation.
89252249|NCT03980067|No Intervention|Standard of Care|The children in the control group receiving standard of care will have access to in room activity including TV distraction if desired, parent support and distraction at bedside, and quiet time.
89252250|NCT00292461|Active Comparator|zonisamide|tablet
89252251|NCT00292461|Active Comparator|lamotrigine|tablet
89252252|NCT03976869|Experimental|Cohort 1|The study will include adolescent patients of 12 to 17 years of age, with subgroups of 12-14 years age and 15-17 years age.
89252253|NCT01068171|Active Comparator|shoe, plain dressing|post-op shoe with plain occlusive dressing
89252254|NCT01068171|Active Comparator|shoe, collagen|post-op shoe with collagen dressing
89252255|NCT01068171|Active Comparator|boot, plain dressing|air boot with occlusive dressing
89252256|NCT01068171|Active Comparator|boot, collagen|air boot with collagen dressing
89252257|NCT01068171|Active Comparator|monitored air boot, plain dressing|air boot with retention strap to monitor whether boot is removed with occlusive dressing
89252258|NCT01068171|Active Comparator|monitored boot with collagen|air boot with retention strap to monitor whether boot is removed with collagen dressing
89252259|NCT01581255||Conventional lung protective ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the conventional lung protective ventilation arm of the OSCILLATE trial.
89252260|NCT01581255||High frequency oscillation ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the high frequency oscillation ventilation arm of the OSCILLATE trial.
89252261|NCT00390858|Experimental|Deferasirox|Initial dose of 10 mg/kg, dose modifications of ± 5 or 10 mg/kg were based on participant response.
89252262|NCT00390780|Active Comparator|Clotrimazole|Clotrimazole troches, 10 mg, 5 times per day for 14 days
89252263|NCT00390780|Experimental|miconazole Lauriad|Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days
89252264|NCT00390546|Experimental|Propranolol|Single dose of 0.5 mg/kg per dose and increased to 1.0 mg/kg per dose ITD for the second and subsequent doses.
89252265|NCT00390546|Experimental|Digoxin|First 2 doses at 0.010 mg/kg per dose TID, then 0.0035 mg/kg per dose TID for the third and subsequent doses
89252266|NCT00390468|Experimental|Tandutinib (MLN518)|500 mg twice daily, a small-molecule inhibitor of the type III receptor tyrosine kinases. Tandutinib (MLN518) previously known as CT53518.
89252267|NCT00400764|Experimental|Phase Ib: Dulanermin 4 mg/kg|Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
89252268|NCT00400764|Experimental|Phase Ib: Dulanermin 8 mg/kg|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
89252269|NCT00400764|Active Comparator|Phase II: Rituximab|Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
89252270|NCT00400764|Experimental|Phase II: Combination Therapy|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
89252271|NCT00400764|Experimental|Phase II: Dulanermin|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
89252272|NCT00302211|Experimental|DB inhaled iloprost 6x/day|inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the double blind period
89252273|NCT00302211|Experimental|DB inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4×/day plus inhaled placebo 2x/day plus sildenafil with or without bosentan during the double blind period
89252274|NCT00302211|Placebo Comparator|DB inhaled placebo 6x/day|Inhaled placebo 6×/day plus sildenafil with or without bosentan during the double blind period
89252275|NCT00302211|Experimental|OL inhaled iloprost 6x/day|Inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
89252276|NCT00302211|Experimental|OL inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4 times per day (4×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
89252277|NCT01045902|Experimental|Arm 1|
89252278|NCT01045902|Active Comparator|Arm 2|
89252279|NCT01041612|Active Comparator|Group A: C-SEMS, inserted above SO|-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.
89252280|NCT01041612|Active Comparator|Group B: C-SEMS, inserted across SO|-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.
88804865|NCT04351477|No Intervention|Control|No use of mechanical massage chair for 3 weeks
88804866|NCT00101816|Experimental|1|
89252281|NCT01041690|Experimental|Bevacizumab|
89252282|NCT01041768|Active Comparator|antidiabetic medical therapy|
89252283|NCT01041768|Experimental|Bariatric Surgery|
89252284|NCT01041846||Decitabine|
89252285|NCT00288015|Experimental|Bevacizumab|Bevacizumab treatment until disease progression or intolerance
89252286|NCT00389064|Experimental|Quetapine XR|Tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily.
89252287|NCT00389064|Placebo Comparator|Placebo|Matching placebo tablets orally administered once daily.
89252288|NCT01045980|Experimental|Bioimpedance and Vitamin D|
89252289|NCT01045980|Experimental|Usual care and Vitamin D|Vitamin D3
89252290|NCT01045980|Experimental|Bioimpedance and Placebo|
89252291|NCT01045980|Placebo Comparator|Usual Care and Placebo|
89252292|NCT00388674||A|
89252293|NCT00388674||B|
89252294|NCT00388362|Experimental|Sirolimus Therapy|Administration of Sirolimus and Prednisone
89252295|NCT03463980|Experimental|Compassion meditation (CM)|The CM participants will attend six weekly sessions (each 120 minute), and will be video and/or audiotaped. Each weekly CM session will entail a 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants will be encouraged to meditate at least 30 minutes a day and will be asked to track their daily meditation time and bring in their tracking sheet to each session.
89252296|NCT03463980|Active Comparator|Support group (SG)|SG participants will attend six weekly sessions, 90 minutes in length. It will be unstructured. Participants will use this time to talk about current concerns and to receive support and guidance from other group members and the leaders.
89252297|NCT01042002|Experimental|High intensity exercise|
89252298|NCT01042002|No Intervention|Control|
89252299|NCT01046058|Experimental|Panel A: TMC435 150 mg|Participants enrolled in Panel A had moderate hepatic failure and received TMC435 150 mg once daily for 7 days.
89252300|NCT01046058|Experimental|Panel B: TMC435 150 mg|Participants enrolled in Panel B had severe hepatic impairment and received TMC435 150 mg once daily for 7 days after the safety of TMC435 150 mg once daily for 7 days was evaluated in participants enrolled in Panel A.
89252301|NCT01046214|Experimental|Budeprion XL™|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
89252302|NCT01046214|Active Comparator|Wellbutrin XL®|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
89252303|NCT01324284|Experimental|Lubiprostone|Lubiprostone with PEG solution versus Placebo with PEG solution
89252304|NCT01324284|Placebo Comparator|lubiprostone versus placebo|
89252305|NCT00387894|Experimental|erlotinib hydrochloride (Tarceva)|During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
89252306|NCT03992976||Teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
89252307|NCT03992976||Parents of teenagers with chronic pain|Semi-structured interviews followed by 'think-aloud' procedure in part two. Semi-structured interviews may last up to 1 hour and are audio-recorded. A pre-piloted interview schedule has been developed and will guide the conversation. 'Think-aloud' procedure involves showing participants some of the online content that has been developed on a computer screen, and asking them to say aloud their commentary on any aspects. Participants will be audio-recorded during the task, and it is not anticipated the task will take longer than 1 hour to complete. Each participant may only take part in one interview and one think-aloud procedure.
89252308|NCT00387426|Experimental|Arm I|Patients receive oral sunitinib malate once daily for 6 weeks.
89252309|NCT00387348|Placebo Comparator|Placebo-Placebo|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
89252310|NCT00387348|Other|Placebo-Escitalopram|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
89252311|NCT00387348|Other|Escitalopram-Placebo|Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks
89252312|NCT03993522|Experimental|CTO Exerciser|"2x Symptom limited cardiopulmonary exercise tests~1x Sub-maximal cardiopulmonary exercise test (20 minutes)"
89252313|NCT03992820|Experimental|TENS arm (trial arm)|The trial group will have the TENS (transcutaneous electrical nerve stimulator) to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.
89252314|NCT03992820|Other|EMLA arm (Control arm)|The control group will have EMLA (Eutatic mixture of local anaesthetic) applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution.
89252315|NCT01042080|Active Comparator|PSV-ET 25|Pressure support ventilation with expiratory trigger set at 25 %.
89252316|NCT01042080|Active Comparator|PSV-ET 50|Pressure support ventilation with expiratory cycling set at 50 %.
89252317|NCT01042080|Experimental|NAVA|NAVA level is adjusted to achieve similar peak inspiratory pressure levels than during PSV.
89252318|NCT00413660|Experimental|CP 690,550 1 mg BID|
89252319|NCT00413660|Experimental|CP 690,550 10 mg BID|
89252320|NCT00413660|Experimental|CP 690,550 15 mg|
89252321|NCT00413660|Experimental|CP 690,550 3 mg BID|
89252322|NCT00413660|Experimental|CP 690,550 5 mg BID|
89252323|NCT00413660|Experimental|CP-690,550 20 mg QD|
89252324|NCT00413660|Placebo Comparator|Placebo|Dummy tablets
89252325|NCT01234532|Experimental|entinostat & anastrozole neoadjuvant|"Neoadjuvant entinostat daily on days 1, 8, 15, 22, and 29 + anastrozole daily on days 4-29 followed by surgery ie either lumpectomy or mastectomy.~Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
89252326|NCT00431444|Active Comparator|Zoledronic Acid|Zoledronic acid 5 mg (single i.v. infusion) + daily oral placebo for 6 months (zoledronic acid group)
89252327|NCT00431444|Active Comparator|Raloxifene|Placebo (single i.v. infusion) + oral raloxifene 60 mg/day for 6 months (raloxifene group)
89252328|NCT01323686|Experimental|Imaging guided LV lead placement|
89252329|NCT01323686|No Intervention|Empiric LV lead placement|LV lead placement using standard clinical routine.
89252330|NCT02635022||FLS|Patients with new hip fracture or newly identified vertebral fractures
89252331|NCT02635022||MMS|Patients prescribed with anti-osteoporosis medications but not fit FLS requirements
89252332|NCT00430352|Experimental|1|
89252333|NCT00287469|Experimental|20mcg Recombinant HEV|20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
89252334|NCT00287469|Placebo Comparator|Placebo|PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
89252335|NCT01068405|Experimental|Methotrexate|Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
89252336|NCT01068405|Placebo Comparator|Placebo|Patients with digital arthritis receiving placebo at 10mg/week during 12 months
89252337|NCT00429572|Experimental|Allogeneic Transplantation|Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.
89252338|NCT00287079|Experimental|Rebif®|
89252339|NCT00287079|Other|No Treatment|
89252340|NCT03976167|Active Comparator|Common nasal cannula|Oxygen administration up to 4 liters according defined protocol
89252341|NCT03976167|Experimental|High flow nasal cannula|Oxygen administered with high flow nasal cannula according child weight and protocol designed for this study
89252342|NCT03975933|Experimental|Free pregnancy tests at baseline but not for the future|We offer free pregnancy test service at baseline but the respondents do not have an opportunity to receive or buy a pregnancy test.
89252343|NCT03975933|Experimental|Free pregnancy tests at baseline and for the future|We offer free pregnancy test service at baseline and a free pregnancy test for future use.
89252344|NCT03975933|Experimental|Free pregnancy tests at baseline and future use (random price)|We offer free pregnancy test service at baseline and the respondents have an opportunity to buy a pregnancy test.
89252345|NCT03975933|No Intervention|Control Group|Control group. No intervention is implemented.
89252346|NCT03975933|Experimental|Pregnancy test for the future use|No free pregnancy tests at baseline, but receive a free pregnancy test for the future.
89252347|NCT03975933|Experimental|Pregnancy test for the future with random price|No free pregnancy tests at baseline, but receive an opportunity to buy a pregnancy test for the future (ranodmized price).
89252348|NCT00429494|Experimental|Leuprolide Acetate|Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.
89252349|NCT00429416|Experimental|LLME to Decrease GVHD Following HSC T|To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
89252350|NCT00429182|Experimental|High-dose chemotherapy|Carboplatin + Cyclophosphamide + Thiotepa
89252351|NCT00429104|Experimental|HER2+ Metastatic Breast Cancer|Herceptin 4 mg/kg IV Over 90 Minutes + GM-CSF 250 mcg/m^2 subcutaneously
89252352|NCT00429026|Experimental|Fludarabine + Cyclophosphamide with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
89252353|NCT00429026|Experimental|Fludarabine + Melphalan with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
89252354|NCT00301821|Experimental|Epratuzumab + Rituximab + CHOP|One arm open label.
89252355|NCT03976713|Experimental|Bufei Yishen granule plus Western medicine|Patients in this arm will receive Bufei Yishen granule in addition to Western medicine.
89252356|NCT03976713|Placebo Comparator|Placebo Bufei Yishen granule plus Western medicine|Patients in this arm will receive placebo Bufei Yishen granule in addition to Western medicine.
89252357|NCT01068483|Experimental|BKM120|Dose escalation followed by dose expansion
89252358|NCT00372996|Experimental|1|CP-751,871 + exemestane Treatment until progression or toxicity
89252359|NCT00372996|Active Comparator|2|
89252360|NCT01046292|Experimental|Ginkgo biloba|
89252361|NCT01046292|Placebo Comparator|Placebo control|
89252362|NCT00399360|Placebo Comparator|Group 1|No Lifestyle Modification and Placebo
89252363|NCT00399360|Active Comparator|Group 2|Lifestyle Modification and Placebo
89252364|NCT00399360|Active Comparator|Group 3|No Lifestyle Modification and Metformin
89252365|NCT00399360|Active Comparator|Group 4|Lifestyle Modification and Metformin
89252366|NCT00428948|Experimental|Tolvaptan|Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
89252367|NCT00428948|Placebo Comparator|Placebo|Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
89252368|NCT00428792|Experimental|Very light breakfast (VLB) then standard breakfast (SB)|Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
89252369|NCT00428792|Experimental|Standard breakfast (SB) then very light breakfast (VLB)|Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
89252370|NCT01037894|Experimental|Acupuncture|Acupuncture and conventional rehabilitation
89252371|NCT01037894|Active Comparator|Control|Conventional rehabilitation only
89252372|NCT00300885|Experimental|Sorafenib + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
89252373|NCT00300885|Active Comparator|Placebo + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
89252374|NCT00386334|Placebo Comparator|Placebo|Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
89252375|NCT00386334|Experimental|Eszopiclone|Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
89252376|NCT01143116|Experimental|Catheter A|"Catheterization with Catheter A, which releases silver ions into the urethra and urinary bladder upon catheterization,.~After activation in the wetting solution the coating retains water creating a smooth liquid surface around the catheter.The products are intended for single use. No additional lubricant were used.~The subject will be treated with investigational products during 24 hours. During this period the subject will be catheterized with the study catheter at six occasions (every 4 hours)."
89252377|NCT01143116|Experimental|Catheter B|"Catheterization with Catheter B, which releases both silver ions and degradable silver particles.. After activation in the wetting solution the coating retains water creating a smooth liquid surface around the catheter.The products are intended for single use. No additional lubricant were used.~The subject will be treated with investigational products during 24 hours. During this period the subject will be catheterized with the study catheter at six occasions (every 4 hours)."
89252378|NCT01037972||Whole body vibration|
89252379|NCT01037972||Conventional physiotherapy|
89252380|NCT01034774|Active Comparator|ACHN-490 Injection|ACHN-490 Injection will be given either 1 or 5 consecutive days at a dose of 15mg/kg.
89252381|NCT01034774|Placebo Comparator|Placebo is Normal Saline|Placebo will be given either 1 or 5 consecutive days to mask when ACHN-490 Injection is given.
89252382|NCT00428714|Experimental|Enzastaurin-Cohort 1|Chemo-naive participants who had androgen-independent prostate cancer with rising prostate-specific antigen (PSA) levels but no clinical or radiographic evidence of metastatic disease. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
89252383|NCT00428714|Experimental|Enzastaurin-Cohort 2|Participants with progressed, metastatic prostate cancer who had received prior treatment with a docetaxel-containing agent. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
89252384|NCT01033214|Experimental|TAArget Thoracic Stent Graft|those treated with the investigational device
89252385|NCT00292227|Experimental|Rotigotine|Rotigotine Patch
89252386|NCT00292227|Placebo Comparator|Placebo|Placebo patch
89252387|NCT00386100|Placebo Comparator|Metformin|MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.
89252388|NCT00386100|Active Comparator|Avandamet (Rosiglitazone maleate/metformin hydrochloride)|AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg
89252389|NCT01068561|Experimental|Test group|open-label study of retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200.
89252390|NCT00300495|Experimental|1 - Amiodarone|Perioperative amiodarone
89252391|NCT00300495|Active Comparator|2 - Control|Control arm, standard care with no perioperative amiodarone
89252392|NCT01068639||A|
89252393|NCT03979989|Experimental|Tapentadol IR|A single oral dose of tapentadol IR was administered in a fasted state (Treatment A).
89252394|NCT03979989|Experimental|Omeprazole, Tapentadol IR|Oral doses of omeprazole were administered once daily in a fasted state on 4 consecutive days (Days -3 to 1), plus 1 capsule of CG5503 IR administered 2 hours after the administration of omeprazole on Day 1 (Treatment B).
89252395|NCT02532387||MGH ED/EDOU patients|"Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
89252396|NCT02532387||BWH ED/EDOU patients|"Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
89252397|NCT02532387||Control subjects|"Contemporary controls: subjects diagnosed with Venous Thromboembolism (VTE) in the ED and who are not eligible for outpatient treatment~Historical controls:~Subjects enrolled in the prospective and retrospective SPEED-D study (PI: Kabrhel) and diagnosed with PE between 2006-2012.~Subjects diagnosed with VTE in the MGH and BWH ED in the 18 months prior to the use of the clinical outpatient treatment of PE protocol."
89252398|NCT01070199|Experimental|liquid to liquid,|
89252399|NCT01070199|Experimental|liquid to solid,|
89252400|NCT01070199|Experimental|solid to liquid|
89252401|NCT01070199|Experimental|solid to solid|
89252402|NCT01325571|Experimental|tacrolimus group|
89252403|NCT01325571|Placebo Comparator|placebo group|
89252404|NCT00386022|Experimental|Young postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
89252405|NCT00386022|Experimental|Older postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
89252406|NCT01068795|No Intervention|enoxaparin fixed|enoxaparin dosage will be fixed during pregnancy
89252407|NCT01068795|Experimental|enoxaparin adjusted|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
89252408|NCT03979755||Study Group|Women cancer survivors living in Campo Belo, Minas Gerais.
89252409|NCT03979755||Control Group|Women in routine follow-up in the public health system in Campo Belo, Minas Gerais.
89252410|NCT01068951|Active Comparator|Mesenchymal stem cells|Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
88806099|NCT01478581|Experimental|Cohort 4|PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week
89252411|NCT01068951|No Intervention|Control|
89252412|NCT00286455|Experimental|Alogliptin 12.5 mg QD|
89252413|NCT00286455|Experimental|Alogliptin 25 mg QD|
89252414|NCT00286455|Placebo Comparator|Placebo QD|
89252415|NCT00385944|Experimental|Prasugrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) prasugrel 10 mg and two placebo tablets, matched to clopidogrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of clopidogrel two 75 mg tablets and one placebo matched to prasugrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
89252416|NCT00385944|Active Comparator|Clopidogrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) Clopidogrel two 75 mg and one placebo tablet, matched to prasugrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of prasugrel one 10 mg tablet and two placebo tablets matched to clopidogrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
89252417|NCT01046370|Experimental|ARP intervention|
89252418|NCT01046370|No Intervention|No intervention|
89252419|NCT01046448||4C|Children with chronic kidney disease stage IIIb to V (GFR 10 to 45 ml/min/1.73m²) at screening.
89252420|NCT00286221|Experimental|Supratentorial PCA fentanyl|
89252421|NCT00286221|Active Comparator|Supratentorial PRN fentanyl|
89252422|NCT00286221|Experimental|Infratentorial PCA fentanyl|
89252423|NCT00286221|Active Comparator|Infratentorial PRN fentanyl|
89252424|NCT03976635|Active Comparator|Removable Mandibular Retractor|Patients in this group will be treated by the Removable Mandibular Retractor (RMR) in order to get rid of the anterior cross bite. This appliance is removable.
89252425|NCT03976635|Experimental|Bone-anchored intermaxillary Traction|Patients will be treated using bone-anchored intermaxillary traction. Class III elastics will be extended from the Adam's clasps placed in the upper removable appliance towards the heads of mini-implants placed between the permanent canine and lateral incisors on either side of the lower dental arch.
89252426|NCT00285207|Placebo Comparator|Placebo|Placebo administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
89252427|NCT00285207|Experimental|A007|0.25% A007 administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
89252428|NCT00398112|Experimental|Arm I|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89252429|NCT01065129|Experimental|Dose Level 1|"AMD3100 320 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
89252430|NCT01065129|Experimental|Dose Level 2|"AMD3100 440 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
89252431|NCT01065129|Experimental|Dose Level 3|"AMD3100 560 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
89252432|NCT01065129|Experimental|Expanded DLT Cohort|After the MTD is determined, patients will be enrolled at the MTD dose of plerixafor. These patients will not receive G-CSF priming but will be treated with plerixafor and azacitidine for 2 cycles.
89252433|NCT03976791|Experimental|Enlarged internal incision|enlarged the internal incision about 0.4mm
89252434|NCT03976791|Placebo Comparator|Regular 2.2mm incision|regular 2.2mm corneal incision for microincision coaxial phacoemulsification
89252435|NCT01042314|Experimental|Donepezil and BMS-708163|
89252436|NCT01069029||Combined surgery|Patient which underwent combined surgery of MH and cataract extraction
89252437|NCT01069029||Successive surgery|Patients which underwent the two successive procedures
89252438|NCT01044654|Experimental|Cohort 1|3 Subjects will receive a single infusion of 0.5-1.0 x 1010 SB-728-T
89252439|NCT01044654|Experimental|Cohort 2|3 Subjects will receive a single infusion of 2.0 x 1010 SB-728-T
89252440|NCT01044654|Experimental|Cohort 3|3 Subjects will receive a single infusion of 3.0 x 1010 SB-728-T
89252441|NCT01044654|Experimental|Cohort 4|Up to 4 HAART failure subjects will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T
89252442|NCT01044654|Experimental|Cohort 5|"Up to 20 subjects with heterozygote CCR5 delta-32 mutation will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T.~Cohort 5 subjects will undergo a structured treatment interruption 2 months following infusion in which their anti-retroviral therapy will be discontinued for 16 weeks. HAART will be reinstituted in subjects whose CD4+ cell counts drop to <350 cells/mm3 and/or whose HIV-RNA increases to >100,000 on three consecutive weekly measurements.~At the end of the STI, subjects with a sustained detectable viral load will be reinstituted on HAART. Subjects with HIV RNA levels below the limit of detection will remain off HAART. Subjects with an undetectable viral load will remain off HAART until HIV RNA levels are detectable or their CD4 count drops below 350 cell/mm3 on three consecutive weekly measurements."
89252443|NCT01065207|No Intervention|patient|
89252444|NCT01046604|No Intervention|No treatment|This is the group of patients that will not undergo any treatment with Lovaza prior to mitral valve repair surgery. This is the 'control' group.
89252445|NCT01046604|Active Comparator|Lovaza treated|This arm will be the group of patients that will be treated with Lovaza prior to undergoing mitral valve repair surgery.
89252446|NCT00424346|Experimental|Canakinumab 600 mg IV + 300 mg q2wk|Participants received canakinumab 600 mg intravenous (IV) loading dose on Day 1 and 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg every 4 weeks.
89252447|NCT00424346|Experimental|Canakinumab 300 mg q2wk|Participants received canakinumab 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
89252448|NCT00424346|Experimental|Canakinumab 150 mg q4wk|Participants received canakinumab 150 mg subcutaneous injections every 4 weeks (q4wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
89252449|NCT00424346|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
89252450|NCT00283959|Experimental|Migalastat|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week extension period.
89252451|NCT01069107|Active Comparator|Consume of health services|One year follow-up of patients randomized to two different levels of health care
89252452|NCT00372528|Experimental|pregabalin|open label treatment
89252453|NCT00283803|Experimental|IAS and Exisulind|Patients will receive intermittent dosing of hormone therapy with commercially supplied luteinizing hormone-releasing hormone (LHRH) agonist and anti-androgen to be chosen by physician per standard of care. Exisulind will be started 3 months prior to the end of the second cycle of hormone therapy. Patients will continue treatment with Exisulind beyond the completion of the second cycle of hormone therapy until they meet criteria for discontinuation.
89252454|NCT01044810||Simultaneous interruption (Exposure gr)|stopped all drugs in NNRTI-based regimens simultaneously after allergic reactions to NVP-based regimens, and later started EFV-based regimens
89252455|NCT01044810||Naive (Control group)|HIV-1-infected patients who started EFV-based regimens as their initial ARV regimens.
89252456|NCT01044810||staggered interruption (exposure group)|"after having allergic reactions to NVP-based regimens, stopped NNRTIs first, continued the other NRTIs for a period of time, i.e. staggered interruption, and later started EFV-based regimens"
89252457|NCT01033370|Other|Open label, non-randomized, pilot study|All subjects who provide consent for trial participation with an acute aortic emergency and elevated BP (systolic blood pressure [SBP] ≥120 mm Hg) requiring IV antihypertensive therapy for up to 48 hours will be administered an infusion of clevidipine to evaluate the efficacy and safety of the IV drug.
89252458|NCT03976089|Experimental|Recipe 4 Success intervention|10 lessons delivered across 10 successive weeks within Early Head Start infrastructure by families' regular Early Head Start home visitors. Lessons involved active coaching in which parents and children prepared healthy snacks or meals. Lessons also included information on children's self-regulation skills and healthy eating habits.
89252459|NCT03976089|Active Comparator|Treatment as usual Early Head Start|Regular Early Head Start home visitors continued to implement evidence-informed developmentally appropriate curriculum designed to promote children's physical health, cognitive skills, and social-emotional functioning as well as parents' capacities to support their children's development.
89252460|NCT03975777|Experimental|low-intensity exercise - high-intensity exercise|low-intensity exercise session followed by a high-intensity exercise session separated by a minimum of 14 days
89252461|NCT03975777|Experimental|high-intensity exercise - low-intensity exercise|high-intensity exercise session followed by a low-intensity exercise session separated by a minimum of 14 days
89252462|NCT03742466|Active Comparator|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
89252463|NCT03742466|Active Comparator|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
89252464|NCT01065285|Experimental|Evaluation of vaccines against flu|Evaluation of vaccines against flu
89252465|NCT01033526|Placebo Comparator|Arm 2|
89252466|NCT01033526|Experimental|Arm 1|
89252467|NCT00397488|Experimental|Sunitinib|This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
89252468|NCT01038206|Experimental|Family Function Intervention|Familias Unidas Intervention Program
89252469|NCT01038206|No Intervention|Treatment as Usual|The Public School system mandates that all high school students receive at least 5 lessons (55 minutes each) per year of HIV prevention.
89252470|NCT01581411|Experimental|IA t-PA|intra-ophthalmic artery injection of tissue plasminogen activator
89252471|NCT02900664|Experimental|PDR + ACZ 100mg Q8W|PDR + ACZ 100mg Q8W
89252472|NCT02900664|Experimental|PDR + ACZ 300mg Q8W|PDR + ACZ 300mg Q8W
89252473|NCT02900664|Experimental|PDR + ACZ RDE TNBC|PDR + ACZ Recommended Dose for Expansion (RDE) Triple Negative Breast Cancer (TNBC)
89252474|NCT02900664|Experimental|PDR + ACZ RDE NSCLC|PDR + ACZ Recommended Dose for Expansion (RDE) Non-Small Cell Lung Cancer (NSCLC)
89252475|NCT02900664|Experimental|PDR + ACZ RDE CRC|PDR + ACZ Recommended Dose for Expansion (RDE) Colorectal Cancer (CRC)
89252476|NCT02900664|Experimental|PDR + CJM 25mg Q4W|PDR + CJM 25mg Q4W
89252477|NCT02900664|Experimental|PDR + CJM 75mg Q4W|PDR + CJM 75mg Q4W
89252478|NCT02900664|Experimental|PDR + CJM 225mg Q4W|PDR + CJM 225mg Q4W
89252479|NCT02900664|Experimental|PDR + CJM 450mg Q4W|PDR + CJM 450mg Q4W
89252480|NCT02900664|Experimental|PDR + CJM 450mg Q2W|PDR + CJM 450mg Q2W
89252481|NCT02900664|Experimental|PDR + CJM 900mg Q4W|PDR + CJM 900mg Q4W
89252482|NCT02900664|Experimental|PDR + CJM 900mg Q2W|PDR + CJM 900mg Q2W
89252483|NCT02900664|Experimental|PDR + CJM 1200mg Q4W|PDR + CJM 1200mg Q4W
89252484|NCT02900664|Experimental|PDR + TMT 0.5mg QD|PDR + TMT 0.5mg QD
89252485|NCT02900664|Experimental|PDR + TMT 1mg QD|PDR + TMT 1mg QD
89252486|NCT02900664|Experimental|PDR + TMT 1mg QD, 3 Weeks on/1 Week off|PDR + TMT 1mg QD, 3 Weeks on/1 Week off
89252487|NCT02900664|Experimental|PDR + TMT 1.5 mg QD, 2 Weeks on/2 Weeks off|PDR + TMT 1.5 mg QD, 2 Weeks on/2 Weeks off
89252488|NCT02900664|Experimental|PDR + TMT 1.5 mg QD, 3 Weeks on/1 Week off|PDR + TMT 1.5 mg QD, 3 Weeks on/1 Week off
89252489|NCT02900664|Experimental|PDR + EGF816 25mg QD|PDR + EGF816 25mg QD
89252490|NCT02900664|Experimental|PDR + EGF816 50mg QD|PDR + EGF816 50mg QD
89252491|NCT02900664|Experimental|s.a. ACZ RDE TNBC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Triple Negative Breast Cancer (TNBC)
89252492|NCT02900664|Experimental|s.a. ACZ RDE NSCLC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Non-Small Cell Lung Cancer (NSCLC)
89252493|NCT02900664|Experimental|s.a. ACZ RDE CRC|Single agent (s.a.) ACZ Recommended Dose for Expansion (RDE) Colorectal Cancer (CRC)
89252494|NCT03975699||Patients in centre 1: Louis-Mourier Hospital|All SCD follow-up consultations were conducted jointly by a paediatrician and a clinical psychologist.
89252495|NCT03975699||Patients in centre 2: Evry hospital|All SCD follow-up consultations were conducted by a paediatrician alone. The unit had close links with the local psycho-medical paediatric care centre when specialized referrals were necessary.
89252496|NCT03975699||Patients in centre 3: Clamart hospital|All SCD follow-up consultations were conducted by a paediatrician alone.
89252497|NCT01033604|Experimental|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
89252498|NCT01033604|Active Comparator|Split skin graft alone|Full thickness defects treated with split skin graft alone.
89252499|NCT03976557|Experimental|BIP CVC|Polyurethane CVC with noble metal coating
89252500|NCT03976557|Active Comparator|Standard CVC|Standard CVC made of polyurethane
89252501|NCT01065363|Experimental|Lifestyle conseling|
89252502|NCT01324596|Active Comparator|Arm A: R-CHOP|Participants receive 6 cycles of conventional R-CHOP chemotherapy on a standard 21 day schedule: Rituximab 375mg/m2 intravenous Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous Prednisolone 100mg od orally
89252503|NCT01324596|Experimental|Arm B: RB-CHOP|"Participants in this arm will receive 1 cycle of conventional R-CHOP chemotherapy, followed by 5 cycles of R-CHOP:~Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous bortezomib - Intravenous Prednisolone 100mg od orally~."
89252504|NCT00424190|Experimental|Ceftaroline for Injection|
89252505|NCT00424190|Active Comparator|IV Vancomycin and IV Aztreonam|
89252506|NCT01045044||Breast cancer, chemotherapy|Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
89252507|NCT01045044||Normal control|Up to 15 normal, healthy women.
89252508|NCT01042470||control group|female patients without pelvic organ prolapse, stage 0 or I (POP-Q)
89252509|NCT01042470||pelvic organ prolapse|female patients with pelvic organ prolapse stage II or higher (POP-Q)
89252510|NCT02859012|Experimental|axitinib|Axitinib 5 mg twice (10mg) daily po medication until progression or development of unacceptable toxicity (4 weeks is considered as one cycle).
89252511|NCT02859012|Active Comparator|observation|Observation. if disease progression is detected, cross-over will be permitted.
89252512|NCT00428246|Active Comparator|1|1 mcg paricalcitol
89252513|NCT00428246|Active Comparator|2|2 mcg paricalcitol
89252514|NCT00428246|Placebo Comparator|3|Placebo
89252515|NCT00274287|Experimental|GM-CSF|Once patients have finished receiving the chemotherapy and no signs of disease progression they may receive GM-CSF as outlined in the protocol
89252516|NCT01042626|Experimental|Normocalcemic Hyperparathyroidism|
89252517|NCT01042626|Experimental|Hypercalcemic Hyperparathyroidism|
89252518|NCT01042626|Active Comparator|Healthy subjects|
89252519|NCT02581670|Experimental|Oligometastatic breast cancer patients|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients medically inoperable, using VMAT RapidArc approach.
89252520|NCT01045200||Follow-up|Patients curatively operated for rectal cancer
89252521|NCT01046760||Rolandic Epilepsy|Patients older than seven years old with clinical and electroencephalographic diagnosis of Rolandic Epilepsy
89252522|NCT00423800|Experimental|Pegetron® - 24 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
89252523|NCT00423800|Active Comparator|Pegetron®- 48 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.
89252524|NCT03932708|Experimental|Urgent Care Antibiotic Stewardship Intervention|All 38 urgent care clinics will implement CDC Core Elements of outpatient antibiotic stewardship as described above.
89252525|NCT00405548|Active Comparator|BNP (nesiritide)|BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
89252526|NCT00405548|Placebo Comparator|Placebo|Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)
89252527|NCT00282243|Experimental|Tacrolimus MR|"After enrollment in the pharmacokinetic period, patients were maintained on their usual dose of tacrolimus twice daily on Day 1 through Day 14 and on Day 15 were converted to tacrolimus modified release (MR) once-daily in the morning for 14 days, converted back to tacrolimus twice daily for 14 days and then converted back to tacrolimus MR formulation once-daily in the morning for 14 days, all based on a 1:1 mg for mg total daily dose conversion. The extended treatment period began on day 57 and consisted of a single dose of tacrolimus extended-release formulation once every morning through the end of the study.~Dose adjustments were allowed in order to maintain the target tacrolimus trough level within the range of 5 to 20 ng/mL and for clinical reasons."
89252528|NCT00272961|Placebo Comparator|placebo|
89252529|NCT00272961|Experimental|ARM 1|
89252530|NCT00272961|Experimental|ARM 2|
89252531|NCT00272961|Experimental|ARM 3|
89252532|NCT00272961|Experimental|ARM 4|
89252533|NCT00282087|Other|gemcitabine/docetaxel then doxorubicin|Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).
89252534|NCT00404924|Placebo Comparator|1|Best Supportive Care
89252535|NCT00404924|Experimental|2|Vandetanib + Best Supportive Care
89252536|NCT00281697|Experimental|Standard chemotherapy + bevacizumab|Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
89252537|NCT00281697|Placebo Comparator|Standard chemotherapy + placebo|Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.
89252538|NCT01070901||Organ transplant recipients|
89252539|NCT00271947|Experimental|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after the conditioning regimen
89252540|NCT00232180|Active Comparator|Eplerenone arm|Eplerenone administered on top of background standard heart failure therapy
89252541|NCT00280683|Active Comparator|Arginine|Enrolled subjects will take L-arginine orally, at 0.1 g/kg/day. Subjects will take three to four 1 g capsules (based on weight) of L-arginine twice daily for three months. L-arginine capsules were obtained from Jarrow Pharmaceuticals.
89252542|NCT00280683|Placebo Comparator|Placebo|Enrolled subjects took three to four placebo capsules that matched color and size of the intervention twice daily for three months. Matching placebo capsules were obtained from Jarrow Pharmaceuticals.
89252543|NCT00270855|Other|Arm Crank Ergometer|Upper body Cycle ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
89252544|NCT00270855|Other|FESLCE|Functional Electrical Stimulation Leg Cycle Ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
89252545|NCT01070277|Placebo Comparator|Placebo arm|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
89252546|NCT01070277|Experimental|Tinidazole and Albendazole treatment|Tinidazole 1 gram BID for 2 days followed by Albendazole 400mg BID for 7 days
89252547|NCT01070355|Placebo Comparator|Placebo|2 capsules twice daily
89252548|NCT01070355|Active Comparator|Eicosapentaenoic acid free fatty acid|2g daily (2 x 500mg capsules twice daily)
89252549|NCT00404768|Experimental|Treatment|GSK221149A
89252550|NCT00404768|Placebo Comparator|Placebo|Placebo
89252551|NCT00270231|Active Comparator|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
89252552|NCT00270231|Placebo Comparator|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
89252553|NCT02532309|Experimental|Rosuvastatin dose adjustment|
89252554|NCT02532309|Experimental|Rosuvastatin fixed dose|
89252555|NCT00258856|Experimental|Menactra® Group 1|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination.
89252556|NCT00258856|Experimental|Menactra® Group 2|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination.
89252557|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 3|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination.
89252558|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 4|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination.
89252559|NCT03909620|Experimental|LDCT arm|All eligible participants will undergo screening with LDCT
89252560|NCT00269919|Experimental|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 2 years.
89252561|NCT01038284|Sham Comparator|Control|
89252562|NCT01038284|Active Comparator|Patient education|
89252563|NCT01038362|Active Comparator|Almonds|National Cholesterol Education Program Step I diet plus almonds for 6 weeks
89252564|NCT01038362|Placebo Comparator|No Almonds|National Cholesterol Education Program Step 1 diet without almonds for 6 weeks
89252565|NCT00258154|Experimental|1|RotaTeq/Infanrix Hexa
89252566|NCT00258154|Placebo Comparator|2|Placebo/Infanrix Hexa
89252567|NCT00257920|Active Comparator|A|
89252568|NCT00257920|Active Comparator|B|
89252569|NCT00268983|Experimental|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
89252570|NCT00268983|Active Comparator|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
89252571|NCT01065753|Experimental|Life-style modification|Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control.
89252572|NCT01070511|Experimental|Tadalafil|
89252573|NCT01070511|Placebo Comparator|Placebo|
89252574|NCT01070589||Group 1: Obese|BMI>30
89252575|NCT01070589||Group 2: control|Group 2:Normal weight (BMI <25). age and gender matched.
89252576|NCT01070667|Experimental|Dronedarone|Patients will receive 400 mg of dronedarone per day for 3 months.
89252577|NCT01070667|Placebo Comparator|Placebo|Patients will receive a placebo tablet once per day for 3 months. AF burden and other parameters described will be monitored from the participants permanent pacemaker. Participants will also be asked to fill out symptom diaries and questionaires.
89252578|NCT00257608|Experimental|1|
89252579|NCT00257608|Placebo Comparator|2|
89252580|NCT01073176|Experimental|TEAMS|TEAMS has been designed to promote executive skills, memory and fine motor control, and includes game-like activities that allow for increases in task complexity.
89252581|NCT00231478|Experimental|1|
89252582|NCT00231478|Experimental|2|
89252583|NCT00413192|Experimental|1|
89252584|NCT01038440|Placebo Comparator|Control|
89252585|NCT01038440|Active Comparator|EPA 0.5 g/d|
89252586|NCT01038440|Active Comparator|EPA 1.5 g/d|
89252587|NCT01038440|Active Comparator|EPA 3.0 g/d|
89252588|NCT01038440|Experimental|SDA 0.5 g/d|
89252589|NCT01038440|Experimental|SDA 1.5 g/d|
89252590|NCT01038440|Experimental|SDA 3.0 g/d|
89252591|NCT01038440|Experimental|SDA 6.0 g/d|
89252592|NCT00207142|Active Comparator|Switch|ATV 400 mg + 2 NRTIs (TBD), ATV once daily, NRTIs (TBD)
89252593|NCT00207142|Active Comparator|Continuation|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
89252594|NCT00207142|Other|Rescue|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
89252595|NCT00268905|Experimental|1|
89252596|NCT00268905|Experimental|2|
89252597|NCT00268905|Experimental|3|
89252598|NCT03974997|Other|serum concentration changes in cytokine TWEAK|We will perform a prospective study in which 50 patients with multiple sclerosis in the isolated clinical syndrome stage will be included over a 12-month period. Mental Cerebral MRIs will be performed for each patient at baseline (T0), month 6, and month 12. Serum dosages of TWEAK will be performed each month for each patient for one year. Patients will also be treated with soluble TNF, the leader in the TNF family of ligands, anti-TWEAK antibodies (which may interfere with the activity and dosage of TWEAK) as well as C-reactive Protein C ( search for intercurrent infectious episode). These dosages will be correlated with the clinical evolution (appearance or not of an inflammatory flare) as well as the data of the imagery (number of lesions raised or not by the gadolinium).
89252599|NCT00206518|Experimental|A: Taxotere/Docetaxel|Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity.
89252600|NCT00206518|Experimental|B: AC Adriamycin/Cytoxan|In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by 4 cycles of single agent Taxotere (100 mg/m2) every 3 weeks.
89252601|NCT01065831|Experimental|Lifestyle counseling|This MINT-TLC group will be asked to attend 12 weekly counseling meetings focused on weight loss (if overweight), limiting sodium, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained Lay Health Advisors. Participants will attend weekly group classes targeted at lifestyle changes for the first 12 weeks (intensive phase); followed by three individual MINT sessions conducted monthly for the following three months (maintenance phase). The MINT-TLC sessions aim to help participants make useful therapeutic lifestyle changes (TLC) and develop skills to maintain these changes long-term.
89252602|NCT01065831|Placebo Comparator|Health Education Control Condition|Participants randomized to this control condition will receive traditional, group health education classes for 12 weeks delivered by experts on various health topics unrelated to hypertension such as cancer, health insurance, and depression.
89252603|NCT03972904|Experimental|Intervention group|The Light-Fat Rice® group
89252604|NCT03972904|Placebo Comparator|Control group|The comparable energy staple food group
89252605|NCT00206440|Experimental|Esomeprazole|Patients receiving chemotherapy (anthracycline-based) will be randomized to esomeprazole for Cycle 1 Days 1-5 and Cycle 2 Days 1-5
89252606|NCT00206440|Placebo Comparator|Sugar pill|Subjects will be given placebo Cycle 1 Days 1-5 and Cycle 2 Days 1-5.
89252607|NCT00268437|Experimental|Pemetrexed/Carboplatin|Pemetrexed+Carboplatin+Radiation
89252608|NCT00423488|Experimental|Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg|Participants were instructed to take one 10-mg ezetimibe tablet and one simvastatin placebo tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
89252609|NCT00423488|Active Comparator|Ezetimibe Placebo + Simvastatin 40 mg|Participants were instructed to take one ezetimibe placebo tablet and one simvastatin 20-mg tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
89252610|NCT03969472|Experimental|probiotic group|apply probiotic after surgery
89252611|NCT03969472|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery without probiotic
89252612|NCT03969472|No Intervention|control|without electrophysiologic therapy and probiotic after surgery
89252613|NCT00404066|Experimental|Neoadjuvant Chemotherapy|Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.
89252614|NCT01581645|Experimental|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
89252615|NCT01581723|Active Comparator|Monopolar TUR|Monopolar diathermy is used to perform tranurethral resection of bladder tumor
88806100|NCT00239642|Experimental|Venofer (0.5 mg/kg)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
89252616|NCT01581723|Experimental|Biploar TUR|Bipolar diathermy is used to perform transurethral resection of bladder tumor
89252617|NCT03993860|Experimental|Intervention arm|Infants will be given fish powder called Chisense (Potamothrissa acutirostris) for a period of 6 months from the time they are 6 months up to the time they are 12 months.
89252618|NCT03993860|Placebo Comparator|Control arm|Infants will be given fish powder called sorghum powder for a period of 6 months from the time they are 6 months up to the time they are 12 months.
89252619|NCT03993548|Experimental|Wellness Intervention|KickStart30 is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
89252620|NCT01038518||Health2010|Cross-sectional general population study
89252621|NCT01038596||osteoarthritic donors|pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors
89252622|NCT01038596||healthy donors|age-matched healthy donors
89252623|NCT01038674|Experimental|Anti-IL-20|
89252624|NCT01038674|Placebo Comparator|Placebo|
89252625|NCT00423332|Placebo Comparator|1|Cediranib placebo
89252626|NCT00423332|Experimental|2|Cediranib
89252627|NCT01040468|Active Comparator|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss
89252628|NCT01040468|Active Comparator|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss
89252629|NCT01040468|Active Comparator|Intensive Lifestyle Modification|Lifestyle intervention for weight loss
89252630|NCT00413036|Experimental|lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
89252631|NCT01034852||Surgical ablation|Patients undergoing surgical ablation for Atrial Fibrillation that have failed one or more previous attempts at catheter ablation for Atrial Fibrillation
89252632|NCT00412958|Experimental|Ocriplasmin 25µg|25µg of ocriplasmin intravitreal injection
89252633|NCT00412958|Experimental|Ocriplasmin 75µg|75µg of ocriplasmin intravitreal injection
89252634|NCT00412958|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
89252635|NCT00412958|Placebo Comparator|Placebo|Intravitreal injection of placebo
89252636|NCT01040546|Experimental|Individualized education|Individualized consultation of health problem, dietary intake and exercise
89252637|NCT01040546|Experimental|Grouped education|Grouped consultation of health problem, dietary intake and exercise
89252638|NCT00423176|Experimental|MFNS + Antibiotic|Mometasone furoate nasal spray (MFNS) twice daily (BID) for 29 days, plus antibiotic. Appropriate antibiotic therapy amoxicillin/clavulanic acid BID.
89252639|NCT00423176|Placebo Comparator|Placebo|Matching placebo nasal spray BID for 29 days, plus amoxicillin/clavulanic acid BID
89252640|NCT01040702|Experimental|ADHD -MPH|adults with ADHD diagnosis who receive a single dose of Methylphenidate
89252641|NCT01040702|Placebo Comparator|ADHD-placebo|adults with ADHD diagnosis who received placebo
89252642|NCT01040702|Experimental|non-ADHD-MPH|healthy adults who received a single dose of Methylphenidate
89252643|NCT01040702|Placebo Comparator|non-ADHD-placebo|healthy adults who received placebo
89252644|NCT00412880|Experimental|BI 2536|Total Patients
89252645|NCT00384930|Placebo Comparator|1|placebo tablet
89252646|NCT00384930|Active Comparator|2|2.5 mg tadalafil tablet
89252647|NCT00384930|Active Comparator|3|5 mg tadalafil tablet
89252648|NCT00384930|Active Comparator|4|10 mg tadalafil tablet
89252649|NCT00384930|Active Comparator|5|20 mg tadalafil tablet
89252650|NCT00423098|Experimental|Standard dose|Mycophenolate sodium was administered orally in combination with a standard dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 1 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
89252651|NCT00423098|Active Comparator|Low dose|Mycophenolate sodium was administered in combination with a reduced dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 0.5 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
89252652|NCT01042704|Experimental|Bendamustine, Lenalidomide and Dexamethasone|Treatment with Bendamustine in combination with Lenalidomide and Dexamethasone will be administered on an outpatient basis. Each treatment cycle will be 28 days dosed according to the Dose Escalation Schema.
89252653|NCT00750698|Experimental|Erlotinib-responsive|"Participants self-administered entinostat in combination with continued erlotinib self-administration.~Erlotinib-responsive participants are those who progressed following either a complete or partial response to erlotinib or a period of stable disease lasting at least 3 months."
89252654|NCT00750698|Experimental|Erlotinib-nonresponsive|"Participants self-administered entinostat in combination with continued erlotinib self-administration.~Erlotinib-nonresponsive participants are those who either progressed immediately during treatment with erlotinib (after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months."
89252655|NCT01046838|Placebo Comparator|Placebo|placebo 3 x daily
89252656|NCT01046838|Active Comparator|sildenafil|40 mg sildenafil 3 x daily
89252657|NCT01038908|Active Comparator|1|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
89252658|NCT01038908|Active Comparator|2|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
89252659|NCT01042782|Experimental|RAD-MitC|RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks
89252660|NCT01038986||CureXcell treated|Patients with chronic and/or refractory wounds for at least 4 weeks with no improvement that have been referred by their physician for CureXcell treatment
89252661|NCT00411788|Experimental|sirolimus and trastuzumab|Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability.
89252662|NCT01046994|Experimental|surgery|biliopancreatic diversion
89252663|NCT01046994|Active Comparator|standard medical care|patients treated according to the rules of good clinical practice
89252664|NCT01040936|Active Comparator|conventional group|patients will be treated by atorvastation 20mg/d after randomization, and continued for one year.
89252665|NCT01040936|Experimental|intensive group|patient will be loaded with 80mg atorvastatin, continued by atorvastatin 40mg/d for 30d, then receive atorvastatin 20mg/d for the following 11 months.
89252666|NCT01041014|Experimental|Professional medical interpreter|Limited English proficient Spanish-speaking patients seen in the treatment arm were provided with the services of a professionally-trained medical interpreter to facilitate communication between the patient and emergency department staff
89252667|NCT01041014|No Intervention|Control, Usual Language Services|Patients randomized to the control arm receive the services of the emergency departments' usual language services (i.e., a telephone language line or ad hoc interpreters).
89252668|NCT01041092|Placebo Comparator|sugar pill|
89252669|NCT01041092|Active Comparator|raloxifene hydrochloride|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
89252670|NCT01041326|Experimental|Leve 1 Radiation|Subjects in Group 1 will receive 39.6 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
89252671|NCT01041326|Experimental|Level 2 Radiation|Subjects in Group 2 will receive 45 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
89252672|NCT01041326|Experimental|Level 3 Radiation|Subjects in Group 3 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 50.4 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
89252673|NCT01041326|Experimental|Level 4 Radiation|Subjects in Group 4 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 54 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
89252674|NCT01041482|Experimental|sorafenib|To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.
89252675|NCT00422942|Experimental|1|
89252676|NCT01039142|Active Comparator|25 mg acitretin|capsule acitretin 25 mg/day will be administered to each patient for a period of 12 weeks
89252677|NCT01039142|Active Comparator|35 mg acitretin|capsule acitretin 35 mg/day will be administered to each patient for a period of 12 weeks
89252678|NCT01039142|Active Comparator|50 mg acitretin|capsule acitretin 50 mg/day will be administered to each patient for a period of 12 weeks
89252679|NCT00422162|Experimental|Duloxetine Hydrochloride (60 mg)|"Up to Week 4: 60 milligrams (mg) every morning and placebo every evening, by mouth (PO).~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders received 60 mg every morning and 60 mg every evening added to the placebo"
89252680|NCT00422162|Experimental|Duloxetine Hydrochloride (120 mg)|"Up to Week 4: 60 mg every morning and 60 mg every evening, PO.~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders continued as before with a placebo capsule added to the evening dose"
89252681|NCT00411632|Experimental|Bexarotene + Erlotinib|Bexarotene 400 mg/m^2 by mouth daily x 28 Days. Erlotinib 150 mg by mouth daily x 28 Days.
89252682|NCT01039298|Active Comparator|A|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The Control arm. Surgical boundaries for oral lesions will be defined under regular white light."
89252683|NCT01039298|Experimental|B|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The FV arm (experimental arm). Surgical boundaries for oral lesions will be defined by FV."
89252684|NCT00422084|Experimental|PA group|Pyronaridine artesunate (PA)
89252685|NCT00422084|Active Comparator|AL group|Arthemether lumefantrine (AL)
89252686|NCT00421928|Experimental|001|tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks
89252687|NCT00421928|Active Comparator|002|oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks
89252688|NCT00421928|Placebo Comparator|003|placebo matching placebo twice a day (BID) during 15 weeks
89252689|NCT00383292|Experimental|Tasisulam|
89252690|NCT01042860|Active Comparator|supplement|lutein supplement
89252691|NCT01042860|Placebo Comparator|placebo|Placebo
89252692|NCT01047072|Experimental|Arm I (transplant)|Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
89252693|NCT01047072|Active Comparator|Arm II (nontransplant)|Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
89252694|NCT01043016|Experimental|Photocyanine injection|Patients receive intravenous injection of Photocyanine injection from dosage of 0.1 mg/kg,0.2 mg/kg,0.33 mg/kg,0.5 mg/kg to 0.6 6mg/kg till the dose-limiting effect occur.
89252695|NCT01045356||children less than 2 months old|
89252696|NCT01045356||children 2 months to 12 months old|
89252697|NCT01045356||Children > 2 months old and less than or equal to 20 kg|
89252698|NCT00372060|Experimental|1|MK0431 + pioglitazone
89252699|NCT00372060|Placebo Comparator|2|Placebo/MK0431 + pioglitazone
89252700|NCT00421304|Placebo Comparator|Placebo|Participants will receive a single intravenous (IV) dose of placebo matched to motavizumab on Day 0 of the study.
89252701|NCT00421304|Experimental|Motavizumab 30 mg/kg|Participants will receive a single IV dose of motavizumab 30 mg/kg on Day 0 of the study.
89252702|NCT00421304|Experimental|Motavizumab 100 mg/kg|Participants will receive a single IV dose of motavizumab 100 mg/kg on Day 0 of the study.
89252703|NCT01043172|Experimental|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
89252704|NCT01047150||Tetrofosmin Rest patients|Patients that had a Rest myocardial perfusion study using Tc99m tetrofosmin
89252705|NCT01047150||Sestamibi stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Sestamibi
89252706|NCT01047150||Tetrofosmin stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Tetrofosmin
89252707|NCT01047150||Sestamibi rest patients|Patients that had a rest myocardial perfusion imaging study using Tc99m Sestamibi
89252708|NCT01043250||Risperidone|Receiving risperidone treatment
89252709|NCT01043250||Olanzapine|Receiving olanzapine treatment
89252710|NCT01043250||Aripiprazole|Receiving aripiprazole
89252711|NCT01043328||GROUP OSCC|"The study group is composed by patients with a condition that requires a procedure/surgery for oral squamous cell carcinoma treatment.~INTERVENTIONS: Collect blood, saliva and oral tissue."
89252712|NCT01043328||CONTROL GROUP|"Group without oral squamous cell carcinoma but with a condition that requires prosthetic procedure/surgery.~INTERVENTIONS: Collect blood, saliva and oral tissue."
89252713|NCT01045434|Experimental|Omeprazole Magnesium DR 20 mg Capsules|Omeprazole Magnesium DR 20 mg Capsules of Dr Reddys Laboratories Limited
89252714|NCT01045434|Active Comparator|Prilosec 20 mg Tablets|Prilosec 20 mg Tablets of Procter and Gamble
89252715|NCT01039454|Placebo Comparator|Placebo|2 way cross over.
89252716|NCT01039454|Active Comparator|Active|2 Way cross over
89252717|NCT01045512|Active Comparator|statins, standardised physical training|
89252718|NCT01045512|No Intervention|to continue with current lifestyle|
89252719|NCT01039532||Basal Bolus regimen|Basal Bolus regimen
89252720|NCT01039532||Biphasic human insulin|Biphasic human insulin
89252721|NCT01045590|Active Comparator|glibenclamide + Rosiglitazone|glibenclamide plus rosiglitazone
89252722|NCT01045590|Placebo Comparator|glibenclamide + placebo|
89252723|NCT01047384|Experimental|Experimental|acupuncture-moxibustion therapy
89252724|NCT01047384|Active Comparator|Regular therapy|Regular therapy
89252725|NCT01043406|Experimental|Single Arm, Device Implant|
89252726|NCT01047462|Active Comparator|Laparoscopic lavage|
89252727|NCT01047462|Active Comparator|Primary resection|
89252728|NCT00396630|Experimental|Rotarix Group|"All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
89252729|NCT00396630|Placebo Comparator|Placebo Group|"All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
89252730|NCT01043484|Experimental|A|Bevacizumab + Capecitabine + Radiotherapy
89252731|NCT01043484|Active Comparator|B|Capecitabine + Radiotherapy
89252732|NCT00396318|Experimental|Tenecteplase|
89252733|NCT00396162|Placebo Comparator|Placebo pill|Placebo pills on same schedule as active intervention.
89252734|NCT00396162|Active Comparator|Probiotic|L. rhamnosus R0011 strain
89252735|NCT00381888|Experimental|Patients Treated with Fondaparinux|Patients treated with at least one dose of Fondaparinux (2.5 mg subcutaneous, Days 1-28 by mouth).
89252736|NCT03992898||Chronic hepatitis cohort|In this cohort, patients were defined as type A acute-on-chronic liver failure (ACLF) patients who have chronic liver disease but without cirrhosis.
89252737|NCT03992898||Cirrhosis cohort|In this cohort, patients were defined as type B and type C ACLF patients with cirrhosis.
89252738|NCT00267969|Experimental|ustekinumab 45 mg|Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.
89252739|NCT00267969|Experimental|ustekinumab 90 mg|Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.
89252740|NCT00267969|Placebo Comparator|Placebo|Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.
89252741|NCT00280293|Placebo Comparator|1|Placebo
89252742|NCT00280293|Active Comparator|2|LAmotrigine
89252743|NCT00421148|Experimental|Sugammadex 0.5 mg/kg|Participants are to receive an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex is to be given.
89252744|NCT00421148|Experimental|Sugammadex 1 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.
89252745|NCT00421148|Experimental|Sugammadex 2 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex is to be given.
89252746|NCT00421148|Experimental|Sugammadex 4 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex is to be given.
89252747|NCT00421148|Placebo Comparator|Placebo|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single 3-mL bolus dose of placebo (sodium chloride 0.9% solution) is to be given.
89290317|NCT01218750|Experimental|edematous tractional epimacular membrane|Diabatic maculopathy comes to the edematous or tractional form. It is believed that epiretinal membranes are comprised from glial components. The processes of these cells may invade through the internal limiting membrane of the retina to the vitreous causing the vitreoretinal adhesion and anomalous posterior detachment of vitreous (APVD). In the macula, APVD causes vitreo-macular traction syndrome, which results in diffuse diabetic macular edema. If vitreoschisis is present, a place of dissection is crucial. If break occurs in front of the hyalocytes remaining on the retinal surface, the vitreous layer is thick and easily shrinks concentrically, which results in the formation of epimacular membrane.
89290318|NCT01376284||Subjects prescribed dutasteride capsules|Subjects with BPH prescribed dutasteride capsules during study period
89252748|NCT00403754|Experimental|Placebo-Ind 150 μg-Ind 300 μg-Ind 600 μg-Salmeterol|"In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 μg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
89252749|NCT00403754|Experimental|Ind 150 μg-Ind 600 μg-Placebo-Ind 300 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 μg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
89252750|NCT00403754|Experimental|Ind 300 μg-Placebo-Ind 600 μg-Ind 150 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 300 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 μg capsules; and in treatment period 4: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation, device on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
89252751|NCT00403754|Experimental|Ind 600 μg-Ind 300 μg-Ind 150 μg-Placebo-Salmeterol|"In treatment period 1: patients received 2 indacaterol (Ind) 300 μg capsules; in treatment period 2: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
89252752|NCT02330510||Alzheimer's Disease|Individuals with early Alzheimer's Disease (AD) or amnestic or multi-domain Mild Cognitive Impairment who have extensive Periventricular White Matter Hyperintensities
89252753|NCT02330510||Transient Ischemic Attack/Mild Subcortical Stroke|Individuals who have had a mild subcortical stroke or a Transient Ischemic Attack (TIA) with extensive Periventricular White Matter Hyperintensities in the absence of cortical infarcts
89252754|NCT00280059|Experimental|1|
89252755|NCT00280059|Active Comparator|2|
89252756|NCT00403130|Experimental|Phase II 3-drug regimen|Gemcitabine + Paclitaxel + Bevacizumab
89252757|NCT03993704|Experimental|Active|450 mg, 1125 mg, or 2250 mg of LHF-535 given once daily for 14 days
89252758|NCT03993704|Placebo Comparator|Placebo|Placebo to match LHF-535 given once daily for 14 days
89252759|NCT01039610|Experimental|Part A|GSK945237 2400mg single dose
89252760|NCT01039610|Experimental|Part B Cohort 1|GSK945237 400 mg QD, 7 Days 4 subjects GSK945237:2 subjects Placebo
89252761|NCT01039610|Experimental|Part B Cohort 2|GSK945237 400 mg QD, 14 Days 4 subjects GSK945237:2 subjects Placebo
89252762|NCT01039610|Experimental|Part B Cohort 3|GSK945237 400 mg BID, 14 Days 4 subjects GSK945237:2 subjects Placebo
89252763|NCT01039610|Experimental|Part B Cohort 4|GSK945237 800 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
89252764|NCT01039610|Experimental|Part B Cohort 5|GSK945237 1200 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
89252765|NCT01039610|Experimental|Part B Cohort 6|GS945237 1600 mg QD, 14 Days 9 subjects GSK945237:3 subjects Placebo
89252766|NCT01039610|Active Comparator|Part C|Linezolid 600 mg BID, 14 Days 9 subjects Linezolid:3 subjects Placebo
89252767|NCT01039610|Active Comparator|Part D|"2 period crossover Period 1: Placebo 1 day; GSK945237 dose to be determined, 5 Days Period 2: Placebo 5 days; moxifloxacin 400 mg single dose~16 subjects"
89252768|NCT00581672||questionnaires|Black men with prostate cancer
89252769|NCT00420290|Active Comparator|Kineret|Interleukin-1 receptor antagonist
89252770|NCT00420290|Placebo Comparator|Placebo|
89252771|NCT00267189|Active Comparator|Reduced CNI dose + everolimus ± steroids|Reduced CNI dose + everolimus (1.5 mg twice daily (b.i.d)) ± steroids
89252772|NCT00267189|Experimental|CNI continuation ± MPA/AZA ± Steroids|Standard CNI dose ± MPA/AZA ± steroids
89252773|NCT03834350|Other|At-Home Breathes Program|Participants will participate in the at-home BREATHES program which will consist of a video education module and using a hand-held spirometry device, SpiroPD.
89252774|NCT01589120|No Intervention|control group|Verbal description of goals of care reflecting usual care
89252775|NCT01589120|Experimental|Video Arm|Video intervention group
89252776|NCT01041560||Stoke|Hemiplegia with unilateral changes in tone and muscle strength
89252777|NCT00402116|Experimental|A|The Phase 1 consisted of the dose escalation of enzastaurin in 2 cohorts of up to 6 patients to assess maximum tolerated dose (MTD). Cohort 1 = radiotherapy/enzastaurin 250 mg per day/temozolomide 75 mg/m^2 therapy. The 6 initial cohort patients were clinically evaluated for dose-limiting toxicities (DLT). If no more than 1 of 6 patients experienced a DLT or tumor progression, patients continued 1 complete adjuvant enzastaurin/temozolomide 28-day cycle. If there was no significant toxicity after the first adjuvant cycle, participants received subsequent adjuvant enzastaurin/temozolomide cycles. If no more than 1 of the 6 initial cohort participants treated at 250 mg of enzastaurin experienced a DLT during radiotherapy and the first adjuvant cycle, up to 6 more participants could be entered at 500 mg of enzastaurin. The Phase 2, using the MTD determined in the Phase 1 (250 mg), evaluated the combination's safety and measured OS.
89252778|NCT00401960|Experimental|Daptomycin adjunctive group|Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
89252779|NCT00401960|No Intervention|standard of care|Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician
89252780|NCT00371826|Experimental|Calcineurin Inhibitor (CNI) Withdrawal|"Every randomized patient in this group received~Day 1 - Day 14: cyclosporine as Calcineurin Inhibitor (CNI) 5 mg/kg twice daily (b.i.d.), dose adjusted to achieve C2 target of 1,500 ng/mL (range 1,400-1,600 ng/mL) + mycophenolate sodium (MPA)720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg/day prednisone~Day 15 - Day 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg/day~Day 61 - Day 120: everolimus dose adjusted to achieve target 6-10 ng/mL + cyclosporine 25% dose reduction per fortnight, to be discontinued by day 120 as per protocol (or commence reduction by day 120 at discretion of investigator, to be completed within 2 months of commencement) + prednisone 10-30mg/day Day 121 - Month 36: everolimus dose adjusted to achieve target 8-12 ng/mL + prednisone 5-10 mg/day"
89252781|NCT00371826|Experimental|Steroid Withdrawal|"Every randomized patient in this group received~Day 1 -14: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve C2 target as per protocol + mycophenolate sodium (MPA) 720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg prednisone per day~Day 15 - 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg per day~Day 61 - 120: Everolimus dose adjusted + cyclosporine adjust dose according protocol guideline (or commence reduction by day 120 at discretion of Investigator, to be completed within 2 months of commencement) + gradual withdrawal of prednisone by 1 mg/week to be discontinued by Day 120.~Day 121 - Month 36: At Day 121, Month 7 and Month 13 Everolimus dose was adjusted to achieve target 6-10 ng/mL + Cyclosporine adjust dose to achieve C2 target as per protocol"
89252782|NCT00371826|Active Comparator|CNI+MPA+ Steroid|"Patients randomized to this group received:~Day 1 - Month 36: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve the protocol defined C2 Targets + mycophenolate sodium 720mg b.i.d. + Methylprednisone/prednisone 500mg intra-operatively, 250mg on day 1, 10-30mg prednisone per day until month 12 (as per local practice), 5-10mg/day months 13-36."
89252783|NCT03993366|Experimental|Simple Meal Announcement|Before every meal, the meal will be simply announced to the algorithm by a member of the study team. Meal bolus computation will be independent of the carbohydrate content of the meal.
89252784|NCT03993366|Active Comparator|Full Carbohydrate counting|The carbohydrate content of the meal selected by the participant will be entered into the dosing algorithm by a member of the study team at the onset of the meal to compute the insulin prandial bolus.
89252785|NCT01047618||Thromboembolism|
89252786|NCT02457702|Experimental|Orally administered Labeled Glycerol|Patients will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.
89252787|NCT00396084|Experimental|Gatifloxacin|10 subjects to receive gatifloxacin 400 mg orally once daily for 7 days.
89252788|NCT00396084|Active Comparator|Isoniazid|20 subjects to receive isoniazid 300 mg orally once daily for 7days.
89252789|NCT00396084|Experimental|Levofloxacin|10 subjects to receive levofloxacin 1000 mg orally once daily for 7days.
89252790|NCT00396084|Experimental|Linezolid every 12 hours|10 subjects to receive linezolid 600 mg orally every 12 hours daily for 7 days.
89252791|NCT00396084|Experimental|Linezolid once daily|10 subjects to receive linezolid 600 mg orally once daily for 7days.
89252792|NCT00396084|Experimental|Moxifloxacin|10 subjects to receive moxifloxacin 400 mg orally once daily for 7 days.
89252793|NCT01043718|Experimental|More-Intensive|
89252794|NCT01043718|Active Comparator|Less-Intensive|
89252795|NCT00395850|Placebo Comparator|1|microcrystalline cellulose
89252796|NCT00395850|Experimental|2|disulfiram at 250 mg/day
89252797|NCT00395850|Experimental|3|Disulfiram at 375 mg/day
89252798|NCT00395850|Experimental|4|Disulfiram at 500 mg/day
89252799|NCT00420212|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
89252800|NCT00420212|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
89252801|NCT00420212|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
89252802|NCT00401258|Other|1|12-week, open-label trial of duloxetine in subjects with IBS.
89252803|NCT00380874|Experimental|1|flexible dosing
89252804|NCT00380874|Placebo Comparator|2|
89252805|NCT00420056|Experimental|PD-0332991|
89252806|NCT01589276||Emergency hernia repairs|
89252807|NCT01589276||Elective hernia repairs|
89252808|NCT00411554|Experimental|Sitagliptin 50 mg QD|sitagliptin 50 mg orally once daily (QD=once daily)
89252809|NCT00411554|Active Comparator|Voglibose 0.2 mg TID|voglibose 0.2 mg orally three times daily (TID= three times daily)
89252810|NCT00400712|No Intervention|Control|natural progression post-stroke
89252811|NCT00400712|Experimental|Intervention|two weeks of goal directed intensive physical rehabilitation therapy at 6 months (and one year)
89252812|NCT00380718|Experimental|Pemetrexed|
89252813|NCT01047696|No Intervention|Open fire|Households continuing to use an open fire for cooking and heating
89252814|NCT01047696|Experimental|Chimney stove|Households randomized to receive a chimney stove (plancha) for cooking and heating
89252815|NCT01045668|Active Comparator|Clinical VT ablation|
89252816|NCT01045668|Active Comparator|clinical VT and substrate ablation|
89252817|NCT00380250|Experimental|Lubiprostone|8 mcg capsule twice daily (BID)
89252818|NCT00380250|Placebo Comparator|Placebo|Matching placebo capsule twice daily (BID)
89252819|NCT00400400|Experimental|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium tablets taken orally twice a day (in the morning and in the evening) at a dose equimolar to the dose of mycophenolate mofetil the participant was taking prior to start of the study + Placebo to mycophenolate mofetil capsules taken orally twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
89252820|NCT00400400|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil capsules taken orally twice a day (in the morning and in the evening) at the dose the participant was taking prior to study start + Placebo to mycophenolate sodium tablets taken twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
89252821|NCT00395694|Experimental|lamictal|
89252822|NCT01041794||1|
89252823|NCT00395538|Other|Biopsy|Subjects are randomized to have the second bone biopsy done 1,2, or 4 years after the start of PTH.
89252824|NCT01047774|Experimental|Soy protein|
89252825|NCT01047774|Placebo Comparator|Milk protein|
89252826|NCT00395460|Experimental|Gadobutrol 0.1 mmol/kg Body Weight (BW) (Gadavist, BAY86-4875)|Participant received 0.1 mmol/kg BW Gadobutrol (= 0.1 mL/kg BW by intravenous injection at a rate of 1.0 mL/sec)
89252827|NCT00395460|Active Comparator|GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)|Participant received 0.1 mmol/kg BW Gadopentetate Dimeglumine (GD) (= 0.2 mL/kg BW by intravenous injection at a rate of 2.0 mL/sec
89252828|NCT01047852|Experimental|NIV|
89252829|NCT01047852|No Intervention|Control|
89252830|NCT00395304|Experimental|Sequence #1|fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol
89252831|NCT00395304|Experimental|Sequence #2|fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate
89252832|NCT00395304|Experimental|Sequence #3|fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast
89252833|NCT00395304|Experimental|Sequence #4|fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate
89252834|NCT00395304|Experimental|Sequence #5|fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast
89252835|NCT00395304|Experimental|Sequence #6|fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol
89252836|NCT00395226|Experimental|Zinc sulfate|220 mg of zinc sulfate
89252837|NCT00395226|Placebo Comparator|Lactose|270 mg lactose
89252838|NCT01047930|Other|AM-Ex; PM-Ex; C|within subject design, with each participant receiving all three conditions
89252839|NCT00394914|Experimental|Pleconaril|Participants will receive Pleconaril nasal spray 4 sprays per nostril twice daily (BID), 24 mg/day for 1 week during the Treatment Period for a total of 14 doses.
89252840|NCT00394914|Placebo Comparator|Placebo|Participants will receive placebo nasal spray 4 sprays per nostril BID for 1 week during the Treatment Period for a total of 14 doses.
89252841|NCT00912132||Low risk singleton cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 19.0-29.9 kg/m2 were in the low-risk cohort.
89252842|NCT00912132||Obese cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 30.0-44.9 kg/m2 were in the obese cohort.
89252843|NCT00366444|Experimental|1|
89252844|NCT00366444|Placebo Comparator|2|
89252845|NCT00365976|Placebo Comparator|1|Placebo
89252846|NCT00365976|Active Comparator|2|Eszopiclone
89252847|NCT01049490|Active Comparator|Intramuscular|15 mcg H1N1 vaccine delivered via intramuscular injection (control)
89252848|NCT01049490|Active Comparator|Intradermal|Intradermal: H1N1 vaccine delivered via intradermal injection: Experimental
89252849|NCT00379236|Experimental|EUFLEXXA™ Double-blind|Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
89252850|NCT00379236|Placebo Comparator|Placebo Double-blind|Each subject received 3 single-dose injections of placebo into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
89252851|NCT00379236|Experimental|EUFLEXXA™ Open Label|All patients who participated in the 26 week double-blind study (including participants randomized to the placebo treatment group) and elected to participate in the open label extension, received three injections of EUFLEXXA™ in the target knee. Injections were given once a week on weeks 26, 27 and 28.
89290319|NCT03971903|Experimental|Attention bias modification treatment|12-session of ABMT
89290320|NCT03971903|Placebo Comparator|Placebo controls|12-session of placebo(i.e.,sham) training
89252852|NCT00379080|Experimental|Arm I - Feasibility|"Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~conventional surgery~oral tandutinib~Pharmacological study~Tissue samples"
89252853|NCT00379080|Experimental|Arm 2 - Dose Escalation (Phase 1)|"Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.~the starting dose for tandtinib is 500mg BID~oral tandutinib~Pharmacological study~Tissue samples"
89252854|NCT00379080|Experimental|Arm 3 - Phase 2|"Patients receive tandutinib as in phase I at the MTD determined in phase I.~600mg was the determined MTD in Dose Escalation~oral tandutinib~Pharmacological study~Tissue samples"
89252855|NCT00378534|Experimental|T Cell Depletion Transplant Participants|Participants with hematological malignancies received a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a delayed T cell depletion add back as donor lymphocyte infusion at day 90.
89252856|NCT00378534|Other|Stem Cell Donors|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. The stem cell collection aspect of this protocol is not investigational.
89252857|NCT00377676|Experimental|Usual Diabetes Therapy plus placebo|Usual diabetes therapy plus placebo
89252858|NCT00377676|Experimental|Drug Cycloset|
89252859|NCT00377520|Experimental|Pemetrexed|
89252860|NCT00377364|Experimental|Acetaminophen|Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days.
89252861|NCT00377364|Placebo Comparator|Placebo|Participants will be given an identical appearing placebo (two 500 mg tablets) four times daily for 7 days.
89252862|NCT03831282|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
89252863|NCT00365508|Experimental|Arm I|Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.
89252864|NCT00365508|Experimental|Arm II|Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).
89252865|NCT01048008|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
89252866|NCT01049568|Experimental|Cell Phone Intervention|
89252867|NCT01049568|No Intervention|Control|"Control group participants will participate in all on-study evaluations, except the intervention exit interviews.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
89252868|NCT00365352|Experimental|XP13512 600MG|XP13512 600MG ONCE DAILY
89252869|NCT00365352|Experimental|XP13512 1200MG|XP13512 1200MG ONCE DAILY
89252870|NCT00365352|Placebo Comparator|Placebo|PLACEBO ONCE DAILY
89252871|NCT03992118|Experimental|Feeding Challenges|Parents will be coached to implement strategies to address factors contributing to feeding challenges based on a multidisciplinary assessment using the medico-oral-behaviour-sensory-environment (MOBSE) approach.
89252872|NCT01045746|Experimental|Group 1|T0, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T1, 16 days wash-out period; T2, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T3
89252873|NCT01045746|Experimental|Group 2|T0, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T1, 16 days wash-out period;T2, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T3
89252874|NCT00376506|Experimental|Implanted Device|Implanted intramuscular neurostimulator device
89252875|NCT00376506|Active Comparator|External Device|External vibrotactile device
89252876|NCT00410384|Placebo Comparator|Placebo|Placebo
89252877|NCT00410384|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
89252878|NCT00410384|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
89252879|NCT00410072|Experimental|TDF 0.5 mg|TDF=tenofovir
89252880|NCT00410072|Experimental|ETV 0.5 mg +TDF 300 mg|ETV=entecavir; TDF=tenofovir
89252881|NCT00409838|Experimental|Abatacept and Methotrexate|
89252882|NCT00409838|Placebo Comparator|Placebo and Methotrexate|(standard of care)
89252883|NCT00409838|Experimental|Abatacept - Open Label|Open-label extension phase
89252884|NCT01041872|Active Comparator|Propofol Astrazeneca|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
89252885|NCT01041872|Experimental|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
89252886|NCT01041872|Experimental|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
89252887|NCT01041872|Experimental|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
89252888|NCT01041872|Experimental|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
89252889|NCT01041872|Experimental|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
89252890|NCT01041950|Experimental|Lumbar drainage|
89252891|NCT01041950|No Intervention|Control|
89252892|NCT01039766|Experimental|oxytocin|
89252893|NCT01039766|Placebo Comparator|Placebo|
89252894|NCT00409682|Active Comparator|Open-label adalimumab (Week 0 to Week 4)|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
89252895|NCT00409682|Active Comparator|Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
89252896|NCT00409682|Active Comparator|High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
89252897|NCT01034930|Active Comparator|Retentive Anchors|23 patients will receive as retention system for overdentures Retentive Anchors (Straumann).
89252898|NCT01034930|Active Comparator|Magnets|23 patients will receive Magnets (Straumann) as retention system for overdenture.
89252899|NCT01034930|Active Comparator|Locator System|23 patients will receive Locator System (Straumann) as retention for the mandibular overdenture.
89252900|NCT03993782|Experimental|A19010-R, B19010-O Use Group|Use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
89252901|NCT03993782|Experimental|B19010-O, A19010-R Use Group|Use of product B19010-O exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations, followed by use of product A19010-R exclusively for 4 days prior to a PK assessment for plasma nicotine concentrations.
89252902|NCT01039844|Experimental|Weekly LOC-paclitaxel Injection|LOC-paclitaxel IV by a 1 hour infusion on Day 1, 8, 15, 22 and 29; repeated every 42 days (6 weeks) per cycle.
89252903|NCT01039922||1|Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location
89252904|NCT01042028|Experimental|Phase II: Arm A|Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
89252905|NCT01042028|Active Comparator|Arm B|Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.
89252906|NCT03993626|Experimental|CXD101 and Nivolumab combination|"CXD101 will be presented as 10mg HPMC capsules and will be taken orally for 5 consecutive days repeated every three weeks on an outpatient basis.~Nivolumab will be presented as a 10 mg/mL solution in a single-dose vial, administered as iv infusion over 60 mins, repeated every two weeks.~CXD101 in combination with nivolumab will be administered in the Phase II component of the trial at doses determined in the Phase Ib component."
89252907|NCT01042106|Experimental|DSP-8658|DSP-8658 2.5, 10, 20, 40 mg once daily
89252908|NCT01042106|Placebo Comparator|Placebo|Placebo 2.5, 10, 20, and 40 mg doses once daily
89252909|NCT01042184|Experimental|Group A|Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
89252910|NCT01042184|Experimental|Group B: Sequential therapy for 10 days|
89252911|NCT01042184|Active Comparator|Group C: Triple therapy for 14 days|
89252912|NCT01035008|Experimental|Diagnostic|The investigators are testing a new method called confocal laser endomicroscopy to see if it can detect pre-cancerous abnormalities in the lining of the cysts found in your pancreas. This will involve using a very thin fiber-shaped microscope which will be passed through a needle during the EUS procedure.
89252913|NCT00398138|Experimental|vaccine|Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 & 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 & -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time & placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) & the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response & have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.
89252914|NCT01042262|Experimental|Oxygen Group|Subjects received 100% oxygen via nasal cannula (flow =2 L/min)
89252915|NCT01042262|Placebo Comparator|Control Group|Subjects were attached to a nasal cannula without any oxygen flow.
89252916|NCT00397982|Experimental|Treatment (enzyme inhibitor, monoclonal antibody)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
89252917|NCT03993470|Experimental|experimental|The short foot exercise daily for 4 weeks
89252918|NCT03993470|Placebo Comparator|Control|A placebo excercise daily for 4 weeks
89252919|NCT01040000|Experimental|NPC-1C/NEO-102|
89252920|NCT01035086|Experimental|Boregine|Intervention: Lupinus angustifolius Boregine; 25 g lupin kernel fibre per day over 4 weeks; lupin kernel fibre was incorporated in different food
89252921|NCT01035086|Active Comparator|Reference|Intervention: Reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood ingredients); 25 g citrus fibre per day over 4 weeks; the citrus fibre was incorporated in different food
89252922|NCT01035086|Placebo Comparator|Placebo|different food without added fibre
89252923|NCT00408902|Experimental|TandutinibTreatment|Patients receive oral tandutinib 500 mg twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89252924|NCT00397514||Congenital Heart Surgery Patients|Pacing protocol prior to patient's extubation with 20 min. of either conventional right ventricular (RV) or biventricular (BiV) pacing, preceded and followed by 10 min. of recovery time.
89252925|NCT03715166|Experimental|Bumetanide/S95008|
89252926|NCT03715166|Placebo Comparator|Placebo|
89252927|NCT01035164|Experimental|Arm 1|
89252928|NCT01035164|Experimental|Arm 2|
89252929|NCT01035164|Experimental|Arm 3|
89252930|NCT00397046|Experimental|Neratinib 80 mg|
89252931|NCT00397046|Experimental|Neratinib 160 mg|
89252932|NCT00397046|Experimental|Neratinib 240 mg|
89252933|NCT00397046|Experimental|Neratinib 320 mg|
89252934|NCT01042340|Experimental|Intervention with energy dense formula|Patients were randomised to intervention with the energy dense formula Calogen.
89252935|NCT01042340|No Intervention|Control group|The patients that were randomised to control group were assigned to ordinary treatment.
89252936|NCT01035242|Experimental|"association splitting"|Association splitting (6 sessions) delivered by psychologists.
89252937|NCT01035242|Active Comparator|cognitive remediation|CogPack training(6 sessions) delivered by either psychologists or psychology students at an advanced master level.
89252938|NCT01042418|Experimental|Whole kernel breakfast|
89252939|NCT01042418|Placebo Comparator|Wheat reference breakfast|
89252940|NCT01042418|Active Comparator|Milled kernel breakfast|
89252941|NCT01042652|Active Comparator|Nevirapine|
89252942|NCT01042652|Experimental|Raltegravir|
89252943|NCT01040078|Experimental|7.5ug H1N1 vaccine|360 subjects to receive two doses 7.5ug H1N1 influenza vaccine on Day 0 and Day 21.
89252944|NCT01040078|Experimental|15ug H1N1 vaccine|360 subjects to receive two doses 15ug H1N1 influenza vaccine on Day 0 and Day 21.
89252945|NCT01040078|Placebo Comparator|seasonal influenza vaccine|180 subjects to receive two doses seasonal influenza vaccine on Day 0 and Day 21.
89252946|NCT01035320|Experimental|simvastatin + ezetimibe|Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.
89252947|NCT01040156||LAmb|
89252948|NCT01040156||Cas|
89252949|NCT01042730|Active Comparator|Pitavastatin 1 mg daily|
89252950|NCT01042730|Active Comparator|Pitavastatin 4 mg daily|
89252951|NCT00396812|Experimental|Rituximab|
89252952|NCT01566578|Experimental|EGF Cream|
89252953|NCT01566578|Placebo Comparator|Placebo cream|
89252954|NCT01042808||1|HIV-1 Infected patients treated with Isentress
89252955|NCT01040234||Active pain treatment|Bilateral dual TAP block
89252956|NCT01042886|Experimental|Family plus community focused intervention|
89252957|NCT01042886|Active Comparator|Standard Behavioral Weight Loss Maintenance Intervention|
89252958|NCT00396656|Experimental|Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)|"After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning."
89252959|NCT00396656|Experimental|Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan|"After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning."
89252960|NCT01043042||Hospitalized patients|patients hospitalized at VUH between 4/1/2008 to 10/31/2009
89252961|NCT00408434|Experimental|CS-7017|CS-7017 from 0.05 to 3.2 mg bid
89252962|NCT01043120|Experimental|Barusiban|
89252963|NCT01043120|Placebo Comparator|Placebo|
89252964|NCT01323764|Active Comparator|Radionuclide SPS|Radionuclide Shunt Patency Study
89252965|NCT01040312||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 with platinum analogues
89252966|NCT03994328||Group 1|500 patients already receiving safinamide (50 or 100 mg/day) as add-on to L-dopa for no more than 2 months.
89252967|NCT03994328||Group 2|500 patients receiving rasagiline 1 mg/day as add-on to L-dopa for no more than 2 months.
89252968|NCT03994328||Group 3|235 patients receiving other SoC drugs as add-on to L-dopa for no more than 2 months.
89252969|NCT01043276|Experimental|Treatment A|
89252970|NCT01043276|Experimental|Treatment B|
89252971|NCT01043276|Experimental|Treatment C|
89252972|NCT01043276|Experimental|Treatment D|
89252973|NCT01043276|Experimental|Treatment E|
89252974|NCT01043354|Experimental|stage-matched intervention|Transtheoretical Model-based stage-matched intervention
89252975|NCT01043354|Experimental|framing effects intervention|counseling based on prospect theory
89252976|NCT01043354|Active Comparator|attention placebo intervention|counseling about general health topics
89252977|NCT00418184|Experimental|1|
89252978|NCT00418184|Placebo Comparator|2|
89252979|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 240 units, total volume 4.8mL; Mode of administration: intramuscular injection"
89252980|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 120 units, total volume 4.8 mL; Mode of administration: intramuscular injection"
89252981|NCT00407030|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 4.8 mL; Mode of administration: intramuscular injection
89252982|NCT00406718|Experimental|PharmCAT|Participants will receive PharmCAT in addition to Treatment as usual, Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
89252983|NCT00406718|Active Comparator|Med-eMonitor|Participants will receive Med-eMonitor™ in addition to treatment as usual. Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
89252984|NCT00406718|Active Comparator|Treatment as Usual|Participants will receive standard treatment as usual which is medication management and limited case management provided by the CMHC.
89252985|NCT01035476|Experimental|Data Card Report|Patients receive detailed reports of acceptance and adherence, with linked recommendations to optimize NIPPV.
89252986|NCT01035476|No Intervention|Standard NIPPV Care|Patients receive routine monitoring and care related to NIPPV.
89252987|NCT01043510|Experimental|A1, first period|
88804867|NCT00102518|Experimental|NCT00102063 and NCT00110461 Subjects|All subjects had either completed or had withdrawn from the double-blind extension phase of study NCT00110461 (OPDC 31-03-240) and study NCT00102063 (OPDC 31-03-239).
88804868|NCT02090894|Experimental|UV Light|
88804869|NCT00103376|Experimental|Part A: Velcade|Patient will complete Part A (Velcade only). If the patient has a complete response, he will come off study. If the patient has progressive disease, he will start Part B (Velcade + antiandrogen). If the patient has a partial response or stable disease, he will start Part B after at least a 7-day break.
88804870|NCT00103376|Experimental|Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist|Patient will start Part B after completing Part A or may be enrolled to part B only.
89252988|NCT01043510|Active Comparator|A2, second period|
89252989|NCT01043510|Active Comparator|B1, first period|
89252990|NCT01043510|Experimental|B2, second period|
89252991|NCT01043588|Other|1 : TURP|Surgery: TransUrethral Resection of the Prostate
89252992|NCT01043588|Other|2 : PVP|Surgery: Photo selective Vaporization of the Prostate
89252993|NCT01043666|Experimental|YM178 group|oral
89252994|NCT01043666|Placebo Comparator|placebo group|oral
89252995|NCT01043666|Experimental|tolterodine ER group|oral
89252996|NCT01035554|Active Comparator|Usual Care (UC) + Printed Materials (PM)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
89252997|NCT01035554|Experimental|UC + Self-Paced Program Instruction (SPPI)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials from the National Institutes of Health.
89252998|NCT01035554|Experimental|Home Blood Pressure Monitor (HBPM) + PM|If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) regarding hypertension education and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
89252999|NCT01035554|Experimental|HBPM + SPPI|"If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them.~If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the PM from the National Institutes of Health."
89253000|NCT00394706|Experimental|1|Use of Impedance Threshold Device (ITD)
89253001|NCT00394706|Sham Comparator|2|Sham ITD
89253002|NCT00394706|Other|3|Analyze early. Upon EMS (emergency medical services) arrival at the scene of a non-traumatic cardiac arrest, the EMS providers assess the cardiac rhythm as soon as possible. Approximately thirty seconds of CPR (cardiopulmonary resuscitation) may be done prior to an assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
89253003|NCT00394706|Other|4|Analyze late. Upon the EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is done prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
88804871|NCT00042224|Experimental|1 ECT plus clozapine|Electroconvulsive therapy ECT plus clozapine for 8 weeks
89253004|NCT00419120|Experimental|Neo-bladder construction|Surgical implantation of autologous neo-bladder construct
89253005|NCT00395642|Experimental|HM with weight and BP remote monitoring|Device based Home Monitoring and weight and blood pressure remote monitoring
89253006|NCT00395486|Experimental|Rosuvastatin|
89253007|NCT00395486|Active Comparator|Atorvastatin|
89253008|NCT01043744|Experimental|Artemether-Lumefantrine|Receive artemether-lumefantrine with direct observation of am dose on days 0, 1, and 2 of study
89253009|NCT01043744|No Intervention|No treatment|No antimalarial treatment given on day 0.
88804872|NCT00042224|Active Comparator|2 Clozapine|Clozapine for 8 weeks
88806101|NCT00239642|Experimental|Venofer (1.0 mg/kg)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
89253010|NCT00395018|Experimental|entecavir|
89253011|NCT01036412|Experimental|Chlorhexidine Gel Therapy|Following 2 x 5-minute applications of 2.5 ml in clinic, 2 x 5.0 ml syringes of 1% chlorhexidine gluconate gel, self-administered for a 5-minute application Week 2 & Week 4
89253012|NCT00375518|Active Comparator|1|Atorvastatin
89253013|NCT00375518|Placebo Comparator|2|placebo
89253014|NCT01045772|Experimental|IL-1 trap|
89253015|NCT01045928|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21 and rituximab IV on day 1of courses 1, 3, 5, 7, 9, and 11.
89253016|NCT00256750|Active Comparator|Cyclosporine (CsA)|
89253017|NCT00256750|Experimental|Belatacept LI (less intensive)|
89253018|NCT00256750|Experimental|Belatacept MI (more intensive)|
89253019|NCT00279201|Active Comparator|Insulin glargine|Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.
89253020|NCT00279201|Experimental|Lispro Low Mix|Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.
89253021|NCT00279201|Experimental|Lispro Mid Mix prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.
89253022|NCT00279201|Experimental|Lispro Low Mix prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase
89253023|NCT00279201|Active Comparator|Basal bolus prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
89253024|NCT00279201|Active Comparator|Basal bolus prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
89253025|NCT03741634|Experimental|Intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
89253026|NCT03741634|No Intervention|No intervention|During the study, participants enrolled at one study location will non receive the Multi-sectoral agricultural intervention. At the end of the study, participants in this arm will be eligible for education in financial management and sustainable farming practices and those who pay the loan down payment will be eligible for a small loan to purchase a human-powered water pump, seeds, fertilizers and, pesticides.
89253027|NCT03969394|Experimental|Heart Failure Patients|Patients with Heart Failure
89253028|NCT03973060|Experimental|Concentric muscular work|4 series of 12 repetitions of concentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
89253029|NCT03973060|Experimental|Eccentric muscular work|4 series of 12 repetitions of eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
89253030|NCT03973060|Experimental|Concentric-eccentric muscular work|4 series of 12 repetitions of concentric-eccentric muscular work, with one minute rest between each repetitions, total working time of 24 minutes.
89253031|NCT03973060|Experimental|Isometric muscular work|6 seconds of contraction, with 20 seconds of rest with 24 repetitions, for a total working time of 12 minutes.
89253032|NCT03969784|Experimental|colorectal cancer patient with peritoneal carcinosis|
89253033|NCT03969784|Active Comparator|colorectal cancer patient without metastasis|
89253034|NCT01073956|Placebo Comparator|Inactive electrotherapy|Inactive electrotherapy is applied to the painful points
88806102|NCT00239642|Experimental|Venofer (2.0 mg/kg)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
88806103|NCT04041830|Experimental|NW (Normal Weight)|20 to 55 years old lean adults
89253035|NCT01073956|Active Comparator|Ultrasound|Ultrasound electrotherapy is applied to the painful points
89253036|NCT01073956|Active Comparator|Monopolar radiofrequency|Monopolar radiofrequency electrotherapy is applied to the painful points
89253037|NCT00203476|Active Comparator|Statin with Niacin|Niacin dose range of 500-1500mg (average 888mg)
89253038|NCT00203476|Active Comparator|Statin with Colestipol|Colestipol dose range 5-15gm (average 9.5gm)
89253039|NCT00203476|Active Comparator|Statin with Ezitimibe|Ezitimibe 10mg (average 10mg)
89253040|NCT00203242|Experimental|Depacon IV and Depakote ER|Subjects will be treated in this single arm study with 2 consecutive days of IV Depacon followed by oral Depakote ER for a total of 1000 mg of Depacon and 1000 mg of Depakote ER each day.
89253041|NCT00200356|Experimental|Edaravone|
89253042|NCT00200356|Active Comparator|Ozagrel|
89253043|NCT01326052|Experimental|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
89253044|NCT01326052|Active Comparator|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
89253045|NCT00227344|Experimental|1|Catheter ablation
89253046|NCT00227344|Active Comparator|2|Antiarrhythmic drugs
89253047|NCT01065909||Diabetes type 2|
89253048|NCT01065909||Chronic Pain|
89253049|NCT01065909||Atrial Fibrillation|
89253050|NCT00227266|Placebo Comparator|Cohort 1a|Patients in Cohort 1a - Placebo Comparator, will be on a placebo for 6 months and then will switch to the active treatment. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
89253051|NCT00227266|Active Comparator|Cohort 1b|Cohort 1b - Active Comparator will be on treatment throughout the study. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor in the liquid form.
89253052|NCT00227266|Experimental|Cohort 2|Cohort 2 pts are on open-label treatment throughout. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
89253053|NCT00256282|Experimental|Docetaxel & Vinorelbine + Sargramostim|Docetaxel, Vinorelbine, and Sargramostim
89253054|NCT01074112||Abdominal Trauma|Patients with mechanism of injury that could produce abdominal bleeding
89253055|NCT01074112||Female Abdominal Pain|Female patients of child bearing age complaining of abdominal pain
89253056|NCT01074112||Difficult Vascular Access|Patients whom vascular access is needed but difficult
89253057|NCT01074112||Abdominal Aortic Anuerysm|Patients who complain of or are suspected of having an abdominal aortic aneurysm
89253058|NCT01074112||Pulseless Electrical Activity|Patients whom are in cardiac arrest and no pulse can be determined yet they show an electrical rhythm on the monitor
89253059|NCT01074112||Kidney Stones (Hydronephrosis)|Patients who complain of flank pain
89253060|NCT01074112||Plueral Effusion|Patients with a history of renal or hepatic problems and complain of difficulty breathing of an unknown etiology
89253061|NCT01074112||ETT placement|field intubated patients who need another means of verifying tube placement
89253062|NCT01074112||Transcutaneous Pacing|Patients who are being externally paced and need a method of determining mechanical capture
89253063|NCT01074112||Paramedic Discretion|Patients in whom the paramedic feels that an ultrasound study would provide useful data in their treatment
88806104|NCT04041830|Experimental|OBESE|20 to 55 years old adults with obesity
89253064|NCT00266877|Experimental|Prior Tarceva or Iressa With EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening
89253065|NCT00266877|Experimental|Prior Tarceva or Iressa w/o EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor without an EGFR mutation demonstrated at screening
89253066|NCT00266877|Experimental|No Prior EGFR Tyrosine Kinase Inhibitor Treatment|HKI-272 administered to patients with no prior EGFR tyrosine kinase inhibitor treatment, adenocarcinoma, < or = 20 pack-year smoking history, and current non-smoker (no requirement for EGFR mutation)
89253067|NCT02532075|Experimental|Inspiratory Warm Up|(IWU). Two sets of 15 breaths
89253068|NCT02532075|Experimental|Expiratory Warm Up|(EWU). Two sets of 15 breaths
89253069|NCT02532075|Experimental|Combination Warm Up|(RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory
89253070|NCT02532075|Other|Control Trial|No warm up
89253071|NCT00256204|Experimental|1mg rasagiline|1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
89253072|NCT00256204|Experimental|2mg rasagiline|2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
89253073|NCT00256204|Placebo Comparator|Placebo|Each arm is followed by 36 weeks of placebo
89253074|NCT00256126|Experimental|Turner Syndrome (TS)|
89253075|NCT00256126|Experimental|Growth Hormone Deficiency (GHD)|
89253076|NCT03972358|Experimental|Medical menstrual regulation|"Mifepristone 200 mg orally on day 1.~Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone)."
89253077|NCT01073332|Placebo Comparator|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
89253078|NCT01073332|Experimental|Arginine antioxidant supplements|Dietary Supplement: Niteworks
89253079|NCT03969316|Active Comparator|Quadratus Lumborum Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound at the anterolateral border of quadratus lumborum muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
89253080|NCT03969316|Active Comparator|Transversus Abdominis Plane Block|After the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. After the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. The maintenance of the anesthesia will be provided with sevoflurane. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both groups and the local anesthetic agent will be administrated with ultrasound between internal oblique and transversus abdominis muscle with 18, 20 or 22 Gauge IV Cannula (Bicakcilar Cooperation, Istanbul, Turkey) according to age and body weight.
89253081|NCT03972046|Experimental|T-Vec + BRAF/MEK|"Participants will begin taking the following 3 medications:~BRAF Inhibitor dabrafenib 150 mg by mouth twice a day; MEK inhibitor trametinib 2 mg by mouth once a day; Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection (Dose #1: 10^6 PFU/mL; Dose #2: 10^8 PFU/mL 21 (+3) days after first dose; Subsequent doses: 10^8 PFU/mL every 14 (+/-3) days).~Dosing to continue for at least 3 months, or up to 6 months if no plateau in response.~May stop earlier than 3 months at physician discretion depending on side effects and response.~Ultrasound of tumor nodal basin(s) monthly.~Labs every 4 weeks: CBC with differential, CMP, LDH CT of chest/abdomen/pelvis every 3 months.~PET CT or brain MRI as needed at discretion of the investigator.~Manual tumor measurement in office prior to each injection."
89253082|NCT01073488|Experimental|EMONC: Community mobilization, HBLSS and Facility Improvement|The intervention group received training in community mobilization activities, Home Based Life Saving Skills (HBLSS) and facility improvement.
89253083|NCT01073488|No Intervention|Control|The control group did not receive an intervention, but collected outcome data through a baseline maternal/newborn birth registry.
89253084|NCT01071772|Experimental|euglycemia|
89253085|NCT01071772|Experimental|hyperglycemia|
89253086|NCT03971890|Experimental|DanceTherapy Group|The experimental group will receive a dance treatment.
89253087|NCT03971890|Experimental|Control Group|The control group will be subjected to a educational treatment.
89253088|NCT00278889|Active Comparator|1|Bevacizumab + FOLFOX
89253089|NCT00278889|Experimental|2|AZD2171 + FOLFOX
89253090|NCT01070745|Experimental|Indomethacin for resistant PDA|Treatment with second course of indomethacin
89253091|NCT01070745|Experimental|Ibuprofen for resistant PDA|Ibuprofen as second course of therapy
89253092|NCT01071057|Active Comparator|Naloxone/morphine|Naloxone (12 µg/ml) mixed in a single infusion with morphine (1 mg/ml). The study solutions will be prepared by a pharmacist and diluted in saline to produce equal volumes to ensure proper blinding.
89253093|NCT01071057|Placebo Comparator|saline/morphine|Patients will be randomly assigned to one of two groups (Naloxone/morphine or saline/morphine) using computer-generated random numbers. On arrival to the PACU patients will be started on IV PCA and randomized study drug
89253094|NCT00278109|Experimental|PBI with Concurrent Chemotherapy|Phase I Single Arm study of PBI with concurrent chemotherapy. Primary endpoint is radiation toxicity. The intervention is partial breast radiation with doxorubicin and cyclophosphamide.
89253095|NCT00296517|Placebo Comparator|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
89253096|NCT00296517|Experimental|Bupropion SR|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
89253097|NCT00224770|No Intervention|Medical Management|Standard of care medical management as per American Heart Association (AHA) guidelines.
89253098|NCT00224770|Active Comparator|MISTIE Surgical Management|"Minimally invasive surgery (MIS) with clot lysis with recombinant tissue plasminogen activator (rt-PA).~MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours, in addition to best medical care.~This includes 54 intent-to-treat patients, and excludes 27 pilots."
89253099|NCT00224770|Active Comparator|ICES Surgical Management|"Intraoperative stereotactic CT-Guided Endoscopic Surgery~Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative-targeting arm as MISTIE arm. Best medical care was provided, but no rt-PA was administered.~This includes 14 intent-to-treat patients, and excludes 4 pilots."
89253100|NCT02531776|Experimental|Subcutaneous insertions of needles|36 subcutaneous needle insertions per participant with 18 differently designed needles. 30test participants in total. No fluid will be injected. Pain perception will be rated by the subjects, penetration force and skin blood perfusion will be measured, and any skin reactions will be assessed.
89253101|NCT00266409|Experimental|Panic: Niravam+SSRI/SNRI|Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI
89253102|NCT00266409|Experimental|Panic: SSRI/SNRI alone|Panic Disorder: Newly prescribed SSRI or SNRI alone
89253103|NCT00266409|Experimental|GAD: Niravam+SSRI/SNRI|Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI
89253104|NCT00266409|Experimental|GAD: SSRI/SNRI alone|Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone
89253105|NCT00277095|Experimental|ProACT (Adjustable Continence Therapy)|Implantation with ProACT (Adjustable Continence Therapy), Single Arm
89253106|NCT00265785|Experimental|Pemetrexed|pemetrexed
89253107|NCT00276159|Experimental|852A Treatment|Patients receiving at least one dose of 852A.
89253108|NCT02532153|Other|Open-Label Ketamine|
89253109|NCT01072227||Single Group|
89253110|NCT00265395|Active Comparator|Standard therapy|Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.
89253111|NCT00265395|Experimental|Extended therapy|Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.
89253112|NCT01582113|Experimental|High Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 500 mg of citicoline, of which they will be instructed to take 500 mg daily. This will be done in a double-blind, randomized fashion.
89253113|NCT01582113|Experimental|Low Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 250 mg of citicoline, of which they will be instructed to take 250 mg daily. This will be done in a double-blind, randomized fashion.
89253114|NCT01582113|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
89253115|NCT00195442||A|Patients with Hemophilia A
89253116|NCT01070823||Relapsing Multiple Sclerosis|Participants receiving or considering treatment with Tysabri® (natalizumab).
89253117|NCT01071135|Experimental|Quetiapine XR|
89253118|NCT03971968||Group 1 = Intervention group|Group 1 suffered from third degree full thickness burns in the face/neck and received a surgical procedure with Integra Artificial Skin in the past
89253119|NCT03971968||Group 2 = Control Group|Group 2 is the healthy skin of a comparable and/or contralateral skin-site of the face/neck
89253120|NCT00275301|Experimental|Open-label Olanzapine.|Open-label Olanzapine.
89253121|NCT02531997|Active Comparator|Hypnotic Relaxation Therapy|Hypnotic relaxation will be performed in three sessions, two weeks apart, over 6 weeks. The hypnosis sessions will build on each other in terms of content.
89253122|NCT02531997|Other|Progressive Muscle Relaxation (PMR)|The PMR will consist of progressive tensing and relaxing of the muscles from head to toe to a soothing sound of the participant's choosing.
89253123|NCT03969238||Patients/Providers|Of the1,000 participants: (1) 900 will enroll as participants who use the helpline resources via verbal consent and (2) 100 will enroll as providers via online consent prior to survey data collection.
89253124|NCT00251745|Experimental|Dexlansoprazole MR 60 mg QD|
89253125|NCT00251745|Experimental|Dexlansoprazole MR 90 mg QD|
89253126|NCT00251745|Placebo Comparator|Placebo|
89253127|NCT00255190|Experimental|Dexlansoprazole MR 60 mg QD|
89253128|NCT00255190|Experimental|Dexlansoprazole MR 90 mg QD|
89253129|NCT03973762|Experimental|DR Grading with CAD|DR Grading with CAD
89253130|NCT03973762|Other|DR Grading by expert panel|DR Grading by expert panel
89253131|NCT00359424|Active Comparator|intravenous (IV) rt-PA alone|Group one will receive the standard dose of intravenous (IV) rt-PA alone given over an hour.
89253132|NCT00359424|Experimental|Endovascular therapy|Group two will receive a lower dose or a standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose (based on the location and extent of the blood clot) a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery.
89253133|NCT03991026|Experimental|Healthy food and Education/Cooking Classes|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, healthy eating attitudes, and demographics. Every week for 6 weeks, participants will pick-up a healthy food bag (e.g. fresh vegetables) for a $3 co-pay and attend an hour-long education classes at East Baltimore Medical Center. All participants will complete a survey at healthy food bag pick-up or an education class. Surveys at bag pick-up will ascertain outcomes like vegetable consumption. Surveys at education classes will ascertain outcomes like healthy eating attitudes. At 6 weeks, all participants will complete a follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again at 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
89253134|NCT03991026|No Intervention|Control Group|At consent, participant will complete the baseline survey. Baseline survey will collect information like vegetable consumption, cooking habits, food security, healthy eating attitudes, and demographics. As a control group, participants will not partake in the healthy food bag pick-ups or cooking classes therefore they will not fill out those associated surveys. After the 6 weeks of the intervention, control participants will be given the follow-up survey equivalent to the baseline survey. The follow-up survey will be completed again after 10 weeks, 18 weeks, and 30 weeks. Participants will also be weighed at each bag pick-up (participants may decline) and relevant health information like blood pressure will be obtained from the EMR from an associated office visit.
89253135|NCT02535234|Active Comparator|Arm 1|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Novel system followed by 7 nights with theTraditional system
89253136|NCT02535234|Active Comparator|Arm 2|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Traditional system followed by 7 nights with the Novel system
89253137|NCT01049646|Active Comparator|Angiotensin II|
89253138|NCT01049646|Placebo Comparator|Saline infusion|
89253139|NCT02286414||Exposed group|Patients recieving direct oral anticoagulants (DOA)
89253140|NCT02286414||Non-exposed group|Patients recieving vitamine K antagonists (VKA)
89253141|NCT00255034|Active Comparator|24 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 24 weeks
89253142|NCT00255034|Experimental|48 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 48 weeks
89253143|NCT01049724||PRK|Those patients undergoing photorefractive keratectomy
89253144|NCT01049724||LASIK|Those undergoing Laser-assisted insitu keratomileusis
89253145|NCT00254566|Experimental|1|
89253146|NCT00254566|Active Comparator|2|
89253147|NCT02531542|Other|READ echography|
89253148|NCT00358956|Experimental|1|
89253149|NCT01048086|Experimental|Retinoic Acid|
89253150|NCT01048086|Placebo Comparator|Placebo|
89253151|NCT01052610|Active Comparator|Active group|Group of children with bronchial asthma and/ or allergic rhinitis 6-18 years old receiving annually house dust mites sublingual allergen extract
89253152|NCT01052610|Placebo Comparator|Placebo group|Group of children with bronchial asthma and/or allergic rhinitis 6-18 years old receiving placebo in sublingual applicator
89253153|NCT03830892|Active Comparator|E-cigarette User (Exclusive)|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette
89253154|NCT03830892|Active Comparator|Dual User|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette/Cigarette
89253155|NCT01048164|Active Comparator|10 Massages|This group consists of individuals that wear lead aprons, and they will receive ten, 30-minute scheduled massage appointments during the hours the participant is working in the cardiac lab, over a 10 week period.
89253156|NCT01048164|Active Comparator|5 Massages|This group consists of individuals that wear lead aprons, and they will receive five, 30-minute scheduled massage appointments, during the hours the participant is working in the cardiac lab, over a 5 week period. This arm will not receive massages for the first 5 weeks and then will receive their massages during the second 5 week period.
89253157|NCT01048164|No Intervention|Control Group|This group will consist of those individuals that wear lead aprons with no desire to participate in the massage study yet are willing to provide information through questionnaires. They will be given the same questionnaire as those in the two massage therapy arms of the study, at the beginning, middle, and end of study.
89253158|NCT01049880|Experimental|Ascorbate|
89253159|NCT00253630|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89253160|NCT00358644|Experimental|1|
89253161|NCT01324908|Experimental|Treatment (Treg predictor of response to ECP)|Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.
89253162|NCT01048320|Other|Treatment|Gemcitabine plus Oxaliplatin in combination with imatinib mesylate
89253163|NCT03990480|Active Comparator|valsartan|Group I treated with valsartan (160 mg/d, n = 100)
89253164|NCT03990480|Active Comparator|amlodipine|Group II amlodipine (10 mg/d, n = 100).
89253165|NCT03990480|No Intervention|Control|30 healthy subjects are enrolled as control group (Group III).
89253166|NCT01052688||Pregnant Women|Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.
89253167|NCT01052766|Experimental|PET/CT and BH PET/CT|In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.
89253168|NCT00364182|Experimental|A|
89253169|NCT00364182|Experimental|B|
89253170|NCT00369486|Active Comparator|1|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study (ETDRS) technique)
89253171|NCT00369486|Experimental|2|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
89253172|NCT00369486|Experimental|3|Anterior peribulbar injection of 20 mg triamcinolone
89253173|NCT00369486|Experimental|4|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
89253174|NCT00369486|Experimental|5|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
89253175|NCT03992664|Experimental|EDUCATION|If the patient is in the experimental team, questionnaires and printed education information will be given first and after the completion of the forms, the intervention will be followed.
89253176|NCT03992664|No Intervention|NON-INTERVENTION|The difference in this group is that it will not be explained or given a form of educational intervention for management of rash.
89253177|NCT00363480|Experimental|SFC 50/250 mcg|Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
89253178|NCT00363246||Group 1|Older veterans who use a wheelchair for their primary means of mobility.
89253179|NCT03990714|Experimental|Intracorporeal anastomosis|The specimen was preferentially extracted via a small Pfannenstiel-type incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). The incision for the extraction of the right colon is sutured in two layers by absorbable suture. The ileum was held by the assistant to prevent rotation of its mesentery. A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon, respectively, and then held by the assistant. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed. Drains were not used routinely.
89290321|NCT01222338|Active Comparator|Immunomodulator intervention|Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
88806105|NCT04271462||Study group|Patients undergoing surgery (>120 min) with the use of sevoflurane based general anaesthesia (in 1.0 MAC concentration).
89253180|NCT03990714|Experimental|Extracorporeal anastomosis|The mobilized colon was externalized preferentially via a transverse or midline incision with the protection of an Alexis Wound Protector (Applied Medical, Rancho Santa Margarita, California, USA). A stay suture was applied 10 cm proximal and distal to the stapled ends of the terminal ileum and colon. An enterotomy and colotomy were made sharply at the antimesenteric corner of the staple lines. An isoperistaltic side-to-side anastomosis was fashioned with a 60-mm laparoscopic stapler. A 2-0 double-barbed suture was used to close the enterocolotomy, in two planes (the first submucosal, and the second sero-serous). The mesenteric defect and the mesocolon after the construction of either type of anastomosis were not closed.The incision for the extraction of the right colon and the realization of the anastomosis is sutured in two layers by absorbable suture. Drains were not used routinely.
89253181|NCT00223990|Experimental|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
89253182|NCT00223990|Active Comparator|RabAvert (rabies vaccine)|RabAvert vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
89253183|NCT01052922|Active Comparator|2 sample InSure|
89253184|NCT01052922|Active Comparator|1 sample OC-Micron|
89253185|NCT01052922|Active Comparator|3 sample g-SENSA|
89253186|NCT03990636|Experimental|Metil 5-aminolevulinate arm|Metil 5-aminolevulinate arm with photo activation.
89253187|NCT03990636|Placebo Comparator|Placebo arm|Placebo (without metil 5-aminolevulinate) arm with photo activation.
89253188|NCT01048398|Experimental|Remifentanil|
89253189|NCT01048398|Active Comparator|Paracetamol|intravenous paracetamol 1g
89253190|NCT03971812||Patient with high grade astrocytoma|Patients meeting inclusion and non-inclusion criteria and having signed informed consent will be included in the study
89253191|NCT03990324|No Intervention|Control group|The control group did not received intervention and sat on a table for approximately 5 minutes
89253192|NCT03990324|Experimental|Stretching group|The stretching group received a standardized manual stretching protocol
89253193|NCT01073644||Sunitinb malate|
89253194|NCT02534922|Experimental|Daily dosing|Daily subcutaneous dosing of Prolanta, a human prolactin receptor antagonist
89253195|NCT03992586|Experimental|Pink lenses|Pink-colored lenses
89253196|NCT03992586|Placebo Comparator|Clear lenses|Clear lenses
89253197|NCT02534766||Patients who attended the MISSION COPD clinics|COPD patients who attended the MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team
89253198|NCT02534766||Health Care Professionals|Health Care Professionals who attended the MISSION COPD clinics in a professional/ clinical capacity.
89253199|NCT01048476|Active Comparator|Group L20|Dietary Supplement: 20mg Lutein; daily supplementation one year
89253200|NCT01048476|Active Comparator|Group L10|Dietary Supplement: 10mg Lutein; daily supplementation one year
89253201|NCT01048476|Placebo Comparator|Group Placebo|Dietary Supplement: Placebo, 0 mg Lutein
89253202|NCT01048476|Active Comparator|Active Comparator: Group LZ|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
89253203|NCT01581060|Experimental|WX-554|
89253204|NCT03990246|Experimental|Acid stable emulsion with solid droplets|Acid stable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
89253205|NCT03990246|Experimental|Acid stable emulsion with liquid droplets|Acid stable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
89253206|NCT03990246|Experimental|Acid unstable emulsion with solid droplets|Acid unstable emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
89253207|NCT03990246|Experimental|Acid unstable emulsion with liquid droplets|Acid unstable emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
89253208|NCT03992742|Experimental|Intervention Group (subgroup A+B+C)|Personalized instant messaging (PIM) + optional cocktail interventions (OCI) + AWARD advice + referral card + warning leaflet+ COSH booklet
89253209|NCT03992742|Experimental|Control Group (subgroup D+E+F)|Regular instant messaging (RIM) + personalized instant messaging (PIM) + AWARD advice + referral card + warning leaflet+ COSH booklet
89253210|NCT00221104|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
89253211|NCT00221104|No Intervention|No intervention|Patient has no intervention.
89253212|NCT00189202|Experimental|Sirolimus, steroid avoidance arm|Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
89253213|NCT01071928|Experimental|Docetaxel and ASA404 in Combination|
89253214|NCT03969160|Experimental|Imaginal exposure|The experimental procedure consists of imaginal exposure to mental imagery of phobic and neutral stimuli, prompted through recorded verbal instructions. Participants' repeat the experimental procedure one week later in a follow-up session. Brain imaging data is only collected during day 1
89253215|NCT00187486|Experimental|Temodar plus Tarceva plus Radiation Therapy|Single arm phase-2 experimental treatment of newly diagnosed patients with Glioblastoma with Temodar plus Tarceva plus Radiation Therapy
89253216|NCT00220636|Experimental|Aripiprazole|Aripiprazole 5 to 30 mg/day
89253217|NCT00362232|Experimental|Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939))|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
89253218|NCT00362232|Active Comparator|Enoxaparin 30 mg twice a day (bid)|Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
89253219|NCT03968926||Vasoplegic ECMO|All patients during VA-ECMO support for cardiogenic shock who presented, within 48 hours after implantation, a vasoplegia defined by a norepinephrine dose greater than 0.1µg/kg/min after a 500ml fluid challenge despite overall blood flow (ECMO + native heart) greater than 2l/min/m2 or allowing to achieve 65% of ScvO2
89253220|NCT01048554|Other|Temozolomide/Bevacizumab|Patients will be treated with a combination of temozolomide at 75 mg/m2/day for six continuous weeks, followed by a two-week rest period and bevacizumab 10 mg/kg every 2 weeks without interruption. Cycles will be repeated every 8 weeks. Patients will be restaged every 8 weeks.
89253221|NCT00219544|Experimental|1|
89253222|NCT00219544|Experimental|2|
89253223|NCT00219544|Experimental|3|
89253224|NCT00219544|Placebo Comparator|4|
89253225|NCT00357552|Experimental|LPV/r monotherapy|Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
89253226|NCT00187096|Experimental|Stratum 1|"Stratum 1 (AML in complete remission)~Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 through -2 Donor pheresis Day -1 Start IL-2 on Day -1, then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0"
89253227|NCT00187096|Experimental|Stratum 2|"Stratum 2 (AML that is refractory or relapsed or AML with increasing minimal residual disease)~Clofarabine 40 mg/m2 IV, days -6 through -2 Etoposide 100 mg/m2 IV, days -6 through -2 Cyclophosphamide 400 mg/m2 IV, days -6 through 02 Donor pheresis Day -1 Start IL-2 Day -1, and then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0."
89253228|NCT00357396|Experimental|Chemo followed by DSCT|"Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -8 to -6, melphalan IV over 20 minutes on days -5 to -3, and thiotepa IV over 4 hours on day -2.~Allogeneic hematopoietic stem cell transplant: Patients undergo allogeneic bone marrow or T-cell depleted peripheral blood stem cell transplantation on day 0.~Graft-vs-host disease (GVHD) prophylaxis: Patients receive treatment according to institutional guidelines and are given treatment against infection.~After completion of study treatment, patients are followed periodically for at least 3 years."
89253229|NCT00186628|Experimental|Prophylactic Rituximab|Rituximab will be infused after a non-myeloablative transplantation regimen of total lymphoid irradiation (TLI) + anti-thymoglobulin (ATG), with the intention of reducing chronic graft-vs-host disease (cGvHD)
89253230|NCT00368550|Experimental|1|Oral sertraline, cognitive-behavioral counseling to maintain abstinence from alcohol
89253231|NCT00368550|Placebo Comparator|2|Placebo, cognitive-behavioral counseling to maintain abstinence from alcohol
89253232|NCT01072162|Experimental|Arm B|25 mg powder for oral suspension single dose fasted.
89253233|NCT01072162|Experimental|Arm C|25 mg powder for oral suspension administered with a meal
89253234|NCT01072162|Experimental|Arm D|25 mg powder for oral suspension administered 2 hours prior to meal
89253235|NCT01072162|Experimental|Arm E|25 mg powder for oral suspension administered 2 hours after to meal
89253236|NCT01072162|Other|Arm A|Commercially available eltrombopag 25 mg tablet
89253237|NCT01050036|Experimental|HCT recipients|"Patient with CBF AML will be eligible in his/her 1st complete remission (CR1) status. Patients who have relapsed or have achieved 2nd complete remission should not be included in this study.~1st postremission therapy after CR1 will be performed with high-dose cytarabine (HDAC) chemotherapy, consisting of intravenous cytarabine 3 g/m2 infusion during 3 hours twice a day on days 1, 3, and 5.~After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information."
89253238|NCT00368472|Experimental|Perampanel|Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study
89253239|NCT00357006|Active Comparator|1|100 mcg Estradiol
89253240|NCT00357006|Active Comparator|2|200 mcg Estradiol
89253241|NCT00357006|Placebo Comparator|3|adjunctive transdermal placebo
89253242|NCT01050114|Other|ARM 1: onaBoNT-A injection + placebo|onaBoNT-A 200 U (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and placebo oral capsule daily
89253243|NCT01050114|Other|ARM 2: Placebo injection + oxybutynin ER|Placebo injection (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and oxybutynin ER 10 mg capsule daily
89253244|NCT01324674|Placebo Comparator|Placebo group|Is the group of subjects that will take placebo
89253245|NCT01324674|Experimental|experimental group|Is the group of subjects that will take Bach´s Flower remedies
89253246|NCT01048632|Experimental|Oxandrolone|Following clinical evaluation, all patients will be receive oxandrolone in addition to their usual medications. Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
89253247|NCT00165646|Experimental|1|
89253248|NCT00165646|Experimental|2|
89253249|NCT00165646|Placebo Comparator|3|
89253250|NCT01050270|Other|Ondansetron /acetylcysteine 20.25h|Ondansetron followed by conventional acetylcysteine regimen
89253251|NCT01050270|Other|Placebo/acetylcysteine 20.25h|placebo followed by conventional acetylcysteine regimen
89253252|NCT01050270|Other|Ondansetron/acetylcysteine 12h|ondansetron followed by modified acetylcysteine regimen
89253253|NCT01050270|Other|Placebo/acetylcysteine 12h|placebo followed by modified acetylcysteine regimen
89253254|NCT03968458|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions.
89290322|NCT01222338|Placebo Comparator|placebo|Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
89290323|NCT01376440|Experimental|Household water treatment|household water treatment with 1.25% sodium hypochlorite
89290324|NCT01376440|No Intervention|control|"Usual practice (the use of Jerrican for water storage, which is considered as safe storage)"
89290325|NCT01126398||Ankle / dist. tibia fracture fixation|
89253255|NCT03992508|Other|complex decongestive treatment|In group 1, the patients were received standard complex decongestive therapy including skin care, manual lymphatic drainage, multi-layer compression bandaging and exercises. During the treatment, written and verbal information was given to the patients about skin care. Manual lymphatic drainage and compressive bandages were applied by a certified physical therapist. The patients received 30-minutes manual lymphatic drainage involving stationary circular, pumping, scooping, and rotary movements. Multi-layer compression bandaging was applied to the affected limb to promote the flow of excess interstitial fluid out of the extremity using a graded pressure for 22-23 hours in a day. The patients strictly followed a lymphoedema exercise program structured with breathing exercise, neck and shoulder range of motion, and stretching exercise to facilitating lymph resorption.
89253256|NCT03992508|Experimental|intermittent pneumatic compression|In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
89253257|NCT03968770|Experimental|Experimental group|Probiotic product plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
89253258|NCT03968770|Placebo Comparator|Control group|Sham probiotical plus usual medical care (NSAIDs use and the promotion of a healthy lifestyle).
89253259|NCT00367770|Experimental|Tracleer|The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.
89253260|NCT00185614|Experimental|Auto- then Allo-HCT|Auto-HCT mobilization is cyclophosphamide 4 g/m2 + filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue [ie, autologous hematopoietic cells transplant (Auto-HCT)]. Post-infusion support is filgrastim 5 µg/kg/day, starting 6 days after melphalan. Stable/responsive disease at 4 weeks continues to allogenic HCT (Allo-HCT) from sibling donor fully-matched for human leukocyte antigen (HLA). Allo-HCT conditioning is total body irradiation (TBI) 200 centigray (cGy) + cyclosporine (CSP) 6.25 mg/kg + mycophenolate mofetil (MMF) 15 mg/kg. Donor mobilization is filgrastim 16 µg/kg/day on day -4 to Day 0; apheresis collections on Day -1 & Day 0, to a target of > 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV & diphenhydramine 50 mg IV. CSP tapering on Day 56 to Day 180, adjusted as needed.
89253261|NCT00162370|Experimental|Definity|All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.
89253262|NCT00361842|Experimental|Irinotecan|
89253263|NCT01324752|Experimental|PA21 and Losartan with food|
89253264|NCT01324752|Experimental|No PA21; Losartan with food|
89253265|NCT01324752|Experimental|PA21 with food and Losartan 2 hrs later|
89253266|NCT01050348|Active Comparator|Atorvastatin calcium|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
89253267|NCT01050348|Placebo Comparator|Sugar Pill|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
89253268|NCT00361296|Experimental|K562/GM-CSF cell vaccine|Vaccinations of 1x10^8 cells are given to participants at weeks 0, 3, 6, 9, and 17.
89253269|NCT03990090|Experimental|TG103|Escalating doses of TG103 administered subcutaneously (SC) once in healthy participants.
89253270|NCT03990090|Placebo Comparator|Placebo|Placebo administered SC once in healthy participants.
89253271|NCT01053390|Active Comparator|epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)|conventional regimen
89253272|NCT01053390|Experimental|Somatotatin|Conventional chemotherapy regimen plus somatostatin
89253273|NCT01048710||Tomofix_small|Surgical treatment using TomoFix TM Small
89253274|NCT01048710||Conservative treatment|"In the control group, patients who refused to have surgery will be allowed to be treated using different options of conservative treatment. The frequency of applications depends on the hospital and will therefore be documented in the study. An arthroscopy is not obligatory under this treatment group, but is permitted.~The following conservative treatment methods are allowed:~Physical therapy~Specific exercises for the muscles~Injections into the knee joint~Brace~Medication~No therapy"
89253275|NCT00356148|Active Comparator|Prophylaxis Group|patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis
89253276|NCT00356148|No Intervention|No Prophylaxis Group|Patients who are BMI over 25 and do not receive antibiotic prophylaxis
89253277|NCT00361218|Other|open-label selective serotonin reuptake inhibitor (SSRI)|citalopram or escitalopram
89253278|NCT02534532||Cohort 1|Females and males ≥65 years old, attending to the primary care centers, located in three different major cities in Colombia, that are willing to participate in the study, and do not present any exclusion criteria
89253279|NCT02534688|Experimental|LNG-IUS group|Single intervention LNG IUS
89253280|NCT02534688|Experimental|DMPA group|Three intervention DmPA 12 wk apart
89253281|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 1|
89253282|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 2|
89253283|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 3|
89253284|NCT02534610|Experimental|Group ETORICOXIB PREOP|Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
89253285|NCT02534610|Experimental|Group ETORICOXIB POSTOP|Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
89253286|NCT02534610|Placebo Comparator|Group PLACEBO|1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.
89253287|NCT02534298|Experimental|single sided deafness|single sided deafness and asymmetrical hearing loss patients functional magnetic resonance imaging
89253288|NCT02534298|Other|control group|Normal hearing subject functional magnetic resonance imaging
89253289|NCT01050426|Active Comparator|Group 1|UFT/LV + RT
89253290|NCT01050426|Active Comparator|Group 2|UFT/LV + RT + Cetuximab
89253291|NCT01053468|Experimental|PA Behavior Intervention|Physical Activity Resource Kit
89253292|NCT01053468|Active Comparator|Standard Materials|Receive physical activity handout from the Canadian Public Health Agency
89253293|NCT03990168|Experimental|Experimental|Participants will receive one anodal tDCS at 1 mA intensity over the left superior temporal gyrus (T3 in 10-20 international system) and the cathode tDCS over the right orbitofrontal area (Fp2 in 10-20 international system). tDCS will be delivered for 20 minutes during fluency intervention for six consecutive days.
89253294|NCT03990168|Sham Comparator|Sham Comparator|Participants will receive sham tDCS while the one anode electrode will be positioned over the left superior temporal gyrus and the cathode will be placed over the right orbitofrontal similar to the active mode. The sham stimulation will break down after 30 seconds at the beginning of 20 minutes of fluency intervention for six consecutive days.
89253295|NCT01053546|Experimental|Arm I (Early exercise group)|Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
89253296|NCT01053546|Experimental|Arm II (Late exercise group)|Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
89253297|NCT01049100|Experimental|operative staging (A)|operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open
89253298|NCT01049100|No Intervention|Standard (B)|No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--> CT controlled biopsy and histological analysis.
89253299|NCT00367458|Experimental|Atorvastatin, then Placebo|Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.
89253300|NCT00367458|Experimental|Placebo, Then Atorvastatin|Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.
89253301|NCT01053702|Experimental|Dose 1|R475
89253302|NCT01053702|Experimental|Dose 2|R475
89253303|NCT01053702|Placebo Comparator|Dose 3|Placebo to match R475 dose
89253304|NCT01050738|Active Comparator|Intracapsulare position|
89253305|NCT01050738|Active Comparator|Extracapsulare position|
89253306|NCT00162136|Experimental|A1|
89253307|NCT00252694|Experimental|candesartan|candesartan cilexetil 32 mg once daily
89253308|NCT00252694|No Intervention|placebo|control
89253309|NCT00185458|Experimental|LNG IUS|Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
89253310|NCT00185380|Experimental|LCS12|Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro
89253311|NCT00185380|Experimental|LCS16|Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro
89253312|NCT00185380|Active Comparator|IUS20 (Mirena)|Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro
89253313|NCT01326208|Experimental|Acute Lung Injury / ARDS|Patient under mechanical suffering from ALI or ARDS
89253314|NCT03968302|Experimental|ARM A|The triple regimen, amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole 40 mg twice a day
89253315|NCT03968302|Experimental|ARM B|The quadruple regimen,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day, omeprazole 40 mg twice a day dose and colloidal bismuth subcitrate 240 mg twice daily
89253316|NCT01074580||Deterioration, Crohn's disease|Patients > 18 years old with a deterioration of Crohn's disease defined by CDAI >150 and requiring treatment with systemic steroids or TNF alfa inhibitors
89253317|NCT01075594||1|Patients with dyslipidemia on lipid lowering therapy
89253318|NCT01077232||Psoriasis Patients|Patients with moderate to severe plaque psoriasis
89253319|NCT01077388|Experimental|Dietician electronic counseling|This arm will receive care and supportive emails and phone calls from a study dietician for about 6 months. We will also provide a blood pressure monitor, a pedometer, and a scale with instructions for using them at home.
89253320|NCT01077388|No Intervention|Self Care|This arm will continue to get care as usual from their regular doctor. They will also get a blood pressure monitor and a scale at the end of the study.
89253321|NCT01077466|Experimental|Natalizumab|24 patients: 12 with secondary progressive multiple sclerosis 12 with primary progressive multiple sclerosis
89253322|NCT00160654|Experimental|Levetiracetam|Subjects received open-label Levetiracetam.
89253323|NCT01582672|Experimental|AGS-003 + Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
89253324|NCT01582672|Active Comparator|Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
89253325|NCT00366678|Experimental|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
89253326|NCT00366678|Active Comparator|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine
89253327|NCT01049178|Experimental|Oral silymarin dose|Dose escalation study
89253328|NCT01049178|Placebo Comparator|placebo|A randomized, double-masked, placebo-controlled cross-over clinical pilot investigation of an inducer of endogenous antioxidant enzymes, silymarin, in humans with atopic asthma.
89253329|NCT01053858|Active Comparator|bevacizumab|intravitreal bevacizumab or triamcinolone determined by single physician
89253330|NCT01053858|Active Comparator|triamcinolone|
89253331|NCT01050894||osteoarthritis patients|
89253332|NCT02534454|Experimental|Active TDCS + Active Retraining|2.0 milliamperes (mA) of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
89253333|NCT02534454|Experimental|Sham TDCS + Active Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
89253334|NCT02534454|Experimental|Active TDCS + Sham retraining|2.0 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
89253335|NCT02534454|Experimental|Sham TDCS + Sham Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
89253336|NCT01050972|Experimental|Cognitive and physical program|Experimental: Cognitive and physical program. Non randomized residents in the territory of Piedmont (Piemonte) Italy.
89253337|NCT01051050|Other|Mandatory use of surgery wiki|Mandatory participation in journal club wiki which will include adding to and reviewing the information posted on the wiki. Contribution to the wiki will be required at least once during the study period.
89253338|NCT01051050|Other|Voluntary use of surgery wiki|Voluntary participation in the journal club wiki
89253339|NCT00355368|Active Comparator|Succinylcholine|
89253340|NCT00355368|Active Comparator|Rocuronium|
89253341|NCT01054014|Experimental|001|JNJ-40346527/Placebo Single oral dose of JNJ-40346527 (either 10 50 150 300 600 or 1000mg) or Placebo
89253342|NCT01054014|Experimental|002|JNJ-40346527/Placebo JNJ-40346527 once daily oral dose for 14 days (either 50 150 300 500 or 750mg) or Placebo
89253343|NCT01054014|Experimental|003|JNJ-40346527 JNJ-40346527 150mg one dose either fasting (or with food) then after 7 days off treatment JNJ-40346527 150mg either with food (or fasting)
89253344|NCT01054092|Experimental|before meal group|ASP1941 will be administered before meal
89253345|NCT01054092|Experimental|after meal group|ASP1941 will be administered after meal
89253346|NCT01055574||ProDisc-L|Subjects who received single-level ProDisc-L total disc replacement prior to physical capability evaluations
89253347|NCT01055574||anterior lumbar interbody fusion (AILF)|Subjects who received single-level anterior lumbar interbody fusion prior to physical capability evaluations
89253348|NCT03989622|Experimental|evaluation of the visual field on the ground|evaluation of the visual field on the ground followed by 10 reeducation sessions
89253349|NCT03989622|No Intervention|usual care|control session followed by 10 re-education sessions
89253350|NCT02534220|Active Comparator|Manual Toothbrush|Patients were instructed in the Roll Brushing Technique, twice daily for 2 min.
89253351|NCT02534220|Experimental|Oscillating-rotating toothbrush|Patients received manufacturer's instructions for use, including brushing twice daily for 2 min.
89253352|NCT00360282|Other|With Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
89253353|NCT00360282|Other|With Vertigo; Rizatriptan - Placebo|These subjects received Rizatriptan on visit 1 and placebo on visit 2.
89253354|NCT00360282|Other|Without Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
89253355|NCT00360282|Other|Without Vertigo; Rizatriptan-Placebo|This group received Rizatriptan on visit 1 and placebo on visit 2.
89253356|NCT00373958|Experimental|13vPnC vaccine|
89253357|NCT00373958|Active Comparator|7vPnC vaccine|
89253358|NCT00373880|Experimental|Aripiprazole (15mg) + Cocaine|Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg).
89253359|NCT00373880|Placebo Comparator|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg)
89253360|NCT00184600|Experimental|Insulin detemir (basal insulin)|Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen.
89253361|NCT00184600|Active Comparator|Insulin aspart (prandial insulin)|Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.
89253362|NCT00184600|Active Comparator|Biphasic insulin aspart 30 (biphasic insulin)|Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.
89253363|NCT03967756|Experimental|AI-assisted withdrawal group|A deep learning-based automatic polyp detection system was used to assist the endoscopist.
89253364|NCT03967756|No Intervention|Routine withdrawal group|Routine withdrawal without any assist.
89253365|NCT00265317|Experimental|A|
89253366|NCT00265317|Active Comparator|B|
89253367|NCT00373490|Experimental|Vorinostat 600 mg|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
89253368|NCT00373490|Experimental|Vorinostat 400 mg|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
89253369|NCT00251589|Experimental|Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 200 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and determined to be the MTD and therefore the recommended Phase II dose. Of the 16 patients treated at this dose level, 4 were assigned to the Phase I portion of the study and 12 were assigned to the Phase II portion
89290326|NCT01376518||respiratory failure|patients with respiratory failure and need of high positive end-expiratory pressure ventilation.
89253370|NCT00251589|Experimental|Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
89253371|NCT00251589|Experimental|Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
89253372|NCT00251589|Experimental|Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 400 mg once a day for 21 out of 28 days + erlotinib 150 mg once a day was evaluated in the Phase I portion of the original study and exceeded MTD. This cohort was then amended (Amendment 1) to identify a more tolerable once daily vorinostat dosing regimen. All patients treated at this dose level were assigned to the Phase I portion of the study.
89253373|NCT00265239|Active Comparator|1|Edaravone Group
89253374|NCT00265239|No Intervention|2|Placebo Group
89253375|NCT00350298|Experimental|GS-CDA1/MDX-1388|Biological: GS-CDA1/MDX-1388 One Intravenous dose
89253376|NCT00350298|Placebo Comparator|Placebo|Biological: normal saline (0.9% sodium chloride) One Intravenous dose
89253377|NCT00159874|Experimental|Sildenafil high dose|As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.
89253378|NCT00159874|Experimental|Sildenafil Low dose|
89253379|NCT00159874|Experimental|Sildenafil medium dose|As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
89253380|NCT03966430|Experimental|damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the damage control surgery group.
89253381|NCT03966430|Sham Comparator|non-damage control surgery group|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the non-damage control surgery group.
89253382|NCT00349908|Experimental|Group 1: Atherosclerosis Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
89253383|NCT00349908|Active Comparator|Group 2: Aneurysm Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
89253384|NCT00184054|Experimental|Arsenic Trioxide (ATO) Plus Ascorbic acid|"Arsenic Trioxide (ATO) given at 0.25 mg/kg/day intravenously for 25 days over a 35-day period.~Ascorbic Acid given at 1000 mg/day intravenously every other day that ATO is given"
89253385|NCT03989856|Experimental|Suturing group|"The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.~The running suture starting from central area, around the ovarian hilus to peripheral tissue, will be performed with intraovarian knots to re-approximate the edges to achieve satisfying hemostasis. Knots will not be detectable on the ovarian surface for prevention of adhesion. Mean time for hemostasis of ovary was recorded in a form. The cyst wall will be removed from the abdomen by means of an endobag. All resected cyst walls will be sent to the pathology laboratory, to confirm the histopathology of endometriosis."
89253386|NCT03989856|Active Comparator|Bipolar group|In bipolar coagulation group, after stripping the ovarian cyst wall, bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). In laparoscopic suturing group, no bipolar coagulation will be performed during or after stripping the ovarian cyst wall.
89253387|NCT02533908|Active Comparator|Fentanyl intranasal|Fentanyl Sintetica 0.1mg/2ml: 1.5ug/kilogram intranasal= 0.03ml/kg once
89253388|NCT02533908|Placebo Comparator|NaCl 0.9% intranasal|NaCl 0.9% Sintetica 18mg/2ml: same dosage as fentanyl= 0.03ml/kg
89253389|NCT02534142||Completed followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and had a colonoscopy following the result.
89253390|NCT02534142||Did not complete followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and did not have a colonoscopy following the result.
89253391|NCT01051128|Experimental|Spasticity. Baclofen|This study is a non-randomized, open-label, multi-center study of the Prometra Programmable Implantable Pump System in the administration of Lioresal® intrathecal (baclofen) in patients suffering from severe muscle spasticity of spinal origin.
89253392|NCT02533986|Placebo Comparator|Control drink|Dietary supplement: Control drink As control, subjects are asked to consume 150 ml control drink containing equal amount of insoluble fiber (cellulose) and sugar for 28 days. In addition, on days-1 and 28, subjects will receive an acute challenge of placebo drink at our clinical facility. After 30 min. control drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
89253393|NCT02533986|Experimental|Berry peel drink|Dietary supplement: Berry peel drink Subjects are asked to consume 150 ml experimental drink containing a berry peel fruit powder. In addition, on days-1 and 28, subjects will receive an acute challenge of test drink at our clinical facility. After 30 min. berry drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
89253394|NCT00183430|Experimental|1|Participants will receive treatment with prazosin plus psychotherapy
89253395|NCT00183430|Placebo Comparator|2|Participants will receive treatment with placebo plus psychotherapy
89253396|NCT00183274|Active Comparator|Open-Label Group|6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
89253397|NCT00183274|Active Comparator|Double-Blind Drug Group|6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
89253398|NCT00183274|Placebo Comparator|Double-Blind Placebo Group|6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
89253399|NCT00183274|Active Comparator|Double-Blind Drug-After-Drug Group|6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
89253400|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Drug Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
89253401|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Placebo Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
89253402|NCT00183196|Active Comparator|1|Naltrexone plus placebo
89253403|NCT00183196|Active Comparator|2|naltrexone + gabapentin
89253404|NCT00183196|Sham Comparator|3|Placebo plus placebo
89253405|NCT00349752|Experimental|Certolizumab pegol 400 mg|Certolizumab pegol 400 mg
89253406|NCT00349752|Placebo Comparator|Placebo|Placebo
89253407|NCT01055652|Experimental|1|
89253408|NCT01054326|Experimental|Supervised physical therapy focusing of rotatorcuff exercises|Patients did specific exercises supervised by a physical therapists twice a week during two months. Focus was on early activation of rotator cuff and scapula stabilizers following different phases in a rehabilitation program Assessments before surgery,1 week after as well as 1,2,3 and 6 months after surgery.
89253409|NCT01054326|Active Comparator|Home exercises|Patients did home exercises following a programme during three months. Assessment considering shoulder function and pain was done before surgery, 1w after as well as 1,2,3 and 6 months after surgery,
89253410|NCT00174460|Active Comparator|Treatment Arm|
89253411|NCT00174460|No Intervention|Control Arm|
89253412|NCT00348816|Experimental|Docetaxel (Single Arm)|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Prednisone 5mg twice a day Radical prostatectomy as standard of care Radiation therapy will be used as standard of care Post radiation Doxcetaxel
89253413|NCT03989310|Experimental|Manganese primed anti-PD-1 antibody plus nPG chemotherapy|Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
89253414|NCT03989310|Experimental|anti-PD-1 antibody plus nPG chemotherapy|Subject received anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
89253415|NCT03966898|Experimental|SHR6390, Letrozole or Anastrozole|SHR6390, Letrozole or Anastrozole
89253416|NCT03966898|Placebo Comparator|Placebo, Letrozole or Anastrozole|Placebo, Letrozole or Anastrozole
89253417|NCT03989544|Experimental|Tezepelumab via Vial-and-syringe|Participants will be randomized to a single dose of tezepelumab via SC administration with Vial-and-syringe
89253418|NCT03989544|Experimental|Tezepelumab via APFS|Participants will be randomized to a single dose of tezepelumab via SC administration with APFS
89253419|NCT03989544|Experimental|Tezepelumab via AI|Participants will be randomized to a single dose of tezepelumab via SC administration with AI
89253420|NCT03966196|Other|Healthy Volunteers|oxymetry and finger pressure in Healthy subjects
89253421|NCT03966196|Experimental|COPD patients|oxymetry and finger pressure in COPD patients
89253422|NCT03987594|Placebo Comparator|TUF|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
89253423|NCT03987594|Experimental|TUF+HD|Subjects allocated into TUF+HD group receive bladder hydrodistension prior to transurethral fulguration of Hunner lesion
89253424|NCT03989700|Experimental|Low dose|Low dose of thiamin supplementation
89253425|NCT03989700|Experimental|High dose|High dose of thiamin supplementation
89253426|NCT03989700|Placebo Comparator|Placebo|placebo supplementation
89253427|NCT03987750|Experimental|Safinamide 100mg|Participants randomized to the 100 mg study arm will receive 100 mg safinamide methanesulfonate film-coated tablets once daily during Week 1 (2 x 50 mg active tablets plus 1 placebo tablet) and throughout the rest of the study safinamide
89253428|NCT03987750|Experimental|Safinamide 150mg|Participants randomized to the 150 mg study arm will receive 100 mg methanesulfonate film-coated tablets once daily during Weeks 1 and 2 (2 x 50 mg active tablets plus 1 placebo tablet), and 150 mg methanesulfonate film-coated tablets once daily(3 x 50 mg active tablets) from Week 3 and throughout the rest of the study
89253429|NCT03987750|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive Safinamide Methanesulfonate matching placebo film-coated tablets once daily (3 x placebo tablets)
89253430|NCT01055730||Pulmonary rehabilitation|
89253431|NCT01051284|Experimental|Cyberknofe and Gemcitabine|Cyberknife radiation and 6 cycles Gemcitabine
89253432|NCT01051362|No Intervention|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
89253433|NCT01055808||Type 2 diabetes treated with insulin|
89253434|NCT00265083|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
89253435|NCT00265083|Placebo Comparator|001|Golimumab (CNTO 148); placebo SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
89253436|NCT00265083|Experimental|002|golimumab 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
89253437|NCT03971097|Active Comparator|Control Group (TAU)|Participants of the study who will receive the normal programming schedule or treatment as usual (TAU).
89253438|NCT03971097|Experimental|Experimental Group (TAU plus self-forgiveness model)|Participants of the study who will receive TAU plus six additional individual counseling sessions that include integration of a self-forgiveness model developed by Everett L. Worthington.
89253439|NCT00264849|Experimental|OAT + Omalizumab|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.
89253440|NCT00264849|Active Comparator|Optimized Asthma Treatment (OAT)|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for 32 weeks.
89253441|NCT01073709|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
89253442|NCT01073709|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
89253443|NCT03974607|Experimental|Physical Activity|Physical Activity Programme (PAP) was planned for the promotion of PA and other healthy habits in inactive adolescents as an agent of change intervention, in which a trained staff actively disseminates effective practices to improve the PA's habits of adolescents.
89253444|NCT03974607|No Intervention|No Physical Activity|The control group will be selected in a targeted manner according to the availability of the center. You will not be given any information about healthy habits nor will any physical training program be applied to you, so that you do not give indications that may produce a variation of your habitual behavior.
89253445|NCT00211809|Experimental|Body dysmorphic disorder|Participants with body dysmorphic disorder
89253446|NCT01071291|Experimental|Arm A|Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2
89253447|NCT01071291|Experimental|Arm B|Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2
89253448|NCT03970941||CERAMENT|Patients having a septic pseudarthrosis managed with two-stage treatment (Masquelet Technique) with CERAMENT®.
89253449|NCT03970941||NO CERAMENT COMPARATIVE COHORT|Patients having had a septic pseudarthrosis managed with two-stage treatment (only Masquelet Technique) without CERAMENT®.
89253450|NCT01073787|Active Comparator|Normal saline|
89253451|NCT01073787|Experimental|Normal saline and possible medication|
89253452|NCT00129766|Active Comparator|palivizumab|15 mg/kg administered intramuscularly for 5 monthly doses
89253453|NCT00129766|Experimental|motavizumab (MEDI-524)|15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses
89253454|NCT01075750||Normal Saline|Patients receiving Normal Saline during and after the renal transplantation.
89253455|NCT01075750||Elomel Isoton|Patients receiving Elomel Isoton during and after renal transplantation
89253456|NCT00150592|Experimental|SPD503 (Guanfacine HCl)|
89253457|NCT00150592|Placebo Comparator|Placebo|
89253458|NCT00149890|Experimental|With Intraoperative Steroids|Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.
89253459|NCT00149890|Active Comparator|Without Intraoperative Steroids|No intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab and the first dose of steroids had to be administered within 8 hours after reperfusion of the graft and basiliximab was given as an intravenous bolus injection.
89253460|NCT00174382|Experimental|1|
89253461|NCT00355134|Experimental|Fingolimod 1.25 mg|"Participants received 1.25 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 1.25 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day."
89253462|NCT00355134|Experimental|Fingolimod 0.5 mg|Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
89253463|NCT00355134|Experimental|Placebo|"Participants received placebo capsules orally once a day for up to 24 months during the core phase. In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day. Upon implementation of a protocol amendment, all patients taking placebo were switched to 0.5 mg fingolimod orally once a day."
89253464|NCT03987516|Experimental|Active intervention|Patients will be included in an active intervention.
89253465|NCT03987516|No Intervention|Control group|Patients in the control group will not receive any intervention
89253466|NCT00171730|Experimental|Pasireotide s.c. Overall|Participants received pasireotide as a daily subcutaneous (s.c) injection, every 12 hours at 9:00 AM and 9:00 PM at the dose at which the biochemical control was achieved (either 200, 400, or 600 microgram (μg)) for as long as the participant benefited from the treatment, and there were no safety or tolerability concerns (median duration of 22.7 months).
89253467|NCT00355056|Sham Comparator|Medical Management|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).
89253468|NCT00355056|Experimental|PFO Closure|Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.
89253469|NCT00348348|Active Comparator|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5%
89253470|NCT00348348|Experimental|Besifloxacin Suspension|Besifloxacin hydrochloride ophthalmic suspension 0.6%
89253471|NCT01324986|Active Comparator|Nissen fundoplication|
89253472|NCT01324986|Active Comparator|Toupet fundoplication|
89253473|NCT03989388|Experimental|Intervention Group|Occupational Self-Analysis Programme
89253474|NCT03989388|Active Comparator|Control group|Vocational guidance or usual rehabilitation (in the case of ABI participants)
89253475|NCT01054482|Experimental|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
89253476|NCT01054482|Active Comparator|Pre-operative concurrent chemoradiation therapy|
89253477|NCT02534064|Experimental|Group A: 2 yogurts|consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
89253478|NCT02534064|Experimental|Group B: 1 yogurt|consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product during 8 weeks.
89253479|NCT02534064|No Intervention|Group C: No yogurt|no changes in dietary habits during 24 weeks.
89253480|NCT02533830|Active Comparator|gum chewing group.|"Group A (81 Women) Who Received One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
89253481|NCT02533830|Placebo Comparator|Placebo group|Group B (81 Women) had Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
89253482|NCT03987438|Experimental|Behavioral intervention|Participants randomized to the behavioral intervention group will be provided with a mobile APP which incorporates behavioral support including health knowledge education, mental health counseling, diet advice, exercise guidance and weight management. Meanwhile, the behavioral support will be modified by endocrinologists, dieticians, sports medicine professionals and psychologists individually based on the feedback of their performance recorded in the APP. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Investigators conduct face-to-face health education, lifestyle guidance, mobile APP software inspection. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
89253483|NCT03987438|No Intervention|Control group|Participants randomized to the control group have regular care in their local hospitals. Every three months, participants in the intervention group will be back to their research centers and be collected with information including HbA1c levels, blood pressure, heart rate tests and adverse events. Every one year, 75g OGTT (0min,60min, 120min points of blood glucose and insulin levels), liver and kidney function, blood lipids, glycosylated hemoglobin, urine routine and electrocardiogram will be evaluated.
89253484|NCT02533752||Main Group|This an observational registry - there is only one group
89253485|NCT02533362|Experimental|ANF-Rho|pegfilgrastim Anti-Neutropenic Factor (ANF)
89253486|NCT00347958|Experimental|Adacel vaccine group|Participants 15 to 69 years of age who received a dose of Adacel vaccine in one of three previous studies (Td501, or Td502, or Td505), revaccinated in Study Td518.
89253487|NCT00354744|Experimental|High Risk Rhabdomyosarcoma|Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
89253488|NCT01051674|Experimental|High fiber diet|
89253489|NCT01051674|Experimental|Low-carbohydrate diet|
89253490|NCT01055964|Experimental|Tacrobell|
89253491|NCT01055964|Active Comparator|Prograf|
89253492|NCT03987204|Experimental|Ivabradine|Patients with permanent atrial fibrillation and previously implanted pacemakers who will be started on ivabradine.
89253493|NCT01051752||NTM infection|Patients with NTM infection are generally middle aged or higher aged, white males with COPD or bronchiectasis. They will be recruited from the outpatient clinics of University Centre for Chronic Diseases Dekkerswald, Tuberculosis Centre Beatrixoord or other outpatient clinics in The Netherlands. Both newly diagnosed and already treated patients with NTM disease will be recruited.
89253494|NCT01056042|Experimental|A|Intramuscular depot medroxyprogesterone acetate
89253495|NCT01056042|Active Comparator|B|ethinyl estradiol 30 micrograms combined with gestodene 75 micrograms
89253496|NCT01051830|Experimental|Interdisciplinary group|Diabetes intervention and rehabilitation program. The rehabilitation program includes geriatric consultation, the rehabilitation program (interventions to improve ROM, muscle strength and endurance, proprioceptive enhancement, balance capacity, aerobic and anaerobic capacity, flexibility, and body composition), and discharge-planning services. The DM intervention includes: dietary and DM education, blood pressure control, dyslipidemia management, a glycemic treatment regimen, and exercises.
89253497|NCT01051830|No Intervention|Control group|Routine care
89253498|NCT01056120||ENERGY-Population|"Patient population in standard clinical care, according to the instructions for use and the inclusion / exclusion criteria. Registry patients should be enrolled consecutively to represent a typical set of patients at each site.~The registry will collect clinical data from patients that have given their prior written consent. All data will be anonymized prior to data entry."
89253499|NCT00373256|Experimental|A|
89253500|NCT00373256|Active Comparator|B|
89253501|NCT01324544|Experimental|Buprenorphine IV|Buprenorphine IV
89253502|NCT00394082|Experimental|ABI-007 plus Bevacizumab|ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
89253503|NCT00393848|Experimental|Experiment 2 - Experimental Group|
89253504|NCT00393848|No Intervention|Experiment 1 - Standard of care Group|
89253505|NCT00393848|Experimental|Experiment 1 - Experimental Group|
89253506|NCT00393848|Placebo Comparator|Experiment 2 - Placebo Group|
89290327|NCT00253643|Experimental|Arm I (FO, GT catechin extract)|Patients receive oral fish oil (FO) 3/day and oral green tea (GT) extract 2/day
89290328|NCT00253643|Experimental|ArmII (FO placebo, GT catechin extract)|Patients receive a fish oil (FO) placebo 3/day and oral green tea (GT) extract 2/day
89290329|NCT00253643|Experimental|Arm III (FO, GT placebo)|Patients receive oral fish oil (FO) 3/day and a placebo mimicking green tea (GT) catechins 2/day
88806106|NCT01791218|Experimental|CABG, AVR or CABG+AVR and PVI|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG
89253507|NCT00393458|Experimental|Indacaterol 300 μg plus placebo to formoterol|Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89253508|NCT00393458|Experimental|Indacaterol 600 μg plus placebo to formoterol|Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89253509|NCT00393458|Active Comparator|Formoterol 12 μg plus placebo to indacaterol|Patients inhaled formoterol 12 μg twice daily via the manufacturer's proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89253510|NCT00393458|Placebo Comparator|Placebo to indacaterol plus placebo to formoterol|Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
89253511|NCT01046006|Experimental|Bortezomib, Rituximab, Dexamethasone|BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of Bortezomib, dexamethasone 40mg iv and Rituximab 375 mg/m2 iv will be administered. A total of 8 infusions of rituximab will be administered. Subsequently patients rated as CR, PR, MR or SD will be followed without any treatment until there is evidence of progressive disease.
89253512|NCT01036646||BSTE-0125-Original Protocol|
89253513|NCT01036646||BSTE-0125.a-Amended Protocol|
89253514|NCT01046162|Active Comparator|Tafil Tablets 2 mg Pharmacia Upjohn|
89253515|NCT01046162|Active Comparator|Xanax Tablets 2 mg Pfizer LLC|
89253516|NCT00417482|Other|Risperidone-risperidone|Risperidone for 16 weeks followed by risperidone for 16 weeks
89253517|NCT00417482|Other|Risperidone-Placebo|Risperidone for 16 weeks followed by placebo for 16 weeks
89253518|NCT00417482|Other|Placebo-Placebo|Placebo for 16 weeks followed by placebo for 16 weeks
89253519|NCT01043900|Placebo Comparator|Sham rTMS|Patients with stable medication regimen receiving 30 daily sessions of PLACEBO rTMS delivered to the right dorsolateral prefrontal cortex
89253520|NCT01043900|Active Comparator|Active rTMS|Patients with stable medication regimen receiving 30 daily sessions of active rTMS delivered to the right dorsolateral prefrontal cortex
89253521|NCT00417248|Experimental|Investigational Treatment|Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
89253522|NCT01046240|Active Comparator|Intravenous palonosetron|Intravenous palonosetron: control arm (standard treatment)
89253523|NCT01046240|Experimental|subcutaneous palonosetron|subcutaneous palonosetron
89253524|NCT00392288|Placebo Comparator|Placebo MDI|double-blind
89253525|NCT00392288|Experimental|Ciclesonide MDI 40 µg BID|double-blind
89253526|NCT00392288|Experimental|Ciclesonide MDI 80 µg BID|double-blind
89253527|NCT00417170|Experimental|Aliskiren 300 mg|Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
89253528|NCT00417170|Active Comparator|Amlodipine 5 mg|Eligible participants received oral Amlodipine 5 mg + Placebo Aliskiren once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
89253529|NCT01046318|Experimental|OPC-262 5 mg|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
89253530|NCT00392990|Experimental|Alternating doxil/Magrath regimen & rituximab/Magrath regimen|Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.
89253531|NCT01046474|Experimental|reducing beverages and sugar and increase physical activity|reduction of beverages and sugar and increasing physical activity
89253532|NCT01046474|No Intervention|control -no intervention|
89253533|NCT01046552|Active Comparator|PES/LC|preoperative ES followed by LC within the same hospital admission
89253534|NCT01046552|Active Comparator|LC/IOES|laparoscopic cholecystectomy with intraoperative ercp under the same anesthesia
89253535|NCT01043978|Experimental|Novel nipple|
89253536|NCT01043978|Active Comparator|Coventional nipple|
89290330|NCT00253643|Placebo Comparator|Arm IV (FO placebo, GT placebo)|Patients receive a fish oil (FO) placebo mimicking fish oil 3/day and another placebo mimicking green tea (GT) catechins 2/day
89290331|NCT01222650|Experimental|KSO-0400 Low Dose|
89290332|NCT01222650|Experimental|KSO-0400 High Dose|
89290333|NCT01222650|Experimental|Silodosin|
89253537|NCT01044134|Experimental|Diet + Water|"Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular 8 × 8 recommendation (eight 8-oz glasses of water)."
89253538|NCT01044134|Active Comparator|Diet|Participants will be counseled on the same standard weight-reducing diet, as described above, with no specific advice regarding water consumption. Furthermore, no specific dietary recommendations will be provided on altering fluid/beverage intake, other than to decrease calorie-containing beverages as noted above. When participants ask for a recommendation regarding water intake, they will be advised that drinking plain water is the best way to satisfy thirst and instructed to drink when thirsty.
89253539|NCT00249873|Experimental|Clopidogrel + ASA|Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
89253540|NCT00249873|Placebo Comparator|Placebo + ASA|Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
89253541|NCT00392210|No Intervention|Spontaneous Fill|
89253542|NCT00392210|Active Comparator|Retrograde Fill|
89253543|NCT01037348|Experimental|ranibizumab 0.5mg|
89253544|NCT03490292|Experimental|Run-In Phase|"6 patients enrolled will receive weekly carboplatin (AUC2) and paclitaxel (50 mg/m2) [intravenous infusion on days 1, 8, 15, 22, & 29] while undergoing radiation therapy [23 fractions, M-F, estimated completion day 35].~Avelumab combined with Chemoradiation - Avelumab (10 mg/kg IV) every 2 weeks starting on the day of the last chemotherapy infusion (day 29). A total of 3 doses administered during the pre-operative period and an additional 6 doses of avelumab post-operatively.~Trial enrollment will resume after at least 5 patients do not have a DLT during the DLT evaluation period or until all 6 patients are seen for post-operative evaluation. If 2 or more patients experience dose limiting toxicities associated with the proposed treatments, further accrual of the subjects will be halted and trial will be suspended. Trial may be reopened in the future with appropriate schedule and dose modifications of the proposed treatment."
89253545|NCT03490292|Experimental|Expansion Cohort|Following a determination of safe and tolerable treatment outcome of the Run-In Phase, Part 2 of the trial will enroll 18 additional patients to evaluate activity of the proposed treatment and to obtain further safety information (carboplatin, paclitaxel, radiation & Avelumab combined with Chemoradiation).
89253546|NCT01046630|Experimental|1|single infusion
89253547|NCT01046630|Active Comparator|2|single infusion
89253548|NCT01046630|Placebo Comparator|3|single infusion
89253549|NCT01037426|Other|Study group|Falls before versus after pacemaker implant
89253550|NCT01046708|Experimental|micronized progesterone|
89253551|NCT01046708|No Intervention|no utrogestan|
89253552|NCT01046786|Active Comparator|Group A|Intraspinal injection of 1.6 million cord blood mononuclear cell
89253553|NCT01046786|Active Comparator|Group B|Intraspinal injection of 3.2 million cord blood mononuclear cell
89253554|NCT01046786|Active Comparator|Group C|Intraspinal injection of 6.4 million cord blood mononuclear cell
89253555|NCT01046786|Active Comparator|Group D|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone
89253556|NCT01046786|Active Comparator|Group E|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone plus 6 week course of oral lithium, titrated to maintain 0.6-1.0 mM serum level
89253557|NCT00391976|Experimental|Tobramycin 300 mg for 28 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 28 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
89253558|NCT00391976|Experimental|Tobramycin 300 mg for 56 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 56 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
89253559|NCT00762554|Active Comparator|1|Epidural Depodur after spinal bupivacaine
89253560|NCT00762554|Active Comparator|2|Epidural fentanyl infusion after epidural lidocaine or spinal bupivacaine
89253561|NCT00391898|Experimental|Levodopa/carbidopa/entacapone|
89253562|NCT00391898|Active Comparator|Levodopa/carbidopa|
89253563|NCT03993080|Experimental|Virtual reality relaxation|Virtual reality relaxation using virtual landscape and audio features and sound
89253564|NCT03993080|No Intervention|Treatment as usual|Seated in similar environment as experimental group for same time
89253565|NCT01046864|Experimental|Arm 1|
89253566|NCT01046864|Experimental|Arm 2|
89253567|NCT01046864|Experimental|Arm 3|Japanese Population
89253568|NCT01046942|Experimental|Clopidogrel+Aspirin, hypercoagulabel|
89253569|NCT01046942|Active Comparator|Aspirin,hypercoagulabel control|
89253570|NCT01047020||ALL survivors|The study sample for this research will be recruited from participants in an institutionally funded cohort study, St. Jude Life, as well as from active ACT patients that meet eligibility criteria. The young adults in St. Jude Life are a highly motivated group who were followed in the After Completion of Therapy Clinic until age 18 years and a minimum of 10 years after their treatment ended if they were older than age 11 at the end of therapy
89253571|NCT01047020||Comparison Group|Potentially eligible comparison group participants will be recruited from the parent, older sibling, relative or friend population who accompany the ACT patient for follow-up at SJCRH. Parents (or siblings, relatives or friends who are 18 years or older) of children in remission, both from the active follow-up cohort (within five years of last treatment) and the After Completion of Therapy (ACT) cohort will be invited to complete the same assessments that the ALL survivor participants will complete. Comparison group participants are frequency matched to potentially eligible participants by race/ethnicity (white, black, other) age group (18 to 29, 30-39, 40-49 years) and gender.
89253572|NCT01049282|Experimental|12 TST negative volunteers antigen only|
89253573|NCT01049282|Experimental|12 TST negative volunteers|
89253574|NCT01049282|Experimental|12 BCG vaccinated volunteers|
89253575|NCT01049282|Experimental|12 with Latent TB infection >= 2 years ago|
89253576|NCT01049438|Experimental|Nasal, body, and systemic decolonization|
89253577|NCT01047098|Experimental|Iron with meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken with meals
89253578|NCT01047098|Experimental|Iron between meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken between meals
89253579|NCT01047098|Placebo Comparator|Placebo|Prenatal vitamin without iron plus capsule containing calcium carbonate (placebo) taken between meals
89253580|NCT01047176||1|Male or female > 18 year of age with indication to PCI
89253581|NCT01047254|Active Comparator|Bupropion|Buproprion 150-300 mg in a flexible dose
89253582|NCT01047254|Placebo Comparator|placebo capsule|Placebo
89253583|NCT01047410|No Intervention|Usual care|Patients assigned to the usual care group receive the standard medical care (usual care) during the 15 months lasting study period. Physical training does not form a part of the usual care of renal transplant and dialysis patients. After randomisation, patients assigned to the usual care group receive the advice to meet the 'Nederlandse Norm Gezond Bewegen (NNGB), i.e. the advice to perform 30 minutes of moderately intense physical activity at at least five but preferably all days of the week.
89253584|NCT01047410|Experimental|Exercise intervention|The exercise intervention in this group is identical to the exercise-only group. Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
89253585|NCT01047410|Experimental|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
89253586|NCT00391586|Experimental|Erlotinib followed by chemotherapy|"Erlotinib: 150 mg orally once daily,~Platinum-based chemotherapy regimen selections include:~Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:~Docetaxel 75 mg/m2, D1~Docetaxel 35 mg/m2, D1,8,15~Paclitaxel 200-225 mg/m2, D1~Paclitaxel 80-100 mg/m2, D1,8,15~Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:~Etoposide 100 mg/m2 D1-3~Etoposide 200 mg/m2 orally D1-3~Pemetrexed 500 mg/m2, D 1~Irinotecan 50 mg/m2 D1,8,15~Other regimens:~Gemcitabine 1000 mg/m2-1250 mg/m2, D1,8 + Carbo AUC 6, or Cis 60-100 mg/m2, D1 or 8~Vinorelbine 25 mg/m2 D1,8 + Carbo AUC 5, or Cis 80 mg/m2 D1"
89253587|NCT00391430|No Intervention|Control|Participants assigned to the control condition will receive no treatment
89253588|NCT00391430|Active Comparator|Sertraline|Participants will receive treatment with sertraline
89253589|NCT00391430|Active Comparator|CBT|Participants will receive cognitive behavioral therapy
89253590|NCT00391274|Experimental|Pemetrexed|
89253591|NCT00391274|Active Comparator|Docetaxel|
89253592|NCT00391118|Experimental|A (Part A)|"Enzastaurin: 1125 milligram (mg) loading dose then 500 mg oral tablet, daily for six 21-day cycles or up to 3 years~Carboplatin: Area under the concentration time curve (AUC) 5 intravenous (IV), every (q) 21 days for six 21-day cycles~Paclitaxel:175 milligrams/square meter (mg/m²) IV, q21 days for six 21-day cycles"
89253593|NCT00391118|Placebo Comparator|B (Part B)|"Carboplatin: AUC5 IV, q21 days for six 21-day cycles~Paclitaxel: 175 mg/m², IV, q21 days for six 21-day cycles~Placebo: oral tablet"
89253594|NCT00390884|Experimental|Fluzone®-Primed Group|Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
89253595|NCT00390884|Experimental|Fluzone®-Naive Group|Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
89253596|NCT01047488|Active Comparator|Imipramine|Imipramine tablets and placebo capsules to pregabalin
89253597|NCT01047488|Active Comparator|Pregabalin|Pregabalin capsules and placebo tablets to imipramine
89253598|NCT01047488|Experimental|Imipramine plus pregabalin|Imipramine tablets and pregabalin capsules
89253599|NCT01047488|Placebo Comparator|Placebo|Placebo tablets to imipramine and placebo capsules to pregabalin
89253600|NCT01047566|Experimental|Addition of dronedarone|Addition of Dronedarone to existing rate control medication (beta blocker and/or calcium antagonist)
89253601|NCT01047566|Active Comparator|Dose Increase|Dose increase of existing rate control medication (beta blocker or calcium antagonist or digoxin)
89253602|NCT00365846|Experimental|Campath 1H induction w/ Sirolimus immunosuppression|Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,
89253603|NCT00264537|Experimental|Group 1: Placebo + Methotrexate|Placebo subcutaneous injections (SC) every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 50 mg SC injections every 4 weeks from Week 28 up to 5 years; Golimumab - Dr's discretion after unblinding (in participants receiving methotrexate plus placebo), 50 mg SC injections every 4 weeks up to 5 years; Golimumab- Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
89253604|NCT00264537|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; placebo capsules weekly from Week 0 for up to 5 years (unless early escape at Week 28); Methotrexate - if early escape, 10 to 20 mg weekly from Week 28 up to 5 years; Methotrexate - Dr's discretion after unblinding (in participants receiving golimumab plus placebo) 10 to 20 mg weekly for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
89290334|NCT01222650|Placebo Comparator|Placebo|
89290335|NCT01126476|Active Comparator|small volume strata|12 in small volume strata
89290336|NCT01126476|Active Comparator|large volume strata|12 in large volume strata
89253605|NCT00264537|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 28 for up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
89253606|NCT00264537|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
89253607|NCT00371462|Active Comparator|Arm 1|MOVE! level 2 group weight loss counseling, the VA standard of care alone (Standard Care);
89253608|NCT00371462|Experimental|Arm 2|MOVE! level 2 + Personal Digital Assistant decision support tool (PDA) (Treatment)
89253609|NCT00371150|Experimental|Arm1|
89253610|NCT00264303|Experimental|Levocetirizine|Levocetirizine, once daily, 4 week duration
89253611|NCT00264303|Active Comparator|Desloratadine|Desloratadine, once daily, 4 week duration
89253612|NCT01071369|Active Comparator|Xylocaine|0.5% Xylocaine
89253613|NCT01071369|Active Comparator|Xylocaine and Celestone|0.5% Xylocaine with 6 mg of non-particulate Celestone.
89253614|NCT01072305|Experimental|Intermittent pneumatic compression (IPC)|IPC from induction of general anesthesia to completion of skin closure.
89253615|NCT01072305|Placebo Comparator|control|IPC - placebo from induction of general anesthesia to closure of the skin
89253616|NCT00370682|Experimental|T-DEN F17|Full Dose (0.5 mL) 0 and 6 months
89253617|NCT00370682|Experimental|T-DEN F19|Full Dose (0.5 mL) at 0 and 6 months
89253618|NCT00370682|Placebo Comparator|Placebo Comparator|0.5 mL sterile buffer at 0 and 6, subcutaneous injection
89253619|NCT00264147|Experimental|Period I: 1|etoricoxib
89253620|NCT00264147|Experimental|Period I: 2|etoricoxib
89253621|NCT00264147|Experimental|Period I: 3|etoricoxib
89253622|NCT00264147|Experimental|Period I: 4|etoricoxib
89253623|NCT00264147|Placebo Comparator|Period I: 5|Placebo
89253624|NCT00264147|Experimental|Period II: 1|etoricoxib
89253625|NCT00264147|Active Comparator|Period II: 2|diclofenac
89253626|NCT01044368|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
89253627|NCT01044368|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
89253628|NCT01044446|Experimental|Icodextrin|peritoneal dialysate
89253629|NCT01044446|Active Comparator|Glucose-based dialysate|peritoneal dialysate
89253630|NCT00263757|Experimental|Therapeutic Positive Airway Pressure|Subjects randomized to this arm received nightly Adaptive Servo-Ventilation during sleep for 12 months.
89253631|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management for 12 months as prescribed by their cardiologist.
89253632|NCT01072383|Experimental|BT061|receiving BT061 (active compound)
89253633|NCT01072383|Placebo Comparator|Placebo|receiving a placebo
89253634|NCT01072461|Active Comparator|Train Paretic Hand and Arm Separate|Eight three hour training sessions of robotically facilitated hand and arm training in complex virtual environments, using activities that train the fingers in isolation and other activities that train the arm in isolation.
89253635|NCT01072461|Experimental|Train Paretic Hand and Arm Together|
89253636|NCT01072461|Experimental|Train Both Hands Together in VE|
89253637|NCT03971019|Experimental|Statin therapy (experimental group)|"On the basis of guiding patients to control their diet and improve their lifestyle, etc.~Simvastatin 20mg/d QN Po (dosage can be adjusted according to the blood lipid level of each reexamination) Atorvastatin 10mg/d QN Po (patients who cannot tolerate the side effects of simvastatin may consider replacing this drug)"
89253638|NCT03971019|Other|Dietary intervention group (control group)|Guiding patients to control diet, improve lifestyle, etc.
89253639|NCT03970707|Experimental|Small Number of Players training protocol A|Small Sided Game: 4 vs 4
89253640|NCT03970707|Experimental|Large Number of Players training protocol B|Small Sided Game: 8 vs 8
89253641|NCT03970707|No Intervention|Control|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
89253642|NCT03974685|Experimental|99mTc-3PRGD2|Volunteers were injected intravenously and then scanned by SPECT/CT. Drugs use generic name：99mTc niacinamide polyethylene glycol bicyclic RGD peptide dosage form:Injection dosage:0.3mCi/kg frequency:single
89253643|NCT03970551|No Intervention|No Physical Intervention|The participant will actively stand up from a seated position without performing any physical counter-maneuvers either prior to or following the stand.
89253644|NCT03970551|Experimental|Supine Knee Raises|The participant will perform 30 seconds of raising their knees to their chest while sitting down before actively standing.
89253645|NCT03970551|Experimental|Leg Crossing|The participant will actively stand and then immediately cross their legs and tense their leg muscles for 60 seconds.
89253646|NCT03970551|Experimental|Cold Pressor Test|The participant will submerge their hands in ice water for approximately 45 seconds.
89253647|NCT03970551|Experimental|Serial 7's Stress Test|The participant will perform a mental arithmetic stress test for 30 seconds prior to standing.
89253648|NCT03970551|Experimental|Functional Electrical Stimulation|The participant will have their quadriceps passively contracted using mild electrical stimulation for approximately 30 seconds prior to standing.
89253649|NCT03970473|Active Comparator|PRM 30 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 30 cm H2O in the semi-fowler position.
89253650|NCT03970473|Active Comparator|PRM 15 cm H2O|In this group, following the laparoscopic surgery and just before the extubation, patients will receive PRM with 15 cm H2O in the semi-fowler position.
89253651|NCT00263211|Experimental|Plavix and Aspirin|Patients will receive a 300 mg loading dose of Plavix on day 1, followed by 75 mg/day, and aspirin 81 mg per day starting day 1. Treatment will be continued until the treating physician elects to resume systemic therapy for the treatment of breast cancer or until unacceptable toxicity is observed. A pill diary will be collected monthly to monitor patients' compliance with the medication regimen.
89253652|NCT00263211|No Intervention|Observation only|Observation by treating physician
89253653|NCT03970317|Experimental|Broad Band Light|Broad Band Light (BBL) motion treatment
89253654|NCT00248625|Active Comparator|N-acetylcysteine (NAC)|Eligible children were adaptively allocated by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive days
89253655|NCT00248625|Placebo Comparator|placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive
89253656|NCT00262821|Active Comparator|Arm I (cisplatin)|Patients receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6).
89253657|NCT00262821|Experimental|Arm II (cisplatin, tirapazamine)|Patients receive tirapazamine IV over 2 hours on days 1, 8, 10, 12, 15, 22, 24, 26, and 29 and cisplatin IV over 1 hour on days 1, 15, and 29.
89253658|NCT00262743|Experimental|polyphenon E|Designed to assess toxicity, treatment response, and pertinent laboratory measurements in patients with previously untreated, asymptomatic, Rai Stage 0-II CLL.
89253659|NCT03974529|Experimental|Intensive running arm|20 patients will be assigned randomly to intensive running arm (intervention arm). They will be required to complete a designed training protocol.
89253660|NCT03974529|Active Comparator|Physiotherapy arm|10 patients will be assigned randomly to physiotherapy arm. They will be required to complete a designed training protocol.
89253661|NCT01326117|Experimental|tadalafil|
89253662|NCT03970239|Experimental|Parkinson's Disease patients|"All study participants undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin). [11C] -DASB is a highly specific PET radiotracer which binds to the serotonin transporter (SERT).~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
89253663|NCT03970239|Experimental|Imaging of healthy volunteers|"All healthy volunteers undergo functional imaging of the serotoninergic system with Positron Emission Tomography (PET) using [18F]-altanserin.~[18F]-altanserin is a highly specific PET radiotracer which specifically binds to the serotonin 5-hydroxytryptamine receptor 2A (5-HT2A) receptor."
89253664|NCT03970161|Experimental|T2DM Patients|Patients without microangioma changes undergoing FFA examination were included in the present study. All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
89253665|NCT03970161|Experimental|healthy control subjects|All of the participants enrolled in the present study underwent a systematic ophthalmic examination.
89253666|NCT03974295|Experimental|Intercourse Group|unlimited unprotected vaginal intercourse starting 24 hours after the frozen embryo transfer
89253667|NCT03974295|No Intervention|Pelvic Rest Group|pelvic rest after frozen embryo transfer until positive pregnancy test
89253668|NCT00262119|Active Comparator|Control Group|PM programming according to actual clinical practice
89253669|NCT00262119|Active Comparator|MVP Only|PM programming according to actual clinical practice + MVP algorithm ON
89253670|NCT00262119|Active Comparator|DDDRP|PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
89253671|NCT00170950|Experimental|Benazepril/amlodipine|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
89253672|NCT00170950|Active Comparator|Benazepril/hydrochlorothiazide|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
89253673|NCT00239577|Experimental|DENGUE FORMULATION 17A GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Dengue vaccine Formulation 17a, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
89253674|NCT00239577|Experimental|DENGUE FORMULATION 17B GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 17b, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6, and one booster dose approximately 5-12 months after the second dose.
89253675|NCT00239577|Experimental|DENGUE FORMULATION 19 GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 19, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6 and one booster dose approximately 5-12 months after the second dose.
89253676|NCT00239577|Placebo Comparator|PLACEBO GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Placebo, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
88806107|NCT01791218|Active Comparator|CABG, AVR or CABG+AVR|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation
89253677|NCT00262041|Experimental|MenACWY-CRM(Ad+)|Subjects received one single dose of adjuvanted formulation of conjugate vaccine.
89253678|NCT00262041|Experimental|MenACWY-CRM(Ad-)|Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.
89253679|NCT00262041|Active Comparator|MenACWY- PS|Subjects received one single dose of the polysaccharide vaccine.
89253680|NCT03969849|Experimental|Part A: Cohort 1|Part A: Cohort 1 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
89253681|NCT03969849|Experimental|Part A: Cohort 2|Part A: Cohort 2 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
89253682|NCT03969849|Experimental|Part A: Cohort 3|Part A: Cohort 3 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
89253683|NCT03969849|Experimental|Part A: Cohort 4|Part A: Cohort 4 randomized 3:1 will receive REGN5713-5714-5715 or matching placebo
89253684|NCT03969849|Experimental|Part B|Part B: Randomized 1:1 will receive REGN5713-5714-5715 or matching placebo in Healthy Participants with birch pollen allergy
89253685|NCT01071447|Active Comparator|Rheumatologist-led clinic|Rheumatologist-led clinic: The subjects are seeing a rheumatologist after six months and after 12-months of intervention and have the possibility to contact the rheumatology clinic
89253686|NCT01071447|Experimental|Nurse-led clinic|The subjects are seeing a rheumatology nurse after six months and a rheumatologist after 12 months of intervention and have the possibility to contact the rheumatology nurse during the intervention.
89253687|NCT00208767|Active Comparator|Valsartan|Valsartan titrated up to 320 mg orally daily
89253688|NCT00208767|Placebo Comparator|Placebo|Patients received a placebo instead of Valsartan
89253689|NCT03969771|Experimental|Frequently Absent|8 weeks of training in Mindfulness-Based Stress Reduction
89253690|NCT03969771|Active Comparator|Normal Attendees (Controls)|8 weeks of training in Mindfulness-Based Stress Reduction
89253691|NCT02531529|Experimental|D group|intraoperative dexmedetomedine infusion
89253692|NCT02531529|Sham Comparator|F group|Intraoperative fentanyl infusion
89253693|NCT01071525|Active Comparator|Niacin|Hypercholesterolemic patients with high-density lipoprotein (HDL) less than 40 mg% will receive Niacin\Laropiprant.
89253694|NCT01071525|No Intervention|Control|Maching subjects will receive no medication, Blood tests will be drawn for laboratory tests.
89253695|NCT03969537||Telemedicine|The patients selected to participate in the study are cervical dystonia (CD) patients who receive treatment at Vanderbilt University Medical Center, where the study takes place.
89253696|NCT03969615|Active Comparator|Supplemental oxygen|5lpm of supplemental oxygen via a nasal cannula or face mask
89253697|NCT03969615|Experimental|SuperNO2VA nasal positive airway pressure device|Intervention arm will receive the SuperNO2VA nasal positive pressure device at 10lpm
89253698|NCT01072695|Experimental|Arm 1|
89253699|NCT01072695|Experimental|Arm 2|
89253700|NCT01072695|Experimental|Arm 3|
89253701|NCT00390806|Experimental|topotecan plus radiation|topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.
89253702|NCT00390806|Active Comparator|Whole brain radiation|Whole brain radiation 3 Gy/day for 10 days
89253703|NCT01049516|Other|Minimal Contact Control|
89253704|NCT01049516|Experimental|PE-Massed|
89253705|NCT01049516|Active Comparator|PE-Spaced|
89253706|NCT01049516|Active Comparator|Present-Centered Therapy (PCT)|
89253707|NCT00390572|Experimental|Sleep Specialty Consultation|Participants randomized to receive a one-time sleep consultation at beginning of study
89253708|NCT00390572|No Intervention|Treatment as Usual|Participants randomized to receive a one-time sleep consultation after completing study procedures (after 10 month study wait-list period).
89253709|NCT01047644|Experimental|3-month flushing schedule|3-month port-flushing schedule
89253710|NCT01047722|Active Comparator|Patient drinks aspirin in Gatorade.|Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.
89253711|NCT01047722|Placebo Comparator|Gatorade Placebo|Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed
89253712|NCT01047800|Experimental|Counseling group|Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
89253713|NCT01047800|No Intervention|Control|Usual management in GI specialty clinic
89253714|NCT00390416|Experimental|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
89253715|NCT00261495|Active Comparator|Oxycodone|
89253716|NCT00261495|Experimental|OROS hydromorphone HCl|
89253717|NCT00168844|Other|Tiotropium Respimat 5mcg (Tio R5)|
89253718|NCT00168844|Other|Tiotropium Respimat 10mcg (Tio R10)|
89253719|NCT00168844|Other|Placebo|
89253720|NCT00365456|Experimental|PTH (1-84)|
89253721|NCT00365456|Active Comparator|Risedronate|
89253722|NCT01047956|Experimental|MethNAC|Methadone and N-acetylcysteine for opioids abstaining
89253723|NCT01047956|Active Comparator|Methadone|Methadone alone
89253724|NCT00147238|Experimental|Ferumoxtran-10 MRI|MR lymphangiography using Ferumoxtran-10 contrast agent.
89253725|NCT00147238|Active Comparator|MRI|MR lymphangiography before injecting Ferumoxtran-10 contrast agent.
89253726|NCT02531464|Experimental|Experimental: supportive care|Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
89290337|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Healthy Subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.
89253727|NCT02531464|No Intervention|Control: usual care|In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) . The PNO screens patients for distress and assesses their needs. She does a bio-psycho-social comprehensive evaluation and may provide help and information. She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory. However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them. If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
89253728|NCT00206427|Experimental|Intervention|Intervention/Lapatinib (GW572016)
89253729|NCT00146848|Active Comparator|DDD-40|DDD-40 for this trial is the comparator arm. Even though patients are receiving a CRT-D device, atrial support pacing in this arm will be limited as the device will not pace unless the rate falls below 40 bpm.
89253730|NCT00146848|Active Comparator|DDDR-40|DDDR-40 programming will initiate atrial support pacing if the rate falls below 40 bpm or if atrial support is needed in response to increased activity.
89253731|NCT00146848|Active Comparator|DDD-70|Atrial support pacing in this arm will be delivered when the rate falls below 70 bpm.
89253732|NCT00205881|Active Comparator|1|Bilaterally Implanted with HiRes 90K device.
89253733|NCT00365378|Experimental|1|HPV 16 L1 VLP vaccine
89253734|NCT00365378|Placebo Comparator|2|Placebo
89253735|NCT00389324|Experimental|Immune Globulin Intravenous (Human)|Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
89253736|NCT00365300|Active Comparator|Pantoprazole|
89253737|NCT00365300|Placebo Comparator|Placebo|
89253738|NCT01048034|Experimental|Azacitidine +/- erythropoetin|
89253739|NCT02535182||Control Arm|Patients who participate as controls on the main study will be controls on this ancillary study. The control arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
89253740|NCT02535182||Propranolol Arm|Patients who participate on the propranolol arm on the main study will be on the propranolol arm on this ancillary study. The propranolol arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
89253741|NCT00370292|Experimental|Pemetrexed - Before Protocol Amendment|
89253742|NCT00370292|Experimental|Pemetrexed - After Protocol Amendment|
89253743|NCT01049594||Preterm infants|Delivery at less than 33 completed weeks of gestation
89253744|NCT03992690|Experimental|WANR protocol|Including training with Brain-machine interfaces, visuo-tactile feedback and assisted locomotion
89253745|NCT03992690|Active Comparator|Classical physiotherapy protocol|Training with classical physiotherapy protocol
89253746|NCT01049672|Active Comparator|Alfentanil|Hospice in-patients who require subcutaneous strong opioid administration will be given alfentanil
89253747|NCT01049672|Active Comparator|Diamorphine|Hospice in-patients who require strong opioids will be given diamorphine
89253748|NCT00369824|Experimental|Cervarix + Boostrix/Menactra Group|Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.
89253749|NCT00369824|Experimental|Cervarix + Menactra/Boostrix Group|Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.
89253750|NCT00369824|Experimental|Cervarix + Boostrix + Menactra Group|Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.
89253751|NCT00369824|Experimental|Boostrix/Cervarix Group|Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.
89253752|NCT00369824|Experimental|Menactra/Cervarix Group|Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.
89253753|NCT00369824|Experimental|Cervarix Group|Subjects received Cervarix at Months 0, 1 and 6.
89253754|NCT00369668|Experimental|High Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; four 90-minute sessions/week for 2 weeks.
89253755|NCT00369668|Active Comparator|Low Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; two 90-minute sessions/week for 2 weeks.
89253756|NCT00369668|Active Comparator|Control|Bilateral training moving both arms coupled with sham neuromuscular electrical stimulation
89253757|NCT01048112|Experimental|Repeated dose group|Will receive one dose of Campylobacter jejuni strain CG8421 at day 0 and a second dose at approximately day 98.
89253758|NCT01048112|Active Comparator|Single dose group|Will receive one dose of Campylobacter jejuni strain CG8421
89253759|NCT02161874|Experimental|T3 with DCD tapered implant|T3 with DCD tapered prevail implant
89253760|NCT02161874|Active Comparator|Nanotite certain tapered implant|Nanotite Certain tapered implant
89253761|NCT02111408||Acute stroke|No interventions. Only tests for depression, sleepapnea and autonomic dysfunction.
89253762|NCT01048190|Experimental|Infants I-1|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains). Group I-1: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
89253763|NCT01048190|Experimental|Infants I-2|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
89253764|NCT01048190|Experimental|Infant I-3|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
89253765|NCT02076698|Experimental|AN-DBS|Deep Brain Stimulation of the Anterior Nucleus of the thalamus
89253766|NCT02076698|Active Comparator|Usual treatment|Usual treatment of epilepsy including vagus nerve stimulation (VNS)
89253767|NCT01048268|Experimental|Healthy volunteers|
89253768|NCT01048268|Experimental|Patients with Type 1 diabetes mellitus|
89253769|NCT01048268|Experimental|Patients with type 2 diabetes mellitus|
89253770|NCT03993236|Experimental|Rosuvastatin/Ezetimibe 10/10mg|The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.
89253771|NCT03993236|Active Comparator|Rosuvastatin 20mg|The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days
89253772|NCT00388154|Experimental|Gemcitabine + Cisplatin|Gemcitabine 900 mg/m^2 by vein (IV) over 1 hour on Day 1 and Day 8. Cisplatin 30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
89253773|NCT00387764|Experimental|pazopanib arm|This was a single arm study, therefore no control arm.
89253774|NCT02535104|Experimental|Treatment group|1 mg/ml solution of ranpirnase applied twice daily
89253775|NCT02535104|Placebo Comparator|Control|Vehicle - innert gel
89253776|NCT01580930|No Intervention|Control group|Group had outcome measures collected and were instructed to not change activity and sedentary time behavior
89253777|NCT01580930|Experimental|Exercise|Participants performed 5 days per week, 40 min per session of exercise training under direct supervision of personal trainer.
89253778|NCT01580930|Experimental|Sedentary time reduction|participants were give strategies to reduce sedentary time
89253779|NCT01580930|Experimental|exercise plus sedentary time reduction|Participants completed exercise training (5 days per week, 40 min per session) plus were given sedentary time reduction intervention
89253780|NCT01049750||type 2 diabetic patients|males; type 2 diabetic patients
89253781|NCT00386360|Placebo Comparator|Placebo|Placebo dose
89253782|NCT00386360|Experimental|Risedronate|35 mg risedronate, orally, once weekly
89253783|NCT03436940|Active Comparator|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.
89253784|NCT03436940|Experimental|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
89253785|NCT00369278|Experimental|Intensified Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1-14: 2880 mg/day (2 x 1440 mg), then day 15-42: 2160 mg/day (2 x 1080 mg), then day 43-End of study (month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 180 days.
89253786|NCT00369278|Active Comparator|Standard Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1 - End of Study(month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 6 months.
89253787|NCT00529373|Experimental|Odanacatib|Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
89253788|NCT00529373|Placebo Comparator|Placebo|Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
89253789|NCT00369122|Experimental|Treatment (radiation therapy, bevacizumab, cisplatin)|"Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45 Gy.~Some patients also undergo low-dose rate brachytherapy twice, 1-3 weeks apart, beginning >= 4 weeks after initiating EBRT or high-dose rate brachytherapy 5 times, >= 48 hours apart, beginning >= 2 weeks after initiating EBRT. EBRT and chemotherapy are halted on the day of high-dose rate brachytherapy. Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, and 35."
89253790|NCT03687125|Experimental|Tinostamustine 180 mg/m^2|Participants received single dose of tinostamustine 180 milligrams per meter square (mg/m^2) intravenous (IV) injection on Day -1 followed by autologous stem cell transplantation (ASCT) on Day 1.
89253791|NCT03687125|Experimental|Tinostamustine 220 mg/m^2|Participants received single dose of tinostamustine 220 mg/m^2 IV injection on Day -1 followed by ASCT on Day 1.
89253792|NCT03999281||Diabetic Foot Ulcers (DFU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 54 with diabetic foot ulcers
89253793|NCT03999281||Venous Leg Ulcer (VLU)|Study began with 214 consecutive patient; After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 134 venous leg ulcers.
89253794|NCT05000489||Minors 1|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
89253795|NCT05000489||Minor 2|a one-time focus group will be conducted with 16-17 year old patients who have a variety of diagnoses
89253796|NCT05000489||Spina Bifida|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Spina Bifida clinic
89253797|NCT05000489||Pulmonology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the pulmonology clinic
89253798|NCT05000489||Endocrinology 1|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type I Diabetes
89253799|NCT05000489||Endocrinology 2|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Endocrinology clinic and have a diagnosis of Type II Diabetes
89253800|NCT05000489||Rheumatology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Rheumatology clinic
89253801|NCT05000489||Gastroenterology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Gastroenterology clinic
89253802|NCT05000489||Neurology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Neurology clinic
89253803|NCT05000489||Cardiology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Cardiology clinic
89253804|NCT05000489||Hematology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Hematology clinic
89253805|NCT05000489||Nephrology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Nephrology clinic
89253806|NCT05000489||Oncology|a one-time focus group will be conducted with adult patients (18-21) who are being seen in the Oncology clinic
89253807|NCT05173493||Amoxicillin-Furazolidone-containing quadruple group|Patients in amoxicillin-furazolidone-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), amoxicillin1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
89253808|NCT05173493||Amoxicillin-Levofloxacin-containing quadruple group|Patients in amoxicillin-Levofloxacin-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), amoxicillin1000mg po bid, bismuth potassium citrate(Lizhudele) 220mg po bid, and levofloxacin 500mg po qd for 14d.
89253809|NCT05173493||Tetracycline-Furazolidone-containing quadruple group|Patients in tetracycline-furazolidone-containing quadruple group will receive esomeprazole (Nexium) 40mg po bid(or vonoprazan fumarate 20mg po bid), tetracycline 500 mg po qid, bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone (Liteling) 100mg po bid for 14d.
89253810|NCT04907513||Amotivational Syndrome|Patients required an external drainage of the cerebrospinal fluid.
89253811|NCT03872843|Active Comparator|Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.
89253812|NCT03872843|Active Comparator|Non-Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Ibuprofen 400 milligram for postoperative pain after ureteroscopy with stent placement.
89253813|NCT00146770|Active Comparator|Placebo/Aldurazyme|Patients received placebo for 26 weeks in the Double-Blind Study then received 182 weeks of Aldurazyme (0.58 mg/kg every week) in this Extension Study; patients received a total of 182 weeks of Aldurazyme.
89253814|NCT00146770|Active Comparator|Aldurazyme/Aldurazyme|Patients received 26 weeks of Aldurazyme in the Double-Blind Study and then received 182 weeks of Aldurazyme in this Extension Study; patients received a total of 208 weeks of Aldurazyme.
89253815|NCT03874013|Experimental|MOD-4023 Treatment Arm|MOD-4023 (investigational treatment): weekly MOD-4023 SC injections for 12 months; initially over the first 6 weeks, MOD-4023 will be administered in 3 stepwise escalating doses (0.25 mg/kg/week, 0.48 mg/kg/week and 0.66 mg/kg/week), each for two weeks sequentially. For the remaining 46 weeks, patients will continue to receive MOD-4023 at a dose of 0.66 mg/kg/week.
89253816|NCT03874013|Active Comparator|Genotropin Treatment Arm|Genotropin® (reference treatment): daily Genotropin® (0.025 mg/kg/day).
89253817|NCT03967678|Placebo Comparator|Beef from standard supply|
89253818|NCT03967678|Experimental|n-3 enriched beef from dietary supplement finished cattle|
89253819|NCT03967678|Active Comparator|n-3 enriched beef from grass finished cattle|
89253820|NCT03966040|Experimental|Immunization schedule of day 0-3-7|Three doses of schedule given at day 0, 3 and 7.
89253821|NCT03966040|Experimental|Immunization schedule of day 0/0-3-7|Four doses of schedule given at day 0/0, 3 and 7.
89253822|NCT03966040|Experimental|Immunization schedule of day 0/0-7|Three doses of schedule given at day 0/0 and 7.
89253823|NCT03966040|Experimental|Immunization schedule of day 0/0-7-14|Four doses of schedule given at day 0/0, 7 and 14.
89253824|NCT03999125|Active Comparator|Group 1|Aflibercept intravitreal injection for CSME
89253825|NCT03999125|Other|Group 2|Ranibizumab Intravitreal Injection for CSME
89253826|NCT03999125|Experimental|Group 3|Dexamethasone Implant for CSME
89253827|NCT05085119|Experimental|FiO2 stepwise modifications|Intubation ICU patients will be challenged with stepwise modifications of FiO2. The following steps will be done: 30, 40, 60, 80, 100, 80, 60, 40 and 30%.
89253828|NCT00168064|Active Comparator|1 (PG - NM (MCH) 0.02%)|PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF
89253829|NCT00168064|Active Comparator|2 (AP - MCH(NM) 0.02%)|AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF
89253830|NCT00166114|Active Comparator|Escitalopram|
89253831|NCT00166114|Active Comparator|Desipramine|
89253832|NCT03686969|Experimental|Octanorm|0.5g/kg/week octanorm 16.5%
89253833|NCT03686969|Placebo Comparator|Placebo|Placebo
89253834|NCT00145600|Experimental|Unfavorable Risk, Group 2|Unfavorable risk, group 2 arm in patients with Hodgkin's disease (n=146)
89253835|NCT00145600|Experimental|Favorable Risk|Favorable Risk arm in patients with Hodgkin's Disease (n=91).
89253836|NCT00145600|Experimental|Intermediate Risk|Intermediate Arm in patients with Hodgkins's disease (n=46).
89253837|NCT00145600|Experimental|Unfavorable Risk, Group 1|Unfavorable risk group 1 closed early due to excessive number of adverse events (n=13).
89253838|NCT05032781|Experimental|Intra-arterial neuroprotective substances|"Cold saline, minocycline, and magnesium sulfate to be infused intra-arterially immediately after thrombectomy via the internal carotid artery. A dose escalation design will be used, as described above in Study Description."
89253839|NCT00991601|Experimental|biopsy arm|patients with tumors in liver and/or pancreas
89253840|NCT04003415|Experimental|Investigational Device Arm|Once consented for the study, participants will undergo testing with the investigational device for a one hour period. Testing will entail the participant wearing an EKG monitor, a respiratory rate monitor, a pulse oximeter, and being positioned next to the investigational device. The investigational device is contactless and captures chest movement of participants which allows it to estimate real time heart rate and respiratory rate. Additional data collected with the EKG monitor, respiratory rate monitor, and the pulse oximeter will be used to validate the vital sign data collected by the investigational device. After data collection is complete, participant involvement will then be over. Participants will have the option to return on a later date for additional testing (up to a maximum of three sessions total), within the six month window of the study. Participants will continue their standard of care therapies for their respiratory condition.
89253841|NCT03968380||Population in Quito|720 randomly chosen people living in District 17D06, Quito (Ecuador)
89253842|NCT03968380||Population in Esmeraldas|720 randomly chosen people living in Eloy Alfaro District, Esmeraldas (Ecuador)
89253843|NCT00991679||Normal control subjects|Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
89253844|NCT00991679||dry eye patients|Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.
89253845|NCT00129376|Experimental|Doxorubicin+cyclophosphamide - Docetaxel|Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles. Later, docetaxel (36 mg/m2) was administered an intravenous infusion, weekly for six weeks followed by a 2-week resting period (8-week cycle).
89253846|NCT05359289|Experimental|Forest therapy training|Participants will expect to have an improvement of cognitive functions via a serial nature-based therapy/intervention.
89253847|NCT05359289|Active Comparator|Senior fitness training|Participants will expect to have an improvement of cognitive functions through a structural senior fitness program.
89253848|NCT05359289|Placebo Comparator|Board Games|Participants will play boards games under a schedule matching the Experimental and Active Comparator arms.
89253849|NCT04878107|Experimental|SBRT/LDRT + Camrelizumab +Apatinib|SBRT（8Gy×3f） LDRT（2Gy×5f） Camrelizumab（200mg，q3w） Apatinib （250mg，qd）
89253850|NCT04878107|Active Comparator|SBRT + docetaxel|docetaxel 75mg/m2 SBRT（8Gy×3f）
89253851|NCT03998969|Experimental|Pantoprazole and DA-5204|Pantoprazole 40mg once daily and 'DA-5204' twice daily by mouth, administered for 4 weeks
89253852|NCT03998969|Active Comparator|Pantoprazole and placebo|Pantoprazole 40mg once daily and 'placebo' twice daily by mouth, administered for 4 weeks
89253853|NCT01564043|Experimental|website and pedometer|
89253854|NCT04708847|Experimental|Pre-immobilization active drug group|Subjects will receive a single subcutaneous dose of GYM329 on Day 1 and a single subcutaneous dose of placebo on Day 15.
89253855|NCT04708847|Experimental|Post-immobilization active drug group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of GYM329 on Day 15.
89253856|NCT04708847|Placebo Comparator|Placebo group|Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of placebo on Day 15.
89253857|NCT01564667|Experimental|Attention Bias Modification Treatment|Attention bias modification training using a computerized spatial attention task (dot-probe) designed to alter threat-bias attention patterns away from threat.
89253858|NCT01564667|Active Comparator|Attentional Control Training|Attention control training using a computerized spatial attention taks (dot-probe) counter balances training toward and away from threat.
89253859|NCT01564745|Other|Cough Determinants|
89253860|NCT01564901||Cohort|
89253861|NCT00129220|Experimental|Olanzapine|olanzapine: 5 to 20 mg per day for 6 weeks
89253862|NCT00129220|Active Comparator|Haloperidol|haloperidol: 2.5 to 10 mg per day for 6 weeks
89253863|NCT00129220|Placebo Comparator|Placebo|placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks
89253864|NCT01326286||Open Radical Prostatectomy|262
89253865|NCT01326286||Robotic Radical Prostatectomy|1303
89253866|NCT01326286||Intensity-Modulated Radiotherapy|638
89253867|NCT01326286||Interstitial Brachytherapy|171
89253868|NCT01326286||combined EBRT and Brachytherapy|143
89253869|NCT01326286||Active Surveillance|448
89253870|NCT01326286||Various other treatments|300
89253871|NCT03686813|Placebo Comparator|Placebo|Each participant will be studied with active drug and placebo.
89253872|NCT03686813|Active Comparator|Sildenafil|Sildenafil 50 mg orally one hour (once) before immersed exercise
89253873|NCT04003259|Experimental|Overweight and obese subjects|1-year lifestyle programme
89253874|NCT00128830|Experimental|Etravirine + 2 antiretrovirals|
89253875|NCT01074892|Active Comparator|MPA 10 mg per oral cyclic for 6 months|The peroral treatment is used 10 days each month
89253876|NCT01074892|Active Comparator|MPA 10 mg per os continuous 6 months|Per oral MPA 10 mg is taken daily for 6 months
89253877|NCT01074892|Active Comparator|LNG-IUD for 6 months|Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months
89253878|NCT03686033|Experimental|Placebo, E2082 2.5 mg, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between all the treatment periods.
89253879|NCT03686033|Experimental|E2082 2.5 mg, E2082 25 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
89253880|NCT03686033|Experimental|E2082 25 mg, Placebo, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
89253881|NCT03686033|Experimental|Placebo, E2082 25 mg, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
89253882|NCT03686033|Experimental|E2082 2.5 mg, Placebo, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
89253883|NCT03686033|Experimental|E2082 25 mg, E2082 2.5 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
89253884|NCT00128206|Active Comparator|B|isoniazid (INH) (900 mg orally) given twice weekly for 9 months
89253885|NCT00128206|Active Comparator|A|rifampin (600 mg orally) given daily for 4 months
89253886|NCT01565057|Experimental|sedimenting meal|To assess whether rates of gastric emptying of a specifically formulated emulsion drink are significantly different from a control drink and that this in turn leads to differences in satiation (cessation in the desire to eat) and satiety (desire to limit further food intake) as measured by visual analogue scale (VAS) satiety questionnaire and blood CCK.
89253887|NCT01074970|Active Comparator|Arm A: Cisplatin Monotherapy|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
89253888|NCT01074970|Active Comparator|Arm B: Combination Therapy|"Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles~Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles"
89253889|NCT03685643|Experimental|Intervention - Dating application topic|The intervention will consist of four short videos with points of discussion, a scenario game, and a risk assessment tool regarding dating application usage.
89253890|NCT03685643|Placebo Comparator|Control - Health and exercise topic|The control will consist of four short videos with discussion points and an interaction game regarding exercise and healthy living tips.
89253891|NCT03968146|Active Comparator|Group E|patients will receive Erector Spinae plane block in addition to intravenous fentanyl
89253892|NCT03968146|Other|Group C|Control group will receive only intravenous fentanyl.
89253893|NCT03966118|Experimental|Ramucirumab + Avelumab + Paclitaxel|Single-Arm
89253894|NCT03968224|Experimental|Metformin/Dapagliflozin|Metformin 1,700 mg/day and Dapagliflozin 10 mg/day for a year.
89253895|NCT03968224|Active Comparator|Metformin|Metformin 1,700 mg/day
89253896|NCT03823378|Experimental|ABBV-599 in M16-063/ABBV-599 in M16-763|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks
89253897|NCT03823378|Experimental|ABBV-105 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
89253898|NCT03823378|Experimental|ABBV-105 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
89253899|NCT03823378|Experimental|ABBV-105 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
89253900|NCT03823378|Experimental|UPA 15 mg/ABBV-105 placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks
89253901|NCT03823378|Experimental|Placebo in M16-063/ABBV-599 in M16-763|Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763
89253902|NCT00142792|Active Comparator|A. Cyclic stim|"Preprogrammed cycles of finger and thumb flexor and extensor stimulation (and flexor stimulation if deemed necessary by the PI) repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~Uses NMES device with EMG-triggered and Cyclic capabilities"
89253903|NCT00142792|Active Comparator|B. Sensory stim|"Sensory-only electrical stimulation. The stimulation will be cyclic in nature but intensity will be set to a level that can be felt by the patient but not sufficient to cause muscle contraction.~Uses NMES device with EMG-triggered and Cyclic capabilities"
89253904|NCT00142792|Active Comparator|C. EMG-Triggered|"EMG-Triggered electrical stimulation. Subjects in this group will attempt to extend their affected wrist and fingers in response to an audio cue. They will be rewarded with stimulation to cause full hand opening once they have generated EMG sufficient to reach a preset threshold level.~Uses NMES device with EMG-triggered and Cyclic capabilities"
89253905|NCT02531620|Experimental|Physiatry|Pre-operative Physiatry assessment and intervention
89253906|NCT02531620|Other|Routine Care|Patients will receive routine pre-operative care, this study arm does not have an intervention.
89253907|NCT00141778|Placebo Comparator|Placebo|matched placebo pills daily beginning 4-7 days before surgery and continuing through discharge
89253908|NCT00141778|Experimental|Ramipril|Ramipril daily (2.5mg, increased to 5mg) beginning 4 to 7 days before surgery and continuing through discharge
89253909|NCT00141778|Experimental|Spironolactone|Spironolactone 25mg daily beginning 4 to 7 days before surgery and continuing through discharge
89253910|NCT03967132|Active Comparator|Control Infant Formula|Milk-based infant formula
89253911|NCT03967132|Experimental|Experimental Infant Formula|Milk-based Infant Formula with oligosaccharides
89253912|NCT03967132|Other|Reference Group|Human-milk fed
89253913|NCT00127660|Experimental|Menu: calories=yes, value pricing=no|There were calories listed on the menu, but no value pricing was in place.
89253914|NCT00127660|Experimental|Menu: calories=yes, value pricing = yes|There were calories listed on the menu, AND value pricing was in place.
89253915|NCT00127660|Experimental|Menu: calories=no, value pricing = no|Calories were not listed on the menu, and value pricing was not in place.
89253916|NCT00127660|No Intervention|Menu: calories=no, value pricing = yes|CONTROL CONDITION: calories were not listed on the menu, and value pricing WAS in place.
89253917|NCT01077934||Injured Extremity without compartment syndrome|
89253918|NCT01077934||Injured extremity with compartment syndrome|
89253919|NCT03817528|Experimental|ITI-007|Open-Label ITI-007 40-60 mg
89253920|NCT01078012|Active Comparator|Trained counselling|Comparison of outcomes before intervention vs. 2 months after
89253921|NCT01326520|Experimental|Phospholipid enriched dairy product|
89253922|NCT01326520|Placebo Comparator|dairy product|
89253923|NCT03965884|Experimental|lumbal stabilization exercise group|
89253924|NCT03965884|Experimental|connective tissue massage group|
89253925|NCT03965884|No Intervention|control group|
89253926|NCT01075906|Experimental|Colchicine|Colchicine Sprinkle Capsules, 0.3 mg - dose administered according to age range on Day 1
89253927|NCT01075906|Experimental|colchicine at steady state|colchicine sprinkle capsules 0.3 mg - dose administered according to age range on Day 15 following once daily dosing of colchicine on Days 2 - 14
89253928|NCT01076062|No Intervention|Expectant management (EM) arm|Standard of care: routine clinic appointments until they deliver, fetal heart rate and contraction monitoring during their 41st week if not delivered. Also if they have not gone into labor the subjects will be scheduled for an induction by 42 weeks.
89253929|NCT01076062|Experimental|Induction of Labor (IOL) arm|Elective induction of labor at 39 weeks.
89253930|NCT00115336|Active Comparator|1-Intravenous ketorolac and oral placebo|Intravenous ketorolac and oral placebo
89253931|NCT00115336|Active Comparator|2-Intravenous placebo and oral ibuprofen|Intravenous placebo and oral ibuprofen
89253932|NCT01076140|Active Comparator|Nebivolol|Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
89253933|NCT01076140|Active Comparator|Lisinopril|20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
89253934|NCT00205803|Experimental|13vPnC|
89253935|NCT00205803|Active Comparator|7vPnC|
89253936|NCT01076218||Diabetes|Patients with type 1 diabetes requiring multiple daily insulin injections or using insulin pumps
89253937|NCT03974373|Experimental|BFP removal|this will be the group evaluated in this study, individuals who performed the BFP removal procedure.
89253938|NCT00127192|Placebo Comparator|1|Placebo QD 12-week
89253939|NCT00127192|Experimental|2|25 mg QD 12-week
89253940|NCT00127192|Experimental|3|50 mg QD 12-week
89253941|NCT00127192|Experimental|4|100 mg QD 12-week
89253942|NCT00127192|Experimental|5|200 mg QD 12-week
89253943|NCT00205179|Experimental|Novasoy treated|100mg/day soy isoflavones
89253944|NCT00205179|Placebo Comparator|Placebo|100mg/day matching placebo
89253945|NCT03973125|Experimental|Treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
89253946|NCT00127036|Experimental|XELOX + Bevacizumab|Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
89253947|NCT00127036|Experimental|XELIRI + Bevacizumab|Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
89253948|NCT00259857|Experimental|1 Alendronate, Calcium, Vitamin D|Crossover study. Year-1, 10 participants will take study medication, calcium and vitamin D supplements and other 10 participants will take placebo, calcium and vitamin D supplements. Year-2, they will crossover to the second arm of the study. Those who took study medication and supplements in year-1, will take placebo and supplements in the year-2, and those 10 participants who took placebo and supplements in the year-1, will take study medications and supplements in the year-2.
89253949|NCT00259857|Placebo Comparator|2 Placebo, Calcium and Vitamin D|Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).
89253950|NCT02531919|Experimental|Sodium Bicarbonate|Dose concentration of 0.5 g/kg/day
89253951|NCT01071681||Group 1|
89253952|NCT01072851|Experimental|Multimedia educational tool|Multimedia education tool - A culturally competent video explaining the importance of and the process of colorectal cancer screening
89253953|NCT01072851|Experimental|Print educational tool|Print media - A culturally competent printed brochure explaining the importance of and the process of colorectal cancer screening
89253954|NCT01072851|Active Comparator|No intervention|Usual and customary waiting room process - Usual and customary office waiting period with access to standard nationally generated colorectal cancer screening informational material in the waiting room and/or exam room.
89253955|NCT00203307|Other|Olanzapine then Placebo|Olazepam
89253956|NCT00203307|Other|Placebo then olanzapine|
89253957|NCT01581801|Other|Gastric Bypass|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo gastric bypass
89253958|NCT01581801|Other|Sleeve Gastrectomy|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo sleeve gastrectomy
89253959|NCT00126568|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89253960|NCT00114634|Experimental|Egg yolk preparation with cholesterol|Dietary cholesterol in the form of liquid egg yolk
89253961|NCT00114634|Placebo Comparator|Egg yolk preparation without cholesterol|"No dietary cholesterol supplementation (egg substitute) Papetti Foods Better 'n Eggs egg substitute"
89253962|NCT00202839|Experimental|24-Week Treatment|Genotype 1 hepatitis C virus [HCV] subjects treated for a total of 24 weeks, during the pilot treatment program (immediately before randomization)
89253963|NCT00202839|Active Comparator|48-Week Treatment|Genotype 1 HCV subjects treated for a total of 48 weeks: 24 weeks during the pilot treatment program (immediately before randomization) plus 24 weeks during the extended treatment program (immediately after randomization)
89253964|NCT00201201|Experimental|Education|PEP-NG targeted and tailored education intervention
89253965|NCT00201201|Other|Control|Control, intervention is care as usual.
89290338|NCT03971825|Experimental|Administration of CC-92252 and Placebo in Psoriasis subjects|Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.
89290339|NCT01126554||Critically ill patients|
89253966|NCT00126490|Experimental|Treatment (bevacizumab, aldesleukin)|Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11. Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10. Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease then receive bevacizumab alone in weeks 1, 3, 5, 7, 9, and 11. Courses with bevacizumab alone repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
89253967|NCT00346632|Experimental|KW-2449|Treatment with ascending doses of KW-2449
89253968|NCT00200967|Experimental|B16 Arg/Arg|B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone hydroflouroalkane (HFA), followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
89253969|NCT00200967|Experimental|B16 Gly/Gly|B16 Gly/Gly genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
89253970|NCT02533440|Experimental|EXPAREL and Local Anesthetics|In the experimental group, patients will receive EXPAREL and local anesthetics, and will be prescribed opioid and non-opioid analgesics (for use only if in pain).
89253971|NCT02533440|Active Comparator|Oral Opioid and Local Anesthetics|In the control group, patients will receive local anesthetics at the time of surgery and oral opioid or non-opioid analgesics (for use only if in pain).
89253972|NCT02533518|Experimental|patients with lung cancer|
89253973|NCT01052064|Experimental|Transcranial magnetic stimulation|There are evidences that rTMS has a modulating effect in cortical and subcortical neural networks, reinforcing or depressing synaptic activity by mean of long term potentiation or depression like mechanism. Depression is the most study neuropsychiatric condition in which rTMS is useful as a therapeutic option; but in other diseases such as ADHD there are many pathophysiological elements that make it very likely that rTMS could be useful for symptomatic treatment modulating activity in prefrontal and basal ganglia neuronal networks.
89253974|NCT01052142|Experimental|Lipovaxin-MM|
89253975|NCT03991572|Active Comparator|Real Stimulation|The Real Stimulation of rTMS lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . Behavior and MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
89253976|NCT03991572|Sham Comparator|Sham Stimulation|The procedure of Sham Stimulation protocol was performed by a placebo coil,lasted 25 mins and delivered at 10 Hz with 1s duration,4s rest, a total of 3000 pulses at 100% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
89253977|NCT01052220|Experimental|BP Education and Self Regulation of BP|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will received a BP educational session at baseline and were asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI made weekly visits with the intervention participants in the HD unit to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
89253978|NCT01052220|No Intervention|Usual Care|Participants in the usual care group did not receive the intervention but continued to receive their standard care in the hemodialysis unit which involved follow-up by the medical provider and BP medication adjustments as needed. .
89253979|NCT01054638||HIV infected patients: HAART naive or experienced|Patients with a claims diagnosis of HIV infection (HIV, AIDS, or ARC) in the NHI or Impact Databases, according to either of the 3-digit International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 042 HIV disease and V08 Asymptomatic HIV infection status
89253980|NCT01054638||Patients with HIV infection HAART naïve|A naïve subcohort of patients consisting of HAART initiators. Among the primary cohort, we will exclude patients with a dispensing for any HAART in the 6-month baseline period prior to the cohort entry date.
89253981|NCT01054794|Active Comparator|Stimulation ON|
89253982|NCT01054794|Sham Comparator|Stimulation OFF|
89253983|NCT03742284|Other|SoftOx Wound Irrigation Solution|SoftOx Wound Irrigation Solution is Medical Device that will be applied to rinse acute wounds.
89253984|NCT00354432|Active Comparator|Arm I - Placebo|Patients receive oral placebo pill and oral placebo powder once daily.
89253985|NCT00354432|Active Comparator|Arm II - Soy|Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.
89253986|NCT00354432|Experimental|Arm III - Venlafaxine|Patients receive oral Venlafaxine pill and placebo powder once daily.
89253987|NCT00354432|Placebo Comparator|Arm IV - Soy + Venlafaxine|Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.
89253988|NCT00140140|Experimental|Part 1: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. No G-CSF support was planned.
89253989|NCT00140140|Experimental|Part 2: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
89253990|NCT00140140|Experimental|Part 2: 90 mg ABI-007 + 20 mg vinorelbine|Weekly intravenous infusion of 90 mg/m^2 ABI-007, followed by an infusion of 20 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
89253991|NCT03966976|Experimental|Vitaphone Arm|Follow-up via VITAPHONE in addition to conventional monitoring.
89253992|NCT03966976|Active Comparator|Conventional Arm|Conventional follow-up
89253993|NCT00346398|Experimental|Oral mucosal immunoprophylaxis (OMIP)|Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.
89253994|NCT00346398|Placebo Comparator|Placebo|Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.
89253995|NCT00346164|Experimental|Arm A: No adjuvant treatment|Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
89253996|NCT00346164|Experimental|Arm B: Low risk; adjuvant radiotherapy|Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
89253997|NCT00346164|Experimental|Arm C: Intermediate & High risk; adjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
89253998|NCT00346164|Experimental|Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
89253999|NCT03991260||The tested injected doses of 99mTc- ADAPT6 500 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 500 µg. Subjects withdrawn from the study for any reason will be replaced.
89254000|NCT03991260||The tested injected doses of 99mTc- ADAPT6 1000 µg|At least five (5) evaluable subjects with HER2-positive status and at least three (3) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose is 1000 µg. Subjects withdrawn from the study for any reason will be replaced.
89254001|NCT03986892||COmPLETE-Health|No intervention
89254002|NCT03986892||COmPLETE-Heart|No intervention
89254003|NCT01052298|Experimental|Arm 1|
89254004|NCT01052298|Experimental|Arm 2|
89254005|NCT01052298|Experimental|Arm 3|
89254006|NCT01052298|Placebo Comparator|Arm 4|
89254007|NCT03987048||Cirrhotic patients with septic shock|All consecutive adult cirrhotic patients admitted to the ICU with septic shock from 2002 to 2013.
89254008|NCT03986658|Experimental|Adolescents|Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
89254009|NCT01056354||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
89254010|NCT01056354||Novel respiratory virus-1|MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus)
89254011|NCT01056354||Novel respiratory virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
89254012|NCT01052454|No Intervention|Wait list|Women assigned to the waitlist have the opportunity of taking the MBSR program at no cost following final study assessment
89254013|NCT01052454|Experimental|Mindfulness-based stress reduction|Women in the MBSR arm attend eight weekly MBSR classes
89254014|NCT01052532||Mitral Regurgitation pre&post operation|Patients with severe Mitral Regurgitation without evidence of ischemia are tested prior to surgery and after valve repair.
89254015|NCT00114244|Experimental|Arm I (sorafenib tosylate)|Patients receive 400 mg oral sorafenib twice daily on days 1-28. Patients experiencing disease progression cross over to Arm II.
89254016|NCT00114244|Experimental|Arm II (sorafenib tosylate, gemcitabine hydrochloride)|Patients receive 400 mg oral sorafenib as in Arm I and 1000 mg/m2 gemcitabine IV over 100 minutes on days 1, 8, and 15.
89254017|NCT01056588|Placebo Comparator|Control Condition|In this condition, participants will receive reinforcement for timely breath samples with no contingency for a specific breath CO level.
89254018|NCT01056588|Active Comparator|CO-Contingent|In this condition, participants will receive reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking.
89254019|NCT01058694|Experimental|Weekly SMS, brief message|Weekly SMS received on Monday at 12 noon
89254020|NCT01058694|Active Comparator|Control Group|Receives a phone, but no messages.
89254021|NCT01058694|Experimental|Daily SMS, Brief message|"Receive daily brief message at 12 noon: This is your reminder"
89254022|NCT01058694|Experimental|Daily SMS, Long Message|"Receive a daily long message at 12 noon: This is your reminder + encouragement"
89254023|NCT01058694|Experimental|Weekly SMS, Long Message|"Weekly message sent at 12 noon on Mondays: This is your reminder + encouragement"
89254024|NCT02533128|Placebo Comparator|Liberal blood pressure management|
89254025|NCT02533128|Active Comparator|Tight blood pressure management|
89254026|NCT01054872|Experimental|Monozygotic (MZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
89254027|NCT01054872|Experimental|Dizygotic (DZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
89254028|NCT01054950|Experimental|Education and counseling|Phone calls using behavioral techniques
89254029|NCT01054950|Placebo Comparator|Control|Single phone call
89254030|NCT01058772|Experimental|INDUCTION of LABOUR|"At enrollment patients assigned to the induction group will be admitted to the obstetric ward and will undergo induction of labour as described in the intervention section.~Once patient's Bishop score exceeds 7 or regular contractions are diagnosed, patients will be transferred to the delivery ward for artificial rupture of membranes (ARM) or Oxytocin augmentation as indicated."
89254031|NCT01058772|No Intervention|EXPECTANT MANAGEMENT|"Patients enrolled in the conservative management arm will be followed up twice weekly for foetal wellbeing by Non-stress test and Biophysical profile. Patients will be followed up to 41+0 weeks.~Patients, who will not deliver by this gestational age, will be admitted for labour induction (see the above protocol). Induction of labour will be offered when non-reassuring foetal status is suspected. All patients in the conservative arm will undergo foetal weight ultrasound estimation prior to induction. Patients with estimated foetal weight over 4000 gr will be offered a C-section."
89254032|NCT01056666|Experimental|Conveen optima urisheaths|
89254033|NCT01056666|Placebo Comparator|absorbent protections|The patient use their usual absorbent protection as comparator. All brands are allowed.
89254034|NCT00337662|Experimental|1|Olanzapine for Not Early Onset response (NEO) patients
89254035|NCT00337662|Active Comparator|2|Risperidone for Not Early Onset response (NEO) patients
89254036|NCT00337662|Active Comparator|3|Risperidone for Early Onset response (EO) patients
89254037|NCT00138424|Experimental|Cidofovir|32 subjects will be randomized to 1 of 3 possible cohorts. Cohort I will receive dose 0.25 mg/kg; Cohort II will receive 0.5 mg/kg, Cohort III will receive 1.0 mg/kg. Maximum tolerated dose is to be determined.
89254038|NCT00138424|Placebo Comparator|Placebo|16 subjects to receive placebo.
89254039|NCT00368966|Experimental|1|
89254040|NCT00368966|Active Comparator|2|
89254041|NCT00114166|Active Comparator|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle until disease progression or adverse effects prohibit further therapy
89254042|NCT00114166|Active Comparator|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle until disease progression or adverse effects prohibit further therapy
89254043|NCT00125242|Experimental|Semantic Feature Analysis (SFA)|Word retrieval treatment for aphasia.
89254044|NCT00125242|No Intervention|Participants for Stimuli Development|Non-brain-injured participants provided data for development of treatment stimuli.
89254045|NCT03992534|Experimental|LACTIN-V|"Name of Product: LACTIN-V (Lactobacillus crispatus CTV-05)~Dosage: LACTINV is a powder formulation of Lactobacillus crispatus CTV-05 provided in a prefilled vaginal applicator at a dose of 2 x 10^9 CFU of L. crispatus CTV-05. Route of Administration: LACTIN-V powder is administered vaginally using a specially designed applicator.~Formulation: LACTIN-V is supplied as a pre-filled, single-use applicator. Each applicator contains LACTIN-V powder at a dose of 2 x 10^9 CFU. The LACTIN-V powder formulation contains L. crispatus CTV-05 and a preservation matrix containing inactive excipients of non-animal origin."
89254046|NCT00337428|Experimental|Group 1|Concomitant/CMF
89254047|NCT00337428|Experimental|Group 2|Non-Concomitant/CMF
89254048|NCT00337428|Experimental|Group 3|Concomitant/FMF
89254049|NCT00337428|Experimental|Group 4|Non-Concomitant/FMF
89254050|NCT01049828||Slightly or Non-Bothered Tinnitus Group|
89254051|NCT01044524|Experimental|1|SLV 334
89254052|NCT00235989|Active Comparator|ET: IFNB-1b 250 mcg => 250 mcg|Extension Treatment 250 mcg continued
89254053|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 250 mcg|Extension Treatment 500 mcg reduced to 250 mcg
89254054|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 500 mcg|Extension Treatment 500 mcg continued
89254055|NCT00235989|Experimental|ET: IFNB-1b 250 mcg => 500 mcg|Extension Treatment 250 mcg increased to 500 mcg
89254056|NCT03741465|Active Comparator|The SFP technique|In the SFP neuraxial positioning technique, fifty participants were planned to sit on the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs hanging freely, forearms on the lap and hand are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
89254057|NCT03741465|Experimental|The ASP technique|In the ASP neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
89254058|NCT00113386|Other|Induction chemotherapy, surgery, consolidation chemotherapy|Induction/surgery/consolidation
89254059|NCT00113386|Other|Chemotherapy and radiation, surgery, consolidation ch|Induction/radiation/surgery/cosolidation
89254060|NCT00353262|Experimental|1|
89254061|NCT01056744|Active Comparator|DES|Implantation of a XIENCE® V everolimus eluting coronary stent (drug-eluting stent, DES)
89254062|NCT01056744|Active Comparator|BMS/DEB|Implantation of a Coroflex Blue® coronary stent (bare metal stent, BMS) postdilated with a Sequent Please® paclitaxel-eluting balloon (drug-eluting balloon, DEB)
89254063|NCT00337272|Placebo Comparator|1 (Placebo)|Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
89254064|NCT00337272|Active Comparator|2 (Ramelteon)|Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.
89254065|NCT00125164|No Intervention|Untreated|Observational Group
89254066|NCT00125164|Experimental|40 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
89254067|NCT00125164|Experimental|80 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 80 μg/kg BID
89254068|NCT00125164|Experimental|120 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 120 μg/kg BID
89254069|NCT03985410|Experimental|Treatment Sequence ABC|Participants will receive a single 3-hour intravenous (IV) infusion of 4 grams (g) of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 milligrams (mg) open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
89254070|NCT03985410|Experimental|Treatment Sequence ACB|Participants will receive a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
89254071|NCT03985410|Experimental|Treatment Sequence BAC|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.
89254072|NCT03985410|Experimental|Treatment Sequence BCA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
89254073|NCT03985410|Experimental|Treatment Sequence CAB|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.
89254074|NCT03985410|Experimental|Treatment Sequence CBA|Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.
89254075|NCT01056900||Chondron Implantation|This clinical trial was a follow-up study involving 127 patients from 10 hospitals, for whom autologous chondrocyte transplantation was already performed. All the subjects were investigated as a single group
89254076|NCT03988686|Experimental|Intervention Group|Radical prostatectomy plus standard care
89254077|NCT03988686|Active Comparator|Comparator Group|Standard care, currently ADT +/- other systemic therapies.
89254078|NCT00136318|Active Comparator|Escitalopram|After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
89254079|NCT00136318|Placebo Comparator|Placebo|After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
89254080|NCT03988218|Experimental|Anorexia|Subjects with anorexia nervosa
89254081|NCT03988218|Active Comparator|Control|Subjects without eating disorders
89254082|NCT01058850|Experimental|Rindopepimut (EGFRvIII Vaccine, CDX-110)|
89254083|NCT00136084|Experimental|HDAC (High-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for HDAC.
89254084|NCT00136084|Experimental|LDAC (Low-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for LDAC.
89254085|NCT00364832|Experimental|Cohort A (0.4/150, 1x/ Week)|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) SC using a dose conversion factor of 0.4/150 microgram (mcg)/ kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254086|NCT00364832|Experimental|Cohort B (0.4/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254087|NCT00364832|Experimental|Cohort C (0.4/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254088|NCT00364832|Experimental|Cohort D (0.8/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254089|NCT00364832|Experimental|Cohort E (0.8/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254090|NCT00364832|Experimental|Cohort F (0.8/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254091|NCT00364832|Experimental|Cohort G (1.2/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254092|NCT00364832|Experimental|Cohort H (1.2/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254093|NCT00364832|Experimental|Cohort I (1.2/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89254094|NCT01326598||T2DM patients with A1C<7.0%|
89254095|NCT01080274||positive ergometry|positive ergometry as specified by a cardiologist on site.
89254096|NCT01080274||negative ergometry.|negative ergometry as specified by cardiologist on site.
89254097|NCT01080274||patients with positive stress test|100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
89254098|NCT00235755|Placebo Comparator|Placebo|
89254099|NCT00235755|Experimental|Retigabine 600 mg|
89254100|NCT00235755|Experimental|Retigabine 900 mg|
89254101|NCT01581879|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
89254102|NCT01581879|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
89254103|NCT00337194|Experimental|Arm I (SGN-30, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
89254104|NCT00337194|Active Comparator|Arm II (placebo, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
89254105|NCT03973749|Experimental|Group 1|Low salycilate diet on day one and High salycilate diet on day 7
89254106|NCT03973749|Experimental|Group 2|High salycilate diet on day one and Low salycilate diet on day 7
89254107|NCT01074021|Experimental|Nimotuzumab plus chemoradiotherapy|
89254108|NCT01074021|Placebo Comparator|placebo plus chemoradiotherapy|
89254109|NCT03969381||1 lymphoma patients|pre therapy and post therapy of lymphoma patients
89254110|NCT01056978||patients|Patients admitted in a palliative care unit
89254111|NCT01326195|Experimental|Skills|Cognitive-Behavioral Dating Violence and HIV Prevention Group
89254112|NCT01326195|Active Comparator|Health Promotion|Psycho-educational Dating Violence and HIV Prevention group
89254113|NCT03985254|Active Comparator|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]), and in subsequent weeks the goal will be the development of muscle strength (load> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
89254114|NCT03985254|Experimental|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]). However, in subsequent weeks the goal will be to develop strength (load> 70% 1RM) and muscle power (load between 40-60% 1RM).
89254115|NCT01058928||Group ID 7.5|Patients with a tracheal tube ID (internal diameter) 7.5 mm
89254116|NCT01058928||Group ID 8.0|Patients with a tracheal tube ID 8.0 mm
89254117|NCT01582581|Active Comparator|Telephonic CBT|Computer guided, cognitive behavioral therapy (CBT) delivered by a clinician-administered telephone intervention.
89254118|NCT01582581|Sham Comparator|Wait List Control|Randomized wait list control with measurement of study outcomes at week 0, 3 and 5 after the initiation of waiting.
89254119|NCT01057056|No Intervention|control group|control group - receiving standard treatment
89254120|NCT03826914|Experimental|Experimental group|Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
89254121|NCT03826914|Placebo Comparator|Control Group|Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.
89254122|NCT01059006|Experimental|PresbyLASIK|Male or female patients with presbyopic symptoms who underwent PresbyLASIK.
89254123|NCT01055340|Experimental|Treatment sequence 1|OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo
89254124|NCT01055340|Experimental|Treatment sequence 2|OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min
89254125|NCT01055340|Experimental|Treatment sequence 3|Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min
89254126|NCT01055340|Experimental|Treatment sequence 4|OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min
89254127|NCT01055340|Experimental|Treatment sequence 5|Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min
89254128|NCT01055340|Experimental|Treatment sequence 6|OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo
89254129|NCT00385736|Experimental|Adalimumab 80/40|
89254130|NCT00385736|Experimental|Adalimumab 160/80/40|
89254131|NCT00385736|Placebo Comparator|Placebo|
89254132|NCT03742206|Experimental|Parasacral|Parasacral Transcutaneous Electrical Stimulation Group: participants in this group will receive two self-adhesive electrodes and will be instructed to position them in the sacral region. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
89254133|NCT03742206|Active Comparator|Posterior Tibial Nerve|Transcutaneous Posterior Tibial Nerve Stimulation Group: participants in this group will receive a neoprene ankle brace that will be connected to the electrostimulator. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
89254134|NCT01057212|Experimental|Bevacizumab and Ixabepilone|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks. Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule to the remaining 40 patients.
89254135|NCT03988452|Active Comparator|Darunavir/r Zidovudine Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
89254136|NCT03988452|Experimental|Darunavir/r Tenofovir Lamivudine|Darunavir 800mg once daily Ritonavir 100mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
89254137|NCT03988452|Experimental|Dolutegravir Zidovudine Lamivudine|Dolutegravir 50mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks
89254138|NCT03988452|Experimental|Dolutegravir Tenofovir Lamivudine|Dolutegravir 50mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks
89254139|NCT01048580|Experimental|Perifosine +Capecitabine|One cycle of therapy will be defined as 3 weeks (21 days). Perifosine 50 mg qd (Days 1-21) + Capecitabine 1000 mg/m2 BID (Days 1-14).
89254140|NCT03988140|Experimental|Implant placed at supra crestal level (SL)|Implants were placed at supra crestal level (SL)
89254141|NCT03988140|Other|Implant placed at crestal level (CL).|Implants were placed at crestal level (CL)
89254142|NCT01049906|Active Comparator|Nerve stimulation and Ultrasound|
89254143|NCT01049906|Active Comparator|Ultrasound without nerve stimulation|
89254144|NCT02533050|Experimental|Patients treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) <10. After randomization, they will be treated with CPAP treatment.
89254145|NCT02533050|No Intervention|Patients non-treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS <10. After randomization, they will be not treated.
89254146|NCT02533050|No Intervention|Control group|Patients with CAD but without SAS (AHI<15).
89254147|NCT00195819|Experimental|Adalimumab|
89254148|NCT00195819|Placebo Comparator|Placebo|
89254149|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent)|
89254150|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (sequential)|
89254151|NCT00527735|Active Comparator|Ipilimumab placebo + paclitaxel + carboplatin|
89254152|NCT03969147|Active Comparator|MRI Comparison|MRI images will be obtained of the airways of healthy volunteers both with the ManMaxAirway oropharyngeal airway adjunct and with no airway adjunct in place in order to observe any changes to the airway anatomy caused by placement of the airway adjunct. The order of the scans (with and without airway adjunct) will be determined by randomization software in advance.
89254153|NCT03969147|Experimental|Tolerability Comparison|Healthy volunteers will self-place either the ManMaxAirway oropharyngeal airway adjunct or the Guedel Oropharyngeal airway adjunct, which will be left in place for an interval of one minute, while supervised by research staff. After completing a questionnaire and resting for a timed interval, they will then self-place the other airway adjunct, which will be left in place for the same length of time as the first, before completing another questionnaire. The order in which the devices are placed by each subject will be determined in advance via computer randomization.
89254154|NCT03969147|Active Comparator|Forced Oscillation|Volunteers from the tolerability comparison arm will also be invited as a subset of subjects to participate in a measurement of resistance to forced oscillation. The volunteers will be subject to forced oscillations in a pulmonary function lab with the ManMaxAirway oropharyngeal airway adjunct in place and with no airway adjunct in order to observe changes in resistance to oscillatory airflow
89254155|NCT00336492|Experimental|002|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
89254156|NCT00336492|Experimental|001|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
89254157|NCT00194025|Experimental|valproate|All participants received open-label, add-on valproate.
89254158|NCT01057368|Active Comparator|Mindfulness Based Stress Reduction|
89254159|NCT01057368|Active Comparator|Health Enhancement Program|
89254160|NCT01057368|No Intervention|Wait List Controls|
89254161|NCT01057368|Active Comparator|Long Term Meditators|
89254162|NCT02531685|Experimental|Cohort 1|13 subjects receive 0.1 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
89254163|NCT02531685|Experimental|Cohort 2|13 subjects receive 0.3 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
89254164|NCT02531685|Experimental|Cohort 3|13 subjects receive 1.0 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
89254165|NCT02531685|Experimental|Cohort 4|"A sentinel group of 5 subjects receive 2.0 mcg dmLT intradermally on days 1, 22, and 43. 1 subject receives placebo.~Safety data from days 1-14 in sentinel will be reviewed and upon approval to proceed, 8 additional subjects receive 2.0 mcg dmLT intradermally on days 1, 22 and 43. 2 subjects receive placebo."
89254166|NCT02531685|Experimental|Cohort 5|Up to 31 subjects receive TBD mcg dmLT intradermally on days 1, 22 and 43. 4 subjects receive placebo.
89254167|NCT03969303||NOTAL OCT v.2.5 and Commercial OCT on AMD Patients|OCT Images will be obtained in the central 10 degrees of the macula in AMD patients using the NOTAL OCT v.2.5 device and a Commercial device (Zeiss Cirrus/Heidelberg SPECTRALIS).
89254168|NCT03969069||Fistula/chronic perianal conditions|Participants symptomatic of FI with chronic perianal disease
89254169|NCT03969069||Obstetric injury <12 months|Participants symptomatic of FI < 12 months following obstetric injury.
89254170|NCT03969069||Obstetric injury >12 months|Participants symptomatic of FI >12 months following obstetric injury.
89254171|NCT03969069||Neurogenic|Participants symptomatic of FI with evidence/history of neurological condition.
89254172|NCT00368108|Experimental|2 mg perampanel|The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
89254173|NCT00368108|Experimental|4 mg perampanel|The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
89254174|NCT00368108|Placebo Comparator|placebo|The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
89254175|NCT00364130|Active Comparator|Active Low Magnitude Mechanical Stimulus|Active Low Magnitude Mechanical Stimulus
89254176|NCT00364130|Placebo Comparator|Inactive Low Magnitude mechanical Stimulus|Inactive, or placebo low magnitude mechanical stimulus
89254177|NCT00521339|Experimental|Apremilast 20 mg BID/ 30 mg BID|Apremilast 20 mg or 30 mg orally twice per day
89254178|NCT01044602|Active Comparator|Best Medical Management|Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
89254179|NCT01044602|Active Comparator|Surgical Treatment|Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
89254180|NCT00363896|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
89254181|NCT00363896|Placebo Comparator|Placebo|Placebo once-daily via inhalation
89254182|NCT00527423|Experimental|Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)|
89254183|NCT01044680|Experimental|Nutriose|17 g NUTRIOSE consumed twice daily for 12 weeks
89254184|NCT01044680|Placebo Comparator|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
89254185|NCT00527111|Experimental|Chemoradiotherapy plus Cetuximab|Pelvic irradiation plus 5-fluorouracil plus cetuximab
89254186|NCT00527111|Active Comparator|Chemoradiotherapy alone|Pelvic irradiation plus 5-fluorouracil
89254187|NCT00384956|Experimental|Azacitidine|Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle. Patients that do not respond after two cycles will have the dose increased to 100 mg/m2. Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle. Individuals who demonstrate a loss of response will resume 28 day cycles.
89254188|NCT04090697|Experimental|Oxandrolone Cohort 1|Participants randomized to Oxandrolone Cohort 1 will receive 0.1mg/kg of oxandrolone suspended in a multi-chain triglyceride (MCT) oil buccally twice per day.
89254189|NCT04090697|No Intervention|Standard of Care|Participants randomized to standard of care will receive the standard therapies provided at the institution at which they are being treated. Control subjects will receive standard therapy with no placebo and no oxandrolone.
89254190|NCT00367640|Experimental|100 IR|100 IR grass pollen allergen extract tablet
89254191|NCT00367640|Experimental|300 IR|300 IR grass pollen allergen extract tablet
89254192|NCT00367640|Experimental|500 IR|500 IR grass pollen allergen extract tablet
89254193|NCT00367640|Placebo Comparator|Placebo|Placebo tablet
89254194|NCT01325220|Active Comparator|STX209 5 mg BID|
89254195|NCT01325220|Active Comparator|STX209 10 mg BID|
89254196|NCT01325220|Active Comparator|STX209 10 mg TID|
89254197|NCT01325220|Placebo Comparator|Placebo|
89254198|NCT01055418|Placebo Comparator|placebo|
89254199|NCT01055418|Experimental|Vitamin C|
89254200|NCT00367484|Experimental|Rebif® (clone 484-39)|Rebif® 44 mcg, three times per week (tiw), subcutaneously (s.c.) During the first 4 weeks of the study, subjects underwent a dose titration regimen of 40% of Rebif® 22 mcg or 20% of Rebif® 44 mcg tiw (8.8 mcg per injection) in the first and second week followed by 100% of Rebif® 22 mcg or 50% of Rebif® 44 mcg (22 mcg per injection) in the third and fourth week. After 4 weeks, subjects received 44 mcg injected s.c. tiw.
89254201|NCT01324778|Experimental|A|
89254202|NCT01324778|Active Comparator|B|
89254203|NCT01057524|Active Comparator|Usual Airway Clearance Technique|Two self administered treatment sessions a day and two treatments a day assisted by a Physiotherapist both using the patient's usual airway clearance method.
89254204|NCT01057524|Experimental|High Frequency Chest Wall Oscillation (HFCWO)|Two self administered treatments a day using HFCWO and two treatment sessions a day assisted by a Physiotherapist using their 'usual' airway clearance method.
89254205|NCT00526799|Experimental|Phase I|Topotecan 3.5 mg/m^2 + Sorafenib dose escalation:
89254206|NCT00526799|Experimental|Phase II|Topotecan 3.5 mg/m^2 + Sorafenib 400 mg po daily.
89254207|NCT03992144|Experimental|amoxicillin|single preoperative oral 500 mg dose of Amoxicillin before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
89254208|NCT03992144|Experimental|metronidazole|single preoperative oral 400 mg dose of metronidazol before extraction of lower 3rd molar and painkillers after extraction for 1st 48 hours then sos.
89254209|NCT03992144|Active Comparator|conventional group|conventional therapy for prevention of dry socket post operative; 400mg metrinidazol 3 times a day for 5 days 500mg of amooxicillin 2 times a day for 5 days painkiller 48 hours after extraction then sos
89254210|NCT01059162|Experimental|IOPtiMate|patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system
89254211|NCT02534870|Experimental|ABT-450/r/ABT-267 + ABT-333|ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.
89254212|NCT00526331|Experimental|Study Group|FloTrac Sensor + Vigileo Monitor used to decide how much fluid to give during surgery.
89254213|NCT00526331|Experimental|Control Group|FloTrac Sensor + Vigileo Monitor only used for data collection during surgery; Standard of Care to decide fluid amount.
89254214|NCT03992066|Experimental|Vadadustat 600 mg|Dialysis-dependent chronic kidney disease (DD-CKD) participants converting from erythropoiesis-stimulating agent (ESA) treatment will be administered fixed-dose treatment for 10 days with vadadustat 600 milligrams (mg) daily.
89254215|NCT03992066|Experimental|Vadadustat 750 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 750 mg daily.
89254216|NCT03992066|Experimental|Vadadustat 900 mg|DD-CKD participants converting from ESA treatment will be administered fixed-dose treatment for 10 days with vadadustat 900 mg daily.
89254217|NCT03992066|Other|Erythropoiesis-stimulating agent|Participants will continue to receive their existing treatment with intravenous erythropoiesis-stimulating agent (ESA; darbepoetin alfa or epoetin alfa) for 10 days.
89254218|NCT01057602||Normal community dwelling elders|Individuals age 65 and older who live in the community
89254219|NCT03992222|Experimental|administration of a physical exercise programme|administration of a Physical exercise program for 24 weeks.
89254220|NCT03992222|No Intervention|control|
89254221|NCT01048736|Active Comparator|Exercise|All treatment groups will receive 4d/wk of exercise
89254222|NCT01048736|Experimental|Exercise + Diet (-250 kcal/d deficit)|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss),
89254223|NCT01048736|Experimental|Exercise + Diet (-600 kcal/d deficit)|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
89254224|NCT01048814||Ovarian, Peritoneal, Fallopian Cancer|Recurrent, Peristent or Refractory
89254225|NCT01048892|Experimental|Treatment (NTX-010)|
89254226|NCT01259648|Experimental|0.5 µg / kg remifentanil|Induction anesthesia includes 0.5 µg/kg remifentanil in addition to classic induction anesthesia protocol.
89254227|NCT01259648|Experimental|1.0 µg/kg remifentanil|Induction anesthesia includes 1.0 µg/kg remifentanil in addition to the classic induction protocol.
89254228|NCT01259648|Placebo Comparator|NaCl|An equivalent volume (1 ml for 10 kg of weight) of isotonic 0.9% NaCl is injected in addition to the classic anesthesia induction protocol
89254229|NCT01048970|Other|Control arm|Patients will receive nutritional assessment one week prior to treatment until completing two cycles
89254230|NCT01048970|Experimental|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
89254231|NCT01049048|Placebo Comparator|Control|This group receives placebo chocolate cookies with no vitamin D3 added.
89254232|NCT01049048|Experimental|Vitamin D3|This group receives 2500 IU of Vitamin D3 added to a chocolate cookie daily.
89254233|NCT01049126||Late stage endometrial cancer|
89254234|NCT01044836|Experimental|Etanercept|
89254235|NCT00520481|Experimental|IMC-A12|Thirty-one participants will receive IMC-A12 at 10 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). An additional 10 participants will receive IMC-A12 at a dose of 20 mg/kg every three weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Radiographic evaluation of response will be performed every 8 weeks for the participants treated with intravenous (i.v.) IMC-A12 at 10 mg/kg and every 9 weeks for the participants treated with i.v. IMC-A12 at 20 mg/kg.
89254236|NCT01044992|Experimental|Drug and radiation|Levodopa and H215O PET
89254237|NCT01045070||coronary heart disease|
89254238|NCT00520403|Experimental|1|
89254239|NCT04810403|Experimental|SOMEBODY Eating Disorder Prevention Program|All participants will be recruited to participate in the SOcial MEdia (SOME) adaptation of activities from the BODY Project (SOMEBODY).
89254240|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (A): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 1 year."
89254241|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab/erlotinib|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year."
89254242|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation: None"
89254243|NCT03998891||salt restricted diet|In this group the patients will received after CRTD a restricted (1500 grams/daily) salt intake.
89254244|NCT03998891||normal salt diet|In this group the patients will received after CRTD a normal (2500 grams/daily) salt intake.
89254245|NCT00519779|Placebo Comparator|2|Placebo oral Omega-3 fish oil supplementation
89254246|NCT00519779|Experimental|1|oral Omega-3 fish oil supplementation
89254247|NCT00526097|Experimental|Bisacodyl 5 mg x 2 once daily|patient to receive two enteric-coated tablets containing 5 mg bisacodyl
89254248|NCT00526097|Placebo Comparator|Placebo|patient to receive two placebo-to-match enteric-coated tablets 5 mg bisacodyl
89290340|NCT01072019|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
89290341|NCT01072019|Active Comparator|MRI generated patient specific custom cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
89290342|NCT01126632||Cap Assisted Colonoscopy|Patients receiving colonoscopies where scope is fitted with cap
89254249|NCT00525785|Experimental|5-Fluorouracil + Folinic Acid + Oxaliplatin|"PreOp Chemotherapy: 2 cycles (each cycle consisting of 4 weeks or 2 treatments) of chemotherapy with oxaliplatin, folinic acid and infusional 5-FU (FOLFOX-48). Oxaliplatin 100 mg/m^2 over 2 hours on day 1, folinic acid intravenous (IV) at 200 mg/m^2 over 30 minutes on day 1, and 5-FU 2,200 mg/m^2 over 48 hours as continuous infusion by outpatient pump starting on day 1. This therapy, FOLFOX-48 repeated every 2 weeks x 4 (8 weeks of induction chemotherapy).~PreOp Chemoradiotherapy begins 12 days after last dose of PreOp Chemo 5FU plus oxaliplatin; A total of 45 Gy (1.8 Gy fx/d) of radiotherapy concurrent to low-dose continuous infusion of 5-FU (300 mg/m^2/d Monday through Friday) & weekly oxaliplatin 45 mg/m^2 over 2 hours for 5 weeks (oxaliplatin administered on the first day of radiation week).~Surgical resection 4-6 weeks after completion of chemoradiotherapy"
89254250|NCT04746287|Experimental|Part A|Single dose administration
89254251|NCT04746287|Experimental|Part B|Multiple dose administration (food Effect)
89254252|NCT04746287|Experimental|Part C|Multiple dose administration
89254253|NCT04746287|Placebo Comparator|Placebo|Matching placebo
89254254|NCT04487561|Other|aspirative drainage|Drainage is the usual treatment after axillary lymphadenectoma for breast cancer
89254255|NCT04487561|Active Comparator|Hemopatch|The hemopatch group will be the group without drainage and with a product patch
89254256|NCT00525161|Experimental|Sorafenib & Endocrine Therapy|Sorafenib & Endocrine Therapy
89254257|NCT00524771||1|Users of NuvaRing
89254258|NCT00524771||2|Users of combined oral contraceptives
89254259|NCT00135694|Experimental|Immunosuppression Withdrawal|Subjects may randomize to this group at 12 to 24 months after transplantation. This is followed by tapered withdrawal of calcineurin inhibitor-based immunosuppression therapy over the course of 1 year.
89254260|NCT00135694|Active Comparator|Immunosuppression Maintenance|Liver transplant, followed by maintenance doses of continuous calcineurin inhibitor-based immunosuppression therapy.
89254261|NCT00519623|Experimental|PassPort(R) Transdermal Insulin Delivery System|
89254262|NCT01076530|Experimental|Arm I|Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
89254263|NCT03966664||Septic patients|Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
89254264|NCT03966664||Healthy controls|Age and sex matched healthy volunteers.
89254265|NCT03966664||Non septic patients|Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
89254266|NCT00519077|Experimental|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
89254267|NCT03966508|Experimental|hyperalgesia measurement|
89254268|NCT00124618|Experimental|cetuximab/Radiation|Cetuximab (C225) and Radiation
89254269|NCT00124462|Other|Realignment to Placebo|Realigning knee brace and custom orthodic- A valgus brace, customized functional orthotic for neutral foot position and motion control footwear.
89254270|NCT00124462|Other|Placebo to Realignment|Non realigning knee brace and flat orthodic- A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
89254271|NCT00124072|Active Comparator|Simvastatin 20 mg + folic acid and B12|Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
88804873|NCT01296763|Experimental|Irinotecan, Cisplatin, Olaparib, then add Mitomycin-C|A 3+3 dose escalation design will be used starting with dose 1. The maximally tolerated dose is defined as the highest dose for which at most 1 out of 6 patients experiences a DLT. We will use 3 patients per dose cohort. If 0 of 3 patients have a DLT (see section 5a) then the escalation will be continued at the next dose level. If 1 of 3 patients have a DLT then three more patients will be enrolled at this dose. If 1 of 6 patients has a DLT then the dose escalation will continue. If 2 or more of the first 3 patients, or >2 of 6 patients treated have a DLT at the dose level, we will reduce the dose to the previous dose level of Olaparib for the phase 2 and then test Mitomycin C (phase 1 dose 5). If DLTs are observed at our dose 1 regimen, we will reduce the duration of Olaparib from day 1 and day 8 to just day 1 (dose level -1) and we will not test Mitomycin C in the trial.
89254272|NCT00124072|Active Comparator|Simvastatin 80 mg + folic acid and B12|Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
89254273|NCT00124072|Active Comparator|Simvastatin 20 mg + placebo|Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
89254274|NCT00124072|Active Comparator|Simvastatin 80 mg + placebo|Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
89254275|NCT01078324||Ischemic colitis|Ischemic colitis, Diverticulosis
89254276|NCT01080352|Experimental|Vitamin C treatment|"Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c.~5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20."
89254277|NCT03965572||Postpartum women who requested cabergoline|A cohort of postpartum women, after a live birth, who request cabergoline for lactation suppression.
89254278|NCT03965572||Control group|An age-matched cohort of women after a live birth who have not requested cabergoline for lactation suppression.
89254279|NCT00362648|Experimental|1|RotaTeq™
89254280|NCT00362648|Placebo Comparator|2|Placebo
89254281|NCT01045148|Other|CyberKnife Radiosurgery|CyberKnife Radiosurgery
89254282|NCT00524303|Active Comparator|Arm 1|Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery
89254283|NCT00524303|Experimental|Arm 2|Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery
89254284|NCT00524303|Experimental|Arm 3|Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery
89254285|NCT04461041|Active Comparator|Empagliflozin|Single 10 mg tablet, administered orally once daily for 6 months
89254286|NCT04461041|Placebo Comparator|Placebo|Single 10 mg tablet, administered orally once daily for 6 months
89254287|NCT00335556|Experimental|Surgery|Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice.
89254288|NCT00335556|Experimental|Treatment (UH-1)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, and carboplatin. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable clear cell sarcoma of the kidney (CCSK) receive no further study therapy.
89254289|NCT00335556|Experimental|Treatment (window/UH-1)|Patients receive vincristine IV on days 1 and 8 and irinotecan hydrochloride IV over 30 minutes on days 1-5 and 8-12 (course 1). Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2.
89254290|NCT00335556|Experimental|Treatment (UH-2)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, carboplatin, and irinotecan hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7.
89254291|NCT00335556|Experimental|Treatment (regimen I)|Patients receive vincristine, doxorubicin hydrochloride, cyclophosphamide, and etoposide. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
89254292|NCT00335556|Experimental|Treatment (regimen DD-4A)|Patients receive dactinomycin, vincristine, and doxorubicin hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
89254293|NCT00518687|Experimental|V710 60 µg|
89254294|NCT00518687|Placebo Comparator|Placebo|
89254295|NCT00134056|Active Comparator|Arm I: placebo|Patients receive docetaxel and prednisone as in arm I. Patients also receive oral placebo once daily on days 1-21. Treatment repeat every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral placebo treatment for up to 52 weeks.
89254296|NCT00134056|Experimental|Arm II: atrasentan hydrochloride|Patients receive docetaxel IV over 1 hour on day 1. Patients also receive oral atrasentan and oral prednisone once daily on days 1-21. Treatment repeats every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral atrasentan treatment for up to 52 weeks.
89254297|NCT00518531|Other|Treatment Sequence B|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
89254298|NCT00518531|Other|Treatment Sequence A|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).
89254299|NCT00351468|Experimental|Eltrombopag|Open-label eltrombopag
89254300|NCT01326442|Experimental|diet only|low glycemic index diet, calorie restricted with exercise 3 times per week.
89254301|NCT01326442|Active Comparator|supplemented|2000 IU vitamin D3 plus 1.8 g EPA + DHA
89254302|NCT00523991|Placebo Comparator|placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
89254303|NCT00523991|Experimental|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
89254304|NCT00350844|Experimental|Hydroxyurea|
89254305|NCT00345540|Experimental|NOV-002 plus Carboplatin|NOV-002 is given by IV bolus on lead-in day -1 at cycle 1, and on day 1 at subsequent cycles, followed by Carboplatin AUC 5. NOV-002 is then continued via daily SC injection, with 28 day cycles.
89254306|NCT00335322|Active Comparator|1|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
89254307|NCT00335322|Active Comparator|2|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
89254308|NCT00335322|Experimental|3|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
89254309|NCT03986346|Experimental|Laser group|Participants in this group receive pulsed dye laser to treat the scar.
89254310|NCT03986346|Active Comparator|Control group|Participants in this group receive standardized care.
89254311|NCT01059396|Experimental|Propranolol|
89254312|NCT01059396|Experimental|carvedilol|
89254313|NCT01059396|Placebo Comparator|Placebo|
89254314|NCT01057680|Experimental|creatine|This arm will involve creatine supplementation 0.1 g per kg body mass per day while participating in a resistance training program (1 hour per day, 3 days per week).
89254315|NCT01057680|Placebo Comparator|Sugar|This arm will involve placebo (maltodextrin) given every day while the participant does a resistance training program (1 hour per day, 3 days per week).
89254316|NCT00523367|No Intervention|esomeprazole|
89254317|NCT01059474|Experimental|DMPS|We will recruit 10 healthy adult volunteers, over 18 years of age, who eat at least three servings of fish per week (since this diet is associated with detectable levels of mercury in the urine which may rise following chelation). Patients with known allergies to DMPS or sulfa drugs or history of neurologic or renal disease will be excluded. We will also control for number of mercury containing dental amalgams. History will be obtained regarding any potential mercury exposures or recent vaccinations.
89254318|NCT01059552|Experimental|vorinostat|Dose escalation of vorinostat, cisplatin, pemetrexed and radiation
89254319|NCT03741894|Placebo Comparator|Primary wound closure|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
89254320|NCT03741894|Experimental|Iodoform and wound closure|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture (Surgilon 3-0 non-absorbable) placements for a week.
89254321|NCT03741894|Experimental|Chlorhexidine and wound closure|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
89254322|NCT03755765|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
89254323|NCT03755765|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
89254324|NCT01061112||CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
89254325|NCT01061112||CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
89254326|NCT01061112||CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
89254327|NCT03741491||Birkebeiner with AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) with AF.
89254328|NCT03741491||Birkebeiner without AF|Persons already included in the Birkebeiner Aging Study (BIAS) (completed the Birkebeiner cross-country ski race in 2009/10 born 1945 and earlier) and BAF-study (completed the Birkebeiner cross-country ski race in 1999 and was born in 1960 and earlier) without AF
89254329|NCT03741491||Control with AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier with AF
89254330|NCT03741491||Control without AF|Persons included in HELMILO 2009 (Health and Environment Study in Oslo 2009), born 1960 and earlier without AF
89254331|NCT04780841|Experimental|RDX013 Cohort 1|RDX013 low dose oral dosage, twice daily
89254332|NCT04780841|Experimental|RDX013 Cohort 2|RDX013 low, mid dose oral dosage, twice daily
89254333|NCT04780841|Experimental|RDX013 Cohort 3|RDX013 high, mid dose oral dosage, twice daily
89254334|NCT04780841|Experimental|RDX013 Cohort 4|RDX013 high dose oral dosage, twice daily
89254335|NCT04780841|Experimental|RDX013 Part B|RDX013 dose from Part A oral dosage, twice daily
89254336|NCT04780841|Placebo Comparator|Placebo Part B|oral dosage, twice daily
89254337|NCT01061190|Active Comparator|Propranolol|
89254338|NCT01061190|Placebo Comparator|Placebo|
89254339|NCT00344448|Experimental|Raptiva|At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.
89254340|NCT00344448|Placebo Comparator|placebo|Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.
89254341|NCT00324168|Active Comparator|1|
89254342|NCT00324168|Placebo Comparator|2|
89254343|NCT01059708||CO poisoned children|Children, ages 6-16, who have been poisoned by carbon monoxide
89254344|NCT00517829|Active Comparator|1- Docetaxel plus Oxaliplatin|Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
89254345|NCT00517829|Active Comparator|2- Docetaxel plus oxaliplatin plus cetuximab|Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
89254346|NCT00343512|Experimental|Therapeutic Intervention|
89254347|NCT00334542|Experimental|Simvastatin|Simvastatin 40 mg for 24-28 weeks
89254348|NCT01059942||Hospitalist physicians/house-staff|Consented Academic Hospitalist and Internal Medicine Residency staff
89290343|NCT01126632||Standard Colonoscopy|Patients receiving standard colonoscopy without the cap on the scope
89290344|NCT01073579||Sabril®|All patients in the U.S. who are prescribed Sabril must participate in this patient registry in order to receive Sabril.
89290345|NCT04813900|Experimental|Patient suspected to suffer from interstitial syndrome needing an arterial blood gas analysis|
89290346|NCT01126788||PADnet + testing|
89254349|NCT00112294|Active Comparator|Cetuximab+Taxane+Carboplatin (C/T/C)|Cetuximab was administered at an initial dose (Week 1) of 400 mg/m^2 intravenous (IV) infusion (infused over 120 minutes) and a weekly maintenance dose of 250 mg/m^2 IV infusion (infused over 60 minutes). A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
89254350|NCT00112294|Active Comparator|Taxane+Carboplatin (T/C)|A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
89254351|NCT00235443|Experimental|1|Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day
89254352|NCT03973437|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
89254353|NCT03973437|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
89254354|NCT00234039|Experimental|Intravesical Gemcitabine|
89254355|NCT03973359|No Intervention|Epidemiology|HCMV-seropositive pregnant women receiving standard care
89254356|NCT03973359|Experimental|Prevention|HCMV-seropositive pregnant women receiving hygienic information
89254357|NCT02531451|Experimental|Ibuprofen|Resistance exercise 20 sessions during 8 weeks Daily consumption of 1200 mg ibuprofen (400 mg x 3) during 8 weeks
89254358|NCT02531451|Active Comparator|Acetylsalicylic acid|Resistance exercise 20 sessions during 8 weeks Daily consumption of 75 mg acetylsalicylic acid (75 mg x 1) during 8 weeks
89254359|NCT01073007|Experimental|Simvastatin|Simvastatin 40 mg daily for 3 months.
89254360|NCT01073007|Placebo Comparator|Placebo|
89254361|NCT03741621|Experimental|High Viscosity|viscous fibre blend added to breakfast cereals consumed in the context of a typical North American diet for 3 weeks duration
89254362|NCT03741621|Experimental|Medium Viscosity|Kellogg's Bran buds with psyllium breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
89254363|NCT03741621|Experimental|Low Viscosity|Kellogg's All Bran breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
89254364|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
89254365|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
89254366|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
89254367|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 of the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
89254368|NCT00323622|Active Comparator|Cohort 1-Prevnar-Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
89254369|NCT00323622|Active Comparator|Cohort 1-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
89254370|NCT00323622|Active Comparator|Cohort 2-Prevnar- Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
89290347|NCT01126788||Parks Flo-lab Test|
89290348|NCT04806802|Experimental|APIOC Sphere or Astigmatism|Single Vision Spherical or Toric Contact Lens
89290349|NCT03934320|Other|FAMCAT|
89290350|NCT01376830||COPD patients|
89290351|NCT01124136|Experimental|Neurostimulation + Medication management|Investigational nerve stimulator device implanted to heart plus standard medication therapy.
89254371|NCT00323622|Active Comparator|Cohort 2-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
89254372|NCT00189423|Experimental|1|Active compression decompression cardiopulmonary resuscitation (ACD-CPR) with an impedance threshold device (ITD)
89254373|NCT00189423|Active Comparator|2|Conventional standard cardiopulmonary resuscitation (S-CPR)
89254374|NCT00323310|Experimental|Gadobenate Dimeglumine|
89254375|NCT01326039|Active Comparator|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
89254376|NCT01326039|Placebo Comparator|saline|perineural isotonic saline 20 ml
89254377|NCT01071759||pregnancy|
89254378|NCT01057758|Placebo Comparator|PLACEBO|Half of the patients will be randomized to the placebo
89254379|NCT01057758|Active Comparator|Simvastatin|Half of the subjects will receive the active drug, Simvastatin.
89254380|NCT02532582||Living Liver Donor Transplant Donors|All adult living liver donors and liver surgery patients at Northwestern Memorial Hospital (same surgical setup is used for living liver donor surgery and liver surgery (e.g. retractors, arterial line for monitoring, surgeons). Living liver donors and liver surgery patients for enrollment to receive neuromuscular monitoring)
89254381|NCT00186537|Active Comparator|fenofibrate|160 mg daily for 12 weeks
89254382|NCT00186537|Active Comparator|rosiglitazone|4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
89254383|NCT00186537|Active Comparator|calorie restricted diet|calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
89254384|NCT03968835||Biological Dressings|Bacitracin will be applied and covered with xeroform and gauze
89254385|NCT03968835||Artificial Dressings|the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft
89254386|NCT01073085|Experimental|Web-based coaching|"Those in the coaching arm will benefit from e-mails with advice, information, support for smoking cessation. These mails will be adapted to their personal profile."
89254387|NCT01073085|Active Comparator|Self-help guide|"Those in the active comparator arm will be allowed to download a self-help guide with step-by-step advice for smoking cessation."
89254388|NCT00517751|Experimental|X-STOP PEEK|In this arm, patients will undergo X-STOP PEEK surgery.
89254389|NCT00322842|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
89254390|NCT00322842|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
89254391|NCT00255723|Experimental|Cytoreductive chemotherapy group 1|Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.
89254392|NCT00255723|Experimental|Cytoreductive chemotherapy group 2|Patients receive ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and etoposide IV over 1 hour twice daily on days 1-3 and 17-19.
89254393|NCT01060176|Experimental|High dosage|Tranexamic acid with a loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h
89254394|NCT01060176|Experimental|Medium dosage|Tranexamic acid with a loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h
89254395|NCT01060176|Experimental|Low dosage|Tranexamic acid with a loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h
89254396|NCT01060176|Placebo Comparator|Control|Saline solution
89254397|NCT04719845|Experimental|Endoscopic laser resection|Using CO2, diode or similar wavelenght laser the stenotic tracheal segment will be vaporized allowing a less than 20% residual stenosis. Dilatation will not be performed after laser resection for residual stenosis.
89254398|NCT04719845|Experimental|Dilatation|Using a ballon or rigid bronchoscope the stenotic tracheal segment will be dilated with or without previous radial incision with electrocautery or laser.
89254399|NCT01071837|Active Comparator|Re-Irradiation|33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)
89254400|NCT01071837|Experimental|Re-Irradiation + APG101|66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion
89254401|NCT01057836|Experimental|Neck strength training|
89254402|NCT01057836|Experimental|Neck endurance training|
89254403|NCT01057836|Active Comparator|Stretching|
89254404|NCT04305977|Other|WAVE-TW Arm|All participants will receive the WAVE-TW intervention.
89254405|NCT00132808|Experimental|Zoledronic Acid 2x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12
89254406|NCT00132808|Experimental|Zoledronic Acid 1x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12
89254407|NCT00132808|Placebo Comparator|Placebo|Placebo given at randomization and Month 12
89254408|NCT03983148|Experimental|Motivational interviewing|Other than usual medical care received by children, their parents in this group will receive three individual, face-to-face interventions on motivational interviewing by a trained registered nurse at baseline, 3-month and 6-month, with each session is about 60 minutes. All sessions of motivational interviewing will be scheduled based on the treatment schedule of the children and conducted in an interview room inside the pediatric oncology unit. A 25-30 minutes semi -structured interview will be conducted for process evaluation at 6-month.
89254409|NCT03983148|Placebo Comparator|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
89254410|NCT03741387|Experimental|Gain-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you save his life? Donors in this group will answer the questions about attitude of saving patients' lives."
89254411|NCT03741387|Experimental|Loss-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you prevent him from death? Donors in this group will answer the questions about the attitude of preventing patients from death."
89254412|NCT04714463||Immediate breast reconstruction|Women undergoing immediate breast reconstruction due to breast cancer or a high risk for breast cancer
89254413|NCT04714463||Delayed breast reconstruction|Women undergoing delayed breast reconstruction due to breast cancer or a high risk for breast cancer
89254414|NCT01061268|Experimental|BLINK™ tears|
89254415|NCT01061268|No Intervention|No topical artificial tear|
89254416|NCT01061346|Experimental|High Fat Diet with Fructose|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
89254417|NCT01061346|Experimental|High Fat Diet with Glucose|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
89254418|NCT01061346|Experimental|Low Fat Diet with Glucose|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein.
89254419|NCT01057914|Experimental|Supplemention|
89254420|NCT01057914|Experimental|Dietary advice|
89254421|NCT01057914|Experimental|Combination treatment|
89254422|NCT01057914|No Intervention|Usual care|
89254423|NCT00517361|Experimental|Carboplatin + Avastin|
88804874|NCT01347541|Experimental|Stepped care|Combination of behavioral therapy and drug therapy
89254424|NCT03984864|Experimental|Exercise therapy Chosen|
89254425|NCT03984864|Active Comparator|Exercise therapy no Chosen|
89254426|NCT00516893|Experimental|Natalizumab High Titer|natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses
89254427|NCT01565135|Experimental|Intervention Practices|Intervention offices will adopt a multimodal vaccine program to increase their patients' vaccine rates.
89254428|NCT01565135|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
89254429|NCT01565213|Active Comparator|CBT cognitive behavioral therapy|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks
89254430|NCT01565213|Active Comparator|MMI Multimodal group intervention|group multimodal intervention
89254431|NCT01565213|Other|CAU|Care as usual given by the GPs
89254432|NCT04171661|Experimental|SASS|SASS applied on chronic skin wounds as skin graft
89254433|NCT04171115|Experimental|10mg of G03-52-01|8 subjects randomized to 10 mg of G03-52-01 and 2 subjects randomized to placebo
89254434|NCT04171115|Experimental|25mg of G03-52-01|8 subjects randomized to 25 mg of G03-52-01 and 2 subjects randomized to placebo
89254435|NCT04171115|Experimental|50 mg of G03-52-01|8 subjects randomized to 50 mg of G03-52-01 and 2 subjects randomized to placebo
89254436|NCT04171115|Experimental|100 mg of G03-52-01|8 subjects randomized to 100 mg of G03-52-01 and 2 subjects randomized to placebo
89254437|NCT00522431|Experimental|1|2% testosterone gel
89254438|NCT00185211|Experimental|Initial IFNB-1b (Interferon beta-1b)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
89254439|NCT00185211|Experimental|Initial Placebo|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
89254440|NCT00516737|Experimental|1|Active Drug
89254441|NCT00516737|Placebo Comparator|2|Matching Pbo Comparator
89254442|NCT03540485|Experimental|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
89254443|NCT03540485|Placebo Comparator|Control|Daily administration of placebo orally, for 24 months between 10pm to 11pm
89254444|NCT01582035|Experimental|Panel 1|TMC647055 in combination with TVR for 10 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
89254445|NCT01582035|Experimental|Panel 2|TMC647055 in combination with TVR for 10 or 14 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
89254446|NCT00132730|Experimental|MK-0873 2.5 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
89254447|NCT00132730|Experimental|MK-0873 1.25 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
89254448|NCT00132730|Experimental|MK-0873 0.75 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
89254449|NCT00132730|Placebo Comparator|Placebo|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)
89254450|NCT00132730|Experimental|MK-0873 2.5 mg + Usual Care|Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
89254451|NCT00132730|Active Comparator|Usual Care|Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
89254452|NCT02531841|Active Comparator|Arm A|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):~Rituximab 375 mg/m²/d i.v. (d0)~Dexamethasone 40 mg/d i.v. (d1-3)~Etoposide 100 mg/m²/d i.v. (d1-3)~Ifosfamide 1500 mg/m²/d i.v. (d1-3)~Carboplatin 300 mg/m² i.v. (d1)"
89254453|NCT02531841|Active Comparator|Arm B|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment High-dose chemotherapy~Carmustine* 400 mg/m² i.v. (d-6)~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)~*if not available at study site, Busulfan can be administered instead:~Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)"
89254454|NCT01074411|Experimental|Treatment (bortezomib, carboplatin)|Patients receive bortezomib IP and carboplatin IP on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89254455|NCT00232557|Experimental|TLC-Asthma|Telephone-based home education and asthma monitoring
89254456|NCT00232557|Active Comparator|TLC-health education|Telephone-based home education
89254457|NCT03973047|Placebo Comparator|Group 1: BMT plus placebo|1 dose of BMT 1.75 mg via autoinjector plus placebo (dosed 30±5 minutes prior to BMT dosing) on Day 1.
89254458|NCT03973047|Active Comparator|Group 2: BMT plus Zofran|1 dose of BMT 1.75 mg via autoinjector plus Zofran 8 mg (dosed 30±5 minutes prior to BMT dosing) on Day 1.
89254459|NCT00522275|Experimental|Lacosamide|Up to 800 mg/day lacosamide (flexible dosing)
89254461|NCT01074567|Experimental|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
89254462|NCT01582659|No Intervention|No ekstra counseling|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made.
89254463|NCT01582659|Active Comparator|2 counseling sessions|Standardized information about childhood constipation is given and the child receives PEG 3350. 2 additional follow up appointments by telephone are made.
89254464|NCT01582659|Active Comparator|Web access|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made but the family are given access to a website with information about childhood constipation.
89254465|NCT00522041|Experimental|Cellegesic (nitroglycerin 0.4%)|Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
89254466|NCT00522041|Placebo Comparator|Placebo 375 mg|Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
89254467|NCT00122980|Active Comparator|1|Hydroxyurea and phlebotomy
89254468|NCT00122980|Active Comparator|2|Transfusion and chelation
89254469|NCT01080508||10 Asa I & II patients|
89254470|NCT03868631|Active Comparator|Soy protein group|
89254471|NCT03868631|Active Comparator|Whey protein group|
89254472|NCT06169774|Experimental|Educational video|Participants will be asked to watch an education video addressing aseptic techniques to safely handle central catheters at home during parenteral nutrition infusions.
89254473|NCT06169774|No Intervention|No educational video|Participants will be managed according to routine care.
89254474|NCT06169722|Active Comparator|200mg|200mg oral once a day
88804875|NCT01347541|Active Comparator|Standard care provided to injured trauma survivors|
89254475|NCT06169722|Active Comparator|400mg|400mg oral once a day
89254476|NCT06169722|Active Comparator|200mg or 400mg|200mg or 400mg oral once a day
89254477|NCT06169683|Experimental|Experienced Lyric Users|This cohort of participants is required to have Lyric hearing instrument experience, and they will be asked to wear Lyric for the duration of the study period and report on their experience.
89254478|NCT06169670|Experimental|Patients Receiving Lipoaspirate with Viality|Patient will be undergoing fat transfers to the face with lipoaspirate processed using the Viality wash system.
89254479|NCT06169657||Inpatients Post-stroke, low level ambulators|Individuals post acute or subacute stroke that that are inpatients at the Shirley Ryan AbilityLab ages 18-75 with initial gait speed 0.0-0.39 m/s
89254480|NCT06169657||Inpatients Post-stroke, high level ambulators|Individuals post acute or subacute stroke that that are inpatients at the Shirley Ryan AbilityLab ages 18-75 with initial gait speed 0.4-0.79 m/s
89254481|NCT06169657||Inpatients with iSCI, low level ambulators|Individuals post-SCI or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-75 with initial gait speed 0.0-0.39 m/s
89254482|NCT06169657||Inpatients with iSCI, high level ambulators|Individuals post-SCI or subacute that that are inpatients at the Shirley Ryan AbilityLab ages 18-75 with initial gait speed 0.4-0.79 m/s
89254483|NCT06169631|Experimental|Experiment 1|The study will consist of 2 groups. A: no current diagnosis of anxiety or other psychological disorders. B: Current diagnosis of anxiety disorder. Results will be analyzed within and between groups. Participants will answer standardized questionnaires and other similar validated psychological scales. An ultrasound transducer will be placed on their head aimed at the brain region of interest. EEG data will be collected throughout the process. After this process, participants will answer a set of post experiment questions.
89254484|NCT06169631|Experimental|Experiment 2a|Current diagnosis of anxiety disorder is required. Participants will receive an MRI. Participants will answer standardized questionnaires and other similar validated psychological scales. An ultrasound transducer will be placed on their head aimed at the brain region of interest. EEG data will be collected throughout the process. After this process, participants will answer a set of post experiment questions
89254485|NCT06169631|Experimental|Experiment 2b|Experiment 2b will expand on Experiment 2a protocol with multiple visits. Each visit will consist of the same activities as Experiment 2a.
89254486|NCT06169618||cervical radiculopathy group|thirty participants with cervical radiculopathy due to discogenic lesions.
89254487|NCT06169618||normal group|thirty participants in normal without any discogenic lesion
89254488|NCT06169605|Experimental|Patients with squamous cell carcinoma of the tongue and floor of the mouth|Intervention group
89254489|NCT06169592||liver transplant group|
89254490|NCT06169566|Active Comparator|Intervention|synbiotics
89254491|NCT06169566|Placebo Comparator|non-intervention|placebo
89254492|NCT06169553|Experimental|Intervention group|Participants in the IRIS program will be offered a one-stop, low-barrier combined care model to address their injection-related infections. Specific program components include: (1) Diagnosis and treatment of injection-related infections; (2) Substance use treatment (3) Peer support; and (4) Care coordination/systems navigation.
89254493|NCT06169540||ADHF|Patients with ADHF (during admission and discharge).
89254494|NCT06169540||CHF|Patients with CHF.
89254495|NCT06169540||Control|Patients with SVT and no other cardiovascular diseases.
89254496|NCT06169501|Experimental|Intervention|All study participants will receive the app-based mindfulness intervention.
89254497|NCT06169488|Experimental|Lumbar Interbody Fusion (LIF)|"Per center standard, the LIF procedure is done in one or two levels between the second lumbar vertebra and sacrum, as a transforaminal lumbar interbody fusion (TLIF) or anterior lumbar interbody fusion (ALIF). Stabilization with screws is mandatory. TLIF employs bilateral pedicle screws. ALIF uses either pedicle or intra-device screws.~At least one surgeon must be proficient in both procedure and implants. TLIF requires visual aids (microscope/magnifying glasses) for precise disc preparation. In the TLIF procedure, surgeons will maximize bone implantation into the disc space, anteriorly, posteriorly, or both.~If the disc space is too narrow for an interbody device, autologous bone grafting into the disc space (local, spongious, or both) with posterior pedicle screw fixation is accepted. Optional posterolateral autologous bone grafting is allowed, but no substitutes or osteoinductive proteins (e.g., BMP). Surgical drain is optional."
89254498|NCT06169488|Active Comparator|Multidisciplinary Rehabilitation|"Rehabilitation, guided by a team of experienced specialists in physical medicine and rehabilitation and physiotherapists trained in cognitive therapy, will direct the multidisciplinary treatment. Patients receive 2.5-5 hour sessions 2-4 days weekly over 3-5 weeks. Standardization is maintained through pre-study training for providers, including seminars, podcasts, videos, and lectures.~Individual screenings start the process, leading to focused discussions on thoughts, feelings, behaviour, and physical symptoms. A plan for the rehabilitation process with clearly defined individual goals will be worked out and revised every week. The three components described within the framework of cognitive functional therapy will be a template for the implementation of the functional and physical rehabilitation, involving pain understanding, exposure with control, and lifestyle changes like physical activity, sleep, diet, stress management, and social engagement."
89254499|NCT06169475|Experimental|dexmedetomidine group|
89254500|NCT06169475|Experimental|esmolol group|
89254501|NCT06169475|No Intervention|control group|
89254502|NCT06169449|Experimental|Weight management Group|Patients in the weight management group used a weight management model that included diet, exercise, accompany and refresh.
89254503|NCT06169449|Other|Control Group|Patients in the control group underwent routine care for self-weight management.
89254504|NCT06169436||Experimental|Patients with upper urinary tract urothelial cancer who underwent nephroureterectomy surgery
89254505|NCT06169423|Other|Educative intervention|"A first theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. This session would be the prebriefing. After this session, the complete simulation, with subsequent evaluation of it giving feedback to the students (debriefing). After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation."
89254506|NCT06169384|Active Comparator|Endoscopic total adenoidectomy|
89254507|NCT06169384|Active Comparator|Endoscopic partial adenoidectomy|
89254508|NCT06169332||Computed Tomography|Experimental computed tomography protocol: a few minutes after the administration of the contrast medium at a very low dose of radiation performed only in those patients in whom there is a doubt of thrombosis in the early arterial phase.
89254509|NCT06169293|Experimental|I-AM-WELL program|
89254510|NCT06169293|No Intervention|Waitlist control|Students will receive the intervention after data is collected from all three time points
89254511|NCT06169202||Fruquintinib in combination with irinotecan and capecitabine|"Phase I: Treatment phase: 6-8 cycles (as determined by the researcher) 1. Irinotecan: 180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1*28 and *6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).~2, Capecitabine: 1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks. 3. Fruquintinib: 4 mg orally once daily, D1-14, repeated every 3 weeks.~Phase II: Maintenance phase:~1, Fruquintinib: 4 mg orally once daily, D1-14, repeated every 3 weeks. 2. Capecitabine: 1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks"
89254512|NCT06169189|Active Comparator|Experimental intervention group|The experimental group will be given 8-week global warming-climate change based training
89254513|NCT06169189|No Intervention|Control Group|The initiative will not be implemented.
89254514|NCT06169163||OSCC group|Patients with histopathology confirmed, treatment naive OSCC
89254515|NCT06169163||Non-cancer controls|"Patients who are undergoing an endoscopy for non-specific upper gastrointestinal (GI) symptoms and are shown to have either:~A healthy upper GI tract~Benign upper gastrointestinal disease"
89254516|NCT06169111|Experimental|Autism Spectrum Disorders (ASD) patients with Maternal Immune Activation (MIA)|
89254517|NCT06169111|Active Comparator|Autism Spectrum Disorders (ASD) patients without Maternal Immune Activation (MIA)|
89254518|NCT06169085|Experimental|young participates|16 young participants(between 18~45 years old) will be given Leritrelvir. D1：400mg QD D3-D5:400mg TID D6:400mg QD
89254519|NCT06169085|Experimental|Elder participates|16 elder participants(Age≥65 years old) will be given Leritrelvir. 16 young participants(between 18~45 years old) will be given Leritrelvir. D1：400mg QD D3-D5:400mg TID D6:400mg QD
89254520|NCT06169059|Experimental|Treatment(Experimental): JLP-2004|Group I(Peroid I-comparator, Peroid II-JLP-2004), Group II(Period I-JLP-2004, Period II-Comparator)
89254521|NCT06169059|Active Comparator|Control(Active Comparator): JC-013|Group I(Peroid I-comparator, Peroid II-JLP-2004), Group II(Period I-JLP-2004, Period II-Comparator)
89254522|NCT06168994|Active Comparator|Amiodarone as comparison|50 patients >>Amiodarone +other treatmen
89254523|NCT06168994|Experimental|Eplerenone plus amiodarone|50 patients >>Amiodarone +other treatmen
89254524|NCT06168968||Cohort 1|(Secondary Prevention) Includes black (n=150) and white (n=150) patients greater than or equal to 18 years of age hospitalized for acute coronary syndrome (ACS), multi-vessel disease, or ischemic stroke undergoing intervention
89254525|NCT06168968||Cohort 2|(Primary Prevention) Includes black subjects (n=75) who are first or second-degree relatives of patients in Cohort 1 and have no history of prior hospitalization for cardiovascular or cerebrovascular disease
89254526|NCT06168955|Experimental|alzheimer's disease patients|Alzheimer's disease patients with positive biomarkers who started their disease before age 75 and benefited from genetic research.
89254527|NCT06168955|Other|Control group|control cell lines from patients free of alzheimer's disease
89254528|NCT06168942|Experimental|Laminar Device|Treatment with the Laminar Left Atrial Appendage Closure System.
89254529|NCT06168942|Active Comparator|Control LAAC|Treatment with a commercially-available left atrial appendage closure device.
89254530|NCT06168903|Experimental|EOI block Group (n=25):bilateral US-guided external oblique intercostal block.|"Patient in a supine position. A linear ultrasound probe will be placed in paramedian sagittal orientation between the midclavicular and anterior axillary lines at the level of the sixth rib, visualizing the external oblique and intercostal muscles. Local anesthetics are injected under the external oblique muscle.~A 22-gauge needle will be advanced in the superomedial-to-inferolateral direction into the fascial plane between the external oblique and intercostal muscles at the caudal end of the sixth rib and between the sixth and seventh ribs.The location of the needle tip will be confirmed by hydrodissection of inter-fascial planes with 3 ml of normal saline. After negative aspiration, a total of 20 mL of bupivacaine 0.25% will be injected in the fascial plane incrementally, aspirating every 5 ml, and the block will be repeated on the other side."
89254531|NCT06168903|Active Comparator|ESPB Group (n=25): bilateral US-guided erector spinae plane block|Patient in a lateral position. A curvilinear ultrasound probe (5-7 MHz) will be placed transversely to identify tip of T9 transverse process 2.5-3 cm from the midline, then it will be rotated longitudinally to get a parasagittal view, visualizing the transverse process as a hyperechoic curvilinear structure with prominent finger-like acoustic shadowing beneath , lamina , spinous process, and costochondral junction medially and laterally. The erector spinae muscles are identified superficially to the tip of the T9 transverse process.The location of the needle tip will be confirmed by hydrodissection of the erector spinae muscle from the tip of the transverse process. After negative aspiration, a total of 20 mL bupivacaine 0.25% will be injected under the fascial plane incrementally, aspirating every 5 ml and the block will be repeated on the other side
89254532|NCT06168773|Experimental|Group I (number of patients = 45):|will receive 1 mg haloperidol intravenously 3 times daily and magnesium sulfate 4 g intravenous infusion (IVI) in 1st day (diluted in 50 ml D5W over 24 hours) then 2g IVI over 24 hours (diluted in 50 ml D5W over 24 hours) for 3 days postoperatively starting the first dose 2- 4 hours after surgery. If the first prophylactic dose is delayed for more than 4 hours post admission, patient is excluded from the study.
89254533|NCT06168773|Experimental|Group II (number of patients= 45):|will receive 1 mg haloperidol intravenously 3 times daily and 50 ml of D5W IVI infusion over 24 hours for 4 days postoperatively starting the first dose 2- 4 hours after surgery.
89254534|NCT06168773|Placebo Comparator|Group III (number of patients = 45)|will receive 1 mL 0.9% of sodium chloride intravenously 3 times daily and 50 ml of D5W IVI infusion for 4 days postoperatively starting the first dose 2- 4 hours after surgery.
89254535|NCT06168734|Experimental|Cefepime-taniborbactam|cefepime-taniborbactam (2g/0.5g) IV every 8 hours.
89254536|NCT06168734|Active Comparator|Meropenem|Comparator: meropenem (2g) IV every 8 hours.
89254537|NCT06168708|Active Comparator|Garamicin group|the participants in this arm will undergo TURP with addition of one ampoule of gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
89254538|NCT06168708|Placebo Comparator|control group|the participants in this arm will undergo TURP with addition of normal saline (2 ml) on the irrigation solution (placebo).
89254539|NCT06168682|Experimental|nasal continuous positive airway pressure|nasal continuous positive airway pressure (3-10cmH20) administered with 6 l/O2 with the SuperNO2VA™ Et produced by Vyaire Medical, Inc.
89254540|NCT06168682|Active Comparator|nasal oxygen insufflation|nasal oxygen insufflation with 6 l/02 will be administered as control-group/standard intervention for endoscopy
89254541|NCT06168669|Other|Singel arm|All patients will be treated with the investigational device.
89254542|NCT06168656|Experimental|Experimental|The experimental group will use a mobile application intervention developed for expectant fathers.
89254543|NCT06168656|No Intervention|No Intervention|Control group receive routine care.
89254544|NCT06168643|Experimental|Core stability|
89254545|NCT06168643|Experimental|Core stability with pregnancy support belt|
89254546|NCT06168630|Experimental|Manual Lymph Drainage|
89254547|NCT06168630|Other|Control group|
89254548|NCT06168591||ELDERLY|MIDDLE-AGED and OLD individuals of both sexes will be recruited. The stratification into ACTIVE and SEDENTARY will be done according to current public health guidelines
89254549|NCT06168552|Experimental|Arm A|The patient underwent Da Vinci robot or fluorescent laparoscopic-assisted radical resection of pancreatic cancer. The day before the operation, anti-EGFR antibody-IR800CW imaging agent was injected into the vein, and the fluorescence test was performed to evaluate the imaging of the primary lesions of the pancreas and the intra-abdominal lymph nodes. And to evaluate for the presence of imaging lesions in the liver, peritoneum, pelvic cavity, etc.
89254550|NCT06168526|Experimental|Acute physical activity|The participants in the experimental activity groups will perform an interval physical activity of different intensity for 16 minutes. The intensity will be controlled during the test by the monitorization of their heart rate using a heart rate monitor. Subsequently, participants will perform an active break in the classroom after finishing one of their usual theory sessions at the intensity of physical activity that proves to have the greatest benefits for cognition and well-being.
89254551|NCT06168513||Case group|The inclusion criteria for this study encompassed fecal specimens obtained from patients with a documented history of tumor, specifically those who received their primary or initial tumor diagnosis at our hospital.
89254552|NCT06168513||Healthy control|(1) Individuals who were in good health, devoid of evident diseases, and possessed normal physical examination reports; (2) Individuals who had not experienced significant chronic illnesses, such as hypertension, diabetes, chronic kidney disease, etc., in recent years, in order to exclude those who had been unwell but had normal physical examination reports; (3) Age and gender were matched with the case group.
89254553|NCT06168500|Experimental|Test Group|
89254554|NCT06168500|Experimental|Control group|
89254555|NCT06168487|Experimental|Cohort 1: Telmisartan Alone|Patients will receive telmisartan alone.
89254556|NCT06168487|Experimental|Cohort 2: Telmisartan + Standard of Care Regimen|Patients will receive telmisartan with cabazitaxel or docetaxel without abiraterone), or telmisartan with docetaxal with abirateron or olaparib or rucaparib, or talazoparib plus enzalutamide.
89254557|NCT06168474|Experimental|Simplified layered consent process|For participants randomized to the SIMPLY-SNAP experimental group, a simplified layered consent process will be used to explain information for the SNAP trial. The research staff member obtaining consent will provide a standardized explanation, providing summarized information in simple English or French contained in a 4-page concise participant information sheet. Throughout the consent process, the research staff member will answer any questions that the participant has, to reflect routine consent discussion practice.
89254558|NCT06168474|Active Comparator|Full-length consent form|For participants randomized to the control group, the existing consent process will be used including going through the currently approved full-length informed consent form. The research staff member will provide an explanation using the full-length informed consent form as per standard clinical trial procedures. Similarly, throughout the consent process, the research staff member will answer any participant questions as per normal procedures.
89254559|NCT06168461|Placebo Comparator|placebo|placebo pill taken once daily at bedtime for 12 weeks
89254560|NCT06168461|Experimental|aspirin|162mg aspirin taken once daily at bedtime for 12 weeks
89254561|NCT06168448||Group 1 : Patients with oral and written information|"Group made up of patients hospitalized at that time in the infectious diseases department who met the eligibility criteria set out in the protocol.~This group of patients will receive the legal oral and written information concerning the additional examination prescribed, as usually delivered by their doctor."
89254562|NCT06168448||Group 2 : Patients with oral and written information + video information|"Group made up of patients hospitalized at that time in the infectious diseases department who met the eligibility criteria set out in the protocol.~This group of patients will receive the legal oral and written information concerning the additional examination prescribed, as usually delivered by their physician, and in addition the video tool will be applied to them."
89254563|NCT06168448||Group 3 : Caregivers|"Nurses and physicians working in the infectious and tropical diseases department.~This group of caregivers will assess the impact of the intervention on their practice."
89254564|NCT06168435|No Intervention|Pre-implementation|Outcomes collected in patient populations prior to roll-out of the eIMPAQc
89254565|NCT06168435|Experimental|Post-implementation|Outcomes collected in patient populations after roll-out of eIMPAQc
89254566|NCT06168422||DES Group|All lesions in these patients were treated with DES
89254567|NCT06168422||DES+DCB Group|These patients were treated using a combination of DES and DCB
89254568|NCT06168422||DCB Group|All lesions in these patients were treated with DCB
89254569|NCT06168409|Experimental|2 mg baxdrostat|2 mg baxdrostat administered orally, once daily (QD).
89254570|NCT06168409|Placebo Comparator|Placebo|Placebo administered orally, once daily (QD)
89254571|NCT06168370|Experimental|CT guided strategy|The intervention group will undergo CT scan after 3 months. If subclinical valve thrombosis is detected, anticoagulation will be started. If no subclinical valve thrombosis is detected, the SAPT is stopped, unless another indication is present.
89254572|NCT06168370|No Intervention|Standard care|Standard of care with lifelong SAPT after TAVI
89254573|NCT06168344|Experimental|Intervention Group|Mothers were assigned to groups by simple randomization method. The website was designed, mothers were given their usernames and passwords and their memberships were created. Pretests (Parent-Baby Introductory Information Form, Quality of Life Scale and Generalized Perceived Self-Efficacy Scale) were administered via the website. Mothers completed the modules in the web-based training program within four weeks. Four weeks later, posttests (Quality of Life Scale and Generalized Perceived Self-Efficacy Scale) were administered via the website.
89254574|NCT06168344|No Intervention|Control Group|Mothers' usernames and passwords were created and website memberships were made. Pretests (Parent-Baby Introductory Information Form, Quality of Life Scale and Generalized Perceived Self-Efficacy Scale) were applied. Website use by mothers in the control group was restricted and access to web-based educational content was closed to all mothers in this group. The mothers in the control group were applied the hospital outpatient clinic routine without any intervention. Four weeks later, posttests (Quality of Life Scale and Generalized Perceived Self-Efficacy Scale) were administered via the website. Pre-test and post-tests of mothers in the control group were collected via the website. After the research data was collected, a web-based training program was opened to the mothers in the control group and they were allowed to benefit from the training content.
89254575|NCT06168292|Experimental|Experimental|The clinical study will be conducted in the following order. Of patients with extrahepatic cholangiocarcinoma requiring biliary drainage, those who meet the inclusion criteria and consent to the study will be enrolled in the study and hospitalized to undergo endoscopic biliary drainage. The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
89254576|NCT06168279|Active Comparator|conventional group|hand occlusal articulation
89254577|NCT06168279|Active Comparator|study group|digital occlusal articulation
89254578|NCT06168227||Observational Group|Patients receive RC48
89254579|NCT06168201||Treated Individuals|Treated individuals with Achondroplasia. This is an observational study.
89254580|NCT06168201||Untreated Individuals|Untreated individuals with Achondroplasia. This is an observational study.
89254581|NCT06168188|Experimental|Neulasta|The 0.15 mL of Neulasta will be filled into 1 mL of syringe equipped with 30 gauge beveled needle for intravitreal injection.
89254582|NCT06168175|Experimental|Lactate|
89254583|NCT06168175|Placebo Comparator|Placebo|
89254584|NCT06168162|Experimental|titrate PEEP|individulaized PEEP starting 7cmH2O titrated to best static compliance (Cstat) ranging from 50 -100 cmH2O
89254585|NCT06168162|Active Comparator|standard|standard PEEP of 5 cmH2O
89254586|NCT06168149||Neonates with respiratory distress syndrome|A total of 80 patients with no systemic maternal disease findings and diagnoses, without chronic drug use, who were measured at least 24 hours after antenatal corticosteroids were administered during pregnancy, and whose delivery occurred within a maximum of 72 hours, will be included in our study as two case groups with and without RDS diagnosis in neonatal follow-up.
89254587|NCT06168149||Neonates who do not develop respiratory distress syndrome|A total of 80 patients with no systemic maternal disease findings and diagnoses, without chronic drug use, who were measured at least 24 hours after antenatal corticosteroids were administered during pregnancy, and whose delivery occurred within a maximum of 72 hours, will be included in our study as two case groups with and without RDS diagnosis in neonatal follow-up.
89254588|NCT06168136|Other|Intervention|Group A: included (42) patients who will receive high protein intake (target: 1.8 g protein/kg body weight /d).
89254589|NCT06168136|Other|Control|Group B: included (42) patients who will receive Standard of nutrition Care: (target: 1.2 g protein/kg body weight /d)
89254590|NCT06168110|Active Comparator|TENS|
89254591|NCT06168110|Sham Comparator|Sham TENS|
89254592|NCT06168097|Experimental|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis|"We Will take Both blood and tissue samples used to study them.~We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
89254593|NCT06168097|No Intervention|100 women undergoing surgery for gynaecological disorders other than endometriosis or adenomyosis|". We Will take Both blood and tissue samples used to study them. 2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3.Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
89254594|NCT06168084|Experimental|Vonorazon and amoxicillin dual therapy|Vonorazon 20 mg daily for 14 days # amoxicillin 1000 mg by mouth three time daily for 14 days
89254595|NCT06168084|Active Comparator|Bismuth-containing quadruple therapy|Tetracycline 500mg three time daily for 14 days#furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
89254596|NCT06168071|Experimental|taVNS with EEG in healthy children|The investigators will enroll 10 children between 7-18 years of age who are admitted to the hospital for EEG monitoring for spell characterization to receive one session of 30 minutes of taVNS. The investigators will titrate taVNS to below perceptual threshold of stimulation and objectively assess tolerability. The following parameters will be used for taVNS: frequency 25 Hz, pulse width 250 µs, and varying intensities from 0.5 milliampere (mA) to 2 mA. Intensity will be titrated to be a level below perceptual threshold in a patient. The participant will have continuous cardiorespiratory monitoring via pulse oximetry and blood pressure every 5 minutes. EEG data will be compared before, during and after taVNS.
89254597|NCT06168032|Experimental|Vaccinated group|Any booster doses(without limitations in the subtypes or brands of the vaccines) recommended or approved by Chinese government will be administered once in the 6th months after latest confirmed COVID-19 infection and during the following 6 months, any conditions including repeated COVID19 infection, critical and/or severe conditions and all-cause death will be recorded.
89254598|NCT06168032|No Intervention|Non-vaccinated group|Patients unwilling to get vaccination will be allocated into these group, but any events including recurrent COVID19 infection, critical and/or severe conditions and all-cause death will be recorded in the following six months.
89254599|NCT06167967|Experimental|ctDNA-guided group|ctDNA-negative group in the high-risk cohort were treated with XELOX regimen for 6 months; ctDNA-positive group in the high-risk cohort was treated with cmFOLFOXIRI regimen for 6 months; ctDNA-positive group in the low-risk cohort were treated with XELOX regimen for 3 months; ctDNA-negative group in the low-risk cohort did not receive adjuvant chemotherapy.
89254600|NCT06167967|Active Comparator|standard treatment group|The standard treatment group in the high-risk cohort were treated with XELOX regimen for 6 months, and in the low-risk cohort were treated with XELOX regimen for 3 months.
89254601|NCT06167941||lung cancer|adenocarcinoma and squamous carcinoma
89254602|NCT06167902|Experimental|Ginseng oligopeptide group|
89254603|NCT06167902|Placebo Comparator|The placebo group|
89254604|NCT06167889||Retrospective cohort based on Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform|A retrospective cohort based on Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform is conducted to collect data and to explore the gender differences and influencing factors of disability and cognitive impairment among the elderly.
89254605|NCT06167889||Retrospective cohort from CLHLS|The data from the China Longitudinal Healthy Longevity Survey (CLHLS) was used to further validate the results.
89254606|NCT06167863||WHO ISUP grading high|high-grade refer to Grades 3 and 4 tumours with an unfavourable prognosis
89254607|NCT06167863||WHO ISUP grading low|low-grade refer to Grades 1 and 2 tumours with a promising prognosis
89254608|NCT06167850|Experimental|Intervention group|Group doing the Copenhagen plank
89254609|NCT06167850|No Intervention|Control group|Group doesn't do Copenhagen plank
89254610|NCT06167837|Experimental|Metoclopramide group|Metoclopramide 10 mg +NSS 10ml IV 30-60 min before EGD
89254611|NCT06167837|Placebo Comparator|Placebo group|NSS 10 ml IV 30-60 min before EGD
89254612|NCT06162494|Experimental|Recombinant Zoster Vaccine Administration and Testing|all participants will receive 2 doses of recombinant zoster vaccine (Shingrix)
89254613|NCT06162000|Experimental|intervention group of nursing students|The group that will use the developed software in case studies
89254614|NCT06162000|No Intervention|Control Group of nursing students|Group that will prepare case studies on paper
89254615|NCT06160336|Experimental|TENS group|
89254616|NCT06160258|Experimental|Ready-to-Eat condition|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat condition for reheating and consumption at home.
89254617|NCT06160258|Experimental|Dried condition|Participants will be provided with whole grains of barley, buckwheat, and quinoa in the dried, bulk condition for home cooking and consumption.
89254618|NCT06159478|Experimental|Binimetinib|
89254619|NCT06159387|Experimental|Cannabis extract|Thirty patients will receive cannabis extract (total daily dose) 384 mg of CBD and 11.4 mg of THC divided into one intake in the morning (1 mL of oily solution - 192 mg of CBD and 5.7 mg of THC) and one intake in the evening ( 1 mL of oily solution - 192 mg of CBD and 5.7 mg of THC) during breakfast and dinner and psychotherapy.
89254620|NCT06159387|Placebo Comparator|Placebo|The other 30 subjects will receive placebo (same volumes of oily solution without active ingredient) and psychotherapy. Titration will be done with an initial dose of 1 mL taken at night and increased over 2 days to 1 mL morning and night. Patients using placebo will make similar increments to maintain the blind nature of the study.
89254621|NCT06159374|No Intervention|Control|Control group
89254622|NCT06159374|Experimental|normoxia-thermoneutral|Training performed under normoxia (200 m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%);
89254623|NCT06159374|Experimental|hypoxia-thermoneutral|Training performed under normobaric hypoxia (3000 m above sea level) and thermoneutral conditions (21°C) and constant humidity (40%);
89254624|NCT06159374|Experimental|normoxia-heat|training performed under normoxia (200 m above sea level) and high ambient temperature (31°C) and constant humidity (40%);
89254625|NCT06159374|Experimental|hypoxia-heat|training performed under normobaric hypoxia (3,000 m above sea level) and high ambient temperature (31°C) and constant humidity (40%);
89254626|NCT06159374|Experimental|normoxia-cold|Training performed in normoxia (200 m above sea level) and low ambient temperature (-11°C) and constant humidity (40%).
89254627|NCT06159374|Experimental|hypoxia-cold|training performed under normobaric hypoxia (3,000 m above sea level) and low ambient temperature (-11°C) and constant humidity (40%);
89254628|NCT06159374|Experimental|hypoxia-heat-humidity|training performed under normobaric hypoxia (3,000 m above sea level) and high ambient temperature (31°C) and high humidity (70%);
89254629|NCT06159309||Long Covid patients|All post-COVID patients that are referred for hyperbaric oxygen (and that are eligible for treatment)
89254630|NCT06158503||AID initiation|"The participants will be selected on the basis that they are planning to start using one of the commercially available AID.~They will start treatment after the initial measurements (baseline), then repeat the measurements at 2 and 4 months post-AID."
89254631|NCT06158490|Experimental|Group A|Drug：JYP0061 oral, once daily（QD）
89254632|NCT06158490|Experimental|Group B|Drug：JYP0061 oral, once daily（QD）
89254633|NCT06158490|Placebo Comparator|Group C|Placebo：JYP0061 oral, once daily（QD）
89254634|NCT06158477|Experimental|JYP0035 monotherapy dose-escalation group|PART-1 Single Dose Escalation Group
89254635|NCT06158477|Experimental|JYP0035 monotherapy dose-expansion group|PART-2 JYP0035 Monotherapy Dose Expansion Group
89254636|NCT06156215|Experimental|PROBOOSTVAXED Intervention M (Messaging + Vaccine Question)|"Vaccine messaging~Vaccine acceptance question All patients will receive an Intake Survey assessing their demographic and vaccination information.~At the end of the Intake Survey, the Clinical Research Coordinator (CRC) will deliver the booster vaccine information flyer and ask the patient if they will watch a short video on booster vaccines. If they agree, the CRC will give them a QR code to view the video on their smartphone or an iPad. After finishing with the video, the CRC will tell the subject that they will be back for the Vaccine Acceptance survey. The CRC will then leave the room and ask the patient's primary provider to deliver the booster vaccine scripted message. This message is short and should not significantly impact provider workflow.~Vaccine Acceptance Survey (Post-Intervention) in the ED: We will administer the Vaccine Acceptance Survey at 30 minutes to 3 hours after the Intake Survey."
89254637|NCT06156215|Active Comparator|Intervention Q (Vaccine Question, No Messaging)|"No vaccine messaging~Vaccine acceptance question asked in the Vaccine Acceptance Survey~Vaccine Acceptance Survey: We will administer the Vaccine Acceptance Survey at some time (generally 30 minutes but up to 3 hours) after the Intake Survey. The surveys in the control group retain the same key primary and secondary outcome questions as in the intervention group Vaccine Acceptance surveys."
89254638|NCT06156215|No Intervention|Control (No Messaging, No Vaccine Question)|"No vaccine messaging~No vaccine acceptance question~The workflow during this arm is identical to the Intervention Q arm except there will be no Vaccine Acceptance Question survey."
89254639|NCT06154083|Experimental|Follitropin-delta 20 mcg/day from D1|
89254640|NCT06154083|Active Comparator|Follitropin-delta 15 mcg/day from D1|
89254641|NCT06153550||Patients who have sternotomy|Patients who have sternotomy wll be included. They will have preparation in Respiratory Physiotherapy before sternotomy.
89254642|NCT06153498|Experimental|Normal renal function group|
89254643|NCT06153498|Experimental|Renal injury group|
89254644|NCT06152497|Placebo Comparator|1: Placebo|Lactose
89254645|NCT06152497|Experimental|H1 blockade: Telfast (180mg Fexofenadine)|H1: Telfast (180mg Fexofenadine)
89254646|NCT06152120|Experimental|ACP Intervention arm|The group which will participate in nurse-facilitated advance care planning intervention.
89254647|NCT06152120|No Intervention|Usual care arm|The group which will not participate in nurse-facilitated advance care planning intervention.
89254648|NCT06149377||Training cohort|Patients (n=386) who accepted neoadjuvant systemic therapy followed surgery were from fujian medical university union hospital from April 1, 2012, to May 30, 2022.
89254649|NCT06149377||External validation cohort|Patients (n=211) who accepted neoadjuvant systemic therapy followed surgery were from Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University and No. 900 Hospital of The Joint Logistic Support Force from April 1, 2012, to May 30, 2022.
89254650|NCT06149377||Test cohort|Patients (n=119) who accepted sentinel lymph node biopsy followed axillary lymph node dissection after neoadjuvant systemic therapy was retrospectively collected from June 1,2022 to May 31, 2023.
89254651|NCT06145763|Experimental|Arm I (iCanQuit app)|Participants use the iCanQuit app, which includes setting up a personalized quit plan, participating in eight levels of the content, receiving on-demand help in coping with smoking urges, and tracking their daily smoking behaviors for at least 45 days on study.
89254652|NCT06145763|Active Comparator|Arm II (NCI QuitGuide app)|Participants use the NCI QuitGuide app for at least 45 days on study.
89254653|NCT06142890|Active Comparator|No cooling intervention (control)|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
89254654|NCT06142890|Experimental|Ceiling fan generating airflow|Adults aged 65-85 years with or without type 2 diabetes and/or hypertension
89254655|NCT06142396|Experimental|Dara-CyBorD|Induction treatment with daratumumab-hyaluronidase (dara SC) in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles of 28 days, followed by restaging with repeat PET-CT, bone marrow evaluation, and myeloma serological testing.
89254656|NCT06139588||POST QUART NATIVE|Native adm used in the setting of mastectomy and implant reconstruction after QUART
89254657|NCT06139588||POST QUART VERITAS|Veritas adm used in the setting of mastectomy and implant reconstruction after QUART
89254658|NCT06139588||POST EXPANDER NATIVE|Native adm used in the setting of expander removal and implant positioning after mastectomy + RT
89254659|NCT06139588||POST EXPANDER VERITAS|Veritas adm used in the setting of expander removal and implant positioning after mastectomy + RT
89254660|NCT06139588||IMPLANT EXCHANGE NATIVE|Native adm used in the setting of implant exchange after mastectomy + RT
89254661|NCT06139588||IMPLANT EXCHANGE VERITAS|Veritas adm used in the setting of implant exchange after mastectomy + RT
89254662|NCT06139588||IMPANT EXCHANGE AFTER QUART NATIVE|Native adm used in the setting of implant exchange after QUART+ Mastectomy and implant reconstruction
89254663|NCT06139588||IMPLANT EXCHANGE AFTER QUART VERITAS|Veritas adm used in the setting of implant exchange after QUART+ Mastectomy and implant reconstruction
89254664|NCT06135870||Women with fibroids undergoing elective hysterectomy or myomectomy|Women between the age of 18-55 with fibroids undergoing elective hysterectomy or myomectomy
89254665|NCT06123741|Experimental|Parental Guidance+Virtual Reality Game|
89254666|NCT06123741|Experimental|Parental Guidance|
89254667|NCT06123741|Experimental|Virtual Reality Game|
89254668|NCT06123741|No Intervention|Control Group|This group implement the rehabilitation plan drawn up in specialized medical care (treatment as usual).
89254669|NCT06119555|Experimental|Cinnamon Group|In the cinnamon group, participants will consume four cinnamon capsules daily for 60 days (each 1.5 grams, totaling 3 grams), two with breakfast and two with dinner.
89254670|NCT06119555|No Intervention|Control Group|The control group will not receive intervention.
89254671|NCT06111339|Experimental|Ketamine|This arm will receive ketamine (n=25)
89254672|NCT06111339|Placebo Comparator|Saline Placebo|This arm will receive the saline placebo (n=25)
89254673|NCT06103513|Active Comparator|Arm 1: Growth hormone 0.2 mg/kg/week|Twenty-five subjects will initiate rhGH therapy at 0.2 mg/kg/week for the first 12 months of treatment
89254674|NCT06103513|Active Comparator|Arm 2: Growth hormone 0.3 mg/kg/week|Twenty-five subjects will initiate rhGH therapy at 0.3 mg/kg/week for the first 12 months of treatment
89254675|NCT06100068|Active Comparator|Standard L-DIBH|Starts with 2 sessions of normal L-DIBH followed by 2 sessions of L-DIBH combined with mental exercises.
89254676|NCT06100068|Experimental|Intervention L-DIBH|Starts with 2 sessions of of L-DIBH combined with mental exercises followed by 2 sessions of normal L-DIBH.
89254677|NCT06099171|Experimental|Oxygen-Ozone Therapy plus Cannabidiol and ß-Caryophyllene Patch|"The patients will undergo 8 session of oxygen-ozone therapy, 2 per week. In each session 10 cc of a gaseous mixture of oxygen-ozone (at a concentration of 10 μg of ozone per ml of oxygen) will be injected with 6 paravertebral injections.~For the fisrt 2 weeks of oxygen-ozone therapy patients will be asked to apply patches with local action based on Cannabidiol and ß-Caryophyllene for 8-24 hours/day for 5 days/week."
89254678|NCT06099171|Active Comparator|Oxygen-Ozone Therapy|The patients will undergo 8 session of oxygen-ozone therapy, 2 per week. In each session 10 cc of a gaseous mixture of oxygen-ozone (at a concentration of 10 μg of ozone per ml of oxygen) will be injected with 6 paravertebral injections.
89290352|NCT01124136|Other|Standard of Care (Control)|Standard of Care treatment is medication management only. Heart failure medications control symptoms and comorbidities, i.e. blood thinners, lipid lowering, and diuretics, and manage heart function, i.e. heart rhythm, rate, and pumping strength.
89254681|NCT06089187|Active Comparator|Saline Group|Anesthesia machine's APL valve will be adjusted to a pressure of 20 cmH20, and during ventilation with a balloon, the endotracheal tube cuffs will be inflated with saline in such a way that there will be no leakage sound from the patient's mouth.
89254682|NCT06089187|Placebo Comparator|Air Group|Anesthesia machine's APL valve will be adjusted to a pressure of 20 cmH20, and during ventilation with a balloon, the endotracheal tube cuffs will be inflated with air in such a way that there will be no leakage sound from the patient's mouth.
89254683|NCT06086899|Experimental|Cervical motion style acupuncture treatment(Trapezius, Rhomboid, Scalene)|"The MSAT group recieved 3 sessions of MSAT; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience conducted the MSAT.~The MSAT group were also treated with other Korean medical treatment everyday: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine."
89254684|NCT06086899|Active Comparator|Korean medical treatment|The control group were received Korean medical treatment everyday after hospitalization: acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
89254685|NCT06086756|Experimental|Positive Mood Induction via positive film clips|"The standardized procedures outlined in our laboratory's previously conducted study (Stathopoulou, Pollack, & Otto, 2018) will be followed. Participants will be presented with two brief film clips on a computer monitor or TV screen. These film clips were selected to elicit positive affect. As utilized in past lab study procedures, participants will be asked to: Let yourself experience whatever emotions you have, as fully as you can. Don't try to hold back, or hold in, your feelings (Stathopoulou, Pollack, & Otto, 2018). Together, the two film clips will last for approximately 5 minutes."
89254686|NCT06086756|Experimental|Negative Mood Induction via negative film clips|"The standardized procedures outlined in our laboratory's previously conducted study (Stathopoulou, Pollack, & Otto, 2018) will be followed. Participants will be presented with two brief film clips on a computer monitor or TV screen. These film clips were selected to elicit negative affect. As utilized in past lab study procedures, participants will be asked to: Let yourself experience whatever emotions you have, as fully as you can. Don't try to hold back, or hold in, your feelings (Stathopoulou, Pollack, & Otto, 2018). Together, the two film clips will last for approximately 5 minutes."
89254687|NCT06084663|Experimental|Apremilast 30 mg Tablets|One tablet was administered orally to each subject as per randomization schedule in each period
89254688|NCT06084663|Active Comparator|Otezla 30 mg film-coated tablets|One tablet was administered orally to each subject as per randomization schedule in each period
89254689|NCT06083844|Experimental|Pembrolizumab in Combination with Bevacizumab and Oral Cyclophosphamide|"Participants will begin receiving the study drug Pembrolizumab in Combination with Bevacizumab and Oral Cyclophosphamide.~Each study cycle is 21 days."
89254690|NCT06063330|Experimental|Low Dose of RQ-01|Subjects in this arm will receive 5 mg per day (for 3 days) of RQ-01
89254691|NCT06063330|Experimental|High Dose of RQ-01|Subjects in this arm will receive 10 mg per day (for 3 days) of RQ-01
89254692|NCT06063330|Placebo Comparator|Placebo|Subjects in this arm will receive 0 mg per day (for 3 days) of RQ-01
89254693|NCT06060418|Experimental|Intervention Group|After deciding on the participant of the intervention group the researcher will start the protocol of intervention The researcher will soak a 4×4 cm sterile gauze pad with 0.2 ml equivalent to 2 drops of 10% Lavender essential oil and will suspend the soaked gauze at a distance of 10cm from the patient's nose with the help of forceps, and he or she will have asked to inhale its scent for 5 min. 15 and 40 minutes after the beginning of the aromatherapy treatment, the researcher will measure the nausea and vomiting scores by using the standardized tool. During this entire 40 minutes, the researcher will strictly monitor the participant's condition. If the nausea score is still higher than 1 or the vomiting persists the participants will be noted as failure of treatment and move to standard care.
89254694|NCT06060418|No Intervention|Control group|The control group received standard care against the complain of nausea and vomiting.
89290353|NCT04674436|Experimental|6 minute walking break|Participants will walk casually for 6 minutes following one hour of game play, then continue play for one more hour.
89290354|NCT04674436|Experimental|6 minute rest break|Participants will rest supine for 6 minutes following one hour of game play, then continue play for one more hour.
88804876|NCT01296841|No Intervention|Standard encounter|"Standard in-house clinical visit between patient and physician."
88804877|NCT01296841|Experimental|Telemedicine Encounter|Remote clinical appointment between patient and physician.
88804878|NCT01349491|Experimental|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
89254695|NCT06057129|Experimental|Unsupervised therapy|This group will perform therapy with the ReHandyBot first with the supervision of a therapist at the rehabilitation clinic. Then, after discharge, if the participant learnt how to safely train with the device, they can bring the device home and train with it unsupervised. On the other hand, if participants are not capable of training without supervision, after discharge they perform unsupervised therapy at home with a booklet of exercises (i.e., without the robot).
89254696|NCT06055803|Experimental|Health Behavior Program|Each participant will have an individualized assessment with plan and goals set at the program intake visit. Program components will include: Physical Activity, Nutrition, Emotional Well-being, Cardiovascular Risk, Survivorship, and other items individualized to the participant as needed (e.g., tobacco cessation). The 12-week program will alternate between group and individual sessions each week. Individualized plans will be reviewed every two weeks at the participant individual sessions.
89254697|NCT06047717|Experimental|Virtual Reality (VR) Driving Task: Cortically Blind Cohort|"Persons who have sustained cortical blindness will perform a driving task in VR, in which they must steer through a series of parameterized turns while maintaining their virtual vehicle centered between the two red lines delineating the road edge."
89254698|NCT06047717|Experimental|Virtual Reality (VR) Driving Task: Healthy Control Cohort|"Healthy controls with no vision loss will perform a driving task in VR, in which they must steer through a series of parameterized turns while maintaining their virtual vehicle centered between the two red lines delineating the road edge."
89254699|NCT06045650||Cases|Participants with borderline personality disorder who meet the inclusion criteria
89254700|NCT06045650||Controls|Participants without borderline personality disorder, who meet the inclusion criteria
89254701|NCT06044233|Experimental|TR group|Subjects in the TR group will take the test preparation (T) 200 mg/ pill × 1 pill on day 1 (D1) and the reference preparation (R) 200 mg/ pill × 1 pill on day 8 (D8).
89254702|NCT06044233|Experimental|RT group|Subjects in the RT group will take the reference preparation (R) 200 mg/ pill × 1 pill on day 1 (D1) and the test preparation (T) 200 mg/ pill × 1 pill on day 8 (D8).
89254703|NCT06043297|Experimental|Apixaban 5 mg Film Tablets|
89254704|NCT06043297|Active Comparator|Eliquis 5 mg Film tablets|
89254705|NCT06038916|Placebo Comparator|Placebo group|Patients in this group will receive basal treatment and placebo.
89254706|NCT06038916|Experimental|Low dose group|Patients in this group will receive basal treatment and placebo+ low-dose STSA-1002.
89254707|NCT06038916|Experimental|High dose group|Patients in this group will receive basal treatment and High-dose STSA-1002.
89254708|NCT06034184|Experimental|Using Virtual Reality for training and learning mass casualty incidents|The nursing students use glasses and handcontrollers (High Fidelity Simulation) in the VR scenario for training and learning mass casualty incidents.
89254709|NCT06034184|No Intervention|Standard education and training|Standard education, including lectures and paper exercises
89254710|NCT06031181|Experimental|Sublobar resection|Sublobar resection is performed for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section
89254711|NCT06028750|Active Comparator|Freehand|Nobel Replace Conical Connection® placed freehand
89254712|NCT06028750|Experimental|X-Guide guided surgery system (X-Nav Technologies®, Pennsylvania, USA)|Nobel Replace Conical Connection® placed using the X-Guide guided surgery system (X-Nav Technologies®, Pennsylvania, USA)
89254713|NCT06027489|No Intervention|Control|Nursing students with dysmenorrhea in the control group were informed that drawing and listening to music practices would be performed after the initial, second and third month evaluations of the study. In the meantime, it was stated that he should not make any interventions other than her routine applications. At baseline, second, and third month, participants will measure pain, menstrual symptoms, and perceived stress on the first day of the menstrual cycle using the VAS, MSS, and PSS, respectively.
89254714|NCT06027489|Experimental|Music Group|In the second and third months, participants listened to a song that lasted 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song to be played was determined by examining the literature, the song was composed by researcher Juan Sebastian Martin-Saavedra and was named Occasio Adolore (Music Piece No. 5-559-355 and Phonogram No. 12-105-295) by the author copyright institution of Colombia. registered under. While the researcher is composing the song, it is to create a piece of music that will reduce the pain felt, activate positive emotions and relax the person. The composed song is available online within the scope of the published article (https://soundcloud.com/jss-martin/occasio-adolore) [21]. Written permission was obtained from Juan Sebastian Martin-Saavedra to use the composed song in the research. The access link of the composed song will be sent to the participants via social media (WhatsApp).
89254715|NCT06027489|Experimental|Drawing Group|In the second and third months, the participants will be asked to paint for 29 minutes and 32 seconds (the duration of the intervention was determined in parallel with the music group in order not to create variability between the groups) for four days (three days before menstruation and the first day of menstruation). The type of paint to be used in the drawn picture (dry pen, crayon or watercolor) is left to the availability of the participants, and it will be stated that they prefer colors and drawings that will raise their emotions, focus their drawings and feed positive emotions in the picture to be drawn. After drawing pictures three days before the menstrual cycle and the first day of menstruation (for a total of four days), pain, menstrual symptoms, and perceived stress on the first day of menstruation will be measured using the VAS, MSS, and PSS, respectively.
89254716|NCT06021054|Experimental|VRDN-001 10 mg/kg|Drug: 5 Infusions of VRDN-001 10 mg/kg
89254717|NCT06021054|Experimental|Placebo Drug|Placebo Drug: 5 Infusions of placebo
89254718|NCT06018792||Pediatric sepsis|Study participants aged 3 months - 18 years who undergo collection of blood for conventional blood culture
88804879|NCT01349491|Placebo Comparator|Placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.
89254719|NCT06018792||Late onset sepsis|Study participants aged up to 3 months who undergo culturing of blood for conventional blood culture Preterm infants aged <32 weeks gestational age as a subgroup
89254720|NCT06018792||Early onset sepsis|Study participants aged up to 3 days who undergo culturing of blood for conventional blood culture
89254721|NCT06018792||Post antibiotic initiation cohort|participants for whom venipuncture is performed for follow up of inflammatory parameters <36h after antibiotic initiation and blood draw for conventional culture or for whom a repeat intravenous catheterization is performed due to failing of a previous one <36h after antibiotic initiation and blood draw for conventional culture
89254722|NCT06017011||Acute charcot neuroarthropathy or Acute on Chronic charcot neuroarthropathy|Patients diagnosed with Acute charcot neuroarthropathy or Acute on Chronic charcot neuroarthropathy will be put on Total contact cast and followed till clinical remission and then after that till 6 months post clinical remission.
89254723|NCT06010966|Sham Comparator|sham group|receive sham itbs
89254724|NCT06010966|Active Comparator|low-dose group|receive low dose of itbs
89254725|NCT06010966|Active Comparator|high-dose group|receive high dose of itbs
89254726|NCT05993026|Experimental|Mental health course|A mental health-promoting student course offered to lower secondary school classes delivered by their teacher or another employee of the school. T
89254727|NCT05989737|Experimental|AEBT online program|Participants will complete the 8-module intervention of Acceptance-enhanced behavior therapy (AEBT). Acceptance-enhanced behavior therapy is a manualized treatment approach created by Woods and Twohig 2008 that provides both Acceptance and Commitment Therapy and Habit Reversal Therapy.
89254728|NCT05989737|No Intervention|Waitlist control|Waitlist condition; only assessment
89254729|NCT05984381|Active Comparator|Prednisolone and Methotrexate (Control Arm)|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) and Methotrexate 15 mg weekly for 16 weeks.
89254730|NCT05984381|Experimental|Prednisolone and Dapsone (Test Arm)|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) and Dapsone 100 mg/day for 16 weeks
89254731|NCT05978141||Participants with T-Cell Lymphoma|Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma
89254732|NCT05965011|Experimental|Intervention (Nordic walking)|"Nordic walking training. These coaching principles will focus on highlighting the participants' strengths and resourcefulness, setting goals, and utilizing solution-focused problem-solving techniques to achieve those goals during practice and related activities . This group sessions will be conducted biweekly to ensure appropriate progression and adherence to the guidelines set by the International Nordic Walking Federation.~In addition to the supervised group sessions, participants will also receive supervised NW training from a certified NW instructor. Participants will be encouraged to set goals and develop strategies to facilitate independent practice for at least three 30-minute sessions per week over a period of 10 weeks. These unsupervised sessions aim to encourage participants to engage in regular practice outside of the group sessions."
89254733|NCT05965011|No Intervention|Control (phone calls)|"The control group will receive regular contact to control for attention and maintain participant engagement throughout the study. Over the course of the 10 weeks, participants in this group will receive 5 biweekly phone calls from the study's graduate research assistant (RA).~During each phone call, the RA will engage in discussions with participants about leading a healthy lifestyle in general, covering topics such as proper nutrition and adequate sleep. Additionally, the RA will gather safety-related data, including information on any falls that may have occurred. The phone calls will also serve as reminders for participants about upcoming assessments and their importance in the study. The investigators will provide a training session to the control group following the completion of the study if they are interested."
89254734|NCT05962242|Experimental|Reduce Dose without Concurrent Chemotherapy Non- Rapid Responder|A reduced dose regimen of 24 Gy in 12 fractions to gross disease and intermediate nodes. Then 36 Gy in 18 fractions to entire volume. Non-responders will receive an additional boost of 10 Gy in 5 fractions to entire volume.
89254735|NCT05962242|Experimental|Reduce Dose with Concurrent Chemotherapy Non-Rapid Responder|A reduced dose regimen of 24 Gy in 12 fractions to gross disease and intermediate nodes. Then 30 Gy in 15 fractions to entire volume. Non-responders will receive an additional boost of 10 Gy in 5 fractions to entire volume.
89254736|NCT05962242|Experimental|Reduce Dose without Concurrent Chemotherapy Rapid Responder|A reduced dose regimen of 24 Gy in 12 fractions to gross disease and intermediate nodes. Then 36 Gy in 18 fractions to entire volume.
89254737|NCT05962242|Experimental|Reduce Dose with Concurrent Chemotherapy Rapid Responder|A reduced dose regimen of 24 Gy in 12 fractions to gross disease and intermediate nodes. Then 30 Gy in 15 fractions to entire volume.
89254738|NCT05961956|Experimental|NVDX3 osteogenic implant|
89254739|NCT05957211|Experimental|All participants|All participants will have a refrigerated 0.09% cyclosporine drop instilled in one eye, and a non-refrigerated 0.09% cyclosporine drop instilled in the other eye. The eye that receives the refrigerated drop is randomly determined.
89254740|NCT05951166|Experimental|PADN with Gradient Denervation System|
89254741|NCT05948462|Experimental|Lorlatinib and Platinum and Pemetrexed|Lorlatinib will be administered by mouth daily plus Pemetrexed by IV infusion every 3 weeks until progression or intolerable toxicity. Platinum-based standard of care chemotherapy by IV infusion will also be given every 3 weeks for the first 4 cycles; carboplatin or cisplatin are the platinum agents that may be selected based on physician discretion. One cycle is defined as 3 weeks.
89254742|NCT05945277|No Intervention|Control|
89254743|NCT05945277|Experimental|Intervention|
89254744|NCT05942638||Concussion Group|
89254745|NCT05942638||Control Group|
89254746|NCT05939999|Experimental|Elastic tape (ET)|The group that will participate in the 8 weeks pulmonary rehabilitation protocol using the elastic tape.
89254747|NCT05939999|Sham Comparator|Sham (SH)|The group that will participate in the pulmonary rehabilitation protocol using micropore tape.
89254748|NCT05934604|Experimental|Magnetic resonance imaging (MRI) group|Healthy volunteers will have two functional magnetic resonance imaging scans (localizer session and the real time functional magnetic resonance imaging neurofeedback session).
89254749|NCT05930886||Hispanic Community|15 adult parents/caregivers self-identified as Hispanic
89254750|NCT05930886||Black/African American Community|15 adult parents/caregivers self-identified as Black/African American
89254751|NCT05908292|Experimental|Episiotomy and Vaginal/Perineal Tear Self-Scar Massage|This Arm will be instructed in and perform self-scar massage to their pelvic floor scar tissue.
89254752|NCT05908292|No Intervention|Standard Postnatal Care|This Arm will not be instructed in or perform self-scar massage to their pelvic floor scar tissue.
89254753|NCT05906797|Experimental|Periodontitis|Subjects diagnosed with periodontitis according to the most recent international guidelines and without cardiovascular diseases.
89254754|NCT05906797|No Intervention|Healthy|Subjects without periodontitis and with good gingival health.
89254755|NCT05897541|Experimental|S-217622|S-217622 will be administered orally for 5 days.
89254756|NCT05897541|Placebo Comparator|Placebo|Placebo matching to S-217622 will be administered orally for 5 days.
89254757|NCT05888337||Contoura LASIK with Phorcides planning strategy|
89254758|NCT05888337||Contoura LASIK with manifest refraction planning strategy|
89254759|NCT05887544||Type 2 diabetes|Overall study population. In addition, a subset of volunteer participants (up to 20 participants) will be asked to consume extra portions of fermented dairy products (skyr, ymer and yogurt) 1-2 days before the spot urine sample to be able to validate markers for specific foods.
89254760|NCT05886244|Experimental|Eculizumab|Eculizumab will be administered by IV infusion.
89254761|NCT05876923|Experimental|Aim 1 (vitals, spirometry, CPET, blood samples, DEXA)|Participants undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study.
89254762|NCT05876923|Experimental|Aim 2 (aerobic based training program, Aim 1 activities)|CLL patients complete aerobic based training program on study. Patients then complete all Aim 1 activities again after completion of aerobic based training program.
89254763|NCT05876923|Active Comparator|Aims 3-4 arm I (indolent NHL usual care)|Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients receive usual care on study.
89254764|NCT05876923|Active Comparator|Aims 3-4 arm II (indolent NHL aerobic based training program)|Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients complete aerobic based training program on study. Patients then complete all baseline activities again after completion of aerobic based training program.
89254765|NCT05876923|Experimental|Aim 5 (repeat baseline activities)|All patients from Aims 3-4 will be invited to repeat Aims 3-4 baseline activities.
89254766|NCT05870566|Experimental|Corneal Crosslinking (CXL)|"The study intervention (CXL) will be administered to reduce CoNV 10 to 12 weeks prior to corneal transplantation. It will be repeated once if insufficient reduction of CoNV should be observed (i.e. there are still corneal neovessels present; to be decided by the respective surgeon). The second intervention will be applied 2 to 4 weeks after the first CXL and at least 4 weeks prior to transplantation).~Corneal transplantation will be performed as standard full-thickness penetrating procedure, and the graft (individualized size between 6.5 to 8.25 mm in diameter) will be secured with 16-24 interrupted single or double running 10-0 nylon sutures (decision by the surgeon).~In case of residual CoNV at the day of keratoplasty, fine needle diathermy will be performed using a 10/0 stainless steel needle."
89254767|NCT05870566|No Intervention|control group|Subjects will be directly scheduled for corneal transplantation without previous CXL. Corneal transplantation will be performed as standard full-thickness penetrating procedure, and the graft (individualized size between 6.5 to 8.25 mm in diameter) will be secured with 16-24 interrupted single or double running 10-0 nylon sutures (decision by the surgeon). In the control group, no fine needle diathermy will be performed, as this procedure combined with corneal transplantation in previously non-crosslinked eyes might lead to fistulas and thereby to potential intraocular infections.
89254768|NCT05862467|Experimental|Written Exposure Therapy|Behavioral therapy: Written Exposure Therapy via telehealth
89254769|NCT05854667|Placebo Comparator|Treatment as Usual plus Placebo|Participants will receive treatment as usual at the clinic as well as once daily lisdexamfetamine matched Placebo orally for 15 weeks.
89254770|NCT05854667|Placebo Comparator|Treatment as Usual plus Placebo plus Contingency Management|Participants will receive treatment as usual at the clinic, once daily lisdexamfetamine matched placebo medication orally for 15 weeks, as well as engagement-focused contingency management.
89254771|NCT05854667|Active Comparator|Treatment as Usual plus lisdexamfetamine (LDX-01)|Participants will receive treatment as usual at the clinic as well as once daily over-encapsulated lisdexamfetamine (LDX-01) orally for 15 weeks.
89254772|NCT05854667|Active Comparator|Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management|Participants will receive treatment as usual at the clinic, once daily over-encapsulated lisdexamfetamine (LDX-01) orally for 15 weeks, as well as engagement-focused contingency management.
89254773|NCT05848583|Experimental|Enteral Nutrition (EN) Formula|Enteral formula
89254774|NCT05841797|No Intervention|Standard of Care (SOC)|"Standard of Care (SOC): For Arm 1 of the pilot trial, SOC will be implemented. SOC for PWLWH in Kenya is carried out according Kenyan National Guidelines and includes integration of antenatal care, HIV care, and HIV-exposed infant follow up within the maternal-child health clinic through 18-24 months postpartum. Provision of ART, HIV education, and adherence counseling is routinely provided. Psychosocial support is provided by either peer educators or lay health workers. WLWH who miss visits are followed up by phone and then traced in the community to encourage return to care.~PWLWH undergo routine VL testing six months after ART initiation or at confirmation of pregnancy if already on ART. VLs are performed every six months through breastfeeding.~Women with VL 200 copies/ml undergo enhanced adherence counseling with repeat VL in three months. While routine screening for IPV and depression are recommended per National Guidelines, they are incompletely implemented."
89254775|NCT05841797|Experimental|In-Person Program Management Plus (PM+)|For Arm 2, the investigators will implement the adapted PM+ utilizing the complete manual of operations and adaptation lessons learned in the non-clinical trial portion of the study. The investigators will train mentor mothers to serve as PM+ Helpers. In-person sessions will likely be delivered at home. Sessions will continue after the birth if not completed during pregnancy. PM+ Helpers will debrief regularly on the progress of participants with clinically trained supervisors - both for their own psychological well-being and to ensure that participants receive adequate care.
89254776|NCT05841797|Experimental|Mobile Program Management Plus (mHealth PM+)|For Arm 3, the investigators will implement the adapted PM+ utilizing the complete manual of operations and adaptation lessons learned in the non-clinical trial portion of the study. The investigators will train mentor mothers to serve as PM+ Helpers. In the mHealth delivered version of PM+, PM+ Helpers will conduct PM+ virtually after an initial meeting to create rapport. Sessions will be delivered by either 1) a PM+ Helper- initiated phone call or 2) a participant-initiated call via a call-in help line. Airtime will be provided so that participation will be free of charge. Sessions will continue after the birth if not completed during pregnancy. PM+ Helpers will debrief regularly on the progress of participants with clinically trained supervisors - both for their own psychological well-being and to ensure that participants receive adequate care.
89254777|NCT05829356|Experimental|Group 1: H3 mRNA /LNP dose 1|Participants will receive one intramuscular (IM) dose of H3 mRNA/LNP at Day 01
89254778|NCT05829356|Experimental|Group 2: H3 mRNA /LNP dose 2|Participants will receive one IM dose of H3 mRNA/LNP at Day 01
89254779|NCT05829356|Experimental|Group 3: H3 mRNA /LNP dose 3|Participants will receive one IM dose of H3 mRNA/LNP at Day 01
89254780|NCT05829356|Experimental|Group 4: H3 mRNA /LNP dose 4|Participants will receive one IM dose of H3 mRNA/LNP at Day 01
89254781|NCT05829356|Experimental|Group 5: H3 mRNA /LNP dose 5|Participants will receive one IM dose of H3 mRNA/LNP at Day 01
89254782|NCT05829356|Active Comparator|Group 6 (Control Group): RIV4 dose|Participants will receive one IM dose of RIV4 at Day 01
89254783|NCT05826054|Experimental|Intervention|In this study, participants will receive increasing dosages of the Study Treatment (Montbretin A, MbA) at each treatment visit. The Study Treatment will be taken with a standardized meal (a meal that has specified quantities of carbohydrates, fats and proteins). At each visit, participants will receive one dose (in pill form) of MbA. As long as they are not experiencing any side effects, this dose will be gradually increased at each study visit (starting from 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, to 300 mg MbA).
89254784|NCT05825105|Experimental|PRP-1|Platelet-rich plasma, short treatment (three sessions every two weeks)
89254785|NCT05825105|Active Comparator|PRP-2|Platelet-rich plasma, long treatment (three sessions every four weeks)
89254786|NCT05820685|Active Comparator|Treatment Strategy #1|
89254787|NCT05820685|Experimental|Treatment Strategy #2|
89254788|NCT05812664|Experimental|bolus feeding group|bolus feeding method;The amount of food to be given for 24 hours calculated for the patient was given as 4 equal amounts for 40 minutes at 4 different times. Starting with 150 cc, the target calorie was reached by increasing 100 cc according to the intolerance before the next feeding hour.
89254789|NCT05812664|Experimental|intermittent feeding group|The formula was started as 40 cc/h continuous infusion. It was interrupted after 5 hours. 30 minutes after the break, PGD was measured and intolerance was checked, and if the residue was negative, it was increased by 40 cc. The amount was increased until reaching the amount of formula that should be given for 24 hours calculated for the patient. This cycle was repeated 3 times in 24 hours. At 24:00, it was stopped and feeding was interrupted between 24:00 and 06:00.
89254790|NCT05812664|Active Comparator|continous feeding group|The same method was applied as in Group 2. However, after 24:00, feeding was not interrupted and continued as the 4th cycle.
89254791|NCT05812352|Experimental|"Audio recording and instructional flashcard with tourniquet (audio kit) - 6 month follow-up"|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application, used for tourniquet application attempt. Participants repeat the tourniquet application attempt with the audio kit at 6 month follow-up
89254792|NCT05812352|Experimental|Instructional flashcard with tourniquet - 6 month follow-up|Instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application, used for tourniquet application attempt. Participants repeat the tourniquet application attempt with the instructional flashcard at 6 month follow-up
89254793|NCT05812352|Experimental|In-person training with tourniquet - 6 month follow-up|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt. Participants repeat the tourniquet application attempt without any POC instruction or re-training at 6 month follow-up
89254794|NCT05812352|No Intervention|Control group with no in-person training and no point-of-care instruction access - 6 month follow-up|There is no in-person training or point-of-care (POC) instructional interventions for this group for tourniquet application attempt. Participants repeat the tourniquet application attempt without any in-person training or POC instructional interventions at 6 month follow-up
89254795|NCT05798611|Experimental|Arm 1 [ART0380 monotherapy (endometrial cancer patients)]|Patients with persistent or recurrent endometrial cancer (EC) will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle.
89254796|NCT05798611|Experimental|Arm 2 [ART0380 monotherapy (solid tumors patients)]|Patients with advanced or metastatic solid tumors will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle.
89254797|NCT05783167||HIV-positive females in Guinea-Bissau|"The study is conducted on female HIV-infected patients in the Nationwide HIV-cohort at the 9 biggest HIV-clinics in Guinea-Bissau.~Participants will be invited to enroll in the project when they present to the HIV-clinics for HIV-treatment and consultations."
89254798|NCT05779163|Experimental|LBL-033|LBL-033 for Injection; Initial dose - MTD; Q2W
89254799|NCT05776862|Experimental|UA and exercise in paraplegia group|Participants will take UA 4 capsules twice daily for 12 weeks while participating in an exercise program, 3 times per week.
89254800|NCT05776862|Experimental|UA in tetraplegia group|Participants will take UA 4 capsules twice daily for 12 weeks
89290355|NCT04674436|No Intervention|Continuous play|Participants will play continuous for 2 hours.
89290356|NCT01218828|Active Comparator|Standard therapy|Hydration with 0.9% saline per a standard protocol (control group)
89254801|NCT05776108|Experimental|CAB IR Formulation (reference)/CAB DT Formulation (Test 1)/CAB DT Formulation (Test 2)|Participants will receive CAB IR Formulation (reference) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment .
89254802|NCT05776108|Experimental|CAB DT Formulation (Test 1)/CAB IR Formulation (reference)/CAB DT Formulation (test 2)|Participants will receive CAB DT Formulation (test 1) under fasted conditions in treatment period 1 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
89254803|NCT05776108|Experimental|CAB DT Formulation (test 2)/CAB IR Formulation (reference)/CAB DT Formulation (test 1)|Participants will receive CAB DT Formulation (test 2) under fed conditions in treatment period 1 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 2 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
89254804|NCT05776108|Experimental|CAB IR Formulation (reference)/CAB DT Formulation (test 2)/CAB DT Formulation (test 1)|Participants will receive CAB IR Formulation (reference) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 2 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
89254805|NCT05776108|Experimental|CAB DT Formulation (test 1)/CAB DT Formulation (test 2)/CAB IR Formulation (reference)|Participants will receive CAB DT Formulation (test 1) under fasted conditions in treatment period 1 followed by CAB DT Formulation (test 2) under fed conditions in treatment period 2 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
89254806|NCT05776108|Experimental|CAB DT Formulation (test 2)/CAB DT Formulation (test 1)/CAB IR Formulation (reference)|Participants will receive CAB DT Formulation (test 2) under fed conditions in treatment period 1 followed by CAB DT Formulation (test 1) under fasted conditions in treatment period 2 followed by CAB IR Formulation (reference) under fasted conditions in treatment period 3. There will be a minimum washout period of 14 days between each treatment.
89254807|NCT05768334|Active Comparator|lubiprostone|50 patients
89254808|NCT05768334|Placebo Comparator|Control arm|50 patients
89254809|NCT05758272|Experimental|mobile phone-based simple physical exercise intervention|Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. The investigators will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.
89254810|NCT05758272|Placebo Comparator|regular text-based intervention|The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
89254811|NCT05751642|Experimental|Cohort 1|Participants will receive a single dose of ALXN1920.
89254812|NCT05751642|Experimental|Cohort 2|Participants will receive a single dose of ALXN1920.
89254813|NCT05751642|Experimental|Cohort 3|Participants will receive a single dose of ALXN1920.
89254814|NCT05751642|Experimental|Cohort 4|Participants will receive a single dose of ALXN1920.
89254815|NCT05751642|Experimental|Cohort 5|Participants will receive a single dose of ALXN1920.
89254816|NCT05751642|Experimental|Cohort 6: Japanese Cohort|Japanese participants will receive a single dose of ALXN1920.
89254817|NCT05751642|Placebo Comparator|Pooled Placebo|Participants will receive Placebo.
89254818|NCT05750472||Neck Pain Group|group evaluated with scales
89254819|NCT05750472||Healthy Group|group evaluated with scales
89254820|NCT05732701|Experimental|Intervention|Algorithm-guided DAPT duration
89254821|NCT05732701|Active Comparator|Standard|Standard-of-care DAPT duration
89254822|NCT05727488|Experimental|Exercise|The SARAH exercise program will be delivered by sending messages and video instructions via a freeware and cross-platform messaging service (WhatsApp Messenger) on a weekly basis.
89254823|NCT05727488|No Intervention|Control|Patients in the control group will not receive any exercise intervention. They will only maintain their routine medical treatment.
89254824|NCT05723640|Experimental|177Lu-LNC1004 Injection group 1|177Lu-LNC1004 Injection, a single dose of 30mCi will be administered every 6 weeks, for a total of 2 cycles.
89254825|NCT05723640|Experimental|177Lu-LNC1004 Injection group 2|177Lu-LNC1004 Injection, a single dose of 60mCi will be administered every 6 weeks, for a total of 2 cycles.
89254826|NCT05723640|Experimental|177Lu-LNC1004 Injection group 3|177Lu-LNC1004 Injection, a single dose of 80mCi will be administered every 6 weeks, for a total of 2 cycles.
89254827|NCT05723640|Experimental|177Lu-LNC1004 Injection group 4|177Lu-LNC1004 Injection, a single dose of 100mCi will be administered every 6 weeks, for a total of 2 cycles.
89254828|NCT05716724||Participants with T2D|The study is non-interventional as there are no interventions involved and the decision to initiate oral semaglutide treatment is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study. Participants will be treated with oral semaglutide (at least 4 weeks on maintenance dose) once daily with or without other oral antidiabetics (OADs) as per local label at the discretion of the treating physician.
89254829|NCT05706181|Experimental|Home-based heat therapy and functional capacity in older adults|The investigators will determine the extent to which home-based leg heat therapy improves functional capacity in older adults. Functional capacity will be assessed before and after heat therapy or sham intervention via the 6-min walk test and the Short Physical Performance Battery.
89254830|NCT05706181|Experimental|Home-based heat therapy and vascular function and exercise hyperemia in older adults|The investigators will determine if home-based leg heat therapy improves vascular function and exercise hyperemia in the older adults of Aim 1. Using state-of-the-art techniques of skeletal muscle microdialysis and high-resolution duplex ultrasound, the investigators will pharmacodissect mechanisms of vascular function and exercise hyperemia before and after each intervention. The outcomes of Aim 2, while providing insight into the mechanisms whereby heat therapy improves functional capacity, should be considered independent of the outcomes of Aim 1 given that vascular health is a key independent, yet modifiable risk factor for cardiovascular morbidity and mortality.
89254831|NCT05701852||cases : patients with chronic pain|
89254832|NCT05701852||controls|
89254833|NCT05694624||Sepsis patients|Patients admitted to the intensive care unit with sepsis diagnosed or suspected
89254834|NCT05694624||Surgical patients|Previously healthy patients who are operated for colon cancer with laparoscopic technique.
89254835|NCT05690581|Experimental|CM369 Ia Dose Escalation|Dose escalation of CM369 as monotherapy
89254836|NCT05690581|Experimental|CM369 Ib Dose Expansion|Dose expansion of CM369 as monotherapy
89254837|NCT05674162|Experimental|Gait measurement|Use of four accellerometers/sensors (1 on each foot, one on the lumbar area and one on the sternum) that measure gait parameters during walking.
89254838|NCT05664789|Active Comparator|N-acetylcysteine|12 week administration of active study compound
89254839|NCT05664789|Placebo Comparator|Placebo|12 week administration of matched placebo
89254840|NCT05659576|Active Comparator|One Stage Consent|Patient will sign one consent form.
89254841|NCT05659576|Experimental|Two Stage Consent|Patient will sign two consent forms.
89254842|NCT05659576|Experimental|Sucralfate|During their RT course, patients randomized to the PS arm will receive a prescription for either: 1) sucralfate, 1 gram/10 mL oral suspension or 2) sucralfate 1 gram tablets.
89254843|NCT05659576|Active Comparator|Usual Care|Standard supportive care by using opioids.
89254844|NCT05656794|Experimental|Arm 1 - Investigational|Radiation treatment (36 Gy in 6 fractions) to be delivered every other day over 2 weeks (excluding weekends).
89254845|NCT05656794|Other|Arm 2 - Standard|Radiation treatment (36 Gy in 6 fractions) to be delivered once a week over 6 weeks.
89254846|NCT05654779|Experimental|LCAR-AMDR Cells Product|Each subject will be treated with LCAR-AMDR Cells
89254847|NCT05637697||Ambulatory|
89254848|NCT05637697||Limited Ambulation|
89254849|NCT05629013|No Intervention|Child Family Team (CFT) as Usual|The CFT is a family meeting model that is an existing mechanism being implemented systemwide in San Diego County Child Welfare Services (CWS). Each child or youth is required to have a CFT meeting within sixty days of entering the CWS to identify areas of behavioral, emotional, or social needs, and to complete an initial case Action Plan.
89254850|NCT05629013|Experimental|Child Family Team (CFT) with After Action Review (AAR)|CFT is being augmented with the after-action review.
89254851|NCT05621525|Experimental|Part A Dose Escalation and Part B Dose Expansion|"Part A: Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD).~Part B: Oral capsules administered at MTD/RP2D defined dose. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)"
89254852|NCT05620875||Group with DO2i <280 ml/min/m2 during cardiopulmonary bypass|
89254853|NCT05620875||Group with DO2i >280 ml/min/m2 during cardiopulmonary bypass|
89254854|NCT05615831|Experimental|Young adult (19-30 years)|Individuals aged 19-30 who are not physically active will participate in resistance training combined with blood flow restriction.
89254855|NCT05615831|Experimental|Older adults adult (aged 65 years and older)|Individuals aged 65 years and older who are not physically active will participate in resistance training combined with blood flow restriction.
89254856|NCT05611307||Surgical/Surveillance|TCS cured with surgical resection and surveillance (surgical/surveillance, Arm 1)
89254857|NCT05611307||Cisplatin-based chemotherapy (CBCT)|TCS treat with one or more lines of cisplatin-based chemotherapy
89254858|NCT05611307||Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT/BMT)|TCS treat with one or more lines of cisplatin-based chemotherapy, and who have undergone bone marrow transplant
89254859|NCT05579626|Active Comparator|high-intensity statin arm|(high-intensity statin arm): rosuvastatin 20 mg PO qd, once daily
89254860|NCT05579626|Active Comparator|low-intensity statin plus ezetimibe arm|(low-intensity statin plus ezetimibe arm ): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
89254861|NCT05564546|Experimental|People exposed to sargassum seaweed stranding|"Participant living on the Atlantic coast of Martinique island (hit by the strandings), close (less than 300 meters) to sargassum seaweed stranding areas: exposed group (85 subjects).~Participants will be examined directly at their place of residence.~Participants will be examinated two times:~at Visit 1 - Day 0 during the strandings period,~at Visit 2 - M+6 months (+/-1 month) after the end of the strandings."
89254862|NCT05564546|Active Comparator|People not exposed to sargassum seaweed stranding|"Participant living on the Caribbean coast of Martinique island (not hit by the strandings): unexposed group (85 subjects).~Participants will be examined directly at their place of residence.~Participants will be examinated two times:~at Visit 1 - Day 0 during the strandings period,~at Visit 2 - M+6 months (+/-1 month) after the end of the strandings."
89254863|NCT05520710|Experimental|Therapy Group|The Therapy Group will receive 6-10 individual sessions of 30-60 minutes each, delivered by a trained Occupational Therapist or Speech-Language Pathologist. The therapy will be delivered over a 4-week timeframe, with the total number of sessions per participant depending on the number of sessions needed to achieve their treatment targets. Each participant in the Therapy Group will identify three cognitive targets for treatment. Progress in reaching those targets will be documented using Goal Attainment Scaling (GAS)
89254864|NCT05520710|Active Comparator|Educational Group|The education group will receive information about self-management of cognitive symptoms at the time of randomization, a common intervention for adults with mild Traumatic Brain Injury.
89290357|NCT01218828|Experimental|LVEDP-based hydration strategy|LVEDP guided hydration with 0.9% saline (treatment group)
89290358|NCT00221195|Other|On-demand first|Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug
89254865|NCT05505565|Experimental|CGM + Traditional Counseling|Subjects in this arm will receive intermittent CGM to be used for 2-weeks each month for the 6-month study period. They will be required to wear a CGM during baseline, 3-month, and 6-month periods. Additional CGM sensors will be supplied for months 1, 2, 4, and 5 and will be optional. They will be provided with a Sworkit(R) account to monitor physical activity completed through the Sworkit(R) website/platform.
89254866|NCT05505565|Active Comparator|Control|Subjects in this arm will receive standard medical care for pre-diabetes. They will be provided with a Sworkit(R) account to monitor physical activity completed through the Sworkit(R) website/platform.
89254867|NCT05494398|Experimental|N-Acetylcysteine|
89254868|NCT05491382|Experimental|Does muscle temperature influence heat loss responses independently from core and skin temperature?|The study will consist of three experimental trials, conducted in a randomized order, where participants will be required to run for one hour at ~60% of their maximal oxygen consumption on one of three different inclines: 1) flatland, 2) uphill, and 3) downhill. Environmental conditions will be maintained at 34°C/93°F and 20% relative humidity.
89254869|NCT05491382|Experimental|Does muscle temperature influence muscle blood flow independently from core and skin temperature?|Following the exercise protocol described above in Arm 1, the participants will then lay supine for one hour while their muscle and skin blood flow, as well as blood pressure are measured.
89254870|NCT05491382|Experimental|What factors contribute to exercise-induced skeletal muscle damage?|For those participants who additionally agree to participate in the muscle microdamage portion of the study, participants will be asked to return to the lab 24h and 48h post-trial. During these subsequent follow-up sessions, an additional blood sample will be drawn from the participants, the participants maximal voluntary contraction and muscle pain will be assessed, and they will be asked to fill out the muscle soreness scale.
89254871|NCT05486728|Experimental|SHJ002|SHJ002 Ophthalmic Solution will be topically administered to each eye BID for 84 days
89254872|NCT05486728|Placebo Comparator|Vehicle|Vehicle will be topically administered to each eye BID for 84 days
89254873|NCT05484895|Experimental|WeTest-WeLink intervention|"Participants will have access to WeTest-WeLink application on the WeChat platform, which provides multi-media contents on HIV-related health information, online self-assessments, linkage to providers, data reports, and personal stories, in addition to two-way communication with non-governmental organizations (NGOs), and free, additional HST."
89254874|NCT05484895|Active Comparator|Control|"Participants will receive contact information to local NGO to request basic information or receive emergency referrals; have access to standard WeChat group; and have free, additional HST."
89254875|NCT05468385|Experimental|Tragus stimulation|Vagus nerve stimulation via tragus
89254876|NCT05468385|Sham Comparator|Sham stimulation|Sham stimulation via earlobe
89254877|NCT05432830|Experimental|"Experimental E-Liquid Order A"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
89254878|NCT05432830|Experimental|"Experimental E-Liquid Order B"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
89254879|NCT05432830|Experimental|"Experimental E-Liquid Order C"|All participants will be given all e-liquids (i.e. 3 flavor conditions all containing nicotine) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across 3 visits).
89254880|NCT05424016|Experimental|Experimental arm|Patients with no contraindications will be included and randomized to receive propranolol orally for 24 months
89254881|NCT05424016|Other|control arm|Patient included with a routine follow-up
89254882|NCT05419648||PV and ET patients|For the main objective, the cohort will be composed of PV and ET patients, some with a history of thrombosis and some without any history of thrombosis. A comparison will also be performed between patients with different MPN (PV or ET) and different driver mutation (JAK2V617F, JAK2 exon 12, CALR, MPL or absence of such mutations)
89254883|NCT05417828||Participant with Chronic stroke|"Participants over 18 years of age~Participants should be able to understand the verbal cues during the training"
89254884|NCT05395117|Experimental|Treatment Arm A: High dose|"Participants will receive the Investigational Medicinal Product (IMP), AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~Midazolam~Rosuvastatin~Digoxin"
89254885|NCT05395117|Experimental|Treatment Arm B: Low dose|"Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~Midazolam~Rosuvastatin~Digoxin"
89254886|NCT05372185|Experimental|VA CALM-S|Active psychotherapy using VA CALM-S, a weekly (9-12 sessions) cognitive behavioral therapy addressing co-occurring anxiety and substance use disorders, using disorder specific and transdiagnostic tools.
89254887|NCT05372185|Active Comparator|Usual Care|Participants in usual care will engage with VA healthcare using standard procedures of their facility.
89254888|NCT05371600|Active Comparator|Group M|Patients receive midazolam IV at 0.04 mg/kg (group M).
89254889|NCT05371600|Placebo Comparator|Group C|Patients receive an equal volume of saline IV (group C, control group).
89254890|NCT05368259|Experimental|AGBS + Moderate Intensity Lifestyle Therapy Group|Patients randomized to treatment will receive the AGBS device
89254891|NCT05368259|No Intervention|Moderate Intensity Lifestyle Therapy (CONTROL) Group|Patients randomized to the control arm will receive moderate-intensity lifestyle therapy.
89254892|NCT05368194|Experimental|Isocaloric Arm|Participants within the isocaloric arm will be provided with food provisions in accordance with their nutrition needs. Participants within this arm will be further randomised to the order of first and second dietary interventions for the crossover design; unprocessed diet or processed diet.
89254893|NCT05368194|Experimental|Excess Calorie Arm|Participants within the excess calorie arm will be provided with food provisions in accordance with their nutrition needs plus an additional 500 kilocalories per day. Participants within this arm will be further randomised to the order of first and second dietary interventions for the crossover design; unprocessed diet or processed diet.
89254894|NCT05366842|Experimental|Stravix|Direct placement of LPT over the spared neurovascular bundles during bilateral nerve sparing radical prostatectomy for prostate cancer.
89254895|NCT05366842|Sham Comparator|Standard of Care|Standard care (no placement of tissue) bilateral nerve sparing radical prostatectomy for prostate cancer.
89254896|NCT05361577|Active Comparator|Active astimulation|Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
89254897|NCT05361577|Sham Comparator|Sham stimulation|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
89254898|NCT05359679|Experimental|Value Champion Training Program|Intervention arm.
89254899|NCT05359679|Active Comparator|Standard Care|Control group.
89254900|NCT05358691|Experimental|AN0025: Dose level one: 250 mg daily|Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
89254901|NCT05358691|Experimental|AN0025: Dose level two: 375 mg daily|Oral, given two hours before chemotherapy or durvalumab; Patients should fast two hours before and one hour after AN0025 administration
89254902|NCT05346120|Experimental|Intervention|Single IV infusion of 6 million cells/kg allogeneic marrow stromal cells (MSCs) lasting approximately 30 minutes
89254903|NCT05346120|Placebo Comparator|Placebo controlled|PlasmaLyte A supplemented with 5% HSA
89254904|NCT05306444|Experimental|CLN-418: Part 1|"Experimental Part 1: Dose escalation~Intravenous IV administrations of CLN-418 on Day 1 of each 21 day treatment cycle~Dose for cohorts to be confirmed following consultation and approval by Safety Review Committee"
89254905|NCT05306444|Experimental|CLN-418: Part 2|"Experimental Part 2: Dose Expansion~Treatment administered at Maximum Tolerated Dose (MTD) and / or Recommended Phase 2 Dose (RP2D) established in Part 1"
89254906|NCT05295472|Experimental|Grapholearn group|Children with DLD who attend a special school for children with DLD. This group will play the computer game GL in school for 5 weeks, 20 sessions, 15-30 min per session. Supervised by a teacher.
89254907|NCT05295472|Active Comparator|Math game group|Children with DLD who attend a special school for children with DLD. This group will play a computer game focusing on math in school for 5 weeks, 20 sessions, 15-30 min per session. Supervised by a teacher.
89254908|NCT05295472|Active Comparator|Usual schooling|Children with DLD who attend a special school for children with DLD. This children will have normal schooling as usual without playing any of the above computer games.
89254909|NCT05289375|Active Comparator|Test group (T)|Group formed by those patients who will receive the drug to be tested Vacucis
89254910|NCT05289375|Placebo Comparator|Placebo control group (P)|Group formed by those patients who will receive placebo, in the same dosage and duration
89254911|NCT05289284||Female soccer cohort|A female soccer cohort will be followed for 10 month regarding injuries
89254912|NCT05288153|Experimental|the metformin group|Patients in the metformin group shall receive oral metformin at 500 mg per day for 6 months.
89254913|NCT05288153|Active Comparator|the folate group|Patients in the folate group shall receive oral folate at 5 mg three times a day for 6 months.
89254914|NCT05278871|Experimental|CSI ultrasound measurement|Participants will have standard volumetric tape measurement across multiple arm locations for lymphedema followed by CSI ultrasound measurements of the same anatomic sites.
89254915|NCT05267522|Experimental|Egg Diet|Egg diet, contains 2 eggs per day and limits saturated fat to 6% of energy intake. Cholesterol intake is 600mg/day. Protein and carbohydrate levels will be maintained at 20% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
89254916|NCT05267522|Active Comparator|Egg-free Diet|Egg-free diet, limits cholesterol to 300 mg/day (no eggs) with saturated fat intake at 12% of energy intake. Protein and carbohydrate levels will be maintained at 25% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
89254917|NCT05267522|Active Comparator|Control Diet|Comparator diet based on the average Australian diet, limited to 1 egg per week, with saturated fat intake at 12% of energy intake. Cholesterol intake is 600 mg/day. Protein and carbohydrate levels will be maintained at 25% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.
89254918|NCT05261269|Experimental|Dose Escalation (DAN-222)|The starting dose of DAN-222 will be administered IV every week (QW) to subjects in the first cohort.
89254919|NCT05261269|Experimental|Dose Escalation (DAN-222 + niraparib)|The starting dose of DAN-222 will be administered IV every week (QW), in combination with daily oral niraparib.
89254920|NCT05260320|Experimental|Standardized Protocol|"Premed~Acetaminophen PO 15mg/kg~Scopolamine patch + PO/IV Midazolam as needed~Induction~Lidocaine (1.5 mg/kg), propofol (1-3 mg/kg), and rocuronium (0.6mg/kg)~Fentanyl 100 mcg bolus~Dexmedetomidine 0.3 mcg/kg bolus~Nasotracheal intubation (NTI)~Dexamethasone 4-8mg q4-6 hours~Tranexamic acid 30mg/kg bolus~Ancef 30 mg/kg bolus~Room~Bolus line~4 Channel/pump infusion line w/: Maintenance IVFs/Carrier, Dexmedetomidine, TXA, Precedex or Phenylephrine~Maintenance~Sevo/isoflurane at 0.5-0.7 MAC with rocuronium boluses as needed~Dexmedetomidine 0.3- 0.5 mcg/kg/hour~Fentanyl 50 mcg boluses~TXA 15 mg/kg/hr~Phenylephrine 0.2-1 mcg/kg/min as needed~Emergence~Stop dexmedetomidine before emergence~Re-dose acetaminophen 15 mg/kg IV~Toradol 0.5 mg/kg~Zofran 0.15 mg/kg~Reverse with sugammadex~OGT placement, extubate awake"
89254921|NCT05260320|No Intervention|Provider Choice Protocol|Patients will be managed with provider-specific protocols, which may vary.
89254922|NCT05259930|No Intervention|Chronic gastrointestinal disease (IBD and liver cirrhotic patients)|Liver cirrhotic patients to receive best practice nutritional assessment and supports
89254923|NCT05259930|Experimental|branched-chain amino acid (BCAA)|Liver cirrhotic patients to receive best practice nutritional assessment and supports in addition to a 12-week course of BCAA supplementation
89254924|NCT05259930|No Intervention|Healthy Control|Controls attending gastroenterology outpatient or endoscopy services with no chronic inflammatory GI disease.
89254925|NCT05250765|Experimental|Bonding with rubberdam|The retainer is bonded under rubber dam isolation
89254926|NCT05250765|Active Comparator|Bonding under relative isolation|The retainer is bonded under relative isolation (hygrophormic suction, cotton pads)
89254927|NCT05239091|Experimental|Dextrose prolotherapy|:%15 dextrose prolotherapy injection will be applied to trigger point
89254928|NCT05239091|Active Comparator|Lidocaine|%2 lidocaine injection will be applied to trigger point
89290359|NCT00221195|Other|Prophylaxis first|Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug
89290360|NCT03933930|Experimental|Lactate-directed therapy|
89254929|NCT05238961|Experimental|Cohort 1 - Critical Asymptomatic Carotid Stenosis Group|Critical Stenosis Group: Diagnosis of Asymptomatic Carotid Artery Disease (aCAD) with >70% stenosis or peak systolic velocity on duplex ultrasound (DUS) ≥ 230 cm/s plus computed tomography angiography (CTA) or magnetic resonance angiography (MRA) confirmation.
89254930|NCT05238961|Experimental|Cohort 2 - Controls-Non-Critical Asymptomatic Carotid Stenosis Group|<40% carotid stenosis No planned revascularization
89254931|NCT05234190|Experimental|Treatment group|
89254932|NCT05229653|Experimental|Low-Dose Ketamine (LDK) Treatment Group|
89254933|NCT05229653|Placebo Comparator|Control Group|
89254934|NCT05226598|Experimental|Pembrolizumab/Vibostolimab + Carboplatin + Cisplatin + Paclitaxel + Nab-paclitaxel + Pemetrexed|Participants receive pembrolizumab/vibostolimab (co-formulation of 200mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous.
89254935|NCT05226598|Active Comparator|Pembrolizumab + Carboplatin + Cisplatin + Paclitaxel + Nab-paclitaxel + Pemetrexed|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 35 cycles (up to ~2 years) PLUS paclitaxel IV (on Day 1 of each cycle) OR nab-paclitaxel IV (on Days 1, 8, and 15 of each cycle) and carboplatin IV (on Day 1 of each cycle) for 4 cycles for Squamous NSCLC; PLUS carboplatin IV (on Day 1 of each cycle) Or cisplatin IV (on Day 1 of each cycle) for 4 cycles and pemetrexed IV (on Day 1 of each cycle) until progression, intolerable adverse events, or participant/physician decision for Non-squamous.
89254936|NCT05208242|Experimental|Hyperoncotic albumin|Hyperoncotic albumin for all fluid resuscitation and also as a daily supplement, guided by daily serum albumin values, for up to 7 days.
89254937|NCT05208242|Active Comparator|Buffered crystalloids|Buffered crystalloid solutions for all fluid resuscitation and maintenance purposes. Participants in this arms will NOT receive any albumin during their participation.
89254938|NCT05200819||COVID 19 Patients|Patients who have survived COVID-19 infection, including those included in the Michigan Medicine COVID-19 Cohort (M2C2) will be eligible to participate.
89254939|NCT05186025||Adults|adult patients aged ≥ 18 with rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, caused by an IgE-mediated allergy to grass/rye or tree pollen; who are treated with MATA grass or MATA trees as part of their routine medical care
89254940|NCT05186025||Children|children aged from >5 to 17 years with rhinitis, conjunctivitis and/or mild to moderate bronchial asthma, caused by an IgE-mediated allergy to grass/rye or tree pollen; who are treated with MATA grass or MATA trees as part of their routine medical care
89254941|NCT05171205|Experimental|Spinal cord stimulation(SCS) implantation|"Phase I:~Spinal cord segment is selected as the puncture location according to the patient's symptom and the condition of the patient's spinal cord. Percutaneous puncture is performed under X-ray guidance. One or two electrodes are placed in the patient's epidural cavity, and the electrode position is adjusted intraoperatively and by the patient's feedback of the current stimulation position until the current can cover the entire area.~An extension lead is connected, an external temporary stimulator is attached, and the patient decides whether to proceed to full implantation in phase II after 7-10 days of phase I testing experience.~Phase II:~The complete SCS system is implanted under local anesthesia or epidural anesthesia after successful testing. A subcutaneous capsular bag is usually created in the lower abdomen and the implanted electrodes are connected to the pulse generator through a connecting wire in the subcutaneous tunnel."
89254942|NCT05169684|Experimental|Arm 1A: Docetaxel + BMS-986218|
89254943|NCT05169684|Experimental|Arm 1B: Docetaxel + BMS-986218 + Nivolumab|
89254944|NCT05169684|Experimental|Arm 2A: Docetaxel|
89254945|NCT05169684|Experimental|Arm 2B: Docetaxel + BMS-986218|
89254946|NCT05169684|Experimental|Arm 2C: Docetaxel + BMS-986218 + Nivolumab|
89254947|NCT05169684|Experimental|Arm 2D (Optional Crossover): BMS-986218 + Nivolumab|
89254948|NCT05168267|Experimental|Cognitive Processing Therapy (CPT) group|Arm = Cognitive Processing Therapy (CPT) Group = 4 groups of 12 (48 total; 24F/24M) receive CPT to treat PTSD
89254949|NCT05165654|Experimental|Active Stimulation with TDCS|10 tDCS; Two, twenty-minute sessions of tDCS to the rSTS for 5 days (10 total sessions).
89254950|NCT05165654|Sham Comparator|SHAM Stimulation|10 passive sham control; Two, twenty-minute sessions of passive sham control to the rSTS for a 30 second ramped up and down at the beginning and end of the 20 min period for 5 days (10 total sessions).
89254951|NCT05162794|Other|Active Surgery|
89254952|NCT05162794|Other|Diagnostic Surgery|
89254953|NCT05162794|Other|No-surgery control|
89254954|NCT05160415|Experimental|Treatment|Drug: EDG-5506
89254955|NCT05160233|Active Comparator|Standard Implementation|All primary care clinics will implement reSET and reSET-O using standard implementation approach.
89254956|NCT05160233|Experimental|Standard Implementation Plus Health Coaching|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
89254957|NCT05160233|Experimental|Standard Implementation Plus Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and a practice facilitator will provide the clinic with support for implementation.
89254958|NCT05160233|Experimental|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
89254959|NCT05155319|Active Comparator|Cohort 1, 1A|Low dose (Day 1) plus placebo (Day 22)
89254960|NCT05155319|Active Comparator|Cohort 1, 1B|Low dose (Day 1) plus low dose (Day 22)
89254961|NCT05155319|Placebo Comparator|Cohort 1, 1C|Placebo (Day 1) plus Placebo (Day 22)
89254962|NCT05155319|Active Comparator|Cohort 2, 2A|High dose (Day 1) plus placebo (Day 22)
89254963|NCT05155319|Active Comparator|Cohort 2, 2B|High dose (Day 1) plus high dose (Day 22)
89254964|NCT05155319|Placebo Comparator|Cohort 2, 2C|Placebo (Day 1) plus Placebo (Day 22)
89254965|NCT05142332|Experimental|Intervention Arm: PROCOVAXED|Covid vaccine educational intervention consisting of vaccine messaging platforms (flyers, videos, scripted face-to-face messaging)
89254966|NCT05142332|No Intervention|Non-interventional Arm: PROCOVAXED|Usual care
89254967|NCT05130450|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 153.
89254968|NCT05117476|Experimental|Module A Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619
89254969|NCT05117476|Experimental|Module A Cohort Expansion|Patients with select solid tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module A Escalation arm
89254970|NCT05117476|Experimental|Module B Combination Therapy Dose Escalation|Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619 in combination with pembrolizumab
89254971|NCT05117476|Experimental|Module B Combination Therapy Cohort Expansion|Patients with select tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module B Escalation arm, in combination with pembrolizumab
89254972|NCT05115188|Other|2-hr OGTT with glucose beverage|For the 2 hour oral glucose tolerance test (OGTT), women fast for 8 hours and then consume 75g of glucose beverage, and serum glucose levels are taken at fasting, 1 and 2 hours after drinking the glucose beverage. The 75g OGTT is the gold standard and is performed for GDM diagnosis.
89254973|NCT05115188|Experimental|2-hr OGTT with Dex4® tablets|Participants will be asked to ingest 21 Dex4® tablets and no more than 300ml of water within 5 minutes. Blood draws will be performed at fasting (before ingesting the dextrose monohydrate tablets), as well as 1 hour after (+/- 15 minutes) and 2 hours (+/- 15 minutes) after ingesting the dextrose monohydrate tablets.
89254974|NCT05113095||Darvadstrocel|Darvadstrocel, 24 mL suspension of 120 million cells as a perilesional injection, once. Participants received interventions as part of routine medical care.
89254975|NCT05112549|Experimental|intrathecal Nivolumab|"This is a prospective, interventional, open label, multicenter phase I trial in leptomeningeal disease in subjects with solid tumor that have a registered indication for intravenous treatment with PD1 antibody. Subject will undergo 6 cycles each 14 days in duration and a safety visit 7 days after the 3th dosage and 7 days after the 6th dosage. The Follow-up phase will start four weeks after the last dose and will continue monthly (up to 4 Follow-up visits in total).The study consists of two parts:~Part I dose - escalation phase (3 + 3 design) with 4 cohorts and each subject will receive an intrathecal nivolumab treatment with a fixed predefined dose (20 mg, 30 mg, 40 mg or 50 mg). On each dose level, exposure of subjects to intrathecal nivolumab will follow a staggered approach. Part II dose expansion phase: subjects will receive an intrathecal PD1 treatment with a fixe dose, depending on the results from Part I."
89254976|NCT05110599|Active Comparator|Bryophyllum 50%|Participants of the verum group take Bryophyllum 50% chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
89254977|NCT05110599|Placebo Comparator|Placebo|Participants of the control group take Placebo chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
89254978|NCT05100082||Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
89254979|NCT05097976|Experimental|Methylprednisolone taper|Methylprednisolone taper - 21 x 4mg tablets beginning on POD 1
89254980|NCT05097976|Placebo Comparator|Placebo taper|2.Placebo taper - 21 sugar tablets beginning on POD 1 with standard management
89254981|NCT05083208|Experimental|PI3Kδ inhibitor Parsaclisib plus Chidamide|"Phase Ib (Explored the appropriate dose of Parsaclisib in combination with chidamide)~Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day.~Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks.~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day.~Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast."
89254982|NCT05082662|Experimental|Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)|
89254983|NCT05082662|Active Comparator|Cataflam® 50 coated tablet (50 mg Diclofenac Potassium)|
89254984|NCT05079334|Other|High Risk / MeTree|High risk for hereditary cancer and completes the MeTree questionnaire
89254985|NCT05076487||African American Women with Food Security|30 African American women with obesity who are food secure
89254986|NCT05076487||African American Women with Food Insecurity|30 African American women with obesity who are food insecure
89254987|NCT05071859||GOBACK|The patient must have been diagnosed with cancer at ≤25 years of age and have been diagnosed with one or more congenital anomalies reported through the APEC14B1 registry intake data. For all patients in APEC14B1 with self-reported congenital anomalies the investigators will: 1) recruit cases; 2) administer the GOBACK Study questionnaire; 3) collect biological samples for sequencing; and 4) obtain medical records to verify anomalies. Medical records will be used to validate self-reported congenital anomalies and is a crucial step prior to sequencing. Additionally, the investigators will be able to identify those with well-established cancer predisposition syndromes that involve congenital anomalies, such as WAGR syndrome.
89254988|NCT05059132|Experimental|Tele-rehabilitation|Participants in the tele-rehabilitation arm will receive a home-based, remotely delivered rehabilitation program.
89254989|NCT05059132|Active Comparator|Education only|Participants in the education arm will receive educational materials only, delivered through telecommunication messages.
89254990|NCT05051072|Other|MRI in morphological sequence, diffusion tensor and resting functional|"standard anatomical sequences T1, FLAIR (Fluid Attenuated Inversion Recovery), TOF(Time-of-flight MR angiography) , DRIVE, sequence centered on the V after injection of gadolinated contrast product as part of routine care,~diffusion tensor sequence (DTI)"
89254991|NCT05036499|Experimental|Personalized Feedback Intervention (PFI)|Personalized Feedback Intervention targeting pain-related anxiety for hazardous drinkers with chronic pain
89254992|NCT05036499|No Intervention|Assessment Only|Assessment only, no active treatment elements
89254993|NCT05032976||Tozinameran (BNT162b2)|Subjects aged 6 months and older who are scheduled for Tozinameran vaccination
89254994|NCT05032976||Riltozinameran (BNT162b2 OMI BA.1)|Subject aged 12 years and older who are scheduled for Riltozinameran vaccination
89254995|NCT05032976||Famtozinameran (BNT162b2 OMI BA.4-5)|Subject aged 5 years and older who are scheduled for Famtozinameran vaccination
89254996|NCT05032976||Raxtozinameran (BNT162b2 OMI XBB.1.5)|Subject aged 6 months to 4 years and 12 years and older who are scheduled for Raxtozinameran vaccination
89254997|NCT05027971||Lithotripsy Cohort|Subjects in this cohort will undergo lithotripsy procedure for the treatment of urinary calculi.
89254998|NCT05027971||Benign Prostatic Hyperplasia (BPH) Cohort|Subjects in this cohort will undergo Holmium Laser Enucleation of the Prostate (HoLEP) procedure for the treatment of BPH.
89254999|NCT05015621|Active Comparator|study group|all subjects will receive study treatment in 21-day cycle, Surufatinib 250mg, QD and Toripalimab, 240mg, IV drip, Q3W, D1, the treatment will continue until one of the following conditions occurs: progression of disease, death, intolerable toxicity, or the end of study treatment (as other criteria specified in the protocol are met), whichever occurs first
89255000|NCT05015621|Other|control group|FOLFIRI group subjects will receive study treatment in 14- day cycle, Irinotecan: 180 mg/m^2, iv drip over 30～90 minutes, on Day 1; Calcium folinate: 400 mg/m^2, iv drip for about 2 hours, given upon completion of infusion of Irinotecan on Day 1; 5-FU: 400 mg/m^2, iv bolus, given upon completion of infusion of Calcium folinate on Day 1, followed by 2400 mg/m^2 continuously iv drip for 46～48 hours.
89255001|NCT05007548|Experimental|Ga68-Dolacga Injection|Ga68-Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
89255002|NCT04998877||Heart Failure with Preserved Ejection Fraction|
89255003|NCT04998877||Healthy Volunteers|
89255004|NCT04993131|Experimental|Liver transplant|The patients will be transplanted according to standard procedures by the institutional protocol. Median time of surgery is 7 hours and 20 minutes. Each surgical procedure will be performed by specialists at the Rikshospitalet liver transplantation team, which consists of seven specialists at the unit. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Complete clearance of the lymphatic tissue around the hepatoduodenal ligament. Frozen section is obtained from the distal end of the common bile duct. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.
89255005|NCT04984291|Experimental|Zimmer Biomet Total Shoulder Arthroplasty System|Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.
89255006|NCT04977830|Other|Thoracic Insufficiency Group|Thoracic insufficiency syndrome patients undergoing surgery
89255007|NCT04973696|Experimental|Toolkit for Optimal Recovery after Orthopedic Injury - Active|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
89255008|NCT04973696|Active Comparator|Minimally Enhanced Usual Care (MEUC) - Control|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
89255009|NCT04966507|Active Comparator|Listerine Cool Mint Antiseptic Mouthwash|Daily use of an antibacterial mouthwash (Listerine Cool Mint Antiseptic Mouthwash) during the 12-week follow-up period.
89255010|NCT04966507|Placebo Comparator|Biotene Oral Rinse|Daily use of a placebo mouthwash with no known antibacterial qualities (Biotene Oral Rinse) during the 12-week follow-up period.
89255011|NCT04947800|Experimental|Arm A: 12 week intervention, 8 week control|Electro acupuncture (EA) intervention will be administered for 12 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 8 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
89255012|NCT04947800|Experimental|Arm B: 8 week intervention, 12 week control|Electro acupuncture (EA) intervention will be administered for 8 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 12 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
89255013|NCT04947800|Experimental|Arm C: 4 week intervention, 16 week control|Electro acupuncture (EA) intervention will be administered for 4 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 16 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
89255014|NCT04933617|Experimental|1- Dose Escalation, Original|Copanlisib (IV) per dose level (30 mg, 45 mg, or 60 mg) on day 1 of each 21-day cycle in combination with standard dosing DA-EPOCH-R to determine RP2D and MTD of copanlisib. Up to 6 cycles total.
89255015|NCT04933617|Experimental|2 - Dose Expansion, Modified|Copanlisib (IV) at the RP2D or MTD on day 1 of each 21-day cycle in combination with standard dosing DA-EPOCH-R. Up to 6 cycles total.
89255016|NCT04931485|Experimental|Intervention: REDUCE Protocol|Fluid resuscitation and de-resuscitation is based on the REDUCE fluid management protocol.
89255017|NCT04931485|Active Comparator|Standard of Care|Fluid resuscitation and de-resuscitation according to the standard of care
89255018|NCT04913415|Other|Low Suction Strategy of Chest Tube Management|
89255019|NCT04913415|Other|Standard Suction Strategy of Chest Tube Management|
89255020|NCT04901078|Experimental|Active|KNX100 which will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
89255021|NCT04901078|Placebo Comparator|Placebo|KNX100 matching placebo will be provided in capsule form for oral administration. The placebo will be encapsulated in HPMC dark green opaque size 0 capsules and packaged in 100 mL HDPE bottles with PP twist-off closures.
89255022|NCT04890834|Active Comparator|Arm I (Standard of care)|Patients and caregivers receive standard care including education pertaining to symptom management, prophylactic dental hygiene and possible extraction, speech pathology for baseline swallowing assessment and prophylactic treatment, and dietary services for regular nutrition consults during CRT. Psychiatry, social work, interventional radiology and supportive care services are consulted as needed.
89255023|NCT04890834|Other|Arm II (exercise, yoga sessions)|Patients and caregivers receive standard care as in arm I. Patients and caregivers also participate in yoga sessions 3 times per week over 60 minutes each for a total of 15 sessions.
89255024|NCT04880317|Experimental|Single arm|
89255025|NCT04858256|Experimental|Cohort 1: PTCL, NOS|Patients will receive single agent pacritinib.
89255026|NCT04858256|Experimental|Cohort 2: AITL/TFH PTCL|Patients will receive single agent pacritinib.
89255027|NCT04858256|Experimental|Cohort 3: CTCL (MF/SS)|Patients will receive single agent pacritinib.
89255028|NCT04858256|Experimental|Cohort 4: Less common PTCL subtypes|Patients will receive single agent pacritinib.
89255029|NCT04853472||Early Stage Peri-Menopause|Mild cycle irregularity over the last 3-6months (minimum), variation of >6 days in length between consecutive cycles including shortened and longer cycles (but not >60 days in length)
89255030|NCT04853472||Late Stage Peri-Menopause|Late stage peri-menopause: Irregular cycles with prolonged periods of amenorrhea >60 days in length (but less than 12 months)
89255031|NCT04853472||Post-Menopause|Greater than 12 months since last menstrual period
89255032|NCT04850430|Experimental|Gastric venous congestion following total pancreatectomy|The gastric venous outflow will be reconstructed after TP. The patients will be assessed concerning gastric venous congestion and gastric ischemia intraoperatively before and after venous outflow reconstruction through onsite evaluation by the surgeon, endoscopic examination, indocyanine green, gastric venous drainage flowmetry, and spectral imaging.
89255033|NCT04848038|Active Comparator|Core and Fusion Training|150 minutes/week of Core and Fusion exercise, a mix of low impact toning, strengthening, flexibility and balance exercises.
89255034|NCT04848038|Active Comparator|Endurance Training|Moderate-intensity endurance training such as brisk walking, 150 minutes/week over 3-5 days. Progression based on a set schedule. In addition 0-2 days of Core and Fusion control exercise will also be recommended.
89255035|NCT04848038|Active Comparator|Weight Training|Progressive resistance training 2 days/week, non-consecutive, of 2 sets (10 - 15 repetitions) of 10 exercises (~75 minutes/week). Progression based on repetition completion and 1-repetition maximum. In addition 3 days of Core and Fusion control exercise will also be recommended.
89255036|NCT04848038|Active Comparator|Combined Endurance and Weight Training|Moderate-intensity endurance training such as brisk walking, 150 minutes/week over 3-5 days. Progression based on a set schedule. Progressive resistance training 2 days/week, non-consecutive, of 2 sets (10 - 15 repetitions) of 10 exercises (~75 minutes/week). Progression based on repetition completion and 1-repetition maximum.
89255037|NCT04812717|Active Comparator|CytoSorb-Yes|Heart failure patients that will receive intraoperative treatment with CytoSorb.
89255038|NCT04812717|No Intervention|CytoSorb-No|Heart failure patients that will not receive intraoperative treatment with CytoSorb.
89255039|NCT04802954|Experimental|High risk group|Patients with hepatocellular carcinoma greater than 1 cm in size. All patients from an ultrasound screening programme who have been diagnosed with a nodule larger than 1 cm and referred to our centres will be included in this group. They will then be excluded of this group if the diagnosis of hepatocellular carcinoma is not retained according to the radiological or histological reference diagnostic standards (gold standard).
89255040|NCT04802954|Experimental|Low risk group|Patients without hepatocellular carcinoma. A 1-year interval ultrasound will be performed to confirm the absence of new nodule in the year following inclusion.
89255041|NCT04798859|Experimental|Family-centered in home rehabilitation|"Seven individualized meetings with the family (7 sessions whereof most will be videoconferences, with the possibility of 1-2 of the sessions being home visits), one parent group seminar and 4 meetings (three videoconferences and one phone call) with school and local care providers during a period of 4-5 months.~Based on target outcomes areas noted by children and parents, individual goals will be established (2-5 per family). Strategies to meet goals will be established for each goal, and goal attainment scaling will be used to quantify goal attainment."
89255042|NCT04798859|Active Comparator|Control group|Usual health care and rehabilitation services provided in the municipality, including school.
89255043|NCT04784832|Experimental|Sequence 1 - Training with same task - Long follow-up|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation Mental training
89255044|NCT04784832|Experimental|Sequence 1 - Training with same task - Short follow-up|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation Mental training
89255045|NCT04784832|Experimental|Sequence 1 - Training with different tasks - Long follow-up|Motor task (different task in immediate post test) Transcranial magnetic stimulation Mental training
89255046|NCT04784832|Experimental|Sequence 1 - Training with different tasks - Short follow-up|Motor task (different task in immediate post test) Transcranial magnetic stimulation Mental training
89255047|NCT04784832|Experimental|Sequence 1 - Training with muscle contractions - Long follow-up|Motor task (isometric muscle contractions in immediate post test) Transcranial magnetic stimulation Mental training
89255048|NCT04784832|Experimental|Sequence 1 - Training with muscle contractions - Short follow-up|Motor task (isometric muscle contractions in immediate post test) Transcranial magnetic stimulation Mental training
89255049|NCT04784832|Active Comparator|Sequence 1 - Control|Motor task (Pretest and Posttests on the same task) Transcranial magnetic stimulation No mental training
89255050|NCT04784832|Active Comparator|Sequence 2 - Physical training with perturbation during preparation - Long follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
88804880|NCT01298167|Active Comparator|Cyanoacrylate Superior/Inferior|This arm contains data from only the Cyanoacrylate used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast Absorbing Gut suture.
89255051|NCT04784832|Active Comparator|Sequence 2 - Physical training with perturbation during preparation - Short follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
89255052|NCT04784832|Active Comparator|Sequence 2 - Physical training with perturbation after preparation - Long follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
89255053|NCT04784832|Active Comparator|Sequence 2 - Physical training with perturbation after preparation - Short follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Physical training
89255054|NCT04784832|Experimental|Sequence 2 - Mental training with perturbation during preparation - Long follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
89255055|NCT04784832|Experimental|Sequence 2 - Mental training with perturbation during preparation - Short follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
89255056|NCT04784832|Experimental|Sequence 2 - Mental training with perturbation after preparation - Long follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
89255057|NCT04784832|Experimental|Sequence 2 - Mental training with perturbation after preparation - Short follow-up|Motor task (Pretest and Posttests) Transcranial magnetic stimulation External pertubation (robotic arm) Mental training
89255058|NCT04784832|Experimental|Sequence 3 - Training (same task) - Long follow-up|Paired Associative Stimulation Mental training (same as the motor task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
89255059|NCT04784832|Experimental|Sequence 3 - Training (same task) - Short follow-up|Paired Associative Stimulation Mental training (same as the motor task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
89255060|NCT04784832|Experimental|Sequence 3 - Training (different task) - Long follow-up|Paired Associative Stimulation Mental training (different of the motor task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
89255061|NCT04784832|Experimental|Sequence 3 - Training (different task) - Short follow-up|Paired Associative Stimulation Mental training (different of the motor task) Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
89255062|NCT04784832|Active Comparator|Sequence 3 - Control 1|Mental Training Motor task (same as the motor task) Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
89255063|NCT04784832|Active Comparator|Sequence 3 - Control 2|Paired Associative Stimulation Motor task Transcranial magnetic stimulation Peripheral nerve stimulation Cervicomedullar stimulation
89255064|NCT04784832|Experimental|Sequence 4 - Immobilization - Short follow-up|Transcranial magnetic stimulation Arm immobilization Motor task Mental training
89255065|NCT04784832|Experimental|Sequence 4 - Immobilization - Long follow-up|Transcranial magnetic stimulation Arm immobilization Motor task Mental training
89255066|NCT04784832|Experimental|Sequence 4 - Cathodal - Short follow-up|Transcranial magnetic stimulation Cathodal transcranial direct current stimulation Motor task Mental training
89255067|NCT04784832|Experimental|Sequence 4 - Cathodal - Long follow-up|Transcranial magnetic stimulation Cathodal transcranial direct current stimulation Motor task Mental training
89255068|NCT04784832|Experimental|Sequence 4 - Anodal - Short follow-up|Transcranial magnetic stimulation Anodal transcranial direct current stimulation Motor task Mental training
89255069|NCT04784832|Experimental|Sequence 4 - Anodal - Long follow-up|Transcranial magnetic stimulation Anodal transcranial direct current stimulation Motor task Mental training
89255070|NCT04784832|Sham Comparator|Sequence 4 - Control|Transcranial magnetic stimulation Motor task Mental training
89255071|NCT04783727|Experimental|Experimental arm|The individualised treatment durations defined by the RNA transcriptomic signature-based model
89255072|NCT04783727|No Intervention|Control arm|The locally accepted standard duration of treatment based on the WHO recommendation for treatment of MDR-TB patients
89255073|NCT04777331|Experimental|Prasinezumab|"Participants will receive an IV infusion of prasinezumab every 4 weeks (Q4W).~Participants will enter into the optional Open Label Extension (OLE) once the double-blind treatment period has completed."
89255074|NCT04777331|Placebo Comparator|Placebo|Participants will receive placebo as an IV infusion Q4W.
89255075|NCT04765488|Experimental|Study group|"A group of patients in relation to whom the Wash In / WashOut procedure will be applied. In this group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
89255076|NCT04765488|No Intervention|Control group|A group of patients in relation to whom will be applied the traditional method of recovery from anesthesia. In this group during the period of awakening we stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness.
89255077|NCT04761471|Experimental|TI stimulation|Temporal interference (TI) stimulation is a type of low-intensity transcranial electrical stimulation with alternating current (tACS). In case of TI stimulation, 2 electric fields in kHz range are delivered to 4 electrodes, which are placed on the surface of the skull, to modulate neural oscillations.
89255078|NCT04751747|Experimental|Supportive care (CT simulation, contrast agent)|Patients undergo CT stimulation with or without IV contrast over 1.5 hours on days -15 to -1, then undergo SOC chemoradiation on days 1-40. Patients also undergo additional CT scan simulations without IV contrast over 20 minutes each on days 15 and 29.
89255079|NCT04745832|Experimental|Rituximab plus Zandelisib|Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles
89255080|NCT04745832|Experimental|Rituximab plus chemotherapy|Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles
89255081|NCT04745572|Experimental|High Carbohydrate Diet|Enrollment in a group-based behavioral weight loss intervention based on the Diabetes Prevention Program curriculum with high carbohydrate diet plan.
89290361|NCT03933930|Experimental|Goal-directed therapy|
89255082|NCT04745572|Experimental|Reduced Carbohydrate Diet|Enrollment in a group-based behavioral weight loss intervention based on the Diabetes Prevention Program curriculum with reduced carbohydrate diet plan.
89255083|NCT04744584||Patients with medication reconciliation|Patient with medication reconciliation during 1st hospitalization
89255084|NCT04744584||Patients without medication reconciliation|Patient without medication reconciliation (MR) at 1st hospitalization but with retrospective MR at the next one (3 to 6 months after)
89255085|NCT04740567|Experimental|Cognitive Intervention|During hospitalization, enrolled patients assigned to the intervention arm will undergo two 20-minute cognitive training sessions daily, 7 days a week. After the patient is discharged from the hospital, cognitive rehabilitation will be administered once a week for 12-weeks at their place of residence. Goal Management Training will be the foundation for cognitive rehabilitation.
89255086|NCT04740567|No Intervention|Usual Care|Enrolled patients will undergo usual care during hospitalization and post-hospital discharge.
89255087|NCT04726592|Placebo Comparator|Control arm|"placebo and standard care :~Placebo IV~Ketoprofen 100 mg IV (if nausea-vomiting)~Metoclopramide 10 mg IV(if nausea-vomiting)"
89255088|NCT04726592|Experimental|Experimental arm|"clorazepate and standard care :~Clorazepate 20 mg IV~Ketoprofen 100 mg IV (if nausea-vomiting)~Metoclopramide 10 mg IV(if nausea-vomiting)"
89255089|NCT04713982|Experimental|Deutetrabenazine|The mode of administration is oral. Subjects will be started on deutetrabenazine at a dose of 6mg/day. Dosing will be up-titrated in increments of 6mg/day per week to achieve optimal chorea control.
89255090|NCT04711356|Experimental|Study Intervention|All study participants will receive an Ad26.ZEBOV vaccine at a dose of 5x10^10 vp given via IM injection
89255091|NCT04708600|Experimental|Group 1|Sham therapy Intervention 1: PET Intervention 2: ART
89255092|NCT04708600|Experimental|Group 2|Sham therapy Intervention 1: ART Intervention 2: PET
89255093|NCT04698915|Experimental|Arm A Active GC4711|
89255094|NCT04698915|Placebo Comparator|Arm B Placebo|
89255095|NCT04693403|Experimental|High-flow oxygen nasal cannula (HFNC)|In the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier and applied continuously through large-bore bi-nasal prongs, with a gas flow rate of 40-60 liters per minute and adjusted based on the clinical response.
89255096|NCT04693403|Experimental|Continuous positive airway pressure (CPAP)|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment. CPAP will be started at 7.5 cm of water. The level will be decreased to 5 cm of water or increased to 10 cm of water as needed based on the clinical response and tolerance.
89255097|NCT04693403|Active Comparator|Standard Low flow Oxygen Arm|Patients assigned to the standard treatment group will receive oxygen delivered through a Non-rebreather face mask until endotracheal intubation, death, or fulfillment of oxygen delivery cessation criteria (an oxygen saturation by pulse oximetry (SpO2) above 92% without oxygen and a respiratory rate below 25 cycles/min).
89255098|NCT04691908|Active Comparator|Phase III Adult-vaccine (A Sample, blind study)|Group 1 (phase III): 2400 volunteers from 18 years old and elder who will be the QazCovid-in® twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89255099|NCT04691908|Placebo Comparator|Phase III Adult-Placebo (A Sample, blind study)|Group 1 (phase III): 600 volunteers from 18 years old and elder who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
89255100|NCT04686851|Experimental|Intervention|Comprehensive Geriatric Assessment and follow-up as add on to standard oncologic care
89255101|NCT04686851|No Intervention|Control|standard oncologic care according to national guidelines
89255102|NCT04686799|Experimental|SD-doxycycline group|12 weeks SD-doxycycline: doxycycline hyclate 20 mg tablet by mouth twice daily
89255103|NCT04675840|Active Comparator|intrathecal morphine|Spinal injection of 15mg Bupivakain and 0,25mg morphine before surgery.
89255104|NCT04675840|Active Comparator|opiate po/iv|Patient given 10mg Oxycodone orally before surgery.
89255105|NCT04663126|Experimental|Treatment group|Patients diagnosed with advanced melanoma (stage III-IV) will receive IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m before the first cycle of clinically scheduled anti-PD-1 immunotherapy.
89255106|NCT04626024|Experimental|All Subjects Enrolled (stop taking TKI)|Patients with a diagnosis of Philadelphia chromosome- or BCR-ABL1-positive CML (as determined by cytogenetics, FISH, or PCR), prior evidence of a quantifiable BCR-ABL1 transcript by RT-PCR, and whom have been taking TKI for > 36 months with a current status of complete molecular remission (CMR). TKI cessation begins within 7 days of study registration. Patients undergo BCR-ABL1 test every month in 24 months.
89255107|NCT04623502|Experimental|13C-Glucose|
89255108|NCT04623502|Experimental|13C-Acetate|
89255109|NCT04623502|Experimental|13C-Lactate|
89255110|NCT04623502|Experimental|13C-Glutamine|
89255111|NCT04623502|Experimental|13C-Fructose|
89255112|NCT04621279||Mild HIE|Mild HIE identified in the first 6 hours of life according to the published PRIME study definition: newborn with evidence of encephalopathy (using the validated Sarnat Exam) NOT meeting prior cooling trials criteria.
89255113|NCT04576065|No Intervention|Usual Care|Patients randomized to usual care will follow-up with primary care providers and specialists as recommended by hospital providers, or seek medical care as needed after hospital discharge.
89255114|NCT04576065|Experimental|Intervention|Patients randomized to intervention will have 6 months of access after hospital discharge for telehealth visits with a nurse practitioner and an activity tracker providing data to the nurse practitioner about subject's daily level of activity.
89255115|NCT04566120|Experimental|Cinnamon extract mouthwash|Participants will be exposed to cinnamon extract mouthwash and will be instructed to use 10 ml of cinnamon extract mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
89255116|NCT04566120|Active Comparator|Chlorohexidine based mouthwash|Participants will be exposed to chlorohexidine based mouthwash. and will be instructed to use 10 ml of 0.12% chlorhexidine based mouthwash 2 times per day for 1 minute; such a regimen will be continued for one month.
89255117|NCT04561375|Active Comparator|Intervention Group|30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.
89255118|NCT04561375|Placebo Comparator|Control Group|placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia
89255119|NCT04556838|Experimental|VVN001, 1%|VVN001, 1% ophthalmic solution
89255120|NCT04556838|Experimental|VVN001, 5%|VVN001, 5% ophthalmic solution
89255121|NCT04556838|Placebo Comparator|Vehicle|VVN001 Ophthalmic Solution Placebo
89255122|NCT04549363|Experimental|Participants undergoing IC|IC will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination and who do not agree to undergo SK.
89255123|NCT04549363|Experimental|Participants undergoing SK|SK will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.
89255124|NCT04539509|Active Comparator|Monitoring|Participants will be given a heart rate monitor to wear on their wrist for the duration of the study (i.e. until recovered, or 8 weeks post-injury, whatever comes first).
89255125|NCT04539509|Placebo Comparator|Monitoring + Treadmill Test|In addition to wearing the heart rate monitor, participants will undergo a treadmill test at each appointment.
89255126|NCT04539509|Experimental|Monitoring + Treadmill Test + Specific Exercise Prescription|In addition to wearing the heart rate monitor, and completing a treadmill test at each appointment, participants will receive an exercise prescription based on the results of the treadmill test. They will be prescribed 30 minutes of structured aerobic exercise, 5 times per week, at a heart rate determined by their treadmill test.
89255127|NCT04535362|Active Comparator|menthol cigarettes|Will smoke only menthol cigarettes for two weeks
89255128|NCT04535362|Active Comparator|non menthol cigarettess|Will only smoke non menthol cigarettes for two weeks
89255129|NCT04523779|Experimental|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
89255130|NCT04523779|No Intervention|Enhanced Usual Care|EUC participants will receive anxiety education materials, a note in their medical record indicating the presence of elevated anxiety symptoms, and 4 brief monthly check-in calls with project staff. The primary outcome, anxiety symptoms, will be evaluated at 4-, 8- and 12-month follow-ups. Due to ethical concerns of withholding needed treatment, EUC participants will NOT be restricted from receiving mental health services including psychotherapy during the study period. The investigators fully expect that EUC participants may receive anxiety treatments (e.g., antianxiety and antidepressant medications or psychotherapy).
89255131|NCT04523181|Active Comparator|Antroquinonol with SOC|Antroquinonol in a dose of 100 mg (1 capsule) administered twice daily (BID) orally, for 14 days.
89255132|NCT04523181|Placebo Comparator|Placebo with SOC|Placebo (1 capsule) administered twice daily (BID) orally, for 14 days.
89255133|NCT04518293|Experimental|Triple - TAI|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
89255134|NCT04518293|Active Comparator|Dual - TA|Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg
89255135|NCT04518293|Active Comparator|Dual - TI|Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg
89255136|NCT04518293|Active Comparator|Dual - AI|Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg
89255137|NCT04488809|Experimental|Deep Water Running|Participants in this group will perform running in a vertical position in water. The sessions will be held in deep pool where the feet of the participants will not touch the ground.
89255138|NCT04488809|Active Comparator|Treadmill Running|Participants in this group will perform running on a treadmill.
89255139|NCT04488809|No Intervention|Control|Participants in this group will not interfere regular exercise for 8 weeks.
89255140|NCT04476797|Experimental|GC4711 + SBRT|
89255141|NCT04476797|Placebo Comparator|Placebo + SBRT|
89255142|NCT04475276|Placebo Comparator|Placebo|Life style modification with the placebo will be given for 12 weeks
89255143|NCT04475276|Experimental|Alphalipoic acid|Life style modification with Alpha lipoic acid in a dose of 600mg twice daily will be prescribed orally for 12 weeks
89255144|NCT04472429|Placebo Comparator|Group A : carboplatin+paclitaxel+placebo|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and placebo on Day 1 of each 28 day cycle
89255145|NCT04472429|Experimental|Group B : carboplatin+paclitaxel+retifanlimab|Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and retifanlimab on Day 1 of each 28 day cycle
89255146|NCT04456387|Experimental|Arm 1-on demand treatment|Part A-Participants will receive on-demand treatment with Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection for 6 months.
89255147|NCT04456387|Experimental|Arm 2- prophylaxis treatment|"Part B-Participants will receive prophylaxis treatment with Recombinant Human Coagulation Factor VIII-Fc fusion for 6 months.~12 Participants of them will receive PK assessment at ED1 and ED35(Participants will be tested for PK assessment at timepoints throughout the study based on exposure days (ED). One ED is equivalent to a 24 hours period in which drug is dosed.)，measured by one-stage assay, they would not be given prophylaxis treatment until the completion of PK blood collection."
89255148|NCT04446442|Experimental|Full Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1 mA will be administered over 20 minutes to the right crusI/II area of the cerebellum with a 15 second fade in period at the beginning and a 15 second fade out period at the end. During the tDCS administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
88804881|NCT01298167|Active Comparator|Fast Absorbing Gut Suture Superior/Inferior|This arm contains data from only the Fast Absorbing Gut Suture used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast absorbing gut suture.
89255149|NCT04446442|Sham Comparator|Sham Administration of Transcranial Direct Current Stimulation|Each subject will undergo psychosocial and behavioral assessments at a session prior to the administration of tDCS. The second session will include the tDCS Administration; a current of 1mA increased over 15 seconds and immediately decreased over 15 seconds to provide sensation associated with tDCS. During the sham administration, subjects will undergo functional MRI scanning. After the tDCS administration, subjects will repeat psychosocial and behavioral assessments.
89255150|NCT04439799|Active Comparator|Testosterone Cypionate Group|Participants in this group will receive the intramuscular Testosterone Cypionate intervention for four months
89255151|NCT04439799|Active Comparator|Natesto Group|Participants in this group will receive the intranasal testosterone (Natesto) intervention for four months.
89255152|NCT04435782|Experimental|JNJ-67896049|Participants will receive JNJ-67896049 tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
89255153|NCT04431674|Experimental|MRg-FUS MB Treatment|Patients with locally advanced breast cancer (LABC) and chest wall tumours will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
89255154|NCT04431648|Experimental|MRg-FUS MB Treatment|Patients with head and neck cancer will receive MRI-guided ultrasound-stimulated microbubble-treatment combined with radiotherapy on a LINAC.
89255155|NCT04428528||Neoadjuvant Chemotherapy Monitoring|"The first arm Neoadjuvant Chemotherapy Monitoring will investigate changes of measured photoacoustic markers and compare to these to histopathological indicators of breast tumor response to NAC. Changes in photoacoustic parameters will be made to a pre-treatment point over the course of treatment. Treatment will not be modified on the basis of our observations.~in this pilot observational study"
89255156|NCT04428528||Breast Mass Characterization|The second arm Breast Mass Characterization will investigate if breast masses (benign vs. malignant) can be characterized during clinical diagnostic work-up. Differences in the photoacoustic tissue-properties will be compared to histopathological evaluation.
89255157|NCT04428515||Radiotherapy Response Monitoring|Those undergoing radiation therapy treatment to their lymph nodes upon diagnosis of head and neck cancer
89255158|NCT04415944|Experimental|Second Look Laparoscopy and HIPEC with Carboplatin|Laparoscopic assessment of disease status of the peritoneal cavity with lysis of adhesions as necessary noting either no gross residual disease or minimal residual disease prior to or after resection. This is performed prior to establishment of a peritoneal perfusion circuit and hyperthermic intraperitoneal chemotherapy.
89255159|NCT04405596|Experimental|Ambroxol|Participants randomized to the 1350 mg/day group will begin with a dose of 450 mg, increasing bi-weekly to a dose of 1350 mg/day.
89255160|NCT04405596|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
89255161|NCT04396821|Experimental|Part A Q2W|Dosed every 2 weeks IV with TST001, starting dose is 1 mg/kg, multiple dose levels will be tested.
89255162|NCT04396821|Experimental|Part A Q3W|Dosed every 3 weeks IV with TST001, starting dose is 3 mg/kg, and multiple dose levels will be tested.
89255163|NCT04396821|Experimental|Part B Cohort A|Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma.
89255164|NCT04396821|Experimental|Part B Cohort B|Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies.
89255165|NCT04396821|Experimental|Part B Cohort C|Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma.
89255166|NCT04354259|Experimental|Ambulatory Cohort - Treatment|to receive a single dose of peginterferon lambda 180µg SC at baseline (day 0).
89255167|NCT04354259|Placebo Comparator|Ambulatory Cohort - placebo|Patients in the arm will be given a single injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
89255168|NCT04354259|Experimental|Hospitalized Cohort - Treatment|To receive a dose of peginterferon lambda 180µg SC at baseline and a second dose on day 5.
89255169|NCT04354259|Placebo Comparator|Hospitalized Cohort - placebo|Patients in the arm will be given an injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse. Patients will be administered a second dose of placebo on day 5.
89255170|NCT04341740|Experimental|Renal Cell Carcinoma or Urothelial Carcinoma Patients|Patients in both cohorts (RCC or UC) will undergo bone marrow aspiration under conscious sedation to withdraw 60 mL bone marrow aspirate and 75 ml of peripheral blood sample.
89255171|NCT04341064|Experimental|SHINE|Participants will be randomized to receive an intervention that provides information on skin cancer and preventive strategies, features a personalized skin cancer prevention packet that focuses on students' UVR exposure and skin cancer risk, and includes the creation of a individualized sun protection action plan.
89255172|NCT04341064|No Intervention|Standard Education|Participants will be randomized to receive information that covers general skin cancer education for pediatric populations.
89255173|NCT04332861||Prospective observational cohort|"For data analysis, the cohort will be subdivided as follows:~Identification and Validation cohorts~Patients with and without complicating factors~Patients with and without measured inflammatory marker levels"
89255174|NCT04332588|Experimental|Herceptin monotherapy cohort|Herceptin monotherapy cohort. Locally advanced HER2+ breast cancer patients receiving neoadjuvant Herceptin monotherapy prior to combination therapy will undergo three contrast-enhanced [18F]FMISO PET/MRI scans. Each imaging session will be identical. Imaging session one will be after diagnosis and before beginning monotherapy. Imaging session two will be within 10 days prior to beginning combination therapy with targeted HER2 agents. Imaging session three will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
89290362|NCT04646590|Experimental|Investigational Vaccine|Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 25 μg NCP-RBD protein. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
89255175|NCT04332588|Experimental|Combination therapy cohort|Locally advanced HER2+ breast cancer patients that receiving neoadjuvant combination therapy including Herceptin will undergo two contrast-enhanced [18F]FMISO PET/MRI imaging. Imaging session one will be after diagnosis and before beginning combination therapy. Imaging session two will be within 10 days prior to beginning the second round of combination therapy with targeted HER2 agents.
89255176|NCT04317482|Other|Standard social stress task|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three standard scenarios presented in counterbalanced order. This will involve approximately 30 minutes of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
89255177|NCT04317482|Other|Stressful experience in the ED|Participants will be given 4.5 minutes to prepare a 4.5-minute public speech on three experiences surrounding their most stressful ED visit. These experiences are presented in counterbalanced order. This will involve approximately 30 of public speaking stress given expected transitions. The public speeches will be presented in front of 1-2 individuals who are evaluating their presentations. Immediately after the public speaking task, participants will be asked to complete a mental arithmetic task for 15 minutes.
89255178|NCT04278898|Experimental|N-acetylcysteine then Placebo|
89255179|NCT04278898|Experimental|Placebo then N-acetylcysteine|
89255180|NCT04272658||value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of immune checkpoint inhibitors in metastatic melanoma"
89255181|NCT04254666|Other|Physical Literacy & Food Literacy Intervention|This is a pilot project to assess the feasibility of a physical literacy and food literacy intervention for adolescents with ID ages 12-16 years.
89255182|NCT04246047|Experimental|Belantamab mafodotin and Bortezomib plus Dexamethasone (Arm A)|
89255183|NCT04246047|Active Comparator|Daratumumab and Bortezomib plus Dexamethasone (Arm B)|
89255184|NCT04242017|Active Comparator|salvage RT + 6 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 6 months ADT
89255185|NCT04242017|Experimental|salvage RT + 24 months ADT|70 Gy to the prostate bed (2 Gy/fraction) + 24 months ADT
89255186|NCT04228068|Experimental|Intervention|The exercise program will be for the first 12 weeks after returning home. The intervention will be provided after patients return home. Each patient will receive 7 home visits in total over the intervention period by a physiotherapist (PT) and/or a physiotherapy assistant (PTA). Participants in the intervention group will receive a copy of the Toolkit before discharge from the hospital, and the study coordinator will walk them through it and explain what should be expected during the intervention period.
89255187|NCT04228068|Active Comparator|Conventional care|Usual care
89255188|NCT04217317|Experimental|CPI-613 in Combination with Bendamustine|CPI-613 at 2500 mg/m2 is infused intravenously (IV) via a central catheter over 2 hrs on Days 1and 2. Bendamustine at 90 mg/m2 is infused IV over 10 minutes on Days 1 and 2 of each treatment cycle, given immediately after CPI-613 administration.
89255189|NCT04210596|Active Comparator|Control group|Connective tissue graft harvested from the palate
89255190|NCT04210596|Experimental|Collagen matrix|Pig-derived collagen matrix (Fibro-Gide, Geistlich Biomaterials, Wolhusen, Switserland)
89255191|NCT04195984|Experimental|Treatment|Transcatheter mitral valve replacement with the Mi-thos® valve and transcatheter delivery system
89255192|NCT04194216|Active Comparator|Treatment arm A|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."
89255193|NCT04194216|Active Comparator|Treatment arm B|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg every 4 hours or clindamycin 150mg every 6 hours, for a duration of three days."
89255194|NCT04164641|Experimental|Noraxon myoRESEARCH™ Software|All participants will be assigned to this group to receive study intervention.
89255195|NCT04150939|Experimental|Treatment (cryoablation)|Beginning 1 week prior to the next scheduled standard of care immunotherapy infusion, patients undergo core biopsy of the lesion to be ablated and a non-ablated lesion and also undergo cryoablation. Patients undergo a mandatory second core biopsy of the non-ablated lesion at 4 weeks after cryoablation.
89255196|NCT04144790||ADHD+RLS|Twelve participants between the ages of 5 and 18 years with a clinical diagnosis of either RLS or ADHD, and iron deficiency.
89255197|NCT04143516|Experimental|Patients with Liver Metastases|The standard of care tumor ablation procedure, post-ablation biopsies and pre- and post-ablation PET scans. If the PET scan is positive (shows areas of cancer in the treated metastases), study participants will undergo additional needle biopsies of the positive areas on the scan. If the biopsies show areas of cancer cells that are still alive, the participants will be immediately retreated with a second ablation procedure.
89255198|NCT04130763|Experimental|FMT Capsule in Combination with Anti-PD-1 Therapy|FMT Capsule in Combination with Anti-PD-1 Therapy
89255199|NCT04130503|Experimental|PAP treatment- Acute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
89255200|NCT04130503|Active Comparator|Usual Care (HLE)|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.
89290363|NCT04646590|Placebo Comparator|Placebo comparator|Placebo for Recombinant Novel Coronavirus Vaccine (CHO cell), 0.5mL/vial, contains 0.25mg Aluminum hydroxide adjuvant. After mixing, take all the liquid and inject intramuscularly into deltoid muscle of upper arm.
89290364|NCT01218906||Cohort Population (Case )|Participants will be examined for febrile illness to diagnose dengue and to identify common causes of fever.
89290365|NCT03931668|Experimental|0.125mg single dose|single dose of TPN-672 0.125mg, 2 subjects
89255201|NCT04130503|Experimental|PAP treatment- Subacute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
89255202|NCT04130503|Other|Exploratory arm|Non-randomized comparison/exploratory group of subjects with ischemic stroke and Apnea-Hypopnea Index (AHI) <15 (approximately 120 participants) and approximately 60 subjects with ICH (who do not need legally authorized representative for consent - most likely mild form of ICH) and any level of AHI.
89255203|NCT04093739||G7 Freedom Constrained Liners|Patients that have been implanted with a G7 Freedom Constrained liner to repair hip malfunction or disease.
89255204|NCT04080804|Experimental|Nivolumab + Relatlimab|Nivolumab 480mg IV + Relatlimab 480mg IV D1 - optional Nivolumab 480 mg IV + Relatlimab 480mg IV D28 (D28 at clinician discretion i.e. surgery postponed)
89255205|NCT04080804|Experimental|Nivolumab + Ipilimumab|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg D1 then Nivolumab 3 mg /kg D14 and then optional Nivolumab 3 mg/kg D28 (D28 at clinician discretion i.e., surgery postponed)
89255206|NCT04071626|Experimental|Ertugliflozin Treatment Arm|Ertugliflozin 5 mg tablet once a day for 12 weeks
89255207|NCT04071626|Placebo Comparator|Placebo|Placebo tablet once a day for 12 weeks
89255208|NCT04070768|Experimental|Gemtuzumab Ozogamicin(GO) + Venetoclax|Gemtuzumab Ozogamicin(GO) + Venetoclax
89255209|NCT04069338|Active Comparator|Device Storz Modulith SLX-F2|Patients receive standard of care treatment for their urolithiasis using the Device Storz Modulith SLX-F2
89255210|NCT04069338|Active Comparator|Dornier Delta III Treatment|Patients receive standard of care treatment for their urolithiasis using the Dornier Delta III lithotripter
89255211|NCT04058743|Active Comparator|TKA with standard cobalt chromium components|Patients randomized to this group will receive the standard cobalt chromium components in their total knee arthroplasty
89255212|NCT04058743|Experimental|TKA with nickel free components|Patients randomized to this group will receive nickel free components in their total knee arthroplasty
89255213|NCT04057742||Group A|30 participants with a positive virtual crossmatch (VXM) at the time of transplant will be monitored for 12 months and undergo protocol biopsies on months 3 and 12 to detect subclinical rejection. Participants may also undergo clinically indicated biopsies for suspicion of rejection. AlloSure, AlloMap, immune cell phenotypes, and inflammatory cytokines will be measured at baseline (within 48 hours of transplant), 3 weeks, 6 weeks, 3 months (Standard of Care (SOC) biopsy), 6 months, 12 months (SOC biopsy), and additionally at the time of any indication biopsy (5-7 time points/participant). Participants in this group will be monitored for 12 months. Participants will be offered the option of donating either 22.5 mL of blood (Allosure+AlloMap+cytokines) or 52.5 mL of blood (Allosure+AlloMap+cytokines+immune cell phenotyping) at each visit. Participants may change their donation volume from 22.5 mL to 52.5 mL at any point during the study.
89255214|NCT04057742||Group B|24 participants with De novo donor specific antibodies (dnDSA) will undergo a SOC biopsy within approximately three months to determine the incidence of Active Antibody Mediated Rejection (AMR). Immune cell phenotyping, AlloSure, and AlloMap will be measured at the time of the SOC biopsy (1 timepoint/patient). This is a single-time point study, unless participants are diagnosed with AMR and require treatment. In this case, they would be enrolled in group C (see below).
89255215|NCT04057742||Group C|15 additional participants with the diagnosis of Chronic Active Antibody Mediated Rejection (cAMR) will undergo standard of care therapy and be monitored for treatment response with a follow-up biopsy at three months. Immune cell phenotyping, AlloSure, and AlloMap will be used at baseline (prior to index biopsy) and 3 month (follow-up surveillance biopsy) (2 timepoints/participant). Participants in this group will be monitored per SOC for three months (time between the two biopsies).
89255216|NCT04051008|No Intervention|Group 1 - Control|No intervention - participants will shop in-person as they usually would. Participants will receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
89255217|NCT04051008|Experimental|Group 2 - Online|Participants will utilize online grocery shopping (shopping at a local grocery store via an online platform). Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
89255218|NCT04051008|Experimental|Group 3 - Default|The default intervention will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make recipes from the provided recipe cards, and that they can modify it as they like. Participants will also receive recipe cards that follow the evidence-based DASH diet and correspond to dietary recommendations for diabetic patients.
89255219|NCT04036682|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|CLN-081 BID in single patient dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations that either have received or never received prior EGFR TKIs.
89255220|NCT04036682|Experimental|Phase 1 Dose Escalation (Rolling Six)|CLN-081 BID in Rolling Six dose escalation cohorts enrolling NSCLC patients with EGFR exon 20 insertion mutations.
89255221|NCT04036682|Experimental|Phase 2a Dose Expansion(s)|CLN-081 BID in expansion cohorts that may be opened at doses that meet pre-specified efficacy and safety criteria in Rolling Six cohorts.
89255222|NCT04036682|Experimental|Module A Food Affect|Single-dose CLN-081 150 mg with and without high fat food intake.
89255223|NCT04036682|Experimental|Module B|CLN-081 BID in NSCLC patients with EGFR exon 20 insertion mutations that have received prior systemic therapy for locally advanced or metastatic disease.
89255224|NCT04036682|Experimental|Module C|CLN-081 BID to patients with EGFR exon 20 insertion mutant NSCLC after prior therapy with an agent approved for the treatment of ex20ins mutant NSCLC.
89255225|NCT04032314||Healthy controls - cross-sectional project design|
89255226|NCT04032314||Patients - cross-sectional project design|
89255227|NCT04032314||Patients - longitudinal project design|
89255228|NCT04024670|Active Comparator|Patients on a high-risk obstetrics unit with an anticipated stay of two or more weeks|patients in this group will receive twice weekly sewing and embroidery interactions with a professional artist in residence.
89255229|NCT04024670|Active Comparator|Patients on a bone marrow transplant unit with an anticipated stay of two or more weeks|patients in this group will receive twice weekly visits with a professional storyteller.
89255230|NCT04024670|No Intervention|HRO Standard of Care|SOC
89255231|NCT04024670|No Intervention|BMT Standard of Care|SOC
89255232|NCT04002167|Experimental|Neurofeedback|The Neurofeedback group will receive 12 sessions of computerized cognitive intervention combined with neurofeedback in the lab.
89255233|NCT04002167|Active Comparator|Cognitive Training|The Cognitive Training group will receive 12 sessions of computerized cognitive intervention in the lab.
89255234|NCT04002167|No Intervention|Waitlist|Both Neurofeedback and Cognitive Training groups will be assigned to waitlist before starting the corresponding intervention.
89255235|NCT03987126|Active Comparator|Human Milk Oligosaccharide (HMO)|"10 g sachet, self-administered for 3 months.~2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have already been shown to very specifically modulate intestinal bacteria, namely the beneficially viewed bifidobacteria, in clinical studies in adults. Modulating bifidobacteria increases the levels of specific short chain fatty acids (SCFAs), such as butyrate, propionate and acetate.These SCFAs have been shown to stimulate colonic sodium and fluid absorption and exert proliferative effects on the colonocyte in experimental animal studies since the 1990s (Scheppach 1994). Therefore, increasing their levels would lead to an improvement in intestinal motility, as has been summarised previously (Koh 2016)"
89255236|NCT03987126|Placebo Comparator|Placebo|"10 g sachet, self-administered for 3 months.~Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape"
89255237|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm I (binimetinib, avelumab)|Patients will receive a 15-day lead-in of binimetinib, followed by binimetinib PO BID and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89255238|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm II (anti-OX40 antibody PF-04518600, avelumab)|Patients will receive a 15-day lead-in of anti-OX40 antibody PF-04518600, followed by anti-OX40 antibody PF-04518600 IV over 60 minutes and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89255239|NCT03971409|Experimental|CLOSED TO ENROLLMENT: Arm III (utomilumab, avelumab)|Patients will receive a 15-day lead-in of utomilumab, followed by utomilumab IV over 60 minutes every 4 weeks and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89255240|NCT03971409|Experimental|Arm A (avelumab, binimetinib, liposomal doxorubicin)|Patients receive a 15 day lead-in of binimetinib orally (PO) twice daily (BID) in the absence of disease progression or unacceptable toxicity. Patients then receive binimetinib PO BID on days 1-28, avelumab intravenously (IV) over 60 minutes on days 1 and 15, and liposomal doxorubicin IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89255241|NCT03971409|Experimental|Arm B (avelumab, sacituzumab govitecan)|Patients will receive a 15-day lead-in of sacituzumab govitecan given on day -15, followed by sacituzumab govitecan day 8 and day 15 of Cycle (C) 1; day 1,8, and 21 of C2; day 1, 15 and 21 of C3; day 8 and 15 of C4, and schedule continues with two weeks on, one week off for 21-day cycles. Patients also receive 10mg/kg avelumab over 60 minutes on day 1 and day 15 of each 28 day cycle. Cycles repeat in the absence of disease progression or unacceptable toxicity.
89255242|NCT03971409|Experimental|Arm C (avelumab, liposomal doxorubicin)|Patients will receive a 15-day lead-in of liposomal doxorubicin, followed by liposomal doxorubicin on Day 1 and 10mg/kg avelumab over 60 minutes on Day 1 and Day 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89255243|NCT03963583|Experimental|HEROIC Intervention Group|This group will receive the HEROIC intervention.
89255244|NCT03963583|Experimental|Waitlist Control Group|The waitlisted group will receive usual care for caregivers for the first 12 weeks, which is normally limited to inclusion in some clinical assessment and teaching during patient visits. Waitlisted participants will receive monthly study postcards to encourage retention. After 12 weeks, they will begin the intervention.
89255245|NCT03962647|Experimental|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
89255246|NCT03962647|Active Comparator|Letrozole Control|
89255248|NCT03947684|Experimental|TMS|Paired-pulse transcranial magnetic stimulation during active contraction to determine the influence of sex hormone fluctuations on cortical excitability in naturally cycling women.
89255249|NCT03933215||Cladribine Tablets|No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any injectable DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.
89255250|NCT03928210|Experimental|Digoxin|Digoxin 0.125 mg or 0.25 mg administered once daily for 7 days or until symptoms of toxicity Generic e.g. DIGOXIN Juvisé or Lenoxin Mite
89255251|NCT03925194|Experimental|Anakinra|
89255252|NCT03925194|Placebo Comparator|Placebo|
89255253|NCT03914807|Active Comparator|Whole (3.25%) milk|
89255254|NCT03914807|Active Comparator|Reduced fat (1%) milk|
89255255|NCT03908684||Head and Neck|The research will involve a clinical evaluation consisting of 200 patients in the head and neck cohort. It will assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity), spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
89290366|NCT03931668|Experimental|0.25mg single dose|single dose of 0.25mg, 10 subjects (8 for TPN-672, 2 for placebo)
89290367|NCT03931668|Experimental|0.5mg single dose|single dose of 0.5mg, 10 subjects (8 for TPN-672, 2 for placebo)
89290368|NCT03931668|Experimental|1mg single dose|single dose of 1mg, 10 subjects (8 for TPN-672, 2 for placebo)
89255256|NCT03908684||Prostate|The research will involve a clinical evaluation consisting of 100 patients in the prostate cohort. It will assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity), spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
89255257|NCT03908684||Rectum|The research will involve a clinical evaluation consisting of 20 patients in the rectal cohort. It will assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity), spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
89255258|NCT03897881|Experimental|mRNA-4157 and Pembrolizumab|Participants will receive up to 9 doses of mRNA-4157 (every 21 days). Participants may continue on pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.
89255259|NCT03897881|Active Comparator|Pembrolizumab|Participants will receive pembrolizumab (every 21 days) until disease recurrence, unacceptable toxicity, or they undergo up to 18 total cycles (approximately 1 year of treatment), whichever is sooner.
89255260|NCT03857321|Experimental|Insulin first, then placebo|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive placebo at visit 3 during second intervention period.
89255261|NCT03857321|Experimental|Placebo first, then insulin|Participants will be randomly assigned to receive placebo administered with an intranasal nebulizer-like device. At visit 3 during second intervention period, participants in this arm will receive insulin.
89255262|NCT03840928||Ankylosing Spondylitis|
89255263|NCT03840928||Fibromyalgia|
89255264|NCT03840928||Gout|
89255265|NCT03840928||Crohn's-related Arthritis|
89255266|NCT03840928||Juvenile Idiopathic Arthritis|
89255267|NCT03840928||Lupus|
89255268|NCT03840928||Myositis|
89255269|NCT03840928||Osteoarthritis|
89255270|NCT03840928||Osteoporosis|
89255271|NCT03840928||Psoriasis|
89255272|NCT03840928||Psoriatic Arthritis|
89255273|NCT03840928||Rheumatoid Arthritis|
89255274|NCT03840928||Scleroderma|
89255275|NCT03831711|Experimental|Diagnostic (68-Ga RM2, PET/MRI)|Patients receive 68-Ga RM2 IV and after 45 minutes undergo PET/MRI over 30-60 minutes.
89255276|NCT03831386|Active Comparator|Vacuum|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care. Participants in this arm will undergo Vacuum-Based IPC.
89255277|NCT03831386|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned at bedside. Participants in this arm will undergo Gravity-Based IPC.
89255278|NCT03818152|Other|study group|Reliability study isokinetic strength assessment of the lower limbs.
89255279|NCT03815656|Experimental|Implanted RC+S|Implanted Medtronic RC+S IPG with dual DBS electrodes in STN and GPi. DBS stimulation will be administered to: 1) STN alone, 2) GPi alone, 3) cooperative STN + GPi, and 4) adaptive, closed-loop stimulation of STN and/or GPi.
89255280|NCT03812185|Other|TEE image before and after suctioning orogastric tube|for intraoperative TEE used cardiac or transplant cases, TEE images will be stored before and after suctioning orogastric tube which is attached to TEE probe cover. This Arm is TEE image BEFORE suctioning.
89255281|NCT03789110|Experimental|Nivolumab+Ipilimumab|"Ipilimumab is administered intravenously every 6 weeks~Nivolumab is administered intravenously every 2 weeks"
89255282|NCT03777800|Experimental|Body Therapy|Participants in the intervention condition will be assigned to a 6-month body therapy treatment focused on 24 individual body treatments including conversations and direct physical treatment of the body combined with home-based daily practice of meditation.
89255283|NCT03777800|Active Comparator|Treatment As usual|Participants in the control condition will be offered treatment as usual, which is psychiatric medication and/or individual psychotherapy as deemed relevant by the psychiatrist.
89255284|NCT03777176|Experimental|Standard of Care + dasiglucagon|4 weeks (Treatment Period 1) + 4 weeks (Treatment Period 2) of dasiglucagon treatment as an SC infusion starting at 10 µg/hr on top of standard of care
89255285|NCT03777176|Other|Standard of Care Only|4 weeks (Treatment Period 1) of standard of care only + 4 weeks (Treatment Period 2) of dasiglucagon treatment as an SC infusion starting at 10 µg/hr on top of standard of care
89255286|NCT03759522|Experimental|Healthy Controls|
89255287|NCT03759522|Experimental|Fibromyalgia Subjects|
89255288|NCT03759522|Experimental|Chronic Fatigue Syndrome Subjets|
89255289|NCT03759522|Experimental|Multiple Sclerosis Subjects|
89255290|NCT03738098|Active Comparator|Traditional Genetic Counseling|Standard of care genetic counseling session
89255291|NCT03738098|Experimental|GUÍA|Standard of care genetic counseling session with Genomic Understanding, Information and Awareness (GUÍA).
89255292|NCT03721341|Active Comparator|Standard arm|Standard of care treatment: palliative radiotherapy, chemotherapy, immunotherapy, hormones, or observation, is at the discretion of the treating oncologist.
89255293|NCT03721341|Experimental|Stereotactic Arm|Stereotactic ablative radiotherapy, plus standard of care treatment: chemotherapy, immunotherapy, hormones, or observation given at the discretion of the treating oncologist.
89255294|NCT03692910|Experimental|Part A (Open-label): SAGE-217|Participants self-administered SAGE-217, 30 milligrams (mg), oral capsule, once daily (QD), in the evening, from Day 1 to Day 14.
89255295|NCT03692910|Experimental|Part B (Double-blind): SAGE-217|Participants were to receive SAGE-217, 30 mg, oral capsule, QD, in the evening, from Day 1 to Day 14 in Part B of the study. However, as per the Sponsor's decision, the Part B of the study was not conducted.
89290369|NCT03931668|Experimental|2mg single dose|single dose of 2mg, 10 subjects (8 for TPN-672, 2 for placebo)
89290370|NCT03931668|Experimental|3mg single dose|single dose of 3mg, 10 subjects (8 for TPN-672, 2 for placebo)
89255296|NCT03692910|Placebo Comparator|Part B (Double-blind): Placebo|Participants were to receive SAGE-217 matching placebo capsule, orally, QD, in the evening, from Day 1 to Day 14 in Part B of the study. However, as per the Sponsor's decision, the Part B of the study was not conducted.
89255297|NCT03682289|Experimental|Arm I (Ceralasertib Monotherapy)|As monotherapy ceralasertib will be given at a starting dose of 160 mg two times per day (BID), on days 1-14 of a 28-day cycle for participants who are BAF250a negative or show an ATM-Mutation by CLIA assay. Treatment will continue until disease progression, unacceptable toxicity, or participant withdrawal from study, whichever occurs first.
89255298|NCT03682289|Experimental|Arm II (Ceralasertib, Olaparib)|In combination with olaparib, ceralasertib will be given at a continuous daily dose of 160 mg daily days 1-7 in each 28-day cycle. Olaparib will be given at a starting dose of 300 mg twice daily days 1-28 of a 28-day cycle for participants who are BAF250a positive. Treatment will continue until disease progression, unacceptable toxicity, or participant withdrawal from study, whichever occurs first.
89255299|NCT03682289|Experimental|Arm III (Ceralasertib, Durvalumab)|In combination with durvalumab, ceralasertib will be given at a continuous daily dose of 240 mg BID days 1-7 of a 28-day dosing schedule. Durvalumab will be given at a flat dose of 1500 mg IV on day 8 of a 28-day cycle for participants with histologically confirmed endometrial cancers. Participants treated with the combination of ceralasertib plus durvalumab may continue treatment beyond first radiographic progression until the occurrence of either confirmed radiographic progression or clinical progression, whichever occurs first.
89255300|NCT03675256|Experimental|Arm 1|immediate Cervarix, delayed MenVeo vaccine
89255301|NCT03675256|Experimental|Arm 2|immediate Gardasil 9, delayed MenVeo vaccine
89255302|NCT03675256|Active Comparator|Arm 3|immediate MenVeo, delayed Gardasil 9 vaccine
89255303|NCT03645863|Experimental|Cohort 1|Subject will receive MT-6548 on Day 1, 4, and 7. Subject will receive Iron supplement A on Day 1, 4, or 7. Subject will receive Iron supplement B on Day 1, 4, or 7.
89255304|NCT03645863|Experimental|Cohort 2|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement C on Day 1 or 4.
89255305|NCT03645863|Experimental|Cohort 3|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement D on Day 1 or 4.
89255306|NCT03643367|Experimental|Sevoflurane Sedation|Patients randomized into experimental group will be treated with sevoflurane during 4 hours
89255307|NCT03643367|Active Comparator|Propofol Sedation|Patients randomized into Control Group will get continued intravenous sedation with propofol
89255308|NCT03626038|Experimental|Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.|"Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System.~Subjects can be enrolled prospectively or retrospectively as indicated in the protocol."
89255309|NCT03587844|Experimental|not been previously treated with brentuximab vedotin.|Patients with MF/SS who have not been previously treated with brentuximab vedotin. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. As of October 2020, the Simon two stage design for Cohort 1 has restarted at the 1.2 mg/kg dose.
89255310|NCT03587844|Experimental|treated with reduced dose brentuximab vedotin|Patients with MF/SS who were previously treated with brentuximab vedotin. Up to 10 patients will be enrolled onto this cohort. Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. The 0.9mg/kg dose did not meet the primary endpoint for response, therefore 1.2 mg/kg has been chosen as the dose for Cohort 2. As of October 2020, enrollment on our exploratory Cohort 2 has opened at the 1.2 mg/kg dose.
89255311|NCT03587844|Experimental|Patients with LyP|Patients with LyP patients with lymphomatoid papulosis will receive brentuximab vedotin 0.9 mg/kg as an intravenous infusion over 30 minutes every three weeks. Cohort 3 will enroll patients concurrently with Cohort 1. Treatment may be held if felt to be in patient's best interest (for example: for toxicity or no active disease). Treatment can be reinitiated after discussion with MSK PI as long as the study is still open and patient has not received alternate systemic therapy.
89255312|NCT03584152|Active Comparator|DRUG ARM A|Norco 5Mg-325Mg Tablet, administered orally every 4 hours for 5 days total
89255313|NCT03584152|Active Comparator|DRUG ARM B|Tylenol 325Mg Caplet, administered orally every 4 hours for 5 days total. Ibuprofen 200 mg administered orally every 4 hours for 5 days total.
89255314|NCT03584100|Experimental|Patients with prior axillary lymph node dissection|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
89255315|NCT03584100|Active Comparator|Healthy Volunteers|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
89255316|NCT03563677|No Intervention|Usual care|Standard evaluation process for patients approaching a center for rare diseases with an unclear diagnosis. The process includes the evaluation of complete medical records byan experienced physician, an outpatient visit to the center, and case discussion between experts. The process may also include an inpatient stay, a local case conference and a case conference between centers for rare diseases from different cities
89255317|NCT03563677|Experimental|New Innovative Care|The innovative evaluation process includes the additional involvement of a psychiatrists/psychosomatic expert in all of the processes described for the usual care arm plus the option to use telemedicine in the process of evaluation in addition to outpatient and inpatient visits and to transfer the patient back into standard care (i.e., primary care physician, rehabilitation, psychological/psychosomatic specialized care, etc.)
88804882|NCT01280695|Placebo Comparator|Placebo|Placebo capsule once daily
88804883|NCT01280695|Experimental|MSDC-0602 100 mg|MSDC-0602 capsule 100 mg once daily
88804884|NCT01280695|Experimental|MSDC-0602 250 mg|MSDC-0602 capsule 250 mg once daily
88804885|NCT01280695|Experimental|MSDC-0602 500 mg|MSDC-0602 capsule 500 mg once daily
89255318|NCT03545464|Experimental|Antihistamines + placebo of cortancyl|"- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.~Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally"
89255319|NCT03545464|Active Comparator|Association of antihistamines and cortancyl|"- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.~Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally"
89255320|NCT03517228|Experimental|total laparoscopic or robotic-assisted hysterectomy|All patients who are consented for a total laparoscopic or robotic-assisted hysterectomy will be eligible for the trial, unless the surgeon does not plan to use a uterine manipulator.
89255321|NCT03505905|Experimental|Pregnenlone (phase 1 and 2)|Participants will receive pregnenolone at phase 1 (baseline-WK 7) and 2 (WK 8-16). The titration schedule is as follows: at baseline a 50 mg (BID, 7 days). WK 1=150 mg (BID, 7 days); WK 2=250 mg (BID, 14 days) and WK 4=250 mg (BID, 14 days) (BID, 14 days). At phase 2 (WK 8) to maintain the double blind of rerandomization, treatment in all conditions recommence at a dosage frequency similar to phase 1. At WK 8=250 mg (BID, 7 days); at WK 9=250 mg (BID, 7 days); WK 10=250 mg (BID, 14 days) and WK 12=250 mg (BID, 14 days) . During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (BID, 4 days) and 50 mg (BID, 4 days), discontinue.
89255322|NCT03505905|Placebo Comparator|Placebo rerandom to placebo|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1= placebo (7 days); at WK 2=placebo (14 days) and WK 4=placebo (14 days). Placebo nonresponders rerandomized to placebo: At WK 8=placebo (7 days);WK 9=placebo (7 days);WK 10=placebo (14 days) and WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo (4 days) and placebo (4 days), discontinue.
89255323|NCT03505905|Experimental|Placebo rerandom to pregnenolone|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo nonresponders who are rerandomized to pregnenolone: At WK 8=250 mg (7 days);WK 9=250 mg (7 days);WK 10=250 mg (14 days) & WK 12=250 mg (14 days). During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (4 days) and 50 mg (4 days), discontinue.
89255324|NCT03505905|Placebo Comparator|Placebo responsive cont placebo|Participants will placebo throughout phase 1 (baseline- WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Responders continue to receive placebo at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo responders remain on placebo: At WK 8, placebo (7 days); WK 9=placebo (7 days); WK 10=placebo (14 days) & WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo= 4 days) and placebo=4 days, discontinue.
89255325|NCT03449381|Experimental|Dose Escalation|
89255326|NCT03449381|Experimental|Dose Expansion|
89255327|NCT03422302|Experimental|Treatment (CT simulation, CPAP, DIBH, SBRT, BiPAP)|Patients undergo free-breathing, DIBH, and CPAP CT simulation scans. If patient has difficulty exhaling on CPAP, then patient undergo BiPAP CT simulation. The attending physician then compares all 3 simulation treatment plans (free-breathing, DIBH, and CPAP/BiPAP) and determines which method to use during SBRT. If CPAP/BiPAP is chosen as preferred method, patients wear CPAP/BiPAP over 1 hour prior to SBRT, then again during SBRT over 30-60 minutes. All other patients complete free-breathing or DIBH during SBRT over 30-60 minutes.
89255328|NCT03403699||nondiabetics|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must be a healthy control and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
89255329|NCT03403699||Diabetic|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) carry the diagnosis of diabetes and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
89255330|NCT03403283||Group 1|Diabetic
89255331|NCT03403283||Group 2|Healthy Controls
89255332|NCT03351348|Active Comparator|Saline + usual post-operative medications|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
89255333|NCT03351348|Experimental|Bupivacaine + usual post-operative medications|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
89255334|NCT03326791|Experimental|Intervention group|Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.
89255335|NCT03326791|Placebo Comparator|Control group|Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.
89255336|NCT03281902||Ancillary-Correlative (genetic profile analysis)|Patents undergo collection of blood and stool samples at baseline, 7 days after letrozole monotherapy treatment, and at completion of each cycle, urine samples at baseline and completion of each cycle, and saliva samples at baseline. Patients also undergo collection of blood and urine samples at disease progression. Biopsy samples are analyzed for genetic profile via genome sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model.
89255337|NCT03220776|Experimental|Gabapentin, then N-Acetylcysteine, then Placebo Oral Capsule|"Three, 1-week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo"
89255338|NCT03220776|Experimental|N-Acetylcysteine, then Placebo Oral Capsule, then Gabapentin|"3, 1 week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg"
89255339|NCT03220776|Placebo Comparator|Placebo Oral Tablet, then Gabapentin, then N-Acetylcysteine|"Three, 1-week conditions. Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg"
89255340|NCT03220776|Experimental|Placebo Oral Capsule, then N-Acetylcysteine, then Gabapentin|"Three, 1-week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg"
89255341|NCT03220776|Experimental|Gabapentin, then Placebo Oral Capsule, then N-Acetylcysteine|"Three, 1-week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg"
89255342|NCT03220776|Experimental|N-Acetylcysteine, then Gabapentin, then Placebo Oral Capsule|"Three, 1-week conditions.~Week 1 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~N-Acetylcysteine: 5 day trial of N-acetylcysteine with titration to 2,400mg~Week 2 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Gabapentin: 5 day trial of gabapentin with titration to 1,200mg~Week 3 condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Placebo Oral Tablet: 5 day trial of matched placebo"
89255343|NCT03201874|Active Comparator|Education Control|In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
89255344|NCT03201874|Experimental|Pain Self-Management Intervention|In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
89255345|NCT03130036|Experimental|No risk of disease|Subjects with no identifiable risk of Alzheimer's Disease
89255346|NCT03130036|Experimental|Asymptomatic|Asymptomatic subjects with increased risk of Alzheimer's disease
89255347|NCT03130036|Experimental|Early Alzheimer's or Mild Cognitive Impairment|Subjects with early Alzheimer's Disease or Mild Cognitive Impairment (MCI)
89255348|NCT03122197|Experimental|Letrozole|"The BN-16-01 main study treatment starting dose will be 2.5mg administered orally once daily. Daily doses up to 10mg and single doses of 30mg have been shown to be safe in prior studies and therefore we expect that letrozole doses up to 20mg in this study will be safe.~The recommended phase II dose (RP2D) will be considered the dose that results in ≥ 2uM letrozole concentration in the tumor or the highest dose achieved (20mg daily for cohort level 7) with < 2/6 patients with DLTs. This dose will be planned for future phase II studies to determine potential efficacy."
89290371|NCT03931668|Experimental|4mg single dose|single dose of 4mg, 10 subjects (8 for TPN-672, 2 for placebo)
89290372|NCT00220805|Experimental|Group 1|
89290373|NCT00220805|Placebo Comparator|Group 2|
89255349|NCT03122197|Experimental|Letrozole and temozolomide|Phase 1 expansion cohort of letrozole 15mg administered in combination with 50 mg/m2 metronomic temozolomide (TMZ) in patients with high grade gliomas. Letrozole 15mg will be administered orally once daily for a 7-day lead-in period. After 7 days subjects will continue letrozole in combination 50 mg/m2 TMZ administered orally once daily.
89255350|NCT03122197|Experimental|Previously Received letrozole and temozolomide|Phase 1 expansion cohort of two identified subjects with gliomas who previously participated in the main study UCCI-BN-16-01 who received as physician's choice of treatment 50 mg/m2 TMZ in combination with dosing of 15 mg letrozole.
89255351|NCT03099434|Active Comparator|Live Donor Champion + Facebook App|The LDC program consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy. At session 3, the the Facebook app will be incorporated and given to candidates. The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network.
89255352|NCT03099434|Active Comparator|Facebook App|The Facebook app provides step-by-step instructions for creating a Facebook post that details each waitlist candidate's struggle with ESRD and their need for a live donor. The post is then uploaded to Facebook so it can be shared with the candidate's Facebook social network. The Facebook App prompts users with specific questions to create a narrative. Links to supplemental resources are auto-populated into the post to provide anyone that views the post with vetted information about the risks, benefits, and process of live donation. Candidates using the Facebook app attend one focus group session held at the transplant center where they are provided with verbal instructions and visual demonstrations of installation and use of the Facebook app.
89255353|NCT03099434|No Intervention|Standard of Care|Standard of Care does not include any of the interventions detailed above, but rather normal routine care as this is the control group.
89255354|NCT03059823|Experimental|Dose Escalation-Q2W|INCMGA00012 treatment once every 2 weeks.
89255355|NCT03059823|Experimental|Dose Escalation- Q3W|INCMGA00012 treatment once every 3 weeks.
89255356|NCT03059823|Experimental|Dose Escalation- Q4W|INCMGA00012 treatment once every 4 weeks.
89255357|NCT03059823|Experimental|Expansion Cohort|INCMGA00012 treatment for locally advanced or metastatic solid tumors.
89255358|NCT03029702|Active Comparator|Usual Care|Participants will undergo standard counseling and be prescribed a treatment for their GDM. Treatments include insulin, glyburide, and metformin.
89255359|NCT03029702|Active Comparator|Individualized Treatment|Participants will undergo standard counseling and be matched to therapy based on their GDM mechanism. Treatments include insulin, glyburide, and metformin.
89255360|NCT03014648|Experimental|Atezolizumab|"Atezolizumab will be given on day 1 of a 21-day cycle at 1200 mg IV over 60 (plus or minus 15) minutes for first infusion; can be decreased to 30 (plus or minus 10) minutes for subsequent cycles.~Atezolizumab will be given as long as the patient continues to experience clinical benefit in the opinion of the investigator or until unacceptable toxicity, symptomatic deterioration attributed to disease progression.~There will be no dose reduction for Atezolizumab. Patients may temporarily suspend study treatment for up to 84 days beyond the scheduled date of delayed infusion if study drug-related toxicity requiring dose suspension is experienced. If Atezolizumab is held because of adverse events for greater than 84 days beyond the scheduled date of infusion, the patient will be discontinued from Atezolizumab and will be followed for safety and efficacy."
89255361|NCT03009045|Experimental|Drug: 200mg oral Tedizolid|200mg oral tablet of tedizolid to be taken once daily
89255362|NCT03006926|Experimental|lenvatinib 8 or 12 mg plus pembrolizumab 200 mg|Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.
89255363|NCT02982629|Placebo Comparator|Usual Care|Patients in this group do not receive any letters or phone calls after missing follow-up appointment.
89255364|NCT02982629|Active Comparator|Reminder Letter Intervention|Patients in this group receive letters and phone calls after missing follow-up appointment to reschedule the appointment.
89255365|NCT02966899|Experimental|Omega-3 fatty acids|30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.
89255366|NCT02890641||Children undergoing epilepsy surgery at the Rothschild Foundation, Paris.|Sequencing of paired blood-brain DNA samples
89255367|NCT02886650|Experimental|Thermocoagulation|
89255368|NCT02861417|Experimental|Group I (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
89255369|NCT02861417|Experimental|Group II (matched donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months.
89290374|NCT01220934||Cohort|
89290375|NCT00220727|Experimental|Group 1|Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.14 mL/kg/min)
89290376|NCT00220727|Experimental|Group 2|Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.08 mL/kg/min)
89290377|NCT01221012||men wearing Semipermeable garment|
89290378|NCT01221012||air permeable garment type BP2|
89290379|NCT01221012||air permeable garment type BP3|
88804886|NCT01280695|Active Comparator|Pioglitazone 45 mg|Pioglitazone capsule 45 mg once daily
89255370|NCT02861417|Experimental|Group III (haploidentical donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score > 3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
89255371|NCT02861417|Experimental|Group IV (matched donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score >3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
89255372|NCT02861417|Experimental|Group V (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
89255373|NCT02861417|Experimental|Group VI (matched or haploidentical transplant, chemotherapy)|Patients receiving fully matched or haploidentical donor transplant receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
89255374|NCT02850900|Experimental|Internet Survey|Subject will receive an electronic survey weekly to complete
89255375|NCT02850900|No Intervention|No Survey|No intervention
89255376|NCT02845505||IVUS-CAMS|patients who undergo coronary computed tomography angiography, invasive coronary angiography and IVUS
89255377|NCT02769338|Experimental|QI with External Facilitation|Receive external facilitation to support implementation of the quality improvement program
89255378|NCT02769338|No Intervention|Control|Non-Intervention VA Medical Centers
89255379|NCT02760498|Experimental|Group 1|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously (IV) every 2 weeks (Q2W).
89255380|NCT02760498|Experimental|Group 2|Patients with unresectable locally advanced CSCC. Cemiplimab administered IV Q2 weeks.
89255381|NCT02760498|Experimental|Group 3|Patients with metastatic CSCC to distant sites or lymph nodes. Cemiplimab administered IV Q3 weeks.
89255382|NCT02760498|Experimental|Group 4|Patients with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] Cemplimab administered IV Q4 weeks.
89255383|NCT02760498|Experimental|Group 6|Patients with advanced CSCC (metastatic [nodal or distant] or locally advanced) who received cemiplimab IV Q3W for at least 27 weeks without experiencing disease progression, will have the option to receive cemiplimab by subcutaneous (SC) injection Q3W (first 12 patients) or Q6W (next ≥ 6 patients) basis.
89255384|NCT02684058|Experimental|LGG cohort: dabrafenib and trametinib|Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)
89255385|NCT02684058|Active Comparator|LGG cohort: carboplatin and vincristine|Participants in the LGG cohort randomized to receive active comparator chemotherapy (carboplatin and vincristine). Participants received one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.
89255386|NCT02684058|Experimental|HGG cohort: dabrafenib and trametinib|Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)
89255387|NCT02644369|Experimental|Pembrolizumab|Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
89255388|NCT02571036|Experimental|Escalation|Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. [Closed for Enrollment]
89255389|NCT02571036|Experimental|Expansion Cohort 1|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. [Closed for Enrollment]
89255390|NCT02571036|Experimental|Expansion Cohort 2|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. [Closed for Enrollment]
89255391|NCT02571036|Experimental|Expansion Cohort 3|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. [Closed for Enrollment]
89255392|NCT02571036|Experimental|Expansion Cohort 4|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.[Closed for Enrollment]
89255393|NCT02571036|Experimental|Expansion Cohort 5|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.[Closed for Enrollment]
89255394|NCT02571036|Experimental|Expansion Cohort 6|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. [Closed for Enrollment]
89255395|NCT02571036|Experimental|Expansion Cohort 7|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas. [Closed for Enrollment]
89255396|NCT02571036|Experimental|Expansion Cohort 8|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.[Closed for Enrollment]
89255397|NCT02571036|Experimental|Expansion Cohort 9|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). [Closed for Enrollment]
89255398|NCT02571036|Experimental|Expansion Cohort 10|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. [Closed for Enrollment]
89290380|NCT01221012||air permeable garment type MO|
89255399|NCT02571036|Experimental|Extension Cohort|150 mg DCC-2618 given once daily in repeated 28-day cycles for active patients from the Escalation and Extension Phases.
89255400|NCT02561273|Experimental|Treatment (combination chemotherapy, lenalidomide)|"Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows:~TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care.~MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
89255401|NCT02506959|Experimental|Treatment (panobinostat, Gem/Bu/Mel, ASCT)|Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.
89255402|NCT02502006|Experimental|High Dose|During each treatment phase, subjects will receive celecoxib (200 mg by mouth twice daily), naproxen (500 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
89255403|NCT02502006|Experimental|Low dose|During each treatment phase, subjects will receive celecoxib (100 mg by mouth twice daily), naproxen (250 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an empty stomach with a full glass of water.
89255404|NCT02457598|Experimental|Tirabrutinib + Idelalisib (Combination I)|"Dose Escalation:~Participants will receive a single dose of tirabrutinib on Day 1 of Cycle 1 and tirabrutinib 20 mg + idelalisib 50 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 20 mg + idelalisib 50 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + idelalisib up to 100 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib for an additional 6 years from the date of Protocol Amendment 8."
89255405|NCT02457598|Experimental|Tirabrutinib + Entospletinib (Combination II)|"Dose Escalation:~Participants will receive a single dose of tirabrutinib 40 mg on Day 1 of Cycle 1 and tirabrutinib 40 mg + entospletinib 200 mg on Day 2 and remainder of Cycle 1. For all subsequent cycles, participants will receive tirabrutinib 40 mg + entospletinib 200 mg. Based on DLTs observed in subsequent cohorts, additional participants will be enrolled and administered escalating dose of tirabrutinib up to 160 mg + entospletinib up to 400 mg to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + entospletinib for an additional 6 years from the date of Protocol Amendment 8."
89255406|NCT02457598|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab (Combination III)|"Dose escalation:~Participants will receive tirabrutinib + idelalisib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and idelalisib doses will depend on results of Combination I data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8."
89255407|NCT02457598|Experimental|Tirabrutinib + Entospletinib + Obinutuzumab (Combination IV)|"Dose escalation:~Participants will receive tirabrutinib + entospletinib + obinutuzumab 1000 mg at 8 doses (tirabrutinib and entospletinib doses will depend on results of Combination II data). Based on DLTs observed, additional participants will be enrolled to determine the maximum tolerated dose (MTD) of tirabrutinib either once daily or twice daily.~Dose Expansion:~Additional participants will receive tirabrutinib + idelalisib + obinutuzumab for an additional 6 years from the date of Protocol Amendment 8."
89255408|NCT02457598|Experimental|Single Agent Tirabrutinib (Combination V)|Participants with relapsed or refractory chronic lymphocytic leukemia (CLL) may be enrolled to receive tirabrutinib 80 mg once daily.
89255409|NCT02447692|Active Comparator|PSV ventilation strategy|The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.
89255410|NCT02447692|Active Comparator|PAV+ ventilation strategy|The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.
89255411|NCT02359825|No Intervention|standard epineural repair <24 hours|epineural repair following treatment with standard epineural repair alone in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired <24 hours after injury); no medication used
89255412|NCT02359825|No Intervention|standard epineural repair >24 - 72 hours|epineural repair following irrigation with standard epineural repair alone in sensory nerve injuries in the upper extremity in short-term chronic injuries (>24-<72 hours after injury); no medication used
89255413|NCT02359825|No Intervention|epineural repair with autografting within 48 hours|epineural repair with auto grafting within 48 hours; no medication used
89255414|NCT02359825|Experimental|epineural repair <24 hours using PEG|epineural repair following treatment with standard epineural repair using PEG in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired <24 hours after injury); PEG is used during the surgical procedure
89255415|NCT02359825|Experimental|epineural repair >24 but <72 hours using PEG|epineural repair following treatment with standard epineural repair using PEG in sensory nerve injuries in the upper extremity in short-term acute injuries (repaired >24 hours but < 72 hours after injury); PEG is used during the surgical procedure
89255416|NCT02359825|Experimental|epineural repair with autografting within 48 hours, using PEG|epineural repair with auto grafting within 48 hours
89255417|NCT02355301||patients with orthopedic disorders|Patients with muscular skeletal impairments receiving a treatment (A, B, C...). The investigators compare these treatments (A, B, C...) in function of ICF model in order to improve the quality of care in orthopedic department.
89290381|NCT01221012||air permeable garment type BP1|
89290382|NCT01225770|Experimental|Green tea|Gargling with green tea
89290383|NCT01225770|Active Comparator|water|Gargling with water
89255418|NCT02347670|Active Comparator|Group 1M- Community Site|"Participants randomized to Group 1-Main will attend follow-up visits at one of the four main community sites. A glaucoma specialist will perform the comprehensive eye examination and a ophthalmic technician will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
89255419|NCT02347670|Active Comparator|Group 2- Office-Based|"Office-Based, Follow-Up Eye Care with Patient Navigation Protocol: Participants randomized to Group 2 will attend follow-up visits at the Wills Eye Hospital Glaucoma Research Center. A glaucoma specialist will perform the eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
89255420|NCT02347670|Active Comparator|Group 3- Office-Based|"Group 3- follow-up eye care at the Wills Eye Hospital. There will be no charge or co-pay for these visits. Those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire. These participants will receive a phone number to call and schedule their appointment and will receive a reminder phone call similar to the standard appointment-reminding procedure commonly used at the Wills Eye Hospital. Group 3 represents a realistic choice currently available for patients and thus will be used to compare with usual care and will have 2-3 visits over the one-year period depending on diagnosis.~Intervention: Office-Based Usual Care"
89255421|NCT02347670|Active Comparator|Group 1R- Community Site|"Participants randomized to Group 1-Randomized will attend follow-up visits at one of the four main community sites, these participants were randomized from the 40 community sites to the closest community location. A glaucoma specialist will perform the comprehensive eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
89255422|NCT02327455|Experimental|Stress Dobutamine Echocardiographic 4DE Image System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
89255423|NCT02323698|Active Comparator|Caffeine/AIH|Subjects with chronic, motor-incomplete SCI receive Caffeine then AIH
89255424|NCT02323698|Active Comparator|Placebo/AIH|Subjects with chronic, motor-incomplete SCI receive Placebo then AIH
89255425|NCT02323698|Active Comparator|Caffeine/SHAM|Subjects with chronic, motor-incomplete SCI receive Caffeine then SHAM
89255426|NCT02308072|Experimental|Olaparib + Cisplatin + IMRT|"Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5~Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment."
89255427|NCT02304809|Experimental|VEMURAFENIB|"all eligible patients entering the study will receive oral Vemurafenib as monotherapy.~Vemurafenib ZELBORAF 240 mg tablets Per OS 960 mg twice daily, to a total daily dose of 1,920 mg Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks Safety will be assessed continuously~Treatment will be pursed until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient refusal."
89255428|NCT02246270|Experimental|Intravesical heparin|Recurrent UTI subject receives intravesical heparin once every week for 6 weeks
89255429|NCT02246270|Active Comparator|Placebo|Recurrent UTI subject receives intravesical saline once every week for 6 weeks
89255430|NCT02115880|Experimental|Prevention programme|
89255431|NCT02115880|No Intervention|Control (treatment as usual)|
89255432|NCT02101008|Other|Disulfiram and chelated zinc|There is only one arm. All patients are treated wtih disulfiram and chelated zinc.
89255433|NCT02006576|Placebo Comparator|COPD, Placebo|Placebo three times daily
89255434|NCT02006576|No Intervention|Control subject|Control subjects, no intervention
89255435|NCT02006576|Experimental|COPD, ibuprofen|600 mg ibuprofen three times daily for 48 weeks
89255436|NCT01913730|No Intervention|No prolonged therapy is scheduled|
89255437|NCT01913730|Experimental|Bortezomib Dexamethasone (Biochemical relapse)|Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
89255438|NCT01851317||Intracuff pressure|Procedure/Surgery: Cuffed endotracheal tube
89255439|NCT01851122|Placebo Comparator|Placebo capsule|
89255440|NCT01851122|Experimental|L-theanine capsule|
89255441|NCT01667952||Cancer Survivors|The purpose of this study is to establish a registry of survivors of cancer, tumors,or a related illness. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among survivors of cancer, tumors, or a related illness.
89255442|NCT01651403|Experimental|Tenofovir DF (Blinded Randomized Treatment)|Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
89255443|NCT01651403|Placebo Comparator|Placebo to match TDF (Blinded Randomized Treatment)|Participants will receive TDF placebo for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
89255444|NCT01651403|Experimental|Tenofovir DF (Open-label Treatment)|Following 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3) of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 120 weeks (protocol amendment 2) or 144 weeks (protocol amendment 3).
89290384|NCT01072097|Active Comparator|Atorvastatin|6 months atorvastatin 20mg/day treatment
89255445|NCT01651403|Experimental|Tenofovir DF (Open-label Extension Phase)|Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in participants of their age and weight.
89255446|NCT01515748|Other|Surgery + Adjuvant Chemotherapy (SC)|Participants underwent surgery within 2 weeks after randomization followed by adjuvant chemotherapy with S-1 [(Gimeracil) + Oxo (Oteracil)] 40 milligrams per square meter (mg/m^2) administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after End-of-Treatment (EOT) until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 10 years).
89255447|NCT01515748|Experimental|Neoadjuvant Chemotherapy +Surgery +Adjuvant chemotherapy (CSC)|Participants received neo-adjuvant chemotherapy with Docetaxel 50 mg/m^2 intravenously (IV) for greater than or equal to (>=)1 hour (hr) on Day 1 of each treatment cycle plus Oxaliplatin 100 mg/m^2 IV for >=2 hr on Day 1 of each treatment cycle plus S-1 [(Gimeracil) + Oxo (Oteracil)] 40 mg/m^2 administered orally twice daily from Day 1 to 14, of each treatment cycle followed by surgery approximately 1-3 weeks after completion of neo-adjuvant chemotherapy and adjuvant chemotherapy with S-1 [(Gimeracil) + Oxo (Oteracil)] 40 mg/m^2 administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after EOT until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 10 years).
89255448|NCT01480440||Trabecular Metal Reverse Shoulder System|Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System
89255449|NCT01398085|Active Comparator|Radioactive iodine (RAI) ablation Arm|Patients will be randomised to receive Radioactive iodine (RAI) ablation I131 1.1 GBq
89255450|NCT01398085|No Intervention|No Radioactive iodine (No-RAI) ablation|Patients will be randomised to receive No Radioactive iodine (No-RAI) ablation
89255451|NCT01352520|Experimental|SGN-35|1.8 mg/kg intravenously Day 1 of 21-day cycle.
89255452|NCT01309672|Experimental|Abiraterone acetate + prednisone|"Abiraterone, 1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); to be taken daily~Prednisone, 5 mg, oral, 5 mg twice daily"
89255453|NCT01088750|Other|surgery alone|watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL
89255454|NCT01088750|Experimental|CVP Chemotherapy|3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)
89255455|NCT00508443|Experimental|Radiation Therapy|Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
89255456|NCT01078480|Experimental|Arm sling treatment|Displaced midshaft fracture of the collar bone treated with an arm sling
89255457|NCT01078480|Experimental|Operation|Displaced midshaft fracture of the collar bone treated with operation using a pre contoured titanium plate and screws.
89255458|NCT00340704|Experimental|1. Low dose group|
89255459|NCT00340704|Experimental|2. Medium dose group|
89255460|NCT00340704|Experimental|3. High dose group|
89255461|NCT01080586|Active Comparator|NEORAL® Capsule 100 mg|
89255462|NCT01080586|Experimental|Cyclosporine 100 mg Capsule|
89255463|NCT03965416|Experimental|Doctor with white coat|Doctor during consultation is wearing a white coat
89255464|NCT03965416|Experimental|Doctor without white coat|Doctor during consultation is not wearing a white coat
89255465|NCT03984630|No Intervention|Control Arm|Participants were informed to continue to receive usual care by their Obstetrician and were asked to send in body weights weekly.
89255466|NCT03984630|Experimental|Intervention Arm|Received snacks high in fiber, attended weekly phone calls, recorded daily food intake and reported weekly body weight for 12 weeks.
89255467|NCT00231777|Experimental|1|40 mg MK0517 IV
89255468|NCT00231777|Active Comparator|2|4 mg ondansetron IV
89255469|NCT01076842|Active Comparator|A Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
89255470|NCT01076842|Active Comparator|B Exenatide|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
89255471|NCT01076842|Active Comparator|C Levemir+Exenatide|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
89255472|NCT01060332||diabetics|
88804887|NCT03008785|Experimental|group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
88804888|NCT03008785|Experimental|group placebo and exercise|The placebo group received 100mg containing starch of corn.
88804889|NCT00103844|Experimental|1|Active Comparator
88804890|NCT00103844|Experimental|2|Active Comparator
88804891|NCT01402141|Experimental|Chungkookjang|
89255473|NCT01060410||Cyclophosphamide,low dose,continuous|
89255474|NCT01061424|Active Comparator|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
89255475|NCT01061424|Experimental|community health worker|community health worker provides home visits for education
89255476|NCT00231465|Experimental|Taxotere® (Docetaxel) + ZD1839 (IRESSA®)|"Patients will receive Taxotere at 75 mg/m2 given IV over 60 minutes on day 1 of a three week cycle.~ZD1839 will be administered orally at 250mg daily starting on day one, concurrently with the Taxotere."
89255477|NCT03986112||hypertensive group|Evaluation of the ability of carotid sonography and inferior vena cava sonography for the post-induction hypotension in hypertensive patients undergoing general anesthesia
89255478|NCT01061502|Experimental|Procellera Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 5-7 days, more frequently if needed
89255479|NCT01061502|Active Comparator|Opsite Transparent Adhesive Dressing|Polyurethane film dressing. Dressing changes every 5-7 days, more frequently if needed
89290385|NCT01072097|Placebo Comparator|Placebo|6 months placebo treatment
89290386|NCT03971747|Experimental|C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
89255480|NCT00254397|Experimental|gp100 + Leuprolide|Group IA: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
89255481|NCT00254397|Experimental|gp100 - No Leuprolide|Group IB: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
89255482|NCT00254397|Experimental|gp100 + MAGE-3 + Leuprolide|Group IIA: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
89255483|NCT00254397|Experimental|gp100 + MAGE-3 - No Leuprolide|Group IIB: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
89255484|NCT03972735|Experimental|NECT + follow up|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2 hours sessions are conducted by two trained facilitators.
89255485|NCT03972735|Placebo Comparator|TAU|"Drug treatment (antipsychotic, mood stabilizing) for people with schizophrenia or with bipolar disorder~Support in day-care hospital~No intervention specifically targeting self-stigma reduction or improvements in social functioning (social cognitive remediation or social skills training)"
89255486|NCT00254163|Active Comparator|Fludarabine, Cyclophosphamide, and Rituximab|Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle)
89255487|NCT00254163|Experimental|Pentostatin, Cyclophosphamide, and Rituximab|Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle)
89255488|NCT03869333|Experimental|Invaplex[AR-Detox] 2.5 μg|Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
89255489|NCT03869333|Experimental|Invaplex[AR-Detox] 10 μg|Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
89255490|NCT03869333|Experimental|Invaplex[AR-Detox] 25 μg|Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
89255491|NCT03869333|Placebo Comparator|Placebo|Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.
89255492|NCT00110890|No Intervention|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
89255493|NCT00110890|Other|Cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet may occur based on iPTH values.
89255494|NCT00182637|Experimental|bortezomib|
89255495|NCT01076920|Experimental|Intervention arm|
89255496|NCT00182325|Experimental|personalized web prenatal information|Personalized health information for pregnancy through personal health record
89255497|NCT00182325|Active Comparator|general web prenatal information|General pregnancy health related websites
89255498|NCT01076998|Experimental|Lubricant eye drop|Lubricant eye drop
89255499|NCT01076998|Active Comparator|Refresh PM Ointment|Refresh PM Ointment
89255500|NCT00122278|Experimental|Dexamethasone|Dexamethasone 10 mg
89255501|NCT00122278|Placebo Comparator|Placebo|Placebo Dexamethasone, 10 mg
89255502|NCT00182091|Active Comparator|AcroGHD Randomized to Growth Hormone|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to growth hormone. This is an interventional arm.
89255503|NCT00182091|Placebo Comparator|AcroGHD Randomized to Placebo|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to placebo. This is an interventional arm.
89255504|NCT00182091|No Intervention|AcroGHS|
89255505|NCT00182091|No Intervention|Active Acromegaly|
89255506|NCT01072071|No Intervention|Control group|Patients will be receiving standard of care ICU treatment of their underlying disease according to internationally accepted guidelines and recommendations.
89255507|NCT01072071|Experimental|Furosemide group|patients will be receiving standard of care ICU treatment of their underlying condition according to international guidelines and recommendations. In addition, furosemide will be administered in continuous infusion as per protocol in order to achieve a preset target diuresis that is adjusted according to haemodynamic tolerance.
89255508|NCT00181155|Experimental|Allopurinol|One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
89255509|NCT00181155|Placebo Comparator|Placebo|One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
89255510|NCT00322452|Experimental|1|gefitinib
89255511|NCT00322452|Active Comparator|2|Carboplatin/Paclitaxel
89255512|NCT03968523|Active Comparator|TAP block|TAP block technique.
89255513|NCT03968523|Experimental|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
89255514|NCT01073241|Active Comparator|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP.
89255515|NCT01073241|Experimental|ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
89255516|NCT00110812|No Intervention|No IL-2|Participants will receive no aldesleukin or HAART
89255517|NCT00110812|Experimental|IL-2 without ART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level. Some Group 2 participants may take part in additional cycles of aldesleukin if they meet certain study criteria.
89255518|NCT00110812|Experimental|IL-2 with pericycle HAART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; Group 3 participants will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Some Group 3 participants may take part in additional cycles of aldesleukin if they meet certain study criteria. HAART is not supplied by the study, and choice of drugs is left to the participant and physician. The HAART regimen should include at least one protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors.
89255519|NCT00516269|Experimental|Methylphenidate then Placebo|Methylphenidate 18 mg oral daily for 2 weeks then Placebo oral daily for 2 weeks
89255520|NCT00516269|Experimental|Placebo then Methylphenidate|Placebo oral daily for 2 weeks then Methylphenidate 18 mg oral daily for 2 weeks
89255521|NCT04642859|Experimental|Dyslexia|Students with dyslexia before and after the intervention
89255522|NCT04639037|Active Comparator|Manual adjustment of vasopressor|Fluid and vasopressor will be managed as standard practice guided by the EV1000 monitoring device (manually infusion of both fluid and vasopressors) Objective being to maintain MAP within a target MAP range of 80-90 mmHg (fluid will be optimized and stroke volume index will be maintained within normal values)
89255523|NCT04639037|Experimental|Automated adjustment of vasopressor|Fluid will be managed using the EV1000 monitoring in order to optimize stroke volume index and vasopressor will be automatically deliver by a closed-loop system to maintain the MAP within the target range of 80-90 mmHg
89255524|NCT03973515|Experimental|PB-201 50/50mg by mouth,every morning and noon for 7 days|
89255525|NCT03973515|Experimental|PB-201 100/50mg by mouth,every morning and noon for 7 days|
89255526|NCT03973515|Experimental|PB-201 100/100mg by mouth,every morning and noon for 7 days|
89255527|NCT03973515|Placebo Comparator|placebo|
89255528|NCT00228813|Other|Granulocyte Colony Stimulating Factor (G-CSF) stimulation|Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.
89255529|NCT00322374|Experimental|25 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
89255530|NCT00322374|Experimental|30 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
89255531|NCT00322374|Experimental|35 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 35 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
89255532|NCT00174447|Experimental|A1|
89255533|NCT00321984|Experimental|Dexlansoprazole MR 30 mg QD|
89255534|NCT00321984|Experimental|Dexlansoprazole MR 60 mg QD|
89255535|NCT00321984|Placebo Comparator|Placebo|
89255536|NCT03982758|Experimental|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
89255537|NCT03982758|Experimental|isometric of lower limbs|Isometric session for lower limbs: 4 series with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute.
89255538|NCT01060488|Active Comparator|Group 1:|
89255539|NCT01060488|Active Comparator|Group 2:|
89255540|NCT01060566|Experimental|VX-770|
89255541|NCT01060566|Experimental|Midazolam|
89255542|NCT01060566|Experimental|Rosiglitazone|
89255543|NCT01060566|Experimental|Fluconazole|
89255544|NCT02533284|Experimental|Magnesium sulfate group|US guided TAP with magnesium sulfate
89255545|NCT02533284|Experimental|B group|TAP bupevecaine
89255546|NCT02533284|Placebo Comparator|C group|control TAP saline
89255547|NCT00515099|Experimental|Antithymocyte globulin|This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
89255548|NCT00515099|Placebo Comparator|Placebo|This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
89255549|NCT03998423|Experimental|1 dose fecal microbiota transplant|This group will receive one dose of Fecal Microbiota Transplant (FMT) at baseline.
89255550|NCT03998423|Experimental|2 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline and a second dose of FMT 8 weeks later.
89255551|NCT03998423|Experimental|3 doses fecal microbiota transplant|This group will will receive one dose of Fecal Microbiota Transplant (FMT) at baseline, second dose of FMT at 8 weeks, and a third dose of FMT at 12 weeks.
89255552|NCT00110266|Experimental|ICL670|Evaluate the safety and tolerability of deferasirox 20 mg/kg/day over one year in patients with MDS
89255553|NCT00174291|Experimental|Somatropin|
89255554|NCT00366548|Experimental|1|
89255555|NCT00366548|Active Comparator|2|
89255556|NCT01074645|No Intervention|Placebo|Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
88804892|NCT01402141|Placebo Comparator|Placebo|
88804893|NCT01402375|Experimental|Hydrocodone (first trial)|Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
89255557|NCT01074645|Active Comparator|Tenofovir disoproxil fumarate (TDF)|Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF
89255558|NCT00252057|Experimental|Re-engineered hospital discharge|"Participants received the Re-Engineered Hospital Discharge, a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call 2-4 days after discharge by a clinical pharmacist."
89255559|NCT00252057|No Intervention|Standard hospital discharge|Participants received the routine, standard hospital discharge.
89255560|NCT00132028|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
89255561|NCT01080664|Experimental|Regimen 1|Regimen 1: AS703569 administered on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
89255562|NCT01080664|Experimental|Regimen 2|Regimen 2: AS703569 administered on Days 1, 2, 3, 4, 5, 6 of a 21-day cycle
89255563|NCT01078636||EMCI (only cohort recruiting in this study)|Newly recruited early amnestic Mild Cognitive Impairment patients; estimated enrollment 200
89255564|NCT01078636||LMCI (not recruiting in this study)|Late Mild Cognitive Impairment patients; approximately 400 LMCI participants anticipated to follow from the original ADNI study
89255565|NCT01078636||CN (not recruiting in this study)|Cognitively Normal patients; approximately 200 CN participants anticipated to follow from the original ADNI study
89255566|NCT01045304|Experimental|Gencitabine + iniparib twice weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles"
89255567|NCT01045304|Experimental|Gencitabine + iniparib weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles"
89255568|NCT01582828|Active Comparator|Epicardial (surgical) ablation|Epicardial Pulmonary vein isolation
89255569|NCT01582828|Experimental|Hybrid|Epicardial (surgical) ablation & Endocardial assessment
89255570|NCT03992300|Experimental|Intraoral scanning|An intraoral scanning is taken. An auxiliary device is used to achieve better accuracy. A zirconia framework is produced
89255571|NCT03992300|Active Comparator|Conventional scanning|A conventional elastomeric impression is taken and a zirconia framework is produced
89255572|NCT00131248|Other|Anti-reflux Medications, then Placebo (group 1)|"3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.~All study medication administered via nipple or orogastric (OG) tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
89255573|NCT00131248|Other|Placebo, then Anti-reflux Medications|"3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.~All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
89255574|NCT00362414|Experimental|Dual Growth Factor|All patients received erythropoietin and beta-hCG. This was the only treatment arm in the study, i.e., all enrollees received active therapy.
89255575|NCT01080820|Placebo Comparator|Placebo + Viread|
89255576|NCT01080820|Active Comparator|Viread|
89255577|NCT01080820|Experimental|CMX157 + Viread|
89255578|NCT01080898||DMLA patients|patients > 50 years with suspicion of choroidal neo-vessels complicating age related macular degeneration (DMLA)
89255579|NCT01048346|Experimental|supported employment|Study consists of one experimental group and one control group. The intervention group received IPS
89255580|NCT03964558|Other|100 mg [14C]-acebilustat|a single oral dose of 100 mg [14C]-acebilustat
89255581|NCT02534792||Revalvulation time early|Early revalvulation by homograft or percutaneous valve
89255582|NCT02534792||Revalvulation time late|Late revalvulation by homograft or percutaneous valve
89255583|NCT01082770|Active Comparator|TEGO|TEGO needle free access devices will be used in patients randomised to this arm
89255584|NCT01082770|Placebo Comparator|Control|Patients will continue to receive current standard of practice, ie a 'bung' cap at the end of the hemodialysis line
89255585|NCT01049204|Active Comparator|Group 1|Nadir CD4 count >200 cells/µl blood and randomised to Maraviroc 150mg BD
89255586|NCT01049204|Placebo Comparator|Group 2|Nadir CD4 count >200 cells/µl blood and randomised to placebo twice daily for 24 weeks
89255587|NCT01049204|Active Comparator|Group 3|Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
89255588|NCT01049204|Placebo Comparator|Group 4|Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks
89255589|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
89255590|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, No prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
89255591|NCT00359294|Experimental|Zalypsis (PM00104)|
89255592|NCT00384332|Experimental|Arm 1|Orally disintegrating olanzapine
89255593|NCT00384332|Experimental|Arm 2|regular olanzapine
89255594|NCT00096226|Experimental|Chemoradiation, Surgery, Chemotherapy|Induction paclitaxel(50 mg/m2 I.V. in a one-hour infusion) and induction carboplatin (AUC 2.0 I.V. in a thirty-minute infusion): 1x/week for 6 weeks. Concurrent radiation therapy (RT): 1.8 Gy/day, 5 fx/week, for a total of 50.4 Gy in 28 fractions plus a boost of 1.8 Gy/day, 5 fx/week, for a total of 10.8 Gy in 6 fractions. Followed by an assessment to determine whether patient will undergo a resection or not. Followed by consolidation paclitaxel (200 mg/m2 I.V. over three hours) and consolidation carboplatin (AUC 6.0 over one hour) q 21 days x 2.
89255595|NCT01078714|Experimental|Bumetanide|
89255596|NCT01078714|Placebo Comparator|Control|
89255597|NCT01582906||Control Group|Participants randomised to the control group would receive usual rehabilitation care via the existing referral pathways.
89255598|NCT01582906||Intervention Group|Participants randomised to the intervention group will be offered two rehabilitation appointments at three month intervals. They will complete the screening tool, the Distress (Concerns) Thermometer before the first appointment; this will be reviewed after three months. Appointments will make use of communication skills recognised to promote motivation via self-efficacy. Self efficacy is a person's belief in their ability to achieve a goal. Their sense of mastery will influence their behaviour, their perception of stress and the effort they put into achieving that goal.
89255599|NCT01081054|Other|Ambulatory Treatment|Patients are treated ambulatory with oral antibiotic for 10 days; for the first five days these patients are contacted by telephone daily to progress oral intake.
89255600|NCT01081054|Active Comparator|Hospital treatment|Patients are hospitalized and treated with antibiotic, for the first days by endovenous antibiotic and with diet progression orally.
89255601|NCT03964324|Experimental|Severe snorers|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are noninvasive.
89255602|NCT01078792||COPD exacerbation|Patients admitted to hospital with COPD exacerbation
89255603|NCT03963076|Experimental|allergic rhinitis|administration of a nasal hypertonic spray twice a day for one month
89255604|NCT00105508|Experimental|Sarizotan|
89255605|NCT00105508|Placebo Comparator|Placebo|
89255606|NCT01082848|Experimental|aripiprazole|
89255607|NCT01082848|Placebo Comparator|placebo|
89255608|NCT01082926|Experimental|Arm I|Patients receive intratumoral GRm13Z40-2 therapeutic allogeneic lymphocytes over 10 minutes on days 1 and 3 and intratumoral aldesleukin over 3 hours on days 2-5 (days 1-5 in week 2). Treatment repeats every week for 2 courses in the absence of disease progression or unacceptable toxicity.
89255609|NCT01083004|Active Comparator|Indocyanine green arm|
89255610|NCT01083004|Active Comparator|Brilliant blue|
89255611|NCT01078870|Experimental|A|
89255612|NCT01078870|Experimental|B|
89255613|NCT01078870|Experimental|C|
89255614|NCT01078948|Experimental|Active 2mA tDCS|The stimulator will be used to deliver anodal stimulation to the left prefrontal cortex and cathodal stimulation to the right prefrontal cortex. The placement of the anode is proposed to enhance activity in the left frontal cortex; the cathode aims to reduce activity in the right prefrontal cortex.
89255615|NCT01078948|Sham Comparator|Sham tDCS|The system setup is identical to that of active tDCS; however, the stimulator will be turned off after 30 seconds.
89255616|NCT03965338|Other|fMRI brain activity|screening
89255617|NCT00105196|Experimental|A1|
89255618|NCT00105196|Placebo Comparator|A2|
89255619|NCT03820024|Experimental|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly based on the CHART algorithm (Appendix 1). Participants on the feedback arm will receive 1 message per week during the 3-month study period.
89255620|NCT03820024|No Intervention|No Messages|No feedback messages
89255621|NCT03819634|Experimental|Lantern infusion set|Multi-slitted lantern infusion set
89255622|NCT00104572|Experimental|(Androgel) testosterone gel|17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
89255623|NCT00104572|Experimental|anastrozole (Aromatase inhibitor)|14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
89255624|NCT00104572|Placebo Comparator|placebo|13 participants will receive a placebo tablet and placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
89255625|NCT01083238|Experimental|1|AZD5069 following a 10-hour fast
89255626|NCT01083238|Experimental|2|AZD5069 30 minutes after the start of a high fat meal
89255627|NCT02531074|Experimental|Mobile Application plus Usual Care|
89255628|NCT02531074|Active Comparator|Food Journal plus Usual Care|
89255629|NCT03964168||Biologic Therapy|Patient's who received and discontinued a biologic therapy
89255630|NCT01083394|Active Comparator|conventional PTA|In stent restenosis is treated with PTA using a conventional balloon.
89255631|NCT01083394|Experimental|PTA with PEB|In stent restenosis is treated with PTA using a paclitaxel eluting balloon.
89255632|NCT01079104|Active Comparator|Control|Standard Medical Therapy
89255633|NCT01079104|Experimental|Hepa Wash|"Treatment with the liver support system Hepa Wash"
89255634|NCT01081444|Active Comparator|1|Active rTMS
89255635|NCT01081444|Placebo Comparator|2|sham rTMS
89255636|NCT03963934|Experimental|Women with uncontrolled hypertension|Women with uncontrolled hypertension and unsatisfactory medication adherence
89255637|NCT00514943|Experimental|BIBW 2992|once daily taken orally
89255638|NCT00514943|Active Comparator|Cetuximab|once every week by intravenous injection
89255639|NCT01083550|Experimental|DA intervention|Decision aid exposure + usual care
89255640|NCT01083550|No Intervention|Control|Usual care
89255641|NCT01079260|Active Comparator|Standard ONS|
89255642|NCT01079260|Experimental|High Energy, Low volume ONS|High energy, low volume ONS
89255643|NCT03864653|Other|MoodGym|"Non-randomized single-arm intervention; eligible persons are newly enrolled methamphetamine use treatment service program (i.e., Getting Off) participants who will be invited to participate in the study during their enrollment, and can enroll in the study at any time during their first two weeks of program participation. Participants who enroll will take the preexisting, low-intensity MoodGym intervention."
89255644|NCT00103402|Experimental|Alfuzosin|10 mg of alfuzosin once daily for 12 weeks
89255645|NCT00103402|Placebo Comparator|Placebo|10 mg of an identical-looking placebo once daily for 12 weeks
89255646|NCT03864341|Experimental|Homelessness Prevention Services|
89255647|NCT00095836|Experimental|Gefitinib 250mg|
89255648|NCT00168831|Other|Tiotropium Respimat 5mcg (Tio R5)|
89255649|NCT00168831|Other|Tiotropium Respimat 10mcg (Tio R10)|
89255650|NCT00168831|Other|Placebo|
89255651|NCT00103012|Experimental|Effect of G. Biloba on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba).
89255652|NCT00103012|Experimental|Effect of Echinacea on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Echinacea purpurea).
89255653|NCT00103012|Experimental|Effect of P. ginseng on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Panax ginseng).
89255654|NCT00512135|Experimental|IncobotulinumtoxinA (Xeomin) (20 units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
89255655|NCT03235505|Experimental|Nicotine containing e-cigarettes|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
89255656|NCT03235505|Active Comparator|Nicotine-free e-cigarettes|Nicotine-free e-cigarettes + varenicline tartrate+ MI
89255657|NCT03235505|Placebo Comparator|Motivational Interview (MI)|Placebo-varenicline + nicotine -free e-cigarettes + MI
89255658|NCT00511901|Placebo Comparator|Placebo & Niferex|Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
89255659|NCT00511901|Active Comparator|epoetin alpha & Niferex|40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
89255660|NCT04580147|Experimental|Intervention (serial IAI)|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
89255661|NCT04580147|Sham Comparator|Control|Patients enrolled in the control group will undergo a sham procedure at post-operative day 30 (+/-7 days) and at post-operative day 60 (+/-7 days)
89255662|NCT03862625|Experimental|a modular adaptive seating system|In the first group, there is home exercises program for scoliosis and a modular adaptive seating system.
89255663|NCT03862625|Active Comparator|home exercises for scoliosis|In the second group there is only home exercise program for scoliosis.
89255664|NCT00163215|Experimental|Somatropin|
89255665|NCT00228423|Active Comparator|75mg Clopidogrel|75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
89255666|NCT00228423|Placebo Comparator|Placebo|Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
89255667|NCT00511667|Experimental|MK0941|
89255668|NCT00511667|Placebo Comparator|Placebo|
89255669|NCT00227877|No Intervention|Control - New England, USA|"Control participants will receive care as usual from their provider"
89255670|NCT00227877|Experimental|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
89255671|NCT00227877|No Intervention|Control - Prague, CZR|"Control participants will receive care as usual from their provider"
89255672|NCT00227877|Experimental|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
89255673|NCT04610099|Active Comparator|Standard SG|100 patients undergo a standard sleeve gastrectomy
89255674|NCT04610099|Experimental|Banded SG|100 patients undergo a banded sleeve gastrectomy
89255675|NCT00513695|Experimental|Treatment (neoadjuvant chemotherapy before surgery)|Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
89255676|NCT00162981|Experimental|Clobazam Low Dose|
89255677|NCT00162981|Experimental|Clobazam High Dose|
89255678|NCT00511433|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
89255679|NCT00511433|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
89255680|NCT00099268|Experimental|Carbidopa/levodopa/entacapone|Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
89255681|NCT00099268|Active Comparator|Immediate release carbidopa/levodopa|Patients received Immediate release carbidopa/levodopa tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
89255682|NCT00511355|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
89255683|NCT00511355|Active Comparator|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets (LNG-EE), 150 mcg LNG and 30 mcg EE
89255684|NCT01083784|Experimental|Prophylactic group|the group that used prophylactic anticonvulsants (valproate, clonazepam)
88804894|NCT01402375|Active Comparator|Codeine (first trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
88804895|NCT01402375|Experimental|Oxycodone (for second trial)|Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
89255685|NCT01083784|No Intervention|Control group|control group
89255686|NCT03998345|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6. If 10mg/kg cannot be tolerated, add a dose level of 400mg to assess the tolerance
89255687|NCT04576637|Experimental|Neurophysiological monitoring during induction|
89255688|NCT00095212|Active Comparator|1 Transdermal Testosterone (Patch)|300 micrograms applied twice a week
89255689|NCT00095212|Placebo Comparator|2 Placebo Patch (identical in appearance)|placebo patch (0 micrograms of testosterone)applied twice a week
89255690|NCT04606979|Experimental|Parkinson Disease - Group 1a - Active tDCS first|Half of the subjects with PD will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive sham (placebo) tDCS.
89255691|NCT04606979|Sham Comparator|Parkinson Disease - Group 1b - Sham tDCS first|Half of the subjects with PD will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the subjects with PD will receive active (anodal, real) tDCS.
89255692|NCT04606979|Experimental|Healthy Controls - Group 2a - Active tDCS first|Half of the healthy controls will receive active (anodal, real) tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive sham (placebo) tDCS.
89255693|NCT04606979|Sham Comparator|Healthy Controls - Group 2b - Sham tDCS first|Half of the healthy controls will receive sham tDCS in the first session. Following cross-over and a three-week washout-period, this half of the healthy controls will receive active (anodal, real) tDCS.
89255694|NCT02999399|Experimental|[D10]phe and Brussels sprouts|All subjects are given 1 microgram [D10]phe before and after consuming Brussels sprouts once daily for 7 consecutive days.
89255695|NCT02801279|Experimental|Kinect-based bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
89255696|NCT02801279|Experimental|Conventional bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
89255697|NCT00120874|Experimental|Group 1|Individualized Management including caregiver training and Memantine
89255698|NCT00120874|Active Comparator|Group 2|Only Memantine
89255699|NCT00120406|Experimental|1|Zilver® PTX™ Drug Eluting Vascular Stent
89255700|NCT00120406|Active Comparator|2|Angioplasty
89255701|NCT00120250|Experimental|Eszopiclone|Subjects received 3mg eszopiclone nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of placebo, followed by another 1 week washout.
89255702|NCT00120250|Placebo Comparator|Placebo|Subjects received placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of 3mg eszopiclone, followed by another 1 week washout.
89255703|NCT01081600||AUY922|Patients with HER2 positive breast cancer which has become trastuzumab resistent.
89255704|NCT01079338|Experimental|caffeine|
89255705|NCT00511199|Experimental|NOMAC-E2|"Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2~monophasic combined oral contraceptive"
89255706|NCT00511199|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
89255707|NCT03964012|Experimental|NmCV-5|"Subjects in this arm will receive polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~A single dose of 0.5 mL will be administered intramuscularly."
89255708|NCT03964012|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.~A single dose of 0.5 mL will be administered intramuscularly."
89255709|NCT01083940|Experimental|Reminders to providers|
89255710|NCT01083940|No Intervention|usual care|
89255711|NCT01009385|Active Comparator|prone position|
89255712|NCT01009385|Active Comparator|sitting position|
89255713|NCT01084096|Active Comparator|Intervention|Eligible women at high risk for preterm birth will be identified and four 6 mg doses of dexamethasone will be administered before delivery.
89255714|NCT01084096|No Intervention|Control|Control arm will not receive a specific intervention for comparison.
89255715|NCT00384176|Active Comparator|1|Bevacizumab + FOLFOX
89255716|NCT00384176|Experimental|2|Cediranib + FOLFOX
89255717|NCT00513305|Active Comparator|Low-dose cytarabine plus arsenic trioxide|Cycle 1 cytarabine 10 mg/m^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m^2 sc bid on days 1 through 7 of a 28-day cycle.
89255718|NCT00513305|Active Comparator|Low-dose cytarabine alone|Cytarabine was administered at a dose of 10 mg/m^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.
89255719|NCT00513071|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
89255720|NCT00510887|Experimental|VR-FND|"Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.~Each cycle will be repeated every 28 days for 8 cycles maximum."
89255721|NCT01012349|Experimental|Test|Administration of GeoLab Association (acetylsalicylic acid, sodium bicarbonate and citric acid)
89255722|NCT01012349|Active Comparator|Comparator|Acetylsalicylic acid - (Aspirin - Bayer)
89255723|NCT01012427|Experimental|Patients with 3.0 cm or smaller renal cancer|The interventions in this study are part of clinical care and include percutaneous image-guided biopsy, percutaneous renal tumor cryoablation, CT/MR imaging of the ablation bed, and repeat pathologic sampling of the tumor bed with percutaneous biopsy. The cryoablation is done as the therapeutic intervention in patients with small renal cancer. The CT/MR imaging is done to evaluate the treatment for residual disease after the ablation. The repeat biopsy (e.g. three cores) is done to confirm that the neoplasm has been eradicated. These patients have continued imaging, and if necessary, percutaneous biopsy to ensure no recurrent disease.
89255724|NCT01012505||20 preterm infants|20 preterm infants without active disease
89255725|NCT03997877|Active Comparator|Control|"The usual physical activity valued by the YPAS questionnaire (Yale Physical Activity Survey) will be maintained. The questionnaire allows to calculate the time in physical activity expressed in hours / week, the energy expenditure expressed in MET-h / week and the summary index of physical activity that takes into account the frequency and duration of physical activity and oscillates from 0 to 137. A value below 51 identifies sedentary patients. Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
89255726|NCT03997877|Experimental|Intervention|"It is intended that the exercise program have a duration of 6 months and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule and without the need for instruments or special facilities. In this sense the walk is adjusted to these assumptions and the goal of 10.000 steps / day can encourage compliance.~The subjects assigned to the intervention group will be supervised and trained by a physiotherapist who will explain the training program and resolve the doubts raised by the patient.~Daily physical activity is controlled through a pedometer that measures the distance traveled daily by the patient and recorded in a walking book.~The therapeutic control will be carried out by telephone call at the second and fourth month of treatment and a face-to-face clinical control at 3 and 6 months."
89255727|NCT00358826|Experimental|VIA-2291 25 mg|VIA-2291 25 mg
89255728|NCT00358826|Experimental|VIA-2291 50 mg|VIA-2291 50 mg
89255729|NCT00358826|Experimental|VIA-2291 100 mg|VIA-2291 100 mg
89255730|NCT00358826|Placebo Comparator|Placebo|Placebo
89255731|NCT04564313|Experimental|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
89255732|NCT01009541|Experimental|Pregabalin controlled release, 82.5 mg|
89255733|NCT01009541|Experimental|Pregabalin controlled release, 165 mg|
89255734|NCT01009541|Experimental|Pregabalin controlled release, 330 mg|
89255735|NCT01009541|Other|Pregabalin immediate release, 150 mg|Reference Treatment
89255736|NCT01052558|Active Comparator|Cataract Surgery Only|
89255737|NCT01052558|Experimental|Treatment with Cataract Surgery & Stents|Ab interno trabecular micro-bypass stent surgery
89255738|NCT00510653|Experimental|Imatinib Mesylate|600 mg/day orally for 6 Weeks
89255739|NCT01565525|No Intervention|Bright Futures|This represents 'usual care' in the pediatric office. The anticipatory guidance regarding nutrition is based on the Bright Futures Pocket Guide.
89255740|NCT01565525|Experimental|Maternal focused intervention|Childhood obesity prevention was approached in this arm via anticipatory guidance aimed at maternal eating habits.
89255741|NCT01565525|Active Comparator|Ounce of Prevention|This is a program of anticipatory guidance given to mothers of infants ages 2 weeks to one year which focuses on serving size per age and tips for introducing new foods for the infant.
89255742|NCT01565681|Experimental|Arm A: ASKP1240 lowest dose|
89255743|NCT01565681|Experimental|Arm B: ASKP1240 second lowest dose|
89255744|NCT01565681|Experimental|Arm C: ASKP1240 third lowest dose|
89255745|NCT01565681|Experimental|Arm D: ASKP1240 fourth lowest dose|
89255746|NCT01565681|Experimental|Arm E: ASKP1240 fifth lowest dose|
89255747|NCT01565681|Experimental|Arm F: ASKP1240 middle dose|
89255748|NCT01565681|Experimental|Arm G: ASKP1240 sixth highest dose|
89255749|NCT01565681|Experimental|Arm H: ASKP1240 fifth highest dose|
89255750|NCT01565681|Experimental|Arm I: ASKP1240 fourth highest dose|
89255751|NCT01565681|Experimental|Arm J: ASKP1240 third highest dose|
89255752|NCT01565681|Experimental|Arm K: ASKP1240 second highest dose|
89255753|NCT01565681|Experimental|Arm L: ASKP1240 highest dose|
89255754|NCT01565681|Placebo Comparator|Arm M: Placebo|Sodium Chloride solution
89255755|NCT00362336|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
89255756|NCT00362336|Experimental|Group 2: CombAct-HIB™ + OPV|
89255757|NCT00362336|Active Comparator|Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)|
89255758|NCT05408273||Postmenopausal women|Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated.
89255759|NCT01052636|No Intervention|Control group|Patients receive only routine hospital care
89255760|NCT01052636|Experimental|Experimental group|Patients receive regular hospital routine care and interdisciplinary intervention program
89255761|NCT00506285|Experimental|A|This arm was 4 weeks long. Subjects were treated using Methylphenidate Transdermal System. Patients were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone contact. MTS was initiated using a 12.5 cm patch. The dose was increased during the first 2 weeks based on treatment response and side effects to the largest tolerated dose/patch size. It was held steady the last 2 weeks.
89255762|NCT00506285|Placebo Comparator|B|This arm was 4 weeks long. Placebo patch was initiated using a 12.5 cm patch and then increased to the largest tolerated patch size during the first 2 weeks and held steady the last two weeks. Subjects were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone visit.
89255763|NCT00506129|Experimental|Fludarabine + Melphalan with PBPC|Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 Days prior to Allogeneic Transplant, Melphalan 70 mg/m^2 IV daily for 2 Days prior to IV Allogeneic Transplant following Fludarabine & Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 & -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
89255764|NCT00358670|Active Comparator|Maintenance Infliximab|Infliximab 5 mg/kg by body weight every 8 weeks
89255765|NCT00358670|Experimental|Intermittent Infliximab|Infliximab 5 mg/kg by body weight at Weeks 0, 2, 6 and 14 following a 50% reduction in Psoriasis Area and Severity Index (PASI) from the Study P04271 Baseline
89255766|NCT01010087|Active Comparator|Standard Oseltamivir dose 75 mg bid|Standard dosing
89255767|NCT01010087|Experimental|High Dose Oseltamivir arm 225mg bid|High dose arm of the study
89255768|NCT00505661|Experimental|Letrozole|2.5 mg by mouth (PO) daily
89255769|NCT00383786|Experimental|GR205171|selective neurokinin-1 receptor antagonist, fixed 5 mg dose every day, for 8 weeks.
89255770|NCT00383786|Placebo Comparator|placebo|sugar pill
89255771|NCT05358977|Experimental|Tisseel|Patients are undergoing bilateral blepharoplasty. In this arm (Tisseel), the patient with undergo blepharoplasty with topical Tisseel placed in the incision prior to standard closure. 1 minute of pressure will be exerted to both eyelids after closure to mask the patient as to which eyelid received the Tisseel.
89255772|NCT05358977|No Intervention|Control|Patients are undergoing bilateral blepharoplasty. In this arm (Control), the patient with undergo blepharoplasty with standard closure along. 1 minute of pressure will be exerted to both eyelids after closure to mask the patient as to which eyelid received the Tisseel.
89255773|NCT01010165||septic arthritis|
89255774|NCT01010165||crystal arthritis|
89255775|NCT01010165||rheumatismal disease|
89255776|NCT05358665||Group 1|There are individuals who use masks for less than 4 hours daily.
89255777|NCT05358665||Group 2|There are individuals who use masks for 4-8 hours daily.
89255778|NCT05358665||Group 3|There are individuals who use masks for more than 8 hours daily.
89255779|NCT00383708|Experimental|1|
89255780|NCT00504881|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
89255781|NCT00504881|Experimental|Brivaracetam|A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day
89255782|NCT00504725|Experimental|Ketamine|Single bolus 0.5mg/kg ketamine IV after induction of anesthesia
89255783|NCT00504725|Placebo Comparator|Placebo|0.9 % saline bolus of equivalent volume
89255784|NCT01010321||all study Population|all
89255785|NCT05407883|Experimental|Intervention-School traffic warden programme|"The intervention will address multiple risk factors related to behaviour through placing traffic wardens at school crossing points. The assumption is that school traffic wardens situated at safe crossing points will increase yield rates of drivers to pedestrians and reduce the risk of pedestrian motor-vehicle collision. They will be placed at safe locations. Visibility and safety at pedestrian crossings will be enhanced by one trained school traffic warden placed a designated safe crossing point. The school traffic warden will assist pupils in crossing at all times during peak hours i.e. 6:00am-8:00am; 01:00pm-02:00pm; 03:00-07:00pm. In total, 11 school traffic wardens will under-go a 3 day road safety training prior to the start of the study. A similar follow up training will be conducted after 3 months and these will be motivated with non-monetary incentives e.g. high visibility jackets and a lollipop stop sign."
89255786|NCT05407883|No Intervention|Control-road safety manuals|The control schools will receive road safety manuals and leaflets developed by the Uganda Red Cross Society and the Uganda National Curriculum Development Centre.
89255787|NCT00383240|Experimental|MF/F MDI 200/10 mcg BID|
89255788|NCT00383240|Experimental|MF MDI 200 mcg BID|
89255789|NCT00383240|Experimental|F MDI 10 mcg BID|
89255790|NCT00383240|Placebo Comparator|Placebo BID|
89255791|NCT00362180|Experimental|Cohort A: mipomersen|Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
89255792|NCT00362180|Placebo Comparator|Cohort A: placebo|Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
89255793|NCT00362180|Experimental|Cohort D: mipomersen|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
89255794|NCT00362180|Placebo Comparator|Cohort D: placebo|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
89255795|NCT00362180|Experimental|Cohort E: mipomersen|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.
89255796|NCT00362180|Placebo Comparator|Cohort E: placebo|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.
89255797|NCT00362180|No Intervention|Cohort F: no intervention|A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.
89255798|NCT00362180|Experimental|Cohort G: mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
89255799|NCT00362180|Placebo Comparator|Cohort G: placebo followed by mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
89255800|NCT00383162|Other|Combination Product - Placebo|Combination product (sumatriptan and naproxen sodium) [Attack 1] followed by placebo [Attack 2]
89255801|NCT00383162|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
89255802|NCT01050140|Experimental|fructose|25% dietary energy from fructose
89255803|NCT01050140|Active Comparator|glucose|25% dietary energy from glucose
89255804|NCT03990584|Experimental|three irrigation activation methods|"Manual dynamic irrigation was performed using a well-fitting gutta-percha cone inserted to WL with in-and-out vertical strokes of 5 mm at a rate of approximately 100 strokes per minute in order to hydrodynamically displace the irrigant.~Passive ultrasonic irrigation was performed using a non-cutting size 25 file attached to a piezoelectric ultrasonic unit.~Sonic irrigation was performed using an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA). A suitable-size activator tip was selected and loosely placed at 2 mm from working length, and the device was operated at 10,000 cycles/min using a pumping action to move the tip to produce vertical strokes of 2-3 mm."
89255805|NCT03990584|Active Comparator|Conventional needle irrigation (control)|Conventional needle irrigation was performed with short, in-and-out vertical strokes of 2-3 mm at a rate of approximately 100 strokes per minute.
89255806|NCT01052792|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
89255807|NCT01052792|Active Comparator|Anaprox DS 550mg Tablets|Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
89255808|NCT03990350||Hispanic children with obesity|
89255809|NCT03990350||Hispanic children without obesity|
89255810|NCT03990350||Caucasian non-Hispanic children with obesity|
89255811|NCT03990350||Caucasian non-Hispanic children without obesity|
89255812|NCT01052870|Other|androgen receptor gene polymorphism|Medication response will be assessed according to androgen receptor genotype
89255813|NCT01052870|Active Comparator|finasteride|medication for treating androgenetic alopecia in women
89255814|NCT00358436|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
89255815|NCT00358436|Placebo Comparator|Placebo|Placebo by inhalation
89255816|NCT00383084|Experimental|1|Group 1 participants will take part in 30 minutes total of self-selected lifestyle physical activity throughout the day, 5 to 7 days per week. Twice a month, they will attend group sessions designed to help participants develop and maintain a more physically active lifestyle. Goal setting, self-monitoring, and pain management will be discussed at these sessions.
89255817|NCT00383084|Active Comparator|2|Group 2 participants will attend monthly fibromyalgia educational sessions, which will focus on understanding the symptoms of FM, learning to manage pain and fatigue, and developing self-help strategies.
89255818|NCT01045382|Experimental|Mensenchymal Stem Cells|"Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.~Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.~MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
89255819|NCT01045382|Placebo Comparator|Placebo|"Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.~Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
89255820|NCT01045538|Experimental|Vorinostat plus XP|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
89255821|NCT00361634|Experimental|Etanercept|Etanercept 50 mg administered by subcutaneous injection once weekly for up to 12 weeks.
89255822|NCT01045616||Prematurity|
89255823|NCT03992924|Active Comparator|angiography-guided PCI|
89255824|NCT03992924|Experimental|FFR-guided PCI|
89255825|NCT03992924|Experimental|OCT-guided PCI|
89255826|NCT00357968|Experimental|Prasugrel to Clopidogrel|One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.
89255827|NCT00357968|Active Comparator|Clopidogrel to Prasugrel|One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.
89255828|NCT03990272|Experimental|artemisia annua allergen extract drops|
89255829|NCT03990272|Placebo Comparator|Placebo drops|
89255830|NCT01324934|Active Comparator|Study Group|immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
89255831|NCT01324934|No Intervention|Control Group|immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.
89255832|NCT01053104||capecitabine 2000mg/m2 (Colorectal)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX)
89255833|NCT01053104||capecitabine 2500mg/m2 (Colorectal)|capecitabine 2500mg/m2 d 1-14, q 3 weekly
89255834|NCT01053104||capecitabine 2000mg/m2 (Breast)|capecitabine 2000mg/m2d 1-14, q 3 weekly
89255835|NCT01053104||docetaxel 75mg/m2 (Breast)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly
89255836|NCT01053182|Active Comparator|Ivor-Lewis|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
89255837|NCT01053182|Active Comparator|Sweet|Esophagectomy via Left Side Thoracotomy
89255838|NCT00357656|Experimental|BI|Bolus infusion of rAHF-PFM
89255839|NCT00357656|Experimental|CI|Continuous infusion of rAHF-PFM
89255840|NCT00357500|Experimental|5-drug metronomic antiangiogenic regimen|Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: < 20 kg at 100 mg; 20-50 kg at 200 mg; > 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).
89255841|NCT00357110|Active Comparator|1|Anastrozole monotherapy
89255842|NCT00357110|Experimental|2|Anastrozole + Fulvestrant
89255843|NCT01053260|Active Comparator|LEARN Program|Participants will receive weekly weight loss counseling based on the LEARN Program for Weight Management.
89255844|NCT01053260|Experimental|LEARN Plus Contingency Management|Participants will receive weekly counseling based on the LEARN Program for Weight Management plus contingency management. Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
89255845|NCT00098722|Experimental|1|
89255846|NCT00098722|Placebo Comparator|2|
89255847|NCT00098722|Experimental|3|
89255848|NCT01079416||Capsule endoscopy|Study device
89255849|NCT01079416||Esophagogastroduodenoscopy|Gold standard
89255850|NCT02531152|Experimental|SAR366234 (Dose 1)|A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days
89255851|NCT02531152|Experimental|SAR366234 (Dose 2)|A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days
89255852|NCT02531152|Experimental|SAR366234 (Dose 3)|A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days
89255853|NCT02531152|Experimental|SAR366234 (Dose 4)|A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days
89255854|NCT02531152|Experimental|SAR366234 (Dose 5)|A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days
89255855|NCT02531152|Active Comparator|Latanoprost|A dose of Latanoprost will be administered 1 drop per eye per day for 28 days
89255856|NCT01084408|Active Comparator|Sequent®Please|
89255857|NCT01084408|Active Comparator|Taxus™Liberté™|
89255858|NCT01079494|Active Comparator|intervention group|physician-pharmacist teamwork
89255859|NCT01079494|No Intervention|control|physician only team
89255860|NCT00098254|Experimental|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
89255861|NCT00095056|Experimental|Sitagliptin|Participants in the Sitagliptin treatment sequence will receive sitagliptin in Phase A and placebo to glipizide in Phase B.
89255862|NCT00095056|Placebo Comparator|Placebo|Participants in the Placebo treatment sequence will receive placebo to sitagliptin in Phase A and glipizide in Phase B.
89255863|NCT00098020|Experimental|Isotretinoin|Subjects will be treated with Isotretinoin.
89255864|NCT03292250|Experimental|Arm1: BYL719|Experimental: BYL719 BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
89255865|NCT03292250|Experimental|Arm2: Poziotinib|Experimental:Poziotinib Poziotinib is a pan-HER tyrosine kinase inhibitor.(oral class)
89255866|NCT03292250|Experimental|Arm3: Nintedanib|Nintedanib is a potent small molecule triple receptor tyrosine kinase inhibitor (PDGFR, FGFR 1-3,VEGFR 1-3 ,VEGFR- 2) is considered to be the crucial receptor involved in initiation of the formation as well as the maintenance of tumour vasculature.(oral class)
89255867|NCT03292250|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class)
89255868|NCT03292250|Experimental|Arm5: Durvalumab,Tremelimumab|"Durvalumab is a human immunoglobulin (Ig) G1 kappa (IgG1κ) monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 on T-cells and CD80 on immune cells and is engineered to reduce antibody-dependent cell-mediated cytotoxicity.(IV class)~Tremelimumab is specific for human CTLA-4; cluster of differentiation a cell surface receptor that is expressed primarily on activated T cells and acts to inhibit their activation.(IV class)"
89255869|NCT01053338|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
89255870|NCT01053338|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
89255871|NCT01050374|Placebo Comparator|1|albendazole + praziquantel
89255872|NCT01050374|Active Comparator|2|mebendazole + praziquantel
89255873|NCT00360698|Other|insulin glulisine+insulin glargine+metformin+glimepiride|Bolus arm
89255874|NCT00360698|Other|insulin glargine+metformin+glimepiride|Control arm
89255875|NCT03990116|Experimental|Lateral kangaroo|Placing the infant in lateral on the parents chest, keeping the head neutral and limbs flexed towards body midline
89255876|NCT03990116|Active Comparator|Prone Kangaroo|placing the baby in upright and ventral position between mother's breasts or over the father chest, in skin-to skin contact with no clothes in between and with lower limbs flexed
89255877|NCT01053416|No Intervention|observation|
89255878|NCT01053416|Experimental|Yag laser iridotomy|the enrolled eyes will undergo an iridotomy performed by using a Yag-laser
89255879|NCT02534714||Retrospective (Part 1) Group|This is a retrospective pilot study in patients diagnosed with any form of spinal disease who underwent spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from November 1, 2012 to October 31, 2014. Only spinal fusion patients with a serum Vitamin D level prior to or at time of surgery and after surgery are included in this review. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The charts reviewed will belong to subjects who were closely followed at the OSF/INI clinic.
89255880|NCT02534714||Prospective (Part 2) Group|"This is a prospective pilot study in subjects diagnosed with any form of spinal disease that underwent cervical, thoracic, and/or lumbar spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from July 1, 2015 to June 30, 2016.~(Screening period July 1, 2015-June 30, 2016)~Only spinal fusion patients with a serum Vitamin D level, and Bone Marrow Density prior to or at time of surgery are included in this study. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The subjects were closely followed at the OSF/INI clinic post-operatively at 3, 6, and 12 months. Pre-op Vitamin D level and Bone Marrow Density will be measured at the baseline, and again at 3, 6, and 12 months."
89255881|NCT02534558|Experimental|miR-29a precursor oligonucleotide|Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
89255882|NCT02534558|Experimental|miR-29a antisense oligonucleotide|Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
89255883|NCT00380978|Active Comparator|early analgesia:combined-spinal epidural|
89255884|NCT00380978|Active Comparator|late analgesia (systemic)|
89255885|NCT02534480|Active Comparator|NGP 555 25 mg|NGP 555 25 mg capsule and placebo by mouth once per day
89255886|NCT02534480|Active Comparator|NGP 555 50 mg|NGP 555 50 mg capsule and placebo by mouth once per day
89255887|NCT02534480|Active Comparator|NGP 555 100 mg|NGP 555 100 mg capsule and placebo by mouth once per day
89255888|NCT02534480|Active Comparator|NGP 555 200 mg|NGP 555 200 mg capsule and placebo by mouth once per day
89255889|NCT02534480|Active Comparator|NGP 555 300 mg|NGP 555 300 mg capsule and placebo by mouth once per day
89255890|NCT00162123|Experimental|First reinduction: Ipilimumab, 0.3 to 10 mg/kg|Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
89255891|NCT00162123|Experimental|First reinduction: Ipilimumab, 3 to 10 mg/kg|Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
89255892|NCT00162123|Experimental|First reinduction: Ipilimumab, 10 to 10 mg/kg|Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
89255893|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 0.3 mg/kg|Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
89255894|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 3 mg/kg|Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
89255895|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 10 mg|Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
89255896|NCT00162123|No Intervention|Follow-up|Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
89255897|NCT00227721|Experimental|Docetaxel & Gemcitabine hydrochloride|Docetaxel, 40 mg/m2, 30 min IV infusion on Days 1 and 8, of a 21 day cycle Gemcitabine hydrochloride, 800mg/m2 30 min IV infusion on Days1 and 8, of a 21 day cycle
89255898|NCT01074723|Experimental|b-cryptoxanthin|
89255899|NCT01074723|Experimental|phytosterols|
89255900|NCT01074723|Experimental|b-cryptoxanthin plus phytosterols|
89255901|NCT01074801|Active Comparator|Closed-loop|Subcutaneous insulin delivery to be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
89255902|NCT01074801|Active Comparator|Control arm|Subcutaneous insulin delivery to be administered according the standard insulin pump settings
89255903|NCT01074879|Experimental|Whey protein|20 g whey protein + 20 g carbohydrates
89255904|NCT01074879|Experimental|Milk protein|20 g milk protein + 20 g carbohydrates
89255905|NCT01074879|Active Comparator|Carbohydrates|40 g carbohydrates
89255906|NCT03972423||IRCTC group|- The IRCTC group, consisting of all patients included in the 3rd phase of the study and for whom the transmission of information in PACU is carried out using the IRCTC.
89255907|NCT03972423||CONTROL group|- The CONTROL group, consisting of all patients included in the 1st phase of the study and for whom the transmission of information in PACU is carried out according to the usual practice.
89255908|NCT00226941|Experimental|Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100|"Cetuximab 250 mg/m² / week~Capecitabine 800 mg/m²~Radiotherapy (XRT)~Oxaliplatin 100 mg/m², Days 2 and 23"
89255909|NCT00226941|Experimental|Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85|"Cetuximab 250 mg/m² / week~Capecitabine 700 mg/m²~Radiotherapy (XRT)~Oxaliplatin 85 mg/m², Days 2 and 23"
89255910|NCT00226941|Experimental|Group A - Cetuximab + Capecitabine-800 + XRT|"Cetuximab 250 mg/m² / week~Capecitabine 800 mg/m²~Radiotherapy (XRT)"
89255911|NCT00226941|Experimental|Group B - Cetuximab + Capecitabine-1000 + XRT|"Cetuximab 250 mg/m² / week~Capecitabine 1000 mg/m²~Radiotherapy (XRT)"
89255912|NCT01074957|Active Comparator|Incentive Spirometry|Incentive Spirometry group (IS) was oriented to take a deep breathing through Voldyne 5000TM (Sherwood Medical; St Loius, MO, USA) from Functional Residual Capacity (FRC) to Total Lung Capacity (TLC).
89255913|NCT01074957|Active Comparator|Exercise group|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
89255914|NCT01074957|Active Comparator|Breath-Stacking|Breath-Stacking group (BS) performed successive inspiratory efforts using a facial mask adapted to an unidirectional valve
89255915|NCT01075503|Experimental|retrograde infraclavicular|Patients were received retrograde infraclavicular brachial plexus block.
89255916|NCT01075503|Active Comparator|interscalene|Patients were received interscalene brachial plexus block.
89255917|NCT01075503|Active Comparator|supraclavicular|Patients were received supraclavicular brachial plexus block.
89255918|NCT02531763|No Intervention|Control|FHS participants who enrolled with family member will not receive the social incentive intervention and will participate individually but will set a daily step goal and receive daily feedback on whether he or she achieved the goal or not.
89255919|NCT02531763|Active Comparator|Intervention|FHS participants who enrolled with a family member will be placed on a team as connected individuals (both in the same family) who will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive the social incentive intervention.
89255920|NCT01075581|Active Comparator|Topical administration|An an intranasal injection of saline will be used as control, and thereafter cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
89255921|NCT01075581|Experimental|Intranasal injection|An intranasal injection of 8 mL epinephrine 1:100,000 will be performed as traditionally practiced in ESS. Thereafter, cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
89255922|NCT00356408|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2
89255923|NCT00509795|Active Comparator|ranibizumab 0.5mg Q4|
89255924|NCT00509795|Experimental|aflibercept injection 2.0mg Q4|
89255925|NCT00509795|Experimental|aflibercept injection 0.5mg Q4|
89255926|NCT00509795|Experimental|aflibercept injection 2.0mg Q8|
89255927|NCT05407649|Experimental|Radiotherapy Combined with GM-CSF|
89255928|NCT05407493||Buccal flap|The buccal flap is slid over the fistula and sutured to the undermined palatal mucosa using horizontal mattress sutures.
89255929|NCT05407493||Double-layer|A combination between a buccal trapezoidal flap and a palatal connective pedicle flap.
89255930|NCT05407493||Buccal flap with L-PRF|A L-PRF plug is interposed between the fistula and the buccal sliding flap.
89255931|NCT03968367|Experimental|Magnetic activated sperm cell sorting for infertile man|A 0.5 mL aliquot of spermatozoa suspended in HTF-modified HEPES buffer, obtained either after sperm wash to remove the seminal plasma or after DGC, was centrifuged and the pellet (maximum of 107 cells) was resuspended in 80 uL of binding buffer with 20 uL of Annexin V-conjugated microspheres, both from the Annexin V microbead kit (Miltenyi Biotec, Huburn, CA, USA), for 15 min at room temperature. After addition of 400 lL of binding solution, the suspension was placed in the separation column (MiniMACS, Miltenyi Biotec). Labeled (apoptotic) cells were retained on the column and non-labeled (viable) cells passed through the column.
89255932|NCT00504257|Experimental|Avastin and Docetaxel|Combination Therapy: Immunotherapy (Avastin) and Chemotherapy (Docetaxel) as outlined in Intervention descriptions. Avastin: 15 mg/kg, In 100 ml normal saline (NS) IV infusion over 90 +/- 15 minutes, Day 1, every 21 day cycle. Docetaxel: 40 mg/m^2, In 250 ml 5% dextrose in pure water (D5W) or NS IV infusion over 1 hour in a non-pvc container and through a polyethylene-lined set, Day 1, 8, every 21 day cycle. Response assessment every 3 cycles (9 weeks).
89255933|NCT01013051||Post Gastric Bypass|
89255934|NCT01013051||Obese Controls|age, BMI, gender matched
89255935|NCT03997955|Experimental|Experimental group|Myofascial induction
89255936|NCT03997955|Sham Comparator|Control group|Sham myofascial induction
89255937|NCT00509093|Experimental|Imatinib Mesylate|
89255938|NCT05407103|Experimental|Cold Acupressure Group|"Personal information form (PIF ) , Labor Monitoring Form (LMF), Visual Analog Scale (VAS), and Childbirth Comfort Questionnaire (CCQ) as pre-test during the latent phase before going about the cold acupressure. Next, she applied the cold acupressure pouches on the respective cold group on their LI 4 point for ten minutes, during the active and transition phases. The application was then suspended for one hour, and then repeated three more times.~Last, posttest took place. Cold group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after cold group to monitor how they were feeling."
89255939|NCT05407103|Experimental|Warm Acupressure Group|"PIF, LMF, VAS, and CCQ as pre-test during the latent phase before going about the warm acupressure. Next, she applied the warm acupressure pouches on the respective warm groups on their LI 4 point for ten minutes, during the active and transition phases. The application was then suspended for one hour, and then repeated three more times.~Last, posttest took place. Warm group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after warm group to monitor how they were feeling."
89255940|NCT05407103|No Intervention|Control Group|The researcher ran PIF, LMF, VAS, and CCQ as pre-test during the latent phase. No intervention was applied to the control group. Last, posttest took place. Control group was given VAS and CCQ during transition phase of dilation between contractions. The researchers then filled out LMF after warm group to monitor how they were feeling.
89255941|NCT05406869|Experimental|pulsed sonic balloon dilatation catheter and pulsed sonic generater|All subjects will receive treatment from the pulsed sonic balloon dilatation catheter
89255942|NCT00160641|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
89255943|NCT04544501|Experimental|Culturally-Targeted Video|
89255944|NCT04544501|Active Comparator|FORCE Fact Sheet|
89255945|NCT03997331|Experimental|Intervention|"Subjects in the Intervention arm will receive the following:~Automated in-app messages containing behavioral and educational content that is tailored to each subject based on an assessment of their entry survey results and on their adherence and glucose data. (Behavioral Support Engine).~Targeted in-app messages and phone calls from clinicians or as designated by the Investigator (through the CRx Care app) based on the subject's adherence and glucose data.~Push notifications that alert the subject that it is time to complete a regimen event (ie take medication or take a fasting blood glucose reading).~Push notifications that alert the subject that they have missed a scheduled regimen event.~In-app messages containing adjustments to the subject's insulin glargine dose when the Investigator(s) approves an adjustment in the CRx Care App. (Treatment Support Engine)."
89255946|NCT03997331|Active Comparator|Control|Subjects in the Control arm will receive the CRx Health solution for self-management of chronic conditions.
89255947|NCT00493025|Experimental|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
89255948|NCT01075035||Normal Healthy Controls|Individuals with no history of Traumatic Brain Injury.
89255949|NCT01075035||Civilian TBI|Civilians who have had a Traumatic Brain Injury
89255950|NCT01075035||Military TBI|Combat military veterans who have had a Traumatic Brain Injury
89255951|NCT01075113|Experimental|Arm A|Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort A has only one dose level: sorafenib 400 mg orally twice a day with vorinostat 300 mg orally. Cohort A was modified to include 2 dose levels: Dose level A1 (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A-1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day). The starting dose upon reopening after approval of this version will be dose level A-1a. Dose level A1 will only be used if dose level A-1a is not tolerable.
89255952|NCT01075113|Experimental|Arm B CLOSED|Reduced Dose 200mg Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort B has 2 dose levels starting at the second dose level (sorafenib 200 mg orally twice a day with vorinostat 400 mg orally). Cohort B has been closed. Cohort B was intended to evaluate the possibility of dose intensification of vorinostat when patients were unable to tolerate standard dose sorafenib, and required dose-reduced sorafenib. The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib.
89255953|NCT01075269||Conventional open thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
89255954|NCT01075269||Robotic thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
89255955|NCT03972267|Sham Comparator|Control Group - Free Gingival Graft|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the Control Group will not receive any kind of treatment in the palatal region.
89255956|NCT03972267|Experimental|Test Group - Free Gingival Graft + EMD|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 8 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. EMD will be applied immediately after the graft removal surgical procedure on the palatal donor area, leaving it in contact with the wound for 5 min. In sequence, it will be covered with an individualized acetate plate that will extend throughout the palatal area and be in position for 2 hours after the procedure
89255957|NCT01073319|Placebo Comparator|Placebo|Matching oral placebo capsule as control.
89255958|NCT01073319|Active Comparator|Rivastigmine 3 mg|
89255959|NCT01073319|Active Comparator|Rivastigmine 6 mg|
89255960|NCT01073397|Experimental|Behavioral|Weekly Integral Yoga sessions lasting 90 minutes for 10 weeks with home practice.
89255961|NCT01073397|Active Comparator|Health and Wellness Classes|Weekly classes on health and wellness lasting 90 minutes for 10 weeks, with additional home practice
89255962|NCT01073397|No Intervention|Waitlist|This group receives usual care for 10 weeks and is then randomized to one of the study arms.
89255963|NCT00160563|Experimental|LCTZ-LCTZ|Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
89255964|NCT00160563|Placebo Comparator|LCTZ-PLC|Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
89255965|NCT00160563|Placebo Comparator|PLC-PLC|Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)
89255966|NCT00380744|Experimental|Part A LY2189102 0.1 mg/kg/wk|"Part A: 2 times (x) 0.1 milligrams/kilogram/week (mg/kg/wk) Loading dose, then 0.1 mg/kg/wk) X 4 weeks (wks), intravenous (IV)~Part B: 2 x 0.02 mg/kg/wk Loading dose, then 0.02 mg/kg/wk X 4 wks, IV"
89255967|NCT00380744|Experimental|Part A LY2189102 0.3 mg/kg/wk|"Part A: 2 x 0.3 mg/kg/wk Loading dose, then 0.3 mg/kg/wk X 4 wks, IV~Part B: 2 x 0.15 mg/kg/wk Loading dose, then 0.15 mg/kg/wk X 4 wks, IV"
89255968|NCT00380744|Experimental|Part A LY2189102 1.0 mg/kg/wk|"Part A: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV~Part B: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV"
89255969|NCT00380744|Experimental|Part A LY2189102 2.5 mg/kg/wk|"Part A: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV~Part B: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV"
89255970|NCT00380744|Placebo Comparator|Placebo|IV, once weekly x 4 wks
89255971|NCT01050452|Placebo Comparator|1|albendazole treatment
89255972|NCT01050452|Active Comparator|2|mebendazole treatment
89255973|NCT01050452|Active Comparator|3|ivermectin treatment
89255974|NCT01050452|Active Comparator|4|albendazole + ivermectin treatment
89255975|NCT01050452|Active Comparator|5|mebendazole + ivermectin treatment
89255976|NCT00380588|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.~Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal."
89255977|NCT00380588|Experimental|Gemcitabine|Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
89255978|NCT00379808|Placebo Comparator|Placebo|1 lactose-containing capsule daily for 1 month
89255979|NCT00379808|Active Comparator|Montelukast 10 mg|1 montelukast 10 mg tablet (masked by capsule) daily for 1 month
89255980|NCT03990038|Active Comparator|Group C|"Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter.~They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery"
89255981|NCT03990038|Active Comparator|Group U|"Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down.~They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total"
89255982|NCT01053494|Active Comparator|Arm I (WAITLIST CONTROL GROUP)|Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
89255983|NCT01053494|Experimental|Arm II (TOUCH)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks."
89255984|NCT01053494|Experimental|Arm III (TOUCH+)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the massage therapist."
89255985|NCT00355784|Other|Control|9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and their plasma growth hormone concentration was allowed to decline naturally.
89255986|NCT00355784|Experimental|Growth Hormone Treatment|8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received exogenous growth hormone treatment administered in 4 daily injections to mimic physiological growth hormone secretion throughout the 2-week overeating period.
89255987|NCT00355784|Experimental|High Growth Hormone Treatment|5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received a relatively high daily dose of growth hormone.
89255988|NCT01053572|Active Comparator|Celestone|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
89255989|NCT01053572|Active Comparator|sodium chloride solution|Group II will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
89255990|NCT01053572|Active Comparator|sodium choride solution|Group III will receive adhesiolysis, local anesthetic, normal sodium chloride solution instead of 10% hypertonic sodium chloride solution and non-particulate Celestone;
89255991|NCT01053572|Active Comparator|Double substitutes|Group IV will receive adhesiolysis, local anesthetic, and 0.9% sodium chloride solution to substitute for the 10% hypertonic sodium chloride, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
89255992|NCT02534636|Experimental|Part A: Single ascending dose|BMS-986165 or Placebo specified dose on specified days
89255993|NCT02534636|Experimental|Part B: Multiple ascending dose|BMS-986165 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
89255994|NCT02534636|Experimental|Part C: Multiple ascending dose|BMS-986165 or Placebo specified dose on specified days
89255995|NCT02534636|Experimental|Part D: Relative Bioavailability|BMS-986165 (Liquid) + BMS-986165 (Capsule) + Famotidine specified dose on specified days
89255996|NCT03990740||Cases|Patients suffering from keratoconus and requiring a first optical corneal transplant
89255997|NCT03990740||Controls|Patients with an indication of orbital exenteration operation due to an orbital tumor
89255998|NCT01053728|Experimental|Cohort 1 : SAR161271 0.3 U/kg|Cross-over design of four formulation of SAR161271 0.3U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
89255999|NCT01053728|Experimental|Cohort 2 : SAR161271 0.6 U/kg|Cross-over design of four formulation of SAR161271 0.6U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
89256000|NCT01053728|Experimental|Cohort 3 : SAR161271 1.2 U/kg|Cross-over design of four formulation of SAR161271 1.2 U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
89256001|NCT01050608||Sprixx Device Group|Treatment group utilizing multimodal hand hygiene device
89256002|NCT01050608||Standard Hand Hygiene Group|Utilizing wall mounted dispensers and CDC based guidelines.
89256003|NCT00355472|Experimental|1|KW-0761
89256004|NCT01053884|Other|Anidulafungin, safety, antifungal drug|single arm study
89256005|NCT03282266|Experimental|PADN + 5-phosphodiesterase|A total of 64 patients are assigned to PADN + 5-phosphodiesterase group after randomization schedule.
89256006|NCT03282266|Sham Comparator|Sham operation + 5-phosphodiesterase|A total of 64 patients are assigned to sham operation + 5-phosphodiesterase group after randomization schedule.
89256007|NCT01050686|Active Comparator|subcutaneous wound drain|subcutaneous wound drain inserted
89256008|NCT01050686|Experimental|no subcutaneous wound drain|no subcutaneous wound drain inserted
89256009|NCT03991754|Experimental|Amiodarone|Oral Amiodarone 600mg / day, divided into 3 doses (200mg every 8 hours) for 6 days before the procedure and then 400mg / day, divided into 2 doses (200mg every 12 hours) during the 6 days following the implantation of TAVI.
89256010|NCT03991754|Placebo Comparator|Control|Patients assigned to the control group will receive placebo tablets identical to those of amiodarone. The administration of these tablets will follow the same scheme as in the amiodarone group. Therefore, they will receive placebo tablets orally, 1 tablet every 8 hours 6 days before the procedure and then 1 tablet every 12 hours during the 6 days following the implantation of TAVI
89256011|NCT00492557|Experimental|13vPnC+TIV Followed by Placebo 1 month later|
89256012|NCT00492557|Active Comparator|Placebo+TIV Followed by 13vPnC 1 month later|
89256013|NCT00508391|Experimental|Simultaneous 1st, Optimized 2nd|Lumax HF-T device programmed to simultaneous biventricular pacing first for 30 days, followed by optimized biventricular pacing for 30 days.
89256014|NCT00508391|Experimental|Optimized 1st, Simultaneous 2nd|Lumax HF-T device programmed to optimized biventricular pacing first for 30 days, followed by simultaneous biventricular pacing for 30 days.
89256015|NCT01010711|Other|migraine dietary supplement|"the average days of migraine during a 4 week-run-in-period are compared with the average days of migraine during intervention with a specific dietary supplement from week 8 - 12"
89256016|NCT01015157|Active Comparator|Standard stapling without reinforcement|Standard Echelon 60 linear stapling with GOLD cartridges
89256017|NCT01015157|Active Comparator|Seamguard gastric stapling line reinforcement|
89256018|NCT01010789|Experimental|Armodafinil|Flexible dose 150-250mg/day
89256019|NCT01010789|Placebo Comparator|Mathing Placebo|
89256020|NCT01015235|Placebo Comparator|Arm 1: Placebo|Placebo
89256021|NCT01015235|Active Comparator|A2: KAI-1678|Test Drug
89256022|NCT01015235|Active Comparator|A3: Ketorolac|Active Comparator
89256023|NCT00508157|Experimental|A|
89256024|NCT00508157|Active Comparator|B|
89256025|NCT04331717|Experimental|Diet and exercise with BAE|After enrollment in the clinical trial, all men will be enrolled in diet and exercise counseling through the weight management program for a total of 4 weeks. If participants lose >5 pounds of total body weight from weight management alone in the first 4 weeks, these participants will be excluded from study and will not undergo BAE but will be encouraged to continue with weight management. Those still enrolled will undergo BAE. Within 7 days of BAE, men will be given ADT (lupron subcutaneous injection).
89256026|NCT01015313|Experimental|intensive sodium management|
89256027|NCT01015313|No Intervention|standard care|
89256028|NCT00378560|Placebo Comparator|1|Placebo
89256029|NCT00378560|Experimental|2|Vaccine
89256030|NCT00508001|Placebo Comparator|1|Best Supportive Care + Placebo
89256031|NCT00508001|Experimental|2|Best Supportive Care + ZD6474 100 mg
89256032|NCT00508001|Experimental|3|Best Supportive Care + ZD6474 300 mg
89256033|NCT01015391|Experimental|T2|
89256034|NCT01015391|Active Comparator|AZA|
89256035|NCT04544033||mild group|"Amendment to MOH COVID-19 Protocol:~Patient with mild clinical symptoms & clinically table.~CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line."
89256036|NCT04544033||moderate group|"Amendment to MOH COVID-19 Protocol:~Patient with non-specific and specific respiratory infection (pneumonia).~CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening)."
89256037|NCT04544033||severe group|"Amendment to MOH COVID-19 Protocol:~Patients with respiratory distress (RR > 30/min, Sa02 < 92 at room air).~Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours.~CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening)."
89256038|NCT01015469|Active Comparator|Group A|Conventional laparoscopic Roux-en-Y gastric bypass (Golden Standard)
89256039|NCT01015469|Experimental|Group B|Conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring
89256040|NCT01010945|Experimental|erlotinib, gemcitabine, nab-paclitaxel|Patients receive the following treatment in 28-day cycles: 1) erlotinib: orally once daily from days 1 through 28 continuous dosing; 2) gemcitabine (following nab-paclitaxel): intravenously over 30 minutes on days 1, 8 and 15 every 28 days; and 3) nab-paclitaxel: intravenously over 30 minutes on days 1, 8 and 15 every 28 days.
89256041|NCT01011023|Experimental|WITHOUT NASOGASTRIC TUBE|1. Experimental group (EG): without NGT, by removing the NGT at the end of the surgery, once the stomach had been aspirated,
89256042|NCT01011023|Active Comparator|WITH NASOGASTRIC TUBE|2. Control group (CG): with NGT, with radiographic corroboration of correct placement after the surgery. Both groups were given: 5-day fasting because it was the therapeutic gold standard at our hospital and our country, intravenous solutions and antibiotics for 5 days, ranitidine, and analgesics, without use of any antiemetic drug. Once the fasting period ended, in the CG the NGT was clamped and withdrawn, and in both groups oral fluids and diet were started. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
89256043|NCT00507689|Experimental|FTC/TDF+HBIg|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF+HBIg in the randomized period.
89256044|NCT00507689|Experimental|FTC/TDF|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF in the randomized period.
89256045|NCT00491387|Experimental|metoprolol succinate|Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
89256046|NCT04539899|Experimental|VR+|For patients in the experimental group, using the virtual reality helmet, the caregiver will position the helmet on the patient when she is placed on the gynecological examination table. He or she will make sure that the patient can see and hear the current sequence. The caregiver can then proceed with the different steps of the IUD insertion. Once the procedure is completed, the caregiver will indicate to the patient that she can remove the headphones.
89256047|NCT04539899|No Intervention|VR-|For patients in the control group, without a helmet, the course of the consultation will not be modified.
89256048|NCT01011257|Active Comparator|Aspirin 81 mg, 1 tab twice daily|All participants to take one aspirin (81mg per tab) twice daily.
89256049|NCT01011257|Active Comparator|Clopidogrel 75 mg 1 tab daily|Only stable CAD participants will take Clopidogrel (75mg per tab) daily.
89256050|NCT01011491|Experimental|Medifast 5 & 1 Plan|Medifast's 5 & 1 Plan is a meal replacement plan for weight loss and weight maintenance.
89256051|NCT01011491|Active Comparator|Food-based|The food-based arm followed a meal plan of self-selected foods that provided the same number of calories as the Medifast 5 & 1 plan.
89256052|NCT01015547|Experimental|Infliximab plus Methotrexate|infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
89256053|NCT01015547|Experimental|Combination of DMARDs|methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.
89256054|NCT01015547|Active Comparator|Methotrexate alone|Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
89256055|NCT00491075|Experimental|Pemetrexed + Gemcitabine|Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.
89256056|NCT04302623|Experimental|Online yoga program|An 8-week online live facilitator-led yoga program.
89256057|NCT04302623|Experimental|Control|Advice only group.
89256058|NCT03998267|Active Comparator|Intervention arm|"For the subjects using the app (intervention group): The mobile app team shall do the following:~Educate/train patients on app usage~Patients will be subscribed to the app and their profile on the app will be created~Subjects will log in their blood sugar readings and communicate with the mobile app team (educators and physician) via the app~Additionally patients will be placed on a diet and lifestyle plan as agreed upon by the patient and health care provider team, best suited towards the patient's needs~Throughout the study, patient will receive notifications and advice on how to follow diet and lifestyle changes~Throughout the study; patient interaction and app usage will be tracked~Patients will additionally be interviewed by the research team together with Droobi to capture app experience at 3 months and 6 months"
89256059|NCT03998267|Placebo Comparator|Standard of care arm|"For the subjects not using the app (the standard of care group):~At time 0, will be seen by the dietician and diabetes educators at HGH endocrine clinics as part of standards of care~The educators contact number and diabetes hotline number will be provided to the patients~o The diabetes hotline number #16099 is a new service provided to diabetes patients at the national diabetes center to help communicate with the diabetes educators with questions relating to their diabetes management, medication adjustment such as dose titrations etc.~Appointments thereafter with the educator and/or dietician will be decided and scheduled according to the individual patient needs, with a minimum visit every 3 months during the study period"
89256060|NCT01011569||cage|patient who underwent stand alone cage insertion after discectomy
89256061|NCT01011569||plate|patient who underwent plate fixation and autologous ilia bone graft after discectomy
89256062|NCT00507455|Placebo Comparator|Placebo|Participants received once daily, oral doses of placebo matching solifenacin succinate and tamsulosin tablets for 12 weeks.
89256063|NCT00507455|Experimental|6 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 6 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
89256064|NCT00507455|Experimental|9 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 9 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
89256065|NCT03997565||Patients TKR|
89256066|NCT03997565||Healthy subjects|
89256067|NCT01011647||Acute coronary conditions|"Patients hospitalized with the following conditions~Unstable angina~Acute myocardial infarction~Congestive heart failure"
89256068|NCT01013363|No Intervention|No music|Participants will not use the digital music player during their procedure.
89256069|NCT01013363|Experimental|Music|Participants will use the digital music player during their procedure.
89256070|NCT04275713|Experimental|Standard Chemoradiotherapy +/- metformin|Metformin will be given orally at doses of 850 mg twice a day. Metformin will be started one week prior to the start of standard cisplatin-based chemoradiotherapy, and will be continued throughout the entire radiation treatment
89256071|NCT04275713|Active Comparator|Standard chemoradiotherapy|"Standard chemoradiotherapy is given as a combination of EBRT and IGT:~45 Gy in 1.8 Gy/fraction to the pelvis/abdomen, 5 fractions/week~55-57.5 Gy in 2.2-2.3 Gy/fraction to pathological lymph nodes as a simultaneously integrated boost (SIB)~4 fractions of brachytherapy, 7.8 Gy/fraction, to the cervix~Concomitant Cisplatin weekly during the external beam radiotherapy (EBRT)"
89256072|NCT01011725|Experimental|Postmenopausal Women- Active Agent Group|
89256073|NCT01011725|Placebo Comparator|Postmenopausal Women- Placebo|Placebo
89256074|NCT01011803|Experimental|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
89256075|NCT01013441|Experimental|Treatment Arm|
89256076|NCT01011881||patients with pleuritis|
89256077|NCT00506831|Experimental|Imatinib mesylate|100 mg daily and increase by 100mg daily every 2 weeks to a maximum of 400 mg daily as tolerated
89256078|NCT04269551|Experimental|BIVV020 IV|Single administration dose 1, plus two optional doses of BIVV020 administered intravenously.
89256079|NCT03996941||seguiPrEP|MSM and TGW using or willing to use PrEP informally will be followed in a prospective cohort to describe safety and efficacy, and to provide them with the necessary clinical controls for using it in a safe manner.
89256080|NCT01015859|No Intervention|DDD long AV delay|Pacemaker is programmed in DDD mode with long AV delay (250 msec)
89256081|NCT01015859|Active Comparator|AAI SafeR|Pacemaker is programmed in AAI SafeR mode
89256082|NCT00506753|Experimental|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
89256083|NCT00506753|Experimental|RT/TU|Relaxation Training followed by Treatment as Usual
89256084|NCT00490919|Experimental|Double-blind BTDS 10 or 20|Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
89256085|NCT00490919|Placebo Comparator|Double-blind Placebo TDS|Placebo transdermal system to match BTDS patches, applied for 7 days
89256086|NCT01011959|Active Comparator|1|dose 1 vs. placebo
89256087|NCT01011959|Active Comparator|2|dose 2 vs. placebo
89256088|NCT01011959|Active Comparator|3|dose 3 vs. placebo
89256089|NCT01011959|Active Comparator|4|dose 4 vs. placebo
89256090|NCT01011959|Active Comparator|5|dose 5 vs. placebo
89256091|NCT01011959|Active Comparator|6|dose 6 vs. placebo
89256092|NCT00503867|Experimental|SIR-Spheres microspheres|SIR-Spheres microspheres
89256093|NCT01015937|Active Comparator|Turmeric|"diabetic nephropathy patient~more than 300 mg/proteinuria"
89256094|NCT01015937|Active Comparator|ACE inhibitor + ATI blocker|"diabetic nephropathy~more than 300 mg/day proteinuria"
89256095|NCT01012193|Active Comparator|adjunctive cilostazol|adjunctive cilostazol 100mg bid to dual antiplatelet therapy
89256096|NCT01012193|Active Comparator|high maintenance-dose clopidogrel|double dose of clopidogrel 150mg/day
89256097|NCT00503399|Experimental|Teriparatide|Teriparatide 20 microgram (µg) subcutaneous (sc) injection once daily (QD).
89256098|NCT00503399|Active Comparator|Risedronate|Risedronate 35 milligrams (mg) oral (po) tablet once weekly (QW)
89256099|NCT00506519|Experimental|AT-150|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 125-175%
89256100|NCT00506519|Experimental|AT-250|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 225-275%
89256101|NCT00506519|Active Comparator|Control|The best standard treatment for the underlying condition only
89256102|NCT00503009|Active Comparator|Arm 1|
89256103|NCT00503009|Active Comparator|Arm 2|
89256104|NCT00503009|Placebo Comparator|Arm 3|
89256105|NCT01016093|Experimental|Intervention|Patients in this arm received zoledronic acid.
89256106|NCT01016093|Placebo Comparator|Control|Patients in this arm received placebo as control group
89256107|NCT00160251|Active Comparator|Arm 1A: PegIntron (PEG) + Ribavirin (RBV)|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is undetected, PEG + RBV will continue for another 36 weeks.
89256108|NCT00160251|Active Comparator|Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is detectable, BOC 400 mg TID will be added for 36 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
89256109|NCT00160251|Experimental|Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEB + BOC 100 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
89256110|NCT00160251|Experimental|Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
89256111|NCT00160251|Experimental|Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
89256112|NCT00160251|Experimental|Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
89256113|NCT00160251|Experimental|Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
89256114|NCT00160251|Experimental|Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800|By first protocol amendment to P03659, this non-randomized arm is added. A single dose of PEG is given first, followed 1 week later by PEG + BOC 800 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
89256115|NCT00160251|Experimental|Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800|By second protocol amendment to P03659, participants from all arms except Arm 1A will be rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.
89256116|NCT01075425|Experimental|Arm I|Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89256117|NCT00506441|Experimental|1|
89256118|NCT00506441|Placebo Comparator|2|
89256119|NCT04190693|Placebo Comparator|Follow-up|No Investigational Medicinal Product (IMP) will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
89256120|NCT04190693|Experimental|IMCY_0098|No Investigational Medicinal Product (IMP) will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).
89256121|NCT00378014|Experimental|Everolimus|Basiliximab plus everolimus-based immunosuppressive regimen following the reduction and cessation of initial CNI regimen plus optional steroids according to local best practice
89256122|NCT00378014|Active Comparator|Calcineurin Inhibitor (CNI)|Basiliximab plus CNI-based immunosuppressive regimen according to local best practice plus optional steroids according to local best practice
89256123|NCT00485303|Experimental|Abiraterone|Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.
89256124|NCT00490841|Experimental|RX Herculink Elite|To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.
89256125|NCT01018823|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, oral, once daily for 14 days
89256126|NCT01018823|Experimental|Ertugliflozin up to 5 mg|Ertugliflozin up to 5 mg, oral, once daily for 14 days
89256127|NCT01018823|Experimental|Ertugliflozin up to 25 mg|Ertugliflozin up to 25 mg, oral, once daily for 14 days
89256128|NCT01018823|Experimental|Ertugliflozin up to 100 mg|Ertugliflozin up to 100 mg, once daily for 14 days
89256129|NCT01018823|Placebo Comparator|Placebo|Placebo to Ertugliflozin once daily for 14 days
89256130|NCT01016249|Active Comparator|Treatment 1. 5% Saline + Epinephrine|Nebulization with 4ml of 5% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
89256131|NCT01016249|Other|Treatment 3. 3% Saline + Epinephrine|Nebulization with 4ml of 3% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
89256132|NCT01016249|Other|Treatment 2 . 0.9% Saline + Epinephrine|Nebulization with 4ml of 0.9% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
89256133|NCT00377858|Experimental|Insulin Lispro Mid Mixture|Insulin lispro mid mixture (MM) up to three times a day (TID)
89256134|NCT00377858|Active Comparator|Insulin Glargine|Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed.
89256135|NCT00502697|Experimental|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic visits. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
89256136|NCT00502697|Other|Conventional prenatal/postpartum care|Women assigned to the control arm of the study received conventional prenatal and postpartum clinic care.
89256137|NCT01013675|Experimental|1|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
89256138|NCT01013675|Active Comparator|2|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
89256139|NCT01018901|Experimental|Arm I|Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.
89256140|NCT01054040|No Intervention|Standard nutrition cardiac care|Patients will receive standard care of group nutrition counselling and individual counselling if requested
89256141|NCT01054118|Experimental|001|JNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose
89256142|NCT01054118|Active Comparator|002|Sitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose
89256143|NCT01054118|Experimental|003|JNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose
89256144|NCT01054118|Placebo Comparator|004|Placebo Placebo suspension and placebo capsule administered as single doses
89256146|NCT03989726|Experimental|High density voltage and fractionation map guided group|"Complex fractionated atrial electrogram (CFAE), voltage and fractionation map will be performed with a multielectrode mapping catheter.~The mapping should be performed in AF.~First, low-voltage zone is defined as an area with bipolar peak-to-peak voltage amplitudes < 0.5mV.~A voltage-map guided segmental PV isolation is performed. Radiofrequency energy is applied in the antral regions of the PVs. High voltage zone over 0.5mV in the antral region is targeted. IF PV isolation in not achieved by voltage-guided segmental ablation, additional Lasso catheter guided segmental antral ablation is performed.~Radiofrequency energy is delivered at target sites for 15-30 sec guided by contact force, lesion size index (LSI) and local electrogram elimination.~If the patient is still in AF after PV isolation, additional fractionation map guided ablation is performed. The fractionation area within low voltage area (<0.5mV) should be targeted."
89256147|NCT03989726|Active Comparator|Circumferential PV isolation|A control group will be chosen from database of patients who underwent AF ablation between 2018-2019. A control group includes the same number of consecutive patients who underwent anatomy-based circumferential PV isolation.
89256148|NCT03989804|Experimental|Targeted follow-up|
89256149|NCT03989804|No Intervention|Usual practice|Usual practice at the fitness center is self-directed use
89256150|NCT01054274|Active Comparator|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
89256151|NCT01054274|Experimental|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
89256152|NCT03989648|Active Comparator|Esmarch bandages|
89256153|NCT03989648|Active Comparator|simple leg elevation|
89256154|NCT01050842|Experimental|Arm I|Patients receive oral bicalutamide and oral raloxifene on days 1-28.
89256155|NCT02534246|Experimental|Pro Core EUS guided Fine Needle Biopsy|Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) with reverse bevel design for diagnosis of pancreatic lesions.
89256156|NCT02534246|Experimental|Shark Core EUS guided Fine Needle Biopsy|SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) with six cutting edge surfaces and an opposing bevel design for diagnosis of pancreatic lesions.
89256157|NCT00485069|Experimental|Ropinirole Hydrochloride|
89256158|NCT01054352|Experimental|001|JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added
89256159|NCT01054352|Experimental|002|JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
89256160|NCT01054352|Experimental|003|JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers
89256161|NCT01054352|Experimental|004|JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3.
89256162|NCT01054430|Other|Normal|Subjects with normal hepatic function
89256163|NCT01054430|Other|Mild Hepatic Dysfunction|Subjects with mild hepatic impairment
89256164|NCT01054430|Other|Moderate hepatic dysfunction|Subjects with moderal hepatice impairment
89256165|NCT00355082|Experimental|lamotrigine 300|300 mg/day treatment
89256166|NCT00355082|Experimental|lamotrigine 250|250 mg/day treatment
89256167|NCT00502307|Experimental|1|Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
89256168|NCT00502307|Placebo Comparator|2|solid oral capsule containing excipients dosed daily for three weeks per month
89256169|NCT01325012|Active Comparator|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle.
89256170|NCT01325012|Active Comparator|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
89256171|NCT00484679|Experimental|1|Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.
89256172|NCT00377312|Experimental|Group 1|Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.
89256173|NCT00377312|Experimental|Group 2|Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.
89256174|NCT00377234|Experimental|1|
89256175|NCT00377234|Active Comparator|2|
89256176|NCT00377156|Active Comparator|Arm I|Patients undergo stereotactic radiosurgery (SRS)
89256177|NCT00377156|Experimental|Arm II|Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.
89256178|NCT00376688|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89256179|NCT00376532||ICD pacing or shock event|Subjects who experienced a device treatment, defined as a pacing event or a shock event
89256180|NCT00376532||No ICD pacing or shock event|Subjects who did not experience a treatment defined as a pacing event or a shock event
89256181|NCT00376220|Experimental|1|"Drug: Riluzole Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.~Other Names:~• Rilutek"
89256182|NCT00376220|Placebo Comparator|2|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
89256183|NCT00375752|Active Comparator|Letrozole|Letrozole 2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvent treatment
89256184|NCT00375752|Experimental|Zolendronic Acid + Letrozole|2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w
89256185|NCT00484289|Experimental|Arm 1: Participants from Phase I study (IM101-034)|
89256186|NCT00484289|Experimental|Arm 2: Participants from Phase II study (IM101-071)|
89256187|NCT00484289|Experimental|Arm 3: New Participants with Methotrexate (MTX) Intolerance|
88804896|NCT01402375|Active Comparator|Codeine (for second trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
89256188|NCT01013831|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
89256189|NCT01016327|Experimental|1|
89256190|NCT03996629|Experimental|Pharmacist-managed anticoagulation service|
89256191|NCT03996629|No Intervention|Usual medical care|
89256192|NCT01013909|Experimental|Arm 1|
89256193|NCT01013909|Experimental|Arm 2|
89256194|NCT01013909|Placebo Comparator|Arm 3|
89256195|NCT01013909|Placebo Comparator|Arm 4|
89256196|NCT01013909|Active Comparator|Arm 5|
89256197|NCT03996551|Experimental|Intervention Group|This group will receive access to the 12-week kidney transplant specific weight gain prevention online resource (ExeRTiOn online resource). After the 12 weeks, they will be offered the option to continue using the website up until the completion of the study (12 months)
89256198|NCT03996551|No Intervention|Control group|This group will not receive the online resource. They will receive the standard encouragement to follow a healthy diet and perform physical activity during routine transplant follow up appointments.
89256199|NCT04150445|Experimental|Internet treatment for overweight and obese patients|The intervention is a treatment of overweight and obesity based on cognitive behavioural therapy provided via the Internet. The treatment lasts for six months and comprises 12 treatment modules. The patient works with each module for two weeks. The modules conclude with one or more exercise tasks to be performed before the next module is activated. The patient has written contact with the therapist via the Internet platform.
89256200|NCT01014065||1|Patients with renal cell carcinoma scheduled to receive sunitinib
89256201|NCT01019213|Placebo Comparator|Septal pacing|Septal lead will be activated.
89256202|NCT01019213|Experimental|His-pacing|His lead will be activated 80 ms before septal lead
89256203|NCT01019291|Experimental|NO2|NO2 400 µg/m3
89256204|NCT01019291|Experimental|Formaldehyde|Formaldehyde 100 µg/m3
89256205|NCT01019291|Experimental|NO2 + Formaldehyde|mixture of Formaldehyde and NO2
89256206|NCT01019291|Placebo Comparator|Placebo|
89256207|NCT01016405||Severity of dry eye in patients undergoing cataract surgery|
89256208|NCT01019447|Active Comparator|Study group|The study group in which Triclosan-coated polyglactin 910 antimicrobial sutures will be used.
89256209|NCT01019447|Active Comparator|Control group|The control group in which polyglactin 910 antimicrobial sutures will be used.
89256210|NCT00490529|Experimental|CpG-MCL Vaccine|An autologous anti-tumor vaccine.
89256211|NCT01019525||Mouth Breathing|Children aged between 8-12 years, with clinical diagnosis of mouth breathing
89256212|NCT01019525||Nasal Breathing|Children aged between 8-12 years old, with normal breathing
89256213|NCT00333840|Experimental|imatinib (STI571)|In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
89256214|NCT00333840|Active Comparator|IFN-a+Ara-C|In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
89256215|NCT00490451|Experimental|LY573636|
89256216|NCT01019603|Experimental|1|Tazarotene foam 0.1%
89256217|NCT01019603|Active Comparator|2|Tazaroc Gel 0.1%
89256218|NCT00321906|Active Comparator|Azathioprine|(tacrolimus,azathioprine/prednisone)
89256219|NCT00321906|Active Comparator|Sirolimus|tacrolimus/sirolimus/prednisone
89256220|NCT00339144|Experimental|Dasatinib (100 mg)|
89256221|NCT00339144|Experimental|Dasatinib (150 mg)|
89256222|NCT00339144|Experimental|Dasatinib (200 mg)|
89256223|NCT00321828|Experimental|Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab|Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
89256224|NCT01061580|Experimental|CABG plus BMAC Injection|Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
89256225|NCT00333138|Experimental|Fingolimod (FTY720) 1.25 mg/day|Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
89256226|NCT00333138|Placebo Comparator|Placebo/Fingolimod (FTY720)|Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
89256227|NCT00333138|Experimental|Fingolimod (FTY720) 5.0 mg/day|Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
89256228|NCT03984474||Single bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
89256229|NCT03984474||Double bundle group|Age 13-65 when enrolled. Only include isolated ACL rupture. Excluded revision surgery. Excluded bilateral ACL rupture. Excluded the contralateral ACL tear after surgery.
89256230|NCT00332202|Experimental|A|
89256231|NCT00332202|Placebo Comparator|B|
89256232|NCT01061658|Experimental|Vaccine - High dosage|
89256233|NCT01061658|Experimental|Vaccine - Lower dosage|
89256234|NCT01061658|Placebo Comparator|Placebo|
89256235|NCT03982836|Experimental|Fructooligosaccharide|All the 25 volunteers received the sandwich containing 20 grams of fructooligosaccharide
89256236|NCT03982836|Experimental|Partially hydrolyzed guar gum|All the 25 volunteers received the sandwich containing 20 grams of partially hydrolyzed guar gum
88804897|NCT01402375|Experimental|Oxycodone (third trial)|Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
89256237|NCT03982836|Placebo Comparator|Maltodextrin|All the 25 volunteers received the sandwich containing 20 grams of Maltodextrin
89256238|NCT01058382||Progesterone Vaginal Suppositories|
89256239|NCT01058382||Intramuscular Progesterone-in-Oil|
89256240|NCT01061814|Experimental|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) SC daily
89256241|NCT01061814|Placebo Comparator|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) SC daily
89256242|NCT01058460|No Intervention|cytology|Subjects in the control arm will receive conventional cytology testing and HPV testing at baseline. Follow up management will be based on the cytology result according to current practice.
89256243|NCT01058460|Experimental|HPV-cytology|Subjects in the HPV-cytology arm will receive HPV testing and cytology testing at baseline. Follow up management will be based on both results.
89256244|NCT00331422|Experimental|Patients Who Received Treatment|All patients receiving treatment with Paclitaxel and Carboplatin followed by surgery to remove cancerous tissue.
89256245|NCT00331344|Experimental|Treatment (combination chemotherapy)|Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
89256246|NCT03983928|Experimental|TQB2450 Combined with Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89256247|NCT01058538|Experimental|L19IL2|
89256248|NCT00321672|Experimental|NGX-4010, 60 minutes|
89256249|NCT00321672|Experimental|NGX-4010, 30 minutes|
89256250|NCT00321672|Other|0.04% conc. capsaicin patch, 60 min.|
89256251|NCT00321672|Other|0.04% conc. capsaicin patch, 30 min.|
89256252|NCT01325142||ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has developed ONJ
89256253|NCT01325142||No ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has NOT developed ONJ
89256254|NCT03985566|Experimental|Fibre Grains|Fibre grains were used to partially replaced Jasmine white rice in this arm.
89256255|NCT03985566|Placebo Comparator|Jasmine white rice|Jasmine white rice is used as a control to compare the outcome.
89256256|NCT00321048|Experimental|ABC (Active Breathing coordinator)|Patients are randomized to ABC arm will receive radiation with ABC. Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the No ABC arm.
89256257|NCT00321048|No Intervention|No Active Breathing Coordinator|Patients randomized to the No ABC arm will receive radiation without ABC.Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the ABC arm.
89256258|NCT00330174|Experimental|1|Acamprosate tablets
89256259|NCT00330174|Placebo Comparator|2|Matching placebo tablets
89256260|NCT03985488||Eview Fluoroscopy Machine|The Eview Fluoroscopy Machine is the standard of care fluoro machine used in endoscopy.
89256261|NCT03985488||Fluoroshield Device|The FluoroShield technology (Omega Medical Imaging) has been developed in an effort to further reduce the degree of radiation exposure to patients and provides. This technology is an additional component that can be fitted to the preexisting Eview fluoroscopy machines, in order to further filter radiation that has passed through the pre-existing machine.
89256262|NCT02533206|Experimental|EPIC|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic. The participant will be discharged home from the clinic following their procedure.
89256263|NCT02533206|Active Comparator|FESS|The control intervention is functional endoscopic sinus surgery (FESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia
89256264|NCT00338286|Experimental|001|epoetin alfa + packed RBC transfusion 40 000 IU SC once a week.
89256265|NCT00338286|Other|002|Standard supportive care (packed RBC transfusion) Per doctor prescription
89256266|NCT00329784|Experimental|Peanut Consumption Group|Participants on this arm will consume peanut protein.
89256267|NCT00329784|No Intervention|Peanut Avoidance Group|Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.
89256268|NCT00337818|Experimental|Cervarix New Process|Subjects aged 15 to 25 years received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process.
89256269|NCT00337818|Experimental|Cervarix Old Process Group|Subjects aged 15 to 25 years who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the old manufacturing process.
89256270|NCT00337818|Experimental|Cervarix Young/Lot 1 Group|Subjects aged 10 to 14 years, who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process (Lot 1).
89256271|NCT03981666|Experimental|Patients with insomnia|adult outpatients with a localized or metastatic breast, colorectal, pulmonary or urological cancer
89256272|NCT00329550|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
89256273|NCT00329550|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
89256274|NCT00329550|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
89256275|NCT00375674|Experimental|A|
89256276|NCT00375674|Placebo Comparator|B|
89256277|NCT00350402|Active Comparator|High Intensity Muscle Strength Training|This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.
89256278|NCT00350402|Sham Comparator|Sham MST|This arm (low intensity MST) was identical to the real intervention in all ways except that the training device was set at 5% maximum inspiratory pressure (MIP). Thus less muscle and breathing effort was required during this sham treatment.
89256279|NCT03991910|Placebo Comparator|control|control patients will be given a placebo
89256280|NCT03991910|Experimental|treatment|Ramipril 5 mg treatment group
89256281|NCT01055600|Experimental|Study|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
89256282|NCT00320190|Active Comparator|Dasatinib|Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
89256283|NCT00320190|Active Comparator|Imatinib|Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
89256284|NCT01050920||Blood Collection|
89256285|NCT02534402|Experimental|Prednisone Group|30mg of prednisone PO (orally) everyday for 5 days.
89256286|NCT02534402|No Intervention|Control Group|no treatment
89256287|NCT00320112|Experimental|Reciprocal Diabetes Peer Support program|peers are paired during the group visit and are encouraged to speak with their partner at least once a week for the 6 month duration of the study.
89256288|NCT00320112|Other|Nurse Case Management|patients are not paired in the NCM arm. they are provided with educational session on diabetes management and informed of case management services.
89256289|NCT03982524|Experimental|CBT complemented with emotion regulation training|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning nonjudgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
89256290|NCT03982524|Active Comparator|Cognitive behavior therapy (CBT)|"This arm is based on conventional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
89256291|NCT01063608|Experimental|Anti-H1N1v Vaccine|
89256292|NCT00319956|Active Comparator|Azithromycin Group|Group receives azithromycin
89256293|NCT00319956|Placebo Comparator|Placebo Group|Group receives placebo
89256294|NCT01062048||All participants|Participants administered Januvia up to 100 mg once daily as monotherapy or combination therapy with a sulfonylurea or with insulin during the re-examination period (up to 6 years)
89256295|NCT01060722|Experimental|MOD-4023, dose level 1|
89256296|NCT01060722|Experimental|MOD-4023, dose level 2|
89256297|NCT01060722|Experimental|MOD-4023, dose level 3|
89256298|NCT00349622|Active Comparator|Ceftriaxone|"Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day."
89256299|NCT00349622|Placebo Comparator|Placebo|"One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day."
89256300|NCT03987698|Experimental|Arm 1: CIK+PD-1i|"SHR-1210 & CIK cells~SHR-1210,200mg/d,intravenous infusion,d1; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
89256301|NCT03987698|Active Comparator|Arm 2: Control|SHR-1210,200mg/d,intravenous infusion,d1; Q3W.
89256302|NCT01051076|Experimental|Factor VIII and von Willebrand Factor|
89256303|NCT01325090|Experimental|BOTOX|Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area
89256304|NCT01325090|Placebo Comparator|PLACEBO|Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area
89256305|NCT03989258|Active Comparator|Cohort 1|High monogenic breast cancer risk
89256306|NCT03989258|Active Comparator|Cohort 2|High polygenic breast cancer risk
89256307|NCT03989258|No Intervention|Cohort StMG|Standard mammography screening in age 50-69
89256308|NCT03989960|Experimental|LISA+SNIPPV group|receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation
89256309|NCT03989960|Active Comparator|InSurE group|receives intubation-surfactant- extubation technique and selects CPAP ventilation
89256310|NCT00360308|Placebo Comparator|Placebo|matching E2007 and matching entacapone
89256311|NCT00360308|Active Comparator|E2007|2 mg once daily in the evening, Weeks 0→2 (2 weeks) and 4 mg once daily in the evening, Weeks 2→18.
89256312|NCT00360308|Active Comparator|Entacapone|200 mg with each dose of Levodopa.
89256313|NCT01054508|Other|Arm 1: Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks)|Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
89256314|NCT01054508|Other|Arm 2: Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks)|Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
89256315|NCT01054664||impaired liver enzymes|
89256316|NCT01054664||normal liver enzymes|
89256317|NCT01054664||hepatitis C antibodies positive|
89256318|NCT00348686|Experimental|Candesartan|Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.
89256319|NCT01055678|Experimental|All Patients|Single arm study analyzing tumor hypoxia after EF5 injection
89256320|NCT00360230|Experimental|SB257049 F2 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
89256321|NCT00360230|Experimental|SB257049 F1 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
89256322|NCT00360230|Experimental|SB257049 F2 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
89256323|NCT00360230|Experimental|SB257049 F1 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
89256324|NCT00360230|Experimental|SB257049 F2 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
89256325|NCT00360230|Active Comparator|SB257049 F1 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
89256326|NCT00360230|Active Comparator|Rabipur 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
89256327|NCT03988946|Experimental|Transcatheter Mitral Valve Replacement|Replacement valve delivered through a transfemoral access and transseptal approach
89256328|NCT03988712||Iron deficiency anaemia with bowel symptoms|Patients with IDA presenting with bowel symptoms like change in bowel habits, weight loss and abdominal mass other than rectal bleed
89256329|NCT03988712||Iron deficiency anaemia with no bowel symptoms|Patients with IDA with no bowel symptoms
89256330|NCT03988712||Iron deficiency anaemia with rectal bleeding|Patients with IDA and rectal bleeding
89256331|NCT03989024|Experimental|Pulsatile Gonadotropin-releasing Hormone|Drug: Gonadorelin. Use Gonadorelin for 3 months to treat PCOS. The pulse was administered with a hormone pump, once every 90 min, and 10ug per pulse.
89256332|NCT03989024|Experimental|Clomiphene|Use Clomiphene for 3 months to treat PCOS
89256333|NCT03988790|Experimental|VOC analysis|VOC analysis in exhaled air in patients with severe asthma treated by monoclonal antibody
89256334|NCT02533622||Standard of care|Patients admitted to the ICU will receive current standard of care related to mobility
89256335|NCT02533622||Progressive mobility|patients admitted to the ICU will receive mobility per Progressive Mobility protocol using TotalCare beds and lifts
89256336|NCT03987308|Experimental|Beinaglutide|Five-week Beinaglutide pump treatment group
89256337|NCT03987308|Experimental|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
89256338|NCT01051154|Active Comparator|Docosahexaenoic acid (DHA)|This group will be receive the DHA supplement
89256339|NCT01051154|Placebo Comparator|Placebo|This group will be receive placebo
89256340|NCT00348374|Active Comparator|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
89256341|NCT00348374|Experimental|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
89256342|NCT02533388|Experimental|Electrical acupoint stimulation|Electrical acupoint stimulation at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints, Stimulus frequency was an alternate dense-disperse frequency of 2/10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, which was adjusted to maintain a slight twitching of the regional muscles according to individual maximum tolerance.
89256343|NCT02533388|Sham Comparator|Sham stimulation|Sham stimulation only connected to the apparatus, but electronic stimulation was not applied.
89256344|NCT01054898|Experimental|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
89256345|NCT01054898|Active Comparator|Usual community services|Standard care for abused women in the community
89256346|NCT03742232|Experimental|PLENVU|PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
89256347|NCT03742232|Active Comparator|SELG-ESSE|SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
89256348|NCT00353366||Cohort Group|Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks
89256349|NCT02534090||Feeding Intolerant Preterm Infants|32 weeks to 36 weeks 6 days old of post menstrual age infants, feeding intolerants monitored with INVOS device for rSO2
89256350|NCT02534090||Feeding Tolerant Preterm Infants (Controls)|32 weeks to 36 weeks 6 days old of post menstrual age infants without problems through the enteral feedings.
89256351|NCT03988478|Experimental|Behavioral, detoxificaiton & psychotherapy|Providing treatment as usual (detoxificaion) & psychotherapy
89256352|NCT00352664|Active Comparator|Donepezil|Oral Donepezil 5 mg daily x 7 days
89256353|NCT00352664|Placebo Comparator|daily x 7 days|Placebo tablet daily x 7 days
89256354|NCT01051232|Placebo Comparator|Cohort 1|PF-00868554 (filibuvir) 100 mg or placebo
89256355|NCT01051232|Placebo Comparator|Cohort 2|PF-00868554 (filibuvir) 300 mg or placebo
89256356|NCT01051232|Placebo Comparator|Cohort 3|PF-00868554 (filibuvir) 500 mg or placebo
89256357|NCT03991442|Experimental|BR1010 and Fimasartan/Amlodipine placebo|BR1010 or Fimasartan/Amlodipine
89256358|NCT03991442|Active Comparator|BR1010 placebo and Fimasartan/Amlodipine|BR1010 or Fimasartan/Amlodipine
89256359|NCT03742310|Experimental|identical supplement group|"Take vitamin D supplements according to genotype. If the genotype result is high risk, we will give vitamin d 800 international unit(IU)/d, when the result is middle risk, we will give 600 international unit(IU)/d, when the result is low risk, we will give 400 international unit(IU)/d."
89256360|NCT03742310|No Intervention|control group|General dose. Whatever the result is, we all give 400 international unit(IU)/d.
89256361|NCT03988556|Experimental|Cohort A1 - Head & neck cancer - Prophylactic intent|"Patients with head & neck cancer starting radiotherapy +/- chemotherapy +/- targeted therapy (no lesions, prophylactic intent).~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing both oral mucositis and radiodermatitis.~."
89256362|NCT03988556|Experimental|Cohort A2 - Head & neck cancer - Curative intent|"Patients with head & neck cancer having started radiation therapy and presenting with grade 1 to 3 lesions of oral mucositis and/or radiation dermatitis (curative intent).~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).~The device will be used on each lesion. All existing lesions will be treated whether they are oral mucositis or radiodermatitis lesions."
89256363|NCT03988556|Experimental|Cohort B1 - Breast cancer - Prophylactic intent|"Patients with breast cancer starting radiation therapy (i.e. no lesions, prophylactic intent).~Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session.~The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing radiodermatitis."
89256364|NCT03988556|Experimental|Cohort B2 - Breast cancer - Curative intent|"Patients with breast cancer having started radiation therapy and presenting with grade 1 to 3 lesions of radiation dermatitis (curative intent).~Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum).~The device will be used on each lesion. All existing lesions will be treated."
89256365|NCT03988244|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
89256366|NCT00490139|Active Comparator|Arm 1: Trastuzumab|"Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total)."
89256367|NCT00490139|Experimental|Arm 2: Lapatinib|"Based on the IDMC results from 18 August 2011, any patient enrolled onto Arm 2 should be considered for a new treatment strategy based on discussion with their physician.~Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total)."
89256368|NCT00490139|Experimental|Arm 3: Trastuzumab followed by Lapatinib|"Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total)."
89256369|NCT00490139|Experimental|Arm 4: Lapatinib in combination with Trastuzumab|"Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total)."
89256370|NCT00348140|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
89256371|NCT00348140|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
89256372|NCT00348140|Placebo Comparator|Arm 3|Placebo
89256373|NCT01055990|Other|Heathy,aged 18-60 years,|They are healthy, are 18-60 years of age, did not have a history of infection with the 2009 H1N1 virus, and are appropriate to vaccination, without any interdictions. And they guardians confirmed that they understood the study procedures, provided written informed consent, and agreed to comply with the following visit schedule. Woman participants all are not pregnant,with a negative pregnancy test before vaccination.
89256374|NCT01055990|Experimental|clinically critical H1N1 patients|The critical H1N1 patients as recipients whose conditions are confirmed according to current standard for critical H1N1 diagnosis. The study wll research H1N1 viral load in blood of critical H1N1 patients and swab nucleic acid testing parallelity; measure H1N1 viral Load in blood and swabs (adopting Real-time PCR method) of 5 to 10 victims; and the planned blood taking time is the tenth day since the fever begins.
89256375|NCT01051388|Active Comparator|Group I|Low-dose PPI (Rabeprazole sodium 10 mg)
89256376|NCT01051388|Active Comparator|Group II|High-dose PPI (Rabeprazole sodium 20 mg)
89256377|NCT01051388|Active Comparator|Group III|Non-PPI (Gefarnate)
89256378|NCT00490061|Experimental|Radiotherapy and Lapatinib with DCE-MRI|DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
89256379|NCT01055366|Experimental|Elazop (Azarga)|Elazop Treatment arm
89256380|NCT03988322|Experimental|Quantitative assessment of imaging biomarkers|This is the intervention arm. In this arm, the participants will be scanned with low-dose CT with pre-defined scanning parameters for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the volume of the nodule. The quantitative assessment of imaging biomarkers of lung cancer, COPD and cardiovascular disease will be recorded.
89256381|NCT03988322|Active Comparator|Visual assessment of imaging biomarkers|This is the control arm. In this arm, the participants will be scanned with low-dose CT with routine scanning parameters used for lung cancer screening in the hospital for two rounds (at baseline and in the second year). The screen-detected lung nodules will be managed according to the diameter of the nodule. The imaging biomarkers related to lung cancer, COPD and cardiovascular disease will be visually assessed.
89256382|NCT04140695|Experimental|Tradipitant|Oral Capsule
89256383|NCT04140695|Placebo Comparator|Placebo|Oral Capsule
89256384|NCT01019681|Experimental|UBC injection into one leg of PVD pt|25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
89256385|NCT01019759|No Intervention|No add-on AF-surgery|patient undergoing only scheduled valve and/or coronary bypass surgery
89256386|NCT01019759|Experimental|PV isolation|patient undergoing add-on epicardial microwave energy pulmonary vein isolation
89256387|NCT00483119|Active Comparator|Group A|IVIg alone (intravenous immunoglobulin)
89256388|NCT00483119|Experimental|Group B|IVIg with cyclophosphamide
89256389|NCT03996707|Other|Immediate protected weight-bearing|Immediate protected weight-bearing
89256390|NCT03996707|Other|Traditional non weight bearing|Strict non-weight-bearing
89256391|NCT00483041|Experimental|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
89256392|NCT00483041|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
89256393|NCT01016639|Experimental|Chemoradiotherapy|
89256394|NCT00501293|Experimental|1|Methylphenidate Transdermal System
89256395|NCT01014221|Experimental|Acupuncture group|acupuncture administered in 8 sessions over 4 weeks
89256396|NCT01014221|Active Comparator|Steroid group|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
89256397|NCT00482729|Experimental|1|Arm 1: drug
89256398|NCT00482729|Active Comparator|2|Arm 2: active comparator
89256399|NCT01019837|Experimental|Monovalent MF59- Adjuvanted vaccine|Focetria (Monovalent MF59-Adjuvanted vaccine) 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate Intra muscular
89256400|NCT00359762|Experimental|Exenatide|
89256401|NCT00359762|Active Comparator|Glimepiride|
89256402|NCT03988010|Experimental|Amantadine Sulphate|200 mg ıv Amantadine Sulphate in 500 cc solution
89256403|NCT03988010|Placebo Comparator|Placebo group|iv 500 cc %0.9 sodium chloride
89256404|NCT01055522|Experimental|ARM 1: L19IL2 + Dacarbazin|
89256405|NCT01055522|Experimental|ARM 2: L19IL2 + Dacarbazin|
89256406|NCT01055522|Active Comparator|ARM 3: Dacarbazin|DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first
89256407|NCT03987152|Other|Sirolimus|Sirolimus administration: during Challenge and Rechallenge phase. Compared with the period 2 months before start of Sirolimus.
89256408|NCT01056146|Active Comparator|Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
89256409|NCT01056146|Experimental|I-InTERACT|Participants will receive the internet-based parenting skills program.
89256410|NCT02533856|No Intervention|Usual Care|Discharge from emergency department by usual care
89256411|NCT02533856|Experimental|ETOC|Discharge from emergency department with increased support services provided by BoardRounds after ED discharge
89256412|NCT00347438|Experimental|Capecitabine|Capecitabine will be given at 1000mg/m2 twice daily for 2 weeks x 8 cycles, with a one-week pause in-between cycles.
89256413|NCT03987230|Active Comparator|Oust™ Demodex® Wipes™|Participant cleans eyelids with Oust™ Demodex® Wipes™
89256414|NCT03987230|Active Comparator|I-LID N LASH PLUS® Eyelid Cleanser|Participant cleans eyelids with I-LID N LASH PLUS® Eyelid Cleanser
89256415|NCT03987230|Active Comparator|Blephadex Lid Wipes|Participant cleans eyelids with Blephadex Lid Wipes
89256416|NCT03987230|Active Comparator|Eye Cleanse Lid Wipes|Participant cleans eyelids with Eye Cleanse Lid Wipes
89256417|NCT03987230|Active Comparator|Blephademodex|Participant cleans eyelids with Blephademodex
89256418|NCT03987230|Placebo Comparator|Sensitive Eyes® Plus Saline Solution|Participant cleans eyelids with Sensitive Eyes® Plus Saline Solution
89256419|NCT00329238|Experimental|Dabigatran|Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
89256420|NCT00329238|Active Comparator|Warfarin (INR of 2.0-3.0)|Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
89256421|NCT00328926|Active Comparator|Luveris® 75 IU|
89256422|NCT00328926|Active Comparator|Luveris® 25 IU|
89256423|NCT00328926|Placebo Comparator|Placebo|
89256424|NCT03982446||Patients with germline mutations|This group will comprise of patients with pancreatic cancer who carry pathogenic mutations in genes associated with a predisposition to cancer.
89256425|NCT03982446||Patients without germline mutations|This group will comprise of patients with pancreatic cancer who did not carry pathogenic mutations in any of the genes tested, that have been previously shown to be associated with a predisposition to cancer.
89256426|NCT01063686|No Intervention|Insemination cervical cap|
89256427|NCT00319254|Experimental|Advanced breast cancer|
89256428|NCT00319098|Experimental|GSK1562902A Group|Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.
89256429|NCT00319098|Active Comparator|Fluarix+Placebo Group|Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.
89256430|NCT00347360|Experimental|lisinopril|lisinopril
89256431|NCT00347360|Experimental|carvedilol|carvedilol controlled release formulation
89256432|NCT00319020|Experimental|Bosentan|Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
89256433|NCT02532738|Experimental|MSC-1|Patients in this arms receive routine treatment with 3×10E6/kg of MSC
89256434|NCT02532738|Experimental|MSC-2|Patients in this arms receive routine treatment with 6×10E6/kg of MSC
89256435|NCT02532738|Placebo Comparator|Ctrl|Patients in this arms receive routine treatment with NS injection
89256436|NCT01056224|Experimental|1.25 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
89256437|NCT01056224|Experimental|1.5 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
89256438|NCT01056224|Experimental|1.75 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
89256439|NCT01056224|Experimental|1 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
89256440|NCT01056224|Experimental|1.25 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
89256441|NCT01056224|Experimental|1.5 ug/kg normo-tensive 65-75 year olds|"1.5 ug/kg normo-tensive 65-75 year olds~A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old."
89256442|NCT01056224|Experimental|1 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
89256443|NCT01056224|Experimental|1.25 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
89256444|NCT01056224|Experimental|1.5 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
89256445|NCT03982680|Experimental|Toripalimab combined with Gem/5-FU|All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles.After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.
89256446|NCT00352118|Experimental|Chemotherapy + Low Dose Radiation|Patients receiving chemotherapy and Low Dose (60 Gy) Radiation per protocol.
89256447|NCT01325376|No Intervention|Self directed|
89256448|NCT01325376|Active Comparator|Technology assisted health behavior|The intervention arm will have access to a dynamic online environment with social networking and device data uploads that include activity data, weight data and laboratory data at frequent intervals to nudge optimal health behavior.
89256449|NCT00318474|Active Comparator|Mycophenolate Mofetil (MMF)|Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
89256450|NCT00318474|Placebo Comparator|MMF Placebo|Subjects receive MMF placebo.
89256451|NCT00350870|Placebo Comparator|Placebo|Placebo (plus Cognitive Behavioral Therapy- CBT)
89256452|NCT00350870|Active Comparator|Disulfiram|Disulfiram (plus CBT)
89256453|NCT00350870|Placebo Comparator|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
89256454|NCT00350870|Active Comparator|Disulfiram plus Contingency Management|Disulfiram plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
89256455|NCT03982290|Active Comparator|Lactobacillus plantarum PS128 (PS128)|Subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 16 weeks.
89256456|NCT03982290|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules, 2 capsules per day, for the first 8 weeks. The following 8 weeks, subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 8 weeks.
89256457|NCT03982290|No Intervention|Normal Control|Normal control group are enrolled by invitation from the age and gender matched healthy children.
89256458|NCT00350792|Experimental|Pemetrexed + Carboplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles.~Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."
89256459|NCT00317772|Experimental|Topotecan + Gefitinib|"Phase I: Topotecan: 2.0, 3.0, or 4.0 mg/m^2 by vein Days 1, 8 and 15 of 28 day cycle.~Gefitinib: 250 mg by mouth daily.~Phase II: Topotecan starting dose: MTD from Phase I by vein Days 1, 8, and 15 of 28 day cycle.~Gefitinib: 250 by mouth daily for 28 Days."
89256460|NCT02533778|Experimental|Interventional mechanical thrombectomy|Mechanical thrombectomy with either Penumbra system, TREVO, or Solitaire device for acute stroke symptom onset between 8 - 24 hours
89256461|NCT01325298|Active Comparator|20 Minute UV-X Light Treatment Duration|"20 Minute UV-X Light Treatment Duration~Note: UV-X is the trademark of Peschke GmbH"
89256462|NCT01325298|Active Comparator|30 Minute UV-X Light Treatment Duration|30 Minute UV-X Light Treatment Duration
89256463|NCT01325454||Patients with parapneumonic effusions|Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).
89256464|NCT00350636|Experimental|Oxybutynin topical gel|Oxybutynin topical gel
89256465|NCT00350636|Placebo Comparator|Placebo topical gel|placebo topical gel
89256466|NCT01051544|Active Comparator|von Willebrand factor-free FVIII concentrates|Patients treated with FVIII concentrates
89256467|NCT01051544|Active Comparator|FVIII/VWF concentrates|Patients treated with FVIII/VWF concentrates
89256468|NCT03985670|Experimental|treatment group|teripalimab 240mg d1 paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1
89256469|NCT03985670|Active Comparator|chemotherapy followed by immunotherapy|paclitaxel 150-175mg/m2 d1 cisplatin 70-75mg/m2 d1 teripalimab 240mg d3
89256470|NCT01058720|Experimental|Vitamin D3|Patients would receive 2000 IU of vitamin D3 daily for 12 weeks
89256471|NCT00346268|Active Comparator|Morphine plus Parecoxib|
89256472|NCT00346268|Active Comparator|Morphine and Placebo|
89256473|NCT00327444|Placebo Comparator|Placebo|"Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study."
89256474|NCT00327444|Experimental|Aflibercept|"Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study."
89256475|NCT01051622|Experimental|PBMC Trafficking|In part B, Patients undergo a blood draw (up to150 mL) and the PBMC's are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.
89256476|NCT01051622|Experimental|T Lymphocyte Trafficking|"In part B, Patients undergo a blood draw (up to150 mL) and the T lymphocyte cells are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.~visit."
89256477|NCT03982134|Experimental|PDR001 with Panobinostat|All enrolled patients will be treated with a combination of PDR001 at 400mg every 4 weeks and panobinostat. Dose and frequency of Panobinostat will vary depending upon the dose-level cohort of the study participants. Each participant will be assigned to a particular dose-level cohort.
89256478|NCT00337610|Experimental|sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day|
89256479|NCT00337610|Placebo Comparator|sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day|
89256480|NCT01062282||Group 1|
89256481|NCT01324856|Experimental|Pancreaticogastro anastomosis|
89256482|NCT01324856|Active Comparator|Pancreaticojejuno anastomosis|
89256483|NCT03981042|No Intervention|Control group|waiting for a 3-minute delay after injection of the atracurium before laryngoscopy
89256484|NCT03981042|Experimental|Monitoring group|waiting for the TOF ratio at 0 at the corrugator supercilli before laryngoscopy
89256485|NCT03985280|Experimental|Cooled radiofrequency|The procedure will be performed under regimen of major ambulatory surgery, it will be done under guidance of combined X-ray and ultrasound. . The nerves will be located b, after applying AL (Lidocaine 1%), a RF needle will be placed in the objective position.After verifying the positive sensitive and negative motor responses the cooled radiofrequency will proceed (previous application of local anesthesia (lidocaine 2%)). Cooled RF will be performed for 2:30 minutes at 60 degrees.
89256486|NCT03985280|Active Comparator|Intraarticular local anesthetic and steroids injections|An intraarticular injection will be done in ambulatory surgery regimen with a 22 Gauge needle. Intraarticular injection will be done under Fluoroscopic guidance (X-rays) with intra articular position confirmation by infusion of iodine contrast (Omnipaque 240). Once the needle position has been verified we will administer 10 mg of bipuvacaine, and 40 mg triamcinolone hexacetonide.
89256487|NCT01058876|Experimental|Usual Cigarette|African American and White Smokers will smoke their usual cigarette and also undergo an oral pharmacokinetics protocol after administration of 3 mg deuteriumlabeled nicotine and 5 mg deuterium-labeled cotinine.
89256488|NCT01058876|Experimental|Low-yield Cigarette|"African American and White smokers will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their usual brand."
89256489|NCT03986918||Ovation and Ovation Tribute|All patients having undergone a total hip arthroplasty that received the Ovation® or Ovation Tribute® (Ortho Development, Draper, Utah) Hip system will be sent the survey.
89256490|NCT03986840|Experimental|Exercise program|The exercise program was applied for 6 weeks. A total of 18 sessions were distributed in 3 weekly sessions. The participants performed a resistance exercises: leg press at an intensity of 40%-60% with 10 repetitions, 12 repetitions of steps with their bodyweight and a plantar flexion followed by a cardiovascular HIIT exercise walking on a treadmill.
89256491|NCT03986840|Active Comparator|Daily activities|The patients who belongs to this group will continue to perform their daily routines.
89256492|NCT03986762|Experimental|Open Label Clav|
89256493|NCT01051700|Experimental|5 mg|GW786034
89256494|NCT01051700|Experimental|10 mg|GW786034
89256495|NCT01051700|Experimental|20 mg|GW786034
89256496|NCT01051700|Placebo Comparator|Placebo|Placebo
89256497|NCT01056458|Active Comparator|Acupressure acupressure|
89256498|NCT01056458|Sham Comparator|sham acupressure|
89256499|NCT01325168|Experimental|study group|32 PTSD patients intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
89256500|NCT01325168|Other|control group|control group - 30 healthy control subjects intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
89256501|NCT00316914|Experimental|Ca/Mg|Patients receive calcium gluconate (Ca) and magnesium sulfate (Mg) IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
89256502|NCT00316914|Placebo Comparator|Placebo|Patients receive a placebo IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
89256503|NCT01059032|No Intervention|Unenhanced images|
89256504|NCT01059032|Other|Enhanced images|Enhanced images
89256505|NCT03991676|Experimental|Values-Based Behavioral Treatment|
89256506|NCT02532816|Experimental|HND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 83.5 mg, zinc oxide 50.95 mg, Calcium carbonate 3104.05 mg, Thiamine Mononitrate1.85 mg, Nicotinic Acid 30.45 mg, Pyridoxine Hydrocloride 2.90 mg, Pteroyl monoglutamic acid 764.90 mcg, Cyanocobalamin 0.95 mcg, Retinol Palmitate (dry) 742.50 mcgRE)
89256507|NCT02532816|Active Comparator|SND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 32.6 mg, zinc oxide 3.78 mg, Calcium carbonate 874.12 mg, Thiamine Mononitrate1.25 mg, Nicotinic Acid 17.95 mg, Pyridoxine Hydrocloride 1.10 mg, Pteroyl monoglutamic acid 329.90 mcg, Cyanocobalamin 0.55 mcg)
89256508|NCT02532816|Placebo Comparator|NDN-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + non fortified biscuit
89256509|NCT00336284|Active Comparator|Home Monitoring|Home Monitoring programmed on.
89256510|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off.
89256511|NCT00316602|Experimental|Healthy Participants|Healthy, vaccinia naive subjects without Atopic Dermatitis, receiving two doses of MVA-BN (IMVAMUNE)
89256512|NCT00316602|Experimental|Atopic Dermatitis Participants|"Vaccinia naive subjects with diagnosed Atopic Dermatitis. Diagnosed AD included subjects with either history of or subjects with currently active AD (defined as scoring AD [SCORAD] <= 30), receiving two doses of MVA-BN (IMVAMUNE)"
89256513|NCT00335972|Active Comparator|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
89256514|NCT00335972|Active Comparator|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
89256515|NCT03983304|Experimental|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
89256516|NCT03983460|Experimental|Dupimulab arm|"At Day 0, patients will receive Dupilumab treatment. The recommended dose of Dupilumab for adult patients is an initial dose of 600mg followed by 300mg given every two weeks administered as subcutaneous injection. Dupilumab could be self-administered by subcutaneous injection into thigh or abdomen or injected in the upper arm in case of administration by the patient's caregiver. It is recommended to rotate the injection site with each injection.~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
89256517|NCT03983460|Active Comparator|Optimized TCS treatment arm|"At Day 0, patients will receive topical corticosteroid treatment (TCS) adapted to the AD severity (potent and very potent TCS) with a personal therapeutic education for treatment optimization. It will be asked to perform, every day, an application of topical corticosteroid (TCS) (betamethasone valerate cream 0.1%, and if not active, clobetasol propionate cream 0.05%) on active lesions. Once the AD lesion is cleared, the patients will continue to apply TCS on healed lesions, twice a week until the end of the treatment period to prevent relapse.~At the end of treatment period, patient with AD IGA >1 will stop the study and patient with AD IGA≤1 will enter in a 3 months-follow-up period. During this period, they will stop treatment initiated at Day 0 and apply rescue TCS if appearance of AD lesion within 3 months. Patients will note in their diary the applications of rescue TCS. The relapse is defined as the necessity to apply TCS rescues."
89256518|NCT01056614|Experimental|Treatment (chemotherapy, PBSC transplant)|Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.
89256519|NCT03983538||Patients receiving chemotherapy|Patients receive a protocol-approved chemotherapy regimen containing Doxorubicin (or Epirubicin), Cyclophosphamide, and Paclitaxel (or Docetaxel) based on the patient and/or physician preference.
89256520|NCT00346034|Experimental|1|
89256521|NCT00345878|Experimental|Cervarix Group|Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.
89256522|NCT00345878|Placebo Comparator|Placebo Group|Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.
89256523|NCT01052090|Experimental|Lifestyle counseling|
89256524|NCT01056692|Active Comparator|Active compound|OC000459 orally
89256525|NCT01056692|Placebo Comparator|Placebo|Placebo given orally
89256526|NCT01059110|Experimental|Salicylate ointment|Salicylate ointment under occlusion (pomade M.O Cochon®)
89256527|NCT01059110|Experimental|Imiquimod|Imiquimod : Aldara®
89256528|NCT01059110|Experimental|5-fluoro-uracil|5-fluoro-uracil cream : Efudix®
89256529|NCT01059110|Experimental|Cryotherapy|liquid nitrogen : Cryotherapy
89256530|NCT01059266|Active Comparator|conventional regimen of PURETHAL Grasses|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml in intervals according to registered scheme (week 8, 10, 12, 16)."
89256531|NCT01059266|Experimental|rush regimen of PURETHAL Grasses|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml (week 1, 2, 3)~Maintenance treatment:~3 monthly doses of 0.5 ml (week 7, 11, 15)."
89256532|NCT03991364|Experimental|Constant gait speed group|experimental group that applied the speed of the robot-assisted gait training constantly
89256533|NCT03991364|Other|Increasing gait speed group|control group that applied the gradual increase of the speed of the robot-assisted gait training
89256534|NCT03985436|Experimental|Trek for Surgical Success|Cognitive behavioral therapy for pain
89256535|NCT03985124|Experimental|Intervention TIK-T|24 kindergartens will receive the full intervention. Dosage: 1 3 hour implementation session for kindergarten leaders; 1 x 2-day training workshop for kindergarten leaders and a lead resource person in each kindergarten who will support teachers in learning and implementing Emotion Coaching with children; 2 full training days for all teachers/childcare workers in Emotion Coaching; 2 x booster sessions for all teachers with the resource person in their kindergarten to assist them in using Emotion Coaching with children in their kindergartens.
89256536|NCT03985124|No Intervention|wait list control|24 kindergartens will be in the 12-month wait list condition
89256537|NCT00335738|Experimental|Group 1 (identified by central review as high risk)|Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.
89256538|NCT00335738|No Intervention|Group 2 (identified by central review as not high risk)|Patients undergo observation periodically for at least 5 years.
89256539|NCT02533076|Other|Cystinosis Patients|Cystinosis patients
89256540|NCT02533076|Other|Healthy volunteers|Healthy volunteers
89256541|NCT01056770|Experimental|Vaccinia-naive group|2.5 * 10^5 pfu/dose
89256542|NCT01056848||CK-LX3401|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia.
89256543|NCT01056848||CK-LX3405|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
89256544|NCT01056848||CK-LX3430|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
89256545|NCT03991598|Experimental|intervention|EDs 1 to 7 will then be randomly phased-in INT every 3 months.
89256546|NCT03991598|No Intervention|control|During the first 6 months and throughout CTRL time
89256547|NCT03991520|Experimental|Active Treatment with Anakinra|10 subjects will be enrolled in this group. Initial treatment will consist of 100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
89256548|NCT03991520|Placebo Comparator|Standard Comparison|10 subjects will be enrolled in this group. This group will be given placebo injections as their initial treatment. The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection. These individuals will self-administer the placebo each evening by subcutaneous injection from within 24 hours of the onset of menses until within 24 hours of last menstrual day.
89256549|NCT01056926|Experimental|Nicotine Patch + Denic Smoking|Subjects will wear a nicotine patch and smoke denic cigarettes for 24 hours prior to scan
89256550|NCT01056926|Experimental|Placebo Patch + Denic Smoking|Subjects will wear a placebo patch and smoke denic cigarettes 24 hours prior to scan
89256551|NCT01056926|Experimental|Nicotine Patch + No Smoking|Subjects will wear a nicotine patch and not smoke for 24 hours prior to scan
89256552|NCT01056926|Experimental|Placebo Patch + No Smoking|Subjects will wear a placebo patch and not smoke for 24 hours prior to scan
89256553|NCT02533700|Experimental|CEOP/IVE/GDP chemotherapy regimen|2 cycles of CEOP(cyclophosphamide,vincristine, epirubucin and prednisone),2 cycles of IVE(ifosfamide, epirubucin, etoposide)and 2 cycles of GDP(gemcitabine, cis-platinum, and dexamethasone)
89256554|NCT02533700|Active Comparator|CEOP chemotherapy regimen for 6 cycles|6 cycles of CEOP regimen(cyclophosphamide,vincristin,epirubucin and prednisone)
89256555|NCT01059500|Experimental|Webtool Output|The webtool output group will receive the numeric PTP estimate from webtool output.
89256556|NCT01059500|No Intervention|Standard of Care/No Webtool Output|The control group will not receive the numeric PTP estimate.
89256557|NCT01052246|Experimental|Clindamycin 1% + benzoyl peroxide 5% & pulsed dye laser|
89256558|NCT01052246|Active Comparator|Clindamycin 1% + benzoyl peroxide 5%|
89256559|NCT01059578|Experimental|Active|GSK206136 once daily
89256560|NCT01059578|Placebo Comparator|Placebo|Placebo once daily
89256561|NCT01059656|Experimental|1:Pazopanib|Pazopanib 800mg/j
89256562|NCT00334958|Placebo Comparator|Placebo|For 12-day Titration Phase and 12 week Maintenance Phase, placebo tablets matching to rufinamide 400 mg oral tablets will be administered according to the same regimen scheme as described for rufinamide. For 12-day Titration Phase, 1 matching placebo tablet will be administered twice daily and increased by 1 tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily.
89256563|NCT00334958|Active Comparator|Rufinamide|For the 12-day Titration Phase, rufinamide will be administered orally in doses starting with 400 milligram (mg) twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the 12 week Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
89256564|NCT01057004||all patients|chronical heart failure and EF ≤ 40 %
89256565|NCT03986528|Experimental|Kanglaite Injection + Chemotherapy|Participants receive Kanglaite Injection PLUS first-line chemotherapy.
89256566|NCT03986528|Active Comparator|Chemotherapy|first-line chemotherapy.
89256567|NCT01057082|Experimental|Juven|Participants in the treatment arm will receive the dietary supplement Juven.
89256568|NCT01057082|Placebo Comparator|Placebo|
89256569|NCT00326898|Experimental|Arm A (sunitinib malate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sunitinib malate PO QD for 4 weeks and placebo sorafenib tosylate PO QD or BID for 6 weeks.
89256570|NCT00326898|Experimental|Arm B (sorafenib tosylate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sorafenib tosylate PO QD or BID for 6 weeks and placebo sunitinib malate PO QD for 4 weeks followed.
89256571|NCT00326898|Placebo Comparator|Arm C (placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive placebo sorafenib tosylate as in Arm A and placebo sunitinib malate as in Arm B.
89256572|NCT01062360|Experimental|Arm 1|
89256573|NCT01062360|Active Comparator|Arm 2|
89256574|NCT01062360|Active Comparator|Arm 3|
89256575|NCT01062360|Placebo Comparator|Arm 4|
89256576|NCT03982056||Main study group|"Assessments performed:~Height~Mass~Body fat density~Bone density~Lean muscle density~Lung volume measurements~Floating technique~Buoyancy"
89256577|NCT03982056||Validation group|"Assessments performed:~Height~Mass~Body fat density~Bone density~Lean muscle density~Lung volume measurements~Floating technique~Buoyancy"
89256578|NCT01063842|Experimental|001|tramadol hydrochloride / acetaminophen and placebo 1 tablet of tramadol/acetaminophen in the morning 1 tablet of placebo in the afternoon and evening for 3 days then 1 tablet of tramadol/acetaminophen in the morning evening and 1 tablet of placebo in the afternoon for 4 days then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
89256579|NCT01063842|Active Comparator|002|tramadol hydrochloride /acetaminophen 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
89256580|NCT01063920|Experimental|LT-NS001|LT-NS001 1200 mg b.i.d. p.o. for 12 weeks
89256581|NCT01063920|Active Comparator|Naprosyn®|Naprosyn® 500 mg b.i.d for 12 weeks
89256582|NCT01062516|Active Comparator|1|oral esomeprazole 20 mg daily
89256583|NCT01062516|Active Comparator|2|oral famotidine 40mg daily
89256584|NCT01063998||Group 1|Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
89256585|NCT01063998||p 2|Patients diagnosed with renal cancer and normal creatinine.
89256586|NCT03981120|No Intervention|Standard Care Group|Patients in the control arm will not undergo laser and acupuncture treatment. The treatment and control group will be compared to the baseline pregnancy rate of women meeting the same inclusion and exclusion criteria from the clinic through a chart review over the two years prior to initiation of the study.
89256587|NCT03981120|Experimental|Laser and Acupuncture Group|"The patients in the treatment arm will have 7 treatments before transfer (2-4 sessions a week), for the 3 weeks from starting estrace leading to the day before embryo transfer, then one (before and after transfer) on the day of transfer (total 8 sessions). Each treatment leading up to transfer day treatment consists of:~Traditional Acupuncture at points Sp9 to SP6 EA2Hz Milliamp (Pantheon device), ST-36 B, LI4 unilateral, LV3 unilateral and/or LU7 unilateral, K6 unilateral.~Bioflex Array (Photobiomodulation) - simultaneously array placements with each treatment over the sacrum (points BL-31, BL 32, BL 33 BL 34, DU2, DU3) and lower Abdomen above uterus (Ren 2 to Ren 6)~Laser acupuncture over ST-9, ST10, SJ 17, ST-11. Ren 3 and Ren 4. 6.75 J per point at ST 9, ST10 (over carotid) and SJ17 (vertebral artery).~On the day of FET on site at IVF clinic there will be a before and after traditional and laser acupuncture treatment."
89256588|NCT01062594|Active Comparator|Supervised exercise group|
89256589|NCT01062594|No Intervention|Control group - no exercise|
89256590|NCT00326118|Active Comparator|Meningitec + Hiberix Group|Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
89256591|NCT00326118|Experimental|Menitorix Group|Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
89256592|NCT00334802|Experimental|A|
89256593|NCT03985358|No Intervention|Control Group|Patients randomized to the Control Group will not receive opioid counseling and will only receive their standard of care instructions for preoperative and postoperative care.
89256594|NCT03985358|Experimental|Treatment Group|Patients randomized to the Treatment Group will have opioid counseling plus standard of care instructions given by the same counselor (investigator on the study) using the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher).
89256595|NCT00307164|Active Comparator|NucleomaxX|Participants received NucleomaxX for 48 weeks
89256596|NCT00307164|Placebo Comparator|Placebo|Participants received NucleomaxX placebo for 48 weeks
89256597|NCT01059890|Experimental|Cefotaxime|
89256598|NCT01059890|Experimental|Metrodinazole|
89256599|NCT01059890|Experimental|Ciprofloxacine|
89256600|NCT01059890|Experimental|Fosfocine|
89256601|NCT01057160|Experimental|intake of rizatriptan 10 mg|
89256602|NCT01057160|Active Comparator|previous used analgesic|
89256603|NCT01057238|Experimental|Intensive Communication|regular family meeting every 5 days.
89256604|NCT01057238|No Intervention|Control|usual care
89256605|NCT03990974|Experimental|Postoperative antimicrobial prophylaxis|Patients will receive postoperative antimicrobial prophylaxis for 3 days in 24 hours after hepatectomy.
89256606|NCT03990974|Sham Comparator|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy, unless the clinicians suggest he/she need antibiotics to treat or prevent infection.
89256607|NCT03827564|Experimental|ITN [TrueTear®] - Intranasal Application|Intranasal application of the ITN. Single application at application visit.
89256608|NCT03827564|Experimental|ITN [TrueTear®] - Extranasal Application|Extranasal application of the ITN. Single application at application visit.
89256609|NCT00307086|Other|Autologous PBSCT|bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant (PBSCT)
89256610|NCT03741998|No Intervention|THRIVE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction using jaw-thrust maneuver.
89256611|NCT03741998|Active Comparator|THRIVE with nasopharyngeal airway|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction with nasopharyngeal airway.
89256612|NCT01059968||adolescent female endurance athletes|High school female cross country runners in San Diego.
89256613|NCT01060046||Patients with previously implanted biologic mesh|All patients undergoing a repeat operation to repair a recurrent hernia or to revise a surgical site which has been previously repaired using a biologic mesh.
89256614|NCT01060046||Control patients|Any patient undergoing a surgical procedure where fascial biopsy would not compromise the integrity of the procedure.
89256615|NCT01060202||Bortezomib|
89256616|NCT01057316|Experimental|Study Group A|
89256617|NCT01057316|Experimental|Study Group B|
89256618|NCT01057316|Experimental|Study Group C|
89256619|NCT02533544||tenofovir disoproxil fumarate monotherapy|a group which treated with tenofovir disoproxil fumarate
89256620|NCT01052402|Experimental|Dose A|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose A) followed by a heterologous booster vaccination (Dose A) on Day 360
89256621|NCT01052402|Experimental|Dose B|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose B) followed by a heterologous booster vaccination (Dose B) on Day 360
89256622|NCT03991208|Experimental|Rest|Pharmacokinetics of Single Dose Malarone at Rest
89256623|NCT03991208|Experimental|Exercise|Pharmacokinetics of Single Dose Malarone under exercise in a heat chamber
89256624|NCT01057472||Term born babies|Term born babies
89256625|NCT01057472||Preterm babies ready for discharge|Preterm babies ready for discharge
89256626|NCT01057472||Preterm stable babies 1500 grams|Preterm stable babies 1500 grams
89256627|NCT00325416|Experimental|Age Group A - Melphalan and Topotecan plus Stem Cell Rescue|Participants 18 - 60 years of age. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
89256628|NCT00325416|Active Comparator|Age Group B - Melphalan and Topotecan plus Stem Cell Rescue|Participants 61 years of age or older. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
89256629|NCT01060280|Active Comparator|Education group|Routine clinical practice (includes usual physiotherapy)plus education on active management.
89256630|NCT01060280|Active Comparator|Group GDS physiotherapy|Routine clinical practice (except usual physiotherapy, which is substituted for Group GDS)plus education on active management.
89256631|NCT01060280|Active Comparator|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which will be substituted by Group and Individual GDS) plus education on active management.
89256632|NCT01061138||Screening Patients|Female patients scheduled for routine annual screening mammograms
89256633|NCT01061138||Biopsy Patients|Female patients scheduled for routine breast biopsy procedures
89256634|NCT01060358||healthy|Healthy and active men and women between 21 and 45 years old with no history of low back pain or low back injury.
89256635|NCT00314808|Experimental|Dronabinol|
89256636|NCT03984734|Active Comparator|Control group|Patients undergoing pancreatoduodenectomy with antrectomy
89256637|NCT03984734|Experimental|Study group|Patients undergoing pancreatoduodenectomy with pylorus-preserving pancreatoduodenectomy
89256638|NCT03981276||Primary participant:|"Participants affected by hereditary spastic paraplegia (HSP) or a phenotypically related disorder Primary participants will be followed at annual intervals. The workup includes clinical, imaging, sensor-based, patient/observer reported and molecular outcome parameters and biosampling.~Participants with unknown genetic diagnosis may receive genetic testing including whole exome or whole genome sequencing and other OMICS techniques."
89256639|NCT03981276||Secondary participant/ First or second-degree|First or second degree unaffected family members of primary participants. Secondary participants may undergo the same study procedures as primary participants.
89256640|NCT03981276||Unrelated healthy control|Unrelated healthy controls Healthy controls may undergo the same study procedures as primary participants.
89256641|NCT01060514|Experimental|Pazopanib + Vinorelbine|
89256642|NCT06252584|Experimental|Multipeptide Vaccination|The vaccine cocktail will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1) as adjuvant. Two vaccinations within a 6-week interval are planned, with the option of one additional booster in case of insufficient response after the first two vaccinations. Peptide vaccination will take place in AML patients that have achieved a morphological complete remission (CR) or a complete remission with incomplete blood count recovery (CRi) with standard first line treatment. MRD positivity is permitted. Vaccination will start 4-28 weeks after last application of intensive chemotherapy). Any maintenance treatment, e.g. with oral azacytidine or midostaurin, or ongoing low intensity therapy, e.g. with HMA, venetoclax etc. is permitted, can be applied throughout the vaccination and continued after study treatment according to the treating physician's decision.
89256643|NCT06252558|Experimental|Symbiotic Group|An over-the counter, once daily symbiotic capsule including: 15 billion CFU probiotic blend and 250mg of prebiotic.
89256644|NCT06252558|Placebo Comparator|Fiber Group|Once daily capsule of microcrystalline cellulose.
89256645|NCT06252532|Active Comparator|Frontal Stimulation|Direct Cortical Stimulation (DCS) in alpha and theta frequencies is applied through electrodes located in the frontal cortex.
89256646|NCT06252532|Sham Comparator|Frontal Parietal Stimulation|Direct Cortical Stimulation (DCS) in in-phase and anti-phase theta frequencies is applied through electrodes located in the frontal and parietal cortex.
89256647|NCT06252506|Experimental|Placebo first, intervention second|Participants allocated to this arm receive placebo on their first study day and the active drug under investigation on the second study day.
89256648|NCT06252506|Experimental|Intervention first, placebo second|Participants allocated to this arm receive the active drug under investigation on their first study day and placebo on the second study day.
89256649|NCT06252480|Experimental|Intensities of tDCS and dual task cognitive functions|We have done in a one arm type. The participants are divided into different intensity group (0.5 mA, 1.0 mA, 1.5 mA and 2.0 mA).
89256650|NCT06252467|Active Comparator|Active Comparator|"Device: Active Photobiomodulation Therapy Phototherapy treatment (Photobiomodulation therapy or placebo) was performed using a Photobiomodulation therapy device (Vectra Genisys Systems, Chattanooga Group, Dallas, TX, USA). The cluster probe consisted of five low-level laser therapy diodes (850 nm) and 28 light emitting diodes therapy (670 nm, 880 nm, and 950 nm). Photobiomodulation therapy was applied in nine sites of each quadriceps femoris muscle~. A dosage of 15 J per site led to a total energy of 135 J per thigh, effectively increasing cycling performance in a previous study. We chose to apply Photobiomodulation therapy specifically to the quadriceps femoris because this muscle group is of utmost significance in generating torque and propelling the pedaling cycle. Its pivotal role in cycling performance made this muscle a prime target for the Photobiomodulation therapy intervention in our study."
89256651|NCT06252467|Placebo Comparator|Placebo Comparator|Device: Placebo Photobiomodulation The placebo treatment was performed in exactly the same manner as the Photobiomodulation therapy treatment, but with the device switched off, and the cluster was held stationary in contact with the skin at a 90° angle, with light pressure on the skin. The total application time of Photobiomodulation therapy or placebo was ~5 min for both limbs (9 points per thigh = 18 points × 16 s per point) before each time-to-exhaustion test.
89256652|NCT06252454|Experimental|Furosemide|Subjects will inhale once 40 mg of furosemide for 23 minutes, next they will be monitored for an hour and then cross over will take place, the subjects will inhale placebo - saline for 23 minutes and another hour of monitoring and observation will take place. Lastly all subject will be given levodropropizine 1 ml (60mg) with last hour of monitoring and observation
89256653|NCT06252454|Placebo Comparator|Placebo|Subjects will inhale once placebo - saline for 23 minutes, next they will be monitored for an hour and then cross over will take place, the subjects will inhale 40 mg of furosemide for 23 minutes and another hour of monitoring and observation will take place. Lastly all subject will be given levodropropizine 1 ml (60mg) with last hour of monitoring and observation
89256654|NCT06252441|Active Comparator|Rectal Diclofenac|This Group will include 23 patients who will receive 100 mg rectal diclofenac before ERCP.
89256655|NCT06252441|Active Comparator|Oral N-acetyl cysteine|This Group will include 23 patients who will receive 1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
89256657|NCT06252389||Achilles Regeneten|bovine collagen patch to augmented repair in acute Achilles tendon rupture with pre-existing tendinopathy
89256658|NCT06252376|Experimental|Supine cognitive testing first|Participants will undergo a computerized cognitive battery in the supine position, followed by a similar battery with alternate test versions in the upright position while on a head-up tilt table.
89256659|NCT06252376|Experimental|Upright cognitive testing first|Participants will undergo a computerized cognitive battery in the upright position, followed by a similar battery with alternate test versions in the supine position while on a head-up tilt table.
89256660|NCT06252363||Practicing physiotherapists|French- or Dutch-speaking physiotherapists currently practicing their profession
89256661|NCT06252298|Experimental|Dose-finding and dose-expansion|"Dose-finding stage: The dose escalation in this study is pre-defined in nine dose groups. The dose escalation starts with 0.01mg and proceeds from low to high doses.~Dose-expansion stage: Patients will be randomly assigned to receive different doses of SCTC21C at a ratio of 1:1. Doses of SCTC21C will be determined based on the data obtained in the Dose-finding stage."
89256662|NCT06252272|Other|Biopsy sample in an area of liver macroscopically free from parenchymal alterations|Patients undergoing abdominal surgery for primary or secondary liver tumors (liver metastases from colorectal, pancreatic, or breast), from which we proceed to the preparation of organotypic cultures of liver (hLSC) derived from liver biopsies taken from patients undergoing abdominal surgery for primary or secondary liver tumors for the molecular characterization of liver fibrosis.
89256663|NCT06252220|Active Comparator|Part 1 - Single Ascending Dose|Single doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.
89256664|NCT06252220|Placebo Comparator|Part 2 - Multiple Ascending Dose|Multiple doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.
89256665|NCT06252207|Experimental|Desflurane|General anesthesia with desflurane.
89256666|NCT06252207|Experimental|Isoflurane|General anesthesia with isoflurane.
89256667|NCT06252194|Experimental|Group A|Metformin 500 mg twice daily along with topical retinoids for 12 weeks
89256668|NCT06252194|Active Comparator|Group B|Doxycycline 100 mg twice daily along with topical retinoids for 12 weeks
89256669|NCT06252181|Experimental|group number 1|group of peripheral arterial disease elderly (n=20) that take their medications and will receive 3 sessions per weeks of 8-week electromagnetic one-hour therapy and one hour elliptical exercise (exercise will be applied 3 times per the week for eight week)
89256670|NCT06252181|Active Comparator|group number 2|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week)
89256671|NCT06252129|Experimental|1. Interventional group|subjects who are being consented to this study and undergoing lymph node dissection as outlined in this protocol
89256672|NCT06252129|No Intervention|Concurrent non-interventional group|
89256673|NCT06252129|Other|Retrospective cohort from 2021-2020|
89256674|NCT06252116||Neuropathic pain patients|Patients were randomized to pregabalin (group A) and duloxetine (group B). Those patients who did not have a 50% reduction in pain levels received duloxetine (group A) and pregabalin (group B). Then, those patients who did not have a 50% reduction in pain levels received tramadol.
89256675|NCT06252103|Active Comparator|group I|the first group 20 patients will receive one tab of ferrous gluconate 300mg administered orally twice per day for 4 weeks (Ferrous-Gluconate®, tab.300mg glucofer, Egypt) two times daily.
89256676|NCT06252103|Active Comparator|group II|20 patients were given lactoferrin 100mg (Pravotin-sachets®,100mg, Hygint, Egypt) with ferrous gluconate twice daily for 4 weeks Patients were assigned to take the medication orally; once daily before breakfast, and Pravotin (100 sachets were be dissolved each in ¼ glass of water and taken before breakfast). Patients were advised to avoid the intake of tea, coffee, milk, milk products, antacids and calcium preparation within 2 hours before or after iron capsules.
89256677|NCT06252090|Experimental|MBT-A|Short term Mentalization-based treatment for adolescents (psychotherapy).
89256678|NCT06252077|Experimental|very low ketogenic diet|patients with overweight and obesity in treatment for weight loss
89256679|NCT06252064|Active Comparator|Combo Group|Rehabilitation treatment combined with drug therapy
89256680|NCT06252064|Active Comparator|Reha Group|Rehabilitation treatment
89256681|NCT06252064|Active Comparator|Drug Group|Drug therapy with Pridinol Mesylate
89256682|NCT06252051|Experimental|Trivalent Vaccine|
89256683|NCT06252038|Experimental|Group Video Diabetes Prevention Program|Participants randomized to the group video DPP for 12-months.
89256684|NCT06252038|Active Comparator|Self Directed Diabetes Prevention Program|Participants randomized to the self directed DPP for 12-months.
89256685|NCT06252025|Experimental|"VR reminiscence therapy system Memo-gration"|This study tailored a variety of instructional material within each virtual scenario, taking into account various memory triggers. Guidance is activated when the user is identified as making physical contact with an object or discussing a specific keyword. This encompasses textual assistance provided within the virtual environment, the display of multimedia information, and the provision of organized voice guidance. Following the system's instructions, users engaged in discussion with the caregiver, and had the freedom to terminate the conversation at their discretion and explore other topics by interacting with different items.
89256686|NCT06252025|Active Comparator|Picture reminiscence therapy|The picture reminiscence therapy group utilized a series of color images depicting screenshots of the Memo-gration, ensuring that the screenshots remained as consistent as feasible with the presented memory cues.
89256687|NCT06251999|Experimental|fospropofol|
89256688|NCT06251999|Placebo Comparator|propofol|
89256689|NCT06251947|Experimental|experimental group|Efbemalenograstim Alfa should be administered subcutaneously, 20mg per injection, within 24-48 hours after the completion of each chemotherapy cycle.
89256690|NCT06251934||Patients with high tumor burden (HTB)|
89256691|NCT06251934||Patients with low tumor burden (LTB)|
89256692|NCT06251934||Patients with central nervous system (CNS) metastases|
89256693|NCT06251934||Patients with without CNS metastases|
89256694|NCT06251934||1L IO-refractory patients|
89256695|NCT06251921|Experimental|Restorations 1|preheated resin-based composite
89256696|NCT06251921|Experimental|Restorations 2|room temperature resin-based composite
89256697|NCT06251908|Experimental|Active intervention arm|Participants allocated to active intervention arm will receive Rewritalize in addition to standard mental health care
89256698|NCT06251908|Active Comparator|Control arm|Participants allocated to the control arm will receive standard mental health care.
89256699|NCT06251895||mild DKA|pH < 7.3 or serum bicarbonate <18 mmol/L
89256700|NCT06251895||moderate DKA|pH < 7.2 or serum bicarbonate <10 mmol/L
89256701|NCT06251895||severe DKA|pH < 7.1 or serum bicarbonate <5 mmol/L
89256702|NCT06251869||hip electrocoagulation|group subjected to the use of electrocoagulation
89256703|NCT06251869||hip scalpel|group subjected to the use of traditional hemostatic technique
89256704|NCT06251869||knee electrocoagulation|group subjected to the use of electrocoagulation
89256705|NCT06251869||knee scalpel|group subjected to the use of traditional hemostatic technique
89256706|NCT06251856|Experimental|lymphedema education|Participants will receive lymphedema education and educational brochures from the researcher on the 2nd day after gynecological cancer surgery.
89256707|NCT06251856|No Intervention|routine discharge education|Routine post-op discharge education is given to patients who undergo gynecological cancer surgery at the institution by nurses on the day of discharge.
89256708|NCT06251843||Parents of children with sickle cell disorder|Parents whose child has been diagnosed with sickle cell disorder in the last 36 months
89256709|NCT06251843||Health professionals|Health professionals involved in the care of children sickle cell disorder
89256710|NCT06251830||Pediatric patients|Pediatric patients referred to the participating imaging centre for a standard MRI procedure.
89256711|NCT06251830||Adult Patients|Adult patients referred to the participating imaging centre for a standard MRI procedure, with neurological signs and symptoms.
89256712|NCT06251830||Healthy Controls|Adult healthy controls
89256713|NCT06251752|Active Comparator|Lateral closing wedge high tibial osteotomy|
89256714|NCT06251752|Active Comparator|Medial opening wedge high tibial osteotomy|
89256715|NCT06251739|Active Comparator|Tablet Ivermectin|A cumulative dose of 60 mg Oral Ivermectin monotherapy (12 mg/day) on five consecutive days (day 1 - day 5) for three consecutive months (180 mg in total)
89256716|NCT06251739|Active Comparator|Capsule Miltefosine|Oral Miltefosine monotherapy for 12 weeks. 50 mg in the morning and 50 mg in the evening with meal x 84 days (Total 100 mg/day)
89256717|NCT06251700|Experimental|Intervention arm|CADe system will be used during withdrawal phase of colonscopy
89256718|NCT06251687|Experimental|Transbronchial Cryobiopsy (TBLC)|Transbronchial lung cryobiopsy (TBLC) has been increasingly utilised to diagnose diffuse parenchymal lung diseases
89256719|NCT06251687|Active Comparator|Transbronchial Lung Biopsy (TBLB)|Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
89256720|NCT06251635|Experimental|Follicular Phase Visits|Participants will undergo two visits during the follicular phase of the menstrual cycle (they will be scanned between day 4-10 of their menstrual cycle). Each of the study periods will involve administration of OLA 5 mg HS (or PL) on day 0, OLA 10 mg HS (or PL) on day 1, and cognitive testing and MRI scanning on day 2. MRI assessments will occur 15 minutes after administering 160 International Units (IU) INI/INP.
89256721|NCT06251635|Experimental|Luteal Phase Visits|Participants will undergo two visits during the luteal phase of the menstrual cycle (they will be scanned between day 16-22, or within 5 days of next expected menses depending on individual cycle duration). Each of the study periods will involve administration of OLA 5 mg HS (or PL) on day 0, OLA 10 mg HS (or PL) on day 1, and cognitive testing and MRI scanning on day 2. MRI assessments will occur 15 minutes after administering 160 International Units (IU) INI/INP.
89256722|NCT06251622||People with Cystic fibrosis treated with CFTR modulators|Children (over 10 years old) and adults with cystic fibrosis, with a stable clinical condition and no contraindications to engaging in moderate-intensity physical activities (PA).
89256723|NCT06251622||Healthy individuals|Healthy children (over 10 years old) and adults without known diseases (chronic respiratory, cardiovascular, metabolic, renal, or neuromuscular diseases) that may affect their peripheral muscle strength.
89256724|NCT06251609|Active Comparator|Naloxone|The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine.
89256725|NCT06251609|Placebo Comparator|Saline|Saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. The trial will be double-blind; patients, investigators, and the clinical team will be blinded. Only the pharmacy providing the numbered syringes will be aware of the allocation but will not be involved with clinical care or outcome evaluation. The saline placebo will be stored in syringes identical to the naloxone syringes without identifying features.
89256726|NCT06251596||Patients with ovulatory cycles|Patients with ovulatory cycles
89256727|NCT06251596||Patients with artificial cycles|Patients with artificial cycles
89256728|NCT06251583|Experimental|Experimental group or Duramesh group|Umbilical trocar closure using Suture-mesh (Duramesh suture).
89256729|NCT06251583|Active Comparator|Control group or poli(4)hidroxibutirate group|Umbilical trocar closure using conventional monofilament suture.
89256730|NCT06251570||Patients with Lung Cancer|Patients with Lung Cancer
89256731|NCT06251570||Control Group|Control Group
89256732|NCT06251557|Experimental|Lumbopelvic Massage and Exercise Training in addition to Standard Urotherapy and Biofeedback Therapy|Group 1 will receive lumbopelvic massage and exercise training in addition to standard urotherapy and pelvic floor EMG biofeedback therapy.
89256733|NCT06251557|Active Comparator|Standard Urotherapy and Biofeedback Therapy|Group 2 will receive only standard urotherapy and pelvic floor EMG biofeedback therapy.
89256734|NCT06251544|Experimental|Arm A: HTR2 T Cells (without lymphodepletion)|Two dose levels will be evaluated in Arm A (without lymphodepletion)
89256735|NCT06251544|Experimental|Arm B: HTR2 T Cells (with lymphodepletion)|Two dose levels will be evaluated in Arm B (with lymphodepletion)
89256736|NCT06251531|Experimental|GD-TG-PBI|Goal-Directed Therapist-Guided Play-Based Intervention
89256737|NCT06251531|No Intervention|Control Group|Routine therapy
89256738|NCT06251518|Experimental|vimida + TAU|"Participants allocated to the intervention group will receive access to vimida in addition to treatment as usual (TAU).~vimida is a digital health application designed for individuals with post-Covid conditions who suffer from fatigue, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by vimida are psychoeducation, activity and recovery, attention, stress management, sleep management, cognitive restructuring, and social resources.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
89256739|NCT06251518|No Intervention|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
89256740|NCT06251479|Experimental|A group behavioral 1|The first group will perform perceptual and verbal and non-verbal motor execution tasks, while behavioral measurement techniques will be used.
89256741|NCT06251479|Experimental|B group behavioral 2|The second group will perform the same tasks as group A and will be subjected to the same measurements as group A. Differently from group A, the members of group B will perform the experimental tasks together with another participant.
89256742|NCT06251479|Experimental|C group neuromoulation 1|The third group is identical to group A except that neurophysiological measurement techniques will also be applied.
89256743|NCT06251479|Experimental|D group neuromodulation 2|The fourth group is identical to group B except that neurophysiological measurement techniques will also be applied.
89256744|NCT06251466|Experimental|Telemonitoring group|Participants randomized in the telemonitoring group receive a glucose meter to monitor their blood glucose levels at home. They need to perform the same measurements as the control group. The only difference lies in how they transmit their blood glucose measurement to the hospital. After each measurement, they need to register these levels once a week in the iHealth Gluco-Smart application. This data is send, via Bluetooth and Wi-Fi, to an online dashboard, called Dharma, for review by the researchers of the Mobile Health Unit of Hospital Oost-Limburg (ZOL) in Genk. Participants measuring abnormal blood glucose levels at one of the four time points are requested to measure their blood glucose levels again on the following day. The researcher contacts the endocrinology department if any abnormal blood glucose values are detected. Interventions including, starting insulin treatment, will be performed by the endocrinologist when necessary.
89256745|NCT06251466|No Intervention|Control group|Pregnant women randomized in the control group receive a glucose meter to monitor their blood glucose levels at home. They need to measure their blood glucose levels four times a week, including: before breakfast, two hours after breakfast, two hours after lunch, two hours after dinner. These values are then called by the pregnant women to the endocrinology department. Interventions including, starting insulin treatment, will be performed by the endocrinologist when necessary.
89256746|NCT06251453||SGLT2 inhibitors users|Adults undergoing cardiothoracic surgery who had been using SGLT2 inhibitors for a minimum of 1 week before surgery, regardless of diabetes status
89256747|NCT06251453||SGLT2 inhibitors non-users|Adults not receiving SGLT2 inhibitors undergoing cardiothoracic surgery
89256748|NCT06251427|Placebo Comparator|Low dose multiple micronutrient fortification|Maize, milk plus low multiple micronutrient fortification
89256749|NCT06251427|Active Comparator|Moderate dose multiple micronutrient fortification|Maize, milk plus moderate multiple micronutrient fortification
89256750|NCT06251427|Active Comparator|High dose multiple micronutrient fortification|Maize, milk plus high multiple micronutrient fortification (double the moderate level)
89256751|NCT06251414|Experimental|Blood Flow Restriction Training，BFRT|Blood Flow Restriction Training (BFRT) is a special training technique aimed at limiting blood flow by using cuffs or elastic bands on the limbs to promote muscle growth and improve strength. BFRT was originally designed for rehabilitation injured athletes as it can improve muscle strength while reducing load, helping to avoid further injuries during the rehabilitation process. But as research deepens, it is gradually being applied to a wider range of fitness and training fields. One major advantage of BFRT is that it allows for efficient training under relatively light loads, reducing the burden on joints and tendons, making it suitable for people who find it difficult to withstand high-intensity training due to injuries or other reasons. Meanwhile, BFRT also has the characteristic of achieving muscle growth and strength growth in a short period of time, and it is considered a time-saving training method. BFRT can not only be used for strength training, but also for rehabilitation, i
89256752|NCT06251414|Experimental|Instrument-Assisted Soft Tissue Mobilization，IASTM|Instrument Assisted Soft Tissue Mobilization (IASTM) is a physical therapy technique that utilizes specially designed tools (such as metal or plastic scraping boards) to assist in the treatment of soft tissue problems. Mainly used in rehabilitation medicine, sports medicine, and plastic surgery, it is used to handle tension, adhesion, pain, and motor dysfunction of muscles, fascia, and tendons. The edge design of IASTM special tools can loosen adhesions in tissues, improving their elasticity and plasticity. Regulating pathological areas through neural pathways, reducing pain and improving neurological function. And different types of treatment tools improve the accuracy of treatment, promote blood circulation, accelerate the rehabilitation process, improve tissue elasticity, expand joint range of motion, and have lower risks and complications compared to invasive surgery.
89256753|NCT06251414|Placebo Comparator|Tuinal|Tuinal is an important physical therapy method in traditional Chinese medicine, which can be traced back to the Shang Dynasty around 2700 BC. With the continuous development of social economy and cultural exchange, Tuinal technology based on traditional Chinese medicine ethics and guided by modern scientific theories gradually emerged. The technical treatment methods are mainly relaxation techniques, supplemented by movement techniques. Following the principle of combining movement and stillness, emphasizing both muscles and bones, and progressing step by step, massage has significant therapeutic effects on skeletal muscle diseases. In clinical practice, massage therapists use various techniques to apply to specific parts or acupoints of the human body, keeping the nerves and muscle tissues in a good state, improving the unblocking of meridians, relaxing soft tissues, restoring flexibility, and relieving symptoms such as muscle spasms and pain.
89256754|NCT06251388|Experimental|treatment group|AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W） after CCRT
89256755|NCT06251362|No Intervention|Normal sleep|The night before the experimental session, where participants will follow their habitual sleep-wake routines.
89256756|NCT06251362|Experimental|Sleep restriction|The night before the experimental session (with sleep restrictions (SR)), where participants will experience acute sleep restriction the night before the test session (i.e., 3 h of early sleep restriction versus normal sleep).
89256757|NCT06251349||Intervention group with prophylactic irradiation|Patients with total hip arthroplasty and irradiation (preoperative on the day before the operation (>24h preoperative)) Quantity: 128 Period: 01.01.2013 - 31.12.2023
89256758|NCT06251349||Control group with prophylactic NSAID-treatment|Patients with total hip arthroplasty and diclofenac treatment Quantity: 384 Period: 01.01.2013 - 31.12.2023
89256759|NCT06251297|Experimental|Reflexology session|Patients included in the study and treated with oxaliplatin based regiment will receive 30-min of a standard reflexology session during each infusion for a maximum of 12 sessions over 6 months).
89256760|NCT06251284|Experimental|Placebo - Control|Participants in this group receive sham oxytocin on the first study day.
89256761|NCT06251284|Experimental|Control - Placebo|Participants in this group receive sham oxytocin on the second study day
89256762|NCT06251258|Experimental|Insomnia|
89256763|NCT06251258|Active Comparator|Control|
89256766|NCT06251219||Case cohort|Clinically diagnosed HFMD children of either sex, aged 6 months - 18 years old in the study sites
89256767|NCT06251180|Experimental|Dose Escalation|Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP
89256768|NCT06251180|Experimental|Dose Expansion [non-GCB DLBCL]|Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP
89256769|NCT06251180|Experimental|Dose Expansion [MCL]|Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP
89256770|NCT06251180|Experimental|Dose Expansion [MZL]|Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP
89256771|NCT06251154|Experimental|Lens 1|All participants wore Lens 1 for 15 minutes (Period 1)
89256772|NCT06251154|Experimental|Lens 2|All participants wore Lens 2 for 15 minutes (Period 2)
89256773|NCT06251141|Active Comparator|Study group gum Health gel|Study group we fill the sockets with gel foam immersed with Gum Health gel
89256774|NCT06251141|Placebo Comparator|Control group gel foam|Control group we fill the sockets with gel foam only
89256775|NCT06251076|Experimental|Cohort 1|Give teclistamab step-up dosing at Princess Margaret Cancer Centre as per product monograph.
89256776|NCT06251076|Experimental|Cohort 2|Give teclistamab step-up dosing at Princess Margaret Cancer Centre with the addition of one dose of prophylactic tocilizumab prior to step-up dose 1.
89256777|NCT06251076|Experimental|Cohort 3|Give teclistamab step-up dosing at Southlake Regional Cancer Centre in the outpatient setting using the best method(s) as determined from Cohorts 1 and 2.
89256778|NCT06251076|No Intervention|Caregiver Cohort|Caregivers of participants in Cohorts 1, 2, and 3 will complete various questionnaires to assess impact.
89256779|NCT06251024|Experimental|Group 1: RSV vaccine candidate|Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the RSV vaccine candidate.
89256780|NCT06251024|Placebo Comparator|Group 2: placebo|Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the placebo.
89256781|NCT06250985|Experimental|Immediate reimplantation|Reimplantation in same procedure as removal of device or shortly thereafter.
89256782|NCT06250985|Active Comparator|Standart care|Reimplantation of device in a second procedure at a later date, after infection has been stabilized/cleared
89256783|NCT06250972|Active Comparator|chemotherapy|Continuing chemotherapy using the previous regimen
89256784|NCT06250972|Experimental|PD1 plus radiotherapy|Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2~6 cycles of chemotherapy. Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.
89256785|NCT06250946|Experimental|Group A|Subjects will receive escalated dose of HRS-7535 administered orally
89256786|NCT06250946|Experimental|Group B|Subjects will receive escalated dose of HRS-7535 administered orally
89256787|NCT06250946|Experimental|Group C|Subjects will receive escalated dose of HRS-7535 administered orally
89256788|NCT06250946|Experimental|Group D|Subjects will receive escalated dose of HRS-7535 administered orally
89256789|NCT06250946|Placebo Comparator|Group E|Subjects will receive Placebo administered orally
89256790|NCT06250933|Experimental|Experiment group|The experimental group will receive education on postpartum maternal care and premature infant care, in addition to routine care provided by healthcare professionals, based on nursing care grounded in Meleis' Transition Theory.
89256791|NCT06250933|No Intervention|Control group|The control group will continue to receive routine care
89256792|NCT06250920|Experimental|Virtual reality-based visual training group|
89256793|NCT06250920|No Intervention|Single-Vision Spectacle Group|
89256794|NCT06250907|Experimental|Dynamic navigation|
89256795|NCT06250907|Active Comparator|Static template|
89256796|NCT06250894|Experimental|Neoadjuvant immunotherapy-chemoradiotherapy|"This is a one arm study, enrolled locally advanced EGJ patients will receive Sintilimab (PD-1 inhibitor) and combined with preoperative chemoradiotherapy and operation.~generic name：PD-1; dosage form：Injection; dosage：200mg (20ml)； frequency：every 3 weeks； duration：3 times before operation and 3-5 times after operation"
89256797|NCT06250881||without ocular complication|The normal group was compared with the pathological group
89256798|NCT06250881||fundus opportunistic infections|AIDS patients are prone to opportunistic fundus infection, which show a characteristic changes in fundus photography. It was designed to describe the characteristics of this group of patients.
89256799|NCT06250881||Microvascular disease|Microvascular disease is an early characteristic of fundus changes in AIDS patients, with characteristic changes in fundus photography.
89256800|NCT06250881||uveitis|The uveitis patients in this study were mainly caused by treponema pallidum infection.
89256801|NCT06250816|Experimental|Children wearing the hospital gown with cartoon characters|The experimental group will have a preoperative visit, the investigator will meet the patient and assess the child's anxiety level using the modified Yale Preoperative Anxiety Scale (m-YPAS). Afterwards, the patient will be asked to choose one of the hospital gowns they want to wear and put it on with parental assistance.
89256802|NCT06250816|No Intervention|Children with standard hospital gown|The control group will have a preoperative visit, the investigator will meet the patient and assess the child's anxiety level using m-YPAS. The patient will be asked to wear the hospital gown used in the hospital in routine practice with parental assistance.
89256803|NCT06250803|Experimental|early pancreatic stent placement (EPSP)|a pancreatic stent will be placed immediately after endoscopic retrograde cholangiography (ERC) or endoscopic sphincterotomy (EST)
89256804|NCT06250803|Other|late pancreatic stent placement (LPSP)|a pancreatic stent will be placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage
89256805|NCT06250777|Experimental|Trastuzumab Deruxtecan|
89256806|NCT06250764||GROUP 1 (periodontally healthy )|An individual to be considered to have periodontal health according to this definition, the percentage of sites with bleeding on probing should be no more than 10%, and the probing depth should be 3 mm or less
89256807|NCT06250764||GROUP 2 (gingivitis)|Patients with gingivitis had PD ≤3 mm, BOP in ≥30% of the probing sites, and no interproximal AL or radiographic bone loss
89256808|NCT06250764||GROUP 3(generalized stage I and stage II periodontitis)|Stage I periodontitis was diagnosed with interdental attachment loss (AL) ranging between 1 and 2 mm at the site of greatest loss. Radiographic bone loss (BL) is limited to less than 15% and no tooth loss. Additionally, the maximum probing depth (PD) is equal to or less than 4 mm or primarily involves horizontal bone loss. Stage II periodontitis was diagnosed with interdental attachment loss (AL) is ranging between 3 and 4 mm at the site of greatest loss. Radiographic bone loss (BL) extends to a range of 15% to 33%, there is no tooth loss. The maximum probing depth (PD) is equal to or less than 5 mm or primarily involves horizontal bone loss.
89256809|NCT06250764||GROUP 4 (generalized stage III and stage IV periodontitis)|Stage III periodontitis is diagnosed with interdental attachment loss (AL) is ≥ 5, radiographic bone loss (BL) extends to mid-third of the root and beyond, tooth loss may become evident ≤4 teeth. Either PD ≥ 6 mm or vertical BL ≥ 3 mm, or Class II/III furcation involvement, or moderate ridge defect. Stage IV periodontitis is diagnosed with interdental attachment loss (AL) is ≥ 5 mm at the site of greatest loss, radiographic BL extending to mid-third of the root and beyond. ≥5 tooth loss due to periodontitis is evident. In addition to Stage III, either masticatory dysfunction, or secondary occlusal trauma (tooth mobility degree ≥ 2), or severe ridge defect, or bite collapse, or teeth drifting and flaring
89256810|NCT06250712|Experimental|Continous ECG Patch|In this arm, continuous patch ECG was used.
89256811|NCT06250712|Active Comparator|Intermittent handheld ECG|In this arm, intermittent handheld ECG was used.
89256812|NCT06250686|No Intervention|Control group|usual care
89256813|NCT06250686|Experimental|Intervention|6 month exercise and nutrition intervention
89256814|NCT06250673|Experimental|Mediterranean Diet Group|Patients taking medication will be given a diet in accordance with the basic Mediterranean diet rules.
89256815|NCT06250673|Experimental|Low Cholesterol Group|Patients taking medication will be given a diet containing <200 mg of cholesterol per day, based on personal wishes.
89256816|NCT06250673|No Intervention|Control Group|They will not take a diet, and take only the medication.
89256817|NCT06250647|Experimental|VK INTERVENTION|administration of a menu diet containing 500mcg of vitamin K (in the food selected) durinf 6 weeks.
89256818|NCT06250647|No Intervention|DIETARY RECOMMENDATIONS|No menu administration but only recommendations for correct diet.
89256823|NCT06250621|Experimental|Test Group (GD)|in this group were considered implant sites treated with a digitally guided surgery procedure
89256824|NCT06250621|Active Comparator|Control Group (FH)|in this group were considered implant sites treated without a digitally guided surgery procedure
89256825|NCT06250608|Experimental|Acute ischemic stroke patients|
89256826|NCT06250595||Inherited Rare Anaemia Disorders, including inherited Bone Marrow Failures|Patients with Inherited Rare Anemia Disorders, including inherited Bone Marrow Failures, stratified by gender, age, and/or variants/types if applicable.
89256827|NCT06250595||Acquired Bone Marrow Failures|Patients with Acquired Bone Marrow Failures, stratified by gender, age, and/or variants/types if applicable.
89256828|NCT06250595||Rare bleeding-coagulation disorders and related diseases|Patients with Rare bleeding-coagulation disorders and related diseases, stratified by gender, age, and/or variants/types if applicable.
89256829|NCT06250595||Hemochromatosis and other rare genetic disorders of iron metabolism and heme synthesis|Patients with hemochromatosis and other rare genetic disorders of iron metabolism and heme synthesis, stratified by gender, age, and/or variants/types if applicable.
89256830|NCT06250595||Myeloid malignancies|Patients with Myeloid malignancies, stratified by gender, age, and/or variants/types if applicable.
89256831|NCT06250595||Lymphoid malignancies|Patients with lymphoid malignancies, stratified by gender, age, and/or variants/types if applicable.
89256832|NCT06250569||first group|women with with adenomyosis
89256833|NCT06250569||second group|women without adenomyosis
89256834|NCT06250556|Experimental|creatine supplementation|
89256835|NCT06250530|Experimental|BodyCAD|For participants randomized to BodyCAD Fine osteotomy, the HKA radiographs and CT scans will be sent to the manufacturer via a secure weblink as per SoC. The films will be used to calculate the desired correction and the instruments and implants manufactured accordingly. The mechanical medial proximal tibial angle (mMPTA) will be recorded for both pre- and planned post-operative situations and used to determine the accuracy of correction (primary outcome).
89256836|NCT06250530|Active Comparator|TOMOFIX|For participants randomized to the TOMOFIX system, preoperative planning will use the HKA radiograph. DICOM images will be transported to MEDICAD software program in which alignment angles and alignment correction will be calculated. The mMPTA will again be utilised to determine the accuracy of correction (primary outcome). The preop CT scan will also be used as per the BodyCAD system and the same indices calculated so as to minimise measurement bias between two different imaging modalities. However, the results of the preoperative 3D CT planning will not be made available to the operating surgeon, again to minimise bias between groups.
89256837|NCT06250517|Experimental|EVLP|
89256838|NCT06250517|Active Comparator|Cold preservation|
89256839|NCT06250504|Experimental|Intervention: Choice of long-acting PrEP and PEP added to Thetha Nami ngithethe nawe|"Tailored peer-led psychosocial support and social mobilisation into community based SRH and differentiated HIV care and prevention, including a choice of effective PrEP or PEP.~At the mobile AYFS in the intervention clusters nurses will offer the choice of either daily oral tenofovir/emtricitabine or injectable long acting cabotegravir (CAB LA) to be delivered to adolescents and young adults at risk of HIV acquisition. Those who decline will have the option of three monthly dapivarine vaginal rings or Post Exposure Prophylaxis (PEP) packs (tenofovir/lamuvidine/dolutegravir) to take home.~Peer navigators will promote long-acting PrEP in addition to oral PrEP. As part of the peer mentorship package, the peer naviators will remind young people of their follow-up visits."
89256840|NCT06250504|Active Comparator|Control (Enhanced SoC): Thetha Nami ngithethe nawe|"Tailored peer-led psychosocial support and social mobilisation into community based SRH and differentiated HIV care and prevention, including oral tenofovir/emtricitabine PrEP.~In the mobile AYFS, young people are offered self-taken vaginal swabs or urine testing for sexually transmitted infections (STIs), family planning support and syndromic and aetiological management for STIs; HIV counselling and two POCT; immediate initiation of ART if living with HIV and oral tenofovir/emtricitabine PrEP if HIV test is negative and they are suitable.~Peer navigators in control clusters will promote oral PrEP during their community based health promotion activities. As part of the peer mentorship package, the peer naviators will remind young people of their follow-up visits and if required accompany young people to the mobile clinics."
89256841|NCT06250439|Experimental|Adult patients with peripheral VA-ECMO for refractory cardiogenic shock|Adult patients with peripheral VA-ECMO for refractory cardiogenic shock, hospitalized in medical ICU of Pitié Salpêtrière Hospital, AP-HP Paris
89256842|NCT06250426|Active Comparator|Active|Pre-thickened oral nutritional supplement with a cooling sensation flavour
89256843|NCT06250426|Placebo Comparator|Control|Pre-thickened oral nutritional supplement without a cooling sensation flavour
89256844|NCT06250400|Experimental|Treatment|"Treatment arm will receive a dose of Histamine Human Immunoglobulin 12mg (2ml) s.c. which consists of one injection of Histamine Human Immunoglobulin 12mg(2ml) vial every week for 4 times.~Treatment arm will also receive a dose of loratadine p.o. which consists of one pill of loratadine 10mg every day for 4 weeks."
89256845|NCT06250400|Placebo Comparator|Placebo|"Placebo arm will receive placebo which consists of one injection of placebo 12mg(2ml) vial every week for 4 times.~Placebo arm will also receive a dose of loratadine p.o. which consists of one pill of loratadine 10mg every day for 4 weeks."
89256846|NCT06250387|Experimental|Patients with mediastinal lymphadenopathy|Patients with suspicion of lymphoma, sarcoidosis and tuberculosis, presenting with mediastinal lymphadenopathy confirmed by a CT scan and/ or PET scan and patients with previous negative EBUS-TBNA.
89256847|NCT06250348||ARDS patients|ARDS patients admitted in ICU ;intubated and mechanically ventilated for less than 24 hours
89256848|NCT06250348||Control group|Healthy subjects without pulmonary nor inflammatory pathology, who underwent a benign surgical procedure (thyroid or parathyroid surgery) requiring general anesthesia with intubation and mechanical ventilation.
89256849|NCT06250270|Experimental|PRO pm, PRO am|Participants arrive to the lab, complete 30 mins resting metabolic rate assessment. Then they are provided with a shake to drink 30 mins before bed. They return to the lab the following morning for 30 min RMR, drink another shake and do 30 mins RMR before leaving the lab.
89256850|NCT06250270|Experimental|PRO pm, PLAC am|Participants arrive to the lab, complete 30 mins resting metabolic rate assessment. Then they are provided with a shake to drink 30 mins before bed. They return to the lab the following morning for 30 min RMR, drink another shake and do 30 mins RMR before leaving the lab.
89256851|NCT06250270|Experimental|PLAC pm, PRO am|Participants arrive to the lab, complete 30 mins resting metabolic rate assessment. Then they are provided with a shake to drink 30 mins before bed. They return to the lab the following morning for 30 min RMR, drink another shake and do 30 mins RMR before leaving the lab.
89256852|NCT06250270|Placebo Comparator|PLAC pm, PLAC pm|Participants arrive to the lab, complete 30 mins resting metabolic rate assessment. Then they are provided with a shake to drink 30 mins before bed. They return to the lab the following morning for 30 min RMR, drink another shake and do 30 mins RMR before leaving the lab.
89256853|NCT06250244|Experimental|LNC1011 Dose escalation|Patients received a single dose of 1.85 GBq (50 mCi) of 177Lu-LNC1011 via intravenous injection, followed by monitoring at 3, 24, 48, 72, and 168 hours post-injection. Subsequent enrollees underwent a 50% incremental dose increase until dose-limiting toxicity was observed.
89256854|NCT06250218|Experimental|Intervention Group|The group will receive the intervention Video Interaction Guidance.
89256855|NCT06249724|Active Comparator|Active stimulation|Low-intensity focused ultrasound stimulation of dorsal root ganglion involved in pain conduction
89256856|NCT06249724|Sham Comparator|Sham stimulation|Zero-intensity focused ultrasound stimulation of dorsal root ganglion involved in pain conduction
89256857|NCT06249126|Other|Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)|Surgical fixation by joint fusion + Surgical fixation with plates and screws, plates, sutures, or rods are used to hold the broken bone together
89256858|NCT06249126|Other|Open Reduction Internal Fixation (ORIF) only|Surgical fixation with plates and screws, plates, sutures, or rods are used to hold the broken bone together
89256859|NCT06247579|No Intervention|The control group|The control group, consisting of resident physicians, will use non-disposable plastic tableware (NDPT) provided by hospital canteens for two months.
89256860|NCT06247579|Experimental|The exposure group|The exposure group, also comprising resident physicians, will use disposable plastic tableware (DPT) made of polystyrene, provided by the same hospital canteens for two months
88804898|NCT01402375|Active Comparator|Hydrocodone (third trial)|Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
88804899|NCT01299103|Active Comparator|Single Treatment|Treatment of facial wrinkle with one treatment only
88804900|NCT01299103|Active Comparator|Double Treatment|Treatment of facial wrinkle with two treatments
89256861|NCT06247566||68Ga-Pentixafor PET/CT|Patients with Primary Aldosteronism (PA) accompanied by bilateral adrenal lesions undergoing 68Ga-Pentixafor PET/CT to discriminate PA forms with unilateral from bilateral excess aldosterone production, so as to determine whether to choose surgical treatment.
89256862|NCT06246877|Experimental|virtual reality applied group|"Before the K-wire is removed and dressed, the three-dimensional video that the child likes and wants to watch will be placed on virtual reality glasses and attached to the child.~During the procedure, the child will be allowed to watch videos through virtual reality glasses."
89256863|NCT06246877|No Intervention|control group|During the removal and dressing of the wire, the child's attention will be diverted by asking some questions (where she lives, the name of the school she attends, what grade she attends, etc.).
89256864|NCT06246864|Experimental|Hydrocolloid dressing group|The premature baby's Oragastric tube will be fixed using a hydrocollaid dressing. Orogastric fixation will not be changed for 24 days. After 24 hours, the fixed patch will be removed using a silicone-based spray remover.
89256865|NCT06246864|Active Comparator|Hypoallergenic Flexible Patch group|Oragastric tube of premature baby Hypoallergenic Flexible Patch will be detected using . Orogastric fixation will not be changed for 24 days. After 24 hours, the fixed patch will be removed using a silicone-based spray remover.
89256866|NCT06246708|Experimental|Intervention Group|Participants receive intervention at baseline for 5 weeks
89256867|NCT06246708|Other|Wait-list Control Group|Participants receive the intervention after 5 weeks
89256868|NCT06246578|Other|Within patient comparison|Simultaneous glucose measurement with Libre 2 sensor and Contour Next One in patients using Dexcom G7
89256869|NCT06245850|Experimental|Baduanjin Group|
89256870|NCT06245850|Active Comparator|REBTgroup|
89256871|NCT06245746|Experimental|UCMSC-Exo intervention|UCMSC-Exo will be preset with 3 escalation dose levels in single time infusion.
89256872|NCT06245356|Other|Colorectal adenocarcinoma|"Trifluridine/tipiracil in association with oxaliplatin with or without:~Panitumumab in RAS wild type tumors~Bevacizumab in RAS wild type of right colon or RAS mutated tumors"
89256873|NCT06245356|Other|Gastroesophageal adenocarcinoma|"Trifluridine/tipiracil in association with oxaliplatin with or without:~Trastuzumab in HER2-positive tumors (3+ IHC or 2+/FISH+)~Nivolumab if CPS≥5 and HER2-negative tumors"
89256874|NCT06243172||Type 2 Diabetes|Individuals with type 2 diabetes
89256875|NCT06243172||Controls|Individuals without type 2 diabetes matched on age and body mass index
89256876|NCT06242665|Experimental|Meal Delivery|"Dietary change (low ultra-processed meal delivery) and nutrition guidance to follow a low UPF diet.~All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following 2 weeks comprise the dietary intervention period. Meal delivery and nutritional guidance is provided by the study team for 14 days in accordance with a low UPF diet.~Visit 3 comprises post-intervention assessment All participants will complete remote assessments at 1 month and 6 month follow-ups."
89256877|NCT06242665|Experimental|Nutritional Guidance|"Dietary change (nutritional guidance)~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Nutritional guidance is provided by the study team for 14 days in accordance with a low UPF diet. Participants are delivered a box of snacks consistent with a low UPF diet.~Visit 3 comprises post-intervention assessment. All participants will complete remote assessments at 1 month and 6 month follow ups."
89256878|NCT06242431|Active Comparator|Group pectoralis nerve block (PECS-II)|PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied.
89256879|NCT06242431|Active Comparator|Group serratus posterior superior intercostal plane block (SPSIPB)|SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.
89256880|NCT06241794|Active Comparator|Group M-TAPA|"M-TAPA:~Aseptic conditions are ensured in the area where the block will be performed. Under ultrasound guidance, a linear probe at the sagittal plane and costochondral angle is used to identify the transversus abdominis, internal oblique, and external oblique muscles at the level of the 10th rib. To visualize the lower surface of the rib cartilage in the midline, a sagittal angle is applied with the probe in the direction of the costochondral angle at the edge of the 10th rib. Using a 22-G, 80-100 mm block needle with an in-plane technique, the needle is advanced cranially. The needle tip is directed towards the posterior surface of the 10th rib cartilage, underneath the condyle. Subsequently, 20 ml of 0.25% concentration bupivacaine is injected beneath the condyle. The same procedure will be applied to the opposite side using the same technique."
89256881|NCT06241794|Active Comparator|Group Serratus Intercostal Plane Block and Rectus Sheath Block|"Serratus intercostal plane block:The serratus anterior muscle and intercostal muscles are identified at the level of 8th rib along the right mid-axillary line.Using block needle,20 ml of 0.25% Bupivacaine is injected into the interfascial plane between these muscles.The SIPB will be performed only on right side.~Rectus sheath block:a linear probe is placed in a transverse position just above the umbilicus and slightly lateral to the midline.After visualizing the rectus abdominis muscle, posterior rectus sheath,and the hypoechoic space between them,block needle is advanced in-plane along the subcutaneous tissue.The needle is progressed until reaching the space between the epimysium of the muscle and the posterior rectus sheath, passing horizontally through the anterior rectus sheath of the rectus abdominis muscle.10 ml of 0.25% bupivacaine is injected.Adequate spread will lift the epimysium of the rectus abdominis muscle while displacing the posterior fascia and peritoneum downward"
89256882|NCT06236893|Experimental|VH-01 vaginal suppository tablet|Participants will be instructed to take VH-01 vaginal suppository tablet (active product) as directed.
89256883|NCT06236893|Placebo Comparator|Placebo vaginal suppository tablet|Participants will be instructed to take the placebo vaginal suppository tablet as directed. The placebo vaginal suppositories do not contain active ingredients and are identical in appearance to the active product.
89256884|NCT06236477|Active Comparator|Personalized Music Group|Those assigned to receive music will be asked to provide a short list of 5-10 songs familiar/well-known to the patient (specifically the song title and artist for each song). Songs will be downloaded onto an electronic mp3 player by the research staff member. The mp3 player will then be provided along with a portable Bluetooth speaker for use during the patient's perioperative period, loaded with the songs of their choice.
89256885|NCT06236477|Placebo Comparator|No Music Group|Those not assigned to the personalized music group will receive standard care without music.
89256886|NCT06236113|Placebo Comparator|Placebo/Control|Pharmacist will check randomization schedule. For placebo/control subject they will prepare an infusion bag of saline with no added medication. The Study Drug Bag will be released with a label that includes: Name of Study, Study Subject #, Patient (Pt) Name, Pt Medical record number (MR#), Pt Date of birth (DOB), and INFUSION RATE.
89256887|NCT06236113|Experimental|Low Dose Ketamine Infusion (LDKI)|Infusion Bag will receive 100 mg of ketamine (Ketamine Infusion Subject). The Study Drug Bag will be released with a label that includes: Name of Study, Study Subject #, Patient Name, Pt MR#, Pt DOB, and INFUSION RATE. (Note: infusion rate is 0.1 mg/kg/hr and concentration of standard ketamine infusion bag is 1 mg/mL. That is, 100 mg of ketamine added to 100 mL saline).
89256888|NCT06234735|Active Comparator|Control Group|The control group will follow the conventional protocol established by the Catalan Institute of Oncology (ICO) for the treatment of lung cancer. In addition, physical activity guidelines will be recommended with the aim of encouraging patients to lead a more active life that helps them improve their physical capabilities. The research team will meet individually with participants in the control group and inform them about the importance of physical activity, motivating them to practice regularly.
89256889|NCT06234735|Experimental|Experimental Group|Motivational interviews will be used to help identify individual motivations, barriers, and preferences towards physical activity (PA). Objectives and personalized exercise regimens (e.g. walking, cycling, nordic walking) with a person-centered approach. Patients will engage in a minimum of 3 PA sessions/week (45min each) for 6 months, reporting via a phone app. Weekly patient-reported outcome measures (PROMs) will track progress. The first 3 months involve group sessions for instruction and correction; the last 3 months include one monthly in-person session combining resistance and aerobic training, with a duration of 1.5 hours. To drive behavior change, personalized weekly challenges will be presented.
89256890|NCT06233474|Other|Safety run-in phase - Allocetra increasing dose|An open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the knee in different doses and select the Allocetra dose and regimen for the randomized phase.
89256891|NCT06233474|Placebo Comparator|Randomization phase - Placebo.|Three intra-articular injections of placebo into the index knee.
89256892|NCT06233474|Experimental|Randomization phase - Allocetra|Three intra-articular injections of Allocetra at a selected dose, into the index knee.
89256893|NCT06233461|Experimental|TAK-279 Dose 1|Participants will be randomized to receive TAK-279 Dose 1 capsules with TAK-279 placebo-matching capsule orally as per investigator's discretion.
89256894|NCT06233461|Experimental|TAK-279 Dose 2|Participants will be randomized to receive TAK-279 Dose 2 capsules with TAK-279 placebo-matching capsule orally as per investigator's discretion.
89256895|NCT06233461|Experimental|TAK-279 Dose 3|Participants will be randomized to receive TAK-279 Dose 3 capsules orally as per investigator's discretion.
89256896|NCT06233461|Experimental|Placebo|Participants will be randomized to receive TAK-279 placebo-matching capsules orally as per investigator's discretion.
89256897|NCT06230549|Experimental|Interventional Arm|Adaptive Radiotherapy
89256898|NCT06230549|Active Comparator|Standard conventional Treatment Arm, IGRT|Standard conventional Treatment Arm, IGRT
89256899|NCT06228209|Experimental|Tier - Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
89256900|NCT06228209|No Intervention|Usual care|Patients will be cared for by the physician who treats their serious illness (cardiologist, oncologist, primary treating clinician) and other illnesses.
89256901|NCT06228040|Active Comparator|Before preanaesthetic teleconsultation implementation|
89256902|NCT06228040|Experimental|After preanaesthetic teleconsultation implementation|
89256903|NCT06227247|Experimental|Meals 4 Moms intervention|"Participants randomized to the M4M condition will receive:~Food budget of $266 per week in credits to spend towards medically-tailored GDM meals~Enhanced educational GDM-specific education on exercise, nutrition, and blood sugar glucose management~Activity tracker and digital scale~Usual GDM care"
89256904|NCT06227247|No Intervention|Usual GDM Care|Usual care (UC) will consist of the current treatment care that is provided by the participant's prenatal care provider. Usual care consists of a special diet, monitoring of blood glucose levels and encouragement/guidance of increasing a participant's exercise.
89256905|NCT06225583||Bertolotti's Syndrome|Subjects with Bertolotti's Syndrome.
89256906|NCT06225583||Non-Bertolotti's Lower Back Pain|Subjects without Bertolotti's Syndrome with lower back pain.
89256907|NCT06224309||18F-BL40 PET/CT scan|Each subject will have two PET/CT scans, one using 18F-BL40 and the other using 18F-FDG. The 18F-BL40 radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
89256908|NCT06222827|Experimental|Group of patients who receive satralizumab|
89256909|NCT06222827|Placebo Comparator|Group of patients who receive placebo|
89256910|NCT06222788|Experimental|NTP treatment|The patients will be treated with NTP intra-operatively.
89256911|NCT06221956|Experimental|relevis + TAU|"Participants allocated to the intervention group will receive access to relevis in addition to treatment as usual (TAU).~relevis is a digital health application designed for individuals with subacute or chronic back pain, accessible through a web browser. The application consists of six physical exercise modules that cover four exercises with thiree different levels of difficulty, each, and ten interactive conversations on different topics (changes in the body, pain development and processing, chronic pain, pain and mood, relaxation and mindfulness, becoming active against pain, stress and pain, nutrition and pain, sleep and pain, work and pain). Conversations are accompanied by illsutrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days."
89256912|NCT06221956|No Intervention|TAU|Participants allocated to the control group will receive access to treatment as usual (TAU).
89256913|NCT06220032|Experimental|Arm A|"Standard R-CHOP 21 treatment regimen:~6 cycles R-CHOP 21 (rituximab*, cyclophosphamide, doxorubicin, vincristine, prednisolone)~*The use of a biosimilar is allowed."
89256914|NCT06220032|Experimental|Arm B -|"Addition of the cardioprotectant dexrazoxane to the R-CHOP 21 regimen:~R-CHOP21 (rituximab*, cyclophosphamide, doxorubicin, vincristine, prednisolone plus dexrazoxane).~*The use of a biosimilar is allowed."
89256915|NCT06219824|Active Comparator|control Group|pulpotomy treatment for the young permanent teeth will be done using conventional powder and liquid Mineral Trioxide Aggregate followed by Glassionomer restoration and stainless steel crown
89256916|NCT06219824|Experimental|Experimental|pulpotomy treatment for the young permanent teeth will be done using premixed ready for use bioceramic MTA followed by Glassionomer restoration and stainless steel crown
89256917|NCT06216639||Individuals between 30 and 34 years of age registered at HCM|Random sample of participants representing the eligible cohort is drawn.
89256918|NCT06216171|Experimental|Adaptive Radiotherapy|Adaptive Radiotherapy, online onboard adaptation of the dosis to actual anatomy of the day by a specialist of radiation oncology and a medical physicist
89256919|NCT06216171|Active Comparator|Standard conventional Treatment Arm, IGRT|Standard treatment option, image guided radiotherapy without online adaptation
89256920|NCT06213207|Experimental|Newborn care service providers with simulation-based training and newborns|Newborn care providers will be the subject for receiving intervention. The will receive 5 days training on managing essential newborn care and birth asphyxia using neonatalie. The service providers will be provided monthly mentoring and coaching. The newborn who receive the services
89256921|NCT06213207|No Intervention|Controlled health facilities with newborn care service providers with no training and newborns|The newborn care providers from control health facilities will not receive any additional training. They provide usual services.
89256922|NCT06210594|Experimental|Education + Household supplies + Nasal antibiotic + Antiseptic regimen|Participants in this arm will receive education about SA and household supplies (e.g., cleaning products, pump lotion, laundry detergent, towels) plus use of a nasal antibiotic (mupirocin) twice daily for 5 days then maintenance with an antiseptic regimen (Nozin twice daily plus chlorhexidine gluconate wash 3 times per week)
89256923|NCT06210594|Active Comparator|Education + Household supplies|Participants in this arm will receive education about SA and household supplies (e.g., cleaning products, pump lotion, laundry detergent, towels).
89256924|NCT06210191|Experimental|union of fracture|Intramedullary headless screw fixation for metacarpal and phalangeal fractures
89256925|NCT06209060|Experimental|Hammock Position Group|Babies in the hammock position group will be placed in a hammock created by the researchers inside the incubator.
89256926|NCT06209060|Experimental|Nesting Group|Babies in the nesting group will be placed in a nest created by the researchers within the incubator.
89256927|NCT06208904|Experimental|GIPRA (Glucose-dependent Insulinotropic Polypepetide Receptor Antagonist)|Intravenous infusion of GIP(3-30)NH2 in a concentration of 1,000 pmol/kg/min
89256928|NCT06208904|Placebo Comparator|Saline|Intravenous infusion of isotonic saline 9 mg/ml added 0,5% human serum albumin
89256930|NCT06202404||High risk group|This is a observational study, patients will be assigned to high-risk or low-risk groups (according to a radiomics model) by the investigators. Both the patients and the treating physicians will be blinded to this procedure. No interventions excluding standard treatment procedure executed by the treating physicians.
89256931|NCT06202404||Low risk group|This is a observational study, patients will be assigned to high-risk or low-risk groups (according to a radiomics model) by the investigators. Both the patients and the treating physicians will be blinded to this procedure. No interventions excluding standard treatment procedure executed by the treating physicians.
89256932|NCT06195423|Experimental|Stop OsteoARthritis (SOAR) program|Participants with a first-time ACL tear followed by reconstruction surgery randomized to the SOAR program group will complete a 6-month SOAR program (one-time Knee Camp, weekly home-based exercise therapy and physical activity with tracking, weekly 1:1 physiotherapist counseling sessions, and optional weekly group-based exercise classes) Consented trained physiotherapists will deliver the SOAR program throughout the study period to one or more SOAR program participants. Physiotherapists and SOAR participants will be randomly paired.
89256933|NCT06195423|Active Comparator|Living Well after ACLR|Participants with a first-time ACL tear followed by reconstruction surgery randomized to the minimal control (Living Well after ACLR) group will complete a 6-month minimal intervention control program (educational video, workbook, activity tracking, and one 1:1 physiotherapist counseling session).
89256934|NCT06191445|Active Comparator|Conventional Landmark Group|The investigator will perform spinal anesthesia using the conventional landmark technique.
89256935|NCT06191445|Active Comparator|USAS Group|The investigator will perform spinal anesthesia using ultrasound-assisted technique.
89256936|NCT06191445|Active Comparator|US-RTG Group|The investigator will perform spinal anesthesia using real-time ultrasound-guided technique.
89256937|NCT06191042|Experimental|si-544|
89256938|NCT06191042|Placebo Comparator|Placebo|
89256939|NCT06179641|Active Comparator|IPACK group|IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) block
89256940|NCT06179641|Experimental|Tibial nerve group|selective tibial nerve block
89256941|NCT06166277||Control group|Awaiting the intervention, medically managed patients will remain in the control group for analysis purposes
89256942|NCT06166277||Procedural group|After undergoing successful radiofrequency cardioneuroablation or permanent pacemaker procedures the patient will cross-over to the procedural group for analysis purposes
89256946|NCT06162351|Experimental|Single arm: treatment with PLX038|Patients will be treated at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection) after at least a first cycle at 1300mg/m2. At the discretion of the treating physician, the PLX038 dose will be increased to 1730 mg/m2 for patients who tolerate at least 1 cycle without any of the following toxicities: febrile neutropenia, grade 4 neutropenia for > 5 days or ANC < 100 109/L for more than 1 day, or other non-hematological toxicities of Grade > 2 [NCI-CTCAE, Version 5].
88804901|NCT01299103|Active Comparator|Triple treatment|Treatment of facial wrinkle with three treatments
88804902|NCT01302379|Active Comparator|Metformin + lifestyle intervention|
89256947|NCT06160271|Experimental|TEP 68Ga-FAPI|Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
89256948|NCT06153459|Active Comparator|Delayed Cord Clamping at 30 Seconds (DCC-30)|The umbilical cord will be clamped between 1 - <60 seconds following delivery, with a goal of around 30 seconds.
89256949|NCT06153459|Active Comparator|Delayed Cord Clamping at 120 Seconds (DCC-120)|"The umbilical cord will be clamped at 60 - 180- seconds following delivery, with a goal of around 120 seconds.~In the DCC-120 group, if there is concern for pregnant individual or baby and their doctor is not able to wait until at least 60 seconds, the doctor may do cord milking, which is four gentle squeezes of the umbilical cord pushing blood from the placenta to baby."
89256950|NCT06146647|Experimental|Intervention condition: 15 minute (approx.) show with positive body image messaging|Those assigned to this arm will watch the 15 minute tv show with positive body image content.
89256951|NCT06146647|Active Comparator|Control condition: 15 minute (approx.) show without positive body image messaging|"Those assigned to this condition will watch a 15 minute tv show that does not contain positive body image content.~The show that will be used for this condition is about a tv character visiting the dentist."
89256952|NCT06146647|Experimental|Intervention condition: Music video with positive body image messaging|Those assigned to this condition will watch the music video containing positive body image messaging.
89256953|NCT06146647|Active Comparator|Control condition: Music video without positive body image content|"Those assigned to this condition will watch a music video without positive body image messaging.~The music video that will be used for this condition is about brushing teeth."
89256954|NCT06144606|Experimental|Autologous CAR T-cell immunotherapy|Tecartus will be delivered at a target dose of 1x106 cells / kg. For those >100 kg, a flat dose of 1 x108 cells will be used. Tecartus will be administered on day 0, following 1 day of rest from conditioning chemotherapy.
89256955|NCT06142357||Secukinumab|Pediatric patients with moderate-to-severe plaque psoriasis receiving secukinumab.
89256956|NCT06140017|Active Comparator|In-Person Group Delivery|"A total of 30 villages will receive a traditional in-person group-based delivery for Msingi Bora, an ECD parenting intervention featuring 16 biweekly village sessions over 8 months, followed by monthly booster meetings for 16 additional months. Sessions will be delivered within by existing village Community Health Volunteers (CHVs). Mothers and children will be invited to attend a total of 32 in-person sessions of roughly 1.5-2 hours apiece over 24 months."
89256957|NCT06140017|Experimental|Hybrid mHealth/In-Person Group Delivery|30 CHVs will deliver a hybrid intervention that combines in-person meetings with remote delivery for Msingi Bora, an ECD parenting intervention. Mother-child dyads will be invited to participate in roughly 10 in-person group sessions in the first 8 months, followed by 5 in-person group sessions over the next 16 months. For those sessions delivered remotely, mothers will receive videos demonstrating the practices, SMS messages, be invited to participate in group SMS/WhatsApp chats with the CHV and other village mothers, and periodic phone calls. The project will provide smartphones to all mothers assigned to this arm for facilitation.
89256958|NCT06140017|No Intervention|Control Group|Mothers and children in 30 villages will not receive any intervention beyond information about child feeding during a baseline survey.
89256961|NCT06132165|Active Comparator|Kybella Injection|
89256962|NCT06132165|Active Comparator|Asclera Injection|
89256963|NCT06132165|Active Comparator|1064nm laser|
89256964|NCT06132165|Active Comparator|755nm laser|
89256965|NCT06130683||Secondary Hyperparathyroidism|Patients who were diagnosed as secondary hyperparathyroidism
89256966|NCT06130683||Primary Hyperparathyroidism|Patients who were diagnosed as primary hyperparathyroidism
89256967|NCT06130683||Normal group|Parathyroid tissue obtained incidentally during other neck surgeries, derived from people without parathyroid disease.
89256968|NCT06130384|Experimental|Bromfenac 0.09%|At the time of the injection, the first eye will be randomized to a drop of artificial tear or bromfenac 0.09% and the second eye will receive the other agent.
89256969|NCT06130384|Placebo Comparator|Artificial Tear|At the time of the injection, the first eye will be randomized to a drop of artificial tear or bromfenac 0.09% and the second eye will receive the other agent.
89256970|NCT06127095||Participants with RRMS|Participants who receive natalizumab intravenously (IV) or subcutaneously (SC) or ocrelizumab, or ofatumumab, as per the standard local prescribing procedures will be enrolled to collect data. Participants will complete an online one-shot questionnaire combining closed and open-ended questions.
89256971|NCT06122870|Experimental|CampETEC HBC group|CampETEC HBC (hyper immune bovine colostrum) and challenge strain C. jejuni CG8421
89256972|NCT06122870|Placebo Comparator|Placebo ProMilk 85 group|ProMilk 85 (placebo) and challenge strain C.jejuni CG8421
89256973|NCT06121219|Experimental|Experimental: Cortically Blind (CB) Subjects|Cortically Blind subjects will be enrolled to perform a daily home visual training task.
89256974|NCT06121219|No Intervention|Normative Comparator: Control Subjects|Healthy control subjects will be recruited to collect normative data by which to compare test results from CB subjects. No home training will be asked.
89256975|NCT06113952||Patients treated with weekly growth hormone|Approximately 200 children with a diagnosis of pGHD who are treatment naïve or currently receiving once weekly Ngenla will be enrolled.
89256976|NCT06113952||Patients treated with daily growth hormone|Approximately 200 children with a diagnosis of pGHD who are treatment naive or currently receiving daily GH injections will be enrolled
89256977|NCT06108232|Experimental|Obinutuzumab+CC-99282|"Participants will receive obinutuzumab and CC-99282 together for up to 12 study cycles. Each study cycle is 28 days.~Participants will first receive the study drugs for Cycles 1-6. Then after participants complete Cycle 6, the study doctor will decide based on the status of the disease if participant will continue to receive the study drugs for Cycles 7-12 or if participant will stop receiving them."
88804903|NCT01302379|Active Comparator|Placebo + lifestyle intervention|
88804904|NCT01302379|Active Comparator|Metformin + standard dietary guidelines|
88804905|NCT01302379|Placebo Comparator|Placebo + standard dietary guidelines|
89256978|NCT06105554|Experimental|Phase 1 (dose escalation)|Phase 1, the dose of belumosudil mesylate participants receive will depend on when participants join this study. The first group of participants will receive the lowest dose level of belumosudil mesylate.
89256979|NCT06105554|Experimental|Phase 2 (dose expansion)|Phase 2, participants will receive belumosudil mesylate at the recommended dose that was found in Phase 1.
89256980|NCT06100250|Experimental|Telehealth intervention|Participants will receive an MI-based telehealth intervention for bacterial STI screening.
89256981|NCT06099665|Experimental|Automated alert|Providers that will receive an automated alert sent via the EHR.
89256982|NCT06099665|No Intervention|Control|Care providers in the control arm will not receive an automated alert.
89256983|NCT06098755||Team 1. President George Washington (1732-1799) Notes:|variables
89256984|NCT06098755||Team 2. President Thomas Jefferson (1743 -1826) Notes:|variables
89256985|NCT06098755||Team 3. President Theodore Roosevelt (1858 - 1919) Notes:|variables
89256986|NCT06098755||Team 4. President Abraham Lincoln (1809 - 1865) Notes:|variables
89256987|NCT06097897|Experimental|Imaging using the SVO-ID|Patients will have their eyes imaged with the SVO-ID as part of a study visit.
89256988|NCT06095856|Experimental|Lf-La-Ks|"On the first day, baseline muscle activity will be measured by the sEMG, then, the leaf gauge will be used till centric relation is located, then, muscle activity will be recorded once more. On the second day, baseline muscle activity will be measured by the sEMG, then, the Lucia jig will be used till centric relation is located, then, muscle activity will be recorded once more.~On the third day, baseline muscle activity will be measured by the sEMG, then, the Kois deprogrammer will be used till centric relation is located, then, muscle activity will be recorded once more.~Patient satisfaction questionnaire will be handed-out to the participants and filled-out at the end of the third day."
89256989|NCT06095856|Experimental|La-Ks-Lf|"On the first day, baseline muscle activity will be measured by the sEMG, then, the Lucia jig will be used till centric relation is located, then, muscle activity will be recorded once more. On the second day, baseline muscle activity will be measured by the sEMG, then, the Kois deprogrammer will be used till centric relation is located, then, muscle activity will be recorded once more. On the third day, baseline muscle activity will be measured by the sEMG, then, the leaf gauge will be used till centric relation is located, then, muscle activity will be recorded once more.~Patient satisfaction questionnaire will be handed-out to the participants and filled-out at the end of the third day."
89256990|NCT06095856|Experimental|Ks-Lf-La|"On the first day, baseline muscle activity will be measured by the sEMG, then, the Koid deprogrammer will be used till centric relation is located, then, muscle activity will be recorded once more. On the second day, baseline muscle activity will be measured by the sEMG, then, the leaf gauge will be used till centric relation is located, then, muscle activity will be recorded once more. On the third day, baseline muscle activity will be measured by the sEMG, then, the Lucia jig will be used till centric relation is located, then, muscle activity will be recorded once more.~Patient satisfaction questionnaire will be handed-out to the participants and filled-out at the end of the third day."
89256991|NCT06092346||Family Member of a subject with known or suspected DPPM|1. At least one month of age;2. Relationship either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected DPPM;3. Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative s possiblecondition; and4. Ability of the subject, parent/s (in the case of children), or an LAR to understand and the willingness to sign a written informed consent document.5. If during the consenting/assenting procedure, clinical suspicion arises that a family member has symptoms of the diagnosed DPPMs, additional review and/or studies may be requested to clarify the clinical status before enrolling a family member as an unaffected participant.
89256992|NCT06092346||Healthy Volunteers|1. No personal or family history of DPPMs;2. At least one month old;3. No symptoms of DPPMs;4. Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of the DPPM under study; 5. And ability of the subject, parent/s (in the case of children), or an LAR to understand and the willingness to sign a written informed consent document.
89256993|NCT06092346||Subjects with known or suspected or uncharacterized DPPMs|1. Regardless of gender, at least one month of age;2. A medical history that, in the expert opinion of the study team, is consistent with the DPPM; 3. Have a primary metabolic or genetic physician, or primary care provider; and 4. Ability of the subject, parent/s (in the case of children), or a Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
89256994|NCT06090773||Acute kidney injury|Patients with acute injuries in ICU patients.
89256995|NCT06090773||Patients with non-acute kidney injury|ICU patients without acute injury patients.
89256996|NCT06086249|Experimental|Regeneration using Injectable platelet-rich fibrin|A 10-mL sample of whole venous blood will be drawn from the patient's forearm (median cubital vein). It will be centrifuged immediately by a tabletop centrifuge at 700 rpm for 3 minutes at room temperature. Injectable platelet-rich fibrin (I-PRF) will be collected. After that, the I-PRF will be injected inside the canals using a plastic syringe needle that will be placed 1mm short of the working length and withdrawn gradually while injecting till reaching the orifices of the canals. After that, a Collagen membrane matrix will be placed above the canal orifice and will left for 5 minutes to partially harden, then a 3 mm thick layer of MTA will be placed directly over it. The cavity will be sealed with composite and covered with a stainless steel crown.
89256997|NCT06086249|Active Comparator|Root canal treatment|The root canal will be obturated with gutta-percha by the cold lateral condensation technique with epoxy resin-based root canal sealer, the cavity will be sealed with composite and covered with a stainless steel crown.
89256998|NCT06084390|Experimental|Interdisciplinary rehabilitation + booster-session (intervention)|Standard care by the interdisciplinary rehabilitation teams in primary healthcare + extended access to the team and a booster visit after 3 months.
89256999|NCT06084390|Active Comparator|Interdisciplinary rehabilitation (control)|Standard care by the interdisciplinary rehabilitation teams in primary healthcare.
89257001|NCT06079567|Experimental|New COMs for FSHD2 patients|
89257002|NCT06073132|Experimental|Part A AC-203|Double-blind, AC-203 Diacerein 1% ointment, QD
89257003|NCT06073132|Placebo Comparator|Part A Vehicle ointment|Double-blind, Vehicle ointment, QD
89257004|NCT06073132|Experimental|Part B AC-203|Open-label extension phase, AC-203 Diacerein 1% ointment, QD
89257005|NCT06071858|No Intervention|Coordinated Specialty Care (CSC; standard of care)|Care as usual; no intervention.
89257006|NCT06071858|Experimental|Enhanced Coordinated Speciality Care (CSC 2.0)|CSC 2.0 arm will be offered 1:1 peer support, digital outreach, care coordination, multi-family group therapy, and cognitive remediation (if applicable).
89257007|NCT06071026|Experimental|1 ml/kg/h|Net ultra filtration setting: 1 ml/kg/h
89257008|NCT06071026|Experimental|2 ml/kg/h|Net ultra filtration setting: 2 ml/kg/h
89257009|NCT06071026|Experimental|3 ml/kg/h|Net ultra filtration setting: 3 ml/kg/h
89257010|NCT06064136|Experimental|Patient with ilio-psoas conflict and having a tenotomy indication|
89257011|NCT06050122|Experimental|Patidegib Gel 2%|Patidegib Gel 2% (w/w), applied topically to the face twice daily for 12 months
89257012|NCT06050122|Placebo Comparator|Vehicle Gel|Vehicle Gel, applied topically to the face twice daily for 12 months
89257013|NCT06041802|Experimental|MK-3475A|Participants will receive MK-3475A subcutaneously for up to 18 administrations.
89257014|NCT06041152|Experimental|Amnestic Mild Cognitive Impairment Participants Receiving Psilocybin|Receiving 2 doses of 25mg of psilocybin separated by 1 week.
89257015|NCT06041152|Experimental|Healthy Participants Receiving Psilocybin|Receiving 2 doses of 25mg of psilocybin separated by 1 week.
89257016|NCT06041152|Placebo Comparator|Amnestic Mild Cognitive Impairment Participants Receiving Placebo|Receiving 2 doses of placebo separated by 1 week.
89257017|NCT06041152|Placebo Comparator|Healthy Participants Receiving Placebo|Receiving 2 doses of placebo separated by 1 week.
89257018|NCT06038162|Active Comparator|VA-ECMO patients with parallel connection|Patients undergoing VA ECMO with indication for concomitant RRT, assigned to parallel connection group.
89257019|NCT06038162|Active Comparator|VA-ECMO patients with integrated connection|Patients undergoing VA ECMO with indication for concomitant RRT, assigned to integrated connection group.
89257020|NCT06036199|Experimental|Focused Ultrasound Pallidotomy|Pediatric and young adult patients between ages of 8 and 22 years with pharmaco-resistant secondary dystonia due to dyskinetic cerebral palsy who have Focused Ultrasound Pallidotomy
89257021|NCT06035731|Experimental|group A: well-being care performed by SOCIO-AESTHETICS|"Group A will benefit from 4 sessions of well being care performed by a qualified socio-aesthetics, during 4 consecutive chemotherapy administrations.~Patients included will have following interventions :~quality of life: PCQ Pain: EVA Anxiety: HADS"
89257022|NCT06035731|No Intervention|group B: control|"Group B (control) will apply the dermo-cosmetic products themselves (self-care) without intervention of the socio-aesthetician, during 4 consecutive chemotherapy administrations.~quality of life: PCQ Pain: EVA Anxiety: HADS"
89257023|NCT06031688|Experimental|Arm A: (Ramucirumab and tepotinib)|Patients receive ramucirumab IV over 30-60 minutes on day 1 of each cycle and tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan and CT scan and/or MRI throughout the trial. Patients also undergo blood sample collection while on study.
89257024|NCT06031688|Active Comparator|Arm B: (Tepotinib)|Patients receive tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan and CT scan and/or MRI throughout the trial. Patients also undergo blood sample collection while on study.
89257025|NCT06029647|Experimental|Mango|The participants will consume one cup of fresh mango (100 kcal) per day for sixteen weeks.
89257026|NCT06029647|Placebo Comparator|Wafer|The participants will consume vanilla wafers (100 kcal) per day for sixteen weeks.
89257027|NCT06027086|Experimental|Durvalumab and DRP-104|
89257028|NCT06026657|Experimental|Arm I (Gemcitabine, TGFBi)|Patients receive gemcitabine intravenously (IV) over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 of cycle 1. Patients undergo CT scan and blood sample collection and may undergo MRI throughout the study.
89257029|NCT06026657|Experimental|Arm II (Gemcitabine, TGFBi x2)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 and 18 of cycle 1. Patients undergo CT scan and blood sample collection and may undergo MRI throughout the study.
89257030|NCT06026657|Experimental|Arm III (Gemcitabine naxitamab, TGFBi)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle followed by naxitamab IV over 30-60 minutes on days 1, 4, and 8 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 of cycle 1. Patients undergo CT scan and blood sample collection and may undergo MRI throughout the study.
89257031|NCT06026657|Experimental|Arm IV (Gemcitabine, naxitamab, TGFBi x2)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle followed by naxitamab IV over 30-60 minutes on days 1, 4, and 8 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 and 18 of cycle 1. Patients undergo CT scan and blood sample collection and may undergo MRI throughout the study.
89257035|NCT06020508||Group 1|Attending anesthesiologists who are trained in epidural placement will perform neuraxial procedures (CSEs, Epidural, Spinals through an epidural needle) utilizing loss of resistance with saline in conjunction with the Lumoptik BrightPoint Epidural Device. The Lumoptik device will be connected between a standard commercially available 17G or 18G, 3.5-inch epidural needle and a saline filled loss of resistance syringe. The anesthesiologist will view the Lumoptik BrightPoint visual display in real time as the epidural procedures are performed. The LOR epidural procedure using haptic feedback will be used as the primary confirmation of correct needle placement in the epidural space. Graphic and color circle information from the Lumoptik visual display will be used as a secondary confirmation of epidural placement.
89257036|NCT06019442|Experimental|Brief alcohol intervention (Health4Her-Automated) + lifestyle health promotion|"The intervention arm will receive:~brief alcohol intervention~lifestyle health promotion focused on physical activity and maintaining a healthy weight for reducing breast cancer risk.~Participants will receive an iPad and earphones to self-complete the intervention. Alcohol and lifestyle information will be delivered by way of an animation on an iPad, and self-completed activities to reinforce intervention content."
89257037|NCT06019442|Other|Lifestyle health promotion|"The control arm will receive:~lifestyle health promotion focused on physical activity and maintaining a healthy weight for reducing breast cancer risk.~Participants will receive an iPad and earphones to self-complete the control intervention. Lifestyle information will be delivered by way of an animation on an iPad, and a self-completed activity to reinforce intervention content."
89257038|NCT06017856||obese and overweight|Overweight and obese subjects, defined as body mass index (BMI) percentile ≥85%, participating the in life-style intervention program in the child sport center at Meir medical center
89257039|NCT06017856||normal weight|normal weight subjects defined as body mass index (BMI) percentile <85%, with no other chronic conditions
89257040|NCT06016244|Experimental|88% oxygen saturation threshold|Patients in this arm will receive supplemental oxygen when SpO2 falls below 88% or when other clinical symptoms indicate a need for supplemental oxygen.
89257041|NCT06016244|Active Comparator|92% oxygen saturation threshold|Patients in this arm will receive supplemental oxygen when SpO2 falls below 92% or when other clinical symptoms indicate a need for supplemental oxygen.
89257042|NCT06016153|Active Comparator|Instructor feedback|BLS training participants will receive feedback from an experienced instructor certified by European Resuscitation Council on the depth and frequency of chest compressions, duty cycle, chest recoil and the quality of ventilation.
89257043|NCT06016153|Experimental|Software feedback|BLS training participants will receive feedback based on a software (InnoMed CardioAid-1 Trainer AED, Innomed Inc., Budapest, Hungary) on the quality of chest compression (exact frequency, depth of chest compression, chest recoil and duty cycle) and tidal volume during ventilation.
89257044|NCT06015542|Experimental|Self-administration of Elranatamab|It is a feasibility study assessing the feasibility and safety of self-administration of Elranatamab in the homes of the patients. The intervention of the study is self-administration of Elranatamab by the patient, thereby changing the administration from an outpatient setting to a home setting. The patients will function as their own controls, as treatment will be given alternately at home and in the outpatient clinic.
89257045|NCT06011733|Experimental|bimekizumab|Study participants randomized to this arm will receive bimekizumab (BKZ) dosage regimen 1 in the Initial Treatment Period (16 weeks) and switch to dosage regimen 2 and placebo to maintain the blinding in the Maintenance Treatment Period (16 weeks).
89257046|NCT06011733|Placebo Comparator|placebo|Study participants randomized to this arm will receive placebo comparator in the Initial Treatment Period (16 weeks) and switch to bimekizumab dosage regimen 1 in the Maintenance Treatment Period (16 weeks).
89257047|NCT06005454|Experimental|Children with Pneumonia in intensive care unit receiving fish oil and the standard treatment|
89257048|NCT06005454|No Intervention|Children with Pneumonia in intensive care unit receiving the standard treatment only|
89257049|NCT06001398|Experimental|Parent Acceptance and Commitment Therapy (PACT)|PACT-F is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature.
89257050|NCT06001398|Active Comparator|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate.
89257051|NCT05995964|Experimental|Stage 1_PF-07275315|Stage 1 PF-07275315 Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
89257052|NCT05995964|Experimental|Stage 1_PF-07264660|Stage 1 PF-07264660 Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
89257053|NCT05995964|Experimental|Stage 1_Placebo|Stage 1 Placebo Injections on Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10 and Week 12.
89257054|NCT05995964|Experimental|Stage 2_PF-07275315 or PF-07264660_Dose A|Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
89257055|NCT05995964|Experimental|Stage 2_PF-07275315 or PF-07264660_Dose B|Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
89257056|NCT05995964|Experimental|Stage 2_PF-07275315 or PF-07264660_Dose C|Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
89257057|NCT05995964|Experimental|Stage 2_PF-07275315 or PF-07264660_Dose D|Stage 2 PF-07275315 or PF-07264660 Injections on Day 1, Week 4, Week 8 and Week 12.
89257058|NCT05995964|Experimental|Stage 2_Placebo|Stage 2 Placebo Injections on Day 1, Week 4, Week 8 and Week 12.
89257059|NCT05994963|Experimental|Part 1 Treatment A|4 capsules of sisunatovir in fasted state
89257060|NCT05994963|Experimental|Part 1 Treatment B|2 tablets of sisunatovir in fasted state
89257061|NCT05994963|Experimental|Part 1 Treatment C|2 tablets of sisunatovir with a high-fat meal
89257062|NCT05994963|Experimental|Part 2 Treatment B|2 tablets of sisunatovir in fasted sate
89257063|NCT05994963|Experimental|Part 2 Treatment D|2 tablets of sisunatovir with a low-fat meal
89257064|NCT05987904||Group 1: Cardiologic Group|This group includes patients who are scheduled for echocardiography.
89257065|NCT05987904||Group 2: Surgery Group|This group includes patients that are scheduled for non-cardiac surgery.
89257066|NCT05986851|Experimental|Daily oral azeliragon|Azeliragon to be administered once daily for several days before, during, and after radiation therapy.
89257067|NCT05986838|Active Comparator|laser puncture group|gallium Arsenide infrared (GaAlAs) laser, using a wavelength at 904nm with a Maximum power output is 150 mW and a power density at 0.417 W/cm2 as well as an energy density of 4 J/cm2 will be employed for 2 minutes on specific acupuncture points
89257068|NCT05986838|Active Comparator|Ultraviolet treatment group|The therapist will place the UV arc lamp at a height of 60 to 80 cm above the lower abdomen region, perpendicular to the skin. Each woman's lamp will be switched on and given an individual timer by the minimum effective dose
89257069|NCT05986838|Active Comparator|Metformin only group|
89257070|NCT05986656|Experimental|Atlas correction|Basic group.
89257071|NCT05986604|Experimental|TranS-C+MSI|Transdiagnostic Intervention for Sleep and Circadian Dysfunction will be combined with the Memory Support Intervention
89257072|NCT05986604|Active Comparator|TranS-C alone|The Transdiagnostic Sleep and Circadian Intervention will be delivered alone
89257073|NCT05984589|Experimental|RISE-PSMT|Personalized self-management training using RISE (Re-Invent, Integrate, Strengthen, Expand) program.
89257074|NCT05984589|Placebo Comparator|SSMT|Standardized self-management training.
89257075|NCT05977322|Experimental|Arm 1|Patients will receive 68Ga-FF58 and only patients with tumor uptake of 68Ga-FF58 will receive 177Lu-FF58.
89257076|NCT05964842|No Intervention|Standard of care (Control)|Patients in this arm will receive the routine TB care, according to the Uganda Ministry of Health guidelines, that is; i) Patient screened for TB ii) Patient identified as presumptive and registered in the presumptive TB register iii) Patient referred for TB testing iv) Patient expected to return and pick results on their own drive vi) Positive TB patients initiated on treatment.
89257077|NCT05964842|Experimental|SMS only|In addition to standard of care, participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
89257078|NCT05964842|Experimental|Phone call only|In addition to standard of care, participants in this arm will receive three phone call reminders to complete TB diagnosis. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
89257079|NCT05964842|Experimental|SMS and mobile money incentives|"In addition to standard of care, participants in this arm will receive three SMS reminders and a transport refund once they complete TB diagnosis. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.~Once participants in this study arm complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money."
89257080|NCT05964842|Experimental|Phone call and mobile money incentives|"In addition to standard of care, participants in this arm will receive three phone call reminders and a transport refund once they complete TB diagnosis. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.~Once participants in this study arm complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money."
89257081|NCT05948917|Experimental|Behavioral: Mind-body Skills Groups|10 mind-body skills groups held once a week.
89257082|NCT05948176||Urban group1|150 boys
89257083|NCT05948176||Urban group2|150 girls
89257084|NCT05948176||Rural group 3|150 boys
89257085|NCT05948176||Rural group 4|150 girls
89257086|NCT05943665|Experimental|MDMA-AT|Participant will receive MDMA administration with assisted therapy (AT) by trained clinicians
89257087|NCT05941442|Experimental|Darigabat|Participants will receive darigabat, up to a maximum dose of 12.5 mg, orally, BID, for two weeks in the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks in the Maintenance Treatment Period.
89257088|NCT05941442|Placebo Comparator|Placebo|Participants will receive darigabat matching placebo, orally, BID for 2 weeks during the Titration period and thereafter for 12 weeks during the Maintenance Treatment Period.
89257089|NCT05939336|Experimental|Mannooligosaccharides|Mannooligosaccharides yeast extract
89257090|NCT05937321|Experimental|Intervention Group- Virtual with Dyad Follow + Share plus|The Share plus intervention is a behavioral intervention administered by a certified diabetes education and care specialist (CDCES) using telehealth. Share plus consists of three educational sessions to facilitate dyads' success in data sharing glucose levels. The Share plus intervention has five major components that are delivered using techniques of motivational interviewing: 1) shared appraisal, 2) communication strategies, 3) problem-solving strategies, 4) action planning and, 5) re-evaluating, practicing, and advancing.
89257091|NCT05937321|Active Comparator|Control Group- Virtual with Dyad Follow + Diabetes Self-Management Education|Participants will receive diabetes self-management education using the Association of Diabetes Care and Education Specialists 7 education curriculum (ADCES7).
89257092|NCT05936931|Other|Aim 3: Single arm, open-label, pre-test/post-test design pilot trial|Single arm, open-label, pre-test/post-test design pilot trial
89257093|NCT05936372|Experimental|EX-TD|Typical developed children that perform acute exercise prior to the learning task
89257094|NCT05936372|No Intervention|CON-TD|Typical developed children that not perform acute exercise prior to the learning task
89257095|NCT05936372|Experimental|EX-DCD|Children with developmental coordination disorder (DCD) that perform acute exercise prior to the learning task
89257096|NCT05936372|No Intervention|CON-DCD|Children with developmental coordination disorder (DCD) that not perform acute exercise prior to the learning task
89257097|NCT05933954|Other|Healthy volunteers 5G-FR2 exposed vs sham-exposed skin|A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not (sham-exposed). The exposure time is 20 min.
89257098|NCT05933954|Other|Patients with dermatoporosis 5G-FR2 exposed vs sham-exposed skin|A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not (sham-exposed). The exposure time is 20 min.
89257099|NCT05933954|Other|Patients with atopic dermatitis 5G-FR2 exposed vs sham-exposed skin|A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not (sham-exposed). The exposure time is 20 min.
89257100|NCT05933954|Other|Skin-cancer prone patients 5G-FR2 exposed vs sham-exposed skin|A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not (sham-exposed). The exposure time is 20 min.
89257101|NCT05917379|Experimental|FMT+Synbiotics|Fecal microbiota capsules(0.75g stool/capsule) (10/day), for 3 days, meanwhile synbiotics(2g/day) for 14 days, another 15 fecal microbiota capsules(0.75g stool/capsule) at week 2
89257102|NCT05917379|Placebo Comparator|Placebo A +Placebo B|Placebo A-capsules 10/day, for 3 days, meanwhile placebo B-vitamin C (2g/day) for 14 days, another 15 Placebo A at week 2
89257103|NCT05917379|Placebo Comparator|FMT + Placebo B|Fecal microbiota capsules (0.75g stool/capsule)(10/day), for 3 days, meanwhile placebo vitamin C (2g/day) for 14 days, another 15 fecal microbiota capsules(0.75g stool/capsule) at week 2
89257104|NCT05917379|Placebo Comparator|Placebo A+Synbiotics|Placebo capsules 10/day, for 3 days, meanwhile synbiotics(2g/day) for 14 days, another 15 Placebo A at week 2
89257105|NCT05911256|Active Comparator|Pharmacist Only|Participants will receive clinical pharmacist management of diabetes. Those participants who meet their HbA1c goal at 6 months will continue with maintenance diabetes management. This includes routine primary care with the primary care provider, routine medication management, and traditional home glucose monitoring. For those not meeting goals in HbA1c they will be randomized again to receive Pharmacist + CGM or receive Pharmacist + CGM + Community Health Worker (CHW) support.
89257106|NCT05911256|Experimental|Pharmacist + CGM|Participants receive clinical pharmacist + CGM support. Those participants who meet their HbA1c goal at 6-months will continue with maintenance diabetes management. This includes routine primary care with the primary care provider, routine medication management, and traditional home glucose monitoring. For those not meeting goals in HbA1c, they will be randomized again to continue with pharmacist + CGM or receive additional CHW support (Pharmacist + CGM + CHW).
89257107|NCT05911256|Experimental|Pharmacist + CGM + CHW|A second randomization step occurs at 6-months. Participants randomized to this condition receive clinical pharmacist, CHW, and CGM support.
89257108|NCT05908448||13-17 year old participants|13-17 year old participants
89257109|NCT05908448||7-12 year old participants|7-12 year old participants
89257110|NCT05908448||2-6 year old participants|2-6 year old participants
89257112|NCT05905289||group A|young female patients diagnosed with malignant ovarian germ cell tumors underwent fertility-sparing surgery and adjuvant chemotherapy will be retrospectively investigated
89257113|NCT05905224|Active Comparator|Group 1 (Control)|
89257114|NCT05905224|Experimental|Group 2 (Experimental)|
89257115|NCT05902208|Experimental|Valaciclovir|
89257116|NCT05902208|Placebo Comparator|Placebo|
89257117|NCT05901883|Experimental|CEL383 Arm|Subjects will receive a single intravenous dose of CEL383
89257118|NCT05901883|Placebo Comparator|Placebo Arm|Subjects will receive a single intravenous dose of placebo
89257119|NCT05897320|Experimental|Eptinezumab 300 mg|Participants will receive a single intravenous (IV) infusion of eptinezumab 300 mg (weight adjusted).
89257120|NCT05897320|Placebo Comparator|Placebo|Participants will receive a single IV infusion of matching placebo to eptinezumab.
89257121|NCT05897320|Experimental|Eptinezumab 100 mg|Participants will receive a single IV infusion of eptinezumab 100 mg (weight adjusted).
89257122|NCT05891795|Experimental|Clascoterone|
89257123|NCT05891795|Placebo Comparator|Vehicle|
89257124|NCT05891275||Patients with a Geographic Atrophy diagnosis|
89257125|NCT05882071||Patients initiating treatment with SGLT2i|
89257126|NCT05882071||Type 2 diabetes mellitus patients initiating SGLT2i|
89257127|NCT05872386|Experimental|Telehealth|Intervention arm
89257128|NCT05872386|Experimental|Treatment as Usual|Treatment as usual (in-person at clinic)
89257129|NCT05867979|Experimental|patients with DSD and inconclusive molecular diagnosis|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
89257130|NCT05860088|Experimental|Beef Diet|Participants will be randomized to consume the beef diet for 8 weeks. After a 2-week period, participants will cross-over to consume the vegetarian diet for 8 weeks.
89257131|NCT05860088|Experimental|Vegetarian Diet|Participants will be randomized to consume the vegetarian diet for 8 weeks. After a 2-week period, participants will cross-over to consume the beef diet for 8 weeks.
89257132|NCT05859126|Experimental|Maternal Choline Supplementation 930 mg/d|Supplementation of 930 mg/d from early second trimester through birth. Offspring are followed for cognitive outcomes.
89257133|NCT05859126|Active Comparator|Maternal Choline Supplementation 480mg/d|Supplementation of 480 mg/d from early second trimester through birth.Offspring are followed for cognitive outcomes.
89257134|NCT05854914|Experimental|Hypnosis video to control postoperative pain.|
89257135|NCT05846542|Experimental|Video-game based therapy group|The video-game based therapy group will receive a conventional physiotherapy and video-game based therapy, two days a week for a total of 8 weeks (15 minutes conventional physiotherapy session+30 minutes video-game based therapy).
89257136|NCT05846542|Active Comparator|Conventional physiotherapy group|The conventional physiotherapy group individuals will be given a conventional physiotherapy two days per week for a total of 8 weeks (conventional physiotherapy session will last 45 minutes).
89257137|NCT05845567|Experimental|Givinostat + Clarithromycin|Givinostat and Clarithromycin Days 1 and 8, Givinostat 50 mg as oral suspension was administered as a single dose, 1 hour after Clarithromycin administration. From Day 4 to Day 10, Clarithromycin 500 mg film-coated tablet was administered twice a day.
89257138|NCT05844761|Experimental|Triggered Imaging with TrueBeam for prostate cancer|Patients will undergo radiotherapy using the Triggered Imaging technique with TrueBeam for prostate cancer. The technology on the TrueBeam allows for monitoring and gating of the radiation beam in relation to the target position.
89257139|NCT05844761|Experimental|Synchrony with Radixact for prostate cancer|Patients will undergo radiotherapy using the Synchrony technique with Radixact for prostate cancer. Multi-Leaf Collimator Adaptation (MLC) and kilovoltage (kV) Intrafraction Monitoring with the Synchrony technique on the Radixact radiotherapy machine.
89257140|NCT05844761|Experimental|Synchrony with Radixact for lung cancer|Patients will undergo radiotherapy using the Synchrony technique with Radixact for lung cancer. MLC Adaptation, Respiratory Motion Tracking, and kV Intrafraction Monitoring with the adaptive Synchrony technique on the Radixact radiotherapy machine.
89257141|NCT05843188|Experimental|High DTP-signature|Take HCQ, 400 mg by mouth, twice daily. Receive FOLFIRI+bevacizumab (irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-FU 2400 mg/m2 over 46 - 48 hours, bevacizumab 5 mg/kg), intravenously, every 2 weeks
89257142|NCT05843188|Active Comparator|Low DTP-signature|Receive FOLFIRI+bevacizumab (irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-FU 2400 mg/m2 over 46 - 48 hours, bevacizumab 5 mg/kg), intravenously, every 2 weeks
89257143|NCT05842317|Experimental|Levatinib plus Tislelizumab|Native-treated aHCC Patients were administered with Levatinib plus Tislelizumab
89257144|NCT05842317|Experimental|Levatinib plus Lenvatinib with Transarterial Chemoembolization(TACE)|Native-treated aHCC Patients were administered with Levatinib plus Tislelizumab with Transarterial Chemoembolization(TACE)
89257145|NCT05834257|Experimental|Normal Saline|5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, Normal Saline as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
89257146|NCT05834257|Experimental|PlasmaLyte|5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, PlasmaLyte as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
89257147|NCT05834257|Experimental|Ringer's Lactate|5 Cardiac surgery patients admitted to the intensive care units will receive, following consent and randomisation, Ringer's lactate as resuscitation fluid. 50mL of blood will be withdrawn before surgery and 24 hours after for each patient in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
89257148|NCT05830422||Good neurological outcome|Patients who showed good neurological outcomes with CPC scores of 1-2 at discharge
89257149|NCT05826535|Experimental|Phase I Dose Level I CAR T experienced cohort|Phase I 3+3 design Dose level 1: 1×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
89257150|NCT05826535|Experimental|Phase I Dose Level II CAR T experienced cohort|Phase I 3+3 design Dose level 2: 3×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
89257151|NCT05826535|Experimental|Phase II CAR T experienced cohort|Single dose determined during Phase I.
89257152|NCT05826535|Experimental|Phase I Dose Level I CAR T naïve cohort|Phase I 3+3 design Dose level 1: 1×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
89257153|NCT05826535|Experimental|Phase I Dose Level II CAR T naïve cohort|Phase I 3+3 design Dose level 2: 3×10e8 (± 20%) IMPT-314 cells Single dose/infusion during 28 day window
89257154|NCT05826535|Experimental|Phase II CAR T naïve cohort|Single dose determined during Phase I.
89257155|NCT05824611||participants|patients with epilepsy included in the study at one of the study locations
89257156|NCT05812144|Other|Patient with type 1 facioscapulohumeral muscular dystrophy|
89257157|NCT05800704|Experimental|Nagasin®|consumption of Nagasin® (synbiotic food supplement) once per day for four weeks
89257158|NCT05800704|Placebo Comparator|Comparator|consumption of the comparator (maltodextrin) once per day for four weeks
89257159|NCT05795530||Cochlear implant recipients|57 consecutive cochlear implant recipients
89257160|NCT05785013|Experimental|Interventional|25 children diagnosed with Hirschsprung disease and planned for elective surgery will be supplemented with Zinc 7 days before the operation . Outcomes will be evaluated thorugh measuring the hospital length stay. Other parameters including inflammatory markers as CRP , CRP /albumin ratio and development of postoperative complications will be assesed and compared between cases and controls
89257161|NCT05785013|No Intervention|Control|25 children diagnosed with Hirschsprung disease and planned for elective surgery will recieve the standard care provided for the cases and will not be supplemented with Zinc . Outcomes will be evaluated thorugh measuring the hospital length. Other parameters including inflammatory markers as CRP , CRP /albumin ratio and development of postoperative complications will be assesed and compared between cases and controls
89257162|NCT05780541|Experimental|PF-07304814 plus SOC|"PF-07304814 250 mg per day for 5 days; administered as a constant rate IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
89257163|NCT05780541|Placebo Comparator|Placebo plus SOC|"Placebo administered by IV infusion~Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion"
89257164|NCT05779930|Experimental|Treatment|"Leukopharesis: cells collected with a target of ≥1 x10^9 TNC with ≥3% CD3+ cells.~Lymphodepleting chemotherapy: 4 days of IV chemotherapy with fludarabine and cyclophosphamide.~Fludarabine 30 mg/m2/day IV x 4 days (days -6 through -3)~Cyclophosphamide 500 mg/m2/day IV x 2 days (days -6 and-5)~anti-CD19 CAR T cells:~0.3 - 1 x 10^6 per kilogram for patients <50 kg~Flat dose of 0.3 - 1 x 10^8 for patients ≥50 kg~The cell infusion will take place on day 0 (at least 2 days after completion of lymphodepleting chemotherapy). The patient will receive pre-medication with acetaminophen and diphenhydramine 30-60 minutes prior to the cell infusion."
89257165|NCT05762965|Experimental|GOS 1|Galacto-oligosaccharide
89257166|NCT05762965|Experimental|GOS 2|Galacto-oligosaccharide
89257167|NCT05759208|Experimental|Placebo|OK-101 Placebo Ophthalmic Solution (vehicle): 1 drop BID in each eye (N = ~80)
89257168|NCT05759208|Experimental|Low Dose OK-101|0.05% OK-101 Ophthalmic Solution: 1 drop BID in each eye (N = ~80)
89257169|NCT05759208|Experimental|High-Dose OK-101|0.1% OK-101 Ophthalmic Solution: 1 drop BID in each eye (N = ~80)
89257170|NCT05736692|Experimental|Brief Sleep Intervention|1-session intervention designed to improve adolescent sleep quality and/or quantity.
89257171|NCT05736692|No Intervention|Control|Care as Usual. Those in this condition will be asked to continue their scheduled/prescribed care until the next study assessment. Note that, to ensure that all participants (control and sleep intervention) are offered the current standard of care, all will get a simple handout on sleep hygiene and any who is not receiving follow-up care will be referred to the Brain Health and Wellness Center (the multidisciplinary program to which all PCSS care at Cincinnati Children's is routed).
89257172|NCT05727384|Experimental|Clazakizumab|Participants received Clazakizumab 5 mg as a subcutaneous injection every 4 weeks for 24 weeks
89257173|NCT05727384|Placebo Comparator|Placebo|Participants received Clazakizumab placebo as a 5 mg subcutaneous injection every 4 weeks for 24 weeks
89257174|NCT05727267|Experimental|Arm A0|HEPLISAV B® and MVA-HBVac high dose
89257175|NCT05727267|Experimental|Arm B0.1|HEPLISAV B® & HBcoreAg low dose and MVA-HBVac low dose
89257176|NCT05727267|Experimental|Arm B0.2|2 x HEPLISAV B® & HBcoreAg medium and MVA-HBVac high dose
89257177|NCT05727267|Experimental|Arm C0.1|HBsAg high dose & HBcoreAg high dose and MVA-HBVac high dose
89257178|NCT05727267|Experimental|Arm C0.2|HBsAg medium dose + adjuvant low dose & HBcoreAg medium dose and MVA-HBVac high dose
89257179|NCT05727267|Experimental|Arm C0.3|HBsAg high dose + adjuvant high dose & HBcoreAg high dose and MVA-HBVac high dose
89257180|NCT05726279|No Intervention|Observational Cohort|Participants treated with standard guideline-based care for 24 hours. Blood pressure treatment thresholds will be used according to standard practice parameters
89257181|NCT05726279|Experimental|Interventional|Autoregulation-guided blood pressure management for 24 hours. Blood pressure will be measured every four hours by arm cuff; however, in lieu of predetermined blood pressure treatment thresholds, an optimal mean arterial pressure (MAP) range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
89257182|NCT05724771|Experimental|Combination of Botox + CGRPmAb|OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL = 50
89257183|NCT05724485|Active Comparator|BCAA group|12.45 grams of branched-chain amino acids orally per day before bedtime for 12 weeks.
89257184|NCT05724485|Placebo Comparator|Placebo group|12.45 grams of placebo (Maltodextrin) orally per day before bedtime for 12 weeks.
89257185|NCT05713123|Experimental|Person suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq)|The study will be offered to patients suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq). When they come in nuclear medicine to have the iodine scan in Anger's camera, if they signed the consent, they will the SPECT/CT whole body in VERITON-CT camera
89257186|NCT05698680|Experimental|Prednisolone 30mg (Day 0-4)|"As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the prednisolone arm will receive prednisolone plus a colchicine placebo. The prednisolone placebos contain a bittering agent due to the bitter taste of prednisolone to ensure a similar taste.~The dosage is according to EULAR guideline and also within the recommended range of the DEGAM guideline. The cumulative total dose taken per participant within the clinical trial is 150 mg for prednisolone."
89257187|NCT05698680|Active Comparator|Colchicine 1.5 mg (Day 0), 1.0 mg (Day 1-4)|"As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the colchicine arm will receive colchicine plus prednisolone placebo.~The dosage is according to EULAR guideline and also within the recommended range of the DEGAM guideline. The cumulative total dose taken per participant within the clinical trial is 5.5mg for colchicine."
89257188|NCT05695820|Experimental|Concentric|Concentric group
89257189|NCT05695820|Experimental|Isometric|Isometric group
89257190|NCT05695820|Experimental|Eccentric|Eccentric group
89257191|NCT05691348|Experimental|Ambulatory pathway|
89257192|NCT05691348|Active Comparator|Conventional hospitalisation|
89257193|NCT05690204|Experimental|Placebo versus SAP 001|Placebo arm
89257194|NCT05690204|Experimental|SAP001 10 mg|SAP001 10 mg
89257195|NCT05690204|Experimental|SAP001 30 mg|SAP001 30mg
89257196|NCT05690204|Experimental|SAP001 60 mg|SAP001 60 mg
89257197|NCT05680922|Experimental|Experimental LB2102|DLL3-Directed Chimeric Antigen Receptor T-cells (CAR T)
89257198|NCT05671224|No Intervention|Standard counseling|Standard induction of labor counseling
89257199|NCT05671224|Experimental|Visual aid counseling|Counseling on induction of labor with either a video or a handout
89257200|NCT05670730|Experimental|AOC 1044-CS1 Part A - Single Dose Levels 1-5|AOC 1044 will be administered once.
89257201|NCT05670730|Placebo Comparator|AOC 1044-CS1 Part A - Single Dose: Placebo|Placebo will be administered once.
89257202|NCT05670730|Experimental|AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3|AOC 1044 will be administered three times.
89257203|NCT05670730|Placebo Comparator|AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo|Placebo will be administered three times.
89257204|NCT05666310|Active Comparator|Zoledronic Acid|
89257205|NCT05666310|Active Comparator|Denosumab|
89257206|NCT05663944|Placebo Comparator|Placebo|15 participants will receive a non-identical placebo tablet. They will be asked to take the placebo daily, exactly as instructed for the intervention arm, be subject to monitoring and random titration to mirror the study drug
89257207|NCT05663944|Experimental|Sirolimus|30 participants will be randomised to the study drug.
89257208|NCT05661708|No Intervention|Control|LEEP was performed in an outpatient setting by a single resident physician (KG). A full blood count was taken (hematocrit 1). The procedure was designed according to colposcopic findings such as the type of transformation zone and position of the lesion. After positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) was applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix. LEEP was performed as described in a previous trial. After the hemostasis that obtained using the ball electrode at a 40-W coagulation setting, the remaining cervical tissue was washed with 20 ccs of sterile saline to ensure no active bleeding from the cervical wound. An empty spray pump was used because we cannot find any identical powder for the placebo
89257209|NCT05661708|Experimental|Chitosan|LEEP was performed in an outpatient setting by a single resident physician (KG). A full blood count was taken (hematocrit 1). The procedure was designed according to colposcopic findings such as the type of transformation zone and position of the lesion. After positioning of the patient, 50 mg of lidocaine spray (5 pumps, 10 mg in each pump) was applied to the ectocervix, then 2 mL bupivacaine hydrochloride was injected submucosally using a 27-gauge needle tip at the 3, 6, 9, and 12 o'clock locations in the ectocervix. LEEP was performed as described in a previous trial. After the hemostasis that obtained using the ball electrode at a 40-W coagulation setting, the remaining cervical tissue was washed with 20 ccs of sterile saline to ensure no active bleeding from the cervical wound. The application of 3 or 4 pumps of chitosan powder was carried out into the wound bed by spray pump which was prepared by a nurse.
89257210|NCT05656781|Experimental|Intervention Arm - Brief Intervention & Contact|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
89257211|NCT05656781|No Intervention|Control|Control will continue treatment as usual which is whatever the clinical team decides upon post discharge. Data will be collected on repeated suicidal behaviour through medical records with consent.
89257212|NCT05651308|Experimental|Intervention|The intervention group will assign care coordinators to PLWD based on perceived need for assistance with care coordination. Perceived need will be measured through a proxy's responses to a previously validated telephone survey on perceptions of care coordination.
89257213|NCT05651308|Active Comparator|Control|Usual care assigns patients to care coordinators in response to a discharge from a hospital or a direct referral from a physician.
89257214|NCT05648240||Patients with polyps|
89257215|NCT05648240||Patients without polyps|
89257216|NCT05643014||Firefighters over 18 years old|This is a within subject, observational study of firefighters. This study will involve three sample collections including buccal cells and urine samples; one collection pre and two collections post-structural fire exposure.
89257217|NCT05642429|Active Comparator|AV-1959D 500 μg|
89257218|NCT05642429|Active Comparator|AV-1959D 1000 μg|
89257219|NCT05642429|Active Comparator|AV-1959D 2000 μg|
89257220|NCT05642429|Placebo Comparator|Placebo|
89257221|NCT05634161||Cognitive Improvement software|Usability assessment of cognitive improvement software
89257222|NCT05625555|Experimental|Ketamine|Participants will be randomly assigned to receive Ketamine or Midazolam
89257223|NCT05625555|Active Comparator|Midazolam|Participants will receive either Ketamine or Midazolam based on what they initially received
89257224|NCT05622799|Experimental|Mind-Body MedicineTraining|A two part (4 days for each part) mind-body medicine training program
89257225|NCT05619627|Experimental|Dexmedetomidine 12 mcg/kg|Group One: Subjects will receive oral dexmedetomidine 12 mcg/kg 2 hours prior to MRI
89257226|NCT05619627|Experimental|Dexmedetomidine 18 mcg/kg|Group Two: Subjects will receive oral dexmedetomidine 18 mcg/kg 2 hours prior to MRI
89257227|NCT05619627|Experimental|Dexmedetomidine 24 mcg/kg|Group Three: Subjects will receive oral dexmedetomidine 24 mcg/kg 2 hours prior to MRI
89257228|NCT05619627|Active Comparator|General anesthesia control|Control group: Subjects will receive general anesthesia for their MRI
89257229|NCT05618444|Experimental|Automated Management (AM)|Receipt of text-based behavioral intervention
89257230|NCT05618444|No Intervention|Usual Care|Control group receiving usual care for obstructive sleep apnea
89257231|NCT05604365|Experimental|Arm 1|Patients Only
89257232|NCT05604365|Experimental|Arm 2|Patients and Caregivers
89257233|NCT05604365|Experimental|Arm 3|Caregivers Only
88804906|NCT01404559|Active Comparator|Prosthetic foot 1 (Ossur Variflex)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 1 (Ossur Variflex).
89257234|NCT05602259|Experimental|Eosinophil detection|Eosinophils will be measured in blood, sputum, bronchoalveolar lavage if available and biopsies.
89257235|NCT05601323|Experimental|HIFU (High-Intensity Focused Ultrasound) + Chemotherapy|"HIFU treatment with Suizenji: up to 2 times per week (1 course) for pancreatic primary lesions; the second course should be at least 60 days apart, up to a maximum of 5 courses.~Chemotherapy (physician's choice): Nal-IRI/FL, mFOLFIRINOX or Gem/nab-PTX"
89257236|NCT05601323|Active Comparator|Chemotherapy|Chemotherapy (physician's choice): Nal-IRI/FL, mFOLFIRINOX or Gem/nab-PTX
89257237|NCT05599061|Experimental|Optimal Medical Treatment (OMT) + PCI|
89257238|NCT05599061|Active Comparator|Optimal Medical Treatment (OMT)|
89257239|NCT05595681|Experimental|Treatment group|20 x 1000000 C2C_ASCs on top of standard care.
89257240|NCT05595681|No Intervention|Control group|Control group with standard care.
89257241|NCT05594979|Experimental|TOTUM-070|Experimental active diet supplement TOTUM-070 taken 2 times per day
89257242|NCT05587803|Experimental|study group|This arm consists of all the patients that fulfill the inclusion and exclusion-criteria and are therefore suitable for the study. The Neurowave brain monitor is attached on the patients forehead and the study starts. At that moment the included patients are monitored by the Masimo/Sedline en the Neurosense/Neurowave monitor.
89257243|NCT05587712|Experimental|Children ≥1 to <18 years old|Participants will receive a subcutaneous (SC) injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
89257244|NCT05587530|Experimental|Treatment engagement and retention intervention for suicidal clients|Participants will receive the manualized treatment engagement and retention protocol for suicidal outpatient clients (single-arm intervention pilot). The manualized treatment engagement and retention protocol will be based on client and staff stakeholder preferences, informed by data from qualitative participatory interviews and secondary data analysis of administrative databases (conducted in phase 1).
89257245|NCT05583279|Experimental|Phase 2|Cohort 1 and 2 youth will then complete baseline assessments (see 4.5) and Cohort 2 will continue receiving TAU while Cohort 1 begins receiving DBT-A (randomized by facility to either in-person or via telehealth delivery) for the next six months while Cohort 1 staff continue consultation with DBT-A. After six months, Phase 2 of this study will conclude with the youth of Cohorts 1 and 2 completing their first follow-up assessment. The implementation plan will be altered accordingly based on feedback from stakeholders prior to the start of Phase 2. The modified implementation plan will be used in the training of the staff in DBT-A at the second four facilities prior to the launch of Phase 3.
89257246|NCT05583279|Active Comparator|No intervention|Cohort 2 will not receive any treatment during Phase 2 of the study, which is the first part of the clinical trial. They will serve as a comparison group for Cohort 1.
89257247|NCT05583279|Active Comparator|Phase 3|Phase 3 will begin with making any modifications to the treatment protocol based on a review of feedback from stakeholder interviews from Phase 2. Cohort 2 facilities will be randomized to delivering DBT-A in-person or via telehealth (one long-term and one short-term facility will be assigned to each condition). Staff in Cohort 2 will receive training and consultation in DBT-A and implement either telehealth or in-person delivered DBT-A in their facilities. Cohort 1 facilities will cross-over from in-person delivery of DBT-A to telehealth delivery, or vice-versa, thereby facilitating a within-facility comparison of DBT-A delivery methods. After six months, Phase 3 will conclude with the youth of Cohorts 1 and 2 completing their second follow-up assessment and all stakeholders of Cohorts 1 and 2 completing stakeholder interviews.
89257248|NCT05577858|Other|Meat based|Animal protein-based dietary intervention
89257249|NCT05577858|Experimental|Pulse based|Pulse-protein-based dietary intervention
89257250|NCT05571189|Experimental|Participants who receive daily activity message|The intervention group will receive instructions for a daily activity sent through SMS text message or email.
89257251|NCT05571189|Placebo Comparator|Participants who receive control message|"The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as I hope you have a good day."
89257252|NCT05563675|No Intervention|Morning administration of LAMA|Participants randomized to this group (with or without the combination of ICS and/or LABA) will be instructed to take their LAMA as usual in the morning between 6 and 12am.
89257253|NCT05563675|Experimental|Bedtime administration of LAMA|Participants randomized to this group (with or without the combination of inhaled corticosteroids (ICS) and/or long-acting beta2-agonists (LABA)) will be instructed to take their LAMA-containing inhalation between 8pm. and 2am.
89257254|NCT05563220|Experimental|Phase 1b Arm A: elacestrant with alpelisib|Elacestrant Dihydrochloride 300 mg or 400 mg + Alpelisib 250 mg or 300 mg
89257255|NCT05563220|Experimental|Phase 1b Arm B: elacestrant with everolimus|Elacestrant Dihydrochloride 300 mg or 400 mg + Everolimus 5.0 mg, 7.5 mg or possibly 10 mg
89257256|NCT05563220|Experimental|Phase 1b Arm C: elacestrant with abemaciclib or ribociclib:|"Elacestrant Dihydrochloride 100 mg, 200 mg, 300 mg + Ribociclib 400 mg or possibly 600 mg~The recommended Phase 2 dose for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)"
89257257|NCT05563220|Experimental|Phase 1b Arm D: elacestrant with either palbociclib, abemaciclib, or ribociclib (no prior CDK4/6i)|"Elacestrant Dihydrochloride 300 mg or 400 mg + Palbociclib 100 mg,125 mg OR The recommended Phase 2 dose for the combination of elacestrant and abemaciclib is evaluated in the ongoing ELECTRA trial (ClinicalTrials.gov Identifier: NCT04791384)~Elacestrant 86 mg, 172 mg, 258 mg + Ribociclib 400 mg or possibly 600 mg"
89257258|NCT05563220|Experimental|Phase 1b Arm E:|Elacestrant Dihydrochloride 300 mg, 400 mg + Capivasertib 200 mg, 320 mg, 400 mg
89257259|NCT05554614|Experimental|BTW app with reward-based feedback|Teens will install the BTW app with reward-based feedback. This tracks driving performance while providing individualized driving feedback using gamification concepts.
89257260|NCT05554614|Experimental|BTW app with situational supervised driving practice|Teens will install the BTW app the same as the app with reward-based feedback in conjunction with a situational supervised driving practice intervention for teen-parent dyads.
89257261|NCT05554614|Sham Comparator|Sham BTW app|Teens will install the sham BTW app with driving performance tracking only.
89257262|NCT05549843|Experimental|Hemophilia group|"Intervention protocol:~Preparatory work: active mobilizations with the patient supine.~Global passive mobilization of the forefoot and midfoot.~Calcaneocuboid mobilization, functional and structural work of said joint.~Astragaloscaphoid mobilization, functional and structural work of said joint.~Talar manipulation dorsally.~Manipulation-tibial displacement:~Tibiotarsal decompression: 2 very gentle high-speed and short-course tibial-tarsal manipulations.~Plantar fascia induction for foot captors of the plantar fascia.~Tibiotarsal sustained traction technique (unwinding)~Sural triceps induction technique:"
89257263|NCT05546918||People with Long COVID|Any people with persisting symptoms related to COVID-19 (With a Long COVID diagnosis or not)
89257264|NCT05546918||Healthcare Professional|Healthcare professionals in charge of Long COVID patients
89257265|NCT05544565|Experimental|Experimental group: Discontinuation of treatment|For patients randomized in the experimental group, the patient receives 3-day IV therapy and the treatment is interrupted.
89257266|NCT05544565|Other|Control group: Usual practice|For patients randomized in the control group, the treatment for acute pyelonephritis is based on the attending clinician's practice and according to the usual practice: 3-day IV therapy followed by a 7-day oral antibiotic therapy.
89257267|NCT05540522|Experimental|Quadrivalent influenza modRNA vaccine, 18 through 64 years of age|Quadrivalent influenza modRNA vaccine (single dose), participants 18 through 64 years of age
89257268|NCT05540522|Active Comparator|Quadrivalent influenza vaccine, 18 through 64 years of age|Licensed quadrivalent influenza vaccine (single dose), participants 18 through 64 years of age
89257269|NCT05540522|Experimental|Quadrivalent influenza modRNA vaccine, ≥65 years of age|Quadrivalent influenza modRNA vaccine (single dose), participants ≥65 years of age
89257270|NCT05540522|Active Comparator|Quadrivalent influenza vaccine, ≥65 years of age|Licensed quadrivalent influenza vaccine (single dose), participants ≥65 years of age
89257271|NCT05539573||Treatment|Patients with planned transcatheter treatment of severe aortic stenosis with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.
89257272|NCT05533242|Experimental|Lu-177-labeled-6A10Fab-fragments|The patient will receive a predetermined dose of Lu-177-labeled- 6A10Fab-fragments via the intracavitary reservoir. Patients will receive 3 RIT-cycles with an interval of 4 weeks. The total activity, adjusted to the volume of the RC, will be injected in 3 fractions with 50%, 25% and 25% of the total activity to achieve the desired boost to the 2 cm margin.
89257273|NCT05527392|Experimental|HINT Synchronous Intervention Group (HINT-S)|a virtual, synchronous version of the 5 HINT-S navigator sessions + HINT booklet
89257274|NCT05527392|Experimental|HINT Asynchronous Intervention Group (HINT-A)|a prerecorded, asynchronous version of the 5 HINT-S navigator sessions + HINT booklet
89257275|NCT05527392|No Intervention|Enhanced Usual Care|HINT Booklet
89257276|NCT05526001|Experimental|ELIXCYTE|Subjects will be intra-articular (IA) injected with 4 mL of ELIXCYTE (containing 32×10^6 ADSCs) at the target knee once
89257277|NCT05526001|Placebo Comparator|Placebo control (Saline)|Subjects will be intra-articular (IA) injected with 4 mL of saline at the target knee once
89257278|NCT05524961|Experimental|Timed-Bright light therapy (BLT group)|10,000lux bright light
89257279|NCT05524961|Active Comparator|Timed-inactivated negative ion generator (Active-control group)|Inactivated negative ion generator
89257280|NCT05524961|Placebo Comparator|Random-time inactivated negative ion generator (placebo group)|Inactivated negative ion generator
89257281|NCT05523622|Other|IOP Measurement|These are the measurements of the intraocular pressure.
89257282|NCT05518370|Experimental|Hippotherapy simulator training group|Hippotherapy simulator training group will receive a traditional physiotherapy and hippotherapy simulator training, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes hippotherapy simulator training).
89257283|NCT05518370|Active Comparator|Traditional physiotherapy group|Traditional physiotherapy group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
89257284|NCT05516277|Experimental|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep provided in individual 60-minute sessions for 5 weekly sessions.
89257285|NCT05516277|Experimental|General Sleep Education Intervention|Manual-based education program focusing on general sleep provided in individual 60-minute sessions for 5 weekly sessions.
89257286|NCT05511428|Experimental|Treatment (daratumumab and hyaluronidase-fihj)|Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
89257287|NCT05503082|Placebo Comparator|w/o CGRPmAb|w/o CGRPmAb
89257288|NCT05503082|Active Comparator|Tx w/ CGRPmAb|Tx w/ CGRPmAb
89257289|NCT05491200|Experimental|Prasugrel-based short DAPT|Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy for 11 months.
89257290|NCT05491200|Active Comparator|Prasugrel based standard DAPT|Prasugrel-based DAPT for 1 year
89257291|NCT05491200|Experimental|OCT guided non-culprit lesion|Complete revascularization of non culprit lesions guided by OCT
89257292|NCT05491200|Active Comparator|Angio guided non-culprit lesion|Complete revascularization of non culprit lesions guided by Angio
89257293|NCT05480943||Hospitalized non-alcoholic veterans|Any veteran with full admission to the VA Sierra Nevada Healthcare System Hospital.
89257294|NCT05472740|Experimental|Active TENS|Participants will be connected to a TENS 7000 that is turned on and working
89257295|NCT05472740|Placebo Comparator|Placebo TENS|Participants will be connected to a TENS 7000 however it will not be connected / will not be working
89257296|NCT05460780|Experimental|MATTISSE TEC|Patient included receive MATTISSE TEC
89257297|NCT05460533|Experimental|Tisagenlecleucel|Patients will receive reinfusion of tisagenlecleucel on day +30-60 after their initial infusion if meeting eligibility criteria. Tisagenlecleucel is an autologous cellular immunotherapy product that is comprised of CD3+T cells that have undergone ex vivo T cell activation, gene modification, expansion, and formulation in infusible cryomedia.
89257298|NCT05457569||Parent Support Group - WP1|Group representatives (SOS Préma, The Neurogroup...)
89257299|NCT05457569||Parents of infants at a high risk of neurodevelopmental disorders - WP1|infants between 34 weeks' gestation and 4 months' corrected age at the time of the first focus group and with at least one risk factor for neurodevelopmental disorder
89257300|NCT05457569||Parents of children with developmental difficulties - WP1|"children between 18 and 48 months corrected age at the time of the first focus group:~with at least one risk factor for neurodevelopmental disorder~presenting an abnormal, non-transient clinical state"
89257301|NCT05457569||Health Professionals - WP1|Private physiotherapists, labor and delivery nurses of the Maternal and Child Protection, Centre d'action médico-sociale précoce (CAMSP) (psychomotricians, psychologists) and doctors involved in the care and follow up of children at risk of developmental disorders whose parents have agreed to participate in the study.
89257302|NCT05457569||Physiotherapist in a private practice - WP2|Physiotherapists working in a private practice
89257303|NCT05457569||Parents - WP2|parents of hospitalized children between 34 weeks of gestation and 4 months of corrected age with at least one risk factor for neurodevelopmental disorder
89257304|NCT05457569||PMI-CAMPS - WP2|Labor and delivery nurses from the Protection Maternelle et Infantile, CAMPS (psychomotricians, psychologists) and doctors involved in the care of children at risk of developmental disorders who are in charge of the follow-up of children whose parents have agreed to participate in the study.
89257305|NCT05453461|Experimental|new COMs for non ambulant FSHD patients|
89257306|NCT05426395|Active Comparator|Dose 1 (2.6 µg)|Adding Vitamin B12 at a dose of 2.6 µg
89257307|NCT05426395|Active Comparator|Dose 2 (10 µg)|Adding Vitamin B12 at a dose of 10 µg
89257308|NCT05426395|Active Comparator|Dose 3 (50 µg)|Adding Vitamin B12 at a dose of 50 µg
89257309|NCT05425888||Hemophilia group|Group of adult patients with hemophilia, diagnosed with bilateral hemophilic ankle arthropathy
89257310|NCT05425888||Control group|Group of healthy subjects with sociodemographic characteristics similar to patients with hemophilia, diagnosed with bilateral hemophilic ankle arthropathy.
89257311|NCT05414383||CADx|Histopathology prediction by CADx device
89257312|NCT05414383||Endoscopist|Real-time histopathology prediction by expert and non-expert endoscopists
89257313|NCT05413291||family members|family members who are 2 years old or older of people with movement disorders
89257314|NCT05413291||patients|subjects with movement disorders who are 2 years old or older
89257315|NCT05411185||the plateau group|People travelling from the plains to areas at altitudes of 3800 meters
89257316|NCT05411185||the plain group|People staying in the plains throughout the whole test
89257317|NCT05405751|Experimental|Patients received BIKTARVY (BIC/FTC/TAF)|"The patient enrolled in the study and access HIV consulting will start treatment with BIKTARVY the same day of the inclusion. The medication will provided by the sponsor and it will be dispensed by pharmacy service.~The delivery of medication to the patient can be delegated by a member of investigator staff who pick up the mediaction from pharmacy service to be delivered to the patient. The patient can pick up the medication directly from the pharmacy service. It will be recorded the face to face on delegated dispensing.~The deliver of medication will be bi-monthly and 2 bottles of tablets will be dispensed. The patients will receive a BIC/FTC/TAF single oral dose per day for 12 months."
89257318|NCT05390268|Experimental|digital tic training|The active treatment including apps released for every session
89257319|NCT05390268|Active Comparator|digital tic learner|The control arm including apps released in the first session
89257320|NCT05376202|Experimental|Phase 1: 75mg Cetuximab and 15mg Cetuximab-IRDye800CW|Patients receive 75mg of Cetuximab, followed by 15mg Cetuximab-IRDye800CW I.V. two days prior to surgery.
89257321|NCT05370859||Mme Study Participants|Participants will complete a baseline survey, 11 weekly surveys, and a follow-up survey at 12 weeks
89257322|NCT05370183|Experimental|Hyperambulatory tenotomy|regarding randomization result, patient wil have a tenotomy of biceps' long head by mini-optics in consultation
89257323|NCT05370183|Active Comparator|Operating room tenotomy|regarding randomization result, patient wil have a tenotomy of biceps' long head upon arthroscopy under normal operating condition
89257324|NCT05367843|Experimental|A-Cohorts: Pre-vaccinated|Participants aged 18-55 years who have been pre-vaccinated against COVID-19 with at least two doses of a SARS-CoV-2 mRNA vaccine will be assigned to five groups that receive increasing doses of PRIME-2-CoV_Beta (two doses, 28 days apart).
89257325|NCT05367843|Experimental|A-Cohorts: SARS-CoV-2 Vaccine-naïve|Participants aged 18-55 years who are SARS-CoV-2 vaccine-naïve will receive one preferred dose level of PRIME-2-CoV_Beta that has been identified as optimal in pre-vaccinated A-Cohorts (two doses, 28 days apart).
89257326|NCT05367843|Experimental|B-Cohorts: Pre-vaccinated elderly|Elderly participants aged 65-85 years who have been previously vaccinated against COVID-19 with at least two doses of a SARS-CoV-2 mRNA vaccine will be assigned to three groups to receive previously identified doses of PRIME-2-CoV_Beta (two doses, 28 days apart).
89257327|NCT05360667|Experimental|Intervention group|The intervention in this group is standard care plus plus exergame-based multicomponent training program
89257328|NCT05360667|Sham Comparator|Control group|The control group receives usual care in the LTCFs.
89257329|NCT05358249|Experimental|JDQ443+trametinib|JDQ443 in combination with trametinib
89257330|NCT05358249|Experimental|JDQ443+ribociclib|JDQ443 in combination with ribociclib
89257331|NCT05358249|Experimental|JDQ443+cetuximab|JDQ443 in combination with cetuximab
89257332|NCT05357443|Active Comparator|Gastric Bypass with Transection of Vagal Nerves|
89257333|NCT05357443|Placebo Comparator|Gastric Bypass Without Transection of Vagal Nerves|
88804907|NCT01404559|Active Comparator|Prosthetic foot 2 (Ossur Ceterus)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 2 (Ossur Ceterus).
89257334|NCT05357313|Experimental|Bright light therapy group|10,000lux bright light
89257335|NCT05357313|Placebo Comparator|Placebo group|inactive negative ion generator
89257336|NCT05355870|Experimental|Cognitive Training|"Participants in the experimental arm will be provided a brochure that included information on basic knowledge of ADRD, signs and symptoms related to ADRD, the definition and the potential benefits of cognitively stimulating activities in maintaining cognitive function, and examples of cognitively stimulating activities.~Participants in this arm will complete a series of cognitive training exercises on a smartphone/tablet. The anticipated training will last for 12 weeks and involve 3-4 sessions per week (20-30 min/ session)."
89257337|NCT05355870|No Intervention|Passive Control|A passive control group will be included in this pilot trial. Participants in this passive control arm will be provided a brochure that included information on basic knowledge of ADRD, signs and symptoms related to ADRD, the definition and the potential benefits of cognitively stimulating activities in maintaining cognitive function, and examples of cognitively stimulating activities.
89257338|NCT05347654|Active Comparator|Standard strategy|Local treatment with silver sulphadiazine and tulle from day 0 to day 8. From the 9t h day and until healing, the dressings are made with tulle, every 48 hours.
89257339|NCT05347654|Experimental|Strategy incorporating a poly-absorbent dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
89257340|NCT05346627|Other|mitochondrial myopathy|Patient affected by mitochondrial myopathy, with genetic confirmation of mitochondrial DNA mutation
89257341|NCT05345899|Other|chronic rheumatism|Population of patients followed for chronic inflammatory rheumatism in remission or lupus in low activity, with chronic residual pain
89257342|NCT05344950|Experimental|AURA|In addition to usual care, participants assigned to this arm will have access to our Audio + Radio (AURA) system.
89257343|NCT05344950|No Intervention|Usual Care|Participants assigned to this arm will receive the standard of care that is provided to all patients.
89257344|NCT05335096|Experimental|Intervention group|
89257345|NCT05335096|Active Comparator|TAU group|
89257346|NCT05327725|Experimental|Fatigue Reduction Diet Intervention|Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol via 8 remote phone or video telehealth sessions with a registered dietitian over 3 months.
89257347|NCT05325632|Experimental|Lead In - Dose level 1|Six participants will be treated at dose level 1: DC vaccine given at the dose of 50 million once per week for 6 weeks
89257348|NCT05325632|Experimental|Lead In: Dose Level 2|Six participants will be treated at dose level 2: DC vaccine given at the dose of 100 million once per week for 6 weeks
89257349|NCT05325632|Experimental|Expansion -Estrogen Receptor (ER) positive|An additional 24 participants will be enrolled at dose level 2 if determined to be safe in lead in phase to have a total of 28 evaluable participants for pathologic response assessment (including 6 pts from the lead in phase).
89257350|NCT05325632|Experimental|Expansion -Estrogen Receptor (ER) negative|An additional 23 participants will be enrolled at dose level 2 if determined to be safe in lead in phase to have a total of 28 evaluable participants for pathologic response assessment (including 6 pts from the lead in phase).
89257351|NCT05314712|Other|Sleep Intervention|Pre and post test of 9-week intervention
89257352|NCT05308602|Experimental|SCTV01C|
89257353|NCT05308602|Experimental|SCTV01E|
89257354|NCT05308602|Active Comparator|mRNA vaccine manufactured by Pfizer or Moderna|
89257355|NCT05308602|Active Comparator|Sinopharm inactivated COVID-19 vaccine|
89257356|NCT05305872|Experimental|Treatment group|Gandouling
89257357|NCT05305872|Placebo Comparator|Control group|Zinc gluconate
89257358|NCT05301400|Active Comparator|Overcast implant single restauration|
89257359|NCT05301400|Active Comparator|Cad/cam direct implant restauration|
89257360|NCT05301400|Active Comparator|Cad/cam implant restauration with transepithelial pilar|
89257361|NCT05298904||Kidney Transplants|Kidney transplant patients who are within one-year post transplant.
89257362|NCT05298033|Experimental|Active NBUVB plus Crisaborole 2% topical ointment|12 participants will receive 6 months of treatment with crisaborole 2% topical along with 6 months of treatment with active NBUVB
89257363|NCT05298033|Experimental|Active NBUVB plus PF-07038124 0.01% topical ointment|12 participants will receive 6 months of treatment with active NBUVB, to be combined with 3 months of treatment with PF-07038124 0.01% topical ointment followed by 3 months of vehicle ointment
89257364|NCT05298033|Active Comparator|Active NBUVB plus vehicle ointment|8 participants will receive 6 months of treatment with active NBUVB combined with 6 months of vehicle ointment application
89257365|NCT05298033|Experimental|Sham phototherapy plus crisaborole 2% topical ointment|12 participants will receive 6 months of treatment with crisaborole 2% topical ointment combined with 6 months of sham phototherapy
89257366|NCT05298033|Experimental|Sham phototherapy plus PF-07038124 0.01% topical ointment|12 participants will receive 3 months of treatment with PF-07038124 0.01% topical ointment, followed by 3 months of vehicle ointment, along with 6 months of sham phototherapy
89257367|NCT05298033|Placebo Comparator|Sham phototherapy plus vehicle ointment|8 participants will receive 6 months of sham phototherapy combined with 6 months of vehicle ointment application
89257368|NCT05297903|Experimental|XmAb20717|Study participants will receive the recommended phase II dose (10mg/kg) of XmAb20717 by intravenous infusion on days 1 and 15 of a 28-day cycle for up to 2 years.
89257369|NCT05292378|Experimental|High CO2 Exposure first, then low CO2 exposure second.|At the first study visit the subject is exposed to 2500 ppm CO2 for 2.5 hours and at the second study visit the subject is exposed to 600 ppm CO2 for 2.5 hours.
89257370|NCT05292378|Sham Comparator|Low CO2 Exposure first, then high CO2 exposure second.|At the first study visit the subject is exposed to 600 ppm CO2 for 2.5 hours and at the second study visit the subject is exposed to 2500 ppm CO2 for 2.5 hours.
89257371|NCT05281393|No Intervention|Control|Access to mobile health platform for resources and information about PrEP
89257372|NCT05281393|Experimental|Experimental|Access to mobile health platform for resources and information about PrEP plus sessions with peer health support navigator, social app interactions, goal setting capabilities
89257373|NCT05269966|Experimental|Brolucizumab|"Brolucizumab, formerly known as ESBA1008, is a humanized single-chain Fv (scFv) antibody fragment.~Its Intravitreal injections.~Brolucizumab 6 mg will be administered by IVT injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients will receive loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) will be performed based on BCVA and OCT to assess whether the patient will require q8w or q12w dosing."
89257374|NCT05269004|Experimental|Ocrelizumab|Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046). Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.
89257375|NCT05267574|Experimental|REN001|100 mg once daily
89257376|NCT05267262|Experimental|Cohort 2 (Alport Syndrome Patients)|R3R01 administered orally as 200 mg tablets twice daily for 84 days.
89257377|NCT05267262|Experimental|Cohort 3 (Focal Segmental Glomerulosclerosis Patients)|R3R01 administered orally as 200 mg tablets twice daily for the 84 days.
88804908|NCT01404559|Active Comparator|Prosthetic foot 3 (Endolite Elite Blade)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 3 (Endolite Elite Blade).
89257378|NCT05262218|Experimental|PBF-680|PBF-680 is an Adenosine A1 receptor antagonist formulated in oral gelatine capsules
89257379|NCT05262218|Placebo Comparator|Placebo|Placebo formulated in oral gelatine capsules
89257380|NCT05258487||VIBe Grade 1|Intraoperative bleeding of grade 1 as defined by the VIBe scale.
89257381|NCT05258487||VIBe Grade 2|Intraoperative bleeding of grade 2 as defined by the VIBe scale.
89257382|NCT05258487||VIBe Grade 3|Intraoperative bleeding of grade 3 as defined by the VIBe scale.
89257383|NCT05258487||VIBe Grade 4|Intraoperative bleeding of grade 4 as defined by the VIBe scale.
89257384|NCT05244915|Experimental|Experimental|Participants will receive a geriatric assessment which consists of validated questionnaires that are used to assess health status of older adults with cancer. Based on participant responses, tailored recommendations will be provided.
89257385|NCT05239975|Experimental|SCTV01C|Participants will be administrated one dose of SCTV01C on Day 0 and Day 180
89257386|NCT05239975|Active Comparator|Comirnaty|Participants will be administrated one dose of Comirnaty on Day 0 and Day 180
89257387|NCT05237752|Experimental|LG00034053|White to slightly brown powder, dosage (6mg, 15mg, 45mg; dose escalation design), single dose administration
89257388|NCT05237752|Placebo Comparator|Placebo|Clear liquid, single dose administration
89257389|NCT05236387||Intent to Treat group|All patients meeting entrance criteria, injected with 99m Tc-TM, and having one or more lymph nodes removed for which the pathologist confirms the type (lymph node versus non-lymph node) and contents (e.g., tumor cells) of the excised tissues will comprise the intent-to-treat population (ITT). This definition also carries over to the lymph nodes; i.e., nodes used for the ITT analysis must come from patients included in the ITT population. The ITT population will serve as the analysis population for all efficacy endpoints, unless indicated otherwise in the description of analyses.
89257390|NCT05230537|Experimental|Iptacopan (LNP023)|Iptacopan (LNP023) oral use capsules
89257391|NCT05230537|Placebo Comparator|Placebo|Placebo matched to study drug, oral use capsules
89257392|NCT05220228|Experimental|Prucalopride|Prucalopride - 1mg for 2 days, and then increased to 2mg for a further 5-8 days. Testing will occur on day 7 ideally, but may take place up to and including day 10.
89257393|NCT05220228|Placebo Comparator|Placebo|Placebo (sucrose / lactose) for 7-10 days
89257394|NCT05212233||Patients with MM and/or CLL|This is a non-interventional study. All enrolled patients will complete a telephone interview. A subset of patients will complete the optional follow-up interview. The clinical practice sites through which patients are being recruited and enrolled on to the study will each complete the Site Survey. Physicians at these sites who treat patients with MM or CLL will be invited to complete the Physician Survey.
89257395|NCT05209282|Experimental|Grup I|Conventional physiotherapy program, Video-based action observation training
89257396|NCT05209282|Experimental|Grup II|Conventional physiotherapy program, Live Action Observation Training
89257397|NCT05209282|Other|Grup III|Conventional physiotherapy program
89257398|NCT05199376|Experimental|Percutaneous cryotherapy|Cryoablation of the tumor
89257399|NCT05185310|Experimental|CTI/AAD (control)|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 1- Cavo-tricuspid isthmus (CTI) ablation with adjustment and/or optimization of antiarrhythmic drug regimen where possible (control arm)
89257400|NCT05185310|Experimental|Posterior wall isolation|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 2-LA Posterior wall isolation by creation of a LA roof and floor line
89257401|NCT05185310|Experimental|Empiric Isolation of common trigger sites|In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 3-empiric ablation of common sites of non-PV triggers of AF in both the right and left atria.
89257402|NCT05174806|Experimental|Topical Pravibismane (MBN-101)|Topical pravibismane (MBN-101) at a dose of 2.5 mg/mL will be applied directly to the infected wound and covered with an appropriate non-antimicrobial dressing. Dosing will occur 3 times per week for the 12 weeks of treatment.
89257403|NCT05174806|Other|Standard of Care|Standard of care treatment without administration of any topical drugs.
89257404|NCT05168449|No Intervention|Control Group|Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, with an access to the previously described mobile application
89257405|NCT05168449|Experimental|Intervention Group|Intervention group will be provided in addition to the usual care, with an access to the mobile application
89257406|NCT05163249|Active Comparator|Cohort 1: osimertinib, 80mg, daily, P.O.|"Patients will continue to receive study medication in 28 day cycles until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.~Patients who progress on first-line treatment of osimertinib monotherapy will have the opportunity to receive second-line treatment of osimertinib plus savolitinib after confirmation of MET status at disease progression."
89257407|NCT05163249|Experimental|Cohort 2: osimertinib 80mg daily, P.O. and savolitinib 300mg BID, P.O.|"All eligible patients will be randomized to receive treatment with osimertinib (80 mg daily) or osimertinib (80 mg daily) in combination with savolitinib (300 mg BID) in this study. Treatment will continue until either objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.~Patients in Cohort 2 can continue on savolitinib monotherapy (if osimertinib was stopped earlier) or osimertinib monotherapy (if savolitinib was stopped earlier) until objective disease progression or meet any of the discontinuation criteria."
89257408|NCT05163119|No Intervention|Control Group|Commercial cell-phone blocking app installed on smartphone, but app will be inactive.
89257409|NCT05163119|Experimental|Commercial Cellphone-Blocking App|Commercial cellphone-blocking app that blocks handheld cellphone use while driving, but allows emergency calls and phone use after pressing the passenger button will be installed on smartphone.
89257410|NCT05163119|Experimental|Driving Mode|Driving mode blocks handheld phone use while driving or facilitates hands free use (exact functionality dependent on smartphone type and service provider).This group will also have the commercial cell-phone blocking app installed on smartphone, but app will be inactive.
89257411|NCT05158894||Ubrelvy-Exposed Women With Migraine|Pregnant women with migraine who took at least 1 dose of Ubrelvy, the exposure of interest, at any time during pregnancy as part of routine care.
89257412|NCT05158894||Unexposed Women With Migraine|Pregnant women with migraine (treated and untreated) who have never taken Ubrelvy (i.e., before or during the enrolled pregnancy) or who have discontinued Ubrelvy at least 3 months prior to the first day of last menstrual period (LMP).
89257413|NCT05154747|Active Comparator|Continuous Therapy (CT) Control Group|The control group is a continuous daily oral combination ART consisting of dolutegravir (DTG), with a tenofovir (TFV) and lamivudine(3TC)/emtricitabine(FTC) backbone
89257414|NCT05154747|Experimental|Long Acting (LA) Injectable Group|The intervention group is a long-acting injectable, cabotegravir (CAB) LA and rilpivirine (RPV) LA given every 8-weeks after an optional 4-week oral lead-in period with oral cabotegravir and rilpivirine, and two loading doses separated by 4 weeks.
89257415|NCT05149131||mCSPC patients in the province of Alberta|mCSPC patients who initiated and received at least one dose of guideline recommended life-prolonging therapy for mCSPC (docetaxel, abiraterone, enzalutamide, apalutamide, or ADT alone) from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff, inclusive.
89257416|NCT05145127|Experimental|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
89257417|NCT05141604|Experimental|Field expansion view|Various configurations of field expansion views will be additionally displayed on HMD
89257418|NCT05132244|Experimental|Intensive Glucose Intervention|Participants will receive standard anti-hyperglycemic treatment as guided by an endocrinologist using a combination of data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Treatment will aim to maintain glucose levels between 4 and 10 mmol/L. Participants will have real-time access to their glucose data via the CGM.
89257419|NCT05132244|Other|Standard Care|Participants will receive standard anti-hyperglycemic treatment only if blood glucose level is above 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a CGM but will not be able to view their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
89257420|NCT05131074|Experimental|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions.
89257421|NCT05131074|Experimental|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions.
89257422|NCT05131074|No Intervention|Control Group|Patients will not receive the Collabree application.
89257423|NCT05130970|Experimental|CSL312|Administered IV and SC
89257424|NCT05130970|Placebo Comparator|Placebo|Administered IV and SC
89257425|NCT05118802||Observational (interview, survey)|"Part I: Patients and clinicians attend semi-structured interviews over 20-30 minutes or cognitive interviews over 60 minutes in support of survey refinement.~Part II: Patients complete survey over 15 minutes."
89257426|NCT05116189|Experimental|Pembrolizumab + paclitaxel ± bevacizumab|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 every 3 weeks [Q3W]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
89257427|NCT05116189|Placebo Comparator|Placebo + paclitaxel ± bevacizumab|Participants receive placebo via IV infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 every 3 weeks [Q3W]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
89257428|NCT05114616|Experimental|Sleep Study and Daytime MWT|Health volunteers completing one overnight sleep study followed by daytime MWT. The sleep study will include standard surface electrodes as well as EEGBuds. Participants will be asked to wear Ellcie Healthy glasses, concurrent with the EEGBuds, during each MWT trial.
89257429|NCT05108558|Active Comparator|Control - Crossover to CCH|Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to CCH treatment and undergo up to 8 injections (or until curvature is <15 degrees). Final assessments would then be performed 6 weeks following the final injection.
89257430|NCT05108558|Experimental|Collagenase Clostridium Histolyticum|Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is <15 degrees). Men would then undergo assessments 6 weeks later, followed by a 6-month no treatment phase and then final assessments.
89257431|NCT05099705|Experimental|Intervention Group (Access to an FSN/TSS)|40 participants will be randomly assigned to the intervention group (i.e., to receive an FSN and have access to the TSS). The FSN may meet with the participant at least twice and provide navigation support.
89257432|NCT05099705|No Intervention|Control Group (Access to Information, training and referral)|15 participants will be randomly assigned to the non-personalized comparison group (i.e., information, training, and referral).
89257433|NCT05093673|Active Comparator|Cathodal Cerebellar tDCS and SFA|Cathodal cerebellar tDCS, 2 milliamp (mA) plus Semantic Feature Analysis (SFA) naming treatment for 15 sessions (25-minutes per each 60-minute treatment session) over the course of 3-5 weeks. The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes. SFA will be delivered by a Speech and Language Pathologist to improve naming
89257434|NCT05093673|Sham Comparator|Sham Cerebellar tDCS and SFA|Sham cerebellar tDCS plus SFA for 15 sessions (25-minutes per each 60-minute treatment session) over the course of 3-5 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SFA will be delivered by a Speech and Language Pathologist to improve naming.
89257435|NCT05093504|Sham Comparator|Control|Standard of care with Sham set-up
89257436|NCT05093504|Experimental|DrugSorb-ATR Intervention|Standard of care + DrugSorb-ATR system
89257437|NCT05093322|Experimental|Part 1- Dose escalation|Dose escalation study with sequential dose escalation of surufatinib in combination with gemcitabine. Patients with any recurrent or refractory solid tumors or lymphoma, who have a known or expected dysfunction of VEGFR-1, -2, and -3; FGFR-1; or CSF-1R pathways may be enrolled.
89257438|NCT05093322|Experimental|Part 2 - Dose expansion|Once the MTD/RP2D has been determined in the part 1 portion of the study, the part 2 disease specific cohorts for patients with refractory or recurrent osteosarcoma, Ewing Sarcoma, and RMS and non- RMS will open for enrollment.
89257439|NCT05090527|Active Comparator|Directly delabeled trough risk stratification tool|"Patients who are stratified as  no penicillin allergy undergo a one dose full dose provocation test with 500 mg amoxicillin."
89257440|NCT05090527|Active Comparator|Low risk patients|Patients stratified as low risk on penicillin provocation undergo a one dose full dose provocation test with 500mg amoxicillin
89257441|NCT05090527|Active Comparator|High risk|Patient stratified as high risk undergo a full allergologic work up, and only some of these will undergo a provocation test.
89257442|NCT05079516|Experimental|Primary motor cortex--Exp 1|Theta burst transcranial magnetic stimulation (cTBS) will be applied over primary motor cortex.
89257443|NCT05079516|Experimental|Somatosensory cortex--Exp 1|Theta burst transcranial magnetic stimulation (cTBS) will be applied over primary somatosensory cortex.
89257444|NCT05079516|Sham Comparator|Vertex sham--Exp 1|Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over the vertex.
89257445|NCT05079516|Experimental|Anterior superior parietal lobule--Exp 2|Theta burst transcranial magnetic stimulation (cTBS) will be applied over Anterior superior parietal lobule.
89257446|NCT05079516|Experimental|Ventral premotor cortex--Exp 2|Theta burst transcranial magnetic stimulation (cTBS) will be applied over Ventral premotor cortex.
89257447|NCT05079516|Experimental|Cerebellar cortex--Exp 2|Theta burst transcranial magnetic stimulation (cTBS) will be applied over cerebellar cortex.
89257448|NCT05079516|Sham Comparator|Vertex sham--Exp 2|Sham theta burst transcranial magnetic stimulation (cTBS) will be applied over the vertex.
89257449|NCT05077384|Experimental|Surufatinib|Oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1
89257450|NCT05073315|Active Comparator|Continued-use Group (Adalimumab)|Randomized participants will receive continuous injection of adalimumab Q2W until last dose at Week 28.
89257451|NCT05073315|Experimental|Switching Group (Adalimumab - ABP 501)|Participants will initially receive adalimumab until Week 10 during the lead-in period. Thereafter, starting from Week 12, participants will switch between ABP 501 and adalimumab Q2W with last dose of ABP 501 at Week 28.
89257452|NCT05067738|Other|Discharge|Phase 1-Patients will continue to be admitted after their surgery as is the current practice. Phase 2-Patients will have their chest tube removed once they meet chest tube removal criteria and will be discharged home once they meet discharge criteria.
89257453|NCT05066009|Experimental|Prescribed medication followed by drug holiday|Participants will complete the study assessments on a day when they take their prescribed medication(s) to promote wakefulness and then will repeat the study assessments on a day when they do not take the medication.
89257454|NCT05066009|Experimental|Drug holiday followed by prescribed medication|Participants will complete the study assessments on a day when they do not take their prescribed medication(s) to promote wakefulness and then will repeat the study assessments on a day when they take their medication as prescribed.
89257455|NCT05065593|Experimental|Face-to-Face Training Group|"After completing all assessments, the intervention group will participate in face-to-face exercise training with a physiotherapist for 3 days for 4 months.~In the first week, patients will be taught body awareness; parameters of correct loading on the muscle will be explained and the limits of safe exercise will be drawn. At the beginning and end of all exercises, there will be short-term active stretching and relaxation exercises performed by the patient as a warm-up and cool-down period. In the first 4 weeks, it is planned to increase the physical fitness levels of individuals with progressive resistance exercises and to make them suitable for aerobic loading. For each patient, the PRE, resistance will be increased from 60% to 80% for as long as the person can. At the end of the 1st month, the time allocated to resistance exercise training will be reduced and until the end of the 4th month, an increasing intensity aerobic exercise training will be given on the stationary bike."
89257456|NCT05065593|Active Comparator|Home-Based Control Group|After the patients assigned to the control group are evaluated by the physiotherapist with field tests and scales for physical functions, the patients will be informed about the importance of lifestyle changes in disease management, gait training will be given to increase their physical activity level and participants will be asked to follow a 45-minute walking program every day within their own means. All patients in the control group will be followed up regularly and their activity levels will be questioned in interim evaluations by asking them to keep a weekly physical activity diary.
89257457|NCT05064462||All the patients included in the study|50 patients, at least 18 years old, first heart transplant
89257458|NCT05064059|Experimental|Favezelimab/Pembrolizumab|Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions.
89257459|NCT05064059|Active Comparator|Standard of Care (Regorafenib or TAS-102)|Participants will receive 160 mg regorafenib orally daily on Days 1-21 of each 28-day cycle. Participants will also receive 35 mg/m^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day treatment cycle.
89257460|NCT05050539|Active Comparator|Early Responders to Low Intensity|Early responders will include those with targeted levels of fidelity by the October assessment. They will continue to receive low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
89257461|NCT05050539|Active Comparator|Non-Responders Continue Low Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to continue receiving low intensity implementation support (i.e., formal commitments, local champions, implementation blueprint, reminder cutting boards, task-focused implementation).
89257462|NCT05050539|Experimental|Non-Responders Increasing to High Intensity|This group will include those not achieving desired levels of fidelity by the October assessment who will be randomized to have high intensity support added (low intensity + holistic individualized facilitation, tailored educational materials).
89257463|NCT05050227|Experimental|cCBT Enhanced Collaborative Care|Participants in the intervention arm will receive computerized cognitive behavioral therapy (cCBT) supported by a depression care manager in addition to the usual care provided.
89257464|NCT05050227|Active Comparator|Usual Care|Participants in the usual care arm will receive the usual care provided as described below.
89257465|NCT05042791|Experimental|SRT combined with pyrotinib and capecitabine|"SRT: SRT needs to be comprehensively considered based on the size, number, and location of the lesion, and SRS and FSRT are performed according to clinical needs.~Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days."
89257466|NCT05042791|Active Comparator|WBRT combined with pyrotinib and capecitabine|"WBRT: WBRT need to be considered based on the size, number, and location of the lesion.~Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days."
89257467|NCT05039008|Experimental|Blood flow restriction group|"The intervention will last 4 weeks, with a periodicity of 3 weekly sessions (34). In total there will be 12 sessions lasting between 15 and 30 minutes.~The exercises will be: squats, knee extension and heel elevation (performing 4 sets of 15 repetitions with 30 seconds of rest between sets)."
89257468|NCT05039008|No Intervention|Control group|The patients included in the control group will not receive any Physiotherapy intervention and will continue with their usual routine, being evaluated in the same periods as the rest of the patients.
89257469|NCT05031910|Experimental|Arm I (VR/3D-CEPs, standard treatment)|Prior to surgery (day 0-13), patients undergo virtual reality 3D tumor resection via VR/3D-CEPs. Patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29 and a 3D model of true tumor is created and imported into the virtual reality environment.
89257470|NCT05031910|Active Comparator|Arm II (standard treatment)|Prior to surgery (day 0-13), patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29.
89257471|NCT05018143|Experimental|STARS|The investigators will deliver an online intervention focused on safety planning (STARS). The intervention content includes life skills interactive modules across 14 domains, a goal tracker, referral to community resources, and scheduling of peer mentoring sessions.
89257472|NCT05018143|Active Comparator|Control Condition|The investigators will deliver an in-person therapeutic session where participants can develop an individualized safety plan for use during a suicidal crisis, focusing on adaptive coping, addressing barriers or ambivalence, and strengthening their self-efficacy.
89257473|NCT05013554|Experimental|SAR443216-Dose Escalation|Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive SAR443216 as intravenous (IV) infusion or subcutaneous (SC) injection.
89257474|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort A|Participants with metastatic breast cancers with HER2 high expression (with amplification) will receive SAR443216 as intravenous (IV) infusion.
89257475|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort B|Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
89257476|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort C|Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
89257477|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort D|Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive SAR443216 as intravenous (IV) infusion.
89257478|NCT05002088||Primary Analysis Population|The primary analysis population will include patients who have signed an Informed Consent Form, and at minimum, the Portico delivery system entered his/her vasculature for an attempted Portico ViV implant. Patients must have met the sizing requirements of the PorticoTM transthoracic aortic valve sizing specification (≥19 mm and ≤27 mm).
89257479|NCT05002088||Exploratory Registry Arm|The exploratory registry arm will collect data for patients that were treated for a failed surgical bioprosthetic aortic valve true inner diameter size of <19 mm or >27 mm.
89257480|NCT04999995||HFrEF|Patients admitted with acutely decompensated HFrEF.
89257481|NCT04999995||HFpEF|Patients admitted with acutely decompensated HFpEF.
89257482|NCT04999995||Non-HF Dyspnea|Patients admitted with acute dyspnea without evidence of HF.
89257483|NCT04999644|Experimental|Full Nicotine Expectancy, Reduced Nicotine Dose|Receive reduced nicotine cigarette expecting full
89257484|NCT04999644|Experimental|Full Nicotine Expectancy, Full Nicotine Dose|Receive full nicotine cigarette expecting full
89257485|NCT04999644|Experimental|Reduced Nicotine Expectancy, Full Nicotine Dose|Receive full nicotine cigarette expecting reduced
88804909|NCT01404559|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
88804910|NCT01351753|Active Comparator|Metformin|
88804911|NCT01351753|Experimental|Metformin + Orlistat|
88804912|NCT01351753|Experimental|Metformin + Topiramate|
88804913|NCT01351753|Experimental|Topiramate|
89257486|NCT04999644|Experimental|Reduced Nicotine Expectancy, Reduced Nicotine Dose|Receive reduced nicotine cigarette expecting reduced
89257487|NCT04984668|Experimental|GT90001+KN046|"GT90001, 100 mg/10 mL/vial. GT90001 will be administered via intravenous infusion (IV) for around 60 minutes, once every 2 weeks (Q2W) in each 14-day cycle.~KN046, 40 mg/1.6 mL/vial, 300 mg/12 mL/vial KN046 will be administered via intravenous infusion (IV) for at least 120 minutes (up to 4h for the first 6 cycles), once every 2 weeks (Q2W) in each 14-day cycle, after 60 minutes post the GT90001 taken."
89257488|NCT04968366|Experimental|DC vaccine group|Subjects will receive five to eight doses of the DC vaccine through i.d. injection into regions near to the groin and axillary during they receive TMZ adjuvant chemotherapy
89257489|NCT04957615|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89257490|NCT04949737||Helicobacter Pylori detection|Systematic biopsies of the tumor and the gastric cavity will be performed during the initial fibroscopy in accordance with the recommendations of the French Society of Digestive Endoscopy (SFED).
89257491|NCT04944940||Healthy Volunteers|Healthy male participants who are age and sex matched to the SBMA participants
89257492|NCT04944940||Patients with Spinal and bulbar muscular atrophy (SBMA)|Male participants with genetically confirmed SBMA
89257493|NCT04937582|Experimental|Confirmed cognitive disorder|"Patients with abnormal QPC score at screening visit and confirmed cognitive disorder on the neuropsychological assessment during Visit V1.~Intervention Completed by MRI (magnetic resonance imaging), EEG (Electroencephalogram) and possible psychiatric evaluation at Visit 1B.~Follow-up 2 years after initial hospitalisation (Visit 2 : neuropsychological assessment ; if needed MRI, EEG, lumbar puncture)"
89257494|NCT04937582|Experimental|Absence of cognitive disorder|Patients with abnormal QPC score at screening and absence of cognitive disorder on the neuropsychological assessment during Visit V1.
89257495|NCT04921878|Experimental|Mitoxantrone Hydrochloride Liposome Injection|"Dose-escalation phase: Patients will receive mitoxantrone hydrochloride liposome injection followed by a 3-week DLT observation period. The initial dose of mitoxantrone hydrochloride liposome injection will be set as 24 mg/m2, and then the dose is sequentially escalated to 30 mg/m2, 36 mg/m2 and 40 mg/m2.~Dose-expansion phase: After DLT observation, two to four dose cohorts will be selected for dose-expansion to further evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection."
89257496|NCT04920162|Other|Skin deseases biospecimens collection|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
89257497|NCT04912427|Experimental|Isatuximab + Boretezomib + Dexamethasone|"Each cycle is 28 days~Cycle 1~Days 1, 8, 15, and 22: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time~Cycles 2-8~Days 1 and 15: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time~Days 8 and 22: Dexamethasone at start time and Bortezomib at 30 minutes after start time~Cycles 9+~Days 1 and 15: Dexamethasone at start time and Isatuximab at 30-60 minutes after start time"
89257498|NCT04911166|Experimental|Atezolizumab and Interleukin-12 Gene Therapy|
89257499|NCT04911127|Placebo Comparator|Placebo|Participants will take capsules containing medium chain triglyceride (MCT) oil
89257500|NCT04911127|Experimental|200mg CBD twice daily|Participants will take capsules containing cannabidiol amounting to 200mg CBD twice daily
89257501|NCT04911127|Experimental|400 mg CBD twice daily|Participants will take capsules containing cannabidiol amounting to 400mg CBD twice daily
89257502|NCT04893382|Experimental|PlasmaLyte|Seven (7) severely burned patients will be infused with PlasmaLyte (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
89257503|NCT04893382|Experimental|Ringer's Lactate|Seven (7) severely burned patients will be infused with Ringer's Lactate (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
89257504|NCT04885920||Participants With IBD|Participants diagnosed with moderately to severely active IBD (UC or CD) who initiated or are currently ongoing vedolizumab IV induction treatment in accordance with the current Summary of Product Characteristics (SmPC) or receiving vedolizumab ongoing or maintenance IV treatment with the option to switch to vedolizumab SC treatment, will be observed prospectively for at least 12 months.
89257505|NCT04848779||Cohort 1|
89257506|NCT04844385|Experimental|Cohort A|Patients in cohort A receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, followed by radiotherapy at a total dose of 60Gy combined with Capecitabine.
89257507|NCT04844385|Experimental|Cohort B|Patients in cohort B receive 2 cycles Toripalimab plus Paclitaxel/Nedaplatin, followed by radiotherapy at a total dose of 50Gy combined with Capecitabine.
89257508|NCT04842630|Experimental|SHR-1916|
89257509|NCT04815525||Normal finding|Colonoscopy finding normal
89257510|NCT04815525||Hyperplastic polyps|Colonoscopy finding of hyperplastic polyps
89257511|NCT04815525||Low-risk adenomas|Colonoscopy finding of low-risk adenomas
89257512|NCT04815525||High-risk adenomas|Colonoscopy finding of high-risk adenomas
89257513|NCT04804644|Experimental|Arm I (SRS)|Patients undergo SRS over 1 day (in some cases several days).
89257514|NCT04804644|Active Comparator|Arm II (HA-WBRT, memantine)|Patients also undergo HA-WBRT QD for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients will also receive memantine PO QD or BID for up to 24 weeks in the absence of disease progression or unacceptable toxicity.
89257515|NCT04800250|Experimental|A - Mucogain matrix on right|The patient will receive mucogain matrix on right side and connective tissue graft on left side.
89257516|NCT04800250|Experimental|B - Mucogain matrix on left|The patient will receive mucogain matrix on left side and connective tissue graft on right side.
89257517|NCT04793217|Experimental|Improving AIDS Care after Trauma+|ImpACT+ (Improving AIDS Care after Trauma+), is an individual-level coping intervention to address traumatic stress and HIV care engagement among South African women with sexual trauma histories. The ImpACT+ individual sessions will focus on coping skills and care engagement during an early critical period, while maintenance check-ins will serve to reinforce positive change and support the ongoing implementation of skills as new challenges arise.
89257518|NCT04793217|Active Comparator|Adapted Problem-Solving Therapy|Participants randomly assigned to the control condition will receive a brief adapted version of problem-solving therapy (PST), based on Problem Management Plus, a component of the World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP). PST is a psychoeducational treatment focused on managing the negative effects of stressful life events. PST has been found to be effective for a range of problems, such as depression, and is recommended for implementation in low-resource settings.
89257519|NCT04784429|Experimental|MPK|Microprocessor controlled knee
89257520|NCT04784429|Active Comparator|NMPK|Non-microprocessor controlled knee
89257521|NCT04775264|Experimental|Pulsed Electric Field Energy Ablation|Ablation of ganglionated plexi (GP) structures on the epicardial surface of the heart delivered as a concomitant procedure during open heart surgery.
89257522|NCT04767568|Experimental|Blood test|"In Cohort A: 200 patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) OR with gross bleeding~In cohort B: 200 patients who have already performed colonoscopy candidates for surgery on their colorectal tumor"
89257523|NCT04764591|Active Comparator|Lateral sagittal approach|Patients in this group will be randomized to receive a lateral sagittal approach for Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
89257524|NCT04764591|Active Comparator|Costoclavicular approach|Patients in this group will be randomized to receive a costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
89257525|NCT04752566|Experimental|Eculizumab|Participants will receive eculizumab.
89257526|NCT04752566|Placebo Comparator|Placebo|Participants will receive placebo.
89257527|NCT04743765|Experimental|Accelerated medical clearance and surgery|Accelerated medical clearance and targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
89257528|NCT04743765|No Intervention|Standard surgical care|Hip fracture repair and surgical care according to treating institution guidelines.
89257529|NCT04741074|Active Comparator|Semaglutide|This arm will receive semaglutide.
89257530|NCT04741074|Placebo Comparator|Placebo|This arm will receive placebo.
89257531|NCT04739319||Age-Related Macular Degeneration|Participants with Age-Related Macular Degeneration
89257532|NCT04731467|Experimental|Part A- Dose escalation of CM24 in combination with nivolumab|
89257533|NCT04731467|Experimental|Part C- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine|
89257534|NCT04731467|Experimental|Part C- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV|
89257535|NCT04731467|Experimental|Part D- Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine|
89257536|NCT04731467|Experimental|Part D- Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV|
89257537|NCT04731467|Active Comparator|Part D- Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine|
89257538|NCT04731467|Active Comparator|Part D- Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV|
89257539|NCT04727229|Experimental|Bupivacaine Hydrochloride|Injection of Bupivacaine Hydrochloride 0.5% near the stellate ganglion.
89257540|NCT04727229|Placebo Comparator|Normal Saline Solution|Injection of Normal Saline near the stellate ganglion
89257541|NCT04727151|Experimental|TAC01-HER2|Lymphodepletion followed by TAC01-HER2 as a single IV infusion, with a potential for a second dose administration.
89257542|NCT04727151|Experimental|TAC01-HER2 plus pembrolizumab|Lymphodepletion followed by TAC01-HER2 as a single IV infusion, followed by pembrolizumab administration.
89257543|NCT04719780|Active Comparator|Waitlist Control Group (CBT)|Individuals in this arm (n=44) are provided with a transdiagnostic cognitive-behavioural treatment for depression and anxiety (MoodGym) that has been empirically validated after their 15-week wait period is complete.
89257544|NCT04719780|Experimental|EFIT Group|Individuals in the EFIT Group (n=44) will receive 12-15 sessions of EFIT in order to treat their symptoms of depression and anxiety.
89257545|NCT04716153|Experimental|Interventional|"Patients in the interventional arm will follow a multifactorial sensory rehabilitation program focused on smell and taste that integrates several non-drug interventions, which are part of the current recommendations: program of workshops at the technical center, hydration of the mucous membranes with daily (3 times a day) liposomal sprays (LipoSaliva® and LipoNasal) between V0 and V1, presentation of visual dishes.~The workshops will take place at the frequency of one session of 2 hours per week and will last for 3 weeks. Each session will accommodate a minimum of 2 participants. The program will include 3 workshops on olfactory rehabilitation and taste rehabilitation.~Exercises (taking up the themes discussed) will be carried out at home between 2 workshops."
89257546|NCT04716153|Other|Control|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified.~Patients in the control group will be able to benefit from the rehabilitation workshops if they wish at the end of the study."
89257547|NCT04716127|Experimental|Women 50 to 65 years with no regular cervical cancer screening|Women aged 50 to 65 years with no cervical smear or no gynecological examination for more than three years, attending the mobile unit for breast cancer screening in the Department of Hérault, or the Medical and Social Care Center in the Department of Aude.
89257548|NCT04715399||Cross-sectional|
89257549|NCT04715399||Longitudinal|
89257550|NCT04715386||Group 1- StrataXRT|
89257551|NCT04714723|Active Comparator|Programmed smartphone intervention group|Subjects will receive programmed-smartphone lifestyle intervention
89257552|NCT04714723|Experimental|Programmed smartphone plus dietitian intervention group|Subjects will receive programmed-smartphone plus dietitian lifestyle intervention
89257553|NCT04713072|Experimental|ABY-035 40 mg|40 mg ABY-035 SC
89257554|NCT04713072|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
89257555|NCT04713072|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 16 weeks
89257556|NCT04710498|Experimental|Atezolizumab|Subjects will receive neoadjuvant atezolizumab intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 (+/- 3 days) of each 21-day cycle for a total of 3 doses prior to surgery, unless there is clinical or radiographic evidence of disease progression.
89257557|NCT04708756|Experimental|Intervention Group A|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
88804914|NCT01351753|Experimental|Metformin + Topiramate + Orlistat|
88804915|NCT01351753|Placebo Comparator|Placebo|
89257558|NCT04708756|Experimental|Intervention Group B|Patients receive the Collabree mobile phone application with a specific set of functions and standard care.
89257559|NCT04708756|No Intervention|Control Group|Patients will not receive the Collabree application and will continue to receive standard care.
89257560|NCT04708054|Experimental|Treatment (venetoclax, busulfan, fludarabine, cladribine)|Patients receive venetoclax PO QD on days -22 to -3, busulfan IV over 3 hours on days -20, -13, -6, -5, -4, and -3, and fludarabine phosphate IV over 1 hour and cladribine IV over 2 hours on days -6 to -3 in the absence of disease progression or unacceptable toxicity. Patients then undergo stem cell transplantation over 1-2 hours on day 0.
89257561|NCT04702854|Experimental|Experimental|Measure of cutaneous melanomas by ultrasound biomicroscopy
89257562|NCT04662359|Other|Ultrasound Assessment of Rheumatoid Arthritis Severity|All patients will receive an ultrasound scan to assess the severity of their arthritis. This scan will then be placed in their medical record to allow their rheumatologist to utilize the scan when making treatment recommendations.
89257563|NCT04645602|Experimental|Lenvatinib + Pembrolizumab|"Participants will take:~Lenvatinib - At a pre-determined dose, 1x daily during each 3 week study cycle up to 35 cycles/2 years~Pembrolizumab - At a pre-determined dose, 1x on Day 1 of each 3 week study cycle up to 35 cycles/2 years~Participants will be given a drug diary and asked to document information in the drug diary about the study treatment.~Participants will be asked to check their blood pressure 3x every week and document in a supplied diary.~Participants will be followed up to one (1) year after study treatment."
89257564|NCT04645147|Experimental|EBV gp_350 Ferritin Vaccination|Adult participants with or without prior EBV infection will receive 3 doses of vaccine
88804916|NCT01353079|Experimental|Short Ragweed Pollen Allergenic Extract|
89257565|NCT04627766|Experimental|Monitored children|PICU Children that will be monitored with the device
89257566|NCT04610671|Experimental|Participants Receiving CG0070 & Nivolumab|Both CG0070 (x 6 instillations) and nivolumab (x 2 doses) will be administered at their single-agent dose and schedule.
89257567|NCT04608032|Experimental|Ecological Cognitive training program for schizophrenia spectrum disorder [ECo-Sz]|To inform the patient about cognitive impairments and their repercussions ; to train the patient in problem-solving skills through exercices ; to implement strategies in daily life. Duration : two month. Frequency : Two one hour individual sessions and one hour of at-home training per week. Modalities : pen and papers exercices (tools, token, cards, maps and chessboard). Modules : Psychoeducation, Attention, Memory, Executive functions, Social cognition and metacognition, Functional impairments
89257568|NCT04608032|Active Comparator|[THoR] Recovery-Oriented Therapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' and functional impact, social skills, motivation and the regulation of sleep and daily activities
89257569|NCT04603014|Experimental|Interdialytic peritoneal ultrafiltration|Will receive incremental interdialytic peritoneal ultrafiltration with a 10% dextrose solution, twice a week for three consecutive weeks
89257570|NCT04593472|Experimental|SHARE|"SHARE components include: 1) a letter from the practice introducing the initiative, 2) access to a designated person (medical assistant, social worker, nurse, or lay person) trained to lead advance care planning discussions, 3) person-family agenda-setting to align perspectives about the role of the caregiver and stimulate discussion about goals of care, and 4) education about communication and available resources, including a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor, a blank easy to complete advance directive, and facilitated registration to the patient portal (for patient and caregiver participants) to extend electronic interactions and information access to family."
89257571|NCT04593472|Placebo Comparator|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
89257573|NCT04579757|Experimental|Surufatinib and tislelizumab (dose escalation_Part 1)|In Part 1 (dose escalation), surufatinib and will be administered orally (PO) once daily (QD) and tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).
89257574|NCT04579757|Experimental|Surufatinib and tislelizumab (indication specific_Part 2)|In Part 2, the indication-specific expansion portion of the study, patients will receive surufatinib at the Recommended Phase 2 Dose (RP2D) dose selected in Part 1 with 200 mg tislelizumab IV, Q3W
89257575|NCT04579679|Experimental|Surufatinib|"Cohorts A, B, and C: oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1~Cohort D:~Surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day and single doses of drug cocktail on Day-2 and Day 15 Cycle 1"
89257576|NCT04577963|Experimental|Part 1|Approximately 6-12 patients with locally advanced or metastatic solid tumors will be enrolled to receive fruquintinib in combination with tislelizumab and assessed for DLTs during the 28-day DLT observation period
89257577|NCT04577963|Experimental|Part 2|"Patients will be enrolled to one of the following expansion cohorts:~Cohort A: TNBC (immuno-oncology [IO]-treated in the metastatic setting)~Cohort B: TNBC (IO-Naïve in the metastatic setting)~Cohort C: EC~Cohort D: MSS CRC"
89257578|NCT04533555|Experimental|Universal genetic testing|Detection of genetic risk using a broad panel of cancer risk genes.
89257579|NCT04533555|Active Comparator|Standard|We will refer a subset of patients who meet guideline criteria based on age, cancer type, and family history, for genetic counseling and testing.
89257580|NCT04533373|Experimental|Neurotized Patients|Neurotization will be performed at the time of reconstruction.
89257581|NCT04533373|No Intervention|Non-Neurotized Patients|No Neurotization will be performed at the time of reconstruction.
89257582|NCT04530123|Experimental|Cohort 1, Group A: Placebo + Placebo + TAK-101 2 mg/kg|Following a single-day 3 gram (g) oral run-in gluten challenge, participants will receive TAK-101 placebo-matching intravenous (IV) infusion dose, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 milligram per kilogram (mg/kg) will be given 23 weeks after the second dose at approximately Week 24.
88804917|NCT01353079|Placebo Comparator|Glycero-COCAs|
88804918|NCT00104234|Other|rhASB/rhASB|N-acetylgalactosamine 4-sulfatase
88804919|NCT00104234|Other|Placebo/rhASB|
89257583|NCT04530123|Experimental|Cohort 1, Group B: TAK-101 2 mg/kg + Placebo + TAK-101 2 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24.
89257584|NCT04530123|Experimental|Cohort 1, Group C: TAK-101 2 mg/kg + TAK-101 2 mg/kg + TAK-101 2 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 2 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24.
89257585|NCT04530123|Experimental|Cohort 2, Group D: Placebo + Placebo + TAK-101 2 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 2 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
89257586|NCT04530123|Experimental|Cohort 2, Group E: TAK-101 4 mg/kg + Placebo + TAK-101 4 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 4 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
89257587|NCT04530123|Experimental|Cohort 2, Group F: TAK-101 4 mg/kg + TAK-101 4 mg/kg + TAK-101 4 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 4 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 4 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1.
89257588|NCT04530123|Experimental|Cohort 2, Group G: TAK-101 1 mg/kg + TAK-101 1 mg/kg + TAK-101 1 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24 (1 mg/kg may not be needed based on review of Cohort 1 data). Cohort 2 would start based on the results of Cohort 1.
89257589|NCT04530123|Experimental|Cohort 2, Group D: Placebo + Placebo + TAK-101 1 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 placebo-matching IV infusion, once each on Days 1 and 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open the second cohort at the 4 mg/kg dose level i.e. if 4mg/kg Groups E and F are not opened.
89257590|NCT04530123|Experimental|Cohort 2, Group E: TAK-101 1 mg/kg + Placebo + TAK-101 1 mg/kg|Following a single-day 3 g oral run-in gluten challenge, participants will receive TAK-101 1 mg/kg, IV infusion once on Day 1 followed by TAK-101 placebo-matching IV infusion, once on Day 8, followed by 12 g/day gluten for 3 days followed by 6 g/day gluten for 3 days starting at Week 2. Participants will then undergo single-day 3 g gluten challenges at Weeks 8, 14, and 20. A third IV infusion dose of TAK-101 1 mg/kg will be given 23 weeks after the second dose at approximately Week 24. Cohort 2 would start based on the results of Cohort 1. This group would be opened only if it is decided not to open the second cohort at the 4 mg/kg dose level i.e. if 4mg/kg Groups E and F are not opened.
89257591|NCT04516772|Other|Visian TICL|STAAR Visian Toric implantable collamer lens (TICL) for the correction or reduction of myopia with astigmatism.
89257592|NCT04501861|Active Comparator|The use of vasopressin compared with norepinephrine|The investigator hypothesize that the use of vasopressin compared with norepinephrine induces a lower mPAP-to-MAP ratio, in cardiac surgical patients with and without pulmonary hypertension who require intraoperative vasopressor support.
89257593|NCT04501861|Active Comparator|The use of norepinephrine compared with vasopressin|The investigators will compare GLS between patients who received norepinephrine versus vasopressin intraoperatively.
88804920|NCT01303939|Other|Glaucoma Patients|Patients who were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
89257594|NCT04498598|Experimental|A/Z Airway|Patients under general anesthesia for surgical procedures who need airway management for ventilation.
89257595|NCT04495439|Other|Treatment with ISS Sleeve|The biocompatible, resorbable ISS sleeve is used for augmentation to enhance screw anchorage. It is melted into the trabecular bone structure of the osteoporotic vertebra using ultrasound. A standard pedicle screw is inserted into the sleeve.
89257596|NCT04495439|Other|Treatment with PMMA|The bone cement Polymethylmethacrylat (PMMA) that is injected into the osteoporotic vertebra.PMMA augmentation of pedicle screws is done using standard cannulated and perforated pedicle screws. The cancellous bone surrounding the screw is enhanced with PMMA bone cement to increase screw anchorage.
89257597|NCT04491058||Carpal tunnel syndrome patients|Subjects with unilateral or bilateral carpal tunnel syndrome
89257598|NCT04491058||Healthy|Subjects without carpal tunnel syndrome
89257599|NCT04474470|Experimental|Dose escalation of NT219 as a single agent|
89257600|NCT04474470|Experimental|Dose escalation of NT219 in combination with ERBITUX®|
89257601|NCT04474470|Experimental|Expansion cohort of NT219 in combination with ERBITUX®|
89257602|NCT04474080|Experimental|Virtual Peer Support Platform|"The intervention program content will be informed by the BASICS-a guide for supporting resilience against burnout, developed by the Ontario Medical Association Physician Health Program, as well as the Person-Environment-Occupation (PEO) model, a transactive approach to modelling occupational performance issues in the field of Occupational Therapy. The BASICS highlights six fundamental domains will underlie the focus of group therapy sessions, where participants will be encouraged to consider how they may incorporate healthy physical and emotional practices both on their own (Person), and during the practice of medicine (Occupation), in addition to identifying barriers to adopting these practices within the healthcare environment (Environment)."
89257603|NCT04474080|Active Comparator|Control period|Residents will continue with their regular academic day activities during the allotted intervention time.
89257604|NCT04469296|No Intervention|control arm|In the control arm, patients will continue their usual diet without further recommendation.
89257605|NCT04469296|Experimental|"specific diet arm Ketogenic arm"|In the specific diet arms, the study diet will be calculated with a dietician, for the ketogenic diet, an iso-caloric ketogenic will be proposed and explained to the patient Each diet will be respected by the patient during 9 days +/- 1 day.
89257606|NCT04469296|Experimental|"specofoc diet arm protein restricted diet"|"In the specific diet arms, the study diet will be calculated with a dietician, for the protein restricted diet, a 20% protein restriction as compared to the usual diet will be calculated and the diet will be explained to the patient.~Each diet will be respected by the patient during 9 days +/- 1 day."
89257607|NCT04467749|Experimental|Suspension Wheel|Participants will be given a set of in-wheel suspension wheels to use in their normal daily routine for three months.
89257608|NCT04467567|Experimental|patients treated with lutathera|Patients undergoing treatment with Lutathera® and who accept to participate in the study, regardless of the cycle of treatment, 1, 2, 3 or 4.
89257609|NCT04460794|Experimental|Ballet-inspired workout programme (Group A)|Participants will continue their usual activities and exercises, and in addition, receive an 8-week home-based programme delivered by trained volunteers via hybrid on-site and virtual contacts, and supported by volunteer healthcare professionals. A self-directed resource package will be developed.
89257610|NCT04460794|Other|Usual care (Group B)|Control participants will continue their usual activities and exercises during the study period. In addition, they will be provided with an information sheet about recommendations with pictorial demonstrations on basic stretching and leg exercises for stroke survivors.
89257611|NCT04437745|Experimental|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
89257612|NCT04437745|No Intervention|Control|No Intervention
89257613|NCT04436107|Experimental|Part 1 : Zanubrutinib + Lenalidomide|"Zanubrutinib for up to 48 months~Lenalidomide on Days 1 - 21 of each 28-Day cycle for up to 48 months"
89257614|NCT04436107|Experimental|Part 2 : Zanubrutinib+Lenalidomide|"Zanubrutinib for up to 48 months~Lenalidomide at the RP2D dose determined from Part 1 administered on Days 1 - 21 of each 28-Day cycle for up to 48 months"
89257615|NCT04432454|Experimental|Treatment|Women who have locally advanced or metastatic ER+/HER2- breast cancer and disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation
89257616|NCT04409223|Experimental|Famitinib|
89257617|NCT04409223|Active Comparator|Sunitinib|
89257618|NCT04392440|Experimental|intervention|
89257619|NCT04392440|Other|control|Usual care
89257620|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label) from Parent Study|Participants assigned to lebrikizumab Q2W (once every 2 weeks) arm will receive investigational product Q2W by subcutaneous (SC) injection.
89257621|NCT04392154|Experimental|Lebrikizumab Q2W (Blinded) from Parent Study|Participants assigned to lebrikizumab Q2W arm will receive investigational product Q2W by SC injection. Some participants will receive loading doses.
89257622|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label Addendum)|Participants enrolling in Open-Label Addendum will receive lebrikizumab Q2W by SC injection after loading doses.
89257623|NCT04392154|Experimental|Lebrikizumab Q4W|"Participants assigned to lebrikizumab Q4W (once every 4 weeks) arm will receive investigational product Q4W by SC injection.~Intervention assigned: Lebrikizumab balanced with Placebo to maintain the blind between treatment arms."
89257624|NCT04392154|Experimental|Lebrikizumab Q4W (Open-Label Extension Addendum)|Participants enrolling in Open-Label extension addendum will receive lebrikizumab Q4W by SC injection.
89257625|NCT04392154|Experimental|Lebrikizumab Q8W (Open-Label Extension Addendum)|Participants enrolling in Open-Label extension addendum will receive lebrikizumab Q8W by SC injection.
89257626|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label Extension Addendum)|Participants enrolling in Open-Label extension addendum will receive lebrikizumab Q2W by SC injection.
89257627|NCT04391920||COVID-19 ICU Patients|
89257628|NCT04380649|Experimental|ALS people with severe disability|
89257629|NCT04373317|Active Comparator|Pimavanserin 34mg|All participants assigned to pimavanserin will receive the FDA-approved dose of 34mg (equivalent to 40 mg pimavanserin tartrate) daily without titration; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability.
89257630|NCT04373317|Active Comparator|Quetiapine|"Quetiapine extended release will be titrated as shown in the following table. During the 8-week treatment phase, there is a maximum of 6 weeks for titration.~Titration Schedule~Visit/call Quetiapine Dose (Flexible)Quetiapine Notes Baseline visit (Visit 00)25 mg IR QHSAll participants must be up-titrated to at least 50 mg/day at week 1 Week 1 call (Visit 01)50 mg XR QHSUp-titration Week 3 visit (Visit 03)100 mg XR QHS (requiring two 50-mg quetiapine XR capsules)Up- or down-titration as appropriate based on psychosis symptoms and tolerability Week 5 visit (Visit 05)150 mg quetiapine XR QHSUp- or down-titration as appropriate based on psychosis symptoms and tolerability Week 6 call (Visit 06)200 mg quetiapine XR QHSUp- or down-titration as appropriate based on psychosis symptoms and tolerability"
89257631|NCT04330703||Cases|Children and adolescents referred for their first visit to the outpatient clinic at the Child and Adolescent Psychiatry Department (BUGL) (n=15) will be invited to participate.
89257632|NCT04330703||Contol|Age and sex-matched child from the same postal area (n=15).
89257633|NCT04330703||Syblings|Same parent siblings close in age to the study subjects (cases only) (+3y) (n=x)
89257634|NCT04328974||the lumbar CSF drainage group|We named the patients treated with the protocol and the lumbar CSF drainage as the lumbar CSF drainage group.
89257635|NCT04321031|Placebo Comparator|Placebo|participants will receive medication for 48 weeks
89257636|NCT04321031|Experimental|PF-06865571 25 milligrams (mg) twice daily (BID)|participants will receive medication for 48 weeks
89257637|NCT04321031|Experimental|PF-06865571 75 mg BID|participants will receive medication for 48 weeks
89257638|NCT04321031|Experimental|PF-06865571 150 mg BID|participants will receive medication for 48 weeks
89257639|NCT04321031|Experimental|PF-06865571 300 mg BID|participants will receive medication for 48 weeks
89257640|NCT04321031|Experimental|PF-06865571 (150 mg BID) + PF-05221304 (5 mg BID)|participants will receive medication for 48 weeks
89257641|NCT04321031|Experimental|PF-06865771 (300 mg BID) + PF-05221304 (10 mg BID)|participants will receive medication for 48 weeks
89257642|NCT04315324|Experimental|Treatment (AKR1C3-activated prodrug OBI-3424)|Patients receive AKR1C3-activated prodrug OBI-3424 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
89257643|NCT04310839||outpatient left laparoscopic colectomy|Left laparoscopic laparoscopic colectomy patient managed on an outpatient basis
89257644|NCT04300309|Experimental|artemether lumefantrine (2.5 mg:30 mg)|artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
89257645|NCT04293185|Experimental|bb1111|"Subjects will receive treatment with a single dose of Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis, transduced with BB305 lentiviral vector (LVV) encoding the human beta-A-T87Q globin gene.~Plerixafor mobilization and apheresis will also be used for collection of rescue cells."
89257646|NCT04291859|Experimental|Lu AF28996|"Participants will receive ascending oral doses of Lu AF28996 OD for 14 days (Day 1 to Day 14) in all OD Cohorts 1-4 (5). On Day 15, the participant will initiate down-titration of Lu AF28996 as per Investigator's judgement.~For the BID Cohort A1, participants will receive Lu AF28996 BID for 24 days (Day 1 to Day 24), followed by down-titration as per Investigator's judgement.~For the BID Cohort A2, participants will receive Lu AF28996 BID for 39 days (Day 1 to Day 39), followed by down-titration as per Investigator's judgement.~For Part B BID Cohorts B1 and B2, participants will receive Lu AF28996 BID for up to 49 days, followed by down-titration as per Investigator's judgement. For Part C TID Cohorts C1 and C2, participants will receive Lu AF28996 for up to 49 days, followed by down-titration as per Investigator's judgement."
89257647|NCT04291261|Other|Extracorporeal photopheresis (ECP) with Uvadex|Patients in this single Arm study all receive the intervention consisting of ECP with Uvadex plus the standard of care treatment which consists of systemic corticosteroids 2mg/kg. Response to treatment will be evaluated on day 28. Patients will receive study treatment till day 56 and thereafter be followed until 1 year.
89257648|NCT04290364||Prospective cohort|Patients newly diagnosed with pancreatic cancer included in the prospective part of the study
89257649|NCT04290364||Retrospective cohort|Patients diagnosed with pancreatic cancer before early palliative care was introduced (historical control patients)
89257650|NCT04271540|Experimental|Subjects treated with Tildrakizumab|Informed consent will be obtained from study participants willing to participate in MiNIMA. Study participants will then undergo the baseline rest/stress cardiac PET scan along with echocardiography. The final PET scan and echocardiogram will occur at 6 months after the intervention.
89257651|NCT04262154|Experimental|Metastatic Prostate Cancer|Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
89257652|NCT04228276|Experimental|Active rTMS|Receive active rTMS
89257653|NCT04228276|Sham Comparator|Sham rTMS|Receive sham rTMS
89257654|NCT04221503|Experimental|Cohort A|Cohort A is for subjects with recurrent glioblastoma who do not have clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort A will initiate and continue TTFields therapy for 5-7 days prior to starting niraparib.
89257655|NCT04221503|Active Comparator|Cohort B|Cohort B is for subjects with recurrent glioblastoma who have a clinical indication for surgical resection of the recurrent tumor. Subjects in Cohort B will receive TTFields for 5-7 days prior to planned surgical resection, undergo surgical resection, resume TTFields postoperatively, and initiate niraparib 5- 7 days after starting TTFields postoperatively.
89257656|NCT04218539|Experimental|Placebo/Placebo|Subjects will receive a dose of placebo, followed by a dose of placebo approximately 7 days later.
89257657|NCT04218539|Experimental|Placebo/Psilocybin|Subjects will receive a dose of placebo, followed by a dose of psilocybin approximately 7 days later.
89257658|NCT04218539|Experimental|Psilocybin/Placebo|Subjects will receive a dose of psilocybin, followed by a dose of placebo approximately 7 days later.
89257659|NCT04218539|Experimental|Psilocybin/Psilocybin|Subjects will receive a dose of psilocybin, followed by a dose of psilocybin approximately 7 days later.
89257660|NCT04201834|Experimental|Risperidone|Participants will initiate risperidone 0.5 mg nightly the day after the baseline visit. Dose assessment will occur at pre-specified intervals during the titration phase (week 2, 3, 4, 6, 7). The investigator will increase the dose by 0.5 mg at the week 2, week 3, week 4, and week 6 visits until either optimal chorea benefit has been obtained, an intolerable adverse event occurs, or the maximum allowable dose (3.0 mg) is reached.
89257661|NCT04200937||BSC Penile Prothesis Recipients|Men for whom BSC Penile Prothesis is recommended.
89257662|NCT04178018|Experimental|Transvaginal photoacoustic imaging/ultrasound|"Baseline transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging for all participants enrolled~Once the surgeon has surgically removed the ovary(ies), they will be imaged with the photoacoustic imaging/ultrasound~For the exploratory outcome measure for high risk participants (approximately 50 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally at 6 months, 12 months, 18 months, 24 months, and at the time of surgery~For the exploratory outcome measure for high risk participants (approximately 10 participants), the transvaginal ultrasound (standard of care) followed by transvaginal ultrasound and photoacoustic imaging will be performed additionally every 2 weeks at follicular phase and at the luteal phase for 3 months"
89257663|NCT04171284|Experimental|SCT-I10A plus Docetaxel|SCT-I10A 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W. Maximum of 6 cycles
89257664|NCT04171284|Active Comparator|Placebo puls docetaxel|Placebo 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W Maximum of 6 cycles
89257665|NCT04171284|Experimental|Maintenance therapy of SCT-I10A|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: SCT-I10A 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
89257666|NCT04171284|Placebo Comparator|Maintenance therapy of Placebo|Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: Placebo 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.
89257667|NCT04159987|Experimental|Spinal muscular atrophy patient|
89257668|NCT04151667|Experimental|A: Daratumumab & Dexamethasone|All participants will receive 1800 mg in 15 ml Daratumumab by subcutaneous injection weekly and be given 20 mg of Dexamethasone orally once a week for 2 months. Patients who receive a partial response or better will continue on this arm.
89257669|NCT04151667|Experimental|B: Daratumumab, Dexamethasone and Lenalidomide|Participants who have less than a partial response to Arm A may have Lenalidomide added to their treatment. Lenalidomide will be given orally on days 1-21 of each 28 day treatment cycle.
89257670|NCT04151667|Experimental|C: Daratumumab, Dexamethasone and Bortezomib|Participants who have less than a partial response to Arm A may have Bortezomib added to their treatment. Bortezomib will be given weekly in subcutaneous injections at a starting dose of 1/3 mg/m^2 Days 1,8 and 15 of each 28 day treatment cycle.
89257671|NCT04127786|Experimental|Group1:VRVg2 Cohort1(C1)-1ry Series:pediatric & adult participants-Booster:102 adult participants|"VRVg-2, 3 injections at Day 0, Day 7, and Day 28~Booster dose of VRVg-2 for a subset of 102 adult participants at Month 12"
89257672|NCT04127786|Active Comparator|Group 2:Verorab C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants|"Verorab, 3 injections at Day 0, Day 7, and Day 28~Booster dose of VRVg-2 for a subset of 34 adult participants at Month 12"
89257673|NCT04127786|Active Comparator|Group 3:Imovax Rabies C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants|"Imovax Rabies, 3 injections at Day 0, Day 7, and Day 28~Booster dose of VRVg-2 for a subset of 34 adult participants at Month 12"
89257674|NCT04127786|Experimental|Group 4:VRVg-2 Cohort 2(C2)-1ry Series:Adult participants-Booster Phase:138 adult participants|"VRVg-2, 2 injections at Day 0 and Day 7~Booster dose of VRVg-2 for a subset of 138 adult participants between Month 24 up to Month 36"
89257675|NCT04127786|Active Comparator|Group 5:Verorab C2-1ry Series:adult participants-Booster Phase:46 adult participants|"Verorab, 2 injections at Day 0 and Day 7~Booster dose of VRVg-2 for a subset of 46 adult participants between Month 24 up to Month 36"
89257676|NCT04127786|Active Comparator|Group 6:Imovax Rabies C2-1ry Series:adult participants-Booster Phase:46 adult participants|"Imovax Rabies, 2 injections at Day 0 and Day 7~Booster dose of VRVg-2 for a subset of 46 adult participants between Month 24 up to Month 36"
89257677|NCT04098523|Other|Epidemiologic screening|All subjects are screened by duplex ultrasound for abdominal aortic aneurysm (AAA) and carotid artery stenosis (CAS). A questionnaire is completed to obtain information on demographic information, risk factors as well as prior treatment for AAA or CAS and current medication. No treatment is given.
89257678|NCT04071951|Experimental|Pharmacist Arm|Pharmacist-Led Medication Reconciliation, Regimen Review, and Adherence and Literacy Assessment and Counseling
89257679|NCT04071951|No Intervention|Usual Care|Patients in this study will receive usual care. Clinically-indicated services, including pharmacist services, may be provided to control group patients.
89257680|NCT04059471|Active Comparator|Standard Dose|Yellow fever vaccine, Institut Pasteur, standard dose as release by manufacturer will be administered subcutaneously once.
89257681|NCT04059471|Experimental|Fractional dose (1000 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 1000IU/dose and administered subcutaneously once.
89257682|NCT04059471|Experimental|Fractional dose (500 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 500IU/dose and administered once.
89257683|NCT04059471|Experimental|Fractional dose (250 IU/dose)|Yellow fever vaccine, Institut Pasteur, will be titrated to about 250IU/dose and administered once.
89257684|NCT04038138|Experimental|Patient with facioscapulohumeral muscular dystrophy|
89257685|NCT04030169|Experimental|Experimental: MDMA-assisted psychotherapy|Two sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
89257686|NCT04024917|Experimental|Coherence cardiac|
89257687|NCT04024917|Active Comparator|Standard care|
89257688|NCT04024111|Experimental|KONTAKT(c)|A social skills group training
89257689|NCT04024111|Active Comparator|Art group|A social Art group
89257690|NCT03956979|Experimental|JM-010 group A|Group A (JM-010 dose fixed combination drug(tablet)) +Placebo 2
89257691|NCT03956979|Experimental|JM-010 group B|Group B (JM-010 8/0.8mg dose fixed combination drug(tablet)) + Placebo 1
89257692|NCT03956979|Placebo Comparator|Placebo|Double-dummy - 2 tablets = Placebo 1 +Placebo 2
89257693|NCT03922776|Experimental|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~at diagnosis, before chemotherapy (pre-CT)~after chemotherapy (post-ct)~Intervention : Collection of two blood samples (5mL)~before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~and then, after chemotherapy (post-CT), up to 3 months after enrollment"
89257694|NCT03915366|No Intervention|Standard of Care (SoC)|"Standard treatment for severe pneumonia and pneumonia in HIV-infected infants:~Ceftriaxone 80 mg/k/day or Ampicillin plus Gentamicin ampicillin 50 mg/kg, or benzylpenicillin 50,000 unit/kg im/iv every six hours plus Gentamicin 7.5 mg/kg/im or iv once a day Cotrimoxazole trimethoprim (TMP) 8mg/kg/dose + sulfamethoxazole (SMX) 40mg/kg/dose three times daily Prednisolone 2mg/kg during 7 days, plus 1mg/kg other 7 days, plus 0.5 mg/kg for 7 days"
89257695|NCT03915366|Experimental|Valganciclovir plus SoC|Treatment for cytomegalovirus (CMV) Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, and Standard or Care as described in Control Group
89257696|NCT03915366|Experimental|Tuberculosis Treatment plus SoC|"Treatment for tuberculosis Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Plus Standard of Care described in the Control Group~Doses of tuberculosis treatment:~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
89257697|NCT03915366|Experimental|Tuberculosis Treatment plus Valganciclovir plus SoC|"Treatment for CMV and for tuberculosis. Fixed-dose dispersible tablet of rifampicin, isoniazid, pyrazinamide (75/50/150 mg) Fixed-dose dispersible tablet of rifampicin/isoniazid (75/50 mg) Ethambutol 100 mg dispersible tablet Valganciclovir (powder for suspension, 50 mg/mL) oral, 16 mg/kg/12 hours for 15 days, Plus Standard of Care described in the Control Group~Doses of tuberculosis treatment:~Isoniazid 10 mg/kg (range 7-15 mg/kg)/day; maximum dose 300 mg/day for 6 months.~Rifampicin 15 mg/kg (range 10-20 mg/kg)/day; maximum dose 600 mg/day for 6 months.~Pyrazinamide 35 mg/kg (range 30-40 mg/kg)/day for 2 months. Ethambutol 20 mg/kg (range 15-25 mg/kg)/day for 2 months."
89257698|NCT03914742|Experimental|Phase 1: Dose Finding|"Recurrent IDH1/2-mutant grade II-III glioma: BGB290: Days 1-28, 60 mg PO BID TMZ: Days 1-28, 20 QD starting dose~TMZ de-escalated treatment schedule if necessary (days 1-21; days 1-14; days 1-7) BGG held constant at 60mg PO BID"
89257699|NCT03914742|Experimental|Phase 2: Arm A Alkylator-resistant|"Grade II-III: Recurrent IDH1/2-mutant glioma (WHO grades II/III) who have failed TMZ AND another alkylator~BGB290 + TMZ at dose combination established in Phase 1"
89257700|NCT03914742|Experimental|Phase 2: Arm B NOT Alkylator-resistant|"Grade II-III:Recurrent IDH1/2-mutant glioma (WHO grades II/III) Failed TMZ OR another alkylator;~>/=12 months since last treatment~BGB290 + TMZ at dose combination established in Phase 1"
89257701|NCT03914742|Experimental|GBM Arm|Exploratory grade IV patients only BGB290 at Ph II dose for 7 days pre-surgery Progressed following RT + Chemo
89257702|NCT03914742|Experimental|Surgical Arm|Recurrent IDH1/2-mutant glioma (WHO grade II-IV) eligible for re-resection BGB-290: 60mg PO BID for 6 days AND day once day of surgery (day 7)
89257703|NCT03893695|Experimental|metastatic HCC|"Stage one - Dose de-escalation:~Each dose cohort will assess toxicity within the 28 days following the first dose of nivolumab and GT90001.~Stage two- the expansion cohort:~14 patients will be enrolled to the expansion cohort where one or no DLT takes place in planned study cohort."
89257704|NCT03879538|Active Comparator|The nitrous oxide group|Nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
89257705|NCT03879538|Placebo Comparator|The Control Group|Control group will receive 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
89257706|NCT03853109|Experimental|Cohort 1|Cohort 1
89257707|NCT03853109|Experimental|Cohort 2|Cohort 2
89257708|NCT03853109|Experimental|Cohort 3|Cohort 3
89257709|NCT03853109|Experimental|Cohort 4|Cohort 4
89257710|NCT03853109|Experimental|Cohort 6|Cohort 6
89257711|NCT03853109|Experimental|Cohort 7|Cohort 7
89257712|NCT03853109|Experimental|Cohort 8|Cohort 8
89257713|NCT03853109|Experimental|Cohort 9|Cohort 9
89257714|NCT03843359|Experimental|Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort|
89257715|NCT03843359|Experimental|Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort|
89257716|NCT03828799|Experimental|Folfirinox-R|Folfirinox + regorafenib
89257717|NCT03817814||Women with Breast Cancer|This is a cross-sectional survey of young women with breast cancer (YWBC) who received a consultation with an MSK Fertility Nurse Specialist before starting cancer treatment.
89257718|NCT03779113|Experimental|Treatment|All patients to received study drug (HMPL-523)
89257719|NCT03742895|Experimental|Olaparib|Participants with HRRm or HRD-positive advanced cancer will receive oral olaparib, 300 mg twice daily (BID).
89257720|NCT03663725|Experimental|Intensified protocol|Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ
89257721|NCT03663725|Active Comparator|Stupp protocol|Concomitant Temozolomide (TMZ) Adjuvant TMZ
89257722|NCT03648840|Other|Higher lifetime alcohol drinking|Half of the participants will have a history of higher lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
89257723|NCT03648840|Other|Lower lifetime alcohol drinking|Half of the participants will have a history of lower lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
89257724|NCT03648840|Other|Resting state connectivity|Some participants will also complete a functional magnetic resonance imaging (fMRI) session to determine resting state connectivity. All participants in this Arm will have completed both of the iv alcohol self-administration sessions (Aversive cue, Neutral cue).
89257725|NCT03641677|Experimental|EVLP|
89257726|NCT03641677|Active Comparator|Control|
89257727|NCT03639194|Experimental|Part A: ABBV-011 Dose Escalation|ABBV-011 via intravenous administration at various doses and dosing regimens until the maximum tolerated dose and/or the recommended Part B dose(s) is declared.
89257728|NCT03639194|Experimental|Part B: ABBV-011 Dose Expansion|ABBV-011 via intravenous administration at dose regimen(s) that will not exceed the maximum tolerated dose determined in Part A.
89257729|NCT03639194|Experimental|Part C: ABBV-011 + Budigalimab Escalation and Expansion|ABBV-011 via intravenous administration at various doses and dosing regimens starting at least 1 dose level below the recommended single-agent dose of ABBV-011 for Part B plus Budigalimab via intravenous administration at fixed doses and various dosing regimens.
89257730|NCT03639194|Experimental|Part D: ABBV-011 Dose Evaluation for Japan|ABBV-011 via intravenous administration will be administered every 3 weeks (Q3wk), on Day 1 of each 21-day cycle or alternate dosing regimens.
89257731|NCT03631849|Experimental|Patients with peri-implantitis|
89257732|NCT03631849|Active Comparator|Patients without peri-implantitis|
89257733|NCT03622749|Active Comparator|Patients|Individuals with Bipolar 1 Disorder
89257734|NCT03622749|No Intervention|Controls|Healthy controls
89257735|NCT03611881|Experimental|Short, Short, Present|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
89257736|NCT03611881|Experimental|Short, Long, Present|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
89257737|NCT03611881|Experimental|Long, Short, Present|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
89257738|NCT03611881|Experimental|Long, Long, Present|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
89257739|NCT03611881|Experimental|Short, Short, Absent|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
89257740|NCT03611881|Experimental|Short, Long, Absent|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
89257741|NCT03611881|Experimental|Long, Short, Absent|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
89257742|NCT03611881|Experimental|Long, Long, Absent|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
89257743|NCT03603912|No Intervention|Control|Written educational literature on healthy eating and exercise guideline
89257744|NCT03603912|Experimental|Metformin|Metformin ER up to 750 mg twice daily
89257745|NCT03603912|Experimental|Lifestyle/Risk Factor Modification|Lifestyle/Risk Factor Modification (LRFM): Diet/nutrition, exercise, and risk factor modification
89257746|NCT03603912|Experimental|Metformin + LRFM|Metformin ER up to 750 mg twice daily + Lifestyle/Risk Factor Modification (LRFM) diet/nutrition, exercise, and risk factor modification
89257747|NCT03603912|No Intervention|No Atrial Fibrillation|Written educational literature on healthy eating and exercise guideline
89257748|NCT03601078|Experimental|Cohort 1: BB2121 in relapsed and refractory multiple myeloma participants|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
89257749|NCT03601078|Experimental|Cohort 1b: BB2121 with talquetamab in relapsed and refractory multiple myeloma participants|
89257750|NCT03601078|Experimental|Cohort 2a: BB2121 in multiple myeloma with Autologous stem cell transplantation participants|
89257751|NCT03601078|Experimental|Cohort 2b: BB2121 in multiple myeloma without Autologous stem cell transplantation participants|
89257752|NCT03601078|Experimental|Cohort 2c: BB2121 in multiple myeloma participants with inadequate response post ASCT|
89257753|NCT03601078|Experimental|Cohort 3: BB2121 with lenalidomide maintenance in newly diagnosed multiple myeloma|
89257754|NCT03599830|Other|Cognitive test passations|3 neuropsychological passations over a period of 6 months.
89257755|NCT03594994|No Intervention|Control|Normal sleep habits < 7h
89257756|NCT03594994|Experimental|Sleep Extension|Extend time-in-bed by one hour
89257757|NCT03590171|No Intervention|Arm HR-A|Induction: Backbone ALL R3
89257758|NCT03590171|Experimental|Arm HR-B|Induction: Backbone ALL R3 + Bortezomib
89257759|NCT03553836|Experimental|Pembrolizumab|Participants receive 200 mg pembrolizumab (2 mg/kg for a maximum of 200 mg in pediatric participants) by intravenous (IV) infusion once every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to ~1 year) in Part 1. Participants who complete the initial treatment of 17 cycles of pembrolizumab and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to ~2 years) in Part 2.
89257760|NCT03553836|Placebo Comparator|Placebo|Participants receive saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in Part 1. Participants who complete the initial treatment of 17 cycles of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to ~2 years) in Part 2.
89257761|NCT03544632|Experimental|Acellular Adipose Tissue (AAT)|This open-label, phase II, dose-escalation study will be conducted in human subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14).
89257762|NCT03539744|Experimental|Arm 1 VenDex|Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
89257763|NCT03539744|Active Comparator|Arm 2 PomDex|Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
89257764|NCT03493568|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Table|switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)
89257765|NCT03493568|Active Comparator|Dolutegravir 50 mg plus one RTI (at label dose)|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
89257766|NCT03488719|Experimental|Cohort 1 (Tesofensine 0.25mg)|Tesofensine 0.25 mg once daily for 23 days (loading dose of 1.0 mg for the first 3 days), plus a single dose of 25 mg, 50 mg or 100 mg metoprolol extended release (ER) in random order on Day 15, Day 18 and Day 21, respectively.
89257767|NCT03488719|Experimental|Cohort 2 (Tesofensine 0.50mg)|Tesofensine 0.50 mg once daily for 23 days (loading dose of 2.0 mg for the first 3 days), plus a single dose of 25 mg, 50 mg or 100 mg metoprolol extended release (ER) in random order on Day 15, Day 18 and Day 21, respectively.
89257768|NCT03488719|Experimental|Cohort 3 (Tesofensine 0.75mg)|Tesofensine 0.75 mg (0.25 mg + 0.50 mg) once daily for 23 days (loading dose of 2.0 mg [4 tablets of 0.50 mg] for the first 5 days), plus a single dose of 25 mg, 50 mg or 100 mg metoprolol extended release (ER) in random order on Day 15, Day 18 and Day 21, respectively.
89257769|NCT03488225|Experimental|Treatment (hyper-CVAD, inotuzumab ozogamicin)|See detailed description.
89257770|NCT03480477||Pelvic Floor Disorders Group|Will collect patient information from new patients who present to the Urogynecology Clinic
89257771|NCT03480477||Control Group|Will collect patient information from patients who present to Gynecologic Clinic for their annual examination
89257772|NCT03480477||Chronic Pelvic Pain Group|Will collect patient information from patients who present to their Chronic Pelvic Pain Clinic appointment
89257773|NCT03467854||VV ECMO|Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.
89257774|NCT03465098|Experimental|enrolled patients|All enrolled patients will be received a strict low carbohydrate (< 3gr/day of carbohydrate) and 12h fasting before 18F-FDG PET/CT exam and 24h after a 18F-FDG PET/CT preceded by a low carbohydrate diet with 12h fasting
89257775|NCT03444701|Experimental|E7130 (2-Week Regimen)|Part 1 (Cycle 1; 28 days): The first cohort of 3 participants will receive 25 micrograms per meters squared (μg/m^2) of E7130, on Day 1 and Day 15 as an intravenous infusion. If a drug-related Grade 2 or higher toxicity excluding clinically insignificant events is not observed in the initial cohort, dose-limiting toxicities (DLTs) will be evaluated in successive dose levels with single participants until such a toxicity is observed. Once the maximum tolerated dose (MTD) will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 2-week or in a 3-week regimen based on the evaluations in Part 1.
89257776|NCT03444701|Experimental|E7130 (3-Week Regimen)|Part 1 (Cycle 1; 21 days): On Day 1, participants will receive E7130 at (-1) a lower dose than the dose at which the first DLT was observed in the 2-week regimen. Once the MTD will be determined. Part 2: Participants with squamous cell carcinoma of the head and neck and urothelial carcinoma will be evaluated at the dose level determined in Part 1 in a 3-week or in a 2-week regimen based on the evaluations in Part 1.
89257777|NCT03444168||Candidate for Lumbar Spine Surgery|Participants have been designated to be a candidate for lumbar spine surgery to treat chronic low back and/or leg pain and you have agreed to proceed with the surgery.
89257778|NCT03444168||Lumbar Failed Back Surgery Syndrome|Participants have been diagnosed with having lumbar failed back surgery syndrome and have persistent and moderate-to-severe low back and/or leg pain for more than 6 months after a lumbar spine surgery.
89257779|NCT03444168||Healthy Volunteer|Participants are a healthy volunteer wishing to participate in a research study.
89257780|NCT03416413|Active Comparator|Ambulatory Phlebectomy|Ambulatory phlebectomy of varicose vein tributaries
89257781|NCT03416413|Active Comparator|Foam Sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
89257782|NCT03413995|Experimental|Rucaparib 600 mg BID, continuous dosing|Rucaparib 600mg by mouth twice daily, continuous dosing
89257783|NCT03407638|Active Comparator|PROUD Intervention|Primary care clinics randomized to the PROUD Intervention will implement the Massachusetts (MA) Model of collaborative care for opioids use disorders (OUDs). The PROUD trial provides financial support to cover the nurse case manager (NCM) salary and technical assistance for the duration of the study, but the health systems-not investigators-implement the MA Model as part of quality improvement, and the health system and its clinicians provide all clinical care.
89257784|NCT03407638|No Intervention|Usual Primary Care|Clinics randomized to usual primary care do not receive any resources or support from the study but are free to improve opioid use disorder (OUD) care in any way they choose.
89257785|NCT03402789|Experimental|Docosahexaenoic acid (DHA) arm|Participants will receive a pill of docosahexaenoic acid 1,200mg daily in addition to 2 hours of daily eye patching of the affected eye.
89257786|NCT03402789|Placebo Comparator|Placebo arm|Participants will receive a placebo pill daily in addition to 2 hours of daily eye patching of the affected eye.
89257787|NCT03347760|Experimental|Experimental arm|All included patients wil receive 68Ga-dotatoc-PET/CT suspected acute myocarditis in first and an other 68Ga-dotatoc-PET/CT 6 months later
89257788|NCT03342664|Experimental|Artemis + Medical Management (MIS)|Minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management
89257789|NCT03342664|Active Comparator|Best Medical Management Alone (MM)|Best medical management alone per standard of care at treating institution
89257790|NCT03314688|Active Comparator|Usual Care Group|"Standardized breast cancer follow up care and materials regarding treatment (i.e., chemotherapy and endocrine therapy when relevant).~Lifestyle intervention books for breast cancer survivors at the end of the 2-year study. Women will also be offered a counselling session with a registered study dietician at the end of the study."
89257791|NCT03314688|Experimental|Dietary/Physical Activity Intervention|Eleven 30-min counseling sessions over six months (weekly, then biweekly, then monthly) with additional sessions in the latter 6 months (5 additional monthly sessions for a total of 16 sessions), timed with their oncology visit or via telephone if not coming in for oncology visit. Sessions focus on motivating health dietary choices and physical activity (home-based program).
89257792|NCT03311451|Other|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
89257793|NCT03306849||Regular menstrual cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
89257794|NCT03306849||Normoandrogenic anovulation|Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
89257795|NCT03306849||Hyperandrogenic anovulation|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
89257796|NCT03292887||Elaprase Treated|Participants with Hunters Syndrome received or receiving treatment with Elaprase as prescribed by their physician following locally approved prescribing information.
89257797|NCT03292887||Elaprase Non-Treated|Participants received no treatment for Hunters Syndrome.
89257798|NCT03292289|Experimental|Study process|Pre- and post-operative consultations. Stomatherapy consultation. Questionnaires
89257799|NCT03274479|Experimental|PBF-1129_40mg|
89257800|NCT03274479|Experimental|PBF-1129_80mg|
89257801|NCT03274479|Experimental|PBF-1129_160mg|
89257802|NCT03274479|Experimental|PBF-1129_320mg|
89257803|NCT03250923|Experimental|silver citrate complex and acemannan|This is a single arm open pilot trial. All participants will receive study drug.
89257804|NCT03244995|Experimental|Group I (CBMB program)|Patients undergo CBMB program consisting of 4-5 deep-breathing and meditation exercise sessions over 60 minutes and 2 weekly telephone calls over 15 minutes for 6 weeks. Patients also complete questionnaires regarding health, mood, sleeping habits, relationship, health care, work productivity, and quality of life.
89257805|NCT03244995|Active Comparator|Group II (waitlist control)|Patients complete questionnaires as in Group I. Patients may undergo CBMB program after completion of study.
89257806|NCT03227146|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
89257807|NCT03225144||Patients|patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols
89257808|NCT03198559|Experimental|Experimental|"Participants current ART regimen:~2 grams disulfiram by mouth per day for a total of 28 days~400mg vorinostat by mouth per day on days 8, 9,10 and days 22, 23, 24"
89257809|NCT03198325|Experimental|Interruption of antiretroviral therapy|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
89257810|NCT03188042|Experimental|rtACS Stimulation Group|
89257811|NCT03188042|Sham Comparator|Sham Intervention Group|Sham stimulation looks like rtACS, but is not active rtACS.
89257812|NCT03132454|Experimental|Arm I (palbociclib, sorafenib)|Patients receive palbociclib PO QD on days 1-28. Patients also receive sorafenib PO QD on days 1-28 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89257813|NCT03132454|Experimental|Arm II (palbociclib, decitabine)|Patients receive palbociclib as in Arm I. Beginning cycle 2, patients receive palbociclib PO QC on days 1-7 and decitabine IV QD over 1 hour on days 8-17 of cycle 2 and days 8-12 of cycles 3-8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89257814|NCT03132454|Experimental|Arm III (palbociclib, dexamethasone)|Patients receive palbociclib as in Arm I. Patients also receive dexamethasone PO QD or IV over 15-30 minutes on days 1-4 and 15-18 beginning on cycle 2. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89257815|NCT03113136|Active Comparator|Low wattage E cigarette device|
89257816|NCT03113136|Active Comparator|High wattage E cigarette device|
89257817|NCT03113136|Active Comparator|Usual brand cigarette|
89257818|NCT03107988|Experimental|Cohort A1 (Dose-finding)|Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be assigned at the time of study registration. The starting dose for cohort A1 is 45 mg/m2/dose
89257819|NCT03107988|Experimental|Cohort A2 (Adult and large BSA)|Lorlatinib will be given at the adult recommended phase 2 dose (RP2D) of 100 mg orally once daily continuously for 28 days.
89257820|NCT03107988|Experimental|Cohort B1 (Expansion)|Lorlatinib will be given orally once daily continuously for 28 days at the RP2D defined by cohort A1. This cohort will not begin enrollment until the recommended phase 2 dose is established from the dose escalation cohort A1.
89257821|NCT03107988|Experimental|Cohort B2 (Combined w/ chemotherapy)|Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
89257822|NCT03104517|Experimental|AMDC-USR (iltamiocel)|Autologous muscle-derived cells for urinary sphincter repair (AMDC-USR; generic name: iltamiocel) is the study product.
89257823|NCT03104517|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
89257824|NCT03059407|Other|Dog therapy only|Canine assisted therapy only during echocardiogram
89257825|NCT03059407|Other|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echocardiogram
89257826|NCT03059407|Other|Standard distraction technique only|Standard distraction techniques only during echocardiogram.
89257827|NCT03026517|Experimental|Dabrafenib, Trametinib & Phenformin|This is a multi-institution single-arm phase I trial with an expansion cohort at the MTD of Phenformin, in patients with metastatic BRAFV600E/K mutated melanoma. In the dose escalation phase, cohorts of patients will be treated with standard dose Dabrafenib (150 mg PO BID) plus Trametinib (2 mg PO QD) and increasing doses of Phenformin. In the dose-escalation phase of the trial, both patients who have already been treated with a BRAF and/or MEK inhibitor, and treatment-naïve patients will be eligible. The maximally tolerated Phenformin dose was determined to be 100 mg BID. The dose-expansion cohort will enroll up to 10 patients who are treatment- naïve for BRAF inhibitor. In this cohort, patients may be treated with any of the 3 FDA-approved BRAFi/MEKi combinations: dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib.
89257828|NCT03019003|Experimental|Oral Decitabine and Durvalumab|Oral decitabine (ASTX 727) will be administered alone in Cycle 1 and the combination of oral decitabine and durvalumab therapy will be given in Cycles 2-12.
89257829|NCT02995837||Obstructive Sleep Apnea Syndrome (OSAS)|"The study duration is estimated at 12-14 months approximately. However, this will depend on the timing of treatment as they will undergo testing pre- and post-OSAS treatment. Participation will entail a total of 8 visits including:~Pre-treatment - neurocognitive testing, and CBF during wakefulness testing duration is one full day. The CBF nighttime testing is one full night.~Post-treatment - Six to twelve weeks after clinically indicated surgical treatment, OSAS participants will have a repeat baseline polysomnogram (one full night) to assess for residual OSA. Six and twelve months after the surgical treatment, the sleep study with the nighttime CBF testing, as well as the daytime neurocognitive testing and CBF testing will be repeated to assess for changes."
89257830|NCT02995837||Controls|The study will include 7 total visits for controls: a baseline sleep study to ensure normalcy, three full days of neurocognitive testing and CBF testing (baseline, 6 and 12 months), and three sleep studies with CBF testing (baseline, 6 and 12 months). A daytime visit and one night time visit may be scheduled during a 24-hour period if the participant and family wish so. Otherwise, they will be scheduled on separate days.
89257831|NCT02990819|Other|Reduced intensity regimen|Conditioning regimen is dependent on patient diagnosis and age. Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care reduced intensity conditioning will include Busulfan, Fludarabine, Thiotepa followed by stem cell infusion.
89257832|NCT02990819|Other|Myeloablative regimen|"Conditioning regimen is dependent on patient diagnosis and age. Patients with chronic granulomatous disease or Wiskott-Aldrich syndrome will receive cyclophosphamide in lieu of thiotepa to ensure engraftment.~Myeloablative regimen with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Standard of care myeloablative regimen will include Busulfan, Fludarabine, Thiotepa, or Cyclophosphamide followed by stem cell infusion."
89257833|NCT02990819|Other|Immunotherapy|Conditioning regimen is dependent on patient diagnosis and age. Severe combined immunodeficiency (SCID) patients will be conditioned with immunotherapy only followed by stem cell transplant using the CliniMACs device to deplete alpha/beta T and CD19+ peripheral stem cells. Immunotherapy regimen will include anti-thymocyte globulin followed by stem cell infusion.
89257834|NCT02968004|Experimental|MOD-4023|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
89257835|NCT02968004|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
89257836|NCT02933827|Experimental|Low dose:|ELIXCYTE 8 mL (ADSC 6.4*10^7 cells in total)
89257837|NCT02933827|Experimental|Middle dose|ELIXCYTE 24 mL (ADSC 19.2*10^7 cells in total)
89257838|NCT02933827|Experimental|High dose|ELIXCYTE 40 mL (ADSC 32.0*10^7 cells in total)
89257839|NCT02868268||Relapsed/Refractory Neuroblastoma Pts|History of high risk neuroblastoma (NBL) according to Childrens Oncology Group (COG) risk classification with relapsed/progressive, refractory or persistent neuroblastoma. Archival or biopsied tumor specimens are provided for gene panel sequencing to subjects with potentially targetable genetic and/or immunologic biomarkers. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receiving this clinical report.
89257840|NCT02797184|Experimental|10mmol KNO3|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
89257841|NCT02797184|Experimental|20mmol KNO3|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
89257842|NCT02790853|Experimental|Diagnostic (multimodal imaging, biopsy)|Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.
89257843|NCT02767505|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
89257844|NCT02767505|Active Comparator|Gastric bypass|Laparoscopic Roux-en-Y gastric bypass
89257845|NCT02606045|Active Comparator|Group I|Subjects randomized to Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
89257846|NCT02606045|Active Comparator|Group II|Group II will receive Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
89257847|NCT02577406|Experimental|AG-221 plus Best supportive care (BSC)|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
89257848|NCT02577406|Active Comparator|Conventional care regimen (CCR)|Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
89257849|NCT02570984|Active Comparator|Active|omalizumab 0.016 mg/kg/IU total IgE
89257850|NCT02570984|Placebo Comparator|Placebo|looks like active drug
89257851|NCT02549937|Experimental|Escalation 50 mg|Escalation cohort at 50 mg/day
89257852|NCT02549937|Experimental|Escalation 100mg|Escalation cohort at 100 mg/day
89257853|NCT02549937|Experimental|Escalation 200 mg|Escalation cohort at 200 mg/day
89257854|NCT02549937|Experimental|Escalation 300 mg|Escalation cohort at 300 mg/day
89257855|NCT02549937|Experimental|Escalation 400 mg|Escalation cohort at 400 mg/day
89257856|NCT02549937|Experimental|Expansion|Subjects will receive RP2D surufatinib daily treatment continuously with every 28-day treatment cycle. Four expansion cohorts will enroll BTC, pNET, EP-NET, and STS patients, respectively.
89257857|NCT02512718|Experimental|Fish Oil Lipid Emulsion|1 g/kg intravenous fish oil lipid emulsion (Omegaven) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
89257858|NCT02512718|Active Comparator|Soybean Oil Lipid Emulsion|1 g/kg intravenous soybean oil lipid emulsion (SOLE) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
89257859|NCT02500108||Treated with domperidone|Patients who received a new prescription for domperidone (ATC A03FA03) in the year prior to the index date.
89257860|NCT02500108||Unexposed (reference) group|Patients with no prescription for domperidone in the year prior to the index date.
89257861|NCT02438722|Experimental|Arm I (afatinib dimaleate, cetuximab)|Patients receive afatinib dimaleate PO QD on days 1-28 and cetuximab IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89257862|NCT02438722|Active Comparator|Arm II (afatinib dimaleate)|Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89257863|NCT02422498|Experimental|Concurrent Cisplatin & Radiation Therapy|
89257864|NCT02347891|Experimental|Belimumab + Standard of Care|"Patients in this arm will be given belimumab with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will continue to receive belimumab during the open label phase of the study (week 40 - week 64)"
89257865|NCT02347891|Active Comparator|Placebo + Standard of Care|"Patients in this arm will be given a placebo with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will receive belimumab during the open label phase of the study (week 40 - week 64)."
89257866|NCT02315586||1|Participants will be enrolled at the NIH Clinical Center.
89257867|NCT02315586||2|IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program
89257868|NCT02304783|Active Comparator|Oral Piroxicam|Piroxicam : 20 mg per pill; one pill per day for five days associated with placebo (1pill) (taken separately)
89257869|NCT02304783|Placebo Comparator|Placebo|Placebo: two pills per day for five days (taken separately)
89257870|NCT02304783|Active Comparator|paracetamol|paracetamol: 2000mg per day for five days two pills taken separately)
89257871|NCT02298348|Other|Sorafenib and Cyclophosphamide/Topotecan|Sorafenib and Cyclophosphamide/Topotecan with growth factor support.
89257872|NCT02282969||Lung Cancer Screening Decision Aids|Participants are asked to look over education materials about lung cancer screening, and interviewed. Some participants will look at a video patient decision aid, with an interview and questionnaire completion. Some participants complete lung cancer screening knowledge questionnaire at first visit, and then again in one month.
89257873|NCT02222909|Experimental|Intervention CBOs|"Will receive co-developed IT intervention developed together with intervention group community based members. Set of primarily web based tools to improve connection with clients, Johns Hopkins Medicine and one another, referrals, and volunteer services."
89257874|NCT02222909|No Intervention|Control CBOs|Community Based Organizations that are being followed for data collection only for the period of one year
89257875|NCT02208375|Experimental|Arm I (olaparib, vistusertib)|CONTINUOUS AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 5-28 of course 1 and alone on days -3 to -1 of week -1) and vistusertib PO BID on days 1-28 (alone on days 1-4 of week 1).
89257876|NCT02208375|Experimental|Arm II (olaparib, vistusertib)|INTERMITTENT AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 3-28 on course 1 and alone on days -5 to -3 of week -1) and vistusertib 4 PO BID for 2 days on and 5 days off (alone on days 1-2 of week 1).
89257877|NCT02208375|Experimental|Arm III (olaparib, capivasertib)|INTERMITTENT AZD5363 DOSING: Patients receive olaparib PO BID on days 1-28 (on days 5-28 of course 1 and alone on days -3 to -1 of week -1) and capivasertib PO BID for 4 days on and 3 days off (alone on days 1-4 of week 1).
89257878|NCT02140554|Experimental|Group A|"Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.~*No Longer Recruiting"
89257879|NCT02140554|Experimental|Group B|"Group B1:~Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.~*No Longer Recruiting~Group B2:~Plerixafor mobilization and apheresis will be used for collection of rescue cells and exploratory manufacturing development. Subjects will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.~*No Longer Recruiting"
89257880|NCT02140554|Experimental|Group C|"Plerixafor mobilization and apheresis will be used for collection of rescue cells, and subjects will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by plerixafor mobilization and apheresis transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene.~*No Longer Recruiting"
89257881|NCT02119611|Other|Single-arm|Therapy
89257882|NCT02091518|Experimental|MRI|"Add-On Research Patients will include patients who are scheduled for a routine clinical MRI who meet the eligibility requirements for this protocol. Protocol participation will consist of an add-on research. MRI scan, which will be performed any point during of the routine clinical MRI scan.~Volunteers will be subjects expressing interest in participation and who meet the eligibility requirements for this protocol. No contrast enhanced research MRIs including gadolinium-based or other contrast agents will be performed in volunteers."
89257883|NCT02090218|Active Comparator|I-Gel|I-Gel supraglottic airway device
89257884|NCT02090218|Active Comparator|LTS, ETI or other airway practice|Laryngeal tube, endotracheal tube or other current airway management practice
89257885|NCT02030964|Experimental|DFMO, Celecoxib, Cyclophosphamide & Topotecan|Reconstituted DFMO powder by mouth for 14 days and celecoxib capsule by mouth daily in each cycle. Cyclophosphamide and Topotecan IV on days 8-12 in cycle 1 and days 1-5 of cycles 2-17. Patients may continue for up to 17 cycles as long as therapy is tolerated (no DLT) and disease progression does not occur (SD or better). *Cycle 1 will include a 7 day lead-in with DFMO and celecoxib to deplete tumor polyamines.
89257886|NCT02023164|Experimental|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
89257887|NCT02023164|Active Comparator|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
89257888|NCT01995708|Experimental|Arm 1 Vaccine|This is a prospective, two-arm phase I randomized trial. Patients will be accrued only from and treated at MSKCCand The Rockefeller University/Center for Clinical & Translational Science . The study will assess autologous LCs presenting CT7, MAGE-A3, and WT1 after electroporation with CT7, MAGE-A3, and WT1 mRNA. Twenty patients will accrue to the study and ten will receive vaccines at 9x10^6 LCs per dose (i.e., combination of 3x10^6 CT7 mRNA-electroporated LCs + 3x10^6 MAGE-A3 mRNA-electroporated LCs + 3x10^6 WT1 mRNA-electroporated LCs) and another ten who will not receive any LC vaccines but will otherwise undergo identical cytoreduction, ASCT, and standard supportive care. At approximately 3 months after ASCT and as deemed clinically appropriate, patients will start lenalidomide maintenance therapy, which is now standard to delay disease progression.
89257889|NCT01995708|Active Comparator|Arm 2 control|Patients receive standard of care treatment after autologous stem cell transplant
89257890|NCT01959139|Active Comparator|Phase II: mFOLFIRINOX|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 1.5 hours on day 2, and 5-fluorouracil (5-FU) IV over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89257891|NCT01959139|Experimental|Phase II: mFOLFIRINOX + PEGPH20|Patients receive pegylated recombinant human hyaluronidase (PEGPH20) IV over 10 minutes on day 1 and oxaliplatin, leucovorin calcium, irinotecan hydrochloride, and 5-fluorouracil (5-FU) as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89257892|NCT01959139|Experimental|Phase I|PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours
89257893|NCT01927471||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles. We will aim to recruit 120 women in this category.
89257894|NCT01927471||Irregular menstrual cycles, no PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, without a pre-existing diagnosis of PCOS. We will aim to recruit 120 women in this category.
89257895|NCT01927471||Irregular menstrual cycles, with PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles with a pre-existing diagnosis of PCOS by a physician. We will aim to recruit 120 women in this category.
89257896|NCT01927432||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles.
89257897|NCT01927432||Irregular menstrual cycles|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.
89257898|NCT01884623|Experimental|Cetuximab|Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV
89257899|NCT01884623|Active Comparator|Methotrexate|Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV
89257900|NCT01859663||Women with a past diagnosis of PCOS|We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
89257901|NCT01859663||Women with a history of regular menstrual cycles|We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
89257902|NCT01859663||Women with a history of irregular menstrual cycles|We aim to recruit 120 women with a history of irregular menstrual cycles, and no previous diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
89257903|NCT01819480|Experimental|Transoral robotic surgery|Transoral robotic surgery
89257904|NCT01802814|No Intervention|SR-A|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.This randomization has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
89257905|NCT01802814|Active Comparator|SR-A + Epratuzumab|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab. This randomization has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
89257906|NCT01802814|No Intervention|SR-B|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab. This randomization has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
89257907|NCT01802814|Active Comparator|SR-B + Epratuzumab|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab. This randomization has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
89257908|NCT01766739|Experimental|GL-ONC1|This is an open-label, dose-escalating, non-randomized, single-center Phase I therapeutic study of GL-ONC1 originally administered intrapleurally as a single dose and now escalating to three consecutive daily doses in patients with a diagnosis (histologically or cytologically documented) of malignant pleural effusions.
89257909|NCT01602380|Experimental|faslodex+placebo|Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets
89257910|NCT01602380|Active Comparator|arimidex +placebo|Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)
89257911|NCT01511809|Experimental|Atazanavir/ritonavir monotherapy|Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
89257912|NCT01511809|No Intervention|Atazanavir/ritonavir triple therapy|Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone
89257913|NCT01476566|Experimental|Educational intervention|A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented.
89257914|NCT01476566|No Intervention|Control group|
89257915|NCT01451476||Healthy females aged >=18|Healthy female volunteers of skin type I or II
89257916|NCT01439412|Experimental|Acupuncture and standard treatment|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
89257917|NCT01439412|Other|Standard treatment in general practice|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
88804921|NCT01303939|Other|Control Patients|Age, gender and race matched (to each glaucoma patient) group of healthy individuals with no ocular diseases with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
89257918|NCT01134575|Experimental|Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
89257919|NCT01134575|Experimental|Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin)|CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
89257920|NCT01134575|Experimental|Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
89257921|NCT01132326|Experimental|Droxidopa|Open-Label Droxidopa
89257922|NCT00150709|Experimental|N159 PBO/LEV|Subjects had previously participated in study N159 in which they had received Placebo (PBO).
89257923|NCT00150709|Experimental|N159 LEV/LEV|Subjects had previously participated in study N159 in which they had received Levetiracetam (LEV).
89257924|NCT00150709|Experimental|N01010+N151 LEV/LEV|Subjects had previously participated in study N01010 or study N151 in which they had received Levetiracetam (LEV).
89257925|NCT00150709|Experimental|N01052 LEV/LEV|Subjects had previously participated in study N01052 in which they had received Levetiracetam (LEV).
89257926|NCT00092235||Cohort 1|Patients who have undergone an allogeneic stem cell transplant and are diagnosed with cGVHD
89257927|NCT00092235||Cohort 2|Pediatric patients who have undergone an allogeneic stem cell transplant and are diagnosed with cGVHD
89257928|NCT00092235||Cohort 3|Patients who have undergone an allogeneic stem cell transplant and choose to submit biopsy, blood and urine samples only
89257929|NCT00092235||Cohort 4|Patients who have undergone an allogeneic stem cell transplant and are not diagnosed with cGVHD
89257930|NCT00044122||Adult Relatives|Relatives of patient with mastocytosis
89257931|NCT00044122||Adults with Mastocytosis|Adults with documented mastocytosis
89257932|NCT00044122||Pediatric Patients with Mastocytosis|Pediatric patients with documented mastocytosis
89257933|NCT00044122||Pediatric Relatives|Pediatric relatives of patients with mastocytosis
89257934|NCT00018889||1|Patients age 2 years and older with a clinical or suspected diagnosis of movement disorder
89257935|NCT03986606|Experimental|Open-label Dose Escalation and Expansion Study of PSB205|"Part 1 (Dose escalation): PSB205 will be administered in sequential cohorts of 3 to 6 subjects each receiving 1 of 5 doses of PSB205 on day 1 of every 21-day cycle (3 weeks) via IV infusion using a standard 3+3 dose escalation design. Dose escalation will continue until an MTD is reached.~Part 2 (Dose Expansion): The clinical anti-tumor effects of PSB205 will be tested at the recommended Phase 2 dose (RP2D) determined during the dose-escalation phase in subjects from three different solid tumor cohorts."
89257936|NCT01057550|Active Comparator|Autologous Fascial Sling|Retropubic, bottom up autologous sling
89257937|NCT01057550|Active Comparator|TVT|Standard retropubic TVT
89257938|NCT01057550|Active Comparator|Pelvicol|Retropubic mid urethral sling made from Pelvicol
89257939|NCT01061216|Experimental|Intradermal insulin infusion (ID)|
89257940|NCT01061216|Active Comparator|Subcutaneous insulin infusion (SC)|
89257941|NCT00314574|Experimental|Xolair|"The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
89257942|NCT00314574|Placebo Comparator|placebo|"The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
89257943|NCT01064154|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
89257944|NCT01064154|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
89257945|NCT00314340|Active Comparator|extended-release morphine|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On one of three study dates, subjects received ER morphine tablets, 45 mg (Mallinckrodt Pharmaceuticals, St. Louis, MO). The dose of ER morphine sulfate (45 mg) was selected because of its approximate equianalgesic effect to the dose of hydrocodone-acetaminophen (30/925 mg)."
89257946|NCT00314340|Active Comparator|hydrocodone|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On the day of the study session, patients received hydrocodone 30 mg plus N-acetyl-para-aminophenol 975 mg (APAP;Qualitest Pharmaceuticals Inc, Huntsville, AL)."
89257947|NCT00314340|Placebo Comparator|placebo|Subjects received a placebo pill if randomized to this arm. Both opioid medications and the placebo were administered in identical capsules.
89257948|NCT00306852|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C
89257949|NCT00306852|Active Comparator|Implant|Baerveldt Implant
89257950|NCT00314262|Experimental|Erlotinib & Celecoxib|
89257951|NCT00333866|Experimental|1|
89257952|NCT00333866|Experimental|2|
89257953|NCT00333866|Experimental|3|
89257954|NCT00333866|Placebo Comparator|4|
89257955|NCT00324740|Experimental|Treatment (vorinostat and isotretinoin)|Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89257956|NCT00333788|Experimental|Certolizumab pegol 400 mg|400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
89257957|NCT00324116|Experimental|Active|
89257958|NCT00332696|Experimental|Octreotide|Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
89257959|NCT00332696|Placebo Comparator|Placebo|Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
89257960|NCT00313716|Active Comparator|Epo1 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger of 10gm/dl
89257961|NCT00313716|Active Comparator|Epo1 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
89257962|NCT00313716|Active Comparator|Epo2 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 10gm/dl
89257963|NCT00313716|Active Comparator|Epo2 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
89257964|NCT00313716|Placebo Comparator|Placebo and TT10|Placebo administration and transfusion threshold 10 gm/dl
89257965|NCT00313716|Placebo Comparator|Placebo and TT7|Placebo administration and transfusion threshold 7 gm/dl
89257966|NCT00313170|Experimental|1|Fulvestrant 250 mg (intramuscular injection 250 mg)
89257967|NCT00313170|Experimental|2|Fulvestrant 250 mg (+ 250 mg loading regimen)
89257968|NCT00313170|Experimental|3|Fulvestrant 500 mg (intramuscular injection 500 mg)
89257969|NCT00332462|Experimental|Cyclosporine (Sandimmun®)|Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
89257970|NCT03986450|Active Comparator|ERAS group|Patients in this group will receive ERAS protocol preoperatively, perioperatively and postoperatively.
89257971|NCT03986450|No Intervention|Control|This group of patients will not receive ERAS care and will undergo a standard laparoscopic hysterectomy.
89257972|NCT00324038|Experimental|buprenorphine transdermal system|Buprenorphine transdermal 7 day analgesic patch
89257973|NCT00324038|Active Comparator|codeine paracetamol tablets|codeine paracetamol combination tablets
89257974|NCT03984110|Experimental|Combination of Ozurdex and Eylea|Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
89257975|NCT03984110|Active Comparator|Eylea Monotherapy|Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
89257976|NCT01057628|Experimental|ASP1941 group|oral
89257977|NCT01057628|Placebo Comparator|placebo group|oral
89257978|NCT03967821||Intervention|
89257979|NCT00331760|Other|Endometrial Cancer: IMRT|Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks.
89257980|NCT00331760|Other|Cervical Cancer: IMRT + Chemotherapy (cisplatin)|Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks and concurrent weekly cisplatin 40 mg/m^2 for five weeks.
89257981|NCT00225147|Experimental|100 IU/kg rhC1INH|100 IU/kg Recombinant human C1 inhibitor
89257982|NCT00225147|Experimental|50 IU/kg rhC1INH|50 IU/kg Recombinant human C1 inhibitor
89257983|NCT00225147|Placebo Comparator|Saline|
89257984|NCT00313014|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
89257985|NCT00313014|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
89257986|NCT00313014|Experimental|Oxycodone Immediate-Release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
89257987|NCT01075659|Experimental|LHN1548|Two single doses of an experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
89257988|NCT01075659|Active Comparator|2019706|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
89257989|NCT01075659|Active Comparator|2020005|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
89257990|NCT01077453|Experimental|Arm I (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.
89257991|NCT01077453|Experimental|Arm II (1.0 mg letrozole)|Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
89257992|NCT01077453|Experimental|Arm III (0.25 mg letrozole)|Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
89257993|NCT01077453|Experimental|Arm IV (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO once daily for 6 months.
89257994|NCT00157209|Experimental|Tecemotide (L-BLP25) plus Best Supportive Care (BSC)|
89257995|NCT00157209|Active Comparator|Best Supportive Care (BSC) Alone|
89257996|NCT00312858|Active Comparator|1|Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
89257997|NCT00312858|Active Comparator|2|Arm 2: ProQuad™ 0.5 mL injection (2 doses ~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.
89257998|NCT03972189|Experimental|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
89257999|NCT00312702|Experimental|10µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
89258000|NCT00312702|Experimental|50µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
89258001|NCT01060878|Experimental|Dose I|
89258002|NCT01060878|Experimental|Dose II|
89258003|NCT01060878|Experimental|Dose III|
89258004|NCT01060878|Placebo Comparator|Placebo|
89258005|NCT00156819|Active Comparator|Fluticasone|Participants continued fluticasone (100 microgram twice daily) treatment.
89258006|NCT00156819|Experimental|Montelukast|Participants were changed to Montelukast (5 or 10 mg each night).
89258007|NCT00156819|Experimental|Fluticasone plus salmeterol|Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
89258008|NCT02532894|Experimental|Esmoke|Inhaling e-cigarette vapor
89258009|NCT02532894|No Intervention|Control|
89258010|NCT01077531|Active Comparator|Otelixizumab|Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
89258011|NCT01077531|Placebo Comparator|Placebo|Matching placebo for intravenous infusion
89258012|NCT03825042|Experimental|Food supplement|A mix of bacopa, lycopene, astaxanthin and vitamin B12 Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
89258013|NCT03825042|Placebo Comparator|Placebo|Inactive compound Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
89258014|NCT01075737||Subjects with Multiple Sclerosis|Subjects with diagnosed MS according to the revised Mc Donald criteria 2005; aged >21 years.
89258015|NCT01075737||Caregivers|Caregivers (aged >21 years) for MS subjects.
89258016|NCT01060956|Active Comparator|Reporting on two bacteria in urine culture|The microbiology laboratory will report on the isolation and susceptibilities of two different bacteria in urine culture
89258017|NCT01060956|Placebo Comparator|"reporting mixed growth"|The microbiology laboratory will report on mixed growth in urine culture
89258018|NCT00129987|Experimental|Nurse group|An initial consultation of up to 45 min offered either by a practice based primary care nurse, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
89258019|NCT00129987|Experimental|Lay educator group|An initial consultation of up to 45 min offered either by a lay educator, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
89258020|NCT00224133|Experimental|Silodosin|Silodosin 8 mg per day with food
89258021|NCT00224055|Experimental|IV iron|Sodium ferric gluconate
89258022|NCT00224055|Active Comparator|oral iron|ferrous sulfate
89258023|NCT03966573|Other|Evaluating function, Radiographic imaging, Forms|"Tests for lower extremity function~Evaluating arthritis of hip and knee, leg length discrepancy and axis deviation radiographically~Evaluating quality of life, function and pain by forms"
89258024|NCT00150345|Experimental|Early treatment|Voriconazole starts within 18 hours of onset of fever intravenously with a loading dose of 6 mg/kg q12h for the first two doses followed by 4 mg/kg q12h (maintenance dose). Switched to oral treatment (200 mg BID) is possible after at least four days. Treatment will be ended if the patient is afebrile (< 38.0 °C) for 7 days with neutrophil counts < 500/µL, or if the patient is afebrile (< 38.0 °C) for 2 days with neutrophil counts > 500/µL.
89258025|NCT00150345|Other|Deferred treatment|"Treatment with voriconazole (for dosage see early treatment arm) is initiated only if a patient is persistently febrile on day 5 after the onset of fever despite antibiotic treatment."
89258026|NCT01077609||Allergic rhinitis (AR) & Flixonase|Patients initiating treatment for allergic rhinitis on intranasal fluticasone propionate
89258027|NCT01077609||AR & prescription for intranasal steroid other than Flixonase|Random sample of patients initiating treatment for allergic rhinitis with an intranasal steroid other than Flixonase
89258028|NCT00223977|Experimental|Sodium ferric gluconate complex 125 mg|125 mg sodium ferric gluconate weekly x 8 weeks
89258029|NCT00223977|Experimental|Sodium ferric gluconate complex 250 mg|250 mg sodium ferric gluconate complex weekly x 4 weeks
89258030|NCT00223977|Active Comparator|Oral iron|325 mg ferrous sulfate three times daily x 8 weeks
89258031|NCT00148941|Experimental|SB213503 lot 1 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 1 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
89258032|NCT00148941|Experimental|SB213503 lot 2 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 2 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
89258033|NCT00148941|Experimental|SB213503 lot 3 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 3 of SB213503 vaccine and a dose of M-M-R II vaccine.~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
89258034|NCT00148941|Active Comparator|Infanrix + IPOL + M-M-R Group|Subjects aged 4 to 6 years received a dose of Infanrix and a dose of IPOL vaccines separately and a dose of M-M-R II vaccine. Infanrix was administered by deep intramuscular injection in the upper left deltoid. IPOL was administered subcutaneously in the lower right deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid.
89258035|NCT01073553|Experimental|Arm 1|
89258036|NCT01073553|Active Comparator|Arm 2|
89258037|NCT00148317|Experimental|Treatment Arm|
89258038|NCT01077765|Experimental|treatment|treatment
89258039|NCT00323882|Experimental|MDX-010|
89258040|NCT00331682|Experimental|Treatment (docetaxel and alvocidib)|Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89258041|NCT00323492|Experimental|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization
89258042|NCT00323492|Active Comparator|Maintain Baseline Regimen|Maintain baseline regimen
89258043|NCT00323492|Experimental|Delayed Truvada|Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
89258044|NCT00323492|Experimental|All Truvada|Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)
89258045|NCT00331136|Experimental|Group A (Tablets)|Pyronaridine artesunate 6:2 mg/kg. The tablet strength is 48:16 mg oral PA, with the number of tablets depending on body weight.
89258046|NCT00331136|Experimental|Group B (Tablets)|Pyronaridine artesunate 9:3 mg/kg. The tablet strength is 72:24 mg oral PA, with the number of tablets depending on body weight.
89258047|NCT00331136|Experimental|Group C (Tablets)|Pyronaridine artesunate 12:4 mg/kg. The tablet strength is 96:32 mg oral PA, with the number of tablets depending on body weight.
89258048|NCT00331136|Experimental|Group D (Granules)|Pyronaridine artesunate 9:3 mg/kg. The sachet of granules strength is 60:20 mg PA, with the number of sachets depending on body weight, and is administered as a suspension with water.
89258049|NCT03983798||Simulation training in psychiatry|Convenient sample of 72 voluntary medical students, allocated among 6 groups of around 12 students, will be recruited at Paris Descartes, Paris Diderot and Brest Universities between september of 2018 and June of 2019.
89258050|NCT01057706|Experimental|9 months of chiropractic care and exercise|chiropractic, exercise
89258051|NCT01057706|Active Comparator|3 months of chiropractic care and exercise|chiropractic, exercise
89258052|NCT00323414|Active Comparator|Polyunsaturated fatty acid (Opti-EPA)|Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks
89258053|NCT00323414|Placebo Comparator|Placebo|Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks
89258054|NCT03984032|Experimental|LMA Protector Cuff Pilot|
89258055|NCT03984032|Active Comparator|LMA Supreme|
89258056|NCT01325324|Other|Study group|Study group
89258057|NCT03983642|Experimental|Intervention group|The intervention group received a session of 40min for an 8 weeks' period. Both games requested the participants to stand on a balance board in front of the television, without shoes, while trying to control their avatars by shifting their body weights.
89258058|NCT03983642|No Intervention|Control group|Participants in the control group were followed-up by an assessor, who made sure that they will not get involved in any type of training program during the eight weeks' period of the trial.
89258059|NCT00330668|Experimental|All rhIGF-1 Subjects|"All subjects entering MS306 began recombinant human insulin-like growth factor-1 (rhIGF-1) twice a day (BID) treatment. Each subject treated in MS301 had an MS306 starting dose that was based on their dose at the completion of MS301 (i.e. subcutaneous injections of rhIGF-1 at 40, 80, or 120 micrograms [μg]/ kilogram [kg] BID).~MS301 untreated control subjects were randomised in MS306 in a 1:1 ratio to a dose of either 80 or 120 μg/kg rhIGF-1 BID.~Following Protocol Amendment 1, all subjects received either 80 or 120 μg/kg rhIGF-1 BID until the implementation of Protocol Amendment 2.~Following Protocol Amendment 2, all subjects were first switched to receive subcutaneous injections of 160 μg/kg rhIGF-1 once a day (QD), followed by individual dose-escalation first to 200 μg/kg rhIGF-1 QD and subsequently to a targeted maximum dose of 240 μg/kg rhIGF-1 QD. Subjects were treated QD until the early termination of the study."
89258060|NCT00306384|Experimental|Alogliptin 12.5 mg|Alogliptin 12.5 tablet, orally, once daily for up to 4 years.
89258061|NCT00306384|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablet, orally, once daily for up to 4 years.
89258062|NCT01062750|Other|adipose tissue derived stromal cells|
89258063|NCT03980964|Experimental|Active NMES|Treatment arm receives an active NMES therapy including a conductive garment with NMES therapy, electrodes, and mobile app.
89258064|NCT03980964|Sham Comparator|Inactive NMES|Control arm receives inactive NMES therapy including a conductive garment (no NMES and no electrodes), and mobile app.
89258065|NCT01062828||Gestational age < 32 weeks|Premature infants with gestational age between <32 weeks regardless of birth weight
89258066|NCT01062906|Placebo Comparator|Control|The control group receives intravenous fentanyl at the induction of anesthesia followed by a continuous infusion of lidocaine during the surgery.
89258067|NCT01062906|Active Comparator|Lidocaine|The Lidocaine group will receive lidocaine as bolus at the induction of anesthesia followed by a continuous infusion of lidocaine until the end of surgery
89258068|NCT00305604|Active Comparator|1|sitagliptin
89258069|NCT00305604|Placebo Comparator|2|Placebo
89258070|NCT03979014|Experimental|Vaccinated Arm|Add vaccine
89258071|NCT03979014|No Intervention|Control|No intervention
89258072|NCT01064232|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
89258073|NCT01064232|Active Comparator|Risperdal|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
89258074|NCT03979092|Experimental|IP-ACLS|
89258075|NCT03979092|Other|Waitlist|
89258076|NCT00501059|Experimental|Acetylsalicylic acid (Aspirin, BAYE4465)|Participants received 1 tablet of enteric-coated acetylsalicylic acid [100 milligram (mg)] orally once daily.
89258077|NCT00501059|Placebo Comparator|Placebo|Participants received 1 tablets of matching placebo orally once daily.
89258078|NCT00344318|Experimental|Synflorix 1 Group|Subjects aged 6-12 weeks from the Philippines receiving Synflorix™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ vaccines at 6, 10, 14 weeks of age.
89258079|NCT00344318|Experimental|Synflorix 2 Group|Subjects aged 6-12 weeks from Poland receiving Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 2, 4, 6 months of age.
89258080|NCT00344318|Active Comparator|Prevenar 1 Group|Subjects aged 6-12 weeks from the Philippines receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ at 6, 10, 14 weeks of age.
89258081|NCT00344318|Active Comparator|Prevenar 2 Group|Subjects aged 6-12 weeks from Poland receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ at 2, 4, 6 months of age.
89258082|NCT00323258|Experimental|Intervention|Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
89258083|NCT00323258|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations. Enrolled patients in the usual care arm were not disclosed to the community pharmacy until the end of the study period when refill records were requested.
89258084|NCT00322868|Experimental|Pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda
89258085|NCT01016717|Active Comparator|Omeprazole|Patients will be taking omeprazole tablets 40 mg QD for 30 days
89258086|NCT01016717|Active Comparator|Pantoprazole|Patients will be taking Pantoprazole tablets 40 mg QD for 30 days
89258087|NCT01016795|Active Comparator|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
89258088|NCT01016795|Active Comparator|Cyclophosphamide and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
89258089|NCT04260737|No Intervention|Standard Care|The control group will receive standard care for localized prostate cancer, i.e., information from their doctor and an information brochure.
89258090|NCT04260737|Experimental|Decision Aid + Standard Care|"The intervention group will receive standard care and intervention that includes a website with the Decision Aid which covers the following:~An overview about prostate cancer;~An overview of different treatment options (e.g. surgery and active surveillance)~The pros and cons of different treatment options (e.g., physical, emotional, social).~A value clarification exercise that is designed to assist participants to weigh the pros and cons of each prostate cancer management option."
89258091|NCT00343382|Experimental|Arm I|Patients receive oral pilocarpine hydrochloride once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
89258092|NCT00343382|Experimental|Arm II|Patients receive oral pilocarpine hydrochloride once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
89258093|NCT00343382|Placebo Comparator|Arm III|Patients receive oral placebo once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
89258094|NCT00343382|Placebo Comparator|Arm IV|Patients receive oral placebo once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
89258095|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Sequential Days|
89258096|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Same Day|
89258097|NCT00329420|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
89258098|NCT00329420|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
89258099|NCT00329420|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
89258100|NCT03983174|Experimental|Drainage seton with flap|Drainage seton will be put around the external anal sphincter with mucosal advancement flap
89258101|NCT03983174|Experimental|EAS sparing seton|Rerouting of the seton around the internal anal sphincter sparing the external sphincter will be done
89258102|NCT00329108|Experimental|A|
89258103|NCT00329108|Active Comparator|B|
89258104|NCT01061294|Other|Advanced CustomVue™ iLASIK procedure|
89258105|NCT00329030|Active Comparator|Rituxan/BEAM|Autologous transplantation using rituxan/BEAM
89258106|NCT00329030|Experimental|Bexxar/BEAM|Autologous transplantation using Bexxar/BEAM
89258107|NCT00328562|Experimental|Iressa and RT|"Iressa plus thoracic RT at the following dose levels:~Level 1: 42.0 Gy in 10 fractions of 4.2 Gy~Level 2: 50.4 Gy in 12 fractions of 4.2 Gy~Level 3: 63.0 Gy in 15 fractions of 4.2 Gy"
89258108|NCT00328172|Placebo Comparator|Placebo|Placebo tablets matching BI 1356
89258109|NCT00328172|Experimental|BI 1356 0.5 mg|BI 1356 dose 1 once daily
89258110|NCT00328172|Experimental|BI 1356 2.5 mg|BI 1356 dose 2 once daily
89258111|NCT00328172|Experimental|BI 1356 5.0 mg|BI 1356 dose 3 once daily
89258112|NCT00328172|Active Comparator|Metformin|Metformin
89258113|NCT02532920||Atopic dermatitis|Atopic dermatitis is diagnosis as Hanifin and Rajka from physician.
89258114|NCT01060748|Experimental|ACE527|"First cohort: ACE527 vaccine doses of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis.~Second cohort: ACE527 vaccine dose of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis."
89258115|NCT01060748|Placebo Comparator|Placebo vaccine|"First cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis.~Second cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis."
89258116|NCT01057784||Bariatric Surgery Patients|Patients undergoing bariatric surgery.
89258117|NCT01057784||Reproductive-Age Women - Bariatric Surgery Patients|This subgroup of patients will include 10 reproductive-age women.
89258118|NCT01061372|Placebo Comparator|Placebo|
89258119|NCT01061372|Experimental|Pregabalin 150 mg/day|
89258120|NCT01061372|Experimental|Pregabalin 300 mg/day|
89258121|NCT00328094|Experimental|CII, Continuous Insulin Infusion|Continuous intravenous insulin infusion to control glucose to <150 mg/dL in patients undergoing open peripheral vascular bypass surgery
89258122|NCT00328094|Active Comparator|IIB, Intermittent insulin boluses|Intermittent intravenous insulin insulin boluses to a blood glucose target of <150mg/dL in patients undergoing peripheral vascular bypass surgery
89258123|NCT00500903|Experimental|PIC Dose Escalation|Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles).
89258124|NCT00500903|Experimental|ECT Dose Escalation|Alisertib 10 or 20 mg, Enteric-coated Tablet (ECT) formulation, orally, once daily (QD) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 2 cycles).
89258125|NCT00500903|Experimental|Relative Bioavailability|Alisertib 40 mg ECT or PIC formulation, orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 2, followed by alisertib 50 mg PIC formulation orally, twice daily (BID) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 9 cycles).
89258126|NCT00295932|Experimental|Arm I|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89258127|NCT00295932|Experimental|Arm II|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89258128|NCT01063140||RabAvert|
89258129|NCT01063140||Imovax|
89258130|NCT00305448|Experimental|1|Fulvestrant 250 mg intramuscular injection
89258131|NCT00305448|Experimental|2|Fulvestrant 250mg (Plus 250mg Loading Regimen)
89258132|NCT00305448|Experimental|3|Fulvestrant 500 mg
89258133|NCT01063218|Other|Emollient|Only one arm: Emollient (Cetaphil Advanced) to be applied twice a day
89258134|NCT01066182|Experimental|DHA supplement|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
89258135|NCT01066182|Placebo Comparator|Sunflower oil capsule|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
89258136|NCT03981198|Other|RAP treatment|Single RAP treatment applied to thigh and multi-treatment applied to the other thigh.
89258137|NCT03980652|Other|Intervention|Change of gloves and use of separate, sterile instruments before closing the abdominal wall
89258138|NCT03980652|No Intervention|Current routine hospital practice|No change of gloves or use of separate, sterile instruments before closing the abdominal wall
89258139|NCT00305058|Experimental|Hydromorphone|0.0075 mg/kg IV hydromorphone
89258140|NCT00305058|Active Comparator|Morphine|0.05 mg/kg IV morphine
89258141|NCT01064388|Experimental|1|
89258142|NCT01064388|Placebo Comparator|2|
89258143|NCT00295854|Experimental|MN-001|
89258144|NCT00295854|Placebo Comparator|MN-001 once daily|placebo tablets
89258145|NCT00327470|Experimental|Open Label|
89258146|NCT03983408|Active Comparator|KRG group|"Enrollment: 60 patients~Drug: Korean Red Ginseng (KRG) 2,000 mg/day for total 24 weeks (2 Korean Red Ginseng extract tablet twice a day, ginsenoside Rg1+Rb1+Rg3 7.0 mg/g per each tablet)"
89258147|NCT03983408|Placebo Comparator|Placebo group|"Enrollment: 60 patients~Drug: Placebo for 12 weeks, following Korean Red Ginseng 2,000mg/day for another 12 weeks"
89258148|NCT01061450|Placebo Comparator|Placebo|Placebo
89258149|NCT01061450|Experimental|Simvastatin|Simvastatin 80 mg/day
89258150|NCT03983330|Experimental|Intervention group|"The trained RA will deliver brief MI to each subject individually via WeChat or WhatsApp in the smart phones throughout the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once per 2-3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering message through WeChat or WhatsApp will be interactive, depended on subjects' actions and responses.~Start from 6 months, minimal messages by merely following the subjects' progress and responding to their questions to maintain contact will be provided to subjects till one-year follow-up.~The readiness of quitting smoking will be assessed at 3-month follow-up. For those who are willing to take further actions to promote their health, i.e. with an intention to quit smoking, health advice on smoking will be given with more emphasis on the health benefits of quitting. The whole intervention will be given through WeChat/WhatsApp."
89258151|NCT03983330|Other|Control group|Subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months
89258152|NCT03986294|Experimental|S1 and liposomal irinotecan|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an iv infusion on day 1 and 15. Treatment will be repeated every 4 wks.
89258153|NCT03986294|Experimental|Liposomal irinotecan, Leucovorin and 5-fluoracil|Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.
89258154|NCT00322556|Experimental|IgPro10|See Intervention Description
89258155|NCT00321932|Active Comparator|Arm I (control)|Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
89258156|NCT00321932|Experimental|Arm II (treatment)|Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
89258157|NCT01057940||PEJ placement|Patients who have failed conventional DPEJ placement and would otherwise require surgical intervention.
89258158|NCT02533310|Experimental|OST treatment with in-vivo spiders|OST consists of increasingly intense interactions with an in-vivo phobic stimuli and human therapist non-phobic behavior modelling.
89258159|NCT02533310|Experimental|VR-OST treatment with virtual spiders|VR-OST consists of simulated OST treatment without the use of live spiders and with the support of a virtual therapist.
89258160|NCT00326612|Active Comparator|Intranasal Midazolam 0.2mg/kg|GIve once for seizure longer than 5 minutes
89258161|NCT00326612|Active Comparator|Rectal Diazepam 0.3-0.5 mg/kg|Given once for seizure longer than 5 minutes
89258162|NCT01060826|Experimental|somatostatin, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
89258163|NCT01060826|Placebo Comparator|Placebo, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
89258164|NCT00325130|Experimental|Group 1|Concomitant Administration
89258165|NCT00325130|Experimental|Group 2|Non-concomitant administration
89258166|NCT00321854|Experimental|Early Pramipexole|Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
89258167|NCT00321854|Experimental|Delayed Pramipexole|Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
89258168|NCT03983252|Experimental|Relapsing Remitting Multiple Sclerosis starting Alemtuzumab|"Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (defined by International Panel Criteria), age 18-60 years, enrolled to start treatment with alemtuzumab.~Subjects will undergo [F-18]PBR06 PET scans at baseline, 6 months and 18 months."
89258169|NCT03982862|Active Comparator|control group|0.9% Normal saline 0.1 ml +Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1cm2 scar volume
89258170|NCT03982862|Experimental|botox group|4U Botox® diluted to 0.1 ml + Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1 cm2 scar volume
89258171|NCT01060904|Experimental|1|brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
89258172|NCT01060904|Experimental|2|brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)
89258173|NCT01058174|Experimental|micafungin|intravenous infusion
89258174|NCT01058174|Active Comparator|standard care|intravenous infusion
89258175|NCT01061762|Experimental|Low Literacy Adherence Counseling|3-counseling sessions for medication adherence improvement tailored for people with poor literacy
89258176|NCT01061762|Active Comparator|Standard Adherence Counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
89258177|NCT01061762|Active Comparator|Health Counseling Comparison|3-sessions of health improvement counseling.
89258178|NCT01058252||Letrozole, recFSH, INVOCell, Monitoring|Infertile couple following MSP with INVO IVF
89258179|NCT01058330|Active Comparator|Plyometric physical training|Individualized plyometric training program to increase strength, coordination, and bone density.
89258180|NCT01058330|No Intervention|Control Group|This group will have no intervention
89258181|NCT01058408|Experimental|Rad001 with cisplatin|
89258182|NCT01060982|Experimental|HIFU treatment|
89258183|NCT01061060|Experimental|Beraprost group|Prostaglandin I2
89258184|NCT01061060|Placebo Comparator|Placebo group|
89258185|NCT00310388|Experimental|Retigabine (INN), Ezogabine (USAN)|Retigabine (Ezogabine): all subjects
89258186|NCT03981770||Group good sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are more than four hours.
89258187|NCT03981770||Group poor sleepers|Duration of sleep was defined as the duration of all Bispectral Index data below 80 in the 12 hours of monitoring (from 18:00pm to 06:00am). Sleeping time are less than four hours.
89258188|NCT03981692|Active Comparator|Consecutive Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. Immediately after these trainings, they should expected to find the letters Z in the mixed letters, search for the five words you read on the previous page, find the similarities between the concepts, find the letter in the given tables, derive the fruit names starting with the letter, count the days of the week etc. Attention, memory and arithmetic training will be given the ability to run.
89258189|NCT03981692|Active Comparator|Integrated Dual Task Training|Sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given to the group. They will be done similar cognitive activities during with this simple balance trainings.
89258190|NCT01063556|Experimental|1|
89258191|NCT01063556|Experimental|2|
89258192|NCT03981458|Active Comparator|Hyalofemme|Hyalofemme is a cream/gel containing hyaluronic acid, designed to be applied vaginally. This is primarily used in treatment of atrophic vaginitis and is applied by the patient once every three days. We intend treatment to continue for 6 months.
89258193|NCT03981458|Active Comparator|Ialuril|Ialuril is a bladder instillation designed to be delivered to the bladder via catheter. This is primarily used in patients suffering from recurrent UTI and acts to help rebuild the lining of the bladder, reducing irritation. Ialuril is applied weekly for 6 weeks, followed by every 2 weeks for 6 weeks, then once monthly for maintenance. Treatment will be continued for 6 months.
89258194|NCT01019915|Other|Heart failure patients. Intervention CRT|CRT implantation in heart failure. Effect of intervention after 6 months of treatment.
89258195|NCT04110041|Experimental|Moderate Intensity|Aerobic exercise maintained for 30 minutes at 50-55% of each participant's individual heart rate reserve (HRRes).
89258196|NCT04110041|Experimental|High Intensity|Aerobic exercise maintained for 30 minutes at 80-85% of each participant's individual heart rate reserve (HRRes).
89258197|NCT00309842|Experimental|Unrelated UCBT for Blood Cancers|Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.
89258198|NCT00325754|Active Comparator|E-Cylinder|22-lb E-cylinder towed on a cart
89258199|NCT00325754|Active Comparator|Lightweight Cylinder|3.6-lb lightweight cylinder that can be carried
89258200|NCT01019993|Active Comparator|good pulmonary functions (group N)|The patients were allocated if they have forced vital capacity (FVC %) and/or forced expiratory volume in 1 sec (FEV1%) of 80% of predicted or more
89258201|NCT01019993|Active Comparator|pulmonary dysfunction (group PD)|The patients were allocated if they have FVC and/or FEV1 of 50%-79% of predicted
89258202|NCT01063790|No Intervention|Usual care|Patients undergoing elective inguinal hernia repair attend the pre-admission clinic no later than one week prior to surgery. During this visit they receive one-on-one pre-operative education from a registered nurse. It includes both verbal and written information. Verbal information provided to patients includes procedural information such as the admission process, and post-operative care in the post-anaesthetic care uni and day surgery unit. Post-discharge pain management information is minimal and consists of direction to not wait until the pain is severe before taking prescribed analgesics.
89258203|NCT01063790|Experimental|Individualized Education|
89258204|NCT03985982|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m injections) into glabellar area.
89258205|NCT03985982|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
89258206|NCT00499889|Experimental|Imatinib, Busulfan, Fludara + Antithymocyte Globulin|Oral Imatinib Mesylate 400 mg twice a day for 9 Days; Busulfan 130 mg/m^2 by vein (IV) daily for 2 Days; Fludara 40 mg/m^2 IV daily for 4 Days; Antithymocyte Globulin (ATG) 2.5 mg/kg IV daily for 3 Days; Tacrolimus levels maintained between 5-15 ng/dl, Day -2 to Day 180; Methotrexate 5 mg/m2 on days 1, 3, 6 and 11; and Donor bone marrow or blood stem cells infused on day 0 with possible donor lymphocyte infusion (DLI) for progressive disease.
89258207|NCT03982472|Experimental|TENS right side|TENS stimulation at the right side
89258208|NCT03982472|Experimental|TENS left side|TENS stimulation at the left side
89258209|NCT03982472|No Intervention|sham stimulation|Sham stimulation
89258210|NCT01058486|Experimental|Activity-Self Management|
89258211|NCT01058486|No Intervention|Usual Care|
89258212|NCT04252703|Active Comparator|Minimalist|The 'Minimalist' strategy is PCI treatment of the culprit lesion only. Other coronary stenoses are to be managed medically. It is recognized that there may be multiple culprit lesions in such patients, though there are no data on how frequently this might be expected. Operators may elect to treat multiple putative culprit lesions in this case.
89258213|NCT04252703|Experimental|More complete|The 'More complete' strategy is PCI of the culprit lesion and fractional flow reserve (FFR)- or instantaneous wave-free ratio (iFR)-guided treatment of other angiographically significant (> 50% diameter) stenoses amenable to coronary stenting in vessels with reference diameters ≥2.5mm. Physiological assessment is strongly encouraged but not mandatory for lesions of ≥90% angiographic stenosis. PCI of chronic total occlusions will not be attempted as part of the study.
89258214|NCT00309608|Experimental|Linagliptin low dose|Patients receive Linagliptin low dose tablets once daily
89258215|NCT00309608|Experimental|Linagliptin medium dose|Patients receive Linagliptin medium dose tablets once daily
89258216|NCT00309608|Experimental|Linagliptin high dose|Patients receive Linagliptin high dose tablets once daily
89258217|NCT00309608|Placebo Comparator|Placebo|Patients receive tablets identical to those containing Linagliptin low, medium and high dose
89258218|NCT00309608|Active Comparator|Glimepiride|Patients receive Glimepiride tablets once daily
89258219|NCT00309452|Active Comparator|Treatment as usual|Referral to community providers.
89258220|NCT00309452|Experimental|STEP Care|Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.
89258221|NCT00308750|Experimental|Enzastaurin/Pemetrexed/Carboplatin|
89258222|NCT00308750|Experimental|Pemetrexed/Carboplatin|
89258223|NCT00308750|Active Comparator|Docetaxel/Carboplatin|
89258224|NCT01061918|Active Comparator|Tecnis MF|
89258225|NCT01061918|Active Comparator|ReSTOR|
89258226|NCT03985826||Childhood ALL survivors|The cohort of childhood ALL survivors will be identified in the Danish part of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-Register .
89258227|NCT03985826||Comparison cohort|A reference cohort (comparison cohort) of individuals will be sampled randomly from the source population matched by age and sex and without a history of childhood cancer in the calendar year where the case was diagnosed (density sampling). For each childhood ALL-patient we will choose ten comparison subjects.
89258228|NCT03985748|Experimental|Breath Actuated Nebulizers (BAN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
89258229|NCT03985748|Active Comparator|Standard Nebulizer (SN)|Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the RIH Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.
89258230|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 1|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
89258231|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 2|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
89258232|NCT00481247|Experimental|Dasatinib|
89258233|NCT00481247|Active Comparator|Imatinib|
89258234|NCT04101461|Active Comparator|Group I: 27 mg elemental iron|will receive PharaFerro27; Devart Lab Company, Egypt; once daily starting at 12 -14 weeks until 37-38 weeks
89258235|NCT04101461|Active Comparator|Group II: 54 mg elemental iron|will receive two tablets of PharaFerro27; Devart Lab Company, Egypt; daily starting at 12 -14 weeks until 37-38 weeks
89258236|NCT01020071|Other|laser treatment|laser peripheral iridotomy and laser peripheral iridoplasty
89258237|NCT01016951|Experimental|A|AZD9164
89258238|NCT01016951|Placebo Comparator|B|Placebo
89258239|NCT01017107|Experimental|Activated protein C|
89258240|NCT01020227|Experimental|Integrative Therapies|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
89258241|NCT01020227|No Intervention|Standard Care|Patients were given no intervention but were contacted at 6 weeks and 6 months for data collection purposes
89258242|NCT01017185|Experimental|Oncolytic virotherapy, intratumoral injection of HF10|
89258243|NCT03996863|Experimental|Otoband efficacy on CINV|"Participants will wear the Otoband during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.~The Otoband will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the OtoBand is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the OtoBand 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
89258244|NCT03996863|Placebo Comparator|Placebo device efficacy on CINV|"Participants will wear the placebo device during infusion following chemotherapy treatments, placed against the skin, on the flat part of the right mastoid bone.~The placebo device will be able to function maximum 16 hours per day. Study participants will be instructed to use the device for 30 minutes in the morning, and then as needed for symptoms while at home for four days. Once the device is applied and turned on they are expected to wear it continually for up to 30 minutes. Subjects can stop the device 5 minutes after cessation of nausea but will be asked to resume stimulation if the nausea recurs within 30 minutes. The participant will be asked to fill out the MASCC Antiemesis Tool questionnaire at 24 hours post infusion and again at day 5 post infusion. Participants will also be asked to fill out an OtoBand Use Questionnaire daily for the four days following their chemotherapy infusion."
89258245|NCT03997019|Active Comparator|group A|opioid analgesia
89258246|NCT03997019|Active Comparator|group B|ESP block
89258247|NCT01014611||Class II NYHA Heart Failure|Fraction of ejection between 40% and 30%
89258248|NCT01014611||Class III NYHA Heart Failure|Fraction of ejection lower than 30%
89258249|NCT01014611||Healthy volunteers|Matched with patients on age and physical activity
89258250|NCT00480857|Experimental|Docetaxel|
89258251|NCT00480779|Other|GLB Group|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
89258252|NCT00480779|Other|GLB DVD|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
89258253|NCT04061993|Experimental|Intervention Group OBV|Intervention Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
89258254|NCT04061993|Active Comparator|Control Group OBV|Control Group in Valdoltra Orthopaedic Hospital. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
89258255|NCT04061993|Experimental|Intervention Group SBNM|Intervention Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and extra one-on-one training to learn strength and sensory-motor exercises. At discharge they will get USB drives with exercise videos, written exercise instructions, training diary and exercise aids for strength and sensory-motor training.
89258256|NCT04061993|Active Comparator|Control Group SBNM|Control Group in General Hospital Novo mesto. Patients will get current standard physiotherapy during hospitalisation and USB drives with exercise videos, written exercise instructions and training diary at discharge.
89258257|NCT00499031|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 120 minutes on day 1.
89258258|NCT00498485|Placebo Comparator|Placebo|Patients were randomized and these received placebo
89258259|NCT00498485|Active Comparator|Sodium Oxybate|Patients were randomized and these received the active drug
89258260|NCT01017341|No Intervention|No hip protector|no hip protector
89258261|NCT00480077|Experimental|Access Arm|HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report
89258262|NCT00480077|Active Comparator|Control arm|HF subjects managed with standard clinical assessment
89258263|NCT01017419||Audiology counseling|
89258264|NCT05045261|No Intervention|A - Standard of care NUC|Patients will continue their standard of care NUC treatment
89258265|NCT05045261|Experimental|B - NUC discontinuation|Patients will stop their NUC treatment 28 weeks after enrolment
89258266|NCT05045261|Experimental|C - NUC discontinuation after SLGN treatment|"Patients will take from enrolment~their standard of care NUC treatment for 28 weeks then stop~3mg SLGN weekly for 24 weeks then stop"
89258267|NCT00498173|Experimental|Atomoxetine|Participants will receive flexibly dosed atomoxetine for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
89258268|NCT00498173|Placebo Comparator|Placebo|Participants will receive blinded, matched placebo for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
89258269|NCT04442009|Active Comparator|Group S = SCPB group|"US-guided SCPB will be performed at the end of the surgery before extubation, with patients in the supine position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the high frequency linear probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath and a 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used.~Sternocleidomastoid (SCM) muscle will be visualized. The 22 G needle will be inserted between the SCM and the prevertebral fascia by using in plane technique horizontally. The needle tip will be corrected with injecting 2 ml of normal saline. Then a 20 mL dose of 0.25% bupivacaine will be injected here. The same procedure will be performed for the opposite site (totally 40 mL dose of 0.25% bupivacaine)."
89258270|NCT04442009|No Intervention|Group C = Control group|Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
89258271|NCT00295620|Experimental|Arm A: Anastrozol|1 mg per day for 2 years
89258272|NCT00295620|Experimental|Arm B: Anastrozol|1 mg per day for 5 years
89258273|NCT01063374|Active Comparator|low glycemic index, diabetic diet|low glycemic index, diabetic diet
89258274|NCT01063374|Active Comparator|high cereal fibre, diabetic diet|high cereal fibre, diabetic diet
89258275|NCT01063452|Experimental|Truvalve|Atkinson Product Design urinary slide valve on the catheter
89258276|NCT01063452|Active Comparator|Control|Drainage bag on the catheter
89258277|NCT03980496|Active Comparator|omeprazole infusion (OI) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OI group is then treated with an 8-mg/h continuous i.v. infusion of OME for 72 h.
89258278|NCT03980496|Active Comparator|omeprazole bolus (OB) group|After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OB group receives a 40-mg i.v. bolus of OME every 12 h.
89258279|NCT02532504|Experimental|CBT seven sheets|"8 sessions of CBT based intervention called change your life with seven sheets of paper"
89258280|NCT02532504|No Intervention|Treatment As Usual|Treatment As Usual
89258281|NCT01066260|Experimental|Probiotic|
89258282|NCT01066260|Placebo Comparator|Placebo|
89258283|NCT01064544|Experimental|Starting with light therapy|Starts with 3 weeks of light therapy, followed by a control period
89258284|NCT01064544|Experimental|Ending with light therapy|Ends with 3 weeks of light therapy after a control period.
89258285|NCT03981510|Experimental|Children being investigated with 3D-transit|"4 groups of each 20 children will be investigated with respectively one or two capsules:~Healthy children (1)~Children with chronic constipation (2)~Children with neurofibromatosis type 1 (2)~Children with cancer receiving treatment with Vincristine (1)"
89258286|NCT02532426||COPD patients with chronic hypoxemia|COPD patients with chronic and severe arterial hypoxemia at rest (paO2<55mmHg).
89258287|NCT02532426||COPD patients with normoxia|COPD patients with normoxia at rest (paO2>67mmHg), matched for age, sex, bronchial obstruction and lean mass.
89258288|NCT01063530|Experimental|Diammine Silver Fluoride|Application fo diammine silver fluoride in cervical lesions
89258289|NCT01063530|Placebo Comparator|Distilled water|Application of distilled water in cervical lesions
89258290|NCT00310440|Experimental|Bone graft substitute|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).
89258291|NCT00310440|Active Comparator|Autologous Bone|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone.
89258292|NCT03978390|Experimental|Superhero images, Reward at the beginning,|Also, Showing superhero images for 5 minutes before starting the dental procedure. Also, providing the children with reward before begging the dental procedure and telling them that they can only keep it if they cooperate during the treatment procedure.
89258293|NCT03978390|Experimental|Superhero images, Reward at the end|Universally-accepted positive reinforcement to increase children cooperation in dental settings
89258294|NCT03978390|Experimental|No Superhero Images, Reward at the beginning|Showing superhero images for 5 minutes before starting the dental procedure
89258295|NCT03978390|Active Comparator|No Superhero Images, Reward at the end|Showing no picture before starting the dental procedure
89258296|NCT00304356|Other|active drug|500 mg nitazoxanide bid given to patient
89258297|NCT01066338||Normal karyotype|The patients were diagnosed as acute myeloid leukemia with normal karyotype.
89258298|NCT01066416|Placebo Comparator|Medical therapy|Patients undergo surgery 6 months after randomization
89258299|NCT01066416|Experimental|Surgery|Patients undergo surgery at time of randomization
89258300|NCT01069302|Active Comparator|High loading and high maintenance|Clopidogrel loading 600mg and maintenance 150mg for 7days
89258301|NCT01069302|Active Comparator|High loading and low maintenance|Clopidogrel loading 600mg and maintenance 75mg for 7days
89258302|NCT01069302|Active Comparator|Low loading and high maintenance|Clopidogrel loading 300mg and maintenance 150mg for 7days
89258303|NCT01069302|Active Comparator|Low loading and low maintenance|Clopidogrel loading 300mg and maintenance 75mg for 7days
89258304|NCT00321620|Active Comparator|zoledronic acid|
89258305|NCT00321620|Experimental|denosumab|
89258306|NCT00304278|Experimental|RADPLAT and Tarceva|"All patients will receive RADPLAT and Tarceva:~Drug: Erlotinib (Tarceva)~150 mg daily X 7 weeks~Other Names:~Tarceva~Drug: Intra-arterial Cisplatin (PLAT)~1 dose (150 mg/sq) per week X 4 weeks~Other Names:~Cisplatin~Radiation: Radiation Therapy (RAD)~5 days per week X 7 weeks"
89258307|NCT03981068|Experimental|Re-Irradiation with protons|60 Gy in 50 fraktions, 10 weekly with protons
89258308|NCT02532686|Experimental|DAAOI-2|DAAOI-2: 500-2000mg/d
89258309|NCT02532686|Placebo Comparator|placebo|
89258310|NCT01063946|Experimental|[14C]-AVE8062|Single, 30 minute, intravenous infusion of 25 mg/m² of [14C]-AVE8062 containing 1.85 MBq (50µCi) at the first cycle, followed by subsequent administrations with non-radiolabelled AVE8062 in combination with cisplatin every 3 weeks, according to the investigator's judgment.
89258311|NCT00291018|Experimental|ProDisc-C|ProDisc-C total disc replacement device intended to treat single level SCDD in the cervical spine from C3-C7
89258312|NCT00291018|Active Comparator|Control|ACDF
89258313|NCT00320606|Experimental|Immunosuppression Withdrawal|"Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.~Participants are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results."
89258314|NCT01064102|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
89258315|NCT01064102|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
89258316|NCT01064700|No Intervention|Baseline|1 week period, in which subjects followed usual schedule, though they were asked to maintain a fairly stable sleep schedule. The baseline period was used for comparison with the experimental intervention.
89258317|NCT01064700|Experimental|Experimental Intervention|Randomized exposure to the 4-week experimental treatments.
89258318|NCT02532114|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO TID and enzalutamide PO daily. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
89258319|NCT00307736|Experimental|Chemotherapy and radiation|Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.
89258320|NCT00320528|Experimental|Pure ADHD|Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
89258321|NCT00320528|Experimental|ADHD+Internalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
89258322|NCT00320528|Experimental|ADHD+Externalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
89258323|NCT03979586|Experimental|Patient phototype I to IV|The study will be conducted in the Laser Dermatological and Plastic Center of the Conception Hospital in Marseille. It will be a prospective, controlled, hemiface, single-blind, independent-evaluator pilot study of 20 patients, 30 to 70 years old, with phototype I to IV (Fitzpatrick scale). By this study in hemiface, each patient will be his own witness. Neither the patient nor the examining doctor will know the choice of the hemiface of application of hyaluronic acid. This will be a single-blind study with independent evaluator. Patients will be included for 3 months, and followed for a period of 3 months.
89258324|NCT00320372||1. 500 VNS Patients|VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.
89258325|NCT00320372||2. 300 Non-VNS Patients|Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.
89258326|NCT00294762|Experimental|Erlotinib|150 mg erlotinib daily
89258327|NCT00294762|Experimental|Erlotinib + chemotherapy (intercalated)|carboplatin AUC 6 on Day 1 to 21 days, paclitaxel 200 mg/m2 on Day 1 to 21 days, erlotinib 150 mg Days 2-15 for 4 cycles then erlotinib 150 mg daily until progression, withdrawal of consent, or unacceptable toxicity
89258328|NCT00294684|Experimental|Corticosteroids|
89258329|NCT00294684|Placebo Comparator|Placebo|
89258330|NCT00307034|Experimental|2-dose group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
89258331|NCT00307034|Experimental|Comparator group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-3-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
89258332|NCT01061996|Experimental|1|
89258333|NCT01069458|Experimental|The High Protein Diet Group|The high protein diet (25% energy from protein, 55% energy from fat, 20% energy from carbohydrate) will be hypo-caloric and achieved by restricting the amount of sugar containing foods and drinks, reducing the intake of bread, rice, pasta, fruits and fruit-juices and increasing the intake of vegetables (instead of bread, rice, pasta and potatoes) and increasing the amounts of protein (from chicken, fish, and meat) and fat from oil and dressings for lunch and dinner and by choosing nuts and protein-rich yoghurts, egg, cheese, chicken wings, shellfish, fish and fish products as snacks.
89258334|NCT01069458|Active Comparator|The Low Fat Diet Group|The low fat diet (30% energy from fat, 20% energy from protein, 50% energy percent from carbohydrate) will be hypo-caloric and achieved by choosing low-fat diary and meat products, restricting amounts of visible fat and fatty snacks and increasing intake of whole meal bread, muesli, brown rice, whole meal pasta in the main meals and by choosing yoghurt with muesli, oat porridge with milk, fruits and hard bread with jam and soft gout-cheese as snacks.
89258335|NCT01064180|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
89258336|NCT01064180|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
89258337|NCT01069536|Active Comparator|2 minutes bolus infusion|
89258338|NCT01069536|Active Comparator|15 minutes slow infusion|
89258339|NCT01069614|Experimental|Skin stretching device|Skin stretching device
89258340|NCT03980106|Experimental|Experimental RI-PI|They receive the Reciprocal Inhibition (RI) technique in the first stage and then the Post-isometric Inhibition (PI) technique in the second stage.
89258341|NCT03980106|Experimental|Experimental PI-RI|They receive the Post-isometric Inhibition (PI) technique in the first stage and then the Reciprocal Inhibition (RI) technique in the second stage.
89258342|NCT01064778|Active Comparator|Low GI|
89258343|NCT01064778|Experimental|High GI|
89258344|NCT00320216|Placebo Comparator|Group I (Placebo)|Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.
89258345|NCT00320216|Experimental|Group II (Ustekinumab 45 mg)|Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
89258346|NCT00320216|Experimental|Group III (Ustekinumab 90 mg)|Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
89258347|NCT00320216|Experimental|Group IV|Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
89258348|NCT00320216|Experimental|Group V|Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
89258349|NCT00290706|Experimental|Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds|Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
89258350|NCT03978156|Experimental|Dronabinol, Then Placebo|Participants will take 2.5 mg of Dronabinol for 2 weeks, 1 week washout and then take 2 weeks of placebo (microcrystalline cellulos). Subjects will take up to 8 capsules daily of the treatment daily during each phase.
89258351|NCT03978156|Experimental|Placebo, Then Dronabinol|Participants will take placebo (microcrystalline cellulos) for 2 weeks, 1 week washout and then take 2.5 mg of Dronabinol for 2 weeks. Subjects will take up to 8 capsules daily of the treatment daily during each phase.
89258352|NCT03978234|Experimental|Single group|Single group
89258353|NCT01064934|Experimental|Lipid apheresis|Lipid apheresis
89258354|NCT01064934|Active Comparator|Standard care|Standard care
89258355|NCT01066494|Experimental|Single-arm|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
89258356|NCT03977766|Experimental|nurse then patient digital prevalidation of chemotherapy|"Outpatient Chemotherapy prevalidation will done~with the help of a nurse, using the digital application, for cycle 2 and 3.~by the patient alone, using the digital application, for cycle 4 and 5."
89258357|NCT03977688||none Cyto|septic shock, refractory, without Cytokin-adsorption therapy
89258358|NCT03977688||cyto|septic shock, refractory, treated with Cytokin-adsorption therapy
89258359|NCT00303108|Experimental|Arm 1|Patients will receive IV Doxil 30 mg/m2 and carboplatin AUC=5 on Day 1 of each cycle. A cycle consists of 28 days. In addition, HER2+ (IHC3+ and FISH+) patients only will receive a one-time loading dose of Herceptin 8 mg/kg IV on Day 1 of Cycle 1 and 4 mg/kg on Day 1 and Day 15 of every cycle thereafter.
89258360|NCT00302952|Experimental|Lovastatin|Participants are randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one 40 mg lovastatin tablet or treatment could be discontinued. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D&C Yellow #10, FD&C Blue #1, and Yellow #6 were added as dyes.
89258361|NCT00302952|Placebo Comparator|Placebo|Participants are randomized to take two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one placebo tablet or treatment could be discontinued. The placebo tablets contained microcrystalline cellulose, NF (Avicel PH 102) and Supro AA Swedish Orange Opaque Capsule Shells, Color 4188.
89258362|NCT00302718|Experimental|Physician-level incentives|Examines the effect of physician-level financial incentives on hypertension quality of care
89258363|NCT00302718|Experimental|Practice-level incentives|Examines the effect of practice-level financial incentives on hypertension quality of care
89258364|NCT00302718|Experimental|Physician- and practice-level incentives|Examines the effect of physician- and practice-level financial incentives on hypertension quality of care
89258365|NCT00302718|No Intervention|No incentives (control)|Physician participants in this arm received only audit and feedback performance reports as did the participants in the intervention arms.
89258366|NCT03976206|Experimental|VSEL Max|We carried out the subdermal application of VSELs with a 1-mL syringe (90,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
89258367|NCT03976206|Experimental|VSEL Medium|We carried out the subdermal application of VSELs with a 1-mL syringe (60,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
89258368|NCT03976206|Experimental|VSEL Mini|We carried out the subdermal application of VSELs with a 1-mL syringe (30,000 cells in 0.4 mL plate-rich plasma) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
89258369|NCT03976206|No Intervention|Control|Subcutaneous injection of 0.4 mL platelet-rich plasma in the same part of the experimental group
89258370|NCT01069848|Experimental|Vedera KXS|
89258371|NCT01066572|Experimental|Lisinopril|Experimental
89258372|NCT01066572|Placebo Comparator|Placebo|Placebo Comparator
89258373|NCT01066650|Active Comparator|Endeavor Resolute|
89258374|NCT01066650|Active Comparator|Xience V|
89258375|NCT00302328|No Intervention|macular hole operation no peeling|
89258376|NCT00302328|Active Comparator|Macular hole operation ICG peeling|
89258377|NCT00302328|Experimental|Macular hole operation TB peeling|
89258378|NCT01066728|Active Comparator|Theophylline|Oral loading dose of 6 mg per kilogram of body weight of theophylline followed by a maintenance dose of 2 mg per kilogram every 8 hours plus room air by nasal prongs at 0.5 l/min for 3 days.
89258379|NCT01066728|Experimental|CO2 inhalation|Equivalent loading and maintenance volume of oral normal saline plus CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
89258380|NCT01070004|Experimental|Blue light|Exposure to 460-nm monochromatic light (blue light)
89258381|NCT01070004|Experimental|Physical activity|15 minutes of physical activity at a low intensity
89258382|NCT03977844|Active Comparator|Technical Assistance|Technical Assistance. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security.
89258383|NCT03977844|Experimental|Community Engagement and Planning|Community Engagement and Planning. At the community program level of randomization, community agencies and their staff will be invited to access weekly webinars and toolkits to improve their abilities to support clients' depression care, disaster preparedness and recovery, financial security, and housing security. In addition, community agencies will be invited to meet with one another to develop novel and investigator supported coalitions using principles of community partnered participatory research that will adapt toolkits and other local assets to seek to enhance community resilience related to threats of disaster risk, financial insecurity, housing insecurity, mental health, or other coalition-determined domains.
89258384|NCT03977844|Active Comparator|Community Resources (CR)|Community Resources (CR). At the Individual level of randomization, individuals in the Community Resources (CR) arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security.
89258385|NCT03977844|Experimental|Community Resources (CR) + eBT|Community Resources + eBT. At the Individual level of randomization, individuals in the CR+eBT arm will receive access to toolkits and local resources related to depression care, disaster preparedness and recovery, financial security, and housing security, along with an interactive component to support CBT-informed coping with mood and stressors at the individual level.
89258386|NCT01065090||training|one group will receive resistance training and one group the normal physiotherapeutic treatment
89258387|NCT01065090||physiotherapy|one group will receive resistance training and one group the normal physiotherapeutic treatment
89258388|NCT00301080|Placebo Comparator|Placebo (original version)|Placebo administered orally twice per day for 4 weeks.
89258389|NCT00301080|Active Comparator|D-cycloserine 200mg|D-cycloserine administered orally at a dose of 200 mg twice per day for 12 weeks.
89258390|NCT00301080|Active Comparator|D-cycloserine 50 mg|D-cycloserine administered orally at a dose of 50 mg twice per day for 12 weeks.
89258391|NCT00301080|Active Comparator|D-cycloserine 250mg|This was the original active comparator arm (before the design was changed): D-cycloserine administered orally at a dose of 250 mg twice per day for 4 weeks.
89258392|NCT00301080|Placebo Comparator|Placebo (revised version)|Placebo administered orally twice per day for 12 weeks.
89258393|NCT01066806|Experimental|high calcium diet|
89258394|NCT01066806|Active Comparator|normal calcium diet|
89258395|NCT03977610|Experimental|Ga68-PSMA ligand|Glass vial with 4~20 mCi(148-740 MBq) of 68Ga-PSMA ligand in ≤10% EtOH with aqueous sterile water for injection solution (approximately 15.5 mL), more than 0.33 mCi/mL @ EOS; One time dose of 2-5 mCi (74-185 MBq) for PET Imaging ; i.v. injection
89258396|NCT01066884|Experimental|1|
89258397|NCT01581216|Experimental|10 minute walk|10-minute walk and exercises for the upper limbs with 1 lb-dumbbells
89258398|NCT01581216|Experimental|20 minute walk|20-minute walk and exercises for the upper limbs with 1 lb-dumbbells
89258399|NCT01581216|Experimental|30 minute walk|30-minute walk and exercises for the upper limbs with 1 lb-dumbbells
89258400|NCT00290238|Experimental|PNT|
89258401|NCT00290238|Sham Comparator|TENS|
89258402|NCT01070082||Adult ICU patients undergoing procedure|
89258403|NCT02532270|Experimental|Group C|Arterial pressure of the patients in Group C is measured by continuous non-invasive arterial pressure (CNAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
89258404|NCT02532270|Experimental|Group N|Arterial pressure of the patients in Group N is measured by intermittent oscillometric non-invasive arterial pressure (NIAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
89258405|NCT01065168||endometrioma|ovarian endometrioma undergoing cystectomy
89258406|NCT01581450|Experimental|Tested drug|Remifentanil at 0.1 µg/kg/min Tested drug (N2O 35%): 35%/15%/50% N2O/N2/O2
89258407|NCT01581450|Active Comparator|Gas Active control|Remifentanil at 0.1 µg/kg/min Gas active control (N2O 50%):50%/50% N2O/O2
89258408|NCT01325766|Active Comparator|Yoga (immediate start) group|This arm will start yoga sessions immediately after screening and will continue sessions for 8 weeks. This group will then continue with home yoga for an additional 8 weeks.
89258409|NCT01325766|Active Comparator|Yoga (waitlist) group|This arm will continue regular CF therapies for 8 weeks and will start yoga sessions at week 9.
89258410|NCT03976284|Experimental|Garden-fresh produce and exercise (GFPE)|Participants are encouraged to double their consumption of minimally processed fiber-rich plant foods, especially garden-fresh produce from the church community garden. Participants are also encouraged to limit pro-inflammatory foods rich in saturated fat, sodium and added sugar. Participants are also encouraged to engage in 150 minutes of moderate to vigorous physical activity per week, most likely in the form of brisk walking.
89258411|NCT00289848|Experimental|1|sitagliptin 100 mg
89258412|NCT00289848|Placebo Comparator|2|placebo
89258413|NCT00289770|Experimental|Group A|Was vaccinated with Lot A in the primary study.
89258414|NCT00289770|Experimental|Group B|Was vaccinated with Lot B in the primary study.
89258415|NCT00289770|Experimental|Group C|Was vaccinated with Lot C in the primary study.
89258416|NCT00289536|Experimental|Low Dose|
89258417|NCT00289536|Experimental|Medium Dose|
89258418|NCT00289536|Experimental|High Dose|
89258419|NCT00289458|Experimental|Aquatic Education|Exercise combined with education
89258420|NCT00289458|Experimental|Aquatic|
89258421|NCT00289458|Placebo Comparator|Control|
89258422|NCT00288912|Active Comparator|Health Education Intervention|Health Education Intervention
89258423|NCT00288912|No Intervention|Usual Medical Care|Usual Medical Care
89258424|NCT00288912|Experimental|Osteoarthritis Self-Management|Osteoarthritis Self-Management
89258425|NCT01066962|Active Comparator|darunavir/r + tenofovir/emtricitabine|
89258426|NCT01066962|Experimental|darunavir/r + raltegravir|
89258427|NCT01067118|Active Comparator|Humalog U-100 Insulin|
89258428|NCT01067118|Experimental|LINjeta U-100|
89258429|NCT01067274|Experimental|R1 Arm A : ATRA|"Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum~All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28"
89258430|NCT01067274|No Intervention|R1 Arm B : no ATRA|Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum
89258431|NCT01067274|Experimental|R2 Arm 1A : AZACITIDINE and ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
89258432|NCT01067274|Experimental|R2 Arm 1B : AZACITIDINE and No ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
89258433|NCT01067274|Experimental|R2 Arm 2A : ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
89258434|NCT01067274|Experimental|R2 Arm 2B : no ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5
89258435|NCT01065246|Experimental|catumaxomab|
89258436|NCT01325844|No Intervention|G group|G group = General anesthesia group
89258437|NCT01325844|Experimental|G+E group|G+E group = General anesthesia + epidural anesthesia group
89258438|NCT01065324||Anally inserted enteroscopy group|Anally inserted enteroscopy group
89258439|NCT01065324||Orally inserted enteroscopy group|Orally inserted enteroscopy group
89258440|NCT01067430|Active Comparator|Etoricoxib 90 mg|Subject will take Etoricoxib 90 mg for 14 days
89258441|NCT01067430|Active Comparator|Diclofenac|Film coated tablet 50 mgs given three times a day for 14 days
89258442|NCT00305864|Experimental|Phase I: MGd 3 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89258443|NCT00305864|Experimental|Phase I: MGd 4 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40.Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89258444|NCT00305864|Experimental|Phase I: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89258445|NCT00305864|Active Comparator|Phase II: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89258446|NCT00295880|Experimental|Transplant Patients|Patients receiving umbilical cord blood transplantation.
89258447|NCT01066130|Experimental|Intensive treatment arm|Every second person with psychosocial problems was randomized into this arm. The intervention consisted of personalized, intensive psychosocial treatment provided by a medical social worker on the basis of the patient's problems for up to 2 years after inclusion.
89258448|NCT01066130|Experimental|Minimal treatment arm|Every second patient with psychosocial problems was assigned to this arm. Patients in this arm received minimal social support by a medical social worker.
89258449|NCT01066130|No Intervention|No need for psychosocial treatment|This arm consisted of individuals who did not need psychosocial treatment or measures. The need for such treatment and measures was determined at baseline for all persons included in the study.
89258450|NCT03979196|Active Comparator|Inpatient Management|Women in this arm will follow the standard of care for admission to high-risk units at Sunnybrook Health Sciences Centre or North York General Hospital.
89258451|NCT03979196|Active Comparator|Outpatient Management|Women in this arm will be encouraged to follow the standard of care established in the high-risk clinics at Sunnybrook Health Sciences Centre or North York General Hospital.
89258452|NCT03978962||Study population|Patients subjects to a Guided Tissue Regeneration or Guided Bone Regeneration procedure
89258453|NCT01325480||Patients with heart failure and wide QRS|Patients undergoing a cardiac resynchronization therapy procedure
89258454|NCT03982784|Experimental|single-injection TQLB(transmuscular quadratus lumborum block)|Single-injection of TQLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
89258455|NCT03982784|Active Comparator|Control|postoperative IPCA is given alone
89258456|NCT03978884|Experimental|Mild Hypertensive|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg
89258457|NCT03978884|Experimental|Mild Hypertensive with Diabetes|Mild Hypertensive with systolic BP >=140 mmHg but less than 160 mmHg at baseline with diastolic >=90 but <100 mmHg and diabetes.
89258458|NCT03978884|Experimental|Severe Hypertension|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg
89258459|NCT03978884|Experimental|Severe Hypertension with Diabetes|Severe Hypertensive with systolic BP >=160 mmHg at baseline or with diastolic >=100 mmHg with diabetes
89258460|NCT00319982|Experimental|I- Diltiazem|Diltiazem- study medication
89258461|NCT00319982|Placebo Comparator|II- Placebo|Placebo Comparator
89258462|NCT00319592|Experimental|ChimeriVax™-JE|Subjects received 2 injections of placebo (normal saline), 1 each on Days 0 and 7, and 1 injection of ChimeriVax™-JE on Day 28.
89258463|NCT00319592|Active Comparator|JE-VAX®|Subjects received 1 injection of JE-VAX® each on Days 0, 7, and 28.
89258464|NCT01066208||WG classification|Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
89258465|NCT01066208||MPA classification|Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
89258466|NCT01066208||CSS classification|Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
89258467|NCT01066208||PAN classification|Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
89258468|NCT01066208||Control Classification|For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
89258469|NCT01066208||WG diagnostic|Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
89258470|NCT01066208||MPA diagnostic|Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
89258471|NCT01066208||CSS diagnostic|Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
89258472|NCT01066208||PAN diagnostic|Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
89258473|NCT01066208||Control diagnostic|Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
89258474|NCT01066208||GCA classification|Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
89258475|NCT01066208||TAK classification|Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
89258476|NCT01066208||GCA diagnostic|Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
89258477|NCT01066208||TAK diagnostic|Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
89258478|NCT00295490|Experimental|240mg Devil claw|Sub clinical dose if the 3 doses employed
89258479|NCT00295490|Experimental|960mg Devil Claw|Active dose
89258480|NCT00295490|Experimental|1920 mg Devil claw|Active dose
89258481|NCT00295490|Placebo Comparator|Placebo|Comparator for all active intervention arms
89258482|NCT03980990|Experimental|Metformin Continuation|Patients undergoing angiography will continue their metformin without interruption at their next scheduled dose following angiography.
89258483|NCT03980990|No Intervention|Metformin Interruption|Patients undergoing angiography will interrupt their metformin for 48 hours post angiography.
89258484|NCT03980756|Experimental|Group A1|Period 1: Test Drug(AD-206 20mg) Period 2: Reference Drug(Esomeprazole 20mg)
89258485|NCT03980756|Experimental|Group A2|Period 1: Reference Drug(Esomeprazole 20mg) Period 2: Test Drug(AD-206 20mg)
89258486|NCT03980756|Experimental|Group B1|Period 1: Test Drug(AD-206 40mg) Period 2: Reference Drug(Esomeprazole 40mg)
89258487|NCT03980756|Experimental|Group B2|Period 1: Reference Drug(Esomeprazole 40mg) Period 2: Test Drug(AD-206 40mg)
89258488|NCT00305006|Experimental|CIMT Intervention|Participants randomized to this arm were provided with 90 minutes of Constraint-Induced Movement Therapy (CIMT), which requires hand restraint and progression of unimanual tasks.
89258489|NCT00305006|Experimental|HABIT Intervention|Participants randomized to this arm were provided with 90 minutes of Hand-Arm Bimanual Intensive Therapy (HABIT), which requires that tasks are progressed bimanually.
89258490|NCT01064258|Active Comparator|fixed CPAP|subject will sleep with a fixed CPAP device at minimal pressure
89258491|NCT01064258|Experimental|autoCPAP|the subject will sleep connected to an autoCPAP device
89258492|NCT01064336||Pregnant women on eltrombopag|Any women with eltrombopag exposure during pregnancy that is reported prior to or after knowledge of the pregnancy outcome, substantiated by health care provider, and meeting the enrollment criteria: documentation that eltrombopag is being taken during pregnancy; timing of the prenatal exposure to eltrombopag (i.e. best estimation of which trimester in pregnancy that there was exposure to Eltrombopag for stratification and reporting purposes ); sufficient information to determine whether the pregnancy is being prospectively or retrospectively registered; whether the outcome of pregnancy was known at the time of the report; source of the report (i.e. health care professional, patient); full provider contact information to allow for follow-up (name, address, etc.)
89258493|NCT01064336||Infants|Infants through the first year of life whose mothers were exposed to eltrombopag during pregnancy.
89258494|NCT03980444|Experimental|control group, no basket of wire|"The dividing person and the patients themselves were not aware of which group they were in. They were double-blind Was.~In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
89258495|NCT03980444|Sham Comparator|using a basket of wires|In group B (using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
89258496|NCT03980600|Experimental|Donor site treatment with NFC dressing/FibDex®|"Patients requiring skin graft donor site treatment were enrolled in the investigation. Patients were selected based on clinical evaluation by a plastic surgeon.~Of the total 33 patients enrolled in the study, nine patients were treated during the optimization phase with experimental NFC dressing Types 1-3. The remaining 24 patients were treated with the final product Type 4 (FibDex®). The mean age of patients treated with NFC dressing/FibDex® was 50 ± 18 years, in the range of 21-74 years.~Suprathel® was used to treat donor sites in the same patients as a reference material. During the optimization phase, Suprathel was intra-individually compared with NFC dressing types 1-3 in five patients out of nine. From the remaining 24 patients, Suprathel was intra-individually compared with FibDex® in 17 patients."
89258497|NCT03978572|Active Comparator|Resistance Training|12 weeks of whole-body progressive resistance training, three days per week, lower-extremity focused (60% of exercises targeting lower extremities)
89258498|NCT03978572|Active Comparator|Moderate-intensity continuous cycling|12 weeks of progressive endurance cycling on a stationary bicycle at a target heart rate, three days per week.
89258499|NCT03978572|Experimental|High-intensity interval cycling|12 weeks of progressive high-intensity interval cycling on a stationary bicycle, three days per week.
89258500|NCT00319436|Experimental|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
89258501|NCT00319436|Active Comparator|Standard Parent Education for Substance Using Mothers|This 12 session comparison intervention was designed to match the Maternal Mentalizing Therapy on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child care and child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
89258502|NCT03978494|Experimental|Period 1: Advagraf®; Period 2: Generic tacrolimus|In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.
89258503|NCT03978494|Experimental|Period 1: Generic tacrolimus; Period 2: Advagraf®|In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.
89258504|NCT03978416|No Intervention|Focus groups|"Information on practical and cultural barriers and promoters of successful weight management will be collected through focus groups. This will include include food access, dietary patterns, physical activity, time and financial constraints, and additional psychosocial and cultural factors.~A total of 30 participants will be recruited for the focus groups."
89258505|NCT03978416|Experimental|Pilot behavioral intervention|A prototype bilingual English-Spanish lifestyle intervention for weight reduction will be created. The prototype will then be iteratively refined during a series of short-term tests with 5 participants per test (two tests lasting 4 weeks, followed by a final test lasting 12 weeks) of intervention delivery.
89258506|NCT01066286||core binding factor positive|core binding factor positive acute myeloid leukemia
89258507|NCT03980288|Experimental|CAR-GPC3 T Cells|The subjects enrolled will be sequentially assigned to Part 1 at 3 dose levels via typical 3+3 dose escalation method and then Part 2, cohort expansion stage, 3 cohorts of CAR T therapy combination with currently available treatment for HCC. stage Part 1: Dose escalating: 3 dose level Part 2: 3 cohorts Cohort 1. Combination with tyrosine kinase inhibitors Cohort 2. Combination with PD-1 / PD-L1 monoclonal antibody Cohort 3. Combination with the drugs may benefit for patient at investigator's discretion
89258508|NCT03980678|Active Comparator|Mineral Rich Algae with orange flavoring|Participants will consume the Aquamin Soluble (Mineral Rich Algae) equivalent of 1000mg Calcium in 250 ml of orange flavoured water.
89258509|NCT03980678|Placebo Comparator|Water with orange flavoring|Participants will consume a placebo of maltodextrin in 250 ml of orange flavoured water (40mg Calcium).
89258510|NCT01064492|Experimental|ABC, ACB, BAC, BCA, CAB, and CBA|
89258511|NCT01581164||HSCT patients|Patients who have been treated with HSCT
89258512|NCT00319046|Experimental|Open-label miglustat|Oral administration of miglustat 100 mg t.i.d. for a period of 2 years
89258513|NCT03980366|Experimental|ECT to treat self-injurious behaviors in adults with ASD|After initial exams and pre-screening, participants will receive bilateral Electroconvulsive Therapy (ECT) for 12 treatments sessions over the course of 4 weeks, plus non-ECT follow-up sessions at 1, 2, 6, and 12 months post-ECT treatment.
89258514|NCT03980210|Experimental|Hyperbaric oxygen therapy|"Successive changes in fraction of inspired oxygen and barometric pressure (ATA: Atmosphere absolute)~Five successive steps:~FiO2 0.21 - 1 ATA~FiO2 1 - 1 ATA~FiO2 1 - 2.5 ATA~FiO2 0.21 - 2.5 ATA~FiO2 0.21 - 1 ATA"
89258515|NCT01325402|Experimental|Part 1 Cohort 1|Patients with mild to moderate Alzheimer's Disease
89258516|NCT01325402|Experimental|Part 1 Cohort 2|Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.
89258517|NCT01325402|Experimental|Part 2|Healthy Volunteers
89258518|NCT03978338|Experimental|Intervention group|The experimental group will take the brain polypeptide solution .
89258519|NCT03978338|Placebo Comparator|Control group|The control group was treated with the same package of placebo .
89258520|NCT00303602|Experimental|A|Sublingual orally disintegrating olanzapine (SODO)
89258521|NCT00303602|Active Comparator|B|Oral olanzapine
89258522|NCT03979976|Active Comparator|ramipril group|Use of ramipril 10mg/day per 12 weeks
89258523|NCT03979976|No Intervention|Control Group|Without ramipril
89258524|NCT00299130|Active Comparator|Placebo + methotrexate (MTX)|"Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 milligrams (mg) intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
89258525|NCT00299130|Experimental|Rituximab 2 x 0.5 g + MTX|"Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
89258526|NCT00299130|Experimental|Rituximab 2 x 1.0 g + MTX|"Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
89258527|NCT00288054|Experimental|Cetuximab + Radiotherapy (no Docetaxel)|
89258528|NCT00288054|Experimental|Cetuximab + Radiotherapy + Docetaxel|
89258529|NCT00287586|Active Comparator|Testosterone|Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
89258530|NCT00287586|Placebo Comparator|Placebo|Participants received placebo-matching testosterone gel daily for 3 years.
89258531|NCT03979716|Experimental|Anosmic patients|
89258532|NCT03979716|Experimental|Hyposmic patients|
89258533|NCT03979716|Experimental|Normosmic patients|
89258534|NCT01070160||A|Women with PCOS initiating Metformin and exposure to vaginal progesterone for 6-8 days prior ro Endometrium Biopsy
89258535|NCT01070160||B|Women with PCOS not planning initiating Metformin and exposure to vaginal progesterone for 6-8 days prior to Endometrium Biopsy
89258536|NCT01070160||Women with PCOS who previously initiated metformin|Women with PCOS who initiated metformin at least 3 months prior to enrollment who have completed a 6-10 day course of progesterone
89258537|NCT00287118|Experimental|Efalizumab|
89258538|NCT03977298|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine
89258539|NCT03977298|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
89258540|NCT03977220|Experimental|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
89258541|NCT01065402|Placebo Comparator|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
89258542|NCT01065402|Experimental|PPB-R-203-Based Meal|"PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. RS intake is associated with several changes in metabolism which may confer some health benefits.~PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition."
89258543|NCT00293202|Active Comparator|Etanercept 25 mg|Etanercept 25 mg injection twice a week
89258544|NCT00293202|Placebo Comparator|Saline|Saline injection twice a week
89258545|NCT00298896|Experimental|SNS-595|SNS-595; 48 mg/m2 administered IV once every 21 days for up to 6 cycles.
89258546|NCT03977376|Experimental|Intervention|Valuation instruments were two validated scales: ESAS y HADS. Experimental nursing instrument: Guide of hosting.
89258547|NCT03977376|No Intervention|Control|Valuation instruments were two validated scales: ESAS y HADS. Without Guide of hosting.
89258548|NCT01067664||Patients undergoing IVF with rFSH and GnRH antagonists|
89258549|NCT00286494|Active Comparator|Placebo|
89258550|NCT00286494|Experimental|Alogliptin 12.5 mg QD|
89258551|NCT00286494|Experimental|Alogliptin 25 mg QD|
89258552|NCT03976050|Experimental|Dose escalation|Subjects in the dose escalation cohorts will receive ascending doses of HL-085 until the MTD is determined. The first three subjects will receive twice-daily doses (BID) of HL-085 6 mg. Additional cohorts may receive doses of HL-085 9, 12 or 18 mg BID respectively and sequentially. If DLTs are observed in <33.3% of subjects at the 18 mg dose.
89258553|NCT00298740|Experimental|Aventis U-400 Insulin|
89258554|NCT03979326|Experimental|Young women during various of phases of menstrual cycle.|The group of 40 young women will have their hamstring muscle stretched in different phases of the menstrual cycle: follicular, ovulatory and luteal. Static stretching will last 3x 45 seconds with a 15 second break between repetitions. Before and after the intervention a series of tests will be performed.
89258555|NCT03975972|Experimental|Occupational Therapy Based Literacy Intervention|For the intervention group, the results from the Inventory of Reading Occupations will be utilized to determine a prescriptive weekly intervention for each participant in the intervention group that will be provided to teachers based on student interest and literacy need. For the intervention group, each participant will be provided with a list of 12 questions that will be used to inform the intervention plan based on the interests of each participant within the intervention group. Collectively, the information from the 12 questions and the results of the Inventory of Reading Occupations will be used to determine a 9-week intervention plan for each participant within the intervention group. The researchers will work with the subjects twice per week, 30 minutes per session in the classroom using the prescriptive intervention that was determined from the assessments utilized.
89258556|NCT03975972|No Intervention|Standard Classroom Based Literacy Intervention|The control group will receive the standard reading instruction provided within the school. With the control group, the researchers will provide occupational therapy support to classroom teachers. But, will provide this support using the materials that are standardly provided within the classroom for literacy instruction. The researchers will provide support to the classroom teachers to students in the control group twice per week for 30 mintues per session in the classroom.
89258557|NCT01067742||Subjects with Mucolipidosis Type IV|
89258558|NCT01067820|Experimental|RVX000222, 200 mg daily|
89258559|NCT01067820|Placebo Comparator|Placebo|
89258560|NCT01067898|Experimental|200 000 IU vitamin D3 every three months|
89258561|NCT01067898|Experimental|100 000 IU vitamin D3 every three months|
89258562|NCT01067898|Placebo Comparator|placebo every three months|
89258563|NCT01065636|Experimental|Diet + Resistance Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised resistance exercise training three times a week
89258564|NCT01065636|Experimental|Diet + Aerobic Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised aerobic exercise training three times a week
89258565|NCT01065636|Experimental|Diet + Combined Aerobic/Resistance Exercise|Weekly behavioral/diet-induced weight loss plus combined supervised resistance exercise training and aerobic exercise training three times a week
89258566|NCT01065636|No Intervention|Control Group (No Diet/No Exercise)|No diet No exercise training
89258567|NCT03979248|Experimental|BMS-986165 + Rabeprazole|
89258568|NCT00285012|Placebo Comparator|placebo|
89258569|NCT00285012|Experimental|varenicline|
89258570|NCT00284934|Active Comparator|Standard dose EC-MPS|Patients received 720 mg/day (360 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) adjusted to maintain the trough blood level (C0) contained between 5.5 and 10 ng/mL. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
89258571|NCT00284934|Experimental|High EC-MPS|Patients received 1440 mg/day (720 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) tapered to reach a trough blood level target contained between 2 and 4.5 ng/mL within 15 days after randomization at the most. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
89258572|NCT01065792||1|Patients with HIV-1 infection taking Stocrin
89258573|NCT00284856|Experimental|1|Arm 1: Montelukast
89258574|NCT00284856|Active Comparator|2|Arm 2: Fluticasone
89258575|NCT00284856|Placebo Comparator|3|Arm 3: Placebo
89258576|NCT00298272|Experimental|Double-blind/Open Label Rituximab|"The double-blind rituximab treatment group received rituximab 500 mg by intravenous (IV) infusion on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to rituximab infusion, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
89258577|NCT00298272|Other|Double-blind Placebo/Open Label Rituximab|"The double-blind placebo treatment group received saline solution IV on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.~Prior to each infusion of placebo, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
89258578|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 50mg|
89258579|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 100mg|
89258580|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 200mg|
89258581|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 400mg|
89258582|NCT00283842|Placebo Comparator|Placebo|
89258583|NCT01068054|Active Comparator|tacrolimus|Tacrolimus arm: active 0.1% tacrolimus eye ointment BID + placebo eye drops QID
89258584|NCT01068054|Active Comparator|cyclosporine|2% cyclosporine eye drops apply QID + placebo eye ointment apply bid
89258585|NCT00298038|Experimental|Rifaximin|Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
89258586|NCT00298038|Placebo Comparator|Placebo|Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
89258587|NCT00283686|Active Comparator|Study A, Arm 1|Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg
89258588|NCT00283686|Active Comparator|Study A, Arm 2|Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg
89258589|NCT00283686|Placebo Comparator|Study A, Arm 3|Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg
89258590|NCT00283686|Placebo Comparator|Study A, Arm 4|Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg
89258591|NCT00297882|Active Comparator|1 Artemether-Lumefantrine (AL)|Study group 1. Subjects in this group received treatment with Artemether-Lumefantrine. Children received 2 mg/kg Artemether and 12 mg/kg Lumefrantrine with milk twice daily (or every 12 hours for 3 days.
89258592|NCT00297882|Active Comparator|2 Amodiaquine-Artesunate (AQ-AS)|Study group 2. Subjects in this group received treatment with Amodiaquine-Artesunate. Children received a co-administered combination of 30 mg/kg Amodiaquine (AQ) plus 4 mg/kg Artesunate (AS) daily for 3 days.
89258593|NCT01065870|Experimental|Group I|Patients with only venous involvement Treated with 6 cycles og GTX and then surgery
89258594|NCT01065870|Experimental|Group II|Patients with arterial involvement and may have venous involvement with tumor treated with 6 cycles of GTX, thenb GX/RT and then surgery
89258595|NCT03975894|Experimental|Intervention|Regular prophylactic blood transfusion given every 6-10 weeks during pregnancy to maintain a HbS% of <30%.
89258596|NCT03975894|No Intervention|Control|Symptom directed blood transfusion during pregnancy.
89258597|NCT00297648|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg
89258598|NCT03741816|Active Comparator|Biodentine|Indirect pulp capping with Biodentine in mature permanent molars with deep carious lesions and reversible pulpitis
89258599|NCT03741816|Experimental|TheraCal LC|Indirect pulp capping with TheraCal LC in mature permanent molars with deep carious lesions and reversible pulpitis
89258600|NCT01068132|Experimental|1|Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
89258601|NCT00283296|Experimental|Endeavor Wheelchair|Participants will receive an introduction to the Endeavor wheelchair, and will complete the Activities of Daily Living Course with their own personal wheelchair and with the Endeavor chair.
89258602|NCT00297492|Experimental|Gradual reduction|Intervention: Reduction Phone Counseling. Intervention: Pre-Quit Nicotine Lozenges. Intervention: Post-Quit Nicotine Lozenges.
89258603|NCT00297492|Active Comparator|Abrupt cessation|Intervention: Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
89258604|NCT00297492|Active Comparator|Minimal intervention|Intervention: Minimal Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
89258605|NCT00496769|Experimental|Apixaban|
89258606|NCT00496769|Active Comparator|Acetylasalicylic acid|
89258607|NCT01014845|Experimental|Hepatitis E vaccine|Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
89258608|NCT01014845|Placebo Comparator|HBV vaccine|Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
89258609|NCT01020461|Experimental|Venous blood sampling|To use Accuvein to improve the effectiveness of venous blood sampling
89258610|NCT01020461|Experimental|Peripheral IV catheter placement|To use Accuvein to improve the effectiveness of placing peripheral IV catheter
89258611|NCT04400357|Experimental|Robotic pancreaticoduodenectomy|Patients randomized in this arm will undergo a robotic pancreaticoduodenectomy.
89258612|NCT04400357|Active Comparator|Open pancreaticoduodenectomy|Patients randomized in this arm will undergo a routine open pancreaticoduodenectomy.
89258613|NCT00488345|Experimental|A|0.75 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by central laboratory in acceptable condition for 10 to 12 patients in cohort. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
89258614|NCT00488345|Experimental|B|1 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by the central laboratory in acceptable condition for 10 to 12 patients in the cohort. Treatment period of tigecycline will be a minimum of 3 days (unless the patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
89258615|NCT00488345|Experimental|C|1.25 mg/kg (up to maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
89258616|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)|Participants administered docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
89258617|NCT00283062|Active Comparator|Leuprolide Acetate - Immediate Treatment (I-HT)|Participants administered leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
89258618|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months.
89258619|NCT00283062|Active Comparator|Leuprolide Acetate - Deferred Treatment (D-HT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with with leuprolide acetate every 3 months for 18 months.
89258620|NCT00282984|Placebo Comparator|placebo|
89258621|NCT00282984|Experimental|varenicline|
89258622|NCT02532348||HIV Patients with antiretroviral therapy|Blood samples in HIV patients under 2 NRTIs (Nucleosidic analogs of Transcriptase Reverse Inhibitors) and 1 PI or 2 NRTIs and 1 NNRTI, for at least one year with a plasmatic viral load under 40 cp/ml.
89258623|NCT02532348||HIV patients without antiretroviral therapy|Blood samples in HIV patients never treated by antiretroviral therapy
89258624|NCT00282438|Experimental|Autologous hematopoietic stem cell transplantation|Autologous stem cells will be injected after conditioning
89258625|NCT00282438|Experimental|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
89258626|NCT01065948|Experimental|Patients|
89258627|NCT04282356|Experimental|Intraperitoneal chemotherapy|Cisplatin 100mg/m2 during surgery IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8 after surgery with at least 3 courses performed (up to 4-6 allowed)
89258628|NCT01068288|Experimental|Expectant Management|Expectant Management
89258629|NCT01068288|Experimental|Operative management|Operative management
89258630|NCT00296244|Other|Steroid -free immunosuppression|Study group - Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
89258631|NCT00296244|Other|Steroid containing immunosuppression|Control group- Basiliximab, Tacrolimus, EC-MPA, steroids
89258632|NCT00274716|Experimental|High BMI:MK-0736 2mg→Placebo|Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
89258633|NCT00274716|Experimental|High BMI:MK-0736 7mg→Placebo|Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
89258634|NCT00274716|Experimental|High BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
89258635|NCT00274716|Placebo Comparator|High BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
89258636|NCT00274716|Experimental|Low BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
89258637|NCT00274716|Placebo Comparator|Low BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
89258638|NCT01068444|Experimental|Pioglitazone|Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
89258639|NCT01068444|Placebo Comparator|Placebo|Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
89258640|NCT00282048|Experimental|AG-013736 (axitinib)|AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity
89258641|NCT03975348|Other|Baseline conventional facemask|The patients will receive oxygen therapy through conventional facemask for 10 minutes
89258642|NCT03975348|Experimental|HFNC 40 L/min up|The patients will receive oxygen/air mixture through high flow nasal cannula at incremental, then decremental flows, starting at 40 L/min for 10 minutes
89258643|NCT03975348|Experimental|HFNC 60 L/min up|High flow nasal cannula at 60 L/min for 10 minutes
89258644|NCT03975348|Experimental|HFNC 80 L/min up|High flow nasal cannula at 80 L/min for 10 minutes
89258645|NCT03975348|Experimental|HFNC 100 L/min|High flow nasal cannula at 100 L/min for 10 minutes
89258646|NCT03975348|Experimental|HFNC 80 L/min down|High flow nasal cannula at 80 L/min for 10 minutes
89258647|NCT03975348|Experimental|HFNC 60 L/min down|High flow nasal cannula at 60 L/min for 10 minutes
89258648|NCT03975348|Experimental|HFNC 40 L/min down|High flow nasal cannula at 40 L/min for 10 minutes
89258649|NCT03975348|Other|Washout conventional facemask|Again, the patients will receive oxygen therapy through conventional facemask for 10 minutes, to reduce the influence of HFNC on CPAP therapy
89258650|NCT03975348|Active Comparator|CPAP|The patients will receive CPAP at 10 cmH2O for 10 minutes
89258651|NCT03975192|Experimental|Intervention Group|50% of subjects will be randomized to the Intervention group and will receive percutaneous electric nerve field stimulation (PENFS) through the BRIDGE Device for 120 hours to treat withdrawal symptoms in patients following opiate exposure in the PICU.
89258652|NCT03975192|No Intervention|Standard of Care Group|50% of subjects will be randomized to the Standard of Care group and will receive be started on the standardized PICU Methadone wean for patients following opiate exposure in the PICU.
89258653|NCT00474539|Experimental|1|
89258654|NCT00474539|Active Comparator|2|
89258655|NCT01017809|Other|Oxali/Topotecan|Patients enrolled to NYU 03-67 will be receiving Oxaliplatin 85 mg/m2 IV over 120 minutes on Day 1 and 15 Topotecan 0.4mg/m2/day CIV from D1 to 15 (in addition to the assigned intervention)
89258656|NCT01014923|Experimental|Intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
89258657|NCT01014923|No Intervention|Control|Parents receive a Department of Transportation booklet on teen driving
89258658|NCT01020539|Experimental|Matched Family Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from a related family donor using bone marrow or cord blood stem cells. Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression. Graft-versus-host-disease (GVHD) prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
89258659|NCT01020539|Experimental|Unrelated Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from an unrelated donor using matched bone marrow or cord blood stem cells.Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression and unrelated donor transplant recipients will additionally receive Anti-Thymocyte Globulin. GVHD prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
89258660|NCT01015001|Active Comparator|Active rTMS|1Hz rTMS sessions applied to the left temporoparietal cortex of the subjects
89258661|NCT01015001|Placebo Comparator|Sham rtms|Same number of pulses but applied with and angled coil (90 degrees) and placed over the fronto´temporal region
89258662|NCT00281580|Placebo Comparator|Placebo|Placebo once daily for eight weeks
89258663|NCT00281580|Experimental|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
89258664|NCT00281580|Experimental|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
89258665|NCT00281580|Experimental|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
89258666|NCT00281580|Experimental|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
89258667|NCT00281580|Experimental|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
89258668|NCT00281580|Active Comparator|Amlodipine 10 mg|Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
89258669|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 2.5|Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
89258670|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 5|Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
89258671|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 10|Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
89258672|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 2.5|Telmisartan 40 / Amlodipine 2.5 for eight weeks
89258673|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 5|Telmisartan 40 / Amlodipine 5 for eight weeks
89258674|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
89258675|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 2.5|Telmisartan 80 / Amlodipine 2.5 for eight weeks
89258676|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 5|Telmisartan 80 / Amlodipine 5 mg for eight weeks
89258677|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
89258678|NCT03997175|Experimental|Intervention|The children were in daily contact with biodiversity sand 5 days a week for two weeks.
89258679|NCT03997175|Placebo Comparator|Placebo|Children were in contact with normal but colored sand that looked as it were the biodiversity sand. All the other details were as above.
89258680|NCT04393181||recipients of hearts with impaired function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with impaired function
89258681|NCT04393181||recipients of hearts with normal function|Patient who has been accepted for heart transplantation at the participating transplantation center and who will receive heart with normal function
89258682|NCT01017887||Airseal port for laparoscopic surgery|Airseal access port for laparoscopic surgery with standard ports.
89258683|NCT01017887||Standard Laparoscopy ports|Uses standard laparoscopy ports.
89258684|NCT01020695||PTSD veterans|18 PTSD veterans
89258685|NCT01020695||controls|20 controls
89258686|NCT00495755|Experimental|Campath (alemtuzumab)|
89258687|NCT01070862|Experimental|thalidomide + dexamethasone|Thalidomide 200 mg/d at bedtime + Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
89258688|NCT01070862|Active Comparator|Vincristin, Adriamycin, Dexamethasone|
89258689|NCT01070862|Experimental|thalidomide, melphalan, endoxan, dexamethasone|
89258690|NCT01070862|Active Comparator|melphalan, endoxan, dexamethasone (MCDex)|
89258691|NCT01070862|Experimental|Thalidomide, Dexamethasone|
89258692|NCT01070862|No Intervention|watch and wait|
89258693|NCT00495677|Active Comparator|PF-00232798 40 mg|
89258694|NCT00495677|Active Comparator|PF-00232798 300 mg|
89258695|NCT00495677|Active Comparator|PF-00232798 400 mg|
89258696|NCT00495677|Active Comparator|PF-00232798 5 mg|
89258697|NCT00495677|Active Comparator|PF-00232798 20 mg|
89258698|NCT00495677|Active Comparator|PF-00232798 150 mg|
89258699|NCT01020851|Experimental|tailored intervention|Participants in this arm will receive 6 monthly telephone calls of a behaviorally tailored intervention based on the transtheoretical model.
89258700|NCT01020851|Active Comparator|attention placebo|Participants in this arm will receive 6 monthly telephone delivered counseling sessions about general health topics
89258701|NCT01018043||001|Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
89258702|NCT00495521|Experimental|Active|4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks
89258703|NCT00495521|Placebo Comparator|Placebo|Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks
89258704|NCT01021085||Pregnant women|Pregnant women who have conceived via ART and are between days 36 and 56 of gestation
89258705|NCT00273858||etanercept|Patients already prescribed to receive etanercept for the first time for treatment of Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary of Product Characteristics (SmPC).
89258706|NCT03975426||conservative group|received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture.
89258707|NCT03975426||absorbable screws|received open reduction and internal fixation with fixation by absorbable screws.
89258708|NCT01068522|Experimental|ICP monitoring|Care based upon intracranial pressure.
89258709|NCT01068522|Active Comparator|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
89258710|NCT00494507|Active Comparator|HYP Dichlorphenamide|Hyperkalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
89258711|NCT00494507|Placebo Comparator|HYP Placebo|Hyperkalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
89258712|NCT00494507|Active Comparator|HOP Dichlorphenamide|Hypokalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
89258713|NCT00494507|Placebo Comparator|HOP Placebo|Hypokalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
89258714|NCT01018121|Experimental|Clinic and Home Behavioral Intervention|
89258715|NCT01018121|Active Comparator|Pediatrician Counseling|
89258716|NCT00292188|Experimental|Active|
89258717|NCT00292188|Placebo Comparator|Placebo|
89258718|NCT00272844|Experimental|Cholesterol supplementation|
89258719|NCT00271596|Experimental|Citalopram|20mg daily citalopram
89258720|NCT00271596|Placebo Comparator|Placebo|Matching daily placebo
89258721|NCT01068756|Other|Dapagliflozin/Rifampin|
89258722|NCT01068834||KIF6 tested|Recruited subjects, completing a valid KIF6 test with results
89258723|NCT01068834||KIF6 test naïve|Database matched cohort not receiving a KIF6 test
89258724|NCT00291642|Placebo Comparator|Placebo (PBO)|A single dose of placebo was administered orally on Day 1.
89258725|NCT00291642|Experimental|Levocetirizine (LCTZ) 2.5 mg|A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.
89258726|NCT00291642|Experimental|Levocetirizine (LCTZ) 5 mg|A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.
89258727|NCT00291642|Experimental|Cetirizine (CTZ) 5 mg|A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.
89258728|NCT00291642|Experimental|Cetirizine (CTZ) 10 mg|A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.
89258729|NCT00280566|Experimental|Ziprasidone|Active treatment, double-blind, randomized arm
89258730|NCT00280566|Placebo Comparator|Placebo|Placebo treatment, double-blind, randomized arm
89258731|NCT00270894|Experimental|Neoadjuvant therapy|Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments.
89258732|NCT01070628|Experimental|Stalevo (levodopa/carbidopa/entacapone)|"125mg or 75mg of levodopa during treatment period 1 in groups 1 and 2 respectively.~150mg or 100mg of levodopa during treatment period 2 in groups 1 and 2 respectively."
89258733|NCT01070628|Active Comparator|Sinemet (levodopa/carbidopa)|150mg or 100mg of levodopa during treatment period 3 in study groups 1 and 2 respectively
89258734|NCT03976830||Children diagnosed with cancer|Patients diagnosed with childhood cancer in participating sites in Central American countries
89258735|NCT01070940|Placebo Comparator|Isotonic saline infusion|
89258736|NCT01070940|Active Comparator|Intravenous L-NMMA dose 2|
89258737|NCT01070940|Active Comparator|Intravenous L-NMMA dose 3|
89258738|NCT01070940|Active Comparator|Intravenous L-NMMA dose 1|
89258739|NCT00317642|Experimental|clofarabine (IV formulation) and cytarabine|"Participants received clofarabine (40 mg/m^2) administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Participants could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)~Complete induction cycle = 5 consecutive days of treatment~Re-induction cycle = 5 consecutive days of treatment at the original or modified dose~Consolidation cycle = 4 consecutive days of treatment at the original or modified dose"
89258740|NCT00317642|Experimental|placebo and cytarabine|Participants received placebo administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Patients could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
89258741|NCT01064726|Experimental|Ibuprofen|
89258742|NCT01064726|Experimental|Fluticasone propionate|
89258743|NCT01064726|Placebo Comparator|Placebo|
89258744|NCT01064804||relative bioavailability|
89258745|NCT01064960|Experimental|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure are treated with the Philips MR-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
89258746|NCT00295022|Placebo Comparator|Placebo (PBO)|Placebo was administered orally on Days 1 and 2.
89258747|NCT00295022|Experimental|Montelukast (MLKT)|10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.
89258748|NCT00295022|Experimental|Levocetirizine (LCTZ)|5 mg of Levocetirizine (LCTZ) was administered orally on Days 1 and 2.
89258749|NCT01062152|Experimental|Revlimid® in Combination with Telintra ®|Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.
89258750|NCT00303446|Active Comparator|Dutasteride|Dutasteride 0.5 mg/day
89258751|NCT00303446|Placebo Comparator|Placebo|Matched placebo
89258752|NCT00316706|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
89258753|NCT00316706|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix™ (hepatitis A vaccine [HAV]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.
89258754|NCT01065038|Experimental|Anagrelide|
89258755|NCT01065038|Active Comparator|Hydroxyurea|
89258756|NCT03980054|Experimental|Arm Pyrotinib|Intervention: Drug: Pyrotinib
89258757|NCT03980054|Placebo Comparator|Arm Placebo|Intervention: Drug: Placebo
89258758|NCT02532608|Experimental|Acute sleep deprivation|Registration of habitual sleep and sleep after sleep deprivation
89258759|NCT00291486|Experimental|Cohort 1|"20 millicurie (mCi) 131I-huA33, 1500 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
89258760|NCT00291486|Experimental|Cohort 2|"30 millicurie (mCi) 131I-huA33, 1500 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
89258761|NCT00291486|Experimental|Cohort 3|"30 millicurie (mCi) 131I-huA33, 1000 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
89258762|NCT00291486|Experimental|Cohort 4|"40 millicurie (mCi) 131I-huA33, 1000 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
89258763|NCT00291486|Experimental|Cohort 5|"40 millicurie (mCi) 131I-huA33, 1250 mg/m2/day capecitabine~All patients received an initial dose of 5 mg huA33 conjugated to 5-8 mCi 131I on day 0.~This was followed 7 ± 2 days later by inpatient administration of a single infusion of 131I-huA33 with a constant protein dose of 10 mg/m2 huA33.~Capecitabine was administered in 2 divided doses per day on days 1-14 of each 21-day cycle for a total of 4 cycles. Daily doses were rounded to the nearest 150 mg."
89258764|NCT00301964|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
89258765|NCT03976986|Experimental|cPOC - pPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by cPOC (continuous-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by pPOC (pulsed-flow).
89258766|NCT03976986|Experimental|pPOC - cPOC|Randomized crossover study (according to a random number table): Patients are allocated randomly to two study groups (cPOC/pPOC). In case of Sat.O2 drop ≤ 85% during HCT, oxygen is administered by pPOC (pulsed-flow). For patients who show a positive POC hypoxic reversal, HCT is repeated at 24 hours and oxygen is administered by cPOC (continuous-flow).
89258767|NCT01070706|Experimental|Paclitaxel, Gemcitabine, Sunitinib|Paclitaxel, Gemcitabine, Sunitinib
89258768|NCT03978026|Experimental|nap in a bed|the participants take a nap of 30 min in a bed in a bedroom
89258769|NCT03978026|Experimental|nap in an armchair|the participants take a nap of 30 min in a car sit in a bedroom
89258770|NCT03978026|Experimental|nap in teh Sombox|the participants take a nap of 30 min in the micro-hotel Sombox
89258771|NCT03978026|Sham Comparator|no nap in a bed|the participant stay awaked for 30 min in a bed in a bedroom
89258772|NCT01581606||Group 1R and 1T AMD Screening|Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
89258773|NCT01581606||Group 2R and 2T Follow up|Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).
89258774|NCT00268242|Experimental|Gemcitabine + Mitoxantrone|Gemcitabine Hydrochloride as administered as a continuous intravenous infusion (I.V.) at 10mg/m^2/minute for 12 hours, starting on Day 1. Mitoxantrone Hydrochloride was given at a dose of 12mg/m^2/day I.V. on days 1, 2, and 3.
89258775|NCT00294554|Active Comparator|Active Memantine|Memantine tablets, formulated in appearance to match the placebo comparator, were initiated at 5 mg daily and advanced by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
89258776|NCT00294554|Placebo Comparator|Placebo Oral Tablet|Placebo tablets were formulated to match active 5mg memantine tablets. Dosing same as the active comparator with initiation at 5 mg daily and advancing by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
89258777|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Standard asthma therapy including oral corticosteroids, albuterol, education and discharge instructions.
89258778|NCT00294398|Experimental|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
89258779|NCT00279708|Active Comparator|Intervention Arm (Atorvastatin)|Atorvastatin: Subjects were assigned to the treatment intervention by way of double blind masking. Atorvastatin 80 mg/day was the initial treatment given, as tolerated for a 12 month period. During the study, a 50% dose reduction was applied for subjects meeting pre-specified criteria.
89258780|NCT00279708|Placebo Comparator|Control Arm (Placebo)|Placebo: In a double-blind fashion, subjects were assigned to receive the sham intervention which appeared the same as the intervention agent. For subjects meeting pre-specified criteria, a 50% dose reduction was applied during the 12 month treatment phase of the study: Placebo vs. Atorvastatin
89258781|NCT03978182|Active Comparator|active accelerated deep rTMS|Stimulation: We will use a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil, which includes a sham option. In analogy to our former accelerated rTMS studies (2, 3), all patients will receive 20 dTMS sessions (5 sessions per day; 4 consecutive days) with a stimulation intensity of 120% of the subject's resting MT, as reported by Levkovitz et al.(4). Furthermore, we selected these FDA approved dTMS parameters, so that for one session each dTMS repetition includes 2-sec pulse trains separated by 20-sec inter-train intervals. Patients will receive 55 trains in each treatment session, for a total of 1980 pulses per session. This makes 9900 pulses/day, and in total 39600 pulses per treatment.
89258782|NCT03978182|Sham Comparator|sham|Built-in sham in the H1 Helmet (same device as active treatment)
89258783|NCT01066442|Experimental|BF2.649 ( Pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
89258784|NCT01066442|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
89258785|NCT01581372|Experimental|Pharmacist care|
89258786|NCT01581372|No Intervention|Usual care|
89258787|NCT02532842||Participants with Schizophrenia|This is a retrospective, non-interventional, multicenter study to retrospectively evaluate hospitalization and medical resource use, patterns of paliperidone palmitate use, and clinical outcomes documented within the medical records of young, adult, newly diagnosed schizophrenia participants for the first 12 months of continuous treatment with paliperidone palmitate. Only retrospective data available from clinical routine practice and documented in a participant's medical record will be collected.
89258788|NCT01069146|Experimental|Mild therapeutic hypothermia|Sepsis treatment according to standard guidelines plus mild therapeutic hypothermia
89258789|NCT01069146|No Intervention|Control|Sepsis treatment according to standard guidelines
89258790|NCT00299702|Active Comparator|002|
89258791|NCT00299702|Experimental|001|
89258792|NCT03979898|Experimental|Astrostem|Autologous Adipose Tissue Derived Mesenchymal Stem Cells
89258793|NCT00291330|Experimental|dabigatran etexilate 150 mg|twice daily
89258794|NCT00291330|Active Comparator|warfarin (INR 2-3)|prn to maintain INR (2-3)
89258795|NCT03975036|Experimental|Anlotinib&pd-1 antibody|Anlotinib 10mg/d,q.d.,p.o.&pd-1 antibody 200mg/d.q.3w.d.l.v
89258796|NCT01069224||RC tear|This study will include a consecutive series of patients who met the study inclusion criteria. Study group patients will be diagnosed RC tear on clinical examination and imaging findings (US and MRI) that will be verified at arthroscopy in order to complete the enrollment.
89258797|NCT01069224||Control group|Control group will include patients suffering from shoulder instability that scheduled for elective surgical repair.
89258798|NCT00267150|Experimental|1|
89258799|NCT03741504|No Intervention|No micro-osteoperforations (No MOPs)|Canine Distalization without micro-osteoperforations Distalization of the upper canine in working phase with coil spring of 100 gr of force
89258800|NCT03741504|Experimental|Micro-osteoperforations (MOPs)|Canine Distalization with micro-osteoperforations at the start of the distalization Distalization of the upper canine in working phase with coil spring of 100 gr of force
89258801|NCT01582230|Experimental|Vildagliptin|Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
89258802|NCT01582230|Placebo Comparator|Placebo|Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
89258803|NCT00278148|Experimental|Dose Level A|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level A: 50 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
89258804|NCT00278148|Experimental|Dose Level B|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level B: 100 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
89258805|NCT00278148|Experimental|Dose Level C|"Erlotinib, Paclitaxel, and Carboplatin with Radiation~Dose Level C: 150 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
89258806|NCT00299546|Placebo Comparator|Group 1: Placebo|Placebo Subcutaneous (SC) injections every 4 weeks (wks) thru Wk 20 (unless early escape at Wk 16); Golimumab - if early escape, 50 mg SC injections from Wk 16 up to 5 yrs; Golimumab - 50 mg SC injections beginning Wk 24 up to 5 yrs (unless early escape); Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
89258807|NCT00299546|Experimental|Group 2: Golimumab 50 mg|Golimumab 50 mg SC injections every 4 wks from Wk 0 up to 5 yrs (unless early escape at Wk 16); Golimumab - if early escape, 100 mg SC injections every 4 wks beginning Wk 16 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
89258808|NCT00299546|Experimental|Group 3: Golimumab 100 mg|Golimumab 100 mg SC injections every 4 wks from Wk 0 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50 mg. Duration of the blinded period will be until the week-24 database lock.
89258809|NCT01071018|Experimental|QOD Schedule|QOD Schedule, MK2206 every other day
89258810|NCT01071018|Experimental|QW Schedule|QW Schedule, MK2206 once weekly
89258811|NCT03975270|Experimental|Sintilimab in Combination With Nab-paclitaxe|Sintilimab 200 mg intravenous drip, first day Nab-paclitaxe120 mg/m2, intravenous drip, first day and eighth day
89258812|NCT01065116|Experimental|AL Blister-pack|
89258813|NCT01065116|Active Comparator|AL unit dose age specific pre-packs|
89258814|NCT03977792|Experimental|Experimental treatment|"Subjects treated with BOR15001L7.~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
89258815|NCT03977792|Active Comparator|Comparator treatment|"Subjects treated with Docosanol 10%.~All subjects will be randomized 1:1 (BOR15001L7:docosanol 10%) to receive either BOR15001L7 or docosanol 10%."
89258816|NCT01062542||Breast Cancer Survivors|
89258817|NCT01062542||Pediatric Cancer Survivors|
89258818|NCT01062542||Control group|
89258819|NCT01066598|Experimental|Rituximab plus prednisone|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d Treat 61 Patients
89258820|NCT01066676|Experimental|Dexibuprofen|Dexibuprofen 400 mg powder for oral suspension
89258821|NCT01066676|Active Comparator|Ibuprofen|Ibuprofen 400 mg powder for oral suspension
89258822|NCT01065194|Experimental|Levosimendan|Chronic stable heart failure
89258823|NCT01065194|Placebo Comparator|Placebo|Chronic Stable Heart Failure
89258824|NCT01065272|Active Comparator|Ventolin - Dexamethasone group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.
89258825|NCT01065272|Placebo Comparator|Ventolin - Placebo group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.
89258826|NCT00299156|Experimental|Oral Clofarabine|10 mg (Group 1) or 20 mg (Group 2) tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
89258827|NCT00277212|Experimental|A1|Phase 1: Single-Blind Treatment, Lamotrigine + Aripiprazole ; Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole
89258828|NCT00277212|Placebo Comparator|A2|Phase 2 Double-Blind Treatment: Lamotrigine + Placebo
89258829|NCT02532296|Active Comparator|Control|Receive usual hospital discharge, care transition and post-discharge care.
89258830|NCT02532296|Experimental|Transition Coach Intervention|In addition to usual care, the intervention group receives care from a trained Transition Coach to support patients for 30 days after discharge.
89258831|NCT03982628||Sepsis|Adults admitted to a mixed medical/surgical ICU for sepsis with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
89258832|NCT03982628||Trauma|Adults admitted to a mixed medical/surgical ICU for trauma (without sepsis) with at least two abdominal CT imaging studies separated by at least 24 hours, ordered as part of their routine clinical care.
89258833|NCT01065584||Standard immunosuppression|Patients receiving standard immunosuppression after liver transplantation including calcineurininhibitors
89258834|NCT01065584||Immunosuppression without calcineurininhibitors|Patients receiving immunosuppression after liver transplantation not based on calcineurininhibitors
89258835|NCT01066754|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets of Dr. Reddy's Laboratories Limited
89258836|NCT01066754|Active Comparator|Allegra|Allegra Tablets 180 mg of Aventis Pharmaceuticals Inc.,
89258837|NCT02531958|Experimental|1 Egg|Consumption of 1 egg per day for 4 weeks
89258838|NCT02531958|Experimental|2 Eggs|Consumption of 2 eggs per day for 4 weeks
89258839|NCT02531958|Experimental|3 Eggs|Consumption of 3 eggs per day for 4 weeks
89290387|NCT03931824|Experimental|PRP group|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times."
89258840|NCT00276744|Experimental|Arm 1|"PART A: Participants will have their tumors collected at the time of conventional surgery. Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Patients will then proceed to receive adjuvant treatment based on physician discretion and will be followed until disease progression.~Capecitabine 1,5 mmol/kg Oral gavage 1- 5 days x 2 weeks Cetuximab 500 mg IP Twice a week x 2 weeks Docetaxel 20 mg/kg IV Once at week x 4 weeks Erlotinib 75 mg/kg IP 1-5 days x 2 weeks Gemcitabine 100 mg/kg IP Twice a week x 4 weeks Irinotecan 50 mg/kg IV Twice a week Mitomycin C 5 mg/kg IP One dose Rapamycin 4 mg/kg IP 1-5 days x 2 weeks~PART B: At the time of progression, patients will be evaluated for Part B of the study and treated with the drug selected in Part A as the most active using approved doses and schedules of administration."
89258841|NCT00251316|Experimental|Lithium Carbonate|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive lithium capsules.
89258842|NCT00251316|Placebo Comparator|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
89258843|NCT02532192|Experimental|Belinostat + RDHAP Chemotherapy|Belinostat administered by vein on Days 1 - 2 of a 21-day cycle. Rituximab administered by vein on Day 2. Cisplatinum administered by vein on Day 2. Cytarabine administered by vein on Day 3 during the initial cohorts, and on Day 2 in the cohort of modified DHAP scheduling. Ciprofloxacin 500 mg twice daily for 10 days and Fluconazole 100 mg daily for 10 days may be utilized at the discretion of the treating physician.
89258844|NCT00293462|Active Comparator|Arm I: GM-CSF Group (GG)|Arm I: Patients were randomized to receive oral sargramostim (GM-CSF) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
89258845|NCT00293462|Active Comparator|Arm II: Salt & Soda Group (SS)|Arm II: Patients were randomized to receive salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving SS treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
89258846|NCT00293462|Active Comparator|Arm III: Salt & Soda Switched to GM-CSF (SG)|Arm III: Patients were randomized to receive oral salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
89258847|NCT00316082|Experimental|Saxagliptin 2.5 mg QAM (A)|PLUS open-label metformin (as needed as rescue medication)
89258848|NCT00316082|Experimental|Saxagliptin 2.5 mg titrated to 5 mg QAM (B)|PLUS open-label metformin (as needed as rescue medication)
89258849|NCT00316082|Experimental|Saxagliptin 5 mg QAM (C)|PLUS open-label metformin (as needed as rescue medication)
89258850|NCT00316082|Experimental|Saxagliptin 5 mg QPM (D)|PLUS open-label metformin (as needed as rescue medication)
89258851|NCT00316082|Placebo Comparator|Placebo (E)|PLUS open-label metformin (as needed as rescue medication)
89258852|NCT00316004|Experimental|7.5% hypertonic saline/6% dextran (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
89258853|NCT00316004|Experimental|7.5% hypertonic saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline
89258854|NCT00316004|Placebo Comparator|0.9% normal saline (NS)|250 ml intravenous bolus administration of 0.9% saline
89258855|NCT00298766|Experimental|1|VELCADE
89258856|NCT03979664|Active Comparator|Active Iontophoresis|One active iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
89258857|NCT03979664|Sham Comparator|Inactive Iontophoresis|One inactive iontophoresis patch will be applied once at the baseline clinical visit. The iontophoresis patches are called Activapatch intellidose 2.5.
89258858|NCT00315458|Experimental|BTDS|Buprenorphine transdermal patches 10 or 20 mcg/h
89258859|NCT00315458|Placebo Comparator|Placebo|Placebo to match buprenorphine transdermal patch 10 or 20
89258860|NCT01065662|Experimental|Cediranib and Temsirolimus|Please see interventions section.
89258861|NCT01062620|Experimental|AXL1717|
89258862|NCT01065740|Experimental|patient education|individual and group meetings with explanations about the disease, lifestyle counseling ; coaching by phone at 1 and 4 months; medical consultation at 3 months; physical exercise with coaching
89258863|NCT01065740|No Intervention|Usual care|
89258864|NCT01066910|Experimental|Parent-only|
89258865|NCT01066910|Active Comparator|Parent and child|
89258866|NCT01581242|Experimental|A|
89258867|NCT01581242|Experimental|B|
89258868|NCT01581242|Experimental|C|
89258869|NCT03982238|Active Comparator|Control group|continuous subcutaneous insulin infusion therapy
89258870|NCT03982238|Experimental|Metformin|metformin therapy
88821568|NCT03502577|Experimental|Treatment (Chemotherapy, BCMA-specific CAR T-cells, LY3039478)|Participants receive fludarabine and cyclophosphamide on days -4 to -2. Participants then receive BCMA-specific CAR T-cells IV over 20-30 minutes on day 0 and LY3039478 PO on days 2, 4, 7, 9, 11, 14, 16, and 18.
88821569|NCT03499808|Experimental|Treatment (isatuximab)|Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
88821570|NCT03491540|Experimental|"1)  MBP and oral antibiotics  group"|Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
88821571|NCT03491540|Placebo Comparator|"2)  MBP alone  group"|Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
88821572|NCT03484403|Active Comparator|Control Group|Study participants will not receive a back brace but will receive back school education and the same physical therapy exercise instruction as the treatment group.
89258871|NCT03982238|Experimental|Dapagliflozin|Dapagliflozin
89258872|NCT00293384|Experimental|Aprepitant, Dexamethasone, Cytoxan & Kytril|"Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.~Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.~Days 2 & 3: Aprepitant 80 mg once daily in the morning."
89258873|NCT00297830|Experimental|Active Zoledronic Acid & Placebo Alendronate|Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.
89258874|NCT00297830|Experimental|Placebo Zoledronic Acid & Active Alendronate|Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.
89258875|NCT01065896||Group 1|
89258876|NCT00296816|Experimental|Oxaliplatin/Docetaxel/Bevacizumab|Participants with International Federation of Gynecology and Obstetrics (FIGO) stage IB through IV ovarian, primary peritoneal, or fallopian tube carcinoma treated with Oxaliplatin, Docetaxel, and Bevacizumab - 28 days after initial surgery
89258877|NCT01066988|Other|Right Eye|ORB Ocular Emulsion or SootheXP
89258878|NCT01066988|Other|Left Eye|ORB Ocular Emulsion or SootheXP
89258879|NCT00314132|Placebo Comparator|Placebo|All subjects received a single injection of placebo on Day 0.
89258880|NCT00314132|Experimental|ChimeriVax™ JE 4 log10 PFU Vaccine|All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.
89258881|NCT03977558|Experimental|Intervention group|Isocaloric diet, based on individual energy requirements calculated from indirect calorimetry and physical activity adjustment Participants will be asked to eat daily ~50g canola oil
89258882|NCT03977558|Active Comparator|Control group|Standard dietary advice that is used as current best practice in the treatment of lipid disturbances of European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) Guidelines for the management of dyslipidemias)
89258883|NCT01081756|Experimental|Subjects treated with r-hCG|Subjects treated with r-hCG
89258884|NCT01081756|Active Comparator|Subjects treated with urinary hCG|Subjects treated with urinary hCG
89258885|NCT03965182|Active Comparator|PEG group|Patients in the PEG group were instructed to take the first sachet of PEG at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
89258886|NCT03965182|Active Comparator|PEG plus SPMC group|Patients in the PEG plus SPMC group will be instructed to take the SPMC sachet at 19:00 hours the day before colonoscopy and the PEG sachet at 6:00 hours on the morning of the day of colonoscopy.
89258887|NCT03965182|Active Comparator|SPMC group|Patients in the SPMC group were instructed to take the first sachet of SPMC at 19:00 hours the day before colonoscopy and the second one at 06:00 hours on the morning of the day of colonoscopy.
89258888|NCT01081990|Placebo Comparator|Placebo Pill|
89258889|NCT01081990|Experimental|Flexeril|
89258890|NCT01079572|Experimental|web-based|The patient will undergo xrays at the closest PACs enabled imaging centre and will login and answer questions online. The surgeon will review the images and patient responses and determine whether the patient needs to be seen more urgently or a per routine.
89258891|NCT01079572|Active Comparator|in-person|Patients will attend their follow-up appointments in-person as per usual
89258892|NCT01079650||children suffering from abdominal or testicle pain|
89258893|NCT01084486|Experimental|Metformin, Adiponectine, Arterial Compliance|
89258894|NCT01084564||1|moderate to severe uncontrolled asthma
89258895|NCT01082146|Experimental|Lurasidone|LURASIDONE 40mg
89258896|NCT01084642||survey|Participants will be asked to complete a survey as a one time assessment.
89258897|NCT00117988|Experimental|Arm I|Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease regression after completion of 8 courses may receive 2 additional courses of treatment beyond their maximal response. After completion of study treatment, patients are followed every 3 months until disease progression.
89258898|NCT03963466|Experimental|group 1|(left side of cheek) 1064-nm Q-Switched fractional laser+drug Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
89258899|NCT03963466|Experimental|group 2|(right side of cheek) 1064-nm Q-Switched laser+drug Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 Drug: Oral tranexamic acid group(menstrual period>2days)
89258900|NCT03963466|Experimental|group 3|(left side of cheek) 1064-nm Q-Switched fractional laser Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24
89258901|NCT03963466|Experimental|group 4|(right side of cheek) 1064-nm Q-Switched laser Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24
89258902|NCT01084876|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
89258903|NCT01084876|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
89258904|NCT00117676|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
89258905|NCT00117676|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
89258906|NCT00251004|Experimental|Low-dose Everolimus Group|"1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
89258907|NCT00251004|Experimental|High-dose Everolimus Group|"3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
89258908|NCT00251004|Active Comparator|Control Group|"1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.~The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
89258909|NCT03973632|Experimental|Group A|Fasting at last 10h before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
89258910|NCT03973632|Experimental|Group B|Feeding with high-fat diet within 30 minutes before taking 200mg（two pills）of SH-1028 tablets on Day 1 of cycle 1，Fasting at last 10h before taking 200mg（two pills） of SH-1028 tablets on Day 1 of cycle 2. Each cycle is 4 days with a 3-days interval.
89258911|NCT01325922|Other|50/50% Tilt|
89258912|NCT03974880||patency group|Freedom from restenosis or clinically driven re-intervention in the treated lesion at 1,3,6,12 months after procedures
88821573|NCT03484403|Experimental|Treatment Group|Study participants in this group will receive a lumbar support back brace and will receive back school education and the same physical therapy exercise instruction as the control group.
89258913|NCT03974880||restenosis group|Restenosis was defined as a reduction in the luminal diameter of more than 50 percent according to any imaging examinations such as duplex ultrasound, CTA, MRI or DSA Re-intervention in the treated segment for the clinical progression at 1,3,6,12 months after procedures
89258914|NCT03974880||the second adverse events group|a composite of all-cause death, myocardial infarction, and stroke and any amputation at 1,3,6,12 months after procedures
89258915|NCT00275262|Experimental|LAD 11.25 mg 3 Month Depot|Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.
89258916|NCT00275262|Placebo Comparator|Placebo Comparator|Three intramuscular injections of matched placebo administered approximately 3 months apart.
89258917|NCT00275028|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88821574|NCT03481010|Experimental|PAO with hip arthroscopy|"Patient's in the Scope PAO group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the Scope-PAO group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy."
88821575|NCT03481010|Active Comparator|PAO without hip arthroscopy|"Patient's in the PAO-only group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the PAO-only group have been randomized to receive a periacetabular osteotomy only."
88821576|NCT03480724|Active Comparator|Google Cardboard VRA|This group of subjects will receive VRA intervention using Google Cardboard Virtual reality head- mounted display powered by a iPod touch.
88821577|NCT03480724|Active Comparator|Oculus Rift VRA|This group of subjects will receive VRA with Oculus Rift
88821578|NCT03480724|No Intervention|Control|This group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint-this group will serve as the control group
88821579|NCT03479268|Experimental|Treatment (pevonedistat, ibrutinib)|Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
88821580|NCT03471663|Experimental|D-0502|D-0502
88821581|NCT03471663|Experimental|D-0502 in combination with palbociclib|D-0502 in combination with palbociclib
88821582|NCT03437668|Experimental|Withania Somnifera Extract (WSE)|WSE 500 mg bid for 12 weeks
88821583|NCT03437668|Placebo Comparator|Placebo tablets|Placebo oral tablet bid for 12 weeks
88821584|NCT03431363||Observational group|Patient dosing options will be stratified into three groups defined as standard, frail/elderly (age > 65 or ECOG 2), and cannabis-experienced (> weekly use of cannabis in the past year outside of NYC Medical Marijuana program). NYC specified cannabis formulation options are defined by THC:CBD ratio as 1:1, low THC:high CBD, high THC:low CBD, and high THC:high CBD.
88821585|NCT03420066||Retrospective data collection|Group includes subjects that were implanted with the Nexus device as part of compassionate use procedure before joining the CIP008 study. Only intervention foreseen by CIP008 study is retrospective collection of data previously recorded as standard of care in medical charts (refer to Intervention/treatment section)
88821586|NCT03399513|Experimental|Ibrutinib and R-CHOEP chemotherapy|"All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (dose capped at 2 mg), etoposide 300 mg/m², prednisolone 500 mg.~In addition, ibrutinib capsules will be administered orally once daily at a dose of 560 mg (4 x 140 mg hard capsules) for 112 days."
88821587|NCT03341078|Placebo Comparator|Placebo|Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
89258918|NCT01072266|Experimental|INCB028060|Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.
89258919|NCT01072422|Experimental|counseling based on answers in TTQ|40 participating primary health care nurses will be randomly assigned to this arm. Each nurse will identify 5 consecutive patients with COPD who smoke (n = 200 total patients). The nurses will ask the patients to fill in the assessment protocol, TTQ. The nurses will then provide an intervention to each patient in the form of individual treatment on the basis of that patient's answers to the TTQ.
89258920|NCT00471497|Experimental|nilotinib 300mg bid (investigating arm)|
89258921|NCT00471497|Experimental|Nilotinb 400 mg bid (investigating arm)|
89258922|NCT00471497|Experimental|imatinib 400mg QD (control arm)|
89258923|NCT01018199|Experimental|Group 1- C-reactive protein (CRP) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating RCP levels
89258924|NCT01018199|Active Comparator|Group 2 - procalcitonin (PCT) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
89258925|NCT04357457|Experimental|Almitrine|
89258926|NCT04357457|Placebo Comparator|Placebo|
89258927|NCT01015079||Entire Taiwan women|
89258928|NCT00493649|Experimental|TC+H|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel (Taxotere) 75 mg/m2 IV (over 1 hour), plus cyclophosphamide (Cytoxan) 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab (Herceptin) 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter.
89258929|NCT00471107|Sham Comparator|Sham TDCS|
89258930|NCT00471107|Experimental|Surface-anodal direct current|0.08 mA/cm2
89258931|NCT00471107|Active Comparator|Surface-cathodal direct current|0.08 mA/cm2
89258932|NCT00488033|No Intervention|1|Standard of Care
89258933|NCT00488033|Other|2|CT Angiography
89258934|NCT01021163|Placebo Comparator|N-acetylcysteine , saline|
89258935|NCT01021241|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner
89258936|NCT01021319||Acute ischemic stroke|Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined andwell-known symptom onset.
89258937|NCT01018355|Experimental|Device closure of PFO|Device closure of PFO followed by 6 month treatment with clopidogrel 75 mg and 75 - 150 mg of aspirin daily followed by a life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
89258938|NCT01018355|Active Comparator|Medical anticoagulative treatment|Life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
89258939|NCT01021397|Experimental|1|Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
89258940|NCT01021397|Placebo Comparator|2|Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
89258941|NCT01022333|Experimental|DIM group (BRCA1 carriers)|This group will have up to 100 women who are carriers of a BRCA1 deleterious mutation. To ensure safety, women in this group will not be able to participate in the study if they are under medications with warfarin, theophylline, or anticonvulsants; or if they are pregnant, breast-feeding or planning to become pregnant within 6 months of the research project. Women in this group will receive 300 mg per day of Rx Balance BioResponse DIM for six weeks. Supplements will be given free of charge. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be during the six weeks of DIM supplementation (4-6 weeks after the first clinic visit).
89258942|NCT01022333|No Intervention|No DIM group (BRCA1 carriers)|This group will have up to a 100 women who are carriers of a BRCA1 deleterious mutation. This group will not receive DIM. Women that choose not to take DIM will be in this group. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be 4-6 weeks after the first clinic visit.
89258943|NCT01022333|No Intervention|General Control Group|This group will have up to 100 women who do not carry a BRCA1 mutation but who come from BRCA1 carrier family (a family with at least one individual that has tested positive for a BRCA1 mutation). A control subject is considered negative for a BRCA1 mutation if she has been confirmed by direct DNA sequencing to not be a carrier of this gene. A blood sample (20cc) and a urine sample (20cc) will be collected from these women at a single clinic visit.
89258944|NCT00117598|Experimental|A|
89258945|NCT00117598|Experimental|B|
89258946|NCT00117598|Active Comparator|C|
89258947|NCT01082302|Active Comparator|oral intake of green tea beverage|Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
89258948|NCT01082302|Experimental|Polyphenon E 15% ointment|3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
89258949|NCT00469859|Experimental|Group 1 (Lestaurtinib dose 50 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
89290388|NCT03931824|Sham Comparator|Placebo group|Injections containing saline were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used. To provide blindness, all injections were done using injectors coated with non transparent tape. All of the PRP injections were done by the same physician each time, with compliance to preventive measures against complications such as infections. Patients and the physician who applied the injection were blinded to the groups, and the solution was prepared by another researcher who was not blind to the groups.
89258950|NCT00469859|Experimental|Group 2 (Lestaurtinib: Dose 62.5 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
89258951|NCT03964948|Other|Healthy Volunteers|20 healthy volunteers will be recruited and will receive a kidney MRI and the same blood and urine labs that are collected for the other arms. Results will be compared to the disease groups.
89258952|NCT03964948|Other|Kidney Transplant|20 subjects that have received a kidney transplant that have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
89258953|NCT03964948|Other|Stage 2-5 CKD|20 subjects that have been diagnosed with stage 2-5 CKD and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.
89258954|NCT03964948|Other|Lupus nephritis|"20 subjects that have that have active lupus nephritis and have had a biopsy performed within the past 12 months will be enrolled. They will receive a kidney MRI and will have blood and urine collected.~Subjects that are post-lupus treatment will receive an additional MRI at the time of the next biopsy."
89258955|NCT01021475|Experimental|Usual drug FD therapy + Visceral Manipulation|
89258956|NCT01021475|Active Comparator|Usual drug FD therapy|
89258957|NCT04265170|Experimental|Single-arm|Eligible patients are treated with BlastX and VAC. The subjects return to the center three times per week for dressing changes and application of BlastX. The duration of the trial is four weeks and 8 weeks for larger wounds (2 subjects only). Subjects undergo study procedures (biopsy for quantitative tissue culture, photography, fluorescence imaging and swabbing for protease testing) on a weekly basis. The standard of care for pressure ulcers will be continued including debridement, off-loading, and nutritional supplementation when appropriate.
89258958|NCT01021631|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hematocrit is lower than 30%
89258959|NCT01021631|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hematocrit is lower than 24%
89258960|NCT01085032|Experimental|Arm A|Behavioral Counseling and Nicotine Patch
89258961|NCT01085032|Placebo Comparator|Arm B|Behavioral counseling and placebo patch
89258962|NCT01085110||Persistent Pain patients|Patients with persistent postherniotomy pain after laparoscopic operation and pain related impaired daily function
89258963|NCT01018433|Experimental|T-SIB|Treatment for self-injurious behaviors; study intervention
89258964|NCT01018433|Other|Treatment as Usual|
89258965|NCT01021709|Experimental|tDCS with alternative electrode montage|Treating major depression with either alternative tDCS electrode montage.
89258966|NCT03998111|Experimental|Trial|Participants will undergo one trial visit where they will ingest an oral glucose load diluted in solution (oral glucose tolerance test) and blood samples will be measured over the following 2-hours. The buffy coat layer from the baseline sample will be obtained to extract DNA.
89258967|NCT00093808|Experimental|capecitabine + vinorelbine + trastuzumab|"Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
89258968|NCT00469079|Active Comparator|1|Nicotine gum or nicotine lozenge; Dosage: 2 or 4 mg; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
89258969|NCT00469079|Experimental|2|Taboka - oral tobacco product Dosage: 0.84 to 1.26 mg free nicotine per g dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
89258970|NCT00469079|Experimental|3|Camel Snus - oral tobacco product Dosage: 6.09 to 9.16 mg dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
89258971|NCT01326754|Other|Artemether-lumefantrine|
89258972|NCT01326754|Other|Artesunate-amodiaquine|
89258973|NCT01326754|Other|Dihydroartemisinin-piperaquine|
89258974|NCT00093496|Experimental|Treatment (chemotherapy)|Patients are stratified according to gemcitabine hydrochloride therapy (gemcitabine hydrochloride-naive/no prior exposure to gemcitabine hydrochloride vs gemcitabine hydrochloride-resistant/prior exposure to gemcitabine hydrochloride as a single agent with disease progression while on treatment). Patients receive tanespimycin IV over 2 hours on days 1 and 8 during course 1 and days 2 and 9 during subsequent courses and gemcitabine hydrochloride IV over 30 minutes on day 7 during course 1 and days 1 and 8 during subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.
89258975|NCT00117286|Experimental|Degarelix (60 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 60 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
89258976|NCT00117286|Experimental|Degarelix (80 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 80 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
89258977|NCT01589380|Placebo Comparator|Placebo Arm|Placebo: Capsule that is containing lactate hydrate, identically appearing with fimasartan will be administered to patient in placebo group, once daily. Same placebo drug which was used in phase 3 clinical trial of fimasartan will be provided by Boryoung Phamaceutical company. Dose titration will be done with same criteria of fimasartan group. 30mg form and 60 mg form of placebo will be identical in its morphology.
89290389|NCT03971357|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
89258978|NCT01589380|Active Comparator|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
89258979|NCT00265122|Experimental|Population 1: Placebo SC followed by ustekinumab SC|Placebo injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
89258980|NCT00265122|Experimental|Population 1: Ustekinumab SC followed by Placebo SC:|Ustekinumab 90 mg injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
89258981|NCT00265122|Experimental|Population 1: Placebo IV followed by ustekinumab IV|Placebo given as 1 intravenous (IV) infusion at Week 0 during Intervention Period 1 and ustekinumab 4.5 mg/kg given as one IV infusion at Week 8 during Intervention Period 2.
89258982|NCT00265122|Experimental|Population 1: Ustekinumab IV followed by Placebo IV:|Ustekinumab 4.5 mg/kg given as one intravenous(IV) infusion at Week 0 during Intervention Period 1 followed by placebo given as one IV infusion at Week 8 during Intervention Period 2.
89258983|NCT00265122|Experimental|Population 2: Ustekinumab SC|Ustekinumab 90 mg injected subcutaneously (SC) once a week at Weeks 0-3 during Intervention Period 1. No intervention given during Intervention Period 2.
89258984|NCT00265122|Experimental|Population 2: Ustekinumab IV|Ustekinumab 4.5 mg given as one intravenous (IV) infusion at Week 0 during Intervention Period 1. No intervention given during Intervention Period 2.
89258985|NCT00116584|Other|heliox|heliox-driven nebulizations for children with moderate to severe bronchiolitis
89258986|NCT00116584|Other|oxygen|oxygen-driven nebulizations for children with moderate to severe bronchiolitis
89258987|NCT00096538|Experimental|valganciclovir|Patients receive oral valganciclovir twice daily for 3 weeks and then once daily for 21 weeks in the absence of disease progression or unacceptable toxicity. All patients are followed for 1 month after completion of therapy. Patients with responding disease are followed monthly for up to 1 year.
89258988|NCT00239928|Experimental|EYE001|
89258989|NCT00116428|Experimental|NAVISTAR® THERMOCOOL® Catheter|
89258990|NCT00116428|Active Comparator|Antiarrhythmic drug|
89258991|NCT03971214|Experimental|PD-1 inhibitor JS-001 consolidation for SCLC|The extensive-stage SCLC patients will receive PD-1 inhibitor JS-001 treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
89258992|NCT01073748|Active Comparator|asthmatic subjects|Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.
89258993|NCT01073748|Other|Healthy children|Children with no asthma as control group.
89258994|NCT00468845|Experimental|1|
89258995|NCT00468845|Experimental|2|
89258996|NCT00468845|Placebo Comparator|3|
89258997|NCT03996317|No Intervention|Standard care|Standard practice where 10L/min O2 is delivered to patient by mask when any fetal tracing abnormalities are identified.
89258998|NCT03996317|Experimental|Room air|O2 will be withheld at times when fetal tracing abnormalities are identified. Patient will continue to breath room air.
89258999|NCT00468299|Active Comparator|Misoprostol and placebo|Women in this arm receive placebo and misoprostol 800 mcg buccally
89259000|NCT00468299|Experimental|Mifepristone and misoprostol|Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally
89259001|NCT01021865||With type 2 Diabetes|
89259002|NCT01021865||Without type 2 diabetes|
89259003|NCT00468143|Experimental|Adderall Extended Release First|This group was treated with Adderall extended release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall immediate release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
89259004|NCT00468143|Experimental|Adderall Immediate Release First|This group was treated with Adderall immediate release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall extended release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
89259005|NCT00467831|Experimental|Multi-Drug Regimen|Losartan, 25 mg by mouth every night at bedtime; Zileuton, 1200 mg by mouth twice daily; N-acetylcysteine, 600 mg by mouth three times daily; Pravastatin, 20 mg by mouth every night at bedtime; Erythromycin, 333 mg by mouth three times daily.
89259006|NCT00467753|Experimental|Oxcarbazepine|Oxcarbazepine is the active drug to be given to subjects in the experimental arm
89259007|NCT00467753|Placebo Comparator|Sugar Pill|Patients are given either active or inactive intervention.
89259008|NCT01021943|Placebo Comparator|Placebo|Half of the subjects will be assigned to receive either spironolactone or placebo for 6 months
89259009|NCT01021943|Active Comparator|spironolactone|Half of the subjects will be randomized to receive spironolactone for 6 months
89259010|NCT01022021|Active Comparator|rituximab|
89259011|NCT01022021|Active Comparator|bendamustine|bendamustine, 90 mg/M2
89259012|NCT00467597||Group 1|
89259013|NCT00115804|Experimental|Fluoxetine|All eligible patients were started on Fluoxetine at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily.
89259014|NCT01085188|Experimental|Assertive Continuing Care (ACC)|Behavioral intervention comprised of the community reinforcement approach plus case management delivered in home and other community settings to youth and their caregivers.
89259015|NCT01085188|Experimental|Contingency Management (CM)|Using a prize drawing system (no, low, medium and large value prizes) with adolescents could earn escalating prize drawing opportunities by completing verifiable pro-social activities and providing negative urine test and breath alcohol test results.
89259016|NCT01085188|Experimental|ACC + CM|This arm is the combination of arms 1 and 2.
89259017|NCT01085188|Active Comparator|Usual Continuing Care (UCC)|UCC consists of a discharge recommendation to seek aftercare services at nearest treatment provider to where the patient lived. This service primarily consisted of outpatient group counseling.
89259018|NCT00467519|Experimental|Group 1|DAPTACEL primed participants
89259019|NCT00467519|Experimental|Group 2|Pentacel primed participants
89259020|NCT00264810|Active Comparator|Treatment Group (stimulation ON)|Group of subjects that have undergone RNS® System implantation that are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the Blinded Evaluation Period. Stimulation is enabled during the Stimulation Optimization Period (second month post-implant) and may continue throughout the subject's participation in the study.
89259021|NCT00264810|Sham Comparator|Sham Group (stimulation OFF)|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the Blinded Evaluation Period. Stimulation is enabled after transition into the Open Label Period (sixth month post-implant) and may continue for the remainder of the subject's participation in the study.
89259022|NCT00467363|Active Comparator|Aspirin|81mg of low-dose aspirin plus 400micrograms of folic acid.
89259023|NCT00467363|Placebo Comparator|Placebo|400micrograms of folic acid.
89259024|NCT03970980|Experimental|FIO2 >90% group|This group receives FIO2 >90% during the surgery.
89259025|NCT03970980|Active Comparator|FIO2 <70% group|This group receives FIO2 <70% during the surgery.
89259026|NCT00091390|Experimental|External Beam Radiotherapy and High Dose brachytherapy boost|
89259027|NCT00239226|Experimental|1. IAS pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (1) includes patients with Delta CTos >50 ms and randomized IAS pacing.~IAS Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
89259028|NCT00239226|Experimental|2. IAS pacing-control group|"(Delta CTos<50ms)~Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (2) includes patients with Delta CTos <50 ms and randomized IAS pacing.~IAS Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
89259029|NCT00239226|Active Comparator|3. RAA Pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (3) includes patients with Delta CTos >50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
89259030|NCT00239226|Active Comparator|4. RAA Pacing - control group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (4) includes patients with Delta CTos <50 ms and randomized Right Atrial Appendage pacing.~RAA Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
89259031|NCT01082536||One ventricle pts, bypass, perfusion|1. Single ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
89259032|NCT01082536||One ventricle pts, bypass only|Single ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion
89259033|NCT01082536||One ventricle pts, no bypass/perfusion|Single ventricle patients who undergo surgery, but do not undergo cardiopulmonary bypass or selective cerebral perfusion.
89259034|NCT01082536||Two ventricle pts, bypass, perfusion|Two ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
89259035|NCT01082536||Two ventricle pts, bypass only|Two ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion.
89259036|NCT01082536||Two ventricle pts, no bypass/perfusion|Two ventricle patients who do not undergo cardiopulmonary bypass or selective cerebral perfusion.
89259037|NCT00467285||Group 1|140 subjects with type 2 diabetes on pioglitazone.
89259038|NCT00467285||Group 2|140 subjects with type 2 diabetes not on pioglitazone.
89259039|NCT01022099|Active Comparator|navigated TKA|
89259040|NCT01022099|Other|conventional TKA|
89259041|NCT01022177|Active Comparator|diabetics|subjects with HbA1c >7,0 and pathological glucose tolerance testing
89259042|NCT01022177|Active Comparator|healthy|healthy subjects with HbA1c <7,0 and negative glucose tolerance testing
89259043|NCT01022255|Experimental|Arm 1|
89259044|NCT00264576|Experimental|cTIV|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
89259045|NCT00264576|Active Comparator|TIV|Received one dose of egg-derived trivalent vaccine (TIV).
89259046|NCT01071174|Placebo Comparator|Placebo Ring|Vaginal Ring containing no drug substance
89259047|NCT01071174|Experimental|Dapivirine Ring|Dapivirine Vaginal Ring 25mg
89259048|NCT00466505|Experimental|Therapeutic Intervention|
89259049|NCT02531568|Experimental|Warfarin and MT-3995|Subjects will be administered a single dose of warfarin on day1. Subjects will be administered MT-3995 Days 8 to 20. Subjects will be administered MT-3995 and warfarin on Day21. Subjects will be administered MT-3995 from Day 22 to 27.
89259050|NCT00467051|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
89259051|NCT00264498|Active Comparator|1|Gemcitabine + Carboplatin
89259052|NCT00264498|Experimental|2|Gefitinib
89259053|NCT00466193|Experimental|Zolpidem 3.5mg|
89259054|NCT00466193|Placebo Comparator|Placebo|
89259055|NCT01072578|Experimental|1|
89259056|NCT01072578|Experimental|2|
89259057|NCT01072734|Experimental|Vaccine group|single group: all included patients will receive the vaccine
89259058|NCT01024985||multiple sclerosis|
89259059|NCT01024985||neuromyelitis optica|
89259060|NCT01024985||controls|
89259061|NCT03971058|Active Comparator|young individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
89259062|NCT03971058|Active Comparator|elderly individuals|Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
89259063|NCT01025063||Lucentis (PRN group)|
89259064|NCT01025063||Lucentis (3 Injections over three months)|
89259065|NCT01025063||PDT (Reduced Fluence) and Lucentis|
89259066|NCT01025141|Experimental|MINISCREW|device
89259067|NCT01025141|Active Comparator|Reference|dental anchorage
89259068|NCT03970668||Linagliptin plus insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment with linagliptin plus insulin
89259069|NCT03970668||Insulin|Patients that presented hyperglycemia immediately after renal transplantation and received treatment only with insulin
89259070|NCT01022411|Experimental|A|Brown rice
89259071|NCT01022411|Placebo Comparator|B|White rice
89259072|NCT00263562|Experimental|Steroid arm|Receipt of methyprednisolone pulse dose: 15mg/kg to a maximum of 1 gram; following this, the patients also received a steroid taper with oral prednisone:Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
89259073|NCT00263562|Placebo Comparator|Comparison Group|Patients receiving usual care, with receipt of placebo (saline in lieu of intravenous methylprednisolone infusion or a number of placebo pills equivalent in number to what would have been received for the prednisone.
89259074|NCT00454181|Experimental|IFN lozenges|500 IU Interferon-alpha lozenges for oral dissolution
89259075|NCT00454181|Placebo Comparator|placebo lozenges|200 mg lozenges containing anhydrous crystalline maltose
89259076|NCT03970434|Experimental|Metformin|
89259077|NCT01073826|Active Comparator|Tocilizumab|Infusion of Tocilizumab and sport intervention
89259078|NCT01073826|Active Comparator|Sitagliptin|Intake of Sitagliptin and sport intervention
89259079|NCT01073826|Placebo Comparator|Placebo|Intake of placebo and sport intervention
89259080|NCT00237744|Experimental|Wrist/Hand FES + Whole Arm Motor Learning|Subjects > 6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning training and FES of the wrist/hand.
89259081|NCT00237744|Experimental|Shoulder/Elbow Robotics + Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning and shoulder/elbow robotics.
89259082|NCT00237744|Experimental|Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function who received whole arm motor learning training without addition of FES or Robotics
89259083|NCT01072812|Experimental|Posiphen® tartrate capsules|
89259084|NCT00237042|Active Comparator|Self Management|Dental hygienist-delivered pain self-management treatment
89259085|NCT00237042|Experimental|Targeted Self Management|Dental hygienist-delivered pain self-management treatment with a focus on menstrual cycle-related changes in pain and other symptoms
89259086|NCT00237042|Experimental|Continuous Oral Contraceptives|"Oral contraceptive (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months with no spacer pills."
89259087|NCT00465647|Experimental|≥ 28 Days to < 13 Months|infant and toddler
89259088|NCT00465647|Experimental|≥ 13 months to < 5 years|young child
89259089|NCT00465647|Experimental|≥ 5 years to < 12 years|older child
89259090|NCT00465647|Experimental|≥ 12 years to < 17 years|adolescent
89259091|NCT00465569|Experimental|Active Treatment|Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
89259092|NCT00465569|Placebo Comparator|Placebo|
89259093|NCT00090766|Experimental|Valganciclovir Age Group <= 2 Years|Eligible participants aged <= 2 years received valganciclovir up to maximum of 900 milligrams (mg) once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * body surface area (BSA) * creatinine clearance (CrCLS).
89259094|NCT00090766|Experimental|Valganciclovir Age Group >2 to <12 Years|Eligible participants aged >2 to <12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
89259095|NCT00090766|Experimental|Valganciclovir Age Group >= 12 Years|Eligible participants aged >= 12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
89259096|NCT01082692|Experimental|3mg DNA/dose|Subjects will receive a 4 dose series of PENNVAX-B containing 3mg of DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8 and Week 16.
89259097|NCT03961828|Experimental|Thalassemia with HCV|The study was carried out upon 50 β-thalassaemic children infected with hepatitis C virus who attended for a medical check-up at the Hematology Unit, Pediatric Department, Tanta University Hospital. Hepatitis C virus infection was diagnosed by serological detection of HCV-Ab, and quantitative detection of serum HCV RNA by polymerase chain reaction (PCR).
89259098|NCT01087060||cysts surgically removed|
89259099|NCT01087060||cysts under surveillance|
89259100|NCT00465179|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off.
89259101|NCT00465101|Other|GreenLight HPS|
89259102|NCT00084136|Experimental|ZDV/3TC+EFV|ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz
89259103|NCT00084136|Experimental|ddI+FTC+ATV|ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine
89259104|NCT00084136|Experimental|TDF/FTC+EFV|TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz
89290390|NCT03971357|Placebo Comparator|Placebo|Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.
89259105|NCT03812380|Experimental|EffCaMgCit|19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
89259106|NCT03812380|Placebo Comparator|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
89259107|NCT01583140|Experimental|Exercise Intervention|Culturally-modified, individually tailored physical activity print materials
89259108|NCT01583140|Active Comparator|Control|Bilingual health education booklets
89259109|NCT01085422|Experimental|Arm A|
89259110|NCT01090570|Experimental|PLX3397 25 mg|
88804922|NCT00104858|Experimental|Treatment|"Patients receive a conditioning regimen comprising fludarabine IV on days -4 to -2 and rituximab IV on days -3, 10, 24, and 38.~Patients undergo single fraction low-dose TBI on day 0. After completion of TBI, patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive rituximab IV on days 10, 24, and 38.~Patients receive an immunosuppressive regimen comprising cyclosporine PO BID on days -3 to 56 followed by a taper to day 180 (related recipients) or on days -3 to 100 followed by a taper to day 180 (unrelated recipients). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related recipients) or TID on days 0-40 followed by a taper to day 96 (unrelated recipients)."
89259111|NCT01090570|Experimental|PLX3397 50 mg|
89259112|NCT01090570|Experimental|PLX3397 100 mg|
88804923|NCT01354015|Experimental|Use of messaging system|Use of DRMS
89259113|NCT01090570|Experimental|PLX3397 200 mg|
89259114|NCT01090570|Experimental|PLX3397 300 mg|
89259115|NCT01090570|Placebo Comparator|Placebo|
89259116|NCT01085656|Experimental|OXi4503|Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
89259117|NCT03961984||Complex anal fistula|Patients with complex transsphincteric anal fistulas were treated with Biodesign® plug.
89259118|NCT03961906|Active Comparator|Tübingen physiotherapy concept|Will receive our therapy concept and perform self-trainings on a regular basis.
89259119|NCT03961906|No Intervention|controls|Will receive standard-care which includes their regular physiotherapy as provided by the local therapist and can include self-trainings as well.
89259120|NCT01087138|Experimental|Exercise|exercise class 3x's/week
89259121|NCT01087138|Experimental|exercise and calcium intake|exercise class 3x's/week and 1500mg calcium/day
89259122|NCT01087138|No Intervention|usual exercise and calcium|usual exercise and calcium intake
89259123|NCT00464945|Experimental|1|
89259124|NCT00464945|Active Comparator|2|
89259125|NCT01025297|Experimental|CYT107|
89259126|NCT00464087|Active Comparator|Heparin|Patients are switched from fondaparinux to heparin, receiving a dose of 60 U/Kg IV during the PCI
89259127|NCT00464087|Active Comparator|Bivalirudin|Patients switched from fondaparinux to bivalirudin, received a bolus of 0.75 mg/kg IV followed by infusion of 1.75 mg/g per hour infusion during the PCI.
89259128|NCT00452699|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
89259129|NCT00452699|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
89259130|NCT00069784|Experimental|Insulin glargine + omega-3 polyunsaturated fatty acids|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~One capsule of omega-3 polyunsaturated fatty acids once daily"
89259131|NCT00069784|Experimental|Insulin glargine + placebo|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)~One capsule of placebo once daily"
89259132|NCT00069784|Experimental|Standard care + omega-3 polyunsaturated fatty acids|• One capsule of omega-3 polyunsaturated fatty acids once daily
88804924|NCT01354015|No Intervention|Usual Care|Usual Care
88804925|NCT01407523|Experimental|Levetiracetam|Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
88804926|NCT01304407|Other|RTS Subjects, Calcium Isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
88804927|NCT01355419||obstructive sleep apnea, CPAP|moderate to severe obstructive sleep apnea requiring CPAP therapy
88804928|NCT00106106|Placebo Comparator|Placebo|For subjects randomized to placebo control, placebo doses were given every 8 hours.
88804929|NCT00106106|Experimental|Acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
88804930|NCT01304641||Atorvastatin Initiators|
88804931|NCT01304641||Simvastatin Initiators|
88804932|NCT01305265|Active Comparator|intervention|Endotracheal tube will be adjusted to 22-26 cm H20 pressure immediately post intubation using a cuff manometer
88804933|NCT01305265|No Intervention|control|endotracheal tube cuff will be inflated using standard technique
89259133|NCT00069784|Placebo Comparator|Standard care + placebo|• One capsule of placebo once daily
89259134|NCT01087216|Active Comparator|Group Laser = Arm As A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
89259135|NCT01087216|Placebo Comparator|Bras B : the control group|patient to accept habitual treatment of corticoid
89259136|NCT01085890|Experimental|Motivational interviewing group|The participants in this arm had 2 group seminars with information on hypertension and related lifestyle factors. They participated in 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
89259137|NCT01085890|No Intervention|Treatment as usual|Participants in this group received treatment as usual for their high blood pressure, but no informational seminars and no extra visits with motivational interviewing and blood pressure measurement.
89259138|NCT03958084|Experimental|Massage group|The deep massage will be applied for three minutes in the ischiotíbial muscles, only in the left limb, towards the muscular fibers. The volunteers will be placed in a ventral decubitus position on the stretcher.
89259139|NCT03958084|Experimental|Ventosa therapy group|The negative pressure ventosa therapy slide winds will be applied for three minutes in the oval direction in the posterior region of the thigh to contemplate the full extent of the ischiotíbial muscles, only in the left limb. The volunteers will be placed in a ventral decubitus position on the stretcher.
89259140|NCT03958084|Experimental|Foam roller group|The foam roller is a self-applied intervention for three minutes where the volunteers will be positioned on bench press on the floor of the room, with the left thigh posteriorly on the foam roller and the leg extended, the right lower limb will be in flexion of hip and knee, only the right foot and the right and left hands will touch the ground. Volunteers will be instructed to move so that they move forward and backward, causing the roller to travel the full length of the hamstring muscles.
89259141|NCT03958084|Experimental|Lumbar mobilization group|Unilateral lumbar mobilization of grade III at the frequency of 2Hz at the joint L4 / L5 of the ipsilateral side of the limb tested. The frequency was guaranteed by a metronome set at 120 beats per minute. Three sets of 1 minute of mobilization were performed with a 30 second interval, totaling a time of 4 minutes and 30 seconds of intervention. The technique was performed with the patient in the ventral decubitus position.
89259142|NCT03958084|Experimental|Proprioceptive neuromuscular facilitation group|Patient in dorsal decubitus, the examiner lifted the participant's leg up to the referred maximum amplitude. He then asked the patient for an isometric contraction of the hamstring muscles against the researcher's resistance for 10 seconds. After contraction, the researcher asked the patient to relax for 10 seconds. Then the member is repositioned passively by the researcher until the new amplitude limit reached. The technique was performed in 2 sets of 4 repetitions with an interval of 1 minute, totaling in an approximate time of 4 minutes of intervention.
89259143|NCT03958084|No Intervention|Control group|The patient remained lying down in the ventral position for 4 minutes. the patient remained lying down in the ventral position for 4 minutes.
89259144|NCT00090610|Experimental|Arm 1 - Combination Therapy|Docetaxel 30mg/m2 mg IV on Days 1 and 8, in combination with carboplatin AUC 6 IV on Day 1, repeated every 21 days X 6 cycles or until disease progression
89259145|NCT00090610|Experimental|Arm 2 - Sequential Therapy|Docetaxel 30mg/m2 IV on Days 1 and 8, repeated every 21 days for 6 cycles until disease progression. Once subjects have completed 6 cycles of docetaxel, they receive carboplatin AUC 6 IV every 21 days for 6 cycles or until disease progression.
89259146|NCT03957772|Active Comparator|Extrafascial injection|"Extrafascial injection of local anesthetic~Ultrasound guided supraclavicular plexus block with extrafascial injection of local anesthetic"
89259147|NCT03957772|Experimental|Intrafascial injection|"Intrafascial injection of local anesthetic~Ultrasound guided supraclavicular plexus block with intrafascial injection of local anesthetic"
89259148|NCT01326988||Patients requiring spinal anesthesia for lower limb surgery|Patients of at least 18 years of age undergoing spinal anesthesia for elective lower limb surgery will be recruited. Therefore inclusion and exclusion criteria are the same as for traditionally administered spinal anesthesia as below. Additionally we will exclude those patients who are incapable of providing fully informed consent, patients who are currently enrolled in other studies and patients with communication difficulties
89259149|NCT03962296|Experimental|Entelon|Three daily oral doses of 50mg tablets were administered to patients
89259150|NCT03962296|Active Comparator|Doxium|Three daily oral doses of 250mg tablets were administered to patients
89259151|NCT03962296|Placebo Comparator|Placebo|Three masking tablets were administered to patients
89259152|NCT01086046|Active Comparator|Heparin|Heparin injection 10 IU/kg/hr within 24h
89259153|NCT01086046|Experimental|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days"
89259154|NCT01090648|Experimental|001|etravirine One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
89259155|NCT01087450||Stage1|1. Prospective dose response group. 3 subjects per dose at 200U/kg, 400U/kg and 600U/kg rHuEPO
89259156|NCT01087450||Stage 2 Randomized, blinded trial|Control group: Randomized to placebo treatment Treatment Group: Randomized to rHuEPO treatment
89259157|NCT04224064|Experimental|Healthy subjects cohort|A single blood sample will be made in healthy subjects.
89259158|NCT04224064|Experimental|Liposarcoma patients cohort|Blood samples will be collected at different times: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
89259159|NCT03741244|Experimental|Temozolomide and apatinib|"Patients have treated with postoperative concurrent chemoradiation. Then Temozolomide (150mg/m2/d d1-5 in the first cycle, followed by 200mg/m2/d d1-5 q28d) + apatinib (500mg/d QD).~After 6 cycles,apatinib single drug maintained until progress."
89259160|NCT03741244|Active Comparator|Temozolomide|Patients were treated with postoperative concurrent chemoradiation.Then Temozolomide alone chemotherapy 6 cycles(first cycle 150mg/m2/d d1-5, later 200mg/m2/d d1-5 q28d).
89259161|NCT01086124||Echocardiography 1 month|Patients will all have an echocardiography 1 month post myocardial infarction and 3 months post myocardial infarction
89259162|NCT03962218|Experimental|Early Aquatic Therapy (EAT)|Aquatic physiotherapy treatment at time 1 (week 1)
89259163|NCT03962218|Other|Late Aquatic Therapy (LAT)|Control for Group 1 for the 5 first weeks of Group 1 treatment. Aquatic physiotherapy treatment at time 2 (week 6).
89259164|NCT01090726|Experimental|Storz videolaryngoscope|Macintosh overview followed by Airtraq overview followed by Storz videolaryngoscope overview and intubation.
89259165|NCT01090726|Active Comparator|Airtraq|Macintosh overview followed by Storz videolaryngoscope overview followed by Airtraq overview and intubation.
89259166|NCT00463385|Experimental|Prednisone|"Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants were discontinued from the study."
89290391|NCT03928548||Low Risk Malnutrition|Participants who are determined to be at low risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
89259167|NCT00463385|Experimental|Pomalidomide|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase.~After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
89259168|NCT00463385|Experimental|Pomalidomide 2 mg + Prednisone|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
89259169|NCT00463385|Experimental|Pomalidomide 0.5 mg + Prednisone|"Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
89259170|NCT01022489|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
89259171|NCT01022489|Placebo Comparator|placebo (sham coil) treatment|
89259172|NCT00463229|Experimental|Interprofessional Team Approach|Participants in the experimental group will receive home care services from a team of professional service providers [Community Care Access Centre (CCAC) Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist] and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
89259173|NCT00463229|No Intervention|Usual Home Care Services|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessment and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessment with clients.
89259174|NCT03839693|Placebo Comparator|Vehicle|Vehicle
89259175|NCT03839693|Experimental|ET-01 345U|botulinum toxin, Type A, Dose 1, 345 U
89259176|NCT03839693|Experimental|ET-01 1100U|botulinum toxin, Type A, Dose 2, 1100 U
89259177|NCT00068692|Experimental|Group I, Arm I|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
89259178|NCT00068692|Experimental|Group I, Arm II|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 8 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
89259179|NCT00068692|Experimental|Group I, Arm III|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV over 1 hour on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 8 weeks for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
89259180|NCT00068692|Experimental|Group II, Arm I|"Patients receive irinotecan, leucovorin calcium, and fluorouracil as in group 1, arm I for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
89259181|NCT00068692|Experimental|Group II, Arm II|"Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in group 1, arm II for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.~Treatment continues in the absence of disease progression or unacceptable toxicity."
89259182|NCT00068692|Experimental|Group II, Arm III|Patients receive leucovorin calcium and fluorouracil as in group 1, arm III for 1 course. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III. Treatment continues in the absence of disease progression or unacceptable toxicity.
89259183|NCT01086202||Tornier Reversed Shoulder Arthroplasty Medial Offset|
89259184|NCT01086202||Lateral offset arthroplasty|
89259185|NCT00463151|Placebo Comparator|1|0mg rebamipide
89259186|NCT00463151|Experimental|2|60mg rebamipide
89259187|NCT00463151|Experimental|3|150mg rebamipide
89259188|NCT00463151|Experimental|4|300mg rebamipide
89259189|NCT01025687|Experimental|glucose beverage|
89259190|NCT01025687|Experimental|noncaloric beverage with TV|
89259191|NCT01025687|Experimental|glucose beverage with TV|
89259192|NCT01025687|Experimental|noncaloric beverage|
89259193|NCT00068380|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89259194|NCT01086280||Patients exposed to Saxagliptin|
89259195|NCT01086280||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
89259196|NCT01087684|Active Comparator|Argon laser trabeculoplasty|Patients received standard argon laser treatment
89259197|NCT01087684|Active Comparator|Selective laser trabeculoplasty|Patients received a standard selective laser treatment
89259198|NCT00067990|Experimental|Losartan 100mg|Losartan 100 mg per day to be started within three months of transplantation and continuing treatment for five years.
89259199|NCT00067990|Placebo Comparator|Placebo|No intervention with continuing follow-up for five years.
89259200|NCT01086436|Experimental|Rotavirus Group|Subjects will receive Rotarix™
89259201|NCT01086436|Placebo Comparator|Placebo Group|Subjects will receive placebo.
89259202|NCT01090804|Experimental|breathing exercise|BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
89259203|NCT00090220|Experimental|qHPV Vaccine in Base Study|Participants received blinded qHPV vaccination at Day 1, Month 2, and Month 6 of the Base Study
89259204|NCT00090220|Placebo Comparator|Placebo in Base Study|Participants received blinded placebo at Day 1, Month 2, and Month 6 in the Base Study. They were eligible to receive open-label qHPV vaccine in Extension 1
89259205|NCT00263328|Active Comparator|Treatment group 1|Standard of care
89259206|NCT00263328|Experimental|Treatment group 2|Treatment group 2 also receives mycophenolate mofetil
89259207|NCT00263328|Experimental|Treatment group 3|Treatment group 3 does not receive mycophenolate mofetil
89259208|NCT03741660|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet
89259209|NCT03741660|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet
89259210|NCT00262860|Experimental|Bortezomib, Gemcitabine Hdrochloride|
89259211|NCT00236184|Placebo Comparator|Placebo|Oral placebo tablet
89259212|NCT00236184|Experimental|Rabeprazole sodium 10 mg|oral rabeprazole 10 mg enteric-coated tablet
89259213|NCT00313820|Active Comparator|Pregabalin|The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
89259214|NCT00313820|Placebo Comparator|Placebo|The change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
89259215|NCT00462761|Experimental|AC220|Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
89259216|NCT03903965||diabetic patients after cataract surgery|diabetic patients after cataract surgery
89259217|NCT03903965||non-diabetic patients after cataract surgery|non-diabetic patients after cataract surgery
89259218|NCT01065974|Active Comparator|Behavior Therapy|"Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring~Stimulus control~Changing eating behaviors~Goal setting~Problem solving~Social support~Cognitive restructuring~Relapse prevention"
89259219|NCT01065974|Experimental|Behavior Therapy + Meal Replacements|The BT +MR condition will implement behavioral treatment strategies in a way that is nearly identical to that of the BT condition. However, participants in this condition also will use MRs during weight loss and weight loss maintenance.
89259220|NCT01065974|Experimental|Nutritrol|"Participants in this condition will be informed about the evidence indicating that the availability, structure and composition of foods they encounter or seek out in their daily lives will play a major role in determining their ability to maintain the weight they lose. We will present the treatment as an opportunity to make numerous changes to their personal food environment involving the variety, energy density, nutritional composition, and portion size of the foods they encounter in every day life.~The Nutritrol condition is comprised of several components:~Food structure~Energy density~Reduce variety of foods high in energy density and increase variety of foods low in energy density~Protein intake~Controlling the personal food environment~Individualized weight loss maintenance prescriptions"
88821588|NCT03341078|Active Comparator|Ibudilast|Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
89259221|NCT00235872|Experimental|Adalimumab 40 mg every other week (eow)|
89259222|NCT00461981|Experimental|FluMist, Influenza Virus Vaccine Live|FluMist, Influenza Virus Vaccine Live, Intranasal
89259223|NCT00461981|Active Comparator|TIV, Trivalent Inactivated Influenza Virus Vaccine|TIV, Trivalent Inactivated Influenza Virus Vaccine, Intramuscular
89259224|NCT03970122|Experimental|GFB-887 SAD active|GFB-887 single dose active
89259225|NCT03970122|Placebo Comparator|GFB-887 SAD placebo|GFB-887 single dose placebo
89259226|NCT00296036|Experimental|Arm I (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily and oral pyridoxine once daily on days 1-21.
89259227|NCT00296036|Experimental|Arm II (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream as in arm I (closed to accrual as of 10/24/2007) and oral placebo once daily on days 1-21.
89259228|NCT00296036|Experimental|Arm III (closed to accrual as of 10/24/2007)|Patients receive placebo cream applied to palms and soles twice daily and pyridoxine as in arm I (closed to accrual as of 10/24/2007).
89259229|NCT00296036|Placebo Comparator|Arm IV (closed to accrual as of 10/24/2007)|Patients receive placebo cream as in arm III and oral placebo as in arm II (closed to accrual as of 10/24/2007).
89259230|NCT00296036|Experimental|Arm V|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily on days 1-21.
89259231|NCT00296036|Placebo Comparator|Arm VI|Patients receive placebo cream applied to palms and soles twice daily on days 1-21.
89259232|NCT01072890|Experimental|Temsirolimus and Pazopanib|
89259233|NCT00089674|Experimental|AMG 162|
89259234|NCT00089674|Placebo Comparator|Placebo|
89259235|NCT01090882|Sham Comparator|Control|Sham wash, sham injection
89259236|NCT01090882|Experimental|Subperitoneal injection|Local anaesthetic injection to diaphragm with sham wash over liver and gall bladder
89259237|NCT01090882|Active Comparator|Topical LA|Local anaesthetic washed over gall bladder and liver. Sham injection of diaphragm
89259238|NCT04187482|Experimental|Exercise training group|All participants will be receiving same exercise training intervention
89259239|NCT01090960|Experimental|A|
89259240|NCT03976388|Experimental|Clinical virtual simulator|A clinical virtual simulator contains an interactive medical case depicting an acutely ill patient seeking care at the emergency department. The case will be delivered in small groups (up to 6 participants) in sessions lasting up to 20 minutes. After the simulation has been completed, a feedback session lasting up to 30 minutes will be delivered as well.
89259241|NCT03976388|Active Comparator|Standard educational session|A small-group discussion (up to 6 participants) using patients with the same condition as the one selected for the clinical simulator will be held for participants allocated to the control group. These sessions will be led by a physician and have a maximum duration of up to 60 minutes.
89259242|NCT01067066|Experimental|TPI 287 + Temodar|Starting dose of TPI 287 90 mg/m^2 IV on Days 1, 8, 15 + Temozolomide (Temodar) PO at 85 mg/m^2 on Days 1-5.
89259243|NCT01069250||Brain injury|Patients after traumatic brain injury or spontaneous intracranial bleeding
89259244|NCT00313586|Experimental|Arm A (azacitidine)|Patients receive azacitidine SC QD on days 1-10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
89259245|NCT00313586|Experimental|Arm B (azacitidine, entinostat)|Patients receive azacitidine as in Arm A and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
89259246|NCT01069328|Experimental|Arm 1|
89259247|NCT01069328|Experimental|Arm 2|
89259248|NCT01069328|Experimental|Arm 3|
89259249|NCT01069328|Experimental|Arm 4|
89259250|NCT01069328|Experimental|Arm 5|
89259251|NCT01069328|Experimental|Arm 6|
89259252|NCT01069406||presence of uterine artery notch|patients with uterine artery notch during the 2nd and 3rd trimester
89259253|NCT01067222|Experimental|BF2.649|
89259254|NCT01067222|Active Comparator|Modafinil|
89259255|NCT01067222|Placebo Comparator|Placebo|
89259256|NCT00312572|Experimental|BTDS10/20|Initial doses (Level 1) of BTDS 10. Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
89259257|NCT00312572|Experimental|BTDS 20|Initial doses (Level 1) of BTDS 20.
89259258|NCT01067300|Active Comparator|Double unit unrelated cord blood transplantation|Transplantation of unrelated cord blood units is done at least 24 hours after last chemotherapy and carried out during the same day. The unit presenting the best degree of HLA compatibility with the patient will be transfused in first. If the 2 units have the same degree of HLA compatibility with the recipient, the unit with the higher cell dose will be transfused in first. A 2 hours time interval between the 2 transfusions will be respected.
89259259|NCT01067300|Active Comparator|single unit unrelated cord blood transplantation|Transplantation of a single unrelated cord blood unit at least 24 hours after last chemotherapy
89259260|NCT01067378|Active Comparator|Expert instructor debriefing|Expert instructor debriefing
89259261|NCT01067378|Experimental|Peer-led debriefing|Peer-led debriefing
89259262|NCT00290888|Active Comparator|ACR|Arthroscopic rotator cuff repair without acromioplasty
89259263|NCT00290888|Experimental|ACR-A|Arthorscopic rotator cuff repair with acromioplasty
89259264|NCT01069640|Experimental|URLC10-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89259265|NCT01069640|Experimental|URLC10-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89259266|NCT01069640|Experimental|URLC10-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89259267|NCT00290732|Experimental|Intraductal arm|Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.
89259268|NCT00290732|Active Comparator|Intravenous arm|Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.
89259269|NCT00312494|Placebo Comparator|Placebo|
89259270|NCT00312494|Experimental|Ziprasidone 20-40mg twice a day (BID)|
89259271|NCT00312494|Experimental|Ziprasidone 60-80mg BID|
89259272|NCT01069718||Clinical Group|In the Clinical group bottle feedings will be attempted by the bedside nurses, using techniques suggested in the feeding plan. The Infant Feeding Specialist will observe at least one feeding per day to assure that the feeding plan is being adhered to. If, in the judgment of the person feeding the infant, the infant is unable to complete the bottle feeding, the remaining volume will be given via an indwelling gavage tube. During all gavage feedings, both total and partial, infants will be offered a pacifier to suck on.
89290392|NCT03928548||High Risk Malnutrition|Participants who are determined to be at high risk for malnutrition based on the Malnutrition Screening Tool (adults) or the STRONGkids (pediatrics).
89290393|NCT01221168||Men with or without Prostate Cancer|"Men with a histological confirmed prostate cancer, and their family members in case of hereditary prostate cancer.~Men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer."
89259273|NCT01069718||NTrainer Group|"In the NTrainer group, three feedings per day will be given via gavage tube while the infant is receiving NTrainer stimulation. The stimulation will be done by alternating 3 minute epochs of NTrainer stimulation with 3 minutes of sucking on a regular pacifier, up to a total time of 30 minutes.~Every other day, 15 minutes prior to a feeding that is not one of the study sessions, each infant's suck strength and coordination will be measured using the NTrainer device in its NeoSuck RT Assessment mode.~On the day after the study intervention period is completed each infant will be assessed by an investigator unaware of the infant's study group assignment."
89259274|NCT00312338|Experimental|Infected Patient treated with Vigamox|Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.
89259275|NCT00312338|No Intervention|Healthy Subjects|Healthy Subjects receiving no treatment
89259276|NCT00290498|Experimental|Arm A|R-HCVAD + R-MTX/Ara-C ((Rituximab-HCVAD (rituximab, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) alternating with Rituximab-Methotrexate-Cytarabine))
89259277|NCT00290498|Active Comparator|Arm B|"R-CHOP ((Rituximab-CHOP (Rituximab, cyclophosphamide, vincristine, and prednisone))~No longer recruiting for this study arm."
89259278|NCT01069796|Experimental|Association bevacizumab paclitaxel capecitabine breast cancer|"bevacizumab 10 mg/kg in IV, D1 and D15~paclitaxel 80mg/m2 in IV, D1 to D8 and D15~capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3"
89259279|NCT02532530|Other|Study group|Adult patients (age ≥ 70 years) undergoing elective on-pump cardiac surgery (i.e. valve replacement with or without 'Coronary Artery Bypass Graft' (CABG) surgery)
89259280|NCT00451451|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
89259281|NCT00451451|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
89259282|NCT00451451|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
89259283|NCT00451451|Active Comparator|Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)|Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
89259284|NCT01062698|Active Comparator|IV thrombolysis + thrombectomy|
89259285|NCT01062698|Active Comparator|IV thrombolysis|
89259286|NCT03976232|Experimental|tDCS-Group|Participants of this arm will receive tDCS and Conventional therapy for 2 weeks.
89259287|NCT03976232|Experimental|CST- Group|Participants of this arm will receive CST and Conventional therapy for 2 weeks.
89259288|NCT03976232|Active Comparator|combination of tDCS and CST|Participants of this arm will receive CST+ tDCS and Conventional therapy for 2 weeks.
89259289|NCT03977324|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
89259290|NCT03977324|Other|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
89259291|NCT01069874|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
89259292|NCT01069874|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
89259293|NCT01022645||Levonorgestrel IUD|
89259294|NCT01022645||Copper IUD or Tubal Ligation|
89259295|NCT01025765|No Intervention|Standard care of CHC|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
89259296|NCT01025765|Experimental|Pioglitazone|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
89259297|NCT01025765|Experimental|Acarbose|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
89259298|NCT01025765|Experimental|Metformin|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
89259299|NCT03824912|Experimental|Test: Ketoconazole Cream 2%|Test: Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd)
89259300|NCT03824912|Active Comparator|Reference: Ketoconazole Cream 2%|Ketoconazole Cream 2% (G&W Laboratories Inc.; Registrant: Teva Pharmaceuticals USA Inc.)
89259301|NCT03824912|Placebo Comparator|Placebo: Cream (Test vehicle)|Placebo Cream (Test vehicle) (Encube Ethicals Pvt Ltd)
89259302|NCT01022723||Lung Cancer patients|Lung Cancer (particular focus on non smokers with adenocarcinoma)
89259303|NCT01022723||Patients with Nasopharyneal carcinoma|Patients with Nasopharyneal carcinoma
89259304|NCT01022723||Breast Cancer patients|Breast cancer patients
88821589|NCT03341078|No Intervention|Controls|Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
89259305|NCT01022723||Prostate Cancer patients|Prostate cancer patients
89259306|NCT01022723||Colorectal Cancer patients|Colorectal cancer patients
89259307|NCT01022723||Gastric Cancer patients|Gastric cancer patients
89259308|NCT01069952|Experimental|Active DBS|Participants will receive deep brain stimulation.
89259309|NCT03765281|Experimental|Navigation|Navigation intervention plus Resource List
89259310|NCT03765281|Active Comparator|Self-Navigation|Resource List intervention
89259311|NCT01062776|Placebo Comparator|5 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
89259312|NCT01062776|Placebo Comparator|10 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
89259313|NCT01062776|Experimental|5 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 5 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
89259314|NCT01062776|Experimental|10 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 10 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
89259315|NCT01025999||RYGB|UWMC patients undergoing RYGB surgery with routine placement of Gastrostomy tube.
89259316|NCT02532218|Active Comparator|Active|ARI-3037MO (niacin analog) 3g bid for 24 wks
89259317|NCT02532218|Placebo Comparator|Placebo|Matching Placebo 3g bid for 24 wks
89259318|NCT01022957|Experimental|Study group|Neurological, ophthalmological, olfactive exams and cerebral MRI
89259319|NCT00461123|Experimental|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
89259320|NCT00461123|Placebo Comparator|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
89259321|NCT00290342|Experimental|Infanrix-IPV Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' combined Infanrix™-IPV (DTPa-IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral thigh.
89259322|NCT00290342|Active Comparator|Infanrix + IMOVAX Polio Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' Infanrix™ (DTPa) vaccine co-administered with Sanofi-Pasteur's IMOVAX Polio® (IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral sides of opposite thighs.
89259323|NCT00460811|Active Comparator|72 ug linaclotide acetate|
89259324|NCT00460811|Active Comparator|145 ug linaclotide acetate|
89259325|NCT00460811|Active Comparator|290 ug linaclotide acetate|
89259326|NCT00460811|Active Comparator|579 ug linaclotide acetate|
89259327|NCT00460811|Placebo Comparator|Matching Placebo|
89259328|NCT00290186|Experimental|Hyperbaric Oxygen Treatment (HBO)|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
89259329|NCT00290186|Active Comparator|Hyperbaric Air Treatment (HBA)|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
89259330|NCT01325636|Experimental|CD4 and CD8 T cell|Injection of specific CD4 and CD8 T cell
89259331|NCT01070108|Active Comparator|Set 1|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
89259332|NCT01070108|Active Comparator|set 2|2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
89259333|NCT01070108|Active Comparator|set 3|3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
89259334|NCT03977246|Experimental|Open-placebo|The open-placebo intervention session
89259335|NCT03977246|Placebo Comparator|Control|The control session
89259336|NCT03977090|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
89259337|NCT01067924|Experimental|Motivational interviewing|
89259338|NCT01067924|Active Comparator|Standard of care|
89259339|NCT01068002||Control, normotensive, pregnancy|Control, normotensive, pregnancy
89259340|NCT01068002||hypertension, pregnancy, no treatment|hypertension, pregnancy, no treatment
89259341|NCT01068002||hypertension, pregnancy, drug treatment|hypertension, pregnancy, drug treatment
89259342|NCT00460655|Active Comparator|BTX|
89259343|NCT00460655|Placebo Comparator|Placebo|
89259344|NCT03982004|Experimental|Epicutaneous cryoimmunotherapy+imiquimod+pembrolizumab+GM-CSF|"Epicutaneous cryoimmunotherapy treatments (6 total) during weeks 1-15 (every 2 weeks for the first 2 treatments, then every 3 weeks until week 15)~Topical imiquimod will be applied 5 days per week (5 days on, 2 days off from weeks 1-15)~Pembrolizumab will be given every 3 weeks for a minimum of 4 cycles starting at Week 3 until disease progression or unacceptable toxicity.~Intra-lesional GM-CSF 250 mcg every 2 weeks x 2 doses then every 3 weeks for 3 doses"
89259345|NCT01062854|Experimental|Earplugs|Subjects randomized to this arm of the study will wear earplugs during their baseline sleep study (polysomnogram).
89259346|NCT01062854|No Intervention|Comparison group|Subjects randomized to the comparison arm will not wear earplugs during their baseline sleep study.
89259347|NCT03981848||Relapse|Relapse of tumor within two years after liver transplantation
89259348|NCT03981848||Non-relapse|Non-relapse of tumor within two years after liver transplantation
89259349|NCT01026155|Experimental|Respiratory muscle traininig|Low caloric diet and physical activities + Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
89259350|NCT01026155|Active Comparator|Control|Low caloric diet and physical activities
89259351|NCT01025921|Placebo Comparator|Inhaled colistin|They will receive inhaled colistin three times daily for 10 days.
89259352|NCT01025921|Placebo Comparator|Inhaled normal saline|Inhaled normal saline three times daily for 10 days
89259353|NCT01068080||Myocardial fatty acid metabolism, Insulin resistance|"Myocardial fatty acid metabolism was evaluated by myocardial fatty acid imaging using BMIPP SPECT.~Insulin resistance was evaluated by HOMA-IR."
89259354|NCT01026233|Experimental|1|brentuximab vedotin
89259355|NCT01062932|Placebo Comparator|Placebo|
89259356|NCT01062932|Active Comparator|Cycloserine|
89259357|NCT01026311|Placebo Comparator|placebo|
89259358|NCT01026311|Active Comparator|Coenzyme Q10|200mg of coenzyme Q10
89259359|NCT01063010|Placebo Comparator|Placebo|Placebo IV for 90 minutes (+ 15 minutes)
89259360|NCT01063010|Experimental|Bevicizumab|IV infusion over 90 minutes
89259361|NCT00460577|Active Comparator|Formoterol (Foradil®)|Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.
89259362|NCT00460577|Active Comparator|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.
89259363|NCT01063088|Experimental|Vaccination|Single 0.5 mL intramuscular injection of PreFluCel 2009/2010
89259364|NCT01581320|Experimental|DP-R206|
89259365|NCT01581320|Active Comparator|Bonviva|
89259366|NCT04909463|No Intervention|Unilateral rib fractures only, no device intervention|Unilateral rib fractures only, no device intervention
89259367|NCT04909463|Experimental|Unilateral rib fractures, device intervention|Unilateral rib fractures, will receive device intervention
89259368|NCT04909463|No Intervention|Bilateral rib fractures, no device intervention|Bilateral rib fractures, no device intervention
89259369|NCT04909463|Experimental|Bilateral rib fractures, device intervention|Bilateral rib fractures, will receive device intervention
89259370|NCT01068236|Experimental|Healthy lifestyle intervention|lifestyle/weight-loss intervention for overweight (95th - 99th percentile) female adolescents (13-15 years of age at study entry) to a usual-care control condition. The intervention will be 20-sessions and combines group visits, individual telephone coaching calls, and tailored pediatric primary care providers (PCP) visits.
89259371|NCT01068236|No Intervention|Usual care|In the usual care control condition adolescents and their family will receive individualized feedback from the assessments as well as handouts outlining healthy means of maintaining / reducing weight for adolescents through improving nutrition and physical activity. In addition, these participants will be encouraged to seek any appropriate health care/education services available through Kaiser Permanente or in the community.
89259372|NCT00289016|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque forming units (PFU)/mL injected into 1 or more tumors with maximum total volume of 4 mL (up to 2 mL per tumor). Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks for up to 15 weeks. After the initial 8 doses, if indications of biological activity were observed, treatment could continue for up to 16 additional doses.
89259373|NCT00288860|Experimental|Telephone Monitoring|Biweekly monitoring and support by telephone (up to 6 calls over 3 months) as augmentation to mental health care as usual.
89259374|NCT00288860|Active Comparator|Treatment-As-Usual|Mental health Treatment As Usual, potentially including case management, pharmacotherapy, and individual and/or group psychotherapy.
89259375|NCT00288704|Placebo Comparator|Placebo|Some subjects were treated with Placebo in the Study. This occurred (if subject randomized to Placebo) either during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24).
88821590|NCT03340714||Device Feasibility (ADAMM)|Patients wear the Automated Device for Asthma Monitoring and Management (ADAMM) from the time of computed tomography (CT) simulation for radiation therapy (RT) planning throughout the entire RT course and for 4 weeks post-RT
89259376|NCT00288704|Active Comparator|rilonacept 160 mg|"If randomized to rilonacept, subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24). All subjects received rilonacept 160 mg during weeks 6-14 (between Parts A and B).~Study drug is administered as a 2.0 mL subcutaneous injection once a week. At baseline (week 0) subjects receive a loading dose of rilonacept 320 mg."
89259377|NCT00288704|Other|Open-Label rilonacept 160 mg|"After week 24 (the end of part B), all subjects went into weekly dosing of open label rilonacept 160 mg. During this phase of the study, adolescents aged 7 and above were entered into the study and rilonacept was dosed as 2.2 mg/kg injections, up to 160 mg, per week.~Study drug is administered as a 2.0 mL subcutaneous injection once a week."
89259378|NCT00288626|Experimental|MS Treatment|Autologous peripheral blood stem cell grafts were CD34+ selected; the participants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.
89259379|NCT01063244|Active Comparator|FoleyBalloon|foley balloon placed in the cervix
89259380|NCT01063244|Active Comparator|foley balloon with weight|foley balloon with weight attached
89259381|NCT00087178|Active Comparator|Arm 1: adriamycin + cyclophosphamide|Patients receive adriamycin IV over 15 minutes followed by cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
89259382|NCT00087178|Experimental|Arm 2: fluorouracil + epirubicin + cyclophosphamide|Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
89259383|NCT00288080|Active Comparator|Androgen suppression + Radiation Therapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of radiation therapy (RT).
89259384|NCT00288080|Experimental|Androgen suppression + Radiation Therapy + Chemotherapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of RT. Following completion of RT, 6 cycles of docetaxel (premedicated with dexamethasone) and prednisone are delivered concurrently with androgen suppression.
89259385|NCT01086514|Experimental|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|In this study we will perform Dual Energy Contrast Enhanced Digital Mammography (DE CEDM) on patients with newly diagnosed breast cancer using a dedicated research system, derived from a standard digital mammography unit and review workstation (Senographe DS and SenoAdvantage) modified to deliver the required dual energy paired exposures and visualization of combined images.
89259386|NCT03957460||continuous and noninvasive hemoglobin monitoring|Group receive the continuous and noninvasive hemoglobin monitoring during laparoscopic gastrectomy.
89259387|NCT01091194|Other|Exercise|Interval-based aerobic exercise
89259388|NCT01091194|No Intervention|Control|No intervention other than regular follow up hospital visits
89259389|NCT01086592|Active Comparator|Control|
89259390|NCT01086592|Experimental|Strengthening exercise|Strong progressive strengthening exercises of lower limbs.
89259391|NCT01086592|Experimental|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
89259392|NCT01086592|Experimental|Electrotherapy+weights|
89259393|NCT01068314|Experimental|Repetitive handgrip exercise|After baseline testing and randomization, subjects in this group are instructed to perform the intervention: daily repetitive handgrip exercise with upper arm compression band. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
88821591|NCT03338933||Control Group|No history of addiction to any substance or gambling. Less than 20 lifetime cigarettes or equivalent.
88821592|NCT03338933||Nicotine Group|Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) criteria for Nicotine Use Disorder. Current smoker, at least 10 cigarettes per day. No history of addiction to any other substance
89259394|NCT01068314|No Intervention|No arm exercise|Time control. Subjects do usual activities without any exercise intervention. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
89259395|NCT03957538|No Intervention|Standard care|Standard consent and explanation
89259396|NCT03957538|Experimental|Virtual reality|Addition of VR headset
89259397|NCT01068392|Experimental|OXP|Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.
89259398|NCT01086826|Active Comparator|RT+CDDP/5-FU|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy."
89259399|NCT01086826|Experimental|RT+CETUXIMAB|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
89259400|NCT01086826|Active Comparator|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):~DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion"
89259401|NCT01086826|Experimental|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RADIOTHRAPY:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
89259402|NCT01091272|Experimental|Cohort 1|Single dose 3 period interleaved cross-over with placebo substitution
89259403|NCT01091272|Experimental|Cohort 2|Single dose 4 period interleaved cross-over, placebo substitution, with food effect
89259404|NCT01091272|Experimental|Cohort 3|Single dose 4 period cross-over, placebo insertion, with food effect
89259405|NCT01091272|Experimental|Optional Cohort 4|Single dose 3 period cross-over with placebo substitution
89259406|NCT00287690|Experimental|Genistein|Supro drink once daily for 3 days
89259407|NCT00287690|Placebo Comparator|Placebo|Drink identical to Supro but containing no genistein, once daily for 3 days
89259408|NCT01063400||Activity monitoring|
89259409|NCT00286754|Experimental|Stage-matched intervention (SMI)|Stage-matched intervention (SMI)
89259410|NCT00286754|Active Comparator|Health Education Intervention (HEI)|Health Education Intervention (HEI)
89259411|NCT00286754|No Intervention|Usual Care (UC)|Usual Care (UC)
89259412|NCT01070186|Experimental|Treatment|See intervention descriptions
89259413|NCT01068470||patients with melanoma or kidney cancer|
89259414|NCT00066742|Experimental|Treatment (tirapazamine, cisplatin, etoposide)|"CHEMORADIOTHERAPY: Patients receive tirapazamine IV over 1 hour on days 1, 8, 10, 12, 29, 36, 38, and 40; cisplatin IV over 1 hour on days 1, 8, 29, and 36; and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning on day 1 of chemotherapy, patients undergo thoracic radiotherapy once daily 5 days a week for 7 weeks.~CONSOLIDATION CHEMOTHERAPY: Within 28 days after completion of radiotherapy, patients with stable or responding disease receive cisplatin IV over 1 hour on days 1 and 22 and etoposide IV over 1 hour on days 1-3 and 22-24.~Treatment continues in the absence of disease progression or unacceptable toxicity."
89259415|NCT01093924|No Intervention|self-guided weight loss maintenance|15-month self-guided weight loss maintenance group will receive monthly reminders to maintain their weight loss and newsletters that contain health information.
89259416|NCT01093924|Experimental|DVD group|15-month weight loss maintenance intervention deliver via DVD.
89259417|NCT01093924|Experimental|face-to-face group|15-month weight loss/weight loss maintenance intervention delivered in a group setting
89259418|NCT01091350|Active Comparator|Diprifusor group|Propofol was infused via Diprifusor TCI (Target-controlled infusion)
89259419|NCT01091350|Experimental|Orchestra group|Propofol was infused via Orchestra TCI
89259420|NCT03956914|Experimental|DSW (deep sea water) group|DSW, 440 ml/day for 8 weeks
89259421|NCT03956914|Placebo Comparator|Placebo group|Placebo, 440 ml/day for 8 weeks
89259422|NCT00460265|Active Comparator|ARM 2|Arm 2 consists of Cisplatin and 5-FU
89259423|NCT00460265|Experimental|ARM 1|ARM 1 Consists of Panitumumab plus Cisplatin and 5-FU
89259424|NCT03956290|Experimental|TREAT pilot study|Metabolically unhealthy overweight or obese potential participants who pass an in-person screen will enroll in a 2-week run-in period when they will use the app, to assess meal patterns under habitual living conditions.
89259425|NCT01094002|Experimental|Occupational therapy intervention (OTI)|198 subjects. The OTI schedule consisted of a daily 45-minute session, Monday through Friday, for the duration of hospitalisation. Activities were carried out in a structured manner and varied according to need and day of admission. On the first day, the patient's needs were analysed, including the need for iatrogenic prevention, retraining in basic and instrumental activities of daily living, technical aids, instruct the primary caregiver in patient mobilisation techniques, and social and occupational motivation. All OTI participants received an average of 5 sessions during hospitalisation.
89259426|NCT01094002|No Intervention|Conventional treatment model group|202 subjects. All subjects received medical treatment, nursing care, physical therapy, and social assistance in accordance with the usual practice of the geriatrics unit.
89259427|NCT03742583|Active Comparator|Square Knot|
89259428|NCT03742583|Active Comparator|Reversing Half-Hitch Alternating Post Knot|
89259429|NCT01091506|Experimental|L-methylfolate|L-methylfolate 15mg (a medical food)
89259430|NCT01091506|Placebo Comparator|Placebo|Placebo
89259431|NCT01026467||Supportive Care (frailty index, geriatric assessment, chemo)|Patients complete a frailty index and geriatric assessment prior to beginning chemotherapy. Patients receive standard-of-care chemotherapy comprising carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 2 courses
89259432|NCT01094080|Active Comparator|standard infant formula|infants are fed a commercial formula during the first 4 month of life, according to protocol
89259433|NCT01094080|Experimental|modified infant formula|infants are fed a modified infant formula (modified protein content and fatty acid pattern) during the first 4 month of life, according to protocol
89259434|NCT01094080|Other|breast milk|infants are breast fed
89259435|NCT01094158|Experimental|high dose|Aramchol 300 mg daily (high dose)
89259436|NCT01094158|Experimental|low dose|100 mg daily (low dose)
89259437|NCT01094158|Placebo Comparator|Placebo|Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.
89259438|NCT01094236|Experimental|Supervisor Treatment Group|Supervisors watched the CD intervention
89259439|NCT01094236|Experimental|Administrators - Treatment|School administrators got access to the intervention binder with CD's, workbook and worksheets
89259440|NCT01094236|Experimental|Students|3rd grade students at participating study schools
89259441|NCT01094236|Experimental|Supervisor Control Group|Supervisors watched a video on playground equipment safety
89259442|NCT01094236|Experimental|Administrators - Control|Administrators did not have access to any treatment materials.
89259443|NCT01094236|Experimental|School Staff|School staff surveyed at staff meetings
89259444|NCT01094314|Active Comparator|sequential medium|
89259445|NCT01094314|Active Comparator|single medium|
89259446|NCT01091584|Active Comparator|intervention group|The intervention is to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse.
89259447|NCT01091584|No Intervention|control group|usual care
89259448|NCT00460109|Experimental|rituximab + denileukin diftitox|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients also receive denileukin diftitox IV over 15-60 minutes on days 1-5. Treatment with denileukin diftitox repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89259449|NCT03956212|Experimental|erythema migrans patients treated with doxycycline|adult patients with erythema migrans will be treated with oral doxycycline
89259450|NCT01091740|Experimental|ZES resolute (Endeavor Resolute)|
89259451|NCT01091740|Active Comparator|EES (Xience)|
89259452|NCT01094392||treatment every 6th week during 6 months|
89259453|NCT01094392||treatment every 2nd week during 6 months|
89259454|NCT01091818|Active Comparator|midazolam|
89259455|NCT01091818|Experimental|dexmedetomidin|
89259456|NCT01091896|No Intervention|1 - no bevacizumab|Patients will not receive bevacizumab before nor during vitrectomy
89259457|NCT01091896|Experimental|2- bevacizumab before vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
89259458|NCT01091896|Experimental|3- bevacizumab after vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
89259459|NCT00065260|Experimental|r-ATG /cyclosporine|A randomized trial of rabbit anti-thymocyte globulin (r-ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
88804934|NCT04545320|Placebo Comparator|Usual care control group|Subjects in the usual care control group will receive a health education program to provide the usual care information. This program will include 3-month biweekly sessions (70 minutes each session, total 6 sessions) for obesity-related health briefing, dietary caloric restriction advice, lifestyle counselling/consultation and stretching exercise.
88804935|NCT04545320|Experimental|HIIT group|A 3-month intervention of HIIT will be given to participants allocated to this group. The once-a-week HIIT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform brisk walking for four 4-min bouts at 85%-95% maximal heart rate (HRmax) with a 3-min active recovery walk at 50%-70% HRmax between each session. There will be a 5-min warm-up and cool-down in each exercise session. The duration of each exercise session will be 35 minutes. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
89259460|NCT00065260|Experimental|Alemtuzumab (Campath-1H)|A randomized trial of rabbit anti-thymocyte globulin (ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
89259461|NCT01327066|Experimental|Droxidopa - Therapeutic|Droxidopa 600 mg
89259462|NCT01327066|Experimental|Droxidopa - Supratherapeutic Dose|Droxidopa 2000 mg
89259463|NCT01327066|Placebo Comparator|Placebo|Placebo
89259464|NCT01327066|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg dose
89259465|NCT01094626|Experimental|Experimental|Fifteen subjects will be randomly selected to undergo S-MRI prior to surgery. These subjects would receive Secretin, administered by IV bolus injection over 1 minute followed by a 30 second saline flush.
89259466|NCT01094626|No Intervention|Controls|Fifteen subjects will be selected as controls, undergoing MRI without secretin-enhancement and matched for age, sex, race and tumor-type.
89259467|NCT03956134|Experimental|Tapentadol Test Product 1 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
88804936|NCT04545320|Experimental|MICT group|A 3-month intervention of MICT will be given to participants allocated to this group. The once-a-week MICT will be performed in small groups on treadmills supervised by certified athletic coaches. Subjects will perform mild walking exercise for ~47 minutes at an intensity of 65-75% HRmax. This exercise volume matches the HIIT volume. Heart rate will be continuously monitored during training using Polar M300 with OH1 optical heart rate sensor.
89259468|NCT03956134|Experimental|Tapentadol Test Product 2 (fasting)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fasting condition.
89259469|NCT03956134|Experimental|Tapentadol Test Product 1 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
89259470|NCT03956134|Experimental|Tapentadol Test Product 2 (fed)|Tapentadol new tablet formulation, given as single oral dose with 240 mL of still mineral water under fed condition.
88804937|NCT01305655|Experimental|Glucarpidase arm|In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.
88804938|NCT04442438|Experimental|Intensive care unit 1|Receives of intervention consisting of monthly moral case deliberation (ethical decision-making) meetings, planned and set up by ICU professionals which have received the task of being more attentive to ethical situations during work.
89259471|NCT03956134|Active Comparator|Tapentadol PR Reference Product|Tapentadol PR tablet formulation given as single oral dose with 240 mL of still mineral water under fasting condition.
89259472|NCT00460031|Experimental|Ketoconazole Plus Lenalidomide|
88804939|NCT04442438|Other|Intensive care unit 2|First non-intervention, then flips to experimental arm type after six months.
88804940|NCT04442438|Other|Intensive care unit 3|First non-intervention, then flips to experimental arm type after six months.
89259473|NCT00451217|Experimental|Rocuronium + Sugammadex|After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
89259474|NCT00451217|Active Comparator|Rocuronium + Neostigmine|After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
89259475|NCT00451217|Experimental|Vecuronium + Sugammadex|After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
89259476|NCT00451217|Active Comparator|Vecuronium + Neostigmine|After the last dose of vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
89259477|NCT01023113|Experimental|PASCAL laser, PRP in 2-3 sitting at 3 days interval.|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by PASCAL laser
89259478|NCT01023113|Active Comparator|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by conventional laser
89259479|NCT00459953|Experimental|Extended treatment|extended cognitive behavioral treatment for smoking cessation; Participants receive an additional 9 sessions of cognitive behavior therapy
89259480|NCT00459953|No Intervention|Control group|Monthly follow-up phone calls for assessment purposes and to control for potential therapeutic effects associated with continued contact
89259481|NCT00459875|Experimental|Sunitinib|The treatment will include Sunitinib malate 50 mg self-administered orally, once daily in the evening, without regard to meals, for 4 consecutive weeks (28 days) followed by 2 weeks (14 days) off, to comprise a complete cycle of 6 weeks.
89259482|NCT00311402|Other|Aggrenox Capsule|
89259483|NCT00311402|Other|Acetylsalicylic Acid (ASA) 81 mg Tablet|
89259484|NCT01026545|Experimental|Cohort 1|
89259485|NCT01026545|Experimental|Cohort 2|
89259486|NCT01026545|Experimental|Cohort 3|
89259487|NCT01026545|Experimental|Cohort 4 (optional)|If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
89259488|NCT01026545|Experimental|Cohort 5 (Japanese)|
88804941|NCT04442438|Other|Intensive care unit 4|First non-intervention, then flips to experimental arm type after twelve months.
88804942|NCT04442438|Other|Intensive care unit 5|First non-intervention, then flips to experimental arm type after twelve months.
88804943|NCT04442438|Other|Intensive care unit 6|First non-intervention, then flips to experimental arm type after Eighteen months.
89259489|NCT01026545|Experimental|Cohort 6 (Japanese)|
89259490|NCT03996083|Experimental|Multicomponent exercise intervention|The multicomponent exercise program consisted of strength and balance exercises performed on two non-consecutive days per week and lasting approximately an hour per session. Strength exercises were mainly focused on lower limb strengthening. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. As for balance exercises, the first weeks consisted of mainly less complex static balance exercises and progressed to more complex and dynamic balance exercises. These exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention.
89259491|NCT03996083|Experimental|Walking intervention|Participants assigned to the walking group walked with the research staff two days per week; additionally, they walked partially supervised by LTNH staff, family members or caregivers the rest of the week. Daily walking goals were set follows: walking between 5 to 10 minutes on the first month, up to 15 minutes on the second, and finally 20 minutes per day on the third month. The final goal was to get as close as possible to the recommendations of engaging in 150 minutes of aerobic exercise per week from the World Health Organization (WHO). Participants were asked to walk as fast as they could and rest was allowed whenever needed. Walking goals were achieved in one or multiple sessions, depending on each participant´s capacities. Those participants that met the walking goals without any rest were encouraged to walk at a faster pace.
88821593|NCT03338933||Nicotine and Alcohol Group|DSM-V criteria for Nicotine Use Disorder and Alcohol Use Disorder. At least 8 heavy drinking episodes in the past month. Current smoker. Alcohol free from 2 to 4 weeks. No history of addiction to other substances or gambling.
89259492|NCT01023191|Active Comparator|Percutaneous insertion|To undergo insertion of catheter using percutaneous technique under local anaesthetic
89259493|NCT01023191|Active Comparator|Open insertion|To undergo insertion of catheter using open technique under general anaesthetic
89259494|NCT00450749|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy.
89259495|NCT00450749|Experimental|Arm II (low-dose lycopene)|Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
89259496|NCT00450749|Experimental|Arm III (high-dose lycopene)|Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
89259497|NCT00292370|Other|Arm 1: Open Label (OL) Paroxetine|Open-label Paroxetine In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.
89259498|NCT00292370|Placebo Comparator|Arm 2 OL Paroxetine + DB Placebo|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.
89259499|NCT00292370|Experimental|Arm 3: OL Paroxetine + DB Quetiapine|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.
89259500|NCT01026701||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
89259501|NCT01092052|Experimental|1|
89259502|NCT01094860|Experimental|Continuous Infusion Nelarabine|Starting dose 200 mg/m2 x 5 days
89259503|NCT01092130|Experimental|Vitamin D|Patients were randomized by an automated computer system to 2000 IU oral cholecalciferol once daily or control (i.e. no extra medication), in a 1:1 ratio for a period of six weeks. Blood was collected in a sitting position on visits 2-4 and patients were asked to collect 24h urine samples prior to visits 2 and 4. Heart failure medication was maintained unchanged throughout the trial. Changes in diuretic dose were permitted if necessary to treat decompensation or renal dysfunction.
89259504|NCT01094938||Repair|
89259505|NCT00064792|Placebo Comparator|OraPlus|
89259506|NCT00064792|Active Comparator|Simvastatin Susp|
89259507|NCT01095016|Experimental|Meptin swinghaler|
89259508|NCT01095016|Active Comparator|Berotec|
89259509|NCT01092286|Experimental|neuromuscular warm-up|coaches in this arm use the prescribed warm-up before team practices
89259510|NCT01092286|No Intervention|no warm-up|coaches use their usual warm-up before team practices
89259511|NCT03956992|Experimental|Mouth gel|A mouth gel with hydroxyapatite
89259512|NCT00450437|Active Comparator|Licensed Meningococcal Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
89259513|NCT00450437|Experimental|Novartis MenACWY Conjugate Vaccine|Novartis meningococcal ACWY conjugate Vaccine
89259514|NCT01095172|Experimental|Rituximab|"Rituximab 375mg/m2~Low dose tacrolimus with mycophenylate mofetil, hydrocortisone and 1 week prednisolone"
89259515|NCT01095172|Active Comparator|Control group|Low dose tacrolimus with mycophenylate mofetil and continued prednisolone
89259516|NCT00286442|Experimental|Alogliptin 12.5 mg QD|
89259517|NCT00286442|Experimental|Alogliptin 25 mg QD|
89259518|NCT00286442|Placebo Comparator|Metformin|
89259519|NCT00063934|Experimental|Treatment (oblimersen, doxorubicin, docetaxel)|"PHASE I (COMPLETED AS OF 8/16/04): Patients receive oblimersen IV continuously on days 1-6 interrupted only to administer doxorubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 6. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 7-13 or pegfilgrastim SC on day 7. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~PHASE II: Patients receive doxorubicin, docetaxel, G-CSF or pegfilgrastim, and oblimersen at the MTD as in phase I.~Patients with resectable tumors after 6 courses undergo surgical resection."
89259520|NCT03955744|Experimental|3D translabial ultrasound|3D translabial ultrasound with concurrent vaginal manometry
89259521|NCT00458783|Active Comparator|Prolonged RBC storage|Transfusion with oldest available matching RBCs.
89259522|NCT00458783|Active Comparator|Short RBC storage|Transfusion with youngest available matching RBCs.
89259523|NCT00063154|Experimental|Pertuzumab|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond.
89259524|NCT01092520|Experimental|Gabapentin|
89259525|NCT03955588||Women undergoing invasive prenatal diagnostic procedures|For women requiring invasive prenatal diagnosis by chorionic villus sampling or amniocentesis, they will be offered the options of having either conventional cytogenetics or aCGH.
89259526|NCT03996161|Active Comparator|Supine position|After the induction of anesthesia, mask ventilation is performed in the supine position.
89259527|NCT03996161|Experimental|Semi-sitting position|After the induction of anesthesia, mask ventilation is performed in the semi-sitting position.
89259528|NCT00311168|Experimental|VIP On, Then VIP Off|Participants first have VIP programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.
89259529|NCT00311168|Experimental|VIP Off, Then VIP On|Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.
89259530|NCT00458705|Experimental|Combination therapy|Combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone (BDD) followed by either thalidomide and dexamethasone (TD) or bortezomib, thalidomide and dexamethasone in patients with symptomatic untreated high-risk or primary resistant multiple myeloma. Three cycles of BDD will be administered. Patients who respond after three cycles will receive two cycles of TD. Patients with stable or progressive disease after three cycles of BDD receive two cycles of bortezomib, thalidomide and dexamethasone. If at any point during the study a patient achieves a complete response (CR), the patient will be given the option to discontinue treatment on-study.
89290394|NCT04424212|Experimental|Experimental: Intervention group CoronaCope|ICBT, were participants receive 8 out of 15 possible modules depending on their current problems and needs, 7 week long internet intervention for reducing mental health issues related to the coronavirus pandemic.
89259531|NCT00062374|Experimental|Treatment (preoperative chemotherapy)|"Neoadjuvant chemotherapy: Patients receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1, 8, 22, and 29. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Within 4 weeks after completion of neoadjuvant chemotherapy, patients undergo radical subtotal or total gastrectomy with lymph node dissection."
89259532|NCT00285818|Active Comparator|Mifepristone|Patients receive mifepristone one day before and for 5 additional days after starting ECT
89259533|NCT00285818|Placebo Comparator|Placebo Oral Capsule|Patients receive a placebo capsule one day before and for 5 additional days after starting ECT
89259534|NCT01023347|Active Comparator|Paclitaxel (Genexol®) and Cisplatin|
89259535|NCT01023347|Experimental|Paclitaxel loaded polymeric micelle (Genexol-PM®) & Cisplatin|
89259536|NCT06202755|Active Comparator|ticagrelor arm|The ticagrelor arm will receive (180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day)
89259537|NCT06202755|Active Comparator|cilostazol arm|The cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day)
89259538|NCT06202703|Experimental|pneumococcal vaccination arm|the participants will receive a registered pneumococcal vaccine according to manufacturers instructions
89259539|NCT06202690|Active Comparator|SP-RATS|SP-RATS Arm: 145 patients, single-port anatomical pulmonary resection will be performed using the SP robotic system. A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision.
89259540|NCT06202690|Placebo Comparator|SP-VATS|SP-VATS Arm: 145 patients, single-port anatomical pulmonary resection was performed using VATS. A 4-cm incision will be made at 5th intercostal space on the anterior or posterior axillary line. A chest tube will be inserted in same incision.
88804944|NCT04753112|Experimental|Treatment|"All the subjects will receive sacubitril/valsartan from weeks 6 to 12. From weeks 1-6 and 12-18 patients will be treated with standard therapy for HFpEF according to PA pressures (diuretics and systemic vasodilators if concomitant hypertension).~All the subjects will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).~Device: Patients eligible for this study are those with an already implanted CardioMEMS device.~Drug: Sacubitril/Valsartan Target dose:97/103mg bid"
88804945|NCT01305811|Experimental|Bi-weekly acupuncture treatment|Bi-weekly acupuncture treatment
89259541|NCT06202677|Experimental|Experimental: Intervention group: Obsessive Compulsive Disorder Program|Participants will complete an 8-day self-guided programme on obsessive compulsive disorder delivered via a mobile phone application with daily exercises guided by cognitive-behavioural and exposure and response prevention principles.
89259542|NCT06202677|Active Comparator|Control group|Participants will complete an 8-day self-guided programme on cooperation delivered via a mobile phone application with daily exercises that differ from the intervention group in terms of content but are comparable in terms of duration.
89259543|NCT06202625|Experimental|avatrombopag|"Avatrombopag 20 mg/d will be taken orally from +D7 after haplo-HSCT until reaching the adjustment indication or to +D60 after haplo-HSCT. Routine treatment is allowed.~Adjustment indication:~When PLT<50×10^9/L or PLT transfusion dependent on the +D30 after haplo-HSCT, increase the dosage to 40 mg/d; When the dosage has been increased to 40 mg/d, and PLT≥80×10^9/L excluding the factor of PLT transfusion, decrease the dosage to 20 mg/d; When PLT≥80×10^9/L for 7 consecutive days excluding the factor of PLT transfusion, or PLT≥300×10^9/L excluding the factor of PLT transfusion, stop administration; When PLT<50×10^9/L or become PLT transfusion dependent after stopping administration, initiate administration again at the dosage 40 mg/d.~PLT transfusion Indication: When PLT<20×10^9/L, and/or with the symptom or risk of bleeding."
89259544|NCT06202625|Placebo Comparator|Placebo|"Placebo 20 mg/d will be taken orally from +D7 after haplo-HSCT until reaching the adjustment indication or to +D60 after haplo-HSCT. Routine treatment is allowed.~Adjustment indication:~When PLT<50×10^9/L or PLT transfusion dependent on the +D30 after haplo-HSCT, increase the dosage to 40 mg/d; When the dosage has been increased to 40 mg/d, and PLT≥80×10^9/L excluding the factor of PLT transfusion, decrease the dosage to 20 mg/d; When PLT≥80×10^9/L for 7 consecutive days excluding the factor of PLT transfusion, or PLT≥300×10^9/L excluding the factor of PLT transfusion, stop administration; When PLT<50×10^9/L or become PLT transfusion dependent after stopping administration, initiate administration again at the dosage 40 mg/d.~PLT transfusion Indication: When PLT<20×10^9/L, and/or with the symptom or risk of bleeding."
89259545|NCT06202586|Experimental|Received low FiO2|Patients undergoing elective thoracic surgery were treated with 30% FiO2 after pulmonary reexpansion following one-lung ventilation and 2-hour postoperative.
89259546|NCT06202586|Active Comparator|Received high FiO2|Patients undergoing elective thoracic surgery were treated with 80% FiO2 after pulmonary reexpansion following one-lung ventilation and 2-hour postoperative.
89259547|NCT06202573|Active Comparator|group1A|patients who have a step counter and we do not motivate them to walk
89259548|NCT06202573|Active Comparator|Group 1B|patients who have a step counter, who do not motivate us to walk, and who will apply ice only on the 1st day after surgery
89259549|NCT06202573|Active Comparator|group 2|without step counter (only photos will be requested)
89259550|NCT06202573|Active Comparator|group 3|patients with step counters whom we motivate to take at least 5000 steps
89259551|NCT06202573|Active Comparator|group 4|patients with step counters whom we motivated to take at least 10000 steps
89259552|NCT06202560|Experimental|Tofacitinib|taking oral Tofacitinib 5 mg twice a day for 12 weeks
88804946|NCT01305811|Active Comparator|Wait list|Wait list for 2 months followed by weekly acupuncture for 4 months
88804947|NCT04770194|Experimental|Cohort 1: 200mg SP-8008 Prototype Capsule A|Treat 200 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
88804948|NCT04770194|Experimental|Cohort 2: 400mg SP-8008 Prototype Capsule A|Treat 400 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
88804949|NCT04770194|Experimental|Cohort 3: 800mg SP-8008 Prototype Capsule A|Treat 800 mg SP-8008 Prototype Capsule A or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
89259553|NCT06202547|Experimental|intraovarian injection of MSC-EVs|The patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
89259554|NCT06202534||Before radiotherapy,|Samples were collected from patients with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, and head and neck cancer. 5 ml of peripheral blood was extracted from these patients before radiotherapy, and flow cytometry was used to detect MDSCs, T cells, and erythroid precursor cells.
89259555|NCT06202534||During radiotherapy|Samples were collected from patients with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, and head and neck cancer. 5 ml of peripheral blood was extracted from these patients during radiotherapy, and flow cytometry was used to detect MDSCs, T cells, and erythroid precursor cells.
89259556|NCT06202534||After radiotherapy|Samples were collected from patients with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, and head and neck cancer. 5 ml of peripheral blood was extracted from these patients after radiotherapy, and flow cytometry was used to detect MDSCs, T cells, and erythroid precursor cells.
89259557|NCT06202534||3 months after radiotherapy|Samples were collected from patients with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, and head and neck cancer. 5 ml of peripheral blood was extracted from these patients 3 months after radiotherapy, and flow cytometry was used to detect MDSCs, T cells, and erythroid precursor cells.
89259558|NCT06202521|Experimental|SARS-CoV-2 domain: CX-4945 (400 mg BID for 5 days) +SOC|Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
88804950|NCT04770194|Experimental|Cohort 4: 800 mg SP-8008 Prototype Capsule B|Treat 800 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
88804951|NCT04770194|Experimental|Cohort 5: 1200 mg SP-8008 Prototype Capsule B|Treat 1200 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
88804952|NCT04770194|Experimental|Cohort 6: 1800 mg SP-8008 Prototype Capsule B|Treat 1600 mg SP-8008 Capsule B or matching placebo. 6 out of 8 subjects were administrated SP-8008 and the other two were received Placebo.
88804953|NCT05606588|Experimental|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for the duration of their medical therapy, in addition to usual care.
89259559|NCT06202521|Placebo Comparator|SARS-CoV-2 domain: Placebo + SOC|Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
89259560|NCT06202521|Experimental|Influenza virus domain: CX-4945 (400 mg BID for 5 days) +SOC|Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
88804954|NCT05606588|No Intervention|Control group|The control group receives treatment as usual. The control group will be given the opportunity to participate in the intervention after therapy.
89259561|NCT06202521|Placebo Comparator|Influenza virus domain: Placebo + SOC|Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
89259562|NCT06202469|Experimental|Supplement 1|Creatine monohydrate
88804955|NCT01409239|Active Comparator|Subcutaneous Insulin|
88804956|NCT01409239|Experimental|Intravenous insulin|
88804957|NCT00108524|Experimental|Low Carbohydrate Ketogenic Diet|Participants receive dietary counseling over 48 weeks aimed at helping them to lower starch and sugar intake.
88804958|NCT00108524|Active Comparator|Low-Fat Diet plus Orlistat|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake, and additionally receive Orlistat taken 3 times daily.
88804959|NCT01410097|Experimental|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
88804960|NCT01410097|Placebo Comparator|Diabetes Support and Education (DSE)|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
88804961|NCT05606354|Experimental|Intervention group (Group A)|"STRECHING EXERCISES:~A. HAMSTRING MUSCLE STRECHING.~B. CALF MUSCLE STRECHING:~2. STRENGTHENING EXCERCISES: 2 exercises will be performed on targeted muscle group Quadriceps. A. QUADRICEP MUSCLE (with ankle weight). B. QUADRICEP MUSCLE (straight leg raise).~3. KNEE RANGE OF MOTION EXERCISES: (FLEXION AND EXTENSION)~4. FUNCTIONAL EXERCISES:~A. SIT TO STAND:~B. CLIMBING STAIRS:~KINESIO TAPING The following KT application techniques will be used for intervention group after identifying the goal. Goal - A: Proprioception Stimulation and Mechanical Correction Tape Technique-A: (Strip Cutting Shape: One Y-shaped + two I-shaped strips).~Goal B: Lymphatic Correction and Muscle Correction Tape Technique-B: (Strip Cutting Shape: Two Y-shaped + two I-shaped strips)."
88804962|NCT05606354|Other|control group (Group.B)|GROUP.B - (CONTROL) - EXERCISES ONLY WITHOUT KINESIO TAPE The exercise types and dosage will be exactly the same for control group (as in experimental group (as mentioned above) But no kinesio tape will be given to this group.
88804963|NCT02093702|Active Comparator|Unstructured Physical Activity and Exercise Education Delivery|50 subjects will receive the standard approach to physical activity and exercise education from a Certified Diabetes Educator.
88804964|NCT02093702|Experimental|Structured Physical Activity and Exercise Education Delivery|50 subjects will receive physical activity and exercise education and behaviour counseling from a qualified Exercise Specialist (Registered Kinesiologist). These subjects will receive access to a community health and fitness centre as well as exercise instruction and on-going support and motivation from a YMCA Wellness Coach who focuses on establishing healthy behaviors towards the attainment of personal goals. Subjects will be requested to complete a lifestyle questionnaire at each appointment with their Wellness Coach. Subjects will receive a Physical Activity and Exercise Journal that will help them keep track of their weekly physical activity and exercise activities.
89259563|NCT06202469|Experimental|Supplement 2|Creatine monohydrate plus ubiquinol
89259564|NCT06202469|Placebo Comparator|Placebo|Inulin
89259565|NCT06202456|Experimental|Huazhi Rougan granule|
89259566|NCT06202430|Active Comparator|Ultrasound Guided High Thoracic Erector Spinae Plane Block|High Thoracic-ESPB The patient was placed in the lateral decubitus. Subsequently, an ultrasound (US)-guided aseptic technique, with a high-frequency linear probe enveloped in a sterile sheath containing a thin film of US gel, was used to locate the transverse process of T2. After LA skin infiltration, a 22-G block was inserted in a cephalocaudal direction until the space between the fascia of the erector spinae and the transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
89259567|NCT06202430|Active Comparator|Ultrasound Guided Shoulder Block|Shoulder Block Suprascapular nerve block (SSNB) approach: A high-frequency linear probe was utilized across the supra-spinous fossa parallel to the spine of the scapula after skin cleaning with an antiseptic solution, if a deep block is required, a low frequency probe was required. A hyperechoic line was identified, followed by an acoustic shadow that corresponds to the floor of the supra-spinous fossa. The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle. Along with Axillary nerve block technique.
89259568|NCT06202417||monotherapy group|patients received fruquintinib alone
89259569|NCT06202417||combine group|patients administered fruquintinib in combination with chemotherapy or/and anti-PD1 antibodies
89259570|NCT06202391|Experimental|Group A (Autogenic inhibition muscle energy technique)|12 sessions will be conducted over a period of 4 weeks with 3 days per week Frequency: 12 sessions, four times a week for 3 consecutive weeks Time duration: apporx. 8 to 10 minutes
89259571|NCT06202391|Experimental|Group B (Reciprocal inhibition muscle energy technique)|"12 sessions will be conducted over a period of 3 weeks with 4 days per week~Frequency: 12 sessions, four times a week for 3 consecutive weeks Time duration: apporx. 8 to 10 minutes"
89259572|NCT06202365|Experimental|Group A (WBV Group)|A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode
89259573|NCT06202365|Sham Comparator|Group B (Sham WBV Group)|They will receive the same intervention while the device turned off for 4 minutes, 2 session/ week for 6 weeks.
89259574|NCT06202352|Experimental|Intervention Group|The group which yoga and meditation are implemented
89259575|NCT06202352|No Intervention|Control|The group which has no implementation
89259576|NCT06202313|Experimental|Cadonilimab + Eribulin|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m^2 IV on Days 1 and 8 of each 21-day cycle.
89259577|NCT06202313|Active Comparator|Eribulin|Participants receive Eribulin 1.4mg/m^2 IV on Days 1 and 8 of each 21-day cycle.
89259578|NCT06202300||Patients with high inflammation level|CAD patients undergoing multimodality imaging with high inflammation burden
89259579|NCT06202300||Patients with low inflammation level|CAD patients undergoing multimodality imaging with low inflammation burden
89259580|NCT06202287||stroke patient|The specified tests will be administered to 50 patients who have experienced strokes and meet the criteria.
89259581|NCT06202183|Experimental|Group A: Exercise Group|"42 participants will be enrolled using a permuted blocked design with varying block size and will complete study procedures as follows:~Baseline in-office visit.~Completion of exercise sessions 3x weekly.~Post-intervention in-office visit."
89259582|NCT06202183|No Intervention|Group B: Waitlist Control Group|"42 participants will be enrolled using a permuted blocked design with varying block size and will complete study procedures as follows:~Baseline in-office visit.~Participants will be asked to maintain baseline exercise behavior and/or usual, daily activities.~Post-intervention in-office visit. Participants will be offered to participate in the exercise program upon the completion of post-intervention assessments."
89259583|NCT06202157|Experimental|LMB (LipoMicel Berberine)|
89259584|NCT06202157|Experimental|DHB (Dihydroberberine)|
89259585|NCT06202105|Experimental|Laparoscopic total gastrectomy|"5 trocars were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.~The right gastroepiploic vein was divided and right gastroepiploic and inferior pyloric artery were transected at their origin from the gastroduodenal artery to dissect group 6.~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.~The left gastric vein was divided and then the left gastric artery was vascularized to remove group 7.~The dissection was continued upward along the splenic artery and its branches to remove group 11p,d and/or along the splenic hilum to remove group 10.~The dissection was then conducted the right and left of the esophago-gastric junction to remove group 1,2.~As a general rule, Roux en Y method was used for esophagoo-jejunal reconstruction for all cases"
89259586|NCT06202105|Active Comparator|Open total gastrectomy|An incision of 15~20 cm length is made in the abdominal midline . Standard total gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, along splenic artery, proper hepatic artery, and/or the splenic hilum) . Roux-en Y esophagojejunal anastomosis is performed for reconstruction.
89259587|NCT06202079|Experimental|GZR4 Injection|GZR4 Injection + Oral Antidiabetic Drug
89259588|NCT06202079|Active Comparator|Insulin Degludec|Insulin Degludec + Oral Antidiabetic Drug
89259589|NCT06202053||The experimental group (patients received the periareolar incision)|
89259590|NCT06202053||The control group (patients underwent the axillary incision)|
89259591|NCT06202001|Experimental|Irinotecan, TAS-102 plus Bevacizumab arm|
89259592|NCT06201975|Experimental|Thyme honey|The experimental group will receive scaling and root debridement and locally delivered 0.5 ml non-diluted Thyme honey on sites with PPD ≥ 5 mm. Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters (Ibrahim et al., 2021).
89259593|NCT06201975|Placebo Comparator|Saline|The control group will receive scaling and root debridement with normal saline irrigation on sites with PPD ≥ 5 mm.
89259594|NCT06201962|Experimental|Massage|Before the procedure, written and verbal consent will be obtained from the newborn's guardian and brief information will be given about the massage to be performed on the newborn. Before applying massage to premature babies, their 24-hour sleep duration will be evaluated with an actigraphy device. Starting from the face with gentle touches, massage will be applied to the baby's forehead, around the eyes and cheeks with 2 fingers, without pressing too much. Then, the chest area will be massaged with circular movements from right to left, and then the upper and lower extremities will be massaged. Finally, the massage will be completed by turning the baby face down and applying gentle pressure to the back area. Massage applications will be performed for 15 minutes every morning and evening for two days. On the morning of the second day, an actigraphy device will be attached to the premature babies' ankles and their 24-hour sleep will be re-evaluated.
89259595|NCT06201962|Experimental|Foot Reflexology|Before the procedure, written and verbal consent will be obtained from the newborn's guardian and brief information will be given about the foot reflexology to be performed on the newborn. In addition to daily routine nursing care and monitoring for premature babies, before applying foot reflexology, the actigraphy device will be attached to the babies' ankles and their 24-hour sleep duration will be evaluated. In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes. Foot reflexology will be performed for 15 minutes every morning and evening for two days. On the morning of the second day, an actigraphy device will be attached to the premature babies' ankles and their 24-hour sleep will be re-evaluated.
89259596|NCT06201962|Experimental|Control|Newborns will receive routine medical treatment and nursing care and will not undergo any procedures. Before the procedure, written and verbal consent will be obtained from the newborn's guardian and brief information about the study will be given. Premature babies will have their 24-hour sleep recorded with actigraphy 1 day in advance. Then, the nursing care that premature babies receive in their daily routine will be given for two days. On the morning of the second day, an actigraphy device will be attached to the left foot of the premature babies and their 24-hour sleep on the second day will be recorded.
89259597|NCT06201949|Experimental|Test group|
89259598|NCT06201949|Active Comparator|Control group|
89259599|NCT06201884|Experimental|Adapted physical activity|Adapted physical activity on a walking platform
89259600|NCT06201780|Active Comparator|cases group|group of cases with cholinergic urticaria
89259601|NCT06201780|Active Comparator|control group|control group not have cholinergic urticaria
89259602|NCT06201676|Experimental|Standard of Care (SOC) + Ketorolac|The treatment arm will receive 15 mg of intravenous (IV) ketorolac every 6 hours during the first five hospital days, in addition to standard of care (SOC) multimodal analgesia according to each site's institutional protocol.
89259603|NCT06201676|Placebo Comparator|Standard of Care (SOC)|The placebo arm will receive 2 mL of intravenous (IV) saline every 6 hours during the first five hospital days, in addition to standard of care (SOC) multimodal analgesia according to each site's institutional protocol.
89259604|NCT06201663|Experimental|Interventional group|"Patients with CIT fulfilling the inclusion criteria will receive romiplostim subcutaneously weekly, either at the time of nadir of a delayed chemotherapy cycle or on the first day of the subsequent chemotherapy cycle and continue until the completion of chemotherapy for maximum 12 weeks.~Starting dose will be 3 μg/kg with the escalation of the dose weekly by 2 μg/kg (maximum dose 10 μg/kg) when the platelet increment was less than 25 x10e9/L to maintain platelet counts above 75x10e9/L."
88804965|NCT00052442|Experimental|135 mg/m^2 Pralatrexate 1/2 weeks|Pralatrexate (PDX) 135 mg/m^2 administered as an intravenous (IV) infusion over one hour into a side arm of a running intravenous infusion of normal saline for 1/2 weeks.
89259605|NCT06201663|No Intervention|Control group|"Patients with CIT fulfilling the inclusion criteria randomized to the control group will not receive romiplostim injections.~Patients are allowed to received supportive care according to the standard of care protocols."
89259606|NCT06201624|Experimental|Isotretinoin|patients will receive oral isotretinoin (1 mg/kg/day) for 3 months
89259607|NCT06201624|Active Comparator|Kligman Formula arm|patients will receive topical triple combination formula at night everyday over the affected areas for 3 months
89259608|NCT06201611|Experimental|Nebivolol+ Standard care arm|This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
89259609|NCT06201611|Active Comparator|Epalrestat + Alpha Lipoic Acid +Standard care|This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
89259610|NCT06201611|Active Comparator|Standard care alone|Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
89259611|NCT06201585|Experimental|Single-port robot-assisted gastrectomy|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
89259612|NCT06201572||Observation group|
89259613|NCT06201572||Control group|
89259614|NCT06201572||Positive control group|
89259615|NCT06201559|Experimental|Sequence TRTR|Participants will be administered with test (T) intervention [Albendazole Indian Pharmacopoeia (IP) 400 mg] in Period 1, reference (R) intervention (Albendazole Tablets 400 mg) in Period 2, T intervention in Period 3 and R intervention in Period 4.
89259616|NCT06201559|Experimental|Sequence RTRT|Participants will be administered with reference (R) intervention in Period 1, test (T) intervention in Period 2, R intervention in Period 3 and T intervention in Period 4.
89259617|NCT06201520|Experimental|MA group (manual acupuncture group)|Acupunctue Needle: 1 inch- 32 gauge（0.3x25 mm）for 20 min after De-qi Acupoints selection: PC4[Ximen], PC6[Neiguan], PC7[Daling], PC8[Laogong], HT2[Qingling], HT7[Shenmen], HT8[Shaofu], LU9[Taiyuan], LI11[Quchi]
89259618|NCT06201520|Experimental|LA group (laser acupuncture group)|laser acupuncture gruoup with LaserPen, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; Nogier C frequency for 4 J each points The acupoints selection is the same as the MA group.
89259619|NCT06201520|Sham Comparator|SLA group (sham laser acupuncture group)|sham laser acupuncture group is designed with the same acupoints selection and no energy output
89259620|NCT06201468|Experimental|group A|"Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Mulligan Mobilization with Movement for peripheral joints combines sustained manual application of 'gliding' force to a joint, with the aim of repositioning the positional faults with concurrent physiological motion of the joint, either performed actively by the subject or passively by the therapist"
89259621|NCT06201468|Experimental|group B|"Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks.~Scapular PNF incorporates functional or diagonal patterns (anterior elevation - posterior depression and posterior elevation - anterior depression) for performing the exercises and can be used to stretch or strengthen the muscles selectively. These techniques help the muscles to relearn the normal timing of recruitment and the amount of activation to sustain the balance between different groups of muscles"
89259622|NCT06201455|Experimental|PEI+GT|Experimental group: Phacoemulsification with intraocular lens implantation (PEI) and goniotomy (GT).
89259623|NCT06201455|Active Comparator|PEI+MED|Controll group: Phacoemulsification with intraocular lens implantation (PEI) and medication therapy (MED).
89259624|NCT06201442||Patients undergoing unilateral Anterior Cruciate Ligament Reconstruction (ACLR)|4 - 5 visits: Clinical examination, magnetic resonance imaging (MRI), 3D motion analysis, Strength assessment, EOS radiography (full leg X-ray scan), X-ray scan knee, Blood sample, Questionnaires and Activity monitoring.
89259625|NCT06201442||Healthy controls without previous Anterior Cruciate Ligament (ACL) injury|2 visits: Clinical examination, MRI, 3D motion analysis, Strength assessment, EOS radiography, X-ray scan knee, Blood sample, Questionnaires and Activity monitoring.
89259626|NCT06201351||Adaptive radiotherapy group|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
89259627|NCT06201338||Open aortic surgery|Patient undergoing open surgery for abdominal aortic aneurysm or abdominal aortic occlusion
89259628|NCT06201312|Experimental|Early Postmenopausal Exercise Group (EE)|
89259629|NCT06201312|Experimental|Late Postmenopausal Exercise Group (LE)|
89259630|NCT06201312|No Intervention|Early Postmenopausal Control Group (EC)|
89259631|NCT06201312|No Intervention|Late Postmenopausal Control Group (LC)|
89259632|NCT06201286|Experimental|Mulligan group (MG)|Mulligan group underwent an exercise program planned as 6 sessions. A one-day gap separated each session, and the entire program spanned 11 days. In Mulligan group, they received SNAG and NAGS techniques as part of the Mulligan concept applications, utilizing tools like the Mulligan belt, sponge, and stretcher. Both groups participated in supervised stretching and strengthening exercises.
89259633|NCT06201286|Other|Control group|Control group underwent an exercise program planned as 6 sessions. A one-day gap separated each session, and the entire program spanned 11 days. Both groups participated in supervised stretching and strengthening exercises.
89259634|NCT06201273|Experimental|High-Intensity Interval Training|This High-Intensity Interval Training (HIIT) program, structured to span 12 weeks, incorporates three sessions per week. Each session comprises 8 to 10 exercise intervals on a cycle ergometer. During these intervals, participants are required to reach an intensity level between 8 and 10 points, based on the modified Borg scale, which ranges from 1 to 10 points. A typical interval involves 1 minute of intensive pedaling, followed by a 2-minute rest period without any activity. To facilitate progressive development, the resistance of the cycle ergometer will be adjusted biweekly to increase the pedaling challenge. Despite these adjustments, participants should consistently maintain their effort intensity within the 8 to 10 point range on the modified Borg scale for each interval.
89259635|NCT06201273|Experimental|Resistance Training|"This training protocol, spanning a duration of 12 weeks, consists of three weekly sessions. In each session, participants will engage in Elastic Resistance Exercises (ERE) using Theraband elastic bands (CLX). The focus will be on both concentric and eccentric contractions, maintaining an intensity level of 8 to 10 as per the Resistance Exercise Scale (OMNI-RES). Each exercise will be conducted for 1 minute, followed by a 2-minute rest period. Each exercise will be repeated three times within the session.~The specific exercises include bicep curls, seated horizontal rows, and wide squats. To ensure proper progression and adaptation, the exercise load will be adjusted biweekly. This adjustment will be based on the physiological adaptations of the subjects to the training, aiming to recalibrate the loads to new resistance thresholds and maintain a consistent intensity of 8 to 10 on the OMNI-RES scale for each exercise."
89259636|NCT06201273|No Intervention|Control|Participants in the control group will be instructed to maintain their current lifestyle and exercise habits throughout the duration of the study. This includes adhering to their prescribed medication regimen as usual.
89259637|NCT06201247|Experimental|Experimental: Experimental: JD123 injection.|The relapsed/refractory AML patients will receive JD123 injections up to 3 dose levels (5.0×108 cells/dose，1.5×109 cells/dose，3.0×109 cells/dose) after FC chemotherapy.
88804966|NCT00052442|Experimental|30 mg/m^2 Pralatrexate 3/4 weeks|PDX 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 3/4 weeks.
88804967|NCT00052442|Experimental|30 mg/m^2 Pralatrexate 6/7 weeks|PDX 30 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
89259638|NCT06201234|Experimental|Arm A: Niraparib + elacestrant*|"Treatment will be given until disease progression, unacceptable toxicity, withdrawal of patient´s consent to study participation, or end of study.~* Together with GnRH analogue in pre- and perimenopausal women, and in men, at least two weeks prior to treatment.~Elacestrant tablets 400 mg orally daily~Niraparib 200 mg orally daily The protocol provides procedures for specific adverse events requiring dose modifications or delays."
89259639|NCT06201234|Active Comparator|Arm B: Niraparib|"Treatment will be given until disease progression, unacceptable toxicity, withdrawal of patient´s consent to study participation, or end of study.~• Niraparib 200 mg orally once daily~The protocol provides procedures for specific adverse events requiring dose modifications or delays."
89259640|NCT06201221||Single-port Laparoscopy group|Single-port Laparoscopy in the Treatment of Benign Ovarian Tumors in Children and Adolescents
89259641|NCT06201221||Multiport Laparoscopy group|Multiport Laparoscopy in the Treatment of Benign Ovarian Tumors in Children and Adolescents
88804968|NCT00052442|Experimental|45 mg/m^2 Pralatrexate 6/7 weeks|PDX 45 mg/m^2 administered as an IV infusion over 15 minutes into a side arm of a running intravenous infusion of normal saline for 6/7 weeks.
89259642|NCT06201208|Experimental|The ST-Facilitation Psychoeducation Program Group|The ST-Facilitation Psychoeducation Program is planned for mothers in the intervention group as an 80-minute session (40-minute session + 20-minute break + 40-minute session) once a week for six weeks, in groups of two to four participants.
89259643|NCT06201208|No Intervention|Control Group|No action will be taken by the researcher during the research. Only data collection will be carried out. At the end of the research, ST-Facilitation Psychoeducation Program will be applied ethically.
89259644|NCT06201195|Active Comparator|Adductor canal block|Usg guidance adductor canal block with %0.25 Bupivacaine 20 ml
89259645|NCT06201195|Active Comparator|Distal adductor canal block with anterior cutaneus nerve block|Usg guidance distal adductor canal block (%0.25 Bupivacaine 20 ml) with anterior cutaneus nerve block (%0.25 Bupivacaine 10 ml)
89259646|NCT06201156|Active Comparator|Group A / Nebulizer Group|Group A/ Nebulizer group will receive 3 puffs of a placebo MDI with a spacer, followed immediately by a standard dose of 0.15 mg/kg of salbutamol in 3 mL of isotonic sodium chloride solution delivered by an oxygen-driven nebulizer at a flow rate of 6 L/min.
89259647|NCT06201156|Experimental|Group B / MDI with Spacer Device Group|Group B/ MDI with Spacer Group will receive 3 puffs (90 pg per puff) of salbutamol MDI with a spacer, followed by 3 mL of nebulized isotonic sodium chloride solution. All treatments will be given at 20-minute intervals.
89259648|NCT06201104|Experimental|Experimental group|Patients in the experimental group will be given patient empowerment training as an intervention. The aim of the training is to ensure that patients have the knowledge, skills and attitudes necessary to manage the care and treatment processes both during their hospitalization and in their daily lives after discharge.
89259649|NCT06201104|No Intervention|Control group|After the pre-test data is collected from the control group by face-to-face interview method, no intervention will be made to the control group. At the end of the second month, the same scales will be re-administered over the phone as post-test data.
89259650|NCT06201065|Experimental|Experimental arm|Hepatic arterial infusion chemotherapy plus lenvatinib and toripalimab
89259651|NCT06201065|Active Comparator|Control arm|Hepatic arterial infusion chemotherapy plus lenvatinib
89259652|NCT06201052||Junior|Junior soccer players 19 male, average training experience: 8 yr.
89259653|NCT06201052||Senior|Senior Soccer players 21 male, average training experience: 16 yr.
89259654|NCT06201039|Experimental|CWI Block|"Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon.~The Continuous placebo Wound Infusion (CWI) will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.~• Intervention: Drug: 0.5% lidocaine hydrochloride at 4ml/h."
89259655|NCT06201039|Placebo Comparator|CWI Placebo|"Control Intervention: Patients in the control arm will undergo the CWI procedure as well. The infusion will contain 0.9% normal saline + 1:400000 adrenaline at 4ml/h.~• Intervention: Drug: 0.9% normal saline at 4ml/h."
89259656|NCT06201013|Placebo Comparator|Standard Urotherapy|Participants were asked to undergo a 30-minute course every 6 weeks at follow-up, including (1) education to dispel doubts about the disease and understand the benefits of curing dysfunction to facilitate better treatment outcomes for children, (2) regular urination to establish good urination habits, (3) dietary guidance to avoid constipation, and (4) how to accurately record symptoms of OAB
89259657|NCT06201013|Active Comparator|Standard Urotherapy Combined with Solifenacin Drug Treatment|Standard Urotherapy plus Solinasine succinate 5mg once daily with a maximum dose of 10mg/day
89259658|NCT06201013|Experimental|Standard Urotherapy Combined with Vitamin D supplementation|Standard Urotherapy plus high dose vitamin D supplement 2400iu/d
89259659|NCT06200974|Experimental|High dose rate prostate brachytherapy|"Radiation. High dose rate prostate brachytherapy is delivered under anesthesia in 2 procedures, 1-2 weeks apart.~HDR brachytherapy is also accomplished as an out-patient."
89259660|NCT06200935||Children with neurodevelopmental disorders|Boys and girls with neurodevelopmental disorders between 3 and 16 years of age, belonging to two educational centers in Madrid, attended by children with this type of disorders. Both centers have similar characteristics in terms of the type of feeding and management of the children attending them
89259661|NCT06200922|Experimental|Synchronous Group|Will receive guidance and perform a real-time guided pelvic physiotherapy protocol through online physiotherapy by the physiotherapist.
89259662|NCT06200922|Experimental|Asynchronous Group|Will receive guidance and perform a pelvic physiotherapy protocol after the evaluation, without the real-time monitoring by the physical therapist
89259663|NCT06200922|Active Comparator|Face-to-face group|Will receive guidelines and will perform a pelvic physiotherapy protocol oriented in person by the physical therapist.
89259664|NCT06200883|Placebo Comparator|Placebo|Placebo oral tablet. In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
89259665|NCT06200883|Active Comparator|CERBRAIN|In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
89259666|NCT06200870||aortic valvular sclerosis group|
88804969|NCT00052442|Experimental|270 mg/m^2 Pralatrexate 2/4 weeks|PDX (270 mg/m^2) administered as an IV bolus over 3-5 minutes into a side arm of a running intravenous infusion of normal saline for 2/4 weeks.
88804970|NCT01410409|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
88804971|NCT01410409|Active Comparator|MEDIC + TKR|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months after a total knee replacement.
88804972|NCT01410409|Active Comparator|Observational Cohort|If the patient can be included, but doesn't want to participate in the randomization, the patient is offered to enter into a prospective observational cohort with the same endpoints and the same follow-up as in the randomized study. The participant can then, in consultation with his/her physician, choose whether they would like MEDIC-treatment or TKR in combination with MEDIC-treatment.
88804973|NCT01356277|Experimental|Multi-component Intervention|"Multi-component Intervention consisting of:~Adherence Support Team (patient, parent, Coach)~standardized education on immunosuppressive medications~identification of adherence barriers~Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~text message, email, or visual cue dose reminders"
89259667|NCT06200870||non-aortic valvular sclerosis group|
89259668|NCT06200857||association francaise de chirurgie AFC working group|"cohort description included all patients aged over 18, undergoing emergency or elective surgery for sigmoid diverticulitis between 2010 and 2019 and with a follow-up of at least 3 months to determine morbi-mortality on the 90th postoperative day.~minor patient, those with a final colorectal cancer and those operated on for right colonic diverticulitis were excluded~with a follow-up of at least 3 months to determine morbi-mortality on the 90th postoperative day.~Non-inclusion criteria for research subjects :~Minor patient~Surgical finding of colorectal cancer The patient operated on for diverticulitis of the right colon"
89259669|NCT06200844|Experimental|Rotavac 5D|Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 10 power 5.0 FFU and administered as a three-dose regimen, 4 weeks apart.
89259670|NCT06200844|Placebo Comparator|Placebo|Placebo administered as a three-dose regimen, 4 weeks apart.
89259671|NCT06200818|Active Comparator|Formocresol|
89259672|NCT06200818|Experimental|Diode laser|
89259673|NCT06200818|Experimental|Er:CrYSGG|
89259674|NCT06200805|Experimental|High Intensity Taijiquan Exercise Group|60 minutes of tai chi exercise 5 times a week
89259675|NCT06200805|Experimental|Moderate Intensity Taijiquan Exercise Group|60 minutes of tai chi exercise 3 times a week
89259676|NCT06200805|No Intervention|control subjects|The control group did not implement any intervention and maintained a normal life and study status.
89259677|NCT06200779|Active Comparator|Intervention group|Patients randomized to the Intervention group will receive a prescription for oriented H. pylori eradication treatment according to the following rules: a) clarithromycin-sensitive strain (independently of levofloxacin resistance test result) - PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days; b) clarithromycin-resistant and levofloxacin-sensitive strain - PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days; c) clarithromycin-resistant and levofloxacin-resistant strain - bismuth quadruple therapy (Pylera®) for 10 days. At least 4 weeks after stopping antibiotics (and at least 2 weeks after stopping PPIs), an eradication control test will be carried out using a respiratory test (urea breath test) or endoscopic biopsies (if clinical indication for that).
89259678|NCT06200779|Active Comparator|Control group|Patients randomized to the Control group will receive a prescription for empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®) for 10 days. At least 4 weeks after stopping antibiotics (and at least 2 weeks after stopping PPIs), an eradication control test will be carried out using a respiratory test (urea breath test) or endoscopic biopsies (if clinical indication for that).
89259679|NCT06200766|Experimental|Momethasone furoate nasal spray (trade name: Yiqing®/ Yiqing®)|Dosage form: nasal spray Specification: 60 press per bottle, 50 µ g of mometasone furoate, drug concentration: 0.05% (g / g) Route of administration: nasal injection Storage: 2℃ ~25℃ storage Manufacturer: Zhejiang Xianju Pharmaceutical Co., Ltd Specific administration method: 2 snap (50 µ g per snap), total 4 snap (total 200 µ g), 1 time / day.
89259680|NCT06200766|Active Comparator|Momethasone furoate nasal spray (trade name: Nasonex ®/ Nasonex ®)|Dosage form: nasal spray Specification: 60 press per bottle, 50 µ g of mometasone furoate, drug concentration: 0.05% (g / g) Route of administration: nasal injection Storage: 2℃ ~25℃ storage Holder manufacturer: MSD Belgium BVBA / SPRL Specific administration method: 2 presses (50 per side nostril µ g per snap), total 4 presses (total 200 µ g), One time / day
89259681|NCT06200766|Placebo Comparator|placebo|Dosage form: nasal spray Specification: 60 press per bottle Route of administration: nasal injection Storage: 2℃ ~25℃ storage Manufacturer: Zhejiang Xianju Pharmaceutical Co., Ltd Specific administration method: 2 presses (50 per side nostril µ g per snap), total 4 presses (total 200 µ g), One time / day
89259682|NCT06200753||Endovascular therapy|
89259683|NCT06200753||Best medical treatment|
89259684|NCT06200688|Experimental|Peanut Ball Group|In this group, pregnant women changed positions with a peanut ball during labor.
89259685|NCT06200688|No Intervention|Control Group|No intervention was applied in this group.
89259686|NCT06200675|Experimental|Compassion-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online compassion-focused exercise, where they will be asked to connect to their inner compassionate self. They will be asked to stay connected to that feeling while rereading what they wrote about their feelings of shame and imagining it was someone else who wrote it. Participants will then be asked to write a compassionate response to themselves. Participants will then be asked to reread this response while remaining connected to their compassionate self.
89259687|NCT06200675|Experimental|Logic-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online logic-based exercise that was adapted from a thought record (Greenberger & Padesky, 1995), which is often completed during cognitive behavioural therapy (CBT) treatment. Participants will be asked to reread what they wrote about their feelings of shame and chose a thought central to their shame to use for this exercise. Participants will be asked to generate evidence for and against their chosen thought, and then generate a more balanced thought. After the exercise, participants will be asked to reread their newly generated more balanced thought.
89259688|NCT06200675|Active Comparator|Placebo control condition|"Participants assigned to this condition will be asked to listen to a portion of an audio recording of The Hobbit (Tolkien, 2009) and then re-read what they wrote about their feelings of shame. They will then be asked to write a reflection about the thoughts and feelings arising from doing so. They will then be asked to re-read what they wrote in this reflection."
89259689|NCT06200662|Other|premature newborns|"premature newborns . 2 groups composed of the same children but benefiting from 2 different analgesic strategies, each applied at one of two different times. The groups compared were the order S then M group and the order M then S group."
89259690|NCT06200662|Other|premature|"premature newborns . 2 groups composed of the same children but benefiting from 2 different analgesic strategies, each applied at one of two different times. The groups compared were the order S then M group and the order M then S group."
89259691|NCT06200636|Experimental|Interventional group|This arm inclcudes all study participants.
89290395|NCT04424212|No Intervention|Control group|Participants in the control group will be instructed to wait. Once intervention group will be finished, participants in control group will be able to access the same intervention.
89290396|NCT01221324||Patients after open resection of colorectal cancer|
89259692|NCT06200623||Asthmatic patients presented to respiratory outpatient clinic|"All subjects will be subjected to Complete history taking including demographic data, residence, educational level, income level, and presence of first- or second-degree medical relative. The first onset age of asthma and duration of asthma will be recorded. Factors that can affect treatment adherence are collected as type and number of medications, cost, inclusion in the health insurance system, availability, asthma-related comorbidities, and choice of drug and device.~: To assess adherence we will use the Morisky Medication Adherence Scale (MMAS-8) as discussed above~To assess patient beliefs, we will use The Beliefs about Medicines Questionnaire as discussed above To obtain information on illness perception we will use The Brief Illness Perception Questionnaire (Brief IPQ) as discussed above To assess asthma control we will use the asthma control test as discussed above"
89259693|NCT06200597|Experimental|Part 1: (LAD603) Cohort 1|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
89259694|NCT06200597|Experimental|Part 1: (LAD603) Cohort 2|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
89259695|NCT06200597|Experimental|Part 1: (LAD603) Cohort 3|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
89259696|NCT06200597|Experimental|Part 1: (LAD603) Cohort 4|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
89259697|NCT06200597|Experimental|Part 1: (LAD603) Cohort 5|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
89259698|NCT06200597|Experimental|Part 1: (LAD603) Cohort 6|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
89259699|NCT06200597|Experimental|Part 1: (LAD603) Cohort 7|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
89259700|NCT06200597|Experimental|Part 1: (LAD603) Cohort 8|Participants will receive single ascending dose of LAD603 SC injection on Day 1.
89259701|NCT06200597|Placebo Comparator|Part 1: Placebo|Participants will receive single ascending dose of matching placebo SC injection on Day 1.
89259702|NCT06200597|Experimental|Part 2: (LAD603) Cohort A|Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.
89259703|NCT06200597|Experimental|Part 2: (LAD603) Cohort B|Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.
89259704|NCT06200597|Experimental|Part 2: (LAD603) Cohort C|Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.
89259705|NCT06200597|Experimental|Part 2: (LAD603) Cohort D|Participants will receive multiple ascending dose of LAD603 SC injection on Days 1, 15, 18 and 22.
89259706|NCT06200597|Placebo Comparator|Part 2: Placebo|Participants will receive multiple ascending dose of matching placebo SC injection on Days 1, 8 15, and 22.
89259707|NCT06200584|No Intervention|control|normal healthy individuals
89259708|NCT06200584|Experimental|psychotic patients|treatment given
89259709|NCT06200571||Nulliparous women with low risk for preeclampsia|Nulliparous women with low risk for preeclampsia by FMF-screening in the first trimester. Follow-up in week 22-24, 32, 36 and 6 months after delivery wtih clinical measurements, ultrasound doppler, blood- and urin samples.
89259710|NCT06200571||Nulliparous women with high risk for preeclampsia without aspirin|Nulliparous women with high risk for preeclampsia by FMF-screening in the first trimester. Follow-up in week 22-24, 32, 36 and 6 months after delivery wtih clinical measurements, ultrasound doppler, blood- and urin samples.
89259711|NCT06200571||Nulliparous women with high risk for preeclampsia with aspirin|Nulliparous women with high risk for preeclampsia by FMF-screening in the first trimester. Follow-up in week 22-24, 32, 36 and 6 months after delivery wtih clinical measurements, ultrasound doppler, blood- and urin samples. Aspirin tablets 150 mg daily in the evening from first trimester to week 36 of pregnancy.
89259712|NCT06200558||For ARON-3S: Patients with metachronous or de novo metastatic hormone/castration-sensitive PCa|Patients with metachronous or de novo metastatic hormone/castration-sensitive PCa treated with ADT+ARSI or ADT+ARSI+docetaxel
89259713|NCT06200558||For ARON-3Lu: Patients receiving Lutetium-177 PSMA for castration resistant PC (CRPC)|
89259714|NCT06200558||For ARON-3GEN: Patients treated with PARP inhibitors (alone or plus ARSI) for CRPC|
89259715|NCT06200532|Experimental|Single cohort of people using home footwear self-assessment kit|"FOOTSAK is a Footwear Self-Assessment Kit intended to empower people with diabetes by providing the necessary tools and instructional materials to enable self-assessment to determine whether footwear has adequate length and width. This feasibility study aims to determine whether people with diabetes and their footwear buddies can use FOOTSAK with sufficient (1) accuracy, (2) reliability and (3) ease of use to identify incorrectly fitting footwear (IFF).~We will recruit ten people with type 1 or 2 diabetes without any minor or major toe or foot amputation to use the FOOTSAK. Given that foot measurements have to be made whilst standing (to ensure full blood flow to feet during measurements), we will also recruit ten 'Footwear buddies' - people with or without diabetes willing to measure the feet of participating people with diabetes (for example, a spouse, partner, carer, friend, neighbour, or housemate)."
89259716|NCT06200519||Neonates born at 35 weeks gestation and above|"Stratification of population for recruitment and data analysis~Gestational age in weeks~Birth weight and centile~Small for gestational age (birth weight <10th centile post-natal)~Large for gestational age (birth weight >90th centile post-natal)~Evidence of antenatal Doppler abnormalities~Maternal gestational diabetes mellitus or pre-existing diabetes mellitus~Maternal pre-eclampsia~Signs of maternal chorioamnionitis~Mode of delivery~Transient Tachypnea of Newborn~Pregnancy conceived by assisted reproductive technologies~Maternal medication use~Suspected or confirmed Trisomy 21~Gestational age at birth 35-36+6 gestation group~Feeding type~Mild neonatal encephalopathy~Moderate and severe neonatal encephalopathy receiving therapeutic hypothermia"
89259717|NCT06200493||Wheelchair Athletes|national squad athletes in either wheelchair rugby or wheelchair basketball
89259718|NCT06200480|Active Comparator|Telephone by nurse|The headache patients will be contacted by nurse by phone after approximately 2 week and 6 week after start of preventive medical treatment. The patient will have a follow-up visit by neurologist after 3 months.
89259719|NCT06200480|No Intervention|Patient-initiated follow-up|The headache patient contact their general practitioner (GP) and/or the neurologist by a study-specific email if they have questions regarding the preventive medical treatment
89259720|NCT06200454||Guillain-Barré syndrome patients|neuromuscular ultrasound of cranial nerves
89259721|NCT06200454||normal participants|neuromuscular ultrasound of cranial nerves
89259722|NCT06200428|Experimental|Experimental group|"First of all, the pregnant women included in the experimental group;~Survey forms and scales will be applied in the pre-test (in weeks 29-30).~Then, a pregnancy pillow will be given and necessary explanations will be given about its use.~Second follow-up 33-34. It will be done during the first week of pregnancy and the scales will be repeated.~The last test is 37-38. It will be done during the gestational week (before birth) and the research will be completed.~Pregnancy pillow provides support and relief to 5 different parts of the body simultaneously.~It protects the health of expectant mothers during pregnancy and helps reduce neck, abdominal, waist, back and leg pain.~It does not lose its shape, become felt or flat with use.~Thanks to its zipper, the cover can be easily removed and washed, and can be put on just as easily."
89259723|NCT06200428|No Intervention|Control group|"To the pregnant women included in the control group, the researcher;~The survey forms and scales will be applied in the pre-test and no other intervention will be applied (in weeks 29-30).~Pregnant women in the control group were given 33-34 and 37-38 days. The last test will be done in a week."
89259724|NCT06200402|Experimental|Intervention|(Antibiotic-Loaded Cement Arm): This group will receive hip prosthesis surgery using antibiotic-loaded cement. The use of antibiotic-loaded cement is intended to investigate its effectiveness in reducing the rate of acute postoperative infections.
89259725|NCT06200402|Placebo Comparator|control|(Non-Antibiotic-Loaded Cement Arm): Participants in this group will undergo hip prosthesis surgery using non-antibiotic-loaded cement. This arm serves as the control to compare the outcomes with the antibiotic-loaded cement group.
89259726|NCT06200376|Experimental|T3011|
89259727|NCT06200363|Experimental|T3011 + Regorafenib|
89259728|NCT06200337|Other|Group A|In the first session, acupuncture was applied at BL65, the second at TB3, and the third at SP3. Each session was seperated 24 hours interval.
89259729|NCT06200337|Other|Group B|In the first session, acupuncture will be applied at SP3, the second at BL65, and the third at TB3. Each session was seperated 24 hours interval.
89259730|NCT06200337|Other|Group C|In the first session, acupuncture will be applied at TB3, the second at SP3, and the third at BL65. Each session was seperated 24 hours interval.
89259731|NCT06200324||Ready-to-Use Parenteral Nutrition|Numeta G13E
89259732|NCT06200324||Individualized parenteral nutrition|Individualized parenteral nutrition
89259733|NCT06200298|Experimental|Erector spinae plane block with naropeine [3,75 mg/mL]|Experimental group: Erector spinae plane block with naropeine [3,75 mg/mL]
89259734|NCT06200298|Active Comparator|Control group : ESPB with saline 0,9%|
89259735|NCT06199856||Hospitalized older adults at risk of sarcopenia|
89259736|NCT06199856||Community-dwelling older adults at risk of sarcopenia|
89259737|NCT06199492|Experimental|tVisio-1|The device collects optical coherence tomography (OCT) images in an effort to identify tumor tissue before physical samples are collected. During the biopsy, a sterilized optical imaging probe will be placed through the standard biopsy guidance needle to collect a few images of the tissue at the tip of the biopsy needle. Then the regular biopsy will continue to collect a few biopsy cores.
89259738|NCT06198426|Experimental|IBI3004|
89259739|NCT06198322|Experimental|Platelet-rich Fibrin|A 20 ml blood sample will be drawn from the median cubital vein into a PRF tube. Centrifugation will be done at 700 rpm for 3 minutes and the liquid of PRF will be suctioned out using a separate syringe. PRF will be injected distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
89259740|NCT06198322|Experimental|Vitamin D3|Subjects will receive vitamin Dꝫ injection distal to the canine on the experimental side three times; at the beginning of canine retraction (T0), 1 month after the start of canine retraction (T1), and 2 months after the start of canine retraction (T2).
89259741|NCT06197893|Experimental|1. GUG+MSS|The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site using a modified sling suture technique.
89259742|NCT06197893|Experimental|2. GUG+CS|The GUG was obtained from the maxillary premolar area, as detailed experimental GUG+MSS group. The dissected graft was fixed to the recipient site using conventional suture technique.
89259743|NCT06197893|Experimental|3. CG+MSS|Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatial region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique, as detailed experimental GUG+MSS group.
89259744|NCT06197893|Experimental|4. CG+CS|The dissected conventional graft, as detailed experimental CS+MSS group, fixed recipient bed with conventional suture technique, as detailed experimental GUG+CS group.
89259745|NCT06193824|Experimental|downhill treadmill walking -10% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% incline)
89259746|NCT06193824|Experimental|downhill treadmill walking -20% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-20% incline)
89259747|NCT06193434|Experimental|IBI356 for Single ascending dose (SAD)|
89259748|NCT06193434|Experimental|IBI356 for Multiple ascending dose (MAD)|
89259749|NCT06193434|Placebo Comparator|Placebo for MAD|
89259750|NCT06193434|Active Comparator|Dupilumab for MAD|
89259751|NCT06193434|Placebo Comparator|Placebo for SAD|
89259752|NCT06192446||Women with hormone-sensitive early breast cancer|"Women older than 18 years of age who have suffered from hormonally dependent breast cancer stages 0-III (from in situ to locally advanced breast cancer) according to the American Joint Committee on Cancer (AJCC) classification and have been undergoing adjuvant endocrine therapy for more than 3 months."
89259753|NCT06191952|Other|Subjective Cognitive Decline Questionnaire (SCD-Q)/no other procedure|Participants will undergo procedure as usual and fill out the questionnaire SCD-Q
89259754|NCT06191952|Other|SCD-Q + digital cognitive testing using Cognigram|Participants will undergo procedure as usual with their GP, additionally they will fill out the SCD-Q and undergo cognitive testing (Cognigram)
88804974|NCT01356277|No Intervention|Attention control|Control group study visits were conducted at the same intervals as intervention visits and consisted of the Coach engaging in active listening and providing non-specific support only. Adherence was NOT discussed with control participants.
89259755|NCT06191952|Other|SCD-Q + Cognigram + blood-based biomarkers|Participants will undergo procedure as usual with their GP, additionally they will fill out the SCD-Q and undergo cognitive testing (Cognigram). The blood-based biomarkers will be determined.
89259756|NCT06191510||Experimental Group|The aim of this study is to assess the effectiveness of usage of xenogeneic bone intentionally left exposed to the oral environment after immediate implant placement in preserving keratinized mucosa and the alveolar ridge height and width preservation, without compromising the healing process.
89259757|NCT06191510||Control group|The aim of this study is to evaluate whether the use of collagen matrix has benefits when compared to xenogeneic bone intentionally left exposed to the oral environment after immediate implant placement.
89259758|NCT06189313|Experimental|Mechanical Thrombectomy via Cleaner Pro|Participants will receive catheter-directed therapy via mechanical aspiration thrombectomy for the treatment of pulmonary embolism (PE) using the Cleaner Pro Thrombectomy System.
89259759|NCT06186427|Experimental|68Ga-DOTA-GPFAPI-04 PET/CT|Imaging was performed 60 minutes after injection of 5mci 68Ga-DOTA-GPFAPI-04 tracer
89259760|NCT06186284|Other|patient|Rehabilitation patients using a technical walking aid will be followed up for development of carpal tunnel syndrome
89259761|NCT06184659|Experimental|Meropenem|Participants in the experimental intervention arm will receive 1 g of IV meropenem three times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).
89259762|NCT06184659|Active Comparator|Piperacillin/Tazobactam|Participants in the control arm will receive 4/0.5 g of intravenous piperacillin/tazobactam four times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).
89259763|NCT06175611||Site 1. Laboratorio Central Health Diagnostics Quirónsalud|COVID-19/Flu A/Flu B/RSV Test Kit
89259764|NCT06175611||SIte 2. Hospital General Universitario Dr. Balmis de Alicante|COVID-19/Flu A/Flu B/RSV Test Kit
89259765|NCT06175611||Site 3. Hospital Universitario de Getafe|COVID-19/Flu A/Flu B/RSV Test Kit
89259766|NCT06175052|Experimental|Personalized Nutrition|This group will receive the nutrition intervention
89259767|NCT06166927||Cuffed Endotracheal tube.|Patients will be intubated using a high-volume low-pressure cuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
89259768|NCT06166927||Uncuffed Endotracheal tube.|Patients will be intubated using an uncuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
89259769|NCT06163118|Experimental|Patient aged 75 or over hospitalized in the Geriatric Short-Stay Unit|"Two caregivers from the Geriatric Short-Stay Unit will successively administer the Deglut'G tool to each patient, blind to each other, and blind to the SLP and ENT doctor examination. All patients will have a SLP examination and an ENT doctor examination aimed at detecting swallowing disorders."
89259770|NCT06162559|Experimental|Tucatinib + trastuzumab + pertuzumab|All patients receive neoadjuvant treatment consisting of trastuzumab, pertuzumab and tucatinib. Patients with hormone receptor positive disease receive concurrent endocrine therapy with an aromatase-inhibitor. Premenopausal women are concurrently treated with a LHRH-agonist. In case of functional tumor volume decrease of at least 65% (responders) after the first three cycles, patients continue treatment for six more cycles of the chemotherapy-free regimen. If tumor response is <65% (non-responders), patients will switch to receive six cycles paclitaxel, carboplatin, trastuzumab and pertuzumab. This is considered non-investigational treatment.
89259771|NCT06154239|Other|Arm A: Self-swab then DDT|Participants will take the self-swab sample, followed by the DDT sample at home. They will then have the clinician swab taken in the clinic.
89259772|NCT06154239|Other|Arm B: DDT then self-swab|Participants will take the DDT sample, followed by the self-swab sample at home. They will then have the clinician swab taken in the clinic.
89259773|NCT06151730||Observational|Patients attend hypertension clinic visits, undergo blood pressure monitoring, electrocardiograms, impedance cardiography testing and blood sample collection and have medical records reviewed throughout study.
89259774|NCT06150872|Experimental|Photochemical tissue passivation group|Photochemical tissue passivation of a saphenous vein graft
89259775|NCT06150872|No Intervention|Standard of care group|Standard of care treatment of a saphenous vein graft
89259776|NCT06144255|Experimental|Intranasal insulin and placebo|A total of 3 possible doses will be tested of insulin 0 units (u) (placebo (diluent), 500u, and 1000u. The order that participants will receive these doses will be in a random order.
89259777|NCT06139341|Experimental|BI 765845 treatment group|
89259778|NCT06139341|Placebo Comparator|Placebo group|
89259779|NCT06138197||Robotic-assisted hysterectomy by da Vinci X surgical system, model IS4200 (INTUITIVE)|Women who undergo robotic-assisted hysterectomy by da Vinci X surgical system, model IS4200 (INTUITIVE)
89259780|NCT06138197||Robotic-assisted hysterectomy by VERSIUS ® surgical system (ROBOTIC SURGICAL SYSTEM)|Women who undergo robotic-assisted hysterectomy by VERSIUS ® surgical system (ROBOTIC SURGICAL SYSTEM)
89259781|NCT06138197||Robotic-assisted hysterectomy by HUGO ™ Robotic Assisted Surgery System (RAS) (MEDTRONIC)|Women who undergo robotic-assisted hysterectomy by HUGO ™ Robotic Assisted Surgery System (RAS) (MEDTRONIC)
89259782|NCT06132243|Experimental|Test Group|Subjects in the first sequence of the first cycle were administered with a test formulation (T) of 50 mg of Jaktinib on an empty stomach, while subjects in the second sequence were administered with a reference formulation (R) of 50 mg of Jaktinib on an empty stomach. The reference formulation (R) or test formulation (T) was administered alternately in the next periods.
89259783|NCT06132243|Active Comparator|Reference Group|Subjects in the first sequence of the first cycle were administered with a test formulation (T) of 50 mg of Jaktinib on an empty stomach, while subjects in the second sequence were administered with a reference formulation (R) of 50 mg of Jaktinib on an empty stomach. The reference formulation (R) or test formulation (T) was administered alternately in the next periods.
89259784|NCT06129214|Experimental|Synovium removal group|
89259785|NCT06129214|No Intervention|Synovium sustain group|
89259786|NCT06128369|Experimental|OCS-01|dexamethasone ophthalmic suspension,1.5% [15 mg/mL]
89259787|NCT06128369|Placebo Comparator|Vehicle ophthalmic suspension|Vehicle of OCS-01
89259788|NCT06125704|Other|Morning physical activity first|Randomized to complete 30 minute of moderate intensity walking or stepping in the morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) on days 4 and 5, and 30 minute of moderate intensity walking or stepping in the late afternoon/evening (between 4pm-8pm, within 30-40 minutes of dinner) on days 9 and 10.
89259789|NCT06125704|Other|Afternoon/evening physical activity first|Randomized to complete 30 minute of moderate intensity walking or stepping in the late afternoon/evening (between 4pm-8pm, within 30-40 minutes of dinner) on days 4 and 5, and 30 minute of moderate intensity walking or stepping in the morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) on days 9 and 10.
89259790|NCT06113211|Active Comparator|Narcotic Postoperative Pain Control|Standard of care control group given standard opioid pain control regimen.
89259791|NCT06113211|Experimental|Nonnarcotic Postoperative Pain Control|Experimental group given nonopioid pain control regimen.
89259792|NCT06110715|Sham Comparator|control group|participants with depressive disorder
89259793|NCT06110715|Experimental|Active group|participants with depressive disorder
89259794|NCT06110520|Experimental|Violet + / Lens +|Subjects use a violet light emitting lamp (device intervention - minimally invasive as it's simply a source of light) with CR-39 lenses for their refractive correction. The lamp introduces violet light (Violet +) and the CR-39 lenses allow for the transmission of violet light through the lenses (Lens +).
89259795|NCT06110520|Experimental|Violet + / Lens -|Subjects use a violet light emitting lamp (device intervention - minimally invasive as it's simply a source of light) with polycarbonate lenses for their refractive correction. The lamp introduces violet light (Violet +) while the polycarbonate lenses block the transmission of violet light through the lenses (Lens -).
89259796|NCT06110520|Placebo Comparator|Violet - / Lens +|Subjects use a lamp with NO violet light (Violet -) with CR-39 lenses for their refractive correction. CR-39 lenses allow for the transmission of violet light through the lenses (Lens +).
89259797|NCT06102798|Experimental|Acupuncture|"Hwato brand disposable acupuncture needles and adhesive pads will be used. The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
89259798|NCT06102798|Sham Comparator|Sham acupuncture|Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be selected. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
89259799|NCT06092931|Experimental|Cohort 1: DC-806 + Midazolam (CYP3A4 substrate) + Repaglinide (CYP2C8 substrate)|Participants will receive a single oral dose of the 2-probe substrate cocktail (midazolam and repaglinide) on Day 1. From Day 4 through Day 8, participants will receive twice-daily (BID) oral doses of DC-806 and a single oral dose of the 2-probe substrate cocktail on Day 7. DC-806 BID dosing will continue until the end of Day 8.
89259800|NCT06092931|Experimental|Cohort 2: DC-806 + Digoxin (P-gp substrate) + Rosuvastatin (BCRP/OATP1B1 substrate)|Participants will receive a single oral dose of the 2-probe substrate cocktail (digoxin and rosuvastatin) on Day 1. From Day 5 through Day 9, participants will receive twice daily oral doses of DC-806 and a single oral dose of the 2-probe substrate cocktail on Day 8. DC-806 BID dosing will continue until the end of Day 9.
89259801|NCT06080646||MDD (Major Depressive Disorder) Group|Individuals (ages 18-70 years) who meet DSM-5 criteria for MDD, as assessed using the Structured Clinical Interview for DSM-5 (SCID-5), with Stable psychiatric medication regime for > 1 month will be recruited for participation in EEG and fMRI sessions in this observational study.
89259802|NCT06080646||Unaffected Comparison Group|50 unaffected comparison participants will be matched as a group to the age, race, educational level, handedness, and parental socio-economic status of the MDD patient group will be recruited for participation in EEG and fMRI testing sessions identical to those administered to the patients
89259803|NCT06077994|Active Comparator|Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)|6 or 8 weeks BEPR+ program
89259804|NCT06077994|Experimental|digital Remote Patient Monitoring + BEPR+ (dRPM+)|6 or 8 weeks BEPR+; daily vitals readings (blood pressure, heart rate, oximetry, body temperature, and body weight) and an additional 12 weeks of dRPM reading once the BEPR+ program concludes
89259805|NCT06073743|Active Comparator|Conventional Physiotherapy Group|30 minutes of upper and lower extremity strengthening exercises, upper and lower extremity stretching exercises, functional exercises to increase joint range of motion, tone regulation exercises, 30 minutes of weight transfer exercises to the upper and lower extremities, exercises to improve elective motor control (including isolated joint movements). exercises), balance and coordination exercises (weight transfer to the right-left, front-back on the balance board, cross-arm-leg exercises, exercises for balance and protective reactions), walking training will be applied.
89259806|NCT06073743|Experimental|Video Game Based Exercise Training Group|30 minutes of upper and lower extremity strengthening exercises, upper and lower extremity stretching exercises, functional exercises to increase joint range of motion, tone regulation exercises, 30 minutes of XBox Video Games (10 minutes of Reflex Ridge, 10 minutes of Rallyball, 10 minutes of River rush games) will be applied.
89259807|NCT06072833|Experimental|Patient Financial Education / Navigation|Individuals who screen positive will all move forward to receive the intervention. This intervention includes partnering with community-based organizations to deliver financial education, connection to resources, and counseling tailored to individual patients and spouses for 6-months.
89259808|NCT06055686|Experimental|Electrical Epidural Stimulation Test|Laboring women who request epidural analgesia will be given an electric stimulation at incremental points during catheter pull back with documentation of where stimulation was seen.
89259809|NCT06054230|Experimental|Genomic Sequencing|
89259810|NCT06053164|No Intervention|Arm 1 - Usual Care|8 weeks of usual care with no supplemental oxygen provided
89259811|NCT06053164|Experimental|Arm 2 - Exertional Oxygen|8 weeks of portable oxygen use (from a concentrator) during exertion
88804975|NCT01410565|Active Comparator|Apaziquone|
88804976|NCT01410565|Placebo Comparator|Placebo|Placebo
88804977|NCT01357135||Metformin + Sitagliptin|Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.
89259812|NCT06053164|Experimental|Arm 3 - Exertional Oxygen + Support|8 weeks of portable oxygen use (from a concentrator) during exertion, plus additional phone calls with a respiratory educator and educational material
89259813|NCT06046898|Experimental|SV - R / SV + R / PSV|Spontaneous ventilation without resistance (SV - R) / Spontaneous ventilation with resistance (SV + R) / Pressure support ventilation (PSV)
89259814|NCT06046898|Experimental|SV - R / PSV / SV + R|Spontaneous ventilation without resistance / Pressure support ventilation / Spontaneous ventilation with resistance
89259815|NCT06046898|Experimental|SV + R / PSV / SV - R|Spontaneous ventilation with resistance / Pressure support ventilation / Spontaneous ventilation without resistance
89259816|NCT06046898|Experimental|SV + R / SV - R / PSV|Spontaneous ventilation with resistance / Spontaneous ventilation without resistance / Pressure support ventilation
89259817|NCT06046898|Experimental|PSV / SV + R / SV - R|Pressure support ventilation / Spontaneous ventilation with resistance / Spontaneous ventilation without resistance
89259818|NCT06046898|Experimental|PSV / SV - R / SV + R|Pressure support ventilation / Spontaneous ventilation without resistance / Spontaneous ventilation with resistance
89259819|NCT06046833|Experimental|Patients with type 1 or type 2 diabetes and gastroparesis|"Both groups will have the same intervention.~FreeStyle Libre 3 sensor for Continuous Glucose Monitoring.~Balanced nutritional drink (Boost plus 8 ounces/237 mL) for a standardized meal challenge."
89259820|NCT06046833|Active Comparator|Patients with type 1 or type 2 diabetes without gastroparesis|"Both groups will have the same intervention.~FreeStyle Libre 3 sensor for Continuous Glucose Monitoring.~Balanced nutritional drink (Boost plus 8 ounces/237 mL) for a standardized meal challenge"
89259821|NCT06036004|Active Comparator|Study Product Intervention: intranasal OXT|Intranasal OXT spray of 40 IU per ml (Syntocinon®).
89259822|NCT06036004|Placebo Comparator|Control Intervention: placebo nasal spray|The placebo nasal spray will be identical in volume, labelling, container system, and other features.
89259823|NCT06034470|Experimental|Treatment (PVEK, FLAG-Ida)|See Detailed Description.
89259824|NCT06030583||Study Group|The research group comprises children aged 8 to 11 diagnosed with Attention Deficit Hyperactivity Disorder.
89259825|NCT06030583||Control Group|The control group consists of children aged 8 to 11 who do not have a diagnosis of ADHD, matched in terms of age and gender with the research group.
89259826|NCT06030336|Experimental|Intervention|The Home Health Report will provide quantitative information about health-relevant pollutants (fine particulate matter, carbon dioxide, nitrogen dioxide, and volatile organic compounds), their levels compared to health-based guidelines, their potential sources, as well as no- and low-cost actions occupants could take to improve indoor air quality. The Home Health Report will be designed to maximize utility to residents. Each Home Health Report will be provided after the corresponding Home Health Box deployment. The second Home Health Box deployment will occur after the household receiving their first Home Health Report. The third and final Home Health Box deployment will occur within one month of the household receiving their second Home Health Report.
89259827|NCT06030336|No Intervention|Control|Households in the control group will also receive three Home Health deployments spaced over several months, but will not receive Home Health Reports after the first and second deployments. At the close of their participation in the study, households in the control group will receive a comprehensive Home Health Report, including results from all three Home Health Box deployments and recommended actions occupants could take to improve their home air quality.
89259828|NCT06028932|Experimental|Sacituzumab govitecan, 10 mg/kg|Sacituzumab govitecan, 10 mg/kg for the first 2 weeks of 21-day cycle until progression or adverse effects prohibit further treatment
89259829|NCT06027879|Experimental|Viral Specific T-Lymphocytes|Viral Specific T-Lymphocytes Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
89259830|NCT06027606|Experimental|Salbutamol|Participants are healthy and between the ages of 18-40 years old
89259831|NCT06027606|Experimental|Budesonide-formoterol|Participants are healthy and between the ages of 18-40 years old
89259832|NCT06027606|Sham Comparator|Placebo|Participants are healthy and between the ages of 18-40 years old
89259833|NCT06008717|Experimental|active subthalamic nucleus deep brain stimulation plus optimal drug therapy|active subthalamic nucleus deep brain stimulation; plus optimal drug therapy
89259834|NCT06008717|Active Comparator|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
89259835|NCT06006013|Experimental|Treatment (cabozantinib, Atezolizumab)|Patients receive cabozantinib orally (PO) once daily (QD) on days 1-21 of each cycle and Atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) at screening and then every 12 weeks on study and undergo collection of blood samples at screening, on study, and at end of treatment. Patients without archival tissue also undergo biopsy at screening.
89259836|NCT06000631|Active Comparator|2-hour session of ROC-Stand training for a total of 48 hours (ROC-Stand(2-hr))|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention based on ecological and dynamic systems theories. Each week the participant will wear a light-weight, head-mounted eye-tracker for recording the first 10-minute of driving and natural play sessions in a 2-hour training session. The 2-hour training session is composed of a 70-minute driving session and a 50-minute natural play session. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving in certain public spaces, upper limb use in functional tasks for exploration in driving sessions, and applying various motor skills for mobility and socialization in natural play sessions. The program will be discussed by the family and the treating therapist.
89290397|NCT05760430|Experimental|Experimental Group|After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
89259837|NCT06000631|Active Comparator|1-hour session of ROC-Stand training for a total of 48 hours (ROC-Stand(1-hr))|The same therapist for the ROC-Stand(2-hr) group will be responsible for the program. The training frequency and guidelines are the same as the ROC-Stand(2-hr) group, except for the training intensity of 1-hour per session and intervention duration for 24 weeks. Each 1-hour session will include a 35-minute car play and a 25-minute natural play. The participants will also wear the head-mounted eye tracker in one training session for recording 20 minutes (the first 10-minute of driving and the first 10-minute of natural play) every week.
89259838|NCT06000631|Active Comparator|1-hour session of conventional therapy for a total of 48 hours (Control(1-hr))|Another licensed, independent therapist will provide the training program to the Control(1-hr) group for 1 hours/per session, 2 sessions/per week for a total of 24-week intervention. The conventional therapy provided in the Control(1-hr) group is based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve certain mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the same public space as the ROC training groups and interact with the therapist and caregivers depending on his/her motor abilities. The participants will also wear the head-mounted eye-tracker for the first 20 minutes in one training session every week.
89259839|NCT05999734|No Intervention|Patients undergoing pediatric thoracotomy will receive general anesthesia alone.|the patients will receive general anesthesia alone. Anesthesia will be induced by inhalation of sevoflurane at 8% concentration which will decreased gradually down to 2% concentration carried by 100% oxygen, with loss of consciousness; a peripheral intra venous cannula with suitable size will be inserted, then the neuromuscular blockade will be facilitated by cisatracurium 0.15 mg/ kg to allow tracheal intubation with appropriate sized endotracheal tube. Fentanyl 1μg/ kg will be given and anesthesia will be maintained with air and O2 (50:50) and along with 2% end tidal concentration of sevoflurane to control the depth of anesthesia. At the end of surgery residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes.
89259840|NCT05999734|Active Comparator|general anesthesia and ultrasound guided MTP block|midpoint between the transverse process and the pleura 0.5mL/kg 0.25% bupivacaine will be injected.
89259841|NCT05999045||choir member|a person who sings in a choir
88804978|NCT01357135||Metformin + Sulfonylurea|Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.
88804979|NCT01357135||Sitagliptin +/- Other Antihyperglycemic Medication|Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.
89259842|NCT05997433|Experimental|7 days|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
89259843|NCT05997433|Active Comparator|14 days|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid
89259844|NCT05997407|Experimental|Organic Conceptions intervention group|Will complete Organic Conceptions intervention.
89259845|NCT05997407|No Intervention|Control group|Will not complete Organic Conceptions intervention.
89259846|NCT05987930|Experimental|bone lid technique|ten patients with mandibular benign lesions which were treated with bone lid technique to enucleate the lesion using piezo-electric device to allow removal of buccal bone cortex with preservation of it to have access to lesion then reposition of bone lid in its place
89259847|NCT05987930|Experimental|standard technique|ten patients with mandibular benign lesions in which the buccal cortex was removed by gridding using surgical rotary bur to allow enucleation of lesion
89259848|NCT05977725||Healthy Volunteers|Lack of upper limb arterial disease.
89259849|NCT05977725||Patients with Chronic Upper Limb Ischemia|Known diagnosis of chronic upper limb ischemia.
89259850|NCT05974046|Experimental|Treatment|[14C]IDV184001AN
89259851|NCT05973422|Experimental|SIGI Insulin Management System Observed and At-Home Use|Current insulin pump users with type 1 diabetes, age 18+, will use the SIGI insulin management system for 1 day observed in the hospital setting, then for 2 more weeks of outpatient use.
89259852|NCT05972135|Experimental|Teclistamab and Tocilizumab|Participants will receive the recommended dosage of Teclistamab according to the TECVAYLI™ USPI (step-up dosing followed by weekly treatment dosing).
89259853|NCT05966753||Patients with Diabetic macular edema cohort|
89259854|NCT05966051||Children attending primary school|In this study will be included children 6-11 years and their families, whose parents will provide written consent to participate,
89259855|NCT05950984||Critically Ill Adults and Children|Adults and children from 1-day old admitted to a critical care unit.
89259856|NCT05946031|Experimental|In-lab procedures|Exclusive cigarette smokers will be recruited and will experience all study procedures in the laboratory.
89259857|NCT05946031|Experimental|Remote procedures|Exclusive cigarette smokers will be recruited and will experience all study procedures remotely.
89259858|NCT05940857||OCS Liver Transplant Recipients|All liver transplant recipients who are transplanted with an OCS-perfused donor liver are eligible for the Registry. Up to 10,000 subjects will be enrolled.
89259859|NCT05939167|Placebo Comparator|placebo control|use saline
89259860|NCT05939167|Experimental|mesenchymal stem cells standard treatment|transplant mesenchymal stem cells for 3 times
89259861|NCT05939167|Experimental|mesenchymal stem cells enhanced treatment|transplant mesenchymal stem cells for 6 times
89259862|NCT05938452|Experimental|Active|Active Comparator
89259863|NCT05938452|Placebo Comparator|Placebo|Placebo Comparator
89259864|NCT05926024||Cohort A|Women who participated in previous studies namely NCT02167932, NCT02328313, and NCT03761706, will be re-contacted and consented to study activities.
88804980|NCT02324335|Placebo Comparator|Placebo Comparator Oral Rinse|Water for Injection
88804981|NCT02324335|Active Comparator|Active Comparator Oral Rinse|Brilacidin 3 mg/mL in Water for Injection
88804982|NCT01411501|Experimental|Acupuncture at ST25 and BL25|the points formula of back-shu point combination with front-mu point.
88804983|NCT01411501|Experimental|Acupuncture at LI11 and ST37|the points formula of He-points
89259865|NCT05926024||Cohort B|Women with breast cancer, who did not receive chemotherapy, will be consented to be included in the study, and their electronic medical data will be used.
89259866|NCT05923242|Experimental|Computerized Intervention Authoring Software (CIAS)|Participants will be provided with a link to begin the study following consent, and the link will direct the participants to a baseline survey. At the end of the survey, participants will be automatically redirected to Computerized Intervention Authoring Software (CIAS). Participants will be encouraged to complete 2 sessions in CIAS, approximately 1 week apart. After completing the second session, CIAS will automatically redirect the participants to a post-test survey. Approximately 30 days after completing the second session, participants will be invited to complete a 30 day follow-up survey.
89259867|NCT05918484||Type 1 diabetes patients|All type 1 diabetes patients using intermittently scanned continuous glucose monitoring (isCGM) in Castilla-La Mancha (Spain).
89259868|NCT05910606|Experimental|Exercise Intervention|Digitally delivered strength, balance and postural control exercises
89259869|NCT05909917|Active Comparator|In-Person|Participants will undergo a previously validated, half-day first responder training course, taught live in-person by local instructors in each study location. Participant knowledge acquisition will be measured via a 23-question pre/post-training assessment, administered in person. Participant skill performance will be measured via direct observation grading of a standardized patient encounter, performed in person.
89259870|NCT05909917|Experimental|Virtual|In a controlled computer laboratory setting, participants will undergo an experimental first responder training course consisting of a half-day of pre-recorded video, lecture notes, and illustrations. Participant knowledge acquisition will be measured via a 23-question pre/post-training assessment, administered in person. Participant skill performance will be measured via direct observation grading of a standardized patient encounter, performed in person.
89259871|NCT05903313||Software diagnosis|Software diagnosis with gold standard of 3 cardiologists' interpretation.
89259872|NCT05903287||Software diagnosis|Software diagnosis with gold standard of 3 specialist physicians' interpretation.
89259873|NCT05890118|Active Comparator|SC Group|In up to 15 volunteers, 0.5mg of Stelara will be administered subcutaneously and serial blood samples will be collected for PK analysis.
89259874|NCT05890118|Experimental|RT-111 Group 1|In up to 20 volunteers, a RaniPill capsule containing 0.5mg of ustekinumab will be administered and serial blood samples will be collected for PK analysis.
89259875|NCT05890118|Experimental|RT-111 Group 2|In up to 20 volunteers, a RaniPill capsule containing 0.75mg of ustekinumab will be administered and serial blood samples will be collected for PK analysis.
89259876|NCT05888779|Experimental|Beverage One (Milk)|Participants will consume milk prior to completing a novel cognitive assessment on paper.
89259877|NCT05888779|Experimental|Beverage Two (Juice)|Participants will consume a fruit drink prior to completing a novel cognitive assessment on paper.
89259878|NCT05882214|Placebo Comparator|maltodextrin group|4 capsule with 1000mg ''maltodextrin''
89259879|NCT05882214|Experimental|β-nicotinamide mononucleotide group|4 capsule with 1000mg ''β-nicotinamide mononucleotide''
89259880|NCT05876871|Other|Diagnostic Intervention|
89259881|NCT05875584||advanced adenomas (AA) group|Prospective enrollment of subjects with advanced adenomas
89259882|NCT05875584||CRC group|Retrospective enrollment of subjects with confirmed colorectal cancer
89259883|NCT05870254|Experimental|ExeRVIEM Protocol|They will carry out the ExeRVIEM program for 8 weeks (2 times a week). Intervention based on exercise therapies with RVI software.
89259884|NCT05870254|Active Comparator|Usual Protocol|They will carry out the usual protocol of Association
89259885|NCT05869825|Active Comparator|The high-flow nasal cannula (HFNC)|The high flow nasal cannula (HFNC) is a unique mode of respiratory support that delivers warmed, humidified oxygen with a wide range of fractions of inspired oxygen (FiO2) and flow rate (liters/min) without an invasive device such as an endotracheal tube (breathing tube).
89259886|NCT05869825|Active Comparator|Non-invasive positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation (NPPV or NIPPV) is a unique mode of respiratory support that delivers pressurized, oxygen-enriched gas to the airway via the nose and/or oropharynx without a more invasive device such as an endotracheal tube (breathing tube).
89259887|NCT05865301||Arm A (Retrospective data)|Participants who have undergone standard of care tisagenlecleucel therapy, Participants will received a questionnaire study using patient reported outcomes.
89259888|NCT05865301||Arm B (Prospective data)|Patients enrolled in ARM B will be asked to participate in the biological sample collection. Participants will received a questionnaire
89259889|NCT05862935|Experimental|Supervised Physical Activity (Phase I: Strength training; Phase II: AMRAP training)|"These patients, in addition to receiving the usual treatment for their pathology, carry out supervised activity consisting of:~Warm-up~Strength circuit; At phase I it will be a standard strength training, while at Phase 2 it will be an AMRAP training)"
89259890|NCT05862935|No Intervention|Control|These patients only receive the usual treatment for their pathology.
89259891|NCT05861128|Experimental|Jaktinib 100mg BID (twice daily)|
89259892|NCT05860634|No Intervention|Catheter office-discontinuation group|The patients randomized to the office-discontinuation group will visit the office for a repeat voiding trial on postoperative day 1. At this visit, the patients will undergo a backfill voiding trial.
89259893|NCT05860634|Experimental|Catheter self-discontinuation group|The patients randomized to the catheter self-discontinuation group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 1.
89259894|NCT05848128|Experimental|5% Tavilermide ophthalmic solution|
89259895|NCT05848128|Placebo Comparator|Vehicle ophthalmic solution|
89259896|NCT05834673|Other|Usual Care Model|"Usual care arm :~The GPs will be educated on the ESC guidelines and Guideline Directed Management therapy (GDMT) Inclisiran is available for this arm"
89290398|NCT05760430|Active Comparator|Control group|After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
89290399|NCT04331158|Experimental|Dry cupping group|The dry cupping will be applied with a force of two suctions generating a negative pressure on the skin during the time of 15 minutes.
89259897|NCT05834673|Other|New Model of Care|"Model of care arm The GPs will be educated on the ESC guidelines and Guideline Directed Management therapy (GDMT) The Participants enrolled via these sites arm will be getting receive monthly SMS messages with regards to regarding cardiovascular health and appointment reminders (low touch engagement nudges) In addition, Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.~Inclisiran is available for this arm."
89259898|NCT05829226|Experimental|Single agent dose escalation|LYT-200 in relapsed/refractory AML or relapsed/refractory high-risk MDS, administered via IV infusion over 60 minutes every week.
89259899|NCT05829226|Experimental|Combination agent dose escalation|LYT-200 in relapsed/refractory AML or relapsed/refractory high-risk MDS, administered via IV infusion over 60 minutes every week, in combination with oral venetoclax Day 1, 100 mg, Day 2, 200mg, Day 3-28, 400 mg and/or azacitidine, 75 mg/m2 subcutaneously given for 7 days per cycle or decitabine 20 mg/m2 IV for 5 days per cycle.
89259900|NCT05821374|Experimental|Deucravacitinib|Participants to receive Deucravacitinib 6 mg tablets orally twice daily for 12 weeks.
89259901|NCT05806021|Experimental|Group A TA 40 mg|intra-articular injection of 40 mg of triamcinolone acetonide, which is the standard dose used
89259902|NCT05806021|Active Comparator|Group B TA 10 mg|intra-articular injection of 10 mg of triamcinolone acetonide
89259903|NCT05806021|Active Comparator|Group C TA 5 mg|intra-articular injection of 5 mg of triamcinolone acetonide
89259904|NCT05795595|Experimental|CTX131|Administered by IV infusion following lymphodepleting chemotherapy.
89259905|NCT05795062||apixaban|Patients treated with apixaban
89259906|NCT05795062||warfarin|patients treated with warfarin
89259907|NCT05791240|No Intervention|Pre-Intervention|The medical team will use standard interpreter practices with this group.
89259908|NCT05791240|Experimental|Interventional|This arm will be given interpreter tablets in order to allow them to call interpreter themselves.
89259909|NCT05774197|Experimental|STAMP+CBT app|"This app will allow the patient to access daily surveys designed to assess pain, stress, mood, and related symptoms.~Based on patient-reported symptoms, this app will disseminate tailored education to manage the symptoms."
89259910|NCT05765487|Active Comparator|Sildenafil Cream, 3.6%|Contains both Sildenafil and L-arginine
89259911|NCT05765487|Placebo Comparator|Placebo Cream|Contains L-arginine, no Sildenafil
89259912|NCT05765487|Other|Vehicle Cream|Contains no L-arginine, no Sildenafil
89259913|NCT05762328|No Intervention|Standard of care|Patients allocated in hospitals randomized to non-interventional arm. Observational analysis of patients treated by clinicians with standard of care.
89259914|NCT05762328|Other|Interventional|Patients allocated in hospitals randomized to interventional arm. Intervention: automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
89259915|NCT05752526|Experimental|DARE-PDM1 1% Diclofenac Vaginal Gel|1% Diclofenac in 2.5 mL Hydrogel
89259916|NCT05752526|Experimental|DARE-PDM1 3% Diclofenac Vaginal Gel|3% Diclofenac in 2.5 mL Hydrogel
89259917|NCT05752526|Placebo Comparator|Placebo|2.5 mL Hydrogel
89259918|NCT05740722|Experimental|Placebo|Placebo vs study drug
89259919|NCT05740722|Experimental|Nicotinamid Riboside|Placebo vs study drug
89259920|NCT05725083|Experimental|Lower thoracic epiduarl|before induction of anesthesia,first the investigators identify the correct targeted thoracic level. All epidural block will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheter will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection. Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15ml/h .for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1 mg bolus , 10 min lockout period . The catheter will be removed under complete aseptic precautions after 48 hrs.
89259921|NCT05725083|Experimental|Erector spinae block|before induction of anasthesia ,highfrequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle.confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.Then the catheter placement 5cm into the space under the erector spinae muscle and suitable test dose will be administered . Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h , for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1mg bolus,10 min lockout period.The catheter will be removed under complete aseptic precautions after 48 hrs.
89259922|NCT05720338|Active Comparator|Standard of care|Intraperitoneal drain will be placed near the pancreatic resection margin, which is the routine standard of care.
89259923|NCT05720338|No Intervention|Omitting Standard of Care|No intraperitoneal drain will be placed in the participants, which omits the routine standard of care.
89259924|NCT05713006|Experimental|Alectinib escalation dose|Alecensa 150 mg Roche
89259925|NCT05709028|Experimental|Oral fosfomycin|"Children who have been diagnosed with an uncomplicated UTI will be administered a single dose of oral fosfomycin trometamol. A second dose will be administered 48 hours later for children with persistent fever or ongoing clinical symptoms attributed to their UTI.~Children who have been diagnosed with a complicated UTI will be administered repeat doses of oral fosfomycin trometamol every 48 hours until the child has received a total 10-day course of antibiotics with presumed or proven efficacy against the urinary pathogen.~Each dose of oral fosfomycin trometamol will be prepared as a 2g dose (of fosfomycin base) for children ≥1 to <12 years of age or a 3g dose (of fosfomycin base) for children ≥12 to <18 years of age."
88804984|NCT01411501|Experimental|Acupuncture at ST25, BL25, LI11 and ST37|the formula of He-point,back-shu point and front-mu point
89259926|NCT05709028|Active Comparator|Standard of Care antibiotics|"Children who have been diagnosed with an uncomplicated UTI will be administered a 3-day course of standard of care antibiotics with known efficacy against the urinary pathogen. At 72 hours after enrolment, if fevers or ongoing clinical symptoms attributed to their UTI persist, an additional 48 hours of antibiotic therapy will be administered.~Children who have been diagnosed with a complicated UTI will be administered a total 10-day course of standard of care antibiotics with known efficacy against the urinary pathogen.~Standard of care antibiotics will be selected by the treating clinician based on institutional prescribing practices, local antibiograms and medication availability."
89259927|NCT05697952|Experimental|E1K 1,200 ㎍/joint|Injected 1,200 ㎍/joint/3 mL on target lesion
89259928|NCT05697952|Experimental|E1K 2,400 ㎍/joint|Injected 2,400 ㎍/joint/3 mL on target lesion
89259929|NCT05697952|Placebo Comparator|Placebo|Injected 3ml of saline on target lesion
89259930|NCT05693363|Experimental|18F-FDG AURA10 Specimen Imager|"Intravenous injection of radiotracer (18F-FDG) (study-specific)~Thoracic surgery (standard-of-care; not study-specific)~High-resolution specimen imaging using the AURA10 PET-CT specimen imager (study-specific)~Postoperative histopathological analysis of specimen (standard-of-care)"
89259931|NCT05691829|Experimental|Untreated Patients With Stage IV NSCLC|Participants will receive radiation in concert with starting chemotherapy with pembrolizumab for up to 6 cycles (18 weeks), followed by continued treatment with pembrolizumab (standard of care). Patients will be followed for 1 year following the completion of the core study period of 6 cycles.
89259932|NCT05690308|Experimental|Experimental visual perturbation treadmill training|Participants assigned to the experimental intervention will receive 6 weeks, 2x per week of visual perturbation treadmill training using the GRAIL system. This will consist of maximum 30 minutes of walking on the treadmill while translations and rotations of the projected environment are applied.
89259933|NCT05690308|Sham Comparator|Control treadmill training|Participants assigned to the control intervention will receive 6 weeks, 2x per week of treadmill only training. This will consist of maximum 30 minutes of walking on the treadmill without any visual perturbations.
89259934|NCT05689788|Experimental|HILT + stretching exercise|High-intensity laser therapy (HILT) will be applied with the punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used. Laser therapy will be applied with the participant in the prone position.The treatment will be complemented with passive static stretching for the upper trapezius, levator scapulae, and scalene muscles (bilaterally) in three series. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
89259935|NCT05689788|Sham Comparator|Sham HILT + stretching exercise|The group will receive a sham treatment of high-intensity laser therapy (HILT). The treatment will be complemented with passive static stretching for the upper trapezius, levator scapulae, and scalene muscles (bilaterally) in three series. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
89259936|NCT05684523|Experimental|Redormin® 500|fixed combination of valerian and hops dry extract, 500 mg, once daily for 21 days
89259937|NCT05684523|Placebo Comparator|Placebo|matching placebo, once daily for 21 days
89259938|NCT05669001|Experimental|TCD601 (siplizumab)|TCD601 administered in combination with belatacept, mycophenolic Acid (MPA), and corticosteroids
89259939|NCT05669001|Active Comparator|ATG|Antithymocyte globulin (ATG), tacrolimus (TAC), mycophenolic acid (MPA), and corticosteroids
89259940|NCT05658601||Cohort 1|
89259941|NCT05657912||ECG Monitoring -TAVR patients|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
89259942|NCT05657054|Experimental|Strength group|Group 1
89259943|NCT05657054|Active Comparator|Control group|Group 2
89259944|NCT05656534|Placebo Comparator|Control|Individuals will take a placebo pill during the Acute Drug Challenge and daily for 28 days.
89259945|NCT05656534|Experimental|Suvorexant Treatment|Individuals will take 10mg of suvorexant (Merck & Co Inc.) during the Acute Drug Challenge and daily for 28 days.
89259946|NCT05650164||Patients with metastatic renal cell carcinoma|Patients with metastatic renal cell carcinoma
89259947|NCT05642845|Other|Sequence TR|25 subjects assigned to the sequence TR will receive a single 40 mg dose of the test product Atorvastatin (1 x 40 mg film-coated tablet), marked as T in the sequence, in Period 1 and Period 3, and a single 40 mg dose of the reference product Liprimar® (1 x 40 mg film-coated tablet), marked as R in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
88804985|NCT01411501|Active Comparator|medicine|oral use of mosapride citrate
89259948|NCT05642845|Other|Sequence RT|25 subjects assigned to the sequence RT will receive a single 400 mg dose of the reference product Liprimar® (1 x 40 mg tablet), marked as R in the sequence, in Period 1 and Period 3 and a single 40 mg dose of the test product Atorvastatin (1 x 40 mg tablet), marked as T in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89259949|NCT05637489|Experimental|Treatment|Patients receive PING administered by RN
89259950|NCT05637489|No Intervention|Control|Usual care
89259951|NCT05637294|Other|Sequence of three treatment periods in the following order: ABC|Splinting at night while sleeping for 6 weeks (period A), then no treatment for 6 weeks (period B), then splinting at day and night for 6 weeks (period C). Each treatment period will be separated by 3-week washout period.
89259952|NCT05637294|Other|Sequence of three treatment periods in the following order: ACB|Splinting at night while sleeping for 6 weeks (period A), then splinting at day and night for 6 weeks (period C), then no treatment for 6 weeks (period B). Each treatment period will be separated by 3-week washout period.
89290400|NCT04331158|Placebo Comparator|Dry cupping sham group|The dry cupping sham group will receive the same procedures as the dry cup group, with the difference that the negative pressure imposed after application will be released in a few seconds.
89259953|NCT05637294|Other|Sequence of three treatment periods in the following order: BAC|No treatment for 6 weeks (period B), then splinting at night while sleeping for 6 weeks (period A), then splinting at day and night for 6 weeks (period C). Each treatment period will be separated by 3-week washout period.
89259954|NCT05637294|Other|Sequence of three treatment periods in the following order: BCA|No treatment for 6 weeks (period B), then splinting at day and night for 6 weeks (period C), then splinting at night while sleeping for 6 weeks (period A). Each treatment period will be separated by 3-week washout period.
89259955|NCT05637294|Other|Sequence of three treatment periods in the following order: CAB|Splinting at day and night for 6 weeks (period C), then splinting at night while sleeping for 6 weeks (period A), then no treatment for 6 weeks (period B). Each treatment period will be separated by 3-week washout period.
89259956|NCT05637294|Other|Sequence of three interventions/treatments in the following order: CBA|Splinting at day and night for 6 weeks (period C), then no treatment for 6 weeks (period B), then splinting at night while sleeping for 6 weeks (period A). Each treatment period will be separated by 3-week washout period.
89259957|NCT05633264||Cohort 1|Psoriasis (PsO) participants who initiate treatment with Deucravacitinib.
89259958|NCT05630963||MDD subjects|Subjects diagnosed with Major Depression Disorder
89259959|NCT05630963||Remitted MDD subjects|Subjects with a history of major depressive disorder episode in the past
89259960|NCT05630963||Control subjects|Subjects with no history of known neurological and psychiatric illness.
89259961|NCT05608369|Active Comparator|Standard of care chemoradiation|Participant will be treated with standard chemoradiation
89259962|NCT05608369|Experimental|Study drug + Standard of care chemoradiation|Participant will be pre-treated with study drug followed by continuation of standard chemoradiation
89259963|NCT05606679||Patients undergoing ART with oocyte donation|Healthy patients with no history of RIF and RM which have undergone or are undergoing ART with oocyte donation and SET.
89259964|NCT05602571|Experimental|ESWT+Exercise|Home exercise program including stretching and eccentric strengthening exercises twice a day for 3 months + 3 sessions of ESWT once a week for 3 weeks.
89259965|NCT05602571|Active Comparator|PRP+ESWT+Exercise|Home exercise program including stretching and eccentric strengthening exercises twice a day for 3 months + 3 sessions of ESWT once a week for 3 weeks + PRP injection
89259966|NCT05602571|Sham Comparator|Sham PRP+ESWT+Exercise|Home exercise program including stretching and eccentric strengthening exercises twice a day for 3 months + 3 sessions of ESWT once a week for 3 weeks + Sham PRP injection
89259967|NCT05589792|Placebo Comparator|Placebo|Placebo capsule before bedtime for 3 nights before the studies (inclusive)
89259968|NCT05589792|Active Comparator|Acetazolamide|Acetazolamide 250 mg before bedtime 3 nights before the study, Acetazolamide 500 mg before bedtime for 2 nights before the study (inclusive)
89259969|NCT05587647|Experimental|Experimental: YEGEP group/Intervention|Mothers will be informed about the program and invited to work. In the phone call, information will be given about the purpose, duration, requirements and volunteering of the study. The planned training schedule will be applied to these mothers.
89259970|NCT05587647|No Intervention|Control group|Annual care trainings are given to parents at the disabled center where the study will be conducted. There is no similar practice to these mothers on the same dates. place in the control group
89259971|NCT05586594|Other|patients labelled as Type 1 or Type 2 Diabetes|"paediatric or adult patients already diagnosed with either type 1 or type 2 diabetes mellitus, following up with Tawam Hospital Diabetes clinics for at least 1 year, (who have negative autoimmunity, lack of significant ketosis and either family history of diabetes in one parent or BMI<40).~Patient with age > 11; both male or female, Emirati patients only, who attended Diabetes clinic Tawam hospital during the last 1 year AND Diagnosed to have Type 1 or Type 2 Diabetes Mellitus diagnosed before the age of 40 and after the age of 6 months (to exclude neonatal diabetes).~• ."
89259972|NCT05584722||Idiopathic or Heritable Pulmonary Arterial Hypertension|Patients diagnosed with pulmonary arterial hypertension, either idiopathic or heritable, defined according to standard criteria.
89259973|NCT05584722||Unaffected Mutation Carriers|Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo.
89259974|NCT05584722||Healthy Controls|Healthy individuals without cardiopulmonary disease
89259975|NCT05584358|Experimental|Dry Blend|A dry blend of mycoprotein and pea protein.
89259976|NCT05584358|Experimental|Extrudate|An extruded blend of mycoprotein and pea protein
89259977|NCT05578677|Other|A|Single-biopsy advance-and-close
89259978|NCT05578677|Other|B|Single-biopsy turn-and-suction
89259979|NCT05578677|Other|C|Double-biopsy advance-and-close
89259980|NCT05578677|Other|D|Double-biopsy turn-and-suction
89259981|NCT05577676|Experimental|Hydrodissection with Normal Saline|This group will be hydrodissected by 5 ml of normal saline, will take Gabapentin 300 mg twice daily, Neurotropic B vitamin twice daily, wear a static wrist splint in neutral position overnight, perform tendon gliding exercises 10 repetitions three times daily and maintain ADL advices.
89259982|NCT05577676|Active Comparator|Hydrodissection with Combination of Triamcinolone, Lidocaine, Normal Saline|This group will be hydrodissected by 5 ml combination of 1 ml of triamcinolone, 1 ml of lidocaine & 3 ml of normal saline, will take Gabapentin 300 mg twice daily, Neurotropic B vitamin twice daily, wear a static wrist splint in neutral position overnight, perform tendon gliding exercises 10 repetitions three times daily and maintain ADL advices.
89259983|NCT05572398|Experimental|STAC-T|"STAC-T is a brief technology-based bullying bystander intervention using four strategies: Stealing the show, Turning it over, Accompanying others, and Coaching compassion. The online curriculum is delivered to middle-school students."
89259984|NCT05572398|No Intervention|Assessment Only Control|
89259985|NCT05555589|Experimental|0.1% RGN-259 Opthalmic Solution|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
89259986|NCT05555589|Placebo Comparator|Placebo Ophthalmic Solution (Vehicle for RGN-259 Ophthalmic Solution)|It is composed of the same excipients as RGN-259 but does not contain Tβ4
89259987|NCT05549063|Experimental|Mobility and Stability Exercise|The patients were divided into two groups. Exercises were applied to both groups for 4 weeks.
89259988|NCT05549063|Active Comparator|Stretching Exercise|The patients were divided into two groups. Exercises were applied to both groups for 4 weeks.
89259989|NCT05544110|Experimental|Active stimulation group|Participants receive active transcranial magnetic stimulation.
89259990|NCT05544110|Sham Comparator|Sham stimulation group|Participants receive sham transcranial magnetic stimulation.
89259991|NCT05538208|Active Comparator|MMFBSA|MMF dosed as per body-surface area
89259992|NCT05538208|Experimental|MMFPK|MMF dosed as per pharmacokinetically-guided precision-dosing
89259993|NCT05531578|Experimental|TAVI TRANSFEMORAL|
89259994|NCT05528796|Experimental|Pregnancies where the fetus has been diagnosed with NIHF|"The unit of analysis will be the proband, i.e. pregnancy/fetus affected with non-immune hydrops fetalis (NIHF).~Pregnant individuals receiving care at one of the participating sites whose fetus has been diagnosed with NIHF of unknown etiology will be eligible for recruitment and enrollment in this study. Biological fathers of the fetus with NIHF will also be enrolled when available in order to determine inheritance of fetal genetic variants when identified."
88804986|NCT03008473|Experimental|video laryngoscope and chest CT iminge|First,the operator calculate the distance between the carina and the glottis by CT image and make a marker on the Uniblocker. Then the operator inserted the Uniblocker into the trachea and advanced toward the left main-stem bronchus via the video laryngoscope untill see marker just at the glottis then stopped the insertion .Second, a single lumen tube with appropriate size was intubated via video laryngoscope into the appropriate depth.Third,the Fiberoptic bronchoscopy(FOB) was inserted into single lumen tube to assess the position of the Uniblocker and the injuries of bronchi and carina
88804987|NCT03008473|Experimental|Conventional intubation of Uniblocker|First, a conventional single lumen tube (SLT) was inserted into trachea at optimal depth via video laryngoscope. Second, a Uniblocker was inserted through SLT and directed to the left main-stem bronchus. Third, an FOB was inserted into the SLT to adjust the Uniblocker to optimal position and assessed the injuries of bronchi and carina.
88804988|NCT01309867|Experimental|Investigational Toric Lens|Bausch + Lomb investigational toric contact lenses
89259995|NCT05518214|Experimental|Beetroot|Participants will receive nitrate-rich (70 ml, containing 6.4 mmol of nitrate) beetroot juice, by Beet It, James White. Participants will take 1 beetroot juice drink everyday for 12 weeks.
89259996|NCT05518214|Placebo Comparator|Placebo|Participants will receive a placebo beetroot juice with the nitrate removed, by Beet It, James White. Participants will take 1 placebo juice drink everyday for 12 weeks.
89259997|NCT05512741||Group Ileus|"Patients that experience POI after colorectal surgery. POI is defined by the presence of 2 of the 5 criteria of Vather from the first postoperative day.~The first 10 consecutive patients experiencing POI will be included in the study."
89259998|NCT05512741||No POI group|Patients that do not experience POI. The 10 patients having the fastest recovery of gastro-intestinal functions after surgery during the period of inclusion will be included in the study
88804989|NCT01309867|Active Comparator|PureVision Toric Lens|Currently marketed Bausch + Lomb PureVision toric contact lenses
88804990|NCT04351633||osteoporosis patient|
89259999|NCT05509062|Active Comparator|Light Tactile Pressure|light tactile pressure with 5-10 mmHg without skin stretch
89260000|NCT05509062|Active Comparator|Medium Tactile Pressure|medium tactile pressure of 11-20 mmHg and medium skin stretch with therapist in a stationary position
89260001|NCT05509062|Active Comparator|Firm Tactile Pressure|firm tactile pressure (> 21 mmHg) and maximal skin stretch with therapist weight shift
89260002|NCT05508906|Experimental|OP-1250 with Ribociclib|Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation).
89260003|NCT05508906|Experimental|OP-1250 with Alpelisib|Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation)
89260004|NCT05498727||Maternal Newborn and Child Health (MNCH) Clinics|Clients attending for routine service delivery at MNCH clinics.
89260005|NCT05498727||HIV Clinics|Patients attending for HIV clinic services
89260006|NCT05498727||Tuberculosis (TB) Clinics|Patients attending TB clinic services.
89260007|NCT05487625|Experimental|Narratives|High-ventilated cigarette smokers will be exposed to a narrative about the negative consequences of smoking ventilated cigarettes and all of the conditions described in the intervention section.
89260008|NCT05487625|Experimental|Fact sheet|High-ventilated cigarette smokers will be exposed to fact sheet about the negative consequences of smoking ventilated cigarettes and all of the conditions described in the intervention section.
89260009|NCT05487625|Experimental|Control|High-ventilated cigarette smokers will be not be exposed to any messages and will complete all of the conditions described in the intervention section.
89260010|NCT05481021||Diabetes Specialist trainee Registrars/Middle grade working in UK|All doctors in in middle grade or similar rank who are in training as Diabetes Specialist trainee Registrars or non-trainee Middle grade doctors working in Diabetes/Endocrinology department in NHS Wales, NHS Scotland or Health and Social Care northern Ireland (health systems in all of UK)
89260011|NCT05477160|Experimental|STAR-0215 Dose 1|Participants will be randomized to receive STAR-0215 or placebo.
89260012|NCT05477160|Experimental|STAR-0215 Dose 2|Participants will be randomized to receive STAR-0215 or placebo.
89260013|NCT05477160|Experimental|STAR-0215 Dose 3|Participants will be randomized to receive STAR-0215 or placebo.
89260014|NCT05477160|Experimental|STAR-0215 Dose 4|Participants will be randomized to receive STAR-0215 or placebo.
89260015|NCT05477160|Experimental|STAR-0215 Dose 5|Participants will be randomized to receive STAR-0215 or placebo.
89260016|NCT05473689|Experimental|Early-CPAP therapy group|Individuals diagnosed with moderate-to-severe sleep-related breathing disorders (SRBDs) who will start CPAP therapy within the first 6 weeks after SCI.
89260017|NCT05473689|Active Comparator|Delayed-CPAP therapy group|Individuals diagnosed with moderate-to-severe SRBDs who will start on CPAP therapy at the 5th month after SCI.
89260018|NCT05473689|No Intervention|Non-CPAP therapy group|Individuals who are diagnosed with no or mild SRBD.
89260019|NCT05445128|Experimental|Part A: Single Day Dosing/Apheresis|Single dose of MGTA-145 in combination with plerixafor followed by apheresis
89260020|NCT05445128|Experimental|Part B: 2-Day Dosing/Apheresis|MGTA-145 in combination with plerixafor followed by apheresis on two consecutive days
89260021|NCT05438212|Active Comparator|Arm I (surgery, stereotactic radiosurgery)|Patients undergo surgery per standard of care. Within 10-30 days after surgery, patients undergo stereotactic radiosurgery for 1 fraction.
89260022|NCT05438212|Experimental|Arm II (stereotactic radiosurgery, surgery)|Within 7 days before surgery, patients undergo stereotactic radiosurgery for 1 fraction. Patients undergo surgery per standard of care.
89260023|NCT05437757|Experimental|Implantation of PCL Breast scaffold|Insertion of a 3D printed medical-grade polycaprolactone-PCL Breast scaffold with autologous fat graft for unilateral or bilateral breast implant revision and congenital defect correction surgery.
89260024|NCT05437211|Experimental|VR-based Experimental Group|Participants will receive Factor VIII or Factor IX infusion using a VR-based solution. The VR-based solution will be provided in a medical device CE marked and specifically developed by Deepsen, a French company specializing in e-health solutions to reduce pain. It includes both a mobile phone application (for an explanation on infusions) and a 3D mask to be used during infusions.
89260025|NCT05427019|Active Comparator|Distal adductor canal block|Participants receiving continuous distal adductor canal block
89260026|NCT05427019|Active Comparator|Distal adductor canal block and Periarticular block|Participants receiving continuous distal adductor canal block and periarticular block
89260027|NCT05424042|Experimental|In-Person Caloric Restriction Arm|This group will undergo a 9-month behavioral diet intervention targeting a 20% reduction in caloric intake. During the first 6 months, participants will meet in-person one time each month individually and three times/month in a group setting with a dietitian and/or behavioral coach. During the remaining three months of intervention, there will be one group and one individual meeting each month. Participants will keep diet records using the Fitbit app on a tablet and weight using a BodyTrace™ smart scale that transmits data through a study-specific Companion App. Participants will use wrist-worn Fitbit step monitors to track their physical activity and receive feedback via the app, with a goal to promote movement across the day, continuously increasing their daily step count.
89260028|NCT05424042|Experimental|Remote Caloric Restriction Arm|This group will have a 20% reduction in caloric intake and meeting schedule, and physical activity goal similar to the In-Person group. However, the remote arm intervention will be delivered via video conferencing.
89260029|NCT05424042|Experimental|Time-Restricted Eating Arm|This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake. During the first 6 months, participants will meet in-person once per month individually and three times per month in a group setting with a dietitian and/or behavioral coach. During the remaining 3 months of intervention, there will be one group and one individual meeting each month. Participants in TRE will be asked to log into the study-specific Companion App each day to document the beginning and end of their feeding cycles with timing of meals/snacks consumed. As in the CR arms, participants will use wrist-worn Fitbit step monitors to track their physical activity and receive feedback via the app, with a goal to promote movement across the day, increasing daily step count. Continuous glucose monitoring will be used at intervals to document glucose levels over a 7-10-day period.
89260030|NCT05416554|Other|Neuropsychological testing|Participants will take neuropsychological testing in-person or via telehealth video
89260031|NCT05415371|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
89260032|NCT05415371|Experimental|Standard Care + Financial Incentives|Financial Incentives participants will receive standard care plus incentives for completing counseling calls and abstinence.
89260033|NCT05415293|Active Comparator|Expecta 200mg DHA supplement|"Women receive one daily softgel 200mg DHA algae-based DHA supplement sold as Expecta."
89260034|NCT05415293|Active Comparator|Promise 275mg DHA supplement|"Women receive one daily softgel 275mg DHA fish oil-based DHA supplement sold as Promise."
89260035|NCT05415293|No Intervention|Control/ no supplement|Women received care as usual and did not take any DHA supplement.
89260036|NCT05411484|Experimental|Pilot Arm|Self-controlled 10 healthy subjects receiving an ablative fractional CO2 laser procedure followed by topical application of NanoDOX® Hydrogel
89260037|NCT05405413|Experimental|Subjects evaluated by Molecular Tumor Board|Subjects whose cases are evaluated by Molecular Tumor Board
89260038|NCT05382130|Experimental|Test All|MNCH, HIV, and TB clinic attendees are offered SARS-CoV-2 testing regardless of symptoms.
89260039|NCT05382130|No Intervention|Screen and Test|Populations are screened and tested for SARS-CoV-2 according to the MOH testing guidelines model.
89260040|NCT05378113|Experimental|Ondansetron premedication Group|The ondansetron group will receive ondansetron 0.15mg/kg IV push followed immediately by propofol 2mg/kg IV for induction. A 10cc normal saline flush will follow injection of propofol.
89260041|NCT05378113|Active Comparator|Lidocaine premedication Group|The lidocaine group will receive lidocaine 2% 1mg/kg IV push followed immediately by propofol 2mg/kg IV for induction. A 10cc normal saline flush will follow injection of propofol.
89260042|NCT05376358|Active Comparator|Usual Care|Participants in this arm will receive no intervention and access treatment as usual per their mental health services provider. A mobile application (AWARE) which is not interactive and is only for purposes of data collection will be downloaded on the adolescents' smartphone.
89260043|NCT05376358|Experimental|MoodRing|Adolescent participants in this arm will download two mobile applications - a data collection non-interactive app to collect passive sensing data (AWARE) and the MoodRing (MR) mobile application with which they can visualize their data about their mood, sleep, activity, enter their own mood score, and access psychoeducational resources including links to a research-based website, SOVA. Their parents will download a parent MoodRing application which provides them with parenting resources and articles and a weekly report of their adolescents' mood as predicted by passive sensing. Clinical providers will receive access to a web portal where they can view their adolescent patients' data who are enrolled in the study.
89260044|NCT05370144|Experimental|Hypofractionated neoadjuvant concurrent chemoradiotherapy|"Drug: Carboplatin and Taxol (paclitaxel)~Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously for 5 weeks on Days 1,8,15,22 and 29.~Radiation: Hypofractionated radiation"
89260045|NCT05356988|Experimental|Physical Activity Group|Physical activity (PA) group participants will receive behavioral nudge e-mails with links to a web-based platform which will provide: physical activity information, at-home exercise demonstrations/videos for survivors of all fitness levels, articles, blog posts, physical activity/sitting recommendations, a space for goal setting, a platform for physical activity tracking, a discussion board, automatic syncing of their Fitbit to the leaderboard, etc.
89260046|NCT05356988|Active Comparator|Balance and Flexibility Group|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure. They will receive access to the HEALED website at the end of the 12-month intervention period.
89260047|NCT05346393|Experimental|TIPS group|TIPS implant (transjugular intrahepatic portosystemic shunt)
89260048|NCT05346393|Active Comparator|Control group|Standard medication therapy with terlipressin and albumin. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
89260049|NCT05342701|Experimental|CHAMP-ASP|"CHAMP, is a mastery climate motor skills intervention, that provides children the opportunity to establish behaviors that reinforce decision-making while participating in a motor activity tasks. Children will participate in CHAMP for 35 minutes/day 3-4 days per week for 19 weeks.~Each 35-min session consists of three parts:~3-5 min of motor skill introductory activity that includes a group motor activity, the teaching of the lesson that includes a demonstration and understanding of developmentally appropriate learning clues;~25 min of motor skill instruction and practice (i.e., 'active motor engagement'), participants will be encouraged to move through 3-4 motor activity stations that align with the TARGET structure; and~3 -5 min motor skill closure activity that involves a review of the lesson and critical elements."
89260050|NCT05342701|No Intervention|Control - Standard of Practice|The Control (standard of practice) condition will be the school typical ASP and will be implemented according to the existing procedures.
89260051|NCT05338970|Experimental|Patritumab deruxtecan|Participants who will be randomized to receive patritumab deruxtecan (HER3-DXd) 5.6 mg/kg q3W.
89260052|NCT05338970|Active Comparator|Platinum-based chemotherapy|Participants who will be randomized to receive platinum-based chemotherapy for 4 cycles: pemetrexed plus either cisplatin or carboplatin. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy may continue treatment with maintenance pemetrexed with no restriction on the number of cycles.
89260053|NCT05325294|Experimental|MiniMed 780G System Utilizing Insulin Lyumjev®|Subjects with insulin-requiring type 1 diabetes age 7-80 using the MiniMed 780G system with Insulin Lyumjev® for a period of three months.
89260055|NCT05321810||Warfarin cohort (Reference)|Patients with NVAF treated with warfarin
89260056|NCT05321810||Apixaban cohort|Patients with NVAF treated with apixaban
89260057|NCT05317364|Active Comparator|Topical vaginal estrogen group|Estradiol vaginal cream 0.01% 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g estradiol vaginal cream 0.01% will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy
89260058|NCT05317364|Placebo Comparator|Placebo group|Placebo cream, 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g of placebo cream will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy.
89260059|NCT05317078|Experimental|Part 1: AMG 794 Monotherapy Dose Exploration|Participants with claudin 6 (CLDN6)-positive advanced/metastatic non-squamous non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC), or other solid tumor indications will be treated in up to 11 multiple ascending cohorts with additional participants optionally enrolled in dose exploration cohorts with target dose levels that have previously been shown to be safe and tolerable.
89260060|NCT05317078|Experimental|Part 2: AMG 794 Monotherapy Dose Expansion|Participants with CLDN6-positive advanced/metastatic NSCLC, EOC, or other solid tumor indications will be treated with the OBD of AMG 794 identified in Part 1.
89260061|NCT05315531|Experimental|Water Intake|3-week intervention period during which articipants will be asked to increase their daily plain water consumption to at least 2.5 L/d of water for males and 2L/d for females.
89260062|NCT05308407|Other|Aim 1. Focus Groups|"Healthcare providers (n=16-24 participants in 4 focus groups) from MD Anderson Cancer Center (MDACC).~AYAs with primary benign or malignant central nervous system tumors (n=16-24 participants in 4 focus groups) treated at MDACC."
89260063|NCT05308407|Other|Aim 2. Pilot randomized controlled trial:|AYAs with primary benign or malignant central nervous system tumors (n=80 patients approached, with n= 40 participants consented and randomized to the intervention (n=20) or usual care control group (n=20)) treated at MDACC, any gender and race, who are ≤1-year post-surgery for a central nervous system tumor.
89260064|NCT05307328|Experimental|SPI-62|Active drug by mouth each morning for up to 12 weeks
89260065|NCT05307328|Placebo Comparator|Placebo|Placebo by mouth each morning for up to 12 weeks
89260066|NCT05304611|Experimental|Adult Dose-escalation study: Arm 1: 300 mg of L9LS|Participants will receive 300 mg SC of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for arm 2.
89260067|NCT05304611|Experimental|Adult Dose-escalation study: Arm 2: 600 mg of L9LS|Participants will receive 600 mg SC of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for arm 3.
89260068|NCT05304611|Experimental|Adult Dose-escalation study: Arm 3: 20 mg/kg of L9LS|Participants will receive highest dose of 20 mg/kg IV of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for subjects aged 6 -10 years.
89260069|NCT05304611|Experimental|Subject 6-10 years Dose-escalation study: Arm 1: 150 mg of L9LS|Subjects age 6-10 years will receive 150 mg of L9LS SC. Once subjects reach day 7 post-administration without safety concerns, will begin arm 2.
89260070|NCT05304611|Experimental|Subject 6-10 years Dose-escalation study: Arm 2: 300 mg of L9LS|Subjects age 6-10 years will receive 300 mg of L9LS SC. Once subjects reach day 7 post-administration without safety concerns, will begin weight de-escalation.
89260071|NCT05304611|Placebo Comparator|Subject 6-10 years Dose-escalation study: Arm 3: Placebo|Half of subjects age 6-10 will receive placebo of Normal Saline for comparison.
89260072|NCT05304611|Experimental|Efficacy study: Arm 1: 150 mg of L9LS|75 children age 6-10 will receive 150 mg of L9LS.
89260073|NCT05304611|Experimental|Efficacy study: Arm 2: 300 mg of L9LS|75 children age 6-10 will receive 300 mg of L9LS.
89260074|NCT05304611|Placebo Comparator|Efficacy study: Arm 3: Placebo|75 children age 6-10 will receive normal saline placebo.
89260075|NCT05304611|Experimental|Year 2 Extension study: Arm 1a: 150 mg of L9LS|42 children who received 150 mg of L9LS in year 1 will receive 150 mg of L9LS.
88804991|NCT01357525|Other|Stereotactic Body Radiotherapy|
89260076|NCT05304611|Placebo Comparator|Year 2 Extension study: Arm 1b: Placebo|42 children who received 150 mg of L9LS in year 1 will receive normal saline placebo.
89260077|NCT05304611|Experimental|Year 2 Extension study: Arm 2a: 300 mg of L9LS|42 children who received 300 mg of L9LS in year 1 will receive 300 mg of L9LS.
89260078|NCT05304611|Placebo Comparator|Year 2 Extension study: Arm 2b: Placebo|42 children who received 300 mg of L9LS in year 1 will receive normal saline placebo.
89260079|NCT05304611|Experimental|Year 2 Extension study: Arm 3a: 150 mg of L9LS|46 children who received placebo in year 1 will receive 150 mg of L9LS.
89260080|NCT05304611|Placebo Comparator|Year 2 Extension study: Arm 3b: Placebo|46 children who received placebo in year 1 will receive normal saline placebo.
89260081|NCT05283148|Other|SCD Bone Pain Study Cohort|Prospective cohort of 50 adults with sickle cell disease (SCD) undergoing research DXA scan to assess bone mineral density and thoracolumbar morphometry for vertebral fracture analysis
89260082|NCT05277051|Experimental|Participants receiving GSK4381562 monotherapy (Arm A)|
89260083|NCT05277051|Experimental|Participants receiving GSK4381562 plus dostarlimab (Arm B)|
89260084|NCT05277051|Experimental|Participants receiving GSK4381562 plus dostarlimab plus GSK4428859A (Arm C)|
89260085|NCT05277051|Experimental|Participants receiving dostarlimab plus GSK4428859A (Arm D)|
89260086|NCT05275101|No Intervention|Control|Individuals who have not experienced suicidal ideation will not complete a suicide intervention.
89260087|NCT05275101|Experimental|Crisis Response Planning (CRP)|The crisis response planning (CRP) session will last between 30 minutes to 1-hour. It will occur face-to-face with a trained study therapist. The CRP session involves the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The CRP active component involves a collaborative process in which the therapist invites the patient to share the events, symptoms, and contextual factors leading up to and surrounding the participant's suicidal crisis. Next, the patient and therapist identify the patient's personal warning signs for an emotional crisis, self-management coping skills, patient's reasons for living, and sources of social support. These components are written, by the patient, on an index card. The index card serves as a concrete reference for patients in the real-world.
89260088|NCT05275101|Active Comparator|Crisis Risk Counseling|The crisis risk counseling session will last between 30 minutes to 1-hour. It will occur face-to-face with a trained study therapist. It will include the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The therapist will conduct a semi-structured suicide risk assessment interview, after which subjects will complete a self-guided safety plan worksheet. The worksheet takes approximately 10-minutes to complete and will be done independently.
89260089|NCT05250687|Experimental|MR guided high intensity focused ultrasound (MR-HIFU)|MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastases.
89260090|NCT05250687|Active Comparator|External beam radiation therapy (EBRT)|Patients will undergo radiotherapy for painful bone metastases.
89260091|NCT05247450|Experimental|FES-t along with conventional physiotherapy|Combined conventional physiotherapy and functional electrical stimulation therapy (FES-t) along with task-specific training
89260092|NCT05247450|Active Comparator|Conventional physiotherapy alone|Conventional physiotherapy alone (current standard of care)
89260093|NCT05233397|Experimental|Stratum 1 and Stratum 2|"Stratum 1: Patients with progressive or recurrent adamantinomatous craniopharyngiomas following radiation therapy.~Stratum 2: Patients with measurable adamantinomatous craniopharyngioma who have undergone surgery but have not previously received radiation therapy. Progressive disease is allowed but not required"
89260094|NCT05222126|Experimental|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve using 5 cc of 5% dextrose.
89260095|NCT05222126|Active Comparator|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 5 cc normal saline.
89260096|NCT05222126|Experimental|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 10 cc 5% dextrose.
89260097|NCT05222126|Active Comparator|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve from , using 10 cc normal saline.
89260098|NCT05219344|Experimental|One set of muscle flossing|This group will receive one set of muscle flossing around the thigh with low pressure. Pressure will be individualized based on thigh circumferences.
89260099|NCT05219344|Active Comparator|Two sets of muscle flossing|This group will receive two sets of muscle flossing around the thigh with low pressure. Pressure will be individualized based on thigh circumferences.
89260100|NCT05218798|Active Comparator|Continous Treadmill Running Test|One of the four testing conditions the subject will be allocated to is a Continous Treadmill Running Test. Vo2max will be measured by using A K4 b2 a portable gas analyzer (COSMED, Italy). The device provides reliable values for oxygen uptake (VO2), carbon dioxide production (VCO2), and pulmonary ventilation (VE) breath by breath. In addition, blood samples (20 μL) were collected from the earlobe for both tests (before, immediately after, 3 min after, and 5 min after the test) and the samples will be analyzed for blood lactate concentration ([LA-]).
88804992|NCT01310179|Experimental|Ad/PNP and fludarabine monophosphate|Ad/PNP will be injected three times into the tumor over 2 days followed by three daily intravenous infusions of F-araAMP (fludarabine monophosphate). Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
88804993|NCT01412281|Experimental|Group A - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
88804994|NCT01412281|Active Comparator|Group B - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
88804995|NCT01412281|Experimental|Group C - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
88804996|NCT01412281|Active Comparator|Group D - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
88804997|NCT01359007|Experimental|FOLFIRINOX|Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.
88804998|NCT01361113|Other|Single Arm Neoadjuvant Pazopanib|Pazopanib 800 mg PO once daily for 8 weeks
88804999|NCT01414153|Experimental|Monotherapy|4.0 mg iSONEP followed by sham injection; given monthly intravitreously for 4 months
88805000|NCT01414153|Experimental|0.5 mg iSONEP & Lucentis/Avastin/Eylea|0.5 mg iSONEP and 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
89260101|NCT05218798|Active Comparator|Continous 2-mile run test|One of the four testing conditions the subject will be allocated to is a Continous 2-mile run test. Vo2max will be measured by using A K4 b2 a portable gas analyzer (COSMED, Italy). The device provides reliable values for oxygen uptake (VO2), carbon dioxide production (VCO2), and pulmonary ventilation (VE) breath by breath. In addition, blood samples (20 μL) were collected from the earlobe for both tests (before, immediately after, 3 min after, and 5 min after the test) and the samples will be analyzed for blood lactate concentration ([LA-]).
89260102|NCT05218798|Active Comparator|30-15 Intermittent Fitness Test - first trial|"Aerobic capacity will be measured using the field-based 30-15IFT test. This intermittent, incremental test consists of 30-second shuttle runs interspersed with 15-second active recovery periods. Running speed will be set at 8 km/h for the first 30-second run and increased by 0.5 km/h in each 30-second phase thereafter. The speed of the last successfully completed stage will be recorded as the test result, i.e. the maximum running speed (V) during IFT. Vo2max will be estimated by the following equation:~Vo2max IFT (ml/min/kg) = 28.3 - 2.15G - 0.741A - 0.0357BM + 0.058A X VIFT + 1.03VIFT where G stands for subjects gender, A for age and BM for body mass, respectively."
89260103|NCT05218798|Active Comparator|30-15 Intermittent Fitness Test - second trial|The procedures will be the same as previously described
89260104|NCT05217641|Experimental|Part A, Group 1: Low dose BG505 MD39.3 mRNA|18 participants Dose: 100mcg of BG505 MD39.3 mRNA formulated administered at months 0, 2, and 6
88805001|NCT01414153|Experimental|4.0 mg iSONEP & Lucentis/Avastin/Eylea|4.0 mg iSONEP followed by 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
88805002|NCT01414153|Active Comparator|Lucentis or Avastin or Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea followed by a sham injection; given monthly intravitreously for 4 months
88805003|NCT03008629|Experimental|Podofix nail brace|for mild ingrown toenails
88805004|NCT03008629|Experimental|Combiped nail brace|for Severe dystrophic ingrown toenails
88805005|NCT03008629|Experimental|Podofix and then Combiped nail brace|for Ingrown toenails with pyogenic granuloma
88805006|NCT01311895|Experimental|H2O|2 mg IV hydromorphone administered over 2-3 minutes as initial dose
88805007|NCT01311895|Experimental|1+1|"1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the following question: Do you want more pain medication?"
88805008|NCT01362127|Active Comparator|Radiochemotherapy|Arm I: Radiochemotherapy + Surgery
88805009|NCT01362127|Active Comparator|Chemotherapy|Arm II: Chemotherapy + surgery
88805010|NCT01312519|Active Comparator|Manual bone marrow sampling device|Hollow needle with a t-shaped handle manually pushed into the bone for the purpose of bone marrow aspiration and core biopsy collection. Manual Bone Marrow Sampling Device.
88805011|NCT01312519|Active Comparator|OnControl Bone Marrow System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest. OnControl Bone Marrow Biopsy and Aspiration System.
88805012|NCT01312675|Experimental|Group A|S.A.F.E.BT plus Standard of Care therapy
88805013|NCT01312675|No Intervention|Group B|Standard of Care therapy alone
88805014|NCT01362205|Experimental|Dexmedetomidine|Dexmedetomidine titrated to achieve predefined goals on selected components of the MINDS score using the minimum amount of medication possible. Blinded study medication will be started at a rate determined by the MINDS score. The maximum infusion rate is 1.4 μg/kg per hour. Uncontrolled SAWS/D symptoms, will be treated with open label lorazepam according to the MINDS score algorithm. Persistent SAWS/D symptoms despite maximum infusion rate of study medication treatment limiting symptoms while receiving higher infusion rates of study medication, ancillary therapies will be administered according to the MINDS score algorithm, at the discretion of the treating physician.
88805015|NCT01362205|Placebo Comparator|Placebo|Blinded placebo study drug administration in equal volume per hour as active study medication arm.
88805016|NCT01362907|Other|Delefilcon A / etafilcon A|Delefilcon A contact lenses worn first, with etafilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
88805017|NCT01362907|Other|Etafilcon A / delefilcon A|Etafilcon A contact lenses worn first, with delefilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
88805018|NCT00052910|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil (5-FU) IV on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
88805019|NCT00052910|Experimental|Arm II|Patients receive epirubicin IV over 3-15 minutes and cisplatin IV over 1 hour on day 1 and 5-FU IV continuously on days 1-21 during course 1. Beginning 1 week later, patients undergo radiotherapy 5 days a week and 5-FU IV continuously for 5 weeks. Patients rest for 28-35 days before beginning course 2 of chemotherapy. Patients then receive epirubicin, cisplatin, and 5-FU as in course 1. Treatment repeats every 21 days for 2 courses.
88805020|NCT01416025|Experimental|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
88805021|NCT01416025|No Intervention|Standard dosing|Standard doses of voriconazole will be used
89260105|NCT05217641|Experimental|Part A, Group 2: Low dose BG505 MD39.3 gp151 mRNA|18 participants Dose: 100mcg of BG505 MD39.3 gp151 mRNA administered at months 0, 2, and 6
89260106|NCT05217641|Experimental|Part A, Group 3: Low dose BG505 MD39.3 gp151 CD4KO mRNA|18 participants Dose: 100mcg of BG505 MD39.3 gp151 CD4KO mRNA administered at months 0, 2, and 6
89260107|NCT05217641|Experimental|Part B, Group 1: BG505 MD39.3 mRNA|18 participants Dose: 250mcg of BG505 MD39.3 mRNA administered at months 0, 2, and 6
89260108|NCT05217641|Experimental|Part B, Group 2: BG505 MD39.3 gp151 mRNA|18 participants Dose: 250mcg of BG505 MD39.3 gp151 mRNA administered at months 0, 2, and 6
89260109|NCT05217641|Experimental|Part B, Group 3: BG505 MD39.3 gp151 CD4KO mRNA|18 participants Dose: 250mcg of BG505 MD39.3 gp151 CD4KO mRNA administered at months 0, 2, and 6
88805022|NCT01363843|Experimental|treatment|"Induction therapy - Modified FOLFOX6 - Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours - Repeat q14 days x 8 cycles~Concurrent Chemoradiation~50.4 Gy Radiation in 28 fractions (45 Gy IMRT, 5.4 Gy 3D conformal boost)~Surgery"
88805023|NCT01417741|No Intervention|Standard Therapy Only|Patients will not receive acupuncture. Standard anti-emetic therapy will be given.
89260110|NCT05214768|Experimental|CC-93538|
88805024|NCT01417741|Experimental|Acupuncture Plus Standard Therapy|Bilateral P6 acupuncture applied after anesthesia induction and removed at the termination of the surgery. Patients will also receive standard anti-emetic therapy.
89260111|NCT05214768|Placebo Comparator|Placebo|
89260112|NCT05200923|Experimental|Pelvic health Electrically Evoked Recording (PEER) 2 Study|Collect physiological signals
88805025|NCT00112112|Active Comparator|FluMist|The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
88805026|NCT00112112|Placebo Comparator|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
89260113|NCT05194566|Active Comparator|Real tACS|tACS 75Hz intervention combined with language tasks and breathing exercises. The device will operate in tACS research active stimulation mode.
89260114|NCT05194566|Sham Comparator|Sham tACS|tACS sham intervention combined with language tasks and breathing exercises. The device will operate in tACS sham simulation research mode.
89260115|NCT05194098|Experimental|Major Depression Disorder Group: iTBS-EEG|Device: MagVenture MagPro R30 device with a Cool-DB80 A/P coil (Farum, Denmark) Stimulation: intermittent theta stimulation (iTBS): the investigators will stimulate a dorsomedial prefrontal cortex target at the scalp location (0x 60y 60z). Standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes, per session; total session length, including setup is 10-15 min.
89260116|NCT05194098|Sham Comparator|Major Depression Disorder Group: SHAM-EEG|"Device: MagVenture MagPro R30 device with a Cool-DB80 A/P coil (Farum, Denmark) Stimulation: sham stimulation (SHAM): Sham stimulation will entail the same procedures for the active stimulation day, but with the sham side of the DB-80 A/P placed exactly on the same anatomical target in the same position and duration, but without any active stimulation.~*Note, iTBS and SHAM stimulation sessions will occur on separate days scheduled one week apart (counterbalanced, across subjects). The two stimulation visits follow identical procedures (with the sole difference being active vs. sham rTMS stimulation), with each followed directly by post-stimulation EEG assessment with SLOT and MID tasks."
89260117|NCT05194098|No Intervention|Baseline Evaluation (Major Depressive Disorder and Healthy Control Groups)|"HC and MDD participants will have visits for clinical assessment and a baseline EEG session to complete reward processing tasks (SLOT AND MID). The SLOT task is a 288-trial EEG task developed in our laboratory. Design features mimic structural characteristics common to real-word slot machines, including sound effects and visualizations, and the display consists of 3 sequentially populated slot reels. Participants initiate each trial via button press, after which timing of the slot reels is automated, such that reward outcome is independent of task performance.~The MID task is a 130-trial EEG task designed to model anticipatory and consummatory sub-stages of reward processing in the context of participants being rewarded based on their response times to a cued target detection task."
89260118|NCT05188170|Experimental|Niclosamide 250 mg/m2 /day divided BID|
89260119|NCT05188170|Experimental|Niclosamide 500 mg/m2 /day divided BID|
89260120|NCT05188170|Experimental|Niclosamide 800 mg/m2 /day divided BID|
89260121|NCT05188170|Experimental|Niclosamide 1200 mg/m2 /day divided BID|
89260122|NCT05178472|Experimental|Arm I (vertebroplasty)|Patients undergo vertebroplasty and, 2-4 weeks later, undergo SRS over 1-3 fractions depending upon the number of affected vertebral bodies. Patients also receive standard of care immunotherapy IV every 2 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
89260123|NCT05178472|Active Comparator|Arm II (no vertebroplasty)|Patients receive standard of care immunotherapy IV every 2 weeks for up to 6 months and undergo SRS over 1-3 fractions depending upon the number of affected vertebral bodies in the absence of disease progression or unacceptable toxicity.
88805027|NCT02092298|Experimental|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.
88805028|NCT00115076|Experimental|psoriasis|moderate to severe plaque psoriasis
88821594|NCT03338933||Alcohol Group|DSM-V criteria for Alcohol use Disorder. At least 8 heavy drinking episodes in the past month. Abstinent for at least 2 weeks and no more than 4 weeks. Less than 20 lifetime cigarettes or equivalent. No history of addiction to any other substances or gambling.
89260124|NCT05162859||Former Exercise Training|Patients that were randomized to high-intensity-interval training, moderate continuous training (OptimEx-Clin) or moderate continuous training + resistance training (Ex-DHF)
89260125|NCT05162859||Former Control|Patients that were randomized to guideline control (OptimEx-Clin) or usual care (Ex-DHF)
89260126|NCT05155059|Sham Comparator|Control|Sham TMS stimulation using a sham coil
89260127|NCT05155059|Experimental|Treatment|Active TMS stimulation using an active TMS coil
89260128|NCT05139602|Experimental|Main Study: Lutikizumab Dose A|Lutikizumab Dose A every week
89260129|NCT05139602|Experimental|Main Study: Lutikizumab Dose B|Lutikizumab Dose B every other week
89260130|NCT05139602|Experimental|Main Study: Lutikizumab Dose C|Lutikizumab Dose C every other week
89260131|NCT05139602|Placebo Comparator|Main Study: Placebo|Placebo every week
89260132|NCT05139602|Experimental|Sub-study: Group 1|Period 1: Lutikizumab Dose A every week. Period 2: Lutikizumab Dose A every week.
89260133|NCT05139602|Experimental|Sub-study: Group 2|Period 1: Lutikizumab Dose A every week. Period 2: Lutikizumab Dose A every other week.
89260134|NCT05126680|Experimental|Intermittent treadmill walking exercise and moderate intensity functional training|Subjects belonging to this group perform a 12-week supervised exercise therapy consisted of intermittent treadmill walking exercise and moderate intensity functional training.
89260135|NCT05126680|Active Comparator|Intermittent treadmill walking exercise|Subjects belonging to this group perform a 12-week supervised exercise therapy consisted of intermittent treadmill walking exercise.
89260136|NCT05120271|Experimental|GPC3+ solid tumors|One time intravenous administration of BOXR1030 after completion of cyclophosphamide and fludarabine LD chemotherapy
89260137|NCT05097326|Active Comparator|Mifepristone|Participants will be given mifepristone with insertion of the cervical Cook balloon for labor induction
89260138|NCT05097326|Active Comparator|Misoprostol|Participants will be given misoprostol with insertion of the cervical Cook balloon for labor induction
89260139|NCT05096884|Experimental|Study arm - Metoprolol Succinate.|The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
89260140|NCT05093530|Experimental|Neumifil|"Neumifil will be administered intranasally using an Aptar delivery system. Each dose will consist of 0.5ml to each nostril, with adjusted concentrations of solution to enable dose ranging. Participants in Part A will receive a single dose of Neumifil and participants in Part B will receive once daily doses of Neumifil for 7 days according to the randomization.~Ascending single doses for Part A are anticipated to be 0.028mg (group A1), 0.085mg (group A2), 0.28mg (group A3), 0.885mg (group A4) and 2.8mg (group A5). Two further groups of up to 9 subjects may be investigated. The planned dose levels may change following review of the safety and tolerability of previous doses. The maximum dose will not exceed 2.8mg.~The starting dose level (dose and dose regimen) in Part B will be determined following review of the safety and tolerability of at least 3 dose levels in part A and subsequent dose levels will be determined following review of the safety and tolerability of previous doses."
89260141|NCT05093530|Placebo Comparator|Placebo|Placebo will be administered intranasally using an Aptar deliver system. Each dose will consist of 0.5ml to each nostril. Participants in Part A will receive a single dose of placebo according to the randomization and participants in Part B will receive once daily doses of placebo for 7 days according to the randomization schedule.
89260142|NCT05074160||OLP Registry primary analysis population|Adult primary liver transplant recipients who are transplanted with an OCS perfused DBD or DCD donor liver according to the approved indication and matching eligibility criteria
89260143|NCT05072145||Non-tele-ED hospital|Patients receiving care in an ED that does not provide any tele-ED service
89260144|NCT05072145||Tele-ED hospital|Patients receiving care in an ED that uses tele-ED services, but patient care did NOT utilize this service
89260145|NCT05072145||Tele-ED used|Patient care was provided through tele-ED services
89260146|NCT05069831|Active Comparator|Abrocitinib 100mg|This arm will receive 100mg of the study drug
89260147|NCT05069831|Active Comparator|Abrocitinib 200mg|This arm will receive 200mg of the study drug
89260148|NCT05061368|Experimental|Sildenafil|Participants will be administered a 25 mg oral dose of sildenafil.
89260149|NCT05061368|Placebo Comparator|Placebo|Participants will be administered an oral placebo indistinguishable from the sildenafil pill.
89260150|NCT05050253|Experimental|SOS group|Peritoneal lavage with super-oxidized solution (SOS)
89260151|NCT05050253|Active Comparator|Control group|Peritoneal lavage with Ringer's solution
89260152|NCT05038852|Other|Group 1 smartphone applications|app is designed to help you learn relaxation skills
89260153|NCT05038852|Other|Group 2 smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
89260155|NCT05024968|Experimental|Treatment (sintilimab)|The study drug is sintilimab. The first dose of study treatment should start on Day 1 of Cycle 1. For the rest of the treatment cycles, the study treatment can be administered 3 day before or 3 days after the scheduled day of administration. Treatment can be delayed for up to 1 week if the administration day is on a holiday or if the subject is otherwise unavailable.
89260156|NCT05024552|Experimental|Dose Escalation Arm|"Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy. The induction and reinduction dose of Vyxeos is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion.~Dose level 1: Vyxeos + 120 mg Gilertinib~In the event of a dose-limiting toxicity (DLT) at the initial dose level, a dose level minus (-) 1 is permitted Dose Level -1: Vyxeos + 80 mg Gilertinib"
89260157|NCT05024552|Experimental|Dose Expansion Arm|Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy in the dose determined in the dose escalation arm.
89260158|NCT05023460|Active Comparator|Paresthesia-free (burst) ONS|"Implanted lead and impulse generator (IPG), paresthesia-free (burst) active stimulation.~Lead implanted subcutaneously over greater occipital nerves. Implanted IPG capable of providing paresthesia-free stimulation continuously."
89260159|NCT05023460|Placebo Comparator|Placebo|Implanted lead and IPG, deactivated.
89260160|NCT05018598|Experimental|CHF5993 100/6/12.5 μg (main phase and extension phase)|"Main phase: 2 inhalations BID, Daily dose is 400/24/50 μg x 26 weeks~Open-label extension phase: 2 inhalations BID, Daily dose is 400/24/50 μg x 24 weeks"
89260161|NCT05018598|Active Comparator|CHF1535 200/6 μg (main phase) / CHF5993 200/6/12.5 μg (extension phase only)|"Main phase: 2 inhalations BID, Daily dose is 800/24 μg x 26 weeks~Open-label extension phase: 2 inhalations BID, Daily dose is 800/24/50 μg x 24 weeks"
89260162|NCT05016557|Experimental|Mycoprotein|Bolus ingestion of mycoprotein providing 25g protein
89260163|NCT05016557|Experimental|Spirulina|Bolus ingestion of spirulina providing 25g protein
89260164|NCT05016557|Experimental|Chlorella|Bolus ingestion of chlorella providing 25g protein
89260165|NCT05002140|Experimental|XRD-0394 40 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
89260166|NCT05002140|Experimental|XRD-0394 80 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
89260167|NCT05002140|Experimental|XRD-0394 160 mg|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT on Day 2 of the RT regimen
89260168|NCT05002140|Experimental|XRD-0394 (Dose TBD)|Subjects will receive a single dose of XRD-0394 capsules approximately 90 minutes before RT. A single biopsy will be performed in each subject (either after RT alone or after XRD-0394 and RT).
89260169|NCT04996160|Experimental|Cohort 1 -(without Ph+ / Ph like mutation)|Dose expansion phase-10 subjects in Cohort 1, 100 mg/m2/daily palbociclib on Days 1 to 5; 11 to 15; and 21 to 30, in combination with chemotherapy. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17.
89260170|NCT04996160|Experimental|Cohort 2-(Ph+ / Ph like ALL subtypes):|Dose escalation phase- 12 subjects in Cohort 2, Palbociclib dose escalation will begin at 75 mg/m2/day, on Days 1 to 5; 11 to 15; and 21 to 30, and escalate or de escalate. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17. Subjects with Ph+ / Ph-like mutation will receive a tyrosine kinase inhibitor (TKI or KI, either dasatinib or ruxolitinib).3 on 3 dose escalation with 2 dose levels.
89260171|NCT04995484|Experimental|Belzutifan in participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single oral 80 mg dose of belzutifan.
89260172|NCT04995484|Experimental|Belzutifan in participants with normal hepatic function|Participants with normal hepatic function will receive a single oral 80 mg dose of belzutifan.
89260173|NCT04993404|Experimental|Cohort A：Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
89260174|NCT04993404|Experimental|Cohort B：Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
89260175|NCT04993404|Experimental|Cohort C：Normal Hepatic Function|Participants with normal hepatic function matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index) will be administered a single oral dose of Jaktinib Hydrochloride Tablets.
89260176|NCT04993404|Experimental|Cohort D：Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 11, inclusive) will be administered a single dose of Jaktinib Hydrochloride Tablets.
89260177|NCT04985929|Experimental|Healthy, Untrained|Untrained participants will be defined as having a V̇O2peak of 30-45 ml.kg-1.min-1 and will be between 18-40 years of age.
89260178|NCT04985929|Experimental|Healthy, Trained|Trained participants will be defined as having a V̇O2peak above 55 ml.kg-1.min-1 (females) and 60 ml.kg-1.min-1 (males) and will be between 18-40 years of age.
89260179|NCT04982562|Other|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
89260180|NCT04977583|Experimental|Screening|Participants in this arm will be screened for unmet social needs and receive a post card that includes a list of generic VA crisis and homeless hotlines.
89260181|NCT04977583|Experimental|Awareness|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, and receive a Resource Sheet tailored to the unmet needs identified in the unmet need screen. The Resource Sheet will include the names of available resources within the VA and/or local community that can help to address the identified need(s) and contact information and hours of operation.
89260182|NCT04977583|Experimental|Assistance|Participants in this arm will be screened for unmet social needs, receive a post card that includes a list of generic VA crisis and homeless hotlines, receive a tailored Resource Sheet, and be offered assistance from a Social Worker. If accepted, the SW will contact the participant and work with them over a period of 8 weeks to help facilitate their connection to resources than can help to address the unmet need(s) identified in the unmet need screen.
89260183|NCT04976335|Active Comparator|Versawrap|
89260184|NCT04976335|No Intervention|No Versawrap|
89260185|NCT04972981|Experimental|Part 1: Dose Escalation|In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of ADCT-901 as monotherapy. Participants can receive ADCT-901 until disease progression, adverse event (AE), or other discontinuation criteria, whichever occurs first.
89260186|NCT04972981|Experimental|Part 2: Dose Expansion|"In Part 2 (dose expansion), participants will receive ADCT-901 monotherapy at the dose identified as the RP2D/MTD in Part 1 (dose escalation).~Participants will be split into two groups:~Group 1: An indication for which ADCT-901 showed in Part 1 to have preliminary activity.~Group 2: A group of participants with Part 1 indications, except for the one selected in Group 1 of Part 2. No more than 30% of participants with the same indication are allowed in this basket group.~Participants can receive ADCT-901 until disease progression, AE, or other discontinuation criteria, whichever occurs first."
89260187|NCT04969328|Active Comparator|ParTNer-STEPs|Parents and adolescents will receive the ParTNER-STEPs program and standard care.
89260188|NCT04969328|No Intervention|Standard care|The adolescent and their parents will receive standard care
89260189|NCT04968756|Experimental|Treatment with the SPECTRALIS CENTAURUS device|"In Stage 1, two laser pattern will be applied in areas of the retina that require ablative laser photocoagulation.~In Stage 2, a laser pattern will be applied along and on the outside of the arcades. Furthermore, a treatment pattern will be applied to an area temporal to the fovea affected by intermediary age-related macular degeneration (AMD) and confluent soft drusen."
89260190|NCT04966637||Individuals with COPD|"This retrospective annual analysis will use the following validated case definition to identify a cohort of individuals with COPD: an individual aged 35 years and older having at least one visit to a physician with a diagnosis of COPD (by ICD-9(-CM) 491-492, 496) or one hospital separation with a diagnosis of COPD (ICD-10-CA J41-44) between April 1, 2016 and March 31, 2019.~This is a retrospective descriptive study with administrative data and no intervention will be administered to the cohort"
89260191|NCT04960280|Experimental|Computerized Auscultation|Patients presenting to the echocardiogram laboratory for routine clinically indicated echocardiography or to the cardiac catheterization laboratory for routine clinically indicated catheterization procedures will undergo a computerized auscultation using the ©VoqX stethoscope and will have their heart sounds auscultated and recorded.
89260192|NCT04925960|Experimental|Epalrestat|Epalrestat will be administered orally, 3 times per day (TID) spaced out as evenly as possible over 24 hours in a divided dose starting on Day 1 of the Study.
89260193|NCT04925960|Placebo Comparator|Placebo|Placebo will be administered orally, 3 times per day (TID) spaced out as evenly as possible over 24 hours in a divided dose starting on Day 1 of the Study.
89260194|NCT04922723|Experimental|Daratumumab|"Daratumumab, IV, 16 mg/KG -~1 dose prior to surgery or biopsy; Weeks 1 - 8 = 1 dose weekly; Weeks 9 - 24 = 1 dose every other week; Weeks 25 onward (determined by disease progression) = 1 dose every 4 weeks"
89260195|NCT04855357|Experimental|Smoke-free home permanent supportive housing (PSH) resident intervention + Staff Intervention|Study staff will deliver a one hour, one-on-one counseling to PSH residents that includes: (1) a step-by-step guide on how to voluntarily adopt a smoke-free home, (2) information on second hand smoke (SHS) and third-hand smoke, alternative combustible tobacco and nicotine product use, cannabis-tobacco co-use, effects of SHS on kids and pets,(3) a worksheet on calculating personal costs related to tobacco use, and (4) pledges to designate one's home smoke-free. At follow-up assessments, the study team will ask participants whether they had a chance to view the intervention materials in between visits and will offer an opportunity for participants to discuss conflicts that they had experienced around smoke-free home adoption and will provide strategies to address these roadblocks.
89260196|NCT04855357|Other|Wait-List Control (Usual Care) then crossover to Smoke-free home PSH resident intervention|The current standard of care includes no interventions for smoke-free home adoption or referrals to smoking cessation resources. Wait-list group receives Smoke-Free Home (SFH) intervention after intervention group complete 6-month follow-up
89260197|NCT04841967|Experimental|TELL Tool Group|Parents in the TELL Tool group will complete a decision support aid that has four interactive, multimedia and multicomponent modules that will be administered digitally. It will take parents about 60 minutes to complete the TELL Tool.
89260198|NCT04841967|Active Comparator|eBook Attention-Control|Parents in the eBook attention-control group will complete one interactive, multimedia and multicomponent program that contains information about good parenting principles and is administered digitally. It will take parents about 60 minutes to complete the eBook attention control.
89260199|NCT04840199|Experimental|Arm A: Letermovir|"Letermovir 480 mg will be administered by one of the following strategies:~Letermovir 240 mg tablets administered orally as two tablets once daily with or without food.~Letermovir 480 mg tablets administered orally as one tablet once daily with or without food.~Participants will be able to switch administration strategy during treatment duration based on availability of study supply."
89260200|NCT04840199|Other|Arm B: No anti-CMV treatment|
89260201|NCT04829383|Experimental|Study Treatment|Atezolizumab 1,200 mg IV and bevacizumab 15 mg/kg IV every 3 weeks (on day 1 of each 21-day cycle). Treatment will continue until disease progression or development of unacceptable toxicity.
89260202|NCT04821063|Experimental|Therapeutic dose: ITF2357 100 mg|Participants will receive a single dose of ITF2357 100 mg administered as 10 milliliters (mL) of ITF2357 10 milligrams per milliliter (mg/mL) oral suspension and 20 mL of placebo matched to ITF2357 oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
89260203|NCT04821063|Experimental|Supratherapeutic dose: ITF2357 300 mg|Participants will receive a single dose of ITF2357 300 mg administered as 30 mL of ITF2357 10 mg/mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
89260204|NCT04821063|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matched to ITF2357 administered as 30 mL oral suspension under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
89260205|NCT04821063|Active Comparator|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg tablet under fasting conditions on Day 1 of respective period as per the assigned treatment sequence.
89260206|NCT04799470|Experimental|PD with DBS|Patients with Parkinson's Disease who were implanted with Medtronic Percept PC for DBS and consent to participate in the study.
89260207|NCT04779229|Experimental|Parent Activation|This group of JPOs will deliver Parent Activation as a service to the juveniles and families on their caseloads.
89260208|NCT04779229|Active Comparator|Usual Services|This group of JPOs will deliver services as usual to the juveniles and families on their caseloads.
89260209|NCT04762875|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis on one or two consecutive days
89260210|NCT04762121||Patients requiring intravenous catheter insertion|Adults (>18 years old) who require intravenous catheter insertion for their operation/procedure
88821595|NCT03337620|Active Comparator|Bupivacaine|Bupivacaine is a local anesthestic that will be delivered to the SPG by the Tx360 device.
88821596|NCT03337620|Placebo Comparator|saline|Saline is being used as a placebo treatment that will be delivered to the SPG by the Tx360 device.
89260211|NCT04761627|Active Comparator|Continued-use Group (Ustekinumab)|Participants will receive subcutaneous injection of ustekinumab up to Week 52.
89260212|NCT04761627|Experimental|Switching Group (Ustekinumab - ABP 654)|Participants will initially receive injection of ustekinumab up to Week 16. Thereafter, starting from Week 28, participants will switch between ABP 654 and ustekinumab every 12 weeks up to Week 52.
89260213|NCT04754321|Experimental|Arm A (pembrolizumab, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo salvage surgery during week 4. Beginning week 8, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 9. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
89260214|NCT04754321|Experimental|Arm B (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo low dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
89260215|NCT04754321|Experimental|Arm C (pembrolizumab, EBRT, salvage surgery, IORT)|Patients receive pembrolizumab IV on day 1 of week 1, and undergo high dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
89260216|NCT04749823|Experimental|Blended treatment program|The blended treatment program will consist of a combination of specific active exercises of the neck and general aerobic exercises. This contains a program of 12 weeks, including 9 supervised online sessions supplemented with 1 to 3 individual home exercises sessions without supervision per week, with a total of 3 sessions/week.
89260217|NCT04749823|Active Comparator|Specific strength exercise program|This group will receive an exercise program with specific strength exercises of the neck muscles. Within a 12-week period, patients will receive 9 online treatment sessions under supervision and 1 to 3 additional home exercise sessions without supervision, with a total of 3 sessions/week..
89260218|NCT04749823|Active Comparator|General aerobic exercise program|This control group will perform general aerobic exercises. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
89260219|NCT04742452|Active Comparator|Superior Capsular Reconstruction|
89260220|NCT04742452|Placebo Comparator|Partial Rotator Cuff Repair|
89260221|NCT04739800|Active Comparator|Arm I (paclitaxel, doxorubicin, topotecan hydrochloride))|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
89260222|NCT04739800|Experimental|Arm II (durvalumab, cediranib maleate, olaparib)|Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate PO QD Monday through Friday, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
89260223|NCT04739800|Experimental|Arm III (durvalumab, cediranib maleate)|Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
89260224|NCT04739800|Experimental|Arm IV (cediranib maleate, olaparib)|Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
89260225|NCT04735770|Experimental|LTAP|Patients receive laparoscopically inserted TAP block with levobupivacain and local wound anesthesia injections with saline.
89260226|NCT04735770|Active Comparator|Local wound analgesia|Patients receive laparoscopically inserted TAP block with saline and local wound anesthesia injections with levobupivacaine.
89260227|NCT04732663||Persistently Symptomatic Covid-19 (PS-CoV)|PS-CoV will be defined as individuals with a history of molecular testing confirmed COVID-19 infection, recovered from acute infection but with ongoing symptoms (self-reported, pulmonary, cardiac, musculoskeletal or other symptoms) of at least 4 weeks' duration. Recovery from acute infection will be defined according to provincial health guidelines: at least 10 days' (14 in those hospitalized; 21 in those with immunocompromise) from onset of symptoms with at least 24 hours without a fever, without taking anti-pyretic medications and improvement of other symptoms.
89260228|NCT04732663||Recovered Covid-19|Recovered Covid-19 Survivors will be defined as individuals without complaint of a persisting covid-19 symptom. Recovered Covid-19 survivors will be matched to PS-CoV for age, sex, body mass index and time post corona virus infection.
89260229|NCT04732663||Control|Covid Naïve Controls will be defined as individuals who have no known history of covid-19. Control participants will be matched to PS-CoV for age, sex and body mass index.
89260230|NCT04721912|No Intervention|Standard of Care|Subjects in the control group will not receive any Probiotic capsules and will be advised to continue their routine prenatal self-care.
89290401|NCT01222962|Experimental|fed treatment|18 healthy volunteers administered with a single dose of Eurartesim
89290402|NCT01222962|Experimental|Fasted Treatment|18 healthy volunteers treated with a single dose of Eurartesim
89290403|NCT01226082|Experimental|Transcranial Direct Current Stimulation|
89260231|NCT04721912|Experimental|Probiotic Dietary Supplement|Participants in the intervention group will begin taking oral study Probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth. The research staff member will sequentially distribute the pre-labeled bottles of study capsules to the intervention group, one bottle of 30 Florajen Digestion probiotic capsules to women in the intervention group at the time of randomization.
89260232|NCT04709549|Active Comparator|Diabetes Prevention Program|The DPP is a behavioral obesity and diabetes prevention program run by the YMCA, over a 12-month period.
89260233|NCT04709549|Experimental|Diabetes Prevention Program + Job and Legal Services|Participants meet with service connectors to receive an individual assessment of your needs and create an individual service plan for job services and be referred to legal support services if also needed.
89260234|NCT04632069|Experimental|NAC + taVNS|NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.
89260235|NCT04627064|Experimental|Abemaciclib-Arm 1|"Arm 1~Abemaciclib will be taken at a standard recommended starting dose 2X daily during 28 day study cycles and will be taken until radiographic progression, unacceptable toxicity or withdrawal.~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both Arm 1 and Arm 2."
89260236|NCT04627064|Experimental|Abemaciclib and MK-6482-Arm 2|"Arm 2~Arm 2 will start enrolling only after there is experience with Arm 1 to see what abemaciclib effects are when given alone,~Dose escalation will occur following a 3+3 design.~Abemaciclib will be taken 2X daily uring 28 day study cycle~MK-6482 will be taken 1x daily during 28 day study cycle~Imaging assessments will be performed every 8 weeks during the first six months of the study, then every 12 weeks, in both arms."
89260237|NCT04625946|Experimental|Metformin|Standard of care ablation with recommendations for lifestyle modification and metformin.
89260238|NCT04625946|Other|Standard of care|Standard of care ablation with recommendations for lifestyle modification.
89260239|NCT04624217|Experimental|SHR-1701|SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel
89260240|NCT04621786|Experimental|Experimental arm|All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.
89260241|NCT04617769|Placebo Comparator|Psychoeducation alone (PSYED)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors.
89260242|NCT04617769|Active Comparator|Psychoeducation followed by exposure (PSYED+EXP)|The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated.
89260243|NCT04617769|Experimental|Psychoeducation & exposure/Antagonistic Actions (PSYED+EXP+AA)|"The participant will receive both PDF and video materials involving psychoeducational materials on trauma and safety behaviors. The participant will then be instructed to start the trauma video clip exposures. There will be six 3-minute video exposure trials with an inter-trial interval of 2 minutes, during which participants will complete ratings of (a) peak subjective distress during the trauma-videoclip; (b) anticipated subjective distress for the next trial; and (c) level of confidence for coping with their own trauma memory should it become activated. Antagonistic action strategies during exposure to the trauma-videoclips will include (a) adopting an open posture; (b) eating a palatable snack; (c) smiling; and (d) wishing on high levels of emotional distress (e.g., come on distress hit me with your best shot). The participant will engage in all of the four antagonistic actions for the six exposure trials."
89260244|NCT04601740||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
89260245|NCT04561167|Experimental|Cuspal reduction in MOD Cavity in endodontically treated teeth|Cavity design is of prime importance for the restoration of endodontically treated teeth. The cavity design plays an important role in the protection of the remaining tooth structure as well as the restoration. Cuspal reducuction and further coverage by the CAD/CAM generated indirect resin composite restoration has been proved in literature by the retrospective study done by (Chrepa V et al 2014) which studied 189 posterior endodontically treated teeth receiving indirect composite onlays with a median follow up time of 37 months and suggested this type of restoration as a viable option with 100% tooth survival and 96.8% restoration survival.
89260246|NCT04561167|Active Comparator|No cuspal reduction in endodontically treated teeth|In the present study, choosing the comparator to be the cavity design without cuspal reduction and further coverage (inlay) is done as an attempt to reduce the application of inlays in endodontically treated teeth. In accordance to the in-vitro study done by (M. D. Al Amri et al 2016) which tested the fracture resistance of endodontically treated mandibular first molars with conservative access cavity and different restorative techniques, catastrophic failures were highest in the composite group (100%), followed by the inlay and the amalgam groups (91.67%) and this was referred to the adhesive bonding mechanism of the composite restoration and the wedging effect of the inlay and the amalgam restorations (Rivera EM andWalton RE 2015)
89260247|NCT04557501|Active Comparator|Control - SOC Treatment|Participants to receive surgery or radiotherapy (+/- hormone therapy) as planned per SOC.
89260248|NCT04557501|Experimental|Experimental - PSMAiTx|Participants undergo PSMA PET/CT prior to treatment, and treated intensified based on image findings.
89260249|NCT04555837|Experimental|Treatment (alisertib, pembrolizumab)|Patients receive alisertib PO BID on days 1-7 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89260250|NCT04508088||Crohn Disease|"This group will be 46 adolescents, ages 13-20, who have been recently (within 3 months) diagnosed with Crohn Disease.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
89290404|NCT04310566|Experimental|Test/Control|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
89260251|NCT04508088||Control|"Controls will be matched for age, Tanner staging, and BMI percentile.~All participants will have a two study visits approximately one year apart during which the listed diagnostic testing will be performed."
89260252|NCT04500392|Active Comparator|Control group|Oxygen(up to 6L/min) supplied with a regular nasal catheter
89260253|NCT04500392|Experimental|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
89260254|NCT04493203|Experimental|Nivolumab plus Axitinib|"Nivolumab 480mg, IV, every 4 weeks, for up to two years.~Axitinib 5mg, PO, BID, for up to two years."
89260255|NCT04491396|Other|GYYB|This is a single-arm pre-post design.
89260256|NCT04460911||PAL + FUL|Patients who initiated palbociclib-fulvestrant combination therapy as first-line or beyond therapy in the advanced or metastatic setting.
89260257|NCT04452344|Active Comparator|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen 300 mg and a placebo pill.
89260258|NCT04452344|Active Comparator|Non-Opioid|Combination of ibuprofen 400 mg/acetaminophen 500 mg
89260259|NCT04425031|Experimental|Low oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg)
89260260|NCT04425031|Active Comparator|High oxygenation target|Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg)
89260261|NCT04417673||Sickle Cell Disease|Individuals with sickle cell disease
89260262|NCT04408963|Experimental|Group 1: CAP256V2LS (5 mg/kg IV)|CAP256V2LS (5 mg/kg) administered by intravenous (IV) infusion (Day 0)
89260263|NCT04408963|Experimental|Group 2: CAP256V2LS (5 mg/kg SC)|CAP256V2LS (5 mg/kg) administered by subcutaneous (SC) injection (Day 0)
89260264|NCT04375904|Experimental|Radiation|Treatment will be delivered via image-guided (IG)-SABR in 8 fractions of 7.5Gy. OAR constraints must be respected but minimum dose coverage of 75% to 95% of the PTV will be allowed and minimum dose of 75% to 99% of the GTV will be allowed. The minimums are chosen to represent at least an equivalent BED to the RT standard fractionation of 55 Gy in 20 fractions based on actual treatment dose of 7.5Gy in 8 fractions. A total of 60 evaluable patients will be required for the study. The sample size was calculated using continuous monitoring for toxicity, up to one year post RT, using a Pocock-type boundary. Accrual will be halted if excessive numbers of ≥ Grade 3 TxR-AEs are seen. The regime will not be considered to be safe if >25% of evaluable patients experience a ≥ Grade 3 treatment-related adverse event (TxR-AE) by the end of 1-year post-RT. This study will be considered adequately safe if ≤ 25% of evaluable patients experience ≥ Grade 3 TxR-AE by the end of 1 year post-RT.
89260265|NCT04375631|Experimental|Arm I (CLAG-M, TBI, HCT, GVHD prophylaxis)|See detailed description.
89260266|NCT04375631|Experimental|Arm II (FLAG-Ida, TBI, HCT, GVHD prophylaxis)|See detailed description.
89260267|NCT04340193|Experimental|Nivolumab + Ipilimumab + TACE|TACE (Trans-arterial ChemoEmbolization)
89260268|NCT04340193|Experimental|Nivolumab + TACE|
89260269|NCT04340193|Active Comparator|TACE|
89260270|NCT04327154|Experimental|Digital nerve repair|There is no comparator for this study. All patients are in the treatment allocated group for digital nerve repair with the TISSIUM™ Nerve Coaptation Device.
89260271|NCT04324463|Experimental|Colchicine|"Outpatients:~0.6 mg twice daily for 3 days, then 0.6 mg once daily for 25 days (total 28 days).~Inpatients:~1.2 mg followed by 0.6 mg 2 hours later, then 0.6 mg twice daily for 28 days.~(*Depending on availability, 0.6 mg tablets can be substituted by 0.5 mg tablets for a regimen in outpatients of 0.5 mg twice daily for 3 days, then 0.5 mg once daily for 25 days [total 28 days]; and in inpatients of 1.0 mg followed by 0.5 mg 2 hours later, then 0.5 mg twice daily for 28 days)."
89260272|NCT04324463|Experimental|Interferon Beta [This arm is now closed to recruitment]|"Inpatients Only:~0.25 mg by subcutaneous injection on days 1, 3, 5 & 7"
89260273|NCT04324463|Experimental|Aspirin (ASA)|"Outpatients:~75 to 100 mg once daily for 28 days.~Inpatients:~75 to 100 mg once daily for 28 days"
89260274|NCT04324463|Experimental|Rivaroxaban|"Inpatients Only:~2.5 mg twice daily for 28 days."
89260275|NCT04324463|No Intervention|Usual Care (Control)|Outpatients and Inpatients: No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented.
89260276|NCT04297137|Experimental|Mycoprotein|Ingestion of 30 g mycoprotein drink
89260277|NCT04297137|Experimental|Spirulina|Ingestion of 30 g spirulina protein drink
89260278|NCT04297137|Experimental|Chlorella|Ingestion of 30 g chlorella protein drink
89260279|NCT04297137|Experimental|Pea|Ingestion of 30 g pea protein drink
89260280|NCT04297137|Experimental|Lupin|Ingestion of 30 g lupin protein drink
89260281|NCT04297137|Active Comparator|Milk|Ingestion of 30 g milk protein
89260282|NCT04291079|Experimental|Part A1: Dose Escalation|Part A1 will determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of SRK-181 as a single agent and will determine the recommended Phase 2 dose (RP2D) of SRK-181 as a single-agent.
89260283|NCT04291079|Experimental|Part A2: Dose Escalation|Part A2 will determine the MTD or MAD of SRK-181 in combination with anti-PD-(L)1 antibody therapy and will determine the RP2D of SRK-181 in combination with anti-PD-(L)1 antibody therapy for use in Part B.
89260284|NCT04291079|Experimental|Part B: Dose Expansion|In Part B, parallel cohorts of patients with Non-Small Cell Lung Cancer (NSCLC), Urothelial Carcinoma (UC), Cutaneous Melanoma (MEL), Clear Cell Renal Cell Carcinoma (ccRCC), Head and Neck Squamous Cell Carcinoma (HNSCC), or other advanced or metastatic solid tumor type that is not NSCLC, UC, MEL, or ccRCC will be enrolled to confirm the tolerability of the RP2D of SRK-181 (determined in Part A2) and to evaluate the anti-tumor activity of SRK-181 in combination with an anti-PD-(L)1 antibody therapy.
89260285|NCT04291079|Experimental|Long Term Extension Phase (LTEP)|"Patients may continue treatment in a LTEP:~Part A1: Patients may continue treatment with SRK-181 as a single agent at the RP2D in the LTEP following 3 cycles of treatment with SRK-181 as a single agent in Part A1.~Part A2: Patients may continue treatment with SRK-181 at the RP2D in combination with anti-PD-(L)1 antibody therapy in the LTEP following 3 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part A2.~Part B: Patients may continue treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy following 9 cycles of treatment with SRK-181 in combination with anti-PD-(L)1 antibody therapy in Part B"
89260288|NCT04253106|Experimental|Unaffected carriers of constitutional mutations|Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.
89260289|NCT04253106|Active Comparator|All patients with FOGD|without observation of macroscopic lesions paired with cases (age and sex)
89260290|NCT04236908|Experimental|Group 1 (NSAIDS only)|NSAIDs only (naproxen 500mg by mouth twice a day as needed)
89260291|NCT04236908|Experimental|Group 2 (Acupuncture+GV26)|Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
89260292|NCT04236908|Experimental|Group 3 (Battlefield Acupuncture+NSAIDS)|Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed)
89260293|NCT04236908|Experimental|Group 4 (Battlefield Acupuncture+GV26+NSAIDS)|GV26 with manual tonification + Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men) plus NSAIDs (naproxen 500mg by mouth twice a day as needed).
89260294|NCT04199741||Phase I|Up to 12 participants with tumors that are found to be >/= 50% positive for DLL3 by IHC
89260295|NCT04199741||Phase II|Up to 18 participants with tumors that are found to be >/= 50% positive for DLL3 by IHC
89260296|NCT04194437|Experimental|OCS Preserved Livers|This is a single-arm trial of OCS preserved livers used for transplantation.
89260297|NCT04186221|Experimental|Treatment arm|
89260298|NCT04168710|Experimental|erector spinae plane block (ESP block) with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
89260299|NCT04168710|Placebo Comparator|ESP block with saline/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
89260300|NCT04150380|Experimental|Supplement|8 weeks of dietary augmentation with oral LGG 1.0 x 1010 colony forming units (CFU) once daily (delivered in a size 1 capsule)
89260301|NCT04150380|Placebo Comparator|Placebo|8 weeks of dietary augmentation with placebo once daily (delivered in a size 1 capsule)
89260302|NCT04149210|Experimental|fluorometholone|Fluorometholone 0.1% eyedrops, one drop twice daily for four weeks
89260303|NCT04149210|Placebo Comparator|Artificial Tears|one drop two times daily for four weeks
89260304|NCT04106466|Experimental|Deep Brain Stimulation (DBS)|Open label active Deep Brain Stimulation (DBS)
89260305|NCT04092192|Active Comparator|Forceps|Subjects randomized to this cohort will have their IVC filter removed using a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed.
89260306|NCT04092192|Active Comparator|Snare|Subjects randomized to this cohort will have their IVC filter removed using an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.
88805029|NCT05605808|Experimental|Aerobic exercises and diet protocol group|The participant will be managed by aerobic exercise by using a treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes after the second week in addition to the diet protocol specific diet designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins for twelve weeks.
89260307|NCT04090619||Observational (questionnaires)|Participants complete 8 questionnaires about appetite, quality of life, symptoms, history of weight loss, nutritional status, body image, and nutritional support over 30 minutes.
89260308|NCT04086082|Experimental|Markerless Image Guidance Arm|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
89260309|NCT04081779|Active Comparator|Arm I (patient-generated SCP)|Patients receive a self-generated SCP (i.e., generated from baseline questionnaire responses).
89260310|NCT04081779|Experimental|Arm II (patient-generated SCP, educational counseling)|Patients receive a self-generated SCP as in Arm I. Patients also receive a 30-minute telephone-based educational counseling session on survivorship care administered by trained lay health counselors.
89260311|NCT04065009|Placebo Comparator|Placebo|Normal saline administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
89260312|NCT04065009|Experimental|Experimental|Local anesthetic (ropivacaine) administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours
89260313|NCT04064424|Experimental|Prevention Advertisement|Participants will be exposed to prevention videos and images through Facebook Advertising
89260314|NCT04064424|Active Comparator|No Advertisement|No prevention videos and images will be shown through Facebook Advertising
89260315|NCT04049656|Experimental|HFVI intervention group|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
89260316|NCT04049656|No Intervention|Standard of Care Group|Subjects receiving a balanced maintenance anesthetic consisting primarily of a sevoflurane hypnotic (titrated to a BIS range of 40-60) and fentanyl analgesia. Subjects randomized to the control group (Standard Practice) will have analgesia administered as needed according to standard clinical monitoring and practice requirements based on the judgment of the clinician responsible for the case. The HFVI monitor will be applied, but the display will be masked in this control group population.
89260317|NCT04028843|No Intervention|WIC Nutrition|Participants will receive weight management advice and care through the standard Women, Infants, and Children program. They will also receive weekly health information related to pregnancy, birth, and infant health through a closed Facebook group.
89290405|NCT04310566|Experimental|Control/Test|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
89290406|NCT01226160|Experimental|Face-down posturing group|Postoperative face-down positioning for 10 days after surgery.
89260318|NCT04028843|Experimental|Healthy Beginnings|Participants will receive the SmartMoms smartphone application, a wireless connected scale, and a Fitbit. The Healthy Beginnings program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the SmartMoms smartphone application, personalized feedback from counselors, and evidence-based behavioral intervention delivered throughout pregnancy.
89260319|NCT04025710|Other|all patients|
89260320|NCT04020029|Experimental|Mindset Intervention|Mindset Intervention will include watching three brief ~10-25 minute films and respond to a number of short reflection activities after viewing the films.
89260321|NCT04020029|Active Comparator|Treatment As Usual (TAU)|TAU Control Arm will complete the same assessments as those participants in the Mindset Intervention Arm, but will not view the short films or complete the corresponding response activities.
89260322|NCT04017819|Active Comparator|Healthy volunteers (Group 1)|Group 1(n = 5) healthy volunteers. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
89260323|NCT04017819|Experimental|Patients with newly diagnosed lung cancer (Group 2)|Group2 (n = 5) newly diagnosed lung cancer. Each participant in this part of the study will receive a single dose of [18F]-C-SNAT4 and then undergo three times of whole body (WB) PET/CT scans (Scan 1: 60 minutes dynamic scan; Scan 2: WB skull base-thigh at 90 minutes +/- 10 minutes post injection; Scan 3: WB skull base-thigh at 120 minutes +/- 10 minutes post-injection of [18F]-C-SNAT4).
89260324|NCT04017819|Experimental|Patients with lung cancer undergoing non-surgical tx (Group 3)|Group 3 (n = 10) lung cancer after non-surgical therapy. Each participant in this part of the study will receive a total of 2 doses of [18F]-C-SNAT4 (on 2 separate occasions spaced at least 1 week apart, each of which will be followed by undergoing a [18F]-C-SNAT4 PET/CT scan)
89260325|NCT04016818|Experimental|18-F FDG Study using Breast-Dedicated PET Camera|Breast-Dedicated PET Camera will be used with standard PET 18-F FDG tracer dose
89260326|NCT04009213|Experimental|LiquiBand FIX8®|LiquiBand FIX8® is an n-butyl-2-cyanoacrylate adhesive monomer and D&C Violet #2 dye
89260327|NCT04009213|Active Comparator|AbsorbaTack™|AbsorbaTack™ is an absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D&C Violet No. 2
89260328|NCT04002297|Experimental|zanubrutinib plus rituximab|
89260329|NCT04002297|Active Comparator|bendamustine plus rituximab|
89260330|NCT03967054|Experimental|Ivermectin mass drug administration|Ivermectin given monthly from July-October (4 times) as a 3-day course of 300 µg/kg/day to all eligible persons per exclusion/inclusion criteria. Per package insert, dosing of IVM will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
89260331|NCT03967054|Placebo Comparator|Placebo mass administration|Placebo given monthly from July-October (4 times) as a 3-day course to all eligible persons per exclusion/inclusion criteria. Dosing of placebo will be according to height to approximate weight: 90-119 cm = 1 tablet/day for 3 days; 120-140 cm = 2 tablets/day for 3 days; 141-158 cm = 3 tablets/day for 3 days; >158 cm = 4 tablet/day for 3 days.
89260332|NCT03962894|Experimental|Early Prehospital Systemic Corticosteroids|Children with asthma attacks who receive systemic corticosteroids in the prehospital environment by emergency medical services
89260333|NCT03962894|No Intervention|Usual Care|Children with asthma attacks treated by emergency medical services who receive usual care en route to emergency departments, where in the ED they then receive systemic corticosteroids
89260334|NCT03962855|Active Comparator|Ifetroban|Ifetroban 250 mg oral capsule administered once daily for a minimum of 4 weeks.
89260335|NCT03962855|Placebo Comparator|Placebo|Matching placebo administered once daily for a minimum of 4 weeks.
89260336|NCT03949283|Active Comparator|Physician Choice Treatment|"Participants will be treated with control chemotherapy treatment (standard-of-care chemotherapy chosen by the physician from the provided list).~Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
89260337|NCT03949283|Experimental|ChemoID-guided treatment|"Participants will be treated with ChemoID-guided standard-of-care chemotherapy drugs from the provided list.~ChemoID-guided treatment will be chosen from the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel.~The treating physician will receive the ChemoID assay results from the ChemoID lab."
89260338|NCT03943173|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. After treatment, patients either undergo surgery then receive standard chemotherapy for up to 4 cycles or receive standard chemotherapy within 14 days for up to 4 cycles then undergo surgery in the absence of disease progression or unacceptable toxicity at the discretion of the treating physician.
89260339|NCT03933904|Experimental|Sirolimus|Oral sirolimus: For adults, loading dose of 5 mg/m^2, rounded to the nearest mg, on day 1. For adults, starting on day 2, oral sirolimus daily at 2.5 mg/m^2/day (rounded to the nearest mg), target trough level 10-15 ng/mL by HPLC, for 12 months. For children, 2 mg/m^2/day, target trough level 5-15 ng/mL by HPLC.
89260340|NCT03932864|Placebo Comparator|Single Ascending Dose of MGTA-145 or placebo|MGTA-145 or placebo dose escalation as single agent, single dose
89260341|NCT03932864|Placebo Comparator|Single Dose MGTA-145 or placebo plus plerixafor|MGTA-145 or placebo in combination with plerixafor, single dose
89260342|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor for 2 sequential d|MGTA-145 in combination with plerixafor on two consecutive days; single dose per day
88805030|NCT05605808|Active Comparator|Diet protocol group|The participant will be managed by a specific diet protocol designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins for twelve weeks.
89260343|NCT03932864|Experimental|Single dose MGTA-145 plus plerixafor followed by apheresis|MGTA-145 in combination with plerixafor followed by apheresis
89260344|NCT03911778||Sacrospinofixation|Patients with apical symptomatic prolapse ≥ II in the POP-Q classification and for whom sacrospinofixation with posterior isthmic BSC Mesh is planned
89260345|NCT03903289|Experimental|Automated red cell exchange|Automated red cell exchange
89260346|NCT03903289|Active Comparator|Manual red cell exchange|Manual red cell exchange
89260347|NCT03903289|Sham Comparator|Simple red cell transfusion|Simple red cell transfusion
89260348|NCT03866798|Experimental|Panzyga|Panzyga
89260349|NCT03860961|Active Comparator|Standard Survivorship Care Plan (SCP)|Practices review a SCP with patients and send it to the PCP during the last week of RT.
89260350|NCT03860961|Experimental|Enhanced Survivorship Care Plan (SCP)|Practices review a treatment plan with patient and send it to the PCP at the beginning of RT. Practices also review a SCP with patients and send it to the PCP during the last week of RT.
89260351|NCT03820947|Experimental|VenaSeal™ Closure System|CEAP 2-5 subjects will be randomized to VenaSeal™ Closure System vs. ETA or Surgical Stripping
89260352|NCT03820947|Active Comparator|Endothermal Ablation (ETA)|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or ETA
89260353|NCT03820947|Active Comparator|Surgical Stripping|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or surgical stripping (outside of the United States only)
89260354|NCT03820947|Other|VenaSeal™ Closure System VLU Study|CEAP 6 active leg ulcer subjects will not be randomized to a comparator, all subjects will be treated with VenaSeal™ Closure System
89260355|NCT03809078|Experimental|68Ga RM2 first followed by 68Ga PSMA11|Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
89260356|NCT03809078|Experimental|68Ga PSMA11 first followed by 68Ga RM2|Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2
89260357|NCT03806257|No Intervention|Control|Subjects in the control arm will receive standard of care, which consists of mobilization to a bedside chair at least once, and ambulate one-half ICU circumference on postoperative day one. On postoperative days two through five, the subject will be mobilized to the bedside chair at least once, and ambulated at least once with target of one full ICU circumference. These subjects will receive gait training and safe ambulation education, and wear a FitBit Charge 2 watch for five days after surgery.
89260358|NCT03806257|Experimental|Enhanced Physical Therapy Protocol|Subjects in the experimental arm will recieve a FitBit Charge 2 watch, and will be mobilized to the bedside chair on postoperative day zero. On postoperative day two subjects will be mobilized to the bedside chair twice, ambulate one-half of the ICU circumference, and receive gait and safe ambulation training. On postoperative days two through five, subjects will mobilize to the bedside chair three times, and will be encouraged to ambulate three times, each time with a target of one full ICU circumference.
89260359|NCT03793218|Experimental|Latera Device|The LATERA (Spirox Inc., Menlo Park, CA) device, an absorbable nasal implant comprised of a 70:30 blend of poly(L-lactide) and poly(D-lactide), is designed to provide support to the upper and lower lateral cartilages, thereby correcting nasal wall collapse. The implant was first used in the US and cleared by the FDA in 2016. It is designed as a ribbed cylindrical structure with a forked distal end. The implant is delivered endonasally, with a 16-gauge catheter, lateral to the upper and lower lateral cartilages and over the ascending process of the maxilla. The forked end rests on the ascending process of the maxilla and the flexible implant provides support the nasal sidewall soft tissue and cartilage. This non-toxic, biocompatible co-polymer has an extensive use in a variety of medical devices including suture materials and implants. In vivo studies demonstrate the copolymer to reliably decompose over an 18-24 month period.
89260360|NCT03793218|Active Comparator|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
89260361|NCT03780062|Experimental|S100B protein dosing|
89260362|NCT03776071|Active Comparator|RT plus TMZ and ENZ; ENZ alone; TMZ and ENZ|Radiotherapy (RT) plus temozolomide (TMZ) and enzastaurin (ENZ) (Concurrent Phase) followed by enzastaurin alone (Single-Agent Phase), then temozolomide and enzastaurin (Adjuvant Phase)
89260363|NCT03776071|Placebo Comparator|RT plus TMZ and placebo; placebo; TMZ and placebo|Radiotherapy (RT) plus temozolomide (TMZ) and placebo followed placebo then by temozolomide and placebo
89260364|NCT03737214|Experimental|Lucerastat|Dose will be based on subject's eGFR.
89260365|NCT03731637||New-onset diabetes|Subjects with biochemically-defined new-onset diabetes
89260366|NCT03716869|No Intervention|Targeted Screening Arm (Current Process)|Students randomized to the targeted screening arm will complete their routine school-based health screenings. Students will be followed through the academic year for referrals to the Student Assistance Program (SAP). SAP currently exists in all Pennsylvania (PA) schools and functions like a triage service. If a student exhibits behavior concerning for MDD (raised by any contact, e.g. teachers, nurse, parent, peer, or even self-referral), SAP will triage the student and based on the initial assessment provide recommendations for school or community-based services.
89260367|NCT03716869|Experimental|Universal Screening Arm (Intervention)|"Students randomized to the universal screening arm will complete the Patient Health Questionnaire (PHQ-9) during the academic year. This screening tool includes nine close-ended questions with a scoring system ranging from 0 to 27. Scores >10 are considered a positive screen. Students with a positive PHQ-9 result will then proceed to SAP triage as per the current process for those referred via the targeted screening arm."
89260368|NCT03702517|Experimental|lateral stair walking exercise|The experimental group received 15 minutes of lateral stair walking exercise
89260369|NCT03702517|Active Comparator|traditional physiotherapy|strengthening exercise, balance training and gait training
88805031|NCT05605808|Active Comparator|Aerobic exercises group|The participant will be managed by aerobic exercise by using a treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes after the second week for twelve weeks as a total treatment time.
88805032|NCT00254072|Active Comparator|Smaller Stapler|3.5 mm Circular Stapler
88805033|NCT00254072|Active Comparator|Larger Stapler|4.8 mm Circular Stapler
88805034|NCT00151814|Experimental|Olmesartan|Children less than 6 years old received 0.3 mg/kg. Children 6 years old or older received 40 mg, if they weighed 35 kg or more; 20 mg if they weighed less than 35 kg.
88805035|NCT00153842|Experimental|Bexarotene|Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).
89260370|NCT03680144|Experimental|Diagnostic (MRI, DSC-MRI)|Participants undergo diagnostic magnetic resonance imaging (MRI) with and without contrast and treatment planning dynamic susceptibility contrast-MRI (DSC-MRI) series before receiving SRS at 4-6 weeks after SRS, and then every 3 months unless clinically indicated sooner.
89260371|NCT03679312|Experimental|COPD Group|COPD to receive either placebo or inhaled nitric oxide (40ppm)
89260372|NCT03679312|Experimental|Control Group|Control group to receive either placebo or inhaled nitric oxide (40ppm)
89260373|NCT03679299||Healthy Control|Healthy controls will be recruited from the general population and will be matched based on age, sex, and BMI. They will be assess at two time points, 48 hours apart. At each testing day, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity.
89260374|NCT03679299||Asthma|Individuals experiencing an asthma exacerbation will be recruited from the University of Alberta Hospital Emergency Department. Once discharged, a blood sample will be taken, and endothelial function will be assessed using brachial artery flow mediated dilation. Arterial stiffness will be assessed using carotid-radial pulse wave velocity. Participants will complete the same assessments at a follow up date 48 hours and 14 days post-discharge, with the addition of a full pulmonary function test, physical activity assessment via a Fitbit, and the completion of two questionnaires: Asthma Control Questionnaire, and Asthma Quality of Life Questionnaire.
89260375|NCT03645122|Experimental|Physiology|Different neural elements will be stimulated and evoked potentials will be recorded via electromyography. Metrics used to quantify evoked potentials will be used to infer changes in physiological functioning of the nervous system.
89260376|NCT03645122|Experimental|Behavior|A visuomotor task will be performed and force signals will be recorded. Metrics used to quantify force signals will be used to infer changes in control processes governing movement.
89260377|NCT03642587||Study Population|People between the ages of 2 and 85 years old with out of hospital cardiac arrest of no obvious cause who are attended to by paramedics who survive or die
89260378|NCT03624478|Experimental|Treatment (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
89260379|NCT03616496|Experimental|ATTR amyloidosis patients|Intervention by this arm: PET/CT with injection of Neuraceq [4 MegaBecquerel /Kilogram (MBq/kg)], blood and urine sampling for protein electrophoresis, bone scintigraphy
89260380|NCT03616496|Experimental|AL amyloidosis patients|Intervention by this arm: PET with injection of Neuraceq (4 MBq/kg), blood and urine sampling for protein electrophoresis, bone scintigraphy
89260381|NCT03616496|Active Comparator|Control subjects with aortic stenosis|"Intervention by this arm: PET with injection of Neuraceq (4 MBq/kg), blood and urine sampling for protein electrophoresis, bone scintigraphy.~Control subjects are patients with aortic stenosis and left ventricular hypertrophy treated by surgery or by Transcatheter Aortic Valve Implantation (TAVI)"
89260382|NCT03593356|Experimental|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
89260383|NCT03593356|Active Comparator|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
89260384|NCT03576742||patients|all who fulfil inclusion criteria and consent to participation; potential biomarkers will be documented
89260385|NCT03501979|Experimental|Tucatinib + Trastuzumab + Capecitabine|Tucatinib will be taken orally at 300 mg twice a day starting with Cycle 1, Day 1. A cycle consists of 21 days. Capecitabine will be taken orally at 1000 mg/m2 twice a day on Days 1-14 starting with cycle 1. Trastuzumab is given intravenously as a loading dose of 8 mg/kg on Cycle 1, Day 1 and then at 6 mg/kg for all subsequent cycles.
89260386|NCT03479138||Neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with long acting beta agonists (LABA) + high doses inhaled corticosteroids (ICS) with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
89260387|NCT03479138||Non neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
89260388|NCT03478553||People with IPF|
89260389|NCT03478553||Family members without IPF|
89260390|NCT03456843|Experimental|Arm I (ADT, docetaxel)|Participants receive antiandrogen therapy with or without docetaxel at the discretion of the treating physician.
89260391|NCT03456843|Experimental|Arm II (ADT, radical prostatectomy, docetaxel)|Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel prior to surgery at the discretion of the treating physician.
89260392|NCT03395184|Experimental|PF-06700841 or placebo|
89260393|NCT03395184|Experimental|PF-06651600 or placebo|
89260394|NCT03377270|Experimental|RST|Respiratory Swallow Training Arm
89260395|NCT03377270|No Intervention|Standard of Care|Standard of Care Arm
89260396|NCT03296826||BRCA1/2 variant carriers|Japanese women who carry BRCA 1/2 variants.
89260397|NCT03286699|Active Comparator|DIET|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
89290407|NCT01226160|Active Comparator|Non-posturing group|avoid a face-up position for 10 days after surgery
88821597|NCT03315962|Experimental|Aim 1: DHO Intervention Arm|A selection of DHO or TB district supervisors that are randomized to the multicomponent SPIRIT intervention.
88821598|NCT03315962|No Intervention|Aim 1: DHO Control Arm|A selection of DHO or TB district supervisors that are randomized to the country standard of care, but not to receive the study intervention.
89290408|NCT01221402|Experimental|Extended-release niacin|
89290409|NCT01221402|Placebo Comparator|Placebo|
88805036|NCT01314001|Placebo Comparator|Placebo (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
88821599|NCT03313778|Experimental|Part A: Dose Escalation and Dose Expansion|Participants will receive mRNA-4157 via an intramuscular (IM) injection on Day 1 of each 21-day cycle for up to 9 cycles.
89260398|NCT03286699|Active Comparator|DIET-PA|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.
89260399|NCT03248310||vascularized lymph node transfer (VLNT)|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
89260400|NCT03248310||non-surgical treatment|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
89260401|NCT03212170|Experimental|FFNP PET/MRI|18F-Fluorofuranylnorprogesterone (FFNP) administration for PET/MRI imaging to assess biopsy-proven primary PR+ breast malignancies.
89260402|NCT03207529|Experimental|Treatment (alpelisib, enzalutamide)|Patients receive alpelisib PO and enzalutamide PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89260403|NCT03179085|Active Comparator|Usual Care / Delayed Intervention|Participants randomized to the control group will receive usual care by their provider for 12 months. They will also attend one group class taught by CHRs in which they will learn basic information about diabetes prevention. DI participants will receive publicly-available literature that reinforces the information given in class, and they will have no other contact with study staff aside from during study data collection visits at baseline and 12 months. After 12 months of usual care, patients will enter into the delayed intervention where they will complete 12 months of Home-Based Kidney Care (HBKC).
89260404|NCT03179085|Experimental|Home-Based Kidney Care Intervention|All subjects randomized to the HBKC arm will be visited by a CHR in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and participant preference will be incorporated into the HBKC intervention arm by allowing participants to prioritize the order in which curriculum topic areas will be emphasized by the CHRs. Topics from currently available NIDDK and IHS kidney education materials will include: (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
89260405|NCT03147287|Active Comparator|Fulvestrant|-Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
89260406|NCT03147287|Experimental|Fulvestrant with Palbociclib|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly"
89260407|NCT03147287|Experimental|Fulvestrant with Palbociclib and Avelumab|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly~Avelumab will be administered intravebously once every 2 weeks"
89260408|NCT03135275|Active Comparator|Staged complete PCI|Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
89260409|NCT03135275|Experimental|Immediate complete PCI|Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
89260410|NCT03104569|Experimental|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ during ERCP when injection of contrast agent
89260411|NCT03104569|No Intervention|Injection of normal contrast agent|Normal temperature nonionic contrast agent can be used in ERCP when injection of contrast agent
89260412|NCT03095248|Experimental|Stratum 1 - NF2 related vestibular schwannomas- NOW CLOSED|Stratum 1 included patients with NF2 with vestibular schwannomas who exhibit hearing loss. Participants received continuous twice daily dosing of selumetinib. Dosing was based on BSA calculated at the beginning of each course. One course is equivalent to 28 days. Therapy continued for up to two years (26 courses) in the absence of disease progression or unacceptable toxicity. Stratum 1 arm was closed in November, 2022.
89260413|NCT03095248|Experimental|Stratum 2: other NF2 related tumors (meningiomas and ependymoma)|Stratum 2 will include patients who have progressive lesions other than VS (including non-vestibular schwannomas, meningiomas, and spinal cord lesions). Participants will receive continuous twice daily dosing of selumentinib. Dosing is based on BSA calculated at the beginning of each course. One course is equivalent to 28 days. Therapy may continue for up to two years (26 courses) in the absence of disease progression or unacceptable toxicity.
89260414|NCT03068442|Experimental|Carotid atherosclerosis group|This group includes all enrolled subjects (those with carotid disease and plans to undergo surgery).
89260415|NCT03049462|Experimental|Cohort 1|Females taking 100 mg of mirabegron
89260416|NCT03049462|Active Comparator|Cohort 2A|Males taking 200 mg mirabegron
89260417|NCT03049462|Placebo Comparator|Cohort 2B|Males taking placebo drug
89260418|NCT03049462|Active Comparator|Cohort 3A|Females taking 100 mg of mirabegron
89260419|NCT03049462|Placebo Comparator|Cohort 3B|Females taking placebo drug
89260420|NCT02990546|Experimental|Intervention|In the intervention arm 10 mg of midodrine will be given orally three times daily starting at the time of stable or decreasing intravenous vasopressor support
89260421|NCT02990546|Other|Control|The control arm will receive standard of care for septic shock with IV vasopressor support as needed to maintain MAP goal > 65 mmHg
89260422|NCT02965963|Experimental|Dopamine|Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max
89260423|NCT02965963|Experimental|Metoclopramide|Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max
89260424|NCT02965963|Experimental|Placebos|Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max
89260425|NCT02865135|Experimental|DPX-E7 + Cyclophosphamide [Phase Ib Cohort]|Participants received: 1) 50 mg twice per day of cyclophosphamide orally 7 days before the vaccination, continuing for 7 days on and then 7 days off, throughout the treatment period; 2) two 0.25 mL priming doses of DPX-E7 3 weeks apart, followed by 0.1 mL booster dose every 8 weeks until clinical progression.
89260426|NCT02865135|Experimental|DPX-E7 + Cyclophosphamide [Phase II Cohort 1]|Participants were enrolled before amendment 10. Participants received: 1) 50 mg twice per day of cyclophosphamide orally 7 days before the vaccination, continuing for 7 days on and then 7 days off, throughout the treatment period; 2) two 0.25 mL priming doses of DPX-E7 3 weeks apart, followed by 0.1 mL booster dose every 8 weeks until clinical progression.
89260427|NCT02865135|Experimental|DPX-E7 [Phase II Cohort 2]|Participants were enrolled after amendment 10. Participants received two 0.50 mL priming doses of DPX-E7 3 weeks apart, followed by 0.2 mL booster dose every 8 weeks until clinical progression.
89260428|NCT02840942|No Intervention|Non-robot|Patients will interact with Child Life as per usual routine, no robot condition
89260429|NCT02840942|Experimental|Coping Robot|Robot will play coping game with children. Robot will speak and child will respond by touching tablet. Child life still present.
89260430|NCT02840942|Experimental|Non-coping Robot|Robot will play distraction only game, in addition to Child Life and routine cares
89260431|NCT02836600|Experimental|LY3039478|LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.
89260432|NCT02811744|Experimental|Amnestic MCI cohort|Patients with Mild Cognitive Impairment (MCI) (up to 14) will be recruited primarily from the Penn Memory Center (PMC). Clinical diagnostic criteria (described in further detail in Study Procedures section) will be used to identify subjects who are meet criteria for amnestic MCI. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
89260433|NCT02811744|Other|Control cohort|Normal control subjects in the same age range (up to 6) will be recruited from a current ongoing study investigating neuroinflammation in late life depression and healthy controls, from the control group in which all subjects receive MRI and lumbar puncture (LP) and from the PMC research cohort. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
89260434|NCT02802384||Cases|People with active Paget's Disease of Bone
89260435|NCT02802384||Controls|Age and sex matched people without history of Paget's Disease of Bone
89260436|NCT02753790|Experimental|Intensity Modulated Radiotherapy (IMRT)|Radiation therapy to a dose of 60 Gray (Gy)/45 Gy to gross disease and 30 Gy to subclinical sites, delivered over 15 fractions
89260437|NCT02740634|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive two Tau PET scans during this study.
89260438|NCT02740634|Experimental|PiB PET Scan, C-11 PiB|All subjects will receive two PiB PET scans during this study.
89260439|NCT02709720|Experimental|1 Experimental group|"2 cycles of metronomic Vinorelbine 50 mg + cisplatin, followed by 2 cycles of Vinorelbine 30 mg + cisplatin concomitant with radiotherapy~Induction chemotherapy:~Cisplatin: 80 mg/m2 day 1 every 21 days, for 2 cycles.~Metronomic oral vinorelbine: 50mg/day, 3 days of each week for 2 cycles.~Concomitant chemotherapy and radiotherapy:~Cisplatin: 80 mg/m2 day 1 every 21 days, for 2 cycles.~Metronomic oral vinorelbine: 30mg/day, 3 days of each week for 2 cycles. 1 cycle equals 21 days~Radiotherapy treatment:~Patients will receive concomitant thoracic radiation therapy, using a technique three-dimensional conformal radiation therapy, using an accelerator linear that operates with energy rays ≥ 6 MV. The total target RTT dose will be 66 Gy in 33 daily fractions of 2 Gy, which will be prescribed in accordance with the document of ICRU reference 50 of ICRU."
89260440|NCT02659956||Individuals without known CNS disease|Family members of patient participants
89260441|NCT02659956||Patient controls|a target population of 50 patient controls will also be enrolled. These individuals will have diseases that share clinical, imaging, or biological features with MS.
89260442|NCT02659956||Patients with multiple sclerosis|Up to 150 adults (age >= 18) with MS, diagnosed by applicable consensus criteria, and by the best judgment of the investigators, at the time of enrollment.
89260443|NCT02635009|Active Comparator|Arm I (PCI using 3DCRT)|Patients undergo PCI using 3DCRT daily for 2 weeks.
89260444|NCT02635009|Experimental|Arm II (PCI with HA using IMRT)|Patients undergo PCI with HA using IMRT daily for 2 weeks.
89260445|NCT02593526|No Intervention|No Diuretic and 37°C dialysate|Standard of care, no diuretic
89260446|NCT02593526|Experimental|No Diuretic and 35.5°C dialysate|Cool dialysate only, no diuretic
89260447|NCT02593526|Experimental|Diuretic and 37°C dialysate|Isothermic dialysate (37°C) and bumetanide (diuretic)
89260448|NCT02593526|Experimental|Diuretic and 35.5°C dialysate|Cool dialysate (35.5°C) and bumetanide (diuretic)
89260449|NCT02580981|Experimental|Genomic Testing|"Newly diagnosed ALL patients will undergo genomic studies listed in Primary Objective 1. Analyses will be performed on a bone marrow (BM) aspirate at initial diagnosis (patients with an absolute blast count of at least 1,000/μL, may submit 2 mL of peripheral blood at diagnosis for each 1 mL of required BM. In patients in whom the aspirate cannot be obtained, a core biopsy will be used).~In addition, flow cytometric analysis and deep sequencing will be used to characterize and monitor the molecular heterogeneity and clonal evolution of disease during front-line therapy. BM, blood, and buccal specimens will be collected on day 29 of induction treatment and possibly at a later time point if relapse occurs."
89290410|NCT04215952|Experimental|SFA Experimental Intervention|A modified version of Semantic Feature Analysis will be administered.
89290411|NCT04215952|Active Comparator|SFA Active Comparator Intervention|A standard version of Semantic Feature Analysis will be administered.
89290412|NCT04214860|Experimental|APR-246|APR-246 4.5 g/day
89260450|NCT02571725|Experimental|Olaparib and Tremelimumab|"Each cycle is 28 days:~Olaparib at 300 mg, orally, twice daily + Tremelimumab at 10 mg/kg, intravenously, every 4 weeks for the first 6 doses, then every 12 weeks until disease progression or unacceptable toxicity.~If 1 of the first 3 patients experiences a regimen-limiting toxicity (RLT), 3 more patients will be treated with 10 mg/kg Tremelimumab in Phase 1. If 2 or more of 6 patients experience RLT, then 6 mg/kg Tremelimumab will be tested~If at 6 mg/kg, 1 or more of 3 patients experience RLT, 3 patients will be treated at 3 mg/kg Tremelimumab~If at 3 mg/kg, 1 or more patients experience RLT, the study will be discontinued for safety purposes~In Phase 2, patients will receive doses of Olaparib and Tremelimumab determined in the Phase 1 portion as described above, based on tolerability."
89260451|NCT02504905|Experimental|PAR-CD|CD and age/sex matched HV control
89260452|NCT02504905|Experimental|PAR-WC|WC and age/sex matched HV control
89260453|NCT02501941|Experimental|Ketamine first|"Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring."
89260454|NCT02501941|Experimental|Other sedation (typically propofol) first|Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
89260455|NCT02470299|Experimental|Ketorolac|Once deemed stable in the first 1-3 post-operative days, patients will be receive age-based ketorolac (30 mg <65, 15mg > 65) daily for three days
88805037|NCT01314001|Active Comparator|Varenicline (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
88805038|NCT01314001|Active Comparator|Transdermal Nicotine (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
89260456|NCT02470299|Placebo Comparator|Placebo|Once deemed stable in the first 1-3 post-operative days, patients will be receive placebo daily for three days
89260457|NCT02444338|Active Comparator|Control Group|optimal standard of care therapy
89260458|NCT02444338|Experimental|Device Group|MitraClip device plus optimal standard of care therapy
89260459|NCT02364557|No Intervention|Standard of Care (SOC)|Standard of care systemic therapy at the discretion of the treating physician.
89260460|NCT02364557|Experimental|Standard of Care + Ablation|Standard of care systemic therapy plus ablation of all metastases by stereotactic body radiotherapy or surgery at the discretion of the treating physician.
89260461|NCT02301182|Active Comparator|ADM X3-MoP Cup|THA: ADM dual-mobility hydroxyapatite coated cups with X3TM HXLPE liners on 28mm BIOLOX® delta femoral heads (Stryker) with femoral stems being 2nd generation Accolade stems of the taper lock type, proximal circumferential coated with a 50µm plasma-spray PureFix HA coating to aid the mechanical engagement in bone coating (Stryker)
89260462|NCT02301182|Active Comparator|CoC Cup|THA: CoC BIOLOX® delta-delta large-head single-mobility cementless fiber-mesh titanium coated acetabular system from Zimmer (Zimmer TrilogyIT cup/CLS spotorno stem) with a grit-blasted osteophilic titanium alloy CLS® Spotorno femoral stems (Zimmer) that has a three-dimensional wedge shape and sharpened ribs in the proximal region
88805039|NCT01314001|Placebo Comparator|Placebo (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
88821600|NCT03313778|Experimental|Part B: Dose Escalation and Dose Expansion|Participants will receive mRNA-4157 via an IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
89260463|NCT02245997|Experimental|patients with high-risk neuroblastoma|Patients undergo external beam radiation therapy using IMRT or proton beam RT twice daily for 5-6 weekdays (10-12 treatments). Patients will be evaluated by physical exams, CT scan or MRI of the primary site, and MIBG at, 6, 12, 18 and 24 months (+/- 6 weeks).
89260464|NCT02225301|Experimental|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
89260465|NCT02179086|Active Comparator|Arm A1 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
89260466|NCT02179086|Experimental|Arm B (photon IMRT)|"Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
89260467|NCT02179086|Active Comparator|Arm A2 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
89260468|NCT02179086|Experimental|Arm C (proton beam radiation therapy)|"Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
89260469|NCT02147418||Group 1: HPV-positive Cancer|Oropharyngeal cancer patients testing positive for human papillomavirus (HPV)
89260470|NCT02147418||Group 2: HPV-positive Cancer|Oropharyngeal cancer patients who test positive for human papillomavirus (HPV)
89260471|NCT02147418||Group 3: Healthy Controls|Patients with benign conditions
89260472|NCT02105545|Experimental|Cancer Treatment Options|Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.
89260473|NCT02089789||CDG|Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol
89260474|NCT02088749|Experimental|small group treatment|lifestyle intervention for obesity delivered to small groups of approximately 12 participants/group
89260475|NCT02088749|Active Comparator|large group treatment|lifestyle intervention for obesity delivered to a large group of approximately 30 participants
89260476|NCT01996865|Experimental|Arm A: Lenalidomide + rituximab followed by lenalidomide|Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but < 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by an optional Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses
89260477|NCT01996865|Active Comparator|Arm B: Lenalidomide + rituximab followed by rituximab|Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but < 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29
89260478|NCT01774487|Experimental|Pentoxifylline|"All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes."
89260479|NCT01763645|Experimental|BCD-021 (CISC BIOCAD)|BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
89260480|NCT01763645|Active Comparator|Avastin (F. Hoffmann-La Roche Ltd)|In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
89260481|NCT01740596|Experimental|C-Pulse® System|C-Pulse® System Counterpulsation
89260482|NCT01740596|No Intervention|Control Arm|Optimal Medical Therapy
89260483|NCT01717131|Active Comparator|Surgery for standard axillary node dissection|Standard axillary dissection
89260484|NCT01717131|Experimental|No axillary lymph node dissection|No surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial)
89260485|NCT01704274|Placebo Comparator|Placebo|Placebo patch
89260486|NCT01704274|Experimental|Low dose GTN 0.0285 mg/hr|Low dose GTN
89260487|NCT01704274|Experimental|High Dose GTN 0.057 mg/hr|High Dose GTN
89260488|NCT01067209||Diabetic/Obese Gastric bypass patients|Subjects with obesity including those with known diabetes or those with a high likelihood of diabetes who will undergo gastric bypass surgery.
89260489|NCT00914719|Active Comparator|Information only|
89260490|NCT00914719|Active Comparator|sexual risk reduction intervention|
89260491|NCT00914719|Experimental|SRRI+ETOH|
89260492|NCT00905645|Experimental|Primary Augmentation|Silimed Gel-Filled Mammary Implant
89260493|NCT00905645|Experimental|Revision-Augmentation|Silimed Gel-Filled Mammary Implant
89260494|NCT00905645|Experimental|Primary Reconstruction|Silimed Gel-Filled Mammary Implant
89260495|NCT00905645|Experimental|Revision-Reconstruction|Silimed Gel-Filled Mammary Implant
89260496|NCT00754260|Experimental|Caffiene reduction group|Caffeine reduction group Intervention is to counseling to reduce caffeine intake
89260497|NCT00754260|No Intervention|No caffeine reduction group|No Caffeine reduction group Intervention is to not counsel regarding caffeine intake
89260498|NCT00684437|Experimental|Factual Gain-Framed|Smoking Risk Message - Factual Gain-Framed (FGF)
89260499|NCT00684437|Experimental|Factual Loss-Framed|Smoking Risk Message - Factual Loss-Framed (FLF)
89260500|NCT00684437|Experimental|Emotional Gain-Framed|Smoking Risk Message - Emotional Gain-Framed (EGF)
89260501|NCT00684437|Experimental|Emotional Loss-Framed|Smoking Risk Message - Emotional Loss-Framed (ELF)
89260508|NCT00342446||Patients with Infertility|Patients of all races with primary or secondary infertility, including women with recurrent miscarriages.
89260509|NCT01095328|Experimental|intervention|Screening for Q-fever during pregnancy
89260510|NCT01095328|No Intervention|control|No screening for Q-fever during pregnancy
89260511|NCT01026779||Cases of rotavirus gastroenteritis|Patients will be eligible as cases if they have been identified by the investigator's ongoing rotavirus surveillance studies as having been hospitalized with laboratory-confirmed rotavirus gastroenteritis between January 1, 2007 and June 31, 2009. To be eligible as a case, the child must meet the following criteria: 1) immunocompetent; 2) born after April 15, 2006 (to select a population that would have been in the age group eligible for at least 1 dose of RV5 (RotaTeq); and 3) > 2 months of age on the day of admission.
89260512|NCT01026779||Control Subjects|Three controls for each case will be identified using KIDSNET, the state child health registry. Controls will be matched to cases by age and county of residence at birth.
89260513|NCT01023425|Experimental|switching group|switching patients with Alzheimer's disease(AD) from galantamine or rivastigmine to donepezil because they were not responding adequately
89260514|NCT01023425|Experimental|naive group|naive patients with AD who initiated therapy with donepezil
89260515|NCT00285584|Active Comparator|Bupropion|Participants in this arm received bupropion.
89260516|NCT00285584|Placebo Comparator|Placebo|Participants in this arm received placebo that looked identical to the active comparator medication.
89260517|NCT01026857|Experimental|PLC Colon release tablet 1 g|40 patients each arm
89260518|NCT01026857|Experimental|PLC colon release tablet 2 g|40 patients each arm
89260519|NCT01026857|Placebo Comparator|Placebo PLC colon release tablet 2 g|40 patients each arm
89260520|NCT01023503||1|Adults, with a new statin prescription or a change in their stain treatment
89260521|NCT03671447|Active Comparator|ICU usual care|control condition
89260522|NCT03671447|Experimental|"Intervention ERIC"|intervention condition
89260523|NCT03853655|No Intervention|Control arm|Patients in this arm will be observed and kept under active follow-up after surgery for the primary.
89260524|NCT03853655|Experimental|Study arm|Intervention in the study arm will be in the form of post-operative adjuvant radiotherapy starting within 6-weeks after primary surgery.
89260525|NCT03807700|Experimental|Experimental denture adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
89260526|NCT03807700|No Intervention|No adhesive|In this arm, participants will not use any denture adhesive.
89260527|NCT01583842|Experimental|124I-MIBG no-carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
89260528|NCT01583842|Experimental|124I-MIBG carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
89260529|NCT01583842|Active Comparator|Imaging Only|Participants with high-risk neuroblastoma will receive imaging only without 124I-MIBG
89260530|NCT01092754|Other|A: Other|
89260531|NCT01092754|Other|B: Other|
89260532|NCT02530606|Experimental|Diagnostic (PAI)|Patients undergo PAI over 15-30 minutes prior to the ovarian excision.
89260533|NCT00291668|Experimental|Certolizumab pegol 200 mg|Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.
89260534|NCT00291668|Experimental|Certolizumab pegol 400 mg|Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.
88821601|NCT03313778|Experimental|Part A2: Dose Expansion|Participants will receive mRNA-4157 via an IM injection on Day 1 of each 21-day cycle and a SoC treatment every 2 weeks (Q2W) on Day 1 of each 21-day cycle starting from Cycle 5 of mRNA-4157 for up to 12 cycles.
89260535|NCT00291668|Placebo Comparator|Placebo|Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.
89260536|NCT01095406|Active Comparator|S1 ventilation|Mechanical ventilation with S1 the thrid hour of ventilation
89260537|NCT01095406|No Intervention|Servo i ventilation|1 hour ventilation in pressure support mode with Servo i
89260538|NCT00458393|Experimental|TDF/FTC|Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).
89260539|NCT00458393|Placebo Comparator|Placebo|Drug. Daily oral placebo
89260540|NCT03955354|Experimental|experimental arm|SHR1210 plus apatinib
89260541|NCT01095484||Rotigotine|Patients who have a documented medical necessity to receive treatment with rotigotine treatment in accordance with standard medical practice.
89260542|NCT01063478|Experimental|RAD001, Chemotherapy, Radiation|RAD001 + Chemotherapy and Radiation
89260543|NCT01327144|Experimental|Famciclovir 500mg|1 tablet each 8 hours for 7 days
89260544|NCT01327144|Active Comparator|Aciclovir 400mg|2 tablets of Aciclovir 400 mg each 4 hours for 7 days
89260545|NCT01026935|Experimental|sutured mesh|200 patients are randomized to inguinal hernia repair with sutured light weight (38g/m2) polypropylene mesh (Lichtenstein repair)
89260546|NCT01026935|Experimental|non-sutured mesh|200 patients are randomized to receive a light weight mesh that adheres to tissues with polylactic micro hooks without sutures
89260547|NCT01323101|Sham Comparator|Control|No doxycycline
89260548|NCT01323101|Experimental|Doxycycline|
89260549|NCT00310856|Experimental|MenACWY-CRM_6-12 M|Subjects received 2 doses of MenACWY-CRM (1 dose at 6 and 12 months of age). Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
89260550|NCT00310856|Experimental|MenACWY-CRM_12 M|Subjects received 1 dose of MenACWY-CRM at 12 months of age. Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
89260551|NCT00310856|Experimental|MenC-CRM_12 M_MenACWY-CRM_18 M|"Subjects received 1 dose of MenC-CRM (at 12 months of age) and 1 dose of MenACWY-CRM (at 18 months of age).~Subjects also received routine vaccines: 1 dose of PCV7 (at 12 months), MMR+Varicella (at 13 months) and DTaP-Hib-IPV (at 18 months)"
89260552|NCT01023893||End-stage renal disease|
89260553|NCT03995615|No Intervention|Group I (Control)|• Group I (Control) - 15 periodontally healthy patient with probing depth< 3mm and ≤ 10% sites with bleeding on probing.
89260554|NCT03995615|No Intervention|• Group II|• Group II - 15 systemically healthy chronic periodontitis patient who had presented >25% of sites with gingival bleeding ,surface demonstrating supra-gingival plaque accumulation and an absence of probing depth ≥ 4mm and clinical attachment level ≥3mm
89260555|NCT03995615|No Intervention|• Group III|• Group III - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1with out scaling and root planing
89260556|NCT03995615|Active Comparator|• Group IV|• Group IV - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28[DAS-28] ≥3.2 to ≤5.1 with scaling and root planing. Periodontal clinical parameters will be assessed
89260557|NCT03670355|Experimental|Tenofovir (TFV) Intravaginal Ring (IVR)|The TFV IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
89260558|NCT03670355|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
89260559|NCT01068782|Experimental|Arm 1|
89260560|NCT01068782|Experimental|Arm 2|
89260561|NCT01068782|Experimental|Arm 3|
89260562|NCT01068782|Experimental|Arm 4|
89260563|NCT01023971||Group A|Patients investigated with mfERG and MP-1
89260564|NCT01023971||Group B|Patients investigated by Laser Doppler Flowmetry
89260565|NCT03975998||Aymptomatic patients with severe mitral regurgitation|Watchful waiting Early Surgery
89260566|NCT01566227|Experimental|number of implants|number of implants (1,2 or 3) used to retained an overdenture
89260567|NCT01024049||Asymptomatic LVD|patients over 18 years old with patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history) and asymptomatic left ventricular dysfunction (LVD).
89260568|NCT01024049||healthy controls|individuals over 18 years old free of disease and treatments.
89260569|NCT01024049||patients with cardiovascular risk|patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history)
89260570|NCT01024049||chronic heart failure patients|patient with chronic heart failure
89260571|NCT01024049||acute heart failure patients|acute heart failure patients
89260572|NCT02532062|Experimental|Supplementation|Participants who are assigned to the Supplementation arm will receive a vitamin D supplement containing 4,000 units of vitamin D3 (cholecalciferol; capsule form) plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
89260573|NCT02532062|Active Comparator|Placebo|Participants who are assigned to the Placebo arm will receive a placebo supplement plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
89260574|NCT01566305|Experimental|Buttermilk with added egg yolk|
89260575|NCT01566305|Experimental|Buttermilk without added egg-yolk|
89260576|NCT01566305|Experimental|Skimmed milk with added egg-yolk|
89260577|NCT01566305|Placebo Comparator|Skimmed milk without added egg yolk|
89260578|NCT01566383|Experimental|Healthy Volunteers|Healthy volunteers who are matched (age, weight, gender) to the general patient population undergoing manometry and pH monitoring for GERD will undergo the same procedures to determine pH levels in people without reflux symptoms as compared to pH levels in those patients who have been diagnosed with reflux.
89260579|NCT00283712|Experimental|Infliximab|"Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
89260580|NCT00283712|Placebo Comparator|Placebo Comparator|"Participants are randomized to receive intravenous infusions of placebo (5 mg/kg comprised of a white lyophilized powder reconstituted in 10 mL of Sterile Water for Injection, USP) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
89260581|NCT03981536|Experimental|AP-101: Dose Level 1|Single dose of AP-101
89260582|NCT03981536|Experimental|AP-101: Dose Level 2|Single dose of AP-101
89260583|NCT03981536|Experimental|AP-101: Dose Level 3|Single dose of AP-101
89260584|NCT00048724|Experimental|PegIntron|PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up
89260585|NCT00048724|No Intervention|Untreated Control|
89260586|NCT00449033|Experimental|Sorafenib (Nexavar, BAY43-9006) + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid). If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met.
89290413|NCT01223040|Experimental|SYSTANE® Balance Lubricant Eye Drops|SYSTANE Balance Lubricant Eye Drops dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
89290414|NCT01126866|Experimental|preoperative chemotherapy|
89260587|NCT00449033|Placebo Comparator|Placebo + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: placebo 2 tablets po bid. If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met.
89260588|NCT01024127||Ancillary-correlative (predictors of AML treatment outcomes)|Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
89260589|NCT00448019|Experimental|FCR + Bevacizumab|FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.
89260590|NCT01024361|No Intervention|Routine|Routine protocol of the service
89260591|NCT01024361|Experimental|CPAP-DR|Infants randomized to this arm will have nasal CPAP installation at delivery room before the 15th minute of life
89260592|NCT00457691|Experimental|1|
89260593|NCT00457691|Placebo Comparator|2|
89260594|NCT00457301||Control|
89260595|NCT00456755|Active Comparator|Shi-Bi-Lin|Consist of 6 herbal. 7.5 g Xanthium sibiricum Patrin ex Widder (Asteraceae, Fructus), 20 g Angelica dahurica (Fisch. ex Hoffm.) Benth. (Apiaceae, Radix), 7.5 g Saposhnikovia divaricata (Turcz.) Schischk. (Apiaceae, Radix),15 g Magnolia biondii Pamp., (Magnoliaceae, Flos), 5 g Gentiana scabra Bunge (Gentianaceae, Radix) and 5 g Verbena officinalis L. (Verbenaceae, Herba).
89260596|NCT00456755|Placebo Comparator|Placebo|The placebo contained brown colored starch resembling the SBL powder
89260597|NCT03820271|Other|SuperMELD|
89260598|NCT00447005|Experimental|Open|
89260599|NCT01024439|Active Comparator|single port|Patients will undergo transumbilical single incision laparoscopic appendicectomy.
89260600|NCT01024439|Active Comparator|conventional Lap|Patients will undergo conventional laparoscopic appendicectomy.
89260601|NCT01024517|Experimental|Single oral dose, solution|
89260602|NCT01024517|Experimental|Single oral dose, solid, fasted|
89260603|NCT01024517|Experimental|Single oral dose, solid, fed.|
89260604|NCT01024595||Without treatment|
89260605|NCT01565759|Experimental|Lithium|This will be a short-term longitudinal study of 4 weeks of duration. Twenty (20) healthy male subjects will be recruited and treated with lithium carbonate for 4 weeks. Lithium carbonate (150 mg, 300 mg, 600 mg) will be administered to the recruited subjects. The study will be performed in one centre at Capital District Health Authority - Dalhousie University, Halifax, Nova Scotia, Canada. Lithium serum levels will be tested at day 8, at day 14 and at the end of the treatment. Additional tests may be performed as necessary (as in the case of side effects).
89260606|NCT00446849|Experimental|MMX Mesalamine|
89260607|NCT01565837|Experimental|Ipilimumab + SART|Patients with oligometastatic but unresectable malignant melanoma will receive induction ipilimumab plus concurrent SART followed by maintenance ipilimumab.
89260608|NCT00456599|Experimental|Oxaliplatin & gemcitabine with radiation|This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
89260609|NCT00456521|Experimental|NB32|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
89260610|NCT00456521|Placebo Comparator|Placebo|Placebo with intensive group lifestyle modification counseling
89260611|NCT01027091||patients with positive slope|patients with positive slope in the levels of free serum calcium levels between 6th and 12th postoperative hour
89260612|NCT01027091||patients with negative or no slope|patients with negative or no slope in the levels of free serum calcium levels between 6th and 12th postoperative hour.
89260613|NCT00456365|Experimental|Pravastatin|Pravastatin
89260614|NCT00456365|Placebo Comparator|Placebo|Placebo
89260615|NCT03843047|Other|Dual cigarette smokers/e-cigarette users|Dual cigarette smokers/e-cigarette users will be recruited.
89260616|NCT03843047|Other|Exclusive cigarette smokers|Exclusive cigarette smokers with minimal prior e-cigarette experience will be recruited.
89260617|NCT01565915|Experimental|Perlane-L|Perlane-L treatment
89260618|NCT01565915|Sham Comparator|Non-Treatment|Non-Treatment Arm
89260619|NCT01027169|Experimental|Arm 1|subjects with mild hepatic impairment
89260620|NCT01027169|Experimental|Arm 2|subjects with moderate hepatic impairment
89260621|NCT01027169|Experimental|Arm 3|matched subjects with normal hepatic function
89260622|NCT00455741|Active Comparator|Young postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
89260623|NCT00455741|Active Comparator|Older postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..
89260624|NCT00445679|Experimental|A|DVS SR 50mg/day
89260625|NCT00445679|Experimental|B|DVS SR 100mg/day
89260626|NCT00445679|Experimental|C|DVS SR 200mg/day
89260627|NCT00445679|Active Comparator|D|Paroxetine 20mg/day
89260628|NCT00455429|Placebo Comparator|Placebo|
89260629|NCT00455429|Experimental|JNJ-26113100 (50 mg) once daily|
89260630|NCT00455429|Experimental|JNJ-26113100 (100 mg) once daily|
89260631|NCT00455429|Experimental|JNJ-26113100 (100 mg) twice daily|
89260632|NCT00455429|Experimental|JNJ-26113100 (250 mg) twice daily|
89260633|NCT00445601|Experimental|Arm I|Patients receive intravesical gemcitabine hydrochloride over 1 hour.
89260634|NCT00445601|Placebo Comparator|Arm II|Patients receive intravesical placebo over 1 hour.
89260635|NCT00444587|Experimental|Trastuzumab + 2nd Line Chemotherapy|
89260636|NCT00444587|Active Comparator|Only Chemotherapy|
89260637|NCT01024673||patients with H1N1|patients who are clinical found to be positive for H1N1 will be enrolled
89260638|NCT00455195|Experimental|Alglucosidase Alfa/Alglucosidase Alfa|Participants who received alglucosidase alfa during the double-blind study and, if they completed the double-blind study, continued that treatment during the extension study. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) until their participation in both the AGLU02704 (NCT00158600) and AGLU03206 studies combined equaled a minimum of 104 weeks.
89260639|NCT00455195|Experimental|Placebo/Alglucosidase Alfa|Participants given placebo during the double-blind study, completed the double-blind study (study AGLU02704, NCT00158600), and qualified to continue into the extension study on alglucosidase alfa. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) for up to 52 weeks. Only the alglucosidase alfa treatment experience is included in this extension study.
89260640|NCT00235716|Experimental|Arm 1|2,000 IU per day of dl-alpha-tocopherol plus placebo for memantine
89260641|NCT00235716|Experimental|Arm 2|20 mg per day of memantine plus placebo for dl-alpha-tocopherol
89260642|NCT00235716|Experimental|Arm 3|Combination of 2,000 IU per day of dl-alpha-tocopherol and 20 mg per day of memantine
89260643|NCT00235716|Placebo Comparator|Arm 4|Matching placebos for dl-alpha-tocopherol and memantine
89260644|NCT00274742|Experimental|Blinatumomab|Patients received blinatumomab as continuous intravenous infusion for 4 weeks. Participants with clinical benefit were permitted to continue for another 4 weeks for a total of 8 weeks. Participants with a clinical benefit 4 weeks after completion of the first cycle of treatment could also receive additional treatment approximately 3 months ater the end of infusion at the same dose level.
89260645|NCT03973398|Active Comparator|Quadratus Lumborum Block anterior subcostal (QLa)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
88821602|NCT03313778|Experimental|Part C: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 35 cycles (approximately 2 years of treatment), whichever is sooner.
89260646|NCT03973398|Active Comparator|Quadratus Lumborum Block posterior (QLp)|Patients in this group will receive Posterior Quadratus Lumborum block postoperative with 30 ml of 0.125 bupivacaine.
89260647|NCT03973398|Placebo Comparator|Quadratus Lumborum Block anterior subcostal control (QLca)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
89260648|NCT03973398|Placebo Comparator|Quadratus Lumborum Block posterior control (QLcp)|Patients in this group will receive Anterior subcostal Quadratus Lumborum block postoperative with 30 ml of 0.9% normal saline.
89260649|NCT03970044|Experimental|Exenatide 2 mg plus Dapagaliflozin 10 mg|Exenatide extended release, 2 mg weekly, injected Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
89260650|NCT03970044|Active Comparator|Exenatide 2 mg|Exenatide extended release, 2 mg weekly, injected 14 weeks of treatment
89260651|NCT03970044|Active Comparator|Dapagaliflozin 10 mg|Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment
89260652|NCT00283400|Active Comparator|dosage tier 1|0.625 g/kg 25% human albumin
89260653|NCT00283400|Active Comparator|dosage tier 2|1.25 g/kg 25% human albumin
89260654|NCT00283400|Active Comparator|dosage tier 3|1.875 g/kg 25% human albumin
89260655|NCT00283400|Active Comparator|dosage tier 4|2.5 g/kg 25% human albumin
89260656|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (initial phase)|
89260657|NCT00444275|Experimental|Esomeprazole 40 mg Once Daily (initial phase)|
89260658|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (Maintenance Phase)|
89260659|NCT00444275|Experimental|Esomeprazole 20 mg on Demand (Maintenance Phase)|
89260660|NCT00444275|Experimental|Antacid Treatment (Maintenance Phase)|
89260661|NCT00454805|Active Comparator|2|Fulvestrant Monotherapy
89260662|NCT00454805|Experimental|3|AZD2171 + Fulvestrant
89260663|NCT00283244|Active Comparator|Arm A|Patients receive gemcitabine hydrochloride 1200mg/m2 IV on days 1 and 8. Patients with progressive disease may cross over to arm B.
89260664|NCT00283244|Experimental|Arm B|Patients receive oral erlotinib hydrochloride 150mg p.o. daily on days 1-21.
89260665|NCT00283244|Experimental|Arm C|Patients receive gemcitabine hydrochloride 1000mg/m2 IV on days 1 and 8 and erlotinib hydrochloride 100mg p.o. daily
89260666|NCT03975686|Experimental|intervention|
89260667|NCT03975686|No Intervention|control|
89260668|NCT00282464|Active Comparator|Ziprasidone 20 and 60mg|For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
89260669|NCT00282464|Placebo Comparator|Placebo|
89260670|NCT01068938||open angle glaucoma, glaucoma suspects|risk of progression, Latanoprost monotherapy
89260671|NCT03976856|Experimental|GB226+Fruquintinib|Geptanolimab combined with Fruquintinib
89260672|NCT00273182||Cohort|Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.
89260673|NCT03976700|Experimental|Bufei Jianpi granule|Patients in this arm will receive Bufei Jianpi granule.
89260674|NCT03976700|Placebo Comparator|Placebo Bufei Jianpi granule|Patients in this arm will receive placebo Bufei Jianpi granule.
89260675|NCT00209274|Experimental|1|Percutaneous mitral valve repair using MitraClip implant. The calculated sample size was 186 patients in the device arm
89260676|NCT00209274|Active Comparator|2|Mitral valve repair or replacement surgery. The calculated sample size was 93 patients in the control arm.
89260677|NCT03976778|Other|a pre-post interventional study|intervention consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
89260678|NCT03975764||Preterm birth|Delivery between 24-32 weeks of gestation
89260679|NCT03975764||Term delivery|Delivery between 37-41 weeks of gastation
89260680|NCT03841331|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
89260681|NCT03841331|Placebo Comparator|5 mg Placebo Tablets|Placebo Tablets
89260682|NCT01069016|Experimental|Sacral nerve modulation first|"Sacral nerve modulation is applied before the pudendal nerve stimulation. There is no wash-out period (pause) between the two treatments."
89260683|NCT01069016|Experimental|Pudendal nerve stimulation first|"Pudendal nerve stimulation is applied before the sacral nerve modulation. There is no wash-out period (pause) between the two treatments."
89260684|NCT01326156|Experimental|Avon patellofemoral replacement|Knee arthroplasty with insertion of patellofemoral joint replacement.
89260685|NCT01326156|Active Comparator|PFC Sigma CR total knee replacement|Knee arthroplasty with total (tricompartmental) knee replacement.
89260686|NCT00262080|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
89260687|NCT00262080|Placebo Comparator|Placebo|Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
89260688|NCT01073904|Experimental|Arm 1|
89260689|NCT01073904|Active Comparator|Arm 2|
89260690|NCT03969810|Experimental|Rounding Summary|"Surrogates who are assigned to the intervention group will receive a written rounding summary every day or every other day that the patient is in the ICU. The summary will be organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.~For patients assigned to the intervention group, the investigators will forward the previous day's summary to the ICU nurse at the beginning of each day shift. After participating in morning rounds, ICU nurses will be asked to modify the summary based on the plan for the day. Nurses will be asked to use the written summary to guide communication with surrogates that day."
89260691|NCT03969810|No Intervention|Usual Care|Usual ICU care
89260692|NCT03973554|Experimental|pearl powder|natural product, support bone and joint health
88805040|NCT01314001|Active Comparator|Varenicline (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
88805041|NCT01314001|Active Comparator|Transdermal Nicotine (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
88805042|NCT00154466|Experimental|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2.
88805043|NCT00154466|No Intervention|postinfarction patients|those in the nontraining group continued their usual lifestyle
88805044|NCT00154466|Placebo Comparator|healthy controls|Age-, weight-, and height-matched subjects without cardiovascular risk factors were selected as healthy controls.
88805045|NCT00117806|Experimental|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury
89260693|NCT03973554|Active Comparator|CPP-ACP|product for professional use containing the active ingredient (CPP-ACP), a special milk-derived protein that has a unique ability to release bio-available calcium and phosphate to tooth surfaces.
89260694|NCT03973320||Primary Total Hip Arthroplasty|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty
89260695|NCT00282308|Experimental|Rituximab + methotrexate (Group A)|Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
89260696|NCT00282308|Active Comparator|Methotrexate (Group B)|Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
89260697|NCT01072968|Experimental|BF2.649|BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg
89260698|NCT01072968|Placebo Comparator|Placebo|Capsules of placebo containing lactose with low, medium and high dosage
89260699|NCT03969732|Experimental|amyloid PET、T807 PET|PET/CT
89260700|NCT03975608|Experimental|"Adaptation of CALM"|"This is the patient group that receives the intervention (IG), i.e., the psychotherapeutic treatment, i.e., the adapted version of the psychotherapeutic program Managing Cancer and Living Meaningfully (CALM) which was originally designed for patients with cancer."
89260701|NCT00282152|Active Comparator|ODT|Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary.
89260702|NCT00282152|Experimental|DBS+ODT|"Subjects receive bilateral subthalamic nucleus (B-STN) DBS and continue to take optimal drug therapy as prescribed by their treating neurologist.~B-STN DBS: Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for mid- and advanced PD. DBS is not approved for early stage PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.~Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary."
89260703|NCT00281840|Experimental|bevacizumab with docetaxel and radiation therapy|
89260704|NCT00281684|Experimental|Placebo|Eligible participants received a single dose of SB705498 matching placebo capsules (4 placebo capsules) via oral route and were followed up to a maximum of 14 days.
89260705|NCT00281684|Experimental|SB705498 400 mg|Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a maximum of 14 days.
89260706|NCT00281684|Experimental|SB705498 1000 mg|Eligible participants received a single dose of SB705498 1000 mg capsules (2 x 200 mg capsules plus 2 x 300 mg capsules) via oral route and were followed up to a maximum of 14 days.
89260707|NCT00281684|Experimental|Co-Codamol|Eligible participants received a single dose of Co-codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via oral route and were followed up to a maximum of 14 days.
89260708|NCT03975452|Experimental|Primary resectable cT2-low lying-T3, N0-N1 rectal tumour|Primary resectable cT2-low lying-T3, N0-N1 adenocarcinoma of the rectum, without evidence of disease in lateral lymph nodes.
89260709|NCT03976622||vitiligo|Patients aged 18 to 75 years with non-segmental vitiligo;
89260710|NCT03976622||psoriasis|Patients aged 18 to 75 years with plaque psoriasis;
89260711|NCT03976622||atopic dermatitis|Patients aged 18 to 75 years with atopic dermatitis;
89260712|NCT03976622||alopecia areata|Patients aged 18 to 75 years with alopecia areata sclerosis;
89260713|NCT00272792|Experimental|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
89260714|NCT00272792|Placebo Comparator|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
89260715|NCT01069094|Experimental|progenta 12.5 mg|Progenta (CDB-4124) 12.5 mg capsule
89260716|NCT01069094|Experimental|progenta 25 mg|Progenta (CDB-4124) 25 mg capsule
89260717|NCT01069094|Experimental|progenta 50 mg|Progenta (CDB-4124) 50 mg capsule
89260718|NCT01069094|Active Comparator|Lucron Depot|Lucron Depot, Leuprolide acetate for depot suspension
89260719|NCT01069094|Placebo Comparator|placebo|Placebo capsule
89260720|NCT00048568|Experimental|Abatacept + Methotrexate|Short Term: Abatacept was dosed by weight with participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. Participants continued treatment with methotrexate (MTX) either orally or parenterally at a minimum dose of 15 mg.
89260721|NCT00048568|Active Comparator|Placebo + Methotrexate|Short Term: Participants received a placebo solution intravenously and methotrexate at the dose employed prior to study enrollment and a minimum of 15 mg.
89260722|NCT00048568|Experimental|Abatacept + Methotrexate Open Label|Open Label: Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.
89260723|NCT00262002|Experimental|UK234+ (MenACWY Ad+ at 2, 3, 4 m)|Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age in the UK group. A fourth dose of MenACWY Ad+ was given at 12 months of age.
89260724|NCT00262002|Experimental|UK24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.
89260725|NCT00262002|Experimental|UKMenC (Menjugate at 2, 4 m)|Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.
89260726|NCT00262002|Experimental|CA246+ (MenACWY Ad+ at 2, 4, 6 m)|Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age of the Canadian group (Prevnar at 6 months was optional and was given if available).One subgroup of subjects was given a reduced dose (1/5) of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.
89260727|NCT00262002|Experimental|CA24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose (1/5) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
89260728|NCT00262002|Experimental|UK24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.
89260729|NCT00262002|Experimental|CA24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
89260730|NCT01092988|Experimental|Exablate 2100|MR Guided Focused Ultrasound treatment
89260731|NCT03955120|Experimental|Sleep Apnea- Dayzz|The intervention group is also provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the adherence to CPAP. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device. The intervention group meets a CPAP technician at the sleep clinic, as detailed below in the Sleep Apnea TAU group
89260732|NCT03955120|Active Comparator|Sleep Apnea- Treatment as Usual|"The treatment as usual [TAU] group meets a CPAP technician at the sleep clinic, who provides the participant with a CPAP device and fits the mask. The will also receive a follow-up visit with the same technician for technical support, mask changes or alterations if needed after an initial 7 to 14-day at home CPAP trial."
89260733|NCT03955120|Experimental|Insomnia - Dayzz|The intervention group is provided access to the dayzz app, a personalized digital sleep training program. The sleep training begins a sleep assessment questionnaire and ongoing sleep and activity data collection which is used to tailor an individualized sleep training program including behavioral and cognitive techniques to improve the insomnia concerns, sleep symptoms, and achieve sleep goals. The dayzz sleep program is composed of three main components, (1) a mobile digital program via the dayzz app, (2) guidance of a sleep trainer, and (3) an ambulatory sleep monitoring device.
89260734|NCT03955120|Active Comparator|Insomnia - Treatment as Usual|"The treatment as usual [TAU] group, will receive standard treatment recommendations for their insomnia, including sleep hygiene suggestions, referral for supportive/non-medical treatments [e.g. relaxation therapies], and if needed hypnotics or other medications prescribed by the sleep clinic physician."
89260735|NCT01583998|Active Comparator|e-MBC|Patients will receive e-MBC
89260736|NCT01583998|No Intervention|Treatment as Usual Control|Patients receive standard treatment
89260737|NCT01584076|Experimental|Donepezil|
89260738|NCT03954964|No Intervention|Control Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement.
88805046|NCT00117806|Placebo Comparator|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
88805047|NCT01363999|Experimental|A|RO5317116/F01 bilayer tablet
89260739|NCT03954964|Experimental|Intervention Group|Subjects participating in a total joint class for patients undergoing planned hip and knee total joint replacement will receive additional education about the disposal of opioids.
89260740|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 3 weeks|260 mg/m^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks
89260741|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 2 weeks|260 mg/m^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks
89260742|NCT00281528|Experimental|130 mg/m^2 ABI-007 weekly|130 mg/m^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks
89260743|NCT01095640|Experimental|adapalene 0.3% topical gel (Actavis Mid-Atlaqntic LLC)|
89260744|NCT01095640|Active Comparator|Differin® (adapalene 0.3% topical gel)|
89260745|NCT01095640|Placebo Comparator|Vehicle Control|
89260746|NCT03955276||Matched Therapy|Targeted therapy matched to each patient's genomic/immunophenotypic tumor profile (whereby oncogenic alterations are matched with targeted agents)
89260747|NCT03955276||Unmatched Therapy|General, unmatched therapy (standard of care)
89260748|NCT01095718|Experimental|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
89260749|NCT01095718|Active Comparator|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step.Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance. Then the therapist asks immediately to the patient to do the steps."
89260750|NCT01095718|Active Comparator|Trial and Error|"Trial and Error refers to the regular unstructured learning and is considered as control condition.~Here the patient is encouraged to complete the task. When there is mistake, the therapist corrects it. Verbal cues will only be provided if the patient is unable to find and complete the correct next step or commit mistakes. The therapist use general instruction: Here is task, I will ask you to actions, followed by specific instruction, and I will help you after you have tried."
89260751|NCT00280748|Other|Single Arm Study|Single Arm Study
89260752|NCT00271856|Experimental|0|Mindfulness Based Stress Reduction (MBSR)
89260753|NCT00271856|Active Comparator|1|HIV education/self-management workshop
89260754|NCT03975374|Experimental|Tobramycin/Dexamethasone opthamic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobramycin/Dexamethasone opthamic solution every 6 hours for 10 days
89260755|NCT03975374|Active Comparator|Tobradex Opthalmic Solution|This group of randomized patients will be instructed to instill 2 gtt of Tobradex Opthalmic Solution every 6 hours for 10 days
89260756|NCT01070264|Experimental|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
88805048|NCT01363999|Experimental|B|RO5317116/F03 bilayer tablet
88805049|NCT01363999|Experimental|C|RO5317116/F04 active-coated tablet
88805050|NCT01363999|Experimental|D|RO4607381/F49 tablet
88805051|NCT00257894|Experimental|Baclofen condition|Baclofen taken orally for 12 days total up to 40 mg/day maximum, divided into 3 equal portions each day. Participants receive 12 mg/day the first 3 days, 30 mg/day the next 3 days, and 40 mg/day on Days 7, 8, 9. Testing is on day 10 after the first dose is taken, with downward titration days 10-12 of 30 mg on Day 10, 20 mg on Day 11 and 10 mg on Day 12.
88805052|NCT00257894|Placebo Comparator|Placebo condition|Placebo capsules identical to active medication, 3/day for 12 days.
88805053|NCT00258128|Experimental|Treatment|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the salsalate 4.0 g/d arm.
88805054|NCT00258128|Placebo Comparator|Placebo|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the placebo arm.
88805055|NCT01364623|Experimental|Low dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.24% testosterone gel to deliver a single dose of 300 μg of testosterone per nostril, for a total dose of 600 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 1 (Low dose testosterone nasal gel, single dose)
89260757|NCT01070420|Active Comparator|FFR via central venous line|
89260758|NCT01070420|Experimental|FFR via peripheral vein|
89260759|NCT00061048|Experimental|Campath-1H|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week.
89260760|NCT01070498|Experimental|Trichuris suis ova (TSO)|
89260761|NCT01581398|Experimental|A1(Genotype2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 800mg/day
89260762|NCT01581398|Active Comparator|A2(Genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 800mg/day
89260763|NCT01581398|Experimental|B1(Non-genotype 2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight
89260764|NCT01581398|Active Comparator|B2(Non-genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight.
89260765|NCT03957148|Experimental|SSB Education|The SSB reduction intervention consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
89260766|NCT03957148|Sham Comparator|Food Safety Education|The sham control (food safety education) consists of 10-weeks of targeted, brief interactions with parents when they come to pick up their children for a center-based early childcare program. The sessions will be twice per week.
89260767|NCT03954808|Experimental|Motor imagery training group|Children with Cerebral Palsy. Motor imagery training group will receive a traditional physiotherapy and motor imagery training within a specific program, two days a week for a total of 8 weeks (30 minutes traditional physiotherapy session+15 minutes MI training). The motor imagery training will be designed for the individual basis with standard protocols. All sessions will be performed in the clinic.
89260768|NCT03954808|Active Comparator|Cerebral Palsy control group|Children with Cerebral Palsy. Traditional physiotherapy control group individuals will be given a traditional physiotherapy two days per week for a total of 8 weeks (traditional physiotherapy session will last 45 minutes).
89260769|NCT03954808|No Intervention|Typically developing control group|Age matched healthy individuals, with no treatment.
89260770|NCT01093378||Fertile group|fertile group
89260771|NCT01093378||Infertility group|Fertility troubles
89260772|NCT00270998|Experimental|Intravaginal Pessary|Pessary restores continence by stabilization of the proximal urethra and urethrovesical junction, facilitating pressure transmission to the proximal urethra.
89260773|NCT00270998|Experimental|Behavioral Therapy|Pelvic floor muscle training and exercise which includes strong contraction of the pelvic floor muscles to prevent incontinence by occluding the urethra and regular practice can improve pelvic muscle support.
89260774|NCT00270998|Experimental|Pessary combined with behavioral therapy|Combination of the explanations above.
89260775|NCT01070576||normal fracture healing|group in which normal fracture healing has occured
89260776|NCT01070576||atrophic|patients in which an atrophic non-union occured
89260777|NCT01070576||hypertrophic|patients in which a hypertrophic non-union occured
89260778|NCT01070654|Experimental|40/30 Recruitment Manoeuvre|Patients with respiratory failure that will be first ventilated for 30 minutes according to standardized baseline protective ventilation and after that will receive the recruitment manoeuvre
89260779|NCT01581632|Other|LipiScan/LipiScan IVUS|valuation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
89260780|NCT03741686|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.
89260781|NCT03741686|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.
89260782|NCT01325948||Patients with COPD|
89260783|NCT01582256||ASD+CNVs|
89260784|NCT01582256||ASD-CNVs|
89260785|NCT01582256||Unaffected siblings of ASD+CNVs|
89260786|NCT01582256||Unaffected siblings of ASD-CNVs|
89260787|NCT01582256||Neurotypicals for ASD+CNVs comparisons|
89260788|NCT01582256||Neurotypicals for ASD-CNVs comparisons|
89260789|NCT00279812|Placebo Comparator|Placebo|Placebo
89260790|NCT00279812|Experimental|50ug selenium enriched yeast|50ug/d selenium enriched yeast (containing 60% selenomethionine)
89260791|NCT00279812|Experimental|100ug selenium enriched yeast|100ug/d selenium enriched yeast (containing 60% selenomethionine)
89260792|NCT00279812|Experimental|200ug selenium enriched yeast|200ug/d selenium enriched yeast (containing 60% selenomethionine)
89260793|NCT00279812|Experimental|Control onion|3 meals/wk containing un-enriched onions equivalent to 4ug/d Se
89260794|NCT00279812|Experimental|Enriched onion|3 meals/wk containing enriched onions equivalent to 50ug/d Se
89260795|NCT01070732|Experimental|Paracetamol|All patients will receive one single dose of 1000mg paracetamol.
89260796|NCT00207714|Experimental|Golimumab (CNTO 148) with Methotrexate (MTX)|
89260797|NCT00207714|Experimental|Infliximab with MTX|
89260798|NCT00207714|Placebo Comparator|Placebo with MTX|
89260799|NCT00207090|Experimental|Ixabepilone + rifampin|
89260800|NCT03969576|Experimental|DEB-TACE|172 subjects in this study group will be receive the treatment of drug-eluting bead TACE
89260801|NCT03969576|Active Comparator|cTACE|172 subjects in this study group will be receive the treatment of conventional TACE
89260802|NCT01071408|Experimental|Stroke Prevention Program + Usual Care|Stroke Prevention Care Program + Usual Care. The Stroke prevention care program is in addition, not a substitute for usual care. Persons randomized to this arm are eligible to all care, including care by stroke specialists, while enrolled in the intervention.
89260803|NCT01071408|No Intervention|Usual care|
89260804|NCT00059332|Experimental|Magnesium Sulfate|Magnesium sulfate (Mg) was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. The bolus-loading dose consisted of 4 grams Mg in 54 ml normal saline. The maintenance infusion contained 16 grams Mg diluted in 240 ml 0.9% normal saline, infused at 10 ml/hr for 24 hours. Paramedics in the field initiated the bolus-loading dose, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose.
89260805|NCT00059332|Placebo Comparator|Normal saline|Normal saline was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. Paramedics in the field initiated the bolus-loading dose of 54 ml normal saline, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose at 10 ml/hr for 24 hours.
88805056|NCT01364623|Experimental|Medium dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 2 (Medium dose testosterone nasal gel, single dose)
88805057|NCT01364623|Experimental|High dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.72% testosterone gel to deliver a single dose of 900 μg of testosterone per nostril, for a total dose of 1800 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 3 (High dose testosterone nasal gel, single dose)
89260806|NCT01095952|Experimental|AVNS ON|Consulta downloaded with AVNS to provide high frequency bursting during fastly conducted AF. AVNS will be programmed on for five months. The feasibility and safety of the AVNS algorithm to reduce inappropriate shocks will be monitored.
89260807|NCT01096030|Experimental|Regorafenib|
89260808|NCT00233454|Experimental|Midostaurin|100 mg midostaurin twice daily as oral capsules
89260809|NCT01093456||chronic kidney disease|ESKD patients treated with peritoneal dialysis
89260810|NCT01093456||Healthy volunteers|healthy volunteers, aged 18 years and above
89260811|NCT00047320|Experimental|Radiation Therapy (CR from Induction)|Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC > 750/L and platelets > 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.
89260812|NCT00233064|Active Comparator|1|Liquid Palivizumab
89260813|NCT00233064|Active Comparator|2|Lyophilized Palivizumab
89260814|NCT03973242|Active Comparator|DF-NBI|Initially, gastric mucosa is observed by conventional wight light endoscopy. Then, converting to dual-focus mode with narrow band imaging is done. Gastric mucosa is observed once again by DF-NBI mode.
88805058|NCT01364623|Experimental|Medium dose TBS-2 multiple doses|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given t.i.d. daily at 0800 hours (± 30 minutes), 1600 hours (± 30 minutes), and 2400 hours (± 30 minutes) on Days 1 and 2 of Period 2, and once in the morning at 0800 hours (± 30 minutes) on Day 3 of Period 2 (Multi-dose group) (Medium dose testosterone nasal gel, multiple dose)
88805059|NCT00258206|Experimental|rituximab + cyclophosphamide|Rituximab 375 mg/m^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m^2 once each during months 3, 6, 9, and 12
89260815|NCT03973242|Placebo Comparator|WL|Conventional white light endoscopy use It is routine practice for the upper gastrointestinal endoscopy.
89260816|NCT03954730|Experimental|Eccentric Training Group|Eccentric training will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
89260817|NCT03954730|Active Comparator|Active Release Technique Group|Active release technique will be performed for quadriceps muscle along with strengthening protocol taken from Clinical Guidelines of NHS for post operative Dynamic Hip Screw rehabilitation.
89260818|NCT03973086|Experimental|Citrus flavonone-O-glycosides (Low dose)|
89260819|NCT03973086|Experimental|Citrus flavonone-O-glycosides (High dose)|
89260820|NCT03973086|Placebo Comparator|Microcrystaline Cellulose- 400mg|
89260821|NCT00268892|Experimental|Degarelix 240/240@40(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (40 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (40 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
89260822|NCT00268892|Experimental|Degarelix 240/240@60(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
89260823|NCT00268892|Experimental|Degarelix 240/240@60(1-4-7-10)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 4, 7, 10) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
89260824|NCT00206076|Experimental|1|mycophenolate mofetil monotherapy
89260825|NCT00206076|Active Comparator|2|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
89260826|NCT03974490|Experimental|Intervention Group|"2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.~3 Times a week, intervention: Start with global body warming, 15 minutes, following the rhythm marked by the metronome. Central part of the session, 60 minutes, with rhythmic auditory stimulation exercises and music. Closure of the session, 15 minutes, round of impressions."
89260827|NCT03974490|No Intervention|Historical control group|2 hours from Monday to Saturday, conventional physiotherapy: strengthening, stretching, dual task training.
89260828|NCT01073046||Place Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is placed (Rusch® distributed by Teleflex Medical Srl)
89260829|NCT01073046||No Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is not placed
89260830|NCT00278954|Other|Gammaplex|Gammaplex
89260831|NCT03973008|Experimental|Adujvant CT+CRT|Four to six weeks after D2 radical surgery, adjuvant chemotherapy was initiated with SOX regimen , repeated every three weeks, and adjuvant radiotherapy was started at the end of two cycles of adjuvant chemotherapy , with synchronous tegiol single drug chemotherapy. And the original SOX regimen was continued for 4 cycles after 3-4 weeks of radiotherapy.
89260832|NCT03973008|Active Comparator|Adujvant CT|The adjuvant chemotherapy was started 4-6 weeks after D2 radical operation. The SOX regimen was repeated every 3 weeks for 8 cycles.
88805060|NCT01063907|Experimental|Phase 1: Cohort 1|Cohort 1: KW 2478 130 mg/m^2 and Bortezomib 1.0 mg/m^2
88805061|NCT01063907|Experimental|Phase 1: Cohort 2|Cohort 2: KW 2478 130 mg/m^2 and Bortezomib 1.3 mg/m^2
88805062|NCT01063907|Experimental|Phase 1: Cohort 3|Cohort 3: KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
89260833|NCT00278564|Experimental|Hematopoietic stem cell transplantation|Intervention as hematopoietic stem cells transplantation after conditioning regimen: Autologous hematopoietic stem cells will be injected after conditioning regimen
89260834|NCT01071564|Experimental|Treatment (RO4929097 and vismodegib)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on day 1 or days -2, -1, and 1 of course 1 and days 1-3 and 8-10 of course 2 and all subsequent courses. Patients also receive vismodegib PO QD beginning day 8 of course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89260835|NCT03975296|Experimental|TMQLB group|
89260836|NCT03975296|Active Comparator|TPVB group|
89260837|NCT03974256|No Intervention|Group standard method|Operators work during 4 days with thermoluminescent dosimeters (TLD), according to the conventional manual method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
89260838|NCT03974256|Experimental|Group automated method|Operators work during 4 days with TLD, according to the automated method of preparation of technetium-99m labelled radioactive medicinal products for diagnostic according with good preparation practices and the recommendations contained in the summary of characteristics
89260839|NCT01073124|Active Comparator|Normal Saline|Normal Saline injected intraarticularly into the knee joint
89260840|NCT01073124|Experimental|Dilute Methylene Blue Dye|1 ml methylene blue dye per 500 ml normal saline injected intraarticularly into the knee
89260841|NCT00268346|Experimental|ZD1839|
89260842|NCT00203892|Experimental|A: CEA peptide 10mcg|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
89260843|NCT00203892|Experimental|B: CEA peptide 100 mcg|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
89260844|NCT00203892|Experimental|C: CEA peptide 1000mcg|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
89260845|NCT00250718|Experimental|Arm 1 Combination Treatment|"Treatment with combination therapy as follows:~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily~At least 2 courses, but no more than 8 courses total, will be administered to each patient"
89260846|NCT00276614|Experimental|Velcade|Velcade IV twice a week for two weeks on Days 1, 4, 8 and 11 of each cycle. A 10 day-rest period (Days 12-21) with no Velcade will follow the 2 weeks of treatment in each cycle. one cycle = 21 days
89260847|NCT00276458|Active Comparator|1|Atorvastatin 40mg tablet + Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day).
89260848|NCT00276458|Experimental|2|Atorvastatin 40mg Pbo tablet + Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day).
89260849|NCT00276380|Experimental|EGb761®|"EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day).~The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
89260850|NCT00276380|Placebo Comparator|Placebo|"6 months, administered orally, in association with acetylsalicylic acid (325 mg/day).~The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
89260851|NCT03975218||Patients with stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
89260852|NCT02531984|Experimental|Withdrawal of Azithromycin treatment|
89260853|NCT02531984|Other|ongoing Azithromycin treatment|
88805063|NCT01063907|Experimental|Phase 1: Cohort 4|Cohort 4: KW 2478 175 mg/m^2 and Bortezomib 1.3 mg/m^2
88805064|NCT01063907|Experimental|Phase 2|KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
89260854|NCT00267956|Experimental|CNTO1275 (ustekinumab)|Group 1: Patients will receive CNTO 1275 63 mg at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive placebo to maintain the blind.
89260855|NCT00267956|Placebo Comparator|Placebo|Group 2: Patients will receive placebo at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive CNTO 1275 63 mg.
89260856|NCT01072292|Experimental|CBT-I|CBT-I
89260857|NCT01072292|Active Comparator|Wellness Education|Wellness Education
89260858|NCT01073696|Active Comparator|granisetron IV|
88805065|NCT01316263|Experimental|PDGFRα mutation negative|Participants with GIST with genotypes that do not have a PDGFRα mutation given 20 milligrams per kilogram (mg/kg) Olaratumab intravenously (IV) every 14 days.
89260859|NCT01073696|Experimental|granisetron patch|
89260860|NCT03954496|Experimental|Active tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2.5mA, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
88805066|NCT01316263|Experimental|PDGFRα mutation positive|Participants with GIST with genotypes that have a PDGFRα mutation given 20 mg/kg Olaratumab IV every 14 days.
88805067|NCT03015857|Active Comparator|phenylephrine,|- Phenylephrine group (n=100): will receive 100 mcg phenylephrine as a single bolus just after intrathecal injection of 10 mg bupivacaine plus 20 mcg fentanyl. The dose will be diluted in 5 mL and given over seconds. A continuous infusion with placebo (normal saline) will start after the first bolus.
89260861|NCT03954496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation, followed by 2 hours of intensive motor therapy of the more affected upper extremity.
89260862|NCT03954418|Experimental|Intervention group|Participants will drink an artificially sweetened drink 2-4 hours before elective caesarean section.
89260863|NCT03954418|No Intervention|Control group|Participants in the control group will refrain from intake of artificial sweeteners.
89260864|NCT03954340|Active Comparator|1 iRemember Treatment|Subjects randomized to this arm of the study will undergo 20 EEG NFB treatments with the iRemember System for the treatment of MCI
89260865|NCT03954340|Sham Comparator|2 Sham Treatment|Subjects randomized to this arm of the study will undergo 20 SHAM treatments
89260866|NCT01096108|Experimental|Standard Contest|Smoking abstinence, 1 prize award (month 1)
89260867|NCT01096108|Experimental|Standard Contest plus MAPS|Smoking abstinence, 1 prize award (month 1) plus motivational and problem-solving counseling (MAPS - Counseling phone calls); 20 weeks.
89260868|NCT01096108|Experimental|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
89260869|NCT01096108|Experimental|Extended Contests plus MAPS|Extended quit and win contests (3 successive monthly contests) plus motivational and problem-solving counseling (MAPS). {Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3) plus Counseling phone calls.
88805068|NCT03015857|Active Comparator|norepinephrine|- Norepinephrine group (n=100): will receive bolus of norepinephrine (10 mcg) directly after spinal block using 10 mg bupivacaine plus 20 mcg fentantanyl followed by continuous infusion of norepinephrine with a rate of 0.1 mcg/kg/min till delivery of the fetus.
89260870|NCT03954028|Active Comparator|CTG Group|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the autogenous connective tissue graft (CTG) material will be randomized to transplant to one side of the arch.
89260871|NCT03954028|Active Comparator|ADM Group|The patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. In this group, the commercial acellular dermal matrix (ADM) materials will be transplanted to the opposite side of the arch with CTG transplants.
89260872|NCT00044512|Experimental|Sorafenib 400 mg b.i.d.|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
89260873|NCT03956524|Experimental|Test group|Single dose of EuTCV will be administered intramuscularly
88805069|NCT03295487|Active Comparator|Group A|post menopausal female with genuine stress incontinence treated by TVT-O and local estrogen cream for 3 months after surgery
89260874|NCT03956524|Active Comparator|Comparator group 1|Single dose of Typbar-TCV™ will be administered intramuscularly
89260875|NCT03956524|Active Comparator|Comparator group 2|Single dose of Typhim Vi® will be administered intramuscularly
89260876|NCT03805438|Experimental|Chloroprocaine dose|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
89260877|NCT01584154|Experimental|cryoablation|
89260878|NCT01584154|Active Comparator|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
89260879|NCT01096264|Other|Healthy volunteer|"Healthy volunteer undergoing two imagery evaluation :~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
89260880|NCT01096264|Other|vEDS patients|"vEDS patients undergoing two imagery evaluations:~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
89260881|NCT01096420|Experimental|acupuncture|
89260882|NCT01096420|Active Comparator|topiramate|
89260883|NCT01096888|No Intervention|Standard WIC care|Patients randomized to this group will receive standard WIC care and an information packet surround healthy eating and activity topics.
89260884|NCT01096888|Active Comparator|Enhanced WIC weight loss program|Participants randomized into this condition will receive standard WIC care, but will also receive weight loss classes provided through the internet. Topics will cover behavioral weight loss topics, based off the protocols of the Look AHEAD program.
89260885|NCT06186258||Patients who underwent successful percutaneous pulmonary revalvulation with the Melody valve|"Data from patients managed for a pulmonary revalvulation procedure with the Melody valve between 01/01/2007 and 31/12/2021 will be collected.~Cases of infective endocarditis will be meticulously examined and classified as certain, possible or refuted, according to the modified Duke algorithm proposed by the European Society of Cardiology.~Cases of endocarditis occurring within one year of pulmonary revalvulation will be classified as early IE and other cases as late IE"
89260886|NCT06186258||Patients who underwent successful percutaneous pulmonary revalvulation with the Sapien 3, XT valve|"Data from patients managed for a pulmonary revalvulation procedure with the Sapien 3, XT valve between 01/01/2007 and 31/12/2021 will be collected.~Cases of infective endocarditis will be meticulously examined and classified as certain, possible or refuted, according to the modified Duke algorithm proposed by the European Society of Cardiology.~Cases of endocarditis occurring within one year of pulmonary revalvulation will be classified as early IE and other cases as late IE"
89260887|NCT06186245|Experimental|Early feeding|If randomized to the experimental group, patient's diet will be advanced to clear liquid for the first day. On the second day, diet will be advanced to full liquid and advanced up to oral (carb controlled 1600 calories) diet as tolerated.
88805070|NCT03295487|Active Comparator|Group B|post menopausal female with genuine stress incontinence treated by TVT-O only
88805071|NCT03015935||Optical|visual-assisted entry
88805072|NCT03015935||Veress|Veress entry
88805073|NCT03016091|Experimental|Arm 1|IV Pembrolizumab 200mg, given every 3 weeks until disease progression or intolerable toxicity
88805074|NCT03206489|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
89260888|NCT06186245|No Intervention|Nothing per mouth|Patient will be kept without PO intake until they are bridged from the insulin drip
89260889|NCT06186206|Experimental|Social Media Messaging Only|In this arm of the clinical trial, four selected communities will receive a culturally tailored social media campaign designed to increase childhood routine and HPV vaccine confidence and uptake. The campaign will be deployed via Facebook and will geographically target these communities. This arm serves as the first intervention group.
89260890|NCT06186206|Experimental|Social Media and Health Worker WhatsApp|In this arm, another set of four communities will receive both the culturally tailored social media campaign (deployed via Facebook) and WhatsApp-based vaccine training for community healthcare workers. This arm serves as the second intervention group.
89260891|NCT06186206|No Intervention|No Intervention (Control)|
89260892|NCT06186193||Mindful Interoceptive Exposure|Mindful Interoceptive Exposure Phone-based interoceptive exposure task as attention exercise with chronic low back pain
89260893|NCT06186180|Experimental|inspiratory muscle training|They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device.
89260894|NCT06186180|No Intervention|control|no intervention
89260895|NCT06186089||Probiotics (PR)|Patients undergoing total gastrectomy take probiotics qd for 3 months after surgery.
89260896|NCT06186089||Total gastrectomy (TG)|Patients undergoing total gastrectomy
89260897|NCT06186089||Double-tract reconstruction (DTR)|Patients undergoing double-tract reconstruction
89260898|NCT06186076|Experimental|Phase 1 Part A: Dose escalation in patients with EGFR sensitizing mutation|All eligible patients will receive the study treatment at selected oral dose(s) once daily, as per the assigned dose level from the pre-defined escalation scheme and SRC(Safety Review Committee) decision.
89260899|NCT06186076|Experimental|Phase 1 Part B: 2 dose levels of TRX-221 in patients with EGFR sensitizing mutation|All eligible patients will receive the study treatment at selected oral dose(s) once daily. Dose-levels will be selected from the Part A.
89260900|NCT06186076|Experimental|Phase 2: Recommended Phase 2 dose(s) of TRX-221 in patients with EGFR C797X mutation|All eligible patients will receive the study treatment at selected oral dose(s) once daily.
89260901|NCT06186050|Active Comparator|High-fat meal with Beetroot Drink|2 sausage egg McMuffins and a hashbrown from McDonalds and 10g of beetroot powder mixed in 250 mL cold tap water drink
89260902|NCT06186050|Placebo Comparator|High-fat meal with Placebo Drink|2 sausage egg McMuffins and a hashbrown from McDonalds and Mio water flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were mixed to match the beetroot supplement
89260903|NCT06186050|Sham Comparator|Low-fat meal control|Kelloggs cornflakes (110g), greek yogurt (400g), skim milk (500 mL), and orange juice (250 mL). Energy-matched to the high-fat meal
89260904|NCT06186024|Experimental|Experimental group|Bridge
89260905|NCT06186011|Active Comparator|Wire-guided|Wire guided localization (WGL) is considered the standard method for intraoperative localization of non-palpable breast lesions, chosen by many centers worldwide. It involves the placement of a wire or barbed needle that is percutaneously introduced into the lesion using a guide. It is cost-effective, easy to place guided by ultrasound or stereotaxis, allows for repositioning in case of error, and its safety and efficacy have been widely demonstrated in the literature.
89260906|NCT06186011|Active Comparator|Intraoperative Ultrasound|The use of intraoperative ultrasound (IOUS) is an effective method that is controlled by the surgeon and does not require the involvement of other departments or preoperative invasive procedures. IOUS has been introduced into clinical practice as a tool for visualizing non-palpable tumors, demonstrating the detection of nearly 100% of lesions, and a rate of negative margins and re-excision similar to WGL. One of the challenges of the technique in ultrasound-guided surgery arises when the tumor is <5mm, making it difficult to visualize by ultrasound, or when there are microcalcifications not visible by ultrasound.
89260907|NCT06186011|Active Comparator|Radioactive seed|Radioactive seeds are composed of a titanium capsule with an I-125 filament inside. They have low radioactivity, which can range from 7 to 200 μCi. During surgery, the seeds are detected using a portable gamma ray detection probe typically used for sentinel lymph node biopsy, configured to detect an I-125 source (27 keV). This probe has a wide detection range through tissue (>10 cm), currently offering the greatest detection range compared to other available localization devices. Radioactive seed localization (RSL) require coordination between the radiology and nuclear medicine departments for marking. The results in terms of lesion localization and margin involvement rates are comparable to WGL.
89260908|NCT06185998|Experimental|plated balloon tracheostomy cannulas|4 interfaces are tested: cap, ventilator, filter and phonation valve
89260909|NCT06185998|Active Comparator|low pressure balloon tracheotomy cannulas|4 interfaces are tested: cap, ventilator, filter and phonation valve
89260910|NCT06185972|Experimental|Experimental: Treatment Arm|All biopsy confirmed breast cancer patients undergoing MRI-guided ultrasound-stimulated microbubble treatment plus radiation therapy
89260911|NCT06185959||Patients in a Psychoeducation and Process Group for Asian and Asian American Psychiatric Outpatients|
89260912|NCT06185946||ultrasonography group|
89260913|NCT06185946||mammoragraphy group|patient with ultrasoundy only
89260914|NCT06185946||CT group|pateint with postive node undergo further staging
89260915|NCT06185946||MRI group|patient whit postive node with staging
89260916|NCT06185920||Patients with severe infection.|Patients with severe infection treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
89260917|NCT06185907||Geriatric gastric cancer patients|
89260918|NCT06185855||Malignant|Malignant Breast Lesion Group: This group would include patients diagnosed with breast cancer who have undergone breast lesion surgery and had preoperative ultrasound examinations at the hospital.
89260919|NCT06185855||Benign|Benign Breast Lesion Control Group: This group would consist of patients with benign breast lesions, who also underwent breast lesion surgery and had preoperative ultrasound examinations.
89260920|NCT06185842|Experimental|Intervention group|breathing exercise, walking exercise and vaccination counseling
89260921|NCT06185842|No Intervention|Control group|
88805075|NCT03206489|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
88805076|NCT03015779|Experimental|experimental group|cultured autologous oral mucosal epithelial cell sheet
89260922|NCT06185829|Active Comparator|Usual neuroleptanalgesic treatment|
89260923|NCT06185829|Experimental|Hypnoanalgesia|
89260924|NCT06185816|Active Comparator|Active Treatment|"ACTIVE treatment will be conducted by the study PIs, who are licensed pain physicians, Participants will receive 3 treatments, once weekly, for three weeks. Treatments are about 20 minutes long. The Stimpod being used is FDA cleared and is commercially available.~The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy"
89260925|NCT06185816|Sham Comparator|Non-Active Treatment|"Participants enrolled in the non-active arm will receive 3 treatments, once weekly, for three weeks. After the trial is completed, participants will be offered three free treatments.~The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation."
89260926|NCT06185777|Experimental|Exercise oncology counseling and referal|Identification & brief consultation Screening: Needs assessment for exercise therapy Information / educational talk Consultation with the patient Risk assessment (with physician clearance) Consultation Referral to exercise therapy
89260927|NCT06185751|Experimental|Part A Dose Escalation: WS-CART-CS1|"Undergo apheresis procedure for WS-CART-CS1 manufacturing.~Anti-multiple myeloma therapy may be given after leukapheresis and up to one week prior to the start of lymphodepleting chemotherapy at the discretion of the treating physician.~Lymphodepleting chemotherapy on days -5, -4, and -3.~Three days following the last dose of lymphodepleting chemotherapy (on Day 0), WS-CART-CS1 will be infused.~Part A is the dose escalation portion of the study with the starting dose of 0.5 x 10^6 cells/kg of WS-CART-CS1."
89260928|NCT06185751|Experimental|Part B Dose Expansion: WS-CART-CS1|"Undergo apheresis procedure for WS-CART-CS1 manufacturing.~Anti-multiple myeloma therapy may be given after leukapheresis and up to one week prior to the start of lymphodepleting chemotherapy at the discretion of the treating physician.~Lymphodepleting chemotherapy on days -5, -4, and -3.~Three days following the last dose of lymphodepleting chemotherapy (on Day 0), WS-CART-CS1 will be infused.~Part B is the dose expansion portion of the study. The dose of WS-CART-CS1 will be determined in Part A of the study."
89260929|NCT06185712|Experimental|Nurse-led disease management education|Individual patient education was provided, and patients were followed up by telephone at two-week intervals beginning the week after their clinic visit.
89260930|NCT06185712|No Intervention|Control Group|No interventions were performed other than routine clinical procedures.
89260931|NCT06185699|Other|N95/FFP2 masks during the whole working hours, and only took off it for less than 1 hour|Individuals (ı) who wore N95/FFP2 masks during the whole working hours, and only took off it for less than 1 hour. In order to detect the presence of Demodex mites, standard superficial skin biopsy (SSSB) was applied
89260932|NCT06185699|Other|3-ply surgical mask during all working hours, only took it off for less than 1 hour|Individuals who wore a 3-ply surgical mask during all working hours, only took it off for less than 1 hour.In order to detect the presence of Demodex mites, standard superficial skin biopsy (SSSB) was applied
89260933|NCT06185699|Other|control (who rarely used masks under pandemic conditions)|people who wore a 3-ply surgical mask for less than 3 days a week, less than 2 hours a day and spending time mostly at home during the day or plus those who worked alone all day in their rooms and who wear a 3-ply surgical mask for less than 1 hour during the day as required. In order to detect the presence of Demodex mites, standard superficial skin biopsy (SSSB) was applied
89260934|NCT06185673|Experimental|BB-301 Treatment|"The phase 1b component of the study is the dose escalation phase which will enroll up to 18 subjects in up to 3 dosing cohorts.~The phase 2a component of the study is the dose expansion phase which will enroll up to 12 subjects."
89260935|NCT06185621|Experimental|100mg aspirin group|Patients received oral 100mg aspirin, one tablet daily for 2 years
89260936|NCT06185608|Experimental|0.25% ropivacaine group|This group will receive a total of 15 mL of 0.25% ropivacaine.
89260937|NCT06185608|Active Comparator|0.5% ropivacaine group|This group will receive a total of 15 mL of 0.5% ropivacaine.
89260938|NCT06185608|Experimental|1% ropivacaine group|This group will receive a total of 15 mL of 1% ropivacaine.
89260939|NCT06185582|Experimental|Pain|A thermode stimulator of 3x3 cm will be placed on the areas and kept in place by means of Velcro tape. The temperature raises 1°C per second from a starting temperature of 32°C until itch reach or 46.5 °C. This temperature will be maintained for 2 minutes. Then the temperature will return to baseline temperature at a rate of 5°C /s.
89260940|NCT06185582|Experimental|Capsaicin|Capsaicin patches (dosage form: transdermal patch 8% Qutenza, Astellas) will be applied on one squared area (4x4 cm2). The patch will be left in place for 20 minutes after which it will be removed.
89260941|NCT06185556|Active Comparator|A: Irreversible electroporation|Irreversible electroporation (IRE) is a primarily non-thermal, local ablative technique that utilizes electrical pulses to destroy tumor tissue. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
89260942|NCT06185556|Active Comparator|B: Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
89260943|NCT06185530|Experimental|Participants undergo the cardiac tests: stress echocardiography with carotid ultrasound|
89260944|NCT06185530|Active Comparator|Participants undergo the cardiac test: CT coronary angiography|
89260945|NCT06185517|Experimental|Comprehension Phase|After an initial translation of the questionnaires into French, the aim of this phase is to ascertain the level of understanding of each questionnaire item and any suggestions, during a telephone or face-to-face interview.
88805077|NCT03015701|Experimental|Arm 1|Mifepristone 200 mg orally daily for two years
88805078|NCT03015701|Placebo Comparator|Arm 2|Placebo orally daily for two years
89260946|NCT06185517|Experimental|Validation Phase|The aim is to validate the French translation of the Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ).
89260947|NCT06185491|Experimental|HGI|Data collection from glucose monitoring systems. Dosage of glycated hemoglobin and glycated albumin
89260948|NCT06185478|Experimental|Imaging|
89260949|NCT06185413|Experimental|Intervention communities|A participatory system dynamics approach will be implemented by the municipal staff and research group.
89260950|NCT06185413|No Intervention|Comparison communities|No intervention will be applied, but according to the wait-list design, the participatory system dynamics approach will be implemented in the comparison community by the municipal staff after follow-up.
89260951|NCT06185400|Experimental|Arm1: Treatment Naive NSCLC|RC48+third-generation EGFR TKIs in treatment-naive patients harboring EGFR mutation and HER2 alterations
89260952|NCT06185400|Experimental|Arm2: Locally Progressed|This cohort includes ERBB2 altered patients after third-generation EGFR-TKIs treatment with locally or slowly progressed disease, who may continue to benefit from third-generation EGFR-TKIs treatment under investigators' evaluation.
89260953|NCT06185400|Experimental|Arm3: Extensively Progressed|This cohort includes ERBB2 altered patients after third-generation EGFR-TKIs treatment with extensively progressed disease, who may be less likely to benefit from third-generation EGFR-TKIs treatment under investigators' evaluation.
89260954|NCT06185374|Experimental|Text Message Intervention|Participants in the experimental arm will receive a series of instructional and motivational text messages, which will be sent starting 7-14 days before and until the day of the colonoscopy procedure.
89260955|NCT06185374|No Intervention|No Intervention|Participants will not receive text messages.
88805079|NCT04353089||Basic Life Support Participants|All persons attending certified Basic Life Support Courses in Denmark from 2016 to 2019
89260956|NCT06185361|Active Comparator|fluoxetine|selective serotonin reuptake inhibitors fluoxetine 20 mg for 12 weeks
89260957|NCT06185361|Active Comparator|desmopressin|0.2 mg desmopressin tablet for 12 weeks
89260958|NCT06185335|Experimental|Cohort 1|Subjects in Cohort 1 will receive ANB-010 at a dose 1. ANB-010 will be administered to the first subject in group 1. Not earlier than in 28 days, the investigational product will be administered to the next two subjects in Cohort 1 (with an interval of at least 24 hours).
89260959|NCT06185335|Experimental|Cohort 2|Subjects in Cohort 1 will receive ANB-010 at a dose 1. Not earlier than 28 days after the ANB-010 administration to the third subject in Cohort 1, the investigational product will be administered to the first subject in Cohort 2. Not earlier than 28 days after the ANB-010 administration to the first subject in Cohort 2, the investigational product will be administered to the next two subjects in Cohort 2 (with an interval of at least 24 hours).
89260960|NCT06185335|Experimental|Cohort 3|Subjects in Cohort 1 will receive ANB-010 at a dose 1. Not earlier than 28 days after the ANB-010 administration to the third subject in Cohort 2, the investigational product will be administered to the first subject in Cohort 3. Not earlier than 28 days after the ANB-010 administration to the first subject in Cohort 3, the investigational product will be administered to the next two subjects in Cohort 3 (with an interval of at least 24 hours).
89260961|NCT06185322|Active Comparator|Neck strengthening exercises group|10 sessions of physical therapy over two weeks.Each session will consist of 20 minutes of hotpack and transcutaneous electrical nerve stimulation and 10minutes of therapeutic ultrasound. Exercise sessions lasting 20minutes will consist of conventional neck isometric strengthening exercises under the supervision of a single physiotherapist. These exercises will be repeated 5 times each, twice daily. A brochure depicting each exercise,accompanied by a description,will be given to the patient.The patient will continue with the exercise program for 3 months and be reminded once a week via telephone.
89260962|NCT06185322|Experimental|Upper Cross Syndrome exercises group|10sessions of physical therapy over two weeks.Each session will consist of 20minutes of hotpack and transcutaneous electrical nerve stimulation and 10minutes of therapeutic ultrasound.Exercise sessions lasting 20minutes will consist of stretching and strengthening exercises under the supervision of a single physiotherapist.Strengthening exercises for the deep neck flexors,upper and middle trapezius,serratus anterior will be performed by the patient.Ten repetitions of each exercise,three times daily will be recommended.Stretching exercises will include those for the upper trapezius,pectoralis majör,levator scapula,suboccipital and sternocleidemastoid muscles and izometric neck flexion-extension exercises.These will be repeated 5times each,twice daily.A brochure depicting each exercise,accompanied by a description,will be given to the patient.The patient will continue with the exercise program for 3 months and be reminded once a week via telephone.
89260963|NCT06185283|Other|milled bar group|". O-Ball impression copings were snapped directly onto each O-Ball mini dental Implants. A Pick-Up closed tray impression technique was made using polyether impression material. MDI Lab Analog was pressed into the coping until a snap fit was observed .The impression was poured into dental stone to form a stone model for scanning~The cast was scanned using 3SHAPE TRIOS and the bar constructed throughout the production steps:~Step 1: Order Creation ,Step 2: scan the lab analog of MDI on the stone model scanned with D700 scanner. Step 3: CAD Designing (first select preparation in teeth view from canine to canine-click abutment button-choose restoration type (bar)-choose restoration material (wax) .Step 4: Sending to CAM for Manufacturing, Step 5: Manufacturing (cutting from disc of modeling wax)."
89260964|NCT06185283|Other|round bar|"Prefabricated plastic bar pattern (RHIN 83 OT BAR multi use) was pre scanned for standardization of all cases. After cast scanning the abutment copy was designed and again standardized for all MDI. The pre scanned bar was inserted over the copies. The same procedure for manufacturing was followed as that of milled -in bar.~The finished bar is brought to the patient's mouth, seated accurately. The denture is then tried, fitted and extensions adjusted in the usual manner. The denture fitting surface was; the hygienic space under the bar was blocked-out with wax.~plastic clip was adapted to their metal sleeve, adapted to the bar, the occlusion was checked and then they were picked-up using auto-polymerized acrylic resin while the patient was instructed to close lightly in centric occlusion. After finishing and polishing procedures, the mandibular denture was clinically remounted to adjust any interferences in the centric and eccentric the occlusal contacts."
89260965|NCT06185270||Patients undergoing minimally invasive distal gastrectomy for early gastric cancer|
88805080|NCT04353089||OHCA|Out-of-hospital cardiac arrest victims in Denmark from mid 2016 til mid 2019
89260966|NCT06185192|No Intervention|Placebo|Participants with HbA1c levels between 6.5-8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
89260967|NCT06185192|Experimental|Viome's Precision Nutrition Program (VPNP)|Participants with HbA1c levels between 6.5-8.9% (inclusive) are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
89260968|NCT06185127|Experimental|DK group|Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion). After the first 15 minutes, a bolus dose of 50 mg ketamine dissolved in 10 ml saline was given.
89260969|NCT06185127|Active Comparator|MF group|Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) and fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam and 150 μg of fentanyl were administered.
89260970|NCT06185114||Young (ages 21-50) requiring multiple extractions|Subjects aged 21-50 requiring multiple extractions will be consented. These subjects will undergo soft tissue, GCF, venous blood sampling and CBCT analysis to determine age-related factors associated with post-extraction wound healing.
89260971|NCT06185114||Old (ages 65-80) requiring multiple extractions|Subjects aged 65-80 requiring multiple extractions will be consented. The older subjects (compared to other group) will undergo soft tissue, GCF, venous blood sampling and CBCT analysis to determine age-related factors associated with post-extraction wound healing.
89260972|NCT06185101|Experimental|STEP-UP intervention group|Participants will engage in a behavioral intervention for pain self-management that incorporates educational podcasts and sessions with a community health worker.
89260973|NCT06185101|No Intervention|Control group|Members of the control group will not initially receive the STEP-UP intervention. After completing the 8-week follow-up telephone survey, individuals in the control group will be invited to take part in the STEP-UP intervention.
89260974|NCT06185088|Other|Participants with Ostomies|Patients who have ostomies, and who are already undergoing a minor procedure for routine health screening or other health matters as standard of care.
89260975|NCT06185049|Experimental|PROCARE+ 2.0 (with add-on modules) and two booster sessions.|In addition to core UP-A preventive intervention, PROCARE 2.0 will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include: rejection, bullying/cyberbullying, addictions, healthy lifestyle habits, exam stress management, ecoanxiety, parental expressed emotion. Two booster sessions would be included (at 6 and 12 months).
89260976|NCT06185049|Experimental|PROCARE+ 2.0 (with add-on modules) and a booster session.|In addition to core UP-A preventive intervention, PROCARE 2.0 will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include: rejection, bullying/cyberbullying, addictions, healthy lifestyle habits, exam stress management, ecoanxiety, parental expressed emotion. A booster sessions would be included at 6 months.
89260977|NCT06185049|Experimental|PROCARE+ 2.0 (with add-on modules) and with 12-month follow-up.|In addition to core UP-A preventive intervention, PROCARE 2.0 will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include: rejection, bullying/cyberbullying, addictions, healthy lifestyle habits, exam stress management, ecoanxiety, parental expressed emotion. Only follow-up would be conducted up to 12 months.
89260978|NCT06185023|Active Comparator|Low-intensity physical exercise|The participants will participate in a low-intensity non-aerobic exercise program for 2 weeks.
89260979|NCT06185023|Experimental|High-intensity physical exercise|The participants will take part in a high-intensity Aphasia Physical EXercise (APEX) intervention designed specifically for individuals with chronic post-stroke aphasia for 8 weeks.
89260980|NCT06184997|Placebo Comparator|CONTROL GROUP|Volunteer participants who will drink water
89260981|NCT06184997|Experimental|ISOTONIC DRINK GROUP|Volunteer participants who will drink Natural isotonic drink based on 20% Atlantic sea water, mixed with lemon and stevia.
89260982|NCT06184958|Active Comparator|Group A:Lidocaine group|5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
89260983|NCT06184958|Active Comparator|Group B:Ketamine group|0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
89260984|NCT06184958|Placebo Comparator|Group C:Placebo group|Placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
89260985|NCT06184932|Experimental|Home-based Arm and Hand Exercise (HAHE)|An occupational therapist (OT) will incorporate participants' preference, goals, and current function to co-create UL exercise activities with participants. The exercise activities will be based on real-life activities that participants are familiar with. During the 6-week TeleRehab period, participants will complete 30 one-hour sessions of UL exercise activities, on their own without immediate supervision.
89260986|NCT06184932|Experimental|Exergame|An occupational therapist (OT) will incorporate participants' preference, goals, and current function to select UL exercise activities with participants from the RehabKit program software. During the 6-week TeleRehab period, participants will complete 30 one-hour sessions of UL exercise activities, on their own without immediate supervision.
89260987|NCT06184906|Placebo Comparator|CONTROLS|Participants in the control arm will undergo a traditional weaning process. This involves primarily the use of industrial baby foods, with a gradual introduction of fresh foods. Legumes will be introduced at around 7-8 months, and fresh fish will be incorporated into the diet after one year of age.
89260988|NCT06184906|Experimental|Treated|"Participants in the experimental arm will follow a Mediterranean Diet (MD) weaning schema. This approach includes exclusively fresh foods that are part of the traditional MD, modified to suit infants. Key elements of this diet include:~Seasonal fruit and vegetables, such as broccoli and cauliflower, served as purees from the beginning of weaning.~A variety of fresh blue fish (e.g., anchovies, mackerel, flag fish, cod, sole) introduced at 7 months, seasoned with garlic and cherry tomatoes.~Use of spices and herbs like thyme, marjoram, rosemary, parsley, garlic, and onion to flavor meals.~Exclusion of salt; meals are instead enhanced with 2 g of Parmesan cheese for taste.~Avoidance of sweets."
89260989|NCT06181838|Active Comparator|Intervention|Standard therapy and lesion extraction
89260990|NCT06181838|Placebo Comparator|Control|Standard therapy without lesion extraction
89260991|NCT06181097|Experimental|negative pressure wound therapy|Both groups will have layered closure with 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. For the NPWT group, the Smith & Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility. For the standard dressing group, the same PICO dressing will be applied, but without the suction.
89260992|NCT06181097|Active Comparator|standard dressing|Both groups will have layered closure with 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. For the NPWT group, the Smith & Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility. For the standard dressing group, the same PICO dressing will be applied, but without the suction.
89260993|NCT06180889|Active Comparator|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days post-surgery.
89260994|NCT06180889|Experimental|KN060 Low (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 low dose once post-surgery.
89260995|NCT06180889|Experimental|KN060 Middle (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 middle dose once post-surgery.
89260996|NCT06180889|Experimental|KN060 Hight (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 hight dose once post-surgery.
89260997|NCT06179238|Other|Patient with urinary catheter receiving patient education|The population of the study consisted of urinary catheterized patients treated in the clinics of a Training and Research Hospital. G*Power power analysis was used to calculate the number of individuals constituting the sample. The effect size was set to 0.80, which is a high level according to Cohen for comparing the means of independent samples. To ensure that the statistical power of the study was above 95%, the sample size was set at a 5% significance level and the effect size was 0.5. (df = 68; t = 1.668) The sample size was calculated as 70 patients. The study is planned to be conducted with 35 patients for each of the two study groups.
89260998|NCT06179238|Other|Patient with urinary catheter without patient education|The population of the study consisted of urinary catheterized patients treated in the clinics of a Training and Research Hospital. G*Power power analysis was used to calculate the number of individuals constituting the sample. The effect size was set to 0.80, which is a high level according to Cohen for comparing the means of independent samples. To ensure that the statistical power of the study was above 95%, the sample size was set at a 5% significance level and the effect size was 0.5. (df = 68; t = 1.668) The sample size was calculated as 70 patients. The study is planned to be conducted with 35 patients for each of the two study groups.
89260999|NCT06179186|Experimental|Intense Pulsed Light|The hair from axilla of one side of the body will be removed with 4 sessions of Intense Pulsed Light
89261000|NCT06179186|Experimental|Diode laser|The hair from axilla of one side of the body will be removed with 4 sessions of Diode Laser
89261001|NCT06178484||Functional treatment|Functional treatment combines the use of splints, rehabilitation and muscle strengthening
89261002|NCT06178484||Surgical treatment|Surgical treatment means ACL tear repair
89261003|NCT06178094|Experimental|Video Diabetes Training group|"The data collection tools will apply in the first and second interviews and metabolic control variables will record.~Diabetes training videos will sent to the Training Group through smartphones after the first meeting as two episodes a week."
89261004|NCT06178094|No Intervention|control group|The data collection tools will apply in the first and second interviews and metabolic control variables will record.
89261005|NCT06177106|Other|Cohort A - history of > 2 Cutaneous squamous cell carcinoma (cSCC)|Participants who have a history of squamous cell skin cancer (n=23) will be exposed to acute solar simulated light (SSL). Participants must have sun damage on the forearm, based on a standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36). Each subject will act as his/her own control to minimize inter-subject variability. Subjects from each cohort will be matched based on age and gender.
89261006|NCT06177106|Other|Cohort B - no history of cSCC|Participants without a history of squamous cell skin cancer (n=23) will be exposed to acute solar simulated light (SSL). Participants must have sun damage on the forearm, based on a standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36). Each subject will act as his/her own control to minimize inter-subject variability.
89261007|NCT06176703|Experimental|Standard treatment with mobile application in diabetes mellitus patients|
89261008|NCT06176703|No Intervention|standard treatment without mobile application in diabetes mellitus patients|
89261009|NCT06170632|Active Comparator|Intervention group|Intervention group (IG): Patients with flare type SEMS placement
89261010|NCT06170632|Active Comparator|Control group (CG)|Control group (CG): Patients with plastic stent placement
89261011|NCT06169995|Experimental|Remimazolam Tosilate for Injection|
89261012|NCT06165991|Active Comparator|Group A: Bupivacaine|Group A: Participants were treated with 0.5% bupivacaine 20mL thoracic paraverteal block combined with Patient-controlled intravenous analgesia (PCIA) analgesia;
89261013|NCT06165991|Active Comparator|Group B: Bupivacaine with drainage tube|Group B: 0.5% bupivacaine 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA;
89261014|NCT06165991|Experimental|Group C: Liposomal bupivacaine|Group C: 1.33% liposomal bupivacaine 20mL thoracic paravertebral nerve block complex PCIA;
89261015|NCT06165991|Experimental|Group D: Liposomal bupivacaine with drainage tube|Group D: 1.33% liposomal bupivacaine 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA.
89261016|NCT06165809|Experimental|TQB3015 tablets|TQB3015 tables is administered as a single dose or multiple dose, 2-40mg once a day; Oral administration on fast condition, 21 days as a cycle.
89261017|NCT06165653|Experimental|Guided Meditation Intervention|
89261018|NCT06165653|No Intervention|Standard of Care|
89261019|NCT06164925||Inpatients of the Tartu University Hospital|"Inclusion Criteria:~Age of 18+ years, able and willing to sign the consent form, inpatients of the Tartu University Hospital, admitted within 72 hours before enrolment.~Exclusion Criteria:~Age of <18 years, inability or refusal to sign the consent form, pregnant or lactating women, more than 72 hours passed since admission, patients isolating with an infection."
89261020|NCT06162819|Experimental|GroupA|Amitriptyline group will be assessed at baseline and will be followed up at 6th week after treatment and at 12th week after treatment
89261021|NCT06162819|Experimental|Group B|Flunarizine group will be assessed at baseline and will be followed up at 6th week after treatment and at 12th week after treatment
89261022|NCT06159075|Experimental|Video with Childhood Maltreatment-Related Content|Participants will view a video of an actor describing the story of an individual who experienced childhood maltreatment and how they overcame its effects on their life.
89261023|NCT06159075|No Intervention|Control Video|Participants in this arm will view a same-length video with the same actor, but without a personal narrative of CM experience.
89261024|NCT06148389|Experimental|lowest dose group|4 subjects will be randomized to receive lowest dose of STSA-1301 subcutaneous injection or dose-matched placebo (First cohort)
89261025|NCT06148389|Experimental|low dose group|8 subjects will be randomized to receive low dose of STSA-1301 subcutaneous injection or dose-matched placebo (Second cohort)
89261026|NCT06148389|Experimental|middle dose group|8 subjects will be randomized to receive middle dose of STSA-1301 subcutaneous injection or dose-matched placebo (Third cohort)
89261027|NCT06148389|Experimental|high dose group|8 subjects will be randomized to receive high dose of STSA-1301 subcutaneous injection or dose-matched placebo (Fourth cohort)
89261028|NCT06148389|Experimental|highest dose group|8 subjects will be randomized to receive highest dose of STSA-1301 subcutaneous injection or dose-matched placebo (Fifth cohort)
89261029|NCT06131827|Experimental|Neural mobilization|Neural mobilization technique will be perormed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval for rest between each set for 4 days weekly for Six week.
89261030|NCT06131827|Experimental|Task based activities|Task based activities consisted of different type of task which will be performed with the doasage of 45 minutes per session 5 days weekly for 6 weeks.
89261031|NCT06131762|Experimental|Active release technique|ART performed from long sitting position, the therapist started by shortening the muscle or fascia of affected limb then apply very specific pressure with hand as we stretch tissue is lengthened. Active movement is done whenever possible according to the instructions given by therapist. ART for 8-10 minutes will be given.
88805081|NCT01068821|Active Comparator|Egg crate foam mattress|Patients will be placed on egg-crate foam mattress instead of a gel pad by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
88805082|NCT01068821|Active Comparator|Gel pad|Patients will be placed on gel pad instead of egg-crate foam mattress by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
89261032|NCT06131762|Experimental|Positional release technique|Positional release technique where participant lie supine with the affected limb out of the plinth and then by application of brief mechanical pressure on tender point with one fingertip in order to determine tenderness. The foot should then be positioned, most probably into pure plantarflexion and gentle fine-tuned by rotation, until the score in the tender point has reduce by at least 70%. This position is held for 90 seconds with 3 repetitions i.e. total of 270 seconds was given.
89261033|NCT06131658|Experimental|Functional motor control excercise|Functional motor control exercise Includes side plank with clamshell, Side plank with hip abduction, Side-lying hip abduction, Lateral monster walk, Hip hikes, Single leg squat, TKE with T-band-hip abduction All exercises done with 2 sets of 10 reps with 3 sessions per week for 6 weeks
89261034|NCT06131658|Experimental|conventional exercise|The conventional exercise included 4 stages of self-myofascial techniques, strengthening, and integration techniques. In the first phase, individuals did fascial release exercises using foam rolls, focusing on tensor fascia latae, iliotibial band, and hip adductor muscles, and tennis balls for the quadratus lumborum. The exercises were performed at high-intensity maximum pain tolerance for 30 seconds or low-intensity minimum pain tolerance for 90 seconds.
89261035|NCT06124950|Experimental|GTI Intervention|Participants will be provided with five GTI sessions (60-75 minutes/session).
89261036|NCT06124950|No Intervention|Standard Care|Standard clinical procedures for assisted reproduction and health education
89261037|NCT06124235|Experimental|Coated Miniscrew|Device Place stent for accurate position of miniscrew, x-ray, inserting miniscrew, xray for showing position of miniscrew, then use Visual analoge scale for pain assessment for first 7 days, peri-implant health and mobility check each month for 3 month and success rate after 4 month.
89261038|NCT06124235|Active Comparator|Uncoated Miniscrew|Device Place stent for accurate position of miniscrew, x-ray, inserting miniscrew, xray for showing position of miniscrew, then use Visual analoge scale for pain assessment for first 7 days, peri-implant health and mobility check each month for 3 month and success rate after 4 month.
89290415|NCT01329432|Sham Comparator|take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing
89290416|NCT01329432|Experimental|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
89290417|NCT03931434|Active Comparator|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
89290418|NCT03931434|Placebo Comparator|Placebo|The Placebo does not contain any Aged Garlic Extract (AGE)
89261039|NCT06121934|Experimental|Carica Papaya Leaf Extract|"The study patients will be followed for clinical and laboratory endpoints in the hospital until study day 5 (or daily as outpatients from discharge to day 5) and reviewed at an outpatient visit at week 2 after discharge.~The patients will be assigned to one of the two treatment arms after randomization:~1) Active drug: Carica papaya leaf extract (CPLE) 500mg 2 capsule t.i.d for 5 days~The oral capsule of CPLE and placebo will be provided by the Institute of Technology Transfer and Innovation (ITTI), an institute in Bangladesh Council of Scientific and Industrial Research (BCSIR), with appropriate masking for a double-blind study. On receipt, the medications will be stored in a secure area by the manufacturer's recommendation."
89261040|NCT06121934|Placebo Comparator|Placebo|"The study patients will be followed for clinical and laboratory endpoints in the hospital until study day 5 (or daily as outpatients from discharge to day 5) and reviewed at an outpatient visit at week 2 after discharge.~The patients will be assigned to standard treatment with placebo after randomization:~Placebo: visually matched placebo 2 capsule t.i.d for 5 days~The oral capsule of CPLE and placebo will be provided by the Institute of Technology Transfer and Innovation (ITTI), an institute in Bangladesh Council of Scientific and Industrial Research (BCSIR), with appropriate masking for a double-blind study. On receipt, the medications will be stored in a secure area by the manufacturer's recommendation."
89261041|NCT06120725|Active Comparator|ticagrelor arm|The ticagrelor arm will receive (180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day)
89261042|NCT06120725|Active Comparator|clopidogrel arm|The clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset followed by 75 mg once daily from the 2nd day to the 90th day)
89261046|NCT06081530|Experimental|Part A: BI 3802876 dose group 1|
89261047|NCT06081530|Experimental|Part A: BI 3802876 dose group 2|
89261048|NCT06081530|Experimental|Part A: BI 3802876 dose group 3|
89261049|NCT06081530|Experimental|Part A: BI 3802876 dose group 4|
89261050|NCT06081530|Experimental|Part A: BI 3802876 dose group 5|
89261051|NCT06081530|Experimental|Part A: BI 3802876 dose group 6|
89261052|NCT06081530|Placebo Comparator|Part A: Placebo|
88805083|NCT03830021|Experimental|Salt reduction program|Salt reduction program.
88805084|NCT03830021|Active Comparator|Healthy lifestyle program|Healthy lifestyle program.
89261053|NCT06081530|Experimental|Part B: BI 3802876|
89261054|NCT06081530|Placebo Comparator|Part B: Placebo|
89261055|NCT06078488|Experimental|Intervention|Individualized and Protocolized Nutrition Care Bundle with Nutritional Supplementation, Education and Support by Nurses trained in Nutritional Management and Dietitians.
88816224|NCT02437188|Experimental|ACT plus TAU|"Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call booster intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period."
89261056|NCT06078488|Experimental|Control|Nursing Care by Nurses trained in Nutritional Management, with or without Supplements.
89261057|NCT06074471|Experimental|MS-SCBPB Group (n=22)|"receive ultrasound-guided supraclavicular brachial plexus block with total volume 20 mL bupivacaine (concentration 0.20%) 9 ml Bupivacaine+9ml lignocaine +2ml Dexamethasone 8mg "
89261058|NCT06074471|Active Comparator|SCBPB Group (n=22):|"receive ultrasound-guided supraclavicular brachial plexus block with total volume 20 mL bupivacaine (concentration 0.5%) 18 ml Bupivacaine+2ml Dexamethasone 8mg"
89261059|NCT06065865|Experimental|Guidance document|The intervention that is investigated in this study is a guidance document, which is used to individualize the treatment trajectory for the parent-child dyad. This guidance document includes different factors that are important in deciding on the order of different types of therapy within one treatment trajectory. The document will guide the therapist in tailoring the treatment trajectory towards the needs of the dyad. The treatment trajectory can consist of EMDR-therapy for the parent, EMDR therapy for the child and NIKA for the parent-child relationship. The guidance document will guide the therapist in deciding on the order of the different therapies.
89261060|NCT06060054|Experimental|Sleep Opportunity|Overnight sleep wearing the device
89261061|NCT06060054|Experimental|Sleep Deprivation|Overnight awake wearing the device
89261062|NCT06058598|Experimental|Intervention Group|Group performing exercise training and receiving standard care
89261063|NCT06058598|Experimental|Control Group|Group receiving lifestyle counseling and receiving standard care
89261064|NCT06052527||Active Covid-19 Infection|Patients with positive SARS-CoV-2 rapid antigen test results within 60 days before the start of the study will be administered pre-defined TCM prescriptions recommended by the Autonomous Treatment System based on machine learning
89261065|NCT06052527||Post-Covid-19 Syndrome|Patients with positive Covid-19 antigen test results obtained more than 60 days before the start of the study will be administered pre-defined TCM prescriptions recommended by the Autonomous Treatment System based on machine learning.
89261066|NCT06052527||Influenza|Patients with negative SARS-CoV-2 rapid antigen test results and who are diagnosed with influenza will be administered pre-defined TCM prescriptions recommended by the Autonomous Treatment System based on machine learning.
89290419|NCT05760196|Experimental|Recurrent or metastatic advanced head and neck malignancy|Patients with a clear pathological diagnosis, imaging diagnosis, and history, no clear recommended standard treatment or inability to tolerate standard treatment, and a clear measurable lesion
89290420|NCT03740568|Other|Normal Progesterone group|Progesterone level >10.64 ng/mL on day 4 of progesterone supplementation
89261067|NCT06030804|Experimental|Dexmedetomidine group|A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/h till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
89261068|NCT06030804|Placebo Comparator|Control group|Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
89261069|NCT06024551|Experimental|Intervention Group|Patients who receive telerehabilitation
89261070|NCT06024551|Other|Control Group|Patients who receive home exercise program
89261071|NCT06010511||Memory clinic patients|We will prospectively include patients with memory complaints and/or vascular brain abnormalities (n=50; over 65 years of age) from the memory clinic (or geriatric clinic) at one of their first visits, prior to any diagnosis.
89261072|NCT06005818|No Intervention|Arm 1: MRD negative patients|
89261073|NCT06005818|Active Comparator|Arm 2 MRD positive patients|Patients are treated with Pembrolizumab 400 mg IV q 6 weeks for a total of 1 year
89261074|NCT06000865|Active Comparator|Interactive action video-game training (AVG)|AVG using a Nintendo Switch gaming station will be administered in 20 sessions over 10 weeks (45 minutes per session, 2 sessions per week). Participants will be in standing position with game controllers or sensors attached to the body while playing games involving muscle stretching and strengthening exercises.
89261075|NCT06000865|Experimental|Conventional physical training (PT)|Participants in the PT will receive 45-minutes conventional physical training.
88816262|NCT02494713|Other|ADT + chemotherapy|Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.
88816263|NCT01650636|Experimental|Cognitive Behavioral Stress Management|
88816264|NCT01650636|Active Comparator|Health Information|
89261076|NCT05996627|Experimental|Arm I (Belumosudil)|Patients receive belumosudil PO QD or BID if taken with strong CYP3A inducers or proton pump inhibitors for days 1 through 28 of each cycle. Cycles repeat every 28 days for a total of 11 cycles, followed by one cycle of tapering prior to discontinuation, in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study.
89261077|NCT05996627|Placebo Comparator|Arm II (Placebo)|Patients receive a placebo PO QD or BID if taken with strong CYP3A inducers or proton pump inhibitors for days 1 through 28 of each cycle. Cycles repeat every 28 days for a total of 11 cycles, followed by one cycle of tapering prior to discontinuation, in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study.
89261078|NCT05974020|Experimental|Group 1- Aerobic Exercise|Group 1 participants will receive general foot care instructions and education on appropriate footwear selection, foot intrinsic muscle training, and in addition, an aerobic exercise protocol.
89261079|NCT05974020|Experimental|Group 2- Intrinsic Muscle Training|Group 2 participants will receive general foot care instructions and education on appropriate footwear selection, along with an exercise protocol focusing on foot intrinsic muscle training.
89261080|NCT05974020|Experimental|Group 3- Control Group|Group 3 will receive only general foot care instructions and education on appropriate footwear selection.
89261081|NCT05972473|Active Comparator|Aflibercept|Drug: Aflibercept 2mg/eye; Intraocular injection
89261082|NCT05972473|Experimental|IBI302 dose 8mg|Drug: IBI302 8mg/eye; Intraocular injection
89261083|NCT05971251|Experimental|Dose Level 1:|45 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
89261084|NCT05971251|Experimental|Dose Level 2|60 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
89261085|NCT05971251|Experimental|Dose Level 3|75 µg/kg Loncastuximab Tesirine every 21 days + Acalabrutinib 100 mg BID for 12 cycles
89261086|NCT05971251|Experimental|Dose level 4:|90 µg /kg Loncastuximab Tesirine (for first 2 cycles followed by 75µg/kg for subsequent 10 cycles) + Acalabrutinib 100 mg BID for a total of 12 cycles.
89261087|NCT05970419|Experimental|High power laser acupuncture group|This group will receive high power laser acupuncture (HPLA) +conventional therapy
89261088|NCT05970419|Active Comparator|Conventional treatment group|This group will receive sham laser and The first line of chronic nonspecific low back pain treatment is the conventional treatment.
89261089|NCT05959135||Diabetic term pregnant patients|Compare the antral cross-sectional area (CSA) with gastric ultrasonography and estimated gastric volumes calculated with Perlas and Roukhomovsky mathematical models
89261090|NCT05959135||Non-Diabetic term pregnant patients|Compare the antral cross-sectional area (CSA) with gastric ultrasonography and estimated gastric volumes calculated with Perlas and Roukhomovsky mathematical models
89261091|NCT05952635|Experimental|Tip bendable suction ureteral access sheath (S-UAS) group|Patients will use S-UAS during flexible ureteroscopy.
89261092|NCT05952635|No Intervention|Traditional ureteral access sheath group|Patients will use traditional UAS during flexible ureteroscopy.
89261093|NCT05946408|Experimental|Supervised Antenatal Exercises|Supervised antenatal exercises twice a week an antenatal education
89261094|NCT05946408|Active Comparator|Antenatal Education|Antenatal education only
89261095|NCT05939752||patient|Patients with an indication for ibrutinib treatment for hematologic reasons
89261096|NCT05916807|Experimental|Stabilization Exercises|Twenty-six (26) patients will be treated with stabilization exercises in breast feeding females suffering from scapular dyskinesia.
89261097|NCT05916807|Experimental|Posture Training|Twenty-six (26) patients will be treated with posture training of breast-feeding females suffering from scapular dyskinesia.
89261098|NCT05907070|Experimental|Mandala group|Mandala drawing and coloring on paper
89261099|NCT05907070|Experimental|Value clarification group|Value clarification by writing on paper
89261100|NCT05907070|No Intervention|Control group|Routine nursing care
88805085|NCT04780061|Experimental|Treatment|"Specific Product: Vitamin D3 50,000 IU~Formulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period~Specific Product: Vitamin K2/D~Formulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3).~Dose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day.~Specific Product: Vitamin C/Zinc~Formulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day."
88805086|NCT04780061|Placebo Comparator|Control|"Specific Product: Vitamin D3 50,000 IU~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg~Specific Product: Vitamin K2/D~Placebo Equivalent: Medium chain triglyceride oil~Specific Product: Vitamin C/Zinc~Placebo Equivalent: microcrystalline cellulose capsule, 350 mg"
89261101|NCT05896150|Experimental|Intercostal cryoanalgesia AND single-injection paravertebral block|"Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery~Cryoanalgesia 5 cm lateral to the neuraxial, on the inferior costal border, CO2 at (-)50C to (-)70C for 2 minutes, repeated on 7 costal levels (T3-T9), after the lung resection and before chest closure."
89261102|NCT05896150|Active Comparator|Single-injection paravertebral block|-Videothoracoscopic-guided single-injection paravertebral block at T5 with 0.4 mL/kg of Bupivacaine 0.5% with adrenalin 5 mcg/mL (maximum 40 mL) at the beginning of surgery
89261103|NCT05884840|Experimental|Intervention group PAD screening program|Patients aged 50-74 years free of any symptomatic or history of CVD and a Framingham-REGICOR risk ≥7%, will be candidates for PAD screening program using REASON's function predicative capacity
89261104|NCT05884840|No Intervention|Control group PAD screening program|Patients aged 50-74 years free of any symptomatic or history of CVD will be candidates as a comparison group to calculate the cost-utility and reduction of CVD risk and events.
88805087|NCT01070693|Experimental|Prolene Hernia System device|Inguinal hernia repair either with a bilayer mesh (PHS)
88805088|NCT01070693|Experimental|Lichtenstein|Inguinal hernia repair with the Lichtenstein technique
89261105|NCT05875142|Active Comparator|T - Digital Tutorial overview|A digital tutorial consisting of a curriculum dashboard for review of 10(?) modules, including videos, PDFs, text and quizzes, which are to be self-administered over two weeks. Modules remain available during the 10-week post tutorial period. Participants receive weekly contact encouraging engagement in all of the materials available to them.
89261106|NCT05875142|Experimental|TM - Digital Tutorial plus training Materials|Participants receive the digital tutorial (T) as described above plus access to 10 modules of digital training materials released weekly over the 10-week post tutorial period.
89261107|NCT05875142|Experimental|TMC - Digital Tutorial plus training Materials plus feedback and Coaching|Participants receive the digital tutorial (T) plus the digital Training materials as described in the two arms above plus they submit audio recordings of sessions with clients and receive feedback on their application of CRAFT and coaching on how to improve.
89261108|NCT05869617|Active Comparator|Land-based exercise|Traditional active exercise in an land-based setting (i.e., gym) has been shown to be effective in improving chronic pain management.
89261109|NCT05869617|Experimental|Aquatic exercise|Exercise completed in a therapy pool with warm water that is matched to the active comparator.
89261110|NCT05856019|Experimental|J Stroke Myofascial Release|Patient is in prone lying position with foot supported. Pressure is applied with the heel of the opposite hand, while a stroke in the shape of the letter J is applied in the direction of the restriction, with two or three fingers, which creates some torque at the end. Myofascial Release techniques will be performed for 20 repetitions.
89261111|NCT05856019|Active Comparator|Ischemic Release on Gastrocnemius through Dry Cupping|Dry cupping will provided to the subjects thrice a week for 4 weeks in the dry cupping therapy group, a plastic cupping bell will be used. Cups will applied to the painful site for 10 minutes in each session. A manual hand pump was used to create the vacuum for suction. The intensity of the vacuum will based on subject tolerance.
89261112|NCT05849584||Pregnant women|
89261113|NCT05847478|Experimental|Auricular acupressure therapy group (AAT)|The participants will be randomly assigned to receive the auricular point patch therapy. The intervention period is 3 months.
89261114|NCT05847478|Experimental|Intermittent low carbohydrate diet group (ILCD)|The participants will be randomly assigned to receive the intermittent low carbohydrate diet. The duration of the study is 3 months, including 1-month intervention period and 2-month self maintenance period.
89261115|NCT05773599|Experimental|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. 4 sessions of laughter yoga will be applied to the experimental group with a low sleep quality score, one day apart. Afterwards, sleep quality and life satisfaction will be evaluated with the posttest.
89261116|NCT05773599|No Intervention|kontrol|A pre-test will be applied to evaluate sleep quality and life satisfaction. The control group with a low sleep quality score will not receive any intervention. In parallel with the experimental group, sleep quality and life satisfaction will be evaluated again with the posttest.
89261117|NCT05763212|Active Comparator|Reverse Walking+Baseline treatment|Conventional treatment was given then received Reverse Walking Training which was provided for 7 min per set, with approximately 3 min of inter-set rest, for a total training duration of 60 min/day, 3 days/week for 3 successive months .
89290421|NCT03740568|Experimental|Low Progesterone group|Progesterone level <10.64 ng/mL on day 4 of progesterone supplementation
89290422|NCT00252239|Active Comparator|1|tenecteplase
89290423|NCT00252239|Active Comparator|2|tissue plasminogen activator, tPA
89290424|NCT01126944|Experimental|system heart mate II|left ventricular assist device
89290425|NCT01126944|No Intervention|normal medical care|Optimal medical treatment for heart failure according to international guidelines
89261118|NCT05763212|Experimental|Whole Body Vibration + Reverse Walking+Baseline treatment|"Conventional Physical Therapy Treatment was given as a baseline treatment which includes Stretching, Range of motion exercises, and Strengthening exercises) performed for 10 min.~Reverse Walking Training which was provided for 7 min per set, with approximately 3 min of inter-set rest, for a total training duration of 30 min/day, 3 days/week for 3 successive months After that Group received Whole Body Vibration including three vibration sessions per week for three months. The participants have to carry out each set of vibration for 2 min in the first month, and then it was increased to 3 min in the second and 5 min in the third month. The rest period between each set was 1 min in the first month, then it became half a minute in the second and third month. Total training duration is 30 min/day, 3 days/week for 3 successive months."
89261119|NCT05759754|Experimental|Traditional Chinese Medicine treatment group|"Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W>30kg), 2 times a day for 12 weeks, orally, as an add-on to any ongoing treatment, including ACE inhibitors/ angiotensin II receptor blocker.~The GSJYF samples were made and packed by Shanghai Fangxin Pharmaceutical Technology Co., LTD. with lot number of 20230830.~Patients receiving a stable dose of ACEI/ARB will be continued."
89261120|NCT05759754|Other|Control group|Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
89261121|NCT05758779|Experimental|Coronary CT scan visualized for patient|The patient is allowed to see the CT image of his/hers coronary vessels, including oral describtion of the findings.
89261122|NCT05758779|No Intervention|Coronary CT scan NOT visualized for patient|The patient is not allowed to see the CT image of his/hers coronary vessels.
89261123|NCT05755087|Experimental|Treatment (Tegavivint)|Patients receive tegavivint IV on study. Patients also undergo CT and/or PET and undergo blood sample collection throughout the trial.
89261124|NCT05743270|Experimental|LA Cohort: RP3 in combination with CCRT followed by nivolumab in Locally Advanced SCCHN|RP3 will be administered via direct intratumoral injection or via CT, ultrasound, or laryngoscopy guided intratumoral injection into superficial, subcutaneous (SC), or nodal lesions and into deeper lesions, including visceral lesions.
89261125|NCT05743270|Active Comparator|LA Cohort: concurrent chemoradiation therapy in Patients With Locoregionally Advanced SCCHN|standard-of-care CCRT (defined as intensity-modulated radiation therapy [IMRT] and cisplatin
89261126|NCT05743270|Experimental|R/M Cohort:RP3 in combination with carboplatin, paclitaxel and then nivolumab in R/M SCCHN|RP3 will be administered via direct intratumoral injection or via CT, ultrasound, or laryngoscopy guided intratumoral injection into superficial, subcutaneous (SC), or nodal lesions and into deeper lesions, including visceral lesions.
89261127|NCT05697549|Experimental|cognitive behavior language therapy|Cognitive behavior language therapy is an extensive form of CBT. And it is focused on the treatment of speech-language related problems. CBLT helped the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. The main aim of CBLT is to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and AAC.
89261128|NCT05695937|Placebo Comparator|DICA-HF + placebo|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus placebo of both phytosterol and krill oil during 120 days.
89261129|NCT05695937|Experimental|DICA-HF + phytosterol|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of phytosterol and placebo of the krill oil during 120 days.
89261130|NCT05695937|Experimental|DICA-HF + krill oil|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of krill oil and placebo of phytosterol during 120 days.
89261131|NCT05695937|Experimental|DICA-HF + phytosterol + krill oil|Participants allocated into this arm (n= 24) will receive the DICA Br adapted to FH (DICA-HF) plus 2g/day of phytosterol and 2g/day of krill oil during 120 days.
89261132|NCT05679518|Experimental|ConquerFear intervention|Participants in the ConquerFear intervention group will receive a manualized intervention, consisting of 6 therapist-led individual sessions.
89261133|NCT05679518|Experimental|CALM intervention|Participants in the CALM intervention group will receive a semi-structured, manualized, individual psychotherapy intervention consisting of 3-6 individual therapy sessions.
89261134|NCT05679518|Active Comparator|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 individual sessions including 2 relaxation training sessions, 2 dietetic consultation sessions, and 2 exercise sessions, which will be led by a trained therapist, a registered dietitian, and an exercise physiologist, respectively.
89261135|NCT05673486|Experimental|PENG block + multimodal IV analgesia|PENG block + multimodal IV analgesia (Nefopam, Paracetamol, Morphine)
89261136|NCT05673486|Active Comparator|Multimodal analgesia alone|Multimodal IV analgesia (Nefopam, Paracetamol, Morphine)
89261137|NCT05654337|Experimental|Dietary and physical activity plan and advice on lifestyle change|Dietary and physical activity schedules and instructed lifestyle change advice provided by a trained health coach and dietary education provided by a trained and licensed dietitian to the obese and overweight at the primary care centre.
89261138|NCT05654337|No Intervention|Routine care for cases with obesity and overwieght|Adults with obesity and overweight attending routine primary care clinics
89261139|NCT05651685||TDApp2|This cohort will use TDApp2: an eHealth tool that formulates participatory, individualized, explainatory and automated treatment recommendations for patients with Attention Deficit Hyperactivity Disorder
89261140|NCT05651009|Experimental|Control group|Cementless Triathlon Tritanium 3D printed TKA
89261141|NCT05651009|Experimental|Study group|GMK Sphere cementless 3D printed TKA
89261142|NCT05638737|Experimental|AZD4831|AZD4831
89261143|NCT05638737|Placebo Comparator|Placebo|Placebo
89261144|NCT05611879|Experimental|Neoadjuvant therapy of Tislelizumab with chemotherapy+surgery|Participants will receive neoadjuvant Tislelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection.
89261145|NCT05604170|Experimental|Ganaxolone (GNX) oral suspension, 3 times a day (TID)|
89261146|NCT05598840|Experimental|APP group|Four months before surgery, the C4T APP, in addition to standard protocol, will be provided to all the patients randomized in the APP group.
89261147|NCT05598840|Active Comparator|Normal VLCD (Very Low Calory Diet) group|Normal preoperative standard protocol will be provided to all the patients randomized in the normal group.
89261148|NCT05588466|Active Comparator|CDS alone|This arm will only receive the CDS.
89261149|NCT05588466|Active Comparator|CDS plus practice facilitation|This arm will receive the CDS and practice facilitation.
89261150|NCT05574920|Experimental|Al18F-NOTA-FAPI-04 PET/CT|Inject Al18F-NOTA-FAPI-04 and then perform PET/CT scan.
89261151|NCT05574907|Experimental|68Ga-FAPI PET/CT|Inject 68Ga-FAPI and then perform PET/CT scan.
89261152|NCT05571670||Patients treated with PI3K/AKT/mTOR inhibitors for cancer|Patients with cancer being treated with PI3K/AKT/mTOR inhibitors will be studied prospectively for the impact of treatment on bile acid metabolism as a function of drug-induced acute insulin resistance. Treatments will be selected by patients' treating oncologist based on standard of care.
89261153|NCT05560386|Experimental|Text messaging program|Enrolled participants received the pilot text messaging program.
89261154|NCT05560386|Experimental|Virtual peer education|Enrolled participants received a virtual peer education diabetes prevention program.
89261155|NCT05517330|Experimental|Treatment Cohort|"Tislelizumab administration on days 1 and 22, and afatinib continuous administration from days 1 to 42~Standard of care surgery"
89261156|NCT05516589|Experimental|Treatment Cohort|"Participants will receive~TP chemotherapy every 3 weeks x 2 cycles (Nab-paclitaxel 260mg/m^2 IV on day1, Cisplatin 75mg/m^2 IV on days 1-3);~Tislelizumab 200mg IV every 3 weeks x 2 cycles;~Afatinib 30mg PO everyday x 6 weeks."
89261157|NCT05492591|Experimental|Group 1|5 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
89261158|NCT05492591|Experimental|Group 2|6 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
89261159|NCT05492591|Experimental|Group 3|7 μg/kg of peginterferon α1b for injection in patients with herpes zoster.
89261160|NCT05492591|Experimental|Group 4|Both valacyclovir tablets and 6 μg/kg of peginterferon α1b for injection plan to be used in patients with herpes zoster.
89261161|NCT05492591|Experimental|Group 5|Both valacyclovir tablets and 7 μg/kg of peginterferon α1b for injection plan to be used in patients with herpes zoster.
89261162|NCT05492591|Active Comparator|Group 6|Only valacyclovir tablets in patients with herpes zoster, positive drug control group.
88805089|NCT02171819|Experimental|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1, 7.5 mcg HA per dose
89261163|NCT05467423|Active Comparator|Standard-dose|The standard-dose arm takes one 100mg of iron per day together with a meal, no matter breakfast, lunch or dinner - one tablet a day.
89261164|NCT05467423|Experimental|Low-dose|The low-dose arm 12mg of iron a day. The first 6mg tablet in the morning on an empty stomach and the second 6mg tablet in the evening either one hour before or after eating - two tablets a day.
89261165|NCT05462912|Other|Open|Each participant will be evaluated at baseline, when the customized foot orthoses will be made, and the corresponding tests will be conducted.
89261166|NCT05460767|Experimental|IBI363|Single arm
89261167|NCT05446129|Experimental|Cohort A: Ezabenlimab + BI 765063|
89261168|NCT05446129|Experimental|Cohort B: Pembrolizumab + BI 765063|
88805090|NCT02171819|Experimental|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1, 15 mcg HA per dose.
88805091|NCT02171819|Placebo Comparator|Placebo|Phosphate buffered saline
89261169|NCT05434741|Experimental|CBT Group|This 12-week intervention program leverages evidence-based traditional and contemporary CBT strategies, with the goal of improving the psychological and physical functioning of older people with HIV by providing education and support to learn strategies to: a.) better manage stressors associated with HIV and aging (e.g., treatment access and engagement, and multi-morbidity), and b.) increase health-promoting behaviors (e.g., physical activity).
89261170|NCT05434741|Experimental|Information-only Group|"Participants in the control group will receive a one-time trifold brochure titled HIV: 50 Years or Older."
89261171|NCT05422573|No Intervention|Standard of care|Pre-test genetic counseling appointment with results returned by phone or EHR. Post-test appointment available upon request.
89261172|NCT05422573|Experimental|Efficiency|Pre-test genetics education by educational video with an OPTIONAL call with a genetic counselor to address questions. Pre-test appointment available by request. Post-test genetic counseling appointment.
89261173|NCT05422573|Experimental|Flipped|Pre-test genetics education by educational video with a REQUIRED call with a genetic counselor to address questions. Pre-test appointment available by request. Post-test genetic counseling appointment.
89261174|NCT05413889|Experimental|intervention group (IG)|The IG will consist of placing the Epic 30-day unplanned readmission risk score in the story board of providers - If a patient is identified as having a high risk of readmission defined as readmission risk >20%, a link to transitional and supportive care services (TSC) will be appear in the story board
89261175|NCT05413889|No Intervention|control group (CG)|The CG will have the same transitional and supportive care services (TSC) orders available to them; however, they will not have the risk of readmission score present in their workflow
89261176|NCT05398328|Active Comparator|metal appliance + fixed retainer|fixed metal appliance MBT 0.022'' slot in active phase followed by bonded wire retainer
89261177|NCT05398328|Experimental|esthetic appliance + fixed retainer|fixed ceramic appliance MBT 0.022'' slot in active phase followed by bonded wire retainer
89261178|NCT05398328|Active Comparator|metal appliance + removable retainer|fixed metal appliance MBT 0.022'' slot followed by removable clear termoplastic retainer
89261179|NCT05398328|Experimental|esthetic appliance + removable retainer|fixed ceramic appliance MBT 0.022'' slot followed by removable clear termoplastic retainer
89261180|NCT05398172|Experimental|treatment|3 treatments once a month
89261181|NCT05381363|Experimental|Intervention: Inhaled Interferon α2b|Inhaled Interferon α2b (10U/ml)
89261182|NCT05381363|Other|Intervention: Standard of Care|Standard of care treatment will be provided according to management guideline.
89261183|NCT05371470|Experimental|Cardiac rehabilitation plus voice analysis|Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care and utilize a voice analysis smartphone app.
89261184|NCT05371470|No Intervention|Cardiac rehabilitation only|Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care.
89261185|NCT05369806|Experimental|Interactive two-way SMS dialogue|Participants will receive automated SMS messages with prompts to reply. They will have the ability to both respond to and initiate SMS dialogue. Trained Study Nurses will monitor and respond to participant messages. The NLP model will be applied to messages and will highlight those determined to be urgent.
88805092|NCT02172755|Experimental|Elderly subjects|14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
88805093|NCT02172755|Experimental|Young subjects|16 young subjects aged between 18 and 40 years During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
88805094|NCT02173535|Experimental|etafilcon test contact lens Variant AP|
88805095|NCT02173535|Experimental|etafilcon test contact lens Variant JG|
89261186|NCT05365178|Experimental|TQB3616 capsule + Fulvestrant injection|"TQB3616 capsule:~180mg was given orally with meals or within 2 hours after meals, once a day， every 28 days for a cycle.~Fulvestrant injection:~500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15"
89261187|NCT05365178|Placebo Comparator|Placebo capsule + Fulvestrant injection|"Placebo capsules:~0mg was given orally with meals or within 2 hours after meals, once a day, every 28 days for a cycle.~Fulvestrant injection:~500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15"
89261188|NCT05351801|Active Comparator|THC (Dronabinol)|Target dose of 10mg per day.
89261189|NCT05351801|Active Comparator|CBD (Epidolex)|Target dose of 800 mg per day.
89261190|NCT05351801|Active Comparator|THC + CBD (Nabiximols)|Target dose of 10.8 mg / 10 mg per day.
89261191|NCT05351801|Placebo Comparator|Placebo|Identical in appearance to the three active comparators.
89261192|NCT05321264|Experimental|Intervention|The intervention is defined as educational support (improving the knowledge of the disease, identification of risks and consequences), behavioral support (promoting skills related to personal, home, and environmental self-care) and attitudinal support (reflecting on benefits and risks).
89261193|NCT05321264|No Intervention|Control|Control group will receive the usual strategy of a health service provider institution.
89261194|NCT05294640|Experimental|Bacteriostatic Saline as Local Anesthesia|Patients receiving bacteriostatic saline as local anesthesia for in-office minor eyelid procedures at University of California, San Francisco Medical Center, Oculoplastics department
89261195|NCT05294640|Active Comparator|Lidocaine with Epinephrine as Local Anesthesia|Patients receiving lidocaine with epinephrine as local anesthesia for in-office minor eyelid procedures at University of California, San Francisco Medical Center, Oculoplastics department
89261196|NCT05221866|No Intervention|Control|UControlPain App with only data collection function. No provider-facing prescription intervention.
89261197|NCT05221866|Active Comparator|UControlPain educational app only|UControlPain app with education components. No provider-facing prescription intervention.
89261198|NCT05221866|Active Comparator|UControlPain app AND provider facing tool|UControlPain app with education components and provider-facing prescription intervention.
89261199|NCT05221866|Active Comparator|Provider facing tool only|UControlPain App with only data collection function. Provider-facing prescription intervention.
89261200|NCT05216094|Experimental|smart phone intervention group|smart phone intervention group stroke subjects completed smart phone App tasks with affected upper limb or bilateral arm movement for 12 weeks
89261201|NCT05216094|Active Comparator|conventional group|stroke subjects receive conventional rehabilitation home program for 12 weeks
89261202|NCT05202223|Experimental|Harmony at HOME|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
89261203|NCT05195528|Experimental|Vonoprazan 10 mg|Participants will be administered vonoprazan at a dose of 10 mg QD in the 4 week Placebo-controlled Treatment Period. Participants randomized to vonoprazan 10 mg in the Placebo-controlled Treatment Period will continue to take the same dose in the 20 week Extension Period.
89261204|NCT05195528|Experimental|Vonoprazan 20 mg|Participants will be administered vonoprazan at a dose of 20 mg QD in the 4 week Placebo-controlled Treatment Period. Participants randomized to vonoprazan 20 mg in the Placebo-controlled Treatment Period will continue to take the same dose in the 20 week Extension Period.
89261205|NCT05195528|Placebo Comparator|Placebo|Participants will be administered the placebo QD in the 4 week Placebo-controlled Treatment Period. Participants randomized to placebo in the Placebo-controlled Treatment Period will be re-randomized to receive either vonoprazan 10 mg QD or vonoprazan 20 mg QD in the 20 week Extension Period.
89261206|NCT05187065|Experimental|Mobile-based education and exercise program|Mobile-based education and progressive relaxation and knee exercise program will be applied to the patients in the experimental group.
89261207|NCT05187065|No Intervention|Standard of care|Mobile-based education and progressive relaxation and knee exercise program will not be applied to the patients in the control group, and the clinical routine will be maintained.
89261208|NCT05170412||Patients|outpatient adults with the diagnosis of Sickle Cell Disease
89261209|NCT05158777|Experimental|Experimental Group with the immunization course of 0,28 days or 0,56 days|1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days or 0,56 days.
88805096|NCT02173535|Experimental|etafilcon test contact lens Variant CS|
88805097|NCT02173535|Experimental|etafilcon test contact lens Variant VC|
88805098|NCT02173535|Experimental|etafilcon test contact lens Variant LA|
88805099|NCT04621175|Active Comparator|EAA+W & Carbohydrate: Balance (BAL) first, then Deficit (DEF)|Participants will consume an essential amino acid plus whey (EAA+W) beverage with added Carbohydrate during energy balance (BAL) first, then again during energy deficit (DEF).
88805100|NCT04621175|Active Comparator|EAA+W & Carbohydrate: DEF first, then BAL|Participants will consume an essential amino acid plus whey beverage with added Carbohydrate during energy deficit first, then again during energy balance.
89261210|NCT05158777|Active Comparator|Control Group|1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days or 0,56 days.
89261211|NCT05152212|Experimental|LVGN7409|Monotherapy Dose Escalation
89261212|NCT05135156|Experimental|Intervention|Access to an investigator-designed web-based educational resource with information about lung transplant for two weeks.
89261213|NCT05135156|Active Comparator|Control|Access to a publicly available web-based educational resource with information about transplant for two weeks.
89261214|NCT05125185|Active Comparator|Standard Counseling|Trained diabetic educators educate patients using flip charts produced based on Malaysian Diabetes educators' manuals, insulin pen models and handouts. All patients were given SMBG diaries and encouraged to titrate their insulin dose based on SMBG
89261215|NCT05125185|Experimental|USM-IAM- based counseling|Trained diabetes educators counselled patients using the USM Insulin adherence module. Each patient was given the module so that they could freely refer to it when necessary. The module contains all information from standard counseling, with additional info on the definition of insulin non-adherence, causes of non-adherence, measures to overcome non-adherence and fasting safely with insulin. All patients were given SMBG diaries and encouraged to titrate their insulin dose based on SMBG
89261216|NCT05111951|Experimental|Mobile health-delivered physical exercise and physical activity|"Duration: 6 months~Supervised online exercise sessions (30-45 min/session) performed as individual or as group sessions. Exercises are tailored to individual needs in physical fitness and target at least moderate exercise intensity to obtain positive effects on cardiovascular health. Targeted dose: 2 sessions/week during months 1-3 and 1 session/week months 4-6.~Prescription of an individual exercise-regime through the mobile-application (dose is determined based on participants needs).~Application of behavior change techniques for physical activity. Two person-centered interviews with a physiotherapist seeking to assess motivation, exercise preferences and barriers to physical activity, and to identify 1-2 individual physical activity goals. The goals are followed-up and revised if needed months 1-6. Educational videos regarding physical activity and health are prescribed."
89261217|NCT05111951|Active Comparator|Mobile health-delivered behavioural change techniques for physical activity|"Duration: 6 months~Remote service and contact with physiotherapists (video and chat) through a mobile application designed for this study.~Behavioural change techniques for physical activity including general advice about physical activity, goal-setting, information and two follow-ups across the intervention period."
89261218|NCT05062889|Experimental|Arm B FOLFOXIRI, part 1 (adjuvant)|FOLFOXIRI Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluoruracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. In the case of oxaliplatin and/or irinotecan interruption because of adverse events, patient's refusal or investigator's choice, the continuation of the other drugs until 12 cycles is recommended.
89261219|NCT05062889|Active Comparator|Arm A mFOLFOX6 or CAPOX (at investigator's choice), part 1 (adjuvant)|"mFOLFOX6 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. The continuation of 5FU/leucovorin until 12 cycles is recommended also if oxaliplatin is interrupted because of adverse events, patient's refusal or investigator's choice.~CAPOX Oxaliplatin 130 mg/sqm iv over 2 hours, day 1; Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14; to be repeated every 3 weeks until 8 cycles. The continuation of Capecitabine until 8 cycles is recommended also if oxaliplatin is interrupted because of adverse events, patient's refusal or investigator's choice.~Pending the results of ct-DNA analysis, up to 2 cycles of FOLFOX/CAPOX before randomization are allowed to start the adjuvant treatment within 8-10 weeks after surgery"
89261220|NCT05062889|Experimental|Trastuzumab and Tucatinib plus mFOLFOX6, part 1 target-driven (adjuvant)|"Tucatinib 300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal); Trastuzumab 4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes), followed by~mFOLFOX6 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by 5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. In the case of oxaliplatin and/or trastuzumab and/or tucatinib interruption because of adverse events, patient's refusal or investigator's choice, the prosecution of the other drugs until 12 cycles is recommended.~Pending the results of ct-DNA analysis, up to 2 cycles of FOLFOX/CAPOX before randomization are allowed to start the adjuvant treatment within 8-10 weeks after surgery"
89261221|NCT05062889|Experimental|Arm B Trifluridine/Tipiracil, part 2 (post-adjuvant)|Trifluridine/Tipiracil: 35 mg/ m2/bid per os days 1-5 and 8-12 to be repeated every 4 weeks until 6 cycles.
89261222|NCT05062889|No Intervention|Arm A Observation, part 2 (post-adjuvant)|Follow-up
89261223|NCT05044910||MAM children with TB disease|
89261224|NCT05044910||Wellnourished children with TB disease|
89261225|NCT05044910||MAM children with latent TB infection|
89261226|NCT05044910||Well-nourished children with latent TB infection|
89261227|NCT05037045|Experimental|GLP-1 RA therapy|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months.
89261228|NCT04997993|Experimental|Leflunomide|Leflunomide, 20-50mg PO daily
89261229|NCT04991779||The neonates with suspected seizures or high risk of seizures|The neonates with suspected seizures or high risk of seizures are monitored by continuous electroencephalogram (cEEG) at least 12 hours since admission. The cEEG will be interpreted by AI-assisted cEEG diagnostic tool at the end of cEEG monitoring. At the same time, the same cEEG will be manually reported according the reference standard.
89290426|NCT01223118|Experimental|Oocyte Vitrification|Each patient will have oocytes randomized into two groups immediately after retrieval. Half of oocytes will be vitrified, thawed and inseminated. The other half will be inseminated only. All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups). Following delivery, buccal swabs will be collected on all infants.
89290427|NCT01127022|Active Comparator|480 mg/d choline intake|480 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [100 mg choline/d]
89261230|NCT04981483|Experimental|Any age and parity with placenta accreta spectrum|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle[outside in-in out then out in-in out] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
89261231|NCT04975269|Active Comparator|Acetazolamide|Acetazolamide (active)
89261232|NCT04975269|Placebo Comparator|Placebo|Placebo
89261233|NCT04956666|Experimental|Lyophilized S95014|"Lyophilized S95014 reconstituted was provided 5 mL of extractable volume with the concentration of 750 U/mL.~The vial of lyophilized powder (3.750 U/vial) was reconstituted with 5.2 mL of Sterile Water For Injection to obtain a 750 U/mL solution for single use."
89261234|NCT04942457|Experimental|Fasting|Participants will be councelled and accompanied to follow a prolonged fasting regime of 7-10 days in an outpatient setting under medical supervision. Additionally qualitative interviews will be conducted by few participants in the experimental arm, as well as their respective Healthcare Providers (Doctors/Medical Staff).
89261235|NCT04942457|No Intervention|Control group|waiting list, usual diet should be maintained
89261236|NCT04942041||local thrombectomy|Large vessel occlusion stroke patients that received thrombectomy at the local center
89261237|NCT04942041||distant thrombectomy|Large vessel occlusion stroke patients that received thrombectomy at the distant center
89261238|NCT04937972|Experimental|SHR-1701 Combined With fluzoparib|
89261239|NCT04931511|Experimental|Gluteal muscle injection plus physical therapy group|Gluteal muscle injection (corticosteroid 1ml+normal saline 4ml) + Subacromial Ultrasound Guided injection (sodium chloride 5ml) + Physical therapy
88805101|NCT04621175|Active Comparator|EAA+W & EAA: BAL first, then DEF|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy balance first, then again during energy deficit.
88805102|NCT04621175|Active Comparator|EAA+W & EAA: DEF first, then BAL|Participants will consume an essential amino acid (EAA) plus whey beverage with added EAA during energy deficit first, then again during energy balance.
89261240|NCT04931511|Experimental|Subacromial Ultrasound Guided injection plus physical therapy group|Gluteal muscle injection(sodium chloride 5ml)) + Subacromial Ultrasound Guided injection(corticosteroid 1ml+normal saline 4ml) + Physical therapy
89261241|NCT04908774|Experimental|Fasting Mimicking Diet Group|The intervention group follows a fasting mimicking diet for 5 days every 6-8 weeks (a total of 3 times in 5 months).
89261242|NCT04908774|No Intervention|Control Group|This group maintains their individual diet during the whole time of the study. After 6 months they are offered a fasting intervention.
89261243|NCT04883983|Active Comparator|Pain Medication as Standardly Prescribed|Patients will receive pain medication as standardly prescribed. Refills at the 2 week followup will be provided as per the standard treatment protocol.
89261244|NCT04883983|Experimental|Open Label Placebo|Initial post-op pain medication will be prescribed. On 2 week followup, refill request will be filled with an open label placebo.
89261245|NCT04861961|Active Comparator|Laparoscopic duodenal switch (DS)|Standard duodenal switch (double anastomoses). Roux-en-Y reconstruction.
89261246|NCT04861961|Active Comparator|Laparoscopic Single Anastomosis Duodenum-Ileal bypass with Sleeve gastrectomy (SADI-S)|"Simplified duodenal switch with one anastomosis. Duodeno-ileal omega reconstruction (Billroth II-like)."
89261247|NCT04861961|Active Comparator|Laparoscopic one anastomosis gastric bypass (OAGBP)|Gastric bypass of one anastomoses. Gastro-jejunal omega reconstruction (Billroth II).
89261248|NCT04853485|Active Comparator|Active TMS targeting both cerebellum and right dorsolateral prefrontal cortex.|Subjects identified as with prominent negative symptoms will be randomized into active group, who will receive active rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
89261249|NCT04853485|Sham Comparator|Sham TMS targeting both cerebellum and right dorsolateral prefrontal cortex|Subjects identified as with prominent negative symptoms will be randomized into sham group, who will receive sham rTMS over cerebellum and right dorsolateral prefrontal cortex navigated by individual MRI.
89261250|NCT04853485|Active Comparator|Active TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into active group, who will receive active rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
89261251|NCT04853485|Placebo Comparator|Sham TMS targeting left inferior parietal lobule|Subjects identified with prominent cognition deficits wil be randomized into sham group, who will receive sham rTMS over left inferior parietal lobule, navigated by individual MRI and functional connectivity map with left hippocampus.
88805103|NCT02986217|No Intervention|Control Group|Participants randomized to the Control Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the control group will receive traditional feedback methods as determined by each participant's training program. Subjects in the control group will repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
88816265|NCT02436876|Experimental|Cohort 1|Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
88816266|NCT02436876|Experimental|Cohort 2|Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
88816267|NCT02436876|Experimental|Cohort 3|Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
88816268|NCT02495103|Experimental|Phase I Component - Vandetanib|Phase I Component
88816269|NCT02495103|Experimental|Phase II Component- Vandetanib/Metformin|Phase II Component
88816270|NCT02382276|Experimental|Nalmefene hydrochloride 20 mg|As-needed; tablets, orally
89261252|NCT04853485|Active Comparator|Active deep TMS using Brainways H7 coil targeting ACC|Subjects identified as with positive symptoms will be randomized into active group, who will receive active deep rTMS over ACC using H7 coil.
89261253|NCT04853485|Placebo Comparator|Sham deep TMS using Brainways H7 coil targeting ACC|Subjects identified with positive symptoms will be randomized into sham group, who will receive sham deep rTMS over ACC using H7 coil.
89261254|NCT04784650|Other|Pre-dialysis population|Pre-dialysis population, consisting both Diabetes Mellitus (DM) and non-DM patients
89261255|NCT04754087|Other|G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene Liners|Up to 300 hips globally will be implanted with a G7 Shell and either the Vivacit-E or Longevity Liner. The liner used by each site will be identified at start-up.
89261256|NCT04738318|Experimental|Treatment Arm (Glucocorticoid)|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone. Following surgery, the participant will be provided with a 1) six-day oral methylprednisolone taper course.
89261257|NCT04738318|Placebo Comparator|Control Arm (Placebo)|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
89261258|NCT04733742|Experimental|Conbined treatment group|intravenous tenecteplase bridging with endovascular treatment
89261259|NCT04733742|Active Comparator|Endovascular treatment alone group|endovascular treatment alone
89261260|NCT04726709|Experimental|Poised for Parkinson's|Alexander-technique-based online course to increase embodied agency in people with Parkinson's disease and their care partners.
89261261|NCT04724915|Experimental|Robot-assisted TKA|Patients undergoing TKA with the assistance of robot technology.
89261262|NCT04724915|Active Comparator|Conventional TKA|Patients undergoing TKA with manual instrumentarium
89261263|NCT04721353|Experimental|Open-label prazosin treatment|Open-label administration of prazosin
89261264|NCT04715217|Experimental|Low Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 0.5×10^6 CAR+T cells/kg.
89261265|NCT04715217|Experimental|Middle Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of middle dose group will be intravenously infuse with 2.0×10^6 CAR+Tcells/kg.
89261266|NCT04715217|Experimental|High Dose Group|CD19-CD22 CAR-T cells injection, infused only once,3-6 subjects of high dose group will be intravenously infuse with 5.0×10^6 CAR+Tcells/kg.
89261267|NCT04715217|Experimental|Amplification Dose Group|CD19-CD22 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 0.5-5.0×10^6 CAR+Tcells/kg.
89261268|NCT04714827|Experimental|Low Dose Group|KQ-2003 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 1.0×10^6 CAR+T cells/kg.
89261269|NCT04714827|Experimental|Middle Dose Group|KQ-2003 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 2.5×10^6 CAR+T cells/kg.
89261270|NCT04714827|Experimental|High Dose Group|KQ-2003 CAR-T cells injection, infused only once,3-6 subjects of low dose group will be intravenously infuse with 5.0×10^6 CAR+T cells/kg.
89261271|NCT04714827|Experimental|Amplification Dose Group|KQ-2003 CAR-T cells injection, infused only once.After determined maximum tolerated dose,15 subjects of amplification dose group will be intravenously infuse with 1.0-5.0×10^6 CAR+Tcells/kg.
89261272|NCT04712175||Patients with SARS-CoV-2 infection|
89261273|NCT04712175||Patients without SARS-CoV-2 infection|
89261274|NCT04684420|Experimental|First Reference GXR (Fasting), Then Test GXR RM (Fasting)|Participants received a single oral dose of 500 milligram (mg) of reference GXR (Glucophage® Extended Release) tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg test GXR RM (Reduced Mass) tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.
89261275|NCT04684420|Experimental|First Test GXR RM (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fasting conditions. There was a washout period of 7 days between two treatment period.
89261276|NCT04684420|Experimental|First Reference GXR (Fed), Then Test GXR RM (Fed)|Participants received a single oral dose of 500 milligrams (mg) of reference GXR tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of test GXR RM tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.
89261277|NCT04684420|Experimental|First Test GXR RM (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 milligrams (mg) of test GXR RM tablet on Day 1 in treatment period 1 followed by single oral dose of 500 mg of reference GXR tablet on Day 8 in treatment period 2 under fed conditions. There was a washout period of 7 days between two treatment period.
89261278|NCT04557449|Experimental|1A Monotherapy Escalation Arm 1|PF-07220060 Monotherapy Escalation
89261279|NCT04557449|Experimental|1A Monotherapy Escalation Arm 2|PF-07220060 Monotherapy Escalation
89261280|NCT04557449|Experimental|1A Monotherapy Escalation Arm 3|PF-07220060 Monotherapy Escalation
89261281|NCT04557449|Experimental|1A Monotherapy Escalation Arm 4|PF-07220060 Monotherapy Escalation
89261282|NCT04557449|Experimental|1B Combination Dose Finding Arm 1|PF-07220060 with Letrozole combination Escalation
89261283|NCT04557449|Experimental|1B Combination Dose Finding Arm 2|PF-07220060 with Letrozole Combination Escalation
89261284|NCT04557449|Experimental|1C Combination Dose Finding Arm 1|PF-07220060 with Fulvestrant Combination Escalation
89261285|NCT04557449|Experimental|1C Combination Dose Finding Arm 2|PF-07220060 with Fulvestrant Combination Escalation
89261286|NCT04557449|Experimental|2B Combination Dose Expansion|PF-07220060 with Letrozole Combination Expansion
89261287|NCT04557449|Experimental|2C Combination Dose Expansion|PF-07220060 with fulvestrant Combination Expansion
89261288|NCT04557449|Experimental|1D Monotherapy Food Effect|PF-07220060 Monotherapy Food Effect
89261289|NCT04557449|Experimental|1A Monotherapy Escalation Arm 5|PF-07220060 Monotherapy Escalation
89261290|NCT04557449|Experimental|1F Combination Dose Finding|PF-07220060 with Enzalutamide Escalation
89261291|NCT04557449|Experimental|1E DDI Cohort|PF-07220060 DDI with Midazolam
89261292|NCT04557449|Experimental|2D Combination Dose Expansion|PF-07220060 with enzalutamide Combination Expansion
89261293|NCT04557449|Experimental|2A Combination Dose Expansion|PF-07220060 with fulvestrant combination dose expansion
89261294|NCT04546438|Experimental|MiraDry® treatment|"The miraDry System is a noninvasive method that utilizes microwave energy to destroy the sweat glands at the dermal-fat interface.~Each participant will be scheduled one MiraDry ® treatment with the possiblity of a second intervention approximately three months apart if the primary objective is not fullfilled efter the first."
89261295|NCT04538352|Experimental|Once-weekly sc semaglutide combined with once-daily insulin|Patients randomized to continue with MDI will be transitioned from their existing regimen to the rapid-acting insulin product insulin aspart and their basal insulin switched to once-daily insulin degludec.
89261296|NCT04538352|Experimental|MDI requiring multiple daily injections of insulin|Patients randomized to MDI will be allowed to continue correction rapid-acting insulin, in addition to their prandial doses of rapid-acting insulin, throughout the duration of the study.
89261297|NCT04449588|Experimental|Treatment group|
89261298|NCT04449588|Experimental|Control group|
89261299|NCT04420923|Experimental|Observe-and-Plan|Patients will follow the same protocol as described by dr. Mantel et al. (2014) in the first Observe-and-Plan study conducted in Lausanne.
89261300|NCT04420923|Active Comparator|Treat-and-Extend|Patients will follow the standard treatment protocol for Treat-and-Extend, used for several years in the participating clinics.
89261301|NCT04400331|Experimental|Valbenazine|Capsule, administered orally once daily.
89261302|NCT04352101|Experimental|Bupropion|Participants randomized to take bupropion for 8 weeks.
89261303|NCT04352101|Active Comparator|Escitalopram|Participants randomized to take escitalopram for 8 weeks.
89261304|NCT04334083|Experimental|Emergency physicians|actors during the work
89261305|NCT04334083|Experimental|medical externship student|spectator during the emergency physician work
89261306|NCT04317872|Experimental|Current protocol|"Current protocol: patients will receive a single shot of 25mg of aacidexam iv (5cc) at induction. After 12 hours these patients will another shot of 10mg of aacidexam iv (2cc) on the ward."
89261307|NCT04317872|Active Comparator|Old protocol|"Old protocol: patients will receive a single shot of 5mg of aacidexam iv at induction (5cc). After arrival 12 hours these patients will receive a placebo, i.e. a shot of 2 cc of NaCl 0.9% iv (Mini-Plasco van B. Braun)."
88805104|NCT02986217|Experimental|Experimental Group|Participants randomized to the Experimental Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the experimental group will then receive feedback within 5 business days of video submission and repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
88805105|NCT02973737|Experimental|arm 1|pyrotinib plus capecitabine pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
88805106|NCT02973737|Active Comparator|arm 2|placebo plus capecitabine placebo(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
88805107|NCT02762669|No Intervention|Control (no oxytocin) + No recovery|A control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. No recovery time.
89261308|NCT04316182|Experimental|Cabozantinib|Cabozantinib at 60 mg/day in monotherapy until symptomatic tumor progression, unacceptable adverse events, patient decision or death
89261309|NCT04309266|Experimental|Robot Assisted Therapy with Metacognitive Skills Training|All participants will be enrolled in the single arm of this study, where they will receive robot assisted therapy combined with metacognitive skills training.
89261310|NCT04244552|Experimental|ATRC-101 Q3W|
89261311|NCT04244552|Experimental|ATRC-101 Q2W|
89261312|NCT04244552|Experimental|ATRC-101 Q3W + Pembrolizumab|Pembrolizumab 200mg IV Q3W or 400mg IV Q6W
89261313|NCT04244552|Experimental|ATRC-101 Q2W + Pegylated liposomal doxorubicin (PLD)|PLD 40mg/m^2 IV Run-in period of 28 days, and then 40mg/m^2 IV Q4W
89261314|NCT04243499|Experimental|IV ICT01 Monotherapy|Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion
89261315|NCT04243499|Experimental|IV ICT01 + IV Pembrolizumab|A range of IV ICT01 doses administered every 3 weeks will be tested in combination with 200 mg pembrolizumab in Part 1 Dose Escalation and up to 2 dose levels of ICT01 plus 200 mg pembrolizumab in Part 2 Cohort Expansion
89261316|NCT04221555|Experimental|the main treatment group|pMMR tumor
89261317|NCT04221555|Active Comparator|the exploratory group|dMMR tumor
89261318|NCT04219163|Experimental|CLL-1.CAR|Group A
89261319|NCT04208087|Experimental|SI-722|
89261320|NCT04208087|Placebo Comparator|Placebo|
89261321|NCT04188743|Experimental|Allogenic FMT|Participants in the allogenic FMT- group will receive FMT-treatment using healthy donor microbiota supplied by the Ghent Stool Bank. The donor stool (50g) is processed shortly after production and tested intensively. It's frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
89261322|NCT04188743|Placebo Comparator|Autologous FMT|Participants in the autologous FMT- group will receive FMT-treatment using their own microbiota to account for effects due to the treatment itself. Their stool is processed as close to the treatment as feasible. It's processed and frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
89261323|NCT04188743|No Intervention|No intervention|"Participants in the No intervention-group will not receive any treatment but will be monitored similarly as the Allogenic FMT and Autologous FMT groups."
89261324|NCT04170556|Experimental|Regorafenib plus Nivolumab|Regorafenib will be initiated at full dose (160 mg/day; 3 weeks on and 1 week off) in monotherapy for the first 8 weeks. After week 8, regorafenib will be continued in combination with nivolumab, until symptomatic tumor progression, unacceptable adverse events, patient decision or death
88805108|NCT02762669|Active Comparator|Continuous oxytocin + No recovery|10-5M oxytocin for 2 hours. No recovery time.
89261325|NCT04159324|Experimental|StroCare treatment group|Optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation
89261326|NCT04159324|No Intervention|control group|routine aftercare stroke treatment
89261327|NCT04140227|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
89261328|NCT04135898|Experimental|SIBP-04|
89261329|NCT04135898|Active Comparator|Bevacizumab|
89261330|NCT03899220|Experimental|Intervention|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence.
89261331|NCT03899220|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Enhanced treatment as usual includes a one session behavioral engagement in care intervention as well as substance use treatment counseling.
89261332|NCT03879694|Experimental|Treatment (SVN53-67/M57-KLH peptide vaccine, octreotide)|Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate IM on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.
89261333|NCT03833479|Experimental|No further treatment|No further treatment
89261334|NCT03833479|Experimental|TSR-042|TSR-042 treatment administered using a 30 -minute IV infusion (with a -5 minute and +15 minute window permitted).
89261335|NCT03807102|Experimental|Tumor Vaccine|Injection of NeoAntigen Tumor Vaccine
89261336|NCT03782259|Placebo Comparator|Placebo|10mg tabs placebo matching dapagliflozin.
89261337|NCT03782259|Active Comparator|Active|10mg tabs of dapagliflozin
89261338|NCT03749460|Experimental|Treatment (nivolumab, ipilimumab, SBRT)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 courses and then every 4 weeks for an additional 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3 fractions of stereotactic body radiation therapy every other day in the absence of disease progression or unacceptable toxicity.
89261339|NCT03743194|Active Comparator|Bupi HCl plus liposomal bupi|"Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.~An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic."
89261340|NCT03743194|Placebo Comparator|Control Group|Standard parenteral analgesia technique with or without incisional local anesthetic infiltration: patients randomized to control group will be given parenteral opioids (such as fentanyl or hydromorphone) until they are converted to the enteral medications such as Percocet.
89261341|NCT03702244|No Intervention|Usual Care|For participants randomized to usual care, the participant's care team will select the specific noninvasive stress test (exercise electrocardiogram, stress nuclear imaging [including PET], stress MR, or stress echocardiogram); OR invasive test: (direct to diagnostic catheterization).
89261342|NCT03702244|Other|Precision evaluation|Participants randomized to a precision strategy will be assigned to either guideline-recommended care without immediately planned testing (low risk) or cCTA with selective FFRct (elevated risk) using a risk tool based on pretest clinical characteristics derived from the PROMISE trial and validated in SCOT-HEART trial. Participants assigned to guideline-recommended care without planned testing will be treated with preventive and antianginal medical treatment per guideline recommendations and clinical judgment and followed without testing.
89261343|NCT03645525|Experimental|Mesenchymal stem cell|Human Umbilical Cord-derived Mesenchymal stem cell in the saline
89261344|NCT03645525|Placebo Comparator|placebo|saline without mesenchymal stem cell
89261345|NCT03640624|Experimental|Intervention|Multidisciplinary treatment
89261346|NCT03640624|Active Comparator|Control|Treatment as usual
89261347|NCT03562845||ARM 1-Bad vs Good Clinical Evolution|"This arm is intended to evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical prognosis as it may be judged at this moment considering clinical outcomes and immune-biomarker evolution in the past 12 to 18 months. Thus, it may confirm the BH-Pilot study findings. Renal transplant patients of two types will be included:~Patients who, over previous months, have had a bad clinical evolution, in which rejection mechanisms were involved~Patients with a good and stable clinical evolution~IMBG sensitivity/resistance profiles will be compared amongst the two groups to evaluate the differences."
89261348|NCT03562845||ARM 2-Stable Renal Transplant Patients|This arm is intended to evaluate robustness of Immunobiogram® as an IVD test. Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days). The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
89261349|NCT03534466|Experimental|intervention group|Baby treadmill + conventional physical rehabilitation training
89261350|NCT03534466|Active Comparator|positive control group|Conventional physical rehabilitation training only
89261351|NCT03527498|Experimental|intervention group|Baby treadmill + physical rehabilitation training
89261352|NCT03527498|Active Comparator|positive control group|Physical rehabilitation training only
89261353|NCT03468959||Mother-child pairs|Families were recruited from lists of children receiving autism services obtained via the California Department of Developmental Services (DDS), from other studies at the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, or by self-referrals. The inclusion criteria were: a) mother or father had a biological child with ASD, and the mother was b) at least 18 years old; c) pregnant or planning a pregnancy, and biologically able to become pregnant; d) living within 2 hours of the MIND Institute; e) sufficiently fluent in English.
89261354|NCT03461146|Experimental|MT-6548|
89261355|NCT03460704|Experimental|CMS (Colistimethate Sodium)|Inhaled colistimethate sodium twice daily. The active pharmaceutical ingredient consisting of pure CMS one million international units (MIU) / 80 mg of CMS / 33 mg colistin base activity (CBA) was provided as a powder for nebuliser solution in 10R Internation Organization for Standardization (ISO) glass vials.
89261356|NCT03460704|Placebo Comparator|Placebo|Saline solution inhaled twice daily, provided and administered at the same way of the IMP.
89261357|NCT03430843|Experimental|Tislelizumab|Tislelizumab on Day 1, given every 21 days
89261358|NCT03430843|Active Comparator|Investigator chosen chemotherapy (ICC)|Paclitaxel on Day 1, given every 21 days or on a weekly schedule; OR Docetaxel on Day 1, given every 21 days; OR Irinotecan on Days 1 and 8, given every 21 days
89261359|NCT03393091||Incidence of possible anaphylaxis|Data will be collected on 1000 consecutive general anaesthetic procedures in Assiut University Hospitals. After each elective operating list the anaesthetist will be asked to complete a form in which they will document the number of patients receiving general anaesthesia on the list and the number of those patients who developed any of the following features: unexpected, unexplained hypotension; unexpected bronchospasm resistant to treatment; angioedema; urticaria; severe itching; widespread erythema
88805109|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes.
89261360|NCT03382600|Experimental|Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)|Participants receive pembrolizumab 200 mg every 3 weeks (Q3W) plus oxaliplatin 130 mg/m^2 Q3W by intravenous (IV) infusion plus TS-1 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course, and will continue for up to ~3 years.
89261361|NCT03382600|Experimental|Pembrolizumab + Cisplatin +TS-1 (Cohort 2)|Participants receive pembrolizumab 200 mg Q3W plus cisplatin 60 mg/m^2 Q3W by IV infusion plus TS-1 BID by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course, and will continue for up to ~3 years.
89261362|NCT03288311|Active Comparator|Protocolized Post-extubation Respiratory Support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
89261363|NCT03288311|Active Comparator|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
89261364|NCT03211416|Experimental|Treatment (sorafenib tosylate, pembrolizumab)|Patients receive sorafenib tosylate PO BID on days -28 to -1 and 1-21. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89261365|NCT03209479||Glatiramer acetate|For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily. Participants will receive interventions as part of routine medical care.
89261366|NCT02836093||evaluations/assessments|
89261367|NCT02787369|Experimental|Combination of ACY-1215 With Ibrutinib|ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
89261368|NCT02787369|Experimental|Combination of ACY-1215 With Idelalisib|ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
89261369|NCT02759861|Experimental|Harvoni x 8 or 12 weeks|patient will receive 8 or 12 weeks depending on clinical data
89261370|NCT02566772|Experimental|TAS3681|All participants will receive TAS3681 in 28-day cycles. The Escalation phase includes participants who have progressed after abiraterone, enzalutamide and chemotherapy. Eleven dose escalation cohorts are planned, one of which includes a preliminary assessment of food effect. The MTD/recommended dose for further development will be used for participants in the Expansion Phase. The Expansion Phase will enroll participants who have progressed after abiraterone or enzalutamide with chemotherapy consisting of no more than 2 prior taxane-based therapies (Group A) or without any chemotherapy (Group B). Participants receive TAS3681 until discontinuation criteria are met.
89261371|NCT02551003|Experimental|Cord blood with hypothermia|Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
89261372|NCT02551003|Active Comparator|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
89261373|NCT02550054|Experimental|Erythropoietin|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
89261374|NCT02550054|Placebo Comparator|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
89261375|NCT02550028|Experimental|Oral levetiracetam|Oral levetiracetam 50 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
89261376|NCT02550028|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 loading dose (add to 40 mg/kg if seizure discontrol). 5 mg/kg 24 hourly maintenance
89261377|NCT02520063|Experimental|Phase I Cohort 1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
89261378|NCT02520063|Experimental|Phase I Cohort 2|Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
89261379|NCT02520063|Experimental|Phase I Cohort -1|Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks
88805110|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes.
89261380|NCT02520063|Experimental|Phase II|Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.
89261381|NCT02472314|Experimental|Liposomal Bupivacaine A|One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
89261382|NCT02472314|Active Comparator|CISB control for A|Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
89261383|NCT02472314|Experimental|Liposomal Bupivacaine B|One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
89261384|NCT02472314|Active Comparator|CISB control for B|Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
89261385|NCT02158507|Experimental|Combination of Veliparib + Lapatinib|Lapatinib will be administered as a tablet at a dosage of 1250 mg/day continuously for 28 days starting on Day 1 of each cycle. Veliparib will be administered as a capsule at a dosage of 200 mg every 12 hours for 28 days starting on Day 2 of each cycle. A cycle of therapy is defined as 28 days. Treatment is administered on an outpatient basis. Patient response will be evaluated every 8 weeks according to the current Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and performance of relevant scans and/or x-rays.
89261386|NCT01830712||Chart review|
89261387|NCT01659879|Experimental|multimedia information|Health information concerning the child's diagnosis, treatment and recovery time after evaluation by the pediatrician, using a 15 minutes long standardized health information package with multimedia elements from the Norwegian website www.syktbarn.no (English version: www.childhealthguide.com)
89261388|NCT01659879|Active Comparator|verbal information|Verbal health information by a nurse in the acute ward concerning the child's diagnosis, treatment and recovery time, after the evaluation by the pediatrician
89261389|NCT01561391|Experimental|Continuous infusion|
89261390|NCT01561391|Experimental|Bolus injection|
89261391|NCT01561391|Experimental|Control|
89261392|NCT01524705|Experimental|Insulin Glargine, metformin, exenatide|Approximately 60 Type 2 diabetes mellitus (DM) participants will be instructed on an American Heart Association/American Diabetes Association (AHA/ADA) meal plan. Insulin Glargine, metformin and exenatide will used as a combination strategy to control individual glycosylated hemoglobin level (HbA1Cs) between 6.7 and 7.3% throughout the trial. The use of exenatide makes this the intervention arm
89261393|NCT01524705|Active Comparator|glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HbA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro). The use of the short acting insulins make this the control arm
89261394|NCT01455805|Active Comparator|Minuteman Fusion Implant|Minuteman™ interspinous interlaminar fusion Implant (interspinous interlaminar fusion device) which gained CE Mark approval in May 2011
89261395|NCT01455805|Other|Surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis.
89261396|NCT01072539||Patients who have approved indications of Tygacil|"Approved indications of Tygacil~-complicated intraabdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia"
89261397|NCT00846313|Active Comparator|Dietary counseling|Patients receive dietary advice at an individual level and are offered contact with clinical dietitian every second week if necessary.
89261398|NCT00846313|No Intervention|Control|
89261399|NCT00715611|Experimental|1|This is a multicenter phase II toxicity study of pleurectomy/decortication (P/D) followed by adjuvant chemotherapy and Intensity Modulated Radiation Therapy (IMRT) to the pleura in patients with malignant pleural mesothelioma. Alternatively, chemotherapy may be administered in the neoadjuvant setting prior to P/D, followed by IMRT. Patients deemed resectable at the time of enrollment will undergo P/D with the goal of a macroscopic complete resection (MCR). Those with disease progression or severe toxicity will stop chemotherapy and undergo a PET scan.
89261400|NCT00667043|Active Comparator|Study group 1|Midazolam and fentanyl; continuous intravenous infusions
89261401|NCT00667043|Active Comparator|Study group 2|Propofol and remifentanil; continuous intravenous infusion
89261402|NCT00218868||skin scrape|
89261403|NCT03953716|Experimental|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
89261404|NCT03953716|Placebo Comparator|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
89261405|NCT03953716|Experimental|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes * 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
89261406|NCT03953716|Active Comparator|Marvelon|1 pill QD*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) *3 menstrual cycle
89261407|NCT01096498|Experimental|Arm 1|
89261408|NCT01096498|Active Comparator|Arm 2|
89261409|NCT01096576|Experimental|A|
89261410|NCT01096576|Placebo Comparator|B|
89261411|NCT01097122|Experimental|Healthy young adult subjects|Forearm vibration will be applied in healthy young adult subjects
89261412|NCT00147537|Experimental|Phase 2 (Arms A & B)|CP-751,871 + paclitaxel + carboplatin
89261413|NCT00147537|Experimental|Phase 1b|"Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin~Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib"
89261414|NCT00222729|Experimental|Pemetrexed & Bevacizumab|
89261415|NCT00147225|Experimental|1 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~Adriamycin - Ifosfamide (AI) regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
89290428|NCT01127022|Experimental|930 mg/d choline intake|930 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [550 mg choline/d]
89290429|NCT01221558|Experimental|6mg lycopene|
89290430|NCT01221558|Experimental|15mg lycopene|
89261416|NCT00147225|Experimental|3 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
89261417|NCT00147225|Experimental|10 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
89261418|NCT00147225|Experimental|10 mcg/kg Pre/Post Chemotherapy|"Cycle 1, Chemotherapy (Control Cycle); Beginning Cycle 2, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy (post dose) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
89261419|NCT00147225|Experimental|5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
89261420|NCT00147225|Experimental|10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"10 mcg/kg AMG 531 + Pre/Pre/Post/Post Chemotherapy Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.~Chemotherapy :~Carboplatin [area under the concentration curve (AUC) = 11]; or~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or~High dose Ifosfamide: 14 gm/m^2."
89261421|NCT00222105|Experimental|1|Doxil, Thalidomide, Dexamethasone
89261422|NCT00146757|Experimental|Aldurazyme (rhIDU) 100 U/kg ONLY every week|Patients received Aldurazyme (recombinant human alpha-L-iduronidase (rhIDU)) once per week at a dose of 100 Units/kg (approximately 0.58 mg/kg) for up to 52 weeks - labeled dose.
89261423|NCT00146757|Experimental|Aldurazyme (rhIDU) 100-200 U/kg every week|After receiving 100 Units/kg dose of Aldurazyme (rhIDU) for the first 25 weeks, patients enrolling after January 1, 2004 were eligible to receive an increased dose of 200 Units/kg from Week 26 onwards if the patient's urinary glycosaminoglycan (uGAG) levels were >200µg/mg creatinine at Week 22.
89261424|NCT00267098|Experimental|Biventricular pacing|
89261425|NCT00267098|Active Comparator|Right ventricular pacing|
89261426|NCT00247676|Experimental|A|
89261427|NCT01073774|Experimental|Side by Side|
89261428|NCT01073774|Active Comparator|couples control condition|
89261429|NCT00267020|Experimental|Enzastaurin+Gemcitabine|
89261430|NCT00267020|Active Comparator|Gemcitabine|
89261431|NCT03975062|Experimental|Abbreviated course group (ACG)|The patients receiving 3-days course of dabigatran etexilate during pre-cardioversion period. After cardioversion has been performed the patients continue with dabigatran etexilate until 30 days after cardioversion
89261432|NCT03975062|Active Comparator|Conventional course group (CCG)|The patients receiving 3-weeks course of dabigatran etexilate before cardioversion of AF. After cardioversion has been performed the patients will continue with dabigatran etexilate until 30 days after cardioversion
89261433|NCT03970772|Experimental|Glucagon injection|Dilute Glucagon (1 mg/ml)
89261434|NCT03970772|Active Comparator|Glucose tablets|Dextrose glucose tablets
89261435|NCT03970928|Active Comparator|goal-directed fluid management (GDFM)|A pulse oximetry probe will be connected to the fourth finger of the hand in which there was not an arterial catheter in all patients and it will be wrapped so that it would not be affected by the external light. The pulse oximeter will then be connected to a monitor including the PVI software which automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor. 0.9 % NaCl at a rate of 2 mL/kg/h will be infused in PVI- guided GDFM group, a 250-mL bolus crystalloid/colloid injection will be administered when PVI was higher than 13 % over 5 min.
89261436|NCT03970928|No Intervention|Conventional fluid management group (CFMG)|This group will receive conventional fluid management described as follows: 0.9 % NaCl at a rate of 4- 8 mL/kg/h will be infused in CFGM group, a 250-ml bolus crystalloid/ colloid injection will be administered when the mean arterial blood pressure (MAP) decreased below 65 mmHg.
89261437|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Males|Arm 1 - Urine from males subjects
89261438|NCT03970850|Active Comparator|Multi-arm - Symptomatic and Asymptomatic Females|Arm 2 - Endocervical, self-collected (in the clinical setting) and physician-collected vaginal swabs and urine from female subjects
89261439|NCT03970850|Active Comparator|Multi-arm - FDA cleared NAATs (Comparator)|Arm 3 - Comparator (for females - vaginal and urine NAATs and for males - 3 urine NAATs)
89261440|NCT00242216|Active Comparator|Atazanavir oral once daily|HIV treatment
89261441|NCT00242216|Active Comparator|Fosamprenavir oral once daily|HIV treatment
89261442|NCT00240110|Placebo Comparator|Lithium carbonate add on Placebo|Lithium carbonate started and stabilized then participants randomized to placebo
89261443|NCT00240110|Experimental|Lithium carbonate add on Valproate|Lithium carbonate started and stabilized then participants randomized to Valproate
89261444|NCT00239720|Experimental|hOKT3gamma1 (Ala-Ala)|Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
89261445|NCT00239720|Placebo Comparator|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
89261446|NCT02532140|Experimental|WCK 5107|A single administration of the investigational product will be administered intravenously in 7 SAD cohorts at different dose level . The SAD cohorts will enroll 10 subjects ( 8 on active drug and 2 on placebo)
89261447|NCT02532140|Experimental|WCK 5107 1000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
89290431|NCT01221558|Placebo Comparator|placebo|
89261448|NCT02532140|Experimental|WCK 5107 2000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
89261449|NCT00266864|Experimental|Testosterone Replacement Therapy|Subjects with Low Testosterone (Hypogonadal) Receive Testosterone Transdermal System (Androderm 5 mg patch)
89261450|NCT00266864|No Intervention|No Intervention|Subjects with normal testosterone levels (eugonadal) participated in identical outcome measurements at parallel time points.
89261451|NCT00266708|Experimental|Risedronate|subjects received Risedronate for one year
89261452|NCT00266708|Placebo Comparator|subjects received placebo|subjects received placebo for 1 year
89261453|NCT00266630|Experimental|Olanzapine Monotherapy|"Olanzapine extension for Study BMAC patients who completed Visit 8.~Patients received olanzapine 5-20 mg for 18 weeks."
89261454|NCT00266630|Experimental|Olanzapine + Mood Stabilizer|"Olanzapine extension for Study BMAC patients who discontinued at Visit 4 or 5.~Patients received an initial dose of olanzapine 10 mg for 1 week and subsequent doses of olanzapine 5-20 mg for 17 weeks.~Patients received one (1) mood stabilizer (lithium, valproate or carbamazepine) for 18 weeks."
89261455|NCT00129129|Experimental|MenHibrix Group|Subjects in the Group were followed during the entire study period, from Day 0 up to study end 6 months post fourth dose vaccinationDuring Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of Menhibrix™ co-administered with Pediarix™ and Prevnar™ (at Day 0 and Months 2 and 4). During Fourth-Dose Phase (Study 102015), subjects primed with 3 doses of Menhibrix™ during the Primary Phase received one dose of Menhibrix™ and one concomitant dose of Prevnar™ at Month 10-13. During Primary Phase, Menhibrix™ was administered intramuscularly (IM) in the right upper thigh, and Pediarix™ and Prevnar™ IM in the left upper and lower thighs, respectively. During Fourth-Dose Phase, Menhibrix™ was administered by the same route and at the same site as during Primary Phase, and Prevnar™ was administered IM in the left upper thigh.
89261456|NCT00129129|Active Comparator|ActHIB Group|During Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of ActHIB™ vaccine co-administered with the Pediarix™ and Prevnar™ vaccines (at Day 0 and Months 2 and 4). Subjects in this Group were followed from Day 0 up to Month 10-13 solely. During Fourth-Dose Phase (Study 102015), these subjects were followed as subjects either in the ActHIB/MenHibrix Group or in the ActHIB/ActHIB Group, receiving then one dose of either Menhibrix™ or ActHIB™ concomitantly with one dose of Prevnar™. During Primary Phase, ActHIB™ was administered intramuscularly (IM) in the right upper thigh, and the Pediarix™ and Prevnar™ vaccines IM in the left upper and lower thighs, respectively.
89261457|NCT00129129|Active Comparator|Menomune Group|Subjects in the Group were followed solely during the period of Primary Phase (Study 101858), up to Month 10. Subjects in the Group, aged 3-5 years at enrolment, received one dose of Menomune™ at Day 0. Menomune™ was administered subcutaneously in the left deltoid region.
89261458|NCT00129129|Experimental|ActHIB/Menhibrix Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase (study 101858) and received at Month 10-13 a fourth dose of Menhibrix™ and a concomitant fourth dose of Prevnar™. Menhibrix™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
89261459|NCT00129129|Experimental|ActHIB/ActHIB Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase of the study (study 101858) and received at Month 10-13 a fourth dose of ActHIB™ and a concomitant fourth dose of Prevnar™. ActHIB™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
89261460|NCT00221403|Active Comparator|Valproate (VPA)|VPA was administered in liquid form, matched for taste and color with the placebo. Medication was administered in a double-blinded manner on a twice-daily basis. Patients randomized to VPA were administered an initial dose of 10 mg/kg/day on a twice daily schedule beginning on day 0. VPA levels were adjusted to achieve a blood level of 80-100 lg/mL. An independent, unblinded study psychiatrist adjusted VPA doses to achieve a therapeutic level
89261461|NCT00221403|Active Comparator|Risperidone|Risperidone was administered in liquid form matched for taste and color to the placebo. Medications were administered in a double-blinded manner on a twice-daily basis.
89261462|NCT00221403|Placebo Comparator|Placebo|The placebo was administered in liquid form, matched for taste and color with the active comparator.
89261463|NCT00145977|Experimental|Experimental|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
89261464|NCT00145977|Active Comparator|Control|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
89261465|NCT00238238|Active Comparator|Arm I - rituximab|Patients receive rituximab IV on days 1, 8, 15, and 22.
88805111|NCT02762669|Active Comparator|Control (no oxytocin) + No recovery + 10-7 oxytocin|A second control experiment will be undertaken in which the myometrial explants will be exposed to PSS for 2-hours without any oxytocin. After 2 hours, the solution will be drained from the organ baths, and replaced with fresh PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
88805112|NCT02762669|Active Comparator|Continuous oxytocin + No recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to 10-7 oxytocin for 10 minutes.
88805113|NCT02762669|Active Comparator|Continuous oxytocin + 30 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 30 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
89261466|NCT00238238|Experimental|Arm II - lenalidomide|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89261467|NCT00238238|Experimental|Arm III - lenalidomide and rituximab|Patients receive lenalidomide as in arm II. Patients also receive rituximab IV on days 8, 15, 22 and 29.
89290432|NCT01226238|Experimental|Online self-help|Provision of online self-help while waiting for psychotherapy
89261468|NCT03970460|Active Comparator|45-54 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
89261469|NCT03970460|Active Comparator|55-59 y.o / cemented modular metal-backed tibial implant|This group will undergo a surgery for a knee arthroplasty following standard procedure at our center
89261470|NCT03970460|Experimental|45-54 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
89261471|NCT03970460|Experimental|55-59 y.o / uncemented Trabecular Metal modular tibial implant|This group will undergo a surgery for a knee arthroplasty with a trabecular metal of the tibial implant
89261472|NCT03970148|Experimental|Nd: YAG laser treatment|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
89261473|NCT01073852|Placebo Comparator|Placebo|Patients will be taking placebo medication throughout study.
89261474|NCT01073852|Active Comparator|Hydroxychloroquine|Patients will be taking hydroxychloroquine throughout study.
89261475|NCT01071122|Experimental|Arm 1|
89261476|NCT01071122|Active Comparator|Arm 2|
89261477|NCT01071122|Active Comparator|Arm 3|
89261478|NCT03973190|Placebo Comparator|RET Group|Closure of the alveolus by first intention through palatal flap sliding according to the technique of Khoury et al. (2000).
89261479|NCT03973190|Active Comparator|SBC Group|Fill bone alveolus with Bone Ceramic® graft (Straumann AG, Basel, Switzerland) and cover it with palatal flap according to the technique of Khoury et al. (2000).
89261480|NCT03973190|Active Comparator|PRO Group|Alveolus sealing by a temporary ovoid pony of acrylic resin.
89261481|NCT01072604|Experimental|Arm 1|
89261482|NCT01072604|Experimental|Arm 2|
89261483|NCT01072604|Active Comparator|Arm 3|
89261484|NCT01072604|Active Comparator|Arm 4|
89261485|NCT00128661|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
89261486|NCT00128661|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
89261487|NCT03975140|Experimental|Hypersensitive acupoint group|
89261488|NCT03975140|Active Comparator|Hyposensitive acupoint group|
89261489|NCT01072760|Experimental|K wire|
89261490|NCT00145509|Active Comparator|Asenapine|Asenapine
89261491|NCT00145509|Placebo Comparator|Placebo|Placebo
89261492|NCT03965871|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
89261493|NCT03965871|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
89261494|NCT03965871|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
89261495|NCT03965871|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
89261496|NCT03965949||Group 1|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG without luteal support
89261497|NCT03965949||Group 2|Natural cycle, spontaneous ovulation or ovulation triggering by exogenous hCG with luteal support (progesterone)
89261498|NCT03965949||Group 3|Hormone Replacement cycle (cyclacur) plus GnRHa suppression with luteal support (progesterone)
89261499|NCT03965949||Group 4|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
89261500|NCT00220779|Experimental|Group 1|IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)
89261501|NCT00220779|Experimental|Group 2|IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)
89261502|NCT00220779|Placebo Comparator|Group 3|placebo (0.1% albumin) 4 ml/kg bw/infusion
89261503|NCT00207740|Experimental|CNTO 148 (golimumab)|
89261504|NCT00207740|Placebo Comparator|Placebo|
89261505|NCT00265382|Other|Open|
89261506|NCT03969602|Experimental|Experimental Group|Participants randomized will receive six individual 1-hour sessions of CBT: two sessions before the operation and four after, delivered by a psychologist trained in CBT for chronic pain. The CBT intervention is tailored to reduce pain catastrophizing. Main techniques are: pain education and the influence of cognitions, emotions and behavior on pain and pain disability; identification of catastrophizing cognitions and replacing them with more adaptive cognitions; stress/anxiety reduction by diaphragmatic breathing and progressive muscle relaxation; emotion regulation skills training; cognitive restructuring; coping skills training to combat helplessness and foster a sense of control and self-efficacy for dealing with acute post-operative pain. The four postoperative sessions build on and further extend the skills learned preoperatively. Each session ends with specific homework assignments. All patients receive a homework book and an individually tailored instruction manual.
89261507|NCT03969602|Active Comparator|Control Group|Participants will have six meetings with members of the research team (in person or through telephone). In a first preoperative meeting a member of the team provides verbal information on the preparation for surgery, surgery itself and recovery from surgery, stressing the importance of postoperative exercise. Any questions raised by the patient are discussed. A booklet is provided with information about: structure of the spinal column and spinal diseases; examinations before surgery; the operative environment; surgical procedures; anesthetic procedures; postoperative care and postoperative pain reduction. A second preoperative (telephone) meeting is scheduled to answer any remaining questions. During the postoperative phase, instructions and an exercise manual are provided, Patients keep a diary to record their training activity. Three, six and eight months after discharge patients are contacted by telephone and their training progress is discussed.
89261508|NCT03969602|No Intervention|Observational Group (low catastrophizing)|Patients will be routinely prescribed medications for pain control and are referred for physical therapy on an out-patient basis in different sites or an in-patient basis in specialized rehabilitation centers following lumbar spinal fusion surgery, depending on the needs. Typically, a full rehabilitation regime starts 2-3 weeks after surgery. Usual programs involve active spinal mobilization aimed at gradually improving the range of motion, exercises to strengthen spinal deep muscles, and segmentary stretching involving the lower limb and back muscles, together with manual therapy. The patients are also given walking exercises and trained in how to change position.
89261509|NCT03974984||"The Hvidovre population:"|We will include patients undergoing laparoscopic hemicolectomy for cancer scheduled for anesthesia with total intravenous anesthesia combined with epidural anesthesia and perioperative NSAID on Hvidovre Hospital.
89261510|NCT03974984||"The Zealand University Hospital population"|"The immunological and oxidative stress in relation to abdominal surgery (IMOX) study is ongoing at Zealand University Hospital, Roskilde. It is a prospective explorative study cohort that consists of 60 patients undergoing laparoscopic colorectal cancer surgery.~The population has been anesthetized according to the standard operating procedure with either total intravenous anesthesia with propofol and remifentanil or volatile anesthesia with sevoflurane combined with a fast acting opioid (remifentanil or sufentanil). Patients anaesthetized with other techniques including epidural or other regional blocks will be excluded from the analysis."
89261511|NCT00206726|Experimental|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days.
89261512|NCT00237692|No Intervention|Arm 1|Control group - a group of hypertensive patient who receive usual care
89261513|NCT00237692|Experimental|Arm 2|Nurse Behavioral intervention with Home BP Telemonitoring Nurse-administered tailored behavior intervention
89261514|NCT00237692|Experimental|Arm 3|Nurse Medication Management with Home BP Telemonitoring -- Nurse administer medication management according to hypertension decision support system
89261515|NCT00237692|Experimental|Arm 4|Nurse Combined intervention with Home BP Telemonitoring - Combination of the nurse administered tailored behavioral & medication management interventions
89261516|NCT00237458|Experimental|Lacosamide|Open-label active treatment
89261517|NCT01581788|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
89261518|NCT01581788|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
89261519|NCT03973346|Experimental|Intervention group|Encounters at primary care clinics with the risk screening tool
89261520|NCT03973346|No Intervention|Comparison group|Propensity score matched comparison encounters
89261521|NCT00265148|Experimental|Rosiglitazone|4 mg once a day for 1 month increasing to 8 mg once a day (Extended Released Tablets)
89261522|NCT00265148|Other|Placebo|Placebo dummy to match
89261523|NCT01072838|Other|Dose Escalation|
89261524|NCT03973424|Experimental|Simple|This arm uses a simplified form of dietary tracking that involves tracking only high-calorie, high-fat foods, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
89261525|NCT03973424|Experimental|Standard|This arm uses standard calorie tracking, in addition to the core behavioral smartphone-delivered intervention that consists of weighing, physical activity, goal setting, adaptive text messages, tailored weekly feedback, and lessons.
89261526|NCT00043186|Placebo Comparator|Placebo|Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.
89261527|NCT00043186|Experimental|Denosumab 6 mg every 3 months|Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
89261528|NCT00043186|Experimental|Denosumab 14 mg every 3 months|Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
89261529|NCT00043186|Experimental|Denosumab 30 mg every 3 months|Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.
89261530|NCT00043186|Experimental|Denosumab 14 mg every 6 months|Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
89261531|NCT00043186|Experimental|Denosumab 60 mg every 6 months|Participants received denosumab 60 mg SC every 6 months until Month 42.
89261532|NCT00043186|Experimental|Denosumab 100 mg every 6 months|Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
89261533|NCT00043186|Experimental|Denosumab 210 mg every 6 months|Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.
89261534|NCT00043186|Active Comparator|Alendronate 70 mg|Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.
89261535|NCT00041470|Experimental|Weekly paclitaxel, vinorelbine and GCSF|"Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.~Paclitaxel weekly. Dose levels:~50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2~Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:~20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2~Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.~G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily"
89261536|NCT03953950|Experimental|Combination of spironolactone and losartan|
89261537|NCT03953950|Active Comparator|Losartan Alone|
89261538|NCT00206102|Experimental|1|Quetiapine fumarate
89261539|NCT00206102|Active Comparator|2|Risperidone
89261540|NCT03954262||TCI group|Group I received TCI at 5-6 ug/ml target effect concentration (Ce)
89261541|NCT03954262||bolus group|groups II received an induction bolus of propofol (2-2.5mg/kg).
89261542|NCT00041080|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily on days 1-28.
89261543|NCT00041080|Experimental|Arm II (tamoxifen)|Patients receive oral tamoxifen twice daily on days 1-28.
89261544|NCT00205712|Placebo Comparator|Ketamine plue saline|Ketamine without dexmedetomidine
89261545|NCT00205712|Experimental|Ketamine plus dexmedetomidine|Ketamine infusion plus dexmedetomidine
89261546|NCT01097200|Other|Elevate meshes|The use of Elevate (American Systems trade mark) meshes for the treatment of pelvic prolapse.
89261547|NCT01097200|Other|Sacrocolpopexy|Sacrocolpopexy for the correction of the prolapse
89261548|NCT03953404||septic shock|
89261549|NCT03953404||severe sepsis|
89261550|NCT03953404||sepsis|
89261551|NCT03953404||sirs positive, not septic|
89261552|NCT03953794||Patients with inflammatory bowel disease|"Patients who have...~a diagnosis of ulcerative colitis or Crohn's disease as confirmed by a clinician~experienced a flare within the past 24 months as determined by a clinician~had quiescent disease for at least 3 months as determined by a clinician"
89261553|NCT03969758|Active Comparator|Ciprofloxacin plus Metronidazole therapy|Will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks. Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
89261554|NCT03969758|Active Comparator|Cefixime plus Metronidazole Therapy|Will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) orally for 2 weeks.Percutaneous aspiration or drainage of the liver abscess will be done for all the participants when there is enough liquid content/pus which is amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively. After 2 weeks of empirical antibiotic therapy, asymptomatic patients with persistent drainage with USG showing significant drainable collection in the liver will receive another 2 weeks of extended antimicrobial therapy of same combination.
89261555|NCT03974672||T drain|Patients treated with a T drain approach
89261556|NCT03974672||Stoma|Patients treated with a stoma
89261557|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and saline|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
89261558|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and triamcinolone 40 mg|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
89261559|NCT01074086|Experimental|RAD 001|RAD 001 in day 1 and day 7 from 10 mg to 50 mg
89261560|NCT01074320||Breast cancer patients on AIs|Breast cancer patients beginning Aromatase Inhibitor therapy
89261561|NCT01072916||IBS|Subjects with IBS-D
89261562|NCT01072916||Healthy|Healthy Subjects
89261563|NCT02531828|Experimental|Biopolymer Film|Application of dressings for surgical correction.
89261564|NCT02531828|Active Comparator|Polyurethane Film, or the like|Application of dressings for surgical correction
89261565|NCT00264290|Experimental|Valganciclovir|900mg PO qd
89261566|NCT00264290|Placebo Comparator|Placebo|900mg PO qd
89261567|NCT00234494|Experimental|Single Group Assignment|Cisplatin + Gemcitabine + Bevacizumab
89261568|NCT01582568||Certolizumab|Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).
89261569|NCT00263666|Experimental|Rotarix Group|Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
89261570|NCT00263666|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
89261571|NCT00195338||1|This is an open label, observational study.This is a post-marketing surveillance study in rheumatology practice patients in Luxemburg.Rheumatologists will be asked to document safety and adherence to therapy of Enbrel when given to adults with active rheumatoid arthritis.All patients initiated with Enbrel will be observed.
89261572|NCT01096654|Active Comparator|CT-scan|In this group treatment will be based on the outcome of the CT-scan only. Patients will be treated by adrenalectomy (Adx) if an unilateral lesion is visible on the CT-scan and the contralateral gland is normal. If bilateral lesions, bilateral enlargement or symmetric normal adrenal glands are present patients will be treated by the mineralocorticoid receptor antagonist (MRA)
89261573|NCT01096654|Active Comparator|Adrenal Vein Sampling|"This group will be treated according to the results of the adrenal vein sampling only. Adrenal vein sampling will be performed under the continuous infusion of ACTH (adrenocorticotropic hormone). A cortisol ratio ≥ 3 between the adrenal vein and the inferior vena cava is set as the criterium for successful cannulation. The criterium for lateralization is a aldosterone/cortisol ratio ≥ 4 between the adrenal veins and a lower aldosterone/cortisol ratio in the contralateral adrenal vein than in the inferior vena cava.~If AVS fails patients will be treated according to the CT-findings as described in the group with CT-scan only. Patients with a successful AVS will be treated by Adrenalectomy if unilateral production of aldosterone is shown. If no unilateral aldosterone production is present, i.e. the aldosterone/cortisol ratio is less than 4, patients will be treated by MRA."
89261574|NCT00035932|Active Comparator|I|"ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice~ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
89261575|NCT00035932|Active Comparator|II|"ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice~ATV, SQV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
89261576|NCT00035932|Active Comparator|III|"LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice~LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
89290433|NCT01226238|No Intervention|Waiting list alone|Waiting for psychotherapy alone
89261577|NCT03953248|No Intervention|Non L-Carnitine|Subjects in this arm will receive standard treatment only (without LC). It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment
89261578|NCT03953248|Active Comparator|L-Carnitine|Subjects in this arm will receive standard treatment in addition to LC IV, as a dose of 1 g/8 hours
89261579|NCT02530372|Experimental|UriCap-F|"The UriCap-F is an FDA cleared Class I device intended for urinary management in women.~The device is comprised of a multiple use unit and a single use unit. The multiple use unit is intended to be reused by the same patient for up to 30 days. It is removed every 24 hours, rinsed under running water, dried and re-applied.~The UriCap is held in position by means of a single-use medically approved adhesive tape."
89261580|NCT03953326|Experimental|HeartPhone Intervention|Participants install the HeartPhone app on their smartphone. This app presents an image on a splash screen every time they activate their device. The image is randomly drawn from an image bank in the app. Repeated exposure to the image is designed to condition a more favorable automatic affective evaluation of physical activity and lead to increased physical activity.
89261581|NCT01097278|Experimental|Arm I|Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
89261582|NCT01097278|Active Comparator|Arm II|Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
89261583|NCT01096732|Experimental|GDC-0449|Study drug.
89261584|NCT01097356|No Intervention|common care|HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear
89261585|NCT01097356|Experimental|probiotic drinkers|HPV+, LSIL patients who will drink the study drink for 6 months
89261586|NCT01100788|Placebo Comparator|Placebo|No treatment
89261587|NCT01100788|Experimental|scFOS 5 g|5 g scFOS
89261588|NCT01100788|Experimental|scFOS 8 g|8 g scFOS
89261589|NCT01097434|Active Comparator|Arm 1|Biodegradable polymer limus-eluting stents
89261590|NCT01097434|Active Comparator|Arm 2|Permanent polymer limus-eluting stent
89261591|NCT00022516|No Intervention|No-CM|No further chemotherapy following standard adjuvant chemotherapy.
89261592|NCT00022516|Experimental|CM-Maintenance|12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)
89261593|NCT03953092|Experimental|SAD Cohort 1|5 mg YG1699 or Placebo
89261594|NCT03953092|Experimental|SAD Cohort 2|10 mg YG1699 or placebo
89261595|NCT03953092|Experimental|SAD Cohort 3|25 mg YG1699 or placebo
89261596|NCT03953092|Experimental|SAD Cohort 4|50 mg YG1699 or placebo
89261597|NCT03953092|Experimental|SAD Cohort 5|100 mg YG1699 or placebo
89261598|NCT03953092|Experimental|MAD Cohort 1|5 mg YG1699 or placebo
89261599|NCT03953092|Experimental|MAD Cohort 2|20 mg YG1699 or placebo
89261600|NCT03953092|Experimental|MAD Cohort 3|50 mg YG1699 or placebo
89261601|NCT01097512|Experimental|Regimen 1: AS703569/gemcitabine|Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle
89261602|NCT01097512|Experimental|Regimen 2: AS703569/gemcitabine|AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle
89261603|NCT01100866|Active Comparator|Group 1|POMELLA™ 2 x 500mg capsule once daily
89261604|NCT01100866|Placebo Comparator|Group 2|POMELLA™ placebo
89261605|NCT01097590|Experimental|Active TLA Gut™ column|The active column contain an engineered protein with the ability to specifically bind the inflammatory cells.
89261606|NCT01097590|Placebo Comparator|Placebo TLA Gut™column|The placebo column is identical to the active column except it does not contain the engineered protein that specifically bind the inflammatory cells.
89261607|NCT00033514|Experimental|treatment|please see intervention description
89261608|NCT00006916|Experimental|Radiation therapy followed by bleomycin via Ommaya reservoir|60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.
89261609|NCT03952858|Experimental|Telerehabilitation Group|Physiotherapist-supervised Telerehabilitation as home exercise in Groups. Participants in the intervention group receive supervised Telerehabilitation by an experienced physiotherapist two days a week during four weeks. A computer and a camera will be installed where the exercise should take place. It will make it possible for the physiotherapist to see how the participants follow the exercise program and for the participants to follow the physiotherapist instructions on the screen. The participants will be instructed in the use of computer and receive a written guide. After four weeks the participants will on their own continue the Otago exercise Program for another 4 weeks by video sessions and still together in their already established groups. Otago Exercise Program consist of a walking plan, balance exercises, and a set of leg muscle strengthening exercises all progressing in degree of difficulty.
89261610|NCT03952858|Active Comparator|Community Center group|"The Community Center Group will receive the traditional exercise programs offered in a Community Center for older people. The exercise program can vary dependent on the offer in the individual community center. Often the training consists of exercises carried out in a range of different training equipments such as exercise bikes, steppers, rowing machines etc. often supervised by a physiotherapist. At some community centers the training will be performed in groups on appointed times. Some citizens are offered one or two times instruction and hereafter they have to train on their own. Some times the citizens are offered few times of training in their own home and hereafter follow the offer at the community center for older people. Before discharge, at the hospital, their plan for rehabilitation will be completed.~Participants in the Community Center Group will be tested by the same instruments at baseline and after 4 and 8 weeks and at 6 months of follow-up."
89261611|NCT02530138|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
89261612|NCT02530138|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
89261613|NCT02529982|Active Comparator|intervention|500 mg curcumin capsule
89261614|NCT02529982|Placebo Comparator|control|placebo
89261615|NCT00454649|Experimental|Axitinib [AG-013736] + chemotherapy combination|"The following separate groups were included:~axitinib~plus carboplatin/paclitaxel in three different schedules~plus paclitaxel~plus docetaxel/carboplatin~plus docetaxel~plus capecitabine~plus gemcitabine/cisplatin~plus pemetrexed/cisplatin"
89261616|NCT01323179||Strong opioids|Patients taking strong opioids preoperatively
89261617|NCT01323179||Weak opioids|Patients taking weak opioids preoperatively
89261618|NCT01323179||Opioid native|Patients not taking opioids preoperatively
89261619|NCT00454571|Experimental|Pazopanib|Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89261620|NCT00454571|Active Comparator|Observation|Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
89261621|NCT01323257|Experimental|001|TMC435 150 mg capsule once daily for 7 days (Trt A C D)
89261622|NCT01323257|Experimental|002|erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
89261623|NCT01323257|Experimental|003|erythromycin 500 mg tablets three times a day for 7 days (Trt C)
89261624|NCT01323257|Experimental|004|TMC435 50 mg capsule once daily for 7 days (Trt F)
89261625|NCT01323257|Experimental|005|Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)
89261626|NCT01323257|Experimental|006|Ritonavir 100 mg tablet once daily for 7 days (Trt E F)
89261627|NCT03837743|Experimental|DUR-928 Topical Solution|DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
89261628|NCT03837743|Placebo Comparator|Vehicle Topical Solution|Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
89261629|NCT03836729|Experimental|TAF/FTC followed by TAF/FTC + GSK3640254|Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
89261630|NCT01025531||patients with newly diagnosed Hepatitis C|Hepatitis C patients newly diagnosed
89261631|NCT00443729|Experimental|1|Raltegravir & Placebo
89261632|NCT00443729|Active Comparator|2|Lopinavir (+) Ritonavir & Placebo
89261633|NCT00443651|Experimental|Rituximab 1000 mg (Stage I patients)|Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
89261634|NCT00443651|Experimental|Rituximab 500 mg (Stage II patients)|Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
89261635|NCT01027637|Experimental|Alloderm reconstruction|All patients recieving the intervention Alloderm for breast reconstruction
89261636|NCT03616067|Experimental|Botox® injection arm|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars).
89261637|NCT03616067|Active Comparator|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear
89261638|NCT01027715|Experimental|EEG seizure treatment group|EEG data available to physicians. Treatment based on EEG seizures. Treatment will be dictated by the detailed treatment protocol. Standard antiepileptic medications will be used.
89261639|NCT01027715|No Intervention|Clinical Seizure treatment Group|Seizure treatment in this group will be based on standard care - treating clinical seizures only. While EEG data will be collected in this group, the data will not be available to the treating physicians. A one-hour EEG report will be available to the treating team. Continuous EEG monitoring and treatment will only be allowed if the initial EEG shows status.
89261640|NCT01027325|Experimental|High CHO/Low Amylose|55% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 25% Fat
89261641|NCT01027325|Experimental|Low Carbohydrate/Hi Amylose|40% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 40% Fat
89261642|NCT01027325|Experimental|High CHO/High Amylose|55% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 25% Fat
89261643|NCT01027325|Experimental|Low Carbohydrate/Low Amylose|40% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 40% Fat
89261644|NCT01027325|Active Comparator|Baseline|40% Carbohydrate 20% Protein 40% Fat
89261645|NCT01027403||Healthy volunteers|
89261646|NCT01027403||Acute decompensated heart failure|
89261647|NCT03029195|Experimental|Study group|Nasoalveolar molding therapy for cleft lip and palate infants
89261648|NCT03029195|No Intervention|Control group|No nasoalveolar molding therapy for cleft lip and palate infants
89261649|NCT03029195|No Intervention|Age matched Norms|Normal (non-cleft) age matched infants
89261650|NCT01030991||HFpEF|HFpEF cohort (observational study)
89261651|NCT00443261|Experimental|1 (SCCHN)|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Patients will receive Azacitidine and cisplatin.
89261652|NCT00439517|Experimental|1|UFOX + Cetuximab
89261653|NCT00439517|Active Comparator|2|FOLFOX4 + Cetuximab
89261654|NCT01031147||Magnetic resonance angiography|Three-dimensional time-of-flight magnetic resonance angiography(3D-TOF-MRA) was used to detect the intracranial aneurysms in this study
89261655|NCT01031225|Experimental|1|
89261656|NCT01028105|No Intervention|No MRSA screening, Group b|Standard of care
89261657|NCT01028105|Other|MRSA screening, Group a|MRSA preoperative screening
89261658|NCT01028183||Extremely Premature Infants|< 30 weeks gestation (N=5000)
89261659|NCT01028183||Premature Infants|30-36 weeks gestation (N=2000)
89261660|NCT01028183||Hospitalized Term Infants|>=37 weeks gestation (N=2000)
89261661|NCT01028183||Healthy Term Infants|>=37 weeks gestation (N=1000)
89261662|NCT01028261|Experimental|ZGN-433|
89261663|NCT01028261|Placebo Comparator|Normal Saline|
88805114|NCT02762669|Active Comparator|Continuous oxytocin + 60 minute recovery + 10-7 oxytocin|10-5M oxytocin for 2 hours. After 2 hours, the solution will be drained from the organ baths, and any residual solution will be removed by washing three times with PSS. Following this, the strip will be exposed to PSS for 60 minutes. The strip will then be exposed to 10-7 oxytocin for 10 minutes.
88805115|NCT01072331|Experimental|MP-513 10 mg, once a day, for 4 weeks|
88805116|NCT01072331|Experimental|MP-513 20 mg, once a day, for 4 weeks|
88805117|NCT01072331|Placebo Comparator|Placebo of MP-513|
89261664|NCT01031303|Experimental|Study Group|
89261665|NCT01028339|Active Comparator|Mannitol|
89261666|NCT01028339|Experimental|Hypertonic saline|
89261667|NCT01028417|Experimental|Group 1|Group 1 receives the intervention - insertion of platinum microcoil followed by nodule excision
89261668|NCT01028417|No Intervention|Group 2|Group 2 receives the standard of care - nodule excision, but without the microcoil insertion
89261669|NCT04700501|Other|EYB Implementation study|All participants will have the opportunity to access an online CBT life skills learning programme.
89261670|NCT04695119||Adult patients with septic shock|"All adult (>=18 yo) patients admitted to participating ICUs with septic shock defined according to the Sepsis III criteria.~Purely observation study with no intervention. Patients are exposed to septic shock and treatment according to standard departmental protocols at each centre."
89261671|NCT01031459||Group 1|
89261672|NCT03495791|Experimental|EI development phase.|
89261673|NCT03495791|No Intervention|Pilot-testing phase.|
89261674|NCT00438815|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
89261675|NCT00438659|Experimental|Mometasone|Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.
89261676|NCT00438659|Placebo Comparator|Placebo|Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm I.
89261677|NCT01028495|Experimental|gemcitabine and RX-0201|"Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.~RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off."
89261678|NCT00437645|Experimental|Valsartan/amlodipine 160/5 mg|Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
89261679|NCT00437645|Active Comparator|Amlodipine 10 mg|Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
89261680|NCT03477383||Adult patients|Adult patients (18 years or older) undergoing heart transplantation
89261681|NCT03477383||Pediatric patients|Pediatric patients (0-17 years) undergoing heart transplantation
89261682|NCT03465371|Experimental|OnDemand Training Intervention|Participants receiving the OnDemand Training Intervention
89261683|NCT03465371|Active Comparator|InPerson Intervention|Participants receiving the InPerson Intervention
89261684|NCT03465371|Active Comparator|Virtual InPerson Intervention|Participants receiving the Virtual InPerson Intervention (the InPerson training via Zoom)
89261685|NCT00437489|Active Comparator|Control|
89261686|NCT00437489|Experimental|Experimental|
89261687|NCT01028573|Active Comparator|Group 1|4L of PEG-ELS (Golytely) consumed on the evening before colonoscopy
89261688|NCT01028573|Experimental|Group 2|2L of PEG-ELS (Golytely) consumed on the evening before and 2L consumed on the morning of colonoscopy
88805118|NCT01072409|Other|Single Arm|Single arm design
88805119|NCT01072643|Experimental|Dexmedetomidine|To study safety of DEX with regard to effect on PVR; There will be 3 study groups (n=8 per group). The groups will be based on DEX doses as follows- Group 1 - Bolus 1 mcg/kg followed by infusion 0.7 mcg/kg/hr Group 2 - Bolus 1.5 mcg/kg followed by infusion 1.05 mcg/kg/hr Group 3 - Bolus 2 mcg/kg followed by infusion 1.4 mcg/kg/hr
88805120|NCT04352543|Experimental|Older adults group|Group of older adults >60 years old.
88805121|NCT04590209|Experimental|Acrosyndrome|"The blood sample, skin biopsy and other biological samples will be taken from patients~The precise description of the semiology of skin lesions, their topography, as well as the analysis of the entire skin integument and mucous, cardiac and pulmonary auscultation and neurological examination will be done as required."
89261689|NCT01028573|Experimental|Group 3|238g of PEG-3350 mixed with 2L of Gatorade
89261690|NCT01028573|Experimental|Group 4|1L of PEG-3350 + Gatorade
89261691|NCT04683575|Experimental|experimental group|Patients with differentiated thyroid carcinoma with low blood selenium are treated with selenium yeast（dosage form：capsule dosage：200μg bid duration: 5 years）.
89261692|NCT04683575|Placebo Comparator|Placebo control group|Patients with differentiated thyroid cancer with low blood selenium are given placebo treatment（dosage form：capsule dosage：200μg bid duration: 5 years）
89261693|NCT04683575|No Intervention|No intervention group|Patients with differentiated thyroid cancer with low blood selenium are not treated.
89261694|NCT01031615|Experimental|Child and Family Traumatic Stress Interv|4-session secondary prevention model that focuses on family communication about symptoms of a child aged 7-16.
89261695|NCT01031615|Active Comparator|Psychoeducational Comparison|4-sessions focused on individual child using psychoeducation and relaxation skills
89261696|NCT00442559|Experimental|Montelukast|Participants were treated for 12 months after randomization: Participants 2 to 5 years of age took one 4 mg chewable tablet and 6 to 14 years of age took one 5 mg chewable tablet daily in the evening. If participants had exacerbated from mild to moderate within 12 weeks, inhaled corticosteroids (ICS) was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
89261697|NCT00442559|Active Comparator|Inhaled Corticosteroids (ICS)|Participants were treated for 12 months after randomization: Each participant's physician selected the ICS agent, dose, and regimen. If participants had exacerbated from mild to moderate within 12 weeks, ICS was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
89261698|NCT01031693|Active Comparator|Group A|Active TMS
89261699|NCT01031693|Sham Comparator|Group B|Sham TMS
89261700|NCT01323491||routine smokers|would-be non-smokers, no actual nicotine replacement therapy
89261701|NCT01323413||stroke|acute ischemic stroke patients
89261702|NCT00441701|Experimental|Part 1: Navarixin 3 mg|Cohort 1: Participants receive navarixin 3 mg (three 1 mg capsules) once daily (QD) for up to 12 weeks
89261703|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 3 mg|Cohort 1: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
89261704|NCT00441701|Experimental|Part 1: Navarixin 10 mg|Cohort 2: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
89261705|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 10 mg|Cohort 2: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
89261706|NCT00441701|Experimental|Part 1: Navarixin 30 mg|Cohort 3: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
89261707|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 30 mg|Cohort 3: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
89261708|NCT00441701|Experimental|Part 2: Navarixin 3 mg|Cohort 4: Participants receive navarixin 3 mg (three 1 mg capsules) QD for up to 12 weeks
89261709|NCT00441701|Experimental|Part 2: Navarixin 10 mg|Cohort 4: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
89261710|NCT00441701|Experimental|Part 2: Navarixin 30 mg|Cohort 4: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
89261711|NCT00441701|Placebo Comparator|Part 2: Placebo to navarixin|Cohort 4: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
89261712|NCT00441545|Experimental|1|Fosrenol (Lanthanum carbonate)
89261713|NCT00441545|Active Comparator|2|Sevelamer hydrochloride
89261714|NCT03995381|Experimental|DAs group|Shared decision making using decision aids
89261715|NCT03995381|No Intervention|Control group|Standard oral explanation guided with booklets
89261716|NCT01031849|Experimental|Kaletra, all patients|Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day
89261717|NCT00436553|Experimental|Verteporfin With Standard Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
89261718|NCT00436553|Active Comparator|Ranibizumab Monotherapy|Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).
89261719|NCT00436553|Experimental|Verteporfin With Reduced Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
89261720|NCT00441467|Experimental|Glufosfamide|Glufosfamide
89261721|NCT01028729|Experimental|Endostar with chemotherapy|All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression.
89261722|NCT03357419|Active Comparator|prophylactic antibiotic|"Each active arm patient will be given the tested drug on admission, 30-60 minutes before the surgery, by the nurses.~2 g dose of cephalexin (or Clindamycin 600 mg for patients suffering from allergy) will be given once, orally, 30-60 minutes prior to skin lesion excision"
89261723|NCT03357419|Placebo Comparator|placebo oral capsule|Each placebo arm patient will be given the placebo drug on admission, 30-60 minutes before the surgery, by the nurses
89261724|NCT01028807|Experimental|1. Experimental group: Early feeding:|After 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
89261725|NCT01028807|Active Comparator|Control group : Obligatory 5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
89261726|NCT01028885|Experimental|Arm I|"Patients undergo MRI and CT scan-based simulation for treatment planning with endorectal balloon target immobilization. The treatment target volumes and surrounding organs at risk are contoured, treatment plan developed and approved.~Patients then undergo 39 fractions of image-guided intensity-modulated radiotherapy over 8 weeks. Patients also undergo weekly MRI scans of the pelvis (in the planned treatment position) during radiotherapy."
89261727|NCT01032005|Placebo Comparator|Fortified salt|Common table salt that has been fortified with iodine only
89261728|NCT01032005|Experimental|Double fortified salt|Common table salt that has been fortified with iron and well as the usual iodine
89261731|NCT00436163|Experimental|Peginterferon Alfa-2a|Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.
89261732|NCT01029041|Experimental|Strengthening exercise|This group does global strengthening exercise
89261733|NCT01029041|Experimental|Stretching exercise|This group does global stretching exercise
89261734|NCT01029041|No Intervention|Control|This group does nor do any kind of exercise during the study
89261735|NCT00006604|Experimental|Step I: Group 1|"Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
89261736|NCT00006604|Experimental|Step I: Group 2|"Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
89261737|NCT00006604|Experimental|Step I: Group 3|"Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 415 mg/m2, 520 mg/m^2; Final Dose: 520 mg/m^2"
89261738|NCT00006604|Experimental|Step I: Group 4|"Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 520 mg/m^2, 620 mg/m^2; Final Dose: 620 mg/m^2"
89261739|NCT00006604|Experimental|Step I: Group 5|"Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
89261740|NCT00006604|Experimental|Step I: Group 5a|"Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
89261741|NCT00006604|Experimental|Step I: Group 6|"Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
89261742|NCT00006604|Experimental|Step I: Group 7|"Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
89261743|NCT00006604|Experimental|Step I: Group 8|"Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
89261744|NCT03951376|Experimental|Intervention|"The schools in this arm will implement the UPRIGHT programme (18 skills related to Mindfulness, Coping, Efficacy and Social and emotional learning) during a minimum of 18 sessions and a maximum of 24 in a period of 6 months, which will be conducted by teachers to adolescents of 1st grade (12-14 years of age).~Teachers will be trained by the UPRIGHT team at the beginning of the school year (3 months) and families will have a combination of face to face training and online training throughout the UPRIGHT platform."
89261745|NCT03951376|No Intervention|Control|Schools in the control arm have their usual curricula and are not provided of any intervention resources or support, apart from those in the common daily activities.
89261746|NCT01097902|Active Comparator|Ibuprophen 800 mg|Oral ibuprofen 800 mg, administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
89261747|NCT01097902|Placebo Comparator|Placebo|Oral placebo administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
89261748|NCT00436007|Experimental|GSK 257049 1 Group|"Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib, Polio Sabin™ and GSK 257049 vaccines at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ vaccines at Month 7.~The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania."
89261749|NCT00436007|Experimental|GSK 257049 2 Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, 3 doses of GSK 257049 vaccine at Months 0, 1 and 7, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. Stamaril™ was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
89290434|NCT01223274|Experimental|CPAP/PEEP Intervention|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
89261750|NCT00436007|Active Comparator|Tritanrix™ HepB/Hiberix™ Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
89261751|NCT01032161||Delirium|Delirium was determined by RASS-PAEDS
89261752|NCT01032161||no Delirium|no Delirium was determined by RASS-PAEDS
89261753|NCT01032317|Other|Single-arm Study|This study was completed prior to the implementation of the requirement for specific identification of study arms. As the requirement was not made retroactive to completed studies, we believe this study to be exempt from the stipulation. Also, per PRS definition, since this is for a single-arm/feasibility study, the data elements are optional.
89261754|NCT01029197|Experimental|CBT Intervention|The CBT intervention includes psychoeducation and coping and social skills delivered in a group format, and exposure therapy delivered in individual sessions
89261755|NCT01029197|Active Comparator|Treatment as Usual|The TAU Condition will receive usual services at the community clinic, which may include medications, individual or group therapy
89261756|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.
89261757|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
89261758|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.
89261759|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
89261760|NCT01097980|Experimental|Trazodone|Trazodone versus placebo in a randomized, double-blind manner
89261761|NCT01097980|Placebo Comparator|Placebo|Patients received placebo
89261762|NCT01029275|Experimental|Arm A|pre-operative medical treatment with Sandostatin
89261763|NCT01029275|No Intervention|Arm B|pituitary surgery as a first line treatment
88805122|NCT01073657|Experimental|Supported Education|Veterans received supported education services. A Veteran peer met weekly as needed with a subject for up to six months in a psycho-social rehabilitation service for meeting education goals. Goals included choosing a college, getting admitted or enrolled, and maintaining enrollment and completing classes.
88805123|NCT01073657|Active Comparator|General Peer Support|Matched attention was provided by a Veteran peer who met weekly with Veterans but who focused on help with any personal goal (eg, employment, housing) but not on education.
89261764|NCT01098058|Experimental|CBT plus treatment as usual|
89261765|NCT01098058|Active Comparator|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
89261766|NCT03994445|Experimental|Intervention group|Intervention group will be enrolled to the intervention program proposed to be (pharmacotherapy + counseling+ motivator phone messages).
89261767|NCT03994445|No Intervention|Control group|Control group will receive the standard treatment of the Ministry of the Health program (pharmacotherapy + counseling) only.
89261768|NCT01029431|Experimental|1|All subjects will have both Air-Q ILA & PLMA
89261769|NCT00434759|Active Comparator|SCP|SCP is a stepped-care program with a self-help module with minimal therapist contact (8 sessions) as first step, followed by therapist-guided intervention depending on status of remission (8 sessions up to a maximum of 16 sessions).
89261770|NCT00434759|Active Comparator|ST|A standard therapy which means a therapist-guided intervention with 16 sessions face-to-face therapy.
89261771|NCT01029509|Experimental|OPB-31121|OPB-31121 200 mg twice daily for 21 days followed by 7 days of rest
89261772|NCT01032473||GAD|Children between the ages of 7-11 years diagnosed with Generalized Anxiety Disorder (GAD)
89261773|NCT01032473||Control|Children between the ages of 7-11 years free of significant medical or behavioral problems (matched to children diagnosed with GAD based on age, gender, and ethnicity).
89261774|NCT04829903|Active Comparator|Group DUL|Group taking Dulaglutide injections
89261775|NCT04829903|Placebo Comparator|Group LIR|Group taking Liraglutide injections
89261776|NCT01029665||CDH survivors|School age (ages 4-6) Congenital Diaphragmatic Hernia survivors treated at Duke University Medical Center.
89261777|NCT01032551|Experimental|Vascular Access Patient Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
89261778|NCT01032551|No Intervention|Usual Care|"The control group (those not randomized to the PtDA) will have usual care. Usual care involves a brief discussion, just prior to the CA procedure, with the treating physician, regarding the patient's eligibility for both vascular accesses, followed by the advantages and disadvantages of both. The details and duration of the discussion is left to the discretion of the treating physician as per their individual standard of care. There will be no access to a formal PtDA in this group."
89290435|NCT01223274|Active Comparator|Control|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
89290436|NCT01221636|Other|Low Metal Abatacept|Reference
88805124|NCT01074125|Experimental|1 g/day|1 g/day KRX-0502 (ferric citrate)
88805125|NCT01074125|Experimental|6 g/day|6 g/day KRX-0502 (ferric citrate)
88805126|NCT01074125|Experimental|8 g/day|8 g/day KRX-0502 (ferric citrate)
88805127|NCT02618213|Active Comparator|Continous Positive Airway Pressure|CPAP is administered through a binasal tube fitted with a Benveniste gas jet administered with humified airflow. Start flow is 12-14 l/min and can be changed to maximum 15 or minimum 12 l/min. Oxygen can be supplied as needed to keep SpO2 (peripheral capillary Oxygen saturation) within acceptable limits.
89261779|NCT00440999|Experimental|pyronaridine artesunate|The tablet strength is 180:60 mg oral PA plus chloroquine-placebo. Depending on their body weight, patients receive 1 to 4 tablets once a day, for 3 days. The actual dose-level range covered by this regimen is 7.2: 2.4 mg/kg to 13.8:4.6 mg/kg pyronaridine artesunate.
89261780|NCT00440999|Active Comparator|chloroquine|"The tablet strength is 155 mg oral chloroquine plus PA-placebo.~Patients receive:~For adults: 620 mg (i.e. 4 tablets) on Days 0 and 1 and 310 mg (i.e. 2 tablets) on Day 2. For children: 10 mg/kg on Days 0 and 1 and 5 mg/kg on Day 2."
89261781|NCT00434213|Experimental|Methylphenidate Transdermal System|To characterize the dermal reactions seen with the use of DAYTRANA
89261782|NCT01029743||Group 1|
89261783|NCT01029743||Group 2|
89261784|NCT01032785||Healthy term newborn|Any healthy term newborn born in Wolfson Medical Center
89261785|NCT01029821|Other|Low-Molecular-Weight Heparin for DVT|Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures
89261786|NCT00006184|Experimental|Recipient - Chemotherapy Group|Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and granulocyte colony stimulating factor (GCSF) followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.
89261787|NCT00006184|Other|Donor - Vaccine Generation Group|3 subcutaneous injections of myeloma protein within 10 weeks before stem cell collection. The first (week 0) second (week 2), and third injection (week 6) with Id-KLH (Anti-idiotype-keyhole limpet hemocyanin) (0.5 mg subcutaneous day 1) and Granulocyte macrophage-colony stimulating factor (GM-CSF) (250 mcg/m^2 subcutaneous on days 1-4). Stem cell collection is 4 weeks after the third vaccination.
89261788|NCT00434057|Other|Biopsied Pigmented Skin Lesions|Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto
89261789|NCT01098136|Active Comparator|Chiropractic treatment|Management for one-sided pelvic pain, as decided by the chiropractor
89261790|NCT01098136|Active Comparator|Conventional health care|Conventional health care for one-sided pelvic pain
89261791|NCT01098136|Active Comparator|Conventional and alternative treatment|Treament of pregnant women with other pelvic pain syndromes.
89261792|NCT00433199|Placebo Comparator|Placebo|Placebo
89261793|NCT00433199|Experimental|T-Gel 1.62%|Testosterone (T) gel 1.62%
88805128|NCT02618213|Active Comparator|High Flow Oxygenation Therapy|HFOT is administered by optiflow Junior ( Fisher&Paykal Healthcare® Auckland, New Zealand) Start flow 12-14 l/min. Oxygen can be supplied as needed to keep Sp02 within acceptable limits
88805129|NCT01108835|Active Comparator|comprehensive care programme|Comprehensive care involving multidisciplinary input.
88805130|NCT01108835|No Intervention|Control group|Control arm with usual care
88805131|NCT03014141|Active Comparator|Oat bran (Oatwell 28)|A beverage containing 11 gram (3 gram of oat beta-glucan) of Oat bran (Oatwell 28) will be consumed before breakfast
88805132|NCT03014141|Placebo Comparator|Maltodextrin|A beverage containing 11 gram of maltodextrin will be consumed before breakfast.
88805133|NCT01076231|Experimental|Arm I|"Patients undergo proton beam radiotherapy over 5.5-7.5 weeks. Patients receive concurrent chemotherapy comprising cisplatin IV on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and days 29-33.Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 4-6 weeks after completion of chemoradiotherapy, patients may undergo surgical resection or additional chemoradiotherapy."
88805134|NCT00117962|Experimental|Std Tx + Pemetrexed|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on days 1, 22, 43, and 64. Patients also undergo thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
88805135|NCT00117962|Experimental|Std Tx + Pemetrexed and Cetuximab|Patients receive pemetrexed disodium, carboplatin, and thoracic radiotherapy as in arm I. Patients also receive cetuximab IV over 2 hours on day 1 and then IV over 1 hour on days 8, 15, 22, 29, 36, and 43.
88805136|NCT01109069|Experimental|PCI-32765|
88805137|NCT00118274|Experimental|Arm I|Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
89261794|NCT03950986|No Intervention|Control|Providers assigned to the control group will receive unmodified vaccine reminders (as they already appear in the VA EHR system). Separate reminders will appear for the different vaccines of interest.
89261795|NCT03950986|Experimental|Treatment|Providers in the treatment group will receive modified clinical reminders for the vaccines of interest. Reminders for the different vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
89261796|NCT01101256||Fondaparinux Prophylaxis group|
89261797|NCT01101256||Fondaparinux Therapy group|
89261798|NCT03226379|Other|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~Health system strengthening~Delivery of a co-designed education program tailored to frontline healthcare workers~Implementation of an algorithm for HIV-related meningoencephalitis~Infectious diseases/AHD mentorship and laboratory capacity building"
89261799|NCT01098292||Healthy Control|"Healthy Control participants do not suffer from any Urological Chronic Pelvic Pain Syndromes or from the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
89261800|NCT01098292||Positive Control|"Positive Control participants do not suffer from any Urological Pelvic Pain Syndromes like Interstitial Cystitis and/or Chronic Prostatitis. However Positive Controls have a history of one of the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
89261801|NCT03178799||FLS|Fracture Liaison Service (Care managers based coordination service for fragility fracture patients with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years.)
89290437|NCT01221636|Experimental|High Metal Abatacept|
89261802|NCT03178799||UC|usual care (Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years. )
89261803|NCT01030055|Experimental|TKI258 - bioavailability|
89261804|NCT01030055|Experimental|TKI258 - food|
89261805|NCT03994991|Experimental|Active TMS|Patients in the active TMS group will receive active TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
89261806|NCT03994991|Sham Comparator|Sham TMS|Patients in the shamTMS group will receive sham TMS 2 times a day for 5 days. In addition, these patients will have MRI before the first TMS session and after the last TMS session.
89261807|NCT01327378||Dialysis, normal glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min < 7.8 mmol/L
89261808|NCT01327378||Dialysis, impaired glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min 7.7<11.1 mmol/L
89261809|NCT01327378||Control, normal glucose tolerance|Healthy Control subjects, N=10 OGTT,120 min <7.8 mmol/L
89261810|NCT03994757|Experimental|MRBI group|
89261811|NCT03994757|Sham Comparator|Control group|
89261812|NCT01098448|Active Comparator|Scaling and root planing|scaling and root planing as a solo therapy
89261813|NCT01098448|Experimental|Periodontal surgery|
89261814|NCT01098448|Experimental|systemic antibiotics|
89261815|NCT01098448|Experimental|Local delivery of tetracycline|
89261816|NCT01098448|Experimental|local antibiotic and systemic antibiotics|
89261817|NCT01098448|Experimental|local antibiotics and surgery|
89261818|NCT01098448|Experimental|systemic antibiotics and surgery|
89261819|NCT01098448|Experimental|local and systemic antibiotics and surgery|
89261820|NCT01032863||Young healthy Indian adults|Persons aged between 25 and 40 years of age who are relatives of patients being treated in Amrita Institute of Medical Sciences (Inpatient or Outpatient) and voluntary blood donors at the same institute who are willing to participate in the study.
89261821|NCT01098526|Experimental|Cohort 1|Subjects will receive a single dose of GSK1349572 100 mg in Period 1 followed by a washout of at least 6 days. Subjects will then receive GSK1349572 50 mg once a day for 5 days in Period 2. Period 3 will begin immediately after Period 2. In Period 3 subjects will receive GSK1349572 50 mg once a day in the morning and Efavirenz 600 mg once a day at bedtime for 14 days. There will be a screening visit up to 30 days before Period 1 and a follow up visit 7-14 days after the end of Period 3.
89261822|NCT01030211|Active Comparator|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
89261823|NCT01030211|Other|Supportive care|No platelet transfusion for patients with platelet count <20x10^3/uL
89261824|NCT01030367|Experimental|1|PETN
89261825|NCT01030367|Experimental|2|ISDN
89261826|NCT01030367|No Intervention|3|
89261827|NCT01032941|Placebo Comparator|Placebo|Patients in this group will be given placebo 2 packets BID for 8 weeks.
89261828|NCT01032941|Experimental|VSL#3|Patients in this group will be given 2 packets of VSL#3 BID for 8 weeks.
89261829|NCT00005908|Experimental|Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine|Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
89261830|NCT00005908|Experimental|Dose B-Cohort 2-Arm 2 Reduced dose-Docetaxel & Capecitabine|Docetaxel 60 mg/m^2 intravenous day 1, capecitabine 937.5 mg/m^2 orally twice daily day 2-15 for 4 cycles
89261831|NCT00432965|Experimental|VAC Therapy|Treatment of Diabetic Foot Ulcers with VAC Therapy
89261832|NCT00432965|Active Comparator|Moist Wound Therapy|Moist Wound Therapy (standard of care)
89261833|NCT01098604|Active Comparator|32mm ceramic head group|patients performed with THA using 32mm ceramic head
89261834|NCT01098604|Active Comparator|28mm ceramic head group|patients performed with THA using 28mm ceramic head
89261835|NCT00440297|Experimental|Modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
89261836|NCT00440297|Active Comparator|ENGERIX-B™2|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
89261837|NCT00432809|No Intervention|Medical therapy|Intensive medical therapy for diabetes
89261838|NCT00432809|Active Comparator|Gastric Bypass|Procedure/Surgery: Bariatric surgery laparoscipic Roux-en-Y Gastric Bypass (RYGB) plus intensive medical therapy
89261839|NCT00432809|Active Comparator|Sleeve Gastrectomy|Procedure/Surgery: Bariatric surgery - laparoscopic sleeve gastrectomy plus intensive medical therapy
89261840|NCT01030445||Elevated Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation above the mean based on age
89261841|NCT01030445||Decrease Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation below the mean based on age
89261842|NCT01030445||Normal Mean Arterial Blood Pressure|Mean arterial pressure within the standard deviation of the mean based on age
89261843|NCT00431951|Experimental|ST-246|250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days
89261844|NCT00431951|Placebo Comparator|placebo|Placebo to match ST-246
89261845|NCT00004978|Experimental|rIL-2|Recombinant interleukin-2 (rIL-2) therapy used with combination anti-HIV medication of choice.
89261846|NCT00004978|No Intervention|No rIL-2|Control arm uses anti-HIV medication of choice without rIL-2.
89261847|NCT01030601|No Intervention|Control|Diabetics undergoing routine cataract surgery
89261848|NCT01030601|Experimental|Treatment|Diabetics undergoing cataract surgery with injection of 0.5mg in 0.05cc of dexamethasone at the end of surgery
89261849|NCT01030679|Experimental|CKD-501 0.5mg|
89261850|NCT01030679|Experimental|CKD-501 1mg|
89261851|NCT01030679|Experimental|CKD-501 2mg|
89261852|NCT01030679|Placebo Comparator|Placebo|
89261853|NCT00430937|Experimental|Daptomycin|4 mg/kg intravenous (i.v.) once daily
89261854|NCT00430937|Active Comparator|Pooled Comparator|
89261855|NCT01101412|Experimental|Arm I: Antimicrobial Solution|Antimicrobial solution into central or peripheral venous catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
89290438|NCT05731804|Experimental|Cohort 1 of Part A|Subjects with mild renal impairment(SIM0417 600 mg; Ritonavir100 mg )
89261856|NCT01101412|Active Comparator|Arm II: Saline Solution|Saline solution into CVC or PVC once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
89261857|NCT03130595||PD outpatients in West Sweden|Cross-sectional random sample of patients with PD that have visited outpatient clinics in West Sweden in the last 6+6 months
89261858|NCT00004888|Experimental|Arm I (combination chemotherapy)|"Patients receive doxorubicin hydrochloride liposome IV over 30 minutes followed by docetaxel IV over 1 hour. Treatment is repeated every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive maintenance therapy of docetaxel IV over 1 hour either weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
89261859|NCT00004888|Experimental|Arm II (combination chemotherapy, trastuzumab)|"Patients receive trastuzumab IV over 90 minutes on day 1, with subsequent doses over 30 minutes. Patients receive doxorubicin HCl liposome IV over 30 minutes followed by docetaxel IV over 1 hour on day 2 of course 1, followed by subsequent doses on day 1 of each course. Antibody therapy continues weekly and chemotherapy every 3 weeks for 8 courses.~Patients may receive maintenance therapy of trastuzumab IV over 30 minutes weekly followed by docetaxel IV over 1 hour weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
89261860|NCT03951220||Group 1- Myeloma|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.~This will be repeated at 6 months."
89261861|NCT03951220||Group 2- MGUS|"Participants will be recruited at the point of either diagnosis or relapse. Any standard investigations that the clinician deems necessary will be carried out. Following recruitment, participants will undergo the first study appointment, the experimental combined MR imaging protocol, the DXA imaging scan and the bone biomarker blood and urine tests.~This will be repeated at 6 months."
89261862|NCT03951220||Group 3- Healthy Volunteers|Participants will have the experimental combined MR imaging.
89261863|NCT00004732|Active Comparator|Carotid Artery Endarterectomy (CEA)|Carotid endarterectomy is surgery to remove plaque buildup that causes narrowing (stenosis) in the carotid artery.
89261864|NCT00004732|Active Comparator|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) is a procedure used to open narrowed carotid arteries. During the procedure, a small, expandable wire tube called a stent is permanently inserted into the carotid artery.
89261865|NCT01098760|Experimental|Arm 1|
89261866|NCT03952390||control|healthy volunteers
89261867|NCT03952390||sepsis|patients with sepsis
89261868|NCT00430781|Experimental|Combination arm|Pazopanib plus lapatinib
89261869|NCT00430781|Active Comparator|Lapatinib monotherapy|Lapatinib
89261870|NCT00430781|Active Comparator|Pazopanib monotherapy|Pazopanib
89261871|NCT01033097|Experimental|DNK333 5 mg|
89261872|NCT01033097|Placebo Comparator|Placebo to DNK333 5mg|
89261873|NCT01033097|Experimental|DNK333 25 mg|
89261874|NCT01033097|Placebo Comparator|Placebo to DNK333 25 mg|
89261875|NCT01033097|Experimental|DNK333 100 mg|
89261876|NCT01033097|Placebo Comparator|Placebo to DNK333 100 mg|
89261877|NCT01033097|Active Comparator|Betamethasone 4 mg|
89261878|NCT01033097|Experimental|DNK333 1 mg|
89261879|NCT01033097|Placebo Comparator|placebo 1mg|
89261880|NCT01323725|Experimental|Team-based financial incentives|Team-based financial incentives
89261881|NCT00429299|Active Comparator|Arm A|Chemotherapy plus trastuzumab
88805138|NCT00118274|Experimental|Arm II|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
89261882|NCT00429299|Experimental|Arm B|Chemotherapy plus lapatinib
89261883|NCT00429299|Active Comparator|Arm C|Chemotherapy plus trastuzumab plus lapatinib
89261884|NCT01033799|Sham Comparator|Control Product|
89261885|NCT01033799|Active Comparator|Tested Product|
89261886|NCT01033877|Experimental|TdaP vaccine|
89261887|NCT01033877|Active Comparator|Td vaccine|
89261888|NCT00428597|Experimental|A|
89261889|NCT00428597|Placebo Comparator|B|
89261890|NCT01033955|Experimental|Drug (Rosuvastatin) Crestor|The first dose of encapsulated study drug or placebo (day 1) will be administered within 4 hours of randomization as a loading dose of 40 mg. The placebo will be identical in appearance to Rosuvastatin. Thereafter, doses of 20 mg will be administered daily starting on the next calendar day at 10 pm daily (+/- 4 hours) as a maintenance dose from days 2 to 14. If the patient is of Asian descent, is <18 years, or serum creatinine is greater than or equal to 248 μmol/L (2.8 mg/dL) dose adjustments will be made according to a dose adjustment algorithm.
89261891|NCT01033955|Placebo Comparator|Placebo|An identical appearing placebo will be administered to patients in the second study arm.
89261892|NCT01033175|Other|COPD patients with ACD|"In the 1st part of this clinical study the prevalence ACD in COPD subjects will be estimated in a consecutive population of COPD subjects who will visit the hospital's pulmonary clinics as outpatients. During the first visit, subjects will give a detailed medical history and will undergo clinical examination and pulmonary function testing 15 minutes post-bronchodilation. Eligible patients will then undergo peripheral venous blood analysis. The first 30 COPD subjects from the population described above, fulfilling the criteria of ACD will constitute the first arm (group of cases).ACD is defined by low Hb levels (men: <13 mg/dl, women: <12 mg/dl), no other cause of anemia present, normal or increased serum ferritin and decreased total iron binding capacity."
89261893|NCT01033175|Other|COPD patients without ACD|"Thirty matched patients with COPD without ACD from the initial cohort will constitute the second arm (the controls)"
89290439|NCT05731804|Experimental|Cohort 2 of Part A|Subjects with moderate renal impairment(SIM0417 375 mg; Ritonavir100 mg )
89290440|NCT05731804|Experimental|Cohort 3 of Part A|Subjects with normal renal function(SIM0417 600 mg; Ritonavir100 mg )
89290441|NCT05731804|Experimental|Cohort 4 of Part A|Subjects with normal renal function(SIM0417 375 mg; Ritonavir100 mg )
89261894|NCT01033253|Experimental|Computerized Tailored Intervention|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
89261895|NCT01033253|No Intervention|Control|Computerized assessments of Transtheoretical Model constructs at 0, 2, 6, and 12 months
89261896|NCT03967665|Experimental|Treatment arm|NAC 400 mg three times per day from -14D pre-HSCT to +2 months
89261897|NCT03967665|No Intervention|Control arm|No-NAC concurrent control according to a 2:1 schedule.
89261898|NCT00144027|No Intervention|Control|The control group will receive treatment as usual; meaning patients in the control group will not receive the medication adherence intervention.
89261899|NCT00144027|Experimental|Antipsychotic adherence intervention|Antipsychotic Medication Adherence Intervention which included the Barriers, Facilitators, and Motivators Checklist summary and Adherence tips provided in hard copy to patient and electronic copy to mental health provider.
89261900|NCT00127803|Placebo Comparator|Placebo|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28, and 56, respectively.
89261901|NCT00127803|Experimental|Low dose vaccine|Participants will receive a 2 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively.
89261902|NCT00127803|Experimental|Medium dose vaccine|Participants will receive a 10 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
89261903|NCT00127803|Experimental|High dose vaccine|Participants will receive a 50 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
89261904|NCT03967431|Experimental|Narrative Enhancement and Cognitive Therapy group|The patients in the experimental group received narrative enhancement and cognitive therapy which contains 20 times group meetings.
89261905|NCT03967431|No Intervention|Control group|The patients in the control group received routine care.
89261906|NCT03967509|Experimental|Behavioral teacher training|Behavioral preschool teacher training (BPTT) delivered in an educational group format during nine 2,5-hour biweekly sessions with training at sessions and in between followed by supervisor's feedback on the practice and two optional coaching occasions on the spot.
89261907|NCT03967509|No Intervention|Waiting list control group|Preschool teachers worked with children as usual.
89261908|NCT01077999|Active Comparator|Carboplatin + paclitaxel + radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
89261909|NCT01077999|Experimental|Carboplatin+ paclitaxel+ panitumumab+ radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy. Panitumumab panitumumab: 6mg/kg in weeks 1-3-5.
89261910|NCT00127413|Experimental|Cognitive Behavioral Therapy - Pain|Cognitive Behavioral Therapy targeting chronic pain
89261911|NCT00127413|Experimental|Cognitive Behavioral Therapy-Integrated|Integrated treatment for comorbid chronic pain and PTSD
89261912|NCT00127413|Experimental|Cognitive Processing Therapy - PTSD|Cognitive Processing Therapy for PTSD
89261913|NCT00127413|Other|Treat as Usual|Participants received care for pain and PTSD as usual from their Primary care provider
89261914|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^7|Arm 1 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^7 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^7 CFU oral dosage through Day 28.
89261915|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^8|Arm 2 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^8 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^8 CFU oral dosage through Day 28.
89261916|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^9|Arm 3 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^9 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^9 CFU oral dosage through Day 28.
89261917|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^10|Arm 4 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^10 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^10 CFU oral dosage through Day 28.
89261918|NCT03971565||Patients with chronic lymphocytic leukemia|Patient with a minimum period of 90 days without treatment
89261919|NCT01037465|Active Comparator|N-acetylcysteine|N-acetylcysteine
89261920|NCT01037465|Placebo Comparator|Placebo|Placebo
89261921|NCT03971331|No Intervention|control group|Patients in control group received usual care that was decided by attending.
89261922|NCT03971331|Experimental|study group|Patients in study group who had been placed the PAC were performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately.
89261923|NCT01582425|Experimental|Isavuconazole and methadone|Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
89261924|NCT00143403|Experimental|1|
89261925|NCT00143403|Active Comparator|2|
89261926|NCT00220701|Experimental|escitalopram|Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
89261927|NCT00220701|Placebo Comparator|Placebo|inactive comparator
89261928|NCT00127101|Experimental|Cohort 1|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
89261929|NCT00127101|Experimental|Cohort 2|Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
89261930|NCT00127101|Experimental|Cohort 2a|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter[2] daily x 7 days per week
89261931|NCT00127101|Experimental|Cohort 2b|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter[2] daily x 7 days per week
89261932|NCT00127101|Experimental|Cohort 6|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
89261933|NCT00127101|Experimental|Cohort 7|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week [150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)
89261934|NCT03967119||Laparoscopic surgery|"The following parameters are assessed and recorded at the following time points in all participants.~The parameters assessed: mean arterial pressure, heart rate, pulse oxygen saturation, SVV, PPV, PWV, peak inspiratory pressure, plateau pressure, positive end-expiratory pressure, respiratory rate (all dynamic variables are assessed at two levels of tidal volume- 6 ml/kg and 12 ml/kg).~The time points: T0, before anesthetic induction; T1, immediately after anesthetic induction; T2, immediately after pneumoperitoneum; T3, 10 min before desufflation; T4, immediately after desufflation.~The desufflation-induced hypotension is defined as more than 20 % decrease in MAP at T4 from MAP at T3."
89261935|NCT00126555|Experimental|Stratum I (Gefitinib, Radiotherapy, Surgery)|"Resectable Strata: Induction Gefitinib (60 days), Surgery followed 3-6 weeks later by daily Radiotherapy 5 days a week for approximately 6-7 weeks then after 4 weeks restart Maintenance Gefitinib for up to additional 12 months post radiation.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
89261936|NCT00126555|Experimental|Stratum II (Gefitinib, Radiotherapy/Surgery)|"Unresectable Strata: Concomitant Radiation/Gefitinib and post-radiation (or post-surgery if surgery is indicated) Gefitinib. Daily Radiotherapy 5 days a week for approximately 6-7 weeks concurrent with Maintenance Gefitinib dose daily up to 12 months.~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
89261937|NCT00004228|Experimental|A0 (localized disease Stg I/II) Modified CCG BFM|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Doxorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Methotrexate, Intrathecal Methotrexate)
89261938|NCT00004228|Experimental|A1 (Disseminated, No CNS - CCG mod BFM w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, prednisone, Methotrexate, Intrathecal Methotrexate)
89261939|NCT00004228|Experimental|A2 (Disseminated, No CNS - CCG mod BFM w/ intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
89261940|NCT00004228|Experimental|B2 (CNS+) NHL/BFM-95 w/intens delayed radiation therapy|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
89261941|NCT00004228|Experimental|B1 (Disseminated CNS- <Amend 7B) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
89261942|NCT00004228|Experimental|B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
89261943|NCT00004228|Experimental|B1 (Disseminated CNS-) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
89261944|NCT01101568|Experimental|Single Sequence|Simvastatin will be administered on Day 1 and Day 10. Rosuvastatin will be administered on Day 3 and Day 12. GSK1292263 will be administered on Days 6 to 14.
89261945|NCT01098838|Experimental|Weekly dosing of LCL161|by mouth (oral)
88805139|NCT00118274|Experimental|Arm III|Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
89261946|NCT01098838|Experimental|Comparison of LCL161|tablet versus liquid
89261947|NCT01098838|Experimental|Twice daily dosing of LCL161|by mouth for 4 days followed by a 3-day rest period every week
89261948|NCT01098916|Experimental|X-rays at home|Home hospitalized elderly patients undergo X-rays at home
89261949|NCT01098916|Active Comparator|Hospital X-rays|Home hospitalized elderly patients undergo X-rays examinations in hospital
89261950|NCT01087840|Experimental|Raltegravir, NPEP|"Drug: Raltegravir Tablet 400mg taken orally, twice daily with or without food for 28 days along with Truvada 1 tablet taken orally daily for 28 days.~Arms: Raltegravir/Truvada"
89261951|NCT01098994|Other|Haptoglobin 1/1|Individuals with type 1 diabetes and the Haptoglobin 1/1 phenotype
89261952|NCT01098994|Other|Haptoglobin 2/1|Individuals with type 1 diabetes and the Haptoglobin 2/1 phenotype
89261953|NCT01098994|Other|Haptoglobin 2/2|Individuals with type 1 diabetes and the Haptoglobin 2/2 phenotype
89261954|NCT01099072|Active Comparator|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
89261955|NCT01099072|Experimental|methylphenidate+carnitine|
89261956|NCT00003526|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89261957|NCT00195260|Experimental|Dose escalation|Dose finding study of monotherapy bosutinib in patients with advanced solid tumors.
89261958|NCT00195260|Experimental|Colorectal Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
89261959|NCT00195260|Experimental|Pancreatic Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
89261960|NCT00195260|Experimental|Non-Small Cell Lung Cancer (NSCLC)|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
89261961|NCT00031486|Experimental|Valacyclovir|
89261962|NCT00031486|Placebo Comparator|Placebo|
89261963|NCT01099150|Experimental|42 healthy volunteers - crossover|"Acute consumption of three interventions (60 g dark chocolate enriched in flavan-3-ols, 60 g standard dark chocolate, or 60 g white chocolate) on three separate days (at least 2 weeks apart) in random order.~Post-prandial measurements at t = 0 h, t = 2 h and t = 6 h."
89261964|NCT00003508|Experimental|Arm: Experimental: Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89261965|NCT01088074|Active Comparator|Histoacryl Tissue Adhesive|Histoacryl Blue (HAB) Tissue Adhesive (n-butyl-2 cyanoacrylate; B. Braun Corp., Melsungen, Germany). Histocryl is a FDA-approved sterile liquid skin adhesive that has been utilized as a substitute for sutures for wound closure for approximately 40 years.
89261966|NCT01088074|Active Comparator|Dermabond|Dermabond High Viscosity Tissue Adhesive (2-ocytl cyanoacrylate; Ethicon, Somerville, NJ). Dermabond is also a FDA-approved liquid bonding agent that has been utilized for wound closure for approximately 10 years and proven as effective as sutures.
89261967|NCT01088074|Active Comparator|Staples|Visistat 35W Stapler (Teleflex Corp, Limerick, PA). The FDA-approved Weck staple system with stainless steel staples has been proven over years of use and remains the standard accepted closure approach due to speed of insertion as well as removal.
89261968|NCT01088074|Active Comparator|Running Subcuticular with Monocryl|Monocryl 4-0 Suture (Ethicon, Somerville, NJ). Monocryl is an FDA-approved absorbable, synthetic, suture indicated for soft tissue approximation.
89261969|NCT03952000|Experimental|Experimental: Exercise|Exercise: Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1.
89261970|NCT03952000|No Intervention|No Intervention: Control|Participants will rest on day 1.
89261971|NCT03951922|Experimental|Therapeutic Horticulture Group|The therapeutic horticulture group will participate in a 6-week horticulture program meeting twice a week for an hour led by an occupational therapist incorporating plant-based activities and education on pain management techniques at a community farm.
89261972|NCT03961594|Other|volume expansion in the ventilated patient|Including 51 patients, ventilated, under vasopressors suffering from septic shock. GLS, cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders. Patients with a 15% increase in cardiac output 20minutes after the end of volume expansion will be classified as persistent responders.
89261973|NCT02530060|Experimental|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive single oral dose of fixed dose combination (FDC) tablet comprising of Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine on Day 1.
89261974|NCT01101646|Experimental|001|rabeprazole sodium four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
89261975|NCT01101646|Experimental|002|rabeprazole sodium two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
89261976|NCT01101646|Experimental|003|rabeprazole sodium four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
89261977|NCT02530216|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
89261978|NCT02530216|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
89261979|NCT01101724|No Intervention|Standard of Care|In this group, the treating attending physician will be free to make rest recommendations as they see fit. An internal survey of physician practice found that the vast majority of physicians instruct patients rest for 1-2 days, then to return to school and physical activity after the patient's symptoms have resolved. The amount of rest will vary from patients to patient based on variation in symptom resolution and patient compliance. This advice is consistent with best practices outlined by the CDC.
89261980|NCT01101724|Experimental|Intervention|Mandated Rest.
89261981|NCT01584700|Other|Renal Artery Denervation|Ontervention
89261982|NCT01101802|Active Comparator|Mycophenolate mofetil|Patients were given 1gm bd mycophenolate mofetil for 8 weeks
89261983|NCT01101802|Placebo Comparator|Sugar pill|
89261984|NCT01099228|Active Comparator|131-I MIBG and 111I-n pentetreotide|131-I MIBG and 111I-n pentetreotide
89261985|NCT01099228|Active Comparator|131-I MIBG and In-111 DOTATATE|131-I MIBG and In-111 DOTATATE
89261986|NCT00003472|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89261987|NCT01099306|Active Comparator|intervention|pharmacist-physician collaborative approach to manage Metabolic syndrome
89261988|NCT01099306|No Intervention|control|physician only team to manage Metabolic syndrome
89261989|NCT01088152|Active Comparator|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for celiac disease in primary care
88805140|NCT00118274|Experimental|Arm IV|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
88805141|NCT01109147|Active Comparator|aripiprazole|"Imagery: A fMRI session is conducted on schizophrenic patients under aripiprazole (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
89261990|NCT01088152|Experimental|Celiac School|Structured education using problem-based learning at 10 sessions
89261991|NCT01099384|Active Comparator|Behavioral: written self-help materials|Behavioral: written self-help materials
89261992|NCT01099384|Experimental|Group behavioral counseling|Group behavioral counseling, weekend program
89261993|NCT01088230|Experimental|Botox®|this group will receive an injection of botox in the wrist flexors and forearm pronators
89261994|NCT01088230|Placebo Comparator|Saline|This group will receive an injection of saline solution in the same muscle groups as the treatment group (wrist flexors and pronators).
89261995|NCT01099462||Children with fever|
89261996|NCT01088308|Experimental|Single Arm|All Patients underwent Intervention.
89261997|NCT01099540|Experimental|Pazopanib|
89261998|NCT00003298|Experimental|Experimental Arm|Patients receive 3 courses of preoperative neoadjuvant chemotherapy given on day 1 every 21 days. Courses consist of an intravenous infusion of cisplatin and a 3 hour intravenous infusion of paclitaxel on day 1. Patients then undergo surgery for tumor removal on day 63, followed 4-6 weeks later by one course of daily intravenous bolus leucovorin calcium and fluorouracil for 5 days. Chemotherapy is repeated 4-6 weeks later for the first 4 days of week 1 and the last 3 days of week 5 of radiation therapy given 5 days a week for 5 weeks. Patients receive two more courses, 4 weeks apart, of fluorouracil and leucovorin calcium for 5 days 4-6 weeks after completing radiation treatment.
89261999|NCT01327456|Experimental|Self-Management Intervention|participants who receive the one-on-one self-management intervention
89262000|NCT01327456|No Intervention|Usual Care|group receives no additional education or intervention then they would as usual care of their COPD
89262001|NCT01099696|Experimental|B. infantis 35624|B. infantis 35624 in white capsules
89262002|NCT01099696|Placebo Comparator|placebo|white placebo capsules (inert)
89262003|NCT03961282|Experimental|Parkinson Disease Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
88805142|NCT01109147|Active Comparator|risperidone|"Imagery: A fMRI session is conducted on schizophrenic patients under rsiperidone (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
88805143|NCT01109147|Other|control|Imagery: A fMRI session is conducted on healthy volunteers. Genetic: pharmacogenetic sampling. One sample was collected for each subject.
89262004|NCT03961282|Experimental|Healthy Participant Group|Each participant is randomized into 3 types of door alterations: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design. Then each participant performs Test #1: Doorway Width and Test #2: Door Frame Color.
89262005|NCT03950908|Other|Single bite|The single bite technique involved removing the forceps with its specimen after each individual biopsy.
89262006|NCT03950908|Other|Double bite|The double-bite technique involved taking an initial biopsy, repositioning the forceps, and taking another biopsy from the same area with the initial specimen still on the forceps.
89262007|NCT03951844|Experimental|Experimental group|Each participant is evaluated while wearing or not wearing the device.
89262008|NCT03960970|Active Comparator|One-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once
89262009|NCT03960970|Experimental|Two-drug Prophylaxis|Mefoxin 2g IV, Piggyback, once and Azithromycin 500mg IV, Piggyback, once
89262010|NCT00002842|Experimental|Hepatic Resection/Portal Vein FUdr/Systemic 5-FU & Leucovorin|Patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks
89262011|NCT01099930|Active Comparator|Non-randomized control group|Patients meeting inclusion/exclusion criteria not consenting to treatment will be requested to consent to control group and followed while receiving standard of care.
89262012|NCT01099930|Experimental|Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of Multiple Sclerosis
89262013|NCT03950596|Active Comparator|One acute resistance load exercise|One hundred volunteers will participate in one acute resistance load exercises to their quadriceps
89262014|NCT03950596|Active Comparator|Three acute resistance load exercises|One hundred volunteers will participate in three acute resistance load exercises to their quadriceps
89262015|NCT03950596|Active Comparator|Control Group|One hundred volunteers will participate in study as a control group
89262016|NCT01100008|Experimental|Magnetic resonance imaging|
89262017|NCT01584310|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
89262018|NCT01584310|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
89262019|NCT03951688|Experimental|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
89262020|NCT03951688|No Intervention|Control Group|No intervention
89262021|NCT00143247|Experimental|Exubera® (inhaled insulin)|Open label, no comparator
89262022|NCT00125853|Experimental|atenolol 25mg daily|atenolol 25mg daily
89262023|NCT00125853|Active Comparator|nebivolol 2.5mg daily|nebivolol 2.5mg daily
89262024|NCT00219141|Experimental|Aliskiren 300 mg|Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan placebo. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan placebo. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
89262025|NCT00219141|Active Comparator|Losartan 100 mg|Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
89262026|NCT00219141|Experimental|Aliskiren/losartan 300/100 mg|Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
89262027|NCT00142935|Experimental|Pre-Release Initiation MMT|Participants assigned to this arm will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
89262028|NCT00142935|Experimental|Post Release Initiation of MMT|Participants assigned to this arm will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
89262029|NCT00142935|Active Comparator|Standard of Care Plus|Participants assigned to this arem will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
89262030|NCT03967041||Sarcopenic patients|
89262031|NCT03967041||Non-sarcopenic patients|
89262032|NCT00233948|Experimental|Arm I|Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89262033|NCT00233480|Experimental|active treatment|atorvastatin 10mg QD x 3 months
89262034|NCT00233480|Placebo Comparator|placebo|matched placebo QD x 3 months
89262035|NCT03801928||Ulcerative Colitis|Group treated with Inflectra for Ulcerative Colitis
89262036|NCT03801928||Crohn's Disease|Group treated with Inflectra for Crohn's Disease
89262037|NCT02530918|Experimental|Part 1 DS-7080a dose escalation|3 sequential ascending dose levels (1.0, 2.0, 4.0 mg), every 4 weeks for 12 weeks
89290442|NCT05731804|Experimental|Cohort 5 of Part B|Subjects with moderate hepatic impairment (SIM0417 750 mg; Ritonavir100 mg )
89262038|NCT02530918|Experimental|Part 2 DS-7080a|Specific dose (either the maximum tolerated dose or 4.0 mg) of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
89262039|NCT02530918|Active Comparator|Part 2 ranibizumab|Ranibizumab 0.5 mg, every 4 weeks for 12 weeks
89262040|NCT02530918|Experimental|Part 2 DS-7080a and ranibizumab|Specific dose of DS-7080a determined in Part 1 and ranibizumab 0.5 mg, every 4 weeks for 12 weeks
89262041|NCT02530918|Experimental|Part 3 DS-7080a|Specific dose of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
89262042|NCT02530918|Experimental|Part 3 ranibizumab|Ranibizumab 0.3 mg, every 4 weeks for 12 weeks
89262043|NCT03950518|Experimental|One-drug Regimes|Drug: Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
89262044|NCT03950518|Experimental|Two-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride
89262045|NCT03950518|Experimental|Three-drug Regimes|Anlotinib Hydrochloride Capsules Arginine hydrochloride Levamisole Hydrochloride
89262046|NCT01102036|Placebo Comparator|Yoghurt without probiotics|Yoghurt without probiotic bacteria
89262047|NCT01102036|Active Comparator|Cultura yoghurt|Cultura yoghurt with L casei F19, acidophilus La5 adn B lactis Bb 12
89262048|NCT01100164|Experimental|eszopiclone 3 mg|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
89262049|NCT01100164|Active Comparator|zopiclone 7,5mg|Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
89262050|NCT03950284|Experimental|immediate loading with all on four technique in FFF|immediately loaded dental implants with the all-on-four technique in free vascularized fibular grafts
89262051|NCT01102114|Placebo Comparator|Placebo Vaccine|
89262052|NCT01102114|Experimental|NicVAX Vaccine|
88805144|NCT01109381|Experimental|Treatment with GT08|Initial phase - omeprazole, N-acetyl cysteine (NAC), lauric acid dose and duration titration from 1 up to 14 days of treatment. Secondary phase - 14 days treatment with omeprazole, NAC, lauric acid
88805145|NCT01110395|Experimental|MR Spectroscopy Post-Heart Transplant|Patients post heart transplant getting heart biopsy
89262053|NCT01327222|Experimental|bevacizumab|three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
89262054|NCT01327222|No Intervention|control|monthly follow-up
89262055|NCT03950362|Experimental|Radiotherapy associated to immunotherapy|"Radiotherapy: 60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder~Concomitant administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)"
89262056|NCT00263588|Experimental|single arm|750 mg lapatinib administered orally twice daily
89262057|NCT00213135|Experimental|Cladribine 5.25 mg/kg|
88805146|NCT00166166|Experimental|Healthy Controls|Healthy subjects had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
88805147|NCT00166166|Experimental|Risk Factors|Non-hypertensive subjects with cardiovascular risk factors had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
88805148|NCT03014219|Experimental|Only 1 arm: treatment with MSC-AFP|Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells.
88805149|NCT04265378|Experimental|Stimulation group|Anodal tDCS + intensive cognitive training
88805150|NCT04265378|Sham Comparator|Sham group|Sham tDCS + intensive cognitive training
88805151|NCT00118352|Experimental|Treatment (chemotherapy, TBI, transplant)|"NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 6 hours once daily on days -6, -5, and -4 OR days -5 and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.~ALLOGENEIC PBSCT: After completion of TBI, patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 12 hours on days -3 to 180 followed by a taper until day 365 in the absence of GVHD. Beginning 4-6 hours after completion of allogeneic PBSCT, patients receive mycophenolate mofetil PO every 8 hours on days 0 to 100 followed by a taper until day 156 in the absence of GVHD."
88805152|NCT01111331|Experimental|BI 10773 25 mg|1 tablet 25 mg BI 10773 qd for 5 days
88805153|NCT01111331|Experimental|BI 10773 25 mg + Warfarin 25 mg|1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose
89262058|NCT00213135|Experimental|Cladribine 3.5 mg/kg|
88805154|NCT01111331|Active Comparator|Warfarin 25 mg|5 tablets 5 mg warfarin single dose
88805155|NCT00167102|Experimental|Alefacept|
88805156|NCT00167102|Placebo Comparator|Placebo|
88805157|NCT03014375|Experimental|Etamicastat|Single administration. 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 50 mg, hard gelatina capsules
89262059|NCT00213135|Placebo Comparator|Placebo|
89262060|NCT00077974|Experimental|1|
89262061|NCT00124917|Experimental|Radiation Therapy|Radiation to tumor area as per protocol
89262062|NCT03967353|No Intervention|Routine Treatment Group|Routine treatment group(6 months treatment regimen-2HRZE/4HR); Routine health education; Dose-taken supervised by family members
89262063|NCT03967353|Experimental|Intervention Group|Using mobile technology management means to manage newly treated smear-positive tuberculosis patients, to guide patients'treatment, infection control, doctor-patient communication, and to strengthen health education on infection control of patients.
89262064|NCT01100398||NAFLD/NASH prevalence|Any subject between the ages of 18-70 without known fatty liver disease who meet inclusion criteria
89262065|NCT01102192||Myasthenia gravis with thymoma|Myasthenia gravis with thymoma
89262066|NCT01102192||Myasthenia gravis without thymoma|Myasthenia gravis without thymoma
89262067|NCT01102192||Thymoma without Myasthenia gravis|Thymoma without Myasthenia gravis
89262068|NCT01102192||cardiac, or thyroid surgery|cardiac, or thyroid surgery
89262069|NCT01102348|Experimental|PEP-uP Protocol (after)|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
89262070|NCT01102348|No Intervention|Standard feeding protocol (before)|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
89262071|NCT00141921|Experimental|Etanercept|Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
89262072|NCT00029146|Experimental|Surgical group|Assigned to undergo extracranial-intracranial arterial bypass in addition to best current practice medical therapy
89262073|NCT00029146|Active Comparator|Non-surgical group|Receives best current practice medical therapy
89262074|NCT01079793|Experimental|ixabepilone|Adjuvant therapy
89262075|NCT03950206|Other|Women with endometriosis|Women undergoing laparoscopic surgery for endometriosis
89262076|NCT01088620|Experimental|Panitumumab plus pemetrexed and cisplatin (PemCisP)|
89262077|NCT01088620|Active Comparator|Pemetrexed and cisplatin (PemCis)|
89262078|NCT00026494|Experimental|Temozolomide and Vinorelbine|Patients will be treated with vinorelbine on days 1 and 8 of each cycle; temozolomide will be administered on days 1 to 7 and 15 to 21 of each cycle. The dose level of temozolomide will be given at a dose of 150 mg/m2/day. A cycle will be defined as 28 days of treatment.
89262079|NCT03950128|Experimental|Mindfulness-Based Skills Training|This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The intervention is given over the course of three 50-minute sessions with homework between sessions.
89262080|NCT03950128|Active Comparator|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions.
89262081|NCT03950050|Experimental|Ambroxol|"Ambroxol therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
89262082|NCT01102504|Experimental|Tomato extract (Ateronon)|Supplementation of tomato extract containing 28 mg/day for 12 months in addition to routine treatment.
89262083|NCT01102504|Placebo Comparator|Placebo|Placebo
88805158|NCT01859819|Experimental|Group B|"De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH <2 X ULN.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine"
88805159|NCT01859819|Experimental|Group C, CNS negative|"De-novo Mature CD 20 + B-ALL (> 25% Bone marrow blasts) without CNS involvement.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine"
89262084|NCT01088776|Experimental|Supplement|
89262085|NCT01088776|Placebo Comparator|Control|
89262086|NCT00023764|Experimental|Arm I|Patients receive an infusion of bortezomib (dose of 1.8 mg/m2) over 3-5 seconds once weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response lasting at least 6 months may receive retreatment.
89262087|NCT01088854|Experimental|positive airway pressure|
89262088|NCT03961126|Experimental|Group autologous platelet-rich plasma injection|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
89262089|NCT03961126|Active Comparator|Group Control|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
89262090|NCT03949816|Experimental|patient-centered communication style|The patient-centered style is characterized by features such as empathetic communication, open questions, and uses an easily understandable language.
89262091|NCT03949816|Experimental|doctor-centered communication style|The doctor-centered style is defined by an authoritarian and goal-oriented communication. The doctor uses medical terms instead of lay language.
89262092|NCT03949816|Active Comparator|information letter|In the active control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
89262093|NCT01584778||Behçet patients|
89262094|NCT01584778||Healthy controls|
89262095|NCT01584778||Allergic rhinitis (diseased) controls|
89262096|NCT00189488|Experimental|Palifermin|Palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and 180 μg/kg administered once prior to transplant and at least 96 hours from last palifermin dose of 60 μg/kg. Participants received conditioning therapy starting at least 24 hours after the last 60 μg dose of palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the 180 μg/kg dose of palifermin on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
89262097|NCT00189488|Placebo Comparator|Placebo|Placebo to palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and placebo to palifermin 180 μg/kg once prior to transplant and at least 96 hours from previous placebo to palifermin 60 μg/kg dose. Participants received conditioning therapy starting at least 24 hours after the last 60 μg/kg dose of placebo to palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the dose of placebo to palifermin 180 μg/kg on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
89262098|NCT03974906|Experimental|GDT group|The fluid in GDT group (Goal-directed fluid therapy) will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the LiDCO monitoring system.
89262099|NCT03974906|No Intervention|Control group|Patients in the control group received conventional fluid therapy, decided by the attending anesthesiologists based on the patient's hemodynamic condition and responses, to maintain MAP >65 mm Hg, heart rate 50-100 bpm, and urine output >0.5 ml/kg/h.
89262100|NCT03969290|Experimental|Sequence 1|Verofilcon A contact lens in the right eye (OD), with etafilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
89262101|NCT03969290|Active Comparator|Sequence 2|Etafilcon A contact lens in the right eye (OD), with verofilcon A contact lens in the left eye (OS), as randomized. Lenses will be worn for one day, approximately 8 hours.
89262102|NCT00233402|Active Comparator|Standard White Light Cystoscopy|
89262103|NCT00233402|Experimental|Standard White Light and Hexvix Fluorescence Cystoscopy|
89262104|NCT00233324|Experimental|Surfactant and Low Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturation of 85% to 89%
89262105|NCT00233324|Experimental|Surfactant and High Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturationof 91% to 95%
89262106|NCT00233324|Experimental|CPAP and Low Oxygen|Administration of continuous positive airway pressure (CPAP) and supplemental oxygen with target saturation of 85% to 89%
89262107|NCT00233324|Experimental|CPAP and High Oxygen|Administration of continuous positive airway pressure (CPAP)and supplemental oxygen with target saturation of 91% to 95%
89262108|NCT00023452|Active Comparator|Daily Isoniazid|Isoniazid (INH) daily for 9 months (240 to 270 total doses).
89262109|NCT00023452|Experimental|Weekly Isoniazid / Rifapentine|Isoniazid / Rifapentine (RPT/INH) weekly for 3 months (11 to 12 total doses) given by Directly Observed Therapy (DOT)
89262110|NCT03974516|Experimental|Careseng 1370|"Four dose cohorts are employed for Careseng 1370 oral administration in healthy volunteers:~Level A (1 sachet): 1 sachet before breakfast;~Level B (2 sachets): 1 sachet before breakfast, 1 sachet before lunch;~Level C (3 sachets): 1 sachet before breakfast, 2 sachets before lunch;~Level D (4 sachets): 2 sachets before breakfast, 2 sachets before lunch"
89262111|NCT03972878|Active Comparator|control snack|control snack
89262112|NCT03972878|Experimental|control cream|control spreadable cream
89262113|NCT03972878|Experimental|cream version 1|control spreadable cream, version 1
88805160|NCT01859819|Experimental|Group C, CNS Positive|"De-novo Mature CD 20 + B-NHL with CNS involvement:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,"
88805161|NCT02176031|Experimental|Natalizumab|"Natalizumab-~(Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion~At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab.~If participants have no response after one dose, they will be not be given a second dose.~Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered.~Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365.~Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert"
88805162|NCT02176343|Experimental|ReSTOR Toric +2.5|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
88805163|NCT02177201|Sham Comparator|Group 1|intravenous administration of 10 ml/kg/h 0.9% saline solution
88805164|NCT02177201|Active Comparator|Group 2|intravenous administration of 20 ml/kg/h 0.9% saline solution
88805165|NCT03013361|Active Comparator|Group B (n=20)|Group B (n=20): The patients in this group were infiltrated with 3 mL of 0.5% bupivacaine.
88805166|NCT03013361|Active Comparator|Group R (n=20):|Group R (n=20): The patients in this group were infiltrated with 3 mL of 0.5% ropivacaine.
88805167|NCT03013361|Placebo Comparator|Group S (n=20, Control):|Group S (n=20, Control): The patients in this group were infiltrated with 3 mL of normal saline.
88805168|NCT01365793|Experimental|Rapid rehydration using 0.45% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.45% saline will be used as the replacement fluid for this arm.
88805169|NCT01365793|Experimental|Rapid rehydration using 0.9% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.9% saline will be used as the replacement fluid.
88805170|NCT01365793|Experimental|Slower rehydration using 0.45% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fluid bolus) with 0.45% saline used as the replacement fluid.
89262114|NCT03972878|Experimental|cream version 2|control spreadable cream, version 2
89262115|NCT03972878|Experimental|cream version 3|control spreadable cream, version 3
89262116|NCT03972878|Experimental|control chocolate bar|control chocolate bar
89262117|NCT03972878|Experimental|chocolate bar version 1|control chocolate bar version 1
89262118|NCT01073072|Experimental|Tutomesh|Technique of abdominal wall reconstruction strengthened by Tutomesh®
89262119|NCT01073072|Active Comparator|conventional repair|Conventional technique to repair incisional or abdominal wall hernias
89262120|NCT01088932|Experimental|SRX246|SRX246
89262121|NCT01088932|Placebo Comparator|Placebo|placebo
89262122|NCT01100554|Experimental|all patients|
89262123|NCT03961048|Experimental|Bilateral catheters|patients receiving bilateral catheters (such as for patients undergoing sternotomies/midline incisions or with planned bilateral thoracotomy incisions)
89262124|NCT03961048|Experimental|Single catheter|patients who only have one catheter in place (such as in patients who have unilateral thoracotomies and not midline sternotomies)
89262125|NCT01100632|Experimental|Treatment|Treatment with the combination of Panax ginseng, vitamins and minerals
89262126|NCT01100632|Placebo Comparator|Placebo|Placebo.
89262127|NCT01100710||healthy volunteers|
89262128|NCT03949426|Experimental|KPG-818|Dose escalation
89262129|NCT03949426|No Intervention|Placebo|Matching placebo
89262130|NCT03949348|Active Comparator|autologous fascia|Patients who underwent a transobturator sling placement using autologous rectus fascia
89262131|NCT03949348|Active Comparator|synthetic mesh|Patients who underwent a transobturator sling placement using synthetic mesh
89262132|NCT03949582|Experimental|Mycoprotein as in Soup|24 will be randomised to soup (12 caucasian and 12 south asian) in order to test raw mycoprotein. Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
89262133|NCT03949582|Experimental|Mycoprotein as in Mince|24 will be randomised to mince (12 caucasian and 12 south asian) in order to test processed mycoprotein (Quorn). Test food will be administrated orally and allowed 15 minutes for consumption at an even pace.
89262134|NCT00022672|Experimental|trastuzumab + anastrozole|Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
89262135|NCT00022672|Active Comparator|anastrozole|1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
89262136|NCT05626036|Active Comparator|Arthrex Tightrope|Syndesmosis fixation performed with Arthrex Tightrope device. This is a high-tension suture fixation with a button based anchor system.
89262137|NCT05626036|Experimental|Synthes Fibulink|Syndesmosis fixation performed with Synthes Fibulink device. This is a high-tension suture fixation with a screw based anchor system.
89262138|NCT00076804|Experimental|1|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
89262139|NCT00076804|No Intervention|2|Self administration of ARVs
88805171|NCT01365793|Experimental|Slower rehydration using 0.9% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fuid bolus) with 0.9% saline used as the replacement fluid.
89262140|NCT00141453|Experimental|1|Olmesartan medoxomil tablets 10mg to 40 mg
89262141|NCT00141453|Placebo Comparator|2|Matching placebo tablets
89262142|NCT00076570|Experimental|Sirolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to sirolimus monotherapy and followed up for 4 years.
88805172|NCT01077401|Experimental|Ranibizumab 0.5mg|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
89262143|NCT00076570|Active Comparator|Tacrolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to tacrolimus monotherapy and followed up for 4 years.
89262144|NCT01079871|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
89262145|NCT01078311||HCC patients on Sorafenib|
89262146|NCT03966963|Experimental|Eye Movement Desensitization Reprocessing (EMDR)|Subjects with trauma-related symptomology resultant from CSA will undertake EMDR; they will be systematically observed through use of their quantitative treatment outcome measures at both pre- and post- treatment alongside one-month follow-up interview data to determine outcomes of interest (namely emotional, behavioural and neuropsychological functioning).
89262147|NCT00124449|Active Comparator|1|
89262148|NCT00124449|Placebo Comparator|2|
89262149|NCT00076336|Experimental|Telbivudine 600 mg|Participants received Telbivudine 600 mg and a matching lamivudine placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
89262150|NCT00076336|Active Comparator|Lamivudine 100 mg|Lamivudine 100 mg and a Telbivudine matching placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
89262151|NCT00185588|Experimental|Stage 1 Dose Exploration 0 - Gemcitabine 700 + vatalanib 1250|Gemcitabine 700 mg/m2 + vatalanib 1250 mg daily
89262152|NCT00185588|Experimental|Stage 1 Dose Exploration 1 - Gemcitabine 850 + vatalanib 1250|Gemcitabine 850 mg/m2 + vatalanib 1250 mg
89262153|NCT00185588|Experimental|Stage 1 Dose Explrtion2 - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
89262154|NCT00185588|Experimental|Stage 2 Dose Expansion - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
89262155|NCT01074476|Experimental|1|Glucosamine sulphate tablets
88805173|NCT01077401|Experimental|Ranibizumab 2.0 mg|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
88805174|NCT01316341|Experimental|BI10773 low dose Per Os(p.o.)|patient to receive a tablet containing low dose BI10773 Per Os(p.o.) plus one placebo
88805175|NCT01316341|Placebo Comparator|Placebo|patient to receive two placebos
88805176|NCT01316341|Experimental|BI10773 high dose Per Os(p.o.)|patient to receive a tablet containing high dose BI10773 Per Os(p.o.) plus one placebo
88805177|NCT01112735|Experimental|ARTISS|ARTISS will be used as an adjuvant to standard of care.
89262156|NCT01074476|Placebo Comparator|2|Placebo tablets
89262157|NCT00232544|Experimental|TLC-CPAP|A telephone-linked communication (TLC) system for promoting adherence to continuous positive airway pressure (CPAP)
89262158|NCT00232544|Placebo Comparator|TLC-Control|A TLC system for providing general health education
89262159|NCT03974126|Experimental|40 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
89262160|NCT03974126|Experimental|80 grams of starch to low and high AMY1 copy number carriers|The postprandial response between individuals that are either carriers of low AMY1 copy numbers (2-4) or high copy numbers (10 or more copies) will be compared
89262161|NCT00231842|Experimental|Ifosfamide with or without cisplatin|Participants with surgically staged carcinosarcoma (CS) with no gross residual disease were initially administered ifosfamide (1.2 g/m2/day for 5 days) with cisplatin (20 mg/m2/day for 5 days) every 3 weeks for 3 cycles followed by pelvic external beam RT and brachytherapy followed by 3 additional cycles of ifosfamide (1.0 g/m2/day) with cisplatin with cisplatin (20 mg/m2/day for 5 days) evrey 3 weeks. cisplatin added toxicity without additional efficacy, so mid-study, cisplatin was eliminated.
89290443|NCT05731804|Experimental|Cohort 6 of Part B|Subjects with normal hepatic function(SIM0417 750 mg; Ritonavir100 mg )
89262162|NCT00076102|Experimental|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
89262163|NCT03968588|Experimental|reduced-dose tacrolimus + standard-dose MMF|Tacrolimus dose was individually adjusted with a target trough blood level of between 3ng/mL and 8ng/mL throughout the study period (6 months after transplantation). MMF started within 72 hours after transplantation and the dose of MMF was 1.5~2.0g per day.
89262164|NCT03968588|Active Comparator|standard-dose tacrolimus + reduced-dose MMF|Control group, target trough blood level was between 5ng/mL and 15ng/mL throughout the study period. MMF dose was 0.5~1g per day and MMF started within 72 hours after transplantation.
89262165|NCT05625880|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns using Picterus JP.
89262166|NCT03974282|Other|Low psychopathy distribution|Participants who score at the low end of the psychopathy distribution
89262167|NCT03974282|Other|High psychopathy distribution|Participants who score at the high end of the psychopathy distribution
89262168|NCT01582646|Other|first period with terbutaline and second period with placebo|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
89262169|NCT01582646|Other|first period with placebo and second period with terbutaline.|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
89262170|NCT03968666||Gynecological surgery with ERAS protocol|Patients scheduled for benign gynecological surgery under ERAS protocol
89262171|NCT03741452|Experimental|Transversalis fascia plane block|The transversalis fascia plane block will be administrated to this group at end of the surgery under general anesthesia. An intravenous patient-controlled analgesia device within tramadol will be given to the patients postoperatively.
89262172|NCT03741452|No Intervention|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with tramadol. No block will be performed.
89262173|NCT03974360|Experimental|Erenumab|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
89262174|NCT00184028|Experimental|Arm 1|On Day 1 of each day treatment cycle, patients receive Taxotere 60 mg/m2 as a 1-hour IV infusion, followed by the administration of oxaliplatin 100 mg/m2. Oxaliplatin will be administered IV over 2 hours at a rate of 10mg/m2/min. This treatment regimen will be repeated every 21 days.
89262175|NCT00183872|Experimental|Arm 1 - Irinotecan and Docetaxel|Irinotecan given day 1 and 8 every 21 days Docetaxel given day 1 and 8 every 21 days
89262176|NCT03815175|Experimental|XIENCE|XIENCE + 1 month DAPT
89262177|NCT01075893||Adenomatous polyp|Patients who have begun the polyp-cancer sequence (ie. are in polyp surveillance after excision of a prior adenomatous polyp) will be used to test those patients at higher risk of colorectal.
89262178|NCT01075893||Patients at normal risk of cancer|Patients found to have endoscopically and histological normal mucosa.
89262179|NCT01075893||Ulcerative colitis|Patients who are under surveillance for known ulcerative colitis will be used to test those patients at higher risk of colorectal.
89262180|NCT01076127|Experimental|Ketllebell group|Basic ketllebell training 3 x 20 min a week for 8 weeks
89262181|NCT01076127|Sham Comparator|Control group|Control group. Receives a health examination before and after the intervention period, and are advised to stay active.
89262182|NCT00262028|Experimental|MenACWY-CRM (2-10 years)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
89262183|NCT00262028|Experimental|MenACWY-CRM (12-23 months)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
89262184|NCT00262028|Active Comparator|MenACWY-PS (2-10 years)|Subjects received one dose of licensed comparator MenACWY polysaccharide (MenACWY-PS) vaccine
89262185|NCT00262028|Experimental|MenACWY-CRM+PnC (12-15 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with PnC
89262186|NCT00262028|Experimental|MenACWY-CRM+DTaP (16-23 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with DTaP
89262187|NCT00183248|Experimental|DBMCs|Kidney transplantation, followed by immunotherapy given along with kidney donor Donor bone Bone marrow Marrow stem cell Cells (DBMCs) infusions
89262188|NCT00183248|Active Comparator|Control Group|Kidney transplantation, followed by immunotherapy
89262189|NCT00183170|Experimental|Alcohol then Placebo|Participants report for their first dosing night where they receive several alcohol drinks. After a wash out period of 1 week they then return and receive several placebo drinks. Participants sleep at the study site, are monitored overnight, and the next morning are awakened and escorted to the performance trials.
89262190|NCT00183170|Experimental|Placebo then Alcohol|Participants report for their first night where they receive several placebo drinks. After a wash out period of 1 week they then return and receive several alcohol drinks. Participants sleep at the study site, are monitored overnight, and the next morning are awakened and escorted to the performance trials.
89262191|NCT00230282|Experimental|Fludarabine, cytoxan, then alemtuzumab|Fludarabine and cyclophosphamide days 1 to 3 for six 28-day cycles. Minimal residual disease positive responders continued on-treatment to receive alemtuzumab 30 mg weekly. MRD negative responders were observed.
89262192|NCT00261950|Experimental|Cinacalcet|All subjects were enrolled into the single arm to receive Cinacalcet. There was no comparator arm.
89262193|NCT00230048|No Intervention|Assessment only|
89262194|NCT00230048|Experimental|Brief intervention|
89262195|NCT00229658||Type 1|Patients with type 1 diabetes
89262196|NCT00229658||Type 2|Patients with type 2 diabetes
89262197|NCT00182078|Placebo Comparator|Placebo|Placebo was administered on a flexible fixed schedule and tapered at 12 weeks.
89262198|NCT00182078|Experimental|Sertraline|Sertraline was administered on a flexible fixed schedule beginning at 25 mg/day and increasing as high as 150 mg/day. At week 12, the medication was tapered at a rate of 25 mg every 3 days until it was discontinued.
89262199|NCT03968510||parathyroidectomy cases|patients who will be operated for primary hyperparathyroidism
88805178|NCT01112735|Other|Standard of care|Standard of care
88805179|NCT03014297|Experimental|everolimus + fosbretabulin|everolimus + fosbretabulin
88805180|NCT01113983|Experimental|TAVI - TF and TA approach|Transcatheter aortic valve implantation and transfemoral/ transapical approach
88805181|NCT01034111|Experimental|Sitagliptin|Sitagliptin as add-on therapy to a stable dose of metformin
88805182|NCT01114997|Active Comparator|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
89262200|NCT00181844|Experimental|Lamotrigine|
89262201|NCT00181766|Experimental|Strattera (atomoxetine)|
89262202|NCT00180674|Experimental|Warfarin anticoagulation|Anticoagulated with warfarin to maintain an INR of 2-3 between 8 and 16 weeks (treatment period).
89262203|NCT00076024|Other|Docetaxel + Placebo|Docetaxel + Placebo
89262204|NCT00076024|Experimental|Docetaxel + AG-013736|Docetaxel + AG-013736
89262205|NCT05626426|Experimental|Active SASm|Patients will receive active treatment with the device every other day over 8 weeks.
89262206|NCT01103050|Active Comparator|QAV680 + Cetirizine Placebo|
89262207|NCT01103050|Experimental|QAV680 + Cetirizine|
89262208|NCT01103050|Active Comparator|Cetirizine + QAV680 Placebo|
89262209|NCT01103050|Placebo Comparator|QAV680 Placebo + Cetirizine Placebo|
89262210|NCT01102816|Experimental|Individualized acupuncture|
89262211|NCT01102816|No Intervention|Routine care|
89262212|NCT00075478|Experimental|Arm I (chemotherapy, TBI, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
89262213|NCT00075478|Active Comparator|Arm II (TBI, transplant, GVHD prophylaxis)|Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
89262214|NCT00175916|Experimental|Brivaracetam|Flexible dosing, can up and down titrate as needed.
89262215|NCT03968432|Sham Comparator|Standard Care|Be Sweet to Babies Videos and Pamphlet. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of the sweet solution during vaccination will be used.
88805183|NCT01114997|Active Comparator|Esmolol|Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min
88805184|NCT01114997|Experimental|Lidocaine + Esmolol (Combo)|"Performed with the administration of both drugs.~Pre-induction:~Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)~Post-induction:~Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
89262216|NCT03968432|Active Comparator|Intervention|Be Sweet to Babies Videos, pamphlet, and MIAS&Q. MIAS&Q includes five questions and statements based on MI approach which was developed by the researcher and was reviewed further by a panel of parent representatives and HCPs representatives and the research team consisting of the supervisor and two Ph.D. committee members. This MIAS&Q intervention consists of four scaled questions and two open-ended questions and presents brief informative and affirmative questions and statements. This aims to help the parents reflect on their own thoughts, and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
88805185|NCT00118742|Experimental|CellCept + CNI (tacrolimus or cyclosporine)|
88805186|NCT00118742|Active Comparator|CellCept + sirolimus|
88805187|NCT01034579|Other|Rebif® Cohort|
88805188|NCT01034579|Other|Copaxone® Cohort|
88805189|NCT01317667|Experimental|Group 1|RVEc vaccine 20 μg/dose x 3 doses
88805190|NCT01317667|Experimental|Group 2|RVEc vaccine 50 μg/dose x 3 doses
88805191|NCT01317667|Experimental|Group 3|RVEc vaccine 100 μg/dose x 1 dose
88805192|NCT00167180|Active Comparator|CML|Patients with Chronic Myelogenous Leukemia (CML) who have failed or refused Gleevec(TM) therapy and will receive Donor Lymphocyte Infusion.
88805193|NCT00167180|Active Comparator|Non-CML or CML that Relapsed after Donor Lymphocyte Infusion|Patients with non-CML or CML who have failed Donor Lymphocyte Infusion (DLI) and will receive induction chemotherapy plus DLI.
88805194|NCT01035047|No Intervention|Inpatient Care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
89262217|NCT00075400|Experimental|Treatment (imatinib mesylate)|Patients receive imatinib mesylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89262218|NCT03972722|Experimental|GLS-010|Full-human anti-pd-1 monoclonal antibodies
89262219|NCT03972644|Active Comparator|Early intervention|Patients will undergo aortic valve replacement immediately
89262220|NCT03972644|No Intervention|Watchfull waiting|Patients will be followed and treated as recommended by guidelines.
89262221|NCT01103206|Experimental|Control group|Parathyroid hormone suppression tests using successively (each test will be separate for a two week period) an intravenous calcium loading or cinacalcet will be performed in a group of 12 healthy volunteers.
89262222|NCT01103206|Experimental|Primary hyperparathyroidism dose I|Parathyroid hormone suppression test using the first dose of cinacalcet in patients with primary hyperparathyroidism.
89262223|NCT01103206|Experimental|Primary hyperparathyroidism dose II|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
89262224|NCT01105468||Mamma Carcinoma, no treatment|
89262225|NCT01105468||Mamma Carcinoma, treatment|
89262226|NCT01105468||No Mamma Carcinoma diagnosed by X-ray|
89262227|NCT03949114|Experimental|test group|"1) Performing a weak debilitating phenotype screening on the patients before surgery;~(2) Do the early rehabilitation intervention process:"
89262228|NCT03949114|Active Comparator|Control group|1) Performing a weak debilitating phenotype screening on the patients before surgery; (2) Patients in the control group were treated according to the general nursing routine after neurosurgery;
89262229|NCT01105546|Experimental|prophylaxis|prophylaxis with recombinant activated FVII 90 µg/kg/day i.v.
89262230|NCT01105546|Active Comparator|on demand treatment|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
89262231|NCT00074152|Active Comparator|Arm I|Patients receive radiotherapy* within 6 months after surgery.
89262232|NCT00074152|Experimental|Arm II|Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.
89262233|NCT00261846|Experimental|SKI-606|
89262234|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
89262235|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
89262236|NCT00169442|Experimental|HB Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine (with HepB at birth), received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
89262237|NCT00169442|Experimental|Tritanrix-HepB Kft.+Hiberix Group|Healthy male and female infants who were primed with Tritanrix™-HepB Kft. and Hiberix™ vaccines, were boosted with Tritanrix™-HepB Kft. vaccine administered intramuscularly into the right upper thigh and Hiberix™ vaccine, administered intramuscularly into the left upper thigh, at 15-18 months of age.
89262238|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
89262239|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
89262240|NCT02530762|Placebo Comparator|Negative control|No added fiber
89262241|NCT02530762|Active Comparator|Positive Fiber control|50g positive control fiber
89262242|NCT02530762|Experimental|Novel Fiber 10g|10g novel fiber
89262243|NCT02530762|Experimental|Novel Fiber 30g|30g novel fiber
89262244|NCT02530762|Experimental|Novel Fiber 50g|50g novel fiber
89262245|NCT00261716|Experimental|IPS and VOMI|Individual Placement and Support (IPS), a form of evidence-based supported employment with 4 sessions of manualized vocationally-oriented motivational interviewing (VOMI) prior to each course of job searching
89262246|NCT00261716|Active Comparator|IPS and IE|Individual placement and support (IPS), a form of evidence-based supported employment with 4 sessions of education about schizophrenia/schizoaffective disorder (IE), as appropriate, prior to each course of job searching
88805195|NCT01035047|Experimental|CDU-CMR Protocol|Patients will be transferred to the clinical decision unit and undergo a stress cardiac MRI evaluation.
89262247|NCT01089166|Experimental|Torrent's Metformin tablets 500 mg|
89262248|NCT01089166|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
89262249|NCT03809104|Experimental|elderly with sarcopenia|Virtual reality-based rehabilitation programs
89262250|NCT00203502|Experimental|Intervention: Dtx Cyclophosphamide Bev|Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg
89262251|NCT03799198|Experimental|WMP + Rx|Participants will receive Cleveland Clinic's Integrated Medical WMP with medication for chronic weight management (Rx) for approximately one year. After discussing with the study doctor, participants will receive one of the following listed 5 drugs approved by the Food and Drug Administration (FDA) for long-term weight loss: 1) orlistat, 2) lorcaserin or lorcaserin extended-release, 3) phentermine/topiramate extended-release, 4) naltrexone/bupropion extended-release and 5) liraglutide 3.0 mg.
89262252|NCT03799198|Active Comparator|WMP alone|Participants will receive Cleveland Clinic's Integrated Medical WMP alone for approximately one year.
89262253|NCT01105780|Experimental|001|JNJ-41443532 250mg tablet once daily for 1 day
89262254|NCT01105780|Placebo Comparator|002|Placebo Matching placebo
89262255|NCT01103518|Experimental|Combination 1|Ethinyl Estradiol + Cyproterone acetate
89262256|NCT01103518|Active Comparator|Combination 2|Ethinyl Estradiol + Cyproterone acetate
89262257|NCT03947086|Active Comparator|Active TDCS Group|Participants will receive active Transcranial Direct Current Stimulation (TDCS) (1.5 mA). Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
89262258|NCT03947086|Sham Comparator|Sham tDCS Group|Participants will receive sham TDCS. The protocol is identical for placebo stimulation, but the current will stop after 30 seconds from the start of stimulation. Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills.
89262259|NCT01103596||HIV-infected patients, 1st wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
89262260|NCT01103596||HIV-infected patients, 2nd wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
89262261|NCT04924504||Type A|Healthy pregnant women without pregestational or gestational diabetes
89262262|NCT04924504||Type B|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose <= 75 units/day
89262263|NCT04924504||Type C|Pregnant women with type 2 diabetes or gestational diabetes with a total daily insulin dose >= 100 units/day
88805196|NCT01317901|Experimental|TRU-016+bendamustine+rituximab|Two dose levels (10 and 20 mg/kg) of TRU 016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.
89262264|NCT03947008|Experimental|First Intuitive Eating Group (IE1)|IE1 will be the first group to participate in an intuitive eating program and will be required to attend five intuitive eating classes. The intuitive eating classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. This group will have an additional final assessment on the last day of the IE2's intuitive eating course. During the assessments, they will complete a questionnaire that will ask them about their body satisfaction and eating attitudes, and have their height and weight measured.
89262265|NCT03947008|Experimental|Second Intuitive Eating Group (IE2)|IE2 will be the second group to will participate in an intuitive eating program and will be required to attend 5 intuitive eating classes. The classes will be 60-minutes each week for 5 weeks. An initial assessment will be conducted on the same day as IE1 but they will take the 5 week course once the first group completes the class. This group will have an additional initial assessment on the day they begin their curriculum. The initial assessment will occur during the first thirty minutes of the first intuitive eating class. A final assessment will be conducted during the last 30 minutes of the last intuitive eating class. During assessments, they will complete a questionnaire that will ask about body satisfaction and eating attitudes, and have their height and weight measured.
89262266|NCT03946852|Experimental|ARP arm|Patients will receive DCD after therapy after the abdominal reperfusion protocol.
89262267|NCT01089244||Group A|"Patients with a suspected WHO II low grade glioma, disease progression within~1 year"
89262268|NCT01089244||Group B|Patients with a suspected WHO II low grade glioma, progression free within 1 year
89262269|NCT03948802||STROKE GROUP|Cerebral ischemic stroke patients treated.
89262270|NCT03948802||CONTROL GROUP|Ambulatory healthy patients
88805197|NCT03008551|Experimental|Empagliflozin group|Each participant will receive empagliflozin 25mg daily for 3 months
88805198|NCT03008551|Active Comparator|Metformin group|Each participant will receive metformin 1500mg daily for 3 months
89262271|NCT01103674|Other|Numeris-AF Guided Coagulation System|
89262272|NCT01089322|Experimental|Stantardized treament|oral and inhaled corticosteroid plus LABA
89262273|NCT01327534|Experimental|prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
89262274|NCT01327534|Active Comparator|clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
88805199|NCT01366495|Experimental|On-site Rapid HIV Testing|On-site rapid testing conducted by research staff co-located for the purposes of this study at the probation/parole office.
89262275|NCT05625568|Placebo Comparator|Placebo|
89262276|NCT05625568|Experimental|5 mg VYNT-0126|
89262277|NCT05625568|Experimental|10 mg VYNT-0126|
89262278|NCT03741166||Subject aged 45-49 with Average CRC Risk|Subjects will be men and women, 45-49 years of age, who enroll in Exact Sciences Protocol 2018-10. Subjects will provide a blood sample at time of enrollment.
89262279|NCT01089400||Influenza A/H1N1 patients|
89262280|NCT01089400||Non influenza A/H1N1 patients|
89262281|NCT03960736|Active Comparator|Group ESPB = Erector spinae plane block group|ESP block (Group ESP) will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
89262282|NCT03960736|Active Comparator|Group TEA = Thoracic epidural analgesia group|TEA will be performed in the preoperative block room.A continuous infusion of 0.125% bupivacaine at the rate of 4 ml/h infusion dose, 6 ml bolus dose and 30 min lockout time will be performed till 48 h postoperative period.
89262283|NCT02530840|Experimental|medical team|personal meetings and follow-up of un-balanced diabetic patients by trained medical team (nurse and doctor), which designed to promote adherence to healthy life style and medical therapy.
89262284|NCT02530840|Experimental|peers group|group meetings and follow-up of un-balanced diabetic patients by trained peers (peers: balanced diabetic patients),which designed to promote adherence to healthy life style and medical therapy.
89262285|NCT02530840|Experimental|SMS notifications|un-balanced diabetic patients receiving daily SMS with content,which designed to promote adherence to healthy life style and medical therapy.
89262286|NCT02530840|No Intervention|control|un-balanced diabetic patients will get the basic and regular treatment for diabetic patients according to Clalit Health Services. In addition, the patients will have the same check-ups like all the patients in the experimental arms.
89262287|NCT01106170|Experimental|Arm 1|Participants will consume 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks followed by 4 weeks of 330 mg of placebo (cornstarch)
88805200|NCT01366495|No Intervention|Off-site Referral for HIV Testing|Off-site referral for rapid HIV testing at a community health center or HIV testing clinic
89262288|NCT01106170|Experimental|Arm 2|Participants will consume 330 mg placebo (cornstarch), by mouth, per day for 4 weeks followed by 4 weeks of 330 mg of ProvexCV for 4 weeks.
89262289|NCT01103752||Surgery|This group (n=220) consist of patients undergoing hip or knee replacement in a fast-track setup and they are tested 3 times for postoperative cognitive dysfunction.
89262290|NCT00232596|Placebo Comparator|Placebo|
89262291|NCT00232596|Experimental|Retigabine|
89262292|NCT04771936|No Intervention|Control Group|The control group who shall be awaiting surgery and not receiving a regular physiotherapy exercise intervention
89262293|NCT04771936|Active Comparator|Conventional Exercise Group|The conventional exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000).
89262294|NCT04771936|Experimental|Conventional Exercise Group with added core exercises|This exercise group shall be subject to a set of conventional exercises based on a program described by Deyle et al (2000) and core exercises aimed at the activation of the core muscles as adapted from Imai et al (2010).
89262295|NCT00073918|Experimental|Treatment (radio labeled monoclonal antibody, chemotherapy)|"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.~CHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.~AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0."
89262296|NCT01071642|No Intervention|continue ace-i and arb's versus dicontinue|
89262297|NCT01071642|Active Comparator|group b|
89262298|NCT01071642|Active Comparator|group c|
89262299|NCT00231894|Active Comparator|Pioglitazone and life-style group|Pioglitazone (30-45 mg/daily) plus life-style diet group
89262300|NCT00231894|Placebo Comparator|Placebo and life style group|Placebo capsules daily plus life-style diet group
89262301|NCT00203424|Experimental|Erlotinib + Bevacizumab|Participants received Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
89262302|NCT00203268|Experimental|Treatment with dihydroergotamine mesylate (DHE-45)|Subjects who treated a moderate to severe migraine 2 and 4 hours after the onset of throbbing headache pain
89262303|NCT00168818|Experimental|dabigatran etexilate 75 mg|daily dose 150 mg once daily, half a dose on the day of surgery
89262304|NCT00168818|Experimental|dabigatran etexilate 110 mg|daily dose 220 mg once daily, half a dose on the day of surgery
89262305|NCT00168818|Active Comparator|enoxaparin|40 mg once daily
89262306|NCT00260832|Experimental|A|Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)
89262307|NCT00260832|Active Comparator|B|
89262308|NCT00168038|Experimental|IgPro10|
89262309|NCT00167414|Experimental|Hypofractionated Stereotactic Body Radiation Therapy|Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
89262310|NCT00166712|Active Comparator|Group 1: Alemtuzumab + TAC + MMF|Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.
89262311|NCT00166712|Active Comparator|Group 2: Alemtuzumab + Sirolimus + MMF|"Sirolimus will be taken by mouth before transplant surgery and will continue taking once daily after surgery. Group 2 will also receive 2 doses of Alemtuzumab: one during surgery and the second will be given on the second day after surgery. Mycophenolate mofetil will be give on the day of surgery and twice daily, by mouth, as instructed by the doctor.~If subjects do not experience kidney rejection after 6 months after surgery, they will be weaned off of the sirolimus and continue taking the mycophenolate mofetil."
89262312|NCT03972566||CREST with Calcinosis cutis|
89262313|NCT03972566||CREST without Calcinosis cutis|
89262314|NCT03973034||Normal people|
89262315|NCT03973034||Benign breast disease patients|
89262316|NCT03973034||Breast cancer patients in early stage|
89262317|NCT02531750||Achilles tendon rupture|Patients with acute Achilles tendon rupture.
89262318|NCT01073306|Experimental|Dengue Virus Subtype 2 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 2.
89262319|NCT01073306|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
89262320|NCT03974438|Experimental|Intervention - Acupunture (SDN)|Patients allocated to the intervention arm will receive SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain.
89262321|NCT03974438|Sham Comparator|Control - Sham acupunture|Patients allocated to the control arm will receive sham-SDN to the area of skin over the spine on the level of the specific dermatome involved in their chronic pain. The sham procedure consists of a blunted needle, that does not penetrate the skin.
89262322|NCT03972410|Experimental|Eye Movement Desensitization and Reprocessing (EMDR)|The EMDR treatment will follow the EMDR Recent Birth Trauma Protocol. This protocol was recently developed by some of the colleagues collaborating in this research project (Catteneo et al., 2018). This EMDR protocol can be used to intervene immediately after birth, or at later times. The main purposes of early intervention is to prevent the onset and development of PTSD and Post-partum Depression in the mother during the months following childbirth and to facilitate mother-newborn bonding.
89262323|NCT03972410|Active Comparator|Supportive Expressive Dynamic Psychotherapy (SEDP)|The SEDP treatment (Luborsky 1984; Book, 1998) is one of the most widespread treatments and can be considered the treatment as usual in Italian maternity wards. This intervention includes both supportive techniques (to create a positive, helpful and empathic relationship with the patient) and expressive techniques (aimed at helping the patient to express and to understand and change problems).
89262324|NCT01074710|Experimental|C13-URA|administered C13-URA 50, 100, 200mg in same subjects
89262325|NCT01074710|Placebo Comparator|Placebo|2 same subjects
89262326|NCT01074788|Experimental|mind body intervention group|
89262327|NCT00073528|Placebo Comparator|Placebo + Letrozole 2.5 mg|Letrozole (2.5 mg once daily orally) with Placebo (which matched with Lapatinib tablet)
89262328|NCT00073528|Experimental|Lapatinib 1500 mg + Letrozole 2.5 mg|Lapatinib (1500 mg once daily orally) with Letrozole (2.5 mg once daily orally)
89262329|NCT01585012|Experimental|Cervical cap|Collection condom with cervical cap inserted
89262330|NCT01585090|Experimental|passive ankle dorsi ﬂexion|doing strengthening exercises of PFM in standing position with passive ankle dorsi ﬂexion (on wooden surface with 15 degree angle)
89262331|NCT01585090|Experimental|active ankle plantar ﬂexion with arm up|doing strengthening exercises of PFM in standing position with active ankle plantar ﬂexion with arm up (standing on toe)(n=20) and horizontal standing position
89262332|NCT01585090|No Intervention|horizontal standing position|doing strengthening exercises of PFM in standing position with horizontal standing position
89262333|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TOB) + Dexlansoprazole 30mg (TPC)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
89262334|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TPC) + Dexlansoprazole 30mg (TOB)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
89262335|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TOB) + Dexlansoprazole 60mg (TPC)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
89262336|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TPC) + Dexlansoprazole 60mg (TOB)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
89262337|NCT03960814||Cohort 1|New users of basal insulins glargine and detemir
89262338|NCT01089712||Patients undergoing cardiac surgery|The patient population for this study consists of all patients undergoing cardiac surgical interventions. All patients who meet the eligibility criteria may be included in the study regardless of gender, race or ethnicity.
89262339|NCT01103830|Experimental|Group 1|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/low-Kcal meal."
89262340|NCT01103830|Active Comparator|Group 2|"4 tablets of Riamet® on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.~Administration of Riamet® will be in fed condition following a high-fat/low-Kcal meal."
89262341|NCT01103830|Other|Group 3|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fed condition, following a high-fat/low-Kcal meal~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
89262342|NCT01103830|Experimental|Group 4|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/high-Kcal meal."
89262343|NCT01103830|Experimental|Group 5|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fasting condition."
89262344|NCT01103830|Other|Group 6|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fasting condition.~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
89262345|NCT01106482|Active Comparator|Arm 1|
89262346|NCT01106482|Active Comparator|Arm 2|
89262347|NCT01106482|Active Comparator|Arm 3|
89262348|NCT01106482|Active Comparator|Arm 4|
89262349|NCT01103908||Pediatric cardiac output (CO) after CPB|Cardiac output measurements made in pediatric patients after cardiopulmonary bypass.
89262350|NCT01106560|Active Comparator|Anterior Approach Group|(AMIS)
89262351|NCT01106560|Active Comparator|Posterior Approach Group|(Posterior)
89262352|NCT01106638|Experimental|Intensive behavioral intervention|Eight session, behavioral intervention targeting HIV-infected smokers
89262353|NCT01106638|Active Comparator|Standard care|Advice to quit, smoking cessation brochure, offer of nicotine patch
89262354|NCT01089868||Group A|Patients who suffer from a suspected GBM and will undergo a microsurgical procedure for diagnosis verification. MRI and Positron Emission Tomography (PET) scans are scheduled prior to microsurgery, post microsurgery and after having completed radiochemotherapy and an additional scan after TMZ chemotherapy.
89262355|NCT01089868||Group B|Patients enrolled in Group B suffer from a suspected GBM which cannot be accessed microsurgically either due to a an eloquent location of the tumor, or patient's refusal to undergo surgery. In these patients, diagnosis will be obtained by means of stereotactic surgery. After an initial PET and MRI scan prior to biopsy, patients will be monitored by post radiochemotherapy as well as post 3-months chemotherapy MRI/PET scans.
89262356|NCT02530684||Knee osteoarthritis|Patients with knee osteoarthritis
89262357|NCT02530684||Control participants|Individuals without signs of knee osteoarthritis
89262358|NCT00072280|Experimental|Chemotherapy plus possible surgery|"Comprised of patients with disease lesions that are initially unresectable, or resected but with resulting grossly positive margins. All patients receive vincristine sulfate, dactinomycin, and cyclophosphamide (VAC), and mercaptoethane sulfonate (MESNA). Depending on response, patients may receive ifosfamide and etoposide (IE). Filgrastim may also be given, as needed. In addition to Chemotherapy, patients may receive Conventional Surgery.~(See Interventions section for drug dosage and administration details.)"
89262359|NCT00072280|Experimental|Surgery only|Comprised of patients with initially resectable disease lesions. All patients undergo Conventional Surgery. Those with a result of clear or microscopically positive margins remain on study in this arm, for observation with no further intervention.
89262360|NCT03948412|Experimental|Closed Incision Negative Pressure Wound Therapy (Prevena)|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. This is left in-situ for 7 days, unless clinically indicated.
89262361|NCT03948412|Active Comparator|Standard Dressings|Patients are randomised intra-operatively to either Prevena or standard dressings as long as inclusion criteria are met, and no exclusion criteria met. Standard care wound dressings are applied for patients in this arm. These are changed as clinically appropriate whilst in hospital.
89262362|NCT03946696||Dementia|Observations of communication and interactions between people with dementia living in a care home and therapy-animals.
89262363|NCT01103986|No Intervention|Control Group|
89262364|NCT01103986|Experimental|motivational/ health literacy education|
89262365|NCT04597606||Cohort|"All patients will be performed a basal test that consist on continuous cyclergometer exercise, under constant load, with spontaneous breathing, after that the same exercise protocol performed will be carried out under non-invasive ventilation (NIV test). Parameters will be titrated previosuly.~Finally the patient will perform the same exercise at a constant load under high flow oxygen therapy ( HFNC test)."
89262366|NCT01104064|Experimental|Real rTMS combined with CIT|
88805201|NCT01366495|Experimental|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
88805202|NCT01366495|No Intervention|Treatment as Usual|Passive referral to HIV community treatment provider.
89262367|NCT01104064|Sham Comparator|Sham rTMS combined with CIT|
89262368|NCT01106716|Placebo Comparator|A1: Placebo|Placebo
89262369|NCT01106716|Experimental|A2: KAI-1678|Experimental
89262370|NCT01106716|Active Comparator|A3: Lidocaine|Lidocaine
89262371|NCT00071812|Placebo Comparator|Placebo plus SOC|
89262372|NCT00071812|Experimental|Belimumab 1 mg/kg plus SOC|
89262373|NCT00071812|Experimental|Belimumab 4 mg/kg plus SOC|
89262374|NCT00071812|Experimental|Belimumab 10 mg/kg plus SOC|
89262375|NCT00071110|Experimental|1|Electroacupuncture (EA).
89262376|NCT00071110|Placebo Comparator|2|Sham
89262377|NCT03960346|Other|Esophageal Effects|To determine the correlation between rate of temperature decline and nadir cryoballoon temperatures rate of temperature decline and nadir esophageal temperatures during pulmonary vein isolation. Esophageal temperature probe is used during cryoablation to measure temperatures and then a 4-7 days post procedure esophagoscopy is performed to evaluate the physical effects on the esophagus.
89262378|NCT01104142||MDI|Subject on multiple Daily Injections
89262379|NCT01104142||CSII|Subjects on Continuous Subcutaneous Insulin Infusion
89262380|NCT01327924||Norditropin NordiFlex® users|
89262381|NCT03946384||patients|Hemophilia B with p.Ile112Thr mutation on factor IX gene
89262382|NCT01104298|Active Comparator|Arm A|"Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
89262383|NCT01104298|Experimental|Arm B|"Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.~Route of administration: for intravenous use after reconstitution and further dilution.~Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
89262384|NCT01106872|Experimental|Treatment|Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma
89262385|NCT00071032|Experimental|Liberal (10 g/dL) Transfusion Strategy|Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.
89262386|NCT00071032|Active Comparator|2|Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.
89262387|NCT03960268|Experimental|Intervention|Brodalumab 210mg subcutaneously every 2 weeks for 24 weeks
89262388|NCT05485480|Experimental|Opioid-sparing: Lidocaine, Ketamine, Magnesium, Clonidine, Fentanyl, Remifentanil, Propofol|"Ketamine: started at 5mg/h; continued until 30min before end of surgery, then reduced to 1mg/h until discharge from recovery.~Fentanyl: bolus of 50mcg before skin incision (in case of insufficient analgesia further boluses of 25mcg, upper limit is 100mcg).~Lidocaine: bolus of 1.5mg/kg of ideal body weight (IBW),(maximum 100mg) at induction of anaesthesia, then continuous infusion of 1.5mg/kg IBW/h (maximum 100mg/h) until discharge from recovery.~Magnesium: infusion of 2g/h for a maximum of 2h after induction of anaesthesia (maximum dose 4g). In case of bradycardia or hypotension, rate is reduced to 1g/h.~Clonidine: bolus of 15mcg if needed. Maximum amount 150mcg. Remifentanil: started at time of induction of anaesthesia until end of surgery."
89262389|NCT05485480|Active Comparator|Conventional group: Fentanyl, Remifentanil, Propofol|"Control Intervention:~Remifentanil: Remifentanil is given as a target controlled infusion using the Minto-model. It is started at the timepoint of induction of anaesthesia and given until the end of surgery.~Fentanyl: 2mcg/kg i.v. is given at the time of induction of anaesthesia and another 1-2mcg/kg is given prior to incision. Further fentanyl boluses (1-2mcg/kg boluses) are given in case there seems to be insufficient analgesia."
88805203|NCT01366885|Experimental|Intervention during pregnancy|5000 IU Vitamin D3 to be given to the mother during pregnancy. 7000 IU Vitamin D3 to be given during breast feeding if breast feeding. If not breastfeeding, infant to be given 400 IU Vitamin D3 during first year of age, then increased to 1000 IU D3 until completion of research trial.
88805204|NCT01424215|Experimental|ICG injection with Spyscope imaging|Indocyanine Green (ICG)
89262390|NCT03960502|Experimental|AG881|On Day 1, after fasting for 10 hours participants, will receive an oral capsule of [14C]AG-881 followed 2 hours later by a single intravenous (IV) infusion of [13C315N3]AG-881.
89262391|NCT01107028||Rehab|Subjects randomized to the Rehab group will have data collected at baseline and then within one week enroll in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
89262392|NCT01107028||Wait|Subjects randomized to the Wait group will have data collected at baseline and wait eight weeks before enrolling in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
89262393|NCT05470270|Experimental|New formulation of hydroxycarbamide|Single arm study with a single administration of hydroxycarbamide
89262394|NCT05372926|Experimental|Venturi mask|Patients will be placed under oxygen therapy with Venturi mask at a constant flow of 15L/min and a set FiO2 of 50%. The real FiO2 will be mesured in the mask at rest.
89262395|NCT05372926|Experimental|High flow nasal canulae|Patients will be placed under high flow nasal canulae oxygen therapy with a constant flow of 50L/min and the real FiO2 provided by Venturi mask.
89262396|NCT03945994|No Intervention|Connecting People Control Group|CMHTs (Community Mental Health Teams) will continue to support people with mental health problems using their standard care.
89262397|NCT03945994|Experimental|Connecting People Intervention Group|CMHTs will receive training on how to implement Connecting People programme. They will receive implementation toolkit to improve their practice in contrast to standard care.
89262398|NCT01107106||Adolescents|250 postmenarcheal adolescent girls
89262399|NCT01107106||Adults|250 adult women
89262400|NCT01107184|Experimental|Preconditioning|The remote ischemic stimulus will be applied after induction of anaesthesia, but before cardiopulmonary bypass.
89262401|NCT01107184|Experimental|Postconditioning|The remote ischemic stimulus during cardiopulmonary bypass.
89262402|NCT01107184|Experimental|Pre and postconditioning|The remote ischemic stimulus will be applied twice, after induction of anaesthesia and during cardiopulmonary bypass.
89262403|NCT01107184|Sham Comparator|Control|
89262404|NCT00259610|Active Comparator|1|methotrexate (MTX) + etanercept
89262405|NCT00259610|Active Comparator|2|methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
89262406|NCT00259610|Active Comparator|3|methotrexate (MTX) or MTX + Etanercept
89262407|NCT00259610|Active Comparator|4|methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
89262408|NCT01107262||Poultry exposed adults|This seroepidemiological study proposes to compare adults with occupational exposure to poultry with non-poultry exposed adult controls for evidence of previous infections with AI viruses.In this study, any person with occupational exposure to poultry i.e. works in poultry production facility or raises a smaller number of poultry on his/her farm will be considered exposed. The questionnaire used in this study will capture poultry exposure data through a group of variables assessing type of occupational setting, length of time of exposure, flock size, type of work performed, and personal protective equipment (PPE) used.
89262409|NCT01107262||Poultry Non-exposed Adult Controls|Controls, adults who were never exposed to poultry, will be enrolled from urban areas such as the capital Beirut. Controls will be invited to volunteer by word of mouth at public/community sites.
89262410|NCT01090258|Experimental|Automated settings|Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
89262411|NCT01090258|Active Comparator|protocolized settings|Ventilator settings performed by the local respiratory therapists according to the local protocols
89262412|NCT01074866|No Intervention|Pressure support|Non invasive ventilation under pressure support (PS)
89262413|NCT01074866|Active Comparator|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally Adjusted ventilatory Assist
89262414|NCT01090336||Clopidogrel group|At the discretion of the attending cardiologist patients are treated with clopidogrel (600mg loading and 75mg daily dose)
89262415|NCT01090336||Prasugrel group|At the discretion of the attending cardiologist patients are treated with prasugrel (60mg loading and 10mg daily dose)
89262416|NCT04460482|Active Comparator|NIRS-guided PCI|Near-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent
89262417|NCT04460482|Active Comparator|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent
89262418|NCT04389112|Experimental|Patients with actinic keratoses|
89262419|NCT04389112|Experimental|patients with squamous cell carcinoma in situ|
89262420|NCT04389112|Experimental|patients with squamous cell carcinomas|
89262421|NCT04389112|Experimental|patient with invasive metastates|
89262422|NCT03945838||Breast cancer related lymphedema|All patients were included in the complete decongestive therapy programme. This therapy includes patient education, skin care, exercises, manual lymphatic drainage (self), and compression bandage therapy.
89262423|NCT05337748|Experimental|Experimental : Lexie Self Test and Fit Group (Lexie STF)|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
89262424|NCT05337748|Active Comparator|Control: Lexie Professional Test and Fit Group (Lexie PTF)|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
89262425|NCT00165698|Active Comparator|1|
89262426|NCT00165698|Active Comparator|2|
89262427|NCT05331196||Patients with colorectal cancer|Patients with colorectal cancer who underwent elective surgery.
89262428|NCT01075022|Experimental|Vitamin D|
89262429|NCT01075022|Placebo Comparator|Placebo|
89262430|NCT03946150||P/FP Ratio|P/FP Ratio is calculated in ARDS Patients retrospectively and analyse whether this new formula with PEEP can appropriately diagnose the Severity of Oxygenation with different levels of PEEP.
89262431|NCT03946150||P/F ratio|P/F ratio is the current Berlin definition of ARDS in Calculating the severity of Oxygenation.
89262432|NCT03944824|Experimental|Exercise (Intervention) Arm|The 25 patients in this arm will receive an interventional exercise plan using resistance bands and once weekly visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
89262433|NCT03944824|Placebo Comparator|Control|The 25 patients in the control arm will not receive an interventional exercise plan or visits from an exercise physiologist while on dialysis for 12 weeks. They will undergo a frailty screening using a Modified Fried Frailty Scale at the beginning and end of the trial to include: Timed up and Go test, Sit-to-Stand Test, Handgrip Strength Test, Low physical activity questionnaire.
89262434|NCT00225758|Experimental|1|Subjects will continue on their prior endocrine therapy with the addition of lapatinib at 1500 mg once daily for 26 weeks or longer.
89262435|NCT01071668||GEM-2 Cohort|Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.
89262436|NCT03944746||SAMMC Emergency Medicine Residents|Emergency Medicine Residents from San Antonio Military Medical Center in San Antonio, Texas.
89262437|NCT03944746||University Hospital Emergency Medicine Residents|Emergency Medicine Residents from University Hospital in San Antonio, Texas.
89262438|NCT03972332||Sensitised|Participants with sensitisation that significantly deviates from the normal mean as assessed by Quantitative Sensory Testing
89262439|NCT03972332||Non-sensitised|All other participants with sensitisation that is not significantly deviating from the normal mean as assessed by Quantitative Sensory Testing
89262440|NCT05330260||Endo-CABG|Group that underwent retrograde arterial cardiopulmonary bypass flow.
88805205|NCT01424215|No Intervention|Standard Critical View Technique|50 patients will be randomized to the no treatment arm. These patients will not get ICG injection but rather will have the standard technique for laparoscopic cholecystectomy performed including the critical view technique to expose the important structures prior to clipping and division.
89262441|NCT05330260||PCI|Surgical control group
89262442|NCT05330260||Healthy controls|Non-surgical control group
89262443|NCT03968354||Steatosis group - Experimental1|Steatosis group
89262444|NCT03968354||NASH group without fibrosis - Experimental 2|NASH group without fibrosis
89262445|NCT03968354||Moderate fibrosis - Experimental 3|Moderate fibrosis
89262446|NCT03968354||Advanced fibrosis - Experimental 4|Advanced fibrosis
89262447|NCT03968354||Control group - Active Comparator|Control group
89262448|NCT03947944|Active Comparator|manifest refraction planning group|The subjects underwent SMILE using manifest refraction planning.
89262449|NCT03947944|Active Comparator|vector planning group|The subjects underwent SMILE using vector planning.
89262450|NCT01104532|Experimental|Dosing Regimen 1|
89262451|NCT01104532|Experimental|Dosing Regimen 2|
89262452|NCT01104532|Experimental|Dosing Regimen 3|
89262453|NCT01104532|Experimental|Dosing Regimen 4|
89262454|NCT03945916|Experimental|Dark chocolate|180g/d dark chocolate
89262455|NCT03945916|Placebo Comparator|Placebo|180g/d of artificial dark chocolate
89262456|NCT03945682|Experimental|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
89262457|NCT03945682|No Intervention|Usual Standard of Care|Participants continue with usual care and existing therapy recorded in study diary
89262458|NCT01107574|Experimental|Gabapentin and Osteopathic Manipulative Medicine|6 weeks of both Gabapentin 900 mg HS given orally was accompanied with Osteopathic Manipulative Medicine treatment 30 minutes weekly to the tender points of the musculoskeletal system of each patient for 6 weeks.
89262459|NCT01107574|Experimental|Gabapentin|Gabapentin was given orally at 900 mg at HS weekly for 6 weeks.
88805206|NCT01370629||All participants|Participants treated with vernakalant IV in acute care and inpatient hospital settings
88805207|NCT02094872|Experimental|Arm I (molecularly targeted therapy)|Patients undergo collection of tissue and blood samples for DNA and RNA analysis via sequencing. Based on the results of the DNA and RNA analysis, patients receive molecularly targeted therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
88805208|NCT01424293|Experimental|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
88805209|NCT01899170|Sham Comparator|Sham-DBS|Only patients. Inactive deep brain stimulation for the initial three months following implantation.
89262460|NCT01107574|Experimental|Osteopathic Manipulative Medicine|6 weeks of Osteopathic Manipulative Medicine Treatment was applied to the patients tender points in the musculoskeletal system weekly by a 30 minute treatment.
89262461|NCT01104610|Active Comparator|NIV-PSV without Target Volume|Pressure Support Non Invasive Ventilation without Target Volume
89262462|NCT01104610|Active Comparator|NIV-PSV with Target Volume|Non Invasive Pressure Support Ventilation with Target Volume set
89262463|NCT01104610|Active Comparator|NIV-CPAP|Pressure Support Ventilation in CPAP mode
89262464|NCT00259298|Experimental|Teriparatide|Participants receive teriparatide 20 microgram once daily by subcutaneous injection for 18 months followed by 6 months off therapy
89262465|NCT01108744|Active Comparator|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
89262466|NCT01108744|Active Comparator|Mannitol|20% mannitol, dosed by patient's ideal body weight
89262467|NCT01581866|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
89262468|NCT01581866|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
89262469|NCT01075334|Experimental|Porimore arm|Infertile men will receive 'Porimore' tablets for a period of time in which three intrauterine insemination cycles will be performed.
89262470|NCT01075334|Active Comparator|Folate and Zinc|
89290444|NCT01127568|Experimental|Propranolol|Propranolol is a beta-blocker (blocking beta- adrenergic receptors) that reduces sympathetic activity. It is a well-known drug typically prescribed to individuals suffering from hypertension, tachycardia, cardiac arrhythmia, tremors, thyroid disease, or migraine.
89262471|NCT01107808|No Intervention|Control|The adolescents randomized to Standard of care group will receive the medical and behavioral counseling regarding their obesity as a patient of the Children's Center for Weight Management (CCWM). They will not receive any pharmacological treatment for their vitamin D deficiency or insulin resistance. Calcium and vitamin D dietary intake will be determined using a specific food frequency questionnaire at each study visit for all groups. This will be used to determine effect of nutrition counseling.
89262472|NCT01107808|Experimental|Calcium and Vit D|The participants in the vitamin D/calcium group will receive standard of care through the CCWM along with the addition of treatment with ergocalciferol (vitamin D2) and calcium carbonate for their vitamin D deficiency. The vitamin D treatment will be 50,000 IU orally weekly for 8 weeks. This treatment regimen for vitamin D deficiency has been found to be safe to children and adolescents. 32 33The dose of calcium supplementation will be calcium carbonate orally 1200mg daily. This is the daily recommended intake of calcium for adolescents
89262473|NCT01107808|Experimental|Metformin/ Vit D|The participants randomized into the vitamin D/calcium/Metformin treatment group will receive standard of care through the CCWM in addition to treatment for their Vitamin D deficiency with the same doses of ergocalciferol (vitamin D2) and calcium carbonate as previously outlined. Additionally, these participants will receive Metformin ER to treat insulin resistance. The Metformin ER will be started at 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks).
89262474|NCT03947554|Experimental|HRG80 Panax ginseng|Panax ginseng standardized to 63.4 mg of total ginsenosides taken orally once daily in the morning after a meal.
89262475|NCT03947554|Active Comparator|Panax ginseng|Panax ginseng standardized to 19.6 mg of total ginsenosides taken orally once daily in the morning after a meal.
89262476|NCT03947554|Placebo Comparator|Placebo|Placebo capsule containing brown sugar and rice flour, taken orally once daily in the morning after a meal.
89262477|NCT04370626||Registry Group|Patients who sustain and present with a PLI injury will have two options for participating in the study. This first arm will evaluate clinical presentations, patient demographic, treatment methods and baseline patient-rated and radiographic outcomes. However, no research-related follow up visits will be conducted. Ongoing data from these participants will be collected from chart reviews of clinical follow-ups alone.
89262478|NCT04370626||Prospective Group|Participants who choose to enroll in the prospective arm will experience the same baseline data collection as those in the registry, with the addition of research-related follow up appointments that will allow research staff to measure and assess patient-rated and clinical outcomes, such as questionnaires and range of motion data.
89262479|NCT04370626||Retrospective Group|In this group, a chart review will be conducted to identify previously treated patients with perilunate injuries. Once identified, the patient will be contacted and ask if they are willing to come in for a long-term follow up visit where clinical, patient-rated, and radiographic data will be collected. If patients are unwilling to attend a long-term visit, our analysis will still include data collected from their chart reviews and electronic questionnaires.
89262480|NCT01104844|Active Comparator|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug
89262481|NCT01104844|Active Comparator|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.
89262482|NCT01104844|Active Comparator|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
89262483|NCT01104844|Active Comparator|ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
89262484|NCT01104844|Active Comparator|Ibuprofen high dose|Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug
89262485|NCT01104844|Placebo Comparator|placebo|2 Placebo tablets
89262486|NCT01104844|Experimental|Full Dose Strength|Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets
89262487|NCT03945526|Active Comparator|Astaxanthin|Astaxanthin supplementation will be given at 2 x 8mg for 7 days.
89262488|NCT03945526|Placebo Comparator|Control|A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation
89262489|NCT03761212||Patient with ankylosing spondylitis or axial spondyloarthritis|No intervention - observational study
89262490|NCT03761212||Healthy controls|Age and sex matched healthy controls
89262491|NCT01105078|Other|Flow rate|Comparison between a flow rate of 2.5/l/min/m2 versus 3.0/l/min/m2
89262492|NCT01105156||Gastric Band Patients|
89262493|NCT03750136|Experimental|high-dose furosemide & hypertonic saline|furosemide i.v., 3% NaCl
89262494|NCT03750136|Active Comparator|high-dose furosemide|furosemide i.v.
89262495|NCT01108042|Experimental|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.
89262496|NCT01105234|Experimental|Calcipotriol ointment|
89262497|NCT01108198|Active Comparator|mometasone furoate cream|The study patient consecutive patients who were referred to outpatient clinic of Pediatric surgery for surgical treatment of non-retractable foreskin. The study patients were randomized to have either mometasone cream or placebo
89262498|NCT01108198|Placebo Comparator|moisturizer|
89262499|NCT05237674|Experimental|Intervention schools|School children exposed to 1-2 weekly sessions, a total of at least five hours pr week, of education outside the classroom.
89262500|NCT05237674|No Intervention|Waiting control schools|The waiting control schools will receive the two-day training course on EOtC one year later immediately after post measurements are conducted.
89262501|NCT03947710|Experimental|High-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume high protein meals during their dialysis sessions for one week.
89290445|NCT01127568|Placebo Comparator|Placebo|The placebo is an inactive capsule that will have no medication effect, but looks exactly like the medication.
88805210|NCT01899170|Active Comparator|Active DBS|Only patients. Active deep brain stimulation for the initial three months following surgery.
88805211|NCT01899170|Experimental|TMS and PET imaging|This experiment includes all participants (cases and controls). Each subject will undergo both active and sham stimulation (cross-over) with Cervel Neurotech Multi-coil TMS and related test/re-test PET imaging with 11C-Carfentanil. Only patients will proceed into deep brain stimulation experiments.
88805212|NCT01425229||Bosentan|Haplotypes of CYP2C9 and OATP1B1 characterisation of CYP2C9 (CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910)) and OATP1B1 (SLCO1B1*15 (rs2306283, rs4149056))
89262502|NCT03947710|Experimental|Low-protein meals|Patients with End Stage Renal disease on maintenance hemodialysis will consume low protein meals during their dialysis sessions for one week
89262503|NCT03947710|Experimental|No meals|Patients with End Stage Renal disease on maintenance hemodialysis will not consume meals during their dialysis sessions for one week
89262504|NCT03945370|Active Comparator|Intervention sequence 1|Ketone drink first - Placebo drink secondly
89262505|NCT03945370|Placebo Comparator|Intervention sequence 2|Placebo drink first - Ketone drink secondly
89262506|NCT01108354||ADHD patients|10 male adult ADHD patients and 10 female adult ADHD patients
89262507|NCT01108354||healthy controls|20 age- and sex-matched healthy volunteers
89262508|NCT01108900||Patients with erectile dysfunction (ED)|100 ED patients in the study that were switched to sildenafil after a previous treatment with udenafil proved ineffective and/or was poorly tolerated
89262509|NCT01105390|Experimental|Treatment (rilotumumab, cisplatin, pemetrexed disodium)|Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
88805213|NCT00258362|Experimental|Patients with Endometrial Cancer|Patients with advanced or current endometrial cancer receiving treatment with induction docetaxel/carboplatin, radiation (Weekly, 5 days/week over 6-7 weeks, tailored 4500 cGy) and followed by 3 courses of consolidation docetaxel (75 mg/m^2 on Day 1 of each course) /carboplatin (Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles).
88805214|NCT00258830|Experimental|Age 18 to 59 years|Participants aged 18 to 59 years at enrollment.
89262510|NCT04250662|Experimental|Active tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
89262511|NCT04250662|Experimental|Active tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes while remaining seated, no guided imagery will be provided.
89262512|NCT04250662|Sham Comparator|Sham tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
89262513|NCT04250662|Sham Comparator|Sham tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject will remain seated, no guided imagery will be provided.
89262514|NCT05164120|Experimental|Interventional|900mg dose TID Administration Total: 2700mg
89262515|NCT05164120|Placebo Comparator|Placebo|900mg dose TID Administration Total: 2700mg
89262516|NCT04162366|Experimental|Aprocitentan 25 mg|
89262517|NCT04162366|Experimental|Placebo|
89262518|NCT04162366|Experimental|Aprocitentan 25 mg or Placebo|
89262519|NCT03947242|Experimental|Pyrotinib + trastuzumab +Vinorelbine|Pyrotinib in Combination With Trastuzumab Plus Vinorelbine
89262520|NCT03944980|Experimental|Arm 1: CIK|"Docetaxel & PD1-T cells~Docetaxel,60mg/m2,intravenous infusion,d1; PD1-T cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W."
89262521|NCT03944980|Active Comparator|Arm 2: Control|"Docetaxel~Docetaxel,60mg/m2,intravenous infusion,d1; Q3W."
89262522|NCT05094700|Experimental|Non-marketed Cosmetic Facial Cleanser|Participants will receive non-marketed cosmetic facial cleanser to apply on cleanse facial skin, twice daily for 4 weeks.
89262523|NCT01108432|Experimental|Electronic Referrals|Dental practices randomized to the experimental group will have options on how to refer patients to the tobacco cessation website.
89262524|NCT01108432|No Intervention|Routine Referral|Dental practices in this arm will refer patients to the Decide2Quit website by using an information prescription.
89262525|NCT03576664|Experimental|Carvedilol first|Carvedilol (25 mg) followed by Placebo oral capsule is administered in a crossover manner.
89262526|NCT03576664|Experimental|Placebo first|Placebo oral capsule followed by Carvedilol (25 mg) is administered in a crossover manner.
89262527|NCT03502408|Experimental|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
88805215|NCT00258830|Experimental|Age 60 years and older|Participants aged 60 years and older at enrollment.
88805216|NCT02095340|Experimental|Positive Training|
88805217|NCT02095340|Sham Comparator|Neutral Training|
88805218|NCT02539368||CT-P13|biosimilar infliximab
89262528|NCT02529826|Experimental|Testicular biopsy|Cancer affected prepubertal boys will undergo testicular biopsy for testicular fragments cryopreservation. The biopsy will be performed by an attending urologist, before any gonadotoxic therapy is initiated. Testicular biopsy specimens will be divided immediately on the operating table. Two thirds of the specimen will be cryopreserved for potential use by the patient at a later date and will have the patient's details and will stay at the sperm bank of Hadassah Medical Center. The other third of specimen will be used for research purposes in an effort to advance the science of isolating and culturing human SSC's for fertility research.
89262529|NCT01108978|Placebo Comparator|Placebo|
89262530|NCT01108978|Active Comparator|Dehypotin|
89262531|NCT01109134|Experimental|Tirofiban intracoronary bolus-only|Tirofiban bolus administered via intracoronary route at the time of primary PCI with no additional peri/postprocedural maintenance infusion
89262532|NCT01109134|Active Comparator|Tirofiban intravenous bolus+infusion|Tirofiban bolus administered intravenously before PCI, followed by periprocedural maintenance infusion
89262533|NCT01108588|Experimental|Sequence 1|Aspirin - Clopidogrel - Placebo
89262534|NCT01108588|Experimental|Sequence 2|Clopidogrel - Placebo - Aspirin
89262535|NCT01108588|Experimental|Sequence 3|Placebo - Aspirin - Clopidogrel
89262536|NCT01108588|Experimental|Sequence 4|Aspirin - Placebo - Clopidogrel
89262537|NCT01108588|Experimental|Sequence 5|Clopidogrel - Aspirin - Placebo
89262538|NCT01108588|Experimental|Sequence 6|Placebo - Clopidogrel - Aspirin
89262539|NCT01208740|Experimental|Metformin|Metformin pre-treatment and co-administration
89262540|NCT01208740|Placebo Comparator|Placebo|Placebo pre-treatment and co-administration
89262541|NCT01208818|Active Comparator|BD|
89262542|NCT01208818|Experimental|C-BD|
89262543|NCT01208818|Experimental|HCO|
89262544|NCT01208818|Active Comparator|Control HD|
89262545|NCT03947320|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
89262546|NCT01111630|Experimental|once weekly|
89262547|NCT01111630|Active Comparator|three times weekly|
89262548|NCT01208896|Experimental|Rituximab|
89262549|NCT03944278|Experimental|Thulium Device|1927 Laser Treatment
89262550|NCT01327768|Experimental|OECs, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of Olfactory ensheathing cells(OECs), Antiplatelet Medication, and Rehabilitation.
89262551|NCT03942796|Active Comparator|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin
89262552|NCT03942796|Active Comparator|pulsed radiofrequency ablation of the dorsal root ganglion und|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion
89262553|NCT01114282|Experimental|VELCADE with pralatrexate|Pralatrexate,10 mg/m2, IV bolus on days 1, 8, and 15 VELCADE,1.3 mg/m2, IV bolus on days 1, 8, and 15
89262554|NCT01111708|Experimental|Close Rectal-Ileo Pouch Anal Anastomosis|
89262555|NCT01111708|Active Comparator|Conventional Ileo Pouch Anal Anastomosis|
89262556|NCT01111708|Active Comparator|Ileo Neo Rectal Anastomosis|
89262557|NCT03944122|Experimental|continuous ultrasound|continuous ultrasound were applied to the patients
89262558|NCT03944122|Experimental|pulsed ultrasound|pulsed ultrasound were applied to the patients
89262559|NCT03944122|Experimental|placebo|placebo (sham) ultrasound were applied to the patients
89262560|NCT01109212|Experimental|Bindarit|Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks
89262561|NCT01109212|Placebo Comparator|Placebo|patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks
89262562|NCT01111864|Experimental|MixMe powder (iron & micronutrients)|
89262563|NCT01111864|Placebo Comparator|MixMe powder (micronutrients, no iron)|
89262564|NCT01111864|Experimental|Sprinkles (iron and micronutrients)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Iron 12.5 mg; Zinc 5 mg
89262565|NCT01111864|Placebo Comparator|Sprinkles (micronutrients, no iron)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Zinc 5 mg
89262566|NCT01211782|Experimental|AC-1204|
89262567|NCT01211782|Placebo Comparator|Placebo|
89262568|NCT01111942|Active Comparator|radiation and weekly carboplatin|
89262569|NCT01111942|Other|conservation surgery|
89262570|NCT01112020|Experimental|CHG Catheter Dressing Patch|
89262571|NCT01112020|Active Comparator|Biopatch|Biopatch Protective Disk with CHG
88805219|NCT02539368||Remicade|infliximab
89262572|NCT01112020|Active Comparator|Tegaderm CHG|Tegaderm CHG IV Securement Dressing
89262573|NCT03944200|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
89262574|NCT03944200|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
89262575|NCT01109290||HED children|
89262576|NCT01109290||HED adults|
89262577|NCT01109290||Control children|
89262578|NCT01109290||Control adults|
89262579|NCT03940534|Active Comparator|Start with Mobile Device|
89262580|NCT03940534|Active Comparator|Start without Mobile Device|
89262581|NCT03942640|Other|perineural injection group|"perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years~Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%.~Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves :~Suprascapular nerve.."
89262582|NCT03942640|Other|deepprolotherapy group|Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .
89262583|NCT01112098|Experimental|Educational Pamphlet and letter|Letter invites patient to self-schedule a DXA; educational pamphlet includes information about DXA scans
89262584|NCT01211860|Experimental|DCCR Treatment|DCCR Treatment 290 mg diazoxide choline
89262585|NCT01589536|Experimental|Interventiongroup|A Stationary psychocardiological interval-rehabilitation.
89262586|NCT01589536|No Intervention|controlgroup|The Patients in the control group receive a personal recommendation concerning psychotherapy outpatient counseling and therapy services at home and take therapeutic help.
89262587|NCT01211938|Active Comparator|single-fraction radiotherapy with concomitant 5FU and Hydrea|six 5-day cycles with a 9-day rest period between each cycle (split course). Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle. The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.
89262588|NCT01211938|Experimental|hyperfractionated radiotherapy with concomitant Cetuximab|Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab. The total dose of radiotherapy is 60 Gy delivered over 5 weeks. Cetuximab (ErbituxÒ) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.
89262589|NCT02947438|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
89262590|NCT02947438|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
89262591|NCT03940768|Experimental|Lactobacillus plantarum 299v receivers|Sanprobi IBS (Lactobacillus plantarum 299v) 2 capsules per day for 4 weeks.
89262592|NCT03940768|Placebo Comparator|Placebo receivers|Sanprobi IBS placebo 2 capsules per day for 4 weeks.
89262593|NCT01209052|Experimental|COHORT 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 10mg, to 50mg, and 200mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
89262594|NCT01209052|Experimental|COHORT 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 25mg, to 100mg, and 400mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
89262595|NCT01209052|Experimental|COHORT 3|Placebo controlled, 14-day, once daily, repeat-dose evaluation with one selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohorts 1 and 2.
89262596|NCT01209052|Experimental|COHORT 4|Placebo controlled, 14-day, once daily, repeat-dose evaluation with a higher selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohort 3.
89262597|NCT01209130|Experimental|A|
89262598|NCT01209130|Experimental|B|
89262599|NCT01209208|Experimental|A|Budesonide
89262600|NCT01209208|Experimental|B|Mesalazine
89262601|NCT01209208|Placebo Comparator|C|
89262602|NCT03940612|Experimental|STP4 (product with probiotics)|Dietary Supplement: STP4
89262603|NCT03940612|Experimental|Placebo (product without probiotics)|Dietary Supplement: Placebo
89262604|NCT01112254|Experimental|MRI±biopsy|a MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm from the initial lesion), not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI ± biopsy results.
89262605|NCT01112254|No Intervention|Standard care|The patients will be operated without additional exams
89262606|NCT03940846||Maastro (Lung1)|Open source dataset available at TCIA.org. The cohort includes CT scans of 422 patients diagnosed with NSCLC.
89262607|NCT03940846||UCSF|A cohort of patients diagnosed with NSCLC at UCSF medical center. It includes CT scans of 165 patients.
89262608|NCT03940846||Radboud|A cohort of patients diagnosed with NSCLC at Radboud medical center. It includes CT scans of 255 patients.
89262609|NCT03940846||Stanford|Open source dataset available at TCIA.org. The cohort includes CT scans of 211 patients diagnosed with NSCLC.
89262610|NCT01114594||PKD|Patients with Autosomal Dominant Polycystic Kidney Disease
89262611|NCT01114594||non-PKD CKD|Patients with non-Polycystic Chronic Kidney Disease
89262612|NCT01114750|Active Comparator|Oral Insulin in Dextran Matrix|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
89262613|NCT01114750|Placebo Comparator|Placebo|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
89262614|NCT01328470|Active Comparator|clopidogrel 75 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
89262615|NCT01328470|Active Comparator|clopidogrel 150 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
89262616|NCT01328470|Active Comparator|adjunctive cilostazol|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; [group 3, 20 patients]) for 14 days.
89262617|NCT01328470|Active Comparator|75mg clopidogrel|control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).
89262618|NCT01109446|Experimental|Platelet Rich Plasma|
89262619|NCT01109446|Sham Comparator|Isotonoic Saline Solution|
89262620|NCT01109446|Active Comparator|Steroid (Triamcinolonacetonid)|
89262621|NCT03940378|Experimental|One-drug Regimes|Basic drug : Anlotinib Hydrochloride Capsules
89262622|NCT03940378|Experimental|Two-Drug Regimens|Basic drug: Anlotinib Hydrochloride Capsules Add Intervention drug: Levamisole Hydrochloride
88805220|NCT01425307|No Intervention|Standard Therapy|Standard Therapy of monthly transfusions
88805221|NCT01425307|Experimental|Treatment Arm|Hydroxyurea will be provided as capsules or liquid
88805222|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F1 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 1 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
88805223|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
89262623|NCT01114984||10% after breast biopsy|Incidence Post-operative pain after breast surgery.
89262624|NCT01114984||20% after lumpectomy|Incidence Post-operative pain after breast surgery
89262625|NCT01114984||30% after simple mastectomy|Incidence Post-operative pain after breast surgery
89262626|NCT01114984||50% after mastectomy with reconstruction|Incidence Post-operative pain after breast surgery
89262627|NCT01114984||50% after radical mastectomy|Incidence Post-operative pain after breast surgery
89262628|NCT01114984||50% after radi mastectomy+reconstruction|Incidence Post-operative pain after breast surgery after radical mastectomy with reconstruction
89262629|NCT01114984||40% after cosmetic augmentation|Incidence Post-operative pain after breast surgery
89262630|NCT01114984||40% after breast reduction|Incidence Post-operative pain after breast surgery
89262631|NCT01112488|No Intervention|Control|usual care
89262632|NCT01112488|Experimental|multidisciplinary intervention|Patient engagement Programme
89262633|NCT03940222|Experimental|I-BiT group|Amblyopic patients will play I-BiT games without patching.
89262634|NCT03940222|Placebo Comparator|Placebo group|Amblyopic patients will patch their dominant eye and they will play placebo I-BiT games.
89262635|NCT01115062|Experimental|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg)
89262636|NCT01115062|Experimental|LMX-4 Cream|LMX-4 (liposomal lidocaine 4%) cream
89262637|NCT01115062|Placebo Comparator|Placebo Patch|Placebo Patch
89262638|NCT01115140|Active Comparator|Group A1|metformin plus placebo
89262639|NCT01115140|Experimental|Group A2|metformin plus folic acid
89262640|NCT01115140|Active Comparator|Group A3|placebo plus folic acid
89262641|NCT01115140|Placebo Comparator|Group A4|placebo cp, 2 cps daily
89262642|NCT01115140|No Intervention|Group B|observation
89262643|NCT01112644|Experimental|OXN PR|Different daily doses; intake every 12 hours
89262644|NCT01112644|Placebo Comparator|PLA|Different daily doses; intake every 12 hours
89262645|NCT01112722|Active Comparator|Apitox, purified honeybee toxin, injections|active treatment drug 'Apitox, purified honeybee toxin, lyophilized in saline'
89262646|NCT01112722|Placebo Comparator|histamine injection|the histamine injection produces a similar local effect of pain and erythema as the active drug
89262647|NCT01209676|Experimental|IMCgp100|IMCgp100 will be injected cutaneously or subcutaneously into the metastasis, and peritumoral area if applicable
89262648|NCT03941938|Experimental|Cyanoacrylate|the anastomotic reinforcement with nebulized cyanoacrylate glue using the special short catheter device for open surgery or the laparoscopic catheter.
89262649|NCT03941938|Active Comparator|No reinforcement|No reinforcement will be applied on the anastomosis line
89262650|NCT01015222|Experimental|Dasatinib, Bevacizumab + Paclitaxel|"Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15~Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation."
89262651|NCT01115218||Glaucoma patients|
89262652|NCT01209754||Pregnant Women|Pregnant women exposed to an HIV prevention study agent during pregnancy
89262653|NCT01209754||Infant|Infants resulting from pregnancies where there exists maternal HIV prevention agent exposure
89262654|NCT01115296|Active Comparator|'L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
89262655|NCT01115296|Placebo Comparator|Placebo|Placebo
89262656|NCT03940456||Inception cohort, former Elsinore pupils|640 former Elsinore pupils (330 female, 310 male). Aged 14 in 1965. Two earlier cross-sectional studies have been done in this group (in 1990 and 2000).
89262657|NCT01112800||Participants|Previously untreated patients referred to St. Jude Children's Research Hospital (SJCRH) between the ages of 0 and 21 years with a diagnosis of osteosarcoma, ESFT, rhabdomyosarcoma and intermediate and high-risk non-rhabdomyosarcoma soft tissue sarcomas whose planned treatment includes administration of a cumulative anthracycline dose ≥ 375 mg/m2.
89262658|NCT01115374|Active Comparator|manual lymphatic drainage|Application of manual lymphatic drainage
89262659|NCT01115374|Experimental|low frequency sound waves|Application of low frequency sound waves
89262660|NCT01209910|Experimental|free water|The subjects in this arm will be able to drink water followings study rules.
89262661|NCT01209910|No Intervention|Control|These subjects will be observed during the study.
89262662|NCT03943420||Experimental Group|Therapy A : Basic treatment + Qianyang Yuyin Granules
89262663|NCT03943420||Negative Control Group|Therapy B : Basic treatment
89262664|NCT03943420||Positive Control Group|Therapy C : Basic treatment + Donepezil
89262665|NCT01212250|Experimental|Carvedilol|Tablet 6.25 mg BD
89262666|NCT01212250|Placebo Comparator|placebo|Placebo tablets 2 BD
89262667|NCT01209988|Experimental|Tamsulosin 0.4mg|Perioperative tamsulosin 0.4mg daily
89262668|NCT01209988|Placebo Comparator|Control|No medication
89262669|NCT02529748|Experimental|Participants for Surface Skin Sampling|Adult volunteers with healthy, intact skin will have surface skin wipe samples collected following contact with the approved test substances to measure the quantitative transfer of the test substances to and from the skin surface.
89262670|NCT03943186||Ectoin Lozenges Honey Lemon|application of 1 Lozenge every three hours or as often as required, not more than 10 lozenges per day
89262671|NCT03943186||Hyaluronic acid/Icelandic moss Lozenges|application as often as required, not more than 6 lozenges per day
89262672|NCT01210066|Active Comparator|Pain Challenge|Cold pressor test
89262673|NCT01210066|Active Comparator|Pain + Opioid Challenge|IV fentanyl 1mcg/kg followed by cold pressor test
89262674|NCT01210066|Active Comparator|Opioid Challenge|Administration of fentanyl 1mcg/kg of subject weight
89262675|NCT01115530|No Intervention|1|Control inpatient GEM rehabilitation and continue twice weekly low level walking/stretching to control for time/interaction with intervention/exercise groups
89262676|NCT01115530|Experimental|2|Resistance exercise (2x/week)
89262677|NCT01115530|Experimental|3|Nutritional (amino acid metabolite) supplement twice daily
89262678|NCT01115530|Experimental|4|Resistance exercise (2x/week) and nutritional (amino acid metabolite) supplement twice daily
89262679|NCT03942172|Experimental|SpotOn Balance|SpotOn Balance Glasses
89262680|NCT01212328|Experimental|Care coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
89262681|NCT01212328|Active Comparator|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
89262682|NCT03939988|Active Comparator|Experimental group|In this study, immediately after the installation of the separators, the subjects of the experimental group will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
89262683|NCT03939988|Placebo Comparator|Placebo group|In the placebo group, the same procedures will be made, but the laser will be switched off.
89262684|NCT01112878|Placebo Comparator|Sugar Pill|"Frequency and Dosage:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
89262685|NCT01112878|Active Comparator|Clonidine|"Dosage: 0.2 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
89262686|NCT01112878|Active Comparator|Gabapentin|"Dosage: 600 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
89262687|NCT01109680|Experimental|14 C labelled Neramexane, capsule|
89262688|NCT01115608|Experimental|Pharmacist follow-up|"The patients will receive pharmaceutical follow-up during one year after discharge from the hospital. Three meetings are arranged, one at discharge, one after three months and the last after one year. Patients will be called up for arrangement of consultation. Written information concerning drugs used will be supplied."
89262689|NCT01115608|No Intervention|Control group|The control group receives no follow-up from the pharmacist, but will after one year, when they are out of the study, receive one follow-up visit and drug review.
89262690|NCT01112956||STD clinic patients|Patients attending sexually transmitted Disease clinics. If the initial testing result reported to the patient is confirmed by the Western Blot test, no follow-up specimens will be collected. If the initial testing result reported to the patient is different from the result by the Western Blot test, patients will be asked to provide a follow-up specimen 3-4 months after initial testing.
89262691|NCT01112956||Pregnant women|Women recruited from prenatal clinic. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
89262692|NCT01112956||Men who have Sex with men (MSM)|Men recruited from a clinic for MSM with high risk for HIV infection. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
89262693|NCT01212406|Placebo Comparator|Placebo|Olive oil
89262694|NCT01212406|Experimental|Vitamin D|Addition of D-cure (100.000U) to standard care
89262695|NCT03939910|Active Comparator|Control arm|bupivacaine 0.25% for pudendal block
89262696|NCT03939910|Experimental|Intervention arm|ropivacaine 0.2 % for the pudendal block
89262697|NCT01109758|Experimental|1|
89262698|NCT01115686|Active Comparator|Branched-chain aminoacids|Branched-chain aminoacids are natural constituents of the food. Branched-chain aminoacids will be orally administered in the form of capsules.
89262699|NCT01115686|Placebo Comparator|placebo|The placebo will be orally administered in the form of capsules
89262700|NCT03939754||Adult attendance to Dedalo activities|Adult attended one Dedalo's activity
89262701|NCT03939754||Adult living in Vercelli|Adult aged 40-75
89262702|NCT01328236|Experimental|V-DD single arm|"INDUCTION THERAPY: V-DD induction therapy for 6 cycles，28 Days per Cycle. Bortezomib - 1.3 mg/m2 IV, Days 1, 4, 8 , 11 of every treatment; Liposomal Doxorubicin - 30 mg/m2 IV, Day 4 of every treatment; Dexamethasone - 40 mg/d IV, Days 1 - 4 of every treatment.~Maintenance treatment for 4 cycles,28 Days per Cycle. Thalidomide - 100mg Qn ; Bortezomib - 1.3 mg/m2 IV ,Days 1, 4, 8 and 11 of every treatment; Dexamethasone - 40 mg/d IV ,Days 1 - 4; Interferon - 300 u Qod,（Specially for IgA type）. Interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
89262703|NCT03939832|Active Comparator|FiO2 0.5|
89262704|NCT03939832|Active Comparator|FiO2 1.0|
89262705|NCT01113034|Active Comparator|DAS181 Dry Powder 10 mg qd x 3 days|
89262706|NCT01113034|Placebo Comparator|Lactose Placebo|
89262707|NCT01212562||Immunocryosurgery|2 weeks daily imiquimod application prior to a session of cryosurgery and subsequently 3 weeks continued daily imiquimod application
89262708|NCT01115842|Experimental|Vitamin D|The patients will be given Vitamin D - 4000IU per day for 5 days (Day 1 through 5)
89262709|NCT01115842|No Intervention|control|
89262710|NCT01115920|Experimental|Arm 1|Cohort 1, Dose 0.010 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
89262711|NCT01115920|Experimental|Arm 2|Cohort 2, Dose 0.025 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
89262712|NCT01115920|Experimental|Arm 3|Cohort 3, Dose 0.050 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
89262713|NCT01115920|Experimental|Arm 4|Cohort 4, Dose 0.100 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
89262714|NCT01115920|Experimental|Arm 5|Cohort 5, Dose 0.250 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
89262715|NCT01116076|Experimental|DECISION+ Program|Exposure to the Decision+ Program
89262716|NCT01116076|No Intervention|Control|Usual Care
89262717|NCT01210378|Experimental|Nitroglycerin|
89262718|NCT01109836|Experimental|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
89262719|NCT01109836|No Intervention|Control|Standard stroke care
89262720|NCT01116154|Experimental|Arm I|Patients receive oral vorinostat twice daily on days 1-14 and oral lenalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89262721|NCT01113190|Active Comparator|CBI in ED with AMET at 3 months|computer-delivered brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
89262722|NCT01113190|Active Comparator|CBI in ED with EUC at 3 months|computer-delivered brief intervention (CBI) at baseline with enhanced usual care-EUC at 3 months
89262723|NCT01113190|Active Comparator|IBI in ED with AMET at 3 months|intervener-delivered brief intervention (IBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
89262724|NCT01113190|Active Comparator|IBI in ED with EUC at 3 months|intervener-delivered brief intervention (IBI) at baseline with enhanced usual care-EUC at 3 months
89262725|NCT01113190|Active Comparator|EUC in ED with AMET at 3 months|enhanced usual care (EUC) at baseline with adapted motivational enhancement therapy-AMET at 3 months
89262726|NCT01113190|Active Comparator|EUC in ED with EUC at 3 months|enhanced usual care (EUC) at baseline with EUC at 3 months
89262727|NCT01210456|Active Comparator|Physiological Saline and N-Acetylcysteine|
89262728|NCT01210456|Active Comparator|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|
89262729|NCT01210612|Active Comparator|Without Unilateral CAI|
89262730|NCT01210612|Active Comparator|With Unilateral CAI|
89262731|NCT01207804|Experimental|Device|
89262732|NCT01116310|Experimental|Fitogyn|4 weeks with placebo followed by 16 weeks with Fitogyn, both taking two capsules per day during the breakfast.
89262733|NCT01116310|Placebo Comparator|Placebo|20 weeks with placebo, taking two capsules per day during the breakfast.
89262734|NCT01210846|Experimental|tivozanib|
89262735|NCT01116388|Other|test product|product free of gluten and casein
89262736|NCT01116388|Other|control product|product containing gluten and milk protein
89262737|NCT01210924||Pediatric ART patients|
89262738|NCT01109914|Experimental|Renal transplant recipients (MMF)|"Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
89262739|NCT01109914|Experimental|Renal transplant recipients (CNI)|"Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
89262740|NCT01109914|Experimental|Healthy volunteers|"Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).~Intervention: vaccination with Dukoral"
89262741|NCT01110070|Experimental|ChonDux plus microfracture|
89262742|NCT01110070|Active Comparator|Microfracture|
89262743|NCT03941626|Experimental|CAR-T/TCR-T cells immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
89262744|NCT01211002|Active Comparator|radiotherapy combined with EP|the dose of radiotherapy is 60-66 Gy / 30-33f.The combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
89262745|NCT01211002|Experimental|adiotherapy / EP /recombinant human endostatin|recombinant human endostatin: The number of courses is 3 ~ 4 and each course last for 28 days.dose:15mg，d1-14, intravenous injection.
89262746|NCT01211080||Threatening hemangioma|The group with cosmetically threatening of functionally threatening hemangiomas warranting active treatment according to our usual criteria (location face, hands, feet with a strong growth tendency and below age of 8 months)
89262747|NCT01113346|Experimental|Filtrum-STI|
89262748|NCT01113346|Placebo Comparator|Placebo|
89262749|NCT01113424|Experimental|NRT-2|2 mg single-dose of a new NRT product
89262750|NCT01113424|Active Comparator|GUM-2|2 mg single-dose of a marketed nicotine gum
89262751|NCT01113424|Experimental|NRT-4|4 mg single-dose of a new NRT product
89262752|NCT01113424|Active Comparator|GUM-4|4 mg single-dose of marketed nicotine gum
89262753|NCT01211158|Active Comparator|Propofol alone|Patients receiving propofol alone.
89262754|NCT01211158|Active Comparator|Ketofol|0.375 mg/kg each of ketamine and propofol (mixed in the same syringe) as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
89262755|NCT03943108||Obese teenagers within the PAIDOS clinic|Obese children within the PAIDOS clinic, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
89262756|NCT03943108||Healthy children|Healthy children living in Mexico City, Mexico.
89262757|NCT03943108||Children with Type 2 Diabetes|Chjildren with Type 2 Diabetes attending the Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.
89262758|NCT01116778|Experimental|eN-Lac® Capsules|
89262759|NCT01116778|Other|Placebo Capsules|
89262760|NCT01110148|Experimental|Video-based informed consent|patients receiving informed consent through video format
89262761|NCT01110148|Active Comparator|traditional informed consent|patients receiving traditional informed consent from the physicians.
89262762|NCT01116856|Experimental|Nutrition|This groups will follow a diet.
89262763|NCT01116856|Experimental|Nutrition + resistance training|In this group, nutrition and resistance training will be combined.
89262764|NCT01116856|Experimental|Nutrition + aerobic training|In this group nutrition and aerobic training will be combined.
89262765|NCT01116856|Experimental|Nutrition + mixed training|In this group the nutrition will be combined with 50% of resistance training plus 50% of aerobic training.
89262766|NCT01110226|Experimental|Period 1: KML001 15mg plus Cisplatin 75mg/m2|KML001 15 mg orally daily days 1-14 with cisplatin IV on day1
89262767|NCT01110226|Experimental|Period 2: KML001 17.5mg plus Cisplatin 75mg/m2|KML001 17.5 mg orally daily days 1-14 with cisplatin IV on day1
89262768|NCT01110226|Experimental|Period 3: KML001 20mg plus Cisplatin 75mg/m2|KML001 20 mg orally daily days 1-14 with cisplatin IV on day1
89262769|NCT01211236|Experimental|Maggot Debridement Therapy|
89262770|NCT01211236|Active Comparator|control|
89262771|NCT03789292|Experimental|CT-P17 Subcutaneous(SC) (adalimumab)|CT-P17 SC (adalimumab)
89262772|NCT03789292|Active Comparator|Humira SC (adalimumab)|Humira SC (adalimumab)
89262773|NCT01212718|Active Comparator|5-FU|FUFA 5-flurouracil and folinic acid control
89262774|NCT01212718|Active Comparator|Folfiri|5-fluouracil and folinic acid in combination with irinotecan (Folfiri) systemic chemotherapy intensified treatment arm
89262775|NCT01211314|Experimental|lercanidipine-enalapril fixed combination|uncontrolled hypertensive patients will receive fixed combination therapy
89262776|NCT01110304|Active Comparator|Conservative treatment|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed.
89262777|NCT01110304|Active Comparator|Surgical treatment|Patients will undergo surgery to treat their AC joint dislocation.
89262778|NCT01207960|Active Comparator|EMDR|Eye Movement Desensitization and Reprocessing
89262779|NCT01207960|No Intervention|WLC|Wait-list control group. EMDR treatment takes place after 4 weeks of no treatment which represents the wait-list comparison interval.
89262780|NCT03942874|Experimental|Treatment|Participants will complete baseline sessions and then complete treatment right away.
89262781|NCT03942874|Experimental|Waitlist Control|Participants will complete a baseline session and then wait for 10 weeks before starting treatment.
89262782|NCT02529514|Active Comparator|Baclofen|Baclofen 25 mg per os for 7 days at 10 pm every day
89262783|NCT02529514|Placebo Comparator|Placebo|Placebo per os for 7 days at 10 pm every day
89262784|NCT01208116||Subgroups|According to the demographic features, subjects may be divided into some subgroups.
89262785|NCT03941002|Placebo Comparator|Clinical pressure support|The level of inspiratory pressure support will be selected by the attending physician
89262786|NCT03941002|Active Comparator|Reduced pressure support|The level of inspiratory pressure support will be reduced by 25%
89262787|NCT03941002|Active Comparator|Lowest pressure support|The level of inspiratory pressure support will be reduced by 50%
89262788|NCT03939130|Experimental|Fructose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive fructose based beverage, prepared as a solution with 10% fructose, water and flavoring powder, totaling 1.0g / kg of body mass / day of fructose.
89262789|NCT03939130|Active Comparator|Glucose-rich diet|Subjects will be submitted to a standard diet associated with a sweetened beverage (provided by the researchers) during 4 weeks. Without knowing the content (blind), they will receive glucose based beverage, prepared as a solution with 10% glucose, water and flavoring powder, totaling 1.0g / kg of body mass / day of glucose.
89262790|NCT03939130|Experimental|Fructose-rich diet and exercise|The subjects will perform the same protocol described in the intervention Fructose-rich diet, except for the inclusion of the physical exercise. During the 4-week intervention, participants will perform three sessions a week of 60 minutes of aerobic exercise at 60% of VO2 peak on cycle ergometer.
89262791|NCT01113970|Experimental|Single Arm|open label, single arm, unblinded
89262792|NCT01211470|Experimental|PMX-30063|3 arms of PMX-300063
89262793|NCT01211470|Active Comparator|Daptomycin.|Daptomycin will be administered according to the approved product monograph information for ABSSSI.
89262794|NCT01211548||contrast CTA of the CAP|All patients being considered for a complex aortic surgery and undergoing medically indicated contrast enhanced CT aortic angiography of the chest abdomen and pelvis will be includedRaw data from CT coronary angiography will be available from all patients.
89262795|NCT01208194|Experimental|MGN1703|Study medication
89262796|NCT01208194|Placebo Comparator|Placebo|
89262797|NCT01208272|Experimental|Binge Eating Disorder/Therapy|
89262798|NCT01114126|Experimental|Neu-P11 2mg|
89262799|NCT01114126|Experimental|Neu-P11 5 mg|
89262800|NCT01114126|Experimental|Neu-p11 20 mg|
89262801|NCT01114126|Experimental|Neu-P11 50 mg|
88805224|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 3D GROUP|Subjects received 3 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0, Day 21 and Day 182 (booster).
89262802|NCT01114126|Placebo Comparator|Placebo|
89262803|NCT03939052|Experimental|Protein intake|Free amino acids vs. Glycomacropeptide (GMP)
89262804|NCT01208350|Experimental|1|
89262805|NCT01208350|Experimental|2|
89262806|NCT01208350|Active Comparator|3|
89262807|NCT03939208|Experimental|Intervention (BRISC) Group|Clinicians randomly assigned to BRISC will implement a flexible intervention that, over four sessions, aims to assess and engage student clients, and identify and address student identified difficulties that are distressing and impacting academic performance/behavior, social, and overall functioning. BRISC uses an explicit, problem-solving structure and a range of techniques common to evidence-based practices (EBP) tailored to the identified needs of the student.
89262808|NCT03939208|Active Comparator|Services as Usual (SAU) Group|"Clinicians in the SAU condition will use a diverse array of treatment as usual strategies over four sessions that may include some directive, skill-building techniques common in EBPs, but, given findings from pilot studies and studies of mental health services as usual in community and school settings, are likely to be provided at an overall lower rate, and at lower intensity, than in BRISC or other EBP."
89262809|NCT01213030|Active Comparator|10 mCi HX4|Patient will be injected with [F-18] FMISO
89262810|NCT01213030|Active Comparator|10 mCi FMISO|Patient will be injected with [F-18] HX4
89262811|NCT01208428|Active Comparator|Conventional cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy for the treatment of major depression
89262812|NCT01208428|Experimental|Religious cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy, but their religious beliefs will be utilized as a resource in the therapy
89262813|NCT01211626|Active Comparator|Part A, Group 1 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 200 mg of ANA773 (n=6) or placebo (n=2)
89262814|NCT01211626|Active Comparator|Part A, Group 2 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 400 mg of ANA773 (n=6) or placebo (n=2)
89262815|NCT01211626|Active Comparator|Part A, Group 3 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 800 mg of ANA773 (n=6) or placebo (n=2)
89262816|NCT01211626|Active Comparator|Part A, Group 4 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1200 mg of ANA773 (n=6) or placebo (n=2)
89262817|NCT01211626|Active Comparator|Part A, Group 5 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1600 mg of ANA773 (n=6) or placebo (n=2)
89262818|NCT01211626|Active Comparator|Part B, Group 6 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 2000 mg of ANA773 (n=6) or placebo (n=2)
89262819|NCT01211626|Active Comparator|Part B, Group 7 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1200 mg of ANA773 (n=6) or placebo (n=2)
89262820|NCT01211626|Active Comparator|Part B, Group 8 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1600 mg of ANA773 (n=6) or placebo (n=2)
89262821|NCT01211626|Active Comparator|Part B, Group 9 HCV Infected Patient|multiple oral doses(5 administrations) every other day of 2000 mg of ANA773 (n=8) or placebo (n=2)
89262822|NCT01211704|Placebo Comparator|Placebo, Counceling|Placebo
89262823|NCT01211704|Experimental|Paliperidone Palmitate|Paliperidone Palmitate
89262824|NCT02529670|Experimental|Laser|15 patients will be positioned in a prone horizontal position under anesthetic monitoring. The intervertebral foramen between the second and third lumbar vertebrae will be accessed by percutaneous puncture guided by fluoroscopy. Laser Photon III® (DCM) will be applied through fiber optics crossing G18 cannulas, during 84 seconds.
89262825|NCT02529670|Active Comparator|Radiofrequency|15 patients will receive radiofrequency in the second dorsal root ganglion through tubes G20, 150 mm long and 5 mm active tip in contact with the target, neuromodulation will be held for 300 seconds at 42oC.
89262826|NCT02529670|Active Comparator|Drug: Lidocaine|In the local anesthetic group, 15 patients will receive the injection of 1 ml lidocaine without vasoconstrictor will be applied in the tubes G18, 150 mm long to block the second dorsal root ganglion.
89262827|NCT03939286|Other|movement group|intensified training (equipment, coordination, balance)
89262828|NCT03939286|Other|control group|continuation of physical activity as usual
89262829|NCT01328704||Triathletes|Group of individuals who are participating in a triathlon training program at the Avera Sports Institute
89262830|NCT01208506|Experimental|Dose level 1|
89262831|NCT01208506|Experimental|Dose level 2|
89262832|NCT01208506|Experimental|Dose level 3|
89262833|NCT01208506|Experimental|Dose level 4|
89262834|NCT01208506|Experimental|Dose level 5|
89262835|NCT01208506|Experimental|Dose level 6|
89262836|NCT01208506|Experimental|Dose level 7|
89262837|NCT01208506|Experimental|Dose level 8|
89262838|NCT03938896|Other|platelet rich plasma|It started with puncture of the vein and taking specific amount of autologous blood from the participantnearly a sample of 20 ml of venous blood (Co AY, 2012).The blood sample was put in a sterile tube containing an anticoagulant as sodium citrate.Then the blood sample wascentrifuged for 15 minutes at 1800 rpmwhich leads to separation of the plasma at the top layer from the packed RBCs at the bottom layer. The RBCs layer is removedthenanother centrifugationwas done at 3500 rpm for 10 minuteswhich leads to formation of a more concentratedplatelet layer after removal of PPP(Anitua et al., 2012).Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area.
89262839|NCT03938896|Other|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle.
89262840|NCT01208584||Chronic posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A, spinal cord injury (SCI) 12-24 months
89262841|NCT01208584||Acute posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A,SCI 2-6 months,
89262842|NCT01208584||Myelomeningocele patients|Myelomeningocele patients (congenital paraplegia, thoracic level of lesion Th1-Th12) ASIA A
89262843|NCT01208584||Volunteers|Volunteers without any neurological deficits
89262844|NCT01213108|Experimental|Örebro prevention program|
89262845|NCT01213108|Active Comparator|Control|Business as usual
89262846|NCT03938818|Other|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures
89262847|NCT03938818|Experimental|Tu'Washindi intervention|"Standard of care will include PrEP delivery according to the usual DREAMS procedures. The Tu'Washindi intervention includes the following components:~PrEP sensitization for men (community level).~Buddy Days (partner level).~Adherence support clubs (individual and peer levels)."
89262848|NCT03938506||intubation using the endotracheal tube size of 6.0 or 8.0|Adult male patients who require endotracheal intubation using the endotracheal tube size of 6.0 or 8.0
89262849|NCT01117636|Experimental|Arm 1|
89262850|NCT01117636|Active Comparator|Arm 2|
89262851|NCT01117636|Placebo Comparator|Arm 3|
89262852|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 40%
89262853|NCT03938740|Experimental|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%|HDV-Insulin Lispro and Insulin Degludec dose reduced by 10%
89262854|NCT01213186|Experimental|Drug: high dose of MSC treatment|Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.
89262855|NCT01213186|Experimental|low dose of MSC treatment|Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
89262856|NCT01213186|Placebo Comparator|low dose of MSC|Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
89290446|NCT05198986||ECMO Prone Position|After baseline assessment in supine position, patients will be positioned in prone position to assess modification of lung mechanics, aeration and hemodynamics
89290447|NCT03932292|Active Comparator|Ectoin Mouth Wash|30 patients obtaining EML03 treatment
89262857|NCT01117714|Active Comparator|EUS/EBUS with FNA|EUS/EBUS staging will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. If present and accessible, at least one lymph node from each accessible station will be aspirated with a separate fine needle using routine FNA and cytological techniques. If multiple lymph nodes are present in a single station, the largest lymph node from that location will be sampled. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the staging procedures will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
89262858|NCT01117714|Active Comparator|Surgical Mediastinoscopy|Within two months following CT scan, surgical mediastinoscopy will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the diagnostic method (medical or surgical) used for staging will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
89262859|NCT01110616|Experimental|Sequence 1|MK3134-Lorazepam-Placebo-MK3134-Lorazepam
89262860|NCT01110616|Experimental|Sequence 2|MK3134-Lorazepam-Placebo-Lorazepam-MK3134
89262861|NCT01110616|Experimental|Sequence 3|MK3134-Placebo-Lorazepam-MK3134-Lorazepam
89262862|NCT01110616|Experimental|Sequence 4|MK3134-Placebo-Lorazepam-Lorazepam-MK3134
89262863|NCT01110616|Experimental|Sequence 5|Lorazepam-Placebo-MK3134-MK3134-Lorazepam
89262864|NCT01110616|Experimental|Sequence 6|Lorazepam-Placebo-MK3134-Lorazepam-MK3134
89262865|NCT01110616|Experimental|Sequence 7|Lorazepam-MK3134-Placebo-MK3134-Lorazepam
89262866|NCT01110616|Experimental|Sequence 8|Lorazepam-MK3134-Placebo-Lorazepam-MK3134
89262867|NCT01110616|Experimental|Sequence 9|Placebo-MK3134-Lorazepam-MK3134-Lorazepam
89262868|NCT01110616|Experimental|Sequence 10|Placebo-MK3134-Lorazepam-Lorazepam-MK3134
89262869|NCT01110616|Experimental|Sequence 11|Placebo-Lorazepam-MK3134-MK3134-Lorazepam
89262870|NCT01110616|Experimental|Sequence 12|Placebo-Lorazepam-MK3134-Lorazepam-MK3134
89262871|NCT01117246|Experimental|Treated bone metastasis|Patients with bone metastasis causing pain.
89262872|NCT03938662|Experimental|S-Adenosyl methionine and choline|Patients in will be administered with formulation of 100 mg of S-Adenosyl methionine and 82.5 mg of choline, once daily for 24 weeks.
89262873|NCT03938662|Placebo Comparator|Placebo|Patients in will be administered with placebo once daily for 24 weeks.
89262874|NCT01110772|Experimental|2-octyl cyanoacrylate|As recommended, povidone iodine is used for skin antisepsis. After drying, a layer of cyanoacrylate is applied on the skin surface with the purpose of immobilizing skin bacteria.
89262875|NCT01110772|Active Comparator|iodine povacrylex in isopropyl alcohol|Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
89262876|NCT01213420|Experimental|Aloë Vera FORMULA F-BC-096|
89262877|NCT01213420|Active Comparator|Aloë Vera FORMULA F-BC-096 with modified preservative|
89262878|NCT01213420|Active Comparator|Eucerin Calming cream|
89262879|NCT01213420|Active Comparator|Nivea Cream|
89262880|NCT01118104|Other|Pulmonary vocational rehabilitation|
89262881|NCT01110850||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
89262882|NCT01110928||Norditropin®|
89262883|NCT01213498|Active Comparator|Atorvastatin|
89262884|NCT01213498|Placebo Comparator|Unikalk|
89262885|NCT01213342|Experimental|Treatment Group|This group will receive Omega-3 EFA supplements for 8 weeks. They will take 4 capsules/day.
89262886|NCT01213342|Placebo Comparator|Placebo Group|This group will receive placebo supplements for 8 weeks. They will take 4 capsules a day.
89262887|NCT01121614|Experimental|LOTUS|LOTUS ultrasonic instrument
89262888|NCT01121614|Experimental|Ethicon Harmonic Scalpel|Ultrasonic instrument
89262889|NCT01121614|Experimental|LigaSure|Bipolar feedback vessel sealing device
89262890|NCT01121692|Experimental|VCT/Women's CoOp|
89262891|NCT01121692|Experimental|Women's CoOp/Men's CoOp|
89262892|NCT01121692|Experimental|Couples CoOp|
89262893|NCT01215760|Active Comparator|MIRROR|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
89262894|NCT01215760|Active Comparator|Home program|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
89262895|NCT01118182||Traumatic Brain Injury (TBI)|Veterans with a positive history of TBI
89262896|NCT01118182||No Traumatic Brain Injury (TBI)|Veterans with a negative history of TBI
89262897|NCT03937492|Experimental|A group|In this group patients follow standard treatment after radius fracture plus GMI procol
89262898|NCT03937492|Active Comparator|B group|In this group patients follow standard treatment after radius fracture
89262899|NCT02529592|Experimental|Endotoxin|Endotoxin at 2ng/kg of body weight administered intravenously
89262900|NCT02529592|Placebo Comparator|Placebo|Placebo administered intravenously
89262901|NCT01118260|Active Comparator|TIVA|Total intravenous anaesthesia (TIVA) with propofol and remifentanil
89262902|NCT01118260|Active Comparator|Spinal|Spinal anaesthesia with bupivacaine and fentanyl
89262903|NCT01121770|Experimental|Arixtra|
89290448|NCT03932292|Active Comparator|Supersaturated solution of calcium and phosphate ions|20 patients taking standard treatment (calcium phosphate mouth wash)
89262904|NCT01118416|Experimental|intervention condition|Participants randomized to the intervention condition will undergo 4 one-hour sessions of motivational interviewing (MI), during which their sexual risk taking and substance use patterns will be discussed with a trained counselor with the goal of reducing instances of unprotected anal sex and substance use.
89262905|NCT01118416|Active Comparator|Education condition|Participants randomized to the education condition will undergo 4 one-hour sessions during which they will view video segments and discuss sexual risk taking and substance use with a health educator, with the goal of reducing instances of unprotected anal sex and substance use by making informed decisions.
89262906|NCT01111396||Patient with ALL under chemotherapy|This group consists of patients with initial diagnosis of acute lymphatic leukemia (ALL), who are enrolled into the GMALL 2003 chemotherapy study. There is no change of the initial GMALL 2003 treatment protocol for the present study.
89262907|NCT01121848|Active Comparator|5-FU & LV|"Day 1: LV 400 mg/m2 (given as a 2-hour infusion)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours.~This chemotherapy regimen will be administered each two weeks."
89262908|NCT01121848|Experimental|XELOX or modified FOLFOX-6|"XELOX:~Day 1: Oxaliplatin 130 mg/m2 (2 hours infusion)~This chemotherapy regimen will be administered each two weeks.~OR modified FOLFOX-6:~Day 1: Oxaliplatin 85 mg/m2 (given as a 2-hour infusion)~Day 1: LV 400 mg/m2 (given as a 2-hour infusion simultaneous to oxaliplatin)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours (Day 1 and 2)~This chemotherapy regimen will be administered each two weeks."
89262909|NCT01122004|Active Comparator|Gabapentin|
89262910|NCT01122004|Active Comparator|Pregabalin|
89262911|NCT03933982|Experimental|Pyrotinib plus Vinorelbine|
89262912|NCT01118494||CKD patients|People who have been diagnosed with CKD，and been in the stage of 3 or 4.
89262913|NCT01118572|Experimental|YM177 group|
89262914|NCT01118572|Active Comparator|etodolac group|
89262915|NCT01118572|Placebo Comparator|placebo group|
89262916|NCT03937648|Experimental|COL-144 50mg|
89262917|NCT03937648|Experimental|COL-144 100mg|
89262918|NCT03937648|Experimental|COL-144 200mg|
89262919|NCT03937648|Experimental|COL-144 400mg|
89262920|NCT03937648|Placebo Comparator|Placebo|
89262921|NCT01219036|Other|Non-adherent|
89262922|NCT01219036|Other|Adherent|
89262923|NCT01216150||aspirin|group treated with aspirin alone
89262924|NCT01216150||aspirin clopidogrel|Goup treated with aspirin and clopidogrel
89262925|NCT01118806||medical residents, vit d|vitamin
89262926|NCT01118806||levels of vitamin d|resident
89262927|NCT01124500|Experimental|methylphenidate via transdermal patch compared to placebo|The proposed study is a within-subject, cross-over, randomized and double-blinded pilot trial, designed to evaluate the efficacy and feasibility of sustained-release, long-acting methylphenidate via transdermal patch compared to placebo in fatigued patients with Head and Neck malignancies
89262928|NCT01216306|Experimental|Television reduction curriculum|Students are taught the television reduction curriculum during the school day and parents are invited to attend after-school meetings to discuss reducing their children's television viewing.
89262929|NCT01216306|No Intervention|Control|Students will be taught the standard preschool curriculum.
89262930|NCT03937414|Experimental|SLNs were tested by the OSNA assay Intraoperatively|SLNs were tested by the OSNA assay Intraoperatively
89262931|NCT01118884|Experimental|sedation|20 healthy uncooperative children aged 36-96 months were examined in a cross-over study design , each patient served as his/her own control. Each patient was assigned randomly to received 1 of 2 drug regimens for initial sedation session and the other regimen administered at second session which was one week later.
89262932|NCT01216384|Experimental|BI 671800 active|SRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose. MRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose followed by multiple doses with a PK sampling interval in between.
89262933|NCT01216384|Placebo Comparator|Placebo|3 subjects will receive placebo in each of the 3 doses in the SRD part and 3 doses in the MRD part
89262934|NCT01219114||1|
89262935|NCT03933592|Active Comparator|Thoracic epidural|thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
89262936|NCT03933592|Experimental|Serratus plane block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 min before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
89262937|NCT01219192|Experimental|M2ES 15mg|
89262938|NCT01219192|Experimental|M2ES 30mg|
89262939|NCT01219192|Experimental|M2ES 45mg|
89262940|NCT01219192|Experimental|M2ES 60mg|
89262941|NCT01119196|No Intervention|glucose-based dialysate|most frequently used Standard of Care (SOC) dialysate
89262942|NCT01119196|Other|Icodextrin dialysate|alternate SOC dialysate
89262943|NCT01119274|Active Comparator|Non-genotype-guided dosing algorithm|
89262944|NCT01119274|Experimental|Genotype-guided dosing algorithm|
89262945|NCT01119352|Experimental|1|
89262946|NCT01119352|Placebo Comparator|2|
89290449|NCT05729542|Active Comparator|Arthrex Tightrope|Syndesmosis fixation performed with ARthrex Tightrope device. This is a high-tension suture fixation with a button based anchor system.
89290450|NCT05729542|Experimental|Synthes Fibulink|Syndesmosis fixation perforemd with Synthes Fibulink device. This is a high-tension fixation with a screw based anchor system.
89262947|NCT03935776|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend a 12-week intensive lifestyle programme.~The intervention includes weekly exercise class and educational workshops, serial blood pressure, body mass index, glucose and lipid measurements.~Weekly multidisciplinary team meetings and targeted and protocol pharmacotherapy to support lifestyle changes."
89262948|NCT03935776|Active Comparator|Standard Healthcare|The control group will receive information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
89262949|NCT01213888|Experimental|Arm II|
89262950|NCT01213888|Placebo Comparator|Arm I. Placebo + Pan-Retinal Photocoagulation|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
89262951|NCT01119430|Placebo Comparator|Fluoxetine plus placebo|
89262952|NCT01119430|Active Comparator|Fluoxetine plus DU125530|
89262953|NCT01124578||Control|Existing used daily change-out device
89262954|NCT01124578||Egret|Extended Use Catheter w/BIOSAFE
89262955|NCT03781336|Experimental|Mindfulness-based self-care|Mindfulness-based self-care (5 weeks)
89262956|NCT03781336|No Intervention|Life as usual control|Life as usual control (5 weeks)
89262957|NCT02529124|Placebo Comparator|CONTROL|a group of subjects receiving a placebo nutrient supplement (per kg of body mass: 0.25g maltodextrin; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
89262958|NCT02529124|Active Comparator|PROTEIN|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
89262959|NCT02529124|Active Comparator|PROTEIN+PHYSICAL ACTIVITY|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks plus a prescribed regimen of physical activity
89262960|NCT03780400|Experimental|Osteoarthritis Physical Activity Care Pathway|4 month physical activity (PA) counseling intervention
89262961|NCT03780244|Experimental|Investigational Study Product|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection (SWFI)
89262962|NCT03780244|Active Comparator|Reference Product|Injection with Sculptra Aesthetic reconstituted with 5ml SWFI
89262963|NCT03937336|No Intervention|Control Group|
89262964|NCT03937336|Experimental|Bike Intervention Group|A 1-month bike-based program (1 session/week)
89262965|NCT01119664|Experimental|No prior chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously untreated with chemotherapy
89262966|NCT01119664|Experimental|Patients with prior Pemetrexed-based chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously treated with chemotherapy
89262967|NCT01216618|Experimental|Device|Subject starts with two clamps including device use follows by a clamp without device use
89262968|NCT01216618|No Intervention|Control|Subject starts with clamps without device
89262969|NCT01119742|Experimental|Butenafine Hydrochloride 1% A|1
89262970|NCT01119742|Experimental|Butenafine Hydrochloride 1% B|2
89262971|NCT01119742|Active Comparator|Butenafine Hydrochloride 1%|3
89262972|NCT01119742|Placebo Comparator|Vehicle A|4
89262973|NCT01119742|Placebo Comparator|Vehicle B|5
89262974|NCT01119820|Experimental|Tissue Donation|This study will involve females over 18 who are scheduled to undergo elective surgery. These patients will be screened for participation in this study, which will only involve the collection of discarded tissue.
88805225|NCT01035749|Experimental|AREPANRIX-UNADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ unadjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
88805226|NCT00123110|Experimental|1|metformin pill plus placebo injection
88805227|NCT00123110|Experimental|2|leuprolide injection plus placebo pill
88805228|NCT00123110|Placebo Comparator|3|placebo pill plus placebo injection
89262975|NCT01219270||GFR >= 60|MDRD eGFR 60 or more
89262976|NCT01219270||GFR <60|Under MDRD eGFR 60
89262977|NCT01219348|Experimental|Indeolamine 2,3 deoxygenase|To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
89262978|NCT01216696|Experimental|Intervention|"Intervention Details:~Drug: ipilimumab~Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first."
89262979|NCT01119976|Experimental|Group A|Reduced calorie diet and exercise plan that changes with phases of the menstrual cycle
89262980|NCT01119976|Active Comparator|Group B|Different reduced calorie diet and exercise plan based on MyPyramid.gov website
89262981|NCT01216774|Experimental|Low load + fatigue|
89262982|NCT01216774|Active Comparator|High load|
89262983|NCT01216774|Placebo Comparator|Low load|
89262984|NCT03935386|Active Comparator|Standard Compression|Standard multi-layer compression dressing with no graft or biologic material added
89262985|NCT03935386|Active Comparator|Standard Compression with application of human allograft|standard compression with application of a cryopreserved skin allograft (TheraSkin)
89262986|NCT03937258|Other|PF-04965842 single dose|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
89262987|NCT03937258|Other|PF-04965842 multiple doses|In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions.
89262988|NCT03937258|Other|Probenecid and PF-04965842|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
89262989|NCT01124656|Experimental|Pioglitazone-Azilsartan QD|(Dependent on glycosylated hemoglobin level at screening)
89262990|NCT01122472|Experimental|Lenalidomide|Lenalidomide daily for 3 weeks every 4 weeks for 24 months
89262991|NCT01122472|Placebo Comparator|Placebo|Placebo daily for 3 weeks every 4 weeks for 24 months
89262992|NCT01214122|Experimental|Treatment A|AZD9668 - 2 x30mg tablets
89262993|NCT01214122|Experimental|Treatment B|Warfarin - 10 x2.5 mg tablets
89262994|NCT03935152|Active Comparator|Dydrogesterone|dydrogesterone 10 mg by mouth every 8 hours until delivery
89262995|NCT03935152|Placebo Comparator|Placebo|placebo by mouth every 8 hours until delivery
89262996|NCT03936868||Tendon transfer for irreversible radial nerve palsy patient|Tendon transfer for irreversible radial nerve palsy patient who had irreversible damage to radial nerve due to trauma with different mechanism especially gun shot injury
89262997|NCT03936946|Experimental|Group 1--October Start Audio Content 1|This group will listen to audio content 1 daily for 28 days beginning in October, and then will receive no further intervention
89262998|NCT03936946|Other|Group 2--November Start Audio Content 1|This group will not be assigned to any interventions during the first month of the trial and will act as a passive control group at that time. They will be assigned to listen to audio content 1 daily for 28 days beginning in November.
89262999|NCT03936946|Sham Comparator|Group 3--October Start Audio Content 2|This group will listen to audio content 2 daily for 28 days beginning in October, and then will receive no further intervention.
89263000|NCT01124812|Experimental|131I-L19SIP|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy: Treatment dose of 131I-L19SIP RIT is titrated in cohorts of 3 patients.
89263001|NCT01216930||All colorectal cancer patients|
89263002|NCT01124968|Experimental|eConsulta|Those patients who are offered to use the eConsulta, a web where they can virtually consult with their primary care doctor or nurse.
89263003|NCT01120132|Experimental|Cyclosporine low dose , Prednisolone Acetate|Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate
89263004|NCT01120132|Experimental|Cyclosporine high dose, Prednisolone Acetate|Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate
89263005|NCT01120132|Experimental|Cyclosporine high dose|Administration of a solution of Cyclosporine (high dose) and Placebo
89263006|NCT01120132|Experimental|Cyclosporine low dose|Administration of a solution of Cyclosporine (low dose) and Placebo
89263007|NCT01120132|Active Comparator|Prednisolone Acetate|Administration of a suspension of Prednisolone Acetate and Placebo
89263008|NCT01120132|Placebo Comparator|Placebo|Administration of Placebo
89263009|NCT01214278|Experimental|Supplement 1|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated capsules
89263010|NCT01214278|Experimental|Supplement 2|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG)
89263011|NCT01214278|Experimental|Supplement 3|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules
89263012|NCT01214278|Experimental|Supplement 4|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)
89263013|NCT01217008|Experimental|GRNOPC1|Subjects who receive an injection of GRNOPC1
89263014|NCT01120366|Active Comparator|SWITCH|Tocilizumab monotherapy
89263015|NCT01120366|Active Comparator|ADD-ON|Tocilizumab plus methotrexate combination
89263016|NCT01219426||students from the University of Nantes|To be more than 18 years old (the legal age to gamble in France)
89263017|NCT01219426||pathological gamblers seeking treatment|To be more than 18 years old (the legal age to gamble in France)and pathological gambler
89263018|NCT01217086|Active Comparator|CT-P13|
89263019|NCT01217086|Active Comparator|Remicade|
89263020|NCT01217164|No Intervention|higher protein|
89263021|NCT03933436|Experimental|Iodine|Iodine swabs.
89263022|NCT03933436|Active Comparator|Normal Saline|Saline flush.
89263023|NCT01120444|Active Comparator|Subcutaneous delivery of insulin|A bolus dose of insulin will be given subcutaneously just prior to a standardized meal.
89263024|NCT01120444|Experimental|Intradermal delivery of insulin|A bolus dose of insulin will be given intradermally just prior to a standardized meal
89263025|NCT03934996|No Intervention|Assesment Runners|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week.
89263026|NCT03934996|Experimental|Runners with educational training|Healthy woman between 25 and 44 years old, not pregnant and running at least 10 km/week with educational training about pelvic floor muscles.
89263027|NCT01217242||Children with cerebral palsy (CP)|ages 2 to < 10 years who are able to walk with or without an assistive device
89263028|NCT01217320|Experimental|creatine supplementation|will receive 5g/d of creatine monohydrate throughout the trial
89263029|NCT01217320|Placebo Comparator|placebo|will receive 5g/d of placebo (dextrose) throughout the trial
89263030|NCT03936712|Experimental|Red Bull drink (RB)|Over the study, three participants were unable to complete all test sessions due to muscle pain or injury . Thus, 19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg) completed all test sessions
89263031|NCT03936712|Placebo Comparator|Placebo drink|19 participants (age: 21.2±1.2 years; height: 1.76±0.8 m; body-mass: 76.6±12.6 kg)
89263032|NCT01214590|Experimental|VascuActive Treatment|
89263033|NCT02529046|Active Comparator|Aerobic exercise associated with CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%).
89263034|NCT02529046|Placebo Comparator|Aerobic exercise|Placebo group received 4 g/day of olive oil.
89263035|NCT01217554||age-matched healthy male participants|age-matched healthy male participants without LBP
89263036|NCT01217554||participants with non specific chronic LBP|male participants with non specific chronic LBP
89263037|NCT01125124|Active Comparator|Silver Nitrate 1|Patients submitted to pleurodesis via pleural catheter using 30ml of 0.5% silver nitrate solution.
89263038|NCT01125124|Experimental|Silver Nitrate 2|Patients submitted to instilation of 30ml 0.3% silver nitrate solution via pleural catheter.
89263039|NCT01125124|Experimental|Silver Nitrate 3|Patients submitted to instilation of 60ml 0.3% silver nitrate solution via pleural catheter.
89263040|NCT01214746|Placebo Comparator|Placebo|
89263041|NCT01214746|Active Comparator|Atorvastatin|
89263042|NCT03935074||group 1|Patients who received intra-arterial chemotherapy as a first line treatment
89263043|NCT03935074||group 2|Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
89263044|NCT01120522|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
89263045|NCT01125280|Experimental|SBO score application|Acute strangulated SBO patients will receive a severity score at emergency admission. According to the score, they will be managed either conservatively or surgically. During surgery, the need of small bowel resection will be evaluated. The endpoint will be to correlate the type and success of treatment with the score in order to validate this new tool in SBO assessment.
89263046|NCT01217632|Placebo Comparator|FG-3019 Placebo|Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
89263047|NCT01217632|Experimental|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
89263048|NCT01122628||DVR-A|Patients with a distal radial fracture treated with a DVR-A locking plate
89263049|NCT01120678||Neonates assessed for sepsis.|
89263050|NCT03933280|Active Comparator|Group P|nalbuphine/propofol group
89263051|NCT03933280|Active Comparator|Droup D|Nalbuphine/dexmedetomidine group
89263052|NCT01217788|Experimental|PH94B intranasal spray|
89263053|NCT01217788|Placebo Comparator|Placebo intranasal spray|
89263054|NCT03933514||GAgP parents|Parents diagnosed with Generalized Aggressive Periodontitis
89263055|NCT03933514||GAgP children|Children from parents diagnosed with Generalized Aggressive Periodontitis
89263056|NCT03933514||Health parents|Parents diagnosed as periodontally healthy
89263057|NCT03933514||Health children|children from parents diagnosed as periodontally healthy
89263058|NCT03936556|Experimental|Marketed Stannous Fluoride Paste|Brush twice daily
89263059|NCT03936556|Placebo Comparator|Marketed Cavity Protection Toothpaste|Brush twice daily
89263060|NCT01120912|Experimental|Oral insulin and placebo|
89263061|NCT01217866||LAVH, techniques|Women aged 35-75 who underwent laparoscopic assisted vaginal hysterectomy via either suture technique vaginally or Enseal coagulation cutting device vaginally
89263062|NCT01122706|Experimental|Taiji|35 healthy participants will regularly during 12 weeks attend Taiji training classes twice a week for one hour. (Sept. 6th till Nov. 25th 2010).
89263063|NCT01122706|No Intervention|waiting list control group|35 healthy participants are not allowed to attend any Taiji training during the intervention period (Sept. 6th till Nov. 25th 2010).
89263064|NCT03785548||Mirror group|This group of patients agree to have the mirror pelvic exam, and they will undergo routine pelvic examination by a physician with the usage of a mirror in the room.
89263065|NCT03785548||No mirror group|This group of patients decline a mirror, and they will undergo the standard pelvic examination.
89263066|NCT01219582||Group 1|
89263067|NCT03934918|Experimental|Treatment|Patients for IOL with intracervical balloon placed in the outpatient clinic and sent home
89263068|NCT03934918|No Intervention|Control|Patients for IOL admitted to Labor and Delivery
89263069|NCT03933358||Euthyroid|
89263070|NCT03933358||Low T3|low triiodothyronine syndrome
89263071|NCT03936634||Newly Diagnosed (ND)|Recruited within 6 weeks of type 1 diabetes diagnosis. Age between 1 and <45 years
89263072|NCT03936634||Unaffected Family members (UFM)|"Participants who are not diabetic but have a first degree relative with type 1 diabetes diagnosed < 45 years of age.~Age between 1 and <45 years"
89263073|NCT01121068||Health care workers|
89263074|NCT01122940|Active Comparator|Epamin: McNeil LA LLC|
89263075|NCT01122940|Experimental|Phenytoin: Laboratorios Pfizer SA DE CV|
89263076|NCT01214902|Experimental|Experimental CIMT|Two month home program that includes restricting the non hemiplegic hand an hour a day during play
89263077|NCT01214902|Active Comparator|Active Play|Two month home program that includes active use of hemiplegic hand during play one hour a day
89263078|NCT03934762|Active Comparator|Placebo|A placebo solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
89263079|NCT03934762|Experimental|Natural aloe vera|A natural aloe vera solution (peel and leaf) will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
89263080|NCT03934762|Experimental|Aloe vera soup|An aloe vera soup solution will be applied on the quadriceps of one of the lower limbs immediately after the exercise protocol and daily for 7 consecutive days.
89263081|NCT01219816|Experimental|Patients under 60 years|Hyper CVAD regimen + Epratuzumab (Cyclophosphamide Vincristine Doxorubicin Dexamethasone)
89263082|NCT01219816|Experimental|Patients older than 60 years or < =60 years|Vincristine + Aracytine + Dexamethasone
89263083|NCT01121302|Experimental|1|dose escalating
89263084|NCT01121302|Placebo Comparator|2|placebo
89263085|NCT01121380|Experimental|Cohort A - 10 mg|
89263086|NCT01121380|Experimental|Cohort B - 20 mg|
89263087|NCT01121380|Experimental|Cohort C - 40 mg|
89263088|NCT01121380|Experimental|Cohort D - 80 mg|
89263089|NCT01121380|Experimental|Cohort E - X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
89263090|NCT01121380|Experimental|Cohort F - 2X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
89263091|NCT01121380|Experimental|Cohort G - 4X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
89263092|NCT01121380|Placebo Comparator|Placebo|In each cohort there is a placebo arm
89263093|NCT01123096||Stress Urinary Incontinence|Patients with the primary complaint of stress incontinence with minimal or no urge incontinence symptoms. They must be able to read English as the study involves use of validated questionnaires which have only been validated in English.
89263094|NCT01215058||1|
89263095|NCT01125592|Experimental|Footbath|Participants in this arm of the study will receive 4 30 minutes ionic footbath sessions, one each week for 4 weeks.
89263096|NCT01123174|Experimental|ALGOS group|Algorithm of case management over the 6 months following the suicidal gesture (systematic telephone contact, postcards and crisis card)
89263097|NCT01123174|No Intervention|Control group|Treatment as usual (referral back to the general practitioner)
89263098|NCT03936322|Experimental|Pregnant women diagnosed with fetal myelomeningocele|Women subjects who are pregnant and diagnosed with myelomeningocele (MMC), also known as fetal spina bifida or neural tube defect, will undergo a minimally invasive fetoscopic repair of MMC.
89263099|NCT01215214|Experimental|midazolam|period 1: midazolam administration alone period 2: ketoconazole 400 mg PO for 4 days administration, midazolam iv single administration period 3: rifampicin 600 mg PO for 9 days administration, midazolam iv single administration
89263100|NCT03936166|Experimental|Single Ascending Dose (Part 1)|
89263101|NCT03936166|Experimental|Multiple Ascending Dose (Part 2)|
89263102|NCT03936166|Placebo Comparator|Elderly Cohort (Part 3)|
89263103|NCT01123252|Active Comparator|Seasonal Affective Rhinitis Group 1|Active Comparator Group
89263104|NCT01123252|Placebo Comparator|Seasonal Affective Rhinitis Group 2|Placebo Group
89263105|NCT01218178||Sodium bicarbonate plus NAC|Sodium bicarbonate plus NAC
89263106|NCT01218178||Saline hydration plus NAC|Saline hydration plus NAC
89263107|NCT01215448|No Intervention|Lifestyle changes|Lifestyle changes(booklet and audio cassette of recommended diet, physical activity and breathing exercises)
89263108|NCT01215448|Experimental|Wheatgrass juice & lifestyle changes|Wheatgrass juice & lifestyle changes
89263109|NCT03936400|Experimental|Randomized controlled trial|Experimental group receiving a couple-based intervention
89263110|NCT03936400|Active Comparator|Active comparator: control group|A control group that receives same but delayed couple-based intervention
89263111|NCT03740854|Active Comparator|Pressure Controlled Ventilation|Patients undergoing pressure controlled ventilation
89263112|NCT03740854|Active Comparator|Volume Controlled Ventilation|Patients undergoing volume controlled ventilation
89263113|NCT01125670|Experimental|fast-fed sequence group|
89263114|NCT01125670|Experimental|fed-fast sequence group|
89263115|NCT01219894||RUTTS Score <30%|Patients with evidence of complete healing of stent at 3 months
89263116|NCT01219894||RUTTS<30%|Group with evidence of incomplete healing of the stent
89263117|NCT03934528|Experimental|Pilot Study|
89263118|NCT01218256|Active Comparator|Hypertrophy resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
89263119|NCT01218256|Active Comparator|Endurance resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
89263120|NCT03934450|Experimental|RPQ (-) enantiomer|Cohort 1 will receive 15 mg of RPQ (3A) every day for 7 days Cohort 2 will receive 22.5 mg of RPQ (3A) every day for 7 days
89263121|NCT03934450|Experimental|SPQ (+) enantiomer|Cohort 1 will receive 15 mg of SPQ (2A) every day for 7 days Cohort 2 will receive 22.5 mg of SPQ (2A) every day for 7 days
89263122|NCT03934450|Active Comparator|Primaquine Phosphate|Cohort 1 will receive 30 mg of RSPQ (1A) every day for 7 days Cohort 2 will receive 45 mg of RSPQ (1A) every day for 7 days
89263123|NCT03934450|Placebo Comparator|Placebo|Cohort 1 will receive placebo (4A) capsules everyday for seven days Cohort 2 will receive placebo (4A) capsules everyday for seven days
89263124|NCT01215682|Active Comparator|vit D|
89263125|NCT01215682|Placebo Comparator|placebo|
89263126|NCT01222156|Experimental|CGCI navigation|Subjects with CGCI navigation to specific target intracardiac anatomical sites
89263127|NCT03932188||Control|Individuals between 13-25 years old that do not meet criteria for any prodromal syndrome, any current or past psychotic disorder, or Cluster A personality disorder diagnosis
89263128|NCT03932188||Prodromal/Early psychosis|Individuals between 13-25 years old that meet diagnostic criteria for a prodromal syndrome or early psychosis
89263129|NCT03932344||SJIA patients on Kineret treatment|SJIA patients on Kineret treatment enrolled in the Pharmachild JIA registry
89263130|NCT01219972||Allografted patients|"All consecutive patients who underwent an allogeneic blood stem cells transplantation performed at saint Louis hospital during the study recruitment period~if alive at 100 days post-transplant~and who gave informed consent"
89263131|NCT01220050|Experimental|Paricalcitol|
89263132|NCT01220050|Active Comparator|Standard therapy|
89290451|NCT01127100|Experimental|Transdermal fentany matrix|Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
89290452|NCT01127100|Active Comparator|gabapentin|Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.
89263133|NCT01123330|Experimental|Motivational Interviewing plus DVD|Caregivers watched a 15-minute educational video designed for the project emphasizing the importance of good oral health in children, and how the caregiver can keep children free from tooth decay. The MI interviewer engaged the parent in a discussion of their thoughts and concerns regarding their child's oral health and what changes they wished to make regarding monitoring their child's oral health. Feedback from the child's dental exam was also reviewed. MI+DVD caregivers received a brochure displaying a photo of their child and for those who chose to set specific goals for their child's oral health, those goals were listed on the brochure. Caregivers choosing not to set specific goals were offered a list of 10 project recommendations regarding dietary intake, oral hygiene, and dental check-ups. The session ended with a dialogue regarding possible barriers to implementing the personal plan and how the caregiver planned to overcome those barriers.
89263134|NCT01123330|Active Comparator|DVD only|Caregivers watched the same educational video. At the end of the video, caregivers were given a glossy-printed brochure displaying the project developed recommendations as well as the child's photograph. The brochure was not re-mailed, as it was for the MI+DVD group and caregivers in this condition did not receive any feedback from the dental examination regarding their child's oral health status.
89263135|NCT01123408|Experimental|clozapine|During the first 6 weeks clozapine was gradually increased to 500 mg/day and then continued. For the next period, it could vary from 200-800 mg/day;
89263136|NCT01123408|Experimental|Olanzapine|During the first 6 weeks olanzapine was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks olanzapine could vary from 10 to 30 mg/day
89263137|NCT01123408|Active Comparator|Haloperidol|During the first 6 weeks haloperidol was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks the dose could vary from 10 to 30 mg/day
89263138|NCT00141297|Experimental|PD-0332991|
89263139|NCT01123486|Experimental|hydromorphone|open label single arm pharmacokinetic-pharmacodynamic study
89263140|NCT01123564|Experimental|Lucentis (ranibizumab)|
89263141|NCT01123564|Active Comparator|Laser|
89263142|NCT01220206|Placebo Comparator|Placebo|2 placebo capsules daily
89263143|NCT01220206|Experimental|one POMx capsule|One POMx capsule, one placebo capsule daily
89263144|NCT01220206|Experimental|2 POMx Capsules|2 POMx Capsules daily
89263145|NCT01222312|Active Comparator|Arm A cisplatin|Cisplatin 75 mg/m2, d1 Docetaxel 75 mg/m2, d1 every 3 weeks (d22) max. 6 cycles
89263146|NCT01222312|Experimental|Arm B oxaliplatin|Oxaliplatin 85 mg/m², d1 Docetaxel 50mg/m2, d1 every 2 weeks (d15) max. 8 cycles
89263147|NCT01218334||1|Cardiac Inpatient
89263148|NCT01218334||2|Cardiac Outpatient
89263149|NCT01218334||3|Cardiac Clinic Patient
89263150|NCT03932266|Experimental|Experimental group|Drug: Endostar Drug: Cisplatin Drug: Docetaxel Radiation
89263151|NCT03932266|Other|Control group|Drug: Cisplatin Drug: Docetaxel Radiation
89263152|NCT03933046|Experimental|children referred to PSG due to suspected SDB|
89263153|NCT03932110|Other|psoriasis vulgaris,|patients who have only psoriasis vulgaris
89263154|NCT03932110|Other|psoriatic arthritis|patients who have psoriatic arthritis
89263155|NCT03932110|Other|healthy control|healthy people
89263156|NCT00141219|Experimental|1|
89263157|NCT00141219|Placebo Comparator|2|
89263158|NCT01123798||Stable controls|Uninjured soldiers to provide normative data for stable physiological status
89263159|NCT01123798||Critical controls|"Critically injured soldiers with no lower extremity traumatic injuries (excepting skin abrasions and small/superficial fragmentation wounds) to provide normative data for the shock physiological status."
89263160|NCT01123798||Lower extremity trauma|Soldiers with severe traumatic lower extremity injuries in stable and shock physiologic status. This is the investigational cohort.
89263161|NCT01222468|Active Comparator|nabilone|nabilone 0.5 mg tablets dose-titrated over an 11-week period to a maximum of 3mg po daily. Subjects are allowed to drop back to the previous dose following a dose increase once if required
89263162|NCT01222468|Placebo Comparator|placebo|look-alike 0.5 mg placebo tablets titrated to a maximum daily dose of 3.0 mg daily over an 11-week phase. Subjects are allowed to drop back to the previous dose following a dose increase once during the 11-week phase if required
89263163|NCT03931798|Experimental|Treatment|Healthy participants were administered the Visual Scanning Test
89263164|NCT01222546|Experimental|CH5132799|
89263165|NCT01222624|Experimental|PankoMab-GEX™, 3-weekly|application, q3w
89263166|NCT01222624|Experimental|PankoMab-GEX™, 2-weekly|application q2w
89263167|NCT01222624|Experimental|PankoMab-GEX™, weekly|application q1w
89263168|NCT03931720|Experimental|anti-tumor response of BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|Patients with relapsed and refractory cancer of ROBO1 expression will be treated with BiCAR-NK/T cells (ROBO1 CAR-NK/T cells).
89263169|NCT01218412|Experimental|Web-based, Mi=Based Intervention|4 session web-based, MI-based intervention.
89263170|NCT03934060|Experimental|Intervention|Supervised exercise training including specific strength training tools and general exercise contents (standard care), 2-3 times per week, 30 minutes per session
89263171|NCT03934060|No Intervention|Control|Supervised exercise training regarding general exercise contents (standard care), 2-3 times per week, 30 min per session
89263172|NCT01220284|Experimental|Satraplatin in combo with vinorelbine|"Escalating doses of satraplatin and oral vinorelbine in subsequent cohorts of 3-6 patients according to the type and severity grade of acute toxicities observed during cycle 1.~The dose escalation process will be discontinued once the MTD is achieved."
89263173|NCT01127464|Experimental|.3 dose level of DCVax -001|.3 dose level of DCVax plus fixed dose of 1.6 ml Poly ICLC
89263174|NCT01127464|Experimental|1 mg dose level of DCVax -001|1 mg dose level of DCVax -001 plus 1.6 ml of poly ICLC
89263175|NCT01127464|Experimental|3 mg dose level of DCVax-001|3 mg dose level of DCVax-001 plus poly ICLC
89263176|NCT01127464|Placebo Comparator|Placebo|sterile saline
89263177|NCT01127464|Experimental|poly-ICLC alone|1.6 mg of poly-ICLC alone
89263178|NCT01222780|Experimental|Marqibo|"Marqibo® (Vincristine sulfate liposomal) will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.~The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.~Detailed pharmacokinetic studies will be performed during the first treatment cycle"
89263179|NCT03931876|Placebo Comparator|Placebo|placebo
89263180|NCT03931876|Active Comparator|Active|AV-006
89263181|NCT01222858|Active Comparator|Internet Education Program|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors.
89263182|NCT01222858|Experimental|Innovative Technology Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback.
89263183|NCT01223014||1|Single cohort of 6 subjects
89263184|NCT01125904|Experimental|crizotinib|
89263185|NCT01125982|Active Comparator|Desflurane|Patients will receive Desflurane to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
89263186|NCT01125982|Active Comparator|Propofol|Patients will receive Propofol to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
89263187|NCT01220362|Other|Group 1|Bupivacaine 0.125%
88805229|NCT01898156|Experimental|BIW-8962|"Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur~Phase 2 - Recommended dose determined in Phase 1"
89263188|NCT01220362|Other|Group 2|Bupivacaine 0.125%/Fentanyl 2mcg/ml
89263189|NCT01220440|Experimental|Methylphenidate, Dexamphetamine, Placebo|The 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
89263190|NCT01123876|Experimental|Veliparib and FOLFIRI|Veliparib in combination with FOLFIRI regimen.
89263191|NCT01123954|Other|Arm 1|
89263192|NCT01124032|Experimental|ADHD adults|
89263193|NCT01124032|Experimental|healthy adults|
89263194|NCT03934294|Experimental|Treatment group: specific acupuncture group(Acu)|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G.~Acupuncture doctor will disinfect the acupoints with alcohol and will perform acupuncture on the marked points with needle Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor."
89263195|NCT03934294|Placebo Comparator|Control group: non-specific acupuncture group (Con-Acu)|"Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related pathologies, and are not reported to improve digestive function.~Acupuncture doctor 1 will disinfect the marked acupoints with alcohol and will perform acupuncture on the marked points. Needle retention time will be 30 minutes. The needles will be withdrawn by acupuncture doctor"
89263196|NCT01218490|Experimental|lymphadenectomy|after surgery of the ovarian cancer, patient will have Pelvis and aortic-cava lymphadenectomy
89263197|NCT01218490|No Intervention|no lymphadectomy|after surgery, the patient will not have pelvic and aortic-cave lymphadenectomy
89263198|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
89263199|NCT01124110|Experimental|Tobacco Tactics Intervention|This intervention contains a website, medications, and nurse counseling.
89263200|NCT01223170|Experimental|Enhanced Internet-based intervention|Behavioral: Tailored content Behavioral: Generic Internet-based information Behavioral: Discussion forum Behavioral: Behavioral monitoring
89263201|NCT01223170|Placebo Comparator|Control|Behavioral: Generic Internet-based information Behavioral: Discussion forum
89263202|NCT01218568|Experimental|Rifaximin plus lactulose|
89263203|NCT01218568|Active Comparator|lactulose|30-60ml/day
89263204|NCT02529280|Experimental|Intervention|The intervention group will receive three components: 1) a culturally sensitive, individually tailored, 30-minute computer-based BCCT video; 2) a bilingual, low-literacy booklet aimed at encouraging patients to communicate with family and friends and 3) assistance from a patient navigator.
89263205|NCT02529280|No Intervention|Usual Care|The usual care control group will receive the usual care breast cancer clinical trial information materials offered by the CTRC to their eligible patients.
89263206|NCT01127542|Experimental|Lenalidomide for early stage poor prognosis CLL|
88805230|NCT02096276||Exposure Group_Prospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and prospective (i.e., registration to registry is done before the outcome of the pregnancy is known)
89263207|NCT01127620|Experimental|Bilastine|20 mg encapsulated tablets
89263208|NCT01127620|Active Comparator|Cetirizine|10 mg encapsulated tablets
89263209|NCT01127620|Placebo Comparator|Placebo|Encapsulated tablets
89263210|NCT01220518|Active Comparator|CT-P13|infliximab
89263211|NCT01220518|Active Comparator|Remicade|infliximab
89263212|NCT01328938|Experimental|Stage I - Arm I: GCPGC I (3.6mg)|GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
89263213|NCT01328938|Experimental|Stage I - Arm II: GCPGC II (6mg)|GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
89263214|NCT01328938|Experimental|Stage II - Arm I: GCPGC|"GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1).~The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I."
89263215|NCT01328938|Active Comparator|Stage II - Arm II: Neulasta|Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)
89263216|NCT01220596|Experimental|Sequential therapy|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
89263217|NCT01220596|Active Comparator|Peginterferon alfa-2a monotherapy|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
89263218|NCT01126216|Experimental|Reduced RT + Pacitaxel/Cisplatin|63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor
89263219|NCT01126216|Active Comparator|Standard RT + 5-Fluorouracil/Cisplatin|70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor
89263220|NCT01329016|Active Comparator|GDM Subjects|Women with GDM requiring treatment
89263221|NCT01329016|No Intervention|Non-pregnant Type 2 Diabetes Milletus Subjects|Non-pregnant women with Type 2 diabetes mellitus who plan to use metformin treatment
89263222|NCT01329016|No Intervention|Healthy Pregnant Women|Healthy pregnant women with normal 1-hour glucose tolerance test
89263223|NCT01223326|Experimental|N-acetylcysteine|Intravenous N-acetylcysteine
89263224|NCT01223326|Placebo Comparator|Placebo|Placebo
89263225|NCT03934138|Active Comparator|Educated open label placebo|These subjects will undergo all the same procedures as in the control group. But before the placebo CTP, they will watch a short movie explaining placebo mechanisms. While applying the placebo cream, they will be told that the cream is inert (placebo), efficient to decrease pain caused by cold and the mechanisms seen in the movie will take place.
89263226|NCT03934138|Placebo Comparator|Conventional placebo|These subjects will watch a video on hand washing. While applying the placebo cream, they will be told that this cream is effective to decreased pain caused by cold.
89263227|NCT01223482||Miscarriage with genetic testing|This is a study population of women that have had a miscarriage and had genetic testing performed. The investigators would like to know what their experiences were following their miscarriage and testing.
89263228|NCT01223482||Miscarriage without genetic testing|This cohort is considered the control group. These women have not had genetic testing done, but are asked questions regarding their miscarriage experience.
89263229|NCT01329094||Patients with severe mental illness|In-patients and out-patients with severe mental illness attending treatment at Aarhus University Hospital, Risskov.
89263230|NCT01329094||Healthy controls|Healthy controls recruited from staff members at Aarhus University Hospital, Risskov
89263231|NCT01124266|Experimental|endoscopist only|
89263232|NCT01124266|Experimental|nurse participation|
89263233|NCT01223638||Congenital hypothyroidism|Patient which were diagnosed with congenital hypothyroidism
89263234|NCT01223638||Controls|Patients without any endocrine or hearing problems
89263235|NCT01127776|Experimental|Apos System|
89263236|NCT01127776|Placebo Comparator|CONTROL|
89263237|NCT03932890|Active Comparator|Lower Volume fluid bolus arm|The 'lower volume' (LV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the LV arm, the trigger will deliver 50mls over 10 mins at a rate of 300ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
89263238|NCT03932890|Experimental|Higher Volume fluid bolus arm|The 'higher volume' (HV) fluid bolus arm will receive a continuous background infusion of 4% dextrose in 0.18% NaCl at 50ml/hr for the entire 4 hour rehydration period. Subjects will be given a hand-held trigger, which when pressed will deliver an additional volume of fluid from the infusion pump; this will be administered over a 10-minute period (thus allowing a maximum of 6 boluses per hour). In the HV arm, the trigger will deliver 200mls over 10 mins at a rate of 1200ml h-1. A green LED will signal to the patient that no additional infusion is running, and that pressing the trigger will activate delivery of another bolus. The volume and lockout periods for the boluses may vary but will remain within the maximum fluid administration of 1200mls per hour.
89263239|NCT03933124|Experimental|Virtual Reality Intervention group|"The intervention group includes 60 patients who will use Virtual Reality for postoperative pain. Participants will use Virtual Reality minimal 10 minutes, minimal 3 times a day on the second, third and fourth day after surgery, on the general ward.~20 participants will receive an Oculus Go immersive 3D nature videos, games, meditation videos, google earth experiences and sports games.~20 participants will receive a Relaxmaker with 2D nature videos~20 participants will receive CareVRx with 3D nature videos and meditation videos."
89263240|NCT03933124|No Intervention|Control group|The control group receives standard postoperative care.
89263241|NCT01126294|Experimental|Melatonin 5 mg|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
89263242|NCT01126294|Experimental|Melatonin 10 mg|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
89263243|NCT01126294|Placebo Comparator|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
89263244|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 mg)|Panel 1: Healthy Male Subjects
89263245|NCT01124344|Active Comparator|Placebo or BMS-866949 (10 mg)|Panel 2: Healthy Male Subjects
89263246|NCT01124344|Active Comparator|Placebo or BMS-866949 (30 mg)|Panel 3: Healthy Male Subjects
89263247|NCT01124344|Active Comparator|Placebo or BMS-866949 (45 mg)|Panel 4: Healthy Male Subjects
89263248|NCT01124344|Active Comparator|Placebo or BMS-866949 (60 mg)|Panel 5: Healthy Male Subjects
89263249|NCT01124344|Active Comparator|Placebo or BMS-866949 (90 mg)|Panel 6: Healthy Male Subjects
89263250|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 - 60 mg)|Panel 7: Females
89263251|NCT01218880|Experimental|M2ES-A|
89263252|NCT01218880|Experimental|M2ES-B|
89263253|NCT01218880|Experimental|M2ES-C|
89263254|NCT01218880|Experimental|M2ES-D|
89263255|NCT00162266|Experimental|Abatacept (10 mg/Kg) - Open Label|
89263256|NCT00162266|Experimental|Abatacept (2 mg/kg) - Double blind|
89263257|NCT00162266|Experimental|Abatacept (10 mg/kg) - Double blind|
89263258|NCT00162266|Experimental|Placebo - Double blind|
89263259|NCT01223716|Experimental|Perceptual learning|
89263260|NCT01223716|Experimental|Video Game|
89263261|NCT01223716|Experimental|Occlusion Therapy|
89263262|NCT03931018|Experimental|70 grams alcohol|"Males and Females: Alcohol 70 grams (220 ml Vodka Absolut®), single dose, oral administration~- 70 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
89263263|NCT03931018|Experimental|100 grams alcohol|"Males: Alcohol 100 grams (312 ml Vodka Absolut®), single dose, oral administration~- 100 grams of alcohol mixed with zero orange soda without bubbles distributed in 6 glasses (total volume 900 ml) over a 2-hour period (20 minutes for glass)"
89263264|NCT01223794||Experimental Group|Fall in higher risk
89263265|NCT01223794||Control Group|Fall in lower risk
89263266|NCT03928444|Experimental|stem cells|one side of the face to be treated with intradermal stem cells
89263267|NCT03928444|Placebo Comparator|control|one side of face treated with intradermal saline
89263268|NCT01126450|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89263269|NCT03930940|Experimental|RIC group|RIC treatment and regular treatment.
89263270|NCT03930940|Other|Control group|Regular treatment alone.
89263271|NCT03931096||children with congenital heart disease|Groupe 1: case: children with congenital heart disease aged 5 to 7 years.
89263272|NCT03931096||control children|Groupe 2: control children recruited in schools aged 5 to 7 years.
89263273|NCT01225978||GeneInsight Clinic (GIC)|The Group/Cohort in this study are geneticists, physicians, and genetic counselors who are using the GeneInsight Clinic (previously known as Patient Genome Explorer) to receive and store genetic test reports and variant update information.
89263274|NCT01223872||Routine Patient Care|
89263275|NCT01223872||Previously-enrolled REACH Clinic Patients|
89263276|NCT01223872||New REACH Clinic Patients|
89263277|NCT01220830|Experimental|RFQMR on Multiple Sclerosis lesions|
89263278|NCT01073384|Experimental|BDP 3 mg|1 mg TID
89263279|NCT01073384|Experimental|BDP 6 mg|2 mg TID
89263280|NCT01073384|Experimental|BDP 9 mg|3 mg TID
89263281|NCT01073384|Experimental|BDP 12 mg|4 mg TID
89263282|NCT01126528|Experimental|Vitamin D3|Vitamin D3 (cholecalciferol)
89263283|NCT01126528|Placebo Comparator|Control|Placebo control group
89263284|NCT01329172|Experimental|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 (PUFA n-3)
89263285|NCT01329172|Placebo Comparator|placebo|sun flower oil
89263286|NCT00225212|Experimental|Rituximab after ASCT|Rituximab 375 mg/m2 starting 6 weeks after ASCT transplant, and for the 5th and subsequent subjects, a second course at the same dose 6 months after ASCT.
89263287|NCT03853330|Active Comparator|Thoracic Epidural Analgesia group|25 patients will receive ultrasound-guided thoracic epidural analgesia for multiple fracture ribs at the level of T8 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
89263288|NCT03853330|Active Comparator|Erector spinae plane block group|25 patients will receive ultrasound-guided ESP block for multiple fracture ribs at the level from T1 to T5 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
89263289|NCT01581944|No Intervention|No Treatment (Control)|Women were randomised to receive no gonadotropin-releasing hormone agonist prior to myomectomy.
89263290|NCT01581944|Experimental|2 Doses Goserelin|Women were randomised to receive 2 doses of 3.6mg of gonadotropin releasing hormone agonist prior to the myomectomy.
89263291|NCT01581944|Experimental|3 Doses Goserelin|Women were randomised to receive 3 doses of the gonadotropin-releasing agonist (3.6mg monthly injections).
89263292|NCT01226056|Experimental|RAD001 in combination with sorafenib|
89263293|NCT01127932|Experimental|CBT for suicide|
89263294|NCT01127932|Active Comparator|Enhanced care control group|This group is designed to be an active control which provides detailed information about substance use, suicide risk, and depression without providing any CBT or other specific therapy.
89263295|NCT00162032|Other|Children (Ages 4-11)|Children 4-11 years of age, intervention Sestamibi
89263296|NCT00162032|Other|Adolescents (Ages 12-16)|Adolescents 12-16 years of age, intervention Sestamibi
89263297|NCT01226134|Experimental|1.Itopride Group|The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks
89263298|NCT01226134|Placebo Comparator|2.Control placebo group|The control group will receive placebo tablets for four weeks
89263299|NCT01126606|Experimental|Group 1|Dermacyd Silver Frutal followed by Dermacyd Silver Frutal+PH_DESYLSTY_FR followed by wash out followed by Glycerine Vegetal Soap Granado Traditional
89263300|NCT01126606|Experimental|Group 2|Glycerine Vegetal Soap Granado Traditional followed by wash out followed by Dermacyd Silver Floral followed by Dermacyd Silver Floral + PH_DESYLSTY_FR
89263301|NCT01329406|Experimental|Milnacipran|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
89263302|NCT01329406|Placebo Comparator|Placebo|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.
89263303|NCT00258674|Active Comparator|Medicare Claims Feedback|Practices randomised to the Medicare Claims Feedback arm received period feedback on their performance on selected diabetes quality of care measures as reflected in the claims data for their diabetes patients.
89263304|NCT00258674|Experimental|Medicare Claims+Medical Record Feedback|Practices randomised to the Medicare Claims + Medical Record Review Feedback arm received periodic feedback on their performance on selected diabetes quality of care measures as reflected in both the Medicare claims for the diabetes patients AND review/audit of their diabetes patients' medical records.
88805231|NCT02096276||Exposure Group_Retrospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and retrospective (i.e., pregnancy outcome is already known at the time of registration to Registry)
89263305|NCT00258674|Experimental|Medicare Claims+Medical Chart Review+DRN|In addition to the performance data from both Medicare Claims data and from review of patients' medical records, practices randomised to the Medicare Claims + Medical Record review + Diabetes Resource Nurse (DRN) had a diabetes resource nurse assigned to them, who was available to provide diabetes education and care-coordination type services for their diabetes patients.
89263306|NCT01126684|Active Comparator|Atorvastatin|
89263307|NCT01126684|Placebo Comparator|Placebo|
89263308|NCT01128010||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
89263309|NCT01128010||controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination
89263310|NCT01224028|Experimental|Tacrolimus group|
89263311|NCT01224028|Placebo Comparator|Placebo|
89263312|NCT01326260||THAM Patients|Patients who were managed with the use of THAM
89263313|NCT01326260||Non-THAM Patients|Patients who did not use THAM but were resuscitated with crystalloids and colloids and may have received sodium bicarbonate for the treatment of acidosis
89263314|NCT01226212|Experimental|Synbiotic|Synbiotic (Synergy 1/B. longum)
89263315|NCT01226212|Placebo Comparator|Placebo|maltodextrose
89263316|NCT01075490|Placebo Comparator|prematurely born, bupivacaine, placebo|
89263317|NCT01075490|Experimental|prematurely born, bupivacaine, clonidine|
89263318|NCT01075490|Placebo Comparator|term neonate, bupivacaine, placebo|
89263319|NCT01075490|Experimental|term neonate, bupivacaine, clonidine|
89263320|NCT01128088||PCA and Volulyte|
89263321|NCT01128088||PCA and Hartmann's|
89263322|NCT01128088||Spinal and Volulyte|
89263323|NCT01128088||Spinal and Hartmann's|
89263324|NCT01126138|Other|Arm A|Vinorelbine plus Capecitabine
89263325|NCT01126138|Other|Arm B|Docetaxel plus Capecitabine
89263326|NCT03930706|Experimental|Group A|Group A will include all the patient that will start with progesterone ((P), Utrogestan®) supplementation after 7 days of E2 (Progynova®) intake and that will perform the FET (after 13 days of E2 and 6 days of P).
89263327|NCT03930706|Active Comparator|Group B|Group B will include the patients that will perform 14 days of E2 intake (Progynova®, 6 mg per day (2 mg every 8 hours) those patients will be asked to perform a supplementary blood test and ultrasound on day 14 of E2 intake, afterwards, they will start with P supplementation (Utrogestan®, 800 mg per day, 400 mg every 12 hours) from day 15 of E2 for 6 days and they will get their FET day 20 of the cycle (after 14 days of E2 and 6 days of P)
89263328|NCT03930862|Active Comparator|ball and socket|It is an attachment retaining implant overdentures to increase retention and stability of the denture
89263329|NCT03930862|Experimental|Locator attachment|attachment retaining implant overdentures
89263330|NCT01224184|Active Comparator|Nutrition|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
89263331|NCT01224184|Experimental|Young Women's|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (Principal Investigator (PI): Dr. Wendee M. Wechsberg).
89263332|NCT03932578|Active Comparator|Atropine group|Patients will receive IV study solution which is 2 ml saline 0.9% as a placebo + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
89263333|NCT03932578|Active Comparator|Metoclopramide group|Patients in will receive IV study solution which is metoclopramide 10 mg in 2 ml + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of preservative-free saline 0.9% as a placebo
89263334|NCT01126762|Experimental|Dietary advice and grocery store card|Dietary advice to consume low mercury, high DHA fish plus a grocery store gift card to support the purchase of fish
89263335|NCT01126762|Experimental|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
89263336|NCT01126762|Placebo Comparator|Control|General dietary advice not focused on fish intake
89263337|NCT00258440|Active Comparator|Weekly Procrit (epoetin alfa) dosing|Weekly dosing schedule subjects will get the study drug once every week until the end of the study.
89263338|NCT00258440|Experimental|Interval Dosing (epoetin alfa) PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who consented to pharmacokinetic testing
89263339|NCT00258440|Experimental|Interval Dosing (epoetin alfa) Non PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who did not consent to pharmacokinetic testing.
89263340|NCT01220986||Right hepatectomy|Intervals from inflow division.
89263341|NCT01329250|Experimental|Moxifloxacin|Moxifloxacinin escalating dose
89263342|NCT00224120|Experimental|Silodosin|Silodosin 8 mg/Day with food
89263343|NCT00224120|Placebo Comparator|Placebo|Matching placebo capsule once daily with food
89263344|NCT01224340|Experimental|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
89263345|NCT01224340|Experimental|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path. The player got points for collected fishes but also credits for time of flying and speed.
89263346|NCT01224340|Experimental|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
89263347|NCT01226446|Experimental|Addition of Vitamin D to Peg-interferon plus Ribavirin|
89263348|NCT01224418|Experimental|Tacrolimus group|
89263349|NCT00257660|Experimental|1|Drug: abobotulinumtoxinA (Dysport®)
89263350|NCT00257660|Placebo Comparator|2|Placebo
89263351|NCT01221064|Other|Early drainage removal|Patients randomised to early drainage removal arm will have the drain removed in postoperative day 1. Lymph will be punctured on a regular basis
89263352|NCT01221064|Other|Late drainage removal|Patients randomised to late drainage removal arm will have the drains kept until total daily drainage is 30ml and then removed
89263353|NCT01129180|Experimental|Arm I|Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine SC on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Attempt to collect Correlative studies will be made.
89263354|NCT03972020|Experimental|Mindfulness Based Intervention|8 group sessions lasting 2.5 hours each, on a weekly basis.
89263355|NCT03972020|Active Comparator|Cognitive Behavioral Therapy|8 group sessions lasting 2.5 hours each, on a weekly basis.
89263356|NCT01221142|Experimental|Hypothermia|Device: Cincinnati Sub-Zero Hyper-Hypothermia to core temperature of 34C for 24 hours, rewarming rate 0,5/2h until the patient reaches 36,5C
89263357|NCT01128166||Patients implanted with a CRT-D (Cardiac Resynch. Therapy)|
89263358|NCT00224042|Experimental|IV iron|
89263359|NCT00224042|Active Comparator|oral iron|
89263360|NCT01129258|Experimental|PF-04991532|
89263361|NCT01129258|Placebo Comparator|Placebo|
89263362|NCT01224496|Experimental|Treatment with Chinese herbal concoction|"Patients must have a marrow study to confirm diagnosis of MDS, AA or MF. MDS is classified according to the WHO criteria and scored according to IPSS. The AA group is further classified into AA, SAA or VSAA . MF is defined by the Italian criteria and risk stratified by the Lilles Scoring system. Diagnosis of thal intermedia and major is based on previously done Hb electrophoresis and severity of disease is assessed by degree of anaemia.and frequency of blood transfusions~TCM diagnosis: Syndrome differentiation according to TCM theory will be assessed as a baseline by experienced TCM collaborators and classified into one of the few defined syndromes as follows~Yin deficiency of spleen and kidney~Yang deficiency of spleen and kidney~Deficiency of both Yin and Yang~Stagnation of dampness and poison in the blood~Excessive heat and poison"
89263363|NCT01221220|Active Comparator|Behavioral Treatment|Six-month, family-based, group, behavioral weight control program
89263364|NCT01221220|Experimental|Behavioral Treatment plus Environmental Strategies|Six-month, family-based, group, behavioral weight control program plus home-based environmental intervention
89263365|NCT01226524|Experimental|Traditional Chinese Medicine|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulations, i.e. Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
89263366|NCT01221376|Experimental|Imatinib Mesylate|
89263367|NCT03928132|Experimental|CPD Workshop on Depression and Diabetes|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will include considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
89263368|NCT03928132|Sham Comparator|CPD Workshop on Depression and Diabetes II|Participants in this arm will take part in a clinical CPD activity on depression and diabetes. The activity will exclude considerations of sex and gender, e.g. the different risk factors and impacts of treatment among women and men.
89263369|NCT01224652|Experimental|paclitaxel|Paclitaxel 70 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
89263370|NCT01224652|Experimental|irinotecan|irinotecan 150 mg/m2 on Days 1 and 15 of a 28-day cycle
89263371|NCT00160706|Experimental|Certolizumab Pegol|3-dose induction regimen of Certolizumab Pegol 400 mg at Weeks 0, 2, 4. Subsequently continue on 4-weekly treatment with Certolizumab Pegol 400 mg until Week 360.
89263372|NCT01226602|Experimental|1|Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder
89263373|NCT01226602|Placebo Comparator|2|Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder
89263374|NCT01221454|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
89290453|NCT05727514|Other|enrolled participants|participation in 4-session music composition program with optional viewing of performance at the end
89290454|NCT01127178|Experimental|E7016 + TMZ|
89263375|NCT01221454|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
89263376|NCT01224730|Experimental|Perifosine 100 mg|Perifosine 100 mg orally daily under Fed and Fasted conditions
89263377|NCT03930784||Participants|Divided for analysis as having suffered post-operative complications or not
89263378|NCT01224808|Experimental|Experimental|
89263379|NCT03927976|Experimental|Path2Quit|After assessment eligibility, given consent, information about text messaging will be collected and participants enrolled in the Path2Quit culturally specific text message program and feedback will be collected on their experience.
89263380|NCT01221532|Experimental|SHHE Peridischarge intervention|Patients receive the Support from Hospital to Home (SHHE) Peridischarge Intervention plus usual care
89263381|NCT01221532|No Intervention|Usual Care|
89263382|NCT01226680|Experimental|Tasocitinib 0.005% QD|
89263383|NCT01226680|Experimental|Tasocitinib 0.003% QD|
89263384|NCT01226680|Placebo Comparator|Vehicle for Tasocitinib|
89263385|NCT00257192|Placebo Comparator|2.0|
89263386|NCT00257192|Active Comparator|1.0|
89263387|NCT01226758|Experimental|FLU-v with adjuvant|
89263388|NCT01226758|Placebo Comparator|Placebo|Adjuvant only placebo
89263389|NCT03927898|Experimental|SBRT+Toripalimab|Participants received SBRT (BED>80Gy) to oligometastatic lesions and then receive Toripalimab (240mg)/q3w till progression of disease.
89263390|NCT01224964|Active Comparator|Montelukast|
89263391|NCT01224964|Active Comparator|long-acting beta2-mimetic|
89263392|NCT03932734||survey|
89263393|NCT01126918|Active Comparator|Brochure Condition|Participants in this condition receive an educational brochure about healthy body image via post-mail.
89263394|NCT01126918|Experimental|Group Condition|Participants in this condition attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
89263395|NCT00256724|Sham Comparator|Sham ITD|sham Impedance Threshold Device
89263396|NCT00256724|Active Comparator|active ITD|active impedance threshold device
89263397|NCT03928054|Experimental|"group 1 Kinesio Taping® KT"|Kinesio Taping® KT
89263398|NCT03928054|Experimental|" Kinesio Taping® with therapeutic alliance KT+AT"|Kinesio Taping® with therapeutic alliance
89263399|NCT03930550|Experimental|Infrared guidance first|"In this arm the infra red guidance is applied to the first passage of the flexible scope to the trachea.~The second passage of the flexible scope is without the infrared light"
89263400|NCT03930550|Active Comparator|Infrared guidance last|"In this arm NO infra red guidance is applied to the first passage of the flexible scope to the trachea.~The second passage of the flexible scope is with the infrared light as guide"
89263401|NCT03967964|Experimental|Group 1: AVD|Vaginal ring with 2.2 grams dehydroepiandrosterone (DHEA), wearing time 72 hours
89263402|NCT03967964|Experimental|Group 2: AVT|Vaginal ring with 35 mg testosterone, wearing time 72 hours.
89263403|NCT03967964|Experimental|Group 3: AVD+T|Vaginal ring with 1.5 grams DHEA and 25 mg testosterone, wearing time 72 hours.
89263404|NCT03967964|Active Comparator|Group 4: DHEA capsule|Capsules with 25 mg DHEA, oral administration every 8 hours for a 72-hour period.
89263405|NCT03967964|Active Comparator|Group 5: Testosterone transdermal gel|Testosterone transdermal gel with dosing valve (pump): administration of 3 pump actuations (equivalent to 5 mg of testosterone each) per day (total daily dose 15 mg), on 3 consecutive days (72 hours).
89263406|NCT01129414|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
89263407|NCT01129414|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
89263408|NCT01129414|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Each intake is under fasted conditions"
89263409|NCT01129414|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
89263410|NCT03967730|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
89263411|NCT03930238|Experimental|VA MapTrek|Veterans in the intervention group receive a Fitbit and access to VA MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required to enroll). Each week, Veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. Throughout each race, participants will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
89263412|NCT03930238|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to VA MapTrek or simply by giving the Veterans a Fitbit.
89263413|NCT03967886|Experimental|YYD601 20mg|Esomeprazole magnesium Dihydrate.
89263414|NCT03967886|Active Comparator|Nexium 20mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
89263415|NCT01129492|Placebo Comparator|Sham Laser|Ten applications of placebo were performed (twice a week) with the same method and Laser equipment, which has a placebo function available with a red ordinary light indistinguishable of the Laser light.
89263416|NCT01129492|Active Comparator|Active Laser|Ten applications of low-level Laser therapy (twice a week) were performed with a continuous wave diode laser device (830nm, beam area of 0.2827cm2), using the punctual method, continuous emission mode, output power of de 50 mW and fluence of 70J/cm2.
89263417|NCT03968042|Placebo Comparator|Regular treatment (RT)|Combination of vitamin B1, B6, C, E and mecobalamine
89263418|NCT03968042|Experimental|RT with NGF|Nerve growth factor adding to regular treatment
89263419|NCT03968042|Experimental|RT with EDV|Edaravone adding to regular treatment
89263420|NCT01225042|Experimental|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
89263421|NCT01225042|Placebo Comparator|placebo|Carrier material powder of identical appearance
89263422|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 40mg|
89263423|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 80mg|
89263424|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 40mg|
89263425|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 80mg|
89263426|NCT01128322|Active Comparator|S-Amlodipine 2.5mg|
89263427|NCT01128322|Active Comparator|S-Amlodipine 5mg|
89263428|NCT01128322|Active Comparator|Telmisartan 40mg|
89263429|NCT01128322|Active Comparator|Telmisartan 80mg|
89263430|NCT01128322|Placebo Comparator|Placebo|
89263431|NCT00157820|Active Comparator|SC true|Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.
89263432|NCT00157820|Experimental|SC sim|Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')
89263433|NCT00157820|Experimental|DC true|Dual chamber ICD initially programmed as a DDED (''DC true arm'').
89263434|NCT01126996||MenC vaccinated healthy children|Children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
89263435|NCT01129570|Experimental|Siliphos - dose escalation|
89263436|NCT00223808|Experimental|Robot-Low|low-dose mechanically-assisted upper limb therapy
89263437|NCT00223808|Experimental|Robot-High|high-dose mechanically-assisted upper limb therapy
89263438|NCT00223808|Active Comparator|Control|additional traditional therapy
89263439|NCT03740620|Active Comparator|intervention group|In the intervention group, a nasotracheal tube is inserted into the nostril with the bevel of the tube facing the cephalad direction of the patient.
89263440|NCT03740620|Active Comparator|conventional group|In the conventional group, a nasotracheal tube is inserted in a usual way, i.e., with the bevel of the tube facing the left side of the patient.
89263441|NCT03971942|Experimental|Neutral ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
89263442|NCT03971942|Experimental|Positive ABMT|8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
89263443|NCT01221610|Experimental|Drug Releasing Balloon|Passeo-18 Lux Drug Releasing Balloon catheter
89263444|NCT01221610|Active Comparator|Standard PT A (POBA)|Uncoated Passeo-18 PTA catheter
89263445|NCT01073540|Experimental|Arm 1|
89263446|NCT01073540|Active Comparator|Arm 2|
89263447|NCT03930472|Experimental|Voucher intervention F&V|Receiving $20 in vouchers at each of up to 4 markets ($80 total) that are good for F&V only
89263448|NCT03930472|Experimental|Voucher intervention SNAP|Receiving $20 vouchers at each of up to 4 markets that are good for any foods that SNAP/EBT benefits can be used for
89263449|NCT03930472|No Intervention|Waitlist control|Delayed intervention/waitlist control (who, at the final data gathering, will receive 5 x $20 in vouchers good at the WFfT 2019 and 2020 markets).
89263450|NCT03741608|Active Comparator|Education, BP cuff & training|High blood pressure management education. Home blood pressure measurement
89263451|NCT03741608|Active Comparator|Education only|High blood pressure management education
89263452|NCT03930160||Mortality outcome|
89263453|NCT01075724|Active Comparator|Forced air|Forced Air Warming
89263454|NCT01075724|Experimental|Resistive HotDog Warming|Warming by resistive Warming
89263455|NCT01071746||Acute decompensation of cirrhosis|acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.
89263456|NCT01225120|Experimental|Gait Training|
89263457|NCT03740386|Experimental|lidocaine|lidocaine 2% 1:80000
89263458|NCT03740386|Experimental|articaine|articaine 4% 1:200000
89263459|NCT03740386|Experimental|bupivacaine|bupivacaine 0,5% 1:200000
89263460|NCT01226836|Experimental|Living Well with COPD for Pulmonary Rehabilitation|
89263461|NCT03927352|Experimental|SCT630|"Participants received 80 mg SCT630 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg SCT630 until week 48."
89263462|NCT03927352|Active Comparator|adalimumab-EU source|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to SCT630 until week 48"
89263463|NCT03929770|Active Comparator|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
89263464|NCT03929770|Experimental|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
89263465|NCT01225198|Placebo Comparator|Placebo Group|Liquid placebo with identical packaging and flavoring to the real supplement.
89263466|NCT01225198|Experimental|Vitamin/Mineral Supplement Group|Multi-vitamin/mineral supplement designed for this study for children and adults with autism spectrum disorders.
89263467|NCT03929848||female|female patient who is scheduled for laryngomicrosurgery
89263468|NCT03929848||male|male patient who is scheduled for laryngomicrosurgery
89263469|NCT01226992|Experimental|Fecal Transplant|2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema. Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.
89263470|NCT01226992|Active Comparator|Oral Vancomycin Taper|2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin
89263471|NCT01127074|Experimental|KS24.22-vaccination|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated. KS24.22 cells were adjusted to 10E7/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
89263472|NCT01127152|Active Comparator|Automatic relays|Automatic relays of noradrenalin using intensive basis.
89263473|NCT01127152|Active Comparator|Manual relays|Relays of noradrenalin using manual method
89263474|NCT03927586|Experimental|cognitive training (COG group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each cognitive intervention session will last for 90 minutes. The COG group received computerized cognitive based training which include memory, executive function, visuospatial , language and attention trainings.
89263475|NCT03927586|Experimental|physical exercise training (PE group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). Each physical exercise intervention session will last for 90 minutes. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The PE group received multimodal exercise program which includes aerobic exercise, balance and muscle strength training.
89263476|NCT03927586|Experimental|sequential training (SEQ group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the SEQ group will first undergo physical exercise training for 45 minutes followed by 45 minutes of cognitive-based training. The participants will first perform 10 minutes of warm-up followed by 25 minutes of physical exercise, and end with 10 minutes of cool-down. The exercise intensity will be similar to the PE group. Following the physical exercise, the participants will take part in 45 minutes of cognitive training. The same tasks used in the COG group will be practiced.
88805232|NCT01425853|Experimental|Chondroitin/Glucosamine (Droglican)|"Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.~Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX."
88805233|NCT01425853|Active Comparator|Celecoxib|Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
88805234|NCT01426867|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each affected eye 3 times a day for 7 days
88805235|NCT01426867|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each affected eye 3 times a day for 7 days
88805236|NCT01426867|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each affected eye 3 times a day for 7 days
89263477|NCT03927586|Experimental|dual-task training (Dual group)|All participants will receive trainings for 90 minutes per day, three days per week for 12 weeks (a total of 36 training sessions). The participants in the DUAL group will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance. The 90 minutes of training session will be break up into 2 to 3 parts, and the participants can rest as needed.
89263478|NCT01128478|Other|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
89263479|NCT01128478|No Intervention|Nil-per-mouth regimen|Conventional management
89263480|NCT01128556|Experimental|Bepreve|topical ocular treatment as indicated
89263481|NCT03927664||Peritoneal Tuberculosis|Patients diagnosed with peritoneal tuberculosis and who have undergone a computed tomographic examination
89263482|NCT01227070||Asthmatic|
89263483|NCT01227070||Healthy Control|
89263484|NCT01127230||Liposuction patients|Patients who already opted and are scheduled for liposuction.
89263485|NCT01129726|Experimental|Intubation|Transillumination-guided Fiberoptic Intubation
89263486|NCT01225432|Experimental|Gait Training|
89263487|NCT03929692|Other|Intervention Group|Intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) providing an online health promotion tool and (4) involvement of participants in planning and conduction of health promotion projects.
89263488|NCT03929692|Other|Control Group|Adolescents of same age as intervention group at follow-up examination that did not participate in health promotion program.
88805237|NCT02203747||Pseudophakic implanted with toric IOL|Subjects bilaterally implanted with toric IOL
88805238|NCT02203747||Pseudophakic implanted with non-toric IOL|Subjects bilaterally implanted with non-toric IOL
88805239|NCT00168428|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
88805240|NCT00168428|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
88816271|NCT02495259|Experimental|ZU-bend stylet with GlideScope technique|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the ZU-bend with the GlideScope technique of a double lumen endobronchial tube (DLT) placement as part of the anesthesia procedure prior to surgery.
89263489|NCT03740464|Experimental|Study group|Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.
89263490|NCT03740464|Active Comparator|Control group|Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.
89263491|NCT03928990|Experimental|Experimental arm|
89263492|NCT03929380|Experimental|10x10 squat protocol|
89263493|NCT03929380|Experimental|As Fast As Possible 100 squat protocol|
89263494|NCT01128634|Other|GSK573719|GSK573719
89263495|NCT01128634|Other|GSK573719/GW642444|GSK573719/GW642444
89263496|NCT03932422||Controlled Hypertensive Patients (CHP)|Hypertensive patients that have blood pressure less than 140 x 90 mmHg. This parameter must be evaluated by ambulatory blood pressure monitoring
89263497|NCT03932422||Resistant Hypertensive Patients (RHP)|Hypertensive patients that have blood pressure more than 140 x 90 mmHg and they use three antihypertensive medicines; or hypertensive patients that have blood pressure less than 140 x 90 mmHg, but they use four or more antihypertensive medicines. This parameter must be evaluated by ambulatory blood pressure monitoring.
89263498|NCT01227148|Experimental|Tightly glucose conntrol|
89263499|NCT01227148|Active Comparator|Conventional glucose control|
89263500|NCT01227226|Active Comparator|Refresh tears|Allergan's Refresh tears artificial tear
89263501|NCT01227226|Active Comparator|Systane Ultra|Alcon's Systane Ultra artificial tear
89263502|NCT01227226|Active Comparator|Visine|Visine artificial tear
89263503|NCT01227226|Active Comparator|Blink tears|AMO's blink tears artificial tear
89263504|NCT01127308|Experimental|[14C]Ertugliflozin|Single dose - oral dosing suspension
89263505|NCT01128712|Other|Group 1|Pregabalin (150mg/day)
89263506|NCT01128712|Other|Group 2|Pregabalin (450mg/day)
89263507|NCT01225510|Experimental|Primary Cohort|
89263508|NCT01225510|Experimental|Exploratory Cohort|
89263509|NCT01227304|Experimental|Test of volume responsiveness using crystalloids|
89263510|NCT01127386|Experimental|fix dose lenalidomide 25mg, basic cachexia management|dose reduction according to toxicity possible
89263511|NCT01127386|Experimental|CRP-response guided lenalidomide, basic cachexia management|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
89263512|NCT01127386|Experimental|placebo|to generate data about basic cachexia management, no direct comparator for treatment arms efficacy
89263513|NCT03927196|Experimental|extended statin counseling group|Extended statins counseling. Patients are handed out information leaflets on the correction of risk factors, SMS reminders.
89263514|NCT03927196|No Intervention|convetional statin counseling group|Сounseling on the prevention of cardiovascular diseases and the use of drugs for this purpose
89263515|NCT01221844|Experimental|Lactoferrin treatment in HT pregnacies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
89263516|NCT01221844|Active Comparator|Ferrous sulfate in HT pregnancies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.
89263517|NCT01128790|Experimental|remote ischemic preconditioning|4 cycles of 5 mins upper limb ischemia induced by blood pressure cuff inflation 20mmHg above systolic blood pressure
89263518|NCT01128790|Sham Comparator|Sham control|4 x 5 mins of upper limb blood pressure cuff inflation to 10mmHg (non-occlusive)
89263519|NCT01128868|Active Comparator|Proximal femur locking plate|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc)
89263520|NCT01128868|Other|Trochanteric nail|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with Trochanteric Nails (PFNA, TFN, GN)
89263521|NCT01130038||Children with DCD and Typical Development|
89263522|NCT01130038||Children with DCD|2 groups Children with DCD and Typical Development
89263523|NCT01130194|Experimental|Experimental|C-MOPP-R chemotherapy, 6 cycles Peripheral blood stem cell mobilization Radioimmunotherapy Autologous Hematopoietic Stem Cell Transplantation
89263524|NCT03928834|Experimental|Adapted Nzira Itsva Intervention|Participants will be attending clinics that provide an enhanced adherence package to the adolescents consisting of viral load (VL) testing using DBS, including the Nzira Itsva(NI) intervention and low-cost genotyping and drug resistance monitoring
89263525|NCT03928834|No Intervention|Standard of Care( SOC)|Participants will be attending clinics that provide the standard of care (SOC) VL testing and management to adolescents
89263526|NCT01221922|Experimental|Acne treatment|Treatment of acne scars
89263527|NCT01222000|Experimental|right controlled against moisturizing cream|
89263528|NCT01222000|Experimental|left controlled against moisturizing cream|
89263529|NCT01227538||Stimulated urinary C peptide|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
89263530|NCT03927040|Experimental|TEMT Administration|Subjects in this arm will received Transcranial Electromagnetic Treatment (TEMT) once daily for a 4-month treatment period utilizing the MemorEM 1000 head device.
89263531|NCT03925012|Experimental|Intervention|Child participants will attend the healthy lifestyle summer program for 4 weeks, five days per week. The summer intervention will include daily one-hour nutrition education, one-hour behavioral counseling, and 3 one-hour exercise sessions. These physical activities include flexibility, games, traditional fitness, and dancing. Counseling and school psychology students, registered dietitian/nutrition educators, and fitness specialists will lead the respective sessions. Parental guardians will participate in a two-hour weekly parental sessions that involve: 1)nutrition education with cooking demonstrations of healthy recipes; 2)behavioral counseling to learn effective parenting strategies on how to support their child's healthy nutrition and exercise habits and goals; and 3)exercise sessions where parents will engage in different physical activities and will receive fitness tips on how to promote an active lifestyle for the entire family.
89263532|NCT03928756|Experimental|Within-participant randomization|Each day, each available participant will be randomly assigned to receive either: a push notification with tailored intervention content; a push notification with engaging, nontherapeutic content; or no push notification.
89263533|NCT01225744|Experimental|Cetuximab plus Irinotecan, Oxaliplatin and UFT|Cetuximab plus Irinotecan, Oxaliplatin, UFToral
89263534|NCT01585636|Experimental|5 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
89263535|NCT01585636|Experimental|10 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
89263536|NCT01585636|Experimental|20 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
89263537|NCT01585636|Experimental|50 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
89263538|NCT01585636|Experimental|100 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
89263539|NCT01585636|Experimental|200 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
89263540|NCT01585636|Experimental|300 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
89263541|NCT01585636|Experimental|Food effect group|6 Subjects received single, 300 mg SQ109 after high-fat, high-calorie meal.
89263542|NCT03926806|Active Comparator|Plain yoghurt|2x200g plain yoghurt/day for 12 weeks
89263543|NCT03926806|Experimental|Vitamin B yoghurt|2x200g yoghurt enriched with vitamins B for 12 weeks
89263544|NCT03926962|Experimental|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
88816272|NCT02495259|Active Comparator|GlideScope with the GlideRite stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the GlideScope with the GlideRite stylet for placement of a double lumen endobronchial tube (DLT) as part of the anesthesia procedure prior to surgery.
89263545|NCT03926962|Placebo Comparator|Placebo|Visually matching placebo
89263546|NCT03926884|Experimental|Tea1 group|"This is the treatment group. This group will be taking 2 grams of the three-seeds mixture twice a day for three weeks."
89263547|NCT03926884|Placebo Comparator|Tea2 group|"This is the control group. This group will be taking 0.02 grams of the three-seeds mixture once a day for three weeks."
89263548|NCT01227694|Experimental|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
89263549|NCT03740308|Active Comparator|Locally Made Zirconia Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions.
89263550|NCT03740308|Experimental|ZR Zirconia Crwons NuSmile ® Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions. (Same as Arm 1 Description)
89263551|NCT01227772|Experimental|Weekly Cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week
89263552|NCT01227772|Experimental|2-weekly cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.
89263553|NCT01227772|Experimental|3-weekly cohort|The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks
89263554|NCT02528578|Experimental|healthy volunteers|
89263555|NCT03919786|Experimental|intervention group|"Durg：0.375% Ropivacaine and 1% lidocaine~topical local anesthesia of pulmonary vein with lidocaine+ropivacaine at the beginning and the end of surgery operation.~Block vagus nerve with lidocaine+ropivacaine 1ml after exposing the pleural apex"
89263556|NCT03919786|Placebo Comparator|normal saline group|Same volume of normal saline will be administrated
89263557|NCT03920020|Other|the concentric isokinetic exercise group|the concentric isokinetic exercise group will perform quadriceps and hamstring concentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
89263558|NCT03920020|Other|the eccentric isokinetic exercise group|the eccentric isokinetic exercise group will perform quadriceps and hamstring eccentric isokinetic exercises in addition to the conventional physiotherapy and exercise program 3 times a week during 6 weeks.
89263559|NCT03920020|Other|the control group|the control group will perform the standard exercise program predetermined by us consisting of stretching exercises and isometric strengthening (these exercises will be done at home, too) and the conventional physiotherapy program will be applied 3 times a week during 6 weeks.
89263560|NCT01132066|Experimental|tDCS|tDCS will provide an increase in cortical excitability. Patients will be randomized to receive tDCS or sham stimulation.
89263561|NCT01132066|Placebo Comparator|sham|Sham stimulation will provide identical subjective sensation as anodal tDCS.
89263562|NCT03924544|Experimental|Decorin Group|26 patients will receive subconjunctival injection of 100 µg decorin 15 minutes before surgery, 1, 3, and 7postoperatively. A30-gauge needle was used to inject 100 µL of decorin. The needle was placed at the nasal margin of the superior rectus muscle
89263563|NCT03924544|Active Comparator|Mitomycin Group|MMC will then be applied in 26 patients to the sclera at a concentration of 0.3 mg/ml using cellulose sponges, which will be removed after 3 minutes followed by copious irrigation with balanced saline solution (BSS).
89263564|NCT01131364|Experimental|F16IL2 in combination with doxorubicin|
89263565|NCT02529202|Experimental|Dexmedetomidine group|Neonates with hypoxic-ischemic encephalopathy will receive a dexmedetomidine maintenance infusion of 0.4 mcg/kg/hr during treatment with therapeutic hypothermia and during re-warming (78 hours total).
89263566|NCT00154310|Experimental|Everolimus + Mycophenolate sodium|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5 mg prednisolone or equivalent and had to be continued throughout the first year. Cyclosporine withdrawal started from Month 4.5 post-transplant.
89263567|NCT00154310|Active Comparator|Cyclosporine + Mycophenolate sodium|Cyclosporine tablets orally twice a day to achieve protocol specific target levels and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
89263568|NCT03771352|Other|RxSight RxLAL IOL|Eligible patients will be implanted with the RxSight RxLAL intraocular lens (IOL)
89263569|NCT03770728|Placebo Comparator|Placebo|Participants received placebo (matched to Efpeglenatide) subcutaneous (SC) injection once weekly up to Week 30 on top of metformin alone or in combination with SU.
89263570|NCT03770728|Experimental|Efpeglenatide 2 mg|Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU.
89263571|NCT03770728|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and was maintained at the 4 mg dose through-out the treatment duration, up to Week 30.
89263572|NCT03770728|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 30 on top of metformin alone or in combination with SU. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 3 and later up-titrated to 6 mg and was maintained at the 6 mg dose through-out the treatment duration, up to Week 30.
89263573|NCT01130428|Experimental|Intervention group|As a mechanical intervention, we will use a vibration platform to administer mechanical stimulation to the forearm of subjects (see Figure 1). All subjects will participate in a single experiment during which they will receive the mechanical intervention a fixed dose of; the duration of an experiment is approximately three hours.
89263574|NCT01227850||Parenteral nutrition patients.|
89263575|NCT02529358|Experimental|EG stand|Standardized text messages
89263576|NCT02529358|Experimental|EG ind|Personalized text messages
89263577|NCT02529358|Other|Control|Standardized text messages after 10 weeks
89263578|NCT01228474|Experimental|SET|Single embryo transfer
89263579|NCT01228474|Active Comparator|DET|Double embryo transfer
89263580|NCT01132222|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
89263581|NCT01132222|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
89263582|NCT03926182|Experimental|Fasted AST2818 tablets following a period of fasting|
89263583|NCT03926182|Experimental|High-fat meal AST2818 tablets following a high-fat meal|
89263584|NCT01132300|Experimental|Treatment|
89263585|NCT03926416|Experimental|CodaVax-H1N1, low dose|Participants will receive a single dose of either CodaVax (5 x 10^3 PFU in 200 uL) and an intramuscular injection of placebo
89263586|NCT03926416|Active Comparator|Fluzone|Participants will receive an intranasal (IN) dose of placebo and an intramuscular (IM) dose of QuadriFlu- Tetravalent Influenza Vaccine (TIV) (Fluzone®)
89263587|NCT03926416|Experimental|CodaVax-H1N1, high dose|Participants will receive a single intranasal (IN) dose of CodaVax-H1N1 (1 x 10^5 PFU in 500 uL)
89263588|NCT03926416|Placebo Comparator|Placebo|Leibovitz's L-15 medium (IN) or saline (IM)
89263589|NCT01130506|Experimental|Treatment (decitabine, vorinostat, cytarabine)|"INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; vorinostat PO on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.~MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and vorinostat PO on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity."
89263590|NCT01130584||Cancer patient|
89263591|NCT01130662|Experimental|Decitabine Midostaurin combination|
89263592|NCT01228006|Experimental|Treatment|NatusGerin
89263593|NCT01228006|Placebo Comparator|Control|Gelatin capsules identical to drug test
89263594|NCT01132456|Experimental|Different patient subset|Patients with dual vessel treatment where each vessel has a lesion with length ≤ 27 mm and reference vessel diameters between 2.25 mm and 4.0 mm.
89263595|NCT01132456|Experimental|38 mm Cohort|Patients with at least one lesion amenable to treatment with a 38 mm length Endeavor Resolute stent. Patients may have one or two lesions, if the two lesions are located in separate target vessels.
89263596|NCT03924388|Experimental|Short-term transcutaneous spinal cord stimulation|"In Project 1, we will measure the immediate effects of one-hour mid-thoracic and/or lumbosacral transcutaneous stimulation on autonomic function.~In mid-thoracic stimulation, the self-adhesive cathode electrode with a diameter of 30 mm will be placed on the skin between the TVII and TVIII spinous processes (approximately corresponding to the T8 spinal segment) at the midline over the vertebral column. For lumbosacral stimulation, the cathode will be placed on the skin between the LI and LII spinous processes (approximately corresponding to the L2/3 to S4/5) at the midline over the vertebral column. Two self-adhesive anode electrodes with a size of 5 × 9 cm will be symmetrically located on the skin over the iliac crests. Before and immediately after the stimulation, the outcomes will be measured in 2 positions, supine and ~ 70° upright (adjusted by tilt-up table)."
89263597|NCT03924388|Experimental|Long-term transcutaneous spinal cord stimulation|"In Project 2, we will measure the effects of one-month stimulation (five one-hour stimulation sessions per week) of mid-thoracic and lumbosacral transcutaneous spinal cord stimulation on autonomic function.~The electrode placement and duration of stimulation will be identical to Project 1. The outcomes at each time point will be measured in two positions, supine and ~ 70° upright (adjusted by tilt-up table). The cardiovascular outcomes will be measured before, after the last stimulation session. Bladder and bowel function will be assessed weekly."
89263598|NCT03924388|Experimental|Project 3|For Project 3, only individuals who have previously been implanted with an epidural stimulator will be invited to participate. They will have only one stimulation session. We will not offer participants to undergo implantation surgery.
89263599|NCT03925948|Experimental|Intervention|This is a one arm study with all participants enrolled into this arm.
89263600|NCT03919630|Experimental|Cervical Thrust Mobilizations|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine.
89263601|NCT03919630|Active Comparator|Cervical Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
89263602|NCT01132534||SE then AFI/NBI|Patients will be randomised to be examined by standard videoendoscopy (SE) then combined AFI/NBI during the esophagogastroduodenoscopy (EGD) examination at same setting.
89263603|NCT01132534||AFI/NBI then SE|Patients will be randomised to be examined by combined AFI/NBI then standard videoendoscopy (SE) during the EGD examination at same setting.
89263604|NCT03925792|Experimental|Treatment Group|Lifestyle Medicine Group 1
89263605|NCT03925792|Experimental|Waitlist Control Group|Lifestyle Medicine Group 2
89263606|NCT03925714|Other|life style|life style control only
89263607|NCT03925714|Active Comparator|Metformin|Metformin 500 mg twice daily
89263608|NCT03925714|Experimental|Nigetella salivata|NS 450 mg twice daily
89263609|NCT03919240|Experimental|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells
89263610|NCT01228552|Active Comparator|Topical, intra-oral ketoprofen gel|
89263611|NCT01228552|Placebo Comparator|Placebo gel|
89263612|NCT03924076|Experimental|Treatment Group|Received UHT milk + paraprobiotic Lactobacillus plantarum IS-10506 5 x 1010 CFU/day (125 mL) for 90 days
89263613|NCT03924076|Placebo Comparator|Placebo Group|Received UHT milk (125 mL) for 90 days
89263614|NCT03925558|Active Comparator|Probiotic formula|Lactobacillus strains
89263615|NCT03925558|Placebo Comparator|Placebo formula|Placebo
89263616|NCT01228162|Experimental|general anaesthesia|patients receiving general anaesthesia and rocuronium bromide for muscle relaxation
89263617|NCT01228162|Active Comparator|spinal anaesthesia|patients receiving spinal anaesthesia without muscle relaxation
89263618|NCT03919084|Active Comparator|THRIVE-Basic|Screening-and-referral usual care model
89263619|NCT03919084|Experimental|THRIVE+|Enhanced screening-and-referral with motivational interviewing and patient navigation services
89263620|NCT03919318|Experimental|AH-Plus|
89263621|NCT03919318|Experimental|EndoSeal MTA|
89263622|NCT03919318|Experimental|Endosequence BC Sealer|
89263623|NCT01329484|Experimental|Cognitive training|
89263624|NCT01329484|Experimental|Reminiscence therapy|
89263625|NCT01329484|Other|Control|This group will receive neither of the above interventions or any other similar interventions
89263626|NCT03923842|Experimental|ARM A: Denosumab Treatment|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
89263627|NCT03923842|Active Comparator|ARM B Control Arm|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. At the end of the 6 cycles, if the patient is not progressing, can continue treatment with Gemcitabine alone.for 12 months
89263628|NCT03924154|Experimental|RVT-1201|RVT-1201 600 mg immediate-release tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=24 [Anticipated])
89263629|NCT03924154|Placebo Comparator|Placebo|Matching placebo tablet, administered orally twice daily with food for 6 weeks, in addition to the patient's current standard of care medication(s) for PAH (n=12 [Anticipated])
89263630|NCT03923998|Experimental|Neoadjuvant chemoradiotherapy followed by surgery|Preoperative chemotherapy with concurrent radiotherapy followed by definitive surgery
89263631|NCT03923764|Experimental|Intervention group|1.3 g protein per kg bodyweight per day for 8 weeks
89263632|NCT03923764|Active Comparator|Kontrol group|habitual diet
89263633|NCT03919006|Active Comparator|Periodontitis|"GCF, saliva and serum samples were taken before and after treatment from periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
89263634|NCT03919006|Active Comparator|Gingivitis|"GCF, saliva and serum samples were taken before and after treatment from gingivitis patients.~Intervention: Non- surgical periodontal treatment (Scaling and oral hygiene instructions)"
89263635|NCT03919006|Placebo Comparator|Periodontally healthy|GCF, saliva and serum samples were taken at baseline from periodontally healthy individuals.
89263636|NCT01132768|Active Comparator|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.
89263637|NCT01132768|Experimental|Olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.
89263638|NCT01230034|Experimental|Imidapril|10 and 20 mg/day, pill
89263639|NCT01230034|Active Comparator|Ramipril|5 and 10 mg/day, pill
89263640|NCT03918616||PD + AD|Patients with newly-diagnosed (onset of suggestive symptoms not later than 3 months) Parkinson disease (PD) or Alzheimer disease (AD) with no previous specific treatment, no anti-inflammatory drugs assumed in the three months preceding the enrolment and no chronic inflammatory diseases or cancer.
89263641|NCT03918616||Control group|An age and gender matched control group (n=50) was formed, on a volunteer basis, by the spouse of the probands participating in the study.
89263642|NCT03925168|Experimental|Experimental|Music therapy
89263643|NCT03925168|No Intervention|Control|No music therapy
89263644|NCT03918694|Active Comparator|Experimental|Participants will receive Vit C tablets
89263645|NCT03918694|Placebo Comparator|Placebo|Participants will receive placebo tablets
89263646|NCT03923608||strength test|The maximum strength test of external shoulder rotators will be performed on 5 different tools with specific protocols.
89263647|NCT03923608||Endurance test|"Test designed by the Laboratory of Sports Physical Therapy (LAFIDE) of FCT / UNESP - Presidente Prudente, used in the prescription of training for gain of localized muscular endurance. Will be realized in the tools: Isokinetic dynamometer, elastic bands, pulley and halter.~The test will consist of the maximum possible repetitions (until fatigue) with loads of 70%, 80% and 90% of the maximum force (in different sessions)."
89263648|NCT01228630|Experimental|Cloratadd-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to comparator drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
89263649|NCT01228630|Active Comparator|Allegra-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to test drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
89263650|NCT05402644||Non-CSPH|BCLC stage A patients who underwent hepatectomy in the group without clinically significant portal hypertension (Non-CSPH)
89263651|NCT05402644||CSPH|BCLC stage A patients who underwent hepatectomy in the group with clinically significant portal hypertension (CSPH)
89263652|NCT03918538|Experimental|The intervention group|"After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual.~The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers."
89263653|NCT03918538|No Intervention|The control group|Participants in the control group received regular medication education.
89263654|NCT01230190|Active Comparator|Probiotic mixture|participants daily ingest a selected probiotic mixture for a period of 3 months
89263655|NCT01230190|Placebo Comparator|Placebo mixture|controls daily ingest a placebo mixture for a period of 3 months.
89263656|NCT01228708|Active Comparator|Intervention|Patients from half the GP practices in Ringkoebing-Skjern municipality that participates in an active implementation of a guideline for COPD
89263657|NCT01228708|No Intervention|Control group|Patients from the half of the GP practice in Ringkoebing-Skjern that do not participate in the active implementation of a guideline for COPD. The GPs are however in postgraduate training groups with intervention groups GPs
89263658|NCT01228708|No Intervention|External control|Patients with GP practice in neighboring county Ikast-Brande where there have been no information or contact at all from the investigators
89263659|NCT05402488|Experimental|Verum stimulation|Verum condition: Auditory stimulation during sleep
89263660|NCT05402488|Sham Comparator|Sham stimulation|Sham condition: Playing no tones during sleep but still recording brain activity (muted tones)
89263661|NCT03923062|Experimental|G I A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
89263662|NCT03923062|Experimental|G I B(left side):will be treated by cryopeeling|left side of the patient's face will be treated by cryopeeling using Liquid Nitrogen.
89263663|NCT03923062|Experimental|G II A (right side): will be treated by chemical peeling|right sideof patient's face will be treated by chemical peeling( Trichloroacetic acid 20% concentration).
89263664|NCT03923062|Experimental|G II B (left side):will be treated by tranexemic acid|left side of patient's face will be treated by tranexemic acid(cyclokapron)
89263665|NCT01228786||Group A|~ 20 sporadic PHPT patients
89263666|NCT01228786||Group B|~10 normocalcemic euthyroid patients (control tissue)
89263667|NCT03918226|Other|Exploratory Laparotomy|Exploratory Laparotomy of patients presenting acute abdomen and whose diagnosis later on confirmed on histopathology to be tuberculosis
89263668|NCT01230268|Experimental|Mulberry fruit extract|Daily 1000 mg oral Mulberry fruit extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
89263669|NCT01133002||VTE management registry|Patients receiving enoxaparin, with or without oral anticoagulation, within Day 0-10 after diagnosis of VTE
89263670|NCT01134406|Experimental|Hydros Joint Therapy|Experimental viscosupplement.
89263671|NCT01134406|Experimental|Hydros-TA Joint Therapy|Experimental viscosupplement.
89263672|NCT01134406|Active Comparator|Synvisc-One|Commercial control.
89263673|NCT01231828|Experimental|Carnitine|Versus placebo.
89263674|NCT01231828|Experimental|Lactulose|Versus placebo
89263675|NCT03923218||Smoker patients with chronic periodontitis|Smoker patients with chronic periodontitis
89263676|NCT03923218||non-smoker patients with chronic periodontitis|non-smoker patients with chronic periodontitis
89263677|NCT03923218||periodontally healthy patients|periodontally healthy patients
89263678|NCT03923140|Experimental|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
89263679|NCT05402410||Training cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
89263680|NCT05402410||Validation cohort|Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis and clinical manifestations.
89263681|NCT01133080|Experimental|Minocycline|
89263682|NCT01133080|Placebo Comparator|Placebo|
89263683|NCT05402098|Active Comparator|Endodontic treatment using traditional access|Straight line access will be achieved following complete removal of pulp chamber roof
89263684|NCT05402098|Experimental|Endodontic treatment using conservative access|Part of pulp chamber roof will be preserved and no efforts will be directed to achieve straight line access
89263685|NCT01133236|Experimental|Salt and Fluid|Intervention: Fluid 800 Ml and Salt 2 g per day Control: FLuid and Salt Free
89263686|NCT01230580|Experimental|Protease Inhibitor Monotherapy|Ritonavir-boosted protease inhibitor
89263687|NCT01230580|Active Comparator|Control|Standard-of-care triple-therapy regimen
89263688|NCT05401942|No Intervention|Routine monitoring|patients with breast cancer who will receive adjuvant treatment and will be followed up during treatment with routine visits.
89263689|NCT05401942|Active Comparator|Tele-monitoring through mobile application|Patients with breast cancer who will receive adjuvant therapy and will be followed up during treatment through tele-monitoring with mobile application and CTCAE checklist for PRO.
89263690|NCT01585792|Experimental|TAK-875 25 mg|
89263691|NCT01585792|Experimental|TAK-875 50 mg|
89263692|NCT01585792|Active Comparator|Glimepiride|
89263693|NCT01585792|Placebo Comparator|Placebo|
89263694|NCT03922672|Experimental|Piano group|This group will consist of the adult with Parkinson's disease and their caregiver for a total of 14 pairs.
89263695|NCT01134484|Experimental|VTD|
89263696|NCT01134484|Active Comparator|TD|
89263697|NCT03922906|Experimental|Motus Pure-Vu System|The Pure-Vu System enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
89263698|NCT03918148||SGLT-2i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a SGLT-2 inhibitor:~dapagliflozin 10 mg, oral, once daily or canagliflozin 100 mg, oral, daily or empagliflozin 10 mg, oral, daily"
89263699|NCT03918148||DPP-4i|"Type 2 diabetic patients treated with metformin and/or insulin starting therapy with a DPP-4 inhibitor:~sitagliptin 100 mg, oral once daily or vildagliptin 50 mg, oral, twice daily or saxaglitpin 5 mg, oral, once daily or linagliptin 5 mg, oral, once daily or alogliptin 25 mg, oral, once daily"
89263700|NCT03917680|Experimental|Type III angioedema|White angioedema. Positive for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
89263701|NCT03917680|Experimental|Idiopathic angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
89263702|NCT03917680|Experimental|Type I or II angioedema|White angioedema. Negative for Factor XII mutation. C1-inhibitors anomaly. Not caused by IEC.
89263703|NCT03917680|Experimental|Post IEC (conversion enzyme inhibitors) angioedema|White angioedema. Negative for Factor XII mutation. No C1-inhibitors anomaly. Caused by IEC.
89263704|NCT03917680|Experimental|Histaminic angioedema|Red angioedema.Negative for Factor XII mutation. No C1-inhibitors anomaly. Not caused by IEC.
89263705|NCT03917680|Other|Control|Healthy individuals, no angioedema.
89263706|NCT03740074|Experimental|PAI|Participants will utilize a MIO Slice wearable device to generate a PAI score, which will be utilized to provide feedback and incentive for physical activity.
89263707|NCT01133470|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
89263708|NCT01133470|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
89263709|NCT01134718|Experimental|001|TMC435 (F021) one morning dose of 150 mg
89263710|NCT01134718|Experimental|002|TMC435 (G006) one morning dose of 150 mg
89263711|NCT01134718|Experimental|003|TMC435 (G007) one morning dose of 150 mg
89263712|NCT03922360|Active Comparator|Best Practices|
89263713|NCT03922360|Experimental|Best Practices + Financial Incentives|
89263714|NCT05401708||DM Naïve|a new patient without a history of DM medication
89263715|NCT01228864|Experimental|Brody Belt|
89263716|NCT01228864|Active Comparator|Conventional Urinary Drainage bag|
89263717|NCT01131442||The patient group|
89263718|NCT01131442||healthy control group|
89263719|NCT03917758|Experimental|Diabetic patients|30 diabetic patients candidate to treatment with SGLT2i in add-on to metformin.
89263720|NCT05206474|Experimental|IRADYN|"One group, all patients will receive IRADYN® (intra-articular administration).~One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
89263721|NCT01134874|Experimental|Standard weight loss intervention|
89263722|NCT01134874|Experimental|Standard weight loss intervention plus technology|
89263723|NCT01134874|Experimental|Technology only|
89263724|NCT01230736|Experimental|DuoTrav|One drop in study eye(s) once daily for 8 weeks
89263725|NCT05401552|Active Comparator|Convenience breakfast meal|One cheese tea biscuit and Eggo waffle
89263726|NCT05401552|Active Comparator|Healthy breakfast meal|One cup of All-Bran breakfast cereal with milk and a piece of fruit
89263727|NCT01133548|Experimental|1|Testosterone Gel 1.62%
89263728|NCT03917368|Experimental|Ultrasound scan of the internal jugular veins|Hospitalised adult patients, requiring a scheduled central venous catheterisation and measurement of the central venous pressure as part of their usual care, will undergo a non-invasive ultrasound scan of the internal jugular veins (both side of the neck) synchronized with an ECG trace, to assess the jugular venous pulse. This procedure will be performed once throughout the study.
89263729|NCT03922438|Experimental|Cleft margin flap with anterior palatal closure|Usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.
89263730|NCT03922516|Other|Reporting order: Plain Film - ULDCT|"The plain film of half the participants (randomized) will be submitted for reporting by a radiologist as a first imaging method. After finishing this report, the same radiologist will assess the ULDCT of this participant. In this second report, the findings of both examinations will be summarized, and a second report will be filed.~Emergency physicians will first receive the report for the plain film of the chest and will be asked for the diagnosis and its probability. Next, the report for ULDCT will be presented to them. Again, diagnosis and probabilities will be documented."
89263731|NCT03922516|Other|Reporting order: ULDCT - Plain Film|"For half the participants (randomized) radiologists will first receive the data from ULDCT of the chest and write a report. Subsequently, they will receive the data from the plain film of the chest and may expand their report (explicitly separated).~Emergency physicians will first receive the report for the ULDCT of the chest and will be asked for probabilities of the nine most frequent diagnoses in chest-imaging plus other. Next, they will be presented with the report for the plain film and will again be asked to give an estimation of the probabilities for the same diagnoses as before."
89263732|NCT03917524||no need for any adjuvant therapy|Patients with oral cavity squamous cell carcinoma post-surgery no need for any adjuvant therapy
89263733|NCT03917524||with risk factors|Patients with oral cavity squamous cell carcinoma post-surgery with major risk factor(s) or 2 minor risk factors Stratification by Risk factors, alcohol, betel nut chewing and cigarette use status
89263734|NCT01135030|Active Comparator|Posterior referencing|
89263735|NCT01135030|Active Comparator|Anterior referencing|
89263736|NCT05401474|Active Comparator|30 L/min|HFNC at 30L/min. FiO2 adjusted to reach SpO2 95%
89263737|NCT05401474|Experimental|45 L/min|HFNC at 45L/min. FiO2 adjusted to reach SpO2 95%
89263738|NCT05401474|Experimental|60 L/min|HFNC at 60L/min. FiO2 adjusted to reach SpO2 95%
89263739|NCT03917602|Experimental|Patients with large macular holes|Patients suffering from large macular holes as documented by spectral domain OCT will undergo pars plan vitrectomy with human amniotic membrane insertion into the macular hole.
89263740|NCT03922282|Experimental|Gasless BABA|BABA robotic-thyroidectomy that do not using carbon dioxide but using elevation of flap.
89263741|NCT03922282|Active Comparator|Classic BABA|BABA robotic-thyroidectomy using carbon dioxide.
89263742|NCT01135108|Placebo Comparator|A1: Placebo|Placebo
89263743|NCT01135108|Experimental|A2: KAI-1678|Experimental
89263744|NCT01135264|Active Comparator|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
89263745|NCT01135264|Experimental|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
89263746|NCT03917212||Patients|Patients with propionic acidemia, isovaleric acidemia, methylmalonic acidemia
89263747|NCT03917212||Controls|Healthy humans
89263748|NCT05201092|Experimental|[14C]-Lu AG06466|Participants will receive a single oral dose of [14C]-Lu AG06466 on Day 1 in the fed state.
89263749|NCT03917290|Experimental|Intervention|Upon clearance to RTP after concussion, participants randomized to NMT will complete training for 20-30 minutes, two times per week, beginning at RTP and continuing at this frequency for 8 weeks.
89263750|NCT03917290|No Intervention|Usual Care|Participants cleared to RTP in the usual care arm will return to sports and not undergo any intervention.
89263751|NCT01230970|Experimental|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
89263752|NCT01135576|Placebo Comparator|Placebo juices|Consumption of non-iron fortified fruit juices as part of the usual diet
89263753|NCT01135576|Experimental|Iron fortified fruit juices|Consumption of iron fortified fruit juices as part of the usual diet
89263754|NCT01133782|Experimental|Rapid result|Result of diagnostic PCR panel provided the following day
89263755|NCT01133782|No Intervention|Delayed result|Result of dagnostic PCR panel provided within 10+/-2 days at follow-up visit.
89263756|NCT02528890||preganat women between 34 - 40 weeks|Eligible pregnant women, who meet the inclusion criteria, will have a vaginal/anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
89263757|NCT01228942|Other|Platinum Sensitive|Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet
89263758|NCT01228942|Other|Platinum resistent|single agent based on Coxen prediction model
89263759|NCT03917134|Experimental|cephalosporin + Metronidazole|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. metronidazole vaginal ovules of 500mg twice a day for 5 days after surgery
88805241|NCT01427881|Experimental|Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126."
88805242|NCT01319539|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
89263760|NCT03917134|Placebo Comparator|cephalosporin + placebo|In this arm, patients randomly selected, will receive cephalosporin in doses of 2 grams administered intravenously before surgery. placebo vaginal ovules twice a day for 5 days after surgery
89263761|NCT03916900|Experimental|Pulpotomy|"Group A (Experimental group) Pulpotomy:~The teeth will be anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain) by inferior alveolar nerve block.Under rubber dam isolation, pulpotomy will be performed with a large sterile round end bur in a high speed hand piece with copious irrigation; pulp tissue will be removed by a sharp spoon excavator to the orifice level. Hemostasis will be achieved by the application of a wet cotton pellet moistened with 2.5% NaOCL for 2 min and repeated if needed.~After hemostasis, Biodentine (Septodont, Saint Maur des Fausses, France) will be mixed according to the manufacturer's instructions and gently placed over the pulp to thickness of 2-3 mm.Biodentine will be covered by resin modified glass-ionomer and teeth will be restored using composite resin.A postoperative radiograph will be taken by parallel technique."
89263762|NCT03916900|Active Comparator|Root canal treatment|"Group B (control group) Root canal treatment:~The teeth were anesthetized with 4% articaine 1:100,000 epinephrine (Artinibsa®; Inibsa Dental, Lliçà de Vall, Spain).Under rubber dam isolation, root canal treatment will be performed in single visit.Working length will be determined using stainless steel k-files (Mani, Inc.) keeping 0.5 to 1.0 mm short of the apex using a RootZX apex locator (J. Morita, Irvine, CA) and confirmed radiographically. Mechanical preparation will be achieved by a crown-down technique using using the M-PRO system (IMD, Shanghai, China) and irrigation with 5 mL 2.5% NaOCl between instruments.Obturation will be done with gutta-percha (Meta Biomed Co. Ltd, Cheongwongun, Chungbuk, Korea) and resin sealer ADseal (Meta Biomed CO., LTD, Korea) using cold lateral condensation technique and restored with composite resin with a base of glass-ionomer cement. A postoperative radiograph will be taken by parallel technique."
89263763|NCT03917056|Experimental|Long needle group|Participants were treated with CAES using long needle.
89263764|NCT03917056|Experimental|Short needle group|Participants were treated with CAES using short needle.
89263765|NCT03916822||ABMR|Biopsy-proven ABMR-Banff criteria, with or without Complement binding donor-specific anti-HLA antibodies
89263766|NCT03916822||TCMR|Biopsy-proven TCMR-Banff 1A, 1B, 2 and 3
88805243|NCT01319617|Experimental|SENSIMED Triggerfish|
89263767|NCT03916822||No Rejection|Biopsy-proven, or clinical criteria
89263768|NCT02528656|Experimental|Pectus Excavatum|Patients with pectus excavatum who do not require surgery, will be treated with the Vacuum bell device.
89263769|NCT02528656|Experimental|Pectus Carinatum|Patients with pectus carinatum who do not require surgery, will be treated with the Dynamic Compression System.
88805244|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation A (Formulation A)|Parallel-Group Phase (PGP): cyclosporine ophthalmic emulsion Formulation A
88805245|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation B (Formulation B)|PGP: cyclosporine ophthalmic emulsion Formulation B
89263770|NCT03921892|Other|In-person parenting education|Participants will complete two six-hour in-person parenting education sessions on two consecutive Saturdays
89263771|NCT03921892|Active Comparator|On-line parenting education|Participants will complete on-line parenting education at the times and locations of their choice over a two-week period.
89263772|NCT01229020||COPD patients|Patients diagnosed with COPD, by the pulmonologist at the institute,who are referred to undergo ventilation/perfusion scans.
89263773|NCT01232140|Experimental|CRP-guided antibiotic treatment|If CRP> 50 mg/l a patient receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment is withheld.
89263774|NCT01232140|Other|GOLD strategy-antibiotic treatment|According to the GOLD strategy a patient with an AECOPD should prescribed antibiotic treatment if a patient has symptoms of increased dyspnea, increased sputum production and change of sputum color. Two of these three criteria should be present, however change in sputum production is obligatory.
89263775|NCT05401162|Experimental|Experimental group|transfusion of autologous blood containing haematopoietic stem cells after conventional chemotherapy
89263776|NCT05401162|No Intervention|Control group|enrolled ovarian cancer patients receive conventional chemotherapy
89263777|NCT01133938||Closed reduction < 12 months of age|
89263778|NCT01133938||Open reduction < 12 months of age|
89263779|NCT01133938||Open reduction with concomitant osteotomies > 12 months fo age|
89263780|NCT01135654|Experimental|Non-Physician Provider|
89263781|NCT01135654|No Intervention|Control|
89263782|NCT01135654|Active Comparator|Primary Care Provider|In clinics randomized to this arm, we will train (and provide technical assistance to) Primary Care providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment.
89263783|NCT01231126|Placebo Comparator|spontaneous vaginal deliveries|
89263784|NCT01231126|Placebo Comparator|elective caesarians|
89263785|NCT01231126|Experimental|induced vaginal delivery by misoprostol|
89263786|NCT01231126|Experimental|caesarians section with induction attempt|
89263787|NCT01232218|Active Comparator|Current Standard Treatment|Current standard treatment for hemiplegic shoulder pain will be provided to this group.
89263788|NCT01232218|Experimental|Standard treatment + study technique|Participants will receive current standard treatment for hemiplegic shoulder pain PLUS an additional stretching/strengthening technique. Both groups will be allotted the same treatment time.
89263789|NCT01135732||study group-previous sphincterotomy|
89263790|NCT01135732||control group-not previous sphincterotomy|
88805246|NCT01319773|Other|Formulation A and cyclosporine ophthalmic emulsion 0.05%|Paired-Eye Phase (PEP): cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion 0.05%
88805247|NCT01319773|Other|Formulation B and cyclosporine ophthalmic emulsion 0.05%|PEP: cyclosporine ophthalmic emulsion Formulation B and cyclosporine ophthalmic emulsion 0.05%
88805248|NCT01319773|Experimental|Formulation A and Formulation B|PEP: cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion Formulation B
89263791|NCT03769090|Experimental|BDA MDI (PT027) 160/180 μg|Budesonide/albuterol sulfate, BDA MDI, PT027 high dose
89263792|NCT03769090|Experimental|BDA MDI (PT027) 80/180 μg|Budesonide/albuterol sulfate, BDA MDI, PT027 low dose
89263793|NCT03769090|Active Comparator|AS MDI (PT007) 180 µg|Albuterol sulfate MDI, PT007
89263794|NCT01135888||HED children|
89263795|NCT01135888||HED adolescents|
89263796|NCT01135888||Control children|
89263797|NCT01135888||Control adolescents|
89263798|NCT03921736|No Intervention|Control Group|Control group consisted of 40 postmenopausal women with normal blood pressure.
89263799|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide|Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
89263800|NCT03921736|Experimental|Hypertensive women group receiving perindopril.|Patients received perindopril 4 mg/day p.o for 1 year.
89263801|NCT03921736|Experimental|Hypertensive women group receiving hydrochlorothiazide and EPT|Patients received hydrochlorothiazide 25 mg/day p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
89263802|NCT03921736|Experimental|Hypertensive women group receiving perindopril and EPT.|Patients received perindopril 4 mg/day p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
89263803|NCT03921736|Experimental|Hipotensive women group receiving EPT.|Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year.
89263804|NCT01231204|Placebo Comparator|Placebo Infusion|Patients will be randomized to receive a continuous infusion of Normal Saline via a Paravertebral Nerve Block.
89263805|NCT01231204|Active Comparator|Ropivicaine 0.4% Infusion|Patients will be randomized to receive a continuous infusion of 0.4% Ropivicaine via a Paravertebral Nerve Block.
89263806|NCT05401006|Active Comparator|Acitretin|Patients will Receive Acitretin (0.25-1 mg /kg/day )for 3months .
89263807|NCT05401006|Active Comparator|Narrowband ultraviolet B|Patients will receive Narrowband UVB( 3session /week ) for 3months.
89263808|NCT05401006|Active Comparator|Combination of Narrowband ultraviolet B and Acitretin|Patients will receive Acitretin (0.25-1 mg /kg/day ) and Narrowband UVB( 3session /week ) for 3 months.
89263809|NCT01134094|Active Comparator|Non-Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
88805249|NCT01319851|Experimental|Alefacept|Pediatric subjects with non-malignant diseases (NMD) will receive pre-conditioning with alefacept 0.5 mg/kg/dose i.v. with the first dose split on days -40 and -39 and the remaining doses given on days -33, -26, -19, and -12 (e.g. weekly for 5 doses).
88805250|NCT04351867|Experimental|experimental group|docetaxel plus oxaliplatin and capecitabine
88805251|NCT04351867|Active Comparator|control group|oxaliplatin plus capecitabine
89263810|NCT01134094|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
89263811|NCT01135966|Active Comparator|Conventional training|
89263812|NCT01135966|Experimental|Whole body vibration training|
89263813|NCT05400928|Experimental|Three-dimensional Directed Pulsed Field Ablation|Paroxysmal atrial fibrillation will be ablated with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
89263814|NCT01231282|Experimental|diffusion-weighted MRI|MRI
89263815|NCT01231360|Active Comparator|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
88805252|NCT02539134|Experimental|Part 1, Cohort 1: TAK-935 100 mg QD|TAK-935 100 milligram (mg), solution, orally, once daily (QD) or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
88805253|NCT02539134|Experimental|Part 1, Cohort 2: TAK-935 300 mg QD|TAK-935 300 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
88805254|NCT02539134|Experimental|Part 1, Cohort 3: TAK-935 300 mg BID|TAK-935 300 mg, solution, orally, twice daily (BID) or TAK-935 placebo-matching solution, orally, BID for up to 10 days.
88805255|NCT02539134|Experimental|Part 1, Cohort 4: TAK-935 600 mg QD|TAK-935 600 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 10 days.
88805256|NCT02539134|Experimental|Part 1, Cohort 5: TAK-935 400 mg QD|TAK-935 400 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
88805257|NCT02539134|Experimental|Part 2, Cohort 6: TAK-935 Dose 1|TAK-935 first decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
88805258|NCT02539134|Experimental|Part 2, Cohort 7: TAK-935 Dose 2|TAK-935 second decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
88805259|NCT00262730|Experimental|Treatment Arm|"RT + TMZ 6wks, followed by~poly ICLC, temozolomide, radiation: radiation therapy"
88805260|NCT01320553|Experimental|SPARC1102 I|1334H 0.15% eye drops will be administered in both eyes at 3 occasions
88805261|NCT01320553|Experimental|SPARC1102 II|1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
88805262|NCT01320553|Experimental|SPARC1102 III|1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
88805263|NCT01320553|Placebo Comparator|Vehicle|Placebo eye drops (solution)will be administered in both eyes at 3 occasions
88805264|NCT04262934|Experimental|Cholecalciferol treatment|Arm A : Cholecalciferol 100.000 UI - oral - every month
88805265|NCT04262934|Active Comparator|No treatment|Arm B : No vitamin D administration
88805266|NCT03009253|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
88805267|NCT03009253|Experimental|Chemotherapy Group|"Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)~Followed by Concurrent chemoradiotherapy:~(Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks)"
88805268|NCT00262964|Experimental|NAFLD-Niacin|Subjects, having previously diagnosed with NAFLD, were given Niacin for 16 weeks. The dosage was 500mg/day for week 1, 1000mg/day for week 2, 1500mg/day for week three and 2000mg/day for weeks 4 through 16.
88805269|NCT00262964|No Intervention|Control|Subjects were found to have intrahepatic triglyceride levels below the threshold for Non-Alcoholic Fatty Liver Disease (NAFLD). For this study that threshold was set at 10% intrahepatic triglyceride content as determined by magnetic resonance spectroscopy. These control subjects did not participate in any intervention. Only baseline features were characterized for this arm.
88805270|NCT00262964|Experimental|NAFLD-fenofibrate|Subjects diagnosed with NAFLD were randomized to fenofibrate, an oral medication, nightly for eight weeks. Subjects will be given a dose of 200mg/day.
88805271|NCT00262964|Placebo Comparator|NAFLD-placebo|These subjects were diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD) and received an 8 week course of a placebo pill. Their baseline characteristics were averaged into the overall NAFLD baseline characteristics along with the baseline data for the two intervention groups.
88805272|NCT01321177|Experimental|Integrated Treatment|Integrated program of treatments and services delivered by a coordinated team of providers.
88805273|NCT01321177|Active Comparator|Community Care|Standard mental health treatments and services offered at the local agency.
88816273|NCT02495259|Active Comparator|Macintosh blade and a regular DLT stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the direct laryngoscopy technique with the Macintosh blade and a regular double lumen endobronchial tube (DLT) stylet as part of the anesthesia procedure prior to surgery.
89263816|NCT01231360|Active Comparator|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
89263817|NCT01229098|Experimental|LEO 80185|
89263818|NCT01136122|Active Comparator|CPAP Arm|Receive effective CPAP treatment for one month
89263819|NCT01136122|No Intervention|Control Arm|Receive no treatment for one month
89263820|NCT01232374|Experimental|Nimotuzumab plus chemo-irradiation|Nimotuzumab，chemotherapy(cisplatin )，radiotherapy
89263821|NCT01232374|Placebo Comparator|Placebo plus chemo-irradiation|Placebo，chemotherapy(cisplatin)，radiotherapy
89263822|NCT01231438|Experimental|Renvela|Treatment for 2 weeks
89263823|NCT01231438|Experimental|Etalpha|Vit D Treatment for 2 weeks
89263824|NCT01131754|Experimental|Heparin sol 100U/L|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
89263825|NCT01131754|Active Comparator|saline|peripheral venous catheter flushing with 3 mL of normal saline from mono-use vials (prepared by the hospital pharmacy) at the end of each drug infusion. Independently of the number of drug infusions, all patients will receive at least two catheter flushes every day.
89263826|NCT05608330|Experimental|PETRUSHKA tool|The intervention is the PETRUSHKA web-based App (also called PETRUSHKA tool), a clinical decision-support system that incorporates a personalised evidence-based prediction model with individual patient preferences, to prescribe the best antidepressant to adults with depression
89263827|NCT05608330|Placebo Comparator|Usual Care|Routine care delivered in the NHS (i.e. selection of the antidepressant based primarily on the clinicians' judgement) termed 'usual care' in this study.
89263828|NCT05604196||STUDY GROUP|Study group included 79 people (48 women and 31 men), with BMI = 30.0-39.9 kg / m2) and excessive total body fat percent (TBF%) content (>30% TBF women and >25% TBF men).
89263829|NCT05604196||CONTROL GROUP|Control group included 41 people (31 women and 10 men), with BMI = 18.5-24.9 kg / m2) and normal total body fat percent (TBF%) content (20-30% TBF women and 15-20% TBF men).
89263830|NCT01136200|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
89263831|NCT01136200|No Intervention|Control|Patients not receiving infectious disease specialist advice
89263832|NCT02528968|Other|Educational Package|Patients will receive a standardised PK focused educational package in the form of a short video film.
89263833|NCT01231594|Experimental|Cohort A|Subjects who have received </= 8 weeks of GSK2118436 monotherapy in the parent study
89263834|NCT01231594|Experimental|Cohort B|Subjects who have received >8 weeks of continuous treatment with GSK2118436 either as monotherapy or combination therapy with another approved anti-cancer agent
89263835|NCT01231594|Experimental|Cohort C|Subjects who have received >8 weeks of continuous treatment with GSK2118436 in combination with a MEK inhibitor, GSK1120212
89263836|NCT01231672||Septic shock patients|
89263837|NCT01136278|Experimental|clonidine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
89263838|NCT05402722|Experimental|Eribulin in combination with anti-PD-1 antibody|Participants receive eribulin1.4mg/m2 and anti-PD-1 antibody intravenously (IV) every 3 weeks (Q3W) .
89263839|NCT03921268|Experimental|Treatment A|Dose A estimated delivered single dose of AZD1402 nebuliser solution administered via a nebuliser.
89263840|NCT03921268|Experimental|Treatment B|Dose B estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
89263841|NCT03921268|Experimental|Treatment C|Dose C estimated delivered single dose of AZD1402 inhalation powder administered via an inhaler.
89263842|NCT01232530||Safety Active Surveillance Group|For the active surveillance, all age groups, including children less than 5 years of age, will be identified from the census database and encouraged to attend the health facility whenever sick. Those with a diagnosis of malaria and treated with an antimalarial drug will be actively monitored for AEs.
89263843|NCT01232530||Safety Passive Surveillance Group|For the people under passive surveillance, sick subjects attending the health facilities, diagnosed with malaria and treated with an antimalarial drug will be identified from the census database. The treatment administered will be recorded in a drug exposure log book and the patients will be encouraged to report passively any AE/ADR.
89263844|NCT01232530||Early Pregnancy Exposure to ACTs Group|All the pregnant women identified during the repeat surveys will be included in a pregnancy cohort. At the time the pregnant woman is identified, her possible exposure to ACTs will be extracted from the drug exposure log book or elicited by history. Births identified through the repeat surveys or any other outcome of pregnancy will be retrospectively matched with antimalarial treatment exposure, particularly during the first trimester of the pregnancy.
89263845|NCT01232530||ACT Effectiveness Monitoring Group|"Besides monitoring AEs and ADRs, data on the effectiveness of ACTs when used in real life conditions and on a large scale will be collected in the active surveillance area. For patients with a microscopically confirmed diagnosis of malaria, clinical symptoms and a blood sample for thick and thin blood smears, will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. Treatment administration will not be supervised."
89263846|NCT01232608|Experimental|Exercise|12 months of exercise training
89263847|NCT01232608|No Intervention|Control|Normal follow-up by primary physician
89263848|NCT05597332|Other|Intervention|Insertion of care bundle in the electronic medical record of patients who develop AKI.
89263849|NCT03921346|Experimental|Arm A (mobile device app)|"Paramedics preparing drugs with the help of the mobile device app PedAMINES™.~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of the mobile device app PedAMINES™."
89263850|NCT03921346|Active Comparator|Arm B (conventional preparation method)|"Paramedics preparing drugs with the help of conventional method.~Each paramedic will have to prepare sequentially 4 direct IV emergency drugs with the help of conventional method"
89263851|NCT01137448|Experimental|Weight Loss|Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.
89263852|NCT01136512||metformin use|Patients with type 2 diabetes treated with metformin
89263853|NCT01136512||no metformin use|Patients with type 2 diabetes who are not being treated with metformin
89263854|NCT05480488|Other|• A (midazolam & warfarin), B (daridorexant, midazolam, & warfarin), & C (daridorexant & midazolam)|"Treatment A - midazolam and warfarin: In the morning of Day 1, subjects will receive a single oral dose of 2 mg midazolam concomitantly with a single oral dose of 25 mg warfarin under fasted conditions.~Treatment B - daridorexant, midazolam, and warfarin: Subjects will receive an o.d. oral dose of 50 mg daridorexant in the morning from Day 1 to Day 7 under fasted conditions. In addition, in the morning of Day 1, the oral administration of 50 mg daridorexant will be followed 1 h later by a single oral dose of 2 mg midazolam concomitantly with a single oral dose of 25 mg warfarin under fasted conditions.~Treatment C - daridorexant and midazolam: In the morning of Day 1, subjects will receive a single oral dose of 50 mg daridorexant followed 1 h later by a single oral dose of 2 mg midazolam under fasted conditions."
89263855|NCT03921112|Active Comparator|lung ultrasound|
89263856|NCT03921112|Active Comparator|x-ray, ABG, RSBI, Vetilator parameters|
89263857|NCT01229332|Placebo Comparator|Carbidopa|
89263858|NCT01229332|Placebo Comparator|Placebo|
89263859|NCT03921034|Active Comparator|continuous ACB with IPACK block|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and IPACK block with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine
89263860|NCT03921034|Sham Comparator|continuous ACB with sham subcutaneous saline injection|ACB bolused with 20 ml of ropivacaine 0.25% with 1:300,000 epinephrine followed by an 8 ml/hr continuous infusion of ropivacaine 0.2% and a sham IPACK block with subcutaneous saline injection along the medial thigh
89263861|NCT01136590|Experimental|tranexamic acid|tranexamic acid will be administered as a bolus (10-mg/kg dose ) or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery
89263862|NCT01136590|Placebo Comparator|placebo|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
89263863|NCT03920956|Experimental|Experimental: 24-hour ABPM by Pharmacists|Patients will meet with the pharmacist to be equipped with a 24-hour ambulatory blood pressure monitor (ABPM). Patients will return the monitor for the pharmacists to download the results to send to their medical provider.
89263864|NCT01229488|No Intervention|No Arms|Project was withdrawn before starting
89263865|NCT01137760|Placebo Comparator|Sugar pill|
89263866|NCT01137760|Experimental|Galactooligosaccharide 2.5 g|
89263867|NCT01137760|Experimental|Galactooligosaccharide 5.0 g|
89263868|NCT01233388||Text message surveillance|enroll for text message surveillance
89263869|NCT01137838||Patients with RA and new to abatacept|
89263870|NCT01137838||Patients with RA and new to infliximab|
89263871|NCT01137838||Patients with RA and new to etanercept|
89263872|NCT01137838||Patients with RA and new to adalimumab|
89263873|NCT03920878|Experimental|Aflibercept injected Pre- and Post-operatively|Pre- and Post-operative time of Aflibercept injections
89263874|NCT03920878|Active Comparator|Aflibercept injected intraoperatively|Intraoperative time of Aflibercept injection
89263875|NCT01136824||Sarcoma Subjects|Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy protocol of doxorubicin plus ifosfamide (AI)
89263876|NCT03920644|Experimental|DPI-386 Nasal Gel|Receives Active Nasal Gel 2 times per treatment day
89263877|NCT03920644|Placebo Comparator|Placebo nasal gel|Receives Nasal Gel 2 times per treatment day
89263878|NCT03920644|Active Comparator|TDS Patch|Receives one patch per treatment.
89263879|NCT01131832|Experimental|Plant sterol|Plant sterol supplementation, 2 grams per day of plant sterols in a margarine
89263880|NCT01137916|Experimental|drug|Imatinib 800 mg
89263881|NCT01233544|Experimental|Stereotactic body radiation therapy|Colorectal liver metastases treated by SBRT
89263882|NCT01233544|Active Comparator|Radiofrequency ablation|Colorectal liver metastases treated by RFA
89263883|NCT01137994|Experimental|Lapatinib plus Chemotherapy|Lapatinib (1250mg once daily) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
89263884|NCT01137994|Experimental|Trastuzumab plus Chemotherapy|Trastuzumab (either 6mg/kg q3-weekly or 2mg/kg weekly) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
89263885|NCT05434390|Experimental|Latino MSM PrEP intervention|The Latino MSM PrEP intervention consists of 4 small group sessions with concurrent peer navigation and counseling.
89263886|NCT05434390|Active Comparator|Control condition|The control condition consists of usual care at the study site (i.e., referrals to PrEP services).
89263887|NCT01138072|Experimental|Treatment A|Simvastatin 20mg (single dose) Day 1
89263888|NCT01138072|Experimental|Treatment B|Atorvastain 20 mg (single dose) Day 3
89263889|NCT01138072|Experimental|Treatment C|Rosuvastatin 10mg (single dose) Day 7
89263890|NCT01138072|Experimental|Treatment X|GSK2248761 200mg single dose Day 10-14, Day 16-17, Day 19-21, Day 23-24
89263891|NCT01138072|Experimental|Treatment D|GSK2248761 200mg + simvastatin 20 mg Day 15
89263892|NCT01138072|Experimental|Treatment E|GSK2248761 200mg + atorvastatin 20 mg Day 18
89263893|NCT01138072|Experimental|Treatment F|GSK2248761 200mg + rosuvastatin 20 mg Day 22
89263894|NCT01138228||Normal vision|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
89263895|NCT01138228||Vein Imaging Device|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
89263896|NCT01136902||Type 2 DM|This group includes subjects diagnosed with type 2 diabetes mellitus with none or minimal diabetic retinopathy.
89263897|NCT01229566|Active Comparator|Active Comparator|Active comparator
89263898|NCT01229566|Placebo Comparator|Placebo|Placebo control
89263899|NCT01229566|Experimental|AKR-963|Investigational drug
89263900|NCT01232686|No Intervention|Control area|In the control areas we will monitor the prevalence and treatment of communicable diseases without giving the participants online access to disease surveillance information
89263901|NCT01232686|Experimental|Intervention area|In these areas we will give study participants online access to epidemiological data for communicable diseases
89263902|NCT01131910|Experimental|Vaccination against TBE|"Less than 60 years old: Two doses of TBE- vaccine separated by a month and a third dose 12 months after the first dose~60 years and above: Three doses, given at 0+1+3 months and a 4 th dose 12 months after the first dose"
89263903|NCT03739606|Experimental|Treatment (flotetuzumab)|Patients receive flotetuzumab IV continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (PR, SD) that did not meet CR, CRi, CRh or MLFS criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89263904|NCT01232764|Experimental|Multi-disciplinary wound care team|Stepped wedge study design i.e. start date of exposure is randomized.
89263905|NCT01136980|Placebo Comparator|Sham placebo procedure|Sham Procedure: SHAM/PPI's An upper GI Endoscopy is performed with a standard endoscope, during 30-45 minutes. The patient is under general anesthesia. EGD explores the esophagus, the stomach, and the GEJ.
89263906|NCT01136980|Active Comparator|TIF Transoral Fundoplication|Intervention: TIF 2.0/Placebo TIF Transoral Incisionless Fundoplication: A fundoplication of 270 degrees and 3cm in length was created. The EsophyX device is introduced over a standard endoscope, through the mouth, into the stomach.
89263907|NCT01137058|Experimental|U-healthcare|glucose meter and U-healthcare
89263908|NCT01137058|Active Comparator|SMBG group|Diabetic patients who do self monitoring of blood glucose only were categorized into self monitoring of blood glucose (SMBG) group.
89263909|NCT01137058|No Intervention|control|conventional treatment
89263910|NCT01233622|Experimental|Vildagliptin (metformin + glimepiride)|
89263911|NCT01233622|Placebo Comparator|Placebo (metformin + glimepiride)|
89263912|NCT01137136||SMAC (SMc AI user Cohort)|All patients who took the AI (Aromatase inhibitor)will be enrolled
89263913|NCT01137214|Active Comparator|CPAP|Continuous Positive Airway Pressure
89263914|NCT01137214|Active Comparator|Adaptive Servo-Ventilator|Non-invasive positive pressure ventilator that applies a constant expiratory pressure, as well as a variable inspiratory pressure.
89263915|NCT01138462|No Intervention|Standard Precautions|control arm, standards precautions for all residents living in the nursing home of control arm, including MRSA carriers
89263916|NCT01138462|Other|Intervention|Intervention arm, standards precautions for all residents living in nursing homes of intervention arm, and topical decolonization for MRSA carriers, including environmental disinfection
89263917|NCT05513014||Secukinumab: Overall Cohort|Patients with Psoriasis who initiated Secukinumab
89263918|NCT05513014||Biologic Experienced|Patients who had the history of use of ≥1 biologic medication for the treatment of PsO at the time of SEC initiation
89263919|NCT05513014||Biologic Naive|Patients who had no history of use of biologic medication for the treatment of PsO at the time of SEC initiation
89263920|NCT01138540|Active Comparator|Semirecumbent position|Semirecumbent position of patients on mechanical ventilation in the bed of the ICU
89263921|NCT01138540|Experimental|lateral-Trendelenburg position|lateral-Trendelenburg position of patients on mechanical ventilation in the bed of the ICU
89263922|NCT01138618||CHEMPAQ-venous-CHEMPAQ-venous|The two arms only differ in order of kind of blood samples.
89263923|NCT01138618||Venous-CHEMPAQ-Venous-CHEMPAQ|The two arms only differ in order of kind of blood samples.
89263924|NCT01138774|Placebo Comparator|Control group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements
89263925|NCT01138774|Experimental|EPA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).
89263926|NCT01138774|Experimental|Lipoic acid group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)
89263927|NCT01138774|Experimental|EPA+LA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).
89263928|NCT01131988|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
89263929|NCT01131988|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
89263930|NCT01229800|Active Comparator|Split dose PEG|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes.
89263931|NCT01229800|Active Comparator|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
89263932|NCT05497258|Experimental|Experimental: with Artificial intelligence assistant system|"The physicians were additionally provided with the feature extracted by the system, a list of suspicious diagnoses predicted by IDEAS-AAP, and corresponding diagnostic criteria according to guidelines. After the readers get the examination results, the IDEAS-AAP will renew its diagnosis prediction.~IDEAS-AAP extracted feature from electronic health record, provided a list of suspicious diagnoses, and corresponding diagnostic criteria according to guidelines. After the readers get the examination results, the IDEAS-AAP will renew its diagnosis prediction."
89263933|NCT05497258|No Intervention|No Intervention: without Artificial intelligence assistant system|
89263934|NCT01232998||Patient Satisfaction with nursing care|
89263935|NCT01232998||satisfaction of waiting time for first time visit|
89263936|NCT01232998||patient satisfaction|
89263937|NCT01234558|Placebo Comparator|Normal Saline|IV placebo
89263938|NCT01234558|Experimental|GLYX-13, 1 mg/kg|
89263939|NCT01234558|Experimental|GLYX-13, 5 mg/kg|
89263940|NCT01234558|Experimental|GLYX-13, 10 mg/kg|
89263941|NCT04797364|Experimental|Pharmacogenetic Testing|Pharmacogenetic testing panel (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, NUDT15, SLCO1B1, TPMT, VKORC1)
89263942|NCT01138852|Experimental|ampicillin-sulbactam|This is the drug used to prevent post-cesarean infection
89263943|NCT01138852|Active Comparator|cefuroxime|This drug was compared to ampicillin sulbactam for prevention of infection
89263944|NCT01138930|Experimental|Berberine|
89263945|NCT01138930|Placebo Comparator|Placebo|
89263946|NCT01139086||Cardiovascular disease|Diagnosis of cardiomyopathy or ischemic heart disease without heart failure
89263947|NCT01139086||Chronic heart failure|Diagnosis of cardiomyopathy or ischemic heart disease LVEF <40%
89263948|NCT01139086||Control|Age and body built matched with chronic heart failure group
89263949|NCT01233154|Experimental|L. paracasei|L. paracasei
89263950|NCT01233154|Experimental|L. acidophilus + B. lactis|L. acidophilus + B. lactis
89263951|NCT01142752||Control|Control group of women with uneventful pregnancy
89263952|NCT01142752||Population at risk with preterm birth|Women medically considered at risk for PTB and actually delivering preterm
89263953|NCT01142752||Population at risk without preterm birth|Women medically considered at risk for PTB but with uneventful pregnancy
89263954|NCT04764994|Active Comparator|Control Group|"Participants who will participated in the control group will receive a conventional physical therapy program for two hours. It will include two parts, each of them will be one hour and 15 minutes rest in between. The first part will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises. The second part will include: arm-reaching tasks, arm-hand tasks, manipulative tasks (grasping and release activities) and upper limb self-dependent tasks and the inclusion of the more affected upper limb in functional tasks of daily living activities.~The conventional treatment program will be applied for both groups by therapists, experienced in stroke rehabilitation.~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
89263955|NCT04764994|Experimental|Study Group|"Participants of study group will receive two hours treatment program that will include three parts, the first and the second parts (similar to that will be applied for participants in control group) will be together for one hour following by 15 minutes rest, then the third part will apply for one hour. The third part of the program will be one hour virtual reality intervention program by using Armeo Spring to simulate a range of upper limb tasks related to arm-reaching to target, reach and grasp (arm-hand activities) and manipulative tasks through using different games and soft-wares.~The conventional treatment part of the program will be applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program will be applied by another experienced physiotherapists, who are well trained in using Armeo Spring System.~Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks."
89263956|NCT01585870|Experimental|Sorafenib + Eribulin|
89263957|NCT01234636|Active Comparator|cis9,trans 11 CLA oil|50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA
89263958|NCT01234636|Placebo Comparator|Placebo oil|50 volunteers cross over design, placebo oil 4g/day
89263959|NCT04746820|Experimental|Experimental (unconscious)|fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
89263960|NCT04746820|Sham Comparator|Control group (healthy, conscious)|fNIRS will be compared to evoked potentials in an experimental group (unconscious neuro-intensive care patients) and in a control group (healthy, conscious subjects)
89263961|NCT01236274||Antipsychotic agents AND MI|In the self-controlled case series study, patients who experienced a myocardial infarction and received an antipsychotic agent during up to standard (UTS) follow-up in the GPRD will be included and will act as their own control.
89263962|NCT01236274||Myocardial Infarction|In the case-control study, all cases with a first recorded occurrence of MI during up to standard (UTS) follow-up in the GPRD will be identified
89263963|NCT01236274||No Myocardial Infarction|In the case-control study, a control group with subjects who never experienced a myocardial infarction will be matched to cases (5:1) by age, gender, General Practitioner and registration in the GPRD on the date of MI of the case
89263964|NCT05222464|Other|Standard of Care Intervention|Standard of care intervention - The intervention will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
89263965|NCT03738436|Active Comparator|traditional neuromuscular training, NMT|Eight-week physical therapy program consisted of neuromuscular training (NMT) starting from 4 weeks post-surgery. The NMT program includes re-position exercise, strengthening, stretching, landing and balance training.
89263966|NCT03738436|Experimental|modified visual feedback, MVF|Starting from 4 weeks post-surgery, eight-week physical therapy program consisted of traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles.
89263967|NCT05210140||Standard dose|Patients are allocated to this group at visit V1 if 10 mg/day escitalopram treatment resulted in optimal escitalopram exposure (25-50 ng/ml) as measured at VK. These patients will continue their treatment with 10 mg/day during the V1-V2 period.
89263968|NCT05210140||Adjusted dose|Patients are allocated to this group at visit V1 if 10 mg/day escitalopram dose resulted in to high (>50 ng/ml) or to low (<25 ng/ml) escitalopram exposure, as measured at VK. These patients will be treated with the adjusted escitalopram dose, different from 10 mg/day, during the V1-V2 period.
89263969|NCT01142986|Experimental|Low Threshold Stepped Care (LTSC)|Subjects in this condition will receive low intensity care during the first 3-months (13 weeks) of study participation, and usual counseling care during the final 3-months (13 weeks) of participation.
89263970|NCT01142986|Experimental|Voucher-Based Stepped Care (VBSC)|Subjects in this condition will receive usual counseling care during the entire 6 months of study participation. They will receive voucher reinforcement, and will have the opportunity to earn voucher incentives during the first 3-months of care (13 weeks).
89263971|NCT01142986|No Intervention|Routine Stepped-Care (RSC)|Subjects in this condition will receive usual counseling care during the entire 6-month study (26 weeks).
89263972|NCT01329718|Experimental|CRC Group|
89263973|NCT01233934|Active Comparator|Dexchlorpheniramine 1% Cream|
89263974|NCT01233934|Experimental|Dexchlorpheniramine 1% Gel|
89263975|NCT01236508|Experimental|Nuclear imaging|PET/CT imaging with F-18 fluorodeoxyglucose
89263976|NCT05195944|Experimental|Semaglutide|In the Semaglutide Arm, participants will receive daily: 1 tablet of Semaglutide and 1 tablet of Sitagliptin placebo for 26 weeks. The dosages of Semaglutide are 3 mg, 7 mg, and 14 mg.
89263977|NCT05195944|Active Comparator|Sitagliptin|In the Sitagliptin arm, participants will receive daily: 1 tablet of 100 mg Sitagliptin and 1 tablet of Semaglutide placebo for 26 weeks.
89263978|NCT05185882||1|"Single leg squat without a clue or focusing method~Single leg squat with an external focus~Sinlge leg squat with an internal focus"
89263979|NCT01140802||IBD patients|Crohn's disease or ulcerative colitis patients
89263980|NCT01140802||Healthy controls (non-IBD)|Patients comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding
89263981|NCT01140802||Relatives of IBD patients|They will be a first degree relative of a IBD patient.
89263982|NCT03559270|Experimental|Placebo/Baricitinib 2-milligram (mg)|Open-label 2 mg baricitinib administered orally once daily (QD) to participants who randomized to placebo in the originating study (JAIW).
89263983|NCT03559270|Experimental|Baricitinib 1-mg/Baricitinib 2-mg|Open-label 2 mg baricitinib administered orally QD to participants who randomized to 1 mg baricitinib in the originating study (JAIW).
89263984|NCT03559270|Experimental|Baricitinib 2-mg/Baricitinib 2-mg|Open-label 2 mg baricitinib administered orally QD to participants who randomized to 2 mg baricitinib in the originating study (JAIW).
89263985|NCT03559270|Experimental|Baricitinib 2-mg Open-Label Addendum|Participants were directly enrolled to receive open-label 2 mg baricitinib orally QD.
89263986|NCT05136586|Experimental|Biofeedback|Relaxing breathing exercise coupled with biofeedback before the circuit, no intervention after
89263987|NCT05136586|Experimental|Meditation|Meditative stimulation audio tape before the circuit, no intervention after
89263988|NCT05136586|Experimental|Control and biofeedback post OSCE|Standardised video before the circuit, Relaxing breathing exercise coupled with biofeedback after the OSCE
89263989|NCT05136586|Sham Comparator|Control and control post OSCE|Standardised video before the circuit, no intervention after
89263990|NCT01234792|Experimental|NIC-6|6 mg Experimental nicotine gum
89263991|NCT01234792|Active Comparator|NIC-4|4 mg Nicotine Gum
89263992|NCT01234792|Active Comparator|NIC-2|2 mg Nicotine Gum
89263993|NCT01143220||ICD / CRT-D patient|Patients implanted with a single or dual chamber ICD or CRT-D device approved in Japan capable of using the IBP feature.
89263994|NCT03467932|Active Comparator|Cohort A: ORMD-0801 once daily - QHS|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
89263995|NCT03467932|Active Comparator|Cohort A: ORMD-0801 twice daily - BID|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
89263996|NCT03467932|Active Comparator|Cohort A: ORMD-0801 three times daily - TID|ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
89263997|NCT03467932|Placebo Comparator|Cohort A: Matched Placebo Oral Capsule|Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
89263998|NCT03467932|Placebo Comparator|Cohort A: Excipient-Matched Placebo three times daily-TID|"Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.~This is an exploratory arm, per FDA. The results of this arm are not included in the primary analysis."
89263999|NCT03467932|Active Comparator|Cohort B:ORMD-0801, 8 mg once daily - QHS:|ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
89264000|NCT03467932|Active Comparator|Cohort B: ORMD-0801 8 mg twice daily - BID|ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
89264001|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg once daily - QHS:|ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
89264002|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg twice daily - BID|ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
89264003|NCT03467932|Placebo Comparator|Cohort B - Matched Placebo Oral Capsule|Cohort B - Matched Placebo Oral Capsule: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
89264004|NCT01585948||Diabetes Mellitus|All patients undergoing coronary angiography who are diabetics.
89264005|NCT01585948||No diabetes mellitus|All patients undergoing coronary angiography that are non-diabetics.
89264006|NCT01585948||Coronary angiography patients|Diabetics and non-diabetics with or without known CV disease who are admitted in the Department of Cardiology in the University Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. The study will include subjects who 1) have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic angiography (with or without previous history of CAD).
89264007|NCT01234012|Experimental|Treatment: IMF-001|100 or 200 mcg will be administered to patients subcutaneously every 2 weeks for 6 injections.
89264008|NCT01236664|Experimental|Memory Training|
89264009|NCT01236664|Active Comparator|Control workshop|
89264010|NCT03396016||Factor V|liver transplant patients having Factor V levels measured during their first postoperative week.
89264011|NCT01234090||Persons with Aphasia|
89264012|NCT01234948||Chronic periodontitis patients|Chronic periodontitis patients had at least one site per quadrant with clinical probing depth (CPD) > 5mm and radiographic evidence of bone loss
89264013|NCT01234948||Generalised chronic gingivitis patients|Generalised chronic gingivitis patients presented with bleeding on probing (BOP) at > 30% of sites, CPDs < 4mm and no evidence of bone loss
89264014|NCT01234948||Periodontally healthy subjects|Healthy subjects had < 10% sites with BOP and no sites with CPD > 3mm
89264015|NCT01143298|Experimental|LEO 27847 oral solution 0.1 mg|LEO 27847 oral solution 0.1 mg
89264016|NCT01143298|Experimental|LEO 27847 tablet 0.10 mg|LEO 27847 tablet 0.10 mg
89264017|NCT01143298|Experimental|LEO 27847 tablet 0.01 mg|LEO 27847 tablet 0.01 mg
89264018|NCT01143376|Active Comparator|Moderate intensity exercise|Moderate intensity exercise
89264019|NCT01143376|Experimental|High Intensity training|High Intensity intermittent training
89264020|NCT01143376|Experimental|Short springs|short springs training
89264021|NCT03318172|Experimental|Group C spinal cord stimulator|Spinal cord stimulator (SCS) implantation with conventional stimulation mode therapy during 2 weeks followed by 2 weeks with high-density stimulation mode therapy.
89264022|NCT03318172|Active Comparator|Group H spinal cord stimulator|Spinal cord stimulator (SCS) implantation with high-density stimulation mode therapy during 2 weeks followed by 2 weeks with conventional stimulation mode therapy.
89264023|NCT04618822|Experimental|Teaching involving whole-body movements|
89264024|NCT04618822|Experimental|Teaching involving hand movements|i.e. arms and hands
89264025|NCT04618822|Active Comparator|teaching involving minimal motor movements|i.e. seated on a chair using paper and pencil
89264026|NCT01139788|Experimental|LY2624587|
89264027|NCT03250390|Experimental|patients|Patients with bronchopulmonary cancer who have not yet received therapeutic treatment.
89264028|NCT03250390|Active Comparator|controls|The controls consisted of 2 groups: smokers and non-smokers.
89264029|NCT01139944||Group 1|Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
89264030|NCT05632666|Experimental|Active treatment group|
89264031|NCT05632666|Sham Comparator|Sham-controlled group|
89264032|NCT01140022||Female Patients 18-25 yo|Female patients aged 18-25 who have come to one of the ED or urgent care sites for care, regardless of the presence of CT symptoms.
89264033|NCT01140100|Active Comparator|propofol-propofol|
89264034|NCT01140100|Experimental|thiopental-propofol|
89264035|NCT01141036|Active Comparator|propofol|propofol
89264036|NCT01141036|Active Comparator|Midazolam|Midazolam
89264037|NCT01235026|Experimental|Synbiotic|"Dietary Supplement: Synbiotic: combination of the prebiotic Oligofructose with the probiotic Bifidobacterium animalis subsp. lactis Bb12"
89264038|NCT01235026|Placebo Comparator|Placebo|Dietary supplement: placebo: maltodextrin
89264039|NCT01141114|Experimental|Use of a Patient Navigator|
89264040|NCT01141114|Other|Usual Care|No Intervention - usual care
89264041|NCT04977856|Experimental|Guided ICBT|Participants in guided ICBT will receive internet-delivered CBT with therapist support. The treatment consists of 8 online modules with interactive features such as videos and illustrations, delivered over a maximum of 10 weeks. The main treatment focus is behavioral activation. The adolescent and the caregiver are provided with their own separate programs and login to the treatment platform. The caregiver's program also consists of 8 chapters, including psychoeducation about depression and how to support their adolescent in treatment. The adolescents and caregivers have regular contact with a personal assigned therapist via written text messages in the platform. Participants are typically in contact with their therapist several times a week. The adolescent and caregiver can continue to access all treatment modules for the whole follow-up period (3 months), but without therapist-support.
89264042|NCT04977856|Experimental|Self-guided ICBT|The self-guided arm is identical to the guided arm, however without the therapist support. To ensure patient safety, there will be clear instructions to the patients and primary caregivers on how to get in contact with the study team in case of acute problems, and there will be clinical routines to detect and manage deterioration or suicidal tendencies.
89264043|NCT04977856|Active Comparator|Treatment as usual (TAU)|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical, or a combination of both. The content of TAU and the treatment techniques used will be monitored.
89264044|NCT04971850|Experimental|Sleep-disordered breathing (SDB)|Patients aged 1 to 20 years old with a suspicion of SDB or a high-risk of SDB due to their pathology and hospitalized at Necker Hospital for a sleep study for their clinical care.
89264045|NCT01236820||Normal|Healthy population
89264046|NCT01236820||CKD Patients|Chronic Kidney Disease, in Stage III-V
89264047|NCT01236820||HD patients|End-stage renal disease patients undergoing hemodialysis
89264048|NCT01143844||Exposed females, ages 11-40|"Prior exposure to alkylating agent chemotherapy and/or radiation therapy~At least 1 year from completion of chemotherapy and/or radiation therapy~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition (other than cancer) known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
89264049|NCT01143844||Unexposed females, ages 40-50|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
89264050|NCT01143844||Unexposed females, ages 11-35|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
89264051|NCT01140178|Experimental|HPPH|a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.
89264052|NCT01235104||Total nephrectomy|
89264053|NCT01143922||Patients with gastrointestinal tract malignancies|All patients with GI tract malignancies undergoing surgery will be subjected to intraoperative ultrasound
89264054|NCT01236898|Experimental|NPC-09|Period 1: NPC-09 800mg single oral dosing NPC-09 800mg three times oral dosing a day Period 2: NPC-09 800mg three times oral dosing a day for 5 consecutive days
89264055|NCT01234246||Patients with colorectal cancer|Patients with colorectal cancer are included
89264056|NCT01234246||Partners|Partners of patients with colorectal cancer are included
89264057|NCT01140256||SGA infants|SGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
89264058|NCT01140256||AGA|AGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
89264059|NCT01140256||SGA infant|Infants who were born small for gestational age were recruited and zinc stable isotopes were administered at birth and at 6 months.
89264060|NCT04906720|No Intervention|Standard of care|Usual standard of care post atrial fibrillation ablation.
89264061|NCT04906720|Experimental|Colchicine|0.6mg colchicine oral twice daily for 7 days.
88805274|NCT01372813|Other|Clear Cell Renal Carcinoma|Clear cell renal cancer is a highly vascular tumor characterized by mutations in the von Hippel-Lindau (VHL) gene in the majority of patients, an alteration that leads to overexpression vascular endothelial growth factor (VEGF) as well as other genes such as transforming growth factor-alpha, platelet derived growth factor and glucose transporter 1. Patients received ZD6474 300 mg/day by mouth daily on days 1-28.
88805275|NCT00124514|Experimental|Triptorelin T1|Triptorelin Pamoate 25 μg/kg body weight
89264062|NCT01140334|Experimental|Reinforced On-Site Integrated Care (ROIC)|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. In addition, they will be able to earn a voucher incentive for each week of psychiatric compliance.
89264063|NCT01140334|Active Comparator|Standard On-Site Integrated Care (SOIC).|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week.
89264064|NCT01141192|Active Comparator|Vitamin D3 supplement|60,000 IU vitamin D3 oral supplement provided every four weeks at weeks 0, 4, 8, and 12 in the form of one 50,000 and two 5,000 IU vitamin D3 supplements in gelcap form.
88805276|NCT00124514|Experimental|Triptorelin T2|Triptorelin Pamoate 50 μg/kg body weight
89264065|NCT01141192|Placebo Comparator|Sugar Pill|Inactive placebo tablets identical in appearance to the active comparator provided every four weeks at weeks 0,4,8,and 12.
89264066|NCT01144000|Experimental|Daptomycin|High dose Daptomycin in hip, knee and shoulder prosthesis infections
89264067|NCT01235182||acute dyspnea, field, diagnostic|All patients with shortness of breath as the primary complaint (defined as eitherthe sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea and were age >18 years.
89264068|NCT01144078|Experimental|High Intensity Interval Exercise|This arms receives the High Intensity Interval Exercise intervention
89264069|NCT01144078|Experimental|Traditional Intensity Exercise|This arms receives the Traditional Intensity Exercise intervention
89264070|NCT01140412|Experimental|Cohort 1|Twice daily regimen
89264071|NCT01140412|Experimental|Cohort 2|Once daily regimen
88805277|NCT00124514|Experimental|Triptorelin T3|Triptorelin Pamoate 75 μg/kg body weight T3
88805278|NCT00124514|Experimental|Triptorelin T4|Triptorelin Pamoate 100 μg/kg body weight T4
89264072|NCT02615860|Experimental|Topical 85% trichloroacetic acid (TCA)|AIN lesions are treated with trichloric acid
89264073|NCT02615860|Active Comparator|Surgical electrocautery (ECA)|AIN lesions are treated with electrocautery
89264074|NCT01234324|Experimental|Arm 1: ECX + Panitumumab|
89264075|NCT01234324|Active Comparator|Arm 2: EXC alone|
89264076|NCT01236976|Experimental|Intervention Group|Participants in Group A will receive a triad of interventions comprising body weight supported treadmill training (BWSTT) using the Therastride Treadmill System, functional electrical stimulation (FES)-assisted cycling, and trunk and upper and lower limb exercise. These interventions will be provided at the spinal unit.
89264077|NCT01236976|Other|Control Group|Participants in Group B will receive an upper body strength and fitness program. This program may be provided at the spinal unit, or an appropriately equipped gymnasium as approved by the SCIPA Full-On Project Committee. It will be based on the Burn Rubber Burn (BRB) exercise program already established in Sydney. BRB is a circuit-based exercise program incorporating resistance and cardiovascular training. For this protocol, the circuit will comprise several stations using different pieces of equipment.
89264078|NCT02334124|Experimental|Home|Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
89264079|NCT02334124|Active Comparator|Ward|Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.
89264080|NCT01140490|No Intervention|Sub-total Parathyroidectomy|
89264081|NCT02528812|Experimental|Ipsi-R|Intervention group 1 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf that exhibited the higher tenderness (Ipsilateral Rolling: Ipsi-R)
89264082|NCT02528812|Experimental|Contra-R|Intervention group 2 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf of the contralateral limb (Contralateral Rolling: Contra-R)
89264083|NCT02528812|Sham Comparator|Sham group|The sham group received light stroking of the skin with TheraBand roller massager on the calf that exhibited the higher tenderness
89264084|NCT02528812|Experimental|Ipsi-M|Intervention group 3 included participants receiving manual massage on the calf that exhibited the higher tenderness (Ipsilateral Manual: Ipsi-M)
89264085|NCT02528812|No Intervention|control group|received no intervention
89264086|NCT01141270|Experimental|AFOLIA|225 IU sc
89264087|NCT01141270|Active Comparator|Gonal-f|225 IU sc
89264088|NCT01141348|Experimental|Special Intervention|
89264089|NCT01141348|Experimental|Delayed Intervention|
89264090|NCT04860934|Active Comparator|Physical therapy|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks
89264091|NCT04860934|Experimental|Physical therapy + Dual Task Training Program|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the selected physical therapy program as control group three times weekly for 8 successive weeks.
89264092|NCT01141504|Placebo Comparator|Placebo|Oral placebo capsules similar in color and size to the intervention
89264093|NCT01141504|Active Comparator|PeakATP 250|Oral supplement capsules containing 250 mg/day of PeakATP
89264094|NCT01141504|Active Comparator|PeakATP 400|Oral supplement capsules containing 400 mg/day of PeakATP
89264095|NCT01141504|Active Comparator|PeakATP 400 plus proprietary blend|Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend
89264096|NCT05632432|Active Comparator|CABG arm (control)|In total, 25 patients are recruited to form the CABG group. During CABG surgery, RAA tissue is removed as detailed for the AAMs-patch group. However, the tissue is collected as a sample for later analyses rather than processed to AAMs (Method 4). CABG is performed without epicardial transplantation of AAMs-patch.
89264097|NCT05632432|Experimental|CABG + AAMs arm (intervention)|In total, 25 patients are recruited to the AAMs-patch group. Here, the AAMs are prepared from the RAA tissue sample by mechanical processing in the operating room during the CABG surgery. The RAA tissue piece is removed during right atrial cannulation, a part of the routine setup of cardiopulmonary bypass. To form an AAMs-patch, the AAMs, embedded in fibrin matrix gel, are placed onto an ECM sheet. This AAMs-patch is kept cold, covered, and sterile until the last stages of CABG surgery. After all the coronary anastomoses are done, the AAMs-patch is epicardially transplanted onto the area identified by preoperative LGE-CMRI to have most suffered from ischemia.
89264098|NCT01235260||001|Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)
89264099|NCT01235260||002|Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
89264100|NCT05396950|Experimental|CPAP Planned|Radiotherapy planning with CPAP in addition to standard plans
89264101|NCT01144858||patients with persistent atrial fibrillation ablation|
89264102|NCT01144234|Experimental|Invitation letter to male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
89264103|NCT01144234|Placebo Comparator|Information letter|In this arm the pregnant women got an information letter about antenatal care.
89264104|NCT01144312|Experimental|pharmacokinetics of fentanyl|
89264105|NCT05395780|Experimental|High-dose MAX-40279 group|High-dose MAX-40279 capsule group (10-15 subjects, 70 mg, BID, PO)
88805279|NCT00124514|Placebo Comparator|Placebo|Normal Saline
88805280|NCT01373671|Other|Mammography exam|Siemens DBT scan
89264106|NCT05395780|Experimental|Low-dose MAX-40279 group|Low-dose MAX-40279 capsule group (10-15 subjects, 50 mg, BID, PO)
89264107|NCT01237288|Experimental|Z-521|
89264108|NCT01238068|Active Comparator|Gamma nail, fracture stabilization, better walking|
89264109|NCT01237366|Experimental|Reslient Affective Processing Therapy (RAPT)|
89264110|NCT01237366|No Intervention|Attention-Control|Participants will complete 7 sessions where they will be asked to write about neutral topics and complete psychological measures for the purposes of matching for attention and reimbursement.
89264111|NCT01144390|Experimental|CBT plus MMT|cognitive behavioral therapy for heroin addicts with methadone maintenance treatment
89264112|NCT01144390|Active Comparator|methadone maintenance treatment|methadone maintenance treatment for heroin addicts
89264113|NCT01144936|Experimental|Panel 1: VX-985 Dose 1|
89264114|NCT01144936|Experimental|Panel 2: VX-985 Dose 2|
89264115|NCT01144936|Experimental|Panel 3: VX-985 Dose 3|
89264116|NCT01144546|Experimental|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before anesthesia induction
89264117|NCT05350540|Experimental|ICG|This study will use intraoperative ICG imaging to assess recipient pharyngeal tissue perfusion. The ICG is the vascular contrast agent and the SPY Elite is the imaging device. 3mL of ICG will be injected using a peripheral IV access, followed by a 10mL saline flush. The pharyngeal mucosa will be imaged to quantify the tissue perfusion. Poorly perfused areas (less than 25%) will be debrided
89264118|NCT05350540|No Intervention|Control|Patients assigned to the observation (control) group will undergo standard of care reconstruction of mucosa
89264119|NCT01145014|Experimental|BI 660848 2 mg|oral drinking solution
89264120|NCT01145014|Experimental|BI 660848 10 mg|oral drinking solution
89264121|NCT01145014|Experimental|BI 660848 20 mg|oral drinking solution
89264122|NCT01145014|Experimental|BI 660848 50 mg|oral drinking solution
89264123|NCT01145014|Experimental|BI 660848 100 mg|oral drinking solution
89264124|NCT01145014|Experimental|BI 660848 150 mg|oral drinking solution
89264125|NCT01145014|Experimental|BI 660848 200 mg|oral drinking solution
89264126|NCT01145014|Experimental|BI 660848 400 mg|oral drinking solution
89264127|NCT01145014|Experimental|BI 660848 600 mg|oral drinking solution
89264128|NCT01145014|Experimental|BI 660848 10,0 mg|immediate release tablet
89264129|NCT01145014|Experimental|BI 660848 50,0 mg|immediate release tablet
88805281|NCT02538900|Experimental|Group 1|Low-intensity, self-paced walking exercise. Home based exercise.
89264130|NCT01145014|Experimental|Placebo|matching placebo (oral drinking solution and IR tablets)
89264131|NCT01329640|Experimental|Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide|
89264132|NCT05335018|Experimental|Treatment|"total 2years. Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
89264133|NCT00114777|Active Comparator|Cyclosporin A|
89264134|NCT00114777|Experimental|Belatacept Less Intensive Regimen (LI)|
89264135|NCT00114777|Experimental|Belatacept More Intensive Regimen (MI)|
89264136|NCT03965559||plasmapheresis group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the plasmapheresis during January 2006 to October 2015
89264137|NCT03965559||double filtration plasmapheresis (DFPP) group|Kidney transplant patients who had been diagnosed or suspected of graft rejection and underwent the double filtration plasmapheresis (DFPP) during January 2006 to October 2015
89264138|NCT03965793|Active Comparator|Manual management of hypotension|Fluid and vasopressor will be managed as standard practice ( manually infusion of both fluid and vasopressors) following the investigators manual individualized hemodynamic protocol.(objective being to keep both stroke volume and MAP within 90 % of the target values)
89264139|NCT03965793|Experimental|Automated management of hypotension|Fluid and vasopressor will be managed with a novel active clinical decision support system to guide fluid administration and automated closed-loop system to maintain MAP within 90% of patient' baseline.
89264140|NCT00122187|Experimental|Electronic Consult System|A new consult system designed to automatically send a gastroenterology consult request for patients with positive fecal occult blood testing (FOBT+) results
89264141|NCT00122187|No Intervention|Usual Care|The usual and customary procedures for addressing FOBT+ results: primary care physicians continued to be responsible for follow up of FOBT+ results.
89264142|NCT00139659|Experimental|Inhaled Insulin|
89264143|NCT00139659|Active Comparator|Subcutaneous Insulin|
89264144|NCT00137631|Experimental|Many Men, Many Voices (3MV) Intervention|Receive 6-session intervention immediately after baseline assessment and randomization
89264145|NCT00137631|No Intervention|Wait list comparison|Receive intervention after 6-month delay (wait list control group)
89264146|NCT01582815|Experimental|JNJ-40411813|
89264147|NCT01582815|Placebo Comparator|Placebo|
89264148|NCT01076439|Active Comparator|Olopatadine Nasal Spray (Patanase)|
89264149|NCT01076439|Active Comparator|Fluticasone Furoate Nasal Spray (Veramyst)|
89264150|NCT01076439|Placebo Comparator|Saline Nasal Spray (Placebo)|
89264151|NCT01078701|Experimental|GHB11L1|Dose levels: 6.0 log10 TCID50/volunteer, 6.5 log10 TCID50/volunteer and 7.0 log10 TCID50/volunteer
89264152|NCT01078701|Placebo Comparator|SPGN buffer|SPGN buffer administration by liquid nasal spray
89264153|NCT01582893|Experimental|HCO1100-P14L|HCO1100 is connected in row with low flux dialyzer P14L
89264154|NCT01582893|Active Comparator|P210H|High flux Filter P210H
89264155|NCT03965715|No Intervention|Gait analysis with barefoot|Participants walk without assistance under gait detection.
89264156|NCT03965715|Experimental|Gait analysis with AFOs|Participants walk with AFOs under gait detection.
89264157|NCT03965715|Experimental|Satisfaction questionnaire|User feedback from the participants was obtained by questionnaire, the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) and SF-36, to compare the satisfaction of AFOs
89264158|NCT03965637|Experimental|vitamin C|Intervention patients will be received double dose of Ascorbic acid via intravenous injection
89264159|NCT03965637|No Intervention|Control|Control patients will not be received any intervention
89264160|NCT01078779|Experimental|Chloroquine|
88805282|NCT02538900|Experimental|Group 2|Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.
88805283|NCT02538900|Active Comparator|Group 3|Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.
88805284|NCT01899248||Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
88805285|NCT01899248||Desflurane|Performing liver transplantation under general anesthesia using desflurane
88805286|NCT01322815|Experimental|Chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40 yeast units (YU) GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
88805287|NCT01322815|Experimental|GI-4000 and bevacizumab|maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
88805288|NCT05463432|Experimental|HR19024|Part 1: Dose escalation of HR19024 montherapy for advanced solid tumor Part 2：PK expansion of HR19024 montherapy for advanced solid tumor Part 3: Efficacy expansion of HR19024 montherapy for advanced solid tumor
88805289|NCT00265538|No Intervention|Arm 1 (Pure Control Group)|Pure control (no intervention letter);
89264161|NCT01078779|Placebo Comparator|Placebo|
89290455|NCT05715580|Active Comparator|Intervention group|The nursing intervention will consist of providing information to the patient with a KT about the importance of following the prescribed therapeutic regimen, at the same time the information they may have about healthy lifestyle habits will be expanded, with special emphasis on those areas in which there has been detected, through the administered questionnaires, a lack of adherence.
88805290|NCT00265538|No Intervention|Arm 2 (Contaminated Control Group)|Intervention control (patient does not receive intervention letter, but provider sees other patients who may bring in letter);
89264162|NCT00114231|Experimental|Treatment (capecitabine, oxaliplatin, radiotherapy, surgery)|"Patients undergo high-dose external beam radiotherapy once daily and receive capecitabine PO BID on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive oxaliplatin IV over 2 hours on days 1, 8, 22, and 29.~Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo local excision of the tumor. Patients with T3 disease or positive resection margins after local excision undergo radical resection of the rectum and receive additional chemotherapy and/or radiotherapy at the discretion of the physician."
89264163|NCT00113919|Experimental|Busulfan|study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days
89264164|NCT00113841|Experimental|Curcumin|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.).
89264165|NCT00113841|Experimental|Curcumin + Bioperine|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily.
89264166|NCT00113607|Experimental|DOXIL + trabectedin|Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
89264167|NCT00113607|Active Comparator|DOXIL|Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.
89264168|NCT01080105|Experimental|AIM + surveillance|Participants will receive access to the AIM website and calls from a motivational coach for 12 weeks plus an additional year of surveillance and optional coach support.
89264169|NCT01080105|Experimental|AIM intervention|Participants will receive access to the AIM web based intervention and calls from a motivational coach for 12 weeks
89264170|NCT01080105|Active Comparator|Educational website|Participants will be given access to a static website with depression prevention related materials and handouts.
89264171|NCT00113529|Experimental|Sunitinib + Gefitinib|"Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib~Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib"
89264172|NCT01079013|Experimental|treosulfan|
89264173|NCT00134901|Experimental|Memantine|Memantine
89264174|NCT00134901|Placebo Comparator|Placebo|Placebo
89264175|NCT01076595||Group 1|
89264176|NCT00122109|Experimental|Videoteleconferencing AMT|"The experimental arm is the group condition that received the AMT treatment intervention via a videoteleconferencing modality as compared to the control condition which is the traditional face-to-face modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
89264177|NCT00122109|Active Comparator|Face to Face AMT|"The control arm is the group condition that received the AMT treatment intervention via a traditional face-to-face modality as compared to the experimental condition which is the videoteleconferencing modality.~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
89264178|NCT01326663|Active Comparator|divalproex sodium|
89264179|NCT01326663|Placebo Comparator|sugar pill|
89264180|NCT00113373|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89264181|NCT01079091|Experimental|ADVOS (Hepa Wash)|"Treatment with the liver support system Hepa Wash"
89264182|NCT01326351|Experimental|Regenerative Injection Therapy|
89264183|NCT01326351|Sham Comparator|Dry needle|
89264184|NCT01326351|Active Comparator|Exercise|
89264185|NCT01079169|Experimental|Cranberry capsule|
89264186|NCT01079169|Placebo Comparator|Placebo capsule|
89264187|NCT00113295|Active Comparator|Paroxetine CR and Placebo|Eleven individuals were randomized to plaecbo augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly titrated up to a maximum of 62.5 mg/day by week 10. Individuals who did not achieve remission and were randomized into the placebo group received placebo augmentation of continued paroxetine CR at the week 10 dose level.
89264188|NCT00113295|Experimental|Quetiapine and continued paroxetine CR|Eleven individuals were randomized to quetiapine augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly tirated up to a maximum of 62.5 mg/day by week 10. Individuals who did not receive remission and were randomized to receive quetiapine started at 25 mg at bedtime for the first week, then flexibly dosed based on response and tolerability to a maximum of 200 mg BID by week 16.
89264189|NCT00112905|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-56. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
89264190|NCT03964857|Other|Refined olive oil (ROO)|Control
88805291|NCT00265538|Experimental|Arm 3 (Intervention Group A)|Intervention group A (the intervention is a letter only mailed to the subject); This intervention group receives an educational letter, which is the intervention. It is an educational intervention only.
88805292|NCT00265538|Experimental|Arm 4 (Intervention Group B)|Intervention group B (intervention letter A + financial incentive for discussion w/ provider and 6 month copay reimbursement); This group receives the same educational intervention as Group A, but also receives the Financial incentive, which is an added intervention.
88816274|NCT02570295|Experimental|Swiss Army Physical Fitness Training|"Sport according to the new sport concept (Swiss Army Physical Fitness Training) of the Swiss Armed Forces"
89264191|NCT03964857|Experimental|Blended Oil 1|BO1, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 2
89264192|NCT03964857|Experimental|Blended Oil 2|BO2, propriety blend of cooking oil containing rice bran, flaxseed and sesame oil blended at proportions different from 'Blended Oil 1
89264193|NCT01326429||Hypernatremia|Patients admitted to the emergency department with a serum sodium exceeding 145 mmol/L.
89264194|NCT01326429||Hyponatremia|Patients admitted to the emergency room with a serum sodium below 135 mmol/L.
89264195|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
88805293|NCT00265538|Experimental|Arm 5 (Intervention Group C)|Intervention group C (intervention letter A, financial incentive for discussion w/ provider + copay reimbursement, PLUS reminder phone call 1-3 days prior to primary care visit). This group receives the same intervention as Group B, but with the added intervention of a reminder phone call to test whether additional prompting is needed to make the intervention more effective.
88805294|NCT05449002|Experimental|Practicing the Opposite (PTO) intervention|This 30-45 minutes Qualtrics-based, digital program uses stories, interactive activities, and engaging graphics to teach youths one core principle: by practicing the positive opposite of unhelpful behaviors (e.g., engaging with rather than avoiding feared stimuli), one can, over time, change their mood, thoughts, and actions. The intervention is comprised of four main sections: 1) An introduction to PTO; (2) Testimonials from young people who have been helped by PTO; (3) Learning how to Practice the Opposite through online activities. (4) Planning how to continue to Practice the Opposite in the participant's life. Of note, after being removed from the waitlist at the clinic and contacted to begin treatment, participants will still receive treatment as usual from the clinic.
89264196|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
89264197|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 1|Participants aged 50-59 years given a 0.5 mL dose administered on day 1.
88805295|NCT05449002|Other|Usual waitlist control group|Usual waitlist procedures involve watchful waiting for a therapist to become available, sometimes complemented by periodic check-ins from the family with clinic administrators. After being removed from the waitlist and contacted to begin treatment, participants in both study conditions will receive treatment as usual in the clinic.
89264198|NCT00427895|Experimental|13vPnC Cohort 3, Vaccination 1|Participants aged 18-49 years given a 0.5 mL dose administered on day 1.
89264199|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 2|Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
89264200|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 2|Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.
89264201|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 2|Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
89264202|NCT01034189|Experimental|Targeted therapy|Concurrent chemoradiotherapy with cetuximab, paclitaxel, and cisplatin followed by, if feasible, esophagectomy
89264203|NCT00425945|Placebo Comparator|Placebo|Placebo delivered as four tablets matching the active product once daily orally.
89264204|NCT00425945|Active Comparator|Pine Bark Extract|Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
89264205|NCT00416195|Experimental|E2007|2 mg E2007 once daily for 2 weeks (Days 1 to 14), then 4 mg E2007 once daily for 2 weeks (Days 15 to 28), then 6 mg E2007 once daily for 2 weeks (Days 29 to 42), then 8 mg E2007 once daily for 2 weeks (Days 43 to 56), then 10 mg E2007 once daily for 2 weeks (Days 57 to 70), then 12 mg E2007 once daily for 6 weeks (Days 71 to 112).
89264206|NCT00416195|Placebo Comparator|Placebo|Matching placebo once daily for 16 weeks (Days 1 to 112)
89264207|NCT00121641|Experimental|Saxagliptin 2.5 mg (A)|Metformin 500-2000 mg (as needed for rescue)
89264208|NCT00121641|Experimental|Saxagliptin 5 mg (B)|Metformin 500-2000 mg (as needed for rescue)
89264209|NCT00121641|Experimental|Saxagliptin 10 mg (C)|Metformin 500-2000 mg (as needed for rescue)
89264210|NCT00121641|Placebo Comparator|Placebo (D)|Metformin 500-2000 mg (as needed for rescue)
89264211|NCT00121641|Experimental|Open-Label Treatment Cohort (Direct Enrollees) (E)|"Saxagliptin 10 mg~Metformin 500-2000 mg (as needed for rescue)"
89264212|NCT00425555|Experimental|Previously treated with oral bexarotene|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
89264213|NCT00425555|Experimental|No prior oral bexarotene treatment|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
89264214|NCT01034267|Experimental|1|(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing
89264215|NCT01323881|Experimental|intermittent theta burst stimulation|
89264216|NCT01323881|Placebo Comparator|sham stimulation|
89264217|NCT00121485|Experimental|HeartMate II|Implantation of HeartMate II LVAS
89264218|NCT00121485|Active Comparator|HeartMate XVE|Implantation of HeartMate XVE LVAS
89264219|NCT01034345|Experimental|Sirolimus|Patients randomized to this arm will discontinue maintenance immunosuppression based on calcineurin inhibitors and start treatment with sirolimus.
89264220|NCT01034345|Active Comparator|Calcineurin inhibitor|Patients randomized to this arm will keep the same maintenance immunosuppression based on calcineurin inhibitors.
89264221|NCT01763866|Placebo Comparator|A10 PBO Q2W|Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.
88816275|NCT02570295|No Intervention|Traditional Sport Concept|Sport according to the traditional sport concept of the Swiss Armed Forces
88816276|NCT02571153|Placebo Comparator|Saline group|Normal saline 0.9% (5 mL)
88816277|NCT02571153|Experimental|Ketamine 0.2|ketamine 0.2 mg/kg (5 mL)
88816278|NCT02571153|Experimental|Ketamine 0.4|ketamine 0.4 mg/kg (5 mL)
89264222|NCT01763866|Placebo Comparator|A10 PBO QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
88816279|NCT02436408|Experimental|Vismodegib|150mg taken orally once daily
89264223|NCT01763866|Active Comparator|A10 EZE (Q2W)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.
89264224|NCT01763866|Active Comparator|A10 EZE (QM)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
89264225|NCT01763866|Experimental|A10 EvoMab Q2W|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
89264226|NCT01763866|Experimental|A10 EvoMab QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks
89264227|NCT01763866|Placebo Comparator|A80 PBO Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
89264228|NCT01763866|Placebo Comparator|A80 PBO QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.
89264229|NCT01763866|Active Comparator|A80 EZE (Q2W)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
89264230|NCT01763866|Active Comparator|A80 EZE (QM)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
89264231|NCT01763866|Experimental|A80 EvoMab Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
89264232|NCT01763866|Experimental|A80 EvoMab QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
89264233|NCT01763866|Placebo Comparator|R5 PBO Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
89264234|NCT01763866|Placebo Comparator|R5 PBO QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
89264235|NCT01763866|Experimental|R5 EvoMab Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
89264236|NCT01763866|Experimental|R5 EvoMab QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
89264237|NCT01763866|Placebo Comparator|R40 PBO Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
89264238|NCT01763866|Placebo Comparator|R40 PBO QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
89264239|NCT01763866|Experimental|R40 EvoMab Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
89264240|NCT01763866|Experimental|R40 EvoMab QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
89264241|NCT01763866|Placebo Comparator|S40 PBO Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
89264242|NCT01763866|Placebo Comparator|S40 PBO QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
89264243|NCT01763866|Experimental|S40 EvoMab Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
89264244|NCT01763866|Experimental|S40 EvoMab QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
89264245|NCT01324037|Experimental|clinically suspected upper extremity deep vein thrombosis|Patients with suspected upper extremity DVT
89264246|NCT01034423|Experimental|omega-3 high quality|
89264247|NCT01034423|Experimental|omega-3 low quality|
89264248|NCT01034423|Placebo Comparator|placebo|
89264249|NCT01034501|Active Comparator|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
89264250|NCT01034501|Sham Comparator|sham procedure|Not activation of laser device
89264251|NCT01037543|Experimental|Cohort 1|1.1 mcg/kg of HM10460A, placebo, or Neulasta
89264252|NCT01037543|Experimental|Cohort 2|3.3 mcg/kg HM10460A, placebo or Neulasta
89264253|NCT01037543|Experimental|Cohort 3|10 mcg/kg of HM10460A, placebo, or Neulasta
89264254|NCT01037543|Experimental|Cohort 4|30 mcg/kg of HM10460A, placebo, or Neulasta
89264255|NCT01037543|Experimental|Cohort 5|90 mcg/kg or HM10460A, placebo, or Neulasta
88816280|NCT04573322|Experimental|Lead-in 0.25 mg/kg|0.25 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
88816281|NCT04573322|Experimental|Lead-in 0.50 mg/kg|0.50 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
89264256|NCT01037543|Experimental|Cohort 6|270 mcg/kg of HM10460A, placebo, or Neulasta
89264257|NCT00120627|Experimental|Arm 1: Mantram + Usual Care|Mantram Repetition Program for PTSD delivered in this study as 6-week, 90-minute per week that targeted PTSD symptoms. It was offered as an adjunct to usual care consisting of medication and case-management.
89264258|NCT00120627|Active Comparator|Arm 2: Usual Care alone|Usual care alone is defined as receiving 6 weeks of medication and case management, as needed by each patient. No group meetings.
89264259|NCT01588925|Experimental|Control group|Cochlear Implantation
89264260|NCT01588925|Active Comparator|Dexamethasone|Cochlear implantation using topical dexamethasone
89264261|NCT01588925|Active Comparator|Dexamethasone+Hyaluronic acid|Cochlear implantation using topical dexamethasone associated with hyaluronic acid
89264262|NCT01589003|Active Comparator|Low GI group|Low Glycaemic index growing up milk
89264263|NCT01589003|Other|High GI group|Hi Glycaemic index growing up milk
89264264|NCT05332756||Moyamoya disease patients|
89264265|NCT05332756||First-degree relatives of patients with Moyamoya Disease|
89264266|NCT01238146|Experimental|Arm I|Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8 hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.
89264267|NCT01238146|Experimental|Arm II|Patients receive rituximab and bendamustine hydrochloride as in arm I.
89264268|NCT05292196|Experimental|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation, four weeks as a treatment cycle.
89264269|NCT05292196|Placebo Comparator|TQC3721 suspension placebo for inhalation|TQC3721 suspension placebo for inhalation, four weeks as a treatment cycle.
89264270|NCT01141894|Active Comparator|Routine fluid treatment|Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h and additionally as needed Voluven at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
89264271|NCT01141894|Experimental|Goal directed haemodynamic treatment|Goal directed haemodynamic treatment Dobutamine 0.2-10 μg/kg/min Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h Voluven 3 ml/kg as fluid challenge at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
89264272|NCT02528422|Active Comparator|50 µg Acyl-Ghrelin|Intravenous injection on examination day.
89264273|NCT02528422|Active Comparator|100 µg Acyl-Ghrelin|Intravenous injection on examination day.
89264274|NCT02528422|Placebo Comparator|Isotonic Sodium Chloride|Intravenous injection on examination day.
89264275|NCT01238224|Placebo Comparator|Placebo|A single dose of placebo is administered 30 min before a mixed meal.
89264276|NCT01238224|Active Comparator|Tadalafil|A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.
89264277|NCT01237444|Experimental|lopinavir/ritonavir plus lamivudine|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
89264278|NCT01237444|Active Comparator|lopinavir/ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype"
89264279|NCT01145170|Experimental|Nimotuzumab|The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
89264280|NCT01145248|Experimental|Malignant biliary disease|
89264281|NCT01145248|Experimental|Benign biliary disease|
89264282|NCT03762616|Experimental|Micro-Ultrasound Biopsy|
89264283|NCT03762616|Experimental|MRI Targeted Biopsy|
89264284|NCT01141972|Active Comparator|Supplement|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency
88805296|NCT00176228|Experimental|lamotrigine|The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg. Increasing the medication to final dose will take 8 weeks and the response on full and tolerable dose is further monitored for response over 6 weeks. Therefore, this is a 18-26 week trial (2 to 12 weeks=screening and wash out; 8 weeks=dosing; 6 weeks=acute trial period on full dose).
88805297|NCT00176306|Experimental|Levofloxacin|Patients receiving levofloxacin 750mg IV
88805298|NCT01429987|Experimental|plecanatide 0.3 mg|Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
88805299|NCT01429987|Experimental|plecanatide 1.0 mg|Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
88805300|NCT01429987|Experimental|plecanatide 3.0 mg|Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
88805301|NCT01429987|Placebo Comparator|Placebo|Subjects receive placebo for 12 consecutive weeks
88805302|NCT00265616|Active Comparator|1|propofol, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
88805303|NCT00265616|Active Comparator|2|thiopental/pentobarbital, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
88805304|NCT04351399||patient with chronic painful inflammatory rheumatism|
89264285|NCT01141972|Placebo Comparator|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
89264286|NCT04316806|Experimental|Probiotic|Treatment with probiotic formula
89264287|NCT04316806|Other|Antibiotic|Treatment with antibiotic rifaximin
89264288|NCT01145326|Sham Comparator|Control|Sham-Functional microneedles (no actual microneedles) application, prior to 4% lidocaine gel (LG4) placement.
89264289|NCT01145326|Experimental|Microneedle|Functional microarray (FMA) (microneedles) application, prior to 4% lidocaine gel (LG4) placement.
88805305|NCT01430299|Other|Demineralized Bone Matrix|a prospective cohort of patients undergoing posterolateral lumbar fusion with Evo3 in the posterolateral space
89264290|NCT01144702|Experimental|artesunate & mefloquine combination|ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to <18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to <9 kg = 1 tablet once daily for 3 days, 9 to <18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.
89264291|NCT01145404|Experimental|Arm A: Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
89264292|NCT01145404|Experimental|Arm B|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
89264293|NCT01237522|Active Comparator|Homozygote for the A270S wildetype|
89264294|NCT01237522|Active Comparator|Homo- or heterozygote for A270S minor alleles|
89264295|NCT02528344|Experimental|HIIT - RA|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
89264296|NCT01238302|Placebo Comparator|Conventional group|
89264297|NCT01238302|Experimental|PRP group|
89264298|NCT01235416|Active Comparator|AMG 706 50mg|50 mg, once daily. (Cohort 1)
89264299|NCT01235416|Active Comparator|AMG 706 75mg|75 mg, twice daily. (Cohort 2)
89264300|NCT01235416|Active Comparator|AMG 706 125mg|125 mg, once daily. (Cohort 3)
89264301|NCT04246996|Active Comparator|Gentamicin Arm|At the completion of the subjects surgery but prior to awakening from anesthesia, 80mg of gentamicin in 50 mL of normal saline will be infused into the subject's bladder through the standard-of-care transurethral catheter by the surgeon. The surgeon will then clamp the catheter and label the catheter with the clamping time. The catheter will be clamped to prevent the gentamicin from immediately flowing out of the bladder and thus allow the gentamicin time to have an effect. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
89264302|NCT04246996|Sham Comparator|Control Arm|If the patient is randomized to no instillation, at the end of the surgery but prior to awakening from anesthesia, the surgeon will clamp the catheter and label the catheter with the clamping time. The purpose of clamping the catheter for subjects receiving usual care will be to ensure patients are masked to study arm assignment if they wake up and notice their catheter. The subject will then proceed as usual to the postoperative anesthesia care unit. A member of the subject's care team will unclamp the catheter after 1 hour. The subject will otherwise have usual pre-operative and post-operative care.
89264303|NCT01238380||Diabetes diagnosed under 30 years|Patients currently under 50 years of age diagnosed with diabetes under 30 years.
89264304|NCT00424463|Experimental|1|
89264305|NCT00424463|Placebo Comparator|2|
89264306|NCT01034735|Experimental|Arm A|
89264307|NCT01034735|Experimental|Arm B|
89264308|NCT01034735|Experimental|Arm C|
89264309|NCT01034813||Burn Range of motion|burn patients with hypertropic scar
89264310|NCT01034813||control range of motion|control subjects without scaring
89264311|NCT00424385|Experimental|Arm 1|Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib
89264312|NCT01037699|Active Comparator|FSH YOUNGER|
88805306|NCT01430299|Other|rh-BMP2|A retrospective cohort of patients who were age- and sex- matched to the prospective cohort who underwent posterolateral lumbar fusion with use of rh-BMP2
88805307|NCT01431313|Experimental|Inhaled Nitrite|Sodium Nitrite Inhalation Solution (AIR001) 45mg dosage with one subsequent escalation dosage of 90mg based on tolerability.
88805308|NCT00176852|Other|RIC Bu/Flu (A) (discontinued)|Full Preparative Regimen for subjects with matched donors using Busulfan on Day -8 and -7, Fludarabine on Day -6 through -2, antithymocyte globulin (ATG) on Day -2 through -1, total lymphoid radiation (TLI) on Day -1, stem cell infusion on Day 0.
89264313|NCT01037699|Active Comparator|FSH OLDER|
89264314|NCT01037699|Experimental|FSH LH YOUNGER (Recombinant Luteotrophin alfa)|
89264315|NCT01037699|Experimental|FSH LH OLDER|
89264316|NCT00423917|Experimental|fulvestrant + bevacizumab|"Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed every 3-6 months for 5 years."
89264317|NCT00845026|Experimental|LY2140023|LY2140023 (80 mg/day), given orally twice daily as two 40-mg tablets for 24 weeks
89264318|NCT00845026|Active Comparator|aripiprazole|aripiprazole (20 mg/day), given orally once daily for 24 weeks
89264319|NCT00845026|Active Comparator|olanzapine|olanzapine (15 mg/day), given orally once daily for 24 weeks
89264320|NCT00845026|Active Comparator|risperidone|risperidone (4 mg/day), given orally, once or BID for 24 weeks
89264321|NCT01145716|Other|Surgical exploration|Descriptive
89264322|NCT01238458|Experimental|[18F]AV-45 PET amyloid binding imaging|
89264323|NCT02445131|Experimental|Bendamustine + GA101 + CAL-101|Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
89264324|NCT01235572|Experimental|Health services research (early discharge, outpatient care)|Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a RN, PA, or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days.
89264325|NCT00691678|Experimental|chondroitin and glucosamine|Postmenopausal breast cancer patients that have joint symptoms induced by aromatase inhibitors and are receiving chondroitin and glucosamine.
89264326|NCT00423605|Experimental|1|
89264327|NCT01237600|Experimental|Cultivated limbal transplantation|
89264328|NCT01237756|Experimental|pediatric|
89264329|NCT01235650||Spinal fusion|Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis
89264330|NCT01142206|Active Comparator|Physical Activity|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week.
89264331|NCT01142206|Experimental|Physical Activity & TV Watching|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week and an additional prescription of reducing TV watching to 10 hours per week or less.
89264332|NCT03994289|No Intervention|Control|Participants remain seated for 2 hours after the intake of a standardized breakfast.
89264333|NCT03994289|Experimental|Motor-assisted cycling|Participants will perform 3 bouts of motor-assisted cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
89264334|NCT03994289|Experimental|FES cycling|Participants will perform 3 bouts of FES cycling, each bout lasting 10 minutes, after the intake of a standardized breakfast.
89264335|NCT01238614|Experimental|PSF-JIT|Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.
89264336|NCT01238614|Experimental|PSF|Mothers in this arm receive screening questions on the prescreener form
89264337|NCT01238614|Placebo Comparator|Control|Mothers in this arm receive no maternal depression CHICA additional care
89264338|NCT05258188|Experimental|Instrument-assisted Soft Tissue Mobilization|"Warm-up will be performed for 10 to 15 minutes by light jogging, elliptical machine, stationary cycle or an upper body ergometer~Instrument-assisted Soft Tissue Mobilization , will be applied at 30 to 60 degrees angle for 40 to 120 seconds~Stretching, for 30 seconds (3 rep)~Strengthening exercises, high repetitions with low intensity exercise~Cryotherapy for 10 to 20 min"
89264339|NCT05258188|Experimental|Compressive Myofascial Release Technique|Compressive myofascial release technique will be applied 5 minutes, after a warmup of 10 to 15 minutes.
89264340|NCT01145872|Experimental|Mindfulness Based Cognitive Therapy|
88805309|NCT00176852|Experimental|MA Bu/Cy (B)|Myeloablative Preparative Regimen for subjects with HLA identical sibling donors consists of Busulfan on day -9 through -6, Cyclophosphamide on day -5 through -2, ATG on day -3 through -1, stem cell infusion on Day 0 and Granulocyte Colony Stimulating Factor on day -3 until ANC >2500 x 2 days.
88805310|NCT00176852|Experimental|RIC Cy/Flu/TBI (A2)|Patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or who has pre-existing organ dysfunction making myeloablative condition ineligible will receive Campath on day -10 through -6, Cyclophosphamide on day -7, Fludarabine on day -6 through -2, total body irradiation (TBI) on day -1, stem cell infusion on Day 0.
89264341|NCT01145872|Active Comparator|Health Enhancement Program|
89264342|NCT05400772||Healthy subjects|
89264343|NCT01237834||Heavy smokers, 15 or more cigarettes/day|Nicotine dependent.
89264344|NCT01237834||Light smokers (chippers)|Less than 2 cigarettes/day, at least 2 days/week. Non nicotine-dependent.
89264345|NCT01237834||Non smokers|
89264346|NCT05214586|Experimental|Spiculotomy and application of a Gel Nail|A nail spicule removal technique will be performed of the edge or nail edges affected by ingrown toenail. After, a gel nail will be applied to remodeling the nail apparatus and avoid damage of the nail in the lateral fold.
89264347|NCT05214586|Active Comparator|Spiculotomy and Nail Re-education with Gauze Bandage|A nail spicule removal technique will be performed and a cord of gauze bandage between the nail channel and the sheet will be applied. This technique consists in the removal of the portion of the nail sheet that causes ingrown toenail in order to release the soft parts.
89264348|NCT01142362|Experimental|0.6mg of DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 0.6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
89264349|NCT01142362|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
89264350|NCT01142362|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
89264351|NCT01235806|Other|MRI|MRI of the scaphoid bone fracture suspicion
89264352|NCT02528266|Experimental|Nerve Capping Device|Implant with the experimental device
89264353|NCT01238770|Experimental|Cyclophosphamid + Pazopanib|Cyclophosphamid + Pazopanib
89264354|NCT01145950|Experimental|Group 1|
88805311|NCT01323517|Experimental|Ipilimumab, Melphalan and Dactinomycin|This is a single-institution phase II trial with a primary outcome of progression free survival (PFS).
89264355|NCT01145950|Experimental|Group 2|
89264356|NCT01243606|Experimental|Single Diagnosis Treatment Protocols|Four disorder-specific cognitive-behavioral treatments will be conducted in accordance with treatment manuals of demonstrated efficacy. SDPs will be matched to the principal anxiety disorder diagnosis.
89264357|NCT01243606|Experimental|Unified Protocol|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders will be individually administered in accordance with a treatment protocol.
89264358|NCT01243606|No Intervention|Waitlist Control|Waitlist participants will not receive treatment during a 16-week waitlist period, but will receive the treatment of their choice immediately following the 16 week waiting period.
89264359|NCT01238926|Experimental|PD vitamin supplementation|
89264360|NCT01238926|Experimental|PD exercise intervention|
89264361|NCT01238926|Experimental|PD vitamin + exercise|
89264362|NCT01238926|No Intervention|PD control|
89264363|NCT05137990|Experimental|HIIT Exercise Intervention|At home (N=12): Participants will complete an exercise session 3 times a week for 14 weeks. Each participant will receive a pre-assembled stationary bicycle to use to complete each session, an iPad to receive the intervention virtually from exercise trainers through Zoom, and a Fitbit to assess real-time heart rate.
89264364|NCT05137990|Placebo Comparator|Stretching Intervention|At home (N=12): Participants will complete a stretching protocol 3 times a week for 14 weeks. Participants will be asked to complete weekly records of flexibility compliance.
89264365|NCT01239004|Placebo Comparator|Placebo|
89264366|NCT01239004|Experimental|Colesevelam|
89264367|NCT01235884|Active Comparator|Lactobacillus reuteri|Dietary Supplement
89264368|NCT01235884|Placebo Comparator|Placebo|Dietary Supplement
89264369|NCT01142440|Experimental|behavioral intervention|
89264370|NCT01142440|No Intervention|convention dental treatment|
89264371|NCT01245322|Active Comparator|Lactobacilli|different lactobacilli.
89264372|NCT03789994|Experimental|Affective touch group|"Survivors in the intervention group will receive a total of 36 sessions of a 15-minute affective touch intervention performed by their family caregivers in their homes. Sessions will be scheduled for every alternate weekday (three times a week) for 12 weeks. A trained research nurse (RN) will conduct three 30-minute caregiver training sessions to support the caregivers in delivering the affective touch.~To put caregivers in a more relaxed mood for delivering the intervention, the RN will work with them to identify a time that they feel less burdensome, and teach them to perform deep breathing for relaxation before the affective touching begins. Also, the survivor-caregiver dyad will be asked to sit in a comfortable position and switch off television or radio during the intervention."
89264373|NCT03789994|Other|Fine motor group|To address the additional attention given by caregivers during affective touch, the control group will be asked to sit beside the survivors when they go through the fine motor exercises which are commonly used for rehabilitation. Caregivers will be instructed to provide only necessary help in preparing the equipment, and to avoid touching or talking to the survivors during the 15-minute exercise session. Two such sessions will be arranged for survivors to master the skills needed, and for caregivers to practise the required level of interaction during the exercise training. Participants will be instructed to do the exercise three times a week (every alternate weekday) over 12 weeks.
89264374|NCT01239238||Care as usual|Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
89264375|NCT03711994|No Intervention|Repeat C/S Control|Repeat C/S done with spinal without Alkantis ice pack but with similar size dressings.
89264376|NCT03711994|Active Comparator|Repeat C/S Treatment|Repeat C/S done with spinal with Alkantis ice pack.
89264377|NCT03711994|No Intervention|Primary C/S - Control|Primary C/S done with Epidural without Alkantis ice pack but with similar size dressings.
89264378|NCT03711994|Active Comparator|Primary C/S Treatment|Primary C/S done with Epidural with Alkantis ice pack.
89264379|NCT00423449|Experimental|Vorinostat + Gemcitabine + Platinum-based agent|
89264380|NCT00423293|Other|5-FU + Mitomycin + IMRT|5-FU + Mitomycin + IMRT
89264381|NCT00423137|Placebo Comparator|Placebo - low dose|Twice daily (b.i.d.)
89264382|NCT00423137|Placebo Comparator|Placebo - high dose|Twice daily (b.i.d.)
89264383|NCT00423137|Experimental|BIBW2948 - low dose|Twice daily (b.i.d.)
89264384|NCT00423137|Experimental|BIBW2948 - high dose|Twice daily (b.i.d.)
89264385|NCT00422903|Placebo Comparator|Letrozole plus placebo|Letrozole 2.5 mg administered orally fro 6 mos. plus placebo 1500 mg administered orally throughout the study until definitive surgery
89264386|NCT00422903|Experimental|Letrozole plus lapatininb|Letrozole 2.5 mg administered orally fro 6 mos. plus lapatinib 1500 mg administered orally throughout the study until definitive surgery
89264387|NCT00422669|Active Comparator|RV Mid-Septal Pacing|Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart
89264388|NCT00422669|Active Comparator|RV Apical Pacing|Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex
88805312|NCT01323595|Experimental|Celecoxib|Celecoxib will be given for 6 days after surgery
88805313|NCT01323595|Placebo Comparator|Sugar pill|Sugar pill for 6 days after surgery.
88805314|NCT01324453|Experimental|Post conditioning + PCI|
88805315|NCT01324453|Active Comparator|Standard PCI|
89264389|NCT00422591|Experimental|Idarubicin + Cytarabine|Idarubicin 12 mg/m2 IV over 1 hour daily x 3 (days 1-3). Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
89264390|NCT00422513|Experimental|methoxy polyethylene glycol-epoetin beta|120-360 micrograms (iv) monthly, starting dose
89264391|NCT00422513|Active Comparator|Epoetin Alfa|As prescribed, (iv), 3 times weekly
89264392|NCT00202878|Experimental|ezetimibe/simvastatin|One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.
89264393|NCT00202878|Active Comparator|simvastatin|One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.
89264394|NCT00414011|Experimental|Moxifloxacin|Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
89264395|NCT00414011|Experimental|Gatifloxacin|Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
89264396|NCT03994133||Daily Home Dialysis patients|Daily Home Dialysis patients with low-flow dialisate for more than 3 months in France
89264397|NCT00231816|Experimental|Concomitant|Zostavax concomitantly with influenza vaccine on Day 1, placebo at week 4
89264398|NCT00231816|Experimental|Nonconcomitant|Influenza vaccine and Zostavax placebo on Day 1, Zostavax at week 4
89290456|NCT05715580|Placebo Comparator|Control group|The control group will be informed of the same aspects following the usual clinical practice, which consists of providing the information in the immediate post-transplant period, and resolving any doubts that the patient may have during the subsequent time.
88805316|NCT01376557|Experimental|Treatment A|
88805317|NCT01376557|Experimental|Treatment B|
88805318|NCT01376557|Experimental|Treatment C|
88805319|NCT01376557|Experimental|Treatment D|
88805320|NCT01376557|Placebo Comparator|Placebo|
88805321|NCT01324687||Control|Group without access to telemedicine in the home for acute care issues.
88805322|NCT01324687||Telemedicine care|Cohort with access to telemedicine in the home for acute care issues.
89290457|NCT01226394|No Intervention|surveillance|
89290458|NCT01226394|Experimental|laparotomy plus HIPEC.|
89290459|NCT03932604|No Intervention|Atrial sensing OFF mode|VDD-ICD programmed as atrial sensing Off mode
89290460|NCT03932604|Active Comparator|Atrial sensing ON mode|VDD-ICD programmed as atrial sensing ON mode
89290461|NCT05198440|Experimental|Neuromodulation of vection|
89290462|NCT01223430|Experimental|Si-Ni-Tang|
89290463|NCT01223430|Placebo Comparator|Placebo|
88805323|NCT01431391|Experimental|Arm 1: Sipuleucel-T followed by ADT|Arm 1: Subjects received one infusion of sipuleucel-T every two weeks for a total of three infusions. Two weeks after the third sipuleucel-T infusion, subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg). An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT.
89264399|NCT00260208|Active Comparator|Cyclosporin A|"The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges.~Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:~Steroids administered and tapered as per local practice~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by the center was to be given to all patients enrolled in the trial from this center."
89264400|NCT00260208|Active Comparator|Tacrolimus|"Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges.~Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:~Steroids administered and tapered as per local practice~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.~The regimen selected by center was to be given to all patients enrolled in trial from this center."
89264401|NCT00202644|Experimental|A|
89264402|NCT00202644|Active Comparator|B|
89264403|NCT01235962|Experimental|pazopanib|Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
89264404|NCT01235962|Placebo Comparator|placebo|placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
89264405|NCT00259740|Experimental|Denosumab|
89264406|NCT00201006|Experimental|Face-to-face counseling|26 biweekly face-to-face group counseling sessions
89264407|NCT00201006|Experimental|Telephone Counseling|26 biweekly telephone counseling sessions
89264408|NCT00201006|Active Comparator|Mail contact|26 biweekly newsletters with weight management advice
89264409|NCT00200850|Active Comparator|Low dose SLIT|Low dose SLIT
89264410|NCT00200850|Active Comparator|High dose SLIT|High dose SLIT
89264411|NCT00200850|Placebo Comparator|Placebo|Placebo
89264412|NCT01073202|Active Comparator|ursodeoxycholic acid|
89264413|NCT01073202|Placebo Comparator|identical-appearing placebo|
89264414|NCT01236040|Experimental|Group A|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
89264415|NCT01236040|Experimental|Group B|Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval.
89264416|NCT01236040|Placebo Comparator|Group C|Subjects will receive 2 doses of a placebo at a 21-day interval.
89264417|NCT01236040|Experimental|Group D|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
89264418|NCT01236040|Experimental|Group E|Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval.
89264419|NCT01236040|Experimental|Group F|Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval.
89264420|NCT01146730|Experimental|Workcoping and IPS|CBT based counseling and supported employment
89264421|NCT01146730|Active Comparator|Ordinary care by GP or NAV|Ordinary care by GP or The Norwegian Labour and Welfare Administration (NAV)
89264422|NCT01146028|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
89264423|NCT01146028|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
88816282|NCT04573322|Experimental|Lead-in 1.0 mg/kg|1.0 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
88816283|NCT04573322|Experimental|Lead-in 1.5 mg/kg|1.5 mg/kg TSC, administered via IV bolus every 6 hours for up to 15 days
89264424|NCT00231114|Experimental|Alair|Treatment of airways with the Alair System
89264425|NCT00231114|Sham Comparator|Sham|Sham treatment of airways
89264426|NCT03613480|Experimental|Motivational Interviewing|Patients will receive 6 brief (20-30mins) counseling sessions based on the principles of Motivational Interviewing by a trained member (psychiatrist) of the research team. The first session will take place at 2 weeks after baseline and the following 5 sessions will be conducted at a monthly basis.
89264427|NCT03613480|No Intervention|Care as usual|Patients will be followed-up by the hepatologists of the Outpatient Department at regular time intervals and will be re-evaluated after 6 months from baseline
89264428|NCT03543046|Experimental|Tortle Midliner|The use of the Tortle Midliner will be in addition to the NICU department process guidelines for positioning relevant to the gestational age of the subject. The Tortle Midliner will be applied no later than 3 hours following birth under the supervision of a study investigator. The size/fit and application of the device will be according to the manufacturer's guidelines. The neutral midline head position, supine or slightly side-lying, with a bed elevation between 15° and 30° will be maintained during the first 72 hours of life.
89290464|NCT01221714||Active/Placebo|ACTIVE VITAMIN; PLACEBO OMEGA MAX
89290465|NCT01221714||Active/Active|ACTIVE VITAMIN; ACTIVE OMEGA MAX
89290466|NCT01221714||Placebo/Active|PLACEBO VITAMIN; ACTIVE OMEGA MAX
89290467|NCT01221714||Placebo/Placebo|PLACEBO VITAMIN; PLACEBO OMEGA MAX
89290468|NCT05198206||The First Affiliated Hospital of Chongqing Medical University|
89290469|NCT05198206||West China Hospital|
89264429|NCT03543046|No Intervention|Control Group|All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
89264430|NCT03530800|Active Comparator|Dronabinol|Subjects will receive dronabinol 5mg once daily for two weeks, 5mg twice daily for the subsequent two weeks, and 5mg three times daily for the final six weeks. Dose escalations will only be done if the investigator deems necessary.
89264431|NCT03530800|Placebo Comparator|Placebo|Subjects will receive placebo for 10 weeks weeks.
89264432|NCT03479008|Other|Healthy volunteers (iterative device development)|This phase will recruit healthy volunteers who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Volunteers will be randomized to receive alternating 5 minute episodes of various vibration frequencies.
89264433|NCT04982146|Experimental|Bromelain + N-Acetylcysteine|Patients with pseudomyxoma peritonei that are not candidates to surgical resection
89264434|NCT04958746|Experimental|Ciprofol|Ciprofol group：0.4/0.2mg/kg
89264435|NCT04958746|Placebo Comparator|Propofol|Propofol group：2.0/1.0mg/kg
89264436|NCT01146106|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
89264437|NCT01146106|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
89264438|NCT05631340|Experimental|case group|Recieving additional discharge education by the researcher and supported by a booklet and mobile app
89264439|NCT05631340|Active Comparator|control group|Recieving standart hoapital discharge education
89264440|NCT03431584|Active Comparator|Infiltration of corticosteroids|
89264441|NCT03431584|Experimental|Infiltration of corticosteroids and hyaluronic acid|
89264442|NCT00259272|Experimental|A|
89264443|NCT01239706|Experimental|NTx 265|
89264444|NCT01239784|Experimental|All Subjects|A total of 20 children and their parents will be recruited for this study. Ten children will have had the Glenn procedure and 10 infants will have had the arterial switch operation.
89264445|NCT01246570|Experimental|Maintenance program|"Patients will attend a motivational exercise session once monthly. They will also be tested (exercise test with measurement of peak oxygen uptake) every third months."
89264446|NCT01246570|Active Comparator|Control|Usual care. The patients will receive the usual care provided by the hospital and community health services
89264447|NCT01239862|Experimental|Autologous cell transplantation|We conducted a prospective, non-randomized, single-center longitudinal study in five patients. Inclusion criteria were age 18-50 years, chronic and accelerated silicosis, forced expiratory volume in 1s <60% and >40%, forced vital capacity ≥60% and arterial oxygen saturation >90%. BMDMCs were administered through bronchoscopy (2×107 cells) into both lungs. Physical examination, laboratory evaluations, quality of life questionnaires, thoracic computed tomography scans, lung function tests, and perfusion scintigraphy were performed before the beginning of treatment and up to 360 days after BMDMC (Bone Marrow Derived Mononuclear Cells) therapy. Additionally, whole-body and planar scans were evaluated 2 and 24 h after instillation.
89264448|NCT03106324||TNE NDMM patients treated with lenalidomide regimen|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
89264449|NCT03106324||TNE NDMM patients treated with non-lenalidomide|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
89264450|NCT01147276|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
89264451|NCT05135806||Group 1|Remote evaluation first: participants will undergo a comprehensive neuropsychological assessment administered remotely via telephone calls or videoconferencing. Each participant will take part to the second evaluation (face-to-face) 8 weeks later.
89264452|NCT05135806||Group 2|Face-to-face evaluation first: participants will undergo a comprehensive neuropsychological assessment administered face-to-face. Each participant will take part to the second evaluation (remotely via telephone calls or videoconferencing) 8 weeks later.
89264453|NCT01250782|Placebo Comparator|Physiological Serum|
89264454|NCT01250782|Active Comparator|Glutamine|
89264455|NCT03913624|Experimental|50 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 50 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
89264456|NCT03913624|Experimental|35 Hz NMES group|Neuromuscular electrical stimulation (NMES) was applied on wrist and finger extensors for 30 minutes, 3 sessions per week for 8 weeks. The main electrostimulation parameters consisted of low-frequency current, a stimulation frequency of 35 Hz, symmetrical rectangular biphasic wave, and pulse duration of 300 μs.
89264457|NCT03913624|No Intervention|Control group|Conventional treatment
89264458|NCT01239940|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
89264459|NCT01239940|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
89264460|NCT03090412|Experimental|Arm I (surgery)|Patients undergo standard of care surgery on day 1.
89264461|NCT03090412|Experimental|Arm II (HPPH, PDT)|Patients receive HPPH IV over 1 hour on day 0 and undergo PDT on day 1.
89264462|NCT01146886|Experimental|BI 135585|1 single dose per subject as oral solution in Part 1, or 3 single doses per subject as oral solution and 2 different tablet formulations in Part 2
89264463|NCT01146886|Placebo Comparator|Placebo to BI 135585|1 single dose per subject as oral solution in Part 1
89290470|NCT05198206||the First Affiliated Hospital of Xi'an Jiaotong University|
89290471|NCT05198206||Guangdong Provincial People's Hospital|
89290472|NCT05198206||Xiangya Hospital of Central South University|
89290473|NCT05198206||The Second Affiliated Hospital of Harbin Medical University|
89264464|NCT01250860|Sham Comparator|Control Group|Control DoboMed group - only specific active exercises: symmetrical positions for exercising; asymmetrical active movements; thoracic spine kyphotization; transverse plane derotation; apical area involvement; concave ribs mobilization; exteroceptive facilitation; respiration-directed movements of the thorax and spine; three-dimensional displacement of vertebra; active autocorrection.
89264465|NCT01250860|Experimental|Experimental group|"Experimental DoboMed and Kaltenborn manual therapy. Suitable techniques were chosen according to manual examination: cervical spine; thoracic spine; lumbar spine; costovertebral articles; pelvis position. During the 15 sessions in group DK we used:derotational manual terapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method; the manual techniques used in continuation study were different from techniques in pilot study."
89264466|NCT02782390|Experimental|Hall Technique|single placement of stainless dental crowns on atypical cavities
89264467|NCT02782390|Active Comparator|Composite Resin|single placement of composite resin on atypical cavities
89264468|NCT04877314|Experimental|Intermittent fasting|
89264469|NCT01146184|Experimental|Single-Incision Cholecystectomy|Extracting the gallbladder laparoscopically is made difficult through a single incision.
89264470|NCT01247896|Experimental|Active|
89264471|NCT01247896|Placebo Comparator|Placebo|
89264472|NCT02526004|Active Comparator|Standard Empiric Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin
89264473|NCT02526004|Experimental|Microbiome Guided Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis
89264474|NCT00421889|Experimental|Single arm|"Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle~Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle"
89264475|NCT01146964|Experimental|Phacoemulsification, Safety, Efficacy|
89264476|NCT01146964|Experimental|MSSICS, Safety, Efficacy|
89264477|NCT01440010||IORT with 50 kV x-rays, 20 Gy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
89264478|NCT01146340|Experimental|SBRT|SBRT 40 Gy in 5 fractions over 29 days delivered using step and shoot IGRT
89264479|NCT03913468||Received Ascorbic Acid IV|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who were treated within the first 24 hours of admission with the combination of IV ascorbic acid, IV thiamine, and IV hydrocortisone, with a duration of 4 days or until patient leaves the ICU.
89264480|NCT03913468||Control Group|Per the medical record, consecutive patients admitted to our institutions ICU with a diagnosis of septic shock within the last 3 years, who did not receive any treatment with IV ascorbic acid.
89264481|NCT03913312|Experimental|DAC combined with unrelated cord blood transplantation|Decitabine (DAC) 15mg/m2/d, d-7 to d-3;Ara-C 1000g/m2/q12h, d-2 to d-1.Single unrelated cord blood (TNC>1.5*107/kg), d0.
89264482|NCT03913546|Sham Comparator|Sham spinal manipulation|Participants in the 'sham' group will receive a sham mechanical thrust (force set at level 0) instead of an actual one. In the force level 0, no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition. Therefore, the subject does not distinguish between intervention or placebo.
89264483|NCT03913546|Experimental|Actual spinal manipulation|Participants in the actual actual spinal manipulative therapy (SMT) group will be assessed through the Activator basic method. SMT will be performed with the Activator IV Adjusting Instrument (Activator Methods International, Phoenix, AZ) varying the force level depending on the adjusted segment.
89264484|NCT01147354|Experimental|experimental group|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
89264485|NCT01147354|Placebo Comparator|control group|The patients in this arm took one placebo capsule daily for 12 weeks.
89264486|NCT01435408|Active Comparator|Conventional treatment.|Conventional primary PCI in STEMI.
89264487|NCT01435408|Experimental|IPost|Ischemic postconditioning in STEMI.
89264488|NCT01435408|Experimental|Deferred primary PCI.|Deferred strategy in STEMI.
89264489|NCT01248286|Experimental|Whole grain rice|
89264490|NCT01248286|Active Comparator|Refined grain rice|
89264491|NCT04744480|Experimental|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
89264492|NCT04744480|No Intervention|The routine induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia.In the routine induction group，all procedures will be the same as those of the topical anesthesia group, The drug will be replaced with constant volume saline.
89264493|NCT03916588||Memory Care Unit Residents|Residents on a locked memory care unit in southeastern Louisiana will be enrolled. Engaged family members and staff will also consent to provide qualitative information on the resident.
89264494|NCT03913780|Active Comparator|Group 1 (Medical record)|For group 1, participants do not have intervention as groups 2 and 3. This group consists of reviewing the medical history of the year 2000 to determine the variables of the study and then compare them with groups 2 and 3. This group of participants they were from the year 2000 and whose information will be strictly taken from their medical history was based on initial training with warm-up and walking, after that, aerobic training was performed from 50 to 70% of their maximum heart rate and they finished their session training with breathing exercises, coordination, balance and walking.
89290474|NCT05198206||Yan'an Hospital of Kunming City|
89290475|NCT05198206||Zhongshan Hospital|
89290476|NCT05198206||Gansu Provincial People's Hospital|
89290477|NCT05198206||Qilu Hospital of Shandong University|
89264495|NCT03913780|Experimental|Group 2: Aerobic exercise + Strength training in MMSS|"For group 2, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more strength exercises for upper limbs with dumbbells, multi-strength equipment and Theraband.~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
89264496|NCT03913780|Experimental|Group 3: Aerobic exercise + Strength training in MMII|"For group 3, participants begin their training with warm-up and walking, after that, performed aerobic exercise in endless band and elliptical bike more the strength training for lower limbs with theraband, multi-strength equipment and exercises for activation of the sole-twin pump.~The prescription of aerobic exercise was given from 50 to 70% of your maximum heart rate and for strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale."
89264497|NCT01147432|Experimental|PF-04427429|
89264498|NCT01147432|Placebo Comparator|Placebo|
89264499|NCT01147432|Active Comparator|EMLA|
89264500|NCT01147510|Active Comparator|Monotherapy of medium dose ICS|
89264501|NCT01147510|Experimental|Combination of low ICS and montelukast|
89264502|NCT03916432|Experimental|Interventional group|HELIOS biodegradable polymer sirolimus-eluting stents
89264503|NCT00421733|Active Comparator|Paricalcitol 1 mcg|One paricalcitol 1 mcg capsule and one matching placebo capsule per dose
89264504|NCT00421733|Active Comparator|Paricalcitol 2 mcg|Two paricalcitol 1 mcg capsules per dose
89264505|NCT00421733|Placebo Comparator|Placebo|Two placebo capsules per dose
89264506|NCT03916354||appropriate GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is in the recommended normal range is in this group.
89264507|NCT03916354||excess GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is over the upper limit of the recommended normal range is in this group.
89264508|NCT03916354||insufficient GWG group|2009 IOM criteria recommended an appropriate range of weight gain during pregnancy and during each pregnant trimester according to BMI. The participants whose GWG value is below the lower limit of the recommended normal range is in this group.
89264509|NCT01249378|Active Comparator|10 g non emulsified of milk fat|They are compared using the repeated measurements taken within subjects
89264510|NCT01249378|Active Comparator|40 g non emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
89264511|NCT01249378|Active Comparator|40 g finely emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
89264512|NCT00421343|Other|Treatment for osteoporosis and falls|calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention
89264513|NCT03915808|Experimental|Conjugated linoleic acid plus lifestyle counselling|supplementation of 3.2 g/day conjugated linoleic acid and receive education sessions regularly
89264514|NCT03915808|Placebo Comparator|Sunflower oil plus lifestyle counselling|supplementation of equivalent sunflower oil, and receive education sessions regularly
89264515|NCT03915730|Experimental|Smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
89264516|NCT03915730|Experimental|Non-smokers with chronic periodontitis|Patients who had teeth with 30% periodontal bone loss, presence of at least two nonadjacent sites per quadrant with probing pocket depths of ≥5 mm, and bleeding on probing were assigned as chronic periodontitis group Never smoked patients were included into the nonsmoker group
89264517|NCT03915730|No Intervention|Smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Patients who have smoked for at least 10 years and a minimum of 10 cigarettes per day were assigned as current smokers.
89264518|NCT03915730|No Intervention|Non-smokers with periodontal healthy|Individuals were diagnosed periodontally healthy as without attachment loss, periodontal disease history, whole mouth bleeding scores of <10% and a probing depth of ≤3 mm Never smoked patients were included into the nonsmoker group
89264519|NCT01147588|Experimental|1|lansoprazole 60 mg + clopidogrel 300 mg/ 75 mg
89264520|NCT01147588|Experimental|2|omeprazole 80 mg + clopidogrel 300/75 mg
89264521|NCT01147588|Experimental|3|esomeprazole 40 mg + clopidogrel 300/75 mg
89264522|NCT01147588|Experimental|4|clopidogrel 300/75 mg alone
89264523|NCT03908710|Other|home Home blood pressure levels in hypertensive participants|Only one arm. No control group.
89264524|NCT03915886|Experimental|JNJ-0440 (Low Dose) or Placebo|Participants will receive single oral dose (low) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
89264525|NCT03915886|Experimental|JNJ-0440 (Medium Dose) or Placebo|Participants will receive single oral dose (medium) of JNJ-0440 or matching placebo under fed conditions. The dose will be escalated based on the preliminary safety data from the preceding cohort as per sponsor and investigator discretion.
89264526|NCT03915886|Experimental|JNJ-0440 (High Dose) or Placebo|Participants will receive single oral dose (high) of JNJ-0440 or matching placebo under fed conditions.
89264527|NCT01253434|Experimental|1|
89264528|NCT01253434|Experimental|2|
89264529|NCT01253434|Experimental|3|
89264530|NCT01253434|Experimental|4|
89264531|NCT01253434|Experimental|5|
89264532|NCT03916120||Postoperative Analgesic Failure|
89264533|NCT03916120||Postoperative Analgesic Success|
89264534|NCT03908164|Experimental|Vaccination at <23+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy before 23+6 gestational weeks (GW). Although the time period for study group 1 is ≤23+6 no pertussis vaccine will be given in this study at less than 16 GW.
89264535|NCT03908164|Experimental|Vaccination at 24-27+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 24 and 27+6 gestational weeks.
89264536|NCT03908164|Experimental|Vaccination at 28-31+6 gestational weeks|Participants will receive a pertussis containing vaccine licensed for use in pregnancy between 28 and 31+6 gestational weeks.
89264537|NCT01147120|Active Comparator|Progressive Muscle Relaxation|
89264538|NCT01147120|Active Comparator|Clinical Massage Therapy|
89264539|NCT03908242|Experimental|Salvianolic Acid A|2 anticipated doses are 90 mg and 180 mg.
89264540|NCT03908242|Placebo Comparator|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
89264541|NCT00230178|Experimental|Arm A|Rasburicase alone given as a single agent for 5 days
89264542|NCT00230178|Experimental|Arm B|Rasburicase alone given as a single agent from Day 1 through Day 3, followed by oral allopurinol given from Day 3 through Day 5 (Day 3 is an overlap)
89264543|NCT00230178|Active Comparator|Arm C|Oral allopurinol alone given as a single agent for 5 days
89264544|NCT03908008|Active Comparator|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
89264545|NCT03908008|Experimental|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
89264546|NCT01253512|Experimental|THR-18 0.25mg/kg|Treatment with combination with Tissue Plasminogen Activator (tPA) treatment
89264547|NCT01253512|Placebo Comparator|Placebo treatment|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
89264548|NCT01253512|Experimental|THR-18 0.5mg/kg|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
89264549|NCT01253590||post op cancer patients experiencing atrial fibrillation|This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.
89264550|NCT01251172|Experimental|Treatment (RO4929097 after autologous stem cell transplant)|"STEM CELL TRANSPLANTATION AND CHEMOTHERAPY: Patients undergo standard mobilization and collection of autologous peripheral stem cells (>= 4.0 x 10^6 CD34+ cells/kg). Patients then receive high-dose melphalan IV on days -3 and -2 and undergo autologous stem cell transfusion on day 0. Patients with progressive disease, stable disease, partial response, stringent complete response, or complete response are taken off study; patients with residual/persistent disease (VGPR) continue to therapeutic treatment.~THERAPEUTIC TREATMENT: Beginning 100-110 days after transplantation, patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89264551|NCT00413777|Experimental|Tolvaptan 45/15 mg/day orally for up to 4 years|Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
89264552|NCT00413777|Experimental|Tolvaptan 60/30 mg/day orally for up to 4 years|Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.
89264553|NCT03912922|Experimental|Sit regime|Subjects will follow the sit regime during four days. Each day consists of 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
89264554|NCT03912922|Experimental|Sit less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 3 hours walking, 4 hours standing and 8 hours sleeping.
89264555|NCT03912922|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours sitting, 1 hour walking, 1 hour standing, 1 hour exercise and 8 hours sleeping. The cycle session will be at approximately 60% maximal power. Exact cycling intensity and duration will be calculated to ensure equal total energy expenditure between the sitting less and the exercise regime.
89264556|NCT01250080|Experimental|Glutamine|
89264557|NCT01250080|Sham Comparator|Control|
89264558|NCT03908320|Experimental|Menstrual Cycle Timing|
89264559|NCT03908320|Active Comparator|Menstrual Cycle Monitoring|
89264560|NCT03908086||RA patients|Incident patients with rheumatoid arthritis as identified by the Danish National Patient Registry and the rheumatology registry, DANBIO.
89264561|NCT03908086||General population|All other adults, as Identified by the Civil Registration System. Patients who develop RA contribute person-years in the general population cohort until RA diagnosis
89264562|NCT01148290|Active Comparator|Tension free vaginal tape|
89264563|NCT01148290|Experimental|Bulking agent injection|
89264564|NCT00197028|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of RTS,S/AS02D at days 14, 44 and 74 and a 3-dose vaccination course of TETRActHib™ vaccine at days 0, 30 and 60. The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
89264565|NCT00197028|Active Comparator|Engerix-B Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine at days 14, 44 and 74 and a 3-dose of TETRActHib™ vaccine at days 0, 30 and 60. The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
89264566|NCT01250158|Experimental|Liver-PILP kit|Liver-PILP kit
89264567|NCT01251250|Experimental|Arm I|Patients receive oral Azadirachta indica once daily on days 1-28. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
89264568|NCT01073982|Placebo Comparator|cherry flavored fruit drink|
89264569|NCT01073982|Experimental|tart cherry juice|
89264570|NCT01250236||verum|brimonidine 0.1% eye drops twice daily
89264571|NCT01250236||placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
89264572|NCT01074060|Experimental|Arm I|"MOBILIZATION: Patients receive cyclophosphamide IV. Patients also receive filgrastim subcutaneously (SC) daily beginning approximately 24 hours later.~TREATMENT/APHERESIS: Beginning 10 days after cyclophosphamide, patients receive plerixafor IV over 30 minutes followed by filgrastim SC on each day of apheresis."
89264573|NCT03907930|Active Comparator|conventional|this arm will have both nephrostomy tube and ureteric catheter after completing the operation
89264574|NCT03907930|Active Comparator|tubeless|the arm will have only ureteric catheter rafter completing the operation
89264575|NCT03915340|Other|Sequence ABAB|16 subjects assigned to the sequence ABAB will receive a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in Periods 1 and 3 and a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89264576|NCT03915340|Other|Sequence BABA|16 subjects assigned to the sequence BABA will receive a single 300 mg dose of the reference product Rytmonorm (1 x 300 mg film-coated tablet), marked as B in the sequence, in Periods 1 and 3 and a single 300 mg dose of the test product Propafenone (1 x 300 mg film-coated tablet), marked as A in the sequence, in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89264577|NCT03907618||Group 1 diagnosed with Diabetes Mellitus|Patients with Type 1 Diabetes Mellitus aged 18-40 years who had ovarian reserve with gynecological examination
89264578|NCT03907618||group 2 control group|Healthy volunteer patients aged 18-40 years who have no diagnosis of Type 1 Diabetes Mellitus and whose ovarian reserve is evaluated by gynecological examination
89264579|NCT01250314|Other|With fracture|Patients with fracture
89264580|NCT01250314|Other|Without fracture|Patients without fracture
89264581|NCT03907696|Other|Intervention|The intervention arm participate in an educational program that aimed at reducing stigma
89264582|NCT03907696|No Intervention|control|regular curriculum with no addition educational contents
89264583|NCT03973710|Experimental|Probiotics group|Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.
89264584|NCT03973710|Placebo Comparator|Placebo group|Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.
89264585|NCT03915028|Experimental|Treated group by thermal cure|Treated group will benefit, within 6 weeks of the inclusion, from the thermal cure in one of the thermal establishments.
89264586|NCT03915028|No Intervention|Control group|Control group will receive a thermal cure after the end of the study
89264587|NCT03972618|Experimental|School and village|Simultaneous installation of filters in schools and the village
89264588|NCT03972618|Experimental|School only|Initial installation in school only
89264589|NCT03972618|Experimental|Village only|Initial installation in village only
89264590|NCT03972618|No Intervention|Control|Control group. No filter installation initially.
89264591|NCT03907306|Experimental|Patients after open hemorrhoidectomy (study group)|Patients to whom during a post-operation period cold argon plasma and a standard treatment will be treated. Cold argon plasma will be applied during 4 minutes at one session on the 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 14th, 21nd, 30th day after operation. The usage of antibacterial and wound healing ointments daily.
89264592|NCT03907306|Active Comparator|Patients after open hemorrhoidectomy (control group)|Patients who during a post-operation period will be treated with a standard treatment.The usage of antibacterial and wound healing ointments daily.
89264593|NCT01582542|Experimental|Desmopressin|
89264594|NCT03907384|Experimental|Mat Pilates training|The MPT group participated in 3-one hour supervised training sessions per week for 12 weeks. All MP sessions were performed in nonconsecutive days. The MP sessions were divided into the following stages: initial warm up and stretching (10 min), general conditioning consisting of MP exercises (40 min) and stretching and cooling down (10 min). The participants performed 12 basic MP exercises (one set of 6-10 repetitions was performed per exercise). Breathing, a core principle of MP, was performed by forced but controlled inspirations and exhalations, while relaxing and contracting the abdomen, respectively. All sessions were supervised by a certified MP instructor.
89264595|NCT03907384|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
89264596|NCT03913000|Experimental|ID-085 single dose|Administration of the study treatment 200 mg to renally impaired subjects will be done by severity, starting with group A (mild), and followed by group B (moderate), C (severe) and D (healthy subjects).
89264597|NCT03913156|Other|Part 1|Part 1 of the study will recruit subjects who are about to be introduced to a concentrated phe-free protein substitute (i.e. second stage protein substitute) for the first time.
89264598|NCT03913156|Other|Part 2|Part 2 of the study will recruit subjects who have already been introduced to a concentrated phe-free protein substitute (i.e. have already transferred from phe-free infant formula onto a second stage protein substitute). This group will be included to evaluate the acceptability of the study product in patients who have already moved onto a second stage protein substitute.
89264599|NCT03912766||Transurethral Prostatectomy|male patients undergoing transurethral prostatectomy (TURP) for benign prostatic hyperplasia, routine surgical removal using resectoscope
89264600|NCT01251328|Active Comparator|General anaesthesia|General anaesthesia is performed under standardized conditions
89264601|NCT01251328|Active Comparator|Sedation|Sedation is performed under standardized conditions
89264602|NCT01250392|Other|Control Arm|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment.
89264603|NCT01250392|Experimental|Active Choice Only Arm|The active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
89264604|NCT00420641|Experimental|GSK372475 Arm|GSK372475 1.0- 1.5 mg/day
89264605|NCT00420641|Experimental|Paroxetine Arm|Paroxetine 20-30 mg/day
89264606|NCT00420641|Other|Placebo|Placebo to Match
89264607|NCT01251406|Placebo Comparator|Placebo|Subcutaneous administration for daily for 8 hours a day for 10 days
89264608|NCT01251406|Experimental|rhNRG-1 Dose 1|Subcutaneous administration for daily for 8 hours a day for 10 days
89264609|NCT01251406|Experimental|rhNRG-1 Dose 2|Subcutaneous administration for 8 hours a day for 10 days
89264610|NCT00257556|Experimental|Menotrophin|
89264611|NCT00257556|Active Comparator|Follitropin alfa|
89264612|NCT03907228|Experimental|RHT-3201|Lactobacillus rhamnosus IDCC 3201, Tyndallization (RHT-3201) (100 billion Colony Forming Units/sachet)
89264613|NCT03907228|Placebo Comparator|Placebo|Dextrose Anhydrous
89264614|NCT03906916|Experimental|Patients with suspicion of invasive candidiasis|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
89264615|NCT03907150||Pneumothorax|Pneumothorax
89264616|NCT03907150||Normal|Normal lung
89264617|NCT03972540|Experimental|Mindful eating intervention|The mindful eating intervention was taught by a mindfulness-based stress reduction instructor certified by the Center of Mindfulness at the University of Massachusetts Medical School.
89264618|NCT01250470|Experimental|Treatment (vaccine therapy)|"Patients receive Montanide ISA-51/survivin peptide vaccine SC followed by sargramostim SC on day 0. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~TREATMENT EXTENSION: After completion of study treatment, select patients may receive additional doses of Montanide ISA-51/survivin peptide vaccine SC and sargramostim SC. Treatment repeats every 3 months in the absence of disease progression or unacceptable toxicity."
89264619|NCT01148368|Experimental|renal impairment patients|renal impairment patients who eGFR is lower than 30 ml/min/1.73m^2 without hemodialysis
89264620|NCT01148368|Active Comparator|healthy volunteers|healthy volunteers group
89264621|NCT03912688|Experimental|single acupoint stimulation|
89264622|NCT03912688|Experimental|dual acupoints stimulation|
89264623|NCT03912688|No Intervention|no stimulation|
89264624|NCT01250548|Active Comparator|2|
89264625|NCT01250548|Placebo Comparator|Apremilast|Placebo Compared to apremilast arm
89264626|NCT01250626||a single-group study|Pediatric OPD, age < 18 y/o.
89264627|NCT03906838|Experimental|Regional Nerve Block|Subjects in the regional anesthesia cohort will have a regional anesthesia block and/or catheter placement administered according to current hospital policies and our established standard of care.
89264628|NCT03906838|No Intervention|No Regional Nerve Block|Subjects in the no regional anesthesia cohort will not get pre-operative regional anesthesia, and their surgery and anesthesia will be performed according to normal policies and standard of care in our hospital.
89264629|NCT03912610||Health control group|5 health volunteer are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
89264630|NCT03912610||Knee osteoarthritis group|5 patients of knee osteoarthritis accompanied with depression or anxiety are included in the group. Each volunteer will take the functional magnetic resonance examination one to collect the data.
89264631|NCT03914638|Experimental|Active|Active intervention arm. Treatment for 8 weeks per treatment period.
89264632|NCT03914638|Placebo Comparator|Placebo|Placebo arm. Treatment for 8 weeks per treatment period.
89264633|NCT01148446|Experimental|R-CHOP|R-CHOP (every 21 days) for six courses Cyclophosphamide: 750 mg/m2, IV, day 1 Doxorubicin: 50 mg/m2, IV, day 1 Vincristine: 1.4 (max 2) mg/m2, IV, day 1 Prednisone: 75 mg/m2, IV, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
89264634|NCT01148446|Experimental|R-mini-CEOP|R-miniCEOP (every 21 days)for six courses Cyclophosphamide: 50 mg/m2, IV, day 1 Epirubicin: 50 mg/m2, IV, day 1 Vinblastine: 5 mg/m2, IV, day 1 Prednisone: 60 mg/m2, IV/PO, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
89264635|NCT00228384|Active Comparator|Gore VIABAHN Endoprosthesis|
89264636|NCT00228384|Active Comparator|Bare Nitinol Stent (BNS)|
89264637|NCT03914404|Experimental|Test group|"γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
89264638|NCT03914404|Experimental|Control Group|"Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
89264639|NCT01147198|Active Comparator|Ready to Use Supplementary Food|Ready to Use Supplementary Food treatment
89264640|NCT01147198|Active Comparator|Premix|Premix Corn Soy Blend-oil treatment
89264641|NCT01073280||undeterminated neurological disease, cerebral endoscopy|patients without neurological diagnosis that require cerebral , meningeal diagnosis
89264642|NCT03905980||Vaginal delivery|woman who terminate their pregnancy by vaginal delivery
89264643|NCT03905980||Cesarean delivery|woman who terminate their pregnancy by cesarean delivery
89264644|NCT01251562|Experimental|Cohort 1|"5.62 mg/kg~Sterile Compound C31510 for Injection"
89264645|NCT01251562|Experimental|Cohort 2|"11.25 mg/kg~Sterile Compound C31510 for Injection"
89264646|NCT01251562|Experimental|Cohort 3|"22.5 mg/kg~Sterile Compound C31510 for Injection"
89264647|NCT01251562|Experimental|Cohort 4|33.0 mg/kg
89264648|NCT01251562|Experimental|Cohort 5|"44.0 mg/kg~Sterile Compound C31510 for Injection"
89264649|NCT01251562|Experimental|Cohort 6|"58.7 mg/kg~Sterile Compound C31510 for Injection"
89264650|NCT01251562|Experimental|Cohort 7|"78.2 mg/kg~Sterile Compound C31510 for Injection"
89264651|NCT01251562|Experimental|Cohort 8|"104.3 mg/kg~Sterile Compound C31510 for Injection"
89264652|NCT01251562|Experimental|Cohort 9|"139.0 mg/kg~Sterile Compound C31510 for Injection"
89264653|NCT01251640|Experimental|Arm 1|
89264654|NCT00257166|Experimental|Ziprasidone oral capsules|
89264655|NCT00257166|Placebo Comparator|Placebo|
89264656|NCT03912142||Three dimensional transperineal ultrasound|"This is a single arm study. All women who delivered vaginally will be included in the study .~The planned interventions are:~Clinical vaginal and rectal examination Three dimensional transperineal ultrasound."
89264659|NCT03905824|Experimental|Debridement and microfracture in LOC + Cells|Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.
89264660|NCT03905824|Active Comparator|Debridement and microfracture in LOC|Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus.
89264661|NCT01254058||Glaucoma Group|
89264662|NCT01254058||Age-Matched Controls|
89264663|NCT03913936|Experimental|NEWLY DIAGNOSED|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
89264664|NCT03913936|Experimental|SURVIVOR|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
89264665|NCT03913936|Experimental|LIVING WITH ADVANCED DISEASE|"Participants will track their symptoms with weekly and monthly standard surveys to monitor for symptoms.~The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician"
89264666|NCT03913858|Other|high-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 1 had 4 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
89264667|NCT03913858|Other|low-flow anesthesia|Before beginning induction, first 3 mg midazolam and fentanyl 150 mvq IV were administered. According to ideal weight and BIS score for 40-60, 2-5 mg propofol and 0.5 mg rocuronium according to true weight were administered. After intubation 50 mg ranitidine and 8 mg ondansetron were routinely administered. Fixing the remifentanil dose to 0.1 mcg/kg/min, infusion was administered. Group 2 had 1 liter/minute (50% O2, 50% air) flow administered. Mechanical ventilator settings were 6-10 ml tidal volume, frequency 12/min (increasing, if necessary, for etCO2 35-45 mmHg), PEEP 5-10 cm/H2O and inspirium/expirium ratio ½. Both groups had remifentanil ended 10 minutes before the end of surgery. Later 1 g paracetamol and 100 mg tramadol IV were administered.
89264668|NCT01148602|No Intervention|'Off Clock'|"Stopwatch timers will NOT be used for off clock weeks, so patients presenting with hyperacute stroke will be managed normally without the visual timer."
89264669|NCT01148602|Active Comparator|"'On Clock"|"LED stopwatch-clock timers will be posted for all patients presenting during ON clock weeks. All patients presenting with hyperacute stroke will be managed normally with the addition of a visual stopwatch timer."
89264670|NCT01254682|Active Comparator|Hyaluronic acid sodium salt (1%, 20mg/2ml)|
89264671|NCT01254682|Other|Standard arthroscopic procedure|
89264672|NCT05570188|Experimental|Treatment group|Patients will get infused with anti-CD19 CAR-NK cells within 1 week after hematopoietic stem cell infusion.
89264673|NCT03905278|Experimental|Parental guidance|"In the experimental condition, the two significant caregivers of the child or the individual caregiver receive the intervention composed of an informational booklet and a psychological intervention. The intervention consists of four sessions, centered on supporting the child in the context of parental cancer principally through communication.~Assessments are conducted at two periods : before and after the intervention."
89264674|NCT03905278|No Intervention|Waiting List group|"In the control condition, the participants receive the informational booklet before being registered in a waiting list for the psychological intervention. The intervention should ideally last two months.~Assessments are conducted at 9 weeks of interval."
89264675|NCT03905590|Experimental|periapical surgery with amniotic membrane|periapical surgery will be done and amniotic membrane will be placed over the defect before closure of flap
89264676|NCT03905590|Active Comparator|periapical surgery without amniotic membrane|periapical surgery will be done without the placement of amniotic membrane over the defect before closure of flap
89264677|NCT00227370|Active Comparator|1|Valganciclovir 900 mg QD for 9 months post lung transplant.
89264678|NCT00227370|Placebo Comparator|2|placebo for 9 months post lung transplant
89264679|NCT03905122||continous veno-venous hemodialysis|to measure the fluid changes by using bioreactance method in continous veno-venous hemodialysis group
89264680|NCT03905122||hemodialysis|to measure the fluid changes by using bioreactance method in hemodialysis group
89264681|NCT03969030|Experimental|Intervention|"Participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the Peer-Educator (PE) according to the participants' preferences, using a tablet-based application, called PEBRApp. The preference assessment entails the following three domains of DSD:~ART Refill~SMS notifications~Support In each of the domains, the participants' preferences will be assessed and the most feasible option will be selected. The PEBRApp not only helps the PE to assess each participants' preference, but also to keep track of the ART refill, and to ensure regular contact between the PE and the participant. The model includes key innovative options such as individualized automatic SMS notifications and decentralized ART delivery."
89290478|NCT05198206||Shanxi Provincial Cardiovascular Hospital|
89290479|NCT05198206||West China Second Hospital|
88816284|NCT04573322|Experimental|Randomized Active TSC|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
89264682|NCT03969030|No Intervention|Control|Participants in the control clusters are offered standard of care: ART visit/refill is coordinated by the nurse, is mostly clinic-based, not adapted to youth, and differentiated according to clinical values (i.e. if VL suppressed then option of ART Refill in a Community Adherence Club).
89264683|NCT03905200||coronary artery disease|Patients who were diagnosed with coronary heart disease at admission and planned to undergo coronary angiography
89264684|NCT01251796|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
89264685|NCT01251874|Experimental|Treatment (veliparib, F 18 fluorothymidine, carboplatin)|Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
89264686|NCT03911674|Experimental|Oral stimulation|Oral stimulation protocol: manual stimulation of the oral sucking
89264687|NCT03911674|No Intervention|Control|No intervention
89264688|NCT03903250|Placebo Comparator|Sugar|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
89264689|NCT03903250|Experimental|A-GPC|100% soluble in liquid. 4 oz. taken in the morning of testing sessions.
89264690|NCT01147978|Experimental|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
89264691|NCT01147978|No Intervention|Usual Procedure|Usual discharge procedure from the ICU
89264692|NCT01252030|Experimental|intervention|stimulation of physical activity by messages sent through e mail or SMS; in combination with monitoring of physical activity with physical activity monitors
89264693|NCT01252030|Placebo Comparator|control|no stimulation of physical activity
89264694|NCT01252108|Experimental|Treatment|All subjects receive SQ109
89264695|NCT01148680|Experimental|immediate registration on islet graft list|"group 1 'immediate registration on infusion waiting list' : patients who will be immediately registrated on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
89264696|NCT01148680|Active Comparator|delayed registration on islet graft list|"group 2 'delayed registration on infusion waiting list' : patients who will be registrated 6 months later on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
89264697|NCT05560048|Experimental|treatment to placebo|Participants should eat rice protein RP-80NY once a day for 28 days, then exchange the treatment sample to placebo after 14 days of wash-out. The dosage of the rice protein RP-80NY or placebo is 0.053 g/kg body weight.
89264698|NCT05560048|Experimental|placebo to treatment|Participants should eat placebo once a day for 28 days, then exchange the treatment sample to rice protein RP-80NY after 14 days of wash-out. The dosage of the rice protein RP-80NY or placebo is 0.053 g/kg body weight.
89264699|NCT03904810|No Intervention|Control|Subjects in this group do not received any intervention
89264700|NCT03904810|Active Comparator|Moderate Intensity Continuous Training ×3/wk|Subjects in this group will receive three sessions of Moderate-Intensity Continuous Training per week throughout the 8 weeks experimental period
89264701|NCT03904810|Active Comparator|High Intensity Interval Training×3/wk|Subjects in this group will receive three sessions of High-Intensity Interval Training per week throughout the 8 weeks experimental period
89264702|NCT03904810|Active Comparator|High Intensity Interval Training×2/wk|Subjects in this group will receive two session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
88816285|NCT04573322|Placebo Comparator|Randomized Placebo|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
88816286|NCT02436330|Experimental|Exergaming and Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting of exergaming combined with didactic teaching.
89264703|NCT03904810|Active Comparator|High Intensity Interval Training×1/wk|Subjects in this group will receive one session of High-Intensity Interval Training per week throughout the 8 weeks experimental period
89264704|NCT03904966|Experimental|ESWT+ Kinesiotaping|Low-dye Kinesio taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
89264705|NCT03904966|Sham Comparator|ESWT+Shamtaping|Sham taping technique 4 times in 5 weeks in addition to extracorporeal shock wave therapy
89264706|NCT03904966|Other|ESWT|Extracorporeal shock wave therapy for 5 sessions (5-week)
89264707|NCT03905044||CC|eyes with congenital cataracts
89264708|NCT03911440|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
89264709|NCT03911440|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
89264710|NCT00191100|Experimental|1|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week~Two week rest period with no chemotherapy or radiation~Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles"
89264711|NCT00191100|Active Comparator|2|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week"
89264712|NCT01254916||Patients with chronic rhinosinusitis|
89264713|NCT03911518|Active Comparator|Control|Incision and drainage.
89264714|NCT03911518|Experimental|Intervention|Loop drainage.
89264715|NCT03911362|Active Comparator|Lumbopelvic Stabilisation Exercises|Starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction
89264716|NCT03911362|Active Comparator|Pelvic Floor Exercises|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres and for slowly contracting muscle fibres,slow contraction by counting to ten hold for a count of ten, then gradually relax by counting to ten.
89264717|NCT01148758|Experimental|Single Arm|
89264718|NCT01254448|Placebo Comparator|Placebo|Subjects will receive a placebo capsule orally once a day for 28 days (Group 1) or 10 days (Group 2).
89290480|NCT05198206||The First Affiliated Hospital of Jilin University|
89264719|NCT01254448|Experimental|TC-5619|Subjects will receive a TC-5619 orally once a day for 28 days (Group 1) or 10 days (Group 2).
89264720|NCT03902548|Experimental|Brain uptake and kinetics in Alzheimer's patients|
89264721|NCT03902548|Experimental|Dosimetry in healthy volunteers|
89264722|NCT03904576|Experimental|Treatment (T)|
89264723|NCT03904576|Placebo Comparator|Reference Treatment (R)|
88805324|NCT01431391|Experimental|Arm 2: ADT followed by sipuleucel-T|Arm 2: Subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg) 12 weeks before infusion 1 of sipuleucel-T. An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT. Twelve weeks after the initial leuprolide 45 mg depot injection, subjects began one infusion of sipuleucel-T every two weeks for a total of three infusions.
88805325|NCT03009097|Active Comparator|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with DFDBA
88805326|NCT03009097|Active Comparator|DFDBA with Atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with DFDBA in combination with Atorvastatin gel.
89264724|NCT01252264||Individuals with craniofacial anomalies|Individuals who have a craniofacial anomaly (head, face, or eye disorder)
89264725|NCT01252264||Control Subjects|Family members of individuals with a craniofacial anomaly
89264726|NCT03902626||Physiotherapy students|Degree course
89264727|NCT03902626||Medical students|Degree course
89264728|NCT01149226|Placebo Comparator|placebo control|
89264729|NCT01149226|Experimental|oral medication chloral hydrate|
89264730|NCT01252342|Experimental|Intramyometrial oxytocin|
89264731|NCT01252342|Placebo Comparator|Intramyometrial Saline|
89264732|NCT03902470|Experimental|Thoracic epidural anaesthesia for vats|"Patients in thoracic epidural (TE) group will pre-medicated using midazolam 3-4 mg intravenous (IV)and fentanyl 50 mcg intravenously(i.v.). Then patients will placed in the lateral decubitus position. An epidural catheter will be inserted between T3-T4 and T4-T5 for all thoracic procedures except sympathectomy and thymectomy. A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5% and 50 mcg of fentanyl.~The objective is to achieve sensory and motor block between C7 and T7 levels. At this level diaphragmatic respiration is maintained. The anaesthesia level will be monitored by warm-cold discrimination."
89264733|NCT03902470|Active Comparator|General anesthesia for vats|Patients will receive general anesthesia as follows, Premedication in the form of 3-4 mg midazolam (IV), induction of a anesthesia with propofol (2mg/kg) and fentanyl (1 mcg/kg). Tracheal intubation and double endotracheal tube insertion will be facilitated with cisatracurium 0.1 mg/kg. and confirmation of it is position will made by fiberoptic bronchoscopy, Anesthesia will be maintained with isoflurane (1-2 %) and cisatracurium (0.05 mg/kg per dose).After the end of the operation, anesthesia will be discontinued, the wound dressing will be applied, and extubation of the patient will be done after reversal of muscle relaxant by neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg) and extubation will be performed after complete neuromuscular recovery.
89264734|NCT03911050|Experimental|Apple consumption|Each subject took apple blends 600 g (made from two apples with seed removal) in a single dose, and samples (urine and blood and feces) at different timepoints were collected following administration of apple blends.
89264735|NCT03911050|Placebo Comparator|Control group|Each subject took breakfast without any apple-related products in a single dose, and samples (urine and blood and feces) at different timepoints were collected following breakfast.
88805327|NCT01325311|Experimental|Arm I (cholecalciferol, genistein)|Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
88805328|NCT01325311|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
89264736|NCT00189540|Active Comparator|Active Group|4.0 mg AMG0001 via intramuscular injections on days 0, 14, and 28
89264737|NCT00189540|Placebo Comparator|Placebo Group|Placebo (saline) via intramuscular injections on days 0, 14, and 28
89264738|NCT03904654|Experimental|Mindfulness-based cognitive therapy (MBCT)|All participants will receive the MBCT intervention, consisting of 8 60-minute consecutive weekly MBCT group sessions.
88805329|NCT01432015|Active Comparator|Fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Oral Placebo given on days 1-3
89264739|NCT01254994|Active Comparator|Control group|The patients were prescribed the tradition comprehensive medical treatment without entecavir.
89264740|NCT01254994|Experimental|ETV group|All the patients were prescribed the tradition comprehensive medical treatment with entecavir. Entecavir was supplied by the Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. Patients took 0.5 mg entecavir following oral fasting one time per day.
89264741|NCT01148914||Baseline level of biomarkers|
88805330|NCT01432015|Active Comparator|Aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. 100 cc of IV placebo administered on day 1
88805331|NCT01080209|Experimental|Brimo PS DDS® 400 μg (2 implants)|Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study.
88805332|NCT01080209|Experimental|Brimo PS DDS® 400 μg (1 implant)|Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study.
89264742|NCT03902236||Cystic fibrosis group|Children diagnosed with cystic fibrosis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
89264743|NCT03902236||Bronchiectasis group|Children diagnosed with bronchiectasis more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
89264744|NCT03902236||Healthy group|Healthy children more than 6 years old Stable medical condition Those who have not participated in a planned training program in the last 3 months
89264745|NCT03904732||Cohort 1|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for primary prevention
89264746|NCT03904732||Cohort 2|hypothetical UK populations of adults aged 50-59 take low-dose aspirin for secondary prevention
89264747|NCT03904732||Cohort 3|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for primary prevention
89264748|NCT03904732||Cohort 4|hypothetical UK populations of adults aged 50-59 do not take low-dose aspirin for secondary prevention
89264749|NCT03904732||Cohort 5|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for primary prevention
89264750|NCT03904732||Cohort 6|hypothetical UK populations of adults aged 60-69 take low-dose aspirin for secondary prevention
89264751|NCT03904732||Cohort 7|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for primary prevention
89264752|NCT03904732||Cohort 8|hypothetical UK populations of adults aged 60-69 do not take low-dose aspirin for secondary prevention
89264753|NCT03911206|Experimental|Arm 1 : Inspirtory muscle training (IMT)|IMT exercises at home will gradually ramp up.
89264754|NCT03911206|Experimental|Arm 2: Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
89264755|NCT03911206|Experimental|Arm 3: IMT and Exercise|a combination of arm 1 and arm 3
89264756|NCT03911206|No Intervention|Arm 4: Routine care|no interventions will occur in this group besides testing procedures and offering access to the study team in case asthma-related questions come up.
89264757|NCT03902158|Experimental|Glasses|
89264758|NCT03902158|No Intervention|Distraction techniques|No glasses will be used
89264759|NCT01149304|Experimental|Group A|Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
89264760|NCT01149304|No Intervention|Group B|Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.
89264761|NCT01254526|Experimental|A|
89264762|NCT01254526|Experimental|B|
89264763|NCT01148992|Active Comparator|Lofexidine|
89264764|NCT01148992|Placebo Comparator|Placebo|
89264765|NCT02527954||Infertile with Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)"
89264766|NCT02527954||Infertile without Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)"
89264767|NCT03910582|Experimental|Experimental group|Subjects in this group will be treated with personalized frozen-thawed embryo transfer. The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
89264768|NCT03910582|Active Comparator|Control group|Subjects in this group will be treated with routine frozen-thawed embryo transfer.The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
89264769|NCT03901846|Other|ColdZyme|"The study is intended to verify the method used to measure the duration of ColdZyme®.~Each participant will be his own control as samples are taken before application of ColdZyme and used as an internal control."
89264770|NCT01148134||Bcr-Abl positive ALL|
89264771|NCT01148134||Bcr-Abl negative ALL|
89264772|NCT01252498||Radiotherapy|Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
89264773|NCT03904186|Experimental|QUIT Treatment for Smoking Cessation and Distress Tolerance|Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.
89264774|NCT03904186|Active Comparator|Time and Intensity-Match Control|Participants in this control arm will receive an intervention matched in time and intensity with the experimental arm.
89264775|NCT03904186|No Intervention|Standard of Care|At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.
89264776|NCT01255072|Active Comparator|Active rTMS + placebo|Patients, free from medication for at least one week (washout of 3 weeks for fluoxetine users) will receive 20 sessions of active rTMS delivered to the left Dorsolateral PreFrontal Cortex. Each patient will take placebo pills for 60 day,starting parallel on the first rTMS day.
89264777|NCT01255072|Sham Comparator|SHAM|Patients, free from medication at least for one week (washout of 3 weeks for fluoxetine users)receiving 20 sessions of Sham TMS delivered to the left dordolateral prefrontal cortex, at the same time this washed out of antidepressives patients start taking Citalopram 20mg/day, for 60 days.
89264778|NCT03904342|Active Comparator|Sophie CBT|The Sophie Cognitive Behavioral Therapy (CBT) intervention is a tablet-based computerized CBT and self-management education intervention that consists of an evidence-based cognitive behavioral therapy self-management curriculum divided into 6 discrete modules. Patients will have up to 8 weeks to work through the modules on the tablet.
89264779|NCT03904342|Active Comparator|iHope CBT|iHope CBT is a telemedically-delivered CBT package. The iHope system comprises a HIPAA-compliant platform on which real, live, licensed clinicians provide cognitive behavioral therapy via video conferencing, phone calls, and text messaging. iHope will be delivered on subjects' preferred electronic device (mobile phone, laptop, tablet).
89264780|NCT03903952|Other|Papanicolaou smear result (control group)|women who did not have intraepithelial neoplasia as a result of smear
89264781|NCT03903952|Other|Papanicolaou smear result (study group)|women who have atypical squamous cells of undetermined significance (ASCUS) as a result of smear
89264782|NCT01149382||islet cell transplant recipients|
89264783|NCT03910348|Experimental|Whole body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting (2-4mm peak to peak) on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA). Each patient received the vibrations under supervision using five different static positions: squat, deep squat, widestep squat, lunge, and hands-front lunge. The exercise programs for each experimental groups consisted of 20 to 60-minute sessions on three days per week for 24 weeks, and they were performed under the supervision.
89264784|NCT03910348|Experimental|High-impact exercise|Depending on their individual calcium and vitamin D intakes, each patient advised to receive supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D.
89290481|NCT05198206||Xinqiao Hospital, Army Medical University|
89264785|NCT03910348|No Intervention|Control|Depending on their individual calcium and vitamin D intakes, each patient received supplemental calcium and vitamin D to ensure a total daily intake of 1,500 mg of calcium and 880 IU of vitamin D. The demographic characteristics of the participants were obtained at the baseline assessment.
89264786|NCT00257010|Experimental|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
89264787|NCT03901768|Experimental|Group dexamethasone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection
89264788|NCT03901768|Experimental|Group triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
89264789|NCT03901768|Experimental|Group dexamethasone with triamcinolone|A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection. 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
89264790|NCT03901768|Placebo Comparator|Placebo group|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
89264791|NCT03903718|Experimental|MEDI8852 (dose 1) - part 1|Participants will receive a single intravenous infusion (IV) of MEDI8852 (dose 1)
89264792|NCT03903718|Sham Comparator|Placebo - part 2|Participants will received a single IV infusion of placebo ( matched to MEDI8852) on day 2
89264793|NCT03903718|Active Comparator|Oseltamivir (OS) 75 mg - part 2|Participants will receive 75 mg orally twice a day for 5 days starting at day 2
88805333|NCT01080209|Experimental|Brimo PS DDS® 200 μg (2 implants)|Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study.
88805334|NCT01080209|Experimental|Brimo PS DDS® 200 μg (1 implant)|Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study.
89264794|NCT03903718|Experimental|MEDI8852 (dose 2) - part 2|Participants will receive a single IV dose of MEDI8852 on day 2 (dose 2)
89264795|NCT03903718|Experimental|MEDI8852 (dose 1) - part 2|Participants will receive a single IV infusion of MEDI8852 on day 2 (dose 1)
89264796|NCT03903718|Experimental|MEDI8852 (dose 2) +OS 75 mg part 2|Participants will receive a single IV infusion of MEDI8852 (dose 2) on day 2 and 75mg of Oseltamivir twice a day for 5 days starting at day 2
89264797|NCT03910504|Active Comparator|Rocuronium 0,3 mg/kg|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.~Patients, who have been randomized to this group, will be obtained single reduced dose of rocuronium (0,3 mg/kg) once intravenous bolus. The dose of rocuronium will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment. The drug will be diluited in a syringe with 20 ml of solution."
89264798|NCT03910504|Experimental|No rocuronium|"One hour before the operation the patient will receive the midazolam from 1 to 5 mg intravenous. After the adequate preoxigenation and denitrogenation, the induction phase will be performed with the propofol 2 mg/kg intravenous bolus (for the sedation). At the same time continues infusion of remifentanyl (up to 1 mcg/kg/min) will guarantee the adequate anaesthesia.~Patients, who have been randomized to this group, will not receive rocuronium, but normal saline will be administered by the anesthesiologist in charge of the patients. The dose of normal saline (20 ml in one syringe) will be prepared by an external investigator, to leave the anesthesiologist blinded of the group treatment."
89264799|NCT03901690|Experimental|Arm Betaglucin|It will be composed of 51 individuals between 18 and 50 years old with anogenital warts to which will be applied betaglucin gel at 0.2%.
89264800|NCT03901690|Active Comparator|Arm Imiquimod|51 individuals between the ages of 18 and 50 will receive 5% imiquimod.
89264801|NCT03901378|Experimental|Single Arm|Pembrolizumab 200mg IV day 1 with Carboplatin AUC 6 IV day 1 or Cisplatin 80mg/m2 day 1 with etoposide 100mg/m2 days 1-3 of 21 day cycle. Repeat 4-6 cycles to be followed by maintenance Pembrolizumab 200mg IV day 1 every 21 days until progression or intolerance for up to 2 years.
89264802|NCT03909958|Other|Electroacupuncture+Routine rehabilitation training Group|42 patients will receive both electroacupuncture（HANS100A）therapy and routine rehabilitation training.
89264803|NCT03909958|Other|Routine rehabilitation training Group|42 patients will receive simple routine rehabilitation training.
89264804|NCT02527876|Experimental|High Intensity Interval Training/FitBit Flex|Meet with personal trainer once per week for 20-minute exercise session
89264805|NCT02527876|Experimental|Moderate Intensity/FitBit Flex|Meet with personal trainer once per week for 30-minute exercise session and exercise two times a week outside of personal trainer
89264806|NCT02527876|Placebo Comparator|Delayed Control/FtBit Flex|No exercise offered
89264807|NCT01252576||women with and without sexual dysfunction|women with and without female sexual dysfunction
88805335|NCT01080209|Experimental|Brimo PS DDS® 100 μg (1 implant)|Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study.
88805336|NCT01080209|Experimental|Brimo PS DDS® 50 μg (1 implant)|Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study.
88805337|NCT01080209|Sham Comparator|Sham|Patients who received sham in a previous study.
88805338|NCT01080677|Placebo Comparator|Placebo|Participants will receive placebo to match caffeine/propranolol (single dose)
88805339|NCT01080677|Experimental|Low dose|Participants will receive caffeine/propranolol 400/40 mg combination tablet (single dose)
88805340|NCT01080677|Experimental|High dose|Participants will receive caffeine/propranolol 1000/40 mg combination tablet (single dose)
88805341|NCT01378273|Placebo Comparator|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
88805342|NCT01378273|Experimental|Epo 1000 U/kg followed by 400 U/kg|Subjects will receive 6 doses of intravenous Epo 1000 U/kg/dose at 48 hour intervals from the time of enrollment. Following the high dose period, subjects will receive subcutaneous Epo 400 U/kg/dose three times a week until 32-6/7 weeks postmenstrual age.
89264808|NCT05619016|Experimental|Patients with HER2 positive GEAC or HER2 low cancer (pilot)|"The participants of the study will undergo two sessions of HER2 PET and one 18F-FDG PET/CT for study purposes. The first HER2 PET is performed within 21 days before initiation of the systemic oncological treatment including HER2-targeted drugs, and is followed by tumor biopsies. A second HER2 PET and a second 18F-FDG PET will be performed adjacent to response evaluation after 3 courses of oncological therapy. Data from the PET investigations will be compared to HER2 expression analyses of the biopsy specimen and correlated to disease and survival data at follow up one year after inclusion.~Within the pilot study, participants with HER2 low mBC will undergo one HER2 PET followed by biopsies."
89264809|NCT01150240||Primary Immunodeficiency Disease|Patients with primary Immunodeficiency disease (PID)
89264810|NCT03901222|Active Comparator|Bi-Anodal tDCS|Subjects will receive 20 min of bi-anodal tDCS
89264811|NCT03901222|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
89264812|NCT03900676|Experimental|VB-1953 topical gel - 2% QD|VB-1953 topical gel - 2% QD
89264813|NCT03900676|Experimental|VB-1953 topical gel - 2% BID|VB-1953 topical gel - 2% BID
89264814|NCT03900676|Placebo Comparator|VB-1953 topical gel- 0% (Vehicle) QD|VB-1953 topical gel- 0% (Vehicle) QD
89264815|NCT03900676|Placebo Comparator|VB-1953 Vehicle|VB-1953 topical gel- 0% (Vehicle) BID
89264816|NCT00256854|Experimental|Ropinirole cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 2 mg controlled release for Restless Legs Syndrome (CR-RLS) in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 1 mg IR at bedtime and continued to receive the same till the end of Week 4.
89264817|NCT00256854|Experimental|Ropinirole cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 2 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
89264818|NCT00256854|Experimental|Ropinirole cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 2 mg IR at bedtime and continued to receive the same till the end of Week 4.
89264819|NCT00256854|Experimental|Ropinirole cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
89264820|NCT00256854|Experimental|Ropinirole cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 4 mg IR at bedtime and continued to receive the same till the end of Week 4.
89264821|NCT00256854|Experimental|Ropinirole cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
89264822|NCT01256242|Experimental|Group 1|Standard Suture Repair + Augment Rotator Cuff
89264823|NCT01256242|Active Comparator|Group 2|Standard Suture Repair
89264824|NCT01256320|No Intervention|Control Group|no shell egg consumption and usual dietary practices
89264825|NCT01256320|Active Comparator|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
89264826|NCT01256320|Active Comparator|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
89264827|NCT03898492|Other|Intervention|The participants in this group participated in exercise two times/week for 8 weeks
89264828|NCT03898492|No Intervention|Control|The participants in the control group were instructed to maintain their daily routines.
89264829|NCT00189462|Active Comparator|Montelukast|Treatment with montelukast for 4 months (4 mg per day)
89264830|NCT00189462|Placebo Comparator|Placebo|Treatment with placebo for 4 months
89264831|NCT03898258||neurogenic bladder|individuals with chronic (≥12 months) neurogenic lower urinary tract dysfunction due to spinal cord injury (SCI)
89264832|NCT01150318|Experimental|1|Patients treated by 131 iodine for thyroid cancer
89264833|NCT01252654||1 IntraLase flaps|Patients who have undergone flap creation with IntraLase laser
89264834|NCT01252654||2 Visumax flaps|Patients who have undergone flaps created with Visumax laser
89264835|NCT03910114||Dotarem Enhancement Group|
89264836|NCT03910114||Gadovist Enhancement Group|
89264837|NCT03910114||Magnevist Enhancement Group|
89264838|NCT01255228|Experimental|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
89264839|NCT01255228|Experimental|diet intervention|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
89264840|NCT03900364|Other|robot-assisted partial nephrectomy|partial nephrectomy performed with the da Vinci Surgical System
89264841|NCT03900364|Other|laparoscopic partial nephrectomy|partial nephrectomy performed with conventional laparoscopic surgery
89264842|NCT03910192|Experimental|Mindfulness meditation coaching|Mindfulness-based coaching - participants will receive instructions on (a) mindfulness meditation and gentle mindful movement through home-based and in-class participation at the Southlake Cardiovascular Rehabilitation Clinic and (b) personal coaching support. The health coach will further assist participants through either face-to-face or telephone-based discussions. They will meet with the health coach at mutually-agreed upon on times for designated time periods.
88805343|NCT01115231||Group 1 (Control)|Case control subjects without AMD diagnosis
89264843|NCT03910192|Active Comparator|dietary cardiovascular risk reduction coaching|Cardiovascular risk reduction education - No change to standard of care where participants will receive instructions (in person or by phone call) on how to integrate exercise and dietary changes in your lifestyle to reduce your risk of future cardiovascular events. These instructions will be centered around the DASH dietary practices.
89264844|NCT02528110|Sham Comparator|Radical gastrectomy without HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX or XELOX)
89264845|NCT02528110|Experimental|Radical gastrectomy with HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX or XELOX)
89264846|NCT03910036|Experimental|PRP group|15 patients to constitute the PRP-group was injected intra-articularly with about 5 ml of PRP in the operated knee joint
89264847|NCT03910036|No Intervention|control group|The other fifteen patients were not injected and constituted control group.
89264848|NCT05667298|Experimental|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|The primary/preferred adjuvant therapy will be immunoradiotherapy (ARM1); however, if this combination is felt to be too high-risk for specific patients, the next preferred therapy will be immunotherapy without radiation (ARM1B).
89264849|NCT05667298|Experimental|Adjuvant chemoradiotherapy|Some patients have medical conditions, i.e., severe auto-immune disease that prohibits them from receiving immunotherapy. In such patients, adjuvant therapy will be provided in the form of concurrent chemoradiotherapy (ARM2).
89264850|NCT01150552||Poultry exposed individuals|Any individual who had an occupational contact with poultry in the previous five years will be considered exposed. Individuals working on poultry farms, poultry wet markets, or keeping limited numbers of poultry in their backyard, are considered exposed.
89264851|NCT01150552||Non-poultry exposed adult controls|Unexposed individuals must have no occupational exposure to poultry in their lifetime and must also not be exposed to poultry purchased from live bird markets.
89264852|NCT01256554|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation. Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
89264853|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD with PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, with Posterior Vitreous Detachment (PVD Positive). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
89264854|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD w/o PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, without Posterior Vitreous Detachment (PVD Negative). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after the first 4 injections, will be on an as needed basis, based on predefined criteria.
89264855|NCT00256698|Active Comparator|1|Anastrozole
89264856|NCT00256698|Experimental|2|Anastrozole + Fulvestrant
89264857|NCT01150630|Experimental|adjuvant PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
89264858|NCT01150630|Experimental|perioperative PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
89264859|NCT01150630|Active Comparator|Adjuvant Gemcitabine|Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months
89264860|NCT03909568|Experimental|Third molar surgery|Split mouth comparison of effect of complete third molar removal vs coronectomy of contralateral third molar
89264861|NCT03969342|Experimental|Trainees|Local mid-level providers who undergo five day training on point of care ultrasound for diagnosing pediatric pneumonia
89264862|NCT03900052|No Intervention|Naïve|Conventional cane with no instruction given
89264863|NCT03900052|Active Comparator|Scale training|Conventional cane, scale training, and instruction on proper cane use
89264864|NCT03900052|Active Comparator|Scale recall|Conventional cane with no further instruction or practice given
89264865|NCT03900052|Experimental|Haptics training|Haptic biofeedback cane with explanation and training.
89264866|NCT03900052|Experimental|Haptics recall|Haptic biofeedback cane with no further instruction or practice given.
89264867|NCT03909802|Experimental|Experimental group|This arm will receive interventions consisting of self-management combined with family management programs.
89264868|NCT03909802|Placebo Comparator|Control group|Usual care refers to incorporating wound assessment, wound irrigation using NaCl, debridement, wound dressing, evaluation, and health education unmet with the self-and-family management of DFU program criteria in this study. All of the usual care will be performed and evaluated by the wound care nurses working at the selected clinics for this study.
89264869|NCT00189306|Experimental|Aldara|Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks
89264870|NCT03898102|Experimental|Regorafenib treatment with Zn supplement|Patients enrolled in this arm received regorafenib with zinc supplementation to examine if zinc supplementation can decrease the incidence of grade 2 or higher HFSR.
89264871|NCT03898102|Active Comparator|Regorafenib treatment only|Patients enrolled in this arm received regorafenib without zinc supplementation, which is the standard treatment of patients of metastatic colorectal cancer who failed previous standard therapy.
89290482|NCT05198206||The First Affiliated Hospital of Guangzhou Medical University|
89290483|NCT05198206||the Second Xiangya Hospital of Central South University|
89290484|NCT05198206||Shengjing Hospital of China Medical University|
89264872|NCT03898336|Experimental|broad-spectrum micronutrients|broad-spectrum micronutrients description: capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
89264873|NCT03898336|Placebo Comparator|placebo|capsules containing placebo
89264874|NCT03972462|Experimental|NPC-12G Gel 0.2% (Period 1)|A single 800 mg quantity weight (1.6 mg sirolimus) dose will be applied to the central face on Day 1.
89264875|NCT03972462|Active Comparator|Rapamune Tablet (Period 2)|Rapamune® (sirolimus) 2 mg tablet for oral dosing.
89264876|NCT01150786|Experimental|selenium|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
89264877|NCT01150786|Placebo Comparator|placebo capsule|The patients in this arm took one placebo capsule daily for 12 weeks.
89264878|NCT01149694|Other|Cohort 1|
89264879|NCT01149694|Other|Cohort 2|
89264880|NCT01149694|Other|Cohort 3|
89264881|NCT01149694|Other|Cohort 4|
89264882|NCT03897790||Patients under vasoconstrictor|Patients older than 65 years old and hypertensive, requiring vasoconstrictor (phenylephrine or Neosynephrine) during general anesthesia.
89264883|NCT01586182|Experimental|Stereotactic Boost|Escalating doses of stereotactic body radiation therapy (SBRT)
89264884|NCT03900130|Experimental|Full group|"There is only one arm in this study. The group of 25 subjects all undergo a repeated measures 2 x 2 factorial design, fully crossed such that all subjects are tested under all four combinations of factors.~The intervention Preload amounts to two factors, caloric load and protein to carbohydrate ratio of the preload, both of which can take on two levels high or low."
89264885|NCT01150864|Active Comparator|Passive Humidifier|The Passive Humidifier (HME)will changed every 24 hours
89264886|NCT01150864|Active Comparator|Active-Passive humidifier|The Active-Passive Humidifier will be changed every 24 hours
89264887|NCT01150864|Active Comparator|Hot Water Humidifier|Hot water humidifier will be set at 36-37 °C
89264888|NCT03909724|Active Comparator|TAS-102 (Lonsurf)|35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period.
89264889|NCT03909724|Experimental|High Dose Intermittent Sunitinib|700 mg once every 2 weeks.
89264890|NCT03899974|Experimental|70% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 70% high-amylose flour)
89264891|NCT03899974|Experimental|85% amylose bread|Mixed meal with 80g of available carbohydrates coming mainly from high-amylose bread (made with 85% high-amylose flour)
89264892|NCT03899974|Active Comparator|Control bread|Mixed meal with 80g of available carbohydrates coming mainly from conventional bread
89264893|NCT01253122|Experimental|TRx0037|
89264894|NCT01253122|Active Comparator|TRx0014|
89264895|NCT01149928||C/S delivered, wet lung|
89264896|NCT01149928||C/S delivered, healthy infants|
89264897|NCT03909646|Active Comparator|Surgical excision|Standard surgical excision with 5 mm safety margin
89264898|NCT03909646|Active Comparator|Photodynamic therapy|PDT with application of methyl aminolevulinate (MAL) cream followed by two illuminations with a one-week interval
89264899|NCT03909646|Active Comparator|5% 5-Fluorouracil|5FU cream, which has to be applied by the patient twice daily for 4 weeks.
89264900|NCT01256866|Active Comparator|DEXMEDETOMIDINE, SEDATION|
89264901|NCT01256866|Active Comparator|Midazolam, sedation,|
89264902|NCT03897946|Experimental|Group A: Hepatitis B exposed, with birth dose|"The 100 HBV-exposed (born to HBsAg-positive mothers) infants who are already enrolled in the parent AVERT study will also be enrolled in the current study, as the HBV-exposed cohort (Group A). These exposed infants will not receive additional interventions on top of the AVERT study since they will already be receiving a birth dose vaccine through the AVERT study."
89264903|NCT03897946|No Intervention|Group B: Hepatitis B unexposed, no birth dose|"For the HBV-unexposed cohort in this study, the investigators will enroll 200 infants born to HBsAg-negative mothers. Half (100) of these infants will receive the routine three-dose series of HBV vaccine according to the standard EPI schedule in the DRC with no additional birth dose vaccine (Group B)."
89264904|NCT03897946|Experimental|Group C: Hepatitis B unexposed, with birth dose|"Group C will consist of the other half (100) of infants in the HBV-unexposed cohort who will receive four doses of HBV vaccine including a birth dose vaccine prior to the routine EPI schedule."
89264905|NCT01257022|Experimental|Family Function Intervention|Familias Unidas Intervention Program
89264906|NCT01257022|No Intervention|Treatment as Usual|Control
89264907|NCT01150942|Experimental|vero cell-derived JE vaccine|vero cell-derived vaccine group
89264908|NCT01150942|Active Comparator|Mouse brain-derived JE vaccine|Mouse brain-derived JE vaccine group
89264909|NCT03899740||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
89264910|NCT01257100||Cases with NPC|Cases with NPC
89264911|NCT01257100||Hospital based controls|Hospital based controls
89264912|NCT03897400||study group|women in reproductive age with crohn's disease
89264913|NCT03897400||control group|women in reproductive age without crohn's disease,
89264914|NCT03909256|Experimental|NUTRI-HAB|"The intervention group participates in a targeted rehabilitation program 'NUTRI-HAB' with a focus on eating problem after treatment for head and neck cancer. The program comprises:~a five day residential stay with patient education~a two day follow-up residential stay after 3 months~two telephone consultations with clinical dietitian between the two residential stays."
89264915|NCT03909256|No Intervention|Control group|"The control group receives no intervention other than usual care in the study period.~After 3 months, the control group will be offered participation in the same residential rehabilitation program as the intervention group parcitipated in."
89264916|NCT01253278|Experimental|20 mg LY2393910|
89264917|NCT01253278|Experimental|60 mg LY2393910|
89264918|NCT01253278|Experimental|150 mg LY2393910|
89264919|NCT01253278|Experimental|450 mg LY2393910|
89264920|NCT01253278|Placebo Comparator|Placebo|
89264921|NCT03899818|Other|new generation DEB|drug-eluting balloon (DEB)
89264922|NCT03899818|Other|second generation DES|standard therapy with second generation drug-eluting stent (DES)
89264923|NCT03899662|Experimental|Cognitive and Physical Training|24 sessions (8 weeks, 3 times per week) of computer based 45 minute cognitive and 45 minute physical training.
89264924|NCT01150006||Healthy male participants|
89264925|NCT01253356|No Intervention|No IABP|Standard of care and no IABP
89264926|NCT01253356|Active Comparator|Intra-Aortic Balloon Pump (IABP)|Standard of care, IABP inserted < or = 3 hours before noncardiac surgery, maintained for > or = 12-24 hours after surgery
89264927|NCT03908944|Active Comparator|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
89264928|NCT03908944|Experimental|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
89264929|NCT03897010|Active Comparator|Silica-calcium phosphate composite Group|Participants underwent socket augmentation procedures and dental implant placement in a staged approach. Atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. Free gingival gingival graft (1.5 to 2 mm thick) was taken from the area between the first and second premolar, 5 mm from gingival margin. Bioactive porous SCPC dental bone graft granules in the size range 90-710 micron were mixed with saline and loosely packed in the extraction sockets as per the manufacturer. The grafted SCPC granules were covered with free gingival graft obtained from the palatal tissues and sutured to stabilize the grafting material in place.
89264930|NCT03897010|Placebo Comparator|Control Group|Participants underwent atraumatic extraction of badly decayed tooth was performed. The socket was debrided with curettes and alveolar spoons; the granulation tissue was carefully removed. The socket left to heal.
89264931|NCT01257178|Experimental|Normal hepatic function|6mg, oral, once on day 1
89264932|NCT01257178|Experimental|Mild hepatic impairment|6 mg, oral, once on day 1
89264933|NCT01257178|Experimental|Moderate hepatic impairment|6 mg, oral, once on day 1
89264934|NCT01257178|Experimental|Severe hepatic impairment|6 mg, oral, once on day 1
89264935|NCT03899506||Olanzapine|Patients receiving 10 mg IM Olanzapine per the ED protocol
89264936|NCT03899506||Midazolam|Patients receiving 5 mg IM Midazolam per the ED protocol
89264937|NCT01257256||infertile patients|male infertile patients(ICD-9:606),female infertile patients(ICD-9:628)
89264938|NCT03897166|Experimental|Trimodality Imaging|Positron Emission Tomography coupled with Computed Tomography computed coupled with Magnetic Resonance Imaging and whole-body Biphoton Absorptiometry
89264939|NCT03896932|Experimental|minipooled- Intravenous immunoglobulin(MP-IVIG)|• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.
89264940|NCT03908866|Experimental|PICC(Peripherally inserted central catheter)|Patients randomly assigned to receive a peripherally inserted central catheter(PICC).
89264941|NCT03908866|Active Comparator|CVC(Central venous catheter )|Patients randomly assigned to receive a centrally inserted central venous catheter(CVC).
89264942|NCT03908554|Experimental|intervention|The WHPP was applied to the intervention group in the workplace for two times a week for five weeks. During the first 5 minutes of the session, breathing exercises, 20 minutes, PMR and 10 minutes, posture exercises were performed. PMR has progressed gradually to every session. The program is under control with a follow-up chart of what the participants do every day, and the participants were supported with various reminders (i.e., graphical leaflets on PMR techniques which also can be used as a guide while practicing at home).
89264943|NCT03908554|No Intervention|Control|Participants of the control group rested in a room for 40 minutes and were told that they could read every session.
89264944|NCT01255384||Non Diabetic-Controls|Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
89264945|NCT01255384||Diabetic Pregnancy|Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
89264946|NCT01257334|Experimental|Treatment Group|BI 10773 10 mg, 25 mg administered once daily
89264947|NCT01257334|Placebo Comparator|Control Group|Placebo administered once daily
88805344|NCT01115231||Group 2 (Age-related Macular Degeneration)|Case (i.e., within 5 years) subjects will be recruited. Cases are defined as subjects with diagnosed AMD.
88805345|NCT01432405|Experimental|Pioglitazone and exenatide|Exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months.
89264948|NCT01150084|Experimental|lunchtime walking|
89264949|NCT01150084|Other|waiting-list control|
89264950|NCT01151176|Active Comparator|Insulin|Intensive Insulin Therapy
89264951|NCT01151176|Other|Regular Insulin|Sub Cutaneous Regular Insulin
89264952|NCT01257412|Experimental|1|
89264953|NCT01257412|Experimental|2|
89264954|NCT01257412|Placebo Comparator|3|
89264955|NCT01257490|Experimental|Intensive counseling|4 sessions of intensive counseling plus bupropion
89264956|NCT01257490|Active Comparator|Brief Counseling|Brief physician advice to quit plus bupropion
89264957|NCT03896542|Experimental|Commercial video game|the group commercial video game received 30 minutes of conventional therapy plus 30 minutes of rehab training using Xbox Kinect-based games.
89264958|NCT03896542|Experimental|Rehabilitation video game|the group rehabilitation video game received 30 minutes of conventional therapy plus 30 minutes of rehab games.
89264959|NCT03896542|No Intervention|The control group|The control group received 30 minutes of conventional therapy
89264960|NCT03896698|Experimental|TUS treatment|AD patients with TUS treatment
89264961|NCT03896698|No Intervention|Non-TUS treatment|AD patients with Non-TUS treatment
89264962|NCT03894280|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
89264963|NCT03894280|Active Comparator|Reference Product|SERETIDE DISKUS 250/50
89264964|NCT03893968|Experimental|Informed by a doctor|Information by a doctor
89264965|NCT03893968|Experimental|Informed by an assistant nurse|Information by an assistant nurse
89264966|NCT01255462|Experimental|LFG316 0.15mg|
89264967|NCT01255462|Experimental|LFG316 0.5mg|
89264968|NCT01255462|Experimental|LFG316 1.5mg|
89264969|NCT01255462|Experimental|LFG316 5mg|
89264970|NCT03899584|Active Comparator|Treatment with 4-aminopyridine|The 4-aminopyridine will be administered in the form of gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as excipient. The dose of 4-aminopyridine will increase 10 mg / every 2 to 4 weeks until reaching the maximum dose proposed by weight ( maximum 1 mg / kg / d).
89264971|NCT03899584|Placebo Comparator|Placebo oral capsule|Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
89264972|NCT03893890||No Treatment|Subjects who participated in and completed studies EN3835-201 and EN3835-202 and had composite improvement of at least 2 levels on both the CR-PCSS and PR-PCSS in the EN3835-201 study, will be eligible for this study. The study will consist of up to two evaluations approximately 3 years after the first dose of study drug was received in the EN3835-201 study.
89264973|NCT01258270|Active Comparator|(AQUACEL® Ag Surgical Dressing|
89264974|NCT01258270|Active Comparator|Standard island gauze and tape dressing|A standard island dressing consists of adhesive tape and gauze.
89264975|NCT01150162|Experimental|Mucosta and Omeprazole|
89264976|NCT01150162|Active Comparator|Omeperazole|
89264977|NCT03893734|Active Comparator|methadone group|Patients in this group will receive a syringe of methadone at the induction of anesthesia and a syringe of saline at the end of anesthesia.
89264978|NCT03893734|Placebo Comparator|hydromorphone group|Patients in this group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
89264979|NCT03899194|Active Comparator|escitalopram|Patients will only be treated with escitalopram from the minimum dosage.
89264980|NCT03899194|Experimental|escitalopram+ fish oil capsules|Patients will be treated with escitalopram from the minimum dosage and fish oil capsules according to direction for use.
89264981|NCT01151800|Experimental|IVR group|
89264982|NCT01151800|No Intervention|Usual care|
89264983|NCT03893578|Experimental|Interventional Arm|Access, delivery, and retrieval of the Conveyor system with correct positioning of the valve delivery system to facilitate correct positioning of the implant at the mitral location in patients with a failing bioprosthetic valve.
89264984|NCT01257646||Recent stroke group|These patients have hemiplegia following a stroke within the last 6 months
89264985|NCT01257646||Old stroke group|The patients have hemiplegia following a stroke that took place at least a year ago
89264986|NCT03896074|Experimental|Atezolizumab|Patients allocated to Arm A will be treated with atezolizumab administered intravenously at 1200 mg every 3 weeks given until disease progression, toxicity or patient refusal
89264987|NCT03896074|Experimental|Atezolizumab plus bevacizumab|Patients in the Arm B will receive atezolizumab administered intravenously at 1200 mg every 3 weeks plus bevacizumab intravenously at 15 mg/kg every 3 weeks given until disease progression, toxicity or patient refusal
89264988|NCT03899116||G50|The tourniquet cuff pressure will be deflated gradually by 50 mm Hg every 2 minutes till complete deflation.
89264989|NCT03899116||G100|The tourniquet cuff pressure will be deflated gradually by 100 mm Hg every 2 minutes till complete deflation.
89264990|NCT03899116||G0|The tourniquet cuff will be released till complete deflation.
89264991|NCT03899038|Experimental|Deceasing|Spinal anesthesia with decreasing dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
89264992|NCT03899038|Active Comparator|Similar|Spinal anesthesia with similar dose. Real-time ultrasound-guided spinal anesthesia Using Taylor's approach.
89264993|NCT01151878|Experimental|Glucomannan|glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks
89264994|NCT01151878|Placebo Comparator|Placebo|maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks
89264995|NCT03893422|Experimental|WB-010|3 capsules administered twice daily with morning and evening meal for 12 weeks
89264996|NCT03893422|Experimental|WB-011|3 capsules administered twice daily with morning and evening meal for 12 weeks
89264997|NCT03893422|Placebo Comparator|Placebo|3 capsules administered twice daily with morning and evening meal for 12 weeks
88805346|NCT01432405|Experimental|Pioglitazone|Pioglitazone 45 mg daily orally for 12 months
89264998|NCT03898882||BMI 20 - 29.9 kg/m2|
89264999|NCT03898882||BMI > 30 kg/m2|
89265000|NCT03893344||Cases|patients with Multiple Sclerosis in different stages diagnosed clinically according to revised McDonald's criteria 2010
89265001|NCT03893344||Control|Healthy peaple
89265002|NCT01589692|Experimental|Internal Fixation|Open Reduction and Internal Fixation: Internal fixation with a volar locking plating system
89265003|NCT01589692|Experimental|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
89265004|NCT01589692|Experimental|Pinning|Percutaneous pinning with any number of Kirschner wires
89265005|NCT01589692|Active Comparator|No Surgery|Closed Reduction and casting: Closed reduction and immobilization with a cast and/or splint
89265006|NCT01151254|Active Comparator|PA-Intravenous Sedation|Propofol based total intravenous anesthesia and postoperative sedation
89265007|NCT01151254|Active Comparator|Volatile sedation|Total inhalational anesthesia and postoperative sedation with the AnaConda device
89265008|NCT01255618||study group, control group|
89290485|NCT05198206||The Second Affiliated Hospital of Nanchang University|
89290486|NCT05198206||Henan Provincial People's Hospital|
89290487|NCT05198206||Southwest Medical University Hospital|
89290488|NCT05198206||The First Affiliated Hospital of Gannan Medical University|
89265009|NCT01257724|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~an online searchable database of HIV-relevant systematic reviews;~monthly email updates highlighting new reviews;~access to user-friendly summaries produced by us or by others (when available);~links to scientific abstracts;~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~an interface for participants to leave comments in the records of systematic reviews in the database;~links to full-text articles (when publicly available); and~access to worksheets that help CBOs find and use research evidence"
89265010|NCT01257724|Active Comparator|Self-serve evidence service|Organizations allocated to the control group will only be provided website access to a listing of systematic reviews that are organized by year of publication with links to the record on PubMed (or another publicly available source when not available on PubMed) and access to worksheets that help community-based organizations find and use research evidence.
89265011|NCT01255774|Experimental|Ranibizumab|Open Label use of Ranibizumab for wet age related macular degeneration
89265012|NCT03895918|Experimental|Delayed Group (delayed parental skills)|Participants continue medication adherence monitoring over 2 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
89265013|NCT03895918|Experimental|Early Group (early parental skills)|Participants continue medication adherence monitoring over 1 week and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
89265014|NCT03895918|Experimental|Late Group (late parental skills)|Participants continue medication adherence monitoring over 3 weeks and then receive parental skills intervention sessions consisting of 4 integrated components: creating consistent medication routines, education in child management strategies, strategies for helping children adhere to medication, and training in specific parental behavioral techniques over 30 minutes weekly for 4 weeks.
89265015|NCT01258426||Normal, IGT, T2DM|
89265016|NCT01255852|Experimental|Atorvastatin group|Patients in atorvastatin group will received 40 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
89265017|NCT01255852|No Intervention|Control group|Patients in control group will receive 20mg atorvastatin daily treatment.
89265018|NCT02527720|Experimental|Mindfulness Therapy|For the current study the investigators have developed a breathing-based, adapted for feasible application among SUD populations, and easy to carry out in clinical or non-clinical settings referred to as breathing-based mindfulness training (BBMT). BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention (more details below).
89265019|NCT01153360|Experimental|T3|triiodothyronine
89265020|NCT01153360|Active Comparator|cyanocobalamin|vitamin B12
89265021|NCT03895606||HIPEC|patients undergoing cytoreductive surgery and hyperthermic intraoperative chemotherapy due to carcinomatosis.
89265022|NCT03895138|Active Comparator|Standard Glucommander Protocol (SGP)|CABG or open valve surgery patients treated for stress hyperglycemia with the standard Glucomander protocol according to the manufacturer recommendations
89265023|NCT03895138|Experimental|Optimized Glucommander (OGM)|CABG or open valve surgery patients treated for stress hyperglycemia with in silico optimized Glucomander protocol
89265024|NCT01257958|Experimental|19 nor vitamin d|
89265025|NCT03893032|Experimental|Modafinil 200mg|single, 200 mg dose of modafinil
89265026|NCT03893032|Experimental|mixed amphetamine salts|single 10 mg dose of mixed amphetamine salts
89265027|NCT03893032|Placebo Comparator|placebo|placebo
89265028|NCT01151956||actinic keratosis patients|patients who see their non-hospital based dermatologist, because of multiple actinic keratoses and who are then routinely treated with topical 5% Imiquimod
89265029|NCT03893110|Experimental|Instrumentation with Carbon/PEEK pedicle screw system|Posterior instrumentation using a Carbon/PEEK pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
89265030|NCT03893110|Active Comparator|Instrumentation with titanium pedicle screw system|Posterior instrumentation using a titanium pedicle screw system two levels above and below the affected segment(s). The medical device is a commercial product, bears a conformity marking and is used in accordance with the instructions.
89265031|NCT01258036||Fractured Mothers|Fractured Mothers and their daughters
89265032|NCT01258036||Non fractured mothers|Mothers non fractured and their daughters
89265033|NCT01259986|Experimental|Laser treatment|
89265034|NCT01258114|Active Comparator|SPA treatment (ST)|"Drug : spa treatment during 18 days soon after randomization the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises) ;~nutritional counseling (french nutritional recommendations booklet) ;~caloric restriction and physical training on demand (non mandatory)."
89265035|NCT01258114|Sham Comparator|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
89265036|NCT03889366|Experimental|NXP001 Oral Capsule|
89265037|NCT03889366|Experimental|NXP001 Oral Suspension|
89265038|NCT03889366|Active Comparator|Emend®|
89265039|NCT01151488|Experimental|Resistance Training|16 weeks of moderate intensity resistance training, 3x/week
89265040|NCT03895294|Experimental|Health care under the strategic purchase-Clinical pathway|Health care under the strategic purchase and the Clinical pathway for the treatment of chronic Hepatitis C
89265041|NCT03895294|Active Comparator|Usual care process prior strategic purchase-clinical pathway|Usual care process prior to the establishment of the strategic purchase and the Clinical Pathway
89265042|NCT01260064|Active Comparator|Open appendectomy|The subjects will have open appendectomy procedure.
89265043|NCT01260064|Active Comparator|Metal endoclip|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
89265044|NCT01260064|Active Comparator|Intracorporeal suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
89265045|NCT03895060|Experimental|autogenous ring blockls with GBR covered by collagen membrane|Vertical and horizontal ridge augmentation using autogenous onlay ring blocks combined with simultaneous guided bone regeneration using native collagen membrane in atrophic anterior maxilla.
89265046|NCT03894982||What is Asthma|"Reviewing asthma is a lung disease. There is no cure, but asthma can be well controlled so that your child can be healthy and join in all their favorite activities.~Asthma causes the airways (breathing tubes in the lungs) to get smaller, making it hard to breathe.Common symptoms of asthma are coughing, wheezing, chest tightness and trouble breathing.~These symptoms are ongoing and get better with asthma medicines."
89265047|NCT03894982||Triggers|Reviewing specifics around children with asthma have extra sensitive airways and many things around them can make their asthma worse. The things around your child that cause an asthma attack are called triggers. Triggers are different for each child. Your doctor can help you figure out your child's triggers. Try to keep your child away from their triggers, especially at home and at school where your child spends most of their time.
89265048|NCT03894982||Medications and Asthma Action Plan|Review what is an asthma action plan, how to use an asthma action and the medications listed on each individuals plan.
89265049|NCT03889054|No Intervention|Control|Current clinical management
89265050|NCT03889054|Active Comparator|Structured health education program|Patient will be referred to a specific consultation to carry out this intervention.
89265051|NCT01153438||Gastric bypass, Gastric banding|
89265052|NCT03894826|Experimental|TREATMENT|Participants will be administered 230 mg/m2/day of oral Vorinostat [100 mg tablets] in addition to standard of care anti-seizure medication for a duration of 6 weeks.
89265053|NCT03889210|Active Comparator|HVMN ketone drink|HVMN ketone drink will be given in a total volume of 100 ml.
89265054|NCT03889210|Placebo Comparator|Placebo|Placebo will be given in a total volume of 100 ml.
89265055|NCT01151566||Renal Compromise|Those referred for CT scan with identified renal compromise necessitating use of no contrast agent
89265056|NCT01151566||Sensitivity to CT Contrast Agents|Those referred for CT scan with prior demonstration of contrast sensitivity requiring use of no contrast
89265057|NCT02527642|Active Comparator|CRM sequential media (C1/C2)|CRM sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
89265058|NCT02527642|Active Comparator|CRM single step media (C3)|CRM single step media is used to culture the embryos from oocyte fertilization to blastocyst stage.
89265059|NCT02527642|Experimental|Vitrolife media G1/2 Sequential|Vitrolife sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
89265060|NCT02527642|Experimental|Vitrolife G-TL Time Lapse media Single Step|G-TL Time Lapse Single step (time lapse) media is formulated for continuous culture from oocyte fertilization to blastocyst stage.
88805347|NCT01082159|Other|lumbar decompression|Percutaneous lumbar decompression with mild® Device Kit.
89265061|NCT03888820|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
89265062|NCT03888820|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
89265063|NCT01153594|Experimental|Recovery Management Checkups (RMC)|Participants in the RMC group are interviewed quarterly. When they were found to be in need of treatment, the participant was transferred from the interviewer to a linkage manager to receive the intervention (described next). They were also able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
89265064|NCT01153594|No Intervention|Control Group|Participants in the control group are interviewed quarterly. While they do not receive any active intervention from the research team, they are able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
89265065|NCT03894748|Experimental|MT10109L(Botulinum toxin type A)|
89265066|NCT03894748|Active Comparator|BOTOX® 50U(Botulinum toxin type A)|
89290489|NCT05198206||University-town Hospital of Chongqing Medical University|
89290490|NCT05198206||Chongqing Health Center for Women and Children|
88805348|NCT01432561|Experimental|Cysteamine bitartrate|Cysteamine bitartrate, 500mg once a day, three days.
88805349|NCT01116401|Experimental|GnRH Agonist Injection|We will be administering an injection of leuprolide acetate (a GnRH agonist) to all participants.
88805350|NCT03008317|Active Comparator|non metallic|PEEK denture base,
88805351|NCT03008317|Placebo Comparator|metallic denture base|cobalt chromium alloy denture base
88805352|NCT01433107|Experimental|Terbinafine|Drug
88805353|NCT01433107|Placebo Comparator|Placebo|Drug
88805354|NCT01082939|Experimental|CFAR|CFAR: Cyclophosphamide 250 mg/m^2/day intravenous (IV) Days 3-5, Fludarabine 25 mg/m^2/day IV Days 3-5, Alemtuzumab 30 mg IV Days 1, 3 and 5 over 2-4 hours, repeated every four weeks for a total of 6 planned cycles, and Rituximab Cycle 1 (Week 1): 375 mg/m^2/day IV Day 2 over 4- 6 hours, Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV Day 2 over 4- 6 hours.
89265067|NCT03894670|Active Comparator|SmartBar™|The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.
89265068|NCT03894670|Experimental|Standard mixed breakfast meal|The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).
89265069|NCT01151644|Active Comparator|VACCINATION OF PATIENTS|
89265070|NCT01151644|Active Comparator|VACCINATION OF HEALTHY CONTROLS|
89265071|NCT01153750|Experimental|Glivec and 5-Fluorouracil/Leucovorin|"All patients will receive Glivec® 600 mg once daily without dose escalation. Glivec® will be given on day -4, -3, -2, -1, 1, 2, 3 and 4. There will be no day 0. Patients will also receive 5-FU (2000mg/qm 24hc.i. d1 + d2) and leucovorin (200mg/qm 2h-infusion) qd15."
89265072|NCT03894592|Active Comparator|Virtual Reality analgesia|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive the intervention which is a virtual reality headset providing immersive interactive content in the video format
89265073|NCT03894592|No Intervention|Control|Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive no intervention
89265074|NCT00187278|Active Comparator|RV Pacing|Standard Pacemaker implant
89265075|NCT00187278|Experimental|Biventricular Pacing|Biventricular Pacemaker implant
89265076|NCT03888664|Experimental|FRDA patients treated with gIFN|1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
89265077|NCT03894124|Other|Study intervention|Pifeltro® (doravirine 100mg) daily dose for 7 days
89265078|NCT01258972|Active Comparator|Angioplasty POBA|Side Branch balloon angioplasty with main branch DES
89265079|NCT01258972|Experimental|Tryton Side Branch Stent|Side Branch treated with Tryton Side Branch Stent with main branch DES
89265080|NCT03888508|Experimental|SIT plus standard therapy|Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses such as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home Sensory integration kit will be prepared which consists of varying textures from soft to hard items (wool, jute, sand paper, velvet), picture cards, sensory brush, elastic band(Thera tube) and also usage of other home based items such as swings, sofa/bed, textured board, black board, wet chalks and paint. Each session would take approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 d Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving as a standard therapy
89265081|NCT03888508|No Intervention|Standard therapy alone|Standard therapy -Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving
89265082|NCT00256308|Experimental|Oxaliplatin|Oxaliplatin-70mg/m2 IV over 120 min once a week during radiation. Radiation-200 centigray (cGy) per day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday.
89265083|NCT01153828||(1) Age <9 months|Age at time of prescription was <9 months
89265084|NCT01153828||(2) 9 months to 6 years|Age at time of prescription was 9 months to 6 years
89265085|NCT01153828||(3) 7 years to 18 years|Age at time of prescription was 7 years to 18 years
89265086|NCT01153828||(4) 19 to 65 years|Age at time of prescription was 19 to 65 years
89265087|NCT01153828||(5) 66 years and older|Age at time of prescription was 66 years and older
89265088|NCT03968952|Active Comparator|SMARThealth Pregnancy|"The components of the SMARThealth Pregnancy intervention include:~Educational and Training component on high-risk pregnancy conditions, focusing on; Anaemia, Hypertensive Disorders of Pregnancy (HDPs) and Gestational diabetes mellitus (GDM).~An mHealth platform providing clinical decision support, lifestyle advice, recall and reminder system for Community Health Workers (CHWs) and Primary Care Physicians (PCPs).~Pregnant women in the intervention group will receive 3 visits at home by their CHW, in addition to their standard antenatal and postnatal care. One visit during the third trimester of pregnancy; one during Week 1 postpartum and; one visit during Week 6 postpartum."
89265089|NCT03968952|No Intervention|Enhanced Standard Care|"The control group will receive enhanced standard antenatal and postnatal care, involving:~An awareness programme for pregnant women, Community Health Workers (CHWs) and Primary Care Physicians (PCPs), held at the villages within the control group Primary Health Centre (PHC) cluster (Enhanced Standard Care). The community and health professionals will receive information on the high-risk conditions of anaemia in pregnancy, HDPs and GDM as part of the awareness programme.~Standard antenatal and postnatal care (consisting of free monthly antenatal care, and up to 7 postnatal visits), delivered by CHWs in partnership with their PHC doctor."
89265090|NCT01151722|No Intervention|no injection|no bevacizumab
89265091|NCT01151722|Experimental|experimental 2|bevacizumab before vitrectomy
89265092|NCT01151722|Experimental|experimental 3|bevacizumab after vitrectomy
89265093|NCT01073358|No Intervention|Group A: No routine hilar lymphadenectomy|Resection of colorectal liver metastases without routine hilar lymphadenectomy
89265094|NCT01073358|Experimental|Group B: Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases.
89265095|NCT01260220|Active Comparator|Circumferential|Completing a complete circle of RF lesions around the left and right pulmonary veins
89265096|NCT01260220|Experimental|Segmental|Isolating the left and right pulmonary veins through RF lesions with a segmental antral approach.
89265097|NCT01071720|Other|CKD-501 1mg (fed-fasted group)|CKD-501 1mg should be administered following a high-fat, high-caloric diet(fed condition) in one period and on an empty stomach(fasting condition) in the other period.
89265098|NCT01071720|Other|CKD-501 1mg (fasted-fed group)|CKD-501 1mg should be administered on an empty stomach(fasting condition) in one period and following a high-fat, high-caloric diet(fed condition) in the other period.
89265099|NCT01258192|Experimental|nab-paclitaxel plus cisplatin|
88816287|NCT02436330|Active Comparator|Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting only of didactic teaching.
88816288|NCT01143818||AndroGel (testosterone gel )1%|AndroGel is topical testosterone gel 1% (1 sachet of 5 g contains 50 mg of testosterone), 1 daily dose.
89290491|NCT05198206||Kunhua Hospital|
89265100|NCT01073436||Discontinuation|Subjects who agree to discontinue their tyrosine kinase inhibitor(TKI)therapy, namely,imatinib mesylate, dasatinib, or nilotinib,and then followed to see if they can maintain a durable remission.
89265101|NCT01260298||MC1 Ultrasonic Device|
89265102|NCT01326078|Experimental|propofol nanoemulsion|3-4 mg/kg of propofol nanoemulsion will be administered by 1mL per 5 seconds, adjustment dose can be given.
89265103|NCT01326078|Active Comparator|propofol lipid emulsion|3-4 mg/kg will be administered by 1 ml per 5 seconds.
89265104|NCT03894358|Active Comparator|FeFum and 7.5 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 7.5 g of prebiotic (high dose/low dose) mixture
89265105|NCT03894358|Active Comparator|FeFum and 3 g prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate and 3 g of prebiotic (high dose/low dose) mixture
89265106|NCT03894358|Active Comparator|FeFum and no prebiotic mixture|Intervention will be 3.6 mg Fe as Ferrous Fumarate
89265107|NCT01155310|Experimental|Helium/Oxygen|Helium/Oxygen 78%/22% will be administered for a maximum of 72 hours.
89265108|NCT01155310|Active Comparator|Air/Oxygen|Air/Oxygen will be administered for a maximum of 72 hours.
89265109|NCT03892876|Experimental|Schizophrenia TS+ve|Schizophrenia patients who receive auditory high frequency Tetanizing Stimulation
89265110|NCT03892876|Sham Comparator|Schizophrenia TS-ve|Schizophrenia patients who receive sham comparator
89265111|NCT03892876|Experimental|Control TS+ve|Healthy controls who receive auditory high frequency Tetanizing Stimulation
89265112|NCT03892876|Sham Comparator|Control TS-ve|Healthy controls who receive sham comparator
89265113|NCT01153906||Exposed cohort|Females 9-25 years of age, who received at least one dose of Cervarix® as part of their routine health care.
89265114|NCT01153906||Unexposed cohort|Females 9-25 years of age, who did not receive Cervarix®
89265115|NCT01260376|Experimental|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
89265116|NCT01260376|No Intervention|Placebo|Placebo tablets will be administered 4 times previous to and during the investigation day
89265117|NCT03888586|Experimental|Dry Needling|Participants were administered trigger point dry kneedling technique 6 times for 1 month, once every 5 days. The subject was positioned prone and the arm position was slightly changed related with the muscle. After the skin inspection it was cleaned with the alcohol. .
89265118|NCT03888586|Experimental|Deep Friction Massage|Deep friction massage was applied transversely unlike the superficial massage and sufﬁciently deep to the ﬁber direction of affected connective tissue to maintain the mobility. Totally 6 sessions were administered twice a week for 3 weeks.
89265119|NCT01262014|Experimental|Experimental single arm|Single arm of pazopanib 800 mg (2x400mg) given as a single agent.
89265120|NCT03886012|Experimental|Otoband efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to the effective power level. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
89265121|NCT03886012|Sham Comparator|Otoband sham efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to an ineffective power level, serving as a placebo. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
89265122|NCT01152034|Experimental|Psychoeducation group therapy|The structured group program comprised of an initial block of 12 weekly sessions with three additional monthly booster sessions, designed to support participants in the application of knowledge and skills to everyday life situations. All participants also received standard psychiatric care as well.
89265123|NCT01152034|Placebo Comparator|Treat as Usual|Patients who were assigned to the control group received standard psychiatric care and standard pharmacological treatment without group-based psychosocial intervention. Weekly phone calls to the control group over the initial 12 weeks were controlled for any extra contact time with researchers outside of the structured intervention group.
89265124|NCT01259050|Experimental|Zinc and Copper|
89265125|NCT03886090|Experimental|motor skill practice + aerobic exercise|acute bout of aerobic exercise following motor skill practice
89265126|NCT03886090|Active Comparator|motor skill practice + rest|seated rest following motor skill practice
89265127|NCT03888430||Standard Oxygen|preoxygenation methods : Standard Oxygen
89265128|NCT03888430||High flow Oxygen|preoxygenation methods : High flow Oxygen
89265129|NCT03888430||Non invasive ventilation|preoxygenation methods : Non invasive ventilation
89265130|NCT03888196|Experimental|Intervention Group|500 mg/day of Panax Ginseng. 2 weeks treatment
89265131|NCT03888196|Placebo Comparator|Control Group|500 mg/day of Celulose. 2 weeks treatment
89265132|NCT03892486|Experimental|The high PUFA diet group|This will receive detailed nutritional recommendations and will consume at least 4 table spoons of olive oil or 30 grams of nuts daily for 12 weeks.
89265133|NCT03892486|No Intervention|Control group|The Control group will receive general nutritional recommendations based on Human Nutrition Recommendations for Polish Population.
89265134|NCT00255840|Active Comparator|A|Study-specified Antiretroviral regimen under care of HIV-trained medical doctor
89265135|NCT00255840|Active Comparator|B|Study-specified Antiretroviral regimen under care of HIV-trained primary care nurse
89265136|NCT01154062|Experimental|low dose|Pazopanib tablet
89265137|NCT01155544|Active Comparator|Aripiprazole|
88816289|NCT02573181|Experimental|V114|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
89265138|NCT01155544|Placebo Comparator|Placebo|
89265139|NCT03972228|Experimental|Microdevice Intervention|The intervention to be administered is the placement of the microdevice containing 19 FDA-approved drugs into the lung lesion and the device's subsequent surgical resection. All study subjects will receive this same intervention; there is only one arm.
89265140|NCT01586416|Experimental|Behavioral Intervention|Brief behavioral intervention on 2-3 sessions of tailored cognitive-behavioral therapy to support chemotherapy adherence and well-being of patients completing chemotherapy for colon cancer.
89265141|NCT03885856||single row repair technique|patients surgically treated for rotator cuff lesion by single row repair technique
89265142|NCT03885856||double row repair technique|patients surgically treated for rotator cuff lesion by double row repair technique
89265143|NCT03885778|Experimental|A-fasted dosing followed by fed dosing|Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing
89265144|NCT03885778|Experimental|B-fed dosing followed by fasted dosing|Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing
89265145|NCT03885700|Experimental|intervention group|
89265146|NCT03885700|No Intervention|control group|
89265147|NCT01260532||Graves' disease|no intervention
89265148|NCT01260532||Hashimoto's thyroiditis|no intervention
89265149|NCT01260532||Healthy subjects|no intervention
89265150|NCT01262170|Experimental|CigRx Lozenge|CigRx Lozenge
89265151|NCT01262170|Active Comparator|Tobacco Lozenge|Tobacco Lozenge
89265152|NCT00224874|Experimental|Etanercept|Enroll within 48 hours of new onset acute GVHD and randomize to Etanercept
89265153|NCT00224874|Experimental|Mycophenolate Mofetil|Enroll within 48 hours of new onset acute GVHD and randomize to Mycophenolate Mofetil
89265154|NCT00224874|Experimental|Denileukin Diftitox|Enroll within 48 hours of new onset acute GVHD and randomize to Denileukin Diftitox
89265155|NCT00224874|Experimental|Pentostatin|Enroll within 48 hours of new onset acute GVHD and randomize to Pentostatin
89265156|NCT03892330|Experimental|liposomal doxorubicin|Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
89265157|NCT03892330|Active Comparator|doxorubicin|Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
89265158|NCT03892330|Active Comparator|pharmorubicin|Drug: pharmorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
89265159|NCT03892330|Active Comparator|pirarubicin|Drug: pirarubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
89265160|NCT03888118|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual ankle therapy and one hour therapy on the Luna EMG device.
89265161|NCT03888118|No Intervention|Control group|A four-week rehabilitation program (Monday to Friday) involving two hours of individual ankle therapy.
89265162|NCT00186186|Experimental|Depakote ER|Depakote ER up to 1500 mg/day
89265163|NCT03892408|Experimental|Optiflow|100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand)
89265164|NCT03892408|No Intervention|Standard|standard anesthesia
89265165|NCT01152268||Adolescent Male Participants|"Self-report questionnaire data will be collected one time, between Days 1-7 post initiation of cancer therapy(e.g. Days 2-8 of being on-treatment for cancer) among eligible participants and their families who enroll on the study. Patients who agree to participate will be asked to complete a battery of paper and pencil questionnaires (which will also be available on-line if preferred) that assess risk/protective factors for sperm banking. When the banking recommendation is Yes or further assessment required, the profiling and referral tool will be given to the family and instructions for completion will be provided. The tool will include a list of key items which will be based on the most influential barriers to banking sperm."
89265166|NCT03969108|Experimental|Indocyanine Green|
89265167|NCT03973944|Other|Cardiac resynchronization therapy|AV coupling by atrio-biventricular pacing
89265168|NCT03885544|Active Comparator|Controlled lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet without red meat for 3 weeks.
89265169|NCT03885544|Experimental|Controlled unprocessed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with unprocessed red meat for 3 weeks.
89265170|NCT03885544|Experimental|Controlled processed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with processed red meat for 3 weeks.
89265171|NCT00185640|Experimental|Non-myeloablative transplantation|Pre-transplant total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) infusion with Day 0 allogeneic hematopoietic cell transplant (HCT), followed by post-transplant immunosuppression by cyclosporine and mycophenolate mofetil.
89265172|NCT01262248||patients with colorectal polyps|
89265173|NCT03885388|Active Comparator|control arm|single methotrexate multicourse treatment MTX:MTX 0.4mg/kg•d, intramuscular, every two weeks
89265174|NCT03885388|Experimental|experimental arm|combination of methotrexate and actinomycin multicourse treatment, every two weeks MTX+ACTD:Act-d 0.6mg/m2 Day1,2 intravenous (IV) MTX 100mg/m2 IV Day1(after Act-d) MTX 200mg/m2 Ivgtt Day1(after MTX,500mlNS)
89265175|NCT03973788|Experimental|Intervention|repetitive transcranial magnetic stimulation
89265176|NCT03884686|Experimental|Web-based intervention|Patients allocated to intervention arm will have unlimited free access to a web-based education resource.
89265177|NCT03884686|No Intervention|Usual care|Patients allocated to usual care will receive all usual care and education opportunities.
89265178|NCT01152346|Other|ARM 1|Sequence- Azacitidine followed by Vidaza®
89265179|NCT01152346|Other|ARM 2|Sequence-Vidaza® followed by Azacitidine
89265180|NCT01260610|Active Comparator|Tenofovir|
89265181|NCT01260610|Active Comparator|Telbivudine|
89265182|NCT01260610|Experimental|Tenofovir plus Telbivudine|
89265183|NCT01152424||Acute eosinophilic pneumonia|
89265184|NCT01152424||Community acquired pneumonia|
89265185|NCT01155622|Active Comparator|32º Celsius|Endovascular Cooling was set at a target temperature of 32°C
89265186|NCT01155622|Active Comparator|34º Celsius|Endovascular Cooling was set at a target temperature of 32°C
89265187|NCT03885076||Acute myeloid leukaemia|Patients with Acute Myeloid Leukaemia (excluding M3) at presentation, remission or with refractory or relapsed disease. There is no intervention. This is an observational tissue collection study.
89265188|NCT05477836|Experimental|Experimental group|Microwave-based colonoscopy
89265189|NCT03884764|Experimental|PRF on S3 + ganglion impar denervation|patients will receive pulsed radiofrequency on sacral root number 3 in conjunction with ganglion impar denervation by alcohol
89265190|NCT03884764|Active Comparator|ganglion impar denervation|patients will receive ganglion impar denervation by alcohol
89265191|NCT03884842|Active Comparator|dupilumab|"Dupilumab 300 mg subcutaneously (SC) every 2 weeks as an investigational drug. For those randomized to dupilumab, a loading dose of 600 mg will be given only at randomization/Visit 2.~Sterile dupilumab of will be provided in 150 mg/mL in glass prefilled syringes (2.25 mL total volume) to deliver 300 mg in 2 mL."
89265192|NCT03884842|Placebo Comparator|matched placebo|Sterile placebo for dupilumab will be provided in identically matched glass prefilled syringes to deliver 2 mL.
89265193|NCT02527486||No predefined subgroups|
89265194|NCT01155700|Experimental|Omalizumab|Omalizumab treatment
89265195|NCT03892252||before surgery|no intervention(s)
89265196|NCT03892252||after surgery|no intervention(s)
89265197|NCT03892252||Normal colonoscopy|People who were diagnosed by colonoscopy without colorectal cancer.
89265198|NCT03887884|Experimental|CVT-301|Single inhaled dose of CVT-301 84 mg
89265199|NCT03887884|Active Comparator|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
89265200|NCT03887962|Experimental|Virtual Environment feedback|"Subjects will be instructed to walk on a treadmill, moving at a constant speed, following a virtual path displayed on a flat screen in front of them. In this group, the gait task may involve avoiding virtual obstacles on the screen in the path or stepping on targets as determined by the therapist."
89265201|NCT03887962|Active Comparator|Control|Subjects will be instructed to walk on a treadmill, moving at a constant speed. The flat screen will play random scenes from the virtual reality environment and thus control for attentional and non-movement related clues.
89265202|NCT03892174|No Intervention|Treatment protocol without adsorption|
89265203|NCT03892174|Active Comparator|Treatment protocol with adsorption|
89265204|NCT01262326|Experimental|Low Carbohydrate Diet|Subjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate.
89265205|NCT01262326|Active Comparator|Low Calorie Diet|Subjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively).
89265206|NCT01262404||HealthEd,Minfdulness,Compassion|HealthEd receives training health education. Mindfulness receives training in mindfulness meditation. Compassion receives training in compassion meditation.
89265207|NCT01154530|Active Comparator|Chlorhexidine mouthwash|Participants randomized to chlorhexidine mouthwash prior to gastroscopy
89265208|NCT01154530|No Intervention|No mouthwash|Mouthwash is not performed prior to gastroscopy as is the standard today.
89265209|NCT03887572||Pre-intervention/control|20 older adult patients (age 65 or older) will be recruited over 3 months prior to implementation of the unit-based MOVIN intervention.
89265210|NCT03887572||Post-intervention|20 older adult patients (age 65 or older) will be recruited over 3 months after MOVIN has been implemented on the unit for a period of 12-14 weeks.
89265211|NCT05077852||Cystoscopy Bladder Cancer|Patients diagnosed with primary bladder cancer at the base, trigone or neck of the bladder by cystoscopy.
89265212|NCT05077852||Cystoscopy IPP|Patients diagnosed with intravesical prostate protrusion (IPP) at the base, trigone or neck of the bladder by cystoscopy.
89265213|NCT03887416|Active Comparator|Dapagliflozin|"The investigational medicinal product (IMP) is Dapagliflozin 10 MG Oral Tablet [Farxiga] given once daily (film coated tablets, oral use).~Dapagliflozin 10 MG Oral Tablet [Farxiga] will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
89265214|NCT03887416|Placebo Comparator|Placebo matching dapagliflozin|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
89265215|NCT01260766|Active Comparator|Active Comparator: Oplon Active Patch|
89265216|NCT01260766|Placebo Comparator|Placebo Comparator: Placebo patch|
89265217|NCT01155856|Experimental|telemedicine|Within 24 hours after admission for exacerbation of COPD, patients in the intervention group are sent home for further treatment (telemedicine based) instead of the conventional treatment at the hospital. Patients in the intervention group will receive the same treatment as the control group and have daily contact with the physician/nurse at the hospital through a videoconference system.
89265218|NCT01155856|No Intervention|control|The control group will receive usual care and treatment at the hospital until discharge(typically between 5-7 days).
89265219|NCT03891940||Patient receiving Anterior Cervical Spine Surgery|"Patients who fulfill the criteria of anterior cervical spine surgery under general anesthesia~Aged from 20-80 years old"
89265220|NCT01260844|Experimental|single dose of briakinumab|single dose briakinumab cocktail of CYP substrates
89265221|NCT03891472|Experimental|Arm 1|
89265222|NCT01589848||von Willebrand women|Referred women who may have von Willebrand Disease
89265223|NCT03887494|Experimental|Y-Strut Implant|Single interventional arm
89265224|NCT01154608|Experimental|pancreatic enzymes|
89265225|NCT01154608|Placebo Comparator|control|
89265226|NCT01262482|Experimental|Oxaliplatin + Sorafenib|
89265227|NCT01261078|Placebo Comparator|Placebo|8 mg bupivacaine only
89265228|NCT01261078|Active Comparator|Epi 25|8 mg of bupivacaine mixed with 25 mcg of epinephrine
89265229|NCT01261078|Active Comparator|Epi 50|8 mg of bupivacaine mixed with 50 mcg of epinephrine
89265230|NCT01261078|Active Comparator|Epi 100|8 mg of bupivacaine mixed with 0.1 mg of epinephrine
89265231|NCT01261078|Active Comparator|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
89265232|NCT03884218|Other|Thermal Comfort|Infra red thermal image
89265233|NCT01155934|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
89265234|NCT01155934|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
89265235|NCT03891628|Experimental|Modified ABC|Modified Attachment and Biobehavioral Catch-Up (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
89265236|NCT03891628|Active Comparator|Modified DEF|Modified Developmental Education for Families (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
89265237|NCT01259206||diabetic patients|
89265238|NCT01259206||diabetic patients and healty controls|there are two groups in this study. One group is obese type 2 diabetic patiens and other group is healty controls.
89265239|NCT03891550|Experimental|SOF/VEL|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks
89265240|NCT01152658|Placebo Comparator|Nacl Injection|"Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).~NACL0.9% solution will be then injected to the control group in sterile conditions under ultrasound control~double blind procedure~."
89265241|NCT01152658|Experimental|PRGF|1. Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).2. The enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control.
89265242|NCT01261156|Experimental|Study Arm 1|
89265243|NCT01261156|Experimental|Study Arm 2|
89265244|NCT03884530|Active Comparator|Ticagrelor ( Brilique) group|the group will receive 180 mg ticagrelor (2 tablets of 90 mg) as a single loading oral dose, and continue on 180 mg ticagrelor (1 tablet of 90 mg every 12 hours) for 3 months
89265245|NCT03884530|Active Comparator|Aspirin Group|The group will receive 300 mg Aspirin (4 tablets of 75 mg) as a single loading oral dose, and will then be commenced on 300 mg Aspirin daily for 2 weeks then 75 mg daily after that for 3 months
89265246|NCT05477680|Experimental|Surgery|Removing different brain lesions using neuronavigation
89265247|NCT03887338|Other|NIV settings titration|Transnasal Fiberoptic Laryngoscopy will be used during ongoing NIV setting titration. Aim is to titrate NIV setting to be more optimal for laryngeal responses.
89265248|NCT03884062||DAAs-SVR.|annual incidence of HCC in chronic hepatitis C patients with advanced liver fibrosis (F3 and F4) after achieving DAAs-SVR.
89265249|NCT03891316||Anaesthesiologists balanced|Anaesthesiologists performing balanced anaesthesia with sevoflurane.
89265250|NCT03891316||Anaesthesiologists TIVA|Anaesthesiologists performing only total intravenous anaesthesia.
89265251|NCT03891316||Surgeons|Surgeons working in the operating room while anaesthesia of the patients is randomly maintained with sevoflurane or propofol.
89265252|NCT03891316||Anaesthesiologists PACU|Anaesthesiologists working in the postoperative care unit.
89265253|NCT03891316||Anaesthesiologists outside the operating room|Anaesthesiologists working outside of the operating room, for example pain service or anaesthesiological walk-in clinic
89265254|NCT03891316||Physicians not exposed|Physicians not having contact with patients on wards/outpatient clinics after exposure with sevoflurane
89265255|NCT03891316||Patients|Patients having undergone sevoflurane anesthesia for elective surgery
89265256|NCT03887260|Active Comparator|GA group|Patients will receive general anaesthesia for nephrectomy/NSS procedures via lumbotomy. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
89265257|NCT03887260|Experimental|ESP group|Patients will receive general anaesthesia with ESP block for nephrectomy/NSS procedures via lumbotomy. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
89265258|NCT03891004|Experimental|Tissue Adhesives Only|For the tissue adhesive, we will use Dermabond, which was FDA approved for skin closure in 1998. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
88805355|NCT01327963|Experimental|Transoral Incisionless Fundoplication|"Intervention: Transoral Incisionless Fundoplication 2.0 technique iteration (TIF 2.0).~With patient in general anesthesia. The EsophyX (brand name) device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro-esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GastroEsophageal Junction (GEJ) below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications."
88805356|NCT01381471||COPD|Patients with a diagnosis code of COPD
88805357|NCT01328743|No Intervention|Treatment as usual|Treatment as usual in an HIV primary care setting. Participants receive assessment of alcohol use but not counseling or advice regarding drinking.
88805358|NCT01328743|Experimental|Brief Alcohol Intervention|Participants receive 3 face-to-face sessions of counseling on alcohol use and 2 follow-up phone calls
89265259|NCT03891004|Active Comparator|Subcuticular Suture Closure Method Only|For the suture arm we will only close the subcuticular layer. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
89265260|NCT03891082|Active Comparator|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border.The absorbable suture is fed posteriorly and vertically to enter the posterior wall of the uterine cavity at the same level as the upper anterior entry point.
89265261|NCT03891082|Active Comparator|Bakri balloon|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium.
89265262|NCT03883984|Experimental|Cysteamine|Cysteamine Bitartrate plus standard asthma care
89265263|NCT03883984|Placebo Comparator|Placebo Oral Tablet|Placebo plus standard asthma care
89290492|NCT05198206||Changdu People's Hospital of Tibet|
88805359|NCT01329679|Experimental|Energy Drink|Energy drink, 2 oz twice daily for 7 days
88805360|NCT01329679|Placebo Comparator|Placebo|Water, lime juice and cherry flavoring, 2 oz twice daily for 7 days
88805361|NCT05422092|Experimental|Canagliflozin treatment group|Canagliflozin 100mg were given to the patients for 24 weeks
88805362|NCT05422092|Placebo Comparator|Pioglitazone treatment group|Pioglitazone 30mg were given to the patients and the dosage will be increased to 45mg 2 weeks later
89265264|NCT03886870|Experimental|Lifestyle and work intervention|Lifestyle intervention with work focus.
89265265|NCT03886870|Experimental|Lifestyle intervention|Lifestyle intervention without work focus.
89265266|NCT03890926||radioactive Iodine-125 seed implantation|All enrolled patients received the intervention previously as a conventional treatment.
89265267|NCT03883672|Experimental|hematopoietic stem cell transplantation|Personality and transactional factors involved in the process and outcomes of hematopoietic stem cell transplantation
89265268|NCT01586494|Experimental|Group 1|
89265269|NCT01586494|Experimental|Group 2|
89265270|NCT05666986||Adolescents who had CDH surgery in the first month of life,|without any other pathology, now aged 12-18 and followed up at the CDH Lille Reference Center
89265271|NCT02527330||Control group|Age- and gender-matched healthy volunteers recruited as normal control group.
89265272|NCT02527330||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=55%
89265273|NCT02527330||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<55%.
89265274|NCT01259362|Active Comparator|Transcranial Magnetic Stimulation|Cocaine addicted will receive a 20 day TMSr to right dorsolateral prefrontal cortex.
89265275|NCT01259362|Sham Comparator|Transcranial Magnetic Stimlation|cocaine addicted will receive a 20 day sham TMSr to right dorsolateral prefrontal cortex
89265276|NCT03886792|Experimental|Triggered Reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
89265277|NCT03886792|Sham Comparator|Social Interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
89265278|NCT03684070|Experimental|Enhanced Walking|FitBit + Lifestyle counseling/education session(8 weeks) + WeChat motivational messages and peer interaction
89265279|NCT03684070|Active Comparator|Walking Only|FitBit + Lifestyle counseling/education session(8 weeks)
89265280|NCT01156090||Vectibix|patients who received at least one treatment of Vectibix
89265281|NCT01261234|Experimental|Cilostazol group|Continuous administration of cilostazol (unrestricted use of other antiplatelet agents and concomitant drugs)
89265282|NCT01261234|Active Comparator|Non-Cilostazol group|Antiplatelet agent other than cilostazol (unrestricted use of concomitant drugs)
89265283|NCT01152736|Experimental|NSC018|Nicotine
89265284|NCT01152736|Active Comparator|Nicotine Gum|Nicorette® Gum
89265285|NCT01262794|Experimental|CDP6038 0.3 mg/kg|
89265286|NCT01262794|Experimental|CDP6038 1 mg/kg|
89265287|NCT01262794|Experimental|CDP6038 3 mg/kg|
89265288|NCT01262794|Experimental|CDP6038 6 mg/kg|
89265289|NCT01262794|Placebo Comparator|Placebo|
89265290|NCT03883438|Active Comparator|Coronally advanced flap and acellular dermal graft|In CAF group, after local anesthesia oblique beveled vertical incisions were made at the most mesial and distal line angles of the recessions. These two incisions were connected with an intra-sulcular and interdental sub-marginal incisions in order to create the external surgical papillae. Then the flap was elevated as a split-full-split approach. The apical portion of the flap was reflected as close to the periosteum as possible by mesio-distal and apical sharp dissection parallel to the mucosa to release residual muscle tension and extended beyond the muco-gingival junction to facilitate the passive coronal replacement of the flap over the defects. In both groups ADMG was used as a sub-epithelial graft considering the manufacturer's instructions. The graft was positioned at the level of cemento-enamel junction and extended to the surrounding bone in the apical direction with full closure of the exposed root surfaces.
88805363|NCT05448456|Active Comparator|Hexakakapron group|women with an episiotomy after vaginal delivery
88805364|NCT05448456|Placebo Comparator|control group|women with an episiotomy after vaginal delivery
88805365|NCT01433731|Placebo Comparator|placebo for SHAPE (SHP-141)|placebo for SHAPE (SHHP-141) topical gelled solution
89265291|NCT03883438|Experimental|Modified coronally advanced flap and acellular dermal graft|Test group received CAF avoiding vertical releasing incisions (mCAF).
89265292|NCT01261468|Active Comparator|Active SCS|
89265293|NCT01261468|Sham Comparator|Inactive SCS|
89265294|NCT03890848|Experimental|Wechat application intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
89265295|NCT03890848|Active Comparator|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
89265296|NCT03890692|Experimental|patients will undergo flexible nasoendoscopy|Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists
89265297|NCT01259518|Experimental|Once monthly administration of TRIN2755|
89265298|NCT01259518|Experimental|Once weekly administration of TRIN2755|
89265299|NCT01154842||Hemodialysis|Adult hemodialysis patients (age>18 years)
89265300|NCT01261546|Experimental|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~Ranitidine 5 mg/kg IV, q.d. for 2 days~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
89265301|NCT01261546|Placebo Comparator|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~Ranitidine 5 mg/kg IV, q.d. for 2 days.~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
89265302|NCT03883360|Experimental|Cannabidiol (CBD)|Participants receive CBD daily for 12 weeks.
89265303|NCT03883360|Placebo Comparator|Placebo|Participants receive vehicle not containing any drug daily for 12 weeks.
89265304|NCT01261702|Placebo Comparator|Placebo|Normal saline IV
89265305|NCT01261702|Experimental|Magnesium sulphate|Magnesium sulphate 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
89265306|NCT01156246|Experimental|1|Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, fasting conditions day 1, visit 3.
89265307|NCT01156246|Experimental|2|Dapagliflozin/metformin tablet, fasting conditions day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 3.
89265308|NCT01263184||sportive wheelchair users|
89265309|NCT01263184||sportive non disabled|
89265310|NCT01263184||non sportive wheelchair users|
89265311|NCT03890770|Experimental|Normal renal function|Single dose
89265312|NCT03890770|Experimental|Mild renal disease|Single dose
89265313|NCT03890770|Experimental|Moderate renal failure|Single dose
89265314|NCT03890770|Experimental|Severe renal failure|Single dose
89265315|NCT03890770|Experimental|End-stage renal disease requiring dialysis|Two single doses administered with washout
89265316|NCT03890302|Experimental|Cohort A|0.5 mg/kg study drug, or placebo, administered once
89265317|NCT03890302|Experimental|Cohort B|2 mg/kg study drug, or placebo, administered once
89265318|NCT03890302|Experimental|Cohort C|4 mg/kg study drug, or placebo, administered once
89265319|NCT03890302|Experimental|Cohort D|8 mg/kg study drug, or placebo, administered once
89265320|NCT03890302|Experimental|Cohort E|Starting dose of 2 mg/kg or approximately half the maximum tolerated dose (MTD) in Part 1 (Cohorts A-D), whichever is lower, up to 4 mg/kg; or placebo. Administered 4 times (approximately once every 2 weeks).
89265321|NCT03886480|Experimental|SaeboVR|Use of the SaeboVR for task specific upper extremity training
89265322|NCT01261858|Experimental|Stainless steel and Kryptonite|Sternal closure with stainless steel and kryptonite
89265323|NCT01261858|Active Comparator|Stainless steel|Sternal closure with only stainless steel
89265324|NCT01263340||People with COPD|
89265325|NCT03886636|Experimental|Neuroscience pain education group|in Group 1, participants received Neuroscience pain education, manual therapy and a home exercise program.
89265326|NCT03886636|Experimental|Manual therapy group|in Group 2, participants received manual therapy and a home exercise program.
89265327|NCT03886636|Active Comparator|Control group|in Group 3, participants received home exercise program only.
89265328|NCT03886402|Experimental|Treatment|Each subject will receive a single injection of autologous adipose-derived stromal vascular fraction (SVF) and will be monitored for 6 months
89265329|NCT03883204|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
89265330|NCT03883204|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
89265331|NCT03890380|Experimental|Magneto Wire|Patients treated with Magneto Wire
89265332|NCT03890458|Experimental|Experimental|
89265333|NCT03890458|No Intervention|Control|
89265334|NCT01154998||Cases|
89265335|NCT01154998||Controls|
89265336|NCT01156324|Placebo Comparator|Control|Participants of the routine care control group will each receive a $50 gift certificate at the end of each IVF cycle for which they completed the questionnaires.
89265337|NCT01156324|Experimental|Online Stress Management Group (Upliv)|Personalized online stress management program consisting of weekly sessions which each include relaxation exercises, stress management strategies, and lifestyle modification advice. Participants in Upliv will also be given a set of personal care products as part of the program.
89265338|NCT01155076|Experimental|Vitality product|Proprietary blend of ginseng, cordyceps, and pomegranate
89265339|NCT01155076|Placebo Comparator|Placebo|Placebo
89265340|NCT01263418|Experimental|Ofatumumab|
89265341|NCT03882814||Pethidine group / study group|Study group; patients given pethidine; The partogram was recorded during delivery. Cervical examination was performed at 2 hour intervals. Recorded in the file. 4 cm and greater cervical dilatation; 50 mg intramuscular (IM) injection was given to pethidine. 200 Montevideo units uterine contractions were reached. Maternal vital signs, maternal complications and neonatal APGAR scores were recorded by the clinician 0-5-15-30-45-60 minutes after pethidine injection.
89265342|NCT03882814||control group|The patients who received placebo injection were included in the control group. Saline was given in placebo.
89265343|NCT03886558|Experimental|Institution Group (n=14)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
89290493|NCT05198206||The Sixth People's Hospital of Chengdu|
89290494|NCT05198206||Chongqing Bishan District People's Hospital|
89290495|NCT05198206||Sichuan Guangyuan People's Hospital|
89290496|NCT05198206||Xinjiang Military Region General Hospital|
89265344|NCT03886558|Experimental|Community Group (n=16)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
89265345|NCT01156402|Experimental|Active Intervention: Obesity Prevention|
89265346|NCT01156402|Experimental|Alternative Intervention/control: Oral Health|
88805366|NCT01433731|Experimental|SHAPE (SHP-141) 0.1%BID|SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly
89265347|NCT01261936||women with a diagnosis of CBD|women in the fertile age, with an ascertained diagnosis of CBD, followed up for heavy periods and needing a specific treatment.
89265348|NCT03890224|No Intervention|Control group|no home non-invasive ventilation (NIV), only hospital NIV
89265349|NCT03890224|Active Comparator|Non-targeted home NIV|Nocturnal home non-invasive ventilation (NIV)
89265350|NCT03890224|Active Comparator|Targeted home NIV|Nocturnal home non-invasive ventilation (NIV) with high monitoring
89265351|NCT03890224|Active Comparator|Rescue home NIV|home non-invasive ventilation (NIV) on demand
89265352|NCT01152970||drug-using youth with violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for an acute violent injury
89265353|NCT01152970||drug-using youth with non-violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for non-violence related care
89265354|NCT03889990|Other|healthy smokers|"Healthy smokers males, aged >18years, with >10 pack/years,receiving no medications~Intervention: the use of an IQOS"
89265355|NCT01153048|Experimental|Specific education intervention with peer educators|
89265356|NCT01153048|No Intervention|General education session in the health structure|
89265357|NCT03647566||No Aortic Disease|Participants with normal calibre aortae and no prior diagnosis of acute aortic syndrome
89265358|NCT03647566||Acute Aortic Syndrome|Participants presenting acutely with a diagnosis of acute aortic syndrome as defined in the European Society of Cardiology guidelines: a compatible clinical presentation with CT or magnetic resonance imaging confirming acute aortic syndrome.
89265359|NCT03647566||Chronic Aortic Disease|Participants with an established diagnosis of acute aortic syndrome.
89265360|NCT03591952|Active Comparator|Suction|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care.
89265361|NCT03591952|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned approximately 100 cm (approximately 40 inches) below the catheter entry point (see picture below) using the 40 inch tubing provided in the thoracentesis kit (CareFusion or Arrow).
89265362|NCT03882502|Experimental|stimulation group|
89265363|NCT03882502|Sham Comparator|sham stimulation|
89265364|NCT01156636|Active Comparator|Sildenafil|
89265365|NCT01156636|Placebo Comparator|Placebo|
89265366|NCT01259674|Experimental|AboMeg-B-09 syrup|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
89265367|NCT01259674|Placebo Comparator|Placebo|Placebo syrup
89265368|NCT03881722|Active Comparator|thickened formula|
89265369|NCT03881722|Experimental|Mg alginate|
89265370|NCT03889678||Peripheral IV|Patients with peripheral intravenous line in place undergoing elective surgery
89265371|NCT01153126|No Intervention|No Intervention: Usual Care|A group receiving usual care plus 5 reliable websites
89265372|NCT01153126|Experimental|Intervention|A group using the Comprehensive Health Enhancement Support System (CHESS.)
89265373|NCT03889288|No Intervention|conventional management of postoperative pain|Patients who have had an aortic valve replacement surgery have a conventional management of pain after surgery. The pain is treated by morphine using a patient-controlled analgesia for the administration. Patients are recruiting prospectively or possibly retrospectively. The management is usual, nothing from the conventional care of patients change, only data will be collected.
89265374|NCT03889288|Experimental|Medical device - electronic-pain killer|In addition to the conventional management of postoperative pain, patients benefit from perioperative treatment sessions with medical device. Patients are recruiting prospectively.
89265375|NCT01153204|Experimental|Group Psychotherapy (GP)|Time-limited group psychotherapy is a technique based on psychodrama, an in-depth method of group psychotherapy. Active methods are used to enable past, present, and future life events to be explored. Sexual issues and their possible solutions are enacted rather than simply discussed. Time-limited group psychotherapy focuses on a central or core issue or a circumscribed area of conflict (psychogenic erectile dysfunction) as the only or major object of intervention efforts.
89265376|NCT01153204|Active Comparator|Sildenafil|Participants took sildenafil citrate 50 mg as needed for sexual activity (on demand), no more than once daily, according to psychiatric prescription. Sildenafil citrate was taken with a glass of water on an empty stomach (at least 2 hours after eating). Participants met with a psychiatrist every month for 30-minutes to report adverse effects and to obtain the following month's dosage of four pills.
89265377|NCT01153204|Active Comparator|Group Psychotherapy (GP) plus Sildenafil|The same as above.
89265378|NCT03760666|Experimental|Brequinar/Brequinar + Ribavirin|Brequinar and ribavirin were dosed orally; brequinar starting doses ranged from 200 mg/m2 to 500 mg/m2. Brequinar doses were adjusted by cohort for starting dose and regimen (either twice-weekly or once-weekly). In addition, the dose for each participant was also adjusted (either escalated or decreased) based on safety, brequinar PK and levels of dihydroorotate (DHO). Ribavirin 1000 mg twice a day (bid) was added in combination with brequinar for the final 3 study participants.
89265379|NCT03760510|Experimental|Adhesive Tape|Patients in adhesive tape arm had endotracheal tube secured with adhesive tape
89265380|NCT03760510|Experimental|Tube Fastener|Patients in the tube fastener arm had endotrachel tube secured with tube fastener
89265381|NCT03882112|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
89265382|NCT03882112|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
89265383|NCT01263574|Placebo Comparator|Heparinized Saline|This group will maintain their central lines patent with heparinized saline.
89265384|NCT01263574|Experimental|Ethanol lock solution group|Administration of the 70% ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
89265385|NCT03882190|No Intervention|group 1|
89265386|NCT03882190|Experimental|group 2|
89265387|NCT03882346|No Intervention|Control Group|Patients in Control Group will receive best supportive care for the disease.
89265388|NCT03882346|Experimental|Experimental Group|Patients in Experimental Group will receive LifeLiver treatment in addition to best supportive care for the disease.
89265389|NCT03464734|Experimental|Pembrolizumab + nab-paclitaxel|pembrolizumab 200 mg + nab-paclitaxel 125 mg/m2, intravenously
89265390|NCT01156870|Experimental|SAR566658|SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
89265391|NCT01156948|Active Comparator|vaginal misoprostol|vaginal misoprostol was administered to this group of nulliparous women
89265392|NCT01156948|Experimental|oral misoprostol|oral misoprostol
89265393|NCT03881956|Other|Women with gestational diabetes|88 women with gestational diabetes (46 for the intervention group and 42 for the control group) were in the arm.
89265394|NCT01157104|Experimental|IDX320 + PBO → IDX320 + IDX184|400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days
89265395|NCT01157104|Experimental|IDX184 + PBO → IDX184 + IDX320|100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days
89265396|NCT01157104|Placebo Comparator|IDX320 PBO + IDX184 PBO|IDX320 matching PBO + IDX184 matching PBO for 14 days
89265397|NCT01157260|Experimental|AST-120|AST-120 administration 2g three times a day
89265398|NCT01157260|No Intervention|Control|Control Chronic Kidney disease stage 3,4
89265399|NCT01157026|Experimental|Tocotrienol Rich Fraction plus Tamoxifen|
89265400|NCT01157026|Active Comparator|Placebo plus tamoxifen|
89265401|NCT01263652|Active Comparator|IMmed|Patients receiving intra-muscular medication and oral placebo
89265402|NCT01263652|Active Comparator|POmed|Patients receiving intra-muscular placebo and oral medication
89265403|NCT01259752|Experimental|compression stockings|
89265404|NCT01259752|Placebo Comparator|standard non compressive stockings|
88805367|NCT01433731|Experimental|SHAPE (SHP-141) 0.5% BID|SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly
89265405|NCT03881644|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigran infusion (0.4 mg/min) for 10 mins"
89265406|NCT03881644|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
89265407|NCT01263730|Active Comparator|Tai Chi Training|The active group will be given 12 weeks of tai chi training
89265408|NCT01263730|No Intervention|Waitlist control group|There is a waitlist control group that will receive the training following a 12 week no treatment period of time
89265409|NCT01265368|Experimental|Study medication|
89265410|NCT01259830|Experimental|Arcoxia® 120 mg|
89265411|NCT01259830|Placebo Comparator|Sugar pill|
89265412|NCT01157338|Active Comparator|diagnostic cardiac catheterization|patients with diagnostic cardiac catheterization
89265413|NCT01157338|Active Comparator|therapeutic cardiac catheterization|patient with angioplasty
89265414|NCT03881878|Experimental|pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : D1 X 11-12 cycles, q3weeks~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (420mg, IV)"
89265415|NCT03881878|Experimental|non-pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) :~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) : D1 X 4cycles q3weeks followed by~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
89265416|NCT01159522|Experimental|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
89265417|NCT00224484|Experimental|GD2-AS04 GROUP|Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
89265418|NCT00224484|Active Comparator|HAVRIX GROUP|Female subjects aged 10-17 years, who received 3 doses of Havrix, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
89265419|NCT00224484|Placebo Comparator|SALINE GROUP|Female subjects aged 10-17 years, who received 3 doses of a saline solution, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
89265420|NCT01265602|Experimental|LAS41007|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
89265421|NCT01265602|Active Comparator|LASW1510|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
89265422|NCT01265602|Placebo Comparator|vehicle|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
89265423|NCT01265680|Experimental|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital
89265424|NCT01265680|No Intervention|Control|No added administration other than our standard of care.
89265425|NCT01157494||children with hemiplegia|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
89265426|NCT03879148|Active Comparator|Erector spinae plane block (Group I)|The ultrasound (US) guided ESPB was performed under aseptic conditions at the level of T5 vertebrae using the GE Vivid Q® US device. A high frequency 12 MHz linear US probe was covered with a sterile sheath and placed longitudinally 2-3 cm lateral to the T5 transvers process. After visualizing trapezius, rhomboid major, erector spinae muscles superficial to the hyperechoic transverse process shadow respectively, a 22-gauge 50 mm block needle (Braun Stimuplex Ultra 360, Germany) was inserted in a cephalad to caudad direction. Once the needle tip had been placed within the interfacial plane below the erector spinae muscle, 2 mL of saline were injected to confirm the proper injection site, and then a 20 mL dose of 0.25% bupivacaine was injected. Patients received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit
89265427|NCT03879148|No Intervention|Control group (Group II)|Patients in control group only received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit.
89265428|NCT01265758|Experimental|Telemetric ECG monitoring|Telemetric 14-days Full Disclosure ECG recording.
89265429|NCT01265758|Active Comparator|Standard 24-hours Holter ECG recording|Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
89265430|NCT01263808|Experimental|Indacaterol 150 µg|Indacaterol 150 µg
89265431|NCT01263808|Experimental|Indacaterol 300 µg|Indacaterol 300 µg
88805368|NCT01433731|Experimental|SHAPE (SHP-141) 1.0% BID|SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly
89265432|NCT01263808|Experimental|Indacaterol 600 µg|Indacaterol 600 µg
89265433|NCT01263808|Placebo Comparator|Placebo|Placebo
89265434|NCT01263808|Active Comparator|Placebo/moxifloxacin|Placebo/moxifloxacin
89265435|NCT01159678|Experimental|online psychoeducation|
89265436|NCT01159756|Experimental|Travacom|Travacom ophthalmic solution
89265437|NCT01071876|Experimental|BF2.649|BF2.649 capsules dosed at 5mg, 10 mg, 20mg
89265438|NCT01071876|Placebo Comparator|Placebo|Capsules of Placebo containing lactose with low, medium and high dosage
89265439|NCT01161706|No Intervention|Control|0 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
89265440|NCT01161706|Experimental|8 fluid ounces vegetable juice|8 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
89265441|NCT01161706|Experimental|16 fluid ounces vegetable juice|16 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
89265442|NCT01581996|Experimental|Lanthanum carbonate treatment|One Treatment arm. All patients will receive the following doses of lanthanum carbonate(Fosrenol)for 10-12 days each: 0 mg, 500 mg tid, 1000 mg tid and 1500 mg tid.
89265443|NCT01157572|Active Comparator|Metoprolol|
89265444|NCT01157572|Placebo Comparator|Placebo|
89265445|NCT01074372|Experimental|Cohort 1|Dose 1 versus placebo
89265446|NCT01074372|Experimental|Cohort 2|Dose 2 versus placebo
89265447|NCT01074372|Experimental|Cohort 3|Dose 3 versus placebo
89265448|NCT01074372|Experimental|Cohort 4|Dose 4 versus placebo
89265449|NCT01161784|Placebo Comparator|Nutrient drink|
89265450|NCT01161784|Experimental|Probiotics|
89265451|NCT01159834||Gardasil, HPV infection|
89265452|NCT03881254|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
89265453|NCT03881254|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
89265454|NCT01265836||1|
89265455|NCT01265914|Placebo Comparator|placebo|
89265456|NCT01265914|Experimental|FP-01.1|
89265457|NCT01263964||stroke, troponin elevation|Patients with stroke (proven by cerebral imaging) and troponin elevation undergoing coronary angiogram
89265458|NCT01263964||non-stemi (controll group)|Patients with troponin elevation suggesting non-stemi undergoing coronary angiogram
89265459|NCT01267942|Experimental|Intravenous intraoperative Enhancin|Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
89265460|NCT01267942|Active Comparator|Postoperative oral Enhancin.|Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.
88805369|NCT05448378|Experimental|D-chiro-inositol|Patients will take D-chiro-inositol. We will make two blood sampling, at the baseline and after one-month treatment
89265461|NCT02527252|Experimental|Craniosacral therapy|"All treatments were applied by two experienced therapists with a 10-year certification in manipulative therapy after completion of their physical therapy degree and more than 20 years of clinical experience with patients. All patients received the intervention on the day of their initial examination. The techniques took 50 minutes and were conducted as follows:~Pelvic Diaphragm Release.~Respiratory Diaphragm Release.~Thoracic Inlet Release.~Hyoid release.~Sacral technique for stabilize L5/sacrum.~CV-4 Still Point Induction."
89265462|NCT02527252|Active Comparator|Classic Massage|Classics massage protocol was compounded by the following techniques of soft tissues massage: effleurage, petrissage, friction, and kneading. The techniques took thirty minutes.
89265463|NCT00254982|Experimental|Group 1 (high-need)|Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
89265464|NCT00254982|Experimental|Group II (low-need)|Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
89265465|NCT01264042|Experimental|FeSo4|
89265466|NCT01074528|Experimental|mindfulness based stress reduction|8-week mindfulness based stress reduction program
89265467|NCT01074528|No Intervention|control group|patients who have to wait before entering the MBSR program or who do not want to follow this program
89265468|NCT01268020|Experimental|[18F]-FMH3-01 PET Imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
89265469|NCT03968796|Active Comparator|Group 1|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
89265470|NCT03968796|Active Comparator|Group 2|"A total of 10 sessions of TENS were administered to each patient for 20 minutes daily.~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
89265471|NCT03968796|Active Comparator|Group 3|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.~Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment."
89265472|NCT03968796|Placebo Comparator|Group 4|"A total of 10 sessions of Sham TENS(the device was not operated) were administered to each patient for 20 minutes daily.~Sham Kinesio taping was performed a total of 3 sessions on the 1st, 4th and 7th days of treatment, but taping was done incorrectly."
89265473|NCT03879226|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
89265474|NCT03879226|Experimental|PBMT + training/ placebo + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
89265475|NCT03879226|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
89265476|NCT03879226|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
89265477|NCT03968718|Experimental|Systematic ePROMs Assessment|"Intervention: The intervention is constituted by a Systematic ePROMs Assessment in routine cancer care in a comprehensive cancer centre.~This will involve preliminary sensitization and training of both clinicians and patients towards the use of ePROMs.~Data filled in by patients through electronic devices will be prompt made available to the clinician during the patient examination."
88805370|NCT05447130|Experimental|Corneal Endothelial Evaluation after Phacoemulsification in Eyes with Pseudoexfoliation Syndrome|
88805371|NCT05447130|Experimental|Corneal Endothelial Evaluation after Phacoemulsification in Eyes without Pseudoexfoliation|
89265478|NCT01264120|Experimental|Health Psychology Intervention|A 50 minute health psychology behavioural intervention with sessions pre-surgery, post-surgery and at 3 month follow up.
89265479|NCT01264120|No Intervention|Control Group|The control group receive usual care through the bariatric surgery process.
89265480|NCT01582698|Experimental|Seropersistence evaluation + 2nd booster vaccination|Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.
89265481|NCT01586572|Experimental|mOPV1- Arm A|Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
89265482|NCT01586572|Experimental|mOPV1- Arm B|Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
89265483|NCT01586572|Experimental|mOPV1-Arm C|Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
89265484|NCT01586572|Experimental|Arm D- bOPV1,3|Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.
89265485|NCT03971916|Experimental|HBM9161 340mg|
89265486|NCT03971916|Experimental|HBM9161 510mg|
89265487|NCT03971916|Experimental|HBM9161 680mg|
89265488|NCT03971916|Placebo Comparator|Placebo|
89265489|NCT03759340|Experimental|ATI 502 0.46% Topical Solution|Subjects will apply ATI-502 Topical Solution, 0.46% twice-daily for 24 weeks followed by a 4-week post-treatment follow up period.
89265490|NCT03881176|Experimental|Active|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
89290497|NCT05198206||Xinjiang Uygur Autonomous Region People's Hospital|
88805372|NCT01434121|Active Comparator|High Dose Ascorbic Acid|Subject receives a high dose of infused Vitamin C
88805373|NCT01434121|Active Comparator|Low Dose Ascorbic Acid|Subject receives a low dose of infused Vitamin C
88805374|NCT01434121|Placebo Comparator|Placebo|Subject receives an infusion of saline
89265491|NCT03877042|Experimental|Experimental|Patients with end-stage knee disease need Total Knee Arthroplasty in both knees.
89265492|NCT00224016|Experimental|Oxybutynin Transdermal System|Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
89265493|NCT00224016|Active Comparator|Oral oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
89265494|NCT03878680||13-14 years age group|Children with age 13-14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
89265495|NCT03878680||6-7 years age goup|Children with age 6-7 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
89265496|NCT01266226|Experimental|ACP treated|The patients are going to get an injection of 4mL autologous conditioned plasma under the footprint following an arthroscopic repair of the rotator cuff.
89265497|NCT01266226|Placebo Comparator|Control group|The patients are going to get an injection of 4mL saline solution under the footprint following an arthroscopic repair of the rotator cuff.
89265498|NCT03881410|Experimental|Shear-wave elastography-guided|Shear-wave elastography-guided bipsy
89265499|NCT03881410|Active Comparator|Convention ultrasound-guided|Convention ultrasound-guided biopsy
89265500|NCT02527174|Experimental|Study treatment arm|"Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts.~Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery."
89265501|NCT01264198|Sham Comparator|Stretching Exercises|The patients will perform twice weekly home based static stretching workout.
89265502|NCT01264198|Experimental|Resistance Training|The patients will perform twice weekly supervised RT for 3 months
89265503|NCT03880942|Active Comparator|Informative Story Book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
89265504|NCT03880942|Placebo Comparator|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
89265505|NCT01266304||community members|Pittsburgh area community members, including people who attend an integrative medicine clinic and people who attend a conventional medicine clinic.
89265506|NCT02526940||blood CD4 cells count < 200/mm3|"patients with blood CD4 cells count at the time of initiation of HAART< 200/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
89265507|NCT02526940||blood CD4 cells count : 200 - 300/mm3|patients with blood CD4 cells count at the time of initiation of HAART between 200 and 300/mm3 Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years
89265508|NCT02526940||blood CD4 cells count >350/mm3|"patients with blood CD4 cells count at the time of initiation of HAART> 350/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
89265509|NCT01161940|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
89265510|NCT01161940|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
89265511|NCT01157650|Experimental|Autologous mesenchymal stem cells|Fistulizing Crohn's disease
89265512|NCT01266538||IBD patients|Patients diagnosed with Inflammatory Bowel Disease (IBD)
89265513|NCT01266538||patients after a Large Bowel Resection|Patients after a Large Bowel Resection, with or without a pouch.
89265514|NCT01266538||Control group|Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy
89265515|NCT01162018|Experimental|Acupuncture Arm|
89265516|NCT01162018|Sham Comparator|Sham Acupuncture|Sham Acupuncture
89265517|NCT01162174|Experimental|100 mg of Oligonol|
89265518|NCT01162174|Experimental|200 mg of Oligonol|
89265519|NCT01162174|Placebo Comparator|0 mg of Oligonol|
89265520|NCT01157728||Relapsing Multiple Sclerosis patients|
89265521|NCT01157728||healthy volunteer|
89265522|NCT01159990|Experimental|Recombinant adenovirus serotype 5 (rAd5) Gag/Pol Env A/B/C|Participants will receive one intramuscular injection of rAd5 Gag/Pol Env A/B/C.
89265523|NCT01159990|Active Comparator|rAd5 gag/pol|Participants will receive one intramuscular injection of rAd5 gag/pol.
89265524|NCT03880630|Experimental|Chronic respiratory disease|Patients with chronic respiratory disease with inspiratory muscle weakness will be recruited for the study
89265525|NCT01160068|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
89265526|NCT01160068|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
89265527|NCT01266616|Experimental|Cohort 1: Vaccine alone IM/EP|HIV MAG pDNA alone IM/EP
89265528|NCT01266616|Placebo Comparator|Cohort 1: Placebo|Placebo given as an injection in each upper arm
89265529|NCT01266616|Experimental|Cohort 2: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 50 mcg of IL-12 pDNA IM/EP
89265530|NCT01266616|Placebo Comparator|Cohort 2: Placebo|Placebo given as an injection in each upper arm
89265531|NCT01266616|Experimental|Cohort 3: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 250 mcg of IL-12 pDNA IM/EP
89265532|NCT01266616|Placebo Comparator|Cohort 3: Placebo|Placebo given as an injection in each upper arm
89265533|NCT01266616|Experimental|Cohort 4: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 1,000 mcg of IL-12 pDNA IM/EP
89265534|NCT01266616|Placebo Comparator|Cohort 4: Placebo|Placebo given as an injection in each upper arm
89265535|NCT01266616|Experimental|Cohort 5: Vaccine plus IL-12 IM|HIV MAG pDNA plus 1,000 mcg (or highest dose reached) IL-12 pDNA IM
89265536|NCT01266616|Placebo Comparator|Cohort 5: Placebo|Placebo given as an injection in each upper arm
89265537|NCT01162252|Active Comparator|Mindfulness-Based Stress Reduction|
89265538|NCT01162252|Active Comparator|Living Well|
89290498|NCT05198206||The First Affiliated Hospital of Anhui Medical University|
89265539|NCT01162330||Babies referred for further hearing tests|Babies referred for further hearing tests after their neonatal hearing screening tests
89265540|NCT01160146||Lifestyle counseling|"Clinicians provide lifestyle management counseling regarding healthful lifestyle behaviors and daily physical activity.~Logging foods for accountability and counting calories~Close attention to portion control and appropriate serving sizes of foods consumed~Consumption of appropriate calorie and sugar free beverages~Good meal distribution and avoidance of meal skipping~Balance of food groups using the MyPlate concept (USDA Choose My Plate)-inclusion of all food groups with emphasis on fruits, vegetables, whole grains, low-fat dairy products and lean meat/fish/poultry~Increasing physical activity with reasonable, sustainable exercise or activity. Working toward a goal of at least 30 minutes, 5 days per week"
89265541|NCT01157806|Experimental|radiochemotherapy instead of surgery|
89265542|NCT01266694|Experimental|Cochicine|Colchicine arm: patient receiving 1 mg per day for 14 days
89265543|NCT01266694|Placebo Comparator|Placebo|patients placebo controlled
89265544|NCT03876886|Active Comparator|AC-T(dose-dense)|A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）
89265545|NCT03876886|Experimental|TP(dose-dense)|T: paclitaxel (PTX） P: carboplatin (CBP)
89265546|NCT03878992|Other|GHD|GHD patients will be studied two times - one time before initiation of GH replacement therapy and one time following three months of GH replacement therapy. The two trial days are identical
89265547|NCT01157884||Kidney Transplantation|
89265548|NCT01266772|Active Comparator|montelukast group|Children with asthma treated with montelukast and budesonide.
89265549|NCT01266772|Placebo Comparator|Placebo group|Children with asthma treated with placebo tablet and budesonide.
89265550|NCT01264354|Experimental|1|Clevudine 30mg
89265551|NCT01264354|Experimental|2|Clevudine 20mg+Adefovir dipivoxil 10mg
89265552|NCT01264354|Experimental|3|Clevudine 20mg
89265553|NCT01264432|Experimental|Treatment (veliparib, LDRWAR)|Patients receive veliparib PO BID on days 1-21 (days 5-21 of course 1). Patients undergo LDFWAR in BID on days 1 and 5 of weeks 1-3. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
89265554|NCT03880318|Other|spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies in spasmodic flat foot
89265555|NCT02527096|Experimental|dolutegravir(Tivicay®) and lamivudine(Epivir®)|
89265556|NCT01160224|Active Comparator|GW766944|This is the active drug (GW766944)
89265557|NCT01160224|Placebo Comparator|Placebo|Placebo Arm.
89265558|NCT03876730||Study group|3-18 aged children with cerebral palsy
89265559|NCT01162564||NG-TSM|Patients receiving NG-TSM to repair an abdominal incisional/ventral hernia
89265560|NCT01162642|Experimental|Green Tea|4 cups daily of green tea for 6 weeks
89265561|NCT01162642|Placebo Comparator|No Green Tea|4 cups daily of placebo tea for 6 weeks
89265562|NCT01266928|Active Comparator|vitaminCE|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
88805375|NCT01435603|Active Comparator|Standard Lifestyle Advice|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant).
88816290|NCT02573181|Active Comparator|Prevnar 13™|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.
89265563|NCT01266928|No Intervention|no drug|no drug
89265564|NCT01157962|Experimental|Group A Sentinel lymphadenectomy|In group A exclusively sentinel lymphadenectomy is performed
88816291|NCT02974491|Experimental|Apple Juice|
89265565|NCT01157962|Active Comparator|Group B radical pelvine lymphadenectomy|in group B radical systematic pelvic lymphadenectomy is done. In patients with tumor free lymph nodes either radical hysterectomy or, in women seeking parenthood, radical trachelectomy is performed. If lymph nodes are tumor-involved systematic pelvic and paraaortic lymphadenectomy followed by primary chemoradiation is recommended.
89265566|NCT03879928|Placebo Comparator|Placebo for SAD|Placebo comparator for SAD
89265567|NCT03879928|Experimental|FM101 75 mg for SAD|Single ascending doses of FM101
89265568|NCT03879928|Experimental|FM101 150 mg for SAD|Single ascending doses of FM101
89265569|NCT03879928|Experimental|FM101 300 mg for SAD|Single ascending doses of FM101
89265570|NCT03879928|Experimental|FM101 600 mg for SAD|Single ascending doses of FM101
89265571|NCT03879928|Experimental|FM101 1200 mg for SAD|Single ascending doses of FM101
89265572|NCT03879928|Experimental|FM101 2400 mg for SAD|Single ascending doses of FM101
89265573|NCT03879928|Placebo Comparator|Placebo for MAD|Placebo comparator for MAD
89265574|NCT03879928|Experimental|FM101 150 mg (QD) for MAD|Multiple ascending doses of FM101
89265575|NCT03879928|Experimental|FM101 450 mg (QD) for MAD|Multiple ascending doses of FM101
89265576|NCT03879928|Experimental|FM101 600 mg (BID) for MAD|Multiple ascending doses of FM101
89265577|NCT03879928|Experimental|FM101 300 mg under fasted condition for FE|Food Effect of FM101
89265578|NCT03879928|Experimental|FM101 300 mg under fed condition for FE|Food Effect of FM101
89265579|NCT01160302|Experimental|Microgranular Curcumin|Consume 4g microgranular curcumin (Curcumin C3 Complex) twice per day
89265580|NCT01162720|Experimental|Short duration tourniquet|Patients allocated to this group will have the pneumatic tourniquet applied to the index limb for approximately 20-30 minutes during cement fixation of the prosthesis.
89265581|NCT01162720|Active Comparator|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied from commencement of surgery and removed just prior to skin closure.
89265582|NCT03879850||Propofol group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - i.v. Propofol - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
89290499|NCT05198206||Yantai Yuhuangding Hospital|
89265583|NCT03879850||Volatile group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - volatile anesthetic agent as Sevoflurane or Desflurane - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
88805376|NCT01435603|Experimental|Advice Plus Lifestyle Intervention|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant) Plus access to an intensive group-based lifestyle intervention offered in a community setting.
88805377|NCT01381861|Experimental|Carotuximab (TRC105) alone|Single arm, open label Carotuximab (TRC105) alone therapy dosed at 10 mg/kg administered intravenously over 1 to 4 hours on days 1, 8, 15 and 22 of each 28 day cycle
88805378|NCT01382719|Placebo Comparator|Placebo|Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
88805379|NCT01382719|Experimental|bremelanotide arm 1|Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
89265584|NCT01158040||Insulin pump|Women suffering from pregestational diabetes mellitus and being treated with insulin pump during pregnancy and delivery
89265585|NCT01158040||IV insulin|Women suffering from pregestational diabetes mellitus and being treated with insulin sub-cutan (SC) during pregnancy and IV insulin during delivery
89265586|NCT01158040||Healthy|Healthy women accepted for delivery in our institute
89265587|NCT01268176|Active Comparator|Low fat meal|Those subjects who receive a low fat meal prior to vitamin D3 administration
89265588|NCT01268176|Active Comparator|High fat meal|Those subjects who receive a high fat meal prior to vitamin D3 administration
89265589|NCT01268176|Active Comparator|No meal|Those subjects who do not receive a meal and continue to fast. They only receive the vitamin D3 dose.
89265590|NCT01268254||red wine|red wine usual consumer versus abstemious
89265591|NCT03878290|Experimental|8-week RiSE|Participate in 8-week Resilience, Stress, and Ethnicity (RiSE) group based stress reduction program in which participants meet every week for approximately 2 hours for 8 consecutive weeks.
89265592|NCT03878290|No Intervention|Control|Treatment as usual
89265593|NCT01264588|Active Comparator|topical calcium glycerophosphate lotion|
89265594|NCT01264588|No Intervention|standard-of-care|
89265595|NCT01267006|Placebo Comparator|Placebo|Part A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule.
89265596|NCT01267006|Experimental|GSK1325756 200 mg|Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
89265597|NCT01267006|Experimental|GSK1325756 50 mg|Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
89265598|NCT01267006|Experimental|GSK1325756 100 mg|Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule.
89265599|NCT01268332|Experimental|Intravaginal Ring|Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
89265600|NCT01268332|No Intervention|No Intravaginal Ring|Intravaginal ring will not be inserted into participants.
89265601|NCT01162798|Active Comparator|Control|commercially available formula
89265602|NCT01162798|Experimental|Test|test formula
89265603|NCT01158196|Experimental|infra-red diode laser|one session, one dose
89265604|NCT01162876|Experimental|saxagliptin|5 mg daily for 14days
89265605|NCT03877588|Other|Primary retroperitoneal sarcoma|All eligible patients are screened in preoperative phase, at least 30 days before surgery, for presence of protein energetic malnutrition (PEM). PEM is defined according to biochemical and physiological parameters (Table). 3 class of PEM are identified: no PEM, mild PEM and serious PEM. Different nutritional oral supplements are provided according to the degree of malnutrition.
89265606|NCT05666908|Experimental|HFNO group|Direct guidance and positioning of DLT intubation with FOB visualization, using HFNO during intubation asphyxia.
89265607|NCT05666908|No Intervention|Control group|The DLT cannula was directly guided and positioned under FOB visualization, and no oxygen therapy equipment was used during intubation.
89265608|NCT03876418|No Intervention|Usual Care|Patients undergo twice daily measurement of intra-abdominal pressure. Clinicians manage patients according to usual care.
89265609|NCT03876418|Active Comparator|Aggressive|Patients undergo aggressive surveillance (q6h) if intra-abdominal pressure is elevated as well as prevention and treatment according to protocol driven guidelines adapted from the World Society of the Abdominal Compartment. This may include nasogastric decompression, limiting fluid administration, drainage of ascites, paralysis and/or abdominal decompression.
89265610|NCT01158274|Experimental|Treatment|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89265611|NCT05666830||1|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
89265612|NCT03876496|Experimental|SensableCareCare System|The Sensable®Care System uses pressure sensors and computer software to sense how patients are positioned on the bed in order to reduce bed falls. The Sensable®Care System Mattress has sensors embedded in them, which will be monitored by the nurses in the unit.
89265613|NCT01267084|Experimental|Part 1|Patients will receive trabectedin+ketoconazole followed by trabectedin alone. Each cycle will be will be separated by 21 days. Patients will receive 6 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
89265614|NCT01267084|Experimental|Part 2|Patients will receive 1 of 2 treatment sequences; Sequence 1: trabectedin+ketoconazole followed by trabectedin alone or Sequence 2: trabectedin alone followed by trabectedin+ketoconazole. Each cycle will be separated by 21 days. Patients will receive 15 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
89265615|NCT01267162||TDF Treatment|
89265616|NCT01158352|Experimental|Nutritional supplemntation formula|Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
89265617|NCT01158352|Placebo Comparator|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
89265618|NCT01162954|Experimental|DA-6034|
88805380|NCT01382719|Experimental|bremelanotide arm 2|Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
88805381|NCT01382719|Experimental|bremelanotide arm 3|High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
88805382|NCT01037309|Experimental|PRO044, cohort 1|Subcutaneous injection of 0.5 mg/kg on day 1, 8, 15, 22 and 29.
89265619|NCT01162954|Placebo Comparator|Placebo|
89265620|NCT01268410||acute respiratory failure|
89265621|NCT01264666|Experimental|Chinese tea flavor liquor|
89265622|NCT01264666|Placebo Comparator|Water|Water combined with meal as control.
89265623|NCT01264666|Placebo Comparator|Chinese Meijiao Liquor|
88805383|NCT01037309|Experimental|PRO044, cohort 2|Subcutaneous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29.
88805384|NCT01037309|Experimental|PRO044, cohort 3|Subcutaneous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29.
88805385|NCT01037309|Experimental|PRO044, cohort 4|Subcutaneous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29.
88805386|NCT01037309|Experimental|PRO044, cohort 5|Subcutaneous injection of maximally 10 mg/kg on day 1, 8, 15, 22 and 29
89265624|NCT01160692|Experimental|Arm 1|
89265625|NCT01160692|Placebo Comparator|Arm 2|
88805387|NCT01037309|Experimental|PRO044, cohort 6|Subcutaneous injection of maximally 12 mg/kg on day 1, 8, 15, 22 and 29
89265626|NCT01158430|Experimental|ACT group therapy|"Third generation cognitive behavioral therapy~Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours"
89265627|NCT01158430|No Intervention|Control|Control group assigned to wait list (treatment as usual). After 9 months they are offered ACT group therapy, but not as part of the research project.
89265628|NCT01264822||Treatment Arm 1 Rabeprazole Sodium|
89265629|NCT03880006|No Intervention|Standard of care|Participants assigned to the Senegalese standard of care treatment for people living with HIV.
89265630|NCT03880006|Experimental|Case management|Individuals in the intervention arm will receive Senegalese standard of care treatment for people living with HIV, and the case management intervention.
89265631|NCT01161004|Experimental|Sugammadex - Nacl 9/00|"Sugammadex - Nacl 9/00:~Patients will first receive sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive Nacl 9/00 5 minutes after the first bolus of sugammadex.~The study is finished 5 minutes after this second injection and care is let to the choice of the anesthesiologist in charge."
89265632|NCT01161004|Experimental|Nacl 9/00 - sugammadex|"Nacl 9/00 - Sugammadex :~Patients wil first receive Nacl 9/00. In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive sugammadex 5 minutes after the first bolus of Nacl 9/00.~Sugammadex is given as: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~The study is finished 5 minutes after the injection of sugammadex and care is let to the choice of the anesthesiologist in charge."
89265633|NCT03876340|Active Comparator|Current treatment|Patients will receive burn care treatment as dictated by the surgical team (current standard of care).
89265634|NCT03876340|Experimental|Algorithm-dictated treatment|Patients will receive burn care treatment as dictated by the treatment algorithm (PLOS ONE 13(11): e0206477.).
89265635|NCT01264900|Experimental|Cognitive Behavioral Therapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment
89265636|NCT01264900|Active Comparator|Supportive Psychotherapy|Twelve weekly 50-minute sessions of individual supportive (client-centered) psychotherapy
89265637|NCT01264978|Experimental|repetitive neuromuscular stimulation|repetitive neuromuscular stimulation of the quadriceps arm are patients actively stimulated at increasing intensity to afford maximal contraction during training sessions
89265638|NCT03876574|Experimental|Treatment|"Patients undergo DSA-guided implantation of hepatic artery infusion pump. All patients receive the intervention Hepatic artery infusion of gemcitabine and floxuridine the next day after pump implantation. The HAI therapy is initiated on day 1, 8: Gemcitabine 1g/m2 for 30 minutes, followed by a blended solution which comprised floxuridine (FUDR) at 0.15 mg/kg/day, dexa-methasone (DXM) at 1 mg/m2/day, low molecular heparin 3200U and saline, lasted for 7 days continuously.Standard treatments of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) are performed as desired."
89265639|NCT01158508|Experimental|Remote Ischemic Preconditioning|Patients with aneurysmal subarachnoid hemorrhage, after aneurysm treatment, will be given prophylactic remote ischemic preconditioning by transient lower limb ischemia.
89265640|NCT01268722|Active Comparator|Balloon|
89265641|NCT01268722|Experimental|Stent|
89265642|NCT01161082|Experimental|Group 1 with atorvastatin|Dose 1 versus placebo
89265643|NCT01161082|Experimental|Group 2 with atorvastatin|Dose 1 versus placebo
88805388|NCT01037309|Experimental|PRO044, cohort 7|Intravenous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29
89265644|NCT01161082|Experimental|Group 3 with atorvastatin|Dose 2 versus placebo
89265645|NCT01161082|Experimental|Group 4 with atorvastatin|Dose 2 versus placebo
89265646|NCT01161082|Experimental|Group 5 with atorvastatin|Dose 3 versus placebo
89265647|NCT01161082|Experimental|Group 6 with atorvastatin|Dose 3 versus placebo
89265648|NCT01161082|Experimental|Group 7 without atorvastatin|Dose 3 versus placebo
89265649|NCT01161082|Experimental|Group 8 with atorvastatin|Dose4 versus placebo
88805389|NCT01037309|Experimental|PRO044, cohort 8|Intravenous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29
89265650|NCT01158586|Experimental|Levobupivacaine|patient control epidural analgeisa using 0.2% levobupivacaine with 2ug/ml fentanyl
89265651|NCT01158586|Active Comparator|Ropivacaine|patient controlled epidural analgesia using 0.2% ropivacaine with 2ug/ml fentanyl
89265652|NCT01158742||1|Caucasians who donated a kidney at Mayo Clinic in Rochester, Minnesota (MN)
89265653|NCT01158742||2|Caucasians who donated a kidney at the University of Minnesota
89265654|NCT01158742||3|African-Americans who donated a kidney at the University of Alabama
89265655|NCT01267396|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
89265656|NCT01267396|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
89265657|NCT05018884||Patients without SSI|Patients who underwent surgery and who developed a surgical site infection (SSI) during 30 days after surgery
89265658|NCT05018884||Patients with SSI|Patients who underwent surgery and who didn't develop a surgical site infection (SSI) during 30 days after surgery
89265659|NCT01163188||Proband|Very low birth weight children (< 32 weeks of gestation) and/ or Very preterm children (< 1500 g birthweight) of the Bavarian Longitudinal Study
89265660|NCT01163188||Controls|Term born children of the Bavarian Longitudinal Study
89265661|NCT01158898|Active Comparator|TPI ASM8 low dose|
89265662|NCT01158898|Active Comparator|TPI ASM8 high dose|
89265663|NCT01158898|Placebo Comparator|Placebo|
89265664|NCT02527018||Healthy Subjects|Measurement of hemodynamic levels (BNP) of healthly term subjects using the Nexfin sphygmomanometer device.
89265665|NCT02527018||Preeclamptic Subjects|Measurement of hemodynamic levels (BNP) of preeclamptic subjects using Nexfin sphygmomanometer device.
89265666|NCT01161238||Lower-limb amputee|Subjects with at least one lower limb amputated at the trans-tibial level
89265667|NCT01267474|Experimental|Nutritional education|
89265668|NCT01267474|No Intervention|Control|
89265669|NCT01267552|Experimental|Non drainage arm|No drains will be placed during operation
88805390|NCT01037309|Experimental|PRO044, cohort 9|Intravenous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29
88805391|NCT01038557|Active Comparator|Refrigerated RBCs 0-14 days old|Standard, refrigerated RBC units stored up to 14 days
88805392|NCT01038557|Active Comparator|Refrigerated RBCs 15-42 days old|Standard, refrigerated RBC units stored 15-42 days
88805393|NCT01038557|Experimental|Frozen RBCs|RBC units stored frozen at -80 degrees Celsius, then thawed and deglycerolized using the ACP 215.
89265670|NCT01267552|Active Comparator|Drainage arm|Closed suction drains will be placed during operation
89265671|NCT01265134||Experimental Group|the healthy elders
89265672|NCT01265134||Control Group|the elders who have fallen once
89265673|NCT01267630||Surgical ICU|Patients are admitted to the surgical ICU of Chiang Mai University Hospital within 48 hours .
89265674|NCT01159132|Active Comparator|1|RAL 400 mg OD
89265675|NCT01159132|Active Comparator|2|RAL 800 mg OD
89265676|NCT01161316|Active Comparator|Control|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
89265677|NCT01161316|Experimental|Experimental|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
89265678|NCT01161550|Experimental|Arm 1|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 25 mg PO BID Days 7-20"
89265679|NCT01161550|Experimental|Arm 2|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 50 mg PO BID Days 7-20"
89265680|NCT03877198|Experimental|CLiO2|Automated oxygen control by the CLiO2 algorithm
89265681|NCT03877198|Experimental|Oxygenie|Automated oxygen control by the Oxygenie algorithm
89265682|NCT01267708||Study Group|All those tested
89265683|NCT03879460|Experimental|Open Label|Open label
89265684|NCT03877120|Sham Comparator|Dexmedetomidine|"Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.~Dosage form: DEX 0.2-0.7 mcg/Kg/min."
89265685|NCT03877120|Active Comparator|Diazepam|Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam
89265686|NCT01159366|Active Comparator|occluded culprit artery|An occluded lesion was defined as a lesion with 100% stenosis or TIMI-flow grade 0 or 1.
89265687|NCT01159366|Active Comparator|non-occluded culprit artery|A non-occluded lesion was defined as a lesion without 100% stenosis or TIMI-flow grade 0 or 1.
89265688|NCT01267786|Active Comparator|Sevoflurane|1MAC intraoperatively
89265689|NCT01267786|Active Comparator|desflurane|1 MAC intraoperatively
89265690|NCT03879382|Experimental|anti-CD19/BCMA CAR-T cells|Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
89265691|NCT03874780|Experimental|Treatment|Subjects treated with Botox (TM) with the Vibe investigational delivery system
89265692|NCT03874390|Experimental|ozone therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
89265693|NCT03874390|Active Comparator|initially periodontal therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
89265694|NCT01265290|Experimental|Telemetric ECG monitoring|Telemetric Full Disclosure ECG monitoring
89265695|NCT01265290|Experimental|24 hours standard Holter monitoring|
89265696|NCT01166932|Active Comparator|amoxicillin/clavulanic acid|patients who received amoxicillin/clavulanic acid
88805394|NCT04352387|Experimental|Montessori Method for Dementia|The design of the Montessori Method for Dementia program covered five aspects, namely cognitive stimulation, life skills, motor movements and fitness, sensory stimulation, and socialization. Each 1-hour session included two to three activities tailored to the local cultural context.
88805395|NCT04352387|Active Comparator|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
89265697|NCT01166932|Active Comparator|ceftriaxone/oxacillin|
89265698|NCT01167010|Experimental|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.
89265699|NCT01167010|Active Comparator|Foraseq|Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
89265700|NCT01167010|Active Comparator|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
89265701|NCT01280188|Experimental|Desmopressin|Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.
89265702|NCT01269502|Experimental|Skin temperature measurement|Regular measurement of skin temperature on feet for one year
89265703|NCT01269502|Active Comparator|Active control|Daily inspection of feet for one year
89265704|NCT03872050||Rosacea|Patients who have been diagnosed with rosacea
89265705|NCT03872050||Migraine|Patients who have been diagnosed with migraine
89265706|NCT01167088|Experimental|Mitoquinone mesylate tablets (MitoQ)|
89265707|NCT01167088|Placebo Comparator|Matching placebo tablet|
89265708|NCT03871972|Experimental|UCB injection group|This pilot study includes only 2 subjects who are enrolled by invitation. Both subjects are included in this single arm.
88805396|NCT01117727|Experimental|Pilot Testing|
89265709|NCT01269580||Diabetic|Adult diabetic patients type 1 or 2, with chronic critical ischemia as defined by TASC 2007 criteria
89265710|NCT01269580||Not diabetic|Adult not diabetic with chronic critical ischemia
89265711|NCT01165060|Experimental|Bezafibrate|All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
89265712|NCT01165294|Experimental|001|ketamine An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
89265713|NCT01165294|Experimental|002|Placebo An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
89265714|NCT03871738|Experimental|Proprioception training|The subjects included in the experimental group will carry out a protocol of proprioception exercises. Each session will last 25 minutes, taking place during 2 sessions a week, in a period of 4 weeks. All interventions will be made before the training session.
89265715|NCT03871738|No Intervention|Control|The subjects included in the control group will not receive intervention and will continue to carry out their daily life in the same way as they have done up to now.
89265716|NCT01165372|Experimental|Artesunate 2mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 2mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
89265717|NCT01165372|Experimental|Artesunate 4mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 4mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
89265718|NCT01165372|Experimental|DHA-piperaquine|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with dihydroartemisinin-piperaquine once daily according to weight for 3 days.
89265719|NCT03871660|Other|Patients with diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
89265720|NCT03871660|Other|Patients without diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
89265721|NCT03871582||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
89265722|NCT01167322|Experimental|NPC-07|Single administration of NPC-07 at a dose of 20mg/kg body weight
89265723|NCT01269814||Go-home group|The patients with a Rockall score of 0 or 1 will be prescribed medical therapy, and will be scheduled for elective gastroscopy.
89265724|NCT01280734|Active Comparator|Melatonin|Circadin(R) 2 mg tablet 2 hours at 23:00
89265725|NCT01280734|Active Comparator|Zolpidem|Stilnox (R) 10 mg tablet at 23:00
89265726|NCT01280734|Placebo Comparator|Placebo|
88805397|NCT01040819|Experimental|Pioglitazone 15 mg|Patients will receive PIO 15 mg/d for two months. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
89265727|NCT03871504|Experimental|submaximal isometric exercise.|submaximal isometric exercise will be performed.
89265728|NCT03871504|No Intervention|Quiet rest.|Subject will rest in seating position for a period that mimics the exercise time.
89265729|NCT01269892|Other|lactose-free milk|it is kind of nutritional regime
89265730|NCT01269892|Other|conventional milk|it is kind of nutritional regime
89265731|NCT01280890|Experimental|Staff training using VIPS framework|The staff will be trained to give person-centred care using the VIPS framework
89265732|NCT01280890|Experimental|Staff training using DCM|Staff will be supervised in how to give person-centred care using Dementia Care Mapping
89265733|NCT01280890|Placebo Comparator|Control group|Traditional lectures using films will be given to care staff
88805398|NCT01040819|Experimental|Pioglitazone 30 mg/d|Patients will receive PIO 15 mg/d for one month. Then, dose will be increased to 30 mg/d for an additional month. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
88805399|NCT03014063||Hemodynamic responders|Those with a mean arterial pressure of at least 65mmHg and a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
89265734|NCT01269970||locally advanced esophageal carcinoma (cT2-3N0/+)|
88805400|NCT03014063||Hemodynamic non-responders|Those without a mean arterial pressure of at least 65mmHg and/or a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
89265735|NCT01587430|Active Comparator|high dose ARA-C|High dose ARA-C will be applied after two 7+3 induction courses during the first and the second consolidation courses: ARA-C 1 g/m2 bid 1-3 days with idarubicin (8mg/m2 3-5 days)and mitoxantrone (10 mg/m2 3-5 days)
89265736|NCT01587430|Active Comparator|standard dose ARA-C|Standard dose ARA-C will be applied after two 7+3 induction courses the first and the second consolidation courses : ARA-C 100 g/m2 bid 1-7 days with idarubicin (8mg/m2 1-3 days)and mitoxantrone (10 mg/m2 1-3 days)
89265737|NCT03874000|Experimental|Sintilimab plus Metformin Hydrochloride|Patients receive metformin hydrochloride 500mg orally (PO) twice daily (BID). Patients also receive Sintilimab 200mg intravenously (IV) in 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
89265738|NCT01165528|Active Comparator|Adaptive support ventilation in ARDS|patients of ARDS will be randomized to this arm to receive mechanical ventilation as per ASV protocol
88805401|NCT01041209|Experimental|BPS|BPS guidance
88805402|NCT01041209|Active Comparator|Guideline|Enforced guidelines
88805403|NCT01084499|Experimental|Femara First, Then Peratra (Sequence 1)|Participants first receives a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period is separated by a 5-week washout period.
88805404|NCT01084499|Experimental|Peratra First, Then Femara (Sequence 2)|Participants first receives a generic letrozole (test - Peratra) , then a branded letrozole (reference - Femara). Each treatment period is separated by a 5-week washout period.
88805405|NCT01085513|Active Comparator|Patients|Patients previously indicated for manometry
88805406|NCT01085513|Active Comparator|Healthy volunteers|Healthy volunteers
88805407|NCT01986348|Experimental|Arm A: Selinexor 60 mg and Surgery|Participants who required surgery received up to 3 doses of oral selinexor tablets 60 milligrams (mg) twice weekly (BIW) on Day 1, Day 3 and between 2 and 48 hours prior to surgery, subsequently underwent surgery for resection of their tumor and resumed selinexor tablets 60 mg BIW after recovery, during Week 1 to 4 of each 4-week cycle, until progression of disease (PD) or development of unacceptable toxicities.
88805408|NCT01986348|Experimental|Arm B: Selinexor 50 mg/m^2|Participants who were not eligible for surgery received selinexor tablets 50 mg per square meter (mg/m^2) BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
88805409|NCT01986348|Experimental|Arm C: Selinexor 60 mg|Participants who were not eligible for surgery received selinexor tablets 60 mg BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
88805410|NCT01986348|Experimental|Arm D: Selinexor 80 mg|Participants who were not eligible for surgery received selinexor tablets 80 mg once weekly (QW) during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
89265739|NCT01165528|Active Comparator|conventional ventilation strategy in ARDS|
89265740|NCT01167400|Experimental|Cybercycling|cybercycling for 3 months
89265741|NCT01167400|Active Comparator|Traditional Stationary Biking|Traditional exercise on a stationary bike for 3 months.
89265742|NCT03757234|Experimental|Omadacycline 200 iv/200 iv|On Day 1, participants received omadacycline 200 milligrams intravenously (iv). On Days 2 through 7, participants continued to receive omadacycline 200 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
89265743|NCT03757234|Experimental|Omadacycline 200 iv/100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
88805411|NCT01118273|Experimental|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|
88805412|NCT01118273|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
88805413|NCT01118273|Experimental|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|
88805414|NCT01118273|Active Comparator|Naproxen Sodium 220 mg (BAYH6689)|
88805415|NCT01118273|Active Comparator|DPH 50mg|
88805416|NCT01118273|Active Comparator|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|
88821603|NCT03313778|Experimental|Part D: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle for up to 9 cycles and pembrolizumab via IV infusion on Day 1 of each 21-day cycle until progression, unacceptable toxicity, or up to 18 cycles (approximately 1 year of treatment), whichever is sooner.
89265744|NCT03757234|Experimental|Omadacycline 200 iv/300 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 300 milligrams per oral (po). All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
89265745|NCT03757234|Experimental|Omadacycline 200 iv/450 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 450 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
89265746|NCT03757234|Active Comparator|Levofloxacin 750 iv/750 po or iv|On Day 1, participants received levofloxacin 750 milligrams iv. On Days 2 through 7, participants received levofloxacin 750 milligrams iv or levofloxacin 750 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
89265747|NCT03756766||RSV positive ARTI|"RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).~Group 1 participants are categorised into 4 groups as follows:~Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.~Group 1c & 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively."
89265748|NCT03756766||Healthy controls|"This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.~This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only."
88805417|NCT05420142|Experimental|Test meal incorporating the study groups innovative plant protein and fibre (variety 3) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 65.64g of plant protein and fibre variety 3 (3.09g leucine), 28.6g butter, 5.12g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
88805418|NCT05420142|Experimental|Test meal incorporating the study groups innovative plant protein and fibre (variety 5) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 67.78g of plant protein and fibre variety 3 (3.09g leucine), 27.79g butter, 4.63g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
88805419|NCT05420142|Experimental|Test meal incorporating the study groups innovative plant protein and fibre (variety 6) product.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 57.66g of plant protein and fibre variety 3 (3.09g leucine), 31.72g butter, 6.62g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
89265749|NCT03874156|Active Comparator|Intervention group|Atorvastatin 40 mg once daily
89265750|NCT03874156|Placebo Comparator|Placebo group|Matched placebo tablet once daily
89265751|NCT01165606|Experimental|Physiotherpy|
89265752|NCT01586650|Experimental|Aerobic training|The patients in this arm perform a 50-minute-walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
89265753|NCT01586650|Placebo Comparator|Stretching exercises|The control group perform global stretching exercises for approximately 20 minutes 3 times a week for 12 weeks.
89265754|NCT01586728|Other|Air - oxygen|One period in room air and one period with nocturnal oxygen therapy, separated by a wash out period of 2 to 6 weeks.
89265755|NCT01586728|Other|Oxygen - Air|One period with nocturnal oxygen therapy and one period in room air, separated by a wash out period of 2 to 6 weeks.
89265756|NCT01281280||VNS Therapy|
89265757|NCT01281280||Best Medical Practice|
89265758|NCT01167478|Experimental|Caffeine|
89265759|NCT01281358|Experimental|HOP-ON intervention|Participants will receive a CD-ROM (or DVD and booklet if no access to computer) highlighting motor skills which could be encouraged with premature infants
89265760|NCT01281358|Active Comparator|SMILES|Participants will received a CD-ROM (or DVD and booklet if no access to a computer) which contains information on interacting with their premature infant
89265761|NCT01281436|Other|Web-based Provider training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
89265762|NCT01281436|Active Comparator|HeartSmartKids with web-based training|The providers assigned to Group 2 will receive the web-based training described in the other arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
89265763|NCT01587196|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
89265764|NCT01281514|Experimental|Treatment|See Detailed Description
89265765|NCT00223080|Active Comparator|Vaccine|ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
89265766|NCT00223080|Placebo Comparator|Placebo|ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
89265767|NCT03871192|Experimental|FACET JOINT UNDER CT GUIDANCE|Injection of the facet joint under computed tomography guidance
89265768|NCT03871192|Active Comparator|NERVE BLOCK UNDER CT GUIDANCE|Injection of the nerve under computed tomography guidance
89265769|NCT03871192|Experimental|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|Injection of the facet joint under fluoroscopy guidance
89265770|NCT03871192|Active Comparator|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|Injection of the nerve under ultrasound guidance
89265771|NCT03871192|Experimental|FACET JOINT UNDER ULTRASOUND GUIDANCE|Injection of the facet joint under ultrasound guidance
89265772|NCT03871192|Active Comparator|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|Injection of the nerve under computed ultrasound guidance
89265773|NCT02526784|Active Comparator|Injection A|Degarelix s.c. standard injections
89265774|NCT02526784|Experimental|Injection B|Degarelix s.c. optimised injections
89265775|NCT02526784|Experimental|Injection C|Degarelix i.m. injections
89265776|NCT03971682|Experimental|Experimental - PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP is a structured individual program for detained youth. This program is based on Compassion Focused Therapy (CFT), which conceptualizes antisocial behavior and psychopathic traits as evolutionary rooted responses to deal with harsh rearing scenarios. The ultimate goal of the PSYCHOPATHY.COMP is to develop a compassionate motivation in these youth.~PSYCHOPATHY.COMP consists of 20 individual sessions, each lasting about 60 minutes, which run on a weekly basis. Sessions must be carried out by therapists skillful in CFT. Sessions are grouped into four modules: (1) The basics of our mind; (2) Our mind according to CFT; (3) Compassionate Mind Training; and (4) Recovery, relapse prevention, and finalization.~The treatment group attended the PSYCHOPATHY.COMP program in addition to the Treatment As Usual (TAU) delivered at Portuguese juvenile detention facilities."
89265777|NCT03971682|Active Comparator|Treatment As Usual - TAU|"Treatment As Usual:~Subjects in this group received Treatment As Usual in Portuguese juvenile detention facilities (school frequency, token economy system for behavior control, frequency of a structured cognitive-behavioral group program, as well as individualized counseling sessions delivered by psychologists from the juvenile justice system) and did not attend the PSYCHOPATHY.COMP program."
89265778|NCT02526706|Experimental|Glaucoma Study Group|Glaucoma patients scheduled for trabeculectomy were recruited for this study and VisionBlue dye is injected prior to the surgery.
89265779|NCT01281592|Experimental|LOR-253 HCl|LOR-253 HCl will be given in ascending doses until the maximum administered dose or appropriate target dose is reached. A biomarker study of up to 10 patients will be conducted upon achieving appropriate dose level.
89265780|NCT03971604|Experimental|group 1|treated with VA
89265781|NCT03971604|Experimental|group 2|treated with VE
89265782|NCT03971604|Experimental|group 3|treated with VA+VE
89265783|NCT03971604|No Intervention|group 4|No intervention
89265784|NCT02531490|Active Comparator|randomized, interventiongroup|Women with a hyperdynamic vasodilated profile, characterized by a mean arterial pressure (MAP)/ Heart rate (Hr) ratio ≤ 1.1 are prescribed a beta-blocker. Women with a hypodynamic vasoconstrictive profile (MAP/Hr ratio ≥ 1.4) are prescribed nifedipine. Women with normodynamic profile (MAP/Hr ratio in between 1.1 and 1.4) are prescribed Methyldopa.
89265785|NCT02531490|No Intervention|randomized, control-group|Women who give informed consent for randomization, and are randomized to the control group will not be medicinally treated for mild to moderate gestational hypertension.
88805420|NCT05420142|Active Comparator|Test meal incorporating the control comparator (whey protein isolates), plus 10g of added pea fibre.|The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 36.59g of unflavoured Optimum Nutrition gold standard 100% whey protein (3.09g leucine), 33.23g butter, 9.09g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
88805421|NCT01383421||Participants With RA Receiving Adalimumab|"Participants with RA who were prescribed adalimumab based on current clinical practice criteria (regardless of participation in the study), with the first dose corresponding to the Enrollment/Baseline visit.~All participants were offered to participate in the PSP while treated with ADA for their RA."
89265786|NCT02531490|No Intervention|not-randomized, control-group|Women who do not want to be randomized, but who give informed consent for follow-up on their data until discharge after delivery. They will receive standard care, i.e. no medication is prescribed for mild to moderate gestational hypertension.
89265787|NCT02526472|Experimental|transabdominal US guidance (UGET)|ET under transabdominal US guidance (UGET)
89265788|NCT02526472|Experimental|TV-US ET guidance (mTVET)|ET after transvaginal US uterine measurement (mTVET)
89265789|NCT03871114||OLP patients|fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks
89265790|NCT03871114||Control group|
88805422|NCT04423848|Experimental|Home Hospital for Lymphoma|The Home Hospital for Lymphoma intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
88805423|NCT01085825|Active Comparator|Manual Vacuum Aspiration|
88805424|NCT01085825|Active Comparator|Electric Vacuum Aspiration|
88805425|NCT04265742|Experimental|Group A. Normal BMD, no fracture|Post-menopausal women with normal bone density (BMD t-score >-1.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
88805426|NCT04265742|Experimental|Group B. Normal BMD, with fracture|Post-menopausal women with normal bone density (BMD T-score >-1.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
89265791|NCT01073592||CNV patiens|
89265792|NCT01272622|Other|Arm I|"Children and adolescents >= 18 years of age new diagnosed with craniopharyngioma~>= 5 years of age and with incomplete resected tumor => randomized in two arms: immediate irradiation after surgery"
89265793|NCT01272622|Other|Arm II|incomplete resection, wait and watch, MRI-controls every 3 months, and irradiation at the time of progression of residual tumor
89265794|NCT01281670|No Intervention|No vibration|
89265795|NCT01281670|Active Comparator|vibration|
89265796|NCT01281748|Experimental|methylprednisolone|
89265797|NCT01281748|Placebo Comparator|normal saline solution|
89265798|NCT03873610|Experimental|Stress and Symptom Management Program 1|
89265799|NCT03873610|Experimental|Stress and Symptom Management 2|
89265800|NCT00220740|Experimental|Group 1|IGIV-C
89265801|NCT00220740|Placebo Comparator|Group 2|
89265802|NCT03870958|Experimental|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
89265803|NCT03870958|Active Comparator|Control|Children allocated to this group will receive the same dietary advices and brushing instructions described in the control arm.
89265804|NCT01167556|Experimental|Family Motivational Intervention|An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
89265805|NCT01167556|Active Comparator|Routine care for parents|Routine care for parents consisting of 2 sessions psycho-education and individual support
89265806|NCT01074606|Experimental|Toric|AcrySof Toric Intraocular Lens (IOL)
89265807|NCT01165918||Donated embryos|
89265808|NCT01273402|Experimental|TF2 and IMP288|TF2 will be administered at least 4 days before the radiolabeled IMP-288.
89265809|NCT01273714|Active Comparator|BST|bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each)
89265810|NCT01273714|Experimental|TT|extracapsular total thyroidectomy
89265811|NCT03873688|Experimental|Experimental Group|Patients in experimental group will perform expiratory muscle training as home programme for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device. The intensity of training will been setted 30% of the maximal expiratory pressure level.
89265812|NCT03873688|Sham Comparator|Sham Group|In sham group, patients will perform expiratory muscle training at home for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device that the intensity of training will been setted 5 cm H₂O.
89265813|NCT03873454|Active Comparator|Experimental Group|The experimental group listened to music and wore Sennheiser non-occlusive headphones
89265814|NCT03873454|Other|Control 1 with no music|This cohort wore non-occlusive earphones but did not listen to music
89265815|NCT03873454|Other|Control 2 with no music|The control 2 patients did not listen to music nor wore earphones.
89265816|NCT01274728||ST-elevated myocardial infarction|Those with a condition of chestpain (or equal complains) and ECG changes confirming STEMI.
89265817|NCT03873298|Experimental|COPD|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
89265818|NCT03873298|Experimental|IPF|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
89265819|NCT00184002|Experimental|DR-COP|"On cycle 1 patients receive Doxil 40 mg/m2 iv day 1 over a minimum of 60 min., Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min., Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5.~On cycle 2 until study completion patients receive Doxil 40 mg/m2 iv day 1, Rituxan 375 mg/m2 iv day 1, Cyclophosphamide 750 mg/m2 iv day 1, Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5~1 cycle = 21 days.~Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
89265820|NCT01167868|Experimental|FosD|Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects
89265821|NCT01167868|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
89265822|NCT01167946|Experimental|Group A|will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks
89265823|NCT01167946|Active Comparator|Group B|will receive 2 consecutive daily pulses every 3 weeks for 24 weeks
88805427|NCT04265742|Experimental|Group C. osteoporotic, no fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) and no history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
88805428|NCT04265742|Experimental|Group D. osteoporotic, with fracture|Post-menopausal women with low bone density (BMD T-score <-2.5) with history of fractures. Intervention: bone densitometry, high resolution peripheral QCT(HR-pQCT), collection of biological samples, questionnaires, clinical tests.
88805429|NCT01085903|Active Comparator|normal subjects|Normal subjects are persons without stroke who receive baseline, CPS, Post CPS and Follow up interventions.
89265824|NCT01167946|Active Comparator|Group C|will receive 3 consecutive daily pulses every 3 weeks for 24 weeks.
88805430|NCT01085903|Active Comparator|stroke subjects|Stroke subjects are persons who have had a stroke affecting the right hemisphere and are subject to neglect or dysphagia who receive modafinil, placebo, baseline, CPS, Post CPS and Follow up interventions.
88805431|NCT05419128|Active Comparator|ACHESS-C|In ACHESS-C, both the drinker and the partner will receive a smartphone, but only the drinker will receive the ACHESS-C app. The partner will receive a smartphone with contact information for standard AUD, SUD, and crisis support.
88805432|NCT05419128|Experimental|FamCHESS-C|In the FamCHESS-C arm, drinker and partner will both receive a smartphone with the FamCHESS-C app, which contains ACHESS-C services plus ABCT/ PartnerCHESS services.
88805433|NCT05419128|No Intervention|Control|Both the drinker and family partner will receive a smartphone with pre-programmed contact information for Alcoholics Anonymous (AA), Narcotics Anonymous (NA), Al-Anon, Adult Children of Alcoholics (ACOA), and crisis hot lines.
88805434|NCT01439035|Experimental|MGH OFDI imaging|OFDI imaging
88805435|NCT05446350|Experimental|Experiment 1|The aim of Experiment 1 is to understand how tACS operates on the neural level
89265825|NCT01326234|Active Comparator|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
89265826|NCT01326234|Sham Comparator|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred.
89265827|NCT01072110||Group 1: Patients with diarrhea undergoing endoscopy|Standard video colonoscope.
89265828|NCT01072110||Group 2: Patients with diarrhea undergoing endoscopy.|Confocal laser endomicroscopy (CLE).
89265829|NCT01166074||SCIG|
89265830|NCT03971292||Validation phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
89265831|NCT03971292||Prospective phase|The project will proceed in two phases: a validation test phase including 5 patients of known genotype and a prospective phase including 10 patients.
89265832|NCT01275508|Experimental|FITC-Adalimumab|
89265833|NCT01073670|Active Comparator|Acetaminophen|Participants received a loading dose of acetaminophen (2600 mg) at induction followed by 1300 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
89265834|NCT01073670|Experimental|Indomethacin|Participants were given 100 mg of indomethacin at induction and then 50 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
88805436|NCT05446350|Experimental|Experiment 2|The aim of Experiment 2 is to increase efficacy of tACS and, consequently, its potential to play an important role in research and everyday life applications
89265835|NCT01073670|Experimental|Combination|Participants were given a loading dose of 1300 mg of acetaminophen and 50 mg of Indomethacin followed by 650mg of acetaminophen and 25 mg of indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
89265836|NCT01582464||Older Adults in a Senior Community|Residents of a Continuing Care Retirement Community (CCRC) that is a part of The Be Group (previously known as Southern California Presbyterian Homes), with no exclusion other than being able to communicate in English and provide consent to participate.
89265837|NCT01168180|Experimental|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
89265838|NCT01168180|Active Comparator|Ultrasound therapy and hot pack|The participants will receive thirty minutes session of Ultrasound therapy and hot pack for 9 sessions over a period of 3 weeks
89265839|NCT03971370|Experimental|Experimental 1|
88805437|NCT05446350|Experimental|Experiment 3|The aim of Experiment 3 is to reveal how tACS can boost speech perception in a multi-speaker scenario.
88805438|NCT05446350|Experimental|Experiment 4|The aim of Experiment 4 is to combine established techniques to create novel opportunities to improve speech perception
88805439|NCT01439581|Experimental|Patients on mapping systems|
89265840|NCT03971370|Experimental|Experimental 2|
88805440|NCT01439581|Active Comparator|Patients not on mapping systems|
88805441|NCT01439815|Placebo Comparator|Placebo Nasal Spray|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
88805442|NCT01439815|Active Comparator|Fluticasone Propionate|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
88805443|NCT01332253|Experimental|Intravenous Ibuprofen|
88805444|NCT01332253|Placebo Comparator|Normal Saline|
89265841|NCT03971370|Active Comparator|Positive Control|
88805445|NCT01332487||Early initiation of 5ARI therapy|Patients starting 5ARI therapy within 30 days of initiating AB therapy
89265842|NCT03873142|Experimental|Mindful parenting intervention|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in a mindful parenting intervention whilst the same variables are measured. Following the intervention, there will be an 8-week follow-up period, and mindful parenting groups will not run during this time.
89265843|NCT01168336|Experimental|betahistine|Betahistine 24 mg tablets
89265844|NCT01168336|Experimental|betahistine XR|betahistine 32 mg tablets
89265845|NCT01168336|Placebo Comparator|placebo|
89265846|NCT00165672|Experimental|1|
89265847|NCT00165672|Experimental|2|
89265848|NCT01166308|Experimental|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial
89265849|NCT01166308|Active Comparator|Standard Treatment: Fractionated Stereotacitc Radiotherapy|Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy
89265850|NCT01168414|Active Comparator|Ganfort|Fixed combination of Bimatoprost and Timolol
89265851|NCT01168414|Active Comparator|Duotrav|Fixed combination of Travoprost and Timolol
89265852|NCT00180414|Experimental|Ventricular Rate Regulation feature ON|
88805446|NCT01332487||Delayed initiation of 5ARI therapy|Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy
88805447|NCT01332721|Experimental|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
89265853|NCT00180414|Active Comparator|Ventricular Rate Regulation feature OFF|
88805448|NCT01384591|Experimental|Losartan and placebo N-acetylcysteine|losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
89265854|NCT01277224|Experimental|Movi2 Program|
89265855|NCT01277224|No Intervention|Control|
89265856|NCT03870646|Experimental|Hypertonic saline|Nebulized hypertonic saline of NaCl (7%) in combination with hyaluronic acid
89265857|NCT03870646|Placebo Comparator|Isotonic saline|Nebulized isotonic saline of NaCl (0,9%)
89265858|NCT03968484|Experimental|<50.000/µl|Transfusion of platelets starting with a platelet count <50.000/µl
89265859|NCT03968484|Experimental|<20.000/µl|Transfusion of platelets starting with a platelet count <20.000/µl
89265860|NCT03873220||Monitoring scratch in children|Sensor technology and digital measures will be used to evaluate scratch and sleep in children with atopic dermatitis who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
89265861|NCT01166464|Experimental|Text Messaging|A text message-based intervention for smoking cessation
89265862|NCT01166464|Placebo Comparator|Control|Individuals in this group will receive generic (non-smoking related) text messages on the same schedule as the intervention arm. This provides a control for staff/program contact time and participant burden.
88805449|NCT01384591|Placebo Comparator|Placebo losartan and placebo N-acetylcysteine|Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
88805450|NCT01384591|Experimental|N-acetylcysteine and placebo losartan|N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
89265863|NCT01281904|No Intervention|Standard of Care|Participants randomized into the standard of care group will be asked to continue following the instructions of the healthcare provider throughout the 10 week study period. They will not be asked to perform any study intervention.
88805451|NCT01086605|Experimental|Arm I|Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
88805452|NCT01086605|Experimental|Arm II|Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89265864|NCT01281904|Active Comparator|Relaxation Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their relaxing effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
88805453|NCT00265850|Active Comparator|Arm A: FOLFOX or FOLFIRI + bevacizumab|Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
88805454|NCT00265850|Experimental|Arm B: FOLFOX or FOLFIRI + cetuximab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
89265865|NCT01281904|Active Comparator|Stimulating Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their excitatory effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
89265866|NCT01168492|Experimental|ketamine|group with triple sedation (ketamine, midazolam, meperidine)
89265867|NCT01168492|Placebo Comparator|placebo|group with conventional sedation and placebo ( midazolam, meperidine and placebo)
88805455|NCT00265850|Experimental|Arm C: FOLFOX or FOLFIRI + cetuximab + bevacizumab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
89265868|NCT03870490|Experimental|Healthy Subjects|VNRX-5133 + cefepime
88805456|NCT01385137|Experimental|Arm I|Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
89265869|NCT00174252|Experimental|Genotonorm (Somatropin)|
89265870|NCT01278082|Experimental|A|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
89265871|NCT01278082|Placebo Comparator|B|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
89265872|NCT03870256|Active Comparator|TA plus misoprostol|Patient receive 600mic gm sublingual misoprostol plus oral tranexamic acid 1 gm
89265873|NCT03870256|Active Comparator|Carbetocin|Patient receives 100 mic gm carbetocin IV
89265874|NCT02526628||Testosterone naïve KS|Men with Klinefelter syndrome without testosterone treatment. After initial examination standard treatment with testosterone will be effectuated according to current guidelines.
89265875|NCT02526628||Testosterone treated KS|Men with Klinefelter syndrome receiving testosterone treatment
89265876|NCT02526628||Controls 1|Matched healthy male controls for testosterone naive KS
89265877|NCT02526628||Controls 2|Matched healthy male controls for testosterone treated KS
88805457|NCT01385137|Placebo Comparator|Arm II|Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
88805458|NCT01086761|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
88805459|NCT01086761|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
88805460|NCT01086761|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
89265878|NCT01166542|Active Comparator|REOLYSIN, paclitaxel, carboplatin|
89265879|NCT01166542|Placebo Comparator|placebo, paclitaxel, carboplatin|
89265880|NCT00169104|Active Comparator|1|Subjects will receive ten doses of G-CSF at a dose of 5 mcgm/kg daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg IV weeks 3 through 14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13 and G-CSF at 5 mcgm/kg SQ daily Monday through Friday weeks 3-14.
89265881|NCT00169104|Placebo Comparator|2|Subjects will receive ten doses of a placebo injection SQ daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg weeks 3-14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13, and G-CSF at 5 mcgm/kg SQ daily Monday through Fridays weeks 3-14.
89265882|NCT01582074||Cases|women with breast cancer
89265883|NCT01582074||Controls|Matched women without breast cancer
89265884|NCT03870412|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle.
89265885|NCT03872674|No Intervention|standard oxygenation(nasal cannula)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula
88805461|NCT01086761|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
88805462|NCT01086761|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
88805463|NCT01086761|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
88805464|NCT00125372|Experimental|Erlotinib and Bexarotene|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.
89265886|NCT03872674|Experimental|high-flow humidified oxygen-delivery system(OptiFlow THRIVE)|Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE
89265887|NCT01168570||SAA monitored group|FMF-Amyloidosis patients receiving colchicine with a purpose to normalize SAA levels
89265888|NCT01168570||Historical control group|FMF-Amyloidosis patients receiving colchicine at a dose determined to stop FMF attacks. obtained from the Fibrillex study
89265889|NCT01168648|Experimental|Yoga as stress management|The intervention consists of following a program of yoga at least three times a week for three months. The yoga program has been designed to reduce stress.
89265890|NCT01168648|Active Comparator|Control group|The group rests without using any specific program for relaxation at least three times a week for three months.
89265891|NCT01168648|Other|Yoga as stress management fewer tests|Eight persons participated in the same intervention as the experimental arm but did not undergo the full range of tests because they did not meet all the inclusion criteria for the study, most commonly because of medication use or body mass index.
89265892|NCT03872986|Experimental|SDF+Giomer|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Beautifil II restorative material
88805465|NCT01087541|No Intervention|Control|Usual clinical health care
89265893|NCT03872986|Experimental|Giomer only|Beautifil II dental restorative material
89265894|NCT03872986|Experimental|SDF+GIC|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Equia forte
88805466|NCT01087541|Experimental|Intervention|Behavioural program of education for health professionals. Standardized program of 6 hours for health professionals ( doctors and nurses )
89265895|NCT03872986|Experimental|GIC only|Equia forte dental restorative material
88805467|NCT01385293|Experimental|Study arm|BKM120 at 100mg orally daily
88805468|NCT00125528|Experimental|1|D-cycloserine 50mg bid/100mg bid/200 mg bid
89265896|NCT03872830|Experimental|Experimental: group1|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
89265897|NCT03872830|Experimental|Experimental: group2|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
88805469|NCT00125528|Placebo Comparator|2|placebo
89265898|NCT03872830|Experimental|Experimental: group3|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:188.5mg Volume:8ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
89265899|NCT03872830|Placebo Comparator|Experimental: group4|Generic name:Placebo; Placebo:normal saline Dosage form:Injection Dosage:4ml/injection Volume:10ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the placebo.
89265900|NCT02526316|Other|P16_37-63 Vaccination|Patients will receive P16_37-63 peptide (100 μg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy.
89265901|NCT03872596|Experimental|Part A: Sequence 1|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg twice a day (BID) prior to randomization.~Treatment Period:~Participants will receive Seroquel IR (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 11-15."
88805470|NCT00125762|Experimental|Single Arm undergoing FibroScan|Single arm active comparison of biopsy to vibration controlled elastography
88805471|NCT01333813|Experimental|Engerix-B Kinder Group|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 7-8 years of age.
88805472|NCT04346485|Experimental|SP TFL RIRS with 145 mcm fiber|Superpulse thulium fiber laser RIRS with 145 mcm laser fiber
89265902|NCT03872596|Experimental|Part A: Sequence 2|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 6-10 and Seroquel IR (tablet, orally, 300mg, BID) on Days 11-15."
88805473|NCT04346485|Experimental|SP TFL RIRS with 200 mcm fiber|Superpulse thulium fiber laser RIRS with 200 mcm laser fiber
88805474|NCT04346485|Active Comparator|Ho:YAG RIRS with 200 mcm fiber|Ho:YAG laser RIRS with 200 mcm laser fiber
88805475|NCT01390909||Medicaid patients with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days
88805476|NCT01390909||Medicaid patients with well-controlled epilepsy|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
88805477|NCT01390909||Medicaid patients with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
88805478|NCT01390909||Patients in a private health plan with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days
88805479|NCT01390909||Patients in a private health plan with well-controlled epileps|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
89265903|NCT03872596|Experimental|Part A: Sequence 3|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 1-5, Seroquel IR (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 11-15."
89265904|NCT03872596|Experimental|Part B: Sequence 1|Participants will receive Seroquel IR (tablet, orally, 25mg) on Day 1 and Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 4.
89265905|NCT03872596|Experimental|Part B: Sequence 2|Participants will receive Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 1 and Seroquel IR (tablet, orally, 25mg) on Day 4.
89265906|NCT00163020|Active Comparator|1 Test Group (170HP)|Test Group will receive weekly doses of 170HP via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
89265907|NCT00163020|Placebo Comparator|2 - Control (Normal Saline)|Control Group will receive weekly doses of placebo (NS) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
89265908|NCT03870100|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
89265909|NCT03870100|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
89265910|NCT03870100|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
88805480|NCT01390909||Patients in a private health plan with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
88805481|NCT01041521|Experimental|Lovaza (omega three fatty acid)|"Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.~Other Names:~Lovaza was previously known as Omacor (omega-3-acid ethyl esters) capsules"
89265911|NCT03870100|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
88805482|NCT01041521|No Intervention|sugar pill|"Dietary Supplement: sugar pill~2 capsules given twice daily Arms: sugar pill"
89265912|NCT03870100|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
89265913|NCT01166620||Patients with rheumatoid arthritis new to abatacept.|
89265914|NCT01166620||Patients with rheumatoid arthritis new to etanercept|
89265915|NCT01166620||Patients with rheumatoid arthritis new to adalimumab|
89265916|NCT01166620||Patients with rheumatoid arthritis new to infliximab|
89265917|NCT03870178|Active Comparator|Active tDCS|Anodal tDCS over trunk motor cortex representation. Intensity: 2mA Time: 20 minutes
89265918|NCT03870178|Sham Comparator|Sham tDCS|Anodal tDCS over trunk motor cortex representation. Itensity: 2mA Time: 20 minutes (30s ON)
89265919|NCT01166698|Experimental|AZD9819|Inhaled suspension
89265920|NCT01166698|Placebo Comparator|Placebo|Inhaled suspension
89265921|NCT01168804|Experimental|single arm bendamustine bortezomib dexamethasone|single arm combination regimen: bendamustine - bortezomib- dexamethasone
89265922|NCT01166776||Umbilical cord|To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
89265923|NCT03872362||Training dataset|No interventions
89265924|NCT03872362||External validation1|No interventions
89265925|NCT03872362||External validation2|No interventions
89265926|NCT01168960|Other|Cognitive Behavioral Treatment|A single intervention study
89265927|NCT01278940|Experimental|Dendritic Cells (DC) malignant melanoma|22 patients were included in this arm.
89265928|NCT01278940|Experimental|DC vaccine plus IL-2|To improve the efficacy of the DC vaccine, IL-2 was administrated at the vaccination site through direct lymph node injection. 9 patients were included in this arm.
89265929|NCT01282450|Experimental|Single arm|Eligible patients
89265930|NCT03873532|Experimental|Active group|300 mg of surufatinib is given by oral administration once a day (QD) every 3 weeks;
89265931|NCT03873532|Active Comparator|Control group|In each 3-week cycle, Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID) for 2 weeks, followed by 1 week rest period (equivalent to 2500 mg/m2 total daily dose).
89265932|NCT01166854||Muscle weakness|Diffuse Optical Spectroscopy
89265933|NCT01169272|Experimental|CRT-SonR 9770|Active implantable defibrillator with ability to cardiac resynchronization therapy
89265934|NCT01169428|Active Comparator|Standard Behavioral Weight-Loss Maintenence|"Attention/Education/Support Control~Group designed to control for educational content as well as multiple nonspecific treatment factors (e.g., support, time invested, leader attention, positive expectancy)"
89265935|NCT01169428|Active Comparator|Behavioral: Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss.
89265936|NCT01169506|Experimental|COPD patients and healthy individuals|
89265937|NCT01169740||Neonatal jaundice|Infants born between July 1st 2010 and July 31st 2010 and admitted to normal newborn nursery
89265938|NCT01169584|Experimental|Single Arm - JX-594|Intratumoral injection of JX-594
89265939|NCT01282684|Active Comparator|single oral dose of 200 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
89265940|NCT01282684|Active Comparator|single oral dose of 400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
89265941|NCT01282684|Active Comparator|single oral dose of 800 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
89265942|NCT01282684|Active Comparator|single oral dose of 1600 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
89265943|NCT01282684|Active Comparator|single oral dose of 1000 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
89265944|NCT01282684|Active Comparator|single oral dose of 1400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
88805483|NCT01042145|Active Comparator|Prednisone|Prednisone, 2mg/kg for 3 days
89265945|NCT01282684|Placebo Comparator|Placebo|2 patients per cohort will be randomly assigned to take placebo. 12 patients total will be randomized to take placebo in this study.
89265946|NCT01169818|Experimental|Intervention group|Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days
89265947|NCT01169818|Active Comparator|Usual standard of care group|Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician
89265948|NCT01169662|Active Comparator|Vegetable/ Fruit juice|450ml active product, 45 ml no added sugar squash (for flavour)
89265949|NCT01169662|Placebo Comparator|Placebo juice|
89265950|NCT01283074||Cohort|
89265951|NCT01282840|Other|Bladder wall blood perfusion pattern|
89265952|NCT01282918|Other|Study group|Patients without DF (Defibrillation) testing during ICD implantation
89265953|NCT01282918|Other|Control group|Patients with DF testing during ICD implantation (according to standardized procedure)
89265954|NCT01172548|Experimental|imatinib mesylate|
89265955|NCT01283230||chronic liver disease|Any cause of liver disease that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis such as hepatitis B, hepatitis C, alcoholic liver disease.
89265956|NCT01283230||Healthy liver and kidney donor|Healthy liver and kidney donor who have normal liver condition
89265957|NCT01172626||epileptic patients|epileptic patients receiving treatment with continuous Sodium Valproate
89265958|NCT01169974||healthy volunteers|
89265959|NCT02526082||Total, observational|Various cardiovascular risk groups described below
89265960|NCT02526082||High-risk intervention|Healthy but at high risk in 1974
89265961|NCT02526082||High-risk control|Healthy but at high risk in 1974
89265962|NCT02526082||Low-risk conrtol|Healthy and at low risk in 1974
89265963|NCT02526082||Sick control|Medications or clinical disease in 1974
89265964|NCT02526082||Refused|Refused or no response in 1974
89265965|NCT03869242|Experimental|Experimental treatment arm|RT with concomitant TMZ and NovoTTF-200A for 6 weeks followed by up to 24 months of maintenance TMZ in combination with NovoTTF-200A.
89265966|NCT03869242|Active Comparator|control arm|RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with NovoTTF-200A.
89265967|NCT01283308|Active Comparator|Standard of Care|Participants randomized to the standard of care group will receive standard lifestyle advice for diabetes prevention consistent with expert recommendations for a healthy lifestyle, including losing 5-10% of their excess body weight, following standard dietary recommendations to reduce calorie and fat intake, and exercising at least 150 minutes per week.
89265968|NCT01283308|Experimental|Lifestyle Intervention|Intervention arm participants will participate in a step-wise model of diabetes prevention with the goal of reducing diabetes risk, primarily through (1) a weight loss of at least 7% and (2) 150 minutes or more per week of moderate level physical activity.
89265969|NCT01172704|Active Comparator|Care as Usual|Participants randomized to CAU receive the standard care given to patients of the Boston Medical Center who are interested in learning more about HIV/AIDS. Included in this care would be referrals for HIV counseling and testing.
89265970|NCT01172704|Experimental|Skills Building - Motivational Interviewing|Participants randomized to SB-MI will receive three individual sessions and a booster. Content of the sessions are as follows; Session 1: Risk Behavior Feedback & Building Motivation; Session 2: Building Motivation & Skill Selection and Practice; Session 3: Developing Change Plan & Skill Practice and Booster Session(s): Review Change Plan Implementation, Maintaining Motivation & Skill Practice.
89265971|NCT01172782|Placebo Comparator|control group|control group (CG) received 6 mg of hyperbaric bupivacaine and 0.05 mL of saline.
89265972|NCT01172782|Active Comparator|2.5 ug hydromorphone recieved group|the 2.5 μg hydromorphone group (2.5HG) received 1.2 (6 mg) mL of 0.5% hyperbaric bupivacaine and 2.5 μg of hydromorphone in 0.05 mL of saline
89265973|NCT01172782|Active Comparator|5 μg hydromorphone group|5 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 5 μg of hydromorphone in 0.05 mL of saline
89265974|NCT01172782|Active Comparator|the 10 μg hydromorpnone group|the 10 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 10 μg of hydromorphone in 0.05 mL of saline.
89265975|NCT01172860|Experimental|EndoVe treatment|Use of the EndoVe device to safely and effectively ablate rectal tumor tissue
89265976|NCT03866746|Active Comparator|Group A|received aflibercept injections alone
89265977|NCT03866746|Experimental|Group B|received 3 aflibercept injections followed by micropulsed laser
89265978|NCT03869320|Experimental|ACT-1004-1239|ACT-1004-1239 will be given as a single oral dose under fasting conditions. Eight doses are planned with a starting dose of 1 mg. The ADME characteristics and absolute bioavailability using a 14C-radiolabeled microtracer will be evaluated as part of the SAD, after the first 3 cohorts have been performed.
89265979|NCT03869320|Placebo Comparator|Placebo|Matching placebo will be given as a single oral dose under fasted conditions. Matching placebo for the oral and intravenous administration of the 14C-radiolabeled ACT-1004-1239 will also be available.
89265980|NCT03869320|Experimental|Food-effect subpart: ACT-1004-1239|ACT-1004-1239 will be given under both fasted (first period) and fed (second period) conditions. The food effect will be evaluated after the first 3 cohorts have been performed.
89265981|NCT03869320|Placebo Comparator|Food-effect subpart: Placebo|Matching placebo will be given under both fasted (first period) and fed (second period) conditions.
89265982|NCT03869398|No Intervention|Control arm: No pre-op medications|patients undergoing total thyroidectomy are started on calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID immediately postoperatively. No pre-operative medications are given
89265983|NCT03869398|Experimental|Intervention arm: Tums and Calcitriol pre-op|patients start calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
89265984|NCT01283620|Other|Usual Care|
89265985|NCT01283620|Experimental|modified CIMT (mCIMT)|
89265986|NCT01284478|Other|Dexamethasone Implant|Patients will be treated with the Ozurdex (Dexamethasone Implant)
89265987|NCT00252720|Experimental|candesartan|candesartan cilexetil 32 mg once daily
89265988|NCT00252720|No Intervention|placebo|control
89265989|NCT01283698|Experimental|LAS 41004 dosage 1|dosage 1, once daily
89265990|NCT01283698|Experimental|LAS 41004 dosage 2|dosage 2, once daily
89265991|NCT01283698|Experimental|LAS 41004 dosage 3|dosage 3, once daily
89265992|NCT01283698|Placebo Comparator|placebo|once daily
89265993|NCT01283698|Active Comparator|Reference|once daily
89265994|NCT03869164|Experimental|ValmpClamp Arm|
89265995|NCT00167778|Experimental|Arm 1|Novel prosthetic pylon
89265996|NCT00167778|Active Comparator|Arm 2|rigid pylon
89265997|NCT01284556|Placebo Comparator|Placebo|placebo tablets
89265998|NCT01284556|Experimental|60 mg group|Patients titrated to 60mg phenobarbital for maintenance period, then titrated down.
89265999|NCT01284556|Experimental|100 mg group|Patients titrated to 100mg phenobarbital maintenance period, then titrated down
89266000|NCT03869086|Experimental|SLOW anthocyanin metabolisers|Participants will be prospectively recruited to the SLOW anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
89266001|NCT03869086|Experimental|FAST anthocyanin metabolisers|Participants will be prospectively recruited to the FAST anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
89266002|NCT01170130|Experimental|Lidmyd|The same group is used for the first and the second part of the experiment. Initially the patients will be given topical cyclopentolate 1% and Phenylephrine 10% and the pupil diameter will be recorded. In the second part of the experiment lidocaine 1% will be introduced intracamerally and the pupil size will be recorded again. The 2 measurements will be statistically compared/evaluated.
89266003|NCT02526238|Experimental|TMS and trunk rotation|TMS and trunk rotation
89266004|NCT02526238|Sham Comparator|Sham TMS and trunk rotation|Sham TMS and trunk rotation
89266005|NCT01163344||Dance Therapy Group|This will group will undergo dance therapy once a week for a series of 8 weeks.
89266006|NCT01163344||Physical Therapy Group|This group will undergo physical therapy sessions once a week for a series of 8 weeks
89266007|NCT00167310|Experimental|1|Eicosapentaenoic acid (omega-3 fatty acid, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
89266008|NCT00167310|Placebo Comparator|2|Placebo (soy bean oil, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
89266009|NCT02525770|Active Comparator|acetabular liner in X3 polyethylene|acetabular in X3 polyethylene
89266010|NCT02525770|Active Comparator|acetabular liner in N2VAC® conventional polyethylene|hip replacement with acetabular liner in N2VAC® conventional polyethylene
89266011|NCT03973476|Experimental|Intervention group|Mothers received a phone support service with their midwife during the 8 weeks after childbirth.
89266012|NCT03973476|No Intervention|Control group|Mothers received standard postpartum care
89266013|NCT03754582|Experimental|Perampanel|Participants with POS with or without secondarily generalized seizures or PGTC seizures will receive perampanel 8 to 12 milligram (mg), tablets, orally, once daily for 28 days (Day -28 to Day -1) in Pretreatment Phase and followed by 8 to 12 mg dose of perampanel as intravenous infusion for 30 minutes, once daily from Day 1 to Day 4 in Treatment Phase, and then again 8 to 12 mg, tablets, orally, once daily from Day 5 to Day 11 in Follow-up Phase as an adjunctive therapy, along with 1 to a maximum of 3 marketed concomitant antiepileptic drugs (AEDs).
89266014|NCT03866824|Experimental|PRP group|
89266015|NCT03866824|Active Comparator|reference treatment|
89266016|NCT03869008|Sham Comparator|Sham Device Group|"15 patients will be randomized to the Sham device for the first half of the treatment window then switch to the gammaCore Sapphire device (study device) for the rest of the study.~The Sham device will look exactly like the gammaCore Sapphire device but will not deliver non invasive vagus nerve stimulation."
89266017|NCT03869008|Experimental|gammaCore Sapphire (Study Device) Group|15 patients will be randomized to the gammaCore Sapphire device for the full length of the treatment window.
89266018|NCT00161616|Active Comparator|A|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage +surgical fixation
89266019|NCT00161616|Other|B|Standard of Care: Surgical fixation only
89266020|NCT03868852|Experimental|Radiotherapy plus apatinib mesylate|All eligible patients signed informed consent. Three-dimensional conformal intensity modulation (IMRT) technique was used to treat the patients with radiation doses 45 Gy - 54 Gy. All patients took apatinib mesylate tablets 250 mg QD orally from 1 week before radiotherapy to the whole radiotherapy period. They were required to take apatinib mesylate tablets with warm boiling water half an hour after meal. The daily medication time should be as consistent as possible.
89266021|NCT01283776|Experimental|treatment arm|Cyclophosphamide
89266022|NCT01163422|Active Comparator|Immediate RVRT|RVRT switched on immediately after pacemaker implant
89266023|NCT01163422|Placebo Comparator|Delayed RVRT|RVRT switched on 4 weeks after pacemaker implant
89266024|NCT01170286|Experimental|DBV712 Viaskin|The experimental arm is composed of subjects treated with whole peanut extract on an epicutaneous delivery system (Viaskin patch)
89266025|NCT01170286|Placebo Comparator|Placebo Viaskin|The placebo arm is composed of subjects treated with a placebo formulation on an epicutaneous delivery system (Viaskin patch)
89266026|NCT01163500|Placebo Comparator|Pill|
89266027|NCT01163500|Experimental|Coenzyme Q10|
89266028|NCT01173094|Experimental|PTA|The patients with short-obstruction in the below-knee artery will be included in this group.
89266029|NCT01173094|Experimental|bypass|The patients with long-obstruction in the below-knee artery will be included in this group.
89266030|NCT01284790|Experimental|Cochlear implants|
89266031|NCT01283854|Experimental|Exercise group|Each participant randomised to the exercise group will receive routine, regular antenatal care. In addition, these women will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist.
89266032|NCT01283854|No Intervention|Control group|Women allocated to the control group will not participate in the home-based exercise program, and will continue their normal physical activity throughout pregnancy. This group will receive routine, regular antenatal care, together with the additional outcome assessments at baseline (14 weeks gestation) and cessation of the study (28 weeks gestation).
89266033|NCT01173250|Active Comparator|stapled ileoanal pouch without diverting ileostomy|
89266034|NCT01173250|Placebo Comparator|stapled ileoanal pouch with diverting ileostomy|
89266035|NCT01163734|Experimental|Ranolazine|
89266036|NCT01163734|Placebo Comparator|Saline 0.9%|Saline 0.9% and placebo tablet
89266037|NCT01284868|Experimental|Mirabegron|
89266038|NCT01163812|Experimental|Laparoscopic D2 gastrectomy|
89266039|NCT01170442|Experimental|vitamin D3 2000 IU|
89266040|NCT01170442|Experimental|vitamin D3 5000 IU|
89266041|NCT01170442|Placebo Comparator|Placebo|
89266042|NCT03866356|Experimental|Intervention group|The intervention group received care according to the SICP (Table 2). One of the researchers gave each participant one-on-one education in line with SICP. They were also provided with the booklet that had been prepared in accordance with SICP. The participants were phoned every week for eight weeks and offered counseling within the scope of SICP and then were reevaluated at the end of eight weeks (Post-intervention). The participants were followed from the eighth to the twelfth week without any intervention (4-week post-intervention).
89266043|NCT03866356|No Intervention|Control group|The control group received no intervention during the eight-week intervention period. The control group received standard care. The women were given no educational materials.
89266044|NCT01173328|Experimental|Pursed-lip Breathing|
89266045|NCT01170520|Experimental|rTMS|
89266046|NCT03868696|Sham Comparator|MUA with sham ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with sham ultrasound (screen concealed from participants)
89266047|NCT03868696|Experimental|MUA with active ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with active ultrasound (screen concealed from participants)
89266048|NCT01170676|Experimental|Puff City GA|Puff City is an NHLBI-funded (C. Joseph, PI; Henry Ford Health System, Detroit, MI), web-based intervention that targets three key asthma management issues in youth: 1) smoking reduction or cessation in those who are smokers, 2) improving adherence to asthma controller medication use, and 3) improving compliance of carrying a rescue inhaler at all times for use at the first sign of asthma symptoms. Puff City Ga. is a replication study in the rural southeastern United States that adds biological assessments in addition to self-report data.
89266049|NCT01170676|Active Comparator|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
89266050|NCT03876184|Experimental|RMO FLi® Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 RMO FLi® Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
89266051|NCT03876184|Experimental|G&H G4 Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 G&H G4 Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
89266052|NCT03876184|Experimental|Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
89266053|NCT03876184|Active Comparator|Conventional superelastic Nickel Titanium|"This group has been allocated with conventional upper and lower round 0.014 superelastic Nickel Titanium archwires for a duration of 8 weeks."
89266054|NCT01173406|Sham Comparator|Standard care (SC)|Standard care
89266055|NCT01173406|Active Comparator|Extended education (ME+SC)|Motivational enhancement education + Standard care
89266056|NCT01163890|Experimental|WHI|
89266057|NCT01163890|Active Comparator|Usual Care|
89266058|NCT01173484||Vomiting-predominant idiopathic gastroparesis|Vomiting with retching and nausea are the most bothersome symptoms
89266059|NCT01173484||Dyspepsia-predominant idiopathic gastroparesis|Unpleasant or troublesome sensation (discomfort or pain) centered in the upper abdomen is the most bothersome symptom; this sensation may be characterized by or associated with upper abdominal fullness, fullness after small meals, bloating, or nausea
89266060|NCT01173484||Regurgitation-predominant idiopathic gastroparesis|Effortless regurgitation of acid or undigested food or heartburn is the most bothersome symptom
89266061|NCT00252564|Experimental|Bev-FOLFOX|"(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via T connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.~Bevacizumab --> oxaliplatin and LV --> bolus 5-FU --> infusional 5-FU~Dosing on Days 1 and 15 of each 28-day cycle"
89266062|NCT00252564|Experimental|FOLF-CB|"(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU.~Cetuximab --> bevacizumab --> LV --> bolus 5-FU --> infusional 5-FU"
89266063|NCT03868462|Other|Optical Coherence Tomography (OCT)|
89266064|NCT01284946|Experimental|Exjade|Safety and efficacy
89266065|NCT01173562|Experimental|Mebendazole|
89266066|NCT01170910|Other|Static incubation|If conservation in static incubation (group 1) is chosen by random selection, the transplant should be carried out while keeping the cold ischemic time (CIT) as short as possible (preferably less than 18 hours). Keep in mind that for reasons of homogeneity for result analysis and for conservation quality, it is recommended that kidneys in group 1 be conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution.
89266067|NCT01170910|Experimental|Pulsatile perfusion|If conservation in a pulsatile perfusion machine (group 2) is chosen by random selection, the kidney will be placed in the perfusion machine within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
89266068|NCT00166296|Experimental|Escitalopram|Escitalopram, 15 mg/day
89266069|NCT00166296|Placebo Comparator|Placebo pill|Placebo
89266070|NCT01173640|Experimental|Midazolam Alone|Baseline pharmacokinetics. On Study Visit Day 1, subjects will receive a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
89266071|NCT01173640|Experimental|Single dose resveratrol|On Study Visit Day 8, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
89266072|NCT01173640|Experimental|Multiple dose resveratrol|Between Study Visit Days 8 and 15, subjects will take a 1 g dose of resveratrol daily. On Study Visit Day 15, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
89266073|NCT03868774|Active Comparator|rTMS standard|Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)
89266074|NCT03868774|Active Comparator|rTMS accelerated model|Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)
89266075|NCT00252174|Experimental|Stage 1 Active methylenedioxymethamphetamine & psychotherapy|8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2.
89266076|NCT00252174|Active Comparator|Stage 1 low dose methylenedioxymethamphetamine & Psychotherapy|4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I
89266077|NCT00252174|Experimental|Stage 2 Active methylenedioxymethamphetamine & Psychotherapy|The 4 subjects assigned in Stage I to the control arm will have the option to continue into Stage 2 to repeat the experimental procedures of Stage I but with open-label MDMA at the near-full to full dosage strength.
89266078|NCT01170988|Other|surgical procedure|T-graft bypass or conventional bypass
89266079|NCT03868306||Iron deficiency anaemia|Microcytic hypochromic anaemic patients with serum ferritin less than 12 Ng /ml
89266080|NCT03868306||Beta thalassemia Trait|Microcytic hypochromic anaemic patients with HBA2 more than 3.2 %
89266081|NCT01077180|Experimental|Rheos Device|
89266082|NCT01077180|Active Comparator|Medical Management|
89266083|NCT01171066|Experimental|Tasman CPAP|
89266084|NCT01164046|Active Comparator|vitamin K antagonists|
89266085|NCT01164046|Active Comparator|Low molecular weight heparin|
89266086|NCT01074762|No Intervention|Routine general practice care|In the comparison group, doctors were free to choose any treatment and change it over time. The study coordinating centre did not contact comparison practices after the end of recruitment (late 1991) until 1995.
89266087|NCT01075464|Experimental|A|
89266088|NCT01075464|Experimental|B|
89266089|NCT01285180||DINO|
89266090|NCT01075542|Experimental|Toric intraocular lens|Bilateral Toric intraocular lens implantation in cataract surgery
89266091|NCT01075542|Other|Monofocal intraocular lens|Bilateral Monofocal intraocular lens implantation in cataract surgery
89266092|NCT01077336||Hospitalized patients with candidemia|
89266093|NCT01075620|Experimental|PFC sigma RP|Posterior stabilized rotating platform knee (press Fit Condylar Sigma rotating-platform, Depuy, Warsaw, Indiana)
89266094|NCT01075620|Active Comparator|LCS RP|non posterior stabilized Low Contact Stress Rotating-Platform; Depuy, Warsaw, Indiana
89266095|NCT03968250|Experimental|Cognitive Behavioral Therapy for Treating Fatigue|This is the patient group that receives the intervention (IG), i.e., the cognitive behavioral therapy for reducing fatigue.
89266096|NCT01074840|Active Comparator|Peanut|Peanut flour will be given in increasing amounts.
89266097|NCT01074840|No Intervention|Control|Subjects will be enrolled who meet the inclusion/exclusion criteria and followed as matched controls. These subjects will not receive any treatment.
89266098|NCT01077492||Suspected mediastianl lymph nodes|Patients with (suspected) lung cancer requiring MLN staging after CT-PET during routine work-up according to existing staging guidelines.
89266099|NCT01074918|Experimental|Potassium Magnesium Citrate|
89266100|NCT01074918|Active Comparator|Potassium Chloride|
89266101|NCT01074996|Active Comparator|S-1,|Subjects will receive S-1 until progression
89266102|NCT01074996|Experimental|S-1 plus Leucovorin|patients will receive S-1 plus Leucovorin until progression
89266103|NCT00160524|Experimental|Certolizumab Pegol|400 mg subcutaneous injection every 4 weeks from Week 2 to Week 362.
89266104|NCT01077570||Repaglinide|
89266105|NCT01075698|Active Comparator|Non-ARB group|
89266106|NCT01075698|Active Comparator|ARB group|
89266107|NCT03966300|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination)
89266108|NCT03966300|No Intervention|Control (standard/usual care)|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting)
89266109|NCT01268800||AML induction|Adults AML patients who were referred for intensive induction therapy
89266110|NCT00159822|Experimental|1|
89266111|NCT01164124|Experimental|Probiotic supplementation|500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
89266112|NCT01164124|Placebo Comparator|Routine feedings|
89266113|NCT01171144||Gastroenteritis Group|All children suffering with gastroenteritis
89266114|NCT01285258|Other|peripartum|patients whom underwent peripartum hysterectomy
89266115|NCT00158262|Experimental|Propranolol|Following the occurrence of an acute psychologically traumatic event, an initial dose of short-acting propranolol 40 mg orally then one hour later, long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
89266116|NCT00158262|Placebo Comparator|Placebo|Following the occurrence of an acute psychologically traumatic event, an initial dose of placebo-matching short-acting propranolol 40 mg orally then one hour later, placebo-matching long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of placebo-matching long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
89266117|NCT03868072|Experimental|Reference/Test|"Period 1: XELJANZ 5Mg Tablet 1T~Period 2: Chong Kun Dang Tofacitinib Tablet 1T"
89266118|NCT03868072|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tofacitinib Tablet 1T~Period 2: XELJANZ 5Mg Tablet 1T"
89266119|NCT02526394|Active Comparator|1|Repevax + Meningitec
89266120|NCT02526394|Active Comparator|2|Repevax + Neis-VacC
89266121|NCT02526394|Active Comparator|3|Repevax + Menitorix
89266122|NCT02526394|Active Comparator|4|Boostrix + Meningitec
89266123|NCT02526394|Active Comparator|5|Boostrix + NeisVacC
89266124|NCT02526394|Active Comparator|6|Boostrix + Menitorix
89266125|NCT02526394|Active Comparator|7|Repevax + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
89266126|NCT02526394|Active Comparator|8|Boostrix + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
89266127|NCT00157950|Experimental|Gardasil™|Gardasil™ 3 dose regimen
89266128|NCT00157950|Placebo Comparator|Placebo|Gardasil™ matching placebo 3 dose regimen
89266129|NCT01283932|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
89266130|NCT01283932|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
89266131|NCT01171222||veteran soccer players from Saarland County, Germany|
89266132|NCT05666752|Experimental|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
89266133|NCT05666752|Placebo Comparator|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
89266134|NCT03966144|Experimental|RoboHear Device|Subjects will wear the Robo-Hear device and receive haptic stimuli. They will be tested on their ability to interpret these haptic sensations as sounds and words.
89266135|NCT01075386||Grade 2|Patients with Endometrial cancer of Grade 1 differentiation
89266136|NCT01075386||Benign|Patients without endometrial cancer
89266137|NCT01075386||Grade 1|Patients with Endometrial cancer of Grade 2 differentiation
89266138|NCT01075386||Grade 3|Patients with Endometrial cancer of Grade 3 differentiation
89266139|NCT03964896|Experimental|Supportive Care (telephone intervention)|During standard of care chemotherapy, patients receive up to 18 telephone calls from a nurse using a standardized triage call script over 20 minutes.
89266140|NCT01171378|Other|Ofatumumab|Single arm study
89266141|NCT01164280|Experimental|Pulse Rate Change|Patients are subjected to different pulse rate settings of their neurostimulator. The effect of pulse rate changes on clinical outcome is measured.
89266142|NCT01164358||study arm I|"patients who have been enrolled in the previous study Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings"
89266143|NCT01164358||study arm II|"patients who have been enrolled in the previous study Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"
89266144|NCT03875560|Experimental|Part A/Single Dose|IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm. When Part A is complete, Enrollment to Part B will commence).
89266145|NCT03875560|Experimental|Part B/Cohort 1|IC14 4 mg/kg/day IV or placebo IV x 1 day.
89266146|NCT03875560|Experimental|Part B/Cohort 2|IC14 8 mg/kg/day IV or placebo IV x 1 day.
89266147|NCT03875560|Experimental|Part B/Cohort 3|IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
89266148|NCT03875560|Experimental|Part B/Cohort 4|IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
89266149|NCT02526862|No Intervention|A-Mask or direct interface|Mask or direct interface
89266150|NCT02526862|Active Comparator|B-Autoadhesive polyurethane dressing|Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
89266151|NCT02526862|Active Comparator|C-Semi-permeable hydrogel-foam|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
89266152|NCT02526862|Active Comparator|D-Hyper hydrogenated fatty acids|Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
89266153|NCT01171456|Placebo Comparator|Metformin Placebo|
89266154|NCT01171456|Active Comparator|Metformin|
89266155|NCT03865888|Active Comparator|Cyclosporins 0.05 % treated eyes|Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
89266156|NCT03865888|Active Comparator|Tacrolimus 0.03% treated eyes|Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months
89266157|NCT01173796|Experimental|PMFL ablation|Radio-frequency catheter ablation of the mitral isthmus only
89266158|NCT01173796|Experimental|Repeat PVAI and triggers ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
89266159|NCT01268956||Lymphatic progenitor cell|Circulating lymphatic progenitor cell
89266160|NCT01268956||Control|healthy people
89266161|NCT03866122|Experimental|Neonatal Temperature Monitor|One or more test devices (NTM, Bempu, Thermospot) will be attached to the infant in the neonatal intensive care unit (NICU) or KMC ward along with the Philips Intellivue patient monitor. Temperature will be monitored continuously using each device for up to 72 hours.
89266162|NCT03875404|Experimental|Deep Brain Stimulation subjects|
89266163|NCT01284010||Group 1|Diagnostic, complete remission, and germ-line specimens are analyzed for DNA profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from pediatric patients.
89266164|NCT01285336|Experimental|The genetic and the functional study|
89266165|NCT01171768||patients with hemoptysis within 2 weeks|
89266166|NCT01171768||patients without hemoptysis within 2 years|
89266167|NCT01171846|Active Comparator|Physiotherapy|
89266168|NCT01171846|No Intervention|Control|Women allocated to the Control group will only receive, by post, the same Lifestyle Advice Sheet as the intervention group.
89266169|NCT01284088|Experimental|PrePex™|Adult male circumcision by the PrePex™ Device
89266170|NCT01284088|Active Comparator|Surgical|Adult male surgical circumcision
89266171|NCT01284166|Experimental|Triple Combination Therapy|Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
89266172|NCT01164514|Active Comparator|Group 1 - vaccine alone|8 subjects to receive vaccine (10 mcg) alone on Days 0, 29 and 59.
89266173|NCT01164514|Experimental|Group 3 - vaccine + CPG 7909 (250 mcg)|8 subjects to receive vaccine (10 mcg) with 250 mcg of adjuvant on Days 0, 29 and 59.
89266174|NCT01164514|Experimental|Group 2 - vaccine + CPG 7909 (500 mcg)|8 subjects to receive vaccine (10 mcg) with 500 mcg of adjuvant on Days 0, 29 and 59.
89266175|NCT01164514|Placebo Comparator|Group 4 - Placebo|4 subjects to receive normal saline (placebo) on Days 0, 29 and 59.
89266176|NCT01164592|Active Comparator|Therapy with adaptive servo ventilation|optimal medical therapy + adaptive servoventilation
89266177|NCT01164592|No Intervention|Optimal medical therapy according to guidelines|optimal medical therapy
89266178|NCT01285414|Experimental|Verubulin & standard of care (RT & TMZ)|Verubulin, at the dose selected in Part A, plus standard of care Radiation Therapy and Temozolomide
89266179|NCT01285414|Active Comparator|Standard of care (RT & TMZ)|Standard of care Radiation Therapy and Temozolomide
89266180|NCT03875248|Other|Arm 1. Blood pressure measurement compared to arterial line|Comparative blood pressure measurement with the investigational device and the invasive reference method (arterial line).
89266181|NCT03875248|Other|Arm 2. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in hypertensive patients with the investigational device and the non-invasive reference method (manual cuff).
89266182|NCT03875248|Other|Arm 3. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in pregnant women with the investigational device and the non-invasive reference method (manual cuff).
89266183|NCT03875014||group 1|Bipolar hemiarthroplasty grop
89266184|NCT03875014||group 2|Total hip replacement dual mobility group
89266185|NCT03875170|Experimental|Proprioceptive neuromuscular facilitation|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility
89266186|NCT03875170|Active Comparator|Muscle stretching|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. It will be done for the hip, quadriceps and hamstring muscles with a voluntary antagonist activation to relax the agonist muscle.
89266187|NCT01172002|Experimental|leflunomide group|
89266188|NCT01172002|Active Comparator|Azathioprine group|
89266189|NCT03867994|Experimental|Group (A)|included 49 patients who received high dose statin (80 mg atorvastatin) 12 hours before CC and 40 mg just before CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
89266190|NCT03867994|Experimental|Group (B)|included 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continued for 24 hours after the CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
89266191|NCT03867994|Experimental|Group (C)|included 47 patients who did not receive any medications but only hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization
89266192|NCT01172080|No Intervention|control|Participants in this group are monitored for adherence to colonoscopy recommendations.
89266193|NCT01172080|Experimental|intervention|Participants to receive a protocol of reminder letters and a phone call regarding due follow up colonoscopy
89266194|NCT01172158||Forgotten ureteral stents|
89266195|NCT01164670||Men|Men over 70 years old.
89266196|NCT01164670||Women|Women over 70 years old.
89266197|NCT01285570|Experimental|Experimental 2|
89266198|NCT01285570|Experimental|experimental 1|
89266199|NCT01285570|Placebo Comparator|Placebo|Placebo comparator daily (QD)
89266200|NCT01164748||Sentinel Node Biopsy|All women who has Sentinel Node Biopsy as their primary treatment of the axilla
89266201|NCT01164748||Axillary Lymph Node Dissection|All women who had Axillary Lymph Node Dissection as primary axillary treatment
89266202|NCT01172236|Experimental|Lactoferrin|
89266203|NCT02525926|Experimental|denervation|
89266204|NCT02525926|Sham Comparator|control group|
89266205|NCT02525848|Active Comparator|dexamethasone|intravenous dexamethasone 8 mg 2 minutes before induction of anesthesia;
89266206|NCT02525848|Active Comparator|gapabentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
89266207|NCT02525848|Active Comparator|Aprepitant|aprepitan 80mg 1 hour before induction of anesthesia.
89266208|NCT03865576||Thomas Jefferson University|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
89266209|NCT03865576||Honor Health in Phoenix|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
89266210|NCT03865576||Emory University Hospital in Atlanta|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors"
89266211|NCT03865576||University of Washington|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device. .~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors and lumbar puncture"
89266212|NCT01172314|Experimental|EAA+LEU vs total AA|
89266213|NCT01172314|Experimental|Total AA vs EAA+LEU|
89266214|NCT01269112|Placebo Comparator|heparin|CVVHDF performed using unfractionated heparin as anticoagulant and Prismasol as reinjection and dialysate fluids
89266215|NCT01269112|Active Comparator|citrate regional anticoagulation|CVVHDF performed using Prismocitrate 18/0 solution (Trisodium citrate 18 mmol/L
89266216|NCT01174420|Experimental|ologen Collagen Matrix|
89266217|NCT01174420|Active Comparator|Mitomycin-C (MMC)|
89266218|NCT01164826|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
89266219|NCT01164826|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
89266220|NCT03867292|Experimental|Myofascial|The subjects that include the experimental group will receive an intervention through myofascial therapy of crossed hands and electrotherapy
89266221|NCT03867292|Active Comparator|Electrotherapy|The subjects that are included in the experimental group will receive an intervention through electrotherapy
89266222|NCT01174498|Active Comparator|t-VNS sytem Vagus stimulation|Subjects experience a transcutaneous vagal stimulation by the t-VNS device
89266223|NCT01174498|Sham Comparator|Sham transcutaneous stimulation|Sham stimulation with an attached t-VNS device
89266224|NCT01284322|Experimental|Fresolimumab|
89266225|NCT01284400|Experimental|Disease management|
89266226|NCT01284400|No Intervention|Usual treatment and care|
89266227|NCT01285648|Other|Cpap|This group joined chest physiotherapy with CPAP via nasal masks for two hours.CPAP was continued from the immediate postoperative day until the second postoperative day, twice a day.
89266228|NCT01285648|Other|Chest Physiotherapy|Chest Physiotherapy consisted of bronchial hygiene techniques and pulmonary expansion, in addition to exercises, and received oxygen supplementation to maintain the pulse oxymetry saturations > 90%.
89266229|NCT01172392|Experimental|PegIFN + Nucleosidic or Nucleotidic Analog|
89266230|NCT01172392|Active Comparator|Nucleosidic or Nucleotidic Analog|
89266231|NCT01269268||active tuberculosis|active TB patients : diagnosed with TB through microbiologic examination
89266232|NCT01269268||healthy control|healthy control : no evidence of respiratory disease, no respiratory symptoms, and no history of close contact of active pulmonary TB patients
89266233|NCT01164904|Experimental|Experimental|Ten escalating dose levels of AMG 181 administered as a single dose SC or IV in healthy volunteers and SC in subjects with mild-to-moderate ulcerative colitis.
89266234|NCT03865186|Experimental|intervention group|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
89266235|NCT03865186|Experimental|control group|no intervention was applied to the control group
89266236|NCT03863938|Experimental|Tegoprazan 50mg under fasting condition|Treatment A: single oral administration of Tegoprazan 50mg tablet under fasting condition once a day
89266237|NCT03863938|Experimental|Tegoprazan 50mg before the meal|Treatment B: single oral administration of Tegoprazan 50mg tablet before the meal once a day
89266238|NCT03863938|Experimental|Tegoprazan 50mg after the meal|Treatment C: single oral administration of Tegoprazan 50mg tablet after the meal once a day
89266239|NCT01175044|Active Comparator|Betadine Lavage|dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000ml of sterile saline irrigation
89266240|NCT01175044|Placebo Comparator|Saline Lavage|2000 ml sterile saline lavage alone
89266241|NCT03864016|Other|Standard group|
89266242|NCT03864016|Experimental|Pupillometry group|
89266243|NCT03860662|Active Comparator|Spastic hemiplegia , Botox|Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu). Two antigenically distinct serotypes of BTX are available on the market as type A and B.
89266244|NCT03860662|Other|Spastic hemiplegia, Baclofen|Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The recommended dosing regimen is initiated with 5 mg 3 times a day. It can be increased by 15-mg/d increments at 3-day intervals as needed. Dosing should not exceed 80 mg/d.
89266245|NCT01177696|Experimental|psychotherapy|"The study aims to evaluate the effectiveness of an intervention of psychotherapy in improving the mental health of caregivers.~This intervention is based on theoretical approaches to care adjusted to cognitive theory, in order to be applied in primary health care centres."
89266246|NCT01177696|No Intervention|Control|
89266247|NCT01177852|Experimental|Notuss® syrup|Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
89266248|NCT01177852|Active Comparator|Dropropizine + Pseudoephedrine and brompheniramine|Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.
89266249|NCT01177930||Feeding with milk with DHA and ARA|
89266250|NCT01177930||Feeding with milk without DHA and ARA|
89266251|NCT01288144|Experimental|Intervention|Quality improvement initiative using computerized decision support
89266252|NCT01288144|No Intervention|Usual care|In control clinics, women will continue to receive usual care.
89266253|NCT01285804|Active Comparator|Cuffed ETT|
89266254|NCT01285804|Active Comparator|Uncuffed ETT|
89266255|NCT01178008|Experimental|Active acupuncture group|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints.
89266256|NCT01178008|Placebo Comparator|Placebo acupuncture group|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
89266257|NCT01288222|Experimental|Unrelated Donor Transplant Patients|Patients with acute myeloid leukemia who have received KIR genotype from an unrelated donor transplant.
89266258|NCT01175122|Experimental|H2N3 MO 2003/AA ca Vaccine|Participants will receive a nasal spray administration of the H2N3 MO 2003/AA ca vaccine on Day 0 and Day 28.
89266259|NCT03863392|Experimental|oral|patients undergoing induction of labour using misoprostol oral solution
89266260|NCT03863392|Experimental|vaginal|patients undergoing induction of labour using vaginal misoprostol
89266261|NCT01175200|Active Comparator|Prasugrel|
89266262|NCT01175200|Active Comparator|Clopidogrel|
89266263|NCT01175200|Active Comparator|Lansoprazole|proton pump inhibitor
89266264|NCT01175200|Placebo Comparator|Placebo|
89266265|NCT01288300|Active Comparator|Comprehensive diabetes self-management intervention|Diabetes education, self-empowerment training, exercise, patient navigator
89266266|NCT01288300|Other|Control|Diabetes self-management lecture
89266267|NCT03865108|Experimental|Pessary and Progesterone|Women already receiving a pessary in addition to the standard progesterone through the TOPS trial will undergo ultrasound imaging and cervical speculum examination for information collection.
89266268|NCT03865108|Placebo Comparator|Progesterone only|Women already receiving the standard progesterone only will undergo ultrasound imaging and cervical speculum examination for information collection.
89266269|NCT01178164|Experimental|Diagnosis of Fabry disease|
89266270|NCT03860350|Active Comparator|Aged Garlic Extract|The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.
89266271|NCT03860350|Placebo Comparator|Placebo|The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
89266272|NCT01174654|No Intervention|Referral to community resources|
89266273|NCT01174654|Experimental|Contingency Management|
89266274|NCT01175278|No Intervention|Observation Arm|Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.
89266275|NCT01175278|Experimental|Balloon Kypholasty|
89266276|NCT01175278|Active Comparator|Control Arm|Non-surgical Management Treatment Group
89266277|NCT01286350|No Intervention|Control|Participants randomized control will continue with usual clinical care.
89266278|NCT01286350|Experimental|Intervention|"Participants randomized to intervention will receive the FL3X Flexible Lifestyle Empowering Change intervention. Adolescents will be paired with a health coach to help learn strategies for improving diabetes control"
89266279|NCT01285882||Representations|
89266280|NCT03863626|Active Comparator|Frusemide IV shots = group A|Frusemide as IV shots
89266281|NCT03863626|Active Comparator|Frusemide IV infusion = group B|Frusemide as continuous IV infusion
89266282|NCT01178242|Experimental|Salivary Gland and Labial Mucous Membrane Transplantation|
89266283|NCT03860116|Experimental|Intervention group|participants in this arm receive the APP-based case management service and standard-of-care followup service.
89266284|NCT03860116|Active Comparator|control group|participants in the control arm receive standard-of-care followup service
89266285|NCT03860194|Experimental|Supp group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Supp group were provided with Protison with High Protein 51(Original Flavor) containing supplements in addition to their regular daily meals to achieve 1.5 g protein/kg (BW)/day on the basis of this guideline."
89266286|NCT03860194|No Intervention|Diet group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Diet group were instructed to consume ordinary high protein foods to achieve 1.5 g protein/kg body weight (BW)/day on the basis of this guideline, and suggested to equally distribute their meal time."
89266287|NCT01178320||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
89266288|NCT01178320||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
89266289|NCT01286506||Mechanically ventilated patients|
89266290|NCT01286506||Non-mechanically ventilated patients|
89266291|NCT03864718||complex anal fistula|
89266292|NCT01175512|Active Comparator|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
89266293|NCT01175512|Placebo Comparator|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
89266294|NCT01178476|Experimental|Hyposafe Hypoglycemia alarm device|EEG based hypoglycemia detection
89266295|NCT01178476|Active Comparator|Regular glucose control|Regular glucose control group
89266296|NCT03864484|Experimental|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, participants watch a video using the iPad Application displaying positive word stimuli.
89266297|NCT03864484|Active Comparator|Usual rehabilitation|The control group receives usual rehabilitation.
89266298|NCT03859570|Experimental|Pentoxifylline|Pentoxifylline and standard of care therapy
89266299|NCT03859570|Placebo Comparator|Placebo|Placebo and standard of care therapy
89266300|NCT01178554|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
89266301|NCT01178554|Experimental|Standard Manual Treatment (SMT)|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
89266302|NCT01178554|Experimental|Modular Maual Treatment (MMT)|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems; Chorpita & Weisz, 2004) to help children with primary problems of anxiety, depression, and conduct.
89266303|NCT03859882|Experimental|Caffeine|Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day
89266304|NCT03859882|Placebo Comparator|placebo|in 2 administration (08:00 and 14:00) per day
89266305|NCT03859726||Compliance group|6hLC≥10% NIRS Sublingual microcirculation
89266306|NCT03859726||Non compliance group|6hLC<10%
89266307|NCT03745768|Experimental|Active iTBS Treatment|Participants received Intermittent theta burst stimulation to the dorsolateral prefrontal cortex for 6 weeks
89266308|NCT03745768|Sham Comparator|Sham Stimulation|Participants received Sham stimulation to the dorsolateral prefrontal cortex for 6 weeks.
89266309|NCT03745222|Experimental|Arm 1:Tislelizumab + cCRT followed by tislelizumab monotherapy|Tislelizumab 200 mg is administered by intravenous (IV) administration and given together upfront with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV adminstration monotherapy. The standard platinum-based chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide
89266310|NCT03745222|Experimental|Arm 2: Placebo + cCRT followed by tislelizumab monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV administration monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
89266311|NCT03745222|Placebo Comparator|Arm 3: Placebo + cCRT followed by placebo monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by placebo monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
89266312|NCT01286584|Active Comparator|varenicline group|
89266313|NCT01286584|Placebo Comparator|placebo group|
89266314|NCT03863314|Active Comparator|In-Person Simulation|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
89266315|NCT03863314|Experimental|Virtual Simulation|Participants will experience virtual simulations of different workplace scenarios such as medical error and workplace harassment via Virtual Reality headset.
89266316|NCT03743038|Experimental|FMX101 vehicle|FMX101 hydrophobic oil based vehicle (Test Article A) topically applied daily for six weeks on one side of the face (in a split-face model)
89266317|NCT03743038|Experimental|Hydro-alcohol solution base|Hydro-alcohol solution based vehicle (Test Article B) topically applied daily for six weeks on the contralateral side of the face (in a split-face model)
89266318|NCT03864250|Experimental|Tacrolimus monotherapy|
89266319|NCT03864250|Active Comparator|Tacrolimus combined with hormone therapy|
89266320|NCT01175746|Experimental|nicardipine|
89266321|NCT01175746|Active Comparator|remifentanil|
89266322|NCT01174810|No Intervention|Control|
89266323|NCT01174810|Experimental|Exenatide|
89266324|NCT01288690|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment.
89266325|NCT01288690|Experimental|Narrative Exposure Therapy|Patients in this condition receive 3 sessions of Narrative Exposure Therapy
89266326|NCT01178632|Experimental|Passiflora, Anxiety Disorders|1 tablet Passiflora;Crataegus;Salix; PO;BID
89266327|NCT01178632|Active Comparator|Valeriane, Anxiety Disorder|1 tablet Valeriana officinalis, PO, BID
89266328|NCT01178710|Experimental|treatment|
89266329|NCT01178710|No Intervention|untreated|control
89266330|NCT03864328|Experimental|RVT-1601 Low Dose|
89266331|NCT03864328|Experimental|RVT-1601 Mid Dose|
89266332|NCT03864328|Experimental|RVT-1601 High Dose|
89266333|NCT03864328|Placebo Comparator|Placebo|
89266334|NCT01174888|Experimental|GROUP I (Dose levels 1-2):|Patients receive midostaurin orally (PO) twice daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89266335|NCT01174888|Experimental|GROUP II (Dose levels 3-6)|Patients receive mitoxantrone hydrochloride IV over 10 minutes, etoposide IV over 1 hour, and cytarabine IV over 6 hours on days 1-6. Patients also receive midostaurin PO twice daily on days 8-21 and bortezomib IV on days 8, 11, 15, and 18. Treatment continues in the absence of disease progression or unacceptable toxicity.
89266336|NCT01178788|Active Comparator|17 alfa hydroxy Progesterone caproate|Women treated with i.m. 17P injection/weekly (Lentogest, IBSA, Italy)
89266337|NCT01178788|Active Comparator|Micronized Progesterone|micronized P 200 mg per vagina /day (Utrogestan, Besins Healthcare, Belgium)
89266338|NCT01178788|Active Comparator|Control|Routine clinical controls
89266339|NCT00153816|Experimental|Full Factorial Placebo|subjects in 2X2 factorial design; randomized to daily placebo
89266340|NCT00153816|Experimental|Full Factorial Calcium|subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate
89266341|NCT00153816|Experimental|Full Factorial Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1000 IU vitamin D3
89266342|NCT00153816|Experimental|Full Factorial Calcium Plus Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate and 1000 IU vitamin D3
89266343|NCT00153816|Experimental|Two Arm Placebo|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily placebo
89266344|NCT00153816|Experimental|Two Arm Vitamin D|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily 1000 IU vitamin D3
89266345|NCT01178866||Clinical course|complicated course group (death within 30 days after surgery or ICU stay > 4 days) and uncomplicated course group (ICU stay ≤ 4 days).
89266346|NCT02525146|Experimental|Intervention|Patients randomized to the intervention arm receive intensive social work case management based on the ARTAS (Antiretroviral Treatment and Access to Services) model. Patients may participate in 6-12 visits over a six-month period aimed at addressing barriers to re-engagement in HIV care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment.
89266347|NCT02525146|No Intervention|Usual Care|Patients randomized to the usual care arm are provide contact information for an HIV primary care clinic and for local AIDS service organizations. Patients are then encouraged to contact these organizations to re-establish care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment. Patients in the usual care arm are offered the intensive casework intervention after their 12-month followup is complete.
89266348|NCT02525224|Other|Nutritional Supplement|Proprietary nutritional supplement
89266349|NCT03966222|Active Comparator|Open vein harvest|For the standard open conventional technique, the saphenous vein will be exposed by a longitudinal leg incision starting from the medial malleolus and ending at the upper medial thigh at the sapheno-femoral junction. The saphenous vein will be dissected free from its perivascular fat pedicle and visible side branches will be ligated and divided.
89266350|NCT03966222|Experimental|Endoscopic vein harvest|We will use the Terumo VirtuoSaph® Plus Endoscopic Vessel Harvesting System for all endoscopic vein extractions, which is an open carbon dioxide (CO2) system. Approximately 6 l/min of CO2 will be continuously insufflated in the subcutaneous tunnel.
89266351|NCT03862846|Experimental|Group|REN001 Low Dose
89266352|NCT01077648||Women diagnosed with advanced breast cancer|Women diagnosed with advanced breast cancer during January 1, 1995-December 31, 2007 and treated as part of the Henry Ford Health System
89266353|NCT03863002|No Intervention|Standard Medical Treatment|Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin <30 g/L), fresh frozen plasma (200-400 mL/day until the INR was <1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome [HRS]).
89266354|NCT03863002|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.
89266355|NCT01174966||Survivor Nonsurvivor|
89266356|NCT00151476||Celecoxib - Routine Medical Care|800 mg total daily dosing
89266357|NCT00151476||Control Group - Routine Medical Care|Observation of subjects treated with routine medical care
89266358|NCT03859804|Experimental|Group 1|In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI
89266359|NCT03859804|Active Comparator|Group 2|In Group 2, patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).
89266360|NCT01077726|Experimental|1|
89266361|NCT01286116|Experimental|Treatment|Parachute implant
89266362|NCT01179100|Placebo Comparator|Normal Saline|Normal Saline: Calculated and adjusted to match loading dose and infusion rate of lidocaine equivalent adjusted for weight.
89266363|NCT01179100|Active Comparator|Lidocaine|
89266364|NCT03864172|Placebo Comparator|Usual intake + placebo fruit juice|Placebo fruit flavoured juice powder
89266365|NCT03864172|Active Comparator|Usual intake +SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF)
89266366|NCT03864172|Active Comparator|Adequate calcium +fruit juice placebo|Placebo fruit flavoured juice powder added with 600 mg calcium to meet RNI intake
89266367|NCT03864172|Active Comparator|Adequate calcium + SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF) and 600 mg calcium to meet RNI intake
89266368|NCT01179178||COPD-patients|
89266369|NCT01179178||Older adults (65-81 y)|
89266370|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 1|HT-100 multiple dose administration (dose 1).
89266371|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 2|HT-100 multiple dose administration (dose 1).
89266372|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 3|HT-100 multiple dose administration (dose 1).
89266373|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 4|HT-100 multiple dose administration (dose 1).
89266374|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 5|HT-100 multiple dose administration (dose 1).
89266375|NCT01286194||Experimental 1|
89266376|NCT01179256|Experimental|CURCUMIN|oral supplementation of curcumin 2000mg
89266377|NCT01179256|Placebo Comparator|PLACEBO|oral PLACEBO TABLET
89266378|NCT03858088||Training set|Cohort of consecutive liver transplants performed in 2016-2017 from 14 liver transplant centers in Italy
89266379|NCT03858088||Validation set|Cohort of consecutive liver transplants performed in 2016-2017 from 2 liver transplant centers in the United Kingdom
89266380|NCT03859180|Experimental|Focused breathing intervention group|Participants randomized to this group will be taught how to perform focused breathing for the self-management of anxiety and asked to practice for 4 minutes each day during a six week period. They may practice focused breathing in addition to the twice daily practices if they experience anxiety. They will be asked to document in a diary each time they practice focused breathing.
89266381|NCT03859180|No Intervention|Control group|The participants randomized to this group with not be required to perform any additional behaviors for the six week period of the study. After completing post-tests they will be taught how to perform focused breathing for the self-management of anxiety.
89266382|NCT01179412|Experimental|2% povidone-iodine|
89266383|NCT03862690||Participants with Type 2 Diabetes Mellitus|A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.
89266384|NCT03863548||Continuation of antithrombotic drugs|operation carried out without stopping anticoagulants
89266385|NCT03863548||Stop anti thrombotic drugs|operation performed with stopping the anticoagulants
89266386|NCT03862768|Experimental|Surgery following imatinib|Surgery requires at least removal of all drug-resistant lesions. Imatinib 400 MG/d should be taken once the patients resume oral diet.
89266387|NCT03862768|Active Comparator|Imatinib escalation or sunitinib|Escalation of imatinib or replacement of sunitinib are both conventional salvage treatments for imatinib-resistant GISTs. There is no high-level evidence to suggest which method is better. So patients are free to choose imatinib 600 MG/d or sunitinib 37.5 MG/d
89266388|NCT03862456|Experimental|azythromycin + periodontal surgery.|Periodontal surgery + Azithromycin (500 mg every 24 h for 3 days).
89266389|NCT03862456|Active Comparator|metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (500 mg every 8 h for 7 days).
89266390|NCT03859102|No Intervention|ERAS Control/non-ERAS group|Standard usual care after cardiac surgery.
89266391|NCT03859102|Experimental|ERAS group|"Enhanced Recovery After Cardiac Surgery. Pre-op carbohydrate drink, Lansoprazole and Gabapentin.~Intra-operative: IV Paracetamol, Dexamethasone, Ondansetron, Local Anaesthetic to wounds.~Post-op: Gabapentin PO, Paracetamol IV then PO, Ondansetron IV for 24hrs. Opiate sparing. Early extubation, early mobilisation, early removal of invasive devices. Early discharge."
89266392|NCT02525068|Experimental|Phase ISafety Run-In|18 patients will receive the combination of enzalutamide and AZD5363 (on an intermittent schedule 4 days on 3 days off) to determine the AZD5363 dose to be used for the randomised phase II and single stage phase II expansion cohort. Approximately three dose-levels of AZD5363 in combination with enzalutamide are planned although other dose levels may be required.
89266393|NCT02525068|Placebo Comparator|Randomised phase II|100 patients will be randomised in a 1:1 ratio to receive 160mg enzalutamide od + AZD5363 bid 4 days on 3 days off (recommended dose from Phase I) vs 160mg enzalutamide od + matching placebo bid 4 days on 3 days off.
89266394|NCT02525068|Experimental|Single stage phase II expansion cohort|Following progression on enzalutamide alone, 18 patients will receive enzalutamide 160mg od and AZD5363 bid (recommended dose from phase I) 4 days on 3 days off
89266395|NCT02524678|Placebo Comparator|Placebo|Placebo
89266396|NCT02524678|Active Comparator|URC102|URC102
89266397|NCT01181206|Active Comparator|Arm 1|
89266398|NCT01181206|Active Comparator|Arm 2|
89266399|NCT05274880|Experimental|Sequence 1|Period 1: CKD-393 administration after a high-fat meal/ Period 2: CKD-393 administration at fasting state
89266400|NCT05274880|Experimental|Sequence 2|Period 1: CKD-393 administration at fasting state/ Period 2: CKD-393 administration after a high-fat meal
89266401|NCT00149994|Experimental|Cyclosporine A|Cyclosporine A was given in a twice-daily schedule at 12-hour intervals. It was administered within the first 4 hours post-operatively (study day 1), at an initial dose of 10-15mg/kg/day in two doses, as close as possible to 15mg/kg/day. After the first oral administration, the dose of Cyclosporine A was adjusted to bring the sample taken 2 hours after oral dose (C-2h) level into the target range by Days 3-5 post-transplantation. C-2h target ranges post-transplantation: 0-3 months: range of 800-1200 ng/ml with midpoint of 1000 ng/ml; 4-6 months: range of 700-900 ng/ml with midpoint of 800 ng/ml; > 6 months: range of 500-700 ng/ml with midpoint of 600 ng/ml is recommended. During the course of the study, the dose of Cyclosporine A was adjusted as necessary to achieve and maintain the C-2h blood Cyclosporine A (CsA) concentrations within the target ranges.
89266402|NCT00149994|Active Comparator|Tacrolimus|Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; > 6 months: range of 5-10 ng/ml is recommended.
89266403|NCT01179646|Active Comparator|Protonix|Protonix 40 mg DR Tablet
89266404|NCT01179646|Experimental|Pantoprazole|Pantoprazole 40 mg DR Tablet
89266405|NCT01075776|Experimental|CNP|Infusion of CNP prior to IR injury
89266406|NCT01075776|Placebo Comparator|Saline|Effect of saline infusion prior to IR injury
89266407|NCT01288768|Active Comparator|Arthroscopy|Knee arthroscopy + Exercise therapy
89266408|NCT01288768|No Intervention|Exercise therapy|Exercise therapy alone
89266409|NCT01079910|Experimental|Experimental toothpaste|0.1% isopropylmethylphenol and 1150ppm fluoride
89266410|NCT01079910|Other|Marketed toothpaste|NaF/Silica toothpaste containing 1150ppm fluoride
89266411|NCT01286896|Experimental|Sunitinib|Sunitinib is administered in oral capsules of 12.5 mg. Patients will start with a continuous once-daily dose of 37.5 mg.
88805484|NCT01042145|Active Comparator|Dexamethasone|Dexamethasone, 0.6mg/kg for one day, then placebo for 2 days
88805485|NCT01334827|Other|Formulations|high volume gel; low volume gel; vaginal film
88805486|NCT01042613|Other|Group A|Research participants are randomly assigned into group A (Accuvein AV300 assisted intravenous catheter insertion)
89266412|NCT03965988|Experimental|Docosahexaenoic Acid|Docosahexaenoic acid
89266413|NCT03965988|Placebo Comparator|Placebo drug|Placebo
89266414|NCT01286974|Experimental|ADME|[14C]linifanib
89266415|NCT01286974|Experimental|Extension|linifanib
89266416|NCT03857854|Experimental|treatment group|pirfenidone group
89266417|NCT03857854|Placebo Comparator|placebo group|control group
89266418|NCT01288846||Acutly ill, Medical ward, consent|group of acutely ill patient who uses three or more drugs, must be able to give consent.
89266419|NCT03858946|Sham Comparator|Simple trapeziectomy|Simple trapeziectomy with two sham incisions for primary thumb carpometacarpal osteoarthritis
89266420|NCT03858946|Experimental|Weilby|Ligament reconstruction interpositions arthroplasty modo Weilby for primary thumb carpometacarpal osteoarthritis
89266421|NCT01287052|Experimental|Nitrous Oxide|
89266422|NCT01181284||Lisinopril|Participants will be randomized 2 to 1 to receive drug versus placebo.
89266423|NCT01288924|Active Comparator|Parecoxib|Parecoxib 2 ml intravenous
89266424|NCT01288924|Placebo Comparator|Control|0.9% sodium chloride 2 ml intravenous
89266425|NCT03857932|Experimental|SLNB and non-slns resection|"Participants only receive SLNB~preoperative CT lymphography~SLNB with stained non-SLN resection~SLNB with ARM dissection"
89266426|NCT03857932|Experimental|SLNB group|Participants only receive SLNB
89266427|NCT01181362|Other|Endoscopy|
89266428|NCT01179724|Experimental|high dose proton pump inhibitor|
89266429|NCT01179724|Active Comparator|H2 receptor antagonist|
89266430|NCT01176136|Experimental|HOPS Intervention|Middle school age children who receive the Homework, Organization, and Planning Skills (HOPS) intervention.
89266431|NCT01176136|No Intervention|Treatment As Usual|Middle school age children randomly assigned to receive treatment-as-usual services available through the school and community.
89266432|NCT03862612|Active Comparator|Erector Spinae Plane Block|This group will receive an Erector Spinae Plane Block under ultrasound guidance while under General Anaesthesia
89266433|NCT03862612|Experimental|Serratus Anterior Plane Block|This group will receive a Serratus Anterior Plane Block under ultrasound guidance while under General Anesthesia
89266434|NCT03862534|Experimental|CAF|After the restoration of the enamel patients were treated with a CAF
89266435|NCT03862534|Experimental|CAF + CTG|After the restoration of the enamel patients were treated with a CAF + CTG
89266436|NCT03857698|Experimental|Evaluation of pain|The patient's pain will be evaluated by VAS (visual analog scale) at the end of the treatment, at the end of the treatment and at the end of the 3 months follow-up. For this, a 10 cm long line will be drawn. 0: painless and 10: the most severe pain is described and the patient will be asked to mark the value corresponding to the pain (rest, activity and night pain) on the scale.
89266437|NCT03857698|Experimental|Evaluation of joint range of motion|The flexion and extension range of motion of the knee joints of the patient will be measured in the prone position using a universal goniometer before and after the training.
89266438|NCT03857698|Experimental|Assessment of balance|Postural stability will be evaluated by a Prokin brand balance device (ProKin, Tecnobody, Bergamo, Italy), a force platform. After the tests are explained to the patients, the physical characteristics of the patients (age, height, body weight) will be recorded on the device and the device will be calibrated. The patients' feet will be placed naked on the platform with reference to the lines on the x and y axis. During the test, the arms will be in free position near the body. The tests will be performed on both feet with both eyes open and eyes closed. Each test will last 30 seconds. After each test has been completed, the device will be recalibrated. As a result of the tests, the ellipse area (mm2) and perimeter (mm) parameters will be recorded for statistical analysis. In addition, the patient's stability limits will be calculated as a percentage.
89266439|NCT03857698|Experimental|Evaluation of functional performance|A timed up and go test is a test that assesses the mobility and lower extremity mobility. For this test, the patient will be asked to lift from a chair with armrest (sitting height: 46 cm), walk 3 meters as fast as possible, turn around the colored band marked on the floor and sit in the same chair. The elapsed time for the motion will be recorded in seconds.
89266440|NCT03857698|Experimental|Lumbar lordosis angle assessment|During the test, patients will be asked to stand upright in a comfortable position. In the evaluation of the lumbar lordosis, the inclinometer will first be fixed to the T12-L1 backbone and then to the L5-Sl backbone and the angular values in both measurements will be collected and recorded as lordosis angle.
89266441|NCT03857698|Experimental|Evaluation of knee functionality|It will be measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). There are three subgroups, namely pain, stiffness and function. A total of 24 questions (pain 5 questions, 2 questions of malfunction and 17 questions of function) and the scale answered by patients are completed in approximately 5 minutes. The scale is a 5-point Likert-type scale (0 = none 1 = mild 2 = moderate 3 = severe 4 = very severe). The score range for the subgroup of pain is 0-20, for the subgroup group 0-8 and for the subgroup of function is 0 - 68. The total WOMAC score is obtained by the sum of these 3 points and the maximum total WOMAC score is 96. There is a linear ratio between the scores obtained from the WOMAC index and the presence of symptoms. The high scores were associated with severe symptoms, more disability and poor health status, whereas low scores indicated that symptoms, pain, and functionality were good.
89266442|NCT03857698|Experimental|Assessment of lower extremity muscle endurance|The patient will be asked to sit on the chair as fast as possible, so that the chair, which has a 46 cm height, will be crossed in the chest. The stopwatch is started with the command given to the patient and stopped in 30 seconds. The number of repetitions will be recorded.
89266443|NCT01287130|Experimental|DL 1|AZD6244 once daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
89266444|NCT01287130|Experimental|DL 2|AZD6244 twice daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
89266445|NCT00149214|Experimental|A: Pemetrexed Plus Doxorubicin, Followed by Docetaxel|
89266446|NCT00149214|Active Comparator|B: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel|
89266447|NCT03034018|Experimental|suvorexant|suvorexant 10-20 mg taken at bedtime for four weeks
89266448|NCT03034018|Placebo Comparator|placebo|placebo taken at bedtime for four weeks
89266449|NCT02524990|Experimental|Home-based follow-up with SQPT|For the intervention, a semiquantitative pregnancy test (SQPT) will be performed at the health center before the participants take mifepristone, and again two weeks later by the participants, at home. Study staff will call the participants at two weeks to follow-up with the participants.
89266450|NCT03965910|Other|group 1|Group 1:Early rehabilitation
88805487|NCT01042613|Other|Group B|(standard technique of insertion of the intravenous cannula)
89266451|NCT03965910|Other|group 2|Group 2:Late rehabilitation
89266452|NCT02525458|Experimental|QAMS-containing PMMA|PMMA containing 5% QAMS
89266453|NCT02525458|Placebo Comparator|QAMS-free PMMA|PMMA containing 0% QAMS
89266454|NCT03967782|Experimental|cohorte 1|18 adolescents with obesity are involved and will perform the three conditions.
89290500|NCT01221792|Active Comparator|carvedilol|Patients randomized to carvedilol will be administered doses ranging from 6.25 to 15.625 mg/day using a flexible-dosing model. After a 1 week titration, investigators my increase daily dose by 6.25 mg/day at weeks 1 and 2 for a maximum dose of 15.625 mg/day. Weeks 3-4 will patients will remain on a stable, tolerable dose. At week 5 patients will have a 1 week taper.
89266455|NCT03858556||Patients with lumbar disc herniation|"3times(baseline, 1weeks, 2weeks) of Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion in inpatients with lumbar intervertebral disc herniation hospitalized at Korean medicine hospital.~-Integrative Korean medicine treatment Procedure/Surgery: Chuna manipulation Drug: Herbal medicine Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s) Other: Other intervention(s)"
89266456|NCT03858556||Normal|"baseline Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion.~-No treatment"
89266457|NCT03857776|Other|Open dialogue about CAM|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
89266458|NCT03857776|Other|Standard care|Standard care including referral to a homepage about complementary alternative medicine
89266459|NCT02555254|Experimental|Low speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
89266460|NCT02555254|Experimental|Fast speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
89266461|NCT01179802|Experimental|1|single event of a prolonged strenuous endurance exercise (mountain marathon)
89266462|NCT01179880|Experimental|1|
89266463|NCT01179880|Placebo Comparator|2|
89266464|NCT03862222||Cognitively normal - low risk|Adults aged 55-80 without subjective memory complaints, family history of Alzheimer's disease, or genetic risk for Alzheimer's disease.
89266465|NCT03862222||Cognitively normal - high risk|Adults aged 55-80 with subjective memory complaints, first degree family history of Alzheimer's disease, and at least one copy of the APOE E4 gene, a risk gene for Alzheimer's disease
89266466|NCT03862222||mild cognitive impairment|Adults aged 55-80 who have a confirmed diagnosis of mild cognitive impairment.
89266467|NCT03862222||mild dementia|Adults aged 55-80 with mild dementia due to probable Alzheimer's disease.
89266468|NCT01181440|Experimental|Dermagraft(R) and conventional care|
89266469|NCT01181440|Other|Conventional care only|
89266470|NCT01176214|Experimental|early tracheostomy|see study description
89266471|NCT01176214|Active Comparator|late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
89266472|NCT01179958|Experimental|aerobic training|24 weeks of aerobic training, 4 times/week
89266473|NCT01179958|Placebo Comparator|stretching/toning|stretching/toning condition, 24 weeks to parallel the active intervention group
89266474|NCT00114972|Experimental|PCI with DES|
89266475|NCT00114972|Active Comparator|CABG (coronary artery bypass graft)|Coronary Artery Bypass Graft
89266476|NCT02444728|Active Comparator|Group1:Hydroxychloroquine|Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
89266477|NCT02444728|Active Comparator|Group 2:Cyclophosphamide|"Cyclophosphamide, Azathioprine & Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months"
89266478|NCT03858790|Experimental|Experimental|Subjects' PINS spinal cord stimulator randomized to this arm is on always
89266479|NCT03858790|Sham Comparator|Control|Subjects' PINS spinal cord stimulator randomized to this arm is off for a week
89266480|NCT01181752||Group A|Baseline/control subjects who are only tested on postoperative day 30
89266481|NCT01181752||Group B|Subjects who will be tested on postoperative day 1 and day 30
89266482|NCT01181752||Group C|"Subjects who cannot proficiently administer the medication on postoperative day 1 will be re-classified as Group C subjects"
89266483|NCT01180114|Experimental|SUUBI-MAKA|Involves creating and broadening asset ownership opportunities and life options for children (ages 12 to 15 years) orphaned due to AIDS in Uganda.
89266484|NCT01180114|Other|Usual Care|No intervention for asset ownership, development of future planning skills, enhancement of mental health and reduction of risk taking behaviors for children orphaned due to AIDS in Uganda.
89266485|NCT01289158||non-classical CMAMMA, classical CMAMMA|
89266486|NCT01289704|Experimental|TreSPE|Treatment with treadmill, proprioceptive and stretching exercises
89266487|NCT01289704|Active Comparator|SPE|Proprioceptive and stretching exercises
89266488|NCT00129402|Experimental|Pooled subjects who received ezetimibe with simvastatin|Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
89266489|NCT00129402|Active Comparator|Pooled subjects who received simvastatin monotherapy|Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
89266490|NCT01180192|Experimental|oxygen|
89266491|NCT01181830|Active Comparator|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate for 8 weeks
89266492|NCT01181830|Placebo Comparator|placebo|administration of 8.1 mmol bid of placebo for 8 weeks
89266493|NCT03739528|Experimental|Levofloxacin + Dexamethasone followed by dexamethasone|Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
89266494|NCT03739528|Active Comparator|Tobramycin + dexamethasone|Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
89266495|NCT03857386||PECS group|Preoperative bilateral PECS I + PECS II Pecs block performed by anaesthetist using ultrasound guidance in plane approach
89266496|NCT03857386||Control group|Bilateral local anesthesia infiltration Local infiltration anesthesia performed by surgeon during the operation
89266497|NCT01587586|Active Comparator|PEGASYS 180 µg Q1W + ribavirin* for 48 weeks|Pegasys 180 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses(48)
89266498|NCT01587586|Experimental|P1101 180 µg Q1W + ribavirin* for 48 weeks|P1101 180 µg Q1W(subcutaneous injection)with Ribavirin, multiple doses
89266499|NCT01587586|Experimental|P1101 270 µg Q1W + ribavirin* for 48 weeks|P1101 270 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses
89266500|NCT01587586|Experimental|P1101 450 µg Q2W + ribavirin* for 48 weeks|P1101 450 µg Q2W(subcutaneous injection)+Ribavirin, multiple doses
89266501|NCT01180270||Cervical dystonia|"patients suffering from cervical dystonia~under routine botulinum toxin treatment"
89266502|NCT01180270||healthy volunteers|control group
89266503|NCT01181908|Experimental|GSK1144814|Subjects will receive either GSK1144814 or placebo at each treatment arm.
89266504|NCT01181908|Placebo Comparator|placebo|Subjects will receive either GSK1144814 or placebo at each treatment arm.
89266505|NCT01289236|Placebo Comparator|Placebo|Placebo BID (twice daily, approximately 12 hours apart)
89266506|NCT01289236|Active Comparator|milnacipran 200 mg|200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)
89266507|NCT01289236|Active Comparator|milnacipran 100 mg|100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)
89266508|NCT01287286|Experimental|AC-Can|Antrodia cinnamomea and concomitant chemotherapy
89266509|NCT01287286|Placebo Comparator|control|Placebo and concomitant chemotherapy
89266510|NCT01289860|Active Comparator|Blueberry drink|30g of blueberry powder (equivalent to 200g fresh blueberries) and 300ml of semi-skimmed milk
89266511|NCT01289860|Placebo Comparator|Control drink|29g of powder consisting of sugars and vitamin C, values of which were matched to that of the blueberry drink, with 1 g of citric acid to match for taste.
89266512|NCT03862378||Group One|All patients underwent gastric or colorectal cancer surgery in the participating centers will be included. Clinical data, drainage cytokine levels will be recorded.
89266513|NCT03858478|Experimental|Biktarvy arm|one tablet of BIKTARVY including [TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg) ] one tablet once a day for 48 weeks
89266514|NCT01289938|Active Comparator|Metoclopramide|Metoclopramide treatment
89266515|NCT01289938|Active Comparator|Diphenhydramine|Diphenhydramine treatment
89266516|NCT00114738|Experimental|EPOCH-R + Bortezomib|Combo chemo etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH)-Rituxan (R) + Bortezomib (B)
89266517|NCT00114738|Experimental|"Bortezomib window"|Bortezomib alone
89266518|NCT00114738|Active Comparator|Bortezomib maintenance|Bortezomib maintenance
89266519|NCT00114738|Other|Observation|At the beginning of part C patients are randomized to receive bortezomib maintenance or observation without bortezomib.
89266520|NCT01180348|Experimental|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
89266521|NCT01180348|Active Comparator|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
89266522|NCT01180426|Experimental|Tosedostat|
89266523|NCT01289314|Active Comparator|Total laparoscopic hysterectomy|
89266524|NCT01289314|Active Comparator|Laparoscopic supracervical hysterectomy|
89266525|NCT02524756|Active Comparator|Group (A)|laparoscopic nerve sparing radical hysterectomy type III/C1
89266526|NCT02524756|Active Comparator|Group (B)|laparoscopic radical hysterectomy type III/C2
89266527|NCT01182064||Non infarct|
89266528|NCT01182064||Posttraumatic acute myocardial infarct without coronary injury|
89266529|NCT01182064||Posttraumatic acute myocardial infarct with coronary injury|
89266530|NCT01290016|Active Comparator|Control 6-8 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention till the end of the study protocol.
89266531|NCT01290016|Experimental|2 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
89266532|NCT01290016|Experimental|4 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counselling to maintain the intake of 4 servings of dairy per day and also receive instruction on how to improve their physical activity.
89266533|NCT01290016|Experimental|4 servings dairy + exercise 9-12 yrs|Subjects in this group will receive family based counselling to maintain the standard recommended intake of 4 servings of dairy per day for 9-14 year olds according to the Canada's Food Guide and also receive instruction on how to improve their physical activity.
89266534|NCT01290016|Active Comparator|Control 9-12 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
89266535|NCT00148122|Experimental|Arm 1|Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, &15)
89266536|NCT03857308|Experimental|Mindfulness Training|
89266537|NCT03857308|Active Comparator|Reappraisal Training|
89266538|NCT01182142|Experimental|Capecitabine|All patients will receive capecitabine.
89266539|NCT03858166|Active Comparator|Standard group|6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy.
89266540|NCT03858166|Experimental|Adjusted group|6mg PEG-rhG-CSF was administrated subcutaneously when ANC < 1000/mm3 after chemotherapy.
89266541|NCT01180738|Active Comparator|Body weight supported treadmill training|
89266542|NCT01180738|Active Comparator|Overground walking training|
89266543|NCT01587742||Patients with a diagnosis of any cancer type|All patients of the study population with a diagnosis of any cancer type based on Read codes and ICD-10 codes
89266544|NCT01587742||Patients with a diagnosis of breast cancer|All patients of the study population with a diagnosis of breast cancer based on Read codes and ICD-10 codes
89266545|NCT01587742||Patients with a diagnosis of prostate cancer|All patients of the study population with a diagnosis of prostate cancer based on Read codes and ICD-10 codes
89266546|NCT01587742||Patients with a diagnosis of colon cancer|All patients of the study population with a diagnosis of colon cancer based on Read codes and ICD-10 codes
89266547|NCT01587742||Patients without a diagnosis of any cancer type|All patients of the study population without a diagnosis of any cancer type
89266548|NCT01182220||Ultrasound L5/S1 catheter placement|Pt will have back scanned with Ultrasound and L5/S1 interspace localized for epidural placement.
89266549|NCT01182220||Control Group|Patients will have catheter placed after clinically evaluating the back as is done routinely resulting in mid lumbar catheter placement in general.
89266550|NCT01180816|Experimental|Temozolomide (Temodar)|
89266551|NCT01587664|Experimental|NewBreez ILP|Implantation of a NewBreez ILP
89266552|NCT01287598|Experimental|Arm 1|Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam
89266553|NCT01287598|Experimental|Arm 2|Regorafenib (Stivarga, BAY73-4506) + rosiglitazone
89266554|NCT03855514|Active Comparator|NuShield|NuShield® is a sterile, dehydrated placental allograft
89266555|NCT03855514|No Intervention|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
89266556|NCT01182532|Active Comparator|Western therapy|
89266557|NCT01182532|Experimental|TCM treatment|
89266558|NCT01182532|Experimental|Western therapy plus TCM treatment|The combination of both western therapy and TCM treatment.
89266559|NCT03862144|Experimental|Netupitant/Palonosetron & Dexamethasone|"Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.~Dexamethasone 12 mg will be added on day 1 only of each cycle."
89266560|NCT03857152|Other|Patient receiving CESM|Patients will receive CESM in addition to normal standard treatment.
89266561|NCT01290172|Experimental|Somatostatin|Patients in this group receive treatment with Somatostatin for 5 days.
89266562|NCT01290172|Placebo Comparator|Placebo|Patients in this group receive a placebo for 5 days.
89266563|NCT03861598|Experimental|Cohort 1|Carvedilol orally with standard chemotherapy starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
89266564|NCT01184482|Experimental|Cetuximab and lapatinib|All patients will receive cetuximab by IB weekly and daily doses of lapatinib orally in 3 week cycles with response assessed every 2 cycles.
89266565|NCT03855124||healthy participants|Participants will be ask to perform a repetitive upper limb task while posture and muscle activity is being monitored.This will be done while wearing a posture shirt or without a shirt
89266566|NCT01184560|Experimental|Sibutramine + Orlistat|"A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence"
89266567|NCT01184560|Placebo Comparator|Sibutramine + Orlistat(Placebo)|"Sibutramine : one of components included into Diet Pills. This reduces appetite, normalizes amount of cholesterol in blood, and reduces abdominal fat.~Orlistat : A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence."
89266568|NCT03861832|Experimental|Nutraceutical, KB220Z|A nutraceutical pill containing pro-dopamine precursors
89266569|NCT03861832|Placebo Comparator|Placebo|A placebo that looks the same and is in a similar bottle
89266570|NCT01290250|Experimental|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
89266571|NCT01290250|Placebo Comparator|Orange juice with low levels of polyphenols|2 daily doses (250 ml each) during 3 months
89266572|NCT03861520||16-24 weeks Pregnant womes|Pregnant Women at (16-24) weeks of gestation for mid trimester anomaly scan with one sonographic fetal soft marker or more.
89266573|NCT01184638|No Intervention|Local anesthesia|Patients received local anesthesia without any intervention of general anesthetics
89266574|NCT01184638|Active Comparator|Inhalational anesthesia|Patients received sevoflurane anesthesia during general anesthesia
89266575|NCT01184638|Active Comparator|Intravenous anesthesia|Patients received intravenous anesthetic (Propofol) during general anesthesia
89266576|NCT01290328|No Intervention|Standard of care|
89266577|NCT01290328|Experimental|Epoetin alfa|150 units/kg/week
89266578|NCT01184716|Active Comparator|Vitamin D fortified bread and milk|
89266579|NCT01184716|No Intervention|Non-fortified bread and milk|
89266580|NCT01184794|Placebo Comparator|Saline|Placebo solution
89266581|NCT01184794|Experimental|levobupivacaine, analgesia|Active drug
89266582|NCT01176682||1|Adult patients treated with NSAID therapy for diagnosed OA, RA or AS, and with GI risk factors
89266583|NCT01587508|Active Comparator|meloxicam - Movatec®|
89266584|NCT01587508|Active Comparator|cyclobenzaprine - Miosan®,|
89266585|NCT01587508|Experimental|meloxicam/cyclobenzaprine hydrochloride|
89266586|NCT00147498|Experimental|5 mg BID|CP 690,550 5 mg BID
89266587|NCT00147498|Experimental|15 mg BID|CP 690,550 15 mg BID
89266588|NCT00147498|Experimental|30 mg BID|Oral tablets administered at a dose of 30 mg BID for 6 weeks
89266589|NCT00147498|Placebo Comparator|Placebo|Placebo
89266590|NCT05267704|Experimental|VR Arm|Pediatric patients age 5-17 using the VR headset during renal biopsy.
89266591|NCT02974036||Patient education for osteoarthritis|The intervention in the education program consists of three group lessons of about 90 minutes each where information about ethiology, risk factors, treatment and coping strategies concerning OA is included. The first two lessons are held by a physiotherapist and the third by a so-called expert patient that is a person with OA who shares his or her experiences of how to live with the disease. After the intervention patients are able to choose if they want to exercise at home or in a group, supervised by a physiotherapist.
89266592|NCT03856762|Experimental|Traditional Jiangnan diet|Subjects will be supplied with traditional Jiangnan diet and APP-based behavioral modification
89266593|NCT03856762|Experimental|Mediterranean diet|Subjects will be supplied with Mediterranean diet and APP-based behavioral modification
89266594|NCT03856762|Experimental|Current Shanghai diet|Subjects will be supplied with current Shanghai diet and APP-based behavioral modification
89266595|NCT01176760|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
89266596|NCT01176760|Experimental|Cardia|Truncally vagotomized subjects (due to cardia resection)
89266597|NCT01176760|Experimental|Ctrl|Healthy matched control subjects
89266598|NCT01080066||Non-Interventional Study|
89266599|NCT01185184|Experimental|1|Subjects will receive in random order, the immediate release tablet containing 10 mg of CP-690,550 and two different controlled-release capsules containing 20 mg of CP-690,550.
89266600|NCT01077882|Placebo Comparator|current therapy|
89266601|NCT01077882|Experimental|current therapy with educational program|
89266602|NCT03856606|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will not be asked to perform interval exercise.
89266603|NCT03856606|Experimental|Prolonged sitting with interval exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will be asked to perform interval exercise every hour on the hour.
89266604|NCT04988464|Experimental|Sleep Scholar|Sleep Scholar is a fully automated, single-session, self-guided, internet-based CBT-I intervention that participants will read from a web browser on their electronic device. Sleep Scholar's content was adapted from Ellis and colleague's, Morin's, and Perlis and colleague's protocols for therapist-guided CBT-I interventions. Sleep Scholar will be completed in approximately 30 minutes and consists of three successive text-based modules: Sleep Education, Initiating Sleep, and Enhancing Sleep Quality. New content (e.g., vignettes and quizzes) was created to tailor the intervention to college students. For example, after each module, short multiple choice and/or true-false question will be administered to assess participants' understanding of Sleep Scholar's strategies. Participants will be automatically provided feedback on their responses to ensure their understanding of Sleep Scholar's strategies.
89266605|NCT04988464|Placebo Comparator|Building Healthy Habits|Building Healthy Habits will be used as the control condition. It combines two modules being utilized as the control condition in an ongoing randomized controlled trial. It is a single-session, self-guided, internet-based intervention that participants will read from a web browser on their electronic device. Building Healthy Habits was piloted by undergraduate research assistants to ensure that it was approximately the same duration as Sleep Scholar (i.e., 30 minutes). It consists of two successive text-based modules focused on healthy movement and healthy eating.
89266606|NCT03861754|Experimental|Lifestyle modification|intensified Behavioural Modification (iBM) group receiving lifestyle counselling
89266607|NCT03861754|Experimental|Lifestyle modification and exercise 1|"Intensified Behavioural Modification and exercise from 0 to 3 months (CWT1) group:~Lifestyle counselling 3 months Exercise intervention from 0 to 3 months"
89266608|NCT03861754|Experimental|Lifestyle modification and exercise 2|"Intensified Behavioural Modification and exercise from 6 to 9 months (CWT2) group:~Lifestyle counselling 3 months Exercise intervention from 6 to 9 months"
89266609|NCT03861754|No Intervention|Control Group|Control group, no intervention, only measurements and questionnaires
89266610|NCT00113568|Experimental|XP12B (tranexamic acid tablets)|
89266611|NCT05266768|Experimental|IBI346|Single arm
89266612|NCT03856372|Experimental|Hypofractionated|42.5 Gy / 16 fractions, 2.66 Gy per fraction, 5 fractions weekly
89266613|NCT03856372|Active Comparator|Conventional|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
89266614|NCT01185262|Experimental|Lenalidomida, Rituximab|Phase I: Lenalidomide will be administered from day 1 to 21 of 28 days cycles, escalating doses (from 2,5mg to 25 mg).Rituximab dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
89266615|NCT03855358|Experimental|TQB2450 Injection and Anlotinib Hydrochioride Capsules|
89266616|NCT01291030|Experimental|hypomagnesemic + magnesium supplement|The patient group of hypomagnesesemic renal transplant recipients randomized to magnesium supplementation (number = 30). The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
89266617|NCT01291030|No Intervention|hypomagnesemic without magnesium supplement|The patient group of hypomagnesesemic renal transplantation recipients, randomized to no magnesium supplementation (number = 30). During 6 months, no magnesium supplementation is started, provided that the serum magnesium level remains > 1,2 milligram/deciliter. In case of cramps, intermittent supplementation is allowed, but will be recorded. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
89266618|NCT01291030|No Intervention|normomagnesemic without magnesium supplement|In the control group of normomagnesemic renal transplantation recipients (number = 10), only a baseline assessment will be performed. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion.
89266619|NCT00113490|Experimental|motavizumab (MEDI-524) 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
89266620|NCT00113490|Active Comparator|palivizumab 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
89266621|NCT01182922|Active Comparator|Doctor's Information Invitation|Standard invitation with additional leaflet containing information concerning particular doctor performing the examination, that is: his personal data (name, surname, academic title, workplace, picture) and data concerning experience and achievements of the center where he is employed.
89266622|NCT01182922|Active Comparator|Gender Preference Invitation|Standard invitation with additional information about possibility of choosing doctor's gender, mentioned below proposed date of examination
89266623|NCT01182922|Active Comparator|Standard Invitation|Standard invitation without additional information about a doctor or possibility of choosing doctor's gender.
89266624|NCT02524522|Active Comparator|INTELLiVENT-ASV mode|Active comparator: Discontinuation of mechanical ventilation in postoperative period will be provided using automatically driven mode - INTELLiVENT-ASV. In the INTELLiVENT-ASV mode target EtCO2 will be 30-35 mm Hg, target SpO2 - 94-98%, quick wean option - activated.
89266625|NCT02524522|Active Comparator|SIMV mode|Active comparator: Discontinuation from mechanical ventilation in postoperative period will be provided using physician driven protocol. The synchronized intermittent mandatory ventilation (SIMV) mode settings will be as follows: PEEP 5 cm of water, FiO2 to achieve SpO2 > 94 %. Inspiratory pressure will be adjusted to deliver a tidal volume (VT) of 8 mL/kg predicted body weight; pressure support will be 2 cm of water higher. Respiratory rate (RR) will be adjusted to provide EtCO2 of 30-35 mm Hg. Respiratory rate and inspiratory pressure will be decreased gradually every 30 minutes. After decrease of inspiratory pressure to 6 cm of water (8 cm of water in case of BMI > 30 kg/m2) and respiratory rate to 6/min, the spontaneous breathing trial (SBT) will be started.
89266626|NCT01326624||NYHA class III or IV|"Patients with NYHA class III or IV during the past month and one or more of the following:~Hospitalization for cardiac decongestion and stabilization.~Advanced heart failure receiving intravenous diuretics/inotropics in an outpatient clinic.~Awaiting cardiac transplantation"
89266627|NCT01326624||left ventricular ejection fraction ≤ 35%|"Patients with left ventricular ejection fraction ≤ 35% and either one of the following:~Coronary revascularization within 3 calendar months prior to enrollment.~Heart failure of non-ischemic origin diagnosed within 3 calendar months prior to enrollment."
89266628|NCT01326624||Awaiting ICD re-implantation|
89266629|NCT01326624||Acute myocardial infarction|Patients hospitalized with acute myocardial infarction and Killip Class III/IV.
89266630|NCT01176994|Experimental|Skin lesions|Individuals with skin lesions whose lesions are not sent for histology by dermatologists
89266631|NCT00146640|Experimental|MR Prednisone|Participants will receive MR prednisone at bed time and placebo matching to IR prednisone in the morning. Total duration of double blind treatment will be 12 weeks.
89266632|NCT00146640|Active Comparator|IR Prednisone|Participants will receive IR prednisone in the morning and placebo matching to MR prednisone at bed time. Total duration of double blind treatment will be 12 weeks.
89266633|NCT01183000|Active Comparator|peritoneal closure|
89266634|NCT01183000|No Intervention|Non closure of the peritoneum|
89266635|NCT01185418||risperidone|
89266636|NCT01185418||aripiprazole|
89266637|NCT01185418||haloperidol|
89266638|NCT01185418||amisulpride|
89266639|NCT01185418||lactose|
89266640|NCT03856450|Active Comparator|Control-arm group|The control-arm group will consist of healthy volunteers with no known prior trauma in the wrists. The diagnostic truth for subjects in the control-arm will be no fracture and the treatment truth will be no treatment.
89266641|NCT03856450|Experimental|Test-arm group|The test-arm group will consist of subjects who present with a wrist injury and initial SOC X-ray imaging results show a confirmed or suspected distal radius or scaphoid fracture, for which additional diagnostic imaging shall be ordered. Diagnostic truth for subjects in the test-arm will be the per-subject clinical diagnosis and the treatment truth will be the per-subject treatment received.
89266642|NCT01183156|Active Comparator|Re-invitation letter|
89266643|NCT01183156|Active Comparator|Educational Meeting|
89266644|NCT01185496||CGM|Blinded/Unblinded CGM wear in adjunct with SMBG meter diabetes management
89266645|NCT01185574|Experimental|Vitamin D supplementation|The study medication (a capsule of 50,000 IU of vitamin D2) will be administered once a week for six months.
89266646|NCT03861364|Active Comparator|High Propofol|High Propofol induction dose
89266647|NCT03861364|Active Comparator|Low Propofol|Low Propofol induction dose
89266648|NCT01177072|Experimental|Components-Based Interventions (CBI)|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
89266649|NCT01177072|Experimental|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
89266650|NCT01177072|No Intervention|Wait List Control|Eligible clients will not be provided therapy at enrollment. After the study period has completed, control clients will be re-interviewed. Those that remain eligible due to symptom cutoff scores will be offered therapy. In the interim, controls will receive a phone call once a month; those with indications of possible harm to self or others will be referred to a psychiatrist.
89266651|NCT01177150|Experimental|001|JNJ-28431754/ Placebo Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses the evening dose will be administered at 10 hours after the morning dose.
89266652|NCT01177150|Experimental|002|JNJ-28431754 Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
89266653|NCT01185730|Experimental|pulmonary hypertension|cohort of patients with pulmonary hypertension
89266654|NCT03855202|Experimental|infusion froup 1|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
89266655|NCT03855202|Experimental|infusion group 2|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
89266656|NCT03855202|Experimental|infusion group 3|PS,dose is 70mg/kg
89266657|NCT03855202|Placebo Comparator|Placebol|0.9% sodium chloride installation after 24 hours
89266658|NCT01185808|Active Comparator|Vitamin D|Vitamin D 5,000IU/day for 6 weeks
89266659|NCT01185808|Placebo Comparator|Placebo|Placebo for 6 weeks.
89266660|NCT01183624|Experimental|Experimental Patch|Herbal Patch
89266661|NCT01183624|Placebo Comparator|Control Patch|Placebo Patch
89266662|NCT01291186|Experimental|BPV6NO|
89266663|NCT01291186|Experimental|BPV7NO|
89266664|NCT01291186|Experimental|BPV8NO|
89266665|NCT01291186|Experimental|BPV9NO|
89266666|NCT01291186|Experimental|BPV10NO|
89266667|NCT01291186|Experimental|BPV11NO|
89266668|NCT01291186|Active Comparator|BPV6O|
89266669|NCT01291186|Active Comparator|BPV7O|
89266670|NCT01291186|Active Comparator|BPV8O|
89266671|NCT01291186|Active Comparator|BPV9O|
89266672|NCT01291186|Active Comparator|BPV10O|
89266673|NCT01291186|Active Comparator|BPV11O|
89266674|NCT04979338|Active Comparator|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #1|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the pre-incision, intra-op, mid-surgery, end of surgery, or continuous time points:~Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)~Local anesthetic (0.25% or 0.5% bupivacaine + 1:200K epinephrine)~Bilateral ultrasound guided pudendal nerve block (20-40 cc of 0.25% bupivacaine + 1:200K epinephrine)~Ultrasound guided Continuous Infraclavicular Brachial Plexus Block~Ultrasound guided Continuous Femoral Nerve Block~Pecs I & II Block (0.25% bupivacaine: 15-30ml per side for Pecs I-III)"
89266675|NCT04979338|Active Comparator|Surgery-specific general anesthetic + ultrasound guided peripheral nerve block #2|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the intra-op, post-op, or end of surgery time points:~Bilateral ultrasound-guided Transversus Abdominis Plane Block (40-60cc of 0.25% bupivacaine with 1:200K epinephrine)~Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
89266676|NCT04979338|Active Comparator|Surgery-specific general anesthetic + local anesthetic at incision site|"Depending on which one of the thirteen possible gender-affirming surgeries the participant is undergoing, a combination of the following anesthetic block(s) will be used in this arm at either the mid-surgery or end of surgery time points:~Bilateral spermatic cord block (0.5% bupivacaine, 10cc per spermatic cord)~Local anesthetic (0.25 or 0.5% bupivacaine + 1:200K epinephrine)"
89266677|NCT01291342||Preeclampsia|30 preeclamptic pregnant women with gestational age >24 weeks and no chronic medical disorders who are not in labor and their fetus is alive.
89266678|NCT01291342||Normal pregnancy|30 normotensive pregnant women with gestational age >24 weeks and no chronic medical disorders who has no obstetrical problems, not in labor and their fetus is alive.
89266679|NCT01291342||Healthy non-pregnant|30 healthy non-pregnant control women not on medications and has not delivered a baby or conceived during the year before the breath collection
89266680|NCT01177306|Experimental|Extended Release Guanfacine|pre and post testing of working memory in subjects whose ADHD has responded to extended release guanfacine. Subjects will be tested before starting study drug and after 6-8 weeks on a stable dose of the study drug.
89266681|NCT03856294|Experimental|Rikkunshito|Rikkunshito: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
89266682|NCT03856294|Placebo Comparator|Placebo|Placebo: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
89266683|NCT01183702|Active Comparator|non-LASIK|These participants have NOT had LASIK surgery.
89266684|NCT01183702|Active Comparator|LASIK|These participants have had LASIK surgery.
89266685|NCT03854968|Experimental|Quality control|The participants home mechanical ventilator will be tested in order to performe a quality control
89266686|NCT01290406|Experimental|BEZ235|
89266687|NCT03854890|No Intervention|Lymphadenectomy without indocyanine green injection|Laparoscopic lymphadenectomy will be performed in a standard way.
89266688|NCT03854890|Experimental|Lymphadenectomy with indocyanine green injection|Injection of indocyanine green to the submucosal layer around rectal cancer 1 day before surgery. Laparoscopic proctectomy with lymph nodes dissection will be performed under near-infrared imaging.
89266689|NCT03854812|Active Comparator|Group M|magnesium sulphate as adjuvant to propofol
89266690|NCT03854812|Active Comparator|Group F|fentanyl as adjuvant to propofol
89266691|NCT01177462||hemineglect stroke patients|Stroke patients with hemineglect
89266692|NCT01177462||Control stroke patients|Stroke patients without hemineglect
89266693|NCT01177462||Normal control|Normal subjects
89266694|NCT03860896|Experimental|GB004|GB004 for oral administration daily
89266695|NCT03860896|Placebo Comparator|Placebo|Placebo for oral administration daily
89266696|NCT01183936|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
89266697|NCT01183936|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
89266698|NCT01184092|Experimental|Sequence 1|
89266699|NCT01184092|Experimental|Sequence 2|
89266700|NCT01184092|Experimental|Sequence 3|
89266701|NCT01184092|Experimental|Sequence 4|
89266702|NCT01184092|Experimental|Sequence 5|
89266703|NCT01184092|Experimental|Sequence 6|
89266704|NCT01186120|Experimental|Biolimus A9-eluting stent|NOBORI stent
89266705|NCT01186120|Active Comparator|Everolimus-eluting stent|PROMUS ELEMENTE stent
89266706|NCT01184170|Experimental|Metabolically Normal|"Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
89266707|NCT01184170|Experimental|Metabolically Abnormal|"Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
89266708|NCT01287910|Other|All Patients|All patients undergo the same study procedures
89290501|NCT01221792|Placebo Comparator|Sugar Pill|Patients randomized to placebo will follow same dosing guidelines as if they were in the active comparator arm, carvedilol.
89290502|NCT05702710||Neonates Undergoing PIRS|All children <28 days of age undergoing PIRS for inguinal hernia repair
89266709|NCT05666674|Experimental|TSA-ON|The trial will be composed of two arms: an experimental group with VR with activated Tremor Stabilization Algorithms (TSA-ON). And an active comparator group that is exposed to VR without Tremor Stabilization Algorithms (TSA-OFF control). In both arms, study subjects will be immersed in a stock VR testing environment and will perform a tremor eliciting PTT test.
89266710|NCT05666674|Active Comparator|TSF-OFF control|The trial will be composed of two arms: an experimental group with VR with activated Tremor Stabilization Algorithms (TSA-ON). And an active comparator group that is exposed to VR without Tremor Stabilization Algorithms (TSA-OFF control). In both arms, study subjects will be immersed in a stock VR testing environment and will perform a tremor eliciting PTT test.
89266711|NCT03860506|Experimental|PSI-697|
89266712|NCT03860506|Placebo Comparator|Placebo|
89266713|NCT01186354|Experimental|Receiving results via web-based program|participants will receive genetic risk results for Type 2 diabetes via a web-based program that they access on their own
89266714|NCT01290562|Experimental|Stereotactic Body Radiotherapy (SBRT)|Cohort 1: Patients with spinal metastases and no prior radiation Cohort 2: Patients with spinal metastases in a previously radiated field Cohort 3: Post-operative patients with spinal metastases
89266715|NCT01186432|Experimental|Active|ranibizumab sustained delivery implant
89266716|NCT03855826|Experimental|Nifekalant Hydrochloride|Nifekalant hydrochloride (50mg) should be dissolved into a 50ml dilution solution (0.9% sodium chloride injection or 5% glucose injection), and configured as 1mg/ml solution of nificaine hydrochloride. The dosage should be taken as needed. The diluted solution should be used within 24 hours. The amount of fluid per hour should not exceed 50ml when intravenously infused. It is recommended to use intravenous pump.
89266717|NCT03855826|Active Comparator|Amiodarone|The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).
89266718|NCT01588288|Experimental|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy
89266719|NCT02355418||Patients for early surgery|A prospective, cross sectional comparison of asymptomatic patients before and after mitral valve repair surgery for chronic severe primary degenerative mitral regurgitation.Once established, it is our intention to restudy subjects in 5 years to provide information on late outcome following surgery.
89266720|NCT02355418||Patients against early surgery|In order to establish the natural history of diffuse fibrosis in mitral regurgitation, an additional cohort of patients with asymptomatic mitral regurgitation who do not wish to consider early repair will be followed.
89266721|NCT01186510|Experimental|Lung perfusion|
89266722|NCT01186510|Active Comparator|no lung perfusion|
89266723|NCT01287988||Ocriplasmin|Subjects who were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study (TG-MV-006 or TG-MV-007)
89266724|NCT01287988||Placebo|Subjects who were exposed to a single intravitreal injection of placebo in a previous phase III study (TG-MV-006 or TG-MV-007)
89266725|NCT03860818|No Intervention|Control Arm|Usual Care
89266726|NCT03860818|Experimental|Intervention Arm|Technology-enabled pharmacist intervention
89266727|NCT01184404|Experimental|Treatment|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
89266728|NCT01184404|No Intervention|Control|
89266729|NCT02525380|Experimental|Doxorubicin loadeing-DC Bead(Device)|"DC Bead comprises hydrogel microspheres that are biocompatible, hydrophilic, non resorbable, precisely calibrated and capable of loading doxorubicin.~DC Bead is produced from polyvinyl alcohol."
89266730|NCT02524366|Experimental|Transcorporal AUS|The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
89266731|NCT02524366|Active Comparator|Standard AUS|The artificial urinary sphincter is placed in the standard fashion.
89266732|NCT02524600|Experimental|"New Technology IQ-SPECT applied to myocardial imaging"|
89266733|NCT01186588|Experimental|001|Canagliflozin One 300-mg dose of canagliflozin on Day 1
89266734|NCT03854266|Experimental|Catheter directed thrombolysis|Low dose alteplase (4/8 milligram) will be infused over 2 hours locally in the pulmonary arteries at the site of the thrombus through an infusion catheter with sideholes (Unifuse, AngioDynamics, US)
89266735|NCT03854266|Active Comparator|Unfractionated heparin|Initial dose of unfractionated heparin is 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time is 1.5-2.3 times control value.
89266736|NCT01187992|Experimental|Full-dose atorovastatin (80 mg/d)|For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
89266737|NCT01187992|No Intervention|Conventional medical treatment|For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL (2.5 mmol/L).
89266738|NCT03854422|Active Comparator|Left Position during colonoscopy|Left position, the patient will be in the left-side position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.Moreover, process recall, sedation amounts and pain scale will be measured after the procedure..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent (midazolam) used during the process is paid attention to be equal. All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
89290503|NCT03932526|Active Comparator|Vinorelbine + placebo group|92 enrolled patients will be assigned to receive oral vinorelbine plus placebo until disease progression or other criteria for administration termination.
88805488|NCT01043393|Experimental|Psoriasis involving 10-15% BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of 10-15% of their body surface area.
89266739|NCT03854422|Active Comparator|Left Supine Position during colonoscopy|Left Supine position, the patient will be in the left and supine ( after splenic flexura) position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.
89266740|NCT03854422|Active Comparator|Dynamic position during colonoscopy|Dynamic position, the patient will be stared as left position during colonoscopy period. If necessary, change of position and pressure will be allowed at any time. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent used during the process is paid attention to be equal. The use of midazolam as an anesthetic agent was planned.All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
89266741|NCT01186666|Experimental|Non ST-elevation acute coronary syndrome|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
89266742|NCT01186666|Experimental|Stable coronary artery disease|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
89266743|NCT01293604|Experimental|Whole Grain Barley Diet|A controlled diet containing at least 4 daily servings of whole grain barley.
89266744|NCT01293604|Active Comparator|Whole Grain Oats Diet|A diet containing at least 4 servings of whole grain oats.
89266745|NCT01293604|Other|Low Whole Grain Diet|A control diet containing 0.7 daily servings of whole grain.
89266746|NCT03849976||Experimental group|Patients accompanied to the operating room by a stretcher bearer trained in therapeutic communication
89266747|NCT03849976||Control group|Patients accompanied to the operating room by a stretcher bearer not trained in therapeutic communication
89266748|NCT03852940|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
89266749|NCT03852940|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
89266750|NCT01191112|Experimental|Peptide Based enteral formula|
89266751|NCT01186822|Experimental|Lung Flute for BHT|The Lung Flute arm participants were instructed to blow twice in to the Lung Flute device vigorously enough to make the reed oscillate, followed by 5 normal breaths. This was repeated 10 times, followed by 3 huff coughs to complete 1 cycle. Two such cycles were recommended twice a day. One of these cycles was performed under supervision of the study personnel at the time of enrollment and at each subsequent study visit. Baseline COPD medication regimen was continued in all participants, although the primary physicians of the participants could make medically necessary changes. Chest physical therapy, additional breathing exercises and formal pulmonary rehabilitation programs were not prescribed to any of the participants during the study.
89266752|NCT01186822|No Intervention|No intervenstion|No intervention. Same population.
89266753|NCT01186900|Experimental|Ultrasound-guided needle aspiration|One arm is ultrasound-guided needle aspiration, the other active comparison is traditional open incision and drainage of skin abscess
89266754|NCT01186900|Active Comparator|open incision and drainage|
89266755|NCT03853018|No Intervention|Control group|The control group is instructed to continue their habitual daily physical activity patterns and sedentary behaviour
89266756|NCT03853018|Experimental|CWAT intervention group|The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
89266757|NCT03853018|Experimental|CWAT + motivation intervention group|Subjects randomised into the CWATLDP intervention will receive the activity tracker and will be stimulated with the aid of coaching sessions and goal setting.
89266758|NCT01187056|Experimental|Training, decision making|General practitioners receive training in shared decision-making and risk communication, and use their newly acquired skills in real-life consultations with 7 patients with high cholesterol.
89266759|NCT01187056|Active Comparator|Training, usual practice|The control group GPs will receive 2 hours of training in the primary care guideline for prevention of cardiovascular disease
89266760|NCT01188070|Sham Comparator|Usual Care Attention Control|Provision of printed educational material and attendance at one group session. This session will focus on nutrition education and flexibility and stretching.
89266761|NCT01188070|Experimental|Psychoeducation plus exercise|Psychoeducation intervention plus an individualized exercise program which will include monitored, individually-prescribed aerobic and resistance exercise.
89266762|NCT01188070|Active Comparator|Psychoeducation|Psychoeducational program to involve group sessions over consecutive weeks. The sessions will use the principles of adult learning, emphasizing active learning, group exercises and discussion, and coaching as well as brief talks to provide content. The curriculum will focus on the strengthening of caregiver self-efficacy through enhancement of knowledge and understanding, the acquisition, strengthening, and practice of caregiving skills, and the development of a more clinical or strategic outlook on the caregiving role.
89266763|NCT01293760|Other|6 weeks interval insertion|IUD is inserted 6 weeks following c-section delivery of baby and placenta
89266764|NCT01293760|Experimental|Immediate insertion|IUD is inserted immediately following c-section delivery of baby and placenta
89266765|NCT01188148|Active Comparator|VPA & Placebo|VPA & Placebo
89266766|NCT01188148|Experimental|VPA & memantine|
89266767|NCT01187134|Active Comparator|Intervention group|
89266768|NCT01187134|No Intervention|Conventional CME|Hospitals receive conventional continuing medical education in lecture style twice a year. They receive current publications and recommendations for national and international meetings regarding diagnosis and therapy of sepsis.
89266769|NCT01187212|Active Comparator|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day (D) 1
89266770|NCT01187212|Experimental|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
89266771|NCT01588600|Active Comparator|Control|Breakfast without fiber
89266772|NCT01588600|Experimental|Low-dose|Low-dose of fiber in breakfast
89266773|NCT01588600|Experimental|High-dose|high dose of fiber added to breakfast
89266774|NCT03849508|Active Comparator|phenylephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of phenylephrine started at an initial rate of 0,5mcg/kg/ min. The rate will be adjusted according to maternal systolic blood pressure.
89266775|NCT03849508|Experimental|Norepinephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of norepinephrine tartrate started at an initial rate of 0,1mcg/kg/min. The rate will be adjusted according to maternal systolic blood pressure.
89266776|NCT03849664|Experimental|Cytoflavin®|Patients of group I will receive the experimental drug Cytoflavin®, manufactured by POLYSAN (Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Cytoflavin® solution(Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered IV for 7 days, and Cytoflavin® enteric-coated tablets (Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered for 25 days (in total 32 days of treatment).
89266777|NCT03849664|Placebo Comparator|Placebo|Patients of group II will receive placebo (manufactured by POLYSAN, Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Placebo solution will be administered IV for 7 days, and placebo enteric-coated tablets will be administered for 25 days (in total 32 days of treatment).
89266778|NCT01291732|Experimental|BI 135585 XX|single dose of BI 135585
89266779|NCT01291732|Placebo Comparator|matching placebo|single dose of matching placebo
89266780|NCT03849742|Experimental|Heath services research (Uber rides)|Patients receive Uber rides to and from scheduled radiotherapy appointments for up to 6 months.
89266781|NCT05671432|Experimental|Group A|Group A: CM326, subcutaneous (SC)
89266782|NCT05671432|Experimental|Group B|Group A: CM326, subcutaneous (SC)
89266783|NCT05671432|Placebo Comparator|Group C|Group C: placebo, subcutaneous (SC)
89266784|NCT01291810|Experimental|TNF Kinoid|
89266785|NCT01291810|Placebo Comparator|Placebo|
89266786|NCT03854188|Experimental|Acupuncture treatment|Patients diagnosed with chronic pelvic pain will be offered acupuncture treatment as an adjuvant therapy to standard of care treatment.
89266787|NCT03853720|Experimental|Intervention arm|combined and simultaneous balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
89266788|NCT01187290|No Intervention|neoadjuvant chemotherapy|Chemotherapy Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
89266789|NCT01187290|Experimental|neoadjuvant chemoradiotherapy|Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
89266790|NCT01188304|Experimental|1|
89266791|NCT01188304|Placebo Comparator|2|
88805489|NCT01043393|Experimental|Psoriasis involving >15% of BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of >15% of their body surface area.
88805490|NCT01335061|Other|BeneFIX|
89266792|NCT01188382||Healthy elderly|Healthy elderly 60-82 years; Normal MRI; No psychiatric or neurological disorder and without signs of advanced atherosclerotic disease
89266793|NCT02524444|Active Comparator|Mefloquine|Tabs Mefloquine 250mg 3 doses 4 weeks apart
89266794|NCT02524444|Active Comparator|Sulphadoxine-Pyrimethamine|500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets 4 weeks apart for 3 doses
89266795|NCT01293916|Active Comparator|Double leg spica cast|The current accepted treatment is the double leg spica cast in the treatment of pediatric diaphyseal femur fractures.
89266796|NCT01293916|Experimental|Single leg spica casts|The study group is the single leg spica cast group
89266797|NCT01291966|Experimental|Motivational interview|
89266798|NCT01187602||Women at average risk for ovarian cancer|Women at average risk for ovarian cancer (no first degree relatives with breast or ovarian cancer) undergoing gynecologic evaluation at UVA for non-malignant or routine indications.
89266799|NCT01187602||Women with ovarian cancer|Women with known or suspected ovarian cancer who are undergoing evaluation and/or treatment at UVA Cancer Center
88805491|NCT01087931|Active Comparator|Bupivacaine|This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.
88805492|NCT01087931|Placebo Comparator|Saline|This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.
88805493|NCT03009409|Active Comparator|Ketamine Group|Participants randomized to the ketamine group will receive a 0.25 mg/kg loading dose of intravenous ketamine immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, for approximately 45 minutes, up to a maximum cumulative dose of 100 mg. This dose is in accordance with the guidelines from the recently published Clinical Practice Guidelines for the management of post-operative pain. The attending anesthesiologist will confirm whether the use of ketamine is appropriate for each patient prior to enrolling the patient in the study.
89266800|NCT01187602||Increased risk for ovarian cancer|Women at increased risk of ovarian cancer based on family history, personal history, or genetic factors defined as either BRCA1 or BRCA2 mutations who still retain both fallopian tubes and both ovaries.
89266801|NCT03852238||Cases: patients with hepatocellular carcinoma on non-cirrhotic|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
89266802|NCT03852238||Control: patients without hepatocellular carcinoma|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
89266803|NCT03853408||First Admission|Cholecystectomy during first admission
89266804|NCT03853408||Second Admission|Cholecystectomy during second admission
89266805|NCT01291576|Active Comparator|Rectal/colorectal segmental resection|
89266806|NCT01291576|Active Comparator|Rectal nodule excision|
89266807|NCT03853642||Single-arm trial|Patient receiving blood sampling, spirometry and Feno
89266808|NCT01292044|Experimental|The study population|The study population consists of patients for whom an echo-guided fine-needle aspiration was performed for one or more thyroid nodes, and for whom surgical node excision is required.
89266809|NCT01191346||3T MRI|Patients receiving 3T MRI
89266810|NCT01191424|Experimental|CHF1535 NEXT DPI|Male and female adolescents and adult patients (≥ 12 years old) treated with CHF1535 NEXT DPI
89266811|NCT01191424|Active Comparator|Free combination BDP and FF|Male and female adolescents and adult patients (≥ 12 years old) treated with a free combination of licenced BDP and FF
89266812|NCT04956718|Other|CPT first|"Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.~All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa."
89266813|NCT04956718|Other|CPT+placebo first|"Participant will be told and read about the 'pain medication' (= Placebo NaCl Nasal spray). Thereafter participant will self-administer a nasal spray, which is in fact a placebo nasal spray containing NaCl solution and Cold Pressor Test (CPT) is performed.~All 20 participants will undergo two study visits. The order in which they will receive CPT and CPT plus placebo differs, with participants being randomly split into two groups. 10 participants first CPT + placebo and then CPT, and 10 participants vice versa"
89266814|NCT01187680|Experimental|Spraygel|
89266815|NCT01187680|Active Comparator|Control|
89266816|NCT01291654|Experimental|Paracetamol|Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days
89266817|NCT01291654|Experimental|NSAID|Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr
89266818|NCT03853174|Active Comparator|ET|Active Comparator: ET Endurance training were prformed. Intensity was gradually increased.
89266819|NCT03853174|Other|RT|Resistance training were prformed. Intensity was gradually increased.
89266820|NCT01187758|Experimental|Educational intervention|Multifacet educational intervention that includes workshops, seminars and focus group meetings
89266821|NCT01187758|No Intervention|Control - no intervention|This group did not have any intervention, but their population was screened for carriage of antibiotic resistant bacteria
89266822|NCT03853096|Experimental|Subcutaneous cefazolin arm|"A patient receiving a standard deltopectoral approach will have the planned incision site divided into thirds. This will produce 6 segments. Each segment will be biopsied using a commercially available dermatology punch and sent for colony count prior to local antibiotic infiltration. Cefazolin will be administered to one half of the incision only, into three segments. Following 60 minutes of operative time, the biopsies will be repeated and sent for colony count for comparison.~Cefazolin administered will be 100mg/mL in 3 aliquots for 3 site administrations leading to a total subcutaneous injection of approximately 900mg. There will be a one time administration of the antibiotics in a subcutaneous route."
89266823|NCT05671276|Active Comparator|Standard Antiplatelet Therapy|DAPT (aspirin 100 mg and clopidogrel 75 mg) from 45 days to 6 month-follow-up, then aspirin alone
89266824|NCT05671276|Experimental|Half-Dose NOAC|Long-term half-dose NOAC (rivaroxaban 10 mg after 45 days)
89266825|NCT03848026||Group 1|middle ear fluid viscosity <439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
89266826|NCT03848026||Group 2|middle ear fluid viscosity >439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
89266827|NCT03852160|Experimental|Esketamine + Oral Antidepressants|Participants will receive esketamine as nasal spray (28 milligram [mg] [initial dose for elderly participants 65-74 years of age] on Day 1 and then uptitrated to 56 mg on Day 4, 56 mg [initial dose for adult participants aged 18-64 years and may be used for all age groups throughout the study] or 84 mg [maximum uptitrated esketamine dose]) twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral anti depressants (AD) (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
89266828|NCT03852160|Active Comparator|Placebo + Oral Antidepressants|Participants will receive matching placebo as nasal spray twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral AD (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
89266829|NCT01193998|Active Comparator|Clinician exposed to Model result|
89266830|NCT01193998|Experimental|Clinician blinded to Model result|
88805494|NCT03009409|Placebo Comparator|Control Group|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion.
89266831|NCT03849352|Other|Lifestyle Arm|Can people living with and beyond colorectal cancer make lifestyle changes with the support of health technology
89266832|NCT01294540|Experimental|Experimental: 1|
89266833|NCT01294540|Placebo Comparator|Placebo Comparator: 2|
89266834|NCT01292122|Experimental|VCT-01-treated STSG donor site wound|Application of VCT-01 to STSG donor site wound at Day 0
89266835|NCT01191502||TECNIS MULTIFOCAL (TMF) INTRAOCULAR LENS|
89266836|NCT01191502||CRYSTALENS HD (CHD) INTRAOCULAR LENS|
89266837|NCT01194076|Experimental|5day intensive treatment|
89266838|NCT02524210|Experimental|Arm A|"Period  Dabigatran~Washout period (at least 6 days)~Period  Rabeprazole + Dabigatran~Washout period (at least 6 days)~Period  Omeprazole + Dabigatran"
89266839|NCT02524210|Experimental|Arm B|"Period Rabeprazole + Dabigatran ~Washout period (at least 6 days)~Period  Dabigatran~Washout period (at least 6 days)~Period  Omeprazole + Dabigatran"
89266840|NCT02524210|Experimental|Arm C|"Period  Rabeprazole + Dabigatran~Period  Omeprazole + Dabigatran~Period  Dabigatran"
89266841|NCT01292200|Experimental|watch DVD and small group discussion|Participants will watch the video in a group and discuss the video.
89266842|NCT01292200|Placebo Comparator|watch video only|watch a 22 minutes long video at home by herself.
89266843|NCT03847792|Active Comparator|Group DB/Dexamethasone-Bupivacaine|Patients were received an intra-articular injection of 8mg dexamethasone added to18mL of 0.25% bupivacaine
89266844|NCT03847792|Active Comparator|Group FB /Fentanyl-Bupivacaine|Patients were received an intra-articular injection of 1 ug/kg fentanyl added to 18 mL of 0.25% bupivacaine
89266845|NCT03847792|Placebo Comparator|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2 mL isotonic saline added to 18 mL of 0.25% bupivacaine
89266846|NCT01294618|Experimental|nilotinib + pegylated interferon alpha 2a (PEG-IFN).|
89266847|NCT01188850|Experimental|6mg of DNA/dose|Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0
89266848|NCT01292278||aSAH|consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage
89266849|NCT01292278||control group|no neurological disease but spinal anesthesia
89266850|NCT01194232|Experimental|Sildenafil|15 subjects will receive 8 week course of Sildenafil administered at a dose of 20 mg per dose three times per day.
89266851|NCT01296334|Experimental|morphine low dose|morphine infusion 10 mg over a 210 min period
89266852|NCT01296334|Experimental|morphine high dose|morphine infusion 20 mg over a 210 min period
89266853|NCT01296334|Experimental|buprenorphine low dose|buprenorphine infusion 0.3 mg over a 210 min period
89266854|NCT01296334|Experimental|buprenorphine high dose|buprenorphine infusion 0.6 mg over a 210 min period
89266855|NCT01296334|Placebo Comparator|placebo|placebo (normal saline) infusion 0.6 mg over a 210 min period
89266856|NCT03851770|Other|refractory epilepsy patients|All patients belong to the refractory epilepsy group. Intervention: Characterization of Vagus nerve stimulation: Evoked potentials (EP) are recorded using an EEG/EP digital acquisition system
89266857|NCT03847558||sexual maturation in patient receiving iron chelation|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
89266858|NCT01194310||phaco alone|patients w/ diagnosis of open angle glaucoma underwent phaco alone
89266859|NCT01194310||phaco-ELT|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus ELT
89266860|NCT01194310||phaco-Trabectome|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus Trabectome
89266861|NCT01189006|Experimental|dextromethorphan|Research clinical trial of double-blind, stratified randomized, parallel group, double-centre study
89266862|NCT01294774|Experimental|KRP203 - 1.2 mg|
89266863|NCT01294774|Placebo Comparator|Placebo to KRP203 - 1.2 mg|
89266864|NCT01292356|Experimental|cetuximab|
89266865|NCT01194388||MicroFx™ PGLA Treated Subjects|
89266866|NCT01194544||population undergoing EGD in health examination.|
89266867|NCT01294852|Experimental|immediate bolus surfactant|
89266868|NCT01294852|Experimental|post-resuscitation surfactant|
89266869|NCT03851848|Experimental|Joint mobilization (JM) group|The Maitland mobilization technique will target three main joints of the affected foot in order to facilitate major ankle and foot movements: (1) Talocrural joint Anterior-posterior (AP) mobilization will be performed to enhance ankle dorsiflexion ROM; (2) first metatarsal phalangeal joint (FMTP) AP glide will be performed to facilitate big toe extension ROM; (3) subtalar joint traction will be performed to increase both foot eversion and inversion ROM, and lateral glide will be performed to reinforce inversion ROM.
89266870|NCT03851848|Experimental|Myofascial release (MFR) group|The MFR technique will be performed as a direct trigger point release followed by deep soft tissue release for the calf muscles (gastrocnemius and soleus) and the plantar fascia .
89266871|NCT01292434|Experimental|Lunch in the Bag Intervention|Lunch is in the Bag behavioral intervention: Parents receive a behavioral intervention that includes handouts/newsletters sent to parents from the early care and education (ECE) center, classroom activities and projects, an implementation support calendar, and teacher training.
89266872|NCT01292434|No Intervention|Control|Parents received no specific nutrition education intervention at the ECE center, other than usual practice.
89266873|NCT03847246|Active Comparator|Baraclude® tablets，1.0 mg|
89266874|NCT03847246|Experimental|Entecavir tablets，1.0 mg|
89266875|NCT01292512|Experimental|Intervention group|"A) Professional level. B) Patient level.~Intervention~Professional level:~General Practitioners (GP) receive updated information on bereavement related symptoms, how to identify complicated grief, and the Dual Process Model (DPM) of coping.~GPs receive suggestions on how to provide psycho-educational support for the patient.~GPs are informed about the results of the initial assessment of their patient prognostic screening for complicated grief.~Patient level:~Patients receive updated information on bereavement related symptoms, the DPM of coping and suggestions on when to seek professional help.~Patients are informed of the results of their initial assessment of their prognostic grief screening.~Patients are encouraged to contact their GP if they worry about handling their bereavement reaction."
89266876|NCT01292512|Other|Control group|Treatment as usual (in the Danish health care system).
89266877|NCT05282914|Experimental|UI058|
89266878|NCT05282914|Active Comparator|UIC202004|
89266879|NCT01296490|Experimental|Stress test|The men will run on a treadmill for 10 minutes until exhaustion. Blood will be drawn before, 5 minutes after and an hour after the test.
89266880|NCT01294930||hip fracture|Patients operated for hip fracture, giving informed consent
89266881|NCT01292590|Experimental|High fat meal|
89266882|NCT03849196|Experimental|2L PEG-Asc|2L PEG-Asc for bowel preparation
89266883|NCT03849196|Active Comparator|1L PEG-Asc & 'Bisacodyl 10Mg Suppository|1L PEG-Asc with 'Bisacodyl 10Mg Suppository for bowel preparation
89266884|NCT05282836|Experimental|Intervention|H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in the treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
89266885|NCT05282836|No Intervention|No intervention|Usual care refers to the standard-of-care (including oxygen therapy) recommended by guidelines.
89266886|NCT01292668|Experimental|Group I|Patients apply methyl-5-aminolevulinate hydrochloride (MAL) cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo laser light treatment for 3-5 minutes.
89266887|NCT01292668|Experimental|Group II|Patients apply MAL cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo light emitting diode treatment for 5-10 minutes.
89266888|NCT01189084||Observational immunotherapy follow-up|
89266889|NCT03851692|Active Comparator|60s (group E)|Intravenous cannulation was released either 60 s following loss of lid reflex in group E
89266890|NCT03851692|Active Comparator|90 or 120 s (groupe L)|Intravenous cannulation was released either 90 or 120 s following loss of lid reflex in group L
89266891|NCT01296724|Other|newborn with digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and digestive pathology
89266892|NCT01296724|Other|Newborn without digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and without digestive pathology
89266893|NCT01296802|Placebo Comparator|Placebo|
89266894|NCT01296802|Experimental|Dexfenfluramine|Dexfenfluramine HCL
89266895|NCT01189162|Experimental|NIMV- nasal respiratory support|Infants with RDS will be treateg with nasal intermittent mandatory ventilation
89266896|NCT01189162|Experimental|HFNC- nasal respiratory support with HFNC|Infants with RDS will be treated with nasal respiratory support with high flow nasal canulla
89266897|NCT03851536|Experimental|Transvaginal Ultrasound Guided ET|Transvaginal ultrasound is used to guide ET
89266898|NCT03851536|Experimental|Transabdominal Ultrasound Guided ET|Transabdominal ultrasound is used to guide ET
89266899|NCT01296880||LCM group|Patients who are having lacosamide (LCM) added to their anti-epileptic drug regimen
89266900|NCT01296880||control group|Patients who are NOT having lacosamide (LCM) added to their anti-epileptic drug regimen
89266901|NCT01296958|Experimental|Targeted screening|Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
89266902|NCT01296958|Active Comparator|Education|Community education about Taenia solium prevention.
89266903|NCT01295008||Patients with the classic form|
89266904|NCT01295008||Fabry disease and healthy controls|
89266905|NCT01191580|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy is a brief, manualized therapy that has shown efficacy in treating major depression in several controlled trials including a large trial for depressed HIV-infected individuals and other randomized trials in depressed individuals with other comorbid medical illnesses. Research shows that Interpersonal Psychotherapy improves social skills and functioning. Interpersonal Psychotherapy has shown remarkable flexibility and efficacy across age ranges, cultures, formats, and modes of delivery. We recently obtained promising pilot data in a small open trial on the acceptability and efficacy of individual IPT for depressed breast cancer patients of diverse ethnic background, socioeconomic status, and cancer progression stage.
89266906|NCT01191580|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a brief, manualized form of cognitive-behavioral therapy (CBT) that has been adapted to treat depression in cancer patients, and has shown highly promising results.
89266907|NCT01191580|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy, a relatively unstructured psychotherapy commonly used in clinical practice, focuses on the patient's affect. It builds a strong therapeutic alliance through careful, empathic listening and validating and encouraging toleration of the patient's emotions. It has shown promising results in depressed individuals with cancer and other medical illnesses.
89266908|NCT01295086|Experimental|Her-TEX|
89266909|NCT03847012|Experimental|patients with coronary artery diseases|The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode.
89266910|NCT03851224|Active Comparator|control group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with no graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
89266911|NCT03851224|Active Comparator|study group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with autogenous bone graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
89266912|NCT03851224|Active Comparator|study group 2|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced withxenograft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
89266913|NCT01194700|Experimental|Evohaler|
89266914|NCT01194700|Experimental|Volumatic spacer|
89266915|NCT01194700|Experimental|Aerochamber Plus|
89266916|NCT01194700|Experimental|Synchro-Breathe|
89266917|NCT01189318|Experimental|Seroquel XR|Patients with MDD receives Seroquel XR.
89266918|NCT01189318|No Intervention|healthy control|
89266919|NCT01194778|Placebo Comparator|placebo|The participants of the placebo group will receive daily 1 placebo sachet containing only sucrose
89266920|NCT01194778|Active Comparator|vitamin K1|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K1.
89266921|NCT01194778|Active Comparator|vitamin K2 - 15 µg|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K2
89266922|NCT01194778|Active Comparator|vitamin K2 - 30 µg|The participants of this group will receive daily 1 sachet containing 30 µg vitamin K2
89266923|NCT01194778|Active Comparator|vitamin K2 - 45 µg|The participants of this group will receive daily 1 sachet containing 45 µg vitamin K2.
89266924|NCT01194934|Experimental|Group A|Group A: 2.0 mg/kg NOX-A12 IV every day for 5 days
89266925|NCT01194934|Experimental|Group B|Group B: 4.0 mg/kg NOX-A12 IV every day for 5 days
89266926|NCT01194934|Active Comparator|Group C|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group C: 5 µg/kg filgrastim SC every day for 5 days"
89266927|NCT01194934|Experimental|Group D|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group D: Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days"
89266928|NCT01353118|No Intervention|gastric bypass|Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
89266929|NCT01353118|Active Comparator|Gastric bypass 2|Gastric bypass 2 (Group B):Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved in a gradual manner with particular attention to the avoidance of hypoglycaemia
89266930|NCT01297036|Active Comparator|Reference arm|Treated with Reference (Aricept, 10 mg donepezil tablet)
89266931|NCT01297036|Experimental|Test arm|Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)
89266932|NCT01189552|Active Comparator|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). LETS ACT is based on the belief that the best way to improve mood, remain sober, and to make long-term life changes is by changing and increasing one's activity level. It has been modified to accommodate the needs of a substance using population currently receiving inpatient substance use treatment. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
89266933|NCT01189552|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
89266934|NCT01297114||Participants aged 60-70|Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
89266935|NCT01297114||Participants aged 20-30|Younger participants will not undergo PET scanning that will be studied with other methods.
89266936|NCT01292824|No Intervention|Standard liver transplant care|Liver Transplantation as per Standard of Care
89266937|NCT01292824|Experimental|ITX 5061|Liver Transplantation as per Standard of Care + ITX5061
89266938|NCT01292902|Active Comparator|healthy volunteers|
89266939|NCT01292902|Other|chronic heart failure|
89266940|NCT01195012|Other|wait-list control arm|Participants wait-listed to start the behavioral obesity treatment program (Helping HAND) after time two data collection (7 months after baseline).
89266941|NCT01195012|Experimental|Intervention arm|see intervention description
89266942|NCT03846700|Experimental|aquablation|patients with prostatic volume included between 30 and 120 ml will be treated with water jet (aquablation). patients with prostatic volume > 65 ml will be compared with holep arm and patients with prostatic volume included between 30 and 65 ml will be compared with pvp arm.
89266943|NCT03846700|Active Comparator|holep|patients with prostatic volume > 65 ml will be treated with holmium laser technique (Holep)
89266944|NCT03846700|Active Comparator|pvp|patients with prostatic volume included between 30 and 65 ml will be treated with photoselective vaporization of prostate (pvp).
89266945|NCT01295164|Active Comparator|Group 1|Measurement of aberrations in patients with keratoconus of grade 1
89266946|NCT01295164|Active Comparator|Group 2|patients with keratoconus of grade 2
89266947|NCT01295164|Experimental|Group 3|patients with keratoconus of grade 3
89266948|NCT01295164|Experimental|Group 4|patients with keratoconus of grade 4
89266949|NCT03848806|Experimental|HAT1 topical|HAT1 topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
89266950|NCT03848806|Active Comparator|Calcipotriol|Calcipotriol topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
89266951|NCT03848884|Experimental|Adherence monitoring and education|
89266952|NCT01195168||PCOS cohort|Women with PCOS as diagnosed by the NIH criteria
89266953|NCT01195168||Control cohort|Women without PCOS
89266954|NCT03850990|Experimental|Placebo group|In the first visit, this group will learn about placebo pills from a video and will be placebo pills to take twice a day for 8 weeks. They will be asked to take the pills in conjunction with following the weight-loss protocol.
89266955|NCT03850990|Experimental|No placebo group|In the first visit, this group will learn about placebo pills from a video but will not be given placebo pills. They will follow the weight-loss protocol without placebo pills.
89266956|NCT00867802|Experimental|Mindfulness- Based Stress Reduction: Active Comparator|Mindfulness-Based Stress Reduction program
89266957|NCT01189864||Ciprofloxicin or Vigamox or other.|
89266958|NCT01189864||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
89266959|NCT01189864||Steroid (FML, Pred Forte, Flarex, etc.)|
89266960|NCT01195246|Experimental|HEPLISAV|0.5 mL HEPLISAV
89266961|NCT01195246|Active Comparator|Engerix-B|2.0 mL Engerix-B
89266962|NCT01195246|Active Comparator|Fendrix|0.5 mL Fendrix
89266963|NCT03846856||Ovarian cancer patients|Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis
89266964|NCT03846934||Ultrasonography thoracic|Ultrasonography thoracic
89266965|NCT05671120|Other|Transcutaneous levator recession|
89266966|NCT01191814|Active Comparator|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
89266967|NCT01191814|Active Comparator|Plastic Stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a plastic stent
89266968|NCT03850834|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|
89266969|NCT03850834|Placebo Comparator|Placebo Enteric-coated Tablets|
89266970|NCT01191892|Placebo Comparator|Placebo|Carboplatin, Gemcitabine and Placebo
89266971|NCT01191892|Experimental|vandetanib|Carboplatin, Gemcitabine and vandetanib
89266972|NCT01191970||Epidural recipients|Subjects who received epidural analgesia during labor
89266973|NCT01191970||Non-epidural recipients|Subjects who did not receive epidural analgesia during labor
89266974|NCT01293058|Other|Intravenous|The investigators administered intravenous naloxone for our opioid overdose patients
89266975|NCT01293058|Other|Intranasal|The investigators administered intranasal naloxone for treatment of our patients
89266976|NCT05671042||Patients with Upper excretory tract tumors|Adult patient with Upper excretory tract tumors Neoadjuvant chemotherapy treatment received between 2010 and 2020.
89266977|NCT01195324|Experimental|001|Canagliflozin/Warfarin Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6 followed 14 days later by Treatment B: Tablets oral warfarin 30 mg single dose on Day 1
89266978|NCT01195324|Experimental|002|Canagliflozin/Warfarin Treatment B: Tablets oral warfarin 30 mg single dose on Day 1 followed 14 days later by Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6
89266979|NCT01195402|No Intervention|Control|Subjects do not receive any kind of active intervention.
89266980|NCT01195402|Active Comparator|pulmonary outpatient rehabilitation|Subjects participate in an outpatient pulmonary rehabilitation program
89266981|NCT01192360|Experimental|Cardiac Patients|In addition to the routine clinical MRI, we will conduct the DCE MR perfusion imaging research component. For this, we will measure native pre-contrast T1 and then inject a tight bolus of gadolinium (0.1mmol/kg) while acquiring high temporal resolution T1-weighted 3D contrast dynamics information over the whole thorax while the patient is holding his / her breath. Overall, the research component will prolong the clinical study by approximately 5 minutes.
89266982|NCT01192360|Experimental|Pulmonary Patients|Patients in this group will receive a full cardiac and pulmonary MRI assessment, with the DCE pulmonary perfusion scan added as described above. Overall, the investigation will take approximately 45 minutes
89266983|NCT01190332|Placebo Comparator|conventional technique of ERCP|
89266984|NCT01190332|Active Comparator|Rendezvous technique|
89266985|NCT01190488|Experimental|Intervention - Decision Aid|In addition to usual care, patients assigned to the intervention group will also be asked to view and/or read the EOL-PtDA during their hospitalization. The EOL-PtDA can be utilized anytime in the course of their hospitalization (all hospital rooms at UCH have a DVD player). This could be before, during, or after the palliative care team consultation.
89266986|NCT01190488|Active Comparator|Active comparison|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
89266987|NCT05668390|Experimental|STALORAL® Birch 300 IR|"Escalation Phase:~The escalation phase starts with 10 IR/mL solution the first 5 days (daily increase from 1 to 5 actuations) and switching to 300 IR/mL solution the next 5 days (daily increase from 1 to 5 actuations).~Maintenance Phase:~The maintenance phase takes place with 5 actuations of the active 300 IR/mL solution from Day 11 onwards"
89266988|NCT05668390|Placebo Comparator|Placebo|"Escalation Phase:~The escalation phase starts with 10 IR/mL Placebo solution the first 5 days (daily increase from 1 to 5 actuations) and switching to 300 IR/mL Placebo solution the next 5 days (daily increase from 1 to 5 actuations).~Maintenance Phase:~The maintenance phase takes place with 5 actuations of the active 300 IR/mL Placebo solution from Day 11 onwards"
89266989|NCT01192438|Experimental|Procedure/surgery|
89266990|NCT03846466|Experimental|Part1 Dose 1A|Single administration
89266991|NCT03846466|Placebo Comparator|Part1 Dose 1P|Single administration
89266992|NCT03846466|Experimental|Part1 Dose 2A|Single administration
89266993|NCT03846466|Placebo Comparator|Part1 Dose 2P|Single administration
89266994|NCT03846466|Experimental|Part1 Dose 3A|Single administration
89266995|NCT03846466|Placebo Comparator|Part1 Dose 3P|Single administration
89266996|NCT03846466|Experimental|Part1 Dose 4A|Single administration
89266997|NCT03846466|Placebo Comparator|Part1 Dose 4P|Single administration
89266998|NCT03846466|Experimental|Part1 Dose 5A|Single administration
89266999|NCT03846466|Placebo Comparator|Part1 Dose 5P|Single administration
89267000|NCT03846466|Experimental|Part1 Dose 6A|Single administration
89267001|NCT03846466|Placebo Comparator|Part1 Dose 6P|Single administration
89267002|NCT03846466|Experimental|Part1 Dose 7A|Single administration
89267003|NCT03846466|Placebo Comparator|Part1 Dose 7P|Single administration
89267004|NCT03846466|Experimental|Part2 Dose 1A|Multiple administration
89267005|NCT03846466|Placebo Comparator|Part2 Dose 1P|Multiple administration
89267006|NCT03846466|Experimental|Part2 Dose 2A|Multiple administration
89267007|NCT03846466|Placebo Comparator|Part2 Dose 2P|Multiple administration
89267008|NCT01293136||intravenous opioids|
89267009|NCT01293136||femoral nerve block|
89267010|NCT01195480|Experimental|Prophylaxis arm|Patients who have relapsed in the bone marrow after previous myeloablative HSCT and achieve remission after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells after a second HSCT with reduced intensity conditioning.
89267011|NCT01195480|Experimental|Pre-emptive arm|In this arm, patients identified at high (> 50%) risk of relapse will be eligible for generation of donor-derived EBV CTL immediately prior to HSCT. These patients will be monitored for evidence of MRD in regular bone marrow aspirates for the first year post-HSCT. MRD positivity post-HSCT is highly predictive of subsequent relapse. In those patients who become MRD+ in the marrow at a level of minimum 5 x 10-4, cryopreserved CTL that have been transduced with a retroviral vector carrying the CD19-zeta transgene will be thawed and administered to the patient pre-emptively.
89267012|NCT01295398|Other|conventional jet-nebulizer|(particles diameter of 4-5 µm)
89267013|NCT01295398|Experimental|a jet-nebulizer adapted for infants|(particles diameter of 2-2.5 µm),
89267014|NCT01295398|Experimental|a mesh-nebulizer adapted for infants|(particles diameter of 2-2.5 µm).
89267015|NCT01195558||Blind with sleep problems|Blind individuals with no light perception and with sleep-related problems who may suffer from Non-24
89267016|NCT01195714|Experimental|Ofatumumab|
89267017|NCT01293370||vocational rehabilitation|Admitted and discharged psychiatric patients receiving vocational rehabilitation
89267018|NCT01195792|Experimental|2 mg GSK1521498|Approximately 20 subjects will be randomised to receive 2 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
89267019|NCT01195792|Experimental|5 mg GSK1521498|Approximately 20 subjects will be randomised to receive 5 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
89267020|NCT01195792|Placebo Comparator|Placebo|Approximately 20 subjects will be randomised to receive matching placebo.
89267021|NCT01295554||Peripheral arterial disease|Peripheral arterial disease
89267022|NCT05668468|Placebo Comparator|Control Group|Daily cellulose capsule
89267023|NCT05668468|Experimental|Experimental Group|Daily Bifidobacterium adolescentis IVS-1,capsule
89267024|NCT01192594|Experimental|MAPP Trained Case Managers|Consumers assigned to case managers who receive training in the Milestones of Adjustment Post-Psychosis Recovery Model
89267025|NCT01192594|Active Comparator|Non-MAPP trained case managers|Consumers of case managers not trained in the Milestones of Adjustment Post-Psychosis Recovery Model
89267026|NCT03848494||Gastroesophageal reflux disease|Patients submitted to primary minimally invasive surgery for gastroesophageal reflux disease or hiatus hernia
89267027|NCT01582750||Local advanced rectal cancer EUS|
89267028|NCT03850132|Experimental|FAM-SOTC-PL|Grief responses, levels of vulnerability, measured using the Adult Attitude to Grief scale (AAG), a self-administered questionnaire
89267029|NCT01190722|Experimental|etoricoxib|active study drug, coxib
89267030|NCT01190722|Active Comparator|diclofenac|active traditional NSAID control
89267031|NCT01192672|Experimental|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
89267032|NCT01192672|Active Comparator|Control Writing|The participants were instructed to write for 30-minute intervals for 4 consecutive days about all of the actions they performed that day for a 24 hour period. The subjects were asked not to write about their feelings or thoughts related to these actions.
89267033|NCT01192672|No Intervention|Usual Care|Subjects in this group did not receive an intervention. They filled out measures at baseline, 1 month, and 3 month follow-up time periods.
89267034|NCT01196260|Experimental|5-fluorouracil plus oxaliplatin|patients will be randomized assigned to receive 5-fluorouracil plus oxaliplatin
89267035|NCT01196338|Active Comparator|Non-weightbearing no ROM|"Patients will be placed in a back slab post-op and will remain non-weight bearing with crutches with no range of motion for a total of 6 weeks.~After 6 weeks post-op, they will be placed in a boot orthosis and permitted to weight-bear as tolerated."
89267036|NCT01196338|Experimental|Early weight-bearing and ROM|"Patients will be placed in a back slab post-operatively. At 2 weeks post op they will have the back slab removed and placed in a boot orthosis. At this time they will be permitted to weight-bear as tolerated and perform limited ankle range of motion exercises.~After 6 weeks post op they will start to wean from the boot orthosis."
89267037|NCT03850210|Experimental|Short Splint|
89267038|NCT03850210|Active Comparator|Traditional, Long Splint|
89267039|NCT01293526|Experimental|Experimental 1|Patients who respond will have their leads placed based on study measurements.
89267040|NCT01293526|Experimental|Control|Leads will be placed using standard procedures.
89267041|NCT01293526|Experimental|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
89267042|NCT01192984|Experimental|KW-0761|
89267043|NCT01196728|Experimental|CM3.1-AC100 dose A|Compound CM3.1-AC100 s.c.
89267044|NCT01196728|Experimental|CM3.1-AC100 dose B|Compound CM3.1-AC100 s.c.
89267045|NCT01196728|Experimental|CM3.1-AC100 dose C|Compound CM3.1-AC100 s.c.
89267046|NCT01196728|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
89267047|NCT01193062|Experimental|Cohort 1|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
89267048|NCT01193062|Experimental|Cohort 2|Subjects will be receive single oral doses of PF-04995274 not exceeding 15mg or a placebo
89267049|NCT01196494|Experimental|intraoperative colon lavage|
89267050|NCT01196494|Active Comparator|stent and deferred surgery|
89267051|NCT01196572|Experimental|Laser IU|Urethral stricture incised by Holmium laser
89267052|NCT01196572|Active Comparator|Cold knife IU|Urethral stricture incised by knife
89267053|NCT01196650|Active Comparator|1|IN 10 003 formulation A
89267054|NCT01196650|Active Comparator|2|IN 10 003 formulation B
89267055|NCT01196650|Placebo Comparator|3|Placebo capsules
89290504|NCT03932526|Experimental|Vinorelbine + Apatinib group|92 enrolled patients will be assigned to receive oral patatinib mesylate in combination with vinorelbine until disease progression or other criteria for administration termination.
89267056|NCT03846154|Experimental|Intervention group|"Children and adolescents in the intervention group received:~A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~Access to schools and school material~Family visits~Their parents received training regarding agriculture and microcredit projects, and financial assistance~FORNET if affected by trauma-related symptoms, and/or acting aggressive~If needed medical assistance is provided~If needed legal assistance is provided"
89267057|NCT03846154|No Intervention|Control group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
89267058|NCT01193296|Experimental|Vildagliptin|
89267059|NCT01193296|Active Comparator|Sitagliptin|
89267060|NCT03845998|Experimental|three-finger method|"The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers. That is what we call the three-finger method.~The intervention is to use the three-finger method."
89267061|NCT03845998|Active Comparator|weight-related method|"The size of the laryngeal mask airway for each patient was determined by the manufacturer's weight-related guidelines. That is what we call the weight-related method.~The intervention is to use the weight-related method."
89267062|NCT01193374|Experimental|Parent/child tailored mailed materials|Family provided newsletters tailored to issues and readiness to change. Family receives educational nutrition DVD, pedometers for family activities and child nutrition/physical activity games
89267063|NCT01193374|Active Comparator|Basic information at single time|Family provided with high quality booklet from American Dietetic Association providing the same information that intervention arm received but not tailored.
89267064|NCT04888156||GAT IOP below 15 mmHg|Glaucoma patients with an IOP measured with GAT below 15 mmHg prior performance of self-tonometry with iCare Home
89267065|NCT04888156||GAT IOP equal or above 15 mmHg|Glaucoma patients with an IOP measured with GAT equal or above 15 mmHg prior performance of self-tonometry with iCare Home
89267066|NCT01196884||Asymptomatic ITP patients|
89267067|NCT01196884||ITP patients treated with Rituximab|
89267068|NCT01196884||ITP patients treated with steroids|
89267069|NCT01196962|Experimental|Internal jugular vein|
89267070|NCT01197040|Experimental|B-Experimental|Experimental
89267071|NCT01197040|Active Comparator|A-Active Comparator|Active Comparator
89267072|NCT05387824|Active Comparator|Group 1: Bladder Training - Control group|BT, consisting of four stages, won't contain any PFMT programs in all groups. In these stages, including urgency supression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women will be encouraged to pause/ stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
89267073|NCT05387824|Experimental|Group 2: Bladder Training + TTNS|Two self-adhesive surface electrodes will be positioned according to the protocol which previously explained, with the negative electrode 2 cm behind the medial malleolus and positive electrode 10 cm proximal. Correct positioning wil be determined by noting a hallux reaction (plantar flexion of great toe or fanning of all toes). The stimulation protocol will be delivered at fixed 20 Hz and pulse width 200 ms in continous mode in accordance with the PTNS stimulation protocol. The intensity of the stimulation current (range 0-50 mA) will be determined once correct positioning are established, according to the comfort level of the person. TTNS sessions will be performed twice a week for 6 weeks. Every session will be lasted 30 min. Treatment will consist of 12 sessions of stimulation.
89267074|NCT05387824|Experimental|Group 3: Bladder Training + MStim|Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is in serted by this magnetic field, an eddy current flow is generated. This eddy current stimulates nerve or muscle of the pelvic floor. To apply MS, the device will be set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients will be interviewed so that they receive the stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
89267075|NCT05436340|Experimental|EHepIcu|
89267076|NCT05436340|No Intervention|Control Grubs|
89267077|NCT03848338|Other|Pilot Group|Intra and Post-operative Electrocochleography
89267078|NCT01193452|Experimental|S-1/LV|S-1 combined with Leucovorin
89267079|NCT01193452|Active Comparator|sLV5FU2|5-FU/LV infusion
89267080|NCT05670886|Experimental|uterine artery ligation + carbetocin|Group (A) , study group (N=55) : patients with multiple pregnancy undergoing cesarean section underwent bilateral uterine artery ligation and received carbetocin.
89267081|NCT05670886|Active Comparator|carbetocin only|Group (B ) , control group (N=55) : patients with twin pregnancy undergoing cesarean section received carbetocin only.
89267082|NCT03845608|Experimental|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity
89267083|NCT03845608|Other|Intraperitoneal Hydrocortisone|Drug Injection: 100mg of Hydrocortisone will be injected In the peritoneum
89267084|NCT03845608|No Intervention|control group|In the controls, carbon dioxide will be removed by the traditional passive deflation of abdominal cavity.
89267085|NCT01197118|Active Comparator|2|chemotherapy alone following radical resection
89267086|NCT01197118|Experimental|1|sequence chemoradiotherapy following radical resection
89267087|NCT03845764||Rapid on-site evaluation (ROSE)|Evaluation, made by a pulmonologist, a pathologist and a molecular pathologist, of the tumor burden in ROSE slides produced from endoscopic procedures aimed at sampling intrathoracic lymphadenopathy and pulmonary nodules
89267088|NCT01197196|Experimental|Behavioral weight loss|
89267089|NCT01197196|Active Comparator|Migraine Education|
89267090|NCT03848572|No Intervention|Usual care|Patients will enter standard 12-month clinical follow-up
89267091|NCT03848572|Experimental|Re-Score strategy|Patients will enter a novel strategy of 12-month follow with repetitive assessment of PRECISE-DAPT score at 3-month intervals
89267092|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 90 mg|
89267093|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 135 mg|
89267094|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 90 mg|
89267095|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 135 mg|
89267096|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 200 mg|
89267097|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 135 mg|
89267098|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 200 mg|
89267099|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
89267100|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
89267101|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
89267102|NCT05416450|Active Comparator|Antimuscarinic Naive (AM-N)|None of the women had previously taken anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) in this group.
89267103|NCT05416450|Active Comparator|Antimuscarinic Refractory (AM-R)|Women with idiopathic OAB refractory to anti-muscarinic agents and oral ß3 adrenoreceptor agonist (mirabegron) when 2 or more were administered for at least 6 weeks each and failure was due to lack of efficacy with or without side effects were included in this group.
89267104|NCT03845530|Active Comparator|Hemodialysis group|Blood sample taken and sent to laboratory for analysis
89267105|NCT03845530|Active Comparator|Peritoneal dialysis|Blood sample taken and sent to laboratory for analysis
89267106|NCT03844594|Experimental|Eptifibatide Drug: Eptifibatide Injection|
89267107|NCT03848650|Experimental|Opsens Medical OptoWire|Subjects who will have or recently had FFR using the Opsens Medical OptoWire Deux FFR system.
89267108|NCT03848182|Experimental|Gemcitabine with TT vaccine booster|Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT
89267109|NCT03845920|Other|tDCS sham + placebo|tDCS= transcranial direct current stimulation drugs= placebo (cellulose [2 grams])
89267110|NCT03845920|Experimental|tDCS sham + tyrosine|tDCS= transcranial direct current stimulation drugs= tyrosine (2 grams)
89267111|NCT03845920|Experimental|tDCS anodal + placebo|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= placebo (cellulose [2 grams])
89267112|NCT03845920|Experimental|tDCS anodal +tyrosine|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= tyrosine (2 grams)
89267113|NCT01197274||Mite-sensitized person|
89267114|NCT00146328|Experimental|Group 1|Patients With Varying Degrees of Tipranavir Treatment Experience
89267115|NCT00146328|Experimental|Group 2|Highly Tipranavir Treatment Experienced Patients
89267116|NCT00146328|Experimental|Group 3|Tipranavir Treatment Naive Patients
89267117|NCT01197352|Experimental|Text message queries with feedback|Weekly prompted queries about drinking behavior with personalized feedback.
89267118|NCT01197352|Active Comparator|Text message queries|Weekly prompted queries about drinking behavior
89267119|NCT01197352|No Intervention|Control|Weekly text reminders to complete final (12 week) instruments
89267120|NCT04918030|Active Comparator|In-hospital staged PCI|Patients randomized to in-hospital staged PCI will have treated during the index procedure (7±3 days), after revascularization of the culprit lesion, all significant non-culprit coronary lesions.
89267121|NCT04918030|Experimental|Out-hospital staged PCI|Patients randomized to out-hospital staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized in 30±15 days for complete revascularization of all significant non-culprit coronary lesions.
89267122|NCT04916938|Experimental|Interactive Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
89267123|NCT04916938|Active Comparator|Treatment as usual|Mother child psychotherapeutic sessions without video feed back.
89267124|NCT01295788|Experimental|Simultaneous RT-CGM and Pump Initiation|The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
89267125|NCT01295788|Active Comparator|Delayed RT-CGM Initiation|The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
89267126|NCT01295866||nasal nitric oxide, atypy status|
89267127|NCT03848104||bone and joint infection treated with cefoxitin|patients having had a bone or joint infection treated by cefoxitin in combination. Cefoxitin has been administered by continuous way, at home. A serum dosage of cefoxitin has been systematically achieved at equilibrium.
89267128|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with pacing
89267129|NCT03844516|Sham Comparator|Peak oxygen uptake test without pacing|Peak VO2 test without pacing
89267130|NCT03844126|Experimental|Patients attending the classes|The patients attending the transition classes will receive a survey to assess transition preparedness before and after attending the class.
89267131|NCT03844204|Experimental|Servo-controlled system|The temperature probe of the servo-controlled system will be positioned on the patient's abdomen with an adhesive tape. The body temperature will be set at 37°C.
89267132|NCT03844204|Active Comparator|No servo-controlled system|The temperature of the infant warmer will be manually set at maximum of power output.
89267133|NCT05670808|Experimental|Epinephrine 1:200,000|In this group participants will receive the epinephrine concentration of 1:200,000 in normal saline
89267134|NCT05670808|Experimental|Epinephrine 1:400,000|In this group participants will receive the epinephrine concentration of 1:400,000 in normal saline
89267135|NCT05670808|Placebo Comparator|Placebo|In this group participants will receive only 10 ml of normal saline (control group)
89267136|NCT01197664|Experimental|Arm I (paricalcitol and chemoradiotherapy)|Patients receive paricalcitol PO daily. Patients also receive standard care chemoradiotherapy with fluorouracil PO.
89267137|NCT01197664|Active Comparator|Arm II (chemoradiotherapy)|Patients receive standard care chemoradiotherapy as in Arm I.
89267138|NCT01199458|Active Comparator|opioid|Preoxygenation for 5 min. Injection of opioid (alfentanil 20 mikrogr/kg iv) after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
89267139|NCT01199458|Placebo Comparator|placebo|Preoxygenation for 5 min. Injection of saline iv. after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
89267140|NCT01199536||1|patients with Helicobacter-positive duodenal ulcer
89267141|NCT03733444|Experimental|GLPG1690, 600 milligrams (mg)|Participants received GLPG1690 (ziritaxestat) 600 mg as film-coated tablet orally, once daily (mean treatment duration was 332.9 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
89267142|NCT03733444|Experimental|GLPG1690, 200 mg|Participants received GLPG1690 (ziritaxestat) 200 mg as film-coated tablet orally, once daily (mean treatment duration was 336.9 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
89267143|NCT03733444|Experimental|Placebo|Participants received GLPG1690 (ziritaxestat) matching placebo tablets orally, once daily (mean treatment duration was 346.2 days). Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
89267144|NCT01199614|Experimental|open-label PTH(1-84)|open-label PTH(1-84) / variable dosing: 25mcg every other day, 25mcg every day, 50mcg every day, 75mcg every day, 100mcg every day
89267145|NCT01296100|Experimental|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
89267146|NCT01296100|Experimental|Lifestyle counseling (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
89267147|NCT01197820|Experimental|Arm 1|30 patients with liver tumour and 15 patients with kidney tumour will be enrolled.
89267148|NCT01586104|Experimental|Treatment (IMRT)|Patients undergo cardiac-sparing whole lung IMRT.
89267149|NCT04871854|Experimental|Svere infected Covid-19 control|Arm one confirmed sever COVID 19 infection admitted to ICU including with or without breast cancer patients comorbidity receive traditional therapy
89267150|NCT04871854|Active Comparator|sever infected Covid -19 pateints study|Arm two patients with confirmed sever COVID 19 infection admitted to ICU with or without breast cancer patients comorbidity tocilizumab
89267151|NCT01588522|Experimental|dose-escalation of compound 31543|compound 31543 Calcitriol, Topical application, 0.25 mL to be applied to each of the four quadrants of the scalp twice daily, morning and night with 10-14 hours between applications
89267152|NCT04834336|Experimental|Physical training plus inspiratory muscle training|"Inspiratory Muscle Training (IMT) will be implemented by using the Power Breathe® device. IMT training will begin with mild to moderate intensity of maximal inspiratory pressure. It will be performed 6 to 10 breaths, 4 sets, and twice daily during the hospitalization when as soon as hemodynamic stability is provided.~Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided."
89267153|NCT04834336|Active Comparator|Physical training|Physical Training will consist of each functional domain (balance, mobility, strength, and endurance) according to patients' functional levels. These will include static and dynamic balance training, mobility training, functional strength training focused on lower extremities, and endurance training as sustained walking. A daily 30 min session during the hospitalization will be performed with one-on-one supervision when as soon as hemodynamic stability is provided.
89267154|NCT03845686||Subacute Stroke Sample|Participants with first-ever left-brain stroke, < 4 weeks post stroke, age >18 years, right-handed, fluent and literate in English prior to stroke, no prior neurological disorders or clinical stroke event, <4 weeks post-stroke; able to undergo an MRI and complete study tasks, and presence of reading deficits.
89267155|NCT03845686||Chronic Stroke Sample|The same group of participants examined in the chronic post-stroke period (>3 months post-stroke)
89267156|NCT01193764|Experimental|cocoa|unsweetened 100% cocoa (Ghirardelli)
89267157|NCT01193764|Placebo Comparator|placebo|hydrolyzed gelatin powder (Gelita)
89267158|NCT04793620|Experimental|TQL1055|TQL1055 + acellular pertussis vaccine
89267159|NCT04793620|Active Comparator|Acellular pertussis vaccine|Acellular pertussis vaccine
89267160|NCT01296256|Experimental|Bendamustine-EAM|
89267161|NCT01197976|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
89267162|NCT01197976|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
89267163|NCT04781062|Experimental|Breast Cancer Stage T1 Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.~If bioptically confirmed T1 breast cancer, patients will undergo a second peripheral blood and urine collection after primary breast cancer surgery."
89267164|NCT04781062|Active Comparator|Benign Breast Lesion Group|"Women with radiologically identified lesions, BIRADS-3/4/5, smaller than 2 cm by radiological assessment (i.e., radiological T1), will be enrolled and invited to donate peripheral blood samples and urine samples at baseline. Radiological images as well as demographic and anatomopathological data will be collected.~If bioptically confirmed benign lesion, no other samples will be collected."
89267165|NCT03731182|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.
88805495|NCT00176930|Experimental|PBSC: No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
89267166|NCT03731182|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1.
89267167|NCT05339308|Experimental|Experimental|Magnesium oil application
89267168|NCT05339308|Placebo Comparator|Control|Natural mineral-free oil application
89267169|NCT03730012|Experimental|Gilteritinib 120 mg + Atezolizumab 420 mg|Participants received 120 milligrams (mg) giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 420 mg adminstered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 535 days for gilteritinib and 112 days for atezolizumab).
89267170|NCT03730012|Experimental|Gilteritinib 120 mg + Atezolizumab 840 mg|Participants received 120 mg giltertinib (3 tablets of 40 mg) orally, once a day in continuous 28-day cycles in combination with atezolizumab 840 mg administered by intravenous infusion (over 60 minutes) once every 2 weeks of 28-day cycle until the participant no longer received clinical benefit from therapy, unacceptable toxicity occurred or the participant met a treatment discontinuation criterion (Maximum treatment duration was 126 days for gilteritinib and 70 days for atezolizumab).
89267171|NCT03728140|Experimental|Self-spent Culture Medium|Changing embryo transfer solution with self-spent culture medium
89267172|NCT03728140|No Intervention|New Culture Medium|embryo transfer with new culture medium in IVF-ET
89267173|NCT03842332|Experimental|Resilience Training|This group will participate in the 12 week Life Skills and Resilience Program that includes vocational skills and adult skills important for an adult in society. Participants will also receive standard case management plus resiliency-focused support to encourage family and young adult interaction with professionals and peers. Case managers will then utilize a resiliency framework for their interaction with the participant.
89267174|NCT03842332|No Intervention|Standard Care|This group will receive case management referral to community training programs when requested by family, or need (as identified by case worker). Standard case management includes intake includes housing counseling, case management with mental health and behavioral services, and referral to day programs as needed and identified by case management
89267175|NCT05288842||Group 1: Controls|
89267176|NCT05288842||Group 2: Alzheimer's Disease|
89267177|NCT05288842||Group 3: Frontotemporal Dementia|
89267178|NCT03844360|Experimental|Antineoplastic Drugs and Anti-infective Drugs|Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
89267179|NCT01198054|Experimental|Lenalidomine|Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)
89267180|NCT01199770|Experimental|experimental pasta B, small|small portion experimental pasta B
89267181|NCT01199770|Experimental|experimental pasta C, small portion|small portion experimental pasta C
89267182|NCT01199770|Placebo Comparator|Control pasta, small|small portion Control pasta
89267183|NCT01199770|Other|No Load|Only water
89267184|NCT01199770|Active Comparator|Control pasta, medium|medium portion Control pasta
89267185|NCT01199770|Experimental|experimental pasta B, medium portion|medium portion experimental pasta B
89267186|NCT01199770|Experimental|experimental pasta C, medium portion|medium portion experimental pasta B
89267187|NCT05273008||Active hockey players|Observational study on 180 Hockey players
89267188|NCT05266300||Retrospective|Historic group. Patients treated in the historic control group did not receive DPYD-genotype before treatment with fluorouracil, capecitabine, tegafur. They received standard start doses of 5-FU, capecitabine, tegafur.
89267189|NCT05266300||Prospective|"Participants enrolled in the prospective group will give a blood sample for immediate DPYD genotyping. Once the results from these tests are in, the treating oncologist have immediate access to the participant's genetic test results and can make dosing decisions/changes to the participant's chemotherapy prescription. The recommended starting doses for 5-FU, capecitabine, tegafur are.~No DPYD-gene variant = normal starting dose (100%)~1 DPYD-gene variant (heterozygous) = Reduced starting dose (50%) Homozygous for 1 DPYD variant or compound heterozygous (>1 variants) = Treatment with 5-FU, capecitabine, tegafur is not recommended ."
89267190|NCT03844984|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
89267191|NCT03844984|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
89267192|NCT03842176||Neoadjuvant chemotherapy|CTC of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
89267193|NCT03842176||Surgery|CTC of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
89267194|NCT03842020|Experimental|Amiodarone dosage|Blood pharmacokinetics samples
89267195|NCT03843658||Rheumatoid Arthritis|Clinician diagnosed rheumatoid arthritis
89267196|NCT03843658||Spondyloarthropathy|Ankylosing spondylitis and psoriatic arthritis
89267197|NCT03843658||Crystalline arthritis|Gout and Pseudo gout
89267198|NCT03843658||Connective Tissue Disease|Lupus, myositis, scleroderma, and sjogren's
89267199|NCT03843658||Non-Inflammatory arthritis|E.g. Osteoarthritis and Fibromyalgia
89267200|NCT03843814|Experimental|APT MRI|"Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.~Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.~An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.~Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment."
89267201|NCT01200004|Experimental|Azacitidine + Lenalidomide|Azacitidine 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle. Lenalidomide starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
89267202|NCT01200004|Experimental|Azacitidine + Lenalidomide + Grifola Frondosa|Once Lenalidomide MTD identified in combination with azacitidine, Grifola frondosa added. Cycle 1, azacitidine on day 1, lenalidomide on day 2 and Grifola frondosa on day 3. Azacitidine daily for 5 days every 28 days while lenalidomide and Grifola frondosa on days 1-21 of subsequent cycles.
89267203|NCT01200004|Experimental|Expansion Group A|Azacitidine + Lenalidomide MTD, then 2 weeks later Grifola frondosa
89267204|NCT01200004|Experimental|Expansion Group B|Azacitidine + Grifola Frondosa, then 2 weeks later Lenalidomide
89267205|NCT01198210|Placebo Comparator|saline|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
89267206|NCT01198210|Active Comparator|ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
89267207|NCT01198210|Active Comparator|dexamethasone|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
89267208|NCT01198210|Active Comparator|dexamethasone-ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
89267209|NCT03843736|No Intervention|Health control group|Participants are healthy women and there are no interventions.
89267210|NCT03843736|Experimental|Lifestyle interventions group|Participants are PCOS patients and only will be given lifestyle interventions.
89267211|NCT03843736|Experimental|Probiotic Agent group|Participants are PCOS patients and will be given lifestyle interventions + Probiotic Agent interventions.
89267212|NCT03843736|Experimental|Oral contraceptive group|Participants are PCOS patients and will be given lifestyle intervention + Oral contraceptive interventions.
89267213|NCT05282680||Type 2 diabetes|Subjects with a diagnosis of type 2 diabetes
89267214|NCT05282680||Type 1 diabetes|Subjects with a diagnosis of type 1 diabetes
89267215|NCT05282680||Diabetic kidney disease|Subjects with diabetic kidney disease (presence of albuminuria +/- eGFR<=60m/kg/m2) or history or presence of end stage renal disease
89267216|NCT01202266|Experimental|5 mg PF-05161704 or Placebo|
89267217|NCT01202266|Experimental|15 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
89267218|NCT01202266|Experimental|50 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
89267219|NCT01202266|Experimental|150 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
89267220|NCT01202266|Experimental|xx mg PF-05161704 or Placebo|Planned dose and dosing regimen will be determined based on emerging PK and safety data.
89267221|NCT01202266|Experimental|xxx mg PF-05161704 or Placebo|Dose will be determined based on data from previous 5 arms.
89267222|NCT01202266|Experimental|yy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 6 arms
89267223|NCT01202266|Experimental|yyy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 7 arms.
89267224|NCT03841630|Experimental|LY3437943|Escalating doses of LY3437943 administered as an injection under the skin in healthy participants
89267225|NCT03841630|Placebo Comparator|Placebo|Matching placebo administered as an injection under the skin in healthy participants
89267226|NCT05668234||Parents|Parent having carried out and completed parent-child psychotherapy with a child in CHU Minjoz (child under 5 years old).
89267227|NCT04088578|Experimental|Vagus nerve stimulation (VNS)|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. VNS will be delivered when a minimum level of accuracy has been achieved.
89267228|NCT04088578|Sham Comparator|Sham stimulation|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. Sham stimulation will be delivered when a minimum level of accuracy has been achieved.
89267229|NCT01198288|Active Comparator|Standard Care|"Drugs for COPD (as prescribed), oxygen therapy if needed*, check-up by the general practitioner and/or respirologist as usual.~Educational leaflet regarding optimization of oxygen therapy and drugs; Benefits of physical activity and proposal of a programme of exercise training; Energy conservation techniques; Nutritional counselling; Activity of daily Living (ADL) diary; Prevention and management of acute exacerbation~Monthly phone call with the aim of verifying:~the patients' clinical conditions;~the patient's adherence to the pharmacological treatments prescribed~the patient's compliance in filling out the clinical diary and the ADL diary"
89267230|NCT01198288|Experimental|domiciliary rehabilitation|"Same as the standard care group plus 10 (ten) home-based visits supervised by a specifically trained respiratory therapist (education+exercise training) Autonomous home-based programme: The patients will be given instructions and training in order to continue the exercise training programme on the days the respiratory therapist is not visiting them.~Counselling addressed at the outdoor activities."
89267231|NCT03841942|Other|clinically-based spacing|All patients (as there are free from symptoms) after inclusion will have a spacing of their infliximab infusion interval which will be maintained until the end of the study.
89290505|NCT01127724|Experimental|group 1- 1000 mcg|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months
89267232|NCT03841942|Other|Trough level-based spacing|Only patients with a baseline infliximab trough level ≥ 7 ug/ml will have a spacing of their infliximab infusion interval which will be maintained until the end of the study. Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
89267233|NCT01200316|Experimental|Standard of Care Group|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
89267234|NCT01200316|Experimental|Rocking Motion Group|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
89267235|NCT01200472|Experimental|Apremilast capsules|Apremilast in 10 mg capsules
89267236|NCT01200472|Placebo Comparator|Placebo|
89267237|NCT01200550||1|
89267238|NCT01200628||Road traffic accident victims|Cohort of patients hospitalized in surgical department after a motor vehicle accident less than 2 weeks
89267239|NCT04638790|Experimental|Early favorable HL|HL without adverse prognostic factors
89267240|NCT04638790|Experimental|Early unfavorable HL|Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, age less than 50 years)
89267241|NCT04638790|Experimental|Advanced stages HL|(age less than 50 years)
89267242|NCT05212402|Experimental|Test Product|28 participants will be given the test product (TP)
89267243|NCT05212402|Placebo Comparator|Placebo|28 participants will be given the placebo product.
89267244|NCT04606498||1- Retrospective|Retrospective Seraph® 100 - this group will be composed of subjects that were treated with Seraph® 100 after the date of the EUA approval (17 April 2020), but before the date that the study is approved at the study site. A waiver of informed consent will be requested from the Institutional Review Board (IRB) to allow the collection of these retrospective data
89267245|NCT04606498||2 - Prospective|Prospective Seraph® 100 - To identify prospective Seraph® 100 patients, the individual site investigators will review currently admitted ICU patients for inclusion criteria and exclusion criteria. The study team will then ask the physician caring for the patient to contact the study team should the patient require therapy with Seraph® 100. Additionally, the study team will review the medical records of admitted patients to see if they have recently been started on Seraph. Patients found to meet eligibility will be offered the opportunity to consent and participate in the study. Note that patients that were started on Seraph® 100 before the date of approval but are still admitted, will not be eligible to give biospecimens.
89267246|NCT04606498||3 - Historical Control|The historical control group will be a sample of convenience, composed of patients admitted to the ICU at participating sites with severe COVID-19 infection, meeting the EUA treatment criteria, but not treated with Seraph® 100 up to the time the PURIFY-OBS protocol is approved at the site. A waiver of informed consent will be requested from the IRB to allow the collection of these retrospective data
89267247|NCT04593082||Pediatric MS Subjects|Subjects with pediatric MS will undergo fasting lab work, non-contrasted MRI, DEXA scan, and surveys.
89267248|NCT04593082||Healthy controls|Non-MS pediatric control subjects who will undergo fasting lab work, DEXA scan, and surveys for comparison to control group.
89267249|NCT05282602|Experimental|Wii Fit Based Exercises|Group A will receive Wii fit Based Exercises
89267250|NCT05282602|Experimental|Proprioceptive Training|Group B will receive proprioceptive training
89267251|NCT01200706|Active Comparator|Amoxicillin given twice a day|
89267252|NCT01200706|Active Comparator|Amoxicillin given three times a day|
89267253|NCT01200784|Experimental|250 mg/d modified release Nicotinamide|
89267254|NCT01200784|Experimental|500 mg/d modified release Nicotinamide|
89267255|NCT01200784|Experimental|750 mg/d modified release Nicotinamide|
89267256|NCT01200784|Experimental|1000 mg/d modified release Nicotinamide|
89267257|NCT01200784|Active Comparator|1000 mg/d immidiate release Nicotinamide|
89267258|NCT01200862|Experimental|BGS649 (Part 1)|BGS649 1mg and 0.1mg in hard gelatin capsules. In part 1 there was individualised dosing to titrate the subject's testosterone into the normal range. If the dose was lower than 0.1mg then specific instructions for dilution of an oral solution of BGS649 were provided.
89267259|NCT01200862|Placebo Comparator|Placebo to BGS649 (Part 2)|Matching placebo to BGS649 (0.3 and 0.1mg). 0.3mg placebo capsule given on Day 1 and 0.1mg placebo capsule on other treatment visits (week 1 to 11).
89267260|NCT01200862|Experimental|BGS649 (Part 2)|0.3 or 0.1mg hard gelatin capsules of BGS649 given orally. 0.3mg on Day 1 and 0.1 on all other treatment visits (week 1 to 11).
89267261|NCT03843502|Experimental|Kava Pharmacokinetics Group|Each subject will take three 75 mg kava dietary supplement capsules in a single dose/timepoint and nine blood draws will be collected over an eight hour period following adminstration of kava.
89267262|NCT01200940|Experimental|Phase I - Low-dose sweetener|68 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
89267263|NCT01200940|Experimental|Phase I - Medium-dose sweetener|170 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
89267264|NCT01200940|Placebo Comparator|Phase I Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
89267265|NCT01200940|Experimental|Phase I- High-dose sweetener|250 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test.
89267266|NCT01200940|Placebo Comparator|Phase II - Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
89267267|NCT01200940|Experimental|Phase II - Diet Soda 1|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
89267268|NCT01200940|Experimental|Phase II - Diet Soda 2|less than or equal to 5 mg/kg sucralose, less than or equal to 50 mg/kg aspartame, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
89267269|NCT01200940|Experimental|Phase II - Water with sucralose and acesulfame-potassium|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
89267270|NCT01201018|Experimental|Oshadi DR|
89290506|NCT01127724|Experimental|Group 2- 100 mcg|Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months
89267271|NCT03841552|Experimental|Augmented Feedback|The exercises were conducted with the aim of improving postural- and movement control and awareness of the lumbar spine in both treatment groups. Both groups received nine 30-minute therapy sessions, during which they performed a series of exercises from an exercise catalogue. The exercises were selected based on their compatibility with the AF-system. Each patient performed impairment-specific exercises. The AF group received additional AF feedback during both the therapy sessions and the home exercise program, by combining the exercises with games designed to target movement control, body awareness, and stabilisation exercises.
89267272|NCT03841552|Active Comparator|Control Group|The control group performed the impairment-specific exercises without AF. The control group was able to receive conventional visual feedback, such as use of mirrors, as deemed appropriate by the therapists but no AF.
89267273|NCT05667844|Experimental|mind-body intervention|
89267274|NCT03841396|Active Comparator|Fraxiparine|Nadroparine, Pre-filled syringe, 3800IU, single dose
89267275|NCT03841396|Active Comparator|Clexane|Enoxaparin, Pre-filled syringe, 40 mg, single dose
89267276|NCT03844438|Experimental|LPM3480226|LPM3480226 tablet will be orally administered，bid，28 days are considered as 1 cycle. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg,200 mg,400 mg,600mg.
89267277|NCT03841474|Experimental|Intervention I|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
89267278|NCT03841474|No Intervention|Control|Cardiovascular patients after PCI without depressive symptoms and without the need for psychiatric intervention
89267279|NCT03841474|Experimental|Intervention II|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
89267280|NCT04507594||Patients undergoing Thoracic Surgery|
89267281|NCT03843112|Active Comparator|Vivag Plus|Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.
89267282|NCT03843112|Placebo Comparator|Placebo|Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.
89267283|NCT01198444||Group 1|
89267284|NCT05670184|Experimental|LSD condition|60 participants will receive LSD.
89267285|NCT05670184|Placebo Comparator|Ethanol condition|60 participants will receive placebo.
89267286|NCT04467814|Experimental|Intervention|
89267287|NCT04467814|Active Comparator|Usual Care|
89267288|NCT01201096||peptide radioreceptor therapy and liver transplantation|
89267289|NCT03842800|Other|ASD Patients|This arm consists of patients diagnosed with Autism Spectrum Disorder (ASD) that will receive an MRI.
89267290|NCT03842800|Other|Schizophrenic Patients|This arm consists of patients diagnosed with Schizophrenia that will receive an MRI.
89267291|NCT03842800|Other|Healthy Controls|This arm consists of healthy control volunteer participants that will receive an MRI.
89267292|NCT03842800|Experimental|Healthy Controls with Ketamine|This arm consists of healthy control volunteer participants that elect to receive ketamine prior to receiving an MRI.
89267293|NCT01201174|No Intervention|Patients with Hereditary Spherocytosis|All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
89267294|NCT04415788|Experimental|Test of Incremental Respiratory Endurance - IMT|Training will consist of six levels (A-F) with six inspirations at each level for up to 36 breaths per session. TIRE data will be stored in the tablet and automatically synced to account on cloud-based online platform for subsequent interrogation and data retrieval. Before every training session, subjects will be required to complete one maximal and sustained inspiratory effort from which the training is based on for that day.
89267295|NCT04415788|Experimental|Threshold - IMT|Subjects assigned to the Standard training regimen will receive a commonly used Threshold inspiratory muscle trainer. This device features a one-way spring-loaded valve at one end and a mouthpiece on the other through which subjects will be required to breathe in hard enough to overcome the resistance provided by the spring-loaded valve, allowing correct inspiration to happen. In other words, air flow is blocked until subjects generate sufficient inspiratory pressure to exceed the device pre-set pressure in cmH2O. The resistance will be set using the device's adjustable pressure setting which is fixed at 50% of the subject's MIP at the time of enrollment. The resistance will be readjusted as needed at week 4 to still reflect 50% of their inspiratory muscle strength at that time. Subjects will be coached to perform up to 36 breaths daily using the device. They will be also instructed to complete the training session within a 30-minute period.
89267296|NCT04415788|Sham Comparator|Sham IMT (Low resistence)|The Sham (Low Resistance) training regimen will use the same methods described above for the Standard IMT, except for the amount of resistance applied within the device. Subjects will receive a Threshold which has been set to its minimal resistance, which is 9 cmH2O. Again, subjects will be instructed to perform up to 36 breaths daily using the device within a 30-minute period.
89267297|NCT01201252||Acute gastroenteritis Group|Suspected/confirmed cases of rotavirus gastroenteritis in children < 5 years of age
89267298|NCT03841006||patient group|symptomatic patient and suspicious to have ODS by history and clinical examination those patient will have MRI defecography
89267299|NCT03841006||asymptomatic group|Asymptomatic group not suspicious to have ODS by history or clinical examination they will undergone MRI defecography
89267300|NCT01202422|Experimental|Pregabalin controlled release, 165 mg|
89267301|NCT01202422|Experimental|Pregabalin controlled release, 330 mg|
89267302|NCT01202422|Other|Pregabalin immediate release, 150 mg|Reference Treatment
88805496|NCT00176930|Experimental|Marrow : No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
89267303|NCT03840694|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
89267304|NCT03840694|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
89267305|NCT03892018|Active Comparator|Fed/ Fasted Treatment Sequence|"Subjects will be assigned a fed/fasted sequence.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose."
89267306|NCT03892018|Active Comparator|Fasted/ Fed Treatment Sequence|"Subjects will be assigned a fasted/fed sequence.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration."
89267307|NCT01201330||ONJ sufferers|history of jaw osteonecrosis
89267308|NCT01201330||Bisphosphonate exposure|patients with exposure to bisphosphonates
89267309|NCT03842644|Experimental|Tension Reduction|Tension reduction device for 3 months post surgery
89267310|NCT03842644|No Intervention|Control|No tension reduction
89267311|NCT01201408||Dental Caries assessment|
89267312|NCT01201564|Active Comparator|intraperitoneal onlay mesh repair|
89267313|NCT01201564|Active Comparator|sublay mesh repair|
89267314|NCT05018104||Lower Limb Orthopedic Surgery Patients who Received Popliteal Sciatic Nerve Blocks|All patients undergoing lower limb surgery who received popliteal sciatic nerve blocks (with or without other peripheral nerve blocks) at St. Paul's Hospital from January 4, 2016 to November 1, 2019
89267315|NCT03725722|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 8 weeks
89267316|NCT03725722|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 8 weeks
89267317|NCT03725722|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 8 weeks
89267318|NCT03725722|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 8 weeks
89267319|NCT03725722|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 8 weeks
89267320|NCT01198912|Placebo Comparator|placebo|
89267321|NCT01198912|Experimental|doxycycline 100 mg|
89267322|NCT03842488|Experimental|RAL 1200 QD|Start treatment with Raltegravir (RAL) 1200mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
89267323|NCT03842488|Active Comparator|DRV/cb|Start treatment with Darunavir/Cobicistat (DRV/cb) 800-150mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
89267324|NCT03842254|Experimental|Single arm|Single dose of erythropoietin 10,000 units to be administered subcutaneously at time of enrollment.
89267325|NCT04223050|Active Comparator|High oxygen saturation|Peripheral oxygen saturation level >94%
89267326|NCT04223050|Active Comparator|Low oxygen saturation|Peripheral oxygen saturation level 88-92%
89267327|NCT01198990|Experimental|Group 1|"Subjects in will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.~eating/physical activity/positive affect/self-affirmation group."
89267328|NCT01198990|Experimental|Group 2|"Subjects will be randomized to the small change eating strategy and a physical activity goal.~eating/physical activity group. No intervention, just the eating strategy and physical activity components."
89267329|NCT01201642|Experimental|Prednisolone|Prednisolone as 5 mg tablets will be given within 72 h after onset of Bell's palsy as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
89267330|NCT01201642|Experimental|Acute stage acupuncture|Accept acupuncture therapy within 10days after onset of Bell's palsy, do not accept prednisolone therapy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints within 72 h after onset of Bell's palsy. Yifeng (TE17), Hegu (LI4) are punctured 0.5-1.0 cun, the others are punctured 0.1-0.3 cun. and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
89267331|NCT01201642|Experimental|Prednisolone + acute stage acupuncture|Accept prednisolone and acupuncture therapy within 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Acute stage acupuncture.
89267332|NCT01201642|Experimental|Resting stage acupuncture|Accepted acupuncture therapy after 10 days of the onset of Bell's palsy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. Penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints 7 d after enrolment. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
89267333|NCT01201642|Experimental|Prednisolone + resting stage acupuncture|Accept prednisolone and acupuncture therapy more than 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Resting stage acupuncture.
89267334|NCT01201642|Other|Other treatment|Do not accept neither prednisolone nor acupuncture therapy. The therapy accepted is different from the five Arms Previously.
89267335|NCT05004064|Experimental|Acalabrutinib and rituximab|Patients with untreated mantle cell lymphoma will receive acalabrutinib and rituximab for up to six cycles. Each cycle will comprise of acalabrutinib 100mg twice daily orally for 28 days and rituximab 375mg/m2 IV on day 1 (+/1 3 days) of every cycle.
89267336|NCT03842410|Other|Single-Incision Sling|Intervention with in office solyx suburethral sling DISST
89267337|NCT03798418|Active Comparator|exercise group|elastic band strengthening exercise
89267338|NCT03798418|Experimental|exercise combine diet counseling group|elastic band strengthening exercise combined diet counseling.
89267339|NCT04982692|Experimental|Intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
89267340|NCT04982692|Placebo Comparator|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
89290507|NCT01127724|Experimental|group 3- 2000 mcg|Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
89267341|NCT01202734|Experimental|001|Methylphenidate HCl Period 1: One tablet oral 36 mg once daily single-dose on Day 1 Period 2: Three tablets oral 18 mg once daily single-dose on Day 1 Period 3: Two tablets oral 36 mg once daily single-dose on Day 1. (Each treatment period will be separated by 3-7 days)
89267342|NCT01201720|Other|Albumin|Albumin solution for infusion 5%. dosage: 43,5 millimole intravenouse use , 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.6 sessions
89267343|NCT01201954|Active Comparator|sucrose|0,5 ml/kg of sucrose administered 2 minutes prior the procedure
89267344|NCT01201954|Placebo Comparator|sterile water|0,5 ml/kg of sterile water administered 2 minutes prior the procedure
89267345|NCT01202812|Experimental|LOVAZA|
89267346|NCT01202812|Placebo Comparator|Placebo capsule|
89267347|NCT03840850|Experimental|Intervention and usual care|Risk communication intervention and usual care including personalized lifestyle advice
89267348|NCT03840850|No Intervention|Usual care only|Usual care including personalized lifestyle advice
89267349|NCT01203748|Experimental|PVI + Lines Ablation|
89267350|NCT01203748|Active Comparator|PVI Ablation|
89267351|NCT01203748|Experimental|PVI + CFE|
89267352|NCT02966314|Placebo Comparator|Placebo|Placebo contains sodium chloride 0.9% and will be provided by Novartis. Placebo will be administered as a subcutaneous injection.
89267353|NCT02966314|Active Comparator|Omalizumab|Omalizumab is a sterile, white, preservative-free, lyophilized powder, contained in a single-use vial that will be reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous injection. Each omalizumab vial contains 202.5 mg of omalizumab, 145.5 mg sucrose, 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mg polysorbate 20. Each vial is designed to deliver 150 mg of omalizumab in 1.2 mL after reconstitution with 1.4 mL SWFI, USP.
89267354|NCT01203904||Pulmicort|
89267355|NCT01203982|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day
89267356|NCT01203982|Active Comparator|Rosuvastatin 40mg|Rosuvastatin 40mg/day
89267357|NCT04938154|Experimental|DBS On|
89267358|NCT04938154|Sham Comparator|DBS Off|
89267359|NCT01204060|Active Comparator|Nasal allergen challenge|
89267360|NCT01204060|Placebo Comparator|Nasal placebo challenge|
89267361|NCT01202890|Experimental|Arm 1|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
89267362|NCT03118804||Weaning Guide by EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT
89267363|NCT03840460||Pancreatic Cancer|Patients who are investigated for and subsequently diagnosed with early/advanced pancreatic adenocarcinoma or a precursor lesion or a pancreatic neuroendocrine tumour.
89267364|NCT01199224|Experimental|Arm A|
89267365|NCT01199224|Experimental|Arm B|
89267366|NCT01199224|Experimental|Arm C|
89267367|NCT01199224|Experimental|Arm D|
89267368|NCT03840304|Experimental|Yoga Group|Participants in the intervention group engaged in a 8-week yoga program delivered at their place of work (IT companies). Sessions were group-based, prescribed three sessions per week during break time (30-mins).
89267369|NCT03840304|No Intervention|Wait-list Group|Participants in Wait-List control were not given any intervention. 8-weeks, group followed usual break time.
89267370|NCT03839056||IC+PIEB+PCEA high flow|Continuous Epidural Infusion to 3ml/h more Programed Intermittent Epidural Boluses of 7ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
89267371|NCT03839056||PIEB+PCEA high flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
89267372|NCT03839056||PIEB+PCEA standar flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of standar flow as clinical practice routine
89267373|NCT03838588||T-MENC Study Group|"In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including:~st: 10 Days after patients received radical resection.~nd: When patients finished the chemotherapy or target drug delivery two cycles.~rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles.~th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA)."
89267374|NCT01204138|Placebo Comparator|placebo|Patient randomized to one of two arms, either placebo, or Apremilast
89267375|NCT01204138|Active Comparator|Apremilast|Patients randomized to either placebo or apremilast
89267376|NCT03840538|Experimental|Probiotic group|Probiotic complex capsule taken twice daily for 5weeks
89267377|NCT03840538|Placebo Comparator|Placebo group|Placebo capsule taken twice daily for 5 weeks
89267378|NCT05668078|Experimental|School-type 1, intervention school-1|We will test all symptomatic students, teachers, and support staff ; and track students symptoms and absenteeism
89267379|NCT05668078|Experimental|School-type 2, intervention school-2|We will test all students, teachers, and support staff every 3 days, irrespective of symptoms (also test whenever develops symptoms) and track students symptoms and absenteeism
89267380|NCT05668078|Experimental|In School-type 3, control school|We will not do any test, only track the students for symptom notification and absenteeism
89267381|NCT01206088|Experimental|nilotinib|
89267382|NCT05281900|Experimental|Physically active volunteers|All volunteers who meet the inclusion criteria will be included in the study.
89267383|NCT02923648||Very/extremely prematurely born with BPD|Very/extremely prematurely born (gestational age [GA]< 32 weeks) with bronchopulmonary dysplasia (BPD) as defined by Jobe and Bancalari 2001, age 18-23 years
89267384|NCT02923648||Very/extremely prematurely born without BPD|Very/extremely prematurely born (GA< 32 weeks) without BPD in the neonatal period, age 18-23 years
89267385|NCT02923648||Asthma full-term control group|Subjects with mild atopic asthma, born at term (GA> 37 weeks), age 18-23 years
89267386|NCT02923648||Healthy full-term control group|Healthy participants, born at term (GA>37 weeks), age 18-23 years
89267387|NCT01204372|Experimental|Treatment|Gemcitabine - Trastuzumab - Erlotinib
89267388|NCT01567228|No Intervention|routine counseling (control group)|Children will receive typical counseling for obesity prevention, dental caries prevention, or school problems per routine standards for pediatrician anticipatory guidance
89267389|NCT01567228|Experimental|CHICA GIS|In randomly assigned experimental clinics, physicians will counsel patients to increase physical activity, seek dental care, or seek academic support services such as tutoring; this counseling will be assisted by an experimental intervention which consist of an electronic medical record that prompts specific counseling in conjunction with a geographic information system. The enhanced electronic medical record will map community resources to support physician counseling and lifestyle modification
89267390|NCT02671240||- Patients with behavioral addiction|
89267391|NCT02671240||- Patients with no behavioral addiction|
89267392|NCT01204450|Other|Single Arm Temsirolimus + Valproic Acid|"Drug: temsirolimus 60-230mg/m2 weekly during each 28 day course, for up to 12 courses~Drug: valproic acid (VPA) All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses"
89267393|NCT03835780||People with inflammatory bowel disease|All individuals with an existing or incident diagnosis of IBD during the study period
89267394|NCT03835780||People with rheumatoid arthritis|All individuals with an existing or incident diagnosis of RA during the study period
89267395|NCT03835780||People with psoriatic arthritis|All individuals with an existing or incident diagnosis of IBD during the study period
89267396|NCT03835780||Controls|Age, gender and primary care practice matched individuals without an existing or incident diagnosis of IBD, RA, or PsA during the study period
89267397|NCT03834454|Active Comparator|Bupivacaine 5 mg|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
89267398|NCT03834454|Active Comparator|Bupivacaine 7.5 mg|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
89267399|NCT02428270|Experimental|GSK2256098 and Trametinib|"GSK2256098, orally, at 0.375 or 0.5 mg, once daily, continuously every 28 day cycles.~Trametinib, orally at 250 mg or 500 mg, twice daily, continuously every 28 day cycles."
89267400|NCT01204528|Active Comparator|Paricalcitol 2 microgram/d|
89267401|NCT01204528|Active Comparator|Paricalcitol 1 microgram/d|
89267402|NCT01204528|Placebo Comparator|Placebo|
89267403|NCT02299492|Experimental|Person-Centered Care Planning|Arm will receive provider level training in Person Centered Care Planning
89267404|NCT02299492|No Intervention|Treatment as Usual|Arm will receive treatment as usual in community mental health clinic
89267405|NCT02178046||Gingivitis|optical measurements
89267406|NCT01566916|Active Comparator|Total Hip Arthroplasty performed via direct anterior approach|
89267407|NCT01566916|Active Comparator|Total Hip Arthroplasty using anterolateral approach|
89267408|NCT01566994|Experimental|TTM Tailored|
89267409|NCT01566994|Experimental|Motivational Enhancement Therapy|
89267410|NCT01566994|Experimental|Integrated Treatment|
89267411|NCT01203124|Placebo Comparator|1|Placebo given once daily on 7 days
89267412|NCT01203124|Experimental|2|Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6
89267413|NCT01203124|Experimental|3|Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6.
89267414|NCT01203124|Experimental|4|Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6.
89267415|NCT01203124|Experimental|5|Active treatment once daily on 7 days
89267416|NCT05281822|Experimental|Experimental group|The BMI (kg/m2) was calculated by measuring the height and weight of the women in the experimental groups. Then, the women in the experimental group were provided with stress management training to help cope with stress conditions, how to use positive coping in conditions in case of stress and tension. In terms of the reliability of the training, each woman was interviewed face-to-face, which lasted for 30-40 minutes.
89267417|NCT03829930|Experimental|Entinostat and Enzalutamide|Entinostat and Enzalutamide
89267418|NCT01203202|Placebo Comparator|PED 0|placebo
89267419|NCT01203202|Experimental|PED 1|PED-1 (clomipramine 15mg)
89267420|NCT01203202|Experimental|PED-2|PED-2 (Clomipramine 30mg)
89267421|NCT03829384|Experimental|mRNA-1944|Escalating dose levels
89267422|NCT03829384|Placebo Comparator|Placebo|Saline
89267423|NCT01203280|Experimental|balance, neck isometric strength and range of motion|
89267424|NCT01204606|Experimental|MMA group|
89267425|NCT01204606|Placebo Comparator|Control group|
89267426|NCT01206244||Normal|Normal subjects
89267427|NCT01206244||Dry eye|clinically diagnosed dry eye with aqueous tear deficiency
89267428|NCT03833518|Experimental|Hand impairment due to stroke or spinal cord injury|Individuals who have experienced a sub-cortical stroke or a cervical spinal cord injury resulting in loss of hand function.
89267429|NCT01298206||H1N1 not exposed controls|For every enrolled H1N1 case, the study will enroll 2 sex matched controls. On the date of enrollment of a case, 2 sex-matched controls will be located from the same clinic from which the case was enrolled. Enrolled controls will then be verified to be free from influenza infection at the time of enrollment by RT-PCR.
89267430|NCT01298206||H1N1 exposed Cases|A swab will be collected from cases to verify presence of pandemic influenza. Testing positive for influenza A/H1N1 by RT PCR to be enrolled will be confirmed as a case. The participant will be presented with a questionnaire that will capture exposure data through a group of variables assessing underlying health conditions, symptoms, use of influenza vaccine, travel, occupational setting, and other demographic variables. Cases will be contacted once during the study.
89267431|NCT01774552||Port-wine stain|Photo Acoustic Microscopy and Optical Coherence tomography
89267432|NCT01298284|No Intervention|EVL\GVS Alone|Endoscopic ligation treatment in the 2nd prevention of gastroesophageal variceal bleeding in patients with HCC
89267433|NCT01298284|Active Comparator|EVL\GVS Combined Propranolol|"Propranolol and endoscopic ligation treatment is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~<EVL\GVS Combined Propranolol>"
89290508|NCT03932370||f-URS|
89290509|NCT03932370||mini-PCNL|
89267434|NCT01204840|Active Comparator|Group A - Control group|"Group A (n=10; control group) will receive the patch protocol consisting of the 100ug estrogen patch (Estradot), a Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), and gonadotropin stimulation with 412 IU of recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris)."
89267435|NCT01204840|Experimental|Group B - treatment group|"Group B will consist of 30 subjects. In addition to the same hormone stimulation patch protocol as Group A, subjects will be treated with growth hormone 10 IU (3.33mg) per day by subcutaneous injection starting day 1 of the last menstrual period in the month prior to gonadotropin stimulation, and will continue daily until the day of human chorionic gonadotropin (hCG) injection."
89267436|NCT05281432||Pes planus individuals|The aim of this study was to evaluate the static and dynamic balance status of male individuals diagnosed with pes planus.
89267437|NCT01203358|Active Comparator|Surfactant 1|Exosurf Neonatal (Burroughs Wellcome Co.)
89267438|NCT01203358|Active Comparator|Surfactant 2|Survanta (Ross Laboratories)
89267439|NCT01203436|Experimental|Supplemental Oxygen|Supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%.
89267440|NCT01203436|Active Comparator|Conventional Oxygen|Conventional oxygenation at a pulse oximetry target of 89% to 94%.
89267441|NCT01485484||Sinus|Optic imaging use near-infrared trans-illumination methods
89267442|NCT03832426|Experimental|Narlaprevir single - Healthy|2 tablets of 100 mg Narlaprevir once a day
89267443|NCT03832426|Experimental|Narlaprevir single - Hepatic Impairment|2 tablets of 100 mg Narlaprevir once a day
89267444|NCT03832426|Experimental|Narlaprevir+Ritonavir - Healthy|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
89267445|NCT03832426|Experimental|Narlaprevir+Ritonavir - Hepatic Impairment|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
89267446|NCT03840070|Experimental|Potenfill|
89267447|NCT01206400||pioglitazone vs placebo|15 patients in pioglitazone group and 15 in placebo group
89267448|NCT03312010|Experimental|High Frequency|Subjects receiving high frequency pulse rate treatment over T9 exiting nerve roots. Subjects and assessors blinded Randomization.
89267449|NCT03312010|Sham Comparator|Sham|Subjects receiving Sham (non-active) treatment over T9 exiting nerve roots. Subjects and assessors blinded to randomization. Subjects and assessors to be unblinded if pain scores are 30 mms or higher with VAS after 1-month follow-up. Upon this moment subjects to receive active stimulation
89267450|NCT01203514|Experimental|Trial 1 Experimental|Infants 401-1,000g birthweight
89267451|NCT01203514|Sham Comparator|Trial 1: Sham Comparator|Infants 401-1,000g birthweight
89267452|NCT01203514|Experimental|Trial 2: Experimental|Infants 1,001-1,250g birth weight
89267453|NCT01203514|Sham Comparator|Trial 2: Sham Comparator|Infants 1,001-1,250g birth weight
89267454|NCT03723070|Experimental|PV Cryoablation|Ablation of the ostium of the pulmonary veins (PV) as a means to electrically isolate the veins in the treatment of atrial fibrillation. A cryoablation balloon will be inserted into the left atrium and cryo applications will be administered to create an endocardial thermal injury by using the Cryterion Cardiac Cryoablation System
89267455|NCT01473784|Experimental|Transoral robotic surgery (TORS)|Patients will undergo TORS for oral and laryngopharyngeal benign and malignant lesions using the Da Vinci Robotic Surgical System. After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
89267456|NCT00842764|Experimental|Holmium: YAG laser|Subjects will go under minimally invasive Holmium: YAG laser blepharoplasty
89267457|NCT01204996|Experimental|1|CNTO888 + docetaxel 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
89267458|NCT01204996|Experimental|2|CNTO888 + gemcitabine 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
89267459|NCT01204996|Experimental|3|CNTO888 + Paclitaxel and carboplatin 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
89267460|NCT01204996|Experimental|4|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
89267461|NCT01297192|Other|Treatment Arm 1|The effect of mirabegron on the pharmacokinetics of solifenacin
89267462|NCT01297192|Other|Treatment Arm 2|The effect of solifenacin on the pharmacokinetics of mirabegron
89267463|NCT01205074|Experimental|Repeatability|
89267464|NCT01205074|Experimental|COPD|
89267465|NCT01205074|Experimental|Smokers|
89267466|NCT01205074|Experimental|CYP450 1A2 Inhibitors|
89267467|NCT01205074|Experimental|Cirrhosis Beta Blockers|
89267468|NCT01205074|Experimental|Alcohol|
89267469|NCT03722524||Patients with arterial hypertension|"The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.~Presumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients."
89267470|NCT03722446|Other|Arrow Catheter Kit.|Arrow FlexTip Plus Epidural Catheterization Kit is a single orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
89267471|NCT03722446|Other|B.Braun Catheter Kit|Perifix FX Springwound Epidural Catheter Kit is a multi-orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
89267472|NCT05667220|Active Comparator|Sitagliptin monotherapy group (Group A)|
89267473|NCT05667220|Experimental|Sitagliptin combined with Beidougen capsule treatment group (Group B)|
89267474|NCT01205308|Active Comparator|Stanol ester spread|Vegetable oil based margarine with stanol ester enrichment
89267475|NCT01205308|Placebo Comparator|control spread|Vegetable oil based margarine without stanol ester enrichment
89267476|NCT01298830|Experimental|GLP-1 CellBeads|
89267477|NCT01203592|Experimental|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
89267478|NCT01297426||Group 1|Lean and obese, diabetic and non diabetics
89267479|NCT05669326|Experimental|NODDI TRACT|"Diffusion MRI (tractography) Tractography is performed on the basis of a diffusion MRI sequence which, after computer processing, will result in a map of the apparent diffusion coefficient and a diffusion tensor beam reconstruction (DTI tractography) performed with the Sisyphus software.~Multi-shell diffusion MRI (NODDI-tract)"
89267480|NCT01297582|Experimental|E|
89267481|NCT01297582|Placebo Comparator|P|
89267482|NCT01203670|Experimental|Soft capsules of Phytalgic|Phytalgic is a food supplement. Its galenic form is soft capsule.
89267483|NCT03829150|Experimental|Dexlansoprazole MR group|Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
89267484|NCT03829150|Experimental|lansoprazole group|Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
89267485|NCT03820804||Diet-treated|Patients with Phenylketonuria under dietary treatment.
89267486|NCT03820804||Sapropterin-treated|Patients with Phenylketonuria under sapropterin treatment.
89267487|NCT01205386||CROSSER|
89267488|NCT01205464|Active Comparator|Doxycycline|Treatment with Capsule Doxycycline 200 mg, once daily, for 21 days.
89267489|NCT01205464|Placebo Comparator|Sugar pill|Capsule Placebo, 200 mg, once daily, for 21 days.
89267490|NCT01205542|Experimental|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
89267491|NCT01205542|Active Comparator|Reference|Health check and advice to continue ordinary physical activity
89267492|NCT01205620|Experimental|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
89267493|NCT01205620|No Intervention|No intervention|No intervention will be performed in this control group
89267494|NCT03828838|Experimental|Lu-177 PSMA-617|Two cycles with 3 and 3-6 GBq Lu-177 PSMA-617 (including 3D-dosimetry)
89267495|NCT01205698|Placebo Comparator|Group 1 - Control A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
89267496|NCT01205698|Experimental|Group 2 - Experimental A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
89267497|NCT01205698|Placebo Comparator|Group 3 - Control B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
89267498|NCT01205698|Experimental|Group 4 - Experimental B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
89267499|NCT03828526|Experimental|High Fidelity Simulation|"Students will be exposed to the intensive care setting where they will have to solve issues related to general nursing care, including the stages of the medication process that involve the nurses' performance and their complexity.~During the experience of the scenario will be provoked external factors, such as telephone ringing, visit of the professional of the infection commission, to evaluate the reactions of the student and the strategies adopted to minimize the occurrence of adverse events against such external factors.~Subsequently, they will participate in the debriefing, where they will be reflected on the positives and those that should be adjusted to promote safer nursing care related to drug administration."
89267500|NCT03828526|Active Comparator|Traditional teaching strategy|Participants will be submitted to an expository-dialogue class, which will be given based on the recent literature and subdivided into the following axes: 1) patient safety; 2) medication process; 3) adverse drug events; 4) the critical patient in intensive care and its specificities. Afterwards, students will be directed to an environment with an anatomical piece for drug preparation and administration training.
89267501|NCT01297660||patients with SCI for at least 5 years|Ages Eligibility: minimum 18 years Genders Eligibility: female and male
89267502|NCT01297738|Experimental|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which is high in fat and sugar (Nutridrink®)
89267503|NCT01297738|Experimental|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume this caloric surplus with their meals, which results in an increase in meal size.
89267504|NCT01297738|Experimental|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which has a high fat and sugar content(Nutridrink®). Subjects consume the Nutridrink 3 times a day in between meals. which results in an increase in meal frequency.
89267505|NCT01297738|Experimental|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
89267506|NCT01297738|No Intervention|Control group|Subjects will not follow any diet but their own ad-libitum, healty diet.
89267507|NCT03819010|Active Comparator|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
89267508|NCT03819010|Active Comparator|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
89267509|NCT01300702||lung cancer surgery|Patients undergoing thoracotomy for lung cancer
89267510|NCT03818932|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
89267511|NCT03818932|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
89267512|NCT03830554|Experimental|intervention group|product name: organic Atlas cedar wood essential oil (Cedrus Atlantica): the intervention group smell 2 drops of organic Atlas cedar wood essential oil (applied on cotton ball) for a period of five consecutive nights (at least 8 hours each night).
89267513|NCT03830554|No Intervention|control group|participants of this group received no intervention.
89267514|NCT01205854|No Intervention|Conventional clinical and laboratory assessment|
89267515|NCT01205854|Experimental|Conventional assessment plus ultrasonography|
89267516|NCT01205932|Experimental|Arm 1|
89267517|NCT01205932|Experimental|Arm 2|
89267518|NCT01205932|Experimental|Arm 3|
89267519|NCT01205932|Active Comparator|Arm 4|
89267520|NCT01300780|Active Comparator|Experimental|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
89267521|NCT01300780|Placebo Comparator|placebo group|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
89267522|NCT01297816|Placebo Comparator|placebo|100mg-
89267523|NCT01297816|Placebo Comparator|minocyclin|
89267524|NCT01206634|Experimental|Regenerative injection therapy|
89267525|NCT01206634|Active Comparator|Exercise|
89267526|NCT01297894|Active Comparator|colistin|Colistimethate sodium 2.5-5mg/kg iv
89267527|NCT01297894|Active Comparator|colistin plus fosfomycin|colistimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
89267528|NCT03830008|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over the list with the general practitioners (GP) in the neighborhood of the participant and the written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by this physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
89267529|NCT03830008|Experimental|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
89267530|NCT01298908|Other|Operative treatment|vein stripping
89267531|NCT01298908|Other|Laser ablation|Ultrasound guided laser ablation
89267532|NCT01298908|Other|Foam sclerotherapy|Ultrasound guided foam sclerotherapy
89267533|NCT01206010|Experimental|Varenicline + Active Tailored Dose|
89267534|NCT01206010|Placebo Comparator|Varenicline + Placebo Tailored Dose|
89267535|NCT01298050||Extracorporeal Membrane Oxygenation|All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
89267536|NCT05621824||Solid mass|Patients with solid mass of pancreas during pancreas MR examination.
89267537|NCT05621824||Cystic lesions|Patients with cystic lesions or expansion of MPD during pancreas MR examination.
89267538|NCT05621824||No clear focus|Patients with no clear focus during pancreas MR examination.
89267539|NCT05665582||Affected family members of patients with Substance use disorders|The family sample was recruited from at a Norwegian addiction treatment unit where close relatives of patients in treatment for SUD participated in a family program.
89267540|NCT01298986|Active Comparator|Pulmonary Vein Isolation|Patients who have paroxysmal or persistent atrial fibrillation but whose left atrium is < /= 5.0
89267541|NCT01298986|Experimental|Hybrid procedure for patients with a left atrium < /= 5.0 cm|A combined procedure where the cardiac surgeon will place the ablation lesions on top of the heart and the electrophysiologist will place the lesions inside the heart. 3D mapping with be used to guide the procedure. The left atrial appendage will be surgically managed.
89267542|NCT01298986|Active Comparator|Cox Maze Procedure|All lesions of the Cox Maze procedure will be completed as originally described by Dr. James Cox using crypthermia. Patients will be randomized if there left atrium is >5.0 cm but < 6.1 cm and are experiencing paroxysmal or persistent atrial fibrillation
89267543|NCT01298986|Experimental|Hybrid Procedure|A collaborative approach between electrophysiologist and surgeons for patients with a left atrium <5.0 cm and < 6.1 cm where the surgeon will epicardially place the ablation lesions and the electrophysiologist will place the lesion lines endocardially. 3D mapping will be used and the left atrial appendage will be surgically managed.
89267544|NCT05665114|Experimental|QN-030a|QN-030a in Adult subjects with r/r AML
89267545|NCT01206712||T2DM patients treated with LANTUS + MET|T2DM patients treated with LANTUS + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
88805497|NCT00176930|Experimental|UCB : No TBI|Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
89267546|NCT01206712||T2DM patients treated with SU + MET|T2DM patients treated with Sulfonylurea (SU) + Metformin(MET)in their routine antidiabetic therapy. These patients do not receive any study specific medication.
89267547|NCT01206712||T2DM patients treated with DPP-4 + MET|T2DM patients treated with Dipeptidylpeptidase 4 inhibitors (DPP-4) + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
89267548|NCT01206712||Healthy subjects|healthy volunteres who do not receive any antidiabetic medication in their routine therapie.
89267549|NCT01206790|Experimental|Narrative Exposure Therapy (NET)|
89267550|NCT01206790|No Intervention|Waitinglist Control Group|
89267551|NCT03814486||patient transfused in platelet in the 6 last months of life|patient with hematological malignancies follow or hospitalised at least once in CHU of Besancon died in the period of the study transfused at least once in the 6 months of life
89267552|NCT03814798|Experimental|Cohort 1|IGSC 20% daily push versus every 2 weeks pump or the reverse sequence
89267553|NCT03814798|Experimental|Cohort 2|IGSC 20% daily push versus once a week pump or the reverse sequence
89267554|NCT03814798|Experimental|Cohort 3|IGSC 20% daily push versus 2 times per week pump or the reverse sequence
89267555|NCT03814798|Experimental|Treatment-Naive IGSC 20% pump dosing|IGSC 20% 150 mg/kg
89267556|NCT03814408|Experimental|RP-L102|RP-L102 is a self-inactivating lentiviral vector carrying the therapeutic FANCA gene
89267557|NCT01299064||Buddhist Clergy and Laypersons|
89267558|NCT05618704|Experimental|Hydrolyzed protein infant formula|All subjects will take the hydrolyzed protein infant formula
89267559|NCT01299142|Experimental|FGI-101-1A6|Intervention: Drug-FGI-101-1A6
89267560|NCT01299142|Placebo Comparator|Placebo|Intervention: Drug-Placebo
89267561|NCT05281120|Active Comparator|mechanical intervention group|"20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm.~Intervention: to stand on the active platform (inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months."
89267562|NCT05281120|Placebo Comparator|mechanical placebo group|"20 subjects participated to the study (1 year double-blind, randomized, placebo controlled, parallel group study) and 10 subjects were randomized to this arm.~Intervention: to stand on the placebo platform (not inducing vertical, sinusoidal acceleration) for 10 minutes each day for 12 months."
89267563|NCT00146172|Experimental|Neratinib 40 mg|
89267564|NCT00146172|Experimental|Neratinib 80 mg|
89267565|NCT00146172|Experimental|Neratinib 120 mg|
89267566|NCT00146172|Experimental|Neratinib 180 mg|
89267567|NCT00146172|Experimental|Neratinib 240 mg|
89267568|NCT00146172|Experimental|Neratinib 320 mg|
89267569|NCT00146172|Experimental|Neratinib 400 mg|
89267570|NCT00146172|Experimental|Neratinib 320 mg MTD|
89267571|NCT01206868|Active Comparator|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
89267572|NCT01206868|Sham Comparator|Control|Standard kidney transplantation
89267573|NCT03814642|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
89267574|NCT03814642|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days
89267575|NCT03814642|Experimental|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
89267576|NCT03814330|Placebo Comparator|Sedation/Analgesia|Patients with applied sedation analgesia will perform State-Trait Anxiety Inventory and Quality of Recovery Score
89267577|NCT03814330|Active Comparator|Laryngeal Mask Airway|Patients with applied Laryngeal Mask Airway will perform State-Trait Anxiety Inventory and Quality of Recovery Score
89267578|NCT03813784|Experimental|A|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 250 mg PO qd.
89267579|NCT03813784|Active Comparator|B|Capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus Oxaliplatin 130 mg/m^2, IV q3w
89267580|NCT03813784|Experimental|C|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210
89267581|NCT03818542|Experimental|Arm 1: ABBV-181 IV|A single dose of ABBV-181 administered via intravenous (IV) infusion on Day 1.
89267582|NCT03818542|Experimental|Arm 2: ABBV-368 IV|A single dose of ABBV-368 administered via intravenous (IV) infusion on Day 1.
89267583|NCT03818542|Experimental|Arm 3: ABBV-927 IV|A single dose of ABBV-927 administered via intravenous (IV) infusion on Day 1.
89267584|NCT03818542|Experimental|Arm 4: ABBV-927 IT|A single dose of ABBV-927 administered via intratumoral (IT) injection on Day 1.
89267585|NCT03818308|Experimental|Sofosbuvir and Velpatasvir|SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks
89267586|NCT03827044|Experimental|Avelumab|6 months of 2 weekly Avelumab
89267587|NCT03827044|No Intervention|No intervention|After standard adjuvant 5FU based chemotherapy, patients will have no active intervention but will start standard follow up.
89267588|NCT01300936||patients with abdominal wall hernias|
89267589|NCT03814096|Experimental|Syphilis POC-prenatal screening|Syphilis prenatal screening late in gestation at 24-28 weeks (at the time of the routine prenatal care clinic visit for the routine Glucose Tolerance Test [GTT]) using the Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
89290510|NCT01127334||Systolic Heart Failure, Dyssynchrony, CRT-D|Patients with systolic heart failure and dyssynchrony that have a CRT-D that have not been optimized in the past 3 months.
89290511|NCT01226550|Experimental|cytoreductive surgery and HIPEC|
89290512|NCT03928470|Experimental|EsoDuo Tab. 20/800mg|EsoDuo Tab. 20/800mg
89290513|NCT03928470|Active Comparator|Nexium Tab. 20mg|Nexium Tab. 20mg
89290514|NCT03927924|Experimental|High-intensity focused ultrasound|
89290515|NCT01223586||Regression|Patients with regression of plaque volume by statin
89267590|NCT05659030|Experimental|Experimental|It is planned to provide training on perinatal mental health to the experimental group in order to eliminate the lack of knowledge of women and to raise awareness. The pre-test will be applied during the pregnancy period before the training. These trainings, which will be held during pregnancy, consist of 3 modules. A training booklet in their preferred language (Turkish or Arabic) will be distributed to women at the end of each module. In addition, the effectiveness of the training will be evaluated at the end of each module and the knowledge deficiencies of women will be eliminated. The trainings will be carried out in the form of group training of 10-12 people, taking into account the physical conditions of the environment. A module training will be given every week and the training will be completed within three weeks. The effectiveness of the training will be evaluated in the postpartum period with the post-test.
89267591|NCT05659030|No Intervention|Control|Routine clinical care will be given to women in the control group. The pre-test will be applied during the pregnancy period and the post-test will be applied in the postpartum period. At the end of the post-test, three module training booklets will be distributed to the women in their preferred language (Turkish or Arabic). In line with their needs, the information deficiencies they request will be corrected.
89267592|NCT00145626|Experimental|Study Participants|"Participants who meet the eligibility criteria for this study. Donor cells will be obtained using the Miltenyi Biotec CliniMACS device.~Interventions: Chemotherapy and antibodies, allogeneic stem cell transplantation."
89267593|NCT01206946|Experimental|Antenatal steroids|
89267594|NCT01206946|Placebo Comparator|Normal saline|
89267595|NCT01207024||knee MRI|knee MRI for all patients undergoing bariatric surgery as usual care
89267596|NCT03813940|Experimental|HPV Vaccine,135μg/0.5ml|Participants in this arm would receive 135μg/0.5ml HPV vaccines
89267597|NCT03813940|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
89267598|NCT03967938|Experimental|Olaparib|tablets of 300mg twice daily until disease progression
89267599|NCT03817918|Experimental|Determination of local pleural strain|The local pleural strain will be determined over three consecutive respiratory cycles using lung ultrasonography
89267600|NCT03817996||HFNC + hypoperfusion + Responders|"Patients treated with HFNC presenting with any sign of hypoperfusion, in whom volume expansion was planned by the attending physician.~Clinical signs of inadequate tissue perfusion were suspected at the bedside by observing hypotension (systolic blood pressure <90 mm Hg or the need for norepinephrine), oliguria (urine output <0.5 mL/kg/hr), and cool, mottled extremities.~Their CO increases >15% after passive leg raising."
89267601|NCT03817996||HFNC + hypoperfusion + Non-Responders|Same as previous but their CO do not increase >15% after passive leg raising maneuver.
89267602|NCT01299298|Experimental|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
89267603|NCT01299298|Placebo Comparator|placebo|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
89267604|NCT00153062|Placebo Comparator|Aggrenox, Clopidogrel placebo, Micardis|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis (80mg) qd
89267605|NCT00153062|Placebo Comparator|Aggrenox placebo, clopidogrel,, Micardis|Clopidogrel (75mg) qd; Aggrenox placebo bid, Micardis (80mg) qd
89267606|NCT00153062|Placebo Comparator|Aggrenox, clop placebo, micardis placebo|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis placebo qd
89267607|NCT00153062|Placebo Comparator|Aggrenox plcebo, clop, micardis placebo|Clopidogrel (75mg) qd, Aggrenox placebo bid, Micardis placebo qd.
89267608|NCT01207180|Experimental|Follow-up phone call from Nurse|Patients in this are will receive a phone call follow-up from a nurse 1-3 days after their discharge from the ED.
89267609|NCT01207180|Placebo Comparator|Satisfaction survey|This group of patients will receive a phone call from a student who will conduct a brief satisfaction survey of the patient's experience in the ED.
89267610|NCT01207180|Placebo Comparator|Control group|Patients in this group will receive no phone call at 1-3 days.
89267611|NCT03813550|Other|PXE cohort 2019-2020|PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples
89267612|NCT00145470|Experimental|Asenapine|Participants received asenapine as a fast-dissolving sublingual (SL) tablet, given twice daily (BID). On Day 1, participants received asenapine 5 mg, BID. On Days 2 to 84, asenapine was dosed flexibly: BID at either 5 or 10 mg. Asenapine doses were up- or down-titrated based on efficacy, safety, and tolerability.
89267613|NCT00145470|Placebo Comparator|Placebo|Participants received placebo on Days 1-84 as a fast-dissolving SL tablet, BID.
89267614|NCT03813706|Active Comparator|LN-prRLN dissection|
89267615|NCT03813706|Experimental|no LN-prRLN dissection|
89267616|NCT03813628|Experimental|polished celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
89267617|NCT03813628|Experimental|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
89267618|NCT03813628|Active Comparator|contralateral natural teeth|the poilshed and glazed all ceramic crowns will be compared by the contralateral natural teeth
89267619|NCT03813394|Experimental|Treatment Arm A|Intravenous pembrolizumab alone,D8 of 21-day cycle.
89267620|NCT03813394|Experimental|Treatment Arm B|Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
89267621|NCT03813316|Experimental|Interventional Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin after receiving extra training on individualized care.
88805498|NCT00176930|Experimental|UCB : No TBI/Bu/Cy/ATG|Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
89267622|NCT03813316|Experimental|Control Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin as per standard care/Diabetes Canada guidelines.
89267623|NCT03813004|Experimental|Young healthy adults|
89267624|NCT01207258|Experimental|Brief Intervention Group|Participants randomly assigned to this group receive a brief motivational enhancement therapy intervention group and are assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
89267625|NCT01207258|No Intervention|Assessed Control Group|This group does not receive the intervention and is assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
89267626|NCT01207258|No Intervention|No Contact Control Group|This group does not receive the intervention and is assessed only at 3 months.
89267627|NCT05624086|Experimental|Exercised group|In this group, Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint (n=23) will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
89267628|NCT05624086|No Intervention|control group|in this group, Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint (n=23) will act as a control (waitlist) group that will receive no trainning
89267629|NCT03817450|Experimental|Daily Mouth Care|The intervention consists of training in Mouth Care Without a Battle (MCWB) techniques and support in established quality improvement techniques. MCWB is a system-level, evidence based, tested approach to person-centered daily mouth care, which includes tooth-brushing, flossing, care of the gums, and denture care. MCWB provides training to all certified nursing assistants (CNAs) and nursing supervisors, and also supports the designation and specialized training of a CNA to serve as a dedicated, full-time Oral Care Aide (OCA) to provide mouth care to the residents who are at greatest risk for pneumonia and require specialized support to achieve good oral hygiene.
89267630|NCT03817450|No Intervention|Standard Mouth Care|Nursing homes will continue to provide standard mouth care to all residents. Nursing home staff will not receive training or supplies in the control condition.
89267631|NCT01301248|Active Comparator|Radiotherapy/Cisplatin(GroupA)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)
89267632|NCT01301248|Experimental|Radiotherapy/Cisplatin/Cetuximab(GroupB)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
89267633|NCT03817684|Experimental|BPN14770 10mg bid|10 mg bid dose of the Drug BPN14770
89267634|NCT03817684|Experimental|BPN 14770 25mg bid|25mg bid dose of the Drug BPN14770
89267635|NCT03817684|Placebo Comparator|Placebo|
89267636|NCT03817372|Active Comparator|Anterior-posterior electrode position|The anterior electrode is placed in the left parasternal area (precordium). The posterior electrode is placed in the left lower-scapular region with the electrode edge left to the spinal column.
89267637|NCT03817372|Active Comparator|Anterior-lateral electrode position|The anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
89267638|NCT01301326|Experimental|subthreshold laser treatment|
89267639|NCT01301326|Active Comparator|threshold laser treatment|
89267640|NCT01302028|Active Comparator|Healthy volunteers with normal renal function|Oral
89267641|NCT01302028|Experimental|T2DM patient with normal renal function|Oral
89267642|NCT01302028|Experimental|T2DM patient with mild renal impairment|Oral
89267643|NCT01302028|Experimental|T2DM patient with moderate renal impairment|Oral
89267644|NCT01302028|Experimental|T2DM patient with severe renal impairment|Oral
89267645|NCT01302106|Experimental|Arm 1|Clofarabine combined with low dose Ara-C
89267646|NCT00152516|Experimental|Levetiracetam|
89267647|NCT00145158|Experimental|Cohort 1: 8 HLA-A2-restricted peptides and CpG 7909|Patients were immunized with a combination of 8 peptides corresponding to defined tumor antigens (MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NY-ESO-1.A2, NA17.A2 and Tyrosinase.A2), mixed with CpG 7909. Patients received six sequential injections at 2-week intervals.
89267648|NCT00145158|Experimental|Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51|Patients were immunized with a combination of 8 peptides corresponding to defined tumor antigens (MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2, NY-ESO-1.A2, and NA17.A2), mixed with Montanide ISA 51. Tyrosinase.A2 was administered without Montanide ISA51. Patients received six sequential injections at 2-week intervals.
89267649|NCT03813082|Experimental|Sleep deprivation young men|Young study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
89267650|NCT03813082|Experimental|Sleep deprivation older men|Older study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
89267651|NCT01302184|Experimental|Experimental Group|Lokomat®
89267652|NCT01302184|Active Comparator|Control Group|Treadmill training
89267653|NCT03812458|Experimental|Guidance|The intervention group will consist of the relatives who will receive a printed brochure and are encouraged to visit a website with detailed information and with simple language regarding the ICU environment (treatments, care, alarms, multidisciplinary team) and the characteristics of critically ill patients (organ dysfunction, prognosis, palliative care, organ dysfunction).
89267654|NCT03812458|No Intervention|Control|The families who will not receive the brochure and are not encouraged to visit the website.
89267655|NCT05624008|Experimental|Bioceramic glass ionomer restoration|Calcium aluminate modified glass ionomer
89267656|NCT05624008|Active Comparator|Resin modified glass ionomer restoration|type II resin modified glass ionomer cement
88805499|NCT00176930|Experimental|PBSC|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
89267657|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) post-EBRT|Prostatic Urethral Lift (PUL) following External Beam Radiotherapy (EBRT)
89267658|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) pre-BT|Prostatic Urethral Lift (PUL) preceding Brachytherapy (BT)
89267659|NCT03817216|Active Comparator|Prostatic Urethral Lift (PUL) post-BT|Prostatic Urethral Lift (PUL) following Brachytherapy (BT)
89290516|NCT01223586||Non regression|Patients without regression of plaque volume by statin
89290517|NCT01127412|Active Comparator|Physical activity stimulating program|Advices to stimulate motor activity and motor development at the age of two weeks, two months, four months, eight months and eleven months
89267660|NCT05623930|Active Comparator|laser on acupuncture points|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
89267661|NCT05623930|Active Comparator|cupping (with scarification)|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
89267662|NCT05623852|Experimental|Arm A: Fucoidan arm|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
89267663|NCT05623852|No Intervention|Arm B, Observational arm|observation
89267664|NCT01302262||Healthy smokers|Healthy male and female smokers. Each subject will undergo PET scan (along with craving and anxiety questionnaires) on two conditions - Smoking and Non-smoking - on two separate visits.
89267665|NCT03812692||MATRx plus test|All participants will complete the MATRx plus test unattended in the home. Not all participants will be predicted responders to oral appliance therapy; both predicted responders and non-responders will undergo an outcome home sleep apnea test with a custom oral appliance in place to validate the prediction made by the test. Twenty participants will also complete an in-lab sleep study prior to the home study.
89267666|NCT03812536|No Intervention|SOC Voiding Protocol|Patients in the control group will follow the standard of care protocol and are required to void post anorectal surgery before being discharged home.
89267667|NCT03812536|Experimental|No Void Intervention|Patients in the experimental group (No Void Intervention) will be discharged home without voiding spontaneously.
89267668|NCT03817294|Active Comparator|Eccentric cycling|
89267669|NCT03817294|Active Comparator|Concentric cycling|
89267670|NCT03817294|Active Comparator|Single leg cycling|
89267671|NCT03817294|Active Comparator|Lower limb resistance training|
89267672|NCT03817060|Active Comparator|Cleavage|Embryos cryopreserved with vitrification at the cleavage stage (day 3) of embryo development
89267673|NCT03817060|Active Comparator|Blastocyst|Embryos cryopreserved with vitrification at the blastocyst stage (day 5 or 6)
89267674|NCT05623696|Experimental|Stimulation of Left DLPFC|Intervention applied to Left DLPFC located by the BeamF3 technique
89267675|NCT05623696|Active Comparator|Stimulation of Right DLPFC|Intervention applied to Right DLPFC located by the BeamF3 technique
89267676|NCT05623696|Sham Comparator|Sham Stimulation|Sham intervention applied to either the left or right DLPFC
89267677|NCT01302340|Active Comparator|Delta-THC|THC will be administered twice daily during three consecutive days per treatment block(0.75 or 1.5 mg twice daily)
89267678|NCT01302340|Placebo Comparator|placebo|Placebo will be administered twice daily during three consecutive days per treatment block.
89267679|NCT00150800|Experimental|Brivaracetam|Brivaracetam used as adjunctive treatment, flexible dosing up to 200 mg /day in b.i.d (twice daily) administration. Dose increase or decrease can be made in increments of maximum 50 mg/day on a weekly basis.
89267680|NCT03812770|Experimental|Sorafenib plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
89267681|NCT03812770|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
89267682|NCT03826108||Cases|Patient who underwent a primary hip (total or partial) or knee arthroplasty and developed a PJI that was culture-confirmed for SA during the first year after the procedure.
89267683|NCT03826108||Controls|Patient who underwent a primary hip or knee arthroplasty and did not develop any type of PJI during the first year after the procedure.
89267684|NCT00144300|Active Comparator|Mirapex|Mirapex tablets three times daily (TID) dosing according to manufacturer's guidelines
89267685|NCT00144300|Active Comparator|Requip|Requip tablets three times daily (TID) dosing according to manufacturer's guidelines
89267686|NCT03812068|Experimental|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
89267687|NCT03812068|Active Comparator|Developmental behavioral intervention|only parent-mediated developmental behavioral intervention
89267688|NCT01582724|Experimental|Self-care acupressure|1
89267689|NCT01582724|No Intervention|Usual care|2
89267690|NCT00149630|Experimental|Disulfiram, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of 250 mg of disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
89267691|NCT00149630|Active Comparator|Placebo, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
89267692|NCT01302496|Experimental|TriMix-DC and Ipilimumab|
89267693|NCT00127842|Other|Etanercept|Open-label etanercept administered by subcutaneous injection at a dose of 50 mg/week for 24 months.
89267694|NCT03720652|Experimental|8-Week Mindful Self-Compassion (MSC)|CNAs in Aim 1 will participate in the standardized, 8-week Mindful Self-Compassion course. Each 8-week session will last for 2.5 hours. Also included is a half day retreat, that CNAs may attend if they are able.
89267695|NCT03720652|Experimental|6-Week Mindful Self Compassion (MSC)|CNAs from both nursing homes in Aim 2 will participate in the 6-week Mindful Self-Compassion course, that was shortened and customized to fit the needs of health care staff. Each 6-week session will last for 1 hour.
88805500|NCT00176930|Experimental|Marrow|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
88805501|NCT00176930|Experimental|UCB|Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
89267696|NCT03968016|Placebo Comparator|Healthy|Control group
89267697|NCT03968016|Active Comparator|Stable heart disease|Stable heart disease and non-hospitalized
89267698|NCT03964740|Experimental|Intervention|Mobile App intervention group
89267699|NCT03964740|No Intervention|Control Group|No intervention group
89267700|NCT00112866|Experimental|Group I (high-dose cilengitide) 2000mg|"Preoperative Treatment: Patients receive high-dose cilengitide IV over 1 hour on days -8, -4, and -1. (High dose 2000mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity."
89267701|NCT00112866|Experimental|Group II (low-dose cilengitide) 500mg|"Preoperative Treatment: Patients receive low-dose cilengitide IV over 1 hour on days -8, -4, and -1. (500mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity"
89267702|NCT03824626||TEVAR patients|patients scheduled for thoracic endovascular aortic repair
89267703|NCT00127608|Experimental|Varicella Group|Subjects aged between 0 and 16 years of age, with clinically-diagnosed primary varicella disease.
89267704|NCT00149396|Experimental|Safety and antitumor effects of NV1020|"Stage 1: Four escalating dose cohorts of NV1020 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, and 1x10^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.~Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy."
89267705|NCT03816904||Breast or prostate cancer|Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer
89267706|NCT03741348|Active Comparator|ES|Erector Spinae Plane Block
89267707|NCT03741348|Placebo Comparator|control|the control group will not receive block
89267708|NCT05080504||Study Population|Subjects with implanted CardioMEMS who are compliant with their measurements.
89267709|NCT01075802|Experimental|Tamoxifen|Dose escalation of tamoxifen in patients with low endoxifen levels
89267710|NCT03967314|Active Comparator|Group T = TLIP block group|After the induction of anesthesia and placement of the patient in a prone position, US-guided mTLIP block was performed via the lateral approach in group T. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
89267711|NCT03967314|Active Comparator|Group W = Wound infiltration group|After the induction of anesthesia and placement of the patient in a prone position wound infiltration was performed in group W. For postoperative analgesia, a dose of 1 g of paracetamol (IV) was administered routinely, every 8 h. All the patients received fentanyl via a patient-controlled analgesia device. The protocol was a 20 mcg bolus without an infusion dose, 20-min lockout time, and 4-h limit
89267712|NCT03816592||Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
89267713|NCT03816592||Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
89267714|NCT01078038|Active Comparator|Cypher|Sirolimus-eluting stent
89267715|NCT01078038|Active Comparator|Xience V|Everolimus-eluting stent
89267716|NCT00223496|Experimental|Aripiprazole|Aripiprazole open-label in doses ranging from 5-30mg QD adjunct to Divalproex 500-2500mg QD.
89267717|NCT05623618|Experimental|Intervention (PACE labelling)|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
89267718|NCT05623618|No Intervention|Control (usual practice)|PACE labelling not implemented. Secondary schools continue with their usual practice.
89267719|NCT02531412|Experimental|Spironolactone|Spironolactone 25 mg PO daily for three days. During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
89267720|NCT02531412|Placebo Comparator|Placebo|Placebo 25mg PO daily for three days During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
89267721|NCT00255944|Experimental|Youthnet messages on Facebook|Participants will receive internet-based messages from the Youthnet program
89267722|NCT00255944|Active Comparator|Messages on Facebook about current events|Participants will receive internet-based messages from the control program
89267723|NCT03811990|No Intervention|Control|
89267724|NCT03811990|Active Comparator|Intervention|
89267725|NCT01071824|Active Comparator|Transverse coloplasty pouch (Short limb)|The short limb is the standard technique of transverse coloplasty pouch.
89267726|NCT01071824|Experimental|Transverse coloplasty pouch (Long limb)|The long limb relates to straight coloanal anastomosis.
89267727|NCT03823456|Experimental|True self-acupressure group|"True self-acupressure group [Enhanced standard care + True self-acupressure intervention protocol]:~Participants in this group will practice the four-week acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly phone call follow up from researchers."
89267728|NCT03823456|Placebo Comparator|Sham self-acupressure group|Patients in this group will practice the four weeks sham self-acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice sham acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly follow up phone call from researchers
89290518|NCT01127412|No Intervention|Control|
89267729|NCT03823456|No Intervention|Enhanced standard care group|The standard care for cancer patients undergoing chemotherapy includes health assessment, regular health advice regarding symptoms that patients report and nutrition advice during taking chemotherapy treatment. Apart from the standard care, we provide participants a leaflet with 10 recommendations which help participants manage insomnia, depression, and anxiety. By providing this leaflet, we slightly enhance the standard care but do not contaminate the effective of the intervention since these tips are basic and participants can easily read about them on the internet or newspaper. In addition, to minimize the bias caused by contacting between interventionist and participants, we also provide participants in the enhanced standard care group weekly follow up phone call in four weeks.
89267730|NCT00143598|Active Comparator|Active ECS|Active Elastic Compression Stockings (ECS) 30-40 mm Hg compression at the ankle.
89267731|NCT00143598|Placebo Comparator|Placebo ECS|Placebo stockings with identical appearance to Active ECS and with < 5 mm Hg compression at the ankle.
89267732|NCT03971240|Experimental|outcome of surgically evacuated traumatic ASDH|we will operate patients with traumatic acute subdural hematoma with some criteria and evaluate the outcome of surgery
89267733|NCT03816826|Experimental|laser|athletes with acute soft tissue injuries will be recruited in the study , patients will be treated using the the laser therapy
89267734|NCT03816826|Experimental|strain/counter strain|athletes with acute soft tissue injuries will be treated with with strain counter strain technique
89267735|NCT03816826|Experimental|combination therapy|combination of laser therapy along with strain counter strain technique to visualize the effect the
89267736|NCT01080144|Experimental|Critical Flicker Frequency|Critical Flicker Frequency Procedure
89267737|NCT01299844|No Intervention|Standard Care|
89267738|NCT01299844|Experimental|Diabetes Peer Counseling|
89267739|NCT01301404|No Intervention|control|patient receive nothing
89267740|NCT01301404|Experimental|carbohydrate drink|10%carbohydrate drink
89267741|NCT03816670|Experimental|poor responders day 2|"poor responders women stimulated with CF from day 2 of menstrual cycle"
89267742|NCT03816670|Experimental|poor responders day 4|"poor responders women stimulated with CF from day 4 of menstrual cycle"
89267743|NCT03816670|Experimental|normal responders day 2|"normal responders women stimulated with CF from day 2"
89267744|NCT03816670|Experimental|normal responders day 4|"normal responders women stimulated with CF from day 4"
89267745|NCT03816670|Experimental|high responders day 2|"high responders women stimulated with CF from day 2"
89267746|NCT03816670|Experimental|high responders day 4|"high responders women stimulated with CF from day 4"
89267747|NCT03816514|Experimental|SpHb monitoring group|In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.
89267748|NCT03816514|Active Comparator|Control group|In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.
89267749|NCT00126672|Experimental|Ramaycin|Rapamycin treatment was initiated with a loading dose of 6 mg by mouth on day 1 followed by 2 mg by mouth daily. The dose was then adjusted to maintain a target blood level of 3-9 ng/ml for the first 16 weeks. After week 16, the dose of Rapamycin was increased to a target level of 9-15 ng/ml unless there was evidence for a partial response or complete response by kidney MRI. Trough Rapamycin levels were checked every 8-12 weeks (at 24 weeks, 32 weeks, 40 weeks, and 52 weeks) in all patients until the 12-month (week 52) study visit. If the Rapamycin dose was below target, the dose was increased by 1-2 mg until the target trough level was achieved. Rapamycin levels were checked every 2-3 weeks while the dose was adjusted. Amendment 20 (Jan 2009) permitted additional Rapamycin treatment during months 12-24 if the treating site investigator judged that this was in the best interest of the study participant.
89267750|NCT01302574|Placebo Comparator|mixed liquid meal|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate
89267751|NCT01302574|Active Comparator|mixed liquid meal + lactisole|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate + 450 ppm lactisole
88805502|NCT00176930|Experimental|Co-Enroll From MT0403|Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)
89267752|NCT01080378|Other|Higher Birth Weight|3447g to 3879g
89267753|NCT01080378|Other|Lower Birth Weight|2624g to 2964g
89267754|NCT01080378|Other|Normal Birth Weight|2965g to 3446g
89267755|NCT03811678|Experimental|50 mg single dose|It includes two groups, one group is a pilot study, 2 healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet . Another group is a formal study, healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
89267756|NCT03811678|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg Kangdaprevir Sodium Tablet (N=20) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
89267757|NCT03811678|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
89267758|NCT03811678|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
89267759|NCT03811678|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
89267760|NCT03811678|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
89267761|NCT03811678|Experimental|100 mg multiple dose|Healthy subjects, receiving 100 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
89267762|NCT03811678|Experimental|200 mg multiple dose|Healthy subjects, receiving 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
89267763|NCT03811678|Experimental|400 mg multiple dose|Healthy subjects, receiving 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
89267764|NCT00145574|Experimental|high dose colesevelam|colesevelam HCl 3.750 g
89267765|NCT00145574|Experimental|Low dose colesevelam|Low dose colesevelam 1.875 g
89267766|NCT00145574|Placebo Comparator|placebo|placebo comparator
89267767|NCT05660668|Experimental|Transbond LR|in finished orthodontic cases a light cured resin composite (Transbond LR) will be added on fixed lingual retainer to see the failure rate (detachment) with follow up every month for 6 months
89267768|NCT05660668|Active Comparator|Transbond XT|in finished orthodontic cases a light cured resin composite (Transbond XT) will be added on fixed lingual retainer to see the failure rate (detachment) with follow up every month for 6 months
89267769|NCT01302652||GH deficient after acromegaly cure (on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are receiving growth hormone treatment.
89267770|NCT01302652||GH deficient after acromegaly cure (not on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are not receiving growth hormone treatment.
89267771|NCT00145496|Experimental|asenapine|
89267772|NCT00145496|Active Comparator|olanzapine|
89267773|NCT01299922|Experimental|cyclosporine+mycophenolic acid+prednison|Triple therapy
89267774|NCT01299922|Active Comparator|mycophenolic acid + prednison|Mycophenolic acid+prednison 106 weeks
89267775|NCT03967574|Experimental|Real tDCS|Participants received the full tDCS intervention for a total of 20 minutes, one time, two weeks following the CSI
89267776|NCT03967574|Sham Comparator|Sham tDCS|The patients were set up in an identical way as with the real tDCS group, but only received active stimulation for 30 seconds, after which the current was gradually stopped. The participants continued wearing the electrodes until the end of the 20 minutes treatment.
89267777|NCT03967574|No Intervention|Control|Participants received no further intervention two weeks following their CSI
89267778|NCT05030818|Experimental|Polypill|Patients will be receiving the polypill at the adequate doses during 3 months
89267779|NCT05030818|Active Comparator|Drugs taken separately|Patients will be receiving during 3 months the same components and at the same doses than with the polypill
89267780|NCT01582022|Experimental|local anesthetic|local anesthetic agent
89267781|NCT01582022|Placebo Comparator|normal saline|comparator
89267782|NCT03967418|Other|Patients with behavioral addictions|Patients suffering from behavioural addiction (sexual addiction, excessive use of video games and eating disorders with bulimia episodes) will be recruited
89267783|NCT03967418|Other|Healthy volunteers|Healthy volunteers will be matched on gender, age and education level to patients
89267784|NCT01301482|Experimental|battlefield auricular acupuncture|
89267785|NCT01301482|No Intervention|placebo|
89267786|NCT01582412|Experimental|Isavuconazole and digoxin|Isavuconazole three times per day (TID) on Days 15 and 16, and once daily (QD) on Days 17 thru 26. Digoxin single dose on Days 1 and 19.
89267787|NCT01300000|Active Comparator|Human Milk|ad lib
89267788|NCT01300000|Active Comparator|Milk based standard infant formula|ad lib
89267789|NCT01300000|Experimental|Milk based investigational infant formula|ad lib
89267790|NCT03816436||Follow- up (FU) assessment on clavicular non- union|clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting
89267791|NCT00255164|Experimental|Dexlansoprazole MR 60 mg QD|
89267792|NCT00255164|Experimental|Dexlansoprazole MR 90 mg QD|
89267793|NCT00255164|Placebo Comparator|Placebo|
89267794|NCT03811444|Experimental|simulation of skin pricking type 420|The evaluator simulated the capillary blood sampling with the safety lancet type 420
89267795|NCT03811444|Experimental|simulation of skin pricking type 430|The evaluator simulated the capillary blood sampling with the safety lancet type 430
89267796|NCT03811444|Experimental|simulation of skin pricking type 520|The evaluator simulated the capillary blood sampling with the safety lancet type 520
89267797|NCT02915614|Active Comparator|PiMM patients|"COPD patients with the Alpha-1 antitrypsin genetic variant PiMM (Smoking-related COPD)"
89267798|NCT02915614|Experimental|PiZZ patients|COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)
89267799|NCT03967652||cancer|Patients with definitively diagnosed of solid tumors
89267800|NCT03967652||Benign disease|Patients with definitively diagnosed of benign disease or precancerous lesion
89267801|NCT03967652||Normal|Healthy volunteers
89267802|NCT01300078|Experimental|MF101 10 grams/day|
89267803|NCT01300078|Experimental|MF101 15 grams/day|
89267804|NCT03816280||Group T2DM-alpha|Patients with diabetes mellitus undergoing CPB with alpha-stat acid-base management
89267805|NCT03816280||Group T2DM-pH|Patients with diabetes mellitus undergoing CPB with pH-stat acid-base management
89267806|NCT03816280||Group Ctrl-alpha|Control patients undergoing CPB with alpha-stat acid-base management
89267807|NCT03816280||Group Ctrl-pH|Control patients undergoing CPB with pH-stat acid-base management
89267808|NCT05578690|Experimental|Lifestyle group|A tailored multifactorial lifestyle intervention consisting of diet, exercise and mentorship in women with overweight or obesity to obtain a healthy lifestyle before and during pregnancy.
89267809|NCT05578690|No Intervention|Standard of care group|The standard of care group will receive no active intervention but are encouraged to seek any possible guidance from the general practitioner for management of pre-pregnancy obesity according to current guidelines.
89267810|NCT01300156|Experimental|ESHAOx arm|Patients who are planned to be treated with ESHAOx chemotherapy
89267811|NCT03811522||Carbon Dioxide Insufflation|Received CO2 insufflation during procedure
89267812|NCT03811522||Air Sufflation|Received ambient insufflation during procedure
89267813|NCT03811288||Participants with type 2 diabetes mellitus (T2DM)|T2DM patients being managed in both primary and specialist care in 10 selected countries.
89267814|NCT00126594|Experimental|Sorafenib Tosylate|Arm I: Oral Sorafenib 400 mg twice daily on days 1-28.
89267815|NCT00126594|Experimental|Sorafenib Tosylate, Recombinant interferon alfa-2b|Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28.
89267816|NCT01080456|Active Comparator|Prograf® Capsule 1 mg|
89267817|NCT01080456|Experimental|Tacrolimus Capsule 1 mg|
89267818|NCT03822052|Active Comparator|Primiparous Patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
89267819|NCT03822052|Active Comparator|Primiparous Patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
89267820|NCT03822052|Active Comparator|Multiparous patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
89267821|NCT03822052|Active Comparator|Multiparous patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
89267822|NCT03811054|Experimental|Apatinib combined with EGFR-TKI|Apatinib 250 millgram（mg/day（d））combined with EGFR-TKI
89267823|NCT00126438|Experimental|123I-mIBG (meta-iodobenzylguanidine)|Single dose
89267824|NCT03821818||Control|Food Allergen Elimination only
89267825|NCT03821818||Allergen Elimination + Willis Exercise|Subjects will have food allergens eliminated and also perform Aerobic-surge, brief high intensity exercise > 75% max HR), five times/day.
89267826|NCT04903756||Patients|Adult patients where major lower limb amputation is being considered.
89267827|NCT04903756||Healthcare professionals|Surgeons, anaesthetists, and allied health professionals involved in decision making with patients where a major lower limb amputation is being considered.
89267828|NCT03967392|Active Comparator|GROUP X(xylocaine)|20 ml bupivacaine 0.5% + 20 ml normal saline.
89267829|NCT03967392|Active Comparator|GROUPX(Dxylocaine and dexamethasone)|20 ml bupivacaine 0.5% + 18 ml normal saline + 8 mg dexamethasone 2 ml
89267830|NCT03821116|Experimental|Milk|At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
89267831|NCT03821116|Experimental|Soured milk (filmjölk)|At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
89267832|NCT00142584|Experimental|1-NEB|Nebivolol
89267833|NCT00142584|Active Comparator|2-MET|Metoprolol
89267834|NCT00126126|Experimental|EBAR Program|Evidence Based Amputee Rehabilitation Program (rehabilitation program based on performance of the Amputee Mobility Predictor
89267835|NCT00126126|No Intervention|Wait List Control|Wait List Control Group
89267836|NCT03816046|Experimental|Technique 1 The Quadrant technique|Intervention: 25 Botulinum Toxin injections. 5 vertical lines and 5 horizontal lines will be draw on the hair bearing area of the armpit amounting to 25 injection points being more concentrated on the center. Each injection consists of 5Units of abobotulinum
89267837|NCT03816046|Experimental|Technique 2 the six injection technique|Intervention: 6 Botulinum Toxin injections. will consist on 6 injections in the hair bearing area equally spaced with each consisting of 8units
89267838|NCT00125268|Active Comparator|MIRE|Subjects randomized to this arm will receive treatment with monochromatic near infrared photo energy (MIRE).
89267839|NCT00125268|Sham Comparator|Sham|Subjects randomized to this arm will receive treatment with the sham device, which is non-active but otherwise identical to the study device.
89267840|NCT03816124|Experimental|Genicular RF|Patients who will receive genicular radiofrequency ablation
89267841|NCT03815968|Experimental|low sodium diet|women diagnosed with oligohydramnios designated for conservative management applying a low-salt diet.
89267842|NCT03815968|No Intervention|regular diet|women diagnosed with oligohydramnios designated for conservative management applying a regular diet.
89267843|NCT03964662|Experimental|Patients with stroke|Rehabilitation of patients with stroke using a new technological device: WeReha
89267844|NCT01080534|Active Comparator|Prograf® Capsule 5 mg|
89267845|NCT01080534|Experimental|Tacrolimus Capsule 5 mg|
89267846|NCT01301560|Experimental|Radiosurgery arm|Radiosurgery before palliative chemotherapy
89267847|NCT01301560|No Intervention|Observation arm|No radiotherapy or local treatment until specific symptoms or sign developed
89267848|NCT03819946|Experimental|Study Group- esophgeal cooling|In this study arm, the participants will have esophageal protection during their catheter ablation procedure, utilizing the esophageal cooling device (Attune Medical, Chicago, IL). During catheter ablation, the cooling device is set to cooling levels.
89267849|NCT03819946|Active Comparator|Control group- esophgeal temperature probe|In this control group, the participants will have esophageal protection utilizing the standard method in current practice, which is an esophageal temperature probe. If recorded temperatures rise above 38 degrees during ablation, ablation treatment is halted in this region.
89267850|NCT05623384|Experimental|Stellate ganglion block combined with facial and glossopharyngeal nerve block group|
89267851|NCT05623384|Experimental|Stellate ganglion block group|
89267852|NCT05623384|Other|Control group|
89267853|NCT00125190|Experimental|rhIGF-1 QD|Subjects received subcutaneous injection (SC) injections of rhIGF-1 once a day.
89267854|NCT03810820|Other|Outpatient TAVI|Consecutive patients scheduled for outpatient TAVI.
89267855|NCT03810664|Experimental|Somatrogon pre-filled PEN|
89267856|NCT03810664|Active Comparator|Somatrogon frozen liquid formulation|
89267857|NCT03810586|Experimental|Comparing blood pressure measurement|In each volunteer, non-invasive measurements of blood pressure will be taken at the same time using a holter manometry device (HUGECARE NIBP Monitor) and the Biobeat BB-613 device, and compared, to show the accuracy and the comparability of the BB-613. As mentioned in the protocol, there would be no medical interventions within the scope of this study. In case hypertension will be observed in a volunteer, the volunteer will be advised by the investigators to see his physician for further evaluation.
89267858|NCT00141726|Experimental|etanercept treatment|Etanercept for lung injury
89267859|NCT03967548|Experimental|0.004% single-dose|96 subjects will be treated with Germinal peptide eye drops 0.004% single dose (16 were pre-tested and 64 were formally tested).
89267860|NCT03819868|Active Comparator|High Cost|Restoration using a high-cost sealant
89267861|NCT03819868|Experimental|Low Cost|Restoration using a low-cost sealant
89290519|NCT03103906|Experimental|Group 1 (Test Product)|Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
89267862|NCT03965598||Ultra-high risk for psychosis (UHP)|"Ultra-high risk for psychosis (UHP) is defined as individuals at the prodromal stage of schizophrenia.~Inclusion Criteria: age of 13-30 years; meet the diagnostic criteria of COPS prodromal syndrome by SIPS clinical interviews; have not received any psychiatric medication; be in good health, without major mental illness or physical illness; normal intelligence, can be operated on a clinical scale; volunteer to participate in the study and sign the written consent form.~Exclusion criteria: exclusion of current or previous psychiatric disorders by SCID interview; meet the diagnostic criteria for substance abuse and substance dependence in DSM-IV; contraindications for MRI; pregnant or lactating women."
89267863|NCT03965598||Healthy controls|"Inclusion Criteria: the gender, age, and education level of the group are matched with the Ultra-high risk group; 13 to 30 years old; right-handed; no history of mental illness; no mental disorder consistent with DSM-IV diagnostic criteria within two or three generations; No contraindications for MRI; volunteer to participate in the study and sign the written consent form.~Exclusion criteria: history of disturbance of consciousness over 5 minutes; history of brain organic disease or head injury; history of alcohol and drug dependence; history of coma; history of endocrine disease; abnormity in examination of blood, heart, liver, or renal function; pregnant or lactating women."
89267864|NCT01301716|Experimental|A|
89267865|NCT01301716|Experimental|B|
89267866|NCT01301716|Experimental|C|
89267867|NCT01075932|Active Comparator|1 g DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA plus 1 g olive oil
89267868|NCT01075932|Active Comparator|2 g DHA-rich fish oil|2 g DHA-rich fish oil containing 900 mg DHA + 180 mg EPA
89267869|NCT01075932|Placebo Comparator|Placebo|2 g olive oil
89267870|NCT01303042|Experimental|Insulin lispro mix 50/50|
89267871|NCT03810430|Active Comparator|intervention group|ten clusters (villages) were received health promotion activities during six months of interventions
89267872|NCT03810430|No Intervention|control group|10 clusters (villages) were not received intervention during the intervention period and by the end of study, it will be compared with the intervention group to measure the change in the primary and secondary outcomes.
89267873|NCT03810118|Experimental|Treatment|All the enrolled patients will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
89267874|NCT01300312|Experimental|1|
89267875|NCT01300312|Active Comparator|2|
89267876|NCT01567384|Experimental|Combination therapy with OSI and Pemetrexed|
89267877|NCT00111228|Experimental|Continuous use of the Guardian RT|Continuous use of the Guardian RT group
89267878|NCT00111228|Experimental|Bi-weekly use of the Guardian RT (once every 2 weeks)|Bi-weekly use of the Guardian RT (once every 2 weeks) group
89267879|NCT00111228|Active Comparator|Control group. SMBG monitoring|Control group. SMBG monitoring group
89267880|NCT04742842|Experimental|Part A: Arm1 (COVIGEN (C19) 0.8 mg ID or Placebo ID)|Participants will be randomized to receive either COVIGEN C19 (0.8 mg) given by ID (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart.
89267881|NCT04742842|Experimental|Part A: Arm2 (COVIGEN (C19) 2.0 mg IM or Placebo IM)|Participants will be randomized to receive either COVIGEN C19 (2 mg) given by IM (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart.
89267882|NCT04742842|Experimental|Part A; Arm 3 (COVIGEN (C19) 4.0 mg IM or Placebo IM)|Participants will be randomized to receive either COVIGEN C19 (4 mg) given by IM (n=40) or saline placebo (n=10), administered in a two dose regimen, 28 days apart
89267883|NCT04742842|Experimental|Part B: Arm 1 (COVIGEN (C20) 1.0 mg ID) in BNT162b2 primed participants|Participants in Part B who have received a 2 dose primary course of Pfizer BNT162b2 vaccine will receive COVIGEN C20 (1mg) vaccine given by ID (n=25)
89267884|NCT04742842|Experimental|Part B: Arm 2 (COVIGEN (C20) 1.0 mg ID) in ChAdOx1-S primed participants|Participants in Part B who have received a 2 dose primary course of Astra Zeneca ChAdOx1-S vaccine will receive COVIGEN C20 (1mg) vaccine given by ID (n=25)
89267885|NCT01080612|Experimental|330 mg pregabalin controlled release: 400 to 500 calories|
89267886|NCT01080612|Experimental|330 mg pregabalin controlled release: 600 to 750 calories|
89267887|NCT01080612|Experimental|330 mg pregabalin controlled release: 800 to 1000 calories|
89267888|NCT01080612|Other|300 mg pregabalin immediate release|
89267889|NCT03810274||3DV+TPS|This experiment included a total of 300 patients with nasopharyngeal carcinoma, using 3DV + TPS software and imported TPS, domestic TPS, these three sets of TPS delineate bilateral crystal, bilateral optic nerve, bilateral eyeball, bilateral parotid gland, oral cavity, spinal cord There are 12 organs in the brainstem and brain, and the accuracy and speed of the 3 sets of TPS sketches are compared.
89267890|NCT03810040|Active Comparator|Odd-numbered days|Once odd-numbered days the zytoges of IVF cycle were collected. The 140 microns denuding pipette was used.
89267891|NCT03810040|Experimental|Even-numbered days|Once even-numbered days the zytoges of IVF cycle were collected. The 150 microns denuding pipette was used.
89267892|NCT01300390||End-stage liver disease pre-transplant|Patients with end-stage liver disease (non-fulminant) awaiting liver transplant
89267893|NCT03819790|Experimental|Insulin Glargine + GLP-1 RA|Insulin Soliqua (a titratable combination of insulin Glargine + GLP-1 RA) will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with or without metformin.
89267894|NCT03819790|Active Comparator|Basaglar/Lantus + gliclazide MR|Basal insulin Basaglar/Lantus will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with gliclazide MR 60 mg OD, with or without metformin.
89267895|NCT01301872|Other|1|All patients meet ALI/less severe ARDS criteria
89267896|NCT01560364||Hemofilter|
89267897|NCT01560442||buprenorphine|
89267898|NCT01560442||Methadone Hydrochloride|
89290520|NCT03103906|Other|Group 2 (No Treatment)|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Participants will massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
89267899|NCT05623150||Descriptive study|"The patients included in this observational study are patients with hepatic steatosis either related to NAFLD or to alcohol-related liver disease.~Patients included in the study may have hepatocellular carcinoma.~Thus, 4 groups of patients can be recruited:~patients with NAFLD without hepatocellular carcinoma,~patients with NAFLD with hepatocellular carcinoma,~patients with alcohol-related liver disease without hepatocellular carcinoma, -patients with alcohol-related liver disease with hepatocellular carcinoma."
89267900|NCT03807934|Experimental|Active High-Definition Stimulation|Active high-definition stimulation of targeted brain regions involved in perception and cognition.
89267901|NCT03807934|Sham Comparator|Sham High-Definition Stimulation|Sham high-definition stimulation of targeted brain regions involved in perception and cognition.
89267902|NCT01300468|Experimental|Dose-escalation|
89267903|NCT01303120|Active Comparator|Femoral Nerve Block|
89267904|NCT01303120|Active Comparator|Combined Nerve Blocks|
89267905|NCT01303120|Active Comparator|Patient-controlled analgesia|
89267906|NCT00110994|Experimental|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine|Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
89267907|NCT00110994|Active Comparator|Placebo + Dacarbazine|Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
89267908|NCT01078194||Weight regain / weight loss failure|Weight regain of more than 10 kg from or weight loss of less than 50% EWL 18 months after lap. gastric bypass
89267909|NCT04435990|Experimental|Experimental:10,000 MM09|10,000 TU/mL of subcutaneous immunotherapy
89267910|NCT04435990|Experimental|Experimental: 30,000 MM09|30,000 TU/mL of subcutaneous immunotherapy
89267911|NCT04435990|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without any active ingredients.
89267912|NCT01560052|Active Comparator|oral methylprednisolone|"oral methylprednisolone~Original Cohort:~Methylprednisolone group; start at 0.8mg/kg/day with a maximal 48mg/kg/day x 2months, taper by 8mg/day every month with optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~Low Dose Cohort:~Methylprednisolone group; start at 0.4mg /kg/day with a maximal dose of 32mg/day and a minimum dose of 24mg/day, reducing over 6-9months.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
89267913|NCT01560052|Placebo Comparator|placebo|"Original Cohort:~Matching placebo; Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines; Low Dose Cohort; Matching placebo: Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
89267914|NCT01560130|Active Comparator|Shape Up Rhode Island + Online Weight Loss + Incentives|
89267915|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program|
89267916|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|
89267917|NCT05515588|Experimental|Part A: BI 690517 (C-14)|
89267918|NCT05515588|Experimental|Part B: BI 690517 fasted (test treatment, T) / BI 690517 (C-14) (reference treatment, R)|
89267919|NCT01303198|Active Comparator|CPAP|Use of CPAP as treatment for sleep apnea
89267920|NCT01303198|Active Comparator|APAP|Use of APAP as treatment for sleep apnea
89267921|NCT01303276||Anti-VEGF group|Patients who are clinically indicated for the intravitreal injection of ranibizumab
89267922|NCT01303276||Age-matched controls|Group of healthy participants who will be age and gender matched
89267923|NCT01303354|Experimental|DXM 4 mg|Dexamethasone 4 mg
89267924|NCT01303354|Experimental|DXM 8 mg|Dexamethasone 8 mg
89267925|NCT01303354|Experimental|DXM 12 mg|Dexamethasone 12 mg
89267926|NCT03804970|Experimental|Intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+ Having the Diabetic Club+Watching brief video and basic explanation for disease
89267927|NCT03804970|Experimental|Adjusted intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+Having the Diabetic Club+Watching brief video and basic explanation for disease( But the intensity of intervention based on the severity of diabetic disease)
89267928|NCT03804970|Active Comparator|Control group|Watching brief video and basic explanation for disease
89267929|NCT05622994|Active Comparator|Rimonabant|Rimonabant 5mg
89267930|NCT05622994|Placebo Comparator|Placebo|Placebo
89267931|NCT01303432|Experimental|Mobilee yogurt|Subjects eating daily on yogurt supplemented with Mobilee
89267932|NCT01303432|Placebo Comparator|Placebo yogurt|Subjects receiving daily a standard yogurt
89267933|NCT05622916|Experimental|Intervention|Daily topical application (twice/day, in the morning and 30-60 minutes before bed at night) for 56 days.
89267934|NCT05622916|Active Comparator|Comparison|Weekly application (1x/week) by the physician for 8 weeks
89267935|NCT03815032|Experimental|Optowire Deux FFR assessment (1)|"A total of 45 consecutive patients will be recruited:~group 1 (n=30): To assess the differences in FFR measurements (drift) made by the OptoWire Deux FFRTM guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires"
89267936|NCT03815032|Experimental|Optowire Deux FFR assessment (2)|group 2 (n=15): To assess the differences in FFR measurements (drift) obtained from an OptoWire DeuxTM FFR guidewire and compare it to the FFR measurement by a VERRATATM guidewire
89267937|NCT04285606|Experimental|Patient-led rehab group|Immobilization in arm sling for a short period time followed by patient-led shoulder exercises for rehab following reverse shoulder arthroplasty
89267938|NCT04285606|No Intervention|Supervised rehab group|Prolonged immobilization in arm sling followed by supervised physical therapy by therapists for rehab following reverse shoulder arthroplasty
89267939|NCT03819556|Active Comparator|Active immunotherapy with milk protein|Daily dose fresh milk protein increased in 11 steps
89267940|NCT03819556|No Intervention|Control|Diet free from milk protein
89267941|NCT03804034|Experimental|Occlusal trauma group|an occlusal interference was placed on the lower teeth as follows. Articulating paper was used to mark the contact area between the upper and lower premolars indicated for extraction. Once established, the marked area on the lower premolar was acid-etched with 37% phosphoric acid for 15 s, washed, and dried. A bonding agent was placed and light-cured for 15 s, and finally, a 1- to 2-mm block of resin was placed over the contact area and light-cured for 40 s. Articulating paper was used again to verify that only the premolars that were going to be extracted had contact during normal occlusion as well as in lateral movements. Patients were given chewing gum and indications to repeat 20 masticatory cycles for 30 s, followed by a 30-s rest interval, and repeat the sequence again for a period of 30 min. This chewing cycle was repeated three times every 8 h for the first 24 h
89267942|NCT03804034|Experimental|Moderate orthodontic force group|A convertible standard buccal tube was bonded over the buccal face of the first molar with resin and a McLaughlin, Bennett, and Trevisi slot size 0.022 bracket was bonded over the buccal face of the premolars. One 0.0017 × 0.025 in titanium molybdenum alloy wire cantilever was inserted into each first molar tube, and the wire was bent buccally to form a helix. The cantilever was clinched to the distal end of the tube, and a tipping and extrusive force was applied on the premolar. The activation angle was 45° with a force of 56 g, which was applied to the tooth for 24 h before it was extracted.
89267943|NCT03804034|Experimental|Occlusal trauma and moderate orthodontic force group|the combination of occlusal trauma and orthodontic force .
89267944|NCT03804034|No Intervention|Control Group|No experimental device to produce occlusal trauma or orthodontic forces
89267945|NCT03819244|Experimental|Diode laser|Soft tissue incision with 940 nm Gallium Aluminum Arsenide diode laser, at implant recovery settings (2.5 W output power, average power: 1.25 W, pulse length : 1.00 ms, pulse interval: 1.00 ms) in second-stage implant surgery.
89267946|NCT03819244|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz, H mode, 10% water and 10% air) in second-stage implant surgery.
89267947|NCT01303588|No Intervention|Waiting Group|
89267948|NCT01303588|Active Comparator|Qigong|
89267949|NCT01303588|Active Comparator|Yoga|
89267950|NCT01303666|Active Comparator|TI of the knee|
89267951|NCT01303666|Active Comparator|Intra-articular CSI|
89267952|NCT03819166|Experimental|experimental group|The participants recruited in the group will receive the input of deep touch pressure during their procedures of dental treatment.
89267953|NCT03819166|Sham Comparator|control group|The participants recruited in the group will not receive the input of deep touch pressure during their procedures of dental treatment.
89267954|NCT01304446|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
89267955|NCT03801460|No Intervention|SOC|Standard of Care
89267956|NCT03801460|Experimental|RAPR|Remotely administered physiological reconditioning program
89267957|NCT04246762|Experimental|Olokizumab 128 mg +Cocktail drugs|"All subjects will receive the following treatment:~Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) orally administered with 240 mL of water on Day 1, single subcutaneous injection of OKZ 128 mg administered on Day 8 and second dose of Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) orally administered on Day 22"
89267958|NCT03796624|Experimental|Investigational Device Micropure 1.2.3.|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. in one of the eyes of the study subject"
89267959|NCT03796624|Active Comparator|Comparator PODEYE|"Implantation of monofocal intraocular lens (IOL) PODEYE in the contralateral eye of the study subject"
89267960|NCT03799978|Experimental|Treatment A: ACT-541468 50 mg under fasted conditions|Single oral dose administered on Day 1 under fasted conditions.
89267961|NCT03799978|Experimental|Treatment B: ACT-541468 50 mg under fed conditions|Single oral dose administered on Day 1 administered after food intake.
89267962|NCT03799510|Experimental|Group 1|Healthy school children with no infectious history of Schistosomiasis receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
89267963|NCT03799510|Experimental|Group 2|School children with an infectious history of S. haematobium and-or S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
89267964|NCT03799510|No Intervention|Group 3|School children with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) not receiving vaccine. Control group.
89267965|NCT03799120|Placebo Comparator|tamsulosin QD + Placebo|0.4 mg tamsulosin QD + Placebo QD
89267966|NCT03799120|Experimental|tamsulosin BID|0.4 mg tamsulosin BID
89267967|NCT03796312|Experimental|Tub Bathing|In this group, preterm infants were given tub bathing.
89267968|NCT03796312|Active Comparator|Sponge Bathing|Separate cotton cloths were prepared for each body area in the sponge bath. The room temperature was set to 26-27°C to prevent hypothermia. The temperature of the water used for sponge bathing was set to 37-38°C. Alongside the bath, the infant was placed on a flat, protected surface and washed from a bowl of water, using the same mild cleanser. The eyes, face, and head were wiped and dried while the baby was wrapped in a blanket. The wrap was opened so that body parts could be washed, dried, and then immediately rewrapped, after which infants were diapered.
89267969|NCT03792724|Experimental|Cohort A|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg every 4 weeks (Q4W) from Cycle 3 and beyond
89267970|NCT03792724|Experimental|Cohort B|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg Q4W from Cycle 3 and beyond
89267971|NCT03792646|Experimental|Experimental|The experimental group will inject 20 grams of whey protein diluted in water after the exercise training.
89267972|NCT03792646|Placebo Comparator|Placebo|The placebo group will inject 20 grams of maltodextrin diluted in water after the exercise training.
89267973|NCT00144170|Other|Tipranavir(TPV)/low dose ritonavir(r)|
89267974|NCT00144170|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
89267975|NCT03799042|Experimental|Vitural Reality|Virtual Reality 3D glass
89267976|NCT03799042|Active Comparator|Inter-generation interaction|Elders-teenager interaction
89267977|NCT03798886||Natural frozen embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. After spontaneous ovulation, embryo transfer will be planned. Luteal phase support will not be used.
89267978|NCT03798886||modified natural embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. When follicle diameter is 16-17 mm we will apply hCG (recombinant hCG). After ovulation, embryo transfer will be done. Luteal phase support will not be used.
89267979|NCT03798808|Experimental|Family Nutriathlon group|Web-based nutrition program (encouraging consumption of fruits, vegetables and dairy products through an online platform)
89267980|NCT03798808|No Intervention|Control group|General nutrition guidelines (e.g. following Canada's Food Guide)
89267981|NCT03798730|Experimental|Solid Model|"Cake~-Control Vanilla Cake and Protein Fortified Vanilla Cake~Biscuit -Control Lemon Biscuit and Protein Fortified Lemon Biscuit"
89267982|NCT03798730|Experimental|Liquid Model|"Whey Protein Beverages~Native sample (protein unheated)~Denatured whey protein (protein heated to denature)"
89267983|NCT03798652||Patients referred for CABG|Patients with known coronary artery disease referred for isolated surgical revascularisation, who will be invited to attend our facility for a research CMR scan, a research 3D transthoracic echocardiogram and a 6 minute walk test
89267984|NCT03796390|Experimental|CD123 CAR-T cells|Patients will be be treated with CD123 CAR-T cells
89267985|NCT03796234|Experimental|Dietary and physiotherapy|A multidisciplinary program was developed. 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
89267986|NCT03796234|Experimental|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
89267987|NCT04186468|Experimental|ICU follow-up clinic|Participants will be invited to visit the ICU follow-up clinic.
89267988|NCT04186468|No Intervention|Usual care|Participants will solely receive usual care.
89267989|NCT03798340|Experimental|Vibratory perturbed task-specific movement training|Intervention: 10 minutes of traditional sensorimotor facilitation followed by 20 minutes of vibratory perturbed task-specific movement training
89267990|NCT03798340|Active Comparator|Traditional task-oriented facilitation|Intervention:10 minutes of traditional sensorimotor training followed by 20 minutes of reach-to-grasp and hand release training.
89267991|NCT00255086|Experimental|Memantine|10mg Memantine
89267992|NCT00255086|Placebo Comparator|Control|10 mg Placebo pill
89267993|NCT00110214|Experimental|Arm I|Patients receive docetaxel IV over 1 hour and placebo IV over 30-90 minutes on day 1. Patients also receive oral prednisone once daily on days 1-21.
89267994|NCT00110214|Experimental|Arm II|Patients receive docetaxel and prednisone as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
89267995|NCT04176172|Active Comparator|Varenicline & Standard Cessation Counseling|varenicline plus standard behavioral smoking cessation treatment
89267996|NCT04176172|Experimental|NMR-Tailored Medication & Standard Cessation Counseling + MAPS|varenicline or nicotine patch plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
89267997|NCT03798262|Active Comparator|Gluten|Patients receive 16 g of gluten acutely and afterwards 2 glutenfree muffins with 8 g of gluten for 5 days sub-acutely
89267998|NCT03798262|Placebo Comparator|Placebo|Patients receive 16 g of whey protein acutely and afterwards 2 glutenfree muffins for 5 days sub-acutely
89267999|NCT01078272|Experimental|Remote Ischemic Preconditioning (RIPC)|Randomized subjects who are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
89268000|NCT01078272|Placebo Comparator|Sham Remote Ischemic Preconditioning|Patients who prior to stenting have the RIPC blood pressure cuff placed but not inflated for 3 5 minute episodes with 5 minute rest periods.
89268001|NCT03795844|Active Comparator|Nathanson retractor|Liver retraction in group 1, a 5 mm incision was made under xiphoid during the operation, and Nathanson retractor was placed and liver left lobe retraction would be achieved.
89268002|NCT03795844|Active Comparator|snake retractor|Liver retraction in group 2 ; 5 mm incision under the xiphoid will be used. Snake retractor was placed and liver left lobe retraction would be achieved.
89268003|NCT03795844|Active Comparator|fan retractor|Liver retraction in group 3 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus
89268004|NCT03795844|Active Comparator|CONTROL GROUP|Liver retraction in group 4 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus will be provided with the aid of laparoscopic grasper without any special tools
89268005|NCT03792802|Active Comparator|classic port sites|. Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent
89268006|NCT03792802|Active Comparator|same dermatome port sites|One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port.
89268007|NCT05669170|Active Comparator|Treatment|Methylphenidate 20 mg
89268008|NCT05669170|Placebo Comparator|Placebo|Placebo
89268009|NCT03792568|Experimental|ALK mutation|
89268010|NCT01303822|Experimental|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
89268011|NCT03798184|Experimental|Selective-etch with bioglass surface roughening|
89268012|NCT03798184|Active Comparator|Selective-etch without bioglass surface roughening|
89268013|NCT03798184|Experimental|Self-etch with bioglass surface roughening|
89268014|NCT03798184|Active Comparator|Self-etch without bioglass surface roughening|
89268015|NCT03798028|Experimental|UC-MSCs treatment|the participants will receive the single-dose UC-MSCs (1×10^6 cells/kg ) in combined with the present treatment.
89268016|NCT03798028|No Intervention|no UC-MSCs treatment|the participants will receive the placebo in combined with the present treatment.
89268017|NCT03799822|Active Comparator|Control|Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
89268018|NCT03799822|Experimental|rivaroxaban|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
89268019|NCT03799822|Experimental|rivaroxaban + K2|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements
89268020|NCT03799900|Experimental|Part 1, Cohort 1: Ketamine Low Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
89268021|NCT03799900|Placebo Comparator|Part 1, Cohort 1: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
89268022|NCT03799900|Experimental|Part 1, Cohort 2: Ketamine Medium Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
89268023|NCT03799900|Placebo Comparator|Part 1, Cohort 2: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
89268024|NCT03799900|Experimental|Part 1, Cohort 3 (Optional): Ketamine High Dose|Optional: some participants will be administered a single IV dose of ketamine on Day 1.
89268025|NCT03799900|Placebo Comparator|Part 1, Cohort 3 (Optional): Placebo|Optional: some participants will be administered a single IV dose of placebo on Day 1.
89268026|NCT03799900|Experimental|Part 2, Qualification Phase: Ketamine|Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.
89268027|NCT03799900|Placebo Comparator|Part 2, Qualification Phase: Placebo|Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.
89268028|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
89268029|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Medium Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
89268030|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
89268031|NCT03799900|Active Comparator|Part 2, Treatment Phase: Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
89268032|NCT03799900|Placebo Comparator|Part 2, Treatment Phase: Placebo|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
89268033|NCT03795688||Basic, non-imaging group|"Pregnant women who will deliver by planned caesarian. Participants enrolled in the study that are not eligible for the imaging subgroup.~All participants start in the basic program. Includes collection of blood, cerebrospinal fluid, saliva, hair, placenta tissues, umbilical cord blood and psychometrics."
89268034|NCT03795688||Extended, imaging group|A subgroup of 70 pregnant women who will deliver by planned caesarian selected towards either high (N=35) or low (N=35) risk for perinatal depression will undergo brain imaging in addition to the elements of the basic program. The extended imaging program includes functional and structural magnetic resonance imaging, positron emission tomography (PET) and a semistructured interview for depression symptoms (HAM-D17).
89268035|NCT03795532|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes. The rest of the session at 22kv (full power).
89268036|NCT03795532|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
89268037|NCT05625022|Experimental|Lianhua Qingke plus conventional therapy|
89268038|NCT05625022|No Intervention|Conventional therapy|
89268039|NCT03792178|Active Comparator|Nano resin composite|are types of synthetic resins which are used in dentistry as restorative material or adhesives.
89268040|NCT03792178|Experimental|Bulk fill composite|Bulk- ll composites are claimed to be restorative materials used in deep preparations and effectively photoactivated in layers up to 4 mm.
89268041|NCT01303978|Experimental|APD421 starting dose|
89268042|NCT03994900|Experimental|Blood sampling for HbNO assessment|
89268043|NCT01304056||Critically ill patients|Patients that are treated in intensive care unit and given ventilatory therapy.
89268044|NCT01304056||Interventional volunteer group|Healthy volunteers
89268045|NCT03799666|Experimental|Pulmonary Rehabilitation Group|Patients will participate in a 12-week community-based pulmonary rehabilitation programme.
89268046|NCT03799666|Active Comparator|Standard Care Group|Patients will continue to receive the standard care, which means the daily medication prescribed by the pshysician from the primary care centre team.
89268047|NCT01304602|Experimental|Irinotecan + BKM120|Irinotecan + BKM120 at the assigned cohort dose level.
89268048|NCT01304134|Experimental|Oxycodone i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
89268049|NCT01304134|Active Comparator|Morphine i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
89268050|NCT00124020|Experimental|Telavancin|
89268051|NCT00124020|Active Comparator|Vancomycin|
89268052|NCT01080690|Active Comparator|EGD|In this arm EGD will be performed before EUS
89268053|NCT01080690|Active Comparator|EUS|In this arm, EUS will be performed before EGD.
89268054|NCT01080846|Experimental|600 mcg of sublingual misoprostol|
89268055|NCT03792412|Experimental|Intervention: Usability Questionnaire|Patients hand over the usability questionnaire to evaluate the self developed structured follow-up program in form of a so-called pass to their family doctor twice in six months. Family doctors examine the postbariatric patient using the pass and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator.
89268056|NCT03792412|Other|Control: Usability Questionnaire|"Patients hand over the usability questionnaire to evaluate the state of the art guideline for postbariatric follow up appointments in form of a folder Metabolische Chirurgie und die perioperative Betreuung to their family doctor twice in six months. Family doctors examine the postbariatric patient using the guideline and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator."
89268057|NCT01076322|Experimental|Treatment-A sequence|Meptin® Swinghaler / Ventolin® MDI
89268058|NCT01076322|Experimental|Treatment-B sequence|Ventolin® MDI / Meptin® Swinghaler
89268059|NCT03795064|Experimental|Immediate Intervention|Patients in this group will be treated with foam sclerotherapy immediately in the first visit to outpatient clinic (immediate intervention).
89268060|NCT03795064|Active Comparator|Early Intervention|Patients in this group will be treated with foam sclerotherapy in the following visit to outpatient clinic at four weeks (early intervention).
89268061|NCT03966066|Experimental|low dose erythromycin group|Erythromycin 3-5mg/kg.d orally for 6 months
89268062|NCT03966066|No Intervention|Non-erythromycin treatment group|systemic treatment
89268063|NCT03792100|Experimental|SmofKabiven emulsion for infusion|SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.
89268064|NCT03792100|Active Comparator|"Hospital compounded All in one emulsion for PN"|"Hospital compounded All in one emulsion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drugs will be 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%."
89268065|NCT00215540|Experimental|SURFAXIN High Dose|SURFAXIN (lucinactant) at 175 mg/kg
89268066|NCT00215540|Experimental|SURFAXIN Low Dose|SURFAXIN (lucinactant) at 90 mg/kg
89268067|NCT00215540|Placebo Comparator|Placebo|Sham air using 3.0 mL/kg volume of air
89268068|NCT03966846|Experimental|Kefir Group|Kefir group received one bottle of kefir (180 ml) daily for 12 weeks. Microbial composition of the kefir included Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. cremoris, Lactococcus lactis ssp. diacetylactis, Leuconostoc mesenteroides ssp. cremoris, Lactobacillus kefyr, Kliyveromyces marxianus, and Saccharomyces unisporus.
89268069|NCT03966846|Placebo Comparator|Control Group|Control group received one bottle of milk (180 ml) daily for 12 weeks.
89268070|NCT03797950|No Intervention|Control|No active intervention
89268071|NCT03797950|Experimental|Voice Reminder (Group A)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Enrolled women will receive reminders via mobile phone to highlight the importance of early vaccinations for newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Information on where and when these vaccines will be available in the woman's community will be provided."
89268072|NCT03797950|Experimental|Cash Incentive (Group B)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Volunteers will encourage enrolled women to seek early vaccination for their newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Volunteers will provide information on where and when these vaccines will be available in the woman's community. Volunteers and enrolled women will receive small monetary rewards via mobile money for receiving OPV0 and BCG vaccinations on time."
89268073|NCT03797716|No Intervention|Standard Care arm|"Participants will receive standard of care from the pre-assessment clinic until discharge.~A typical preparatory National Health Service pathway would include: meeting a specialist nurse in the preoperative assessment clinic; a preoperative anaesthetic and surgical consultation; interaction with health play specialists on the day of surgery; and distraction interventions such as hand-held tablets during induction of anaesthesia. Participants may have inhalation or intravenous induction depending on the primary management plan of the anaesthetist in charge.~Participants in the standard care arm will also receive a virtual reality cardboard headset, which can be taken home, personalised and decorated before use with virtual reality apps available to download from the app stores."
89268074|NCT03797716|Experimental|Intervention arm|Participants allocated to the intervention arm will receive the same peri-operative management as the standard care arm and will also receive an access code enabling them to use the Little Journey app in the weeks leading up to their operation. We suggest the Little Journey app is used in the days to weeks leading up to the child's operation depending on their age. On downloading the app, if parents/carers insert the age of the child and date of surgery into the Little Journey app they will be sent a push notifications reminding them when to use it according to their child's age. However, it can be used as frequently as the child and/or their parents or carers wish before the operation.
89268075|NCT01304212|Active Comparator|femoral block|
89268076|NCT01304212|Experimental|local infiltration + femoral nerve block|Combination of local infiltration with drugs and femoral nerve block
89268077|NCT01304212|Active Comparator|several drugs local infiltration|
89268078|NCT03797638|Experimental|Patients with writer's cramp|Patients with writer's cramp
89268079|NCT03797638|Other|Control subjects|Control subjects, without writer's cramp, matched with case subjects with age, gender and hand writing
89268080|NCT01560520||Accelerometer|
89268081|NCT00143390|Experimental|1|
89268082|NCT00143390|Experimental|2|
89268083|NCT01305616|Active Comparator|Group 1, glaucoma and cataract|Group1 were those patients with visually significant cataract (less than grade 2) and mild to moderate open angle glaucoma
89268084|NCT01305616|Sham Comparator|Group2, cataract patients|This group included those patients with visually significant cataract and normal other eye examination.
89268085|NCT03238534|Active Comparator|Omeprazole 20mg|"Patients will be provided with enough amount of 20 mg omeprazole [30' before meal] and Neobianacid® placebo [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole + Neobianacid® placebo; Lunch: Neobianacid® placebo; Midafternoon: Neobianacid® placebo; Dinner: Neobianacid® placebo; Before going to bed: Neobianacid® placebo.~Day14-27 Breakfast: Omeprazole+ Neobianacid® placebo on demand Lunch: Neobianacid® placebo on demand Dinner: Neobianacid® placebo on demand Any other time: Neobianacid® placebo on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
89268086|NCT03238534|Experimental|Neobianacid®|"Patients will be provided with enough amount of Omeprazole placebo [30' before meal] and Neobianacid® [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole placebo + Neobianacid® Lunch: Neobianacid® Midafternoon: Neobianacid® Dinner: Neobianacid® Before going to bed: Neobianacid®~Day14-27 Breakfast: Omeprazole placebo + Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
89268087|NCT05624476||experimental group|Patients with urinary tract infection received treatments guided by both culture and mNGS
89268088|NCT05624476||control group|Patients with urinary tract infection received treatments guided by culture first
89268089|NCT03792022||Group 1|Adherence to timely vaccine uptake
89268090|NCT01304290|No Intervention|Control|
89268091|NCT01304290|Experimental|Glucose/Insulin Clamp|
89268092|NCT03797248||Cohort 1|adjuvant chemotherapy combined with Chinese herbal medicine
89268093|NCT03797248||Cohort 2|adjuvant chemotherapy only
89268094|NCT01304368|Active Comparator|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
89268095|NCT01304368|No Intervention|Waiting list|Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
89268096|NCT00141102|Experimental|A|
89268097|NCT00141102|Active Comparator|B|
89268098|NCT03663712|Experimental|Dose|"Drug: Talimogene Laherparepvec~There will be two parts to this phase I study: 1) Dose Escalation Cohort; 2.) Dose Expansion Cohort~In the Dose Escalation Cohort, three subjects will be enrolled at the starting dose of 4x106 PFU, and the dosing will continue in the standard '3+3' dose escalation scheme. If the starting dose is tolerated, enrollment will continue at 4x107 and 4x108 PFU. Once the MTD is determined, six subjects will be enrolled to the Dose Expansion Cohort at the MTD. All subjects will be dosed with talimogene laherparepvec intraperitoneal (IP) once every 2 weeks for up to 4 doses (in addition to the initial seroconversion dose, which all patients will receive)."
89268099|NCT03797092|Active Comparator|Active|Allogeneic adipose-derived stromal cells (CSCC_ASC)
89268100|NCT03797092|No Intervention|Control group|No treatment
89268101|NCT03796936|Experimental|3MDR With Eye Movement Component (EM+)|All participants will complete 10 treatment sessions (3 preparatory, 6 3MDR and 1 concluding), led by a trained therapist, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component. For those in the EM+ intervention group, the EM component starts after the participant has thoroughly discussed a picture with the therapist; a red ball starts at one edge of the screen, moves rapidly back and forth across it, and upon reaching either edge, a 2-digit number appears superimposed in white on the ball. The number changes every time the ball meets either edge. The participant is asked to track the ball and call out the displayed numbers.
89268102|NCT03796936|Active Comparator|3MDR Without Eye Movement Component (EM-)|All participants will complete 10 treatment sessions (three preparatory sessions, six 3MDR sessions and one concluding session; see Table 1), led by a therapist who has been completed training in the conduct of this form of therapy, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component.There will be no exposure to the distractor stimulus (red ball) for those in the EM- intervention group.
89268103|NCT03796780|Active Comparator|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil for 6 weeks
89268104|NCT03796780|Placebo Comparator|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil for 6 weeks
89268105|NCT01080924|Experimental|Low frequency ultrasound spectroscopy|Low frequency ultrasound spectroscopy after broncholysis
89268106|NCT03573856|Active Comparator|Active Living|Three component behavioral intervention consisting of group-based classes, individual motivational interviewing-based sessions, and resource toolbox
89268107|NCT03573856|Placebo Comparator|Health and Safety|One component health and safety program consisting of group classes
89268108|NCT01078428|Active Comparator|Silicone gel|Gel containing silicone gel
89268109|NCT01078428|Placebo Comparator|Vaseline|Gel containing petrolatum gel
89268110|NCT01560598||Reflux esophagitis|those with endoscopically proven reflux esophagitis
89268111|NCT01560598||Normal|those with normal GFS finding (without definite mucosal break at Z-line)
89268112|NCT01081002|Active Comparator|Anesthesia (=A) with lidocaine 10%|3 min before sedation 4 puffs of terbutaline diluted lidocaine solution (Xylocaine ® 10% spray, Astra Zeneca, London, UK) will be sprayed on the pharynx
89268113|NCT01081002|Placebo Comparator|A with diluted gentian root solution|3 min before sedation 4 puffs of highly diluted gentian solution will be sprayed on the pharynx
89268114|NCT03789136||Primary colon cancer|
89268115|NCT03789136||Liver metastases|
89268116|NCT03789136||Inguinal hernia (control)|
89268117|NCT03789136||Abdominal hysterectomy (control)|
89268118|NCT03789058|Active Comparator|Surgical with conventional NSAID 3 times/day|Control group will have surgical intervention to remove wisdom tooth and receive conventional NSAID treatment three times per day
89268119|NCT03789058|Experimental|Surgical with conventional NSAID 2 times/days|The experimental group will have surgival intervention to remove wisdom tooth and receive NSAID treatment only two times per day: once after breakfast and once after lunch, but not at night.
89268120|NCT03788824||pCLE group|pCLE is used to distinguish the inflammation activity of UC, and compared with histology
89268121|NCT03788902|Experimental|ADHD group|This group was examined twice - once after taking Ritalin and once after taking placebo
89268122|NCT03788902|No Intervention|Healthy control|Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD
89268123|NCT05669092|Experimental|ARM A: dMMR/MSI-H patients|patients will receive 12 cycles of PD-1 antibody
89268124|NCT05669092|Experimental|ARM B: dMMR/MSI-H patients|patients will receive 5*5Gy short-course radiotherapy, followed by 12 cycles of PD-1 antibody
89268125|NCT05669092|Experimental|ARM C: pMMR/MSS patients|patients will receive CRT followed by 6 cycles of XELIRI
89268126|NCT05669092|Experimental|ARM D: pMMR/MSS patients|patients will receive CRT followed by 12 cycles of FOLFRINOX
89268127|NCT00255008|Active Comparator|Genotype 1 SEA PEG-IFN/RIB 48 w|Genotype 1 hepatitis C virus (HCV)-infected Southeastern Asian (SEA) subjects treated for up to 48 weeks with PEG-Intron (peginterferon alfa-2b; PEG-IFN) REDIPEN and REBETOL (ribavirin; RIB) combination therapy
89268128|NCT00255008|Active Comparator|Genotype 1 Caucasian PEG-IFN/RIB 48 w|Genotype 1 HCV-infected Caucasian subjects treated for up to 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
89268129|NCT00255008|Experimental|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 24 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
89268130|NCT00255008|Active Comparator|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
89268131|NCT01306240|Experimental|Early strategy|Intratracheal poractant alpha (Curosurf®) after tracheal intubation
89268132|NCT01306240|Active Comparator|Delayed strategy|Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 > 60%
89268133|NCT03714022|Experimental|Treatment A|Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.
89268134|NCT03714022|Active Comparator|Treatment B|Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.
89268135|NCT05624164|Experimental|Lateralized microfracture group|Participants with medium to larger size rotator cuff tears will be treated with arthroscopy rotator cuff repair with microfracture at the lateral side of the footprint immediately.
89268136|NCT05624164|No Intervention|No microfracture group|Participants with medium to larger size rotator cuff tears will be treated with arthroscopy rotator cuff repair without microfracture.
89268137|NCT00143312|Experimental|1|
89268138|NCT05619640||Group 1|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Uninfected; No viral RNA detected
89268139|NCT05619640||Group 2|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Ambulatory mild disease Viral RNA detected but asymptomatic course, Symptomatic but not given any medication and Symptomatic given medication
89268140|NCT05619640||Group 3|The study group divided into 3 groups according to COVID-19 WHO Clinical progression scale: Hospitalized moderate disease Hospitalized but no oxygen therapy and Hospitalized and given oxygen by mask or nasal cannula
89268141|NCT03967028||Study group|primigravida scheduled for cesarean section
89268142|NCT03791866|Experimental|30% target total enteral nutrition|
89268143|NCT03791866|Experimental|60% target total enteral nutrition|
89268144|NCT03791866|Active Comparator|100% target total enteral nutrition|
89268145|NCT03967262|Experimental|Intervention|
89268146|NCT03967262|No Intervention|Control|
89268147|NCT04833946|Active Comparator|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
89268148|NCT04833946|Placebo Comparator|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast & 30 minutes before bedtime
89268149|NCT01077206|Active Comparator|Simvastatin 80mg|
89268150|NCT01077206|Active Comparator|Simvastatin 40mg|
89268151|NCT03791710|Placebo Comparator|control group|this group of patients are treated with the regular conventional methods like application of topical agents e.g silver sulphadiazine
89268152|NCT03791710|Active Comparator|fat grafting group|this group of patients will have the autologous fat grafting for their burn wounds
89268153|NCT05623540||bisphosphonates users|Patients who underwent primary total joint arthroplasty with bisphosphonates use
89268154|NCT05623540||bisphosphonates nonusers|Patients who underwent primary total joint arthroplasty without bisphosphonates use
89268155|NCT05622838||Pregnant Pre-eclamptic women with IUGR at 32-36 weeks|
89268156|NCT05622838||Pregnant Pre-eclamptic women with healthy fetus at 32-36 weeks|
89268157|NCT05622838||Normal pregnant women with healthy fetus|
89268158|NCT01305694|Experimental|MSC|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia.
89268159|NCT03791476|Placebo Comparator|Control Group|Intervention is saline solution placebo (0.9% Sodium Chloride IV to equal volume of investigational arm: intraoperatively, and then every 12 hours x 2 = total of 3 doses)
89268160|NCT03791476|Experimental|rhC1INH|Intervention is rhC1INH 100 U/kg intraoperative followed by 50 U/kg every 12 hours x 2 = total of 3 doses (200 U/kg)
89268161|NCT03791632|No Intervention|witness|2 control CE2 classes without oral sensitization actions
89268162|NCT03791632|Experimental|group intervention 1|2 CE2 classes with a classical lecture style presentation
89268163|NCT03791632|Experimental|group intervention 2|2 CE2 classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
89268164|NCT03791632|Experimental|group intervention 3|2 CE2 classes with digital media intervention
89268165|NCT03791554|Active Comparator|Group A : Lateral closed Tunnel|"Laterally closed tunnel procedure with subepithelial connective tissue graft (sCTG) After local anesthesia, root planing will be performed. Recession defect - a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~• Recipient site; Using either single or mattress sutures, the graft will be pulled and fixed mesially and distally at the inner aspect of the pouch. The graft will be adapted to the CEJ by means of a sling suture. Margins of the pouch will be pulled together over the graft and sutured with interrupted sutures to accomplish tension-free complete or partial coverage of the graft as well as the denuded root surface."
89268166|NCT03791554|Active Comparator|Group B : Tunneling|"Tunnel procedure with subepithelial connective tissue graft (sCTG) - Control:~At the recipient site (recession defect): a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~Then the graft is placed and secured in the recipient site. The flap is displaced to be in a coronal position using a sling suture with no suturing to approximate the margins together."
89268167|NCT05620732|Experimental|Treatment group|Patients treated with Claudin 18.2 CAR-T cells.
89268168|NCT01306318|Experimental|1|
89268169|NCT01306318|Active Comparator|2|
89268170|NCT03788668|Active Comparator|Hyoid suspension with barbed reposition pharyngoplasty|
89268171|NCT03788668|No Intervention|barbed reposition pharyngoplasty|
89268172|NCT00254540|Experimental|SU-011248 capsule|
89268173|NCT05380492|Experimental|Low Dose|VOY-101 Low Dose (single dose, IVT)
89268174|NCT05380492|Experimental|Mid Dose|VOY-101 Mid Dose (single dose, IVT)
89268175|NCT05380492|Experimental|High Dose|VOY-101 High Dose (single dose, IVT)
89268176|NCT05380492|Active Comparator|Randomized Cohort--MTD|VOY-101 MTD (single dose, IVT)
89268177|NCT05380492|Active Comparator|Randomized Cohort--MTD-1|VOY-101 Lower Dose than MTD (single dose, IVT)
89268178|NCT05380492|Sham Comparator|Randomized Cohort--Sham|Control arm (sham procedure)
89268179|NCT03973658||First time users of hearing aids|Hearing aid fitting and usage
89268180|NCT01077440||Men - age 18+|
89268181|NCT01326494|Active Comparator|Arm 1 Oral Cortico Steroid|A filled prescription will be given to be used upon early onset of symptoms.
89268182|NCT01326494|No Intervention|Usual care for Asthma treatment|monitor the readmission of URTI induced asthma in children over a 12 month period
89268183|NCT03794674||MPI test group|50 eligible patients. Frailty level independently assessed by two reviewers based on the medical records and assessed by one research assistant based on bedside testing.
89268184|NCT01306396|Other|Intervention group|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake about 50%.
89268185|NCT01306396|No Intervention|Control group|"Families participating in the control group are given only one dietary counseling based on the references of the DGE at the beginning of the study if they wish."
89268186|NCT03794830|Experimental|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
89268187|NCT03794830|Active Comparator|electrotherapy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions of electrotherapy).
89268188|NCT01306474||Prednisone|profess to convinced 1-1.5mg/Kg.d
89268189|NCT01306474||methotrexate to band prednisone|profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d
89268190|NCT05297188||experimental group|Patients will be divided into experimental and control groups by block randomization. No application will be applied to the experimental group for first night sleep. On the morning of the first night, patients' comfort levels and sleep quality will be measured by Visual Analogue Scale and Richard-Campbell Sleep Scale. The second night, an ergonomic sleep mask will be worn to this group. In the morning of the second night, patients' comfort and sleep quality will be measured with the same scales. The patients will be asked to sleep between 22.00 and 24.00 on the second night, and intensive care lights will decrease, the noise level will be minimized, and patients will not wake up during the night outside their treatment.
89268191|NCT05297188||control group|Patients will be divided into experiment and control groups by block randomization. No application will be made to the control group for sleep on the first night. On the morning of the first night, patients' comfort levels and sleep quality will be measured by Visual Analogue Scale and Richard-Campbell Sleep Scale. On the second night, ear plugs and eye mask will be worn to this group. In the morning of the second night, patients' comfort and sleep quality will be measured with the same scales. Patients will be asked to sleep between 22.00 and 24.00 on the second night, and intensive care lights will decrease, noise level will be minimized and patients will not wake up during the night outside their treatment. It will be collected using the form.
89268192|NCT01306552|Active Comparator|Student-intervention only group|"Schools randomized to intervention only (arm 1) will agree to visit the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?).~One school class of students will visit the parcours once during a school day. The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
89268193|NCT01306552|Active Comparator|Multi-component intervention|Schools randomized to the student-parent intervention arm also will agree to visit the KARUNA e.V. smoking prevention parcours. In addition, the schools will agree to have one parents' night presented by trained health coaches informing parents about smoking prevention topics in youth during the school year. Trained health coaches will give an evaluated smoking prevention presentation for parents at the parents' nights at the end of the first school year. Also, participating parents will receive information about successful ways to prevent smoking and promote smoking cessation in their children once by mail.
89268194|NCT01306552|Active Comparator|Control Group|Schools randomized to the control school will be offered to participate in the nutrition and exercise prevention program offered by KARUNA e.V. during the 2-year study.
89268195|NCT03791242|Active Comparator|Group 1|33 morbidly obese patients with severe OSAS and suitable for gastric bypass surgery, who underwent 4 weeks of CPAC treatment (these patients will not be required to change their eating habits) according to the standard
89268196|NCT03791242|Active Comparator|Group 2|33 morbidly obese patients with severe OSAS and BS candidates who underwent CPAC + KMED treatment for 4 weeks
89268197|NCT03791164|Experimental|Pain Toolkit plus the Back Book|Participants who are being discharged from the regional back pain pathway who are allocated the 'Pain Toolkit' booklet along with the control intervention 'the Back Book'. They follow the interventions in the 'PainToolkit' for 12 months and are followed up 6 months and 1 year.
89268198|NCT03791164|Active Comparator|Back Book|Participants who are being discharged from the regional back pain pathway who are allocated 'the Back Book'. They are followed up 6 months and 1 year. This is the control group.
89268199|NCT03790930||thin layer CT|Thin-layer CT will be manually labeled and used to train, validate and test deep learning algorithm.
89268200|NCT01305850|Active Comparator|Aliskiren|
89268201|NCT01305850|Active Comparator|Aliskiren plus Losartan|
89268202|NCT01305850|Active Comparator|Enalapril plus Losartan|
89268203|NCT01305850|Placebo Comparator|placebo|
89268204|NCT03790696|Experimental|Active Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
89268205|NCT03790696|Sham Comparator|Sham Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
89268206|NCT03790774|Experimental|Neurofeedback|Three times per week, for six weeks, participants will receive biofeedback about the quality of their electroencephalograms (EEG; neurofeedback) during a letter identification task.
89268207|NCT01306630|Other|tivozanib + capecitabine|
89268208|NCT01306708|Active Comparator|nimesulide|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral non-steroidal anti-inflammatory (nimesulide 100 mg, twice per day, for 14 days);
89268209|NCT03794518|Experimental|Pioglitazone Plus dapaglifliozin|Pioglitazone 15mg and dapaglifliozin 10mg together in T2DM patients having HF and HFpEF conditions
89268210|NCT03794518|Placebo Comparator|Placebo|Beta blockers, ACEI, ARB, and aldosterone
89268211|NCT05566288|Experimental|Sequence 1|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Placebo (negative control) (8 placebo tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet) There will be a minimum 5 day washout between dosing periods."
89268212|NCT05566288|Experimental|Sequence 2|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Placebo (negative control) (8 placebo tablets) There will be a minimum 5 day washout between dosing periods."
89268213|NCT05566288|Experimental|Sequence 3|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Placebo (negative control) (8 placebo tablets)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets) There will be a minimum 5 day washout between dosing periods."
89268214|NCT05566288|Experimental|Sequence 4|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Placebo (negative control) (8 placebo tablets)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets) There will be a minimum 5 day washout between dosing periods."
89268215|NCT05566288|Experimental|Sequence 5|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Placebo (negative control) (8 placebo tablets)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet) There will be a minimum 5 day washout between dosing periods."
89268216|NCT05566288|Experimental|Sequence 6|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Placebo (negative control) (8 placebo tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets) There will be a minimum 5 day washout between dosing periods."
89268217|NCT05566288|Experimental|Sequence 7|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets)~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Placebo (negative control) (8 placebo tablets) There will be a minimum 5 day washout between dosing periods."
89268218|NCT05566288|Experimental|Sequence 8|"Participants will receive the assigned study drug after an overnight fast on Day 1 during each of 4 periods in the following order:~Moxifloxacin 400 mg PO (positive control) (1 tablet)~Cytisinicline, 6 mg (therapeutic dose) (2 cytisinicline tablets+6 placebo tablets)~Placebo (negative control) (8 placebo tablets)~Cytisinicline, 24 mg (supratherapeutic dose) (8 cytisinicline tablets) There will be a minimum 5 day washout between dosing periods."
89268219|NCT03788278||PTSD patients|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
89290521|NCT01223664|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
89268220|NCT03788278||Non PTSD participants|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
89268221|NCT03790540|Experimental|Injection with the aid of DentalVibe|"1 mL of Mepivacaine HCl 2%, 1/20000 Levonordefrin will be injected using a 27 gauge dental needle.~DentalVibe is a small, handheld cordless device that has a charging docking station. A demonstration of DentalVibe (DV) will be performed by putting it into direct contact with the children's nails before applying the device intraorally. Then, the device will be placed on the oral mucosa to enclose the injection site before administering local anesthesia and Potential subject-expectancy effects and pressure from the placement of DV will be controlled. The device will be turned on to stimulate the area of needle penetration. After 5 seconds of vibration, the needle will be inserted. The device will continue vibrating during needle insertion and anesthetic injection."
89268222|NCT03790540|Active Comparator|Injection with topical benzocaine 20%|Topical anesthesia -Benzocaine gel 20%. Tissues will be dried using (2 X 2) gauze to enhance the absorption of the benzocaine gel 20% around the site of the needle penetration and will be left in contact with the soft tissue for one minute. Then the local anesthetic solution (1 ml Mepivacaine HCl 2%, 1/20000 Levonordefrin) will be injected using a 27 gauge dental needle.
89268223|NCT03794596|Experimental|(Arm A) Avelumab + PPI|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
89268224|NCT03794596|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
89268225|NCT01306786|Active Comparator|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
89268226|NCT01306786|Active Comparator|Triple Therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
89268227|NCT03788590|Experimental|Jenscare TAVI|Patients undergoing a Jenscare TAVI and delivery system
89268228|NCT03788200|Active Comparator|post-injury bracing with rigid cervical collar|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
89268229|NCT03788200|Active Comparator|posterior C1-2 instrumented fusion|Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
89268230|NCT01304758|Experimental|ExAblate Treatment|
89268231|NCT05571748|Experimental|G6PD deficiency (only) - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 G6PD deficient individuals.
89268232|NCT05571748|Placebo Comparator|G6PD deficiency (only) - Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 120 G6PD deficient individuals.
89268233|NCT05571748|Experimental|G6PD deficiency and CHO metabolism disorder - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals with G6PD deficiency and a CHO metabolism disorder.
89268234|NCT05571748|Placebo Comparator|G6PD deficiency and CHO metabolism disorder - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals with G6PD deficiency and a CHO metabolism disorder.
89268235|NCT05571748|Experimental|CHO metabolism disorder (only) - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals with a CHO metabolism disorder.
89268236|NCT05571748|Placebo Comparator|CHO metabolism disorder (only) - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals with a CHO metabolism disorder.
89268237|NCT05571748|Experimental|Controls - Intervention|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 10 individuals without G6PD deficiency and/or any CHO metabolism disorder.
89268238|NCT05571748|Placebo Comparator|Controls - Placebo|Placebo for 4 weeks in a counterbalanced manner to 10 individuals without G6PD deficiency and/or any CHO metabolism disorder.
89268239|NCT03788356|Experimental|Diaphragmatic breathing|Diaphragmatic breathing exercise for 15 minutes.
89268240|NCT03788356|Experimental|10% inspiratory muscle training|Inspiratory muscle training at 10% intensity of maximal inspiratory pressure for 15 minutes
89268241|NCT03788356|Experimental|30% inspiratory muscle training|Inspiratory muscle training at 30% intensity of maximal inspiratory pressure for 15 minutes
89268242|NCT03788356|Experimental|60% inspiratory muscle training|Inspiratory muscle training at 60% intensity of maximal inspiratory pressure for 15 minutes
89268243|NCT05695144|Experimental|tDCS active stimulation combined with rTMS sham stimulation group|1
89268244|NCT05695144|Experimental|rTMS active stimulation combined with tDCS sham stimulation group|2
89268245|NCT05695144|Experimental|tDCS active stimulation combined with rTMS active stimulation group|3
89268246|NCT05695144|Experimental|tDCS sham stimulation combined with rTMS sham stimulation group|4
89268247|NCT03790618|Placebo Comparator|Placebo|Subjects will attend one session during which they will receive a placebo capsule.
89268248|NCT03790618|Experimental|Low dose MDMA|Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
89268249|NCT03790618|Experimental|High dose MDMA|Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
89268250|NCT03790618|Experimental|Methamphetamine|Subjects will attend one session during which they will receive 20mg methamphetamine.
89268251|NCT03790228|Experimental|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
89268252|NCT01304836|Active Comparator|10 Days of Steroids|Advagraf + Basiliximab + MMF + Steroids (10 days)
89268253|NCT01304836|Experimental|Optional Steroid bolus only|Advagraf + Basiliximab + MMF + Steroids (bolus only)
89268254|NCT01306864|Experimental|Hemospray Treatment|Hemospray Kit
89268255|NCT03788122|Other|Parents eligible for fetal surgery|Parents eligible for fetal surgery will undergo two or three in-depth face-tot-face interviews, to determine their perception of acceptability of fetal surgery.
89268256|NCT01304914||Healthy, term-delivered babies|
89268257|NCT01307176|Experimental|Home exercise program|Balance and walking exercise program
89268258|NCT01307254||Non alcoholic fatty liver disease|
89268259|NCT01307254||control|
89268260|NCT01307332|Experimental|MabCampath-1h|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
89268261|NCT01307410||with CAD|Patients with hypertension and dyslipidemia with prior CAD
89268262|NCT01307410||without CAD|Patients with hypertension and dyslipidemia without prior CAD
89268263|NCT03790462|Experimental|Music intervention group 1|"Raga A will be played for 10 minutes & data collected."
89268264|NCT03790462|Experimental|Music intervention group 2|"Raga B will be played for 10 minutes & data collected."
89268265|NCT03790462|Experimental|Music intervention group 3|"Raga C will be played for 10 minutes & data collected."
89268266|NCT03790462|No Intervention|Control group|Subject relaxes without music for 10 minutes and electrophysiological parameters will be collected
89268267|NCT01305928|Active Comparator|Fax|
89268268|NCT01305928|Experimental|Warm Hand-off|
89268269|NCT03790384|No Intervention|Bacillus Calmette-Guérin|Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).
89268270|NCT03790384|Experimental|Mytomicin and Bacillus Calmette-Guérin|Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation
89268271|NCT05694910|Experimental|Reiki Group|Personal Information Form (PIF), Visual Analog Scale (VAS), and National Cancer Institute (NCI) -Common Terminology Criteria for Adverse Events (CTCAE) will be administered to the patients. Then vital signs and laboratory findings will be recorded. After the protests will be completed, the primary investigator with Reiki second degree will apply Reiki to the patients for 30 minutes. On the second day and the third day, 30 minutes distance Reiki will be applied to the patients. Post-tests will be applied to all patients after one week and vital signs and laboratory findings will be recorded.
89268272|NCT05694910|No Intervention|Control Group|Personal Information Form (PIF), Visual Analog Scale (VAS), and National Cancer Institute (NCI) -Common Terminology Criteria for Adverse Events (CTCAE) will be administered to the patients. Then vital signs and laboratory findings will be recorded. After a week, the posttest will be applied to the patients and vital signs and laboratory findings will be recorded.
89268273|NCT03787732|Active Comparator|Fluid Bolus|For patients randomized to fluid bolus administration, the bedside nurse will obtain 500 mL of a crystalloid solution of the operator's choosing, connect this volume to intravenous infusion tubing, and attach the tubing to any intravenous catheter or intraosseous device. The crystalloid solution will then be placed above the level of the intravenous or intraosseous device and allowed to infuse by gravity or pressure bag. At any time after the initiation of fluid bolus administration, the operator can choose to begin the procedure by administering sedation. Fluid loading will continue until all 500 mL are infused. Fluid infusing prior to the decision to perform endotracheal intubation will not be altered by the current study.
89268274|NCT03787732|Active Comparator|No Fluid Bolus|For patients randomized to no fluid bolus administration, no additional intravenous crystalloid administration will be initiated between randomization and two minutes after completion of endotracheal intubation. Fluid infusing prior to the decision to perform endotracheal intubation will not be affected by the study. Treating clinicians may initiate a fluid bolus at any time for the treatment of cardiovascular collapse (not considered a protocol violation). Treating clinicians may also initiate a fluid bolus at any time if felt to be mandatory for the safe treatment of the patient (if between randomization and two minutes after intubation and in the absence of cardiovascular collapse this will be recorded as a protocol violation).
89268275|NCT01307488|Experimental|ATV/r+3TC|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
89268276|NCT01307488|Active Comparator|ATV/r+2 NRTIs|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
89268277|NCT03790072|Experimental|Treatment Arm|"After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0."
89268278|NCT01306006|Active Comparator|MV-for-all|Measles vaccine provided to all children aged 9 months -3 years of age
89268279|NCT01306006|No Intervention|National policy|Measles vaccine provided to children aged 9-11 months, if there are sufficient children to open a measles vaccine vial.
89268280|NCT01304992|Experimental|Lupin Protein|Lupin protein (cultivar: Lupinus angustifolius Boregine; incorporated in a drink)
89268281|NCT01304992|Active Comparator|Reference protein|Reference Protein (75% sodium caseinate (EM7; DMV international) and 25% milk protein (Megglosat HP; Meggle), incorporated in a drink)
89268282|NCT01304992|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
89268283|NCT03787342|Experimental|"DFI Double Flap Incision"|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
89290522|NCT01223664|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
89290523|NCT01221870|Experimental|Tesetaxel once every 3 weeks|Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months
89268284|NCT03787342|Experimental|"MPRI Modified PRI"|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
89268285|NCT03787342|Experimental|"CALF Coronally Advanced Lingual Flap"|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
89268286|NCT03787342|Active Comparator|"PRI Periosteal Releasing Incision"|A full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured as a whole unit.
89268287|NCT05694754|Experimental|1 session|Participants will receive 1 session from monday to friday,during 4 weeks, with 600 total pulses per session
89268288|NCT05694754|Experimental|3 sessions|Participants will receive 3 sessions from monday to friday,during 4 weeks, with 1800 total pulses per session with a 10 minutes rest interval
89268289|NCT03794128||1 - patient-specific neoantigen cancer vaccine production|
89268290|NCT03794128||2 - shared neoantigen cancer vaccine screening|
89268291|NCT03794440|Experimental|Sintilimab +IBI305|
89268292|NCT03794440|Active Comparator|Sorafenib|
89268293|NCT05534542|Active Comparator|core stabılızatıon|use of ıntradıalıtıc core stabılızatıon ın hemodıalysıs patıents
89268294|NCT05534542|Active Comparator|aerobıc exercıse|use of ıntradıalıtıc aerobıc exercıse ın hemodıalysıs patıents
89268295|NCT03789682||FUSCC cystectomy cohort|patients underwent cystectomy in Fudan University Shanghai Cancer Center
89268296|NCT05527522|Placebo Comparator|Control|Control arm: Who received the usual practice.
89268297|NCT05527522|Experimental|Intervention|Intervention arm: Who received an individualized diet, educational intervention with/without nutritional supplements depending on the degree of malnutrition plus usual practice
89268298|NCT05694598|Experimental|VGR-R01|Single-dose Subretinal Administration of VGR-R01
89268299|NCT01307566|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP)
89268300|NCT00139776|Active Comparator|Celecoxib - Continuous use|
89268301|NCT00139776|Active Comparator|Celecoxib - Intermittent use|
89268302|NCT03787186|Experimental|GLPG1690 oral and IV|GLPG1690 film-coated tablets followed by [14C]-GLPG1690 solution for infusion
89268303|NCT03787186|Experimental|[14C]-GLPG1690 capsules|[14C]-GLPG1690 capsules
89268304|NCT03787420|Active Comparator|traditional communication system|
89268305|NCT03787420|Experimental|intelligent communication system|
89268306|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 2|Patients enrolling from Phase 2 studies
89268307|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 3|Patients enrolling from Phase 3 studies
89268308|NCT01037777||presymptomatic carriers|
89268309|NCT01037777||non carrier relatives|
89268310|NCT01037855||Group 1: 6-23 months|
89268311|NCT01037855||Group 2: 2-8 years|
89268312|NCT01037855||Group 3: 9-17 years|
89268313|NCT01037855||Group 4: 18-44 years|
89268314|NCT01037855||Group 5: 45-60 years|
89268315|NCT01037855||Group: >60 years|
89268316|NCT03713320|Experimental|Cobomarsen|Cobomarsen will be administered by intravenous 2-hour infusion at a dose of 282 mg on Days 1, 3, 5, 8, and weekly thereafter
89268317|NCT03713320|Active Comparator|Vorinostat|Vorinostat will be administered orally at a dose of 400 mg (four 100-mg capsules) once daily with food, at approximately the same time each day.
89268318|NCT03712930|Experimental|Pamiparib|Participants will receive pamiparib for a period up to 1 year
89268319|NCT00420407|Experimental|I|Vasopressin
89268320|NCT00420407|Placebo Comparator|2|bolus of NS (normal saline) followed by continuous infusion of NS, no vasopressin added
89268321|NCT03793972|Experimental|Triage with referral to primary care|Triage and referral according to eMTS.
89268322|NCT03793972|Active Comparator|Triage without referral to primary care|Weekends with usual care
89268323|NCT01037933|Active Comparator|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
89268324|NCT01037933|Active Comparator|Non-humor intervention|"A 45-minute non-humorous DVD The A to Z of Steam Railways using a portable DVD player."
89268325|NCT03787108||Children with suspected NAFLD|Children with overweight or obesity. Both children that are and children that are not suspected of having NAFLD (based on ultrasound and laboratory findings) are included.
89268326|NCT03789448|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
89268327|NCT03789448|Experimental|Early Access to ART for All|HIV-positive individuals who are aged 18 years or older are initiated on ART regardless of client's immunological and clinical staging (excluding pregnant or breastfeeding women)
89268328|NCT03789370|Active Comparator|Propofol|Total intravenous anaesthesia with propofol for maintainance of anaesthesia.Dose adjusted according to the Bispectral Index (BIS) indication (maintained 40-50). Initial dose 10 mg/kg/h for10 min, 8 mg/kg/h for 10 min and then 6 mg/kg/h).
89268329|NCT03789370|Active Comparator|Sevoflurane|Sevoflurane for maintainance of anaesthesia. Dose 1 MAC adjusted according to the Bispectral Index (BIS) indication (maintained 40-50).
89268330|NCT00420095|Active Comparator|1|Human insulin mix 30/70
89268331|NCT00420095|Experimental|2|Insulin lispro low mix
89268332|NCT03789526|Experimental|Group 1|Group one: 26 patients DM patients with tenosynovitis were injected by triamcinolone under ultrasound guidance.
89268333|NCT03789526|No Intervention|Group 2|Group two: 26 patients DM patients with tenosynovitis were injected by triamcinolone under clinical guidance.
89268334|NCT01038089|Experimental|resveratrol|Resveratrol
89268335|NCT01305070|Active Comparator|Standart balloon angioplasty|Admiral Xtreme, Invatec
89268336|NCT01305070|Active Comparator|Paclitaxel-eluting balloon arm|In.Pact Admiral, Invatec
89268337|NCT00419393|Experimental|Keppra XR (Levetiracetam XR)|1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
89268338|NCT01038167|Experimental|Part A|Part A will be administered in two periods, separated by a washout. In Period 1, subjects will receive cyclosporine alone. In Period 2, subjects will receive cyclosporine in combination with telaprevir.
89268339|NCT01038167|Experimental|Part B|Part B will be administered in two periods, separated by a washout. In Period 1, subjects will receive tacrolimus alone. In Period 2, subjects will receive tacrolimus in combination with telaprevir.
89268340|NCT01307722|Experimental|Patients under LA distensibility-guiding management|The management of guide group will be adjusted by LA distensibility, including the adjustments of inotropic agents, diuretics, beta-blocker, ACEI, and AIIB.
89268341|NCT01307722|No Intervention|patients under conservative monitor and management|This group will be treated by conventional management and traditional echocardiography can be performed as in-charge doctor request. Renal function will be checked 1 time per 3 months.
89268342|NCT03787030|Experimental|Vitamin E acetate|Commercially available plastic tubes containing vitamin E acetate ointment (Filme Olio, Hulka SRL, Italy) were purchased from pharmacies. The dosage for all the patients was 1ml of ointment (containing 1100% vitamin E), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
89268343|NCT03787030|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
89268344|NCT03993977|Experimental|ROTEM-arm|Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.
89268345|NCT03993977|Active Comparator|Control-arm|Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).
89268346|NCT03786874|Active Comparator|20 teams the first year (G1)|control group
89268347|NCT03786874|Experimental|20 teams second year (G2)|case group with implementation of the multi-unit team accompaniment intervention.
89268348|NCT03786562|Placebo Comparator|Placebo group|
89268349|NCT03786562|Active Comparator|Nalbuphine group|
89268350|NCT02173613|Experimental|Procalcitonine|every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.
89268351|NCT02173613|No Intervention|contrôle|Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.
89268352|NCT02639728|Experimental|Regular coffee|Will receive a 4oz cup coffee, three times daily (at 8:00, 12:00, and 16:00 hours)and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
89268353|NCT02639728|Experimental|Decaffeinated coffee|Will receive a 4oz cup of decaffeinated coffee (at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
89268354|NCT02639728|Experimental|Warm water|Will receive a 4oz cup of warm water at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
89268355|NCT01038401|Other|HIV-1-infected patients on effective HAART|
89268356|NCT01038401|Other|Non Infected HIV Volunteers|
89268357|NCT03793894|Active Comparator|Enhanced usual care|"All trial participants will receive smoking cessation counseling (standard of care) and will be given the AHRQ Is Lung Cancer Screening Right for me? patient decision aid to review independently while in the hospital."
89268358|NCT03793894|Experimental|Inpatient SDM + CHW Navigation|In addition to the smoking cessation counseling and decision aid received by all subjects, intervention subjects will receive shared decision making (SDM) + CHW navigation.
89268359|NCT03786328|Other|Clinical cases of Mental Disorder|The group of individuals identified with a clinical mental disorder on the basis of the diagnostic interviews This group will be assigned to Standard Psychiatric Treatment
89268360|NCT03786328|Other|Subclinical cases of Mental Disorder|The group of individuals identified with a sub-clinical mental condition on the basis of the diagnostic interviews This group will be assigned to Preventive Psychological Treatment
89268361|NCT01305148|Experimental|Randomized - Genetic|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
89268362|NCT01305148|No Intervention|Randomized - Clinical|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
89268363|NCT01305148|Experimental|Registry|Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
89268364|NCT01305226|Experimental|Test - THR-100|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase 60 subjects are to be recruited into Test arm, and administered 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
89268365|NCT01305226|Active Comparator|Streptokinase|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
89268366|NCT05694208|Experimental|Experimental group|The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
89268367|NCT05694208|No Intervention|Control Group|It is the group in which no intervention will be made other than data collection.
89268368|NCT03785938|Experimental|Probiotic|"Participants will start the course of liquid probiotic on the first day of their course of chemotherapy. This can be taken orally, or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day"
89268369|NCT03785938|Placebo Comparator|Placebo|"Participants will start the course placebo on the first day of their course of chemotherapy. This can be taken orally or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day~Placebo will be delivered in similar, packaging, appearance and taste."
89268370|NCT01305304||1|"15 healthy male veteran runners (marathon, triathlon, orienteering) aged between 40 and 65 years with a history of competitive running at a national level during a period of at least 5 years, implicating normally a runner career with at least 50km per week over more than 10 years"
89268371|NCT01305304||2|15 healthy male volunteers, matched for age and bmi, without a history of competitive physical exercise (i.e. sedentary controls)
89268372|NCT01308346|Experimental|Bioresorbable Vascular Scaffold (BVS)|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
89268373|NCT01308346|Active Comparator|XIENCE V® or XIENCE PRIME®|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) or XIENCE PRIME®
89268374|NCT03785704|Experimental|Xinmailong injection group|given 5 mg/kg of Xinmailong injection every cycle on d0, d1, d2, d3, d4 on the same chemotherapy regimen (EC-T) as those in the control group.
89268375|NCT03785704|No Intervention|control group|receive conventional EC-T regimen chemotherapy (Epirubicin 45mg/m2 d1, 2 + cyclophosphamide 600mg/ m2 d1, repeated every 14 or 21 days for 4 cycles, followed by paclitaxel 175 mg/m2 (or docetaxel 75 mg/m2) on day 1, repeated every 21 days for 4 cycles).
89268376|NCT05694130|Placebo Comparator|Prednisolone monotherapy|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
89268377|NCT05694130|Experimental|Prednisolone plus Tacrolimus|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks. Oral tacrolimus 1-2mg twice daily for 12 weeks.
89268378|NCT01308112|Experimental|Supplemental iron|
89268379|NCT01308112|Placebo Comparator|Placebo|
89268380|NCT03786172|Experimental|Smoking cessation Intervention|Standardised counseling session + motivational gadget + Nicotine replacement therapy (NRT)
89268381|NCT03786172|Active Comparator|Usual care|A 10-second brief advice to quit smoking
89268382|NCT03793816|Active Comparator|BiZact™ device|"BiZact™ device will be used appropriately to its purpose to remove one tonsil by:~Incision of the anterior palatal arch~Locating of the cranial pole of the tonsil~Dissection of the tonsil capsule~Localized coagulation of bleeding vessels~Detaching of the inferior pole from the pharynx tissue"
89268383|NCT03793816|Active Comparator|Cold steel dissection (CD)|Cold steel dissection (CD) with localized cauterization for hemostasis serves as the comparative procedure within each patient (cross-over).
89268384|NCT03793582||Study group|All subjects agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
89268385|NCT05567302|Experimental|Manual therapy|Manual therapy, manipulative therapy, is a completely manual treatment method that includes special techniques and is known as a treatment that aims to correct bony deformities and is highly effective when combined with exercise.
89268386|NCT05567302|Active Comparator|myofascial release|Foam rollers are a popular tool for helping athletes release muscle knots or trigger points.Myofascial release is a soft tissue method that provides removal of adhesions and tissue tension in tissues due to overload and repetitive use.
89268387|NCT05693974||stage I-II ovarian cancer|30 patients with stage I-II ovarian cancer
89268388|NCT05693974||stage III-IV ovarian cancer|30 patients with stage III-IV ovarian cancer
89268389|NCT05693974||benign ovarian cancer|40 patients with benign ovarian cancer
89268390|NCT05693974||healthy people|30 healthy people
89268391|NCT00419159|Experimental|Everolimus (RAD001) 70 mg/week|
89268392|NCT00419159|Experimental|Everolimus (RAD001) 10 mg/day|
89268393|NCT03785782||Women scheduled for biopsy|40 participants with diagnosed BIRADS-4a, 4b, 4c, or -5 masses will be recruited. The investigators aim to have approximately 10 in each of the BIRADS categories (4a, 4b, 4c, 5), resulting in 40 total subjects for Aim #1.
89268394|NCT03785782||Women scheduled for neoadjuvant chemo|40 participants with malignant masses undergoing neoadjuvant chemotherapy (NAC) will be recruited.
89268395|NCT05693662|Experimental|Patient Education Booklet|"Before applying to the parents of the children with ASD included in the experimental group, After the pre-test data are collected, 8 sessions of Awareness-Based Self-Compassion training will be given to the parents in the experimental group. The first two sessions will be held face-to-face, and the remaining sessions will continue online. Each session will be planned for 3 days to 7 days for its activity and continuity. One week after the Awareness-Based Self-Compassion training (after 8 sessions were completed), parents were given the Parental Stress Scale (PASS), Adult Resilience Scale, Warwick-Edinburgh Mental Well-Being Scale, Self-Compassion Scale. Short Form (SSS-F), Conscious Awareness Scale (CIFS) post-test will be filled face to face."
89268396|NCT03717064|Experimental|Pitavastatin|"Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days.~Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4."
89268397|NCT03716050|Other|Group 1|Breast skin after mastectomy will be clinically examined by the surgeon to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No treatment, including dye study, ointment, or vacuum dressing will be applied to the breast after implant placement.
89268398|NCT03716050|Active Comparator|Group 2|Breast skin after mastectomy will be clinically examined by the surgeon, and nitroglycerin (NTG) cream will be applied to the breast skin after implant placement. This cream does not have systemic effects but may improve blood flow to the remnant breast skin after mastectomy.
89268399|NCT03716050|Active Comparator|Group 3|Breast skin after mastectomy will be clinically examined by the surgeon, and an incisional vacuum-assisted dressing (iVAC) will be placed over the breast incisions after implant placement, which may improve blood flow to the skin and help wound healing.
89268400|NCT03716050|Active Comparator|Group 4|Breast skin after mastectomy will be clinically examined by the surgeon, and both NTG cream will be applied to the breast skin and an iVAC will be placed over the incisions after implant placement.
89268401|NCT03716050|Active Comparator|Group 5|Blood flow to breast skin after mastectomy will be examined using a fluorescent dye study called fluorescent angiography (FA) to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No further intervention will be used after implant placement.
89268402|NCT03716050|Active Comparator|Group 6|Blood flow to breast skin breast skin will be examined using FA, and NTG cream will be applied to the skin after the implant is placed.
89268403|NCT03716050|Active Comparator|Group 7|Blood flow to breast skin breast skin will be examined using FA, and an iVAC will be placed over breast skin incisions after the implant is placed.
89268404|NCT03716050|Active Comparator|Group 8|Blood flow to breast skin breast skin will be examined using FA, and both NTG cream and iVAC will be used as interventions after the implant is placed.
89268405|NCT01305382||Heart Transplant Cohort|This group consist of transplant subjects within 10 years of heart transplant
89268406|NCT01305382||Heart Failure Sub group|Consist of subjects with advanced heart failure (NYHA class III and IV)
89268407|NCT01305382||Healthy Volunteer|This groups consist of healthy individuals
89268408|NCT05693584|Experimental|Virtual reality glasses|Experimental group:Group applying virtual reality glasses
89268409|NCT05693584|No Intervention|Routine practices|No procedure was performed on the patients other than the routine practices of the clinic.
89268410|NCT03782038|Experimental|Micro-coring of scars with MCD|Micro coring of acne scars and straie will be conducted in up to 3 treatments and followed 6 months post last treatment with MCD.
89268411|NCT02069860|Experimental|Access for heamodialysis treatment|The Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a permanent vascular access for hemodialysis treatment
89268412|NCT01310920||sick sinus syndrome|
89268413|NCT01310920||control|
89268414|NCT03785860|Placebo Comparator|Placebo|On the Placebo arm of the intervention, participants will consume a placebo powder.
89268415|NCT03785860|Active Comparator|Dietary Fiber|On the Dietary Fiber arm of the intervention, participants will consume a fiber powder.
89268416|NCT00413231|Experimental|Valiant Thoracic Stent Graft System|"160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.~There were no other arms for this study."
89268417|NCT01988584|Experimental|umbilical cord blood (UCB) cells|Children who have banked UCB with CBR will receive an umbilical cord blood stem cell infusion at the baseline/treatment visit.
89268418|NCT01988584|Experimental|bone marrow-derived mononuclear cells (BMMNCs)|Children in the BMMNC group will undergo bone marrow harvest and stem cell infusion at the baseline/treatment visit.
89268419|NCT01988584|Experimental|saline infusion (placebo), then umbilical cord blood (UCB) cells|Five children in each group will be randomly assigned to receive an inactive substance (placebo) at the baseline/treatment visit. Parents will be given the opportunity to cross-over to either the umbilical cord blood or bone marrow harvest group at the one year visit.
89268420|NCT01988584|Experimental|saline infusion (placebo), then bone marrow-derived mononuclear cells (BMMNCs)|
89268421|NCT02113163|Active Comparator|Cohort A - Low Dose|Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg
89268422|NCT02113163|Active Comparator|Cohort B - High Dose|Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg
89268423|NCT00413153|Active Comparator|1|Boosted Reyataz (300mg atazanavir + 100mg ritonavir)
89268424|NCT00413153|Active Comparator|2|Kaletra (pre-study dose)
89268425|NCT01308502|Experimental|Probe|Children with airway obstruction
89268426|NCT01310998|Experimental|schizophrenic disorder|
89268427|NCT01310998|Experimental|other psychotic disorder|
89268428|NCT01310998|Experimental|no mental disorder|
89268429|NCT02107937|Experimental|DCVAC/OvCa with Standard of Care|DCVAC/OvCa in parallel with chemotherapy (Standard of Care)
89268430|NCT02107937|Experimental|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa sequentially after chemotherapy
89268431|NCT02107937|Active Comparator|Standart of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
89268432|NCT03781882|Active Comparator|Intervention group|All patients in this group will be manged as usual with infiltration of platelet rich plasma in thee wound edges during closure of the wounds
89268433|NCT03781882|Active Comparator|Control group|All patients in this group will be managed by repair of wounds without infiltration of platelet rich plasma
89268434|NCT01038479|Active Comparator|Childsmile programme with xylitol|Childsmile program with maternal xylitol consumption;
89268435|NCT01038479|Placebo Comparator|Childsmile programme only|Childsmile programme
89268436|NCT03793192|Experimental|PACE2 Intervention|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity. In addition, participants randomized to the PACE2 intervention will receive written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
89290524|NCT01221870|Experimental|Tesetaxel once weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
89268437|NCT03793192|No Intervention|Enhanced Usual Care|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity.
89268438|NCT01035125|No Intervention|Waiting list|
89268439|NCT01035125|Experimental|Self-management program|One week self-management program
89268440|NCT03793270||patients|"1. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year).~drugs described in the clinic."
89268441|NCT03793270||patients 2|2. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.
89268442|NCT03793270||healthy donors|3. Group 3: 30 healthy controls. No drugs.
89268443|NCT01312090|Active Comparator|Conventional weight loss treatment group|Eating and physical activity counseling and behavioral therapy for weight loss.
89268444|NCT01312090|Experimental|Cryo group|"Eating and physical activity counseling and behavioral therapy for weight loss will be provided to all subjects.~The subjects in the cryo group will be given whole-body cryotherapy 1-3 times a week for the 4-month-treatment period"
89268445|NCT01312402|Active Comparator|Topical Brinzolamide (Azopt)|ophthalmic drop given three times a day
89268446|NCT01312402|Placebo Comparator|placebo ophthalmic drop in 5 mL solution|masked non-active eye drop (absence of Brinzolamide)
89268447|NCT01312480|Other|Intervention Group|The smoking cessation intervention is a Public Health Services-approved intervention based on the 5A's Model, which includes (1) Ask if the patient smokes, (2) Advise every patient to quit, (3) Assess readiness to quit, (4) Assist in quitting and finding services and (5) Arrange for cessation services and follow up. Practitioners will complete a 5A checklist for each patient in this arm.
89268448|NCT01312480|Other|Control Group|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
89268449|NCT00412607|Experimental|NaviStar ThermoCool Catheter|
89268450|NCT03785392|Active Comparator|Group 1 Inplane|Study with the technique Inplane group
89268451|NCT03785392|Active Comparator|Group 2 out of plane|Study with the technique out of plane
89268452|NCT01035203|Active Comparator|Cognitive behavioural therapy|
89268453|NCT01035203|Experimental|Exercise|Endurance training (walking on a treadmill) 3 x weekly for 4 weeks
89268454|NCT05693428|Other|Propofol|Anesthesia
89268455|NCT05693428|Other|Isofluran|Anesthesia
89268456|NCT05693428|Other|Sevofluran|Anesthesia
89268457|NCT01035281|Experimental|Nabilone|A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate.
89268458|NCT01035281|Placebo Comparator|Placebo|All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion.
89268459|NCT01035359|Active Comparator|external fixation|Operation with external fixation and optional addition of k-wire
89268460|NCT01035359|Experimental|Volar plate|Operation with a Synthes volar two column plate (TCP)
89268461|NCT01561066|Sham Comparator|conservative therapy|Conservative therapy includes orrection of electrolytic disturbances, suppression of gastric/intestinal secretion with octreotide, nutritional support.
89268462|NCT01561066|Active Comparator|Application of autologous PRFG|The application of the glues through the external opening of the fistula was controlled by the drainage tube, which was based on fistulography to assure total occlusion of the internal hole. To allow the adhesion of the fibrin glues patch, all fistulous tracts were debrided to produce a smooth surface. At the time of procedures, the two components were mixed together to yield a gelatinous substance. After the FG was instilled, any redundant glue was removed from the external openings.
89268463|NCT03793036|No Intervention|FAST group|preoperative fasting
89268464|NCT03793036|Experimental|CHO group|preoperative nutrition The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
89268465|NCT00419003|Experimental|Lamotrigine Pre-Treatment|Patients who met enrolment criteria for phase 1 were randomly allocated to lamotrigine or placebo by a permuted block procedure consisting of blocks of two or four patients. The randomization list was created by a biostatistician with no patient contact. 300 mg of lamotrigine 2 hrs prior to ketamine infusion. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
89268466|NCT00419003|Placebo Comparator|Placebo Pre-Treatment|2 hours prior to ketamine infusion each patient received three capsules of placebo identical in size, weight, appearance, and taste to the lamotrigine tablets. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
89268467|NCT03793348|Experimental|Micro-exisional skin removal|Micro-coring of skin on the facial and neck areas will be conducted in one treatment and followed for 90 days post treatment.
89268468|NCT01035437|Experimental|HPPH|HPPH
89268469|NCT00418691|Active Comparator|Immediate Release (IR) Methylphenidate|10 mg by mouth (PO) twice daily for 4 Weeks
89268470|NCT00418691|Active Comparator|Sustained Release (SR) Methylphenidate|200 mg PO once daily for 4 Weeks
89268471|NCT00418691|Active Comparator|Modafinil|18 mg PO once daily for 4 Weeks
89268472|NCT03777592|Active Comparator|ESPB with local agent|ESPB will be performed using 20ml of 0.5% ropivacaine.
89268473|NCT03777592|Sham Comparator|ESPB with saline|ESPB will be performed using 20ml of saline.
89268474|NCT03781258|Other|Anit-thrombotic monotherapy|Patients with HeartMate 3 LVAS transitioning from Warfarin and Acetylsalicylic Acid (ASA) therapy to receive anti-thrombotic monotherapy (ASA).
89268475|NCT03781102|Experimental|Intervention|Arm 1, or intervention participants (n=60), will participate in a 16-week face-to-face diabetes prevention group program '16-Week Diabetes Prevention Program for Mothers and Children' and then will transition to a 16-week follow-up period.
89268476|NCT03781102|Other|Wait-listed Control|Arm 2, or wait-listed controls (n=60), will receive the typical standard of care during the first 16-weeks, followed by the 16-week face-to-face group diabetes prevention program '16-Week Diabetes Prevention Program for Mothers and Children'.
89268477|NCT05397340|Experimental|L-GPi/R-STN|Participants randomized in this arm will receive L-GPi/R-STN stimulation for 1 year.
89268478|NCT05397340|Active Comparator|Bi-STN|Participants randomized in this arm will receive bilateral STN stimulation for 1 year.
89268479|NCT00412373|Experimental|001|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
89268480|NCT00412373|Experimental|003|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
89268481|NCT00412373|Placebo Comparator|002|Placebo for 6 weeks
89268482|NCT05357170||Sepsis Survivors|"Feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first feces collection"
89268483|NCT05357170||Healthy Control Population|One time collection of feces and blood upon enrollment used for comparison to identify microbial genes associated with persistent systemic inflammation in sepsis survivors.
89268484|NCT05357170||Trauma Survivor|"Feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first feces collection"
89268485|NCT05357170||Traumatic Brain Injury (TBI)|"Feces collected at admission (day 1(+5)) and between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.~Blood will be collected at time of first and second feces collection."
89268486|NCT05692726||Patients|Patients with non-hypervolemic hypotonic hyponatremia
89268487|NCT01308658|Experimental|001|Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
89268488|NCT01308658|Experimental|002|ritonavir 100-mg once daily on Day 1 to Day 5
89268489|NCT03785314|Active Comparator|injection under sitting position|saline injection under sitting position during thoracic epidural catheterization
89268490|NCT03785314|Active Comparator|injection under lateral decubitus position|saline injection under lateral decubitus position during thoracic epidural catheterization
89268491|NCT03785002|Experimental|vegetarian|Individuals who do not consume meat (vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
89268492|NCT03785002|Active Comparator|non vegetarian|Individuals who do consume meat (non vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
89268493|NCT03780946||Magnetic group|Magnetic anastomosis for pancreaticojejunostomy
89268494|NCT03780946||Control group|Traditional hand-sewn for pancreaticojejunostomy
89268495|NCT03777514|Active Comparator|IV iron|"Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart.~Participants in this group will also receive oral vitamin C as a placebo."
89268496|NCT03777514|Active Comparator|oral iron|Ferrous sulfate 325 mg (oral) tabs morning and evening. Participants in this group will also receive intravenous normal saline as a placebo.
89268497|NCT01313260||Epilepsy patients|Epilepsy patients selected before undergoing intracranial EEG recordings
89268498|NCT01313260||control group|Healthy volunteers
89268499|NCT03777124|Experimental|SHR-1210 +apatinib|subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day
89268500|NCT03777124|Active Comparator|chemotherapy|Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W
89268501|NCT00418379|Experimental|300 IR (4M)|300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
89268502|NCT00418379|Experimental|300 IR (2M)|300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
89268503|NCT00418379|Placebo Comparator|Placebo|Placebo tablet
89268504|NCT03780556|Active Comparator|Lornixicam|Patients received lornoxicam 8 mg intravenous to control pain
89268505|NCT03780556|Active Comparator|Pethidine|Patients received pethidine 50mg intravenous to control pain
89268506|NCT01038791|Active Comparator|usual ventilation|application of usual mechanical ventilation without humidification system
89268507|NCT01038791|Experimental|heated humidifier|mechanical ventilation with heated humidifier
89268508|NCT01038791|Experimental|heat and moisture exchanger|mechanical ventilation with heat and moisture exchanger
89268509|NCT03780868|Active Comparator|external DCR|"A curvilinear incision of 10-15 mm length was made along the anterior lacrimal crest .~The smaller end of the blunt dissector was used to fracture Lamina papyracea, the parchment like bone of the posterior half of the lacrimal fossa. the nasal mucosa was stripped from lacrimal bone with the help of Traquair's periosteal elevator, An osteotomy of approximately 12.5 x10mm was created with successive punching of bone by Cittelli's punch. Lacrimal sac and nasal mucosa were opened in a 'H' fashion with the no.11 Bard-Parker blade and Bowman's probe was in place, to form a large anterior and smaller posterior flap."
89290525|NCT05675098|Experimental|Methylphenidate|Participants in this group will receive 2.5mg Methylphenidate and 100mg placebo (Modafinil shape) in addition to physical therapy program
89290526|NCT05675098|Experimental|Modafinil|Participants in this group will receive 100mg Modafinil and 2.5mg placebo (Methylphenidate shape) in addition to physical therapy program
89290527|NCT05675098|Placebo Comparator|Placebo|Participants in this group will receive 2.5mg placebo (Methylphenidate shape) and 100mg placebo (Modafinil shape) in addition to physical therapy program
89290528|NCT01223742|Experimental|ACETYL-L-CARNITINE|
89268510|NCT03780868|Active Comparator|silicone intubation with MMC|"Bowman's probe was gently inserted into the inferior canalicular system, until a hard stop was felt in the lacrimal sac, after which it was rotated into the NLD to reach below the inferior concha. The probe was then withdrawn via the inferior punctum and the process was repeated for the upper canaliculus.~After irrigation with normal saline to confirm duct patency, irrigation was performed by introducing 1 ml of MMC (0.5 mg/ml) into the duct with a syringe, the ocular surface then irrigatedby normal saline. Intubation was done by a silicone tube connected by each of its end to a malleable steel guide. A grooved director was placed under the inferior turbinate to guide the probe out of the nose, after which the steel guide was cut from the silicone tube"
89268511|NCT00418145|Experimental|megadose oral methylprednisolone|1400 mg qd/5 days
89268512|NCT00418145|Experimental|IV methylprednisolone|1000 mg/qd/5 days
89268513|NCT03780634|Experimental|HAIC plus PD-1 antibody|Participants received PD-1 antibody intravenously and hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89268514|NCT03780634|Active Comparator|HAIC plus sorafenib|Participants received sorafenib capsules 400mg bid in continuous 21-day treatment cycles, and received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89268515|NCT03780478|Experimental|SPG Block|Sphenopalatine ganglion block
89268516|NCT03780478|Placebo Comparator|Placebo Control|Saline injection
89268517|NCT03785080|Experimental|restart NOAC very early|restart NOAC within 24 hours
89268518|NCT03785080|Active Comparator|restart NOAC early|restart NOAC at 72 - 84 hours
89268519|NCT03777358||Three-dimensional transvaginal ultrasonography (3D-TVS)|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then, hysteroscopy will be performed.
89268520|NCT03777280|Experimental|peek framework Removable partial denture|polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
89268521|NCT03777280|Active Comparator|cobalt chromium framework Removable partial denture|it's the gold standard framework which has many benefits such as they are used in thin sections and are less bulky,provide high strength and stiffness,and some disadvantages include hypersensitivity,metal display and oral galvanism,
89268522|NCT00417989|Experimental|722 sensor augmented pump|722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year
89268523|NCT00417989|No Intervention|Multiple Daily Injections (MDI)|MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year
89268524|NCT03784768|Experimental|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
89268525|NCT03784768|Active Comparator|Control Group|Patients in the control group will be received 60-minute conventional pysiotherapy session for 5-days in a week, over 4-week. Each physiotherapy session will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
89268526|NCT03780712||Sepsis Risk Group|419 infants born from mothers at risk to deliver babies with neonatal infections in Cotonou hospitals (Benin) 166 infants without sepsis born from mothers enrolled in a study to monitor pregnancy-associated malaria and Intrauterine growth restriction in Benin
89268527|NCT01038947|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
89268528|NCT03777046|No Intervention|Screen fail subjects|Mothers and their babies that meet inclusion criteria for the study, but score less than 10 on the Edinburgh Postpartum Depression Scale (EPDS)
89268529|NCT03777046|Active Comparator|PPD Control subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
89268530|NCT03777046|Experimental|PPD Intervention subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
89268531|NCT03780166|Experimental|Parsaclisib|
89268532|NCT02043587|Experimental|Chemotherapy for ALL|"Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15~1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2~1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4~1A-C repeat x1(2A-C) then 3rd Course B (3B)~Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)~Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1~Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)~1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint."
89268533|NCT01561222|Placebo Comparator|placebo|
89268534|NCT01561222|Experimental|Calcitriol|
89268535|NCT05289154|Experimental|self- applied acupressure plus Qigong plus advice literature|"daily 20 min of self- applied acupressure over 8 weeks on acupuncture points Yintang, LI4, Pe6, ST36, SP6 and depending on further symptoms plus DU23/24 in hyposmia, LU7 in dyspnoea, GB34 in pain conditions, GB20 in headache OR Anmian in sleeping disorders.~The 16 sessions of 45 min Qigong course over 8 weeks will contain live online guided exercises with breathing, stretching and tapping of meridians and exercises such as the crane exercise."
89290529|NCT01223742|Placebo Comparator|placebo|
89268536|NCT05289154|Active Comparator|advice literature|advice literature contains naturopathic remedies such as application of massage-oils, use of herbal teas, meditation techniques, breathing exercises for reconvalescence after COVID19.
89268537|NCT01035515|Experimental|Arm One|Arm 1 of 6 cross-over arms
89268538|NCT01035515|Experimental|Arm Two|Arm 2 of 6 cross-over arms
89268539|NCT01035515|Experimental|Arm Three|Arm 3 of 6 cross-over arms
89268540|NCT01035515|Experimental|Arm Four|Arm 4 of 6 cross-over arms
89268541|NCT01035515|Experimental|Arm Five|Arm 5 of 6 cross-over arms
89268542|NCT01035515|Experimental|Arm Six|Arm 1 of 6 cross-over arms
89268543|NCT01308892|Active Comparator|High flavaonol chocolate|
89268544|NCT01308892|Placebo Comparator|Low flavanol chocolate|
89268545|NCT01039025|Experimental|TMC|Topotecan, Melphalan, and Cyclophosphamide
89268546|NCT01308970|Experimental|Stress Management Group 1|
89268547|NCT01308970|Experimental|Stress Management Group 2|
89268548|NCT01308970|Experimental|Stress Management Group 3|
89268549|NCT03776968|Experimental|HC1119|Fasting state:40 mg, 80 mg, 160 mg; After meal: 160mg;
89268550|NCT03779776|Experimental|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d, containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
89268551|NCT03779776|Placebo Comparator|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d,VD 80 IU/kg/d ) within daily on parenteral nutrition until fed 120ml/kg.
89268552|NCT00412217|Experimental|Erlotinib|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
89268553|NCT00412217|Placebo Comparator|Placebo|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.
89268554|NCT05510440|Experimental|Effect of citrulline supplementation combined with long distance running on systemic inflammation|14-day protocol of supplementation with 6 g of citrulline.
89268555|NCT05510440|Placebo Comparator|Effect of placebo supplementation combined with long distance running on systemic inflammation|14-day protocol of supplementation with 6 g of placebo.
89268556|NCT01312558|Experimental|Prudent diet group|Participants follow CPAP therapy, a prudent diet while receiving counselling to increase their physical activity.
89268557|NCT01312558|Experimental|Mediterranean diet group|Participants follow CPAP therapy, Mediterranean diet, while receiving counselling to increase their physical activity.
89268558|NCT01035593|Active Comparator|Standard of Care (PP + IVIG)|Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
89268559|NCT01035593|Experimental|PP + IVIG + rhC1INH|Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).
89268560|NCT03784534|Experimental|Healthy volunteers|"Subjects will be asked to perform:~high= density (64 sensors) EEG~clinical and behavioral data will be also collected from each subject to evaluate their motor skills: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer~anatomical MRI (T1 and tensor imaging) scan)"
89268561|NCT03784534|Experimental|Patients|"Patients will be asked to perform:~high= density (64 sensors) EEG~clinical and behavioral data will be also collected from each patient to assess their motor recovery progress: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, Fugl Meyer, test of Ashworth~anatomical MRI (T1 and tensor imaging) scan)"
89268562|NCT03776734|Experimental|cryotherapy application|effect of cold application
89268563|NCT01317784|Experimental|All tests.|Choose from all 16 possible tests.
89268564|NCT01317784|Active Comparator|HIV/HCV|Choice of 10 different HIV and hepatitis C tests in the bundle.
89268565|NCT01317784|Active Comparator|HIV/Syphilis|Choice of 7 different tests for HIV and syphilis.
89268566|NCT01317784|Active Comparator|HIV only|Choice of 4 rapid tests for HIV only.
89268567|NCT03780088|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
89268568|NCT03779698|Experimental|BiodentineTM pulpotomy group|A Bioactive Dentine Substitute (BiodentineTM, Septodont Ltd., Saint Maur des Faussés, France) was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface.
89268569|NCT03779698|Active Comparator|Formocresol pulpotomy group|A sterile cotton pellet moistened with 1:5 concentration formocresol (Buckley's Formocresol, Sultan Healthcare, Englewood, NJ, USA) then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing.
89268570|NCT03779542||open-angle group|ACD > 2.68 measured by the swept source AS-OCT and angle > Shaffer 2 in four quadrants under gonioscope
89268571|NCT03779542||narrow-angle group|ACD≤2.68 measured by the swept source AS-OCT and angle≤Shaffer 2 in four quadrants under gonioscope
89268572|NCT03779464|Experimental|S/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
89268573|NCT03779464|Active Comparator|Gem/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and Gemcitabine 1000 mg/m² (D1, D8, q3w)
89268574|NCT05489380|Other|Accumeasure last|Optical polyp size assessment, followed by biopsy forceps and then AccuMeasure measurement
89268575|NCT05489380|Other|AccuMeasure first|optical assessment, followed by AccuMeasure measurement and then biopsy forceps assisted assessment (2)
89268576|NCT03776578||Head and neck Cancer surgery not treatment and rehabilitation|The patients with oral cavity cancer who weren't treated by radical operation and free flap reconstruction,and can't provide them with preventive swallowing rehabilitation
89290530|NCT03928002|Experimental|4DFlow magnetic resonance imagery|2D MRI, essential for diagnosis and monitoring of PAH, with an additional 8 minutes for 4D flow
89268577|NCT03776578||Head and neck Cancer surgery treatment and rehabilitation|Head and neck cancer treatment has developed over the last decade, with improved mortality and survival rates, It is well accepted that pre-treatment swallow function is indicative of post-treatment status and is helpful in identifying patients with high risk of aspiration and dysphagia.Preventive swallowing rehabilitation including evaluation patient's swallowing function and propose rehabilitation and adaptive maneuver or change in food texture. The aim is to ensure safe swallowing and prevent deglutitive muscles from deconditioning. Investigators include patients with advanced oral cavity cancer who were treated by radical operation and free flap reconstruction, and provided them with preventive swallowing rehabilitation.Investigators then analyze the swallowing function, oral intake status, and nasogastric tube dependence rate and tracheostomy tube dependence rate.
89268578|NCT01314820|Active Comparator|normal saline injection|20 cc normal saline injection into the knee joint
89268579|NCT01314820|Sham Comparator|sham injection|knee injection without saline
89268580|NCT03784690|Experimental|Individualized BP group|Individualized intraoperative BP management
89268581|NCT03784690|Placebo Comparator|Standard treatment group|Standard intraoperative BP management
89268582|NCT05091502|Other|Healthy volunteers|
89268583|NCT01309048|Experimental|Patients with painful bone metastasis|Patients with bone metastasis causing pain
89268584|NCT01309126|Experimental|Arm 1: Imprime PGG + cetuximab|Biological/Vaccine + Drug
89268585|NCT01309126|Active Comparator|Arm 2: cetuximab|Drug
89268586|NCT03784378|Experimental|Participants previously enrolled on Study of RXDX-105|Participants were previously enrolled on Study of RXDX-105
89268587|NCT03784456|Experimental|25% protein group|This experimental arm will be given meals containing 25% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
89268588|NCT03784456|Active Comparator|15% protein group|This control arm will be given meals containing 15% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
89268589|NCT01314898|Experimental|Treatment|
89268590|NCT03779386|Experimental|Music during labor and delivery|Music during labor and delivery
88805503|NCT01473745|Active Comparator|modified alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The modified alar cinch suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
88805504|NCT01473745|Placebo Comparator|conventional alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The conventional alar base cinch suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
88805505|NCT01088711|Experimental|Healthy Omarigliptin|Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
88805506|NCT01088711|Placebo Comparator|Healthy Placebo|Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
88805507|NCT01088711|Experimental|T2D Omarigliptin|Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
88805508|NCT01088711|Placebo Comparator|T2D Placebo|Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).
88805509|NCT00127790|Active Comparator|CBT for Insomnia (CBT-I)|Cognitive-Behavioral Therapy for Insomnia (CBT-I)consisting of 10 individual sessions and including sleep education, sleep restriction therapy, stimulus control therapy, sleep hygiene, cognitive therapy, relaxation training and relapse prevention.
88805510|NCT00127790|Active Comparator|CBT for Pain (CBT-P)|Cognitive-Behavioral Therapy for Pain (CBT-P)consisting of 10 individual sessions and including pain education, pacing strategies, problem solving, goal setting, cognitive therapy, relaxation training and relapse prevention.
88805511|NCT00127790|Experimental|CBT for Insomnia & Pain (CBT-I/P)|Combined Cognitive-Behavioral Therapy for Insomnia & Cognitive-Behavioral Therapy for Pain (CBT-I/P)over 10 individual sessions.
88805512|NCT00127790|No Intervention|Wait-List Control (WL)|Waitlist Control condition (WL) with no contact during the intervention period.
89268591|NCT03779386|No Intervention|No music during labor and delivery|No music during labor and delivery
89268592|NCT03779308|Experimental|Intervention|The participants will receive whole body vibration therapy while standing with hand support on a vibration platform.
89268593|NCT03776422|Experimental|Mobile self-help intervention|This study uses automated self-help interventions designed as a kit of smartphone tools.
89268594|NCT03778918||inflammatory bowel disease|inflammatory bowel disease such as Ulcerative colitis and Crohn's disease
89268595|NCT03778918||IBS or Normal Control|irritable bowel syndrome patients normal patients
89268596|NCT03784144|Experimental|Cognitive Strategy|Performing a mathematical subtracting task (starting at 300, by sevens)
89268597|NCT03784144|Active Comparator|Control|The patients will perform both tests without any cognitive condition
89268598|NCT01560676|Active Comparator|HEALTH[e]TEEN|8 lessons over 6-8 weeks Education on healthy eating and physical activity Behavioral support for self-monitoring and goal setting
89268599|NCT01560676|Active Comparator|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks Education on healthy eating and coping skills training Behavioral support for self-monitoring and goal setting
89268600|NCT01315366|Active Comparator|High dose vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a supplement of vitamin D3 EuroD (20,000 IU/wk) for one year.
89268601|NCT01315366|Placebo Comparator|Low dose Vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a weekly placebo (EURO D Placebo) supplement for one year.
89268602|NCT03778762|Active Comparator|Blind tracheal intubation through AirQ|Patients were intubated through the air-Q blindly
89268603|NCT03778762|Placebo Comparator|Fiberscopic tracheal intubation through AirQ|Patients were intubated through the air-Q using fibreoptic bronchoscope
89268604|NCT01315756|No Intervention|Control group|Treatment as usual.
89268605|NCT01315756|Experimental|Few Touch Application (FTA)|"This arm will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user."
89268606|NCT01315756|Experimental|FTA and health counseling|This arm will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via sms from the diabetes nurse which is based on the patient's initiative (via sms). In addition, the diabetes nurse will call the patients three times during this period and discuss progress.
89268607|NCT01319656|Active Comparator|Group A|Intervention group(n = 163)
89268608|NCT01319656|Active Comparator|Group B|Delayed intervention (n = 163)
89268609|NCT01319656|No Intervention|Group C|No intervention group (n = 163)
89268610|NCT03778684|Experimental|Normal Body mass index without central obesity|
89268611|NCT03778684|Experimental|High Body mass index with central obesity|
89268612|NCT03784222|Experimental|treatment group|188 first episode schizophrenia patients, receiving blonanserin treatment, 60 of the patients receive MRI and serum BDNF test
89268613|NCT03784222|Other|control group|60 subjects without schizophrenia, only receiving MRI and/or serum BDNF
89268614|NCT01319890||Right Colectomy for colonic tumors|The group of patients enrolled will be patients with biopsy proven right colon tumors, both benign and malignant. These patients will then be subdivided into those having conventional laparoscopic right colectomy and SILS right colectomy
89268615|NCT03783910|Experimental|GRT9906|"Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment).~Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg [40 mg twice daily]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks."
89268616|NCT03783910|Placebo Comparator|Placebo|Participants received Placebo (2-6 tablets daily) oral for up to 6 weeks.
89268617|NCT03778450||Analgesics, Opioid|Patients are only included if they have been diagnosed in at least three quarters in the study period with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3. At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
89268618|NCT03778450||Non-Opioid Analgesic|Patients are only included if they have been diagnosed in at least three quarters in 2012 with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3.At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
89268619|NCT03776500|Experimental|Panel A - Active|N = 6, 150 mg twice daily of PBTZ169
89268620|NCT03776500|Placebo Comparator|Panel A - Placebo|N = 2, 150 mg twice daily of PBTZ169 matching placebo
89268621|NCT03776500|Experimental|Panel B - Active|N = 6, 300 mg twice daily of PBTZ169
89268622|NCT03776500|Placebo Comparator|Panel B - Placebo|N = 2, 300 mg twice daily of PBTZ169 matching placebo
89268623|NCT03776500|Experimental|Panel C - Active|N = 6, 600 mg once daily of PBTZ169
89268624|NCT03776500|Placebo Comparator|Panel C - Placebo|N = 2, 600 mg once daily of PBTZ169 matching placebo
89268625|NCT03776500|Experimental|Panel D - Active|N = 6, 600 mg twice daily of PBTZ169
89268626|NCT03776500|Placebo Comparator|Panel D - Placebo|N = 2, 600 mg twice daily of PBTZ169 matching placebo
89268627|NCT01319968||Postpartum patients|100 postpartum women attending the clinic for their postpartum visit will be evaluated for vaginal atrophy, vaginal symptoms and dyspareunia.
89268628|NCT05000164|Experimental|Market Product|Eligible subjects will be dispensed the study lenses in a bilateral fashion and will be in the treatment for approximately 5 weeks.
89268629|NCT03778528||Down syndrome|Individuals with Down syndrome undergoing cataract surgery.
89268630|NCT03778528||Control|Age-matched controls undergoing cataract surgery.
89268631|NCT03776110|Experimental|GRT9906 80-mg dose group|"In one period, 80 mg GRT9906 (2 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4.~In the second period, a total of 7 doses of placebo (2 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
89268632|NCT03776110|Experimental|GRT9906 120-mg dose group|"In one period, 120 mg GRT9906 (3 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on the day before Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (3 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
89268633|NCT03776110|Experimental|GRT9906 160-mg dose group|"In one period, 160 mg GRT9906 (4 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (4 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
89268634|NCT03776110|Experimental|GRT9906 200-mg dose group|"In one period, 200 mg GRT9906 (5 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 120 mg was administered on Day T. The dose administration on Day T was performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (5 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
89268635|NCT03778216|Experimental|FBT-ARFID|Family Based Treatment of child ARFID
89268636|NCT03778216|No Intervention|Usual Care|Continued usual care for ARFID with the exception of any Family Based Treatment
89268637|NCT05616130||Trauma|Data collection from medical records; bone marrow collection at time of surgical intervention; serial blood sampling; serial interviews to complete surveys and questionnaires which assess overall health, quality of life, daily living activities and mobility; serial physical function tests - hand grip strength measurement and short physical performance battery and telephone follow up call
89268638|NCT05616130||Elective Hip Repair|Data collection from medical records; bone marrow collection at time of surgical intervention; serial blood sampling; serial interviews to complete surveys and questionnaires which assess overall health, quality of life, daily living activities and mobility; serial physical function tests - hand grip strength measurement and short physical performance battery and telephone follow up call
89268639|NCT03776344|Experimental|Virtual Reality|Patients randomized to the experimental group will benefit from the usual standard care following surgery and during the second day the opportunity to use virtual reality for 15 minute. Along VR, they will complete the psychological and physiological measures.
89268640|NCT03776344|No Intervention|Non-VR condition (Standard of Care)|Patients randomized to the control group will benefit from the usual standard care following surgery and during the second day will complete the psychological and physiological measures.
89268641|NCT03783988|Other|Open uncontrolled pharmacokinetic study|Single armed - All subjects receive one dose of topical combination gel containing TRIAC and DHEA
89268642|NCT03778138|Experimental|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
89268643|NCT03777670||Cases|Infants with suspected sepsis
89268644|NCT03777670||Controls|Infants with no suspicion of sepsis
89268645|NCT03777748|Experimental|Two dental implants in the edentulous maxilla and mandible|Edentulous maxilla und mandible are treated with two diameter-reduced tissue level implants (Straumann, Basel) and anchored with CM LOC® and CM LOC Flex® attachments (Cendres+Métaux SA, Bienne).
89268646|NCT03783754|Experimental|Triple Pill (Active Treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
89268647|NCT03783754|Placebo Comparator|Placebo|received via blinded study oral capsules
89268648|NCT01309438|Experimental|Normal renal function|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
89268649|NCT01309438|Experimental|Mild renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
89268650|NCT01309438|Experimental|Moderate renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
89268651|NCT03776032|Experimental|Darbepoetin alfa|Participants received once a week darbepoetin alfa, administered by subcutaneous injection at a starting dose of 2.25 µg/kg for up to 12 weeks. The dose of darbepoetin alfa may have been adjusted based on hemoglobin levels to a maximum dose of 4.5 µg/kg /week.
89268652|NCT03776032|Placebo Comparator|Placebo|Participants received once a week placebo, administered by subcutaneous injection for up to 12 weeks.
89268653|NCT01309516|Experimental|Complex Intervention (LTP-TH)|The 12 sessions of complex intervention (LTP-TH) will be delivered to mothers.
89268654|NCT01309516|No Intervention|Control group|Control group will receive standard postnatal follow-up.
89268655|NCT03775876|Active Comparator|Propofol|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Propofol. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 2mg/Kg/h and modified to a maximum of 4 mg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four.
89268656|NCT03775876|Active Comparator|Dexmedetomidine|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Dexmedetomidine. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 1mcg/kg over 10 minutes then 0.2 mcg/Kg/h and modified to a maximum of 0.7 mcg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four with a maximum.
89268657|NCT01320514||Fibrin Sealant (Artiss)|
89268658|NCT03773536|Experimental|ASAQ + SLD Primaquine|Artesunate + amodiaquine (WHO prequalified Artesunate/Amodiaquine Winthrop®) was administered orally as a fixed dose combination, at a dose of approximately artesunate 4 mg/kg + amodiaquine 10mg/kg once daily for 3 consecutive days. Primaquine was administered orally, as a single dose (0.25 mg/kg) together with the first artesunate + amodiaquine dose. All doses of medicine were administered under direct supervision. Any patient who vomited within a 30 minute observation period was re-treated with the same dose of medicine and observed for an additional 30 minutes. If the patient vomited again after the second study drug administration, he/she was withdrawn and offered rescue therapy (Artesunate IV).
89268659|NCT03773848|Experimental|A- hook plate|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with hook plate. X-ray was applied to check the grade of reduction before the operation is completed.
89268660|NCT03773848|Experimental|B- tightrope|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with tightrope. X-ray was applied to check the grade of reduction before the operation is completed.
89268661|NCT01320592|Experimental|PD0332991 and Paclitaxel|PD0332991 in combination with weekly paclitaxel at a fixed dose of 80 mg/m2
89268662|NCT03773692|Experimental|Passive feedback and JITAI|"Passive feedback and JITAI~Second Phase - PA Level Feedback Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)"
89268663|NCT03783676|Experimental|Remifentanil group|Will receive remifentanil bolus and infusion guided by an algorithm
89268664|NCT03783676|Placebo Comparator|Control group|Will receive normal saline bolus and infusion guided by the remifentanil algorithm
89268665|NCT03783598|Experimental|intervention group|The intervention group received problem solving therapy as 6 modules. Each module was included at least 1 session per week that is nearly 60 minutes, and the amount of weekly sessions was arranged according to the needs of the person.Individuals has an opportunity was provided for identify problems meaningful for themselves and to start their change from the activities they valued by using the COPM.
89268666|NCT03783598|No Intervention|control group|Control group had not any intervention we have an education to control group about diabetes and healthy life conditions.
89268667|NCT01309594|Experimental|Hematopoietic stem cell transplantation|Extraction of bone marrow cells from HIV positive patients with advanced liver cirrhosis and transplant their bone marrow back into the patients
89268668|NCT01320748|Experimental|Dual Processing|
89268669|NCT01320748|Active Comparator|Relapse Prevention|
89268670|NCT03775642|Experimental|Intervention video|The intervention video will employ debiasing strategies to correct women's misinformation about the safety of the IUD and implant safety.
89268671|NCT03775642|Placebo Comparator|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration.
89268672|NCT04422886|Experimental|Physio+tDCS|Receives 20 minutes of active tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
89268673|NCT04422886|Sham Comparator|Physio+sham|Receives 20 minutes of sham tDCS immediately prior to physiotherapy session, 4 days per week for a total of 16 sessions.
89268674|NCT03783520|Experimental|Er,Cr:YSGG Laser|In laser group, each root canal was dried with paper points and then Er,Cr:YSGG (Biolase™, Waterlase™, San Clemente, CA, USA) was used for intracanal disinfection with the following parameters: panel output power of 0,75 W, pulse frequency of 20 Hz, and 1% water pressure to 10% air pressure ratio laser with RFT3 tips (415 µm diameter radial firing tip RFT3 Endolase, Biolase Technology, Inc; calibration factor of 0.85). The fiber was placed at 1mm short of the WL. Irradiation was delivered along the entire length of the root canal with helicoradial movements, 1mm per seconds in speed. This procedure was repeated three times and kept for 20 seconds between each irradiation.
89268675|NCT03783520|Active Comparator|Sodium hypochlorite|In control group, each canal were irrigated with 6 ml of 2,5% NaOCl. For the final irrigation, 5 ml of sterile saline were used. During irrigation, needle was inserted 1 mm short of the WL.
89268676|NCT05582200||Healthy subjects|Healthy subjects
89268677|NCT05582200||Patients with Alzheimer's disease|Patients with Alzheimer's disease
89268678|NCT03775720|Experimental|Low genetic risk group|Dietary advice to maintain salt intake to 6g/day
89268679|NCT03775720|Experimental|High genetic risk group|Dietary advice to reduce salt intake to 4g/day
89268680|NCT01320904|Placebo Comparator|Closed Kinetic Chain and NMES placebo|"During the stimulation period the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.~We used a 10-channel electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings."
89268681|NCT01320904|Other|Closed Kinetic Chain Group|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
89268682|NCT03775564|Experimental|REMEDRUGBY|TAU + RemedRugby Program
89268683|NCT03775564|Active Comparator|TAU + TOUCH RUGBY|TAU + Touch Rugby Program
89268684|NCT01320982|Active Comparator|minocycline|minocycline
89268685|NCT01320982|Active Comparator|pramipexole|pramipexole
89268686|NCT01320982|Active Comparator|acetylsalicylic acid|acetylsalicylic acid
89268687|NCT01320982|Placebo Comparator|Placebo|Placebo
89268688|NCT01321060|Active Comparator|Conservative treatment|Conservative treatment group with only drugs.
89268689|NCT01321060|Experimental|Continuous catheter drainage|Once the diameter of the fluid collection is more than 6cm, continuous catheter drainage will be applied.
89268690|NCT01321060|Experimental|Repeated aspiration|Once the diameter of the fluid collection is more than 6cm, aspiration is applied and draw the tube out immediately after aspiration.
89268691|NCT03773224|Active Comparator|Irrigation|Layer by layer irrigation of the surgical wound with gentamicin-saline solution
89268692|NCT03773224|No Intervention|Control|The surgical wound is closed layer by layer without irrigation
89268693|NCT03783208|Experimental|G-CSF|Patients in the G-CSF group will receive G-CSF once a day on hCG day, before hCG injection. The procedure involved the administration of G-CSF through slow infusion into the endometrial cavity using a soft embryo transfer catheter.
89268694|NCT03783208|Placebo Comparator|Control group|Normal saline of 1 mL was infused into the endometrial cavity in the same way in patients in the control group
89268695|NCT03773068|Experimental|Group 1 - BAY1817080 Dose 1|Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
89290531|NCT03928002|Active Comparator|Cardiac catheterization|cardiac catheterization procedure using the Fick method; gold standard
89290532|NCT05197816|Experimental|Deep brain stimulation|All patients will undergo adaptive deep brain stimulation with results compared before and after stimulation
88821604|NCT03313778|Experimental|Part E1: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab every 6 weeks (Q6W) via IV infusion, and SoC chemotherapy every 3 weeks (Q3W) for up to 4 cycles during the perioperative and adjuvant phases.
89268696|NCT03773068|Experimental|Group 2 - BAY1817080 Dose 2|Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg [13C715N]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
89268697|NCT03773068|Experimental|Group 3 - BAY1817080 Dose 3|Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence
89268698|NCT01321138|Active Comparator|Femoral nerve block|Continuous femoral nerve block with bolus of ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2 % 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 30 patients.
89268699|NCT01321138|Placebo Comparator|PCA morphine|Patients with iv morphine with self administration with a PCA-system, associated with paracetamol and ibuprofen.
89268700|NCT01320046||Patients with urinary incontinence|Patients attending the urogynecological clinic for urinary incontinence-100 patients. In this group we will recruit patients with UI, and will assess co-existence of VCD
89268701|NCT01320046||Patients with vulvar contact dermatitis|Patients attending the vulvovaginal clinic with vulvar contact dermatitis (100 patients). In this group we will recruit patients with VCD, and will assess co-existence of UI.
89268702|NCT01320046||Age matched control group|"Patients attending the general clinic for annual checkup, which will be matched for age with the two other groups (200 patients).~These patients will be evaluated for symptoms of UI and VCD"
89268703|NCT05540782||Survivors of Prostate Cancer|This is a cross-sectional study with a one-time data collection process and no subsequent follow-ups. If patients did not opt out of receiving study-specific text communications, they may also receive text messages with reminders about surveys and/or direct links to REDCap to complete the surveys. Text-based communications will be delivered using the secure, HIPAA-compliant Mosio texting platform developed for clinical research.
89268704|NCT01320124||osteoarthritis, total knee arthroplasty|The main cohort will have a total knee arthroplasty and will not develop a contracture post surgery. We will analyze differntial gene expression in all subjects.
89268705|NCT01320124||contracture post arthroplasty|A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
89268706|NCT01309750||C. diff|Patients with Clostridium difficile colitis admitted to the intensive care unit will be the study group.
89268707|NCT03772756|Experimental|EUS-RFA group|Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy
89268708|NCT03772756|Active Comparator|control group|the control group will receive chemoradiotherapy only
89268709|NCT03775252|Experimental|Ketogenic diet|Group of patients treated with ketogenic diet after the first neurophysiological screening.
89268710|NCT04664998|Active Comparator|Male participants|200 male participants whose partners are enrolled in the parent study (Kampala Women's Bone study). All male participants will undergo the same study procedures at each visit, such as HIV and STI testing, and urine tenofovir testing if on PrEP.
89268711|NCT04664998|Active Comparator|Female participants|300 female participants from the parent study (Kampala Women's Bone study) will be enrolled to recruit their male sexual partner(s). All female participants will receive HIV testing, STI testing, and urine tenofovir testing (if on PrEP) at quarterly visits.
89268712|NCT03772678|Placebo Comparator|Placebo|0.9% Saline For SAD and MAD arms.
89268713|NCT03772678|Experimental|Single Ascending Dose - Low Dose|LSALT peptide (1mg/mL in 0.9% saline) Single escalating dose - 0.01mg, 0.1mg, 0.3mg, 0.5mg intravenously Escalation to 2.5mg and 5mg doses in next cohorts if no adverse effects are seen after 10-14 days.
89268714|NCT03772678|Experimental|Single Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Single dose - 1mg intravenously over 2h Escalation to next dose in next participant every 72h if no adverse effects are seen.
89268715|NCT03772678|Experimental|Multiple Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Dose will be determined based on results of SAD arm. LSALT will be administered intravenously once or twice daily for 3 days.
89268716|NCT04628572||Cohort 1|Eligible adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice
89268717|NCT03772912||Total Knee Arthroplasty Patients|Patients undergoing primary or revision total knee arthroplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
89268718|NCT03772990|Experimental|Calcium chloride|Participants randomly assigned to the experimental group will receive 15 mg/kg of calcium chloride (bolus) intravenously during separation from cardiopulmonary bypass
89268719|NCT03772990|Placebo Comparator|0,9% Sodium Chloride|Participants randomly assigned to the placebo group will receive equivalent amount of placebo intravenously during separation from cardiopulmonary bypass
89268720|NCT03782896||mastectomy group|All patients who received the mastectomy (breast conserving surgery and sentinel lymph node dissection)
89268721|NCT03775018|Experimental|Transversus abdominis plain blockade|The patients will undergo Transversus abdominis plain blockade, associated with intravenous analgesia
89268722|NCT03775018|Active Comparator|Intravenous analgesia|The patients will receive intravenous analgesia with Acetaminophen (1g/6h)
89268723|NCT03773458|Other|Eligible patients for AI test.|Device: An artificial system for the screening of scoliosis
89268724|NCT03782662|Experimental|RV521 plus Itraconazole|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D7 plus Itraconazole 100 mg capsules for oral administration, a 200 mg dose administered once daily on D4 - D10, inclusive
89268725|NCT03782662|Experimental|RV521 plus Verapamil|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D11 plus Verapamil, 80 mg tablets for oral administration, an 80 mg dose administered TDS daily on D4 - D14, inclusive
89268726|NCT03782662|Experimental|RV521 plus Rifampicin|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D10 plus Rifadin, Rifampicin, 300 mg capsules for oral administration, a 600 mg dose administered once daily on D4 - D10, inclusive
89268727|NCT03782662|Experimental|RV521 plus Midazolam|RV521 drug substance in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
89268728|NCT03782662|Placebo Comparator|Placebo plus Midazolam|Placebo for RV521 in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
89268729|NCT01309984|Active Comparator|arm 1|
89268730|NCT01309984|Active Comparator|arm 2|
89268731|NCT03772132|Experimental|Chemotherapy|The patients wil receive conventional chemotherapy FORFIRINOX
89268732|NCT03772054|Active Comparator|Propofol|After spinal anesthesia, patients in this arm will receive an intravenous target controlled infusion to site effect (TCI/Ce) infusion of propofol to achieve hypnosis guided to a bispectral index (BIS) level of 40-60 during surgery.
89268733|NCT03772054|Experimental|Sevoflurane|After spinal anesthesia, patients in this arm will receive an inhalation induction with sevoflurane to achieve hypnosis guided to 0.7-0.9 minimum alveolar concentration (MAC) during surgery.
89268734|NCT03771820|Experimental|NC-6004 +pembrolizumab|"NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.~In phase IIa portion, NC-6004 dose goes up from 90 mg/m2 up to 135 mg/m2. In phase IIb portion, the dose should be the determined RPII dose in phase IIa portion."
89268735|NCT03771820|Active Comparator|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
89268736|NCT03771742|Active Comparator|transverse TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
89268737|NCT03771742|Experimental|paramedian sagittal TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the para-sagittal scan, in-plain, caudal to cephalic approach.0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
89268738|NCT03774940|Experimental|fever|patients that have fever after PNL
89268739|NCT03774940|Active Comparator|No fever|Patients without fever after PNL
89268740|NCT03771976||Over 35 years of age|Primiparous women over 35 years of age.
89268741|NCT03771976||Between 20-34 years of age|Primiparous women between 20 and 34 years of age.
89268742|NCT01320358|Experimental|ECMPS-IEM|
89268743|NCT05531890|Experimental|Group 1 GTX-102 medium dose fast or slow in Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered fast or slow over two periods
89268744|NCT05531890|Experimental|Group 2a GTX-102 high dose fast in Period 1 and Period 2|"GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered fast over two periods~Note: Note under US IND"
89268745|NCT05531890|Active Comparator|Group 2b Oral comparator in Period 1 and Period 2|"0.1 mg/kg betamethasone solution oral drops solution over two periods~Note: Not under US IND"
89268746|NCT05531890|Experimental|Group 3 GTX-102 high dose fast or low dose fast in Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) or GTX-102 Betamethasone oral spray low dose (0.025 mg/kg) administered fast over two periods
89268747|NCT05531890|Experimental|Group 4a GTX-102 high dose fast in Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered fast over two periods
89268748|NCT05531890|Active Comparator|Group 4b betamethasone intramuscular in Period 1 and Period 2|0.1 mg/kg betamethasone solution as intramuscular injection administered over two periods
89268749|NCT03782584|Experimental|Modified Pilates Exercise Group|they will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week.
89268750|NCT03782584|Other|Control Group|they will be given daily life advises to prevent neck pain
89268751|NCT03782428|Active Comparator|Probiotic group|27 participants received probiotics twice daily for six months
89268752|NCT03782428|Placebo Comparator|Placebo group|25 participants received placebo twice daily for six months
89268753|NCT00123474|Experimental|1|
89268754|NCT00123474|Experimental|2|
89268755|NCT00123474|Experimental|3|
89268756|NCT00123474|Experimental|4|
89268757|NCT00142298|Experimental|telbivudine|telbivudine 600 mg p.o. daily for 104 weeks.
89268758|NCT03774628|Experimental|Chengdu Kanghua (one booster shot)|one dose, A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
89268759|NCT03774628|Experimental|Chengdu Kanghua (two booster shots)|two doses at 0 and 3 days, on A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
89268760|NCT03774706|Active Comparator|Misoprostol with TA|two tablets sublingual misoprostol plus IgM tranexamic acid in 100 ml saline by slow iv
89268761|NCT03774706|Active Comparator|Misoprostol with placebo to TA|two tablets sublingual misoprostol plus placebo to tranexamic acid ( 110 ml saline) by slow iv
89268762|NCT03967496||No Delirium|No Delirium: CAM-ICU score of less than 3 throughout Post-Anesthesia Care Unit stay
89268763|NCT03967496||Initial Delirium|Initial Delirium: CAM-ICU score of 3 or more at 15 minutes following end of anesthesia and/or at 30 minutes following end of anesthesia
89268764|NCT03967496||Delirium|Delirium: CAM-ICU score of 3 or more immediately prior to discharge from Post-Anesthesia Care Unit
89268765|NCT03709654|Experimental|Treatment Arm|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.
89268766|NCT03709654|Placebo Comparator|Vehicle Control|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.
89268767|NCT00412061|Experimental|Octreotide+ Everolimus|Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
89268768|NCT00412061|Placebo Comparator|Octreotide+ Placebo|Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.
89268769|NCT03964350|Experimental|Ethanol|Subjects will receive ethanol (0.4 or 0.8 g/kg) which will be administered in a gelatin vehicle.
89268770|NCT03964350|Placebo Comparator|Placebo (gelatin vehicle)|Subjects will receive placebo of black cherry sugar-free jello.
89268771|NCT01310452|Active Comparator|neutral protamine insulin, metformin|NPH insulin once daily plus oral metformin twice or thrice daily during 26 weeks
89268772|NCT01310452|Experimental|insulin detemir, metformin|Insulin detemir once daily plus oral metformin twice or thrice daily during 26 weeks
89268773|NCT01078506||Hong Kong Chinese|Without a history of known intracranial pathologies.
89268774|NCT01035671|Experimental|Low Dose|A0001 (0.5 g BID)
89268775|NCT01035671|Experimental|High Dose|A0001 (0.75 g BID)
89268776|NCT01035671|Placebo Comparator|Placebo|Placebo
89268777|NCT03966534|No Intervention|Control Group|Blood culture obtained as first test after venipuncture and prior to biochemistry test
89268778|NCT03966534|Experimental|Diversion Group|Biochemistry test obtained as first test after venepuncture and prior to blood culture
89268779|NCT03771196|Experimental|Bioactive-Restorative material|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
89268780|NCT03771196|Active Comparator|Resin Modified Glass Ionomer (RMGI)|Fuji II Lc, fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics a wear-resistant, self-adhesive, light-cured resin coating.
89268781|NCT03770962|Experimental|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will observe the birth or give any assistance needed."
89268782|NCT03770962|No Intervention|One midwife|This is standard care. One midwife is responsible for the care of the woman and her unborn baby during labor and birth.
89268783|NCT04560868|Active Comparator|Control|
89268784|NCT04560868|Experimental|Experimental|
89268785|NCT03769558||JIA patients prescribed abatacept|
89268786|NCT03769480||Study Group|Study Group=Athletes with Disability
89268787|NCT03769480||Control Group|Control Group=Healthy Athletes
89268788|NCT03769402|Active Comparator|Citric acid|Citric acid PH1 and concentration 50% was used for 30 seconds on bone surface before washing it off and filling the defect with xenograft
89268789|NCT03769402|Placebo Comparator|Control|Control test
89268790|NCT04466410|Experimental|0.015 milligram (mg) XT-150|0.015 mg of XT-150. Cohort 1 of the study
89268791|NCT04466410|Experimental|0.15 mg XT-150|0.15 mg of XT-150. Cohort 2 of the study
89268792|NCT04466410|Experimental|0.45 mg XT-150|0.45 mg of XT-150. Cohort 3 of the study
89268793|NCT04466410|Placebo Comparator|Placebo|PBS for injection.
88821605|NCT03313778|Experimental|Part E2: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab Q6W via IV infusion, and SoC chemotherapy Q3W for up to 4 cycles during the perioperative and adjuvant phases.
89268794|NCT04444180||Clinical high risk for psychosis (CHR)|No intervention. Just use virtual hand illusion (VHI) paradigm to observe the outcome of individuals with CHR at one-year follow-up node and analyze the predictive role of self-representation in transition into psychosis.
89268795|NCT04444180||First episode of schizophrenia (FES)|In contrast to FES, it is anticipated to observe CHR individuals with similar behavioral performance to FES may presented higher risk of transition.
89268796|NCT04444180||Healthy control (HC)|In contrast to HC, it is anticipated to observe CHR individuals with similar behavioral performance to HC may presented lower risk of transition.
89268797|NCT01321294|Active Comparator|Nissen fundoplication|
89268798|NCT01321294|Active Comparator|Toupet fundoplication|
89268799|NCT00411671|Experimental|Sorafenib|Sorafenib 400 mg By Mouth Twice Daily for 28 Days.
89268800|NCT04419688|Experimental|STT-5058|
89268801|NCT04419688|Placebo Comparator|Placebo|
89268802|NCT03770806|Experimental|Femoral Nerve Block|Standard Ultrasound-guided femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
89268803|NCT03770806|Experimental|Adductor Canal Nerve Block|Standard Ultrasound-guided adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
89268804|NCT03770806|Experimental|No Block|For subjects who choose to have medication alone with no block for their routine care, there will be no changes to their care, which includes receiving the multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg. They will be in an observational group only with no randomization.
89268805|NCT01039103|Experimental|Nanocort|PEG-liposomal prednisolone sodium phosphate (Nanocort) 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
89268806|NCT01039103|Active Comparator|Solu-Medrol|Methylprednisolone (Solu-Medrol) 1 g, IV, infusion over 2 hours on days 1, 2 and 3
89268807|NCT01036061|Experimental|GSK618334 low Dose|GSK618334 Low Dose
89268808|NCT01036061|Experimental|GSK618334 Medium Dose|GSK618334 medium dose arm
89268809|NCT01036061|Experimental|GSK618334 High Dose|GSK618334 High Dose Arm
89268810|NCT01036061|Experimental|GSK618334 Placebo|Placebo for all 3 dose levels
89268811|NCT03770104|Experimental|Intervention Group (5.5 plus weight)|ETT insertion depth using Spanish recommendations Patients included in the intervention group arm who are included in the study will be intubated using Spanish recommendations (5.5 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
89268812|NCT03770104|Experimental|Control Group (6 plus weight)|ETT insertion depth using international recommendations Patients included in the intervention group arm who are included in the study will be intubated using international recommendations (6 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
89268813|NCT01036139|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
89268814|NCT01036139|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
89268815|NCT03770026|Active Comparator|Clomiphene citrate only|Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.
89268816|NCT03770026|Experimental|Platelet-rich plasma plus Clomiphene|Women who did not conceive on the Clomiphene citrate-only cycle will receive Clomiphene citrate 100 mg/ day starting from the third day of the cycle. Intrauterine Autologous platelet-rich plasma will be done on the cycle days 8 and 10.
89268817|NCT01561846|Active Comparator|regular cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trialy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
89268818|NCT01561846|Experimental|CLA enriched cheese|
89268819|NCT01321450||Group A|Preparation with Harmonic WAVE
89268820|NCT01321450||Group B|Preparation with conventional modalities
89268821|NCT03769870|Other|Teneligliptin|
89268822|NCT03769870|Other|Atorvastatin|
89268823|NCT03769870|Other|Teneligliptin + Atorvastatin|
89268824|NCT03769792|Experimental|Impedance spectroscopy|"24 women will be included in the study and divided into two subgroups.~12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification.~Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification.~The planned interventions are:~Blood and faeces tests~Impedance spectroscopy test~Full gynecological and proctological examination~Transanal ultrasonography~Anorectal manometry"
89268825|NCT01321918|Other|Case subjects|
89268826|NCT01321918|Other|Control subjects|
89268827|NCT03769324||Normal Eye Group|Normal eye receiving Osmolarity Test
89268828|NCT03769324||DED Group|Dry Eye Disease receiving Osmolarity Test
89268829|NCT03769246|Experimental|Upright Go Device Group|"Patients receiving the Upright device will have a brief training on the use of the device and proper posture. They will be asked to download the Upright app on their phone from the Playstore.~Patients will wear the device once daily for training. They will attach the device applying an adhesive on their upper back, as instructed, and the device will be attached to the adhesive by velcro. Once completed they should remove adhesive."
89268830|NCT03769246|Active Comparator|Control Group|The control group will receive a 15-20 minute instruction on proper posture by the physician and will receive an ergonomic handout.
89268831|NCT03769012|Experimental|Treatment|Beta-Glucan
89268832|NCT03769012|Placebo Comparator|Placebo|Placebo
89268833|NCT03835481|Experimental|25 mg BI 730357|25 mg BI 730357 + placebo under fasted conditions.
89268834|NCT03835481|Experimental|50 mg BI 730357|50 mg BI 730357 + placebo under fasted conditions.
89268835|NCT03835481|Experimental|100 mg BI 730357|100 mg BI 730357 + placebo under fasted conditions.
89268836|NCT03835481|Experimental|200 mg BI 730357|200 mg BI 730357 + placebo under fasted conditions
89268837|NCT03835481|Experimental|400 mg BI 730357|400 mg BI 730357 + placebo under fasted conditions.
89268838|NCT03768934|No Intervention|Control|No airtime incentive for completing the survey
89268839|NCT03768934|Experimental|1X Incentive|1X airtime incentive
89268840|NCT03768934|Experimental|2X incentive|2X airtime incentive
89268841|NCT03768934|Experimental|Lottery Incentive|Lottery airtime incentive where odds of winning lottery are 1 out of 20
89268842|NCT04071964||Groupe 1|Patients with colorectal cancer undergoing resection with anastomosis
89268843|NCT04071964||Groupe 2|Patients with colorectal cancer undergoing resection without anastomosis (Abdominoperineal resection)
89268844|NCT04071964||Groupe 3|"Patients with rectal cancer without surgery (Watch and wait)"
89268845|NCT04071964||Groupe 4|Control group consisting of patients who do not have surgical pathologies of the colon and rectum
89268846|NCT03768778|Other|Debridement|
89268847|NCT02680366|Experimental|collagen/ABMNC scaffold|collagen/ABMNC scaffold covered on Foley catheter balloon inserted after hysteroscopic adhesiolysis
89268848|NCT02680366|Active Comparator|Foley catheter balloon|Foley catheter balloon inserted after hysteroscopic adhesiolysis
89268849|NCT00708695||Treatment 2: Transportation, Child Screening/Referral|The 514 families received: 1) free transportation for prenatal care; and 2) child developmental screening and referral services.
89268850|NCT00708695||Treatment 4: Nurse Home Visiting through Age 2|The 228 families: 1) free transportation for prenatal care; 2) nurse home-visiting during pregnancy and through child's second birthday; and 3) child developmental screening and referral.
89268851|NCT01567540|Experimental|DPPIV Inhibition|The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).
89268852|NCT01039259||subjects with lip piercing|
89268853|NCT01039259||subjects with tongue piercing|
89268854|NCT01039337|Active Comparator|Hip school|This group will receive hip school during the intervention period of 6 weeks.
89268855|NCT01039337|Active Comparator|Hip School and Manual Treatment|This group receives both hip school and manual treatment during the 6 weeks.
89268856|NCT01039337|Active Comparator|Minimal control intervention|An information leaflet including exercises.
89268857|NCT01885637|No Intervention|Control group|In the control group, the patients continue to be attached to the health care system in line with current practice. This means that the patient typically remains in hospital or ambulatory and may have contact with one or more hospitals, GP and possibly homecare later in the process. Caregivers in the control group may receive psychological counseling through referral from a GP.
89268858|NCT01885637|Other|Intervention Group|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
89268859|NCT01036841|Active Comparator|desmopressin tablet|
89268860|NCT01036841|Experimental|desmopressin MELT-formulation|
89268861|NCT01039493||Patients|
89268862|NCT01039493||Providers|
89268863|NCT03709576|Experimental|Pevonedistat and Azacitidine|The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.
89268864|NCT00122460|Experimental|Cetuximab Plus Chemotherapy|
89268865|NCT00122460|Active Comparator|Chemotherapy alone|
89268866|NCT03768466|Experimental|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
89268867|NCT03768388|Other|Fasting State|A single 600 mg dose of levoketoconazole administered in a fasting state.
89268868|NCT03768388|Other|Fed State|A single 600 mg dose of levoketoconazole administered in a fed state.
89268869|NCT01320436|Active Comparator|Treatments arm|Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
89268870|NCT01320436|Placebo Comparator|Control arm|Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.
89268871|NCT04794088|Active Comparator|Intravenous imatinib mesylate (Impentri®)|Patients receiving the active investigational medicinal product will be receiving imatinib 200mg b.i.d. (administered as an 8 mg/mL solution for i.v. infusion) for 7 days.
89268872|NCT04794088|Placebo Comparator|Placebo solution|Patients receiving the placebo comparator will be receiving the same amount of intravenous solution, however containing 0.01M acetate buffer with 1.9% glycerol.
89268873|NCT03763084|Experimental|acetaminophen|For patients randomized to OVA group, OVA 500mg was given every 8 hours for the first 48 hours postoperatively. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
89268874|NCT03763084|Active Comparator|Sufentanil|Sufentanil injection 500μg /10ml in normal saline, total volume 50 ml.Constant infusion dosage is 0.05μg/kg/h. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
89268875|NCT03763006|Experimental|Ocudox lid wiped|
89268876|NCT03763006|Active Comparator|Povidone Iodine|
89268877|NCT03768154|Experimental|study arm|all patients will receive all four intervention in the same sequential method
89268878|NCT01321528||IBSR Intervention group|30 nurses in the geriatric departments in TASMC
89268879|NCT03762928|Experimental|midazolam/efavirenz|
89268880|NCT03762928|Experimental|PF-06651600/midazolam/efavirenz|
89268881|NCT01561456|Experimental|AXL1717|AXL1717
89268882|NCT01561456|Active Comparator|Docetaxel|Docetaxel
89268883|NCT01321996|Other|68Ga-DOTANOC PET/CT in patients with IPF and NSIP|one arm study: all patients were studied by 68Ga-DOTANOC PET/CT
89268884|NCT00137436|Experimental|A|SU011248 in combination with docetaxel and prednisone
89268885|NCT03762772|Experimental|TAF/EVG vaginal insert|Post-dose sampling at 4 and 48 hours or at 24 and 72 hours, per randomization
89268886|NCT03762538||G/G group|Patients who are determined to be G/G genotype.
89268887|NCT03762538||G/A A/A group|Patients who are determined to be G/A or A/A genotypes.
89268888|NCT03762382|Experimental|TFV/LNG IVR (10mg/20μg) (Continuous)|Tenofovir/Levonorgestrel Intravaginal Ring
89268889|NCT03762382|Experimental|TFV IVR (10mg) (Continuous)|Tenofovir Intravaginal Ring
89268890|NCT03762382|Placebo Comparator|Placebo IVR (Non-eluting)|Placebo Intravaginal Ring
89268891|NCT03767998|Experimental|IMST group|Interventions: Respiratory muscle training for IMST. Inspiratory muscle training for patients with inspiratory muscle weakness (MIP less than 70% of normal range). IMT will commence from 30% to 60 % of MIP and then adjust one level of training loading according to the tolerance of continuously breathing through a respiratory trainer for two sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week.
89268892|NCT03767998|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
89268893|NCT03767998|Experimental|EMST group|Intervention: Respiratory muscle training for EMST. For patients with only swallowing disturbance. Training resistance will be adjusted accordingly. The loading will be performed with the previous resistance setting or even lower if training load is not tolerated or not completed.
89268894|NCT03767920|Active Comparator|bupivacaine and dexamethasone|Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
89268895|NCT03767920|Active Comparator|bupivacaine and placebo to dexamethasone|BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
89268896|NCT03834623|Experimental|CC-122 Plus Nivolumab|Participants will take CC-122 orally at 2mg daily for 5 consecutive days every 7 days, with intravenous nivolumab (240mg) in days 1 and 15 within a 28-day cycle.
89268897|NCT03767764||HCC|Patients with diagnosis of Hepatocellular carcinoma
89268898|NCT03767764||Cirrhosis|Patients with the diagnosis of cirrhosis who is following a screening program for diagnosis of HCC
89268899|NCT03767764||Chronic liver diseases|Patients with the diagnosis of Chronic liver diseases without cirrhosis
89268900|NCT03767764||Control|Normal human serum from donors without liver disease
89268901|NCT03993743|Experimental|CD147-CART|Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery
89268902|NCT03773926|Experimental|Neuro-feedback therapy|"EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.~Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback."
89268903|NCT01039649||Lung Radiation|Patients with tumors in the lung that require radiation therapy
89268904|NCT03762304||Intervention group|The intervention group consists of individuals with a measured blood pressure just above the hypertensive cut-off of 140 mmHg systolic or 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact upper bound on blood pressure will be determined empirically. Individuals in the intervention group were told that that their blood pressure was high, that high blood pressure can lead to life threatening consequences, that blood pressure control can reduce these negative consequences, and that they should seek follow-up care for their blood pressure.
89268905|NCT03762304||Control group|The control group consists of individuals with a measured blood pressure just below the hypertensive cut-off of 140 mmHg systolic and 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact lower bound on blood pressure will be determined empirically. These individuals were not given the care encouragement intervention.
89268906|NCT01039727|No Intervention|care as usual|care as usual
89268907|NCT01039727|Experimental|autosuggestive support|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
89268908|NCT01039727|Experimental|autosuggestive support ++|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
89268909|NCT03762226||Patient with Macular edema|Patients with clinically significant macular edema due to diabetes or retinal vein occlusion, undergoing at least 4 monthly intravitreal anti-VEGF injections.
89268910|NCT03993899|Active Comparator|Cochlear implant (CI) with FineHearing Strategy then HDCIS|cochlear implant with FineHearing strategy first during 15 days then with HDCIS strategy during 15 days
89268911|NCT03993899|Active Comparator|CI with HDCIS Strategy then FS4|cochlear implant with HDCIS strategy first during 15 days then with FS4 strategy during 15 days
89268912|NCT03762148|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
89268913|NCT03762148|Experimental|ferrous sulphate|labelled iron as ferrous sulphate
89268914|NCT03762148|Experimental|ferric pyrophosphate|labelled iron as ferric pyrophosphate
89268915|NCT03762148|Experimental|ferrous fumarate + 3.5 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 3.5 g GOS
89268916|NCT03762148|Experimental|ferrous fumarate + 7 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS
89268917|NCT03762148|Experimental|ferrous sulphate + 15 g GOS|labelled iron as ferrous sulphate + prebiotics in the form of 15 g GOS
89268918|NCT03762148|Experimental|ferrous fumarate + Vitamin C|labelled iron as ferrous fumarate + Vitamin C
89268919|NCT03762148|Experimental|ferric pyrophosphate + 15 g GOS|labelled iron as ferric pyrophosphate + prebiotics in the form of 15 g GOS
89268920|NCT03762148|Experimental|ferrous fumarate + 7 g GOS + Vitamin C|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS + Vitamin C
89268921|NCT01589159|Experimental|Experimental|
89268922|NCT03711292|Experimental|Stepped Wedge Cluster Randomized|Antibiotic stewardship intervention
89268923|NCT03937895|Experimental|Experimental: single arm|"Biological: 'SMT-NK' Inj. (allogeneic Natural Killer cell) weekly administration for 2 weeks. After that, 1 week is a withdrawal period. (Phase 1: up to *cycle 3, Phase 2a: up to cycle 9)~Drug: Pembrolizumab administration of Pembrolizumab 200mg/m2 at first week during cycle.~Cycle: 1 cycle is 3 weeks in total.'SMT-NK' Inj is administered at first and second week, and Pembrolizumab is administered at first week. The third week is a withdrawal period."
89268924|NCT03761992|Active Comparator|Gingko Biloba Extract|Gingko Biloba Extract 240 mg.
89268925|NCT03761992|Placebo Comparator|Placebo|Placebo Pill
89268926|NCT03761836|Experimental|ShangRing|Males aged 13 years and above will undergo circumcision through ShangRing procedure, with regular follow-up visits to evaluate pain, wound healing and incidence of adverse events. The ShangRing will be removed after 7 days, with a last follow-up visit at 60 days.
89268927|NCT03767452|Experimental|Single-Arm|Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.
89268928|NCT03767374||Main study group (HIV-negative)|"2000 HIV-negative individuals seeking care at the STI clinic of Saint-Antoine Hospital~Inguinal swab sample~Anal swab sample~Fecal sample~Risk factor assessment"
89268929|NCT03767374||Exposure-matched group (HIV-positive)|"500 HIV-positive men who have sex with men from the Infectious Diseases Unit of Saint- Antoine Hospital. These individuals will be compared to 500 HIV-negative MSM from the main study group, matching on age (+/-5 years).~Inguinal swab sample~Anal swab sample~Fecal sample~Risk factor assessment"
89268930|NCT03767296|Experimental|Dose Bolus of E-P-E|Ephedrine Hydrochloride 3 MG/ML- Phenylephrine - Ephedrine Hydrochloride 3 MG/ML
89268931|NCT03767296|Experimental|Dose Bolus P-E-P|Phenylephrine- Ephedrine Hydrochloride 3 MG/ML - Phenylephrine
89268932|NCT03767296|Experimental|Dose Bolus E-E-E|Ephedrine Hydrochloride 3 MG/ML- Ephedrine Hydrochloride 3 MG/ML - Ephedrine Hydrochloride 3 MG/ML
89268933|NCT03767296|Experimental|Dose Bolus P-P-P|Phenylephrine-Phenylephrine-Phenylephrine
89268934|NCT03761758|Experimental|Lens Design 1|Spectacle lenses design 1, fitted into spectacle frames
89268935|NCT03761758|Experimental|Lens Design 2|Spectacle lenses design 2, fitted into spectacle frames
89268936|NCT03761758|Experimental|Lens Design 3|Spectacle lenses design 3, fitted into spectacle frames
89268937|NCT03761602||Proper selenium and iodine condition|"The subjects should have proper dietary intake of selenium and iodine, according to Chinese Dietary Reference Intakes (DRIs) (intake of selenium 65μg/d and iodine 230 μg/d).~The Serum iodine concentration are 45-92μg/L，and the urinary I/Cr 150-249μg/g Cr.~The Serum selenium concentrations are 18-40μg/L."
89268938|NCT03761602||Excessive selenium or iodine condition|"The subjects have excessive dietary intake of selenium and iodine, usually more than 2 times of DRIs. The Serum iodine concentration are more than 100μg/L，and the urinary I/Cr more than 300μg/g Cr.~The Serum selenium concentrations are more than 40μg/L."
89268939|NCT03761602||Insufficient selenium or iodine condition|"The subjects have insufficient dietary intake of either selenium or iodine, compared with DRIs. The Serum iodine concentration are less than 45μg/L，and the urinary I/Cr less than150μg/g Cr.~The Serum selenium concentrations are less than 18μg/L."
89268940|NCT03761524|Experimental|Customized V plate fixation|Computed tomography (CT) scan of the Facial bones (Axial cuts, DICOM file, Gantry tilt zero and minimal thickness of 1mm )is taken for the patients and a customized V pattern plate
89268941|NCT03761524|Active Comparator|Conventional miniplates fixation|Conventional superior-inferior miniplates fixation of mandibular angle fixation
89268942|NCT00410813|Experimental|Arm I|Patients receive oral dasatinib once daily.
89268943|NCT00410813|Experimental|Arm II|Patients receive oral dasatinib twice daily.
89268944|NCT02366572|Placebo Comparator|Cereal control|100% Wheat Flour
89268945|NCT02366572|Experimental|Cereal with pea protein|Pea protein
89268946|NCT02366572|Experimental|Cereal with pea starch|Pea starch
89268947|NCT02366572|Experimental|Cereal w/ pea starch + pea fibre: 5g|Pea starch + pea fibre: 5g
89268948|NCT02366572|Experimental|Cereal w/ pea protein + pea starch: 10g|Pea protein + pea starch: 10g
89268949|NCT02366572|Experimental|Cereal w/ pea protein + pea fibre + pea starch: 20g|Pea protein + pea fibre + pea starch: 20g
89268950|NCT03767140|Experimental|Verum acupucnture|Real acupuncture treatment
89268951|NCT03767140|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
89268952|NCT01322074||Total knee arthroplasty|Patients operated with elective, unilateral total knee arthroplasty.
89268953|NCT03760978||dex group|Critically ill patients <18 year-old receiving prolonged sedation with endovenous dexmedetomidine (dosage 0.2 mcg/Kg/hour to 1.8 mcg/Kg/hour) more than 24 hours
89268954|NCT03760900|Experimental|infusion group|Autologous Umbilical Cord Blood Stem Cells Therapy
89268955|NCT03766984|Experimental|Diclofenac 25 mg|Participants receive 1 tablet of diclofenac sodium 25 mg with 250 milliliters of purified water.
89268956|NCT03766984|Experimental|Tramadol 25 mg|Participants receive 1 tablet of tramadol hydrochloride 25 mg with 250 milliliters of purified water.
89268957|NCT03766984|Experimental|Diclofenac/Tramadol 25 mg/25 mg FDC|Participants receive 1 fixed-dose combination tablet of diclofenac sodium 25 mg/tramadol hydrochloride 25 mg with 250 milliliters of purified water.
89268958|NCT03758872||historical comparaison whithout cuff|517 patients included in 2017 without CUFF and 517 patients will be included in 2018 with CUFF for polyp detection
89268959|NCT00405821|Active Comparator|Acyclovir 400mg tablet twice daily|
89268960|NCT00405821|Placebo Comparator|Placebo tablet twice daily|
89268961|NCT03766828||inside-out-access technique with inside-out access device|
89268962|NCT03766828||access technique including Sharp recanalization|
89268963|NCT03928600|Experimental|Combined method induction group|"25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol)~After 4 hours of last misoprostol initiate oxytocin.~Cervical Foley will be removed after 12h of placement or when fails out."
89268964|NCT03928600|Placebo Comparator|Current department guidelines group|"Following current department guidelines, as usual, with the method considered more suitable.~If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin.~If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place."
89268965|NCT01322152|Experimental|wXELIRI regimen|
89268966|NCT05414344|Experimental|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
89268967|NCT05414344|Experimental|Trauma-Informed and Peer-Supported Brief Intervention (TIPS-BI)|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
89268968|NCT05414344|Experimental|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
89268969|NCT01446016|Experimental|Chloroquine with Taxane or Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone) Chemotherapy|Chloroquine (250 mg) was given daily orally with either Paclitaxel or Docetaxel or Abraxane or Ixabepilone chemotherapy every 3 weeks (1 cycle) fro a maximum of 6 cycles.
89268970|NCT00137046|Active Comparator|Subcutaneous Insulin|
89268971|NCT00137046|Experimental|Inhaled Insulin|
89268972|NCT03760354|Experimental|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
89268973|NCT03760354|Placebo Comparator|Placebo (no corticosteroid treatment)|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
89268974|NCT01322230|Experimental|Control|Screen shots with voiceover and no interactivity
89268975|NCT01322230|Experimental|WISEMD Original|Learner control of pacing through multi-media content
89268976|NCT01322230|Experimental|Social Networking|social networking features (Forum and Social Presence)
89268977|NCT01322230|Experimental|Social Networking plus Emotional Design|Social networking features plus user interface enhancements
89268978|NCT03760276|Experimental|Voriconazole TBD mg tablet orally, every 12 hours for 7 days|
89268979|NCT03766594|Active Comparator|Sildenafil group|Includes 45 women who received Sildenafil citrate (Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
89268980|NCT03766594|Active Comparator|Control group|Includes 45 women who received placebo oral tablets (apparently identical to Respatio(R) 25mg tablets, four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
89268981|NCT03758794|Active Comparator|interactive lecture module|interactive lecture
89268982|NCT03758794|Active Comparator|online educational module|online educational using a special link
89268983|NCT03766360|Experimental|FAP Intervention Group|All of the clients in the FAP intervention group will begin treatment at the same time and complete 3 assessments.
89268984|NCT03766360|No Intervention|Control Group|The clients in the control group will take their assessments at the same time as those in the FAP intervention group.
89268985|NCT00122382|Active Comparator|ABA + MTX|abatacept 10 mg/kg intravenous (IV) + methotrexate
89268986|NCT00122382|Active Comparator|Placebo (PLA) + MTX|placebo IV + methotrexate
89268987|NCT01028716|Experimental|Treatment (nonmyeloablative HCT, TBI)|Patients receive fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is >= 1,000/mm^3 for three consecutive days.
89268988|NCT02531724|Active Comparator|Levosimendan|Levosimendan will be given as a loading dose of 12 ug/kg during 30 minutes, and then a continuous infusion of 0,1 ug/kg/min for 180 minutes.
89268989|NCT02531724|Placebo Comparator|Placebo|Sodium chloride will be given as a loading dose during 30 minutes and then a continuous infusion for 180 minutes at a rate mimicking the levosimendan group above.
89268990|NCT03758482|Other|Men|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
89268991|NCT03758482|Other|Women|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
89268992|NCT03760198|Experimental|botulinum toxin type A|
89268993|NCT03760198|Placebo Comparator|Placebo|
89268994|NCT03760042|Other|Group A (Crisaborole RIGHT SIDE / Vehicle LEFT SIDE)|Crisaborole ointment 2% applied to sensitive skin locations on right side of body. Crisaborole placebo vehicle ointment applied to sensitive skin locations on left side of body
89268995|NCT03760042|Other|Group B (Crisaborole LEFT SIDE / Vehicle RIGHT SIDE)|"Crisaborole placebo vehicle ointment applied to 7 sensitive skin sites on right side of body.~Crisaborole ointment 2% applied to 7 sensitive skin locations on left side of body"
89268996|NCT03759964|Active Comparator|Ferric Carboxymaltose group|Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
89268997|NCT03759964|Placebo Comparator|Placebo group|Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery
89268998|NCT00106704|Experimental|Sitagliptin|Sitagliptin 10 mg tablet daily for 54 weeks
89268999|NCT00106704|Placebo Comparator|Placebo/ Pioglitazone|Placebo tablet daily for 24 weeks followed by Pioglitazone tablet daily for 30 weeks
89269000|NCT03759886||Oral Antibiotics|The patients get mechanical bowel preparation and oral antibiotic prophylaxis with 4g Paromomycin (Paromomycin Sulfate Powder) and 1 g Metronidazole p.o. and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
89269001|NCT03759886||iv Antibiotics|The patients get mechanical bowel preparation and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
89269002|NCT03965364||INCRAFT|Endovascular abdominal aortic aneurysm repair
89269003|NCT03766282||Animal study|Critically ill animal on ECMO. PK data from critically ill animal on ECMO will be compared with data from controls and healthy animal on ECMO.
89269004|NCT03766282||Clinical study|To describe variation of plasma concentration of drugs in patients receiving ECMO, as compared with patients without ECMO.And develop population PK model for ECMO patients.
89269005|NCT01081158|Experimental|Treatment-naïve 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days."
89269006|NCT01081158|Experimental|Treatment-experienced: 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days"
89269007|NCT01081158|Experimental|Treatment-naïve: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
89269008|NCT01081158|Experimental|Treatment-experienced: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
89269009|NCT02627872||COPD patients (GOLD I-II)|Participants with mild-to-moderate COPD (GOLD I-II)
89269010|NCT02627872||Smoker Control Group|Actively smoking participants with normal lung function (do not have COPD)
89269011|NCT02627872||Healthy Never-smoker Control Group|Healthy participants that never have smoked
89269012|NCT00105066|Placebo Comparator|Placebo|placebo
89269013|NCT00105066|Experimental|Metformin|Metformin 850 mg twice daily
89269014|NCT03766204||ARDS patients|137 patients were enrolled consecutively over a two-year time period (2017-2018) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 18 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
89269015|NCT03766204||Healthy volunteers|Forty healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
89269016|NCT01081236||Compensated liver cirrhosis|
89269017|NCT01081236||Decompensated liver cirrhosis|
89269018|NCT01322308|Placebo Comparator|sugar pill|tablet similar to comparator
89269019|NCT01322308|Active Comparator|pioglitazone|30 mg tablets QD (taken once daily)
89269020|NCT05208268||Pariet|Participants with gastric and duodenal ulcer being administered with Pariet 5 mg, tablet within the scope of the approved label for Korea under the medical judgment of the investigator will be observed up to maximum of 24 weeks.
89269021|NCT03766048|Experimental|Single-Anterior-Mesh, SAM|
89269022|NCT03766048|Sham Comparator|Double-Mesh, DM|
89269023|NCT00104520|Placebo Comparator|Placebo (pooled two times a day [BID]/three times a day [TID])|
89269024|NCT00104520|Experimental|AZLI (pooled two times a day [BID]/three times a day [TID])|
89269025|NCT03759652||infected, before-after studyt: 2003|neurosurgical patients; 2003: the beggining of active and target HAI surveillance
89269026|NCT03759652||infected, before-after studyt: 2017|neurosurgical patients; 2017: the effective of active and target HAI surveillance
89269027|NCT03759574||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
89269028|NCT03759574||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
89269029|NCT03963882|Experimental|Group A|Patients in group A don't receive neoadjuvant chemotherapy
89269030|NCT03963882|Experimental|Group B|Patients in group B receive neoadjuvant chemotherapy and achieve imaging response
89269031|NCT03963882|Experimental|Group C|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy
89269032|NCT03963882|Experimental|Group D|Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy
89269033|NCT05180188|No Intervention|Placebo periode|In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health.
89269034|NCT05180188|Experimental|Exercise periode|In the second period, participants will perform regular moderate-intensity exercise 3 times/week.
89269035|NCT01081314|Experimental|Standard DBT + PTSD Protocol|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team) plus a modified version of Prolonged Exposure therapy for PTSD.
89269036|NCT01081314|Active Comparator|Standard DBT|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
89269037|NCT03114046|Experimental|Baseline Phase|This project will conduct a single-subject pre-experimental AB mixed methods design, considering A phase as the baseline strand. During this phase multiple assessments will be administered. This phase will last 2 consecutive weeks, with 5 visits total.
89269038|NCT05145322|Experimental|Group 1|Group 1: Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins
89269039|NCT05145322|Experimental|Group 2|Lesion-specific cavity design with wide bevel throughout the cavity margins
89269040|NCT03759262|Experimental|Vitamin D (Cholecalciferol)|All subjects will be enrolled to this arm. A single dose of ultra-high-dose vitamin D will be given.
89269041|NCT03765658|Experimental|GRT0151Y dose escalation|GRT0151Y will be administered to participants as 50 mg capsules in a dose escalation range of 150, 200, 250, 300, 350 and 400 mg. Dose levels were increased by increments of 50 mg to a maximum of 400 mg, only after the previous dose level was found to be well-tolerated. During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.
89269042|NCT00135330|Experimental|Exenatide Arm|
89269043|NCT00135330|Experimental|Exenatide plus Rosiglitazone Arm|
89269044|NCT00135330|Experimental|Rosiglitazone Arm|
89269045|NCT05128318|Experimental|Patients with BMI < 30 kg/m2|Collection of subcutaneous and visceral adipose tissue pieces of 1-2 cm3 during abdominal surgery procedures
89269046|NCT03765580|Placebo Comparator|Control group|No fish
89269047|NCT03765580|Experimental|1 portion of fish per week|140g fish/week
89269048|NCT03765580|Experimental|2 portions of fish per week|280g fish/week
89269049|NCT03765424||GCA cases|"GCA cases were patients with a clinical diagnosis of GCA based on a rheumatologists evaluation of history taking, physical examination, laboratory screening and initial PET report (reporting potential large vessel inflammation but not considering cranial artery inflammation).~GCA was considered large vessel (LV) and/or cranial (c) GCA cases:~LV-GCA cases were patients with a clinical diagnosis of GCA and verified LV inflammation by 18F-FDG PET/CT with or without concomitant c-GCA.~C-GCA cases, for the exploratory analysis of the performance of US and PET in c-GCA, were patients with a clinical diagnosis of GCA fulfilling the 1990 American College of Rheumatology (ACR) criteria, with or without concomitant LV-GCA."
89269050|NCT03765424||controls|Controls were GCA suspected patients in whom GCA diagnosis was dismissed.
89269051|NCT01076478|Placebo Comparator|Arm 1|2 tablets BID
89269052|NCT01076478|Experimental|Arm 2|100 mg Cilostazol (2 tablets BID)
89269053|NCT01076478|Experimental|Arm 3|200 mg Cilostazol (2 Tablets BID)
89269054|NCT01076556|Experimental|Treatment (rituximab, cyclophosphamide, alvocidib)|Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1).
89269055|NCT00134784|Experimental|Assess [123I]B-CIT SPECT imaging|To assess[123I]B-CIT SPECT imaging in early Parkinson's disease subjects on placebo compared to early verses later Levodopa. Subjects on Levodopa 150mg/day, Levodopa 300 mg/day, and Levodopa 600 mg/day will be assessed.
89269056|NCT03965442||Control|"Patients who underwent mastectomy under standard general anesthesia~Patients in placebo group received general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump."
89269057|NCT03965442||Esmolol|Patients in esmolol group received general balanced inhaled anesthesia with sevoflurane and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
89269058|NCT01078740||Non-CF subjects|Rectal tissue obtained from study subjects without cystic fibrosis (CF) as part of scheduled colonoscopy/biopsies performed for clinical care
89269059|NCT01078740||CF subjects|"Rectal tissue obtained from study subjects with cystic fibrosis (CF) in one of three ways:~Rectal biopsy as part of scheduled colonoscopy/biopsies performed for clinical care~Sigmoidoscopy/biopsy added onto a scheduled, unrelated procedure or surgery performed under general anesthesia~Sigmoidoscopy/biopsy performed for the sole purpose of obtaining rectal tissue for the current study"
89269060|NCT00134082|Experimental|Immunotherapy|All participants received two days of rituximab, then four days of high-dose cyclophosphamide followed by filgrastim. Participants then received six doses of KGEL vaccine over 24 weeks interspersed with four additional doses of rituximab.
89269061|NCT01081392|Experimental|LPS sequence 1|Nebulizers A then B then C
89269062|NCT01081392|Experimental|LPS sequence 2|Nebulizers B then C then A
89269063|NCT01081392|Experimental|LPS sequence 3|Nebulizers C then A then B
89269064|NCT01081392|Experimental|LPS sequence 4|Nebulizers A then C then B
89269065|NCT01081392|Experimental|LPS sequence 5|Nebulizers C then B then A
89269066|NCT01081392|Experimental|LPS sequence 6|Nebulizers B then A then C
89269067|NCT03765346|Experimental|Oxycodone IR ADF and placebo to match oxycodone API|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of manipulated oxycodone IR ADF (mass of 540 mg, containing oxycodone hydrochloride 30 mg).
89269068|NCT03765346|Active Comparator|Oxycodone API and placebo to match oxycodone IR ADF|Participants receive a single intranasal dose of oxycodone API powder (mass of 30 mg, containing oxycodone hydrochloride 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
89269069|NCT03765346|Placebo Comparator|Placebo to match oxycodone API and to match oxycodone IR ADF|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
89269070|NCT01078818|Experimental|IV trivalent saccharose hydroxide ferrous|
89269071|NCT01078818|Active Comparator|Oral ferrous fumarate|
89269072|NCT01078818|Placebo Comparator|Oral and intravenous Placebo|
89269073|NCT03964038|Active Comparator|gilteritinib|Participants will receive a single dose of gilteritinib under fasting conditions.
89269074|NCT03964038|Experimental|gilteritinib mini-tablet oral suspension|Participants will receive a single dose of gilteritinib oral suspension with water under fasting conditions.
89269075|NCT03964038|Experimental|gilteritinib mini-tablet|Participants will receive a single dose of gilteritinib mini-tablets under fasting conditions.
89269076|NCT01079052|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
89269077|NCT01079052|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
89269078|NCT01326468|Experimental|Cohort A - Temsirolimus with Cisplatin|Temsirolimus with cisplatin, Erbitux and radiation therapy
89269079|NCT01326468|Experimental|Cohort B - Temsirolimus|Temsirolimus with Erbitux and radiation therapy
89269080|NCT03703336|Experimental|ROTAVIN Liquid Formulation|Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
89269081|NCT03703336|Active Comparator|ROTAVIN-M1 Frozen Formulation|Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
89269082|NCT01076634|Experimental|IDeg 100 U/mL|
89269083|NCT01076634|Experimental|IDeg 200 U/mL|
89269084|NCT03702166|Other|Interventional CPT|This study will examine the effectiveness of Cognitive Processing Therapy (CPT) for the alleviation of PTSD and tinnitus-related distress among individuals with co-morbid PTSD and tinnitus.
89269085|NCT00132678|Experimental|001|Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
89269086|NCT00132678|Placebo Comparator|002|Placebo Matching placebo intramuscular (IM) injection every 2 weeks
89269087|NCT01081548|Experimental|Generic|
89269088|NCT01081548|Active Comparator|Lipitor|
89269089|NCT00101868|Experimental|Discharge communication software|Computerized-Physician-Order-Entry software application to facilitate communication at time of hospital discharge to patients, retail pharmacists, community physicians. Software had required fields, pick lists, standard drug doses, alerts, reminders, online reference information. Software prompted discharging physician to enter pending tests, order tests after discharge. Hospital physicians used software on day of discharge to generate four documents automatically: personalized letter to outpatient physician, legible prescriptions, and legible discharge order
89269090|NCT00101868|Active Comparator|Usual care discharge process|Hospital physicians and ward nurses completed handwritten discharge forms on the day of discharge. The forms contained blanks for discharge diagnoses, discharge medications, medication instructions, post discharge activities and restrictions, post discharge diet, post discharge diagnostic and therapeutic interventions, and appointments. Patients received handwritten copies of the forms, one page of which also included medication instructions and prescriptions
89269091|NCT00101400|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
89269092|NCT03821064|Experimental|Patient Navigation|45 patients (15 African American, 30 white) will interact with a patient navigator three times over three months to identify and address barriers before they cause breakdowns in care delivery, employing resources, education, and care coordination from the day of surgery until post-operative radiation treatment begins.
89269093|NCT03963726|Experimental|Stereotactic radiotherapy|In this study, the liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
89269094|NCT03963726|Experimental|Microwave ablation therapy|In this study, 3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
89269095|NCT03966456||nivolumab|Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
89269096|NCT03966456||pembrolizumab|Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
89269097|NCT03966456||toripalimab|Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
89269098|NCT03966456||sintilimab|Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.
89269099|NCT01076712|Experimental|Physiotherapy Interventions|Physiotherapy Interventions including strengthening exercise, balance training, gait training with visual cue, gait training with treadmill.
89269100|NCT01076712|Other|Education|Education
89269101|NCT01076790|Active Comparator|Dexmedetomidine|Analgo-sedative, adjuvant of propofol anesthesia
89269102|NCT01582932|Experimental|Calcipotriene 0.005% Foam|Foam is a vitamin D3 analog (calcipotriene) foam 0.005%. It is applied twice a day for 8 weeks to psoriasis lesions (except the face).
89269103|NCT03965520|Active Comparator|usual training|exercise intensity arranged by cardiopulmonary exercise test results
89269104|NCT03965520|Experimental|Novel exercise training|exercise intensity monitor by near-infrared spectrometer
89269105|NCT03965286||Patients with chronic HCV will be on direct antiviral drugs|is defined as the presence of detectable viral replication for at least six months diagnosed by quantitative HCV RNA polymerase chain reaction (PCR)
89269106|NCT02531334|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
89269107|NCT02531334|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
89269108|NCT02531178|Experimental|low dose ABBV-257|Low dose every other week (eow), Weeks 0-8
89269109|NCT02531178|Experimental|Medium dose of ABBV-257|Medium dose every other week (eow), Weeks 0-8
89269110|NCT02531178|Experimental|high dose of ABBV-257|high dose every other week (eow), Weeks 0-8
89269111|NCT01079208|Placebo Comparator|standard starter infant formula|standard starter infant formula
89269112|NCT01079208|Experimental|test starter formula|test infant formula
89269113|NCT01079208|Experimental|test starter formula with synbiotics|starter formula with synbiotics and adapted protein levels
89269114|NCT01079286|Experimental|nelfinavir and temsirolimus|dose escalation
89269115|NCT01081704|Experimental|001|ustekinumab Single dose of 45 mg subcutaneous injection
89269116|NCT01081704|Experimental|002|ustekinumab Single dose of 90 mg subcutaneous injection
89269117|NCT00141518|Experimental|Duodopa Naïve|Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
89269118|NCT00141518|Experimental|Duodopa Non-naïve < 2 Years|Duodopa non-naïve participants treated with Duodopa for < 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
89269119|NCT00141518|Experimental|Duodopa Non-naïve ≥ 2 years|Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
89269120|NCT03973736||PDAC patients diagnosed in 2008-2011|
89269121|NCT03973736||PDAC patients diagnosed in 2013-2016|
89269122|NCT02531360|Experimental|[18F]MNI-815 (MNI-815)|At the [18F]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of [18F]MNI-815
89269123|NCT01076114||Control|Patients with no evidence of glaucoma or as a suspect with normal intraocular pressure, normal cup to disc ratio with no other ocular pathology and a normal ophthalmic exam.
89269124|NCT01076114||Glaucoma Suspect|Patients with abnormal cup to disc ratio or increased intraocular pressure (>21mm/Hg) with an otherwise normal ophthalmic exam.
89269125|NCT00098748|Experimental|1|
89269126|NCT00098748|Experimental|2|
89269127|NCT00098748|Experimental|3|
89269128|NCT00130520|Experimental|open label|
89269129|NCT01076946||TLVBS|patients with transient left ventricular ballooning
89269130|NCT00132132|Experimental|Intervention|This is a long term randomized controlled study looking at the effect of a Behavioral program on BMI in a population 10-20years old with a BMI greater than or equal to 85%. The intervention is a Behavioral education program which meets monthly for 4 hour session and includes exercise, education, empowerment and incentives. Both groups are referred to a dietician. The primary outcome is change in BMI and the secondary outcome is improvement in fasting metabolic parameters (lipid panel, insulin, glucose).
89269131|NCT00132132|No Intervention|Standard of Care/Control|Education on physical activity and nutrition in a primary care office setting
89269132|NCT00130442|Experimental|Arm 1- PI-88 plus dacarbazine|PI-88 (muparfostat) 190 mg daily by subcutaneous injection and dacarbazine 1000 mg/m2 on day 1 of each 21 day cycle
89269133|NCT00130442|Active Comparator|Arm 2- dacarbazine alone|dacarbazine 1000 mg/m2 on day 1 of every 21 day cycle by intravenous infusion
89269134|NCT00130208|Experimental|Sulodexide|Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
89269135|NCT00130208|Placebo Comparator|Placebo|All patients will be on standard of care ACE or ARBs.
89269136|NCT00253370|Experimental|BAY 43-9006, docetaxel, cisplatin|Patients receive oral BAY 43-9006 400mg twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89269137|NCT01071980|Active Comparator|Specific resistance training|3 x 20 min a week of specific resistance training for 20 weeks
89269138|NCT01071980|No Intervention|Control|Control group
89269139|NCT03966482|Experimental|Group before-after|Speech therapy with Semiocluded vocal tract exercise.
89269140|NCT03966170|Experimental|Citicoline|Citicoline as neuroprotector
89269141|NCT03966170|Placebo Comparator|Placebo drug|Placebo
89269142|NCT01076426|Experimental|Probiotics|probiotics treatment
89269143|NCT01076426|Placebo Comparator|Placebo|
89269144|NCT00140426|Placebo Comparator|placebo|double blind study of risperidone for anorexia nervosa. this is the subject group that receives placebo.
89269145|NCT00140426|Active Comparator|risperidone|Study is double blind, placebo controlled. This is the subject group on active medication
89269146|NCT03966560|Experimental|Primary open-angle glaucoma|"Participants over 40 years of age and diagnosed with primary open-angle glaucoma.~Medical treatment was initiated for the diagnosed participants."
89269147|NCT03966560|No Intervention|Healthy|Healthy volunteers who do not have systemic disease that may affect the choroidal thickness and have no ocular features that may affect test measurements.
89269148|NCT01072058|Other|TNF blockers|
89269149|NCT01072214|Experimental|1.6 mg|The actual dosage is 10 mg/ml (GW786034) given 4 times a day for a maximum daily dosage of 1.6mg
89269150|NCT01072214|Experimental|TBD COHORT 2|Dose escalation amount to be determined (TBD) after results from Cohort 1 analyzed
89269151|NCT01072214|Placebo Comparator|Placebo|Subjects will receive placebo (drops without drug).
89269152|NCT01072214|Experimental|TBD COHORT 3|Dose escalation amount to be determined (TBD) after results from Cohort 2 analyzed
89269153|NCT00121134|Experimental|Group A|Bevacizumab Alone
89269154|NCT00121134|Experimental|Group B|Bevacizumab with cyclophosphamide and methotrexate
89269155|NCT00121134|Experimental|Group C|capecitabine, 14 days on/7 days off scheduling, and bevacizumab
89269156|NCT00121134|Experimental|Group D|capecitabine 7 days on/7 days off scheduling, and bevacizumab
89269157|NCT03966690|Experimental|leg curl device starters|Group A randomly assigned to start with legcurl device
89269158|NCT03966690|Experimental|legpress device starters|Group A randomly assigned to start with legpress device
89269159|NCT03966378|Experimental|Grape seeds extract|Every week the grape seeds extract (gel) put into the tray and apply it to the upper teeth of the participant.
89269160|NCT03966378|Active Comparator|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste apply to the teeth twice daily.
89269161|NCT00119262|Experimental|Arm I (combination chemotherapy, 18 courses of bevacizumab)|See detailed description.
89269162|NCT00119262|Active Comparator|Arm II (combination chemotherapy, 22 courses of bevacizumab)|See detailed description.
89269163|NCT01077102|Experimental|Eccentric exercise training|
89269164|NCT01077102|Active Comparator|Concentric exercise training|
89269165|NCT03703882|Experimental|Dose 1|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day.
89269166|NCT03703882|Placebo Comparator|Placebo|Matching placebo
89269167|NCT00131664|Active Comparator|Avandamet|Avandamet 2 mg / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily over 6 months
89269168|NCT00131664|Active Comparator|Avandia and Amaryl|Avandia + Amaryl 4 mg + 1 mg once daily titration up to 8 mg + 2 mg once daily over 6 months
89269169|NCT00131664|Active Comparator|Metformin|Metformin 500 mg twice daily titration up to 1000 mg twice daily over 6 months
89269170|NCT03765268|Active Comparator|Neurectomy|In this group we did mesh hernioplasty of inguinal hernia with neurectomy of iliohypogastric and ilioinguinal nerve
89269171|NCT03765268|Active Comparator|Nerve Sparing|In this group we did mesh hernioplasty of inguinal hernia with preservation of iliohypogastric and ilioinguinal nerve
89269172|NCT03765190|Experimental|Radiation: Proton Therapy+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
89269173|NCT03765112|Experimental|OCTA|Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.
89269174|NCT00131508|Experimental|2|Glutamine
89269175|NCT00131508|Placebo Comparator|1|
89269176|NCT03765034|Experimental|Constraint-induced Movement Therapy|A passive constraint cast is applied to the participant's unaffected arm to prevent use for 8 weeks.
89269177|NCT03765034|Active Comparator|Usual Occupational Therapy|Usual and standard care occupational therapy is administered for 8 weeks.
89269178|NCT05088772||Hyperbaric Oxygen Therapy - Experimental Group|Patients receiving hyperbaric oxygen therapy at the Hyperbaric Medicine Unit (University Health Network, Toronto, ON, Canada)
89269179|NCT05050318|Experimental|Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP), a second dose was administered at Day 28.
89269180|NCT05050318|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years|Participants aged 3 to <9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
89269181|NCT05050318|Experimental|Group 3: Fluzone High-Dose Quadrivalent Influenza Vaccine: >=65 Years|Participants aged >= 65 years received a 0.7-mL dose of Fluzone High-Dose Quadrivalent vaccine intramuscularly at Day 1.
89269182|NCT03764956|Experimental|Low Glycemic Index therapy|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only
89269183|NCT03764956|Active Comparator|Modified Atkins Diet|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio
89269184|NCT03778996|Experimental|Maintenance Treatment: Ewing's Sarcoma|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus
89269185|NCT03778996|Experimental|Salvage Treatment: Sarcoma|Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus
89269186|NCT01321762||1|Pregnant Women with singleton pregnancy
89269187|NCT03764722|Experimental|Levosimendan|
89269188|NCT03756610|Active Comparator|Active tACS & active boosting group|The active tACS & active boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of active tACS.
89269189|NCT03756610|Other|Active tACS & sham boosting group|The active tACS & sham boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
89269190|NCT03756610|Sham Comparator|Sham tACS & sham boosting group|The sham tACS & sham boosting group will be stimulated with 10 sessions of sham alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
89269191|NCT05024734|Experimental|Epirubicin|"Patients in that PDOs show highest response to this drug in-vitro will be treated with Epirubicin.~If no significant drug selection can be performed in-vitro, Epirubicin will be the default for instillation."
89269192|NCT05024734|Experimental|Mitomycin|Patients in that PDOs show highest response to this drug in-vitro will be treated with Mitomycin.
89269193|NCT05024734|Experimental|Gemcitabine|Patients in that PDOs show highest response to this drug in-vitro will be treated with Gemcitabine.
89269194|NCT05024734|Experimental|Docetaxel|Patients in that PDOs show highest response to this drug in-vitro will be treated with Docetaxel.
89269195|NCT03699124|Active Comparator|GP 1: two doses of FD MVA-BN--Lot 1|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 1
89269196|NCT03699124|Active Comparator|GP 2: two doses of FD MVA-BN--Lot 2|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 2
89269197|NCT03699124|Active Comparator|GP 3: two doses of FD MVA-BN--Lot 3|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 3
89269198|NCT05461066|Experimental|Intervention|Smoking cessation intervention in community pharmacies
89269199|NCT05461066|Active Comparator|Control|Usual care of smoking cessation in community pharmacies
89269200|NCT03764644|Experimental|Combined ABMT and CBT|9 sessions of Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
89269201|NCT03764644|Sham Comparator|Combined Sham ABMT and CBT|9 sessions of Sham Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
89269202|NCT03764566||Trauma control group|Individuals with adverse childhood experiences (e.g.childhood abuse or neglect) will be included as the experimental group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
89269203|NCT03764566||Healthy control group|Individuals with no trauma history will be added as the healthy control group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
89269204|NCT03764566||Clinical control group|Individuals with Borderline Personality Disorder (BPD) will be added as a clinical control group. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
89269205|NCT05002972|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
89269206|NCT05460910|Experimental|core stability exercise, treadmill|core stability exercises and treadmill training
89269207|NCT05460910|Experimental|core stability exercises|core stability exercises without treadmill training
89269208|NCT03756220|Experimental|Treatment|Combination therapy of vitamin C and thiamine for 2 days.
89269209|NCT03756220|Placebo Comparator|Control|Normal Saline Solution
89269210|NCT04651114|Experimental|Decision-making tool|Women will receive the decision making tool and use for a 3 month period.
89269211|NCT03764410|Experimental|Diabetic group DG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
89269212|NCT03764410|Active Comparator|No diabetic group NG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
89269213|NCT03764332|Other|Stabilometry|The Podoprint pressure platform was used as a measuring device. The Podoprint platform is a low profile floor platform consisting of 1.4 sensors / cm2 with a sampling frequency of 40Hz.
89269214|NCT04980040||Nesina® Tablet|Participants with a diagnosis of Type 2 Diabetes who took Nesina® tablet (alogliptin), as prescribed by the physician, are observed in this study.
89269215|NCT00131352|Experimental|Synvisc|Participants with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL hylan G-F 20 (Synvisc).
89269216|NCT00131352|Placebo Comparator|Saline Control|Participants (control group) with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL phosphate buffered saline.
89269217|NCT04633642|Experimental|Ultrasound Group (UAW group)|UAW debridement was performed using an UAW SONOCA 185 device (Söring GmbH, Germany). The UAW device generates an ultrasound low frequency of 25kHz and is equipped with three UAW instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth, which ranges from superficial to deep. The UAW instrument piezoelectrically transforms the electrical energy delivered from the UAW device into mechanical oscillations in the sonotrode tip. For most wounds in the UAW group, a two-minute treatment with 40% intensity was performed by holding the sonotrode in contact mode, holding it perpendicular to the wound bed and moving it across in an up-and-down pattern.
89269218|NCT04633642|Active Comparator|Surgical group|"All debridement procedures were performed by the same surgeon (J.L.M.), who is specialist in diabetic foot surgery with more than 20 years of experience.~Surgical debridement involved removal of all necrotic and devitalized tissue that was incompatible with healing, as well as surrounding callus."
89269219|NCT00136916|Experimental|Inhaled Insulin|Inhalable short-acting insulin
89269220|NCT00136916|Active Comparator|Subcutaneous insulin|
89269221|NCT04633564|Experimental|MYL-1402O|"Patients will begin Period 1 receiving bevacizumab combination therapy (MYL-1402O15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as MYL-1402O ).~In Period 2, eligible patients will continue to receive bevacizumab ( MYL- 1402O) every 3 weeks as monotherapy."
89269222|NCT04633564|Active Comparator|Avastin|"Patients will begin Period 1 receiving bevacizumab combination therapy ( Avastin15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV) on Day 0 of Cycle 1 for up to 6 cycles of therapy. Each cycle will consist of 3 weeks (21 days ± 3 days) and a cycle will start with the administration of bevacizumab (as Avastin).~In Period 2, eligible patients will continue to receive bevacizumab (Avastin) every 3 weeks as monotherapy."
89269223|NCT04960228|Experimental|Altruism Video Intervention|Participants will watch a 3-minute video about COVID-19 vaccination that elicits altruistic motives. The role of this arm is to test whether altruistic themes are an effective way to promote COVID-19 vaccination amongst young people and whether a video format is preferable for this group.
89269224|NCT04960228|Active Comparator|Informational Text Intervention|Participants will read a brief informational text including information drawn from the Public Health Agency of Canada website (https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html#self). The purpose of this arm is to provide an active comparator with information about COVID-19 preventative health behaviors that has been strongly recommended to the public since the beginning of the pandemic. By doing this, we will assess if the video intervention changes vaccination intentions more than a presentation of general, well-known COVID-19 related information.
89269225|NCT03756064|Experimental|Experimental group|Pyrotinib+Trastuzumab+Docetaxel +Carboplatin
89269226|NCT03756064|Placebo Comparator|Control group|Placebo Oral Tablet+Trastuzumab+Docetaxel +Carboplatin
89269227|NCT03755986|Other|ATOMO Diagnostic Test|All patients will receive an ATOMO diagnostic test to use. There is no comparative arm.
89269228|NCT04619992|Other|Current users of Hollister standard with tip hydrophilic intermittent catheters|Subjects in this arm are current users of Hollister standard with tip hydrophilic intermittent catheters.
89269229|NCT04619992|Other|New users of Hollister standard with tip hydrophilic intermittent catheters|Subjects in this arm are new users of Hollister standard with tip hydrophilic intermittent catheters.
89269230|NCT00136604|Experimental|ACAC GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccines at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
89269231|NCT00136604|Experimental|ACHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
89269232|NCT00136604|Experimental|HibACPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
89269233|NCT00136604|Experimental|HibHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm.
89269234|NCT00136604|Experimental|CC GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix + Meningitec vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
89269235|NCT03764176|Active Comparator|Conventional impression|"The intervention of this arm will be conventional impression: polyether impression will be taken with a customized tray."
89269236|NCT03764176|Experimental|Digital impression|"The intervention of this arm will be digital impression: digital impression will be taken using a CS 3600 intraoral scanner ."
89269237|NCT03764020|Experimental|Melatonin|"Intervention group1:~Melatonin,capsule,3 mg, one dose one hour before bedtime, three weeks"
89269238|NCT03764020|Placebo Comparator|Placebo|"Intervention group2 :~Placebo, capsule, 3 mg, one dose one hour before bedtime, for three weeks"
89269239|NCT00130728|Experimental|erlotinib HCl + bevacizumab|oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
89269240|NCT00130728|Placebo Comparator|erlotinib HCl + placebo|oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
89269241|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation|
89269242|NCT04947436|Active Comparator|Mechanical insufflation/ exsufflation|
89269243|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation and Mechanical insufflation/ exsufflation|
89269244|NCT03966326|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
89269245|NCT03966326|Active Comparator|PECS II group|Patients in PECS II group will receive general balanced inhaled anesthesia with sevoflurane and fentanil
89269246|NCT02531256|Experimental|LMA Protector|Single Use Supraglottic Airway Device with 2 ports for gastric access (male and female port)
89269247|NCT01321840|Experimental|Treatment|This group will be treated with SART.
89269248|NCT01321840|No Intervention|No treatment|This group will not be treated with SART but will regularly be examined by a gynecologist to detect sudden aggravation of the disease.
89269249|NCT01077674||Entropy - BIS|Patients undergoing surgery in sevoflurane anaesthesia.
89269250|NCT00119106|Experimental|tenofovir disoproxil fumarate|Participants in the Tenofovir arm will receive daily oral tenofovir
89269251|NCT00119106|Placebo Comparator|Placebo|Participants in the Placebo are will receive daily oral placebo
89269252|NCT03755908||asthmatic children|Children with the diagnosis of asthma and normal spirometry results. Each subject will undergo evaluation including: asthma control questionnaire, spirometry, FOT and Fractional exhaled nitric oxide (FeNO).
89269253|NCT05460598|Active Comparator|interventional group: beddings with cooling effects|"Cooling beddings: linen made of the Outlast Technology https://www.outlast.com/en/. This product is made of 100 % lyocell and utilizes phase change materials based on natural wax. When this phase change material melts, heat is extracted from the environment and stored in microcapsules called thermocules. When the body cools down, these thermocules harden again release the heat from the linen. This might help to balances the body temperature and prevent warmth-aggravated itch.~- The mattress is made of polyurethane foam and designed as a cool gel topper to be placed onto the standard hospital mattress. Heat is also absorbed and stored into this topper. This topper is covered with an Obatex cover. It protects the cool gel topper from moisture and organic liquids and is made of polyamide fabric."
89269254|NCT05460598|Placebo Comparator|control group: commonly used bedding|
89269255|NCT03758014|Experimental|Chlorogenic Acid for Injection|3 mg/kg per day, injection for 28 days，5 weeks per circle; max. 8 circles
89269256|NCT03758014|Active Comparator|Lomustine|110 mg/m2 taken as a single oral dose every 6 weeks; max. 4 circles
89269257|NCT04925908||Control Group|Infants of mothers with suspected but negative for COVID-19
89269258|NCT04925908||Case Group|Infants Born to COVID-19 positive mothers
89269259|NCT00135356|Active Comparator|Switch arm|
89269260|NCT00135356|Active Comparator|Control Arm|
89269261|NCT00118716|Experimental|FSC 100/50 mcg BID|Participants received FSC 100/50 microgram (mcg) one inhalation as a combination product via DISKUS, twice daily in morning after awakening and in evening for up to 28 days
89269262|NCT00118716|Experimental|FP 100 mcg BID|Participants received FP 100 mcg one inhalation via DISKUS, twice daily in morning after awakening and in evening for up to 28 days.
89269263|NCT04584346|Experimental|Arm A|Ketogenic Diet
89269264|NCT04584346|Active Comparator|Arm B|Standard American Diet
89269265|NCT01079858|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
89269266|NCT01081860||Carpal tunnel syndrome|Patients with carpal tunnel syndrome
89269267|NCT01081860||Trigger finger|Patients with trigger fingers
89269268|NCT01081860||Dupuytren Contracture|Patients with Dupuytren
89269269|NCT01081860||Trauma to the hand|Patients with an acute trauma to the hand
89269270|NCT03755830|Active Comparator|vitiligo patients|Two skin biopsies (lesional and non-lesional) will be taken from every patient.
89269271|NCT03755830|Experimental|healthy controls|A skin biopsy will be taken from each control subject.
89269272|NCT05124782||Patients with rheumatoid arthritis|Patients seen in virtual consultation
89269273|NCT00118482|Experimental|fludrocortisone acetate|
89269274|NCT00118482|Placebo Comparator|Placebo|
89269275|NCT03966950|Experimental|melatonin group|for the melatonin group, 10 mg of melatonin will be taken per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
89269276|NCT03966950|Placebo Comparator|placebo group|For the placebo group, placebo will be administered per os in the evening before the surgery and in the immediate postoperative night and the first and second postoperative days.
89269277|NCT03755752|Experimental|Phacoemulsification with Trypan Blue|Phacoemulsification with Trypan Blue capsule staining of the anterior lens capsule in patients with diabetic retinopathy
89269278|NCT03755752|Experimental|Phacoemulsification without Trypan Blue|Phacoemulsification without Trypan Blue capsule staining of the anterior lens capsule in patients with
89269279|NCT03755674|Experimental|CHRONOTYPE-ADJUSTED DIET|Patients that undergo a chronotype adjusted diet
89269280|NCT03755674|No Intervention|CONTROL|Patients following a traditional or conventional hypocaloric diet
89269281|NCT01076582|Experimental|Arm 1|
89269282|NCT01076582|Active Comparator|Arm 2|
89269283|NCT01081938|Experimental|1|Insulin Glargine + Insulin Glulisine
89269284|NCT01081938|Active Comparator|2|Insulin Glulisine
89269285|NCT01082796|Other|CYP2C19 EMs group|cyp2c19*1/*1 carriers
89269286|NCT01082796|Other|CYP2C19 PMs group|cyp2c19*2/*2 or *2/*3
89269287|NCT03763786|Experimental|No GnRH antaogonist|Cetrorelix Acetate (NOT given) Daily 0.25mg Subcutaneous injection for 7 days
89269288|NCT03763786|Active Comparator|Standard GnRH antoagonist|Cetrorelix Acetate (control) Daily 0.25mg Subcutaneous injection for 7 days
89269289|NCT03965936|Placebo Comparator|lipofilling|subcutaneous injection of lipoaspiate (microfat) in one temporal region
89269290|NCT03965936|Active Comparator|lipofilling enriched with adipose tissue derived stem cells|subcutaneous injection of lipoaspiate enriched with adipose tissue derived stem cells in one temporal region
89269291|NCT01079364|Experimental|Insulin glargine + Insulin glulisine|Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
89269292|NCT01079364|Active Comparator|Premixed insulin|twice daily premixed insulin (before breakfast and evening meal).
89269293|NCT01077752|Experimental|1|Patients with continuous ropivacaine preperitoneal infusion
89269294|NCT01077752|Active Comparator|2|Patients with intravenous lidocaine infusion
89269295|NCT01077752|Placebo Comparator|3|Patients without local anesthetics
89269296|NCT03763630|Active Comparator|Intervention arm|House dust-mite SLIT
89269297|NCT03763630|Placebo Comparator|Control arm|Normal saline
89269298|NCT03763630|No Intervention|Observation cohort|ITEC observational cohort, no intervention administered
89269299|NCT01082016|No Intervention|Control|Monitor sleep in ICU without attempts at promotion
89269300|NCT01082016|Experimental|Sleep promotion|Measure sleep in ICU with sleep promotion program in effect
89269301|NCT03964844||CASE|Patients who had an episode of diarrhoea caused by C. difficile in an hematological unit (2003-2018)
89269302|NCT03964844||CONTROL|Patients who have had an episode of diarrhoea not caused by C. difficile in an hematological unit (2003-2018)
89269303|NCT03964844||PROSPECTIVE COHORT|All patients diagnosed with an hematological/oncological disease or with any immunosuppressive condition, who have a positive detection of toxigenic Clostridium difficile in 2019.
89269304|NCT01079442|Active Comparator|Treatment arm: coffee|coffee administration
89269305|NCT01079442|Placebo Comparator|Water arm|The control drink consists of 100 ml warm water
89269306|NCT03755596|Experimental|Treatment|Oral treatment with single-dose 160mg Z. officinale extract in tablet form.
89269307|NCT00129272|Active Comparator|Bupropion (Wellbutrin-SR)|Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-SR (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
89269308|NCT00129272|Placebo Comparator|Matching Placebo|Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
89269309|NCT03963804||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
89269310|NCT03963804||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
89269311|NCT01326338|Experimental|Nitazoxanide Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years
89269312|NCT01326338|Placebo Comparator|Placebo Suspension|Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years
89269313|NCT03963648|Experimental|CRSwNP|Study group that will undergo fractioned exhaled nitrogen oxide measurements as well as tests of lungfunction and sleep studies. All tests are non-invasive.
89269314|NCT01326416|Active Comparator|S: Nutritional Supplementation alone|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
89269315|NCT01326416|Active Comparator|A: Physical Reconditioning alone|Physical reconditioning sessions led by a trainer three times a week for 6 months.
89269316|NCT01326416|Active Comparator|AS: Physical Reconditioning + Nutritional Supplementation|Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
89269317|NCT01326416|No Intervention|C: Lifestyle counseling|Usual advice given in consultation on the need for a balanced diet and regular physical activity
89269318|NCT02531282|Experimental|Health promotion in patient education|The self-management patient education has been developed at the Healthy Life Centre in Trondheim municipality based on cognitive behavioural theory and psychomotor physiotherapy. The intervention is developed in a health promotion framework focusing on salutogenesis aiming to improve the participants ability to activate their own resources for health behaviour changes .
89269319|NCT02531282|Active Comparator|Physical activity in groups|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. .
89269320|NCT04899232|Experimental|AT3 less than 100% with SOC plus AT3 supplement|Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.
89269321|NCT04899232|No Intervention|AT3 less than 100% with SOC only|Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.
89269322|NCT04899232|No Intervention|AT3 more than 100% with SOC only|Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.
89269323|NCT03757936|Experimental|HLX04+HLX10|HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
89290533|NCT05179330|Experimental|Group A (no visual feedback-visual feedback)|Participants in group A (6 patients with sABI and 6 healthy controls), will perform a single rehabilitation session with OMEGO®. In total, they will perform 18 minutes divided as follows: 5 minutes of treatment with OMEGO® without visual feedback, 3 minutes of break, and additional 5 minutes of treatment with OMEGO® plus visual feedback
89269324|NCT04574908|Active Comparator|Blinded Ward|Continuous ward monitoring with hallway monitor screens covered. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.Continuous monitoring accessible to clinicians with pre-specified alerts at Systolic Blood Pressure alert <70, no Mean Arterial Pressure alert, heart rate >150 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <80%. Every 4 hourly checks by nursing teams unless otherwise ordered. These alarms are consistent with current standard of care.
89269325|NCT04574908|Experimental|Unblinded Ward|Continuous ward monitoring with hallway monitor screens accessible for viewing but with alarm limits more narrow. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will be able to view the hallway monitors showing the vital signs in all of the rooms and/or log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered. Continuous monitoring accessible to clinicians with pre-specified alerts at Mean Arterial Pressure (MAP) <65 mmHg, heart rate >110 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <90%. Every 4 hourly checks by nursing teams unless otherwise ordered.
89269326|NCT04559698|Experimental|immediate training group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the immediate training group will take part in the first 11-week course.
89269327|NCT04559698|Experimental|waitlist control group|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week. The participants in the waitlist control group will take part in the second 11-week course.
89269328|NCT03963258|Active Comparator|control group|Over a 3-week period, the subjects in the control group received 1 hour daily of conventional upper limb training 5 times a week,including compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
89269329|NCT03963258|Experimental|whole-body vibration group|Subjects in the whole-body vibration group received half an hour of daily conventional upper limb training, followed by whole-body vibration training for an additional half hour per day,5 days per week during a 3-week period
89269330|NCT03763474|Experimental|Euglyca|Patients randomized to the Euglyca group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose.
89269331|NCT03763474|No Intervention|Control|
89269332|NCT01082094|Experimental|ACRX-100|"Cohort 1 = Low dose~Cohort 2 = Middle dose~Cohort 3 = High Dose"
89269333|NCT03753568|Experimental|Study group|The participants use either direct oral anticoagulants or oral diabetic medication.
89269334|NCT01082172|Experimental|Thoracic Stent Graft|Thoracic Stent Graft implanted device
89269335|NCT01079676|Experimental|Filgrastim|
89269336|NCT01079676|Active Comparator|Granulokine|
89269337|NCT03753256|Active Comparator|Transbond XT|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive a bonding primer (Transbond XT) The investigators will evaluate in this arm~the development of demineralization~its adverse effects after application"
89269338|NCT03753256|Experimental|Protecto®CaF2Nano|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Protecto®CaF2Nano).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
89269339|NCT03753256|Experimental|Pro Seal®|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Pro Seal®).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
89269340|NCT03753256|Experimental|Opal® Seal|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Opal®Seal).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
89269341|NCT01082250|Other|Reference Formulation|Dosed 12.5% drugload 3X40mg
89269342|NCT01082250|Other|Test Formulation|25% Drugload 1X120mg
89269343|NCT05460286|Experimental|CSMT group|Chiropractic Spinal Manipulative Treatment group
89269344|NCT05460286|Experimental|SD group|Spinal Decompression group
89269345|NCT01082406|Experimental|Trial part 1|
89269346|NCT01082406|Experimental|Trial part 2|
89269347|NCT03755362|Active Comparator|Standard treatment (control)|Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
89269348|NCT03755362|Experimental|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
89290534|NCT05179330|Experimental|Group B (visual feedback-no visual feedback)|Participants in group B (6 patients with sABI and 6 healthy controls), will perform a single rehabilitation session with OMEGO®. In total, they will perform 18 minutes divided as follows: 5 minutes of treatment with OMEGO® plus visual feedback, 3 minutes of break, and additional 5 minutes of treatment with OMEGO® without visual feedback
88821606|NCT03313778|Experimental|Part E3: Dose Expansion|Participants will receive mRNA-4157 via IM injection on Day 1 of each 21-day cycle, pembrolizumab Q3W via IV infusion, and SoC chemotherapy Q2W or Q3W for up to 4 cycles during the perioperative and adjuvant phases.
89269349|NCT03755284|Experimental|sacral Massage Group|"The massage was applied only to the pregnant women in the intervention group at every phase of labour. There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~For the pregnant women included in the experimental group:~In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour."
89269350|NCT03755284|No Intervention|Control Group|"There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~One-on-one interviews were conducted with the pregnant women, and the voluntary disclosure forms, which explained the purpose of the study, were completed.~The prepared questionnaire form was applied. Routine nursing/midwifery care was applied. The state-trait anxiety inventory (STAI FORM TX-I) was applied and evaluated in the active (5-7 cm) phase.~The Visual Analogue Scale (VAS) was evaluated once in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases.~Birth action follow-up form and postpartum interview forms were applied"
89269351|NCT00133952|Experimental|Ruboxistaurin|32 mg taken orally daily for up to 48 months
89269352|NCT00133952|Placebo Comparator|Placebo|Taken orally daily for up to 48 months
89269353|NCT03755050||Sleigh Accident|Accident while using a sleigh
89269354|NCT03755050||Climbing Accident|Accident occurred while climbing (rock, ice)
89269355|NCT03755050||Cycle Accident|Accident occurred while using any form of cycle in the mountains (e.g. bike, mountainbike, e-bike)
89269356|NCT03755050||Canyoning Accident|Accident occurred while doing canyoning
89269357|NCT03755050||Hiking Accident|Accident occurred while hiking in mountainous area.
89269358|NCT03755050||Snowshoeing Accident|Accident occurred while doing Snowshoeing
89269359|NCT03755050||Mountainous Water-sport Accident|Accident occurred while doing any type of Water-sport (e.g. canoeing, kayaking, tubing, swimming) in mountainous environment.
89269360|NCT03755050||Skiing/Snowboarding|Accident occurred while using ski or a snowboard either in backcountry or on ski slope
89269361|NCT00118092|Experimental|Treatment (tanespimycin)|Patients receive 17-N-allylamino 17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses of treatment beyond documentation of CR.
89269362|NCT01083108|Active Comparator|Non-surgical Arm|Low-calorie Diet
89269363|NCT01083108|Experimental|Surgical Arm|Roux-en-Y Gastric Bypass
89269364|NCT04555096|Experimental|Active GC4419|Arm A
89269365|NCT04555096|Placebo Comparator|Placebo|Arm B
89269366|NCT00097500|Experimental|Exenatide Arm|Exenatide and Metformin
89269367|NCT00097500|Active Comparator|Insulin Glargine Arm|Insulin Glargine and Metformin
89269368|NCT01082484|Experimental|Treprostinil|Treprostinil iontophoresis (250, 25 and 2.5 microM)
89269369|NCT01082484|Experimental|Iloprost|Iloprost iontophoresis (200, 20 and 2 microM)
89269370|NCT01082484|Placebo Comparator|NaCl 0.9%|
89269371|NCT04551898|Experimental|BGB-DXP593 Low Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
89269372|NCT04551898|Experimental|BGB-DXP593 Medium Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
89269373|NCT04551898|Experimental|BGB-DXP593 High Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
89269374|NCT04551898|Placebo Comparator|Placebo|Participants will receive placebo on Day 1, and followed up for safety for up to 85 days
89269375|NCT03757780||Pregnant ladies who are caffeine using|ladies who uses caffeine during pregnancy
89269376|NCT04849780|Experimental|ARM 1|Eligible subjects will be randomized to the TEST lens to wear in both eyes for approximately 2 weeks.
89269377|NCT04849780|Experimental|ARM 2|Eligible subjects will be randomized to the CONTROL lens to wear in both eyes for approximately 2 weeks. Then the subject will receive the TEST lens to wear in both eyes for approximately 2 weeks.
89269378|NCT03757702||Fibromiyalgia group|women with FMS between 18-65 years of age and being volunteered.
89269379|NCT03757702||Healthy group|healthy women and being volunteereed
89269380|NCT03757624|Active Comparator|Gastric specimen measurements after 24 hours from % 10 formol|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after formol solution
89269381|NCT03757624|Active Comparator|Gastric specimen measurements after surgery in operating room|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after surgery in operating room peroperatively
89269382|NCT03754894|Experimental|goup 1(with readymade plastic stent )|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
89269383|NCT03754894|Experimental|group 2 (control)|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement then suturing the flap in place.
89269384|NCT04823494|Experimental|Pro-Fit followed by Self Fit|Hearing aids fit by a professional hearing care provider using best practices followed by patient ...
89269385|NCT04823494|Experimental|Self-Fit followed by ProFit|Hearing aids fit by patient followed by ...
89269386|NCT05459974|Active Comparator|Colchicine arm|
89269387|NCT05459974|Placebo Comparator|Placebo arm|
89269388|NCT03754816|Experimental|Experimental group|The combination of PECS II and parasternal block performed by injecting Levobupivacaine 0.375% 40 ml, injected between minor and major pectoralis muscles, between minor and serratus muscles and between major and intercostal muscles
89290535|NCT01129518|Experimental|Two Dose MenC Group|Two doses of MenC-CRM197 priming at 3 and 4 months of age.
89290536|NCT01129518|Experimental|Single Dose MenC-CRM197 Group|One dose of MenC-CRM197 priming at 3 months of age.
89290537|NCT01129518|Experimental|Single Dose MenC-TT Group|Single dose MenC-TT priming at 3 months of age
89269389|NCT04542694|Experimental|Favipiravir (Areplivir)|"Arm 1 (n=100) receives the study drug Areplivir film-coated tablets:~on day 1 of therapy - 1600 mg (8 tablets) 2 times a day; on days 2-14 of treatment - 600 mg (3 tablets) 2 times a day. The drug is taken orally every 12 hours, swallowing whole tablet without chewing and washing down with a glass of water. The course of treatment is 14 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient."
89269390|NCT04542694|Active Comparator|Standard of care|"Arm 2 (n=100) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health (but not Favipiravir) by decision of the investigator and taking into account the availability of drugs at the study site. Might include hydroxychloroquine (with or without azithromycin), chloroquine, lopinavir/ritonavir or other recommended schemes.~Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime."
89269391|NCT00117312|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
89269392|NCT00117312|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
89269393|NCT00117312|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
89269394|NCT00117312|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
89269395|NCT01589328|Experimental|Early Palliative care|"The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
89269396|NCT01589328|No Intervention|Contol: usual oncologic care|Patients randomly assigned to usual oncologic care were not scheduled to meet with the palliative care service unless a meeting was requested by the patient, the family, or the oncologist; those who were referred to the service did not cross over to the early palliative care group or follow the specified palliative care protocol.
89269397|NCT01589406||group A group B|A:Patients for surgical intervention B:Patients for radiotherapy
89269398|NCT03965208|Active Comparator|Unfractionated heparin|Patients randomized to this group will receive anticoagulation with unfractionated heparin
89269399|NCT03965208|Experimental|Bivalirudin|Patients randomized to this group will receive anticoagulation with bivalirudin
89269400|NCT01083264|Experimental|Arm 1|
89269401|NCT01083264|Experimental|Arm 2|
89269402|NCT01083264|Experimental|Arm 3|
89269403|NCT00129116|Experimental|Menhibrix F1/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 1 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
89269404|NCT00129116|Experimental|Menhibrix F2/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 2 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
89269405|NCT00129116|Experimental|Menhibrix F3/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 3 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
89269406|NCT00129116|Experimental|Menitorix/Infanrix-penta Group|Subjects received Menitorix vaccine and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menitorix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
89269407|NCT00129116|Active Comparator|Menjugate/Infanrix-hexa Group|Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
89269408|NCT00117156|Experimental|Fludarabine and Rituximab|"Fludarabine:~25 mg/m2 on days 1-5 of 28 day cycle up to 6 cycles~Rituximab:~375 mg/m2 on day 1 of 28 day cycle up to 6 cycles Rituximab dose was split between days 1 and 3 for patients with absolute lymphocyte counts > 10x10^9/L~Patients received three cycles of therapy followed by re-staging with chest/ abdomen/ pelvic CT scan. Patients with progressive disease discontinued treatment. Patients with stable or responding disease continued therapy for another 3 cycles."
89269409|NCT01083420|Active Comparator|Dexamethasone|Dexamethasone 0.01% mouthwash
89269410|NCT01083420|Experimental|Minocycline|Minocycline 0.2% mouthwash
89269411|NCT01083498|Experimental|Ablative fractional laser|"In each patient, a square test region of 5-10 cm2 was treated with ablative fractional laser in three sessions in combination with intermittent topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream) to prevent laser-induced postinflammatory hyperpigmentation.~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
89269412|NCT01083498|No Intervention|Control|"In each patient, a square test region of 5-10 cm2 was treated with topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream)alone (to allow comparison of the regions).~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
89269413|NCT00096954|Experimental|Omalizumab|Omalizumab (Xolair) administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
89269414|NCT00096954|Placebo Comparator|Placebo|Placebo administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
89269415|NCT00096486|Experimental|Gefitinib and Everolimus (RAD001)|"Phase I: Patients receive oral everolimus once on day 1. Beginning on day 8, patients receive oral gefitinib once daily. Beginning on day 22, patients receive oral everolimus once daily. Both drugs are then given concurrently for the rest of the treatment. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.~Phase II: Patients receive oral everolimus at the MTD determined in phase I and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
89269416|NCT00116844|Experimental|Sequence 1: VALTREX 1 g once daily, Placebo|VALTREX 1 g once daily, Placebo
89269417|NCT00116844|Experimental|Sequence 2: Placebo, VALTREX 1 g once daily|Placebo, VALTREX 1 g once daily
89269418|NCT03963336|Active Comparator|Group A|12 IIH patients for whom serum D-dimer was assessed by ELISA.They received acetazolamide and anticoagulant LMWH in the prophylactic dose for 2 weeks then continued on acetazolamide. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
89269419|NCT03963336|Active Comparator|Group B|12 IIH patients for whom serum D-dimer was assessed by ELISA. They received acetazolamide only. Follow up after 1 and 6 months through HIT6 test and ophthalmological assessment (visual acuity, Frisen classification for papilledema, visual field, and visual evoked potentials)
89269420|NCT03963336|No Intervention|Control group|24 healthy subjects for whom serum D-dimer was assessed by ELISA.
89269421|NCT03966794|Experimental|Epidural Electrical Stimulation|
89269422|NCT03966794|Experimental|Functional scaffold & Epidural Electrical Stimulation|
89269423|NCT01076738||single group study|
89269424|NCT00132314|Experimental|Arm 1|long-acting injectable risperidone
89269425|NCT00132314|Active Comparator|Arm 2|oral antipsychotic medication
89269426|NCT04539262|Experimental|Remdesivir (RDV), Part A|Participants will receive inhaled RDV 31 mg administered daily for 5 days.
89269427|NCT04539262|Experimental|RDV + Placebo, Part A|Participants will receive inhaled RDV 31 mg administered daily for 3 days followed by placebo to match RDV daily for 2 days.
89269428|NCT04539262|Placebo Comparator|Placebo, Part A|Participants will receive placebo to match inhaled RDV in Part A daily for 5 days.
89269429|NCT04539262|Experimental|RDV, Part B|Participants will receive inhaled RDV 62 mg administered daily for up to 5 days.
89269430|NCT04539262|Experimental|RDV + Placebo, Part B|Participants will receive inhaled RDV 62 mg administered daily for up to 3 days followed by placebo to match RDV daily for 2 days.
89269431|NCT04539262|Placebo Comparator|Placebo, Part B|Participants will receive placebo to match inhaled RDV in Part B daily for 5 days.
89269432|NCT04539262|Experimental|RDV, Part C|Participants will receive inhaled RDV 39 mg administered daily for 5 days.
89269433|NCT04539262|Placebo Comparator|Placebo, Part C|Participants will receive placebo to match inhaled RDV in Part C daily for 5 days.
89269434|NCT03754738|Experimental|Balloon guide catheter group|mechanical thrombectomy with a balloon guide catheter group
89269435|NCT03754738|Active Comparator|Non-balloon guide catheter group|mechanical thrombectomy with a non-balloon guide catheter group
89269436|NCT03702010|Active Comparator|CME branch|In this study, the conventional spinal cord stimulation method (control Branch-CME branch)
89269437|NCT03702010|Experimental|EME branch|In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)
89269438|NCT04538170||ORC|Group orchidectomy following cancer
89269439|NCT04538170||GAC|Group sex reassignment surgery
89269440|NCT04537234|Experimental|Group 1: High-Dose Quadrivalent Influenza Vaccine (QIV-HD)|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
89269441|NCT04537234|Active Comparator|Group 2: Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD)|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
89269442|NCT04537078|Active Comparator|the progestin primed double stimulation group|luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Duphaston at 20 mg/day will be started from the first day of the ovulation induction.Decapeptyl in a dose of 2 ampules of 0.2 mg will be administered when leading follicle >18 mm in diameter for triggering.Then, Controlled ovarian hyper-stimulation the next day after the previous oocyte pickup simultaneously with Duphaston. Starting from the next menstrual cycle Day 3, patients will receive oral estradiol valerate (Cyclo-Progynova (white tablets) daily.When endometrial thickness ≥ 7 mm.Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage.
89269443|NCT04537078|Active Comparator|the flexible GnRh antagonist|This step will be done twice in two different cycles In each cycle: luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Cetrotide ampule will be given daily as the biggest oocyte reaches size 14 mm. Decapeptyl ampules 0.2 mg will be administered when leading follicle >18 mm in diameter. While in the second cycle HCG triggering (Choriomon)in a dose of 10,000 IU will be administered when the leading follicle >18 mm in diameter. Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the first cycle and fresh embryos of the second cycle.
89290538|NCT01129518|Experimental|Control Group|Zero dose MenC priming
89290539|NCT01226784|Active Comparator|Physcial exercise|15 weeks of progressive resistance group exercise, twice/week supervised by physical therapist
89269444|NCT04532164|Experimental|Photoallergic reaction test|During the Induction Phase, participants received Butenafine HCl 1% on the treated irradiated skin test site followed by UV irradiation and on the treated non-irradiated skin test site without UV radiation, two times per week for three consecutive weeks. After 10 days of Rest Phase, during the Challenge Phase, participants received same procedure on the two virgin sites (treated sites) as in Induction Phase, and two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Test sites were evaluated at 24, 48, and 72 hours after irradiation using the same grading scale used during Induction Phase.
89269445|NCT01561924|Experimental|Ex vivo|
89269446|NCT00116688|Experimental|Romiplostim|Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.
89269447|NCT04531540|Experimental|Repeated Insult Patch Test|During the Induction Phase, participants received 0.2 g Butenafine HCl 1% covered by an occlusive patch on the upper back skin test site three times a week for a total of 9 applications. Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system. After 14 days of Rest Phase, on the first day of Challenge Phase, participants received same procedure on original Induction Phase test site and on a virgin test site. The patches were removed and the sites scored 48 hours after application and scored again at 96 hours after application. The test sites were evaluated using the Induction Phase scoring system.
89269448|NCT04799782|Active Comparator|Mirtazapine|The drug will be taken for a one week peroid.
89269449|NCT04799782|Placebo Comparator|Placebo|The drug will be taken for a one week peroid.
89269450|NCT03754504|Experimental|Cranberry|Whole Cranberry Powder Supplements
89269451|NCT03754504|Placebo Comparator|Placebo|Placebo
89269452|NCT03697252|Experimental|KarXT|
89269453|NCT03697252|Placebo Comparator|Placebo|
89269454|NCT03701074|Experimental|ibuprofen and acetaminophen arm (intervention arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).
89269455|NCT03701074|Active Comparator|ibuprofen and placebo arm (control arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.
89269456|NCT03757468|Active Comparator|RME (rapid maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with the standard hyrax expansion screw anchored on second deciduous molars
89269457|NCT03757468|Experimental|Leaf (leaf maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with Leaf Expander appliance anchored on second deciduous molars.
89269458|NCT03754348|Experimental|NT1 group|hypothalamus neuroinflammation evaluation in Narcoleptic patients
89269459|NCT03754348|Other|Control group|hypothalamus neuroinflammation evaluation in control patients (patients without hypersomnia or inflammatory pathology)
89269460|NCT03754348|Experimental|KLS group|hypothalamus neuroinflammation evaluation in Kleine-Levin syndrome patients
89269461|NCT01322620||A|
89269462|NCT03754192|Other|perfusion computed tomography|Will be realsed before liver surgery
89269463|NCT03757390|Experimental|Sequence 1|"period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg~period 2: receive CJ-30060 5/160/10mg"
89269464|NCT03757390|Experimental|Sequence 2|"period 1: receive CJ-30060 5/160/10mg~period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg"
89269465|NCT01322698||The study population|The target population includes patients in ICUs at the Nîmes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils > 500/mm3) at risk of developing invasive candidiasis.
89269466|NCT03753958|Experimental|Control group|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
89269467|NCT03753958|Experimental|aPDT group|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
89269468|NCT03753880|Experimental|Hemopatch|Hemopatch used to cover the resection surface after LR
89269469|NCT05459428||Confocal laser endomicroscopy scoring of the extent of intestinal metaplasia|Get pictures and Videos from gastric antrum body and angle by confocal laser endomicroscopy in order to calculate the CGGIM score.
89290540|NCT01226784|Active Comparator|Relaxation exercise|15 weeks of relaxation exercise, twice/week supervised by physical therapist
89269470|NCT05459428||Artificial intelligence scoring of the extent of intestinal metaplasia|Get pictures and Videos from gastric antrum body and angle by Artificial intelligence in order to calculate the CGGIM score.
89269471|NCT05458804|Experimental|Active experimental group|The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions
89269472|NCT05458804|No Intervention|Passive Control group|Participants in the control group did not participate in the training, and were instructed not to perform specific physical activities aimed at improving the examined abilities
89269473|NCT03753802|Experimental|Treated|The treated group will receive chest physiotherapy treatment using slow extended and passive expiratory maneuvers.
89269474|NCT03753802|Placebo Comparator|Control|The control group will not receive physiotherapy treatment.
89269475|NCT03757156|No Intervention|Aspirin maintenance group|People who are taking aspirin continue to take aspirin.
89269476|NCT03757156|Experimental|Aspirin withdrawal group|People who are taking aspirin stop to taking aspirin.
89269477|NCT05401240|Experimental|CEPT informed|the patient is informed and asked to returned to the outpatient department (OPD) in order to received cardiac rehabilitation, as well as to take an important examination (cardiopulmonary exercise testing) for his/her cardiorespiratory fitness.
89269478|NCT05401240|No Intervention|CPET not informed|the patient is asked to returned to the outpatient department (OPD) in order to received cardiac rehabilitation, but not informed about the cardiopulmonary exercise testing.
89269479|NCT04728802|Active Comparator|Proxalutamide + Usual Care|Proxalutamide + usual care as determined by care provider
89269480|NCT04728802|Placebo Comparator|Placebo + Usual Care|Placebo + usual care as determined by care provider
89269481|NCT03757078||Patients with acute hemorrhoids|Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)
89269482|NCT03750916|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1) Drug: Anlotinib Hydrochloride plus Docetaxel
89269483|NCT05322148|Active Comparator|cyclosporine 0.1% / loteprednol 0.2% group|60 total patients will be randomized in a 2 to 1 proportion with 40 in the cyclosporine 0.1% / loteprednol 0.2% group and 20 in the cyclosporine 0.05% group. All patients will undergo treatment in both eyes.
89269484|NCT05322148|Active Comparator|cyclosporine 0.05% group|60 total patients will be randomized in a 2 to 1 proportion with 40 in the cyclosporine 0.1% / loteprednol 0.2% group and 20 in the cyclosporine 0.05% group. All patients will undergo treatment in both eyes.
89269485|NCT03750760|Active Comparator|Alirocumab (enhanced care)|"Alirocumab (150 mg) administered by subcutaneous injection, every two weeks for 7 weeks.~Atorvastatin (80 mg), oral administration daily."
89269486|NCT03750760|Active Comparator|Atorvastatin (standard care)|Atorvastatin (80 mg), oral administration daily. Ezetimibe (10 mg), oral administration daily, from week 4 if LDL-C is ≥ 70 mg/dL (1.8mmol/L) at week 4.
89269487|NCT01076894|Active Comparator|epidural anesthesia|
89269488|NCT01076894|Active Comparator|intercostal anesthesia|
89269489|NCT04715932|Active Comparator|Hesperidin 1000mg|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
89269490|NCT04715932|Placebo Comparator|Placebo 1000mg|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
89269491|NCT00130832|Experimental|1|RotaTeq and OPV concomitantly
89269492|NCT00130832|Experimental|2|RotaTeq and OPV on staggered schedule
89269493|NCT04964362||Individuals with Spinal Cord Injury|Individuals with recent spinal cord injuries, both veterans and civilians, will be followed for 1 year for inquiry into injustice appraisals.
89269494|NCT00096018|Experimental|Dose escalation|Thalidomide (100 mg/day, 200 mg/day, or 300 mg/day) on Day 1 followed by Fludarabine 25 mg/m2/day for 5 days starting on Day 7 (cycle = 28 days
89269495|NCT04713748|Other|Tasso- SST blood collection|About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
89269496|NCT04713748|Other|Regular Venipuncture|About 100 participants will have blood collected by two methods-regular phlebotomy and Tasso-SST, in this pilot study.
89269497|NCT01079754|Experimental|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
89269498|NCT01079754|Active Comparator|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
89269499|NCT03757000|Experimental|YY-20394|"YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).~YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day."
89269500|NCT03750604|Active Comparator|patients with OAB|"Patients were asked to fill (OABSS) for more accurate evaluation of bothersome degree. Waist Circumference is evaluated. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to CT detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
89290541|NCT03740412|Experimental|Sedentary behaviour reduction (behaviour change techniques)|Intervention group attending visits 1, 2, 3, 4, 5
89290542|NCT03740412|No Intervention|Usual care|Will receive usual orthopaedic care, attending visits 1, 4, 5
89269501|NCT03750604|Placebo Comparator|normal variants healthy without symptoms|"WC is evaluated crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL. And in males:VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
89269502|NCT04702984|Experimental|LID021201|LID021201 contact lenses worn in both eyes for 7 days. Lenses will be removed nightly for cleaning and disinfection with OPTI-FREE multipurpose solution.
89269503|NCT04701658|Experimental|Bamlanivimab|Participants received 700 milligram single intravenous infusion of Bamlanivimab.
89269504|NCT04701658|No Intervention|Controls|"Matched controls who received standard of care.~[The study was originally designed to include a matched control arm. However, due to low enrollment, it was amended to be a single arm study with Bamlanivimab arm only. No matched controls were utilized.]"
89269505|NCT03750526|Experimental|rTMS and AR group|Ten participants in group A will undergo repetitive transcranial magnetic stimulation (real, 1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
89269506|NCT03750526|Active Comparator|Sham rTMS and AR group|Ten participants in group B will receive repetitive transcranial magnetic stimulation (sham,1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
89269507|NCT03750526|Active Comparator|AR group|Ten participants in group C will undergo augmented reality exercise 60 minutes a day and 3 days per week for four weeks.
89269508|NCT03750526|Active Comparator|Conventional physiotherapy group|Ten participants allocated to the group D will receive conventional physiotherapy 60 minutes a day and 3 days per week for four weeks.
89269509|NCT03756922|Experimental|Part 1|To receive a single dose of FDL176 on Day 1, followed by FDL169 TID for 28 days starting on Day 29; and another single dose of FDL176 on Day 42.
89269510|NCT03756922|Experimental|Part 2|To receive FDL169 TID for 3 days from Day 1, followed by FDL176 QD for 19 days starting on Day 8; and FDL169 TID for 3 days from Day 24.
89269511|NCT03756922|Experimental|Part 3|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
89269512|NCT03756922|Experimental|Part 4|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
89269513|NCT01322776|Experimental|Bortezomib,Fludarabine,Cyclophosphamide|
89269514|NCT03756844|Experimental|Just Right Challenge Food Club Protocol|There was only one arm in this study. All participants received the Just Right Challenge Food Club Protocol and single subject (time series) data was collected.
89269515|NCT03750214|Experimental|Biop Coplposcopy System|Biop Colposcopy system procedure
89269516|NCT00128102|Experimental|Vorinostat|Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
89269517|NCT00128102|Placebo Comparator|Placebo|Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
89269518|NCT03965858|Experimental|Esketamine low dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
89269519|NCT03965858|Experimental|Esketamine medium dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
89269520|NCT03965858|Experimental|Esketamine high dose|Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
89269521|NCT03965858|Placebo Comparator|Placebo|Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
89269522|NCT03965780|Experimental|Training group|Participants in the training group will receive a 13-week training program delivered via videoconference. The program includes 13 modules delivered via videoconference over the course of the 3-month program in weekly 60- to 90-minute sessions. Participants will receive a training manual, be shown filmed vignettes, and will have access to a chatroom and an online resource centre.
89269523|NCT03965780|No Intervention|Wait-list control group|Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above.
89269524|NCT04668274|Experimental|Part 1: JOTROL (Resveratrol) 200 mg (Treatment A)|Participants received JOTROL (resveratrol) 200 (2*100) milligram (mg) (Treatment A), gelatin capsule (gelcap), orally, once on Day 1 in fasted conditions in Study Period 1.
89269525|NCT04668274|Experimental|Part 1: JOTROL (Resveratrol) 500 mg (Treatment B)|Participants who completed Study Period 1 received JOTROL (resveratrol) 500 (5*100) mg (Treatment B), gelcap, orally, once on Day 1 in fasted conditions in Study Period 2. A 14 days washout period was maintained in study period 1 and 2.
89269526|NCT04668274|Experimental|Part 1: JOTROL (Resveratrol) 700 mg (Treatment C)|Participants who completed Study Period 2 received JOTROL (resveratrol) 700 (7*100) mg (Treatment C), gelcap, orally, once on Day 1 in fasted conditions in Study Period 3. A 14 days washout period was maintained in study period 2 and 3.
89269527|NCT04668274|Experimental|Part 2: JOTROL (Resveratrol) 500 mg (Treatment D)|Participants who completed Study Period 3 (Part 1) received JOTROL (resveratrol) 500 (5*100) mg (Treatment D), gelcap, orally, once on Day 1 in fed conditions in Study Period 4. A 14 days washout period was maintained in study period 3 and 4.
89269528|NCT01077908|Experimental|ACT plus standard therapy|Adoptive Cellular Therapy (ACT) prepared using Multimer or Gamma Catch Selection in combination with standard best available antiviral drug therapy
89269529|NCT01077908|Active Comparator|Best available antiviral drug therapy|
89269530|NCT03750058|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
89269531|NCT04406194|Experimental|FAVICOVIR then AVIGAN|Participants first received Favicovir 200 mg FT manufactured by Atabay in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
89269532|NCT04406194|Experimental|AVIGAN then FAVICOVIR|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favicovir 200 mg FT manufactured by Atabay in a fasting state.
89269533|NCT03822884|Experimental|Hemax® PFS 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
89269534|NCT03822884|Experimental|Hemax® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
89269535|NCT03822884|Active Comparator|Erypo ® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
89269536|NCT03822416|Experimental|Intervention|Intervention group will receive counseling and nicotine replacement therapy including the nicotine patch and/or nicotine lozenges.
89269537|NCT03822416|Other|Control|Control group will receive information about mental illness and smoking cessation and a listing of community resources available for assistance with smoking cessation.
89269538|NCT04405570|Experimental|Molnupiravir 200 mg|Molnupiravir 200 mg, twice daily (BID) for 5 days
89269539|NCT04405570|Experimental|Molnupiravir 400 mg|Molnupiravir 400 mg, twice daily (BID) for 5 days
89269540|NCT04405570|Experimental|Molnupiravir 800 mg|Molnupiravir 800 mg, twice daily (BID) for 5 days
89269541|NCT04405570|Placebo Comparator|Placebo (PBO) twice daily (BID) for 5 days|
89269542|NCT01080092|Experimental|breathing technique group|technique as a stress management technique, reinforced by biofeedback
89269543|NCT01080092|Placebo Comparator|no breathing technique|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
89269544|NCT00127712|Experimental|Amiodarone|Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days
89269545|NCT00127712|No Intervention|No treatment|Patients in this group receive no intervention
89269546|NCT01322854|Experimental|IMRT + integrated boost|28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed by an integrated boost
89269547|NCT01322854|Other|Conventional RT + sequential boost|Conventional radiotherapy of the whole breast in 28 fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4 Gy
89269548|NCT05461144||Type1diabetes patients|Males and females diagnosed with T1D, aged over 18 years old who are currently under the care of the Warwickshire Institute for the Study of Diabetes, Endocrinolgy and Metabolism (WISDEM) at the University Hospitals Coventry and Warwickshire.
89269549|NCT01082744|Active Comparator|Continuous paravertebral block with ropivacaine|
89269550|NCT01082744|Experimental|Continuous paravertebral block with ropivacaine and sufentanil|
89269551|NCT04404010|Active Comparator|Immersive Virtual Reality|"Participants randomized to the immersive virtual reality (iVR) study arm, considered the intervention group will receive training on completion of a reverse shoulder arthroplasty using an iVR simulator (PrecisionOS Technology)."
89269552|NCT04404010|Other|Surgical Video|"Participants randomized to the standard video study arm, considered the control group will receive training on completion of reverse shoulder arthroplasty using a technical surgical instructional video."
89269553|NCT03748030||Confirmed Left-Sided Breast Cancer|T1/T2 N0, T1/T2 N1, T3/T4 and/or N2/N3 Left-Sided Breast Cancer Patients receiving standard radiation therapy will receive PET/MRI, ECG/EKG, and bloodwork before, within a month, and within a year post treatment.
89269554|NCT03749824|Experimental|Omega-3|Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure.
89269555|NCT03749824|Placebo Comparator|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
89269556|NCT04401202|Experimental|NSO|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
89269557|NCT04401202|No Intervention|Control|Standard of care
89269558|NCT00096356|Active Comparator|Arm 1 - CoQ10 & Vitamin E|CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.
89269559|NCT00096356|Placebo Comparator|Arm 2 - Placebo & Vitamin E|Placebo-Vitamin E 100 mg/day in 3 doses
89269560|NCT03747874|Other|past medical history of sudden hearing loss|sleep examination and ventilatory polygraphy device for 1 night
89269561|NCT03749590|Experimental|Magnesium|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate)."
89269562|NCT03749590|Placebo Comparator|Placebo (NaCl 0,9%)|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~To each infusion 10 ml NaCl 0.9% (Placebo) will be added ."
89269563|NCT03749512||Observational Group|Group of patients with lung tumor qualified for thoracic surgery intervention with routine, preoperative complete blood count test and routine postoperative histopathological examination of lung tumor.
89269564|NCT03718156|Experimental|PREPARED Trial Intervention|Participating nursing staff will be trained to apply the PREPARED Trial interventions, and will apply this knowledge to modify the therapeutic nursing plans of residents under their care who are enrolled in the study, accordingly.
89269565|NCT03718156|No Intervention|Care as Usual|Participating nursing staff will only be provided with general information about delirium, but will not be trained or instructed to modify the therapeutic nursing plans that are in place for residents enrolled in the study. However, at the end of the follow-up period, nursing staff in the control arm will be provided with the PREPARED Trial intervention training program (including bedside coaching), which they can then use after the study has ended at their facility.
89269566|NCT03747796|Active Comparator|supine position|The children will be in the supine position after ingestion of a standard volume of clear fluid.
89269567|NCT03747796|Experimental|Semi-sitting position|The children will be in the semi-sitting position after ingestion of a standard volume of clear fluid.
89269568|NCT03749356|Experimental|Once-Daily Tacrolimus|One arm: TacroBell SR Cap.
89269569|NCT01562470|Experimental|herbal-based cellulite cream|Trial subjects will apply the treatment cream to one thigh and placebo to the other thigh, by random allocation.
89269570|NCT01562158|Placebo Comparator|Placebo|
89269571|NCT01562158|Experimental|Low dose|
89269572|NCT01562158|Experimental|Medium dose|
89269573|NCT01562158|Experimental|High dose|
89269574|NCT03749200|Experimental|Obemat2.0 Intervention Group|Intervention: Obemat2.0 therapy (11 Motivational Interview Visits, 3 Workshops) Duration: 12 months (+3 months). Setting: Primary care centers Providers: pediatritians and nurses trained to perform motivational interview Visits description: The interviews follow a structure: 1. Checking the accomplishment of objectives to congratulate and motivate the patient. 2. A specific topic per visit is explained to the participant and family. 3. A task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight and physical activity are defined to be accomplished until the next visit. The follow-up of the structure is ensured by means of a printed material that the therapists provide each visit to participants.
89269575|NCT03749200|Active Comparator|Control Group|Control Intervention: regular practise in primary care (11 individual monthly visits) Duration: 12 months (+3 months). Setting: Primary care centers. Providers: standard pediatritians and nurses Children and their families receive the usual recommendations conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity. At visits, the family receive explanations about carrying out a balanced diet, divided into 5 meals, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports regular practise is recommended. Monthly visits are organized in which weight and height are measured and compliance with advice is reviewed.
89269576|NCT03612232|Experimental|Cabozantinib|oral cabozantinib as tablets continuously (60 mg single dose, tablets)
89269577|NCT05297110|Active Comparator|atherolive group|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
89269578|NCT05297110|Placebo Comparator|placebo group|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
89269579|NCT04315246|Experimental|177Lu-DTPA-omburtamab|Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to five cycles.
89269580|NCT04358068|Experimental|Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|"Hydroxychloroquine 400 mg (administered as two 200 mg capsules) orally twice daily for 2 doses starting on Day 0, followed by 200 mg (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Azithromycin 500 mg (administered as two 250 mg capsules) orally as a single dose on Day 0, followed by 250 mg (administered as one 250 mg capsule) orally once daily for 4 doses (4 days)."
89269581|NCT04358068|Placebo Comparator|Arm B: Placebo for Hydroxychloroquine and Azithromycin|"Placebo for Hydroxychloroquine (administered as two matching placebo capsules) orally twice daily for 2 doses starting on Day 0, followed by Placebo for HCQ (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Placebo for Azithromycin (administered as two matching placebo capsules) orally as a single dose on Day 0, followed by Placebo for Azithromycin (administered as one matching placebo capsule) orally once daily for 4 doses (4 days)."
89269582|NCT03694210|Experimental|EndoRotor Therapy|Physicians will perform direct endoscopic necrosectomy using the EndoRotor in patients with walled off necrosis.
89269583|NCT04339972|Experimental|Active LIFUP then Sham LIFUP|Real LIFUP is delivered to the participant for visit 1, followed by sham lifup visit 2
89269584|NCT04339972|Sham Comparator|Sham LIFUP then Active LIFUP|Sham LIFUP is delivered to the participant for visit 1, followed by real lifup visit 2
89269585|NCT00096278|Active Comparator|Arm I (mFOLFOX6)|Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89269586|NCT00096278|Experimental|Arm II (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
89269587|NCT03748654|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Field Analyzer and with the Virtual Reality Headset
89269588|NCT00095940|Experimental|Treatment (surgery, lapatinib)|"Molecular Biology Phase: Patients randomized to receive lapatinib prior to surgery receive oral lapatinib twice daily for 7-14 days. Surgery is performed after 7-14 days of lapatinib treatment. For patients randomized to not receive lapatinib, surgery is performed within 3 weeks of registration. After surgical resection, all molecular biology participants start lapatinib treatment within 10 days post-surgery. The first dose of lapatinib post-surgery initiates course 1. Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.~Lapatinib Continuation/Phase II: Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity."
89269589|NCT00114218|Experimental|Treatment (gemcitabine hydrochloride, docetaxel)|Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
89269590|NCT00095628|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89269591|NCT01082562|Experimental|Arm 1 - BMS-844421|
88821607|NCT03300427|Experimental|sacubitril/valsartan|subjects received sacubitril/valsartan 100 mg orally twice daily (BID). The dose was then up-titrated to 200 mg BID (or maintained at the starting dose level, if up-titration was not possible).
89269592|NCT01082562|Placebo Comparator|Arm 2 - 0.9% sodium chloride injection solution|
89269593|NCT01082562|Experimental|Arm 3 - BMS-844421|
89269594|NCT01082562|Placebo Comparator|Arm 4 - 0.9% sodium chloride injection solution|
89269595|NCT01082562|Experimental|Arm 5 - BMS-844421|
89269596|NCT01082562|Placebo Comparator|Arm 6 - 0.9% sodium chloride injection solution|
89269597|NCT01082562|Experimental|Arm 7 - BMS-844421|
89269598|NCT01082562|Placebo Comparator|Arm 8 - 0.9% sodium chloride injection solution|
89269599|NCT01082562|Experimental|Arm 9 - BMS-844421|
89269600|NCT01082562|Placebo Comparator|Arm 10 - 0.9% sodium chloride injection solution|
89269601|NCT01082562|Experimental|Arm 11 - BMS-844421|
89269602|NCT01082562|Placebo Comparator|Arm 12 - 0.9% sodium chloride injection solution|
89269603|NCT01082562|Experimental|Arm 13 - BMS-844421|
89269604|NCT01082562|Placebo Comparator|Arm 14 - 0.9% sodium chloride injection solution|
89269605|NCT01082562|Experimental|Arm 15 - BMS-844421|
89269606|NCT01082562|Placebo Comparator|Arm 16 - 0.9% sodium chloride injection solution|
89269607|NCT01086930|Experimental|Intervention Group|"In addition to standard care participants in Group A will receive:~• One hour of extra hand training five times per week for 8 weeks using the ReJoyce Workstation.~The training will be supervised by a therapist and provided to the target hand. The hand exercises will be incorporated into computer games and will involve the following tasks using different manipulanda:~reaching~grasping~manipulating~pulling~rotating~releasing"
89269608|NCT01086930|Other|Standard Care Group|Participants in the control group will not receive any training on the instrumented workstation or electrical stimulation to the hand or upper limb. They will however continue to receive standard care as well as three 15-minute specific hand activity sessions per week specifically devoted to the practice of hand activities in a one-to-one format with a therapist (as per the treatment received by the experimental group).
89269609|NCT03748576|Experimental|Mobile technologies group|m-health group (Intervention Group) participants were managed continuously through WeChat group chat during prenatal clinic interval.
89269610|NCT03748576|No Intervention|control group|Standard Clinic Prenatal Care (Control Group): regular routine prenatal care following Chinese standard.
89269611|NCT03963180|No Intervention|control group|the control group received 3 cups hot water on the 6th, 12th and 18th hours after the operation
89269612|NCT03963180|Experimental|study group|drank 3 cups of caffeinated coffee on the 6th, 12th and 18th hours after the operation.
89269613|NCT03963024|Experimental|Single Arm Treatment|"Conditioning treatment Treosulfan+TMI; SCT; GvHD prophylaxis;"
89269614|NCT01082718|Experimental|Pregnant women|Pregnant women with P. falciparum malaria
89269615|NCT01082718|Active Comparator|Non pregnant women|Non pregnant women with P. falciparum malaria
89269616|NCT02531100|Experimental|BonyPid-500TM implantation|Standard of care (SOC) treatment (Manual and ultrasonic debridement and surface decontamination) followed by BonyPid-500TM implantation.
89269617|NCT02531100|Other|SOC treatment|Standard of care treatment (Manual and ultrasonic debridement and surface decontamination) only
89269618|NCT01583010|No Intervention|Standard Treatment Group|Patients receiving ultrasound guided regional anaesthesia without using Advanced Needle Visualization Technology(R)
89269619|NCT01583010|Active Comparator|ANV ® Group|Patients receiving ultrasound guided regional anaesthesia with using Advanced Needle Visualization Technology(R)
89269620|NCT04380142|Experimental|ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD)|After an open-label LD/CD Stabilization Period, participants will receive double-blind ABBV-951 by continuous subcutaneous infusion (CSCI) and oral placebo for LD/CD for 12 weeks
89269621|NCT04380142|Active Comparator|Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951|After an open-label LD/CD Stabilization Period, participants will receive double-blind oral LD/CD and CSCI of placebo for ABBV-951 for 12 weeks
89269622|NCT04375696|Experimental|Product|75 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
89269623|NCT04375696|Placebo Comparator|Placebo|75 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in > 75 kg
89269624|NCT03748498|Experimental|laser group|Low level laser was applied for 60 second per tooth using Nd-YAG laser.
89269625|NCT03748498|Placebo Comparator|placebo group|The same procedures as in the laser group were performed, been completed but the laser was not activated in this group.
89269626|NCT04336228|Placebo Comparator|Healthy Control Group|The healthy placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
89269627|NCT04336228|Placebo Comparator|Obsessive-Compulsive Disorder / High Compulsivity Control Group|The OCD/high compulsivity placebo control group will be administered the exact same procedure as the intervention group, the only difference being that this group will be administered a placebo tablet.
89269628|NCT04336228|Experimental|Healthy Intervention Group|The healthy intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
89269629|NCT04336228|Experimental|Obsessive-Compulsive Disorder / High Compulsivity Intervention Group|The OCD/high compulsivity intervention group will be administered 20mg of Escitalopram daily for 3-4 weeks.
89269630|NCT03937180|Other|Usual care|Patients will receive 'usual care' left at the discretion of the treating general practitioner (GP). They are expected to follow the Belgian guidelines, which propose education of the patient about the harmful effects of chronic benzodiazepines and z-drugs ((z-)BZD) use, the alternatives, and the advice to discontinue (z-)BZD use. A stepped approach is recommended. First, a minimal intervention strategy such as a discontinuation letter or a short advice is applied. If unsuccessful, a brief intervention, which may span one or more consults, is recommended. During such an intervention, the GP will - based on the principles of motivational interviewing- assess the patient's readiness for change and match the appropriate intervention. A tapering scheme will be developed which typically consists of a 10-20% reduction in the daily dose of the (z-)BZD every 2-4 weeks.
89290543|NCT03924960|Experimental|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
89269631|NCT03937180|Experimental|Blended care|Usual care is supported by the use of an interactive e-tool. The e-tool provides psycho-education about sleep and sleep medication, and exercises featuring cognitive behavioural techniques to enhance the self-management of the patient. It's purpose is to motivate patients to discontinue the use of (z-)BZD, to adapt alternative remedies and to support them in this process. The patient can grant the participating GP access to all his answers in the e-tool, making it possible to discuss their findings and experiences face-to-face. During consultations, the GP will also assess the patients' readiness for change and match the appropriate intervention. A tailored gradual taper of the (z-)BZD will be agreed upon, which typically consists of a 10-20% reduction in the daily dose every 2-4 weeks. Follow-up appointments are scheduled depending on the needs of the patient until the end of dose reduction.
89269632|NCT03917446||Euvolaemic|Patients with stroke volume variation less than 8%
89269633|NCT03917446||Hypovolaemic|Patients with stroke volume variation greater than 13%
89269634|NCT04335136|Active Comparator|Group A (active) APN01|Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01
89269635|NCT04335136|Placebo Comparator|Group B (placebo control)|
89269636|NCT03748108|Experimental|lidocaine|A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
89269637|NCT03748108|Placebo Comparator|Placebo|A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.
89269638|NCT04171414|Experimental|"CT-P17 SC AI (adalimumab)"|CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)
89269639|NCT04167670|Experimental|Vonoprazan dual therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g, three times daily, for 14 days.
89269640|NCT04167670|Experimental|Vonoprazan triple therapy|Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg, BID, for 14 days.
89269641|NCT04167670|Active Comparator|Lansoprazole triple therapy|Participants will receive lansoprazole 30 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg BID, for 14 days.
89269642|NCT03747406|Experimental|ESP group|The patient rolled to his side, the level between T9 and T10 identified using ultrasound. An 8-14 MHz curved array probe (Siemens ACUSON X300 Ultrasound System) will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced inplane until contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration confirmed. The same procedure will be repeated in the contralateral side.
89269643|NCT03747406|Experimental|TAP group|The patient in supine position. Under complete aseptic conditions, a linear array transducer 5-12 MHz (Siemens ACUSON X300 Ultrasound System) will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
89269644|NCT03747406|No Intervention|opioid group|will receive intravenous morphine with general anesthesia and total opioid consumption will be calculated
89269645|NCT03747250|Experimental|Videolaryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of videolaryngoscope
89269646|NCT03747250|Active Comparator|Direct laryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of direct laryngoscopy
89269647|NCT00113516|Experimental|1|
89269648|NCT03251326|Experimental|Nabilone|Nabilone capsules (4 mg)
89269649|NCT03251326|Active Comparator|Propranolol|Propranolol capsules (40mg)
89269650|NCT03251326|Experimental|Smoked cannabis|(0.0 and 5.6% THC)
89269651|NCT03251326|Placebo Comparator|Placebo|Placebo capsules
89269652|NCT04140292|Experimental|Vitamin D3 + Photodynamic therapy (PDT)|Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.
89269653|NCT04138810|Experimental|post-op VCE|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The VCE group will conduct their encounter via the videoconference section of the MyChart mobile applications. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
89269654|NCT04138810|Active Comparator|Office post-operative visits|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The traditional follow up group will receive a telephone call from the office nurse as is current standard of care. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
89269655|NCT00127166|Experimental|Montelukast/Salmeterol|Period I - Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
89269656|NCT00127166|Experimental|Salmeterol/Montelukast|Period I - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
89269657|NCT00125138|Experimental|Melperone HCl - 20 mg|
89269658|NCT00125138|Experimental|Melperone HCl - 40 mg|
89269659|NCT00125138|Experimental|Melperone HCl - 60 mg|
89269660|NCT00125138|Placebo Comparator|Placebo|
89269661|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 1|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/medium low dose) after extraction of third molars
89269662|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 2|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/low dose) after extraction of third molars
89269663|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 3|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ medium low dose) plus one tablet of placebo after extraction of third molars
89269664|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 4|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ low dose) plus one tablet of placebo after extraction of third molars
89269665|NCT04132336|Active Comparator|Naproxen sodium|Participants received a single dose of one tablet of naproxen sodium (low dose) plus one tablet of placebo after extraction of third molars
89269666|NCT04132336|Active Comparator|Caffeine|Participants received a single dose of two tablets of caffeine (medium low dose) after extraction of third molars
89269667|NCT04132336|Placebo Comparator|Placebo|Participants received a single dose of two tablets of matching placebo after extraction of third molars
89269668|NCT04131556|Experimental|Part 1: Sequence ABC|Participants will receive 200 milligram (mg) of maribavir tablet orally (Sequence A) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
89269669|NCT04131556|Experimental|Part 1: Sequence BCA|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
89269670|NCT04131556|Experimental|Part 1: Sequence CAB|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
89269671|NCT04131556|Experimental|Part 1: Sequence CBA|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
89269672|NCT04131556|Experimental|Part 1: Sequence ACB|Participants will receive 200 mg of maribavir tablet orally (Sequence A) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
89269673|NCT04131556|Experimental|Part 1: Sequence BAC|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 and with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
89269674|NCT04131556|Experimental|Part 2: Sequence DEGF|Participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 1 followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 4 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 7 and then followed by participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
89269675|NCT04131556|Experimental|Part 2: Sequence EFDG|Participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 1 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 4 followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 7 and then followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
89269676|NCT04131556|Experimental|Part 2: Sequence FGED|Participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 1 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 4 followed by participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 7 and then followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
89269677|NCT04131556|Experimental|Part 2: Sequence GDFE|Participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 1 followed by participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 4 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 7 and then followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
89269678|NCT04315636|Experimental|Surfactant nebulisation|The experimental group will receive a positive end-expiratory pressure (PEEP, +/- noninvasive positive pressure ventilation) and nebulised surfactant via a customised vibrating membrane nebuliser. Nebulisation will commence with the first application of a PEEP and will continue for a maximum of 30 minutes.
89269679|NCT04315636|No Intervention|Standard care|The control group will receive standard care (PEEP, +/- noninvasive positive pressure ventilation, without surfactant nebulisation).
89269680|NCT04295356|Active Comparator|Auto injector|a single dose (40 mg) of CT-P17 via AI
89269681|NCT04295356|Active Comparator|Pre-filled syringe|a single dose (40 mg) of CT-P17 via PFS
89269682|NCT03691948|Experimental|ROPEs|
89269683|NCT03691948|Active Comparator|Control|
89269684|NCT04126174|Active Comparator|Femtosecond limbal relaxing incision (LRI)|Eyes will be treated with arcuate incisions from a femtosecond laser system.
89269685|NCT04126174|Active Comparator|Manual LRI|Eyes will be treated with arcuate incisions completed manually with a blade.
89269686|NCT04124926|Experimental|Healing Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 8 weeks.
89269687|NCT04124926|Active Comparator|Healing Phase: Lansoprazole 30 mg|Participants will receive oral lansoprazole 30 mg once per day (QD) for a maximum of 8 weeks.
89269688|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 10 mg|Participants will receive oral vonoprazan 10 mg once per day (QD) for a maximum of 24 weeks.
89269689|NCT04124926|Experimental|Maintenance Phase: Vonoprazan 20 mg|Participants will receive oral vonoprazan 20 mg once per day (QD) for a maximum of 24 weeks.
89269690|NCT04124926|Active Comparator|Maintenance Phase: Lansoprazole 15 mg|Participants will receive oral lansoprazole 15 mg once per day (QD) for a maximum of 24 weeks.
89269691|NCT03746158|Experimental|Curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
89269692|NCT05321056|Experimental|Intervention group: Mask on model face|"The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model.~Vitamin B2 saline solution of the same dose will be dripped into each patient's mouth before EGD examination, as a fluorescent tracer."
89269693|NCT05321056|No Intervention|Control group: No mask on model face|"No mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model.~Vitamin B2 saline solution of the same dose will be dripped into each patient's mouth before EGD examination, as a fluorescent tracer."
89269694|NCT03753100|Active Comparator|Periprosthetic BMD; anterolateral approach|Periprosthetic bone mineral density will be measured using a DXA scanner from GE Lunar Prodigy. The initial scan was performed post-operatively during hospitalization
89269695|NCT03753100|Active Comparator|Periprosthetic BMD; lateral approach|Periprosthetic bone mineral density will be measured using DXA scanner from GE Lunar Prodigy.The initial scan was performed post-operatively during hospitalization.
89269696|NCT03747094|Active Comparator|Fentanyl group|
89269697|NCT03747094|Experimental|Ketamine group|
89269698|NCT04274686|Experimental|Bag-Mask Ventilation with Tegaderm|Patients will receive bag-mask ventilation with Tegaderm placement
89269699|NCT04274686|Active Comparator|Bag-Mask Ventilation without Tegaderm|Patients will receive bag-mask ventilation without Tegaderm placement
89269700|NCT03753022|Sham Comparator|Group G5|Patients submitted to CABG and peep 5
89269701|NCT03753022|Experimental|Group G10|Patients submitted to CABG and peep 10
89269702|NCT03753022|Experimental|Group G15|Patients submitted to CABG and peep 15
89269703|NCT03752944|Experimental|prebent plate|fixation of le fort I osteotomy using prebent plate
89269704|NCT03752944|Active Comparator|Conventional four miniplates|fixation of le fort I osteotomy using conventional four miniplates
89269705|NCT03752788|Experimental|Dual-task Training Fixed Priority|"Dual-task Training with fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
89269706|NCT03752788|Active Comparator|Dual-task Training Variable Priority|"Dual-task Training with variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
89269707|NCT04113694|Experimental|Extended Wear Infusion Set|Each subject is given 12 Extended Wear Infusion Sets to wear.
89269708|NCT03745846|Experimental|Composite Gel Containing Black Raspberry|Drug:Composite Gel Containing Black Raspberry 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
89269709|NCT03745846|Placebo Comparator|Composite Gel Containing Black Raspberry-placebo|Drug:Composite Gel Containing Black Raspberry-placebo 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
88821608|NCT03300427|Active Comparator|valsartan|subjects received 80 mg orally twice daily (BID). The dose was then up-titrated to 160 mg BID (or maintained at the starting level, if up-titration was not possible)
89269710|NCT04105972|Active Comparator|TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks.
89269711|NCT04105972|Experimental|ELX/TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
89269712|NCT04102540|Experimental|Infographic intervention group|Participants in the infographic intervention group will receive health education using infographics during a study visit scheduled immediately following their regularly scheduled clinic visits.
89290544|NCT03924960|Active Comparator|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
89290545|NCT03924960|Other|Control|Usual care control group
89290546|NCT01223820|Experimental|Capsaicin|
89269713|NCT00124982|Experimental|Open-label Abatacept (ABA)-Previous User|In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
89269714|NCT00124982|Experimental|Open-label ABA-Current User|In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
89269715|NCT00124982|Experimental|Long-term ABA|Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.
89269716|NCT04263142|Experimental|Part 1: Treatment AB|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
89269717|NCT04263142|Experimental|Part 1: Treatment BA|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
89269718|NCT04263142|Experimental|Part 2: Treatment CDE|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
89269719|NCT04263142|Experimental|Part 2: Treatment DEC|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
89269720|NCT04263142|Experimental|Part 2: Treatment ECD|Participants will receive a single dose of GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
89269721|NCT04095286|Experimental|AMB dispersed in water/AMB oral tablet/reference AMB|Eligible participants will receive a single oral dose of 5 milligram (mg) AMB tablet dispersed in water during treatment period 1 followed by a single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive a single oral dose of reference 5 mg AMB tablet. There will be a washout period of 7 days between doses in each treatment period.
89269722|NCT04095286|Experimental|AMB oral tablet/reference AMB/AMB dispersed in water|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive single dose of 5 mg AMB tablet dispersed in water. There will be a washout period of 7 days between doses in each treatment period.
89269723|NCT04095286|Experimental|Reference AMB/AMB dispersed in water/AMB oral tablet|Eligible participants will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
89269724|NCT04095286|Experimental|AMB dispersed in water/reference AMB/AMB oral tablet|Eligible participants will receive single dose of 5 mg AMB tablet dispersed in water during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
89269725|NCT04095286|Experimental|AMB oral tablet/AMB dispersed in water/reference AMB|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of reference 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
89269726|NCT04095286|Experimental|Reference AMB/AMB oral/AMB dispersed in water|Eligible participants in this arm will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB tablet dispersed in water There will be a washout period of 7 days between doses in each treatment period.
89269727|NCT04093414|Active Comparator|Selective or Non selective His Bundle Pacing|Pacemaker wires placed in Bundle of His
89269728|NCT04093414|Active Comparator|Left Bundle Area Pacing|Pacemaker wires placed in Left Bundle Branch area
89269729|NCT04093258|Experimental|Test/Control|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
89269730|NCT04093258|Experimental|Control/Test|Eligible subjects between 40-70 years of age who are habitual soft contact lens wearers and hyperopic or myopic and have presbyopia will be randomized to one of two sequences (Test/Control or Control/Test) with a 4-10 day washout period in between each fitting.
89269731|NCT04253236|Experimental|Cohort 1|Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
89269732|NCT04253236|Experimental|Cohort 2|Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
89269733|NCT04087720|Experimental|Pegloticase|Participants receive 8 mg pegloticase every 2 weeks from Day 1 through Week 22
89269734|NCT03747016|Experimental|High energy 2|In the second step, the experimental group (Group E2) was given high energy digestible food 300ml before the time of gastric emptying found in the first step before surgery.
89269735|NCT03747016|Active Comparator|Glucose 2|In the second step, Group G2 is given 5% glucose injection 300ml before the time of gastric emptying found in the first step before surgery.
89269736|NCT03747016|Placebo Comparator|Normal saline 2|In the second step, Group N2 is given normal saline 300ml before the time of gastric emptying found in the first step before surgery.
89269737|NCT03747016|No Intervention|Control 2|In the second step, the control group (Group C2) was not given any diet before surgery.
89269738|NCT03747016|Experimental|High energy 1|In the first step,The experimental group (Group E1) is treated with high energy digestible food 300ml.
89269739|NCT03747016|Active Comparator|Glucose1|In the first step, Group G1 is given 5% glucose injection 300ml
89269740|NCT03747016|Placebo Comparator|Normal saline 1|In the first step, Group N1 is given normal saline 300ml.
89269741|NCT04086472|Experimental|Clesrovimab 100 mg|Participants receive a single IV infusion of clesrovimab 100 mg on Day 1.
89269742|NCT04086472|Experimental|Clesrovimab 200 mg|Participants receive a single IV infusion of clesrovimab 200 mg on Day 1.
89269743|NCT04086472|Experimental|Clesrovimab 300 mg|Participants receive a single IV infusion of clesrovimab 300 mg on Day 1.
89269744|NCT04086472|Experimental|Clesrovimab 900 mg|Participants receive a single IV infusion of clesrovimab 900 mg on Day 1.
89269745|NCT04086472|Placebo Comparator|Placebo|Participants receive a single IV infusion of placebo on Day 1.
89269746|NCT03752632|Experimental|Veinplicity with tourniquet (treatment)|Veinplicity with tourniquet
89269747|NCT03752632|Active Comparator|Tourniquet (control)|Control: Tourniquet
89269748|NCT04249336|Experimental|BioMin F Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
89269749|NCT04249336|Active Comparator|Colgate Sensitive Pro relief Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
89269750|NCT04249336|Active Comparator|Sensodyne Rapid Action Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
89269751|NCT04249336|Placebo Comparator|Colgate Total Trade Mark|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
89269752|NCT03752476||case|Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
89269753|NCT03752476||control|Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
89269754|NCT04245202|Active Comparator|Active Comparator: HFNCOT|Set between 2 to 25 l/min, adjusted to obtain peripheral oxygen saturation >92%.
89269755|NCT04245202|Active Comparator|Active Comparator: St-FMOT|To obtain oxygen saturation >92%
89269756|NCT03979924|Other|Interventional Step|The interventional step will comprise the same follow-up as the observational step, except for the addition of an early and preventive care, conducted by a specialized physiotherapist using an active exercise handbook elaborated with the patient's therapeutic education transversal Unit (Utep). This aims at increasing the patient's adhesion to the program and to limit the reduction of mouth opening and its consequences ( Trismus rehabilitation)
89269757|NCT03752320||POP+ and POP-|POP+: patients with postoperative pneumonia POP-: patients without postoperative pneumonia
89269758|NCT03752164|Experimental|Yoga and Mindfulness|An intervention consisting of one session lasting 30 minutes where a certified yoga instructor teaches the children gentle yoga and mindfulness skills.
89269759|NCT04079842|Experimental|INVSENSOR00029|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
89269760|NCT04078126|Experimental|Budesonide and formoterol fumarate (MDI BFF)|Subject treated with MDI BFF followed by washout period
89269761|NCT04078126|Active Comparator|Symbicort Turbuhaler|Subject treated with Symbicort followed by washout period
89269762|NCT04073368|Active Comparator|AXA1957 high dose|AXA1957 20.3g
89269763|NCT04073368|Active Comparator|AXA1957 low dose|AXA1957 13.5g
89269764|NCT04073368|Active Comparator|AXA1125|AXA1125 24g
89269765|NCT04073368|Placebo Comparator|Placebo|Placebo 24g
89269766|NCT03745456||Subarachnoid Hemorrhage patients|Patients with severe subarachnoid hemorrhage (Hunt and Hess 4-5, Fisher 3-4) will be included initially in the first 6 hours after the onset of symptoms.
89269767|NCT04380688|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
89269768|NCT04380688|No Intervention|Arm 2|Best Supportive Care
89269769|NCT00124748|Experimental|Imatinib 400 mg|Oral dose of 400mg Imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol.
89269770|NCT00124748|Experimental|imatinib 800 mg|Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.
89269771|NCT01078064||Study group|Patients with symptoms suggesting gastroesophageal reflux and referred to perform an impedance study.
89269772|NCT04070326|Experimental|Lanadelumab 150 mg: Age 2 to <6 Years|Participants aged 2 to <6 years received lanadelumab subcutaneous (SC) injection at a dose of 150 milligrams (mg) for every 4 weeks (q4wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B).
89269773|NCT04070326|Experimental|Lanadelumab 150 mg: Age 6 to <12 Years|Participants aged 6 to <12 years received lanadelumab SC injection at a dose of 150 mg for every 2 weeks (q2wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B). Participants could switch to a dosing regimen of 150 mg q4wks in Treatment Period B at the investigator's discretion and sponsor's medical monitor approval, if they were well controlled (e.g., attack free) for 26 weeks with lanadelumab treatment in this study.Participants aged 6 to <12 years received lanadelumab SC injection at a dose of 150 mg for every 2 weeks (q2wks) over 52-week Treatment Period (26-week Treatment Period A and 26-week Treatment Period B). Participants could switch to a dosing regimen of 150 mg q4wks in Treatment Period B at the investigator's discretion and sponsor's medical monitor approval, if they were well controlled (e.g., attack free) for 26 weeks with lanadelumab treatment in this study.
89269774|NCT01078142|Experimental|Single arm|Bendamustin, Rituximab, Temsirolimus
89269775|NCT03689452|Placebo Comparator|Control|15 participants will receive 3 mL of preservative free normal saline injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
89269776|NCT03689452|Experimental|Treatment|15 participants will receive 3-6 mL of platelet rich plasma injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
89269777|NCT04067050|Experimental|comfilcon A asphere|Subjects will wear their comfilcon A asphere contact lenses for two months. Lenses will be worn on a daily wear, reusable basis for at least 8 hours per day, 5 days per week.
89269778|NCT04067050|Active Comparator|Habitual Spectacles|Subjects will wear their single vision habitual spectacles for two months for at least 8 hours per day, 5 days per week.
89269779|NCT04060654|Experimental|SUBLOCADE|All subjects will receive SUBLOCADE 300mg on Day 1, followed by injections every 4 weeks at a dose determined by the Investigator (either 100 mg or 300 mg) for up to 5 total injections
89269780|NCT00096200|Experimental|Arm I (closed to accrual 10/10/2008)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression crossover to arm II
89269781|NCT00096200|Experimental|Arm II|Patients receive oral sorafenib twice daily on days 2-19. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89269782|NCT04059094|Placebo Comparator|Placebo|2 puffs ofmatching placebowere inhaledorally via theRespimat®inhaler twice dailyfor a treatmentperiod of 4 weeksin patients withcystic fibrosis.
89269783|NCT04059094|Experimental|BI 1265162 50 μg b.i.d.|2 puffs of 25micrograms (μg)BI 1265162(Total: 50μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:100μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
89269784|NCT04059094|Experimental|BI 1265162 100 μg b.i.d.|2 puffs of 50micrograms (μg)BI 1265162(Total: 100μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:200μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
89269785|NCT04059094|Experimental|BI 1265162 200 μg b.i.d.|2 puffs of 100micrograms (μg)BI 1265162(Total: 200μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:400μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
89269786|NCT04059094|Experimental|BI 1265162 20 μg b.i.d.|2 puffs of 10micrograms (μg)BI 1265162(Total: 20μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:40μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
89269787|NCT03745378||Cases|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, who experienced secondary cancer(s) diagnosed at presentation of MPN or during the course of the myeloproliferative disease.
89269788|NCT03745378||Controls|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, without history of secondary cancer.
89269789|NCT00096044|Experimental|Oral Lenalidomide|Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
89269790|NCT01082822|Sham Comparator|standard of care|In the first step, the patient was periodontally treated until the inflammation was eliminated through control of bacterial biofilm and oral hygiene for about 6 months. Then the rigid fixed appliances were placed on the diseased teeth, reverse beveled open-flap surgery was performed in the buccal and palatal maxillary sides of the periodontitis-caught teeth to allow granulation tissue debridement and proper root preparation. The roots were completely scaled, and 17%EDTA was applied for 2 minutes to demineralize the root surfaces and bone wall defects, the flap was sutured.
89269791|NCT01082822|Experimental|PDLSC cell sheet transplantion|Periodontal ligament stem cell derived cell sheet or pellet with carrier such as Bioss was implanted into periodontal defect area at post surgical treatment.
89269792|NCT01082822|Experimental|the bio-ss implantation|implantation of Bioss at post surgical treatment
89269793|NCT03963128|Active Comparator|Supplemented Vitamin D3|
89269794|NCT03963128|Placebo Comparator|Placebo|
89269795|NCT01082900|Experimental|Prophylactic CPAP intervention|Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the DR via T piece (Neopuff)
89269796|NCT01082900|Active Comparator|No Intervention|Provision of standard care in the Delivery Room
89269797|NCT01082978|Experimental|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
89269798|NCT01082978|Experimental|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
89269799|NCT01082978|No Intervention|Usual standard of care|Patients randomized to this arm of the trial will not be given a Portable Health File. This arm is the concurrent control comparator arm.
89269800|NCT03963050|Experimental|CF|30 participants (randomized in 3 groups) with CF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
89269801|NCT03963050|Experimental|PF|30 participants (randomized in 3 groups) with PF will perform a program of intervention for 1 hour a day, 3 days per week, for 1 year.
89269802|NCT01083056||Epimacular Gliosis Without Macular Hole|
89269803|NCT01083056||Epimacular Gliosis With Macular Hole|
89269804|NCT01083134||percentage of stenosis|
89269805|NCT03962660|Experimental|HaRTS-TRENDS|See description below.
89269806|NCT03962660|Active Comparator|Standard Care (SC)|See description below.
89269807|NCT03962582|Experimental|Supportive Back Comparison|Motion Concepts matrx back to be attached to individual's wheelchair in place of the individual's back. It will be adjusted for size and to support the spinal curves as compared to a fabric back
89269808|NCT01083212|Experimental|1|Gemfibrozil day 1-5 + AZD1656 day 4, 1 week without, Placebo day 1-5 + AZD1656 day 4
89269809|NCT01083212|Experimental|2|Placebo day 1-5 + AZD1656 day 4, 1 week without, Gemfibrozil day 1-5 + AZD1656 day 4
89269810|NCT01083290|Experimental|Order of strenghts; 25 mg, 50 mg, 100 mg|
89269811|NCT01083290|Experimental|Order of strenghts; 50 mg, 100 mg, 25 mg|
89269812|NCT01083290|Experimental|Order of strenghts; 100 mg, 25 mg, 50 mg|
89269813|NCT01326650|Experimental|Vitamin D|daily vitamin D supplement
89269814|NCT01326650|Placebo Comparator|placebo|daily placebo supplement
89269815|NCT03689374|Experimental|Semaglutide|"Run-in period (12 weeks): subjects will be treated with metformin and insulin glargine (IGlar) U100.~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in will receive semaglutide for 52 weeks in addition to metformin and IGlar U100.~Metformin will be considered as background therapy during the trial."
89269816|NCT03689374|Active Comparator|Insulin aspart|"Run-in period (12 weeks): subjects will be treated with metformin and insulin IGlar U100.~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in receive insulin aspart for 52 weeks in addition to metformin and IGlar U100.~Metformin will be considered as background therapy during the trial."
89269817|NCT01083446|Active Comparator|A|Nutritional intervention, standard Israeli breakfast
89269818|NCT01083446|Active Comparator|B|Nutritional Intervention, fast
89269819|NCT03745300|Active Comparator|GROUP 1|Scaling and root planing (SRP) followed by 1.2% atorvastatin gel local drug delivery
89269820|NCT03745300|Active Comparator|GROUP 2|Scaling and root planing (SRP) followed by 1.2% simvastatin gel local drug delivery
89269821|NCT03745300|Placebo Comparator|GROUP 3|Scaling and root planing (SRP) followed by placebo gel local drug delivery
89269822|NCT00112736|Experimental|Phase 1 (erlotinib & temsirolimus)|"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.~pharmacological study: Correlative studies"
89269823|NCT00112736|Experimental|Phase 2 temsirolimus MTD & erlotinib|"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.~PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.~therapeutic conventional surgery: Undergo surgical resection~laboratory biomarker analysis: Correlative studies"
89269824|NCT00123422|Experimental|Breathing retraining|Exercise training with computerized training program
89269825|NCT00123422|Experimental|Heliox|Exercise training with helium oxygen combination
89269826|NCT00123422|Active Comparator|Exercise|Exercise training
89269827|NCT04052620|Experimental|Diclofenac diethylamine (DDEA) 2.32%/ Placebo gel|Participants will receive 4 tubes, DDEA 2.32% gel and Placebo gel (2 each) and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm^2). DDEA 2.32% gel will be applied in morning and late afternoon and Placebo gel will be applied in noon and late evening for 7 days.
89269828|NCT04052620|Active Comparator|DDEA 1.16% gel|Participants will receive 4 tubes of DDEA 1.16% gel and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm^2) in morning, noon, late afternoon, and late evening for 7 days.
89269829|NCT01083524|Experimental|Group 1|Dichloroacetate Sodium 3.0 mg/kg, BID
89269830|NCT01083524|Experimental|Group 2|Dichloroacetate Sodium 6.25 mg/kg, BID
89269831|NCT01083524|Experimental|Group 3|Dichloroacetate Sodium 12.5 mg po bid
89269832|NCT05018260|Experimental|GCMRT|Attention bias modification: participants will receive gaze-contingent feedback according to their viewing patterns on disgusted and neutral faces
89269833|NCT05018260|Experimental|attention control|Attention control modification: participants will receive gaze-contingent feedback according to their viewing patterns on rounded and sharp geometric shapes
89269834|NCT03752086|Experimental|Greater omentum binding|Bind greater omentum to pancreatic stump after distal pancreatectomy
89269835|NCT03752086|Experimental|Pancreatic stump exposed|pancreatic stump exposed without binding greater omentum after distal pancreatectomy
89269836|NCT04238650|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
89269837|NCT04238650|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
89269838|NCT03752008|Experimental|Active Play (AP)|This arm received the Active Play curriculum intervention (described in following section).
89269839|NCT03752008|Experimental|Outdoor Play (OP)|This arm received the Outdoor Play curriculum intervention (described in following section).
89269840|NCT03751930||Patients with Autism Spectre Disorders|Taken biological samples on patients with Autism Spectre Disorders
89269841|NCT03751930||Healthy volunteers|Taken biological samples on patients healthy volunteers
89269842|NCT00095576|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
89269843|NCT00095576|Placebo Comparator|Placebo|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.
89269844|NCT04049578|Experimental|Balovaptan|
89269845|NCT04044352|Experimental|Group 1|2 mL (approximately 5x10^6/mL tissue culture infective dose (TCID50)) of influenza A/Bethesda/MM2/H1N1challenge virus administered intranasally via a sprayer on Day 1. N=80.
89269846|NCT04043962|Experimental|Web-based CBT (Web-MAP)|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
89269847|NCT04043728|Experimental|Mindfulness|This module introduces mindfulness training skills, with the goal of cultivating nonjudgmental, present-focused experience of emotions, thoughts, and physical sensations related to cigarette smoking. By progressing though a series of experiential exercises (e.g., awareness of the breath, anchoring in the present), this module seeks to reduce maladaptive attempts to control negative emotions and facilitate tolerance of the physical and emotional symptoms of nicotine withdrawal.
89269848|NCT04043728|Experimental|Interoceptive Exposure (Practice Quitting)|This module introduces interoceptive exposure, a technique in which participants purposefully and systematically complete exercises to evoke physical sensations typically associated with anxiety and distress, in order to reduce fear and avoidance of these sensations. Interoceptive exercises will focus on a gradual exposure to nicotine withdrawal symptoms, through a series of 'practice quit attempts' (i.e., brief periods of smoking abstinence without intention to permanently quit).
89269849|NCT04043728|Experimental|Behavioral Activation (Countering Emotional Behaviors)|This module introduces behavioral activation, which seeks to increase positive emotions by systematically introducing greater engagement with natural rewards. Treatment sessions focus on the identification of avoidance strategies, including cigarette smoking as a coping strategy for negative emotions. The goal of this treatment module is to replace smoking with adaptive coping strategies to facilitate contact with and enjoyment of reinforcing activities that are incompatible with smoking.
89269850|NCT04043416|Experimental|System + Fall Prevention First, then Fall Prevention|"Participants in this arm will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the first 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program. Following the 6 week washout period, the participants in this arm will just participate in the Fall Prevention program alone.~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
89269851|NCT04043416|Experimental|Fall Prevention first, then System +Fall Prevention|"Participants in this arm will participate in the Fall Prevention program alone during the first 6 week campaign. Following the 6 week washout period the participants will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the second 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
89269852|NCT00095498|Experimental|Denosumab 180 mg|Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
89269853|NCT00095498|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
89269854|NCT00095498|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections on Day 1 and at Month 6.
89269855|NCT04237792|Experimental|dexmedetomidine low dose group|low dose of dexmedetomidine to be given
89269856|NCT04237792|Experimental|dexmedetomidine middle dose group|middle dose of dexmedetomidine to be given
89269857|NCT04237792|Experimental|dexmedetomidine high dose group|high dose of dexmedetomidine to be given
89269858|NCT00122954|Experimental|Fish oil concentrate|Fish oil concentrate
89269859|NCT00122954|Placebo Comparator|Placebo oil|Placebo oil
89269860|NCT04491994|No Intervention|Standard of Care (SOC)|Patients selected in supportive arm will be given daily standard doses of oral Vit C (2g), Vit D (alfacalcidiol 1µg), Zinc (50mg) and paracetamol (as required).
89269861|NCT04491994|Experimental|HCQ arm|Patients selected in experimental arm will be given Tab HCQ (400mg BD on D0 followed by 200mg BD D1-D5) in addition to supportive treatment
89269862|NCT01326572||female, male, HIV, lung disease|All participants in the University of Pittsburgh Multicenter AIDS Cohort Study are eligible for this protocol. All participants in the UCSF Women's HIV study are eligible and all Men from the UCLA men's HIV study are eligible
89269863|NCT04041700|Experimental|Osia 2 system|
89269864|NCT03225430|Active Comparator|Comprehensive Behavioural Intervention|"Participant will received psychoeducation about tic disorders, creating a tic hierarchy that will be revised during future sessions, introduce concept of function-based intervention, behavioral reward program, self-monitoring training, habit reversal training for their tics. They will received an introduction of relaxation techniques and diaphragmatic breathing exercise and an introduction of progressive muscle relaxation (PMR) exercise.~They will received booster sessions for three months and he will do hierarchy review, inconvenience review, function-based intervention and competing response review, review of relaxation techniques and relapse prevention review."
89269865|NCT03225430|Experimental|Cognitive psychophysiological (CoPs)|The participant will received a rational about the treatment and awareness training about tics and creating list of tics. He will identifying high and low risk situations provoking tics, do video record and make a list of inconveniences of tic. He will do a screening session of the video and muscle discrimination exercises. Worked on a situational profile with a Kelly's grill and beginning relaxation and breathing exercises. He will identifying style of planning and work on it to do an advantages and inconveniences list to adopt this style. Some behavioral and cognitive re structuration about style of planning and how to modifying. At the end, he will received a relapse prevention informations and how to generalize the learnings and a record of the therapy. Finally, he will have to practice all this techniques at home for four week and do a last session to discuss home practice and received strategies for the future.
89269866|NCT03746938|Experimental|VB-C01|Surgical technique: Via left lateral thoracotomy, the heart is lifted and supported on two deep pericardial points with 4-0 or 5-0 Prolene double arrmed suture. Each suture is passed through the reinforced frame of the collagen membrane containing the stem cells (VB-C01) and then tied, while the upper part of the patch is held with forceps. After securing the lower part of the pericardial layer, the heart is allowed to slowly recover its position with the pericardial cavity while the collagen membrane is mobilized to cover all of the target area. If necessary, some sutures can be used to fix the patch VB-C01 to the epicardial surface of the heart. Each suture is likewise passed through the reinforced frame of the membrane.
89269867|NCT04036630|Experimental|2kHz tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269868|NCT04036630|Sham Comparator|sham tACS (Experiment 1)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269869|NCT04036630|Experimental|2kHz tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269870|NCT04036630|Sham Comparator|sham tACS (Experiment 2)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269871|NCT04036630|Experimental|2kHz tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269872|NCT04036630|Sham Comparator|sham tACS (Experiment 3)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269873|NCT04036630|Experimental|env tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269874|NCT04036630|Active Comparator|time-reversed env-tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269875|NCT04036630|Sham Comparator|sham tACS (Experiment 4)|The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.
89269876|NCT03751852|Experimental|Exercise coaching group|This intervention is an integration of aerobic exercise, yoga, mindfulness and exercise coaching. Exercise class and coaching will be provided weekly in the first 8 weeks. In the next 8 week, exercise class will be provided weekly while exercise coaching will be provided bi-weekly. The exercise class includes aerobic exercise coached by a well-trained intervention officer, and the yoga and mindfulness coached by a certified yoga instructor. The exercise coaching session followed by some stretching and aerobic exercise session. Both motivational coaching and aerobic exercise will be coached by a well-trained intervention officer.
89269877|NCT03751852|Active Comparator|Psychoeducation group|This group is similar with the exercise coaching group while exercise coaching session will be substituted by psychoeducation session.
89269878|NCT04227340|Experimental|Photobiomodulation Therapy (PBM)|The PBM will be administered extra-oral and intra-oral.
89269879|NCT03744988||control group|serum androgen levels will be measured in 25 normotensive pregnant women
89269880|NCT03744988||mild preeclampsia|serum androgen levels will be measured in 25 mild preeclamptic patients
89269881|NCT03744988||severe preeclampsia|serum androgen levels will be measured in 25 severe preeclamptic patients
89269882|NCT04033432|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on day 1. Treatment repeats every 14 days for cycles 1-6 and then every 21 days for subsequent cycles. Patients may continue to receive sEphB4-HSA treatment until no longer clinically benefiting (PCWG3), unacceptable toxicity, treatment delay >= 4 weeks, or prohibitive illness/change in patient?s condition, or patient decides to withdraw from study.
89269883|NCT04223830|Experimental|Exalt DScope 01B|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
89269884|NCT04032652|Active Comparator|1200 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 1200 mg asacol
89269885|NCT04032652|Active Comparator|2400 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 2400 mg asacol
89269886|NCT04031404|Experimental|Glucose drink followed by placebo|Participants will consume the glucose drink at session 1, then they will consume the placebo (water) at session 2.
89269887|NCT04031404|Experimental|Placebo followed by glucose drink|Participants will consume the placebo (water) at session 1, then they will consume the glucose drink at session 2.
89269888|NCT05256628|Other|Early Weightbearing|Patients randomized to early weightbearing will be permitted to begin immediate postoperative weightbearing as tolerated with crutches for additional stability.
89269889|NCT05256628|Other|Protected Weightbearing|Patients in the protected weightbearing group will be instructed to be touch weightbearing for a period of 6-weeks postoperatively before commencing to be weightbearing as tolerated.
89269890|NCT03746782||ACS using clopidogrel + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of clopidogrel + aspirin
89269891|NCT03746782||ACS using ticagrelor + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of ticagrelor + aspirin
89269892|NCT03746782||Healthy Donors|Apixaban combined with blood specimens (in vitro) from healthy participants
89269893|NCT03746626||Hospice 1|Strathcarron Hospice, Scotland. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
89269894|NCT03746626||Hospice 2|Arthur Rank Hospice, England. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
89269895|NCT03746626||Hospice 3|All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
89269896|NCT03751696|Experimental|Group coaching|There will be a total of 4 sessions of group coaching intervention within 8 weeks. Each session is in a group of 5-6 women and lasts for approximately 1-1.5 hours. The sessions will be conducted by experienced social workers online.
89269897|NCT03751696|Active Comparator|SMS Self-help tips|The participants in the control group will receive four self-help tips on mental well-being on the same schedule as the group coaching group.
89269898|NCT04476784|Other|LID018869, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
89269899|NCT04476784|Other|Biofinity, then LID018869|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
89269900|NCT04026568|Experimental|Single dose 4AP|15mm opaque capsule containing 10mg of 4-AP
89269901|NCT04026568|Placebo Comparator|Placebo|Opaque capsule identical looking to the 4AP placebo pill
89269902|NCT04025632|Experimental|0.3 mg/kg zilucoplan|Daily subcutaneous (SC) injection
89269903|NCT04025632|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection
89269904|NCT04024228|Experimental|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
89269905|NCT04024228|Active Comparator|Group 2: QIV-SD|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
89269906|NCT04023994|Placebo Comparator|Placebo|In Cohorts 1-5, there were ten participants in total who received placebo, two in each cohort.
89269907|NCT04023994|Experimental|RO7126209 (0.1 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.1 mg/kg).
89269908|NCT04023994|Experimental|RO7126209 (0.4 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.4 mg/kg).
89269909|NCT04023994|Experimental|RO7126209 (1.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (1.2 mg/kg).
89269910|NCT04023994|Experimental|RO7126209 (3.6 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (3.6 mg/kg).
89269911|NCT04023994|Experimental|RO7126209 (7.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (7.2 mg/kg).
89269912|NCT04023682|Other|Anesthesia Provider hands|"Each provider will serve as their own control.~Control phase is at baseline using standard hygiene practices.~Intervention phase will include the addition of Provodine hand sanitizer"
89269913|NCT04018612|Active Comparator|High Dose Acetaminophen|High Dose Acetaminophen Post Op
89269914|NCT04018612|Active Comparator|Low Dose Acetaminophen|Low Dose Acetaminophen Post Op
89269915|NCT04018612|Placebo Comparator|Placebo|Placebo Post Op
89269916|NCT04209400|Experimental|Sci-B-Vac®|The 3-antigen HepB vaccine, Sci-B-Vac® contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac® was supplied in 1.0 ml vials.
89269917|NCT04209400|Active Comparator|Engerix-B®|The single-antigen HepB vaccine, Engerix-B® (GSK), contains the small S recombinant protein. Engerix-B® was supplied in 1.0 ml vials.
89269918|NCT03751540||OSTAP|Data of patients (performed oblique subcostal transversus abdominis plane-OSTAP- block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
89269919|NCT03751540||SIPB plus rectus sheath block|Data of patients (performed serratus intercostal plane block-SIPB- plus rectus sheath block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
89269920|NCT04207840|Experimental|Primatene Mist, E004|Participants who dosed with Primatene Mist.
89269921|NCT04207840|Active Comparator|Epinephrine Injection Auto-Injector (Generic of EpiPen)|Participants who were dosed with an Epinephrine Injection Auto-Injector.
89269922|NCT04207840|Active Comparator|Albuterol HFA|Participants who dosed with Albuterol HFA.
89269923|NCT03744754||Women with endometriosis|Women with endometriosis disease aged 18-36 years, with appropriate endometriosis diagnosis, based on transvaginal sonography, magnetic resonance imaging and/or previous surgery.Ovarian reserve was assessed by antral follicle counting (AFC) and measurement of serum anti-Mullerian hormone (AMH) levels Enrolled after preservation fertility procedure (vitrification of mature oocytes)
89269924|NCT03746548|Other|CM-ADHEAR|First patients use the Contact Mini (conventional bone conduction device used with a soft band or headband) then ADHEAR (adhesive bone conduction device)
89269925|NCT03746548|Other|ADHEAR - CM|First patients use ADHEAR (adhesive bone conduction device) then CM (conventional bone conduction device used with a soft band or headband)
89269926|NCT05226520|Experimental|Probiotic NCC3001|Sachets of NCC3001 and excipient (maltodextrin) to be administered orally every day for 6 weeks
89269927|NCT05226520|Placebo Comparator|Matched Placebo Comparator|Sachets of matching placebo containing maltodextrin, yeast extract, cystein HCl and pea flour to be administered orally every day for 6 weeks
89269928|NCT04006366|Other|Intervention|To test the effects of a 10-hour time restricted eating intervention before and after the 12 weeks of treatment on weight (primary), caloric and macronutrient intake, and a variety of psychosocial measures, including sleep, physical activity, blood pressure and eating behaviors (all secondary).
89269929|NCT03744520|Experimental|ESP block group|The patients who had paravertebral interfacial plane block for postoperative analgesia
89269930|NCT03744442|Active Comparator|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
89269931|NCT03744442|Active Comparator|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
89269932|NCT03744442|Active Comparator|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
89269933|NCT04191148|Experimental|LBP-EC01|crPhage cocktail
89269934|NCT04191148|Placebo Comparator|Placebo|Lactated Ringer's solution, injection, USP
89269935|NCT04004260|Experimental|Experimental group|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.
89269936|NCT04004260|Other|Weekly check-in control group|The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.
89269937|NCT03744364|Active Comparator|Misoprostol|Group of women allocated to misoprostol induction.
89269938|NCT03744364|Active Comparator|Dinoprostone|Group of women allocated to dinoprostone induction.
89269939|NCT03744208|Experimental|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
89269940|NCT05069896|Experimental|Mirikizumab - Prefilled Syringe|Mirikizumab administered by subcutaneous injection (SC) via a prefilled syringe (PFS) at 3 different injection sites (arm, thigh, and abdomen).
89269941|NCT05069896|Experimental|Mirikizumab - Autoinjector|Mirikizumab administered by SC via an autoinjector (AI) at 3 different injection sites (arm, thigh, and abdomen).
89269942|NCT01562626|Experimental|Dose escalation|
89269943|NCT04470622|Experimental|Treatment Group 1|Aprepitant injectable emulsion.
89269944|NCT04470622|Placebo Comparator|Treatment Group 2|Saline placebo.
89269945|NCT04465630|Other|Pseudophakic eyes with Open Angle Glaucoma|Eligible subjects enrolled in the trial will receive surgery for Open Angle Glaucoma using the OMNI® Surgical System.
89269946|NCT04182880|Placebo Comparator|Placebo|Placebo
89269947|NCT04182880|Experimental|CPL-01|CPL-01
89269948|NCT04465396|Experimental|Cohort 1 (Teduglutide 3 mg): Treatment A1, Then Treatment B1 (A1B1)|Teduglutide, 3 mg, subcutaneous (SC) injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A1), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B1). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants with >=40.0 kg to <=75.0 kg of weight were included in Cohort 1.
89269949|NCT04465396|Experimental|Cohort 1 (Teduglutide 3 mg): Treatment B1, Then Treatment A1 (B1A1)|Teduglutide, 3 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B1), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A1). A Washout Period of 7 days was maintained between the Treatment Periods 1 and 2. Participants with >=40.0 kg to <=75.0 kg of weight were included in Cohort 1.
89269950|NCT04465396|Experimental|Cohort 2 (Teduglutide 4 mg): Treatment A2, Then Treatment B2 (A2B2)|Teduglutide, 4 mg, SC injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A2), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants >75.0 kg to <=120.0 kg of weight were included in Cohort 2.
89269951|NCT04465396|Experimental|Cohort 2 (Teduglutide 4 mg): Treatment B2, Then Treatment A2 (B2A2)|Teduglutide, 4 mg, SC pen injector, once on Day 1 of Treatment Period 1 (Treatment B2), followed by same dose SC injection using a syringe, once on Day 1 of Treatment Period 2 (Treatment A2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants >75.0 kg to <=120.0 kg of weight were included in Cohort 2.
89269952|NCT03751462|Experimental|Pseudoexfoliation syndrome|Patients with pseudoexfoliation syndrome or traumatic cataract will be examined using the Purkinjemeter device concerning IOL wobble, tilt and decentration
89269953|NCT03744130|Experimental|patients with UC|"Patients with endoscopically proven UC with various extents of disease activity.~Diagnostic Test: Contrast-enhanced Ultrasound"
89269954|NCT03744130|Experimental|patients with CD|Patients with proven CD with various extents of disease activity Diagnostic Test: Contrast-enhanced Ultrasound
89269955|NCT03999892|Experimental|Pilot weight management module|Consumers with serious mental illness who attend a psychiatric rehabilitation program will participate in a pilot of modules of a group-based diet and physical activity program. Staff/ peer leaders a psychiatric rehabilitation program will observe sessions.
89269956|NCT03996694|Experimental|Treatment A: Belbuca 300 µg and oral placebo|Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
89269957|NCT03996694|Experimental|Treatment B: Belbuca 600 µg and oral placebo|Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
89269958|NCT03996694|Experimental|Treatment C: Belbuca 900 µg and oral placebo|Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
89269959|NCT03996694|Active Comparator|Treatment D: Oxycodone 30 mg and buccal placebo|Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
89269960|NCT03996694|Active Comparator|Treatment E: Oxycodone 60 mg and buccal placebo|Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
89269961|NCT03996694|Placebo Comparator|Treatment F: Oral Placebo and buccal placebo|Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
89269962|NCT04179838|Experimental|Sleep-Deprived first, then Non-Sleep Deprived|Participants will first be tested after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with normal sleep (non-sleep deprived, 8 h sleep).
89269963|NCT04179838|Experimental|Non-Sleep Deprived first, then Sleep-deprived|Participants will first be tested after 1 night with normal sleep (non-sleep deprived, 8 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep).
89269964|NCT03744052|Experimental|Adult Participants|Messages regarding physical activity will be texted to participants.
89269965|NCT03994120|Active Comparator|Motor Cortex rTMS|Motor Cortex rTMS
89269966|NCT03994120|Active Comparator|PPC rTMS|PPC rTMS
89269967|NCT03994120|Placebo Comparator|vertex rTMS|vertex rTMS
89269968|NCT04178590|Experimental|SRP + Injectable Platelet-Rich Fibrin|Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin
89269969|NCT04178590|Placebo Comparator|SRP + placebo|Scaling and root planing in conjunction with saline
89269970|NCT03743974|Active Comparator|Interscalene block|Site of injection for ISB was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control, and ultrasound-controlled of extra-plexus injection of the mixture posterior to the C6 root
89269971|NCT03743974|Experimental|Supraclavicular block|"Site of injection for SCB was superficial and lateral to the trunks of the brachial plexus, and not directly deep inside the corner pocket zone, with neurostimulation control and visualization of the lung"
89269972|NCT03751384|Experimental|Capsules|Dietary Supplement: Möllers Omega-3 Ekstra Sterk
89269973|NCT03751384|Active Comparator|Drink|Dietary Supplement: Nutrifriend Cachexia
89269974|NCT03746392|Experimental|Jumpstart Intervention|
89269975|NCT03746392|No Intervention|Usual Care|
89269976|NCT03743896|No Intervention|Control group|No intervention
89269977|NCT03743896|Experimental|Test group|single dose (2g), topical application of Transdermal Glucosamine Cream (containing 10% w/w of glucosamine sulfate)
89269978|NCT01562860|Active Comparator|Carpal Tunnel and Pronator Teres Release|Patients enrolled in this arm of the study will have both surgical procedures performed at the same time
89269979|NCT01562860|Active Comparator|Carpal Tunnel Release only|Patients enrolled in this arm will have only Carpal Tunnel Release performed. In they still have symptoms of median nerve neuropathy, they will be scheduled for an additional procedure to release the pronator Teres in a separate surgery.
89269980|NCT04175392|Active Comparator|Treatment Group: Probiotic|Probiotic 1 billion units Supplement Once Daily
89269981|NCT04175392|Placebo Comparator|Control Group: Placebo|Placebo Capsule Once Daily
89269982|NCT01562938|Placebo Comparator|Placebo|Placebo
89269983|NCT01562938|Active Comparator|MEDI-557 low-dose|
89269984|NCT01562938|Active Comparator|MEDI-557 high-dose|
89269985|NCT03737422|Active Comparator|hesperidin and flaxseed|
89269986|NCT03737422|Placebo Comparator|control|
89269987|NCT03743818|Experimental|dry needling|dry needling in trigger point in vastus medialis of quadriceps
89269988|NCT03743818|Active Comparator|standardized treatment protocol|in the standardized treatment protocol the investigators including ultrasound, tens, and isometric quadriceps contractions
89269989|NCT03743818|Active Comparator|hialuronic acid|infiltration of hyaluronic acid in the affected knee
89269990|NCT03986866|No Intervention|No Video|Patients are not shown the informational video on the safe usage of opioids.
89269991|NCT03986866|Experimental|Video|Patients are shown an informational video on the safe usage of opioids.
89269992|NCT03743740|Experimental|Group 1|"first, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.~then, exercises will be suspended for 4 weeks. then, patients will undergo home based program 3 days per week for 6 weeks."
89269993|NCT03743740|Experimental|Group 2|first, patients will undergo home based program 3 days per week for 6 weeks. then, exercises will be suspended for 4 weeks. then, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
89269994|NCT03751306|Active Comparator|Control-Cardiorespiratory Rehabilitation|These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.
89269995|NCT03751306|Placebo Comparator|Transcranial Photobiomodulation Placebo|In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.
88821609|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 4 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q4W via intramuscular (IM) route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
89269996|NCT03751306|Experimental|Transcranial Photobiomodulation|In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.
88821610|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 8 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q8W via IM route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
89269997|NCT01562002|Experimental|Bone Marrow mesenchymal stem cell|Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant
89269998|NCT01562002|Active Comparator|Allogenic limbal stem cell Transplant|Stem Cell with Amniotic Membrane Transplant
89269999|NCT03737344|Active Comparator|IL-1Ra Kineret®|100mg doses of the trial drug Kineret® will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
89270000|NCT03737344|Placebo Comparator|IL-1Ra Placebo|100mg doses of the placebo will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
89270001|NCT03751228|Experimental|BMS-986165 taste evaluation|BMS-986165 taste evaluation using Active Pharmaceutical Ingredient (API) and Prototypes of the API containing various flavors and sweeteners
89270002|NCT05668546|Experimental|surgical knee group|This study analyzed 58 knees of 29 unilateral TKA candidates, divided into the surgical and non-surgical knee groups
89270003|NCT05668546|Experimental|non surgical knee group|This study analyzed 58 knees of 29 unilateral TKA candidates, divided into the surgical and non-surgical knee groups
89270004|NCT03980938|Experimental|neflamapimod first|"neflamapimod in Treatment Period 1, placebo in Treatment Period 2~neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food.~Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food."
89270005|NCT03980938|Placebo Comparator|placebo first|"placebo in Treatment Period 1, neflamapimod in Treatment Period 2~Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.~neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food."
89270006|NCT03743584|Experimental|Targeted temperature management at 33°C|Cooling and temperature control at 33°C, according to the study protocol of the TTM2-trial
89270007|NCT03743584|Active Comparator|Standard care, early treatment of fever|Standard of care and normothermia. If temperature 37,8 °C or above use of device for temperature control.
89270008|NCT03108352|Experimental|Conbercept ophthalmic injection|Conbercept ophthalmic injection
89270009|NCT03108352|Sham Comparator|Sham Comparator|sham / Conbercept ophthalmic injection
89270010|NCT03751150|No Intervention|Control|Normal training, no intervention
89270011|NCT03751150|Experimental|Intervention INT|The intervention consists of an exercise program developed by a team specialised in orthopaedics, physiotherapy and biomechanics, based on the results from a recent prospective study in Gothenburg, Sweden. The exercises included cover muscle control training for the core, abductors, quadriceps and foot pronators, as well as foamrolling for the abductors, quadriceps, hamstrings, calf muscles and gluteal muscles. The runners will be instructed to perform the training program twice a week for the entire intervention period.
89270012|NCT03656692|Other|Acthar Gel|Participants received Acthar 1 mL (80 units [U]) subcutaneously (SC) 2 times per week for 36 weeks followed by a taper to Acthar 1 mL (80 U) SC once a week for 2 weeks, then 0.5 mL (40 U) SC once a week for 2 weeks.
89270013|NCT03751072||Relapse/Refractory|
89270014|NCT03751072||MRD positive|
89270015|NCT03682120|Experimental|Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
89270016|NCT03682120|Experimental|Arm 2|7.5 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
89270017|NCT03682120|Experimental|Arm 3|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
89270018|NCT03682120|Experimental|Arm 4|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) unadjuvanted administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=53
89270019|NCT03736642||restrictive anorexia nervosa with hunger|
89270020|NCT03736642||restrictive anorexia nervosa without hunger|
89270021|NCT03736642||constitutional thinness|
89270022|NCT03736642||control subjects without eating disorders|
89270023|NCT01329796|Experimental|Pertubation with Endole® (lignocaine)|Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
89270024|NCT01329796|Placebo Comparator|Placebo|Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
89270025|NCT04428502||Patients with psoriatic arthritis|Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease
89270026|NCT03736330|Experimental|Combinations treatment|Drug: Axitinib 5mg orally twice a day Combination Treatment：Anti-PD-1 Combinations of D-CIK Immunotherapy
89270027|NCT04428424||Patients with rheumatoid arthritis|Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease
89270028|NCT01562080|Experimental|Dietary supplement|red yeast, astaxanthin, berberine, policosanol, coenzyme Q10, folic acid
89270029|NCT01562080|Placebo Comparator|microcrystalline cellulose|
89270030|NCT03655756|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Therapeutic Classification:~Noncellular, Therapeutic Cancer Vaccine > Immunomodulator~Route of Administration:~Intratumoral injection of cutaneous, subcutaneous or nodal lesions~Mechanism of Action:~Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface.~Physiological Effect:~This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions."
89270031|NCT03735784|Experimental|AWARE condition|AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback.
89270032|NCT03735784|No Intervention|Standard Care condition|"Participants in the Standard Care condition have access to usual care at the drop-in center where the study is being conducted."
89270033|NCT00095238|Active Comparator|1|
89270034|NCT00095238|Placebo Comparator|2|
89270035|NCT01083888|Experimental|1 group|Participants received a single oral dose of ASP1517 on Days 1 and 8
89270036|NCT03962478|Experimental|Stent with high-intensity focused ultrasound ablation|Patients undergo stent insertion with high-intensity focused ultrasound ablation on day 1.
89270037|NCT03962478|Active Comparator|Stent without high-intensity focused ultrasound ablation|Patients undergo stent insertion on day 1.
89270038|NCT01087008|Experimental|Zoledronate acid|
89270039|NCT01087008|Other|No treatment control|
89270040|NCT01087086|Experimental|Crononutrition|"Dietary pattern:~Personalized diet~Caloric restriction (-30% Total energy intake)~High adherence to the Mediterranean Diet~Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat)~Low glycemic index/load~Increased antioxidant capacity of the diet"
89270041|NCT01087086|Placebo Comparator|American Heart Association|"Dietary pattern:~Personalized diet~Caloric diet (-30% Total energy intake)~Macronutrients distribution according to the American Heart Association (AHA) guidelines"
89270042|NCT01084044|Experimental|ulinastatin|
89270043|NCT01084044|Active Comparator|saline solution|
89270044|NCT01084044|Placebo Comparator|Sugar pill|
89270045|NCT01090362||Cohort 1|Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.
89270046|NCT01090362||Cohort 2|Cohort completed with 11,351 patients enrolled from 30 countries
89270047|NCT01090362||Cohort 3|Cohort 3 completed with 11,139 patients enrolled globally from 32 countries
89270048|NCT01090362||Cohort 4|Cohort 4 completed with 11,2780 patients enrolled from 35 countries.
89270049|NCT01090362||Cohort 5|Final cohort completed with 12,186 patients enrolled.
89270050|NCT01090440|Experimental|Three-way cross- over|Three regimens will be administered in this study: A: GSK1144814 Tablet (100mg) Fasted State; B: GSK1144814 Tablet (200mg) Fasted State and C: GSK 1144814 Tablet (100mg) Fed State (FDA high fat breakfast).
89270051|NCT01090518|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
89270052|NCT01090518|Placebo Comparator|Prolonged Exposure therapy with placebo|
89270053|NCT00082368|Experimental|PET (positron emission imaging) Imaging with Tc-94m Sestamibi|PET sestamibi scans followed by tariquidar and repeat imaging
89270054|NCT03960216|Sham Comparator|Minimal Periodontal Treatment (MPT)|Once the hopeless teeth have been extracted, randomized patients will receive a periodontal prophylaxis, in the form of supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and, after the last session, placebo capsules (one every 24 h for three days).
89270055|NCT03960216|Experimental|Intensive Periodontal Treatment (IPT)|Once the hopeless teeth have been extracted, randomized patients will receive non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse, 2x, 10 days) and after the last session, systemic antibiotics (azithromycin 500 mgrs, every 24 h for three days).
89270056|NCT03958032||Participants with gastric cancer|All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
89270057|NCT01090596|Active Comparator|Naproxen-Treated|
89270058|NCT01090596|Placebo Comparator|placebo|
89270059|NCT01084200|Experimental|Propofol|anesthesia maintenance with propofol and remifentanil
89270060|NCT01084200|Experimental|Sevoflurane|Sevoflurane and Remifentanil for anesthesia maintenance
89270061|NCT01084200|Experimental|Sevoflurane+Propofol|Sevoflurane+Propofol for anesthesia maintenance
89270062|NCT01084356||hand|patients admitted for Tc MDP for evaluation of carpal/metacarpal and finger bone lesions
89270063|NCT01084356||thyroid|patients admitted for Tc thyroid scan
89270064|NCT01084356||parathyroid|patients investigated for parathyroid adenoma
89270065|NCT01084356||sentinel node|patients who are due to sentinel node biopsy
89270066|NCT03957798|No Intervention|Control (Treatment as Usual)|TAU consists of inpatient substance abuse treatment, followed by referral to outpatient treatment. For those who live within the outpatient geographic catchment area of the treatment center, patients are subsequently admitted to outpatient levels of care at treatment center. For the non-opioid population (primarily marijuana), this consists of the intensive outpatient program counseling sessions starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress with 12 wks target length of service. For the opioid population, this consists of a specialty youth opioid program with group and individual counseling, relapse prevention medications treatment, psychiatric assessment and treatment, also starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress, with indefinite target length of service. For those not within the outpatient geographic catchment area, patients are referred to local continuing care and outpatient levels of care convenient to their homes.
89270067|NCT03957798|Experimental|Intervention (Treatment as usual + game)|
89270068|NCT01087164|Experimental|Compliance|Parents will be randomized to receive high or no compliance condition where those in the experimental group will be asked about whether or not they will protect their daughter from cervical cancer or for males, their son from genital warts.
89270069|NCT01087164|Experimental|Message sidedness|Parents will be given either a one-sided verbal message or a two-sided verbal message about the HPV vaccine.
89270070|NCT01084434|Experimental|Probiotic group|Group of 25 volunteers consuming probiotic product once a day for 7 weeks
89270071|NCT01084434|Experimental|Prebiotic group|Group of 25 volunteers consuming prebiotic product once a day for 7 weeks
89270072|NCT01084434|Experimental|Synbiotic group|Group of 25 volunteers consuming synbiotic product once a day for 7 weeks.
89270073|NCT01084434|Placebo Comparator|Placebo group|Group of 25 volunteers consuming placebo product once a day for 7 weeks
89270074|NCT01087242|Placebo Comparator|controlled group|Tang-min Lin analogue 6g,tid,po
89270075|NCT01087242|Experimental|Tang-min Lin pill|Tang-min Lin pills 6g,tid,po
89270076|NCT00094770|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
89270077|NCT00094770|Active Comparator|Glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
89270078|NCT00069576|Active Comparator|Nutritional counseling & self blood glucose monitoring|Within one week of enrollment, women in the treatment group receive formal nutritional counseling and will be instructed on the technique of self blood glucose monitoring using a memory-based reflectance meter.
89270079|NCT00069576|No Intervention|No treatment|This group will not receive any specific dietary therapy except for written information concerning general nutritional recommendations for normal pregnancy.
89270080|NCT01090674||1|Patients with amyotrophic lateral sclerosis.
89270081|NCT01087398|Experimental|Intervention|
89270082|NCT01087476|Experimental|doxycycline hyclate|Patients will be randomly assigned to receive either a sub-microbial dose of doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
89270083|NCT00069264|Experimental|E7389|
89270084|NCT00069108|Experimental|XELOX|Participants received XELOX (oxaliplatin and capecitabine). Oxaliplatin was administered 130 mg/m^2 intravenous (IV) infusion over 2 hours (every 3 weeks [Day 1]) before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of Day 1 and last dose the morning of Day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) for up to 8 cycles (24-weeks).
89270085|NCT00069108|Active Comparator|FOLFOX-4|Participants received FOLFOX-4 (combination of oxaliplatin, leucovorin [LV] and 5-fluorouracil [5-FU] combination). Oxaliplatin was administered as an 85 mg/m^2 IV infusion over 2 hours (on Day 1 only); with LV infusion as 200mg/m^2 over 2 hours followed by 5-FU, given as 400mg/m^2 bolus injection over 2-4 minutes, and then as a 600 mg/m^2 continuous infusion over 22 hours. On Day 2, Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection over 2-4 minutes, and 5-FU 600 mg/m^2 continuous infusion was repeated over 22 hours. It was (2-week cycles comprising 48 hours of infusion and 12 days of rest) for up to 12 cycles (24- weeks).
89270086|NCT03961776||non-metastatic rectal adenocarcinoma nRCT indicated|Patients with histologically confirmed non-metastatic rectal adenocarcinoma and for whom treatment with nRCT has been indicated.
89270087|NCT00094536|Experimental|Extended Treatment Regimen|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
89270088|NCT00405587|Experimental|PLX4032|Open-label, sequential dose escalation
89270089|NCT01040429|Active Comparator|Clonidine capsula|
89270090|NCT01040429|Placebo Comparator|Lactose capsula|
89270091|NCT00581243|Experimental|1|2 mg SLV-313 SR (fixed dose)
89270092|NCT00581243|Experimental|2|5 mg SLV-313 SR (fixed dose)
89270093|NCT00581243|Experimental|3|10 mg SLV-313 SR (fixed dose)
89270094|NCT00581243|Experimental|4|xx mg SLV-313 SR (titration)
89270095|NCT01039883|Experimental|1|Subjects randomized to study product sequence 1 will receive the single albaconazole 400-mg tablet during the first dosing period and the four 100-mg albaconazole capsules during the second dosing period.
89270096|NCT01039883|Experimental|2|Subjects randomized to study product sequence 2 will receive the four 100-mg albaconazole capsules during the first dosing period and the single albaconazole 400-mg tablet during the second dosing period.
89270097|NCT00405275|Active Comparator|Arm 1|Etanercept and Methotrexate. Participants also received placebo hydroxychloroquine and sulfasalazine
89270098|NCT00405275|Active Comparator|Arm 2|Hydroxychloroquine, sulfasalazine and methotrexate. Participants also received placebo etanercept.
89270099|NCT00404651|Experimental|Group 1|Participants receive vaccine Batch A
89270100|NCT00404651|Experimental|Group 2|Participants receive vaccine Batch B
89270101|NCT00404651|Experimental|Group 3|Participants receive vaccine Batch C
89270102|NCT00404651|Active Comparator|Group 4|Participants receive Infanrix hexa™
89270103|NCT03908021||children with type 1 diabetes mellitus|Saliva from 50 children ages 5 to 15 years old who had been diagnosed with type 1 diabetes mellitus and are followed at the Pediatric Endocrinology Clinic, Hadassah University Hospital Mt. Scopus and Ein Kerem, Jerusalem, Isreal,
89270104|NCT03908021||Control|50 healthy children, preferably their siblings, matched in age and gender.
89270105|NCT00404495|Experimental|Temozolomide + Irinotecan|
89270106|NCT01039961|Experimental|1 mg IV|Unit Dose Strength: 0.4 mg/mL
89270107|NCT01039961|Experimental|?mg IV|dose to be determined based on PK of first IV dose
89270108|NCT01039961|Experimental|15 mg (oral)|two 7.5 mg tablets
89270109|NCT00409409|Experimental|300 IR|300 IR grass pollen allergen extract tablet
89270110|NCT00409409|Placebo Comparator|Placebo|Placebo tablet
89270111|NCT00409331|Experimental|IMRT + Amifostine|Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.
89270112|NCT00409175|Experimental|1.|Fx-1006A
89270113|NCT00409175|Placebo Comparator|2.|Placebo
89270114|NCT00362219|Placebo Comparator|Placebo|Gel with no active ingredient
89270115|NCT00362219|Active Comparator|Morphine .25 mg|Gel with 0.25 mg morphine per 100cm2 square of wound
89270116|NCT00362219|Active Comparator|Morphine - .75 mg.|Gel with 0.75 mg morphine per 100cm2 square of wound.
89270117|NCT00362219|Active Comparator|Morphine 1.25 mg.|Gel with 1.25 mg morphine per 100cm2 square of wound.
89270118|NCT01040507||primary laparoscopic gastric bypass|
89270119|NCT01040585||Central America and the Caribbean|Panama, Costa Rica, Honduras, El Salvador and Nicaragua
89270120|NCT01040039||HCV+HIV+|
89270121|NCT01040039||HCV+HIV-|
89270122|NCT01040117|Experimental|Sensory-motor Integration Training|
89270123|NCT01040117|Active Comparator|Conventional neurorehabilitation|
89270124|NCT01040663|Other|Dash Diet|Subjects receive DASH diet for 4 weeks
89270125|NCT01040663|Other|Low GI Diet|Subjects will receive Low GI diet for 4 weeks
89270126|NCT01040663|Other|Western Style Diet|Subjects will receive western style diet for 4 weeks
89270127|NCT01040741||Group 1: 6-23 months|
89270128|NCT01040741||Group 2: 2-8 years|
89270129|NCT01040741||Group 3: 9-17 years|
89270130|NCT01040741||Group 4: 18-44 years|
89270131|NCT01040741||Group 5: 45-60 years|
89270132|NCT01040741||Group: >60 years|
89270133|NCT01040897|Active Comparator|Active Control Arm|At Active Comparative Sites, Pediatric Residents will be trained to address injury prevention issues using The Injury Prevention Program (TIPP) approach
89270134|NCT01040897|Experimental|Health Communication and Obesity Prevention|Pediatric Residents will be training in effective health communication skills and given a toolkit of literacy/numeracy sensitive educational materials to use with families with children age 2 months to18 months during each well child visit
89270135|NCT01040195|Active Comparator|Combination DMARD|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily. All patients will also receive folic acid 5 mg thrice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. In the absence of any contraindication, patients will be randomized into two groups Group 1 to receive Combination Disease Modifying therapy with Sulfasalazine, Methotrexate and hydroxychloroquine (HCQ). Patient will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day.
89270136|NCT01040195|Placebo Comparator|Placebo|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily All patients will also receive folic acid 5 mg twice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. Group 2 patients will receive Sulfasalazine and placebo for methotrexate and hydroxychloroquine.
89270137|NCT01040975|Experimental|Motivational Interviewing intervention|Web-based intervention targeting MD communication and Summary Report
89270138|NCT01040975|No Intervention|Control|MD receives Summary Report only
89270139|NCT01040273|Experimental|Experiment|Anesthetics intraarticular injection
89270140|NCT01040273|Placebo Comparator|Placebo|saline intraarticular injection
89270141|NCT00408629|Experimental|adalimumab group|
89270142|NCT00408629|Experimental|placebo group|
89270143|NCT00408317|Experimental|Ultrase® MT20|
89270144|NCT00408317|Placebo Comparator|Placebo|
89270145|NCT01041131||Failed and/or Complicated VBG|
89270146|NCT00112502|Active Comparator|Arm I: TMZ|Oral Temozolomide (TMZ) 150 mg/m^2 once daily on days 1-7 and 15-21.
89270147|NCT00112502|Experimental|Arm II: TMZ + Thalidomide|Temozolomide as in arm I and oral Thalidomide (Thal) once daily on days 1-28 (starting dose 200 mg).
89270148|NCT00112502|Experimental|Arm III: TMZ + Isotretinoin|Temozolomide as in Arm I and oral Isotretinoin 40 mg/m^2 twice daily on days 1-21.
89270149|NCT00112502|Experimental|Arm IV: TMZ + Celecoxib|Temozolomide as in arm I and oral Celecoxib 400 mg twice daily on days 1-28.
89270150|NCT00112502|Experimental|Arm V: TMZ + Thalidomide + Isotretinoin|Temozolomide as in arm I, Thalidomide as in arm II, and Isotretinoin as in arm III.
89270151|NCT00112502|Experimental|Arm VI: TMZ + Thalidomide + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, and Celecoxib as in Arm IV.
89270152|NCT00112502|Experimental|Arm VII: TMZ + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
89270153|NCT00112502|Experimental|Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
89270154|NCT01080170||Anastrazole|Newly diagnosed, non-metastatic, hormone-receptor positive breast cancer patients, who have undergone lumpectomy, have been advised to not require chemotherapy, but will need to undergo radiation therapy and will be initiating therapy with anastrazole.
89270155|NCT01080170||Control group - 2|Healthy controls.
89270156|NCT03965546|Experimental|ET140202-T cell combine with Sorafenib|Sorafenib treatment everyday and autologous ET140202-T cell administered by intravenous (IV) infusion
89270157|NCT03965546|Experimental|ET140202-T cell combine with TAE|TAE treatment ahead every two times of autologous ET140202-T cell administered by intravenous (IV) infusion
89270158|NCT03965546|Experimental|solo ET140202-T cell|autologous ET140202-T cell administered by intravenous (IV) infusion
89270159|NCT01083914||OPCAB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
89270160|NCT01083914||CPB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
89270161|NCT01083914||MECC|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
89270162|NCT01080404|Experimental|Bariatric surgery (overall study)|A prospective follow-up study is to estimate the prevalence of OSA and associated metabolic abnormalities in Finnish morbidly obese subjects and to evaluate the effects of bariatric surgery on OSA and associated metabolic abnormalities. The study is conducted in seven hospitals in Finland and 300 patients are planned to be recruited in the study.
89270163|NCT01080404|Experimental|Bariatric surgery (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 (15/center) patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
89270164|NCT01080404|Active Comparator|CPAP (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
89270165|NCT01083992|Other|Galvus + vitamin D|Galvus in combination with vitamin D
89270166|NCT01083992|Other|Galvus|vitagliptin as monotherapy
89270167|NCT01084070|Experimental|Early oral feeding|
89270168|NCT01084070|Active Comparator|Traditional Care|
89270169|NCT01084226|Active Comparator|Sterol|Additional plant sterols incorporated in the rye bread
89270170|NCT01084226|Placebo Comparator|control|No added plant sterol in the identical-looking rye bread
89270171|NCT01084304||Active|Use of ovulation tests to aid conception
89270172|NCT01084304||Control|No ovulation tests to aid conception
89270173|NCT01078532|Experimental|SMART PHR|Patients receive the active PHR
89270174|NCT01078532|Other|Passive PHR|Usual PHR Care
89270175|NCT03822182|Other|Control/Bupivicaine +DMSO|Group 1 will serve as the control and receive the standard injection consisting 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone.
89270176|NCT03822182|Active Comparator|Liposomal bupivicaine|Group 2 will receive a block with 15ml 0.5% bupivacaine and 10ml (133mg) of liposomal bupivicaine (Exparel) and 5.4ml of Normal Saline
89270177|NCT03822182|Active Comparator|Liposomal Bupivicaine +DMSO|Group 3 will receive 15ml of 0.5% bupivicaine and 10ml (133mg) of Liposomal Bupivicaine (Exparel) and 0.4ml (4mg) dexamethasone and 5ml normal saline
89270178|NCT01078610||Psoriatic arthritis patients|
89270179|NCT03741296|Active Comparator|single stage revision|One surgery where the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided and washed out before a new artificial hip joint (prosthesis) is implanted. All the procedures will be done in a single surgery.
89270180|NCT03741296|Active Comparator|two-stage revision|"Patients will undergo 2 separated surgeries. In the first operation, the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided, washed out and a spacer will be placed in the hip (temporarily replace prosthesis).~A secondary surgery to re-implant the hip will be performed with an interval period of 4-10 weeks when the infection is cleared.~The site will be debrided and irrigated, and any component/spacer will be removed. A new artificial joint will then be implanted."
89270181|NCT03964766|Experimental|rotary instrumentation|endodontic treatment will be performed with the use of pedo rotary files that will be activated by engine
89270182|NCT03964766|Active Comparator|hand istrumentation|endodontic treatment will be performed with the use of conventional hand files
89270183|NCT01080482|Active Comparator|Prograf® Capsule 5 mg|
89270184|NCT01080482|Experimental|Tacrolimus Capsule 5 mg|
89270185|NCT03965624|Experimental|Ixazomib|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, in combination with dexamethasone 20 mg weekly. The investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see below) or de-escalation in case of response and severe adverse events.
89270186|NCT00111800|Placebo Comparator|Placebo|Participants received oral dose of matching placebo capsule to denagliptin (DEN) once daily in the morning, 30 minutes (min) prior to breakfast during the main phase 12-weeks treatment period. Participants who were randomized to placebo in the main phase 12-weeks treatment period received oral dose of DEN 2.5 milligram (mg) once daily in the morning, 30 min prior to breakfast during the extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of placebo to the participants.
89270187|NCT00111800|Experimental|DEN 2.5 mg|Participants received oral dose of DEN 2.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 2.5 mg to the participants.
89270188|NCT00111800|Experimental|DEN 7.5 mg|Participants received oral dose of DEN 7.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 7.5 mg to the participants.
89270189|NCT00111800|Experimental|DEN 15 mg|Participants received oral dose of DEN 15 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 15 mg to the participants.
89270190|NCT00111800|Experimental|DEN 30 mg|Participants received oral dose of DEN 30 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 30 mg to the participants.
89270191|NCT00111800|Experimental|DEN 45 mg|Participants received oral dose of DEN 45 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 45 mg to the participants.
89270192|NCT01084460||EUS-suspected gastric GISTs|In this retrospective study, 50 patients with EUS-suspected gastric GISTs, less than 3 cm were enrolled and had EUS follow-up at least two times over a period of more than 24 months.
89270193|NCT01326806|Experimental|Sex Education + Standard Care|Participating mothers will receive sex education information while their child is having a physical exam.
89270194|NCT01326806|Active Comparator|Hygiene & Nutrition Education + Standard Care|Participating mothers will receive information on hygiene and nutrition while their child is having a physical exam.
89270195|NCT01326806|No Intervention|No Education + Standard Care|Participating mothers who are passive controls will not receive any additional information while their child is having a physical exam.
89270196|NCT02530892||Measurement Group|"This group contains oocytes and embryos which have their mechanical properties (elasticity and viscosity) measured prior to fertilization (oocytes) or within 24 hours after fertilization (embryos). The investigators are calling this mechanical measurement the EmbryoHug. All participants in the study will have half their embryos measured in this group. Outcomes will be evaluated after 6 days of embryo culture, at the time of pregnancy test, at 5-6 weeks, and at 8-10 weeks, and correlated with EmbryoHug parameters."
89270197|NCT01080560|Active Comparator|NEORAL® Capsule 100 mg|
89270198|NCT01080560|Experimental|Cyclosporine 100 mg Capsule|
89270199|NCT00094328|Other|Bicalutamide with Anastrozole|Bicalutamide in combination with Anastrozole
89270200|NCT00094172|Experimental|Atorvastatin|80 mg/day
89270201|NCT00094172|Placebo Comparator|Placebo|Once daily.
89270202|NCT01084616||Vaginal Dryness|
89270203|NCT01084616||Non-vaginal dryness|
89270204|NCT00094094|Experimental|Axitinib|AG-013736 is a vascular endothelial growth factor [VEGF] inhibitor
89270205|NCT01078766|Experimental|CIMT+HABIT|"Form of summer camp, for six hours per day for 10 consecutive work days."
89270206|NCT03962816|Experimental|20 µg at months 0, 1, and 6|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
89270207|NCT03962816|Experimental|20 µg at months 0, 1, 2,and 6|20 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
89270208|NCT03962816|Experimental|60 µg at months 0, 1, 2,and 6|60 µg recombinant hepatitis B vaccine with four injections at months 0, 1, 2, and 6
89270209|NCT01080638|Experimental|Abciximab IC bolus|After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
89270210|NCT01080638|Active Comparator|Abciximab IV bolus and 12hr continuous|
89270211|NCT01084850||Diabetes Type II|Patients with type 2 Diabetes Mellitus
89270212|NCT01084850||Control|Patients with no diabetes
89270213|NCT01084928|Experimental|Intervention Arm (Diet and Exercise)|The lifestyle intervention will include a 16-week intervention period, followed by an 8 week, less intensive maintenance period.
89270214|NCT01079000|Active Comparator|Control - usual care (UC)|Usual care after an ED visit for asthma will include the provision of discharge instructions/plan, and action plan, and verbal instructions for follow-up with their PCP, and a faxed copy of the ED chart to the patient's PCP.
89270215|NCT01079000|Experimental|Opinion leader (OL) guidance to patients' PCPs|In addition to UC, OL guidance will be provided to the patients' PCP. A letter signed by an influential, respected, and local clinical leader (Respirologist) will encourage follow-up within two weeks and provide management suggestions.
89270216|NCT01079000|Experimental|Care manager education to patients|In addition to UC and OL guidance provided to the patients' PCP, care manager self-management education will be provided to patients. A care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged.
89270217|NCT03965312|Experimental|Temperature monitoring (1) and incubator test (2) groups|"In the first (1) phase of the study, the temperature probe and monitor will be attached to infants along with the Philips Intellivue patient monitor. Temperature will be monitored continuously for up to 72 hours.~In the second (2) phase of this study, infants at risk for hypothermia and not eligible for skin-to-skin care will be placed in the incubator."
89270218|NCT00110396|Experimental|Rebif New Formulation Cohort|
89270219|NCT03819218|Experimental|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
89270220|NCT00407537|Experimental|Caduet|Open label caduet added to usual care regimen followed by investigators.
89270221|NCT00094458|Experimental|003|infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
89270222|NCT00094458|Experimental|001|infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
89270223|NCT00094458|Experimental|002|infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
89270224|NCT00406367|Experimental|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection"
89270225|NCT00406367|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
89270226|NCT01041365||Healthy adolescents|Healthy adolescent African American and Caucasian females, ages 14-18
89270227|NCT01084512||Healthy group|control subjects
89270228|NCT01084512||Paraplegic group|Paraplegic subjects
89270229|NCT01084512||Tetraplegic group|tetraplegic subjects
89270230|NCT01041443|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-10. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
89270231|NCT03961464|Experimental|d-cycloserine|oral, capsule, 250 mg
89270232|NCT03961464|Experimental|Placebo|oral, capsule, lactose
89270233|NCT01087632|Experimental|Armolipid Plus|Armolipid Plus is an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg
89270234|NCT01087632|Placebo Comparator|Placebo|Placebo matching Armolipid plus
89270235|NCT00394589|Experimental|Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
89270236|NCT00394589|Experimental|Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
89270237|NCT00394589|Active Comparator|Control|Continuation of infliximab 3 mg/kg every 8 weeks
89270238|NCT00068406|Experimental|Treatment (conventional surgery, radiation therapy, cisplatin)|"Patients undergo radiotherapy daily on days 1-5 and receive concurrent cisplatin IV over 30 minutes on day 1. Treatment repeats weekly for approximately 6.5 weeks (a total of 32 fractions of radiotherapy) in the absence of unacceptable toxicity.~Six to eight weeks after the completion of chemoradiotherapy, patients with a complete clinical response may undergo incisional biopsy of the primary tumor and bilateral inguinal/femoral nodes (if the groin nodes were initially unresectable). Patients with microscopic or gross resectable residual disease may then undergo radical resection of the residual tumor. Patients with unresectable disease after the completion of chemoradiotherapy receive additional radiotherapy with 1-2 courses of concurrent cisplatin."
89270239|NCT00403559|Experimental|Elidel Cream (pimecrolimus)|Elidel Cream to be applied twice daily for 4 weeks
89270240|NCT00403559|Active Comparator|Ketoconazole Cream (Nizoral)|Ketoconazole Cream to be applied twice daily for 4 weeks
89270241|NCT01087710|Experimental|novel nutritional formula|
89270242|NCT01087710|Active Comparator|Control nutritional product|1 8oz serving per day for 12 weeks
89270243|NCT00403481|Experimental|Active treatment|Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.
89270244|NCT03759275||Stage 1|For the Baseline Investigation and Technical Preparation Stage
89270245|NCT00402779|Experimental|Erlotinib|Balanced randomization: Erlotinib 150 mg continuous administration for 1 year.
89270246|NCT00402779|Placebo Comparator|Placebo|Balanced randomization: Placebo continuous administration for 1 year.
89270247|NCT00394433|Experimental|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA)|Patients received bevacizumab 10 mg/kg IV on day 1 every 3 weeks while on study. Additionally, they received docetaxel 30 mg/m2 IV over 30 minutes, followed by cisplatin 25 mg/m2 IV over 30 minutes, followed by irinotecan 50 mg/m2 IV over 30 minutes on days 1 and 8 of each 3-week cycle until disease progression or unacceptable toxicity. Dose reductions were not permitted for bevacizumab although treatment could be held up to 2 months. If bevacizumab was discontinued, treatment with other agents could continue. When docetaxel, cisplatin, or irinotecan was held on day 1 of a cycle, all agents were held.
89270248|NCT00092534|Experimental|Quadrivalent Human Papillomavirus (HPV) Vaccine|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
89270249|NCT00092534|Placebo Comparator|Placebo|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
89270250|NCT01324193|Other|Pre-diaylsis patients|Chronic Kidney Disease patients not receiving dialysis getting pomegrante Supplementation
89270251|NCT01324193|Other|Dialysis patients|Chronic Kidney Disease patients receiving dialysis getting pomegranate supplementation
89270252|NCT00068250|Experimental|Phase I: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
89270253|NCT00068250|Experimental|Phase I: Temozolomide 150 mg|Rituximab, methotrexate, temozolomide 150 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
89270254|NCT00068250|Experimental|Phase I: Temozolomide 200 mg|Rituximab, methotrexate, temozolomide 200 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
89270255|NCT00068250|Experimental|Phase II: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
89270256|NCT01080872||Titanium-NO coated stent|Patients receiving titanium-nitride-oxide coated stents during the intervention.
89270257|NCT01080872||Everolimus eluting stent|Patients receiving everolimus eluting stents during the intervention.
89270258|NCT00393887|Experimental|1|Biodesign IHM Graft placement
89270259|NCT00393887|Active Comparator|2|Polypropylene mesh placement
89270260|NCT03957720|Experimental|homo-R778L|When patients carrying homo-R778L mutation are in hospital, they receive DMPS treatment. Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
89270261|NCT03957720|Experimental|R778L+truncation mutation|"When patients carrying R778L and truncation mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
89270262|NCT03957720|Experimental|Homo-P992L|"When patients carrying Homo-P992L mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient ,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
89270263|NCT03957720|Experimental|P992L+truncation mutation|"When patients carrying P992L and truncation mutation are in hospital, they receive DMPS treatment.~Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; When being off hospital, they receive DMSA treatment. Adult patient,Dosage Form:DMSA:750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form:DMSA:35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;"
89270264|NCT03957720|Experimental|T935M+other point mutations|When patients carrying T935M and other point mutations are in hospital, they randomly receive DMPS or penicillamine treatment; Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days; Dosage Form: penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years; When being off hospital, they receive DMSA treatment or penicillamine. Adult patient,Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Pediatric patient,Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
89270265|NCT03957720|Experimental|Presymptomatic patients with Wilson's disease|"According to different age group, they receive various dosage of Zinc Gluconate treatment.~Patient aged≤6 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:BID, Zinc Gluconate Duration: 5 years; Patient aged from 6 to 14 years,Dosage Form: Zinc Gluconate: 140mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years; Patient aged≥14 years,Dosage Form: Zinc Gluconate: 210mg once, Zinc Gluconate Frequency:TID, Zinc Gluconate Duration: 5 years;"
89270266|NCT00393029|Experimental|Patients with metastatic melanoma|Melanoma is a serious form of skin cancer that develops in the skin cells that make our skin color (melanocytes).
89270267|NCT00393029|Experimental|Patients with other metastatic cancers|
89270268|NCT00402233|Other|Placebo|
89270269|NCT00402233|Other|Pramipexole 0.5 mg Tid|Pramipexole 0.5 mg tid (three times a day)
89270270|NCT00402233|Other|Pramipexole 0.5 mg Bid|Pramipexole 0.5 mg bid (bis in die (two times a day))
89270271|NCT00402233|Other|Pramipexole 0.75 mg Bid|Pramipexole 0.75 mg bid (bis in die (two times a day))
89270272|NCT03993431|Experimental|Bio-active cement|Bio-active cement dispensed into the crown, and the crown was properly positioned over the tooth, cement was allowed to self-set for 20 seconds while maintaining gentle pressure on the crown, then flash cured using a light curing unit to remove excess cement, buccal and lingual surfaces were light cured for extra 10 seconds each.
89270273|NCT03993431|Active Comparator|Packable glass ionomer|Dentin conditioner was applied to the prepared crown surfaces for 20 sec, then rinsed, and dried. Capsule was activated, mixed for 10 seconds in an amalgamator, then loaded into the capsule applier to extrude cement directly into the crown, the crown was properly positioned over the tooth, cement was allowed to self-set for 2 minutes while maintaining gentle pressure on the crown, excess cement was removed before complete setting of cement.
89270274|NCT01044017|Experimental|A|
89270275|NCT01044017|Experimental|B|
89270276|NCT01044017|Placebo Comparator|C|
89270277|NCT00092456|Experimental|RotaTeq™ Lot 1|~8.81 X 10^7 IU/Dose of RotaTeq™
89270278|NCT00092456|Experimental|RotaTeq™ Lot 2|~8.01 X 10^7 IU/Dose of RotaTeq™
89270279|NCT00092456|Experimental|RotaTeq™ Lot 3|~6.91 X 10^7 IU/Dose of RotaTeq™
89270280|NCT00092456|Placebo Comparator|Placebo|
89270281|NCT00067470|Placebo Comparator|Placebo|
89270282|NCT00067470|Active Comparator|rhASB|
89270283|NCT00401843|Experimental|Part 1: Siltuximab Plus Bortezomib|Siltuximab 6 milligram per kilogram (mg/kg) will be administered as intravenous infusion once every 2 weeks along with bortezomib 1.3 milligram per square meter (mg/m^2) during cycle 1.
89270284|NCT00401843|Experimental|Part 2: Bortezomib + Placebo|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with matching placebo administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with matching placebo once every 2 weeks during 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 milligram per day (mg/day) will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
89270285|NCT00401843|Experimental|Part 2: Bortezomib + Siltuximab|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with Siltuximab administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with Siltuximab administered as intravenous infusion once every 2 weeks for 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
89270286|NCT00401531|Experimental|Group 1: DTaP IPV Hep B PRP T + Prevnar™|
89270287|NCT00401531|Active Comparator|Group 2: Infanrix hexa™ + Prevnar™|
89270288|NCT00401375|Experimental|MNTX 12 mg|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) as an intravenous (IV) infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
89270289|NCT00401375|Experimental|MNTX 24 mg|Participants will receive MNTX 24 mg as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
89270290|NCT00401375|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
89270291|NCT00400985|Other|Implantable Device diagnostics|All enrolled subjects were implanted with a device. Audible Device diagnostics turned on or off
89270292|NCT00400517|Experimental|GM-CSF Injections and Oral Thalidomide|taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
89270293|NCT01044095|Active Comparator|Autologous prime boost regimen 1|FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)
89270294|NCT01044095|Active Comparator|Autologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)
89270295|NCT01044095|Experimental|Heterologous prime boost regimen 1|FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later
89270296|NCT01044095|Experimental|Heterologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later
88805513|NCT03008395|Experimental|EMMA|These participants will receive diabetes self-management education using the dialogue tools, which emphasize empowerment and use the principles of motivational communication and behaviour modification. There will be a series of four visits using the dialogue tools to guide the patient toward meaningful self-management tasks. This is not the typical approach, where providers tell the patient the behaviours they, not the patient, consider priorities. This intervention will evaluate if medical outcomes (A1c) and adherence are improved using a patient-centered not a clinician-cantered approach in individuals with poor diabetes control.
89270297|NCT01324427|Experimental|virtual medical visit|"This is a pilot trial involving a maximum of 84 patients undergoing either allogeneic or autologous stem cell transplant aimed at determining the feasibility and acceptance of a virtual medical visit by patients and health care personnel. During this pilot trial we expect to perform 84 virtual medical visits using telemedicine."
89270298|NCT00392171|Experimental|Temozolomide|Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
89270299|NCT00391625|Experimental|GA-GCB|15-60 U/kg every other week via intravenous infusion
89270300|NCT03993275||Patients with Stroke|30 Patients suffering a stroke will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 4 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
89270301|NCT03993275||Patients with Multiple Sclerosis|50 Patients suffering multiple sclerosis will be included in the study. After clinical measurements of balance, gait, trunk control and cognition, patients will train 2-3 times a week for on average 3 weeks with the MindMotion GO system. Afterwards, clinical measures will be repeated.
89270302|NCT00091832|Experimental|Denosumab 60 mg every 12 weeks|Denosumab 60 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
89270303|NCT00091832|Experimental|Denosumab 120 mg every 4 weeks|Denosumab 120 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
89270304|NCT00091832|Experimental|Denosumab 180 mg every 4 weeks|Denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
89270305|NCT00091832|Active Comparator|IV bisphosphonates every 4 weeks|Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion for 25 weeks.
89270306|NCT00091832|Experimental|Denosumab 180 mg every 12 weeks|Denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
89270307|NCT00091832|Experimental|Denosumab 30 mg every 4 weeks|Denosumab 30 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
89270308|NCT00391391|Experimental|1|Split, Inactivated, Trivalent Influenza Vaccine
89270309|NCT00391391|Experimental|2|Split, Inactivated, Trivalent Influenza Vaccine
89270310|NCT00391391|Active Comparator|3|Split, Inactivated, Trivalent Influenza Vaccine
89270311|NCT00391391|Active Comparator|4|Split, Inactivated, Trivalent Influenza Vaccine
89270312|NCT01044251|Placebo Comparator|Placebo|10 days of treatment with placebo in a bid fashion that will look like the study medication.
89270313|NCT01044251|Experimental|Frovatriptan|Frovatriptan 2.5 mg po bid for 10 days
89270314|NCT01044329|Active Comparator|Intravitreal bevacizumab|
89270315|NCT01044329|Active Comparator|Intravitreal triamcinolone|
89270316|NCT01018589|Experimental|A|Cicatrix cream
89270317|NCT00091442|Experimental|DOXIL and docetaxel combination therapy|DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
89270318|NCT00091442|Active Comparator|Docetaxel monotherapy|Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
89270319|NCT00390689|Experimental|Pramipexole 0.25 mg once daily|Pramipexole 0.25 mg given once daily
89270320|NCT00390689|Experimental|Pramipexole 0.5 mg once daily|Pramipexole 0.5 mg given once daily
89270321|NCT00390689|Experimental|Pramipexole 0.75 mg once daily|Pramipexole 0.75 mg given once daily
89270322|NCT01085240|Other|Start Later|The participants receive the Mission Possible intervention but it is delayed by 3 months.
89270323|NCT01085240|Experimental|Start Now|The participants start the Mission Possible program right away.
89270324|NCT01079078|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
89270325|NCT01079078|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
89270326|NCT03965156|Active Comparator|Erector Spinae Plane Block|Bilateral Ultrasound Guided Erector Spinae Plane Block
89270327|NCT03965156|Active Comparator|transversus abdominis plane block|Ultrasound guided transversus abdominis plane block
89270328|NCT01080950||fever zinc vit. d|patients with fever but without sepsis
89270329|NCT01080950||sepsis zinc vit. d|patients with sepsis
89270330|NCT00121238|Experimental|Experimental treatment: cilengitide|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. After 3 courses, patients undergo evaluation. Patients achieving a complete prostate-specific antigen (PSA) response (i.e., PSA < 0.2 ng/mL) receive 2-3 additional courses of therapy. Patients with partial PSA response or stable disease continue treatment indefinitely in the absence of disease progression or unacceptable toxicity. Patients demonstrating disease progression by CT scan, MRI, or bone scan are removed from the study.
89270331|NCT00390455|Experimental|Arm I (lapatinib)|Patients receive lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 and 15 of course 1 and on day 1 of each subsequent course. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89270332|NCT00390455|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 and fulvestrant as in Arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89270333|NCT03812510|Experimental|A-101|Topical Solution
89270334|NCT01583114|Experimental|perindopril|
89270335|NCT01583114|Placebo Comparator|placebo|same form, administration, posology, frequency and duration as perindopril
89270336|NCT01085474||1|1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
89270337|NCT01085474||2|Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)
89270338|NCT01079312|Active Comparator|Propofol infusion|Anaesthesiologist's managed intravenous infusion of propofol 10mg/ml
89270339|NCT01079312|Active Comparator|Patient-controlled sedation|self-administration of propofol and remifentanil mixture during ERCP
89270340|NCT00390299|Experimental|Arm A (resection cavity administration)|Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by MV-CEA administered into the resection cavity.
89270341|NCT00390299|Experimental|Arm B (intratumoral and resection cavity administration)|Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
89270342|NCT01044485|Other|lapatinib + docetaxel|"dose level Lapatinib (OD) Docetaxel (q3wks) Systematic Growth factor Minus 0 1250 mg 75 mg/m2 + systematic growth factor support~0, 1250mg 75 mg/m2 No~+1 1500mg 75mg/m2 No~Minus +1* 1500mg 75mg/m2 + systematic growth factor support~+2 1250mg 100mg/m2 No~Minus +2* + systematic growth factor support~+3 1500mg 100mg/m2 No~Minus +3* + systematic growth factor support~Apart within the minus dose levels, G-CSF support should be added only as rescue strategy if severe neutropenia occurred during the first cycle of studied dose.Patients will receive 4 cycles of the association. In case of benefit of the treatment, they should continue the treatment with lapatinib until progression.* patients will be included at level minus X only if 2 DLT out of 6 patients based on febrile neutropenia occurred at level X"
89270343|NCT00119678|Active Comparator|Abatacept + Prednisone|Double Blind Period
89270344|NCT00119678|Placebo Comparator|Placebo + Prednisone|Double Blind Period
89270345|NCT00119678|Experimental|Abatacept|Open Label
89270346|NCT00110084|Experimental|Nab-paclitaxel/Gemcitabine|
89270347|NCT00390221|Placebo Comparator|Placebo|Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
89270348|NCT00390221|Experimental|150 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
89270349|NCT00390221|Experimental|300 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
89270350|NCT00389831|Placebo Comparator|Placebo|Subjects receiving a single dose of placebo nasal spray on all 4 treatment days
89270351|NCT00389831|Experimental|Rotigotine Nasal Spray|Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4
89270352|NCT00389597|Experimental|1 Level|Cervical artificial disc (investigational device) at 1 level compared with control procedure (ACDF) at one level
89270353|NCT00389597|Experimental|2 Level|Cervical artificial disc (investigational device) at 2 levels compared with control procedure (ACDF) at two levels
89270354|NCT00389519|Placebo Comparator|Placebo|once per day
89270355|NCT00389519|Experimental|ramipril low dose|0.3125, 0.625, or 1.25 mg once a day, based on subject weight
89270356|NCT00389519|Experimental|ramipril mid dose|1.25, 2.5, or 5 mg once a day, based on subject weight
89270357|NCT00389519|Experimental|ramipril high dose|5, 10, or 20 mg once a day, based on subject weight
89270358|NCT00389441|Experimental|A|
89270359|NCT01018667||CRT group|
89270360|NCT01018667||OPT group|
89270361|NCT00118898|Experimental|EFV, FTC/TDF, and placebo ABC/3TC|Participants will receive EFV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
89270362|NCT00118898|Experimental|EFV, ABC/3TC and placebo FTC/TDF|Participants will receive EFV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
89270363|NCT00118898|Experimental|RTV-boosted ATV, FTC/TDF, and placebo ABC/3TC|Participants will receive RTV-boosted ATV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
89270364|NCT00118898|Experimental|RTV-boosted ATV, ABC/3TC, and placebo FTC/TDF|Participants will receive RTV-boosted ATV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
89270365|NCT00118430|Experimental|Stepped Care|Stepped care group
89270366|NCT00118430|Active Comparator|Usual Care|Treatment as usual group
89270367|NCT00118430|No Intervention|No Treatment|Participants without depression group
89270368|NCT01085552|Other|1|Group A consists of 11 Caucasian male subjects Group B consists of 12 Japanese male subjects
89270369|NCT03962426|Active Comparator|Social Cognitive Training (SCT)|10 hours of computerized SCT using tablet with 30-minute sessions, 4-5 times per week
89270370|NCT03962426|No Intervention|Treatment as usual (TAU)|This arm is getting treatment as usual, meaning antipsychotic medication (any needed medication in general) and psychotherapy/occupational therapy
89270371|NCT01085708|Experimental|1|
89270372|NCT01085708|Experimental|2|
89270373|NCT01085708|Experimental|3|
89270374|NCT01085708|Active Comparator|4|
89270375|NCT01081106|Other|Low-Level Laser Therapy|
89270376|NCT01085942||Asymptomatic rotator cuff tear|Subjects identified with an asymptomatic rotator cuff tear
89270377|NCT00090584|Experimental|Combination therapy|Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication (tolterodine) and behavioral training.
89270378|NCT00090584|Active Comparator|Drug therapy alone|Women assigned to this arm received 10 weeks of anti-cholinergic medication (tolterodine), only.
89270379|NCT01326884|Other|1|Endovascular Repair
89270380|NCT03965000||Patients|Patients carrying one or both mutations.
89270381|NCT03965000||Controls|Patients not carrying a mutation Familial renal glucosuria causing mutation in the SLC5A2 gene and without impaired glucose tolerance and type 1 or 2 diabetes mellitus.
89270382|NCT01079468||Total Hip Arthroplasty|
89270383|NCT01079468||Total Hip Resurfacing Arthroplasty|
89270384|NCT01081184||primary Sjögren syndrome|
89270385|NCT01081184||Healthy volunteers|
89270386|NCT03964922|Experimental|immune escape mecanims|Cohort study with a representative sample of patients
89270387|NCT01079546||Sq.CC of head and neck TASMC|
89270388|NCT01079546||hadassa Jerusalem|
89270389|NCT01079546||sheba hospital|
89270390|NCT01079546||rambam Haifa|
89270391|NCT01079546||belinson Petah Tikva|
89270392|NCT01079546||Nazeret|
89270393|NCT01079546||soroka beer sheva|
89270394|NCT01079624|Experimental|GIP two doses and GLP-1 one dose|Intervention with infusion of GIP or GLP-1 intravenously
89270395|NCT01079624|Placebo Comparator|Saline infusion|Control
89270396|NCT01086020|Active Comparator|atorvastatin|patients will be treated with atorvastatin 10mg/d after randomization, and continued for two years
89270397|NCT01086020|Experimental|atorvastatin and ezetimibe|patients will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d after randomization, and continued for two years
89270398|NCT03670810|Experimental|100 milligram (mg) Lasmiditan|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
89270399|NCT03670810|Experimental|200 mg Lasmiditan|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
89270400|NCT03670810|Placebo Comparator|Control 1 Sequence|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
89270401|NCT03670810|Placebo Comparator|Control 2 Sequence|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
89270402|NCT03670810|Experimental|100 mg Lasmiditan Maximum Extended Enrollment (MEE)|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
89270403|NCT03670810|Experimental|200 mg Lasmiditan MEE|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
89270404|NCT03670810|Placebo Comparator|Control 1 Sequence MEE|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
89270405|NCT03670810|Placebo Comparator|Control 2 Sequence MEE|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
89270406|NCT03670810|Experimental|Open Label Extension|Participants initially received 100 mg Lasmiditan at the first OLE visit, with flexible dosing (50, 100, or 200 mg) thereafter to optimize efficacy and tolerability.
89270407|NCT01086098||All paced patients|
89270408|NCT03962192|Experimental|Survey tools|Survey instruments are shared with reviewers.
89270409|NCT01086176||Patient-control|
89270410|NCT01086254|Experimental|Iniparib/ Gemcitabine/ Cisplatin|"Iniparib, 5.6 mg/kg, 60-min IV infusion twice weekly (days 1, 4, 8, and 11). Infusion starts after completion of GC regimen administration.~Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion."
89270411|NCT01086254|Active Comparator|Gemcitabine/ Cisplatin|Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.
89270412|NCT01081340|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building reciprocal social ties between the intervention group members
89270413|NCT01081340|Active Comparator|Home visit|Home visits focused on preventable infant injuries
89270414|NCT01086332|Experimental|phase 1/2|An escalating study of gemcitabine when combined with 1250 mg of nelfinavir twice daily. Dose of gemcitabine is increased for new subjects based on the experiences and tolerance of prior subjects. When the maximum tolerated dose is identified, a recommended phase 2 dose will be assigned and further subjects will receive that dose.
89270415|NCT03962270|Experimental|Treatment group|
89270416|NCT03962270|Sham Comparator|Control group|
89270417|NCT01811368|Experimental|Treatment (ibritumomab tiuxetan, allogeneic PBSCT)|"CONDITIONING REGIMEN: Patients receive rituximab IV on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine PO BID or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28."
89270418|NCT00089648|Experimental|1|
89270419|NCT01086488|Experimental|Nasopharyngeal Carcinoma|A: Experimental B: Active Comparator
89270420|NCT00118040|Experimental|Arm I (lower dose genistein)|Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
89270421|NCT00118040|Experimental|Arm II (higher dose genistein)|Patients receive oral genistein as in arm I but at a higher dose. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
89270422|NCT00118040|Placebo Comparator|Arm III (placebo)|Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
89270423|NCT03961958|No Intervention|No protocolled propofol reduction|In phase 1, target-controlled infusion propofol anesthesia was adjusted to maintain BIS 40 to 60.
89270424|NCT03961958|Experimental|Two protocolled propofol reductions|In phase 2, there were 2 planned reductions in propofol target concentration: (1) immediately after loss of consciousness-reduction calculated using a predefined formula, and (2) before positioning-reduction equal to the average percentage decrease in CO after knee-chest position in phase
89270425|NCT01081418|Experimental|Standard care|Standard care comprised a treatment network consisting of open and closed inpatient wards, day-clinics, an outpatient centre, and eight private psychiatrists. Each patient was treated by a private psychiatrist or by a psychiatrist in the outpatient centre. Home visits were possible, but office visits were the general rule. Patients were allowed to use all treatment offers in the outpatient centre. Outside office hours, patients could refer themselves to the psychiatric hospital. Psychosocial treatments as supportive therapy, psychoeducation, psychotherapy, and family intervention were provided infrequently and in a less intensive and unsystematic way, and only in the minority of cases. This 'standard of care' definition is in accordance with other studies.
89270426|NCT00389207|Active Comparator|NVP bid|nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
89270427|NCT00389207|Experimental|NVP qd|nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
89270428|NCT00389207|Active Comparator|ATZ/r|ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)
89270429|NCT01018745|Experimental|BMS-907351 (XL184)|
89270430|NCT00388583|Experimental|Fluzone Intradermal (ID) Vaccine Group|Participants received a dose of Fluzone Intradermal (ID) Influenza Vaccine
89270431|NCT00388583|Active Comparator|Fluzone Intramuscular (IM) Vaccine Group|Participants received a dose of Fluzone Intramuscular (IM) Influenza Vaccine.
89270432|NCT00117572|Active Comparator|Induction plus chemoradiotherapy|"Induction therapy: Two 21-day cycles of chemotherapy consisting of docetaxel (75 mg/m2, day 1), cisplatin (75 mg/m2, day 1), and 5-fluorouracil (750 mg/m2/day, days 1-5). Total duration of 6 weeks.~Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks."
89270433|NCT00117572|Active Comparator|Chemoradiotherapy|Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks.
89270434|NCT00388505|Experimental|Tobramycin inhalation powder (TIP)|Participants received four 28 mg capsules of tobramycin inhalation powder (TIP) delivered with the T-326 inhaler twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
89270435|NCT00388505|Active Comparator|Tobramycin solution for inhalation (TOBI)|Participants received one 300 mg (in 5 mL) ampoule of tobramycin solution for inhalation (TOBI) delivered with a nebulizer twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
89270436|NCT00388349|Experimental|Gemcitabine + Autologous HCT|Gemcitabine and high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue. Chemotherapy includes Gemcitabine + Vinorelbine + Carmustine + Etoposide + Cyclophosphamide.
89270437|NCT00117338|Placebo Comparator|1|Placebo
89270438|NCT00117338|Active Comparator|2|montelukast sodium
89270439|NCT00388037|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89270440|NCT00387881|Placebo Comparator|Placebo|
89270441|NCT00387881|Experimental|Treximet|
89270442|NCT00084656|Experimental|Arm 1|
89270443|NCT00387725|Experimental|Group A|20ug Experimental
89270444|NCT00387725|Experimental|Group 2|60ug Experimental
89270445|NCT00387725|Experimental|Group 3|200ug Experimental
89270446|NCT00387725|Active Comparator|Group 4|Active comparator
89270447|NCT01086566|Experimental|Multiple Boost Group-15 mcg|25 healthy adults who have previously received both Clade 1 and Clade 3 vaccines as a participant in study DMID 05-0043 will receive a single dose of 15 mcg of A/Indonesia/5/05.
89270448|NCT01086566|Experimental|Primed Group-15 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 15 mcg of A/Indonesia/5/05.
89270449|NCT01086566|Experimental|Unprimed Group-90 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 90 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
89270450|NCT01086566|Experimental|Unprimed Group-15 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 15 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
89270451|NCT01086566|Experimental|Primed Group-90 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 90 mcg of A/Indonesia/5/05.
89270452|NCT01045811|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
89270453|NCT01045811|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
88821611|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 4 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to continue CAB LA plus RPV LA Q4W administration via IM route.
88821612|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 8 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to receive CAB LA plus RPV LA Q8W via IM route.
88821613|NCT03298945|Active Comparator|Golytely|4-L split-dose Golytely bowel prep
88821614|NCT03298945|Experimental|Miralax-Gatorade prep|2-L split-dose Miralax-Gatorade bowel prep
88821615|NCT03298022|Experimental|ALTB-168|intravenous doses of ALTB-168
88821616|NCT03288025|Experimental|Nutrition and Exercise|5 days a week of moderate exercise and biweekly diet counseling on Low Glycemic Index/ Mediterranean Diet for 12 weeks.
88821617|NCT03288025|No Intervention|Standard of Care|Counseling at baseline on diet as recommended by USDA and on the benefits of regular aerobic exercise.
88821618|NCT03279094|Experimental|Haploidentical stem cell transplantation|
89270454|NCT00387647|Experimental|Azacitidine Treatment|Azacitidine 50 mg/m^2 subcutaneously daily for 5 days (Monday through Friday) on days 1 through 5, every 28 days for 6-12 cycles.
89270455|NCT01086722|Experimental|"karolinska cocktail"|The karolinska cocktail contains dextromethorphan, caffeine, losartan and omeprazol
89270456|NCT01086800|Other|HLSE plus PAP|
89270457|NCT01086800|Other|HLSE plus Oxygen|
89270458|NCT01086800|Other|Healthy Lifestyles and Sleep Education|
89270459|NCT00386009|Placebo Comparator|1|Placebo
89270460|NCT00386009|Active Comparator|2|tadalafil
89270461|NCT01045889|Experimental|R-CHOP + PBSCT|All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation
89270462|NCT00373685|Experimental|Celecoxib|dosing as per USPI label
89270463|NCT00373685|Active Comparator|NSAIDs|
89270464|NCT00373529|Experimental|Clofarabine|Participants received an induction cycle of clofarabine 30 mg/m^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m^2/day intravenous infusion for 5 consecutive days.
89270465|NCT00373295|Experimental|Baclofen 60 mg, Placebo, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
89270466|NCT00373295|Experimental|Baclofen 90 mg, Placebo, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
89270467|NCT00373295|Experimental|Baclofen 60 mg, Baclofen 90 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
89270468|NCT00373295|Experimental|Baclofen 90 mg, Baclofen 60 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
89270469|NCT00373295|Experimental|Placebo, Baclofen 90 mg, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
89270470|NCT00373295|Experimental|Placebo, Baclofen 60 mg, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
89270471|NCT03395795|Other|Single arm|Single arm trial, every patient enroll in this study will follow the same protocol with classic and NAVA mode non-invasive ventilation.
89270472|NCT01044563|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
89270473|NCT01044563|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
89270474|NCT00385541|Active Comparator|A|Patients receive morphine 1mg/dose PCA for postsurgical pain; max 10 mg/hr; lockout 6 minutes.
89270475|NCT00385541|Active Comparator|B|Patients receive hydromorphone 0.2mg/dose PCA for postsurgical pain; max 10mg/hr; lockout 6 minutes.
89270476|NCT01046045|Active Comparator|Everolimus|before and after everolimus; in other words, comparison of specified outcome before and after treatment with everolimus
89270477|NCT01046045|Active Comparator|Calcineurin-inhibitor immunosuppression|Cyclosporin-based immunosuppression without everolimus
89270478|NCT01044719|Active Comparator|10 days|
89270479|NCT01044719|Active Comparator|14 days|
88805514|NCT03008395|Active Comparator|Treatment as Usual|The participants will receive standard diabetes education via group and individual sessions with certified diabetes educators. In this method the patient is provided structured education in which there is an emphasis on covering clinician-determined aspects of diabetes knowledge and self-management. The emphasis vis on diabetes educator recommendations.
88805515|NCT01120223|Experimental|LEO 80185 gel once daily application|
88805516|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraaticulary Only|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Intraaticular Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter"
89270480|NCT01044719|Active Comparator|21 days|
89270481|NCT00392015|Experimental|Dose-escalation|NMRC-M3V-Ad-PfCA
89270482|NCT00392015|Experimental|Regimen-comparison|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
89270483|NCT01044875|Active Comparator|green laser 532 nm conventional|Current type of laser used for treatment of proliferative diabetic retinopathy
89270484|NCT01044875|Active Comparator|Yellow 577 nm laser|new laser wavelength for treatment of PDR
89270485|NCT01046201||Obese Children|
89270486|NCT01044953||Soccer Players|German professional soccer players
89270487|NCT01045109|Experimental|open-label vitamin D3|One arm: open-label receiving vitamin D3 4,000 IU daily
89270488|NCT01045343|Active Comparator|Control Arm|
89270489|NCT01045343|Experimental|Integrated Diagnostics Arm|
89270490|NCT00094302|Placebo Comparator|Placebo|Placebo of spironolactone
89270491|NCT00094302|Experimental|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
89270492|NCT00372905|Experimental|bortezomib, Ibritumomab tiuxetan, rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
89270493|NCT00384839|Experimental|1|azacitidine for injectable suspension
89270494|NCT01046279||Glioma Patient receiving Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
89270495|NCT01084590|Experimental|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
89270496|NCT01084590|Active Comparator|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
89270497|NCT00384293|Experimental|1|MK0524A
89270498|NCT00384293|Placebo Comparator|2|placebo
89270499|NCT01087866|Experimental|Metformin|
89270500|NCT01087866|Active Comparator|Insulin|
89270501|NCT01046357|Experimental|Active|AZD7687 oral suspension
89270502|NCT01046357|Experimental|Placebo|placebo oral suspension
89270503|NCT01084746|Active Comparator|PC-based tailored intervention|
89270504|NCT01084746|Active Comparator|Printed educational materials|
89270505|NCT01084746|No Intervention|No patient intervention|Patients will not receive a patient-directed intervention.
89270506|NCT01090830|Experimental|Belinostat|This is a one arm, open label study of the investigational medication Belinostat.
89270507|NCT01084824|Active Comparator|Liquid nitrogen and canthardin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.
89270508|NCT01084824|Placebo Comparator|Liquid nitrogen and placebo|Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.
89270509|NCT01088022|Experimental|Aprepitant, Palonosetron, dexametasone|
89270510|NCT01088022|Placebo Comparator|Placebo, Palonosetron, Dexamethasone|
89270511|NCT00067002|Experimental|Double Cord Blood Transplant Group|Two Unmanipulated Cord Blood units. Rituxan 375 mg/m2 by vein for patients with CD20 + malignancies. Melphalan 140 mg/m2 by vein on Day -8. Thiotepa 5 mg/Kg by vein on Day -7. Fludarabine 40 mg/m2 by vein on Days -6 to -3.
89270512|NCT00067002|Experimental|One Expanded Cord Blood Transplant Group|One Unmanipulated and One Expanded Cord Blood Unit. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Cyclophosphamide 50 mg/kg by vein on Day -6. Mesna 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg). Total body irradiation (TBI) given on Day -1 at 2 Gy.
89270513|NCT01090986||1|Patients with a restrictive pulmonary disease and hypercapnic chronic respiratory failure with standard criteria for NIV. Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
89270514|NCT02530944||Lupus patients|People diagnosed with Systemic Lupus Erythematosus by a physician
89270515|NCT03962556||Non-Trigger Point|
89270516|NCT03962556||Trigger Point|
89270517|NCT01084902|Experimental|latnoprost|once daily
89270518|NCT01084902|Active Comparator|Brinzolamide|two times daily
89270519|NCT01084980|Experimental|Tacrolimus|
89270520|NCT01088100||Patients with POCD - cases|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
89270521|NCT01088100||Patients without POCD - controls|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
89270522|NCT01085058|Experimental|A: lenograstim|total group
89270523|NCT01583556||Standard treatment|This study will employ a prospective, non-randomized design. After the questionnaires are filled the patients choose whether or not to schedule a second appointment for evaluation of their fracture: The first group will be scheduled for a second visit (standard treatment) as our daily practice after 1-3 months. They will be contacted after 2-6 months either by phone or email and will complete again some questionnaires (Quick DASH, satisfaction, return to work).
89270524|NCT01583556||Optional follow-up group|The alternative (Optional follow-up group) will be to take a handout describing the recovery and providing instructions for how to contact us should they get off course. The questionnaires will be repeated either by phone or email in 2-6 months.
89270525|NCT03961542|Experimental|Intervention Group|"This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.~Differences in fasting glucose and longitudinal changes over the study period should be additionally examined."
89270526|NCT03961542|No Intervention|Control Group|Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²).
89270527|NCT01088178|Experimental|Immediate Postplacental|Within 10 minutes from delivery of placenta
89270528|NCT01088178|Experimental|Early Postpartum|After 10 minutes from delivery of placenta but within 48hrs from delivery
89270529|NCT01088178|Experimental|Interval|After 6 weeks postpartum
89270530|NCT01091064|Experimental|Early depart|Patients who will be liberated at triage with mild acute viral bronchiolitis
89270531|NCT01091064|No Intervention|Medical visit group|Patients with acute viral bronchiolitis who will wait to be seen by the physician
89270532|NCT01091142|Experimental|NP001|
89270533|NCT01091142|Placebo Comparator|Placebo|
89270534|NCT01088256|Active Comparator|etoricoxib, peripheral hyperalgesia|14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days
89270535|NCT01088256|Active Comparator|etoricoxib, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days
89270536|NCT01088256|Placebo Comparator|placebo, peripheral hyperalgesia|14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days
89270537|NCT01088256|Placebo Comparator|placebo, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days
89270538|NCT03957486|Experimental|Same group|arterial cannulation on same arm of continuous hemoglobin monitoring
89270539|NCT03957486|Placebo Comparator|Different group|arterial cannulation on different arm of continuous hemoglobin monitoring
89270540|NCT03957408|Experimental|Visual Stimuli|Participants will be presented various visual stimuli in which accommodative response is measured.
89270541|NCT01326858|Experimental|Olopatadine, 0.7%|Olopatadine hydrochloride ophthalmic solution, 0.7%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic vehicle and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
89270542|NCT01326858|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
89270543|NCT01326858|Active Comparator|Zaditor|Ketotifen fumarate ophthalmic solution, 0.025%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and olopatadine hydrochloride ophthalmic solution vehicle, Periods 2 and 3, as randomized
89270544|NCT01088334||IVTE, follow-up|no malignancy at basal screening, no extensive screening
89270545|NCT01088334||IVTE, screening|No malignancy at basal screening, screening by means of CT-Chest/abdomen and mammography in women
89270546|NCT00091572|Experimental|A|"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (7 days on / 7 days off continuously)"
89270547|NCT00091572|Active Comparator|B|dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks
89270548|NCT01091220|Placebo Comparator|Placebo|0.9% saline
89270549|NCT01091220|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg
89270550|NCT03961386|Experimental|FallsTalk-C|FallsTalk CG intervention
89270551|NCT03961386|Active Comparator|FallsTalk|FallsTalk intervention
89270552|NCT03961386|No Intervention|PostCardOnly|Postcard only- Control group
89270553|NCT00084266|Experimental|1|Subjects receiving linezolid for the treatment phase of the study
89270554|NCT00084266|Active Comparator|2|Subjects receiving vancomycin for the treatment phase of the study
89270555|NCT01091298|Experimental|Group 1|
89270556|NCT01091298|Placebo Comparator|Group 2|
89270557|NCT03957564|Experimental|Patients receiving neoadjuvant chemotherapy.|"Compare the monitoring of CTC, ctDNA and cfDNA with the results of CT scan and the blood level of CEA ,CA19-9 and CA72-4 tumor markers to explore the clinical value of dynamic detection of CTC, ctDNA and cfDNA in neoadjuvant chemotherapy and operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer.~Explore the clinical value of different types of CTC in neoadjuvant chemotherapy and Operation for locally advanced or resectable gastric or gastro-oesophageal junction cancer. CTC can be classified into three types: epithelial CTC, mesenchymal CTC, hybrids CTC.~Explore the consistency between plasma ctDNA and tumor related DNA in pathological tissues after operation.~To explore the relationship between the dynamic changes of plasma CTC, ctDNA and cfDNA levels and the prognosis of patients after operation."
89270558|NCT01086878|Experimental|Cotrimoxazole|
89270559|NCT00091026|Experimental|Arm I (cetuximab, gemcitabine hydrochloride, bevacizumab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22; gemcitabine IV over 30 minutes on days 1, 8, and 15; and bevacizumab IV over 30-90 minutes on days 1 and 15.
89270560|NCT00091026|Experimental|Arm II (gemcitabine hydrochloride, bevacizumab, erlotinib)|Patients receive gemcitabine and bevacizumab as in arm I. Patients also receive oral erlotinib once daily on days 1-5, 8-12, and 15-26.
89270561|NCT01087034||Milwaukee brace|Children with an infantile scoliosis requiring Milwaukee bracing
89270562|NCT01087034||Cheneaux brace|Children with an infantile scoliosis requiring Cheaneaux bracing
89270563|NCT03961074||Exposure group|Chinese women with iron deficiency anemia (IDA) during pregnancy.
89270564|NCT03961074||Control group|Chinese women without iron deficiency anemia (IDA) during pregnancy.
89270565|NCT01583634||Healthy volunteers|9 subjects (male and female)
89270566|NCT01088490||critically ill|Critically ill patients admitted to ICU
89270567|NCT01583790||no group|laparoscopic sleeve gastrectomy
89270568|NCT01091376|Experimental|Concomitant Erlotinib and radiotherapy|Patients received Erlotinib and radiation therapy.
89270569|NCT00116558|Experimental|Early NIPPV Intervention|Participants with >80% predicted forced vital capacity (FVC).
89270570|NCT00116558|Active Comparator|Standard of Care NIPPV|Participants with 50-74% predicted forced vital capacity (FVC).
89270571|NCT00116558|Active Comparator|Standard of Care NIPPV and Nutritional Monitoring|Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.
89270572|NCT01085292|Experimental|Group A|
89270573|NCT01085292|Experimental|Group B - D|
89270574|NCT01085370|No Intervention|Control Group|standard medical care only
89270575|NCT01085370|Experimental|Intervention group|2 sessions with early psychological interventions
89270576|NCT00116168|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
89270577|NCT00116168|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
89270578|NCT00116168|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
89270579|NCT00116168|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
89270580|NCT00115934|Active Comparator|MBTS|Blalock-Taussig pulmonary artery shunt
89270581|NCT00115934|Active Comparator|RVPAS|Right ventricular to pulmonary artery shunt
89270582|NCT00115778|Experimental|First IVIG, then Placebo|Study participants will receive three doses of IVIG given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of placebo over 12 weeks.
89270583|NCT00115778|Experimental|First Placebo, then IVIG|Study participants will receive three doses of 0.1% albumin solution (placebo) given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of IVIG over 12 weeks.
89270584|NCT01081574|Experimental|10 mg Bilastine once daily for 7 days|10 mg Bilastine dispersible oral tablet
89270585|NCT00100178|Experimental|MMF and DBZ|DZB given by intravenous infusion (1 mg/kg)at baseline and 2 weeks later, and MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years.
89270586|NCT00100178|Experimental|MMF Alone|MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years and saline intravenous infusions given at baseline and two weeks later.
89270587|NCT00100178|Placebo Comparator|Placebo|Placebo pills given daily for two years and saline intravenous infusions given at baseline and two weeks later.
89270588|NCT01090388||1|Participants voluntarily completed a telephone interview using a questionnaire compiled using validated, patient-centered measures of cancer outcomes and psychosocial status.
89270589|NCT01087112|Active Comparator|Child Health Centre care|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Additional treatment was initiated in 1/3 of the cases. This was registered at the end-point interview.
89270590|NCT01087112|Experimental|Mother-Infant Psychoanalytic tmt|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief that the infant understands verbal communication. The analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
89270591|NCT00099632|Experimental|7-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.
89270592|NCT00099632|Experimental|21-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.
89270593|NCT00099632|Experimental|7-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.
89270594|NCT00099632|Experimental|21-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.
89270595|NCT00099632|Experimental|7-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.
89270596|NCT00099632|Experimental|21-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r
89270597|NCT01087190|Experimental|INH treatment group|"randomly allocated to INH treatment group in renal transplant recipients with ELISPOT (+)~INH 300 mg po qd for 9 months"
89270598|NCT01087190|No Intervention|Control group|"randomly allocated to control group in renal transplant recipients with ELISPOT (+)~no treatment"
89270599|NCT01087190|No Intervention|Observation group|"allocated to observation group in renal transplant recipients with ELISPOT (-)~no treatment"
89270600|NCT04116398|Experimental|Ozurdex®, 700µg dexamethasone intravitreal injection|Intravitreal injection of dexamethasone (Ozurdex®)
89270601|NCT00098774|Experimental|Intensive Combination Chemo & Immunotherapy|"Induction Cycles 1-3: Methotrexate 8gm/m^2 days 1 & 15; Leucovorin 100 mg/m^2 days 2 & 16; Rituximab 375 mg/m^2 days 3, 10, 17 & 24 of cycle 1, days 3 & 10 of cycle 2; Temozolomide 150 mg/m^2/day PO days 7-11~Induction Cycle 4: Temozolomide 150 mg/m^2/day PO days 7-11; Methotrexate 8gm/m^2 day 15; Leucovorin 100 mg/m^2 day 16~Consolidation Cycle 5: Methotrexate 8gm/m^2 days 1; Leucovorin 100 mg/m^2 days 2; Temozolomide 150 mg/m^2/day PO days 7-11~Consolidation Cycle 6: Cytarabine 2 g/m^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m^2/day starting day 14 until ANC recovers (>= 500 for 2 consecutive days or >= 1500 for one day)"
89270602|NCT01081652|Experimental|Crinone 8% group|Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally
89270603|NCT01081652|Active Comparator|Intramuscular progesterone group|Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily
89270604|NCT01087424|Experimental|R mini CHOP|Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks
89270605|NCT01087580|Experimental|Chemotherapy alone, no radiation therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days~B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel"
89270606|NCT01087580|Experimental|Chemotherapy with Radiation Therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel~GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
89270607|NCT03961412|Experimental|family-based intervention + education materials|The participants will identify their accompanying influential person (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. Their accompanying influential person is eligible if they are (a) aged 18 or older and (b) willing to participate in the study.
89270608|NCT03961412|Active Comparator|women only intervention + education materials|Only the participants will attend the 1.5-2 hour face-to-face intervention on cervical cancer and screening.
89270609|NCT01087658|Experimental|Glutamine and calcium magnesium|"Glutamine 10g p.o. 3-times a day beginning at day -2 for 7 consecutive days during each chemotherapy cycle. 1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
89270610|NCT01087658|Active Comparator|Calcium magnesium|"1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
89270611|NCT03958058||Anti-borrelial antibiotic therapy|
89270612|NCT03958058||No antibiotics|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
89270613|NCT01090622|Placebo Comparator|Matching Placebo|
89270614|NCT01090622|Experimental|XPF-001|
89270615|NCT01081730||001|ustekinumab as prescribed
89270616|NCT01081730||002|anti-TNF biologics as prescribed
89270617|NCT01081730||003|non-anti-TNF biologics as prescribed
89270618|NCT01081730||004|systemic non-biological treatments as prescribed
89270619|NCT01081730||005|general population non-treated cohort
89270620|NCT01090700|Experimental|001|TMC435 TMC435 150 mg daily for 7 days
89270621|NCT01090700|Other|002|Escitalopram Escitalopram 10 mg daily for 7 days
89270622|NCT01090700|Experimental|003|TMC435 + Escitalopram TMC435 150 mg + escitalopram 10 mg daily for 7 days
89270623|NCT03957980|Other|Telehealth Intervention First|The participants in this arm of the study received occupational therapy via telehealth in the first 12 weeks of enrollment, then received no other intervention for the duration of the study.
89270624|NCT03957980|Other|No Intervention First|The participants in this arm of the study did not receive an intervention in the first 12 weeks of enrollment, but received occupational therapy via telehealth during the second 12 weeks of enrollment.
89270625|NCT01087892|Active Comparator|Dietary supplement Probiotic drink|"Double blind~Probiotic containing the live strain 100g/day orally, twice daily for the duration of the course of antibiotics plus seven days"
89270626|NCT01087892|Placebo Comparator|Dietary supplement probiotic placebo drink|"Double blind~'placebo' is actually a control product~Placebo drink contains no strain 100gs orally, twice daily for the duration of the course of antibiotics plus seven days"
89270627|NCT03957902|Experimental|Arm 1 (100 mg/24h)|
89270628|NCT03957902|Experimental|Arm 2 (300 mg/24h)|
89270629|NCT03957902|Experimental|Arm 3 (100 mg/12h)|
89270630|NCT00384059|Experimental|1|13-valent pneumococcal vaccine
89270631|NCT00384059|Active Comparator|2|7-valent pneumococcal vaccine
89270632|NCT00383123|Experimental|Fluarix Group|"Subjects in this group received Fluarix™ and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
89270633|NCT00383123|Active Comparator|Fluzone Group|"Subjects in this group received Fluzone and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
89270634|NCT01046435|Placebo Comparator|Supragingival scaling plus placebo|Plaque control instructions, supra gingival scaling and two placebos
89270635|NCT01046435|Experimental|Root planing plus antibiotics|Plaque control instructions, subgingival scaling,root planing, metronidazole 250 mg and amoxicillin 500 mg. three times a day for 7 days
89270636|NCT00382967|Experimental|Datscan Product|
89270637|NCT00382967|No Intervention|Control|
89270638|NCT01046591||Cleft|Those with a repaired cleft palate
89270639|NCT01046591||Comparison|Those without a cleft palate repair
89270640|NCT00858364|Placebo Comparator|Placebo|Participants received placebo once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
89270641|NCT00858364|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
89270642|NCT01045577|Active Comparator|Masitinib (AB1010)|Masitinib (AB1010)
89270643|NCT01045577|Placebo Comparator|Placebo mactching masitinib|Placebo matching masitinib
89270644|NCT03992885|Experimental|combination therapy with ectiecinib, pemetrexed and platinum|ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally;Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle, a total of 6 cycles.Maintenance therapy: ectinib: ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally, pemetrexed 500mg/m2,d intravenous infusion, day 1,21 days for a cycle
89270645|NCT05668702|Experimental|capillary blood glucose measurement|the researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
89270646|NCT03739294|Experimental|PILOT: 4 puffs once|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms
89270647|NCT03739294|Experimental|PILOT: 4 puffs once a day for 7 days|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms for 7 days
89270648|NCT03739294|Experimental|LARGE: 4 puffs once|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) once
89270649|NCT03739294|Experimental|LARGE: 4 puffs once a day for 7 days|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) daily for 7 days
89270650|NCT03739294|Experimental|LARGE: 1 puff once|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (1 puff) once
89270651|NCT03739294|Experimental|LARGE: 1 puff once a day for 7 days|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 (1 puff) daily for 7 days
89270652|NCT03739216||Open label|Open label registry study of patients treated with the ClariFix device for chronic rhinitis.
89270653|NCT03739060|Active Comparator|Active TENS group|Conventional transcutaneous electric nerve stimulation
89270654|NCT03739060|Placebo Comparator|Placebo TENS group|0 amperes transcutaneous electric nerve stimulation
89270655|NCT03631732|Experimental|B/F/TAF|Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
89270656|NCT03631732|Active Comparator|Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF|Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
89270657|NCT03732508|Experimental|Irinotecan liposome plus SHR1316 plus fluorouracil|
89270658|NCT03732430|Experimental|Anti-PD-1 antibody|IBI308 200mg intravenous drip every three weeks following adaptive radiation therapy.
89270659|NCT03630016|Active Comparator|Reference CO-Oximetry|Reference Co-Oximetry
89270660|NCT03630016|Experimental|Owlet BabySat v1.0|Owlet BabySat v1.0
89270661|NCT03630016|Experimental|Owlet Smart Sock V2 v1.1|Owlet Smart SockTM 2 , OSS v1.1 Sensor and Custom Adult Thumb Sock
89270662|NCT03628924|Experimental|Group 1: Guselkumab Regimen 1|Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
89270663|NCT03628924|Experimental|Group 2: Guselkumab Regimen 2|Participants will receive guselkumab dose 2 subcutaneously.
89270664|NCT03628924|Experimental|Group 3: Placebo then Guselkumab|Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
89270665|NCT03738982|Experimental|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
89270666|NCT03735706|Active Comparator|Control group - 120 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.~The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV."
89270667|NCT03735706|Experimental|90 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.~A radiation dose reduction from 120 to 90 kV.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1."
89270668|NCT03735706|Experimental|100 kV - 0.417 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.~The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg."
89270669|NCT03735706|Experimental|90 kV - 0.365 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg."
89270670|NCT03735550||Group A age: 18-49|Women aged 18-49 who had breast ultrasound performed with a result of BI-RADS 4b, 4c or 5. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to breast ultrasound. The planned number of participants in the group: n=700 people.
89270671|NCT03735550||Group B age: 50 and above|Women aged 50 and above who had mammography and/or breast ultrasound performed (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa). Women were recruited if they had a result of BI-RADS 4, 4a, 4b, 4c or 5 on mammography or BI-RADS 4a, 4b, 4c or 5 on ultrasound. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques. The planned number of participants in the group: n=2100 people.
89270672|NCT03735550||Group C 18-49; 50 and above|"Subgroup C1 (n=100 people): women aged 18-49 years, who underwent breast ultrasound with a result of BI-RADS 1 or 2.~Sub-group C2 (n=100 people): women aged 50 and above, who had mammography or breast ultrasound performed; with a result of BI-RADS 1 or 2 (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa).~Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques."
89270673|NCT03627832|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for 6 weeks
89270674|NCT03627832|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
89270675|NCT00112437|Placebo Comparator|Placebo|
89270676|NCT00112437|Experimental|Odanacatib 3 mg|
89270677|NCT00112437|Experimental|Odanacatib 10 mg|
89270678|NCT00112437|Experimental|Odanacatib 25 mg|
89270679|NCT00112437|Experimental|Odanacatib 50 mg|
89270680|NCT03735472||Aneurysm/Dissection|Thoraflex™ Hybrid
89270681|NCT03738592|Experimental|cochlear implant children|18 cochlear implant children wil include in this study
89270682|NCT03738592|Other|normal hearing children|18 normal hearing children wil include in this study
89270683|NCT03653416|Experimental|Ipack group|20 cc of bupivacaine(o.25%) will be injected with the help of ultrasound guidance. Patients will receive adductor canal catheter and peri articular infiltration as well.
89270684|NCT03653416|Active Comparator|Pai (peri articular) group|Patients will receive adductor canal catheter and peri articular infiltration.
89270685|NCT03738514|Active Comparator|Group 1|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
89270686|NCT03738514|Sham Comparator|Group 2|dentifrice containing 5% potassium nitrate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
89270687|NCT03738514|Placebo Comparator|Group 3|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
89270688|NCT01076673|Experimental|PBSC and Hyaluronic Acid|Peripheral blood stem cells and hyaluronic acid injections
89270689|NCT01076673|Active Comparator|Hyaluronic Acid|Hyaluronic Acid
89270690|NCT00112359|Placebo Comparator|Placebo three times a day (TID)|
89270691|NCT00112359|Experimental|AZLI 75 mg three times a day (TID)|
89270692|NCT01080183|Experimental|Feedback form|patients receive feedback regarding their prms in addition to doctor receiving report
89270693|NCT01080183|No Intervention|usual care|patients do not receive feedback form prior to the encounter, clinicians continue to receive patient reported measures prior to the appointment
89270694|NCT00119379|Experimental|uridine supplementation|NucleomaxX 36 grams TID every other day
89270695|NCT00119379|Active Comparator|Switch to Tenofovir|Switch of AZT or d4T to Tenofovir Disoproxil Fumarate
89270696|NCT00118911|Experimental|Cognitive-Behavioral Therapy|Participants will receive cognitive-behavioral therapy following our protocol.
89270697|NCT00118911|Active Comparator|Relaxation with Educational Support|Applied relaxation plus educational support (RES).
88805517|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Patellar Tendon Site|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Patellar Tendon Site Only~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter"
89270698|NCT01076751||CRPC patients|
89270699|NCT01080339||Physical Activity and Nutrition|Supervised physical activity in the form of novel gaming and exercise equipment several times per week for 12 weeks will be provided in addition to weekly nutrition education sessions.
89270700|NCT01080339||Nutrition Education Only|Children in this group will receive weekly group nutrition sessions, identical to those provided for the Physical Activity + Nutrition group
89270701|NCT01076829|Active Comparator|Spice patty|hamburger meat cooked with spice mixture
89270702|NCT01076829|Placebo Comparator|salt patty|Subjects consume salt containing hamburger meat
89270703|NCT01080417|Active Comparator|Cellcept® 250 mg Capsule|
89270704|NCT01080417|Experimental|Mycophenolate Mofetil Capsule 250 mg|
89270705|NCT01079481|Experimental|taxol plus everolimus|
89270706|NCT01076907|Experimental|Warm water loading of sigmoid colon|Warm water loading of sigmoid colon and irrigation when spasms occur.
89270707|NCT01076907|Placebo Comparator|Control|No water loading, only air and waiting for spasms to subside.
89270708|NCT03965169|Experimental|Patients undergoing prone spinal surgery|Patients undergoing elective spinal surgery in prone position under general anesthesia, which is performed by neurosurgeons in Seoul National University Hospital
89270709|NCT03964779||Anovulatory women|40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility
89270710|NCT03964779||Tubal factor women|40 infertile women with tubal (mechanical) factor of infertility with/without associated male factor of infertility
89270711|NCT03964779||male factor couple|40 women with exclusive male factor of infertility and will be used as a control group
89270712|NCT00131937|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89270713|NCT01079559|Active Comparator|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery. All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
89270714|NCT01079559|Experimental|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
89270715|NCT01079637|Experimental|Midfoot Fusion Bolt|
89270716|NCT01079637|Experimental|Cast treatment|
89270717|NCT01080495|Other|TEE (transesophageal echcardiography)|all patients get TEE and all parameters (radial strain, fractional shortening and fractional area change) are evaluated
89270718|NCT00131469|Active Comparator|Teriparatide (FORTEO)|Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
89270719|NCT00131469|Placebo Comparator|Placebo|Daily SQ placebo for 18 months
89270720|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Pts w/out Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
89270721|NCT00372593|Experimental|Arm B: Experimental - with GMTZ, AML Pts w/out Down Syndrome|Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, & 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
89270722|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Patients with Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
89270723|NCT01324583|Experimental|Arm 1|"Patients will receive cabazitaxel as the dose of corresponded level~1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²"
89270724|NCT03992807|Experimental|A patient decision aid|A patient decision aid that includes not only the standard general information, but also the quantitative risk information on the possible outcomes of cataract surgery as well as value clarification exercise.
89270725|NCT03992807|Active Comparator|A usual education booklet|A traditional booklet with standard general information developed by the National Eye Institute (NEI) to help patients understand cataract.
89270726|NCT03666988|Experimental|Part 1: GSK3368715 dose escalation|Eligible participants with solid relapsed/refractory tumors will receive escalating doses of GSK3368715 at a starting dose of 50 mg, administered orally once daily.
89270727|NCT03666988|Experimental|Part 1: GSK3368715 PK/PD/Metabolite/Biomarker|Additional participants in Part 1, treated at or close to the expected the maximum tolerated dose (MTD)/RP2D, will be evaluated for metabolic and biomarker profiling. Participants may be enrolled into this cohort(s) even after MTD/RP2D has been identified and Part 2 has been initiated.
89270728|NCT03666988|Experimental|Part 1: GSK3368715 Food effect|Eligible participants will receive single dose of GSK3368715 at starting dose of 50 mg tablet orally in fasted state followed by fed state in Period 1 and Fed followed by fasted state in Period 2.
89270729|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion - DLBCL participants|Eligible participants with relapsed/refractory DLBCL will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
89270730|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion-solid tumor participants|Eligible participants with relapsed/refractory solid tumors (pancreas cancer, NSCLC, and bladder cancer) will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
89270731|NCT00382109|Experimental|Tacro-MTX/Sirolimus GVHD Prophylaxis Regimen|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors) and oral sirolimus (dose 2.5mg/m2/day - 4 mg max starting dose) daily starting on day 0 followed by a taper starting on day 180 through day 207.
89270732|NCT00382109|Active Comparator|Tacro-MTX GVHD Prophylaxis|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally (when able) daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors).
89270733|NCT03640000|Experimental|Determination of impedance signals|This single arm study is designed to measure impedance signals from implanted leads in different positions in the heart. Signals obtained at different pre specified position are compared to each other to determine the robustness of the acquired measurements.
89270734|NCT03735394|Experimental|Gingival Biotype|A Periodontal probe was used to differentiate between thick and thin biotypes and patients were classified into 3 possible categories of Gingival Biotype (A1, A2 and B) according to Müller & Eger (https://doi.org/10.1034/j.1600-051x.2000.027009621.x). On each group two measurements were taken on the most protruded lower and upper central incisor: 1/ a tangential radiographic film and 2/ an ultrasonic probe measurement with the PIROP Biometric scanner (G-scan) form Echoson
89270735|NCT03738358|Experimental|Trehalose|
89270736|NCT03738358|Placebo Comparator|Placebo|
89270737|NCT03651622|Experimental|Hypocaloric, low carbohydrate|Behavioral intervention to include lifestyle counseling on hypocaloric, low carbohydrate diet (15-20% calories from carbohydrate, 59-63% as total fat (<10% saturated fat, at least 37% monounsaturated fat, remaining as polyunsaturated fat). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
89270738|NCT03651622|Experimental|Hypocaloric, moderate low fat|Behavioral intervention to include lifestyle counseling on hypocaloric, moderate low fat diet (30% calories from fat) weight management based on the Look AHEAD study. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
89270739|NCT03651622|Experimental|Mediterranean, no caloric restriction|Behavioral intervention to include lifestyle counseling on selecting a healthy Mediterranean diet, no caloric restriction. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
89270740|NCT00381797|Experimental|Arm I|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and irinotecan hydrochloride IV over 90 minutes on day 16 or 17 for course 1. Patients receive bevacizumab and irinotecan hydrochloride on days 1 and 15 for all subsequent courses. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo MRIs of the brain, magnetic resonance perfusion/diffusion, and fludeoxyglucose F 18 positron emission tomography at baseline and periodically during treatment."
89270741|NCT03738124|Experimental|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA Thoracic Stent Graft System is administered.
89270742|NCT03738046|Experimental|Pilot Treatment Arm|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
89270743|NCT03665038|Experimental|Brexanolone|Participants will receive a 60-hour single continuous IV infusion of brexanolone, at 30 mcg/kg/hour (0 to 4 hours), at 60 mcg/kg/hour (4 to 24 hours), at 90 mcg/kg/hour (24 to 52 hours), followed by a taper to 60 mcg/kg/hour (52 to 56 hours), and 30 mcg/kg/hour (56 to 60 hours) during the study.
89270744|NCT03664024|Experimental|Pembrolizumab Standard of Care|Participants will receive standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then pembrolizumab plus pemetrexed maintenance for up to 31 additional cycles. The platinum doublet would be pemetrexed plus the investigator's choice of either cisplatin or carboplatin.
89270745|NCT03737890|Experimental|Inspiratory muscle Training|4 weeks of inspiratory muscle training
89270746|NCT03737890|Active Comparator|Hold Relax Pectoral Stretch|4 weeks of hold relax pectoral stretch
89270747|NCT00381563|Other|Intervention to placebo|Participants will wear the patellofemoral realigning knee brace for 6 weeks, followed by the non-aligning knee brace for 6 weeks.
89270748|NCT00381563|Other|Placebo to intervetion|Participants will wear the non-aligning knee brace for 6 weeks, followed by the patellofemoral realigning knee brace for 6 weeks.
89270749|NCT01045655|Experimental|MOMCare intervention|Depression care treatment with study depression care specialist (brief interpersonal psychotherapy or pharmacotherapy)
89270750|NCT01045655|No Intervention|Care Plus|Usual care group; referral to community mental health treatment
89270751|NCT04516733|Other|single arm|patient with glioblastoma
89270752|NCT03735160||Nasal intubation with pressure sensor|anesthetized patient with nasotracheal intubation
89270753|NCT01310218|Other|extended postoperative dressing|Bulky dressing for 2 weeks
89270754|NCT01310218|Other|short postoperative dressing|2 day bulky dressing followed by bandaid.
89270755|NCT03732274|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.
89270756|NCT03735082|Experimental|apatinib+Paclitaxel+Carboplatin|apatinib 250mg, d1-14,14day/cycle; Paclitaxel 175mg/m2,d1,14days/cycle; Carboplatin AUC=4,d1,14day/cycle
89270757|NCT00381095|Experimental|1|flexible dosing
89270758|NCT00381095|Placebo Comparator|2|
89270759|NCT03619174|Active Comparator|Active Treatment|Treatment dose
89270760|NCT03619174|Placebo Comparator|Sham Treatment|Sub-therapeutic dose
89270761|NCT05665894||Breast hematoma group|Patients of age between 18 and 75 years old after breast conservative surgery (BCS), VAB or vacuum-assisted excision (VAE) procedure in our facility, who developed clinically significant and large hematoma (>25 mm). In our institution, we routinely offer a trial of Vacuum-Assisted Evacuation (VAEv) for >25 mm hematoma that does not fulfill the criteria for immediate surgery and causes discomfort, pressure symptoms, infection, or pain classified on VAS > 3.
89270762|NCT03737656|Experimental|Progesterone Vaginal Ring (Group A)|Insertion of the vaginal ring on Day 1 and continuous use until 91 days of treatment are completed. In this group, 28 participants will be included.
89270763|NCT03737656|Experimental|Progesterone Vaginal Ring (Group B)|Insertion of the vaginal ring on Day 1, removal for 2 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
89270764|NCT03737656|Experimental|Progesterone Vaginal Ring (Group C)|Insertion of the vaginal ring on Day 1, removal for 4 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
89270765|NCT00112047|Active Comparator|EFV+CBV|Participants in this group received EFV 600 mg once daily + Combivir ([CBV]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study extension received Atripla ([ATR]; the fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg) taken once daily until the end of the study (Week 240). At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
89270766|NCT00112047|Experimental|EFV+FTC+TDF|Participants in this arm received 3 component drugs: efaviren (EFV; 600 mg) + emtricitabine (FTC; 200 mg) + tenofovir disoproxil fumarate (tenofovir DF [TDF]; 300 mg) as 3 separate pills once daily from the start of the study. At 96 weeks Truvada ([TVD] the fixed-dose combination pill containing FTC/TDF [200/300 mg] once daily) replaced the 2 component drugs FTC + TDF; participants continued to receive EFV 600 mg once daily. At Week 144 all participants who opted to roll over into the further 96-week study extension received ATR. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
89270767|NCT03737578|Experimental|Daily hemodialysis patients|"Description: End stage renal disease patients starting daily hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
89270768|NCT03737578|Active Comparator|Conventional hemodialysis patients|"Description: End stage renal disease patients currently treated by conventional hemodialysis or starting conventional hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
89270769|NCT03658876|Active Comparator|EPO group|
89270770|NCT03658876|Active Comparator|Iron group|
89270771|NCT03618628|Experimental|People using a CFO|People who are currently wearing a carbon fiber off loading orthosis (CFO) will have a new CFO fabricated for them based on the results of our finite element (FE) model. We will then test both CFOs ability to reduce peak plantar compared to barefoot and the peak plantarflexor power of both braces.
89270772|NCT03734926|Experimental|Part 1|Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
89270773|NCT03734926|Experimental|Part 2 Cohort A|Participants with hepatocellular carcinoma.
89270774|NCT03734926|Experimental|Part 2 Cohort B|Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.
89270775|NCT03734848|No Intervention|Group 1|patients did not receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
89270776|NCT03734848|Active Comparator|Group 2|patients receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
89270777|NCT03639922|Active Comparator|Imatinib|Imatinib 400mg (2 tablets of 400mg) per day for 6 days
89270778|NCT03639922|Placebo Comparator|Placebo|2 placebo tablets per day for 6 days
89270779|NCT03616600|Experimental|Treatment|Wearing the orthokeratology lenses for 3 months
89270780|NCT03616600|No Intervention|Control|Not wearing any contact lenses
89270781|NCT03734614||Patients with adjuvant aspirin|After surgery, patients would use low-dose aspirin (100mg) longer than 1 year
89270782|NCT03734614||Patients without adjuvant aspirin|After surgery, patients would not use low-dose aspirin or use asprin shorter than 1 year
89270783|NCT00380393|Experimental|GSK257049 Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
89270784|NCT00380393|Active Comparator|Rabipur Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
89270785|NCT01046747|Active Comparator|Pre-drill|These pins will be pre-drilled
89270786|NCT01046747|Active Comparator|No pre-drill|these pins will not be pre-drilled, but will rely on the self drilling function of the pin for insertion
89270787|NCT00380081|Experimental|placebo/zolpidem 3.5/zolpidem 1.75|
89270788|NCT00380081|Experimental|placebo/zolpidem 1.75/zolpidem 3.5|
89270789|NCT00380081|Experimental|zolpidem 3.5/placebo/zolpidem 1.75|
89270790|NCT00380081|Experimental|zolpidem 3.5/zolpidem 1.75/placebo|
89270791|NCT00380081|Experimental|zolpidem 1.75/placebo/zolpidem 3.5|
89270792|NCT00380081|Experimental|zolpidem 1.75/zolpidem 3.5/placebo|
89270793|NCT03579940|Experimental|Lasmiditan - Japanese|Single (50 milligram (mg), 100 mg, 200 mg, 400 mg) and repeated (2 × 200 mg) doses of Lasmiditan administered orally in up to three of three study periods.
89270794|NCT03579940|Placebo Comparator|Placebo - Japanese|Single and repeated (2 X placebo) doses of Placebo administered orally in up to one of three study periods.
89270795|NCT03579940|Experimental|Lasmiditan - Caucasian|Single (50 mg, 100 mg, 200 mg) dose of Lasmiditan administered orally in up to three of three study periods.
89270796|NCT03579940|Placebo Comparator|Placebo - Caucasian|Single dose of Placebo administered orally in up to one of three study periods.
89270797|NCT03729934|No Intervention|Control|This arm receives no treatment control.
89270798|NCT03729934|Experimental|Ketone Ester|This arm receives 25 g ketone ester.
89270799|NCT03729934|Experimental|Ketone Salt|This arm receives 25 g ketone salt.
89270800|NCT03732040|Sham Comparator|standerd preventive measures|tooth brushing twice daily with fluoride tooth paste and dental flossing and mouthwash
89270801|NCT03732040|Experimental|miswak stick|use of miswak stick twice daily
89270802|NCT03732040|Experimental|Use of Miswak plus tooth brushing and tooth paste|use of miswak stick and tooth brush with fluoride toothpaste twice daily
89270803|NCT00098306|Experimental|1|
89270804|NCT00098306|Experimental|2|
89270805|NCT00098306|Experimental|3|
89270806|NCT03615040|Experimental|Anti-ST2|Anti-ST2 (MSTT1041A) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
89270807|NCT03615040|Placebo Comparator|Placebo|Placebo (no active component) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
89270808|NCT02531204|Experimental|ASP1585 granules preceding group|
89270809|NCT02531204|Active Comparator|ASP1585 capsules preceding group|
89270810|NCT00068822|Experimental|Vertebroplasty|Participants will receive percutaneous vertebroplasty
89270811|NCT00068822|Placebo Comparator|Control Group|Participants will receive sham vertebroplasty without PMMA
89270812|NCT03964064|Experimental|I125 Seed Implantation|3D-printing Template-assisted CT-guided I125 Seed Implantation Prescription dose: gtv140-160gy ctv100-140gy Particle activity: 0.4-0.5mCi
89270813|NCT03964064|Experimental|Stereotactic Radiotherapy|According to the tumor volume, location, organ function and other factors, the dosage of stereotactic directional radiotherapy was determined. The range of BED value of radiotherapy was 80-100 for tumors above 5 mm from gastrointestinal tract and 60-80 for tumors below 5 mm from gastrointestinal tract.
89270814|NCT01090778|Other|Norditropin SimpleXx sc bolus injection|Single sc bolus injection of 3 mg growth hormone without interval exercise
89270815|NCT01090778|Other|Norditropin SimpleXx single sc injection|Single sc bolus injection of 3 mg growth hormone with interval exercise
89270816|NCT01090778|Other|Norditropin SimpleXx contin. sc infusion|Continuous sc infusion of 3 mg growth hormone without interval exercise
89270817|NCT01090778|Other|Norditropin SimpleXx cont. sc infusion|Continuous sc infusion of 3 mg growth hormone with interval exercise
89270818|NCT00068588|Experimental|Treatment (GTI-2040, capecitabine)|Patients receive GTI-2040 IV continuously on days 1-15 of the first course and days 1-14 of all subsequent courses. Patients also receive oral capecitabine twice daily on days 2-15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89270819|NCT01088126|Active Comparator|Focal ablation|PV isolation + CFAE-targeted focal ablation
89270820|NCT01088126|Active Comparator|Linear ablation|PV isolation + CFAE-guided linear ablation
89270821|NCT01088204|Active Comparator|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
89270822|NCT01088204|Experimental|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
89270823|NCT01088282|Active Comparator|Implantation of difractive multifocal IOL|
89270824|NCT01088282|Sham Comparator|Implantation of monofocal IOL|
89270825|NCT01081808|Other|Armed Activated T Cells|Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)
89270826|NCT03650452|Placebo Comparator|Placebo|TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
89270827|NCT03650452|Experimental|TAK-935|TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing <60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
89270828|NCT03729856|Experimental|B5 week,intervention,follow-up|Participants will undertake their usual activities for the 5 week baseline period. Participants will begin the 16 week intervention period at week 6 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 22, participants will have no contact with intervention personnel during the 5 week follow-up period.
89270829|NCT03729856|Experimental|B8 week,intervention,follow-up|Participants will undertake their usual activities for the 8 week baseline period. Participants will begin the 16 week intervention period at week 9 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 25, participants will have no contact with intervention personnel during the 5 week follow-up period.
89270830|NCT03729856|Experimental|B11 week,intervention,follow-up|Participants will undertake their usual activities for the 11 week baseline period. Participants will begin the 16 week intervention period at week 12 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 28, participants will have no contact with intervention personnel during the 5 week follow-up period.
89270831|NCT03734458|Experimental|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
89270832|NCT03734458|Experimental|Group B - PRF only with a CAF|Group B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
89270833|NCT03734458|Active Comparator|Group C - CTG with a CAF|Group C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
89270834|NCT03731962|Active Comparator|Developed Contrast Induced Nephropathy|Coronary Angiography
89270835|NCT03731962|Other|Without CIN|Coronary Angiography
89270836|NCT03734380|Experimental|Laboratory-based gait retraining (LGR)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they walk at a self-selected speed on the instrumented staircase. The training time will be progressively increased from 15 to 30 minutes over the six sessions. The auditory feedback will be gradually removed in the last three sessions.
89270837|NCT03734380|Experimental|Sensor-based gait retraining (SGR)|Subjects will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. The training schedule, duration, and intensity will be identical to those of the LGR group.
89270838|NCT03734380|Experimental|Walking exercise control (Ctrl)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups.
89270839|NCT03729700|Experimental|Almond supplementation|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
89270840|NCT03729700|No Intervention|Control snack|The control snack will be a typical western diet snack. The calorie-matched control snack will be commercially available individually wrapped food products.
89270841|NCT01310296|Other|Radiolabeled Lofexidine Oral Solution|Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.
89270842|NCT01310296|Experimental|Lofexidine Intravenous Solution|Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.
89270843|NCT03734146|Experimental|Aerobic exercise (AE)|Engage in supervised aerobic exercise for 60 minutes on 3 days per week for 8 weeks. Exercise is performed on a recumbent bike or treadmill at 50-80% of their heart rate reserve.
89270844|NCT03734146|Experimental|Resistance exercise (RE)|Engage in supervised resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 3 sets of 8-12 repetitions of 12 exercises for the major muscle groups.
89270845|NCT03734146|Experimental|Combined Resistance and Aerobic Exercise|Engage in supervised aerobic resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 30 min aerobic exercise at 50-80% heart rate reserve and 30 min of resistance exercise comprising 2 sets of 8-12 repetitions of 9 exercises for the major muscle groups.
89270846|NCT03734146|No Intervention|No training control|No exercise training. Participants will refrain from any moderate-vigorous exercise or resistance training for 8 weeks.
89270847|NCT05665816||Intervention|Subjects with PAD treated with the PULSAR® -18 T3 Stent will be assessed for eligibility for the registry and consecutively included in the registry. Once informed consent is obtained, the required data will be collected.
89270848|NCT03731884||Elapsed time of onset-of-pain-to-PCI <3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) prior to 3 hours from the onset of symptoms
89270849|NCT03731884||Elapsed time of onset-of-pain-to-PCI >3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) after at least 3 hours from the onset of symptoms
89270850|NCT03729622|Active Comparator|Immediate Intervention|Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
89270851|NCT03729622|Placebo Comparator|Delayed Intervention|Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
89270852|NCT01310140||Major Depressive Disorder|
89270853|NCT01310140||Major Depressive Disorder with Psychotic Features|
89270854|NCT03729466|No Intervention|Control group|There will be no intervention for 8 weeks
89270855|NCT03729466|Experimental|Intervention group|clinical pilates will be given to the intervention group for 8 weeks
89270856|NCT03734068||Chemoembolization|Chemoembolization Using LifePearl and Doxorubicin
89270857|NCT03575806|Experimental|TACE+Tcm group|Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.
89270858|NCT03575806|Active Comparator|TACE group|Active comparator: TACE to treat HCC.
89270859|NCT03610048|Experimental|ALKS 5461|Sublingual tablets
89270860|NCT03733912||Pregnancy|Infertile women undergoing in vitro fertilization cycle got pregnancy successfully. The pregnancy persisted over 12 weeks.
89270861|NCT03733912||Non-pregnancy|Infertile women undergoing in vitro fertilization cycle failed to reach pregnancy.
89270862|NCT03733834||SD therapy|SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
89270863|NCT03733834||NSD therapy|Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
89270864|NCT03733756|Experimental|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
89270865|NCT03733756|Active Comparator|POEM involving longitudinal muscle|participants are operated POEM involving the whole layer of muscle, both circular and longitudinal muscle
89270866|NCT03731728|Experimental|Group CBT plus TAU|"Participants enrolled in the group CBT plus TAU arm of the study will receive a 2-hour session of group CBT every week for 14 weeks in addition to being wait-listed to receive treatment as usual."
89270867|NCT03731728|Experimental|Group Exercise plus TAU|"Participants enrolled in the group exercise plus TAU arm of the study will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks in addition to being wait-listed to receive treatment as usual."
89270868|NCT03731728|No Intervention|Wait-listing for TAU|"Participants enrolled in the wait-listing for treatment as usual or TAU arm of the study will be wait-listed to receive individual therapy or counselling from an Addiction and Mental Health therapist as per current standard protocol for managing patients with MDD at Addiction and Mental Health Clinics of Edmonton Zone."
88805518|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%; Intraarticular and Patellar Tendon Sites~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter"
89270869|NCT03606460|Experimental|Cohort 1|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.
89270870|NCT03606460|Experimental|Cohort 2|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
89270871|NCT03729310|Other|Propel Implant|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
89270872|NCT03729310|Other|Nasopore soaked with triamcinolone|"This packing' is a sponge-like material which dissolves while releasing triamcinolone, which is another type of steroid. Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA."
89270873|NCT05666440|Active Comparator|Visco-Circumferential-Suture-Trabeculotomy|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.
89270874|NCT05666440|Active Comparator|Rigid probe Viscotrabeculotomy|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.
89270875|NCT03729076|Experimental|Crystalloid|Patients will receive rapid co-load of plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia.
89270876|NCT03729076|Active Comparator|Colloid|Patients will receive rapid co-load of 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia.
89270877|NCT03728998|Other|PLR & Clearsight measurements|All patients 16years or older presenting to the ED with uncomplicated sepsis (see inclusion and exclusion criteria) will undergo a Passive Leg Raise (PLR, non-invasive) and multiple measurements by the Clearsight non-invasive hemodynamic monitoring system. Followed by a fluid challenge (common practice; non interventional)
89270878|NCT03733522|Active Comparator|Rubber dam isolation|"Absolute isolation~local anesthesia~use of dental clamp and rubber dam~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
89270879|NCT03733522|Experimental|Relative isolation|"Relative isolation~no local anesthesia~use of cotton roll and saliva ejector~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
89270880|NCT03731650|Experimental|active comparator|
89270881|NCT03731650|Experimental|placebo|
89270882|NCT03605836|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
89270883|NCT03605836|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
89270884|NCT03605836|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
89270885|NCT03605836|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
89270886|NCT03605680|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
89270887|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
89270888|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
89270889|NCT03605680|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
89270890|NCT03728764|Other|single arm|
89270891|NCT03733288|Experimental|SLAMM|Multi-component intervention (Education and training sessions, Support emails, Team leader training)
89270892|NCT03733288|Experimental|SLAMM+|Multi-component intervention (Education and training sessions, Support emails, Team leader training, Height-adjustable workstation)
89270893|NCT03728686|Experimental|3mins|Different given time: Fentanyl 2mcg/kg was given at either time 3 minutes before intubation
89270894|NCT03728686|Active Comparator|2mins|Different given time: Fentanyl 2mcg/kg was given at either time 2 minutes before intubation
89270895|NCT03728686|No Intervention|control|Different given time: Fentanyl 2mcg/kg was given at either time 1 minute before intubation
89270896|NCT03728530|Experimental|Experimental Group|Deep /breathing exercises including Purse lip, diaphragmatic breathing and powered breathing
89270897|NCT03728530|No Intervention|Control Group|The participants from control group did not perform any exercise.
89270898|NCT03728374|Experimental|Anlotinib|
89270899|NCT03728296|Experimental|islet body treatment group|
89270900|NCT03572218|Experimental|BWL + BIAS|The behavioral weight loss (BWL) + weight bias internalization and stigma (BIAS) group will include standard BWL treatment (described in more detail in Intervention section) combined with a weight stigma-reduction intervention. During the initial 12 weeks, the weekly 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically in the context of weight management.
89270901|NCT03572218|Active Comparator|Standard BWL|The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
89270902|NCT03728218|Experimental|Orthokeratology Contact lenses|
89270903|NCT03728218|Experimental|Soft Multifocal Contact lenses|
89270904|NCT03731494||Nickel oral hyposensitization treatment|The patients take capsules at different doses in nickel content until reaching the maximum dose of 1.5 mcg per week for a total of 12 months.
89270905|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.7 mg/m^2|Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
89270906|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.9 mg/m^2|Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
89270907|NCT00111813|Experimental|vorinostat 300 mg + bortezomib 1.3 mg/m^2|Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
89270908|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 0.9 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
89270909|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.1 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
89270910|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.3 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
89270911|NCT00118287|Experimental|Treatment (chemotherapy, chemoprotection)|Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
89270912|NCT03965247|Experimental|Lithium|Increasing amounts of lithium for 11 plus or minus 1 day. Day 1: 400 mg at night Day 2: 600 mg at night Day 3-11: 800 mg at night. The lithium intervention was prepared from 200mg Priadel prolonged release tablets. The intervention was provided in blue and white gelatine capsules to be taken orally.
89270913|NCT03965247|Placebo Comparator|Rayotabs|The placebo intervention was 200mg Rayotabs. The intervention was provided in blue and white gelatine capsules to be taken orally - same as the lithium intervention to maintain blinding.
89270914|NCT01079715|Experimental|Propranolol|Oral Propranolol administration is the experimental arm of this study
89270915|NCT01079715|No Intervention|Control|Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group
89270916|NCT00130689|Other|Cetuximab|Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity.
89270917|NCT01326585|Experimental|Dexamethasone|Subjects receive intravenous intraoperative dexamethasone
89270918|NCT01326585|Placebo Comparator|Saline solution|Subjects receive intravenous intraoperative normal saline solution
89270919|NCT03964935|Experimental|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After scaling, root planing, and polishing (SRP), the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
89270920|NCT03964935|Active Comparator|Minocycline HCL|Minocycline HCL Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
89270921|NCT03964935|Placebo Comparator|Distilled water|Used to irrigate periodontal pockets after SRP
89270922|NCT03605212|Experimental|Cohort 1|Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
89270923|NCT03605212|Experimental|Cohort 2|Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
89270924|NCT03605212|Experimental|Cohort 3|Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
89270925|NCT03605212|Experimental|Cohort 4|Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
89270926|NCT03605212|Active Comparator|Adults|Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
89270927|NCT03603652|Experimental|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.
89270928|NCT00117507|Experimental|Deferasirox|Participants received deferasirox 20mg/kg/day OD for 12 months. Deferasirox was taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets was dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
89270929|NCT03731416|Placebo Comparator|GBR by xenograft|"Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~In the study group: bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~• The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
89270930|NCT03731416|Active Comparator|GBR by xenograft ,autogenous bone|Intervention In the control group:first crestal incision then two vertical incisions by blade 15c,full thickness flap reflection, bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area(atrophic maxilla) then covered by a native collagen membrane which will be stabilized by tacks.Then The flap will then be closed using interrupted 4/0 resorbable sutures.
89270931|NCT03621046|Experimental|Zolpidem|A single oral zolpidem tablet (5 mg) administered in clinic and then each day for the following 3 days
89270932|NCT03621046|Placebo Comparator|Placebo|A single oral placebo administered in clinic and then each day for the following 3 days
89270933|NCT03965013|Experimental|Part 1 (healthy): NNC0268-0965|A single dose of NNC0268-0965 given s.c. (subcutaneously, under the skin)
89270934|NCT03965013|Placebo Comparator|Part 1 (healthy): placebo|A single dose of placebo (NNC0268-0965) given s.c.
89270935|NCT03965013|Experimental|Part 2 (type 1 diabetes): NNC0268-0965|A single dose of NNC0268-0965 given s.c.
89270936|NCT03965013|Active Comparator|Part 2 (type 1 diabetes): insulin glargine|A single dose of insulin glargine given s.c.
89270937|NCT03603496|Experimental|Transitional Tobacco Care Management (TTCM)|TTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call. At each contact the patient is offered a return call from the hospital-based tobacco coach for counseling, medication advice, and coordination of care with the patient's outpatient health care team.
89270938|NCT03603496|Active Comparator|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Quitline staff will contact patient to offer up to 5 proactive telephone calls from a tobacco coach. Patient may also be eligible for NRT sample. Feedback from the quitline will be sent back to the patient's medical chart.
89270939|NCT03603028|Experimental|Exergaming|
89270940|NCT03602482|Experimental|Standing|Participants will complete cognitive testing while standing.
89270941|NCT03602482|Active Comparator|Supine|Participants will complete cognitive testing while supine.
89270942|NCT00096135|Experimental|CNS Patients-Treatment (combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
89270943|NCT00096135|Experimental|Testicular Relapse Patients (Combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, testicular radiation therapy, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
89270944|NCT00116805|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
89270945|NCT00116805|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
89270946|NCT00116649|Experimental|Aldara 5%|Aldara® (imiquimod) cream, 5% supplied in 250 mg single-use packets.
89270947|NCT01082835||the group of Jiangzhuo Qinggan prescription|
89270948|NCT01082835||the group of irbesartan|
89270949|NCT01080651|Active Comparator|CYP2C19 extensive metabolizer|
89270950|NCT01080651|Active Comparator|CYP2C19 poor metabolizer|
89270951|NCT01082913|Experimental|Sacral Surface Electrical (SSE)|
89270952|NCT01082913|No Intervention|control|
89270953|NCT01086891|Experimental|1|Patients with chronic obstructive pulmonary disease who show arterial oxygen desaturation to effort.
89270954|NCT01086891|Experimental|2|Patients with interstitial lung disease who show arterial oxygen desaturation to effort
89270955|NCT01082991|Other|prevention|
89270956|NCT02531061|Experimental|active erosion|"HR-pQCT for measure bone parameters in active erosion group. The active erosion group will be defined by grades 2 and 3, ie by the presence of Doppler signals confluence in less than 50% of the synovial surface (grade 2) and in over 50% of the surface synovial for grade 3"
89270957|NCT02531061|Experimental|inactive erosion|"HR-pQCT for measure bone parameters in active erosion group. The inactive erosion group will be defined by grades 0 and 1, ie the absence of Doppler signal for grade 0 and the presence of some non confluence Doppler signals for the grade 1"
89270958|NCT01087047||Physiological modifications|Pregnant women who attend the routine ultrasound control in our institution before 14 weeks of pregnancy
89270959|NCT01087047||MRI and acoustic|Women undergoing an MRI for obstetrical purpose
89270960|NCT01083069||COOL|Patients after therapy with mild hypothermia
88805519|NCT00178178|Placebo Comparator|Drug: Placebo|"Breg Pain Care 3000 Catheter with Placebo~Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter"
89270961|NCT01083069||UnCool|Patients without therapy with mild hypothermia due to non-operational cooling-devices
89270962|NCT01080885|Experimental|Busy Bodies/Better Bites|Healthy Eating/Physical Activity Intervention
89270963|NCT01080885|Active Comparator|Healthy Spots/Safe Tots|Injury Prevention and Safety Intervention
89270964|NCT03962907|Experimental|Carrier group - intervention|BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun
89270965|NCT03962907|No Intervention|Carrier group - control|
89270966|NCT03962907|Experimental|Non - carrier group - intervention|Lifo-Scrub sol 4%®, 500ml, B. Braun
89270967|NCT03962907|No Intervention|Non - carrier group - control|
89270968|NCT00083889|Active Comparator|2|
89270969|NCT00083889|Experimental|1|
89270970|NCT03572062|Experimental|Arm 1|Low dose formulation A and SIIV
89270971|NCT03572062|Experimental|Arm 2|Low dose formulation B and SIIV
89270972|NCT03572062|Experimental|Arm 3|Mid dose formulation A and SIIV
89270973|NCT03572062|Experimental|Arm 4|Mid dose formulation B and SIIV
89270974|NCT03572062|Experimental|Arm 5|High dose formulation A and SIIV
89270975|NCT03572062|Experimental|Arm 6|High dose formulation B and SIIV
89270976|NCT03572062|Experimental|Arm 7|High dose formulation C and SIIV
89270977|NCT03572062|Placebo Comparator|Arm 8|Placebo and SIIV
89270978|NCT03572062|Experimental|M0M2 Arm 1|High dose formulation B
89270979|NCT03572062|Placebo Comparator|M0M2 Arm 2|Placebo
89270980|NCT03728062|Experimental|Mindfulness meditation during lunch break|"Participants performed mindfulness meditation during lunch break at work place for a month, beginning with 15 minutes and ending with 30 minutes. They had available a quiet room and mp3 audios with guided meditations based on the MBSR program."
89270981|NCT03728062|Experimental|Physical exercise during lunch break|Participants performed physical exercises during lunch break at a gym for a month, beginning with 15 minutes and ending with 30 minutes. They were instructed to do cardio exercise such as running through a park or going to the gym for running, rowing, cycling or elliptical exercise. 20-140 beats per minute must be reach.
89270982|NCT03728062|No Intervention|Control group|Participants continue their normal lunch routine.
89270983|NCT03639532|Experimental|COC|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on ceramic(COC) bearing couple is implanted. The group with intervention COC THA.
89270984|NCT03639532|Active Comparator|COP|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on highly cross-linked polyethylene bearing couple is implanted. The group with intervention COP THA.
89270985|NCT03727828||Patients with heart failure|Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
89270986|NCT03727828||healthy control|
89270987|NCT03571516|Experimental|Teduglutide|Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
89270988|NCT03571516|Other|Standard of Care (SOC)|Participants will receive standard medical therapy for 24 weeks.
89270989|NCT03600376|Experimental|Ryanodex and Standard of Care|In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
89270990|NCT03600376|Other|Standard of Care only (SOC)|Standard of Care treatment will consist of the immediate start of cooling measures.
89270991|NCT03961659|Active Comparator|Liraglutid|Liraglutid will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutid could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
89270992|NCT03961659|Active Comparator|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but dapagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
89270993|NCT03961659|Active Comparator|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to100mg three times daily if appropriate. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 4-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but acarbose could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
89270994|NCT03599362|Experimental|Multi Agent Chemotherapy Cancer Patients|Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.
89270995|NCT03741309|Active Comparator|Group I|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
89270996|NCT03741309|Sham Comparator|Group II|dentifrice containing Calcium sodium phosphosilicate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
89270997|NCT03741309|Placebo Comparator|Group III|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks.
89270998|NCT01083147||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
89270999|NCT03598036|Experimental|Voclosporin|"Cohort 1:~Maximum dose of 3 capsules (7.9mg) BID~Cohort 2~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1."
89271000|NCT00082407|Experimental|Exenatide Arm|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
89271001|NCT00082407|Active Comparator|Biphasic Insulin Aspart Arm|subcutaneous injection, twice daily; titration to target blood glucose level
89271002|NCT03643432|Active Comparator|Usual care|The usual care arm will consist of routine physiotherapy treatment, without the intervention.
89271003|NCT03643432|Experimental|Exercise adherence intervention|The intervention arm will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment.
89271004|NCT03732976|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
89271005|NCT03732976|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
89271006|NCT01083225|Experimental|Client feedback|
89271007|NCT01083225|Active Comparator|Treatment as usual|
89271008|NCT01080963|Active Comparator|Daptomycin|
89271009|NCT01080963|Active Comparator|Cefuroxime|
89271010|NCT01083303|Experimental|weaning at 1500 g|weaning infants from an incubator at 1500 g
89271011|NCT01083303|Active Comparator|weaning at 1600 g|weaning infants from an incubator at 1600 g
89271012|NCT01083381|Active Comparator|treatment group|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.
89271013|NCT01083381|Placebo Comparator|Control group|Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.
89271014|NCT03810183|Experimental|QAW039 450 mg|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet.
89271015|NCT03810183|Placebo Comparator|Placebo|Placebo once daily for 6 weeks administered orally as a tablet.
89271016|NCT01087359|Active Comparator|LPS + melatonin night|
89271017|NCT01087359|Placebo Comparator|LPS + placebo night|
89271018|NCT01087359|Active Comparator|LPS + melatonin day|
89271019|NCT01087359|Placebo Comparator|LPS + placebo day|
89271020|NCT01087359|Experimental|LPS night|
89271021|NCT01087359|Experimental|LPS day|
89271022|NCT01083459||PCV13 immunized|Children who receive the 13-valent pneumococcal conjugate vaccine
89271023|NCT01083459||PCV13 unimmunized|PCV13 unimmunized Household members of PCV13 immunized children
89271024|NCT03962517|Experimental|Training with GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with the device."
89271025|NCT03962517|Active Comparator|Training without GEMS-H|"Participants will participate in 18 sessions of training + 5 sessions of testing for up to 3 month.~Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments without the device."
89271026|NCT01087437|Experimental|gastrolith calcium treatment|
89271027|NCT01083537|Experimental|Cisplatin|"Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
89271028|NCT01083537|Experimental|Paclitaxel|"Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
89271029|NCT03597022|Experimental|BAY1093884 100mg|Subjects received BAY1093884 100 mg once a week until premature termination of the study
89271030|NCT03597022|Experimental|BAY1093884 225mg|Subjects received BAY1093884 225 mg once a week until premature termination of the study
89271031|NCT03597022|Experimental|BAY1093884 400mg|Subjects received BAY1093884 400mg once a week until premature termination of the study
89271032|NCT01087515|Other|Blood donation|
89271033|NCT03571204|Active Comparator|Group 1: ART prior to 3BNC117 + 10-1074 in HIV-1 subject|Subjects who began anti-retroviral therapy (ART) during primary HIV-1 infection within 12 weeks of diagnosis. ART was stopped after study day 3 and were given 3BNC117 and 10-1074 intravenously. Both 3BNC117 and 10-1074 were administered at 30 mg/kg dose level in separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
89271034|NCT03571204|Placebo Comparator|Group 1: ART prior to placebo treatment in HIV-1 subject|Subjects who began anti-retroviral therapy (ART) during primary HIV-1 infection within 12 weeks of diagnosis. ART was stopped after study day 3 and were given normal saline intravenously. Subjects received two separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
89271035|NCT03571204|Experimental|Group 2: 3BNC117 + 10-1074 in HIV-1 subject|Subjects who were not on anti-retroviral therapy (ART) during primary HIV-1 infection within the past 2 years. Subjects were given 3BNC117 and 10-1074 intravenously. Both 3BNC117 and 10-1074 were administered at 30 mg/kg dose level in separate bags of 250 mL normal saline in sequential administration. Subjects received 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy was 24 weeks.
89271036|NCT03569098|Experimental|Dysport Dose 1|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
89271037|NCT03569098|Experimental|Dysport Dose 2|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
89271038|NCT03569098|Placebo Comparator|Placebo|Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
89271039|NCT03727282|Other|Liberal strategy|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician
89271040|NCT03727282|Experimental|ejection volume index|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index
89271041|NCT03568942|Experimental|Female subjects with acute cystitis|Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (>=10 WBC/mm^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
89271042|NCT00110019|Experimental|Arm I (paclitaxel, carboplatin, sorafenib tosylate)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive sorafenib tosylate PO BID (approximately every 12 hours) on days 2-19.
89271043|NCT00110019|Active Comparator|Arm II (carboplatin, paclitaxel, placebo)|Patients receive paclitaxel and carboplatin as in Arm I. Patients also receive placebo PO BID (approximately every 12 hours) on days 2-19.
89271044|NCT03595618|Experimental|GLPG1972 75 mg|Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
89271045|NCT03595618|Experimental|GLPG1972 150 mg|Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
89271046|NCT03595618|Experimental|GLPG1972 300 mg|Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.
89271047|NCT03595618|Placebo Comparator|Placebo|Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.
89271048|NCT02954848|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
89271049|NCT02954848|Experimental|TAK-438 10 mg|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
89271050|NCT03642262|Experimental|Treatment A: Mucinex® ER 600 mg|Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
89271051|NCT03642262|Active Comparator|Treatment B: Guaifenesin 200 mg|Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.
89271052|NCT03727204||Aarhus University Hospital|100 patients undergoing on-pump cardiac surgery at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
89271053|NCT03727204||Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand|50 patients undergpoing on-pump cardiac surgery at at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
89271054|NCT03727126|Experimental|Robotic esophagectomy|Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system
89271055|NCT03727126|Active Comparator|Thoracolaparoscopic esophagectomy|Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques
89271056|NCT03727048|Active Comparator|Control|To the control group post ankle fracture surgery, per subject 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
89271057|NCT03727048|Experimental|Intervention|To the treatment group post ankle fracture surgery, per subject 30mg of IV ketorolac intraoperatively; 20 tablets of 10mg ketorolac with instructions to take every 6 hours, and 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
89271058|NCT03732742|Experimental|TOF repair with preservation of PV|Surgical intervention by repair of Tetralogy of Fallot with preservation of pulmonary valve, recently interested has shifted to preserving the integrity of the pulmonary valve.
89271059|NCT03732742|Experimental|TOF repair with trans-annular patch|Surgical intervention by repair of Tetralogy of Fallot with trans-annular patch, right ventricular hypertrophy, right ventricular dilatation and pulmonary vavle regurgitation has been recognized as one of the most important risk factors for both right and left ventricular performance after the repair of Tetralogy of Fallot.
89271060|NCT00109707|Experimental|CML-CP With Prior Imatinib Only|Imatinib-resistant / intolerant PH+ CML-CP patients
89271061|NCT00109707|Experimental|CML-AP With Prior Imatinib Onl|Imatinib-resistant / intolerant PH+ CML-AP patients
89271062|NCT00109707|Experimental|CML-CP|Imatinib-resistant / intolerant PH+ CML-CP patients
89271063|NCT00095979|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89271064|NCT01087593|Experimental|Treatment with transdermal 17β-estradiol|
89271065|NCT01087593|Placebo Comparator|Control|
89271066|NCT01087671|Other|Open-lable study with one arm|
89271067|NCT00082173|Experimental|1|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
89271068|NCT00082173|Placebo Comparator|2|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks
89271069|NCT01087749|Experimental|Chronic Kidney Disease|Propranolol, Losartan, and Eprosartan will be administered to patients who have been diagnosed with Chronic Kidney disease and have a glomerular filtration rate (GFR) below 40ml/min.
89271070|NCT01087749|Experimental|Healthy Volunteers|Propranolol, Losartan, and Eprosartan will be administered to healthy volunteers without chronic kidney disease.
89271071|NCT00108069|Experimental|GBM (Glioblastoma multiforme)|
89271072|NCT00108069|Experimental|AG (Anaplastic glioma)|
89271073|NCT01081119|Experimental|Project CHOICE|Middle school receives Project CHOICE
89271074|NCT01081119|No Intervention|No Project CHOICE|Middle school does not receive Project CHOICE
89271075|NCT00079274|Experimental|Arm A (combination chemotherapy)|Patients received oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours on days 1. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
89271076|NCT00079274|Experimental|Arm B (combination chemotherapy)|Patients received irinotecan IV over 2 hours on day 1 and leucovorin calcium and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
89271077|NCT00079274|Experimental|Arm C (combination chemotherapy)|Patients received the same treatment as in arm A for 6 courses followed by the same treatment as in arm B for 6 courses (total of 12 courses). Treatment continues in the absence of unacceptable toxicity or recurrent disease.
89271078|NCT00079274|Experimental|Arm D (combination chemotherapy, monoclonal antibody)|Patients received cetuximab IV over 1 hour on days 1 and 8 and oxaliplatin, leucovorin calcium, and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
89271079|NCT00079274|Experimental|Arm E (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and irinotecan, leucovorin calcium, and fluorouracil as in arm B. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
89271080|NCT00079274|Experimental|Arm F (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and chemotherapy as in arm C.
89271081|NCT00079274|Other|Arm G (Locally directed therapy)|Patients determined to have mutated KRAS (or KRAS not evaluable) were assigned to an event monitoring arm in which adjuvant therapy was determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification was the responsibility of the treating oncologists.
89271082|NCT01081964|Active Comparator|Levofloxacin 500mg|Levofloxacin 500mg once daily for 7 days
89271083|NCT01081964|Experimental|Zabofloxacin 5 days|Zabofloxacin 400mg for 5 days
89271084|NCT01081964|Experimental|Zabofloxacin 3 days|Zabofloxacin 400mg for 3 days
89271085|NCT03960944|Experimental|Yoga in School Group|30-mins yoga sessions were conducted in schools for 8-weeks
89271086|NCT03960944|No Intervention|Control Group|Usual Activities in school
89271087|NCT01088360||Patients with rheumatoid arthritis initiating abatacept|
89271088|NCT01088360||Pts with RA initiating other biologic disease-modifying drugs|
89271089|NCT01088360||Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs|
89271090|NCT00079040|Experimental|Treatment (cisplatin, etoposide, bevacizumab)|"Chemotherapy: Patients receive cisplatin IV over 30-60 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Bevacizumab therapy: Beginning concurrently with chemotherapy, patients receive bevacizumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 17 courses (1 year) in the absence of disease progression or unacceptable toxicity."
89271091|NCT01088516|Experimental|Aluvia-based HAART|Study regimen: ZDV/3TC (combivir) + 2 Aluvia Tabs all PO BID to start at 14-30 weeks gestational age (GA) and continue through labor and as long as the mother breastfeeds
89271092|NCT03961022|Active Comparator|ReWin(d)|Subjects have to take ReWin(d) capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
89271093|NCT03961022|Placebo Comparator|placebo|Subjects have to take Placebo capsules (3 times a day, total 2 g/day) during breakfast, lunch and diner, during 4 weeks + 3 days after acute exercice
89271094|NCT00078806|Experimental|Part 1: Etanercept|"Participants received 0.4 mg/kg etanercept administered subcutaneously twice a week for up to 6 months in Part 1A.~Participants who had a partial response entered Part 1B and received 0.8 mg/kg etanercept twice weekly for up to 4 months."
89271095|NCT00078806|Placebo Comparator|Part 2: Placebo|Participants who met response criteria in Part 1 were randomized to receive placebo twice a week for up to 3 months.
89271096|NCT00078806|Experimental|Part 2: Etanercept|Participants who met response criteria in Part 1 were randomized to continue receiving etanercept twice a week at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to 3 months.
89271097|NCT00078806|Experimental|Part 3:|Participants who experienced a flare or completed 3 months of treatment in Part 2 entered Part 3 and received open-label treatment with etanercept at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to a maximum of 12 months, including treatment in Part 2.
89271098|NCT01090856|No Intervention|No pre-dilation side branch|
89271099|NCT01090856|Active Comparator|Pre-dilation side branch|
89271100|NCT01082042||Standard Care|Individuals who attended the local falls group
89271101|NCT01082042||Intervention group|Individuals who undertook the 12 week exercise (Nintendo WiiFit) intervention
89271102|NCT00078338|Experimental|Rebif®|
89271103|NCT00078338|Active Comparator|Copaxone®|
89271104|NCT01088594|Experimental|1|pioglitazone 45 mg
89271105|NCT01088594|Experimental|2|Rosiglitazone 8 mg
89271106|NCT01088594|Placebo Comparator|3|Placebo
89271107|NCT01583192|Active Comparator|chloride-hexidine soluted in alcohol|"patients will have skin preparation with chloride-hexidine soluted in alcohol prior to their forefoot surgery.~Skin swabs will be taken prior to skin preparation, after skin preparation and after skin closure at the end of the operation"
89271108|NCT01583192|Active Comparator|povidine-jodine soluted in alcohol|skin perparation will be done with povidine-jodine soluted in alcohol prior to forefoot surgery.
89271109|NCT01090934|Experimental|high resolution EEG|
89271110|NCT01090934|Active Comparator|Stereo Electroencephalography|
89271111|NCT01082120|Experimental|1|AZD1656 day 1-5, AZD1656 + Pioglitazone day 6-10, Pioglitazone day 11-15
89271112|NCT01082120|Experimental|2|Pioglitazone day 1-5, AZD1656 + Pioglitazone day 6-10, AZD1656 day 11-15
89271113|NCT03808688|Other|Netarsudil Ophthalmic Solution 0.02%|
89271114|NCT03808298|Experimental|Treatment Sequence 1: A, B, C|
89271115|NCT03808298|Experimental|Treatment Sequence 2: A, C, B|
89271116|NCT03808298|Experimental|Treatment Sequence 3: B, A, C|
89271117|NCT03808298|Experimental|Treatment Sequence 4: B, C, A|
89271118|NCT03808298|Experimental|Treatment Sequence 5: C, A, B|
89271119|NCT03808298|Experimental|Treatment Sequence 6: C, B, A|
89271120|NCT03808298|Experimental|Treatment Sequence 7: A, B, D|
89271121|NCT03808298|Experimental|Treatment Sequence 8: A, D, B|
89271122|NCT03808298|Experimental|Treatment Sequence 9: B, A, D|
89271123|NCT03808298|Experimental|Treatment Sequence 10: B, D, A|
89271124|NCT03808298|Experimental|Treatment Sequence 11: D, A, B|
89271125|NCT03808298|Experimental|Treatment Sequence 12: D, B, A|
89271126|NCT00077636|Experimental|1|
89271127|NCT00077636|Experimental|2|
89271128|NCT03963674|Experimental|Diacutaneous fibrolysis|
89271129|NCT03963674|No Intervention|Control|
89271130|NCT01088828||Group A|"Foetuses with clubfoot identified in utero (n=15). Of these:~around 10 will be born with clubfoot and will form most of Group B,~around 5 will be born without clubfoot and will form part of group C."
89271131|NCT01088828||Group B|Neonates affected by clubfoot (n=10)
89271132|NCT01088828||Group C|Control group of unaffected neonates (n=10)
89271133|NCT01088828||Group D|Young adults having completed treatment (n=5)
89271134|NCT01088828||Group E|Control group of young unaffected adults (n=5)
89271135|NCT03957746|Experimental|3 sets of resistance exercise|
89271136|NCT03957746|Experimental|6 sets of resistance exercise|
89271137|NCT03957746|Experimental|9 sets of resistance exercise|
89271138|NCT03957746|No Intervention|Rest|
89271139|NCT01091012|Other|Sildenafil 20mg oral|
89271140|NCT01091012|Other|Sildenafil 10mg intravenous|
89271141|NCT01583582|Experimental|Refined peptide concentrate, 1200 mg|Refined peptide concentrate, 1 200 mg, once a day
89271142|NCT01583582|Experimental|Refined peptide concentrate, 2 x 600 mg|Refined peptide concentrate, 600 mg, twice a day
89271143|NCT01583582|Placebo Comparator|Refined peptide concentrate, 0 mg|
89271144|NCT01082276|Other|Rifampin/Lurasidone|Healthy Normal Subject
89271145|NCT01088906|Experimental|1 ARM|pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days
89271146|NCT01091090|Experimental|Cognitive behavioral|Subjects with receive a cognitive behavioral intervention for smoking cessation
89271147|NCT01091090|Active Comparator|Control|Treatment as usual
89271148|NCT00095199|Experimental|Cetuximab & Pemetrexed|
89271149|NCT00095199|Active Comparator|Pemetrexed|
89271150|NCT00095199|Experimental|Cetuximab & Docetaxel|
89271151|NCT00095199|Active Comparator|Docetaxel|
89271152|NCT00075764|Active Comparator|Arm I|Patients receive oral anastrozole once daily on days 1-28.
89271153|NCT00075764|Experimental|Arm II|Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.
89271154|NCT03568162|Experimental|ISB 830 - Part 1 Group 1|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
89271155|NCT03568162|Experimental|ISB 830 - Part 1 Group 2|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
89271156|NCT03568162|Experimental|ISB 830 - Part 1 Group 3|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
89271157|NCT03568162|Placebo Comparator|Placebo - Part 1 Group 4|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
89271158|NCT03568162|Experimental|ISB 830 - Part 2 Group 5|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
89271159|NCT03568162|Placebo Comparator|Placebo - Part 2 Group 6|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
89271160|NCT03726970|Experimental|Tube Potential difference|Different kVp values of the CBCT machine 70, 80 ,90 kVp
89271161|NCT03726970|Experimental|MAR tool|MAR option in the software off and on
89271162|NCT03567616|Experimental|Part 1: Dose Escalation|Venetoclax (400 mg oral [PO], once daily [QD]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly [qw]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol
89271163|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) positive|Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
89271164|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) negative|Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
89271165|NCT03567382|Experimental|High-risk HBV dyads|Mothers with high-risk HBV (defined as viral load >10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
89271166|NCT03567382|Experimental|Low-risk HBV dyads|Mothers with low risk HBV (defined as a viral load <10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.
89271167|NCT03595384|Experimental|Soccer-based adaptation to the DPP|Hispanic overweight male participants taking part in a 24 week soccer program as part of diabetes prevention.
89271168|NCT05666128|Experimental|HD-6277 100mg tab|
89271169|NCT05666128|Experimental|HD-6277 50mg tab|
89271170|NCT05666128|Placebo Comparator|Placebo|
89271171|NCT03731026|Other|Group 1|Patient will receive an IV injection of up to 200MBq 68Ga-RM2. Each patient will have torso PET/CT imaging at 2 timepoints. Alternate patients will have imaging at 1 and 2h post-injection then the next patientat 1 and 3h post-injection, with axillary gamma probe measurements (using a collimator) of 68Ga-RM2 at the same time points.
89271172|NCT03731026|Experimental|Group 2|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 2 scans will acquire LightPath® images of both intact and incised cancer specimens with varying parameters to optimise imaging.
89271173|NCT03731026|Experimental|Group 3|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 3 scans will acquire LightPath® images of intact and incised cancer specimens using a final and consistent imaging procedure.
89271174|NCT03730870|Experimental|Pharmacogenomics report|Clinician reviews pharmacogenomics report for subject prior to prescribing FDA-approved medications.
89271175|NCT03730870|No Intervention|Control|"Clinician prescribes FDA-approved medications as customarily performed without additional guidance from pharmacogenomics report (treatment-as-usual)."
89271176|NCT03591874|Experimental|OCU-300|Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
89271177|NCT03591874|Placebo Comparator|Placebos|Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.
89271178|NCT03730714|Active Comparator|Ggroup LAM|Patients will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
89271179|NCT03730714|Active Comparator|Ggroup LAMG|Patients will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique.
89271180|NCT03730714|Active Comparator|Group CG|Patients will receive normal saline 0.9% to soak the surgicel according to the planned technique.
89271181|NCT03726892|Active Comparator|The SYNERGY stent|
89271182|NCT03726892|Active Comparator|Xience|
89271183|NCT03566680|Experimental|Orthokeratology Group|All subjects will be fit in orthokeratology contact lenses.
89271184|NCT00106353|Experimental|1.0|
89271185|NCT01087983|Experimental|Lapatinib + Sirolimus|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Sirolimus starting oral dose 1 mg daily.
89271186|NCT01087983|Experimental|Lapatinib + Metformin|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Metformin Starting oral dose 1000 mg daily.
89271187|NCT00080301|Experimental|A|
89271188|NCT00080301|Active Comparator|B|
89271189|NCT01088061||lean women with PCOS|
89271190|NCT01088061||Obese women with PCOS|
89271191|NCT01088061||lean control women|
89271192|NCT01088061||Obese control women|
89271193|NCT01083927|Active Comparator|Rotational Narrow Strip Graft|Technique of surgery
89271194|NCT01083927|Active Comparator|Full Graft|Surgical technique
89271195|NCT03961503||Daptomycin (DAP)|DAP : Cohort of patients who received daptomycin as the first line treatment for at least 48 hours for the defined indication
89271196|NCT03961503||Vancomycin (VAN)|VAN : Cohort of patients who received vancomycin as the first line treatment for at least 48 hours for the defined indication
89271197|NCT01084317||asthmatic children|patients under 18 age, with newly diagnosed asthma
89271198|NCT00079677|Experimental|1|Armodafinil 150 mg/day
89271199|NCT00079677|Placebo Comparator|2|Placebo
89271200|NCT03961425|Active Comparator|NO CO2|Traditional De Airing maneuver
89271201|NCT03961425|Active Comparator|CO2 Cannula|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by non specific needle cannula
89271202|NCT03961425|Active Comparator|CO2 Cardia|CO2 at 8 l/min since 2 minutes before aortic cross clamp delivered by commercial diffuser Cardia
89271203|NCT01088139|No Intervention|Control|
89271204|NCT01088139|Experimental|Nutritional Supplementation|
89271205|NCT03964155|Experimental|Patients with SDRA|Patients within 24 hours from meeting the Berlin criteria for moderate or severe ARDS and receiving inhaled sedation with sevoflurane
89271206|NCT01081275|Active Comparator|CI Therapy|CI therapy involves repetitive practice with the more-affected hand on typical daily living activities (such as stacking objects, pouring, moving objects) for 3.5 hours per day, along with physical restraint of the better hand to keep it from assisting, and home practice exercises.
89271207|NCT01081275|Active Comparator|CAM treatments|CAM treatments are holistic physical treatments designed to work on the entire body to improve quality of life and overall health. This study will use yoga, relaxation exercises, aquatherapy (pool therapy), and massage.
89271208|NCT01081353|Experimental|Arm 1|
89271209|NCT01081353|Active Comparator|Arm 2|
89271210|NCT01081353|Active Comparator|Arm 3|
89271211|NCT01081353|Active Comparator|Arm 4|
89271212|NCT01084395|Experimental|Adolescent Safer Sex Intervention|
89271213|NCT01084395|Experimental|Parent Safer Sex Intervention|
89271214|NCT01084395|Other|Adolescent Health Promotion Control|
89271215|NCT01084395|Other|Parent Health Promotion Control|
89271216|NCT00095121|Placebo Comparator|Placebo (PLB)|Participants randomized to receive placebo received placebo during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
89271217|NCT00095121|Experimental|Adefovir Dipivoxil (ADV)|Participants randomized to receive ADV received ADV during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
89271218|NCT03962829|Placebo Comparator|Placebo condition|Participants receive placebo capsule
89271219|NCT03962829|Active Comparator|mCPP condition|Participants receive active (mCPP) capsule
89271220|NCT00094809|Active Comparator|Pegfilgrastim|6 mg pegfilgrastim
89271221|NCT00094809|Placebo Comparator|Placebo|6 mg placebo
89271222|NCT03962751|Experimental|Sequential Post Feedback Information Delivery|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment.
89271223|NCT03962751|Experimental|Sequential Post Feedback Information Delivery +Text Messages|Participants receive the first component of their PFI immediately following Baseline and subsequently receive 1 component each week until they receive all 4 components. Participants will complete a Post Feedback Survey and a 3 week follow back and Knowledge assessment. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
89271224|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content.
89271225|NCT03962751|Experimental|Simultaneous Post Feedback Information Delivery +Text Messages|Participants receive all 4 feedback components immediately after providing consent to the Pilot Feasibility Study following the Screening/Baseline Survey. Participants complete a brief 10 minute Post-Feedback Survey and a 3 Week Followup Survey to assess knowledge of the intervention feedback content. Additionally, participants receive the Text Message Booster Component in the days before and during their birthday celebration(s).
89271226|NCT03962751|No Intervention|Baseline Assessment Only|Participants complete baseline survey and conclude participation.
89271227|NCT01084473|Experimental|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
89271228|NCT01084473|Active Comparator|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
89271229|NCT01084473|Placebo Comparator|Placebo|The study subjects will be given a saline infusion.
89271230|NCT01088373|Experimental|Azacitidine, Lenalidomide|
89271231|NCT00075218|Placebo Comparator|B|
89271232|NCT00075218|Active Comparator|A|
89271233|NCT01089140|Experimental|. Tranexamic acid low dose 10 mg/kg|
89271234|NCT01089140|Experimental|Tranexamic acid 100mg/kg|
89271235|NCT01089140|Placebo Comparator|Saline Placebo|
89271236|NCT00094653|Active Comparator|1|Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
89271237|NCT00094653|Experimental|2|MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
89271238|NCT00094653|Active Comparator|3|MDX-010 (ipilimumab) + Placebo
89271239|NCT03564184|Experimental|MT during and after NICU|Consists of music therapy during NICU hospitalization, and music therapy after discharge from initial NICU hospitalization, along with standard care.
89271240|NCT03564184|Experimental|MT during NICU|Consists of music therapy during NICU hospitalization, along with standard care.
89271241|NCT03564184|Experimental|MT after NICU|Consists of music therapy after discharge from initial NICU hospitalization, along with standard care.
89271242|NCT03564184|Experimental|No MT|Consists of standard care.
89271243|NCT05665348|Active Comparator|DOULET ATEZOLIZUMAB-BEVACIZUMAB|Standard treatment of HCC by the combination atezolizumab-bevacizumab, 1 cure each 3 weeks during 24 months
89271244|NCT05665348|Experimental|TRIPLET ATEZOLIZUMAB BEVACIZUMAB IPILIMUMAB|Standard treatment of HCC by the combination atezolizumab-bevacizumab with addition of ipilimumab for the 4 firsts cures of treatment each 3 weeks, then only treatment by the doublet atezolizumab-bevacizumab each 3 weeks. The total duration of treatment is 24 months.
89271245|NCT03726814|Experimental|EPC treatment group|
89271246|NCT03726736|Experimental|Anlotinib combined Docetaxel|patients treated with anlotinib and Docetaxel (21 days for 1 cycle) until PD (progressive disease)
89271247|NCT03726736|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until PD (progressive disease)
89271248|NCT03591406|Experimental|Ferric carboxymaltose (FCM)|Subjects treated with FCM given by IV injection or drip infusion
89271249|NCT03591406|Active Comparator|Iron sucrose (IS)|Subjects treated with IS given by IV injection or drip infusion
89271250|NCT03560986|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
89271251|NCT03560986|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
89271252|NCT03560518|Experimental|Rapastinel 450mg|Rapastinel 450 mg (prefilled syringe, weekly intravenous IV administration)
89271253|NCT03560518|Experimental|Rapastinel 900mg|Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)
89271254|NCT03560518|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration)
89271255|NCT03726580||control group|regional anesthesia
89271256|NCT03726580||general anesthesia(S)|general anesthesia with sevoflurane
89271257|NCT03726580||general anesthesia(I)|general anesthesia with isoflurane
89271258|NCT03726580||total intravenous anesthesia|total intravenous anesthesia with propofol.
89271259|NCT03726502|Active Comparator|ureteroscopy with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
89271260|NCT03726502|Placebo Comparator|ureteroscopy alone|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
89271261|NCT03726502|Active Comparator|with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
89271262|NCT03726502|Placebo Comparator|without safety guide-wire|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
89271263|NCT03560206|Experimental|Family SWaP intervention|an educational-behavioral intervention consisting of 6 weekly education sessions (45 minutes) followed by 5 bi-weekly sessions (15-20 minutes) that will be held at the dyad's preferred time delivered to their homes using a video conferencing program through a mini iPad.
89271264|NCT03560206|Active Comparator|Usual Care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
89271265|NCT02892760|Experimental|with C-brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
89271266|NCT03635086|Experimental|Group A: Two MV-CHIK lyophilized low dose|Participants received two vaccinations with MV-CHIK lyophilized formulation, low dose, on day 0 and day 28.
89271267|NCT03635086|Experimental|Group B: Two MV-CHIK liquid frozen low dose|Participants received two vaccinations with MV-CHIK liquid frozen low dose formulation on day 0 and day 28.
89271268|NCT03635086|Experimental|Group C: Two MV-CHIK liquid low dose stabilizing and protecting solution (SPS®)|Participants received two vaccinations with MV-CHIK liquid low dose SPS® formulation on day 0 and day 28.
89271269|NCT03635086|Experimental|Group D: Two MV-CHIK liquid frozen high dose|Participants received two vaccinations with MV-CHIK liquid frozen high dose formulation on day 0 and day 28.
89271270|NCT03635086|Experimental|Group E: One MV-CHIK liquid frozen high dose/placebo|Participants received one vaccination with MV-CHIK liquid frozen high dose formulation on day 0 and placebo on day 28.
89271271|NCT03588910|Active Comparator|Number of oxycodone tablets typically prescribed|Participants will receive a prescription for 10 tablets of 5 mg oxycodone (1 tablet every 6 hours as needed) as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
89271272|NCT03588910|Experimental|Half the number of oxycodone tablets typically prescribed|Participants will receive 5 tablets of 5mg oxycodone as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
89271273|NCT03726424||mutation|patients carrying one or more specific pathogenic mutations
89271274|NCT03726424||control|patients not carrying the pathogenic mutation(s)
89271275|NCT05666050|Experimental|Intervention group|The intervention group will receive mobile health intervention sending message service(SMS)
89271276|NCT05666050|No Intervention|Control group|The control group will receive the existed current health delivery approach, no mobile health sending message service
89271277|NCT03726190||OLLIF|Patients who underwent Oblique Lateral Lumbar Interbody Fusion
89271278|NCT03726112|Active Comparator|SpotOn Specs|Eyeglasses with Neuro-Balance Active (NBA) Spots
89271279|NCT03726112|Sham Comparator|Sham Specs|Eyeglasses with spots placed in peripheral zones previously identified as neutral
89271280|NCT03726034|Experimental|Life story book training|The migrant caregivers will receive training (six weekly 1.5-hour sessions) about life story approach by a part-time trained interventionist with psychology or social work background with at least three years of working experience working with older people and have basic knowledge about the life story work. After training, the migrant caregivers will be asked to produce the life story book individually at home with the older adults
89271281|NCT03726034|Active Comparator|Communication skills training|The migrant caregivers who have randomly assigned into the control group will receive communication skills training (two 1.5-hour sessions) offered by another trained interventionist with psychology or social work background with at least three years of working experience working with older people. They would not receive any additional training on life story work.
89271282|NCT03587974|Experimental|REACH-VN|In-home psychosocial intervention to enhance caregiver knowledge and skills and to reduce stress delivered in 4-6 sessions over the course of 2-3 months
89271283|NCT03587974|No Intervention|Enhanced control|Single session with education about nature of dementia
89271284|NCT03730402|Active Comparator|bupivacaine block|laparoscopic assisted plane block of standardized dose of bupivacaine plain
89271285|NCT03730402|Active Comparator|liposomal bupivacaine block (Exparel 266 milligram Per 20 ML)|laparoscopic assisted plane block of standardized dose of bupivacaine plain
89271286|NCT03730402|Placebo Comparator|saline block|laparoscopic assisted plane block with placebo saline injection
89271287|NCT00103857|Experimental|1|MK0431 100 mg q.d.
89271288|NCT00103857|Active Comparator|2|Metformin 500 mg b.i.d.
89271289|NCT00103857|Active Comparator|3|Metformin 1000 mg b.i.d.
89271290|NCT00103857|Experimental|4|Coadministration of MK0431 and Metformin 50/500 mg b.i.d.
89271291|NCT00103857|Experimental|5|Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.
89271292|NCT00103857|Placebo Comparator|6|Placebo/Metformin 1000 mg b.i.d.
89271293|NCT00103857|Experimental|7|Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.
89271294|NCT03587584|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
89271295|NCT03587584|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
89271296|NCT03586726|Experimental|Balovaptan + Rifampicin|Participants received the study drugs in 2 periods. There was a minimum of a 14-day to a maximum of a 21-day washout between the last dose in Period 1 and the first dose in Period 2.
89271297|NCT03586648|Experimental|Test/Control|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
89271298|NCT03586648|Experimental|Control/Test|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
89271299|NCT02892448|Active Comparator|Unilateral Hip Resurfacing|Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
89271300|NCT02892448|Active Comparator|Bilateral Hip Resurfacing|Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
89271301|NCT02892448|Active Comparator|Non-Metal on Metal Total Hip|Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
89271302|NCT05665192||Cohort 1|Participants that have discontinued RUX therapy and initiated FEDR prospectively
89271303|NCT03725644|Experimental|parent-training program|Parents in the treatment group received the parent-training program based on the DIR model. The parent-training program encouraged child-initiated activities according to the functional developmental levels. The treatment intensity and duration were the same for both groups including 3-week courses and 11-week home programs. The investigators in this study are two registered pediatric occupational therapists who have at least five years of early intervention experience and had studied the DIR model.
89271304|NCT03725644|Experimental|traditional program|Parents in the control group received the traditional program based on the developmental approach. The traditional program provided parent-lead activities that fit child's developmental stage.
89271305|NCT03722134|Experimental|MOCA|The refluxing GSV was treated with ClariVein catheter (endovenous mechanochemical ablation).
89271306|NCT03722134|Active Comparator|EVLA|The refluxing GSV was treated with endovenous laser ablation.
89271307|NCT03722134|Active Comparator|RFA|The refluxing GSV was treated with radiofrequency ablation.
89271308|NCT03722056||gastric GIST|patients with suspected gastric GIST with size > 2cm are subjected for laparoscopic resection.
89271309|NCT03721900|Experimental|SHX-001 Active Low Dose|Ketamine transdermal patch
89271310|NCT03721900|Placebo Comparator|Placebo|placebo transdermal patch
89271311|NCT03721900|Experimental|SHX-001 Active high dose|ketamine transdermal patch
89271312|NCT03585712|Other|Arm A: Delayed then Missed Pill|Treatment period 2, Day 42 +/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: missed pill of Norgestrel 75 mcg
89271313|NCT03585712|Other|Arm B: Missed then Delayed Pill|Treatment period 2, Day 42 +/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg
89271314|NCT03585244||Individuals with Prader-Willi Syndrome|Individuals with Prader-Willi Syndrome aged 12 and over will be recruited to gather data on weekly weight over six months
89271315|NCT00074984|Placebo Comparator|Placebo|Patients randomized to placebo
89271316|NCT00074984|Active Comparator|Fabrazyme (agalsidase beta)|Patients randomized to Fabrazyme (agalsidase beta).
89271317|NCT01082510|Active Comparator|BCG maintenance therapy|
89271318|NCT01082510|Experimental|UFT maintenance therapy|
89271319|NCT03730168|Experimental|study group and control group|"Two groups; study group included 30 diabetic male patients who where trained by circuit weight training program in the form of sets of resistance exercises (in the form of dumbbells and sand bags) for the muscles of lower limb and upper limb .The training sessions were performed 3 days per week for a period of 12 weeks. All patient were on their prescribed routine medications .~The control group were on there prescribed medications only ."
89271320|NCT03583450|Experimental|Perioperative virtual reality headset|Perioperative virtual reality headset with mobile app and routine anesthetic care
89271321|NCT03583450|No Intervention|Control|Routine anesthetic care
89271322|NCT03583372|Experimental|Vibegron + Placebo to match Tolterodine|
89271323|NCT03583372|Active Comparator|Tolterodine + Placebo to match vibegron|
89271324|NCT03725566|Experimental|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
89271325|NCT03582826|Experimental|MEBO/PATM cohort|"Nutrition counselling and stress-management counselling behavioral interventions will be given to minimize subjects symptoms and observe corresponding changes in their microbiomes.~The following subcohorts were formed for analyses of different outcomes: MEBO and PATM subcohorts, TMAU positive and negative subcohorts, Active MEBO, Active PATM, Regression and Remission; MEBO/PATM Cohort that Submitted Gut Samples, MEBO/PATM cohort that answered QoL survey, MEBO/PATM Subcohort that observed and documented both flareups and improvements."
89271326|NCT03582826|No Intervention|non-MEBO cohort|Data volunteers that never experienced episodes of uncontrollable socially debilitating metabolic body odor (MEBO) or PATM
89271327|NCT01582958|Experimental|Treatment|This arm will receive the usual Pulmonary Rehabilitation Program plus OMT, the intervention.
89271328|NCT01582958|Placebo Comparator|placebo|Receives normal pulmonary rehabilitation care plus positioned to receive OMT but OMT is not provided.
89271329|NCT01582958|No Intervention|Control|This arm receives only pulmonary rehabilitation care.
89271330|NCT03518008|Other|DD T2, then Clariti 1 Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable modality.
89271331|NCT03518008|Other|Clariti 1 Day, then DD T2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second. Each product worn bilaterally for 1 week in a daily disposable modality.
89271332|NCT01091324|Active Comparator|Dextromethorphan|
89271333|NCT01091324|Active Comparator|Silymarin|
89271334|NCT01091324|Placebo Comparator|sugar pill|
89271335|NCT03725488||Active|Evaluate stress among dental students by Questionnaire
89271336|NCT03725488||the present level of stress, comfort zone & coping with stress|Evaluate how stress was coped, the coping mechanisms used through Questionnaire
89271337|NCT03810014|Experimental|Arm 1|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
89271338|NCT03810014|Experimental|Arm 2|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
89271339|NCT03810014|Experimental|Arm 3|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
89271340|NCT03810014|Experimental|Arm 4|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
89271341|NCT05782621|Experimental|Acupoint focused ultrasound|the patients will receive Acupoint focused ultrasound therapy three times a week for four weeks
89271342|NCT05782621|Experimental|Laserpuncture|the patients will receive Laserpuncture therapy three times a week for four weeks
89271343|NCT05782621|Active Comparator|conventional treatment|the patients will receive conventional treatment three times a week for four weeks
89271344|NCT05782595|Experimental|Aquatic therapy|Aquatic exercise program: Each woman in group (A) will receive aquatic exercises for 40 minutes.
89271345|NCT05782556||Patients allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|Patients allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) due to cirrhotic and non-cirrhotic portal hypertension
89271346|NCT05782543|No Intervention|Hypothermic machine perfusion|
89271347|NCT05782543|Active Comparator|Normothermic machine perfusion|
89271348|NCT05782530||medical stuff in obstetrics|medical doctors, nurses, midwives
89271349|NCT05782504|Experimental|Treatment arm|4 treatment sessions, each lasting 60 minutes, within a 4-week perioperative period, with 2 preoperative (in the last 2 weeks before surgery) and 2 postoperative (in the first 2 weeks after surgery) sessions.
89271350|NCT05782465||Participants with IM of OLGIM Stage 2 to 4|Participants with Intestinal Metaplasia of Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) that is evaluated to be Stage 2 to 4.
89271351|NCT05782452||Bilateral congenital cataract probands who were consecutively enrolled|
89271352|NCT05782439|Experimental|Healthy adults|Manual and instrumental evaluation to identify if there is an equal or different stiffness between the right and left ileotibial band.
89271353|NCT05782426|Experimental|paclitaxel polymeric micelles for injection, platinum combined with sindilizumab injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
89271354|NCT05782374||Patients diagnosed with r/r PCNSL|Adult patients diagnosed with relapsed or refractory PCNSL who in the period between August 2020 and May 2022 were candidates for treatment with ibrutinib alone or in combination with R-CHOP or R-CHOP like (in compassionate use, or off- label).
89271355|NCT05782348|Experimental|Test Group I|A commercially available fluoride toothpaste (1450 ppm F) A commercially available Smart Electric toothbrush Cognitive behavioral intervention (CBI)
89271356|NCT05782348|Active Comparator|Control group I|A commercially available fluoride toothpaste (1450 ppm F) A commercially available Smart Electric toothbrush
89271357|NCT05782348|No Intervention|Control group II|A commercially available fluoride toothpaste (1450 ppm F) A commercially available soft bristle toothbrush
89271358|NCT05782322|Experimental|PD-RAS|training involving RAS
89271359|NCT05782322|Active Comparator|PD-noRAS|training without the aid of RAS
89271360|NCT05782322|Experimental|HC-RAS|training involving RAS
89271361|NCT05782322|Active Comparator|HC-noRAS|training without the aid of RAS
89271362|NCT05782257|Active Comparator|Zinc Supplementation|Those allocated in this arm will be provided with 90 capsules of gluten-free Zn gluconate 25 mg (7 mg of elemental Zn; Jamieson®) and will be instructed to take 1 tablet daily with a meal and at least 2 hrs apart from other medications, and iron or copper supplements
89271363|NCT05782257|Experimental|Zinc Optimized Diet|Instructions provided by a dietitian to establish a target of 11 mg/day (female) and 14 mg /day (male) provided by Zn-rich food sources, adjusted for dietary phytate intake.
89271364|NCT05782192|Experimental|SAL067|SAL067 12mg once daily
89271365|NCT05782192|Active Comparator|Alogliptin|Alogliptin 25mg once daily
89271366|NCT05782192|Placebo Comparator|placebo|placebo once daily
89271367|NCT05782166|Placebo Comparator|Betel Quid Cessation via Educational Booklet|Participants will be given only an educational booklet on screening day (Day-1) and will be followed up on Day-22 and Month-3 to assess their current chewing status and other related parameters.
89271368|NCT05782166|Experimental|Betel Quid Cessation via Educational Booklet & Intervention Module|Participants will undergo a 5-intervention sessions which will enhance their self-efficacy o quit their chewing behaviour. During the intervention sessions, they will be guided on how to monitor their chewing triggers, the lifestyle changes that they can potentially make, how to tap on their social support system to aid in their cessation efforts and others. The intervention will last for 22 days and a follow-up session will be made on Month-3.
89271369|NCT05782114|Experimental|The experimental Group A|"Extracorporeal Shockwave therapy (four sessions one session per week)~+Traditional physical therapy program (Instruction to wear Thumb Spica splint, Ultrasound therapy, stretching exercise & strengthening exercise) (two sessions per week for 4 weeks)."
89271370|NCT05782114|Active Comparator|The control Group B|Traditional physical therapy program (Instruction to wear Thumb Spica splint, Ultrasound therapy, stretching exercise & strengthening exercise) (two sessions per week for 4 weeks).
89271371|NCT05782049|Other|Group of case patients|"Patients with Rheumatoid Arthritis~Patients with Sjögren's Syndrome"
89271372|NCT05782049|Other|Group of control patients|Patients with Sicca, Asthenia, Polyalgia Syndrome (SAPS)
89271373|NCT05782023|Experimental|Digital empowerment|Usual-care + preventive intervention through digital empowerment
89271374|NCT05782023|No Intervention|Usual care|Usual-care (cardiologist visit at 1, 3 and 12 months after AMI)
89271375|NCT05781945|Experimental|probiotic +|
89271376|NCT05781945|Active Comparator|standard therapy|
89271377|NCT05781932|Experimental|Histoacryl medical tissue glue|specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4[(toluene)amino]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)
89271378|NCT05781867|Placebo Comparator|control|26patients will be included in this group and will receive conventional physiotherapy in form of pursed lip breathing, diaphragmatic breathing exercise and Active Range of Motion of both upper extremities
89271379|NCT05781867|Experimental|manual therapy|26patients will be included in this group and will receive manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor and major, scaleni ) and conventional physiotherapy
89271380|NCT05781854|Active Comparator|Group P (PIEB-group)|After the initial epidural loading dose of 10 ml, 30 patients will receive programmed intermittent epidural boluses (5 ml every 45 min with the first bolus 30 minutes after epidural initiation) + patient controlled epidural analgesia (PCEA) as 5 ml boluses with a 20-minute lockout period).
89271381|NCT05781854|Active Comparator|Group C (CEI-group)|After the initial epidural loading dose of 10 ml, 30 patients will receive continuous epidural infusion (5 ml/h starting immediately after the loading dose) + patient controlled epidural analgesia (PCEA) as 5 ml boluses with a 20-minute lockout period).
89271382|NCT05781841||patients with cutaneous warts|"Under complete sterile precautions, Skin biopsy will be taken from patients with wart lesion.~The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed"
89271383|NCT05781841||healthy volunteers|"Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 2 mm disposable punches .~The specimen will be put in sterile plane tube containing saline and will be transferred immediately to the central research laboratory to be processed"
89271384|NCT05781815|Active Comparator|DHS|patients with trochanteric fracture treated with DHS
89271385|NCT05781815|Active Comparator|DHS with Trochanteric stabilizing plate|patients with trochanteric fracture treated with DHS with trochanteric stabilizing plate
89271386|NCT05781789||Patient participants|"Patient booked for elective surgery and:~Age 21 to 70 years English literacy Willing to provide signed consent Of any nationality Able to give own legal consent"
89271387|NCT05781789||Healthcare provider participants|"Criteria:~Age 21 to 70 years~Healthcare professionals comprising clinic staff (surgical outpatient clinics, PAS), clinicians (anaesthetists, surgeons), and health service managers)~working in the perioperative clinical areas"
89271388|NCT05781763|Experimental|HIIT-intervention group|12 weeks of structured high intensity interval training followed by 9 month of self-selected training
89271389|NCT05781763|Active Comparator|Control group|Continuing with their usual exercise habits during 12 months
89271390|NCT05781737||Ulcerative colitis|
89271391|NCT05781737||Crohn disease|
89271392|NCT05781737||Control group|
89271393|NCT05781685|Experimental|Testosterone|Sublingual testosterone
89271394|NCT05781685|Placebo Comparator|Placebo|Placebo
89271395|NCT05781646|Experimental|Xpert|Centrifuged CSF sent for Xpert MTB/RIF
89271396|NCT05781633|Experimental|eutidrone+ etoposide+ bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.
89271397|NCT05781529|Experimental|Injectable platelets rich fibrin|Injectable platelets rich fibrin was prepared where 10 ml of patient venous blood was centrifuged without anti-coagulants (plain plastic glass-coated) at 700 rpm speed for only 3 minutes, xenograft was mixed with I-PRF to make sticky bone, sticky bone was placed into extraction socket till the socket was fully filled up to the gingival margin
89271398|NCT05781529|Experimental|Hyaluronic acid|Hyaluronic acid (HA) syringe containing 1 mL of cross-linked hyaluronic at a concentration of 20 mg/ml in a saline phosphate buffer solution at sterilized content was used. HA was mixed with particulate xenograft 1:10 ratio to form a putty consistency for condensation and was placed into extraction socket till the socket was fully filled up to the gingival margin
89271399|NCT05781529|Active Comparator|Xenograft|Xenograft was mixed with saline, placed in extraction socket till the socket is fully filled up to the gingival margin
89271400|NCT05781490|Experimental|Lumentin® 44|Lumentin® 44 Powder for oral foam
89271401|NCT05781477|Experimental|Bmum GROUP|Mothers in this group were given supportive breastfeeding support with web based
89271402|NCT05781477|No Intervention|control group|Mothers in the control and intervention groups were given standard care based on the Baby-Friendly Hospital Intervention Standard.
89271403|NCT05781451|Experimental|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
89271404|NCT05781373|No Intervention|Fixed PEEP group|Protective intraoperative ventilation with: 6 ml/kg IBW tidal volume recruitment maneuver and fixed PEEP¨level of 6 cmH2O
89271405|NCT05781373|Experimental|Individualized PEEP group|Protective intraoperative ventilation with: 6 ml/kg IBW tidal volume recruitment maneuver and individualized PEEP¨level in order to achieve the lowest driving pressure
89271406|NCT05781269|Experimental|VLCKD-group|The VLCKD will be applied with the specific products of the ketogenic protocol supplied by Laboratoire Therascience starting from the Active Phase. During this phase the patients will take 4-6 LIGNAFORM products which will be followed by the Selective Phase in which in one or both of the main meals the LIGNAFORM product will be replaced with a protein dish and the phases of reintroduction of fruit (phase three), dairy products and legumes (phase four), bread and derivatives (phase five) and cereals (phase 6). At the end of the previous phases, a normocaloric maintenance diet will be set, with a carbohydrate intake not exceeding 45% of total daily calories. In these subjects, VLCKD diet will be maintained for 2 weeks every 2 months of maintenance diet.
89271407|NCT05781269|Experimental|r-MedDiet|The dietary treatment of the r-MedDiet group will provide for an average caloric deficit equal to 1000 kcal of the estimated total daily energy expenditure starting from the basal metabolic rate measured with indirect calorimetry and multiplied by the level of physical activity (LAF) defined on the basis of the Godin questionnaire. The diet will be personalized in 3 or 5 meals/day. Upon reaching the target weight, a Mediterranean-type diet plan will be set with a caloric intake equal to the estimated energy requirement
89271408|NCT05781230|Experimental|HIE program|HIE program ; High Intensity Exercises Program. 3 sets of 15 repetition
89271409|NCT05781230|Experimental|LIE Program|Low Intensity Exercises program 2 sets of 8 repetition
89271410|NCT05781139||Early onset Alzhiemer|before age of 65 and above age of 50
89271411|NCT05781139||Late onset Alzhiemer|Above the age of 65
89271412|NCT05781139||Vascular dementia|Any patient diagnosed with vascular dementia
89271413|NCT05781139||control group|persons who has no dementia
89271414|NCT05781061|Experimental|Asynchronous Screening|Participants will be screened for medication abortion eligibility using written or online materials and questionnaires, without a synchronous conversation between the prescribing clinician and the patient.
89271415|NCT05781048|Experimental|HRS-6209|
89271416|NCT05781022|Active Comparator|group (1) endoscopic group|"For patients in EG, we began with assessment of the site & size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
89271417|NCT05781022|No Intervention|group (2) surgical group|surgical repair of perforation after adequate drainage
89271418|NCT05780996|Active Comparator|Very high-power short-duration|A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used. In this group vHPSD (90W) will be performed. This power settings will be used for all ablation points.
89271419|NCT05780996|Active Comparator|High-power short-duration|A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used. Ablation of the anterior aspect of the pulmonary veins will be performed with high-power short-duration (50 W) with target ablation index =550. Ablation of the posterior wall of the pulmonary veins will be performed with vHPSD (90W).
89271420|NCT05780944|Experimental|Breastfeeding First, Bottle-feeding Second, PBF Third|Mother-infant dyads will visit the laboratory on three different days. During the first visit, they will be observed during breastfeeding. During the second visit, they will be observed during bottle-feeding. During the third visit, the mother will be taught the PBF approach and will be observed using it during bottle-feeding.
89271421|NCT05780944|Experimental|Bottle-feeding First, Breastfeeding Second, PBF Third|Mother-infant dyads will visit the laboratory on three different days. During the first visit, they will be observed during bottle-feeding. During the second visit, they will be observed during breastfeeding. During the third visit, the mother will be taught the PBF approach and will be observed using it during bottle-feeding.
89271422|NCT05780905|Placebo Comparator|Placebo|Subjects randomized to placebo for 1 year.
89271423|NCT05780905|Active Comparator|Active|Subjects randomized to semaglutide for 1 year.
89271424|NCT05780840|Experimental|Dihydroxyacetone|
89271425|NCT05780840|Placebo Comparator|Placebo|
89271426|NCT05780827||Healthy volunteers|No symptoms and signs of oral and maxillofacial dysfunction are required
89271427|NCT05780827||Patients with temporomandibular joint disorder|Patients with temporomandibular joint disorder
89271428|NCT05780554|Active Comparator|Cyclophosphamide 50 mg/kg|
89271429|NCT05780554|Experimental|Cyclophosphamide 25 mg/kg|
89271430|NCT05779709|Experimental|Urotherapy group|The purpose of urotherapy education was to teach children to empty the bladder regularly and completely. The standardized urotherapy which included instructions on daily fluid intake of at least 1,200 ml evenly distributed daily as described and voiding at 2-hour intervals until bedtime in which the voiding and defecation positions were taught not to perform avoidance maneuvers. In this training, families were given basic information about the anatomy and physiology of the lower urinary tract (LUT) and anorectum, normal voiding and defecation, fluid consumption and voiding habits of children. The children were allowed to pee whenever they wanted occasionally at any time. Children were also asked to report the number of wet days during 8 weeks
89271431|NCT05779709|Experimental|Reformer pilates group|The basic pilates principles were explained to the children. The diaphragmatic breathing, neutral position of the pelvis, centering and pelvic floor control were teached with appropriate language for their age. Verbal help were given to maintain centering during each movement. The exercises (30 min) were started by doing 10 repetitions in combination with diaphragm breathing, and progressed 12 repetitions after 3 weeks, 15 repetitions after 6 weeks (frog series, leg circles series, hundred series, box series, side splits series).İndividual reformer pilates training consisting of 30 minutes two days a week was given to the exercise group by an expert physiotherapist for 8 weeks.
89271432|NCT05777811|Active Comparator|Vertically Coronally advanced flap combined with connective tissue graft|
89271433|NCT05777811|Active Comparator|Free Gingival Graft|
89271434|NCT05776992|Experimental|balance games|virtual reality games
89271435|NCT05776992|Active Comparator|balance training|Biodex balance training
89271436|NCT05774925|Experimental|Healthy Periodontium|Full-mouth clinical periodontal measurements recorded and saliva obtained.
89271437|NCT05774925|Experimental|Gingivitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
89271438|NCT05774925|Experimental|Periodontitis|Full-mouth clinical periodontal measurements recorded and saliva obtained.
89271439|NCT05774652|Experimental|Diet + physical activity|Diet + physical activity Dietary advise and advise on physical activity
89271440|NCT05774652|No Intervention|Control group|No intervention
89271441|NCT05769543|Active Comparator|WATSU application|
89271442|NCT05769543|Placebo Comparator|Control|
89271443|NCT05766722|Experimental|All patients 18 years old or older undergoing uncomplicated cataract surgery.|
89271444|NCT05763758||Healthy Control|Healthy participants will undergo multimodal neuroimaging during resting state, no-pain and painful tonic pressure presentation. At FSU, EEG and fMRI will be simultaneously acquired. At MGH, sequential MRI and MEG/EEG will be acquired.
89271445|NCT05763758||Patients with chronic low back pain|Subjects with chronic low back pain (cLBP) patients will undergo multimodal neuroimaging during resting state, no-pain and painful tonic pressure presentation. The study will only be performed at MGH, sequential MRI and MEG/EEG will be acquired.
89271446|NCT05869942|Active Comparator|groupA (Diseased group)|patients with Vitiligo
89271447|NCT05869942|Active Comparator|group B(Control group)|Normal control group not diseased
89271448|NCT05869916|Experimental|experimental group|"In this study, the Psychological First Aid: A Guide for Field Workers program published by the World Health Organization in 2011 was adapted to the needs and culture of the region/people where the research will be conducted. Psychological First Aid training was given by the psychiatric nurse participating in the study after a two-day training organized by the Psychiatric Nursing Association."
89271449|NCT05869916|No Intervention|control group|No interference
89271450|NCT05869890|Other|Flexible Ureteroscopy with Dusting|Flexible ureteroscopy with the dusting lasing technique. MOSES parameters will be set to an energy of 0.3-0.4 Jules and a frequency of 50-80 hertz
89271451|NCT05869890|Other|Flexible Ureteroscopy with Fragmentation|Flexible ureteroscopy utilizing the Fragmentation lasing technique. MOSES parameters will be set to 0.8-1 JULES and a frequency of 8-10 hertz
89271452|NCT05869890|Other|Flexible Ureteroscopy with Hybrid|Flexible ureteroscopy utilizing the Hybrid lasing technique which will use both sets of parameters.
89271453|NCT05869695||OSPRO-ROS: 100 patients presenting musculoskeletal pain|Patients between 18 and 75 years of age with primary complaints involving the cervical spine, lumbar spine, shoulder or knee. Were able to read and comprehend Spanish.
89271454|NCT05869695||OSPRO-YF: 100 patients presenting musculoskeletal pain|Patients between 18 and 75 years of age with primary complaints involving the cervical spine, lumbar spine, shoulder or knee. Were able to read and comprehend Spanish.
89271455|NCT05869565|Active Comparator|Normal saline arm|Sodium chloride (0.9%) referred as 0.9% NaCl for 72 hours post symptom onset (60-72 hourspost randomization);
89271456|NCT05869565|Active Comparator|normal saline sodium acetate 3;1|Sodium chloride (0.9%) and sodium acetate (0.9%) mixture 3:1 ratio for 72 hours post symptom onset (60-72 hours post randomization
89271457|NCT05869565|Active Comparator|normal saline sodium acetate 2;1|Sodium chloride (0.9%) and sodium acetate (0.9%) mixture 2:1 ratio for 72 hours post symptom onset (60-72 hours post randomization);
89271458|NCT05869565|Active Comparator|normal saline sodium acetate 1;1|Sodium chloride (0.9%) and sodium acetate (0.9%) mixture 1:1 ratio for 72 hours post symptom onset (60-72 hours post randomization).
89271459|NCT05869500|Experimental|Left Bundle Branch Area Pacing|
89271460|NCT05869500|Active Comparator|Right Ventricular Pacing|
89271461|NCT05869435|Other|FastWire System - Peripheral|This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs). This is a First in Human study
89271462|NCT05869409||People diagnosed with a psychotic disorder or an affective disorder|
89271463|NCT05869396||echocardiogrpahy|Patients with with previously unknown systolic murmurs, unstable cardiovascular clinical conditions, recent (within 6 months) de-compensation of heart failure or hospital admission for coronary disease (high-risk group).
89271464|NCT05869396||non echocardiography|Patients without previously unknown systolic murmurs, unstable cardiovascular clinical conditions, recent (within 6 months) de-compensation of heart failure or hospital admission for coronary disease (low-risk group).
89271465|NCT05869370|Experimental|High intensity resistance training|
89271466|NCT05869370|Experimental|Low intensity resistance training combined with blood flow restriction|
89271467|NCT05869344|Experimental|Black bean protein hydrolysates (BPH) treatment|Participants received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage
89271468|NCT05869344|Placebo Comparator|Placebo|Participants received 120 mL non-caloric commercial beverage
89271469|NCT05869292|Experimental|Test: Immediate implant loading|Implants will be immediately following surgical procedure loaded with temporary restorations.
89271470|NCT05869292|Experimental|Control: Early implant loading|Implants will not be received prosthetic restoration, and will left with healing abutments (HA) for 6 weeks.
89271471|NCT05869279|Experimental|CARCIK-CD19|Gene therapy product composed of T lymphocytes differentiated according CIK-cell protocol (leading to production of CD3+ cells also expressing CD8 and to a lesser extent CD4 or CD56) that have been genetically modified to express CAR with specificity for targeting CD19 molecule expressed on the surface of B cells. The CARCIK-CD19 contains cells that express the anti-CD19 single chain fragment variable (scFV) linked to an intracellular signaling domain comprising the TCR CD3 ζ chain and tandem costimulatory domains as the CD28 and OX40 (CD19-CD28OX40).
89271472|NCT05869227|Experimental|Capecitabine combined with treprizumab maintenance group|Capecitabine, 1000 mg/m2/dose, twice a day, days 1-14; 21 days/cycle Treprizumab, 240mg, intravenously, day 1 and 21 days/cycle
89271473|NCT05869227|Placebo Comparator|Placebo combined with teriprizumab maintenance group|Placebo, 1000 mg/m2/dose, twice a day, days 1-14; 21 days/cycle Treprizumab, 240mg, intravenously, day 1 and 21 days/cycle
89271474|NCT05869201|Experimental|Flu-M Quadro with preservative|150 volunteers were vaccinated with the Flu-M Quadro Inactivated Split Influenza Vaccine with a preservative
89271475|NCT05869201|Experimental|Flu-M Quadro without preservative|150 volunteers were vaccinated with the Flu-M Quadro Inactivated Split Influenza Vaccine without a preservative
89271476|NCT05869201|Active Comparator|Ultrix® Quadri|150 volunteers were vaccinated with Ultrix® Quadri Vaccine
89271477|NCT05869110|Experimental|Experimental Intervention|Olfactory stimulation
89271478|NCT05869110|Placebo Comparator|Placebo|Propylene glycol
89271479|NCT05869097||TAS-102 plus BEV group|In TAS-102 plus BEV group, Patients received TAS-102 (35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days) and bevacizumab (5 mg /kg, intravenously, on days 1 and 15, every 28 days). Bevacizumab was approved to be a 30-minute intravenous infusion before TAS-102.
89271480|NCT05869097||TAS-102 monotherapy group|In TAS-102 monotherapy group, TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days were given to patients.
89271481|NCT05869084|Experimental|pulmonary function tests|
89271482|NCT05869045||Patients with Diaphragmatic dysfunction (DD)|Patients with diaphragmatic dysfunction measured by point-of-care ultrasound using the diaphragm shortening fraction (DSF) method, which resulted in values lower than 10%. DSF is calculated by the formula: diaphragmatic thickness at the end of inspiration - diaphragmatic thickness at the end of expiration/diaphragmatic thickness at the end of expiration×100
89271483|NCT05869045||Patients without Diaphragmatic dysfunction (DD)|Patients without diaphragmatic dysfunction measured by point-of-care ultrasound using the DSF method, which resulted in values higher than 10%.
89271492|NCT05868993|Experimental|Brachial Plexus Block Group 1|Interscalene
89271493|NCT05868993|Experimental|Brachial Plexus Group 2|Supraclavicular
89271494|NCT05868993|Experimental|Brachial Plexus Group 3|Suprascapular
89271495|NCT05868980||supine|supine position: Evaluation position for the first 10 minutes after birth
89271496|NCT05868980||right-side|right-side position: Evaluation position for the first 10 minutes after birth
89271497|NCT05868980||left-side|left-side position: Evaluation position for the first 10 minutes after birth
89271498|NCT05868980||prone|prone position: Evaluation position for the first 10 minutes after birth
89271499|NCT05868967|Experimental|[14C]DWP14012|Type: [14C]DWP14012 suspension containing 40 mg/80 μCi Dosage: orally take the suspension
89271500|NCT05868915|Experimental|HV-101|"Participants with Advanced Solid Tumors~Interventions:~Biological: HV-101~Drug: IL-2~Drug: Fludarabine Drug: Cyclophosphamide"
89271501|NCT05868811|Experimental|Music Together|
89271502|NCT05868811|Placebo Comparator|Play Group|
89271503|NCT05868798|No Intervention|Control|Participants performed each individual test without ammonia inhalants.
89271504|NCT05868798|Experimental|Ammonia inhalants|Participants performed each individual test with ammonia inhalants.
89271505|NCT05868759|Experimental|patients|Candidates for an ankle prosthesis
89271506|NCT05868720|Experimental|Risperidone group|
89271507|NCT05868720|Experimental|Aripiprazole group|
89271508|NCT05868681|Experimental|Study group|Proprioceptive training, which will be carried out 1 session lasting one hour twice per week for 5 weeks using Delos instrument with Riva method
89271509|NCT05868681|No Intervention|Control group|Normal physiotherapy performed according to standard protocols.
89271510|NCT05868655|Experimental|Exercise with supervisor|
89271511|NCT05868655|Active Comparator|Standart Exercise|
89271512|NCT05868642|Experimental|T group|Subaracnhoid block levobupivacaine 0.5%, 10 mg (2 ml) via subarachnoid injection plus 1mg for each metameric level needed to achieve the T10 level sensory block (evaluation with pinprick test at 10 minute after the firts injection and at 4 minute from the second injection)
89271513|NCT05868642|Active Comparator|S group|levobupivacaine 0.5%, 15 mg (3 ml) via subarachnoid injection
89271514|NCT05868616||Group 1 - Implantation|Patients admitted for CRT implantation according to current ESC/AHA guidelines
89271515|NCT05868616||Group 2 - 6 months control|Patients admitted for 6 months routine checkups of their CRT devices
89271516|NCT05868603|Experimental|Remineralization gel with CPP- ACP (GC Tooth MousseTM, Tokyo, Japan)|"CPP-ACP containing remineralization gel (Tooth Mousse GC, Tokyo, Japan) will be put into the Essix appliance with a reservoir and applied for 5-7 minutes twice a day for one month.~Before and after the applying remineralization gel, the laser fluorescence values will measure with a DIAGNOdent pen (KaVo Dental corporation, East Main street Lake Zurich, lL)."
89271517|NCT05868603|Experimental|Remineralization gel with calcium glycerophosphate (R.O.C.S.® Medical Mineral Gel, Russia)|Remineralization gel containing calcium glycerophosphate (R.O.C.S.® Medical Minerals Gel, Russia) will be put into the Essix appliance with a reservoir for 5-7 minutes twice a day for one month. Before and after the applying remineralization gel, the laser fluorescence values will measure with a DIAGNOdent pen( KaVo Dental corporation, East Main street Lake Zurich, lL).
89271518|NCT05868603|No Intervention|Control Group|No intervention.
89271519|NCT05868590|Experimental|Active Magnesium Containing Toothpaste-ROCS|The participants will ask not to eat for 4 hours and not to brush for 24 hours in advance of the test.In the first stage, the preliminary plaque in the children will record by the first researcher using plaque dye.After plaque disclosing the researcher brush children's teeth with ROCS active magnesium toothpaste for 1 minute with a standard toothbrush then the plaque staining will apply again.Also remaining plaque measurements will made using the Gc D lite Pro curring light on detection mode.Dental plaque on the upper anterior incisors will photograph intra-orally before and after brushing under standardized conditions.
89271520|NCT05868590|Experimental|Fluoride Toothpaste-COLGATE|After 2 weeks, the same participants will ask not to eat for 4 hours and not to brush for 24 hours in advance of the retest.Initial, the preliminary plaque in the children will record by the first researcher using plaque dye. After plaque disclosing the researcher brush children's teeth with Colgate fluoride toothpaste for 1 minute with a standard toothbrush then the plaque staining will apply again.Also remaining plaque measurements will made using the Gc D lite Pro curring light on detection mode.Dental plaque on the upper anterior incisors will photograph intra-orally before and after brushing under standardized conditions.
89271521|NCT05868564|Experimental|Atherectomy+Drug-coated balloon|The lesion treated by atherectomy + UltrafreeTM drug-coated balloon.
89271522|NCT05868564|Active Comparator|Drug-coated balloon|The lesion treated by UltrafreeTM drug-coated balloon only.
89271523|NCT05868551||Persons with onchocerciasis nodules with OAE and without epilepsy|nodulectomy to extract adult worms
89271524|NCT05868538||Patients|
89271525|NCT05868538||control|
89271526|NCT05868512|Other|Dry needling|
89271527|NCT05868512|Experimental|therapeutic ultrasound|
89271528|NCT05868499|Experimental|EXG34217|single autologous CD34+ cells contacted ex vivo with EXG-001
89271529|NCT05868486|Experimental|Whole Body MRI and Liquid Biopsy|Patients undergo WBM without contrast and blood sample collection for liquid biopsy
89271530|NCT05868473|Other|Mobilization With Movement|Mobilization With Movement for Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
89271531|NCT05868473|Experimental|Kinesotaping|Kinesotaping for Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
89271532|NCT05868434|Experimental|Main arm of the study|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy will be performed in these patients.
89271533|NCT05868395|Experimental|Polatuzumab, bendamustine and rituximab|Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle, bendamustine 90 mg/m2 i.v. day 2 & 3 of cycle 1, then on day 1 & 2 of each subsequent cycle and rituximab 375 mg/m2 i.v. on day 1 of each cycle every 3 weeks.
89271534|NCT05868343|Active Comparator|Center-based cardiac rehabilitation program|
89271535|NCT05868343|Experimental|Hybrid cardiac rehabilitation program|
89271536|NCT05868317|Experimental|Induction CT followed by short course RT|Induction chemotherapy with modified 5 fluorouracil, oxaliplatin and irinotecan followed by short course radiotherapy ( 5x5 Gy), then 5 fluorouracil and oxaliplatin based chemotherapy. Surgery will be performed 6 to 8 weeks after completion of RT.
89271537|NCT05868304|Active Comparator|Group 1 - Standard strengthening group (no BFR)|"Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
89271538|NCT05868304|Experimental|Group 2 - Low-load BFR group|"Participants will warm up on a stationary bike for 5 minutes BFR will be applied to non-dominant limb (dominant limb is determined as the preferred leg for kicking a ball)~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
89271539|NCT05868200|Experimental|Capitano zenzero toothpaste|Participants will be given the test interventions, Capitano zenzero toothpaste, and will be asked to brushing teeth with this product for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing.
89271540|NCT05868200|Active Comparator|Colgate total toothpaste|Participants will be given the test interventions, Colgate total toothpaste, and will be asked to brushing teeth with this product for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing.
89271541|NCT05868187|Experimental|Exercise, Problem-Solving and Education|Individualized exercise program Weekly Goals setting and problem-solving session to create a weekly action plan Four Assigned interactive educational modules
89271542|NCT05868187|No Intervention|Usual Care|Participants will complete their daily routines as they typically do.
89271543|NCT05868135||Patients with moderate depression|
89271544|NCT05868135||Patients with social anxiety disorder|
89271545|NCT05868135||Patients with panic disorder|
89271546|NCT05868031|Experimental|Art work|The artwork group was tasked with preparing anatomical models by hand. This hands-on approach was designed to engage the students in a more active and creative manner, allowing them to develop a deeper understanding of the subject matter. By visualizing and creating the anatomical structures themselves, the students were able to retain the information better and apply it in a practical context.
89271547|NCT05868031|Experimental|Atlas groups|The atlas group was provided with a selection of anatomical pictures from atlases and encouraged to use them as a resource to aid their learning throughout the semester. This approach focused on visual learning and aimed to provide the students with a comprehensive and detailed understanding of the anatomical structures and how they interact with one another.
89271548|NCT05868018||DPT A|Students from University A received their typical evidence based practice education over 3 years.
89271549|NCT05868018||DPT B|Students from University B received their typical evidence based practice education over 3 years.
89271550|NCT05868018||DPT C|Students from University C received their typical evidence based practice education over 3 years.
89271551|NCT05868018||MSPT|Students from University D received their typical evidence based practice education over 2 years.
89271552|NCT05867823|Experimental|OcuApp Users|the experimental group will use a movile aplication (OcuApp), to generate a personal self-analisys about meaningful activities.
89271553|NCT05867823|Active Comparator|Three-part work users|The intervention on the control group will focus on offering to the participants an informative three-part work on the positive effects of performing activities.
89271554|NCT05867784||supplementary group|take vitamin D supplementation (400 IU/day) during VDZ treatment
89271555|NCT05867784||non-supplementary group|not take vitamin D supplementation (400 IU/day) during VDZ treatment
89271556|NCT05867771|Experimental|PM1022|PM1022 Injection
89271557|NCT05867758|Experimental|intervention group|Group of participants (9 to 12) participating in the psychosocial group intervention (8 sessions, one per week) and receiving the self-help digital materials each week.
89271558|NCT05867758|No Intervention|Control group - waiting list|Group of participants (9 to 12) receiving the self-help digital materials each week, who will take part in the psychosocial group intervention once the data collection will be over
89271559|NCT05867745||Lead nurse for Transition/Regional Nurse Advisors|The Lead Nurse and RNAs will be interviewed using telephone or online via Zoom. The interviews will be recorded using a Dictaphone rather than being saved via Zoom. Recordings will then be saved on the University's secure, password protected SharePoint for the study. Only the research team, and the designated transcriber, will have access to interview data. At the start of the project, interviews have been conducted in a PPI format to explore in depth the programme, expectations of how it should work and its implementation in order for the research team to devise the study. For the purposes of the research, interviews will be undertaken at one year, two years, and at the end of the programme to further explore implementation of the programme, including what works well, challenges encountered and their perceptions of the impact the programme has on families' experiences.
89271560|NCT05867745||Young people|"Young people aged 12 to 25 years will be invited to participate. Young people will be asked to complete surveys at baseline, six months to one year and 18 months.~Survey: Online surveys (Qualtrics) will be used to collect data from young people participating in the case studies. Young people will be asked to provide basic demographic details: age, gender, health condition, and type of service they attend (children's/young person's/adults') and length of time since transfer to adult services (if already transitioned).~Letter/email/video to a friend: Young people will also be asked to write a 'letter/email to a friend' to describe their experiences. This will be completed online with the survey. They will be invited to write a letter/email or record a video about a recent clinic appointment/encounter with a health professional."
89271561|NCT05867745||Parents|"Case study: Parents/carers will be invited to participate alongside young people. We will aim transition (including preparation, transfer and within adult services). Survey: Parents/carers of young people participating in the case study will be invited to complete an online survey (Qualtrics). Basic demographic details will be requested about the parent: age and gender; and their child: age, gender, health condition, and type of service they attend (children's/young person's/adults'), length of time since transfer to adult services (if already transitioned).~Letter/email/video about their experiences: Parents will also be asked to complete a written task/video. They will be asked to describe their experiences relating to the shift in responsibility towards their child as the primary partner in their own healthcare, how their child is moving (or has moved) towards greater independence and competence in self-management."
89271562|NCT05867745||Transition champions/key professionals|Transition champions and key professionals in participating Trusts who are involved in the care of young people included in the case studies will be identified by the RNAs. We will aim to involve staff from various professional roles. They will be invited to complete an online survey (using Qualtrics) during the first year and one at the end of the second year, towards the end of the project. The surveys will explore their views on the implementation of the programme, experiences of building/making changes to a transition service, including what works well, challenges encountered and their perceptions of the impact the programme has on families' experiences. One professional from each case study site will be interviewed via Zoom/telephone to explore these aspects more in-depth at the same time points as the surveys. Ideally, we will aim to interview the same professionals at both time points. Data access and storage for will be the same as for the Lead Nurse/RNA interviews.
89271563|NCT05867693|Experimental|IBS patients assigned to palmithoylethanolamide/polydatin treatment|Eligible patients (patients with symptoms meeting Rome IV criteria for diagnosis of IBS) will be randomly assigned to either co-micronised form palmithoylethanolamide/polydatin 200 mg/20 mg
89271564|NCT05867693|Placebo Comparator|IBS patients assigned to placebo treatment|Eligible patients (patients with symptoms meeting Rome IV criteria for diagnosis of IBS) will be randomly assigned to Placebo
89271565|NCT05867680|Experimental|Treatment|Treatment group participants received the eMB intervention during the 8-week trial period.
89271566|NCT05867680|No Intervention|Control|The control group received a PDF community resources informational sheet, also available to the intervention group via the eMB program.
89271567|NCT05867641|Other|VR&R Therapy|Recruited dyads will include one person diagnosed with dementia and their informal caregiver (i.e., family/friend). The caregiver will assist their loved ones with dementia to use VR-therapy at home. Caregivers may use the time while their loved ones are engaged for respite, remaining nearby to supervise and assist.
89271568|NCT05867602|Experimental|Intervention arm|the intervention group will receive intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g, plus SOC
89271569|NCT05867602|No Intervention|Control arm|the control arm will receive the standard of care (SOC), including moderate sodium restriction, maximal daily tolerated doses of diuretics, and post-paracentesis albumin
89271570|NCT05867589|Experimental|68Ga/18F-FAPI-04|For the injection, subjects will receive a target dose of 0.1~0.15mCi/Kg 68Ga/18F-FAPI-04 as a bolus injection.
89271571|NCT05867537|Active Comparator|Gluten-free diet in Crohn disease|
89271572|NCT05867537|Active Comparator|Gluten-free diet in ulcerative colitis|
89271573|NCT05867537|Active Comparator|Gluten-free diet in Primary sclerosing cholangitis|
89271574|NCT05867524|Experimental|High IL-6 c-aAb|Individuals with top percentile IL-6 c-aAb
89271575|NCT05867524|Experimental|Low IL-6 c-aAb|Individually matched controls with low IL-6 c-aAb
89271576|NCT05867511|Experimental|Intervention group|This Group will be using the iPAL App for 8 Weeks
89271577|NCT05867485|No Intervention|Control Group:|"Initially, the Patient Diagnostic Information Form was completed. Patients were informed about the discharge process according to the regular ward procedure and were informed about their participation in the study after discharge.~One month later, patients were contacted by phone, and the Daily Life Activities Scale (DLAS) and Quality of Life Scale (SF-12) forms were completed during 10-15 minute conversations."
89271578|NCT05867485|Experimental|Study Group:|"After obtaining informed consent from the patients, they were enrolled in the study.~The COVID-19 Discharge Education Brochure, prepared by the researchers, was provided to the patients face-to-face within 10-15 minutes.~One month after the discharge education, patients were contacted by phone, and the Daily Life Activities Scale (DLAS) and Quality of Life Scale (SF-12) forms were completed."
89271579|NCT05867459||CKD PREGNANT PATIENT|The Group of pregnant CKD PT as mentioned in introduction and according to KIDOG definition of CKD regardless cause of CKD
89271580|NCT05867394|Experimental|Stress ball|Data were collected by the investigator 25-30 minutes before coronary angiography and the first measurement of vital signs was made. After the stress ball application, State Anxiety Inventory data were collected for the second time and the second measurement of vital signs was made. Vital signs were measured and noted for the third time after coronary angiography.
89271581|NCT05867394|No Intervention|Control|25-30 minutes before the coronary angiography procedure, data were collected from the patients by the investigator and the first measurements of their vital signs were recorded. Vital signs were measured a second time just before coronary angiography without any intervention. Vital signs were measured and recorded for the third time after coronary angiography ischemia.
89271582|NCT05865275|Experimental|Test group|it is the group for testing the effectiveness of low power of a diode laser on the onset of dental sensitivity
89271583|NCT05865275|Placebo Comparator|Placebo group|this represents the control group with tooth bleaching without preliminary laser treatment
89271584|NCT05865080|Active Comparator|group K|group K (63 patients): Received 0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution,
89271585|NCT05865080|Placebo Comparator|group C|group C (Controlled) (63 patients): Received 10 ml of normal saline followed by infusion of 0.1 ml/kg/hr. as 20 ml solution.
89271586|NCT05864547||Stroke patients|Patients with first time stroke admitted to the stroke unit, St. Olavs hospital, Trondheim, Norway. The planned cohort size is 15-20 patients.
89271587|NCT05864547||Healthy controls|Age and gender matched healthy volunteers without previous stroke. The same number of healthy controls as recruited patients will be recruited through ads in the local newspaper.
89271588|NCT05864105|Experimental|PM8002+FOLFOX-4|PM8002 20mg/kg Q2W day 1: oxaliplatin [85 mg/m2, 2-h infusion] plus leucovorin [200 mg/m2, 2-h infusion], followed by 5-fluorouracil [400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion]; day 2: leucovorin [200 mg/m2, 2-h infusion], followed by 5-fluorouracil [400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion]
89271589|NCT05864040|Experimental|Subjects to undergo laparoscopic radical/simple nephrectomy|Adult subjects between 18 and 90 years old, that provided informed consent prior to any clinical investigation-related procedure, who have been scheduled for a laparoscopic radical/simple nephrectomy surgery and who are able and willing to comply with all study requirements to be evaluated for each study visit.
89271590|NCT05863286|Experimental|botulinum toxin type A injection in lateral pterygoid muscle|"Botulinum toxin type A vial will be reconstituted with normal saline to obtain a 10 U/0.1 ml solution, 0.25 ml of this solution containing 25 U BTX-A will be loaded in a 1-ml insulin syringe attached to a needle with 27 Gauge and 31 mm length.~The Lateral pterygoid muscle will be approached extra orally through the space formed by the zygomatic arch and the sigmoid notch of the mandible below the center of the zygomatic arch. The needle will be advanced perpendicular to the skin with the mouth closed. The muscle is approximately 3 to 4 cm deep. Aspiration will be carried out to avoid unintentional intravascular injection. According to the assigned group, the inferior head of Lateral pterygoid muscle will be injected with BTX-A"
89271591|NCT05863286|Placebo Comparator|"Placebo Saline 0.9% injection in lateral pterygoid muscle"|"0.25 ml of normal saline will be loaded in a 1-ml insulin syringe attached to a needle with 27 Gauge and 31 mm length.~The Lateral pterygoid muscle will be approached extra orally through the space formed by the zygomatic arch and the sigmoid notch of the mandible below the center of the zygomatic arch. The needle will be advanced perpendicular to the skin with the mouth closed. The muscle is approximately 3 to 4 cm deep. Aspiration will be carried out to avoid unintentional intravascular injection. According to the assigned group, the inferior head of Lateral pterygoid muscle will be injected with normal saline"
89271592|NCT05857228||Primary epithelial cells|Population: The investigators will use frozen dissociated cells from our biobank in earliest possible format (P0 or P1) to preserve original viruses and epigenetic marks. Polyp samples from T2 CRSwNP will be selected according to clinical phenotype together with blood test and histology.
89271593|NCT05857228||Patients in remission of CRSwNP|Population: Perfect sinus cavity outcome after ESS under continued intranasal corticosteroids (INCS) or dupilumab.
89271594|NCT05857228||Effect of sinus surgery on the sinus virome|Population: Patients undergoing ESS for CRSwNP, including at least 30% of subjects with aspirin sensitivity.
89271595|NCT05857228||Healthy volonteers|Population: Participants with no sino-nasal symptoms and normal sense of smell as assessed by UPSIT-40 testing.
89271596|NCT05855408|Experimental|Group 1|Subjects are assigned to receive one dose of intramuscularly administered Ad5-nCoV vaccine as the second booster.
89271597|NCT05855408|Experimental|Group 2|Subjects are assigned to receive one dose of aerosolized Ad5-nCoV vaccine as the second booster.
89271598|NCT05855408|Experimental|Group 3|Subjects are assigned to receive two doses of DelNS1-2019-nCoV-RBD-OPT1 vaccine as the second booster.
89271599|NCT05855408|Experimental|Group 4|Subjects are assigned to receive one dose of SYS6006 vaccine as the second booster.
89271600|NCT05855408|No Intervention|Group 5|Subjects are not assigned any vaccines served as a blank control.
89271601|NCT05840237|Experimental|Oxaloacetate Arm|1,000 mg of Anhydrous Enol-Oxaloacetate taken BID with Breakfast and Lunch
89271602|NCT05840237|Placebo Comparator|Placebo Arm|1,000 mg of white Rice Flour taken BID with Breakfast and Lunch
89271603|NCT05834725|Experimental|Resilience Coaching plus Usual Care|Promoting Resilience in Stress Management (PRISM) is a 1:1, remotely delivered, resilience coaching program for adolescents with chronic illness, consisting of skill-building sessions in stress management, goal setting, cognitive re-framing, and benefit-finding. Sessions are held every 1-2 weeks for a total of 4 required and one optional session and each session lasts about 30-45 minutes.
89271604|NCT05834725|Active Comparator|Usual Care|Usual care consists of an individualized treatment combining physical therapy, occupational therapy and psychological counseling. This is determined by the treating provider.
89271605|NCT05831748|Experimental|Experimental Group|15 Transfemoral and Transtibial amputees will be included in this group. Patients will be treated with classic physiotherapy exercises for 12 weeks. Patients will practice exercises 3 times a week, one time in clinics with a physiotherapist and 2 times as home exercise.
89271606|NCT05831748|Active Comparator|Active Comparator group|15 Transfemoral and Transtibial amputees will be included in this group. Patients will be treated with Clinical pilates exercises for 12 weeks. Patients will practice exercises 3 times a week, one time in clinics with a physiotherapist and 2 times as home exercise.
89271607|NCT05828368|No Intervention|GROUP I: 40 systemically healthy subjects with healthy periodontium.|Systemically healthy subjects with healthy periodontium having probing pocket depth (PPD) ≤3mm, no clinical attachment loss (CAL=0) and bleeding on probing ≤ 10% of sites.
89271608|NCT05828368|Experimental|GROUP II: 40 periodontitis patients without coronary artery disease|Systemically healthy subjects with periodontitis having interdental clinical attachment loss ≥ 3-5mm (stage II/III periodontitis) and probing pocket depth (PPD) ≥5mm (stage II/III periodontitis) and bleeding on probing ≥10% of sites.
89271609|NCT05828368|Experimental|GROUP III: 40 coronary artery disease patients without periodontitis.|Patients diagnosed with coronary artery disease with healthy periodontium having probing pocket depth (PPD)≤3mm, no clinical attachment loss (CAL=0) and bleeding on probing ≤ 10% of sites (CAD).
89271610|NCT05828368|Experimental|GROUP IV: 40 periodontitis patients with coronary artery disease.|Coronary artery disease (CAD) patients with periodontitis having interdental clinical attachment loss ≥3-5mm (stage II/III periodontitis) and probing pocket depth (PPD) ≥5mm (stage II/III periodontitis) and bleeding on probing ≥ 10%.
89271611|NCT05825885||5-7 days E2 therapy|Patient group treated with e2 for 5-7 days
89271612|NCT05825885||8-10 days E2 therapy|Patient group treated with e2 for 5-7 days
89271613|NCT05825885||11-13 days E2 therapy|Patient group treated with e2 for 5-7 days
89271614|NCT05772195||Before major system reorganisation|Theme 1 - elective recovery plan 2017/18-2019/20
89271615|NCT05772195||Before major system reorganisation - intra-pandemic|Theme 1 - elective recovery plan 2020/21-2021/22
89271616|NCT05772195||Post system reorganisation|Theme 1 - elective recovery plan 2023/24 and 2024/25
89271617|NCT05768373|Experimental|3M™ Clinpro™ Fluoride Aqueous Solution|Investigational product.
89271618|NCT05768373|Active Comparator|3M™ Vanish™|Commercialized product
89271619|NCT05756088||Low MFR (less than or equal to 1.5)|Subjects who are found to have a low MFR of less than or equal to 1.5.
89271620|NCT05756088||Normal MFR (greater than 1.5)|Subjects who are found to have normal MFR of greater than 1.5.
89271621|NCT05753683|Active Comparator|Standard: mHealth-Women's CoOp|Participants assigned to receive an evidence-based mHealth alcohol and other drug use and sexual risk reduction intervention for young African American women. The app will be installed on each participant's smartphone by study staff after randomization.
89271622|NCT05753683|Experimental|Enhanced: mHealth-Women's CoOp+Group|Participants assigned to receive an evidence-based mHealth alcohol and other drug use and sexual risk reduction intervention for young African American women, in addition to a virtual peer group component. The app with a link to the virtual group will be installed on each participant's smartphone by study staff after randomization.
89271623|NCT05743959||Patients with stage I-III biliary tract cancers|Patients with stage I-III biliary tract cancers eligible for curative surgical resection
89271624|NCT05737108|Experimental|Group A-test samples|This group will be given test bilberry capsule for 30 days and then have a washout period for 20 days.
89271625|NCT05737108|Placebo Comparator|Group A-placebo|This group will be given placebo for 30 days and then have a washout period for 20 days.
89271626|NCT05734690|Experimental|Medication & Education-First|Patient will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm.
89271627|NCT05734690|Active Comparator|Education-First|Patient will first receive curated patient education, an alert to providers, and provider education, and then after 3 months begin participation in the remote heart failure clinic.
89271628|NCT05702268|Experimental|High-dose|40 mg ICP-332 tablet 3 tablets, once a day
89271629|NCT05702268|Experimental|Low-dose|40 mg ICP-332 2 tablets + 1 placebo tablet once daily
89271630|NCT05702268|Placebo Comparator|Blank control|Placebo 3 tablets once daily
89271631|NCT05684575|Other|Phone satisfaction questionnaire|Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
89271632|NCT05674370|Experimental|Novel, graphene-based, point-of-care device|Subjects will receive one additional nasal swab at the same time as clinical collection.
89271633|NCT05658731|Experimental|Stratum A (new diagnosis, substructure informed radiation therapy)|Patients will undergo radiation therapy which has been planned according to dose constraints to specific brain substructures.
89271634|NCT05658731|Other|Stratum B (patients ≥ 2 years after standard radiation therapy)|Patients who completed radiation therapy under standard planning procedures ≥ 2 years ago.
89271635|NCT05658731|Other|Stratum C (healthy controls matched to Stratum A)|Healthy patients who are matched to Stratum A patients
89271636|NCT05642572|Experimental|Arm A (capmatinib, osimertinib, ramucirumab)|Patients receive capmatinib PO, osimertinib PO, and ramucirumab IV on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
89271637|NCT05642572|Experimental|Arm B (capmatinib, osimertinib)|Patients receive capmatinib PO and osimertinib PO on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.
89271638|NCT05639166|Experimental|Active|IBIO123 10 mg
89271639|NCT05639166|Placebo Comparator|Placebo|Matching Placebo
89271640|NCT05614869|Experimental|Treatment Group|Subjects undergoing 1 of 4 types of surgery will be enrolled and treated with the PREVENA Plus Incision Management System
89271641|NCT05609513|Experimental|8 HIV clinics randomized to HTN BASIC|The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.
89271642|NCT05609513|Experimental|8 HIV clinics randomized to HTN PLUS|In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
89271643|NCT05609513|No Intervention|Control Period for all 16 clinics|Outcome data will be collected during the control period prior to intervention roll-out in all 16 clinics.
89271644|NCT05583890||Healthy participants|Continuous glucose monitors will be fitted for 7 days, along with activity trackers and a food diary to monitor the impact of these factors on blood glucose concentrations. Participants will also complete questionnaires related to health inequalities and quality of life.
89271645|NCT05583890||Pancreatic cancer patients undergoing chemotherapy|Continuous glucose monitors will be fitted for 7 days, along with activity trackers and a food diary to monitor the impact of these factors on blood glucose concentrations whilst they are undergoing chemotherapy. Participants will also complete questionnaires related to health inequalities and quality of life.
89271646|NCT05583890||Pancreatic cancer patients not undergoing chemotherapy|Continuous glucose monitors will be fitted for 7 days, along with activity trackers and a food diary to monitor the impact of these factors on blood glucose concentrations. Participants will also complete questionnaires related to health inequalities and quality of life.
89271647|NCT05520866|Experimental|PrehabPal Web app|Web app based initial geriatric assessment will be given followed by daily tailored prehabilitation activities in the domains of exercise, nutrition, anxiety reduction, home preparation, and advanced care planning. Each participant is paired with a central health coach who monitors engagement and provides support through the Web app portal.
89271648|NCT05520866|No Intervention|Written Surgery Prehabilitation Instructions|Participants will be provided paper-based prehabilitation instructions that include information about exercise, nutrition, anxiety reduction, home preparation, and advanced care planning. A paper diary is provided to record any prehabilitation activities.
89271649|NCT05518799|Other|Patients with prostate cancer|
89271650|NCT05518799|Other|Male patients with other types of solid tumours|
89271651|NCT05500846|Experimental|Cryoablation Arm|Minimally invasively trans-perineal puncture of both cryo-needles and temperature-needles will be placed under real-time image guidance to the targeted area of cancer lesion or temperature-monitoring sites, respectively. The targeted tissue surrounding the tip of cryo-needles will be freeze down to targeted temperature for killing the cancer cells, and other non-treated area will be left in the prostate for aiming of maintain QOL (quality-of-life). The Minimally invasive cryoablation surgery will be performed under general anesthesia within one and half hour for aiming to be provided total 50 patients. (The used device for this arm has been clinically approved for cryoablation of renal cancer in Japan.)
89271652|NCT05486806||participants|all participants in this study must have a diagnosis of a neurodegenerative movement disorder
89271653|NCT05447702|Experimental|Camrelizumab + Apatinib + Chemotherapy|Participants received neoadjuvant therapy with four 4-week cycles of camrelizumab (200 mg, q2w) plus apatinib (250 mg, qd) and nab-paclitaxel (125 mg/m2, qw), followed by four 2-week cycles of camrelizumab (200 mg, q2w) plus apatinib (250 mg, qd) and epirubicin (90 mg/m2, q2w) + cyclophosphamide (600 mg/m2, q2w).
89271654|NCT05426421||No actigraphy|Participants will receive viral load testing at transition from LPV/r-based to DTG-based ART, and subsequent routine viral load data will be analysed. Questionnaires will be filled in and dried blood spots collected at transition and at four weeks. Medical history as well as clinical and socio-demographic data will be collected.
89271655|NCT05426421||With actigraphy|Participants will receive viral load testing at transition from LPV/r-based to DTG-based ART, and subsequent routine viral load data will be analysed. Baseline actigraphy data will be collected for two weeks prior to transition (actigraphy period 1), and for four weeks after transition (actigraphy period 2 from 0-2 weeks after transition; actigraphy period 3 from 2-4 weeks after transition). Sleep diaries will be filled in during all actigraphy periods. Questionnaires will be filled in and dried blood spots taken at transition as well as two and four weeks after transition. Medical history as well as clinical and socio-demographic data will be collected.
89271656|NCT05418010|Active Comparator|Tysabri® 300mg|Tysabri® 300mg, administered via intravenous infusion in a 4 week cycle, for a total of 6 cycles
89271657|NCT05418010|Placebo Comparator|Placebo|Placebo, administered via intravenous infusion in a 4 week cycle, for 3 cycles, followed by Tysabri® 300mg, administered via intravenous infusion for a total of 3 cycles
89271658|NCT05391971|Experimental|Stellate Ganglion Block (SGB) Group|
89271659|NCT05391971|Placebo Comparator|Control Group|
89271660|NCT05370014|Experimental|iCINGS Fam Intervention|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM) is 14-week, nurse coordinated, Community Health Worker (CHW) supported telehealth intervention structure. After baseline assessment, dyads randomized to the intervention group (n= 125 dyads) will have two planning sessions (over 2 weeks) followed by eight topic-guided sessions delivered by a member of the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly), Follow up assessments will occur at month 4 and month 7.
89271661|NCT05370014|No Intervention|Attention Control|After baseline assessment, dyads randomized to the attention control group (n= 125 dyads) will receive monthly (3 in total; 7-10 min each) scripted phone calls on focused on general health risks and health promotion. Monthly telephone calls will cover readily accessible evidence-based public health messaging from the Centers for Disease Control and Prevention (CDC) Your Health, NIH and other public health community facing websites related to COVID-19 mitigation such as risk reduction and prevention strategies including flu vaccines, asymptomatic spread, and contact tracing. Follow up assessments will occur at month 4 and month 7.
89271662|NCT05323383|Experimental|Mindfulness meditation|Participants in the mindfulness meditation condition will practice one, 20-minute breath and body focused meditation.
89271663|NCT05323383|Active Comparator|Self-Hypnosis|Participants in self-hypnosis will practice one, 20-minute audio-guided hypnosis session with suggestions tailored towards enhancing positive affect and fostering decentering.
89271664|NCT05323383|Other|Control|Participants in the attention control condition will listen to a 20-minute natural history recording.
89271665|NCT05309863||Residential treatment|Patients administered for residential treatment of severe obesity will be included. Patients are treated according to standard of care in a multimodal program, focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support. Residential treatment is possible for a duration of maximum 1 year.
89271666|NCT05309863||Ambulatory treatment|Patients in specific pediatric obesity care pathways will be included. Patients are treated according to standard of care in a multimodal ambulatory program focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
89271667|NCT05308927||Incident patients|Children initiated Norditropin® upon their inclusion in the study but independently from the decision to participate in this study
89271668|NCT05308927||Prevalent patients - finished growth upon inclusion|Children were already treated with Norditropin® before their inclusion in the study and finished their growth upon their inclusion. Data collected retrospectively from medical records
89271669|NCT05308927||Prevalent patients - not finished growth upon inclusion|Children were already treated with Norditropin® before their inclusion in the study and did not finish their growth upon inclusion. Data collected both retrospectively and prospectively
89271670|NCT05303142||Individuals with a history of EHI|Service personnel who have a history of EHI.
89271671|NCT05303142||Control participants without a history of EHI|"Matched control participants with no history of EHI. They will be matched to the experimental group for parameters that are known to influence thermoregulatory responses to exercise heat-stress.~Relative aerobic fitness (V̇O2max; ml∙kg-1∙min-1)~Body mass (kg)~Body surface area (m2)~Age~Sex"
89271672|NCT05301101|Experimental|Cancer patients receiving definitive radiation therapy with overlap of a previously treated field|This is a re-irradiation study in solid tumor patients receiving definitive high dose radiation therapy to treatment volumes that include overlap with previously irradiated organs at risk.
89271673|NCT05297526|Experimental|Intervention Group|The intervention group will receive a culturally adapted children's book that contains the same oral health educational information as the control brochure, but celebrates Tribe-specific culture and utilizes entertainment education. The children's book includes vibrant illustrations by a Tribal artist, and has eBook and audio narration options for multi-media use and/or those with limited literacy.
89271674|NCT05297526|Active Comparator|Control Group|The control group will receive a standard educational brochure about children's oral health designed by the the National Institutes for Health (NIH) for American Indian/Alaska Native parents.
89271675|NCT05296447||Roll Over|No intervention - all subjects that previously received RGX-314 in a parent study
89271676|NCT05287555|Active Comparator|Control|"Home non-invasive mask ventilation with prisma VENT device. Modem for the daily transmission of specific therapy parameters.~Standard care according to clinical standard (technical support by the provider and three hospital follow-up appointments after 2, 6 and after 12 months) with assessment of health status and NIV therapy settings.~Study specific: During visits, recording of HRQOL by SGRQ and S3NIV questionnaires, hospitalizaion and physician visits.~Therapy data from NIV device."
89271677|NCT05287555|Experimental|Telemonitoring|"Home non-invasive mask ventilation with prisma VENT device. Modem for the daily transmission of specific therapy parameters. An electronic feedback system provides patients with feedback and recommendations on their therapy based on the data submitted.~The study center regularly reviews and reacts to all therapy data and other information according to the remote care scheme of intervention.~Telemonitoring care patients also receive an SpO2 sensor for monitoring of oxygen saturation.~Ambulantory implementation of three blood gas analyses to check the health status after 2, 6 and 12 months. There are no regular routine inpatient stays.~Study specific: During visits, recording of HRQOL by SGRQ and S3NIV questionnaires, hospitalizaion and physician visits."
89271678|NCT05265377|Experimental|STELO Exoskeleton|3 treatment sessions will be performed with the Stelo exoskeleton.
89271679|NCT05256316||Previously admitted COVID-19 patients in intensive care units|Infectious Diseases Physicians from participating hospitals will identify patients with COVID-19 admitted to their hospital who had an intensive care unit stay during the first 60 days after hospital admission.
89271680|NCT05210803||Roll over|No intervention All subjects that previously received RGX-314 in a parent study
89271681|NCT05178550|Experimental|Group 1 (low dose-high dose)|Participants receive 25 IU/kg heparin on days 1 and 2, and 50 IU/kg Heparin on days 4 and 5
89271682|NCT05178550|Experimental|Group 2 (high dose-low dose)|Participants receive 50 IU/kg heparin on days 1 and 2, and 25 IU/kg Heparin on days 4 and 5
89271683|NCT05168566|Experimental|Sutetinib Maleate Arm|Sutetinib capsules monotherapy
89271684|NCT05157945|Experimental|ALTO-300|ALTO-300 tablet PO; daily dosing 8 weeks
89271685|NCT05157061|Experimental|GOS arm|A single daily dose of a food supplement containing GOS for 8 weeks
89271686|NCT05157061|Placebo Comparator|Placebo arm|A single daily dose of maltodextrin, matching in taste, smell, appearance, and solubility, but without active ingredients (i.e. GOS), for 8 weeks
89271687|NCT05118750|Experimental|ALTO-300|ALTO-300 tablet PO; daily dosing 8 weeks
89271688|NCT05104242|No Intervention|Standard diet - Control group|The standard diet will include energy intake of 30-35 kcal/kg of ideal body weight (IBW)/day and protein intake of 0.75 g/kg of IBW/day for females and 0.84 g/kg of IBW/day for males
89271689|NCT05104242|Experimental|Low AGE diet - Intervention group|"The low AGE diet will be the same as the standard diet in terms of calories (i.e. 30-35 kcal/kg/day) and protein (0.75-0.84 g/kg/day). However, it will reduce the dietary AGE content by changing cooking methods in food preparation to avoid exposure to dry heat such as frying, broiling, grilling and roasting, and to favour cooking with lower temperatures and high-water content as in stewing, steaming, boiling and poaching. In addition, the low-AGE group will be instructed to choose foods with low content of AGEs based on a food choice list that will contain examples of foods commonly available in the UK to be chosen as allowed, moderate intake, or occasional. The goal will be to reduce dietary AGE intake to less than 8000 kU/day."
89271690|NCT05095220||Observational Cohort|
89271691|NCT05093036|No Intervention|Arm 1: routine PrEP care at the CSH, monitoring 4 times per year (standard-of-care)|"Study participants in arm 1 follow routine care procedures, i.e. the number of monitoring visits is four times a year.~Experienced PrEP users: first monitoring visit is three months after the enrolment into the study.~PrEP-naïve participants: first monitoring visit is one month after enrolment in the study and start of PrEP use. The second monitoring visit is 2 months after the first monitoring contact (3 months after enrolment)."
89271692|NCT05093036|Experimental|Arm 2: routine PrEP care at the CSH, monitoring 2 times per year|"Study participants in arm 2 follow routine care procedures but with a reduced frequency of monitoring visits, i.e. the number of monitoring visits is reduced from four to two times a year. Timing of the first monitoring visit differs per PrEP user type:~Experienced PrEP users: first monitoring visit is six months after the enrolment into the study.~PrEP-naïve participants: first monitoring visit is one month after enrolment in the study and start of PrEP use. The second monitoring visit is five months after the first monitoring visit (6 months after enrolment)."
89271693|NCT05093036|Experimental|Arm 3: online PrEP care, monitoring 4 times per year|"Study participants in arm 3 receive internet-based PrEP care, i.e. video consultations and online-mediated testing for HIV, STIs and renal function, online PrEP ordering and (at home) delivery of PrEP. Monitoring occurs four times per year.~Experienced PrEP users: first monitoring contact is three months after the enrolment into the study.~PrEP-naïve participants: first monitoring contact is one month after enrolment in the study and start of PrEP use. The second monitoring visit is 2 months after the first monitoring contact (3 months after enrolment)."
89271694|NCT05093036|Experimental|Arm 4: online PrEP care, monitoring 2 times per year|"Study participants in arm 4 receive internet-based PrEP care, i.e. video consultations and online-mediated testing for HIV, STIs and renal function, online PrEP ordering and (at home) delivery of PrEP. Monitoring occurs two times per year.~Experienced PrEP users: first monitoring contact is six months after the enrolment into the study.~PrEP-naïve participants: first monitoring contact is one month after enrolment in the study and start of PrEP use. The second monitoring visit is five months after the first monitoring contact (6 months after enrolment)."
89271695|NCT05087758|Experimental|Matrion decellularized placental membrane|Matrion placental membrane graft will be use to treat subjects diagnosed with a diabetic foot ulcer.
89271696|NCT05087758|Active Comparator|Conventional Care Wound Management|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diabetic foot ulcer diagnosis.
89271697|NCT05085782|Experimental|Propranolol|"Pain neuroscience education (10 short videos - 2 to 4 mins each)~6 weekly sessions of Reconsolidation therapy with propranolol. At the beginning of each session, participants will take 2 to 4 capsules of 20 mg propranolol (dose calculated based on sex and height). One hour after ingestion of the propranolol, participants will undergo a reactivation procedure, wherein they will be asked to describe/visualize painful movements/activities."
89271698|NCT05085782|Placebo Comparator|Placebo|"Pain neuroscience education (10 short videos - 2 to 4 mins each)~6 weekly sessions of Reconsolidation therapy with a placebo. At the beginning of each session, participants will take 2 to 4 capsules of 20 mg placebo (dose calculated based on sex and height). One hour after ingestion of the placebo, participants will undergo a reactivation procedure, wherein they will be asked to describe/visualize painful movements/activities."
89271699|NCT05075356|Experimental|Single participant arm|"The iToBoS intervention is a total body imaging device, to image the total skin surface in order to detect and monitor for signs of skin cancer.~The imaging process involves laying down on a bed that has a framework of cameras arched over it. The imaging process takes less then 10 minutes, and requires the participant to lay in two different positions (face-up and face-down).~The study visit also includes individual dermoscopic images taken of certain moles on the skin. This is done in combination with a clinical skin examination. Participants are given the option of providing a saliva sample for genetic research. Participants are then asked to complete a series of questionnaires.~There a three visits in total (month 0, 6 and 12), in which these procedures are repeated (except for saliva sample)."
89271700|NCT05057897|Other|Cohort 1 - immunocompromised participants with solid organ transplant|Previously unvaccinated immunocompromised participants with solid organ transplant will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
89271701|NCT05057897|Other|Cohort 2 - immunocompromised participants with hematopoietic stem cell transplant|Previously unvaccinated immunocompromised participants with hematopoietic stem cell transplant will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
89271702|NCT05057897|Other|Cohort 3 - immunocompromised participants with solid organ cancer receiving cytotoxic chemotherapy|Previously unvaccinated immunocompromised participants with solid organ cancer receiving cytotoxic chemotherapy will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
89271703|NCT05057897|Other|Cohort 4 - immunocompromised participants with chronic inflammatory disorders|Previously unvaccinated immunocompromised participants with chronic inflammatory disorders will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
89271704|NCT05057897|Other|Cohort 5 - immunocompromised participants with primary immunodeficiency|Previously unvaccinated immunocompromised participants with primary immunodeficiency will receive a primary vaccination series with 3 IM doses of AZD1222 separated by 4 weeks and will be followed to the end of the study. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1, and the third dose will be administered 28 days after dose 2.
89271705|NCT05057897|Other|Cohort 6 - immunocompetent participants|Previously unvaccinated immunocompetent participants will receive a primary vaccination series with 2 IM doses of AZD1222 separated by 4 weeks, followed by a booster dose of AZD1222 administered 6 months after the first dose. The first dose will be administered on Day 1, the second dose will be administered 28 days after dose 1. Participants will receive a third dose booster 6 months after dose 1 and will continue to be followed to the end of the study.
89271706|NCT05053620||Single arm|All patients.
89271707|NCT05053074|Experimental|NHF - NHF/CO2|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) alone, then NHF (30l/min) plus 1% CO2.
89271708|NCT05053074|Experimental|NHF/CO2 - NHF|Patients with chronic respiratory failure are treated with nasal high flow during wakefulness. First with NHF (30l/min) plus 1% CO2 , then NHF (30l/min) alone.
89271709|NCT05033028|No Intervention|Treatment-as-Usual|Participants will receive the same treatment as if they had not joined the study
89271710|NCT05033028|Experimental|Smartphone with dose changes after using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days play a 2-4 minute game.
89271711|NCT05033028|Experimental|Smartphone with dose changes before using|Participants will have an app installed on their phone and have to complete a brief questionnaire and some days to play a 2-4 minute game.
89271712|NCT05033028|Experimental|Focus group with Study Physicans|Study physicians asked to participate in a focus group session or 1:1 interviews if unable to attend the focus group during year one of the study and once annually towards the end of years 2, 3, 4, and 5 of the study
89271713|NCT05033028|Experimental|Focus group with Clinicians|Clinicians asked to participate in a 1:1 interview and a separate focus group at roughly the same time. Prior to the first structured interview with our study team, you will participate in a 1-hour training and familiarization session with the SOAR system using synthetic or training data.
89271714|NCT05022615||Mild Non-Proliferative Diabetic Retinopathy (NPDR)|Presence of at least one retinal microaneurysm or hemorrhage as determined by clinician.
89271715|NCT05022615||Moderate NPDR|Increasing hemorrhages and microaneurysms as well as cotton wool spots, venous beading (VB) or Intraretinal microvascular abnormalities (IRMA) to a mild degree as determined by clinician
89271716|NCT05022615||Severe NPDR|"4-2-1 rule-that is, one has severe NPDR if hemorrhages or microaneurysms, or both, appear in all four retinal quadrants; venous beading appears in two or more retinal quadrants; or prominent IRMAs are present in at least one retinal quadrant as determined by clinician."
89271717|NCT05022615||Proliferative Diabetic Retinopathy (PDR)|Neovascularization, either on or within one disc diameter (DD) of the optic disc (NVD) or elsewhere in the retina (NVE); a preretinal hemorrhage (PRH); or vitreous hemorrhage (VH) as determined by the clinician.
89271718|NCT04978363|No Intervention|Arm 1. NONE|Participants will be tested while wearing no boot and no assistive device.
89271719|NCT04978363|Experimental|Arm 2. BOOT|The first intervention condition tested is a walking boot only on the subject's right lower extremity.
89271720|NCT04978363|Experimental|Arm 3. HFC+BOOT|The second intervention condition tested is a Hands Free Crutch (HFC) with the walking boot, both worn on the subject's right lower extremity.
89271721|NCT04978363|Experimental|Arm 4. SAC+BOOT|The third intervention condition tested is standard axillary crutches (SAC) with the walking boot worn in non-weight bearing on the subject's right lower extremity.
89271722|NCT04978363|Experimental|Arm 5. HFC|The fourth intervention condition tested is the Hands Free Crutch worn on the subject's right lower extremity without the walking boot.
89271723|NCT04978363|Experimental|Arm 6. SAC|The fifth and last intervention condition tested is standard axillary crutches with the subject non-weight bearing on the right lower extremity without the walking boot.
89271724|NCT04942054|Experimental|SCO-120|
89271725|NCT04923048|Experimental|GB261|Participants will receive GB261 via intravenous (IV) infusion as a single agent on Day 1, Day 8 and Day 15 of Cycle 1 and 2 followed by Day 1 of each cycle（21 days per cycle） afterwards until disease progression or other situations specified in the protocol, whichever comes earlier.
89271726|NCT04876625|Experimental|OA plus MS 8wk|Oral Appliance plus Mouth Shield for 8-weeks
89271727|NCT04876625|Active Comparator|OA Alone 4wk|Oral Appliance is used alone for first 4 weeks followed by 4 weeks of Oral Appliance plus Mouth Shield
89271728|NCT04845048||Health care professionals between 18 and 59 years old|Health care professionals
89271729|NCT04845048||General population 75 years old or more|Elderly 75y plus
89271730|NCT04845048||General population 60 and 74 years old|Elderly between 60-74y
89271731|NCT04838912|Experimental|Cool Kids ASA|The Cool Kids (Chilled) ASA anxiety program
89271732|NCT04831697|Experimental|Multi-Caregiving Intervention|The multi-caregiving intervention consists of individual-based, social support, and health-educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15minutes); and Structured Diabetes Education and Skills Training (15 minutes). The final 5min will be used for debriefing/reviewing goals.
89271733|NCT04831697|Active Comparator|Diabetes Enhanced Usual Care Intervention|This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
89271734|NCT04830072|Experimental|AR group|Brief AWARD advice + active referral + leaflet + 3 months chat-based support with AR pictures
89271735|NCT04830072|Active Comparator|Control group|Brief AWARD advice + active referral + leaflet + 3 months chat-based support
89271736|NCT04779411||Food Frequency Questionnaire Validation Group|"The validation procedure will span over four weeks, consisting of administering the Lutein and Zeaxanthin Food Frequency Questionnaire (FFQ L/Z) and 24-hour diet recalls at multiple timepoints. Timepoints for the eight 24-hour diet recalls will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on week days.~The weekly L/Z FFQ will be completed at the conclusion of each of the four weeks.~The monthly L/Z FFQ will be completed at baseline and at the conclusion of week four."
89271737|NCT04779411||Electronic Device Use Questionnaire Validation Group|The validation procedure will occur over eight weeks consisting of administering eight 24-hour diary of electronic device use (24-hour ED use diary) and the Electronic Device Use Questionnaire (EDUQ) at three time points. The time points for the eight 24-hour ED use diaries will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on weekdays. The EDUQ will be completed at baseline and at the conclusion of weeks four and eight.
89271738|NCT04746781|Active Comparator|Risk notification/education arm|We will send all participants a short message service (SMS) message with a link to a website that educates the public about their risk for developing T2DM and about the availability and efficacy of the DPP to address their risk
89271739|NCT04746781|Experimental|Mobile 360° Video intervention arm|After risk notification and education, participants will receive links to two 3-minute immersive Mobile 360° Videos (in which the viewer moves their phone to 'look around' the world of the video) on their smart phones. These videos are intended to influence affective and experiential perceptions of risk. The first video tells an emotional story of the negative effects on an individual's health and family life as they progress from prediabetes to T2DM and develop cardiovascular complications. The second video provides the viewer with a vicarious experience of the changes in vision that occur as diabetic retinopathy develops and worsens.
89271740|NCT04746781|Experimental|Motivation and Problem Solving (MAPS) arm|After risk notification and education, participants will be called by a health coach trained in counseling/coaching. The coach will guide them in setting goals related to their health, and addressing any practical barriers to enrolling/engaging in the DPP if that is consistent with their health goals. Per their preference, participants will receive up to 5 phone calls from the health coach over a 4 week period.
89271741|NCT04732195|Experimental|Pilocarpine microneedle patch|Participants will receive in their left forearm the microneedle patch. Upon application to skin, the MNs penetrate into the skin's upper layers and dissolve in the interstitial fluid to release the loaded drugs. MN patches are painless and can be administered with little or no training.
89271742|NCT04732195|Active Comparator|Pilocarpine Iontophoresis|Participants will receive in their right forearm the pilocarpine iontophoresis. Uses a gel disc containing Pilocarpine that drives the medication into the skin with a small electric current (iontophoresis) followed a 30-minute period of sweat collection.
89271743|NCT04706975|Active Comparator|Difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg tablet administered twice daily
89271744|NCT04706975|Placebo Comparator|Placebo|Oral placebo tablet administered twice daily
89271745|NCT04704921|Experimental|RGX-314 Dose 1|RGX-314 Dose 1 administered via subretinal delivery one time.
89271746|NCT04704921|Experimental|RGX-314 Dose 2|RGX-314 Dose 2 administered via subretinal delivery one time.
89271747|NCT04704921|Active Comparator|Control Arm|Ranibizumab administered via intravitreal injection approximately every 28 days
89271748|NCT04703426|Experimental|Sargramostim (GM-CSF) + Pembrolizumab (anti-PD-1)|"Participants will receive 12 weeks of sargramostim (GM-CSF) and pembrolizumab (anti-PD-1). Participants may be pre-medicated with drugs to reduce the chance of having a sensitivity reaction to the study treatment of pembrolizumab (anti-PD-1) and sargramostim (GM-CSF).~Study cycles are 21 days in length:~Pembrolizumab (anti-PD-1) will be given by intravenous infusion once on day 1 of every 21 day cycle~Sargramostim (GM-CSF) will be self-administered by participants via a subcutaneous (below the skin) injection daily for days 1 - 14 of each 21- day cycle.~Participants will be assessed at 12 weeks for disease response/progression and further study treatment."
89271749|NCT04703023||COPD|Secretions are collected from Bronchoscopy in clinical routine in COPD patients
89271750|NCT04703023||lung healthy|Secretions are collected from Removal of endotracheal tubes after elective surgery in lung healthy patients
89271751|NCT04681482||Apixaban Group|The cohort prescribed apixaban and diagnosed with Atrial Fibrillation
89271752|NCT04681482||Warfarin Group|patients prescribed warfarin only diagnosed with Atrial Fibrillation.
89271753|NCT04635644|Active Comparator|Erector Spinae Plane Block|Patients will receive Erector spinae plane block.
89271754|NCT04635644|Active Comparator|Intrathecal morphine ITM|Patients will receive Intrathecal morphine.
89271755|NCT04580277|Experimental|Chronic pouchitis|This arm will include subjects with chronic pouchitis and will receive tofactinib 10 mg twice daily for 8 weeks
89271756|NCT04569682|Active Comparator|transrenal artery perfusion group|
89271757|NCT04569682|Experimental|transrenal vein perfusion group|
89271758|NCT04567550|No Intervention|Observation Control Arm|Observation Control
89271759|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
89271760|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
89271761|NCT04567550|Experimental|RGX-314 Treatment Arm (Dose 3) and Topical Steroid|RGX-314 Dose 3 and Topical Steroid
89271762|NCT04544020||subjects|subjects with alcoholic hepatitis receiving NG feeding
89271763|NCT04535713|Experimental|Single arm|A total of 260 patients will receive gemcitabine 600 mg/m2 (maximum dose: 1000 mg) on D1 and D8, doxorubicin 18 mg/m2 on D1 and D8 (maximum dose: 32 mg), docetaxel 25 mg/m2 on D1 and D8 (maximum dose: 42 mg), on Days 1 and 8. After the first cycle, nivolumab 240 mg IV will be added on Day 1 of each cycle (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced.
89271764|NCT04526132|Experimental|Experimental: group1|Generic name: Felbinac Trometamol Injection; Placebo:Normal saline Dosage form: Injection Dosage:8ml Volume:4ml
89271765|NCT04526132|Placebo Comparator|Experimental: group2|Generic name:Placebo Placebo:Normal saline Dosage form:Injection Dosage:8mg Volume:4ml
89271766|NCT04514653|Active Comparator|Ranibizumab control|Control treatment arm
89271767|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 1)|RGX-314 Dose 1
89271768|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 2)|RGX-314 Dose 2
89271769|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 3)|RGX-314 Dose 3
89271770|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 3) and Local Steroid|RGX-314 Dose 3 and Local Steroid
89271771|NCT04514653|Experimental|RGX-314 Treatment Arm (Dose 3) and Topical Steroid|RGX-314 Dose 3 and Topical Steroid
89271772|NCT04505670|Experimental|Donepezil and Topical Zinc Oxide|donepezil 5mg daily and topical zinc oxide 20% three times daily
89271773|NCT04505670|Placebo Comparator|Placebo and Topical Zinc Oxide|Placebo daily and topical zinc oxide 20% three times daily
89271774|NCT04500535||Cohort 1|Immuno-oncology (IO)-naïve patients
89271775|NCT04500535||Cohort 2|IO-experienced patients for whom last IO discontinuation was not primarily related to IO-toxicity
89271776|NCT04500535||Cohort 3|IO-experienced patients for whom last IO discontinuation was primarily due to IO-toxicity
89271777|NCT04493320|Experimental|L-DOPA, Then Placebo|"Step 1 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 300 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.~Participants will then enter a 1 week taper period.~Step 2 (3 Weeks): Participants will receive L-DOPA matching placebo tablets daily.~Participants will then enter a 1-week taper period."
89271778|NCT04493320|Experimental|Placebo, Then L-DOPA|"Step 1 (3 Weeks): Participants will receive 3 L-DOPA matching placebo tablets daily. Participants will then enter a 1-week taper period.~Step 2 (3 Weeks): Participants will first receive 150 mg of L-DOPA daily in Week 1, 300 mg of L-DOPA in Week 2, and 450 mg L-DOPA in Week 3.~Participants will then enter a 1-week taper period."
89271779|NCT04478890||Observational Group|Characterize right ventricular function while undergoing LVAD implantation
89271780|NCT04440059|Experimental|ICP-022|Subjects will take ICP-022 150mg once daily (QD).
89271781|NCT04417166|Experimental|Pembrolizumab and Radiotherapy|"Induction Phase:~Standard Involved Field Radiation Therapy (IFRT) and pembrolizumab. Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 6 cycles. IFRT will start at first cycle of Pembrolizumab and will be delivered concurrently.~Patients with complete remission (CR), partial response (PR) and stable disease (SD) after Induction Phase will continue with pembrolizumab maintenance.~Maintenance Phase:~Pembrolizumab 200 mg IV will be given over 30 minutes on day 1 of each 21 day cycle up to 34 cycles or until disease progression or unaccepted toxicity"
89271782|NCT04408495|Experimental|Intervention group_MRA|Recruitment maneuvers and high PEEP
89271783|NCT04408495|Active Comparator|Control group|No recruitment maneuvers and low PEEP
89271784|NCT04384627|Active Comparator|Pre-IC GTV|The gross tumor volume (GTV) is delineated according to the pretreatment tumor extension
89271785|NCT04384627|Experimental|Post-IC GTV|The gross tumor volume (GTV) is delineated according to the post-IC tumor extension
89271786|NCT04317547|No Intervention|Control Group|The Azūga™ in-vehicle driving feedback technology will be installed.32 This driving feedback technology consists of a pager-sized device plugged into the vehicle's on-board diagnostic (OBD) port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone). All feedback features will be disabled. Control dyads will receive no driving feedback. The parent will not receive STS. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
89271787|NCT04317547|Experimental|Intervention Group|Parents will receive STS, which will include 1) Individualized virtual communication training and a booster session delivered by a traffic safety communication specialist; and 2) An online parent-teen safe driving communication guide. In addition, the Azūga™ in-vehicle device and app will be installed as described above and all feedback features will be enabled. Three types of feedback will be provided to teens: 1) Direct audio feedback; 2) Detailed cumulative driving data; and 3) A customized weekly driving summary report. Parents in this group will receive access to the teen's cumulative driving data and a weekly driving summary report. Additionally, a wireless mini-camera will be installed on the dashboard in teen's car to identify the participating driver using facial verification technology.
89271788|NCT04316221|Active Comparator|Control|The standard of nutrition care in Guatemala includes the following clinical care, as determined to be necessary by the MHA medical and nutrition teams: frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
89271789|NCT04316221|Experimental|Intervention|The intervention group will receive an intervention to promote daily egg consumption for a six month period, in addition to the local standard of nutrition care. Specifically, intervention group participants will be provided with enough eggs for the infant to consume one egg, daily, for six months, and also with education on preparation and consumption of eggs.
89271790|NCT04306341|Experimental|Experimental|Neurofeedback in conjunction with Dialectical Behavior Therapy
89271791|NCT04306341|No Intervention|Control|Dialectical Behavior Therapy (treatment as usual)
89271792|NCT04296331||POC only|Participants who enter the DC Department of Corrections within the first 2 months of the study will be offered opt-out Point-of-Care (POC) rapid testing
89271793|NCT04296331||POC + Ag/Ab|Participants who enter the DC Department of Corrections within the third and fourth months of the study will be offered opt-out POC and 4th generation laboratory-based antigen/antibody testing (Ag/Ab)
89271794|NCT04296331||Ag/Ab only|Participants who enter the DC Department of Corrections within the fifth and sixth months of the study will be offered Ag/Ab testing.
89271795|NCT04291144||Patients|Inclusion criteria are mild to moderate DLB, age above 50, ability to give informed consent.
89271796|NCT04291144||Healthy controls|Age above 50.
89271797|NCT04275037|Experimental|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
89271798|NCT04275037|Active Comparator|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
89271799|NCT04275037|No Intervention|Control Group|The control group will receive usual medical care
89271800|NCT04267380||Corrona US RA Registry 11 mg|patients with RA who have been exposed to tofacitinib 11 mg QD tablet
89271801|NCT04267380||Corrona US RA Registry 5 mg|patients with RA who have been exposed to tofacitinib 5 mg BID tablet
89271802|NCT04189744|Placebo Comparator|IPTp-SP plus MTZ placebo (control)|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and metronidazole placebo administered as directly observed therapy.
89271803|NCT04189744|Active Comparator|IPTp-SP plus MTZ|3 tablets each containing 500mg sulphadoxine and 25mg pyrimethamine and 4 tablets each containing 500mg metronidazole administered as directly observed therapy .
89271804|NCT04189744|Active Comparator|IPTp-DP plus MTZ|3 tablets of 40mg of dihydroartemisinin and 320mg of piperaquine, first dose and will be administered as directly observed therapy with the remaining two doses on the next two consecutive days at home. 4 tablets each containing 500mg metronidazole administered as directly observed therapy.
89271805|NCT04175470|Experimental|Arm A: Discontinue treatment after first treatment cycle|
89271806|NCT04175470|Experimental|Arm B: Continue treatment until progression|
89271807|NCT04165330|Experimental|AL3818 plus nivolumab|"Part 1: All participants will be assigned to receive AL3818 capsules orally, once daily at sequential deescalating doses (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (on Day 1 and Day 15) for a single 21-day cycle. Participants may continue study treatment at the AL3818 cohort dose at investigator discretion.~Part 2: All participants will receive AL3818 capsules orally, once daily at the RP2D determined from Part 1 (on treatment Days 1-14 followed by no AL3818 treatment from Days 15-21) in combination with nivolumab injection treatment (every 2 weeks starting on Cycle 1, Day 1) in 21-day cycles, for up to 24 cycles of total AL3818 therapy."
89271808|NCT04151628|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
89271809|NCT04129268|Other|No exercise control|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
89271810|NCT04129268|Experimental|175kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
89271811|NCT04129268|Experimental|350kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
89271812|NCT04129268|Experimental|700kcal Cycle ergometry exercise at 60% VO2max|"The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).~350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis."
89271813|NCT04115878|Active Comparator|High dose ato-oxy|
89271814|NCT04115878|Active Comparator|Low dose ato-oxy|
89271815|NCT04114903||Study A|Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users.
89271816|NCT04114903||Study B|Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity.
89271817|NCT04101422|No Intervention|Development of Augmented Reality (AR) Application|Investigators will collaborate with an AR software specialist to develop AR stimuli that are embedded within a basic digital application.
89271818|NCT04101422|Experimental|Pilot Testing of AR Application|AR stimuli (smoking, e.g, cigarette, ashtray, lighter; and non-smoking, e.g., pen, notebook, eraser) will be piloted on a small group of smokers to receive feedback and modify as needed. Participants will answer questions from a 10 point Likert scale that will asses urge from 1 (absolutely no urge to smoke) to 10 (strongest urge to smoke) and reality/co-existence (how realistic the item looks, and it's integration into the environment), from 1 (Not at all) to 10 (Very Much). Participants will then be asked additional open-ended questions about the quality of the images following the ratings of the images.
89271819|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 1: Cue Reactivity|Participants will attend 1st lab based session that will test cue-reactivity. Participant will be randomized to view either AR images, or in vivo items first. Order of presentation of items will also be randomized within the type (AR or in vivo).Session 1 should last under 1 hour.
89271820|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 2: Extinction|Participants will be randomized into either the extinction or control group. 28 trials of AR cues will be presented for each group. Both groups will receive the same neutral cue in Trial 1 (to establish baseline urge) and the same smoking cue in Trial 2 (for pre-test cue-reactivity). The extinction group will receive smoking cues for trials 3-26, whereas the control group will receive neutral cues. Both groups will receive matched smoking cues for trial (27) followed by matched neutral cues for the final trial (28), for post-test cuereactivity. Each cue will be presented for 1 minute and will be shown 4 times in trials 3-26. Following each cue, participants will complete the single-item measure of urge. Following the final trial (28) for both groups, participants will be presented with one of their own cigarettes and asked to take at least one puff. Latency to smoke will later be determined using time stamps on the video recording. Session 2 is expected to last 1.25 hours.
89271821|NCT04101422|Experimental|Testing AR Application|Participants will be instructed to use the AR app that presents smoking-related stimuli (cigarette, ashtray, lighter) in locations/situations where they typically smoke with the goal of at least 5 uses per day for 7 days. Usage and rating data will be collected in real-time. Participants will also be asked to rate their urge to smoke on the smartphone app at selected times. Participants will complete a telephone interview to provide additional feedback on the app, answer questions related to smoking behavior, and receive an in-person interview on their perceptions of the app as a potential cessation tool. Participants will use the smart phone application for 7 days.
89271822|NCT04007536||Part 1|Participants from 2 through 10 years of age who have MPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
89271823|NCT04007536||Part 2|Participants from 2 through 30 years of age who have MPS II; Part 2 will entail a single collection of cerebrospinal fluid (CSF), urine, and blood. Clinical assessments are optional in Part 2.
89271824|NCT04007536||Part 3|Participants <8 years of age who have the neuronopathic form of mucopolysaccharidosis type II (nMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
89271825|NCT04007536||Part 4|Participants 6 to 17 years of age with the non-neuronopathic form of mucopolysaccharidosis type II (nnMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.
89271826|NCT03966755|Experimental|UFA dietary recommendations|Dietary intervention aimed at increasing UFA consumption.
89271827|NCT03966755|No Intervention|Standard dietary recommendations|Standard of care dietary recommendations as currently performed in the clinic (2015-2020 United States Department of Agriculture (USDA) Dietary Guidelines for Americans)
89271828|NCT03900884|Experimental|Letrozole + Palbociclib + Venetoclax|"The Letrozole dose is 2.5 mg (D1-28) for all dose levels.~Starting dose Level 1: Palbociclib 100 mg (D1-21) and Venetoclax 100 mg (D1-21) daily."
89271829|NCT03890107||Pediatric tympanostomy tube patients|Patients diagnosed with otitis media and scheduled for tympanostomy tube placement will be imaged with the OtoSight
89271830|NCT03887078|Experimental|A. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
89271831|NCT03887078|Experimental|B. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
89271832|NCT03887078|Experimental|C. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
89271833|NCT03887078|Experimental|D. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
89271834|NCT03887078|Experimental|E. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
89271835|NCT03887078|No Intervention|F. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to usual care."
89271836|NCT03887078|Experimental|G. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
89271837|NCT03887078|No Intervention|H. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to usual care."
89271838|NCT03884946|Active Comparator|Immediate Delivery|Participants randomized into the Immediate Delivery arm (n = 150) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.
89271839|NCT03884946|Placebo Comparator|Delayed Delivery|Participants randomized into the Delayed Delivery arm (n = 150) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
89271840|NCT03875833|Experimental|Collagen Nerve Wrap Conduit|
89271841|NCT03875833|No Intervention|Control|
89271842|NCT03870906|Experimental|WhatsApp interaction|Individual and group chat interactions.
89271843|NCT03870906|Placebo Comparator|Text message|Regular text messages with similar frequency to those in the Intervention group.
89271844|NCT03859232|Experimental|Delta Dry® Pantaloon Group|
89271845|NCT03859232|Active Comparator|Cotton Padding Group|
89271846|NCT03841604|Experimental|Experimental|"Safinamide methanesulfonate film coated tablets once daily, 50 mg and 100 mg. Safinamide methanesulfonate 50 mg and 100 mg tablets was administered orally, OD, with or without food, at breakfast time when the subject was taking their morning dose of L-DOPA.~Subjects received study drug 50 mg (from Day 1 to Day 7) and then 100 mg (from Day 8 onwards). The dose of 100 mg/day (titrated from 50 mg/day after 1 week) was selected based on the results of previous studies in patients with PD and from the results of a post hoc analysis that investigated the effects of safinamide on pain."
89271847|NCT03841604|Placebo Comparator|Placebo|Safinamide methanesulfonate matching placebo film coated tablets once daily. The matching placebo was administered orally, OD, in tablets, with or without food, at breakfast time when the subject was taking their morning dose of L-DOPA.
89271848|NCT03827109|Experimental|Mentoring program|The Mentoring Program consists of year-long, 1:1 mentee-mentor relationships with group educational activities, online educational information, and a parent support component. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month. Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. They also provide opportunities to socialize with other mentors and mentees: lunch and games are provided before or after the educational event. Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing. Parents join the mentees and mentors for the educational topics. Due to the COVID-19 pandemic, these activities can be conducted virtually.
89271849|NCT03827109|Active Comparator|Educational activity program|The Educational Activity comparison group consists of separate educational group events on the same topics (with no social time), educational information posted online, and monthly encouragement to engage in activities in the community. Due to the COVID-19 pandemic, participants are encouraged to interact socially in safe ways, e.g., outdoors or virtually.
89271850|NCT03772509|Experimental|CATI|Introduction and consent via computer assisted telephone interview
89271851|NCT03772509|No Intervention|IVR|Introduction and consent via interactive voice response
89271852|NCT03761030|Experimental|L-DOPA Arm|Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa (37.5 mg carbidopa/150mg levodopa twice daily and placebo once daily) for one week, and finally increase to 112.5mg carbidopa/450mg levodopa (37.5 mg carbidopa/150mg levodopa three times daily and no placebo) for the final six weeks. Each subject assigned to the L-DOPA arm will be titrated to 450mg L-DOPA unless they cannot tolerate higher doses, in which case subjects will have their dosage reduced to the maximum tolerable dose
89271853|NCT03761030|Placebo Comparator|Placebo Arm|Subjects assigned to the placebo arm will take placebo oral tablet three times daily throughout the study.
89271854|NCT03742505|Experimental|Vitamin D|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Vitamin D Group and will receive a single dose of cholecalciferol at enrolment.~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
89271855|NCT03742505|Placebo Comparator|Placebo|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Placebo Group and will receive a single dose of placebo at enrolment.~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
89271856|NCT03663205|Experimental|Tislelizumab combined with Platinum and Pemetrexed|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Cisplatin 75 mg/m2 administered as an intravenous (IV) infusion over 2 hours Q3W (every 3 weeks) for 4 to 6 cycles or Carboplatin AUC 5 administered as an IV infusion over 15 minutes Q3W for 4 to 6 cycles. Pemetrexed 500 mg/m2 administered as an IV infusion over 10 minutes Q3W.
89271857|NCT03663205|Active Comparator|Cisplatin or Carboplatin and Pemetrexed|
89271858|NCT03617744|Experimental|Surgical Intervention|Open Sleeve gastrectomy procedure will be performed immediately following liver transplantation (as a single surgery) or within 2 weeks of transplantation (as a second open surgery)
89271859|NCT03617744|No Intervention|No Surgical Intervention|Liver transplantation will proceed as per routine practice
89271860|NCT03575910||Acute Rejection (AR)|Heart transplant patients diagnosed with an ISHLT grade 2R or 3R via endomyocardial biopsy.
89271861|NCT03575910||Mild Rejection (MR)|Heart transplant patients diagnosed with an ISHLT grade 1R via endomyocardial biopsy.
89271862|NCT03575910||Non-Rejection (NR)|Heart transplant patients diagnosed with an ISHLT grade 0R via endomyocardial biopsy.
89271863|NCT03572088|Active Comparator|Terlipresssin|Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
89271864|NCT03572088|Placebo Comparator|Control|patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)
89271865|NCT03560934|Experimental|Frequent Cannabis Users|"Subjects categorized as frequent cannabis users (>3x/week for 3 months) will receive a single dose of 10-60mg dronabinol on the second or third night of their stay in the clinical laboratory, one hour prior to bedtime and five minutes after completion of a study snack. The other night, participants will receive a placebo.~Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is ~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 10-60mg of dronabinol will be administered by OHSU's research pharmacy services."
89271866|NCT03560934|Experimental|Non Cannabis Users|Non-cannabis users (who have not used cannabis more than 10 times in their lifetime) will undergo the same single dose dronabinol and placebo as the frequent cannabis user arm, under the identical study procedure.
89271867|NCT03541187|Experimental|G. cockroach allergenic extract|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
89271868|NCT03541187|Placebo Comparator|Placebo|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
89271869|NCT03535675|Experimental|Muscadine Plus|Each treatment cycle consists of once daily oral dosing of 4000 mg Muscadine Plus, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of study drug and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
89271870|NCT03535675|Experimental|Placebo|Each treatment cycle consists of once daily oral dosing of 4000 mg placebos, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of placebo and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
89271871|NCT03527472|Experimental|Memantine|At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
89271872|NCT03527472|Placebo Comparator|Placebo|At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
89271873|NCT03488966|Experimental|MB-EAT|Behavioral: group psychotherapy. Eight weekly sessions, each session is 2 hours in duration.
89271874|NCT03488966|No Intervention|Waitlist Control|Wait list control.
89271875|NCT03440736|Active Comparator|Secukinumab 300 mg subcutaneous (s.c.)|Patients in arm A received therapy with Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24).
89271876|NCT03440736|Experimental|Secukinumab 300 mg subcutaneous (s.c.) and lifestyle intervention|Patients in arm B received therapy with Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24). In addition they participated in a lifestyle intervention program.
89271877|NCT03388788|Experimental|Normal Weight|Healthy lean controls [18.5<BMI<25 kg/m2 and WC <94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
89271878|NCT03388788|Experimental|Overweight|Healthy obese [30≤BMI<40 and waist circumference (WC) ≥94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
89271879|NCT03386006|Experimental|Noom Coach for Bariatric Health|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app.
89271880|NCT03386006|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period."
89271881|NCT03321539|Experimental|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21days for three cycles
89271882|NCT03321539|Active Comparator|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles
89271883|NCT03306121|Experimental|TPF+CCRT|Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
89271884|NCT03306121|Active Comparator|CCRT+ PF|Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
89271885|NCT03240081|Active Comparator|50mcg estradiol cream|Subjects randomized to 50mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
89271886|NCT03240081|Active Comparator|100mcg estradiol cream|Subjects randomized to 100mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
89271887|NCT03236857|Experimental|Venetoclax with or without chemotherapy|Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.
89271888|NCT03122808||Neonatal encephalopathy|"The inclusion criteria will be:~Moderate or severe neonatal encephalopathy~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~Non-hypoxic-ischaemic aetiology or postnatal hypoxic-ischaemia~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
89271889|NCT03122808||Control|"The inclusion criteria will be:~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~APGAR score of less than 5 at 1 minute or less than 7 at 5 or 10 minutes~Admission to the neonatal unit~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
89271890|NCT03097120|Active Comparator|unopposed estrogen|0.625 mg of conjugated equine estrogen
89271891|NCT03097120|Active Comparator|estrogen-plus-medroxyprogesterone|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
89271892|NCT03097120|Placebo Comparator|placebo|placebo
89271893|NCT03074643|Placebo Comparator|RecProt|Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
89271894|NCT03074643|Active Comparator|6-mon HiProt|Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
89271895|NCT03074643|Active Comparator|18-mon HiProt|"Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
89271896|NCT03003520|Experimental|DUR + R-CHOP|"On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 (maximum dose of 2.0 mg total), and cyclophosphamide 750 mg/m^2); Participants also were administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months."
89271897|NCT03003520|Experimental|DUR + R2-CHOP|"Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2), participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP. Participants were also administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. In addition, a daily oral lenalidomide 15 mg was administered from Day 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.~Enrollment into Arm B was discontinued."
89271898|NCT02989597|Experimental|Intra-operative Methadone Hydrochloride|Patient who will be given a single dose of intra-operative methadone, and having standard care otherwise
89271899|NCT02989597|Active Comparator|Control|Patients administered standard of care
89271900|NCT02986698|Experimental|in utero hematopoietic stem cell transplantation|"Perform in utero hematopoietic stem cell transplantation at the time of intrauterine transplantation in fetuses with alpha-thalassemia major. The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose of 1 x 10^7-10^9 cells/kg fetal weight with equal to or less than 1% CD3+ T cells (equivalent to 10^5-10^7 T cells/kg fetal weight) in a final volume of 2-5ml suspended in 5% human serum albumin in Normosol buffer (Hospira, Inc.).~Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT. All participants will receive one dose of stem cells but may receive additional transfusions as clinically indicated."
89271901|NCT02958527||venlafaxine|Patients with no experience of using time Effexor(venlafaxine) who will be administered time Effexor(venlafaxine)for the first
89271902|NCT02860273|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO at 21%~Constant Treadmill Load Test (CTLT) using HFNCO at 21%"
89271903|NCT02860273|Other|Control Group|"Incremental Load Treadmill Test (ILTT) at Room Air~Constant Treadmill Load Test (CTLT) at Room Air"
89271904|NCT02768701|Experimental|Experimental: Single Arm|Subjects will receive a single dose (300 mg/m2) of cyclophosphamide given the day before cycle 1 of pembrolizumab (200 mg), which will be administered every 3 weeks.
89271905|NCT02692105|Active Comparator|Low dose rate brachytherapy|Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
89271906|NCT02692105|Experimental|High dose rate brachytherapy|"Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
89271907|NCT02621944|Experimental|Participants 1-10|"This group will receive a 0.5 mg/kg enteral dose of Melatonin. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
89271908|NCT02621944|Experimental|Participants 11-20|"This group will the Melatonin dose of 3 mg/kg enteral, only if the group Participants 1-10 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
89271909|NCT02621944|Experimental|Participants 21-30|"This group will receive Melatonin dose of 5 mg/kg enterally, only if the group Participants 11-20 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
89271910|NCT02586025|Experimental|Trastuzumab, Pertuzumab, and Chemotherapy|Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
89271911|NCT02586025|Experimental|Trastuzumab, Placebo, and Chemotherapy|Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
89271912|NCT02465164|Other|Cook catheter|Control
89271913|NCT02465164|Active Comparator|Cook catheter plus low dose oxytocin|Test group
89271914|NCT02297672|Experimental|Breast seed implant|Stranded palladium seed interstitial radioactive seed implant to seroma with margin with 3 dimensional ultrasound and CT guidance
89271915|NCT02260271||Database Entry/Biospecimen Collection|Medical information of infants born with HIE entered into RedCap database. In addition, Blood, urine, buccal samples will be collected.
89271916|NCT01955512|Placebo Comparator|Placebo|Arm given placebo
89271917|NCT01955512|Experimental|Clopidogrel|Group given clopidogrel
89271918|NCT01899963||Tele-ophthalmology Referral Group|This group includes patients referred to a retinal specialist via a teleophthalmology referral system.
89271919|NCT01899963||Conventional Referral Group|This group includes patients referred to a retinal specialist via a conventional fax system.
89271920|NCT01789008|Other|Transient elastography|evaluation of fibrosis stage by transient elastography
89271921|NCT01789008|Active Comparator|liver biopsie|evaluation of fibrosis stage by liver biopsie
89271922|NCT01721577|Experimental|Phase 1: AXL1717, 300mg|In the first phase, 10-20 patients will be enrolled and treated with 300mg (original range of starting dose was 300-520mg) BID of AXL1717 for 28 days. The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 and to assess the safety and toxicity of AXL1717. The study has a 3+3 design and the first cohort will be treated with 300 mg AXL1717 BID for 28 days repeated in up to 5 cycles. The highest dose level without DLT or with maximally one DLT out of 6 patients will be the RP2D. Non-progressing patients may be treated for a total of five 28-day cycles (24 weeks).
89271923|NCT01705886||Knee Arthroplasty|"Patients undergoing knee replacement surgery. This may be a Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty.~The MAKO® Robot Assisted surgeries use the RESTORIS Multicompartmental Knee System.~The total knee arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System."
89271924|NCT01411332|Active Comparator|Arm I: SIMRT|'Participants in this group will receive the Standard Fractionated Intensity Modulated Radiotherapy (SIMRT) consisting 40 fractions over 8 weeks.
89271925|NCT01411332|Active Comparator|Arm II: HTIMRT|Participants in this group will receive the Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT) consisting of 38 fractions over 7.5 weeks.
89271926|NCT00323908||1|Women at high risk for developing breast cancer
89271927|NCT00227617|Experimental|FOLFOX with Bevacizumab|"Starting on Day 1, administered every two weeks:~5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes"
89271928|NCT05747742|Experimental|RLRL of 50% intensity|"Participants will be treated with RLRL (50% intensity) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary. Cross over arms after one month of use and one month of washout period."
89271929|NCT05747742|Active Comparator|RLRL of 100% intensity|"Participants will be treated with RLRL (100% intensity) twice per weekday with an interval of at least 4 hours, each treatment last 3 minutes.~Single-vision spectacles with power for correcting distance refraction will also be used if necessary. Cross over arms after one month of use and one month of washout period."
89271930|NCT05747404||Functional tricuspid regurgitation|Patients with functional tricuspid regurgitation
89271931|NCT05747404||Control subjects|Healthy volunteers
88805520|NCT03008239|Experimental|FiberSense sensor|"Type 1, Type 2 and prediabetic subjects will wear one FiberSense sensor, randomly allocated to either the upper arm (50%) or abdomen (50%) for 28 days. In addition, these subjects will wear a Dexcom sensor on the other side of the abdomen for 7 days in one of the four study weeks.~In all 4 CAPD subjects, one FiberSense sensor will be placed in the upper arm for 28 days. No additional comparator sensor will be placed in CAPD subject."
88805521|NCT01441843|Active Comparator|Lorazepam|Lorazepam 4mg/4ml
88805522|NCT01441843|Placebo Comparator|NaCl 0.9%|NaCl 0.9% 4ml
88805523|NCT00178646|Experimental|1 - Low Volume, High Dose|Botox (onabotulinumtoxinA), 150 units prepared as 100 units per 1 ml of preservative-free normal saline
88805524|NCT00178646|Active Comparator|2 - High Volume, High Dose|Botox (onabotulinumtoxinA), 150 units prepared as 50 units per 1 ml of preservative-free normal saline
88805525|NCT00178646|Other|3 - High Volume, Low Dose|Botox (onabotulinumtoxinA), 75 units prepared as 25 units per 1 ml of preservative-free normal saline
88805526|NCT02204761|Experimental|Treatment|Proton beam radiation therapy
89271932|NCT05727670|Experimental|main group|This group consists of patients with dental retention who will be treated using digital technologies and devices to create a place in the dentition
89271933|NCT05724043|Experimental|SmartJournal|Nursing homes in the intervention group will receive the SmartJournal intervention. They will be provided with toolboxes including tablets with SmartJournal installed, antibacterial touchscreen wipes, flashlights for monthly oral inspections, instruction video, instruction book and SmartJournal information posters. They will also receive oral hygiene equipment packages including toothbrushes for permanent teeth and prosthetic devices, dental floss, interdental brushes, toothpaste and inspection mirrors. Training, follow-up and technical support for SmartJournal usage will be provided by project staff employed at the Oral Health Centre of Expertise Rogaland. The intervention will last for 12 weeks.
89271934|NCT05724043|No Intervention|Control group|Nursing homes in the control group will also receive oral hygiene equipment packages but will, in contrast to the intervention group, continue with existing oral care routines.
89271935|NCT05714878|Experimental|Prehabilitation arm|Patient receives prehabilitation intervention including exercise, nutrition and psychological support.
89271936|NCT05714878|No Intervention|Control arm|Patient receives regular care recommended by the WHO without supervision and support.
89271937|NCT05713916|Experimental|Intervention: Population Health Coordinator|For subject randomized to the intervention arm, population health coordinators will notify the established longitudinal specialty clinician (cardiologist or nephrologist) or the primary care provider (PCP) that their patient has a recent echocardiogram demonstrating left ventricular hypertrophy (LVH). The outpatient clinician will be notified via the electronic health record (EHR) messaging system that the finding of LVH -- in the absence of significant valvular heart disease or a previously diagnosed cardiomyopathy -- may reflect undiagnosed or untreated hypertension.
89271938|NCT05713916|No Intervention|Observation: Usual Care|Those subjects randomized to the observation arm will receive usual care and their clinicians will not be notified about the finding of LVH on a prior echocardiogram until after study completion.
89271939|NCT05710081|Active Comparator|Intervention|Bacterial Lysate - Broncho-Vaxom (OM-85) 3.5mg granules once daily for 10 days per month for 24 months
89271940|NCT05710081|Placebo Comparator|Placebo|Placebo - 3.5mg granules once daily for 10 days per month for 24 months
89271941|NCT05703191||Nitric Oxide|Inhaled Nitric Oxide
89271943|NCT05692479||Group 1 and Group 2|Women With and Without Premenstrual Syndrome
89271944|NCT05683366||Single Group|No interventions, single group.
89271945|NCT05679882|Active Comparator|Outdoor Environment|Exposure to outdoor environmental noise
89271946|NCT05679882|Experimental|Outdoor Environment with Machine-Learning Selected Masking Sounds|Exposure to outdoor environmental noise and masking sounds
89271947|NCT05677867|Experimental|Formulation A (Reference) followed by Formulation B (Test)|
89271948|NCT05677867|Experimental|Formulation B (Test) followed by Formulation A (Reference)|
89271949|NCT05676268||Patients with oral implants supporting full ceramic fixed dental prostheses|
89271950|NCT05675670|Experimental|Intervention|Patients randomized to intervention will have access to the screening tool
89271951|NCT05675670|No Intervention|Control|Patients randomized to control will continue routine practice.
89271952|NCT05671341||Parkinson's Patients with Motor Freezing|Individuals with Parkinson's Disease with motor freezing were included in this group.
89271953|NCT05671341||Parkinson's Patients Without Motor Freezing|Individuals with Parkinson's Disease without motor freeze were included in this group.
89271954|NCT05657470|Experimental|TNK group|
89271955|NCT05657470|No Intervention|control group|
89271956|NCT05652257|Experimental|[14C]-brensocatib|Healthy participants will receive single oral dose of [14C]-brensocatib on Day 1 under fasted conditions.
89271957|NCT05652127|Experimental|Intervention: Child play of Mightier|Ad lib child biofeedback video game play in home
89271958|NCT05648552||Stroke group|Chronic subcortical stroke participants with motor dysfunction
89271959|NCT05648552||Healthy controls group|Well-matched healthy controls
89271960|NCT05642247||CD patients who received Ustekinumab treatment|1. Inpatients with Crohn's disease diagnosed in the Sixth Affiliated Hospital of Sun Yat-Sen University from January 2020 to June 2022. 2.The patients were treated with Ustekinumab and followed up regularly for 20 weeks. 3. Complete pre-treatment cross-sectional imaging data (CTE/MRE and US)
89271961|NCT05639686|Placebo Comparator|Total Intravenous Anesthesia (TIVA)|Patients will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, and lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with propofol 150mg/kg/min, remifentanil 0.05-2µg/kg/min, and rocuronium or succinylcholine as indicated. This is standard of care for this procedure. Within 10 minutes of induction, patients in the control group will be administered a 100mL bolus of normal saline as placebo.
89271962|NCT05639686|Experimental|Transexemic Acid (TXA) and Inhalational Anesthesia|Patients will be induced with fentanyl 1-2µg/kg, propofol 2mg/kg, lidocaine 1mg/kg. After orotracheal intubation, anesthesia will be maintained with isoflurane 1.5-2% or sevoflurane 1-2%, as well as rocuronium or succinylcholine as indicated. Again standard of care procedure is applied. Within 10 minutes of induction, patients in the study group will be administered 15mg/kg TXA suspended in 100mL of normal saline intravenously.
89271963|NCT05633576|Active Comparator|steroid eye drops|In this treatment arm, patients will self-administer the steroid eye drops three times a day for four consecutive weeks.
89271964|NCT05633576|Placebo Comparator|Placebo|In this treatment arm, patients will self-administer the placebo eye drops three times a day for four consecutive weeks.
89271965|NCT05627986||chronic shoulder impingement syndrome|Subjects with shoulder impingement more than 6 months will be included to assess pain threshold, neurophysiological measurements of scapular muscles.
89271966|NCT05627986||control group|Healthy controls without any shoulder and neck problems will be included to compare the differences in pain threshold, neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with chronic or acute shoulder impingement syndrome.
89271967|NCT05622929|Experimental|Intervention group|Real-world evidence (RWE) platform to provide data on their clinical practice + usual care + Digitally-enabled Multifaceted Quality Improvement Intervention
89271968|NCT05622929|Active Comparator|Control group|RWE platform to provide data on their clinical practice + usual care
89271969|NCT05621993||Combination therapy group|Patients who are treated with the combination therapy of Azvudine and Chinese herbal medicine will be included in this group. The combination therapy is Azvudine treatment (5 mg once a day) within 48 hours of first positive nucleic acid testing for COVID-19, combined with Chinese herbal medicine treatment.
89271970|NCT05621993||Sequential therapy group|Patients who are treated with the sequential therapy of Azvudine and Chinese herbal medicine will be included in this group. The sequential therapy is Azvudine treatment (5 mg once a day) after 48 hours of first positive nucleic acid testing for COVID-19, combined with Chinese herbal medicine treatment.
89271971|NCT05621993||Non-standard therapy group|Patients are treated with Azvudine combined with Chinese herbal medicine treatment. But Azvudine treatment is discontinued before the nucleic acid turns negative.
89271972|NCT05621993||The control group|Patients are treated with Chinese herbal medicine without Azvudine.
89271973|NCT05615935|Experimental|Get a learning material and a experiential HIV Testing|These participants in the experimental group will be provided a learning material about HIV testing, then an experiential HIV Testing, which includes HIV testing and counselling, education and discussion, and a post-test interviews will be provided.
89271974|NCT05615935|No Intervention|Get a learning material only|These participants in the control group will be provided a learning material about HIV testing only. After the post-test, the experiential HIV Testing will be provided to them.
89271975|NCT05615428||observational group|"Inclusion criteria:~GA ≤29+6, inborn at a participating centre~Age less than 45 minutes as gastric aspirate must be sampled within 45 minutes from delivery.~Exclusion criteria:~Treated with surfactant beforerandomisation and obtaining gastric aspirates~Diagnosis of major malformations (major congenital heart defects, congenital diaphragmatic hernia, gastroschisis/omphalocele, pulmonary abnormalities including pulmonary hypoplasia and trachea-oesophageal fistula~Antenatal suspicion of significant oligohydramnios and lung hypoplasia~Any intrauterine intervention except if done for genetic testing"
89271976|NCT05615402|Experimental|Training group|Group A: strength training 3x/week + nutrition optimalisation
89271977|NCT05615402|Experimental|Nutrition group|Group B: nutrition optimalisation
89271978|NCT05586685|Experimental|GroupA diaphragmatic release + conventional|"Group A: diaphragmatic release +conventional The patients will be positioned in the supine position. The therapist stood at the head of the patient contact thoracic cage and ask the patient to take inspiration and move laterally then ask the patient to expire.~conventional Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks: Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch the pectoral area from the supine lying position"
89271979|NCT05586685|Experimental|Group B: conventional|Group B: conventional posture correction exercises Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position
89271980|NCT05586074|Experimental|Clifutinib|Subjects received 40 mg dose orally once a day in continuous 28-day cycles, at least 2 hours before and after food. Clifutinib treatment continued until sujects met one of the treatment discontinuation criteria.
89271981|NCT05586074|Active Comparator|Salvage Chemotherapy|Subjects received chemotherapy in 28-day cycles. Subjects on Low-Dose Cytarabine (LoDAC) received 10 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10~14 days. Subjects on azacitidine received 75 mg/m^2 daily by SC for 7 days. Subjects on decitabine received 20 mg/m^2 daily by IV injection for 5 days. Subjects on LoDAC or azacitidine or decitabine treatment continued until they met discontinuation criteria. Subjects on Ara-C±IDA chemotherapy received cytarabine 1~3 g/m^2 daily by IV for 3 days and idarubicin 10 mg/m^2 daily by IV for 3 days. Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC for 6 days (days 1-6), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 1~2 g/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Subjects receiving Ara-C±IDA or FLAG-IDA received 1 cycle of therapy and were assessed for response on day 28+/-2 days.
89271982|NCT05584254|Experimental|Elderly with gastrointestinal symptoms|The target group for the intervention and cohort of interest used for comparison of baseline characteristics between control groups. Went into a cross-over design with 2 yeast-derived beta-glucan supplements and a placebo.
89271983|NCT05584254|No Intervention|Senior orienteers|A model of healthy aged elderly used as a control group for the baseline characteristics.
89271984|NCT05584254|No Intervention|Young healthy adults|A cohort of young healthy adults used as a control group for the baseline characteristics.
89271985|NCT05583630||Ligament tension measurement group|All participants will receive ligament tension measurement by the tension device during operation
89271986|NCT05578599|Other|Experimental Treatment|Treatment with the Swiftsure CSS device in addition to standard oral care procedures
89271987|NCT05573542||Patients with Parkinson's|Individuals with confirmed diagnosis of Parkinson's disease by neurologist.
89271988|NCT05573542||Patients with irritable bowel syndrome|Individuals with IBS according to ROME IV criterias
89271989|NCT05573542||Healthy controls|Healthy individuals lacking both IBS and Parkinson's disease, in addition to other criteras stated in the Eligibility section.
88805527|NCT01089569|Active Comparator|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
88805528|NCT01089569|Active Comparator|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
89271990|NCT05571566|No Intervention|Pre-implementation phase|All patients with acute appendicitis who undergo appendectomies will be eligible to participate, and families will be consented prior to surgery. The explanation of the procedure will be done verbally by the surgeon as it is the standard care at the hospital. A parental anxiety assessment will be done before surgery with the Amsterdam Preoperative Anxiety and Information Scale (APAIS). In addition, an email from one of the primary caregivers will be collected, and the caregiver will receive an email with a link to the post-operative questionnaire 10 days post-discharge. At 14 days post-discharge, they will receive a reminder email again with the link to the questionnaire. All responses to the questionnaire are voluntary and anonymous.
89271991|NCT05571566|Active Comparator|Post-implementation phase|The education tool will be distributed to families whose child is undergoing an appendectomy. The explanation of the procedure will also be done verbally by the surgeon as it is the standard care at the hospital. The parental anxiety assessment will be done in the same way as above, before surgery with the Amsterdam Preoperative Anxiety and Information Scale (APAIS). In addition, the email of one of the primary caregivers will be collected, and the caregiver will receive an email with a link to the post-operative questionnaire 10 days post-discharge. At 14 days post-discharge, they will receive a reminder email with the link to the questionnaire. All responses to the questionnaire are voluntary and anonymous.
89271992|NCT05552365|Experimental|Active Intervention|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder.
89271993|NCT05552365|Other|Treatment as Usual|Participants are re-directed to mental health support services. All participants given a mental health brochure which has contact details of mental health services for children.
89271994|NCT05549453|Experimental|SNBT device use|SNBT device is used for motor cortex localization, motor threshold determination and for targeting the intracranial electric field induced by the device to the intarcranial location required for the use of the device for its intended use
89271995|NCT05545605|Experimental|Intervention group|Subjects randomized to the trial group will receive sodium oligomannate 450mg twice daily for 24 weeks.
89271996|NCT05545605|Placebo Comparator|Control group|Subjects randomized to the control group will receive a 450mg placebo capsule twice daily for 24 weeks that has exactly the same appearance and smell as the Intervention group.
89271997|NCT05541146|Experimental|Intraperitoneal chemotherapy|Intraperitoneal chemotherapy in gastric cancer patients with peritoneal carcinomatosis.
89271998|NCT05532358|Experimental|anle138b (TEV-56286) as perpetrator (part I)|"Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days)~Victim drugs:~Caffeine 200 mg Midazolam 2 mg"
89271999|NCT05532358|Experimental|anle138b (TEV-56286) as victim (part II)|"Drug: fluvoxamine 100 mg QD for 5 days~Victim drug:~TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine"
89272000|NCT05527067||α-synucleinopathy|Participants with clinical diagnosis of α-synucleinopathy.
89272001|NCT05527067||Healthy controls|Healthy controls
89272002|NCT05525416|Experimental|Low Altitude|Participants will be assessed at an altitude of <1050m.
89272003|NCT05525416|Experimental|High Altitude|Participants will be assessed on a high-altitude expedition at an elevation of 3,800m.
89272004|NCT05516680|Experimental|Experiment group|electro-acupuncture and MRI-navigated rTMS
89272005|NCT05516680|Active Comparator|Control group|MRI-navigated rTMS
89272006|NCT05491512|Experimental|Cohort A|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC)
89272007|NCT05491512|Experimental|Cohort B|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). Participants in Cohort B will receive 1 cycle of carboplatin and Paclitaxol one week prior to the start of radiation. Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel). Paclitaxel can be substituted with Abraxane and the dose will be 50mg/m^2. For Cohort B, patients over 70yrs will be able to enroll regardless of Cisplatin or carboplatin/5-fluorouracil (FU) eligibility.
89272008|NCT05491512|Experimental|Cohort C|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). For participants in Cohort C where induction chemotherapy is used, additional pre-treatment 18F-FMISO PET and post induction pre radiation FMISO PET Scans will be obtained. These patients will start with induction chemotherapy of carboplatin, paclitaxel with or without cetuximab for 6 weeks and follow the same precision chemoradiation algorithm as Cohort A. A window of +/- 2 days is acceptable during the induction phase Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel). For patients who cannot tolerate paclitaxel, Abraxane and the dose will be at 100mg/m^2.
89272009|NCT05491512|Experimental|Cohort D|Participants diagnosed with hypoxia negative human papilloma virus (HPV) associated oropharyngeal carcinoma (OPC). Cohort D will just have T1- T2N0 participants. Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel). Will follow the guidelines for Cohort A and Cohort B for chemotherapy options.
89272010|NCT05460325|Experimental|Lanadelumab 300 mg|Participants will receive lanadelumab 300 milligram (mg), subcutaneously, once every 2 weeks (Q2W) from Day 0 to Day 182 (26 weeks).
89272011|NCT05449405|Active Comparator|Chlorpheniramine Malate (1%) Nasal Spray|Chlorpheniramine Malate (1%) Nasal Spray
89272012|NCT05449405|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray
89272013|NCT05447273||Patients with penile squamous cell carcinoma.|Patients with penile squamous cell carcinoma.
89272014|NCT05441735|Experimental|experimental group|will have access to information on the Long-Term Care Plan 2.0 through the app-based digital care program, while the
89272015|NCT05441735|No Intervention|control group|will only have access to information on the Long-Term Care Plan 2.0 through conventional paper-based media.
89272016|NCT05434806|Experimental|Post menomausal women (PMW)|40g/day of Jarlsberg cheese will be given three PMW's in the first designlevel. Based on the change in serum osteocalcin level after 4 weeks, the daily Jarlsberg cheese dose for five new PMWs in the second designlevel will be calculated. The results obtained by these five will be used to calculate the dose for seven new PMWs in the third design level.
88805529|NCT01089569|Active Comparator|Exenatide + Insulin Glargine|"Exenatide: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study~+ Insulin Glargine: 0.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results"
88805530|NCT01898234|Experimental|Revaclear|
89272017|NCT05434806|Experimental|Men passed the age of 65 years|40g/day of Jarlsberg cheese will be given three men in the first designlevel. Based on the change in serum osteocalcin level after 4 weeks, the daily Jarlsberg cheese dose for five new men in the second designlevel will be calculated. The results obtained by these five will be used to calculate the dose for seven new men in the third design level.
89272018|NCT05434169|Experimental|Positive Therapeutic communication|
89272019|NCT05434169|Active Comparator|Nocebo communication|
89272020|NCT05434169|Active Comparator|Neutral communication|
89272021|NCT05430529|Experimental|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
89272022|NCT05430529|Active Comparator|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
89272023|NCT05416931|Experimental|ACD440 Gel 14mg/g|Topically applied to painful neuropathic area twice daily for 7 days
89272024|NCT05416931|Placebo Comparator|Placebo Gel|Topically applied to painful neuropathic area twice daily for 7 days
89272025|NCT05411549|Experimental|Mediterranean Diet|Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete the Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora
89272026|NCT05411549|No Intervention|No Diet Modification|Participants enrolled in group 2 will be NOT counselled by a dietician. Participants will complete the Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora
89272027|NCT05398510|Experimental|Treatment for intravenously/subcutaneously|Treatment for intravenously: 6 dose groups； Treatment for subcutaneously: 3 dose groups.
89272028|NCT05398510|Placebo Comparator|Placebo for intravenously/subcutaneously|Treatment for intravenously: 6 dose groups； Treatment for subcutaneously: 3 dose groups.
89272029|NCT05394740|Experimental|Regorafenib, Nivolumab+CapeOX/FOLFOX|Regorafenib and Nivolumab+CapeOX (Cohort A) / Nivolumab+FOLFOX (Cohort B)
89272030|NCT05390021|Experimental|PET/MRI IN ENDOMETRIAL CANCER|PET/MRI in one study visit of approximately four hours
89272031|NCT05389761|Experimental|Enzyme DAO administration|DAO enzyme supplementation for 6 months
89272032|NCT05389761|Placebo Comparator|Placebo administration|Placebo supplementation for 6 months
89272033|NCT05389033|Experimental|Active probiotic|Lactobacillus acidophilus (CUL60 and CUL21), Bifidobacterium bifidum (CUL20), Bifidobacterium animalis subs p. Lactis (CUL34), 25 billion CFU, (Proven Probiotics, United Kingdom)
89272034|NCT05389033|Placebo Comparator|Placebo|"Chicory Root Extract (Min 90% Fructo-oligosaccharides) - Providing:~100mg FOS Microcrystalline Cellulose - 137.26 mg"
89272035|NCT05388279|Experimental|JS012|
89272036|NCT05388279|Experimental|JS012 combination with chemotherapy|
89272037|NCT05371951|Experimental|Erchonia HLS|635 nanometers (nm) laser application
89272038|NCT05355480||Healthy Subjects|Collection of handwriting samples
89272039|NCT05355480||Patients with Parkinson's disease|Collection of handwriting samples
89272040|NCT05353517||Healthy Subjects|Device: focal muscle vibration to induce spinal plasticity theta burst stimulation and paired associative stimulation to induce plasticity in M1
89272041|NCT05353517||Patients with Parkinson's disease|Device: theta burst stimulation and paired associative stimulation to induce plasticity in M1 Device: focal muscle vibration to induce spinal plasticity
89272042|NCT05343039|Experimental|Treatment Group|Participants will receive a tVNS device.
89272043|NCT05343039|Experimental|Non-Treatment Group|Participants will not receive a tVNS device.
89272044|NCT05328726|Experimental|Drug:GZR-18 administered via subcutaneous injection|For Assigned Interventions: GZR-18 administered once via subcutaneous injection at doses of 1.0 ug/kg, 5.0 ug/kg, 10.0 ug/kg, 20.0 ug/kg, 30.0 ug/kg, 40.0 ug/kg & 50.0 ug/kg
89272045|NCT05328726|Placebo Comparator|Placebo control|Commercially obtained sterile, normal saline for injection will be used as the matching placebo. Placebo will be dosed in an identical manner to active study drug. The volume of placebo will be calculated according to body weight using active drug dose for volume calculation in order to maintain the study blind.
89272046|NCT05306678|Experimental|Prolonged sitting|Prolonged sitting
88805531|NCT01898234|Experimental|Helixone high flux|
88805532|NCT01898234|Experimental|Xevonta|
88805533|NCT01898234|Experimental|Helixone low flux|
88805534|NCT01043939|Active Comparator|Purple Grape Juice First|After 4 week run-in period, drink 6 ounces of purple grape juice twice daily, then 4 week washout, week 12 drink 6 ounces of clear apple juice for 4 weeks twice daily
89272047|NCT05306678|Experimental|Breaking sitting|Breaking prolonged sitting
89272048|NCT05306613|Experimental|Prolonged sitting|Participants sat on a chair during the trial.
89272049|NCT05306613|Experimental|Breaking sitting|Participants walked regularly during the trial.
89272050|NCT05273996|Other|Depressed|Subjects receive FDA-approved antidepressants
89272051|NCT05263726|Experimental|DSMP through a mobile applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
89272052|NCT05263726|No Intervention|Usual Care|Routine care
89272053|NCT05262244|Active Comparator|AMD with bevacizumab-800CW|Patients with AMD receive bevacizumab-800CW followed by angiography
89272054|NCT05262244|Placebo Comparator|AMD with vedolizumab-800CW|Patients with AMD receive vedolizumab-800CW followed by angiography
89272062|NCT05244213|Experimental|Sintilimab plus chemo|3 cycles of neoadjuvant Sintilimab (200mg every 3 weeks) with nab-paclitaxel and carboplatin (nab-paclitaxel 260 mg/m2, d1 and carboplatin AUC 5, d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including EGFR-TKIs for up to 1 year or till disease progression or unacceptable toxicity.
89272063|NCT05235178||Study group|Due to catastrophic bleeding events in patients who are anticoagulated with FXa inhibitors undergoing emergency surgery on the proximal aorta and lack of antidote (not available in Norway and most likely not compatible with heparin), the department has decided to use hemadsorber in these cases.
89272064|NCT05231148|Other|infected non united fractures|patient of any age and any sex with infected non united fractures of long or short bones
89272065|NCT05202704|Experimental|Experimental: Hidden conditioning procedure + Positive Expectation|Patients with chronic low back pain will receive verbal delivered positive instructions regarding manipulative therapy. Then, after the spinal manipulative therapy they will be submitted to a hidden conditioning procedure in which the pain threshold will be surreptitiously downgrade to conditioning pain decrease to manipulative therapy (G1).
89272066|NCT05202704|Active Comparator|Active Comparator: Positive expectations|Patients with chronic low back pain will receive verbal delivered positive instructions regarding spinal manipulative therapy (G2) before the administration of a spinal manipulative therapy approach.
89272067|NCT05202704|Active Comparator|Active Comparator: Neutral Expectations|Patients with chronic low back pain will receive verbal delivered neutral instructions regarding spinal manipulative therapy (G3) before the administration of a spinal manipulative therapy approach.
89272068|NCT05169112|No Intervention|Standard of Care|Standard of Care
89272069|NCT05169112|Experimental|Standard of Care plus Androgen Deprivation Therapy (Lupron Depot)|22.5 mg intra-muscular injection of Lupron Depot every 3 months for 12 months (4 injections total)
89272070|NCT05158361|Experimental|Acupuncture|Participants will receive acupuncture.
89272071|NCT05158361|Sham Comparator|Sham acupuncture|Participants will receive sham acupuncture.
89272072|NCT05157451|Experimental|Arm I (SBRT)|Patients undergo SBRT every other day for a total of 5 days over 2 weeks.
89272073|NCT05157451|Experimental|Arm II (Y-90 radioembolization)|Patients receive Y-90 radioembolization via injection on day 1.
89272074|NCT05137223||Adolescent Only Focus Groups|20 early adolescents (ages 10-14) with physician-diagnosed persistent asthma (i.e., prescribed a controller medication) receiving care at a FQHC
89272075|NCT05137223||Caregiver Only Focus Groups|20 informal caregivers (e.g., parent, grandparent) of early adolescents with physician-diagnosed persistent asthma receiving care at a FQHC
89272076|NCT05137223||Adolescent and Caregiver Focus Groups|10 adolescents with physician-diagnosed persistent asthma receiving care at a FQHC and their caregivers (both of whom did not participate in either previous group for a total of 20 participants in the group cohort)
89272077|NCT05133011|Experimental|Low muscle strength|The participants underwent before tongue base reduction surgery used Iowa Oral Performance Instrument (IOPI) system test upper tongue muscle strength were the last 5%
89272078|NCT05133011|Experimental|Normal groups|The participants underwent before tongue base reduction surgery used Iowa Oral Performance Instrument (IOPI) system test upper tongue muscle strength were greater than 5%
89272079|NCT05131347|Experimental|motor intervention|Children in the motor intervention group will receive a 8-week motor intervention program. Each week will be of 1.5-hour duration.
89272080|NCT05131347|Active Comparator|cognitive intervention|Children in the cognitive intervention group will receive a 8-week cognitive training program. Each week will be of 1.5-hour duration.
89272081|NCT05123300|No Intervention|A) Conventional Imaging|Conventional Imaging with NaF (sodium fluoride)-PET/CT used for staging
89272082|NCT05123300|Experimental|B) Interventional Imaging|Staging with the interventional18F-PSMA-1007 PET/CT.
89272083|NCT05114135|Experimental|Subject group|undergoing instrumented TLIF with instrumented PLF using investigational product as synthetic bone graft
89272084|NCT05108116||Study group|"18-30 year-old, healthy volunteers~Age: 18-30 years~BMI: <30~No previous surgery on lower limb or spine~No known developmental disorder~Without any orthopaedic complaint"
89272085|NCT05104060|Experimental|pectoralis minor intervention group|The participants in pectoralis minor group will received manual therapy for pectoralis minor by investigators, the technique including stretch and soft tissue mobilization. The participants asked to perform the scapular control exercise and shoulder strength exercise. Participants will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
89272086|NCT05104060|Active Comparator|shoulder strengthening group|The participants in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
89272087|NCT05104060|No Intervention|Healthy subject group|Healthy participants will be recruited. No Intervention will be provided. The correlation between measures of pectoralis minor length and scapular kinematics will be assessed. Measurement will be the same as pectoralis minor intervention group and shoulder strengthening group
89272088|NCT05097209|Experimental|Camrelizumab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
89272089|NCT05097209|Active Comparator|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
89272090|NCT05093361|Active Comparator|Operative Treatment|Total Hip Arthroplasty
89272091|NCT05093361|Active Comparator|Conservative Treatment|Physical therapy
89272092|NCT05082298|Experimental|Dental Fear Intervention|All participants will receive a brief 2-step treatment for dental fear (Dental FearLess app, In-Chair Treatment)
89272093|NCT05033171|Experimental|Study group|"Patients with scoliosis induced surgical indication (Cobb-degree>45).~Posterior screw-rod fixation segmentdesis~Before the implantation, right after the implantation and after the in situ bending 3D scanning of the rod using Artec Eva Spider type manual 3D scanner will be performed. Scanning is possible from a more than 60 cm distance, so that means the operational area stays sterile.~EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery (as in the actual clinical protocal)."
89272094|NCT05029310|Experimental|All patients use both patiromer and tacrolimus|Pharmacokinetic investigation of tacrolimus performed in both the presence and absence of patiromer for all patients.
89272095|NCT05025293|Experimental|ZOLearly|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 5mg zoledronate (Aclasta) will be administered intravenously.~The ZOLearly group will have no further infusions during the study period."
89272096|NCT05025293|Placebo Comparator|ZOLlate|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 100ml NaCl 9mg/ml (placebo) will be administered intravenously.~3 months after hip fracture surgery (at the out-patient clinic): A single dose of 100 ml containing 5mg zoledronate (Aclasta) will administered intravenously."
89272097|NCT05021640|Experimental|Cohort 1 DCR-AUD|Single dose, subcutaneous administration of 80 mg of DCR-AUD (HV)
89272098|NCT05021640|Placebo Comparator|Cohort 1 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
89272099|NCT05021640|Experimental|Cohort 2 DCR-AUD|Single dose, subcutaneous administration of 240 mg of DCR-AUD (HV)
89272100|NCT05021640|Placebo Comparator|Cohort 2 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
89272101|NCT05021640|Experimental|Cohort 3 DCR-AUD|Single dose, subcutaneous administration of 480 mg of DCR-AUD (HV)
89272102|NCT05021640|Placebo Comparator|Cohort 3 DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
89272103|NCT05021640|Experimental|Cohort 4 (OPTIONAL) DCR-AUD|Single dose, subcutaneous administration of 960 mg of DCR-AUD (HV)
89272104|NCT05021640|Placebo Comparator|Cohort 4 (OPTIONAL) DCR-AUD Placebo|Single dose, subcutaneous administration of Placebo for DCR-AUD (HV), volume to match active single dose
89272105|NCT05012293|Experimental|Experimental: Fatigue Manipulation|
89272106|NCT05011318|Experimental|Fatigue Manipulation|
89272107|NCT05009784|Active Comparator|Traffic Sound|600 seconds of traffic sound
89272108|NCT05009784|Experimental|Traffic and Masking Sounds|600 seconds of traffic and masking sound
89272109|NCT05009784|Active Comparator|Silence|600 seconds of no sound
89272110|NCT05004857|Experimental|Patient arm|The subject population will be newborn infants admitted to the Newborn Nursery (NN) at Tulane Lakeside Hospital. The investigators are anticipating some mothers can be recruited from the prenatal clinics who expect to deliver at Tulane Hospital during pregnancy as well.
89272111|NCT05002049|Experimental|Citizen Science Behavioral Intervention|The intervention group (IG) participants will receive the whole citizen science intervention of the SEEDS project, and participants will be assessed at baseline and end-of-study.
89272112|NCT05002049|No Intervention|Control Group (No intervention)|The controls group (CG) participants will not receive any kind of intervention, and participants will only be assessed at baseline and end-of-study.
89272113|NCT05000905|Experimental|Adaptive Attention Training|Participants will complete approximately 15 hours of an at-home training on a novel adaptive attention training program ('Engage'), which will consist of completing thirty, 30-minute sessions over a total of 6-8 weeks.
89272114|NCT05000905|Active Comparator|Low-dose Adaptive Attention Training|Participants will complete approximately 1 hour of at-home training on 'Engage' which consists of two, 30-minute sessions at the beginning and middle of a 6-8 week period.
89272115|NCT05000905|Other|No Contact Group (Not Randomized)|An additional thirty participants will be enrolled separately (not randomized) into the no-contact group. Participants in the no-contact group will not complete any study activities for 6-8 weeks after completing the baseline assessments. After this period, participants will be prompted to log into Nexus to complete end of study assessments (same set of assessments administered/completed at baseline).
89272116|NCT04996173|Placebo Comparator|Control|Bronchoscopic Balloon Dilation with Radial Cuts
89272117|NCT04996173|Active Comparator|Intervention|Bronchoscopic Balloon Dilation with Radial Cuts & truFreeze Spray Cryotherapy
89272118|NCT04991974|No Intervention|Usual Care (UC)|The UC Arm will include standard services from the sexual health clinic / city health department [at the time of the study, no standardized intervention for opioid use disorder treatment linkage].
89272119|NCT04991974|Active Comparator|Patient Navigation (PN)|The PN Arm will include all UC Arm services, with the addition of a Patient Navigator who will assist the participant in selecting a community OUD treatment program, facilitate an intake appointment, help to resolve barriers and coordinate OUD treatment entry, and support early retention in OUD treatment.
89272120|NCT04991974|Experimental|Patient Navigation + Buprenorphine Initiation (PN+BUP)|The PN+BUP Arm will include all PN Arm services, with the addition of meeting with the sexual health clinic's buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to OUD treatment in the community. The standard buprenorphine bridge prescription will be for buprenorphine/naloxone film: 8/2mg, up to 16mg per day, 7 day supply.
89272122|NCT04935489|Experimental|Patients receiving accelerated rTMS|
89272123|NCT04917692|Experimental|empagliflozin|empagliflozin 2.5 mg daily
89272124|NCT04888013|Placebo Comparator|control group|Routine care for childbirth
89272125|NCT04888013|Experimental|experimental 2|Building childbirth environment
89272126|NCT04888013|Experimental|experimental 1|Building childbirth environment and labor delivery recovery room
89272127|NCT04881747|Active Comparator|100 milligram (mg) Lasmiditan immediate release (IR) (Reference)|Participants received 100 mg lasmiditan as IR tablet formulation administered orally.
89272128|NCT04881747|Experimental|100 mg Lasmiditan oral disintegrating (OD) Without Water (Test)|Participants received 100 mg lasmiditan as OD tablet formulation administered orally without water.
89272129|NCT04881747|Experimental|100 mg Lasmiditan OD With Water (Test)|Participants received 100 mg lasmiditan as OD tablet formulation administered orally with water.
89272130|NCT04879875|Experimental|Group 1|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed immediately after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
89272131|NCT04879875|Experimental|Group 2|"Patients scheduled for limb (arm/leg) surgery with tourniquet where IscAlert is removed 72 hours after surgery.~All patients will receive 3 sensors in the limb undergoing surgery and two control sensors in the opposite limb. The sensor in the opposite extremity which is not to be operated serves as a reference value for CO2."
89272132|NCT04874155|Active Comparator|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation - Phase 1
89272133|NCT04874155|Sham Comparator|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation - Phase 1
89272134|NCT04874155|Active Comparator|Open-Label|Open-Label - Phase 2 lasting 4-wks, during which all subjects will receive open-label Active treatment
89272135|NCT04862949||Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
89272136|NCT04841772|Active Comparator|Vegan Protein|
89272137|NCT04841772|Placebo Comparator|Placebo|
89272140|NCT04804917||Participants in the MindMyMind RCT|"The study participants comprise the 396 youths (and their parents) who participated in the Mind My Mind RCT. The study participants were randomized to the experimental MMM intervention (n=197) or MAU (n=199) and followed in the trial until 26 weeks after randomization, from September 7, 2017, to August 28, 2019.~The MMM consisted of 9-13 weekly, individual therapy sessions. The CBT methods were organized in modules for anxiety, depression and behavioral problems. Flowcharts described the sequencing and dosing of modules to match the problems at hand. The therapy was completed within 17 weeks, followed by a booster session after four weeks.~The MAU was enhanced by two care-coordination visits (week 2 and 17). The MAU interventions included anonymous counseling, pedagogical advice, network meetings, educational support, psychological treatment, or no treatment."
89272141|NCT04800146||Cohort 1|patients with solid tumors treated with chemotherapy (ongoing or completed no more than 6 months before enrollment). Specific type of chemotherapy inducing similar immunosuppression will be selected (including but not limited to platinum-based combinations, anthracycline combinations, triweekly docetaxel).
89272142|NCT04800146||Cohort 2|patients with solid tumors treated with single agent immune-check points inhibitors (ongoing or completed no more than 6 months before the enrollment
89272143|NCT04800146||Cohort 3|patients with solid tumors treated with hormonal agents (ongoing or completed no more than 6 months before enrollment): any anti-androgen for prostate cancer and any anti-estrogen for breast cancer patients.
89272144|NCT04800146||Cohort 4|patients with previously untreated mature B cell tumors in watch and wait
89272145|NCT04800146||Cohort 5|patients with mature B cell tumors treated with anti-CD20 monoclonal antibody either alone or in combination with chemotherapy (ongoing or completed no more than 12 months before enrollment
89272146|NCT04800146||Cohort 6|patients with hematological malignancies treated with pathway inhibitors (ongoing or completed no more than 12 months before enrollment). Different type of targeted agents can be considered, including Bruton tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors or phosphoinositide-3 kinase (PI3K) inhibitors
89272147|NCT04800146||Cohort 7|patients with hematological malignancies who have received autologous stem cell or allogenic transplant within 12 months
89272148|NCT04800146||Cohort 8|non-cancer subjects (age and gender matched) referred to the Division of Infectious Diseases, Lugano, EOC for vaccination against SARS-CoV-2.
89272149|NCT04795622|Experimental|Treatment Ulthera System|
89272150|NCT04795622|Other|Delayed-treatment Ulthera System|
89272151|NCT04791033||Adenomyosis|Patients with adenomyosis
89272152|NCT04791033||Other benign gynecological conditions|Patients with other benign gynecological conditions (i.e: myomas, endometriosis).
89272153|NCT04787003|Experimental|Oncolytic virus (OVV-01) injection for patients with advanced solid tumors|Oncolytic virus (OVV-01) injection combined with or without immune checkpoint inhibitors in the treatment of patients with advanced solid tumors.
89272154|NCT04786691|Placebo Comparator|Black coffee first|12 oz of black coffee with no additives is the first intervention tested
89272155|NCT04786691|Active Comparator|Coffee with half and half first|12 oz of black coffee with 1 oz of half and half is the first intervention tested
89272156|NCT04786691|Active Comparator|Coffee with non-dairy creamer first|12 oz of black coffee with 1 oz of liquid non-dairy creamer is the first intervention tested
89272157|NCT04784871|Experimental|5waysA Intervention|The intervention, 5WaysA, is a 10 week modified web-based version of the original Five Ways to Wellbeing course. The intervention consists of a two-hour main webinar with live lecturing from a facilitator introducing the Five Ways to Wellbeing framework and teaching the participants how to implement the five health promotive activities in life, a booster session webinar four weeks later, as well as an SMS message twice a week in the six following weeks. Each SMS encourages participants to engage in one of the five activities, register activities/goals and queries about the degree of participation in the activity introduced in the previous SMS.
89272158|NCT04784871|Other|5waysA Active wait-list control|The active wait-list control group will get the same intervention as the interventions group, five months later. The active wait-list control group will be encouraged (in SMS messages) to write down an activity log once a week in ten weeks, while waiting. The participants in this group will also answer questionnaires after the intervention group has finished the intervention
89272159|NCT04784871|Other|5waysA Inactive wait-list control|The inactive wait-list control group will get the same intervention as the interventions group, five months later. The inactive wait-list control group will not do anything specific while waiting for the intervention. The participants in this group will also answer questionnaires after the intervention group has finished the intervention
89272160|NCT04781959|Active Comparator|5 Days of Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy.
89272161|NCT04781959|Active Comparator|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
89272162|NCT04745156|Experimental|RNS System Implantation|This is a device feasibility study, therefore participants will only be enrolled into the investigational arm and will receive the RNS System Implantation.
89272163|NCT04729608|Experimental|Batiraxcept+PAC|Combination of batiraxcept and PAC
89272164|NCT04729608|Placebo Comparator|Placebo+PAC|Placebo-controlled arm with PAC
89272165|NCT04710355||Chronic pain|Failed back surgery syndrome
89272166|NCT04703790||Adults from the United States|Adult participants 18 years of age or older who are panelists recruited and maintained by Ipsos (KnoweledgePanel). All participants live within the United States.
89272167|NCT04689568|Active Comparator|Moodkit|MoodKit is a cognitive behavioral therapy (CBT)-based app designed to provide tools for managing depressed mood, anxiety and stress.
89272168|NCT04689568|Active Comparator|Moodgym|Moodgym is an online cognitive behavioral therapy (CBT)-based program designed to prevent or reduce symptoms of depression and anxiety by helping users identify and overcome problem emotions and to develop good coping skills.
89272169|NCT04689568|Active Comparator|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey. The Toolkit offers help to people who are experiencing problems with a mood disorder as well as with stress and anxiety.
89272170|NCT04686136|Experimental|Atogepant 60 mg|Taken once daily
89272171|NCT04679636|Experimental|Experimental group|receive biofeedback training for heart rate variability for eight weeks
89272172|NCT04679636|No Intervention|Control group|receive conventional treatment
89272173|NCT04670770|Experimental|SHR1459|SHR1459
89272174|NCT04652245|Experimental|Treatment A (Dymista) and Treatment B (Placebo), separated by at least 14 days of wash-out period|Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray and Placebo nasal spray
89272175|NCT04652245|Experimental|Treatment B (Placebo) and Treatment A (Dymista), separated by at least 14 days of wash-out period|Placebo nasal spray and Fixed drug combination of Azelastine hydrochloride 137 μg / Fluticasone propionate 50 μg nasal spray
89272176|NCT04642287|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
89272177|NCT04642287|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
89272178|NCT04635735|Experimental|Ipilimumab After Stem Cell Transplantation|The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.
89272179|NCT04611334|Experimental|experimental group|HRV biofeedback
89272180|NCT04611334|No Intervention|control group|routine care
89272181|NCT04606589|No Intervention|Standard-of-care|The standard-of-care arm will receive intermittent monitoring of pulse rate and blood oxygen saturation with a conventional pulse oximeter. Temperature and respiratory rate will also be monitored intermittently with a digital thermometer and manual counting of breaths respectively.
89272182|NCT04606589|Experimental|neoGuard vital signs monitor|The intervention group will receive continuous vital signs monitoring of pulse rate, blood oxygen saturation, temperature and respiratory rate with the neoGuard device.
89272183|NCT04595513|Experimental|Stage 1 Open Label|Phase I/II, open-label PK and initial safety analysis. TAVT-18 administered orally twice/daily to achieve precision dosing target of 10 ng/ml. Whole blood sirolimus levels are assessed at defined intervals on days 1, 7, and 14. After day 14, participants can elect to continue open-label treatment with TAVT-18 until 12 months of age. Final developmental outcomes are assessed at 24 months of age.
89272184|NCT04576403|Active Comparator|Intervention group|Activated mittens
89272185|NCT04576403|Sham Comparator|Control group|Deactivated mittens
89272186|NCT04576195|Experimental|Real PENS|One single session of PENS
89272187|NCT04576195|Sham Comparator|Sham PENS|One single session of Sham-PENS
89272188|NCT04572880|Active Comparator|Trabeculectomy|
89272189|NCT04572880|Active Comparator|XEN®|
89272190|NCT04572880|Active Comparator|Preserflo®|
89272191|NCT04566783||Women and men fulfilling PGAD-criteria|"Inclusion criteria:~- Female and male patients or subjects between 18-65 years of age fulfilling the diagnostic criteria of persistent genital arousal disorder (PGAD) according to Leiblum & Nathan (2001).~Exclusion criteria:~- Any exclusion criteria for magnetic resonance imaging (MRI), mental retardation, severe and acute somatic or mental disease such as acute psychosis, brain damage, Alzheimer's disease, severe bacterial infection requiring immediate medical treatment.~Age:~- 18 - 65 years of age~Gender:~- Female and male subjects"
89272192|NCT04566783||Controls|"Inclusion criteria:~- Age and education matched healthy controls."
89272193|NCT04543110|Experimental|Single Arm|Immune-Modulating Radiation with Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
89272194|NCT04510766||Part A|Upon confirmation of the suitability for NGS analysis of the selected tumor sample, tumor DNA will be extracted and molecular profile will be performed using the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 according to manufacturer's instructions
89272195|NCT04510766||Part B|"FFPE tumor archival tissue will be used to perform RNA-Seq with NGS HTG EdgeSeq Oncology Biomarker Panel Assay using the HTG machine following the manufacture's protocol. Blood samples for liquid biopsy will be collected at two time points: 1) Any time after enrollment in an early clinical trial and before starting the investigational agent~(1 x 10 ml blood sample in EDTA tube as source of normal DNA for comparative analysis; 2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection; 2) At the time of radiological or clinical tumor progression (2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection). Blood samples will be collected and stored to create a biobank of liquid biopsy for future analysis."
89272196|NCT04507659|Experimental|Jaktinib 100mg|100 mg bid.po
89272197|NCT04507659|Experimental|Jaktinib 75mg|75 mg bid.po
89272198|NCT04507659|Placebo Comparator|Placebo|Placebo bid.po
89272199|NCT04506970||Intrauterine Growth Restriction|Pregnant women carrying a fetus identified with intrauterine growth restriction during the third trimester (>28 weeks gestation)
89272200|NCT04506970||Normal pregnancy|Pregnant women identified with an uncomplicated pregnancy during the third trimester (>28 weeks), matched for fetal sex and gestational age with women enrolled in the IUGR group.
89272201|NCT04490148|Active Comparator|remote PFT (rPFT) longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment.
89272202|NCT04490148|Experimental|remote PFT (rPFT) + Nurse Coaching longitudinal|Subjects will undergo standard pulmonary function testing as part of standard clinical procedure. They will also undergo weekly remote pulmonary function testing using the telemedicine interface and study equipment, and receive monthly coaching from an ALS nurse.
89272203|NCT04487717||Low risk|good prognosis
89272204|NCT04487717||Intermediate risk|moderate prognosis
89272205|NCT04487717||High risk|poor prognosis
89272206|NCT04487652|Placebo Comparator|Placebo spray|Spray consists of matrix out of water, phospholipids and glycerine, plus coloration Colour Sunset Yello E 110 to mimic the test spray
89272207|NCT04487652|Experimental|CoQ10 spray|The CoQ10 spray contains a high quality Kaneka A10 containing CoQ10 trans-isomers which is embedded in a matrix out of water, phospholipids and glycerine. Adana Pharma GmbH is processing the CoQ10 substance into the matrix. One application contains 7 mg CoQ10.
89272208|NCT04485871|Experimental|Omega-3 fatty acids|3.6 g EPA:DHA / day (2:1)
89272209|NCT04429334|Experimental|nangibotide|Continuous infusion of experimental agent for up to 120 hours
89272210|NCT04429334|Placebo Comparator|placebo|Continuous infusion of matched placebo for up to 120 hours
89272211|NCT04408443|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
89272212|NCT04408443|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 4 months followed by 2 months of follow up.
89272213|NCT04405739|Experimental|EIDD-2801 twice daily (BID) for 5 days|EIDD-2801 orally twice daily (BID) for 5 days at Dose A, Dose B, Dose C, Dose D, Dose E, Dose F
89272214|NCT04405739|Placebo Comparator|placebo (PBO) twice daily (BID) for 5 days|Placebo (PBO) orally twice daily (BID) for 5 days matched for size and appearance to active IP
89272215|NCT04396457|Experimental|Pembrolizumab+Pemetrexed|"200 mg of pembrolizumab is intravenously infused over 30 minutes and more on day 1.~500 mg/m^2 of pemetrexed is intravenously infused over 10 minutes and more on day 1.~*Administration of folic acid and vitamin B12 is started 1 week before the start of treatment with pemetrexed.~And repeat the administration every 3 weeks as one cycle until the treatment cessation criteria are met. Upper limit of the pembrolizumab administration is 35 cycles, and the pemetrexed administration will continue until the treatment cessation criteria are met."
89272216|NCT04395521|Experimental|Facebook group arm|Access to a diabetic foot self-management support program via a Facebook group platform for three months plus the standard care.
89272217|NCT04395521|No Intervention|Standard care arm|Carry on with the routine diabetes care offered to the participants in their health facilities.
89272218|NCT04377204|Active Comparator|Lidocaine Group|Local injection of 1% lidocaine with 1:100,000 epinephrine one time pre-operatively prior to general anesthesia
89272219|NCT04377204|Active Comparator|Lidocaine with Bupivacaine|Local injection of 1% lidocaine with 1:100,000 epinephrine mixed 1:1 with 0.5% marcaine bupivacaine with 1:200,000 epinephrine, one time pre-operatively prior to general anesthesia
89272220|NCT04346589|Experimental|Antibodies (immunoglobulins) infusion|Anti-coronavirus antibodies obtained with double-filtration plasmapheresis (DFPP )from convalescent patients.
89272221|NCT05934357|Experimental|Intervention Treatment|Experimental treatment will contain a cereal product that contains a dietary fiber. This will be consumed three times daily for two weeks.
89272222|NCT05934357|Placebo Comparator|Control treatment|Control treatment will contain a corn meal cereal product that will be consumed three times daily for two weeks.
89272223|NCT05934344|Experimental|Observational learning from the therapist|Patients with MCI (Mild Cognitive Impairment) will undergo intervention using therapist-led imitation exercises. They will engage in a 5-week exercise program based on observation and action. Data will be collected at the beginning and end of the program.
89272224|NCT05934344|Experimental|peer learning|Patients with MCI (Mild Cognitive Impairment) will undergo intervention using exercises by imitation from individuals residing in the facility but without cognitive impairment. They will participate in a 5-week exercise program based on observation and action. Data will be collected at the beginning and end of the program.
89272225|NCT05934344|No Intervention|control group|Patients with cognitive impairment who will receive the standard treatment provided by the facility.
89272226|NCT05934318|Experimental|L-citrulline arm|L-citrulline arm is the intervention arm consisting of a twice daily 6.0 g sachet, each containing 5.000 g of quality-assured L-citrulline powder, 0.672 g maltodextrin and 0.286 g lactose anhydrous, 0.03 g citric acid, 0.012 g lemon flavour + antenatal standard of care with enhanced monitoring. The sachets will be provided at enrolment and each subsequent monthly ANC visit.
89272227|NCT05934318|No Intervention|Placebo arm|Placebo arm is the control arm consisting of a twice daily 6.0 g sachet of quality-assured placebo, each consisting of 3.6 g maltodextrin and 2.358 g lactose monohydrate, 0.03 g citric acid, 0.012 g lemon flavour + antenatal standard of care with enhanced monitoring. The sachets will be provided at enrolment and each subsequent monthly ANC visit.
89272228|NCT05934279|Experimental|Resistance Training|Training aimed at improving balance and strengthening muscle strength (RT) will be held twice a week, 45 min per session for 8 weeks
89272229|NCT05934279|No Intervention|Control Group|Group without training program
89272230|NCT05934266|Experimental|Tissue adhesive|Group of 80 patients in which mesh fixation is done using cyanoacrylate glue
89272231|NCT05934266|No Intervention|Standard suture|Group of 80 patients who undergo hernioplasty with standard suture
89272232|NCT05934188||Young Healthy Subjects (N = 40)|"20-50 years old~Cognitively healthy (Mini-Mental State examination ≥ 26)~Absence of significant neurological disorders"
89272233|NCT05934188||Old Healthy Subjects (N = 40)|"60-90 years old~Cognitively healthy (Mini-Mental State examination ≥ 26)~Absence of significant neurological disorders"
89272234|NCT05934188||Patients with prodromal Alzheimer's Disease (N = 40)|"Subjective cognitive complaint (corroborated by the informant)~Episodic memory deficit on neuropsychological testing~Clinical Dementia Rating = 0.5~Mini-Mental State Examination (MMSE) > 23~Independently functioning in activities of daily living"
89272235|NCT05934188||Patients with Parkinson's Disease (N = 40)|"Recent diagnosis of Parkinson's Disease~Mild-moderate score at the Unified Parkinson's Disease Rating Scale (UPDRS)~Cognitively healthy (Mini-Mental State examination ≥ 26)~In case of taking medications for Parkinson's Disease: stable dosage for at least 6 months"
89272236|NCT05934188||Patients with Multiple Sclerosis (N = 40)|"Recent diagnosis of relapsing-remitting Multiple Sclerosis~Expanded Disability Status Scale score ≤ 4.0~Cognitively healthy (Mini-Mental State examination ≥ 26)~In case of taking medications for Multiple Sclerosis: stable dosage for at least 6 months"
89272237|NCT05934123||Intervention group|Infants admitted to the 11 EMNODN neonatal units
89272238|NCT05934123||Control group|Infants admitted to all other neonatal units in England and Wales
89272239|NCT05934097|Experimental|Regimen A (FT596 in combination with standard schedule R-CHOP)|FT596 in combination with standard schedule R-CHOP (rituximab, cyclophosphamide, doxorubicin, and vincristine on Day 1; prednisone on Days 1-5; and FT596 on Day 8) for a total of six 21-day cycles.
89272240|NCT05934097|Experimental|Regimen B (FT596 in combination with alternate schedule R-CHOP)|FT596 in combination with alternate schedule R-CHOP (prednisone on Days 1-5; rituximab, cyclophosphamide, doxorubicin, and vincristine on Day 5; and FT596 on Day 8) for a total of six 21-day cycles
89272241|NCT05934071||patients affected by HFrEF on ARNI|patients affected by HFrEF in optimized medical therapy including ARNI, eligible for glyphozine
89272242|NCT05934058||StoP Consortium + UK Biobank|"In the PRS development 338,480 cases and controls from the UK Biobank + 3,650 cases and controls from the StoP consortium studies are going to be enrolled.~Cases are defined as primary gastric carcinoma patients, with histological confirmation.~Controls are selected from cancer-free patients matched with the cases."
89272243|NCT05934058||StoP Consortium|"In the analysis on the aetiology of Gastric Cancer 13,500 cases and 32,000 controls from the StoP consortium studies will be enrolled.~Cases are defined as primary gastric carcinoma patients, with histological confirmation.~Controls are selected from cancer-free patients matched with the cases."
89272244|NCT05934045||ALCL patient samples (serum)|serum collected at diagnosis, during treatment and/or at relapse
89272245|NCT05933993||Mothers, following an elective cesarean sections|The cohort in this study consists of Danish mothers, undergoing an elective cesarean section in one og the three participating hospitals.
89272246|NCT05933928|Experimental|İntervention group (High validity simulation application group) (n:40)|"Practices will be carried out with the students in the intervention group with the NOELLA Birth Simulator, which is a high-reality simulator located in the Simulation laboratory of the Department of Midwifery of the Faculty of Health Sciences of Hamidiye. A simulator will be practiced with a separate scenario including early, late, variable deceleration, reactive, sinusoidal and non-reactive trace interpretation and intervention."
89272247|NCT05933928|No Intervention|Control group (Case-based teaching technique group) (n:40)|To the control group students; Cases on early, late, variable deceleration, reactive, sinusoidal and non-reactive tracing will be prepared by dividing into groups of 5 people. Semi-structured cases will be evaluated and clinical intervention will be discussed with group work. Practice will be done in the basic skills laboratory of the midwifery department.
89272248|NCT05933915|Experimental|Intervention Group (Laughter yoga group) (n:40)|Laughter yoga will be practiced to midwives in the intervention group.
89272249|NCT05933915|No Intervention|Control Group (n:40)|The control group will not be subjected to any application.
89272250|NCT05933876||OC-SABR|Patients diagnosed with Oligometastatic Cancer (OC) that will receive Stereotactic ABlative Radiotherapy (SABR) that has been prescribed per clinical protocol.
89272251|NCT05933876||Controls|Individuals who have never been diagnosed with cancer or oligometastasis.
89272252|NCT05933863||immunotherapy cohort|Extensive stage SCLC patients receiving first-line chemotherapy plus PD-(L)1 antibody treatment will be enrolled in this cohort. Baseline tumor tissue samples and peripheral blood samples will be collected for transcriptome and immunohistochemistry analysis etc.
89272253|NCT05933863||chemotherapy cohort|Extensive stage SCLC patients receiving only first-line etoposide plus platinum chemotherapy will be enrolled in this cohort. Baseline tumor tissue samples and peripheral blood samples will be collected for transcriptome and immunohistochemistry analysis etc.
89272254|NCT05933837||Patients with MINS|Troponin I level equal to or above 59 ng/L
89272255|NCT05933837||Patients without MINS|Troponin I level under 59 ng/L
89272256|NCT05933811|Experimental|Pediatric patients with unilateral impalpable maldescended testis|Patients in the pediatric age group who presented by unilateral impalpable undescended testis
89272257|NCT05933798|Experimental|Intervention Group|"Participants who were actively followed up during the study period with a personalized integrated care plan developed following the ICOPE screening and assessment, identified as at-risk for loss in intrinsic capacity."
89272258|NCT05933798|Active Comparator|Control Group|Pariticpants who continued receiving usual care during the study period.
89272259|NCT05933759|Experimental|Intervention group|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps, and telemedical coaching.
89272260|NCT05933759|Active Comparator|Control group|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps.
89272261|NCT05933720|Active Comparator|Patients who undergo routine conservative treatment|The patients who undergo routine conservative treatment for peripheral atherosclerotic occlusive disease as per clinical guidelines
89272262|NCT05933720|Experimental|Patients who undergo treatment with polypeptides|The patients who undergo treatment with a complex of polypeptides isolated from the vessels of cattle is administered in / m, adults 1 vial (5 mg) 1 time / day 2 times a week. The course of treatment is 10 injections.
89272263|NCT05933720|Active Comparator|Patients who undergo femoral-popliteal bypass with a synthetic graft above the knee|Patients who undergo the surgical method of treatment i.e. femoral-popliteal bypass grafting with a synthetic graft above the knee and routine conservative treatment as per clinical guidelines
89272264|NCT05933720|Experimental|Patients who undergo femoral-popliteal bypass grafting and treatment with polypeptides|Patients who undergo the surgical method of treatment i.e. femoral-popliteal bypass grafting with a synthetic graft above the knee with following treatment with a complex of polypeptides isolated from the vessels of cattle is administered in / m, adults 1 vial (5 mg) 1 time / day 2 times a week. The course of treatment is 10 injections.
89272265|NCT05933694|No Intervention|Control|Participants to report 50 spirometry records alone
89272266|NCT05933694|Experimental|Intervention|Participants report the same 50 spirometry records provided in the control arm with an artificial intelligence-powered spirometry interpretation report
89272267|NCT05933668|Experimental|YK0901 cells|"Patients will undergo lymphocytapheresis, then treatment with TCR-T cells (at escalating doses) + IL-2.Accelerated titration and 3 + 3 dose escalation were used in this trial . Five dose levels were set up: the dose level was 1: 1× 108 ± 20%（8×107~1.2×108）; the dose level was 2: 1 × 109 （±20%：8×108~1.2×109）; the dose level was 3: 5 × 109 （±20%：4×109~6×109）; the dose level was 4: 2 × 1010 （±20%：1.6×1010~2.4×1010）; the dose level was 5: 5 × 1010 （±20%：4×1010~6×1010）."
89272268|NCT05933655|Experimental|Peer Coach|The research coordinator will set up a time for the subject to have a brief discussion with a peer coach from the study team approximately 1 week after randomization. During the coaching session, the peer coach will encourage the subject to mention their heart health goals to their primary care clinician during their next primary care appointment. The peer coach will also help the subject brainstorm ways to remove any barriers that may prevent them from having the discussion with their clinician. The peer coaching session and the subsequent medical appointment will be audio-recorded.
89272269|NCT05933655|No Intervention|Control|The subject will not be asked to meet with the peer coach or anyone from the study team prior to their next visit with their primary care clinician. Their subsequent primary care appointment will be audio-recorded.
89272270|NCT05933629|Active Comparator|Standard Training|Participants assigned to this arm will complete a 3-hour training workshop on the intervention. After completing the training, participants will be asked to implement the intervention into their routine clinical practice.
89272271|NCT05933629|Experimental|Extended Training|Participants assigned to this arm will complete the same 3-hour training workshop on the intervention as Arm #1. After completing the training, participants will also be asked to implement the intervention into their routine clinical practice. However, participants in this group will be asked to attend bi-weekly consultation sessions with members of the study team for 3 months following training.
89272272|NCT05933590||Chronic Migraine Group|This group consists of 25 individuals diagnosed with chronic migraine. They will undergo cervical joint repositioning error assessment in different head positions.
89272273|NCT05933590||Control Group|This group consists of 25 age-matched healthy controls without a history of migraine. They will undergo the same cervical joint repositioning error assessment in different head positions.
89272274|NCT05933564||Chronic Pain Patients with Varying Cognitive Reserve|Community-dwelling adults aged 65-85 years with chronic pain (≥3 months) attributable to osteoarthritis or neuropathic conditions.
89272275|NCT05933551|Experimental|After the training, the knowledge levels and skills of the nurses about the Z technique|
89272276|NCT05933512|Experimental|Group A:SCTV01E-2|one dose of SCTV01E-2 on D0
89272277|NCT05933512|Active Comparator|Group A:SCTV01E|one dose of SCTV01E on D0
89272278|NCT05933512|Experimental|Group B:SCTV01E-2|one dose of SCTV01E-2 on D0
89272279|NCT05933486|Experimental|Tongluo-Kaibi tablet plus placebo of pregabalin|
89272280|NCT05933486|Active Comparator|placebo of Tongluo-Kaibi tablet plus pregabalin|
89272281|NCT05933473|Active Comparator|LM-LAD (Crossover stenting (CO))|Crossover stenting (CO) from the LM into the LAD, using standard provisional bifurcation techniques and proximal stent optimization (POT), where post dilatation was typically performed.
89272282|NCT05933473|Active Comparator|ostial LAD (Ostial stenting(OS))|Ostial stenting of the LAD (OS) with no cross-over back to the LM.
89272283|NCT05933460|Experimental|Active Group|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Crocus sativus (Saffron extract 28mg) was administered 3 times per day in people with diabetes type 1 for 6 months on continuous glucose monitoring systems.
89272284|NCT05933460|Placebo Comparator|Placebo group|A sachet of a combination of 4 strains of probiotics (1billion CFU(Lactobacillus rhamnosus, Bifidobacterium animalis lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg without crocus sativus was administered 3 times per day in people with diabetes type 1 for 6 months on continuous glucose monitoring systems.
89272285|NCT05933447|Experimental|Rodatristat Ethyl|
89272286|NCT05933447|Active Comparator|Moxifloxacin|
89272287|NCT05933447|Placebo Comparator|Placebo for Rodatristat|
89272288|NCT05933447|Placebo Comparator|Placebo for Moxifloxacin|
89272289|NCT05933369|Experimental|Intervention|Patients in the intervention group will receive a protocol-defined clinical pharmacist intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits.
89272290|NCT05933369|No Intervention|Control|Patients in the control group will receive the usual pharmacist care.
89272291|NCT05933356|Experimental|Experimental group|"The experimental group, in addition to scheduled activities, will be provided with the individual brain training exergames (a program for improving cognitive function and eye-hand coordination) three times a week and 30 minutes each time.~Exergame and no intervention are more informative than 1 and 2"
89272292|NCT05933356|Other|control group|The control group will be maintained with their scheduled activities in daycare as usual.
89272293|NCT05933343|Active Comparator|Ethibond suture|Patients with complex anal fistula will undergo placement of Ethibond™ 1 suture as a drainage seton
89272294|NCT05933343|Active Comparator|Vessel loop|Patients with complex anal fistula will undergo placement of vessel loop as a drainage seton
89272295|NCT05933304||Vaccinated Cohort|Participants who receive Moderna COVID-19 vaccine during a pre-specified time frame and meet eligibility criteria will be included in this cohort. Participants will be followed up through Electronic Health Record (EHR) for occurrence of COVID-19 outcomes until the end of the study period, or censoring events (termination of KPSC membership allowing for a 31-day gap, death, receipt of a COVID-19 vaccine).
89272296|NCT05933304||Unvaccinated Cohort|Participants who have not received Moderna COVID-19 vaccine or any other COVID-19 vaccine as of the index date of their matched vaccinated participant and who meet eligibility criteria will be included in this cohort. Participants will be followed up through EHR for occurrence of COVID-19 outcomes until the end of the study period, or censoring events (termination of KPSC membership allowing for a 31-day gap, death, receipt of a COVID-19 vaccine).
89272297|NCT05933291||COVID-19 with steroid|COVID-19 ARDS patients with steroid treatment
89272298|NCT05933291||COVID-19 without steroid|COVID-19 ARDS patients without steroid treatment
89272299|NCT05933291||non-COVID-19 with steroid|non-COVID-19 ARDS patients with steroid treatment
89272300|NCT05933291||non-COVID-19 without steroid|non-COVID-19 ARDS patients without steroid treatment
89272301|NCT05933213|Experimental|Mescaline sodium enteric-coated tablets group|"Treating with glucocorticoids + mescaline sodium enteric-coated tablets~(1) Induction period: Prednisone tablets: orally, recommended dose 0.4-0.8 mg/kg/d, with gradual dose reduction (10% per month) at the end of 3-6 months; mescaline sodium enteric-coated tablets: orally, twice a day, at 720-1440 mg/d, for 3-6 months; (2) Maintenance period: Prednisone tablets 5-7.5 mg/d, mescaline sodium enteric-coated tablets 360-540mg/d, maintenance treatment for 1 year"
89272302|NCT05933213|Active Comparator|Morte-mescaline group|"Treating with glucocorticoids + morte-mescaline~Induction period: Prednisone tablets: oral, recommended dose 0.4-0.8 mg/kg/d, with gradual dose reduction (10% per month) at the end of 3-6 months; mortifamate: oral, twice a day, dose 1-2 g/d, 3-6 months;~Maintenance period: Prednisone tablets 5-7.5 mg/d, mortifamate 0.5-0.75 g/d, with maintenance treatment for 1 year."
89272303|NCT05933135||Normal factor XIII acitivity|Patients with GI bleeding and normal factor XIII activity
89272304|NCT05933135||Reduced factor XIII activity|Patients with GI bleeding and reduced factor XIII activity
89272305|NCT05933031|Experimental|Tegoprazan 50 mg|Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
89272306|NCT05933031|Experimental|Tegoprazan 100 mg|Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
89272307|NCT05933031|Active Comparator|Lansoprazole|Lansoprazolee/Clarithromycin/ Amoxicillin BID peroral, 14 days
89272308|NCT05933018|Other|type 1 diabetes|patients with type 1 diabetes underwent liver elastography
89272309|NCT05932927||Chronic liver disease with hepatopulmonary syndrome|Liver disease (usually cirrhosis with portal hypertension) ；Positive CE-TTE（Contrast enhanced contrast ultrasound）；Abnormal arterial oxygenation: Alveolar-arterial oxygen gradient (AaO2) ≥ 15 mm Hg (>20 mm Hg if age > 64)
89272310|NCT05932927||Chronic liver disease without hepatopulmonary syndrome|Liver disease (usually cirrhosis with portal hypertension) ； Negative CE-TTE
89272311|NCT05932875|Active Comparator|Peanut/Carbohydrate Consumption Exercise Training|Participants in this group will undergo 16 weeks of concurrent exercise training (4 sessions/week) consuming a peanut-based rice/oatmilk smoothie after each workout
89272312|NCT05932875|Placebo Comparator|Carbohydrate Consumption Exercise Training|Participants in this group will undergo 16 weeks of concurrent exercise training (4 sessions/week) consuming a rice/oatmilk smoothie after each workout
89272313|NCT05932836||Pancancer corhor|No interventions to be administered.
89272314|NCT05932836||Hepatocellular carcinoma patients who undergo hepatic artery infusion with mFOLFOX6|No interventions to be administered.
89272315|NCT05932823||Laminar Airflow|total hip arthroplasty performed in an operating room using laminar airflow ventilation system
89272316|NCT05932823||Turbulent Airflow|total hip arthroplasty performed in an operating room using turbulent airflow ventilation system
89272317|NCT05932797|Active Comparator|Intervention group|Multimodal rehabilitation: physical, psychological and cognitive training and treatment program at the Teaching and Research Assistance Center of the University of Magellanus.
89272318|NCT05932797|No Intervention|Control group|Individuals who must maintain their daily habits and/or usual care at their health center.
89272319|NCT05932784||OHCA patients receiving TEE|Out-of-hospital cardiac arrest (OHCA) patients undergo transesophageal echocardiography (TEE) during resuscitation to determine if their aortic valve is being compressed.
89272320|NCT05932771|Experimental|1.Trial for young male participants: Consuming hydrolyzed collagen (HC) with reistance exercise|Young male participants consumed one of three different HC doses (0 grams, 15 grams, or 30 grams) with 4 sets of 10 repetitions of barbell back squat exercise at 10-repetition maximum load in a random order and a seven-day wash-out period interspersed between each trial.
89272321|NCT05932771|Experimental|2.Trial for young female participant: Consuming hydrolyzed collagen (HC) with reistance exercise|The intervention procedure is exactly same as Arm 1 except for the number of visits. Young female participant was asked to visit the laboratory on four occasions during two consecutive months. Therefore, there were two trials in each month, where female participants' estrogen level was lower (i.e., onset of menses) or higher (i.e., ovulation). Dates for the trials were determined based on self-report of onset of menses and previous menstrual cycle length.
89272322|NCT05932771|Experimental|3.Trial for older male participants: Consuming hydrolyzed collagen (HC) with reistance exercise|The age range of older male participants was 40 - 65 years. The intervention procedure is exactly same as Arm 1
89272323|NCT05932771|Experimental|4.Trial for older female participants: Consuming hydrolyzed collagen (HC) with reistance exercise|The age range of older female participants was 40 - 65 years. The intervention procedure is exactly same as Arm 2
89272324|NCT05932706|Active Comparator|real stimulation|The central electrode was placed over F3, with return electrodes at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 30 minutes per session, twice daily over 7 consecutive days, and the stimulus frequency was set as IAF.
89272325|NCT05932706|Sham Comparator|sham stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15 and 15 s); no current was delivered during the 30-minute intervention. Participants will receive sham tACS twice daily for two weeks.
89272326|NCT05932576||The HPV vaccine group|Women aged 9-45 years who received the last dose of HPV vaccine within the past 12 months were included, and each subject was evaluated within 3-12 months after the last dose of HPV vaccine. Adverse reaction symptoms were queried by telephone follow-up and face-to-face, and peripheral blood tube (3ml) was collected to detect the concentration of comprehensive antibody to HPV vaccine.
89272327|NCT05932563||The HPV vaccine group|"For retrospective cohort population: This study will be based on the database with HPV typing results before HPV vaccination, and the epidemiological characteristics such as adverse reaction symptoms after HPV vaccination in this population will be followed up by telephone or face-to-face, and 1 cervical exfoliated cell and 1 peripheral blood tube will be collected within 1-12 months after HPV vaccination.~For the prospective cohort:~All subjects will be enrolled at the time of the first dose of HPV vaccine, followed up 30-60 days after the last dose of HPV vaccine and 12 months after the last dose of HPV vaccine. One cervical exfoliated cell was collected at enrollment and two follow-up visits, and one peripheral blood tube was collected at 30-60 days follow-up after the last dose of HPV vaccine."
89272328|NCT05932563||Unvaccinated HPV group|Exfoliated cervical cells were collected to test for HPV genotyping, or HPV genotyping results had been available for nearly 1 year prior to enrollment
89272329|NCT05932550|Experimental|Maraviroc 300 mg/day|Open-label study
89272330|NCT05932524|Experimental|Low-dose baricitinib plus high-dose dexamethasone|Oral baricitinib is given at a dose of 2 mg daily for 6 consecutive months. Dexamethasone is administrated at 40 mg per day for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10). Treatment will be discontinued if very severe or life-threatening adverse events developed or at the patients' request.
89272331|NCT05932524|Active Comparator|High-dose dexamethasone|Dexamethasone is administrated at 40 mg per day for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10). Treatment will be discontinued if very severe or life-threatening adverse events developed or at the patients' request.
89272332|NCT05932498|Experimental|PENG group|Participants with PENG block
89272333|NCT05932498|Active Comparator|QL group|Participants with QL block
89272334|NCT05932485|Experimental|Left stellate ganglion block|Left stellate ganglion block under ultrasound guidance was administered with 0.375% Ropivacaine hydrochloride 5 ml
89272335|NCT05932485|No Intervention|Control|do nothing
89272336|NCT05932433|Experimental|Exercise|Exercise during 6 weeks, twice a week.
89272337|NCT05932433|No Intervention|Control|There is no intervention
89272338|NCT05932420|Placebo Comparator|Control group|Placebo is provided
89272339|NCT05932420|Experimental|Experimental groep|Ketone ester is provided
89272340|NCT05932407||Vortioxetine Tablet Treatment|Participants with depression who received Vortioxetine tablet treatment in accordance with package insert.
89272341|NCT05932407||SSRI Treatment|Participants with depression who received SSRI treatment in accordance with package insert.
89272342|NCT05932394|Experimental|Control group|In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered, recording its value as R0. The following day, at 9:00 a.m., another nurse uses the CAM-ICU scale, noting its value as R1. If postoperative delirium was detected during the day and night, the unit's usual treatment was followed: administration of haloperidol and/or dexmedetomidine.
89272343|NCT05932394|Active Comparator|Intervention group|In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered, recording its value as R0. At night, the projection of images provided by the patient are replaced by a nocturnal visual projection (night sky with stars and moon), ensuring that the patient is able to identify that it was nighttime. Finally, at 9:00 a.m., a nurse who had not worked at night and therefore did not know which patients had received the intervention, administers the CAM-ICU scale again, recording its value as R1.
89272344|NCT05932381|Experimental|Complete decongestive therapy|the patients will receive complete decongestive therapy twice a week for ten weeks
89272345|NCT05932381|Active Comparator|medical treatment|the patients will receive routine medical treatment for ten weeks
89272346|NCT05932316|Other|Salbutamol first|Individuals included in this arm will receive 4 puffs of Salbutamol prior to the second set of spirometry testing, and 4 puffs of Placebo prior to the third set of spirometry.
89272347|NCT05932316|Other|Placebo First|Individuals included in this arm will receive 4 puffs of placebo prior to the second set of spirometry testing and 4 puffs of Salbutamol prior to the third set of spirometry testing.
89272348|NCT05932277|Experimental|Cocktail Probe Substrates + BMS-986419|
89272349|NCT05932264|Experimental|Cohort 1: Apatinib + Fluzoparib|
89272350|NCT05932264|Experimental|Cohort 2: Apatinib + Fluzoparib + Adebrelimab|
89272351|NCT05932212|Experimental|AK104|AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
89272352|NCT05932186|Active Comparator|Interscalene block|Patients will receive inter scalene brachial plexus block combined with general anesthesia
89272353|NCT05932186|Active Comparator|Upper trunk block|Patients will receive upper trunk brachial plexus block combined with general anesthesia
89272354|NCT05932147|Experimental|Pilates group|This group includes 34 patients who have axillary web syndrome will receive Pilates exercise with traditional physical therapy exercise program (strength, core stability, flexibility, muscle control, posture and breathing). Patients will receive 3 sessions per week for 9 weeks; time of session is 30 minutes.
89272355|NCT05932147|Experimental|Manual lymphatic massage group|This group includes 34 patients who axillary web syndrome will receive Manual lymphatic drainage massage with traditional physical therapy exercise program (strength, core stability, flexibility, muscle control, posture and breathing). Patients will receive 3 sessions per week for 9 weeks; time of session is 30 minutes.
89272356|NCT05932134|No Intervention|Usual care|Usual care as RCC protocol in Chang Gung Memorial hospital
89272357|NCT05932134|Experimental|UC + high protein diet (HP)|The HP groups will maintain unchanged total daily caloric intake and increasing protein content to 1.5g/kg/day.
89272358|NCT05932134|Experimental|UC + HP + core muscle rehabilitation|Protein provision was not reduced in case of renal failure. Core muscle rehabilitation is sitting on bedside with or without aids, for 30 minutes, twice per day, 5 days per week, for 3 weeks.
89272359|NCT05932134|Experimental|UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES)|NMES was applied for 30 min, twice per day, 5 days per week, for 3 weeks via surface rectangular electrodes. Electrodes were placed on back designed to activate latissimus dorsi and abdominal wall designed to activate the transversus abdominis and internal and external oblique muscles. Electrical muscle stimulation was performed by using a commercial stimulator (GEMORE, GM300E, Taipei, Taiwan) with biphasic waves at a simulation frequency of 30 Hz and pulse width of 400s, cycling 2s on and 4s off. Electrical muscle stimulation intensity was gradually increased until a visible muscle contraction was observed (median 60 mA [range 50-65 mA].
89272360|NCT05932121||PTC patients underwent thyroid lobectomy via trans-axillary approach|Case: PTC patients underwent thyroid lobectomy via trans-axillary approach.
89272361|NCT05932121||PTC patients underwent thyroid lobectomy via open approach|Controls: PTC patients underwent thyroid lobectomy via open approach.
89272362|NCT05932095|Experimental|TCM Daoyin intervention group|Participants randomized to TCM Daoyin intervention group receive health education plus a TCM Daoyin training program. The TCM Daoyin training program was a 12-week, instructor-led group training program.
89272363|NCT05932095|Active Comparator|Health education control group|Participants randomized to the health education control group only receive health education and no additional training program.
89272364|NCT05932056|Experimental|Miles de Manos (Thousands of Hands) Intervention|"Parents and teachers from schools randomized to this arm will receive the Miles de Manos (Thousands of Hands) intervention. Miles de Manos (Thousands of Hands) comprises 3 components: a cognitive-behavioral skills training component for parents (8 sessions), a cognitive-behavioral skills training component for school staff (10 sessions), and a bridge component that brings parents, teachers, and school administrators together to talk about how to support each other's efforts related to youth violence prevention (4 sessions). Core elements include effective communication, clear expectations, limits and consequences, positive reinforcement, adult supervision and monitoring, effective problem solving, and emotion regulation. Miles de Manos (Thousands of Hands) is highly interactive and involves brief lectures, small and large group discussions, role-plays, and interactive exercises."
89272365|NCT05932056|No Intervention|Control|Parents and teachers from schools randomized to this arm will receive services as usual as provided by their schools.
89272366|NCT05932030|Other|patients and health professionals|The intervention is a survey administered to patients and health professional. The two questionnaires are identical, with only the socio-demographic section differing. The questionnaire is composed of closed questions, scale scores and short-answer questions.
89272367|NCT05932017||Patients receiving routine, pre-diagnosed, standard of care procedures.|Single cohort of patients receiving previously prescribed treatment. The only variable will be the modality of visualization utilized on each side of the mouth during the surgical procedure.
89272368|NCT05932004|Other|Reformer pilates group|Reformer pilates
89272369|NCT05932004|Other|Control group|intervention waiting group
89272370|NCT05931978|Experimental|CKD dashboard + Routine CKD care|Filled out PROMs before consultation and discussed the CKD consultation dashboard together with their clinician in the (already scheduled) routine care follow up consultation.
89272371|NCT05931978|No Intervention|Routine CKD care|In the period of the study PROMs and the dashboard are not yet implemented for this group of patients.
89272372|NCT05931926||Patients with adrenal insufficiency|10 patients with adrenal insufficiency due to pituitary desease will be recruited for this arm.
89272373|NCT05931926||Healthy controls|10 healthy controls will be recruited for this arm.
89272374|NCT05931848|Experimental|Otago exercise group|"The treatment program, which will last for 16 weeks, 3 days a week, a total of 48 sessions will be held. The program will be held one day a week with a maximum of 8 participants per group, under the supervision of a physiotherapist, in the Kadikoy Municipality Social Life Center, in the form of group exercise training, and two days a week at the participants' homes, with the implementation of the Otago Home Exercise Program non-supervised. Participants will be informed that the program should be implemented on non-consecutive days. All warm-up and strengthening exercises will be applied in combination with breathing. While the home exercise program is being taught to the patients, information will be given about the situations where the exercise is contraindicated and should be stopped.~Within the scope of group exercise training, it is planned to implement a structured program of approximately 45-60 minutes, including warm-up, strengthening, balance and cool-down exercises."
89272375|NCT05931848|No Intervention|control group|The control group will not be included in any exercise program, and they will be informed that they can participate in the same program after 16 weeks if they prefer. At the same time, a one-session training will be given to all participants of intervention and control groups at the Kadıköy Municipality Social Life Center, where information about the factors that increase the risk of falling and house arrangements will be provided.
89272376|NCT05931822|Active Comparator|Silver Diamine fluoride modified glass ionomer restoration|
89272377|NCT05931822|Active Comparator|fluoride varnish and glass ionomer restoration|
89272378|NCT05931757|Experimental|Treatment Group|The patients would be treated with Olverembatinib, Given PO, combined with Blinatumomab, Given intravenously
89272379|NCT05931744|Active Comparator|Oral steroid|patients given prednisone 1 mg/kg for 3 days then tapered by 5mg daily for two weeks
89272380|NCT05931744|Experimental|Budesonide Intrapolyp injection|patients given budesonide 0.5 mg/2ml intrapolyp injection once weekly for 5 consecutive weeks
89272381|NCT05931744|Placebo Comparator|Saline intrapolyp injection|patients given 2ml normal saline intrapolyp injection once weekly for 5 consecutive weeks
89272382|NCT05931731|Experimental|Mechanical interference|the patients will receive mechanical interference and conventional treatment three times a week for four weeks
89272383|NCT05931731|Experimental|Neural mobilization|the patients will receive neural mobilization and conventional treatment three times a week for four weeks
89272384|NCT05931731|Active Comparator|conventional treatment|the patients will receive conventional treatment only three times a week for four weeks
89272385|NCT05931705||High risk|
89272386|NCT05931679|Active Comparator|Interactive VR|a virtual classroom - learners wearing VR headsets in the safety of their home are immersed in a computer-generated simulation centre. Through their avatars, they can interact from a first-person perspective with their environment, colleagues and instructors. The virtual patient has been in a car accident and the learners, by interacting with the virtual trauma bay environment, must work together to perform a primary trauma survey and resuscitate the patient. The interactive VR environment provides the team with real time information (e.g. oxygen saturation levels, heart rate) in a realistic environment that includes the uncertainty, noise, and time pressures of a real case.
89272387|NCT05931679|Active Comparator|360 degree video|An immersive environment based on high-definition 360o video obtained from our simulation centre. Single learners, wearing a VR headset, find themselves in the resuscitation room, at the foot of the bed, leading a trauma team through the assessment and resuscitation of a patient in a virtual choose-your-own-adventure scenario. At several key points in the videos, learners are presented with interactive decision points, and their choices determine how the rest of the video unfolds.
89272388|NCT05931679|Active Comparator|Theatre-based education|Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
89272389|NCT05931640|Experimental|Virtual Reality|Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
89272390|NCT05931640|Experimental|Plyometric Training|Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
89272391|NCT05931614|Experimental|Unlimited fluid intake|Patients have no restrictions of fluid intake
89272392|NCT05931614|No Intervention|Restricted fluid intake|Patients have restrictions in fluid intake of 1500 ml/day
89272393|NCT05931588|Experimental|Pilates exercises, streching and breathing|the intervention Pilates exercises, streching and breathing exercises is administered under supervision
89272394|NCT05931588|Experimental|streching and breathing|home based exercise program which is streching and breathing.
89272395|NCT05931562|Active Comparator|Control|Participants will recieve dietary education based on the healthy eating guidleines provided by the Health Service Executive (HSE).
89272396|NCT05931562|Experimental|Fermented Foods|Fermented foods diet (4-6 portions/day)
89272397|NCT05931562|Experimental|High Fibre|High fibre diet (24-35 grams/day)
89272398|NCT05931562|Experimental|Combined Diet|Combined diet high in fibre and fermented foods (fibre aim 24-35 grams/day, fermented foods aim 4-6 portions/day)
89272399|NCT05931536||Low fibre consumers|Healthy adults consuming less than or equal to 18 grams of fibre per day.
89272400|NCT05931536||Moderate fibre consumers|Healthy adults consuming between 18.1-24.9 grams of fibre per day.
89272401|NCT05931536||High fibre consumers|Healthy adults consuming greater than or equal to 25 grams of fibre per day.
89272402|NCT05931510|Experimental|Group A|Myofascial release
89272403|NCT05931510|Experimental|Group B|Post isometric relaxation
89272404|NCT05931458|Active Comparator|Group 1|Infliximab
89272405|NCT05931458|Experimental|Group 2|Appendectomy
89272406|NCT05931445|Experimental|Monitoring group|ePRO monitoring will be conducted once weekly after study enrollment, along with standard care of treatment.
89272407|NCT05931445|No Intervention|Non-monitoring group|Standard care of treatment will be given without ePRO monitoring.
89272408|NCT05931354||CIN_Group|Those with a previous history of cervical cancer or CIN before incident VaIN and those with VaIN detected concomitantly with cervical cancer or CIN for whom both vaginal biopsy and cervical specimens were available in our hospital were eligible.
89272409|NCT05931328|Experimental|thiotepa+pomalidomide|thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
89272410|NCT05931263|Experimental|C-BEAM|Chidemide，carmustine, etoposide, cytarabine, and melphalan plus autologous stem cell transplantation
89272411|NCT05931263|Sham Comparator|BEAM|carmustine, etoposide, cytarabine, and melphalan plus autologous stem cell transplantation
89272412|NCT05931250|Experimental|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) device using 50x70 mm electrodes that are placed bilaterally between EEG coordinates C3/C5 for left hemisphere and C4/C6 for right hemisphere (corresponding to S1 and M1 of the eye). The alternating current electrodes are in-phase and have the same peak to peak stimulation 3mA, for 30 minutes duration at 10Hz. An impedance value under 15 ohms is required at all times to ensure patient comfort and safety.
89272413|NCT05931250|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) device using 50x70 mm electrodes that has the anodal electrode placed contralateral to most prominent ocular pain or, in the case of bilateral pain symptoms, contralateral to the dominant hand between EEG coordinates C3/C5 for left hemisphere and C4/C6 for right hemisphere (corresponding to S1 and M1 of the eye), and the cathode placed on the patient's upper arm. A current peaking at 3mA will ramp up for 20 secs and be delivered for a total of 20 minutes, thereafter, ramping down for 20s. An impedance value under 15 ohms is required at all times to ensure patient comfort and safety.
89272414|NCT05931237|Experimental|Cranberry extract capsules (PREBIOCRAN(TM))|Cranberry extract capsules consumed twice a day providing 82.3 mg of flavan-3-ols daily.
89272415|NCT05931224|Experimental|Experimental Group|
89272416|NCT05931224|Experimental|Comparator Group|
89272417|NCT05931198|Experimental|Upper limb amputee population|
89272418|NCT05931055||ovarian cancer group|patients confirmed with ovarian cancer
89272419|NCT05931055||ovarian cyst group|patients confirmed with benign ovarian csyt
89272420|NCT05931042||Group recieving Trastuzumab + Chemotherapy|Two different treatment regimens of Trastuzumab were giving in the 9 studies Dosage of trastuzumab was 4 mg/kg loading dose followed by 2 mg/kg every 3 weeks in four clinical trials included in this systematic review Dosage of trastuzumab was 8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks in five clinical trials included in this systematic review The different chemotherapeutic agents given included Paclitaxel, docetaxel, fluorouracil, epirubicin, carboplatin, cyclophosphamide, methotrexate, and fluorouracil.
89272421|NCT05931042||Group receiving chemotherapy|Different neoadjuvant chemotherapy regimens were given in the nine clinical trials included in this systematic review. The different chemotherapeutic agents given included Paclitaxel, docetaxel, fluorouracil, epirubicin, carboplatin, cyclophosphamide, methotrexate, and fluorouracil.
89272422|NCT05931029||The control group|The control group received Idebenone orally, at a dose of 30mg per time, three times a day, after meals for 12 consecutive weeks.
89272423|NCT05931029||The treatmen group|The treatment group received Naohuan Dan combined with Idebenone. At a dose of one per day, delivered with warm water in the morning and evening, and taken orally for 12 consecutive weeks.
89272424|NCT05930990|Experimental|Mamas in Harmony (and usual care)|Mamas in Harmony is a 1 hour face to face intervention for mothers and their infants, delivered in groups of 10-12 mother-infant dyads, every week for 8 weeks. Mothers and infants also receive usual postnatal care from health and social care services.
89272425|NCT05930990|No Intervention|Control (usual care only)|Mothers and infants receive usual postnatal care from health and social care services.
89272426|NCT05930977||patient undergone total thyroidectomy followed by thyroid auto transplantation|
89272427|NCT05930912||Participant Case|The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.
89272428|NCT05930873|Experimental|experimental group|treatment within an immersive room
89272429|NCT05930873|Placebo Comparator|control group|Traditional Treatment by presenting image stimuli in a paper format
89272430|NCT05930847|Experimental|Digital game group|In addition to routine drug use, children of the digital game group were followed up with 15 sessions of 15 minutes of digital games for respiratory training.
89272431|NCT05930847|Active Comparator|Routine medical treatment group|The children continued their current asthma treatment in the same way. They did not receive any extra treatment.
89272432|NCT05930821|Experimental|Aerobic and Resistance Exercise Program (GEMS program)|This intervention condition will deliver the Guidelines for Exercise in Multiple Sclerosis (GEMS) program. Participants in this condition will receive a 16-week home-based, remotely supported aerobic and resistance exercise training intervention.
89272433|NCT05930821|Active Comparator|Flexibility and Stretching Program (FLEX-MS program)|Participants in this condition will receive a 16-week home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.
89272434|NCT05930795|Active Comparator|Patients with pelvic organ prolapse undergone pectopexy surgery|
89272435|NCT05930795|Active Comparator|Patients with pelvic organ prolapse undergone lateral suspension surgery|
88805535|NCT01043939|Active Comparator|Apple Juice First|After 4 week run-in period, drink 6 ounces of clear apple juice twice daily, then 4 week washout, week 12 drink 6 ounces of purple grape juice for 4 weeks twice daily
88805536|NCT01899482|Experimental|Manual Lymphatic Drainage|One educational session in group, and 10 individual sessions of manual lymphatic drainage in lower extremity, during approximately one month.
88805537|NCT01899482|Active Comparator|Control|One educational session in group.
89272436|NCT05930769||Case group|Patients that have undergone laparoscopy, with surgical indication of myomectomy or adenomyomectomy, with augmented reality (AR).
89272437|NCT05930769||Control group|Patients that have undergone laparoscopy, with surgical indication of myomectomy or adenomyomectomy, without augmented reality (AR).
89272438|NCT05930652||Young adults|The population of Polish Students, who graduated from high schools/ passed leaving exams, started university studies between 2020 and 2023, and were living in Poland during this period (2020-2023: COVID-19, lockdown, economic crisis, political changes, climate changes, and the war in Ukraine).
89272439|NCT05930639|Experimental|Surgical Site Infection (SSI) prevention package; Identification of risk factors|"Risk factors of the individual created in line with the literature; Advanced age, history of skin or soft tissue infection, DM, alcohol addiction, smoking, preoperative albumin <3.5 mg/dl, total bilirubin>1.0 mg/dl, immunosuppression, long postoperative stay, long preoperative stay, high BMI,ASA score > II,preoperative low Hgb level.~Risk factors associated with the surgical procedure; Presence of drain, prolongation of surgery time, preoperative skin preparation, blood transfusion, non-sterile equipment, insufficient ventilation, heavy operating room traffic, insufficient hemostasis.~Participants will be evaluated in terms of these risks."
89272440|NCT05930639|Experimental|Surgical Site Infection (SSI) prevention package; Antibiotic prophylaxis|determined antibiotic (active ingredient: imipenem cilastatin sodium)
89272441|NCT05930639|Experimental|Surgical Site Infection (SSI) prevention package;achieving and maintaining normothermia|Body temperature will be recorded with an infrared thermometer. The patient will be warmed with various passive heating techniques before and after the operation. To prevent hypothermia, the operating room ambient temperature will be kept in the range of 23-26°C.
89272442|NCT05930639|Experimental|Surgical Site Infection (SSI) prevention package; maintenance of normoglycemia|In the 2017 guidelines, perioperative glycemic control with a blood glucose level of <200 mg/dL is recommended for patients with and without DM. Ideal blood glucose control should provide good glycemic control with a minimal incidence of hypoglycemia.
89272443|NCT05930639|Experimental|Surgical Site Infection (SSI) prevention package;patient education|SSI definition, SSI signs and symptoms, Hand hygiene, smoking, hair removal in the operation area, shower and bath before surgery. Conditions that require hospitalization, factors affecting wound healing, wound care, control time and who should be contacted will be discussed.
89272444|NCT05930639|No Intervention|control group|"Antibiotic prophylaxis is applied to both groups. In the clinic where the study will be conducted, the blood glucose level of patients with a diagnosis of DM is controlled (5 measurements per day). All patients are fasted after 21.00 in the evening. The blood glucose levels of patients without a diagnosis of DM are not routinely checked. The body temperature of the patients is not monitored intraoperatively. No extra intervention is applied to maintain normothermia in the clinic and operating room.~There is no training on prevention of infection. There is no intervention in the control group."
89272445|NCT05930626||SMC-C|Swedish Mammography Cohort-clinical (SMC-C) is a clinical sub-cohort established between 2003 and 2008, consisting of 5022 women, 56-80 years of age, living in Uppsala. These women have completed a detailed questionnaire on diet and lifestyle factors and underwent a health examination, dual-energy X-ray absorptiometry and biological sampling.
89272446|NCT05930626||60YO|The cohort of 60-years olds (60YO) was established with the aim to study CVD etiology and consists of 4,232 men and women aged 60 years who were randomly selected from Stockholm County and with baseline examination during 1 year in 1997-98. The study participants underwent a health examination, completed a questionnaire, and donated blood samples.
89272447|NCT05930548|Active Comparator|Resin modified glass ionomer|RMGI is recommended to restore carious cervical lesions; especially with its ability to inhibit secondary caries due to its fluoride releasing ability. The main advantage of RMGI is its capability to chemically bond to tooth structure, even in the presence of moist dentin. RMGI reaction can be achieved by both acid-base reaction (induced by glass ionomer component) and polymerization reaction (induced by resin component). Thus, RMGI has better mechanical properties, wear resistance, and improved esthetics compared with conventional glass ionomer (AlQranei MS et al, 2021). In addition, the coefficient of thermal expansion of glass ionomer which is similar to that of tooth structure, allows for proper marginal adaptation without marginal leakage (Bollu IP et al, 2016).
89272448|NCT05930548|Experimental|Low shrinkage giomer|Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
89272449|NCT05930470|Sham Comparator|Delayed intervention|Sham treatment first, then Magnetic Mitohormesis Therapy treatment
89272450|NCT05930470|Experimental|Immediate intervention|Magnetic Mitohormesis Therapy treatment first, then Sham treatment
89272451|NCT05930392|Active Comparator|GINGIVAL DEPIGMENTATION USING MICROSURGERY|Surgical excision of hyper-pigmented gingival tissue using microsurgical blade (keratome 2.2) and magnification loupes under local anaesthesia. Application of periodontal dressing followed by post-operative instructions.
89272452|NCT05930392|Active Comparator|Conventional surgical technique of gingival depigmentation|Surgical excision of hyper-pigmented gingival tissue using conventional surgical blade (#15) under local anaesthesia. Application of periodontal dressing followed by post-operative instructions.
89272453|NCT05930899||CVD Group|CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.
89272454|NCT05930899||Control Group|"control groups will be defined as:~No echocardiographic evidence of AS (or any aortic valve abnormality) and~60 years of age"
88805538|NCT03013907|Experimental|UPLIFT|Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
89272455|NCT05930379|Experimental|LSVT-Loud delivered by telerehabilitation|F - Frequency: 7 times/week for 4 weeks according to a mixed model (4 days of synchronous sessions followed by independent practice + 3 asynchronous sessions); I - Intensity: sessions customized according to the patient's functional abilities to ensure the progression of difficulty in rehabilitation sessions; T- Time: each synchronous session will last about 60 minutes, each independent practice will last about 5-10 minutes, and each asynchronous session will last about 30 minutes; T- Type: Individual speech therapy sessions with the Lee Silverman Voice Treatment-Loud method delivered by telerehabilitation.
89272456|NCT05930379|Active Comparator|LSVT-Loud in the clinic|"The frequency, intensity, time of the rehabilitation sessions will be the same as the experimental group.~T- Type: Individual speech therapy sessions with the Lee Silverman Voice Treatment-Loud method delivered in the clinic."
89272457|NCT05930366|Active Comparator|Gingival depigmentation using microsurgery|Surgical excision of hyper-pigmented gingival tissue using microsurgical blade (keratome 2.2) and magnification loupes under local anaesthesia.
89272458|NCT05930366|Active Comparator|Gingival Depigmentation using Diode Laser|Ablation of hyper-pigmented gingival tissue using Diode Laser under local anaesthesia.
89272459|NCT05930314|Experimental|CNCT19 cell injetion|CNCT19 administration：0.25 to 0.5 x 10^8 CAR-positive viable
89272460|NCT05930301||single|Mode of administration：IV Administration dosage：10^7/100ml Dosing frequency：Every three weeks
89272461|NCT05930262|Experimental|the intervention group|TCM acupuncture therapy Conventional drug therapy Rehabilitation therapy Breathing training
89272462|NCT05930262|Active Comparator|the control group|Conventional drug therapy Rehabilitation therapy Breathing training
89272463|NCT05930249|No Intervention|Standard health counseling|
89272464|NCT05930249|Experimental|Personalized multidomain intervention|
89272465|NCT05930236|Experimental|ultrasound guided infiltration verified by fluoroscopy|The 22G needle is introduced along a caudal-cranial axis to infiltrate at each level a volume of 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol (Methylprednisolone) 40mg with 1mL of Omnipaque (contrast product). At each level, contrast medium will be injected at the same time as the linisol-depomedrol mixture so that once the BBM under ultrasound is completed, an X-ray check is performed.
89272466|NCT05930184|Active Comparator|local wound infiltration|0.25% Bupivacaine 20ml was injected into the wound subcutaneous tissue after the laparoscopic port was removed
89272467|NCT05930184|Experimental|peri-wound Transversus Abdominis Plane Block|0.25% Bupivacaine 20ml was injected into the transversus abdominis plane around the wound before the laparoscopic port was removed
89272468|NCT05930132|Other|classic lateral lamellectomy|"Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period."
89272469|NCT05930132|Other|submucosal conchoplasty|Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
89272470|NCT05930080|Experimental|SKCPT group|
89272471|NCT05930080|Active Comparator|Celebrex group|
89272472|NCT05930054|Other|tooth-bone-borne (TBB) group|The TBB appliance was composed of a central expansion jackscrew (Dentarum), 4 tubes, 2 bands on the upper first molars to facilitate placement of the appliance, and 1.5-mm diameter stainless steel arms extending to the premolar teeth. Soldered stainless steel tubes (internal diameter: 2.0 mm; external diameter: 3.0 mm; length: 2.0 mm) served as guides for miniscrew placement. The size of the screws (PSM) was chosen as 1.8 mm in diameter and 11 mm in length, considering the 2 mm height of the tubes, 1 to 2 mm gap between the appliance and the palate surface, 1 to 2 mm gingiva thickness, and 5 to 6 mm length required for the bicortical placement of the screw in the bone.
89272473|NCT05930054|Other|bone-borne (BB) group|The BB appliance was composed of a central expansion jackscrew, 4 tubes as described in TBB group, and less acrylic used around it to adjust its position. In order to carry it to the mouth after preparation on the cast model, essix was used, which also included the patient's teeth
89272474|NCT05930015|Experimental|Music intervention only|Music only (the fast tempo of 120-130 bpm music will be selected) The effect was achieved by playing music selected by the researchers during originally physical education classes in school.
89272475|NCT05930015|Experimental|Sports games intervention only|Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice.
89272476|NCT05930015|Experimental|Music and sports games intervention|Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class.
89272477|NCT05930002|Active Comparator|Ivermectin group|received standard treatment plus Ivermectin in the form of oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days
89272478|NCT05930002|Active Comparator|Colchicine group|received standard treatment plus Colchicine 0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
89272479|NCT05930002|Active Comparator|Control group|received the standard treatment according to the protocol of the Egyptian Supreme Council of University Hospitals (http://scu.eg/pages/university_hospitals) (Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks and needed protocol of management according to case assessment and severity)
89272480|NCT05929989||active disease|
89272481|NCT05929989||control|
89272482|NCT05929963||HCV Ab(+）HCVRNA（-）|HCV Ab（+） HCVRNA(-) in pregnant women
89272483|NCT05929963||HCV Ab(+）HCVRNA（+）|HCV Ab(+）HCVRNA（+）in pregnant women
89272484|NCT05929963||HCVAb(-) HCVRNA(-)|HCV Ab(-）HCVRNA（-）in pregnant women
89272485|NCT05929599|Placebo Comparator|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment is as follows:~Treatment medications: antipyretic paracetamol, antibiotics following the treatment protocol for community-acquired pneumonia in children by the Ministry of Health, and antibiotics with susceptibility results, such as Amoxicillin, Augmentin, or Benzylpenicillin. In cases of severe pneumonia, the following antibiotics may be used: Benzylpenicillin + Gentamicin; Cephalosporins (Cefotaxime, Ceftriaxone) + Amikacin; Oxacillin, Bristopen, Vancomycin if Staphylococcal pneumonia is suspected.~Oxygen therapy: Indicated for all cases of severe pneumonia when SpO2 <92%. Use an oxygen mask or nasal cannula."
89272486|NCT05929599|Experimental|Navax|"Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion CFU/5 mL (LiveSpo®️ Navax):~Routine treatment is as follows:~Treatment medications: antipyretic paracetamol, antibiotics following the treatment protocol for community-acquired pneumonia in children by the Ministry of Health, and antibiotics with susceptibility results, such as Amoxicillin, Augmentin, or Benzylpenicillin. In cases of severe pneumonia, the following antibiotics may be used: Benzylpenicillin + Gentamicin; Cephalosporins (Cefotaxime, Ceftriaxone) + Amikacin; Oxacillin, Bristopen, Vancomycin if Staphylococcal pneumonia is suspected.~Oxygen therapy: Indicated for all cases of severe pneumonia when SpO2 <92%. Use an oxygen mask or nasal cannula."
89272487|NCT05929092|Experimental|40 patients with malignant hematological diseases who underwent UCBT|
89272488|NCT05928923|Experimental|cpap|usage cpap 3 months
89272489|NCT05928923|No Intervention|Usual care|Usual care 3smonths
89272490|NCT05928897|Experimental|Disitamab Vedotin Combined With Sintilimab|Disitamab Vedotin (2.5mg/kg, ivgtt, Q3W) Combined With Sintilimab (200mg, ivgtt, Q3W) untill diseases progress
89272491|NCT05928663|Experimental|double surgical gloves|
89272492|NCT05928663|Other|single surgical gloves|
89272493|NCT05928494|Experimental|İntervention group (n:39)|Postpartum care applications were carried out with the high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the midwifery department to the students in the intervention group.
89272494|NCT05928494|No Intervention|Control group (n:39)|Postpartum care practices were performed on the standard adult patient model in the basic skills laboratory of the midwifery department for the students in the control group.
89272495|NCT05928195|Experimental|Moderate-Dose Guayusa Extract|Acute, single dose of 600 mg Organic Guayusa Extract
89272496|NCT05928195|Experimental|High-Dose Guayusa Extract|Acute, single dose of 1200 mg Organic Guayusa Extract
89272497|NCT05928195|Placebo Comparator|Placebo|Acute, single dose of Placebo (dextrose)
89272498|NCT05925894|Active Comparator|Group 1: Mydriatic Eyedrops|Group 1 patients included instillation of one drop each of tropicamide 0.5% and phenylephrine 10% ( VISUMIDRIATIC FENILEFRINA) at 30, 20, and 10 min prior to surgery.
89272499|NCT05925894|Experimental|Group 2: Insert Device Mydriasert®|Group 2 patients had the Mydriasert® (Phenylephrine Hydrochloride,Tropicamide) device placed in the inferior conjunctival sac at least 1 h before surgery
89272500|NCT05925894|Experimental|Group 3: Intracameral Anesthesia Mydrane®|Group 3 patients received 0.2 mL intracameral Mydrane®(0.2 mg/ml + 3.1 mg/ml + 10 mg/ml tropicamide, lidocaine hydrochloride, phenylephrine hydrochloride) immediately following the clear corneal incision; the surgeon allowed 45-60 s for adequate pupil dilation before performing continuous curvilinear capsulorhexis (CCC)
89272501|NCT05924867|Experimental|Intervention group|"The wounds of participants in the postoperative incision infection group and ulcer infection group will be given plasma activated saline irrigation (100 ml plasma activated saline for every 10 cm2 wound), drainage, and wet compress. The wounds of participants in the fat liquefaction group will be uniformly rinsed with plasma saline for 5-10 min to clean the incision, then drained and suction with negative pressure.~The researchers will determine the dressing change time according to the size of the patient's wound and the number of secretions, starting every day or every other day, and waiting for the incision to be fresh or less secretions at an interval of 2-3 days."
89272502|NCT05924867|Active Comparator|Control group|"The wounds of participants in the postoperative incision infection group and ulcer infection group will receive routine dressing change treatment, namely cleaning with chlorhexidine disinfectant (100 ml chlorhexidine disinfectant for every 10 cm2 wound area), drainage, bandaging. The wounds of participants in the fat liquefaction group will be receive conventional treatment, namely negative pressure sputum aspiration.~The researchers will determine the dressing change time according to the size of the patient's wound and the number of secretions, starting every day or every other day, and waiting for the incision to be fresh or less secretions at an interval of 2-3 days."
89272503|NCT05924620|Experimental|Patients with PA using finerenone|Patients with PA divided into this group need to take finerenone for 60 days (20mg qd)
89272504|NCT05924620|No Intervention|Patients with PA using spironolactone|Patients with PA divided into this group need to take spironolactone for 60 days (20mg qd)
89272505|NCT05924282||Sole PET group|Tumor recurrence was detected solely by PET; the surgery was performed and the extent of the resection was guided by the PET.
89272506|NCT05924282||Combined CT/MRI plus PET group|Tumor recurrence was detected by computed tomography (CT) / magnetic resonance imaging (MRI) and PET; the surgery was performed and the extent of the resection was guided by the CT/MRI+PET.
89272507|NCT05924282||Control group|Tumor recurrence was detected but no surgery was performed.
89272508|NCT05924269||Cardiac Surgery|Patients undergoing cardiac surgery
89272509|NCT05921006|Experimental|RJ4287 Tablets|single-dose or Multiple-doses, ascending dosing groups (cohorts) will be evaluated
89272510|NCT05921006|Placebo Comparator|Placebo|Single or multiple doses of Placebo
89272511|NCT05915351|Experimental|Treatment|Enfortumab vedotin, 1.25 mg/kg IV on D 1,8,15 every 28 days
89272512|NCT05913024|Experimental|Enterovirus Type 71 Vaccine,Inactivated(Vero Cells),high dose|Participants received two doses of the vaccine, 28 days apart
89272513|NCT05913024|Experimental|Enterovirus Type 71 Vaccine,Inactivated(Vero Cells),low dose|Participants received two doses of the vaccine, 28 days apart
89272514|NCT05913024|Active Comparator|Enterovirus Type 71 Vaccine,Inactivated(Human Diploid Cell)|Participants received two doses of the vaccine, 28 days apart
89272515|NCT05910073||Lamina curved plate|Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
89272516|NCT05909657||Sickle Cell Disease patients = or > 18 years in Jamaica|surveys, interviews
89272517|NCT05909657||Adult Caregivers of Sickle Cell Disease Children/Adolescents under 18 years|surveys, interviews
89272518|NCT05909657||Healthcare Providers: SCD Physicians, Nurses and Pharmacists|surveys and interviews
89272519|NCT05909618|Experimental|Cohort 1 metastatic melanoma with brain metastases who failed immunotherapy|The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression The subsequent 8 patients will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression
89272520|NCT05909618|Experimental|Cohort 2 - Patients with recurrent or progressing GB following radiation and temozolamide.|The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression The subsequent 8 patients will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression
89272521|NCT05909618|Experimental|Cohort 3: Patients with newly diagnosed GB|crizanlizumab starting from 4 weeks after completing radiation therapy. The first 2 subjects will receive crizanlizumab 2.5 mg/kg at C1D1 and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks. The subsequent 6 subjects will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by crizanlizumab every 4 weeks. Treatment will continue for up to 12 months or until disease progression or unacceptable toxicity.
89272522|NCT05905263|Experimental|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are in the application, the interface will be introduced through the images projected to the computer simultaneously.
89272523|NCT05902884|Other|Patients|Patients with FSHD
89272524|NCT05902884|Other|Controls|Healthy volunteers
89272525|NCT05902117|Experimental|Troponin and Copeptin assay|Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
89272526|NCT05900180|Active Comparator|Every-other-week therapy with home programming|Receipt of standard speech therapy care (every-other-week) for 8.0 sessions
89272527|NCT05900180|Experimental|Weekly therapy with home programming|Receipt of speech therapy care (every week) for 8.0 sessions
89272528|NCT05899010|Active Comparator|Vaginal progesterone 600mg|Vaginal progesterone 600mg daily (200mg tid) will be started and maintained until 10 weeks of pregnancy or either up to menses or up to negative pregnancy test performed 10 days after ET
89272529|NCT05899010|Experimental|Vaginal progesterone 800mg|Vaginal progesterone 800mg daily (400mg bid) will be started and maintained until 10 weeks of pregnancy or either up to menses or up to negative pregnancy test performed 10 days after ET.
89272530|NCT05898906||Children with special needs Group|Children who have diagnosed neurodevelopment disorders including cerebral palsy, autism spectrum disorder,
89272531|NCT05898906||Control Group|Typically developing children
89272532|NCT05897437||ADHD group|Children with ADHD
89272533|NCT05897437||Control Group|Typically developing children
89272534|NCT05896085|Experimental|REThink game|Participants will complete the online standardized scales and then complete the REThink therapeutic game's assessment system in 3D or VR version.
89272535|NCT05895890||Cohorte|The study will include a population of patients with excessive alcohol consumption seen in consultation or hospitalized for alcohol addiction problems and/or exploration of alcohol-related liver damage
89272536|NCT05894473|Active Comparator|Motor-Motor Dual Task Physical Exercises|Motor-Motor Dual Task Physical Exercises will be given to the participants
89272537|NCT05894473|Active Comparator|Cognitive-Motor Dual Task Physical Exercises|Cognitive-Motor Dual Task Physical Exercises will be given to the participants
89272538|NCT05894473|Active Comparator|Physical exercise|Physical exercise will be given to the participants
89272539|NCT05888064||Prospective non-invasive MRI acquisitions are planned to be performed|Prospective non-invasive MRI acquisitions are planned to be performed
89272540|NCT05888064||retrospective group|patients treated for skull base chordoma with particle therapy
89272541|NCT05885958|Experimental|Immediate|Patients will be given up to 30 minutes to void during the active void trial postoperatively.
89272542|NCT05885958|Experimental|Extended|Patients will be given up to 60 minutes to void during the active void trial postoperatively.
89272543|NCT05885217||group 1|mild form of acne vulgaris
89272544|NCT05885217||group2|moderate form of acne vulgaris
89272545|NCT05885217||group 3|severe form of acne vulgaris
89272546|NCT05885217||group 4|control group
89272547|NCT05878912|Experimental|Diet|Diet intervention (in addition to standard clinical care)
89272548|NCT05878912|No Intervention|Control|Standard clinical care only
89272549|NCT05877573|Experimental|short-course radiotherapy plus chemotherapy and immunotherapy|A total of 53 patients receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 2 cycles of CAPOX chemotherapy.
89272550|NCT05875649||Group|Acute myeloid leukemia patients with first-induction failure
89272551|NCT05872542|Experimental|Silver Diamine Fluoride (SDF)|SDF will be applied once to affected carious teeth surfaces at the end of the first visit. Under proper isolation, only gross debris will be removed and SDF will be applied directly to the carious lesion using micro brush according to the manufacturer's instructions.
89272552|NCT05872542|Active Comparator|Glass ionomer restoration (GI)|GI will be applied to carious lesions following the manufacturer's instructions.
89272553|NCT05872542|Active Comparator|Sodium Fluoride varnish with silver nano-particles (NaF-AgNP)|NaF-AgNP will be applied once to affected carious teeth surfaces at the end of the first visit. Under proper isolation, only gross debris will be removed and NaF-AgNP will be applied directly to the carious lesion using micro brush according to the manufacturer's instructions.
89272554|NCT05870709||sacubitril/valsartan|patient with a first ambulatory sacubitril/valsartan prescription
89272555|NCT05870514|Experimental|Fospropofol disodium for injection|Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
89272556|NCT05870514|Active Comparator|Propofol|Patients in the active comparator group received propofol at an initial infusion rate of 3 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
89272557|NCT05867862|No Intervention|Conventional dental care|The instructions regarding OH given to the children and their parents will be the same than the one usually given by the maxilla-facial surgeons or the orthodontists during their annual follow-up visits. If the patients are in need of dental care, they will be encouraged to contact their dentist.
89272558|NCT05867862|Experimental|Oral hygiene improvement|"A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist. During this consultation the children will be incited to have a better OH, oral and written explanations will be provided. The goal is to have the best understanding of the importance of a good OH and brushing technique from the children and the parents.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months, in order to try and keep the child and parent motivation to a maximum and also assess the OH of the patient."
89272559|NCT05866913|Placebo Comparator|Control group|Passive shoulder mobilizations for 90 seconds.
89272560|NCT05866913|Experimental|Experimental group 1|Sciatic nerve glide in a seated slump position for 90 seconds.
89272561|NCT05866913|Experimental|Experimental group 2|Passive stretching of the hamstring muscles with straight leg raising for 90 seconds.
89272562|NCT05859880|Experimental|Active intervention|Participants will attend four group-based expressive writing sessions led by a trained facilitator. All sessions will be delivered via videoconference. Sessions will occur weekly over the course of 4 consecutive weeks and will not exceed 60 minutes in length. Each session will include a 15- to 20-minute writing stint whereby participants are asked to write about their deepest thoughts and feelings regarding their loved one's cancer and their role as caregiver. All participants will be given a Rocketbook for this purpose, a spiral notebook that has the look and feel of a standard paper notebook but uses a pen with erasable ink. The writing stint will be followed by a group discussion; participants will be invited to share what they wrote about (if so desired) and their reactions to the writing process. Each session will end with a debriefing and erasure of the writing content just created. This will ensure privacy of the material and may be perceived as cleansing.
89272563|NCT05859880|Placebo Comparator|Waitlist control|Procedures are exactly the same as for the experimental arm but delayed.
89272564|NCT05858385||Severe RTOM|The oral evaluation of all patients was conducted by the same senior dentist, who evaluated the oral mucosal radiation toxicity weekly at baseline (before RT) and after RT, and performed RTOM scores.RTOM is classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0). RTOM is divided into four levels: 0 (no oral mucosal inflammation), I (mucosal erythema), II (mucosal pseudomembranous reaction, plaque ≤ 1.5cm, discontinuous) Level III (fusion pseudomembrane reaction, continuous plaque diameter>1.5cm), Level IV (necrosis or deep ulcer or accompanied bleeding, excluding bleeding caused by trauma), among which RTOM above level III is classified as severe RTOM.
89272565|NCT05858385||Non Severe RTOM|The oral evaluation of all patients was conducted by the same senior dentist, who evaluated the oral mucosal radiation toxicity weekly at baseline (before RT) and after RT, and performed RTOM scores.RTOM is classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0) . RTOM is divided into four levels: 0 (no oral mucositis), I (mucosal erythema), II (mucosal pseudomembranous reaction, plaque ≤ 1.5cm, discontinuous) Grade III (fusion pseudomembrane reaction, continuous plaque diameter>1.5cm), Grade IV (necrosis or deep ulcer or accompanied bleeding, excluding bleeding caused by trauma), of which Grade I and II are non severe RTOM.
89272566|NCT05854719|No Intervention|Normally hearing children|No intervention, only initial testing (normal-hearing controls).
89272567|NCT05854719|Experimental|Children with hearing impairment/loss with intervention|These children participate in speechreading training for two months at home.
89272568|NCT05854719|No Intervention|Children with hearing impairment/loss with no intervention|These children will serve as controls for two months with no speechreading training.
89272569|NCT05851911||Control group 1|Mother not vaccinated with COVID-19 vaccine
89272570|NCT05851911||Control group 2|The mother was vaccinated with COVID-19 vaccine before pregnancy, and was not infected during pregnancy
89272571|NCT05851911||Control group 3|The mother was vaccinated with COVID-19 vaccine before pregnancy, and was infected during pregnancy
89272572|NCT05851911||Experimental group|The mother was not vaccinated with COVID-19 vaccine before pregnancy, so she was infected during pregnancy
89272573|NCT05851794|Active Comparator|endomanometric laparoscopic Nissen fundoplication|use endomanometry and endoscope during laparoscopic Nissen fundoplication
89272574|NCT05851794|Active Comparator|laparoscopic Nissen fundoplication alone|laparoscopic Nissen fundoplication only
89272575|NCT05851560|No Intervention|Control|control group that does not use antiadhesive material
89272576|NCT05851560|Experimental|Oxidized regenerated cellulose(ORC) Group|The group that uses Oxidized regenerated cellulose(ORC) as antiadhesive material during thyroid surgery.
89272577|NCT05851560|Experimental|Hyaluronic acid(HA) Group|The group that uses Hyaluronic acid(HA) as antiadhesive material during thyroid surgery.
88805539|NCT03013907|Active Comparator|Usual Care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
89272578|NCT05850923|Experimental|a speech competition experimental group|The speech competition training was arranged twice a day, each lasting 15 minutes. The training included word search in sequence, word search out of order and word sorting. Patients need to follow the instructions in time for training. The reaction time, accuracy rate and the number of auditory hallucinations during the task were recorded.
89272579|NCT05850923|Active Comparator|Control group|The patient will listen to the soothing music twice a day, each lasting 15 minutes.
89272580|NCT05847894||Test group|Individuals with one or more pulmonary diseases
89272581|NCT05847894||Control group|Individuals who do not suffer from pulmonary diseases
89272582|NCT05838963||Study Participants|This group will consist of at least 200 patients with carpal tunnel syndrome who are undergoing nonsurgical management. Participants will complete the CTQ-SSS and other functional measures at baseline, 3 months, 6 months, and 12 months. The primary outcome will be progression to carpal tunnel release (CTR) surgery. Logistic regression models will be used to assess the predictive value of baseline CTQ-SSS scores for progression to CTR surgery, adjusting for potential confounding factors such as age, sex, and baseline symptom severity. The results of this study can help clinicians identify patients who may benefit from early surgical intervention.
89272583|NCT05835869|Experimental|Study population|
89272584|NCT05835193||Study Group|Pre-school students in Alexandroupolis, Greece
89272585|NCT05833516||Hyperadducted Right Radial Arm (HARRA)|The primary operators will wear real time radiation dose monitoring at the left eye, right eye, thorax and abdomen level. At the end of each diagnostic procedure the cumulative radiation dose (measured in µSv) data at each level will be collected. The radiation dose exposure in patients randomized to hyperadducted right radial arm will be recorded for primary outcome.
89272586|NCT05833516||Left Arm Drag over technique|The primary operators will wear real time radiation dose monitoring at the left eye, right eye, thorax and abdomen level. At the end of each diagnostic procedure the cumulative radiation dose (measured in µSv) data at each level will be collected. The radiation dose exposure in patients randomized to Left Arm drag over technique will be recorded for primary outcome.
89272587|NCT05830656|Experimental|Control, Then exposure to nearby nature, Then exposure to virtual nature|During the first week, the participants continue their normal routine at work and in leisure time. On the second week, the participants visit a nearby natural area after finishing their workday on three days (Tuesday, Wednesday, and Thursday). On the third week, the participants watch virtual nature videos with Virtual Reality (VR) goggles after finishing their workday on three days (Tuesday, Wednesday, and Thursday).
89272588|NCT05830656|Experimental|Control, Then exposure to virtual nature, Then exposure to nearby nature|During the first week, the participants continue their normal routine at work and in leisure time. On the second week, the participants watch virtual nature videos with Virtual Reality (VR) goggles after finishing their workday on three days (Tuesday, Wednesday, and Thursday). On the third week, the participants visit a nearby natural area after finishing their workday on three days (Tuesday, Wednesday, and Thursday).
89272589|NCT05827289|Experimental|CAPABLE cohort|Group that receives the CAPABLE application during treatment
89272590|NCT05825300|Experimental|No-blood-type message|This group will receive a message that does not mention that the patient's blood type is in short supply.
89272591|NCT05825300|Experimental|Blood-type message|This group will receive a message that states their blood type is in short supply.
89272592|NCT05815433|Experimental|Donor Human Milk|Infants randomized to the intervention group will receive DHM each time supplementation is required for the first 7 days of life.
89272593|NCT05815433|No Intervention|Standard Care (Infant Formula)|Infants randomized to the standard care group will receive formula each time supplementation is required for the first 7 days of life.
89272594|NCT05812755|Active Comparator|Vericiguat|10 mg vericiguat administered orally once daily for three days (through day of surgery)
89272595|NCT05812755|Placebo Comparator|Placebo|placebo administered orally once daily for three days (through day of surgery)
89272596|NCT05803954|Experimental|Group A (SNAGs group)|
89272597|NCT05803954|Experimental|Group B (Neural mobilization group)|
89272598|NCT05803954|Active Comparator|Group C (traditional physical therapy)|
89272599|NCT05803772|Other|Active to Placebo Cross|Participants will first receive a single dose of APHD-012 12 g daily, under fasting conditions prior to main daily meals for 6 weeks (day 1-42), followed by washout period of 4 weeks (day 43-70), and subsequent crossover to the other treatment APH-012P for 6 weeks (day 71-112).
89272600|NCT05803772|Other|Placebo to Active Cross|Participants will first receive a single dose of APH-012P daily, under fasting conditions prior to main daily meals for 6 weeks (day 1-42), followed by washout period of 4 weeks (day 43-70), and subsequent crossover to the other treatment APHD-012 12 g for 6 weeks (day 71-112).
89272601|NCT05803148|Experimental|Experimental group: Cardioneuroablation|In this arm, the catheter ablation of the GPs will be performed in the order of LSGP, LIGP, RIGP, left atrial RAGP and right atrial RAGP. Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and educating patients to avoid triggering factors as much as possible. At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
89272602|NCT05803148|Active Comparator|Control group: Midodrine|In this arm, Midodrine will be applied without the following contraindications: hypertension, chromaffin cell carcinoma, acute nephritis, severe renal dysfunction, glaucoma, prostatic hyperplasia with urinary retention, mechanical urinary obstruction, hyperthyroidism. Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and educating patients to avoid triggering factors as much as possible. At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
89272603|NCT05802849|Experimental|a group with the use of acetazolamide|acetazolamide is prescribed at a dose of 250 mg 3 times a day
89272604|NCT05802849|No Intervention|a group of standart therapy|standart therapy includes main and additional medicine for treatment of chronic heart failure
89272605|NCT05799261|Active Comparator|Control (standard protocol)|The control group will be treated according to standard protocols of the Department of Periodontology of the university of Bern and receive conventional scaling and root planing. Supra- and subgingival hard and soft tissue deposits are being removed by means of hand instruments and ultra-sonic scalers followed by rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists.
89272606|NCT05799261|Experimental|Test (Guided Biofilm management)|"The test group will be treated according to a novel treatment concept (Guided biofilm management, GBM):~Staining of all tooth surfaces to detect soft and hard deposits.~Removal of supra- and subgingival hard and soft bacterial deposits by means of an erythritol powder air-polishing.~If present, the supra- and subgingival hard deposits (e.g. calculus) will be removed by means of a slim ultrasonic tip (Piezon PS, EMS, Nyon Switzerland) without any additional use of hand instruments.~Another sub- and supragingival application of erythritol powder air-polishing without any rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists."
89272607|NCT05795959|Experimental|Intervention|Participants randomized to this arm of the study will receive usual care with supplemental education and support provided by a lay VA volunteer trained on evidence-based lung cancer care.
89272608|NCT05795959|No Intervention|Control|Participants randomized to this arm of the study will receive usual clinical care.
89272609|NCT05795764|Experimental|Crisis Response Planning|CRP is a brief psychotherapeutic intervention that can be provided to patients at risk of suicidal behavior. When using the intervention, a provider works with the patient (1) to conduct a narrative assessment of the events preceding suicidal thoughts or behavior, and (2) to develop a personalized plan for identifying and managing distress that could escalate to a suicide attempt. The CRP, which is typically handwritten by the patient on an index card, includes personal warning signs of distress, emotion regulation strategies, reasons for living, and contact information for friends/family as well as professional (psychological/medical) and emergency resources.
89272610|NCT05795764|Active Comparator|Treatment as Usual|Existing clinical practices in the emergency department include the following elements recommended by the VA/DoD Clinical Practice Guidelines: (1) all patients are screened for suicidal ideation at every visit; (2) for those with positive screens, a suicide risk assessment interview is conducted by a mental health professional; (3) a safety planning form with means restriction (such as the Stanley-Brown; Stanley & Brown, 2012) is completed; and (4) patients are referred for follow-up mental health treatment as needed. Other elements of TAU could include behavioral and psychotropic interventions, referrals to specialty mental healthcare, and admission for psychiatric inpatient care.
89272611|NCT05791344||ECG Monitoring -TAVR patients|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
89272612|NCT05789472|Experimental|Football Group|Assessment
89272613|NCT05789472|Experimental|Basketball Group|Assessment
89272614|NCT05789472|Experimental|Volleyball Group|Assessment
89272615|NCT05787665||With Lung Ultrasonography|Patient who meet inclusions criteria, and which lung ultrasonography were performed during their medical care in Emergency Department
89272616|NCT05787665||Without Lung Ultrasonography|Patient who meet inclusions criteria, and which lung ultrasonography were not performed during their medical care in Emergency Department.
89272617|NCT05771506||COPD Group|Balance assessment, Pulmonary function test, Respiratory muscle strength test, Peripheral muscle strength test, 6-minute walk test, Cognitive assessment
89272618|NCT05771506||Control Group|Balance assessment, Pulmonary function test, Respiratory muscle strength test, Peripheral muscle strength test, 6-minute walk test, Cognitive assessment
89272619|NCT05767437|Experimental|Abdominal drawing-in maneuver exercise, afterward Sham therapy(conventional physiotherapy)|Participants first received Abdominal drawing-in maneuver exercise 2 times a week for 4 weeks. Each session is 40 minutes for additional 10 min with conventional therapy. Afterward a washout period of one month, they then received sham therapy (conventional therapy_release pain or upper limb mobilization) 2 times a week for 4 weeks. Each session is 40 minutes.
89272620|NCT05767437|Experimental|Sham therapy(conventional physiotherapy), afterward Abdominal drawing-in maneuver exercise|Participants first received sham therapy(release pain or upper limb mobilization)2 times a week for 4 weeks. Each session is 40 minutes. Afterward a washout period of one month, they then received Abdominal drawing-in maneuver exercise 2 times a week for 4 weeks. Each session is 40 minutes for additional 10 min with conventional therapy
89272621|NCT05761743||PHPT and DM Patients, Parathyroidectomy|Patients with primary hyperparathyroidism with type 2 diabetes, that decided with their physician/surgeon to continue with a parathyroidectomy (independent of research).
89272622|NCT05761743||PHPT and DM Patients, NO Parathyroidectomy|Patients with primary hyperparathyroidism with type 2 diabetes, that have decided with their physician/surgeon to be managed medically with no parathyroidectomy.
89272623|NCT05761509||Single arm|"200 subjects exposed to HIV, leading to prescription of 28-day doravirine based post exposure prophylaxis (PEP).~The study referred to treatments that are using routinely in the medical care of subjects under PEP. These treatments are the following:~Delstrigo®: Fixed-dose combination containing 100mg of doravirine, 245 mg of tenofovir disoproxil and 300 mg of lamivudine, one tablet to be taken orally once daily, with or without food.~Pifeltro®: doravirine dosed at 100 mg, on tablet to be taken orally once daily, with or without food, in combination with tenofovir disoproxil/emtricitabine."
89272624|NCT05757531|Experimental|[¹⁴C]-LY3437943|Single dose of [¹⁴C]-LY3437943 administered subcutaneously (SC).
89272625|NCT05753605||Oura Ring Arm|Participant will be provisioned an Oura smartring.
89272626|NCT05753605||BYOD (Bring Your Own Device) Arm|Participant will use their personal wearable.
89272627|NCT05752747|Experimental|Cold Massage Group|Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
89272628|NCT05752747|Experimental|ShotBlocker© Group|It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
89272629|NCT05752747|No Intervention|Control Group|No intervention will be applied to the control group.
89272630|NCT05748366|Experimental|Serratus Anterior Plane Block|Subjects will undergo serratus anterior plane block, in addition to standard of care analgesic medications at the discretion of the treatment team.
89272631|NCT05748366|Active Comparator|Standard Analgesic Medications|Subjects will receive standard of care analgesic medications at the discretion of the treatment team.
88805540|NCT00128180|Active Comparator|Active|Methylprednisolone
88805541|NCT00128180|Placebo Comparator|Placebo|Placebo
88805542|NCT01899560|Other|Unique arm|Experimental and comparator
89272632|NCT05747599|Experimental|Intervention|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
89272633|NCT05747599|Active Comparator|Usual Care|Community treatment referrals
89272634|NCT05739305||Cancer|Death certificates of patients died by cancer or with cancer.
89272635|NCT05739305||Cardiovascular|Death certificates of patients died by cardiovascular conditions or complications.
89272636|NCT05739305||Tuberculosis|Death certificates of patients died by or with tuberculosis, including patients with HIV.
89272637|NCT05739305||Infants|Death certificates of pediatric patients with more than a month of birth, and less than 18 years old.
89272638|NCT05739305||Congenital malformations|Death certificates of patients died by congenital malformations, independently of age.
89272639|NCT05739305||Maternal|Death certificates of patients died by obstetrical conditions during pregnancy or delivery.
89272640|NCT05739305||Contagious|Death certificates of patients died by contagious/infectious diseases.
89272641|NCT05738161|Experimental|Magrolimab in combination with Cisplatin and Gemcitabine|Magrolimab therapy in combination with standard first line platinum-based chemotherapy (with Cisplatin / Gemcitabine) in advanced urothelial carcinoma.
89272642|NCT05737550|Experimental|Subjects with confirmed SUD|Evaluation of the usability of Previct Drugs when used in the intended population (patients with SUD).
89272643|NCT05729347|Experimental|Virtual Reality|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
89272644|NCT05729347|No Intervention|Control|No intervention (i.e. virtual reality headset) will be applied to the participant.
89272645|NCT05728749||Asthma patients|Trimbow pMDI prescribed for maintenance treatment of adult asthma as per the licensed indication.
89272646|NCT05726266|Experimental|Music Group|Patients randomized to this group will listen daily to a musical playlist for 30 - 60 minutes in a row through a mobile device. This will be performed in addition to the opioid treatment.
89272647|NCT05726266|Placebo Comparator|Audiobooks Group|Patients randomized to this group will listen to an audiobook daily for 30 - 60 minutes in a row through a mobile device. This will be performed in addition to the opioid treatment.
89272648|NCT05719454|Experimental|CNT Setup Algorithm Version 1|When performing the Setup Algorithm Version 1, each subject's blood pressure is measured with a standard cuff system while the BackBeat-CNT is activated, and system parameters are varied successively according to a specified sequence or based on the blood pressure measurements obtained during previous activations of BackBeat CNT, until the Setup Algorithm is complete. The parameter values as determined by the Setup Algorithm will constitute the programming of the Moderato IPG for the 24 hour activation following setup.
89272649|NCT05719454|Experimental|CNT Setup Algorithm Version 2|When performing the Setup Algorithm Version 1, each subject's blood pressure is measured with a standard cuff system while the BackBeat-CNT is activated, and system parameters are varied successively according to a specified sequence or based on the blood pressure measurements obtained during previous activations of BackBeat CNT, until the Setup Algorithm is complete. The parameter values as determined by the Setup Algorithm will constitute the programming of the Moderato IPG for the 24 hour activation following setup.
89272650|NCT05719454|Other|CNT therapy optimization without use of the Setup Algorithm|For this optimization procedure, each subject's blood pressure is measured with a continuous blood pressure measurement system while the BackBeat-CNT is activated, and system parameters are varied according to a specified sequence until the desired blood pressure reduction is achieved. The parameter values that provide the desired blood pressure reduction will be recorded, for possible use by the investigator following trial completion
89272651|NCT05715606|Experimental|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
89272652|NCT05714046|Experimental|Yoga Group|In addition to routine tennis training yoga exercise training was applied to the yoga group 2 days a week for 8 weeks with the telerehabilitation method.
89272653|NCT05714046|Experimental|Control Group|Routine Tennis training and information training was given to Control group.
89272654|NCT05710926|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Personality Disorder as manualized by Beck, Davis, Freeman and Beck in their book (2016) will be delivered to partecipants in the active control group.
89272655|NCT05710926|Experimental|Evolutionary Systems Therapy for Schizotypy|Evolutionary Systems Therapy for Schizotypy as manualized by Cheli and colleagues in their trial (2023) will be delivered to partecipants in the experimental group.
89272656|NCT05709561|Active Comparator|Acupressure Group|Acupressure was applied to the acupressure group twice a week in the first week by the researcher. Then, in the second week, it was observed that the students themselves applied this application twice this week under the supervision of the researcher.Then the acupressure group was asked to apply acupressure two days a week for 12 weeks, a total of 24 times.
89272657|NCT05709561|Active Comparator|Mindfulness Group|The researcher and students practiced mindfulness once a week for 8 weeks. Then the students were asked to do 3 cycles of application alone every day. mid-test was applied.
89272658|NCT05709561|Placebo Comparator|Plasebo Group|Acupressure and mindfulness practices were not applied to the control group and they continued their routine care.
89272659|NCT05705804|Experimental|Group P|Pitavastatin 4mg group
89272660|NCT05705804|Experimental|Group PE|Pitavastatin 4 mg Ezetimibe 10 mg combined administration group
89272661|NCT05705804|Active Comparator|Group A|Atorvastatin 40 mg administration group
89272662|NCT05703347|Active Comparator|Condition 1|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
89272663|NCT05703347|Active Comparator|Condition 2|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
89272664|NCT05703347|Active Comparator|Condition 3|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
89272665|NCT05703347|Active Comparator|Condition 4|Fixed guideline-based sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
89272666|NCT05703347|Active Comparator|Condition 5|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
89272667|NCT05703347|Active Comparator|Condition 6|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
89272668|NCT05703347|Active Comparator|Condition 7|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
89272669|NCT05703347|Active Comparator|Condition 8|Fixed guideline-based sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
89272670|NCT05703347|Active Comparator|Condition 9|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
89272671|NCT05703347|Active Comparator|Condition 10|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
89272672|NCT05703347|Active Comparator|Condition 11|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
89272673|NCT05703347|Active Comparator|Condition 12|Personalized sleep goal, Digital sleep health messaging without virtual study visit consultation, Active caregiver-directed loss-framed incentive, Active supportive feedback.
89272674|NCT05703347|Active Comparator|Condition 13|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Inactive supportive feedback.
89272675|NCT05703347|Active Comparator|Condition 14|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Inactive caregiver-directed loss-framed incentive, Active supportive feedback.
89272676|NCT05703347|Active Comparator|Condition 15|Personalized sleep goal, Digital sleep health messaging with virtual study visit consultation, Active caregiver-directed loss-framed incentive, Inactive supportive feedback.
89272677|NCT05703347|Experimental|Condition 16|Core intervention, Sleep goal, Sleep guidance messaging, Caregiver-directed loss-framed incentive, Supportive feedback.
89272678|NCT05699434||Obstetrics and Gynecology residenst and experts|Obstetrics and Gynecology residents and expert knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey ( Istanbul)
89272679|NCT05696301|Experimental|Interventionnal Group|These women will receive Tecar by Winback® technology [CE medical 1984, Norma 60601-2, ISO9001, ISO13485, CET 400 VA and RET 100 Watts, weight 4 Kg]. Each session will last for 20 minutes, and each individual will have 3 sessions over a period of 3 weeks
89272680|NCT05696301|Sham Comparator|Control|The women will follow the same study design as the experimental group with activation of the portable placebo device identical to the active medical . Each session will last for 20 minutes, and each individual will have 3 sessions over a period of 3 weeks.
89272681|NCT05694091||Patients in the control group were followed up without delirium postoperatively.|If the 3D-CAM scale all show a negative resluts
89272682|NCT05694091||Patients in the case group were followed up with delirium postoperatively.|If the 3D-CAM assessment is positive at any time point after surgery
89272683|NCT05693441|Active Comparator|Active berry product|Once daily consumption over the period of the study
89272684|NCT05693441|Placebo Comparator|Reference berry-like product|Once daily consumption over the period of the study
89272685|NCT05690906|Experimental|ReSpace™ & gauze packing|All of the subjects will undergo palcement of ReSpace™ hydrogel together with gauze packing in the vagina before brachytherapy
89272686|NCT05690906|Active Comparator|gauze packing|All of the subjects will undergo palcement of gauze packing alone in the vagina before brachytherapy
89272687|NCT05685979||Patients undergoing robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|Patients with ASA( American Society of Anesthesiologists) physical status 1-3 who underwent robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.
89272688|NCT05685797|Experimental|TN patients with intervention|Patients with TN receiving 2 times of trigeminal nerve block and radiofrequency thermocoagulation
89272689|NCT05685797|No Intervention|Control group|Healthy volunteer without any intervention
89272690|NCT05675696|Experimental|ARDS Patients Intubated on Mechanical Ventilation|ARDS patients in the ICU who are intubated on mechanical ventilation will be included. During ventilation, an esophageal catheter will be used to measure the esophageal pressure, which estimates pleural pressure at the level of the catheter. The esophageal catheter's position will be confirmed by a chest radiograph once inserted. The ventilator settings may be changed to see if these ventilator adjustments can reduce potential lung stress in ARDS patients. There is no set criteria for adjusting the ventilator settings based on the study device, but the goal would be to adjust the volume until the inspiratory effort measured by the catheter disappears so as to protect the patient. A one-to-two-hour study session will be performed for data collection. The esophageal catheter will be removed at the end of the study session or can be left in place for use as a feeding tube if needed for patient care.
89272691|NCT05665777|Experimental|Active treatment (Qingyan Lihou Decoction)|It consists of 22 kinds of Chinese medicine as ingredients. It was prepared in granule form.
89272692|NCT05665777|Placebo Comparator|Placebo|The placebo medication is composed of starch and an edible pigment and will be matched as closely as possible to the appearance and taste of Qingyan Lihou Decoction granules.
89272693|NCT05665660|Experimental|CARE - Intervention arm for mammography education|CARE is a culturally tailored mammography education module.
89272694|NCT05665660|Experimental|CARE + COACH - Intervention arm for mammography education + a patient navigator|CARE + COACH is the CARE education module in addition to a COACH, which is access to an Apache paraprofessional women's health coach. The Coach functions like a patient navigator.
89272695|NCT05655936|Active Comparator|Usual Care Group|The usual care group will receive remote blood pressure monitoring for approximately 6 weeks via the clinical home blood pressure monitoring program at Magee Women's Hospital of UPMC and be discharged after delivery as usual. This monitoring is standardly offered to women post-delivery with hypertensive disorders of pregnancy. Participants will text in their blood pressures to the medical record systems and be monitored by clinical staff.
89272696|NCT05655936|Experimental|Postpartum Doula Intervention Group|The intervention group will receive study devices (blood pressure cuff, scales, etc.) and instructions on 10-12 months of remote blood pressure, and weight monitoring. An electronic referral will be sent to the Healthy Start program to initiate postpartum Doula support for 8-12 weeks, and a Doula moderated social support group for 6 months. The postpartum Doula will deliver a heart health focused intervention aimed at reducing blood pressure by approximately 12 weeks postpartum.
89272697|NCT05654675||Oncologic patients|"Lymphoma and lung cancer patients will undergo an additional dynamic FDG PET/CT examination on top of their standard care PET/CT examination.~In addition, blood samples will be drawn at three time points"
89272698|NCT05653752|Experimental|YL202 Dose escalation|YL202 will be administrated intravenously (IV) per dose level in which the patients are assigned.
89272699|NCT05652907|Experimental|FSD201|Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally from Day 0 to Day 56.
89272700|NCT05652907|Placebo Comparator|Placebo|Participants will receive placebo matched to 600 mg FSD201 tablets twice daily (BID) orally from Day 0 to Day 56.
89272701|NCT05643625|Experimental|Pilates exercise and myofascial release group|In this study, pilates exercise and myofascial release technique will be applied for 8 weeks, 2 days a week. Participants will be evaluated at the beginning of the study, at the end of the first session and after 8 weeks.
89272702|NCT05643625|Active Comparator|Pilates Exercise|In this study, pilates exercise will be applied for 8 weeks, 2 days a week. Participants will be evaluated at the beginning of the study, at the end of the first session and after 8 weeks.
89272703|NCT05636787|Experimental|Arm B - TreoMel|Chemotherapy regime consisting of treosulfan on three days at 14 g/m2 followed by 200 mg/m2 melphalan given on two days at 100 mg/m2.
89272704|NCT05636787|Active Comparator|Arm A - Mel|Chemotherapy regime consisting of 200 mg/m2 melphalan, split into two days à 100 mg/m2.
89272705|NCT05633316|Experimental|ICSIA|Intracytoplasmic sperm injection will be performed using the automated system named ICSIA (investigational device)
89272706|NCT05633316|Experimental|Control|In this control group oocytes will undergo manual ICSI as is routinely performed.
89272707|NCT05632679|Experimental|personalized music intervention|
89272708|NCT05632679|Active Comparator|selected audio book|
89272709|NCT05632679|No Intervention|standard care|
89272710|NCT05631912|Experimental|Autologous TRAC locus-inserted CD19-targeting STAR-T cells|"A conditioning chemotherapy regimen of fludarabine and cyclophosphamide (FC regimen) will be administered followed by investigational treatment, autologous targeting CD19 synthetic T-cell receptor antigen receptor T cells.~Post leukapheresis, administration of short half-life chemo-agents, Bruton tyrosine kinase inhibitor (BTKi) and/or dexamethasone should be considered to bridge the following FC regimen in patients with bulky tumor burden, rapidly aggressive progression, and/or indications of imperious symptom control."
89272711|NCT05623839|Experimental|LY3305677|LY3305677 administered subcutaneously (SC)
89272712|NCT05623839|Placebo Comparator|Placebo|Placebo administered SC
89272713|NCT05617898|Experimental|Motivational Interview Intervention|This arm involves three 45-minute sessions on motivational interviewing targeting sensitivity to social reward.
89272714|NCT05617898|Active Comparator|Active Control Intervention|This arm involves three 45-minute sessions on didactic training on nutrition.
89272715|NCT05617495|Active Comparator|15-Minute mbNF|Participants receiving mindfulness training and 15-minute session of mbNF
89272716|NCT05617495|Active Comparator|30-Minute mbNF|Participants receiving mindfulness training and 30-minute session of mbNF
89272717|NCT05615948|Other|Intervention Group|All individuals 18 years old or older who have Major Depressive Disorder and have failed to achieve response or remission to at least one proven antidepressant trial with minimum affective dose for a duration of at least 6 weeks.
89272718|NCT05615532|Experimental|LY3209590 (Part A - Upper Arm)|LY3209590 administered subcutaneously (SC) into the upper arm
89272719|NCT05615532|Experimental|LY3209590 (Part A - Thigh)|LY3209590 administered SC into the thigh
89272720|NCT05615532|Experimental|LY3209590 (Part A - Abdominal Wall)|LY3209590 administered SC into the abdominal wall
89272721|NCT05615532|Experimental|LY3209590 (Part B - IV Dose)|LY3209590 administered intravenously (IV)
89272722|NCT05615532|Experimental|LY3209590 (Part B - SC Dose)|LY3209590 administered SC into the abdominal wall
89272723|NCT05614349|Experimental|Paxlovid|Nirmatrelvir/ritonavir (Paxlovid™) BD x 5 days
89272724|NCT05614349|No Intervention|Control group|Usual care (i.e., supportive care and symptom relief)
89272725|NCT05614349|Experimental|Other Emerging Interventions (arm 3)|Additional treatment regimens will be decided by the Canadian COVID-19 Out-Patient Therapeutics Committee based on doses and durations studied in past trials and the latest evidence
89272726|NCT05614349|Experimental|Other Emerging Interventions (arm 4)|Additional treatment regimens will be decided by the Canadian COVID-19 Out-Patient Therapeutics Committee based on doses and durations studied in past trials and the latest evidence
89272727|NCT05610358|Experimental|Intervention|Participants in the intervention group will be provided the smartphone application and they will practice application based rehabilitation for 12 weeks.
89272728|NCT05610358|No Intervention|Control|Participants in the control group will not practice rehabilitation program.
89272729|NCT05609812|Experimental|Atacicept Dose|Atacicept Dose once weekly subcutaneous (SC) Injection
89272730|NCT05609812|Placebo Comparator|Placebo to match Atacicept|Placebo to match Atacicept once weekly subcutaneous (SC) injection
89272731|NCT05608421|Experimental|1MoreStep Intervention|The intervention arm is 8 sessions (7 group and one individual) that meet weekly with a community health educator who is a Black woman and has experience implementing prior behavioral interventions with people who have experienced trauma and/or are LWH.
89272732|NCT05608421|Active Comparator|Equal Attention Control|The Equal Attention Control consists of 8 sessions (7 group and one individual) that meet weekly for 60-90 minutes. The control sessions provide equal attention and psychotherapeutic experience of a support group where participants can address issues important in their lives.
89272733|NCT05595460|Experimental|RYZ101 + SoC|RYZ101 (Actinium 225 radiolabeled somatostatin analog (SSA)) 6.5 MBq/175 μCi in combination with standard of care (SoC) carboplatin + etoposide + atezolizumab
89272734|NCT05594667|Experimental|PEX010|25mg of PEX010 (one-time administration)
89272735|NCT05591911||Patients over 60 years old presenting with acute urinary tract infection symptoms|
89272736|NCT05589818|Experimental|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab (200mg IV every 3 weeks) for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV.
89272737|NCT05589623|Experimental|Copenhagen adduction exercise|The CAE is a body-weight exercise that mainly works the groin and hip adductors. It has a significant eccentric component, meaning the muscles work while lengthening. The CAE is a simple isolated eccentric exercise that does not require special equipment. Due to the heaviness and the high dynamic demands of CAE, a modified progressive Copenhagen adduction (MPCA) program has been created. The MPCA exercise was adapted from the original CAE to lessen the risk of delayed onset muscle soreness (DOMS) and facilitate high participant compliance. An experienced physical therapist will include the MPCA in the usual rehabilitation program for eight weeks, twice weekly. Sessions will last between 30 and 120 minutes.
89272738|NCT05589623|Active Comparator|Usual rehabilitation program|The rehabilitation program will be an active exercise based on the available literature and considers the clinical experience in managing groin injuries. An experienced physical therapist will supervise the rehabilitation program for two sessions weekly for eight weeks, with difficulty and volume progressing incrementally. Sessions will last between 30 and 120 minutes.
89272739|NCT05584345|Active Comparator|CONTROL|Traditional physiotherapy applications will be applied.
89272740|NCT05584345|Experimental|RESPIRATORY EXERCISES GROUP|In addition to traditional physiotherapy and respiratory exercises wiil be applied.
89272741|NCT05578443|Experimental|Astragalus membranaceus|
89272742|NCT05578443|Experimental|Routine treatment|
89272743|NCT05573360|Other|Sequence 1|NGF5-A/NGF4-B/NGF6-B/NGF6-E/Systane, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
89272744|NCT05573360|Other|Sequence 2|NGF4-B/NGF6-B/NGF6-E/Systane/NGF5-A, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
89272745|NCT05573360|Other|Sequence 3|NGF6-B/NGF6-E/Systane/NGF5-A/NGF4-B, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
89272746|NCT05573360|Other|Sequence 4|NGF6-E/Systane/NGF5-A/NGF4-B/NGF6-B, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
89272747|NCT05573360|Other|Sequence 5|Systane/NGF5-A/NGF4-B/NGF6-B/NGF6-E, 1 drop instilled to each eye, with a wash-out period of 1 to 7 days between each instillation
89272748|NCT05572606|Experimental|Hypnotherapy for bloating symptoms|Subjects experiencing bloating symptoms will receive hypnotherapy delivered electronically
89272749|NCT05572359|Experimental|Total knee arthroplasty cryo-and compression group|use of the cryo- and compression brace during the six postoperative weeks
89272750|NCT05572359|No Intervention|Total knee arthroplasty regular care group|regular care during the six postoperative weeks
89272751|NCT05572359|Experimental|Unicompartmental knee arthroplasty cryo- and compression group|use of the cryo- and compression brace during the six postoperative weeks
89272752|NCT05572359|No Intervention|Unicompartmental knee arthroplasty regular care group|regular care during the six postoperative weeks
89272753|NCT05571319|Experimental|Open-label arm|All participants to receive metformin extended-release 1000mg to 2000mg daily for 12 weeks.
89272754|NCT05570227|Experimental|[U-13C]Glucose Infusion|A 13.3% solution of sterile, pyrogen-free [U-13C]glucose in sterile water will be infused intravenously rapidly over 10 minutes to a total dose of 8 grams (bolus dose). Then the infusion will change to a rate of 4 grams/ hour. The infusion will continue until the time of tumour excision or biopsy, planned 2-3 hours.
89272755|NCT05570227|No Intervention|No [U-13C]Glucose Infusion|Blood and tissue samples to be collected for translational research studies, no other additional intervention.
89272756|NCT05570162|Experimental|Low Flash adherence|Adult (>18 yrs old) type 1 diabetes patients with 4 or less daily Flash scans
88805543|NCT01121939|Experimental|1|combination of bevacizumab, pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers
88805544|NCT00181610|Active Comparator|1|Placebo group normal saline twice per day
88805545|NCT00181610|Active Comparator|2|Recombinant human prolactin 60 mcg/kg every 12 hours
88805546|NCT00181610|Active Comparator|3|Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours
88805547|NCT03013751|Experimental|Drug|Udenafil administered for 52 weeks
88805548|NCT02205307|Experimental|PINPOINT or SPY Elite|A low anterior resection will be performed according to the surgeon's standard practice with the addition of intraoperative imaging using PINPOINT near infrared fluorescence imaging or SPY Elite intraoperative imaging to assess colon and rectal tissue perfusion
88805549|NCT02205307|No Intervention|STANDARD|A low anterior resection will be performed according to the surgeon's standard practice
88805550|NCT01897844|Experimental|ITF2984/Placebo 2000 mcg sc bid|ITF2984/Placebo 2000mcg s.c. b.i.d. for 14 days
88805551|NCT01897844|Experimental|ITF2984/Placebo 3000 mcg sc bid|ITF2984/Placebo 3000mcg s.c. b.i.d. for 14 days
88805552|NCT01897844|Experimental|ITF2984/Placebo 100 mcg sc bid|ITF2984/Placebo 100mcg s.c. b.i.d. for 14 days
88805553|NCT01045031||Controls|"Controls were subsequently contacted via personal contact and three additional advertisements (two in an Austrian newspaper (Krone) and one in an Austrian bicyclist journal (Bicyclist Sports). The controls were matched according to age, sex and years of education"
89272757|NCT05569278|Experimental|GEH200486 Cohort 1|Participants will receive 0.05 mmol/kg of GE200486 0.5 M injection
89272758|NCT05569278|Experimental|GEH200486 Cohort 2|Participants will receive 0.1 mmol/kg of GE200486 0.5 M injection
89272759|NCT05569278|Experimental|GEH200486 Cohort 3|Participants will receive 0.2 mmol/kg of GE200486 0.5 M injection
89272760|NCT05569278|Experimental|GEH200486 Cohort 4|Participants will receive 0.3 mmol/kg of GE200486 0.5 M injection
89272761|NCT05561452|Experimental|Single PRP Injection + Exercise|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
89272762|NCT05561452|Experimental|Multiple PRP Injection+ Exercise|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
89272763|NCT05561452|Sham Comparator|Saline Injection + Exercise|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote® My Lab 70 XVision 6-18 Mhz, linear probe).~A home exercise program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be taught and the patients be instructed to perform at least for 20 minutes daily."
89272764|NCT05555407|Experimental|Wireless patch system (WPS)|Subjects scheduled for a gastric emptying scan will have a wireless patch system (WPS) placed.
89272765|NCT05551520|Other|Normative|ImPACT will be administered to participant's for a baseline test.
89272766|NCT05551520|Other|Reliability|ImPACT will be administered to participant's within 60 days of baseline test.
89272767|NCT05542615|Experimental|Patient|Sixty patients with chronic Viral C hepatitis, who have been treated with direct-acting antivirals, with a sustained viral response and who still have advanced fibrosis (F3-F4).
89272768|NCT05534438|Experimental|Participants with oligometastatic breast cancer|Participants with oligometastatic breast cancer with isolated progression after sustained (>=6 month) response to systemic therapy. Participants will receive image guided, SBRT to the progressive lesion identified on imaging. Participants will be maintained on their existing line of systemic therapy. Systemic therapy will be held during days of radiation and resume following completion of radiation.
89272769|NCT05532163|Experimental|Natalizumab|Participants will receive natalizumab 300 milligrams (mg) (2*150 mg), SC injection, once every 4 weeks (Q4W) up to Week 24.
89272770|NCT05515081|Other|vaccinated healthy subject|Procedure/Surgery: blood sample collection at regular intervals
89272771|NCT05512403|Experimental|Patients with Low Grade Glioma (LGG) without any MRI contrast enhancement|"Patients presenting with brain lesions that lack contrast enhancement on MRI, that are suspected to be LGGs and that are referred for biopsy or surgery within the following 6 months will be eligible for the study. The initial MRI should be performed a maximum of 3 weeks before patient inclusion and should at least include the conventional morphological sequences (T1, T1 sequences with injection of contrast product and T2 FLAIR).~Patients will be selected in a neuro-oncological multidisciplinary consultation meeting."
89272772|NCT05502367|Experimental|ABI-2280 0.1mg|0.1mg vaginal tablet
89272773|NCT05502367|Experimental|ABI-2280 0.3mg|0.3mg vaginal tablet
89272774|NCT05502367|Experimental|ABI-2280 1.0mg|1.0mg vaginal tablet
89272775|NCT05492825|Experimental|Yoga|Participants in the yoga group will receive a manualized intervention of 12 weekly, group-based, 60-minute yoga classes, and guided home practice.
89272776|NCT05492825|Experimental|Physical Therapy|Participants in the PT group will receive a manualized intervention of 12 weekly, individual, 60-minute PT sessions, with home practice, based on the Saper protocol.
89272777|NCT05492825|Other|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians.
89272778|NCT05487209||postmenopausal group|
89272779|NCT05487209||non-menopausal group|
89272780|NCT05481905|Experimental|ENX-101 15mg daily|
89272781|NCT05481905|Experimental|ENX-101 30mg daily|
89272782|NCT05481905|Placebo Comparator|Placebo daily|
89272783|NCT05475600|Experimental|Classical APA group|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on Rated Perceived Exertion (RPE) Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20 min / stretching / Objective: to bring the body back to a resting state
88821619|NCT03277105|Experimental|Dara SC|Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
89272784|NCT05475600|Experimental|APA with Exergaming device|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20 min / stretching / Objective: to bring the body back to a resting state
89272785|NCT05475600|Experimental|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3 sessions per week Duration of session: 30 to 60 min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10 min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30 min physical activity with an Exergaming device 3 - Cool down: 20 min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
89272786|NCT05467631|Active Comparator|Plain Tea Tree Oil Control|Topical application of 1ml 20% tea tree oil in almond oil base as a carrier twice daily for 2 weeks.
89272787|NCT05467631|Experimental|Verum|Topical application twice daily of 1ml mixture for 2 weeks of essential oils containing tea tree oil, rosemary, clove, pepper, in a formulation with skin permeation enhancers including limonene.
89272788|NCT05459675|Experimental|Very low-calorie diet|Patients in the very low-calorie diet group will be prescribed a very low-calorie diet (meal replacement) for 12 weeks, then the patients will be monitored up to 1 year
89272789|NCT05459675|Experimental|Bariatric surgery|Patients in the bariatric surgery group will be undergone bariatric surgery LRYGB and will be follow-up according the current guideline
89272790|NCT05458440|Other|Covid-19 Convalescent donors|The protocol will be explained during hospitalisation for each donor infected by SARS-CoV-2. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
89272791|NCT05432544|Experimental|SAD, SHR-1918|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 injection
89272792|NCT05432544|Placebo Comparator|SAD, SHR-1918 placebo|Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 placebo injection
89272793|NCT05416944|No Intervention|Routine management (control) group|Routine intraoperative blood pressure management with a lower intervention threshold of 65 mmHg. In contrast to the patients assigned to the personalized management group, the individual mean nighttime MAP assessed using preoperative automated blood pressure monitoring is not taken into account and the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring.
89272794|NCT05416944|Experimental|Personalized management (intervention) group|In patients randomized to the personalized management group, intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg. The perioperative trial intervention period starts with the beginning of the induction of general anesthesia and ends two hours after surgery ends.
89272795|NCT05416281|Experimental|Robotic Vacuum Intervention|This will include a home visit for environmental assessment AND a robotic vacuum intervention. Silicone wristbands will be used to evaluate exposure before and after a cleaning intervention.
89272796|NCT05416281|No Intervention|No Intervention|This will include a home visit for environmental assessment.
89272797|NCT05411341||Study Group|100 patients with diagnosed cataract or presbyopia who will undergo implantation of intraocular lenses surgery
89272798|NCT05408117|Experimental|A= left/superior half of wound|Patients with skin of color undergoing dermatologic surgery with planned standard elliptical excision with wound length of 3 cm or greater
89272799|NCT05408117|Experimental|B= right/inferior half of wound|Patients with skin of color undergoing dermatologic surgery with planned standard elliptical excision with wound length of 3 cm or greater
89272800|NCT05405868|Experimental|Nicotinamide|Participants will receive Nicotinamide for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.
89272801|NCT05405868|Placebo Comparator|Matching Placebo|Participants will receive matching placebo for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.
89272802|NCT05397184|Experimental|Single-dose intravenous infusion of a banded dose of CAR7+ T cells/kg BECAR7|Single-dose intravenous infusion (weight-based dosing) of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months Patients will undergo careful screening to confirm that this treatment is adequate for them. Chemotherapy will be given prior to BE CAR-7 infusion. Patients will then receive a single infusion of the BE CAR-7 cells and will be closely monitored in hospital via blood and bone marrow tests for safety and to check the levels of BE CAR-7 and leukaemia cells. Patients are expected to be in hospital for 4-6 weeks for the BE CAR-7 therapy and the transplant will be scheduled 2-4 weeks after the end of BE CAR7 if leukaemia cells are no longer detectable. Patients will be monitored on the study for 1 year every month for the first 3 months and then every 6 months and then long term in routine clinics.
89272803|NCT05397041|Experimental|BMB-101|Participants receiving BMB-101 orally
89272804|NCT05397041|Placebo Comparator|Placebo|Participants receiving Matched Placebo orally
89272805|NCT05393271|Experimental|Part 1 (SAD): Participants receiving VH4011499|
89272806|NCT05393271|Placebo Comparator|Part 1 (SAD): Participants receiving placebo|
89272807|NCT05393271|Experimental|Part 2 (MAD) Drug-Drug Interaction (DDI) cohort: Participants receiving VH4011499 + Midazolam|
89272808|NCT05393271|Placebo Comparator|Part 2 (MAD) DDI cohort: Participants receiving placebo + Midazolam|
89272809|NCT05393271|Experimental|Part 2 (MAD) Non DDI cohort: Participants receiving VH4011499|
89272810|NCT05393271|Placebo Comparator|Part 2 (MAD) Non DDI cohort: Participants receiving placebo|
89272811|NCT05393271|Experimental|Part 3 (Single dose): Participants receiving VH4011499 (new formulation)|
89272812|NCT05391087|Active Comparator|Mean Arterial Pressure (MAP) Group|Target MAP: Baseline MAP +/- 20% and MAP>65mmHg Baseline MAP: MAP average in the ward at rest the day before surgery Low MAP intervention If PPV>14, apply 500ml crystalloid If PPV>9 and any additional finding regarding hypovolemia, apply 500ml crystalloid If PPV<10, start/titrate noradrenaline infusion
89272813|NCT05391087|Active Comparator|Cardiac Index (CI) Group|"CI: Baseline CI +/- 20% and CI > 2.2 L/m2/min Baseline CI: CI calculated by MostCare monitor before the anesthesia induction starts Low CI intervention If PPV>9, apply mini fluid challenge (MFC). If MFC is positive, apply 500ml crystalloid.~If MFC is negative, evaluate MAP. If MAP is elevated start/titrate remifentanil. If MAP is not elevated start/titrate dopamine/dobutamine in accordance with systemic vascular resistance index (SVRI)"
89272814|NCT05385991|Experimental|SARS-CoV-2 beta S vaccine arm 1|SARS-CoV-2 beta S vaccine Antigen dose 1, no adjuvant, IM
89272815|NCT05385991|Experimental|SARS-CoV-2 beta S vaccine arm 2|SARS-CoV-2 beta S vaccine Antigen dose 1, no adjuvant, IN
89272816|NCT05385991|Experimental|SARS-CoV-2 beta S vaccine arm 3|SARS-CoV-2 beta S vaccine Antigen dose 2, adjuvant dose 1, IM
89272817|NCT05385991|Experimental|SARS-CoV-2 beta S vaccine arm 4|SARS-CoV-2 beta S vaccine Antigen dose 2, adjuvant dose 1, IN
89272818|NCT05385991|Experimental|SARS-CoV-2 beta S vaccine arm 5|SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 1, IM
89272819|NCT05385991|Experimental|SARS-CoV-2 beta S vaccine arm 6|SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 1, IN
89272820|NCT05385991|Experimental|SARS-CoV-2 beta S vaccine arm 7|SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 2, IM
89272821|NCT05385991|Experimental|SARS-CoV-2 beta S vaccine arm 8|SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 2, IN
89272822|NCT05383157|Experimental|Brief mindfulness|A 15-minute mindfulness intervention integrating mindful breathing and mindfulness of pain techniques.
89272823|NCT05383157|Active Comparator|Usual care|15 minutes of usual chronic pain care delivered in an academic pain clinic environment.
89272824|NCT05372172||Cognitively unimpaired|A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
89272825|NCT05372172||Mild cognitive impairment|A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
89272826|NCT05372172||Alzheimer's disease|A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
89272827|NCT05368168|Experimental|Group 1: Posterior tibial nerve stimulation (PTNS)|Patients operated on at the Hospital Álvaro Cunqueiro for rectal neoplasia with anastomosis below 10 cm and who, after randomization, WILL BE treated with posterior tibial nerve stimulation.
89272828|NCT05368168|No Intervention|Group 2: Standard of care|Patients operated on at the Hospital Álvaro Cunqueiro for rectal neoplasia with anastomosis below 10 cm and who, after randomization,WILL NOT BE treated with posterior tibial nerve stimulation.
89272829|NCT05356806||One|Patients with treated periodontitis who have had dental implants placed at the Periodontics Specialist Clinic of the UCM School of Dentistry, and are going to be rehabilitated.
89272830|NCT05355818|Experimental|Delgocitinib cream|Delgocitinib cream 20 mg/g twice daily
89272831|NCT05355818|Placebo Comparator|Cream vehicle|Cream vehicle twice daily
89272832|NCT05355571|Active Comparator|Active|Participants will consume a probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day for 10 days alongside an oral antibiotic at standard dosage administered for fixed period
89272833|NCT05355571|Placebo Comparator|Placebo|Participants will consume a placebo alongside an oral antibiotic at standard dosage administered for fixed period
89272834|NCT05340959||Adult patient with single or multiple missing tooth or teeth requiring dental implants|"Adult patient with single or multiple missing tooth or teeth requiring dental implants, 40 dental implants will be placed in osteotomy sites based on radiographic findings (CBCT), the primary stability will be measured immediately after implant installation and secondary stability will be measured after 12 weeks .~Both primary and secondary stability will be measured by three devices:~Osstell®: based on Resonance Frequency Analysis (RFA).~Periotest®: based on damping effect.~AnyCheck®: based on tapping-motion."
89272835|NCT05332561|Experimental|Arm 1 Atezolizumab (Immune Evasion)|Atezolizumab Dosage: 1200 mg, intravenous, on d1, q21d
89272836|NCT05332561|Experimental|Arm 2 Inavolisib (PI3K)|Inavolisib Dosage: 9 mg, oral, on d1-d28, q28d
89272837|NCT05332561|Experimental|Arm 3 Ipatasertib (AKT)|Ipatasertib Dosage: 400 mg, oral, on d1-d21, q28d
89272838|NCT05332561|Experimental|Arm 4 Olaparib (PARP, DNA-Repair)|Olaparib Dosage: 300 mg, oral, bid d1-d28, q28d
89272839|NCT05332561|Experimental|Arm 5 Sacituzumab Govitecan (TROP-2)|Sacituzumab Govitecan Dosage: 10 mg/kg BW, intravenous, on d1 and d8, q21d
89272840|NCT05332561|Experimental|Arm 6 Trastuzumab/Pertuzumab (ERBBB)|Trastuzumab/Pertuzumab Administration: subcutaneous; Initial dose: Trastuzumab 600 mg, Pertuzumab 1200 mg, 30 000 units hyaluronidase; Maintainance dose: Trastuzumab 600 mg, Pertuzumab 600 mg, 20 000 units hyaluronidase; Frequency: on d1, q21d
89272841|NCT05332561|No Intervention|Arm 7 Observation|Observation
89272842|NCT05329948|Experimental|haptonomy application|The data will be obtained by applying a pre-test to the pregnant women and their spouses included in the experimental group before the application. After the pre-test data are collected, 5 sessions of haptonomy will be applied to the couples in the experimental group. Each session (Breath awareness and diaphragm breathing 5 minutes, Feminine energy attunement and heart-looking energy work 5 minutes, Physical communication with the baby in the womb with touches 10 minutes, meditation from the heart to the uterus 15 minutes, awareness of the environment, closing breath and feedback 5 minutes) It will be 40 minutes. For the effectiveness and continuity between each session, planning will be made for 3 days to 7 days. The final test will be applied 1 week after the hapatonomy application (after 5 sessions are completed).
89272843|NCT05329948|No Intervention|Control|no application will be made
89272844|NCT05328791|Experimental|Mindfulness+Diet intervention|Diet and mindfulness intervention
89272845|NCT05328791|Experimental|Diet intervention|Diet intervention
89272846|NCT05326815||Osteopenia, no past medical therapy|Patients diagnosed with osteopenia on DEXA scan who have not been on any medical therapy in the past
89272847|NCT05323591||Filgotinib|Participants will receive treatment for moderate to severe active RA with at least one dose of filgotinib in accordance with the product label.
89272848|NCT05319470||Study Group|100 patients with diagnosed glaucoma receiving travoprost without preservatives
89272849|NCT05307952|Experimental|Fitting and Training Intervention|"All participants will undergo the full set of diagnostic visits and both Fitting and Training interventions.~The Fitting Intervention is an adjustment of their processors' MAPs based on their error pattern.~The Training Intervention is a personalized training via an app focusing on their most frequent errors."
89272850|NCT05307432|Active Comparator|Enhanced Usual Care|ED staff deliver SPI+ (Safety Planning Intervention plus 2 or more post-discharge telephone calls) to suicidal patients who are not admitted to an inpatient unit.
89272851|NCT05307432|Experimental|Suicide Prevention Consultation Center|ED staff refer suicidal patients not admitted to an inpatient unit to the off-site Suicide Prevention Consultation Center (SPCC). SPCC clinicians will deliver SPI+ (Safety Planning Intervention plus 2 or more post-discharge telephone calls) to patients via telehealth.
89272852|NCT05303935|Experimental|Quetiapine|Quetiapine 50mg in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
89272853|NCT05303935|Placebo Comparator|Placebo|Placebo sugar pill in the form of one capsule, taken before bedtime. Dosage is taken on one instance for one night only.
89272854|NCT05298449|Experimental|HU-045 group|"HU-045 Injection group will receive intramuscular injection of HU-045 to a total of 5 glabellar line sites 4 U/0.1ml each.~HU-045 will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
89272855|NCT05298449|Active Comparator|Xeomin® group|"Xeomin® Injection group will receive intramuscular injection of Xeomin® to a total of 5 glabellar line sites 4 U/0.1ml each.~Xeomin® will be reconstituted from a powder into liquid form by adding 2.5cc of 0.9% sterile saline to the vial, and appropriate volumes will be administered."
89272857|NCT05296525|Other|GDA-201|"Phase 1 dose escalation with up to 4 dose levels to reach MTD and determine recommended phase 2 dose (RP2D).~Phase 2 RP2D will be administered to all patients."
89272858|NCT05292547|Active Comparator|Arm 1|Subjects receive 20 rTMS sessions in 2 weeks
89272859|NCT05292547|Active Comparator|Arm 2|Subjects receive 20 rTMS sessions in 4 weeks
89272860|NCT05292547|Active Comparator|Arm 3|Subjects receive 20 rTMS sessions in 5 weeks
89272861|NCT05292469|No Intervention|Control arm|Routine hypertension care
89272862|NCT05292469|Experimental|Intervention arm|Comprehensive approach to hypertension management that includes BP audit and feedback by physician (nurse and doctor), and patient support to monitor BP, and home based patient care by community health workers to encourage self-monitoring of BP followed by tailored educational counselling on behavioral and lifestyle change in addition to routine care.
89272863|NCT05291247||Heavily calcified femoropopliteal disease|"Subject must be between 21 and 85 years old~Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5~Willing to comply with the specified follow-up evaluation~Written informed consent prior to any study procedures"
89272864|NCT05291130||Plasmafit® Vitelene® Vitamin E ceramic femoral heads|Plasmafit® Acetabular Cup System with Vitelene® is a highly crosslinked polyethylene stabilized with vitamin E and bioceramic femoral heads
89272865|NCT05291130||Plasmafit® Vitelene® Vitamin E metal femoral heads|Plasmafit® Acetabular Cup System with Vitelene® is a highly crosslinked polyethylene stabilized with vitamin E and metal femoral heads
89272866|NCT05291130||Plasmafit® polyethylene metal femoral heads|Plasmafit® Acetabular Cup System with polyethylene and metal femoral heads
89272867|NCT05283200|Experimental|Yoga|"The goal for the yoga intervention is to provide participants with instructor-guided safe, gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction. We aim for participants to utilize the skills and strategies taught through this intervention to reduce seizure frequency, anxiety symptoms, disability, and improve quality of life.~Participants enrolled in the Yoga intervention group will receive one month of Instructor-Guided 70-minute virtual live yoga classes, twice per week, led by an experienced yoga therapist and co-instructor. During Months 2-3 participants in the Yoga Intervention will receive one 70-minute virtual live yoga class per week. Each session will have a set of specific poses, breathing exercises, meditation, and yoga philosophies developed by our yoga experts."
89272868|NCT05283200|Experimental|Cognitive Behavioral Therapy|"The goal of the Cognitive Behavioral Therapy (CBT) intervention is to provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills. We aim for participants to utilize the skills and strategies taught through this intervention to reduce seizure frequency, depression and anxiety symptoms, disability and improve quality of life.~Participants enrolled in the CBT intervention group will receive 3 months of Instructor-Guided 90-minute, virtual group counseling session, once per week, led by a psychologist and a co-therapist."
89272869|NCT05283200|Experimental|Music|"The aim of this intervention is for participants to learn and develop skills to reduce stress which may, in turn, decrease seizure frequency and improve quality of life. Participants will be exposed to a variety of ways that they might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.~Participants enrolled in the Music Intervention group will receive one month of Instructor-Guided Intervention 70-minute virtual live music therapy sessions, twice per week, led by an experienced music therapist and co-instructor. An two months of a 70-minute virtual live music therapy session once per week."
89272870|NCT05283200|No Intervention|Standard of Care|Participants randomized to the Standard of Care Control Group will receive their usual standard epilepsy care. Participants will receive a brief monthly call for checking-in and collection of seizure frequency. Upon completion of the study, participants will receive access to online materials for all intervention modalities if they wish.
89272871|NCT05283200|No Intervention|Enhanced Standard of Care|Participants randomized to the Enhanced Standard of Care Control Group will receive their usual standard epilepsy care and weekly scheduled, scripted, follow-up phone calls from a study team member to check-in on their health, epilepsy management, and seizure frequency. Upon completion of the study, participants will receive access to online materials for all intervention modalities if they wish.
89272872|NCT05280691|Other|Family Support Intervention|Families in the intervention group receive the Family Support Intervention in addition to usual care
89272873|NCT05280691|No Intervention|Usual Care|Families in the control group will receive usual care.
89272874|NCT05279508|Experimental|Prevention treatment group|"10 week stroke prevention program with six group sessions on pre-set themes targeting modifiable stroke risk factors . The group sessions are chaired by health professionals but also consists of peer learning to support change in lifestyle habits and activity patterns and reduce stroke risk. The change process is supported with a mHealth application for daily registrering of six domains; stroke risk factors, EEA, stress and goal achievement.~A lifestyle and stroke risk analysis will be performed at baseline measures, at follow up and at 12 month follow up."
89272875|NCT05279508|No Intervention|Standard treatment group|Usual care within primary healthcare. At baseline, follow up and at 12 month follow up a lifestyle and stroke risk analysis will be conducted.
89272876|NCT05276505|No Intervention|Control Group - Standardized care|"Standardized nursing care applications~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
89272877|NCT05276505|Experimental|Experimental Group- Lavender Aromatherapy Tablet|"Before 20 minutes from breast biopsy. Lavender aromatherapy tablets. A small (approximately 1x 0.5 inch), rectangular, absorbent tablet containing 2 ml of lavender essential oil (10) was adhered to the patient's shoulder level in the waiting room.~Patients were asked to inhale the aromatherapy tablet for 20 minutes before the procedure.~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
89272878|NCT05276505|Experimental|Experimental Group- Lavender-Mint Aromatherapy Tablet|"Before 20 minutes from breast biopsy. Lavender-Mint aromatherapy tablets. A small (approximately 1x 0.5 inch), rectangular, absorbent tablet containing 2 ml of lavender essential oil (10) was adhered to the patient's shoulder level in the waiting room.~Patients were asked to inhale the aromatherapy tablet for 20 minutes before the procedure.~Evaluation with STAI scale (anxiety levels) breast biopsy Evaluation with the STAI scale (anxiety levels) after the breast biopsy procedure"
89272879|NCT05274022|Placebo Comparator|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits.
89272880|NCT05274022|Experimental|Standard of Care Physical Therapy Program with Speed Walking Intervention|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. Additionally, subjects will complete the speed walking intervention. Participants will perform at 2 minute warm up followed by 1 minute of walking at their fastest tolerable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing. The subjects will perform 4 cycles of this followed by a 2 minute cool down at the end.
89272881|NCT05247710||Patients diagnosed with non-superficial basal cell carcinoma|
89272882|NCT05247190|Experimental|Treating self-criticism|8-session group intervention targeting self-criticism given 2-hrs/week with booster session after 3-months.
89272883|NCT05243797|Experimental|Arm A: Teclistamab-Lenalidomide (Tec-Len)|Teclistamab will be administered via a subcutaneous injection (SC)
89272884|NCT05243797|Active Comparator|Arm B Lenalidomide Alone (Len)|Lenalidomide orally.
89272885|NCT05243797|Experimental|Arm C Teclistamab-Alone (Tec)|Teclistamab will be administered via a subcutaneous injection (SC)
89272886|NCT05236829||Healthy group|Healthy women aged 18-55 who have not been diagnosed with any chronic disease and pituitary adenoma
89272887|NCT05236829||Patient with Prolactinoma group|Women between the ages of 18-55 diagnosed with Prolactinoma
89272888|NCT05233878||Cohort group|Patients over 18 with a confirmed diagnosis of one or multiple cervical paragangliomas
89272889|NCT05221008|Experimental|group A|Experimental: SHR6508 Placebo Comparator: normal saline
89272890|NCT05221008|Experimental|group B|Experimental: SHR6508 Placebo Comparator: normal saline
89272891|NCT05221008|Experimental|group C|Experimental: SHR6508 Placebo Comparator: normal saline
89272892|NCT05221008|Experimental|group D|Experimental: SHR6508 Placebo Comparator: normal saline
89272893|NCT05209581||Study Group|Adult refugees/immigrants living in accommodation structures
89272894|NCT05206266|Experimental|Turmeric, then Turmeric+Black Pepper|Participants first receive Turmeric (Turmeric provided at 300mg, 1g or 3g; n=10 subjects/amount with no black pepper) for 1 week. After a 1 week washout, participants then receive Turmeric at the previous amount plus Black Pepper (Turmeric provided at 300mg, 1g or 3g daily; n=10 subjects/amount and Black Pepper 300mg/subject daily) for 1 week.
89272895|NCT05206266|Experimental|Turmeric+Black Pepper, then Turmeric|Participants first receive Turmeric+Black Pepper (Turmeric provided at 300mg, 1g or 3g daily; n=10 subjects/amount and Black Pepper at 300mg/subject daily) for 1 week. After a 1 week washout, participants then receive Turmeric daily at the previous amount for 1 week (Turmeric provided at 300mg, 1g or 3g; n=10 subjects/amount with no black pepper).
89272896|NCT05196100|Experimental|Confidence socket|Participants to receive a confidence socket system
89272897|NCT05195333|Experimental|First group|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient. You will be asked to do these exercises as home exercise with 10 repetitions 3 days a week, until the 34th week of pregnancy.
89272898|NCT05195333|Experimental|Second group|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy
89272899|NCT05195333|No Intervention|Third group|The participants will not be given any exercise program, they will be asked to continue their routine care.
89272900|NCT05190757||Laryngeal Mask Airway|
89272901|NCT05190757||Face Mask|
89272902|NCT05169489|Experimental|bbT369 Experimental Arm|Open label, single arm treatment with bbT369
89272903|NCT05169268||MainRexult Group|Subjects with schizophrenia and related disorders receiving Abilify Maintena (aripiprazole 1 monthly depot) together with Rexulti (Brexpiprazole)
89272904|NCT05166746|Active Comparator|Clindamycin + LACTIN-V (L.crispatus)|Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.
89272905|NCT05166746|Active Comparator|Clindamycin + placebo LACTIN-V|Oral Clindamycin 300 mg 2 times per day for 7 days followed by LACTIN-V placebo (Osel, Inc.) until completion of the clinical pregnancy scan at week 7-9.
89272906|NCT05166746|Placebo Comparator|Placebo clindamycin + placebo LACTIN-V|Matching clindamycin placebo 2 times per day for 7 days followed by LACTIN-V placebo (Osel Inc.) until completion of the clinical pregnancy scan at week 7-9.
89272907|NCT05165121|Other|Human Factors|The purpose of the human factor study was to verify the feasibility of self-fitting MDHearing Smart hearing aid by listeners with a mild to moderate sensorineural hearing loss.
89272908|NCT05165121|Other|Clinical Study|The clinical study included two groups of subjects (self-fit and professional-fit groups) with the main purpose to compare the fitting outcomes between the two fitting groups. The professional-fit group aimed to show whether the MDHearing Smart hearing aids can be fitted by audiology professional on each user reliably and if each user can benefit from using the MDHearing smart hearing aids. The self fit group intended to show whether the MDHearing Smart hearing aids can be fitted by each user reliably and if each user can use the MDHearing app on their smartphone or tablet to make adjustments to achieve a good aided benefit.
89272909|NCT05160298|Experimental|Ropivacaine group|Performance of an echo-guided bilateral erector spinae block at the arrival in the intensive care unit with 20ml of Ropivacaine 2mg/ml in each side.
89272910|NCT05160298|Sham Comparator|Control group|Performance of a sham block at the arrival in the intensive care unit with no drugs administration
89272911|NCT05155579|Experimental|Groups 1a, 2a and 3a|60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a two vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1a is 20 children aged 5-11 months, group 2a is 20 children aged 12-23 months, and group 3a is 20 children aged 24-36 months.
89272912|NCT05155579|Experimental|Group 1b, 2b and 3b|60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a single vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1b is 20 children aged 5-11 months, group 2b is 20 children aged 12-23 months, and group 3b is 20 children aged 24-36 months.
89272913|NCT05155579|Experimental|Group 4a|150 participants, aged 6-7 months at the time of randomisation (to ensure third vaccination is given at approximately 9 months), who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart. At the time of the third dose they will receive their measles-rubella and yellow fever vaccinations at the same time as R21/Matrix-M.
89272914|NCT05155579|Active Comparator|Group 4b|150 participants, aged 6-7 months at the time of randomisation, who will receive a measles-rubella and yellow fever vaccination 2 months after randomisation.
89272915|NCT05155579|Experimental|Group 4c|Group 4c is 50 participants, aged 6-7 months at the time of randomisation, who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart.
89272916|NCT05155579|Experimental|Group 5a|30 children who will receive 3 doses of 5µg R21/50µg Matrix-M, pentavalent, rotavirus, pneumococcal and OPV vaccines at 6, 10 and 14 weeks of age. They will receive IPV two weeks following the third dose.
89272917|NCT05155579|Active Comparator|Group 5b|30 children who will receive 3 doses of pentavalent, rotavirus, pneumococcal and OPV vaccines at 6, 10 and 14 weeks of age. They will receive IPV two weeks following the third dose.
89272918|NCT05155579|Experimental|Group 6a|30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 6 months after the first dose.
89272919|NCT05155579|Experimental|Group 6b|30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 12 months after the first dose.
89272920|NCT05154916|Experimental|Experimental:|Bronchoscopy of Virtual Reality Based Relaxation Program Will Be Applied
89272921|NCT05154916|No Intervention|No Intervention|Bronchoscopy of Virtual Reality Based Relaxation Program Will Not Be Applied
89272922|NCT05152810|Experimental|Active Transcranial Magnetic Stimulation|
89272923|NCT05152810|Placebo Comparator|Transcranial magnetic resonance imaging placebo|
89272924|NCT05150002|Experimental|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
89272925|NCT05143281|Experimental|Dexamethasone Ophthalmic Insert Day of Surgery|Day of surgery, in OR placement
89272926|NCT05143281|Experimental|Dexamethasone Ophthalmic Insert Day 1 Post Op|Day 1 Post-Op, In-office (HOPD)
89272927|NCT05139719|Experimental|HEC585 tables does A|
89272928|NCT05139719|Experimental|HEC585 tables does B|
89272929|NCT05139719|Placebo Comparator|placebo|Placebo once daily up to 24 weeks in main stage; HEC585 dose A once daily up to 96 weeks in extended stage
89272930|NCT05137210|Experimental|Male-specific counseling and facility navigation|
89272931|NCT05137210|Experimental|Home-Based ART Initiation|
89272932|NCT05137210|Experimental|Stepped Intervention|
89272933|NCT05128422|Experimental|NBO+EVT group|Normobaric hyperoxia Combined with Endovascular therapy group were given 100% oxygen via a face mask initiated before vascular recanalization (10L/min for 4h) . In addition, the patient will be given endovascular therapy surgery.
89272934|NCT05128422|No Intervention|EVT group|The Endovascular therapy group were given room air. And the patient will also be given endovascular therapy surgery.
89272935|NCT05119270|Experimental|Femtosecond laser assisted cataract surgery with Active Sentry handpiece|Participants suffering from cataract who are candidates for femtosecond laser assisted cataract surgery
89272936|NCT05119270|Experimental|Standard phacoemulsification with the Active Sentry handpiece|Participants suffering from cataract who are candidates for standard phacoemulsification with the new Active Sentry handpiece
89272937|NCT05119270|Experimental|Standard phacoemulsification with the OZil handpiece|Participants suffering from cataract who are candidates for standard phacoemulsification with the traditional OZil handpiece
89272938|NCT05117710|Active Comparator|Ebselen|The intervention will be 7-10 days administration of ebselen 600 mg twice daily taken orally. Ebselen has been manufactured to Good Manufacturing Practice (GMP) standards and will be provided by Sound Pharmaceuticals Inc. in 200 mg capsules.
89272939|NCT05117710|Placebo Comparator|Placebo|The intervention will be 7-10 days administration of placebo 600 mg twice daily taken orally.Identical placebo capsules have been manufactured and formulated in the same facilities as the active treatment.
89272940|NCT05105022|Experimental|propofol|Propofol at a dose of 2mg/kg will be administered I.V. .
89272941|NCT05105022|Active Comparator|Sevoflurane|Sevoflurane (4%) will be used for inhalational induction.
89272942|NCT05102760|Active Comparator|Fascia Iliaca Compartment|Fascial Iliaca block (FIC) (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED
89272943|NCT05102760|Active Comparator|PENG Block|Pericapsular Nerve Group (PENG) Block (20mL of Bupivacaine 0.50%)
89272944|NCT05099718|Experimental|Hyaluronic acid|Application 3-times per day for 7 days.
89272945|NCT05099718|Placebo Comparator|Saline solution|Application 3-times per day for 7 days.
89272946|NCT05096624|Experimental|DD-TENS (Digital Denture-Transcutaneous Electrical Nerve Stimulation)|Patient with Complete Removable Prostheses according to DD-TENS system
89272947|NCT05096624|Active Comparator|Gold standard|Patient with Complete Removable Prostheses according to usual care
89272948|NCT05096624|Active Comparator|Digital denture System|Patient with Complete Removable Prostheses according to Digital Denture system
89272949|NCT05096468|Experimental|S-ketamine and pregabalin|
89272950|NCT05096468|Placebo Comparator|Normal saline and placebo capsule|
89272951|NCT05093842|Experimental|Sedentary Behavior Reduction Intervention|Biweekly virtual health coaching, height-adjustable work station, and fitbit - targetting decreasing sedentary behavior, increasing standing, and increasing steps per day. Printable information on physical activity recommendations also provided.
89272952|NCT05093842|Active Comparator|Usual Care Control|Printable information on physical activity recommendations only
89272953|NCT05088421|Experimental|BWC0977|"SAD Cohorts: Subjects will receive single doses of BWC0977 via IV infusion over 2 hours. Planned doses to be studied are 120, 240, 480, 720, and 1050mg.~MAD Cohorts: Subjects will receive multiple doses of 240mg TID 7 days, 350mg TID 7 days BWC0977 via IV infusion over 2 hours in the first 2 cohorts. The dose for the B3 cohort will be determined based on safety and tolerability data from the previous two cohorts Up to three dose groups will be studied."
89272954|NCT05088421|Placebo Comparator|Placebo|"Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hour.~MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hour for 10 consecutive days. Frequency of infusions will be determined based on safety, tolerability and PK data obtained for BWC0977 in SAD Cohorts."
89272955|NCT05085392|Experimental|Experimental Group Yoga|35 rural teachers in a southwestern Montana school district participating in a trauma-informed yoga intervention
89272956|NCT05085392|No Intervention|No Intervention|No participants were assigned to the No Intervention Arm
89272957|NCT05084365|Experimental|sulforaphane|The goal of the study is to investigate whether adding sulforaphane will benefit cognitive function in individuals who have PD.
89272958|NCT05084365|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
89272959|NCT05079789|Experimental|Amiloride|Treatment wirh Amiloride, start dose 5 mg
89272960|NCT05079789|Active Comparator|Furosemide|Treatment with Furosemide, start dose 40 mg
89272961|NCT05069324||Acromegaly patients not adequately controlled by any kind of SSAs monotherapy|Acromegaly patients not adequately controlled by any kind of SSAs monotherapy, requiring PEG in combination with SSAs or PEG monotherapy
89272962|NCT05069324||Acromegaly patients adequately controlled by medical treatment|Acromegaly patients adequately controlled by medical treatment, by any kind of SSAs or by PEG
89272963|NCT05069324||Healthy controls|Healthy volunteers matched with patients for age and sex
89272964|NCT05063227||Study group|As this is a single-group, observational study all patients will be monitored with all three nociception monitoring systems (the Surgical Pleth Index (SPI), the Pupillary Pain Index (PPI) and the Nociception Level (NOL)) and data on heart rate changes as a variable used in current clinical practice to choose the opioid dosage during general anesthesia will be obtained additionally.
89272965|NCT05057884|Experimental|Breathing training|The respiratory pattern modulation training is performed at home for 12 weeks twice daily for 15 min per session and consists of three components: 1) education on abnormal ventilation in heart failure, the effect of ventilation on PaCO2 and the autonomous nervous system, and chemoreceptor sensitivity; 2) 1-3 sessions of guided and monitored face-to-face training with slow nasal abdominal breathing and intermittent apnoea supported by the Healer vest (L.I.F.E., Milan, Italy) measuring electrocardiogram (ECG), and chest excursions at the level of the xiphoid, thoracic manubrium, and abdomen; 3) independent home-based apnoea training supported by hand-outs, videos and weekly phone calls to monitor progress and adherence, answer questions and encourage further progression with duration of breath-hold.
89272966|NCT05057884|No Intervention|Control|The control group receives standard of care. They perform the study measurements before and after the intervention period of 12 weeks. They are offered to perform the breathing training after study completion.
89272967|NCT05051995|Placebo Comparator|Open-label placebo ABAB Sequence|The N-of-1 trial will, on the level of the individual patient, test whether open-label placebo reduces negative side effects caused by discontinuation of antidepressants compared to no treatment. After antidepressant discontinuation, subjects will be randomized to 2 arms differing in the treatment order (ABAB; BABA). Subjects in this arm (ABAB) will start with open-label placebo (A) for 2 weeks; they will then crossover to no treatment (B) for 2 weeks and repeat this sequence once again.
89272968|NCT05051995|Placebo Comparator|Open-label placebo BABA Sequence|The N-of-1 trial will, on the level of the individual patient, test whether open-label placebo reduces negative side effects caused by discontinuation of antidepressants compared to no treatment. After antidepressant discontinuation, subjects will be randomized to 2 arms differing in the treatment order (ABAB; BABA). Subjects in this arm (BABA) will start with no treatment (B) for 2 weeks; they will then crossover to open-label placebo (A) for 2 weeks and repeat this sequence once again.
89272969|NCT05039554|Active Comparator|acceptance and commitment therapy (ACT) alone|Participants randomized to this cohort will receive only acceptance and commitment therapy.
89272970|NCT05039554|Active Comparator|Valera smartphone application (app) alone|Participants randomized to this cohort will receive the Valera app and will receive a smartphone with network connectivity if necessary.
89272971|NCT05039554|Experimental|ACT + Valera app|Participants randomized to this cohort will receive both ACT and the Valera app (and a smartphone with network connectivity if necessary).
89272972|NCT05039554|Placebo Comparator|treatment as usual (TAU)|Participants randomized to this cohort will not receive any experimental treatments.
89272973|NCT05039151||septic shock|50 patients with a diagnosis of septic shock established within 24 hours of admission with oedemas
89272974|NCT05039151||control|35 non-septic patients with oedema from another cause
89272975|NCT05036018|Active Comparator|Group 1|Patients treated with the ACURATE neo2 valve using a minimalist approach
89272976|NCT05036018|Active Comparator|Group 2|Patients treated with the ACURATE neo2 valve under standard of care
89272977|NCT05036018|Active Comparator|Group 3|Patients treated with the Evolut Pro or Pro+ valve using a minimalist approach
89272978|NCT05036018|Active Comparator|Group 4|Patients treated with the Evolut Pro or Pro+ valve under standard of care
89272979|NCT05029934|Active Comparator|EndoClot group|patients who are being provided with EndoClot adhesive spray after polyp resection
89272980|NCT05029934|Sham Comparator|Control group|no further prophylactic bleeding prevention after polyp resection
89272981|NCT05025423|Experimental|venetoclax and rituximab in patients over 60 yrs old with previously untreated mantle cell lymphoma|Venetoclax dose escalation for Cycles 1-4. If Complete response (CR) at Cycle 4, continue with cycles 5-12 at fixed venetoclax 400mg dose. If partial response (PR) at Cycle 4, continue with cycles 5-8 at fixed venetoclax 800mg dose. If CR at Cycle 8 after PR, continue with cycles 9-12 at fixed venetoclax 800mg dose. If continued PR at Cycle 8, reduce venetoclax to 400mg and add bendamustine 90 mg/m2.
89272982|NCT05024994|Experimental|E7820|Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
89272983|NCT05023993|Active Comparator|Arm I (home exercise)|Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.
89272984|NCT05023993|Experimental|Arm II (home exercise, nicotinamide riboside)|Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside PO daily for 6 weeks.
89272985|NCT05021926|Experimental|Investigational device|DKL crosslinked sodium hyaluronate 26
89272986|NCT05021926|Experimental|Comparator product|Juvéderm Voluma™ with lidocaine (Allergan, Inc)
89272987|NCT05021913|Experimental|Investigational device|DKL crosslinked sodium hyaluronate 23
89272988|NCT05021913|Active Comparator|Comparator product|Juvéderm Volift™ with lidocaine (Allergan, Inc)
89272989|NCT05021328|Experimental|Anlotinib combined with SBRT|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Toripalimab 240mg iv drip D1 + Anlotinib 12mg, QD, PO, D1-D14；~Maintenance (D22~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
89272990|NCT05021328|Experimental|Anlotinib combined with SBRT and Toripalimab|"Induction therapy (D1-D21): SBRT 7Gy✖️5 QD, D1-D5 + Anlotinib 12mg, QD, PO, D1-D14；~Maintenance (D22~1year): Toripalimab 240mg iv drip D1 Q3W + Anlotinib 12mg, QD, PO, D1-D14, Q3W, until progression (up to approximately 1 year)"
89272991|NCT05016037|Other|Lexically Based Speech Intelligibility Recast|Speech recasts are likely to improve speech intelligibility in Down Syndrome. The goal of this study is to induce change in speech intelligibility in order to study phonological, acoustic and suprasegmental sequelae of improvements in speech.
89272992|NCT05011292|Active Comparator|Control Group|The control group includes parents that will view an educational video about a topic other than infant SCB consumption.
89272993|NCT05011292|Experimental|Intervention Group|The intervention group will include those parents who participate in the study after the control data has been collected and two SCB reduction-related videos have been introduced (one for showing at the 4-month visit and one for the 12-month visit).
89272994|NCT05001620|Experimental|Palliative Care Consultation in Post-Acute Care|Subjects will receive usual care plus a telehealth palliative care consultation by specialty providers who will document their findings in the Electronic Health Record (EHR), and communicate their findings and recommendations to the clinical team.
89272995|NCT04999241|Experimental|EEN combined therapy group|in the induction of remission phase, EEN will be used combine with corticosteroids or infliximab
89272996|NCT04999241|Active Comparator|Non EEN combination group|in the induction of remission phase, corticosteroids or infliximab will be used without EEN
89272997|NCT04992065|Experimental|Oral NNC0385-0434 15 mg once-daily (OD)|15 mg NNC0385-0434 co-formulated with 500 mg Salcaprozate sodium (SNAC) tablet once daily
89272998|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 15 mg)|15 MG placebo administered as tablets (without SNAC) once daily
89272999|NCT04992065|Experimental|Oral NNC0385-0434 40 mg OD|40 mg study drug co-formulated with 500 mg SNAC tablet once daily
89273000|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 40 mg)|placebo administered as tablets (without SNAC) once daily
89273001|NCT04992065|Experimental|Oral NNC0385-0434 100 mg|100 mg NNC0385-0434 co-formulated with 500 mg SNAC tablet once daily (51 participants)
89273002|NCT04992065|Placebo Comparator|Oral placebo (NNC0385-0434 100 mg)|placebo administered as tablets (without SNAC) once daily
89273003|NCT04992065|Active Comparator|Subcutaneous evolocumab 140 mg Q2W|140 mg evolocumab Subcutaneous (s.c.) injections every 2 weeks (51 participants). The s.c. evolocumab arm is open-label to limit unnecessary injections
89273004|NCT04985747|Experimental|Polished palate|Participants will receive maxillary complete dentures with smooth palatal surfaces without modification.
89273005|NCT04985747|Experimental|Roughened palate|Participants will receive maxillary complete dentures with roughened palatal surfaces
89273006|NCT04985747|Experimental|Open palate|Participants will receive maxillary complete dentures with opened palatal surfaces
89273007|NCT04967690|Experimental|SI-053|Single arm study. Dose escalation will follow a rule-based 3 + 3 design using increasing doses of SI-053. Subjects will receive a single i.c. dose of room-tempered SI-053 gel, which will be applied onto the walls of the cavity formed after tumor resection using a sterile spatula.This will be followed by chemo-radiotherapy commencing at least 21 and no later than 35 days after SI-053 administration. The dose escalation part of the trial will follow a rule-based 3 + 3 design using a total of six dose levels of SI-053 (optional dose of 50 mg will be used to de-escalate in case of DLT at 75 mg) that consist of increasing amounts of TMZ in a constant amount of excipient and sterile WFI. These dose levels are planned to be tested in 21 subjects, including three more subjects at preliminary RP2D.The dose expansion phase will enroll an additional six subjects,to be treated at the RP2D in order to gather additional safety and preliminary efficacy data at that dose.
89273008|NCT04965857||Slides from the German Co-Screening program|From 25,000 LBC slides (ThisPrep, Hologic Inc., USA) from the German Co-screening program evaluated using the Genius Digital cytology system all abnormal findings according to Munich III groups (II-p - V) and each 10th normal slide (Munich III group I and II) will be selected for the prospective evaluation by manual microscopy.
89273009|NCT04954326|Experimental|S95014 lyophilizate|Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL. The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water for Injection to obtain a 750 U/mL solution for single use.
89273010|NCT04954326|Active Comparator|S95014 liquid|Liquid S95014 is provided as 3.750 U per 5 mL solution in a single use vial to obtain a 750 U/mL solution for single use.
89273011|NCT04942717||Aim 1|For the survey component, recruitment will focus on patients who have not participated in a semi-structured interview as part of the Aim 1 research. For Aim 1, we will seek to recruit approximately 36 patients and 12 family members for the initial key informant interviews, 20 patients for the followup survey, and 10 for the English/backtranslated-English side-by-side comparison.
89273012|NCT04942717||Aim 2|"Patients who provide consent during Months 9-11 (i.e., first three months of Control Period of pilot trial) will be in the control group, with follow-up for outcomes data collection occurring during Months 12-14. Patients who provide consent during Months 16-18 (after implementation of the intervention at the end of Month 15) will be in the intervention group and will be followed for three more months (Months 19-21) for outcomes data collection. We will enroll a total of 130 patients (65 in control period, 65 in intervention period) during the pilot trial across the two trial sites, SBH and Jacobi, to reflect, as much as possible, the relative patient numbers and the demographic composition of the sites. During the intervention period, family who accompany patients to clinic and are included (patient option to include one family member) in the CONVO values discussions will be approached (in person or via video conferencing platform or telephone) for participation at the clinic."
89273013|NCT04942574|Experimental|First experimental visit : Total Sleep Deprivation|The participants enrolled in this arm will have a total sleep deprivation on their first experimental visit and a normal sleep on their second experimental visit.
89273014|NCT04942574|Experimental|First experimental visit : Normal Sleep|The participants enrolled in this arm will have a normal on their first experimental visit and a total sleep deprivation sleep on their second experimental visit.
89273015|NCT04933435|Active Comparator|Interventional Radiology Liver Directed Therapies (ILDT)|ILDT includes ablations such as microwave ablation and percutaneous local ablation and embolotherapies including bland embolization, chemoembolization and radioembolization.
89273016|NCT04933435|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is a non-invasive, outpatient procedure typically delivered in 3-10 fractions of radiation.
89273017|NCT04927364|Experimental|Active dTMS|Participants will receive 30 dTMS treatments, administered 3 times per day over 10 consecutive business days, Each treatment visit will last approximately 30 minutes in total.
89273018|NCT04914819|Active Comparator|Online Behavioral Weight Loss|Participants will attend a virtual introduction to weight loss session and be enrolled in a 16-week online behavioral weight loss program. Participants will complete a virtual weigh-in at the start and end of the study.
89273019|NCT04914819|Active Comparator|Usual Care|Participants will complete a virtual weigh-in at the start and end of the study. No additional intervention will be provided.
89273020|NCT04906096|Experimental|PAXALISIB|"The research study procedures include: screening for eligibility and study treatment including evaluations and follow up visits.~Paxalisib (GDC-0084)~Each study treatment cycle lasts 28 days, up to 24 months."
89273021|NCT04905537||Sick Neonates or Stillbirth|Infants and their parents enrolled through Neonatal Intensive Care Unit or stillbirths through Obstetrics Department of member hospitals who are un-randomized to receive genomic sequencing. Results disclosure sessions will include a discussion of: family history report, results from standard newborn screening, any potentially medically relevant findings from the baby's medical history/ physical exam, and the results of the genomic sequencing report.
89273022|NCT04902339|Experimental|MORE+NF|
89273023|NCT04902339|Active Comparator|MORE|
89273024|NCT04902339|Active Comparator|Supportive Psychotherapy|
89273025|NCT04898114|Experimental|NebMag|Nebulized magnesium sulfate and oral sildenafil
89273026|NCT04898114|Placebo Comparator|Control|Nebulized placebo (isotonic saline) and oral sildenafil
89273027|NCT04897217|Active Comparator|Megestrol Acetate Arm - Control Arm|Megestrol Acetate 160 mg by mouth daily
89273028|NCT04897217|Experimental|Levonorgestrel IUD - Comparison Arm|Levonorgestrel intrauterine device with 52 mg progestin (Releases 20mcg/daily)
89273029|NCT04892251|Experimental|MORE+KAP|8 weeks of Mindfulness-Oriented Recovery Enhancement plus two ketamine assisted psychotherapy sessions
89273030|NCT04892251|Active Comparator|MORE|8 weeks of Mindfulness-Oriented Recovery Enhancement
89273031|NCT04888221|Experimental|tocilizumab 162mg/0.9mL administered subcutaneously (SC) weekly during 24 weeks|Tocilizumab 162mg/0.9mL administered subcutaneously (SC) weekly during 24 weeks
89273032|NCT04888221|Placebo Comparator|placebo administered subcutaneously (SC) weekly during 24 weeks|Placebo administered subcutaneously (SC) weekly during 24 weeks
89273033|NCT04875091|Experimental|Intervention|
89273034|NCT04867707|Experimental|Zanamivir treatment|Study participants will receive 5 days of treatment with a zanamivir inhaler.
89273035|NCT04867447||Case-Immigrants psychotic patients|"Individuals who have presented at least one non-affective psychotic episode with an immigrant status, defined as a person who migrates to another country, usually for permanent residence"
89273036|NCT04867447||Control-Non immigrants psychotic patients|Individuals who have presented at least one non-affective psychotic episode who do not have an immigrant status.
89273037|NCT04862000||Endometriosis or adenomyosis|participants suffering pelvic endometriosis, endometrioma, deep infiltrating endometriosis or adenomyosis
89273038|NCT04860661|Placebo Comparator|N group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 10 ml normal saline
89273039|NCT04860661|Experimental|Es group|15 minutes after umbilical cord amputation, the patient was intravenously injected with 0.25mg/kg esketamine, PCIA regimen: sufentanil 100 μ g, esketamine 80 mg, diluted to 100 ml with 0.9% normal saline, set analgesia pump background infusion dose 2 ml/h, single bolus dose 2 ml, locking time 8 minutes.
89273040|NCT04853199|Experimental|Quercetin group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal
89273041|NCT04853199|Placebo Comparator|Placebo Group|Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal
89273042|NCT04841590|Experimental|Experimental Group|The experimental group (EG) will receive treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
89273043|NCT04841590|Sham Comparator|Control Group|The control group (CG) will not receive any treatment
89273044|NCT04834297|Experimental|SVS mattress|Infants randomized to the experimental arm will have the SVS mattress placed in their crib within 48 hours of birth and will continue till discharge home after the completion of monitoring phase of NOWS or till determination is made to initiate pharmacotherapy for NOWS.
89273045|NCT04834297|No Intervention|Standard mattress|Infants randomized to the no intervention arm will continue to be cared for using the standard hospital crib mattress throughout their birth hospitalization.
89273046|NCT04826991|Active Comparator|Active UV Device|A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.
89273047|NCT04826991|Sham Comparator|Inactive UV Device|A household water treatment device with a lamp not emitting germicidal UV but still emitting light (appears identical to the active UV device).
89273048|NCT04818346|Experimental|INCB054707 Dose A followed by Dose C|Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
89273049|NCT04818346|Experimental|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).
89273050|NCT04818346|Experimental|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).
89273051|NCT04818346|Placebo Comparator|Placebo followed by INCB054707 Dose C|Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
89273052|NCT04813276|Experimental|Serious game intervention|Participants receive the Strong Together serious game program on a tablet computer.
89273053|NCT04813276|Active Comparator|Enhanced care as usual|Participants receive a paper-based self-advocacy guide.
89273054|NCT04812171||smoker participants|"Current cigarette smokers older than 18 years, without previously reported systemic disease, not taking medications influencing imunological system or bone metabolism.~Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment."
89273055|NCT04812171||non-smoker participants|Healthy non-smokers paired with smoker group according to age and gender. Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
89273056|NCT04812171||diabetic participants|Participants reporting diabetes melitus type II, having gycated hemoglobin test, not taking medications influencing imunological system or bone metabolism, non-smokers Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
89273057|NCT04812171||non-diabetic participants|Healthy non-smokers paired with diabetic group according to age and gender. Received adequate endodontic treatment of at least one tooth and attending follow-up at six months and one year following root-canal treatment.
89273058|NCT04808271|Active Comparator|Bif195 capsules|The capsule will contain approximately 15*10^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
89273059|NCT04808271|Placebo Comparator|Placebo capsules|The capsule contain only excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
89273060|NCT04801485|Active Comparator|D-chiro inositol|500 mg twice a day
89273061|NCT04801485|Placebo Comparator|Placebo|500 mg twice a day
89273062|NCT04795141|Experimental|#1: Cohort 1-High Dose Q2W|Cohort 1: ABY-035 High Dose, every 2 weeks, subcutaneous injection
89273063|NCT04795141|Experimental|#2: Cohort 1-High Dose Q4W|Cohort 1: ABY-035 High Dose, every 4 weeks, subcutaneous injection
89273064|NCT04795141|Experimental|#3: Cohort 1-Low Dose Q2W|Cohort 1: ABY-035 Low Dose, every 2 weeks, subcutaneous injection
89273065|NCT04795141|Experimental|#4: Cohort 2-Low Dose QW|Cohort 2: ABY-035 Low Dose, every week, subcutaneous injection
89273066|NCT04795141|Experimental|#5: Cohort 2-High Dose QW|Cohort 2: ABY-035 High Dose, every week, subcutaneous injection
89273067|NCT04795141|Placebo Comparator|#1: Cohort 1-Placebo Q2W|Cohort 1: Placebo, every 2 weeks, subcutaneous injection
89273068|NCT04795141|Placebo Comparator|#2: Cohort 2-Placebo QW|Cohort 2: Placebo, every week, subcutaneous injection
89273069|NCT04766632|Experimental|one group|patients with high grade glioma
89273070|NCT04753970|Experimental|Cilostazol|Cilostazol 100mg BID
89273071|NCT04753970|No Intervention|No intervention|
89273072|NCT04741204|Experimental|White women|White women on metformin Extended release 750 mg BID
89273073|NCT04741204|Experimental|Black women|Black women on metformin Extended release 750 mg BID
89273074|NCT04735081||First group before practice change|Infectious spondylodiscitis when prolonged immoblization in bed was recommanded in our hospital
89273075|NCT04735081||Second group after practice change|Infectious spondylodiscitis when early verticalization was recommanded in our hospital
89273076|NCT04727723||Lutathera®|Lutathera® will be administered according to the local label and according to the recommended treatment regimen in adults consisting of four equally divided doses of Lutathera® for a total of 29.6 GBq (800 mCi).
89273077|NCT04725188|Experimental|Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m^2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity.
89273078|NCT04725188|Experimental|Arm 2: Pembrolizumab/Vibostolimab coformulation|Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years.
89273079|NCT04725188|Active Comparator|Arm 3: Placebo + Docetaxel|Participants receive normal saline IV infusion, Q3W for up to 35 cycles up to approximately 2 years plus Docetaxel 75 mg/m^2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity.
89273080|NCT04723394|Experimental|AZD7442|Up to approximately 1700 participants will be randomized in a 1:1 ratio. Arm 1 (n=up to approximately 850) will receive a single dose (× 2 IM injections) of 600 mg of AZD7442.
89273081|NCT04723394|Placebo Comparator|Placebo|Up to approximately 1700 participants will be randomized in a 1:1 ratio. Arm 2 (n=up to approximately 850) will receive saline placebo.
89273082|NCT04719897|Experimental|FIRST: Repairing Thoughts|
89273083|NCT04718792|Experimental|Psilocybin|10 patients will receive a single administration of psilocybin
89273084|NCT04713033|Experimental|Experiment 1|Experiment 1 (Aim 1) will utilize a 16-channel sEMG array to characterize cervical-cranial muscle activity networks in typical speakers at baseline and after a vocal loading task. Flexible laryngoscopy will be performed to exclude any existing pathology and confirm eligibility in the healthy control group. Aim 2 will quantify how cervical muscle networks are perturbed in patients with two different types of dysphonia and examine if standard-of-care treatment restores cervical-cranial muscle networks to more typical states.
89273085|NCT04713033|Experimental|Experiment 2|In Experiment 2 (Aim 2), the study will measure muscle networks in patients with muscle tension dysphonia before and after a course of voice therapy. Patients with muscle tension dysphonia represent an intact but potentially maladaptive network.
89273086|NCT04713033|Experimental|Experiment 3|In Experiment 3 (Aim 2), the study will measure patients with unilateral vocal old paralysis, representing a neurologically impaired network, before and after a vocal fold medialization procedure.
89273087|NCT04706195|Experimental|Person-centred care|PCC in the form of a combined eHealth and structured telephone support combined with an eHealth support on top of usual care
89273088|NCT04706195|No Intervention|Usual care|Regular evidence-based treatment and care as outlined in treatment guidelines and followed as usual at their local primary care center
89273089|NCT04701931||Subjects presenting with Normal Eyes|Subjects with no known ocular diseases will be imaged on the Maestro2 OCT, Zeiss Cirrus HD-OCT 5000, and TRC-50DX
89273090|NCT04701931||Subjects with retinal pathology present in the eye|Subjects with no known ocular diseases will be imaged on the Maestro2 OCT, Zeiss Cirrus HD-OCT 5000, and TRC-50DX
89273091|NCT04693624||Hormonal levels|Blood samples are collected for analysis of progesterone, hCG, inhibin-A, and 17-OH-Progesterone levels.
89273092|NCT04681651|Experimental|NBO group|Normobaric Hyperoxia combined with endovascular mechanical thrombectomy
89273093|NCT04681651|Placebo Comparator|Control group|Inhale air placebo plus endovascular mechanical thrombectomy
89273094|NCT04678258|Active Comparator|Group 1: MVG ablation|Group 1 - MVG: high-resolution mapping and maximum voltage guided stepwise CTI ablation (stepwise voltage guided approach (SVG)).
89273095|NCT04678258|Active Comparator|Group 2 - control: linear ablation|Group 2 - control: conventional bipolar mapping and conventional linear CTI ablation.
89273096|NCT04667585|Experimental|Interim PET-CT with dose de-escalation|Participants will receive an interim PET-CT approximately 2 weeks into radiation therapy.
89273097|NCT04667585|Active Comparator|Interim PET-CT with standard radiation|
89273098|NCT04665336|Experimental|Intervention Group Lifestyle counseling|"Obese individuals with evening chronotype will be trained on sleep hygiene in order to create behavioral changes in line with circadian rhythms and an intervention program called Circadian Timing Program which was created by the researcher in line with the relevant literature will be implemented for 12 weeks. This program includes sleep hygiene recommendations and regulation of daylight exposure, sleep, meal, caffeine intake and exercise times. To determine participants' sleep times they will be asked to keep a sleep diary and sleep records will be taken with the smart bracelet. Participants will be given a password to access the research website. The website of the study will be used for the training, control, motivation and communication of the Participants."
89273099|NCT04665336|No Intervention|Control group|Participants will be asked to follow their normal daily lifestyle, maintain normal sleep and eating habits and no further instructions or suggestions will be provided during the study.
89273100|NCT04663061|Experimental|High intensity medical weight loss (HIWL)|Participants randomized to the HIWL treatment group will be placed on a meal replacement-based weight loss protocol. Participants will consume a minimum of 80 grams of protein daily in 4-5 servings of meal replacement. Participants will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-24, caloric prescriptions will be between 1100 to 1600 calories a day, using a combination of meal replacements and food, for continued weight loss. Beyond week 25, caloric intake will be individually tailored to achieve continued gradual weight loss or maintenance of body weight based on individual weight loss goals. We will recommend continued use of at least 1 serving of meal replacement per day for maintenance of weight loss.
89273101|NCT04663061|Active Comparator|Diabetes self-management education (DSME)|"The DSME intervention will be administered and delivered at the Wake Forest Baptist Health Diabetes Center, located next to the Weight Management Center, by a team of certified diabetes educators, nurses, and nutritionists in group and individual settings.~The diabetes education program is accredited by the American Diabetes Association in recognition of meeting national standards for diabetes self-management education. The goal of the program is to provide participants with information to make informed decisions about how to best integrate diabetes management strategies into their daily lives. Assessment, planning, implementation, and evaluation are the basic components of the diabetes education process."
89273102|NCT04663061|Experimental|High intensity medical weight loss (HIWL) plus continuous glucose monitoring (CGM)|Participants randomized to the HIWL + CGM treatment group will be placed on a meal replacement-based weight loss protocol as described in the HIWL arm. In addition, the participants in this arm will receive a supply of continuous glucose monitors to use throughout the trial. The CGM we provide will give the patient instant feedback on blood glucose levels and be readable using a mobile phone device or an associated CGM reader. The data from the CGM will be integrated into the Carium app and used to help guide the patient's actions based on defined care pathways.
89273103|NCT04661033|Experimental|Isatuximab Part A/Cohort 1|Isatuximab dose subcutaneous (SC) every 2 weeks x 2 doses
89273104|NCT04661033|Experimental|Isatuximab Part A/Cohort 2|Isatuximab dose subcutaneous (SC) every 2 weeks x 6 doses
89273105|NCT04661033|Experimental|Isatuximab Part A/Cohort 3 (optional)|Isatuximab dose subcutaneous (SC) every 2 weeks x 2 doses
89273106|NCT04661033|Experimental|Isatuximab Part B|Isatuximab dose subcutaneous (SC) every 2 weeks x 6 doses
89273107|NCT04656145|Experimental|Chlorhexidine Gluconate Gel Dressing|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to receive the intervention.
89273108|NCT04656145|No Intervention|Standard of Care|All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to received standard drain care - gauze (no intervention).
89273109|NCT04646616|Experimental|Community popular opinion leader (POL)|After successful completion of the new COVID-19 training module, POLs will reach out to members of their social networks to model and diffuse social norms to reduce the risk of COVID-19 infection and transmission, screen for symptoms and counsel regarding COVID-19, SAVAME syndemic factors, and refer at-risk or affected individuals to appropriate community services (e.g. free COVID-19 testing and treatment, mental health services, substance use services, violence prevention, support groups, etc.). As in other POL based interventions and pragmatic trials, POLs be asked to follow up with their community contacts to monitor their situation and provide additional support, but there will be flexibility with the frequency and number of follow up contacts depending on their needs identified and the preferences of the community contact. POLs will be continually supported by the research team via face-to-face biweekly booster sessions (if COVID-19 situation requires it) or by zoom.
89273110|NCT04639583|Experimental|Observational Arm|Any infant consented to participate in the study will have the NIRS applied for the first 96 hours of life. It will be the goal to apply the NIRS sensors in the first 12 hours of life. All infants will have the same treatment if in the study, but clinicians will not be able to see the data obtained so that there is no clinical interpretation during this time.
89273111|NCT04635657||Meningioma Group|This group will include all patients in the study, regardless of location (frontal or temporal lobe) or surgical approach (endoscopic endonasal or craniotomy). Fifty patients will be included in the cohort
89273112|NCT04618718|Experimental|Intervention|ProtEmbo device will be used as distal protection device in subjects undergoing TAVR
89273113|NCT04613206|Experimental|Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.7 mL HD-IIV (60µg of each influenza antigen) 28-42 days apart
89273114|NCT04613206|Experimental|Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine|two doses of 0.5 mL SD-IIV (15µg of each influenza antigen) 28-42 days apart
89273115|NCT04613206|Experimental|One Dose High Dose Quadrivalent Inactivated Influenza Vaccine|one dose of 0.7 mL HD-IIV (60µg of each influenza antigen) followed by placebo 28-42 days later
89273116|NCT04610892|Experimental|MEDI6570 Low dose|Monthly Subcutaneous administration.
89273117|NCT04610892|Experimental|MEDI6570 Medium dose|Monthly Subcutaneous administration.
89273118|NCT04610892|Experimental|MEDI6570 High dose|Monthly Subcutaneous administration.
89273119|NCT04610892|Placebo Comparator|Placebo Low dose|Monthly Subcutaneous administration.
89273120|NCT04610892|Placebo Comparator|Placebo Medium dose|Monthly Subcutaneous administration
89273121|NCT04610892|Placebo Comparator|Placebo High dose|Monthly Subcutaneous administration
89273122|NCT04601285|Experimental|Dose Escalation|
89273123|NCT04596514|Experimental|Intervention group - REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
89273124|NCT04596514|Active Comparator|Control group - ACLS|Advanced cardiovascular life support as described in the guidelines
89273126|NCT04590508|Experimental|Xanthohumol|Participants will take capsules containing 24 mg of xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
89273127|NCT04590508|Placebo Comparator|Placebo|Participants will receive capsules filled with a rice protein vehicle by mouth once daily with the first daily meal.
89273128|NCT04585581|Experimental|diet + training|
89273129|NCT04585581|Active Comparator|controls|
89273130|NCT04582695|Active Comparator|Written Exposure Therapy|
89273131|NCT04582695|Experimental|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|
89273132|NCT04580043|Experimental|cTBS + Habit Override Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Habit Override Training.
89273133|NCT04580043|Active Comparator|Sham TBS + Habit Override Training|Sham Transcranial Magnetic Stimulation, paired with Habit Override Training.
89273134|NCT04580043|Active Comparator|cTBS + Sham Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Sham Training.
89273135|NCT04580043|Sham Comparator|Sham TBS + Sham Training|Sham Transcranial Magnetic Stimulation, paired with Sham Training.
89273136|NCT04567043|Experimental|Mindfulness-Oriented Recovery Enhancement+JITAI|Participants will attend a telehealth Mindfulness-Oriented Recovery Enhancement (MORE) group plus mindfulness JITAI weekly for eight weeks.
89273137|NCT04567043|Active Comparator|Supportive Psychotherapy|Participants will attend a telehealth supportive psychotherapy group weekly for eight weeks.
89273138|NCT04557527|Other|control|Pars plana vitrectomy, retinopexy with laser or cryotherapy, and intravitreal gas tamponade.
89273139|NCT04557527|Active Comparator|treatment|Pars plana vitrectomy, laser retinopexy, suprachoroidal viscobuckle.
89273140|NCT04544852|Placebo Comparator|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge."
89273141|NCT04544852|Active Comparator|Targeted intervention programme|"Intervention B involves a targeted intervention programme tackling issues relating to a lack of education, inconvenience and cost would improve screening rates amongst the spouses."
89273142|NCT04543383|Experimental|Part 1|Participants will receive two oral doses of milvexian (on Days 1 to 3), one in the morning and one in the evening. On Day 4, participants will only receive the morning dose of milvexian. On Day 4, four hours after the morning dosing of milvexian, each participant will receive an intravenous (IV) infusion of 4-Factor Prothrombin Complex Concentrate (4F-PCC) or matching placebo as per the treatment sequence AB and BA; in treatment period 1 and treatment period 2 where Treatment A=Dose 2 of milvexian + Dose 1 of 4F-PCC; Treatment B=Dose 2 milvexian + Placebo. A washout period of 14 days to 21 days will be maintained between each treatment period 1 and 2.
89273143|NCT04543383|Experimental|Part 2 (Group 1)|Participants will receive an oral dose of milvexian in morning in fed state on Day 1 and IV injection of Recombinant Human Factor VIIa (rFVIIa) or placebo matching to rFVIIa on Day 1 after 4 hours post morning milvexian dose in the following treatment sequence: DEF1, EF1D, F1DE, EDF1, F1ED and DF1E; in treatment period 1, treatment period 2 and treatment period 3 respectively where Treatment D=Dose 1 of milvexian +Dose 1 of rFVIIa; Treatment E=Dose 3 of milvexian+Dose 1 of rFVIIa; Treatment F1=Dose 3 of milvexian+Placebo; Treatment F2=Dose 1 of milvexian+Placebo. A washout period of 4 days will be maintained between each treatment period 1, 2 and 3.
89273144|NCT04543383|Experimental|Part 2 (Group 2)|Participants will receive an oral dose of milvexian in morning in fed state on Day 1 and IV injection of rFVIIa or placebo matching to rFVIIa on Day 1 after 4 hours post morning milvexian dose in the following treatment sequence: DEF2, EF2D, F2DE, EDF2, F2ED and DF2E; in treatment period 1, treatment period 2 and treatment period 3 respectively where Treatment D=Dose 1 of milvexian+Dose 1 of rFVIIa; Treatment E=Dose 3 of milvexian+Dose 1 of rFVIIa; Treatment F1=Dose 3 of milvexian+Placebo; Treatment F2=Dose 1 of milvexian+Placebo. A washout period of 4 days will be maintained between each treatment period 1, 2 and 3.
89273145|NCT04532606|Experimental|Remimazolam group|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain Bispectral Index (BIS) value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
89273146|NCT04532606|Active Comparator|Propofol group|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
89273147|NCT04513145|Experimental|Treatment Group (Ropivacaine)|The treatment group will consist of patients undergoing total knee arthroplasty who receive standardized 100 cc periarticularinjection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients will then receive 10cc of ropivacaineinto their adductor canal.This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
89273148|NCT04513145|Placebo Comparator|Control Group (Saline)|The control group will consist of patients undergoing total knee arthroplasty who receive a standardized periarticular injection into the lateral femoral periosteum, posterior capsule, medial periosteum, capsule and skin. Patients randomized in this group will then receive 10cc of saline into their adductor canal. This will be administered by injecting into the adductor canal without dissecting down to the saphenous nerve and without ultrasound guidance.
89273149|NCT04495985||Thyrogen (rh-TSH)|Group 1: Female patients prepared for radioactive iodine treatment by rh-TSH (Thyrogen)
89273150|NCT04495985||Withdrawal from thyroid hormone|Group 2: Female patients prepared for radioactive iodine treatment by withdrawal from thyroid hormones
89273151|NCT04460885|Experimental|Insulin icodec|Insulin icodec + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
89273152|NCT04460885|Active Comparator|Insulin glargine|Insulin glargine + non-insulin anti-diabetic drugs. The pre-trial non-insulin anti-diabetic background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period
89273153|NCT04456426||Patients treated with COVID-19|All populations of patients admitted with COVID-19 in healthcare institutions involved. No intervention but standard care designed by national guidelines will be provided.
89273154|NCT04452188|Experimental|Normoxia|"On bypass, goal PaO2 on cardiopulmonary bypass of 60-100 mm Hg using lower fraction of inspired oxygen (FiO2) (blended sweep gas) via oxygenator~Post-bypass, goal of PaO2 <100 mm Hg by anesthesia and in ICU via oxygen titration via mechanical ventilator for 24 hours post-op."
89273155|NCT04452188|Active Comparator|Standard of care|Frequent blood gases will be checked per protocol on bypass and correlated with the blood parameter monitoring system to maintain a PaO2 of 200-300 per standard practice
89273156|NCT04440202|Active Comparator|Conventional sea bream group|This arm will consume 2 portions (each 200 g cooked) of conventional fish (sea bream) fillet per week for a 1-month period.
89273157|NCT04440202|Experimental|Enriched sea bream group|This arm will consume 2 portions (each 200 g cooked) of fish fillet bred with bioactive lipids from olive oil by-products per week for a 1-month period.
89273158|NCT04435158|Experimental|Cohort 1：SHR-1222|Subcutaneous injection of SHR-1222 dosage 1 monthly × 6 months
89273159|NCT04435158|Experimental|Cohort 2：SHR-1222|Subcutaneous injection of SHR-1222 dosage 2 monthly × 6 months
89273160|NCT04435158|Experimental|Cohort 3：SHR-1222|Subcutaneous injection of SHR-1222 dosage 3 monthly × 6 months
89273161|NCT04435158|Experimental|Cohort 4：SHR-1222|Subcutaneous injection of SHR-1222 dosage 4 every 2 months × 6 months
89273162|NCT04435158|Experimental|Cohort 5：SHR-1222|Subcutaneous injection of SHR-1222 dosage 5 every 2 months × 6 months
89273163|NCT04435158|Experimental|Cohort 6：placebo|Subcutaneous injection of placebo × 6 months
89273164|NCT04425395|Experimental|Healthy adult population aged 18 to 60 years.|Their pain tolerance will be tested using the Cold Pressor Task while producing vocalisations. Produced vocalisations will be audio recorded and physiological measures will be taken using two techniques: Nociception Level Index and video pupillometry.
89273165|NCT04417192|Experimental|Olaparib or Olaparib Plus Pembrolizumab|Cohort 1 : Olaparib will be administered for 6 weeks before surgery. Cohort 2 : Olaparib and Pembrolizumab will be administered simultaneously for 2 cycles(6 weeks) before surgery.
89273166|NCT04416958||CIED for cardiac resynchronisation|Patients implanted with an CIED for cardiac resynchronisation aiming to avoid pacing induced ventricular dyssynchrony, e.g. His bundle pacing, LBB-area pacing, CRT. These different implanted types of devices may be further analysed as subgroups.
89273167|NCT04414930|Placebo Comparator|TCT + PBO|
89273168|NCT04414930|Active Comparator|TCT + AMPH|
89273169|NCT04414735|No Intervention|1- Control group (Standard immunosuppression)|1- Control group (n=15): Standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate), according to the clinical protocol of the Nephrology and Kidney Transplant Department.
89273170|NCT04414735|Experimental|2- Treatment group (ECP+Standard immunosuppression)|2- Treatment group (n=15): Extracorporeal photopheresis in combination with standard immunosuppression (Thymoglobulin, Prednisone, Tacrolimus, and Everolimus or Mycophenolate) according to the clinical protocol of the Nephrology and Kidney Transplant Department
89273171|NCT04409002|Experimental|Niraparib+Dostarlimab + Radiation|"Each study treatment cycle lasts 21 days~Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment~Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study~Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1"
89273172|NCT04407962|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
89273173|NCT04407962|No Intervention|Control group|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
89273174|NCT04404361|Experimental|Pacritinib and SOC|Pacritinib 400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC
89273175|NCT04404361|Placebo Comparator|Placebo and SOC|4 capsules once daily [QD] on Day 1, then 2 capsules twice daily [BID] from Day 2 to Day 14) + SOC
89273176|NCT04401826|Experimental|The conventional approach|Conventionnal ECL using piezosurgery and microsurgical tools
89273177|NCT04401826|Active Comparator|The intervention approach:|Conventionnal ECL with tunneling using piezosurgery and microsurgical tools
89273178|NCT04394910|Experimental|Pomegranate Juice|Dietary supplementation with 8 oz. commercially-available pomegranate juice consumed daily.
89273179|NCT04394910|Placebo Comparator|Placebo Juice|Dietary supplementation with 8 oz. placebo juice (identical to pomegranate juice but lacking polyphenols) consumed daily.
89273180|NCT04384016|Experimental|Evaluating the Safety of Skyvaricella Inj.|"The main target:~• Evaluating the safety of Live Attenuated Varicella Vaccine SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection"
89273181|NCT04384016|Experimental|Evaluating the Immunogenicity of Skyvaricella Inj.|"Secondary target~• Evaluating the immunogenicity of Live Attenuated Varicella Vaccine SKYVaricella injection in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
89273182|NCT04364646|Active Comparator|Usual Care|Women in the usual care group receive medications and/or talk therapy. Sleep and light levels are monitored at home with wrist actigraphy during 3rd trimester of pregnancy (weeks 28-40) and weeks 2-6 and18 after the baby is born (postpartum weeks 2-6 and 18).
89273183|NCT04364646|Experimental|Personalize Integrated Chronotherapy|Women in the integrated chronotherapy group receive usual care (medications and/or talk therapy, as above) and also receive a bright light box to sit with every morning for up to 60 minutes as prescribed by the study doctor.
89273184|NCT04353375|Experimental|HMPL-453|HMPL-453 150mg QD HMPL-453 300mg QD
89273185|NCT04343885|Experimental|177Lu-PSMA+ Docetaxel|7.5 GBq (± 10%) 177Lu-PSMA every 6 weeks x 2 cycles. Docetaxel 75 mg/m2 commencing 6 weeks later, every 3 weeks x 6 cycles
89273186|NCT04343885|Other|Docetaxel (Control)|Docetaxel 75 mg/m2 every 3 weeks x 6 cycles
89273187|NCT04338061|Experimental|Evobrutinib + Teriflunomide matched Placebo: DB Period|
89273188|NCT04338061|Active Comparator|Teriflunomide + Evobrutinib matched Placebo: DB Period|
89273189|NCT04310995|Experimental|Nicorandil|
89273190|NCT04310995|Experimental|Diltiazem|
89273191|NCT04310995|Experimental|Isosorbide Mononitrate|
89273192|NCT04310644||Postural Orthostatic Tachycardia Syndrome|Patients with orthostatic intolerance because of Postural orthostatic tachycardia syndrome diagnosed in our outpatient clinic by tilt table examination.
89273193|NCT04310644||Ehlers Danlos Syndrome|Patients with hypermobile or classical EDS who are already diagnosed including genetical testing for classical or vascular EDS and Marfan Syndromes
89273194|NCT04310644||Autoimmune autonomic neuropathy/Pure autonomic failure|Patients who have an autoimmune autonomic neuropathy based on clinical diagnosis and antibody testing in our outpatient clinic. Cardial MIBG Scintigraphy should have been performed.
89273195|NCT04310644||Healthy controls|Healthy controls with no documented cardiovascular or neurological disorders and no symtoms of autonomic failure/dizziness/fainting
89273196|NCT04310644||others|Patients who have comorbidities as mast cell activation syndrome, chronic fatigue and/or Post COVID syndrome, based on clinical diagnosis in our outpatient clinic.
89273197|NCT04310462|Experimental|New eRX Interface|Providers assigned to the intervention arm will be presented with a new eRX interface upon writing new prescriptions for hydroxychloroquine in the EHR.
89273198|NCT04310462|No Intervention|Standard Interface|Providers assigned to the no intervention arm will be presented with the usual ordering interface when prescribing new prescriptions for hydroxychloroquine in the EHR.
89273199|NCT04302324|Experimental|daratumumab/clarithromycin/pomalidomide/dexamethasone|"Induction Phase: 8 cycles (cycle length of 28 days)~Daratumumab SC:~1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8~Clarithromycin~500mg PO BID until VGPR or 8 cycles, whichever occurs first~Pomalidomide 4mg PO on Days 1-21~Dexamethasone 20mg IV as pre-medication on Day 1, 8 40mg PO on the day after daratumumab for Cycle 1 Days 15 and 22 40mg PO pre-daratumumab weekly for Cycle 2-6 20mg PO pre-daratumumab weekly for Cycle 7-8~Maintenance Phase (Cycle 9+): Up to 24 cycles (cycle length of 28 days)~Daratumumab 1800 mg SC on Day 1~Pomalidomide 4mg PO on Day 1-21~Dexamethasone 20mg PO pre-daratumumab weekly for Cycles 9 and beyond"
89273200|NCT04299386|Experimental|NeoPhylaxis|Nanocrystalline gel for nonsurgical cleaning of implants
89273201|NCT04299386|Experimental|ImplanTreat|Nanocrystalline gel for surgical cleaning of Implants
89273202|NCT04299386|No Intervention|Nonsurgical cleaning without gel|Cleaning dental implants non-surgically using the electric brush without the gel
89273203|NCT04299386|No Intervention|Surgical cleaning without gel|Cleaning dental implants surgically using the electric brush without the gel
89273204|NCT04290741|Experimental|Auricular (Battlefield) Acupuncture|Auricular acupuncture involves placement of needles based on battlefield acupuncture protocol which involves the placement of needles in up to 5 sites on each ear to treat pain.
89273205|NCT04290741|Experimental|Peripheral Acupuncture|Peripheral acupuncture involves placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
89273206|NCT04290741|No Intervention|Control|Standard of care without acupuncture
89273207|NCT04289363||ED patients|Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc.
89273208|NCT04284943|Active Comparator|Long limb Roux-en-Y reconstruction|Long limb Roux-en-Y reconstruction method follows subtotal gastrectomy for gastric cancer.
89273209|NCT04284943|Active Comparator|Conventional Roux-en-Y reconstruction|Conventional Roux-en-Y reconstruction method follows subtotal gastrectomy for gastric cancer.
89273210|NCT04284943|Active Comparator|Billroth II reconstruction|Billroth II reconstruction method follows subtotal gastrectomy for gastric cancer
89273211|NCT04280952|Experimental|CONVIVO|tumor tissue identification with the CONVIVO system
89273212|NCT04270175|Experimental|daratumumab/pomalidomide/dexamethasone|"Pomalidomide:~(4mg orally) on days 1-21 of a 28-day cycle~Dexamethasone:~20mg IV as premedication on days 1, 8, 15, and 22~20mg orally the day after daratumumab dosing for cycles 1-2 of induction~40mg IV as premedication on days 1 and 15 on daratumumab treatment days~40mg orally on non-daratumumab days (8 and 15) for cycles 3-6~20mg on day 1 of every cycle as premedication on daratumumab dosing day 1 in maintenance cycles (cycles 7 and beyond)~If you are a subject age 70 and older, the dexamethasone dosing will be reduced by 50% at the time of induction.~Daratumumab:~1800mg sub-cutaneously weekly x8 weeks~1800mg sub-cutaneously every 2 weeks during induction (cycles 3-6)~1800mg sub-cutaneously every 4 weeks cycles 7 and beyond"
89273213|NCT04267549|Experimental|treatment|"Eligible patients will be given sintilimab(200mg iv, day 1), apatinib(250mg,once daily), S-1 (60mg, twice daily, day1-14) and nab-paclitaxel(without peritoneal metastases: 260 mg/m^2 iv for 3h; with peritoneal metastases: 200mg/m^2 iv plus 60mg/m^2 ip; day 1) every 3 weeks for at least 3 cycles.~The feasibility of surgery will be evaluated by a multidisciplinary team every 2-4 cycles.~Patients assessed as inoperable will be allowed to continue maintenance therapy with the original regimen until disease progression or intolerable toxicity. For patients assessed as operable, apatinib will be discontinued and one more cycle of sintilimab combined with S-1 and nab-paclitaxel will be administered; radical surgery will be performed within 2-4 weeks after the end of treatment.~Safety run-in stage will be set in the first 6 patients to determine the safety. The study will be terminated if dose-limiting toxicities (DLTs) occur in more than 2 patients."
89273214|NCT04262336|Active Comparator|DB-020 for Injection, 12%/placebo|dosage
89273215|NCT04262336|Active Comparator|DB-020 for Injection, 25%/placebo|dosage
89273216|NCT04249726|Experimental|Direct composite resin restoration|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations
89273217|NCT04249726|Active Comparator|Full coverage metal-ceramic crown|Root filled teeth with occlusal cavities and at least 3 intact axial walls will receive composite resin restorations followed by full coverage metal-ceramic crown
89273218|NCT04244266||Ideal Body Weight|groups of patients divided according to neostigmine dose weight, ideal body weight (IBW)
89273219|NCT04244266||Total Body Weight|groups of patients divided according to neostigmine dose weight, total body weight (TBW),
89273220|NCT04244266||Adjusted Body Weight|groups of patients divided according to neostigmine dose weight, , adjusted body weight (ABW)
89273221|NCT04242238|Experimental|Advanced High-grade Sarcoma|Dose Escalation: Up to 18 pts with locally advanced or metastatic high-grade sarcomas Dose Expansion: 10 pts per each diagnosis - undifferentiated pleomorphic sarcoma or myxofibrosarcoma, Leiomyosarcoma, Dedifferentiated liposarcoma
89273222|NCT04235959|Placebo Comparator|Placebo|Participants received placebo once weekly (QW) subcutaneously (SC).
89273223|NCT04235959|Experimental|Tirzepatide - Cohort 1 (2.5 to 10 Milligram (mg)) and Cohort 2 (2.5 to 15 mg)|"Participants in Cohort 1 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15.~Participants in Cohort 2 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15, 12.5 mg for Weeks 16 through 19, and 15 mg for Weeks 20 through 23."
89273224|NCT04235101|Experimental|SYD985 + Niraparib|SYD985, Intravenous, every 3 weeks (Q3W) Niraparib taken orally and either 100 mg, 200 mg or 300 mg once daily for either 1, 2 or 3 weeks.
89273225|NCT04231747|Experimental|CC-97540 monotherapy|Subjects will be assigned to receive CC-97540 followed by 3 consecutive doses of lymphodepleting chemotherapy (fludarabine IV (30 mg/m2/day) and cyclophosphamide IV (300 mg/m2/day).
89273226|NCT04228692|Active Comparator|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary
89273227|NCT04228692|Experimental|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
89273228|NCT04224870||Surgical Incision|A single cohort study, of 12 participants with a scheduled surgical procedure, of at least 4 hours, for up to six (6) timed tissue sampling at surgical incision. No investigational therapy is planned.
89273229|NCT04223557|Experimental|FPU treatment|Transcutaneous non-invasive ultrasound will be administered to the peri-renal fat for one time via a focused power ultrasound system (FPU) device.
89273230|NCT04223557|Sham Comparator|Sham treatment|Partcipates will receive the same procedure as those in experimental arm except that the device will not be activated.
89273231|NCT04204811||Participants with Ovarian Cancer|Participants are diagnosed with Stage III or Stage IV ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian tube carcinoma)
89273232|NCT04187131|Experimental|augmented reality|
89273233|NCT04182360|Active Comparator|Carbetocin 10mcg|Patient is given 10mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89273234|NCT04182360|Active Comparator|Carbetocin 20mcg|Patient is given 20mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89273235|NCT04182360|Active Comparator|Carbetocin 40mcg|Patient is given 40mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89273236|NCT04182360|Active Comparator|Carbetocin 60mcg|Patient is given 60mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89273237|NCT04182360|Active Comparator|Carbetocin 80mcg|Patient is given 80mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89273238|NCT04182360|Active Comparator|Carbetocin 100mcg|Patient is given 100mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89273239|NCT04168645|Experimental|Presence of SUD with BCBT|Patients diagnosed with SUD who are randomly assigned to receive BCBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of CBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
89273240|NCT04168645|No Intervention|Presence of SUD with TAU|Patients diagnosed with SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
89273241|NCT04168645|Experimental|Absence of SUD with BCBT|Patients without SUD who are randomly assigned to receive BCBT will participate in all aspects of their prescribed treatment plan (i.e., TAU) and will receive up to 4 sessions of BCBT (depending on length of stay), lasting 1.5 hours for the first session and 1 hour for the remaining sessions.
89273242|NCT04168645|No Intervention|Absence of SUD with TAU|Patients without SUD who are randomly assigned to receive TAU will participate in all aspects of the prescribed treatment plan given by the inpatient unit.
89273243|NCT04155606|Active Comparator|Interventional Therapy|Neurosurgery or Endovascular procedure
89273244|NCT04155606|No Intervention|Conservative Management|Monitoring with pharmacological therapy if need arises.
89273245|NCT04147533|Experimental|initially treated patients|The dose of tyrosin kinase inhibitors (imatinib, or nilotinib, or dasatinib) in patients meeting all of the inclusion criteria and none of the exclusion criteria will be reduced in two consequent steps, during the first 6 months after study entry by 50%, during the second 6 months by 50% again; the medication is discontinued then and the patients are followed each month in the first 6 months after withdrawal, each 1,5 month in the next 6 months, and each 3 months in the next 12 months.
89273246|NCT04136587|Active Comparator|Healthy Controls|"Inclusion criteria:~Colonoscopy performed for the following indications: anemia, blood in stool, constipation, change in bowel habits, screening for colon cancer, follow up after polyps, weight loss~Macroscopic normal colonoscopy except for diverticulosis (without any signs of inflammation), ≤ 3 polyps (except hyperplastic polyps of the colon and rectum), angiodysplasia~Exclusion criteria:~Diagnosis of IBD or any other inflammatory condition of the small and large intestine~Diagnosis of irritable bowel syndrome (IBS)~Autoimmune disorders~Obesity (BMI> 30)~Regular intake of NSAIDs (> 2 tablets/ week), immunosuppressants~Intake of antibiotics within the last 3 months~Intestinal infection by enteric pathogens~Probiotic therapy"
89273247|NCT04136587|Active Comparator|Crohn's disease|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)~Inclusion criteria:~Colonoscopy indicated by routine clinical care~Established diagnosis of Crohn´s disease (also if established by the study colonoscopy)~Exclusion criteria:~• Intestinal infection by enteric pathogens"
89273248|NCT04136587|Active Comparator|Ulcerative Colitis|"2 Subgroups: inactive disease (10 patients) and active disease (10 patients)~Inclusion criteria:~Colonoscopy indicated by routine clinical care~Established diagnosis of ulcerative colitis (also if established by the study colonoscopy)~Exclusion criteria:~• Intestinal infection by enteric pathogens"
89273249|NCT04136587|Active Comparator|Colorectal carcinoma|"Inclusion criteria:~• Diagnosis of a lesion with suspicion for colorectal cancer during endoscopy which is confirmed later by histology~Exclusion criteria:~• None"
89273250|NCT04136587|Active Comparator|Colitis/Enteritis of other origin|"Inclusion criteria:~Diagnosis of intestinal inflammation at endoscopy or histology~E.g.: Infectious colitis /enteritis; ischemic Colitis; microscopic colitis; graft versus host disease (GVHD); NSAID colitis; Colitis of unknown cause~Exclusion criteria:~• None"
89273251|NCT04121962|Experimental|Peer Mentor|Peer Mentor Training is 5 groups with a 30 day reunion session. This condition is focused on training participants with communication skills to promote HIV and STI home-based testing and treatment and pre-exposure prophylaxis (PrEP) to individuals in their social networks. Participants will also learn how to use the Star website to request home-based testing kits. Peer Mentor training is conducted by a two health educators. The sessions are held once a week and will last approximately 90 minutes.
89273252|NCT04121962|Active Comparator|Control|Participants will receive information on how to use the website to request at-home test kits
89273253|NCT04112368|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
89273254|NCT04112368|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
89273255|NCT04096443|Experimental|Intervention|Fecal microbial transplant capsules
89273256|NCT04088188|Experimental|Arm A (ivosidenib, cisplatin, gemcitabine)|Patients receive ivosidenib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89273257|NCT04088188|Experimental|Arm B (pemigatinib, cisplatin, gemcitabine)|Patients receive pemigatinib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89273258|NCT04087811||Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) - Interspinous Spacer
89273259|NCT04085796||Older patients|Older patients who received the ICCI while in the hospital's A&E
89273260|NCT04085796||ICCI Professional|The member of staff who delivers the ICCI at the site
89273261|NCT04066192|Placebo Comparator|Placebo|Participants in this Arm will take a medically inert placebo. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the capsule orally each morning.
89273262|NCT04066192|Active Comparator|BREX 2mg|The BREX 2mg group will start at the same dose at the BREX 4mg group and titrate up at the same rate, so the BREX 2mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, and 2mg on day 5, to reach its final 2mg dose for day 5-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
89273263|NCT04066192|Active Comparator|BREX 4mg|The BREX 4mg group will start at the same dose as the BREX 2mg group and titrate up at the same rate, so the BREX 4mg Arm will take .5 mg of brexpiprazole on day 1-2, 1 mg on day 3-4, 2mg on day 5-6, and 4mg on day 7 to reach its final 4mg dose for days 7-14. To ensure pill equivalence between groups, tablets will be packaged in the same capsule; thus, each participant will take one capsule per day. Participants will be instructed to ingest the medication orally each morning.
89273264|NCT04062123|Experimental|Dexmedetomidine|Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.
89273265|NCT04062123|Experimental|Propofol|Subjects in this group will receive propofol during the drug portion of the experiment.
89273266|NCT04062123|Experimental|Fentanyl|Subjects in this group will receive fentanyl during the drug portion of the experiment.
89273267|NCT04061941||Stimulant Users|Stimulant users that fulfill SCID-5 clinician version definition for assessment on stimulant use disorder under DSM-5
89273268|NCT04032717|Experimental|Open-label Q-GRFT enema|Open-label Q-GRFT enema administered rectally once as a single dose (Arm 1)
89273269|NCT04032717|Experimental|Randomized, blinded Q-GRFT enema|Blinded Q-GRFT enema administered rectally once as a single dose (Arm 2)
89273270|NCT04032717|Placebo Comparator|Randomized, blinded placebo enema|Blinded placebo enema administered once as a single dose (Arm 3)
89273271|NCT04024267|Experimental|Eurythmy therapy (ERYT)|"Eurythmy therapy (ERYT) is a standardized movement therapy and for each medical condition standardized ERYT exercise (series) exist. In such, in the present study, the cancer series O-E-M-L-I-B-D that is specific and standardized for breast cancer patients will be applied. Patients can perform and maintain the postures without stress and tension. Patients are instructed by ERYT therapists in sessions with 1 to 4 patients."
89273272|NCT04024267|Active Comparator|CoordiFit|The CoordiFit program consists of standardized exercises that address physical coordination, stability, balance and dexterity. These exercises serve as a control intervention and are non-specific with respect of cancer-related fatigue and breast cancer. They mimic those of ERYT but have no mindfulness features. Patients are instructed by physical therapists in session with 1 to 4 patients.
89273273|NCT04022343|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib orally once daily for 12 weeks in the absence of disease progression or unacceptable toxicity. The assigned starting dose for cabozantinib is 60 mg/day. Two dose reduction levels of cabozantinib are permitted
89273274|NCT03992261|Experimental|Halobetasol Propionate Foam|2 weeks of application, 2 times daily
89273275|NCT03991884|Experimental|Dose -1 (0.3 mg/m^2)|Patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on day 8. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89273276|NCT03991884|Experimental|Dose 1 (0.3 mg/m^2)|Dose 1 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89273277|NCT03991884|Experimental|Dose 2 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 2 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89273278|NCT03991884|Experimental|Dose 3 (0.6 mg/m^2, 0.3 mg/m^2)|Dose 3 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89273279|NCT03990493|Experimental|PV-001-DV in Combination with PV-001-DC|Intratumoral injection of PV-001-DV (1 injection) and IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
89273280|NCT03989895|Experimental|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
89273281|NCT03989869|Experimental|VEMA|Immediate medical abortion treatment
89273282|NCT03989869|No Intervention|Standard of Care|Delayed care until an intrauterine pregnancy has been confirmed with ultrasound.
89273283|NCT03988985|Experimental|PATIENT-GP-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will receive feedback after depression screening. The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
89273284|NCT03988985|Active Comparator|GP-FEEDBACK|Using a randomized-controlled study design in one third of the cases only the attending general practitioner will receive feedback after depression screening. The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
89273285|NCT03988985|No Intervention|NO-FEEDBACK|Using a randomized-controlled study design one third of the patients and their attending general practitioner will not receive any feedback.
89273286|NCT03986593|Other|Cryoablation +- cementoplasty treated patients|cone beam computed tomography guided cryoablation +- cementoplasty
89273287|NCT03974945||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-60 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
89273288|NCT03968679|Experimental|Unilateral elective nodal irradiation|Exclusion of contralateral neck from elective nodal irradiation, based on results of SPECT/CT and (in case of contralateral drainage) contralateral sentinel node procedure.
89273289|NCT03964376|Experimental|Nasal High Flow Group|Nasal High-Flow oxygen delivery will be applied starting at airflow of minimum 20 Litre/minute. It will be titrated in 15Litre/minute increments to 35 Litre/minute and a maximum 50 Litre/minute as determined by patient comfort. O2 supplementation will be managed by the anesthesia and surgical health care team to maintain the oxygen saturation level in the blood between 92-95%. In the Nasal High-Flow group, when SPO2 is in the range of 92-95%, air will be given instead of oxygen for the 1st 3 nights and during the day, if required, till discharge, whichever is earlier.
89273290|NCT03964376|Other|Usual Care Group|In the usual care, patients will receive oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via facemask titrated to keep SpO2 level in the range of 92-95%. When SpO2 level reaches in the range of 92-95%, oxygen delivery will be discontinued.
89273291|NCT03936647|Active Comparator|Standard conventional treatment (surgical or endovascular)|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
89273292|NCT03936647|Experimental|WEB embolization device|Endovascular treatment with WEB, including standard management of thrombo-embolic risk
89273293|NCT03917264|Active Comparator|Tooth-borne treatment|Titanium curettes
89273294|NCT03917264|Experimental|Implant-specific treatment|Implant brush
89273295|NCT03915821|Experimental|Patients diagnosed as major depression according to DSM V|"All patients presented with major depression disorder not received ECT previously within 6 monthes, admitted to the study site ( Psychiatry department, in Assiut University Hospital, Assiut, Egypt). They Fulifilled will be recruited within 6 monthes duration .~The patients classified into group A comprised that will be treated with Unipolar ECT, and group B comprised that will be treated Biploar ECT."
89273296|NCT03913325|Experimental|PREVSAM model|
89273297|NCT03913325|Active Comparator|Treatment as usual|
89273298|NCT03907501|Experimental|Synbiotic|Two grams of organic Triphala powder (Banyan Botanicals, Inc.) with 1 capsule VSL#3® (VSL Pharmaceuticals, Inc.) probiotic taken with a few ounces of room temperature water in the morning and at bedtime for 8 weeks. Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.) and VSL#3® (VSL Pharmaceuticals, Inc.) capsules.
89273299|NCT03907501|Active Comparator|Probiotic|Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.). Subjects will take 2 grams of organic Triphala powder with a few ounces of room temperature water in the morning and at bedtime.
89273300|NCT03907501|Placebo Comparator|Placebo|Subjects will be provided both written and verbal instructions and given a kit containing placebo capsules. Subjects will be instructed to take 2 (inert) capsules with room temperature water in the morning and at bedtime.
89273301|NCT03900533|Experimental|Adjunctive group emotion regulation skills training|Participants will receive a 7 week group emotion regulation skills training together with parents adjacent to treatment as usual provided by the child- and adolescent psychiatric clinic
89273302|NCT03900533|Active Comparator|Treatment as usual (TAU)|Participants will receive treatment as usual for 7 weeks as provided by the child- and adolescent psychiatric clinic
89273303|NCT03900000|Other|Short_Physiotherapy|one period of physiotherapy (8 weeks)
89273304|NCT03900000|Other|Long_Physiotherapy|two periods of physiotherapy (à 8 weeks)
89273305|NCT03890289|Experimental|Idelalisib Plus Obinutuzumab|"Single arm: Regimen: GAUDEALIS q28 days~Obinutuzumab Dose: 1000 mg IV Day 1, 8, 15 (1st cycle)~Obinutuzumab Dose: 1000 mg IV Day 1 (2nd cycle onward)~Idelalisib Dose: 150 mg BID oral Daily (24 weeks)"
89273306|NCT03816956|Experimental|Study treatment|Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously on the day of randomization.
89273307|NCT03816956|Placebo Comparator|Placebo treatment|Control group: Placebo administered intravenously on the day of randomization.
89273308|NCT03803397|Experimental|PV-001-DC alone|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells
89273309|NCT03800602|Experimental|Treatment (nivolumab, metformin)|Patients receive metformin PO BID starting on day 1. After 14 days of metformin only period patients also receive nivolumab IV every 4 weeks starting on day 15. Courses repeat every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity or consent withdrawal.
89273310|NCT03779191|Experimental|Intervention|Patients in this intervention arm will receive the therapeutic combination of Alectinib dosed PO 600 mg bis in die (BID) with meals and Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
89273311|NCT03775902|Experimental|Healthy subjects|Two experimental day where the effect of Nicorandil (20mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
89273312|NCT03775902|Experimental|Insulin resistant|Two experimental day where the effect of Nicorandil (20mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
89273313|NCT03765463|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 4 two-hour sessions in an intensive format.
89273314|NCT03743662|Experimental|Recurrent Glioblastoma, No Surgery|One cohort is for patients with recurrent GBM who are not undergoing surgical debulking as part of their treatment plan
89273315|NCT03743662|Experimental|Recurrent Glioblastoma, Surgery|The second cohort is for patients with recurrent GBM who are undergoing surgery as part of their treatment.
89273316|NCT03736564|Experimental|68Ga-DOTATATE PET/CT|Subjects will undergo imaging by 68Ga-DOTATATE PET/CT
89273317|NCT03712891|Experimental|Patients receiving coffee postoperatively|Patients who self-identify as coffee drinkers and receive coffee postoperatively
89273318|NCT03712891|No Intervention|Patients not receiving coffee postoperatively|Patients who self-identify as coffee drinkers and do not receive coffee postoperatively
89273319|NCT03651206|Experimental|Arm A - Niraparib|Niraparib, 200 mg or 300 mg, daily dose
89273320|NCT03651206|Experimental|Arm B - Niraparib + TSR-042 (Dostarlimab)|"Niraparib, 200 mg or 300 mg, daily dose~TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter"
89273321|NCT03651206|Active Comparator|Arm C - Chemotherapy drugs|"Chemotherapies (Standard of care)~For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days~For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days"
89273322|NCT03650322|Experimental|Yoga Practice|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet twice a week for 75 minutes each for the duration of 12 weeks. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
89273323|NCT03650322|Active Comparator|Stretching and Toning|This 12 week, progressive stretching and toning course will aid participants in building whole body strength and flexibility by utilizing weights, chairs, mats, and various other exercise equipment. Sessions will meet three times a week for 50 minutes and will offer 'easy' and 'hard' modifications taught by an exercise leader.
89273324|NCT03650322|Experimental|Aerobic Walking|Participants will partake in treadmill walking that encourages them to reach a pre-determined heart rate range. Sessions will be conducted three times a week for 50 minutes, and offer participants to self-select a speed and incline to meet their target heart rate zone.
89273325|NCT03525613|Experimental|APL-2 15mg 0.1 mL Monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
89273326|NCT03525613|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
89273327|NCT03525613|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure monthly for 24 months
89273328|NCT03525613|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
89273329|NCT03517163||Prospective Group|Individuals enrolled or just finished kindergarten who were diagnosed with Autism Spectrum Disorder through the DSM-5 diagnostic criteria
89273330|NCT03511807|Experimental|Electrical/ Acoustic stimulation|
89273331|NCT03500692||MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
89273332|NCT03495882|Experimental|AGEN1884 + AGEN2034|AGEN1884 in combination with AGEN2034 in subjects with Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors (cervical)
89273333|NCT03485417|Active Comparator|Aripiprazole Arm|Aripiprazole (oral or depot) Oral: 10-30mg daily Depot: 300-400mg every four week; Intramuscularly
89273334|NCT03485417|Active Comparator|Paliperidone Arm|Paliperidone (oral or depot) Oral: 3-12mg Depot: Intramuscularly; a) sustenna 50-150mg every four weekly, or b) trinza 273-819mg every 12 weekly
89273335|NCT03485417|Other|Treatment as Usual Arm|Treatment as Usual arm
89273336|NCT03485274|Active Comparator|Vortioxetine Arm|Oral: 5-20mg daily
89273337|NCT03485274|Active Comparator|Treatment as Usual|Any medication or Rx other than vortixoetine
89273338|NCT03474575|Other|COPD patient|Prevention of re-hospitalization rate for Early supported discharge and enhanced homecare to patient admited for COPD exacerbation
89273339|NCT03457077|Experimental|Brief Intervention|Participants will receive a brief intervention at week 0
89273340|NCT03457077|Other|Delayed Intervention|Participants will receive a brief intervention at 6 months
89273341|NCT03434028|Other|Restrictive Fluids|The general approach will be to use vasopressors to treat hypotension as opposed to intravenous fluids. Maintenance fluids should not be used.
89273342|NCT03434028|Other|Liberal Fluids|The general approach is to use fluid boluses to treat hypotension.
89273343|NCT03433404|Experimental|Soft Tissue Mobilization|The arm will utilize a Physical Therapy technique call soft tissue mobilization.
89273344|NCT03433404|Active Comparator|Soft Tissue Massage|This arm will utilize standard soft tissue massage applied to the low back in pregnant patients complaining of third trimester low back pain.
89273345|NCT03433404|No Intervention|No manual treatment|Group will still receive acetaminophen, heating pad application, and/or rest which is standard of care.
89273346|NCT03393845|Experimental|Pembrolizumab + Fulvestrant|Pembrolizumab 200m IV q3W + Fulvestrant. Loading dose 500mg IV IM q2W x3 followed by 500mg IM q4W
89273347|NCT03391427|Experimental|Lidocaine|This group will receive lidocaine infusion perioperatively
89273348|NCT03391427|Experimental|Ketamine|This group will receive ketamine infusion perioperatively
89273349|NCT03391427|Experimental|Lidocaine+ketamine|This group will receive a combination of lidocaine and ketamine infusion, perioperatively
89273350|NCT03391427|Placebo Comparator|placebo|This group will receive saline infusion as placebo perioperatively
89273351|NCT03384446|Active Comparator|Tooth-borne treatment|A cleaning aid that resembles tooth cleaning instruments and is empirically used for implant surface cleaning.
89273352|NCT03384446|Experimental|Implant-specific treatment|A cleaning aid that has been specifically designed for implant surface cleaning.
89273353|NCT03373084||hamstring muscle lesions|Patients with hamstring muscle lesions in sport will be included. As usual practice they will have Magnetic Resonance Imaging (MRI) or ultrasound, and will answer to self-questionnaire
89273354|NCT03339765|Experimental|Serious game intervention|Participants randomized to the intervention will receive the Strong Together serious game program on a tablet computer. The goal of this serious game is to teach the participant how to advocate for her needs relate to her cancer and treatment. The research team will send participants weekly notifications for 12 weeks to alert them that a new serious game session is available and encourage them to complete one session per week.
89273355|NCT03339765|No Intervention|Enhanced care as usual|If randomized to the enhanced care as usual arm, the research team will give participants a paper-based self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
89273356|NCT03307343|Experimental|Intervention|The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.
89273357|NCT03307343|No Intervention|Control|Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.
89273358|NCT03290950|Experimental|Cohort 1|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
89273359|NCT03290950|Experimental|Cohort 2|Single arm, two-stage phase II trial of combination therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients. Patients achieving ≥PR at end of 4 cycles will continue to receive the planned total of 8 cycles of combination therapy. Patients may go onto receiving additional maintenance phase therapy with lenalidomide under a separate treatment protocol. Patients ≤ PR after completing 4 cycles will go off study therapy.
89273360|NCT03269396|Experimental|Larynx Allograft Transplantation|Cadaveric laryngotracheal transplantation
89273361|NCT03267849|Experimental|persons drinking water|all persons in the study will have images of the eye at baseline eye pressure, then the intervention will be to drink 2 bottles of water to increase eye pressure or decrease eye pressure, then will have images taken a second time
89273362|NCT03264404|Experimental|Pembrolizumab|Patients with advanced pancreatic cancer will receive pembrolizumab with the hypomethylating agent azacitidine.
89273363|NCT03254758|Experimental|Mesenchymal stem cell|"Phase 1 Dose escalation : low Mid High Single administalation of ADR-001~Phase 2 The recommended dose of ADR-001"
89273364|NCT03241745|Experimental|Nivolumab|Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
89273365|NCT03218384|Experimental|Ferric Carboxymaltose|HF patients with functional iron deficiency assigned to receive one-time dose of Ferric Carboxymaltose 750 mg. Participants will undergo serial assessment before and 4 weeks after study drug administration
89273366|NCT03218384|Active Comparator|Placebo|HF patients with functional iron deficiency assigned to receive one-time dose of Placebo (saline injection). Participants will undergo serial assessment before and 4 weeks after study drug administration.
89273367|NCT03208387||Children Medulloblastoma Survivors|Participants previously treated for M0 non-disseminated medulloblastoma with cranio-spinal irradiation plus a boost to the posterior fossa
89273368|NCT03208387||Children Astrocytoma Survivors|Participants previously treated for a low grade cerebellar astrocytoma, with surgery only and neither chemotherapy nor cranial irradiation.
89273369|NCT03208387||Age-Matched Healthy Children Controls|
89273370|NCT03157115|Experimental|Impaired left ventricular ejection fraction|Patients with reduced left ventricular ejection fraction (< 50 %)
89273371|NCT03157115|Active Comparator|Control|Patients with a normal left ventricular ejection fraction (≥ 50 %), without heart failure. The patients from the reduced left ventricular ejection fraction group will be matched with patients from the control group for sex, age, BMI and cardiovascular treatment.
89273372|NCT03129555|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
89273373|NCT03129555|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
89273374|NCT03129555|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
89273375|NCT03129555|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
89273376|NCT03129490|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
89273377|NCT03129490|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
89273378|NCT03129490|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
89273379|NCT03129490|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
89273380|NCT03121014|Experimental|Patient Treatment|Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
89273381|NCT03118570|Experimental|Setrusumab 20 mg/kg (Blinded)|Setrusumab 20 mg/kg intravenous (IV) infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
89273382|NCT03118570|Experimental|Setrusumab 8 mg/kg (Blinded)|Setrusumab 8 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
89273383|NCT03118570|Experimental|Setrusumab 2 mg/kg (Blinded)|Setrusumab 2 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
89273384|NCT03118570|Experimental|Setrusumab 20 mg/kg (Open-Label)|Setrusumab 20 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
89273385|NCT03118570|Placebo Comparator|Placebo|Placebo IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
89273386|NCT03076320|Experimental|PFD+M-DDO|"Pirfenidone with M-DDO Active ingredients: Pirfenidone 10% with modified oxide diallyl disulfide (M-DDO) 0.016% Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency an duration: topically applied every 12 hours for 6 months."
89273387|NCT03076320|Active Comparator|A+PBO|"Adapalene with benzoyl peroxide Active ingredients: 0.1% Adapalene with 2.5% benzoyl peroxide. Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 month"
89273388|NCT03066739|Active Comparator|LO-low dose remifentanil|low dose remifentanil (LO, 0.1 micrograms/kg/mL),
89273389|NCT03066739|Active Comparator|HI-high dose remifentanil with placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
89273390|NCT03066739|Active Comparator|HN-high dose remifentanil with ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone).
89273391|NCT03033303|Experimental|Hu3F8/GM-CSF Plus Isotretinoin|In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
89273392|NCT03021135|Active Comparator|Conventional Mucosal Resection|C-EMR will be made with saline injection with the indigo carmine.
89273393|NCT03021135|Experimental|Underwater Mucosal Resection|UW-EMR will be made after the complete filling of lumen with water.
89273394|NCT03013829|No Intervention|Usual Care|"Potential LKDs and recipients will receive standard-of-care LD (Live Donor) and KPD education. As noted previously, during standard care, incompatible potential LKDs are informed of the KPD option and the potential LKD is provided with living donation information and a link to the UNOS KPD website, which includes a written description of KPD. This information is available in English and Spanish. For those who do not have internet access, the written educational materials are mailed. The potential LKD is advised to call the donor nurse coordinator with any questions about KPD and/or to initiate the full donation evaluation. This process occurs for the intended recipient only if their potential donor decides to initiate the full evaluation.~For study purposes, potential LKDs and waitlisted recipients assigned to the UC group will be sent an email after randomization, which will include a link and a reminder to review their transplant center's standard of care educational materials."
89273395|NCT03013829|Experimental|Video-Based KPD education|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch the embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
89273396|NCT03009981|Active Comparator|Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide|Patients will receive degarelix OR leuprolide with bicalutamide.
89273397|NCT03009981|Experimental|Arm B: Degarelix/Apalutamide|Patients will receive apalutamide and either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
89273398|NCT03009981|Experimental|Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone|Patients will receive apalutamide and abiraterone acetate, in addition to either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
89273399|NCT02986087|Experimental|Fetal Tracheal Occlusion|Fetuses with severe or moderate congenital diaphragmatic hernia will be offered fetal tracheal occlusion to increase lung growth.
89273400|NCT02971683|Active Comparator|Abatacept subcutaneous + Standard Treatment|Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
89273401|NCT02971683|Placebo Comparator|Placebo of Abatacept subcutaneous + Standard Treatment|Placebo of Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
89273402|NCT02921022|Experimental|Patients without a prior thromboembolic event (TE)|Patients without a prior TE will be treated with prophylactic dose and schedule of rivaroxaban (10 mg QD), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
89273403|NCT02921022|Experimental|Patients with a prior thromboembolic event (TE)|Patients with a prior TE will be treated with therapeutic dose and schedule of rivaroxaban (15 mg BID for 21 days for induction if indicated, then 20 mg QD for chronic treatment), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
89273404|NCT02899299|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
89273405|NCT02899299|Active Comparator|Pemetrexed and Cisplatin (or Carboplatin)|Specified dose on specified days
89273406|NCT02899195|Experimental|Durvalumab|Pemetrexed/cisplatin will be given for up to six 3-week cycles with the addition of concurrent durvalumab every 3 weeks. The first 6 patients who are enrolled and commence treatment will be monitored for safety of the combination. Use of carboplatin in place of cisplatin will be permitted for patients who are ineligible for cisplatin due to impaired renal function at screening. For patients that receive cisplatin, carboplatin may also be substituted after Cycle 1 for cisplatin related toxicity (e.g., grade 3 ototoxicity, grade 3 nausea) at the investigator's discretion. After completion of Cycle 6 of concurrent therapy, patients with stable or responding disease per modified RECIST for malignant mesothelioma will continue on single agent durvalumab every 3 weeks until progression. Maximum duration of durvalumab treatment is 12 months starting from Cycle 1 of concurrent treatment (inclusive of any treatment delays or missed treatments).
89273407|NCT02833233|Experimental|Cryoablation and Immune Therapy|Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.
89273408|NCT02814916|Experimental|Dalbavancin, single dose|
89273409|NCT02814916|Experimental|Dalbavancin, two doses|
89273410|NCT02814916|Active Comparator|Comparator|
89273411|NCT02804594|Active Comparator|N-acetyl cysteine|1250 mg of N-acetyl cysteine three times daily
89273412|NCT02804594|Placebo Comparator|Placebo|placebo three times daily
89273413|NCT02786940|Experimental|Live Remote Cardiac Monitoring|Patients in this arm will receive the Cardiophone device, a live remote cardiac monitoring with transmission of cardiac rhythm (device-triggered: if rhythm abnormalities detected by device algorithm; or patient-triggered by pressing the transmit button because of symptoms) for 15 days.
89273414|NCT02786940|Active Comparator|Usual Care|Patients in this arm will receive the Mobile Cardiac Telemetry device for 48-hour Holter monitoring as part of usual care. This device combines holter, event monitoring and mobile cardiac telemetry (continuous cardiac monitoring of every single beat) into one unit. The holter functionality will be used for the first 48 hours (usual care). The diagnostic yield from the 48 hour holter monitoring will be compared to the 15-day live monitoring.
89273415|NCT02757794|Active Comparator|Cognitive remediation parents|
89273416|NCT02757794|Placebo Comparator|Remediation standard|
89273417|NCT02728050|Experimental|Treatment (sorafenib, G-CLAM)|See Detailed Description.
89273418|NCT02711878|Experimental|Let's Move Program|Participants in this group will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes in their home while wearing a heart rate monitor and a pedometer. Participants will then enter a maintenance exercise period for 65 weeks.
89273419|NCT02711878|Active Comparator|Let's Flex Program|Participants in this group will be asked to stretch five times per week for twelve weeks for a minimum of thirty minutes in their home. Participants will then enter a maintenance exercise period for 65 weeks.
89273420|NCT02600208|Experimental|Single Experimental Arm|Alpha Beta T cell depletion is performed for all PBSC grafts using the CliniMACs device
89273421|NCT02581943|Experimental|Arm I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
89273422|NCT02581943|Experimental|Arm II (pembrolizumab, paclitaxel, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1, paclitaxel IV over 1 hour and carboplatin IV over 1 hour on days 1, 7 and 14. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
89273423|NCT02527200|Experimental|Liraglutide|
89273424|NCT02527200|Placebo Comparator|Placebo|
89273425|NCT02510040||Convergence insufficiency|Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
89273426|NCT02510040||Divergence insufficiency|Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
89273427|NCT02510040||Small-angle hypertropia|Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
89273428|NCT02464436|Experimental|human retinal progenitor cells (hRPC)|Single subretinal administration of human retinal progenitor cells (hRPC)
89273429|NCT02414269|Experimental|modified T cells alone (without chemotherapy)|Following enrollment, leukapheresis product will be obtained in the blood donor facility at MSKCC and cryopreserved in the Cell Therapy and Cell Engineering Facility (CTCEF). Before protocol treatment, the leukapheresis product will be thawed, and T cell isolation, transduction, and expansion of iCasp928z T cells will be performed in the MSKCC CTCEF Facility. It is estimated that it will take approximately 3 to 6 weeks to generate T cells for treatment.
89273430|NCT02414269|Experimental|modified T cells with cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2) , 2 - 7 (Day (-7) -(-2) days before T cell infusion. On Day 1 , patients will be admitted to the MSKCC Inpatient Service (if not already inpatients) for intravenous hydration, clinical monitoring, and blood work for immune monitoring. Standard MSKCC antiemetic therapy will be administered prior to chemotherapy to prevent nausea/vomiting. Administration of corticosteroids will be avoided as steroids may impede the efficacy of CAR T cells.
89273431|NCT02414269|Experimental|CAR T cell and pembrolizumab|Pembrolizumab 4 weeks (+3/-1 week window) after completing CAR T cell administration. Patients will receive 3 doses of pembrolizumab given on a recurring schedule followed by reassessment. Those responding or deriving clinical benefit, without unacceptable toxicity, will continue pembrolizumab. Patients will be followed weekly for the first four weeks. Patients in cohorts 9 and in Phase II will receive pembrolizumab 4 weeks(+3/- 1 week window) following CAR T cell administration.
89273432|NCT02390518|Experimental|Stereotactic Radiosurgery|
89273433|NCT02369354|No Intervention|Usual Care|Usual medical care at the Duke Kidney Transplant Clinic
89273434|NCT02369354|Other|TALKS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings
89273435|NCT02369354|Other|TALKS PLUS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings plus live donor financial assistance intervention
89273436|NCT02341989|Experimental|Bleomycin-Etoposide-Cisplatin|One course of adjuvant BEP.
89273437|NCT02341989|Active Comparator|Carboplatin|One course of adjuvant carboplatin AUC7
89273438|NCT02312401|Experimental|Multiparametric MRI|Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 & 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.
89273439|NCT02285192|Experimental|intracervical 18F-FDG injection during a dynamic PET/CT|The first 20 eligible patients will be consented to undergo intracervical 18F-FDG injection during a dynamic PET/CT scan. Study enrollment will occur in the clinic during the visit in which they are consented for surgery. Recruited patients will undergo 18F-FDG-guided PET imaging on the day of their scheduled staging surgery. The experimental PET/CT is anticipated to take 2 hours. The second stage of accrual will replace PET/CT with PET/MRI imaging. In every other aspect, patients will receive standard peri- and postoperative care.
89273440|NCT02267603|Experimental|Treatment (pembrolizumab)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression* or unacceptable toxicity.~* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years."
89273441|NCT02244125|Other|Previous IFM/DFCI 2009 arm A|"Patients previously randomized into IFM/DFCI 2009 trial arm A (or if transplantation was not done) will receive:~The treatment phase:~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The consolidation phase:~Melphalan 200mg/m2 followed by ASCT (Autologous Stem Cell Transplantation)~2 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The maintenance phase: Until progression or discontinuation for any other reason~Pomalidomide and Dexamethasone"
89273442|NCT02244125|Other|Previous transplantation IFM/DFCI 2009 arm B|"Patients previously randomized into IFM/DFCI 2009 trial arm B (RVD plus Transplant) will receive:~The treatment phase:~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The consolidation phase:~5 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The maintenance phase: Until progression or discontinuation for any oher reason~Pomalidomide and Dexamethasone"
89273443|NCT02243878|Experimental|Arm A (treatment)|"Participants will receive Stereotactic radiotherapy, a 16 Gy dose of radiation, delivered to the macula.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
89273444|NCT02243878|Sham Comparator|Arm B (control)|"Participants will receive a sham treatment.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
89273445|NCT02208362|Experimental|Stratum I (T lymphocytes intratumoral)|"CLOSED TO ACCRUAL 03/02/2018.~Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions."
89273446|NCT02208362|Experimental|Stratum II (T lymphocytes intracavitary)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intracavitary catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions
89273447|NCT02208362|Experimental|Stratum III (T lymphocytes intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intraventricular catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available.
89273448|NCT02208362|Experimental|Stratum IV (T lymphocytes intratumoral and intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
89273449|NCT02208362|Experimental|Stratum V (T lymphocytes intratumoral and intraventricular)|Patients receive IL13 [EQ]BBzeta/truncated CD19[t]+ Tn/mem via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
89273450|NCT02207985|Experimental|Hematopoetic stem cell transplantation|Patients with pancreatic adenocarcinoma that have undergone Whipple surgery and show no sign of disease recurrence can be treated with hematopoietic stem cell transplantation to achieve an immunological anti-tumor effect.
89273451|NCT02199236|Experimental|endorectal brachytherapy, concurrent chemo and questionnaires|This is a phase I, dose-escalation study to evaluate the safety of endorectal brachytherapy with concurrent capecitabine or 5-fluoruracil (5-FU) in the management of locally recurrent/residual rectal or anal cancer in patients who have received pelvic external beam radiation therapy (EBRT) +/- chemotherapy. We will use magnetic resonance imaging (MRI) with dynamic contrast enhancement (DCE) and diffusion weighted imaging (DWI) series to contribute to the assessment of tumor response.
89273452|NCT02136797|Experimental|CMVpp65-CTL T-cells|The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
89273453|NCT02099734||A: suspicion of germ cell tumor and/or a testicular mass|patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
89273454|NCT02099734||B: family members of Group A|relatives of patients with GCTs or testicular tumors
89273455|NCT02099734||C: healthy controls unrelated to Group A or B|healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
89273456|NCT02098252|Active Comparator|Interventional therapy|"Interventional therapies include:~neurosurgery (surgical resection when the lesion is considered by a multidisciplinary team to be safely 'operable'); radiation therapy (when the AVM is smaller than 3 cm, and considered to not be safely 'operable'); radiosurgery, alone or in combination, with or without endovascular procedure; curative embolization (when the lesion is considered curable by embolization).~Patients with AVMs that the multidisciplinary team judges could potentially benefit from endovascular treatment prior to surgical resection or radiation therapy will then also be pre-randomly allocated to embolization or to no embolization."
89273457|NCT02098252|No Intervention|Conservative management (medical management)|The conservative, or medical management arm, involves pharmacological therapy as deemed appropriate for medical symptoms as determined by the treating investigator. Should patients in the conservative management arm develop hemorrhage or infarction related to their AVM, they then potentially become candidates for interventional therapy.
89273458|NCT01986634|Other|Laser Treatment|Patients enrolled will have split face laser treatment. Patients will serve as their own control.
89273459|NCT01972243||venous thromboembolism|
89273460|NCT01935089|Experimental|Interferon alpha|pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks
89273461|NCT01916122|Experimental|(FES) PET/CT for Imaging|"FES PET/CT studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 5 mCi (+/- 10%) of FES PET/CT will be injected intravenously. 60 (+/- 10) minutes following tracer injection, the patient will be positioned on a GE Discovery PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first, 60-80mAs, 120-140kVp, with a 5mm slice thickness while the patient was free breathing. PET will be acquired at 3-5 minutes per bed position using the 3D mode, approximately 6-7 bed positions. FES PET/CT imaging will take less than 60 minutes. Scans will be reconstructed with iterative reconstruction.~If follow-up FES PT/CT scans are performed on a patient, then the same parameters will be used as the initial FES PET/CT scan."
89273462|NCT01803152|Experimental|Part 1-DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cells Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 20;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
89273463|NCT01803152|Active Comparator|Part 2-Gemcitabine/DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Gemcitabine: Post-Leukapheresis, administered once weekly for 3 weeks;~Dendritic Cells Vaccine (DC Vaccine): Post-Gemcitabine therapy, Recommended Phase 2 Dose (RP2D) administered once weekly for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 12, 16, 20 and 32;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
89273464|NCT01773707|Experimental|abatacept IV infusion|CTLA4-Ig (Abatacept) will be administered as 14 (30 minute) infusions over one year (3 infusions every other week the first month; monthly for the following 11 months)
89273465|NCT01773707|Placebo Comparator|Placebo|The placebo arm will receive 14 (30 minute) IV infusions (containing saline) given 3 times (every other week) the first month and monthly for the following 11 months.
89273466|NCT01737827|Experimental|INC280|The protocol consists of two independent parts (Dose-Determining Part and Dose Expansion Part). Approximately 6 patients will be treated with INC280 300 mg twice a day in the Dose-Determining Part. Approximately 50 patients will be treated with INC280 in the Dose Expansion Part. The dose for the Expansion Part can be lower, equal or higher than in the Dose-Determining Part will be determined after the Dose Determining Part at the dose decision analysis.
89273467|NCT01668563|Active Comparator|Endovascular management|Endovascular treatment will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
89273468|NCT01668563|Active Comparator|Surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
89273469|NCT01628640|Experimental|Arm A (viral therapy in single tumor location)|Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
89273470|NCT01628640|Experimental|Arm B (viral therapy in multiple locations)|Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
89273471|NCT01521026|Experimental|Cognitive Training|Cognitive training group
89273472|NCT01521026|No Intervention|Standard Pharmacotherapy|
89273473|NCT01504815|Active Comparator|Cisplatinum + conventional RT|Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks
89273474|NCT01504815|Experimental|Cisplatinum + adaptive high dose RT|Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks
89273475|NCT01349582|Active Comparator|flow diversion|Flow diverters are low porosity braided endovascular stent devices. They can be used with or without coiling.
89273476|NCT01349582|Active Comparator|Best standard treatment|Best standard treatment can by any of the standard management options: coiling, stenting plus coiling, surgical clipping, parent vessel occlusion, observation
89273477|NCT01349582|Other|Registry for flow diversion|Flow diversion when randomization between flow diversion and best standard treatment is not possible and the only alternative is flow diversion for compassionate use. In this case there will be no random allocation but the patient will be entered into a registry
89273478|NCT01340612|Active Comparator|coiling|endovascular coiling with any type of currently approved coil (first or second generation)
89273479|NCT01340612|Active Comparator|coiling plus stenting|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.
89273480|NCT01334944|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.
89273481|NCT01140373|Experimental|autologous T cells & cyclophosphamide.|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells targeted to Prostate-Specific Membrane Antigen (PSMA) administered one day after pretreatment with cyclophosphamide.
89273482|NCT01139892||Surgical management|Surgical clipping will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, bypasses, and other flow-redirecting treatments that do not directly clip the aneurysm will not be included.
89273483|NCT01139892||Endovascular management|Endovascular treatment will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling or stents, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
89273484|NCT01048918||No Treatment|
89273485|NCT00902720|Experimental|Cryopreservation|The ovarian tissue is frozen and banked at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
89273486|NCT00840047|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive methionine.
89273487|NCT00810732|Experimental|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
89273488|NCT00810732|Active Comparator|Nifedipine|Nifedipine 30 mg extended release tablets, orally administered once daily (open label arm)
89273489|NCT00810732|Placebo Comparator|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
89273490|NCT00764920||Skin Imaging|non-invasive imaging modalities for assessment of skin
89273491|NCT00719888|Experimental|Treatment (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
89273492|NCT00719888|Experimental|Arm II (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
89273493|NCT00571727|Experimental|mecasermin, injections BID of rhIGF-1|
89273494|NCT00427349|Experimental|AMG 706+Octreotide|"Patients receive oral AMG 706 and octreotide acetate intramuscularly (IM) once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the morning. AMG 706 was taken daily without breaks in treatment.~One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles."
89273495|NCT00285935|Experimental|Treatment with SSRI|"Depressed participants will receive 8 weeks of treatment with one of the following serotonin-specific reuptake inhibitors:~fluoxetine (Prozac®), sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)~The specific drug used for treatment will be selected by the study clinician based on clinical interviews and the participants preferences. Participants will be monitored for response and side effects by study clinician and will return after 8 weeks for a follow up study visit."
89273496|NCT00250770||1|"Healthy postmenopausal and perimenopausal women with no history of endometrial carcinoma.~Women undergoing hysterectomy for benign conditions."
89273497|NCT00230165||Normal|Normal, healthy volunteers 18 years of age or older of either sex and any ethnic background
89273498|NCT00230165||Glanzmann thrombasthenia|Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation
89273499|NCT00200174|Active Comparator|A|Raloxifene followed by combination therapy
89273500|NCT00200174|Active Comparator|B|Exemestane followed by combination therapy
89273501|NCT00195091|Experimental|Tetrathiomolybdate (TM)|"Induction period - TM 40 mg is administered three x per day with meals and TM 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Maintenance Period - Total TM dose per day will be in 20 mg increments to tailor the therapy to individualized patient needs to maintain the Cp level at 5-17mg/dL. Thus all dose modifications will be dependent on individual patient Cp levels. TM 40 mg p.o. BID with meals and TM 20 mg at bedtime. Subjects who have no evidence of disease (NED) and are receiving a benefit of TM can continue taking the drug for up to 120 months."
89273502|NCT00098787|Experimental|Arm A (High TS, IROX/bev)|Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
89273503|NCT00098787|Experimental|Arm B (High TS, FOLFOX/bev)|Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
89273504|NCT00098787|Experimental|Arm C (Low or intermediate TS, FOLFOX/bev)|Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.
89273505|NCT00091169|Experimental|Arm I|Patients receive oral levocarnitine (L-carnitine) twice daily on weeks 1-4.
89273506|NCT00091169|Placebo Comparator|Arm II|Patients receive oral placebo twice daily on weeks 1-4.
89273507|NCT00074165|Experimental|All subjects|
89273508|NCT00059930|Experimental|Adjuvant Hepatic Arterial Infusion & Combination Chemotherapy|This is a Phase I study with the primary objective of defining the maximum tolerated dose of hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump in combination with intravenous oxaliplatin plus systemic fluorouracil (5FU)/leucovorin (LV) in the adjuvant setting after resection of hepatic metastases from colorectal cancer. A total of eleven dose levels will be considered.
89273509|NCT00057876|Active Comparator|Gemcitabine|
89273510|NCT00057876|Experimental|Gemcitabine + Radiation|
89273511|NCT00057837|Experimental|PET (Topotecan/Etoposide/Cisplatin/G-CSF)|Patients receive topotecan intravenously (IV) over 30 minutes on days 1-3; etoposide IV over 60 minutes immediately followed by cisplatin IV over 60 minutes on days 8-10; and filgrastim (G-CSF) subcutaneously daily beginning on day 11 and continuing until blood counts recover.
89273512|NCT00057837|Experimental|PIE (Irinotecan/Cisplatin/Etoposide)|Patients receive irinotecan IV over 90 minutes and cisplatin IV over 60 minutes on days 1 and 8 and oral etoposide twice daily on days 3 and 10 of each cycle.
89273513|NCT00046930|Experimental|Zosuquidar|Induction treatment with daunorubicin, cytarabine and zosuquidar (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
89273514|NCT00046930|Active Comparator|Placebo|Induction treatment with daunorubicin, cytarabine and placebo (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
89273515|NCT00042939|Active Comparator|Irinotecan/Docetaxel|"Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. This constituted a cycle of treatment. Patients were evaluated after 2 cycles."
89273516|NCT00042939|Experimental|Irinotecan/Docetaxel/Cetuximab|"Patients received Cetuximab intravenously once a week for 6 weeks. On day 1 of cycle 1 only, an initial dose of 400 mg/m² (over 120 minutes) was administered. Thereafter, a once-a-week maintenance dose of 250 mg/m² (infused over 60 minutes), was given. The infusion rate never exceeded 5 ml/minute.~On the day of the initial dose, the administration of Cetuximab was followed by the administration of docetaxel, after a 60-minute observation period. (The observation period was 30 minutes following maintenance doses.) Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Cetuximab was administered once a week for 6 consecutive weeks. A cycle of treatment was 6 weeks."
89273517|NCT00008385|Placebo Comparator|Arm I|Participants receive an oral yeast placebo as in arm II.
89273518|NCT00008385|Experimental|Arm II|Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
89273519|NCT00003927|Experimental|High Dose chemotherapy followed by cell rescue|Doxorubicin, cyclophosphamide, Taxol, amifostine
89273520|NCT00003910|Experimental|Methotrexate (Cy if no response to MTX)|MTX given orally at 10 mg/m2 in divided doses once weekly. Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days. Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule.
89273521|NCT00003907|Experimental|Hepatocellular carcinoma|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
89273522|NCT00003907|Experimental|Neuroendocrine hepatic metastases|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
89273523|NCT04334499||Age Related Macular Degeneration|Subjects with Age Related Macular Degeneration upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
89273524|NCT04334499||Glaucoma|Subjects with Glaucoma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
89273525|NCT04334499||Diabetic Retinopathy|Subjects with Diabetic Retinopathy upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
89273526|NCT04334499||Ocular Trauma|Subjects with Ocular Trauma upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
89273527|NCT04334499||Control|Subjects with no ocular disease or trauma comorbidities upon evaluation for ocular surgery that may involve the discard of vitreous humor tissue.
89273528|NCT04331067|Active Comparator|Arm A: Neoadjuvant chemo + nivolumab|-Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.
89273529|NCT04331067|Experimental|Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab|"As of Amendment #7 IRB approved 10/13/2022: The study will no longer enroll to Arm B. Cabiralizumab will no longer be given.~Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.~Cabiralizumab will be given IV at a dose of 4 mg/kg every 2 weeks for 12 weeks."
89273530|NCT04329221|Experimental|Topical Calcipotriol ointment plus 5-Fluorouracil cream|Topical Calcipotriol 0.0025% ointment plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
89273531|NCT04329221|Placebo Comparator|Topical vaseline plus 5-Fluorouracil 2.5% cream|Topical Vaseline plus 5-Fluorouracil 2.5% cream will be administered by the participants to their face, scalp and upper extremities twice a day for 6 consecutive days.
89273532|NCT04316013|Active Comparator|A|Sevoflurane + intravenous lidocaine
89273533|NCT04316013|Active Comparator|B|Sevoflurane
89273534|NCT04316013|Active Comparator|C|Propofol TIVA + intravenous lidocaine
89273535|NCT04316013|Active Comparator|D|Propofol TIVA
89273536|NCT04313257|Active Comparator|Passive Occlusion|This arm will include those participants who will follow a daily occlusive treatment of 2 hours.
89273537|NCT04313257|Experimental|Active Occlusion|This arm will include patients who will be treated with monocular therapy with video-games of one hour on a daily regimen.
89273538|NCT04295798|Experimental|Traditional tDCS|At the beginning of stimulation, the current will be increased manually from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. Participants will be instructed to notify study personnel if and when they feel any uncomfortable sensation. The ramp-up will be stopped at this point and for the remainder of the session tDCS will be delivered at an intensity of 0.1 mA below the highest level reached. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
89273539|NCT04295798|Sham Comparator|Traditional Sham|A traditional sham will be used to maximize blinding of traditional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration as described with the Traditional tDCS will be used; however, current will automatically be ramped down 60 seconds after ramp-up.
89273540|NCT04295798|Experimental|Personalized tDCS|Baseline MRI's will enable personalization of tDCS via current flow modeling and optimized to each participant with the goal of generating an average nE over the dlPFC of the same size as the one delivered by a traditional montage using sponges in an average subject at 1.5 mA of current. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
89273541|NCT04295798|Sham Comparator|Personalized Sham|An active sham will be used in which very low-level currents (0.5mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
89273542|NCT04281849|No Intervention|Usual care|Patients in the usual care arm will receive educational material from the Heart Failure Society of America (HFSA) with the current recommendations for exercise for patients with heart failure.
89273543|NCT04281849|Experimental|BAMS-HF Program|
89273544|NCT04278794|Experimental|Transitional Care Stroke Intervention (TCSI)|Participants randomly assigned to the intervention group will be offered the intervention in addition to usual care provided by in-patient and outpatient stroke rehabilitation services. The TCSI is a 6-month stroke transitional care intervention, provided in addition to usual stroke care, that includes four core components: comprehensive hospital discharge plan, structured home visits and telephone support, monthly intraprofessional case conferences, and linkages to primary care and other healthcare and community services. The TCSI will be delivered by an interprofessional team of care providers at the study site, including an occupational therapist, registered nurse, speech language pathologist, physical therapist, and social worker from a hospital-based outpatient stroke rehabilitation setting.
89273545|NCT04278794|No Intervention|Control|Usual care provided by in-patient and out-patient stroke rehabilitation services.
89273546|NCT04270474|Experimental|Active Intervention (ACT)|Pharmacist-based Deprescribing
89273547|NCT04270474|Sham Comparator|Usual Care (UC)|Usual Care
89273548|NCT04264897|Experimental|Metformin|"The investigators use a ramp up dosing protocol in which the amount of metformin (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day, which is a standard clinical dose (1500-2000 mg/day). If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
89273549|NCT04264897|Placebo Comparator|Placebo|"Subjects assigned to the placebo group will receive visually identical pills (silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate).~The same dosing schedule will be followed as for metformin. The investigators use a ramp up dosing protocol in which the amount of placebo (Hunter Pharmacy) will begin at 500 mg/day in week 1, increase to 1000 mg/day in week 2, and then to 1500 mg/day in week 3, as tolerated. At week 3 and for the remaining 9 weeks, the dose will remain at 1500 mg/day. If a subject has gastrointestinal discomfort with 1500 mg/day the dose, the investigators will lower the dose to 1000 mg/day. The investigators will split the dose with 1/2 given in the a.m. and 1/2 in the p.m. and taken with meals to minimize GI discomfort."
89273550|NCT04262908||Patients implanted with hip or knee prostheses|Patients who had hip or knee arthroplasty will be followed and asked at 3-months visit if they resumed their job or not. In both cases, further informations will be gathered
89273551|NCT04262713|Other|Patients implanted with Meije duo stem size 1 or 2|"Among this arm, patients that meet criteria ( weight>~60kg and / or a long neck / varus and / or a DEVANE score ≥ 4 ) will perform hip X ray"
89273552|NCT04241315|Experimental|Near-Infrared Imaging group|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
89273553|NCT04241315|Other|No Imaging Group|All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.
89273554|NCT04225026|Experimental|GC4419 (avasopasem manganese)|
89273555|NCT04199637|Experimental|Experimental group|Experimental group is provided therapeutic video games
89273556|NCT04199637|No Intervention|Control group|Control group is provided regular care
89273557|NCT04175769|Experimental|Experimental intervention|Standard intervention of immunotherapy or combination of immunotherapy and chemotherapy, plus the experimental intervention nutritional product.
89273558|NCT04175769|Placebo Comparator|Non-experimental intervention|Standard intervention of immunotherapy or combination of immunotherapy and chemotherapy, plus the non-experimental intervention placebo product.
89273559|NCT04145934|Experimental|training|The subjects receive the ADSTEP intervention
89273560|NCT04145934|No Intervention|waitlist|These subjects receive two brochures on fall prevention and walking aid selection, and a letter is sent to their care provider informing them that the subject has reported falling. Subjects in this group will be offered the ADSTEP intervention once their study participation is complete.
89273561|NCT04139538|Experimental|Invisalign treatment|Aligner patients will be treated with Invisalign® aligners to correct malocclusion
89273562|NCT04139538|Active Comparator|selfligating bracket treatment|Multibracket patients will be treated with self ligating orthodontic brackets
89273563|NCT04139343||SMA cohort|Individuals who have a diagnosis of SMA who are NOT receiving Spinraza (nusinersen).
89273564|NCT04139343||SMA Spinraza cohort|Individuals who have a diagnosis of SMA who are receiving Spinraza (nusinersen).
89273565|NCT04139343||Control cohort|Control participants will only come to a baseline visit and the only tests that will be completed are the EMG Measures (MUNE, CMAP, decomposition EMG) and EIM. There will be no further testing for those participants. This visit will take approximately 30-60 minutes. A total of 40 control participants are being recruited for this study.
89273566|NCT04111627|Experimental|Aerobic exercise plus Duloxetine|Participants will have a starting duloxetine dosage of 30 mg/day and be titrated up to a daily optimal dosage of 60 mg/day as tolerated during the first 12-weeks of the study. Twelve weeks after the receipt of their prescription, participants will be evaluated for the need to increase medication dosage to 90 mg/day. After duloxetine initiation, participants will be provided an exercise prescription that includes a progressive walking program aiming to achieve 50 minutes of moderate-intensity physical activity, three times per week, over 24 weeks.
89273567|NCT04105491||Aligner Patients|Patients who decided to be treated with Invisalign® aligners
89273568|NCT04090710|Active Comparator|Standard of Care I/N alone|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
89273569|NCT04090710|Experimental|Standard of Care I/N plus primary disease SBRT|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for one cycle, followed by SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks. Approximately one week following completion of SBRT, patients will start cycle 2 of immunotherapy as per standard of care. The total time elapsed between the start of cycle 1 and 2 of I/N should be no more than 6 weeks. After completion of up to four cycles of I/N, patients will proceed to standard of care maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression (as determined by RECIST 1.1), intolerance, or patient/physician decision to stop treatment.
89273570|NCT04064463|Active Comparator|Control Group|Standard care
89273571|NCT04064463|Experimental|Experimental Group|Standard care plus contingency management
89273572|NCT04042480|Experimental|SGN-CD228A|SGN-CD228A monotherapy
89273573|NCT04025528||Hypercapnic|Obese patients with daytime hypercapnia
89273574|NCT04025528||Eucapnic|Obese patients with normal daytime carbon dioxide levels
89273575|NCT04023825|Experimental|experimental group|Patients will receive loco regional anesthesia
89273576|NCT04023825|No Intervention|control group|Patients will not receive loco regional anesthesia
89273577|NCT04019665|Other|SAGE and MMSE score|
89273578|NCT03982277|Experimental|High dose Rifampin + DTG|High dose Rifampicin (35mg/kg ) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
89273579|NCT03982277|No Intervention|Standard dose Rifampin + DTG|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen
89273580|NCT03982277|Experimental|High dose Rifampin + EFV|High dose rifampicin (35mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
89273581|NCT03982277|No Intervention|Standard dose Rifampin + EFV|Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen
88805554|NCT01045031||marathon athletes|Runners participating in the 2008 Wachau half marathon (21,2 km) and the Vienna City marathon (42,5 km) as well as bicyclists participating at the Corinthian marathon (180km). Inclusion criteria:1) participation in at least one of these 3 marathons in the preceding two years,2)still in continuous training during the recruitment phase (at least 2 hours/week), 3) aged over 60. Exclusion criteria:(a) present or past exposure to neurotoxic substances (b) if they did not speak German as their native language (c) diseases that markedly affect CNS functions (d) manifest cardiovascular disease, (e) chronic alcoholism (daily alcohol intake > 60 g or diagnosed history of alcoholism) and (f) unwillingness to give informed consent.
89273582|NCT03979443|No Intervention|Inpatient|patients staying in the hospital for 1-3 nights after surgery
89273583|NCT03979443|Active Comparator|Outpatient|discharge on the day of the surgery, usually within 6-8 hours after procedure
89273584|NCT03955978|Experimental|TSR-042 and Brachytherapy|"Patients will receive four doses of TSR-042. The first dose is given 21 days prior to the first planned brachytherapy fraction. The second dose is given 21 (+3) days later, corresponding to the time of brachytherapy fraction #1. The third dose is given 21 (+3) days after dose 2, corresponding to the time of brachytherapy fraction #4. The fourth dose is given 21 (+3) days after dose corresponding to 1 weeks after brachytherapy fraction #6.~Brachytherapy will consist of 6 weekly fractions of 6 Gy per fraction (total 36Gy)"
89273585|NCT03927703|Experimental|SB206 12%|SB206 12% topically once daily
89273586|NCT03927703|Placebo Comparator|Placebo Comparator|Placebo topically once daily
89273587|NCT03918499|Experimental|Treatment (pembrolizumab, cyclophosphamide, and IRX-2)|Participants receive pembrolizumab IV over 30 minutes on day 1. Participants also receive cyclophosphamide IV on day 1 and IRX-2 SC for 10 days starting on day 4 during cycles 1, 5, 9, 13, 17, 21, 25, 29, and 33. Treatment repeats every 3 weeks for up to 35 cycles in the absence of disease or unacceptable toxicity.
89273588|NCT03904602|Experimental|Edema Wear|Edema Wear fuzzy wale compression garment worn on lower extremities continuously for 5 days or until discharge if less than 5 days.
89273589|NCT03870945|Experimental|Dose level 1 with 1x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 1x10^6 MBCART2019.1 per kg BW in a single infusion. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
89273590|NCT03870945|Experimental|Dose level 2 with 2.5x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
89273591|NCT03868735|Experimental|CleanSweep Closed Suction System|Device that includes balloon sweeping technology
89273592|NCT03868735|No Intervention|Standard in-line suction device|In-line suction device already in on intubated patients with an endotracheal tube
89273593|NCT03838549|Experimental|implant for breast reconstruction|20 patients female with genetic risk for breast cancer and who ask for prophylactic mastectomy. They will have a prophylactic mastectomy with immediate breast reconstruction
89273594|NCT03833193|Experimental|Hypofractionated radiotherapy|The patients received daily accelerated radiotherapy with a total dose of 60Gy, delivered at 3Gy per fraction, five fractions per week, completed within 4 weeks.
89273595|NCT03819829|Other|Blood sample|Blood sample
89273601|NCT03803943|Experimental|Parent-Implemented Communication Intervention (PICT)|Participants assigned to the PICT condition will receive weekly hour long intervention sessions in their home for 6 months. Parents will learn four sets of communication support strategies: (a) visual (e.g., modeling language within the child's line of sight), (b) interactive (e.g., following the child's attentional focus), (c) responsive (e.g., responding to all communicative attempts), and (d) linguistically stimulating (e.g., modeling language targets, expanding child communication).
89273602|NCT03803943|Placebo Comparator|No Intervention - Business-as-usual control|Participants assigned to the BAU control group will not receive the PICT intervention.
89273603|NCT03802695|Experimental|Arm A|Recipients with HLA-identical or 1-allele mismatched (7/8 alleles) related or unrelated donor; with single-agent GVHD prophylaxis given
89273604|NCT03802695|Experimental|Arm B|Recipients with haploidentical-related donors; with single-agent GVHD prophylaxis given
89273605|NCT03802695|Experimental|Arm C|Recipients with an HLA-identical related or unrelated donor; no GVHD prophylaxis given
89273606|NCT03786952|Experimental|Stress, immediate, males|Stress immediately before learning in males
89273607|NCT03786952|Experimental|Stress, delayed, males|Stress 30 minutes before learning in males
89273608|NCT03786952|Sham Comparator|Sham control, immediate, males|Sham control immediately before learning in males
89273609|NCT03786952|Sham Comparator|Sham control, delayed, males|Sham control 30 minutes before learning in males
88805555|NCT00131378|Experimental|Male on GH|"Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
88805556|NCT00131378|Placebo Comparator|Male on Placebo|"Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
89273610|NCT03786952|Experimental|Stress, immediate, females|Stress immediately before learning in females
89273611|NCT03786952|Experimental|Stress, delayed, females|Stress 30 minutes before learning in females
89273612|NCT03786952|Sham Comparator|Sham control, immediate, females|Sham control immediately before learning in females
89273613|NCT03786952|Sham Comparator|Sham control, delayed, females|Sham control 30 minutes before learning in females
89273614|NCT03782688||Single-arm cohort|Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)
89273615|NCT03732261|Experimental|Intervention|Intervention Group: Women randomized to the intervention group will be given a 3month membership to a community based exercise program, a pedometer and individual dietary recommendations. They will be asked to attend a minimum of three 45 minute to 60 minute exercise sessions per week but no more than five and will gradually build to walk 10,000 steps per day. Childcare and breastfeeding support will be provided. Trained research assistants will lead all group sessions. Weekly workout volume will be calculated and weekly steps will be monitored by research assistants. For the dietary intervention, the women will be provided 6oz of plain yogurt fortified with vitamin D post workout for the 12-week intervention. If any yogurt is out of date (expired), we will dispose of the expired yogurt. Weekly monitoring for the consumption of the yogurt and energy intake will be conducted by face-to-face or telephone interviews by research assistants.
89273616|NCT03732261|No Intervention|Control|Minimal Care Group: Women randomized into the minimal care group will be asked not to participate in any structured exercise or make any changes in their diet. They will be permitted to walk their infants in strollers at a leisurely pace (no faster than 2 mph) for no more than 30 minutes per day. After the endpoint measurements of the 12-wk intervention, the minimal care group will be asked to join the community based program provided to the intervention group. The participants will be given the pedometer, individual dietary recommendations and yogurt. Additionally, support by the PI and research assistants for exercise and diet will be provided until the one-year postpartum laboratory measurement.
89273617|NCT03730324|Active Comparator|Standard care|Study subject will undergo sampling of plasma and urine biomarkers.
89273618|NCT03730324|Experimental|Magnetic Resonance Imaging.|Prior to biopsies a magnetic resonance imaging scan will be performed.
89273619|NCT03727490|Active Comparator|Control|This group will have the subscapularis left un-repaired, which is the standard of care for our institution for reverse shoulder arthroplasty.
89273620|NCT03727490|Experimental|Study|This group will have the subscapularis tendon repaired through a bone to bone repair that will add approximately 5 minutes to the surgical procedure.
89273621|NCT03724448|Experimental|ALEOZEN group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
89273622|NCT03724448|Placebo Comparator|placebo group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
89273623|NCT03711474|Experimental|Treatment 1; Dexamethasone|"Drug: Treatment 1; Dexamethasone. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10 and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the single dose steroid administration group or the single dose saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of incision."
89273624|NCT03711474|Placebo Comparator|Treatment 0; Placebo|"Drug: Treatment 0; Saline placebo. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10, and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of the incision."
89273625|NCT03693287|Active Comparator|Personalized-Parenteral Nutrition (P-PN)|"These patients will receive personalized parenteral nutrition (PN) as it is customary in the participating centers.~Dosing range: glucose from 9 to 13 g/kg/d, AA from 2.0 to 3.0 g/kg/d, and FAT from 1.5 to 2.5 g/kg/d.~Intravenous macronutrient intakes:~PN day 1: 2.0 g/kg of AA, 1.6 g/kg of FAT and 9 g/kg of glucides.~PN day 2: 2.5 g/kg of AA, 2.0 g/kg of FAT and 11 g/kg of glucides.~PN day 3 and the days after: 3.0 g/kg of AA, 2.5 g/kg of FAT and 13 g/kg of glucides.~Intravenous vitamins will be supplied according to local clinical practice. Variations in macronutrient intakes will be tolerated within ±20%.~Nutritional goal: to ensure at least 2.5 g/kg/d of AA and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
89273626|NCT03693287|Experimental|Standardized-Parenteral Nutrition (S-PN)|"These patients will receive standardized parenteral nutrition (PN) by using a triple chamber bag (Numeta G13%E®).~Dosing range: 80-300 ml/d. Intravenous macronutrient intakes: 65 ml/kg at PN day 1, 80 ml/kg at PN day 2 and then 100 ml/kg from PN day 3.~Nutritional goal: to ensure at least 2.5 g/kg/d of amino acids (AA) and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
89273627|NCT03677713|Active Comparator|Nasal Packing|Nasal packing will be placed at the end of surgery.
89273628|NCT03677713|Experimental|No Nasal Packing|No nasal packing will be placed during or after the surgery.
89273629|NCT03647826|Experimental|Mind Power Intervention Group 1|"Entire school classes will be randomly divided into two interventions (Mind Power Intervention Group 1 or Mind Power Intervention Group 2). The content in the two interventions are exactly the same, except the time when they are conducted.~The first arm is the Mind Power Intervention Group 1. This intervention is the first and starts in September 2018 and last for 10 weeks."
89273630|NCT03647826|Experimental|Mind Power Intervention Group 2|"The second arm is the Mind Power Intervention Group 2. This arm starts the intervention in January 2019 (six months later than Group 1). Group 2 function as a Control Group.~The Experiment containes arm 1 and arm 2; With an delayed intervention design."
89273631|NCT03493958|Experimental|Feasibility and acceptability of Sleep Healthy Using the Internet (SHUTi) for CBT-I|Individuals with alcohol use disorder (AUD) in recovery with insomnia completed six online classes that include interactive educational content and case studies about insomnia and its precipitating factors. These sessions are designed to parallel traditional (in-person) cognitive behavioral therapy for insomnia (CBT-I) sessions and are tracked and customized. New sessions are available seven days after completion of the previous session. The program includes a variety of interactive features, including goal setting, feedback based on user-identified symptoms, animations, quizzes, vignettes, and video-based expert explanations. Participants have maximum of 9-11 weeks to complete the six sessions.
89273632|NCT03486223|Experimental|Placebo then GSK2256294|Subjects will receive placebo oral capsule daily by mouth for 7 days, then seven week washout and then GSK2256294 daily by mouth for 7 days.
89273633|NCT03486223|Experimental|GSK2256294 then Placebo|Subjects will receive GSK2256294 daily by mouth for 7 days, then seven week washout and then placebo oral capsule daily by mouth for 7 days.
89273634|NCT03482024|Experimental|Tirzepatide - Control|Group 1 - Tirzepatide 5 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.
89273635|NCT03482024|Experimental|Tirzepatide - Mild Renal Impairment|Group 2 - Tirzepatide 5mg administered SC to participants with mild renal impairment.
89273636|NCT03482024|Experimental|Tirzepatide - Moderate Renal Impairment|Group 3 - Tirzepatide 5mg administered SC to participants with moderate renal impairment.
89273637|NCT03482024|Experimental|Tirzepatide - Severe Renal Impairment|Group 4 - Tirzepatide 5mg administered SC to participants with severe renal impairment.
89273638|NCT03482024|Experimental|Tirzepatide - End Stage Renal Disease (ESRD)|Group 5 - Tirzepatide 5mg administered SC to participants with ESRD.
89273639|NCT03480139||Pregnant Women|Pregnant women aged 18 years and older
89273640|NCT03468309||Genecept Assay and G-DIG decision tool|Veterans who have been prescribed 5 or more medications, with at least two being for a mental health diagnosis. Also allowable would be one medication for a mental health diagnosis and another medication for side effects related to a medication prescribed for the mental health diagnosis.
89273641|NCT03451253|Experimental|amino acid mixture beverage|amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
89273642|NCT03451253|Active Comparator|glucose based sports drink|glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.
89273643|NCT03443076|Experimental|EPA + DHA in SMEDS Formulation|Subject will receive a single 500 mg oral dose of EPA + DHA in a SMEDS formulation
89273644|NCT03443076|Active Comparator|EPA + DHA (Lovaza)|Subject will receive a single 840 mg oral dose of EPA + DHA as Lovaza
89273645|NCT03430167|Other|Group I - Formal Therapy|Supervised physical therapy will be ordered 2 times/week initially for 6 weeks and then tailored to a minimum of 1 visit/week based upon the individual progress of each patient. Home exercises will be provided to the patient by the therapist to be performed daily. Supervised physical therapy will be discontinued once the patient demonstrates independence with the final phase of rehabilitation, which represents the graduated strengthening program.
89273646|NCT03430167|Other|Group II - Home Therapy|In the study group all patients will be instructed in a standardized fashion regarding a home exercise program. This program will involve a standardized a set of five exercises. These exercises will be reviewed with patients in clinic in a standardized fashion and patients will be provided with an instructive hand-out.
89273647|NCT03423147|Experimental|Chlorhexidine gluconate vaginal scrub and cloth|Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
89273648|NCT03423147|Active Comparator|Standard Treatment|Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.
89273649|NCT03418532|Experimental|single arm|MP0250 DARPin® drug candidate (6 mg/kg or 8 mg/kg or 12 mg/kg, infusion) on day 1 of each 21 day cycle. Osimertinib according to label
89273650|NCT03417401|Experimental|RVC with tPA for CRVO|Single arm phase I open label study were CRVO patients will have a vitrectomy with retinal vein cannulation and a single infusion of tPA (0.25mg/ml) intravenously with a maximum dose of 1mg.
89273651|NCT03414385|Experimental|Exercise group|Research volunteers will be asked to undergo an acute bout of aerobic exercise at moderate intensity for ~120 minutes. Before and after the exercise the volunteer will undergo leg biopsy.
89273652|NCT03322631|Experimental|Tirzepatide|Participants received escalating doses of 2.5 milligrams (mg), 5 mg, 10 mg and 15 mg of tirzepatide administered into the subcutaneous (SC) tissue of the abdominal wall.
89273653|NCT03322631|Placebo Comparator|Placebo|Participants received placebo administered into the SC tissue of the abdominal wall.
89273654|NCT03290612|Experimental|Vitamin C then Placebo|Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.
89273655|NCT03290612|Experimental|Placebo then Vitamin C|Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.
89273656|NCT03288753|Experimental|Adults and children above 14 years old|"Visit 1:~Satisfaction questionnaire on Neuro 1 Speech intelligibility in quiet on Neuro 1 Speech intelligibility in noise on Neuro 1 VRB (Vocale Rapide dans le Bruit) on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2"
89273657|NCT03288753|Experimental|children up to 14 years old|"Visit 1 Satisfaction questionnaire on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2~The questionnaires have to be filled in by the parents. The child can participate in the completion of the questionnaire if he is willing and understands the questions."
89273658|NCT03190473|Experimental|Svelte|
89273659|NCT03190473|Active Comparator|Control|
89273660|NCT03157999|Experimental|Intervention group (CAST)|Participants in the intervention group will receive the CAST hospital-to-home transition intervention in addition to usual care.
89273661|NCT03157999|No Intervention|Control group (usual care)|Participants assigned to the control group will receive usual care at discharge from hospital to home.
89273662|NCT03107546|Other|Skin graft|full thickness skin graft
89273663|NCT03107546|Experimental|Hyalomatrix|skin graft substitute
89273664|NCT03090750|Experimental|Lavender|Lavender oil
89273665|NCT03090750|Experimental|Bergamot|Bergamot oil
89273666|NCT03090750|Placebo Comparator|Water|Water
89273667|NCT03086642|Experimental|T-Vec|All enrolled patients will receive a test dose of talimogene laherparepvec (10^6 plaque forming units (PFU)/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
89273668|NCT03077776|Experimental|All included patients|"Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:~(optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy~At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).~Biopsy of a metastatic site in the event of disease recurrence.~Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery."
89273669|NCT03057795|Experimental|Treatment (brentuximab vedotin, nivolumab)|Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89273670|NCT03018704|Placebo Comparator|Placebo|a placebo control arm
89273671|NCT03018704|Experimental|Topiramate|Topiramate an FDA approved anticonvulsant has been shown effective in the treatment of alcohol use disorder but there is no data supporting use in minority patients. The medication was dosed orally twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
89273672|NCT02978612|Experimental|Arm Capecitabine|Capecitabine 1000 mg/m2 bid day 1-14 q3 weeks, 8 cycles
89273673|NCT02978612|No Intervention|Arm No treatment|no chemotherapy, observation
89273674|NCT02974608||Children 0-10 years|Children living in selected villages surrounding the district of Ouelessebougou
89273675|NCT02974608||Pregnant Women + Newborns|Pregnant women of any age and their newborn children
89273676|NCT02974608||Women of Child Bearing Age Potential|Non-pregnant women of child-bearing age
89273677|NCT02970500|Experimental|Methylphenidate HCl 10Mg SR|Participants of the intervention group (n=20) will receive 1 capsule of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 1 and 2 capsules of Methylphenidate HCl 10 mg SR each morning during 14 days during phase 2.
89273678|NCT02970500|Placebo Comparator|Placebo Group|Participants of the control group (n=20) will receive 1 capsule of placebo each morning during 14 days during phase 1 and 2 capsules of placebo each morning during 14 days during phase 2.
89273679|NCT02881515|Experimental|Blood Pressure Reactivity|Blood Pressure Responses to a cold pressor test and acute exercise will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
89273680|NCT02881515|Experimental|Blood Pressure Variability|Twenty four hour blood pressure variability will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
89273681|NCT02861846|Other|Presence of biomarkers of AD in cerebrospinal fluid|Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
89273682|NCT02663349|Experimental|Supported SCIT|Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One 2-hour group session will be offered once a week for 12 weeks. In addition, 30 minutes of individual training will be provided weekly by an instructor.
89273683|NCT02617407|Experimental|Livionex® Dental Gel|Study patients assigned to this arm will use Livionex toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
89273684|NCT02617407|Active Comparator|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Study patients assigned to this arm will use PreviDent 5000 plus or Tom's of Maine Children's (age 6 years and younger) toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
89273685|NCT02562040|Active Comparator|Watchful Waiting with Supportive Care|All Watchful Waiting with Supportive Care (WWSC) participants will receive information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
89273686|NCT02562040|Experimental|Early Adenotonsillectomy|All Early Adenotonsillectomy (eAT) participants will receive information about healthy sleep habits for children, undergo adenotonsillectomy within 4 weeks of randomization and receive appropriate clinical referrals for management of co-morbidities
89273687|NCT02558491|Experimental|Decision Support System|Blinded continuous glucose monitor (CGM) data will be collected prior to the Experimental Admission and analyzed by the study team to determine the optimal insulin therapy parameters for each insulin pump and multiple daily injections (MDI) participant. These optimized parameters will be used during the Experimental Admission.
89273688|NCT02558491|Active Comparator|Usual Care|Insulin pump and MDI participants will use their own insulin parameters, including basal rate, correction factor and carbohydrate-insulin ratio, and determine their own insulin usage during the Control Admission.
89273689|NCT02537509|Active Comparator|Cholecalciferol|Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
89273690|NCT02537509|Placebo Comparator|Placebo of cholecalciferol|Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
89273691|NCT02490878|Experimental|bevacizumab + corticosteroids|"The patient will receive bevacizumab 10 mg/kg IV given on days 1 and 15 of a 28 day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be treated as per treating MD."
89273692|NCT02490878|Experimental|placebo + corticosteroids|"The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on days 1 and 15 of a 28-day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be allowed to receive bevacizumab according to the protocol."
89273693|NCT02458027|Experimental|20g Hemp Protein Shake|Hemp protein shake, 20 grams, given once at beginning of acute trial.
89273694|NCT02458027|Experimental|40 g Hemp Protein|Hemp protein shake, 40 grams, given once, at beginning of acute trial.
89273695|NCT02458027|Active Comparator|20 g Soybean Protein Shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial.
89273696|NCT02458027|Experimental|40 g Soybean Protein|Soybean protein shake, 40 grams, given once, at beginning of acute trial.
89273697|NCT02458027|Placebo Comparator|Control Shake|Non-protein control shake, given once, at beginning of acute trial.
89273698|NCT02421601|Experimental|SI-6603|SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
89273699|NCT02382614|Experimental|Spiration Valve System|The treatment group will have valves deployed to achieve leak isolation.
89273700|NCT02382614|No Intervention|Medical Management|The control group for this study will receive standard chest tube drainage management and standard-of-care interventions. This group will be evaluated and followed in the same manner as the treatment group, but without having valves placed.
89273701|NCT02332850|Experimental|Arm I (20 mg dexamethasone, isatuximab, carfilzomib)|"20 mg dexamethasone IV given on days 1, 8, 15, 22 (pre- SAR650984 and carfilzomib), then dexamethasone 4 IV or PO mg Day 2, 9, 16.~All patients will receive a fixed dose of Isatuximab (SAR650984) according to their assigned dose cohort. Patients receive isatuximab IV over 4-6 hours on days 1 and 15 of every cycle for the starting cohort, and days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Carfilzomib IV will be administered over 10 minutes on days 1, 2, 8, 9, 15, and 16 . Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue treatment after 8 courses if clinical benefit is present at the investigator's discretion (carfilzomib may be switched to days 1, 2, 15, and 16 after 8 cycles per investigator discretion)."
89273702|NCT02332850|Experimental|Arm II (40 mg dexamethasone, isatuximab, carfilzomib)|"40 mg dexamethasone IV given on Days 1, 8, 15 and 22 (use as premed to isatuximab).~All patients will receive a fixed dose of Isatuximab (SAR650984) according to the assigned dose. Patients receive isatuximab IV over 4-6 hours on day 1, 3-4 hours on Day 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycle (patients may be eligible for rapid siatuximab given over 75 minutes), and carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
89273703|NCT02284802|Experimental|Confocal endomicroscopy|Pts will be submitted to confocal endomicroscopy examination of the area of interest during endoscopy. A presumptive diagnosis will be made. This diagnosis will be compared to the definitive histologic diagnosis provided by endoscopic biopsies of the area of interest.
89273704|NCT02205762|Experimental|Stratum I|"Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).~Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences."
89273705|NCT02205762|Experimental|Stratum II|"A uniform intensive 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms INDOMETHACIN and 6-MP/MTX (mercaptopurine and Methotrexate)."
89273706|NCT02205762|Experimental|Stratum III|"Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.~The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum."
89273707|NCT02205762|Experimental|Stratum IV|To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
89273708|NCT02205762|Experimental|Stratum V|"Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH~- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice."
89273709|NCT02205762|Experimental|Stratum VI|"Natural history and management of other SS-LCH not eligible for stratum I group 2.~Treatment Options- Management (mostly wait & see and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.~Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.~Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V."
89273710|NCT02204228||TITAN™ Reverse Shoulder System (TRS)|TITAN™ Reverse Shoulder System (TRS) is a semi-constrained total shoulder construct.
89273711|NCT02197923||Biopsy: adenomyosis|Myometrial biopsy Pipelle
89273712|NCT02197923||Biopsy: Healthy|Myometrial Biopsy Pipelle
89273713|NCT02146378||Vyndaqel|
89273716|NCT01941563|Experimental|SI-6603|SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
89273717|NCT01941563|Sham Comparator|Control|Sham injection
89273718|NCT01934218|Active Comparator|Gel-One|3 mL, a single intra-articular injection of Gel-One
89273719|NCT01934218|Placebo Comparator|Phosphate Buffered Saline (PBS)|3 mL, a single intra-articular injection of PBS
89273720|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 5 mg|Intravenous infusion of 5mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks
89273721|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 10 mg|Intravenous infusion of 10mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
89273722|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 20 mg|Intravenous infusion of 20mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
89273723|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 5 mg|Intravenous infusion of 5mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
89273724|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 10 mg|Intravenous infusion of 10mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
89273725|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 20 mg|Intravenous infusion of 20mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
89273730|NCT01812447|Experimental|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
89273731|NCT01812447|Experimental|Spiration Valve System, α-1|α-1 antitrypsin deficiency subjects will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management. There is no randomization for this group.
89273732|NCT01812447|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
89273733|NCT01789229||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions."
89273734|NCT01789229||Benign controls|Patients with a benign tumor or an inflammatory disease - to be matched by age.
89273735|NCT01789229||Healthy controls|People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
89273736|NCT01763125||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions. Blood samples will be taken."
89273737|NCT01763125||Benign controls|"Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.~Blood samples will be taken."
89273738|NCT01763125||Healthy controls|"People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.~Blood samples will be taken."
89273739|NCT01725919|Experimental|Immediate CI therapy|
89273740|NCT01725919|Active Comparator|Delayed CI therapy|
89273741|NCT01656603|Experimental|unlicensed CBU|The Principal Investigators will be the transplant physicians at participating US transplant centers
89273742|NCT01545674||Pregnant Women Blood Draw|Pregnant Women with elevated risk of trisomic pregnancy to donate a blood sample through one time blood draw
89273743|NCT01282606|Experimental|Drug I: SI-6603 (Low)|
89273744|NCT01282606|Experimental|Drug II: SI-6603 (Middle)|
89273745|NCT01282606|Experimental|Drug III: SI-6603 (High)|
89273746|NCT01233674||patients referred for standard of care MRI|
89273747|NCT01233648|Active Comparator|AF|
89273748|NCT01233648|Active Comparator|SR|
89273749|NCT01233635|Experimental|A Group 1 no drug|Patients who have not taken ACE/ARB, randomized to no drug.
89273750|NCT01233635|Experimental|A Group 2|Patients who have not taken ACE/ARB, randomized to take cozaar.
89273751|NCT01233635|Experimental|B|Patients currently taking ACE/ARB will have their prescription changed to cozaar.
89273752|NCT01172561|Active Comparator|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
89273753|NCT01172561|Experimental|Lay Health Advisor Intervention|The Lay Health Advisor education intervention - The intervention consisted of an intensive, reinforced, one on one, interactive ed. program (an initial meeting, then 2 calls and a series of 4 postcards mailed at regular intervals and a 2nd visit. Woman were enrolled for about 12 to 14 months.
89273754|NCT01168921|Experimental|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle.
89273755|NCT00634946|Experimental|I|
89273756|NCT00634946|Experimental|II|
89273757|NCT00634946|Experimental|III|
89273758|NCT00634946|Placebo Comparator|IV|
89273759|NCT00512577|Active Comparator|A|Patients will not receive a pre-operative transfusion.
89273760|NCT00512577|Active Comparator|B|Patients will receive a pre-operative blood transfusion. Those presenting with an admission Hb of less than 9g/dL will receive a simple (also called a 'top-up') transfusion, those presenting with an admission Hb of more than or equal to 9g/dL will undergo a partial exchange transfusion.
89273761|NCT00481936|Experimental|Dose Escalating|"Patients will be treated with VB6-845 as a monotherapy IV infusion, once weekly in 4-week cycles. Patients will continue to receive treatment up until the treatment stopping criteria or patient withdrawal criteria are met.~Dose escalation will begin at a dose level of 1.00 mg/kg. Doses will be escalated according to the modified Fibonacci design with dose multipliers of 2.00, 1.67, 1.50, 1.40, and 1.33."
89273762|NCT00385606|Active Comparator|cisplatino plus gemcitabine|Gemcitabina 1200 mg/m2 infusion of 30 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks for 6 cycles.
89273763|NCT00385606|Experimental|cisplatino plus gemcitabine plus rofecoxib|Gemcitabina 1200 mg/m2 infusion of 30 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks + rofecoxib 50 mg/die per os until progression of disease.
89273764|NCT00385606|Experimental|cisplatino plus gemcitabine 10 mg/m2/min|Gemcitabina 1200 mg/m2 infusion of 120 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks for 6 cycles.
89273765|NCT00385606|Experimental|cisplatino plus gemcitabine 10 mg/m2/min plus rofecoxib|Gemcitabina 1200 mg/m2 infusion of 120 minutes at day 1, 8 + cisplatin 80 mg/m² day 1, every 3 weeks + rofecoxib 50 mg/die per os until progression of disease.
89273766|NCT03721744|Experimental|Napabucasin+Paclitaxel+Gemcitabine|Napabucasin will be administered twice daily, at 240 mg bid (480 mg total daily dose).Paclitaxel 80 mg/m^2 will be administered intravenously. Gemcitabine 600 mg/m^2 will be administered intravenously following paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression based on RECIST 1.1 criteria
89273767|NCT03721744|Active Comparator|Standard of care treatment options|Patients will receive standard of care treatment options treatment, including Fluorouracil and Leucovorin, Gemcitabine, Onivyde plus Fluorouracil and Leucovorin (if Onivyde has been approved to treat pancreatic cancer in the country/region), or best supportive care (BSC) alone, one of which will be assigned by the investigator for each patient.
89273768|NCT01589354|Experimental|Interscalene brachial plexus block|
89273769|NCT01589354|Experimental|Intra-articular injection|
89273770|NCT03960788|Experimental|MRI with Gadoxetate Sodium|Subjects will receive Gadoxetate Sodium during MRI.
89273771|NCT01583738|Experimental|V0251|
89273772|NCT01583738|Placebo Comparator|Placebo|
89273773|NCT00097370|Experimental|mepolizumab|750mg Intravenous, monthly and individual dosing schedule
89273774|NCT01583816|Experimental|Resiquimod Gel 0.03% or placebo|Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once
89273775|NCT01583816|Experimental|Resiquimod or placebo|Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once
89273776|NCT01583816|Experimental|Resiquimod or vehicle|Once daily, 5x for 1 week, break of 8 weeks, cycle repeated once
89273777|NCT01583816|Experimental|Resiquimod gel 0.01%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
89273778|NCT01583816|Experimental|Resiquimod gel 0.03%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
89273779|NCT01583270|Experimental|Arabinoxylan|Porridge rich in arabinoxylan. 50 g available carbohydrate
89273780|NCT01583270|Experimental|rye kernels|Porridge made from rye kernels. 50 g available carbohydrate
89273781|NCT01583270|Experimental|arabinoxylan and rye kernels|Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate
89273782|NCT01583270|Experimental|semolina|Semoline porridge. 50 g available carbohydrate
89273783|NCT01583348||Women with gallstones|30 women with symptomatic gallstone disease with an indication for elective cholecystectomy
89273784|NCT01089218|No Intervention|control|control without intervention
89273785|NCT01089218|Active Comparator|Amoxicillin/clavulanate|
89273786|NCT03957668|Experimental|PEG 3350|The content of each sachet of PEG 3350 (17 g powder) is dissolved in 240 mL of water, drink it once daily at bedtime, for a duration of 14 days.
89273787|NCT03957668|Active Comparator|Lactulax|15 ml of Lactulax syrup (containing 10 g of lactulose) is drunk with 240 ml of water once daily at bedtime, for a duration of 14 days
89273788|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 60~89 mL/min|Administration of GLA5PR 75 mg as 60~89 mL/min(CLcr)
89273789|NCT03963362|Experimental|Administration of GLA5PR 75 mg over 90 mL/min|Administration of GLA5PR 75 mg over 90 mL/min(CLcr)
89273790|NCT03963362|Experimental|Administration of GLA5PR 150 mg as 60~89 mL/min|Administration of GLA5PR 150 mg as 60~89 mL/min(CLcr)
89273791|NCT03963362|Experimental|Administration of GLA5PR 150 mg over 90 mL/min|Administration of GLA5PR 150 mg over 90 mL/min(CLcr)
89273792|NCT03963362|Experimental|Administration of GLA5PR 75 mg as 30~59 mL/min|Administration of GLA5PR 75 mg as 30~59 mL/min(CLcr)
89273793|NCT01091402||chronic urticaria|
89273794|NCT01091402||asthma|
89273795|NCT01091402||seasonal allergic rhinitis|
89273796|NCT01091402||normal controls|
89273797|NCT03515824|Experimental|Part A: MK-1696 20 mg|Participants received 20 mg of MK-1697 by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
89273798|NCT03515824|Experimental|Part A: MK-1697 65 mg|Participants received 65 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
89273799|NCT03515824|Experimental|Part A: MK-1697 200 mg|Participants received 200 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
89273800|NCT03515824|Experimental|Part B: Expansion Cohort|Participants with select tumor types were to receive MK-1697 at the RP2D by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
89273801|NCT01091558||Colonoscopy|Healthy volunteer who is having a screening colonoscopy
89273802|NCT01091558||Ulcerative Colitis|Patients with confirmed ulcerative colitis who are scheduled for endoscopy for medical reasons.
89273803|NCT01089374|Other|Partial breast radiation after lumpectomy|Radiation per NSABP B-39/R0413 protocol.
89273804|NCT01089452|Active Comparator|Perindopril monotherapy|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
89273805|NCT01089452|Active Comparator|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
89273806|NCT01089452|Experimental|Olmesartan/amlodipine FDC|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
89273807|NCT04880980|Active Comparator|Efficacy of double dose oral terbinafine in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral terbinafine for the treatment of dermatophyte skin infections.
89273808|NCT04880980|Active Comparator|Efficacy of double dose oral itraconazole in treatment of dermatophytic infections of skin|This group of participants will be given double than usual dose of oral itraconazole for the treatment of dermatophyte skin infections
89273809|NCT01089530|No Intervention|Standard care|
89273810|NCT03960710||Neuronal network Training group|"The following radiological variables, related to each CT examinations, will be collected for each patient:~Injection modalities (without injection, injected)~Major hepatectomy surgery~Importance of hepatic dysmorphia~Presence of intraperitoneal fluid effusion~Presence of renal polycystosis (especially on the right side)."
89273811|NCT03960710||Neuronal network Validation group|"The following radiological variables, related to each CT examinations, will be collected for each patient:~Injection modalities (without injection, injected)~Major hepatectomy surgery~Importance of hepatic dysmorphia~Presence of intraperitoneal fluid effusion~Presence of renal polycystosis (especially on the right side)."
89273812|NCT01089686|Active Comparator|Venoplasty (treatment)|Patients will be randomized to treatment or non-treatment arm with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the treatment arm of the study will receive venoplasty at the time of the diagnostic venogram.
89273813|NCT01089686|Sham Comparator|Sham procedure (non-treatment)|Patients will be randomized to treatment or non-treatment with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the non-treatment arm of the study will receive the diagnostic venogram only.
89273814|NCT01082666|Experimental|Continuous control|Continuous control of cuff pressure using a pneumatic device
89273815|NCT01082666|Active Comparator|Manual control|Manual control of cuff pressure is a routine practice in ICU patients
89273816|NCT03511378|Experimental|Lupin's Pegfilgrastim|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
89273817|NCT03511378|Experimental|Neulasta®|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
89273818|NCT01583504|Experimental|High volume saline injection|Patients randomised to this trial arm will receive an ultrasound guided steroid and local anaesthetic injection around the achilles tendon in the same way as the control arm patients. In addition they will receive an injected bolus of normal saline (through the same needle) of between 14-25ml until the new vessels seen on ultrasound scan disappear. They will be then given a programme of stretching and strengthening exercises in the same way as patients on the control arm.
89273819|NCT01583504|Active Comparator|Control Arm|"Patients on this trial arm will receive an ultrasound guided injection of steroid and local anaesthetic between Kager's fat pad and the achilles tendon. They will then be given a programme of stretching and strengthening exercises.~Patients on this trial arm will be offered the high volume saline injection at their 6 week follow up appointment after outcome measures have been taken by the blinded assessor. The whole cohort of patients will then be followed up at 12 and 40 weeks"
89273820|NCT01091636|Experimental|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Ovarian Cancer after primary cytoreductive surgery or interval cytoreductive surgery
89273821|NCT01091636|No Intervention|No HIPEC|Primary cytoreductive surgery or interval cytoreductive surgery
89273822|NCT01583036|Experimental|Session 1 digoxin alone, Session 2 retigabine plus digoxin|Session 1: Single administration of digoxin (0.25mg) and PK assessments up to 144hrs post-dose. Session 2: Retigabine up-titration to 1200mg (TDD) with co-administration of digoxin (0.25mg) at 3 doses or retigabine during the up-titration (600mg, 900mg and 1200mg) and PK assessments up to 144hrs post-dose following wach co-administration.
89273823|NCT03511066|Experimental|CT-P27 90 mg/kg|CT-P27 will be administrated once in IV infusion.
89273824|NCT03511066|Experimental|CT-P27 45mg/kg|CT-P27 will be administrated once in IV infusion.
89273825|NCT03511066|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
89273826|NCT01091714|Active Comparator|PRN Dry Eye Omega Benefits|4 capsules per day = 2240 mg Omega-3s
89273827|NCT01091714|Active Comparator|Nature's Made|2 capsules per day = 2400mg Omega-3s
89273828|NCT01091714|Active Comparator|Thera Tears|4 capsules per day = 2332mg Omega-3s
89273829|NCT01091792|Experimental|Bevacizumab|Bevacizumab + temozolomide + radiotherapy followed by adjuvant bevacizumab + temozolomide
89273830|NCT03510910|Experimental|Acetaminophen along with a reduced quantity of Percocet|
89273831|NCT03510910|Experimental|Percocet only|
89273832|NCT01091870|Placebo Comparator|Placebo: soluble blue pigment|Soluble blue pigment for placebo controlling.
89273833|NCT01091870|Experimental|Sildenafil, 75mg daily|Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.
89273834|NCT01091870|Experimental|Sildenafil, 150 mg daily|Sildenafil citrate, 150 mg daily divided in 3 doses from third to 14th day after subarachnoid hemorrhage.
89273835|NCT01089764|Experimental|Couplelinks.ca Intervention|Intervention arm - Couple participates in the Couplelinks.ca program.
89273836|NCT01089764|No Intervention|No Intervention|Couple is waitlisted for participation in the Couplelinks.ca program.
89273837|NCT01089842|Experimental|Health coaching|
89273838|NCT01089842|No Intervention|Control|
89273839|NCT03509350|Experimental|Treatment Protocol|Participants randomized to the treatment protocol will receive the VICTAS Intervention, consisting of intravenous vitamin C, thiamine, and hydrocortisone for four days or until ICU discharge.
89273840|NCT03509350|Placebo Comparator|Control Protocol|A placebo to match the VICTAS intervention will be administered for four days or until ICU discharge. During the treatment period, if an indication for steroids exist, the treating physicians are permitted to initiate open-label corticosteroid therapy based on local practice and international guidelines. If this occurs, the hydrocortisone/placebo will be withheld and subjects will be started on open-label corticosteroids.
89273841|NCT01089920|Experimental|High dose coffee|High dose of polyphenols from soluble coffee
89273842|NCT01089920|Experimental|Medium dose coffee|Medium dose of polyphenols from soluble coffee
89273843|NCT01089920|Experimental|Low dose coffee|Low dose of polyphenols from soluble coffee
89273844|NCT01089920|Experimental|High dose green tea|High dose of green tea polyphenols from infusion
89273845|NCT01089920|Experimental|Medium dose green tea infusion|Medium dose of green polyphenols from infusion
89273846|NCT01089920|Experimental|Low dose green tea infusion|low dose of polyphenols from an infusion of green tea
89273847|NCT03956420||Study group|Implemented ERAS (Early Recovery After Surgery) elements
89273848|NCT03956420||Control group|The control group will consist of patients treated during the study in accordance with the current standards used in the Department
89273849|NCT03478696|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
89273850|NCT03478696|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
89273851|NCT03719638|Active Comparator|D-blade group|Intubation will be done using D-blade of videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
89273852|NCT03719638|Active Comparator|Macintosh group|Intubation will be done using Macintosh videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
89273853|NCT03477838|Experimental|CGM Intervention arm|Patients eligible for care at the free clinic with diabetes and A1c greater than 8% on insulin therapy will be identified for CGM use.
89273854|NCT00072176|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89273855|NCT00071396|Experimental|Campath-1H + Rituximab|"Campath 15 mg/day continuous intravenous (IV) infusion x 6 days, then twice a week for 3 weeks as 30 mg injection under skin to complete 4 week treatment course.~Rituximab 375 mg/m^2 IV infusion day 1, then 500 mg/m^2 on days 8, 15 + 22."
89273856|NCT03473236|Experimental|Cohort 1A|Dose 1 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
89273857|NCT03473236|Experimental|Cohort 2A|Dose 2 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
89273858|NCT03473236|Experimental|Cohort 3A|Dose 3 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
89273859|NCT03473236|Experimental|Cohort 4A|Dose 4 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
89273860|NCT03473236|Experimental|Cohort 5A|Dose 5 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
89273861|NCT03473236|Experimental|Cohort 1B|Dose 1 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
89273862|NCT03473236|Experimental|Cohort 2B|Dose 2 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
89273863|NCT03473236|Experimental|Cohort 3B|Dose 3 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
89273864|NCT03550378|Experimental|MEDI0382|Participants will receive subcutaneous (SC) dose of MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
89273865|NCT03550378|Placebo Comparator|Placebo|Participants will receive SC dose of placebo matched to MEDI0382 once daily for 32 days.
89273866|NCT05660590|Active Comparator|Low bandage pressure|Compression bandages applied with low pressure (20-30 mmHg)
89273867|NCT05660590|Active Comparator|high bandage pressure|Compression bandages applied with low pressure (45-55 mmHg)
89273868|NCT03639454|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
89273869|NCT03639454|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
89273870|NCT03721588||Major depressive disorder|MDD; patients with diagnosis of major depressive disorder, Clinical interviews, psychometric scales were applied.
89273871|NCT03721588||MDD and ADHD|MDD; major depressive disorder ADHD; attention deficit hyperactivity disorder, Clinical interviews, psychometric scales were applied.
89273872|NCT03725254|Active Comparator|radical surgery|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical surgery.
89273873|NCT03725254|Experimental|radical chemoradiotherapy|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical chemoradiotherapy.
89273874|NCT03472534|Other|study in healthy volunteers|diacerein 1% ointment
89273875|NCT03725020|Experimental|Fluoride varnish|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply the test varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The NFV test varnish has mint flavour and the active ingredient is ammonium fluoride dissolved in ethanol, water and an acrylate polymer.
89273876|NCT03725020|Placebo Comparator|Varnish without Fluoride|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply either the placebo varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The placebo varnish has an identical composition as the test varnish except for the ammonium fluoride. Thus, taste, colour and handling properties are the same.
89273877|NCT03721432|Experimental|Pregabalin group (P)|received pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
89273878|NCT03721432|Placebo Comparator|Control group (C)|received placebo capsules sixty minutes prior to epidural insertion.
89273879|NCT03721354|Experimental|NAVA vs PSV -TCCD|Ultrasound evaluation, using trans cranial doppler technique will be performed to evaluate the cerebral blood flow speed (average/systolic speed) near the point of emergency, in the middle tract and at the bifurcation of M1 bilaterally, at the end of every ventilation trial (NAVA and PSV).
89273880|NCT03639298|Experimental|training|children submitted to the Intendu training with motion based cognitive video games software
89273881|NCT03639298|No Intervention|no training|children not submitted to the training, entering the study as a control group
89273882|NCT03724864|Experimental|Stevia snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
89273883|NCT03724864|Active Comparator|Maltitol snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
89273884|NCT03724864|Placebo Comparator|Sugared snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
89273885|NCT03549130|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
89273886|NCT03549130|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
89273887|NCT03470194|Active Comparator|Interpretation Modality: In person|Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
89273888|NCT03470194|Active Comparator|Interpretation Modality: Telephonic|Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit
89273889|NCT03724786|Experimental|Calculated collection|"Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the 6-hour collection will be multiplied by four, and the result will serve as the calculated collection, for pregnancy management. The additional 18 hour collection will serve for: 1. Patient blinding. 2. Calculation of the total 24-hour protein collection for reference."
89273890|NCT03724786|No Intervention|Control collection|Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the total 24-hour collection will serve for pregnancy management. The initial 6-hour collection will serve for patient blinding.
89273891|NCT03469336|Other|All subjects|All subjects will receive all six interventions/treatments applied to six different treatment fields.
89273892|NCT03719560|Experimental|CNS prophylaxis protocol|Patients will receive central nervous system prophylaxis protocol using high-dose methotrexate and cytarabine.
89273893|NCT03469258|Experimental|Zenpep|"Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously.~Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date"
89273894|NCT03503188|Experimental|All participants|
89273895|NCT03502798|Experimental|scanning a/LCI|
89273896|NCT03719482|Experimental|[18F]MNI-1054|To measure blood metabolites of [18F]MNI-1054 in the healthy volunteers and to perform invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the brain.
89273897|NCT03724708|Experimental|Hang up technique|"where the enrolled patients will have the IUD applied in the middle of the uterine cavity and then attached to the fundus of the uterus by an absorbable suture Hang up technique"
89273898|NCT03724708|Active Comparator|Postpartum insertion|will include patients where IUD will be inserted after 6 weeks post-partum.
89273899|NCT03724708|Active Comparator|Control|will serve as our control group where the enrolled patients will have the IUD just applied into the middle of the uterine cavity at the level of the fundus without attachment
89273900|NCT03639220|Active Comparator|Photobiomodulation Therapy (PBMT) active|Participants received active PBMT
89273901|NCT03639220|Placebo Comparator|Photobiomodulation Therapy (PBMT) placebo|Participants received placebo PBMT
89273902|NCT00066170|Experimental|Group 1.|Xyrem + Modafinil Placebo
89273903|NCT00066170|Placebo Comparator|Group 2:|Xyrem Placebo + Modafinil Placebo
89273904|NCT00066170|Active Comparator|Group 3|Xyrem Placebo + Modafinil at established dose
89273905|NCT00066170|Experimental|Group 4:|Xyrem + Modafinil at established dose
89273906|NCT03957122|Experimental|individualized rTMS|Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).
89273907|NCT03957122|Active Comparator|standard rTMS in responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.
89273908|NCT03957122|Active Comparator|standard rTMS in non-responders|Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.
89273909|NCT01094054|Active Comparator|Dietary and lifestyle modification|Patients in this arm will eat meals that are identical in size and caloric composition to those consumed by participants in the other arm who undergo adjustable gastric banding
89273910|NCT01094054|Experimental|Adjustable gastric banding|Subjects will undergo gastric banding as per clinical practice
89273911|NCT03741218|Experimental|1|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast the placebo (PLA) the first time and grape (GRAP) the second time.
89273912|NCT03741218|Experimental|2|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast grape (GRAP) the first time and the placebo (PLA) the second time.
89273913|NCT00065468|Active Comparator|A|
89273914|NCT00065468|Experimental|B|
89273915|NCT00065468|Experimental|C|
89273916|NCT00071006|Experimental|Single arm study|
89273917|NCT00094575|Active Comparator|Arm 1|Standard Open Repair of Abdominal Aortic Aneurysm
89273918|NCT00094575|Active Comparator|Arm 2|Endovascular Repair of Abdominal Aortic Aneurysm
89273919|NCT01089998|Experimental|Arm 1|
89273920|NCT01089998|Experimental|Arm 2|
89273921|NCT01089998|Experimental|Arm 3|
89273922|NCT01089998|Experimental|Arm 4|
89273923|NCT00057746|Active Comparator|Arm I|Prophylactic cranial irradiation, 2.5 Gy fx
89273924|NCT00057746|Experimental|Arm II|Prophylactic cranial irradiation, 2.0 Gy fx
89273925|NCT00057746|Experimental|Arm III|Prophylactic cranial irradiation, 1.5 Gy fx
89273926|NCT01094132|Other|Review by colposcopy + multispectral digital colposcopy|All patients belong under this arm, as all will be reviewed by both conventional colposcopy and by Multispectral Digital Colposcopy (MDC). The nature of these techniques are explained below.
89273927|NCT03960398||Patients concerned by iatrogenic diseases|Patients living in the South-East of France and consulting in the emergency department of Toulon La Seyne sur Mer hospital for iatrogenic diseases
89273928|NCT01090232|Experimental|chronic HEV infection|in kidney-transplant recipients with chronic HEV infection
89273929|NCT01090232|Active Comparator|control|the host responses in kidney-transplant recipients without viral infection (controls)
89273930|NCT00094107|Experimental|Axitinib [AG-013736]|
89273931|NCT00102063|Active Comparator|Aripiprazole 10 mg/day Group|Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
89273932|NCT00102063|Active Comparator|Aripiprazole 30 mg/day Group|Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
89273933|NCT00102063|Placebo Comparator|Placebo Group|Participants were given a single pill administered once daily
89273934|NCT00065156|Experimental|Lenalidomide|
89273935|NCT01092026|Experimental|cord blood transplant|Eligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells
89273936|NCT01094210||G1|500 ppm F Test Toothpaste
89273937|NCT01094210||G2|1100 ppm F Control Toothpaste
89273938|NCT01094366|Sham Comparator|No Paracervical Block for Pain Control|Subject will not receive a paracervical block during the procedure
89273939|NCT01094366|Active Comparator|Paracervical Block for Pain Control|Subject will receive a paracervical block during the procedure.
89273940|NCT01327040|Experimental|sensitization duration 1.375h|This group will experience a 1.375h sensitization duration prior to the 12h light exposure
89273941|NCT01327040|Experimental|sensitization duration 5.5h|This group will experience a 5.5h sensitization duration prior to the 12h light exposure
89273942|NCT01327040|Experimental|sensitization duration 22h|This group will experience a 22h sensitization duration prior to the 12h light exposure
89273943|NCT01327040|Experimental|sensitization duration 0.33h|This group will experience a 0.33h sensitization duration prior to the 12h light exposure
89273944|NCT01094444|Experimental|Vitamin K3-lotion|A lotion containing 1.5 mM Vitamin K3.
89273945|NCT01094444|No Intervention|B|Standard lotion without Vitamin K3
89273946|NCT00064298|Experimental|Arm I - JuicePlus|Patients receive oral fruit and vegetable extracts twice daily.
89273947|NCT00064298|Placebo Comparator|Arm II - Control|Patients receive oral placebo twice daily.
89273948|NCT00078819|Placebo Comparator|Placebo|"Participants received placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a > 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
89273949|NCT00078819|Experimental|Etanercept|"Participants received 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a > 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
89273950|NCT01088607|Experimental|UDCA Withdrawal and Reinstitution|Each study subject will undergo serial UDCA withdrawal and reinstitution.
89273951|NCT01583205|Experimental|Coping Effectiveness Training|Coping Effectiveness Training -ALS (CET-ALS) is an eight session intervention derived from Coping Effectiveness Training (CET), a manualized intervention based on stress and coping theory. It is designed to strengthen coping skills and alleviate distress for either the patient or care partner following a diagnosis of ALS.
89273952|NCT03961191||Benign group|Patients with benign cervical histology, including normal findings, inflammation and LSIL
89273953|NCT03961191||HSIL group|Patients with cervical histology of HSIL
89273954|NCT03961191||Cancer group|Patients with cervical histology of cancer
89273955|NCT00098865|Experimental|Thalidomide and Temozolomide|"Thalidomide:~Oral thalidomide on days 1-28 of a 28 day cycle initiated at 3 mg/kg and increased to maximum dose of 24 mg/kg or 1000 mg as tolerated.~Temozolomide:~Oral temozolomide on days 1-5 of 28 day cycle given at 200 mg/m2 or 150 mg/m2 for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal radiation.~Patients were treated for 6 cycles unless disease progression or excessive toxicity. Treatment could continue beyond 6 cycles if absent disease progression"
89273956|NCT01084863|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
89273957|NCT01084863|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
89273958|NCT01081587|Experimental|Nutritional Support Team|
89273959|NCT01081587|Active Comparator|Usual care|
89273960|NCT02954458|Experimental|Standard of care (SOC) treatment +/- teduglutide (TED)|Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
89273961|NCT03719404|Experimental|sodium hypochlorite group|sodium hypochlorite and EDTA are used in endodontic retreatment cases
89273962|NCT03719404|Experimental|chlorhexidine group|chlorhexidine and citric acid are used in endodontic retreatment cases
89273963|NCT03500224|Experimental|[14C]-TAK-954 0.5 mg|[14C]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie [µCi] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
89273964|NCT03721198|Active Comparator|Acidulated phosphorous flouride|Acidulated phosphorous flouride used once at the first of the study
89273965|NCT03721198|Experimental|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish (CLINPRO XT ) is used once at the first of the study only
89273966|NCT04868734|Experimental|Supportive Psychotherapy|Supportive Psychotherapy do to subjects
89273967|NCT04868734|No Intervention|Casual Treatment|Do Casual Intervention
89273968|NCT03720886|Experimental|rhPTH（1-34） 28.2μg|Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
89273969|NCT03720886|Experimental|rhPTH（1-34） 56.5μg|Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
89273970|NCT03720886|Active Comparator|teriparatide acetate(Teribone™)|Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.
89273971|NCT03720808|Experimental|Balloon Blowing|Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
89273972|NCT03720808|Experimental|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
89273973|NCT03720808|Experimental|Coughing|Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
89273974|NCT03720808|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
89273975|NCT03720496|Experimental|CD19-TriCAR-T|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
89273976|NCT00077649|Active Comparator|PEG-IFN Alfa-2a 180 μg +Ribavirin 1200 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
89273977|NCT00077649|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 1600 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
89273978|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1200 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered po daily in split doses for 48 weeks
89273979|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1600 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1600 mg of ribavirin (200 mg/tablet) administered po daily in split doses for 48 weeks.
89273980|NCT03494374|Experimental|treatment group|Treatment with UCBL and exercise therapy
89273981|NCT00038948|Active Comparator|A|Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression
89273982|NCT00038948|Active Comparator|B|Continued calcineurin inhibitor therapy
89273983|NCT03953378||"Group RA patients"|Patients with Rheumatoid Arthritis (RA) fulfilling the American College of Rheumatology and European League Against Rheumatism 2009 criteria.
89273984|NCT03953378||"Group PsA patients"|Patients with Psoriatic Arthritis (PsA) fulfilling the Classification for PsA (CASPAR) criteria.
89273985|NCT03953378||"Group Healthy donors"|Anonymous healthy donors from the Etablissement Français du Sang.
89273986|NCT01084941|Experimental|Lifestyle intervention|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
89273987|NCT01084941|Active Comparator|Standard of care group|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
89273988|NCT01088685|Experimental|Experimental Blister Patch|Experimental Hydrogel Blister patch
89273989|NCT01088685|Active Comparator|Marketed Pflaster|Scholls Blasen Pflaster
89273990|NCT01096940|Experimental|1|AZD1656
89273991|NCT01096940|Experimental|2|Simvastatin
89273992|NCT01096940|Experimental|3|AZD1656 + simvastatin
89273993|NCT01085019|Experimental|Dietary supplement: Cinnamon|
89273994|NCT01085019|Experimental|Dietary supplement: Oregano|
89273995|NCT01085019|Experimental|Dietary supplement: Ginger|
89273996|NCT01085019|Experimental|Dietary supplement: Rosemary|
89273997|NCT01085019|Experimental|Dietary supplement: Black pepper|
89273998|NCT01085019|Placebo Comparator|Dietary supplement: Placebo|
89273999|NCT02530424|Experimental|Trast-pert-palbo-fulve|Patients will receive an association of drugs (trastuzumab, pertuzumab, palbociclib plus or minus fulvestrant) as neoadjuvant chemotherapy. Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination. After completion of surgical treatment patients will receive irradiation as locally acceptable.
89274000|NCT01088763|Experimental|Arm I|"GROUP A: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~GROUP B: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-5, 8-12, 15-19, and 22-26. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients may also receive concurrent oral dexamethasone twice daily on the days of gamma-secretase inhibitor RO4929097 administration.~Once the MTD or recommended phase II dose of RO4929097 plus dexamethasone in children with solid tumors, including CNS tumors, or lymphoma has been identified, this dose is used for patients with relapsed-refractory T-ALL (phase 2 portion of the study) to evaluate RO4929097 in combination with dexamethasone using one of the studied schedules."
89274001|NCT03953456|Experimental|elafibranor 120mg followed by placebo|Participants will first receive elafibranor 120mg for 6 weeks. After a washout period of 4-6 weeks, they will then receive placebo for 6 weeks
89274002|NCT03953456|Placebo Comparator|placebo followed by elafibranor 120mg|Participants will first receive placebo for 6 weeks. After a washout period of 4-6 weeks, they will then receive elafibranor 120mg for 6 weeks
89274003|NCT01088841|Active Comparator|75 g glucose + 150 ppm lactisole|
89274004|NCT01088841|Active Comparator|75 g glucose + 300 ppm lactisole|
89274005|NCT01088841|Active Comparator|75 g glucose + 450 ppm lactisole|
89274006|NCT01088841|Placebo Comparator|75 g glucose|
89274007|NCT02530580|Experimental|20 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, 2 capsules as a single oral dose
89274008|NCT02530580|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, 2 capsules as a single oral dose
89274009|NCT03963921|Experimental|F4 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
89274010|NCT03963921|Experimental|F3 patient population|A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:
89274011|NCT01094600|Experimental|Secretin|Single arm (open label).
89274012|NCT01097174||CyPass Micro-stent|Patients in whom CyPass Micro-stent implantation was attempted.
89274013|NCT01097252|Active Comparator|weekly cisplatin|Weekly cisplatin 40mg/m2 during radiation therapy
89274014|NCT01097252|Experimental|tri-weekly cisplatin|cisplatin 75mg/m2 three cycles, every 3 weeks
89274015|NCT03957356|Experimental|HLBLS-200|HLBLS-200, absorbent hemostactic powder, will be applied intraoperatively to stop blood oozing during hepatic resection.
89274016|NCT03956264|Experimental|VR|"VR Installation 5 min before the drain removal and stop 10 min after the procedure.~If Pain assessed by numerical rating scale (NRS) > 4, administration of morphine."
89274017|NCT03956264|Active Comparator|Kalinox®|"Start of Kalinox® administration by inhalation with a facial mask 1 min before the drain removal and stop after the procedure according to the usual procedure of the service.~If Pain NRS > 4, administration of morphine."
89274018|NCT00054704|Experimental|Riluzole|Riluzole was dispensed either once or twice a day as 50 mg tablets. Riluzole dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
89274019|NCT00054704|Placebo Comparator|Placebo|Placebo pills resembling 50 mg riluzole tables were dispensed either once or twice a day. Dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
89274020|NCT01097408|Experimental|AZD7295|
89274021|NCT01097408|Placebo Comparator|Matched placebo|
89274022|NCT01097486|Active Comparator|Allograft|Cervical Spinal Fusion with Allograft
89274023|NCT01097486|Experimental|NeoFuse|Cervical Spinal Fusion with NeoFuse
89274024|NCT01092494||OC use|OC use after postoperative gonadotropin-releasing hormone agonist treatment
89274025|NCT01092494||OC non-use|Only postoperative gonadotropin-releasing hormone agonist treatment
89274026|NCT02530814||Lake Apopka Farmworkers|This group will have a onetime blood collection and questionnaires regarding health status and health concerns.
89274027|NCT02530814||Existing Data Group|The investigators will collect existing data from the National Health and Nutrition Examination Survey (NHANES) for the range of concentrations of these chemicals in the blood of Americans.
89274028|NCT01092572|Experimental|Simvastatin 40 mg/d|simvastatin 40 mg per day taken orally
89274029|NCT01092572|Placebo Comparator|Sugar pill|
89274030|NCT01092650|Active Comparator|Smoked|Deuterated Phenanthrene spiked in a study cigarette
89274031|NCT01092650|Experimental|Oral|Deuterated phenanthrene in an oral dose
89274032|NCT03952988|Experimental|Probiotic|
89274033|NCT03952988|Placebo Comparator|Placebo|
89274034|NCT03953222|Experimental|Experimental|A single group of people with Parkinson's disease will undergo real-time feedback intervention.
89274035|NCT01097564||COL4A1 genetic testing|COL4A1 genetic testing
89274036|NCT03952910|Experimental|Experimental group|Online pain education program will be accessible by the intervention group
89274037|NCT03952910|No Intervention|Control group|No intervention for the control group, only one-page simple material related to pain will be provided.
89274038|NCT01094678|Experimental|Stent|
89274039|NCT01097720||LTG-exposed|Children exposed to LTG during pregnancy.
89274040|NCT01097720||VPA-exposed|Children exposed to VPA during pregnancy.
89274041|NCT01097720||CBZ-exposed|Children exposed to CBZ during pregnancy.
89274042|NCT03952676|Experimental|Moving cupping intervention|Participants will received moving cupping therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
89274043|NCT03952676|Placebo Comparator|Moving cupping placebo control|Participants will received moving cupping placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
89274044|NCT00031694|Experimental|Treatment (paclitaxel, bryostatin 1)|Patients receive paclitaxel IV over 1 hour on day 1 followed by bryostatin 1 IV over 1 hour on day 2 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89274045|NCT03953066|Active Comparator|women with vaginal delivery|30 women with spontaneous vaginal delivery will be included in group 1 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
89274046|NCT03953066|Active Comparator|women with emergency cesarean section|30 women with emergency cesarean section will be included in group 2 serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
89274047|NCT03953066|Active Comparator|women with elective cesarean section|30 women with elective cesarean section will be included in group 3serum IL-6 levels before and after delivery and colostral milk melatonin levels will be measured
89274048|NCT03957044|Experimental|sensory integration group|This group was given the education of sensory integration with vestibular education.
89274049|NCT03957044|No Intervention|Control group|The control group was given the education of sensory integration without vestibular education.
89274050|NCT01094756|Active Comparator|Obese group - Group 1|If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
89274051|NCT01094756|No Intervention|Lean group - Group 2|If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
89274052|NCT01097798|Experimental|Aliviador|
89274053|NCT01097798|Active Comparator|Gelol|
89274054|NCT00093795|Active Comparator|Group 1: TAC X 6|Doxorubicin, cyclophosphamide, and docetaxel.
89274055|NCT00093795|Active Comparator|Group 2: AC X 4 then P X 4|Doxorubicin, cyclophosphamide, and paclitaxel
89274056|NCT00093795|Experimental|Group 3: AC X 4 then PG X 4|Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
89274057|NCT01584128||Oxidized regenerated cellulose|Patients undergoing laparoscopic hysterectomy who have oxidized regenerated cellulose placed at the vaginal cuff at the time of their surgery.
89274058|NCT03952442|Active Comparator|control group|
89274059|NCT03952442|Experimental|experimental group|
89274060|NCT03467152|Experimental|Irsenontrine|Participants will be randomized to receive a 50 milligram (mg) once daily oral dose of Irsenontrine for 12 weeks.
89274061|NCT03467152|Placebo Comparator|Placebo|Participants will be randomized to receive a 50 mg once daily oral dose of Irsenontrine-matched placebo for 12 weeks.
89274062|NCT01094834|Experimental|DWP05195|
89274063|NCT01097876|Experimental|Active PF-04447943|
89274064|NCT01097876|Placebo Comparator|Placebo PF-04447943|
89274065|NCT01092806|Active Comparator|Prograf|Patients are treated until steady-state conditions with Prograf and then investigated with clamp
89274066|NCT01092806|Experimental|Advagraf|The patients are treated with Advagraf until steady-state conditions and then investigated with clamp
89274067|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR alone(n=10)|HTEA Group + N(LVMI)+ AVR alone(n=10)
89274068|NCT03719248|Active Comparator|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)
89274069|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR + CABG(n=10)|HTEA Group + N(LVMI)+ AVR + CABG(n=10)
89274070|NCT03719248|Active Comparator|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)
89274071|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)
89274072|NCT03719248|No Intervention|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)
89274073|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR + CABG(n=10)|(GA) Group+ N(LVMI)+ AVR + CABG(n=10)
89274074|NCT03719248|No Intervention|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)
89274075|NCT01092962|Experimental|Mycophenolate mofetil|Mycophenolate mofetil
89274076|NCT01092962|Active Comparator|Cyclophosphamide|Cumulative dose of 148mg/kg of cyclophosphamide in 84 days (2mg/kg/day during 12 weeks)
89274077|NCT03639142|Experimental|Plum group|Children will receive plums at dose 3,5g/kg/d as an oral treatment for constipation.
89274078|NCT03639142|Active Comparator|Polyethylene glycol group|Children will receive PEG at dose 0,5g/kg/d as an oral treatment for constipation.
89274079|NCT03466060|Active Comparator|etafilcon A|Eligible subjects were randomized to the etafilcon A lens in both eyes throughout the entire duration of the study.
89274080|NCT03466060|Active Comparator|senofilcon A|Eligible subjects were randomized to the senofilcon A lens in both eyes throughout the entire duration of the study.
89274081|NCT03466060|Active Comparator|senofilcon C|Eligible subjects were randomized to the senofilcon C lens in both eyes throughout the entire duration of the study.
89274082|NCT00092547|Experimental|qHPV Vaccine in Base Study|Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.
89274083|NCT00092547|Placebo Comparator|Placebo in Base Study|Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.
89274084|NCT00092547|Experimental|qHPV Vaccine in Extension Study|Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.
89274085|NCT03802994|Experimental|1.Aging RT|Renal transplant recipients between 65-75 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
89274086|NCT03802994|Active Comparator|2.Young RT|Renal transplant recipients between 35-45 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
89274087|NCT03802994|Active Comparator|3.Healthy elderly|Healthy persons between the ages 65-75 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
89274088|NCT03802994|Active Comparator|4.Elderly DMII or HTN and normal renal function|Persons between the ages 65-75 with DMII or hypertension but normal renal function who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
89274089|NCT03802994|Experimental|5.Healthy young|Healthy persons between the ages 35-45 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23) or are willing to receive PPV23 and 1 year later Prevnar 13.
89274090|NCT01088919|Experimental|Dosing Regimen 1|
89274091|NCT01088919|Experimental|Dosing Regimen 2|
89274092|NCT01088919|Experimental|Dosing Regimen 3|
89274093|NCT01088919|Experimental|Dosing Regimen 4|
89274094|NCT01085175|Experimental|Cohort 1|Low risk Heart Failure patients
89274095|NCT01085175|Experimental|Cohort 2|High risk Heart Failure patients with history of Implantable Cardioverter-Defibrillator firing
89274096|NCT03465904|Experimental|Verum|2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
89274097|NCT03465904|Sham Comparator|Sham|2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
89274098|NCT03802916|Experimental|Low dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
89274099|NCT03802916|Experimental|High dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
89274100|NCT03724474|Experimental|Be SMART Condition|"Subjects randomly assigned to the Be SMART condition (n=30) will first meet with a credentialed health coach to help create personally relevant weekly, short-term (6-weeks) and long-term (12-weeks) PA and sleep goals, and an initial action and coping plan. At 6- weeks (study mid-point), Be SMART subjects will complete a short telephonic booster session with the health coach. Throughout the 12-week intervention, our agent-based feedback system will communicate weekly messages via short message service (SMS) based on their weekly goal achievement, informed by the continuous collection of their Fitbit data. In addition, subjects in the Be SMART condition will also take their morning blood pressure using a blue-tooth enabled device that wirelessly sends this data to the Be SMART server."
89274101|NCT03724474|Active Comparator|Fitbit Only Condition|Subjects who are randomly assigned to the active control condition (n=30) will receive a Fitbit device and wireless blood pressure monitor (same as Be SMART condition). However, subjects in the Fitbit Only condition will not meet with a health coach for establishing SMART goals and creating an action/coping plan, nor will Fitbit Only subjects receive any feedback messages or prompts from the Be SMART server, although data from their Fitbit devices will be continuously collected throughout the q12 week intervention.
89274102|NCT03720340|Active Comparator|Recombinant human interleukin-11|Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.
89274103|NCT03720340|Placebo Comparator|Saline|Only 10ml 0.9% NS was administered twicely to patients through respiratory tract.
89274104|NCT01093040|Experimental|Cohort 1|CAT-354 will be administered by SC injection
89274105|NCT01093040|Experimental|Cohort 2|CAT-354 will be administered by SC injection
89274106|NCT01093040|Experimental|Cohort 3|CAT-354 will be administered by SC injection
89274107|NCT03719014|Experimental|NovaCross|the NovaCross is a guidewire positioning and support micro-catheter for improving chronic total occlusion (CTO) crossability. The NovaCross gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extandable segment, both at its distal tip.
89274108|NCT01584050|Active Comparator|L-MTHF|
89274109|NCT01584050|Active Comparator|folic acid|
89274110|NCT01584050|Placebo Comparator|placebo (methyl cellulose)|
89274111|NCT01310608|Experimental|A-View|
89274112|NCT01310608|No Intervention|No A-View|
89274113|NCT03724240|Placebo Comparator|Placebo solution|Placebo Comparator: Placebo The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 containing sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml. The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks. The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
89274114|NCT03724240|Experimental|gpASIT+™ (Grass Pollen-ASIT+™)|Experimental: gpASIT+™ The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 with a grass pollen peptide concentration of 100 µg/mL. Excipients are sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml.The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks.The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
89274115|NCT03952832|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89274116|NCT01311076|Experimental|TAK-329 50 mg|
89274117|NCT01311076|Experimental|TAK-329 200 mg|
89274118|NCT01311076|Active Comparator|Insulin 0.2 U/kg|
89274119|NCT01311076|Placebo Comparator|Placebo|
89274120|NCT01095068|Experimental|physical exercise|Physical exercise
89274121|NCT01098656|Experimental|lenalidomide|
89274122|NCT01098656|No Intervention|Observation|
89274123|NCT01098734|Placebo Comparator|Group 1|0%; vehicle cream
89274124|NCT01098734|Active Comparator|Group 2|0.5% WBI-1001 cream
89274125|NCT01098734|Active Comparator|Group 3|1.0% WBI-1001 cream
89274126|NCT01093118|Experimental|TMI-358|Active treatment
89274127|NCT01093118|Placebo Comparator|MMI-467|
89274128|NCT03956108|Experimental|MRI/Fusion biopsies|Stockholm3+MRI+targeted biopsies
89274129|NCT03956108|Active Comparator|Systematic biopsies|PSA+systematic biopsies
89274130|NCT03465436|Experimental|100 milligrams (mg) Lasmiditan|A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.
89274131|NCT03465436|Experimental|400 mg Lasmiditan|A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
89274132|NCT03465436|Placebo Comparator|Placebo|Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.
89274133|NCT03465436|Active Comparator|Moxifloxacin|A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.
89274134|NCT01098890|Placebo Comparator|Placebo|Placebo will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
89274135|NCT01098890|Active Comparator|tPA (tissue plaminogen activator)|Intraventricular TPA will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
89274136|NCT03963999|Experimental|Patients Undergoing HCT|All patients enrolled will undergo grayscale US, Doppler US, US SWE and CEUS at specific time points as outlined in the protocol based on disease course.
89274137|NCT03955796|Experimental|RayOne Hydrophobic Aspheric|Patient will receive the hydrophobic IOL during cataract surgery
89274138|NCT03955796|Experimental|RayOne Aspheric|Patient will receive the non-hydrophobic IOL during cataract surgery
89274139|NCT03963765|Active Comparator|Group I (Standard DL-PDT)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
89274140|NCT03963765|Experimental|Group II (DL-PDT with microneedles)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~A motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) was applied without bleeding~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
89274141|NCT03963765|Experimental|Group III (DL-PDT with CO2 laser)|"Superficial skin curettage all face with a dermatological curette~All exposed skin was covered with pure chemical sunscreen~After 15 minutes and removing excess sunscreen, Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density <1% (Pixel Alma Lasers ®) was applied, single-pass~A uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
89274142|NCT03963765|Experimental|Group IV (DL-PDT with microdermabrasion)|"Superficial skin curettage all face with a dermatological curette~Microdermabrasion with aluminum oxide crystal (Pan Eletronic®) was performed after superficial skin curettage. Three passes on the skin in different directions (vertical, horizontal, and oblique) were applied~All exposed skin was covered with pure chemical sunscreen~After 15 minutes, a uniform layer of methyl-aminolevulinate (MAL) (Metvix®, Galderma- 1g) was applied to the face without occlusion~In all protocols, the patients remained indoor for 30 min after procedures and then exposed to daylight in an open environment for 2 hours. After this period, the skin was cleaned with 0.9% saline, and the sunscreen reapplied."
89274143|NCT03720964||presbycusis affected patients|affected by a more severe age related hearing loss than expected according to the norm ISO 7029
89274144|NCT03720964||controls|not affected by age related hearing loss according to the norm ISO 7029
89274145|NCT01081743|Experimental|Social worker|
89274146|NCT01081743|No Intervention|Control|Control group is followed-up as usually (usual care)
89274147|NCT03962673|Experimental|UVB- exposure|Each participant will receive a pre-determined dose of UVB light. Serum Vitamin D and microbiome samples of each participant will be compared before and after the UVB light exposures.
89274148|NCT00053846|Experimental|buspirone hydrochloride|buspirone hydrochloride
89274149|NCT00053846|Placebo Comparator|Placebo|Placebo
89274150|NCT01089075|Placebo Comparator|placebo/20 mg hydrocortisone|Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone
89274151|NCT01089075|Active Comparator|20 mg hydrocortisone/placebo|Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo
89274152|NCT01098968|No Intervention|Normal PE|2 Physical Education sessions / week
89274153|NCT01098968|Experimental|PE Volume|4 Physical Education sessions/week (increased volume)
89274154|NCT01098968|Experimental|PE Volume + Intensity|4 Physical Education sessions/week of high intensity (increased volume and intensity)
89274155|NCT01099046|No Intervention|medication only|medication = anti-diuretics
89274156|NCT01099046|Active Comparator|medication + water intake|anti-diuretics + water intake (at least 2.0 litters per day)
89274157|NCT01099046|Active Comparator|medication + tympanic tubing|anti-diuretics + tympanic tubing (under local anesthesia)
89274158|NCT01099046|Active Comparator|medication + regular sleep|anti-diuretics + regular sleep (regular sleep program under dark everynight)
89274159|NCT00090987|Experimental|Imatinib mesylate|Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months
89274160|NCT01085253||Parkinson|"without gait impairment~with gait and/or balance impairment~with sleep disorders (RBD)~abnormalities of the brainstem and basal ganglia will be studied in relation with parkinsonism, gait and presence of RBD"
89274161|NCT01085253||PSP|supranuclear palsy patients study the abnormalities with the brainstem and basal ganglia and relation with the observed neurological signs (eye movements, balance, neuropsychological assessment and parkinsonism)
89274162|NCT01085253||controls|age matched controls
89274163|NCT03464422|Experimental|Young gay and bisexual men of color|Approximately 30 young MSM of color will take part in weekly 90-minute group treatment sessions over 10 weeks. All participants will complete outcome assessments at baseline and three months post-treatment, as well as an exit interview.
89274164|NCT03720184|Experimental|HAR group|Treated group is exposed to an haematic antegrade autologous repriming of the MiECC CLass IV circuit, reducing the haemodilution related to CPB initiation to a fix amount of 300ml
89274165|NCT03720184|No Intervention|Control Group|Control group is not exposed to HAR. The extracorporeal circuit is a MiECC primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit
89274166|NCT03489304|Other|Zaleplon|Open-label zaleplon 5-10mg daily
89274167|NCT03724006|Experimental|INTERVENTION group (I)|Group I will be composed by parents of children with the diagnosis of CHD who will receive a psychoeducational intervention plus usual routines of the Service.
89274168|NCT03724006|No Intervention|CONTROL group (C)|Group C will be composed by parents of children with the diagnosis of CHD who will receive the usual routines of the Service. After completing the data collection, the possibility of receiving the psychoeducational intervention under study will be offered to this group.
89274169|NCT03720106|Other|treatment arm|In this arm the GOAL therapy plan is used.
89274170|NCT03720028||Child w Angelman/Rett syndrome|Children with Angelman or Rett syndrome, up to 14 years of age
89274171|NCT03720028||Parent|Parents of Children with Angelman or Rett syndrome
89274172|NCT03718702|Experimental|Intervention group|ePain will be accessible by the intervention group.
89274173|NCT03718702|No Intervention|Control group|No intervention will be applied to control group and they can download an educational pamphlet only.
89274174|NCT03718624|Experimental|paclitaxel,apatinib and S-1|
89274175|NCT03543358|Experimental|Arm A: Post-Treatment Follow-Up/Optional Retreatment|Arm A includes participants who enter the extension study while in post-treatment follow-up. This arm includes optional rovalpituzumab tesirine retreatment plus dexamethasone per participant per retreatment period.
89274176|NCT03543358|Experimental|Arm B: Continued Treatment|Arm B includes participants who enter the extension study while receiving ongoing rovalpituzumab tesirine treatment plus dexamethasone in the parent study.
89274177|NCT03485950|Experimental|Group I (ceftolozane-tazobactam)|Participants receive ceftolozane-tazobactam IV over 1 hour every 8 hours for up to 14 days in the absence of disease progression or unacceptable toxicity. After at least 3 days, participants may switch to different PO or IV antibiotics at the discretion of the study doctor.
89274178|NCT03485950|Active Comparator|Group II (standard of care antibiotic treatment)|Participants receive standard of care antibiotic treatment consisting of either cefepime IV over 30 minutes every 8 hours, meropenem IV over 30 minutes every 8 hours, or piperacillin-tazobactam IV over 1 hour every 6 hours for up to 14 days in the absence of disease progression or unacceptable toxicity.
89274179|NCT00060944|Experimental|Yondelis weekly schedule|Yondelis weekly schedule: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1 8 and 15 of each 28-day treatment cycle. Patients will be pretreated with 10 mg of dexamethasone i.v. 30 minutes prior to each infusion.
89274180|NCT00060944|Experimental|Yondelis once every 3 weeks schedule|Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.
89274181|NCT03719872||Participants undergoing laparoscopy|Participants undergoing laparoscopic abdominal surgery with surgical insufflation receiving pre-operative transabdominal ultrasound and post-operative transabdominal ultrasound.
89274182|NCT01095224|Experimental|rAd35 Env A and rAd5 Env A|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
89274183|NCT01095224|Experimental|rAd35 Env A and rAd5 Env B|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
89274184|NCT01095224|Experimental|rAd35 Env A and rAd35 Env A|Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
89274185|NCT01095224|Experimental|rAd5 Env A and rAd5 Env A|Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
89274186|NCT01095224|Experimental|rAd5 Env A and rAd5 Env B|Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
89274187|NCT03462082|No Intervention|Baseline STN-DBS|Maintenance of baseline bilateral STN-DBS settings.
89274188|NCT03462082|Experimental|Asymmetric STN-DBS 1|Unilateral 50% reduction of voltage (e.g. right side)
89274189|NCT03462082|Experimental|Asymmetric STN-DBS 2|Unilateral 50% reduction of voltage (e.g. left side)
89274190|NCT03956732|Experimental|High protein yoghurt and vitamin D supplement|Subjects will receive high protein yoghurt and vitamin D tablets.
89274191|NCT03956732|Experimental|High protein yoghurt and placebo supplement|Subjects will receive high protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
89274192|NCT03956732|Experimental|Medium protein yoghurt and vitamin D supplement|Subjects will receive medium protein yoghurt and vitamin D tablets.
89274193|NCT03956732|Placebo Comparator|Medium protein yoghurt and placebo supplement|Subjects will receive medium protein yoghurt and placebo tablets of identical appearance and taste but without vitamin D.
89274194|NCT01093274|Active Comparator|Polyethylene glycol|Preparation with Polyethylene Glycol and bisacodyl
89274195|NCT01093274|Experimental|Picolax|Preparation with Sodium Picosulphate and Bisacodyl.
89274196|NCT01093352|No Intervention|Standard|Standard expose and bond.
89274197|NCT01093352|Experimental|Alveolar-decortication|Following surgical exposure of the impacted canine, additional perforations will be made in the surrounding cortical bone prior to wound closure.
89274198|NCT01099124|Experimental|M2ES combined with chemotherapy|
89274199|NCT01584206|Experimental|Ezetimibe|Compare on and off ezetimibe
89274200|NCT03955952||Bariatric Surgery|Patients with type 2 diabetes with BMI >=30 that underwent bariatric surgery
89274201|NCT03955952||Non-Surgical Control|Matched non-surgical controls with type 2 diabetes and BMI >=30
89274202|NCT03541252|Experimental|Basal Cell Carcinoma Patients|Patients (>18 years) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on the face/scalp, <50mm on the trunk/extremities)
89274203|NCT00031460|Experimental|Acyclovir|
89274204|NCT00031460|Placebo Comparator|Placebo|
89274205|NCT03951974|Experimental|Experimental|Participants in the experimental group will receive training in utilizing social regulation of emotion strategies in an individualized format. They will meet with an interventionist for 5 weeks (1 in-person session and 4 telephone sessions) for 1-1.5 hours each week, and keep a journal documenting their emotion challenges and regulation strategy use.
89274206|NCT03951974|Other|Control|Participants in the control group will not receive training in utilizing social regulation of emotion strategies. While they will still meet with the interventionist on the same schedule and for approximately the same length of time, they will simply be asked to report the emotion regulation strategies that they naturally employ. They will also keep a journal documenting their emotion challenges and regulation strategy use.
89274207|NCT03540160|Experimental|Experimental: 5 mg Serlopitant Tablets|Serlopitant Tablets
89274208|NCT03952052|Other|Patient enrolled|Recurrent mutations determination
89274209|NCT03955562|Experimental|Intervention|Communities that receive a pedestrian footbridge.
89274210|NCT03955562|Experimental|Comparison|Communities that do not receive a pedestrian footbridge.
89274211|NCT01099280|Experimental|oxytocin group|2 milliunits/min and doubled every 30 minutes to a maximum of 32 milliunits/min or until four contractions in 10 minutes was achieved
89274212|NCT01099280|Experimental|dinoprostone and oxytocin|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
89274213|NCT03459196|Experimental|Treatment Group|A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
89274214|NCT01093430|Experimental|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
89274215|NCT01093430|Active Comparator|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
89274216|NCT01095302|Experimental|Ombrabulin/ docetaxel/cisplatin|AVE8062 combined with docetaxel and cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
89274217|NCT03955718|Experimental|Motherly App|A smartphone app with an automated intervention that provides strategies to prevent maternal depression and to promote child development: (1) behavioral activation, (2) sleep hygiene, (3) physical activity, (4) social support, (5) nutrition, (6) prenatal care schedule, and (7) educational content.
89274218|NCT03955718|Active Comparator|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
89274219|NCT03459040|Experimental|alpha-1-antitrypsin (AAT)|16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
89274220|NCT02530736||IPF_RESP|Pulmonary Rehabilitation: a 6 - 8 week exercise and education programme (this is part of usual care)
89274221|NCT03457636|Experimental|doxycycline anhydrous and adapalene/benzoyl peroxide|All subjects will receive at Baseline doxycycline anhydrous 40 mg (Oracea) to be taken once daily and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily for 12 weeks
89274222|NCT01099436|Experimental|TAC + Zoledronic acid|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)
89274223|NCT01099436|Active Comparator|TAC|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC)
89274224|NCT01099514|Experimental|Nilotinib|Nilotinib 400 mg (2 capsules) PO BID q 28 days
89274225|NCT03951896|Experimental|PRP|"Interventions:~A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects."
89274226|NCT03951896|Placebo Comparator|Placebo|For the control group, same amount of blood was sampled and they were given a same amount of waiting time with the other group, with the resulting injection preparate being 2 ml's of 0,9% saline instead.
89274227|NCT01099670|Experimental|7.5 mg NRL001|Nine subjects will receive 7.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
89274228|NCT01099670|Experimental|10 mg NRL001|Nine subjects will receive 10 mg NRL001 in a 2 g suppository; three will receive matching placebo.
89274229|NCT01099670|Experimental|12.5 mg NRL001|Nine subjects will receive 12.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
89274230|NCT01099670|Experimental|15 mg NRL001|Nine subjects will receive 15 mg NRL001 in a 2 g suppository; three will receive matching placebo.
89274231|NCT03955484||Patients who had benign prostatic hyperplasia|"Male patients presenting with lower urinary tract symptoms to urology outpatient clinic~According to the European Association of Urology Guidelines:~International prostate symptom score> 8 Prostate volume> 40 ml Q max <15 ml /sn Patients who did not receive any treatment for lower urinary tract symptoms and applied for the first time Patients who have not undergone lower urinary tract surgery"
89274232|NCT01099748|Active Comparator|Methadone|Dose of methadone must not change from 1 week prior to study start and through the duration of the study.
89274233|NCT01099748|Experimental|Lersivirine + Methadone|
89274234|NCT03951662||With alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers with high bilirubin and AST levels.
89274235|NCT03951662||Without alcoholic hepatitis|HIV-positive patients receiving antiretroviral therapy and who are heavy drinkers without high bilirubin and AST levels.
89274236|NCT03481816|Experimental|Arm 1/Dose De-Escalation|Subjects enrolled to dose de-escalation cohorts.
89274237|NCT03481816|Experimental|Arm 2/Dose expansion|Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.
89274238|NCT02530346|Active Comparator|Mechanical Bowel Preparation|"Patients will receive enteric polyethylene glycol at 100 ml/kg/dose during 4 hours, and up to 3 times, prior to surgery.~Enemas with normal saline 20 ml/kg/do will be administered through the stomas 3 times a day"
89274239|NCT02530346|Experimental|No Mechanical Bowel Preparation|Patients will not receive any preparation prior to surgery
89274240|NCT01099826|Experimental|lifestyle counseling tailored|
89274241|NCT01099826|Experimental|lifestyle counseling motivational|
89274242|NCT01099826|No Intervention|control|
89274243|NCT03723616|Active Comparator|Hookah Tobacco Smokers|Young adults, ages 18-34, who smoke hookah tobacco
89274244|NCT03723616|Active Comparator|Open to Smoking Hookah Tobacco|Young adults, ages 18-34, who do not smoke hookah tobacco but are open to trying
89274245|NCT03956888|Experimental|N-acetylcysteine treatment|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
89274246|NCT03719794|Active Comparator|Probiotics arm|The active comparator arm will be of a 12-week probiotic supplement regimen (one capsule daily, containing 20 x 109 CFU of Bifidobacterium animalis ssp. Lactis Lafti®B94 and Lactobacillus plantarum R1012)
89274247|NCT03719794|Placebo Comparator|Placebo arm|The placebo comparator arm will be of a 12-week placebo supplement regimen.
89274248|NCT01099904|Experimental|1|Normal Renal Function
89274249|NCT01099904|Experimental|2|Mild Renal Impairment
89274250|NCT01099904|Experimental|3|Moderate Renal Impairment
89274251|NCT03955406|Active Comparator|Conventional group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 6% with fresh gas flow rate 4 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 1% higher value than the EtAA concentration required to achieve 0.7 MAC. And after 10 minutes fresh gas flow rate will be reduced to 1L/min.
89274252|NCT03955406|Active Comparator|Fixed Fresh Gas Flow Rate group|After standart intravenous anesthesia induction end endotracheal intubation desflurane vaporizer will be set at 18% with fresh gas flow rate 1 L/min (50% O2, 50% air) until the EtAA concentration reaches 0.7 MAC (minimum alveolar concentration) Then, the desflurane vaporizer will be at a 2% higher value than the EtAA concentration required to achieve 0.7 MAC.
89274253|NCT01093664|Experimental|AFFITOPE AD02|
89274254|NCT03538054|Experimental|Dextromethorphan|Participant will take one dextromethorphan 10mg capsule in the morning and at night.
89274255|NCT03538054|Placebo Comparator|Placebo|Participants will take one placebo capsule in the morning and at night.
89274256|NCT03480802|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
89274257|NCT03480802|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
89274258|NCT00050960|Experimental|bexarotene with carboplatin and paclitaxel|
89274259|NCT00050960|Experimental|carboplatin and paclitaxel|
89274260|NCT03719716|Experimental|Early support group|This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
89274261|NCT03719716|No Intervention|Usual care group|No change to standard care from oncology services and primary care
89274262|NCT03456856|Experimental|Ivabradine|The starting dose of ivabradine was 5 mg twice daily (BID), although investigators had the discretion to start participants at 2.5 mg BID if participant had a history of conduction defects, or bradycardia that could lead to hemodynamic compromise. Dose was adjusted at Day 15 (and at any other clinical visit) between 2.5 - 7.5 mg BID based on heart rate and signs/symptoms of bradycardia.
89274263|NCT00058214|Experimental|Treatment (perifosine)|Patients receive oral perifosine once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.
89274264|NCT00097773|Placebo Comparator|Cycled TOBI & placebo|Tobramycin inhalation solution and oral placebo for six consecutive quarterly cycles
89274265|NCT00097773|Active Comparator|Cycled TOBI & oral ciprofloxacin|Tobramycin solution for inhalation and oral ciprofloxacin for six consecutive quarterly cycles.
89274266|NCT00097773|Placebo Comparator|Culture based TOBI & placebo|Tobramycin solution for inhalation and oral placebo administered only when quarterly respiratory cultures are found positive for Pa.
89274267|NCT00097773|Active Comparator|Culture based TOBI & oral cipro|Tobramycin solution for inhalation and oral ciprofloxacin administered only when quarterly respiratory cultures are found positive for Pa.
89274268|NCT01095380|Active Comparator|Treadmill training - manual assist (TM)|Participants in the TM group received partial body weight support unilateral or bilateral manual assistance from a trainer for stepping
89274269|NCT01095380|Active Comparator|Treadmill training - electrical stimulation (TS)|Participants in the TS group received partial body weight support and bilateral functional electrical stimulation to assist stepping
89274270|NCT01095380|Active Comparator|Overground Training (OG)|Training over ground with body weight support and electrical stimulation for dorsiflex assistance
89274271|NCT01095380|Active Comparator|Treadmill training - locomat robot (LR)|Treadmill training with partical body weight support and assistance of a robotic gait orthosis for stepping
89274272|NCT03480022|Experimental|Liraglutide Pen Injector (Saxenda)|Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily
89274273|NCT03480022|Placebo Comparator|Placebo liraglutide pen injector|Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily
89274274|NCT01093742|Experimental|cohort 1|HM10560A 0.089 mg/kg or Placebo
89274275|NCT01093742|Experimental|cohort 2|HM10560A 0.179 mg/kg or Placebo
89274276|NCT01093742|Experimental|cohort 3|HM10560A 0.357 mg/kg or Placebo
89274277|NCT01093742|Experimental|cohort 4|HM10560A 0.714 mg/kg or Placebo
89274278|NCT01081821|Experimental|001|single dose NJ-39758979/ matching placebo Single oral dose of JNJ-39758979 (either 50 100 300 600mg) or Placebo
89274279|NCT01081821|Experimental|002|multi-dose JNJ-39758979 /matching placebo JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
89274280|NCT01095458|Experimental|Phone based weight management group|Group based weight management program delivered via conference calls
89274281|NCT01095458|Experimental|Clinic based weight management group|Traditional clinical based group weight management program
89274282|NCT01584596|Experimental|Adapted Diet and Physical Activity|Adapted diet and physical activity guidelines sessions
89274283|NCT01584596|Active Comparator|Adapted Diet|Adapted dietary guidelines sessions
89274284|NCT03723382||Patients with stroke with structured management|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
89274285|NCT03723382||Patients with stroke without structured management|Control subject who have stroke and did not managed according to the SECRET 6 level metrics
89274286|NCT01584674|Experimental|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
89274287|NCT01584674|No Intervention|Control (untreated hemiface)|No treatment will be administered on the control hemiface
89274288|NCT03716986|Other|SatO2|
89274289|NCT01093820|Experimental|Epopoetinum beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
89274290|NCT03718468|Experimental|GC Flu Quadrivalent|
89274291|NCT03718468|Active Comparator|Fluarix tetra|
89274292|NCT03533608|Experimental|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
89274293|NCT00049322|Experimental|Arm I-bevacizumab|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning 1 week prior to the first chemoembolization at a dose of 10 mg/kg. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
89274294|NCT00049322|No Intervention|Arm II-chemoembolization|chemoembolization as part of standard of care
89274295|NCT03437512|Experimental|Active tDCS and fluency training|Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
89274296|NCT03437512|Sham Comparator|Sham tDCS and fluency training|Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
89274297|NCT00058058|Experimental|MRI Evaluation of Contralateral Breast|The cohort is a distinct population of women at high risk for breast carcinoma: women with a recent (within 60 days) personal diagnosis of breast cancer who will have MRI to evaluate the contralateral breast.
89274298|NCT03532048|Experimental|Intervention Group|The Papás Saludables, Niños Saludables Program
89274299|NCT03532048|Other|Wait-list Control|The Papás Saludables, Niños Saludables Wait-list Control
89274300|NCT01093898||No intervention|
89274301|NCT03639376||Passive smoking-exposed children|This group consists of children whose family members have smoked at home since the birth of the child.
89274302|NCT03639376||Passive smoking-unexposed children|This group consists of children whose family members have not smoked at home since the birth of the child.
89274303|NCT01100918|Active Comparator|1: Dyssynchrony positive|
89274304|NCT01100918|Active Comparator|2a: Dyssynchrony negative|
89274305|NCT01100918|Active Comparator|2b: Dyssynchrony negative|
89274306|NCT00008138|Experimental|chemo/debulking surgery/IP chemo|neoadjuvant chemotherapy (carboplatin and paclitaxel) followed by debulking surgery followed by intraperitoneal chemotherapy (carboplatin and paclitaxel)
89274307|NCT01100996|No Intervention|fasted control|Volunteers are fasted for 10 hours and subjected to experimental endotoxemia
89274308|NCT01100996|Placebo Comparator|control feeding|Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS
89274309|NCT01100996|Active Comparator|enriched feeding|volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS
89274310|NCT01101074||6-23 months|
89274311|NCT01101074||2-8 years|
89274312|NCT01101074||9-17 years|
89274313|NCT01101074||18-44 years|
89274314|NCT01101074||45-60 years|
89274315|NCT01101074||>60 years|
89274316|NCT03436732|Experimental|1/Dose Escalation|Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses
89274317|NCT03436732|Experimental|2/Dose Expansion|Dose expansion - patients with mesothelioma treated with LMB-100+SEL-110 at recommended phase 2 dose (RP2D)
89274318|NCT01100060|Experimental|Group 1|Co-administer the test chloroquine (CQ) formulation (620 mg CQ base) plus microsphere azithromycin (AZ) (2000 mg) on Day 1.
89274319|NCT01100060|Active Comparator|Group 2|Co-administer the individual tablets of CQ 2 x 500 mg (600 mg CQ base) tablets plus AZ IR 4 x 500 mg tablets on Day 1.
89274320|NCT01100216|Active Comparator|Nicotine Lozenge|4 mg nicotine lozenge (LOZ
89274321|NCT01100216|Active Comparator|Camel Snus Frost|
89274322|NCT01100216|Active Comparator|Stonewall Spearment Tablet|
89274323|NCT01100216|Active Comparator|Skoal Wintergreen|
89274324|NCT01100294|Experimental|Vaccination with Fluval P|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
89274325|NCT03436420|Experimental|Gemcabene|Children receiving 12 weeks of treatment with gemcabene
89274326|NCT00027560|Experimental|TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES|This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
89274327|NCT03951740|Experimental|Group of cardiac patients|All patients completed the study wearing two wrist-worn activity trackers and the Oxycon mobile as reference method during a laboratory activity protocol.
89274328|NCT01327352|Experimental|Oshadi D|"2 dose levels of Oshadi D in 2 food regimen will be administered as following:~Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.~On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration~On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.~On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.~On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast."
89274329|NCT03951428||All Participants|
89274330|NCT01100450|Experimental|Resistance Training|
89274331|NCT03951506|Experimental|Experimental-Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
89274332|NCT03951506|Experimental|Experimental-conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
89274333|NCT03951350|No Intervention|Control (TAU)|Patients will follow the usual treatment provided by their GP (treatment-as-usual, TAU).
89274334|NCT03951350|Experimental|Lifestyle Modification Program (LMP)|It will consist of 6 weekly group sessions (lasting 90 minutes each).
89274335|NCT03951350|Experimental|Lifestyle Modification Program (LMP) + ICTs|It will consist of 6 weekly group sessions (lasting 90 minutes each).
89274336|NCT02530190|No Intervention|Control|20 minutes of supine rest
89274337|NCT02530190|Active Comparator|Intermittent pneumatic compression|20 minutes of intermittent pneumatic compression
89274338|NCT02530190|Active Comparator|Massage|20 minutes of massage therapy
89274339|NCT01100684|Experimental|Treatment|0.5 mg asimadoline bid
89274340|NCT01100684|Placebo Comparator|Placebo|Placebo
89274341|NCT03451084|Experimental|Part 1: Dose Level 1|
89274342|NCT03451084|Experimental|Part 1: Dose Level 2|
88805557|NCT00131378|Experimental|Female on GH|"Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
88805558|NCT00131378|Placebo Comparator|Female on Placebo|"Participants received placebo.~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
89274343|NCT03451084|Experimental|Part 1: Dose Level 3|
89274344|NCT03451084|Experimental|Part 1: Dose Level 4|
89274345|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine|
89274346|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level & Azacitidine|
89274347|NCT02529878|Experimental|conversion treatment|after 3 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent
89274348|NCT03451006|Experimental|Metformin|Metformin 500mg tablet by mouth, every 6 to 8 hours for one year
89274349|NCT03451006|Active Comparator|Placebo|Placebo by mouth every 6 to 8 hours for one year
89274350|NCT05625854|Experimental|Blow a fan to the face combine aromatherapy|
88805559|NCT01445821|Active Comparator|Cyclophosphamide rATG/HSCT|The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. Peripheral blood stem cells (PBSC) will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
88805560|NCT01445821|Experimental|Cyclophosphamide rATG/Fludarabine/HSCT|The conditioning regimen will be 120 mg/kg of intravenous cyclophosphamide given in 2 equal fractions on days -3 and -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Fludarabine 30 mg/m2 will be given IV on days -5, -4, and -3. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
89274351|NCT05625854|Experimental|Blow a fan to the face|
89274352|NCT05625854|Placebo Comparator|Blow a fan to the feet|
89274353|NCT01327118|Placebo Comparator|Isoton sodium chloride|
89274354|NCT01327118|Active Comparator|Prostaglandin F2alpha|
89274355|NCT03450070|Experimental|Test Panel|Light Therapy Mask Cream
89274356|NCT03723304||Direct liver transplant|All the cases listed for liver transplantation and then transplanted/dropped-out without undergoing any neo-adjuvant loco-regional treatment
89274357|NCT03723304||Bridging followed by transplant|All the cases listed for liver transplantation and then transplanted/dropped-out after undergoing at least one neo-adjuvant loco-regional treatment
89274358|NCT03449758|Experimental|Sarilumab|Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.
89274359|NCT03716752|Active Comparator|bone graft and collagen barrier|peridoontal regeneration using bone graft and collagen barrier as treatment of vertical bony defects with recession defect
89274360|NCT03716752|Experimental|Modified connective tissue graft wall with wing technique|peridoontal regeneration using bone graft and modified connective tissue graft wall with wing as treatment of vertical bony defects with recession defect
89274361|NCT01310686||Wet AMD Non-Responders to Anti-VEGF|
89274362|NCT03449446|Experimental|Selonsertib (SEL)|Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.
89274363|NCT03449446|Experimental|Firsocostat (FIR)|Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
89274364|NCT03449446|Experimental|Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
89274365|NCT03449446|Experimental|Selonsertib (SEL) + Firsocostat (FIR)|Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
89274366|NCT03449446|Experimental|Selonsertib (SEL) + Cilofexor (CILO)|Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
89274367|NCT03449446|Experimental|Firsocostat (FIR) + Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.
89274368|NCT03449446|Experimental|Placebo|Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
89274369|NCT03435016|Other|Diagnosis|
89274370|NCT03716674|Experimental|Parkinson's Disease patients|
89274371|NCT03716596|Experimental|SBRT and PD-1|Stereotactic body radiotherapy, radiation dose is 40-50 Gy in total. Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
89274372|NCT03718390|Experimental|Sentinel Group 1 LYN-PLT|Sentinel dosing in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
89274373|NCT03718390|Experimental|Sentinel Group 2 LYN-PLT|Sentinel dosing (second) in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
89274374|NCT03718390|Experimental|Group 3 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind). and evaluation of gastric retention by MRI
89274375|NCT03718390|Experimental|Group 4 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI
89274376|NCT03718390|Experimental|Group 5 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI.
89274377|NCT03449134|Placebo Comparator|Placebo|Participants receive dose-matched placebo tablets twice daily (BID) during the 12-week main study period and 40-week extension period.
89274378|NCT03449134|Experimental|Gefapixant 15 mg BID|Participants receive a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 12-week main study period and 40-week extension period.
89274379|NCT03449134|Experimental|Gefapixant 45 mg BID|Participants receive a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 12-week main study period and 40-week extension period.
89274380|NCT03722992|Other|Mindfulness Cohort|Mindfulness-based stress reduction (MBSR) treatment group
89274381|NCT05650840|Experimental|Charcoal -based whitening toothpaste|signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt
89274382|NCT05650840|Active Comparator|Calcium carbonate /perlite containing whitening toothpaste|signal whitening moonlight toothpaste Unilever Mashreq - Egypt
89274383|NCT03722914|Active Comparator|benzonatate soft capsules group|
89274384|NCT03722914|Placebo Comparator|control group|
89274385|NCT03716518|Experimental|TCM group|Tonifying Spleen and Kidney Sequential Regimen(TSKSR) will be prescribed to the participants in each course of chemotherapy.
89274386|NCT03716518|Placebo Comparator|Placebo group|Placebo of Tonifying Spleen and Kidney Sequential Regimen(TSKSR)similar in color,smell and texture with TSKSR will be prescribed to participants in each course of chemotherapy.
89274387|NCT03529162|Active Comparator|Suture Anchor Technique (SA)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached to the humerus using an FDA-approved suture anchor (SA) device for the suture anchor technique. The device to be used will be the Mitek Super Quick Anchor.
89274388|NCT03529162|Active Comparator|Pectoralis Major Technique (PMT)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached by suturing the biceps tendon into the pectoralis major tendon.
89274389|NCT03722758|Active Comparator|Spectrum TPH3, tooth restoration|Restoration with micro hybrid resin composite
89274390|NCT03722758|Active Comparator|Riva LC, restorative material|Restoration with resin-modified glass ionomer cement
89274391|NCT03447730|Experimental|Part 1: SYNB1020|Part 1 comprised a sentinel open-label cohort of subjects enrolled sequentially to receive SYNB1020, which was administered orally at a dose of 5 × 10^11 colony-forming units (CFU) 3 times daily (TID) given immediately after meals from Days 1 through 6.
89274392|NCT03447730|Experimental|Part 2: SYNB1020|Subjects randomized to receive SYNB1020 in Part 2 received SYNB1020 administered orally at a dose of 5 × 10^11 CFU TID given immediately after meals from Days 1 through 6.
89274393|NCT03447730|Placebo Comparator|Part 2: Placebo|Subjects randomized to receive control in Part 2 received matching placebo (100 mL masking solution) administered orally TID given immediately after meals from Days 1 through 6.
89274394|NCT03716440|Experimental|Nature group|Nature exposure intervention.
89274395|NCT03716440|Active Comparator|Non-nature group|Non-nature exposure intervention.
89274396|NCT03722602|Experimental|Rehabilitation group|Patients with stroke receiving standard inpatient rehabilitation for five weeks
89274397|NCT03716362||Neonates who will be admitted at Neonatal Intensive Care Unite|
89274398|NCT03718078|Experimental|Confocal Laser Endomicroscopy|lt includes patients will undergo probe-based Confocal Laser Endomicroscopy during laparoscopic hepatic masses resection.
88805561|NCT01092767|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|Valiant Thoracic Stent Graft with the Captivia Delivery System
88805562|NCT02543892|Experimental|Adult 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
88805563|NCT02543892|Placebo Comparator|Adult Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
89274399|NCT01310764|Sham Comparator|Mitomycin C|Those with trabeculectomy and intraoperative application of mitomycin C.
89274400|NCT01310764|Active Comparator|Bevacizumab|Those with trabeculectomy and adjunctive intraoperative subconjunctival injection of bevacizumab.
89274401|NCT03429556|Placebo Comparator|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
89274402|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 1|Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.
89274403|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 2|Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.
89274404|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 3|Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.
89274405|NCT03444766|Experimental|Monotherapy|administering nivolumab only
88805564|NCT02543892|Experimental|Adult 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
88805565|NCT02543892|Placebo Comparator|Adult Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
88805566|NCT02543892|Experimental|Toddler 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
88805567|NCT02543892|Placebo Comparator|Toddler Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
89274406|NCT03526432|Experimental|Bevacizumab + Atezolizumab|
89274407|NCT01310842||Pilot Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 5 in-person counseling sessions.
89274408|NCT01310842||Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 7 in-person counseling sessions.
89274409|NCT03716206|Experimental|exergames group|The exergames intervention is one hour per day, four or five days per week for three weeks.
89274410|NCT03716206|Active Comparator|conventional group|The conventional group intervention is one hour per day, four or five days per week for three weeks.
89274411|NCT03722368|Experimental|RCHC|Participation in the Resilience and Coping of the Healthcare Community Intervention.
89274412|NCT03722368|Experimental|RCHC+|Participation in the Resilience and Coping of the Healthcare Community Intervention, support groups and one on one counseling.
89274413|NCT03722368|Other|Waitlist Control|This group will receive treatment as usual and will be offered services once the study is complete.
89274414|NCT03426436|Other|Test|Obtain two consecutive 15-lead ECGs; The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
89274415|NCT03425188||remedē System Subjects|Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.
89274416|NCT03717766||Patients|Intraaxial brain tumors that are tributary to surgical treatment. Prospective observational study of the use and effectiveness of intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology in the resection of intracranial supratentorial tumors.
89274417|NCT05664724|Experimental|Receives interdisciplinary sessions|Interdisciplinary care by a team that includes: orthopedic surgeon, physiotherapist, a patient navigator, and the patient
89274418|NCT03722290|Experimental|Metformin|Metformin 500mg twice a day per os for 9 weeks
89274419|NCT03423238|Active Comparator|Rehab Only|Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
89274420|NCT03423238|Experimental|Rehab+Weight Loss (WL)|Patients will be randomized to Rehab+WL using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation in addition to a weight-loss intervention, which includes meeting with dietitian, exercise, health education, and exercise compliance, calorie-restricted diet, behavioral modification, and weight-loss compliance.
89274421|NCT03717688|Placebo Comparator|Placebo|No treatment. Participants are subjected to a standardized meal
89274422|NCT03717688|Active Comparator|Entrestro as single dose|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
89274423|NCT03717688|Active Comparator|Sitagliptin as single dose|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
89274424|NCT03717688|Active Comparator|Entrestro + sitagliptin as single dose|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
89274425|NCT03714100|Experimental|MFBB intervention|All participants will attend Tai Ji Quan: Moving for Better Balance classes twice a week for 16 weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
89274426|NCT03717610|Experimental|Complete cytoreductive surgery plus HIPEC with cis-platinum100mg/m2 for 90 min|
89274427|NCT03717532|Experimental|Patients with Patellopain syndrome with Cuff|Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
89274428|NCT03717532|Placebo Comparator|Patients with Patellopain syndrome with Placebo Cuff|
89274429|NCT02953678|Experimental|Ruxolitinib in combination with corticosteroids|Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
89274430|NCT03412084|Experimental|Stand up intervention|four week behavioral intervention based on self-regulation theory which is designed to facilitate the development of action plans to break up prolonged sitting
89274431|NCT03412084|No Intervention|Control|No behavioral intervention - the control group will go about their daily life, but come in for assessments at the same time points as the intervention group
89274432|NCT00090753|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.
89274433|NCT00090753|Active Comparator|Comparator ESA|Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.
89274434|NCT00048932|Active Comparator|Double-blind abatacept|Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants > 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period
89274435|NCT00048932|Placebo Comparator|Double-blind Placebo|Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.
89274436|NCT00048932|Active Comparator|Open-label Abatacept|Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.
89274437|NCT01085409||Tinnitus|Patients with tinnitus
89274438|NCT01085409||Artery disease|Subjects with mobility constraints as a results of severe artery disease which in some cases led to leg amputation.
89274439|NCT01085409||Anxiety|Subjects with anxiety complaints
89274440|NCT01085409||Controls|Healthy controls
88805568|NCT02543892|Experimental|Toddler 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
89274441|NCT01081899|Experimental|The LCP-I Program.|The Italian version of the Liverpool Care Pathways version 11 for hospital) Programme.
89274442|NCT01081899|No Intervention|standard healthcare practices|No specific interventions are planned in the control wards.
89274443|NCT03812679|Experimental|AMIA APD Solution Generation System|A simulated treatment will take place before the patient receives study treatment, during week 1 and after 4, 8 and 12 weeks of study treatment period. The dialysis solution generated by the simulated treatment will be collected from the system in the heater bag and used to evaluate the chemical composition of the final dialysis solution produced by patients using the AMIA APD Solution Generation System. Also, product water from the Water Device (pre-sterilizing filters) will be collected and tested at each visit.
89274444|NCT01081977|Active Comparator|Early Cord Clamping Group|Early Cord Clamping Group (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate).
89274445|NCT01081977|Experimental|Delayed Cord Clapming Group|Delayed Umbilical Cord Clamping Group (Clamping of Umbilical Cord within 2 minutes of shoulder delivery of neonate).
89274446|NCT01583127|Experimental|School-Wide (SW)-PBIS intervention|SW-PBIS intervention
89274447|NCT01583127|No Intervention|Control|Practice as usual
89274448|NCT02952820|Experimental|lemborexant 5 milligrams (mg)|Lemborexant 5 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
89274449|NCT02952820|Experimental|lemborexant 10 mg|Lemborexant 10 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
89274450|NCT02952820|Placebo Comparator|Placebo matched to lemborexant|Lemborexant-matched placebo will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
89274451|NCT03962439|Experimental|High-Demand Photography|A structured, high-demand photography course targeting 210 hours of engagement over 16 weeks.
89274452|NCT03962439|Active Comparator|Moderate-Demand Photography|A structured, moderate-demand photography course targeting 210 hours of engagement over 16 weeks.
89274453|NCT03962439|Placebo Comparator|At-Home Engagement Group|Participation, alone at home, in tasks that are relatively low in intellectual engagement.
89274454|NCT01082055||Currently receiving antiarrythmic drugs|
89274455|NCT01583361|Experimental|Arm A:Neoadjuvant sox|Patients in arm a will receive (N=2-4) cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and (8-N) cycles of adjuvant SOX adjuvant chemotherapy.
89274456|NCT01583361|Active Comparator|Arm B:Adjuvant SOX|Patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.
89274457|NCT01085487||Group 1|
89274458|NCT01085487||Group 2|
89274459|NCT01085487||Group 3|
89274460|NCT01085565|Experimental|Exablate treatment|
89274461|NCT03962361||Sudden cardiac death of ischemic cause|Patients admitted to the Coronary Care Unit for sudden cardiac death of ischemic cause and remain comatose (GCS < 8 points).
89274462|NCT01089309|Experimental|Aldosteron blokade, Arterial stiffness, Glucose homeostasis|
89274463|NCT03962205|Experimental|Cognitive Behavioral life-style and well-being intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification and then 4 group-based 2-hour weekly sessions of the well-being intervention in addition to the treatment as usual.
89274464|NCT03962205|Placebo Comparator|Cognitive Behavioral life-style intervention|Participants will receive 12 group-based 2-hour weekly sessions for life-style modification in addition to the treatment as usual.
89274465|NCT03717454|Experimental|Drug treatment|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.
89274466|NCT03717454|Experimental|Surgery|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.
89274467|NCT01311310|Experimental|remote ischemic preconditioning|
89274468|NCT01089387|Experimental|injection of bone marrow cells|
89274469|NCT01085721|Experimental|Dexchlorpheniramine pseudoephedrine guaifenesin|
89274470|NCT01085721|Active Comparator|Dexchlorpheniramine|
89274471|NCT01085799|Experimental|Health Education Intervention|Groups of schools receiving the health education intervention
89274472|NCT01085799|No Intervention|Control Schools - Regular curriculum|Groups of schools not receiving the health education intervention
89274473|NCT00006392|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
89274474|NCT00006392|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
89274475|NCT00006392|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
89274476|NCT00006392|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamine E placebo and selenium placebo daily for 7-12 years
89274477|NCT01089621|Experimental|Duloxetine|
89274478|NCT03951272|Experimental|Lyoplant® Onlay|All the model including 2.5cm×2.5cm, 5.0cm×5.0cm,2.5cm×7.5cm,7.5cm×7.5cm,10.0cm×12.5cm will be used in this study
89274479|NCT03951272|Active Comparator|DURAFORM™ Dural Graft Implant|All the model including 2.54cm×2.54cm,5.08cm×5.08cm, 2.54cm×7.62cm, 7.62cm×7.62cm,10.16cm×12.70cm will be used in this study
89274480|NCT01101152|Experimental|Female|
89274481|NCT01101152|Experimental|Male|
89274482|NCT00379769|Experimental|rosiglitazone in addition to background metformin|Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
89274483|NCT00379769|Experimental|rosiglitazone in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
89274484|NCT00379769|Active Comparator|Sulfonylurea in addition to background metformin|Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
89274485|NCT00379769|Active Comparator|Metformin in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
89274486|NCT00006164|Experimental|1|Peg-interferon alfa-2a 90 mcg/week
89274487|NCT00006164|Active Comparator|2|Standard of care followup
89274488|NCT00378599|Experimental|PEG-Intron plus Rebetol (RBV)|PEG-Intron plus RBV treatment for up to 48 weeks with 24-week follow up. SCH 54031 PEG-Intron 1.5 ug/kg SC per week plus SCH 18908 REBETOL twice daily (BID) PO with food, dosed as followed: Weeks 1 and 2, RBV Dose 400 mg (2 capsules, 1 AM and 1 PM). At the end of Weeks 2 and 4 of Treatment (tx), a complete blood count (CBC) was performed. An increase in RBV dose was permitted only if the hemoglobin was >10 g/dL. At Weeks 3 and 4, RBV dose was 800 mg (4 capsules, 2 AM and 2 PM). From Weeks 5 to 48, RBV doses could be increased based on subject body weight. For subjects weighing <65 kg, maximum dose of RBV was to be 800 mg (4 capsules, 2 AM and 2 PM), for subjects weighing 65-85 kg, max dose of RBV was 1000 mg/day (5 capsules, 2 AM and 3 PM), for subjects weighing >85 kg, max dose of RBV was 1200 mg/day, 6 capsules, 3 AM and 3 PM).
89274489|NCT01046981|Experimental|Tumescent Antibiotic Delivery|TAD followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours
89274490|NCT01046981|Experimental|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours.
89274491|NCT00378209|Experimental|lenalidomide, dexamethasone, bortezomib combination|Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.
89274492|NCT01047059|Experimental|Trial Intervention|150mg Erlotinib daily, 15mg/kg b.w. Bevacizumab on d1, d22, d43 as medication FDG-PET, FLT-PET and DCE-MRI as diagnostical tools
89274493|NCT01045733|Experimental|IQ Toric IOL|AcrySof IQ Toric intraocular lens (IOL) randomly assigned to one eye, with AcrySof IQ Aspheric IOL with Limbal Relaxing Incision (LRI) procedure in the fellow eye for contralateral implantation.
89274494|NCT01045733|Active Comparator|IQ Aspheric IOL + LRI|AcrySof IQ Aspheric intraocular lens (IOL) with Limbal Relaxing Incision (LRI) procedure randomly assigned to one eye, with AcrySof IQ Toric IOL in the fellow eye for contralateral implantation
89274495|NCT00377819|Experimental|denosumab|
89274496|NCT00377819|Active Comparator|alendronate|
89274497|NCT03419962||COPD patients|Chronic obstructive pulmonary disease
89274498|NCT00377429|Experimental|catumaxomab|
89274499|NCT03715816|No Intervention|No breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory.
89274500|NCT03715816|Experimental|Passive breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they can have a rest.
89274501|NCT03715816|Experimental|Active breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they will be performing some mobilisation exercises for the back, shoulder, and neck.
89274502|NCT03992963|Active Comparator|Hearing Aid without frequency lowering enabled|
89274503|NCT03992963|Experimental|Hearing Aid with frequency lowering enabled|
89274504|NCT03713788|Experimental|Experimental pain group|subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. They were instructed to immerse it to wrist-level and keep the hand open.
89274505|NCT03713788|No Intervention|Control group|Participants rested in a seated position for 5 minutes.
89274506|NCT01047137|Placebo Comparator|Control|Participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention.
89274507|NCT01047137|Experimental|Intervention|Participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques.
89274508|NCT03715738|Experimental|arm 1 : Creaform3D + MyotonPRO|"A clinical questionnaire is completed by the investigator (chest circumference, thorax turn, breast measurements).~The breast density is assessed by the surgeon and scored from 1 to 5 (Likert scale) and then by the MyotonPRO The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair during 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~Intraoperatively, the weight of tissues removed is weighed (in grams), recorded in the observation notebook.~In post-operative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete"
89274509|NCT01047215|Active Comparator|Aripipazole|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
89274510|NCT01047215|Active Comparator|Quetiapine|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
88805569|NCT02543892|Placebo Comparator|Toddler Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
88805570|NCT00182000|Active Comparator|Seromycin|
89274511|NCT03715660|Experimental|Xpert monitor- evaluated patients|Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy.
89274512|NCT03713242|Experimental|Group A: ACT-541468 in subjects with mild hepatic impairment|Single oral dose administered on Day 1.
89274513|NCT03713242|Experimental|Group B: ACT-541468 in subj. with moderate hepatic impairment|Single oral dose administered on Day 1.
89274514|NCT03713242|Experimental|Group C: ACT-541468 in subjects with severe hepatic impairment|Single oral dose administered on Day 1.
89274515|NCT03713242|Experimental|Group D: ACT-541468 in healthy subjects.|Single oral dose administered on Day 1.
89274516|NCT03715582|Experimental|trimetazidine|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours before the procedure.
89274517|NCT03715582|Experimental|placebo|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When randomized to the placebo oral tablets group, the patient will receive placebo (orally, 2 single dose tablets) also 2 hours prior to PCI.
89274518|NCT00376961|Experimental|R-CHOP + Velcade|6 21-day cycles of standard R-CHOP with 1.3 mg/m^2 Bortezomib given on days 1 and 4 of each cycle. This is followed by 8 3-month cycles of maintenance with 1.3 mg/m^2 Bortezomib on days 1, 4, 8 and 11 of each cycle.
89274519|NCT03418324|Experimental|Arm A: TRC105 + Abiraterone|Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone
89274520|NCT03418324|Experimental|Arm E: TRC105 + Enzalutamide|Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide
89274521|NCT01047371||Patients with Osteoarthrosis|All consecutive patients scheduled for total hip or knee arthroplasty
89274522|NCT03713164|Active Comparator|Pomegranate Juice (PJ)|single dose of 8oz Pomegranate Juice (PJ)
89274523|NCT03713164|Active Comparator|Ellagic Acid (EA)|500 mg Ellagic Acid (EA) capsules
89274524|NCT00376259|Experimental|Combination therapy|Combination therapy: 600 mg of telbivudine (LdT) by mouth plus 10 mg of adefovir (ADV) by mouth once daily for 96 weeks.
89274525|NCT00376259|Active Comparator|Adefovir monotherapy|Adefovir monotherapy: 10 mg of adefovir by mouth once daily for 96 weeks.
89274526|NCT03715348|Active Comparator|Fresh Frozen Plasma (FFP)|"Patients randomised to the comparator arm will receive Fresh Frozen Plasma (FFP)~FFP will be provide as a solution for intravenous administration, once thawed.~The dose of the FFP will be ~ 15 mL/kg.~Subjects may receive multiple doses of FFP as required if bleeding continues, as per usual care"
89274527|NCT03715348|Experimental|Prothrombin Complex Concentrate (PCC)|"Patients randomised to the experimental arm will receive PCC at ~15 IU/kg. PCC will be reconstituted into a solution for intravenous administration.~Subjects will receive a single dose of PCC, and if bleeding continues, standard treatment will be administered"
89274528|NCT01324505|Experimental|One-sequence cross-over arm|
89274529|NCT01049321|Experimental|DASH diet|DASH: Dietary approaches to stop hypertension eating plan
89274530|NCT01049321|Placebo Comparator|Diabetic diet|Diabetic diet: a usual diabetic diet
89274531|NCT01049399|Placebo Comparator|Placebo|once daily administration of powder for oral suspension.
89274532|NCT01049399|Experimental|NP031112 800 mg|Group dosed with 800 mg once daily for 52 weeks
89274533|NCT01049399|Experimental|NP031112 600 mg|Group treated with 600 mg once daily for 52 weeks
89274534|NCT01049477|Experimental|Music therapy|Experimental arm includes women undergoing cesarean section delivery listening to music before and after c/s. STAI will be completed pre and post operatively.
89274535|NCT01049477|No Intervention|No music group|Subjects will not listen to music before and after c/s. STAI will be completed pre and post operatively.
89274536|NCT01041599||Diabetic patients|Hypertensive and normotensive patients with type 2 diabetes mellitus
89274537|NCT01041599||Hypertensive patients|Patients with essential hypertension
89274538|NCT01041599||Healthy subjects|Healthy subjects
89274539|NCT01041755|Experimental|Intravenous infusion of L- Ornithine L- Aspartate|a) 20 g L-ornithine-L-aspartate
89274540|NCT01041755|Active Comparator|Lactose enemas|b) 20% Lactose enemas
89274541|NCT02535143|Experimental|Test Group|Group will prepare a test cavity in an acrylic block. They will receive 250 ml of a commercially available energy drink containing caffeine and taurine (Red Bull, Red Bull GmBh Austria) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
89274542|NCT02535143|Placebo Comparator|Control Group|Group will prepare a test cavity in an acrylic block. They will receive 250ml of a commercially available carbonated apple juice (Appy Fizz, Parle Agro, Mumbai, India) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
89274543|NCT01049555|Other|Alzheimer and apathy|Alzheimer's disease patients with apathy
89274544|NCT01049555|Other|alzheimer without disease|Alzheimer's disease patients without apathy
89274545|NCT01049555|Other|Case control|subject without apathy neither Alzheimer's disease
89274546|NCT01041833|Experimental|atRA group|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
89274547|NCT01041833|Placebo Comparator|Placebo Group|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
89274548|NCT03410056|Placebo Comparator|Phase 1b: Placebo|Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).
89274549|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 1|A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
89274550|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 2|A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
89274551|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 3|A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
89274552|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 4|A medium/high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
89274553|NCT03410056|Placebo Comparator|Phase 2a: Placebo|Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.
89274554|NCT03410056|Experimental|Phase 2a: Efavaleukin alfa|Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.
89274555|NCT03409666|Experimental|Taperloc Complete Microplasty stem|Subjects in need of a total hip artthroplasty who received the Taperloc Complete Microplasty stem.
89274556|NCT03409666|Active Comparator|Taperloc Complete Reduced Distal stem|Subjects in need of a total hip arthroplasty who received the Taperloc Complete Reduced Distal stem.
89274557|NCT03715270||breast reconstruction surgery patients|Patients will be imaged with imaging device (Presygen™/si-1) during surgical procedure. Image surgical area. Surgical procedure will follow standard of care. No clinical decisions will be made on device readings. A surgeon will complete a survey regarding his assessment of the imaging device.
89274558|NCT03440944|Active Comparator|Ultrasound Guided Peripheral IV Catheter|Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.
89274559|NCT03440944|Active Comparator|Midline Catheter|Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.
89274560|NCT00365105|Active Comparator|Zoledronic acid|Zoledronic acid, vitamin D and calcium supplements.
89274561|NCT00365105|Experimental|Zoledronic acid + Radiopharmaceuticals|Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153.
89274562|NCT01041911|Active Comparator|Euphorbia 50 mg|This arm subjects will be given 50 mg Euphorbia prostrata
89274563|NCT01041911|Active Comparator|Euphorbia 100 mg|In this arm subjects will be given 100 mg Euphorbia
89274564|NCT01041911|Active Comparator|Euphorbia 200 mg|In this arm subject will be given 200 mg Euphorbia tablets
89274565|NCT01041911|Placebo Comparator|Placebo|In this arm subjects will be given placebo tablets
89274566|NCT00399893|Experimental|Octreotide|Octreotide to be administered by subcutaneous injection three times daily while on study
89274567|NCT00399893|Placebo Comparator|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
89274568|NCT03992027|Experimental|Immediate CF-CBT Intervention|This group will enter immediately into the 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT).
89274569|NCT03992027|Other|Waitlist control|This group will enter into the same 8-session cystic fibrosis-specific cognitive-behavioral intervention program (CF-CBT) 3 months after enrollment.
89274570|NCT04587479|Experimental|JAB-8263|Monotherapy, dose escalation
89274571|NCT01049711||erythropoietin|
89274572|NCT01042067||Warfarin treatment group|Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
89274573|NCT00048542|Experimental|Double-Blind Adalimumab + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received adalimumab plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
89274574|NCT00048542|Placebo Comparator|Double-Blind Placebo + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received placebo plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
89274575|NCT00048542|Experimental|Double-Blind Adalimumab|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received adalimumab, but no concomitant MTX treatment, during the Double-Blind Phase.
89274576|NCT00048542|Placebo Comparator|Double-Blind Placebo|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received placebo, but no concomitant MTX treatment, during the Double-Blind Phase.
88805571|NCT00182000|Placebo Comparator|Placebo|
89274577|NCT00048542|Experimental|OLE BSA Adalimumab + MTX|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), concomitantly with MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
89274578|NCT00048542|Experimental|OLE BSA Adalimumab|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), but not MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
89274579|NCT00048542|Experimental|OLE FD Adalimumab + MTX|Subjects received adalimumab concomitantly with MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
89274580|NCT00048542|Experimental|OLE FD Adalimumab|Subjects received placebo without concomitant MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
89274581|NCT03955328|Experimental|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
89274582|NCT03814590|Experimental|Group Low Dose_PLAIN_A|Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
88805572|NCT01092923|Experimental|Air/Oxygen|Sevoflurane with Air/Oxygen Mix
88805573|NCT01092923|Experimental|sevoflurane in N2O/O2|
88805574|NCT00267644||Hydrated patients|Group 1 (n=63) were pediatric patiens that wer hydrated.
89274583|NCT03814590|Experimental|Group Medium Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274584|NCT03814590|Experimental|Group High Dose_PLAIN_A|Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274585|NCT03814590|Placebo Comparator|Group Placebo_A|Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274586|NCT03814590|Experimental|Group Low Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274587|NCT03814590|Experimental|Group Low Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274588|NCT03814590|Experimental|Group Low Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274589|NCT03814590|Experimental|Group Medium Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274590|NCT03814590|Experimental|Group Medium Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274591|NCT03814590|Experimental|Group Medium Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274592|NCT03814590|Experimental|Group High Dose_PLAIN_B|Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274593|NCT03814590|Experimental|Group High Dose_AS01E_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274594|NCT03814590|Experimental|Group High Dose_AS01B_B|Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274595|NCT03814590|Placebo Comparator|Group Placebo_B|Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.
89274596|NCT01088568|Experimental|TICL group|
89274597|NCT01088568|Active Comparator|LASIK group|
89274598|NCT01085448|Other|Low back pain|Individuals with current low back pain.
89274599|NCT01583244||Patients with active rheumatoid arthritis|Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis
89274600|NCT01085526|Active Comparator|alutard phl prat. treatment group|18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured
89274601|NCT01085526|No Intervention|control group|control
89274602|NCT01085526|Active Comparator|alutard phl.prat., treatment group2|basophil activity, basophil biology measured
89274603|NCT01085604||Low back pain|Individuals with current low back pain attributed to poor trunk neuromuscular control (clinical instability).
89274604|NCT00048074|Experimental|1|oral placebo daily and IV ibandronate 2 mg q 2 mo
89274605|NCT00048074|Experimental|2|oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
88805575|NCT00267644||Dehydrated Group|Group 2 (n=13) were pediatric patients that were dehydrated.
88805576|NCT03013049|Active Comparator|Non cultured epidermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, non cultured epidermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and non cultured epidermal cell suspension will be done.
89274606|NCT00048074|Experimental|3|oral placebo daily and IV ibandronate 3 mg q 3 mo
89274607|NCT01102868|Sham Comparator|Needle in acupuncture point Li11|Acupuncture needle in the acupuncture point Li11
89274608|NCT01102868|Experimental|IMS of musculus pronator teres|Acupuncture needle in musculus pronator teres
89274609|NCT02529956|Experimental|UCB4940 8 mg|Single intravenous (iv) infusion of UCB4940 8 mg over at least 60 minutes.
89274610|NCT02529956|Experimental|UCB4940 40 mg|Single intravenous (iv) infusion of UCB4940 40 mg over at least 60 minutes.
89274611|NCT02529956|Experimental|UCB4940 160 mg|Single intravenous (iv) infusion of UCB4940 160 mg over at least 60 minutes.
89274612|NCT02529956|Experimental|UCB4940 480 mg|Single intravenous (iv) infusion of UCB4940 480 mg over at least 60 minutes.
89274613|NCT02529956|Experimental|UCB4940 640 mg|Single intravenous (iv) infusion of UCB4940 640 mg over at least 60 minutes.
89274614|NCT02529956|Placebo Comparator|Placebo|Single intravenous (iv) infusion of Placebo over at least 60 minutes.
89274615|NCT03831191|Experimental|50 mg LY3375880|"Induction Period:~Participants received 50 mg LY3375880 administered SC Q4W."
89274616|NCT03831191|Experimental|150 mg LY3375880|"Induction Period:~Participants received 150 mg LY3375880 administered SC Q4W."
89274617|NCT03831191|Experimental|600 mg LY3375880|"Induction Period:~Participants received 600 mg LY3375880 administered SC Q4W."
89274618|NCT03831191|Placebo Comparator|Placebo|"Induction Period:~Participants received placebo administered subcutaneously (SC) every 4 weeks (Q4W)."
89274619|NCT01102946|Experimental|PRP plus ranibizumab|Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab
89274620|NCT01102946|Active Comparator|PRP|Patients will only be submitted to panretinal photocoagulation
89274621|NCT03955094|Experimental|AMBU® AURAGAIN™ device|Assess feasibility of AMBU® AURAGAIN™ as an intubating device in paediatrics
89274622|NCT01103024|Experimental|AIN457 300mg s.c every 2 weeks|
89274623|NCT01103024|Experimental|AIN457 300mg s.c every 4 weeks|
89274624|NCT01103024|Experimental|AIN457 150mg s.c every 4 weeks|
89274625|NCT01103024|Placebo Comparator|Placebo s.c every 2 weeks|
89274626|NCT01103102|Active Comparator|Lowest Dose|
89274627|NCT01103102|Active Comparator|Intermediate Dose|
89274628|NCT01103102|Active Comparator|Highest Dose|
89274629|NCT01103102|Placebo Comparator|Placebo Control|
89274630|NCT02534831|Experimental|Soft Tissue Manual Therapy Protocol|Soft tissue manual therapy protocol. Seven techniques of manual therapy in 30 minutes.
89274631|NCT01049789|Active Comparator|TAU|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement TAU will receive that treatment method.
89274632|NCT01049789|Experimental|COMB|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement COMB will receive that treatment method.
89274633|NCT01103258|Active Comparator|high ligation and stripping|surgery consisting of high ligation in combination with long saphenous stripping
89274634|NCT01103258|Active Comparator|duplex guided foam sclerotherapy|duplex guided foam sclerotherapy
89274635|NCT01101386||Voriconazole|Pharmacokinetic Monitoring
89274636|NCT00005906|Experimental|Octreotide|Patients with lymphangioleiomyomatosis and lymphatic tumors, ascites or pleural effusions who are symptomatic will receive subcutaneous injections of octreotide starting at a dose of 100 micrograms per day. Doses will be gradually increased to a maximum of 800 micrograms per day, two months after enrollment, if there is no response to lower doses.
89274637|NCT01095614||12 women with oral contraception|
89274638|NCT01095614||12 women without any contraception|
89274639|NCT03951038|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with saline added up to a volume of 80ml in total ) and the equal volume of 0.9% normal saline will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
89274640|NCT03951038|Experimental|Lateral TLIPB group|Participants in this group will be conducted by ultrasound and receive a single injection between the longissimus and iliocostalis muscles both sides of the spine, and combined with PCIA post-operatively. The regimen of the Lateral TLIPB is 0.2% 20 ml ropivacaine respectively and the regimen of PCIA is same with PCIA group.
89274641|NCT03949010|Experimental|Kinesiotaping with space correction technique|
89274642|NCT03949010|Experimental|Kinesiotaping with muscle inhibition technique|
89274643|NCT03949010|Active Comparator|Home exercise program|
89274644|NCT01103336|Experimental|Nicorandil in saline|
89274645|NCT01103336|Placebo Comparator|saline|
89274646|NCT03950960|Experimental|BMS-986256 +Itraconazole|
89274647|NCT03955016|Experimental|Rehabilitation group|15 weeks pulmonary rehabilitation program consisting of 2 weeks inpatient, 2 weeks outpatient and 11 weeks home-based rehabilitation.
89274648|NCT03955016|No Intervention|Control group|Usual care
89274649|NCT03954860|Experimental|No Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. No drainage tube was placed after operation.
89274650|NCT03954860|Active Comparator|Drainage|The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. Drainage tube should be placed after operation.
89274651|NCT03949166|No Intervention|Fasting|After completion of an epidural block patients that agreed to participate in the study and were randomised to the fasting arm will be allowed to drink water and clear fluids during labor and delivery as accepted by the institute protocol.
89274652|NCT03949166|Experimental|Eating|After completion of an epidural block patients that agreed to participate in the study and were randomized to the eating arm will be allowed to eat during their labor and delivery. They will be provided with the list of food that was approved and accepted by the anesthesia team. They will be asked to try eating every 2 hours but if they feel lack of need to eat or any side effects preventing them to eat they can choose not to eat. When reaching full dilatation of 10cm they will ber asked to stop eating.
89274653|NCT01095692|Active Comparator|only surgery|
89274654|NCT01095692|Experimental|surgery + TOT|
89274655|NCT01103570|Experimental|group 1 cholecystocholangiography|cholangiography via gall bladder
89274656|NCT01103570|Experimental|group2 cystic duct cholangiography|cystic duct cholangiography
89274657|NCT03949088|Experimental|Linear descending UF profile|2-step descending Na profile, linear descending UF profile 3 weeks (9 sessions)
89274658|NCT03949088|Experimental|Run-in & washout phases|constant Na concentration, constant UF rate 3 weeks (6+3 sessions)
89274659|NCT03949088|Experimental|Ascending/descending UF profile|2-step descending Na profile, ascending/descending UF profile 3 weeks (9 sessions)
89274660|NCT03409276|Experimental|Group 1 (Treatment): Protein Vaccine/GLA-SE|Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Month 2.
89274661|NCT03409276|Placebo Comparator|Group 1 (Control)|Participants will receive placebo at Day 0 and Month 2.
89274662|NCT03409276|Experimental|Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.
89274663|NCT03409276|Placebo Comparator|Group 2 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
89274664|NCT03409276|Experimental|Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE|Participants will receive 2 mg of the env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Months 1, 3, 6, and 8.
89274665|NCT03409276|Placebo Comparator|Group 3 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
89274666|NCT00004562|Active Comparator|Optimal Medical Therapy Only (MED)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification
89274667|NCT00004562|Experimental|Percutaneous Coronary Intervention (PCI)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting
89274668|NCT00004412|Other|Standard local care dressing|Each subject provided his/her own dressing e.g,standard local care includes cleaning, saline irrigation, dressing changes only for 8 weeks twice a week.
89274669|NCT00004412|Experimental|Arginine Butyrate|Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.
89274670|NCT00004412|Other|Crossover|Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed & traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.
89274671|NCT03715192|Experimental|LY3462817 - IV|Escalating doses of LY3462817 administered as a single intravenous (IV) infusion in healthy participants
89274672|NCT03715192|Placebo Comparator|Placebo|Normal saline administered as a single IV infusion in healthy participants
89274673|NCT03715192|Experimental|LY3462817 - SC|Single dose of LY3462817 administered as subcutaneous (SC) injections in healthy participants
89274674|NCT03713008|Experimental|Fluid bolus|Patients included in the study will receive fluid bolus.
89274675|NCT03715114|Experimental|GV-971 900 mg|900 mg oral
89274676|NCT03715114|Experimental|GV-971 1200 mg|1200 mg oral
89274677|NCT03715114|Experimental|GV-971 1500 mg|1500 mg oral
89274678|NCT03715114|Placebo Comparator|Placebo|Oral placebo
89274679|NCT01311232||Case|Patients with HBV reactivation
89274680|NCT01311232||Control|Patients without HBV reactivation
89274681|NCT03440320|Experimental|MY-Skills Intervention - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
89274682|NCT03440320|Active Comparator|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
89274683|NCT01091532|Experimental|Cohort 1|Subjects will be assigned to receive either UK-396,082 or placebo
89274684|NCT01091532|Experimental|Cohort 2|Subjects will be assigned to receive either UK-396,082 or placebo
89274685|NCT01091532|Experimental|Cohort 3|Subjects will be assigned to receive either UK-396,082 or placebo
89274686|NCT01091532|Experimental|Cohort 4|Subjects will be assigned to receive either UK-396,082 or placebo
89274687|NCT05621200|Active Comparator|Transcranial direct current stimulation (tDCS)|Single session of anodal tDCS at 2 mA over the cerebellar hemispheres
89274688|NCT05621200|Active Comparator|Transcranial alternate current stimulation (tDCS)|Single session of gamma tACS (50 Hz) at 3 mA over the cerebellar hemispheres
89274689|NCT05621200|Sham Comparator|Placebo stimulation (sham)|Single session of sham tDCS over the cerebellar hemispheres
89274690|NCT01091610||1|all emergency medical staff having suffered an accident during work
89274691|NCT01091610||2|non emergency medical personnel having suffered an injury due to a medical mission, e.g. transported patient having suffered additional injury due to an ambulance accident or collision of an ambulance with another vehicle.
89274692|NCT03712774||neoadjuvant chemoradiation|Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
89274693|NCT03712774||definitive chemoradiation|Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
89274694|NCT00004088|Experimental|HD chemotherapy followed by PBPC Rescue|Patients receive high-dose (HD) melphalan intra-venously (IV) on day -1. Peripheral blood progenitor cells (PBPCs) are reinfused on day 0. Filgrastim (G-CSF) is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive IV high-dose busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBPCs are reinfused on day 0 and G-CSF is administered IV or subcutaneously (SC) daily until blood counts recover.
89274695|NCT01091688|Experimental|Just-in-Time intervention|"The infants and physicians in the experimental group will receive the Just-in-Time intervention sheets at the time of discharge."
89274696|NCT01091688|No Intervention|Routine discharge care|The infants and physicians in the routine discharge care arm will receive the same information and details as is per normal routine in the nursery.
89274697|NCT03962322|Experimental|Weaning TDI|A tissue doppler evaluation, using a sector transducer, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration in the modality of ventilation which precedes the trial, during the SBT and after extubation.
89274698|NCT03439072|Other|G-Pen followed by Lilly Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
89274699|NCT03439072|Other|Lilly Glucagon followed by G-Pen|1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
89274700|NCT01095770|Active Comparator|Ablation Frontiers Ablation|This group will undergo AF ablation using Ablation Frontiers Technology.
89274701|NCT01095770|Active Comparator|LASSO ablation|This group will undergo atrial fibrillation ablation with traditional LASSO technology
89274702|NCT01095770|Active Comparator|Reveal XT monitoring|This group will be monitored pre and post ablation using a Reveal XT implantable loop recorder.
89274703|NCT01095770|Active Comparator|Permanent Pacemaker - dual chamber|This group will be monitored pre and post ablation with a dual chamber permanent pacemaker
89274704|NCT03712696|Experimental|DIGNICAP™|DigniCap® System
89274705|NCT03717220|Other|flaps|flap transferring is used for reconstruction of multiple small-to-moderate soft-tissue defects
89274706|NCT01085838|Experimental|Cohort 1|The first cohort of 5 patients will start with a dosage of 100 mg erlotinib daily
89274707|NCT01085838|Experimental|Cohort 2|The second cohort of patients will receive 150 mg of erlotinib daily
89274708|NCT01085838|Experimental|Cohort 3|The third cohort of five patients will be enrolled to receive 300 mg of erlotinib daily
89274709|NCT03715036|No Intervention|Fundal height|Patients will have routine fundal height measurement
89274710|NCT03715036|Experimental|Point-of-care US|Patients will receive POC US for DVP and AC.
89274711|NCT00003896|Experimental|Paclitaxel/cisplatin/Liposomal Doxorubicin|paclitaxel, cisplatin and liposomal doxorubicin
89274712|NCT01091766|Active Comparator|bupivacaine|test solution consists of bupivacaine 0.125%
89274713|NCT01091766|Active Comparator|bupivacaine+epinephrine|test solution consists of bupivacaine 0.125% with epinephrine 1:200000
89274714|NCT01091766|Active Comparator|epinephrine|test solution consists of epinephrine 1:200000
89274715|NCT03712540|Experimental|BMS-986278 + Rifampin|Treatment period A: BMS-986278 alone Treatment period B: Rifampin followed by BMS-986278
89274716|NCT01091844|Active Comparator|Spontaneous Fill Technique|"We allow the bladder to spontaneously fill, then allow the patient to void and afterward catheterize the patient to check a postvoid residual (spontaneous fill technique)."
89274717|NCT01091844|Active Comparator|Retrograde Fill Technique|"We assess bladder emptying by filling the bladder retrograde through the catheter already in place with 300 mL of saline and then removing the catheter and allowing the patient to void (retrograde-fill technique). We will determine postvoid residual indirectly by subtracting voided volume from the 300 mL infused volume. No catheterization will be performed with this technique unless they void less than 200 mL."
89274718|NCT03714802|Experimental|Szabo T-Stenting Technique|Patients received 2-stents implantation guided with Szabo technique in bifurcation lesion.
89274719|NCT03714802|Placebo Comparator|T-Stenting Technique|Patients received 2-stents implantation guided with T-stenting technique in bifurcation lesion.
89274720|NCT00003830|Active Comparator|Arm I: Conventional axillary dissection|Sentinel node resection immediately followed by axillary dissection
89274721|NCT00003830|Experimental|Arm II: Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.
89274722|NCT03714724|Active Comparator|Group 4|"Patients who received 0-4 cmH2O PEEP in mechanical ventilation were referred to as Group 4.~Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded."
89274723|NCT03714724|Active Comparator|Group 8|Patients who received 5-8 cmH2O PEEP in mechanical ventilation were referred to as Group 8. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
89274724|NCT03714724|Active Comparator|Group 12|Patients who received 9-12 cmH2O PEEP in mechanical ventilation were referred to as Group 12. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
89274725|NCT03638986||Swiss version first|This group will first complete the Swiss version and second the German version of the TFI
89274726|NCT03638986||German version first|This group will first complete the German version and second the Swiss version of the TFI
89274727|NCT03714646|Placebo Comparator|Placebo|
89274728|NCT03714646|Active Comparator|beta glucan|
89274729|NCT03714646|Experimental|beta glucan and Resistant Starch|
89274730|NCT03712384||Young adult with severe anorexia|Young adult with severe Anorexia hospitalized during adolescence at Institut Mutualiste Montsouris
89274731|NCT03714568|Experimental|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
89274732|NCT03714568|Experimental|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
89274733|NCT05472220|Experimental|Phase 1: Dose Escalation|Patients with advanced solid tumors will be adminsitered Alpelisib and Carboplatin in 21 day cycles until unacceptable toxicity, disease progression or death. At baseline, patients will undergo cross-sectional imaging of the abdomen with HP13C. Participants will wear a glucose monitor for the first two treatment cycles.
89274734|NCT05472220|Experimental|Phase 2: Dose Expansion|Patients with HPV+ squamous cell carcinoma will be administered the recommended phase 2 dose of Alpelisib and Carboplatin in 21 day cycles until unacceptable toxicity, disease progression or death. At baseline, patients will undergo cross-sectional imaging of the abdomen with HP13C. Participants will wear a glucose monitor for the first two treatment cycles
89274735|NCT03407482|Experimental|GDC-0853 (200mg) BID|Participants previously enrolled in the parent GA30044 Study, now received GDC-0853 (200mg) orally twice daily (BID).
89274736|NCT00003782|Experimental|Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel|Doxorubicin + Cyclophosphamide, then Docetaxel
89274737|NCT00003782|Experimental|Arm 2: Doxorubicin + Docetaxel|Doxorubicin + Docetaxel
89274738|NCT00003782|Experimental|Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide|Doxorubicin + Docetaxel + Cyclophosphamide
89274739|NCT03389308|Experimental|Treatment period|"Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying diacerein 1% ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.~Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.~The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject."
89274740|NCT03714490|Experimental|Experimental group|The intervention of Experimental group includes: Radiotherapy, followed by chemotherapy with capecitabine, oxaliplatin, and then surgery. The detail of procedure: 1, short-course preoperative radiotherapy(SCPRT) , which consists of SCPRT, 5 Gray(Gy) x 5, 4Gy for boost on the gross tumour volume(GTV) with MRI-simulation alone; 2,then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy.
89274741|NCT03714490|Active Comparator|Control group|The intervention of Control group includes:Radiotherapy, capecitabine, and surgery. The detail of procedure: 1, long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively; 2, 6-8 weeks after chemoradiation, total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends.
89274742|NCT03407170|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months
89274743|NCT01103648|Active Comparator|Simvastatin arm|A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
89274744|NCT01103648|Active Comparator|Ezetimibe arm|A subset of individuals started the study period taking monotherapy with ezetimibe. After a 12-week period, simvastin was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
89274745|NCT01103648|Experimental|Simvastatin-Ezetimibe arm|To each subset of individuals which started the study period taking monotherapy with simvastatin or ezetimibe (active comparators), the other drug (ezetimibe or simvastatin, respectively) was combined for more 12 weeks (combination period = experimental arm).
89274746|NCT05625620|Experimental|Experimental: Real tPCS|All patients will be randomized into daily cerebello- spinal tPCS or sham stimulation. Randomization will occur in a ratio of 1:1. Real tPCS arm will receive active tPCS. Then they will be crossed over to Sham tPCS arm.
89274747|NCT05625620|Experimental|Sham tPCS|All patients will be randomized into daily cerebello- spinal tPCS or sham stimulation. Randomization will occur in a ratio of 1:1. Sham tPCS arm will receive active tPCS. Then they will be crossed over to Real tPCS arm.
89274748|NCT05625464|Experimental|Intervention|Received SCTP monitoring and standard of care
89274749|NCT05625464|No Intervention|Control|Received standard of care only
89274750|NCT03406858|Experimental|Treatment (pembrolizumab, HER2Bi-armed activated T cells)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.
89274751|NCT01095848|Experimental|0.25ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
89274752|NCT01095848|Experimental|1ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
89274753|NCT05621330|Experimental|QL0911|
89274754|NCT05621330|Placebo Comparator|Placebo|
89274755|NCT01095926|Experimental|Doxorubicin|
89274756|NCT01103726|Experimental|Stage 1|
89274757|NCT01103726|Experimental|Stage 2|
89274758|NCT01584986|Active Comparator|ACP treated|Autologous angiogenic cell precursors (ACPs) were injected into the ischemic gastrocnemius muscle in addition to the conventional treatment.
89274759|NCT01584986|No Intervention|Control|Control patients were treated with the conventional therapy.
89274760|NCT01585064||DAS28-IOMS|Physicians randomized to the DAS28-IOMS will treat patients according to a protocol aimed at achieving a DAS28 score under 2.4.
89274761|NCT01585064||0SJ-IOMS|Physicians randomized to the 0SJ-IOMS will treat patients according to a protocol aimed at attaining a count of zero swollen joint (28 joints evaluated).
89274762|NCT01585064||Routine Care (RC)|Physicians randomized to the RC group will treat study patients as per routine care and according to their own judgment.
89274763|NCT01585142|Experimental|BabyNes system formula|
89274764|NCT03406702|Experimental|CX-8998|T-type calcium channel blocker
89274765|NCT00003656|Experimental|All subjects|Weekly ATRA-IV with recombinant interferon alfa
89274766|NCT00003590|Experimental|Hydroxyurea|
89274767|NCT01327430|Experimental|Phospholipid supplementation|Supplementation of milk phospholipid
89274768|NCT03948620||Children whose mother prescribed antibiotics during pregnancy|"Children whose mother were prescribed an only monotherapy of macrolides or penicillins from 5 gestational weeks (GW) to delivery. A monotherapy is defined as one or more consecutive prescriptions for a single antibiotic (i.e. same drug substance) separated by no more than 30 days and uninterrupted by prescriptions for other antibiotic drug substances.~The investigators will also build a negative control cohort which includes children whose mother were prescribed an only monotherapy of macrolides or penicillins from 50 to 10 weeks before conception."
89274769|NCT01096004|Experimental|1|
89274770|NCT01096004|Placebo Comparator|2|
89274771|NCT03948542||Outcome|Nerve conduction studies (NCV) Functional assessment according to Daniels and Worthingham
89274772|NCT03416374|Experimental|Combination Therapy + Ixazomib Therapy|Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)
89274773|NCT03799952|Experimental|Intervention|Participants are offered to attend a 12-week exercise program, classes offered twice a week, each class 60 minutes in length.
89274774|NCT03799952|No Intervention|Control|"Participants are instructed to continue with their daily activities and their normal physical activity levels for 12-weeks."
89274775|NCT00077766|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants will be administered with RO0503821 ([methoxy polyethylene glycol-epoetin beta] {Mircera}) intravenously (IV), every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram [µg]) was based on the dose of darbepoetin alfa at the time of randomization (< 40, 40 to 80, or > 80 µg per week, respectively).
89274776|NCT00077766|Active Comparator|Darbepoetin (1x/1-2 Weeks)|Eligible participants will be administered with darbepoetin alfa IV, every week or every 2 weeks during Weeks 1 through 52.
89274777|NCT03714412|Experimental|Implantation|Eligible patients will undergo implantation with the Cardiovalve system
89274778|NCT04149912||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
89274779|NCT01096082|Placebo Comparator|Placebo|
89274780|NCT01096082|Experimental|Lithium Carbonate|
89274781|NCT03388138|Active Comparator|K-Lens|etafilcon A with ketotifen. Subjects between the ages of 18-40 will be randomized into the K-Lens arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
89274782|NCT03388138|Placebo Comparator|Placebo Contact Lens|1-Day Acuvue. Subjects between the ages of 18-40 will be randomized into the Placebo arm and will be scheduled for a total of two study visits with approximately 6-9 days in between.
89274783|NCT05613530|Experimental|"digital MAX néonat (intervention group or  MAX + group)"|"Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes."
89274784|NCT05613530|Active Comparator|"MAX néonat on poster/paper (control group or  MAX - group)"|Participants have no cognitive aid
89274785|NCT01327586|Experimental|ATM|Advisor-Teller Money Manager
89274786|NCT01327586|Active Comparator|Individual Drug Counseling|
89274787|NCT01101620|Active Comparator|Levosimendan|
89274788|NCT01101620|Placebo Comparator|Placebo|
89274789|NCT03954548|Experimental|With CB-17-08 CADe|
89274790|NCT03954548|No Intervention|Without CB-17-08 CADe|
89274791|NCT02952898|Experimental|Test Drug|GDC 695 gel applied topically as directed.
89274792|NCT02952898|Active Comparator|Reference Drug|Diclofenac sodium gel, 3% applied topically as directed.
89274793|NCT02952898|Placebo Comparator|Placebo|Vehicle gel applied topically as directed.
89274794|NCT01101698|Active Comparator|Vitamin K2, calcification score changes, vitamin D|90 μg vitamin K2+10μg cholecalciferol
89274795|NCT01101698|Active Comparator|Vitamin D, calcium score changes|10μg cholecalciferol (vitamin D)
89274796|NCT05563142|Experimental|Group Perclose ProStyle closure|50 patients treated with Perclose ProStyle suture-mediated closure device to achieve hemostasis
89274797|NCT05563142|Active Comparator|Group manual compression|50 patients treated with manual compression and one figure of eight suture
89274798|NCT05592886|Experimental|Intervention arm|Receive SMT04 formula
89274799|NCT05592886|Placebo Comparator|Placebo arm|Receive active placebo
89274800|NCT05592340|Active Comparator|Control|Calorie labels shown on online restaurant menu
89274801|NCT05592340|Experimental|Carbon footprint labels|Carbon footprint labels shown on online restaurant menu next to every item in addition to calorie labels
89274802|NCT00045734|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study/ laboratory biomarker analysis"
89274803|NCT05513768||women who gave birth prematurely|women who had serum taken in the first trimester and gave birth earlier than 37 weeks according to the time of delivery
89274804|NCT05513768||those who gave birth on time|women who have had serum taken in the first trimester, stored and delivered on time
89274805|NCT03387046|Experimental|D-aspartate + IFN beta-1a + Methylprednisolone|Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
89274806|NCT03387046|Placebo Comparator|Placebo + IFN beta-1a + Methylprednisolone|Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
89274807|NCT03712306|No Intervention|Control group|No intervention. Participants will only receive a brochure on general healthy eating habits.
89274808|NCT03712306|Experimental|Dietary advice|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products.
89274809|NCT03712306|Experimental|Dietary advice and advice on timing|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products, as well as advice regarding the consumption of protein rich food products in close proximity of usual physical activity.
89274810|NCT00045110|Experimental|Phase 1 Dose Escalation|"Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~erlotinib hydrochloride given orally~Other: pharmacological study."
89274811|NCT00045110|Experimental|Phase 2 recurrent malignant gliomas and nonprogressive GBM|"Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose (150mg/day.~patients requiring surgery treated 7 days prior to tumor removal (150mg/day)~PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)~erlotinib hydrochloride given orally~Other: pharmacological study, laboratory biomarker analysis."
89274812|NCT03353740|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
89274813|NCT04814602|Active Comparator|Control|Healthy controls Proglumide 400 mg given once by mouth
89274814|NCT04814602|Experimental|Hepatic Impaired|Cirrhosis Child-Pugh A and B Proglumide 400 mg given once by mouth
89274815|NCT01311466|Experimental|Liver transplantation|The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital
89274816|NCT00003476|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89274817|NCT00003470|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89274818|NCT03948308|Experimental|Interventional arm|blood sample before, during and after treatment for infection
89274819|NCT01104038|Active Comparator|Nutrition Education/Lifestyle Counseling|Children in this group will receive weekly group nutrition sessions , 30 minutes per week for 12 weeks, identical to those provided for the EXCEL intervention group and delivered by a registered dietician.
89274820|NCT01104038|Experimental|EXCEL|The EXCEL arm is the experimental arm of the study. Participants in this arm will receive supervised physical activity in the form of novel gaming (technology-mediated physical activity, 60 minutes per session, three times per week , for 12 weeks and 12 weeks of group nutrition education sessions.
89274821|NCT01104194|Experimental|Fish-oil|
89274822|NCT01104194|Placebo Comparator|Placebo|Olive oil capsules, identical in appearance to fish oil capsules
89274823|NCT01327664|Experimental|AIN457 300mg s.c every 2 weeks|
89274824|NCT01104272|Experimental|Energy Level 1|Subcutaneous Adipose Tissue Treated With Energy Level 1.
89274825|NCT03386344|Placebo Comparator|Placebo|Following a 2 week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 106 weeks.
89274826|NCT03386344|Experimental|Sotagliflozin 200 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
89274827|NCT03386344|Experimental|Sotagliflozin 400 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
89274828|NCT00399035|Placebo Comparator|FOLFOX + placebo Cediranib|FOLFOX + placebo Cediranib
89274829|NCT00399035|Placebo Comparator|Xelox + placebo Cediranib|Xelox + placebo Cediranib
89274830|NCT00399035|Experimental|FOLFOX + Cediranib|FOLFOX + Cediranib
89274831|NCT00399035|Experimental|XELOX + Cediranib|XELOX + Cediranib
89274832|NCT00073749|Experimental|Inotuzumab ozogamicin|Inotuzumab ozogamicin, iv, dose escalation and expanded cohort at 1.8mg/m2
89274833|NCT03960801|Experimental|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
89274834|NCT03960801|Active Comparator|Neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
89274835|NCT01089699|Active Comparator|Professionally-led online support|Members assigned to 10-week online support group with a professional counsellor.
89274836|NCT01089699|Active Comparator|Peer-led online support|
89274837|NCT01089699|Active Comparator|self-study materials|
89274838|NCT02530827||LIPO-HIPO-|HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
89274839|NCT02530827||LIPO+HIPO-|HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
89274840|NCT02530827||LIPO+HIPO+|HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
89274841|NCT00398567|Experimental|Part 1 - dose level 1 (160 mg)|All subjects receiving HKI-272 dose level 1 in combination with trastuzumab
89274842|NCT00398567|Experimental|Part 1 - dose level 2 (240 mg)|All subjects receiving HKI-272 dose level 2 in combination with trastuzumab
89274843|NCT00398567|Experimental|Part 2 - expanded MTD cohort|All subjects receiving HKI-272 in combination with trastuzumab
89274844|NCT05842226|Experimental|Intervention group|Micro-teaching enriched with standard patient will be applied.
89274845|NCT05842226|No Intervention|Control group|The control group will receive palliative care brochure for patients and their relatives.
89274846|NCT05842018|Experimental|Toripalimab, Chemotherapy and Antiangiogenic Agents|
89274847|NCT05842005|Experimental|Mesh-reduced Sling|Mesh-reduced sling will improve stress urinary incontinence (SUI) symptoms in women with SUI and normal urethral closure pressure at 2 months and 12 months after surgery.
89274848|NCT05841992|Experimental|Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CTscan|Patients of Prostate cancer PET/CT imaging: In two consecutive days each patient underwent a PET/CT scan after intravenous administration of 68Ga-PSMA617 and Al18F-PSMA-617, respectively.
89274849|NCT05841966|Experimental|Intraoperative Transoral Ultrasound|Transoral ultrasound of the tonsils and tongue base under general anesthesia.
89274850|NCT05841901|Experimental|Huang-long Zhi-xiao Granule|Huang-long Zhi-xiao Granule, Honey ephedra 6g, shot dried 10g, earth dragon 10g, Ganoderma lucidum 20g, Qianhu 12g, perilla seed 10g, Zhejiang fritillary 9g, soaphorn thorn 9g, scorched mulberry white peel 20g, fried white nuts 10g, fructus nume 10g, licorice 6g.
89274851|NCT05841901|Placebo Comparator|Huang-long Zhi-xiao Granule placebo|The Huang-long Zhi-xiao Granule placebo is prepared by adding 5% of the drug on the basis of dextrin and bitter agent, and its appearance, weight, color and smell are consistent with Chinese medicine granules.
89274852|NCT05841888||Group 1|standard perioperative care (SC)
89274853|NCT05841888||Group 2|Enhanced Recovery after Surgery (ERAS)
89274854|NCT05841875|Experimental|C reactive protein|For the patients assigned to the intervention group, the attending physicians will be instructed to follow a flowchart created by the research team that uses clinical variables and the serum CRP value to guide the prescription and the duration of antibiotic therapy, that will be available in the application for mobile devices developed specifically for this study. Antibiotic suspension will be encouraged when CRP value is < 35mg/L and after a minimal duration of 3 days (if peak CRP is below 100mg/L), or when CRP value reduces by 50% and after a minimal duration of 5 days (if peak CRP is above 100mg/L or if the patient fills the criteria for sepsis or septic shock). Before suspension, the physician will be instructed to make sure the patient is in clinical improvement, without any signs of persistent infectious focus and if the Sequential Organ Failure Assessment (SOFA) score is stable or in decrease.
89274855|NCT05841875|No Intervention|Best practice|For patients in the control group, it will be encouraged that the prescription and duration of antimicrobial therapy be carried out in accordance according to the best current evidence avaiable. Through the digital clinical decision support tool, the therapy duration for each participant will be suggested, based on the infectious focus and response to treatment. Such recommendations will be based on best practices for the use of antibiotic therapy available in the medical literature. As well as in the intervention group, the final responsibility for the prescription, choice of antibiotic treatment regimen(s) and duration of treatment will be entirely with the assistant team. For participants allocated to the control group, it will be recommended to stop monitoring CRP levels after 72 hours of antibiotic therapy, a period in which this biomarker can help in the diagnosis of the infectious condition.
89274856|NCT05841849|Experimental|oral group|patients receive oral palonosetron and aprepitant
89274857|NCT05841849|Active Comparator|intravenous group|patients receive intravenous palonosetron and fosaprepitant
89274858|NCT05841836|Experimental|the Suture-Mediated Closure System|Produced by Zhejiang Zylox Medical Device Co., Ltd.
89274859|NCT05841836|Active Comparator|Perclose ProGlide Suture-Mediated Closure System|Perclose® ProGlide Suture-Mediated Closure System
89274860|NCT05841823|Experimental|Virtual reality exposure therapy (VRET)|In this group, each session of VRET will last 25 minutes and consists of three parts: 5 minutes of relaxation, 10 minutes of exposure to high-risk situation and 10 minutes of exposure to aversive situation. Each participants will receive 20 sessions of VRET, 5 sessions per week for 4 weeks.
89274861|NCT05841823|Active Comparator|Acceptance and commitment therapy (ACT)|In this group, participants will receive a 50-minutes ACT session per week for 4 weeks. Hence, a total of 4 sessions will be administered to each participant.
89274862|NCT05841823|No Intervention|Treatment-as-usual control (TAU)|While for the control group, participants will receive non-specific ingredients of the psychotherapeutic approach schedule at a 50-minutes session per week for 4 weeks.
89274863|NCT05841771|Experimental|AZA-VEN maintenance|hypomethylating agents (azacytidine 32mg/m2 or decitabine 5mg/m2) for 5 days and venetoclax 400mg/d for 7 days, repeated every 28 days until up to 1-year posttransplant.
89274864|NCT05841745||Robotically-Assisted Percutaneous Coronary Intervention|All patients older than 18 years, who underwent R-PCI (defined as completion of at least one procedural step robotically) with the CorPath GRX System (Corindus Vascular) and completed one-year follow-up including patients with either stable coronary artery disease, unstable angina, or acute myocardial infarction (MI).
89274865|NCT05841732|Other|Usual Care|"Participants allocated to the usual care group will be informed that they can access their GP in the usual way (GPs consultation, pain medication, referral for other treatments/ services) and that they should contact their GP if their condition worsens. In addition, they will receive a minimal educational intervention focused on symptom management and promotion of physical activity (stay active)."
89274866|NCT05841732|Experimental|MyBack|Patients in the MyBack group will participate in a patient-centred, tailored exercise programme informed by a behavioural change approach in addition to receiving usual care. The MyBack intervention programme will consist of 12 bi-weekly sessions (60 minutes each) over 6 weeks complemented by 12 exercise sessions to be carried out autonomously by the participants over the following 6 weeks
89274867|NCT05841680|No Intervention|Waitlist Control|Participants complete pre, post, and follow-up questionnaires. They have the option to view the SSI module after completing follow-up questionnaires.
89274868|NCT05841680|Active Comparator|Single Session Intervention Receivers|Participants complete pre then receive the SSI module. Then they complete post and follow-up questionnaires.
89274869|NCT05841654|Experimental|Azilsartan treatment group|In the Azilsartan group, Azilsartan will be added in or switched to the original antihypertensive treatment plan, starting as 20 mg Qd, and gradually increased to 40 mg Qd according to the blood pressure. If the blood pressure is still not be controlled, antihypertensive drugs other than ACEI, ARB or ARNI will be added until the blood pressure is controlled.
89274870|NCT05841654|Active Comparator|Conventional treatment group|In the routine treatment group, antihypertensive treatment programs other than ACEI, ARB or ARNI will be adopted, and the use of antihypertensive drugs will be adjusted until the blood pressure control is controlled.
89274871|NCT05841641|Experimental|Laser Bandage|Graft site charred with Diode Laser at 5 Watts to created charred layer
89274872|NCT05841641|Experimental|Hemostatic agent with surgical stent|Graft donor site secured with hemostatic agent with surgical stent
89274873|NCT05841602||study group|8-13 age group (N=128).
89274874|NCT05841589|Experimental|Green tea extract mouth rinse|group green tea extract
89274875|NCT05841589|Experimental|Garlic with lime extract mouth rinse|garlic with lime extract
89274876|NCT05841589|Experimental|Pomegranate extract mouth rinse|pomegranate extract
89274877|NCT05841589|Experimental|Chlorhexidine mouth rinse|chlorhexidine
89274878|NCT05841576|Experimental|COMET monitoring device|Anaesthetists for patients allocated to the intervention group were asked to strive and maintain the intraoperative mitoPO2 to the individualised preoperative baseline mitoPO2 with a minimum of 66 mmHg
89274879|NCT05841576|No Intervention|Control group|Patients allocated to the control group were treated as per anaesthetist preference and followed our institution's conventional care
89274880|NCT05841498|Active Comparator|Immunoadsorption|"Immunoadsorption will be conducted with the Plasauto Sigma extracorporeal therapy system in combination with the TR-350 adsorber over 7 days (3 times daily, 2 times every other day). During each session 2-2.5 times the participant's plasma volume will be treated. This therapy regimen is proven by studies with groups of patients suffering from other autoimmune diseases (Boedecker, Luessi et al. 2022). The material needed for the immunoadsorption is provided by Diamed, the provider of Plasauto Sigma and TR-350 adsorber. To exclude possible beneficial or adverse effects of heparin on participants' symptoms, regional anticoagulation will be performed using citrate.~This is a cross-over study: Each participant will receive immunoadsorption and sham treatment with a wash-out period of 8 weeks in between."
89274881|NCT05841498|Sham Comparator|Sham-apheresis|The sham procedure will also be conducted with the Plasauto Sigma extracorporeal therapy system without an inserted adsorber. To ensure that sham treatment is indistinguishable from immunoadsorption for the subjects, the therapy regimen is identical except for the missing adsorber. For both verum therapy and sham procedure, the devices are placed behind a portable wall and covered with a curtain not visible to the patient. However, since the setup of the machines differs depending on the procedure, it is not possible to blind the supervising staff as well. To exclude possible beneficial or adverse effects of heparin on participants' symptoms, regional anticoagulation will be performed using citrate. If a subject does not have sufficiently large peripheral veins, a large-bore central venous catheter will be placed for both IA and sham treatments.
89274882|NCT05841446|Experimental|Test/reference|Subjects first receive a single-dose of 2.5mg test apixaban tablet (T, produced by Disha Pharmaceutical Group Co., Ltd. China) in the first treatment period and to receive the reference (R, Bristol-Myers Squibb Manufacturing Company,USA )in the second treatment period.
89274883|NCT05841446|Experimental|Reference/test|Subjects first receive a single-dose of 2.5mg reference apixaban tablet (R, Bristol-Myers Squibb Manufacturing Company, USA )in the first treatment period and to receive test tablet (T, produced by Disha Pharmaceutical Group Co., Ltd. China) in the second treatment period.
89274884|NCT05841407|Experimental|High nitrate|High nitrate isotonic drink
89274885|NCT05841407|Active Comparator|No nitrate|No nitrate isotonic drink
89274886|NCT05841394|Active Comparator|Esomeprazole Sodium|40 mg twice daily (q12h)
89274887|NCT05841394|Experimental|Ilaprazole Sodium|10 mg once daily, 20 mg dosed in the first day.
89274888|NCT05841381|Experimental|arm 1|Pyrotinib Plus trastuzumab and paclitaxel
89274889|NCT05841381|Active Comparator|arm 2|trastuzumab and paclitaxel
89274890|NCT05841368||Adult ICU patients|Adult patients in ICU setting
89274891|NCT05841368||Pediatric ICU patients|Pediatric patients in ICU setting
89274892|NCT05841342||Healthy Control|Healthy male or female aged 2-80 years with negative EBV-DNA quantitative test results within the last week.
89274893|NCT05841342||CAEBV or EBV-HLH Patients|"Patients aged 2-80 years who fulfilled the diagnostic criteria for CAEBV or EBV-HLH.~The diagnostic criteria for CAEBV as defined in the recently revised World Health Organization classification include persistent IM-like symptoms for more than three months, increased EBV DNA (>10^2.5 copies/mg) in peripheral blood, histological evidence of organ disease, and EBV RNA or viral protein in affected tissues.~Patients diagnosed with EBV-HLH must meet five of the following eight HLH-2004 diagnostic criteria:~temperature 38.5 ℃ and above;~splenomegaly;~two or three lines of hemocytopenia, i.e. hemoglobin (HB) <90 g/L, platelets (PLT) <100 × 10^9/L or neutrophils (N) <1 × 10^9/L;~triacylglycerol (TG) ≥ 3 mmol/ L or fibrinogen (Fbg) <1.5 g/L;~serum ferritin (SF) ≥ 500 mg/L;~phagocytosis found in bone marrow, spleen, liver or lymph nodes;~soluble CD25 (sCD25) ≥ 2400 U/mL;~low or absent natural killer (NK) cell activity."
89274894|NCT05841329|Active Comparator|active group|receive active tDCS before VRET
89274895|NCT05841329|Sham Comparator|sham group|receive sham tDCS before VRET
89274896|NCT05841303|Experimental|Vit. C injection|"Derma pen device model M8 with 24 -micro needle will be adjusted with 1.5 mm depth at the 6th mode speed of 700 cycles/min with intermittent motion used on the sextant gingival area for 30-40 seconds/tooth.~vitamin C will be injected with microneedle at two points for each site in the attached gingiva of one site of the jaw either the left or the right side at 3 mm apical to the free gingival margin in the facial side of the tooth until the blanching of the gingiva will be seen and apical to the mucogingival junction.~- Vitamin C will again be injected at the same site after 1 week and after 2 weeks from the baseline final injection which will be given."
89274897|NCT05841303|Active Comparator|Injectable-platelet Rich Fibrin (i-PRF)|"The derma pen will be used same as vitamin C group. I-PRF will be immediately aspirated using micro needle. I-PRF will be injected on the site with thin gingival phenotype (split mouth technique) with micro needling with derma pen at two points for each site in the attached gingiva at 3 mm apical to the free gingival margin in the facial side of the tooth until the blanching of the gingiva was seen and apical to the mucogingival junction.~4. I-PRF will again be injected at the same site after 1 week and after 2 weeks from the baseline final injection which will be given."
89274898|NCT05841264||children's in urban area|children's in this have good socioeconomic state, small family number, good hygiene
89274899|NCT05841264||children in rural area|children's in this have bad socioeconomic state, large family number, bad hygiene
89274900|NCT05841264||children in semi urban area|children's in this have bad socioeconomic state, small family number, bad hygiene
89274901|NCT05841251|Active Comparator|phenylephrine|phenylephrine-soaked pack will be applied after induction of surgery and intubation.
89274902|NCT05841251|Active Comparator|tranexamic acid|Single intravenous dose of tranexamic acid 15 mg/kg will be given in 100 mL normal saline over 10 minutes.
89274903|NCT05841225|Experimental|experimental group|
89274904|NCT05841225|Placebo Comparator|control group|
89274905|NCT05841186|Other|24h group|Pegfilgrastim is administrated 24 hours after completing the chemotherapy in the 24-hour group.
89274906|NCT05841186|Other|48h group|Pegfilgrastim is administrated 48hours after completing the chemotherapy in the 48-hour group.
89274907|NCT05841186|Other|72h group|Pegfilgrastim is administrated 72 hours after completing the chemotherapy in the 72-hour group.
89274908|NCT05841147|Experimental|The intervention group|An intravenous bolus (6µg/kg) over a 3 min period and a maintenance dose of 0.1µg/kg/min for 18 hour were used in this group.
89274909|NCT05841147|Active Comparator|The control group|The same dose of normal saline was used instead of tirofiban.
89274910|NCT05841069|Active Comparator|Short conservative treatment|Conservative treatment will be performed within no more than 24 h. Surgery will be performed in the absence of contrast in colon according to X-ray examination and if signs of clinical degradation will appear.
89274911|NCT05841069|Experimental|Prolonged conservative treatment|Conservative treatment will be performed within N h, where N = 72 h minus duration of acute intestinal obstruction. Surgery will be performed in the absence of contrast in colon according to X-ray examination and if signs of clinical degradation will appear.
89274912|NCT05841043|Experimental|SHR8028 eye drops|
89274913|NCT05841043|Placebo Comparator|Vehicle|
89274914|NCT05841017|Experimental|Intervention group|The intervention group will participate in a psychoeducational group (1) and in individual psychological intervention based in Cognitive Behavioural Therapy (2).
89274915|NCT05841017|No Intervention|Control group|Usual clinic care.
89274916|NCT05840926|Experimental|Probiotic Streptococcus salivarius K12 Treatment Group|Children treated with Probiotic Streptococcus salivarius K12 Treatment for continuous 3-months
89274917|NCT05840926|Active Comparator|Control Group|Children who did not receive any probiotic treatment
89274918|NCT05840913|Experimental|1.8 ml group|Participants in this group will be given 1 cartridge of articaine solution pre-operatively to endodontic treatment
89274919|NCT05840913|Experimental|3.6 ml group|Participants in this group will be given 2 cartridges of articaine solution pre-operatively to endodontic treatment
88805577|NCT03013049|Experimental|Non cultured dermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done.
88805578|NCT03013439|Experimental|cohort 1 iron isomaltoside|treated with first dose level of iron isomaltoside
88805579|NCT03013439|Experimental|cohort 2 iron isomaltoside|treated with second dose level of iron isomaltoside
89274920|NCT05840822|Placebo Comparator|Placebo|Nightly dose of two placebo capsules
89274921|NCT05840822|Experimental|75mg CBD|Nightly dose of one 75mg CBD capsule and one placebo capsule
89274922|NCT05840822|Experimental|150mg CBD|Nightly dose of two 75mg CBD capsules
89274923|NCT05840809||Participants|"Women who require first-line treatment for drug-sensitive tuberculosis whilst breastfeeding and their babies.~This regimen consists of rifampicin, isoniazid, ethambutol and pyrazinamide for 2 months (intensive phase) followed by a further four months of rifampicin and isoniazid (continuation phase)"
89274924|NCT05840796|Experimental|soy protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day."
89274925|NCT05840796|Other|casein protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day."
89274926|NCT05840068|Experimental|Metformin and Chemotherapy|Metformin (500 mg twice daily) plus chemotherapy is administered to Group A (n=57)
89274927|NCT05840068|Other|Chemotherapy alone|Chemotherapy is administered alone to Group B (n=50).
89274928|NCT05839665|Active Comparator|Humidified high-flow oxygen|Humidified high-flow nasal oxygen delivered via the Optiflow device. Repeated series with 100% oxygen with flows varying between 30 to 50 l/min. Volunteers will also be pre-oxygenated with both opened and closed mouth.
89274929|NCT05839665|Experimental|Standard nasal cannula|Standard nasal cannula connected to an oxygen rotameter Repeated series with 100% oxygen with flows varying between 15 to 50 l/min. Volunteers will also be pre-oxygenated with both opened and closed mouth.
89274930|NCT05839665|Active Comparator|Facemask|"Tight-fitting facemask. Two series will be done where pre-oxygenation will be performed with four minutes of tidal volume breathing and eight vital capacity breaths.~This arm is not randomised. All study subjects will start with facemask pre-oxygenation and are thereafter randomised to standard nasal cannula or humidified high-flow nasal cannula."
89274931|NCT05837312|Experimental|Reconnecting to Internal Sensations and Experiences|The interoceptive training consists of four 25-30 minute modules (plus 15-minutes worth of optional weekly practice) that focus on multiple aspects of interoception including: body awareness, body sensations and movement, eating, health and selfcare, emotional awareness, and understanding the self in relation to others. These modules are delivered weekly.
89274932|NCT05836311||Patients treated with one Perclose Proglide|Patients undergoing transfemoral TAVI implantation treated with one Perclose Proglide Suture
89274933|NCT05836311||Patients treated with two Perclose Proglide Suture|Patients undergoing transfemoral TAVI implantation treated with two Perclose Proglide Suture
89274934|NCT05834803|Active Comparator|Renal artery stenting|Percutaneous transluminal renal angioplasty with stent placement.
88805580|NCT03013439|Experimental|cohort 3 iron isomaltoside|treated with third dose level of iron isomaltoside
89274935|NCT05834803|Sham Comparator|Sham treatment|Sham treatment.
89274936|NCT05833412||Suspected sepsis|These patients will undergo molecular diagnosis by performing the Septicyte Rapid® test on whole blood (EDTA) which allows to know the risk of sepsis (low, intermediate, high) and after 6-8 hours of blood culture incubation, filmarrays blood culture identification (BCID2®) a molecular test approved for direct identification of BSI causing pathogens from blood culture will be performed.
89274937|NCT05814393|Experimental|JW0201+C2202+C2203|Treatment period for 24 weeks (After the treatment period, take JW0201+C2202+C2203 for 28 weeks)
89274938|NCT05814393|Placebo Comparator|C2202+C2203|Treatment period for 24 weeks (After the treatment period, take JW0201+C2202+C2203 for 28 weeks)
89274939|NCT05807555||Infant with sepsis (Case)|Patient hospitalized in the pediatric intensive care unit (ICU) for severe sepsis
89274940|NCT05807555||Healthy child of the same sex and age (Control)|Healthy children will be matched to cases by age and gender
89274941|NCT05782816|Active Comparator|Low dose oxytocin|The low dose oxytocin group will receive a controlled infusion pump at a proximal port on the peripheral IV line. The infusion will start at 2 milli-units/min and will be increased by 2 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min. Oxytocin infusion rate is adjusted to maintain adequate uterine contractions.
89274942|NCT05782816|Active Comparator|High dose oxytocin|The high dose oxytocin group will receive a controlled infusion pump at a proximal port on the peripheral IV line. The infusion will start at 6 milli-units/min and will be increased by 6 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min. Oxytocin infusion rate is adjusted to maintain adequate uterine contractions.
89274943|NCT05781919|Experimental|Group A|Patients with L1, L2 or M INRGSS neuroblastoma in which their surgical planning will be performed using gold standard imaging (TC and/or MRI) and immersive virtual reality HMD device.
89274944|NCT05781919|Active Comparator|Group B|Patients with L1, L2 or M INRGSS neuroblastoma in which their surgical planning will be performed using only gold standard imaging (TC and/or MRI)
89274945|NCT05778565|Experimental|Extraocular muscle stretching arm|
89274946|NCT05778123||TBI|Patients with traumatic brain injury.
89274947|NCT05778123||Control|Patients with hydrocephalus.
89274948|NCT05778110||TBI|Patients with traumatic brain injury.
89274949|NCT05778110||ICH|Patients with hypertensive intracranial hemorrhage.
89274950|NCT05770817||6-20-year-old youth|6-20-year-old youth
89274951|NCT05768932|Experimental|Dose-escalation substudy of BAL0891 monotherapy|Increasing doses of BAL0891 will be administered IV on D1 and D8 Q3W (Regimen A). BAL0891 will be investigated in a dose range of 5-480 mg with Regimen A. Optionally, and based on cumulative safety, PK, and PD data, BAL0891 may be administered on D1 Q3W (Regimen B), D1 and D15 Q4W (Regimen C), or on D1, D8, and D15 Q4W (Regimen D).
89274952|NCT05768932|Experimental|Dose-escalation substudy of BAL0891 in combination with carboplatin|Carboplatin will be dosed at AUC5 Q3W, with an option to use AUC6 (either instead of, or after exploring, AUC5) if the cumulative data collected at that time support a higher dose of carboplatin.
89274953|NCT05768932|Experimental|Dose-escalation substudy of BAL0891 in combination with paclitaxel|Paclitaxel will be dosed at 70 mg/m2 on D1, D8, and D15 Q4W, with an option to use 80 mg/m2 (either instead of, or after exploring, 70 mg/m2) if the cumulative data collected at that time support a higher dose of paclitaxel.
89274954|NCT05757778|Experimental|Neurotized Breast|"For patients undergoing bilateral implant-based breast reconstruction following nipple-sparing mastectomy, one breast will be neurotized by connecting the lateral intercostal nerve to the nipple with interposing standard nerve grafting techniques. The neurotized breast will serve as the experimental breast. The other breast will not receive any breast neurotizing procedure."
89274955|NCT05757778|No Intervention|Non-Neurotized Breast|"For patients undergoing bilateral implant-based breast reconstruction following nipple-sparing mastectomy, one breast will not receive any breast neurotizing procedure. The non-neurotized breast will serve as the control breast."
89274956|NCT05751863|Experimental|Analgesia First Sedation|Subjects will be randomized to receive analgesia-first sedation by intermittent doses of Fentanyl (25 mcg), instead of continuous IV infusions. If the intermittent IVP x4 fails to achieve the target pain score, an infusion starts at 50 mcg/hr and titration by 25 mcg q15 minutes. If sedation score is not achieved, propofol infusion starts at 5 mcg/kg/min to achieve goal RASS of 0 to -2. Subjects will be assessed for a ventilator weaning trial daily.
89274957|NCT05751863|Active Comparator|Protocol Directed Sedation and Daily Sedation Interruption|Subjects will receive Fentanyl for analgesia and midazolam for sedation management. The RASS score is used to guide sedation to a goal of 0 to -2 and daily sedation by IV Midazolam at 1 mg/hr and titrated by 1 mg/hr q60 mins. Midazolam boluses are allowed by 1 mg IVP q5 mins x2 before increasing the infusion rate. Propofol and dexmedetomidine are permitted under existing institutional sedation protocol. Fentanyl IV starts at 50 mcg/hr and is titrated by 25 mcg/hr q15 mins to achieve target pain score. Fentanyl bolus of 25 mcg IVP q5 min x2 doses is given before increasing the infusion rate. Daily sedation interruption (DSI) is performed daily and ventilator weaning trial if they pass.
89274958|NCT05744193|Active Comparator|Commercial Liquid Human Milk Fortifier|Liquid human milk fortifier to be added to human milk
89274959|NCT05744193|Experimental|Liquid Human Milk Fortifier - Standard Protein|Liquid human milk fortifier to be added to human milk
89274960|NCT05744193|Experimental|Liquid Human Milk Fortifier - High Protein|Liquid human milk fortifier to be added to human milk
89274961|NCT05704491||K+A+|diabetic retinopathy according to AI present (K+) AND diabetic retinopathy according to the doctor present (A+)
89274962|NCT05704491||K+A-|diabetic retinopathy according to AI present (K+) AND diabetic retinopathy according to the doctor absent (A-)
89274963|NCT05704491||K-A+|diabetic retinopathy according to AI absent (K-) AND diabetic retinopathy according to the doctor present (A+)
89274964|NCT05704491||K-A-|diabetic retinopathy according to AI absent (K-) AND diabetic retinopathy according to the doctor absent (A-)
89274965|NCT05697770|Experimental|Sodium bicarbonate|Sodium bicarbonate 8.4% (1000 mEq/L) will be diluted in a D5W solution (500 mL bag). For preparation, 300 mL of D5W will be removed and 300 mL of sodium bicarbonate 8.4% added to prepare the bicarbonate solution in a total volume of 500 mL (final concentration: 600 mEq/L).
89274966|NCT05697770|Active Comparator|5% dextrose|Standard 500 mL bag of D5W.
89274967|NCT05669287|Experimental|CT Perfusion|All patients will receive a baseline CT Perfusion scan. A subgroup of patients with chemotherapy treatment will receive a follow-up CT Perfusion after 3 months.
89274968|NCT05654740|Experimental|Virtual Reality experiences|Virtual Reality experiences are offered regularly
89274969|NCT05654740|No Intervention|No Virtual Reality|Virtual Reality experiences are not offered
89274970|NCT05640947|Experimental|LAMS gastro-gastrostomy|
89274971|NCT05637398|Active Comparator|Colchicine 0.5 bid|Eligible HFpEF patients will be randomized in 1:1 ratio by an investigator with either colchicine 0.5 twice daily or usual care for 12 weeks
89274972|NCT05637398|No Intervention|Usual Care|Eligible HFpEF patients will be randomized in 1:1 ratio by an investigator with either colchicine 0.5 twice daily or usual care for 12 weeks
89274973|NCT05621408|Experimental|Attention Training Techniqe|The treatment manual will consist of up to six weekly group sessions with 45-90 minutes duration.
89274974|NCT05621408|No Intervention|Wait-list control|The wait-list control condition will not receive any psychological intervention during the six weeks waiting period. Subsequently, this group will also receive the intervention if the study entry criteria is still fulfilled
89274975|NCT05604729|Experimental|BoNT A (botulinum neurotoxin type A)|Botulinum neurotoxin, 25 units (U) into each masseter at three sessions.
89274976|NCT05604729|Placebo Comparator|Placebo|Saline solution
89274977|NCT05604729|Placebo Comparator|Control|Saline solution, no tooth wear
89274978|NCT05595707|Experimental|Early Percutaneous dilatational tracheostomy|PDT reccomended for patients with high risk for prolonged mechanical ventilation.
89274979|NCT05595148|Active Comparator|Immediate WBAT|Recent studies have highlighted that early WBAT is may be safe following fixation of lower extremity, pelvis, and acetabulum fractures where the standard of care has been delayed WBAT, but high-quality prospective studies on this topic are needed.
89274980|NCT05595148|Active Comparator|Delayed WBAT|Though immediate postoperative WBAT has become the standard of care following fixation of pertrochanteric, femoral shaft, and tibial shaft fractures, most surgeons restrict patient weight bearing following fixation of other lower extremity and pelvis/acetabulum fractures. Progression to full weight bearing varies greatly by type of fracture, fixation method, and surgeon. Weight bearing restrictions following fracture fixation have been shown to be associated with various poor outcomes (increased complications, prolonged hospital length of stay, etc.), particularly in geriatric patients. Thus, it is important for us to understand if it is safe to allow early weight bearing following lower extremity and pelvis/acetabulum fracture fixation, as this could help expedite patient mobility and return to function, and potentially reduce complications.
89274981|NCT05583071|Experimental|combination of Tafasitamab (Minjuvi®), Lenalidomide, Rituximab and Methotrexate|All patients will receive tafasitamab (Minjuvi®) 12 mg/KG body weight and rituximab 375 mg/m² on days 0 and 5, followed by methotrexate 3,5 g/m² on day 1 as an intravenous infusion. Lenalidomide will be administered orally at 20 mg/day during the first cycle and at 25 mg/day during subsequent cycles on days 4-17 of each 21-day cycle for a total number of 4 cycles. The treatment duration per patient will be 84 days.
89274982|NCT05534087|Experimental|mFOLFIRINOX intensified chemotherapy|"6 cycles of mFOLFIRINOX~- Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks"
89274983|NCT05534087|Active Comparator|FOLFOX or CAPOX adjuvant chemotherapy|"FOLFOX 6 cycles or CAPOX 4 cycles~FOLFOX regimen: 6 cycles every 2 weeks or~CAPOX regimen: 4 cycles every 3 weeks"
89274984|NCT05497882|Experimental|Training Prototype|Testing of 3 e-learning modules
89274985|NCT05490641|Experimental|Biofeedback Group|
89274986|NCT05490641|Active Comparator|Standard Care Group|
89274987|NCT05483101||alternative units|In alternative birth units : personalized follow-up with a midwife from the beginning of pregnancy, birth and parenthood preparation classes and delivery (birth room).
89274988|NCT05483101||conventional units|In standard maternity care, most full time midwives are rostered to work. They follow women during their pregnancy but not through labour. All low-risk pregnant women benefit from 5 prenatal consultations with a general practitioner, a midwife or an obstetrician, then 2 consultations with a midwife in maternity hospital of delivery. Couples have got the option to elaborate a birth project if desired
89274989|NCT05480917|Other|IRIS|
89274990|NCT05478603|Experimental|Group 1: PF-07081532 Participants without hepatic impairment|Participants without hepatic impairment will receive a single 20 mg dose of PF-07081532, administered orally as 1 PF-07081532 20 mg tablet.
89274991|NCT05478603|Experimental|Group 2: PF-07081532 Participants with mild hepatic impairment|Participants with mild hepatic impairment will receive a single 20 mg dose of PF-07081532, administered orally as 1 PF-07081532 20 mg tablet
89274992|NCT05478603|Experimental|Group 3: PF-07081532 Participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single 20 mg dose of PF-07081532, administered orally as 1 PF-07081532 20 mg tablet.
89274993|NCT05478603|Experimental|Group 4: PF-07081532 Participants with severe hepatic impairment|Participants with severe hepatic impairment will receive a single20 mg dose of PF-07081532, administered orally as 1 PF-07081532 20 mg tablet.
89274994|NCT05441826|Experimental|VB119|VB119 100 or 200mg IV doses administered 4 times
89274995|NCT05440019||HEALTHY WOMEN IVI VALENCIA|"Participants will be exposed to four sessions of image captures using FERTIGO® device.~Prior to the session, a vaginal ultrasound (US) will be performed, for measuring the endometrial thickness as in the usual practice."
89274996|NCT05430165||Aim 1 Prospective Cohort|All eligible admitted trauma patients in the trauma registry and a qualitative study of 110 in-depth interviews (IDIs).
89274997|NCT05403034|Experimental|OBPP children|OBPP children operated on to treat shoulder stiffness.
89274998|NCT05396456|Experimental|Muscle Fiber Fragment (MFF) injections|autologous muscle fiber fragment injections, harvested in an autologous fashion from the quadriceps muscle, for the treatment of Fecal Incontinence (FI) symptoms in men and women with a demonstrated anal sphincter defect and who have failed conservative treatments
89274999|NCT05394298|Experimental|Short-treatment of any active antibiotic regimen|7 days from the initiation of an appropriate antimicrobial therapy and documented resolution of bacteremia (negative control blood cultures performed on day 2 or 3)
89275000|NCT05394298|Active Comparator|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment from the date of the last positive blood culture and documented resolution of bacteremia (negative control blood cultures performed on day 2 or 3)
89275001|NCT05393908|Active Comparator|TAP Block Group|Participants will receive a surgeon administered TAP block consisting of liposomal bupivacaine during their repeat cesarean delivery.
89275002|NCT05393908|No Intervention|Standard of Care Postoperative Pain Control|Participants will not receive a surgeon administered TAP block consisting of liposomal bupivacaine during their repeat cesarean delivery and will receive the routine standard of care for post-operative pain control.
89275003|NCT05390359|Experimental|High-intensity and short-duration|The technique consists of the percutaneous electrical stimulation of the tendon applying a galvanic current through a ultrasound-guided needle.
89275004|NCT05390359|Experimental|Low-intensity and long-duration|The technique consists of the percutaneous electrical stimulation of the tendon applying a galvanic current through a ultrasound-guided needle.
89275005|NCT05390359|Experimental|High-intensity, short-duration and 20 Hz|The technique consists of the percutaneous electrical stimulation of the tendon applying a alternating current through a ultrasound-guided needle.
89275006|NCT05390359|Sham Comparator|Sham electrolysis|The technique consists of an introduction ultrasound-guided needle without electrical stimulation.
89275007|NCT05364827|Experimental|CTCA prior to CTO PCI|A diagnostic CTCA will be conducted prior to CTO PCI by at a level 2 CTCA trained operator. The results will be discussed with the CTO operator prior to the CTO PCI.
89275008|NCT05364827|No Intervention|No CTCA prior to CTO PCI|Patients will be listed directly for the CTO PCI procedure without undergoing CTCA prior
89275009|NCT05341219|Experimental|light needle therapy|The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
89275010|NCT05341219|Sham Comparator|sham light needle therapy|The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
89275011|NCT05330078|Experimental|Keloid treatment with botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
89275012|NCT05330078|Placebo Comparator|Keloid treatment with vehicle control (saline)|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
89275013|NCT05317585|Experimental|Continuous Glucose Monitoring (CGM)|Patients will be randomized to application of a continuous glucose monitor (CGM). They will apply the device in the clinical setting and be instructed how to download their information onto their smartphones or using the CGM device reader. They will use the CGM for the duration of the pregnancy until delivery.
89275014|NCT05317585|Active Comparator|Fingerstick Glucose Monitoring|Patients will be randomized to checking their blood glucose with fingerstick monitors at time of fasting in the AM, and 2 hours after each meal. This is the standard of care for patients in the pregnancy diabetes clinic.
89275015|NCT05309564|Experimental|Intervention|Intervention with single botulinum neurotoxin injection into masseter.
89275016|NCT05309564|No Intervention|Control|No intervention
89275017|NCT05301413|Active Comparator|Standard|Standard Diabetes Prevention Program (DPP)
89275018|NCT05301413|Experimental|Culturally Tailored DPP|DPP culturally tailored for African Americans
89275019|NCT05301413|Experimental|Culturally Tailored DPP Enhanced with Socioeconomic Supports|Culturally tailored DPP plus promotions for class attendance, hybrid attendance (in-person and virtual), and linkage to care services provided by a community health worker
89275020|NCT05297708||All Participants|he population would be pediatric patients 6 years to <19 years of age who were referred for elevated blood pressure. At the initial clinic visit, the participant will be consented and a thorough history will be taken. An ECHO and non-invasive vascular measurements will be taken (central BP, augmentation index, pulse wave velocity). Patients will have an ambulatory blood pressure monitor (ABPM) placed and be trained to use a home blood pressure monitor (HBP) which will be sent home with them. The monitors in this study are FDA-approved and are being used as indicated. After one day at home, patients will return the ABPM via mail and continue to take measurements with the HBP for 20 days.
89275021|NCT05263635|Experimental|Music therapy + Standard of Care Enhanced Recovery After Surgery (ERAS)|All participants will have complete Enhanced Recovery After Surgery (ERAS) standard of care. A preoperative music intervention will be played first in the preoperative holding area, a second music intervention played immediately following the induction of anesthesia in the operating room, and a third music intervention played in the recovery room when the patient is awake and responsive.
89275022|NCT05263635|Active Comparator|Standard of Care Enhanced Recovery After Surgery (ERAS)|Participants randomized into the control group will receive complete Enhanced Recovery After Surgery (ERAS) standard of care and no music therapy sessions.
89275023|NCT05262426|Experimental|Standard PrEP Counseling, MES-PrEP and Enhanced YaCool|Participants in this arm will receive standard PrEP counseling, followed by two mHealth interventions (MES-PrEP and Enhanced YaCool) to improve PrEP uptake and support PrEP adherence.
89275024|NCT05262426|Experimental|Standard PrEP Counseling and MES-PrEP|Participants in this arm will receive standard PrEP counseling, followed by one mHealth intervention (MES-PrEP) to improve PrEP uptake and support PrEP adherence.
89275025|NCT05262426|Experimental|Standard PrEP Counseling and Enhanced YaCool|Participants in this arm will receive standard PrEP counseling, followed by one mHealth intervention (Enhanced YaCool) to improve PrEP uptake and support PrEP adherence.
89275026|NCT05262426|Active Comparator|Standard PrEP Counseling|Participants in this arm will receive the standard PrEP counseling.
89275027|NCT05249569|Experimental|Axitinib / Avelumab /Bavituximab|Axitinib 5 mg PO BID Avelumab 10 mg/kg IV every 2 weeks (2 doses in a 4-week cycle) Bavituximab 3 mg/kg IV every 1 week (4 doses in a 4-week cycle) Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
89275028|NCT05243030|Experimental|MES-PrEP and MTM|Participants in this arm will receive standard PrEP counseling, followed by mHealth interventions to improve PrEP uptake and support PrEP adherence.
89275029|NCT05243030|Active Comparator|Standard PrEP Counseling|Participants in this arm will receive the standard PrEP counseling.
89275030|NCT05212662|Experimental|TTI-0102|Cysteamine-pantetheine disulfide (TTI-0102) is supplied in a vial as a powder to be dissolved in water and administered orally.
89275031|NCT05212662|Placebo Comparator|Placebo|Placebo is supplied in a vial as a powder to be dissolved in water and administered orally.
89275032|NCT05204316|Experimental|Participants|Participants will provide spoken narratives on their headache disorder
89275033|NCT05199506|Experimental|Each leg/buttock will be treated with the RAP device|Each leg will be treated with standard RAP treatment settings.One leg will receive treatments with 100Hz and the other with 50hz
89275034|NCT05193084||Work Stream 1 (WS1)|"The general aim of this work stream is to assess the hypothesis can the volumes measured by the Heartfelt device be useful in titrating and optimising drug management for patients undergoing home-IV diuretics and after completion of IV-diuretic treatment.?~We will characterise the data collected by the Heartfelt device in the participants' home, correlating it to weight readings (either from the scales or paper weight diary) and medical observations recorded while patients are being treated with IV Diuretics.~Patients from WS1 will be invited to keep the device in their home for 3 months in total, which will therefore cover periods during which they do not receive IV diuretics, but are still at relatively high risk of decompensation. That data will be analysed in the same fashion as the data collected in WS2."
89275035|NCT05193084||Work Stream 2 (WS2)|"The general aim of WS2 is to assess the hypothesis can the Heartfelt device be used to monitor heart failure stability and detect fluid overload in patients recently discharged after an episode of decompensated heart failure?.~This work stream will also aim to examine whether the Heartfelt device gives an indication of the number of days prior to hospital admissions that the Heartfelt device can detect changes in foot volume. This will be achieved by comparing the data collected by the Heartfelt device in the participants' home, and correlating it to weight readings and medical observations. Hospital admissions will be a particularly useful correlation point as it would provide information on the detection of the forming oedema leading up to this event. In future, the information collected during this study will be used to design and power an interventional study to demonstrate the effectiveness of such data in providing a leading indicator of hospitalisation."
89275036|NCT05177822|Experimental|anakinra|
89275037|NCT05177822|Placebo Comparator|placebo|
89275038|NCT05099237|Active Comparator|1. Colorectal Cancer|"This cohort seeks to investigate the feasibility of using two commercially available health and wellbeing trackers to monitor patients with colorectal cancer who are about to start treatment. Participants will be asked to:~Wear the OURA ring and the Withings ScanWatch for the duration of their planned cancer treatment up to a maximum of 26 weeks (6 months).~Complete weekly wearable device satisfaction surveys and weekly cancer specific patient reported outcomes measures (modified FACT-C survey).~Report specific symptoms on an ad-hoc basis as they wish."
89275039|NCT05099237|Active Comparator|2. Lung Cancer|"This cohort seeks to investigate the feasibility of using two commercially available health and wellbeing trackers to monitor patients with lung cancer who are about to start treatment. Participants will be asked to:~Wear the OURA ring and the Withings ScanWatch for the duration of their planned cancer treatment up to a maximum of 26 weeks (6 months).~Complete weekly wearable device satisfaction surveys and weekly cancer specific patient reported outcomes measures (modified FACT-L survey).~Report specific symptoms on an ad-hoc basis as they wish."
89275040|NCT05099237|Active Comparator|3. Haematological Cancer|"Participants (with haematological malignancy about to start treatment with CAR T-cell therapy or another cellular therapy product) will be asked to:~Wear an OURA ring and Withings ScanWatch for approx five weeks including whilst they are in hospital (prior to CAR T-cell therapy and continue for 28 days post infusion)~Wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.~Supported to take daily weights using Withings Body Scale.~Asked to complete weekly electronic quality of life surveys~Provide a series of 12 blood samples to measure inflammatory molecules at various intervals"
89275041|NCT05098522|Experimental|Arm 1: IRL201104|IRL201104 IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70
89275042|NCT05098522|Placebo Comparator|Arm 2: Placebo|Placebo IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70
89275043|NCT05096663|Active Comparator|Arm A (standard of care)|Patients receive standard of care consisting of docetaxel IV over 30-60 minutes on day 1; gemcitabine IV over 30 minutes on days 1 and 8; pemetrexed IV over 10 minutes on day 1; or ramucirumab IV over 30-60 minutes and docetaxel IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89275044|NCT05096663|Experimental|Arm B (pembrolizumab, nogapendekin alfa)|Patients receive pembrolizumab IV over 30 minutes and nogapendekin alfa SC on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients then receive nogapendekin alfa SC on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89275045|NCT05080699|Experimental|Peptamen Intense in obese home enteral nutrition patients after stroke|Subjects currently enrolled in Mayo Clinic Home Enteral Nutrition (HEN) program and anticipated to require tube feedings to provide 90% or more of feeding needs will be placed on a Peptamen Intense VHP for up to 12 weeks.
89275046|NCT05032573|Experimental|Olive Oil|Incorporating 60 mL of olive oil into usual diet and Dietary Guidelines recommendations
89275047|NCT05032573|Active Comparator|Control|Dietary Guidelines recommendations
89275048|NCT05000840||HbA1c <7.5%|For participants with HbA1c ≥ 7.5%, Community Scientists will offer enrollment in existing SDRI diabetes education programs and will schedule a follow-up contact for 3 and 6 months later for repeat testing. Study participation for each participant will end upon completion of 6 month follow up.
89275049|NCT05000840||HbA1c ≥7.5%|For participants with HbA1c < 7.5%, Community Scientists will schedule a follow-up contact 6 months later. Study participation for each participant will end upon completion of 6 month follow up.
89275050|NCT04994873|Experimental|STEP: Positivity skill enhancement|This intervention includes the Enhanced TAU described below plus it entails 4 in-person sessions delivered during an inpatient psychiatric admission, followed by mood monitoring and skills messages delivered post-discharge via app, to promote the practice of increasing attention to positive affect and experiences as a means of reducing risk for suicidal behavior.
89275051|NCT04994873|Active Comparator|Enhanced TAU|his comparison intervention involves regular programming of the inpatient psychiatric unit, followed by safety plan and resources loaded onto an app that the participant has access to post-discharge.
89275052|NCT04990973|Experimental|Mediterranean Diet and then AAD|Healthy participants that are randomized to the MedDiet followed by a 4-week washout and a crossover to the AAD.
89275053|NCT04990973|Experimental|Average American Diet (AAD) and then Mediterranean Diet|Healthy participants that are randomized to AAD followed by a 4-week washout and a crossover to the Mediterranean Diet.
89275054|NCT04982796|Experimental|Psilocybin-enhanced psychotherapy|Psilocybin will be administered twice (25mg & 30mg two weeks apart) in addition to a 6-week psychotherapy protocol while admitted to a residential rehabilitation treatment program.
89275055|NCT04982796|Other|Treatment-as-Usual|Treatment-as-usual while admitted to a residential rehabilitation treatment program.
89275056|NCT04975867|Experimental|Hypothermia group|Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
89275057|NCT04975867|Active Comparator|Normothermia group|For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
89275058|NCT04969536|Experimental|Branched chain amino acid supplementation|Consumption of 8 ounces of water with addition of 2.5 g of leucine, 1.25 g of isoleucine, and 1.25 g of valine immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
89275059|NCT04969536|Placebo Comparator|Placebo|Consumption of 8 ounces of a flavor matched beverage sweetened with a sucralose-based drink mix immediately prior to and again 30 minutes into a 60 minute treadmill run at 65% of VO2max.
89275060|NCT04941911|Active Comparator|Intervention group|Octreotide intravenous infusion, 100mcg bolus with a subsequent infusion of 100mcg per hour during surgery.
89275061|NCT04941911|Placebo Comparator|Placebo group|Sodium chloride 0.9% w/v
89275062|NCT04875936|Experimental|Motor Imagery and Contingent Neurofeedback (NFB)|This group will receive real-time fMRI NFB on the bases of participant's own brain activity
89275063|NCT04875936|Sham Comparator|Motor Imagery and Non-contingent Neurofeedback (NFB)|This group will receive group will receive fMRI NFB based on another participant's brain activity
89275064|NCT04856865|Experimental|Arm 1|
89275065|NCT04856865|Experimental|Arm 2|
89275066|NCT04855240|Experimental|Drug - ACP-044 Dose A|ACP-044 Dose A
89275067|NCT04855240|Experimental|Drug - ACP-044 Dose B|ACP-044 Dose B
89275068|NCT04855240|Placebo Comparator|Placebo|Placebo
89275069|NCT04850612||Healthcare professionals and researchers (HCPR)|All researchers and healthcare professionals involved in the management of patients with CSDH
89275070|NCT04850612||Patients and carers|Patients who have previously had a diagnosis of CSDH, and their carers
89275071|NCT04824443|Experimental|Participants who were hospitalized for COVID-19|Participants will be post-cancer treatment patients who were hospitalized for COVID-19.
89275072|NCT04809623|Experimental|Edecesertib|Participants will receive edecesertib orally once daily for 4 weeks
89275073|NCT04809623|Experimental|Placebo|Participants will receive placebo orally once daily for 4 weeks
89275074|NCT04797195|Experimental|CKD-PD app user group|Patients on peritoneal dialysis using the CKD-PD app and home monitoring equipment to measure and record blood pressure, body weight, and dialysis fluid removed
89275075|NCT04797195|No Intervention|Usual care group|Patients on peritoneal dialysis using handwritten notebook to record record blood pressure, body weight, and dialysis fluid removed; measurements obtained through usual method
89275076|NCT04788303|Active Comparator|Full intervention|Full intervention: school meal, garden, education, and community workshops
89275077|NCT04788303|Active Comparator|Partial intervention|Partial intervention: garden, education, and community workshops
89275078|NCT04788303|No Intervention|Control|Control: standard of care
89275079|NCT04779879|Active Comparator|Sotrovimab (Gen1)|Part A (double-blinded) participants will be randomized to receive 500 mg of an IV infusion of Sotrovimab Gen 1 material or 500 mg of an IV infusion of VIR-7831 Gen 2 material
89275080|NCT04779879|Active Comparator|Sotrovimab (Gen2)|"Part B (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or by IM injection~Part C (open-label) participants will be randomized to receive 500 mg of Sotrovimab Gen2 material by IV infusion or 250 mg by IM injection"
88805581|NCT03013439|Experimental|cohort 4 iron isomaltoside|treated with fourth dose level of iron isomaltoside
88805582|NCT00131456|Active Comparator|Venlafaxine|Venlafaxine
89275081|NCT04768101|Experimental|Parkinson's Disease participants with MCI|Patient volunteers will also undergo a C-11 PiB PET scan. This procedure utilizes a common radiotracer that is used routinely in clinical PET scans and will be purchased here from PETNET and certified for human use. All PET scans will be performed by a certified PET technologist at the Vanderbilt University Institute of Imaging Science.
88805583|NCT00131456|Placebo Comparator|Placebo|Placebo
89275082|NCT04751968|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
89275083|NCT04751968|Other|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
89275084|NCT04701073|No Intervention|"Control group usual care"|Promotion of physical activity and taking usual medicines for pain relief
89275085|NCT04701073|Experimental|Intervention group : lumbar belt|wearing the LombaStab belt during 3 months in addition to usual care (promotion of physical activity and taking usual medicines for pain relief).
89275086|NCT04695860|Experimental|Open label Burosumab|Burosumab Q4W, 1mg/kg body weight s.c.
89275087|NCT04693806|Experimental|Continuous CO2 Level|embryos will remain in a single incubator set at a continuousCO2 level
89275088|NCT04693806|No Intervention|Sequential CO2 Level|Current standard of care
89275089|NCT04675099|Active Comparator|Control|Standard Early Intervention services
89275090|NCT04675099|Experimental|Intervention|pCARE
89275091|NCT04653402|Experimental|Study arm 1|Placing a closed suction drain after hydrocelectomy for primary vaginal hydrocele
89275092|NCT04653402|Active Comparator|Study arm 2|Not placing a drain after hydrocelectomy in primary vaginal hydrocele
89275093|NCT04644640|Active Comparator|Telerehabilitation|
89275094|NCT04644640|Active Comparator|In-Person Rehabilitation|
89275095|NCT04633824||Patients with private insurance|
89275096|NCT04633824||Patients with public/self-payer insurance|
89275097|NCT04631692|No Intervention|Usual care|Usual care in participating primary care practices.
89275098|NCT04631692|Active Comparator|Health literacy intervention|Health literacy intervention combining health literacy and colorectal cancer screening training for general practitioners with a short brochure and video targeting eligible patients.
89275099|NCT04599075|Experimental|Intravenous Insulin Infusion|Patients will be randomized to discontinuation of the CSII pump intrapartum and initiation of IV insulin infusion per hospital protocol.
89275100|NCT04599075|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Patients will be randomized to continuation of their CSII pump intrapartum and will be managed in accordance with the CSII hospital protocol.
89275101|NCT04574583|Experimental|Phase I Dose Level 1(DL1) 25mg SX-682 monotherapy sequentially foll/by 1200mg BinTraFusp Alfa +CV301|"Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL2 50 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.~Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrollment to the next dose level begins"
89275102|NCT04574583|Experimental|Phase I Dose Level 2 (DL2) 50 mg SX-682 sequentially followed by 1200mg BinTraFusp Alfa + CV301|"Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL2 50 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.~Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrollment to the next dose level begins"
89275103|NCT04574583|Experimental|Phase I Dose Level 3 (DL3) 100 mg SX-682 sequentially followed by 1200mg BinTraFusp Alfa +CV301|"Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL1 100 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.~Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrolling onto the next dose level."
89275104|NCT04555122|Experimental|Intervention Group|Advertisements will be sent to participants to attempt to increase adherence to stay-at-home orders and social distancing. There are 3 types of advertisements. This will occur for 7 days.
89275105|NCT04555122|No Intervention|Control Group|Control Group will be people who will not receive any advertisements.
89275106|NCT04535167|Experimental|PF-07304814|"Part 1:~Cohort 1-5~Part 2:~Cohort 6-9"
89275107|NCT04535167|Placebo Comparator|Placebo|"Part 1:~Cohort 1-5~Part 2:~Cohort 6-9"
89275108|NCT04528771|Experimental|SNO|12 patients in the S-nitrosylation arm will receive SNO (six-hour treatment with a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr).
89275109|NCT04528771|Placebo Comparator|Placebo|12 patients in the placebo arm will receive nitrogen gas (six-hour treatment).
89275110|NCT04523363|Experimental|Metformin|Study subjects will be randomized to the metformin medication arm. They will take a 500 mg tablet orally twice a day starting at 14 weeks of pregnancy until delivery.
89275111|NCT04523363|No Intervention|Standard of Care|Study subjects will be randomized to standard of care and receive routine prenatal care without further intervention for their prediabetes.
89275112|NCT04517786|Experimental|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
89275113|NCT04506411|Experimental|TPG|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
89275114|NCT04506411|Active Comparator|STE|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
89275115|NCT04506411|Placebo Comparator|Control|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
89275116|NCT04498845|Active Comparator|Basic intervention group|Participants in the basic intervention group will have a 1-hour in-home assessment plan and family educational session.
89275117|NCT04498845|Experimental|Intermediate intervention group|Participants in the intermediate intervention group will have a 1-hour in-home assessment plan and educational session and refer worker to a 1-hr worker take home prevention educational session.
89275118|NCT04498845|Experimental|Advanced intervention group|Participants in the advanced intervention group will have a 1-hour in-home assessment plan and educational session, refer worker to a 1-hr worker take home prevention educational session, and provision of D-LEAD all-purpose cleaner and laundry detergent.
89275119|NCT04496284|Experimental|Vitrification via slush nitrogen|Blastocyst stage embryos will be vitrified via slush nitrogen
89275120|NCT04496284|No Intervention|Vitrification via liquid nitrogen|Blastocyst stage embryos will be vitrified via conventional liquid nitrogen. This is the current standard of care.
89275121|NCT04495894|Experimental|Preoperative Ketorolac|Participants randomized to receive ketorolac prior to surgery for stage I/II NSCLC and stage III RCC. Participants will receive standard-of-care surgery. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered.
89275122|NCT04495894|No Intervention|Control Group|Participants randomized to the control group receiving the standard of care during surgery for stage I/II NSCLC and stage III RCC. Open, video-assisted thoracic surgery, laparoscopy, or robotic surgery are allowed. Standard anesthesia will be administered. The concurrent control group is to obtain untreated biologic samples for biologic correlative studies and secondary endpoints.
89275123|NCT04490317||Acute CO poisoning|A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin >5% (>10% in smokers).
89275124|NCT04478721|Experimental|Temocillin|Patients enrolled in this arm, will receive 2g each 8 hours of intravenous temocillin.
89275125|NCT04478721|Active Comparator|Meropenem|Patients enrolled in this arm, will receive 1g each 8 hours of intravenous meropenem.
89275126|NCT04456764|Experimental|SaFTiE|The SaFTiE intervention includes: [a] real-time text-message assessments of fatigue and sleep during and between scheduled shift work; [b] tailored text-message alerts that promote adopting evidence based strategies for mitigating fatigue when high levels of fatigue or sleepiness are reported; [c] a mobile app that delivers goal setting, summary data of sleep/fatigue indicators from all study participants, and video interviews of EMS clinicians focused on sleep and fatigue.
89275127|NCT04456764|Placebo Comparator|Attention Placebo Control|The attention placebo control includes: [a] real-time text-message assessments of teamwork during and between scheduled shift work; [b] text-message alerts that promote techniques for mitigating poor teamwork when episodes of poor teamwork are reported; [c] a mobile app that delivers goal setting, summary data of teamwork indicators from all study participants, and video interviews of EMS clinicians focused on teamwork.
89275128|NCT04441567|No Intervention|Phase 1|Participants in phase 1 will be observed and data about their recovery time will be collected from which recovery curves will be calculated for Phase 2
89275129|NCT04441567|Experimental|Phase 2|Participants in Phase 2 will have their clinic visits potentially revised based on the phase 1 recovery curves which may increase or decrease the number of clinic visits they receive based on the PROMs reported.
89275130|NCT04432883|Active Comparator|Experimental: Active cathodal tDCS + Speech-language training|In this arm, 31 patients with stroke induced Aphasia will undergo 15 sessions of active tDCS (x 30 minutes of stimulation) combined with 1 hour simultaneous speech-language training on consecutive weekdays.
89275131|NCT04432883|Sham Comparator|Comparator: Placebo cathodal tDCS + Speech-language training|In this arm, 31 patients with stroke induced Aphasia will undergo 15 sessions of sham tDCS (x 30 minutes sham) combined with 1 hour simultaneous speech-language training on consecutive weekdays..
89275132|NCT04391491||Heart failure with preserved ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFpEF (Symptoms of HF (NYHA II-IV); LVEF >50%; Elevated levels of natriuretic peptides (NT-pro BNP > 300 pg/ml in sinus rhythm, >600 pg/ml in AF);Relevant structural heart disease (Left ventricle hypertrophy (LVH) and/or Left atrium enlargement (LAE); left atrial volume index (LAVI) >34 mL/m2 or a left ventricular mass index (LVMI) =115 g/m2 for males and =95 g/m2 for females)
89275133|NCT04391491||Microvascular angina|Patients of both sexes and > 18 years with a confirmed diagnosis of MVA (Angina-like chest pain: signs of exercise-induced ischemia (ST-depression on exercise ECG (>1 mm down-sloping or rectilinear ST-segment depression in >2 leads)); No fixed stenosis (>50%) in epicardial coronary arteries or branches at baseline coronary arteriography)
89275134|NCT04391491||Pulmonary hypertension|Patients of both sexes and > 18 years with a confirmed diagnosis of secondary PH due to left heart disease (Left ventricular systolic dysfunction, left ventricular diastolic dysfunction, Valvular disease, Congenital/acquired left heart inflow/outflow obstruction and congenital cardiomyopathies) or chronic thromboembolic pulmonary hypertension defined by echo when peak tricuspid regurgitation velocity =2.8 m/s and presence of other echo 'PH signs'
89275135|NCT04391491||Heart failure with redused ejection fraction|Patients of both sexes and > 18 years with a confirmed diagnosis of HFrEF (Symptomatic HF (NYHA class II-IV), left ventricular ejection fraction ≤ 35% (at any time in the past))
89275136|NCT04386252|Experimental|Phase 1 Antigen Dose Exploration|AV-COVID-19 consisting of autologous DC loaded with 0.1 mcg, 0.33 mcg or 1.0 mcg SARS-CoV-2 spike protein, with or without GM-CSF
89275137|NCT04386252|Experimental|Phase 2|Separate cohorts of patients who have 0 or >1 risk factor related to poor outcome for COVID-19 infection will receive AV-COVID-19 consisting of optimal antigen and GM-CSF formulation.
89275138|NCT04359394||PP patients|patients with active PP
89275139|NCT04304001|Experimental|Community Health Advisor|Intervention arm participants will be scheduled to receive the CHA intervention within 4 to 6 weeks after enrollment, a FIT kit, a mailed targeted CRC brochure, and a follow-up telephone survey at 3- and 12-months post-intervention
89275140|NCT04304001|Active Comparator|Usual care|Control group participants will receive a FIT kit, a mailed targeted CRC brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
89275141|NCT04301596||SSc patients|
89275142|NCT04283500|Experimental|BUP treatment arm|Subjects will be given BUP 32mg in 2 doses, and observed for at least 90 minutes after the 2nd dose. The whole process will take a total of about 3-4 hours including the consenting process. Subjects will be asked questions and be examined repeatedly. Subjects will have 4 in-person visits and a phone call in addition to review of medical records.
89275143|NCT04279977||Inpatient Rehabilitation Facility|Individuals post-stroke who are discharged to an inpatient rehabilitation facility.
89275144|NCT04279977||Skilled Nursing Facility|Individuals post-stroke who are discharged to a skilled nursing facility.
89275145|NCT04223791|Experimental|DOR/ISL|A fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and placebo to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) for 96 weeks.
89275146|NCT04223791|Active Comparator|BIC/FTC/TAF|50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to FDC DOR/ISL for 96 weeks. Participants will be offered the option to receive open-label FDC DOR/ISL from Week 144 to Week 156.
89275147|NCT04171921|Active Comparator|Robotic ventral hernia repair|
89275148|NCT04171921|Active Comparator|Open ventral hernia repair|
89275149|NCT04155034|Active Comparator|Arm I (PCI, MRI)|Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
89275150|NCT04155034|Experimental|Arm II (MRI)|Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
89275151|NCT04151485|Experimental|Mind/Body Group|All persons allocated to the intervention group will take part in a 10-week Mind/Body skills development fertility program parallel with fertility workup and treatment.
88805584|NCT05461872||girls with adnexal mass|"All girls who presented with adnexal mass from 0-21 years old (inclusive).~Subjects will be identified from review of clinical records.~Girl aged 21 or below who attended the NTEC cluster from 1990-2021 with available medical records."
88805585|NCT01897922|Active Comparator|Marketed routine infant formula|
88805586|NCT01897922|Experimental|Infant formula containing a probiotic source|
89275152|NCT04151485|Active Comparator|Support Group|All persons allocated to the comparison intervention group will take part in a 10-week fertility support program parallel with fertility workup and treatment.
89275153|NCT04147273|Other|Evaluation of CGM compared with standard measurements|Two products were studied: white bread (Butter Toast®, Golden Toast, Wittenberg, Germany) and whole grain bread (1688 Mehrkorn®, Harry-Brot, Schenefeld, Germany). One portion (containing 50 g digestible carbohydrates) was eaten immediately before the beginning of the test in the morning after an overnight fast of at least 10 h. Before testing, participants ate as usual on the previous day without a standard meal and refrained from consuming alcohol and exercising for 72 h. A 200-ml glucose drink (Accu-Chek Dextrose O.G.-T. Saft®, Roche Diabetes Care, Mannheim, Germany), containing also 50 g of carbohydrates, was used as the reference product.
89275154|NCT04141085||Healthy volunteers without infertility|Healthy volunteers without a history of infertility who have regular menstrual cycles and whom have not had any intrauterine procedures performed in the last 90 days prior to participation in the study
89275155|NCT04141085||Infertile Patients|Infertile patients with a history of infertility but without concern for endometrial dysfunction as the cause of their infertility.
89275156|NCT04115293|Experimental|0.3 mg/kg zilucoplan (RA101495)|
89275157|NCT04115293|Placebo Comparator|Placebo|
89275158|NCT04035499|Experimental|Experimental Arm:single|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©® is a progressive walking and resistance exercise program
89275159|NCT04002505|Experimental|Head Injury Subject|Subjects that present to the Emergency Department with a blunt head injury within the past 24 hours, determined to be low risk by the Canadian CT Head Rules (CCHR), and are being considered for a head CT by the treating provider will use the shared decision making tool Concussion and Brain Bleed app (CBC) with their clinician
89275160|NCT03996200|Experimental|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
89275161|NCT03982030|Experimental|Dalbavancin|Participants with susceptible gram-positive infections requiring prolonged parenteral antibiotic therapy will be treated with dalbavancin.
89275162|NCT03958695|Active Comparator|Tunable-tension transobturator tape (TTT)|
89275163|NCT03958695|Active Comparator|Transobturator mid-urethral tape (TOT)|
89275164|NCT03915067|Placebo Comparator|Placebo|Participants received matching placebo as superficial intramuscular injections administered to the platysma muscle on Day 1.
89275165|NCT03915067|Experimental|BOTOX® Low Dose|Participants received BOTOX® Low Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.
89275166|NCT03915067|Active Comparator|BOTOX® High Dose|Participants received BOTOX® High Dose as superficial intramuscular injections administered to the platysma muscle on Day 1.
89275167|NCT03913611|Other|Traditional Rehabilitation|In this arm, patients will undergo the standard rehabilitation protocol, with sling use for 6 weeks.
89275168|NCT03913611|Experimental|Accelerated Rehabilitation|In this arm, patients will undergo the accelerated rehabilitation protocol, with no sling use outside the immediate postoperative period.
89275169|NCT03910491|Experimental|Intervention|All participants who enroll in the study will be assigned to a PriCARE group program that will adhere to the approximately 9 hour PriCARE curriculum.The trainings are administered to groups of approximately 4-12 caregivers at a time and are led by 2 mental health providers trained in the PriCARE curriculum. The curriculum will be delivered in 2-6 sessions over a 2-20 week period.
89275170|NCT03903133|Other|vitamin E supplementation|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
88805587|NCT01093469|Experimental|Aquaphor Healing Ointment|Aquaphor Healing Ointment three times daily to atopic dermatitis
88805588|NCT01093469|Active Comparator|Atopiclair Nonsteroidal Cream|Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis
88805589|NCT01093469|Active Comparator|EpiCream Skin Barrier Emulsion|EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis
89275171|NCT03841305|Active Comparator|portal vein embolization|Liver preparation before major hepatectomy : portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.
89275172|NCT03841305|Experimental|liver venous deprivation|Liver preparation before major hepatectomy : Patients with the liver venous deprivation (LVD) technique that combines both PVE and hepatic vein embolization (HVE) during the same procedure.
89275173|NCT03828370|Active Comparator|Usual & Customary Information Group|"Study Cohort Assessment:~Baseline 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
89275174|NCT03828370|Experimental|B-SMART Intervention Group|"Study Cohort Assessment:~Baseline Web App Intervention 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
89275175|NCT03778307||Trauma exposed without PTSD|Individuals with a history of trauma exposure who do not have current PTSD
89275176|NCT03778307||Trauma exposed with PTSD|Individuals with a history of trauma exposure and a current diagnosis of PTSD
89275177|NCT03739502|Experimental|HBO arm|
89275178|NCT03739502|No Intervention|non-HBO arm|
89275179|NCT03727633|Experimental|Treatment arm|hepatic intra-arterial injection of an emulsion of Idarubicine and Lipiodol
89275180|NCT03726931|Experimental|[18F]FES|All patients will receive an additional PET/CT scan: [18F]FES PET/CT scan.
89275181|NCT03694002|Experimental|Arm A (ramucirumab, carboplatin, paclitaxel)|Patients receive ramucirumab IV over 60 minutes, carboplatin IV, and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not progressed may continue to receive ramucirumab for up to 1 year.
89275182|NCT03694002|Active Comparator|Arm B (carboplatin, paclitaxel)|Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89275183|NCT03654404|Experimental|Positive Psychology|"Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment.~At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
89275184|NCT03625115|No Intervention|Usual Care (Control)|Dyads randomized into this control arm will continue with usual care consisting of information about early intervention services and routine Child Find procedures.
89275185|NCT03625115|Experimental|Family Navigator (Intervention)|Dyads randomized to the Intervention arm with be assigned a designated Family Navigator (FN) who will engage, inform, and assist the participating parents to follow-through with the process of EI referrals and services.
89275186|NCT03550118|Experimental|Aim 2 - Adjustable Socket - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on socket size adjustments while walking.
89275187|NCT03550118|Experimental|Aim 3 - Adjustable Socket - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on socket size adjustments while walking.
89275188|NCT03550118|Experimental|Aim 4 - Adjustable Socket - Automatic Controls|An adjustable socket is tested where a control system is used to automatically control the adjustments. This arm focuses on socket size adjustments while walking.
89275189|NCT03550118|Experimental|Aim 6A - Release/Recovery - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
89275190|NCT03550118|Experimental|Aim 6B - Release/Recovery - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
89275191|NCT03550118|Experimental|Aim 8 - Panel Pull During Resting|"The purpose of Aim #8 was to determine if vacuum-like action (panel pull) during resting between periods of activity facilitated limb fluid volume recovery and retention in transtibial prosthesis users. Liner attached to panels."
89275192|NCT03550118|Experimental|Aim 9 - Panel Pull During Ambulation|"Extending from the Aim #8 results, we sought to determine in Aim #9 if vacuum-like action during ambulation facilitated limb fluid volume recovery and retention. Vacuum-like action was achieved by quickly pulling the panels and liner (liner attached to panels) radially outward during late stance phase and then moving them back to their original position during early swing."
89275193|NCT03550118|Experimental|Aim 10 - Adjustable Socket Out of Lab Testing|"Participants took the investigational device home in one of three test modes. In the first mode, the panels were in a locked flush position, similar to their traditional prosthesis. Participants were not able to adjust the panels in this first mode. The second mode allowed participants to manually make panel adjustments, incrementally enlarging or tightening the panels radially. Lastly, the third mode implemented the automated controller developed in the previous aims. Participants were still able to make manual adjustments to the panel positions but during walks adjustments would also occur automatically. Each mode was tested for a minimum of 1 week."
89275194|NCT03503396|Experimental|BAC feedback|Participants will receive a warning when their BAC is above a set limit (cutpoint is not disclosed by well below legal limit). Warning will notify them that their results indicate it is not safe for them to drive.
89275195|NCT03503396|Active Comparator|No Feedback|Participants will not receive any information on their BAC from their device.
89275196|NCT03447314|Experimental|Part 1a: 50ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 50 nanogram (ng) intravenously (IV) on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3174998 24 milligram (mg) administered at 3-week intervals (Q3W) via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
89275197|NCT03447314|Experimental|Part 1a: 100ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
89275198|NCT03447314|Experimental|Part 1a: 150ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
89275199|NCT03447314|Experimental|Part 1a: 200ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
89275200|NCT03447314|Experimental|Part 1a: 250ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
89275201|NCT03447314|Experimental|Part 1b: 50ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
89275202|NCT03447314|Experimental|Part 1b: 100ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
89275203|NCT03447314|Experimental|Part 1b: 150ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
89275204|NCT03447314|Experimental|Part 1b: 200ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
89275205|NCT03447314|Experimental|Part 1b: 250ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
89275206|NCT03447314|Experimental|Part 1c: 50ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
89275207|NCT03447314|Experimental|Part 1c: 100ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
89275208|NCT03447314|Experimental|Part 1c: 150ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
89275209|NCT03447314|Experimental|Part 1c: 200ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
89275210|NCT03447314|Experimental|Part 1c: 250ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
89275211|NCT03447314|Experimental|Part 2a: GSK1795091 + 24 mg GSK3174998|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3174998 24 mg.
89275212|NCT03447314|Experimental|Part 2b: GSK1795091 + 80 mg GSK3359609|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3359609 80 mg.
89275213|NCT03447314|Experimental|Part 2c: GSK1795091 + 200 mg Pembrolizumab|Participants will be administered GSK1795091 at a dose identified in Part 1 along with pembrolizumab 200 mg.
89275214|NCT03424174|Experimental|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
89275215|NCT03424174|Active Comparator|Standard Total Knee Arthroplasty|Implantation Standard Total Knee Arthroplasty
89275216|NCT03423121|Experimental|TUDCA Treatment|Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.
89275217|NCT03423121|Placebo Comparator|Placebo oral capsule|Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.
89275218|NCT03413423|Experimental|BAT-CS|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
89275219|NCT03413423|Active Comparator|Smoking Cessation and Health & Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
89275220|NCT03364530|Other|Gemcitabine-Oxaliplatin Regimen|
89275221|NCT03350230||oncofertility patients|oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis
89275222|NCT03335475|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
89275223|NCT03335475|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participant will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
89275224|NCT03303066|Experimental|Phase 2 Part: FG-4592|Fixed starting doses (different doses for lower body weight & higher body weight) of FG-4592 administered orally 3 times a week (TIW) for up to 26 weeks; dose adjustments to Hb levels are allowed during the study.
89275225|NCT03303066|Experimental|Phase 3 Part: FG-4592|Fixed starting doses (different doses for lower body weight & higher body weight) of FG-4592 administered orally TIW for up to 26 weeks; dose adjustments to Hb levels are allowed during the study.
89275226|NCT03303066|Placebo Comparator|Phase 3 Part: Placebo|Placebo (matching to FG-4592) administered orally TIW for up to 26 weeks.
89275227|NCT03289910|Experimental|Arm A (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89275228|NCT03289910|Active Comparator|Arm B (topotecan hydrochloride, carboplatin)|Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89275229|NCT03253133|Experimental|Oxaliplatin|"IP neoadjuvant chemotherapy protocol:~Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.~Intravenous chemotherapy protocol:~Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed."
89275230|NCT03252756|Experimental|Placebo for 4 weeks, followed by phytocannabinoid cannabidiol (CBD) for 4 weeks|600mg/day Saline taken by mouth (PO) for 4 weeks, immediately followed by 1200mg saline/ day (PO) for an additional 4 weeks (8 total weeks).
89275231|NCT03252756|Experimental|CBD for 8 weeks|600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
89275232|NCT03209609|Experimental|VEST supported vein graft|Coronary artery bypass vein graft supported with the VEST implant
89275233|NCT03209609|Active Comparator|Standard of care vein grafts|Coronary artery bypass vein grafts
89275234|NCT03164356|No Intervention|Arm 1|In Arm 1, bioimpedance measurements are taken by research staff. The participants also wear an ActiGraph monitor for at least one week prior to their prosthetist preforming modifications to their socket.
89275235|NCT03164356|Experimental|Arm 2 - Experimental|Conclusions drawn from data gathered in Arm 1 will be given to the participant's prosthetist, along with their bioimpedance data from Arm 2, to inform the practitioner's decision on when a modification to the socket is warranted. The results will be compared to those of Arm 3.
89275236|NCT03164356|No Intervention|Arm 3 - Control|Bioimpedance data will be collected from participants in Arm 3 in parallel with those in Arm 2. However, no data will be provided to the participant's prosthetist.
89275237|NCT03091660|Active Comparator|Arm I (BCG solution)|INDUCTION: Patients receive TICE BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive TICE BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
89275238|NCT03091660|Experimental|Arm II (Tokyo-172 strain BCG solution)|INDUCTION: Patients receive Tokyo-172 strain BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
89275239|NCT03091660|Experimental|Arm III (Tokyo-172 strain BCG solution with priming)|PRIME: Patients receive Tokyo-172 strain BCG vaccine once ID. INDUCTION: Within 21 days, patients receive Tokyo-172 strain BCG solution as in Arm II. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution as in Arm II.
89275240|NCT03091595|Experimental|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
89275241|NCT03091595|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
89275242|NCT03089541|Experimental|Survey Arm|Will receive incentives for completing surveys and evidence of tobacco use status daily for 1 week
89275243|NCT03028402||Asymptomatic Controls|Individuals who have no history of neck pain, trauma or surgery, similar in age and sex to the surgical patients
89275244|NCT03028402||C5-C6 arthrodesis|Patients scheduled to undergo C5-C6 anterior cervical arthrodesis
89275245|NCT03028402||C6-C7 arthrodesis|Patients scheduled to undergo C6-C7 anterior cervical arthrodesis
89275246|NCT03028402||C4-C5-C6 arthrodesis|Patients scheduled to undergo C4-C5-C6 anterior cervical arthrodesis
89275247|NCT03028402||C5-C6-C7 arthrodesis|Patients scheduled to undergo C5-C6-C7 anterior cervical arthrodesis
89275248|NCT03025971|Other|Single arm observational study|Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.
89275249|NCT02926391||Cervical|30 patients who need anterior cervical corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
89275250|NCT02926391||Thoraco-lumbar|30 patients who need anterior thoracolumbar corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
89275251|NCT02923232|Experimental|Accommodative contact lens|The accommodative contact lens is composed of traditional hydrogel lens material but has an internal cavity to allow lens deformation that increases its refractive power at an downward angle.
89275252|NCT02861781||Type 2 diabetes|Type 2 diabetes according to ADA criteria
89275253|NCT02861781||Insulin resistance non diabetes|HOMA-IR criteria ≥ 3
89275254|NCT02861781||Insulin sensitivity non diabetes|HOMA-IR criteria < 3
89275255|NCT02626312|Experimental|Treatment (radiation therapy)|Patients undergo radiation therapy 5 days a week for a total of 15 or 25 fractions in the absence of disease progression or unacceptable toxicity.
89275256|NCT02386553|Experimental|Nusinersen|Nusinersen administered as an intrathecal injection
89275257|NCT02307058|Experimental|LEAD RT Group|Participants in this group will receive the Lattice Extreme Ablative Dose (LEAD) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 8 weeks.
89275258|NCT02307058|Experimental|HEIGHT RT Group|Participants in this group will receive the Hypofractionated Extended Image-Guided Highly Targeted (HEIGHT) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 7 and a half weeks.
89275259|NCT02301572||Aggressive onset MS|Two or more relapses in the preceding year and 2 or more gadolinium enhancing lesions on brain MRI scan or a significant T 2 lesion burden or One relapse if it results in sustained EDSS of 3.0 along with 2 or more gadolinium enhancing lesions or significant T2 lesion burden ( T2 lesion burden being determined by factoring the number of lesions, the size of the lesions and lesion location)
89275260|NCT02245048||Stress Echocardiography (SE)|Subjects will undergo CIMT measurements.
89275261|NCT02047396||Myocardial Infarction subjects|Subjects with first Myocardial Infarction presenting to one of the Mayo Clinic Hospitals in Rochester, Minnesota.
89275262|NCT01981993||patients at ICU with sepsis|
89275263|NCT01980797||Bicuspid aortic valve disease|"Group/Cohort Label - Bicuspid aortic valve~Group/Cohort Description -~Patients diagnosed with bicuspid aortic valve~All ages ≥8 years~Able to provide fully informed consent"
89275264|NCT01980797||Tricuspid aortic valve control patients|"Group/Cohort Label - Tricuspid aortic valve control patients~Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched.~Patients not diagnosed with bicuspid aortic valve~All ages ≥8 years~Able to provide fully informed consent"
89275265|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 1|Combination chemotherapy and inotuzumab ozogamicin - Dose level 1 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and 0.4 mg/m2 inotuzumab ozogamicin IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89275266|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 2|Combination chemotherapy and inotuzumab ozogamicin - Dose level 2 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.6 mg/m2 on day 1 and 0.4 mg/m2 on day 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89275267|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 3|Combination chemotherapy and inotuzumab ozogamicin - Dose level 3 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.4 mg/m2 on day 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89275268|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 4|Combination chemotherapy and inotuzumab ozogamicin - Dose level 4 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.4 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89275269|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - Dose Level 5|Combination chemotherapy and inotuzumab ozogamicin - Dose level 5 Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89275270|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin) - MTD|Combination chemotherapy and inotuzumab ozogamicin - Maximum Tolerated Dose Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour at 0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89275271|NCT01767311|Experimental|Core Study: Lecanemab 2.5 mg/kg biweekly|2.5 mg/kg biweekly
89275272|NCT01767311|Experimental|Core Study: Lecanemab 5.0 mg/kg biweekly|5.0 mg/kg biweekly
89275273|NCT01767311|Experimental|Core Study: Lecanemab 10 mg/kg biweekly|10 mg/kg biweekly
89275274|NCT01767311|Experimental|Core Study: Lecanemab 5.0 mg/kg monthly|5.0 mg/kg monthly
89275275|NCT01767311|Experimental|Core Study: Lecanemab 10 mg/kg monthly|10 mg/kg monthly
89275276|NCT01767311|Placebo Comparator|Core Study: Lecanemab-matched Placebo|Matching placebo biweekly
89275277|NCT01767311|Experimental|Extension Phase: Lecanemab 10 mg/kg|All participants who fulfill Extension Phase inclusion and exclusion criteria will have the option to participate in the Extension Phase to receive lecanemab 10 mg/kg biweekly for up to 60 months or until the benefit-to-risk ratio from treatment with lecanemab is no longer considered favorable, whichever comes first. Additionally, participants who have received Extension Phase treatment for at least 18 months may opt to enter the dosing regimen substudy during which they will receive either lecanemab 10 mg/kg once every 4 weeks (Q4W) or once every 3 months (Q3M).
89275278|NCT01698918|Experimental|Everolimus+letrozole/exemestane (first line and second line treatment)|Participants received everolimus in combination with letrozole as first-line treatment. Only participants who had disease progression in the first line setting (core phase) were offered second-line treatment (everolimus in combination with exemestane)
89275279|NCT01495403|Experimental|hydroxychloroquine|
89275280|NCT01347697|Experimental|Porcine collagen implant (biological mesh)|Reconstruction with an acellular porcine dermal collagen implant (biological mesh).
89275281|NCT01347697|Active Comparator|Gluteus maximus flap|Reconstruction with a gluteus maximus myocutaneous flap.
89275282|NCT01223092||Patients undegoing infertility treatment|Male and female patients undergoing infertility treatment
89275283|NCT01208974|Experimental|Phase 1 MTD NAC RT|"Participants will undergo a Nipple-Areolar Complex (NAC)-sparing mastectomy with immediate reconstruction and axillary surgery, if indicated, on Week 1. Anytime between Weeks 5-8, participants will undergo a dose-escalation/de-escalation of prophylactic NAC radiation treatment (RT) twice daily (minimum of 4 hours apart) for 5 days. Dose escalation/de-escalation design are as follows:~Dose Level I - 10 fractions of 2.0 Gy for a total of 20 Gy~Dose Level II - 10 fractions of 2.5 Gy for a total of 25 Gy~Dose Level III - 10 fractions of 3.0 Gy for a total of 30 Gy~Dose Level IV - 10 fractions of 3.5 Gy for a total of 35 Gy~Participants will be treated between cohorts of 2-6 patients per dose level starting at dose level II. Dose escalation stops when 2 out of 2-6 participants encounter Dose Limiting Toxicities (DLT).~Standard of care chemotherapy, at treating physician's discretion, can be initiated 2 weeks after RT."
89275284|NCT00897117||Resectable non-small cell lung cancer|Patients with clinical stage I or II invasive lung cancer that can be completely removed by surgery and who have not undergone chemotherapy or radiotherapy before surgery
89275285|NCT00840177|Experimental|treatment|"Induction (1 cycle):~pravastatin 1280 mg/d PO D 1-8 idarubicin 12 mg/m2/d IV D 4-6 cytarabine 1.5 g/m2/d continuous IV D 4-7~Consolidation (up to 2 cycles):~pravastatin 1280 mg/d PO D 1-6 idarubicin 12 mg/m2/d IV D 4-5 cytarabine 1.5 g/m2/d continuous IV D 4-5"
89275286|NCT01347580|Experimental|Ticagrelor|Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
89275287|NCT01347580|Experimental|Placebo|Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
89275288|NCT00398411|Experimental|Moxifloxacin|moxifloxacin 400 mg tablets once daily
89275289|NCT00398411|Placebo Comparator|Placebo|identical appearing placebo
89275290|NCT03352414|Experimental|Alvimopan|alvimopan 12 mg PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
89275291|NCT03352414|Placebo Comparator|Placebo|Placebo pill PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
89275292|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 months to < 6 months|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
89275293|NCT00364793|Experimental|EFV+ddI+FTC in patients >=6 months to < 2 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
89275294|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 2 years to < 3 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
89275295|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 years to <= 6 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
89275296|NCT03351478|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.
89275297|NCT03351478|Active Comparator|Empagliflozin 25 mg|Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.
89275298|NCT03351478|Placebo Comparator|Placebo|Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.
89275299|NCT04572737|Experimental|Experimental|Participants will take part in an 8-week home-based activity plan to break up sitting time by 60 minutes per day.
89275300|NCT00363545|Experimental|Liquid Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the liquid formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
89275301|NCT00363545|Experimental|Lyophilized Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the lyophilized formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
89275302|NCT01042301|Experimental|Long-term type 1 diabetic patients|Long-term type 1 diabetic patients
89275303|NCT01042301|Active Comparator|control patients|control patients
89275304|NCT01042301|Experimental|diabetic and transplanted patients|diabetic and transplanted patients
89275305|NCT01042301|Experimental|subjects with high risk for diabetes|subjects with high risk for diabetes
89275306|NCT01042301|Experimental|patients with recent type 1 diabetes|patients with recent type 1 diabetes
89275307|NCT01042301|Experimental|patients with Latent Autoimmune Diabetes|patients with Latent Autoimmune Diabetes
89275308|NCT03351244|Experimental|BI 409306 50 mg|1 film-coated tablet of 50 milligrams (mg) of BI 409306 plus 1 tablet of 25 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
89275309|NCT03351244|Experimental|BI 409306 25 mg|1 film-coated tablet of 25 milligrams (mg) of BI 409306 plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
89275310|NCT03351244|Placebo Comparator|Placebo|1 film-coated tablet of 25 milligrams (mg) of matching Placebo plus 1 tablet of 50 mg matching placebo were administered orally once daily for a treatment period of 28 weeks, followed by a withdrawal/taper period of 7 days, followed by a follow-up period of 3 weeks.
89275311|NCT03386032|Experimental|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
89275312|NCT03386032|Sham Comparator|Placebo Cream|Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
89275313|NCT03386032|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
89275314|NCT03712150||Healthy|"Healthy adults~- Participants will receive single session of tdcs after application"
89275315|NCT05452486|Experimental|Auditory Processing Disorder (APD) Assessment|All participants will receive both experimental conditions (i.e., test materials in English, test materials in Spanish) in a counterbalanced order.
89275316|NCT00077610|Experimental|RO0503821 (1x/2 Weeks)|Participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram [mcg]) that was based on the Epoetin dose (<8000, 8000-16000, >16000 International units [IU]/Week) administered during the week preceding the switch to the study drug.
89275317|NCT00077610|Experimental|RO0503821 (1x/4 Weeks)|Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (<8000, 8000-16000, >16000 IU/Week) administered during the week preceding the switch to the study drug.
89275318|NCT00077610|Active Comparator|Epoetin (1-3x/Weeks)|Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.
89275319|NCT03385564|Experimental|BI 655064 120 mg|120 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every 2 weeks plus the administration of matching placebo as subcutaneous injection in a prefilled syringe once every 2 weeks (in the alternative weeks without BI 655064 administration) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
89275320|NCT03385564|Placebo Comparator|Placebo|Matching placebo were administered as solution for subcutaneous injection in a prefilled syringe once every week over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
89275321|NCT03385564|Experimental|BI 655064 180 mg|180 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every 2 weeks plus the administration of matching placebo as subcutaneous injection in a prefilled syringe once every 2 weeks (in the alternative weeks without BI 655064 administration) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
89275322|NCT03385564|Experimental|BI 655064 240 mg|120 milligrams (mg) BI 655064 were administered as solution for subcutaneous injection in a prefilled syringe once every week (240 mg every 2 weeks) over a treatment period of 52 weeks, followed by a 12-week follow-up period. The patients received 1 injection per week.
89275323|NCT05344924|Experimental|Cohort I（TACE-A-A Cohort）|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
89275324|NCT05344924|Experimental|Cohort II (A-A Cohort)|Patients will receive penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
89275325|NCT01085994||Procalcitonin-guided group|
89275326|NCT01085994||Routine practice group|
89275327|NCT03741270|Experimental|Vaccine|
89275328|NCT00066222|Experimental|Radiation Therapy + Chemotherapy|Accelerated high dose thoracic radiation therapy (RT) with concurrent cisplatin/etoposide chemotherapy, followed by 2 cycles of adjuvant cisplatin/etoposide chemotherapy
89275329|NCT00397943|Experimental|M72/AS01B Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS01B vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
89275330|NCT00397943|Experimental|M72/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
89275331|NCT00397943|Active Comparator|Mtb72F/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator Mtb72F/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
89275332|NCT00397943|Active Comparator|Non-adjuvanted Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator GSK Biologicals' candidate recombinant M. tuberculosis vaccine, non-adjuvanted, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
89275333|NCT00397943|Placebo Comparator|Control Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the adjuvant system alone, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
89275334|NCT00066066|Placebo Comparator|Scaling and root planing alone|Full mouth scaling and root planing (SRP) alone plus a placebo pill taken twice daily for 2 weeks.
89275335|NCT00066066|Active Comparator|SRP + Metronidazole|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 days
89275336|NCT00066066|Active Comparator|SRP + MET + Amoxicillin + Doxycycline|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 d and Amoxicillin (AMOX) 500 mg tid for 14 days and local drug delivery of Doxycycline (TET LDD) in pockets >4mm
89275337|NCT01091922|Placebo Comparator|Low Flavanol|Low flavanol drink containing 23 mg of total flavanols. Macro- and micro-nutrient matched with active comparator
89275338|NCT01091922|Active Comparator|High Flavanols|High Flavanol drink containing 495 mg of total flavanols
89275339|NCT00363467|Other|Autologous Hematopoietic Progenitor Cell Transplantation|G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion
89275340|NCT00397631|Experimental|1|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
89275341|NCT00397631|Active Comparator|2|sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.
89275342|NCT00077376|Experimental|Treatment (trastuzumab, ixabepilone, carboplatin)|"Induction therapy: Patients receive trastuzumab (Herceptin®) IV over 30 minutes* on days 1, 8, 15, and 22 and ixabepilone IV over 1 hour and carboplatin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of unacceptable toxicity.~NOTE: *Trastuzumab is given over 90 minutes on day 1 of course 1 (induction therapy) only.~Maintenance therapy: Patients receive trastuzumab IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89275343|NCT01088724|Experimental|chemotherapy|
89275344|NCT03957174|Experimental|Reboxetine|Single dose of 4mg
89275345|NCT03957174|Experimental|Rivastigmine|Single dose of 3mg
89275346|NCT03957174|Placebo Comparator|Placebo|Single dose of placebo
89275347|NCT00363311|Active Comparator|Dutasteride|Dutasteride 0.5mg
89275348|NCT00363311|Placebo Comparator|Placebo|Matching placebo
89275349|NCT02534987|Experimental|iCPR2 intervention|EMR integrated clinical prediction rule system guiding antibiotic prescription choices for strep and pneumonia
89275350|NCT02534987|No Intervention|iCPR2 control|Standard education/academic detailing on appropriate treatment of strep and pneumonia
89275351|NCT00362609|Active Comparator|Low dose|
89275352|NCT00362609|Active Comparator|High dose|
89275353|NCT03991871|Placebo Comparator|Control Group|35 hours ECP treatment, initial treatment pressure is 75 mmHg
89275354|NCT03991871|Experimental|Intervention Group|35 hours ECP treatment, initial treatment pressure is 300 mmHg
89275355|NCT00362375|Experimental|Healthy Love Workshop|Single-session, small-group HIV prevention intervention
89275356|NCT00362375|Active Comparator|HIV101|Single-session, small-group intervention providing facts regarding HIV/AIDS
89275357|NCT02534753|Experimental|Single Group|
89275358|NCT01042457|Other|Mycophenolate mofetil|
89275359|NCT00362297|Active Comparator|Standard dose|
89275360|NCT00362297|Experimental|High-dose|
89275361|NCT00065442|Placebo Comparator|APC-Placebo|
89275362|NCT00065442|Active Comparator|Sipuleucel-T|
89275363|NCT01042691|Experimental|Oxaliplatin|Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR and Leucovorin directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. This study will examine the addition of a one hour isolated hepatic perfusion with oxaliplatin to this standard treatment
89275364|NCT01050023|Experimental|1 - Active Treatment|Provant device activated to emit RF energy
89275365|NCT01050023|Sham Comparator|2 - Inactive Treatment|Provant device not activated to emit RF energy
89275366|NCT01092000||Faculty/Staff|
89275367|NCT01092000||Graduate Students|
89275368|NCT01092000||Undergraduate Students|
89275369|NCT01050101|Placebo Comparator|High GI low fiber meal|No fiber control meal
89275370|NCT01050101|Active Comparator|Low GI high fiber viscous meal|80:20 ratio of viscous polysaccharide fiber to insoluble non-viscous producing fiber
89275371|NCT01050101|Active Comparator|Low GI high fiber non-viscous meal|20:80 ratio of viscous polysaccharide fiber source to insoluble non-viscous producing fiber
89275372|NCT00090402|Placebo Comparator|Fish Oil Placebo & Lipoic Acid Placebo|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram placebo-lipoic acid per day. Placebo fish oil capsules consisted of soybean oil flavored with lemon flavor and 5% fish oil to match fish oil capsules. LA placebo contained no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate.
89275373|NCT00090402|Active Comparator|Fish Oil Only|Three 1-gram fish oil concentrate capsules in triglyceride form (675 milligrams DHA and 975 milligrams EPA), 2 in the morning and 1 in the evening, plus one 600 milligram placebo-lipoic acid (containing no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate) per day.
89275374|NCT00090402|Experimental|Fish Oil Plus Lipoic Acid|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram lipoic acid (LA) capsule in the racemic form per day.
89275375|NCT02534597|Experimental|pctm|Receives the earliest Promotores training, followed by direct caregiver training, materials support, and technical assistance.
89275376|NCT02534597|Experimental|p_ctm|Receives the earliest Promotores training, followed by delayed caregiver training, delayed materials support, and delayed technical assistance.
89275377|NCT02534597|Experimental|_pmt|Receives the delayed Promotores training, followed by receipt of materials support and technical assistance.
89275378|NCT02534597|Experimental|_p_mt|Receives the delayed Promotores training, followed by delayed receipt of materials support and technical assistance.
89275379|NCT02534597|Experimental|_pct|Receives the delayed Promotores training, followed by caregiver training and technical assistance.
89275380|NCT02534597|Experimental|_p_ct|Receives the delayed Promotores training, followed by delayed caregiver training and technical assistance.
89275381|NCT02534597|Experimental|_pt|Receives the delayed Promotores training, followed by technical assistance.
89275382|NCT02534597|Experimental|_p_t|Receives the delayed Promotores training, followed by delayed technical assistance.
89275383|NCT02534597|Experimental|_pc|Receives the delayed Promotores training, followed by a full caregiver training only.
89275384|NCT02534597|Experimental|_p_c|Receives the delayed Promotores training, followed by delayed caregiver training.
89275385|NCT01043003|Experimental|Arm I|Patients and caregivers undergo the Bilingual Breast Cancer Educational Intervention (BBCEI) comprising teaching sessions over 50-65 minutes about 4 specific domains (i.e., physical, psychological, social, and spiritual well being) once weekly during month 1 and also undergo evaluation sessions at months 1, 4, and 7. Patients and caregivers receive reinforcement telephone calls every other week.
89275386|NCT01043003|Active Comparator|Arm II|Patients and caregivers undergo usual care comprising evaluation sessions at months 1, 4, and 7. Patients and caregivers may undergo the 4 BBCEI teaching sessions during month 7. Patients and caregivers receive reinforcement telephone calls every other week.
89275387|NCT02534519||people negative in bg MNSs antigen U|"Blood group (bg) system MNSs. Individuals with phenotype U-. Homo- and heterozygous individuals may be considered."
89275388|NCT02534519||people positive in bg MNSs antigen St(a)|"Blood group (bg) system MNSs. Individuals with phenotype St(a)+. Homo- and heterozygous individuals may be considered."
89275389|NCT01050335||Surgical resident or attending|
89275390|NCT00361283|Other|atorvastatin|80mg of atorvastatin given once daily for 16 weeks
89275391|NCT00077064|No Intervention|Observation|Clinical observation
89275392|NCT00077064|Experimental|Captopril|Captopril
89275393|NCT01043471|Experimental|Chewing gum|
89275394|NCT01043471|Placebo Comparator|Water|
89275395|NCT02534441|Experimental|Skin patch testing to 6 known and 3 novel surfactants|
89275396|NCT01086072||Myocardial Infarction - STEMI|
89275397|NCT01086072||Myocardial Infarction - NSTEMI|
89275398|NCT03962010|Experimental|Dose level 1|
89275399|NCT03962010|Experimental|Dose level 2|
89275400|NCT03962010|Experimental|Dose level 3|
89275401|NCT03962010|Experimental|Dose level 4|
89275402|NCT03962010|Placebo Comparator|Placebo|
89275403|NCT03962010|Active Comparator|Dulaglutide|
89275404|NCT00396383|Experimental|Participants with Multiple Myeloma (MM)|Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.
89275405|NCT01092078|Experimental|Motivational Interviewing|Individuals in the motivational interviewing (MINT) arm of the study will receive telephone-based lifestyle interviewing for 6-months. Counseling will be aimed at modifying diet and/or physical activity behaviors associated with decreasing blood pressure.
89275406|NCT01092078|Experimental|Patient Navigation|Participants in the patient navigation arm will receive patient navigation for colonoscopy.
89275407|NCT01092078|Experimental|PLUS|Both patient navigation for colorectal cancer screening and motivational interviewing for blood pressure control
89275408|NCT01050413||1|colon cancer, prostate cancer, lung cancer, ovarian cancer
89275409|NCT01088880|Experimental|Canakinumab|
89275410|NCT02534363|Active Comparator|Aripiprazole & cognitive battery|Aripiprazole 5-30 mg/day. Cognitive battery at baseline and at 1 year.
89275411|NCT02534363|Active Comparator|Quetiapine & cognitive battery|Quetiapine 100-600 mg/day. Cognitive battery at baseline and at 1 year.
89275412|NCT02534363|Active Comparator|Ziprasidone & cognitive battery|Ziprasidone 40-160 mg/day. Cognitive battery at baseline and at 1 year.
89275413|NCT01092234|Active Comparator|Traditional ward|
89275414|NCT01092234|Experimental|Observational unit|Organizational change. Innovative organization of in-hospital care
89275415|NCT01043549|Active Comparator|Stimulation|Repetitive transcranial stimulation of the posterior parietal cortex
89275416|NCT01043549|Sham Comparator|Sham stimulation|
89275417|NCT03961230|Experimental|Oral Chinese medicine|Participants in experimental group will receive Jueyin granule two times daily after meals three times per week for 8 weeks.
89275418|NCT03961230|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Jueyin granule placebo two times daily after meals three times per week for 8 weeks.
89275419|NCT01050491|Placebo Comparator|sitaxsentan, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
89275420|NCT01050491|Placebo Comparator|placebo, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
89275421|NCT01088958|Experimental|Micronutrient Sprinkles|Sales of Sprinkles in these groups of villages by community vendors
89275422|NCT01086306||Patients exposed to Saxagliptin|
89275423|NCT01086306||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
89275424|NCT01050725||Radiation therapy patients|Individuals receiving radiation therapy as definitive or neo-adjuvant therapy for selected malignancies, including head and neck, lung, esophageal, rectal cervical and prostate cancers.
89275425|NCT01089036||survival|ECMO survival patients
89275426|NCT01089036||ECMO non-survival|ECMO non-survivals
89275427|NCT01050803|Experimental|FDSME group|In the FDSME group, sessions will be held interactive; and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
89275428|NCT01050803|Active Comparator|Control group|
89275429|NCT03962244||SEMS Group|The outcome of using self-expanding metal stents (SEMS) in the treatment of postoperative leakage after esophagogastrostomy
89275430|NCT03962244||EVT Group|The outcome of using endoscopic vacuum therapy (EVT) in the treatment of postoperative leakage after esophagogastrostomy
89275431|NCT00395447||Straight-forward Device Replacement|Subject with a straight-forward device replacement without lead revisions or additions.
89275432|NCT00395447||Device Replacement with Upgrade|Subjects with a device replacement and planned lead upgrade, revision, or addition.
89275433|NCT03404674|Experimental|Group A1: CssBA 5 ug|Participants received an intramuscular injection of 5 ug CssBA on days 1, 22, and 43.
89275434|NCT03404674|Experimental|Group A2: DmLT 100 ng|Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.
89275435|NCT03404674|Experimental|Group B: CssBA 5 ug + DmLT 100 ng|Participants received an intramuscular injection of 5 ug CssBA + 100 ng dmLT on days 1, 22, and 43.
89275436|NCT03404674|Experimental|Group C: CssBA 5 ug + DmLT 500 ng|Participants received an intramuscular injection of 5 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
89275437|NCT03404674|Experimental|Group D: CssBA 15 ug + DmLT 500 ng|Participants received an intramuscular injection of 15 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
88805590|NCT01045187|Other|endometrial cancer|Patients are treated with electronic brachytherapy for an FDA cleared indication.
88805591|NCT02543658|Experimental|Neostigmine|Intramuscular injection of neostigmine on the basis of conventional conservative treatment
89275438|NCT03404674|Experimental|Group E: CssBA 45 ug + DmLT 500 ng|Participants received an intramuscular injection of 45 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
89275439|NCT00064662|Other|Burch|The Burch colposuspension
89275440|NCT00064662|Other|Sling|Pubovaginal sling, using autologous rectus fascia
89275441|NCT03404518|Experimental|Norco and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
89275442|NCT03404518|Active Comparator|Ibuprofen and Norco|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
89275443|NCT03404206|Experimental|Naproxen Sodium (Aleve, BAY117031)|Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
89275444|NCT03404206|Active Comparator|Ibuprofen (Advil)|Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
89275445|NCT03404206|Placebo Comparator|Placebo|Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization
89275446|NCT03403426|Experimental|Wingman Crossing Catheter|Use of the device to support CTO crossing
89275447|NCT00394901|Placebo Comparator|Placebo|
89275448|NCT00394901|Experimental|Pregabalin 150mg/day|
89275449|NCT00394901|Experimental|Pregabalin 300mg/day|
89275450|NCT00394901|Experimental|Pregabalin 600mg/day|
89275451|NCT03349060|Experimental|PF-04965842 100 mg|
89275452|NCT03349060|Experimental|PF-04965842 200 mg|
89275453|NCT03349060|Placebo Comparator|Placebo|
89275454|NCT01051037|Experimental|Arm 1|Subjects will undergo PET/CT simulation, 3 Fraction SBRT, RFA, and then undergo follow up.
89275455|NCT03990935|Active Comparator|sodium fluoride varnish|"The fluoride varnish will be bifluorid 10 single use by voco (Germany). It Contains 5 % sodium fluoride (equal to 22,600 ppm fluoride).~A thin coat will be applied on the tooth surface by using a brush. 10-20 s are sufficient for the varnish to be absorbed and then dry with air. Participants will be informed that they should not brush their teeth for 12-24 hours after the application and not to eat, or drink for at least 30 minutes after use to get the best results."
89275456|NCT03990935|Experimental|Ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
89275457|NCT03348904|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum doublet
89275458|NCT03348904|Active Comparator|Arm B|Platinum doublet chemotherapy
89275459|NCT03348904|Experimental|Arm C|Nivolumab plus placebo in combination with platinum doublet chemotherapy.
89275460|NCT00359021|Experimental|001|TMC125 200 mg twice daily until commercially available
89275461|NCT02534207|Experimental|Basmisanil in Japanese Healthy Volunteers|Japanese healthy volunteers will receive a single oral dose of RO5186582 within 15 minutes after completing a standard meal.
89275462|NCT00360269|Experimental|Active|Atomoxetine plus Motivational Enhancement Therapy
89275463|NCT00360269|Placebo Comparator|Placebo|Placebo plus Motivational Enhancement Therapy
89275464|NCT03990857|Experimental|Intervention|Group of participants with a recent DM2 debut (less than 5 months) treated according to the comprehensive care protocol in DM2 with comorbidities attended in Primary care nurse office
89275465|NCT03990857|No Intervention|comparison group|Participants in the study that do not receive the intervention. usual care.
89275466|NCT01052597|Placebo Comparator|Placebo|
89275467|NCT01052597|Experimental|Curcumin|
89275468|NCT01051115|Experimental|Dasatinib|Patients will be treated with dasatinib monotherapy 100mg daily. At four weeks patients will be re-evaluated. Patients with less than a partial response will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib.
89275469|NCT00076752|Experimental|Autologous HSCT in SLE|"Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).~SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion."
89275470|NCT03960918|No Intervention|usual neuro-rehab training|stroke patient under usual neuro-rehab training
89275471|NCT03960918|Experimental|Novel exercise training|stroke patient under aerobic exercise training
89275472|NCT03384940|Experimental|DS-8201a Cohort A|Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks
89275473|NCT03384940|Experimental|DS-8201a Cohort B|Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks
89275474|NCT03384940|Experimental|DS-8201a Cohort C|Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks
89275475|NCT00075582|Experimental|Regimen I (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)
89275476|NCT00075582|Experimental|Regimen II (chemotherapy, radiotherapy, surgery)|Patients receive VAC chemotherapy and radiation therapy as in regimen I and VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21, 25-33, and 37-45 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, and 46 (dactinomycin is omitted during radiation therapy). Some patients do not receive radiation therapy; some start it at week 13 and some at week 24. Some patients have conventional surgery (second-look) at Week 13 (closed to accrual as of 9/23/2011).
89275477|NCT01092312|Experimental|Signature Knee Guide|Vanguard Knee System with Signature Knee Guide
89275478|NCT01092312|Active Comparator|Conventional Approach|Vanguard Complete Knee System with Conventional Approach
89275479|NCT00063258|Active Comparator|Chemotherapy + Tarceva|
89275480|NCT00063258|Active Comparator|Chemotherapy Alone|
89275481|NCT01086462|Experimental|GSK2239633|Single dose infusion of study drug over 15 minutes
89275482|NCT00088530|Experimental|Experimental Arm|Pixantrone (BBR2778)
89275483|NCT00088530|Active Comparator|Comparator Arm|To be chosen by the investigator, among vinorelbine, oxaliplatin, ifosfamide, etoposide or mitoxantrone
89275484|NCT00359801|Experimental|Exubera|
89275485|NCT00359801|Active Comparator|Usual Diabetes Care|
89275486|NCT02533817|Experimental|Dietary Sugar - Fructose|Each participant consumed 20% daily caloric requirement as fructose.
89275487|NCT02533817|Active Comparator|Dietary Sugar - Glucose|Each participant consumed 20% daily caloric requirement as glucose.
89275488|NCT03990701|Experimental|Single Arm|All patients will undergo standard-of-care investigations (CT imaging of adrenals and AVS) and the research test (11C-metomidate PET-CT) with a dose of 150 - 300 Megabecquerel (MBq) (11C-metomidate) to identify functional unilateral adrenal disease.
89275489|NCT01052675||Pharmacodependance cases|Case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.
89275490|NCT01051193|Experimental|TRI476|TRI476
89275491|NCT01052753||ADHD group|
89275492|NCT01052753||Control group|
89275493|NCT01051271|Active Comparator|diphenhydramine|
89275494|NCT01051271|Placebo Comparator|saline|
89275495|NCT03991637|Experimental|NICMP Spectral Reading|Non-invasive spectral data is collected from this arm to function as the intervention of interest.
89275496|NCT03991637|Active Comparator|Venipuncture CMP|"A standard CMP blood draw is performed to function as the gold standard reference value.~Specifically, the outcome of the experimental arm is cross-validated against the active comparator arm to determine the NICMP accuracy, relative to the venipuncture method."
89275497|NCT01051427|Active Comparator|Nasal catheter|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized not to put Surgiflo. So they receive the usual treatment with a nasal catheter balloon into the nose.
89275498|NCT01051427|Experimental|Surgiflo|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized to put into the nose Surgiflo.
89275499|NCT01052909|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
89275500|NCT01052909|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
89275501|NCT00045032|No Intervention|Observation Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.
89275502|NCT00045032|Experimental|Herceptin 1-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
89275503|NCT00045032|Experimental|Herceptin 2-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
89275504|NCT01052987|Experimental|Tranilast|Tranilast tablets
89275505|NCT01052987|Active Comparator|Allopurinol|Allopurinol tablets
89275506|NCT01052987|Experimental|Combination|Tranilast plus Allopurinol
89275507|NCT01052987|Active Comparator|High dose Allopurinol|400 mg Allopurinol
89275508|NCT01052987|Experimental|High dose combination|Combination of Tranilast 300 mg and Allopurinol 400 mg
89275509|NCT02533973|Active Comparator|Xamiol® gel|calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as diproprionate) once daily as required, for up to 28 weeks
89275510|NCT02533973|Active Comparator|. Daivonex® scalp solution|calcipotriol 50mcg/g twice daily as required, for up to 28 weeks
89275511|NCT02533895|Experimental|Treatment with AV0113|"14 sarcoma and 7 non-sarcoma are treated with AV0113, an anti-tumour immune therapy with autologous DCs loaded with tumour cell lysates in order to establish the feasibility and safety of tumour vaccination.~Peripheral blood mononuclear cells (MNCs) are obtained from patients by leukocyte apheresis. Monocytes enriched by density gradient centrifugation from MNCs will be used to generate immature DCs. These immature DCs will be loaded with autologous tumour cell lysates obtained by needle biopsy or surgery prior to tumour vaccination. The antigen loaded immature DCs will then receive a final maturation stimulus transmitted by exposure to lipopolysaccharide and interferon-gamma. Maturation enables DCs to present antigen with high efficiency to T-lymphocytes."
89275512|NCT02533895|Other|Historic control|In order to be able to compare the survival data of 14 sarcoma patients treated with AV0113, 42 historic control sarcoma patients from the data base of the Department of Orthopaedics, Medical University Vienna, that will be matched for disease, recurrences, relapses etc. will be included into this study.
89275513|NCT01051505|Experimental|1|
89275514|NCT01051505|Placebo Comparator|2|
89275515|NCT02534051|Active Comparator|Clinical care pathway|The intervention is the clinical care pathway designed by investigators, informed by the national guideline co-authored by one of the team, and supplemented by the review of the literature
89275516|NCT02534051|No Intervention|Usual Care|The control group will receive the usual prenatal care.
89275517|NCT01581125|Experimental|Sleep:wake 2|Sleep and wake durations for arm 2 for inpatient portion of protocol. .There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 1.
89275518|NCT01581125|Experimental|Sleep:wake 1|Sleep and wake durations for arm 1 of the inpatient portion of the protocol. There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 2.
89275519|NCT01053065|Active Comparator|Atorvastatin 10 mg/day|Arm composed of 20 patients, receiving atorvastatin 10 mg/day
89275520|NCT01053065|Active Comparator|Atorvastatin 80 mg/day|Arm composed of 20 patients, receiving atorvastatin 80 mg/day
89275521|NCT01053065|Active Comparator|Cholestyramine - Sitosterol|Arm composed of 20 patients receiving cholestyramine 8 g/day plus sitosterol 2.5 g/day
89275522|NCT02533661|Experimental|Family-centered intervention program|"The FCIP group received:~In-hospital intervention: modulation of the NICU, teaching of child development skills, feeding support,massage,parent support and education,transition home preparation.~After-discharge: clinic (1, 2, 4, 9 months) and home visits (0, 6, 12 months) for teaching of child development skills, feeding support, dyadic interaction activities, modulations of home environment, parent support and education."
89275523|NCT02533661|No Intervention|Usual care program|"The UCP group received:~In-hospital intervention: environmental modulation and teaching of child development skills.~After-discharge:telephone calls (0, 1, 2, 4, 6, 9 and 12 months): consultation on general care concerns"
89275524|NCT01051583|Experimental|Avastin , diode laser cyclophotcoagulation|Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
89275525|NCT01051583|Active Comparator|Diode Laser cyclophotocoagulation|Diode laser cyclophotocoagulation to control intraocular pressure
89275526|NCT01053143|Experimental|Study Group|Participants aged 18 years and older at enrollment.
89275527|NCT02533583||symptomatic newborn|the symptomatic newborn cohort( symptomatic definition see detail),all of babies will referred for chest X-ray,and within 2 hours performing echocardiography to exclude critical and serious heart disease.All clinical assessment will do by attending doctor.
89275528|NCT02533583||Asymptomatic newborn|the asymptomatic newborn cohort will gave pulse oximetry and clinical assessment every 8 hours within 3 days.everybody have positive results will been preformed chest X-ray and echocardiography.All clinical assessment will do by attending doctor.
89275529|NCT01053299|Active Comparator|No treatment|Every child, without exception, born in the peroid 1.2.1998 - 31.12.2006, still alive, will be called for to take a Xray of their hips aimed at comparing the ultrasound-values taken newborn.
89275530|NCT03950804||CHAPLE patients, without eculizumab treatment|Patients with suspected CHAPLE syndrome undergo flow-cytometry based CD55 surface staining of peripheral blood samples. Those patients with loss of CD55 protein expression are diagnosed with CHAPLE syndrome. A subgroup of the CHAPLE patients describe only mild symptoms and are not treated with eculizumab, but monitored closely for any disease progression.
89275531|NCT03950804||Control subjects- no intervention|Healthy subjects with no history of any chronic disease. All investigational analyses are performed on both the case and the control subjects. Therefore, the same type of biological specimens collected from the case group are collected from the control group simultaneously.
89275532|NCT03950804||Non-CHAPLE PILs|PIL patients with intact CD55 on flow-cytometry assesment undergo genetic testing to exclude a potential missense mutation in the CD55 gene that impairs its function while retaining protein expression. Overall, patients and their parents undergo exome sequencing as trios, and examined for potential gene mutations underlying their disease. Non-CHAPLE PILs are also examined by high-throughput investigation similarly to CHAPLE patients.
89275533|NCT03950804||CHAPLE patients on eculizumab|Among CHAPLE patients, there is a subgroup who receive eculizumab treatment. These patients are prospectively followed and biological samples collected at baseline as well as periodically under therapy. Eculizumab (Soliris) is being provided for CHAPLE patients on an off-label basis upon approval of the physician's request of the drug by Turkish Medicines and Medical Devices Agency (TMMDA) of Turkish Ministry of Health. The dosage and interval of the drug is determined according to manufacturer's recommendations based on the weight of the patients.
89275534|NCT03950882|Experimental|PXL770|PXL770 500 mg once daily (QD) for 4 weeks
89275535|NCT03950882|Placebo Comparator|Placebo|placebo once daily (QD) for 4 weeks
89275536|NCT00356915|Experimental|Itraconazole tablets|Itraconazole 200 mg tablets
89275537|NCT00356915|Active Comparator|Itraconazole capsules|Two Itraconazole 100 mg capsules were taken daily.
89275538|NCT00356915|Placebo Comparator|Placebo tablets|The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
89275539|NCT01051973|Experimental|Cognitive behavior therapy|
89275540|NCT01051973|Active Comparator|Stress management|
89275541|NCT00356759|Sham Comparator|12-weekly INR|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
89275542|NCT00356759|No Intervention|Standard management|Dosing warfarin every 4 weeks, all INRs true values
89275543|NCT03804710|Experimental|Test Product 1|Participants will apply 2 pumps of the test product (approximately 0.3ml x 2= 0.6ml) to the randomly assigned side of the face, including forehead and chin, and 6 pumps of test product (approximately 0.3 ml x 6 = 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) topically twice-daily (in the morning and evening) after cleansing.
89275544|NCT03804710|Experimental|Test Product 2|Participants will apply pea-sized amount of the test product (approximately 0.6ml) to the randomly assigned side of the face, including forehead and chin, and walnut-sized amount of the test product (approximately 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) twice-daily (in the morning and evening) after cleansing.
89275545|NCT03804710|Placebo Comparator|Standard soap cleanser|Participants will use wet soap with warm water and form lather. Participants will cleanse their entire face and both lower legs (between the knees and ankles) twice daily (morning and evening).
89275546|NCT00356603|Experimental|Sumatriptan|Sumatriptan
89275547|NCT01052051|Experimental|vitamin D3 and calcium carbonate|Daily vitamin D3 2000 IU/day and calcium carbonate 1500mg/day supplementation
89275548|NCT01052051|Placebo Comparator|Placebo for vitamin D3 and calcium carbonate|Placebo for daily vitamin D3 and calcium carbonate
89275549|NCT03948230|Active Comparator|Sodium chloride / Water|300mg sodium chloride consumed in a capsule on two occasions with 300ml water
89275550|NCT03948230|Active Comparator|Sodium chloride / no water|300 mg sodium chloride consumed
89275551|NCT03948230|Active Comparator|Sodium chloride / colored water|300mg sodium chloride consumed in a capsule on two occasions with 300ml coloured water
89275552|NCT03948230|Placebo Comparator|Placebo / water|Placebo consumed in a capsule on two occasions with 300ml water
89275553|NCT03948230|Placebo Comparator|Placebo / no water|Placebo capsule consumed
89275554|NCT03948230|Placebo Comparator|Placebo / coloured water|Placebo consumed in a capsule on two occasions with 300ml colored water
89275555|NCT03990155|Experimental|HFNCOT+ECCO2R|Patients on NIV+ECCO2R who have reached at least for 4 consecutive hours, a RR <25 bpm + pH >7.35 + absence of clinical signs of respiratory distress after treatment with NIV+ECCO2R
89275556|NCT01096394||Ovarian cancer|Patients with presumed Stage III-IV ovarian, primary fallopian tube, or primary peritoneal papillary serous carcinoma.
89275557|NCT03948152|Active Comparator|Standard of Care|
89275558|NCT03948152|Experimental|Mask Advice Tool|
89275559|NCT01104428|Placebo Comparator|placebo|
89275560|NCT01104428|Experimental|"Drug:ziying"|
89275561|NCT05370872|No Intervention|Care-as-usual|Clients in this group will complete functional testing in the clinic using the care-as-usual approach.
89275562|NCT05370872|Experimental|Remote functional testing|Clients in this group will complete functional testing using the remote functional testing approach.
89275563|NCT03947996|Experimental|Stretching|Stretching
89275564|NCT03947996|Experimental|Walking|Walking
89275565|NCT01104506|Active Comparator|Painless plexus|Patient with a painless avulsion of brachial plexus
89275566|NCT01104506|Active Comparator|Healthy|Healthy volunteers
89275567|NCT01104506|Experimental|Painful plexus|Patient with a painful avulsion of brachial plexus
89275568|NCT00002558|Experimental|chemotherapy administered with G-CSF and PBSC support|The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.
89275569|NCT03950648|Experimental|Spatial Cognitive Training|map reading and route-learning skills
89275570|NCT01101932|Experimental|(Part 1) PF-04308515|
89275571|NCT01101932|Placebo Comparator|(Part 1) Solution Placebo|
89275572|NCT01101932|Experimental|(Part 2) PF-04308515 Tablet|
89275573|NCT00001880|Experimental|Stem Cell Transplantation in Patients With Progressive and Incurable Metastatic Solid Tumors|Cyclosporin beginning day -4 then stem cells given on Day 0 followed by intravenous Methotrexate on days +1, +3, and +6.
89275574|NCT01096472|Experimental|LAS41003|Once daily
89275575|NCT01096472|Active Comparator|LAS189962|Once daily
89275576|NCT01096472|Active Comparator|LAS189961|Once daily
89275577|NCT01102010|Experimental|Blood transfusion|"Restrictive strategy: Blood transfusion when hemoglobin is less than 6 mmol/l (9.7 g/dl)~Liberal strategy: Blood transfusion when hemoglobin is less than 7 mmol/l (11.3 g/dl)"
89275578|NCT05627648|Active Comparator|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
89275579|NCT05627648|Placebo Comparator|Placebo|Intracordal injection, once per week, 3 weeks
89275580|NCT03950726||Study Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection through the same incision
89275581|NCT03950726||Control Group|patients with complex crohn's disease who had a previous open appendectomy through a mc burney incision scheduled for ileo-colic resection who underwent standard laparoscopic resection
89275582|NCT03953924|No Intervention|Control group|No interventions were performed for the control patients during the study. While those in the control group were given conventional care ( nursing procedure, education about diet, exercise and so on)
89275583|NCT03953924|Experimental|Intervention group|The patients in intervention group received conventional care, transtheoretical model-based (TTM-based) intervention and motivational interviewing (MI).
89275584|NCT01102088|Experimental|Radiation + Chemotherapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.~Chemotherapy Administration: Schedule of chemotherapy, and modifications of chemotherapy drugs during chemoradiation treatment will be at the discretion of the treating medical oncologist per their standard of practice and with consideration to standard chemotherapy drugs in the treatment of esophageal cancer."
89275585|NCT03947528|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
89275586|NCT03947528|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fed condition
89275587|NCT01104896|Active Comparator|Nicotine|One or two 15mg nicotine patch(es) applied from 6am to 10pm according to the patients tobacco dependence measured by the Fagerström scale.
89275588|NCT01104896|Placebo Comparator|Placebo|One or two patch(es) with placebo
89275589|NCT01105052|Active Comparator|Bibliotherapy|A group receiving a self-help book to work on for six weeks with no therapist support.
89275590|NCT01105052|Experimental|Bibliotherapy with support|A group receiving a self-help book to work on for six weeks, together with brief weekly telephone calls (<15 minutes) from a therapist.
89275591|NCT01105052|No Intervention|Wait-list control group|This group receives no intervention until about five months after the two treatment groups, when participants in this group receive the self-help book without therapist support.
89275592|NCT00043550|Experimental|1 Sertraline/Venlafaxine|Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8
89275593|NCT00043550|Active Comparator|2 Supportive Expressive Therapy|Participants will receive supportive-expressive psychotherapy.
89275594|NCT00043550|Placebo Comparator|3 Pill Placebo|Participants receive placebo.
89275595|NCT03950258|Experimental|endovascular embolization|patients under the age of 18 years with arteriovenous shunts manifested by systemic or neurological manifestations will undergo endovascular embolization
89275596|NCT00041756|Placebo Comparator|Placebo|Placebo tablet
89275597|NCT00041756|Experimental|25 mg PG-530742|25 mg PG-530742
89275598|NCT00041756|Experimental|50 mg PG-530742|50 mg PG-530742
89275599|NCT00041756|Experimental|100 mg PG-530742|100 mg PG-530742
89275600|NCT00041756|Experimental|200 mg PG-530742|200 mg PG-530742
89275601|NCT03950180|Active Comparator|PCCI group|In addition to standard of care counseling the additional provision of the patient's specific Prostate Cancer Comorbidity Index score and life expectancy estimation was provided.
89275602|NCT03950180|No Intervention|Standard care|Standard of care was defined as prostate cancer counseling reflecting the best practices of a multidisciplinary team of urologists, radiation oncologists and medical oncologists.
89275603|NCT01102244|Experimental|Tobradex ST|tobramycin 0.3%, dexamethasone 0.05%
89275604|NCT01102244|Active Comparator|Azasite|azithromycin 1%
89275605|NCT01105208|Experimental|Arm 1|
89275606|NCT01105208|Active Comparator|Arm 2|
89275607|NCT01105286|Experimental|Calcipotriol ointment|
89275608|NCT00041132|Experimental|Hyper-CVAD + MTX/Ara-C + Rituximab|"21-day cycles of Hyper-CVAD and high-dose methotrexate/cytarabine are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.~Hyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and filgrastim 5 ug/kg on days 8-21.~Methotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21."
89275609|NCT01102322||1|
89275610|NCT00040742|Placebo Comparator|Placebo|Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
89275611|NCT00040742|Experimental|0.5g ginger|Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
89275612|NCT00040742|Experimental|1.0g ginger|Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
89275613|NCT00040742|Experimental|1.5g ginger|Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
89275614|NCT00040664|Experimental|2 to 5 years (FPV/RTV)|Two to five years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
89275615|NCT00040664|Experimental|6 to 11 years (FPV/RTV)|Six to twelve years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
89275616|NCT00040664|Experimental|12 to 18 years (FPV/RTV)|Twelve to Eighteen years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
89275617|NCT03947372|Active Comparator|OA (open Appendectomy)|Open Appendectomy
89275618|NCT03947372|Experimental|LA (Laparoscopic Appendectomy)|Laparoscopic Appendectomy
89275619|NCT02952586|Experimental|Avelumab + SOC Chemoradiation Therapy|"Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
89275620|NCT02952586|Placebo Comparator|Placebo + SOC CRT|"Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
89275621|NCT03949946||High-risk|Female participants confirmed to be BRCA1/2 or TP53 gene carriers
89275622|NCT03949946||Patients|Female participants confirmed to have invasive ductal carcinoma of the breast
89275623|NCT03950102|Experimental|SBRT|SBRT will be used as the primary bridging therapy for HCC patients on waitlist
89275624|NCT01096628|Experimental|Chiropractic + Exercise|
89275625|NCT01096628|Active Comparator|Exercise|
89275626|NCT03949790|Active Comparator|Intercostal block with ESPB|Performed ESPB in VATs with intercostal nerve block
89275627|NCT03949790|Active Comparator|Intercostal block without ESPB|Not Performed ESPB in VATs with intercostal nerve block
89275628|NCT01096706|Experimental|Nitric Oxide Clamp|Forearm blood flow response to Urocortins 2, 3 and Substance P in the presence of Nitric Oxide clamp
89275629|NCT01096706|Placebo Comparator|Saline Placebo|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of saline placebo.
89275630|NCT01096706|Experimental|Fluconazole|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of intra-arterial Fluconazole.
89275631|NCT01096706|Experimental|Aspirin|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of cyclooxygenase inhibition with Aspirin.
89275632|NCT01096706|Experimental|Combined|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of inhibition of cycloxygenase, EDHF and NO pathways with Aspirin, Fluconazole and NO clamp.
89275633|NCT03949712|Experimental|Right motor cortex (M1) tSMS|tSMS will be applied to the right motor cortex for 30 minutes.
89275634|NCT03949712|Experimental|Left motor cortex (M1) tSMS|tSMS will be applied to the left motor cortex for 30 minutes.
89275635|NCT03949712|Sham Comparator|Sham tSMS|Sham tSMS will be applied to the left or right motor cortex (randomized) for 30 minutes.
89275636|NCT01102400|Experimental|1|
89275637|NCT01327820||Open aortic aneurysm repair|
89275638|NCT01327820||Endovascular aortic aneurysm repair|
89275639|NCT01327820||Infra-inguinal lower limb revascularisation|
89275640|NCT05555368|Other|single group|The Qo0R-15 scale will be administered to 150 patients.
89275641|NCT01105442||Bupivacaine|Patients who received bupivacaine + sufentanil
89275642|NCT01105442||Levobupivacaine|Patients who received levobupivacaine and morphine on demand
89275643|NCT01108640||Elective surgical patients|
89275644|NCT01108640||Massive resuscitation patients|
89275645|NCT01108640||surgical patients on pressors|
89275646|NCT01105520||intralspinal processes|Patients with intralspinal processes
89275647|NCT01105598|Experimental|Cohort 1|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
89275648|NCT01105598|Experimental|Cohort 2|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
89275649|NCT01105598|Experimental|Cohort 3|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
89275650|NCT01105598|Experimental|Cohort 4|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
89275651|NCT01105598|Experimental|Cohort 5|Free-living subjects (18 active/6 placebo) with mild dyslipidemia
89275652|NCT03384316|Experimental|1/Arm 1-Dose De-Escalation|Dose De-Escalation
89275653|NCT03384316|Experimental|2/Arm 2 - Dose Expansion|Dose Expansion
89275654|NCT01584752||Fistula patients|Gore-BioA Fistula Plug
89275655|NCT01584830|Experimental|Arm 1|
89275656|NCT01584830|Placebo Comparator|Arm 2|
89275657|NCT01105676|Experimental|single group single arm study|Open no masking is used. All involved know the identity of the intervention assignment
89275658|NCT03403192|Active Comparator|EZ-Blocker in the left lung|This arm will receive the EZ-Blocker in the left lung of their body, which functions as a bronchial blocker.
89275659|NCT03403192|Active Comparator|EZ-Blocker in right lung|This arm will receive the EZ-Blocker in the right lung of their body, which functions as a bronchial blocker.
89275660|NCT03403192|Active Comparator|DLT in left lung|This arm will receive the DLT in the left lung of their body, which functions as a bronchial blocker.
89275661|NCT03403192|Active Comparator|DLT in right lung|This arm will receive the DLT in the right lung of their body, which functions as a bronchial blocker.
89275662|NCT03944642|Experimental|Intervention|Participants will receive the standard prenatal care and invited to participate of a breastfeeding workshop during the third trimester of pregnancy, with active and intentional participation of the pregnant woman and her partner/relative; based on adult education methodology. In addition, women participants will have continuous support during their breastfeeding process, up to 6 months of the child's life, through a virtual support group (whats-app), where they will receive messages that promote their self-efficacy in relation to their ability to breastfeed and may ask questions that are related to breastfeeding. Professionals in this group will be train before delivering the intervention.
89275663|NCT03944642|No Intervention|Standard Care|This group will receive the standard pre and postnatal regular care, for mother and child. Professionals who provide direct care will maintain their usual attention.
89275664|NCT01328210|Experimental|blood letting|Blood letting was performed immediately after baseline assessment and after 4 weeks. First blood removal consisted of 400ml, second blood removal was tailored according to subsequent serum ferritin levels between 300- 400 ml.
89275665|NCT01328210|No Intervention|waiting list control|This group received no specific treatment but was offered treatment after termination of the 6-week study phase
89275666|NCT03709420|Placebo Comparator|Placebo|Matching placebo capsule
89275667|NCT03709420|Experimental|FOR-6219|"Part I (SAD): Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.~Part II (MAD): Multiple oral doses of 50 mg QD, 75 mg BID and 150 mg BID.~Part III: Multiple oral doses of 10 mg, 25 mg, 75 mg and 150 mg BID"
89275668|NCT04958096|Experimental|Prefrontal Cortex (PFC)|The Prefrontal Cortex (PFC) treatment group will be have an implant bilaterally at the HDE-approved ALIC site and the PFC.
89275669|NCT04958096|Experimental|Anterior Cingulate Cortex (ACC)|The Anterior Cingulate Cortex (ACC) treatment group will be have an implant bilaterally at the HDE-approved ALIC site and the ACC.
89275670|NCT04940156|Other|Confirm Rx|Patient with cardiac implantable electronic devices with an atrial lead will have Confirm Rx Implantable Cardiac Monitor injected in the anterior chest wall.
89275671|NCT04940156|Other|LINQ|Patient with cardiac implantable electronic devices with an atrial lead will have LINQ Implantable Cardiac Monitor injected in the anterior chest wall.
89275672|NCT02529800|Experimental|Sequence 1|High fat diet+HGP0412 → High fat diet+HIP1402 → fasted state+HIP1402
89275673|NCT02529800|Experimental|Sequence 2|High fat diet+HIP1402 → fasted state+HIP1402 → High fat diet+HGP0412
89275674|NCT02529800|Experimental|Sequence 3|fasted state+HIP1402 → High fat diet+HGP0412 → High fat diet+HIP1402
89275675|NCT01105832|Experimental|Proximal humeral fracture - intervention|20 patients will be randomized to 20 micrograms daily of Teriparatide (Forsteo)
89275676|NCT01105832|No Intervention|Proximal humeral fracture|20 patients will receive standard treatment (physiotherapy)
89275677|NCT01105910|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
89275678|NCT01105910|Active Comparator|Sensitive Eyes|Sensitive Eyes Eye Drops (Bausch & Lomb)
89275679|NCT03949322|Experimental|Adapted Physical Activity Program|Patients in the experimental group take part in a program of Adapted Physical Activity lasting 6 weeks, with 2 sessions per week.
89275680|NCT03949400||Patients diagnosed with knee OA|Patients diagnosed with knee OA and assigned to undergo exercise therapy and education.
89275681|NCT01102634|Experimental|Acu-TENS|Application of TENS over acupuncture points
89275682|NCT01102634|Placebo Comparator|Placebo-TENS|Application of Acu-TENS but with no electricity
89275683|NCT03946982|Experimental|Low thoracic patient controlled epidural analgesia|
89275684|NCT03946982|Active Comparator|Lumbar epidural patient controlled epidural analgesia|
89275685|NCT03946982|Active Comparator|Low thoracic epidural morphine|
89275686|NCT03946982|Active Comparator|Lumbar epidural morphine|
89275687|NCT03944564|Active Comparator|Condition 1: sitting|Four hours of sitting condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
89275688|NCT03944564|Active Comparator|Condition 2: static standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
89275689|NCT03944564|Active Comparator|Condition 3: dynamic standing|Four hours of static standing condition will be applied with ad-libitum breaks for toilet use and stretching. During this condition all cognitive, motor and pain scales will be monitored.
89275690|NCT01102712|Experimental|BTVA|
89275691|NCT00356525|Experimental|Less Than One Year: Pemetrexed|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
89275692|NCT00356525|Experimental|Less Than One Year: Pemetrexed + Gemcitabine|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
89275693|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Carboplatin|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
89275694|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Gemcitabine|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
89275695|NCT03766958||Registry Patients With Nodify Lung Results|Patients providing consent to have data collected to observe how Nodify Lung results were used in the clinical management of their lung nodules.
89275696|NCT03766958||Contemporaneous Group Without Nodify Lung|Contemporaneous group who did not have Nodify Lung test results for use in the clinical management of their lung nodules.
89275697|NCT01106066|Experimental|S-1/oxaliplatin/RT|Radiotherapy + 4 dose levels of oxaliplatin/S-1
89275698|NCT01327898|Experimental|1|empowerment theory-based small group discussion
89275699|NCT01327898|Active Comparator|2|single session individual resilience counseling
89275700|NCT02533739|Experimental|Patient group|This group will consist of vestibular patients and/or participants with vertigo.
89275701|NCT02533739|Sham Comparator|Control group|This group will consist of participants without vestibular/vertigo impairments.
89275702|NCT03946592|Placebo Comparator|Placebo group|Inject the Drug into submental fat via subcutaneous
89275703|NCT03946592|Experimental|DWJ211 group|Inject the Drug into submental fat via subcutaneous
89275704|NCT03944408|Experimental|A metal bare stent with 125I seeds|125I seeds fixed on the metal bare stent, then stent implantation
89275705|NCT03944408|Other|A metal bare stent|A metal bare stent implantation
89275706|NCT01052129|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr.Reddy's Laboratories Limited
89275707|NCT01052129|Active Comparator|Anaprox DS 550 mg Tablets|Anaprox DS 550 mg Tablets of Roche Pharmaceuticals Inc
89275708|NCT03991325||difficult laryngoscopy|group of patients with Cormack and Lehane grade III or IV
89275709|NCT03991325||easy laryngoscopy|group of patients with Cormack and Lehane grade I or II
89275710|NCT01106144||Acute myeloid leukemia|
89275711|NCT01053377|Active Comparator|Tamiflu|
89275712|NCT01053377|Placebo Comparator|Placebo Tamiflu|
89275713|NCT03946904|Experimental|preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. The lesion in this case was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
89275714|NCT03946904|Experimental|no preconditioning|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG.the lesion in this case was prepared with high power laser setting first to ablate the enamel, dentin, and caries.
89275715|NCT03991559|Active Comparator|Dose-Escalation, intranasally|With a standard 3+3 dose escalation design, the enrollment will proceed until the maximum tolerated dose (MTD) has been defined or the highest dose level has been reached.
89275716|NCT03991559|Active Comparator|Dose-Escalation, inhalation|With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.
89275717|NCT03949634|Experimental|PLD plus CTX sequential docetaxel or PTX|pegylated liposomal doxorubicin 35 mg/m2,i.v.,d1, plus cyclophosphamide（CTX） 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel（PTX） 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
89275718|NCT03949634|Active Comparator|DOX plus CTX sequential docetaxel or PTX|doxorubicin（DOX） 60 mg/m2,i.v.,d1, plus cyclophosphamide 600 mg/m2,i.v.,d1, sequential docetaxel 100 mg/m2,i.v.,d1, or paclitaxel 80mg/m2,i.v.,d1,8,15, once every 21days, for 4 cycles.
89275719|NCT01052285|Placebo Comparator|Placebo|TAP block with 25 ml of saline Ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline.
89275720|NCT01052285|Active Comparator|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% Local infiltration with 40 ml of ropivacaine 0,375% Tap block with 25 ml of saline
89275721|NCT01052285|Experimental|Transversus abdominis plane block|25 ml of Ropivacaine 0,75%, Ilioinguinal block with 10 ml saline and local infiltration with 40 ml of saline.
89275722|NCT03944330|Active Comparator|a treatment group|All study participants were provided with a standard hospital diet that provided B25-30 kcal/kg/day
89275723|NCT03944330|No Intervention|control group|All study participants were not intervened with diet
89275724|NCT04713800|Experimental|ZR-TiB|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR)
89275725|NCT04713800|Active Comparator|PFM-GA|Porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM)
89275726|NCT00356369|Experimental|Nimenrix Group|Subjects receiving GSK Biologicals' meningococcal vaccine 134612
89275727|NCT00356369|Active Comparator|Mencevax Group|Subjects receiving Mencevax™ ACWY
89275728|NCT03383614|Experimental|cohort 1 (8 subjects)|6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
89275729|NCT03383614|Experimental|cohort 2 (8 subjects)|6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
89275730|NCT03383614|Experimental|cohort 3 (8 subjects)|6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
89275731|NCT03403036|Experimental|Brodalumab|Brodalumab (210 mg) via subcutaneous injection using prefilled syringes
89275732|NCT00356135|Experimental|Prasugrel 10/10 mg|Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
89275733|NCT00356135|Experimental|Clopidogrel 75/75 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of clopidogrel 75 mg and placebo, followed by maintenance dose of clopidogrel 75 mg taken for 13 to 15 days.
89275734|NCT00356135|Experimental|Prasugrel 60/10 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 60 mg and placebo followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
89275735|NCT01053455||Starting on NCPAP|randomized to start on NCPAP
89275736|NCT01053455||Starting on SiPAP|randomized to SiPAP
89275737|NCT01052363|Experimental|CA4P + Avastin|
89275738|NCT01052363|Experimental|Avastin + CA4P|
89275739|NCT03383146|Placebo Comparator|Placebo|Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
89275740|NCT03383146|Experimental|Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
89275741|NCT01052441||CT Scan|Subjects with typical or atypical chest pain suspected of coronary artery disease and referred for an elective invasive coronary angiography (ICA), and scheduled to undergo CCTA before ICA or after ICA, if no intervention has been performed.
89275742|NCT01053533|Experimental|Chinese herbal medicines plus western therapy|
89275743|NCT01053533|Active Comparator|western therapy|including supportive therapy and antivirus therapy when necessary
89275744|NCT03989921||normo responders|that have an AMH dosage greater than or equal to 1.2 ng/mL
89275745|NCT03989921||poor responders|with a dosage of less than 1.2 ng/mL
89275746|NCT01052519|No Intervention|obese control|
89275747|NCT01052519|Active Comparator|obese goal-directed|
89275748|NCT01052519|Active Comparator|non-obese goal directed|
89275749|NCT01053611|Active Comparator|Group 1 BIS value 30|
89275750|NCT01053611|Active Comparator|Group 2 BIS value 30|
89275751|NCT01053611|Active Comparator|Group 3 BIS value 30|
89275752|NCT01053611|Active Comparator|Group 4 BIS valaue 30|
89275753|NCT01053611|Active Comparator|Group 1 BIS value 50|
89275754|NCT01053611|Active Comparator|Group 2 BIS value 50|
89275755|NCT01053611|Active Comparator|Group 3 BIS value 50|
89275756|NCT01053611|Active Comparator|Group 4 BIS value 50|
89275757|NCT01053611|Active Comparator|Group 1 BIS value 70|
89275758|NCT01053611|Active Comparator|Group 2 BIS value 70|
89275759|NCT01053611|Active Comparator|Group 3 BIS value 70|
89275760|NCT01053611|Active Comparator|Group 4 BIS value 70|
89275761|NCT03712072||Children with Cerebral Palsy|Data from the participants with Cerebral Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
89275762|NCT03712072||Children with BPBP|Data from the participants with Brachial Plexus Birth Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the TMS session.
89275763|NCT03712072||Typically Developing Children|Data from the typically developing participants will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
89275764|NCT03616964|Experimental|2 milligram (mg) Baricitinib|Participants received one 2 mg baricitinib tablet and one placebo tablet matching 4 mg baricitinib administered orally once daily (QD) for 52 weeks.
89275765|NCT03616964|Experimental|4 mg Baricitinib|Participants received one 4 mg baricitinib tablet and one placebo tablet matching 2 mg baricitinib administered orally QD for 52 weeks.
89275766|NCT03616964|Placebo Comparator|Placebo|Participants received 2 placebo tablets: one placebo tablet matching 4 mg baricitinib and one placebo tablet matching 2 mg baricitinib administered orally QD for 52 weeks.
89275767|NCT01208714|Active Comparator|revascularization|The patients randomized to this treatment will undergo PTA with stenting of the renal artery.
89275768|NCT01208714|Active Comparator|medical therapy|The patients randomized to this treatment will undergo optimal medical therapy
89275769|NCT00350519|Experimental|PROCRIT (epoetin alfa)|Participants will receive PROCRIT (epoetin alfa).
89275770|NCT00350519|Experimental|STANDARD THERAPY|Participants will receive standard of care.
89275771|NCT01208792|Experimental|Disease group|Two hundred patients with PAH will be included: 50 patients with idiopathic PAH (iPAH), 20 with PAH associated with HIV infection, 20 with porto-pulmonary hypertension, 20 with PAH secondary to congenital heart disorders, 40 with SSc, 20 with SLE, 20 with MCTD and 10 with a PAH associated with a Sjögren's syndrome. Two hundred patients without PAH will also be included: 80 patients with SSc and 20 in each of the following groups: HIV infection, porto-pulmonary hypertension, SLE, congenital heart disorders, MCTD and with Sjögren's syndrome.
89275772|NCT01208792|Other|Control group 1|Two hundred healthy blood donors age and sex-matched with patients with PAH, will be included as controls.
89275773|NCT01208792|Other|Control group 2|Twenty patients with proximal chronic thromboembolic pulmonary hypertension (CTPH) will also be included in a control arm of the study.
89275774|NCT01106300||Multi-organ failure|Sedated ventilated patients in multi-organ failure
89275775|NCT01106300||Single-organ failure|Sedated ventilated patients in single organ failure
89275776|NCT01053689|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
89275777|NCT01053689|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
89275778|NCT01106378||NEVO™ Sirolimus-eluting Coronary Stent System.|Subjects treated during routine clinical practice with the NEVO™ Sirolimus-eluting Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease.
89275779|NCT01106378||CYPHER Select® Plus Coronary Stent|Subjects treated during routine clinical practice with the CYPHER Select® Plus Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease
89275780|NCT03989765|Experimental|Intervention arm|Municipalities in the intervention arm will, in Stage 1, be part of developing the intervention to reduce the rate of compulsion. In Stage 2 they will implement the intervention through their services.
89275781|NCT03989765|No Intervention|Control municipality|As all outcome measures will be collected from the National Patient Register, there will be treatment as usual.
89275782|NCT01106612|Experimental|Initial coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
89275783|NCT01106612|Active Comparator|Initial nuclear stress test|Stress radionuclide myocardial perfusion imaging
89275784|NCT01055561|Experimental|Patients|
89275785|NCT01055561|Experimental|Healthy volunteers|
89275786|NCT01111448|Experimental|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle
89275787|NCT03382912|Experimental|Pegilodecakin+Nivolumab|"Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
89275788|NCT03382912|Active Comparator|Nivolumab|Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).
89275789|NCT03367286||Computed Tomography Perfusion (CTP)|
89275790|NCT03367286||Magnetic Resonance Perfusion (MRP)|
89275791|NCT03942926|Experimental|Sirolimus|Patients in sirolimus group will receive sirolimus for 6 months.
89275792|NCT03942848|Experimental|intrathecal Ziconotide followed by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
89275793|NCT03942848|Placebo Comparator|intrathecal Ziconotide preceded by placebo|Each of the 44 patients will receive alternatively treatment or placebo, for 6 months. The treatment for each period will be randomly assigned. A washout period of 15 days will be applied between the two periods of infusion.
89275794|NCT03946826|Experimental|PDL+ Halometasone Cream group|PDL+ Halometasone Cream Halometasone Cream, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
89275795|NCT03946826|Experimental|PDL+Vaseline group|PDL+Vaseline Vaseline, bid ,external use for 6 months; 3 nails were randomly selected to be treated with PDL laser therapy (6ms, 11±2J/cm2) once a month for a total of 6 times
89275796|NCT03946826|Active Comparator|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
89275797|NCT03946826|Placebo Comparator|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
89275798|NCT03711136||Frozen elephant trunk surgery|
89275799|NCT03711136||Standart surgery|
89275800|NCT03946280|Other|Fluoroscopy Group|Patient undergoing common flutter (AFL) ablation procedure using conventional X-ray based fluoroscopy for for catheter tracking
89275801|NCT03946280|Experimental|3D Group|Patient undergoing common flutter (AFL) ablation procedure using the low X-ray 3D navigation technique for for catheter tracking
89275802|NCT01311622|Experimental|warfarin|
89275803|NCT01311622|Experimental|warfarin and fostamatinib|
89275804|NCT04553120|Experimental|Alternating treatments condition - 10 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
89275805|NCT04553120|Experimental|Alternating treatments condition - 9 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
89275806|NCT04553120|Experimental|Alternating treatments condition - 13 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
89275807|NCT04553120|Experimental|Alternating treatments condition - 12 days wait|The intervention will be based on exposure therapy to cockroaches using P-ARET. Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive restructuring, and reinforcement and relapse prevention.
89275808|NCT01053767|No Intervention|Arm 1|This is a phlebotomy study.
89275809|NCT01106768||test cohort|Evaluation of oral health needs of children with attention deficit disorder with or without hyperactivity
89275810|NCT01106768||not disorder cohort|children without attention deficit disorder
89275811|NCT00349973|Experimental|1|Dipyridamole
89275812|NCT00349973|Active Comparator|2|Olanzapine
89275813|NCT01106924|Experimental|Probiotic|daily probiotic consumption
89275814|NCT01106924|Placebo Comparator|Placebo|daily placebo consumption
89275815|NCT03989687|Experimental|glass ionomer sealant|glass ionomer sealant
89275816|NCT03989687|Experimental|isolation|isolation type either rubber dam or cotton roll isolation
89275817|NCT03946436|Experimental|I-AVI|The I-AVI group were involved in a regular tennis training process, two times a week for one hour. Additionally right after the tennis lessons they played a Virtua Tennis 4 active video game for 20 minutes per participant. They use the playstation kinect console. The intervention lasted 6 months.
89275818|NCT03946436|Active Comparator|NO-AVI|The NO_AVI group were involved in a regular tennis training process, two times a week for one hour. The training process lasted 6 months.
89275819|NCT01053923||MRI Scan|
89275820|NCT01107002|Experimental|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
89275821|NCT01111682|Active Comparator|Mannitol|0.9% normal saline infusion and boluses of mannitol
89275822|NCT01111682|Active Comparator|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
89275823|NCT03942692||Children with anaphylactic reaction|Children who underwent an anaphylactic reaction between the 1st July 2014 and the 31st June 2016 treated in Paediatric Emergency Department of Femme-Mère-Enfant Hospital in Lyon in France.
89275824|NCT01109186||kidney-transplanted patients|
89275825|NCT01107080||Degradation|30 mastectomy, partial mastectomy, and mammoplasty samples will be analyzed to define the effective post-excision time window in which the device must be used before the results can no longer be evaluated. The mammoplasty specimens are necessary to assess normal tissue outcomes.
89275826|NCT01107080||Reproducibility|25 Partial Mastectomy cases will be analyzed to distinguish between different implementation methods of the technology.
89275827|NCT03741140|Other|medial frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the medial frontal lobe will be included in this arm, and will undergo motivation phenotyping.
89275828|NCT03741140|Other|lateral frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the lateral frontal lobe will be included in this arm, and will undergo motivation phenotyping.
89275829|NCT03741140|Other|Healthy participants|20 healthy participants (up to 10 healthy participants can be replaced) will be included in this arm, and will undergo motivation phenotyping.
89275830|NCT03946046|Experimental|Clinical targeting|Clinical localization method (observation and palpation of target muscles)
89275831|NCT03946046|Experimental|Ultrasonography targeting|Ultrason-guided method
89275832|NCT04464122||Neuroendocrine toumor group|30 patients (18-80 years, males and females) affected by histologically-proven neuroendocrine neoplasms, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to medical therapy.
89275833|NCT04464122||Control group|Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (18-80 years, males and females)
89275834|NCT03187262|Experimental|Daratumumab|"Daratumumab will be administered in three phases: Induction, consolidation and maintenance~During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day~During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle~During maintenance, daratumumab will be administered on day 1 of each 28-day cycle"
89275835|NCT03944252|Experimental|A (avelumab)|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
89275836|NCT03944252|Experimental|B (cetuximab + avelumab)|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
89275837|NCT01107158||Group 1|Control group: these patients have mechanical dystocia; cholesterol metabolism factors are a priori not involved.
89275838|NCT01107158||Group 2|These patients have uterine dystocia
89275839|NCT01112150|Active Comparator|Pumping group|Patients in this arm will get a pumping session 2-3 times a day .
89275840|NCT01112150|Active Comparator|No pumping|These patients will not receive pumping but only classical treatment clinically indicated (diuretics, oxygen, Digoxin, Nitrates, ACE inhibitors etc, as necessary)
89275841|NCT03944174||Single Trans-sacral Screw|
89275842|NCT03944174||Two Iliosacral Screws|
89275843|NCT03381196|Experimental|Treatment Arm 1 (pimodivir + SOC treatment)|Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).
89275844|NCT03381196|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
89275845|NCT01208948|Active Comparator|Alpha lipoic acid 600 mg|
89275846|NCT01208948|Placebo Comparator|placebo pill|
89275847|NCT01209026|Experimental|FF/GW642444M (200/25mcg)|Inhaled fluticasone furoate (200mcg) /GW642444M (25mcg) combination Days 1- 7; placebo tablet taken orally single dose (po SD) on Day 7.
89275848|NCT01209026|Experimental|FF/GW642444M (800/100 mcg)|Inhaled fluticasone furoate (800mcg) /GW642444M (100mcg) combination Days 1- 7; placebo tablet (po SD) on Day 7.
89275849|NCT01209026|Active Comparator|Moxifloxacin|Inhaled placebo on Days 1-7; moxifloxacin (400mg po SD) on Day 7
89275850|NCT01209026|Placebo Comparator|Placebo|Inhaled placebo on Days 1-7; placebo tablet (po SD) on Day 7.
89275851|NCT01107314||trauma patient|SBP less than 90mmHg
89275852|NCT01107470||Group A1|Age 18-34y (with short protocol)
89275853|NCT01107470||Group A2|age 35-42y ( with short protocol)
89275854|NCT01107470||Group B1|age 18-34y ( with long protocol)
89275855|NCT01107470||Group B2|age 35-42y ( with long protocol)
89275856|NCT01107548|Experimental|Evidence-based treatment, lifestyle counseling|
89275857|NCT01109264|Experimental|Bendamustine Hydrochloride|
89275858|NCT01109264|Active Comparator|Chlorambucil|
89275859|NCT01209104|Experimental|Cohort 1-PK and and safety of GSK1325756 in subjects 40-64y|This arm assesses the pharmacokinetics and safety of a single oral ose of 100mg of GSK1325756 administered to subjects in the age range 40y-64y when administered in the fasted state, in the presence of a high-fat meal and in the presence of a proton-pump inhibitor.
89275860|NCT01209104|Experimental|Cohort 2- PK and safety of GSK1325756 in subjects aged 65y-80y|This arm assesses the pharmacokinetics and safety of a single dose of 100mg of GSK1325756 administered to a group of subjects in the 64y-80y age range in the fasted state
89275861|NCT01109342||Vaccine Recipients|Participants received HIV preventive vaccine VRC-HIV ADV014-00-VP in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
89275862|NCT01109342||Placebo Recipients|Participants received a placebo vaccine in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
89275863|NCT03943940|Experimental|BM-MNC and UC-MSC|30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.
89275864|NCT03943940|Other|Stand medicines|30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines.
89275865|NCT01311700|Active Comparator|Early metoprolol initiation strategy|
89275866|NCT01311700|No Intervention|Delayed metoprolol initiation strategy|
89275867|NCT01107704|Experimental|Family Support Intervention|
89275868|NCT01107704|No Intervention|Control Group|
89275869|NCT01107782|Experimental|sildenafil|
89275870|NCT01107782|Placebo Comparator|Placebo control|
89275871|NCT01107860||Group I|
89275872|NCT01107860||Group II|
89275873|NCT03944096|Experimental|FMT+MTX|"FMT One FMT is performed at baseline by gastroscopic guidance. The same FMT is repeated 4 weeks later. The transplant consists of 50 g mixed feces obtained from 3-5 non-related healthy donors. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the recipient.~Drug: Methotrexate (MTX) Weekly methotrexate"
89275874|NCT03944096|Placebo Comparator|autologous FMT+MTX|"autologous FMT (the feces used in FMT is from participant themselves) One identical FMT is performed at baseline using gastroscopic guidance and is repeated 4 weeks later. The corresponding participant's feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the participant himself or herself.~Drug: Methotrexate (MTX) Weekly methotrexate"
89275875|NCT03709108|Other|Experimental-Control|Subjects randomized to this Arm would go through the Experimental Admission (SI-informed bolus calculator) first and Control Admission (regular bolus calculator) second
89275876|NCT03709108|Other|Control-Experimental|Subjects randomized to this Arm would go through the Control Admission (regular bolus calculator) first and Experimental Admission (SI-informed bolus calculator) second
89275877|NCT01107938|Experimental|10 mg ilaprazole|
89275878|NCT01107938|Experimental|15 mg ilaprazole|
89275879|NCT01107938|Active Comparator|40 mg esomeprazole|
89275880|NCT01209338|Active Comparator|sensitized group|One arm will be a sensitized group which would have received cancer health awareness sessions and / or screening earlier at least once in the past.
89275881|NCT01209338|No Intervention|non-sensitized group|The second arm will belong to an area which has never been exposed to any form of cancer awareness or screening activities thus this group is a completely non-sensitized group.
89275882|NCT02950558|Active Comparator|Ropivacaine|Single injection of ropivacaine immediately prior to surgery
89275883|NCT02950558|Experimental|Ropivacaine plus Nerve Block|Single injection of ropivacaine immediately prior to surgery plus 5 day ambulatory popliteal nerve block.
89275884|NCT02812706|Experimental|Isatuximab|Isatuximab will be administered intravenously (IV) once every week (QW) for 4 weeks followed by once every other week (Q2W)
89275885|NCT05514028||Cyst Benign|100 patients
89275886|NCT05514028||Ovarian Cancer|120 patients
89275887|NCT05514028||Borderline Ovarian Cancer|30 patients
89275888|NCT05504590|Experimental|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
89275889|NCT05504590|Active Comparator|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
89275890|NCT03345472|Experimental|Treated|Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
89275891|NCT03710980||Healthy Adult Volunteer|
89275892|NCT04252040|Experimental|Active tDCS with guided imagery|Subjects will receive 2 miliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
89275893|NCT02624414|Other|Anti TNF induction therapy 6-12 months|All subjects will be identified through The Royal Melbourne Hospital's IBD clinic, associated specialty clinics and the colonoscopy waiting list of The Royal Melbourne Hospital. The potential participants who have been commenced on Anti TNF induction therapy 6-12 months prior to commencement of the study will be identified. The potential participants identified in this way will be informed of the project at the time of contact and assessment; in some instances the potential participant will be informed of the project via telephone where subjects are remote. The potential participants will be provided an Ethically-approved information sheet at this time. Consent will be gained at the time of assessment.
89275894|NCT03709030|No Intervention|Standard Care|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with abdominal ultrasound as first line imaging, as per standard care
89275895|NCT03709030|Experimental|Direct MRCP|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with magnetic resonance cholangiopancreatography (MRCP) as first-line imaging
89275896|NCT01585220|Experimental|Neuramis|
89275897|NCT01585220|Active Comparator|Restylane®|
89275898|NCT03945344|Experimental|Treatment A|Tiotropium with concomitant charcoal
89275899|NCT03945344|Experimental|Treatment B|Tiotropium without concomitant charcoal.
89275900|NCT01108172|Active Comparator|Usual Care|
89275901|NCT01108172|Experimental|Virtual Ward|
89275902|NCT01108250|Experimental|polypoidal choroidal vasculopathy|patients with polypoidal choroidal vasculopathy
89275903|NCT01108250|Active Comparator|control|control group with no polypoidal choroidal vasculopathy
89275904|NCT01108328|Experimental|PolyGlycopleX (PGX)|5 grams of PGX 3 times per day with each main meal (breakfast, lunch and dinner)
89275905|NCT01108328|Placebo Comparator|Rice flour|5 grams of rice flour 3 times per day at each main meal (breakfast, lunch and dinner)
89275906|NCT01209416|Active Comparator|Ghrelin / Acipimox|Ghrelin infusion and tablet acipimox
89275907|NCT01209416|Active Comparator|Ghrelin / placebo|Ghrelin infusion and placebo tablets
89275908|NCT01209416|Active Comparator|Placebo / Acipimox|saline infusion and tablet Acipimox
89275909|NCT01209416|Placebo Comparator|Placebo / placebo|saline infusion and placebo tablets
89275910|NCT00349349|Experimental|ofatumumab|Anti-CD20 antibody therapy
89275911|NCT01112462|Experimental|Tablet|Paracetamol 500 mg/Phenylephrine 5 mg tablet
89275912|NCT01112462|Active Comparator|Sachet|Paracetamol 1000 mg/Phenylephrine 10 mg sachet
89275913|NCT02950480|Experimental|Zafirlukast|Zafirlukast
89275914|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
89275915|NCT01328522|Experimental|SAR153191 drug product 1|"SAR153191 drug product 1 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
89275916|NCT01328522|Experimental|SAR153191 drug product 2|"SAR153191 drug product 2 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
89275917|NCT01109030|Active Comparator|Pioglitazone+Citalopram+Chlordiazepoxide|Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
89275918|NCT01109030|Placebo Comparator|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks."
89275919|NCT05494528|Experimental|Ropeginterferon alfa-2b monotherapy|Subjects will be treated with 450 µg of Ropeginterferon alfa-2b every two weeks
89275920|NCT05494528|Active Comparator|Entecavir monotherapy|Subjects will be treated with 0.5 mg of Entecavir monotherapy once per day
89275921|NCT03942380|Other|Cell-free tumor DNA|The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.
89275922|NCT03942380|Other|Identifying recurrence|The aim is to identify recurrence through serial monitoring patients with blood samples.
89275923|NCT03987815|Experimental|Study Arm|Nivolumab 240 mg fixed dose every 2 weeks, for maximum of 3 cycles
89275924|NCT04804930||patients with systemic scleroderma|
89275925|NCT04804930||healthy subject|healthy subject without systemic scleroderma or known hair or scalp disease
89275926|NCT01209494||Invasive EP Study Group|200 patients are studied before clinically indicated (according to AHA/ACC/ESC guidelines) first ICD implantation or ICD exchange. Invasive EP study is performed to test inducibility of malignant arrhythmia. In addition MAP recordings are performed for measurements of restitution properties. Pacing is done for 12-lead ECG and MAP recordings for analysis of BVR and TWA, if applicable.
89275927|NCT01209494||Noninvasive EP Study Group|"The assignment of patients to the invasive and noninvasive EP groups does not occur by randomization or for intervention.~In the noninvasive EP study group, 500 patients with chronically implanted ICD (>3 month after implantation) are investigated using non-invasive EP study via ICD programmer. Programmed electrical stimulation is performed to test for inducibility of malignant arrhythmia. In addition pacing is done for measurements of BVR from the 12-lead ECG."
89275928|NCT03711916|Experimental|Breast flap creation with PlasmaBlade|During participant's scheduled bilateral mastectomy, breast flap on one breast will be created using low thermal dissection device (PlasmaBlade) on one breast and standard Bovie cautery in the contralateral breast.
89275929|NCT03711916|No Intervention|Breast flap creation with Bovie Cautery|During participant's scheduled bilateral mastectomy, breast flap will be created using standard Bovie cautery on the breast contralateral to the one that was created using PlasmaBlade.
89275930|NCT00348881|Experimental|Group 1: DTaP-Hep B-PRP-T + OPV vaccine|Participants received 3 doses of the DTaP-Hep B-PRP-T concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
89275931|NCT00348881|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of the Tritanrix-HepB/Hib™ concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
89275932|NCT04164290|Active Comparator|treatment group 1|Jiashen tablet, 0.47g, oral, once a day
89275933|NCT04164290|Active Comparator|treatment group 2|Jiashen tablet, 0.94g, oral, once a day
89275934|NCT04164290|Active Comparator|treatment group 3|Jiashen tablet,1.88g, oral, once a day
89275935|NCT04164290|Active Comparator|treatment group 4|Jiashen tablet,2.82g, oral, once a day
89275936|NCT04164290|Active Comparator|treatment group 5|Jiashen tablet,3.76g, oral, once a day
89275937|NCT04164290|Active Comparator|treatment group 6|Jiashen tablet,4.23g, oral, once a day
89275938|NCT04164290|Placebo Comparator|control group 1|Jiashen placebo tablet,0.47g, oral, once a day
89275939|NCT04164290|Placebo Comparator|control group 2|Jiashen placebo tablet,0.94g, oral, once a day
89275940|NCT04164290|Placebo Comparator|control group 3|Jiashen placebo tablet,1.88g, oral, once a day
89275941|NCT04164290|Placebo Comparator|control group 4|Jiashen placebo tablet,2.82g, oral, once a day
89275942|NCT04164290|Placebo Comparator|control group 5|Jiashen placebo tablet,3.76g, oral, once a day
89275943|NCT04164290|Placebo Comparator|control group 6|Jiashen placebo tablet,4.23g, oral, once a day
89275944|NCT03376516|Experimental|All patients|All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
89275945|NCT03987737|Experimental|small catheter|In the study arm, a small catheter will be placed in the rectum by the MRI technician and the examination will be executed with the small catheter in situ.
89275946|NCT03987737|No Intervention|control group|In the control arm, subjects will be scanned immediately after rectal evacuation on the toilet without small catheter in situ.
89275947|NCT01209572|Experimental|calorimetric chamber|
89275948|NCT01209572|Experimental|Free living conditions|
89275949|NCT01055717|Placebo Comparator|Placebo muffin made with no oats|
89275950|NCT01055717|Active Comparator|Test muffin made with AV-enriched oats|
89275951|NCT02257580|Experimental|E-Aminocaproic acid (EACA)|An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
89275952|NCT02257580|Placebo Comparator|Placebo|Equivalent volume of normal saline prepared by the pharmacy.
89275953|NCT01055795|Experimental|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
89275954|NCT03987269|Active Comparator|Intervention, Virtual Reality Group|The intervention group to experience the virtual reality embodied narrative experience.
89275955|NCT03987269|Placebo Comparator|Control, Narrative Video Group|The control group to watch the same narrative video content that has been formatted for standard television
89275956|NCT01108484|Experimental|Supervised exercise|Cardiorespiratory and resistance training
89275957|NCT01108484|Experimental|Exercise + diet counseling|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food)
89275958|NCT01108484|Experimental|Exercise + diet counseling + psycho support|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food) + Weekly sessions to modify the behaviour
89275959|NCT01108484|No Intervention|Control|They will keep their usual way of life
89275960|NCT01055951|Experimental|Solo MicroPump|
89275961|NCT01056029|Experimental|G-202|
89275962|NCT03797144|Experimental|Fenestrated Screw System|
89275963|NCT03943784||Endoscopic Variceal Ligation|From January 2014 to April 2017, all paediatric patients with a known chronic liver disease with suspicion of portal hypertension who presented grade 2 or 3 esophageal varices or red spots in the upper endoscopy received primary prophylaxis with endoscopic variceal ligation.
89275964|NCT03943784||Propranolol Group|Patients in the Endoscopic Variceal Ligation group were compared with an historical cohort of 30 consecutive patients with portal hypertension and grade 2 or 3 esophageal varices or red spots who received propranolol as primary prophylaxis from January 2009 to December 2013. All patients were treatment-naïve in regards of their upper gastrointestinal bleeding prophylaxis at the time of the first upper endoscopy.
89275965|NCT00347009|Other|Adefovir Dipivoxil|10mg once daily in patients with CHB related advanced fibrosis/cirrhosis.
89275966|NCT01947140|Experimental|Phase I: Schedule A|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
89275967|NCT01947140|Experimental|Phase I: Schedule B|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
89275968|NCT01947140|Experimental|Phase II|Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle
89275969|NCT03945110|Experimental|Arm A|Patients in this Arm will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later.
89275970|NCT03945110|No Intervention|Arm B|Patients in this Arm will receive usual bladder care only.
89275971|NCT03945110|Experimental|Arm C|Patients in this Arm will be Spinal Urology Outpatients or Inpatients who are eligible for inclusion and experiencing significant urinary tract infection recurrence and/or complications. Patients will receive a series of seven iAluRil® intravesical instillations over a 12-week period as follows: Once per week for 4 weeks; then once every two weeks for 4 weeks; then once 4 weeks later. Patients will be encouraged and supervised to self-administer iAluRil® intravesical instillations.
89275972|NCT01845116|Other|Single Arm|Single Omegaven® Intervention Arm
89275973|NCT01108562|Placebo Comparator|Control Group|Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.
89275974|NCT01108562|Experimental|Lidocaine Group|Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.
89275975|NCT01328132|Active Comparator|Saline|
89275976|NCT01328132|Experimental|25% albumin|
89275977|NCT00346697|Experimental|LOVAZA|4 g/d of omega-3 fatty acid esters, plus dietary counseling
89275978|NCT00346697|Placebo Comparator|Placebo|Corn oil placebo, plus dietary counselling
89275979|NCT03942614|Experimental|Nordic pole walking|walking with a pair of poles customized to an individual's height and stride length
89275980|NCT03942614|No Intervention|Control|usual daily routine and activities of daily living
89275981|NCT01666340|Experimental|high intensity aerobic training|Exercise intervention: High intensity group performing high intensity training where they are required to raise their heart rate several times during the workout and reach perceived exhaustion of 16 on a Borg scale
89275982|NCT01666340|Other|Moderate intensity training|Exercise intervention: Moderate intensity Group of people asked to perform moderate training where they exercise at a given intensity (moderate as per Borg scale) for a certain amount of time
89275983|NCT01112540|Placebo Comparator|Placebo Group|
89275984|NCT01112540|Experimental|Morphine|
89275985|NCT03986801|Experimental|PASS pharmaceutical interview|
89275986|NCT03986801|No Intervention|Usual management out of hospital|
89275987|NCT03400852|Experimental|Period 1: MNK-1411|Participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 1
89275988|NCT03400852|Experimental|Period 1: Placebo|Participants receive placebo at a volume appropriate to body weight during Period 1
89275989|NCT03400852|Experimental|Period 2: MNK-1411|All participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 2
89275990|NCT03986645|Experimental|4DFLOW|Acquire MR 4DFLow data.
89275991|NCT01056419|Active Comparator|Total thyroidectomy|
89275992|NCT01056419|Active Comparator|Anti-thyroid drug|
89275993|NCT04097366|No Intervention|Standard of Care|Control arm, no supplementary imaging is given. Participants have mammographic screening 3-yearly as per current standard of are.
89275994|NCT04097366|Active Comparator|Abbreviated MRI (ABB-MRI)|Supplementary imaging with abbreviated MRI at study entry and 18 months after baseline mammogram.
89275995|NCT04097366|Active Comparator|Automated Breast Ultrasound (ABUS)|Supplementary imaging with automated breast ultrasound at study entry and 18 months after baseline mammogram.
89275996|NCT04097366|Active Comparator|Contrast Enhanced Mammography (CESM)|Supplementary imaging with contrast enhanced spectral mammography at study entry and 18 months after baseline mammogram.
89275997|NCT05304832|Experimental|AquaPlyo group|Participants in this group received the AquaPlyo training program
89275998|NCT05304832|Active Comparator|Control group|Participants in this group received the standard exercise program.
89275999|NCT01056497|Experimental|alpha lipoic acid|
89276000|NCT01056575|Experimental|OC000459|
89276001|NCT03986567|Active Comparator|control|Providing with a paper notification card to the STI diagnosed young person
89276002|NCT03986567|Experimental|intervention web app|providing to the STI diagnosed young person, with a code number to enter into the app to notify sexual partners
89276003|NCT03986567|Experimental|intervention game|providing to the STI diagnosed young person, with a code number to enter into the app and play a game to get motivated to notify sexual partners
89276004|NCT03398356|Other|group A|metformin dose 3 x 500 mg
89276005|NCT03398356|Other|group B|metformin dose 3 x 1000 mg
89276006|NCT03398356|No Intervention|group C|healthy volunteers who had basic parameters assessment and blood tests only at the beginning of the study
89276007|NCT03945578|Active Comparator|Control Group|"This group performed a supervised Pelvic Floor Muscle Training (PFMT) protocol associated with a manual sham therapy (MST) sessions.~The PFMT protocol consisted of 20 sessions of 45-60 minutes each, twice a week, totalizing a five weeks treatment.~The MST protocol was performed once a week, during five weeks lasting approximately 15 minutes."
89276008|NCT03945578|Experimental|Experimental Group|"The experimental group performed the same PFMT protocol as the CG, but associated with a Visceral Manual Therapy (VMT) protocol.~The VMT sessions were held once a week, for five weeks. Each session lasted approximately 20 minutes."
89276009|NCT04051190|Experimental|VLED group|Participants will undergo a 10-week VLED.
89276010|NCT04051190|Experimental|Sleeve Gastrectomy group|Participants will undergo standard clinical practice prior to surgery.
89276011|NCT04051190|Experimental|Gatric Bypass group|Participants will undergo standard clinical practice prior to surgery.
89276012|NCT03708874||Group 1.Intraoperative bupivacaine|intraperitoneal bupivacaine wash-emergency laparoscopic cholecystectomy
89276013|NCT03708874||Group 2.Intravenous paracetamol|intravenous paracetamol-emergency laparoscopic cholecystectomy
89276014|NCT00992420||GRAVITAS Study Arm A|"Tailored clopidogrel regimen - total first day dose 600-mg, then 150-mg every day for 6 months"
89276015|NCT00992420||GRAVITAS Study Arm B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets) and then clopidogrel 75-mg and 1 placebo tablet every day for 6 months."
89276016|NCT00992420||GRAVITAS Study Arm C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets) and then the standard clopidogrel regimen of 75-mg and 1 placebo tablet every day for 6 months.
89276017|NCT01114256||Fine needle aspiration (FNA) biopsies|Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.
89276018|NCT00346151|Experimental|Belatacept|Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.
89276019|NCT03941210||HIV+/TB+|"Frozen samples and data from participants recruited in the ANRS 12095 CAMELIA clinical trial and the ANRS 12153 CAPRI NK study will be used for this study arm~All plasma samples were collected before any treatment during IRIS diagnosis and at W8 post TB treatment initiation"
89276020|NCT03941210||HIV+/TB-|"Participants included in this study arm will be HIV+ and TB-~One time collection of 5 ml of blood will be drawn in EDTA tube for each patient before starting cART and sent to the laboratory for protocol analysis"
89276021|NCT03941210||HIV-/TB+|"Participants included in this study arm will be HIV- and TB+~Collection of 5 ml of blood drawing in EDTA tube will be requested for each patient before starting TB drug treatment and after week 2 and 8 of treatment"
89276022|NCT03941210||HIV-/TB-|"Participants included in this study arm will be HIV- and TB-~Clinical examination to rule out overt evidence of TB and, whenever needed, routine TB testing as per national guidelines (sputum smear ± chest X-ray) in case of symptoms/clinical manifestations suggestive of TB."
89276023|NCT03940976|Experimental|Afatinib|
89276024|NCT01109498|Experimental|Dose cohort 3 x 10^11gc/kg|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
89276025|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
89276026|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X], 1xE12 gc/kg|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
89276027|NCT00130286|Experimental|rhGH + rosi|Recombinant human growth hormone + rosiglitazone
89276028|NCT00130286|Experimental|rhGH placebo + rosi|Placebo for recombinant human growth hormone + rosiglitazone
89276029|NCT00130286|Experimental|rhGH + rosi placebo|Recombinant human growth hormone + placebo for rosiglitazone
89276030|NCT00130286|Placebo Comparator|Double placebo|Placebo for recombinant human growth hormone + placebo for rosiglitazone
89276031|NCT03940898|Active Comparator|study group-active rTMS|Participants in the study group received 100%MT(motor threshold) repetitive transcranial magnetic stimulation with the intermittent theta burst stimulation paradigm.
89276032|NCT03940898|Sham Comparator|control group-shame rTMS|Participants in the control group received rTMS pseudo-stimulation intervention. The stimulation head was inverted by 180 degrees or 90 degrees according to the model of the stimulation device to achieve pseudo-stimulation and the remaining stimulation parameters were consistent with the study group.
89276033|NCT00346073|Experimental|Boostrix Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
89276034|NCT00346073|Experimental|Adacel Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
89276035|NCT03940664||neovascular group|patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment
89276036|NCT03940664||non-neovascular group|patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.
89276037|NCT01211834|Experimental|Tocilizumab 8mg/kg+DMARDs|
89276038|NCT01211834|Placebo Comparator|Placebo+DMARDs|
89276039|NCT03941990|Experimental|Nitrous oxyde|will inhale experimental treatment throughout the entire procedure (50% N2O - 50% 02)
89276040|NCT03941990|Placebo Comparator|Placebo|will inhale medical air throughout the entire procedure (22% O2 + N2 Q.S.)
89276041|NCT03374488|Experimental|Pembrolizumab 200 mg + Epacadostat 100 mg BID|Pembrolizumab + epacadostat
89276042|NCT03374488|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
89276043|NCT01209728|Experimental|Primary insomnia patients and healthy subjects|Elderly participants, including primary insomnia patients and healthy subjects
89276044|NCT00345683|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and a fourth dose of Menhibrix vaccine at 12-15 months of age in this study (study Month 10-13). Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
89276045|NCT00345683|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in this study (study Month 10-13). ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
89276046|NCT03943862|Experimental|Intervention (2Share) + treatment as usual|"Study participants randomized to the experimental group receive the intervention (2Share) while maintaining their current treatment (treatment as usual). 2Share is a peer-led group intervention containing three two-hour sessions within two weeks plus an additional booster session four weeks later.~Fidelity to manual is rated in each session by study staff."
89276047|NCT03943862|No Intervention|Treatment as usual|Participants randomized to the control group do not receive the group program but maintain their current treatment (treatment as usual).
89276048|NCT01211912|Experimental|Arm 1 (20 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally after a baseline ultrasound and 60 minutes before a repeat ultrasound.
89276049|NCT01211912|Experimental|Arm 2 (34 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally 30 minutes to 24 hours before a scheduled cesarean section.
89276050|NCT03943472|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA CAR-T cells to patients with multiple myeloma
89276051|NCT03943472|Experimental|anti-BCMA CAR-T+ Immune inhibitors|Administration of anti-BCMA CAR-T cells + Immune inhibitors to patients with multiple myeloma
89276052|NCT01056731|Experimental|Aliskiren and Aliskiren_HCTZ|aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg
89276053|NCT01207544|Experimental|fitball program|This group will undergo the fitball program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
89276054|NCT01207544|Active Comparator|Task-oriented program|This group will undergo the task-oriented motor training program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
89276055|NCT01056809|Active Comparator|Traditional strategy|First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
89276056|NCT01056809|Active Comparator|Alternative strategy|First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment
89276057|NCT01114412||Patients|Patients with overactive bladder syndrome
89276058|NCT01114412||Healthy volunteers|Healthy volunteers
89276059|NCT01056887||Primary Polydip, D. insipidus|
89276060|NCT01328678||Alopecia Areata|Individuals with Alopecia Areata (AA)
89276061|NCT01056965|Experimental|davunetide (Al-108, NAP) nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with either davunetide 15 mg or placebo. Davunetide and placebo will be administered intranasally with a multi-dispensing, metered nasal spray pump device.
89276062|NCT01056965|Placebo Comparator|Placebo nasal spray|
89276063|NCT01114490|Experimental|Part 1 - Group 1|Moderate Hepatic Patients
89276064|NCT01114490|Experimental|Part 1 - Group 2|Healthy Subjects
89276065|NCT01114490|Experimental|Part 2 - Group 1|Mild Hepatic Patients
89276066|NCT01114490|Experimental|Part 2 - Group 2|Healthy Subjects
89276067|NCT01057043|No Intervention|Waiting list|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
89276068|NCT01057043|Experimental|Cupping|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
89276069|NCT01112774|Experimental|tDCS/Spinal cord injury|Subjects will be randomized to receive 10 sessions of either active or sham tDCS. Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
89276070|NCT01112774|Experimental|tDCS/Healthy subjects|Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
89276071|NCT01209806|Active Comparator|simethicone|
89276072|NCT01209806|No Intervention|no simethicone|
89276073|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
89276074|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→OC slow→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
89276075|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→tablet→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
89276076|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→OC slow→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
89276077|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→tablet→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
89276078|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→OC fast→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
89276079|NCT03828383|Experimental|In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
89276080|NCT03828383|Sham Comparator|Limited In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
89276081|NCT01054001|Active Comparator|Early|men with on- demand sildenafil 100mg dosing from the early postoperative period
89276082|NCT01054001|Active Comparator|Delayed|men with on- demand sildenafil 100mg dosing from the delayed postoperative period
89276083|NCT03940820|Experimental|anti-tumor response of ROBO1 CAR-NK cells|Patients will receive a single dose of ROBO1 CAR-NK cells without any conditioning chemotherapeutic regimen.
89276084|NCT01057355|Experimental|Cyst ethanol lavage|Subjects receiving the study intervention
89276085|NCT01054235|Experimental|experimental|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes). For control ,none of the intervention will be given.
89276086|NCT03940274|Experimental|Intervention|Participants will undergo a walking program using a treadmill, a body-weight support system, and an assistive device.
89276087|NCT01057511|Active Comparator|progesterone|Each subject in this group will be give progesterone oil 20mg via intramuscular route once a day for 7 days totally
89276088|NCT01057511|Experimental|Crinone 8%|Each subjects in this group will be given Crinone 8% 90mg via vaginal route once a day for 7 days totally.
89276089|NCT01114802|Experimental|Project Onward website + social network|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
89276090|NCT01114802|Active Comparator|Project Onward website|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy.
89276091|NCT03986177|Experimental|Intervention|The intervention arm will receive a multi-faceted self-management intervention package.
89276092|NCT03986177|No Intervention|Enhanced care|The control arm will receive usual care plus basic asthma education from a trained nurse educator.
89276093|NCT01209884||Healthy Elderly sub-group|Healthy males between the age of 80-85 years old who have not experienced chronic disease during their lifetime.
89276094|NCT03986255|Experimental|Lumbar Puncture|Participants will undergo Lumbar puncture procedure
89276095|NCT03942146|No Intervention|Control group|No information on smoking cessation
89276096|NCT03942146|Active Comparator|Written information, GynOp|"When reporting being a current smoker in the health declaration on-line the participant receives the following written recommendation in the web-based health declaration You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended"
89276097|NCT03942146|Active Comparator|Doctor informed|"The smoking status of the participant is alerted to the surgeon when filling in the preoperative form with the text  the patient smokes, recommend smoking cessation"
89276098|NCT03942146|Active Comparator|Written information, GynOp + doctor informed|A combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the participant is a smoker and instructed to recommend smoking cessation as in group 3.
89276099|NCT01209962||Cohort|"The majority of recruited patients will be treated on protocol HUM00004531 A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer."
89276100|NCT00345605|Experimental|HDA|"High Dose Arm~Wash-out then 7 days of:~Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA"
89276101|NCT00345605|Experimental|LDA|"Low Dose Arm~Wash-out followed by 7 days of:~Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA"
89276102|NCT01109732|Experimental|Systematic physical training|Hospital-based SET two days per week for 12 weeks and one home-based exercise session every week. The group-based SET was based on The Norwegian Ullevaal Model, a modified cardiac rehabilitation program, and was slightly adjusted to be applicable to this patient group. Each SET session lasted for 60 minutes and consisted of warm-up exercises, three high-intensity, two moderate-intensity and cool-down exercises, including stretching. The exercises were generally simple aerobic dance movements and walking and involved the use of both upper and lower extremities. The warm-up exercises included large muscle movements that were repeated later in the higher-intensity intervals, but with greater force and a larger range of movement.
89276103|NCT01109732|No Intervention|Treatment as of today|The control group did not receive any additional follow-up regarding exercise at discharge beyond the general advice about the importance of exercise that is routinely provided at the hospital.
89276104|NCT01210040|Active Comparator|Folic Acid|2.8mg of Folic Acid given weekly
89276105|NCT01210040|Experimental|Folic Acid and Iron|2.8mg Folic Acid and 60mg Iron given weekly
89276106|NCT01054313|Experimental|Docetaxel + Sirolimus|Starting doses of Docetaxel 30 mg/m^2 IV every 3 weeks + Sirolimus 1 mg daily
89276107|NCT01114958|Experimental|IA Cisplatin / IV Thiosulfate|Single-arm study
89276108|NCT03394924|Experimental|EDP-305 1 mg|Subjects will take 2 tablets once a day orally for 12 weeks
89276109|NCT03394924|Experimental|EDP-305 2.5 mg|Subjects will take 2 tablets once a day orally for 12 weeks
89276110|NCT03394924|Placebo Comparator|Placebo|Subjects will take two tablets once a day orally for 12 weeks
89276111|NCT01324973|Experimental|eWellness program|A comprehensive program that delivers web-based, evidence-based weight management; and structured peer supports. The program is designed to meet the needs of individuals with mental illness.
89276112|NCT01324973|No Intervention|Control group|Care as usual
89276113|NCT03943394||Denovo MDS/ AML|"Patients with de-novo myeloid neoplasm either myelodysplastic syndrome and/ or acute myeloid leukemia which are diagnosed by complete blood count , blood film, bone marrow aspirate, bone marrow biopsy , immunophenotyping and bone marrow biopsy with these inclusion criteria • Myelodysplastic syndromes: the diagnosis of MDS must be confirmed by a bone marrow aspirate and/or biopsy : blast count must be < 20%;~• Acute myeloid leukemia with multilineage dysplasia: the diagnosis of AML-TLD must be confirmed by a bone marrow aspirate and/or biopsy NOTE: there must be evidence of >= 20% blasts on the review of the bone marrow aspirate and/or biopsy;"
89276114|NCT03943394||therapy related MDS/ AML|PCM1-JAK2 fusion gene detection in patients with therapy related Myelodysplastic syndrome / Acute myeloid leukemia patients
89276115|NCT03742115|Experimental|Etoposide standard group|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
89276116|NCT03742115|Experimental|Etoposide reduction group|Etoposide 150 mg/m2 once a week; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
89276117|NCT03742115|Active Comparator|Corticosteroid group|dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering, with or without IvIG (0.5 g/kg IV, once every 4 weeks)
89276118|NCT01115036|Experimental|panobinostat|
89276119|NCT01207622|Active Comparator|Atomoxetine|
89276120|NCT01207622|Placebo Comparator|Placebo|
89276121|NCT01212146|Experimental|Probiotic-enriched Artichokes|Artichokes containing approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme
89276122|NCT01212146|Active Comparator|Ordinary artichokes|Ordinary artichokes (probiotic free) of identical shape, texture, and appearance of probiotic-enriched artichokes
89276123|NCT00345293|Experimental|DC/PC3 vaccine|3 subcutaneous injections of ex vivo-generated autologous dendritic cell vaccine: 1) pulsed with apoptotic PC3 cells; 2) pulsed with apoptotic PC3-M1 cells, and 3) pulsed with keyhole limpet hemocyanin (KLH, control antigen)
89276124|NCT03942068|Experimental|albumin-bound paclitaxel+apatinib|albumin-bound paclitaxel:260mg/m2，q3w，d1 apatinib:500mg，qd，po
89276125|NCT03989531|Experimental|Adrecizumab on top of standard of care|8 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion
89276126|NCT03989531|Placebo Comparator|Placebo on top of standard of care|100 mL saline as single dose infusion
89276127|NCT01328288||1|long-term follow-up of HIV-infected children
89276128|NCT01054391|Experimental|NEC Arm|Utilization of NEC (Neurovascular Embolization Cover) for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistulae
89276129|NCT01112852|Active Comparator|EVL + vasoconstrictor|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
89276130|NCT01112852|Experimental|EVL + PPI|Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5
89276131|NCT01311934||HBV-infected|
89276132|NCT01311934||HCV-infected|
89276133|NCT01054469|Placebo Comparator|TAP block with placebo|
89276134|NCT01054469|Active Comparator|TAP block with ropivacaine|
89276135|NCT01115114|Placebo Comparator|Treatment as Usual (TAU)|Study Intervention 1 Treatment as usual (TAU) will be psychiatry follow-up at local Community Mental Health Clinic at least every 3 months.
89276136|NCT01115114|Active Comparator|IMBED|Study Intervention 2 A Primary Care Provider (PCP) will be located within the community mental health clinic one day weekly to specifically run a Metabolic Syndrome Clinic.
89276137|NCT01115114|Active Comparator|Liaison|Study Intervention 3 A Medical Case Manager(MCM) will be assigned to a patient who is identified on the basis of routine screening to need medical follow-up for metabolic syndrome.
89276138|NCT01207700|Experimental|CHW based intervention post ACS|CHW trained and supervised for intervening upon post ACS patients to improve adherence to evidence based care
89276139|NCT01207700|No Intervention|Standard Care|Patients will be followed upto 12 months without a community health worker intervention as per standard practices of the hospital
89276140|NCT01115192|Experimental|Group A|Patients with chronic blepharitis, that will be treated with blephacura
89276141|NCT01115192|Experimental|Group B|Patients with chronic blepharitis that will be treated with diluted baby shampoo
89276142|NCT03940430|Active Comparator|Lactoferrin in iron deficiency anemia|lactoferrin ( pravotin) 100mg twice daily
89276143|NCT03940430|Active Comparator|Ferrous sulfate in iron deficiency anemia|ferrous sulphate (hemojet)
89276144|NCT03940430|Active Comparator|Lactoferrin and ferrous sulfate in iron deficiency anemia|Lactoferrin 100 mg twice daily and ferrous sulfate
89276145|NCT01115270||Hydrocephalus Patients|Those patients diagnosed with Normal Pressure Hydrocephalus.
89276146|NCT01115270||Normal Participants|Individuals who are not diagnosed with Normal Pressure Hydrocephalus.
89276147|NCT00355121|Experimental|Group 1|DAPTACEL® + IPOL on Day 0 and Menactra on Day 30
89276148|NCT00355121|Experimental|Group 2|DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30
89276149|NCT00355121|Experimental|Group 3|Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30
89276150|NCT03940118|Active Comparator|Catheter secretion suctioning|Secretions are aspirated with a catheter at -120 to -150 mBar
89276151|NCT03940118|Experimental|Secretion suctioning + hypertonic saline|Hypertonic saline is nebulized prior to aspiration of secretions.
89276152|NCT03940118|Experimental|Ins-exsufflation|Mechanical insufflation-exsufflation with device programmed at 50/-50 mmHg
89276153|NCT03940118|Experimental|Ins-exsufflation + Hypertonic Saline|Mechanical insufflation-exsufflation and hypertonic saline
89276154|NCT02533349|Active Comparator|Proton pump inhibitor + prokinetics|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with prokinetics (Motilitone, 30mg, 1T, TID) for 3months.
89276155|NCT02533349|Placebo Comparator|Proton pump inhibitor + placebo|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with placebo (Motilitone, 30mg, 1T, TID) for 3months.
89276156|NCT01115426|Other|anti-angiotensin II drugs|Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.
89276157|NCT03942458|Experimental|Vicagrel|Vicagrel 24mg loading followed by 6mg/day for 6 days
89276158|NCT03942458|Active Comparator|Clopidogrel|Clopidogrel 300mg loading followed by 75mg/day for 6 days
89276159|NCT03989297||NPC patients|Consecutive patients who were pathologically diagnosed with NPC and for whom fresh-frozen tissue samples were available were included.
89276160|NCT01210196||mild affected Fabry patients|
89276161|NCT03989375|Experimental|experiment group|
89276162|NCT03989375|No Intervention|control group|
89276163|NCT03989453|Experimental|Chi Kung group|This group receives physical training based on Chi Kung.
89276164|NCT03989453|No Intervention|Control Group|This group does not receive any treatment.
89276165|NCT01115504|Experimental|Thiamine|Thiamine tablets of 300mg are prescribed for 1 months
89276166|NCT01115504|Placebo Comparator|Plascebo|Tablets of 300mg placebo are prescribed for 1 months
89276167|NCT03940040|Active Comparator|Usual Care|Patients will under go usual care ( pulmonary rehabilitation on room air or with nasal oxygen supplementation)
89276168|NCT03940040|Experimental|High flow nasal oxygen|Patients will undergo pulmonary rehabilitation with high flow nasal oxygen
89276169|NCT01212380|Experimental|Arm 1|Patients receive carfilzomib IV over 30 minutes once daily on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Performance of pharmacology, pharmacodynamic and pharmacogenomic studies allow assessment of carfilzomib mechanism of action and also to understand how the variability of these different features correlate with clinical benefit/response and also toxicity.
89276170|NCT00343889|Experimental|Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine|Participants received 3 doses of the DTaP-Hep B-PRP~T concomitantly with Oral Polio Vaccine (OPV), 1 dose each at 6, 10, and 14 weeks of age.
89276171|NCT00343889|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of Tritanrix-Hep B/Hib™ concomitantly with Oral Polio Vaccine (OPV) at 6, 10, and 14 weeks of age.
89276172|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on with MSM|
89276173|NCT03939884|Experimental|Professional Therapy Muscle Care™ roll-on without MSM|
89276174|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment with MSM|
89276175|NCT03939884|Experimental|Professional Therapy Muscle Care™ Ointment without MSM|
89276176|NCT03939884|Active Comparator|Voltaren Emulgel|
89276177|NCT03939884|Placebo Comparator|Non-medicinal Placebo|
89276178|NCT01054547|Placebo Comparator|Liposomal ropivacaine, topical|The topical anesthetics were applied at the region of right and left maxillary lateral incisors at the buccal mucosa.
89276179|NCT01054547|Placebo Comparator|Liposomal ropivacaine, palatal mucosa|Topical formulations were applied at the palatal mucosa at the right canine region and efficacy of topical formulations was accessed through insertion of a 30 gauge needle and injection of anesthetic solution.
89276180|NCT01212536|No Intervention|Conventional|conventional laryngoscopy for intubation
89276181|NCT01212536|Experimental|Airtraq|laryngoscopy with Airtraq for intubation
89276182|NCT01115894|Experimental|active medication + psychotherapy|
89276183|NCT01115894|Experimental|placebo + psychotherapy|
89276184|NCT01115894|Experimental|active medication+brief supportive counseling|
89276185|NCT01115894|Experimental|placebo + brief supportive counseling|
89276186|NCT03986489|Experimental|Mindfulness-based dance/movement therapy|Participants assigned to the M-DMT group condition will receive care as usual plus 12 weekly 90-minute group M-DMT sessions delivered online by a board-certified dance/movement therapist. The therapist is instructed to follow the M-DMT manualized protocol.
89276187|NCT03986489|Active Comparator|Chronic pain social support group|Participants assigned to the control condition will participate in a 12-session (90-minute session/week) online social support group.
89276188|NCT01115972|Experimental|single-add first group|single administration first, then concomitant administration
89276189|NCT01115972|Experimental|combi-add first group|concomitant administration first, then single administration
89276190|NCT02533271|Experimental|TNT group|The intervention of TNT group is Short-course radiotherapy with neoadjuvant chemotherapy, which consists of a short-course radiotherapy (SCRT, 5 Gy x 5 alone), then after 7-10 days of radiotherapy completed, patients will receive neoadjuvant chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy. If patients are eligible for postoperative chemotherapy this should consist of at least 2 cycles, which are the same as neoadjuvant chemotherapy.
89276191|NCT02533271|Other|CRT group|The intervention of CRT group is long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively, followed by a total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends. If patients are eligible for postoperative chemotherapy this should consist of at least 6 cycles of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once every 3 weeks.
89276192|NCT01116050|Placebo Comparator|Placebo|
89276193|NCT01116050|Experimental|MISOPROSTOL|
89276194|NCT01057823||Inpatient Elders Age 50 and up|The study population is community-dwelling ambulatory patients age 50 or above hospitalized on the University of Chicago general medicine service. Exclusion criteria include: (1) transfer from the ICU or another hospital; (2) cognitively impaired; (3) not ambulatory; (4) residents of a nursing home or skilled nursing facility; (5) on bedrest; (6)documented sleep disorder in their medical history (i.e. obstructive sleep apnea, narcolepsy, etc).
89276195|NCT03939650|Experimental|Diaana|"The patient fulfill Diaana~The resident physician reads the Diaana summary~The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
89276196|NCT03939650|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementray exams (blood tests, x-ray, ...)~The senior physician see the patient at the follow-up consultation. He establishes the gold-standard diagnosis highlighted by complementary exams and imagery."
89276197|NCT03941522|Experimental|Intervention group (23-hour stay)|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
89276198|NCT03941522|No Intervention|Control group (conventional hospitalization)|Patients randomized to the group conventional hospitalization will be hospitalized as per the current conventional care after ileostomy closure.
89276199|NCT01057979|Experimental|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
89276200|NCT01057979|Active Comparator|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
89276201|NCT03941678|Experimental|Creatine|0.3 g/kg/d creatine for 7 days; 0.1 g/kg/d creatine for 63 days
89276202|NCT03941678|Placebo Comparator|Placebo|0.3 g/kg/d placebo for 7 days; 0.1 g/kg/d placebo for 63 days
89276203|NCT05282290|Experimental|Experimental group|"Lower systolic blood pressure to 90-110 mm Hg.~Blood pressure not lower than 90/60 mm Hg~Hypotensive maintenance treatment for 48 hours."
89276204|NCT05282290|Active Comparator|The control group|"Subjects with basic blood pressure(BBP) > 140/90 mm Hg should have BBP lowered to about 140/90 mm Hg.~Subjects whose BBP was less than 140/90mm Hg were kept BBP."
89276205|NCT01311778|Placebo Comparator|Placebo|Subjects will receive placebo
89276206|NCT01311778|Experimental|CBD 400 mg|Subjects will receive 400 mg CBD
89276207|NCT01311778|Experimental|CBD 800mg|Subjects will receive 800 mg CBD
89276208|NCT00354341|Experimental|Group 1 (Early Epoetin Beta)|Along with their standard treatment participants will receive epoetin beta at a starting dose of 2000 International Units (IU) subcutaneously (SC) once weekly to reach and maintain target hemoglobin (Hb) between 13 and 15 grams per deciliter (g/dL), for 15 months. Epoetin beta doses will be adjusted according to individual participant's Hb level. Standard treatment will be as per investigator discretion.
89276209|NCT00354341|Active Comparator|Group 2 (No/Late Epoetin Beta)|Participants will receive their standard treatment for 15 months but no treatment for anemia correction unless Hb level will be less than (<) 10.5 g/dL on 2 consecutive visits of 2 weeks interval or the Hb level will be <10 g/dL on a single determination. In such cases participants could receive epoetin beta at a starting dose of 2000 IU SC once weekly to reach and maintain a target Hb level of 10.5 to 11.5 g/dL. Standard treatment will be as per investigator discretion.
89276210|NCT03708718|Active Comparator|Prednisolone|"Prednisolone 5mg enteric-coated tablets, over-encapsulated in a hard gelatine capsule and filled with lactose BP. The prednisolone will be self-administered, orally with water before or after a meal once a day. Dosing will be continuous for a total of 6 months.~The total dose prescribed will be equivalent to approximately 0.3mg/kg/day. The minimum dose prescribed will be 10mg per day (2 capsules) and a maximum of 30mg per day (6 capsules).~From August 2020: The prednisolone is no longer over-encapsulated. Prednisolone 5mg enteric-coated tablets will be prescribed and taken as above."
89276211|NCT03708718|Placebo Comparator|Placebo oral capsule; From August 2020 - 'no additional treatment'|"The placebo will be a hard gelatine capsule filled with lactose BP and identically matched to the prednisolone capsules. The placebo will be self-administered once a day, orally with water before or after a meal. Dosing will be continuous for a total of 6 months.~From August 2020 - no placebo capsule will be administered."
89276212|NCT01054859|Experimental|Treatment A|0.5 g/Kg alcohol plus 200 mg avanafil tablet
89276213|NCT01054859|Active Comparator|Treatment B|0.5 g/kg alcohol
89276214|NCT01054859|Active Comparator|Treatment C|200 mg avanafil tablet
89276215|NCT00354107|Experimental|Treatment (monoclonal antibody therapy, chemotherapy)|"Patients receive monoclonal antibody SGN-30 IV alone on day 1 in weeks 1-8. Beginning in week 5, patients receive ICE chemotherapy comprising ifosfamide IV over 2 hours on days 1-3, carboplatin IV over 1 hour on day 1, and etoposide IV over 1 hour on days 1-3. Treatment with ICE repeats every 3 weeks for 6 courses** in the absence of unacceptable toxicity. Patients also receive intrathecal therapy comprising methotrexate, cytarabine, and hydrocortisone once on day 29 (week 5).~Cohorts of 3-6 patients receive a pre-determined dose of monoclonal antibody SGN-30 with possible dose de-escalation to 1 dose level below in the event of ≥ 2 of 6 patients experience dose-limiting toxicity (DLT). The dose at which ≤ 1 of 6 patients experience DLT will be used in a phase II study."
89276216|NCT00354029|Placebo Comparator|Placebo|Saline 0,9%
89276217|NCT00354029|Active Comparator|S (+) Ketamine|
89276218|NCT00353873|Active Comparator|Fluticasone propionate (FLIXOTIDE™)|Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily
89276219|NCT00353873|Experimental|Fluticasone propionate/salmeterol (SERETIDE™)|Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily
89276220|NCT01058057|Experimental|Atorvastatin|Atorvastatin 80mg seven days pre-treatment before PCI
89276221|NCT01054937|Experimental|4SC-203|
89276222|NCT01054937|Placebo Comparator|Placebo|
89276223|NCT03986099|No Intervention|Standard of care|SOC viral load
89276224|NCT03986099|Active Comparator|Near point of care|POC viral load
89276225|NCT03796676|Placebo Comparator|Placebo|Placebo
89276226|NCT03796676|Experimental|PF-04965842 100 mg QD|active
89276227|NCT03796676|Experimental|PF-04965842 200 mg QD|active
89276228|NCT03342898|Experimental|Group 1: YF-17D + Placebo/TDV/TDV|YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).
89276229|NCT03342898|Experimental|Group 2: TDV + Placebo/TDV/YF-17D|TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.
89276230|NCT03342898|Experimental|Group 3: TDV + YF-17D/TDV/Placebo|TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.
89276231|NCT03988673|No Intervention|decision aid with information only (control)|decision aid with information only, without values clarification method (VCM)
89276232|NCT03988673|Active Comparator|decision aid with implicit VCM|decision aid with information plus an implicit VCM
89276233|NCT03988673|Active Comparator|decision aid with explicit VCM|decision aid with information plus an explicit VCM
89276234|NCT03988517|Active Comparator|levothyroxine at Iftar|Patients took levothyroxine 30 minutes before breaking the fast at sunset (iftar)
89276235|NCT03988517|Active Comparator|Levothyroxine at Suhour|Patients took levothyroxine 30 minutes before an early morning meal before sunrise (suhour)
89276236|NCT00339833|Experimental|Salsalate|Salsalate (3g/day) for 7 days
89276237|NCT00339833|Placebo Comparator|Placebo|Placebo
89276238|NCT01058213|Active Comparator|Aerobic training alone|8 weeks of gentle chair (sham) training followed by 8 weeks of interval aerobic training on a stationary bicycle
89276239|NCT01058213|Experimental|Sequential Resistance then Aerobic Training|8 weeks of resistance training of the lower body followed by 8 weeks of interval aerobic training on a stationary bicycle
89276240|NCT01058213|Active Comparator|Concurrent resistance and aerobic training|8 weeks of gentle chair (sham) exercise followed by 8 weeks of concurrent resistance training of the lower body and interval aerobic training on a stationary bicycle
89276241|NCT01311856||Standard Arm (mail/telephone)|
89276242|NCT01311856||Internet Arm|
89276243|NCT01058291|Experimental|KW-6500|
89276244|NCT01058291|Placebo Comparator|KW-6500 Placebo|
89276245|NCT03711682|Experimental|Cinnamon (Intervented)|
89276246|NCT03711682|Placebo Comparator|Wheat Flour (Placebo)|
89276247|NCT01055249|Other|Group A|Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
89276248|NCT01055249|Other|Group B|Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
89276249|NCT01055327||Infants/foetuses w/malformations registered in EUROCAT network|Pregnancies resulting in foetus/infant with malformation registered through participating registers within the EUROCAT network
89276250|NCT03988361||Control group|Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC only (conventionally semen preparation).
89276251|NCT03988361||Study group|"Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC and MACS.~The sperm used in this group is considered to be enriched in non apoptotic cells."
89276252|NCT03708484|Active Comparator|Aerobic Interval Training|Aerobic Interval Training is active comparator
89276253|NCT03708484|Experimental|Aerobic + Resistive Interval Training|Aerobic + Resistive Interval Training is experimental
89276254|NCT03793556|Experimental|GERDOFF® + omeprazole|"GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).~Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days)."
89276255|NCT03793556|Active Comparator|Omeprazole|Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
89276256|NCT03392194|Experimental|Sleep hygiene & Yoga (SH+Y)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment. After completing the SH sessions, they will receive 10 weeks of the yoga intervention (8 in-person yoga sessions and 2 weeks of yoga home practice maintenance assessment).
89276257|NCT03392194|Active Comparator|Sleep hygiene (SH)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment.
89276258|NCT04782466|Experimental|Intervention|The participant receives the intervention immediately following baseline measurements.
89276259|NCT04782466|Other|Waitlist attention-control|The participant receives the control condition for 6 months following baseline measurements. After 6 months, the baseline measurements are repeated and then the participant receives the intervention.
89276260|NCT01113086|Experimental|Left active anodal DLPFC|We will place the anodal electrode on the left dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
89276261|NCT01113086|Experimental|Right active anodal DLPFC|We will place the anodal electrode on the right dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
89276262|NCT01113086|Placebo Comparator|Sham tDCS|Sham tDCS: For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds.
89276263|NCT01113086|Other|Open-Label Arm|In addition to this study we will have an open label arm in which subjects who received sham stimulation through the course of the study will have the opportunity to receive active stimulation free of charge. The same parameters and identical procedures as is done in the original study will be used. Data will be collected as an open label, which will therefore provide additional information. Data obtained from this open label portion of the study will be kept separate.
89276264|NCT01113164|Experimental|Ondansetron, Placebo, Sertraline|LL-carriers receiving ondansetron compared to either placebo or sertraline, will result in a significant reduction in alcohol consumption.
89276265|NCT01113164|Experimental|Sertraline, Placebo, Ondansetron|SL and SS-carriers receiving sertraline compared to either placebo or ondansetron, will result in a significant reduction in alcohol consumption.
89276266|NCT03828617|Experimental|20vPnC Lot 1|20vPnC Lot 1
89276267|NCT03828617|Experimental|20vPnC Lot 2|20vPnC Lot 2
89276268|NCT03828617|Experimental|20vPnC Lot 3|20vPnC Lot 3
89276269|NCT03828617|Active Comparator|13vPnC|13vPnC
89276270|NCT01113242||A:|Patients with idiopathic PD and with MMSE < à 26
89276271|NCT01113242||B:|Patients with idiopathic PD and with MMSE ≥ à 26
89276272|NCT03391960|Other|Disinfecting barrier cap|"In the participating wards, disinfecting barrier cap was used on every needless connector used for accessing CVC IV lines.~Compliance with disinfecting barrier cap was observed weekly."
89276273|NCT01210430|Active Comparator|Losartan|
89276274|NCT01210430|Active Comparator|Ascorbic Acid (VItamin C)|
89276275|NCT01210430|Placebo Comparator|Normal Saline|
89276276|NCT05489146|Active Comparator|tRNS and FES facilitated task practice|In this arm, participants received real transcranial random noise stimulation with FES facilitated task practice
89276277|NCT05489146|Sham Comparator|sham tRNS and FES facilitated task practice|In this arm, participants received sham transcranial random noise stimulation with FES facilitated task practice
89276278|NCT01210586|Active Comparator|Nicotine Patch|Nicotine Patch for Smoking Cessation
89276279|NCT01210586|Placebo Comparator|Placebo Patch|
89276280|NCT01210742|Experimental|Viscosupplementation with routine management|
89276281|NCT01210742|Active Comparator|Routine management|Routine management for knee OA (NICE guidelines)
89276282|NCT01113320|Placebo Comparator|Placebo|
89276283|NCT01113320|Active Comparator|Safinamide|
89276284|NCT01210898|Experimental|Group 1|
89276285|NCT01210898|Experimental|Group 2|
89276286|NCT01210898|Experimental|Group 3|
89276287|NCT01210898|Experimental|Group 4|
89276288|NCT01210898|Experimental|Group 5|
89276289|NCT01210898|Experimental|Group 6|
89276290|NCT01210898|Experimental|Group 7|
89276291|NCT01210898|Experimental|Group 8|
89276292|NCT01210898|Experimental|Group 9|
89276293|NCT01210898|Experimental|Group 10|
89276294|NCT01210898|Experimental|Group 11|
89276295|NCT01210898|Experimental|Group 12|
89276296|NCT01210898|Experimental|Group 13|
89276297|NCT01116128|Experimental|D-MP|
89276298|NCT03390166|Active Comparator|GPO Tri Fluvac vaccine|630 volunteers will receive a single dose of the seasonal trivalent inactivated influenza vaccine (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) produced by GPO Thailand. To be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
89276299|NCT03390166|Active Comparator|Licensed Influenza vaccine|315 volunteers will receive acLicensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2017 (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
89276300|NCT01207856|Active Comparator|group A|specific cognitive rehabilitation
89276301|NCT01207856|Active Comparator|Groupe B : non specific rehabilitation|
89276302|NCT01207856|Other|group C|group C for MRI, neuropsychological and ecological assessments
89276303|NCT01116206|Experimental|Prucalopride|prucalopride 2- milligram (mg), orally once daily for 12 weeks
89276304|NCT01116206|Placebo Comparator|Placebo|Matching placebo, orally once daily for 12 weeks
89276305|NCT01210976|Experimental|levosimendan|
89276306|NCT01210976|Placebo Comparator|placebo|
89276307|NCT03828539|Experimental|Erenumab|70 mg and 140 mg Erenumab
89276308|NCT03828539|Active Comparator|Topiramate|Topiramate in the highest tolerated dose (50 - 100 mg/day)
89276309|NCT01109888|Active Comparator|Cetrotide|
89276310|NCT03336502|Experimental|Posaconazole|All participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral suspension three times daily for up to 18 additional days.
89276311|NCT01116284|Experimental|Revision of gastric bypass|A laparoscopic plication of the gastrojejunostomy will be performed after three 5-mm trocars are placed in the upper abdomen. Then using Ethibond suture, laparoscopic plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period with an expected discharge from the hospital within 24 hours.
89276312|NCT01325051|No Intervention|Raltegravir|To test raltegravir to see if it can be detected in gastrointestinal tissue of healthy men.
89276313|NCT01212692|Experimental|Mentally stimulating activities|
89276314|NCT01212692|Active Comparator|Mentally stimulating activities- other|
89276315|NCT01058447|Experimental|1|
89276316|NCT01109966|Active Comparator|Amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
89276317|NCT01109966|Active Comparator|New amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
89276318|NCT03708406||Children with Cleft lip and palate|Children with Cleft lip and palate
89276319|NCT03708406||Children with Cleft palate|Children with Cleft palate
89276320|NCT01055405|Experimental|Sildenafil plus pulmonary rehabilitation|
89276321|NCT01055405|Placebo Comparator|Placebo plus pulmonary rehabilitation|
89276322|NCT01116362|Other|secondary repair|secondary closure beyond the first week.the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
89276323|NCT01116362|Other|primary repair|during first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
89276324|NCT01058525|Active Comparator|nerve block|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000)
89276325|NCT01058525|Experimental|median nerve block after hydro-dissection|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000) after hydro-dissection (glucose 5% solution)
89276326|NCT01211132|Active Comparator|Cap arm|
89276327|NCT01211132|Active Comparator|Standard arm|
89276328|NCT01055483|Experimental|LBH589|
89276329|NCT01110044|Experimental|Group A|Subjects will be administered 251154 vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
89276330|NCT01110044|Active Comparator|Group B|Subjects will be administered no vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
89276331|NCT03987971|Experimental|Deep acupuncture on GB26|
89276332|NCT03987971|Sham Comparator|Superficial acupuncture on GB26|
89276333|NCT03987971|No Intervention|waiting list|
89276334|NCT01116518|Active Comparator|physiotherapy|
89276335|NCT01116518|Active Comparator|acromioplasty|
89276336|NCT01116518|Active Comparator|acromioplasty and rotator cuff reconstruction|
89276337|NCT00338741||1|Rebif exposed pregnancies
89276338|NCT00338741||2|Non-Rebif exposed pregnancies
89276339|NCT03370510|Experimental|Pivotal Response Treatment (PRT)/oxytocin (OXT) nasal spray|Participants will receive oxytocin nasal spray 45 minutes prior to each PRT session.
89276340|NCT03370510|Placebo Comparator|Pivotal Response Treatment (PRT)/placebo nasal spray|Participants will receive a placebo nasal spray 45 minutes prior to each PRT session.
89276341|NCT03985865|Experimental|Intragastric quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
89276342|NCT03985865|Experimental|intragastric denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
89276343|NCT03985865|Placebo Comparator|Intragastric placebo|0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
89276344|NCT03985865|Experimental|Intraduodenal quinine hydrochloride|10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
89276345|NCT03985865|Experimental|Intraduodenal denatonium benzoate|1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
89276346|NCT03985865|Placebo Comparator|Intraduodenal placebo|0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
89276347|NCT01116674||Glycemic Control|Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of > 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is > 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
89276348|NCT00351611|Experimental|Active|Active drug
89276349|NCT00351611|Placebo Comparator|Placebo|placebo comparator
89276350|NCT01211210|Active Comparator|A: 5Fu with Radiation|Patients receive fluorouracil IV continuously and undergo radiotherapy once daily 5 days a week for 5-6 weeks.
89276351|NCT01211210|Experimental|B: FOLFOX with radiation|Patients receive FOLFOX for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFOX
89276352|NCT01211210|Experimental|C: FOLFOX alone|Patients receive FOLFOX for 4 cycles
89276353|NCT01116752|Active Comparator|Strict control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive strict glycemic control (80-140 mg/dL)
89276354|NCT01116752|Active Comparator|Conservative control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive conservative control (190-220 mg/dL).
89276355|NCT01110278||Urge Incontinent Women|Women with documented urge/urgency incontinence with established care at the Oregon Health and Science University.
89276356|NCT01110278||Control Women|Women with no urge/urgency incontinence with established care at the Oregon Health and Science University.
89276357|NCT01058603|Active Comparator|D3|
89276358|NCT01058603|Experimental|D5|
89276359|NCT01116830|Placebo Comparator|Placebo|
89276360|NCT01116830|Experimental|RO4917838|
89276361|NCT00351533|Experimental|1|Enteral fish oil
89276362|NCT00351533|Placebo Comparator|2|Enteral saline
89276363|NCT01208012|No Intervention|Metformin|Patients taking Metformin at individual dose
89276364|NCT01208012|Experimental|Metformin and Liraglutide|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
89276365|NCT03939806||Oxytocin|This group will be given 3 IU / 3 ml oxytocin (intravenously) after the clamping of the umbilical cord. Uterine tonus will be assessed after 60 seconds and if it is lower than 7, oxytocin 3 IU / 3 ml will be repeated, up to a maximum of three times. If uterine tonus is still lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
89276366|NCT03939806||Carbetocin|This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.
89276367|NCT03939494|Experimental|Telehealth Intervention|This arm receives 26 hours of telehealth encounters with a registered dietitian in conjunction with their normal clinic/program care.
89276368|NCT03939494|No Intervention|Standard of Care Control|This arm will participate in their normal clinic/program routine.
89276369|NCT03939572|Active Comparator|Accurate step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will simply display their accurate step count."
89276370|NCT03939572|Experimental|Deflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display a deflated step count."
89276371|NCT03939572|Experimental|Inflated step count feedback|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display an inflated step count."
89276372|NCT03939572|Experimental|Accurate feedback + mindset intervention|"All arms are given identical instructions in the onboarding session, including information about the study purpose and Apple Watch. They complete the same set of physiological, cognitive, and psychological measures and receive an Apple Watch to wear for the following 5 weeks. Throughout the 5 weeks, participants complete short daily surveys and longer weekly surveys. Finally, participants come in for an offboarding lab session in which the same measures are collected as in the onboarding session.~In this arm, participants' Apple Watches will display their accurate step count. Additionally, participants in this arm will receive a meta-mindset intervention."
89276373|NCT01113554|Experimental|Arm I|Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
89276374|NCT00351377|Experimental|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily in a dose that was equimolar to the dose of Mycophenolate mofetil the participant was taking at the time of study entry. The planned duration of treatment 6 to 8 weeks.
89276375|NCT01110356|Experimental|Ferinject|
89276376|NCT01110356|Placebo Comparator|Saline|
89276377|NCT01113788||imaging|imaging with usual catheter/fluoroscopy, no cartosound
89276378|NCT03941366|Other|Neoadjuvant Chemotherapy and Follow-up Surgery|All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.
89276379|NCT01211366|Active Comparator|Conventional Transfusion|Infants will receive PRBCs, crystalloid, and colloid for hemodynamic instability per the usual routine at the discretion of the attending intensive care physician
89276380|NCT01211366|Experimental|Cell Saver|Infants will receive washed cell-saver RBCs for hemodynamic instability in the first 24 hours post-operative period as long as Hgb is < 13 gm/dL and cell-saver is available.
89276381|NCT01212848|Experimental|TMS|
89276382|NCT01212848|Sham Comparator|Sham|
89276383|NCT00337727|Other|1|Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
89276384|NCT00337727|Other|2|Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.
89276385|NCT03939338||Participates|
89276386|NCT03987893|Experimental|PEG+Lactulose|this arm will recieve PEG3350 in addition to standard of care
89276387|NCT03987893|Active Comparator|Lactulose alone|this arm will recieve only standard of care for management of hepatic encephlaopathy with ACLF
89276388|NCT01116908|No Intervention|Control|
89276389|NCT01116908|Active Comparator|LifeStraw Family|
89276390|NCT01058681|Other|isocaloric|impacts of isocaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
89276391|NCT01058681|Other|hypercaloric|impacts of hypercaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
89276392|NCT01058681|Other|per os and IV glucose during the clamp|impacts of per os glucose on LH pulsatility in euglycemic and hyperinsulinemic clamps
89276393|NCT01211444|Experimental|HGNS System|
89276394|NCT01061099|Active Comparator|Stratum A|Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
89276395|NCT01061099|Active Comparator|Stratum B|Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
89276396|NCT01113866||heart failure|
89276397|NCT00324233|Active Comparator|SC|Speedicath (SC) catheter is a catheter for intermittent catherisation
89276398|NCT00324233|Experimental|SCCM|SpeediCath Compact Male (SCCM) is a compact catheter for intermittent catherisation to be used by males
89276399|NCT01113944|Active Comparator|Program 1|Program 1
89276400|NCT01113944|Active Comparator|Program 2|Program 2
89276401|NCT01114022|Active Comparator|Active comparator|cylindrical PVC cuff
89276402|NCT01114022|Experimental|Experimental 1|cylindrical polyurethane cuff
89276403|NCT01114022|Experimental|Experimental 2|conic PVC cuff
89276404|NCT01114022|Experimental|Experimental 3|conic polyurethane cuff
89276405|NCT01213004|Experimental|thoracic (study group 1) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
89276406|NCT01213004|Experimental|abdominal (study group 2) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
89276407|NCT01117064|Active Comparator|NMTD adjustment testing|We will determine effective NMTD device settings for reducing AHI.
89276408|NCT01117064|Active Comparator|CPAP vs NMTD device|We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
89276409|NCT01117064|Active Comparator|NMTD efficacy and tolerability|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
89276410|NCT03938714|Active Comparator|CH( Conventional Hemorrhoidectomy)|Closed Conventional Hemorrhoidectomy
89276411|NCT03938714|Experimental|HS( Harmonic Scalpel)|Harmonic Scalpel Hemorrhoidectomy
89276412|NCT01208558|Active Comparator|Diet A and physiotherapy|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people, i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid junk food and juice. In order to match carbohydrate intake between the arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end."
89276413|NCT01208558|Active Comparator|Diet B and physiotherapy|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A.~Other Name: Whole grains Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.~Other Name: Exercise"
89276414|NCT01208558|Active Comparator|Diet A only|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Other Name: No grains"
89276415|NCT01208558|Active Comparator|Diet B only|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.~Other Name: Whole grains"
89276416|NCT01208558|No Intervention|Control|Only follow-up. No intervention.
89276417|NCT01117142||CLL/SLL|Chronic lymphocytic leukemia/small lymphocytic lymphoma
89276418|NCT01117142||Healthy Volunteers|Healthy Volunteers
89276419|NCT01117142||MBL|Monoclonal B-cell lymphocytosis
89276420|NCT01117142||MCL|Mantle Cell Lymphoma
89276421|NCT03335566|Experimental|Sonazoid™|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
89276422|NCT03335566|Active Comparator|SonoVue®|Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
89276423|NCT01213160|Experimental|AZD4547|
89276424|NCT04774120||Young Patients (Patients aged 18 to 65 years.)|Propofol infusion rate will be started at 20-25 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
89276425|NCT04774120||Elderly patients (Patients aged 65 to 85 years. )|Propofol infusion rate will be started at 15-20 mg/kg/hr until SR achieved. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
89276426|NCT01110512|Experimental|Flavonid|
89276427|NCT01110512|Active Comparator|Daflon|
89276428|NCT03707704||SCI patients in primary rehabilitation|
89276429|NCT01117220|Placebo Comparator|2|
89276430|NCT01117220|Active Comparator|1|
89276431|NCT03707626||LAD with collaterals with and without wellens sign|
89276432|NCT05236972|Experimental|Sintilimab|Sintilimab 200mg iv drip Q3W for 8 courses
89276433|NCT05236972|Experimental|XELOX|Patients receive chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 or 8 courses
89276434|NCT03941054|No Intervention|Control arm|No intervention
89276435|NCT03941054|Experimental|Pressure Release|Digitopressure treatment of the Myosfascial Trigger Points
89276436|NCT01114100|Active Comparator|sertraline, panic education|treatment with sertraline after panic education
89276437|NCT01114100|Placebo Comparator|placebo after panic education|treatment with placebo after panic education
89276438|NCT01114100|No Intervention|care as usual|patient received no diagnosis an no panic education, they had a 24 weeks follow up with a visit at 12 weeks and 24 weeks to evaluate their complaints
89276439|NCT01110590|Experimental|Arm 1|
89276440|NCT01110590|Experimental|Arm 2|
89276441|NCT01110590|Experimental|Arm 3|
89276442|NCT01110590|Placebo Comparator|Arm 4|
89276443|NCT03369418|Active Comparator|Active|Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
89276444|NCT03369418|Sham Comparator|Inactive|"Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur."
89276445|NCT02529644|Active Comparator|Comparison (Standard Information Arm)|The comparison/standard information churches will receive standard multilevel HIV education information that is similar in type to those provided to the intervention churches. These churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. These churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
89276446|NCT02529644|Experimental|Intervention|Taking It to the Pews (TIPS) will be delivered through church-based multilevel (community, church-wide, ministry group, interpersonal/individual) activities by trained church leaders using religiously/ culturally-tailored study materials packaged in a TIPS HIV Tool Kit and following a scripted, study implementation manual.
89276447|NCT03938948|Experimental|Treatment Arm|62 participants shall be enrolled
89276448|NCT01117298|Experimental|Tadalafil|
89276449|NCT01117298|Placebo Comparator|Placebo|
89276450|NCT01117376|Active Comparator|Erythromycin|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
89276451|NCT01117376|Active Comparator|Methylnaltrexone|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
89276452|NCT01213238|Experimental|Oxaliplatin + Capecitabine + Bevacizumab|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle. Bevacizumab 10 mg/kg by vein on day 1 of a 21 day cycle.
89276453|NCT01213238|Experimental|Oxaliplatin + Capecitabine|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 -14 of a 21 day cycle.
89276454|NCT01110668|Experimental|Nilotinib|
89276455|NCT03938558|Experimental|Dance intervention group|"Dancers at beginners level~Dancers at advanced level"
89276456|NCT03938558|Active Comparator|Art intervention group|"Paint artists~Word artists~Film artists~Photographers"
89276457|NCT01114178||claudicants|patients referred for a treadmill test
89276458|NCT01110824|Experimental|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
89276459|NCT01110824|No Intervention|Control|Control arm without intervention
89276460|NCT03936140|Experimental|Iloprost 10|"Iloprost 10μg of inhaled iloprost (Ventavis®)~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
89276461|NCT03936140|Experimental|Iloprost 20|"Iloprost 20μg of inhaled iloprost (Ventavis®)~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
89276462|NCT03936140|Placebo Comparator|Distilled water|"Distilled water~Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position."
89276463|NCT03938090|Placebo Comparator|Standard biventricular pacing|Cardiac resynchronization therapy (CRT) devices will be programmed as per standard biventricular pacing settings
89276464|NCT03938090|Active Comparator|Optimised MultiSite Pacing (MSP)|Cardiac resynchronization therapy (CRT) devices will be programmed as per optimal MSP programming settings; determined by greatest change in dP/dtmax and narrowest QRS duration.
89276465|NCT01117532|Experimental|EFT|Four 90 minute group EFT classes
89276466|NCT01117532|No Intervention|No Treatment|
89276467|NCT01110980|Experimental|Swallowing therapy|Swallowing therapy in combination with individual dietary counselling
89276468|NCT01110980|Active Comparator|Individual dietary counselling|Swallowing therapy only on indication. (usual care)
89276469|NCT01117610|Active Comparator|epidural injection (group I)|patients in Group I will receive epidural injection of 0.1% ropivacaine 10 ml before skin incision.
89276470|NCT01117610|Placebo Comparator|epidural injection group (group C)|control group will receive no medication preoperatively and during operation
89276471|NCT01117688|Active Comparator|B - without SGW|Ureteroscopy without SGW in place.
89276472|NCT01117688|Active Comparator|A - with SGW|Ureteroscopy with SGW in place.
89276473|NCT03334630|Experimental|DiamondTemp Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter
89276474|NCT03334630|Active Comparator|TactiCath Quartz Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter
89276475|NCT01111136|Experimental|stress intervention|Stress intervention.
89276476|NCT01215890|Active Comparator|risedronate plus calcium and viamin D|
89276477|NCT01215890|Placebo Comparator|placebo plus clacium and vitamin D|
89276478|NCT03740828||Women undergoing IVF treatment|Device: KIDScore D3 study
89276479|NCT01117922|Experimental|Intervention|After consent, subjects will be assigned to either a usual care group (no intervention) or an intervention group (targeted interconceptional interventions).
89276480|NCT01117922|Other|Usual Care Group|This group will receive usual care.
89276481|NCT01118000|Experimental|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
89276482|NCT01213394|Experimental|CellCept optimization|
89276483|NCT01213394|Active Comparator|Control|
89276484|NCT03708172|Active Comparator|rTMS + Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive active cognitive training (CT) which consists of completing computer-based tasks designed to enhance executive function.
89276485|NCT03708172|Sham Comparator|rTMS + Sham Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive sham cognitive training (CT) which consists of completing computer-based tasks.
89276486|NCT03938012||Lung and head and neck tumours|"Age 18 years or older~Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung or head and neck region~No other active malignancy within the past 24 months~Refractory disease"
89276487|NCT03707548|Experimental|Group BPT|"Six group BPT sessions (using a waiting-period comparator and pre-/post design)~A nested randomized controlled trial (RCT) is included to evaluate the short-term efficacy of smartphone-triggered bodily interventions compared with the smartphone triggered control intervention of audio-typed fairy tales."
89276488|NCT03938168||Pain patients|30 patients eligible for adhesiolysis because of chronic adhesion-related pain. Patients are recruited at the RadboudUMC, MUMC+ and Pantein hospital departments of surgery. These are patients with chronic pain after previous abdominal surgery who have been selected for operative treatment after evaluated with CineMRI. CineMRI is used to map adhesions. This technique has been established to provide insight in localization of adhesions in relation to the pain, and risk of bowel injury based on extensiveness of adhesions.
89276489|NCT03938168||Control group|The control group will comprise of 30 patients undergoing an abdominal reoperation during which adhesiolysis has to be performed for reasons other than chronic adhesion-related pain.
89276490|NCT01118078||Biomarker (DNA methylation, gene expression, RT-PCR)|Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression analysis, DNA methylation, and genomic re-sequencing by microarray analysis-based methods, including PCR analysis, DNA methylation analysis-specific RT-PCR, and quantitative RT-PCR (reverse transcriptase-polymerase chain reaction)
89276491|NCT03937934|Experimental|Subjects with long term health condition|Subjects that have been identified as having food insecurity based on a two question screening tool, and also has one of more of the following chronic diseases Hypertension, Heart disease, Stroke/TIA, DM 2, Cancer/history of cancer, obesity or osteoarthritis will receive weekly nutrition educaiton
89276492|NCT03368170|Experimental|Mesdopetam (IRL790)|Capsule 2.5 mg, oral administration
89276493|NCT03368170|Placebo Comparator|Placebo|Identical capsule, oral administration
89276494|NCT01111214||group 1|Hospitalized children ≤14 years of age with invasive pneumococcal disease
89276495|NCT01121822|Experimental|Group 1|Participants at age 18 to 59 years
89276496|NCT01121822|Experimental|Group 2|Participants at age 60 years or older
89276497|NCT03937856|Experimental|Intervention group|Participant groups will include enrolled patients with rheumatic disease who use the smartphone mindfulness meditation application for 30 days.
89276498|NCT03937856|No Intervention|Control group|Usual care participants.
89276499|NCT01118156||Mental Health Clinicians|MH Clinicians at the Denver and Grand Junction VA Medical Centers
89276500|NCT01208636||Sun exposed people|Sun exposure >3 hours daily for at least 5 days weekly for the last 3 months.
89276501|NCT01213550|Experimental|Chlorhexidine|
89276502|NCT01213550|Placebo Comparator|Placebo mouthrinse|
89276503|NCT01213628|Experimental|Standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
89276504|NCT01213784|Experimental|optimized diabetic control|each participant will be assigned to be optimized in a dedicated diabetic clinic
89276505|NCT01213784|No Intervention|control|participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.
89276506|NCT01213862|Experimental|intervention and control|"Group I - Intervention: Routine follow-up in a reference health institution with four home visits and four telephone contacts with specialist nurses.~Group II - Control: Routine follow-up with the health team in the reference institution."
89276507|NCT01121978|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole or vision deterioration occurs
89276508|NCT01121978|Experimental|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
89276509|NCT01216046|Experimental|Treatment Arm|Subjects randomized to study drug will take VX-809 for 14 days followed by a 14 day washout. Next subjects will take VX-770 for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 for 14 days.
89276510|NCT01216046|Placebo Comparator|Placebo Arm|Subjects randomized to placebo will take VX-809 placebo for 14 days followed by a 14 day washout. Next subjects will take VX-770 placebo for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 placebo for 14 days.
89276511|NCT01219010|Experimental|001|Siltuximab 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
89276512|NCT01216280|Placebo Comparator|2 x 10 mg placebo capsule|2 x 10 mg placebo capsules, administered orally with water, b.i.d.
89276513|NCT01216280|Experimental|10mg Natura-alpha + 10 mg placebo|10 mg Natura-alpha capsule + 10 mg placebo capsule administered orally with water, b.i.d.
89276514|NCT01216280|Experimental|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
89276515|NCT01118234|Experimental|Rituximab|Treatment with Rituximab 375 mg/m² every 3 months for 24 months
89276516|NCT01118234|No Intervention|Observation|Observation for 24 months
89276517|NCT00324155|Experimental|Arm A: Ipilimumab and Dacarbazine|In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
89276518|NCT00324155|Active Comparator|Arm B: Placebo and Dacarbazine|
89276519|NCT03937544|Experimental|CD19 CAR-T CELLS|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
89276520|NCT01118390|Experimental|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
89276521|NCT01118390|Active Comparator|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
89276522|NCT01216358||Arm 1: Combined contraceptive|Initiating an estrogen/progesterone contraceptive
89276523|NCT01216358||Arm 2: Progesterone only contraceptive|Initiating a progesterone-only contraceptive
89276524|NCT01216358||Arm 3 (control): Non-hormonal contraceptive|Initiating or using non-hormonal contraception or not using contraception
89276525|NCT01124474|No Intervention|Standard fluid management|Standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
89276526|NCT01124474|Other|Vigileo model number MHM1|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
89276527|NCT01122056|Active Comparator|A = Active group|Patients will receive interactive exercise training session from an experienced multiple sclerosis
89276528|NCT01122056|No Intervention|B = Control group (Placebo Comparator)|Patients will receive general advice about benefits/side effects of physical activity in multiple sclerosis.
89276529|NCT01118546||controls 2|patient without CAD, not on aspirin and without history of hypersensitivity
89276530|NCT01118546||case of hypersensitivity|patient with CAD on aspirin, with a history of hypersensitivity
89276531|NCT01118546||controls 1|patient with CAD on aspirin, without history of hypersensitivity
89276532|NCT01216436|Experimental|Vaccine plus untransfected DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.
89276533|NCT01216436|Experimental|Vaccine plus GITRL RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.
89276534|NCT01216436|Experimental|Vaccine plus antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.
89276535|NCT01216436|Experimental|Vaccine plus GITRL/ antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.
89276536|NCT01219088|No Intervention|Controlled group|Spinal anesthesia with 0.5% bupivacaine alone
89276537|NCT01219088|Active Comparator|Femoral nerve block|Spinal anesthesia plus femoral nerve block with 20 mL of 0.25% bupivacaine
89276538|NCT01219088|Active Comparator|Intrathecal morphine|Spinal anesthesia plus 0.1 mg of intrathecal morphine
89276539|NCT01219088|Active Comparator|Periarticular bupivacaine infiltration|Spinal anesthesia plus periarticular infiltration with 20 mL of 0.25% bupivacaine
89276540|NCT01122134||20 adults with severe malaria|20 adult patients admitted with severe malaria
89276541|NCT01118702|Active Comparator|001|Concerta one 54mg tablet once
89276542|NCT01118702|Active Comparator|002|Ritalin-SR 3-20mg tablets once
89276543|NCT01118702|Active Comparator|003|Novo-Methylphenidate ER-C one 54mg tablet once
89276544|NCT02529410|Experimental|Triventricular pacing|2 Left ventricular leads and one right ventricular lead
89276545|NCT02529410|Active Comparator|Biventricular leads|1 left ventricular lead and one right ventricular lead
89276546|NCT01118858||Case|Pediatric patients who have a primary diagnosis of ADHD, combined type, hyperactive impulsive, or inattentive type (ADD).
89276547|NCT01118858||Control|Healthy subjects: Age and gender matched subjects who do not meet any of the exclusion criteria
89276548|NCT03935828|Experimental|Topical Sinonasal Antibiotics|For topical antibiotics, the compounding pharmacy will use pre-determined doses using data extrapolated from oral and intravenous doses and data that has detailed the effect of the medication on solubility, pH, and particle properties. Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml, Tobramycin 0.7mg/ml, Levofloxacin 0.4mg/ml, and Amphotericin B 20mcg/ml, all to be prescribed for 21 days, applied twice a day. Although the dosing schedule for these topical antibiotics has not been definitively studied, the majority of the data supports a range from two to three times daily for three to four weeks. Patients will be instructed by the pharmacist how to dissolve the cream, powder, or vial of antibiotic in saline, and to irrigate each nostril with 120 ml total. Doses will not be varied during the study period.
89276549|NCT03935828|Active Comparator|Oral Antibiotics|Oral antibiotics will be prescribed for 21 days, as available (albeit limited) evidence recommends antimicrobial therapy in CRS for at least 3 weeks. For oral antibiotics, the choices providers will be given include: Augmentin 500 mg every 12 hours, Cefuroxime 500 mg every 12 hours, Clarithromycin 500 mg every 6 hours, Levofloxacin 500 mg once daily, or Clindamycin 300 mg every 6 hours, as these are standard of care for treatment of Chronic Rhinosinusitis.
89276550|NCT01219166||laparoscopic Roux-en-Y-gastric-bypass without cholecystectomy|
89276551|NCT01219166||laparoscopic Roux-en-Y-gastric baypass with cholecystectomy|
89276552|NCT03334396|Experimental|4 milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match.
89276553|NCT03334396|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
89276554|NCT03334396|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
89276555|NCT03334396|Placebo Comparator|Placebo|Placebo administered orally once daily.
89276556|NCT03334396|Experimental|4 mg Baricitinib Maximum Extended Enrollment Cohort|4 mg Baricitinib administered orally once daily. Placebo 1 mg, and 2 mg administered orally every day to match.
89276557|NCT03334396|Experimental|2 mg Baricitinib Maximum Extended Enrollment Cohort|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
89276558|NCT03334396|Experimental|1 mg Baricitinib Maximum Extended Enrollment Cohort|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
89276559|NCT03334396|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo administered orally once daily.
89276560|NCT01122290||negative emotion|Children experienced induction of mild negative emotion through a jigsaw with a missing piece (negative emotion group)
89276561|NCT01122290||neutral emotion|Vs. Same task with No missing piece (neutral emotion).
89276562|NCT01118936|No Intervention|Washout|
89276563|NCT01118936|Active Comparator|Mablet|
89276564|NCT01118936|Placebo Comparator|Placebo|
89276565|NCT01119014|Experimental|Aripirazole|
89276566|NCT01119014|Experimental|Quetiapine prolong|
89276567|NCT03937310||Surgical intervention for non-union|The investigation group will consist of cases undergoing surgical intervention for non-union
89276568|NCT03937310||Acute fracture fixation|The control group will consist of cases undergoing acute fracture fixation
89276569|NCT01119092|Sham Comparator|Sham intervention plus standard treatment|"This group will receive a laying of hands treatment in addition to standard treatment. The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between."
89276570|NCT01119092|No Intervention|Control Group|This group will be individuals who suffer from the same injury but will be instructed to stretch at home 5 days a week for 2 weeks.
88805592|NCT02543658|Other|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
89276571|NCT01119092|Experimental|Grade IV AP joint mobilization plus standard treatment|This group will receive 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
89276572|NCT01219244|Experimental|Caloric restriction|
89276573|NCT01219244|Experimental|omega-3 supplementation|
89276574|NCT01219244|Experimental|resveratrol supplementation|
89276575|NCT01219244|Placebo Comparator|placebo|
89276576|NCT01219244|Experimental|2nd step: intervention + physical /cognitive training|most effective dietary intervention plus physical and cognitive training
89276577|NCT01219244|Placebo Comparator|2nd step: most effective dietary intervention plus control|most effective dietary intervention plus control
89276578|NCT01119170|Placebo Comparator|control starter formula|
89276579|NCT01119170|Experimental|D-lactate probiotics|
89276580|NCT01119326|Placebo Comparator|Placebo|Placebo procedure
89276581|NCT01119326|Experimental|Autologous Fat Transfer (AFT) group|Subjects will be registered in the context of either the Early AFT subgroup, or the Delayed AFT subgroup based on the timing of their wound closure: early AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 2-4 weeks of definitive closure (STSG) or healing (secondary closure) and the delayed AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 6 months or more of definitive closure (STSG) or healing (secondary closure
89276582|NCT01119404||Metabolic Syndrome|120 men with metabolic syndrome
89276583|NCT01119404||Coronary Heart Disease (CHD)|120 men with angiographically verified CHD
89276584|NCT01119404||Control|80 physically active men
89276585|NCT03937232|Active Comparator|Cross-Education|Cross education has been defined as the unilateral training of a limb with resisted exercise for the benefit of transferring strength to the contralateral (often injured or immobilized) limb. Participants randomized to cross-education will be provided with a hand-grip strengthener, adjusted to provide resistance at 70-80% of their maximum grip strength. They will be given written, illustrated instructions for performing grip strengthening exercises for their uninjured hand in a seated position with both forearms comfortably supported; this will be demonstrated during the teaching session. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
89276586|NCT03937232|Active Comparator|Mirror Visual Feedback|Mirror visual feedback is the performance of movements with an uninjured hand in front of a mirror hiding the injured hand, thus creating the illusion of bilateral movement. Participants randomized to mirror visual feedback will be provided with a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization of exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete a three sets of 10 repetitions for finger flexion and extension (mimicking the fisting motion of the grip strengthening exercises) twice daily. A diary for tracking exercise completion and attendance for usual care will also be provided.
89276587|NCT03937232|Experimental|Cross-education + Mirror Visual Feedback|In this group, participants will perform the cross-education resistance exercise in front of the mirror, visualizing the performance of the resistance exercises. Participants randomized to cross education with mirror visual feedback will be provided with both a hand-grip strengthener and a portable mirror and stand, and instructed with accompanying demonstration on how to set up on a table for comfortable visualization. They will be given written, illustrated instructions for performing mirror visualization hand grip strengthening exercises completed by the uninjured hand only from a position of neutral rotation of the forearm. The instructions will ask for the participant to complete 3 sets of 10 repetitions twice daily, with additional instructions for appropriate grading of resistance. A diary for tracking exercise completion and attendance for usual care will also be provided.
89276588|NCT03937232|Active Comparator|Usual Care|Participants randomized to usual care will be encouraged to attend the recommended rehabilitation, and provided with a diary for frequency of rehab attendance, and tracking any exercises completed at home.
89276589|NCT01119482|Other|Vaccination|Healthy volunteers before and after vaccination
89276590|NCT01119560||Ancillary-Correlative (Questionnaire, saliva & tissue sample)|The biologic mother of the patient is asked to complete a Diet History Questionnaire about diet during pregnancy, and information on demographics, lifestyle factors, medication used during pregnancy, history of breast feeding, and family history of cancer or birth defects. Parents are given ORAgene saliva collection kits for self-collection. Saliva bio-specimen samples are collected from both biologic parents and the patient. Tissue samples previously stored in a tissue bank are obtained for deceased patients, if available. DNA is extracted from samples, amplified and analyzed using real-time PCR quantitation assay, and genotyped using single nucleotide polymorphisms.
89276591|NCT01119638|Active Comparator|Escitalopram Drug|"Drug:~Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion."
89276592|NCT01119638|Active Comparator|Risperidone Drug|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
89276593|NCT03937388|Experimental|Cochlear implant recipients|
89276594|NCT03935672|Other|All trial participants|"Baseline plasma and saliva tests for future translational analysis~Baseline planning FDG PET CT scan~Patients will start their 6 weeks of CCRT within two to three weeks following the planning scans. Cisplatin chemotherapy will be administered. 33 daily fractions of radiotherapy will be delivered over 6 weeks.~A second FDG-PET-CT scan (iPET) and repeat plasma and saliva tests will be carried out after 2 weeks of CCRT (on RT days 9 - 12) and the iPET assessed for residual FDG-avid disease. The biological GTV will be re-outlined based on the residual avid region of the tumour on the second PET-CT (bGTV_iP)~At the end of treatment, plasma and saliva tests will be carried out at 4 weeks post treatment and again at the 3 month post-treatment PET-CT~Swallowing and QoL assessments will be repeated 4 weeks (+/- 2 weeks) after treatment and will be repeated at 6, 12 and 24 months post-treatment. The plasma and saliva samples will be repeated at 12 and 24 months"
89276595|NCT01216592||COPD|
89276596|NCT03338998|Experimental|BAF312|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally
89276597|NCT03338998|Placebo Comparator|Placebo|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally - matching placebo
89276598|NCT03935984|Experimental|Treatment Group|All subjects in this arm will be treated with calcitonin 200IU 2x per day for 2 days, then 1x on day of SPECT-CT imaging
89276599|NCT01219322|Experimental|intravenous bicarbonate|Intravenous bicarbonate(05meq/cc ) 50 cc will be injected.
89276600|NCT01219322|Placebo Comparator|Intravenous injection of 50 cc normal saline|Injection of volume equivalent of normal saline to compare the establish the effect of same volume as the experimental drug
89276601|NCT01119872|Other|Compliance-guided PEEP group|Positive End-Expiratory Pressure(PEEP) level was set daily, according to the method described by Suter in 1978. Static compliance (Cst) was calculated at different levels of PEEP at a constant tidal ventilation of 6-8 ml/kg of predicted body weight. Cst was determined by dividing tidal volume by the difference between the pressure at the end of inflation hold and the PEEP. The maximum value of Cst in individual patients was considered as the best PEEP.
89276602|NCT01119872|Other|FiO2-driven-PEEP group|"PEEP was set based on the patient fraction of inspired oxygen (FiO2) according to the Positive End-Expiratory Pressure(PEEP) strategy reported in 2000:Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network."
89276603|NCT01219400|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
89276604|NCT03707470|Experimental|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
89276605|NCT03707470|Active Comparator|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 15 mmHg at both the ankle and thigh)
89276606|NCT03707470|Sham Comparator|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
89276607|NCT01124630|Experimental|CS-1008 with FOLFIRI|Experimental drug CS-1008 in combination with FOLFIRI
89276608|NCT01214018||Reference|Nearest relatives of brain-dead patients who donated organs
88805593|NCT01045265||Raltegravir treated men|Single group study of seminal plasma pharmacokinetics of raltegravir in men receiving chronic raltegravir therapy
88805594|NCT00183092|Experimental|quinacrine|
89276609|NCT01214018||Opposition|Nearest relatives of brain-dead patients opposed to organ donation
89276610|NCT01214018||Medical/Legal|Nearest relatives of brain-dead patients for whom organ donation was not an option because of medical or legal reasons
89276611|NCT05683054|Active Comparator|Standard dosing group|In the standard based arm, patients will continue to receive adalimumab according to the standard dosing schedule of 40 mg every other week (maintenance phase).
89276612|NCT05683054|Active Comparator|Dose tapering group|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab at three consecutive measurements.
89276613|NCT03937076|No Intervention|intercostal block|patients will get intercostal block at the end of the surgery, control group
89276614|NCT03937076|Experimental|PECS II block|patients with get PECS II block at the end of the surgery, research group
89276615|NCT01120106|Active Comparator|levosimendan|levosimendan continuous infusion at a rate of 0.1 mcg/kg<min
89276616|NCT01120106|Placebo Comparator|placebo|saline infusion
89276617|NCT03338296|Experimental|Lorcaserin hydrochloride XR 20 mg QD|Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.
89276618|NCT03338296|Placebo Comparator|Placebo|Participants will receive placebo QD for up to 52 weeks.
89276619|NCT03935516|Experimental|Flexed Elbow|The first group will be placed in a cast with the elbow bent.
89276620|NCT03935516|Experimental|Extended Elbow|The second will be placed in a cast with the elbow straight.
89276621|NCT03933644|Other|Ambu Aura Gain TM with gastric tube|
89276622|NCT03933644|Other|Ambu Aura Gain TM without gastric tube|
89276623|NCT01214096|Placebo Comparator|placebo|
89276624|NCT01214096|Experimental|rhNRG-1|recombinant human neuregulin-1
89276625|NCT03935438|Experimental|Patients after ACS|Patients after acute coronary syndrome undergoing cardiac rehabilitation.
89276626|NCT03933566||Ultrasound-Guided|Ultrasound-Guided Superficial Cervical Plexus Block
89276627|NCT03933566||Landmark-Based|Landmark-Based Superficial Cervical Plexus Block
89276628|NCT01122368|Experimental|1 Micafungin|IV
89276629|NCT01122368|Placebo Comparator|2 Placebo|IV
89276630|NCT03338062|Experimental|Theragnostic SBRT Planning|The theragnostic SBRT plan using the HIDA scan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
89276631|NCT03338062|No Intervention|Standard SBRT Planning|The standard SBRT plan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
89276632|NCT01216826|Experimental|Everolimus|
89276633|NCT03364192|Experimental|Peer-delivered Whole Health Coaching|Whole Health Coaching is a Veterans Health Administration variation of integrative health coaching. For this study it will be administered by a peer support specialist.
89276634|NCT01122524||Chromosomal Abnormality|Fetus affected by chromosomal abnormality
89276635|NCT01122524||No Chromosomal Abnormality|Fetus not affected by chromosomal abnormality
89276636|NCT01328912|Experimental|Remote ischemic preconditioning stimulus|
89276637|NCT01328912|Placebo Comparator|Control|
89276638|NCT01120340|Active Comparator|mesalamine|Posology: mesalamine: 1,6 g/die for ten days every month for 24 months
89276639|NCT01120340|Placebo Comparator|placebo|
89276640|NCT03707392|Active Comparator|Control|Standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
89276641|NCT03707392|Experimental|Treatment|Ostomy care educational video combined with standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
89276642|NCT05682976||AD patient treated by Tralokinumab|AD patient treated by Tralokinumab
89276643|NCT01214408|Experimental|GRP-A|
89276644|NCT01214408|Experimental|GRP-B|
89276645|NCT01214486|Experimental|Raltegravir|
89276646|NCT05412550|Experimental|Exercise self-management|The EXP intervention will integrate conventional telehealth care with exercise self-management training and include structured 1:1 sessions (six) with an interventionist, peer group sessions (six), real-time step count feedback throughout the 18 months using a wrist-worn Fitbit with an LED interface, and tailored messaging with text messages designed using six key behavior-change techniques promoting exercise self-management.
89276647|NCT05412550|Active Comparator|Attention control|The CTL intervention will incorporate the annual multidisciplinary team telehealth sessions, 12 attention-control telehealth sessions (six individual, six peer-group), and general health education text message prompts to match the timing and duration of the EXP group.
88805595|NCT00183092|Placebo Comparator|placebo|
89276648|NCT03710512||hydroset|patients receiving hydroset at osteotomy site
89276649|NCT03710512||Control|patients not receiving hydroset at osteotomy site
89276650|NCT03936842|Experimental|Single Arm|"Eligible patients who are referred to the one-stop diagnostic clinic with breast pain alone and have completed a clinical assessment will be given a patient information sheet inviting them to participate in the study. They will be met by the interviewing clinician at the same visit."
89276651|NCT03708016|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
89276652|NCT03708016|Active Comparator|Robot gait training without brain stimulation|Lokomat robot training and sham tDCS on the leg motor areas
89276653|NCT01219478||control|0 metabloil risk
89276654|NCT01219478||1|1 metabloil risk
89276655|NCT01219478||2|2 metabloil risk
89276656|NCT01219478||3|3 metabloil risk
89276657|NCT01214564|Experimental|1|Up to three days of treatment
89276658|NCT01216904|Placebo Comparator|Placebo patch|
89276659|NCT01216904|Active Comparator|Nicotine patch|
89276660|NCT05682898||More than 7 weeks|Timing of colorectal cancer surgery is more than 7 weeks after confirmed COVID-19 infection by COVID-19 nucleic acid test.
89276661|NCT05682898||Less than 7 weeks|Timing of colorectal cancer surgery is less than 7 weeks after confirmed COVID-19 infection by COVID-19 nucleic acid test.
89276662|NCT01125020|Active Comparator|gemcitabine and oxaliplatin|
89276663|NCT01125020|Active Comparator|doxorubicin, 5-Fu and cisplatin|
89276664|NCT01312012|Experimental|The effectiveness and feasibility, using antiviral therapy|Experimental: Subjects receive tenofovir disoproxil fumarate (TDF) oral use prior to delivery in pregnant women with positive serum HBeAg and HBsAg and high HBV DNA levels > 10^8copies / mL, to reduce the rate of mother to infant transmission of HBV infection, and also to monitor the safety of the therapy.
89276665|NCT01312012|No Intervention|Control|Subjects receive no intervention, but with blood tests for mothers and infants before and after delivery, as a comparative group to experimental arm.
89276666|NCT03935204|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
89276667|NCT03935204|Placebo Comparator|Placebo|Participants in this arm would receive 1.0ml aluminium adjuvant.
89276668|NCT01216982|Active Comparator|Lovaza, omega-3 fatty acid ethyl ester|
89276669|NCT01216982|Placebo Comparator|Placebo|one gram corn oil in a soft gelatin capsule
89276670|NCT03707080||Prospective|"The prospective DAA-PASS cohort will include a subset of HCV RNA positive participants in the TARGET-HCC study who meet entry criteria including hepatitis C (with no prior history of DAA therapy) and newly diagnosed Barcelona Clinic Liver Cancer (BCLC) Stage A HCC.~Participants will be enrolled in the countries participating in TARGET-HCC which will include: United States (US), France, Germany, Italy, and Spain."
89276671|NCT03707080||Historical|The historical cohort will be derived from the ITA.LI.CA database, which includes data on all consecutive patients with HCC who were managed within participating centers in Italy. The historical cohort will include patients from the ITA.LI.CA database who have active HCV infection who were not treated for HCV (IFN-based or DAA-based regimens) during the followup period, with initial HCC diagnosis BCLC Stage A, and subsequent successful treatment of HCC with curative therapy.
89276672|NCT03936764|Other|Group 1|5 Preoperative Pulmonary Rehabilitation sessions / week during 3 weeks.
89276673|NCT03936764|Other|Group 2|3 Preoperative Pulmonary Rehabilitation sessions / week during 5 weeks.
89276674|NCT01120496|Experimental|hypertonic saline|hypertonic saline (HS)
89276675|NCT01120496|Placebo Comparator|normal saline (NS)|normal saline (NS)
89276676|NCT03707002|Active Comparator|scFOS|scFOS consumed at 5g/day for 6 weeks
89276677|NCT03707002|Placebo Comparator|Placebo|maltodextrin consumed at 5g/day for 6 weeks
89276678|NCT01125254|Experimental|Amlodipine|amlodipine 5mg qd
89276679|NCT01125254|Placebo Comparator|Controls|placebo
89276680|NCT01214876||Children 1-5 years old|
89276681|NCT01214876||Children 6-10 years old|
89276682|NCT01214876||Adults 25 years and above|
89276683|NCT03710434|Experimental|Part A - nano-suspension|Subjects will receive single dose of AZD4635 50mg nano-suspension (reference) in the fasted state.
89276684|NCT03710434|Experimental|Part A - solid oral formulation|Subjects will receive single dose of AZD4635 50mg solid oral formulation, in the fasted state.
89276685|NCT03710434|Experimental|Part B-solid oral formulation with food|Subjects will receive a single dose AZD4635 solid oral formulation after high fat meal.
89276686|NCT03710434|Experimental|Part B - solid oral formulation with PPI|Subjects will receive 30 mg lansoprazole BID and a single dose of AZD4635 solid oral formulation in the fasted state.
89276687|NCT03710434|Experimental|Part B - dose exploration 1|If dose adjustment is required, subjects will receive a different single dose (XX mg) of AZD4635 solid oral formulation, in the fasted state.
89276688|NCT03710434|Experimental|Part B - dose exploration 2|If dose adjustment is required, subjects will receive a different single dose (YY mg) of AZD4635 solid oral formulation, in the fasted state.
89276689|NCT03710434|Experimental|Part B - variant 1|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state and optional [14C] AZD4635 IV microtracer.
89276690|NCT03710434|Experimental|Part B - variant 2|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
89276691|NCT01120574|No Intervention|1|Oxygen therapy group.
89276692|NCT01120574|Active Comparator|2|Home mechanical ventilation plus oxygen therapy group.
89276693|NCT03706924|Experimental|VM-1500FDC|VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting
89276694|NCT03706924|Active Comparator|Elpida® & Truvada®|Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting
89276695|NCT01120652|Experimental|Mind-Body Skills Training|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices.
89276696|NCT01120652|Active Comparator|Supportive Counseling|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice.
89276697|NCT05682820||Patients with ACL tear|Patients with ACL tear- MRIs will be assessed
89276698|NCT05682820||Patients without ACL tear|Patients without ACL tear - MRIs will be assessed
89276699|NCT01120730|Active Comparator|HES|Fluid resuscitation with HES
89276700|NCT01120730|Placebo Comparator|ringers lactat|Standard treatment
89276701|NCT03706846|Other|Fasting 2 hours|Fasting 2 hours
89276702|NCT03706846|Other|Fasting 6 hours|Fasting 6 hours
89276703|NCT05682586|No Intervention|standard therapy|Participants will receive standard therapy, including oxygen therapy，glucocorticoid and other antiinflammatory drugs and supportive treatments according the ninth edition of Chinese guidelines for the treatment of COVID-19 infection.
89276704|NCT05682586|Active Comparator|Paxlovid treatment|Participants will receive paxlovid treatment on the basis of standard therapy.
89276705|NCT05682586|Experimental|UC-MSCs treatment|Participants will receive two doses of UC-MSCs instillation at the first and fourth day after the assignment.
89276706|NCT01217138|Other|Original epinephrine autoinjector group|Participants were given original epinephrine autoinjector trainer wrapped by a gray sticky paper.
89276707|NCT01217138|Active Comparator|Modified epinephrine autoinjector group|Participants were given the same epinephrine autoinjector trainer wrapped by a gray sticky paper which was modified by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.
89276708|NCT03710356|Experimental|Danazol|Danazol
89276709|NCT01125332|Placebo Comparator|group gel KY|
89276710|NCT01125332|Experimental|group gel lidocaine|
89276711|NCT01217294|Sham Comparator|spinal morphine, sham block|"Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as specified by the anaesthetist performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham ultrasound guided fascia iliaca plane block with saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
89276712|NCT01217294|Active Comparator|ultrasound guided fascia iliaca block|"Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
89276713|NCT03783962|Experimental|Active Intervention - Cooking|Twelve cooking classes will be run every other week after the in-person weight loss meetings. These lessons will be patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for individuals specifically interested in weight loss. Classes will begin with a brief lecture on the day's topic, followed by a laboratory session. Participants work in teams of two in the Nutrition and Food Sciences (NFS) foods lab to actively practice skills and cook a meal. Subjects will receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. Classes will be taught by a chef trained in the pedagogy by Dr. Trubek and participants will have the opportunity to sample the food they prepared at the end of class.
89276714|NCT03783962|Active Comparator|Demonstrations - Cooking|"The demonstration condition will serve as an attention only control. Previous research suggests that demonstrations of cooking have little to no impact on cooking behavior, therefore, cooking demonstrations can be used to even out the time and attention devoted to the active cooking participants without introducing bias into the study design. Subjects in the demonstration condition will also begin with a brief lecture on the day's lesson followed by a cooking demonstration that covers the same topics as the active intervention group. All participants will receive the same printed information and also have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group."
89276715|NCT03361228|Experimental|INCB001158 + Epacadostat + Pembrolizumab|
89276716|NCT03361228|Experimental|INCB001158 + Epacadostat|
89276717|NCT03936686|Active Comparator|Children in grades 4 or 5|This group was comprised of participants that were in grades 4 or 5 in school.
89276718|NCT03936686|Active Comparator|Adolescents in grades 10 or 11|This group was comprised of participants that were in grades 10 or 11 in school.
89276719|NCT03936686|Active Comparator|College Age Participants|This group was comprised of participants that were sophomores or juniors in college/university that were non-health career majors.
89276720|NCT03936686|Active Comparator|Cardiac Rehab Adults|This group was comprised of participants that were adults over the age of 40 that had completed a phase II cardiac rehabilitation program.
89276721|NCT03936686|Active Comparator|General Adults|This group was comprised of participants that were adults over the age of 40 that had never attended an outpatient cardiac rehabilitation program before.
89276722|NCT05175898||VA-ECMO|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) during cardiac arrest.
89276723|NCT05175898||ECMELLA|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella® micro-axial pump.
89276724|NCT01121042|Active Comparator|Ondansetron|Ondansetron oral capsule 8mg daily
89276725|NCT01121042|Placebo Comparator|Placebo|Placebo (100% lactose) matched oral capsule
89276726|NCT05677438|Experimental|Test Group1|
89276727|NCT05677438|Experimental|Test Group2|
89276728|NCT05677438|Experimental|Test Group3|
89276729|NCT05677438|Placebo Comparator|Placebo Group|
89276730|NCT01217372|Experimental|Lemon supplementation YES|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
89276731|NCT01217372|No Intervention|Lemon supplementation NO|No lemon supplementation
89276732|NCT01121120|Experimental|TXA127|300mcg/kg/day administered subcutaneously up to 28 days
89276733|NCT01121120|Placebo Comparator|Placebo|300mcg/kg/day administered subcutaneously up to 28 days
89276734|NCT03933488|Experimental|TAK-994: Part A|TAK-994 tablet or matching placebo, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety, tolerability, and PK (pharmacokinetic) data from previous cohorts.
89276735|NCT03933488|Experimental|TAK-994: Part B|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety, PK, and PD (pharmacodynamic) data from Part A. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
89276736|NCT03933488|Experimental|TAK-994: Part C|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
89276737|NCT03933488|Experimental|TAK-994: Part D|TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese elderly participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
89276738|NCT03933488|Experimental|TAK-994: Part E|TAK-994 tablet or matching placebo, orally, once or twice on Day 1, followed by a washout period of 2 days and on Day 4 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
89276739|NCT03706768|Other|Glycocalyx|degree of glycocalyx breakdown in patients with aSAH
89276740|NCT01217450|Experimental|Treatment (selumetinib, cetuximab)|Patients receive oral MEK inhibitor AZD6244 once or twice daily on days 1-28 and cetuximab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89276741|NCT05682508|Experimental|Education group|The training planned four step. In the first interview, a pre-test will be applied by the researcher. The patient will then be trained and given a training booklet. The second interview will take place 30 days after the end of the first training. The topics will be summarised and the benefits of adherence to diet and fluid control will be emphasised. The third interview will be held 30 days after the second interview. In this interview, the patient's questions will be answered and the necessary training sections will be explained again for patient. The issues that prevent the patient from complying with fluid and diet control will be discussed with the patient and positive developments in the patient prognosis will be reinforced. The last interview will be held 30 days after the third interview. In all interviews, data will be collected with data collection tools and clinical parameters of the patient will be recorded.
89276742|NCT05682508|No Intervention|Control grup|No training will be given to the control group. In the first interview will be applied data collection tools and will be recorded clinical parameters. Last interview with control group will be held 90 days after first interview. Data collection tools will be applied and clinical parameters will be recorded in last interview. The training booklet will be given also to patients in control group at the end of the research.
89276743|NCT01219556||Group 1|
89276744|NCT03710278||LPat Device|Performing Lumbar Puncture assisted by LPat
89276745|NCT01217528|Active Comparator|Group A|"Group A:~VT zone: 350ms~VF zone: 280ms"
89276746|NCT01217528|Experimental|Group B|"Group B:~VT zone: 320ms~VF zone: 250ms"
89276747|NCT01121198|Experimental|ASP1941 single arm|
89276748|NCT01121198|Experimental|ASP1941 repeated arm|
89276749|NCT01121198|Placebo Comparator|placebo single arm|
89276750|NCT01121198|Placebo Comparator|placebo repeated arm|
89276751|NCT01121276|Experimental|NN1218, formulation A|
89276752|NCT01121276|Experimental|NN1218, formulation B|
89276753|NCT01121276|Experimental|NN1218, formulation C|
89276754|NCT01121276|Experimental|NN1218, formulation D|
89276755|NCT01121276|Active Comparator|insulin aspart|
89276756|NCT05682430|Active Comparator|Heart rate-based HIIT|12 weeks heart-rate based HIIT intervention.
89276757|NCT05682430|Experimental|VIFT speed-based HIIT with mechanical work|12 weeks VIFT speed-based HIIT with mechanical work.
89276758|NCT01214954|Active Comparator|Control group|Standard rehabilitation
89276759|NCT01214954|Experimental|Resistance training|10 weeks of supervised progressive resistance training initiated within the first week after total hip replacement.
89276760|NCT05175508|Experimental|Azacytidine Combined With ARTA|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle with ATRA 20mg tid by po on days 1-21 of every cycle 28 days
89276761|NCT05175508|Experimental|Azacytidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle
89276762|NCT01125410|Experimental|Dequalinium chloride 10mg|
89276763|NCT01125410|Active Comparator|clindamycin vaginal cream 2%|
89276764|NCT03933332||Ventilator length of use|measured in days
89276765|NCT03706534|Active Comparator|Manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored. Radiologists also make assessment decision without any intervention from artificial intelligence. 10 radiologists review manually.
89276766|NCT03706534|Experimental|Review by S-Detect for Breast|The same images will be separately processed by the artificial intelligence system (S-Detect for Breast) by Samsung. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
89276767|NCT03706534|Experimental|Review with assistance of S-Detect for Breast|Second, the images will be reviewed by the radiologists with the help of artificial intelligence system, which is an interactive tool automatically providing recommendations on BIRADS descriptor choices that can be modified by the radiologists. The radiologists, after selecting all the descriptors of BIRADS, will decide the assessment categories. These decisions will be compared with the ground truths generated from the biopsy results or a 24-month follow-up (CADx).
89276768|NCT01328834|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase
89276769|NCT01121354|Experimental|Cefazolin 2g (Test)|
89276770|NCT01121354|Active Comparator|Cefazolin 1.5g (Control)|
89276771|NCT01122602|Experimental|Arm 1|
89276772|NCT01122602|Active Comparator|Arm 2|
89276773|NCT01122602|Placebo Comparator|Arm 3|
89276774|NCT03935048|Experimental|Higher Protein, Low Glycemic Load with Potatoes|Higher Protein, Low Glycemic Load with Potatoes (HPLG-P): low- to moderate- glycemic load meals containing white potatoes. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
89276775|NCT03935048|Active Comparator|Higher Protein, Low Glycemic Load with Processed Potatoes|Higher Protein, Low Glycemic Load with Processed Potatoes (HPLG-PP): low- to moderate- glycemic load meals containing processed white potato products. Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing white potatoes.
89276776|NCT03935048|Placebo Comparator|Higher Protein, Low Glycemic Load - Control|Higher Protein, Low Glycemic Load (HPLG-C): low- to moderate- glycemic load meals containing control carbohydrate (e.g. rice, pasta). Participants will consume low- to moderate-glycemic meals for 16 weeks and will need to consume at least 4 meals containing control carbohydrate sources.
89276777|NCT03359590|Experimental|Sitagliptin arm|Sitagliptin 100 mg
89276778|NCT03359590|Placebo Comparator|Placebo arm|Placebo comparator
89276779|NCT01219712|Active Comparator|Preoperative Optimization|"Patients with proximal femur fracture who are > 65 yrs old and have an increased NT-proBNP would be randomized to either Standard Management or Optimized Management.~The main aim of optimization is to achieve a normal oxygen delivery to the tissues preoperatively.~Hb would be optimized to > 90 g/l~SaO2 > 96%~Stroke volume index (SVI) > 30~Heart rate should ideally be < 80~Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal."
89276780|NCT01219712|No Intervention|Standard treatment|Patients who are randomized to this group would be managed according to existing routines within the hospital. Consequently, these patients would be transferred to the Orthopaedic ward after initial management in the Emergency Department, including fluid therapy, oxygen and pain management. Since these patients have a significantly high NT-proBNP, a Cardiologist would be consulted and a decision for optimization taken together with the attending Anaesthesiologist and Orthopaedic Surgeon prior to surgery.
89276781|NCT03710200|Active Comparator|Bologna 00+S. cerevisiae yeast|Bread made with Bologna flour (type 00) (modern variety)+S. cerevisiae yeast
89276782|NCT03710200|Experimental|Bologna 1+S. cerevisiae yeast|Bread made with Bologna flour (type 1) (modern variety)+S. cerevisiae yeast
89276783|NCT03710200|Experimental|Bio2+S. cerevisiae yeast|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+S. cerevisiae yeast
89276784|NCT03710200|Experimental|ICARDA+S. cerevisiae yeast|Bread made with Icarda mix (type 1) (heritage mix varieties)+S. cerevisiae yeast
89276785|NCT03710200|Experimental|Bologna 1+sourdough|Bread made with Bologna flour (type 1) (modern variety)+sourdough
89276786|NCT03710200|Experimental|Bio2+sourdough|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+sourdough
89276787|NCT03710200|Experimental|ICARDA+sourdough|Bread made with mix Icarda flour (type 1) (heritage mix varieties)+sourdough
89276788|NCT03710200|Experimental|Grossi+sourdough|Bread made with mix Grossi flour (type 1) (heritage mix varieties)+sourdough
89276789|NCT01217762|Experimental|11 Gy IRay|Day 0 Lucentis followed by 11 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 2)
89276790|NCT01217762|Experimental|16 Gy IRay|Day 0 Lucentis followed by 16 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 27)
89276791|NCT01217762|Experimental|16 Gy IRay - Radiation First|16 Gy IRay and Lucentis PRN (N = 13)
89276792|NCT01217762|Experimental|24 Gy IRay|Day 0 Lucentis followed by 24 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 19)
89276793|NCT01121432||Mediastinal lymphadenopathy|
89276794|NCT05682274|Active Comparator|Group I|Partial restoration with the apical border at the level of CEJ in combination with CAF+CTG
89276795|NCT05682274|Active Comparator|Group II|Partial restoration with the apical border within 1 mm apical to the CEJ.
89276796|NCT01215266|Active Comparator|Sorafenib|
89276797|NCT01215266|Placebo Comparator|Placebo|
89276798|NCT05682196|Experimental|Rituximab plus standard of care (RTX)|Rituximab i.v of two perfusions (375 mg/m²) administered in a 14 day-interval added to a standard of care treatment
89276799|NCT05682196|Active Comparator|Standard of care treatment (Control)|Standard of care treatment
89276800|NCT03936374|Experimental|BMS-986205 + Omeprazole|
89276801|NCT05366920|Active Comparator|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle Intervention: Procedure: dissection of gallbladder in laparoscopic cholecystectomy
89276802|NCT05366920|Active Comparator|5 mm suction irrigation blunt dissection|Laparoscopic cholecystectomy made with 5mm suction irrigation blunt dissection starting from gallbladder fundus Intervention: Procedure: dissection of gallbladder in laparoscopic cholecystectomy
89276803|NCT01219790|Experimental|irradiation + zometa|
89276804|NCT05682040|Other|Active|
89276805|NCT03936296|Active Comparator|fusion arm|Patients in this arm will be undertaken standard transrectal prostate biopsy and MR guided MR-US fusion prostate biopsy
89276806|NCT03936296|Other|Standard arm|Patients in this arm will be undertaken only standard transrectal prostate biopsy
89276807|NCT05085964|Other|QR421a RNA antisense oligonucleotide for intravitreal injection|There is only one treatment arm in the PQ-421a-002 study; All participants that are eligible to be dosed will receive QR-421a in an open label fashion.
89276808|NCT01215500|Experimental|Radiation therapy|
89276809|NCT01125488|Experimental|LNG-IUS|LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.
89276810|NCT01125488|Active Comparator|GnRH agonist|The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.
89276811|NCT01215578|Experimental|patient treated|patient who receive sunitinib (SUTENT)
89276812|NCT01215656|Experimental|Probiotic|follow on formula with the probiotic Lactobacillus fermentum
89276813|NCT01215656|Active Comparator|Control|follow on formula without probiotics
89276814|NCT01120418|Experimental|Besifloxacin Ophthalmic Suspension 0.6%|Topical ocular administration three times daily (TID) for 5 days
89276815|NCT03706378|Other|Glucose Reference 1|50g glucose dissolve in 250 ml of water
89276816|NCT03706378|Other|Glucose Reference 2|50g glucose dissolve in 250 ml of water
89276817|NCT03706378|Other|Glucose Reference 3|50g glucose dissolve in 250 ml of water
89276818|NCT03706378|Experimental|Wheat Yellow Noodle|Boiled 170.6g of wheat yellow noodle
89276819|NCT03706378|Experimental|Beta-glucan Yellow Noodle|Boiled 230.4g of beta-glucan yellow noodle.
89276820|NCT03706378|Experimental|Rice Roll|Steamed 197.6g of rice roll
89276821|NCT03706378|Experimental|Rice Roll with resistant starch|Steamed 232.6g of rice roll fortified with resistant starch
89276822|NCT03706378|Experimental|Sucrose jelly|Jelly made with 25g of sucrose and 48g of wheat white bread
89276823|NCT03706378|Experimental|Isomaltulose jelly|Jelly made with 25g of isomaltulose and 48g of wheat white bread
89276824|NCT01125644|Experimental|Single Arm|"Patients are males and females between 18 and 75 years of age with proven fungal etiology confirmed by mycological culture test and by hystopathological exam (patients with definite diagnosis), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology (patients with clinical diagnosis)."
89276825|NCT05577988|No Intervention|Control arm|Standard of Care : Systematic de-escalation to a high potency antiplatelet single therapy
89276826|NCT05577988|Other|Intervention arm|single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.
89276827|NCT01222052|Experimental|Arm A Taxane-containing|3 courses FEC q3weeks followed by 3 courses Docetaxel q3weeks
89276828|NCT01222052|Active Comparator|Arm B standard anthracyclin|6 courses of FEC q3weeks
89276829|NCT01222052|No Intervention|Observation|
89276830|NCT03710044|Experimental|Cyclosporine A treatment|Oral cyclosporine A treatment
89276831|NCT01222208|Active Comparator|Oral Nutrition|Subjects will receive an oral nutrition regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as pressurized whey protein
89276832|NCT01222208|Placebo Comparator|Peripheral Parenteral Nutrition|Subjects will receive a peripheral parenteral nutrition (PPN) regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as amino acids.
89276833|NCT03706300|Experimental|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets 1200/120 mg of Dr. Reddy's Laboratories Limited
89276834|NCT03706300|Active Comparator|Mucinex D|Mucinex D extended-release bi-layer tablets 1200/120 mg of Reckitt Benckiser Inc., USA
89276835|NCT03934892||lactate during CPB|check lactate levels routinely during cardiac operations with cardiopulmonary bypass, choose the peak lactate data
89276836|NCT05082220|Experimental|10 ml ESPB group|ESPB group using 10 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
89276837|NCT05082220|Experimental|20 ml ESPB group|ESPB group using 20 ml mixture of local anesthetics and contrast medium using ultrasound and fluoroscopy
89276838|NCT01122758||COPD cohort|"Inclusion criteria:~Patients ≥ 35 years.~Diagnosis of COPD (GOLD PBD FEV1/FVC ratio <0.70).~Being in a stable phase of disease (8 weeks without exacerbation).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Recent exacerbation (<8 weeks).~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
89276839|NCT01122758||Control cohort|"Inclusion criteria:~Patients ≥ 35 years.~Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio >=0.70).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
89276840|NCT01219868|Experimental|Physician-nurse team|
89276841|NCT05160142|Experimental|Intervention|Participate in the DICE program, which entails culinary and diabetes educational programming delivered weekly for 10 consecutive weeks.
89276842|NCT03932006|Experimental|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
89276843|NCT03932006|Experimental|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
89276844|NCT03932006|Active Comparator|Imrecoxib|Imrecoxib 0.1g twice a day,orally
89276845|NCT04737226|Experimental|Basketballers|
89276846|NCT04737226|Experimental|Volleyballers|
89276847|NCT04737226|Experimental|Runners|
89276848|NCT01222364|Active Comparator|Standard Cord Clamping|
89276849|NCT01222364|Experimental|Delayed Cord Clamping|
89276850|NCT05155540|Active Comparator|Direct mechanical thrombectomy|Direct mechanical thrombectomy performed within 4.5 of stroke onset without giving intravenous recombinant tissue plasminogen activator.
89276851|NCT05155540|Active Comparator|Bridging therapy|Mechanical thrombectomy performed within 4.5 of stroke onset after giving intravenous recombinant tissue plasminogen activator at a dose of 0.9 mg/Kg
89276852|NCT01329224||TAM patients|All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic.
89276853|NCT01122836|Experimental|Massage Dose 1|This arm receives weekly 60-minute massage for 4 weeks after a 4-week period of no treatment.
89276854|NCT01122836|Experimental|Massage - Dose 2|This arm receives weekly 60-minute massage for 4 weeks.
89276855|NCT01122836|Experimental|Massage - Dose 3|This arm receives 2 weekly 30-minute massage for 4 weeks.
89276856|NCT01122836|Experimental|Massage - Dose 4|This arm receives 2 weekly 60-minute massages for 4 weeks.
89276857|NCT01122836|Experimental|Massage - Dose 5|This arm receives 3 weekly 30-minute massages for 4 weeks.
89276858|NCT01122836|Experimental|Massage - Dose 6|This arm receives 3 weekly 60-minute massages for 4 weeks.
89276859|NCT05155384|Experimental|biopsychosocial model-based treatment|Biopsychosocial model-based management will be applied including pain neuroscience education, functional exercises, and relaxation training.
89276860|NCT05155384|Active Comparator|Conventional physiotherapy|Conventional physiotherapy will be applied including standard exercises and electrical stimulation.
89276861|NCT05360758||Patients diagnosed with CLL with treatment criteria, first line or relapsed/refractory.|
89276862|NCT01222442|Experimental|1|400 µg AZD3199 + moxifloxacin placebo
89276863|NCT01222442|Experimental|2|1200 µg AZD3199 + moxifloxacin placebo
89276864|NCT01222442|Active Comparator|3|AZD3199 placebo + moxifloxacin 400 mg
89276865|NCT01222442|Placebo Comparator|4|AZD3199 placebo + moxifloxacin placebo
89276866|NCT03709966|Experimental|FitBit|Portable technological support to monitor physical activity, similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status.
89276867|NCT03709966|Active Comparator|Routine|Physical activity promotion supported by a kinesiologist
89276868|NCT01219946||1|Patients with Chronic Obstructive Pulmonary Disease
89276869|NCT03706222||Drug interaction of Elbasvir/Grazoprevir|Patients treated with elbasvir/grazoprevir will be enrolled. DDI will be evaluated.
89276870|NCT05681728|Experimental|Pembrolizumab combined with chemotherapy|
89276871|NCT03706144|Experimental|Prodigy Intervention Group|Teachers will use the Prodigy Math Training with their students in school for at least 20 minutes per day, 3 days per week, from August to December 2018.
89276872|NCT03706144|No Intervention|Control Group|Instruction as usual = TAU
89276873|NCT03931850|Experimental|Dual guidance (ultrasound and neurostimulation)|This arm : patients will be received pudendal nerve block by dual guidance technique ( ultrasound and neurostimulation)
89276874|NCT03931850|Active Comparator|ultrasound-guided only|This arm : patients will be received pudendal nerve block by ultrasound-guided only.
89276875|NCT03931928|No Intervention|Control group (Group 1)|All patients receive Placebo
89276876|NCT03931928|Experimental|Group 2|"Patients will receive (Z)-endoxifen dosed according to CYP2D6 genotype"
89276877|NCT03931928|Experimental|Group 3|Patients will receive (Z)-endoxifen dosed according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening
89276878|NCT05523310||Training group|The training group will be used to develop the prediction model, based on their reported daily questionnaire. Participants in the training group will not be included in the Validation group
89276879|NCT05523310||Validation group|"The validation group will be used only for validation (test) of the prediction model (Naïve group). Participants in the validation group could not be recruited from the training group"
89276880|NCT03934970||Diabetic Neuropathy|Thirty Egyptian patients with type 2 diabetes mellitus complaining of symptoms suggestive of peripheral neuropathy including 12 males and 18 females with a mean of 50.90 ± 9.18.
89276881|NCT03934970||Healthy Control Subjects|Fifteen normal healthy Egyptian volunteers including10 males and 5 females with a mean age of 45.67±7.77 years.
89276882|NCT05133310|No Intervention|Standard Care Group|Patients will receive the standard chemotherapy regimen assigned for their treatment and, they will be followed and monitored until the end of treatment and hospitalization.
89276883|NCT05133310|Experimental|Simvastatin Treatment Group|Patients will combine the standard CALGB treatment scheme plus Simvastatin 10mg orally every 24 hours during the first 7 days of treatment and then continue with 20mg every 24 hours until the end of treatment and hospitalization.
89276884|NCT01217918|Experimental|Cohort 1|PH-797804
89276885|NCT01217918|Experimental|Cohort 2|PH-797804
89276886|NCT01217918|Experimental|Cohotr 3|PH-797804
89276887|NCT04576000||Open-Label Group|Eligible patients will include those who will be prescribed Janus Kinase inhibitor as part of their routine medical care.
89276888|NCT01217996|Other|Intervention Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (intervention).
89276889|NCT01217996|Other|Control Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (control).
89276890|NCT03706066||PanOptix|Cataract surgery with implantation of Acrysof IQ PanOptix IOL
89276891|NCT03740750|Placebo Comparator|control|sham heat and sham TENS
89276892|NCT03740750|Experimental|heat only|heat applied to the back for 4 hours with sham TENS
89276893|NCT03740750|Experimental|Tens only|Tens applied for 4 hours with sham heat
89276894|NCT03740750|Experimental|Heat and Tens continuous|Heat and Tens applied together for 4 hours
89276895|NCT03740750|Experimental|Tens 15|Tens applied only 15 minutes each hour for 4 hours, sham heat
89276896|NCT03740750|Experimental|Heat and Tens 15|Heat applied for 4 hours with tens only applied the last 15 minutes of each hour
89276897|NCT01222910|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
89276898|NCT01222910|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
89276899|NCT04533568|Experimental|ibuprofen|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
89276900|NCT04533568|Experimental|dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
89276901|NCT01222988|Other|very low calorie diet program|
89276902|NCT03931694||All patients with chronic pain follow in pain clinic|
89276903|NCT03705988|Experimental|Intervention Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted continuously from 500 μA~2mA.
89276904|NCT03705988|Sham Comparator|Sham Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted lower than 100 μA.
89276905|NCT01223144|Experimental|Patients with essential tremor|Patients with essential tremor
89276906|NCT01223144|Active Comparator|age- and sex-matched control subjects|age- and sex-matched control subjects
89276907|NCT05500924|Experimental|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
89276908|NCT05500924|Experimental|Control group|5 sets of functional activities each will be repeated for 3 times: Sit to stand Squat Stand to sit Stairs stepping Bridging
88805596|NCT05445258|Experimental|InnoCath AB® Balloon|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
88805597|NCT01045499|Experimental|laparoscopic gastric banding|Adolescent patients who have undergone laparoscopic adjustable gastric banding. Weight, BMI, and co-morbidity data will be compared to patient's pre-operative values.
89276909|NCT03934580|Experimental|hallucinated meal|A breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated under hypnosis by participants for 15 minutes
89276910|NCT03934580|Active Comparator|real meal|A real meal (white bread plus ham and cheese with 250 ml still water) is consumed by participants in 15 minutes
89276911|NCT05494216|Active Comparator|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Individual bound sperm selection is done followed y ICSI
89276912|NCT05494216|Active Comparator|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for ICSI.
89276913|NCT01312168|No Intervention|Healthy non-OSA control|
89276914|NCT01312168|Experimental|OSA receiving therapeutic CPAP|
89276915|NCT01312168|Sham Comparator|OSA receiving subtherapeutic CPAP|
89276916|NCT03934502|Experimental|Evobrutinib: Treatment Sequence A, B, C, D|Participant will receive single oral dose of evobrutinib after an overnight fast of at least 10 hours (Treatment A) for 3 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by 2 hours after start of low-fat meal (Treatment D) for 2 days. There will be 48 hours washout period between each treatment period.
89276917|NCT03934502|Experimental|Evobrutinib: Treatment Sequence B, D, A, C|Participant will receive single oral dose of evobrutinib within 30 minutes after start of a light meal (Treatment B) for 3 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days. There will be 48 hours washout period between each treatment period.
89276918|NCT03934502|Experimental|Evobrutinib: Treatment Sequence C, A, D, B|Participant will receive single oral dose of evobrutinib 1 hour prior to a low-fat meal (Treatment C) for 3 days, followed by after an oversight fast of at least 10 hours (Treatment A) for 2 days, followed by 2 hours after start of a low-fat meal (Treatment D) for 2 days followed by within 30 minutes after start of a light meal (Treatment B) for 2 days. There will be 48 hours washout period between each treatment period.
89276919|NCT03934502|Experimental|Evobrutinib: Treatment Sequence D, C, B, A|Participant will receive single oral dose of evobrutinib 2 hours after start of a low-fat meal (Treatment D) for 3 days, followed by 1 hour prior to a low-fat meal (Treatment C) for 2 days, followed by within 30 minutes after start of a light meal (Treatment B) for 2 days, followed by after an overnight fast of at least 10 hours (Treatment A) for 2 days. There will be 48 hours washout period between each treatment period.
89276920|NCT05287282|Experimental|TECAR application|
89276921|NCT05287282|Active Comparator|selected abdominal exercises program|
89276922|NCT01123226|Experimental|Diversified HVLA spinal manipulation|
89276923|NCT01123226|Active Comparator|Trigger point pressure release|
89276924|NCT01223222|Placebo Comparator|1% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
89276925|NCT01223222|Active Comparator|2% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
89276926|NCT01223222|Active Comparator|5% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
89276927|NCT02529332|Experimental|Omega-3 Supplementation Group|Omega-3 supplementation
89276928|NCT02529332|No Intervention|Control Group|
89276929|NCT03932942|Experimental|Point-of-care testing of respiratory pathogens on admission|Point-of-care testing of respiratory pathogens on admission. The subjects will receive the point-of-care testing of respiratory pathogens at pediatric emergency room. The results are ready within 1 one hour.
89276930|NCT03932942|No Intervention|Routine ED protocol|Diagnostic tests for respiratory pathogens will be obtained according to clinical judgement and tested on microbiological laboratory. The results are ready on the next office day.
89276931|NCT03931382|Experimental|Virtual Reality|In this arm, participants will receive 45 minutes of preparation using a simulated virtual reality experience designed in collaboration with Medical Imaging and Child Life Specialists.
89276932|NCT03931382|Active Comparator|Mock MRI|In this arm, participants will receive 45 minutes of preparation using the standard of care simulator, conducted by a Child Life Specialist
89276933|NCT03931382|Active Comparator|Booklet|In this arm, participants will receive 45 minutes of preparation using the standard of care MRI Preparation Booklet for non-sedated MRIs.
89276934|NCT01312324|Experimental|neoadjuvant chemotherapy|3 cycles of docetaxel/cisplatin before operation
89276935|NCT03931226||Departmental cohort|Department level of the Haute-Garonne through the use of the 'POMME' cohort (PrescriptiOns Medicines Mother Children)
89276936|NCT03931226||National cohort|"National level through the use of the EGB database (General Sample of Beneficiaries)"
89276937|NCT05681416|Other|Healthy men with familial risk|≥ 2 first-degree relatives with PCA diagnosed at any age oder ≥ 1 first-degree relative with PCA diagnosed at the age <60
89276938|NCT05681416|Other|healthy men with genetic risk|BRCA1/2 Germline mutation
89276939|NCT05681416|Other|Men with PCA and genetic oder familial risk|familial risk = ≥ 2 first-degree relatives with PCA diagnosed at any age oder ≥ 1 first-degree relative with PCA diagnosed at the age <60 genetic risk= BRCA1/2 Germline mutation
89276940|NCT01127672|Active Comparator|control|corticosteroid injection into the origin of the plantar fascia
89276941|NCT01127672|Active Comparator|experimental|platelet rich plasma injection into the origin of the plantar fascia
89276942|NCT05452408|Experimental|Antitumor B KAC|ATB will be administered on an outpatient basis.
89276943|NCT01125878|Active Comparator|Starch Composite B|fiber mixture
89276944|NCT01125878|Active Comparator|Starch Composite C|fiber mixture
89276945|NCT01125878|Active Comparator|Starch Composite D|fiber mixture
89276946|NCT01125878|Placebo Comparator|Placebo|Placebo
89276947|NCT04955314|Experimental|PA mobilizations on their main painfull vertebral segment|Patients who will be treated with PA mobilizations on their main painfull vertebral segment.
89276948|NCT04955314|Experimental|PA mobilizations on an adjacent vertebral segment from the most painful|Patients who will be treated with PA mobilizations on an adjacent vertebral segment from the most painful.
89276949|NCT01218074|Active Comparator|Thromboelastography alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performances.
89276950|NCT01218074|Experimental|Aggregometry+Tromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
89276951|NCT04473742|Experimental|Patients exposed to silica|
89276952|NCT04473742|Active Comparator|Patients exposed to asbestos fibres|
89276953|NCT01218152||cancer patients|patients who are seen by oncologists and who are willing to donate an extra blood sample when blood is taken routinely
89276954|NCT01218152||NF1 patients|patients, who have neurofibromatosis type 1 and who have developped an MPNST,donating a blood sample
89276955|NCT04459156|Experimental|Healthy Participants|healthy control subjects
89276956|NCT04459156|Experimental|Chronic Obstructive Pulmonary Disease patients|Established diagnosis of Chronic Obstructive Pulmonary Disease
89276957|NCT04459156|Experimental|Healthy Young Participants|healthy young subjects with age 18-30 years old
89276958|NCT01223300||Osteoporosis|
89276959|NCT04427488|Experimental|Morning Chronotype (MC) Group|In the MC group, exercises were applied in the morning hours for the first 6 weeks and in the evening hours for the next 6 weeks.
89276960|NCT04427488|Experimental|Evening Chronotype (EC) Group|The EC exercises were applied in the evening hours for the first 6 weeks and in the morning hours for the next 6 weeks
89276961|NCT01220258|Experimental|Azithromycin ophthalmic solution, 1%|
89276962|NCT01220336|Experimental|Health Coaching|
89276963|NCT01218230|Active Comparator|Intravitreal Pegaptanib|
89276964|NCT04395586||Culture-proven infected patients|
89276965|NCT01125956|No Intervention|Control|This group will receive usual diabetes care through their primary care clinicians.
89276966|NCT01125956|Experimental|Peer counseling|A peer counselor will be assigned to each participant who currently has good diabetes control but had poor control in the past 3 years.
89276967|NCT01125956|Experimental|Financial incentives|Patient participants in the financial incentive arm will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
89276968|NCT01223534|Active Comparator|Arm A, Standard practice, TST|Participants allocated to screening as stablished by current practice (TST)
89276969|NCT01223534|Experimental|Arm B, Experimental, TST plus QFT-IT|Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.
89276970|NCT02891200|Experimental|Healthcare professional (HCP) Arm|Healthcare professional (HCP) Arm includes a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
89276971|NCT02891200|Experimental|HCP plus Peer arm|HCP plus Peer arm involves delivering of HCP support as in HCP Arm , along with adding Peer Support Program services. This program is offered to participants by especially trained 'peer mentors' with oversight from a social worker.
89276972|NCT01223612|Experimental|Ranibizumab|Intravitreal injection of ranibizumab
89276973|NCT01223612|Active Comparator|Laser|Modified ETDRS laser
89276974|NCT01126034|Experimental|intervention|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~The name and medical record # of the patients involved~Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~A reminder of the adverse effect of long-term metoclopramide therapy~A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~A request that the physician document the discontinuation trial in the electronic medical record"
89276975|NCT01126034|No Intervention|non-intervention|No intervention letters were sent to subjects in this arm
89276976|NCT01127750|Experimental|FTY720|
89276977|NCT05177224|Experimental|Participants with dual mobility cup|
89276978|NCT02946580|Experimental|MOVANTIK™ (naloxegol)|Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
89276979|NCT02946580|Placebo Comparator|Sugar pill|Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).
89276980|NCT01223690|Placebo Comparator|Placebo|250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
89276981|NCT01223690|Active Comparator|Clarithromycin|1000 mg of clarithromycin diluted in 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
89276982|NCT05681338|Experimental|the medium intensity coughing technique|Immediately before the subcutaneous heparin injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
89276983|NCT05681338|No Intervention|the standard injection technique|During the subcutaneous heparin injection, patients were not asked to perform any action, and the injection was given by the standard technique.
89276984|NCT05168488|Experimental|All participants|There is only one study arm consisting of all participants.
89276985|NCT03931304||Cases group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
89276986|NCT03931304||Control group|Cytoreductive surgery alone
89276987|NCT01123304|Experimental|MORAb 028|
89276988|NCT05381350|Experimental|Experimental group aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain）|400 participants aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
89276989|NCT05381350|Active Comparator|Control Group aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain）|200 participants aged 18-59 years and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
89276990|NCT05381350|Experimental|Experimental group aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain）|100 participants aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
89276991|NCT05381350|Active Comparator|Control Group aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain）|50 participants aged 60 years and above and received 2 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
89276992|NCT05381350|Experimental|Experimental group aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain）|400 participants aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
89276993|NCT05381350|Active Comparator|Control Group aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain）|200 participants aged 18-59 years and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
89276994|NCT05381350|Experimental|Experimental group aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain）|100 participants aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine (Omicron variant).
89276995|NCT05381350|Active Comparator|Control Group aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain）|50 participants aged 60 years and above and received 3 doses of COVID-19 vaccine（CZ strain） will receive one dose of inactivated COVID-19 vaccine（CZ strain）.
89276996|NCT05381350|Active Comparator|Historical control group|Backup serum samples will be selected from 250 healthy adult subjects aged 26-45 years who received two doses of inactivated COVID-19 vaccine(CZ strain)from clinical trial of lot-to-lot consistency of an inactivated SARS-CoV-2 Vaccine(Pro-NCOV-4001) to detect neutralizing antibodies against the CZ, Delta and Omicron strains.
89276997|NCT03934736|Experimental|HEPLISAV-B®|A single dose of 0.5 mL HEPLISAV-B® administered intramuscularly in the deltoid muscle at Week 0 (Visit 1), Week 4 (Visit 2), Week 8 (Visit 3), and Week 16 (Visit 4).
89276998|NCT05176834|Experimental|B-Cure laser pro|In case of appearance of mucositis, patients will receive standard treatment as usual (rinses, painkillers, etc.). In addition, study participants will treat themselves with the B-Cure laser pro before each radiation therapy session at the clinic and will continue with daily treatment until the disappearance of the mucositis should it develop.
89276999|NCT01223768|Experimental|Acetyl-L-carnitine|
89277000|NCT01223768|Placebo Comparator|placebo|
89277001|NCT04759066|Experimental|Experimental|Participants will wear HEALiX device
89277002|NCT01126112|Experimental|Panitumumab|Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.
89277003|NCT01127828|Active Comparator|Probiotic yoghurt (Cultura)|Cultura yoghurt containing: L bulgaricus, S thermophilus
89277004|NCT01127828|Placebo Comparator|Yoghurt with no probiotic|
89277005|NCT02529176|Experimental|Best-practice alert|Receive the best-practice alert (BPA) during the course of their clinical work in the electronic medical record.
89277006|NCT02529176|No Intervention|No alert|Physicians will receive no best-practice alert from the electronic medical record.
89277007|NCT03934424|Experimental|Weight Stigma|Weight stigma, read a weight stigma article for 5-10 minutes on one day
89277008|NCT03934424|Other|Ethnic stigma|Ethnic stigma, read an ethnic stigma article for 5-10 minutes on one day
89277009|NCT05358808|Experimental|γδ T cells (IMP, TCB008)|"After inclusion, all patients will receive lymphodepleting chemotherapy with fludarabine 30mg/m2 Day -6 to Day -3 [total 120 mg/m2] and cyclophosphamide 0.5g/m2 [total 1.5 g/m2) Day -5 to Day -3,]. This will be followed by a rest day (Day -2).~TCB008 treatment (consisting initially of one dose of 7 X 10^7 or 7 X 10^8 cells ) is administered on Day 0"
89277010|NCT01220492|Experimental|conventional plus MSC treatment|participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
89277011|NCT01220492|Experimental|conventional plus placebo treatment|participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
89277012|NCT01123538|Other|Natural progesterone|Combined menopausal treatment containing natural progesterone
89277013|NCT01123538|Active Comparator|Chlormadinone acetate|Combined menopausal treatment containing chlormadinone acetate
89277014|NCT03931148|Experimental|Intervention|"After first consultation for diagnosis of neurodegenerative disorder :~Geriatric Assessment with specific neuropsychologic tests of decision making~fRMI~EEG High Resolution~Qualitative interview"
89277015|NCT01223924|Experimental|M2ES 7.5-90mg|M2ES dose escalating
89277016|NCT01223924|Placebo Comparator|Placebo|placebo contract
89277017|NCT01220570|Experimental|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)
89277018|NCT01220570|Experimental|Ridaforolimus|Ridaforolimus (MK-8669)
89277019|NCT01220570|Experimental|Dalotuzumab|Dalotuzumab (MK-0646)
89277020|NCT03930758|Experimental|Uphill exercise before the meals|40 minutes of uphill treadmill exercise at +6o slope completed 1 hour before eating the meal
89277021|NCT03930758|Experimental|Uphill exercise after the meals|40 minutes of uphill treadmill exercise at +6o slope started 1 hour after eating the meal
89277022|NCT03930758|Experimental|Downhill exercise before the meals|40 minutes of downhill treadmill exercise at -6o slope completed 1 hour before eating the meal
89277023|NCT03930758|Experimental|Downhill exercise after the meals|40 minutes of downhill treadmill exercise at -6o slope started 1 hour after eating the meal
89277024|NCT03930758|Sham Comparator|Sedentary trial|A trial with no exercise
89277025|NCT04682860|Placebo Comparator|Placebo|In the placebo arm, patients will be slowly injected with 2 ml of normal saline within 30 seconds
89277026|NCT04682860|Active Comparator|Hyoscine N butylbromide|In the treatment arm, the patient will be injected intravenously with 1ml 20 mg of Hyoscine butylbromide and 1 ml of normal saline intravenously within 30 seconds.
89277027|NCT01127906|Other|Randomized cross-over sequence|Randomized unbalanced sequence of incomplete block design with replicates within sequence
89277028|NCT01127984|Experimental|treatment with tissucol|patients treated with tissucol, local application in the pocket of PM / ICD
89277029|NCT01127984|Active Comparator|vacuum drainage system|patients treated with application of vacuum drainage system.
89277030|NCT01123616|Active Comparator|non-triclosan-coated|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
89277031|NCT01123616|Active Comparator|triclosan coated suture|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
89277032|NCT01123694||Xeroderma Pigmentosum patients|Xeroderma Pigmentosum patients who attend Camp Sundown, a camp for children with this condition.
89277033|NCT03638830|Experimental|Group 1|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®"
89277034|NCT03638830|Experimental|Group 2|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation) full dose + Maxipime®"
89277035|NCT03638830|Placebo Comparator|Group 3|placebo (like full dose) in combination with the drug Maxipime®
89277036|NCT01220648|Experimental|Nilotinib in conjunction with low dose interferon alfa|
89277037|NCT03638752|Experimental|Comprehensive education group|"The details of Comprehensive education are as follows:~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
89277038|NCT03638752|No Intervention|standard education|"The details of standard education are as follows:~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients that there would be some normal physiological reaction when gastroscopy, such as the throat discomfort and nausea/vomiting."
89277039|NCT01218386|Experimental|Study Group|"Start with estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~If day 25 is Monday: 6 days Tuesday: 10 days Wednesday: 9 days Thursday: 8 days Friday: 7 days Saturday: 6 days Sunday: 6 days of Progynova, 2x2 mg per day After this pretreatment: Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation"
89277040|NCT01218386|Active Comparator|Control group|Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation
89277041|NCT03933098|Experimental|Test group A: Lot 1 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 1 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
89277042|NCT03933098|Experimental|Test group B: Lot 2 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 2 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
89277043|NCT03933098|Experimental|Test group C: Lot 3 Vi-DT (typhoid conjugate vaccine)|"One dose of Vi-DT (typhoid conjugate vaccine) Lot 3 will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
89277044|NCT03933098|Active Comparator|Test group D: Typbar TCV|"One dose of Typbar TCV will be administrated intramuscularly at Enrollment visit (Day 0).~MR for age group at 9-15 months."
89277045|NCT01123772|Placebo Comparator|Control|Vehicle control
89277046|NCT01123772|Experimental|INO-8875|Active drug
89277047|NCT05309746||Ovarian Tissue Cryopreservation|Children faced with a fertility threatening diagnosis will be offered ovarian tissue cryopreservation. Pre-surgery assessment will be done while the child is in the hospital or in the pediatric oncology, surgery, or anesthesia clinic as an outpatient. The surgical procedure used to remove the child's ovary is called laparoscopy. It is not required for the treatment of the child's cancer or other medical condition. Laparoscopic surgery is done under general anesthesia (the child will be asleep during the surgery) in the operating room.
89277048|NCT03930836|Active Comparator|control group|high/low dosage intervention, intensive or not (motor function rehabilitation)
89277049|NCT03930836|Experimental|interface group|high/low dosage intensive intervention using the interactive interface (motor function rehabilitation)
89277050|NCT00323609|Active Comparator|Kyphoplasty|
89277051|NCT00323609|Active Comparator|Vertebroplasty|
89277052|NCT01224080|Experimental|Adiana Device|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
89277053|NCT01220804||NPDR|Type 2 diabetic patients with nonproliferative diabetic retinopathy (NPDR)
89277054|NCT01220804||Control Population|Healthy volunteers
89277055|NCT01224314|Active Comparator|dialysis fluid potassium high|potassium concentration in the dialysis fluid 1 mmol/L higher than usual
89277056|NCT01224314|Active Comparator|dialysis fluid potassium low|potassium concentration in the dialysis fluid 1 mmol/L lower than usual
89277057|NCT01128140|Experimental|Motivational Enhancement Therapy|
89277058|NCT01128140|Active Comparator|Education|
89277059|NCT04598152|Experimental|Transcranial Direct Current Stimulation during fMRI|Each subject will undergo transcranial direct current stimulation twice while completing a task in the functional magnetic resonance imaging scanner.
89277060|NCT01224392|Active Comparator|Concomitant chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
89277061|NCT01224392|Experimental|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
89277062|NCT01224470|Active Comparator|bupivacaine|0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
89277063|NCT01224470|Placebo Comparator|saline|
89277064|NCT04406428|Experimental|NKI followed by EBD|
89277065|NCT04406428|No Intervention|Standard EBD|
89277066|NCT01126346|Experimental|Arm I|Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
89277067|NCT05052502|Experimental|reactive focal mass drug administration (rfMDA)|Reactive FMDA (rfMDA) led by VMVs in response to cases in study area sub-district, in both villages and forest workers; quantitative G6PD testing for all individuals and 14-day PQ for G6PD non-deficient.
89277068|NCT05052502|Active Comparator|Control|Standard of care including case management through health facilities and malaria posts/VMVs; village-based RACD conducted by district staff in some areas.
89277069|NCT01126502|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive alvespimycin hydrochloride IV over 60 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89277070|NCT01224548|Experimental|vegan group|participants from sites of this group will receive vegan nutritional intervention starting from Feb 2011
89277071|NCT01224548|No Intervention|control group|participants from sites of the control group will not receive the same nutritional information until June 2011
89277072|NCT01218464|Experimental|Conventional plus MSC treatment|Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
89277073|NCT01218464|Experimental|Conventional plus pacebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
89277074|NCT01124084||Health Care Providers|
89277075|NCT03933956|Experimental|Empagliflozin-treated|Oral empagliflozin tablets 10mg daily, taken for 30 days.
89277076|NCT01218620|Experimental|Regimen I (Arm I)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
89277077|NCT01218620|Experimental|Regimen I (Arm II)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
89277078|NCT01218620|Experimental|Regimen II (Arm I)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
89277079|NCT01218620|Experimental|Regimen II (Arm II)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
89277080|NCT00323297|Placebo Comparator|placebo|
89277081|NCT00323297|Experimental|Active|
89277082|NCT01126658||All subjects act as their own contral|
89277083|NCT02529098|Sham Comparator|asymptomatic patients|fMRI Asymptomatic patients
89277084|NCT02529098|Experimental|symptomatic patients|fMRI patients with visual difficulties
89277085|NCT02529020|Experimental|Mouthguard|All subjects perform all tests wearing mouthguard.
89277086|NCT02529020|Experimental|No mouthguard|All subjects perform all tests without mouthguard
89277087|NCT01224860|Experimental|Telmisartan|
89277088|NCT01224860|Experimental|Losartan|
89277089|NCT01224938||Asthma patients|Asthmatics of all classes of severity will be included.
89277090|NCT01224938||Healthy control population|A healthy control population will be included to compare with the asthmatics.
89277091|NCT00323063|Active Comparator|Arm I (Gemcitabine Hydrochloride)|Patients receive gemcitabine hydrochloride IV on days 3 and 10.
89277092|NCT00323063|Experimental|Arm II (Gemcitabine Hydrochloride + Imatinib)|Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate once daily on days 1-5 and 8-12.
89277093|NCT03930290||Pregnant patients|Pregnant patients in their 2nd trimester.
89277094|NCT03930368|Experimental|Intervened arm|as in a single-arm before-and after study, the only one arm will receive intervention of low GI diet with supplementation of RCS.
89277095|NCT02532881|Experimental|Treatment as ususal (TAU) + Video Access|Patients in this arm receive access to various videos on the study website as well as treatment as usual (written information provided by the clinic).
89277096|NCT02532881|Placebo Comparator|Treatment as usual (TAU)|Patients in this arm receive treatment as usual (written information provided by the clinic).
89277097|NCT01329302|Active Comparator|Group A: Direct aspiration|
89277098|NCT01329302|Active Comparator|Follicular Flushing|
89277099|NCT01220882|No Intervention|Radiographic skeletal age assessment|Participant group studied will include all pediatric patients presenting to our institution with a unilateral or bilateral SCFE. Patients with metabolic and endocrine conditions will be included.
89277100|NCT01047449|Active Comparator|SVG harvest - conventional, placebo|
89277101|NCT01047449|Experimental|SVG harvest - no-touch, fish oils|
89277102|NCT01047449|Placebo Comparator|SVG harvest - no-touch, placebo|
89277103|NCT01047449|Active Comparator|SVG harvest - conventional, fish oils|
89277104|NCT01220960|Experimental|Art Therapy intervention group|For participants who will be part of the art therapy intervention, the art therapy group will be a closed group for eight women with breast cancer who are in treatment and recently have had surgery. The group will meet once a week for two hours over a period of 8 weeks, and will focus on exploring the expressive capabilities of art making in a supportive group. This group will be held in the conference room at the Cedars Breast Clinic. Each week will revolve around a theme that pertains to the experience of women living with breast cancer, and will be guided by the women's needs in the group. A broad range of art materials will be made available and various art techniques explored. No art experience is necessary. The intervention group will also need to fill out simple questionnaires before the art therapy groups starts and after the group finishes
89277105|NCT01220960|No Intervention|Control Group|The group not assigned to the intervention group will be asked to fill out questionnaires at two separate times (before and after the intervention group is run). The Control group will be offered the opportunity to join an open art therapy group upon completing the questionnaires.
89277106|NCT01047605|Experimental|PP1|Neurapas balance
89277107|NCT01047605|Experimental|PP2|Pascoflair 425 mg
89277108|NCT01047605|Placebo Comparator|PL1|P-Tabletten weiß
89277109|NCT03934346|Other|Zinc transport kinetics|Three different amounts of dietary zinc are used in the creation of a standard curve for determining zinc absorption kinetics: 4 mg, 7 mg, and 15 mg of zinc.
89277110|NCT03983213||Pat. after mpfl reconstruction|All 45 subjects operated with mpfl reconstruction included to chek-up after follow-up.
89277111|NCT01329068|Active Comparator|Individual consult|regular individual consult
89277112|NCT01329068|Active Comparator|group medical consult|regular group medical consult
89277113|NCT01061489|Experimental|sensory-cognitive training|
89277114|NCT01061489|Experimental|physical fitness|
89277115|NCT01061489|No Intervention|waiting list (control group)|
89277116|NCT01225094|Experimental|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.
89277117|NCT01225094|Placebo Comparator|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
89277118|NCT01128374|Experimental|intervention|Therapy
89277119|NCT03932474|Experimental|SAMEUp|SAMEUp, the Investigational Food Supplement (IFS), is an oral formulation (tablet) containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
89277120|NCT03932474|Placebo Comparator|Placebo|Placebo is an oral formulation of inert tablet. Placebo and SAMEUp are identical in shape, size, colour and taste.
89277121|NCT00322049|Experimental|Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )|"Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;~DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection. All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection."
89277122|NCT00322049|Active Comparator|Cohort B: Control vaccines|Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine
89277123|NCT00322049|Experimental|Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )|Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years
89277124|NCT01221038||group 1|young women not using OC
89277125|NCT01221038||group 2|young women using OC
89277126|NCT01221038||group 3|young men (database)
89277127|NCT01124318|Active Comparator|Lactofiltrum|
89277128|NCT01124318|Placebo Comparator|Placebo|
89277129|NCT03930134|Experimental|sparse uterine suture|women who had a french ambulatory casarean section including a sparse uterine closure
89277130|NCT03930134|Active Comparator|one layer uterine closure|women who had a misgav ladach caesarean section section, including a one layer classical uterine closure
89277131|NCT01225328|Experimental|Intervention|Telephone-delivered Behavioral Activation/Problem Solving (BA/PS) intervention
89277132|NCT01221116|No Intervention|1: Type of surgery|Two types of patients are compared (placebo vs levosimendan): CABG - coronary artery bypass grafting and AVR - aortic valve replacement (either with or without CABG - coronary artery bypass grafting)
88805598|NCT00132002|Experimental|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88805599|NCT00183794|Experimental|Arm 1|Patients will receive Docetaxel 75mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8. Cycles will be repeated every 3 weeks.
88805600|NCT00270296|Experimental|Trizivir (TZV) Arm|Participants in the TZV Arm (Arm 1A) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
89277133|NCT03929744|Experimental|LY3502970 (Part A)|Single dose of LY3502970 administered orally.
89277134|NCT03929744|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally.
89277135|NCT03929744|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
89277136|NCT03929744|Placebo Comparator|Placebo (Part B)|Multiple doses of placebo administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
89277137|NCT03929744|Experimental|LY3502970 (Part C)|Single dose of LY3502970 administered orally in each of two study periods.
89277138|NCT03929744|Experimental|LY3502970 (Part D)|Single dose of LY3502970 administered orally.
89277139|NCT03929744|Placebo Comparator|Placebo (Part D)|Single dose of placebo administered orally.
89277140|NCT03929744|Experimental|LY3502970 Formulation 1 (Part E)|Multiple doses of LY3502970 - formulation 1 administered orally.
89277141|NCT03929744|Experimental|LY3502970 Formulation 2 (Part E)|Multiple doses of LY3502970 - formulation 2 administered orally.
89277142|NCT01225406||third line naive|Children on second line or other regimen who switch or start third line regimen
89277143|NCT01225406||third line experienced|children who are on third line regimen
89277144|NCT01128608|Active Comparator|Control Group - Healthy Subjects|Healthy volunteers with normal EGD.
89277145|NCT01128608|Active Comparator|NERD Group|Subjects with NERD. Heartburn symp x2 wk for 3 months. Normal EGD and abnormal 24 hour pH.
89277146|NCT01126814|Experimental|one|
89277147|NCT03929510|Experimental|Period A|Single oral dose of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF 06651600).
89277148|NCT03929510|Experimental|Period B|Single oral dose of 200 milligrams (mg) unlabeled PF-06651600 followed at time of peak plasma concentration (Tmax) by an Intravenous (IV) dose of 60 micrograms.14C -PF-06651600 containing approximately 300 nCi 14C (ie, radiolabeled PF-06651600).
89277149|NCT03929276|Experimental|high-intensity laser therapy & exercises|High-intensity laser therapy application with iLux Laser device + exercise program
89277150|NCT03929276|Placebo Comparator|Shame laser & exercises|Sham high-intensity laser therapy application with iLux Laser device + exercise program
89277151|NCT03929276|Active Comparator|control - exercises only group|exercise program
89277152|NCT01221428|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery.
89277153|NCT01225484|Active Comparator|CFNB, periarticular infiltration|
89277154|NCT01225484|Active Comparator|Intraarticular catheter, periarticular infiltration|
89277155|NCT03929354|Experimental|Risk Factors Modification Programme|"Patients in the intervention arm will attend the 12-week intensive lifestyle programme which includes healthy lifestyle change such as smoking cessation, healthy food choices and increasing physical activity levels, as well as management of cholesterol, diabetes, and blood pressure.~The 12-week programme will consist of 12 sessions of 2.5 hours each per week.~Each of the weekly sessions will incorporate an individualised meeting between the multidisciplinary healthcare team and each patient to review the progress and health goals.~The weekly sessions will also include a one-hour group exercise programme and an educational workshop."
89277156|NCT03929354|Active Comparator|Standard Care|Standard care is defined as giving information and advice to the patients to modify their lifestyles but without providing a structured intervention or an individualised plan.
89277157|NCT01128686||CHB patients who started LAM as an initial antiviral treatment|CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to this investigation
89277158|NCT01218932|Experimental|A|Primaquine only, followed by chloroquine/primaquine, followed by chloroquine only
89277159|NCT01218932|Active Comparator|B|Primaquine alone, followed by chloroquine, followed by chloroquine/primaquine
89277160|NCT03928496|Experimental|Abobotulinumtoxina|300 units of abobotulinumtoxinA was reconstituted with 2.4 ml of 0.9% preservative free sterile saline so that each 0.1 ml contained 12.5 units of Abobotulinumtoxina 0.1 ml were injected into 31 sites of the head and neck
89277161|NCT03928496|Placebo Comparator|Placebo|0.9% preservative free sterile saline. 0.1 ml were injected into 31 sites of the head and neck
89277162|NCT01225796|Experimental|Sodium bicarbonate|This group will receive oral sodium bicarbonate 650mg three times daily for 6 months.
89277163|NCT01225796|No Intervention|Control|This group will not receive any sodium bicarbonate.
89277164|NCT01128998|Experimental|S-1 and Sorafenib|
89277165|NCT00321893|Experimental|Arm I: Budesonide|Inhaled Budesonide 800 ug twice daily for 1 year
89277166|NCT00321893|Placebo Comparator|Arm II: Placebo|Inhaled placebo twice daily for 1 year
89277167|NCT01225874|Experimental|Stratum 3|Patients receive oral dexamethasone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; pegaspargase intramuscularly (IM) on day 4, 5, or 6; cytarabine intrathecally (IT) on day 1; and methotrexate IT on day 8 (some patients also receive methotrexate IT on days 15 and 22).
89277168|NCT01225874|Experimental|Stratum 4|Patients receive oral prednisone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; IM SC-PEG E. coli asparaginase on days 2, 5, 8, 12, 15, and 19; daunorubicin hydrochloride IV over 15-20 minutes on days 8, 15, and 22; and methotrexate IT on days 1 and 8 (some patients also receive methotrexate IT on days 15 and 22).
89277169|NCT01226030|Experimental|M2ES 7.5mg|M2ES 7.5mg
89277170|NCT01226030|Experimental|M2ES 15mg|M2ES 15mg
89277171|NCT01226030|Experimental|M2ES 30mg|M2ES 30mg
89277172|NCT01226030|Experimental|M2ES 60mg|M2ES 60mg
89277173|NCT01226108|Active Comparator|antinitus patch|One patch per day, Duration: three weeks, Administration: behind the ear
89277174|NCT01329458||Focal liver lesions|Focal liver lesions: patients discovered with new, uncharacteristic focal liver lesions at standard ultrasound
89277175|NCT03928340|Active Comparator|combined metformin and insulin|
89277176|NCT03928340|Other|Insulin only|
89277177|NCT00371345|Experimental|Dasatinib|Participants with either a Human epidermal growth factor (Her2/neu)-amplified tumor type or ER and/or PgR positive tumor types received oral dasatinib twice daily (BID).
89277178|NCT01226186|Active Comparator|Nurse dispensed oral morphine solution.|
89277179|NCT01226186|Active Comparator|Self medicated oral morphine solution.|
89277180|NCT01128764|Experimental|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
89277181|NCT01128764|Active Comparator|CBT for depression|CBT for depression only
89277182|NCT03929198|Experimental|Intervention|The intervention group participated in a 6-week Pritikin diet, exercise program, and behavioral modification.
89277183|NCT03929198|No Intervention|Control|This group did not receive any intervention.
89277184|NCT03982823|Experimental|Hand-Sewn Sleeve Gastrectomy|
89277185|NCT03982823|Active Comparator|Stapled Sleeve Gastrectomy|
89277186|NCT01128920|Experimental|Skin and Needle Hygiene Intervention|
89277187|NCT01128920|Experimental|Assessment-Only Condition|
89277188|NCT03928886|Experimental|Senographe Pristina patient-assisted compression model|Senographe Pristina is a commercial mammography medical device consisting of the Senographe Pristina FFDM system (2D) and Senographe Pristina DBT option (3D). Senographe Pristina includes the hardware and software components required for multi-modality functioning and is designed to improve patient experience, patient throughput, and radiographer experience. The system offers two compression modes - standard mode and the optional patient-assisted compression. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
89277189|NCT03928886|Active Comparator|Senographe Pristina standard compression mode (usual care)|Senographe Pristina standard mode
89277190|NCT01228214|Experimental|Amiloride,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
89277191|NCT01228214|Placebo Comparator|Placebo,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
89277192|NCT00321737|Experimental|Dexlansoprazole MR 30 mg QD|
89277193|NCT00321737|Experimental|Dexlansoprazole MR 60 mg QD|
89277194|NCT00321737|Placebo Comparator|Placebo|
89277195|NCT03925064||Diabetic pregnancies|Pregnant women with pregestational or gestational diabetes mellitus
89277196|NCT03925064||non-diabetic pregnancies|Pregnant women without pregestational or gestational diabetes mellitus
89277197|NCT03924674|Active Comparator|Stepped Wedge Group 1: Sept. 2019 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
89277198|NCT03924674|Active Comparator|Stepped Wedge Group 2: Nov. 2019 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
89277199|NCT03924674|Active Comparator|Stepped Wedge Group 3: Jan. 2020 Launch|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
89277200|NCT01325363|Experimental|Schizophrenia|Schizophrenic patients
89277201|NCT01325363|Experimental|Control|Neurotypical subjects
89277202|NCT01126892|Experimental|Nilotinib|
89277203|NCT01061645|Experimental|MOC31-PE|
89277204|NCT01047761|Experimental|exercise|Multimodal exercises that include walking, breathing exercises, dynamic balance, and core strengthening.
89277205|NCT01226342|Experimental|TCEMS|Patients who will receive transcutaneous electrical muscle stimulation
89277206|NCT01061801|Experimental|Emotional expression, patient present|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the presence of the patient (one session).
89277207|NCT01061801|Experimental|Emotional expression, patient absent|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the absence of the patient (3 sessions).
89277208|NCT01061801|Active Comparator|Comparison|Caregivers are asked to talk about their plans for the upcoming week (time management, sessions 1 and 3) and positive aspects of their life (session 2).
89277209|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 1|Benralizumab single dose administration subcutaneously
89277210|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 2|Benralizumab single dose administration subcutaneously
89277211|NCT03928262|Experimental|Benralizumab - Subcutaneous administration of Dose 3|Benralizumab single dose administration subcutaneously
89277212|NCT03983135|Experimental|Study group|Patients who undergo revisional bariatric surgery
89277213|NCT01221584||1|Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
89277214|NCT01047917|Experimental|Meditation DVD|All participants will receive a Meditation DVD to practice at home daily for a total of 4 weeks.
89277215|NCT01129154|Experimental|panitumumab|Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
89277216|NCT03982667|Experimental|PCT group|For patients randomly assigned to the PCT-guided group, measurements of serum PCT concentrations (Day 1, 3, 7, and 9) will be taken and made available to the attending physicians. This means 3 ml of whole blood will be sampled from the arterial line of the patients for each measurement the serum PCT in plain tubes. The samples will be immediately assayed for the PCT measurement using the available device and the results will be ready in next 30 minutes after running the system.
89277217|NCT03982667|No Intervention|Standard-of-care group|
89277218|NCT01226498|Experimental|Fresh blood auto-transfusion|
89277219|NCT01226498|Experimental|Old blood auto-transfusion|
89277220|NCT03740594|Active Comparator|KMC 60 min group|
89277221|NCT03740594|Active Comparator|KMC 120 min group|
89277222|NCT03740594|Active Comparator|control group|
89277223|NCT01061957||Raltegravir patients|HIV patients who initiated raltegravir due to virological failure
89277224|NCT01061957||Haart naive patients|HIV patients initiating HAART for the first time
89277225|NCT01129232|Experimental|GAD-alum|GAD-alum administered at 0 and 1 months after inclusion
89277226|NCT01129232|Placebo Comparator|Placebo|
89277227|NCT01047995|Active Comparator|Group 1|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
89277228|NCT01047995|Active Comparator|Group 2|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2,~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
89277229|NCT01129388|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
89277230|NCT01129388|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
89277231|NCT01129388|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily"
89277232|NCT01129388|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily"
89277233|NCT01127048|Experimental|Prospan Hustenzäpfchen|
89277234|NCT01127048|Placebo Comparator|Placebo|
89277235|NCT03928574||Ultrasound-Guided|Ultrasound-Guided Plane Block
89277236|NCT03928574||Conventional|Conventional Block
89277237|NCT01228292|Active Comparator|Standard Anticoagulation|Hemodialysis is performed using standard anticoagulation using unfractionated heparin if no contra-indications for the use of heparin exist. If contra-indications for heparin exist a heparin coated hemofilter (Evodial) will be used. The use of unfractionated heparin or no heparin (with coated hemofilter) is a decision to be taken before every hemodialysis.
89277238|NCT01228292|Experimental|Citrasate|Hemodialysis is performed with Citrasate
89277239|NCT03924596|Experimental|Luban Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
89277240|NCT03924596|Active Comparator|Uralyt-U Calcium Oxalate|25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)
89277241|NCT03924596|Experimental|Luban Uric acid|25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)
89277242|NCT03924596|Active Comparator|Uralyt-U Uric acid|25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2
89277243|NCT01127126|Active Comparator|Bryophyllum|muscle relaxing substance
89277244|NCT01127126|Placebo Comparator|Placebo|control group postmenopausal women suffering from overactive bladder
89277245|NCT00320801|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h, applied for 7-day wear
89277246|NCT00320801|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h, applied for 7-day wear
89277247|NCT01127204|Active Comparator|arm 1 (reference strategy)|AZT-3TC-LPV/r twice a day
89277248|NCT01127204|Experimental|arm 2 (simplification strategy)|ABC-3TC-EFV once a day
89277249|NCT01228370|Experimental|Silodosin|Silodosin 8mg once a day for 12 weeks
89277250|NCT01221740|Experimental|Milnacipran|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
89277251|NCT01228448|Experimental|Participants 1-39|PET Scan done right after one radiation treatment is complete and will take 15-20 minutes. After undergoing their first PET scan, participants will have the option to undergo 1-2 additional scans throughout radiation treatment in the same manner as the first scan.
89277252|NCT01226576|Experimental|Treatment|ExAblate Treatment Arm
89277253|NCT03928106|Other|intervention|pharmacist responsible for enrollment will administer the following interventions: identifying the medication discrepancies make the recommendations to correct these discrepancies contact the physician to resolve these discrepancies
89277254|NCT03928106|Other|control|pharmacists will identify medication discrepancies no recommendation will be written by pharmacists to solve these discrepancies
89277255|NCT01226654|Other|MS Patients|All subjects enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
89277256|NCT01226654|Other|Healthy Patients|Patients enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
89277257|NCT03932396||Single group of subjects who fulfill the inclusion criteria|All the population condemned to a non-custodial sentence that is presented in the Service of Management of Penalties and Alternative Measures of the Center of Social Insertion (CIS) José Hierro CP Dueso during the study period (March 2019 and March 2021) , with ages between 18 and 79 years (approximately 1000 people / year) and willing to participate (signs the IC).
89277258|NCT03924284||NPA positive|NPA specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
89277259|NCT03924284||NPA negative|NPA specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
89277260|NCT03924284||Saliva positive|Saliva specimens that are tested positive for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
89277261|NCT03924284||Saliva negative|Saliva specimens that are tested negative for influenza A virus by commercially available assay or by the Public Health Laboratory Services Branch of Hong Kong
89277262|NCT00320489|Experimental|Olanzapine Pamoate Depot|Olanzapine pamoate depot
89277263|NCT00320489|Active Comparator|Olanzapine|Oral olanzapine
89277264|NCT01127282|Experimental|Vitamin|Vitamin(vitamin A 15mg,C 500mg,E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
89277265|NCT01127282|Placebo Comparator|Control|Placebo(digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
89277266|NCT03924206||Minimally invasive surgery with smoke evacuation system (SES)|minimally invasive surgical procedures during which a smoke evacuation device is used
89277267|NCT03924206||Minimally invasive surgery without SES|minimally invasive surgical procedures during which no smoke evacuation device is used
89277268|NCT03924206||Open surgery with SES|open surgical procedures during which a smoke evacuation device is used
89277269|NCT03924206||Open surgery without SES|open surgical procedures during which no smoke evacuation device is used
89277270|NCT03923816|Experimental|Group (R)|Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
89277271|NCT03923816|Experimental|Group (C)|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).
89277272|NCT03927872||cardioembolic stroke|
89277273|NCT03927872||non cardioembolic stroke|
89277274|NCT01129466|Active Comparator|Supplement A followed by supplement B|
89277275|NCT01129466|Active Comparator|Supplement B followed by Supplement A|
89277276|NCT01127360|Experimental|Bevacizumab|Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
89277277|NCT01127360|Active Comparator|Ranibizumab|Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
89277278|NCT03992573|Experimental|Study group|
89277279|NCT03992573|No Intervention|Control group|
89277280|NCT03928028|Active Comparator|Family Based Treatment (FBT)|Families will receive 15 sessions of FBT alone.
89277281|NCT03928028|Experimental|FBT w/ Parent-focused Cognitive Remediation Therapy|Family Based Treatment with Parent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of parent focused CRT followed Family Based Treatment over six months.
89277282|NCT03928028|Experimental|FBT w/Adolescent-focused Cognitive Remediation Therapy|Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of adolescent focused CRT followed by Family Based Treatment over six months.
89277283|NCT03923894|Experimental|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
89277284|NCT03923894|Placebo Comparator|Placebo|Placebo 2.07 g/day for 8 weeks.
89277285|NCT03923660|Experimental|Concentric-eccentric|Concentric-eccentric
89277286|NCT03923660|Experimental|Eccentric-concentric|Eccentric-concentric
89277287|NCT01221818|Experimental|1|
89277288|NCT01221818|Experimental|2|
89277289|NCT01221818|Experimental|3|
89277290|NCT01221818|Experimental|4|
89277291|NCT01221818|Experimental|5|
89277292|NCT01221818|Experimental|6|
89277293|NCT01228604|Experimental|Methylphenidate|
89277294|NCT03932084|Experimental|Control group|"During hospitalization:~Monitor subjects' blood glucose;~One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
89277295|NCT03932084|Experimental|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c<7% and LAGE<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
89277296|NCT01228682||Patients who are treated with Samsca.|
89277297|NCT01131416|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
89277298|NCT01131416|No Intervention|Conventional|Conventional postoperative feeding schedule
89277299|NCT01221896||Hyperparathyroidism|Patients with hyperparathyroidism, prior to surgery.
89277300|NCT03923114|Other|Patient group with treatment response|PET/CT imaging of patients with response to GLP-1 receptor agonist treatment
89277301|NCT03923114|Other|Patient group without treatment response|PET/CT imaging of patients with no response to GLP-1 receptor agonist treatment
89277302|NCT03923192|Other|ICDAS II|Visual tactile examination based on ICDASII scoring system
89277303|NCT03923348|Experimental|Leva Users|Subjects with pure urge urinary incontinence (UUI) or urge-predominant mixed urinary incontinence (U-MUI) who are candidates for pelvic floor physical therapy or other first line treatments for UUI/U-MUI use the leva® system twice-daily at home in addition to behavioral therapies for 8 weeks.
89277304|NCT01228760|Experimental|Dose level 1|
89277305|NCT01228760|Experimental|Dose level 2|
89277306|NCT01228760|Experimental|Dose level 3|
89277307|NCT01228760|Experimental|Dose level 4|
89277308|NCT01228760|Experimental|Dose level 5|
89277309|NCT01228760|Experimental|Dose level 5A|
89277310|NCT01228760|Experimental|Dose level 6|
89277311|NCT01228760|Experimental|Dose level 7|
89277312|NCT01228760|Experimental|Dose level 8|
89277313|NCT01228760|Experimental|Dose level 9|
89277314|NCT01228760|Experimental|Chemotherapy-naïve subjects|
89277315|NCT01228760|Experimental|Chemotherapy exposed subjects|
89277316|NCT03927404|Experimental|Adaptive Vacuum test Prosthesis|The experimental socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
89277317|NCT00320411|Experimental|Lapatinb|Lapatinib 1500mg QD
89277318|NCT01221974|Experimental|Essure,Hydrosalpinx, Infertility|
89277319|NCT01132040|Experimental|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
89277320|NCT01132040|Active Comparator|Mysoline|Mysoline Tablets of Yamanouchi Pharma Technologies Inc,
89277321|NCT03992495||Neck pain|People suffering from neck pain at the time of recruitment
89277322|NCT03992495||Healthy|Participants with no significant past neck pain, chronic pain or other relevant medical disorders.
89277323|NCT03927560|Experimental|Robotic Assisted Percutaneous Coronary Intervention|
89277324|NCT01226966||A|
89277325|NCT01228838|Experimental|NGX-1998, 10% w/w capsaicin|
89277326|NCT01228838|Experimental|NGX-1998, 20% w/w capsaicin|
89277327|NCT01228838|Placebo Comparator|Placebo liquid|
89277328|NCT03919838|Active Comparator|Probiotics|Participants will receive two lozenges containing probiotic bacteria and cranberry.
89277329|NCT03919838|Placebo Comparator|Placebo - No probiotics|Participants will receive a control two lozenges containing no probiotic bacteria.
89277330|NCT01129700|Experimental|short-course CRT-5FU|
89277331|NCT01229852|Experimental|Active DSF-rTMS|Active rTMS treatment.
89277332|NCT03923036||Metastatic colorectal cancer|"The French county Calvados registry of digestive cancers will allow to identify patients with a metastatic colorectal cancer diagnosed between 2004 and 2014.~Patients will be included if the cancer was diagnosed at the metastatic stage between 2004 and 2014 or non-metastatic before 2004 that became metastatic between 2004 and 2014 (synchronous and metachronous tumors)"
89277333|NCT03919916|Experimental|Serratus plane block and patient controlled analgesia|"Initial local anaesthetic bolus of 0.4 ml/kg of 0.25% levobupivacaine. Subsequent continuous local anaesthetic infusion of 0.125% levobupivacaine~Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes"
89277334|NCT03919916|Active Comparator|Patient controlled analgesia only|Patient controlled analgesia programmed with morphine to deliver on demand boluses of 1 mg and limited by a lockout time of 5 minutes
89277335|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, Low Dose|Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA
89277336|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, High Dose|Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA
89277337|NCT01129856|Placebo Comparator|Ocular Iontophoresis Placebo|Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA
89277338|NCT03919604||ECLS group|Patients with CF undergoing LUTX. Need for intraoperative extracorporeal life support
89277339|NCT03919604||Non-ECLS group|Patients with CF undergoing LUTX. No need for intraoperative extracorporeal life support
89277340|NCT01129934|Experimental|Morphine-Promethazine|Pain relief by administration of morphine-promethazine combination
89277341|NCT01129934|Active Comparator|morphine|pain relief by administration of morphine
89277342|NCT01130012|Other|Lifestyle, follow-up, early care, standard care high/low risk|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
89277343|NCT01130012|Other|Close follow-up|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
89277344|NCT03922568||Density Gradient Centrifugation (DGC)|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
89277345|NCT03922568||Physiological ICSI (PICSI)|Semen processing is done by double layer DGC method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
89277346|NCT03922568||Magnetic Activated Cell Sorting (MACS)|Semen processing is done by double layer DGC method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
89277347|NCT01131572|Other|N-acetylcysteine|open label treatment. Each subject receives N-acetylcysteine.
89277348|NCT03922178|Experimental|Elective coronary surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and anesthesiology wards. Subjects referred for elective coronary surgery will be prospectively included during the length of the study.
89277349|NCT01131650||diabetic retinopathy|
89277350|NCT01131650||diabetica retinopathy prevalence|
89277351|NCT01228916|Experimental|Tobacco Cessation and Secondhand Smoke Reduction|Community based interventions to raise awareness regarding secondhand smoke exposure, clean indoor air laws, smokefree homes, risks of tobacco use and benefits of cessation; include talks, healthcare provider training, radio public service announcements and talk shows, tleevision interviews, cessation classes and individual sessions, health fairs, community marches for smokefree spaces, materials and resources for assisting in tobacco use cessation, estsablishing smokefree homes, adhering to smokefree laws
89277352|NCT01228916|No Intervention|Delayed Intervention Control|Assessment only during comparison period (no interventions will be provided over and above any secular trends in communities); delayed intervention will be provided at end of 1 year comparison period
89277353|NCT01132196|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
89277354|NCT01132196|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
89277355|NCT01228994|Active Comparator|Baclofen 30 mg/day|Baclofen medication
89277356|NCT01228994|Placebo Comparator|Placebo pill|placebo pill
89277357|NCT01228994|Active Comparator|Baclofen 60 mg/day|Baclofen medication high dose
89277358|NCT03927170|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
89277359|NCT03927170|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
89277360|NCT01132274|Active Comparator|Conventional catheter ablation|Radiofrequency catheter ablation through fluoroscopic guidance
89277361|NCT01132274|Experimental|Non-fluoroscopic catheter ablation|Radiofrequency catheter ablation guided by the EnSite NavX (St.Jude Medical, St Paul, MN, USA) mapping-system
89277362|NCT03922022|Experimental|EIM group|patients will go to different classes: (i) Hypertension basic exercise class (ii) Hypertension advanced exercise class (iii) diabetes basic exercise class (iv) diabetes advanced exercise class; if the patient has normal BMI AND reported some regular exercise, they will be prescribed the advanced level class. There is no control group for this pilot study
89277363|NCT03921632|Experimental|Education Program Effectiveness|Outpatients and inpatients from UNC Center of Excellence for Eating Disorders clinic
89277364|NCT01227356|Experimental|imatinb + pegIntron|
89277365|NCT01132352|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
89277366|NCT01132352|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
89277367|NCT03919760||NAVIGATE EPI|"This group of first episode psychosis patients is receiving NAVIGATE early psychosis intervention (EPI) as their regular clinical standard of care.~The project team is implementing NAVIGATE at several early psychosis intervention (EPI) programs in different geographic regions of Ontario. The team will recruit consecutive referrals to these programs in order to determine longitudinal change in functioning and symptoms (hypothesis #3).~Additionally, the primary data collected for these patients will be linked deterministically to data sources held at the Institute for Clinical Evaluative Sciences (ICES) via their unique health card number. Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
89277368|NCT03919760||Non-NAVIGATE EPI|"This group of first episode psychosis patients received early psychosis intervention other than NAVIGATE as their regular clinical standard of care.~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
89277369|NCT03919760||Non-EPI|"This group of first episode psychosis patients did not receive early psychosis intervention as their regular clinical standard of care.~The data already collected for these patients (not as a part of study/recruitment) is held at the Institute for Clinical Evaluative Sciences (ICES). Routine system-level outcome measurements will be compared among NAVIGATE subjects and two control populations (hypothesis #2 - see other groups/cohorts)."
89277370|NCT01131728|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
89277371|NCT01131728|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
89277372|NCT03927326|Experimental|Local infiltration|Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.
89277373|NCT03927326|Experimental|Transversus abdominis plane block|Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.
89277374|NCT03919682|Experimental|Training, Phase 1|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in April-May 2015
89277375|NCT03919682|Experimental|Training, Phase 2|Community health workers and nurses affiliated with 7 health centers received the breast cancer early detection trainings in November-December 2015
89277376|NCT03919682|No Intervention|Control|6 health centers served as controls and did not receive training during the study period
89277377|NCT01132430|Placebo Comparator|Usual care|Standard medical care within 4-6 week period
89277378|NCT01132430|Experimental|Motivational interviewing|Brief MI sessions within 4-6 week period
89277379|NCT01132586|Experimental|Treatment (lenalidomide, cytarabine, idarubicin)|"INDUCTION:~COHORT I: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 96 hours on days 5-8, and idarubicin IV over 1 hour on days 5-7.~COHORT II: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 24 hours on days 5-11, and idarubicin as above.~Patients with residual disease on day 18 undergo a second course of induction therapy.~CONSOLIDATION:~COHORT I: Patients receive lenalidomide PO QD on days 1-14, idarubicin IV over 1 hour on days 5-6, cytarabine IV continuously on days 5-7. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.~COHORT II: Patients 2 receive 4 courses of consolidation therapy comprising lenalidomide PO QD on days 1-14 and cytarabine IV every 12 hours on days 5, 7, and 9. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
89277380|NCT01130246|Experimental|A-002 500 mg|Once daily oral administration
89277381|NCT01130246|Placebo Comparator|Matched Placebo|Once daily oral administration
89277382|NCT03921710|Active Comparator|CAPA-IVM|Immature oocytes are culture in the new capacitation-IVM system.
89277383|NCT03921710|Active Comparator|Standard-IVM|Immature oocytes are cultured in the standard IVM system.
89277384|NCT03921476||Subjects on spironolactone for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris
89277385|NCT03921476||Subjects on oral antibiotics for a diagnosis of acne vulgaris|Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris
89277386|NCT01329536||AD Patients with Agitation|Patients with a diagnosis of probable Alzheimer's Disease who show signs of agitation based on the Cohen-Mansfield Agitation Inventory
89277387|NCT01329536||AD Patients without Agitation|Patients with a diagnosis of probable Alzheimer's Disease who do not show signs of agitation based on the Cohen-Mansfield Agitation Inventory and are matched in both age and gender to the AD Patients with Agitation
89277388|NCT03921086|Other|Hypertensive patients|Newly diagnosed or poorly controlled hypertensive patients will be initiated on appropriate therapy as per a specific algorithm.
89277389|NCT03739970|Experimental|Investigational Group- Silk Peptide|"Ingredient: Silk Peptide~Type: Yellow granule stick~Weight: Silk Peptide 9g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
89277390|NCT03739970|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Microcrystalline Cellulose~Type: Yellow granule stick~Weight: Silk Peptide 0g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
89277391|NCT02528864||Normal endometrium|Control group (n=30) comprising surgical candidates with normal endometrial tissue will be collected for comparison.
89277392|NCT02528864||Endometrial/uterine cancer|"1st year: 50 eligible patients surgical candidates of endometrial cancer with pre-operative imaging and biological samples collected during operation.~2nd year: Enroll another 50 surgical candidates and complete the data regarding clinical MRS/diffusion-weighted imaging and tissue high resolution MRS. Together with the 50 cancer subjects in the first year there will be in total 100 cancer subjects for analysis.~3rd year: Collect enough positive events with any myometrial involvement (n=30), cervical stromal invasion (n=10) and nodal metastasis (n=10). Together with the 100 cancer subjects in the first and second years there will be in total 150 cancer subjects for analysis."
89277393|NCT01227590|Experimental|Pharmacokinetics single-arm|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
89277394|NCT01132742||hospitalised children|
89277395|NCT03927248|Experimental|Nivolumab and PAC-1|Patient will be accrued and started on dose 1 level of PAC-1 (500 mg). If no DLT is observed in first cycle of therapy (28 days), dose of PAC-1 will be escalated to 625 mg in second cycle of therapy for the same patient. If patient remains on study and has no dose limiting toxicities, then in third cycle, dose will be escalated to 750 mg and continue in following cycles, if no dose adjustment is needed because of toxicities. Nivolumab will be administered by IV infusion at a dose of 480 mg.
89277396|NCT03926780|Active Comparator|Warfarin|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin by the regular starting dose with follow up of the INR to target (2-3)
89277397|NCT03926780|Experimental|Rivaroxaban|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban in a dose of 20 mg per day
89277398|NCT01585532||TB suspects with alternative final diagnosis|
89277399|NCT01585532||Confirmed tuberculosis patients|
89277400|NCT01229306|Experimental|reisolation of all PV and additional anterior line|
89277401|NCT01229306|Placebo Comparator|reisolation of all pulmonary veins|
89277402|NCT03921164||Patients scheduled for a neuroradiology procedure|Interventional neuroradiology procedure under general anesthesia requiring a continuous monitoring of mean arterial pressure and cardiac output, including electrocardiogram, pulsated oxygen saturation, endtidal CO2, respiratory rate, tidal volume and monitoring of neuromuscular function. In addition, for all patients, data from trans-oesophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.
89277403|NCT01229384|Experimental|Positive Airway Pressure Nebulization|Will administer nebulized medications using Positive Airway Pressure Nebulization
89277404|NCT01229384|Active Comparator|Standard Nebulization|Current standard of administering nebulized medications without positive airway pressure
89277405|NCT03920930|Experimental|Early-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached."
89277406|NCT03920930|Active Comparator|Late-intraoperative Local infiltration technique|"A distal regional anaesthesia is performed in which the nerves are blocked by a local anaesthetic in the tissue in the immediate vicinity of the operating area (tissue infiltration technique). The LIA is applied after the preparation of the femur and tibia bone shortly before the prosthesis is inserted and during the retreat from the knee joint."
89277407|NCT01585610|Experimental|DVD Program|
89277408|NCT01585610|Active Comparator|Standard Care Printed Materials|
89277409|NCT03926936|Experimental|Low-grade uterine sarcoma|
89277410|NCT03926936|Experimental|low-grade endometrial carcinoma|
89277411|NCT03926936|Experimental|sex cord stromal tumors|
89277412|NCT03926936|Experimental|low-grade serous ovarian cancer|
89277413|NCT03927014||Preeclampsia|The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
89277414|NCT03927014||Control|The control groups' samples will obtain during the routine obstetrical care examination in the third trimester of pregnancy.
89277415|NCT03920618|Active Comparator|ETV group|50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.
89277416|NCT03920618|Active Comparator|TDF group|50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.
89277417|NCT03920618|Experimental|TAF group|50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.
89277418|NCT03920852|Experimental|Ruxolitinib cream|
89277419|NCT01131806|Active Comparator|MD Flu/Sal|fluticasone125 mcg/ salmeterol 25 mcg 2puffs (medium dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
89277420|NCT01131806|Experimental|HD Flu/Sal|fluticasone 250 mcg/salmeterol 25 mcg 2puffs (high dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
89277421|NCT03919058|Active Comparator|Regime 1: control regime|All participants start with the control regime, where baseline activity will be measured.
89277422|NCT03919058|Experimental|Regime 2: Sit regime/sit less regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
89277423|NCT03919058|Experimental|Regime 3: Sit less regime/sit regime|The order of the regimes will be randomized, half of the participants will execute the sit regime as second regime, the other half will execute the sit less regime as second regime. Subjects have to follow a pre-defined activity protocol and receive an activity tracker (Polar M200) in order to self-monitor their activity.
89277424|NCT03919058|Experimental|Regime 4: Exercise regime|The exercise regime is the final regime for all participants. This is comparable with the sit regime, but 1h of sitting is replaced with 1 exercise bout.
89277425|NCT03920540|Experimental|GC1111|All subjects should receive the GC1111 for 52 weeks.
89277426|NCT03920540|Active Comparator|Comparator|All subjects should receive the comparator for 52 weeks.
89277427|NCT01229540|No Intervention|Lifestyle counseling|
89277428|NCT03927092||Multiple Sclerosis patients|Patients that attended an annual patient education seminar at the investigators' university hospital were asked to fill out the Turkish version of the Multiple Sclerosis Knowledge Questionnaire
89277429|NCT01227746||Tumor biopsies|
89277430|NCT01229618|Experimental|1|0.14 ml/kg bw - hyperpolarized pyruvate
89277431|NCT01229618|Experimental|2|0.28 ml/kg bw - hyperpolarized pyruvate
89277432|NCT01229618|Experimental|3|0.43 ml/kg bw - hyperpolarized pyruvate
89277433|NCT03919136||Primary Objective|Evaluation of the devices accuracy referenced to interventional (A-line) measurement.
89277434|NCT02528708|Placebo Comparator|Placebo|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
89277435|NCT02528708|Experimental|Fibrinogen concentrate|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
89277436|NCT03920228|Experimental|Open label period|
89277437|NCT03920228|Placebo Comparator|Randomized period - Dosing A|
89277438|NCT03920228|Experimental|Randomized period - Dosing B|
89277439|NCT03920228|Experimental|Randomized period - Dosing C|
89277440|NCT03920150|Active Comparator|Control|5 ml alcoholic solution containing 24'000 IU vitamin D for 3 months
89277441|NCT03920150|Active Comparator|IMP|Vitamin D oily capsules containing 24'000 IU vitamin D for 3 months
89277442|NCT03920150|Active Comparator|IMP + loading dose|Vitamin D oily capsules containing 24'000 IU vitamin D for an individual number of weeks calculated with the formula: 40 x (100 - actual value [nmol/l] x body weight [kg] / 24'000 IU.
89277443|NCT01229696|Active Comparator|At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
89277444|NCT01229696|Active Comparator|5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
89277445|NCT01131962|Active Comparator|band ligation group|this group will have immediate control of the hematemesis by endoscopic band ligation.
89277446|NCT01131962|Active Comparator|sclerotherapy group|This group will have immediate control of hematemesis by endoscopic sclerotherapy
89277447|NCT01130324||VIBATIV treated pregnant women|Women treated with telavancin (any dose or duration) during pregnancy.
89277448|NCT01230008||Radiotherapy in mediastinal lymphoma|Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
89277449|NCT01230008||Radiotherapy in mediastinal lymphoma|Radiotherapy will no be administered in patients treated with R-CHOP
89277450|NCT01230008||Radiotherapy in primary mediastinal lymphoma|Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
89277451|NCT01229774|Experimental|Etoricoxib|
89277452|NCT01229774|Active Comparator|Diclofenac|
89277453|NCT03918590|Active Comparator|A single drop of nepafenac 0.3% suspension|A single drop of nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
89277454|NCT03918590|Other|Patching|A light pressure patch applied for two hours
89277455|NCT03918590|Placebo Comparator|A single drop of preservative-free Artificial Tears|A single drop of preservative-free Theratears tear drop, (Akron, Ann Arbor, MI).
89277456|NCT01231724|Active Comparator|Allstate Nasal Spray|
89277457|NCT01231724|Placebo Comparator|Placebo Nasal Spray|
89277458|NCT01130402||Neck masses|Patients with previously untreated neck masses
89277459|NCT03918746|Experimental|internet Attachment-Based Compassion Therapy (iABCT)|"The intervention will consist of an internet version of Attachment-Based Compassion Therapy (iABCT).~The length of the intervention will depend on the pace of each participant that will be advised to carry out one module per week, taking days between sessions to complete homework assignments. It is estimated that the online intervention can be completed in eight weeks, with a maximum period of ten weeks. However, each participant will be free to advance at his/her own pace. Formal telephone support will be not systematically provided, but participants will contact for technical assistance (i.e., web accessibility problems or forgotten password) if necessary."
89277460|NCT01230086|Active Comparator|ICD implantation only|ICD Implantation without testing of defibrillation threshold testing
89277461|NCT01230086|Active Comparator|Modified upper limit of vulnerability testing|"Modified testing of upper limit of vulnerability"
89277462|NCT01230086|Active Comparator|VF-Induction|traditional VF-induction with T-Wave shock
89277463|NCT03926390|No Intervention|Non bovine colostrun|Preterm received preterm formula
89277464|NCT03926390|Active Comparator|Bovine colostrum group|Preterm received bovine colostrum as trophic feeding
89277465|NCT00320255|Placebo Comparator|Cohort 1: Placebo|Participants received placebo tablets once daily
89277466|NCT00320255|Placebo Comparator|Cohort 1: Apixaban, 5 mg|Participants received apixaban as tablet, 5 mg, once daily
89277467|NCT00320255|Active Comparator|Cohort 1: Apixaban, 10 mg|Participants received apixaban as tablet, 10 mg, once daily
89277468|NCT00320255|Active Comparator|Cohort 1: Apixaban, 20 mg|Participants received apixaban as tablet, 20 mg, once daily
89277469|NCT00320255|Placebo Comparator|Cohort 2: Placebo|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.
89277470|NCT00320255|Active Comparator|Cohort 2: Apixaban, 5 mg|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.
89277471|NCT03926234||emergency triage patients|triage Level I triage Level II triage Level III triage Level IV
89277472|NCT03926546|Experimental|Individual ERP|Individual Exposure and Response Prevention for OCD
89277473|NCT03926546|Experimental|Group ERP|Group Exposure and Response Prevention for OCD
89277474|NCT01134302|Active Comparator|Arm 1|Hybrid Management
89277475|NCT01134302|Active Comparator|Arm 2|Norwood Management
89277476|NCT05402618||minimally invasive surgery|
89277477|NCT05402618||open surgery|
89277478|NCT01231802|Experimental|Arm 1: Eniluracil/5-FU/Leucovorin|Arm 1: (weekly, 28-day cycle): Approximately eighty subjects will orally self-administer eniluracil approximately 13 hr (range of 11-16 hr) before receiving 5 FU and leucovorin. The next day they will orally self-administer 5-FU and leucovorin. On the third day, they will orally self-administer leucovorin. The regimen is taken once per week for three consecutive weeks followed by one-week off-treatment.
89277479|NCT01231802|Active Comparator|Arm 2: Capecitabine|Arm 2: (bid daily, 21-day cycle): Approximately sixty subjects will self-administer oral capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
89277480|NCT01134380||[*1] Genotype - Good responders to Clopidogrel|This group of patients is defined thanks to the DNA extracted from their saliva: [*1] genotype patients are good responders to clopidogrel
89277481|NCT01134380||[*2] genotype with adapted thienopyridine treatment|This group of patients is defined thanks to the DNA extracted from their saliva: [*2] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted
89277482|NCT01231880|Experimental|Four monthly IPT|IPT give once a school term (every four months)
89277483|NCT01231880|Experimental|Monthly IPT|IPT given every month
89277484|NCT01231880|Placebo Comparator|Placebo|No active drug in the placebo
89277485|NCT05402306|Experimental|Treatment group|A two-week intensive group treatment with MCT mainly focusing on attention training. The participants will be allocated into treatment in groups of six. Group sessions will be conducted two times a day for approximately 60 minutes.
89277486|NCT05402306|No Intervention|Waitlist control group|Cohorts of 12 included patients will be randomly assigned to active treatment or waitlist for two weeks. The waitlist patients will receive the same treatment immediately after four-week waiting period.
89277487|NCT00370331|Experimental|Treatment arm plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
89277488|NCT00370331|Placebo Comparator|placebo plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
89277489|NCT03739892|Other|stroke patients|stroke patients with upper limb motor deficit receiving standard care of rehab
89277490|NCT01232036|Active Comparator|A|Reference
89277491|NCT01232036|Experimental|B|Test
89277492|NCT01232036|Placebo Comparator|C|Placebo
89277493|NCT01130480|Experimental|A|
89277494|NCT01130558|Active Comparator|Ordering template and education|Internal medical residents who were asked to use the insulin order template and received education about basal-bolus insulin ordering.
89277495|NCT01130558|Active Comparator|Education|Internal medical residents who received education about basal-bolus insulin ordering.
89277496|NCT01130636|Experimental|Tamiflu|Lactating women (up to 20 subjects) who present with clinical symptoms indicative of influenza will be recruited (a maximum of 6 months period of recruitment) to receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules, provided free of charges for the study) at a standard dose of 75 mg twice daily. These subjects will have a 12 hour pharmacokinetic plasma, urine and breast milk study undertaken after the steady state in oseltamivir concentrations (both active and inactive metabolites will be measured) is reached in blood, i.e. after three days after treatment.
89277497|NCT04363138||bacterial infection|Patients with bacterial infection
89277498|NCT04363138||No bacterial infection|Patients without bacterial infection
89277499|NCT03926156|Experimental|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
89277500|NCT03926156|Active Comparator|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
89277501|NCT03926078|Other|Patients under 18 years of age|Group A consists of patients that receive a chest radiography in the current work-up of PE.
89277502|NCT03926078|Other|Patients aged 18 years or older|Group B consists of patients that receive a CT scan in the current work-up of PE.
89277503|NCT01228058||Adult trauma patients|Patients admitted to the emergency department (ED) as the highest level of acuity following a traumatic injury at three Level 1 trauma centers in the United States (UT Houston, UC San Francisco, Oregon Health Center).
89277504|NCT01134458|No Intervention|Control|Receive primary care and management of CVD according to the discretion of their primary care provider. They will also receive generic educational information concerning CVD at baseline and at study end (at their request). We will collect outcomes at baseline and 3-months.
89277505|NCT01134458|Experimental|Web-based Intervention|Given current risk assessment for CVD based on Health Dialog Cardiac Risk Calculator, recommendations for behavior change, and Health Dialog's Living with Coronary Heart Disease. Can change initial patient risk information provided by the Risk Calculator during the initial visit, noting what they are will work on during the study. Sent monthly email reminders to log onto the system to choose that months' behavioral modules. Given a choice of at least 2 health behavior modules per month (smoking cessation, exercise, diet, and weight) to improve their CVD risk. Information on risk, CVD knowledge, medication management and side effects will be provided to all participants. It will also provide tailored information to help the individual initiate and maintain these behaviors.
88805601|NCT00270296|Experimental|Kaletra Arm|Participants in the Kaletra Arm (Arm 1B) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive Lamivudine/Zidovudine (3TC/ZDV) and Lopinavir/Ritonavir (LPV/RTV) twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
88805602|NCT00270296|Experimental|Nevirapine (NVP) Arm|Participants in the NVP Arm (Arm 2) will be pregnant women who have have CD4 counts less than 200 cells/mm3. These participants will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
88805603|NCT00270842|Placebo Comparator|Education Control Group|Education group that is the control group for the study. Is a 10 week course with diverse health education topics.
88805604|NCT00270842|Experimental|Functional Balance Training|Exercise group that participated in functional balance training
89277506|NCT01134536|Experimental|Tapentadol Oral Solution (OS)|
89277507|NCT01134692|Placebo Comparator|Propranolol + Placebo|
89277508|NCT01134692|Active Comparator|Propranolol + Norfloxacin|drug
89277509|NCT01134692|Experimental|Propranolol + Probiotic|VSL#3
89277510|NCT01134848|Active Comparator|Morphine-neostigmine|
89277511|NCT01134848|Active Comparator|Secretin|
89277512|NCT03926000|Active Comparator|Pregabalin (PG)|Patients will receive 150 mg pregabalin one hour before the procedure.
89277513|NCT03926000|Placebo Comparator|Control placebo (C)|Patients will receive placebo tablet one hour before surgery.
89277514|NCT01230320|Experimental|Simplified (S) technique|"Complete dentures fabricated according to a simplified technique, divided into the following four sessions:~Maxillary and mandibular casts will be obtained from irreversible hydrocolloid impressions made in stock trays.~Record bases will be adjusted according to vertical dimension and centric relation measurements, without facebow transfer. Casts will be mounted in a semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationships.~Insertion of finished dentures."
89277515|NCT01230320|Active Comparator|Conventional (C) technique|"Complete dentures fabricated according to a conventional technique:~Initial impression and the obtainment of custom trays;~Final impression with border molding using compound;~Facebow transfer;~Determination of maxillomandibular relationship;~Try-in of anterior teeth;~Try-in of posterior teeth;~Insertion of finished dentures."
88805605|NCT00270842|Experimental|Tai chi|Exercise Group that participated in tai chi training classes
88805606|NCT01046669|Sham Comparator|Control|Standard medical care for septic shock
88805607|NCT01046669|Experimental|Treatment|Two (2) PMX cartridges will be administered approximately 24 hours apart plus standard medical care for septic shock
88805608|NCT01047527|Active Comparator|8 weeks transdermal nicotine|8 weeks of transdermal nicotine
88805609|NCT01047527|Active Comparator|24 weeks transdermal nicotine|24 weeks of transdermal nicotine
88805610|NCT01047527|Experimental|52 weeks transdermal nicotine|52 weeks of transdermal nicotine
89277516|NCT02529254|Experimental|Video coaching|14 residents in general surgery from PGY-1(post graduate year-1) to PGY-4 Block randomized to the intervention group who will receive a 30 minute video coaching session as the intervention
89277517|NCT02529254|No Intervention|Control|14 residents in general surgery from PGY-1 to PGY-4 block randomized to the control group
89277518|NCT01134926|No Intervention|intra-uterine residua. expectant management|The patients in this arm will not get any treatment and be followed up by US examinations
89277519|NCT01134926|Experimental|Intra-uterine residua. misoprostol|The patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.
89277520|NCT05401604|Experimental|Moderate probiotic beer consumption|1 can of 330ml (3.5-5% alcohol) probiotic beer. Ingredients: water, grains, raspberry puree, yeast, and lactic acid bacteria (Lactobacillus paracasei Lpc-37®, or Lactobacillus paracasei LAFTI®L26).
89277521|NCT05401604|Placebo Comparator|Moderate normal beer consumption|1 can of 330ml (3.5-5% alcohol) normal beer. Ingredients: water, grains, raspberry puree, and yeast.
89277522|NCT01135004||Pneumothorax patients|Primary spontaneous pneumothorax patients undergoing thoracoscopic bullectomy
89277523|NCT03918200||Study|Women with unexplained infertility
88805611|NCT03013127|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg i.v. every 3 weeks for up to 35 cycles
88805612|NCT01047839|Experimental|>=2 months to <3 years|IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and 28
88805613|NCT01047839|Experimental|>=3 to <12 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
88805614|NCT01047839|Experimental|>=12 to <18 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
88805615|NCT01048697|Experimental|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
88805616|NCT01049243|Other|Fluocinonide Cream 0.1%|Fluocinonide Cream 0.1% open label
89277524|NCT03918200||Control|Fertile women who had normal physical and pelvic examination, regular menstrual cycles, don't use hormonal contraceptive, had one child at least.
89277525|NCT04307056|Experimental|HIFU|Patients Treated with high intensity focused ultrasound (HIFU)
89277526|NCT04307056|Active Comparator|Prostatectomy|Patients Treated by Radical Prostatectomy
89277527|NCT01135082|Other|1|Receive valent pneumococcal conjugated vaccine in HIV - infected children
89277528|NCT01135082|Other|2|Receive valent pneumococcal conjugated vaccine in HIV negative children
89277529|NCT05043532|Active Comparator|Two passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of two passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
89277530|NCT05043532|Active Comparator|Three passes performed during EUS-FNB of pancreatic adenocarcinoma|Once the pancreatic mass is identified on endoscopic ultrasound examination, total of three passes will be performed during find needle biopsy and placed in 10% formalin for processing for molecular profiling.
89277531|NCT01135160||TKA/THA|All patients receiving TKA/THA meeting inclusion but not exclusion criteria
89277532|NCT01228136|Active Comparator|Tranexamic acid|
89277533|NCT01228136|Placebo Comparator|Placebo|
89277534|NCT04259164|Active Comparator|QMF149|Mometasone furoaat / Indacaterol
89277535|NCT04259164|Experimental|QVM149|Mometasone furoaat / Indacaterol / Glycopyrronium
89277536|NCT03918356|Experimental|Inclusion Body Myositis patients|Subjects with clinically or clinico-pathologically defined IBM will be included in this study. Patients with consistent clinical and laboratory features including ages 18 to 80 years, duration of symptoms> 12 months, serum creatine kinases (CK) no greater than 15 times upper limit of normal, prominent weakness of quadriceps and/or finger flexor weakness>shoulder abduction weakness along with some characteristic histopathological findings of endomysial inflammatory infiltrate, rimmed vacuoles and protein accumulation or 15-18 nm filaments will be considered as clinically or clinicopathologically defined IBM as proposed by the European Neuromuscular Center (ENMC IBM working group, 2013).
89277537|NCT03918356|Experimental|Idiopathic Inflammatory Myopathies patients|Subjects with more than 2 of the following criteria, symmetric proximal weakness, elevated CK, electromyography (EMG) suggesting myositis, muscles biopsy showing inflammatory changes, and typical skin rashes of dermatomyositis (DM) will be recruited as dermatomyositis and polymyositis (DM/PM) based on Bohan and Peter criteria.
89277538|NCT03918356|Placebo Comparator|control|Healthy controls without any known neuromuscular disorders and no family history of Amyotrophic lateral sclerosis (ALS) will be recruited for the study.
89277539|NCT01133054|Experimental|low FFR|FFR<0.75
89277540|NCT01133054|No Intervention|high FFR|FFR > 0.75
89277541|NCT05401448|Placebo Comparator|Placebo|sterile 0.9% NaCl
89277542|NCT05401448|Experimental|Influenza|Influenza (tetravalent vaccine)
89277543|NCT05401448|Experimental|MMR|measles, mumps, and rubella vaccine
89277544|NCT01133132|Placebo Comparator|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
89277545|NCT01133132|Experimental|Intervention|For those subjects randomized to the Survivorship CHESS condition they will receive a smartphone and access to a web based information system that provides access to clinical information about colon cancer treatment, survivorship, exercise planning and tracking functions to allow these subjects to monitor their self defined exercise goals and objectives.
89277546|NCT01130714|Experimental|Resistance training|Group assigned to complete resistance training during duration of chemotherapy.
89277547|NCT01130714|No Intervention|Control|Usual care.
89277548|NCT01230476|Experimental|Cetuximab and chemotherapy|2 cycles of neoadjuvant cisplatin and 5FU (3 weekly), given with weekly cetuximab, followed by 7 doses of weekly cisplatin and cetuximab concurrent with radiotherapy
89277549|NCT01135472|Experimental|Nexium|ARM 1: NEXIUM 40MG ONCE DAILY, ARM 2: NEXIUM 40MG TWICE DAILY, ARM 3: NEXIUM 80MG TWICE DAILY
88805617|NCT03013205|Experimental|PT+IA+CHL|"Intraarticular triamcinolone injection~Intraarticular Xylocaine injection~Coracohumeral ligament triamcinolone injection~Physiotherapy"
89277550|NCT01133210|Experimental|Maraviroc|Subjects will receive 12 weeks of treatment with maraviroc (300 mg po bid).
89277551|NCT01133210|Placebo Comparator|Placebo|Subjects will receive 12 weeks of treatment with placebo
89277552|NCT01135550|Active Comparator|Standard Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
89277553|NCT01135550|Active Comparator|Control Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
88805618|NCT03013205|Active Comparator|PT+IA|"Intraarticular triamcinolone injection~Intraarticular Xylocaine injection~Physiotherapy"
89277554|NCT05401370|Active Comparator|MB group|Mb group will undergo surgeries with methylene blue staining
89277555|NCT05401370|No Intervention|Control group|Control group will undergo surgeries without methylene blue staining
89277556|NCT03917888|Experimental|Lung ultrasound|Patients will be monitored for ventilator associated pneumonia using lung ultrasound combined with clinical features
89277557|NCT03917888|No Intervention|Chest x-ray|Patients will be monitored for ventilator associated pneumonia using chest x-ray and clinical features.
89277558|NCT01130792|Experimental|Lactobacillus GG|LGG once daily for 4 weeks
89277559|NCT01130792|Placebo Comparator|Inulin|
89277560|NCT01130870|Active Comparator|Sensory threshold - Amplitude|Stimulation amplitude set at sensory threshold.
89277561|NCT01130870|Experimental|25% below sensory threshold - Amplitude|Stimulation amplitude 75% of sensory threshold.
89277562|NCT01130870|Experimental|50% below sensory threshold - Amplitude|Stimulation with amplitude set 50% below sensory threshold
89277563|NCT01135628|Active Comparator|MHE and diet plus lactobacillus reuteri|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and lactobacillus reuteri.
89277564|NCT01135628|Active Comparator|MHE and diet|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods.
89277565|NCT01135628|Active Comparator|MHE and diet plus nitazoxanide|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and nitazoxanide.
89277566|NCT05401136||Participants|Consecutive people who use drugs and visit the addiction care centre
89277567|NCT01135706||Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram with a diagnosis of Pulmonary Hypertension
89277568|NCT01135706||Non Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram without a diagnosis of Pulmonary Hypertension.
89277569|NCT01232192|No Intervention|Antenatal model|
89277570|NCT01232192|Experimental|Antenatal Model|
89277571|NCT01135784|Active Comparator|MIGRA-ZEN RELIEF PLUS|Active treatment
89277572|NCT01135784|Placebo Comparator|Placebo for Migra zen plus|Placebo
89277573|NCT01135862|Experimental|platelet administered|patients will receive 6 packs of platelets
89277574|NCT01135862|No Intervention|no platelets administered|patients will not receive platelets
89277575|NCT01135940|Experimental|1|2-octylcyanoacrylate (Dermabond) closure
89277576|NCT01135940|Active Comparator|2|Standard staple closure
89277577|NCT02962960|Experimental|Anifrolumab - Lower dose|1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
89277578|NCT02962960|Placebo Comparator|Placebo matching for lower dose of Anifrolumab|1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
89277579|NCT02962960|Experimental|Anifrolumab - Higher dose|2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
89277580|NCT02962960|Placebo Comparator|Placebo matching for higher dose of Anifrolumab|2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
89277581|NCT01136018||intentional lateral caudal approach|
89277582|NCT01133366|Active Comparator|warfarin alone|
89277583|NCT01133366|Experimental|warfarin with mipomersen|
89277584|NCT01136096|Experimental|Lifestyle counseling|To promote participants' exercise behaviors with individualized home-based exercise program was designed based on the Health Belief Model and Transtheoretical Model
89277585|NCT01136096|Other|Control|Received oral instruction and written general education information without individualized exercise program
89277586|NCT01232270|Active Comparator|fentanyl|
89277587|NCT01232270|Placebo Comparator|saline|
89277588|NCT05400902|Experimental|HAIC Combined with Sintilimab and Bevacizumab|
89277589|NCT01233206|Experimental|Experimental group|Patients receiving metformin pretreatment and co-administration
89277590|NCT01233206|Placebo Comparator|Control group|Placebo
89277591|NCT00369941|Experimental|MK-0518 400 mg b.i.d.|MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
89277592|NCT00369941|Active Comparator|Efavirenz 600 mg q.h.s.|Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
89277593|NCT01133444|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
89277594|NCT01133444|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
89277595|NCT01232348||Symbicort|Those with an exposure
89277596|NCT01230632|Experimental|Dietary Supplement|3 days high fat food
89277597|NCT01062035||ACP (advanced colon polyp) Group|Between the ages of 50 and 60 years old and have an ACP (advanced colon polyp)
89277598|NCT01062035||Control Group|Individuals between the ages of 50 and 60 years old who have had a negative screening colonoscopy.
89277599|NCT01232426|Experimental|Operative|operative treatment of a Mallet fracture with a biodegradable Meniscus Arrow®
89277600|NCT01232426|Active Comparator|Conservative|Conservative treatment of a Mallet fracture with a Mallet splint
89277601|NCT05608772|Active Comparator|RYGB procedure arm 1|After failed sleeve, the patients will get a revisional procedure. The RYGB
89277602|NCT05608772|Active Comparator|OAGB procedure arm 2|After failed sleeve, the patients will get a revisional procedure. The OAGB
89277603|NCT05608772|Active Comparator|SADI-S procedure arm 3|After failed sleeve, the patients will get a revisional procedure. The SADI-S
89277604|NCT00319553|Experimental|Adacel® Vaccine Group|
89277605|NCT00319553|Active Comparator|BOOSTRIX® Vaccine Group|
89277606|NCT03739736||Combination of TB/HIV prevention activities (A)|Communities in the intervention group (A) were exposed to a combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. In this arm, ART was initiated regardless of CD4 count
89277607|NCT03739736||Standard of care (C)|"The standard of care arm (C) communities have access to TB/HIV testing, care and treatment services (usually at the health facility) and according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility."
89277608|NCT03739736||Combination of TB/HIV prevention activities (B)|The intervention in arm B was the same as in arm A, consisting in a package of combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. Differently to arm A, in arm B national guidelines on CD4 count were used for ART initiation. During the trial the thresholds for commencement of ART changed from 500 CD count to 350 CD count and then, in 2016, to universal ART regardless of CD4 count.
89277609|NCT01137656|Other|Acetylcholine and Blood|This is single arm study. Acetylcholine and blood is infused in brachial artery of non-dominant arm. Blood flow
89277610|NCT03917732|Experimental|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
89277611|NCT03917732|Active Comparator|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
89277612|NCT00369785|Experimental|Arm I - Donepezil|Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
89277613|NCT00369785|Placebo Comparator|Arm II - Control|Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
89277614|NCT05476562||First-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
89277615|NCT05476562||Second-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
89277616|NCT05476562||Third-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
89277617|NCT05476562||Fourth-line Therapy|A cohort of adult patients with CML who were treated with TKIs were identified using the IBM® MarketScan® Commercial and Medicare Supplemental databases (commercial claims; the MarketScan database)
89277618|NCT01136252|Experimental|Adalimumab|
89277619|NCT00369707|Experimental|Bortezomib and Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
89277620|NCT01136564|Active Comparator|Paricalcitol|
89277621|NCT01136564|Placebo Comparator|Placebo|
89277622|NCT05568758|Experimental|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
89277623|NCT05568758|Experimental|exercises|Stretching exercises (hamstring stretch-lower back stretch) Strenghening exercises(abdominal curl up-supine bridging-trunk extension)
89277624|NCT02943460|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for up to 12.6 weeks
89277625|NCT02943460|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.7 weeks
89277626|NCT02943460|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.3 weeks
89277627|NCT02943460|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants received cilofexor for an additional up to 97.4 weeks.
89277628|NCT03768206|Experimental|PATH|PATH participants will receive Standard Outpatient Physical Therapy. In addition, physical therapist discuss physical activity & assist with goal setting during therapy sessions.
88805619|NCT01094717|Experimental|acitretin and active excimer laser|patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to randomly assigned left or right side of body psoriasis lesions.
89277629|NCT03768206|Active Comparator|PATH-12|PATH-12 participants will receive Standard Outpatient Physical Therapy. In addition, PATH-12 participants will receive a Physical activity session (1-hour) focusing on physical activity and goal setting at 12 weeks after surgery.
89277630|NCT03767894|Experimental|MyHand orthosis|Subjects are trained to control and use the MyHand orthosis either with a shoulder harness or an electromyography (EMG) band. The MyHand orthosis aims to aid in fine motor skills such as picking up and holding items of varying shape, size and weight.
89277631|NCT04752904|Experimental|ClearSight group|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem, with a finger cuff around the middle finger, and the anesthesiologist manages blood pressure based on this.
89277632|NCT04752904|No Intervention|Control group|The blood pressure is measured at 1-minute intervals by non-invasive blood pressure monitor using the arm cuff, and the anesthesiologist in charge manages the blood pressure based on the measured blood pressure.
89277633|NCT01232660|Active Comparator|Delayed|Delayed addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
89277634|NCT01232660|Experimental|Immediate|Immediate addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
89277635|NCT01137734|Experimental|Valtech Cardinal Mitral Annuloplasty Ring|All subjects enrolled in the study are implanted with the Valtech Cardinal Mitral Annuloplasty ring.
89277636|NCT03766646|Experimental|Speech|Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
89277637|NCT03766646|Active Comparator|Non-speech|Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
89277638|NCT03765164|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to GlycoMark 1,5-AG test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
89277639|NCT03765164|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to GlycoMark 1,5-AG test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
89277640|NCT01233362|Active Comparator|Arm 1: Adults; 14 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
89277641|NCT01233362|Active Comparator|Arm 2: Adults; 28 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
89277642|NCT01233362|Active Comparator|Arm 3: children; 14 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
89277643|NCT01233362|Active Comparator|Arm 4: children; 28 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
89277644|NCT01233362|Active Comparator|Arm 5: Adults; 14 days Interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
89277645|NCT01233362|Active Comparator|Arm 6: Adults; 28 days interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
89277646|NCT03917576|Active Comparator|Normoglicamic group|Control normoglycaemic participants
89277647|NCT03917576|Active Comparator|Hyperglicaemic group|Control hyperglicaemic group
89277648|NCT03917576|Experimental|Experimental group|Experimental Type 2 Diabetes Mellitus Group
89277649|NCT01136720||patients injected with the Halifax produced 18-FDG|
89277650|NCT02826382|Experimental|Dynamic imaging group|Dynamic imaging of suspected bone metastases with the investigation drug [68Ga]P15-041
89277651|NCT02826382|Experimental|Whole body dosimetry group|Determination of human dosimetry of the investigation drug [68Ga]P15-041
89277652|NCT00369629|Experimental|Cohort 1|"Pemetrexed at a dose of 400 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
89277653|NCT00369629|Experimental|Cohort 2|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
89277654|NCT00369629|Experimental|Cohort 3|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1000 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
89277655|NCT00369629|Experimental|Cohort 4|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1200 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
89277656|NCT04744090|Experimental|Roflumilast add-on|Eligible patients will take 500 Mcg of roflumilast once daily (up to 28 days) plus standard of care.
89277657|NCT04744090|Placebo Comparator|Placebo control|Eligible patients will take placebo plus standard of care.
89277658|NCT01233440|Experimental|Cohort 1|25 IU/kg dose
89277659|NCT01233440|Experimental|Cohort 2|50 IU/kg dose
89277660|NCT01233440|Experimental|Cohort 3|75 IU/kg dose
89277661|NCT02469064|Experimental|Respiratory Muscle Training|Experimental group receives as additional treatment respiratory muscle training.
89277662|NCT02469064|Active Comparator|Conventional physical therapy|Conventional Cardiopulmonary Physical Therapy
89277663|NCT01230944|Active Comparator|Laparoscopic Nissen|Laparoscopic Nissen fundoplication
89277664|NCT01230944|Active Comparator|Open Nissen|Open (conventional) Nissen fundoplication
89277665|NCT03917342|Active Comparator|Control Group|EEG measure in 15 healthy women undergoing elective hysteroscopy under single shot spinal anesthesia. Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
89277666|NCT03917342|Active Comparator|Healthy parturients|EEG measure in 15 healthy parturients undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
89277667|NCT03917342|Active Comparator|Preeclamptic parturients|EEG measure in 15 parturients with preeclampsia undergoing elective cesarean delivery under single shot spinal anesthesia.Bupivacaine 10mg (+-2mg) spinal dose with 15 mcg Fentanyl spinal dose
89277668|NCT03739658|Experimental|Cognitive Based Neuromuscular Education|It will be applied for one hour. There are individual and partner parts. For example, in this training, the athlete will throw the tennis ball up and down on one foot.
89277669|NCT03739658|Experimental|Game Based Education|It will be applied for one hour. There are individual and partner parts. The active game will be played using the Xbox game console and the kinect sensor.
89277670|NCT03739658|No Intervention|Control Group|You will not receive any training. Athletes who continue their training as athletes in the other group.
89277671|NCT01137188|Experimental|Intervention group|Intensive weight loss program and regular group sessions with clinical dietician. Complete dietary substitution with a low calorie diet containing 800-1000 kcal/day for 8 weeks
89277672|NCT01137188|No Intervention|No intervention|Study subjects will receive routine dietary counseling for 8 weeks and will cross over to intervention upon completion
89277673|NCT01232816||Delayed graft function|These are patients in whom dialysis is required following transplantation.
89277674|NCT01232816||Immediate function|These are patients in whom no dialysis is required and creatinine declines by >20% in the first 24 hours following transplantation.
89277675|NCT05528666||Overall cohort|Included all patients
89277676|NCT05528666||Previous Non-HET|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
89277677|NCT05528666||Previous HET|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
89277678|NCT01133600|Active Comparator|daptomycin|Dosed at 6mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if creatinine clearance (CrCl)is <30ml/min.
89277679|NCT01133600|Active Comparator|vancomycin|Dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
89277680|NCT01138202|Experimental|1|boosted LPV/r 400/100 mg BID + 2 NRTI
89277681|NCT01138202|Experimental|2|boosted LPV/r 600/150 mg BID + 2 NRTI
89277682|NCT01133834||patients with meningococcemia|Patients with meningococcemia admitted at the Intensive Care Unit
89277683|NCT01138280|Experimental|Heat disinfection|Experimental arm: Heat disinfection link to RO water treatment system and piping system to dialysis machine
89277684|NCT01138280|No Intervention|Conventional RO water treatment|Placebo arm: conventional chemical disinfection link to RO water treatment system.
89277685|NCT01232972|Experimental|oocyte freezing|includes any women who elects to preserve her fertility by vitrifying her unfertilized eggs.
89277686|NCT05502224|Other|Specific fatigue management program|
89277687|NCT01137266|Active Comparator|skin resistence|1) the location with the lowest resistance
89277688|NCT01137266|Active Comparator|irradiation|2) the site that causes an irradiation sensation
89277689|NCT01137266|Active Comparator|random|3) a random stimulation site.
89277690|NCT01233128||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
89277691|NCT01133912|Experimental|paclitaxel, gemcitabine, lapatinib|paclitaxel 80mg/m2 D1, D8 gemcitabine 1000mg/m2 D1, D8, every 3 weeks, 6 cycle lapatinib(Tykerb®)1000mg every day
89277692|NCT01140542|Active Comparator|Roflumilast|500µg, once daily
89277693|NCT01140542|Placebo Comparator|Placebo|
89277694|NCT01234610|Experimental|Exercise|Exercise
89277695|NCT01234610|No Intervention|Control|No exercise
89277696|NCT01233596|Active Comparator|Monocanalicular intubation|Monocanalicular intubations (MCI; n=35 eyes) through the inferior canaliculus intubations performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
89277697|NCT01233596|Active Comparator|Bicanalicular intubation|Bicanalicular intubation (BCI; n=35 eyes) performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
89277698|NCT05320094|Experimental|Mavacamten|
89277699|NCT05320094|Experimental|Mavacamten and activated charcoal with sorbitol - Dose A|
89277700|NCT05320094|Experimental|Mavacamten and activated charcoal with sorbitol - Dose B|
89277701|NCT03917030|Experimental|Open flap debridement with osteoplasty|In this arm, periodontal surgery consists of open flap debridement followed by osteoplasty in the furcation entrance area.
89277702|NCT03917030|Active Comparator|Open flap debridement without osteoplasty|In this arm, periodontal surgery consists of open flap debridement only. No osteoplasty will be performed.
89277703|NCT01233752||Group A|Homozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the more frequent allele of the polymorphism A118G of OPRM1 gene
89277704|NCT01233752||Group B|Both homozygous and heterozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the less frequent allele of the polymorphism A118G of OPRM1 gene
89277705|NCT01140620|Experimental|ketamine and risperidone|Oral risperidone pretreatment and intravenous ketamine infusion
89277706|NCT01140620|Active Comparator|ketamine and placebo|Oral placebo risperidone pretreatment and intravenous ketamine infusion
89277707|NCT01140620|Active Comparator|saline and risperidone|Oral risperidone pretreatment and intravenous saline infusion
89277708|NCT01140620|Placebo Comparator|saline and placebo|Oral placebo risperidone pretreatment and intravenous saline infusion
89277709|NCT01140620|No Intervention|Patients with Schizophrenia|Patients with schizophrenia will not receive study drug and will not undergo randomisation.
88805620|NCT01094717|Experimental|acitretin and sham excimer laser|Patients in this arm were treated with acitretin 25 mg daily and sham (placebo) excimer laser to randomly assigned left or right side of body psoriasis lesions.
89277710|NCT01234688|Experimental|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
89277711|NCT01234688|No Intervention|Control|Patients allocated to the control group remained in regular dialysis treatment during the same timeframe.
89277712|NCT03917108|Active Comparator|retraction cord|
89277713|NCT03917108|Other|subgingival clamp|
89277714|NCT05298644|Experimental|Dose finding ≥5 to <12 years|on Day 1 and Day 29 either VLA2001 half dose or VLA2001 full dose
89277715|NCT05298644|Experimental|Dose finding ≥2 to <5 years|on Day 1 and Day 29 either VLA2001 half dose or VLA2001 full dose
89277716|NCT05298644|Other|Confirmatory ≥5 to <12 years|Day 1: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 29: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 57: Active Comparator
89277717|NCT05298644|Other|Confirmatory ≥2 to <5 years|Day 1: Active Comparator Day 29: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose) Day 57: VLA2001 selected dose (= either VLA2001 half dose or VLA2001 full dose)
89277718|NCT01140698||Term and preterm newborn infants|5 infants of each gestational age of 24-42 weeks
89277719|NCT04725266|Experimental|family-based intervention plus routine care|This group of participants including drug abusers and their families will be receiving family-based intervention which is a well-designed intervention with group sessions and routine care provided by professional social workers in local social service center.
89277720|NCT04725266|Active Comparator|routine care|The group of participants will receive routine care which is widely used in social service providers and mainly includes individual counselling service for drug abusers.
89277721|NCT01140776||OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
89277722|NCT04676594||Diagnosis of Pulmonary Fibrosis on Chest CT|Retrospective chart review of patients with a diagnosis of pulmonary fibrosis on chest CT.
89277723|NCT01138592||Primary Care Patients|Any patient undergoing a telemedicine evaluation involving auscultation of the heart and lungs.
89277724|NCT03739580|Experimental|drug-coating balloon|drug-coating balloon (Orchid) intervention
89277725|NCT03739580|Active Comparator|stent deployment|metal bare stent intervention
89277726|NCT03916952||Healthy younger|All participants between 18 and 65 years of age that completed the test
89277727|NCT03916952||Healthy older|All participants > 65 years of age that completed the test
89277728|NCT01138670||Cardiac device group|
89277729|NCT03916718||Dementia|The target population includes patients seen at Ochsner Clinic Foundation, >=55 years old, diagnosed with dementia, and meeting other inclusion/exclusion criteria. this study will recruit subjects identified as high utilizers of the Ochsner System. This will be defined by >= 2 ED visits, >= 2 Hospitalizations, or some combination prior to baseline. We will co-variate by insurance plan.
89277730|NCT04657250|Experimental|Smoking cessation + quitline linkage text messages|Text messaging for smoking cessation + text messages with proactive linkage to quitline
89277731|NCT04657250|Placebo Comparator|Passive quitline referral|Single text message with contact information for the Quitline
89277732|NCT01231178|Active Comparator|Alginate based beverage|
89277733|NCT01231178|Placebo Comparator|Control beverage|
89277734|NCT01140854||Hypertension (case)|Elderly patients 60 years old or older undergoing simple lumbar spine surgery under general anesthesia will receive neurologic/neuropsychometric examinations.
89277735|NCT01140854||Normotension (control)|Middle-aged patients (40-60 years) undergoing simple lumbar spine surgery under general anesthesia as controls to compare their performance to those patients >60 years - will also receive neurologic/neuropsychometric examinations.
89277736|NCT01234844|Other|care of guinea pigs|"Each patient serves as own control receiving pet therapy and usual occupational therapy on alternate days."
89277737|NCT04619654|Experimental|Cataract Surgery with concurrent MIGS|
89277738|NCT01140932|Experimental|Intervention|Medical and behavioural intervention
89277739|NCT01138748|Experimental|Radiation therapy|
89277740|NCT01138904|Active Comparator|IROX arm: FOLFIRI -> FOLFOX|"IROX arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
89277741|NCT01138904|Active Comparator|OXIR arm: FOLFIRI -> FOLFOX|"OXIR arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
89277742|NCT01231256|Experimental|preventive health consultation|Half participants randomized to a one hour preventive health consultation with their own general practitioner and a follow up consultation 3 months later
89277743|NCT01231256|No Intervention|Control|Controls are not offered preventive health consultations, but had questionnaires as the intervention arm
89277744|NCT01138982|Experimental|Mentoring program|Mentor and mentee meet at least every second week, for 2-4 h on every occasion, during 1 year (i.e., for a minimum of two school semesters). Meetings take place outside school and work hours, and the pairs choose activities of their own preferences. No monetary incentives exist, and the mentors are laymen volunteers. The program objective is to establish a safe and supportive relationship, by which the youth is assumed to benefit in social, emotional, and academic development, and as a consequence, be less prone to use alcohol and drugs.
89277745|NCT01138982|No Intervention|Control group|No intervention provided, only brief phone calls to control for attention bias
89277746|NCT01139060|Experimental|Intervention Group|18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression
89277747|NCT01139060|No Intervention|Usual Care|
89277748|NCT01235000||2010-11 influenza vaccine recipients|Participants of an earlier clinical trial (TITRE II) to evaluate prime-boost response across B lineages in 2009-10
89277749|NCT01134146|Experimental|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy (IMRT) Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
89277750|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region abdomen|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
89277751|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region upper arm|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
89277752|NCT04582448|Experimental|Insulin icodec treatment sequence with injection region thigh|Each subject will be randomised to one of six treatment sequences, consisting of three single-dose administrations of insulin icodec (s.c. in the abdomen, the upper arm and the thigh) in a balanced manner on three separate treatment visits.
89277753|NCT01141010|Sham Comparator|Plain language|Conventional plain language will be given without any psychological intervention
89277754|NCT01141010|Active Comparator|Pre-psycho-language|Prior surgery psychological linguistic intervention
89277755|NCT01141010|Active Comparator|Intra-psycho-language|Intraoperative psychological linguistic intervention
89277756|NCT01141010|Active Comparator|Post-psycho-language|Postoperative psychological linguistic intervention
89277757|NCT01141010|Active Comparator|Combined language|Psychological linguistic intervention will be given in a combination of pre-, intra- and post-operatively
89277758|NCT01141088|Experimental|Bilateral stent-in-stent insertion|The passage of the bilateral metal stent across the stricture, stent-in-stent method.
89277759|NCT01141088|Active Comparator|Bilateral side-by-side insertion|The passage of the bilateral metal stent across the stricture, side-by-side method.
89277760|NCT05290142|Active Comparator|Self-Guided Digital Training (DT)|"Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available online on a smartphone app as well as a website that can be accessed through an internet-enabled device.~Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface."
89277761|NCT05290142|Experimental|Digital Training with Coaching (DT-C)|In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. Participants will also be able to send text messages to coaches.
89277762|NCT01139138|Experimental|Panitumumab + Irinotecan + Everolimus|
89277763|NCT05403008|Other|Zirconomer improved|a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
89277764|NCT05403008|Active Comparator|Nano hybird resin composite|Resin composite (RC) is the gold standard esthetic restoration in proximal cavities due to their high aesthetic properties, increased mechanical durability and enhanced adhesion to tooth structure.
89277765|NCT02446912|Experimental|Anifrolumab - higher dose|Anifrolumab
89277766|NCT02446912|Placebo Comparator|Placebo|Placebo
89277767|NCT02446912|Experimental|Anifrolumab - lower dose|Anifrolumab
89277768|NCT01235078||Intraosseous vascular access|subjects with urgent vascular access needs in whom intraosseous vascular access has been attempted and/or established.
89277769|NCT02528630|Experimental|Exercise group|Performed a session regarding joint protection and energy conservation and a progressive resistance strength training program for intrinsic muscles of the hand for 12 weeks.
89277770|NCT02528630|Active Comparator|Control group|Performed a session regarding joint protection and energy conservation
89277771|NCT02528552|Active Comparator|LH80 PRO|Low level laser therapy
89277772|NCT02528552|Sham Comparator|Sham device|No low level laser therapy
89277773|NCT05402852|Experimental|Drug：EuBone® capsule|Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
89277774|NCT05402852|Placebo Comparator|control：placebo|Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
89277775|NCT01134224|Experimental|NN5401 - low dose|
89277776|NCT01134224|Experimental|NN5401 - medium dose|
89277777|NCT01134224|Experimental|NN5401 - high dose|
89277778|NCT01134224|Active Comparator|biphasic insulin aspart 30 - low dose|
89277779|NCT01134224|Active Comparator|biphasic insulin aspart 30 - medium dose|
89277780|NCT01134224|Active Comparator|biphasic insulin aspart 30 - high dose|
89277781|NCT05308888|Experimental|Intervention|All patients will have to undergo an 18F-FDG PET-CT.
89277782|NCT01312636||A|
89277783|NCT01141166|Experimental|nutritional and physical rehabilitation plan|
89277784|NCT01233830|Experimental|1|
89277785|NCT01233830|Placebo Comparator|2|
89277786|NCT04849234||New born|New born population aged 37 Weeks of Amenorrhea (SA) to 42 Weeks of Amenorrhea (SA) will be included. Their cries will be longitudinally registered.
89277787|NCT01231490|Experimental|Active|
89277788|NCT01231490|Placebo Comparator|Placebo|
89277789|NCT01231568|Experimental|Cohort 1 Treatment Sequence 1|Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
89277790|NCT01231568|Experimental|Cohort 1 Treatment Sequence 2|Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
89277791|NCT01231568|Experimental|Cohort 2 Treatment Sequence 1|Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
89277792|NCT01231568|Experimental|Cohort 2 Treatment Sequence 2|Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
89277793|NCT04065334|Experimental|low dose training|
89277794|NCT04065334|Active Comparator|high dose training|
89277795|NCT01141244|Experimental|Treatment (temsirolimus, irinotecan, temozolomide)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 or on days 1, 8, and 15 and temozolomide PO and irinotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
89277796|NCT04011748|Experimental|Hair regrowth by SCE|AA subjects will receive Stem Cell Educator therapy. Hair regrowth will be evaluated during six-month follow-up studies.
89277797|NCT04011748|Experimental|Minoxidil therapy|Control subjects will receive treatment with topical 5% minoxidil
89277798|NCT03638284|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS):All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Inhibitory stimulation will be delivered to the frontal lobes.
89277799|NCT01141322|Experimental|UDCA treatment|Patients with drug-induced liver injury will be randomly allocated to UDCA treatment group: oral intake ursodeoxycholic acid (UDCA) 13-15 mg/kg BW/day into 3 divided doses after meal till the endpoint or the 8th week. UDCA is 100 mg per tab.
89277800|NCT01141322|Placebo Comparator|Placebo|Patients with drug-induced liver injury will be randomly allocated to placebo group. The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
89277801|NCT05402774|Other|point-of-care ultrasound group|
89277802|NCT05402774|No Intervention|Control group|
89277803|NCT01141400||depression & initial prescription for an antidepressant|A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
89277804|NCT01142804|Experimental|Enhanced Usual Care Group|Participants received weekly emailed tips of the week to provide support for walking.
89277805|NCT01142804|Experimental|WalkLink Group|Participants received weekly emailed tips of the week, plus evidence-based online fitness walking program.
89277806|NCT01142804|Experimental|WalkLink+ Group|Participants received weekly emailed tips, plus evidence-based online fitness walking program, plus online/in-person social network intervention.
89277807|NCT01141556|Placebo Comparator|Placebo|Placebo (NaCl) i.v. intraoperatively, followed by an daily bolus of Placebo (NaCl) i.v. until discharge from ICU (no longer than 13 days)
89277808|NCT01141556|Active Comparator|Selenase|Selenase Bolus 4000 microgram i.v. intraoperatively, followed by an daily bolus of Selenase 1000 microgram i.v. until discharge from ICU (no longer than 13 days)
89277809|NCT01233908||PTSD|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and developed an associated posttraumatic stress disorder
89277810|NCT01233908||PTSD - negative|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and did not develope an associated posttraumatic stress disorder
89277811|NCT01139372|Experimental|FID 115958D|Lubricant eye drop
89277812|NCT01236248|Experimental|Prevention Program|Girls and their mothers who are assigned to participate in a tobacco, alcohol, and other drug use prevention program aimed at young girls.
89277813|NCT01236248|No Intervention|No Prevention Program|Girls and their mothers who are assigned to participate in questionnaires only.
89277814|NCT01139528|Active Comparator|Operative treatment|Closed reduction of the fracture and osteosynthesis with 2-3 intramedullary K-wires (Bouquet method), cast treatment for 7-10 days followed by 5 weeks of buddy-strapping before removal of the K-pins
89277815|NCT01139528|No Intervention|Conservative treatment|No attempt of reduction of the fracture, 7-10 days of cast treatment followed by 5 weeks of buddy-strapping
89277816|NCT01235312||Healthy subjects|
89277817|NCT01235312||Patients suffering from Diabetes mellitus|
89277818|NCT01235312||Patients suffering from peripheral arterial occlusive disease|
89277819|NCT01719640|Experimental|MSC+MC|infusion of BMMSC+BMMNC and insulin injection
89277820|NCT01719640|Active Comparator|MC|infusion of BMMNC and insulin injection
89277821|NCT01719640|Active Comparator|Insulin|insulin injection
89277822|NCT04411784||Main group|Patient with Acute Severe Ulcerative Colitis based on Modified Truelove and Witts Severity Index managed during the study period
89277823|NCT04411784||Control Group|Patients with ASUC managed in the unit from 1st Jan to 31st June 2019
89277824|NCT01141790|Placebo Comparator|Silence|"The control group listened silence and was evaluated the same things."
89277825|NCT03638362|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half of participants began study consuming placebo beverage and the other half TCJ.
89277826|NCT03638362|Experimental|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half pf participants began study consuming placebo beverage and the other half TCJ.
89277827|NCT01141868|Experimental|Internet Intervention|
89277828|NCT01141868|Experimental|Delayed Intervention|Receive access to the online Internet intervention after completing post-assessments.
89277829|NCT02439658||Dofetilide patients|Patients admitted for dofetilide initiation
89277830|NCT02439658||Sotalol patients|Patients admitted for sotalol initiation
89277831|NCT05191394|Other|Evolution of anti-SARS-CoV-2 titer over time in vaccinated adult patients treated with TPE.|"Assessment of the possible variation of anti-SARS-CoV-2 antibody titer in adult patients regularly treated with therapeutic plasma exchange.~For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session."
89277832|NCT03749720|Other|Cervical cancer patients|Baseline- and follow-up blood samples are collected from the cervical cancer patients at time of diagnosis and during treatment and clinical follow-up. HPV DNA is measured in these samples.
89277833|NCT00736840|Other|CLD (chronic liver disease)|Chronic liver disease subjects with recent biopsy will be tested with a breath tests using a 13C enriched substrate metabolized by their liver
89277834|NCT04908514|Experimental|ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.|
89277835|NCT01142024|Placebo Comparator|saline|saline hydration
89277836|NCT01142024|Experimental|Glutathione|
89277837|NCT04895098||combination therapy group|750 Subjects in the statin and ezetimibe combination therapy group
89277838|NCT04895098||monotherapy group|250 Subjects in the statin monotherapy group
89277839|NCT01235390|Experimental|5 g of walnuts|
89277840|NCT01235390|Experimental|40 g of walnuts|
89277841|NCT01142102|Experimental|Arm 1|Radiation Therapy
89277842|NCT04628962||Asthma-COPD Overlapped (aCOPD)|50 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
89277843|NCT04628962||Non-Exacerbator COPD (neCOPD)|50 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects
89277844|NCT04628962||frequent Excacerbator with Emphysema COPD (eeCOPD)|50 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects
89277845|NCT04628962||frequent Excacerbator with chronic Bronchitis COPD (ebCOPD)|50 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects
89277846|NCT04628962||Asthma patients (AST)|200 subjects affected by asthma comparable by age and sex with the other recruited subjects
89277847|NCT04628962||Healthy subjects (CTRL)|200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects
89277848|NCT00318461|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
89277849|NCT00318461|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
89277850|NCT00318461|Experimental|Lira 1.8 + Met|Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
89277851|NCT00318461|Active Comparator|Met Mono|Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
89277852|NCT00318461|Active Comparator|Met + Glim|Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo
89277853|NCT01235468|Experimental|CB expnasion|ex-vivo expansion of cord blood for transplantation
89277854|NCT01235624|Other|patient|Patient suffering of adRP that accept to participate at this study have a blood prelevement for genetic analysis (intervention)
89277855|NCT01142180|Active Comparator|TAE group|Patients will be undergone TAE after endoscopic hemostasis.
89277856|NCT01142180|Active Comparator|No TAE group|No TAE procedure will be performed after endoscopic treatment.
89277857|NCT01142258|Experimental|Trazodone|Study group will receive trazodone 50mg
89277858|NCT01142258|Placebo Comparator|Placebo|Inert pill
89277859|NCT04043312|Sham Comparator|Control|Patients will receive one hour of sham stimulation.
89277860|NCT04043312|Experimental|Active|Patients will receive one hour of active magnetic stimulation to the left stellate ganglion.
89277861|NCT01139606|Experimental|Vibration trainig|
89277862|NCT03764072|Placebo Comparator|Placebo|Participants received placebo matched to VX-150 for 2 days.
89277863|NCT03764072|Experimental|VX-150 - Dose Level 1|Participants received VX-150 1500 milligrams (mg) as first dose, followed by VX-150 750 mg every 12 hours (q12h) for 2 days.
89277864|NCT03764072|Experimental|VX-150 - Dose Level 2|Participants received VX-150 1000 mg once daily (qd) for 2 days.
89277865|NCT03764072|Experimental|VX-150 - Dose Level 3|Participants received VX-150 500 mg q12h for 2 days.
89277866|NCT03764072|Experimental|VX-150 - Dose Level 4|Participants received VX-150 500 mg as first dose, followed by VX-150 250 mg q12h for 2 days.
89277867|NCT03764072|Experimental|VX-150 - Dose Level 5|Participants received VX-150 250 mg qd for 2 days.
89277868|NCT05133830|Experimental|Treatment Arm 1|Participants will receive OCA at dose level 1, 4 hours after the linerixibat administration
89277869|NCT05133830|Experimental|Treatment Arm 2|Participants will receive OCA at dose level 2 along with linerixibat
89277870|NCT05133830|Experimental|Treatment Arm 3|Participants will receive OCA at dose level 1 along with linerixibat
89277871|NCT05133830|Experimental|Treatment Arm 4|Participants will receive OCA at dose level 2, 4 hours after the linerixibat administration
89277872|NCT01233986||Case group - Large artery atherosclerosis|
89277873|NCT01233986||Control group-Small vessel occlusion|
89277874|NCT01139684|Experimental|Exercise|
89277875|NCT01234064|Active Comparator|Graduated Compression Stockings|
89277876|NCT01234064|Other|No Graduated Compression Stockings|
89277877|NCT03333928|Active Comparator|HTD1801 500 mg BID|
89277878|NCT03333928|Active Comparator|HTD1801 1000 mg BID|
89277879|NCT03333928|Placebo Comparator|Placebo BID|
89277880|NCT03739424|Experimental|Whole egg powder arm|The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.
89277881|NCT03739424|Active Comparator|Whole milk powder arm|The whole milk powder arm will be part of our food product intervention. Food products created using whole milk powder will be provided and consumed 10x/week for 9 months. These items will have the equivalent amount of protein as the whole egg group. They will be isocaloric in nature.
89277882|NCT03739424|Placebo Comparator|Gelatin arm|The gelatin food products will be a part of our food product intervention. Food products created using gelatin will be provided and consumed 10x/week for 9 months. These items will be isocaloric in nature to the other treatment arms but will not contain additional protein.
89277883|NCT01139840|Active Comparator|vitamin D2|
89277884|NCT01139840|Active Comparator|vitamin D3|
89277885|NCT01142882|Active Comparator|Traditional Prevention|educator-delivered, small-group HIV & disease prevention education
89277886|NCT01142882|Experimental|Web-based Prevention|self-directed, interactive & customized web-based HIV & disease prevention education
89277887|NCT01139918||Cohort A|40 patients with moderate psoriatic arthritis and moderate psoriasis
89277888|NCT01139918||Cohort B|40 patients with mild psoriatic arthritis and moderate psoriasis
89277889|NCT01139918||Cohort C|40 patients with moderate psoriatic arthritis and mild psoriasis
89277890|NCT02945410|Experimental|Caloric Restriction and High Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 1.7 g protein/kg BW/day.
89277891|NCT02945410|Active Comparator|Caloric Restriction and Normal Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 0.8 g protein/kg BW/day.
89277892|NCT02945410|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.7 g protein/kg BW/day.
89277893|NCT01142960|Active Comparator|Placebo|Starch
89277894|NCT01142960|Experimental|Lycium Barbarum|Lycium Barbarum supplement
89277895|NCT02945254|Active Comparator|Background noise|Overnight sleep study with filtered white noise
89277896|NCT02945254|No Intervention|Silence|Overnight sleep study with normal environmental noise
89277897|NCT05032508|Experimental|xylocaine|
89277898|NCT05032508|Placebo Comparator|Placebo|
89277899|NCT01140074|Experimental|Zinc sulfate|Children in active treatment group will be given zinc sulfate 10-20 mg per day orally plus probiotics
89277900|NCT01140074|Placebo Comparator|Placebo|Children will be given placebo plus probiotics
89277901|NCT04823026||Group 1|"70 young infants with proven bacterial infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
89277902|NCT04823026||Group 2|"70 young infants with non-bacterial infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
89277903|NCT04823026||Group 3|"30 young infants without infection.~Interventions:~Diagnostic test: Host RNA expression profiling (whole transcriptome profiling) using whole blood RNA sequencing. Cases will be randomly assigned to a Discovery Cohort (identification of diagnostic RNA profiles) or a Validation Cohort (validation of the identified RNA profiles)."
89277904|NCT05010512|Other|DT1, then Infuse|Delefilcon A contact lenses worn first, with kalifilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
89277905|NCT05010512|Other|Infuse, then DT1|Kalifilcon A contact lenses worn first, with delefilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.
89277906|NCT01235858|Other|Gown group|Anesthesiologists wearing sterile gown for epidural insertion
89277907|NCT01235858|Other|No Gown group|Anesthesiologists not wearing gown for epidural insertion
89277908|NCT01329692|Experimental|Lifestyle counseling|"This is a seven-week group education, counseling, nutrition, exercise, and journaling program of the Duke Metabolic and Weight Loss Surgery Center designed to help postoperative bariatric surgery patients who are failing to progressively lose weight resume an expected pattern of weight loss and improved overall outcome.~Weeks 1 and 2 consist primarily of a review of current dietary habits. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed."
89277909|NCT01329692|No Intervention|RYGB regular post-op care|Regular care and follow-up after RYGB surgery
89277910|NCT01236482|Active Comparator|Oxytocin|
89277911|NCT01236482|Experimental|Oxytocin - ergometrine|
89277912|NCT03992651|Experimental|Experimental group|One single group of healthy subjects
89277913|NCT02943070|Experimental|Rezum Treatment|Patients received the Rezum transurethral needle ablation procedure to treat benign prostatic hyperplasia.
89277914|NCT03629678|No Intervention|Control group (Booklets)|Group 1 will receive the control arm with a paper booklet of the patient-centered SCD-guidelines with education by a health care provider at a single visit
89277915|NCT03629678|Active Comparator|mobile health application|Group 2 will receive continuous access to technology-based patient-centered SCD-specific guidelines using a user-driven technological platform, plus a paper booklet of the guidelines with education by a health care provider at a single visit. The mobile app will include interactive content and a fully searchable collection of the SCD-specific guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
89277916|NCT01048151|Experimental|Single|TNFerade™ Biologic + Radiation
89277917|NCT01236014||Eltrombopag & standard of care|
89277918|NCT01236014||Romiplostim & standard of care|
89277919|NCT01236014||Standard of care|
89277920|NCT01142570|Active Comparator|Group 1|Patients will be receive caloric support as dictated by Hariss-Benedict Formula (Group 1)
89277921|NCT01142570|Active Comparator|Group 2|Patients will be receive caloric support as dictated by Indirect Calorimetry (Group 2)
89277922|NCT01142570|Active Comparator|Group 1A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the first(Group 1A)group will receive caloric support calculated by the HARISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight."
89277923|NCT01142570|Active Comparator|Group 2A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight."
89277924|NCT01142570|Active Comparator|Group 3A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the third group will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight."
89277925|NCT03963154|Experimental|Implantation of a therapeutical patch|All the patients will receive a single central subretinal implantation in one eye of a monolayer of Human Embryonic Stem Cells-derived Retinal Pigmented Epithelium (hESC-derived RPE). The implanted eye will be the one with the worst visual acuity.
89277926|NCT03776474||Allergic|Minors allergic to cow's milk and/or eggs
89277927|NCT03776474||Non-allergic|Minors without history of allergy to cow's milk and/or eggs
89277928|NCT03776474||Acquired tolerance|Minors formerly allergic to cow's milk and/or eggs
89277929|NCT02145208|Experimental|Medi-Tate iTind|TIND System
89277930|NCT01234142|Experimental|Cohort 1|
89277931|NCT01234142|Experimental|Cohort 2|
89277932|NCT01234142|Experimental|Cohort 3|
89277933|NCT01234142|Experimental|Cohort 4|
89277934|NCT01140152||No rejection|Intestinal transplant recipients with no evidence of biopsy proven rejection
89277935|NCT01140152||Rejection|Intestinal transplant recipients who had evidence of biopsy proven rejection
89277936|NCT01234220||Adrenal Venous Sampling (AVS)|Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.
89277937|NCT01143194|Experimental|oréVida™ 60mg/day|
89277938|NCT01143194|Experimental|oréVida™ 120mg/day (1)|
89277939|NCT01143194|Experimental|oréVida™ 120mg/day (2)|
89277940|NCT01143194|Placebo Comparator|Placebo|
89277941|NCT01140308|Placebo Comparator|Sugar Pill|Simvastatin 20mg + Placebo
89277942|NCT01140308|Active Comparator|Co Q10|Simvastatin 20mg + CoQ10
89277943|NCT02143726|Active Comparator|sorafenib|Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89277944|NCT02143726|Experimental|sorafenib and everolimus|Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89277945|NCT05397392||acute kidney injury|Acute kidney injury caused by heart disease or cardiac dysfunction due to acute renal damage
89277946|NCT05397392||chornic kidney disease|Chornic kidney injury caused by heart disease or cardiac dysfunction due to chronic kidney disease
89277947|NCT03503864|Experimental|ATO-combined chemotherapy|Patients receive combined induction chemotherapy with arsenic trioxide.
89277948|NCT02088112|Experimental|Escalation|MEDI4736 will be combined with gefitinib to assess safety and tolerability
89277949|NCT02088112|Experimental|Expansion Arm|MEDI4736 will be combined with gefitinib
89277950|NCT01237964|Experimental|Xiaflex ( Collagenase use)|all 10 patients will be selected from out burn's clinic pool and will be injected using collagenase
89277951|NCT05397080|Experimental|TAU + multicomponent treatment VIRTUAL FIBROWALK|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
89277952|NCT05397080|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
89277953|NCT05397080|Active Comparator|TAU + multicomponent treatment VIRTUAL + 4 face-to-face sessions|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training. In this arm a 4 face-to-face session will be added to solve doubts and emphasize the most important points of therapy
89277954|NCT01140386||hospital pediatric patients 1/1/2000-12/31/2008 documented VTE|Age <18 Hospitalized for greater than or equal to 24 hours VTE documented during hospital admission
89277955|NCT01312870|Experimental|postoperative nutritional supplements|postoperative nutritional supplements in addition to standard hospital diet
89277956|NCT01312870|Placebo Comparator|standard hospital diet|patients receiving standard hospital diet
89277957|NCT01238042|Experimental|Light Dose Escalation|Light Dose escalated from 150 joules/cm to 200 joules/cm
89277958|NCT03484910|Experimental|BFB group|Exercise therapy - Six-week training program of stationary cycling with a real-time visual EMG biofeedback
89277959|NCT03484910|Active Comparator|CON group|Exercise therapy - Six-week training program of stationary cycling without EMG biofeedback
89277960|NCT01313026|Active Comparator|PNE first|patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
89277961|NCT01313026|Active Comparator|TAI first|Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
89277962|NCT01144910||BHR non-atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
89277963|NCT01144910||BHR atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
89277964|NCT01234298|Experimental|SPD489 Low-Dose|
89277965|NCT01234298|Experimental|SPD489 High-Dose|
89277966|NCT01234298|Placebo Comparator|Placebo|
89277967|NCT05308342|Experimental|UC-MSCs+hormone replacement group|Group A was the hormone replacement combined with transplantation of umbilical cord mesenchymal stem cells group(test group).
89277968|NCT05308342|Active Comparator|hormone replacement group|Group B was the hormone replacement group (control group).
89277969|NCT01585922|Experimental|NPPV|Use the NPPV to treat moderate ARDS
89277970|NCT01585922|Active Comparator|IMV|Use invasive mechanical ventilation in treating the patients allocated to this group.
89277971|NCT03332212|Experimental|Cohort A (Empagliflozin + Placebo)|Heart Failure with Reduced Ejection Fraction
89277972|NCT03332212|Experimental|Cohort B (Empagliflozin + Placebo)|Heart Failure with Preserved Ejection Fraction
89277973|NCT01779388|Other|Bronchoscopy guided by fluoroscopy|Bronchoscopy guided by fluoroscopy followed by ENG
89277974|NCT01779388|Experimental|Bronchoscopy guided by electromagnetic navigation|Bronchoscopy guided by ENG followed by fluoroscopy
89277975|NCT01140464|Active Comparator|Enhanced Usual Care|Usual care treatment of depression in primary care settings. Usual care considered enhanced as patients and their parents were given screening results and encouraged to seek care from their primary care doctor and behavioral health services.
89277976|NCT01140464|Active Comparator|Collaborative Care|Collaborative care intervention for depression. Involves care management, evidence based treatments in primary care setting, symptom monitoring and stepped care design
89277977|NCT04872842||unstable intracranial aneurysms|Unstable intracranial aneurysms are defined as the intracranial aneurysms that grows or ruptures.
89277978|NCT04872842||stable intracranial aneurysms|Stable intracranial aneurysms are defined as the intracranial aneurysms that have no significant morphological changes.
89277979|NCT03331666|Active Comparator|Evolocumab|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.
89277980|NCT03331666|Placebo Comparator|Placebo|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.
89277981|NCT01234376||Control patients|
89277982|NCT01234376||Patients with eosinophilic esophagitis|
89277983|NCT03867916|Experimental|Health services research (Patient COUNTS)|Patients attend focus groups to help develop patient portal and navigation program. Patients use in-person navigation program. Patients also complete data collection and surveys over 15 minutes via web portal at baseline, 3 months, and 6 months and user experience survey at end of program participation.
89277984|NCT04828538|Active Comparator|1 - Vitamin D, Omega 3, Vitamins B, C, Zinc|"Vitamin D of F1 Omega 3 of F2 Vitamins B, C, Zinc of F3~[60 days]"
89277985|NCT04828538|Active Comparator|2 - Vitamin D, Omega 3|"Vitamin D of F1 Omega 3 of F2 Placebo of F3~[60 days]"
89277986|NCT04828538|Active Comparator|3 - Vitamin D, Vitamins B, C, Zinc|"Vitamin D of F1 Placebo of F2 Vitamins B, C, Zinc of F3~[60 days]"
89277987|NCT04828538|Active Comparator|4 - Vitamin D|"Vitamin D of F1 Placebo of F2 Placebo of F3~[60 days]"
89277988|NCT04828538|Active Comparator|5 - Omega 3, Vitamins B, C, Zinc,|"Placebo of F1 Omega 3 of F2 Vitamins B, C, Zinc of F3~[60 days]"
89277989|NCT04828538|Active Comparator|6 - Omega 3|"Placebo of F1 Omega 3 of F2 Placebo of F3~[60 days]"
89277990|NCT04828538|Active Comparator|7 - Vitamins B, C, Zinc|"Placebo of F1 Placebo of F2 Vitamins B, C, Zinc of F3~[60 days]"
89277991|NCT04828538|Placebo Comparator|8 - No Interventions|"Placebo of F1 Placebo of F2 Placebo of F3~[60 days]"
89277992|NCT01145144|Experimental|DHEA supplementation|DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
89277993|NCT01145144|No Intervention|only induction of ovulation by same long protocol without DHEA|
89277994|NCT03331042|Experimental|Sequence 1|SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
89277995|NCT03331042|Experimental|Sequence 2|D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
89277996|NCT03331042|Experimental|Sequence 3|D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
89277997|NCT03331042|Experimental|Sequence 4|Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
89277998|NCT03762668|Other|MDACL, then DACL|Modified delefilcon A contact lenses (MDACL) worn first, followed by delefilcon A contact lenses (DACL), as randomized. Each product worn bilaterally (in both eyes) for approximately 1 week in a daily disposable modality.
89277999|NCT03762668|Other|DACL, then MDACL|DACL worn first, followed by MDACL, as randomized. Each product worn bilaterally for approximately 1 week in a daily disposable modality.
89278000|NCT03638206|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
89278001|NCT03728842||Spontaneous regression|Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
89278002|NCT00566488|Experimental|Thymus and Parathyroid transplantation|Thymus/Parathyroid Transplantation in Complete DiGeorge Syndrome Infants
89278003|NCT03762200|Other|SURGICEL Powder - Single arm|Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
89278004|NCT04943302|Experimental|Isatuximab + bendamustine|Bendamustine will be administered by IV at a dose of 70mg/m2 on cycle days 1 and 8 for up to 6 cycles. Isatuximab will be administered by IV at a dose of 10mg/kg on cycle 1 days 1, 8, 15, and 22; cycle 2-6 days 1,8; and cycle 7-12 day 1.
89278005|NCT01234454|Experimental|Risperidone Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
89278006|NCT01234454|Experimental|Olanzapine Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
89278007|NCT01234454|No Intervention|Thiothixene|Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day. Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.
89278008|NCT03638518|Experimental|Acupuncture|"In the acupuncture experimental group, the technique applied included the use of the following acupuncture points of Traditional Chinesse Medicine: GV20, ST36 and BL60 . One needle insertion was performed in each session and in the case of the last two points the needle insertions were done bilaterally.~Patients laid supine on a treatment table with their legs exposed. The skin on the acupuncture points was prepared with 70% ethyl alcohol. One-time-use disposable sterile stainless steel needles (0,26x50mm) were inserted into acupuncture points.~After insertion, acupuncture needles were manually manipulated to obtain the de qi sensation. The needles remained in place for 20 minutes and there were no further manipulations during the retention time."
89278009|NCT03638518|Experimental|Physiotherapy|The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
89278010|NCT03638518|No Intervention|control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
89278011|NCT01143350|Experimental|EHPAD Training and Stimulation|"EHPAD of the group of Training / Stimulation will benefit:~after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
89278012|NCT01143350|Placebo Comparator|2- EHPAD control|EHPAD of the reference group, will have their habitual functioning
89278013|NCT03711370|Experimental|Opaque Bottle Group|This group was given a set of opaque bottles to use during infant feedings for a full 12-week period.
89278014|NCT03711370|Active Comparator|Clear Bottle Group|This group was given a set of clear bottles to use during infant feedings for a full 12-week period.
89278015|NCT03379844|Experimental|Holmium-166 radioembolization|
89278016|NCT01145456|Experimental|Treatment (RO4929097 and gemcitabine hydrochloride)|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89278017|NCT04939636|Active Comparator|Vitamin D3 capsules 4000IU/100µg|Get Vitamin D3 capsules 4000IU/100µg.
89278018|NCT04939636|Active Comparator|Vitamin D3 capsules 600IU/15µg|Get Vitamin D3 capsules 600IU/15µg.
89278019|NCT03621124||Brown Adipose Tissue Positive patients|Patients with known malignancy and incidental finding of positron emission tomography/ computerized tomography (PET/CT) scans positive for brown adipose tissue (BAT). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
89278020|NCT03621124||Brown Adipose Tissue Negative Patients|Patients with known malignancy and no evidence of brown adipose tissue BAT activity positron emission tomography/ computerized tomography (PET/CT) scans to be matched to group 1 for primary tumor and stage, sex, age (±5 years), BMI (±3 Kg/m2). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
89278021|NCT01145534|Active Comparator|Glibenclamide|Patients used 5 mg glibenclamide daily for 60 days
89278022|NCT01145534|Experimental|Experimental|Patients ingested the infusion of Cissus verticillata L. prepared as 1 g in 150 mL of hot water for 10 min. This was done daily for 60 days
89278023|NCT04652674|Experimental|Group I|Patients who will undergo telemedicine visit approximately 1 week postoperatively, then an in-person clinic visit approximately 4 weeks postoperatively
89278024|NCT04652674|Active Comparator|Group II|Patients who will undergo in-person clinic visit approximately 1 week postoperatively, then a telemedicine visit approximately 4 weeks postoperatively
89278025|NCT01145612|Experimental|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
89278026|NCT01145612|Experimental|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
89278027|NCT01238354|Active Comparator|Without friend|Being in the weight loss programme without friend or family member
89278028|NCT01238354|Experimental|With friend|Having the friend or family member stay together with the patient for 2-3 days for every 3 week stay at the clinic in the weight loss programme
89278029|NCT04399382||Non-radiographic group|Participants with non-radiographic axial SpA
89278030|NCT04399382||Radiographic group|Participants with radiographic axial SpA (a.k.a. ankylosing spondylitis)
89278031|NCT01145690||Internet-based CBT|All participants in this cohort received Internet-based CBT for social anxiety disorder in 2005. All participants were Swedish adults with a DSM-IV diagnosis of social anxiety disorder.
89278032|NCT01145768|Experimental|1|Each cohort will have 9 volunteers that will receive TC-5214
89278033|NCT01145768|Placebo Comparator|2|Each cohort will have 3 volunteers that will receive placebo
89278034|NCT01143584|Experimental|Rapid escalation|Weekly escalation of cabergoline dose in macroprolactinomas Start with 1 mg/week. increase by 1mg/wk every week till 4 weeks. after 4 weeks Cabergoline dose would be increased @1mg/wk every 4 weekly till normalization of prolactin and >50% decrease in tumor volume from baseline.
89278035|NCT01143584|Active Comparator|Conventional escalation|"Conventional escalation of cabergoline~In the Conventional escalation group schedule of cabergoline dosing will be 0.5 mg once a week for 4 weeks. Cabergoline will be incrementally dose adjusted on the basis of individual Prolactin values till amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or till primary endpoint."
89278036|NCT01145846|Experimental|Arm I (AI regimen)|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3)
89278037|NCT03526588|Experimental|Autologous umbilical cord blood|
89278038|NCT01238510|Active Comparator|Provisional fKBT|Stent technique that final kissing balloon technique(fKBT) is performed if side branch flow was aggravated to TIMI0-2 after stent deployment
89278039|NCT01238510|Active Comparator|Routine fKBT|Stent technique that fKBT was mandatory irrespective of side branch flow after stenting.
89278040|NCT04239274|Experimental|Transcranial Direct Current Stimulation (tDCS)|
89278041|NCT04239274|Experimental|Transcranial Pulsed Stimulation tPCS|
89278042|NCT04239274|Sham Comparator|No Stimulation|
89278043|NCT03134456|Experimental|single arm: pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
89278044|NCT05207228|No Intervention|Treatment as usual|After completing the inpatient care (at discharge of inpatient care), patients randomized to TAU will receive day-care / outpatient treatment.
89278045|NCT05207228|Experimental|Treatment as usual + CBT4CBT|After completing the inpatient care (at discharge), the patients randomly assigned to the experimental condition will receive the TAU + CBT4CBT a web-based treatment which has been tested on individuals with cocaine use disorder in America by the team of Dr. K.M. Carroll.
89278046|NCT01313104|Experimental|Screening|See Detailed Description
89278047|NCT01238744|Placebo Comparator|Study I: control drink|
89278048|NCT01238744|Experimental|Study I: flaxseed drink|
89278049|NCT01238744|Active Comparator|Study II: flaxseed drink|
89278050|NCT01238744|Experimental|Study II: flaxseed tablets|
89278051|NCT01143662|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per week
89278052|NCT01143662|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per week
89278053|NCT01143662|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per week
89278054|NCT01143662|Active Comparator|Group 4|Pegasys 180mcg per week
89278055|NCT01145924|Active Comparator|EBUS TBNF|single arm trial, patients with enlarged mediastinal nodes will be examine
89278056|NCT04882150|Experimental|Part A: SAD|SAD = single ascending dose. Each participant will receive a single dose of BMS-986196 or placebo.
89278057|NCT04882150|Experimental|Part B: MAD|MAD = multiple ascending dose. Each participant will receive multiple doses of BMS-986196 or placebo.
89278058|NCT04882150|Experimental|Part C: FE/Formul.|FE/Formul. = food and formulation effects and relative absorption. Participants will receive two formulations of BMS-986196 (solution and suspension), each formulation with and without food.
89278059|NCT05173688|Experimental|Low maintenance dose propofol group|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h
89278060|NCT05173688|Experimental|High maintenance dose propofol group|The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
89278061|NCT01146548|Experimental|the fluoxetine group|Multiple System Atrophy's patients with fluoxétine
89278062|NCT01146548|Placebo Comparator|the placebo group|Multiple System Atrophy's patients with placebo
89278063|NCT03478930|Experimental|Cohort A: Study GA39688 Omalizumab|Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
89278064|NCT03478930|Experimental|Cohort A: Study GA39688 Placebo|Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
89278065|NCT03478930|Experimental|Cohort B: Study GA39855 Omalizumab|Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
89278066|NCT03478930|Experimental|Cohort B: Study GA39855 Placebo|Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
89278067|NCT01312714|Active Comparator|Cholecalciferol|
89278068|NCT01312714|Placebo Comparator|Placebo|
89278069|NCT04188028|Experimental|CYP2D6 gene score 0|CYP2D6 gene score 0: carrier of two non-functional alleles
89278070|NCT04188028|Experimental|CYP2D6 gene score ≥1|CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles
89278071|NCT01312792|Experimental|Modified IMCI guideline|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
89278072|NCT01312792|Active Comparator|Current IMCI guideline|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
89278073|NCT03038438|Experimental|Abre|Abre Venous Self-expanding Stent System
89278074|NCT03523000|Active Comparator|Active Solution followed by Inactive Placebo Solution|"Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml~6 hour washout followed by~Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline"
89278075|NCT03523000|Placebo Comparator|Inactive Placebo Solution followed by Active Solution|"Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline~6 hour washout followed by~Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml"
89278076|NCT01143740|Experimental|Single Arm|
89278077|NCT04705480|Experimental|Pregabalin|
89278078|NCT04705480|Experimental|Gabapentin|
89278079|NCT04705480|Active Comparator|Neither Pregabalin nor Gabapentin|
89278080|NCT01238978|Experimental|Vildagliptin|
89278081|NCT01238978|Active Comparator|other Oral Antidiabetic Drug in a different therapeutic class|
89278082|NCT01239134|Experimental|TRX518|
89278083|NCT03327220|Experimental|iovera° Device Treatment Group|Iovera° device presurgical cryoneurolysis treatment, 5 (+/- 2) days prior to TKA. Additionally, all participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
89278084|NCT03327220|No Intervention|Standard of Care Treatment Group|All participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
89278085|NCT01245608|Experimental|Polypill|Single daily dose of PolyPill and 6-monthly visits
89278086|NCT01245608|No Intervention|Control|Only 6-monthly visits
89278087|NCT00318149|Experimental|Fluarix 18-40 Y Group|Subjects (aged 18-40 years [Y]) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
89278088|NCT00318149|Experimental|Fluarix ≥65 Y Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
89278089|NCT00318149|Experimental|Fluarix-AS25 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.
89278090|NCT00318149|Experimental|Fluarix-AS50 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.
89278091|NCT00318149|Experimental|Fluarix- AS01B Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.
89278092|NCT00318149|Experimental|Fluarix- AS01E Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.
89278093|NCT01236716|Experimental|Albumin paclitaxel plus carboplatin|Treatment of Albumin paclitaxel plus carboplatin
89278094|NCT01236716|Active Comparator|Gemcitabine plus carboplatin|Treatment of Gemcitabine plus carboplatin
89278095|NCT03440008||Control|Able-bodied, age matched subjects with no foot and ankle pathology
89278096|NCT03440008||OA|Subjects with ankle OA, with all classifications of ankle misalignment (varus, neutral, valgus)
89278097|NCT01236794|Experimental|Lifestyle and Exercise Intervention|
89278098|NCT04154800|Experimental|Part A:SAD|Single Ascending Dose
89278099|NCT04154800|Experimental|Part B: MAD|Multiple Ascending Dose
89278100|NCT04154800|Experimental|Part C: DDI|Drug-Drug Interaction
89278101|NCT04154800|Experimental|Part A (SAD) Placebo|
89278102|NCT04154800|Experimental|Part B (MAD) Placebo|
89278103|NCT01236872|Experimental|Beetroot juice|250ml beetroot juice ingestion
89278104|NCT01236872|Placebo Comparator|Water|250ml low-nitrate water placebo
89278105|NCT01048229|Experimental|Rasagiline|
89278106|NCT01048229|Active Comparator|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
89278107|NCT04703296|Experimental|Mindfulness training (MT) group|Receives 4 weeks of mindfulness training followed by a testing session.
89278108|NCT04703296|No Intervention|No-training control (NTC) group|Receives 4 weeks of no mindfulness training followed by a testing session.
89278109|NCT04770376||Cohort A: patients treated with chemotherapy (I-II line) associated to bevacizumab|Quantification of biomarkers will be performed on 100 patients treated with bevacizumab through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
89278110|NCT04770376||Cohort B: patients treated with chemotherapy (I-II line, not associated to antiangiogenic drugs)|Quantification of biomarkers will be performed on 50 patients treated with chemotherapy through the collection of the following samples at different timepoints: 1 serum sample; 2 CTAD plasma samples; 2 K2EDTA plasma samples. The samples will be collected as follows: before the start of chemotherapy; 3 weeks after start of chemotherapy, before start of treatment with bevacizumab; 9 weeks after start of chemotherapy; 15 weeks after start of chemotherapy; 52 weeks after start of chemotherapy; at progression of disease.
89278111|NCT05291026|No Intervention|control group|Type 2 diabetes patients, 18 years old and above, enrolled in the out-patient, diabetes clinic of the tertiary health facility, receiving only standard of care, and who gave their informed consent
89278112|NCT05291026|Experimental|intervention group|type 2 diabetes patients, 18 years old and above, enrolled in the out-patient diabetes clinic of the tertiary health facility, receiving standard of care in addition to a mobile phone - based health education and follow-up messaging on a frequency of once a day corresponding to how often they are expected to take their medications (that is every day), and who gave their informed consent.
89278113|NCT00317603|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
89278114|NCT04112602||Patients with MPS|In this cohort are included patients under 18 years old with MPS (all types). The objective is to be representative of the diversity of MPS, and of this evolution.
89278115|NCT04112602||Non-MPS patients|In this control group are included patients under 18 years old, with no respiratory problems, no MPS.
89278116|NCT01048307|Experimental|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system)."
89278117|NCT01048307|Placebo Comparator|Saline irrigation (standard care control)|"Saline (control group):~cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
89278118|NCT03326518|Experimental|Lumentin® 44|Contrast agent
89278119|NCT03326518|Active Comparator|Diluted Omnipaque®|Contrast agent
89278120|NCT03326518|Active Comparator|Movprep®|Contrast agent
89278121|NCT02049905|Experimental|Aldoxorubicin|Aldoxorubicin is administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously on Day 1 every 21-day cycles until tumor progression or unacceptable toxicity occurs.
89278122|NCT02049905|Active Comparator|Investigator's Choice of Treatment|"These treatments include:~Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;~Pazopanib, 800 mg orally each day until tumor progression or unacceptable toxicity occurs;~Gemcitabine, 900 mg/m2 by IVI over 90 minutes on Days 1 and 8, plus docetaxel, 100 mg/m2 by IVI over 1 hour on Day 8 of a 28 day cycle until tumor progression or unacceptable toxicity occurs;~Doxorubicin, 75 mg/m2 by IVI over 5 to 30 minutes every 21 days for a maximum cumulative dose of 550 mg/m2 or unacceptable toxicity occurs; or~Ifosfamide 2.0 g/m2 administered over 2 to 4 hours on Days 1-4 of a 21 day cycle + mesna per standard site administration regimen until tumor progression or unacceptable toxicity occurs."
89278123|NCT03620812|Experimental|rapeseed protein|Three interventions are planned, in which the subjects will eat a test meal with added rape protein isolate (arm 1), a test meal with added soy protein isolate (arm 2) and a test meal without additional protein (arm 3) in random order on 3 days. The subjects are randomly assigned to one of the 3 treatment arms, ultimately resulting in 6 sequences (cross-over)
89278124|NCT03620812|Active Comparator|soy protein|
89278125|NCT03620812|Placebo Comparator|no protein|
89278126|NCT01062191|Experimental|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Nanoflex Powder Dressing applied to joint
89278127|NCT01062191|Active Comparator|Aquacel AG, typical carboxymethylcellulose dressing|Sodium CMC dressing control applied to joint
89278128|NCT02037659||Gastric Varices treatment|DermaBond (glue) treatment of Gastric Varices.
89278129|NCT03994510|Other|Patients with Borderline Personality Disorder|At each visit, these patients will have an interview that will allow for a clinical evaluation, as well as completing the hetero-questionnaires and self-questionnaires
89278130|NCT03985787|Experimental|All Participants|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
89278131|NCT03981965|Experimental|Focus guidelines|"Participants enrolled in a 2-phase physical activity program divided in 2 phases as described above. Briefly, The activity consisted in a 1-h set of exercises twice per week. The first 12-week phase was performed in group under the direct supervision of a health monitor. The second 12-week phase was autonomous, and consisted of the same physical performance while maintaining virtual link through a social network based on the mobile phone.~The FOCUS guidelines provided 2 features, the participation in monthly health talks provided by the principal investigator and the availability of a virtual mailbox to transmit any comment or suggestion."
89278132|NCT03981965|Active Comparator|Active group|Participants enrolled in a 2-phase physical activity program divided into 2 phases as described above. This group lacked the monthly talks and did not have access to the virtual mailbox.
89278133|NCT03981965|No Intervention|Inactive|Women of similar clinical characteristic who did not participate in the PA program.
89278134|NCT03325894|Experimental|SHP465|Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.
89278135|NCT01058759|Experimental|Arm B: Enoxaparin|
89278136|NCT01058759|Active Comparator|Arm A: No Enoxaparin|
89278137|NCT01239368|Experimental|Cohort B - Relapsed Multiple Myeloma|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) .Rapamycin (Rapa) for Relapsed Multiple Myeloma
89278138|NCT01239368|Experimental|Cohort A - Prevention of Relapse|Th1/Tc1.Rapa Prevention of Relapse
89278139|NCT03985709|Experimental|Probiotcal group|Probiotic (Lactobacillus casei) once daily taken by 3 months
89278140|NCT03985631|Experimental|Telerehabilitation|Tai Chi intervention by telerehabilitation (3-month intervention, three sessions per week: two supervised session and one unsupervised session).
89278141|NCT01146002|Other|Guanfacine treated.|Single arm - all patients treated with study drug. Comparison is against pre-treatment performance.
89278142|NCT05288608||Simple palliation|Treatment of patients who are referred for palliative radiotherapy to uncomplicated metastases.
89278143|NCT05288608||Complex palliation|Treatment of patients who require treatment to a site of previous radiation, patients undergoing concurrent systemic therapy, and those requiring a radiation dose exceeding 8 Gy.
89278144|NCT05632172||maxillary group|implant insertion
89278145|NCT01146626|Active Comparator|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
89278146|NCT01146626|Experimental|Peg+ Ribavirine|Peg+ Ribavirine
89278147|NCT01245686|Active Comparator|One-on-one counseling|Participants in this arm will receive 4 intensive one-on-one counseling sessions (either in person or on the phone) and 3 brief maintenance sessions.
89278148|NCT01245686|Active Comparator|Web counseling|Participants in this arm will receive 4 intensive counseling sessions over the web. They will also receive 3 maintenance sessions over the web.
89278149|NCT01245842|No Intervention|Usual care|
89278150|NCT01245842|Experimental|Exercise group|
89278151|NCT03667586|Experimental|Group Cognitive Behavioral Therapy|Cognitive behavioral psychotherapy sessions will be conducted at an appropriately accommodated office of the Psychiatry Department in groups of 6-10 patients and will be coordinated by a qualified psychologist of the research team. Each session will be of 90 minutes duration. The initial two sessions will be psycho-educational and the remaining sessions will be based on the principles of Cognitive Behavioral Therapy (CBT). In total, the psychotherapeutic intervention will last for 6 months with participants attending weekly sessions for the first 3 months and monthly follow-up sessions for the next 3 months.
89278152|NCT03667586|Placebo Comparator|Standard care|Regular brief follow-ups by the gastroenterologists and the nurse of the research team
89278153|NCT02924324|Active Comparator|Propofol First, then Propofol & Ropivacaine|1st Bone Marrow procedure (BM) Intervention A: propofol first. Then second BM procedure with propofol & ropivacaine
89278154|NCT02924324|Experimental|Propofol and Ropivacaine First, then Propofol|1st BM procedure: Intervention B: propofol & ropivacaine first. Then second BM procedure with propofol
89278155|NCT02528240|Experimental|+ L-PRF|With leukocyte and platelet rich fibrin
89278156|NCT02528240|Active Comparator|- L-PRF|Without leukocyte and platelet rich fibrin
89278157|NCT01239524|Other|DE-group|surgical denervation by excising 1 cm of proximal thoracodorsal nerve
89278158|NCT01239524|Other|IN group|thoracodorsal nerve is saved intact
89278159|NCT05137574|Active Comparator|Group P|Patients sedated with propofol
89278160|NCT05137574|Active Comparator|Group K|Patients sedated with ketamine
89278161|NCT01146080|Experimental|Promus Element|21 consecutive patients with Promus Element implanted to treat coronary artery lesion
89278162|NCT01146080|Active Comparator|Promus|21 consecutive patients with Promus stent implanted to treat coronary artery lesions
89278163|NCT05018546|Experimental|Gravity Irrigation|RIRS under Gravity irrigation
89278164|NCT05018546|Experimental|Pressure Irrigation|RIRS under Pressure irrigation.
89278165|NCT02852330|Experimental|Voltage tomography|Voltage tomography measurements will be made with the SA16 research software and CS19 (1.6.2) software during and/or immediately after electrode insertion during cochlear implantation and at scheduled post-operative clinical visits.
89278166|NCT01239602||Normal control|
89278167|NCT01239602||with Stem cell therapy plus G-CSF|
89278168|NCT01239602||G-CSF along|
89278169|NCT01236950|Experimental|Delmopinol mouthrinse|Subjects use the delmopinol mouthrinse
89278170|NCT01236950|No Intervention|Control|Subjects with no use of mouthrinse
89278171|NCT01236950|Experimental|Essential oils mouthrinse|Subjects using the essential oils mouthrinse
89278172|NCT04971746|Experimental|GLPG4716 and pirfenidone|
89278173|NCT04971746|Experimental|GLPG4716 and nintedanib|
89278174|NCT00369161|Active Comparator|Very low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 1.5 and 3 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
89278175|NCT00369161|Active Comparator|Low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 4 and 7 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
89278176|NCT01246388||Chronic Liver Disease|
89278177|NCT01143974|Experimental|PC Regimen|
89278178|NCT01239836|Experimental|Self-management|
89278179|NCT01239836|Sham Comparator|General Health Lecture|
89278180|NCT01239836|Experimental|Combined workshop and self-management|
89278181|NCT01239836|Experimental|Workshop|
89278182|NCT04904042|Experimental|Use of plasma of neutral argon|Use of plasma of neutral argon in the eradication of tumor implants at the mesentery level, with different doses (established according to the percentage of energy used) and distances of application and time. It will also be compared in-vivo with control therapy of Monopolar electrofulguration at a power of 100 in cut mode with ball-tip terminal.
89278183|NCT01146158|Experimental|surgery Axillary dissection|surgery Axillary dissection
89278184|NCT02637986|Experimental|ARM A - suffered from one episode of UTI|Women who suffered from one episode of UTI during pregnancy before recruitment
89278185|NCT02637986|Placebo Comparator|ARM A - suffered from one episode of UTI - placebo|Women who suffered from one episode of UTI during pregnancy before recruitment
89278186|NCT02637986|Experimental|ARM B -suffered from more than one episode of UTI|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
89278187|NCT02637986|Placebo Comparator|ARM B -suffered from more than one episode of UTI - placebo|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
89278188|NCT02437916|Experimental|AMG 228 monotherapy|Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.
89278189|NCT01247480||Breast cancer patients|
89278190|NCT00337571|Experimental|A1|5 mg
89278191|NCT00337571|Experimental|A2|10 mg
89278192|NCT00337571|Experimental|A3|15 mg
89278193|NCT00337571|Placebo Comparator|B1|
89278194|NCT01247792|No Intervention|"Before"|No Intervention Observation of current practice
89278195|NCT01247792|Other|"After"|SOPs for decision-making and communication Assessment of practice after implementation of SOPs
89278196|NCT01247870|Experimental|Metformin|Metformin 1 g twice daily for 28-35 days
89278197|NCT01247870|Placebo Comparator|Placebo|Matched placebo capsules
89278198|NCT02528396|Experimental|BioChaperone insulin lispro|
89278199|NCT02528396|Active Comparator|Humalog®|
89278200|NCT01062347|Experimental|zinc supplementation (20 mg/d, for 7 d)|
89278201|NCT03985319|Experimental|YYD601 20mg|Esomeprazole IR 10mg + esomeprazole SR 10mg
89278202|NCT03985319|Active Comparator|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg. Astrazeneca
89278203|NCT01237028|Experimental|oral calcitriol|Calcio®
89278204|NCT01237028|No Intervention|placebo|
89278205|NCT01146236|Active Comparator|Sutures|Orthopedic surgical wound closed with sutures
89278206|NCT01146236|Active Comparator|Staples|Orthopedic surgical wound closed with metallic staples
89278207|NCT04831658|Experimental|Orelabrutinib combined with PD-1 and fotemustine|To observe the efficacy and safety of a new generation of BTK inhibitor abutinib combined with PD-1 and formustine in the treatment of newly-treated patients with primary central nervous system lymphoma (PCNSL)
89278208|NCT01240850|Active Comparator|Prednisone|
89278209|NCT01240850|Experimental|Methotrexate+Prednisone|
89278210|NCT04813016|Active Comparator|Early tramal/bupivacaine|patients received 50 ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% immediately before creation of a pneumoperitoneum and placement of the first two trocars before starting the surgery.
89278211|NCT04813016|Active Comparator|Late tramal/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
89278212|NCT04813016|Active Comparator|Early dexmedetomedine/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% before creation of a pneumoperitoneum and placement of the first two trocars before the start of surgery.
89278213|NCT04813016|Active Comparator|Late dexmedetomedine/bupivacaine|patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.
89278214|NCT01146314|Experimental|Lifestyle intervention|A 6-month 14 session lifestyle intervention led by a psychologist and a dietitian for 90 minutes group sessions. Intervention sessions were help weekly, biweekly, and monthly over the course of 6 months.
89278215|NCT00368927|Experimental|Arm I|Patients receive oral sulindac twice daily for 6 months.
89278216|NCT00368927|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
89278217|NCT01146938|Experimental|hepatic impairment patients|Hepatic impairment patients group Child-Pugh score A or Child-Pugh score B (not Child-Pugh score C)
89278218|NCT01146938|Active Comparator|Healthy volunteers|healthy volunteers group
89278219|NCT01237106|Experimental|In Vitro Maturation (IVM)|
89278220|NCT01324661|No Intervention|Control|Individuals who receive the ball during a computerized ball tossing game about the same number of times as the other players in the game.
89278221|NCT01324661|Other|Ostracism|Participant would receive the ball of a ball-tossing game once or twice in the beginning and then never again for the duration of the game.
89278222|NCT02686502|No Intervention|Mode 1|Current guidelines. Subjects attending the examinations and the tests but not participating the individualized intervention. The subjects will receive general guidance on healthy exercise and diet.
89278223|NCT02686502|Active Comparator|Mode 2|Individualized lifestyle intervention. Exercise intervention will be based on submaximal ergometer test (estimated VO2max), clinical status, personal goals and preferences. Intervention also includes diet counseling, multiprofessional team support, peer support and use of mobile health applications.
89278224|NCT02686502|Active Comparator|Mode 3|Highly individual lifestyle intervention. In addition to Mode 2 arm intervention optimal intensity zones and volumes for individual exercise training will be determined based on advanced cardiopulmonary exercise test.
89278225|NCT04792112|Experimental|Guideline + decision support tool|A decision support tool summarizing harms and benefits of late preterm antenatal corticosteroids will be integrated into the clinical practice guideline available to clinicians in the hospitals in the experimental arm.
89278226|NCT04792112|No Intervention|Guideline only|Clinicians in the hospitals in the 'no-intervention' arm will have access to the standard guideline only (without the integrated decision support tool).
89278227|NCT01237184||biocortical fixation|Bi-cortically fixed implants intentionally engaging sinus floor beyond up to 1-2mm without graft but using stopper drill and self-threading concept
89278228|NCT01237184||unicortical fixation|Short implants placed in proximity of the sinus without sinus floor involvement
89278229|NCT01237184||indirect sinus lift|implants engaging both crest and sinus floor but with green stick fracture
89278230|NCT01242410|No Intervention|Expectant Management|
88805621|NCT01094717|Experimental|tazarotene and active excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and excimer (active) laser to randomly assigned left or right side of body psoriasis lesions.
89278231|NCT01242410|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
89278232|NCT04770662|Other|research group|patients who are willing to participate in the study
89278233|NCT04742582|Active Comparator|Preterm Infants - fed fermented formula|Feeding infants with fermented formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
89278234|NCT04742582|Placebo Comparator|Preterm Infants - fed standard formula|Feeding infants with standard formula milk. Preterm infants will be fed either with fermented formula milk or with standard formula
89278235|NCT04742582|Other|Reference Group: Pre-term Infants - breastfed|The breastfeeding infants were the reference group
89278236|NCT01146392||1|Primary care patients with COPD diagnosis
89278237|NCT02655692|Placebo Comparator|Placebo|Saline dose
89278238|NCT02655692|Experimental|Low Dose Ketamine|Low Dose Ketamine (.20 mg/kg)
89278239|NCT02655692|Experimental|High Dose Ketamine|High Dose Ketamine (.50 mg/kg)
89278240|NCT02243384|Experimental|Laparoscopic Hepatectomy|Laparoscopic Hepatectomy
89278241|NCT02243384|Active Comparator|Radiofrequency Ablation|Radiofrequency Ablation
89278242|NCT01146470|Experimental|RGC 200 mg|
89278243|NCT01146470|Experimental|RGC 400 mg|
89278244|NCT01146470|Placebo Comparator|Placebo|
89278245|NCT04696640|Experimental|Remote Patient Monitoring|All participants who have successfully established remote data-sharing from their glucose monitors to the research team's Glooko account by conclusion of the one-month baseline period will advance to the six-month intervention period.
89278246|NCT01237262|Active Comparator|TNF alfa inhibitors|Male and female adult patients with a diagnosis of moderate to severe psoriasis (when PASI score is > 10 and BSA is > 10%). The overall study enrolment plan is 20 patients. Patients will be screened before the beginning of clinical trial by blood sample in order to exclude major contraindications to use of anti TNF α drugs.
89278247|NCT03913754||Lupus Patients with kidneys failure|Assessment of quality of life on everydays life trough questionnare
89278248|NCT03913754||Lupus Patients without kidneys failure|Assessment of quality of life on everydays life trough questionnare
89278249|NCT03913676|Experimental|Velibra|All treatment will be provided via the Velibra website: https://velibra.broca.io/en/registration/voucher. While the Velibra treatment is only six weeks long, participants will have free access to the program for 24 weeks. They can access this website as often as they would like. The Velibra program is self-guided, so participants determine how often they access the material (the program encourages participants to complete one of six sessions per week for six weeks).
89278250|NCT01147328||1|Patients who did not have their data accessed in the VHR by a provider within 6 months after they consented will be part of the control group
89278251|NCT01147328||2|Patients who had their data accessed in the VHR by a provider within 6 months after they consented will be part of the intervention group
89278252|NCT01329770|Experimental|Ascorbic Acid and alpha-tocopherol|Two daily doses of the combination of antioxidants, administered at breakfast and dinner
89278253|NCT01329770|Placebo Comparator|Placebo|Two daily doses of placebo, administered at breakfast and dinner
89278254|NCT03913520|Other|Congenital Heart Disease|Undergoing evaluation at 30 days
89278255|NCT03644654|Active Comparator|Standard care group|Fluid management will be done according standard care
89278256|NCT03644654|Experimental|Noninvasive monitoring group|Fluid management will be provided using noninvasive hemodynamical monitor ClearSight (Edwards)
89278257|NCT00316589|Experimental|Healthy subjects|Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)
89278258|NCT00316589|Experimental|HIV-infected, vaccinia-naive|Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
89278259|NCT00316589|Experimental|HIV-infected, vaccinia-experienced|Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
89278260|NCT03913364|Experimental|Experimental Obese mothers|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
89278261|NCT03913364|Placebo Comparator|Placebo Obese mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
89278262|NCT03913364|Experimental|Experimental normal weight mothers|One portion (50g) of an ice-cream containing B. bifidum 900791 (>10(exp7)/g) every other day during the last month of gestation and the first month of lactation
89278263|NCT03913364|Placebo Comparator|Placebo normal weight mothers|One portion (50g) of an ice-cream without probiotic every other day during the last month of gestation and the first month of lactation
89278264|NCT01251068|Experimental|gest age, cerebral ,somatic oxygenation measurement|
89278265|NCT01147562|Other|Lung Cancer Patients|Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor
89278266|NCT01048385|Experimental|CoQ10|This group will be treated concomitantly with Coenzyme Q10
89278267|NCT01048385|Placebo Comparator|Control|Treated with capsules containing the vehicle.
89278268|NCT03916640|Experimental|Co-formulation of insulin analog and pramlintide (ADO09)|Subcutaneous injection of ADO09 formulation + injection of placebo (0.9% NaCl) to ensure double dummy.
89278269|NCT03916640|Active Comparator|Humulin® + Symlin®|Simultaneous, separate subcutaneous injections of human insulin and pramlintide.
89278270|NCT03916640|Active Comparator|Humalog®|Subcutaneous injection of insulin lispro + injection of placebo (0.9% NaCl) to ensure double dummy.
89278271|NCT03916250|Experimental|PF-06700841 cream 0%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
89278272|NCT03916250|Experimental|PF-06700841 cream 0.1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
89278273|NCT03916250|Experimental|PF-06700841 cream 0.3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
89278274|NCT03916250|Experimental|PF-06700841 cream 1%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
89278275|NCT03916250|Experimental|PF-06700841 cream 3%|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
89278276|NCT03916250|Experimental|White petrolatum|All participants will have 6 application sites where 6 patches of investigational products will be completely randomly assigned, for the purpose of determining irritation potential
89278277|NCT02533037|Active Comparator|Traditional Instability Tools|Participants will use traditional instability tools during the impairment-based rehabilitation intervention.
89278278|NCT02533037|Experimental|Ankle destabilization shoes|Participants will use ankle destabilization shoes during the impairment-based rehabilitation intervention.
89278279|NCT03916406|Experimental|Sequence 1|midazolam alone followed by combination of PF 06835919 and midazolam
89278280|NCT03916406|Experimental|Sequence 2|PF 06835919 in combination with midazolam followed by midazolam alone
89278281|NCT00316277|Experimental|Buprenorphine/Nx with EMM|
89278282|NCT00316277|Active Comparator|Buprenorphine/Nx with SMM|
89278283|NCT01249352|Active Comparator|STANDARD CHEMORADIATION|"Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles Fluorouracil 1000 mg/m2, IV IV doses in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
89278284|NCT01249352|Experimental|CHEMORADIATION + NIMOTUZUMAB|"Nimotuzumab 200 mg, IV weekly IV doses for up to 26 weeks. Cisplatin 75 mg/m2, IV IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.~Fluorouracil 1000 mg/m2, IV IV dose in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
89278285|NCT03916172|Experimental|APT Treatment|Participants in this arm will receive the Open Door Approach to Parenting Teenagers (APT). It offers 6 weekly 50-minute appointments with an optional 7th review session.
89278286|NCT03916172|No Intervention|Waiting List|Participants in this group will be placed on a waiting list and will receive APT treatment after no longer than 25 weeks.
89278287|NCT03912974|Active Comparator|Pretreatment with escitalopram|Pretreatment with escitalopram (10 mg for 7 days orally, 20 mg for another 7 days orally), followed by administration of psilocybin (25 mg orally) on the study day
89278288|NCT03912974|Placebo Comparator|Pretreatment with placebo oral capsule|Pretreatment with placebo, followed by administration of psilocybin (25 mg orally) on the study day
89278289|NCT00368849|Experimental|40 milligram twice a day atomoxetine|Participants received 40 milligram twice a day atomoxetine for 4 weeks.
89278290|NCT00368849|Placebo Comparator|Twice a day matching placebo|Participants received twice a day matching placebo for 4 weeks.
89278291|NCT01757522||ARDS group|Patients under mechanical ventilation since less than 24 hours at inclusion and presenting acute respiratory distress syndrome criteria.
89278292|NCT01757522||ALI group|Patients under mechanical ventilation and presenting acute lung injury criteria.
89278293|NCT01757522||Control Group|Patients under mechanical ventilation for a non-respiratory cause
89278294|NCT03912896|Experimental|Children with autism spectrum disorder|
89278295|NCT01144676|Experimental|Group A1: Dapivirine Vaginal Ring|
89278296|NCT01144676|Placebo Comparator|Group A2: Placebo Vaginal Ring|
89278297|NCT01144676|Experimental|Group B1: Dapivirine Vaginal Ring|
89278298|NCT01144676|Placebo Comparator|Group B2: Placebo Vaginal Ring|
89278299|NCT00316199|Experimental|A|
89278300|NCT01251224|Active Comparator|Education Group|This group will receive IPM education at baseline, and then the full IPM intervention after completing the study.
89278301|NCT01251224|Experimental|IPM Group|This group will receive the full IPM intervention at baseline.
89278302|NCT01573208|Experimental|Register|Register
89278303|NCT03985475||Person with a skin infection|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
89278304|NCT01147718|Experimental|digoxin plus albiglutide|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of albiglutide, followed by a further single dose of 0.5mg digoxin on Day 38.
89278305|NCT03985553|Other|Parenting Self-Management Program|Participants were provided a Parenting Self -Management Program booklet with the twenty-four fact sheets at the beginning of the four-week program on topics such as adaptive babycare techniques, advocacy in the courts, emergency planning, safety in the community, talking to children about disability, managing pain/fatigue, connecting to other parents with SCI/D, and wheelchair adjustment/management during and after pregnancy. Sessions included topic introduction, participant interaction, goal setting, resource utilization, and program evaluation. Participants were allowed to choose which resources they wanted and what tips to incorporate into their parenting roles. Participants were asked to develop a weekly goal to encourage achievement, allowing individuals to identify what they wanted or decided to do that could be related to parenting directly or indirectly, such as health and wellness goals that gave them more energy or strength to complete parenting tasks.
89278306|NCT03913052|Experimental|Injection|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine was performed once when the knee joint was in the supine position and the knee was in the extension.
89278307|NCT01251302||Prospective Cohort|Patient presenting with chest pain or anginal equivalent and receiving a resulted age, sex and gene expression score (ASGES) to assist in diagnosis.
89278308|NCT01251302||Retrospective Cohort|Patients presenting with chest pain or anginal equivalent who did not receive an age, sex and gene expression score (ASGES) to assist in diagnosis. Note: this cohort was historical.
89278309|NCT03916016|Experimental|Intervention Group|The intervention group received enhanced integrated behavioral health care.
89278310|NCT03916016|Active Comparator|Control Group|The control group received care as usual only.
89278311|NCT03915938|Experimental|Group S-Ketamine|S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.
89278312|NCT03915938|Placebo Comparator|Group Placebo|A previously prepared identical solution containing only normal saline will be infused at the same infusion rates of group ketamine.
89278313|NCT03915782|Experimental|Remote Ischemic Conditioning (RIC) positive|Patients with remote ischemic conditioning
89278314|NCT03915782|Sham Comparator|Control group|The control group will receive a sham procedure (same procedure than Remote Ischemic Conditioning (RIC) with brachial cuff inflation to 30 millimeters (mm) of mercury (Hg) during 40 minutes).
89278315|NCT01237496|Experimental|1|
89278316|NCT03915704|Experimental|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed. The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
89278317|NCT03915704|Experimental|Shotblocker|ShotBlocker is a small, flat, yellow horseshoe-shaped plastic tool that is non-invasive, appropriate for every age group, does not have the characteristics of medication or adverse effects. ShotBlocker has short, blunt points that provide contact with skin on one side, and a hole that exposes the injection site in the middle of the tool. It is used by being held on the skin surface during injection. The pointed surface of the tool is placed on the administration area right before the injection
89278318|NCT03915704|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
89278319|NCT01251458|Experimental|Torisel|
89278320|NCT01416428|Experimental|QDx2 Dosing Schedule|"QDx2 is defined as patients receiving Oprozomib Tablets once daily on Days 1, 2, 8, and 9 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
89278321|NCT01416428|Experimental|QDx5 Dosing Schedule|"QDx5 is defined as patients receiving Oprozomib Tablets once daily on Days 1 to 5 of the 14-day cycle.~The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM."
89278322|NCT00316121|Experimental|1|
89278323|NCT00316121|Active Comparator|2|
89278324|NCT03912740|Active Comparator|Remifentanil Analgesia|Continuous intraoperative analgesia with remifenanil + 0.9% sodium chloride
89278325|NCT03912740|Active Comparator|Remifentanil and Dexmedetomidine Analgesia|Continuous intraoperative analgesia with remifenanil + dexmedetomidine
89278326|NCT01058915|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day for one year
89278327|NCT01058915|Active Comparator|Rosuvaststin 40mg|Rosuvastatin 40mg/day
89278328|NCT00915902|Experimental|Omega-3-acid ethyl esters (Lovaza)|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. GlaxoSmithKline supplied the study drug and the placebo. The study drug, Omega-3-acid ethyl esters (Lovaza) was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week treatment period. The study drug contained minimally 1.5 g DHA (docosahexaenoic acid) and 1.86 g EPA (eicosapentaenoic acid).
89278329|NCT00915902|Placebo Comparator|Placebo|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. The corn oil placebo was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week non-treatment (placebo) period.
89278330|NCT01250132|Other|Moderate to severe Traumatic Brain Injury|"Assessment of hypopituitarism. Blood tests at different moments:~day 0~when leaving intensive care unit~month 3~month 12"
89278331|NCT01147796|Active Comparator|Thrombus|patients with positive TEE (thrombus)
89278332|NCT01147796|Placebo Comparator|No thrombus|patients with negative TEE (no thrombus)
89278333|NCT03912116|Experimental|Amniotic Umbilical Cord Particulate Injection|100mg Amniotic Umbilical Cord Particulate in 8cc saline
89278334|NCT03912116|Placebo Comparator|Saline Injection|8cc saline
89278335|NCT01251692|Experimental|1|A retrospective chart review of 26 eyes of 23 patients with recurrent corneal erosions treated by PTK from 1996 to 2000 was performed. All eyes had failed to respond to conventional therapy. Data regarding the preoperative and postoperative best-corrected visual acuity (BCVA), spherical equivalent (SE), symptomatic relief, incidence of recurrence, and complications arising from the laser treatment were analyzed. The mean duration of symptoms prior to PTK was 18 months (range, 8 to 36 months). The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser. Mean postoperative follow-up was 12 years (range, 10 to 14 years).
89278336|NCT01144832|Placebo Comparator|placebo capsule|
89278337|NCT01144832|Active Comparator|ebastine|
89278338|NCT01147952|Experimental|12 week exercise training|
89278339|NCT01147952|No Intervention|Conventional Care|
89278340|NCT01251848|Active Comparator|Treatment A|
89278341|NCT01251848|Active Comparator|Treatment B|
89278342|NCT01251848|Experimental|Treatment C|
89278343|NCT03911882||Celergen Administration|The food supplement Celergen was administered to fibromyalgia patients following a protocol of a daily intake for the period of a total of 3 months (90 days)
89290222|NCT03934476|Experimental|Ketogenic diet + Exercise HIIT|"Ketogenic diet:~< 50 g carbohydrates - CHO/d (based on the 1-week pre-intervention habitual diet monitoring)~protein restriction ≤ 1.5 g/kg free-fat mass (FFM)/day.~fat type intake recommendation:~natural fats~trans-FA reduction~Exercise intervention:~- HIIT: 5 min warm-up - slow walking, 3 min interval of high-intensity walking (above VT2), 3 min interval of low-intensity walking (40 % VO2peak); 5 min cool-down - slow walking:~Cycle 1~week 1-3 - 3 sessions/week, total time 31 min/session (4 intervals)~week 4 - regeneration: only 2 sessions with 2 intervals, keep total time 31 min/session, (+ GXT)~Cycle 2~week 5-7 - 3 sessions/week, total time 43 min/session (6 intervals)~week 8 - regeneration: only 2 sessions with 4 intervals, total time 31 min/session, (+ GXT)~Cycle 3~week 9-11 - 3 sessions/week, total time 55 min/session (8 intervals)~week 12 - regeneration: only 2 sessions with 6 intervals, total time 43min/session, (+GXT)"
89290223|NCT03934476|No Intervention|Control Group|The study subjects in this arm will undergo no dietary changes and no exercise intervention.
89290224|NCT03163732|Other|Large molecular profiling panel|This panel is FOne Panel with a 324 cancer-related gene.
89290225|NCT03163732|Other|Limited molecular profiling panel|This panel is CONTROL Panel with a 87 cancer-related gene.
89290226|NCT01215474||NSCLC Stadium III-IV|
89290227|NCT01123824|Experimental|Sequence clopidogrel 300/75 mg - 600/150 mg|"Period 1:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Period 2:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
89278344|NCT03911648||Group B;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% caudally, the maximum given volume was 20 ml. N=42
89278345|NCT03911648||Group L;|Patients had 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1% caudally, the maximum given volume was 20 ml. N=44
89278346|NCT03915314||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
89278347|NCT03915314||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
89278348|NCT01250288||Consumers|Consumers (patients or their designated proxies) who have registered to use the personal health management technology platform offered by the Brooklyn Health Information Xchange (BHIX) or Long Island Patient Information Xchange (LIPIX).
89278349|NCT01250288||Providers|Providers who are authorized to view the data entered by consumers in either (1) BHIX's personal health management system, along with BHIX health information exchange data; OR LIPIX's secure messaging system (SMS), along with LIPIX health information exchange data.
89278350|NCT03911804|Experimental|Bolus group|
89278351|NCT03911804|Active Comparator|Infusion group|
89278352|NCT01237652||ISH and normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
89278353|NCT01237652||ISH, Normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
89278354|NCT01252004||TT Syndrome|Will be included over a period of one year, prospectively, all patients newly diagnosed
89278355|NCT01237730|Active Comparator|Cefuroxime group|Use the cefuroxime as prophylactic antiobiotics, according to the clinical guideline.
89278356|NCT01237730|Experimental|Tailored antibiotics group|Tailored antibiotic is selected according to the patient's oropharyngeal microorganisms.
89278357|NCT01148030||Single|3M Skin and Nasal Antiseptic
89278358|NCT01252082|Active Comparator|Scalig and Rootplaning|patients will receive scaling and root planing therapy
89278359|NCT01252082|No Intervention|control|patients in control group will not receive periodontal treatment in the time period of the study
89278360|NCT01252160|Experimental|QUTENZA|Cutaneous patch
89278361|NCT00337103|Experimental|1|
89278362|NCT00337103|Active Comparator|2|
89278363|NCT00415532|Experimental|Romiplostim|Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10^9/L for up to 52 weeks.
89278364|NCT00415532|Other|Standard of Care|Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.
89278365|NCT00315731|Experimental|tositumomab and iodine I 131 tositumomab|Subjects participating in this study will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I-131 tositumomab, immediately following an infusion of 450 mg of unlabeled tositumomab. Using the dosimetric data from three of the six imaging time points and the subject's weight, a patient-specific activity (mCi) of Iodine I-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). All subjects will then receive an infusion of unlabeled tositumomab (450 mg) immediately followed by an infusion of the subject specific dose of tellurium-derived Iodine I-131 tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy.
89278366|NCT03911570||Glucosamine Sulfate Group (GS Group)|GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
89278367|NCT03911570||Control Group|Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).
89278368|NCT01250366|Experimental|Arm 1: INX-08189 (9 mg) or Placebo|
89278369|NCT01250366|Experimental|Arm 2: INX-08189 (25 mg) or Placebo|
89278370|NCT01250366|Experimental|Arm 3: INX-08189 (50 mg + 9 mg) or Placebo|
89278371|NCT01250366|Experimental|Arm 4: INX-08189 (50 mg) or Placebo|
89278372|NCT01250366|Experimental|Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin|
89278373|NCT01250366|Experimental|Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin|
89278374|NCT01250366|Experimental|Arm 7: INX-08189 (100 mg) or Placebo|
89278375|NCT03915080|Other|Oktokog alpha (Advate)|Personalized treatment according to individual PK using intravenous injection of oktokog alpha with dose and dose interval according to MyPKFIT and phenotypic evaluation.
89278376|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
89278377|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
89278378|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
89278379|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
89278380|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant
89278381|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group C)|Patients receiving CTLs following allogeneic stem cell transplant
89278382|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
89278383|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
89278384|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
89278385|NCT00075504|Experimental|triapine, gemcitabine|Triapine IV over 4 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15, repeat every 28 days
89278386|NCT01092390|Experimental|Lovaza|4 grams per day
89278387|NCT01092468|Placebo Comparator|Diathermy|Perforator flap elevation using conventional diathermy technique
89278388|NCT01092468|Active Comparator|Harmonic Scalpel|Perforator flap elevation using Harmonic Scalpel
89278389|NCT01092624|Experimental|Pessary and solifenacin|
89278390|NCT01092624|Placebo Comparator|Pessary and placebo|
89278391|NCT01237574||Patients|Patients with chronic alcoholic and/or metabolic liver disease
89278392|NCT03957096|Experimental|SGN-CD47M|
89278393|NCT00087438|Experimental|Stereotactic body radiation therapy (SBRT)|20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
89278394|NCT00321464|Active Comparator|zoledronic acid|
89278395|NCT00321464|Experimental|denosumab|
89278396|NCT02889796|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)
89278397|NCT02889796|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX
89278398|NCT02889796|Active Comparator|Adalimumab|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX
89278399|NCT02889796|Experimental|Placebo to Filgotinib 200 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
89278400|NCT02889796|Experimental|Placebo to Filgotinib 100 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
89278401|NCT02889796|Placebo Comparator|Placebo Never Received Filgotinib|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.
89278402|NCT03911258|Experimental|Nasal flora in CF patient|
89278403|NCT01237808|Active Comparator|Standard arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) without ATRA
89278404|NCT01237808|Experimental|Investigational arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)
89278405|NCT03911024|Active Comparator|HIV|
89278406|NCT03911024|Placebo Comparator|General Health|
89278407|NCT01252316|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
89278408|NCT01252316|Active Comparator|Recruitment with Volunteers|UPHS volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
89278409|NCT01252316|Active Comparator|Recruitment with Nurses|UPHS Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
89278410|NCT01252316|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
89278411|NCT03911180|Experimental|PFN straight parallel blade|All patients with pertrochanteric fracture that is eligible will undergo PFNA with straight parallel blade.
89278412|NCT01148108|Experimental|Mantle Cell Lymphoma|Patients with relapsed or refractory mantle cell lymphoma
89278413|NCT01148108|Experimental|Diffuse Large B Cell Lymphoma|Patients with relapsed or refractory diffuse large B cell lymphoma
89278414|NCT01148108|Experimental|Multiple Myeloma|Patients with relapsed or refractory multiple myeloma
89278415|NCT01252394||Hemodialysis patients|
89278416|NCT03910946||diabetic and renal|all cases included in the study will be subjected to : Full clinical history to rule out active TB ( history of current prolonged cough, haemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, fatigue.) Chest x ray TST (tuberculin sensitivity test) : injecting a 0.1 mL of liquid containing 5 TU (tuberculin units) PPD (purified protein derivative) into the top layers of skin of the forearm and read skin tests 48-72 hours after the injection
89278417|NCT01250444|Experimental|Inspiratory Muscle Training|It will me performed a loaded training of ventilatory muscles in patients with Hypertension. Its is done with the practice of breathing exercises associated to an training device, specific for this kind of intervention.
89278418|NCT03910790|Experimental|19 Gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle
89278419|NCT03908762|Experimental|iSage|The provider will choose a treatment algorithm embedded within the app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The app is downloaded by the patient while in the examination room, and the patient is instructed to perform daily fasting glucose fingerstick measurements and follow the app's recommendations for insulin adjustment. Data on telephone or visit contact with a healthcare provider will be collected via the EMR. Hypoglycemic events (defined as blood glucose <70 mg/dl, measured or perceived) are recorded in the iSage application as well as patient report. Providers are asked to review the patients transmitted blood sugar logs as necessary, and those reviews are recorded. Return visits are managed by the HCP and will be logged as resource utilization.
89278420|NCT03908762|Active Comparator|Conventional Management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet. In the case of glargine or detemir (Basaglar, Lantus, Levemir) adjustments of 1 unit of insulin/day are made until the fasting blood sugars (2 of 3 consecutive values) are 80-130 mg/dl. In the instance of Toujeo or Tresiba, adjustments of 2 units are made every 5 days. Volunteers will have meters downloaded (or interviewed where necessary) to obtain data on fasting blood sugar and episodes of hypoglycemia (perceived or measured <70 mg/dl). The PCP is free to request glucose logs and set return appointments as needed to manage the patient.
89278421|NCT03910634|Experimental|IMRT combined with carboplatin|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
89278422|NCT03910634|Placebo Comparator|IMRT combined with carboplatin and fluorouracil|Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
89278423|NCT03910712|Experimental|Pyrotinib and trastuzumab plus aromatase inhibitor|Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89278424|NCT03910712|Active Comparator|Trastuzumab plus aromatase inhibitor|Participants will receive trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89278425|NCT01252472||Flomax|Male patients scheduled for cataract surgery with current or past use of Flomax
89278426|NCT01252472||Control|Male adult patients scheduled for cataract surgery with no history of Flomax use
89278427|NCT01250600|Experimental|Remote-care|Home exercise monitored by the remote care system
89278428|NCT01250600|Active Comparator|Control|Home exercise under expert's instruction
89278429|NCT02528474|Experimental|Pantera Lux|
89278430|NCT02528474|Active Comparator|SeQuent Please|
89278431|NCT03908606|Experimental|Periodontitis patients with diabetes type 2|scaling and root planing was administered to all patients. Serum samples were collected before and after treatment to assess hs-CRP levels. Glycated hemoglobin was measured before and after treatment
89278432|NCT03908606|Experimental|Periodontitis patients|scaling and root planing will be done to periodontitis patients. Serum samples were collected before and after treatment to assess hs-CRP levels.
89278433|NCT03908606|No Intervention|Healthy control group|We measured serum levels of hs-CRP in all healthy control subjects
89278434|NCT01250678||neurocognitive impaired|MS patients treated with natalizumab who at the beginning of the study suffer from cognitive impairment
89278435|NCT01250678||neurocognitive non-impaired|MS patients treated with natalizumab who at the beginning of the study do not suffer from cognitive impairment
89278436|NCT03910556||no complication|the patients who did not develop any kind of complication and no re-craniotomy
89278437|NCT03910556||with complication (s)|the patients who developed at least one of non-neurological complication or required re-craniotomy
89278438|NCT03659578|Experimental|Thymosin α1|Patients are treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
89278439|NCT03910322|Placebo Comparator|Placebo|Placebo arm. Similar trial product, but without Bif195 bacteria
89278440|NCT03910322|Experimental|Low-dose Bif195|Active trial product with minimum 15 billion CFU daily dose
89278441|NCT03910322|Experimental|High-dose Bif195|Active trial product with minimum 50 billion CFU daily dose
89278442|NCT01148186|Experimental|Educational intervention|Administration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.
89278443|NCT01148186|No Intervention|Wait-list group|
89278444|NCT01252550|Active Comparator|Activia®|Activia® (125g/pot)
89278445|NCT01252550|Placebo Comparator|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
89278446|NCT01253486|Experimental|Disease-related expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period
89278447|NCT01253486|Active Comparator|Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
89278448|NCT01253486|Sham Comparator|Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
89278449|NCT01253486|No Intervention|Control condition|Participants in the control condition do not receive any intervention and complete only the assessments
88805622|NCT01094717|Experimental|tazarotene and sham excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and sham excimer laser to randomly assigned left or right side of body psoriasis lesions.
89278450|NCT02889562|Active Comparator|Apixaban|"Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in dose modifications. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
89278451|NCT02889562|Active Comparator|Warfarin|"While patients are hospitalized, warfarin will be dosed daily, with daily INR monitoring per hospital protocol. Daily doses may vary from 0.5mg to 15mg by mouth, as determined by patient specific factors such as patient size, hepatic function, INR, concomitant medications, diet, or other factors. Based on these factors or others not listed, there may also be days in which the patient is prescribed to not get does not receive a dose of warfarin.~After discharge from the hospital, warfarin dosing will be subsequently managed by an anticoagulation clinic, per established protocols. All patients will have a goal INR of 2-3 during the duration of the study. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
89278452|NCT03914768|Experimental|Immunomodulatory DC vaccine to target DIPG and GBM|Patients will receive immune modulatory treatment consisting of cyclophosphamide (200 mg/m2) and bevacizumab (15 mg/kg), before and after DC vaccine injection, respectively.
89278453|NCT03915236|Experimental|Group 1: MON4STRAT Strategy|
89278454|NCT03915236|Active Comparator|Group 2: Conventional treatment|
89278455|NCT03323164|Active Comparator|Timolol|Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.
89278456|NCT03323164|Active Comparator|Brimonidine|Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.
89278457|NCT03914690|Experimental|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Centre Configuration, melted configured with saline to 1ml/kg solution.
89278458|NCT03914690|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
89278459|NCT03914456|Experimental|Body Weight Supported Treadmill Training|"The rehabilitation program consisted of five hours per day of the treatment, five times a week for two months (40 sessions). The treatment protocol included kinesiotherapy (passive and active mobilizations, muscle lengthening), BWSTT, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training. The duration of each event was approximately one hour.~The initial time of the treatment on the BWSTT was 20 minutes, and the modification of the time depended on the endurance and capability of each patient. Training charge began at 40% body weight supported and at treadmill speeds of at least 1.5 km per hour. The treadmill speed was increased progressively to 2.5 km per hour, and the level of weight supported was adjusted within sessions to achieve knee extension."
89278460|NCT03323086|Experimental|Brief Intervention (BI) with Technology Extender|Participants assigned to BI condition will receive a face to face session lasting 45-60 minutes delivered by a health coach. Following the session, participants will be given access to a study website and receive texts-of-the day on study topics.
89278461|NCT03323086|Other|Brochure|Participants assigned to the Brochure condition will receive materials prepared by the Centers for Disease Control and Prevention on the study topics.
89278462|NCT03908294||Chronic hepatitis C under antiviral treatment with DAA|Patients with chronic hepatitis C infection and planned DAA treatment are enrolled prospectively. Parameters of glucose metabolism and liver fibrosis are measured at baseline, during therapy and up to one year after end of treatment.
89278463|NCT03914534|Experimental|Test Formulation of Valproic Acid|Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2
89278464|NCT03914534|Active Comparator|Reference Formulation of Valproic Acid|Valcote tablets 500 mg Single dose administered in dosing period 1 or 2
89278465|NCT03913988|Active Comparator|LUCID DREAMING, STRESS REDUCTION, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:~Psychoeducation regarding lucid dreaming, stress reduction, and sleep hygiene~Practice of lucid dreaming induction techniques~Guided visualization~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
89278466|NCT03913988|Active Comparator|LUCID DREAMING, SLEEP HYGIENE|"This group will meet for 6 online sessions, every other week, over the 12-week study. Each online session will run for 1 hour. Each of the 6 sessions will consist of the following:~Psychoeducation regarding lucid dreaming and sleep hygiene~Practice of lucid dreaming induction techniques~Guided visualization~Opportunity for participants to discuss their experience with lucid dreaming induction techniques, adherence to the lucid dreaming home exercise program and tracking log, using their dream diaries, and adherence to the sleep hygiene program and tracking log."
89278467|NCT03913988|Active Comparator|SLEEP HYGIENE|"This group will meet for 2 online group sessions and 4 email communications. The 2 online group sessions will each last 1 hour and occur in weeks 1 and 12. The 4 email communications will occur in weeks 3, 5, 7, and 9 and consist of individual communication between each participant and the PI or co-investigator. Each email communication will require 10 minutes of participants' time.~The control group will be asked to engage in Sleep Hygiene techniques in which they adhere to a recommended protocol and record their adherence in a Sleep Hygiene Tracking Log, requiring 5 minutes per day.~Through the 2 online sessions and the individual email with the investigators, participants will have the opportunity to discuss their experience with adherence to the sleep hygiene program and tracking log. Investigators will help participants trouble shoot problems adhering to the sleep hygiene protocol."
89278468|NCT03914222|Other|CardioSpire Device|Patients blows into Respirix device or uses BIPAP machine for a few breaths solely to obtain signal.
89278469|NCT03910400|Experimental|MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
89278470|NCT03910400|Experimental|Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
88805623|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 1|
89278471|NCT02888080|Experimental|ACZ885|ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
89278472|NCT02888080|Placebo Comparator|Placebo|Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
89278473|NCT03910088|Placebo Comparator|control group|received conventional treatment in the form of good oral hydration, 500 mg of acetaminophen plus 65 mg of caffeine oral tablets thrice daily, 3 cups of coffee daily, 50 mg of diclofenac potassium oral tablets twice daily and recumbent positioning for 48 hours
89278474|NCT03910088|Active Comparator|Pregabalin|received the conventional treatment plus 100 mg of pregabalin oral tablet every 8 hours for 48 hours
89278475|NCT03910088|Active Comparator|Hydrocortisone|received the conventional treatment plus 100 mg of hydrocortisone IV every 8 hours for 48 hours.
89278476|NCT03610438|Experimental|Cohort 1|Cohort 1 will entroll 38 Ph+ patients
89278477|NCT03610438|Experimental|Cohort 2|Cohort 2 will enroll 38 Ph- patients
89278478|NCT03909932||Patients enrolled in the cross-sectional study|Patients over 18 years old, consulting in neuro-urology department.
89278479|NCT03908372|Experimental|Induction chemotherapy(IC)+IMRT|Induction chemotherapy for two cycles, the patients with complete response will receive 60 Gy to the gross target volume of nasopharynx, partial response 64 Gy, and the absence of response will receive concurrent chemoradiotherapy as the same as CCRT arm
89278480|NCT03908372|Active Comparator|Concurrent chemoradiotherapy(CCRT)|cisplatin 100mg/m2 IV on d1 of each 21 days for two cycles at least and 70 Gy radiotherapy
89278481|NCT03322462|Experimental|Flortaucipir PET Scan|
89278482|NCT03908138|Active Comparator|RDD group|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
89278483|NCT03908138|Active Comparator|VDD group|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
89278484|NCT05617664|Placebo Comparator|patients with primary nocturnal enuresis will be followed up with behavioral therapy alone.|
89278485|NCT05617664|Active Comparator|patients with primary nocturnal enuresis will take desmopressin 120 mcg oral tablets.|
89278486|NCT05617664|Active Comparator|patients with PNE will take mirabegron 25 mg oral tablets.|
89278487|NCT01252862|Experimental|Two iStents devices|Two iStents devices will be implanted
89278488|NCT03909776|Active Comparator|IA group|Cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion.
89278489|NCT03909776|Sham Comparator|IV group|Cisplatin was given at 100-120 mg/m2 as 6-h infusions.
89278490|NCT01253096|Experimental|L19IL2|
89278491|NCT03913910||Lipogems|Lipogems injection in the internal orifice, mucosal, submucosal and muscular layer, in the fistula tract and external orifice.
89278492|NCT03914144||Normal Vaginal Delivery|The group of patients who achieved a normal delivery will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
89278493|NCT03914144||Insturmental Vaginal Delivery|The group of patients who underwent instrumental delivery (ventouse or forceps) will be retrospectively assessed as to whether they had any episode of catheter insertion during their delivery.
89278494|NCT03914144||Emergency Caesarean Section|Each patient will be recorded how many catheter episodes occurred during their labour and delivery.
89278495|NCT03914144||Elective Caesarean Section|We expect all patients in this group to have an indwelling catheter sited before their elective caesarean sections, however we will assess each patient individually to confirm whether they had a catheter for their delivery.
89278496|NCT01148264|Experimental|olanzapine|
89278497|NCT01148264|Active Comparator|metoclopramide|
89278498|NCT03909464||Patients receiving neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving known neurotoxic agents. Common neurotoxic agents include vinca alkaloids (ie. vincristine), taxanes (ie. Taxol), platins (ie. Oxaliplatin) and some other drugs beyond these categories (ie. Bortezomib).~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:~EORTC-QLQ CIPN20 Questionnaire~Michigan Neuropathy Screening Instrument Questionnaire"
89278499|NCT03909464||Patients receiving non-neurotoxic chemotherapy regimen|"Patients receiving chemotherapy regimens involving agents with negligible or doubtful risk of neurotoxicity.~Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device, as well as completing two questionnaires at each visit:~EORTC-QLQ CIPN20 Questionnaire~Michigan Neuropathy Screening Instrument Questionnaire"
88805624|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 2|
88805625|NCT05308121||Group: Pregnant women (first pregnancy)|This group will consist of women in the first trimester of pregnancy. Pregnant women will be evaluated 3 times in total, each measurement being in a different trimester.
89278500|NCT03907358||cataract in old age|
89278501|NCT03907358||cataract in young age|
89278502|NCT03909308|No Intervention|Control session|Control session without any exercise. The participants remained in seated rest throughout 45 min.
89278503|NCT03909308|Experimental|Beach Tennis session|The participants performed a beach tennis training session throughout 45 min.The session started with a standardized 5-minute warm-up consisting of basic techniques (i.e., serve, volley, forehand, and backhand) followed by three 12-minute beach tennis matches with 2-minute intervals between the games. We used regular beach tennis rules in the game, which was played on a regular beach tennis court (i.e., 16 m long by 8 m wide and net 1.70 m high).
89278504|NCT01253252|Experimental|Specific procedure|"A [18F] Fluorodeoxyglucose PET Scan Imaging will be added to their conventional follow up (CT scan, usual blood sampling, ECG…) i.e. within one month before endovascular surgery (inclusion visit), at one month and 6 month of follow-up.~Furthermore, blood sampling for biological investigations (biological markers of the inflammation, proteolysis and coagulation potentially related to morphology and evolution of AAA) will be done."
89278505|NCT00086580|Experimental|Combination Arm (FluCAM)|
89278506|NCT00086580|Active Comparator|Fludarabine Alone|
89278507|NCT03908996|Experimental|Profile by Sanford|All enrolled subjects are assigned to participate in the Profile by Sanford weight management program for a period of 12 months..Subjects will follow the Profile program and will be provided a nutritional plan which includes consuming Profile nutritional supplements and other food items. Subjects will work with a Profile lifestyle coach to develop a personalized nutrition plan, discuss their activity, and lifestyle behavior. Subjects on this research study will follow the Profile by Sanford weight loss and management plan as all Profile members. All enrolled subjects will collect and return a fecal specimen prior to beginning the Profile by Sanford weight management plan and again after 6 months of participation.
89278508|NCT03908840|Experimental|TBI 302 Safety, Tolerability|5 Cohorts, Dose escalation TBI 302 will be formulated in 0.9% saline. TBI 302 in a syringe will be administered over approximately 1 hour under constant observation once per week for 4 weeks (on Days 1, 8, 15 and 22).
89278509|NCT01253330|No Intervention|Comparison 1st|Not enrolled in the CMSText website text messaging system during last 3 months of study participation.
89278510|NCT01253330|Experimental|Participant 1st|Enrollment in the CMSText website text messaging system during first 3 months of study participation.
89278511|NCT03908918|Experimental|Active group|Mobile-app delivered mindfulness intervention. Dosage: 4 times per week for 4 weeks
89278512|NCT03908918|Other|Waitlist control|Waitlist control - receiving the app after 6 months
89278513|NCT03908528|Experimental|Chemotherapy plus Placebo for six Months|• Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus Placebo.
89278514|NCT03908528|Experimental|Chemotherapy plus alpha lipoic acid for six Months|• Group two: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks in addition to oral 600 mg alpha lipoic acid (ALA) once daily.
89278515|NCT04850170|Experimental|Experimental group|"The first ten subjects will be enrolled in a pilot study. The following sixty subjects will be separated randomly to experimental group and control group.~The first ten subjects and the experimental group will be arranged manual therapy and rehabilitation for six months."
89278516|NCT04850170|Active Comparator|Control group|The control group will be arranged rehabilitation.
89278517|NCT03903458|Experimental|Tinostamustine and Nivolumab|Experimental drug combination arm
89278518|NCT03584542||Patients in general practitioners' offices|No interventional study. Only one questionnaire will be done
89278519|NCT03584542||Patients of specialized centers for drug addict patients|No interventional study Only one questionnaire will be done
89278520|NCT03584542||General practitioners|No interventional study Only one questionnaire will be done
89278521|NCT00086502|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg
89278522|NCT00086502|Placebo Comparator|Placebo|Placebo
89278523|NCT03903302|Active Comparator|CS 1 I SAD|Single dose pharmacokinetics of CS1 I
89278524|NCT03903302|Active Comparator|CS 1 II SAD|Single dose pharmacokinetics of CS1 II
89278525|NCT03903302|Active Comparator|CS 1 III SAD|Single dose pharmacokinetics of CS1 III
89278526|NCT03903302|Active Comparator|CS 1 II MAD|Multiple dose pharmacokinetics of CS1 II
89278527|NCT03620656||The smartphone group|Patients recruited from the cardiology ward where 10 different smartphone devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor Smartphone devices and gold-standard 12-lead ECG to determine the diagnostic accuracy.
89278528|NCT03620656||The smartwatch group|Patients recruited from the cardiology ward where 2 different wearable devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor wearable and gold-standard 12-lead ECG to determine the diagnostic accuracy.
89278529|NCT02528084|Experimental|yoga intervention|patients in the group are asked to follow an online video instructing them various yoga poses. Patients in this group are asked to do the yoga exercises 2-3 times a week, for a total of 6 weeks.
89278530|NCT02528084|Experimental|standard exercises intervention|patients in this group are asked to follow an online standard exercises video. Patients in this group are asked to follow specific exercises 2-3 times a day, for a total of 6 weeks.
89278531|NCT02528084|No Intervention|control|patients in this group carry forth with their daily activities. They are not asked to follow the online yoga video or the online standard exercise video.
89278532|NCT03907592|Experimental|L-carnitine Group|Group participated in the training protocol and supplemented by 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout 24 weeks.
89278533|NCT03907592|Experimental|Leucine Group|Group participated in the training protocol and supplemented by 4000mg of L-leucine per day throughout 24 weeks.
89278534|NCT03907592|Experimental|Control Group|Group participated in the training protocol without any supplementation throughout 24 weeks.
89278535|NCT01313338||Acute coronary syndrome|
89278536|NCT03907436|Sham Comparator|USDA diet arm|Participants will receive dietician counseling based on the USDA guidelines for Americans, 2010. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the Mediterranean arm.
89278537|NCT03907436|Experimental|Mediterranean diet arm|Participants will receive dietician counseling on a standard Mediterranean diet although they will not be told this diet is labelled as a Mediterranean diet. Participants will receive 10 weekly pdf handouts via email with information pertaining to these diet recommendations. Participants will receive same surveys (including 14 point Mediterranean diet adherence score), 24 hour diet recalls, and biological sample draws at the USDA diet arm.
89278538|NCT03001024|Experimental|Implementation of WayToServe Español|The experimental design to be employed in the trial evaluation of WayToServe Español (WTS-E) in this direct-to-Phase II project is a two-arm randomized field trial design (WTS-E vs. Usual and Customary [UC] training) with three assessment points (pretest - immediate post-test - 9 month follow-up).This constitutes a 2 (level of RBS training intervention) x 3 (level of time assessment) mixed factorial design. Spanish dominant onsite and off-site licensed alcohol premises will be the unit of analysis, stratified by type of premise (onsite vs. off-site sales) and state (New Mexico vs. Texas).
89278539|NCT03001024|Active Comparator|Usual and Customary RBS Training|The Investigators have carefully considered the over-time assessment factor in this design, and have chosen two follow-up assessments over a 9 month-period because a) our prior WayToServe® trials have shown that an immediate post-training assessment will document intervention effects when training effects are at optimum levels immediately after the training; b) the sustained effect of WTS-E needs to be demonstrated to show long-term not just short-term impact (9 months being between our previous 6-month and 1-year follow-ups). Finally, c) all follow-ups can be completed within the approximately 2-year period of a Phase II project. The immediate post-training assessment will occur for both arms of the design, one month after premises in the intervention arm are given access to WTS-E.
89278540|NCT03636542|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
89278541|NCT03636542|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
89278542|NCT03305770|Experimental|DD T2|Verofilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
89278543|NCT03305770|Active Comparator|DT 1|Delefilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
89278544|NCT03898622|Active Comparator|Group with levothyroxine|Patients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. That meet the inclusion criteria. Levothyroxine 25 mcg (1/4 tablet of 100mcg) was administered in fasting the first month, the doctor evaluated with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 uim / L the second month increase to a dose of 50 mcg (1/2 tablet of 100mcg fasting, or similarly if the patient had a TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5u / L ) to complete three months of intervention.
89278545|NCT03898622|Placebo Comparator|Group Placebo|"atients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. that meet the inclusion criteria.~Placebo (1/4 tablet) was administered in fasting the first month, the doctor assessed with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 UM / L the second month increase at a dose (1/2 tablet fasting, or similarly if the patient had TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5 / month) to complete three months of intervention."
89278546|NCT03907514|Experimental|Intervention Group (IG)|"The adolescents in this group will use the FALE application through a smartphone in the waiting room before the dental appointment. When starting to answer the application, the adolescent will report his/her level of dental anxiety through the question, How do you feel about coming to see your dentist today?, and record his/her answer on a seven-point face scale. Then the participant will continue to answer the 12 other questions, and finally registers his/her anxiety level once more through the same question."
89278547|NCT03907514|No Intervention|Control Group (CG)|"Similarly to IG, the adolescents in this group will use the FALE application through a smartphone, but only to record their level of anxiety by answering the question How do you feel about coming to see your dentist today? using a seven-point face scale. Instead of continuing to answer the other questions, the application will guide him to wait for the one-minute interval (expected time to answer the questionnaire) and, once more, ask the same question regarding his/her feeling about the experience with the dentist."
89278548|NCT00086190|Active Comparator|paroxetine|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
89278549|NCT00086190|Active Comparator|venlafaxine extended release|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
89278550|NCT00086190|Placebo Comparator|placebo|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
89278551|NCT01256372|Experimental|AP214; dose-level 1|AP214; dose-level 1
89278552|NCT01256372|Experimental|AP214; dose-level 2|AP214; dose-level 2
89278553|NCT01256372|Placebo Comparator|Placebo to AP214|Placebo
89278554|NCT03320824|Experimental|New Dermal Filler|hyaluronic acid
89278555|NCT03320824|Active Comparator|Dermal Filler|hyaluronic acid
89278556|NCT03898544||Group primary TKA|Patients operated of primary TKA Stryker for knee osteoarthritis.
89278557|NCT03898544||Group TKA revision|Patients operated of a first revision of TKA for a mechanical failure, with the revision Stryker TKA
89278558|NCT01150292|Experimental|DHA - Sunflower oil|400 mg DHA supplementation by day for 2 weeks then placebo for 2 weeks after a wash out period of 6 to 9 weeks
89278559|NCT01150292|Experimental|Sunflower oil - DHA|Placebo during 2 weeks then 400 mg DHA supplementation by day for 2 weeks after a wash out period for 6 to 9 weeks
89278560|NCT01760291|Experimental|WATCHMAN|WATCHMAN LAA Closure Technology
89278561|NCT03982355||Breast Cancer|Anonymised MRI scans (pre-therapy) of locally advanced breast cancer sufferers.
89278562|NCT03982355||Rectal Cancer|Anonymised MRI scans (pre-therapy) of locally advanced rectal cancer sufferers.
89278563|NCT03275350|Active Comparator|XR-NTX|Extended-release naltrexone
89278564|NCT03275350|Active Comparator|TAU|Treatment as usual
89278565|NCT01254734|Experimental|Arm I|Patients undergo transoral robotic microsurgery.
89278566|NCT04783714|Experimental|Active Group|"Active treatment comprises of 3 soft gel capsules daily (with food) of Swisse Nutra+ Cholesterol Balance, a novel combination nutraceutical containing bergamot juice extract, artichoke leaf extract, hydroxytyrosol and plant sterols, totaling a daily dose of 375 mg bergamot juice extract, 150 mg artichoke leaf extract, 50 mg hydroxytyrosol and 1.8 g sunflower phytosterols.~Each capsule contains 125mg of bergamot juice extract, 50mg artichoke leaf extract, 16.67mg hydroxytyrosol and 600mg plant sterols.~The intervention will be administered for 4 months (112 days)."
89278567|NCT04783714|Placebo Comparator|Placebo|3 soft gel capsules of matching placebo daily (total daily dose of 696 mg palm olein and 232 mg olive oil).
89278568|NCT03903146|Experimental|Intervention Group|This group of participants was assigned to receive the intervention by the bicultural/bilingual team of Peer counselor and Lactation Consultant. An intensive support intervention (1 prenatal visit, 1 in-hospital visit, 1 home postpartum visit, and free phone calls) were conducted individually to mothers participating until 6 months after the birth of the infant.
89278569|NCT03903146|No Intervention|Control Group|All participants in this group received traditional prenatal care in the clinic and received the usual educational material (in their proficient language) about breastfeeding during prenatal care provided by the Special Supplemental Nutritional for Women, Infants, and Children (WIC) program implemented in the clinics. Women were also able to receive one breastfeeding consultation during their hospital stay in the birthing center as part of the actual protocol established in the UK Chandler Hospital (Baby-friendly Hospital that includes support of breastfeeding during hospital stay). Women in the usual care group did not have any contact with the study IBCLC/PC.
89278570|NCT03557242|Other|Warfarin plus Aspirin|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
89278571|NCT03557242|Other|Aspirin Monotherapy|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
89278572|NCT03557242|Other|Registry Arm|Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g. atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
89278573|NCT01150370|Experimental|Males undergoing circumcision|
89278574|NCT01256528|Experimental|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
89278575|NCT01150448|Experimental|001|Paliperidone palmitate Treatment A All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
89278576|NCT01150448|Experimental|002|Paliperidone palmitate Treatment B Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq patients who do not wish to have multiple blood samples collected will also be assigned to Treatment B
89278577|NCT03898466|Experimental|Fluticasone Furoate|"Daily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
89278578|NCT03898466|Placebo Comparator|Matching Placebo|"Daily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours.~The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints"
89278579|NCT03319732|Experimental|AERT 80 mg|Arbaclofen extended release tablet, 20 mg
89278580|NCT04531384|Experimental|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 weekly individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants.
89278581|NCT04531384|Other|treatment as usual|Participants in the treatment-as-usual group were offered standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions, which consisted of weekly group and/or individual therapy, as determined by the clinical team.
89278582|NCT02870530|Experimental|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
89278583|NCT01150526|Placebo Comparator|Placebo|Oral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
89278584|NCT01150526|Experimental|CaHMB Pre|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
89278585|NCT01150526|Experimental|CaHMB Pre and Post|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
89278586|NCT01150526|Experimental|HMB Free Acid Gel Pre|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
89278587|NCT01150526|Experimental|HMB Free Acid Gel Pre and Post|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
89278588|NCT01150604|Experimental|Self-help course|
89278589|NCT02868970|Other|Community (2 in NB, 2 from NS)|There are four communities involved in the study, two in New Brunswick and two in Nova Scotia. All pharmacies in each community will be allocated to one intervention. Interventions include: High-Dose TIV, Meningococcal B Vaccine, Meningococcal ACWY vaccine, Tdap, Herpes Zoster vaccine and Travel Health vaccines (Hepatitis A, Hepatitis B, Typhoid Fever).
89278590|NCT01256606||Positive for fetal aneuploidy|
89278591|NCT01256606||Negative for fetal aneuploidy|
89278592|NCT01254812||Bilateral dual TAP-block|
89278593|NCT01254812||Placebo Bilateral dual TAP-block|
89278594|NCT03902834|Experimental|Intervention|
89278595|NCT03304522|Experimental|VX-150|
89278596|NCT03304522|Placebo Comparator|Placebo|
89278597|NCT03902990|Experimental|Dual task|Treadmill training + cognitive tasks + standard exercise programme
89278598|NCT03902990|Active Comparator|Single task|Treadmill training + standard exercise programme
89278599|NCT03902990|Active Comparator|Control|Standard exercise programme
89278600|NCT03907202|Active Comparator|KBP-089|"Three cohorts:~Cohort 1: starting dose 5 µg, maximum dose 20 µg, uptitration step 7 days, dose increment 5 µg~Cohort 2: starting dose 7.5 µg, maximum dose 60 µg, uptitration step 3 days, dose increment 7.5 µg~Cohort 3: starting dose 5 µg, maximum dose 120 µg, uptitration step 3 days, dose increment 5, 10, 15 and 20 µg"
89278601|NCT03907202|Placebo Comparator|Placebo|For all the cohorts, sentinel dosing for the first two patients will be performed 1:1 in a blinded manner.
89278602|NCT03903068|Experimental|NEXALIN Stimulator Group|In this study, the group is the treatment group. Patients are randomly assigned to participate, and patients will be given current parameters for setting time and flow.
89278603|NCT03903068|Sham Comparator|Pseudo-Stimulator Group|In this study, the group is the control group. Patients are randomly assigned to participate, and patients will be given simulated electrical stimulation.
89278604|NCT03446170|Experimental|Loss-framed, branded|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on branded packages.
89278605|NCT03446170|Experimental|Loss-framed, plain|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on plain or standardized packages.
89278606|NCT03446170|Experimental|Gain-framed, branded|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on branded packages.
89278607|NCT03446170|Experimental|Gain-framed, plain|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on plain or standardized packages.
89278608|NCT03446170|No Intervention|Control|Participants assigned to this arm use their regular cigarette packs and complete study measures only.
89278609|NCT04613050|Active Comparator|Group A (Respiratory Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive respiratory training for 6 weeks.
89278610|NCT04613050|Active Comparator|Group B : (Aerobic Training Group)|It will include 30 patients of both sexes, recovered from COVID-19 infection. In addition to medical drugs, they will receive aerobic training for 6 weeks
89278611|NCT04613050|No Intervention|Group C : (control group)|It will include 20 patients of both sexes, recovered from COVID-19 infection on medical drugs only will receive no exercise as control group.
89278612|NCT03902678|Experimental|EUS - FNA for benign PVT by imaging|Intervention: Procedure/Surgery: EUS guided fine needle aspiration of portal vein thrombus
89278613|NCT03315286|Experimental|Device: SHADE Ultraviolet Sensor|Patients will receive an Ultraviolet (UV) sensor that will quantify their UV exposure through a linked smartphone application. Patients will also receive clinical counseling by their dermatologist regarding sun protection and avoidance
89278614|NCT03315286|Active Comparator|Standard of Care Counseling|Patients will receive clinical counseling by their dermatologist regarding sun protection and avoidance
89278615|NCT01253720|Experimental|PACE CALL/Fit4Life|"Fit4Life intervention activities:~Website: Provides weekly nutrition, physical activity, and weight loss information.~Counseling Calls: Participants and their parents will get phone calls from their Health Coach to assess progress & problems.~Health Coach Question & Answer: Participants will be assigned a Health Coach that they can contact at any time to ask questions or express any concerns.~Text & Picture Messages: Participants will receive daily text messages to help remind them of being healthy. Messages will relate to the weekly topics and general checking in questions.~Parent Materials: Parents will receive a packet of printed materials that relate to parenting skills regarding being a healthy role model for their child and healthy eating and exercise tips."
89278616|NCT01253720|No Intervention|Control|The Control group will receive monthly mailings on basic nutrition and physical activity information.
89278617|NCT03897686|Experimental|NOLTREX™, II-III grade OA|72 patients with II-III grade of gonarthrosis will randomised to receive PAHG
89278618|NCT03897686|Placebo Comparator|Placebo, II-III grade ОА|72 patients with II-III grade of gonarthrosis will randomised to receive saline solution
89278619|NCT03897842|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
89278620|NCT02527772|Experimental|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8;Liposomal Doxorubicin 30mg/m2,d1.q4w
89278621|NCT02527772|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks
89278622|NCT03273946||Subjects receiving fluticasone propionate|Eligible subjects will receive FP 50 µg twice daily inhaled via a pediatric pMDI with a face mask in clinical practice.
89278623|NCT01150916|Active Comparator|Heart failure|Patients must fulfill Framingham and/or Boston criteria for heart failure and have systolic or diastolic disfunction in rest echocardiography.
89278624|NCT01150916|Active Comparator|Liver Cirrhosis|Patients must have a biopsy proven diagnosis of liver cirrhosis or the diagnosis established on clinical basis in cases of known etiology of liver disease, peripheral signs of chronic liver disease, esophageal varices at endoscopy and an imaging method with evidence of cirrhosis.
89278625|NCT01150916|Active Comparator|Other causes of ascites|Patients must fulfill stringent diagnostic criteria for the cause of ascites, by clinical criteria, laboratory and imaging tests and histology when appropriate.
89278626|NCT01150916|Active Comparator|Concurrent heart failure and cirrhosis|Patients must fulfill the aforementioned criteria for both conditions.
89278627|NCT00660218|Experimental|Radiation therapy, cetuximab, paclitaxel poliglumex|Radiation therapy to 69.96 Gy, 2.12 Gy per day for 33 treatments, starting week 2. Cetuximab loading dose of 400 mg/m² week 1, 250 mg/m² weekly for 7 weeks. Paclitaxel poliglumex starting week 2 40 mg/m².
89278628|NCT00314951|Experimental|fidaxomicin|Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours [q12h] regimen) with intermittent matching placebo to fidaxomicin
89278629|NCT00314951|Active Comparator|Vancomycin|Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours [q6h] regimen).
89278630|NCT03906734|Experimental|alfieri technique + Septal myectomy|Septal myectomy plus mitral valve repair using alfieri stich
89278631|NCT03906734|Active Comparator|Subvalvular intervention + Septal myectomy|Septal myectomy plus subvalvular mitral valve intervention
89278632|NCT00085644|Experimental|Adalimumab|
89278633|NCT00085644|Placebo Comparator|Placebo|
89278634|NCT01254968||examining group|20 healthy subjects (11 men, 9 women, average age 23.94)
89278635|NCT01254968||control group|6 healthy subjects (3 men, 3 women, average age 23.6)
89278636|NCT01048463|Placebo Comparator|EN|The subjects take in 150g of Nutriall per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d. During the test period patients are treated with the first course of XELOX.
89278637|NCT01048463|Experimental|ENLDEPA|The subjects take in the same dose of Nutriall for the same duration as those in EN group. In addition, they take in 3 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
89278638|NCT01048463|Experimental|ENHDPEA|The subjects take in the same dose of supportan for the same duration as those in EN group. In addition, they take in 6 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
89278639|NCT01256996|Experimental|Low-abrasive powder|
89278640|NCT03897764|Experimental|Superior Hypogastric Block group|The group which superior hypogastric block performed intraoperatively
89278641|NCT03897764|Placebo Comparator|placebo controlled group|The group which placebo used
89278642|NCT01257074|Experimental|Drug 1|Penciclovir 10mg/g
89278643|NCT01257074|Active Comparator|Drug 2|Acyclovir 50mg/g
89278644|NCT03315208|Experimental|Unified Protocol + Treatment As Usual|Participants in this arm are offered 16 twice-weekly group UP sessions in addition to TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
89278645|NCT03315208|Active Comparator|Treatment As Usual Alone|Participants in this arm undergo TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
89278646|NCT03906812|Active Comparator|Unmonitored floor admission|Participants in this arm will be admitted to an unmonitored floor bed.
89278647|NCT03906812|Active Comparator|Floor admission with telemetry|Participants in this arm will be admitted to a telemetry bed.
89278648|NCT03961932|Experimental|Normal Renal Function|Healthy participants with Normal Renal Function (estimated Glomerular Filtration Rate (eGFR) ≥ 90 mL/min/1.73m^2)
89278649|NCT03961932|Experimental|Mild Renal Impairment|Presence of Mild Renal Impairment (eGFR 60-89 mL/min/1.73m^2)
89278650|NCT03961932|Experimental|Moderate Renal Impairment|Presence of Moderate Renal Impairment (eGFR 30-59 mL/min/1.73m^2)
89278651|NCT03961932|Experimental|Severe Renal Impairment|Presence of Severe Renal Impairment (eGFR ≤ 29 mL/min/1.73m^2), not on hemodialysis
89278652|NCT03961932|Experimental|End-Stage Renal Disease|Presence of End-Stage Renal Disease (ESRD) requiring hemodialysis
89278653|NCT01326936|Experimental|Unworked VP|Online education using typical virtual patient (VP) approach. Five unworked VPs presented to subjects for study.
89278654|NCT01326936|Experimental|Guided Learning|Online education replaces two unworked VPs in Arm 1 with identical worked example VPs (case studies) for learners to study
89278655|NCT03906500|Experimental|Intervention|"The intervention consist of three main components.~School environmental component~The component targeting the high school environment consisted of two separate elements:~Revision of school alcohol policy~Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student components~The Student components consisted of three main elements:~Web-based education for the student committees organizing events where alcohol is sold and the student introduction committee~Pocket movie campaign~Social norms campaign~Parent components~The parent component consisted of three separate elements:~Parent Information Meeting~Parent Information Folder~Parent Information Website"
89278656|NCT03906500|No Intervention|control group|Control high schools was asked to continue business as usual and promised to receive the intervention in the school year starting in 2020
89278657|NCT04177992|Experimental|Servo control|"Automated control of oxygen. The oxygen saturation target range will be set to 93%.~Automated oxygen control can be over-ridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets."
89278658|NCT04177992|No Intervention|Manual control|Standard practice. Oxygen adjustments will be made by clinical/nursing staff to maintain a target oxygen range of 90%-95%.
89278659|NCT01150994|No Intervention|Treatment as Usual|
89278660|NCT01150994|No Intervention|Screening Alone|Enhanced screening among ED patients
89278661|NCT01150994|Experimental|Safety Assessment and Follow-up Telephone Intervention|SAFTI: Safety Assessment in the ED combine with a Follow-up Telephone Intervention.
89278662|NCT01086696|Experimental|1|subjects with tumor types typically treatedwith taxanes
89278663|NCT01086696|Experimental|2|subjects with tumor types typically treatedwith taxanes
89278664|NCT01149278|Active Comparator|high pressure|
89278665|NCT01149278|Placebo Comparator|normal pressure|
89278666|NCT00314795|Experimental|Peginesatide|"Peginesatide 0.05 mg/kg injection, subcutaneously as a starting dose followed by peginesatide 0.1 mg/kg injection, subcutaneously once every 4 weeks for up to 6 months.~Individual dose of peginesatide injection was modified based on hemoglobin levels. Dose adjustments were made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL."
89278667|NCT01086774|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
89278668|NCT03902522|Experimental|Leronlimab (PRO 140)|Subjects will be on existing ART for one week followed by PRO 140 700mg weekly SC Inj. + existing ART for the next week. Subsequently, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
89278669|NCT01092858|Experimental|Arm 1|
89278670|NCT01092858|Placebo Comparator|Arm 2|
89278671|NCT03902756|Experimental|Flow-Volume loop guided endotracheal cuff inflation|Endotracheal cuff will be inflated by Flow-Volume loop guided until getting proper sealing.
89278672|NCT03902756|Active Comparator|Stethoscope-guided endotracheal cuff infration|Endotracheal cuff will be inflated by Stethoscope-guided until getting proper sealing.
89278673|NCT01529879|Experimental|New abutment connection implant|Implant with new abutment connection
89278674|NCT01529879|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
89278675|NCT01253798|Active Comparator|Group training on land|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip.
89278676|NCT01253798|Active Comparator|Group training in water|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip
89278677|NCT03985397|Experimental|Experimental group (EG)|At the first interview, after the application of the scales to the intervention group patients, planned discharge training and the manual prepared by the researcher were given. The second interview was performed 4 weeks later and the same scales were reapplied.
89278678|NCT03985397|No Intervention|Control group|In the first interview, scales were applied to the control group patients but planned discharge training was not given. The second interview was carried out 4 weeks later, and after the same scales were reapplied to the control group patients, planned discharge training was given. Therefore, the right of individuals to get education was not prevented.
89278679|NCT03902288|Experimental|Patients with type 2 diabetes|Patients with type 2 diabetes at early stages of type 2 diabetes (FSG: 7.1 15.8 mmol/L)
89278680|NCT03902288|Active Comparator|Healthy individuals|Healthy individuals match age and gender to the experimental group
89278681|NCT00314327|Experimental|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
89278682|NCT03897452|Experimental|Fentanyl for procedural pain|"A dose of Fentanyl 5 microgram/ml, 0.5 microgram/kg (anticipated medium pain) or 2 microgram/kg (anticipated strong pain) will be given prior to a painful procedure during NICU-care. Repeated doses or complementary analgesics will be administered according to pain assessment and clinical judgement.~This is not an RCT with several arms."
89278683|NCT03906032|Experimental|Intra-medullary hip Nail|Surgery
89278684|NCT03906032|Active Comparator|Sliding hip screw|Surgery
89278685|NCT01151072|Experimental|IDeg i.m. thigh|
89278686|NCT01151072|Experimental|IDeg i.v.|
89278687|NCT01151072|Experimental|IDeg s.c. abdomen|
89278688|NCT01151072|Experimental|IDeg s.c. deltoid|
89278689|NCT01151072|Experimental|IDeg s.c. thigh|
89278690|NCT03906266|Active Comparator|nutric score|> 5 indicates high risk for malnutrition < 4 indicates low risk for malnutrition
89278691|NCT03906266|Placebo Comparator|adductor pollicis|< 20 mm indicates high high risk for malnutrition > 20 mm indicates low risk for malnutrition
89278692|NCT03906266|Placebo Comparator|SGA score|SGA 1 indicates no malnutrition SGA 2 indicates good diet SGA 3 indicates high risk for malnutrition
89278693|NCT03906266|Placebo Comparator|NRS 2002 score|> 3 indicates high risk for malnutrition
89278694|NCT03897140|Experimental|Patients scheduled for an echocardiogram|Patients ≥18 years scheduled for an echocardiographic examination. This is a non-randomized, un-blinded, study in patients with an indication for an echocardiographic examination. Enrolled patients will be stratified into two groups based on known cardiac abnormalities to ensure a sufficient number of patients with cardiac abnormalities and into 3 strata of BMI: normal, overweight and obese.
89278695|NCT01253876|Experimental|Soy milk|
89278696|NCT01253876|Experimental|Caw's milk|
89278697|NCT03896906|Experimental|Group N|pre-oxygenation with High-flow nasal cannula
89278698|NCT03896906|Active Comparator|Group M|pre-oxygenation with simple mask
89278699|NCT01257386|Experimental|Asacol®|Import Mesalazine
89278700|NCT01257386|Active Comparator|Mesalazine|Marketed Mesalazine
89278701|NCT01257464|Active Comparator|Sitagliptin|
89278702|NCT01257464|Placebo Comparator|Placebo|
89278703|NCT01257620|Placebo Comparator|Placebo|Placebo
89278704|NCT01257620|Experimental|Probiotic|Life Start Two
89278705|NCT01255046|Active Comparator|Donepezil plus STA-1|
89278706|NCT01255046|Placebo Comparator|Donepezil plus placebo|
89278707|NCT02528006|Other|Titanium Bridges|Surgery
89278708|NCT03902054|Experimental|Experimental Group - High dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of high dosage investigational sIPV
89278709|NCT03902054|Experimental|Experimental Group - Medium dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of medium dosage investigational sIPV
89278710|NCT03902054|Experimental|Experimental Group - Low dosage|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of low dosage investigational sIPV
89278711|NCT03902054|Active Comparator|Control Group -commercialized sIPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized sIPV
89278712|NCT03902054|Active Comparator|Control Group -commercialized IPV|Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively; Intervention: Three-dose regimen of commercialized IPV
89278713|NCT03901976|Other|Bed Exit Detection On|prevention of fall by a true bed exit detection
89278714|NCT03902210|Experimental|Online Yoga|The intervention will be 12-weeks in duration and will consist of a series of pre-approved online yoga classes (6 manufactured specifically for the cancer-afflicted patients instructed by Udaya yoga therapist, Jules Mitchell, MS). Patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes. Participants will be instructed to view a safety handout (see yoga safety & modifications handout) before gaining access to the Udaya video library. Yoga therapist, Jules Mitchell and PIs Huberty and Palmer will pre-approve Udaya videos that are appropriate for this population.
89278715|NCT03902210|Placebo Comparator|Podcast|The podcast control group will be asked to view 60 minutes per week of online podcast videos. The podcast videos will contain general cancer-related health education material. To match the online yoga group for time and attention, 60 minutes per week will be prescribed, however, participants will have the ability to view additional videos each week. Furthermore, participants will also track their podcast video viewing each week in a daily log (see podcast group weekly log) by recording each time they view a video, the video that they viewed, and how long they viewed the video.
89278716|NCT03902132|Experimental|Core Stability exercises group|Core Stability exercises
89278717|NCT03902132|Active Comparator|Traditional low back physical therapy group|Traditional low back physical therapy management
89278718|NCT03901898|Experimental|Training, audit, and reminders|An investigator will deliver a 20-30-minute briefing on intervention delivery to all staff at participating practices, followed by one-on-one audit training (1 hour) with the staff member responsible for conducting the audit. Each practice conducts an audit of their patients with diabetes to identify all people who have not attended retinopathy screening with the national programme. At 6 months, practices conducts a re-audit. Practice staff add electronic alerts to the records of eligible patients, to prompt GPs and nurses to remind patients. Practices are reimbursed at study entry with further payment following intervention cessation based on number of patients audited. Face-to-face verbal reminders are delivered by GPs and practice nurses to eligible patients attending for an appointment during the study period. All eligible patients receive a reminder phone call from a practice nurse and a GP-endorsed reminder letter accompanied by an information leaflet.
89278719|NCT03901898|Other|Wait list control|In control practices, the intervention will be delivered after 6 months. For the audit, administrators or practice nurses will use date restricted data extraction from the electronic medical record to capture data for the 12-month period prior to the intervention (study baseline) and 6 months after the study intervention period, during which they will have acted as control practices (follow-up). This will satisfy the baseline data collection prior to the delivery of the intervention to this group on study completion. This approach was chosen as collecting data at baseline (i.e. 6 months before intervention start) would constitute an intervention in those practices; knowledge of non-attenders would lead to a change in usual care as the control group would likely follow up patients immediately. Control practices will receive the same supports and training as intervention practices.
89278720|NCT01255124||Health infants (ClinicalTrials.gov ID: NCT01183611)|The subjects participated in the clinical trial 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' in 2007 (ClinicalTrials.gov ID: NCT01183611).
89278721|NCT03906188|Experimental|LitEmotion group|This group will play to LitEmotion video game.
89278722|NCT03906188|No Intervention|Control group|This group will no do receive any intervention with the video game
89278723|NCT03901742|Active Comparator|Standard Enteral Nutrition|Standard Enteral Nutrition: cow's milk based infant formula (Nidina, Nestlé, Barcelona, Spain).
89278724|NCT03901742|Active Comparator|Protein-enriched nutrition|Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain)
89278725|NCT03901742|Active Comparator|High Protein-enriched Nutrition|High Protein-enriched Enteral Nutrition: polymeric infant formula (Infatrini; Nutricia, Madrid, Spain) supplemented with 2.6 g of protein/100 mL of formula. The source of the protein supplement would be a nonhydrolyzed protein cow's milk-based formula (Resource Protein Instant; Nestlé, Barcelona, Spain). Final composition 5.1 g/100 mL.
89278726|NCT01149356|Experimental|Arm I|Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89278727|NCT01149356|Active Comparator|Arm II|Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89278728|NCT03905954||Parkinson's Diagnosis|Usual care
89278729|NCT01148576|Other|control group|patients only with chronic hepatitis B
89278730|NCT01148576|Active Comparator|model group|patients with chronic hepatitis B and hepatic steatosis
89278731|NCT01148576|Experimental|Essentiale group|patients with chronic hepatitis B and hepatic steatosis
89278732|NCT01148576|Experimental|treatment group 2|patients with chronic hepatitis B and hepatic steatosis
89278733|NCT01253954||ICU patients with IFI|1
89278734|NCT03901586|Experimental|Patients who had Richter intervention|
89278735|NCT03901508|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
89278736|NCT03901508|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
89278737|NCT03901352|Experimental|Mirogabalin|"The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.~The patients with creatinine clearance (CLcr) 30 to < 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose"
89278738|NCT03901352|Placebo Comparator|Placebo|Placebo (14-weeks)
89278739|NCT01149200|Experimental|TC-6499|
89278740|NCT01149200|Placebo Comparator|Placebo|
89278741|NCT03905486|Active Comparator|G1: patients will receive pregabalin|pregabalin as a mono-therapy will be administered in increment doses for 3 months
89278742|NCT03905486|Active Comparator|G2: patients will receive pregabalin and milnacipran|pregabalin and milancipran as a combination therapy will be administered in increment doses for 3 months
89278743|NCT03901040|Other|obese patient|we will perform endoscopic ultrasound botulinum toxin (100 IU)injection to gastric antrum of obese patient with BMI more than 30 will
89278744|NCT03901118|Experimental|chiauranib plus etoposide|Patients receive the combined treatment of chiauranib plus etoposide, 28 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Etoposide is given orally, 50mg once daily for 21 days, 7 days off, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
89278745|NCT03901118|Experimental|chiauranib plus paclitaxel|Patients receive the combined treatment of chiauranib plus paclitaxel, 21 days for a cycle, 6 cycles at most. In the pilot trial, Chiauranib is given orally, 25mg once daily. After patients finish the blood collection for pharmacokinetics(PK), and if the efficacy and safety are acceptable, Chiauranib is given orally, 50mg once daily. Paclitaxel is given in intravenous infusion on Day 1, 8 and 15, in the pilot and formal study. After 6 cycles combined treatment, patients enter the single agent therapy of chiauranib.
89278746|NCT03896594|Experimental|HL237 200mg|HL237 100mg 1 tablet twice a day
89278747|NCT03896594|Experimental|HL237 400mg|HL237 100mg 2 tablets twice a day
89278748|NCT03896594|Experimental|HL237 800mg|HL237 400mg 1 tablet twice a day
89278749|NCT01151228|Placebo Comparator|Zero volume|Patients will not ingest any apple juice prior to the second ultrasound.
89278750|NCT01151228|Experimental|50 mL|Patients will ingest 50 mL apple juice prior to the second ultrasound.
89278751|NCT01151228|Experimental|100 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
89278752|NCT01151228|Experimental|200 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
89278753|NCT01151228|Experimental|300 mL|Patients will ingest 300 mL apple juice prior to the second ultrasound.
89278754|NCT01151228|Experimental|400 mL|Patients will ingest 400 mL apple juice prior to the second ultrasound.
89278755|NCT03896282|Active Comparator|daycare facility|After surgery patient stay at daycare facility for mobilisation and stay until discharge or transfer to standard patient ward if nor discharged by 20.000
89278756|NCT03896282|Active Comparator|standard patient ward|After surgery patients are transferred to standard patient ward for mobilisation and stay until discharge.
89278757|NCT03895892|Placebo Comparator|Water Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
89278758|NCT03895892|Experimental|Experimental 1|Ketone salts supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
89278759|NCT03895892|Experimental|Experimental 2|Ketone salts/caffeine supplement mixed in water will be ingested before completing a 20km Time trial and a 30 second all-out Wingate test
89278760|NCT03896204|Experimental|telephone-supported group|
89278761|NCT03896204|Experimental|Other group|
89278762|NCT01151306|Placebo Comparator|Lactose tablet|
89278763|NCT01151306|Active Comparator|Simvastatin 20mg|
89278764|NCT01257776|Active Comparator|Mesenchymal stem cells 0,5 million * weight (kg)|Group of low dose of Mesenchymal stem cells.
89278765|NCT01257776|Active Comparator|Mesenchymal stem cells 1 million * weight (kg)|Group of mid dose of mesenchymal stem cells
89278766|NCT01257776|No Intervention|Controlled group|Controlled group with no intervention
89278767|NCT05543720|No Intervention|Control|Control groups will be compared to 350 patients who received standard of care via propensity-matched controls from the ICES provincial database.
89278768|NCT05543720|Experimental|Telemonitoring (Medly MCC)|Medly is a smartphone application allows patients with heart failure, diabetes, depression, hypertension, and/or COPD to measure and record their daily self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
89278769|NCT02527850|Experimental|treatment with real laser|10 min irradiation with B-cure soft laser on 3 points of quadriceps muscle.
89278770|NCT02527850|Sham Comparator|sham laser|10 min irradiation with sham B-cure soft laser on 3 points of quadriceps muscle.
89278771|NCT01149590|Experimental|CT Calcium Score & Coronary Angiography|CT Scan
89278772|NCT01149590|No Intervention|No CT Scan|No CT Scan
89278773|NCT03900572|Experimental|HPV vaccine|Subjects receive 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
89278774|NCT03900572|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
89278775|NCT05528120|Experimental|KG|
89278776|NCT05528120|Experimental|GK|
89278777|NCT05570786|Experimental|Gestrinone|Subdermal implant-bioabsorbable gestrinone pellet (85 mg) All patients will undergo insertion of an intrauterine system of levonorgestrel release (Kyleena®) as a contraceptive method
89278778|NCT05570786|Placebo Comparator|Placebo|Subdermal implant-bioabsorbable placebo pellet (cholesterol) All patients will undergo insertion of an intrauterine system of levonorgestrel release (Kyleena®) as a contraceptive method
89278779|NCT01257854||Busulfan, pharmacogenetic, pharmacokinetic, children|Children who receive Busulfan IV and have a pharmacokinetic of Busulfan
89278780|NCT01255202||twin preganacies|
89278781|NCT05561894|Placebo Comparator|A (control)|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation index guided fluid therapy): PPVI will be measured using invasive blood pressure monitor. Ringer acetate solution will be administrated whenever PPV is higher than 12%.
89278782|NCT05561894|Active Comparator|B|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation index guided fluid therapy): PPVI will be measured using invasive blood pressure monitor. Ringer acetate solution will be administrated whenever PPV is higher than 16%.
89278783|NCT03895970|Experimental|Lenvatinib plus Pembrolizumab|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.~Pembrolizumab is a recombinant anti-human PD-1 monoclonal antibody."
89278784|NCT00336479|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
89278785|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
89278786|NCT00336479|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
89278787|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
89278788|NCT03905564|Experimental|Doxylamine succinate/pyridoxine hydrochloride|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination) administered with 250 mL of water (at room temperature) under fasting conditions.
89278789|NCT03905564|Active Comparator|Diclegis (Registered Trademark)|Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets) administered with 250 mL of water (at room temperature) under fasting conditions.
89278790|NCT03895424|Experimental|Iron Fatty Acid Complex (IFAC)|The iron fatty acid complex encapsulated and administered to the participants
89278791|NCT03895424|Experimental|Micellarized iron fatty acid complex (MIFAC)|Micellarized form of the iron fatty acid complex which is enscapsulated and administered to the participants
89278792|NCT03895424|Active Comparator|Control Ferrous Sulfate|Ferrous sulfate that is provided in the form of a solution along with a capsule that contains the same amount of fat that is present in the other two arms.
89278793|NCT01151384|Experimental|LE-DT|
89278794|NCT01062659||chronic Hepatitis C|Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment
89278795|NCT01257932||Diagnostic Tool|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
89278796|NCT01254110||1|Enterally fed with leucine
89278797|NCT01254110||2|Enterally fed with glutamine
89278798|NCT01254110||3|Enterally fed with protein powder
89278799|NCT03895190|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
89278800|NCT03895190|Experimental|Experimental: Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
89278801|NCT03905408|Experimental|50 mL Dextrose|50 mL of 50% dextrose
89278802|NCT03905408|Experimental|100 mL Dextrose|100 mL of 50% dextrose
89278803|NCT03905408|Experimental|150 mL Dextrose|150 mL of 50% dextrose
89278804|NCT03905408|Experimental|200 mL Dextrose|200 mL of 50% dextrose
89278805|NCT01258010|Experimental|Tranexamic acid|Study subjects will be randomized to receive a bolus dose of 30 mg/kg of tranexamic acid administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of tranexamic acid of 16 mg/kg/h administered up to 6 hours after surgery.
89278806|NCT01258010|Placebo Comparator|Normal saline (NaCl 0.9%)|Study subjects will be randomized to receive a bolus dose of normal saline (NaCl 0.9%) of equivalent volume administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
89278807|NCT00314249|Placebo Comparator|Placebo|Placebo, oral administration, twice daily for 12 weeks
89278808|NCT00314249|Experimental|Milnacipran|Milnacipran 100mg/day (50mg BID [twice a day])
89278809|NCT01255280|Active Comparator|Information, Motivation, Behavioral skills|The comparison condition will only receive the two IMB risk reduction sessions. The intervention will begin with modules that focus directly with sexual risk reduction practices. It will begin with a discussion of one's sexual history, sexual risk limits, and barriers (e.g., motivation or skills) to staying in their sexual risk limits. This session will also involve a Q&A discussion and the use of a fact sheet regarding HIV acquisition risk behaviors (information). The next session will involve motivational interviewing and the formulation of an individualized behavioral skills plan as needed.
89278810|NCT01255280|Experimental|Behavioral Activation Therapy and Risk Reduction Counseling|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions-1 baseline session focused on orienting and rationale, 2 focused on risk reduction (consistent with the IMB model: information, motivation, and behavioral skills), 6 incorporating behavioral activation therapy/risk reduction counseling, and 1 final session on relapse prevention. Each session will last approximately fifty minutes in length; and will also involve a review of the previous materials,and hence the behavioral activation approach will be woven back into the risk reduction content.
89278811|NCT01148654||1- Preterm Labor 22.0-33.6 weeks gestational age|Pregnant women between 22.0 and 33.6 weeks gestational age presenting to the Hospital of the University of Pennsylvania (HUP) complaining of Preterm labor (PTL), preterm premature rupture of membranes (PPROM), or cervical insufficiency (CI).
89278812|NCT01148654||2- Preterm birth 34-36.6 weeks gestational age|Pregnant women delivering at the University of Pennsylvania between 34.0 and 36.6 weeks gestational age
89278813|NCT03900104|Experimental|Transcervical endometrial injection arm|Tracer injection performed by a transcervical catheter in endometrial cancer patients.
89278814|NCT03900104|Active Comparator|Cervical injection arm|Tracer injection was administered via the cervical route in endometrial cancer patients.
89278815|NCT01258088|Active Comparator|Cohort 1: AN2728 Ointment|
89278816|NCT01258088|Placebo Comparator|Cohort 1: AN2728 Vehicle|
89278817|NCT01258088|Active Comparator|Cohort 3: AN2728 Ointment|
89278818|NCT01258088|Placebo Comparator|Cohort 3: AN2728 Vehicle|
89278819|NCT03905018|Experimental|tadalafil|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the first will receive a single dose of tadalafil 20 mg orally
89278820|NCT03905018|Placebo Comparator|calcined magnesia (placebo)|Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included. They should not be under treatment with iPDE5 or statins, nor should they have uncontrolled ischemic heart disease. To carry out this test, two groups will be created: the second will receive 20 mg of calcined magnesia (placebo),after a single administration
89278821|NCT01589588|Experimental|Mask 1|
89278822|NCT01589588|Experimental|Mask 2|
89278823|NCT01589588|Experimental|Mask 3|
89278824|NCT01589588|Placebo Comparator|Mask 3, placebo|
89278825|NCT01589666|Experimental|Spray-dried S/D-treated plasma|"Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a universal product."
89278826|NCT01258166||Tramuatic ulnar translocation|Patients who suffered a traumatic ulnar translocation following injury.
89278827|NCT03894722|Placebo Comparator|Group I (control; saline only)|Control Group: Intraoperative irrigation with saline solution only.
89278828|NCT03894722|Experimental|Group II (0.5% concentration of PVP-I )|Experimental Group: Intraoperative irrigation with 0.5% concentration of PVP-I solution.
89278829|NCT03894722|Experimental|Group III (1% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 1% concentration of PVP-I solution.
89278830|NCT03894722|Experimental|Group IV (3% concentration of PVP-I)|Experimental Group: Intraoperative irrigation with 3% concentration of PVP-I solution.
89278831|NCT03894800|Active Comparator|Methoxyflurane (M)|"A session starts with a CPT - cold pressor test (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale metoxyflurane through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
89278832|NCT03894800|Active Comparator|Fentanyl (F1)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.025 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs.Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
89278833|NCT03894800|Active Comparator|Fentanyl (F2)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.05 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
89278834|NCT03894800|Placebo Comparator|NaCl (C)|"A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second."
89278835|NCT03894644|Experimental|Group A: simulation training before instruments|Group A performed simulation training before the recognition of real surgical instruments.
89278836|NCT03894644|Active Comparator|Group B:instruments before simulation training|Group B performed the recognition of real surgical instruments without prior simulation training.
89278837|NCT03900182|Active Comparator|HBO treated group|Patients in the treated group were evaluated three - at baseline, after 6 weeks of HBOT and after 6 weeks of neuropsychological treatment or no treatment.
89278838|NCT03900182|Sham Comparator|crossover group|Patients in the crossover group were evaluated three times: baseline, after 6 weeks control period of no treatment, and after subsequent 6 weeks of HBOT
89278839|NCT03900026|Placebo Comparator|Placebo Treatment|Participants will receive subcutaneous injections of the placebo Q2W (every 2 weeks)
89278840|NCT03900026|Experimental|Evolocumab Treatment|Participants will receive subcutaneous injections of 140mg of evolocumab Q2W (every two weeks)
89278841|NCT01149668|Experimental|PCI-24781|
89278842|NCT01586234|Experimental|DSAEK with graft shaping and smoothing|
89278843|NCT01586234|Active Comparator|Standard DSAEK|
89278844|NCT01149746|Experimental|Tamsulosin|0.4 mg Capsule
89278845|NCT01149746|Active Comparator|Flomax®|0.4 mg Capsule
89278846|NCT01149824|Other|Dose Escalating|
89278847|NCT01151696|Experimental|hydroxyzine|Patients will receive intravenous hydroxyzine 1mg/kg at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
89278848|NCT01151696|Placebo Comparator|Placebo|Patients will receive intravenous placebo at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
89278849|NCT01254266|Experimental|conservative treatment|conservative weight reduction treatment in an inpatient unit.
89278850|NCT01254266|Experimental|bariatric surgery|inpatient program as a pre- and post- operational 'envelope' for bariatric surgeries.
89278851|NCT03894176||PTX3 concentration|First quartile, second quartile, third quartile and fourth quartile of PTX3 in ng/mL
89278852|NCT03894332||SBT Success|Patients took part of this cohort when succeeding the Spontaneous Breathing Trial (SBT).
89278853|NCT03894332||SBT Failure|"Patients took part of this cohort when failing the Spontaneous Breathing Trial (SBT).~SBT Failure is defined by one or more of the following criteria occurring during the SBT:~loss of ≥ 2 points of Glasgow Coma Scale~respiratory rate/ tidal volume ≥105 breaths/min/L~arterial partial pressure of oxygen ≤60 mmHg on inspired oxygen fraction (FiO2) ≥0.5 and/or pH <7.32 or a decrease in pH ≥0.07 units at the end of the SBT~systolic Blood Pressure <90 mmHg or ≥180 mmHg or increased by ≥20%~Heart Rate >140 beats/min or increased by 20%~onset of major heart arrhythmias, or electrocardiographic signs of cardiac ischemia~Respiratory Rate ≥35 breaths/min or increased by ≥50%~increased effort, respiratory distress (as indicated by diaphoresis, accessory respiratory muscles recruitment, facial signs of distress and/or paradoxical breath)"
89278854|NCT03894332||Extubation Success|Patients took part of this cohort when, after extubation, did not need continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours.
89278855|NCT03894332||Extubation Failure|"Need for continuous positive airways pressure (CPAP), non invasive ventilation (NIV) or reintubation within 48 hours from extubation, as defined by:~Respiratory Rate >25 breaths/min for 2 hours~Heart Rate >140 beats/min or sustained increase or decrease >20%~clinical signs of respiratory muscle failure~arterial partial pressure of oxygen (PaO2) <80 mmHg on inspired oxygen fraction (FiO2) ≥50%~Arterial partial pressure of carbon dioxide >45 mmHg with pH <7.33"
89278856|NCT02527928||desoxycholate|Amphotericin B desoxicholate
89278857|NCT02527928||Anfolipidcomplex|Amphotericin B complex lipid
89278858|NCT02527928||ABLiposomal|Amphotericin B liposomal
89278859|NCT01149980|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
89278860|NCT01149980|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
89278861|NCT03904784||School withdrawal teenagers|The study is based on questionnaries, interview with teenagers and/or their familly
89278862|NCT03899714|Active Comparator|Ankle evertors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the ankle evertors, the ice bag will be applied to the lateral side of the ankle encompassing the lateral malleolus.The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
89278863|NCT03899714|Active Comparator|Hip adductors|Ice packs will be applied to the selected muscles according to the random selection that will be performed previously. The ice bags will be filled with crushed ice, weighing approximately one half of a kilogram. They will be wrapped in a thin cotton towel, and applied on the skin along the anatomical location of the tested muscles. For the hip adductors, the ice bag will be applied to the medial side of the thigh, covering the entire area from the groin, to just above the knee joint. The cryotherapy session will be lasted for exactly 20 minutes . Sessions will be separated by a 30-minute rest interval
89278864|NCT01258244||Audiovisual feedback on CPR|EMS technicians will receive audiovisual feedback from the ZOLL device on depth, frequency, and interruptions to cardiac compressions
89278865|NCT03893708|Experimental|Prenatal yoga|Each class will be outlined as follows: 1) opening greeting/intention setting, 2) pranayama (i.e., breathing exercises), 3) warm-up/sun salutations (i.e., flowing sequence), 4) yoga sequence (e.g., combination of sun salutations, vinyasa, and standing, seated, and/or balancing poses), 5) cool-down 6) Savasana (i.e., final resting pose), and 7) class closing. Meditation and breath awareness (e.g., linking each movement with breath) will be emphasized throughout each class. All classes will focus on safety and alignment and be appropriate for women during pregnancy by incorporating modifications to poses/exercises as necessary (e.g., yoga block, strap). Certified yoga instructors with a bachelors degree in a health related field and experience teaching pregnant women will instruct all yoga classes. Participants will be provided with a 'yoga during pregnancy' safety packet that includes a list of prenatal yoga poses that women may do at their own leisure at home.
89278866|NCT03893708|Active Comparator|Pregnancy education|Participants will be asked to attend a group-based pregnancy education group (similar to a birth education class). The class format will include a didactic portion followed by group discussion (N=12). The following evidence-based topics (based on the American College of Obstetrics and Gynecologists) to be discussed may include (but not limited to): financial management in preparation for baby, preparing for labor and delivery, transitioning into motherhood, sleep hygiene, and baby bonding. A labor and delivery nurse and certified Dula will instruct all classes.
89278867|NCT02527616|Experimental|IV followed by IC (investigation)|The patient undergoes the FFR measurement with the standard measurement first followed by FFR measurement using the FFR Infusion Microcatheter
89278868|NCT02527616|Experimental|IC (investigation) followed by IV|The patient undergoes the FFR measurement using the FFR Infusion Microcatheter measurement first followed by measurement via the standard measurement
89278869|NCT01258322|Experimental|pioglitazone|
89278870|NCT01148732||Patient needed intubation in emergency department|
89278871|NCT03893786|Experimental|Robotic Treatment|"Fifteen patients with Parkinson's Disease will perform ten 45-minutes training sessions of the upper limb using the Armeo®Spring applied bilaterally, an electromedical device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upper limb training and it is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
89278872|NCT03893786|Active Comparator|Conventional Treatment|Fifteen patients with Parkinson's Disease will undergo ten 45-minutes training sessions of the upper limb with a traditional approach, performing the same excercises of the experimental group, i.e. flexo-extension of the wrist, prono-supination of the forearm, etcc.
89278873|NCT01255358|Experimental|Ery-Dex|Patients treated with monthly treatment of Ery-Dex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)
89278874|NCT03899558|Experimental|Intervention|HNHF device (intervention) + usual care
89278875|NCT03899558|No Intervention|Control|Usual care alone
89278876|NCT03904706|Experimental|Audits only|"Formalized audit teams with monthly meetings at each facility.~Audit Intervention phases:~Identification of facility leadership (i.e physicians or leading health care providers) to be trained on best practices in obstetric and perinatal care in the implementation of the audits.~Training of identified audit leaders (main investigator is typically a physician)~a. 5-day training workshop to include: i. Day 1: maternal death and near misses, perinatal, neonatal deaths and morbidity outcomes ii. Day 2: 'Three-delay' framework and identifying modifiable factors iii. Day 3: data collection and setting up the audit system iv. Days 4-5: mentoring on the identification of the audit teams and initiating audit implementation~Creating audit team (composed of at least two obstetricians, 2 pediatricians plus the main investigator)~Establishing and launching the audit cycle (monthly meetings)~Annual re-certification of audit leaders"
89290228|NCT01123824|Experimental|Sequence clopidogrel 600/150 mg - 300/75 mg|"Period 1:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Period 2:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
89278877|NCT03904706|Experimental|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
89278878|NCT03904706|No Intervention|Control|Monthly outcome data will be collected from health facilities where no audits will be conducted. Data from this group will help evaluate the effectiveness of the intervention arms on perinatal and neonatal mortality.
89278879|NCT03899480|Experimental|Haploidentical Natural Killer Cells|Day -7 the subject will undergo inguinal lymph node biopsy & colonoscopy to obtain ileal & rectal biopsies. Blood samples will be obtained. PBMCs will be obtained to sort into CD4 subsets & measure frequencies of HIV RNA & DNA. On Day -1, the donor will undergo apheresis & donor cells will be obtained & incubated overnight. On Day 0 subjects will be infused with N-803 activated NK cells. Subjects will receive 1st dose of N-803 4 hrs after the infusion. Plasma will be obtained at 2, 4 & 12 hrs after. Subjects will return on Days 2, 4, 7, 10, & 14 for blood draw. Subjects will return Days 21 & 42 for blood work & to receive 2 additional doses of N-803, for a total of 3 doses. Subjects will be monitored for toxicity assessment by targeted physical exam & laboratory evaluations on Days 2, 4, 7, 10, 21, & 42. On day 49, we will perform lymph node biopsy & colonoscopy to obtain ileal & rectal tissues. The patient will then be followed until day 100 post infusion.
89278880|NCT03899246|Experimental|Capsaicin Arm|Single arm to receive eight percent topical capsaicin applied to up to 4 sites of recurrent pain over one hour on an every three month schedule. Participants in this arm will receive pretreatment with topical five percent lidocaine.
89278881|NCT03893552|Experimental|Patient with sleep disordered breathing symptoms|Patients referring to the clinic of sleep disorders will be asked to participate in this study. A negative expiratory pressure will be applied via a cough-assist attached to a facial mask.
89278882|NCT03893864|Experimental|Intervention Group (CoQ10)|Runner athletes > 50 years old, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions
89278883|NCT03893864|Active Comparator|Control Group|Runner athletes > 50 years old with the same characteristics as the Experimental arm, served as control group, maintaining the training sessions Both groups were evaluated before and after the month of intervention or no intervention.
89278884|NCT03893474|Other|Control Arm|All investigations are the same in both arms, but patients within this arm will be seen in the hospital as per standard practice.
89278885|NCT03893474|Other|Study Arm|All investigations are the same in both arms, but patients within this arm will be seen in a community optometrist practice.
89278886|NCT03893084|Experimental|Intervention|Preconception guidance prepared by reference to the guidelines published in the literature, women were given pre-pregnancy training.
89278887|NCT03893084|No Intervention|Control|The women in the control group were not given training, and routine practice was performed.
89278888|NCT01148888|Experimental|Magnesium Sulfate|The study will be conducted in the 45 minute interval between the completion of spinal instrumentation and the completion of skin closure. Once the spinal instrumentation is complete and the integrity of the spinal cord pathways is confirmed using SEPs and MEPs, magnesium will be administered for the remainder of surgery.
89278889|NCT01150136||1|Children with proven CF and known genotype, age 0-17 yr
89278890|NCT03904394|Placebo Comparator|Placebo Mouthwash|
89278891|NCT03904394|Active Comparator|Antibacterial Mouthwash|
89278892|NCT03899168|Experimental|Social Tag Popularity|Popularity of Social Tags (antidepressants more popular vs. psychotherapy more popular)
89278893|NCT03899168|Experimental|Confidence in Prior Attitudes|Confidence in prior attitudes (high vs. low: recalling situations in which participants were confident or uncertain about their thoughts)
89278894|NCT03899168|Experimental|Source Credibility|Credibility of the source (tagging community: experts - many years of professional experience vs. novices - students in the first semester)
89278895|NCT03899324|Experimental|Group 1: Experimental Bumetanide|bumetanide with a titration period
89278896|NCT03899324|Placebo Comparator|Group 2: Placebo comparator|placebo intake identically to group 1
89278897|NCT01258478|Experimental|rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
89278898|NCT01258478|Sham Comparator|usual care|Usual care before surgery is provided
89278899|NCT05507996|Experimental|A single-arm study of recombinant adeno-associated virus|An open, single-arm study of recombinant adeno-associated virus
89278900|NCT03893006|Experimental|UnAssisted (UA)|This term refers to driving a vehicle manually without any vehicle automation technology. It will serve as a baseline concerning behaviors, representations and neural results associated with unassisted automobile driving.
89278901|NCT03893006|Experimental|Assisted (A)|This term refers to driving with warning technology which upon activation sounds an a warning when the vehicle is too close to the edge of the road (off-road warning , Navarro, Mars, & Hoc, 2007; Suzuki & Jansson, 2003) or too close to the vehicle in front of it (anti-collision warning; Lee, McGehee, Brown, & Reyes, 2002).
89278902|NCT03893006|Experimental|Shared Control (SC)|This term refers to shared tactical control between the driver and the automated assistive technology, both working simultaneously on the physical trajectory of the vehicle, laterally (Griffiths & Gillespie, 2005; Mulder, Abbink, & Boer, 2012) as well as longitudinal (Adell, Várhelyi, & Hjälmdahl, 2008).
89278903|NCT03893006|Experimental|Partly Autonomous (PA)|"This term refers to a situation where the lateral and longitudinal control of the driving are delegated to the automated assistive technology. It consists of a level of automatisation that today is possible to put into application and which often is referred to by the name Highly Automated Driving (Navarro, 2018). In this case, the driver is no longer the one who physically ensures the lateral and longitudinal control of the vehicle, but instead supervises the actions of the automated assistive technology."
89278904|NCT03893006|Experimental|Fully Autonomous (FA)|This term refers to a completely automated driving experience. The on-board technologies take over all the driving tasks for any driving situation.
89278905|NCT03893006|Experimental|Any Automation (AA)|This term refers to a situation where the drivers can choose the automation device of their choice among the five types presented above and can change it whenever they think it is good to do so.
89278906|NCT01254500||patients with brain lesions|
89278907|NCT01254500||young normal controls|
89278908|NCT01254500||old normal controls|
89278909|NCT02527538||Pleth|The masimo probe is attached on the index fingertip and cover with black cover in all patients. Record the pleth variability index and blood pressure
89278910|NCT01258556|Experimental|Probiotic yogurt|
89278911|NCT01258556|Placebo Comparator|Placebo yogurt.|
89278912|NCT01148966|Experimental|Treatment (photodynamic therapy)|Patients receive aminolevulinic acid PO 4 hours before undergoing surgery.
89278913|NCT01258634|Other|Pre-op treatment|
89278914|NCT03904628|Experimental|150 mg, BIW in every 28d|TG02 capsules were given orally at 150 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
89278915|NCT03904628|Experimental|200 mg, BIW in every 28d|TG02 capsules were given orally at 200 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
89278916|NCT03904628|Experimental|250 mg, BIW in every 28d|TG02 capsules were given orally at 250 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
89278917|NCT01258712|Experimental|1|
89278918|NCT01258712|Placebo Comparator|2|
89278919|NCT03904160|Sham Comparator|Nurse-lead group|Nurse-lead sessions for weight management. Ten sessions lasting 90 minutes each in three groups of 10-14 participants. Each session comprise education about healthy diet, psychoeducation and discussions.
89278920|NCT03904160|Experimental|Web-based group|Web-based weight management system with peer-based conversation possibility. Three groups of 10-14 participants who gather together for three nurse-lead sessions in the weeks 0, 5, and 12. The web-based program can be used for a year.
89278921|NCT03904160|Experimental|Web-based personal|Web-based weight management system with conversation possibility with the nurse for 12 weeks. Altogether 37 participants who can use the web-based weight management system for one year.
89278922|NCT01258868|Experimental|1|Celebrex+ tumor cell vaccine
89278923|NCT01255514|Experimental|VAD|VAD : high dose dexamethasone -> response(CR, PR)-> VAD chemotherapy(vincristine + doxorubicin + dexamethasone)-> PBSC -> aSCT
89278924|NCT01255514|Experimental|PAD|PAD : high dose dexamethasone -> response(MR,NC,PD)-> PAD chemotherapy(bortezomib + doxorubicin + dexamethasone)-> PBSC -> aSCT
89278925|NCT01254578|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo blood and bone marrow biopsies and aspirate collection at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies. Buccal swab samples are also collected at baseline and analyzed for genetic polymorphisms."
89278926|NCT03892850|Experimental|nurse prescription|experimental group receiving pharmacological nurse prescription
89278927|NCT03892850|Active Comparator|medical prescription|control group receiving medical prescription
89278928|NCT01152008||healthy volunteers|
89278929|NCT03904082|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) at the T4 vertebral level will performed preoperatively to patients in the ESP group (Group I).
89278930|NCT03904082|Active Comparator|Serratus Anterior Plane Block Group (SAP)|Single- shot ultrasound (Esaote Mylab30 )guided SAP block with 15 ml 0.25% bupivacain (Marcain 0.5%, Astra Zeneca, Turkey) the T4 vertebral level will performed preoperatively to patients in the SAP group( Group II).
89278931|NCT03904082|Placebo Comparator|Control Group|The Control group receive no intervetion ( Group III).
89278932|NCT03903926|Experimental|Cohort one|5000 volunteers (6-35 months)-EV71 vaccine
89278933|NCT03903926|No Intervention|Cohort two|10000 unvaccinated volunteers (6-35 months)
89278934|NCT03903926|No Intervention|Cohort three|500 unvaccinated volunteers (36-71 months)
89278935|NCT03903848|Experimental|Exercise session|One session of physical exercise
89278936|NCT01152086|Active Comparator|Hiking first|This group first starts with mountain hiking over 9 weeks followed by a 9 weeks control period.
89278937|NCT01152086|Active Comparator|Control first|This group first starts with the control period (9 weeks) followed by the 9 weeks mountain hiking intervention.
89278938|NCT03904238|Experimental|CBT-H (Individual format)|Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
89278939|NCT03904238|Experimental|CBT-H (Group format)|Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
89278940|NCT01149044|Active Comparator|Upfront Thrombectomy followed by PCI|Upfront manual aspiration thrombectomy followed by PCI
89278941|NCT01149044|Active Comparator|PCI Alone|PCI without upfront manual aspiration thrombectomy
89278942|NCT03315130|Experimental|0.1 mg/kg zilucoplan (RA101495)|
89278943|NCT03315130|Experimental|0.3 mg/kg zilucoplan (RA101495)|
89278944|NCT03315130|Placebo Comparator|Placebo|
89278945|NCT01152164||rectal cancer patients|
89278946|NCT03892382|Active Comparator|Active rTMS|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
89278947|NCT03892382|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
89278948|NCT03273166|Experimental|INVSENSOR00001 sensor|This is a nonrandomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
89278949|NCT01152242|Active Comparator|Part 1|Part I of the trial
89278950|NCT01152242|Active Comparator|Part 2|Part II of the trial
89278951|NCT03341806|Experimental|Patients with Recurrent Glioblastoma|Part A - Avelumab Part B - Avelumab + MRI-guided LITT therapy
89278952|NCT01255826|Active Comparator|Sustained lung inflation followed by CPAP|"Sustained pressure-controlled inflation using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel, Auckland, New Zealand).~This will be followed by early CPAP."
89278953|NCT01255826|Active Comparator|Conventional self inflating bag and mask ventilation|Intermittent bag and mask ventilation using a self-inflating bag with an oxygen reservoir.
89278954|NCT03904004||Esophageal motility disorders|Individuals with sympmtoms related to esophageal motility disorders who receive a endoscopic or surgical treatment
89278955|NCT03903770|Experimental|Intervention|Upper extremity rehabilitation
89278956|NCT01152320|No Intervention|Standard of Care|
89278957|NCT01152320|Experimental|Intervention|Spirometry Fundamentals™ CD training program
89278958|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin with Erlotinib|
89278959|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin without Erlotinib|
89278960|NCT01152398|Experimental|MVA-BN-HER2|
89278961|NCT01255982||1|Diagnosed with bipolar I or II disorder, and with an acute episode of bipolar depression at inclusion
89278962|NCT03903614|Experimental|Sensory Motor Lateralization (SML)|This was a group of 8 junior high school students who received SML in school for handwriting difficulty during the 2012-13 School Year. The participants received left eye-and-ear occlusion, fitness exercises, fine motor speed training, and handwriting practice on their right hand only.
89278963|NCT03903614|Active Comparator|Conventional School-Based OT (CON)|This was a group of 8 junior high school students who received conventional school-based Occupational Therapy service for handwriting difficulty during the 2012-13 School Year. The participants received a like fitness exercises, fine motor speed training, and handwriting practice on their dominant hand instead.
89278964|NCT01150214||DE-MRI|All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
89278965|NCT01256138||transplantation|
89278966|NCT01256138||control|
89278967|NCT03892148|Active Comparator|Standard|Use of loop diuretics and thiazide diuretics leaves to the discretion of the responsible physician
89278968|NCT03892148|Experimental|Protocol|use of loop diuretics and thiazide diuretics according to the CARRESS-HF protocol developed by the Heart Failure Network
89278969|NCT01152476|Active Comparator|group SR|
89278970|NCT01152476|Active Comparator|group S|
89278971|NCT03892304||Adult women with Cystic Fibrosis|Cohort of 164 women diagnosed with Cystic Fibrosis (CF) who were patients at the Cystic Fibrosis Adult Referral Centre in Lyon, France in 2017 (compared to 155 in 2014). Women attending the CF adult centre in 2017 were asked to complete a written questionnaire.
89278972|NCT03892070|Experimental|HMB GROUP|HMB Supplementation with 1.5 g of HMB taken twice daily. Supplementation will be provided for 12 weeks
89278973|NCT03892070|Placebo Comparator|PLACEBO GROUP|Mannitol 1.5 g twice daily. Supplementation will be provided for 12 weeks
89278974|NCT03903380|Active Comparator|MT treatment + Usual care exercise|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where usual care exercise protocol will be introduced.~The manual therapy protocol that will be used is the one proposed by Beltrán-Alacreu et al. (2015). The mentioned protocol consist of specific passive movements in the facet cervical joints, global mobilization of the cervical spine and high-velocity technique in the thoracic región."
89278975|NCT03903380|Experimental|MT treatment + Augmented reality (AR) exercises|"The intervention will be divided into two parts, the first one where MT treatment will take place and the second part where AR will be applied as an exercise method.~The same manual therapy protocol will be used for both groups.~For this group, the Microsoft HoloLens Development Edition device will be used, which is a holographic device that allows us to interact with high definition holograms in its environment. The application that will be used will be the Roboraid software, this app is a shooter, which requires the cervical movement to move the pointer and be able to play."
89278976|NCT03891758|Experimental|BK1310|
89278977|NCT03891758|Active Comparator|ActHIB® and Tetrabik|
89278978|NCT01259180|Experimental|Acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
89278979|NCT01259180|Sham Comparator|Sham acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
89278980|NCT01259180|No Intervention|Control group|observation.
89278981|NCT01259258|Active Comparator|varicocelectomy with dye|subinguinal varicocelectomy for 40 patients who received 2 ml intratunical space injection of methylene blue before spermatic vein ligation
89278982|NCT01259258|Active Comparator|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
89278983|NCT01152632|Experimental|specific points of Bladder meridian and Shanjiao meridian|In traditional Chinese acupuncture theory, Bladder meridian and Shanjiao meridian have been considered as the main pathological meridian location of migraine. Meanwhile, specific points on both meridians have been used widely in its treatment for a long time.
89278984|NCT01152632|Experimental|non-specific points of Bladder meridian and Shanjiao meridian|Non-specific points of Shaoyang meridians are also used in cure of migraine. It is conventionally thought to be less effective using non-specific points than specific ones.
89278985|NCT01152632|Active Comparator|specific points of Stomach meridian|Specific points of Stomache meridian for migraine were searched in Chinese ancient data. And this group is set to compare with specific points of Shaoyang meridians for their possible different brain networks.
89278986|NCT01152632|Placebo Comparator|non-acupoints|Three non-acupoints were chosen,two of which were located on the arm and one one the leg.
89278987|NCT01152632|No Intervention|waiting list|
89278988|NCT01256216|Other|Signature Custom Cutting Guides|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Signature Cutting Guides Surgical Technique.
89278989|NCT01256216|Other|CAS (Computer Assisted Surgery)|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Computer Assisted Surgery Technique.
89278990|NCT01259882|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Cohort 1
89278991|NCT01259882|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Cohort 2
89278992|NCT01259882|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Cohort 3
89278993|NCT01259882|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Cohort 4
89278994|NCT01259882|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Cohort 5
89278995|NCT01259882|Experimental|Cohort 6: Experimental intervention: PF-05089771 or placebo|Cohort 6
89278996|NCT01155440|Experimental|LIDOCAINE group|Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
89278997|NCT01155440|Active Comparator|Epidural group|Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
89278998|NCT01259960||BMI < 25|Body Mass Index (BMI) according to WHO definition. BMI < 25 is defined as 'normal weight'.
89278999|NCT01259960||25 <= BMI < 30|Body Mass Index (BMI) according to WHO definition. BMI >= 25 and < 30 is defined as 'overweight'.
89279000|NCT01259960||BMI >= 30|Body Mass Index (BMI) according to WHO definition. BMI >= 30 is defined as 'obese'.
89279001|NCT03889262|Active Comparator|Control Group|Participants in this group will receive only Neurodevelopmental therapy (NDT) based rehabilitation for 45 minutes in each session, twice a week, during 8 weeks, 16 sessions in total. Number of participants in this group is anticipated to be 20.
89279002|NCT03889262|Active Comparator|Study Group|After 16 sessions (8 weeks) of only Neurodevelopmental therapy (NDT) based rehabilitation, simulated hippotherapy treatment will be added to rehabilitation program of the same participants. Their NDT treatment will be reduced to 25 minutes whereas hippotherapy will be applied for 20 minutes in each session, 2 sessions a week, 8 weeks in total.
89279003|NCT03889652||Cataract group|"Group 1 includes patients who are planned for cataract extraction without any other preexisting retinal or optic nerve pathology that may affect the RNFL thickness.~OCT (investigation) before and after cataract extraction"
89279004|NCT03889652||Combined cataract and glaucoma group|Group 2 includes patients who are diagnosed with POAG controlled on medical treatment and have cataract and planned for cataract extraction only OCT is done before and after cataract extraction
89279005|NCT01259336|Active Comparator|Itraconazole|Role of itraconazole in CCPA
89279006|NCT01259336|Experimental|treatment in cavitary pulmonary aspergillosis|Patients in this arm are given conservative management with antitussives, brochial artery embolisation.
89279007|NCT03891134|Experimental|enriched Branched Chain Amino Acid intervention|enriched Branched Chain Amino Acid nutrition supplement 3.6 g twice a day for 5 weeks then withdrawal nutrition supplement for 12 weeks
89279008|NCT03886142|Active Comparator|radiofrequency|genicular nerves pulsed radiofrequency
89279009|NCT03886142|Active Comparator|intra-articular platelet rich plasma|injection of platelet rich plasma in the affected joint
89279010|NCT01259414|Experimental|group1|Chemoembolization with solvent with specific gravity less than lipiodol
89279011|NCT01259414|Experimental|group2|Chemoembolization with Solvent with specific gravity equivalent to lipiodol
89279012|NCT03891212|Experimental|The prone group|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.
89279013|NCT03891212|No Intervention|The supine group|Patients assigned to the supine group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
89279014|NCT03314662|Experimental|aQIV|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
89279015|NCT03314662|Experimental|aTIV-1|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
89279016|NCT03314662|Experimental|aTIV-2|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
89279017|NCT03886298|Experimental|radiofrequency splanchnic denervation|
89279018|NCT03886298|Active Comparator|retrocrural celiac denervation|
89279019|NCT03890978|Experimental|intervention|The intervention group will receive EBF promotional messages from the time of discharge until 6 months post delivery.
89279020|NCT03890978|Other|control|the control group will receive child health care-related messages (except breastfeeding messages) from the time of discharge until 6 months post delivery.
89279021|NCT01262066|Experimental|LifeSkills workshop intervention|Participants attended 10 1-hr weekly sessions. The content of the groups followed the LifeSkills Workshop manual and Video(Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
89279022|NCT01262066|No Intervention|Enhanced usual care|The Usual Care group received a self-help brochure on BP control developed by the National Heart, Lung, and Blood Institute (NHLBI). In addition, with the participants' permission, their BP readings were sent to their listed physicians, along with the 1-page JNC-7 express summary for the management of high BP.
89279023|NCT03314272|No Intervention|Sliding scale protocol|"Consists of giving insulin every 30 minutes based on the blood glucose readings as follows:~<150 mg/dl: 0 units of insulin~150-220 mg/dl: 2 units of insulin~201-250 mg/dl: 4 units~251-300 mg/dl: 6 units~301-350 mg/dl: 8 units~351-400 mg/dl: 10 units~> 400 mg/dl: inform the MD on call"
89279024|NCT03314272|Experimental|Space Glucose Control|"Automated protocol consisting of an insulin infusion pump named The Space Glucose Control System.~Intervention:~For glucose measurement, a sample of blood gas will be taken every 30 minutes. Actrapid HM will be used in a 4IU/ ml concentration for infusion in a 50 ml syringe.~The range of glucose will be recorded throughout the intra-operative period. The number of hypoglycemic (<70mg/dl) and hyperglycemic (> 200mg/dl) events will be recorded."
89279025|NCT03638050||In-hospital acute myocardial infarction patients|Functional Capacity Assessment
89279026|NCT03891056|Active Comparator|Gastric bypass|Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
89279027|NCT03891056|Active Comparator|Slevee gastrectomy|Twenty patients will be randomly assigned to perform a sleeve gastrectomy
89279028|NCT01260116||1|Ziprasidone,Zeldox capsule
89279029|NCT03271528|Experimental|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
89279030|NCT03271528|Placebo Comparator|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
89279031|NCT01262144||Case group|
89279032|NCT01153412|No Intervention|Control Group|Control group no intervention
89279033|NCT01153412|Experimental|Osteopathic Manipulative Treatment|Osteopathic Manipulative medicine group
89279034|NCT01155596|No Intervention|Control group|Base on positive pressure ventilation with intubation and mechanical ventilator, weaning processes will undergo by Pulmonologists.
89279035|NCT01155596|Experimental|Experimental group|Experimental group is weaning with the support of negative pressure ventilator.
89279036|NCT02507596|Experimental|Nano-crystalline hydroxyapatite silica gel|hydroxyapaptite bone graft with nano particle size in silica gel will be used to fill in the defect after opening a periodontal flap
89279037|NCT02507596|Sham Comparator|Open flap debridement|an open periodontal flap without adding bone graft.
89279038|NCT03889184|Experimental|rehabilitating meals-on-wheels service|the intervention group will for 8 weeks receive a rehabilitating meals-on-wheels service
89279039|NCT03889184|No Intervention|Usual care|the control group will receive usual care
89279040|NCT04480372|Experimental|NSCLC (cohort 1) and inoperable MPM (cohort 2)|"Cohort 1 consists of NSCLC patients. Cohort 2 consists of MPM patients.~Patients will be treated with gemcitabine at the dose of 1000 mg/m2 i.v. on day 1 and day 8 of each cycle (every 3 weeks) and with atezolizumab at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).~The trial treatments will be continued for max. 2 years or until discontinuation criteria are met (see Ch. 9.3), whichever occurs first. The follow-up phase will last up to 5 years from treatment start."
89279041|NCT03885440||Young adult, without OSAS|20<=Age<40 years old, apnea-hypopnea index(AHI)<5
89279042|NCT03885440||Young adult, with OSAS|20<=Age<40 years old, AHI>=5
89279043|NCT03885440||older adult, without OSAS|Age>=40 years old, AHI<5
89279044|NCT03885440||older adult, with OSAS|Age>=40 years old, AHI>=5
89279045|NCT01153490|Placebo Comparator|Placebo|
89279046|NCT01153490|Active Comparator|Quetiapine ER|
89279047|NCT01586390|Experimental|MOK|Adjustable and removable brace made out of Softcast material
89279048|NCT01586390|Active Comparator|WRAP|Softcast ankle cast
89279049|NCT04461262|Experimental|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
89279050|NCT04461262|Other|Standard Care|Foley catheter, uncoated
89279051|NCT03890510|Active Comparator|Low PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 6~9% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
89279052|NCT03890510|Active Comparator|High PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 13~16% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
89279053|NCT03301714|No Intervention|Control: Standard of Care|Regular dental care under the standard clinic operation
89279054|NCT03301714|Experimental|Intervention 1: Group-based oral health education|Group based oral health education
89279055|NCT03301714|Experimental|Intervention 2: Individual-based oral health education|Individual-based motivational interviewing
89279056|NCT01259570|Active Comparator|Skimmilk enriched with VD encapsulated in CM|
89279057|NCT01259570|Active Comparator|VD will be dissolved in milkfat and homogenized into skimmilk|VD will be dissolved in milkfat and homogenized into skimmilk
89279058|NCT01259570|Active Comparator|3% fat milk wherein the VD will be in CM|3% fat milk wherein the VD will be in CM
89279059|NCT01259570|Active Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
89279060|NCT03885752|Active Comparator|the control group|
89279061|NCT03885752|Placebo Comparator|the gum group|
89279062|NCT03890276|Active Comparator|HMS EL&C training without video|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will be able to: 1) distinguish normal and abnormal findings, 2) competently and confidently manage normal labor and birth to help prevent complications, 3) employ evidence-based practices, 4) rapidly identify and manage complications when they arise and 5) provide respectful care
89290229|NCT03093688|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells and CD8+T cells .
89279063|NCT03890276|Experimental|HMS training with video supplementation|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will ALSO receive the training with interspersed with short video clips that that aim to improve understanding and skills acquisition ('Videos used to supplement live trainer'). Video supplementation is meant to standardize the cascaded training in the future as the training is offered at a much larger scale in low and middle income countries.
89279064|NCT01153568|Placebo Comparator|Placebo|placebo
89279065|NCT01153568|Experimental|Vitamin D 3|Vitamin D3 will be available in doses of 60, 90, 120, and 150 µg
89279066|NCT03885674|Experimental|Reminder Interventions|Receive daily reminders from Kessler Foundation study personnel on when to take their medication.
89279067|NCT03885674|No Intervention|Standard Condition|This group will not receive reminders on when to take their medication from Kessler Foundation staff and will receive the usual and standard care.
89279068|NCT03885206|Experimental|Hospital|Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual.
89279069|NCT03885206|No Intervention|Municipal acute ward|Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician.
89279070|NCT01153646|Experimental|Cohort 1: 1x10e9 and Cohort 2: 1x10e10 T cells per infusion|Group of patients receiving genetically modified T-cells
89279071|NCT03890198|Experimental|chimeric Antigen Receptor T cell|LCAR-C182A Cells
89279072|NCT03889808||Non immunosuppressed patients|without treatment or treated with Salicylates and that have not received immunosuppressive therapy, steroids, or biologics in the last 6 months.
89279073|NCT03889808||Patients with immunosuppressive therapy|Azathioprine, 6-Mercaptopurine, Methotrexate in standard dosage at least the past 6 months and that have not received steroids or biologics in the last 6 months.
89279074|NCT03889808||Patients with biologic agents|in standard dosage at least the past 6 months and that have not received steroids in the previous 6 months.
89279075|NCT03889808||Patients with steroid treatment|Must have received daily steroid treatment ≥ 20 mg for ≥ 2 weeks.
89279076|NCT03889808||Healthy subjects|A healthy subject is defined as not having and immunosuppressive underlying condition, not receiving immunosuppressive therapy, has not received antibiotic treatment in the last 6 months, has no past C. difficile infections and has not been in contact with the health care system or hospitalized in the previous 6 months.
89279077|NCT03890042|Active Comparator|Dienogest group|
89279078|NCT03890042|Active Comparator|Gynera group|
89279079|NCT01153802|Experimental|Healthy Male Volunteers|All the 12 subjects enrolled in the study were exposed to at least one dose of GSK1360707 15 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. All the subjects completed the study. The initial dose, given in the study as a single-dose was 15 mg GSK1360707. The remaining subjects were dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose did not exceed 150 mg per day, the maximum total dose given in the FTIH study.
89279080|NCT03299686|Experimental|CJM112|Study treatment
89279081|NCT03299686|Placebo Comparator|Placebo to CJM112|Placebo
89279082|NCT03889964||patients with stable COPD|
89279083|NCT03885284|Experimental|Dose Level 1|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 8-12 of cycle 6"
89279084|NCT03885284|Experimental|Dose Level 2|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 15-19 of cycle 6"
89279085|NCT01153100|No Intervention|Standard insulin drip therapy|Standard insulin drip therapy
89279086|NCT01153100|Active Comparator|Insulin drip and glargine|Insulin drip and glargine 0.25 units per kg body weight
89279087|NCT01262222||pts undergoing major surg procedure referred to cardiology|Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
89279088|NCT03889496|Other|Scheduled for (partial) pancreatectomy or Whipple procedure|I.v. injection with In-111-DTPA-exendin-4 and SPECT/CT scan
89279089|NCT03884738|Active Comparator|Concentric|Leg Curl Training
89279090|NCT03884738|Active Comparator|Eccentric|Nordic Hamstring Training
89279091|NCT03884738|Active Comparator|Neuromuscular Electrical Stimulation|Stimulation Training
89279092|NCT01153256|Experimental|group M|
89279093|NCT01153256|Placebo Comparator|Group R-0.6|
89279094|NCT01153256|Placebo Comparator|Group R-0.9|
89279095|NCT01153334|Experimental|Early intensive rosuvastatin therapy|
89279096|NCT01153334|Placebo Comparator|Conventional statin therapy|
89279097|NCT01259804|Experimental|Peanut immunotherapy|Peanut flour
89279098|NCT03881930|Experimental|Experimental group|"Balance rehabilitation with modified visual input:~In experimental group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with modified visual input."
89279099|NCT03881930|Active Comparator|control group|"Balance rehabilitation with no modified visual input:~In control group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with no modified visual input."
89279100|NCT01153880||Age <9 months definitive|Age at time of prescription was <9 months
89279101|NCT01153880||Age <9 months uncertain|Age at time of prescription was uncertain for <9 months
89279102|NCT01153880||9 months to 6 years|Age at time of prescription was 9 months to 6 years
89279103|NCT01153880||7 to 18 years|Age at time of prescription was 7 to 18 years
89279104|NCT01153880||19 to 65 years|Age at time of prescription was 19 to 65 years
89279105|NCT01153880||66 years and older|Age at time of prescription was 66 years and older
89279106|NCT01260428||healthy active subjects|with and without high altitude intolerance
89279107|NCT05499338|Experimental|Experimental group|The experimental group received a lecture session explaining what stretching is, its advantages and the importance of stretching in injury prevention. The specific intervention programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
89279108|NCT05499338|No Intervention|Control group|The control group performed the initial and final assessments and continued to perform their team's standard/habitual stretches. To record whether they performed the stretches prescribed by the club, the researchers went to the end of the training unknown sessions and recorded whether the players performed them or not.
89279109|NCT03884894||sepsis diagnosis by blood colture/molecular biology|fullterm/ preterm neonates hospitalized in NICU with suspect of sepsis
89279110|NCT03881774|Experimental|experimental arm|cord blood derived CAR T cells group
89279111|NCT01260506|Experimental|VB-111|Antiangiogenic and vascular disruptive agent
89279112|NCT01262300|Experimental|VZV vaccine|"Varicella Zoster Virus vaccine (Zostavax), single dose X 1 injection~All subjects in this trial will receive the VZV vaccine. The Investigators will primarily compare immune responses in those that are receiving high dose vs. standard dose vitamin D supplementation and those that have high and low 25-hydroxyvitamin D levels."
89279113|NCT01154114|Experimental|moderate hepatic impaired subjects|Male and female subjects with moderate hepatic impairment defined by a Child-Pugh score of 7-9 will be included. The subjects will be administered 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets daily for 10 consecutive days.
89279114|NCT01154114|Experimental|normal healthy volunteers|Healthy male and female subjects will be included and will be matched as closely as possible to the group of moderate hepatic impairment subjects for gender, age and body mass index. Each subject will receive daily 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets for 10 consecutive days.
89279115|NCT03462758|Other|Control Group|IUD placed 6-8 weeks postpartum (standard of care, interval placement)
89279116|NCT03462758|Experimental|Intervention Group|IUD placed 2-4 weeks postpartum (early postpartum placement, EPP)
89279117|NCT01157312|Experimental|minimal stimulation protocol|5 days of CC (100mg/day) from day 3 followed by 150 IU of highly purified uFSH on cycle day 9 for three treatment cycles
89279118|NCT01157312|Active Comparator|clomiphene citrate(CC)|5 days of CC (100mg/day) from cycle day 3 for three treatment cycles.
89279119|NCT01157390|Experimental|Infant formula|The infants will be fed with Wondersun infant formula with high proportion of palmitic acid at the sn-2 position
89279120|NCT01157390|Active Comparator|Breast feeding|Complete breast feed within the first 3 month
89279121|NCT01155674||Sepsis patients|Patients presenting sepsis
89279122|NCT01155674||SIRS patients|Patients presenting with the systemic inflammatory response syndrome
89279123|NCT01155674||Healthy subjects|Healthy blood donors
89279124|NCT01157468||Cases|"The Case group is constituted with patients with Systemic Lupus Erythematosus from Martinique, divided en 2:~30 patients with a quiescent lupus~30 patients with an active lupus"
89279125|NCT01157468||Controles|"The Control group is constituted by people coming to give blood to the French Blood Establishment of Martinique."
89279126|NCT03888248|Active Comparator|Exercises|Daily muscle-strengthening exercises
89279127|NCT03888248|Experimental|Whole-body vibration + exercises|Home-based whole-body vibration therapy plus daily muscle-strengthening exercises
89279128|NCT01262378|Other|Harmonic knife|surgery using the Harmonic knife
89279129|NCT01262378|Active Comparator|HF knife|
89279130|NCT03888326|Experimental|Robotic Rehabilitation plus 1x1 anodal tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to 20 minutes, 2mA anodal tDCS (Soterix 1x1 tDCS) over the ipsilesional sensory cortex during the first 20 minutes of each robotic session. Current is ramped up to 2mA over 30 seconds and ramped back down over 30 seconds at the end of the 20 minutes.
89279131|NCT03888326|Sham Comparator|Robotic Rehabilitation plus sham tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to sham anodal tDCS over the ipsilesional sensory cortex. Current is ramped up to 2mA over 30 seconds and immediately ramped back down over 30 seconds. This is repeated after 20 minutes.
89279132|NCT03888326|No Intervention|Standard of Care Rehabilitation|No additional therapy/treatment provided. The individual continues with their normal daily routine
89279133|NCT01154270|Experimental|IMRT + C12-boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
89279134|NCT03881618|Experimental|electroacupuncture+auricular pressure|a group :electroacupuncture+auricular pressure for 20 minutes twice a week for 4 weeks
89279135|NCT03881618|Active Comparator|auricular pressure|b group :auricular pressure for 20 minutes twice a week for 4 weeks.
89279136|NCT03881540|Active Comparator|tDNA-MI group|Follow tDNA intervention and motivational interviewing counselling
89279137|NCT03881540|Active Comparator|tDNA-CC group|Follow tDNA intervention and conventional counselling
89279138|NCT03881540|Other|UC group|Follow a conventional diet with standard diabetes support and lifestyle education
89279139|NCT01157546|Placebo Comparator|Control|group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
89279140|NCT01157546|Experimental|TAP|group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
89279141|NCT01263860|Experimental|24-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
89279142|NCT01263860|Active Comparator|48-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
89279143|NCT03884582||HealthyVolunteers|
89279144|NCT03881306|Experimental|D-TACE|D-TACE for inoperable NEN liver metastases. Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin
89279145|NCT01154348|Experimental|Washout period, S-707106 tablet|14-day washout of metformin, followed by S-707106 once daily for 14 days under fed conditions
89279146|NCT01154348|Placebo Comparator|Washout, placebo|14-day washout of metformin followed by placebo for S-707106 once daily for 14 days under fed conditions
89279147|NCT01154348|Experimental|Maintenance, S-707106 tablet plus metformin|14-day maintenance of metformin, followed by S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
89279148|NCT01154348|Placebo Comparator|Maintenance, placebo plus metformin|14-day maintenance of metformin, followed by placebo for S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
89279149|NCT00075270|Experimental|Arm 1|Lapatinib 1500 mg, once daily and Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks
89279150|NCT00075270|Placebo Comparator|Arm 2|Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks and Placebo
89279151|NCT01155752|Experimental|PULMOZYME|active drug
89279152|NCT01155752|Placebo Comparator|placebo|cross over to placebo
89279153|NCT03888170||Non-pregnant|Women aged 18-45 years old undergoing elective hysterectomy (either vaginal, laparoscopic, or open routes) for benign indications.
89279154|NCT03888170||Pregnant|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age.
89279155|NCT03888170||Pregnant with hypertension|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age with pregnancy complicate by chronic hypertension, gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, or superimposed preeclampsia.
89279156|NCT03884348||PAM-treated clarithromycin-resistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations
89279157|NCT03884348||PAC-treated nonresistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations
89279158|NCT03881384||ctDNA level|ctDNA level during neoadjuant chemotherapy
88805626|NCT05308043||Retinoblastoma patients|Retinoblastoma patients who undergo standard medical care in Beijing Tongren Hospital. The anonymous image of these patients will be prospectively collected and labelled by senior ophthalmologists.
89279159|NCT01264172|Active Comparator|PCCP, Proximal femur fracture|Patients, who received a minimal-invasive surgical treatment with the PCCP-plate
89279160|NCT01264172|Active Comparator|Osteosythesis with nails, prox. femur frac.|Patients, who received a minimal-invasive surgical treatment including a osteosynthesis with nails
89279161|NCT01264172|Active Comparator|DHS, proximal femur fracture|Patients, who received a conventional surgical treatment with the dynamic hip screw (DHS)
89279162|NCT02527382|Experimental|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a distal clamp is placed on the rectal stump.
89279163|NCT02527382|No Intervention|Open stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while no distal clamp is placed on the rectal stump.
89279164|NCT01154426|Experimental|Treatment (gemcitabine hydrochloride and ABT-888)|Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21* days in the absence of disease progression or unacceptable toxicity.
89279165|NCT01589744|Experimental|Suction cup Hemostatic Intra-Uterin|The suction haemostatic cup will be positioned into the uterus, and the aim is to stop haemorrhage
89279166|NCT01154504|Other|clinical treatment|"Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized.~Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3)."
89279167|NCT01154504|Experimental|ultrafiltration|"ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3).~Diuretic will be withdrawn during ultrafiltration."
89279168|NCT01154504|Experimental|isovolumetric hemofiltration|Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3).
89279169|NCT01157624|Active Comparator|oxygen|
89279170|NCT01157624|Placebo Comparator|air supplement|
89279171|NCT00074958|Experimental|Fabrazyme|1.0 mg/kg of Fabrazyme given to the patients every 2 weeks
89279172|NCT01157702|Experimental|Vaccine|Vaccination with one dose (0.5 mL) of inactivated influenza vaccine
89279173|NCT03881462|Experimental|Axillary nerve block|Axillary nerve block is performed in standardized manner and muscle force is measured before and after the block.
89279174|NCT01093950||PROSPECTIVE BODY CONTOURING SUBJECTS|"It is anticipated that the participants will undergo body contouring procedures including lipoplasty [internal fat suction removal], abdominoplasty [surgical removal of lower abdominal skin and fat], breast reduction [surgical removal of breast skin, fat, and breast tissue to reduce breast size], breast augmentation [surgical breast enlargement], thigh lift [surgical removal of upper thigh tissue], and brachioplasty [surgical removal of upper arm tissue].~These procedures will be evaluated by pre- and post-operative digital scans, analog measurements, and clinical examinations and photographs."
89279175|NCT03881072|Other|Ultrasounicelastography|Ultrasounicelastography:non-invasive, convenient and comprehensive evaluation method.
89279176|NCT03880916|Experimental|Duloxetine group|"Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
89279177|NCT03880916|Placebo Comparator|Placebo group|"Phase I (preemptive): 2weeks before operation (Placebo for 2weeks)~Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
89279178|NCT01155908|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
89279179|NCT01155908|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
89279180|NCT03880760|Experimental|Probiotics capsule|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
89279181|NCT03880760|Placebo Comparator|Placebo capsule|Taking 1 placebo capsule twice a day before meals for six months.
89279182|NCT03880448|Experimental|Metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (metronidazole 500mg/8h/7days)
89279183|NCT03880448|Placebo Comparator|Placebo + periodontal surgery|Periodontal surgery + Placebo (cornstarch 500mg/8h/7days)
89279184|NCT02527226|No Intervention|No facial exercises|This group will not receive any training in facial exercises.
89279185|NCT02527226|Experimental|Facial exercises|This group will receive instruction to perform a series of self-administered exercises of facial expression and movements.
89279186|NCT01157780|Experimental|fish oil|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
89279187|NCT01157780|No Intervention|standard of care|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
89279188|NCT03884192|Experimental|Sintilimab Arm|Sintilimab consolidation therapy
89279189|NCT03884192|No Intervention|Observation Arm|Observation
89279190|NCT03880604|Active Comparator|Triple tourniquets plus TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus1-gram tranexamic acid (10 ml) in 100 ml saline infusion
89279191|NCT03880604|Active Comparator|Triple tourniquets plus placebo to TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
89279192|NCT01264250|Experimental|1|
89279193|NCT01264250|Placebo Comparator|2|
89279194|NCT03887858|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
89279195|NCT03887858|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~Period 2: Harnal-D Tab. 1T"
88805627|NCT01095887|Experimental|eculizumab|Eculizumab was given on Day 0, day 1, and weekly for the first four weeks after transplant.
88805628|NCT01096823|Experimental|Iyengar Yoga|
89279196|NCT03887546|Experimental|Intervention group|"Intervention is administrated with Inspiratory Muscle Trainer. 20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the second week.~12 weeks, 5 days/week, 15 minutes/day."
88805629|NCT01096823|No Intervention|Waitlist Control|
88805630|NCT03110315|Experimental|Suvorexant|Suvorexant - 10 mg (one tablet) taken by mouth once daily at bedtime with option to up-titrate to 20 mg (two tablets) taken by mouth once daily at bedtime.
88805631|NCT03110315|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth once daily at bedtime and two tablets taken by mouth daily at bedtime if subject up-titrates.
89279197|NCT03887546|Active Comparator|Control group|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day
89279198|NCT02940574|Experimental|Syntocinon (Oxytocin, product code RVG 03716)|Administration via nasal spray
89279199|NCT02940574|Placebo Comparator|Placebo (Physiological water(sodium chloride (NaCl) solution))|Administration via nasal spray
89279200|NCT01154582|Experimental|Egg|
89279201|NCT01154582|Experimental|Cottage cheese|
89279202|NCT03880370||group 1(group without low back pain)|Participants inclusion criteria an age 18 to 55 years of age who practice sports equal to greater than three hours per week who have not had low back pain or ciatalgia in the last 12 months.
89279203|NCT03880370||group 2 (low back pain group)|Participants inclusion criteria an age 18 and 55 years of age who practice sports equal to greater than three hours a week, with a history of at least one episode of low back pain and / or ciatalgia in the last 12 months lasting no longer than three months and diagnosis of hernia lumbar disc using MRI.
89279204|NCT01264328|Experimental|Panitumumab + Paclitaxel|Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the first day and in 30 minutes thereafter (if no infusional reaction was observed) plus intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour infusion, until progression or unacceptable toxicity. Panitumumab does not require prophylactic premedication from the first infusion. Paclitaxel was administered with: dexamethasone 10 mg, diphenhydramine 30 mg and antiH2 (cimetidine 300 mg or ranitidine 50 mg). Dose modifications of paclitaxel included 4.8 mg/kg (80% of the initial dose) and 3.6 mg/kg (60%) when recovered from a grade 3-4 skin toxicity to grade ≤2. Continuing paclitaxel on the day of the planned infusion required no grade ≥2 mucositis and hematologic recovery with an absolute neutrophil count ≥1,500/ml and a platelet count ≥75,000.
89279205|NCT01157858|Active Comparator|Everolimus + octreotide LAR|Octreotide LAR combined with everolimus
89279206|NCT01157858|Active Comparator|Octreotide LAR|Octreotide LAR monotherapy
89279207|NCT01264406||Exercise Group (20 KKW)|Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session.
89279208|NCT01264406||Exercise Group (8 KKW)|One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per wee, which will result in each session lasting approximately 30 minutes
89279209|NCT01264406||Control group|This group will be instructed to maintain their baseline level of exercise.
89279210|NCT01157936|Active Comparator|Allopurinol treatment|
89279211|NCT01157936|Placebo Comparator|Placebo|
89279212|NCT01262534||1|Clinical profile of patients Comorbidities and associated type of treatments will be collected.
89279213|NCT01262534||2|Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
89279214|NCT01262534||3|Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
89279215|NCT01264484||Advantage prosthetic heart valve|All patients who were enrolled and implanted with an Advantage valve in the Herzzentrum Nordrhein-Westfalen (Bad Oeynhausen, Germany) and Deutsches Herzzentrum München (Munich, Germany) during the previous Advantage clinical study study and who agree to participate in this long-term follow-up study by informed consent.
89279216|NCT01260818|Experimental|Tranexamic Acid|
89279217|NCT01260818|Placebo Comparator|control group|
89279218|NCT03884426||Patients with MVP|The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.
89279219|NCT03884426||Normal relatives|Related healthy patients, for an average of 6 individuals per family
89279220|NCT01262612|Active Comparator|immediate treatment with cediranib|8 patients with ascites and 8 patients with pleural effusion will start immediate treatment with cediranib
89279221|NCT01262612|Active Comparator|start cediranib after 28 days BSC|patients in group B will start with cediranib after one month best supportive care.
89279222|NCT03887390|No Intervention|Usual Care|Participants in this arm will receive care as usual.
89279223|NCT03887390|Experimental|Depression Medication Choice|Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.
89279224|NCT01158014|Experimental|Fibrin Glue, surgery|Conjunctival autograft will be glued using fibrin glue to pterygia bed after removal
89279225|NCT01158014|Active Comparator|Control|Conjunctival autograft will be sutured using 10/0 vicryl sutures to pterygia bed after removal
89279226|NCT03884114|Other|All participants|All participants are evaluated on a scenario of pediatric asthma exacerbation using three different evaluation tools: (i) the simulation game EfficAsthme developed to train individuals on the management of pediatric asthma exacerbations; (ii) a MCQ on the same subject developed for the purpose of the study and (iii) HF-simulation, considered as the gold-standard for its enhanced realism.
89279227|NCT01158092|Active Comparator|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
89279228|NCT01158092|Active Comparator|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
89279229|NCT03884036|Active Comparator|Vitamin D group|Vitamin D 200,000 IU (1 cc) IM
89279230|NCT03884036|Placebo Comparator|Control group|Normal saline 1 cc IM
89279231|NCT01158170|Experimental|prophylactic cranial irradiation|Patients receive Erlotinib or gefitinib until disease progression or intolerable toxicity, and prophylactic cranial irradiation 25GY over 10 fractions.
89279232|NCT01158170|Active Comparator|Conctrol|Patients received Erlotinib or gefitinib until disease progression,or intolerable toxicity
88805632|NCT01097915||PROP taste sensitivity|"PROP Sensitive and non sensitive individuals are defined as Tasters and Non-tasters, respectively. Taster are further divided in Super-taster who perceived PROP as extremely bitter and Medium tasters who perceived PROP as moderately bitter."
89279233|NCT03880136|Experimental|Sequence 1|Period 1: CTP-543 with meal Period 2: CTP-543 without meal
89279234|NCT03880136|Experimental|Sequence 2|Period 1: CTP-543 without meal Period 2: CTP-543 with meal
89279235|NCT01264562||Chemotherapy group|Breast cancer patients treated with chemotherapy
89279236|NCT01264562||Non-chemotherapy group|Breast cancer patients not treated with chemotherapy
89279237|NCT01264562||Healthy controls|Women without a cancer diagnosis, matched for age and education
89279238|NCT01260974|Experimental|Caspofungin|Study group
89279239|NCT03879980|Placebo Comparator|Non-QL block|The control (non-QL block) group only received fentanyl IV during surgery.
89279240|NCT03879980|Experimental|Bilateral QL block|The patients were in the semi-lateral supine position to show up the side to be blocked. Using USG and 1-6 MHz convex transducer placed in the transverse plane above the iliac crest at the level of the umbilicus. A Stimuplex® 20G 100-mm needle was advanced in anteroposterior direction toward the junction of tapered abdominal muscle layer and QL muscle, and 20 ml of 0.25% bupivacaine was deposited in the anterolateral border of QL muscle at the junction with the transversalis fascia reach outside the anterior layer of transversalis fascia. The lateral approach QL (type I) blocks were performed at both sides of patients. The total amount of bupivacaine was 100 mg for each patient
89279241|NCT03883958|Active Comparator|TPVB|
89279242|NCT03883958|Experimental|ESPB|
89279243|NCT01264640|Experimental|A|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
89279244|NCT01262690|Experimental|Dose|6 treated, 3 placebos
89279245|NCT03887468|Active Comparator|"EvoCit"|"Standardized hemodialysis treatments 3x4hours/week. Intervention: EvoCit procedure using a heparin-grafted AN69ST dialyzer in combination with a citric acid enriched dialysate without any systemic anticoagulation."
89279246|NCT03887468|Active Comparator|"EvoHep"|"Control: EvoHep procedure using a heparin-grafted AN69ST dialyzer in combination with a conventional bicarbonate-based dialysate and standardized systemic anticoagulation using unfractionated heparin."
89279247|NCT01155986|Placebo Comparator|Placebo Plaster|Active Comparator
89279248|NCT01155986|Active Comparator|Lidocaine Plaster|
89279249|NCT01261130|Experimental|Part I-A: 10μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation A
89279250|NCT01261130|Experimental|Part I-B: 30μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation B
89279251|NCT01261130|Experimental|Part I-C: 100μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation C
89279252|NCT01261130|Experimental|Part I-D: 10μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation D
89279253|NCT01261130|Experimental|Part I-E: 30μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation E
89279254|NCT01261130|Experimental|Part I-F: 100μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation F
89279255|NCT01261130|Experimental|Part II-A: 10μgNaGST1/Alhydrogel|Part II (endemic area), Formulation A
89279256|NCT01261130|Experimental|Part II-B: 30μgNaGST1/Alhydrogel|Part II (endemic area), Formulation B
89279257|NCT01261130|Experimental|Part II-C: 100μgNaGST1/Alhydrogel|Part II (endemic), Formulation C
89279258|NCT01261130|Experimental|Part II-D: 10μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation D
89279259|NCT01261130|Experimental|Part II-E: 30μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation E
89279260|NCT01261130|Experimental|Part II-F: 100μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation F
89279261|NCT01261130|Active Comparator|Part II-G: Butang® hepatitis B vaccine|Part II (endemic), HepB comparator
89279262|NCT03887312|Experimental|t-CETA|Telephone-delivered Common Elements Treatment Approach (t-CETA). t-CETA sessions of up to 30 minutes will be delivered 1-2 times per week for approximately 8-12 weeks. The number and content of sessions will be tailored to each child, thus there will be some variation.
89279263|NCT03887312|Active Comparator|Médecins du Monde treatment as usual|Treatment as usual provided by Médecins du Monde. The number and content of sessions will vary depending on the needs of the child.
89279264|NCT03887156|Other|Arm 1|One arm
89279265|NCT01154660|Experimental|Neutral|
89279266|NCT01154660|Active Comparator|Trendelenberg|
89279267|NCT01158326|Active Comparator|Resfenol Solution oral|Acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride active drug
89279268|NCT01158326|Placebo Comparator|Placebo|Placebo oral solution
89279269|NCT01586546|Experimental|Face-to-Face MBM Skills Group|
89279270|NCT01586546|Experimental|Online MBM Skills Group|
89279271|NCT01586546|Other|Waitlist Control I|This group will be given the option to participate in a face-to-face MBM skills group intervention after conclusion of study.
89279272|NCT01586546|Other|Waitlisted Control II|This group will be given the option to participate in an Online MBM skills group intervention after conclusion of study.
89279273|NCT03879824|Experimental|Radial Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the radial artery (right radial artery only) during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary radial artery access during TAVI"
89279274|NCT03879824|Active Comparator|Femoral Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the contralateral femoral artery artery during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary femoral artery access during TAVI"
89279275|NCT01264796|Experimental|behavioral intervention, counseling|2hr group education for 6 weeks
89279276|NCT01264796|No Intervention|delyed intervention|control group
89279277|NCT01156064||Case (subjects with digestive diseases)|The investigators cases are subjects with confirmed digestive diseases.
89279278|NCT01156064||Control|Healthy individuals aged between 18 and 90 years who are asymptomatic for digestive diseases.
89279279|NCT01264874|Experimental|Vitamin D3|Vitamin D3 administration
89279280|NCT01264874|Placebo Comparator|placebo|matched placebo
89279281|NCT01262768|Experimental|2D Portion Size Measurment Aids (PSMAs)|The 2D PSMAs are life-size photographs of the 3D PSMAs.
89279282|NCT01262768|Experimental|3D Portion Size Measurement Aids (PSMAs)|The 3D PSMAs include foam rubber replicas of a golf ball, a hockey puck, a tennis ball and a baseball.
89279283|NCT01586468|Placebo Comparator|NaCl Solution|
89279284|NCT01586468|Experimental|WF10 0.5 ml/kg BW|
89279285|NCT01158482||IVC Filter Placement or Removal|Patients undergoing IVC filter placement and/or IVC filter removal at Stanford Medical Center.
89279286|NCT01262924|Experimental|Group A|dTPa vaccine
89279287|NCT01262924|Experimental|Group B|Pa vaccine
89279288|NCT01262924|Active Comparator|Group C|Tedivax-Adult™/ Td-Rix™
89279289|NCT01158560|Experimental|Vitamin D and gargling|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and asked to gargle with tap water twice daily
89279290|NCT01158560|Experimental|Vitamin D and general health advice|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and will receive general health advice in place of gargling advice
89279291|NCT01158560|Placebo Comparator|Placebo and general health advice|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be given general health advice in place of gargling advice.
89279292|NCT01158560|Placebo Comparator|Placebo and gargling|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be asked to gargle with tap water twice daily
89279293|NCT01158794||Study participants|Participants with sickle cell disease and transfusional iron-overload, and non-sickle cell disease (thalassemia major, cancer patients, etc.) and iron overload. Participants with iron overload, defined as too much iron in the body as a consequence of too many blood transfusions.
89279294|NCT03879746|Active Comparator|tamsulosin group|the first group will include 40 patients treated with daily administration of tamsulosin 0.4 mg
89279295|NCT03879746|Active Comparator|paroxetine group|the second group will include 40 patients treated with daily administration of paroxetine 20 mg
89279296|NCT03879746|Active Comparator|combined group|the third group will include 40 patients treated with daily administration of tamsulosin 0.4 mg and paroxetine 20 mg
89279297|NCT03879746|Placebo Comparator|placrbo group|the fourth group will include 40 patients will be given placebo
89279298|NCT03879590|Experimental|Budesonide and Doxophylline|Budesonide at the same dose in which the subject is currently treated (GINA step 3 or 4) plus doxophylline at a dose of 18 mg / kg per day
89279299|NCT03879590|Active Comparator|Low budesonide and Doxophylline|Reduced dose of inhaled budesonide (GINA step down) plus doxophylline to a dose of 18 mg / kg per day, maximum of 800 mg / day (Group B)
89279300|NCT01265108|Experimental|Intravenous iron sucrose|Infusion of 200 mg iron sucrose (Venofer) in 100 ml normal (0.9%) saline.
89279301|NCT01265108|Placebo Comparator|Intravenous normal saline|Infusion of 100 ml normal (0.9%) saline.
89279302|NCT01159028|Experimental|BP1001|Subjects are treated with open-label study drug (BP1001) in a dose-escalation model.
89279303|NCT01159028|Experimental|BP1001 in combination with LDAC|AML subjects are treated with open-label escalating study drug (BP1001) in combination with low dose ara-C (LDAC)
89279304|NCT03886844||Prolacta group|Infants, who received a human milk fortifier based on human milk (12/2015-11/2018), started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity
89279305|NCT03886844||"Frauenmilch Supplement=FMS group"|Infants, who received a human milk fortifier based on bovine milk (05/2012-06/2015), started with an enteral intake of 100 ml/kg
89279306|NCT03887000|Experimental|MAGNESIUM|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
89279307|NCT03887000|Experimental|PLACEBO|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
89279308|NCT01154738|Experimental|Lidocaine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine
89279309|NCT01154738|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
89279310|NCT01265186||Ventilated term newborns|Ventilated newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
89279311|NCT01265186||Control group: healthy term newborns|Control group: healthy newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
89279312|NCT01263080|Active Comparator|mirtazapine+folic acid|mirtazapine 30mg QD, folic acid 0.4mg QD
89279313|NCT01263080|Active Comparator|mirtazapine+folic acid placebo|mirtazapine 30mg QD, folic acid placebo 1 tablet QD
89279314|NCT01263080|Active Comparator|mirtazapine placebo+folic acid|mirtazapine placebo 1 tablet QD, folic acid 0.4mg QD
89279315|NCT01263080|Placebo Comparator|mirtazapine placebo+folic acid placebo|mirtazapine placebo 1 tablet QD, folic acid placebo 1 tablet QD
89279316|NCT01261364|Active Comparator|Treatment as Usual|
89279317|NCT01261364|Experimental|Pharmacogenetic guided treatment|
89279318|NCT01263158|Experimental|Expectant group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Expectancy of standard oxytocin treatment for 3 hours.
89279319|NCT01263158|No Intervention|Early oxytocin group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Oxytocin treatment started within 20 minutes.
89279320|NCT01261442||Diabetic patients with DSPN|
89279321|NCT01261442||Diabetic patients without DSPN|
89279322|NCT01263236|Experimental|LY2940094 - single dose|Single oral dose of 2-800 milligram (mg) LY2940094
89279323|NCT01263236|Experimental|LY2940094 - multiple dose|Daily oral dose of 2-200 mg LY2940094 for 14 days
89279324|NCT01263236|Experimental|Placebo|Single oral dose or daily oral dose for 14 days
89279325|NCT03879356|Other|Aluminum phosphide patients|effect of N-acetyl cysteine and supportive measures in outcome of aluminum phosphide poisoning cases
89279326|NCT01159418|Experimental|Panobinostat (LBH589), Carboplatin and Paclitaxel|
89279327|NCT03886766|Experimental|Sequence 1,2,3|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period C/ Visit 10: Efavirenz solution, 3 mg, oral administration (product 3)
89279328|NCT03886766|Experimental|Sequence 2,3,1|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period B/ Visit 6: Efavirenz solution, 3 mg, oral administration (product 3) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
89279329|NCT03886766|Experimental|Sequence 3,1,2|Period A/ Visit 2: Efavirenz solution, 3 mg, oral administration (product 3) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
89279330|NCT01261520|Other|Culturally-tailored video|The culturally-tailored video was designed to focus on Chinese women's cultural health beliefs and align with Chinese customs, norms, and values, which includes two segments: 1) a soap-opera and 2) recommendation from a Chinese female physician.
89279331|NCT01261598|Other|1|Patients treated with curative and exclusive radiotherapy (60 Gy minimum), with possibly prior chemotherapy
89279332|NCT01261598|Other|2|Patient treated with concomitant chemotherapy and radiotherapy (60 Gy minimum), with possibly prior chemotherapy chemotherapy Treatment
89279333|NCT01265342|Placebo Comparator|Placebo|
89279334|NCT01265342|Experimental|Beclomethasone|Beclometasone suspension 400 mcg will be administered through a nebuliser twice a day, in the morning and in the evening, for 10 days
89279335|NCT03883334|Experimental|Immunomodulator group|Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.
89279336|NCT03883334|No Intervention|Control group|combine antiretroviral therapy only
89279337|NCT01159496|Experimental|Active|
89279338|NCT01159496|Placebo Comparator|Placebo|
89279339|NCT01265576|Placebo Comparator|Sorafenib with placebo|Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
89279340|NCT01265576|Experimental|Sorafenib plus VT-122|
89279341|NCT01261676||Caesarean section|
89279342|NCT01261676||Vaginal birth (control)|
89279343|NCT03883256|Active Comparator|high flow nasal cannula|Subjects perform a constant-load exercise test with high flow nasal cannula oxygen device.
89279344|NCT03883256|Active Comparator|nasal cannula|Subjects perform a constant-load exercise test with nasal cannula oxygen device.
89279345|NCT01261754|Active Comparator|Metastatic prostate adenocarcinoma|
89279346|NCT01261754|Active Comparator|Healthy Volunteers|
89279347|NCT01261754|Active Comparator|Newly Diagnosed, High-Risk Prosate Cancer Patients|
89279348|NCT01265654||All patients|Patients with ABC and two lines of hormonal treatment
89279349|NCT01265732|Active Comparator|oral single dose dispersion 100mg|Subjects receive a single dose of PF-04191834 as a dispersion
89279350|NCT01265732|Active Comparator|oral wet milled suspension 100mg|Subjects receive a single dose of PF-04191834 as a suspension
89279351|NCT01265732|Active Comparator|oral wet milled suspension 300mg|Subjects receive a single dose of PF-04191834 as a suspension
88805633|NCT02983487||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing"
89279352|NCT03883022|Experimental|Vancomycin (V Group)|
89279353|NCT03883022|Active Comparator|Without Vancomycin (NV Group)|
89279354|NCT01159652|Placebo Comparator|Bedtime Placebo|
89279355|NCT01159652|Placebo Comparator|Middle of the Night Placebo|
89279356|NCT01159652|Experimental|Zolpidem|
89279357|NCT01159652|Experimental|Zaleplon|
89279358|NCT01159730|Experimental|Multiple doses of VB-201|
89279359|NCT01159730|Placebo Comparator|Placebo|
89279360|NCT01159808|Experimental|INX-08189|
89279361|NCT01159808|Placebo Comparator|Placebo|
89279362|NCT03886532||Medical Marijuana|Those subject taking only medical marijuana as standard of care. Will collect registry data and collect blood samples.
89279363|NCT03886532||CBD only products|Those subjects taking only CBD products as standard of care. Will collect registry data and collect blood samples.
89279364|NCT01261832|Experimental|Dual antiplatelet therapy for 1 year|Dual antiplatelet therapy for 1 year : dual antiplatelet combination therapy with aspirin and clopidogrel for 1 year
89279365|NCT01261832|Experimental|Triple antiplatelet therapy for 1 month|Triple antiplatelet therapy for 1 month : triple antiplatelet therapy including cilostazol for 1 month and after then, dual antiplatelet therapy for 11 months
89279366|NCT01261832|Experimental|Triple antiplatelet therapy for 6 months|Triple antiplatelet therapy for 6 months : triple antiplatelet combination therapy including cilostazol for 6 months and after then, dual antiplatelet therapy for 6 months and cilostazol
89279367|NCT03882866|Experimental|3D-printed non-coplanar template|3D-printed non-coplanar template is used in this group.
89279368|NCT03882866|Active Comparator|3D-printed coplanar template|3D-printed coplanar template is used in this group.
89279369|NCT03883178|Experimental|Neurolysis|
89279370|NCT01265810|Other|sodium chloride -> supersaturated calcium-phosphate|Patients in this arm start first with sodium chloride 0.9% mouth rinses and go crossover to supersaturated calcium-phosphate mouth rinses.
89279371|NCT01265810|Other|supersaturated calcium-phosphate -> sodium chloride|Patients in this arm start first with supersaturated calcium-phosphate mouth rinses and go crossover to sodium chloride 0.9% mouth rinses.
89279372|NCT01156298||Cohort 1|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI will be performed each patient's 15 year anniversary date.
89279373|NCT01156298||Cohort 2|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Patients will be waiving written informed consent and asked to provide concomitant medication, self-reported EDSS, and SF-36 only.
89279374|NCT01265888|Experimental|Dosing Group 1|1 Liter per Minute (LPM)of inhaled nitric oxide via nasal cannula: approximately 5 parts per million (ppm)
89279375|NCT01265888|Experimental|Dosing Group 2|2 LPM of inhaled nitric oxide via nasal cannula: approximately 15 ppm
89279376|NCT01265888|Experimental|Dosing Group 3|4 LPM of inhaled nitric oxide via nasal cannula: approximately 20 ppm
89279377|NCT01154894|Experimental|Placebo-controlled trial|
89279378|NCT03886376|Experimental|Deep Massage|The deep massage was performed three times during a training week, after a physical training and before the swimming training
89279379|NCT03886376|Active Comparator|Superficial Massage|The superficial massage was performed three times during a training week, after a physical training and before the swimming training
89279380|NCT03886376|No Intervention|Control|The control group kept their normal routine of training. Immediately after the physical training the athletes were instructed to wait for 12 minutes (passive recovery) until the beginning of the swim training.
89279381|NCT03886688|Experimental|single ascending|Drug or placebo, oral, fast, single dose ascending
89279382|NCT03886688|Experimental|multiple ascending|Drug or placebo, oral, fast, multiple dose ascending
89279383|NCT03886688|Experimental|Food Effect|Drug or placebo, oral, fed or fast, single dose
89279384|NCT01154972|Experimental|Single arm study - Sentinel Node Localisation|
89279385|NCT01261910|No Intervention|Usual education (standard care)|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant.
89279386|NCT01261910|Experimental|Intensive initial education|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant. In addition, participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
89279387|NCT01155128|Experimental|Lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
89279388|NCT01155128|Placebo Comparator|lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
89279389|NCT01155206|Experimental|high glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a dose that has been shown to achieve high physiological plasma levels. The IV glucagon will be administered at a rate of 3ng/kg/min.
89279390|NCT01155206|Experimental|low glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a low rate that is designed to mimic basal plasma glucagon concentration. The IV glucagon will be administered at a rate of 0.65ng/kg/min.
89279391|NCT03675386|Active Comparator|Control Group|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
89279392|NCT03675386|Experimental|Interventional Group|Patients in the interventional group will be given a Transitional Pain Service follow-up appointment at the following postoperative time points (2 to 6 visits for the first two months, and then 1 to 2 visits on a monthly basis until one year). At each visit, patients will meet with the clinical psychologist and chronic pain specialist. Patients in the intervention group will have access to the Manage My Pain (MMP) App. which allows people living with pain to quickly and easily track their pain and function on a daily basis on their smartphones or a browser on their desktop or mobile device. One-page clinical reports will capture the changes in patients' outcome data between clinical visits over the course in time.Clinic visits can be offered in person at the hospital or over telehealth (video conference) based on the patient's preference and clinician's judgment for telehealth suitability.
89279393|NCT03879278|Other|Treatment 2 mg/kg|Five IV doses of 2 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
89279394|NCT03879278|Other|Treatment 5 mg/kg|Five IV doses of 5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
89279395|NCT03879278|Other|Treatment 12.5 mg/kg|Five IV doses of 12.5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
89279396|NCT03879200|No Intervention|Standard Individual care|Historical controls Individual care follows standard individual Swedish antenatal care, i.e.8-9 30 minutes appointments with a midwife during a normal pregnancy including information and regular pregnancy check-ups. Women are offered classes (3 x 2 hours) that provide preparation for birth and parenthood according to the same guidelines. Obstetricians and general practitioners have a consultant role.
89279397|NCT03879200|Experimental|Group antenatal care|Group antenatal care will follow the same guidelines as for individual care but with tailored content provided in language supported group sessions.
89279398|NCT01159886|Active Comparator|left lateral|After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus position. Then terminal ileal intubation will be attempted.
89279399|NCT01159886|Active Comparator|supine|After confirmation of cecal intubation, patient will undergo randomization to the supine position. Then terminal ileal intubation will be attempted.
89279400|NCT03878888|Experimental|Exparel use in TAP block|Exparel used in bilateral TAP block for open abdomen surgery
89279401|NCT03878888|No Intervention|no TAP block|these patients, N=20, did not received a bilateral TAP block for postoperative pain control. Instead, pain control involves PO/IV pain medications
89279402|NCT03878966|Experimental|Invasive Strategy group|Our study will be conducted on at least thirty patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)-which include ST depression myocardial infarction and unstable angina- who will be subjected to the early invasive strategy . Polymer-free drug eluting stents will be used for these patients instead of the usually used polymer-permanent drug eluting stents .
89279403|NCT01266200|Active Comparator|Minimal-invasive treatment (Mantis)|Patients, who received a minimal-invasive surgery and the fracture was fixed by a system called Mantis
89279404|NCT01266200|Active Comparator|Conventional technique (XIA)|Patients who received a surgical treatment including one long cut (conventional operation technique) and the fracture was fixed by a conventional system called XIA
89279405|NCT01159964|Experimental|Cohort 1|Subjects will receive investigational dose-level A (different from dose-levels B and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
89279406|NCT01159964|Experimental|Cohort 2|Subjects will receive investigational dose-level B (different from dose-levels A and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
89279407|NCT01159964|Experimental|Cohort 3|Subjects will receive investigational dose-level C (different from dose-levels A and B). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
89279408|NCT01266278|Experimental|Kinesiotape|Kinesiotape will be applied to the correct shoulder position of the participants.
89279409|NCT01266356||Experimental Group|
89279410|NCT01266356||Control Group|
89279411|NCT03882710|Experimental|metoprolol XR capsule|
89279412|NCT03882710|Placebo Comparator|placebo capsule|
89279413|NCT01267838|Active Comparator|T Stenting group|PCI of bifurcation lesion with modified T Stenting.
89279414|NCT01267838|Active Comparator|Culotte stenting group|PCI of bifurcation lesion with Culotte stenting
89279415|NCT01161602|Experimental|0.2mg Pumosetrag|
89279416|NCT01161602|Experimental|0.5mg Pumosetrag|
89279417|NCT01161602|Experimental|0.8mg Pumosetrag|
89279418|NCT01161602|Placebo Comparator|Placebo|
89279419|NCT01263392|Active Comparator|Polyvinyl Chloride Catheter|Re-use clean polyvinyl chloride catheters for intermittent catheterization of children with spina bifida.
89279420|NCT01263392|Active Comparator|Hydrophilic catheter|Use hydrophilic catheters (Speedicath) for intermittent catheterization of children with spina bifida.
89279421|NCT03882632|Experimental|Patients with Fecal Incontinence|Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally
89279422|NCT01161758|Active Comparator|Passive cervical mobilisation|Grade III cervical mobilization technique as described by Maitland. Applied to left C5/6 Segment.
89279423|NCT01161758|Placebo Comparator|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique.
89279424|NCT01161758|No Intervention|Non-contact control|Non-contact control, which involved the subject resting in the treatment position without any physical contact between the researcher and the subject.
89279425|NCT01161836|Experimental|iniparib|"Segment 1: 400 mg [14C]-iniparib single administration~Segment 2: Iniparib, 5.6mg/kg, extension treatment with or without additional chemotherapy"
89279426|NCT05051306|Experimental|High-load resistance exercise|4 high-load resistance exercises that target all major muscle groups.
89279427|NCT05051306|Experimental|Low-load resistance exercise|4 low-load resistance exercises that target all major muscle groups.
89279428|NCT05051306|No Intervention|Sedentary control|Subjects in control trial stayed sedentary during the period.
89279429|NCT01266434|Experimental|simvastatin|
89279430|NCT01266434|Placebo Comparator|B1-6-12|
89279431|NCT01266512|Experimental|IMRT & docetaxel-cisplatin|"Concurrent chemo-RT:~Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -~Resting period: 2 weeks -~Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 -~Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration"
89279432|NCT01156454||Surgery followed by x-ray assessment|After nodes are removed they are taken to radiology to be x-rayed
89279433|NCT01158638|No Intervention|Usual Care|Usual Care
89279434|NCT01158638|Active Comparator|10,000 Steps Group|Each participant randomized to this study arm will receive a pedometer and a generic recommendation to accumulate 10,000 Steps per Day.
89279435|NCT01158638|Experimental|Web Mediated Step Group|Participants randomized to this study arm receive an introduction to the study website. Each person utilizes the website to track their daily physical activity steps. Goals are given on a weekly basis to increase steps by 10% per day per week over baseline values. The website channels each participant through a series of motivational messages designed to increase compliance with recommended physical activity targets
89279436|NCT01160042|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
89279437|NCT01160042|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
89279438|NCT03882476|Experimental|Experimental|The experimental arm will involve patients monitored by InSight.
89279439|NCT03882476|No Intervention|Control|The control arm will have no intervention and will involve patients with the usual standard of care.
89279440|NCT01267916|Experimental|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
89279441|NCT01267916|Experimental|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
89279442|NCT01267916|Experimental|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
89279443|NCT01267916|Experimental|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
89279444|NCT01267916|Experimental|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
89279445|NCT01267916|Experimental|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
89279446|NCT01156610|Experimental|Integrated Cessation Counseling|"IVR System: IVR will be used for two purposes: (1) to facilitate access to treatment for low-SES and minority smokers and (2) perform six-month outcome assessment.~Tobacco Treatment Specialist Calls: A tobacco treatment specialist will make four attempts to contact the patient by phone within 14 days. On contacting the patient, the specialist will screen the patient for readiness to quit, provide brief (10 to 15 minutes) counseling tailored to the patient's readiness to quit, and provide information and support for use of medications that could be or were prescribed and about relevant community resources.~NRT: Patients who do not have a contraindication and smoke > 10 cigarettes per day, will be offered a free 6-week kit of generic nicotine patches (2 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches). Individuals who smoke 5-10 cigarettes/day will be offered a 6-week course, starting with the 14 mg patch. Those with a contraindication will not get NRT."
89279447|NCT01156610|Active Comparator|Usual Care|"IVR Call: Similar to the initial IVR call for the intervention arms, the initial control arm call will confirm the participant's identify and provide a brief description of the study (obtaining information about health behaviors), with the opportunity for the individual to accept or decline participation. Following this introduction, the IVR script will confirm smoking status. The phone script will collect specific information about current smoking (cigarettes/day), prior quit attempts, and motivation to quit during the next month. No further contact will be made with patients in the control clinics until the outcome assessment call. In the control practices, the IVR machine will also generate a text note documenting the information obtained for the patients' EHR for use by the patient's health care providers as part of their visit-based best practices."
89279448|NCT03882788|Active Comparator|Volatile Anesthesia|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane.~Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
89279449|NCT03882788|Active Comparator|Narcotic based anesthesia|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose)."
89279450|NCT01161914|Active Comparator|Cerezyme®|60 U/kg infusion (every 2 weeks for 24 weeks)
89279451|NCT01161914|Experimental|ISU302|60 U/kg infusion (every 2 weeks for 24 weeks)
89279452|NCT01266668||Primary breast DLBCL|Primary breast DLBCL was defined as that involving single extranodal organ (i.e. breast) regardless of the status of nodal disease.
89279453|NCT01266668||Nodal DLBCL|The disease was only limited to the lymph nodes or lymphoid organs without extranodal organ involvements.
89279454|NCT01160120|Other|1|Patients can be either treatment-naïve or treatment-experienced when entering this clinical trial. After meeting the inclusion and exclusion criteria, patients will start with generic FDC of TDF/3TC/EFV 1 pill a day at night time. Only patient who are on individual TDF 3TC and EFV will undergo TDM sampling ( 11-13 hours after dosing) at baseline.
89279455|NCT01268072||Cohort 2|Subjects who are recruited on admission to hospital for AECOPD.
89279456|NCT01268072||Cohort 1|Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
89279457|NCT03882554|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
89279458|NCT01156688|Active Comparator|Sublingual Misoprostol|
89279459|NCT01156688|Active Comparator|Buccal misoprostol|
89279460|NCT03876704|Experimental|High dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
89279461|NCT03876704|Active Comparator|Conventional dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.1 piece/kg (equals to 230 U/kg vitamin A，40 U/kg vitamin D, 0.64 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
89279462|NCT03878654|Experimental|Tauroursodeoxycholic Acid|TUDCA 1750 mg daily for 12 weeks
89279463|NCT03878732||Caucasian female|
89279464|NCT03878732||Hispanic female|
89279465|NCT01266746||Macular hole|The patients of idiopathic macular hole enrolled in the study
89279466|NCT01266746||Macular hole retinal detachment|The patients of macular hole retinal detachment enrolled in the study
89279467|NCT01266746||Myopic traction maculopathy|The patients of macular hole with myopic traction maculopathy enrolled in the study
89279468|NCT03878576|Active Comparator|REFERENCE: white bread - BGL0 [RP]|Participants consume a meal of bread BGL0 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
89279469|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL2 [IP1]|Participants consume a meal of bread BGL2 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
89279470|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL3 [IP2]|Participants consume a meal of bread BGL3 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
89279471|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL4 [IP3]|Participants consume a meal of bread BGL4 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
89279472|NCT03878264|Experimental|Part 1|On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.
89279473|NCT03878264|Experimental|Part 2|On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.
89279474|NCT03878186|Experimental|Cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT). Participants will receive the usual care and 6 sessions of cognitive behavioral therapy
89279475|NCT03878186|Other|Usual Care (UC)|Participants will receive Usual Care only
89279476|NCT03882164||Rejection|Patient undergone liver transplant with diagnosis of rejection within 10 days
89279477|NCT03882164||No-Rejection|Patient undergone liver transplant wothout diagnosis of rejection within 10 days
89279478|NCT01160276|Active Comparator|Cyclosporine|The first group is composed of 14 renal graft recipients under cyclosporine
89279479|NCT01160276|Active Comparator|Tacrolimus|The second group is composed of 14 renal graft recipients under tacrolimus
89279480|NCT01162070|Active Comparator|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
89279481|NCT01162070|Experimental|Experimental strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
89279482|NCT01162148|Experimental|1|conventional
89279483|NCT01162148|Experimental|2|sham IMT
89279484|NCT01162148|Experimental|3|Conventional plus threshold IMT
89279485|NCT01162148|Experimental|4|threshold IMT alone
89279486|NCT03882398|Experimental|Experimental group|The experimental group (EG) participated in a once a week physical exercise program for 8 weeks. The session consisted of balance training, followed by aerobic endurance training with exercise peddlers. At the beginning of the program, each session lasted 25 minutes and progressed to 35 minutes, in the last two weeks
89279487|NCT03882398|Active Comparator|Control Group|The control group (CG) only performed routine balance exercises once a week (10 min)
89279488|NCT01266980|Experimental|Severe Renal Imparement|Nine subjects with severe renal impairment (as defined by a Clcr<30mL/min) will be recruited for this study. they will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
89290230|NCT01126086|Experimental|Mild impairment|Patients with mild hepatic impairment
89290231|NCT01126086|Experimental|Moderate impairment|Patients with moderate impairment
89290232|NCT01126086|Experimental|Healthy subjects|Matched healthy subjects
89279489|NCT01266980|Experimental|Matched healthy volunteers|For each of the 9 renally impaired subjects a healthy control subject (as defined by a Clcr>80mL/min matched to the severe subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years)) will be recuited. They will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
89279490|NCT03878420|Experimental|PBM Treatment|The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
89279491|NCT03878420|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
89279492|NCT01263548||Vyvanse|This is an open-label study which means that all study participants will be taking active study medication, Vyvanse.
89279493|NCT03882086|Experimental|foot reflexology group|The intervention group was comprised of 30 women in the early postpartum period. Pretest data were collected on the 14th day postpartum. Then a total of four reflexology sessions were applied for 15 minutes in each foot, in the afternoons, every other day between postpartum 14th-20th day, as the women were available. And posttest data were collected on the 20th day postpartum at the end of the four-reflexology sessions.
89279494|NCT03882086|No Intervention|standard care group no reflexology|The control group of this study was comprised of 30 women in the early postpartum period who had sleep problem and gave vaginal birth. Pretest data were collected on the 14th day postpartum. On the 20th day postpartum, the posttest data were assessed during home visits. These women only received routine postpartum care from public health nurses but did not access the reflexology
89279495|NCT02527070|Experimental|Red LED|Light emitting diodes, 670 nm, 50 mW/cm2, Quantum Warp10 (Quantum Devices Inc, Barneveld, WI, USA); RESPeRATE; Heat/cold provocation
89279496|NCT02527070|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/cm2, Omnilux new-U (Photomedex, Horsham, PA, USA); RESPeRATE; Heat/cold provocation
89279497|NCT01162226|Experimental|training program|
89279498|NCT01160432|Experimental|Methadone naloxone combination product 2/0,04 mg/ml|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml
89279499|NCT01160432|Active Comparator|Methadone 2 mg/ml|Normal treatment except the dilution of methadone solution (5 mg/ml → 2 mg/ml).
89279500|NCT03882242|Experimental|Intervention Program Facilitators|"Participants will learn about and deliver (facilitate) a prevention program In favor of Myself to school-children"
89279501|NCT03877718|Experimental|Arm 1: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)
89279502|NCT03877718|Experimental|Arm 2: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)
89279503|NCT03877718|Experimental|Arm 3: Sumatriptan succinate 100 mg|Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg
89279504|NCT03877718|Experimental|Arm 4: Promethazine HCl 18.75 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg
89279505|NCT03877718|Experimental|Arm 5: Promethazine HCl 37.5 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg
89279506|NCT03877718|Experimental|Arm 6: Placebo|Maximum dose within a 24 hour period: One capsule of placebo
89279507|NCT01160510||Women undergoing mammography|women undergoing mammography at the UVM Breast Cancer Surveillance Consortium site
89279508|NCT03877952|Experimental|Study Participants|On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast.
89279509|NCT01267058|Experimental|Group A|Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine
89279510|NCT01267058|Active Comparator|Group B|Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
89279511|NCT01267058|Active Comparator|Group C|Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
89279512|NCT02526914|Experimental|Intranasal Oxytocin|Participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
89279513|NCT02526914|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
89279514|NCT02526914|Placebo Comparator|Intranasal placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient. Participants will self-administer 5 puffs per nostril.
89279515|NCT03876938|Active Comparator|aprepitant|aprepitant / dexamethasone/ ondansetron
89279516|NCT03876938|Experimental|olanzapine 10 mg|olanzapine 10 mg/dexamethasone/ ondansetron
89279517|NCT03876938|Experimental|olanzapine 5 mg|olanzapine 5 mg/dexamethasone/ ondansetron
89279518|NCT03876782||IOLMaster group|IOL power for all cataract participants will be measured with IOLMaster and Verion
89279519|NCT03876626|Other|Provider Participants|Employees who work with medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as providers. Provider participants will receive access to a web based system that allows them to view information for their enrolled clients, securely message clients, and track medication refills. Providers will be asked to participate in a 30-day usability interview and a end-of-study assessment.
89279520|NCT03876626|Other|Patient Participants|Clients who receive medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as patients. Patient participants will be provided access to a mobile app that allows them to track their mood, stress, and medication adherence, access an anonymous online community, securely message providers, and receive medication refill alerts
89279521|NCT01162460|Active Comparator|Carbamazepine controlled release|
89279522|NCT01162460|Experimental|Eslicarbazepine acetate|
89279523|NCT03882008|Experimental|Abatacept|Abatacept 125mg subcutaneous injection weekly for 24 weeks
89279524|NCT01267214|Experimental|Osteotomy plus Hyalgan|Osteotomy at Week 0 Hyalgan injection at Week 2, 3, 4, 5, 6, 24, 25, 26, 27, 28
89279525|NCT01267214|Other|Osteotomy alone|
89279526|NCT01156922|Experimental|Rituximab|Rituximab induction two infusions (500 mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
89279527|NCT03877874||Asthmatic children|"Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily~Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)."
89279528|NCT03877874||Non-Asthmatic children|no intervention
89279529|NCT01160588||Sertraline treatment|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and sertraline treatment.
89279530|NCT01160588||Healthy Controls|Healthy control participants will undergo MRI scanning and EEG's.
89279531|NCT01160588||Cognitive Behavioral Therapy|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and talk therapy (CBT).
89279532|NCT03876470||All Participants|All participants will receive HCV treatment as determined by their provider. HCV treatment is not assigned by the study.
89279533|NCT01263626||Cough as Primary Complaint|"Male and female volunteers 18 years of age and older~Cough as chief complaint~Referred to the GI clinic to evaluate if reflux is the cause of their chief complaint~pH testing for standard of care purposes"
89279534|NCT01263626||Healthy Volunteers|"Male and female volunteers 18 years of age and older~No history of chronic or acute cough and throat clearing~Ability to read a 5th grade script written in English for approximately 20 minutes"
89279535|NCT01162616|Other|Iron absorption|
89279536|NCT03877562|Experimental|Olanzapine plus CORT118335|Participants will receive olanzapine 10 mg oral tablets and double-blind CORT118335 600 mg after breakfast once daily for 14 days.
89279537|NCT03877562|Placebo Comparator|Olanzapine plus Placebo|Participants will receive olanzapine 10 mg oral tablets and double-blind placebo matching CORT118335 oral tablets after breakfast once daily for 14 days.
89279538|NCT01160666|Experimental|1: Belilumab|
89279539|NCT03876548|Experimental|Cadexomer Iodine Gel|Patients willy apply product to treatment site every other day for the next 28 days and cover with dressing or bandage.
89279540|NCT03760250|Experimental|Imiquimod|5% Imiquimod cream once daily to keloid area 5-times a week for 6 weeks, starting 1-week prior to keloid excision
89279541|NCT01162694|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
89279542|NCT01162694|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the uploaded data and receive feedback from their endocrinologist every 2 weeks.
89279543|NCT01157000|Experimental|001|Canagliflozin On Day 1 all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
89279544|NCT01160900|Experimental|multivessel revascularization|Complete Revascularization : the Infarcted related artery was opened followed by dilatation of other significantly narrowed arteries during the same procedure
89279545|NCT01160978|Active Comparator|Simvastatin 80 mg group|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
89279546|NCT01160978|Experimental|Control Rx|The transplant recipients who have received an organ from non-treated donors.
89279547|NCT01162772||Female Diabetics|female, 25-75 years old, no pregnancy, with/out Hormone replacement therapy T2DM, HbA1c > 7% with metformin mono-therapy
89279548|NCT01162772||Male diabetics|25-75 years, T2DM, HbA1c > 7% with metformin mono-therapy
89279549|NCT01268228||Residual ic ECG ST elevation in SB|
89279550|NCT01268228||Residual ic ECG ST elevation in MB|
89279551|NCT01161056||Healthy Control Group|
89279552|NCT01161134|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
89279553|NCT01161134|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
89279554|NCT01161212|Other|Control group|
89279555|NCT01161212|Other|Intervention group|
89279556|NCT03874442|No Intervention|Controls|
89279557|NCT03874442|Experimental|CliniPup|
89279558|NCT01267370|Active Comparator|Soy polysaccharide fiber|Dietary fiber for treatment of chronic constipation in children
89279559|NCT01267370|Placebo Comparator|purified soy extract, with no fiber)|blinded control group
89279560|NCT03877328|Experimental|Virtual Coach|BiotechCoachForAll
89279561|NCT01162850|Active Comparator|Polypodium Leucotomos|Oral Polypodium Leucotomos twice daily plus sunscreen SPF 45 for 12 weeks.
89279562|NCT01162850|Placebo Comparator|Placebo|Oral Placebo twice daily plus sunscreen SPF 45 for 12 weeks.
89279563|NCT01268384|Experimental|FDR_GX|Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles
89279564|NCT01269398|No Intervention|GO-LIF procedure, posetrior facets fusion|
89279565|NCT01269398|Other|solid fusion, GO-LIF procedure|ability to achieve solid fusion, comibing the GO-LIF procedure for spinal fixation and stabilization with percutaneous posetrior facets fusion
89279566|NCT03874598|Experimental|Ear acupuncture|
89279567|NCT03874598|Active Comparator|Psychoeducation|
89279568|NCT01269476|Experimental|SNX-001|
89279569|NCT01269476|Placebo Comparator|Placebo|
89279570|NCT03876392|Experimental|magnetic resonance imaging|Detection of bone marrow metastases with magnetic resonance imaging
89279571|NCT03874676||PEACE Rounds Clinicians|Nurses, physicians, care managers, chaplains, and other clinicians who attend PEACE rounds as part of their routine work in the hospital.
89279572|NCT03874520|Experimental|Video triage|The sick child will be assessed on video by the operator at the call-center.
89279573|NCT03874520|No Intervention|Telephone triage|The sick child will be assessed solely over the telephone by the operator at the call-center.
89279574|NCT01162928|Experimental|1|3-chamber-bag combined with Oxepa
89279575|NCT01162928|Active Comparator|2|3-chamber-bag combined with Pulmocare
89279576|NCT01269554||Children with diarrhea in Bissau|
89279577|NCT01269554||Children without diarrhea in Bissau|
89279578|NCT01269554||Children without diarrhea in Finland|
89279579|NCT01269554||Children with diarrhea in Finland|
89279580|NCT01269554||Adults without diarrhea in Finland|
89279581|NCT01269554||Adults with diarrhea in Finland|
89279582|NCT01269554||Adults without diarrhea in Bissau|
89279583|NCT01269554||Adults with diarrhea in Bissau|
89279584|NCT01161368|Experimental|lapatinib, vinorelbine|"Drug: Lapatinib, Vinorelbine Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
89279585|NCT01267682|No Intervention|Usual care|Participants receive standard clinical care
89279586|NCT01267682|Experimental|Treatment|Behavioral: cognitive stimulation
89279587|NCT01163006|Experimental|polydextrose|
89279588|NCT01163006|Experimental|soluble glucofibre|
89279589|NCT01163006|Placebo Comparator|isocaloric dietary control|
89279590|NCT01163006|Placebo Comparator|full caloric control|
89279591|NCT01268462|Experimental|Heliox + PEP (Group 1)|
89279592|NCT01268462|Experimental|Oxygen+PEP(Group 2)|
89279593|NCT01268462|Experimental|Heliox ( Group 3)|
89279594|NCT01268462|Active Comparator|Oxygen (Group 4)|
89279595|NCT01269632|Other|HIV infected|young adult infected by HIV
89279596|NCT01269632|Other|HIV uninfected|a control group of HIV uninfected young adult will be included for comparison in physiopathological module (metabolic, cardiovascular, and immunological)
89279597|NCT01268540|Experimental|NHT15|Aspheric Toric Intraocular Lens Models NHT15
89279598|NCT01268540|Active Comparator|FY-60AD|Aspheric Non-toric Intraocular Lens: Model FY-60AD
89279599|NCT01268540|Experimental|NHT30|Aspheric Toric Intraocular Lens Model NHT30
89279600|NCT01268540|Experimental|NHT53|Aspheric Toric Intraocular Lens Models NHT53
89279601|NCT01268618|Experimental|Probiotic|
89279602|NCT01268618|Placebo Comparator|Placebo|
88805634|NCT02983487||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing~Blood sampling:~A blood sample collected by fingerprick"
89279603|NCT01267760|Active Comparator|conventional HD|conventional 4-hour HD
89279604|NCT03877250||Non Small Cell Lung Cancer (NSCLC)|Participants with pathologically confirmed newly diagnosed or recurrent advanced NSCLC that is PD-L1 high by immunohistochemistry
89279605|NCT03877172|No Intervention|Face-mask oxygen therapy|Oxygen delivered through a conventional face mask to keep saturation above 92%.
89279606|NCT03877172|Active Comparator|High-flow nasal cannula|High-flow nasal cannula delivered at 50 L/min and FiO2 adjusted to keep saturation above 92%.
89279607|NCT01165034|No Intervention|Usual care|Best usual practice including general respiratory specialist and primary care
89279608|NCT01165034|Experimental|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
89279609|NCT01280162|Experimental|3 day therapy|Total dose split over 3 days (3 tablets per day)
89279610|NCT01280162|Experimental|2 day therapy|Total dose split over 2 days (4.5 tablets per day)
89279611|NCT01167062|Placebo Comparator|Placebo|
89279612|NCT01167062|Experimental|Tamsulosin Hydrochloride OCAS 0.4 mg|
89279613|NCT01268696||control group|healthy volunteers
89279614|NCT01268696||Metabolic group|Patients with metabolic syndrome
89279615|NCT01165190||Pioglitazone group|
89279616|NCT01280240|Active Comparator|Monofer 500 mg|
89279617|NCT01280240|Active Comparator|Monofer 250 mg|
89279618|NCT01163240||pediatric|
89279619|NCT01165268|Active Comparator|Dapagliflozin (T2DM)|
89279620|NCT01165268|Active Comparator|Dapagliflozin (Healthy Subjects)|
89279621|NCT03876158|Active Comparator|Prometra® Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refill #1, refill #2, refill #3) and will be compared to retrospectively collected pain (VAS) scores and drug doses from the last refill prior to peristaltic pump explant.
89279622|NCT03876158|Other|Prior records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
89279623|NCT01280318|Other|1|patients with operable head and neck squamous cell carcinoma
89279624|NCT01280318|Other|2|patients treated by neck ansd head surgery for a non-oncological disease
89279625|NCT01280318|Experimental|3|patients treated before surgery with 3 doses of neoadjuvant cetuximab
89279626|NCT01165346|Experimental|Stereotaxic radiation by CyberKnife|Implantation of fiducials Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days
89279627|NCT01280396||SGAs|patients receiving SGAs
89279628|NCT03874364|Active Comparator|Lidocaine gel, counselling, monitor|
89279629|NCT03874364|Active Comparator|Lidocaine gel, counselling, no monitor|
89279630|NCT03874364|Active Comparator|Lidocaine gel, no counselling, monitor|
89279631|NCT03874364|Active Comparator|Lidocaine gel, no counselling, no monitor|
89279632|NCT03874364|Placebo Comparator|Lubricating gel, counselling, monitor|
89279633|NCT03874364|Placebo Comparator|Lubricating gel, counselling, no monitor|
89279634|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, monitor|
89279635|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, no monitor|
89279636|NCT01167218||verify now assay|subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
89290233|NCT03936114|Experimental|SMART|
89290234|NCT01361152|Experimental|Fixed-bearing group|Fixed-bearing group
89290235|NCT01361152|Experimental|Mobile-bearing group|Mobile-bearing group
89279637|NCT01167296|Active Comparator|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.removed uterine stent was sent for bacterial culture too.
89279638|NCT01167296|Experimental|without Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
89279639|NCT01163396|Experimental|FOLFOXIRI plus bevacizumab|BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks
89279640|NCT01163552|Experimental|Surgical Debulking and Intrathoracic Hyperthermic Chemotherapy|Patients in this trial will undergo surgical debulking followed by intrathoracic hyperthermic chemotherapy perfusion.
89279641|NCT01269788|Active Comparator|pH positive-omeprazole|
89279642|NCT01269788|Placebo Comparator|pH positive-placebo|
89279643|NCT01269788|Active Comparator|pH positive-fluoxetine|
89279644|NCT01269788|Active Comparator|pH negative-omeprazole|
89279645|NCT01269788|Active Comparator|pH negative-fluoxetine|
89279646|NCT01269788|Placebo Comparator|pH negative-placebo|
89279647|NCT01163630|Experimental|1|esomeprazole 20mg/ASA 81 mg FDC after a 10-hour fast
89279648|NCT01163630|Experimental|2|esomeprazole 20mg/ASA 81 mg FDC 30 minutes after start of a high-fat, high-calorie breakfast
89279649|NCT01280708||Capture data|
89279650|NCT03871946||Experimental group|"Experimental group subjects with impaired fasting glucose (IFG) (Group 1) underwent an oral glucose tolerance test (OGTT), and patients with levels > 140 mg/dL at the 2nd hour were excluded because they were diagnosed with impaired glucose tolerance"
89279651|NCT03871946||control group|The control group (Group 2) comprised 73 patients whose fasting blood glucose level was <100 mg/dL and who agreed to participate in the study.
89279652|NCT03874130|Active Comparator|Scopolamine|0.2 mg scopolamine HBr per dose
89279653|NCT03874130|Active Comparator|IV Scopolamine|4.0 μg/kg; 15 minute IV infusion
89279654|NCT01280786|Experimental|Elesclomol Sodium|
89279655|NCT01163708|Active Comparator|Navigation alone|Navigation system alone vs Prophecy technique with Navigation system validation
89279656|NCT01163708|Experimental|Prophecy and Navigation validation|
89279657|NCT01280864||Interstitial Cystitis Alone|
89279658|NCT01280864||Irritable Bowel Syndrome Alone|
89279659|NCT01280864||Healthy Controls|
89279660|NCT01269866|Other|Cymbalta|Cymbalta 60 to 120 mg
89279661|NCT01281020||Treatment with fixed combination|Patients who receive treatment with latanoprost/timolol fixed combination
89279662|NCT01281020||Treatment with unfixed therapy|Patients who receive latanoprost and timolol therapy
89279663|NCT03757988|Experimental|Single Arm Experimental Walking Group|This is a pilot project with one single group that will be evaluated on the adherence to a walking protocol (Exercise Intervention- PACE-Life). Subjects will be walking two times a week under the supervision of the psychiatric clinic. In addition, subjects will be encouraged to add walking on their own on the days when subjects are not exercising under the supervision of the clinic. This pilot will be used to inform the final design of the subsequent randomized clinical trial that will be implemented following this pilot.
89279664|NCT01269944||Medial compartment knee osteoarthritis|Patients with medial compartment osteoarthritis of the knee, as proven by x-rays and clinical examination
89279665|NCT05387642|Experimental|Double-blind Sequence 1|Double-blind treatment sequence of 10 mg, 20 mg, and placebo in the morning
89279666|NCT05387642|Experimental|Double-blind Sequence 2|Double-blind treatment sequence of 20 mg, placebo, and 10 mg in the morning
89279667|NCT05387642|Experimental|Double-blind Sequence 3|Double-blind treatment sequence of placebo, 10 mg, and 20 mg in the morning
89279668|NCT05387642|Experimental|Open-label Period PRAX-114|Open-label extension period - 10 mg or 20 mg PRAX-114 once daily in the morning for 28 days
89279669|NCT05382026|Experimental|1% chocolate milk|250 ml of 1% chocolate milk consumed immediately after resistance training sessions + 250 ml of chocolate milk consumed 1 hour after resistance training sessions
89279670|NCT05382026|Active Comparator|Pea-based beverage|250 ml of pea beverage consumed immediately after resistance training sessions + 250 ml of pea beverage consumed 1 hour after resistance training sessions
89279671|NCT05382026|Placebo Comparator|Placebo: Low protein plant-based beverage|250 ml of placebo beverage consumed immediately after resistance training sessions + 250 ml of placebo beverage consumed 1 hour after resistance training sessions
89279672|NCT01587404|Experimental|Constant Catheter Contact Force|No alteration of catheter contact force during recording period
89279673|NCT01587404|Experimental|Variable catheter contact force|change in contact force from low to high after 30seconds of recording.
89279674|NCT01165502|Experimental|CM3.1-AC100|Compound CM3.1-AC100 s.c.
89279675|NCT01165502|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
89279676|NCT01281098|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at week-0 that can be repeated every 6 weeks.
89279677|NCT01281098|Experimental|Pegaptanib + Panretinal Photocoagulation (PRP)|Group 2: Combination treatment of pegaptanib intravitreous injections at weeks 0, 6 and 12 that can be repeated every 6 weeks. Plus PRP after first injection (2 weeks +/- 1 week)and that can be repeated every 12 weeks.
89279678|NCT03871400|Other|NanoMetalene/PEEK|
89279679|NCT03871400|Other|NanoMetalene/Allograft|
89279680|NCT03874208|Other|Patient group|To assess the predictive accuracy of comaScore evaluated in the day 7 - day 45 period post brain injury to predict unfavorable outcome at 1-year after the first insult in patients admitted in ICU after CA, TBI and aSAH, that remain comatose at least 7 days after brain injury.
89279681|NCT03874208|Other|Test group|MRI calibration in each center : test protocol compliance, data transfer procedures and quality of the MRI sequences
89279682|NCT03871322|Active Comparator|Vitamin D group|vitamin D supplementation - time to fracture healing
89279683|NCT03871322|Active Comparator|Vitamin D and K2 group|Vitamin D and K 2 supplementation - time of fracture healing
89279684|NCT03871322|Placebo Comparator|Placebo group|Placebo - time to fracture healing
89279685|NCT00313781|Experimental|A|For patients treated with docetaxel and prednisone only, who progress during treatment, CP-751,871 will be added to the regimen to test reversibility of chemoresistance.
89279686|NCT00313781|Active Comparator|B|
89279687|NCT03871478|Active Comparator|Lidocaine|Buffered lidocaine 1% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
89279688|NCT03871478|Active Comparator|Bupivacaine|Bupivacaine 0.5% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
89279689|NCT03871478|Active Comparator|Lidocaine and Bupivacaine|"Buffered lidocaine 1% with epinephrine 1:200,000 and bupivacaine 0.5% with epinephrine 1:200,000 injected sequentially.~Injected at the start of every Mohs excision stage"
89279690|NCT01281332|Active Comparator|Menopod device|Menopod®
89279691|NCT01281332|Sham Comparator|Sham device|Inactive device.
89279692|NCT01281410|No Intervention|Standard physiotherapy|Standard Physiotherapy without Inspiratory Muscle Training
89279693|NCT01281410|Experimental|Inspiratory muscle training|Inspiratory muscle training with a device named Respifit in addition to the usual physiotherapy program
89279694|NCT01281488|Experimental|Treatment 1 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.018 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
89279695|NCT01281488|Experimental|Treatment 2 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.036 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
89279696|NCT01281488|Experimental|Treatment 3 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.07 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
89279697|NCT01281488|Experimental|Treatment 4 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.14 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
89279698|NCT01281488|Experimental|Treatment 5 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.21 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
89279699|NCT01281566|Experimental|001|Cisapride 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
89279700|NCT01281566|Placebo Comparator|002|Placebo liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
89279701|NCT03876002|Experimental|[18F]PBR06|To perform kinetic modeling using plasma-based (metabolite corrected plasma concentration) or reference region based methods or simplified quantification methods to assess the ability of [18F]PBR06 PET to measure microglial activation in brain.
89279702|NCT01164020|Placebo Comparator|placebo control|this only receives placebo (dextrose)
89279703|NCT01164020|Experimental|placebo and exercise|this is trained and receives placebo
89279704|NCT01164020|Experimental|creatine supplementation|this is non-exercise trained and receives creatine supplementation
89279705|NCT01164020|Experimental|Creatine and Exercise|this is exercised trained and receives creatine supplementation
89279706|NCT00368537|Active Comparator|1|Arm 1: Tigecycline
89279707|NCT00368537|Active Comparator|2|Arm 2: Ampicillin-Sulbactam or Amoxicillin-Clavulanate plus or minus a glycopeptide
89279708|NCT01165580|Experimental|Single Arm|
89279709|NCT01268852|Active Comparator|Damon|Standard self ligating orthodontic Damon brackets
89279710|NCT01268852|Experimental|Insignia|Innovative self ligating orthodontic bracket
89279711|NCT01048619|Experimental|ON 01910.Na|The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
89279712|NCT03875924||VWD BERHLINGO|Patients with constitutional von Willebrand Disease, of any severity, with or without inhibitor followed in one of the investigator centers
89279713|NCT01281722||healthy adults|healthy adults with the age among 20 to 95 years old
89279714|NCT01281722||melanoma cases|the people who are diagnosed melanoma in NTU hospital
89279715|NCT01281800|Active Comparator|Cisplatin with pemetrexed|
89279716|NCT01281800|Experimental|Cisplatin with gemcitabine in long infusion|
89279717|NCT01586858||RAVE subjects|
89279718|NCT01059149|Experimental|receive real rTMS|For real rTMS, pulses will be delivered at a frequency of 5 Hz for 6s with a 54s interval, with an intensity equal of 90% of the motor threshold as established at Baseline. 20-min real stimulation sessions will be administered 5 days a week for a period of 2 weeks
89279719|NCT01059149|Placebo Comparator|sham rTMS|For sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo procedures will be used administered 5 days a week for a period of 2 weeks.
89279720|NCT03870932|Experimental|Motor imagery rehabilitative group (MIG)|"All patients performed 10 treatment sessions, lasting 60 to 90 minutes, twice a week, in groups of three to four patients. The gold standard was to choose simple and safe exercises in order to encourage the patient to repeat the schedule at home. The exercises proposed in the MIG have been chosen respecting the following principles: slowness, painlessness, promoting attention, easy to imagine. The main purpose of motor imagery-based exercises was to bring the patient back to feeling and self-perceiving the execution of the movement. More than the quantity of repetition, the quality of the movement, free from pain, was important."
89290236|NCT03934242||New born group 1|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, before nurses formation on the newborn's bedding
89279721|NCT03870932|Active Comparator|Control rehabilitative Group (CG)|The CG received a conventional rehabilitation protocol, based on ten 1-hour sessions, held twice a week (over a 5-week period), previously investigated as efficient in FM by the authors and published. The exercises included low-to-moderate impact aerobic training, walking in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes), for a total of 20 consecutive minutes, posture exercises for the back and proprioceptive exercises for the trunk, to improve axial stability. Each exercise was repeated 10 times (3 sets of 10), with a resting period of at least 3 minutes between sets. All sessions ended with stretching and diaphragmatic breathing exercises.
89279722|NCT03982121|Experimental|A|FOLFOX IV + NIVOLUMAB IV
89279723|NCT03982121|Experimental|B|FOLFOX IV + GLA IT
89279724|NCT03982121|Experimental|C|FOLFOX IV + IPILIMUMAB IT
89279725|NCT03982121|Experimental|D|FOLFOX IV + NIVOLUMAB IV + GLA IT
88805635|NCT02983487||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
88805636|NCT03013595|Experimental|TRAM feedback|"The completion of the Transition Readiness and Appropriateness Measure (TRAM, a standardized structured assessment ) prior to the transition boundary by the child and adolescent mental health service (CAMHS) clinician, young person and parent/carer.~Feedback of TRAM findings to the CAMHS clinician to support decisions made regarding transition, communication with stakeholders and the transition process. Clinicians will be expected to communicate the findings to the young person and parent/carer, and, if a referral is made, to send the TRAM feedback to the adult clinician along with the referral letter.~The clinicians will also receive information prior to recruitment begin on the use of TRAM and the way in which it fits in with optimal transition."
89279726|NCT03982121|Experimental|E|FOLFOX IV + NIVOLUMAB IV + IPILIMUMAB IT
89279727|NCT03982121|Experimental|F|LFOX IV + NIVOLUMAB IV + GLA IT + IPILIMUMAB IT
89279728|NCT03871010||Neutropenia patients, Dept. of Haematooncology|Patients with neutropenia from the Department of Haematooncology were included in this group.
89279729|NCT03871010||No neutropenia patients, Dept. of Haematooncology|Patients without neutropenia from the Department of Haematooncology were included in this group.
89279730|NCT03871010||No neutropenia patients, other clinical depts.|Patients with neutropenia from the other clinical departments of the University Hospital Ostrava were included in this group.
89279731|NCT01167686|Experimental|Food supplement|Half of the subjects participating in the trial (91) will recieve four tablets of the food supplement (Gardemont Goldrain Plus) three times a day for seven consecutive days from inclusion.
89279732|NCT03871088|Active Comparator|Eicosapentaenoic acid (EPA)|Eicosapentaenoic acid (EPA) is an omega-3 fatty acid. In physiological literature, it is given the name 20:5(n-3).
89279733|NCT03871088|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In physiological literature, it is given the name 22:6(n-3).
89279734|NCT03871088|Active Comparator|EPA/DHA combination|EPA/DHA means the combination of omega-3 fatty acids Eicosapentaenoic and Docosahexaenoic acids.
89279735|NCT03871244|Experimental|Restrictive arm (intervention)|Less red blood cell transfusions. The protocol will require that no red blood cell transfusion be given unless the hemoglobin level is below or equal at 70 g per L.
89279736|NCT03871244|Active Comparator|Standard care arm (comparator)|Clinical teams will follow their usual transfusion practices.
89279737|NCT01167764|Active Comparator|tranexamic acid|tranexamic acid 250mg po 3 times/day for 1 months
89279738|NCT01167764|Placebo Comparator|placebo|placebo po 3 times/day for 1 months
89279739|NCT01164176|Experimental|RAD001 group|
89279740|NCT01164332|Other|Method A|First experimental detection method
89279741|NCT01164332|Other|Method B|Second experimental detection method
89279742|NCT03875846||Intraoperative Hemodynamic Improvement|The primary outcome will examine the magnitude of change in the Toe-Brachial Index (TBI) between the beginning and the end of the procedure. The two measurements will be taken before- and after- vascular sheaths had been placed.
89279743|NCT02526992|Other|patients with anti-TNF therapy|patients with rheumatoid polyarthritis inadequately controlled by a conventional treatment, occurring during the first 12 months of initiation of an anti-TNF therapy
89279744|NCT01164410||Pediatric Colonoscopy|Patients undergoing colonoscopy in the Department of Pediatric Gastroenterology at the Cleveland Clinic Children's Hospital in Cleveland, Ohio.
89279745|NCT00313313|Experimental|Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)|Metformin 500-2500 mg (as needed)
89279746|NCT00313313|Experimental|Saxagliptin 5 mg + Glyburide 7.5 mg (B)|Metformin 500-2500 mg (as needed)
89279747|NCT00313313|Placebo Comparator|Placebo + Glyburide 7.5 mg (C)|Metformin 500-2500 mg (as needed)
89279748|NCT01586936||eptacog alpha users|
89279749|NCT01167920|Active Comparator|Virtual Hypertension Clinic Group|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals till the end of the study.
89279750|NCT01167920|No Intervention|Usual Care Group|The Usual Care Group (UCG) patients will be told their BP is not in control and encouraged to work with their physician to improve it. There will be no further structured intervention during the rest of the study.
89279751|NCT03873974||Negative trial arm|"Venous blood samples will be taken for central laboratory analysis with:~DualDur dark-field microscopic test~DualDur dark-field automatic microscopic test~Western blot IgM and IgG~Bózsik Western blot IgM and IgG~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~DualDur Polymerase chain reaction"
89279752|NCT03873974||Positive trial arm|"Venous blood samples will be taken for central laboratory analysis with:~DualDur dark-field microscopic test~DualDur dark-field automatic microscopic test~Western blot IgM and IgG~Bózsik Western blot IgM and IgG~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~DualDur Polymerase chain reaction"
89279753|NCT01268930|Active Comparator|Bipolar coagulation|In this arm, after the complete excision of ovarian endometrioma, ovarian hemostasis is provided by bipolar electrocoagulation.
89279754|NCT01268930|Active Comparator|Hemostatic matrix|In this arm, after complete excision of ovarian endometrioma, ovarian hemostasis is provided by hemostatic matrix.
89279755|NCT01165658|Experimental|Proton Therapy|The radiation prescription dose ranges from 45 Gy in 3 Gy fractions to 60 Gy in 4 Gy fractions. Patients will be assigned to receive 1 of 3 doses of radiation therapy, based on when they joined the study. The first group of at least 3 participants will receive the lowest total radiation dose. If the first dose is tolerated well by the first group of participants in this study, then the next group of participants will receive the second, higher dose of radiation. If this dose is tolerated, then a third group will be treated at the highest dose.
89279756|NCT03870542||Deceased donor kidney transplantation|Patients receiving kidney transplants from deceased donor in the participating centers during the study period
89279757|NCT01168154|Active Comparator|Lactobacillus Reuterii|
89279758|NCT01168154|Placebo Comparator|Placebo|
89279759|NCT01587170||Uninjured control subjects|Uninjured, control subjects who are not taking any of the contraindicated drugs.
89279760|NCT01587170||Spinal-cord injured subjects|Patients who have suffered a spinal cord injury (>1year ago).
89279761|NCT03873662||Pediatric patients after out-of hospital cardiac arrest|Pediatric patients after out-of hospital cardiac arrest admitted to Department of pediatric anesthesia and intensive care University hospital in Brno in selected study period with blood sample analysis for neurologic outcome prognostication
89279762|NCT01168388||Movement disorder|
89279763|NCT02526758|Experimental|beclomethasone / formoterol|beclomethasone 100ug and formoterol 6ug , 2 inhalations, twice daily ,for three months
89279764|NCT02526758|Active Comparator|budesonide / formoterol|budesonide 160ug and formoterol 4.5ug, 2 inhalations ,twice daily ,for three month
89279765|NCT01168466|No Intervention|Neurofeedback|Waitlist control group.
89279766|NCT01168466|Experimental|QEEG-based Neurofeedback Training|A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
89279767|NCT01281878|Experimental|Pyridoxal-phosphate|Treatment with pyridoxal-phosphate in increasing dosages every six weeks starting with 5mg/kg body weight up to 20 mg/kg body weight. treatment duration 24 weeks
89279768|NCT01164488|Experimental|1|
89279769|NCT01164566|Experimental|Arm I|Patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.
89279770|NCT01272362|Experimental|Indacaterol|
89279771|NCT01282034|Active Comparator|Marrow stimulation|
89279772|NCT01282034|Experimental|Medical device: MaioRegen|
89279773|NCT00312845|Experimental|Bortezomib + Rituximab|
89279774|NCT00312845|Active Comparator|Rituximab|
89279775|NCT01282190|Experimental|Motivational interview|
89279776|NCT01282268|Active Comparator|Arbaclofen|
89279777|NCT01282268|Placebo Comparator|Placebo|
89279778|NCT01165736|Active Comparator|Intravenous: PF-05186462|
89279779|NCT01165736|Active Comparator|Oral: PF-05186462|
89279780|NCT01165736|Active Comparator|Intravenous: PF-05089771|
89279781|NCT01165736|Active Comparator|Oral: PF-05089771|
89279782|NCT01165736|Active Comparator|Intravenous: PF-05150122|
89279783|NCT01165736|Active Comparator|Oral: PF-05150122|
89279784|NCT01165736|Active Comparator|Intravenous: PF-05241328|
89279785|NCT01165736|Active Comparator|Oral: PF-05241328|
89279786|NCT03870308|Experimental|Deep Brain Stimulation subjects|
89279787|NCT01168544|Experimental|loading dose and 50.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25 (OH)D level + 50.000 IU vit D3/month consolidation
89279788|NCT01168544|Experimental|Loading dose and 25.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
89279789|NCT01168544|Active Comparator|800 IU vit D3/dag|800 IU vit D3/dag
89279790|NCT03985241|Experimental|Functional Assessment of Myocardial Ischemia by icECG|Evaluation of ST-Shifts in the icECG acquired downstream of a coronary lesion during pharmacologic inotropic stress using dobutamine (40mcg/kg/min).
89279791|NCT03875066|Other|A to B|Subjects were involved in an control training program (A). After 2 weeks washout period, Subjects were trained using the other program (B).
89279792|NCT03875066|Other|B to A|Subjects were involved in an control training program (B). After 2 weeks washout period, Subjects were trained using the other program (A).
89279793|NCT00368069|Experimental|Keppra® XR|Keppra® extended release formulation -XR
89279794|NCT00368069|Placebo Comparator|Placebo|placebo
89279795|NCT01165814|Active Comparator|Tramadol at fixed intervals|
89279796|NCT01165814|Active Comparator|Tramadol on request|
89279797|NCT01165814|Active Comparator|Naproxen at fixed intervals|
89279798|NCT01165814|Active Comparator|Naproxen on request|
89279799|NCT01269086|No Intervention|Usual Care|Traditional care with no systematic assessment of family member´s health problems or risk factors.
89279800|NCT01269086|Experimental|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
89279801|NCT00367991|Active Comparator|A|recombinant human erythropoietin 200 U/kg IV daily for 3 days
89279802|NCT00367991|Placebo Comparator|B|Normal saline volume to match active treatment IV daily for 3 days
89279803|NCT01168700|Placebo Comparator|Placebo|Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.
89279804|NCT01168700|Experimental|Aged garlic extract (Kyolic ®)|Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.
89279805|NCT00367835|Experimental|SPD503 (Guanfacine hydrochloride)|
89279806|NCT00367835|Placebo Comparator|Placebo|
89279807|NCT02526446|Experimental|Self-administered acupressure|The intervention consists of a total of 28 hours over a period of 8 weeks. It comprises of individual learning and practice, self-practice at home, and home follow-up.
89279808|NCT02526446|Other|Wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
89279809|NCT01168778|No Intervention|Control|
89279810|NCT01168778|Experimental|Intervention|
89279811|NCT03874832|Experimental|STS101 1.5 mg|STS101 (dihydroergotamine nasal powder), 1.5 mg
89279812|NCT03874832|Experimental|STS101 3.0 mg|STS101 (dihydroergotamine nasal powder), 3.0 mg
89279813|NCT03874832|Experimental|STS101 6.0 mg|STS101 (dihydroergotamine nasal powder), 6.0 mg
89279814|NCT03874832|Active Comparator|DHE intramuscular injection|Dihydroergotamine mesylate
89279815|NCT03874832|Active Comparator|DHE nasal spray|Dihydroergotamine mesylate
89279816|NCT01273688|Active Comparator|Eccentric training only|Eccentric training only active control group (Flex-Bar)
89279817|NCT01273688|Experimental|Eccentric training and elbow brace|Combined eccentric training (Flex-Bar) and elbow brace (Epi-Hit)
89279818|NCT01164800|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
89279819|NCT01164800|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
89279820|NCT01169012|Other|Single Arm Trial|Single Arm Trial
89279821|NCT03873896|Experimental|Blocked finger|The experimental arm will be the ring finger of the volunteer that is blocked (randomized either right or left hand) with a digital nerve block (described elsewhere in the submission). The skin wrinkle test (diagnostic test) will be applied to this arm
89279822|NCT03873896|Active Comparator|Unblocked finger|The control arm will be the finger of the same volunteer that is not under the influence of digital nerve block. This will be the corresponding digit (the ring finger) on the opposite hand of the side that was blocked (determined by coin toss). The skin wrinkle test (diagnostic test) will be applied to this arm
89279823|NCT01169090|Experimental|SK-0403 100 mg QD|
89279824|NCT01169090|Experimental|SK-0403 200 mg QD|
89279825|NCT01169090|Experimental|SK-0403 400 mg QD|
89279826|NCT01169090|Experimental|SK-0403 200 mg BID|
89279827|NCT01169090|Sham Comparator|Placebo|
89279828|NCT01169090|Active Comparator|Sitagliptin 100 mg QD|
89279829|NCT01282502|Experimental|Midostaurin with chemoradiation|
89279830|NCT01169246||Paradym VR, DR and CRT models|
89279831|NCT01282580|Experimental|Dietary fish (canned salmon, albacore)|Fish products: Canned albacore and salmon will be provided at no cost to the patient. Supplies of tuna and salmon will be provided in quantities sufficient for one month of daily intake by the subject. If desired, a subject can request a sufficient amount to allow for preparation of a meal for the family or household at no more than two times per week. Labels or portions of labels from the cans will be collected at the monthly study visits, and canned supplies will be replenished monthly or at more frequent intervals if needed. Subjects will be allowed to keep unused cans.
89279832|NCT01282580|Experimental|Lovaza-Omega 3 fatty acid capsules|Lovaza capsules will be provided at no cost to the patient. Pill bottles will be provided to the patient, with the start date and number of pills recorded. The supplement will be provided in sufficient supply for one month at a time. Pill bottles will be collected at monthly follow-up visits, and any unused capsules will be documented and discarded as biohazardous waste.
89279833|NCT01269242|Experimental|bindarit 600 mg|
89279834|NCT01269242|Experimental|bindarit 1200 mg|
89279835|NCT01269242|Placebo Comparator|placebo|
89279836|NCT01164878||Before|ELBW infants before change of feeding policy
89279837|NCT01164878||After|ELBW infants after change of feeding policy
89279838|NCT01169714|Experimental|Dosing Healthy Adult|Ascending Doses in Healthy Adult Volunteers
89279839|NCT01169714|Experimental|Dosing Healthy Elderly|Dosing in Healthy Elderly volunteers
89279840|NCT01274702|Experimental|Visual Reconstitution Therapy|
89279841|NCT01274702|Active Comparator|Saccadic Eye Movement Training|
89279842|NCT01169792||Breast cancer patients|Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
89279843|NCT01169324|Experimental|DBS on|baseline settings
89279844|NCT01169324|No Intervention|DBS off|DBS off
89279845|NCT05343494|Experimental|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
89279846|NCT01169402|Experimental|Fluconazole|
89279847|NCT01169480|Experimental|Massage Giver|Participants in the experimental group will be asked to give one 50-minute Swedish massage to another volunteer.
89279848|NCT01169480|No Intervention|Passive Controls|Participants in this arm will wait in a classroom (as usual) and do nothing out of their ordinary routines.
89279849|NCT01274780|Experimental|Darunavir / Ritonavir|
89279850|NCT01274780|Experimental|Atazanavir / Ritonavir|
89279851|NCT01169870|Experimental|Genexol-PM|Genexol-PM 300mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 1 hour on day 1, every 3 week cycle.
89279852|NCT01169870|Active Comparator|Paclitaxel|Paclitaxel 175mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 3 hour on day 1, every 3 week cycle.
89279853|NCT01169948||Patients awaiting cardiac surgery|
89279854|NCT01282658||Colorectal cancer|
89279855|NCT01165970|Active Comparator|Glandosane|After in situ exposition the enamel and dentin samples will demineralize with Glandosane.
89279856|NCT01165970|Experimental|Saliva natura|After in situ exposition the enamel and dentin samples will remineralize with Saliva natura
89279857|NCT01282736|Experimental|Integrative Response Therapy|IRT is based on affect regulation theories of binge eating and adds emphasis on cognitive restructuring techniques. IRT is a 10 session, group-based, guided-self-help treatment that works to decrease binge eating by primarily enhancing emotion coping skills, in addition to transforming faulty interpretations and reducing vulnerabilities (e.g., interpersonal events) that risk overwhelming emotion and problematic cognitions.
89279858|NCT01282736|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy guided self-help (CBT-GSH), based on the restraint model of binge eating, has been adapted from individual format to a 10 session, group-based therapy for the purpose of this study. The book 'Overcoming Binge Eating' is employed in the present study and consists of Part 1, an educational background on BED, and Part 2, a 6 step treatment program to overcome binge eating.
89279859|NCT01166048|Placebo Comparator|Milk powder pill|Patients will receive 2 placebo pills per day for a period of 4 weeks.
89279860|NCT01166048|Experimental|Duloxetine|In the experimental arm of the study patients will receive duloxetine, which will be titrated up to a dosage of 120mg over a period of two weeks and continued at this dosage for two weeks.
89279861|NCT01282892||patients with NAFLD|
89279862|NCT01282892||excess of visceral fat|
89279863|NCT03869762|Experimental|Denosumab & Enzalutamide|"120mg subcutaneous injection on Day 1 of every four week cycle, for a maximum of 24 cycles, or until clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason.~160mg PO daily; (4 x 40 mg capsules) until confirmed clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason)"
89279864|NCT01283126|Experimental|Euglycemic and hypoglycemic clamp|Subjects will complete clamp study visit.
89279865|NCT03873350|Experimental|Living kombucha|
89279866|NCT03873350|Placebo Comparator|Heat-sterilized kombucha|
89279867|NCT03873350|No Intervention|Water|
89279868|NCT01282970|Experimental|BI 135585|once daily doses as oral solution or tablet formulation over 14 days
89279869|NCT01282970|Placebo Comparator|Placebo to BI 135585|once daily doses as oral solution or tablet formulation over 14 days
89279870|NCT03869918|No Intervention|Usual Care|Participant is assigned to undergo standard of care.
89279871|NCT03869918|Experimental|Exercise Group|If the participant is assigned to the exercise group, she will either exercise at home or take a class at the participating facility under the supervision of an instructor.
89279872|NCT03869918|No Intervention|Observational Group|If a subject is eligible, but does not want to exercise, she will be in a third group that is an observation group.
89279873|NCT01283048|Experimental|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
89279874|NCT03873740|Experimental|Single vaccine group A|This group receive two doses injection of EV71 inactived vaccines(Vero cells) on Day 0 and 30, and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
89279875|NCT03873740|Experimental|Single vaccine group B|This group receive two doses injection of EV71 inactived vaccines(human diploid cells)on Day 0 and 30, two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
89279876|NCT03873740|Experimental|Sequential vaccination group A|One dose injection of EV71 inactived vaccines(Vero cells) on Day 0，following one dose of EV71 vaccine(EV71 inactived vaccines(human diploid cells), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
89279877|NCT03873740|Experimental|Sequential vaccination group B|One dose injection of EV71 inactived vaccines(human diploid cells)on Day 0，following one does of EV71 vaccine(Sinovac Vaccine Technology Co., Ltd), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
89279878|NCT01172756|Experimental|Arm 1|
89279879|NCT01172756|Experimental|Arm 2|
89279880|NCT01172756|Experimental|Arm 3|
89279881|NCT01172756|Placebo Comparator|Arm 4|
89279882|NCT02525822|Experimental|IDP-123 Lotion|IDP-123 Lotion, applied topically to the face, once daily for 12 weeks.
89279883|NCT02525822|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream (tazarotene 0.1%), applied topically to the face, once daily for 12 weeks.
89279884|NCT02525822|Placebo Comparator|Vehicle Cream|Vehicle Cream, applied topically to the face, once daily for 12 weeks.
89279885|NCT02525822|Placebo Comparator|Vehicle Lotion|Vehicle Lotion, applied topically to the face, once daily for 12 weeks.
89279886|NCT01172834|Experimental|Lifestyle counseling|
89279887|NCT01283204|Active Comparator|SP(S-1 with cisplatin)|"SP <Every 3 weeks>~Day 1~14 : TS-1 80mg/m2/day (PO)~Day 1 : CDDP 60mg/m2/day IVF 2hours~Day 15~21 : Rest"
89279888|NCT01283204|Active Comparator|FL/Tax(Paclitaxel with Leucovorin with 5-FU)|"FL/Tax <Every q 3 weeks>~Day1 : Paclitaxel 175mg/m2 IVF for 2hours~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
89279889|NCT01283204|Active Comparator|FL/Doc(Decetaxel with Leucovorin with 5-FU)|"FL/Doc <Every q 3 weeks>~Day1 : Docetaxel 75mg/m2 IVF for 1hour~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
89279890|NCT01283204|Active Comparator|FOLFOX(Oxaliplatin with Leucovorin with 5-FU)|FOLFOX <Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
89279891|NCT03869528|Active Comparator|5 sprays|5 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
89279892|NCT03869528|Experimental|10 sprays|10 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
89279893|NCT01166204|Experimental|Single group|
89279894|NCT03869294||LAPC or MPC patients with GS first-line chemotherapy|
89279895|NCT01283360|Placebo Comparator|HEC Placebo Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
89279896|NCT01283360|Active Comparator|Tenofovir 1% Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
89279897|NCT01172990|Experimental|Conventional Group|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- Percutaneous Coronary Intervention PCI between 24 to 48 hours from randomisation according to local policy and guidelines
89279898|NCT01172990|Active Comparator|Immediate Invasive Group|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting Percutaneous Coronary Intervention(PCI) will be performed according to local policy and guidelines
89279899|NCT01166360||Patients 2009|Patients undergoing cardiac surgery in 2009
89279900|NCT01166360||Patients 2008|Patients undergoing cardiac surgery in 2008
89279901|NCT03267940|Experimental|Run-in Portion: PEGCISGEM|Participants will receive 3.0 micrograms per kilogram (mcg/kg) PEGPH20 on Days 1, 8, and 15 in combination with 25 milligrams per meter square (mg/m^2) of CIS plus 1000 mg/m^2 of GEM administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
89279902|NCT03267940|Experimental|Run-in Portion: PEGCISGEMATEZO|After 6 participants from the PEGCISGEM arm are treated for at least 1 cycle without significant toxicities, new participants will be enrolled in this arm to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
89279903|NCT03267940|Experimental|Expansion Portion: PEGCISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
89279904|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Twice Weekly|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
89279905|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly|After the implementation of Protocol Amendment #3 and as communicated to the Investigators via a letter dated 22 March 2019, participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 4, 8, 11, 15 and 18 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 Cycle 1) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of Cycle 1 (cycle length = 21 days) by IV infusion. Participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle from Cycle 2 and beyond by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
89279906|NCT03267940|Active Comparator|Expansion Portion: CISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the run-in portion safe and tolerable, new participants will be enrolled to receive 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
89279907|NCT01284452|Placebo Comparator|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
89279908|NCT01284452|Active Comparator|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
89279909|NCT03873506|Experimental|Mesenchymal Stem Cell|A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)
89279910|NCT03378128|Experimental|diagnostic laparoscopic assessment after neoadjuvant chemo|All patients will undergo a diagnostic laparoscopic assessment of disease following neoadjuvant chemotherapy
89279911|NCT03866720|Active Comparator|Carbohydrate rich breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
89279912|NCT03866720|Experimental|Whey protein enriched breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
89279913|NCT03866720|No Intervention|Extended morning fast|Participants will extend their overnight fast until the ad libitum lunch is provided.
89279914|NCT03866876||Hôpital Femme Mère Enfants births|
89279915|NCT04590430|Experimental|HFB30132A|Participants will receive HFB30132A administered across 3 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
89279916|NCT04590430|Placebo Comparator|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
89279917|NCT01170026|Experimental|Family Check-up/Individual MI|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use plus 2 session Individual Motivational Intervention for the adolescent
89279918|NCT01170026|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
89279919|NCT05276440||General Anesthesia|
89279920|NCT05276440||Erector Spinae Plane Block|
89279921|NCT05276440||Rhomboid Block|
89279922|NCT01277978||Carbetocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 100 ug Carbetocin (the clinical standard dose) following delivery of the baby.
89279923|NCT01277978||Oxytocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 5 IU oxytocin (the clinical standard dose) following delivery of the baby.
89279924|NCT03296566|Experimental|Patient Liaison Intervention|The participants randomized to the intervention group will be exposed to the patient liaison in receiving their colposcopy report results and recommendations. Rather than receive results from their referring/family physician, an experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients.
89279925|NCT03296566|No Intervention|Control|The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
89279926|NCT01284764|No Intervention|midnight fasting|The patients in this group will have midnight fasting the day before endoscopic examination
89279927|NCT01284764|Active Comparator|Mosapride, low volume of water|The patients in this group will take mosapride and a 500mL water at evening of the day before endoscopic examination.
89279928|NCT03866330|Active Comparator|osteoarthritis of the knee|Intraarticular injection of WJMSC
89279929|NCT03866330|Active Comparator|osteoarthritis of the hip|Intraarticular injection of WJMSC
89279930|NCT03866330|Active Comparator|osteoarthritis of the glenohumeral joint|Intraarticular injection of WJMSC
89279931|NCT03620734||GAHT and PrEP|HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
89279932|NCT03620734||GAHT and ART|HIV-positive TGW on ART will have their plasma HIV RNA measured at the same day ART is initiated and at week 15 (12 weeks after ART provision). CD4 count will be measure at week 15.
89279933|NCT01166516|Other|Treatment with HUD IBV Valve System|Treatment with HUD IBV Valve System in Post-Approval Study
89279934|NCT01173224|Experimental|Cohort 2: 20 mg 10 days|Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg).
89279935|NCT01173224|Experimental|Cohort 3: 30 mg 1 day|Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
89279936|NCT01173224|Experimental|Cohort 1: 20 mg, 1 day|Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg).
89279937|NCT01283750|No Intervention|Augmented Usual Care|
89279938|NCT01278212|Experimental|AHF-RT|"accelerated hypofractionated radiotherapy (AHF-RT)~30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy"
89279939|NCT03755882|Experimental|TEST/CONTROL|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
89279940|NCT03755882|Experimental|CONTROL/TEST|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
89279941|NCT01585688|Experimental|hLL1-DOX|
89279942|NCT01170182|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited
89279943|NCT01170182|Active Comparator|Prilosec|Prilosec® 40 mg Merck & Co. Inc
89279944|NCT01170260|Active Comparator|Info-only sexual risk reduction|Corresponding intervention gives information only on STDs/HIV
89279945|NCT01170260|Experimental|Sex plus alcohol risk reduction|Corresponding intervention gives info focusing on sex and alcohol risk reduction only
89279946|NCT01170260|Experimental|Sex + alcohol + marijuana risk reduction|Corresponding intervention gives info on sex, alcohol, and marijuana risk reduction
89279947|NCT01284920|Experimental|dose-escalation cohort-1|MDV3100 low dose arm
89279948|NCT01284920|Experimental|dose-escalation cohort-2|MDV3100 middle dose arm
89279949|NCT01284920|Experimental|dose-escalation cohort-3|MDV3100 high dose arm
89279950|NCT01284920|Experimental|dose-expansion cohort|dose expansion with MDV3100 middle dose
89279951|NCT01173302|Experimental|Post vaccination|All the subjects had been vaccinated with antirabies vaccine.
89279952|NCT00312377|Active Comparator|1|Docetaxel monotherapy
89279953|NCT00312377|Experimental|2|Vandetanib + Docetaxel
89279954|NCT01173380|Sham Comparator|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
89279955|NCT01173380|Active Comparator|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
89279956|NCT01173458||Blood Draw|"Approximately 1 and one-half teaspoons of blood will be drawn at times specified.~one sample prior to treatment initiation~one sample after completion of treatment~one sample every 6 to 8 weeks during follow up visits~one sample at the time of Relapse"
89279957|NCT01173536|Active Comparator|A|
89279958|NCT01173536|Active Comparator|B|
89279959|NCT01173536|Experimental|C|
89279960|NCT03866486||IVUS-guidance group|The patients who underwent drug-eluting stents implantation with IVUS guidance.
89279961|NCT03866486||Angiography-guidance group|The patients who underwent drug-eluting stents implantation with angiography guidance without IVUS.
89279962|NCT01580891|Experimental|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)
89279963|NCT01580891|Active Comparator|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)
89279964|NCT01580891|Placebo Comparator|Placebo topical cream|Placebo topical cream (Taro Pharmaceuticals Inc.)
89279965|NCT01059383|Experimental|VECAM 40/300|
89279966|NCT01059383|Active Comparator|Esomeprazole 20 mg|
89279967|NCT03295318|Experimental|Adjuvanted study formulation NmCV-5|"Subjects in this arm will receive adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
89279968|NCT03295318|Experimental|Non-adjuvanted study formulation NmCV-5|"Subjects in this arm will receive non-adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
89279969|NCT03295318|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
89279970|NCT01173614||Normal subjects|Subjects with two normal eyes.
89279971|NCT03872648||TW-VP (centralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC in a specialized clinic with a centralized structure
89279972|NCT03872648||TW-VP (decentralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC from different medical locations (decentralized structure)
89279973|NCT01284998||B-BOP lock|Subjects who needs a fixation of osteotomy of the basis of the first metatarsal and for whose surgeon has recommended that a B-BOP® Lock plate from INTEGRA be implanted can be enrolled in this study
89279974|NCT03311230|No Intervention|Control|Participants in this arm will receive no other interventions during the 9 month study period
89279975|NCT03311230|Experimental|Supportive social incentive|Participants will identify a family member or friend to support them during a gamification intervention.
89279976|NCT03311230|Experimental|Competitive social incentive|Participants will compete in a gamification intervention in groups of three.
89279977|NCT03311230|Experimental|Collaborative social incentive|Participants will collaborate in groups of three in a gamification intervention
89279978|NCT01285154||Traditional Steel Triple Osteotomy|Traditional technique
89279979|NCT01285154||Modified Triple Osteotomy|Modified technique
89279980|NCT01285232|Experimental|Anakinra|Anakinra 150 mg/day during four weeks
89279981|NCT01285232|Placebo Comparator|Placebo|Placebo during four weeks
89279982|NCT03866018|Experimental|Adapted physical activity|Patients will participate in an adapted physical activity workshop.
89279983|NCT01173770|Experimental|Cohort 1: ADC3680B vs. Placebo|
89279984|NCT01173770|Experimental|Cohort 2: ADC3680B vs. Placebo|
89279985|NCT01173770|Experimental|Cohort 3: ADC3680B vs Placebo|
89279986|NCT01173770|Experimental|Cohort 4: ADC3680B vs. Placebo|
89279987|NCT01173770|Experimental|Cohort 5: ADC3680B vs. Placebo|
89279988|NCT01173770|Experimental|Cohort 6: ADC3680B|
89279989|NCT03869138|Experimental|Virtual-reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
89279990|NCT03869060|Experimental|Inoculated Group|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) given as a single dose [0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL)] inoculated subcutaneously.
89279991|NCT03872804|Experimental|Vitiligo patient|Patient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
89279992|NCT01170338|Experimental|active Chantix|active drug to help smoking cessation
89279993|NCT01170338|Placebo Comparator|sugar pill|
89279994|NCT03866096|Experimental|Experimental|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training and a CORE strengthening program
89279995|NCT03866096|Active Comparator|Control|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training.
89279996|NCT00312221|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
89279997|NCT00312221|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
89279998|NCT00312221|Experimental|Oxycodone Immediate-Release (Oxy IR) 40 mg|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
89279999|NCT03872570|Active Comparator|phenylephrine|starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
89280000|NCT03872570|Active Comparator|norepinephrine|starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
89280001|NCT03865862|Experimental|Experimental|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
89280002|NCT03865862|Active Comparator|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
89280003|NCT01062737|Experimental|ASU (Avocado Soybean Unsaponifiable)|
89280004|NCT01170416||12-Lead Body Surface Mapping - Focal VT .|Body surface mapping (BSM) will be completed in patients with a defined focal VT site during the EP study.
89280005|NCT01170416||12-Lead BSPM - Scar related VT, exit not identified|Body surface mapping will be competed on patients with scar related VT where the exit cannot be identified
89280006|NCT01170416||12-Lead BSPM - Scar related VT exit identified|Body surface mapping will be competed on patients with scar related VT where the exit is identified
89280007|NCT01170416||12-Lead BSPM - Supraventricular tachycardia|Body surface mapping will be completed on patients requiring an EP study for the treatment of symptoms related to supraventricular tachycardia
89280008|NCT01173926|Experimental|IAsp|
89280009|NCT01173926|Experimental|IDeg|
89280010|NCT01173926|Experimental|IDegAsp|
89280011|NCT02526602|Experimental|Preservation (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are preserved.
89280012|NCT02526602|Active Comparator|Opening (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are opened.
89280013|NCT03349268|Active Comparator|Pulsed xenon ultraviolet light (PX-UV) Device Emitting Germicidal UV|Pulsed xenon ultraviolet light (PX-UV) Device to be used to disinfect rooms following post-discharge terminal cleaning
89280014|NCT03349268|Sham Comparator|Sham Device - Non Emitting Germicidal UV|Sham Device to be run in rooms following post-discharge terminal cleaning. No Germicidal UV is emitted.
89280015|NCT01170494|Active Comparator|D2 2000 IU daily|
89280016|NCT01170494|Active Comparator|D3 2000 IU daily|
89280017|NCT01170494|Active Comparator|D2 1000 IU + D3 1000 IU daily|
89280018|NCT01170494|Active Comparator|D2 25000 IU Q2wk|
89280019|NCT01170494|Active Comparator|D3 25000 IU Q2wk|
89280020|NCT01170494|Active Comparator|D2 50000 IU Q4wk|
89280021|NCT01170494|Active Comparator|D3 50000 IU Q4wk|
89280022|NCT01170494|Placebo Comparator|placebo daily|
89280023|NCT01587326|Experimental|Escitalopram|Escitalopram 10 mg/d to 20 mg/d
89280024|NCT03294538|Experimental|Generic Estradiol Vaginal Cream USP, 0.01%|Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
89280025|NCT03294538|Active Comparator|Estrace Vaginal Cream USP, 0.01%|Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
89280026|NCT03294538|Placebo Comparator|Vehicle Vaginal Cream|Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.
89280027|NCT03872336|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg 80mg in succession after each severe BP
89280028|NCT03872336|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg 80mg in succession after each severe BP
89280029|NCT01170572||Long bone fracture|Patients presenting to accident and emergency during the study period with long bone or clavicle fracture
89280030|NCT01170728||Virtue® Male Sling|Device: Coloplast Virtue® Male Sling
89280031|NCT02987530|Experimental|Dolutegravir + Emtricitabine/Tenofovir|Patients will take Dolutegravir 50 mg (= Tivicay, 1 tablet per day) with Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
89280032|NCT02987530|Active Comparator|Darunavir/Cobicistat + Emtricitabine/Ténofovir|Patients will take Darunavir 800 mg / Cobicistat 150 mg (=Rezolsta, 1 tablet per day) + Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
89280033|NCT03865550|Placebo Comparator|Placebo|
89280034|NCT03865550|Active Comparator|Ketamine|
89280035|NCT01285388|Experimental|MB12066 10mg|
89280036|NCT01285388|Active Comparator|MB12066 30mg|
89280037|NCT01285388|Active Comparator|MB12066 100mg|
89280038|NCT01285388|Active Comparator|MB12066 150mg|
89280039|NCT01285388|Active Comparator|MB12066 200mg|
89280040|NCT01285388|Placebo Comparator|placebo|
89280041|NCT01174316|Experimental|autotitrating NIV|approximately 24 hours using autotitrating non-invasive ventilation for as many hours as possible whilst an inpatient in hospital
89280042|NCT01174316|Active Comparator|Standard non-invasive ventilation|approximately 24 hours using standard non-invasive ventilation for as many hours as possible whilst an inpatient in hospital.
89280043|NCT01285466|Experimental|BEZ235 + paclitaxel|
89280044|NCT01285466|Experimental|BKM120 + paclitaxel|
89280045|NCT01285466|Experimental|BEZ235 + paclitaxel + trastuzumab|
89280046|NCT01285466|Experimental|BKM120 + paclitaxel + trastuzumab|
89280047|NCT01166828|Experimental|1|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
89280048|NCT01166828|Active Comparator|2|TAC participants will have six phone contacts every other week for three months.
89280049|NCT03265600|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
89280050|NCT03265600|Other|Low-dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.
89280051|NCT01285544|Experimental|Lipinon-test formulation of atrovastain - 20mg|
89280052|NCT01285544|Active Comparator|Lipitor- branded formuation of atorvastatin-20mg|
89280053|NCT01174394|Experimental|DCEAS|"Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
89280054|NCT01174394|Placebo Comparator|n-CEA|"Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
89280055|NCT01174472|Active Comparator|Conventional Balloon Angioplasty (COBA)|Patients with lesions treated with conventional balloon angioplasty
89280056|NCT01174472|Experimental|Drug Eluting Balloon Angioplasty (DEB)|Patients with lesions treated with Drug Balloon Angioplasty
89280057|NCT00335153|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances."
89280058|NCT01170806|Active Comparator|Orlistat (Lipiblock) treatment|Lipiblock is a new Orlistat formulation, produce by Germed Pharma, Brazil. Capsule 120mg
89280059|NCT01170806|Active Comparator|Orlistat (Xenical) treatment|Xenical is a innovator Orlistat formulation, produced by Roche
89280060|NCT03868436|Other|Methoxyflurane (MEOF)-active treatment|single arm study all subjects will be treated with Methoxyflurane 3 mL
89280061|NCT02526836|Other|Comparison group|"including the number of cases with complete data who underwent surgery using the conventional method.~Conventional surgery"
89280062|NCT02526836|Active Comparator|Intervention group|"including a convenient sample of about 20 patients which is expected to be recruited, for whom Complete Mesocolic Excision (CME) and Central Vascular Ligation (CVL) will be done.~Complete mesocolic excision with central vascular ligation"
89280063|NCT01285622||Gynecology patients|female subjects scheduled for elective robotic gynecological surgery under general anesthesia.
89280064|NCT03265132|Experimental|anakinra|2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
89280065|NCT03265132|Placebo Comparator|Placebo|Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
89280066|NCT01280084||No labour analgesia/nitrous oxide|Women who use no analgesia during labour or who only used nitrous oxide.
89280067|NCT01280084||Systemic opioids|Women who receive only systemic opioids for analgesia during, either intravenously or intramuscularly
89280068|NCT01280084||Intermediate dose epidural fentanyl|Women who receive a total epidural fentanyl dose less than 150 micrograms
89280069|NCT01280084||High dose epidural fentanyl|Women who receive a total epidural fentanyl dose more than 150 micrograms
89280070|NCT02533193|Active Comparator|enhanced recovery after surgery protocal|ERAS perioperative cares patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
89280071|NCT02533193|Active Comparator|Conventional perioperative cares|Conventional perioperative cares patents will be managed by our hospital's critical pathways.
89280072|NCT03865160|Experimental|Arm A, Interventional group|Treatment period 1: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 3: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months
89280073|NCT03865160|Experimental|Arm B, Control group|Treatment period 1: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months Treatment period 3: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months
89280074|NCT01059461|Experimental|Cerebrolysin®, neuroregeneration|Injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
89280075|NCT01324739|Active Comparator|B-type natriuretic peptide|the effect of B-type natriuretic peptide on glucose metabolism will be compared with placebo during an intravenous glocose tolerance test
89280076|NCT01324739|Placebo Comparator|Placebo|comparison of the effect of b-type natriuretic peptide on glucose metabolism and placebo
89280077|NCT01285700|Active Comparator|Lamazym 25|25 U/kg
89280078|NCT01285700|Active Comparator|Lamazym 50|50 U/kg
89280079|NCT01171040||Consecutive patients received echocardiographic examinations|Consecutive patients received echocardiography are willing to participate in this study.
89280080|NCT01062815|Experimental|Cycling Parenteral Nutrition|Infants in the intervention cycling group will receive infusion of carbohydrate/amino acids and intralipid over a 20-hour period. During the 4-hour window period, infants in this group will receive dextrose solution only at the same rate calculated for the carbohydrate/amino acid infusion.
89280081|NCT01062815|Active Comparator|Continuous Parenteral Nutrition|Infants in this control group will receive infusion of carbohydrates/amino acids and intralipids continuously, over 24 hours.
89280082|NCT02939950|Experimental|Bausch + Lomb Samfilcon A Soft Contact Lens|Participants will wear Bausch + Lomb samfilcon A soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
89280083|NCT02939950|Active Comparator|Bausch + Lomb Pure Vision Soft Contact Lens|Participants will wear Bausch + Lomb pure vision soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
89280084|NCT03992105|Other|historical cohort|150 homeless patients in crisis, identified from an extraction of the database of psychiatric emergencies of the same territory, and matched for age, sex, and main diagnosis.
89280085|NCT01286246|Experimental|Vaginal progesterone|
89280086|NCT01286246|Placebo Comparator|Placebo|
89280087|NCT01324817||Hopitalized|Patients admitted to the hospital
89280088|NCT05275660|Experimental|HFB30132A|Participants will receive HFB30132A administered across 2 fixed-dose cohorts via intravenous infusions (to be administered sequentially)
89280089|NCT05275660|Placebo Comparator|Placebo|Placebo will be administered to participants across three fixed-dose cohorts similar to the active treatment.
89280090|NCT03753542|Experimental|Intervention|The Intervention group will received multimedia education, booklet and weekly tele-nursing follow-up about chemotherapy and side effects management
89280091|NCT03753542|No Intervention|Control|The Control group will receive routine care
89280092|NCT03981887|Experimental|Nafithromycin 200 mg as IV infusion|Nafithromycin 200 mg administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
89280093|NCT03981887|Placebo Comparator|placebo administered as IV infusion|Placebo administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.
89280094|NCT01063127||1|group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation.
89280095|NCT01063127||2|group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation.
89290237|NCT03934242||New born group 2|New born who was born at the maternity of the CHU of Reims during a period of inclusion of one month, after nurses formation on the newborn's bedding
89280096|NCT03868280|Active Comparator|Supine Positioning, Fracture Table|During the supine fracture table phase, patients will be positioned supine on a fracture table. The operative leg will be placed in a boot, attached to the traction limb. The non-operative leg will either be scissored away from the operating area in a traction boot (without traction placed) or placed in a stirrup at 90 degrees of hip flexion in hemi-lithotomy. A central post will be used to prevent patient movement during application of traction, and all bony prominences will be padded. Fluoroscopy will be obtained through standard practices intraoperative to document assessment of rotation.
89280097|NCT03868280|Active Comparator|Lateral Positioning, Free drape|During the lateral positioning phase, patients will be placed in lateral position after anaesthetic has been provided. A beanbag will be placed below the patient, and the patient will be safely turned to a lateral position. The beanbag will be inflated, the leg will be prepped, and a free drape will be applied. No traction will be used. Alternatively, some participating sites may use stulberg positioners rather than an inflatable beanbag, based on hospital preference. This positioning mirrors the positioning utilized for the direct lateral, posterior or posterolateral approach to a total hip arthroplasty or hemiarthroplasty
89280098|NCT03984773|No Intervention|Control|Clinicians will receive current standard communications regarding serious illness performance.
89280099|NCT03984773|Experimental|Mortality Estimates and Nudges|Clinicians will receive a weekly email with upcoming patients that have high mortality estimates to consider for a serious illness conversation. Clinicians will have the opportunity to review the list and pre-commit (using an opt-out design) to patients appropriate for a conversation. They will receive a nudge on the day of the patient visit through a text message reminding them of their pre-commitment to conduct a serious illness conversation
89280100|NCT03292588|Experimental|Mepolizumab|Intervention: Mepolizumab plus guidelines-based standard of care asthma treatment.
89280101|NCT03292588|Placebo Comparator|Placebo|Intervention: Placebo for mepolizumab plus guidelines-based standard of care asthma treatment.
89280102|NCT03752528||Part A Cohort|Representative data set of participants from study RB-US-13-0003 or both studies RB-US-13-0003 and INDV-6000-301 who received at least 2 doses of SUBLOCADE 12-36 months prior. Part A consists of a single visit (Visit 1) for both screening and collection of blood and urine samples.
89280103|NCT03752528||Part B Cohort|Part A participants with a quantifiable (i.e. positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e. negative) result for naloxone continue in the study for two additional visits (Visits 2 and 3) which are conducted approximately 30 days apart during which blood and urine samples are collected.
89280104|NCT03865004|Placebo Comparator|Placebo|
89280105|NCT03865004|Active Comparator|Paracetamol|
89280106|NCT03865004|Active Comparator|Dexketoprofene|
89280107|NCT01285778|Experimental|Panitumumab, mytomicin C, 5-FU, radiation|
89280108|NCT03292432|Active Comparator|Standard of Care (SOC)|Standard of Care for adherence support at Site
89280109|NCT03292432|Experimental|TERA Intervention (TERA)|Triggered, escalating, real-time adherence (TERA) intervention for 12 weeks.
89280110|NCT01285856|Active Comparator|buprenorphine|populations of patients treated with HDB will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
89280111|NCT01285856|Active Comparator|methadone|populations of patients treated with methadone will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
89280112|NCT01063205|Placebo Comparator|Placebo|
89280113|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 1800 mg|
89280114|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 3600 mg|
89280115|NCT01175096|Active Comparator|RAD001|2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day Dose level modifications/interruptions must follow guidelines. One treatment cycle consists of 28 days.
89280116|NCT02532959||Diagnostic Breath Analysis|Patients at risk of SIRS
89280117|NCT01174706|Experimental|Usual care arm|Patients randomized to this group will receive usual care. Usual care at the three study sites varies but will be defined as whatever information is usually given to patients regarding the prescription medication or over the counter medicine they were prescribed at emergency department discharge.
89280118|NCT01174706|Experimental|Information prescription|Patients randomized to this arm will receive written information from Medline Plus regarding the prescription or over the counter medicine they have been prescribed at ED discharge plus information on their health condition.
89280119|NCT01174706|Experimental|Informationist|Patients in this arm will receive the same information as patients in group 2 but will also be given contact information for a clinical informationist if they have further questions about their prescription medicine or over the counter medicine prescribed at ED discharge.
89280120|NCT01174706|Experimental|practical assistance|Subjects will be offered practical assistance with obtaining prescription such as location of most convenient pharmacy and hours of operation, programs that offer drugs more cheaply, fax prescription from ED to pharmacy
89280121|NCT01285934|Experimental|Hematopoietic Stem Cell Transplantation|Patients who meet eligibility and have completed pre-HSCT testing in section 7.0 (study parameters) may be enrolled in the transplant arm and will undergo an Autologous Hematopoietic Stem Cell Transplantation
89280122|NCT01285934|Other|control arm of intensive insulin therapy|The control arm of intensive insulin therapy (IIT) will enroll all patients who meet eligibility but decline HSCT or whose insurance does not approve payment for HSCT before expiration of eligibility (within 5 months of disease onset)
89280123|NCT01063361|Experimental|Low glycemic Index Diet|Low glycemic Index Diet, emphasizing pulses
89280124|NCT01063361|Active Comparator|High Cereal Fibre Diet|
89280125|NCT03291808|Experimental|Weight loss intervention|Such designs are widely used in efficiently informing decisions to proceed to Phase III clinical trials. This trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss).18 Therefore, this will be a single arm 6-month study of 40 participants (20 at each site). All participants will be assigned to the weight loss intervention.
89280126|NCT01060085||Breast Cancer|Women shown to have DCIS or invasive breast cancer by fine needle aspiration cytology and/or core needle biopsy.
89280127|NCT03864770|Experimental|Extracorporeal shock wave therapy and general physical therapy|In this arm, the subjects will receive the intervention of extracorporeal shock wave therapy and general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
89280128|NCT03864770|Active Comparator|Only general physical therapy|In this arm, the subjects will only receive the intervention of general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
89280129|NCT05275348|Experimental|Tele-EF|Remote delivery of Enhance Fitness.
89280130|NCT05275348|Active Comparator|In-person EF|In-person delivery of Enhance Fitness.
89280131|NCT01060163|Experimental|group ET|Patients receiving early CABG <=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
89280132|NCT01060163|Placebo Comparator|group EP|Patients receiving early CABG <= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
89280133|NCT01060163|Experimental|group LT|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
89280134|NCT01060163|Placebo Comparator|group LP|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with placebo(saline solution)
89280135|NCT01060163|Experimental|group BT|Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
89280136|NCT01060163|Placebo Comparator|group BP|Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)
89280137|NCT03864380||Person running a marathon|"Exams performed before (1 month maximum) and after the marathon (1 hour maximum) :~Color retinography Optical Coherence Tomography - Angiography (OCT-A) Blood pressure measurement"
89280138|NCT01063439|Experimental|BuEAM: Experimental|BuEAM: Experimental Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day Intervention: Drug: Busulfan, etoposide, cytarabine, and melphalan
89280139|NCT03263806|Active Comparator|SOC Group Management|Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
89280140|NCT03263806|Experimental|CTFFR-Guided Group Management|Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.
89280141|NCT03741959|Experimental|Experimental|The experimental group will undergo three groups of exercises: 1) active self-correction exercises (20 minutes) defined as the best possible trunk alignment the patient can achieved in the three-dimensional planes; 2) passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint and to counteract the evolution of the misalignment; 3) functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks.
89280142|NCT03741959|Active Comparator|Control|The control group will undergo strengthening exercises and gait training as the usual practice in Parkinson Disease. Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks (Bartolo et. al., 2010).
89280143|NCT03751280|Experimental|PEAR-004|Eligible participants were able to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.
89280144|NCT03751280|Sham Comparator|Sham|Eligible participants were able to access a sham control downloaded on a mobile device (iOS and Android based) as needed to receive notifications prompting the participant to open the sham app, which displayed a prescription timer for the remaining duration of app availability.
89280145|NCT05275270|Active Comparator|Group A|patients were treated with an active gel containing oxytocin
89280146|NCT05275270|Placebo Comparator|Group B|patients were treated with placebo gel without oxytocin
89280147|NCT01060241|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
89280148|NCT01060241|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
89280149|NCT01048931|Experimental|single-port LAVH|single port LAVH
89280150|NCT03865784|Experimental|Experimental|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises with tension and stretching will be performed
89280151|NCT03865784|Active Comparator|Control|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises technique will be performed without tension or stretching
89280152|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|"For patients whose clinician is randomized to the decision aid arm:~The study coordinator will provide the decision aid for the parent/clinician dyad.~The study coordinator will provide a color-printed copy of the decision aid to the clinician prior to the clinician having the antibiotics discussion with the parents.~The study coordinator will offer to provide the treating clinician a concise refresher of the content included in the decision aid in the context of the trial.~The clinician will then, using the decision aid as a tool to facilitate discussion regarding the natural course of AOM, pain control, antibiotics exposure and deeper infections.~The clinician will then engage the parents in a shared decision regarding the use of immediate antibiotics versus a wait and watch prescription that is consistent with both the parent's values and preferences and the clinician's level of comfort."
89280153|NCT02872558|Other|Usual Care|the clinician will discuss management options with the parent in the clinician's usual fashion.
89280154|NCT05275192|Experimental|Videoscope-assisted periodontal regeneration minimally invasive surgery|Videoscope-assisted periodontal regeneration minimally invasive surgery - Test group
89280155|NCT05275192|Active Comparator|Periodontal regeneration minimally invasive surgery|Periodontal regeneration minimally invasive surgery - Control Group 1
89280156|NCT05275192|Active Comparator|Guided tissue regeneration surgery|Guided tissue regeneration - Control Group 2
88805637|NCT03013595|No Intervention|Usual care|Patients, parent/carers and clinicians in the control arm will complete the TRAM prior to the transition boundary, but the clinicians won't receive any feedback from it nor any information on the benefits of using the decision support tool.
89280157|NCT01283906|Experimental|MuGard|Mucoadhesive Oral Wound Rinse
89280158|NCT01283906|Sham Comparator|Control Rinse|Aqueous Control Rinse.
89280159|NCT05253898|Active Comparator|Pelvic Floor Physical Therapy|"Group 1 includes a training program about correctly using pelvic floor muscles. At the first session, an educational program will be given to all women about the anatomy and function of the pelvic floor muscles. Then, the pelvic floor muscles contractions will be controlled by vaginal palpation for approximately 10 minutes.~Then it will follow with 5 minutes of warm-up exercises, 30 minutes of fast and slow pelvic floor muscles contractions in different positions, and 10 minutes of abdominal breathing, general relaxation, stretching, and cool-down exercises.~It is planned to teach contractions with internal palpation for 10 minutes before the first session to ensure that the patients' pelvic floor contractions are performed correctly. PFT treatment will be given as two sessions per week, 45 minutes, and 8 weeks as group sessions."
89280160|NCT05253898|Active Comparator|Therapeutic Yoga Training|"Group 2 program includes therapeutic yoga training. It will begin with education about the positive effects of yoga on the body and pelvic floor.~Then it will follow with 5 minutes of warm-up exercises, 30 minutes of different asanas coordinated with breathing, and 10 minutes of yogi breathing and cool-down exercises.~Also, a home exercise program will be given based on yoga sessions. Participants will receive a detailed description of the home program."
89280161|NCT03868202|No Intervention|Premenopausal women|Participants will bring into clinic their first voided urine of the day on cycle days 9, 12 and 15 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH.
89280162|NCT03868202|Active Comparator|Postmenopausal women|Participants will bring into clinic their first voided urine of the day on assigned days 1, 4 and 7 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. The participants will then be started on EstroGel© for 14 days from day 7-21. During that time that they are on EstroGel©, the participants will bring into clinic their first voided urine of the day on assigned days 15, 18, and 21 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. After the last urinary collection and blood draw, they will discontinue the EstroGel and be started on micronized progesterone if they have a uterus for 12 days.
89280163|NCT00311363|Experimental|GEn (XP13512) 1200 mg|GEn (XP13512) 1200 mg
89280164|NCT00311363|Placebo Comparator|Placebo|Placebo
89280165|NCT03867968|Experimental|TIPS Intervention|The Traumatic Brain Injury Positive Strategies (TIPS) program, is a comprehensive educational and training resource to help families. The web-based product will include: (a) the Training Center, which will provide training in a range of evidence-based strategies within a problem-solving framework; and (b) the TBI Resource Center, an extensive library of educational materials, information, and resources about childhood TBI.
89280166|NCT03867968|Active Comparator|Control|An existing website related to traumatic brain injury.
89280167|NCT03868358|Active Comparator|Real Stimulation|Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks
89280168|NCT03868358|Placebo Comparator|Sham Stimulation|Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks
89280169|NCT01171274|Active Comparator|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~One class of 90 minutes per week, 10 minutes training at home each day."
89280170|NCT01171274|Active Comparator|Exercise information|"9 weeks of exercises practiced at home.~Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
89280171|NCT00333983|Experimental|Arm 1|Robot Exercise Group
89280172|NCT00333983|Active Comparator|Arm 2|Traditional Upper Extremity Exercise Group
89280173|NCT01171352||ICU Dialysis Patients|Any patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole determinant for that level of care, will be invited to participate. The patient must have acute or chronic needs for dialytic support during their ICU stay.
89280174|NCT01171430|Experimental|MRI WHOLE BODY|
89280175|NCT01175252||Gastroenteritis Cohort|All children suffering with gastroenteritis
89280176|NCT01171508||Breast cancer patients|12 breast cancer patients aged 30-70 years undergoing a lumpectomy at Herlev Hospital. ASA score I-III.
89280177|NCT01171586|Experimental|SMS Only|"The SMS only group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The SMS only group will also receive a brief printed or web based outline on weight loss resources and information."
89280178|NCT01171586|Experimental|SMS + Phone Counseling|"This group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The group will also receive monthly counseling calls from a Health Coach to discuss barriers and solutions and will receive a brief printed or web based outline on weight loss resources and information."
89280179|NCT01171586|No Intervention|Control|The Control group will receive a binder with an attractive set of Standard Print Materials related to weight loss that is comparable to what one would receive from community resources such as libraries, magazines and national non-profit or governmental organizations such as 5-A Day, American Heart Association and the like.
89280180|NCT03863678|Experimental|Neurodevelopmental therapy|Group 1 will only receive Neurodevelopmental therapy (NDT), for 12 sessions.
89280181|NCT03863678|Experimental|Neurodevelopemental therapy and dry needling therapy|Group 2 will receive Neurodevelopmental therapy (NDT) and dry needling therapy, for 12 sessions.
89280182|NCT01171664|Placebo Comparator|Placebo|Placebo containing no active pharmaceutical ingredients
89280183|NCT01171664|Experimental|STAHIST|STAHIST tablet for the symptomatic treatment of Seasonal Allergic Rhinitis
89280184|NCT01175330|Placebo Comparator|CABG and intralipid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
89280185|NCT01175330|Active Comparator|CABG and omega-3 fatty acid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
89280186|NCT02526056|Experimental|Physiotherapists|The physiotherapist have to play the exergame once.
89280187|NCT02526056|Experimental|elderly people|The elderly people have play the exergame twice.
89280188|NCT01171742|Experimental|IHIO|Intermittent hepatic inflow occlusion (IHIO) by clamping of the portal triad, minimizes blood loss and operation time during liver resection. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. IHIO'll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
89280189|NCT01171742|Sham Comparator|Control|The donor liver parenchyma'll be transected without IHIO.
89280190|NCT01174862||Aspirin responder|Normal aspirin responsiveness in ASPI test (Multiplate)
89280191|NCT01174862||Aspirin non-responder|Reduced aspirin responsiveness in ASPI test (Multiplate)
89280192|NCT03262012|Experimental|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
89280193|NCT03262012|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
89280194|NCT03262012|Experimental|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
89280195|NCT03262012|Active Comparator|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
89280196|NCT01174940|Experimental|Extracorporeal Photopheresis|Patients will receive 2 ECP treatments on day -10 and day -8 and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
89280197|NCT01283984|Experimental|1|AZD2115
89280198|NCT01283984|Placebo Comparator|2|Placebo to AZD2115
89280199|NCT01175408|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
89280200|NCT01175408|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the data to their endocrinologist and receive feedback based on the uploaded glucose data.
89280201|NCT01175408|Active Comparator|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
89280202|NCT01175408|Active Comparator|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
89280203|NCT03637894|Active Comparator|Infants born by CS-fed fermented formula|Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
89280204|NCT03637894|Placebo Comparator|Infants born by CS-fed standard formula|Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
89280205|NCT03637894|Other|Infants born by CS-breastfed|"Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.~The breastfeeding infants were the reference group"
89280206|NCT03637894|Active Comparator|Infants born by ED-fed fermented formula|Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
89280207|NCT03637894|Placebo Comparator|Infants born by ED-fed standard formula|Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
89280208|NCT03637894|Other|Infants born by ED-breastfed|"Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.~The breastfeeding infants were the reference group."
89280209|NCT03863600||Midwife-led continuity of care|Women receiving midwife-led model of care though the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
89280210|NCT03863600||Regular care|Women receiving regular maternal care through the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
89280211|NCT03864302|Experimental|Motor Imagery|"The intervention group is informed about the concept of motor imagery (MI) for performance enhancement and are instructed in using the modified PETTLEP framework for TURB (table 1).(18) The intervention group performs a MI training session (MITS) prior to each VR simulation procedure.~Table 1: PEELP framework:~Physical: Sitting in front of the simulator, aloud to touch and move the scope Environment: Simulated sounds from the OR, including electrical device feedback from devices and vital measures Task: Four standardized TURB cases Timing: Each MI session is temporal to a simulated TURB case, max. 10 minutes Learning: Think aloud the major steps of the procedure using Emotions: Imagine the emotions when the surgery progresses and when an adverse event occurs Perspectives: Internal perspective thinking then I…"
89280212|NCT03864302|No Intervention|Control|The control group proceeds directly to standard VR-simulator training.
89280213|NCT03288142|Experimental|Intervention: Hypertension Coaching Application and Home Monitor:|"The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) (Lark HTN Pro), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app."
89280214|NCT03288142|Active Comparator|Control:Tracking Application and Home Monitor:|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
89280215|NCT01286090|Experimental|001|Cisapride One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
89280216|NCT01286090|Experimental|002|Placebo One tablet taken orally 4 times a day for up to 8 weeks.
89280217|NCT00310817|Experimental|MenACWY-CRM(Ad+) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine with adjuvant (Ad+) on day 1 and second dose at 28 days or at 6 months or at 12 months after the first vaccination.
89280218|NCT00310817|Experimental|MenACWY-CRM(Ad-) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant (Ad-) on day 1 and second dose either at 28 days or at 6 months or at 12 months after the first vaccination.
89280219|NCT00310817|Experimental|MenACWY-CRM(Ad-) 36 to 59 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant on day 1 and second dose on day 169 or day 337.
89280220|NCT00310817|Active Comparator|MenACWY-PS (36 to 59 Months)|Subjects received one dose of MenACWY polysaccharide (PS) vaccine on day 1 and second dose of MenACWY-CRM conjugate vaccine without adjuvant on day 169 or day 337.
89280221|NCT03863912|Active Comparator|Disney|watch Disney movies and fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
89280222|NCT03863912|Other|Control|fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
89280223|NCT03863990||Patients with PAH|Adult male and female patients from Argentina diagnosed with pulmonary arterial hypertension (PAH) of WHO functional class I between 01-Jan-2012 and 31-Dec-2017 and with at least one year of follow-up.
89280224|NCT03863366|Experimental|Prucalopride|1mg prucalopride capsule
89280225|NCT03863366|Placebo Comparator|Placebo|Lactose placebo capsule
89280226|NCT01060397|Experimental|Extended Brief Intervention|FRAMES motivational interviewing approach
89280227|NCT01060397|Experimental|Control|Usual care
89280228|NCT01175486|Experimental|Actos|Actos 30 mg for 6 months
89280229|NCT01175486|Active Comparator|Acarbose|Acarbose 50mg tid for 6 months
89280230|NCT02526134|Experimental|Laying of medical devices|radio opaque markers
89280231|NCT01063673||Active runners|Observational follow-up study on 39 runners
89280232|NCT01177748||Patients on the Stroke Unit|
89280233|NCT02747498|Active Comparator|circumferential pulmonary vein isolation|Procedure with circumferential pulmonary vein isolation for atrial fibrillation
89280234|NCT02747498|Experimental|Posterior box isolation in addiction to pulmonary vein isolation|Posterior box isolation in addiction to circumferential pulmonary vein isolation
89280235|NCT01175564|Experimental|Active|Each cohort will have 9 volunteers that will receive TC-5214
89280236|NCT01175564|Placebo Comparator|Placebo|Each cohort will have 3 volunteers that will receive placebo
89280237|NCT01177826||Group 1|Cases
89280238|NCT01177826||Group 2|Controls
89280239|NCT01177904|Active Comparator|Progesterone 5 Weeks|The study group stop receiving P4 on the day of their first US at 5 weeks pregnancy
89280240|NCT01177904|Other|Control Group : P4 8 weeks|Progesterone will be given until 8 weeks of pregnancy
88805638|NCT05307341|Active Comparator|Treatment|One dose of sufentanil 30 mcg sublingual will be given pre-operatively when entering the operating room and one dose post-operatively in the PACU in addition to standard of care pain management.
88805639|NCT05307341|No Intervention|Control|A multimodal approach to analgesia will be used in all subjects in the perioperative setting and will be used in both the control and treatment groups. Intraoperative dosing of opioids will be based on the anesthesiologist's clinical judgement related to the pain and hemodynamic response to surgical stimuli and on an as needed basis in the PACU. Administration of opioids in the PACU will be in response to moderate-to-severe pain.
89280241|NCT02940886|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
89280242|NCT02940886|Active Comparator|Iron sucrose|Administered IV
89280243|NCT03860714||study group|400 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China].We do the neuropsychological tests,MMSE,CCI，CDR,QoR-40,GDS,CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，NRS once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
89280244|NCT01177982|Active Comparator|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club
89280245|NCT01177982|Experimental|Reduced RBT (r-RBT)|Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
89280246|NCT01177982|Experimental|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
89280247|NCT01177982|Active Comparator|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club Recovery housing CAP short term housing admission Recovery sponsor
89280248|NCT01177982|Active Comparator|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
89280249|NCT01177982|Active Comparator|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
89280250|NCT01177982|Experimental|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
89280251|NCT01177982|Experimental|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
89280252|NCT02525978|Experimental|Healthy Controls|Healthy controls will complete the video task and imaginal task in one session
89280253|NCT02525978|Experimental|Depressed + Ketamine|Subjects with major depressive disorder (MDD) who are scheduled to receive ketamine infusions will complete the video task and imaginal task twice. The first visit will be before any ketamine treatment. The second visit will be within 1 week after first ketamine infusion. This is NOT at treatment study. Study inclusion is open to participants with MDD who are already planning to receive ketamine treatment at Emory. No treatment is offered through this study.
89280254|NCT03863444|Active Comparator|Control Group|Routine Care
89280255|NCT03863444|Experimental|Intervention Group|Routine Care + Prenatal Preparation Education
89280256|NCT01172054|Experimental|VAX128|Novel H1N1 Influenza vaccine
89280257|NCT01172054|Placebo Comparator|Placebo|one IM injection
89280258|NCT03285958|Experimental|STEPS Intervention Group|Participants will receive a wearable physical activity monitor and will be asked to report their daily step count in 3 different ways (2 weeks each of SMS text messages, Interactive Voice Response calls (IVR), automatic upload) during the 6-week study period.
89280259|NCT03285958|No Intervention|STEPS Control Group|Participants in this group will not receive a wearable physical activity monitor and will not be asked to report their step count.
89280260|NCT01178060|Active Comparator|Personalized Risk Information|Patients received personalized stroke and heart attack risk assessment information.
89280261|NCT01178060|Other|Standard Education|Patients received general risk information on heart attack and stroke.
89280262|NCT01288196|Experimental|001|CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg
89280263|NCT01288196|Experimental|002|CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg
89280264|NCT01288196|Experimental|003|CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg
89280265|NCT01288196|Placebo Comparator|004|Placebo IV A single 30-minute IV infusion of placebo
89280266|NCT01288196|Experimental|005|CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
89280267|NCT01288196|Placebo Comparator|006|Placebo SC A single SC dose of placebo administered in up to 3 SC injections
89280268|NCT01175642|Experimental|Cognitive remediation|Cognitive remediation
89280269|NCT01175642|Active Comparator|Functional Adaptive Skills Training|Functional and social skills group treatment
89280270|NCT01175642|Active Comparator|Combined Treatment|Combined cognitive remediation and functional adaptive skills training
89280271|NCT05216614|Experimental|Fluvoxamine|"This arm will be given the active treatment, oral fluvoxamine capsules of 25 mg each.~The first six weeks will be gradual titration (weeks 1 & 2 25mg BID, weeks 3 & 4 75mg BID, weeks 5 & 6 100mg BID).~The following six weeks will be fixed dose of 100mg TID.~The last two weeks will be a taper down (first week 50mg BID and second week 25mg BID)~There will be 14 weeks of active treatment and assessments will be conducted after completion of week 12, prior to beginning taper down period."
89280272|NCT05216614|Placebo Comparator|Placebo|"Placebo capsules that look, smell, and taste like fluvoxamine capsules will be given to the placebo arm.~To preserve double-blinding of the study, subjects will receive one capsule BID during the first six weeks following the titration schedule and one capsule TID during the next six weeks for the fixed-dose period.~Subjects will then taper-down placebo to imitate the fluvoxamine arm for two weeks.~Assessments will be conducted at 12 weeks following completion of fixed-dose period, prior to starting taper down period."
89280273|NCT03860636||Fresh Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at three different points during their treatments.~The day they receive their HCG trigger,~The day of transvaginal oocyte retrieval (TVOR) and~The day of embryo transfer (ET)."
89280274|NCT03860636||Frozen Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at two different points during their treatments.~The day we coordinate with embryologist (day of progesterone +/-1)~The day of embryo transfer (ET)."
89280275|NCT05666648||Sixty patients completed trial in two groups|
89280276|NCT03285646|Experimental|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
89280277|NCT03285646|Experimental|Placebo|SC every 4 weeks
89280278|NCT03860402||Pre-warmed drug|Pre-warmed (38°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
89280279|NCT03860402||Room temperature drug|Room temperature (20°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
89280280|NCT01175720|Experimental|test and control|The test and control technique will be tested in a split-mouth design.
89280281|NCT01288352|No Intervention|Usual care|Usual care closely follows the suggestions laid out in the current European Society of Cardiology (ESC) guidelines for AF treatment. In addition to antithrombotic therapy and therapy of underlying heart disease, usual care usually consists of an initial attempt to control symptoms by rate control therapy. Rhythm control interventions are recommended when symptoms can not be controlled by optimal rate control therapy in the usual care group.
89280282|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~Optimal antiarrhythmic drug therapy (Dronedarone, Amiodarone, Flecainide, Propafenone),~Catheter ablation with the aim of pulmonary vein isolation (PVI),~Antiarrhythmic drug therapy and catheter ablation may be supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
89280283|NCT03867656|Experimental|GLP-2|Glucagon-like peptide 2
89280284|NCT03867656|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
89280285|NCT03867656|Placebo Comparator|Placebo|Saline
89280286|NCT01172210||Bulimia Nervosa|
89280287|NCT01172210||Bulimia Nervosa w/ Alcohol Use Disorder|
89280288|NCT01172210||Healthy Controls|
89280289|NCT03309202|Experimental|Cohort 1_Without impairment|Single, 25 mg dose of PF-05221304
89280290|NCT03309202|Experimental|Cohort 2_Mild impairment|Single, 25 mg dose of PF-05221304
89280291|NCT03309202|Experimental|Cohort 3_Moderate impairment|Single, 25 mg dose of PF-05221304
89280292|NCT03309202|Experimental|Cohort 4_Severe impairment|Single, 25 mg dose of PF-05221304
89280293|NCT01284218||Aripiprazole cohort|
89280294|NCT01284218||Other atypical cohort|
89280295|NCT01284218||Other antidepressant cohort|
89280296|NCT01284218||Mood stabilizer cohort|
89280297|NCT01284218||Stimulant cohort|
89280298|NCT03860324|No Intervention|Control-group|No peripheral nerve block
89280299|NCT03860324|Experimental|Single-shot erector spinae plane block|The patient is positioned in lateral decubitus. The anesthesiologist uses a linear high-frequency probe in a longitudinal direction laterally to the mid-sagittal plane at the level of L4 until the transverse process is identified and, more superficial, the erector spinae muscle. A 22G needle of 80mm is introduced in-plane craniocaudally towards the transverse process of L4 until its tip is in the plane deep to the erector spinae muscle. Single-shot block with 30ml of ropivacaine 0,5% + adrenaline 100mcg
89280300|NCT03860324|Active Comparator|Single-shot fascia iliaca block|The patient is positioned in dorsal decubitus. The anesthesiologist uses a linear high-frequency probe in a transversal direction, below the crural arch so as to identify the femoral artery. Afterwards the probe is moved laterally to find the iliac muscle and its fascia. A 22G needle of 80mm is introduced in-plane latero-medially until its tip is below the fascia iliaca (between the muscle and its fascia). Single-shot block with 40ml of ropivacaine 0,2%.
89280301|NCT01175876|Experimental|1|Device: RIPC RIPC consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins Procedure: Carotid Artery Stenting
89280302|NCT01175876|Sham Comparator|2|Procedure: Carotid Artery Stenting
89280303|NCT03860012|Experimental|Folic Acid 800 mcg once weekly|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
89280304|NCT02525198|Placebo Comparator|Placebo|Placebo group: 12 month daily ingestion of placebo oil and flavonoid-poor matched extract
89280305|NCT02525198|Experimental|fatty acid/flavonoid blend|Experimental group: 12 month daily ingestion of 1.5 g EPA+DHA and 500 mg flavonoids
89280306|NCT03860090|Active Comparator|AXILLARY VEIN ACCESS|This group of subjects will receive the implant of device via fluoroscopy-guided axillary puncture technique.
89280307|NCT03860090|Active Comparator|CEPHALIC VEIN ACCESS|This group of subjects will receive the implant of device via optimized cephalic vein cutdown technique.
89280308|NCT03859934|Active Comparator|Melatonin|10 mg melatonin each day 1 hour before bedtime for 3 months
89280309|NCT03859934|Placebo Comparator|Placebo|Placebo each day 1 hour before bedtime for 3 months
89280310|NCT03867812|No Intervention|Fasting + alcoholic drink|No food (0 calories) but 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
89280311|NCT03867812|Experimental|SOBAR bar + alcoholic drink|One 70g bar (210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
89280312|NCT03867812|Active Comparator|Control food + alcoholic drink|48.5g of General Mills Chexmix (Honey Nut Flavor, 210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
89280313|NCT03867812|Active Comparator|Full meal + alcoholic drink|Stouffer's Bistro Crostini 5 Cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie (635 calories total) followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
89280314|NCT01178372|Active Comparator|lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
89280315|NCT01178372|Active Comparator|probiotics|
89280316|NCT01178450|Active Comparator|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
89280317|NCT01178450|Experimental|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
89280318|NCT00074490|Experimental|Arm IVD cohort 1 (Th2 DLI)|Patients receive low intensity fludarabine phosphate intravenous (IV) and cyclophosphamide IV on days -6 to -3. Patients undergo donor lymphocyte infusion (DLI) with sirolimus generated donor T-helper 2 (Th2) cells on day 14 (single T-Rapa cell DLI in patients with cluster of differentiation 4 (CD4) count between 100 and 200 inclusive)
89280319|NCT00074490|Experimental|Arm IVD cohort 2 (conventional DLI)|Patients receive low intensity fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3. Patients undergo DLI with unmanipulated donor T-cells on day 14 (single T- cell DLI in patients with low CD4 count between 100 and 200 inclusive)
89280320|NCT00074490|Experimental|Arm IVD cohort 3 (multiple Th2 DLI)|Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14 (multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300)
89280321|NCT00074490|Experimental|Arm IVA (12-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine by mouth twice a day (PO BID) on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic peripheral blood stem cells (PBSC) on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14.
89280322|NCT00074490|Experimental|Arm IVB (6-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
89280323|NCT00074490|Experimental|Arm IVC (6-day expanded Th2 DLI and High-Dose Sirolimus)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
89280324|NCT01286636|Experimental|artificial neural network|
89280325|NCT01286636|Active Comparator|Polysomnogram|
89280326|NCT03862976|Experimental|computerized cardiotocography|computerized cardiotocography
89280327|NCT03862976|Active Comparator|standard cardiotocography|standard cardiotocography non stresstest
89280328|NCT03859856||women with Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus
89280329|NCT03859856||women without Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus to serve as control
89280330|NCT03961152|Experimental|PainCoach-app group|In the PainCoach-app group, in addition to receiving the aforementioned usual care, the PainCoach app was downloaded on each patient's smartphone or tablet. Patients could use this app whenever they wanted until day 14 after surgery. They were not subjected to any different treatment compared to the control group, i.e. advice on pain management was delivered in an extra and different way, but the pain medication itself was exactly the same for both groups.
89280331|NCT03961152|No Intervention|Control group|The control group received usual care.
89280332|NCT02525900|Placebo Comparator|Wound Infiltration|0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
89280333|NCT02525900|Experimental|TAP Blocks|20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
89280334|NCT02525900|Experimental|TAP Catheters|20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.
89280335|NCT01094028|Experimental|Saline group|Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.
89280336|NCT01288508|Active Comparator|Supra Fiber|
89280337|NCT01288508|Active Comparator|Psyllium|
89280338|NCT03960762|Active Comparator|Group A = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
89280339|NCT03960762|Active Comparator|Group B = SAP group|SAP block (Group SAP) will be performed in the preoperative block room. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
89280340|NCT03863054||>40% wound area reduction after 1 month|Subjects to continue with standard practice for the next 12 weeks, or until the wound has completely healed.
89280341|NCT03863054||<40% wound area reduction after 1 month|Subjects to be fitted with NATROX™ after 1 month, over a period of 12 weeks or until the wound has completely healed.
89280342|NCT01175954|Experimental|Lacosamide Open-Label|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
89280343|NCT01288586||Device|Scandinavian Total Ankle Replacement System (STAR Ankle)
89280344|NCT01286714|Experimental|clips OST|
89280345|NCT01288664|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase for 6 months
89280346|NCT03859778||pharmacy students|
89280347|NCT03285490|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment was applied once daily for 5 consecutive days on the face or scalp.
89280348|NCT03285490|Placebo Comparator|Placebo|The Vehicle Ointment was applied once daily for 5 consecutive days on the face or scalp.
89280349|NCT02525276|Experimental|training + HT|training + HT
89280350|NCT02525276|Experimental|training - HT|training - HT
89280351|NCT02525276|Placebo Comparator|-training + HT|-training + HT
89280352|NCT02525276|No Intervention|- training - HT|- training - HT
89280353|NCT01284374||Male Adolescents|Male adolescents, 13-17 years old, who are seen at community adolescent health clinics and are offered HPV vaccine
89280354|NCT01284374||Parents of Male Adolescents|Parents of Male Adolescents, whose adolescents are being seen at community adolescent health clinics and are offered HPV vaccine
89280355|NCT01284374||Health Care Providers for Males 13-17 yo|Health care providers who provide medical care to male adolescents in pediatric and adolescent clinics
89280356|NCT02939716|Active Comparator|Rhubarb|300g frozen rhubarb, microwaved; served with 65g lactose free cream and saccharine sweetener
89280357|NCT02939716|Active Comparator|Bread|2 slices of white bread, 40g each; served with 10g butter
89280358|NCT02939716|Experimental|Lettuce|300g lettuce; served with 30g mayonnaise
89280359|NCT01176110|Experimental|thermal management with LMA PerfecTemp™|
89280360|NCT01176110|Active Comparator|no specific thermal management|
89280361|NCT01172444|Experimental|Test|Sandoz Mesalamine 1 g Suppository
89280362|NCT01172444|Active Comparator|Reference|Canasa 1 g Suppository
89280363|NCT01172444|Placebo Comparator|Placebo|Sandoz 1 g Placebo Suppository
89280364|NCT01178684||1: HIV-pos on d4T with neuropathy|
89280365|NCT01178684||2: HIV-pos on d4T without neuropathy|
89280366|NCT01178684||3: HIV-neg without peripheral neuropathy|
89280367|NCT01178684||4 HIV-pos on d4T with asymtomatic neuropathy|
89280368|NCT01288742|Experimental|001|TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).
89280369|NCT01288742|Experimental|002|Digoxin One 0.25-mg tablet for 1 day (Trt A)
89280370|NCT01288742|Experimental|003|Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
89280371|NCT01288742|Experimental|004|Rosuvastatin One 10-mg tablet for 1 day (Trt C).
89280372|NCT01288742|Experimental|005|Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
89280373|NCT01178840|Other|WC then FC2|The couples will use 4 PATH Woman's Condom then 4 FC2 female condom.
89280374|NCT01178840|Other|FC2 then WC|The couples will use 4 FC2 female condom then 4 PATH Woman's Condom.
89280375|NCT01178918||Healthy volunteers from recipients of H1N1 vaccine|
89280376|NCT01178996|Experimental|Thymosin alpha 1|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
89280377|NCT01178996|Placebo Comparator|Placebo|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
89280378|NCT03862898|Experimental|lumbar stabilization group- thoracic|Lumbar stabilization and thoracic mobilization in a closed kinetic chain (LSTMC) group performed this exercises from the least to the largest painless motion amplitude and accordingly divided into three phases. The first phase lasted for two weeks, the second three and the last third phase, also for three weeks, and a total of 8 weeks.
89280379|NCT03862898|Active Comparator|lumbar stabilization group|Lumbar stabilization in a closed and opened kinetic chain (LSCO) group also performed exercises from the least to the largest painless motion amplitude in three phases.
89280380|NCT01179074|Active Comparator|Oesophageal stent alone|Patients of inoperable oesophageal cancer in this arm underwent oesophageal stenting with self expandable metal stents
89280381|NCT01179074|Active Comparator|Oesophageal stent followed by EBRT|Patients in this arm underwent oesophageal stenting with self expandable metal stents followed by external beam radiotherapy (30Gy/10#/2weeks)
89280382|NCT01180868||patients with cancer|patients with hematological malignancies and solid tumors
89280383|NCT01180868||patients with autoimmune dosorders|patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
89280384|NCT01180868||healthy subjects|
89280385|NCT03862586|Experimental|N-acetyl cysteine|Twenty two infertile women with the onset of endometrial preparation for evaluating genes expression, received 1200 mg of oral N-acetyl cysteine for at-least six weeks before starting ovarian stimulation
89280386|NCT03862586|Placebo Comparator|Placebos|Eighteen infertile women with the onset of endometrial preparation for evaluating genes expression, received placebo effervescent tablet for at-least six weeks before starting ovarian stimulation
89280387|NCT01180946|Active Comparator|Ergocalciferol|Weekly ergocalciferol for 16 weeks
89280388|NCT01180946|Placebo Comparator|Placebo|Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.
89280389|NCT01179152|Active Comparator|Budicort|75 children will receive treatment with Budicort 200 mcg
89280390|NCT01179152|Active Comparator|Symbicort|75 children will receive treatment with Symbicort 160 mcg
89280391|NCT01179152|No Intervention|counselling|75 children who will not treated as their request but will be folowedup
89280392|NCT01179230||PET SPECT|Subjects will have both types of imaging performed, PET and SPECT
89280393|NCT01286948|Active Comparator|Levonorgestrel (LNG) gel (Levogel)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
89280394|NCT01286948|Active Comparator|oral LNG (1.5mg)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
89280395|NCT01179308|Active Comparator|General-epidural anesthesia|Epidural and general anesthesia
89280396|NCT01179308|Active Comparator|General anesthesia|General anesthesia alone
89280397|NCT01179386||methylphenidate|30 adolescents who are treated with Methylphenidate will perform the driving simulator and seat pressure mapping tests, in 2 different days : 1. with their regular methylphenidate medication and 2: without the methylphenidate medication after a 4 days washout period. Results will be recorded and statistical test will be performed.
89280398|NCT01179386||no medication|30 adolescents : control group , not suffering from ADHD and without methylphenidate medication will perform the driving simulator and seat pressure mapping tests. Results will be recorded and statistical test will be performed.
89280399|NCT01289366||Patients with IBD|
89280400|NCT03858296|Experimental|Emotional awareness|4 modules of emotional awareness training
89280401|NCT03858296|Experimental|Cognitive reappraisal|4 modules cognitive reappraisal training
89280402|NCT03858296|Experimental|Awareness + reappraisal|4 modules emotional awareness and cognitive reappraisal training
89280403|NCT03088826|Active Comparator|MSIR and Acetaminophen Group|The patients in this group will receive 1 tablet 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen
88805640|NCT01099475|Experimental|Pringle manoeuvre 15 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 2 cycles of 15 minutes of hepatic inflow occlusion will be applied each followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
89280404|NCT03088826|Active Comparator|Oxycodone and Acetaminophen Group|The patients in this group will receive 1 tablet 10mg Oxycodone combined with 650mg of Acetaminophen
89280405|NCT01289444|Active Comparator|Healthy Living Control|"Session 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered, with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~Session 3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides. The Administered by the trained RA-Control to prevent contamination with the FACE condition."
89280406|NCT01289444|Experimental|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
89280407|NCT00367133|Active Comparator|1|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
89280408|NCT00367133|Experimental|2|Intravitreal injection of 1mg of triamcinolone acetonide
89280409|NCT00367133|Experimental|3|Intravitreal injection of 4mg of triamcinolone acetonide
89280410|NCT03862508|Experimental|Experimental|Five Plyometric exercises
89280411|NCT03862508|No Intervention|Control|Subjects included in the control group will not receive any intervention
89280412|NCT03859310||Normal|no glaucoma or retinal pathology or corneal conditions
89280413|NCT03859310||Glaucoma|diagnosis of glaucoma
89280414|NCT03859310||Retina|diagnosis of AMD, DR or other retinal pathology
89280415|NCT03859310||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
89280416|NCT01287026|Experimental|1|Open Label
89280417|NCT01176188|Experimental|Comfort Care|Parental soothing, including tactile and auditory strategies, followed by a quiet period with the application of earmuffs to block auditory stimulation
89280418|NCT01176188|Active Comparator|Usual Care|
89280419|NCT01179464|Active Comparator|Aminobiphosphonates|Aminobiphosphonates
89280420|NCT01179464|Experimental|Aminobiphosphonates and Statin|Aminobiphosphonates and Statin
89280421|NCT03859076|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions & a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, & specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, & stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
89280422|NCT03859076|Active Comparator|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
89280423|NCT02525042||Patients with ankylosing spondylitis|Patients with ankylosing spondylitis
89280424|NCT02525042||Comparator 1|family controls
89280425|NCT02525042||Comparator 2|population controls
89280426|NCT01179542||first trimester|first trimester
89280427|NCT01179542||third trimester|third trimester
89280428|NCT01179542||prgnancies complicated with IUGR|prgnancies complicated with IUGR
89280429|NCT01179542||preeclampsia|preeclampsia
89280430|NCT01179620|Experimental|Certoparin|
89280431|NCT01179698|Other|Stryker navigation system|
89280432|NCT01288820|Experimental|DHP+PQ|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
89280433|NCT01288820|Active Comparator|AS-AQ +PQ|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
89280434|NCT01181024|Experimental|A: HV ascending dose|
89280435|NCT01181024|Experimental|B: HV food effect|
89280436|NCT01181024|Experimental|C: Hepatitis C|
89280437|NCT01181180|Experimental|balance treatment|
89280438|NCT00057330|Experimental|Herpes Simplex Virus Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus (HSV) vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
89280439|NCT00057330|Experimental|Havrix Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
89280440|NCT01181336|Experimental|Group 2|"FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
89280441|NCT01181336|Experimental|Group 3|"FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
89280442|NCT01181336|Experimental|Group 4|High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
89280443|NCT01181336|Experimental|Group 1|FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
89280444|NCT01181336|Placebo Comparator|Control Group|Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)
89280445|NCT03283696|Experimental|Olaratumab + Doxorubicin + Ifosfamide + Mesna|Olaratumab 15 milligrams per kilogram (mg/kg) on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin and ifosfamide was administered. When the safety of the 15-mg/kg dose of olaratumab was established, a 20-mg/kg loading dose cycle of olaratumab on Days 1 and 8 of a 21-day cycle in Cycle 1 only, followed by 15 mg/kg on Days 1 and 8 of subsequent cycles in combination with doxorubicin and ifosfamide plus mesna, was administered.
89280446|NCT01176344|Experimental|Vitamin D supplementation|Participants in the intervention arm will receive 50,000 IU (1.25 mg) cholecalciferol capsules given once monthly
89280447|NCT01176344|Placebo Comparator|Placebo|The control arm will receive identical inert placebo capsules given once monthly.
89280448|NCT01583946||Male low past-oriented SWB|
89280449|NCT01583946||Male high past-oriented SWB|
89280450|NCT01583946||Female low past-oriented SWB|
89280451|NCT01583946||Female high past-oriented SWB|
89280452|NCT01583946||Black Female high past-oriented SWB|
89280453|NCT01583946||Black Female low past-oriented SWB|
89280454|NCT01583946||Black male low past-oriented SWB|
89280455|NCT01583946||Black male high past-oriented SWB|
89280456|NCT03857906||IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease Intra-Aortic Ballon Pump insertion 1-6 hours prior to surgery
89280457|NCT03857906||No-IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease No IABP
89280458|NCT02939560|Experimental|rTMS|Participants will receive rTMS sessions according to the study protocol.
89280459|NCT02530788|Active Comparator|Selenium Supplement (sodium selenite)|Active arm receiving Selenium in form of sodium selenite
89280460|NCT02530788|Placebo Comparator|Placebo|Placebo arm receiving Sodium Chloride solution
89280461|NCT01313806|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
89280462|NCT01313806|Placebo Comparator|Placebo|
89280463|NCT01089192|Experimental|Torrent's Metformin tablets 750 mg|
89280464|NCT01089192|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
89280465|NCT03748706|Experimental|Simufilam (PTI-125)|Simufilam (PTI-125) 100 mg oral tablets administered twice daily (BID)
89280466|NCT02564380|Experimental|Arm A: Pembrolizumab|Pembrolizumab 200 mg every three weeks until disease progression (maximum 2 years)
89280467|NCT02564380|Placebo Comparator|Arm B: Placebo|Placebo i.v. every three weeks until disease progression (maximum 2 years)
89280468|NCT01093092|Experimental|Treatment (calcitriol, cisplatin, gemcitabine hydrochloride)|Patients receive calcitriol PO on days 1, 2, 8, 9, 15 and 16; cisplatin IV over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89280469|NCT01289054||Cohort 1 - Pregnancy/Fetal Exposure|
89280470|NCT01289054||Cohort 2 - Interrupted TKI|
89280471|NCT01179776|Experimental|Ilomedin and standard low dose treatment|
89280472|NCT01179776|Placebo Comparator|Placebo|
89280473|NCT01179854|Experimental|500 mg|Group of active treatment of Remegal 500 mg
89280474|NCT01179854|Experimental|Remegal 750 mg|Group of active treatment of Remegal 750 mg
89280475|NCT01179854|Experimental|Remegal 1000 mg|Group of active treatment of Remegal 1000 mg
89280476|NCT01179854|Placebo Comparator|Placebo|Placebo
89280477|NCT01289600|Active Comparator|Pressure support ventilation, ARDSnet|"Mechanical ventilator is set to pressure support ventilation (6 ml/kg) for 30 min with positive end expiratory pressure (PEEP) set according to the higher arm of the ARDS network consensus."
89280478|NCT01289600|Active Comparator|Pressure control ventilation, ARDSnet|"Mechanical ventilator is set to pressure control ventilation (6 ml/kg) for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
89280479|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, ARDSnet|"Mechanical ventilator is set to NAVA for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
89280480|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, titrated|Mechanical ventilator is set to NAVA for 30 min with PEEP titrated using the diaphragm EMG signal.
89280481|NCT01181414|Experimental|Atrioventricular junction ablation|Atrioventricular junction ablation by using radiofrequency energy.
89280482|NCT01181414|Active Comparator|Drug control of ventricular rate|Drug control of ventricular rate.
89280483|NCT01093170|Experimental|RNA-144101|
89280484|NCT03747302|Experimental|HPV Messaging|Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
89280485|NCT03747302|Other|Control Message|Subjects are randomized to receive one of five messages about electronic cigarettes.
89280486|NCT01094340|Other|Thalidoide|CSF
89280487|NCT03858920||General Responder Cohort (GRC) WTC Responders|General Responder Cohort (GRC) and who have chosen to undergo annual medical monitoring and treatment of their WTC-related conditions at Mount Sinai's Irving J. Selikoff Center for Occupational and Environmental Medicine (SCOEM), which is directed by Dr. M. Crane
89280488|NCT03858920||General Responder Cohort (GRC) Non WTC Responders|Members of the World Trade Center General Non Responder Cohort.
89280489|NCT00056862|Experimental|Low-dose pegIFN/standard-dose RBV|Patients receive a lower dose of peginterferon alfa-2a (90 mcg per week) and standard dose of ribavirin (800 mg/d) for chronic hepatitis C, genotype 2/3, for 24 weeks.
89280490|NCT00056862|Active Comparator|Standard-dose PegIFN/RBV|Patients receive the standard, recommended doses of peginterferon alfa-2a (180 mcg per week) and ribavirin (800 mg/d) for chronic hepatitis c, genotype 2/3, for 24 weeks.
89280491|NCT03858842||PF-ILD and SSc-ILD patients|PF-ILD and SSc-ILD patients
89280492|NCT01287182|Placebo Comparator|Placebo|
89280493|NCT01287182|Active Comparator|Ateronon|
89280494|NCT00056316|Experimental|Behavioral Skills Training|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
89280495|NCT00056316|Active Comparator|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
89280496|NCT01180088|Experimental|ANTERIOR APPROACH|SURGICAL TECHNIQUE
89280497|NCT03308968|Placebo Comparator|Placebo|Double-blind (DB) period: Participants with CM or EM will receive 3 injections of placebo 1.5 milliliters (mL) SC on Day 0 and single injection of placebo 1.5 mL SC on Days 28 and 56. Open-label (OL) period: Participants with CM or EM will receive fremanezumab (TEV-48125) 225 milligrams (mg) SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
89280498|NCT03308968|Experimental|Fremanezumab Quarterly|DB period: Participants with CM or EM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of placebo 1.5 mL for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
89280499|NCT03308968|Experimental|Fremanezumab Monthly|DB period: Participants with CM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). Participants with EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
89280500|NCT01289132|Placebo Comparator|Placebo|
89280501|NCT01289132|Experimental|Azilsartan 5 mg QD|
89280502|NCT01289132|Experimental|Azilsartan 10 mg QD|
89280503|NCT01289132|Experimental|Azilsartan 20 mg QD|
89280504|NCT01289132|Experimental|Azilsartan 40 mg QD|
89280505|NCT01289132|Experimental|Azilsartan 80 mg QD|
89280506|NCT01289132|Active Comparator|Candesartan Cilexetil 8 mg titrated to12 mg QD|
89280507|NCT01287260|Experimental|Arm1|
89280508|NCT01287260|Active Comparator|Arm 2|
89280509|NCT03857516||Recipients of cardiac resynchronization therapy|Consecutive patients with de novo implantation of a cardiac resynchronization defibrillator or pacemaker.
89280510|NCT01181570|Experimental|Adalimumab|
89280511|NCT01181570|Placebo Comparator|Placebo|
89280512|NCT05200312|Experimental|Treatment-naive DLBCL|Treatment-naive high-risk DLBCL patients will be enrolled. R/R2-CHOP were allowed in cycle 1 due to poor physical condition or liver and renal failure caused by lymphoma progression. Patients achieving Complete Remission (CR) or Partial Remission (PR) after 2 cycles will receive another 2 cycles. Patients achieving CR or PR after 4 cycles will finish 6 cycles. Patients achieving CR after 6 cycles with double-hit/triple-hit/double-expression/median to high risk aaIPI will undergo Autologous Stem Cell Transplantation (ASCT). Other patients will be administered rituximab for another 2 cycles and then turn to follow-up. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for another 3 years. Patients achieving Stable Disease (SD) or PD (Progression Disease) after 2 or 4 cycles will quit the study. After 6 cycles, patients achieving SD or PD will quit the study and patients achieving PR will receive second-line therapy.
89280513|NCT01180166|Experimental|nimotuzumab|Combination of nimotuzumab and capecitabine concurrent chemoradiotherapy is received by patients.
89280514|NCT03862196|Experimental|Intervention|Participants will receive 2 tailored text messages weekly from a trained counselor during 3 months.
89280515|NCT03862196|No Intervention|Control|Participants will receive standard of care: pre and post counseling after being diagnosed with HIV
89280516|NCT03637738|Experimental|RIOP-Intrabeam® system|"Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.~Additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient."
89280517|NCT03637738|Active Comparator|conventional surgery +RTE|surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
89280518|NCT02940730|Active Comparator|Dalbavancin via IV|Dalbavancin will be administered via intravenous administration. Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
89280519|NCT02940730|Active Comparator|Dalbavancin via IP|Dalbavancin will be administered as an intraperitoneal administration. Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
89280520|NCT03741062|Experimental|J. Morita AdvErl Evo Er:YAG laser|Immediately following completion of the surgical procedure, this group will receive photobiomodulation treatment of the palatal tissue donor site with Er:YAG laser according to the parameters recommended by experts in this field and which have shown to induce maximal proliferation of human gingival fibroblasts (Energy Setting: 80 mJ, Pulse Rate: 25 Hz, Duration: 30 s).
89280521|NCT03741062|Sham Comparator|Control|This group will receive sham treatment of the palatal tissue donor site. The laser unit will be turned off. The clinician will simulate usage of the Er:YAG laser in a manner that is indistinguishable to the patient from the experimental group.
89280522|NCT01587560|Active Comparator|Pyrocarbon|Patients receiving a shoulder surface replacement implant made of pyrocarbon (the PyroTITAN Humeral resurfacing Arthroplasty)
89280523|NCT01587560|Active Comparator|CoCr|Patients receiving a shoulder surface replacement implant made of Cobalt-Chrome(CoCR) (the TITAN Humeral Resurfacing Arthroplasty)
89280524|NCT03281668|Experimental|Intervention|Intervention consists of High Intensity Interval Training (HIIT) session which is af 3-5 minute warm up, followed by 10 repetitions of 1 minute bouts at individualized training intensity with 1 minute rest periods.
89280525|NCT01181648||oropharynx cancer survivors|This study has two components. First, we will conduct a cross-sectional survey of 200 oropharynx cancer survivors, diagnosed with HPV+ tumors, who are at least 12 months from their last treatment. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis.
89280526|NCT01587638||Hypertensive users of Beta blocker|Patients aged ≥18 years and at least 1 diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) during this time frame in a US Managed care population
89280527|NCT01176422||advanced Myelodysplastic Syndrome or acute myeloid leukemia|advanced MDS and AML with/without associated cytogenetic abnormality
89280528|NCT03858452|Active Comparator|Pelvic floor muscles training group|Pelvic floor muscles exercises twice a day for 30 min
89280529|NCT03858452|Active Comparator|Diaphragm muscles training group|Breathing exercises twice a day for 30 min
89280530|NCT03858452|Active Comparator|Abdominal muscles training group|Abdominal muscles exercises twice a day for 30 min
89280531|NCT01287338|Experimental|Lower Puncta Delivery|
89280532|NCT01287338|Experimental|Double Puncta Delivery|
89280533|NCT01289288|Experimental|Mailed printed materials and in-office training|
89280534|NCT01289288|No Intervention|Control|Usual care
89280535|NCT01180322|Active Comparator|Arm A|Standard Therapy
89280536|NCT01180322|Experimental|Arm B|"Investigational Therapy Azacitidine Prior"
89280537|NCT01180322|Experimental|Arm C|"Investigational Therapy Azacitidine Concurrent"
89280538|NCT01180322|Experimental|Arm D|"Investigational Therapy Azacitidine After"
89280539|NCT01287494|Experimental|Depression Care Management|"DCM Intervention for Depressed Elders in Primary Care~Treatment guidelines (TG): Eight weeks treatment with Sertraline, another 8 weeks treatment augmentation with Bupropion if patients fail to respond in the initial trial, For more complicated cases, the transfer to psychiatrists is indicated.~Care managers: Screening, Adherence support, psychoeducation and communication.~Psychiatric Consultation"
89280540|NCT01287494|No Intervention|Care as Usual|
89280541|NCT03858218||Pediatric cancer survivors group|Childhood cancer survivors refers to those who have completed cancer treatment for at least six months, the pediatric cancer survivors must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese.This group will be required to fill in the questionnaires set.
89280542|NCT03858218||Healthy children group|Healthy children must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese. This group will be required to fill in the questionnaires set.
89280543|NCT02524964|Experimental|sodium tanshinone IIA sulfonate|sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days)
89280544|NCT02524964|Sham Comparator|control|same volume/day of normal saline.
89280545|NCT01289756|Experimental|CYP2D6 EM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
89280546|NCT01289756|Experimental|CYP2D6 IM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
89280547|NCT01289756|Experimental|CYP2D6 PM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
89280548|NCT01289756|Experimental|CYP2D6 UM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
89280549|NCT01181882|Experimental|Fish Oil and Aspirin|
89280550|NCT01181960||001|Risperidone long acting injectable - New Starts Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
89280551|NCT01181960||002|Risperidone long acting injectable - Continuous Users Patients who have been on Risperidone long acting injectable for at least 6 months before baseline with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
89280552|NCT01181960||003|Paliperidone Palmitate -New and Continuous Users Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
89280553|NCT01181960||004|Other Antipsychotics - New Starts Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
89280554|NCT01287572||Conscious sedation group|Pediatric patients 0 to 18 years requiring conscious sedation for procedures done in the pediatric ICU excluding burned patients or patients with severe eczema or other skin disease.
89280555|NCT03858374|Experimental|Experimental group|Patients in experimental group were transferred by air-suspending mattress.
89280556|NCT03858374|Active Comparator|control group 1|Patients in control group 1 were transferred by slide board.
89280557|NCT03858374|Active Comparator|control group 2|Patients in control group 2 were transferred by bedsheet.
89280558|NCT01180556|Experimental|Probiotics supplementation|Supplementation by probiotics for 4 weeks
89280559|NCT01180556|Placebo Comparator|Placebo|Supplementation of placebo for 4 weeks
89280560|NCT03861884||Cognitive assessments|Neurocognitive assessments, Birmingham Cognitive Screen
89280561|NCT03861884||MRI at 3T|Brain Imaging: MRI at 3T
89280562|NCT03861884||MRI at 7T|Brain imaging: Ultrahigh Field MRI at 7T
89280563|NCT03858062|Active Comparator|Open loop|14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring
89280564|NCT03858062|Experimental|Closed loop|4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)
89280565|NCT01182038|Experimental|Birth seat group|Randomized to birth on a midwife designed birth seat
89280566|NCT01182038|No Intervention|Non-birth seat group|Randomized to birth in any other position except on the midwife designed birth seat.
89280567|NCT01180712|Active Comparator|Blaeberry concentrated caspule|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a total daily dose of 1.4 grams of mirtoselect (a concentrated blaeberry extract) a day formulated in hard gelatin capsules (0.47 gram per capsule) administered thrice a day for 21 days.~Mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/)"
89280568|NCT01180712|Placebo Comparator|Placebo capsules containing lactose|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a placebo consisting of lactose formulated in hard gelatin capsules administered thrice a day for 21 days."
89280569|NCT03857438||Bipolar Mania|Diagnosis of BD type I, manic episode according to DSM-5 given by the following doctor
89280570|NCT03857438||Healthy Control|showing normal mental capacity during interview, have more than five years of public education, no diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine, no presence of family history of mood or psychotic disorder, and no presence of psychiatric disorder during interview or in the past, no presence of severe organic disease.
89280571|NCT01176656||SU|T2DM patients with a prescription for a sulfonylurea but no insulin
89280572|NCT01176656||Antidiabetic without SU|T2DM patients with an oral antidiabetic drug other than an SU, and no insulin
89280573|NCT01176656||Insulin|T2DM patients using insulin, with or without other oral antidiabetics
89280574|NCT03861650|Experimental|Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate is prepared from bone marrow by aspiration by wide bore needle and then prepared by centrifugation to get rich mix of MSCs to improve healing
89280575|NCT03861650|Sham Comparator|Saline|Sham or placebo drug in the control group
89280576|NCT03857360|Active Comparator|Pentabiocel|Oral administration of one sachet of Pentabiocel for 12 consecutive weeks.
89280577|NCT03857360|Placebo Comparator|Placebo|Oral administration of one sachet of Placebo per day for 12 consecutive weeks.
89280578|NCT03855410|Experimental|S4E App intervention|Participants in the S4E group will receive the tobacco modules via iPads in a private room. The intervention will last approximately 20 minutes. Content includes the theoretically driven components of S4E: (a)Storytelling scenarios, (b) an introduction video, tobacco use knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent tobacco use, (e) clinician-youth communication, and (f) highlighting prevention principles. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
89280579|NCT03855410|Experimental|Attention-Matched Control|Participants in the Attention-Matched Control group will receive a portable document format (PDF) version of the tobacco module content, an enhancement to the care they would receive should they not join the study. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
89280580|NCT01290770||obese men|obese men with chest pain like angina
89280581|NCT01290848|Experimental|Township of Uxbridge|The Take TIME for Your Child's Health campaign will target parents and caregivers of children up to 8 years of age.
89280582|NCT01290848|No Intervention|Township of Guelph/Ermosa|For a control group the investigators have selected a community that is similar in size, household composition, population density, distance from Toronto and economic status to the Township of Uxbridge.
89280583|NCT05668520||weight stable|stage 2 and 3 as defined by the UHDRS Total Functional Capacity score will be recruited. Ten will have reported at least 5% weight loss in a 12-month period,
89280584|NCT05668520||weight loss|stage 2 and 3 as defined by the UHDRS Total Functional Capacity score will be recruited. Ten will have reported at least 5% weight loss in a 12-month period,
89280585|NCT01184534||Questionnaires + Video|
89280586|NCT01184534||Questionnaires|
89280587|NCT01184612|Active Comparator|(BSF) MI sessions|5 semi-structured manualised MI sessions was conducted by existing prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual.
89280588|NCT01184612|Active Comparator|(BSF+) MI sessions with supervision|5 semi-structured manualised MI sessions was conducted by ordinary prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual, followed by ongoing Motivational Interviewing training with feedback based on audio taped sessions in peer supervision groups.
89280589|NCT01184612|Active Comparator|(UPI) Usual Planning Interview|5 sessions was conducted by prison staff according to usual working practices, with the exception that content was structured into 5 sessions and audio recorded. The provision of a government decree served as a basis for the intervention, covering planning of prison activities and post release arrangements including strategies for drug use cessation.
89280590|NCT01182116|Experimental|J Pouch side to end|Colorectal surgery Function Quality of Life
89280591|NCT05275556|No Intervention|Colonoscopy (Standard of Care)|The control arm is colonoscopy with High Definition White Light Endoscopy (HD-WLE) per standard of care.
89280592|NCT05275556|Experimental|CADe Device|The intervention arm is colonoscopy with HD-WLE per standard of care plus the CADe Device.
89280593|NCT03857282|Active Comparator|Aerobic Exercises|Bicycling Exercise (lower Limb)
89280594|NCT03857282|Experimental|Tai Chi Exercises|Tai Chi Exercises (yang 24 Postures)
89280595|NCT03307174|Active Comparator|Continuous epidural infusion|"At our institution, the most commonly utilized form of administration of medication through an epidural (our active comparator/control) is as follows:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl infused at a constant rate of 8ml/hr. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 15 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
89280596|NCT03307174|Experimental|Programmed intermittent epidural bolus|"For the programmed intermittent epidural bolus group:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl will be administered as a bolus of 4ml every 30 minutes. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 10 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
89280597|NCT01184690|Active Comparator|Single-operator DBE|Single-operator double-balloon endoscopy
89280598|NCT01184690|Active Comparator|Dual-operator DBE|Dual-operator double-balloon endoscopy
89280599|NCT03448978|Experimental|Descartes-08 plus fludarabine/cyclophosphamide pretreat|Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
89280600|NCT03857204|Experimental|performing US scans for fetal weight assessment.|
89280601|NCT01587716|Experimental|1. Inhaled GSK2339345/Placebo Single Dose (Cohort 1)|administered three ascending doses of GSK2339345 or placebo as a solution via an aqueous droplet inhaler over four treatment periods, with at least 5 days washout between doses
89280602|NCT01587716|Experimental|2. Inhaled GSK2339345/Placebo Repeat Dose (Cohort 2)|administered a dose of GSK2339345 or placebo, four times a day on two consecutive days. Each subject will receive either GSK2339345 or matching placebo as a solution administered via an aqueous droplet inhaler
89280603|NCT01184768||participants in the 6th tromsø study|
89280604|NCT03258814||Active Supervised Training (AST)|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
89280605|NCT03258814||Standard of Care (SOC) Physiotherapy|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.
89280606|NCT01184924|No Intervention|Control|Usual Care only. Usual care is defined as the care these subjects would like to seek from any health care practitioner or other program they may seek for healthy living. The subjects in this arm will be offered the AF Tai Chi intervention after an 8 week followup data collection
89280607|NCT01184924|Experimental|Tai Chi|Usual care plus Tai Chi. These subjects will be allowed to seek care from any health practitioner or any other programs and will receive the AF Tai Chi program for 8 weeks.
89280608|NCT01290926|Experimental|Capecitabine & Sorafenib|Sorafenib 200mg in the morning,400mg in the evening; escalation to 400mg twice daily after 1 cycle, Oral, Continuous dosing Capecitabine 850mg/m2 twice daily, Oral Days 1-14, weeks 1-2
89280609|NCT04922866||elderly patients following hepatectomy|elderly patients (aged ≥65 years) scheduled for any type of liver resection
89280610|NCT01185002|Experimental|MgC boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered MgC boosts."
89280611|NCT01185002|Experimental|Suprep boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered Suprep boosts"
89280612|NCT01185002|Experimental|Suprep boosts - Reduced dose|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered a reduced dose of Suprep boosts"
89280613|NCT01176734|Experimental|active t-VNS|active t-VNS
89280614|NCT02940080|Experimental|Anthocyanins and yellow potato|168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water
89280615|NCT02940080|Experimental|Yellow potato|350 g of steam-cooked mashed potatoes in water
89280616|NCT01185236|Experimental|simvastatin/ezetimibe (vytorin) group|vytorin 10/20mg po once daily for 12weeks
89280617|NCT01185236|Active Comparator|atorvastatin group|atorvastatin 20mg po once daily for 12weeks
89280618|NCT02524886|Active Comparator|Immediate stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start immediately after surgery
89280619|NCT02524886|Sham Comparator|Delayed stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start 3 months after surgery
89280620|NCT02524652|Experimental|Local infiltration analgesia|Infiltration of the knee by the surgeon with local anaesthetics under general anaesthesia.
89280621|NCT02524652|Active Comparator|Adductor canal block|Injection of local anaesthetics under ultrasound guidance in the adductor canal by the anaesthesiologist after the surgery, before awaking the patient.
89280622|NCT01176812||Dermal Fillers|Facial Wasting
89280623|NCT03855254|Experimental|Positive communication|
89280624|NCT03855254|No Intervention|Control (neutral communication)|
89280625|NCT03855254|Experimental|Negative communication|
89280626|NCT03861416|Experimental|Unifuzol® 1.4% 500 ml|Patients receive the infusion of investigational drug L-arginine 1.4% 500 ml IV daily for 10 days
89280627|NCT03861416|Experimental|Unifuzol® 1.4% 250 ml|Patients receive the infusion of L-arginine 1.4% 250 ml + placebo 250 ml IV daily for 10 days
89280628|NCT03861416|Placebo Comparator|Placebo 500 ml|Patients receive the infusion of placebo solution for intravenous infusions 500 ml IV daily for 10 days.
89280629|NCT01185314|Other|1|EGFR mutation testing
89280630|NCT01182584||Graves' disease|
89280631|NCT01182584||Healthy volunteers|
89280632|NCT01176890|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
89280633|NCT01176890|Experimental|Cardia|truncally vagotomized subjects (due to esophagus resection)
89280634|NCT01176890|Experimental|Healthy controls|Healthy control subjects
89280635|NCT03257410|Experimental|Theranova 400|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
89280636|NCT03257410|Active Comparator|Elisio-17H|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
89280637|NCT02524574|Experimental|cardiac Rehabilitation|
89280638|NCT03861026|Experimental|Intervention group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
89280639|NCT03861026|No Intervention|Control group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design."
89280640|NCT01185470|Experimental|Subjects with Implantable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
89280641|NCT00056160|Experimental|CC-5013/Dex|CC-5013 (lenalidomide) plus oral high-dose dexamethasone
89280642|NCT00056160|Experimental|Placebo/Dex|Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
89280643|NCT01185626|No Intervention|Usual care|The gynaecological oncologist (GO) provides care as usual. Currently, hospitals provide follow-up following the Dutch guidelines, meaning that they see their patients on given time points based on the number of years after diagnosis. Most hospitals give their patients leaflets regarding the diagnosis and treatment they receive, however none of them provide personalized information. All information is given during the initial treatment phase, but none of the GOs give additional information during follow-up. None of the GOs is actively screening on psychosocial needs. As this might change in time, we will ask the providers and patients about the type of information they provide, respectively, receive.
89280644|NCT01185626|Experimental|SCP care|After initial treatment, the GO provides the patient with a paper SCP and takes time to discuss all items in the SCP. Each time during follow-up meetings between patient and GO, the patient will receive an updated SCP if applicable. The paper SCP is extracted from the online registration system 'ROGY' (Registrationsystem Oncological GYnaecology) and combines personal patient and disease data with tailored information that is related to the specific situation of this patient. Recurrences, toxicities or additionally involved specialists will be registered in ROGY and automatically updated in the personal SCP.
89280645|NCT03857126||Pregnancy volunteer subjects|"Subjects who will agree to participate in the investigator's study will be pregnant healthy subjects with no particular antecedent, followed at the University Hospital of Grenoble for a physiological pregnancy; their child will be not affected by any prenatal pathology.~Subjects will be enrolled in a 30 min monitoring phase to collect signals from ECG-PCG-CTG abdominal and thoracic non invasive sensors."
89280646|NCT01290146|Active Comparator|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
89280647|NCT01290146|Experimental|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~SBP ≥100 mmHg: 0.1 mcg/kg/min"
89280648|NCT01177124|Experimental|MBSR 6 Weeks Program|
89280649|NCT01177124|No Intervention|Usual Care (UC)|
89280650|NCT00061932|Experimental|Stratum 1 (previously untreated)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8.
89280651|NCT00061932|Experimental|Stratum 2 (previously treated)|(closed to accrual as of 9/19/2006): Patients receive bortezomib as in stratum 1.
89280652|NCT01177202|Experimental|Group A|HAC1 Dose = 15ug; Alum Dose = 0
89280653|NCT01177202|Experimental|Group B|HAC1 Dose = 15ug; Alum Dose = 0.75mg
89280654|NCT01177202|Experimental|Group C|HAC1 Dose = 45ug; Alum Dose = 0
89280655|NCT01177202|Experimental|Group D|HAC1 Dose = 45ug; Alum Dose = 0.75mg
89280656|NCT01177202|Experimental|Group E|HAC1 Dose = 90ug; Alum Dose = 0
89280657|NCT01177202|Experimental|Group F|HAC1 Dose = 90ug; Alum Dose = 0.75mg
89280658|NCT01177202|Placebo Comparator|Group G|Saline
89280659|NCT01177202|Active Comparator|Group H|H1N1
89280660|NCT03856970|Experimental|Part 1: Healthy Volunteers|Microgestin® (EE 30 μg and NET 1500 μg) single dose (Day 1). After a 10-14 day washout, Microgestin® single dose (Day 14) PLUS IW-3718 1500 mg twice daily (Days 13 to 19).
89280661|NCT03856970|Experimental|Part 2: Healthy Volunteers|Levothyroxine 600 μg single dose (Day 1). After a 35-39 day washout, levothyroxine 600 μg single dose (Day 39) PLUS IW-3718 1500 mg twice daily (Days 38 to 41).
89280662|NCT03856970|Experimental|Part 3: Healthy Volunteers|"Phase 1: Glyburide 5 mg single dose (Day 1). After a 7-10 day washout, glyburide 5 mg single dose (Day 11) PLUS IW-3718 1500 mg twice daily (ie, Days 10 to 14).~Phase 2: Digoxin 0.25 mg single dose (Day 23). After a 10-14 day washout, digoxin 0.25 mg mg single dose (Day 35) PLUS IW-3718 1500 mg twice daily (Days 34 to 42)."
89280663|NCT02530710|Experimental|Q203|Q203 drug products (10mg and 100mg tablets)
89280664|NCT02530710|Placebo Comparator|Placebo|Placebo tablets (same excipients used in Q203 drug products)
89280665|NCT06193967|No Intervention|BASIC|Children will be asked to track their intake of fruits, vegetables, sweet and salty snack foods, and sugary drinks in the web-based dietary self-monitoring (DSM) log for 4 weeks. Each child will be provided with a personal URL to access their log, which can be accessed from any internet-capable device (computer, phone, etc.). Caregivers will be asked to review their child's log each day and complete a caregiver check-in in the DSM log.
89280666|NCT06193967|Experimental|PRAISE|In addition to conditions of the BASIC group, caregivers will also be asked to provide praise to their child for engaging in DSM over the 4 weeks. Additionally, when the caregiver completes caregiver check-ins in the DSM log, they will receive a prompt to also complete a praise check-in.
89280667|NCT06193967|Experimental|GAME|In addition to the conditions of the BASIC group, the child's log will also include a virtual pet that evolves over time as he/she uses the log. As the child earns points, the pet will level up and grow over time.
89280668|NCT06193967|Experimental|PRAISE+GAME|In addition to conditions of the BASIC group, caregivers will also be asked to provide praise to their child for engaging in DSM over the 4 weeks. Additionally, when the caregiver completes caregiver check-ins in the DSM log, they will receive a prompt to also complete a praise check-in. The child's log will also include a virtual pet that evolves over time as he/she uses the log. As the child earns points, the pet will level up and grow over time.
89280669|NCT06193902|Experimental|LEU011|Infusion of target dose of LEU011
89280670|NCT06193876|Active Comparator|Petitgrain group|In this group petitgrain oil will be used
89280671|NCT06193876|Active Comparator|Ylang-ylang group|In this group ylang-ylang oil will be used
89280672|NCT06193876|Placebo Comparator|Placebo group|In this group water will be used
89280673|NCT06193850||Uro-andrologic patients|Subjects belonging to general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.
89280674|NCT06193837||Group 1|Having prophylactic antibiotic in laparoscopic cholecystectomy
89280675|NCT06193837||Group 2|Not having prophylactic antibiotics in laparoscopic cholecystectomy
89280676|NCT06193785|Experimental|Hypnosis|hypnosis realised by expert practitioner during electromyogram realisation
89280677|NCT06193785|No Intervention|control|standard electromyogram realisation
89280678|NCT06193772|Active Comparator|"IPDT as usual for on track patients"|"IPDT as usual for patients who are identified as on track at week 3."
89280679|NCT06193772|Experimental|"IPDT adapted for at risk patients"|"Customized IPDT after therapist feedback for patients who are identified as at risk at week 3."
89280680|NCT06193772|Active Comparator|"IPDT as usual for at risk patients"|"IPDT as usual for patients who are identified as at risk at week 3."
89280681|NCT06193759|Experimental|Embryonal brain tumors|These patients are young children (<4 years of age) with newly diagnosed high-risk embryonal malignancies with residual disease and are expected to have a modest male predominance reflecting the sex-based incidence of pediatric brain tumors. Patients will have residual disease after surgery and completion of chemotherapy and will have a Lansky performance status of ≥60.
89280682|NCT06193746||study group|wear the laser watch on wrist 3times/weak up to 30 minute for 12 weeks ,
89280683|NCT06193746||control group|taking advises only
89280684|NCT06193733|Experimental|Procedure: injection of the cell therapy product|"Procedures per cycle (total of 3 cycles):~8 days before autologous cell injection: Cytapheresis - Autologous cell injection - 2 days after cell injection: lab assessment."
89280685|NCT06193720|Experimental|Arnica Montana|Patients will take Arnica montana before and after surgery
89280686|NCT06193720|Placebo Comparator|Control|Patients will take placebo pills to compare the results
89280687|NCT06193707|Experimental|the Experimental Group|"Teleconsultations: This involves using video calls, or phone calls once a month to connect patients for consultations, follow-ups, and discussions about conditions and symptom management.~Remote Monitoring and Wearable Devices: Wearable devices and remote monitoring tools like Infrared Breast Temperature Detector and Dynamic blood pressure detector will be used once a week to track patients' vital signs and symptoms remotely.~Mobile Applications: Specialized mobile apps will be used to provide a platform for patients to access educational materials, track their progress, manage management schedules, record symptoms, and connect with support groups or online communities.~Educational Platforms and Remote Health Education: Online platforms and resources provide educational materials about breast cancer, treatment options, potential side effects, lifestyle adjustments, and overall wellness. These resources empower patients by providing comprehensive information."
89280688|NCT06193707|Active Comparator|the Control Group|Ultrasound follow-up review is recommended no less than 3 to 6 months later. If there is no change at 2-year follow-up, it can be downgraded to BI-RADS 2; if there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
89280689|NCT06193694|No Intervention|Receive wellness materials|Control group - 50% of the study early career pediatric surgeon population will be randomized to the control group in a 1:1 manner after baseline burnout data is obtained. 33% of the coaches who volunteer will also be randomized to a control group in a 1:2 manner after baseline burnout data is obtained.
89280690|NCT06193694|Experimental|Formal Coaching|Study group - 50% of the study population will be randomized to the intervention or coaching group in a 1:1 manner after baseline burnout data is obtained. Similarly, 67% of the coaches who volunteer will be randomized to the intervention or coaching group in a 2:1 manner after baseline burnout data is obtained.
89280691|NCT06193681|Experimental|Pedi@ctivity Exercise Mobile Application|
89280692|NCT06193681|Experimental|Supervised Exercise Group|
89280693|NCT06193642|Experimental|experimental|"Through gait analysis acquisition sessions in the most comprehensive configuration possible on a test group of patients, the aim is to identify measures to be collected at regime for simplified evaluation including patient acceptability.~Patients will be asked to complete quality of life questionnaires."
89280694|NCT06193577|Experimental|Phaseolus Vulgaris L. Dry Extract|Test
89280695|NCT06193577|Placebo Comparator|Placebo|Control
89280696|NCT06193564|Experimental|Combined CSE with tDCS|Combined cervical stabilzation exercises with tDCS
89280697|NCT06193564|Experimental|control group|Only cervical stabilzation exercises
89280698|NCT06193564|Placebo Comparator|placebo tDCS and CSE|Placebo tDCS and cervical stabilzation exercises
89280699|NCT06193551|Other|Patients undergoing a paraesophageal or large (>5 cm) hiatal hernia repair|This is a single arm, open label, nonrandomized study evaluating 100 subjects diagnosed with a paraesophageal or large hiatal hernia planning to undergo surgical repair with the study investigators.
89280700|NCT06193538|Experimental|Intratumoral injection of NV-A01 adenovirus|
89280701|NCT06193525|Experimental|Talazoparib|"Talazoparib Capsule, oral use~1 mg per day until PD or unacceptable toxicity"
89280702|NCT06193473|No Intervention|Control Group: Group in which only observation is made by the clinical pharmacist|For patients in this group, no intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. The participant will take standard treatment. Evaluations will be recorded. Follow-up was performed to determine whether the patients had a re-admission within 3 months.
89280703|NCT06193473|Experimental|Intervention Group: Group to which the clinical pharmacist makes recommendations|For patients in this group, intervention (i.e. recommendation) will be made to physicians by the clinical pharmacist. Within the intervention group, patient characteristics such as the length of hospital stay, reason for hospitalization, underlying conditions, and the appropriateness of prescribed medications were evaluated for the patients who received antithrombotic treatment and met the inclusion criteria. Through medication reviews, evaluations were made to identify drug-related problems and provide solutions to these problems. The clinical pharmacist provided recommendations to the physicians regarding significant clinically important problems. Additionally, follow-up was performed to determine whether the patients had a re-admission within 3 months.
89280704|NCT06193460|Experimental|laser group|The anaesthesia will be reversed by the photobiomodulation mode of the diode laser (low-level laser therapy).
89280705|NCT06193460|No Intervention|control group|The anesthesia will be withdrawn without intervention.
89280706|NCT06193395|Experimental|Patients referred due to Pelvic Floor Disorders including anal incontinence|all patients with PFDs are eligible
89280707|NCT06193369|Experimental|Intervention|Participants assigned to the intervention arm will the receive digital peer navigation intervention.
89280708|NCT06193369|No Intervention|Waitlist Control|Participants assigned to the control arm will receive usual care. After completion of the study, they will have the option to receive the digital peer navigation intervention.
89280709|NCT06193343|Experimental|Interventional Group|Participants who meet study criteria and are enrolled in adaptive daily step promotion intervention
89280710|NCT06193330|Experimental|antibiotic-coated plate|participants will receive antibiotic-coated plate for treatment of their type III open long bone fractures
89280711|NCT06193330|Active Comparator|External Fixator|participants will receive external fixator for treatment of their type III open long bone fractures
89280712|NCT06193304|Experimental|Eliglustat|Three repeated doses of eliglustat solution, separated by 2-hour intervals, held in the mouth for 30 seconds with swishing but without ingestion
89280713|NCT06193187|Experimental|Sequence 1: TRTR|According to the randomization table, subjects will be randomly assigned to the Sequence 1: Test (T)-Reference (R)-Test (T)-Reference (R) for Period 1,2,3 and 4, respectively. The washout period between doses will be at least 7 days.
89280714|NCT06193187|Experimental|Sequence 2: RTRT|According to the randomization table, subjects will be randomly assigned to the Sequence 2: Reference (R)-Test (T)-Reference (R)-Test (T) for Period 1,2,3 and 4, respectively. The washout period between doses will be at least 7 days.
89280715|NCT06193148|Experimental|Jaktinib 100mg|6 Participants will receive Jaktinib 100 mg, orally; 2 Participants will receive placebo, orally.
89280716|NCT06193148|Experimental|Jaktinib 400mg|6 Participants will receive Jaktinib 400 mg, orally; 2 Participants will receive placebo, orally.
89280717|NCT06193148|Experimental|Jaktinib 600mg|6 Participants will receive Jaktinib 600 mg, orally; 2 Participants will receive placebo, orally.
89280718|NCT06193148|Experimental|Jaktinib 800mg|6 Participants will receive Jaktinib 800 mg, orally; 2 Participants will receive placebo, orally.
89280719|NCT06193122||Standard neoadjuvant treatments|Patients will be assessed using ultrasound imaging 3D and spectroscopy at the following intervals: once immediately prior to commencing neoadjuvant treatment. Once treatment begins, patients will be imaged at weeks 2, 4, 8, 12 and then prior to their surgery.
89280720|NCT06193109||the patients with sepsis or septic shock|devide two groups : (1) They had right ventricular dysfunction and (2) They had no right venticular dysfunction.
89280721|NCT06193057|Active Comparator|Traditional|In the STANDARD group, patients will undergo a primary TAR by implanting a prosthetic model of a standard design, that is the same for all using the usual surgical technique and instrumentation (based on the use of external leg guidance)
89280722|NCT06193057|Experimental|Custom|In the PERSONALIZED group, patients will undergo a primary TAR by implanting a prosthetic model with a design specifically based on each patient's actual ankle morphology and using PSI surgical technique and instrumentation.
89280723|NCT06193031|Experimental|Cohort 1: Tyvaso®+C16TR Dose A or Tyvaso®+Placebo|Participants received a single dose of Tyvaso® on Day 1, then randomized to receive either a single dose of C16TR for inhalation (Dose A) or matching placebo on Day 2 in Cohort 1.
89280724|NCT06193031|Experimental|Cohort 2: C16TR Dose B or Placebo|Participants were randomized to receive a single dose of C16TR for inhalation (Dose B) or matching placebo on Day 1 in Cohort 2.
89280725|NCT06193031|Experimental|Cohort 3: C16TR Dose C or Placebo|Participants were randomized to receive a single dose of C16TR for inhalation (Dose C) or matching placebo on Day 1 in Cohort 3.
88805641|NCT01099475|Experimental|Pringle manoeuvre 30 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 1 cycle of 30 minutes of hepatic inflow occlusion will be applied followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
89280726|NCT06193005||very low adaptive group|The subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score.
89280727|NCT06193005||low adaptive group|The subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score.
89280728|NCT06193005||high adaptive group|The subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score.
89280729|NCT06193005||very high adaptive group|The subjects were divided into very low adaptive group, low adaptive group, high adaptive group and very high adaptive group according to the quartile of adaptive ability score.
89280730|NCT06192992|Sham Comparator|Sham|Blood flow without heating
89280731|NCT06192992|Experimental|Two feet|Blood flow during heating of two feet
89280732|NCT06192927|Experimental|TenoMiR intralesional injection|"Drug: TenoMiR (Low Dose), Single injection Mimic of miR29a~Other Names:~• CWT-001~Drug: TenoMiR (High Dose), Single injection Mimic of miR29a~Other Names:~• CWT-001"
89280733|NCT06192927|Sham Comparator|0.9% saline subcutaneous sham injection|Drug: 0.9% saline Subcutaneous single injection
89280734|NCT06192914||Food Anaphylaxis Patients|Patients with anaphylaxis to legumes, tree nuts, seeds, cereals and pseudocereals within the last 12 months
89280735|NCT06192901||Study eye AT ELANA 841P|Subjects who underwent bilateral cataract surgery with the implantation of the IOL AT ELANA 841P in the first eye.
89280736|NCT06192901||Study eye AT LISA 839MP|Subjects who underwent bilateral cataract surgery with the implantation of the IOL AT LISA tri 839MP in the second eye.
89280737|NCT06192875||Observational|Patients undergo blood and urine sample collection on study. Patients' medical records are reviewed.
89280738|NCT06192862|No Intervention|Text reminder group (control)|Randomized subjects to the text reminder group will be asked about their intention to undergo CRC screening in the next 6 months. For those who are at pre-contemplation and contemplation stage, a standard text message will be delivered to invite them to undergo CRC screening by informing them that they are due to CRC screening because they are aged >50 years and are yet to receive CRC screening. No HBM-based health education video or personalized risk assessment will be provided. The chatbot then asks the subject's intention to undergo CRC screening again. For those who propelled to preparation stage or those who are at preparation stage at the beginning, the website link of the government-subsidized CRC screening program which lists the names of all primary care physicians and their contact and co-payment information will be provided.
89280739|NCT06192862|Experimental|Chatbot outreach group|"Subjects in chatbot outreach group will be asked about their intention to undergo CRC screening in the next 6 months and their TTM stage will be determined according to their answers. For subjects who are at preparation stage, the chatbot will further request for the preferred district to have a consultation under the government-subsidized CRC screening.~For subjects who are at pre-contemplation stage, the chatbot will deliver an HBM-based health education video filmed by gastroenterologists and colorectal cancer survivor who has been diagnosed by screening. The subject's intention will be asked again after the video.~For those who upgrade to contemplation stage or remain at pre-contemplation stage and those who are at contemplation stage at the beginning, the chatbot will assess the personalized risk of CRC using the Asia-Pacific Colorectal Screening Score (APCS). Finally, the subject's intention to undergo screening will be asked for the last time."
89280740|NCT06192849|Experimental|Furmonertinib|This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
89280741|NCT06192836||Group 1-|"Operation will be performed by Dr BL~Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~Volume of diuresis at postoperative first six hours~Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~Duration of the surgery.~Need for additional dose of uterotonics~Need for surgical methods to manage postpartum bleeding~Duration of hospital stay"
89280742|NCT06192836||Group 2|"Operation will be performed by Dr AC~Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~Volume of diuresis at postoperative first six hours~Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~Duration of the surgery.~Need for additional dose of uterotonics~Need for surgical methods to manage postpartum bleeding~Duration of hospital stay"
89280743|NCT06192836||Group 3|"Operation will be performed by Dr SM~Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~Volume of diuresis at postoperative first six hours~Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~Duration of the surgery.~Need for additional dose of uterotonics~Need for surgical methods to manage postpartum bleeding~Duration of hospital stay"
89280744|NCT06192836||Group 4|"Operation will be performed by Dr AS~Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~Volume of diuresis at postoperative first six hours~Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~Duration of the surgery.~Need for additional dose of uterotonics~Need for surgical methods to manage postpartum bleeding~Duration of hospital stay"
89280745|NCT06192836||Group 5|"Operation will be performed by Dr EDD~Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~Volume of diuresis at postoperative first six hours~Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~Duration of the surgery.~Need for additional dose of uterotonics~Need for surgical methods to manage postpartum bleeding~Duration of hospital stay"
89280746|NCT06192836||Group 6|"Operation will be performed by Dr SKE~Patients' postoperative 30th minute, 1st and 2nd hour systolic blood pressure, diastolic blood pressure, pulse rate, shock indexes~Volume of diuresis at postoperative first six hours~Hemoglobin and hematocrit values at preoperatively and 2nd, 6th, 24th hours postoperatively.~Duration of the surgery.~Need for additional dose of uterotonics~Need for surgical methods to manage postpartum bleeding~Duration of hospital stay"
89280747|NCT06192797|Experimental|HAIC-len-puco|Patients with advanced intrahepatic cholangiocarcinoma who was initially evaluated unsuitable for the radical therapy and received combined HAIC plus lenvatinib (Len) and pucotenlimab as conversion therapy for downstaging.
89280748|NCT06192771|Active Comparator|Arm 1 - Control|Participants in this Arm will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
89280749|NCT06192771|Experimental|Arm 2 - Intervention|Participants in this Arm will receive the ESSI-SURG behavioural intervention by a live SLP.
89280750|NCT06192745|Experimental|Group 1|"Children will participate in 2 exposure conditions in their own homes (i.e., experimental and internal negative control), facilitated by research staff (one week apart, counterbalanced to control for possible order effects). The internal negative control will be the same for all groups, but the experimental exposure will differ. Both exposures will take place for 1 hour before bed in room lighting (40-50 lux).~Experimental exposure: children in Group 1 will be exposed to a tablet with unfiltered bright screen light and exciting media content (BL/EC).~Internal negative control exposure: children will participate in non-screen-based quiet activities"
89280751|NCT06192745|Experimental|Group 2|"Children will participate in 2 exposure conditions in their own homes (i.e., experimental and internal negative control), facilitated by research staff (one week apart, counterbalanced to control for possible order effects). The internal negative control will be the same for all groups, but the experimental exposure will differ. Both exposures will take place for 1 hour before bed in room lighting (40-50 lux).~Experimental exposure: children in Group 2 will be exposed to a tablet with unfiltered bright screen light and calming media content (BL/CC).~Internal negative control exposure: children will participate in non-screen-based quiet activities"
89280752|NCT06192745|Experimental|Group 3|"Children will participate in 2 exposure conditions in their own homes (i.e., experimental and internal negative control), facilitated by research staff (one week apart, counterbalanced to control for possible order effects). The internal negative control will be the same for all groups, but the experimental exposure will differ. Both exposures will take place for 1 hour before bed in room lighting (40-50 lux).~Experimental exposure: children in Group 3 will be exposed to a tablet with filtered dim screen light and exciting media content (DL/EC).~Internal negative control exposure: children will participate in non-screen-based quiet activities"
89280753|NCT06192745|Experimental|Group 4|"Children will participate in 2 exposure conditions in their own homes (i.e., experimental and internal negative control), facilitated by research staff (one week apart, counterbalanced to control for possible order effects). The internal negative control will be the same for all groups, but the experimental exposure will differ. Both exposures will take place for 1 hour before bed in room lighting (40-50 lux).~Experimental exposure: children in Group 4 will be exposed to a tablet with filtered dim screen light and calming media content (DL/CC).~Internal negative control exposure: children will participate in non-screen-based quiet activities"
89280754|NCT06192732|Experimental|More plant-based diet|Participants receive the dietary counselling focused on a more plant-based diet during weight loss
89280755|NCT06192719||Gallbladder Cancer/Dysplasia|Patients affected by gallbladder cancer or dysplasia, both before and after starting their treatment
89280756|NCT06192719||Gallstone disease|Patients affected by cholelithiasis before cholecystectomy (only patients scheduled for cholecystectomy will be recruited)
89280757|NCT06192706|Experimental|Tria Aortic Valve|Patients receiving the Foldax Aortic Valve
89280758|NCT06192693|Experimental|1|FMT (from healthy lean euglycemic non-obese donors)
89280759|NCT06192693|Placebo Comparator|2|Placebo of FMT
89280760|NCT06192654|Experimental|Small intestinal submucosa (SIS) graft urethroplasty|this group will use a small intestinal submucosa graft in urethroplasty.
89280761|NCT06192654|Active Comparator|Autologous oral bucal mucosa graft urethroplasty|this group will use an autologous oral bucal mucosa graft in urethroplasty.
89280762|NCT06192641|Active Comparator|Melatonin|Patients will receive 3 mg melatonin in capsule for 30 days. They will be instructed to ingest melatonin once a day, at night, one hour before bed.
89280763|NCT06192641|Placebo Comparator|Placebo|Patients will receive placebo capsule composed of cellulose and indigestible fiber for 30 days. They will be instructed to ingest melatonin once a day, at night, one hour before bed.
89280764|NCT06192628|Active Comparator|Parkinson's Education and Exercise Programme [PEEP]|12 week programme of exercises and educational sessions
89280765|NCT06192628|Experimental|Parkinson's Education and Exercise Programme and Behavioural Change [PEEP-BC]|12 week programme of exercise and education with additional behavioural change techniques to promote exercise adherence and exercise self-efficacy.
89280766|NCT06192615|Experimental|Intravenous Dexmedetomidine|After admission to the ICU and discontinuation of mechanical ventilation, intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg) and a sublingual placebo (inert film) will be administered nightly for the first three nights while the patient is in the intensive care unit.
89280767|NCT06192615|Experimental|Sublingual Dexmedetomidine|After admission to the ICU and discontinuation of mechanical ventilation, sublingual dexmedetomidine (120 μg) and an intravenous placebo (0.9% saline over 40 minutes) will be administered nightly for the first three nights while the patient is in the intensive care unit.
89280768|NCT06192615|Placebo Comparator|Placebo|After admission to the ICU and discontinuation of mechanical ventilation, an intravenous placebo (0.9% saline over 40 minutes) and a sublingual placebo (inert film) will be administered nightly for the first three nights while the patient is in the intensive care unit.
89280769|NCT06192602|Experimental|Acceptance-based, insight-inducing medication adherence therapy (AIM-AT)|Acceptance-based Insight-inducing and Medication Adherence Therapy (AIM_AT) consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team. The integrative AIM_AT program based on the principles of motivational-interviewing technique (MI) and mindfulness- and acceptance-based therapy, which have been tested in our previous controlled trials and increasingly been shown to reduce both positive and negative psychotic symptoms and ambivalent attitude towards medication adherence and inducing treatment/illness insight.
89280770|NCT06192602|Active Comparator|Conventional Psychoeducation Group program (CPG)|Psychoeducation groups (12-18 members/group) will be led by one trained psychiatric nurse in each center experienced in psychiatric rehabilitation, and are guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis. The psychoeducation program consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
89280771|NCT06192602|Other|Treatment-as-usual only (TAU)|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services. The main services provided by the four ICCMWs mainly include day-time occupational and living skills training workshops, family mutual support groups, public and mental health education, social and recreational services, supportive groups services on specific mental health problems, referrals to community psychiatric and social care services, and individual and family counseling service as needed. In addition, the center users will also receive community mental health services provided by public hospital and outpatient departments.
89280772|NCT06192550|Experimental|Group 1: Matrix Pro|Subjects undergoing treatment with the Matrix Pro applicator.
89280773|NCT06192550|Experimental|Group 2: Sublime/Sublative|Subjects undergoing treatment with either 1) Sublime applicator only, 2) Sublative RF applicator only, 3) Combined treatment of Sublime and Sublative RF applicators.
89280774|NCT06192550|Experimental|Modified Matrix Pro|Subjects undergoing treatment with a Matrix Pro Modified applicator with lower RF power settings.
89280775|NCT06192537|Experimental|Intervention|
89280776|NCT06192511|No Intervention|Standard of Care|Standard education provided about the Michigan BioTrust includes a brief verbal description from hospital staff and a brochure. Materials will be provided in English, Spanish, or Arabic.
89280777|NCT06192511|Experimental|Intervention|The intervention group will receive standard of care in addition to the opportunity to access a website with engaging information about the Michigan BioTrust and a 4-minute video. Materials will be provided in English, Spanish, or Arabic.
89280778|NCT06192472|Experimental|1% Sodium Tetradecyl Sulphate|Superficial leg veins will be removed by phlebectomy operations. Sections of vein 3-5cm in length will be filled with sclerosant.
89280779|NCT06192472|Experimental|3% Sodium Tetradecyl Sulphate|Superficial leg veins will be removed by phlebectomy operations. Sections of vein 3-5cm in length will be filled with sclerosant.
89280780|NCT06192472|Experimental|0.5% Polidocanol|Superficial leg veins will be removed by phlebectomy operations. Sections of vein 3-5cm in length will be filled with sclerosant.
89280781|NCT06192472|Experimental|3% Polidcanol|Superficial leg veins will be removed by phlebectomy operations. Sections of vein 3-5cm in length will be filled with sclerosant.
89280782|NCT06192459|Experimental|Modality physical therapy vs combined therapy|Participants in this are will receive one month of modality physical therapy followed by one month of modality therapy combined muscle strengthening and joint mobility training.
89280783|NCT06192459|Experimental|Combined therapy vs modality physical therapy|Participants in this are will receive one month of modality therapy combined muscle strengthening and joint mobility training followed by one month of modality physical therapy.
89280784|NCT06192433|Experimental|High-frequency repetitive transcranial magnetic stimulation group (40Hz)|High-Frequency Group (40Hz): Participants in this arm receive high-frequency transcranial magnetic stimulation (rTMS) at 40Hz for a specified duration and intensity on the bilateral dorsolateral prefrontal cortex (DLPFC). The stimulation parameters and rest periods are outlined in the study description.
89280785|NCT06192433|Active Comparator|Moderately high-frequency repetitive transcranial magnetic stimulation group (10Hz)|Moderately High-Frequency Group (10Hz): Participants in this arm receive moderately high-frequency transcranial magnetic stimulation (TMS) at 10Hz for a specified duration and intensity on the bilateral dorsolateral prefrontal cortex (DLPFC). The stimulation parameters and rest periods are outlined in the study description.
89280786|NCT06192407|Experimental|High Palmitic Acid Diet (HPA)|Participants will ingest the HPA diet for one week. The saturated fatty acid will be high in palmitic acid which is the most prevalent saturated fatty acid in the American diet. The HPA diet will be proceeded by a one week controlled diet were the fat content is balanced between monounsaturated and saturated fatty acids.
89280787|NCT06192407|Experimental|High Oleic Acid/Low Palmitic Acid Diet (HOA)|Participants will ingest the HOA diet for one week. The monounsaturated fatty acid will be high in oleic acid which is the most prevalent monounsaturated fatty acid in the Mediterranean diet. The HOA diet will be proceeded by a one week controlled diet were the fat content is balanced between monounsaturated and saturated fatty acids.
89280788|NCT06192394|Sham Comparator|Control Group|"Patients in the control group will undergo the standard bowel preparation determined by the hospital, which includes the following steps:~No solid food should be consumed after the evening meal 2 days before colonoscopy.~Only clear liquids should be consumed the day before colonoscopy.~If the colonoscopy is scheduled for 12:00 PM, nothing should be eaten or drank after midnight on the preceding night; if the colonoscopy is scheduled for the afternoon, nothing should be consumed after 06:00 AM on the same day.~The entire X-M Diet syrup should be consumed with plenty of water within 1 hour at 4:00 PM and 8:00 PM the day before colonoscopy. Additionally, an enema (BT Enema) should be administered at 11:00 PM the night before and at 07:00 AM on the day of colonoscopy."
89280789|NCT06192394|Active Comparator|Chewing Gum Group|"All patients in the gum-chewing group will receive the following interventions in addition to standard bowel preparation:~Patients will be instructed to chew xylitol gum for 20 minutes at three intervals (17:00-19:00, 19:00-21:00, 21:00-23:00) after consuming the prescribed X-M Diet syrup on the day before the procedure.~Following the administration of an enema on the procedure day, patients will be instructed to chew gum every 2 hours for 20 minutes until one hour before the scheduled procedure time."
89280790|NCT06192394|Active Comparator|Vibration Group|"All patients in the vibration group will receive the following procedures in addition to standard bowel preparation:~One hour after consuming the prescribed X-M Diet syrup on the day before the procedure, patients will be instructed to perform 5 cycles of abdominal vibration application. On the procedure day, after the administration of an enema, they will be instructed to perform 3 cycles (each consisting of a 10-minute stimulation and a 20-minute rest period) of abdominal vibration until one hour before the scheduled procedure time.~A vibrating massage belt will be used for the vibration applications.~Patients will be instructed to wear the vibration belt on the abdominal area, starting with low intensity. They will be informed that they can adjust the intensity according to their comfort levels, increasing or decreasing it as needed. They will have the flexibility to adjust the vibration level to a tolerable level whenever they wish."
89280791|NCT06192381|No Intervention|traditional health education group (control group)|Traditional health education group (control group) (n = 68) who received health education with the traditional face-to-face method
89280792|NCT06192381|Experimental|web-based health education group (intervention group)|Web-based health education group (intervention group) (n = 68) who received health education with the Web-Based Learning Module (WBL).
89280793|NCT06192368|Other|Sequence of virtual reality followed by tablet game.|Over a period of two weeks (weeks 1 and 2), participants randomized to this sequence will be asked to use virtual reality for 15 minutes during four break periods. These two weeks of virtual reality will be followed by a week with no exposure (week 3). In the following two weeks, participants will be asked to play a game on a tablet for 15 minutes during four break periods (weeks 4 and 5).
89280794|NCT06192368|Other|Sequence of tablet game followed by virtual reality:|Over a two-week period (weeks 1 and 2), participants randomized to this sequence will be asked to play a game on a tablet for 15 minutes during four break periods. These two weeks of tablet gaming will be followed by a week with no exposure (week 3). In the following two weeks, participants will be asked to use virtual reality for 15 minutes during four break periods (weeks 4 and 5).
89280795|NCT06192329|Sham Comparator|Warm water immersion|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 97°F water for ~30 min, followed by immersion to the hip level for ~60 min (total immersion time of 90 min).
89280796|NCT06192329|Experimental|Hot water immersion|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 105°F water for ~30 min, followed by immersion to the hip level for ~60 min (total immersion time of 90 min).
89280797|NCT06192303||CIP cohort|
89280798|NCT06192303||non CIP cohort|
89280799|NCT06192290|No Intervention|Control Group|(1) aged 60 years or older; (2) diagnosed with CAD and were recommended to undergo elective CABG by a cardiologist; (3) intact cognitive function; (4) agree to be visited by the researchers at home; and (5) didn't have previous experiences with CABG. These Patients receive the usual care only.
89280800|NCT06192290|Experimental|Intervention Group|(1) aged 60 years or older; (2) diagnosed with CAD and were recommended to undergo elective CABG by a cardiologist; (3) intact cognitive function; (4) agree to be visited by the researchers at home; and (5) didn't have previous experiences with CABG. These Patients will receive the Video film presentations and content (16 parts)
89280801|NCT06192277|Experimental|Low risk|Low risk patients will participate in the DOC challenge
89280802|NCT06192277|No Intervention|High risk|Any participant defined as more than low risk will not receive the DOC
89280803|NCT06192225|Experimental|Slow PACE arm|The intervention consists of performance of pre-trained guided Slow PACE breathing by the patient at induction of anesthesia for breast cancer surgery.
89280804|NCT06192225|No Intervention|Control arm|Care as usual
89280805|NCT06192199||Patients with acute pulmonary embolism|
89280806|NCT06192199||Patients without acute pulmonary embolism|
89280807|NCT06192147|Experimental|intervention group|On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
89280808|NCT06192147|No Intervention|control group|basic conventional treatment
89280809|NCT06192134|Experimental|CPM group|group receiving CPM therapy
89280810|NCT06192121|No Intervention|Control|Standart Health Care which is provided regular from ministry of health for 3 months
89280811|NCT06192121|Experimental|Experiment|Standart Health Care which is provided regular from ministry of health for 3 months Web Based Education for 3 months 3 reminder messages (SMS) per week
89280812|NCT06192095|No Intervention|Without skin barrier film|Routine care without skin barrier film around the insertion site of a vascular indwelling catheter
89280813|NCT06192095|Experimental|With skin barrier film|Routine care with preventive use of skin barrier film around the insertion site of a vascular indwelling catheter
89280814|NCT06192056|Active Comparator|Intervention group|The RNT-focused web based self-help program will be given to the intervention group.
89280815|NCT06192056|No Intervention|Waitlist group|Waitlist group will be given only pre and post test measures at the same time with the intervention group.
89280816|NCT06192043|Experimental|Experimental treatment group|"Experimental Group:~Participants in the experimental group would receive 6-8 sessions of Psychoeducational based program~Waitlist Control group:~Participants in the control group would not receive a psychoeducational-based Program"
89280817|NCT06192043|No Intervention|No intervention Control Group|"Control Group:~Participants in the control group didn't receive any Psychoeducational Intervention or any treatment"
89280818|NCT06192030||Retrospective cohort|The cohort was retrospectively enrolled in The Sixth Affiliated Hospital, Sun Yat-sen University from August 2010 to August 2022. It is a training cohort.
89280819|NCT06192030||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a validation cohort.
89280820|NCT06191991|Experimental|Atorvastatin with ALG-055009|Single dose PO administration of 40 mg atorvastatin (Day 1), then a washout period of at least 2 days, followed by PO QD administration of 0.9 mg ALG-055009 for 14 days (Days 3-16) and single dose PO administration of 40 mg atorvastatin (Day 15).
89280821|NCT06191991|Experimental|Rosuvastatin with ALG-055009 (optional)|Single dose PO administration of 10 mg rosuvastatin (Day 1), then a washout period of at least 4 days, followed by PO QD administration of 0.9 mg ALG-055009 for 11 days (Days 5-15) and single dose PO administration of 10 mg rosuvastatin (Day 11).
89280822|NCT06191939|Experimental|Mindful Self-Compassion for Lung Cancer (MSC-LC)|Group-based psychosocial intervention adapted from Mindful Self-Compassion that focuses on the development of mindfulness and self-compassion skills to reduce lung cancer stigma.
89280823|NCT06191939|Active Comparator|Enhanced standard of care with waitlist|Control group that will receive a list of mental health resources and will complete questionnaire assessments during a parallel timeframe as participants in the intervention condition and be placed on a waiting list to receive the MSC-LC intervention after study completion.
89280824|NCT06191900|Experimental|GT201 treatment group|
89280825|NCT06191822|Other|Nutrition|Set personalized nutrition goals
89280826|NCT06191822|Other|Fitness|Set personalized fitness goals
89280827|NCT06191822|Other|Sleep|Set personalized sleep goals
89280828|NCT06191809|Active Comparator|PPOS protocol|Ovarian stimulation protocol used progestin as premature LH surge inhibitor
89280829|NCT06191809|Active Comparator|GnRH-ant protocol|Ovarian stimulation protocol used GnRH antagonist as premature LH surge inhibitor
89280830|NCT06191770|Active Comparator|Morphine Arm|NRS score used
89280831|NCT06191770|Active Comparator|Nalbuphine Arm|Both Groups
89280832|NCT06191484|Experimental|WELL Behavioral Probe|Digital monitoring of sleep, meals, and social activity, for 3 months.
89280833|NCT06190340|Experimental|100 mg TNP-2092 capsules|
88805642|NCT01099631|Experimental|Salmonella typhimurium 10 to the 5th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
88805643|NCT01099631|Experimental|Salmonella typhimurium 10 to the 6th -- Level 2|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
89280834|NCT06190340|Experimental|300 mg TNP-2092 capsules|
89280835|NCT06190340|Experimental|600 mg TNP-2092 capsules|
89280836|NCT06190340|Placebo Comparator|Placebo|
89280837|NCT06188728|Placebo Comparator|Control group|Group-I comprised of 30 subjects, 15 male and 15 female. The group was assigned no intervention and kept as the control group.
89280838|NCT06188728|Experimental|LSM group|Group II comprised 30 subjects with the equal bifurcation of male and female. Group II was assigned the intervention of lifestyle modification (the combination of diet, physical activity, and behavior therapy)
89280839|NCT06188728|Experimental|PSH group|"Group III comprised of 30 subjects, 15 male and 15 female. Group III was assigned the 5gm psyllium husk fiber (in swelled form) two times a day, i.e., 30 minutes before breakfast and 30 minutes before dinner.~All the subjects in the physical demonstration were briefed about the preparation and usage of psyllium husk fiber."
89280840|NCT06188728|Experimental|LSM&PSH|Group IV comprised of 30 subjects, 15 male and 15 female. Group IV was assigned both the intervention of psyllium husk fiber @ 5gm two times a day, 30 minutes before breakfast and dinner in swelled gel form with the combination of lifestyle modification
89280841|NCT06188585|Experimental|Test Group|UI-EWD
89280842|NCT06188585|Active Comparator|Control Group|Conventional endoscopic therapy
89280843|NCT06187805||Up to 15 patients|Patients who have had a transcrestal elevation using autogenous bone supporting an OSSIX Volumax collagen scaffolding.
89280844|NCT06187285|Experimental|Empagliflozin 25 mg|
89280845|NCT06187285|Active Comparator|Sitagliptin 100 mg|
89280846|NCT06187077|Experimental|DHA-Enhanced FAITH! App|This group will use the FAITH! App with guided support from a Digital Health Advocate (DHA) within their church.
88805644|NCT01099631|Experimental|Salmonella typhimurium 10 to the 7th -- Level 3|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
88805645|NCT01099631|Experimental|Salmonella typhimurium 10 to the 8th - Level 4|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
88805646|NCT01099631|Experimental|Salmonella typhimurium 10 to the 9th - Level 5|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
89280847|NCT06187077|Other|FAITH! App|This group will use the FAITH! App on their own, with no DHA support.
89280848|NCT06186687|Experimental|Myofunctional Therapy Exercise|Seventeen patients whom already diagnosed by an Ear, Nose and Throat specialist as having risk of obstructive sleep apnea based on the questionnaire and FN study that showed pharyngeal muscle collapse in the pharyngeal area (velopharyngeal area/retropalatal), performed MT two times per day for 20 minutes every day for six weeks. Exercises were performed at home with monitoring by the exercise log book, submitting a clear video of each exercise, and being evaluated once a week by the doctor. Patient compliance was classified as good if the patient performed >75% of the exercises weekly. This study evaluated the velopharynx/retropalatal area (with FN), symptoms of daytime sleepiness with the Epworth Sleepiness Scale (ESS) questionnaire, and snoring intensity and frequency taken from the Berlin questionnaire that were filled out before and after undergoing training for 6 weeks.
89280849|NCT06184867|Experimental|Relational Agent (RA)|RA participants will be provided with access to Alex, the RA. After completing the RA, RA participants can proceed directly to GT.
89280850|NCT06184867|Active Comparator|Enhanced Usual Care (EUC)|EUC participants will be sent a clinical letter informing them of their increased risk of hereditary cancer, availability of GC and GT services, and contact information to schedule an appointment with a genetic counselor at the LIFE Center.
89280851|NCT06182839|Active Comparator|Canagliflozin (Invokana) 300 mg tablet|
89280852|NCT06182839|Placebo Comparator|Placebo tablet|
89280853|NCT06182384|Experimental|Sequence A|
89280854|NCT06182384|Experimental|Sequence B|
89280855|NCT06181487|Experimental|Experimental group|The experimental group will undergo 60 minutes of high-intensity functional training.
89280856|NCT06181487|No Intervention|Control group|The control group will follow the curriculum standards set by the Sports University.
89280857|NCT06179290|Experimental|Study Product A: Ploom HTP Menthol HTS; MX3 (681)|Subjects in A arm (Group 1 Menthol) will be required to smoke Ploom HTP Menthol HTS; MX3 (681) study product at least 5 times per day ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
89280858|NCT06179290|No Intervention|Study Product B: Continue Smoking (menthol)|Subjects in B arm (Group 1 Menthol) will continue to smoke their menthol UBCC ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
88805647|NCT01099631|Experimental|Salmonella typhimurium 10 to the 10th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
88805648|NCT05307029||Group A edentulous patients|edentulous patients rehabilitated with fixed full-arch prosthesis on 4 implants
88805649|NCT05307029||Group B edentulous patients|edentulous patients rehabilitated with fixed full-arch prosthesis on 6 implants
89280859|NCT06179290|Active Comparator|Study Product C: Smoking Abstinence (menthol)|Subjects in C arm (Group 1 Menthol) will remain abstinent from cigarette smoking for the duration of the study during both the confinement and ambulatory phases. There will be 30 subjects assigned to this arm with a randomization ratio of 1.
89280860|NCT06179290|Experimental|Study Product D: Ploom HTP Tobacco HTS; R8 (120)|Subjects in D arm (Group 2 Non-menthol) will be required to smoke Ploom HTP Tobacco HTS; R8 (120) study product at least 5 times per day ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
89280861|NCT06179290|No Intervention|Study Product E: Continue Smoking (non-menthol)|Subjects in E arm (Group 2 Non-menthol) will continue to smoke their non-menthol UBCC ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
89280862|NCT06179290|Active Comparator|Study Product F: Smoking Abstinence (non-menthol)|Subjects in F arm (Group 2 Non-menthol) will remain abstinent from cigarette smoking for the duration of the study during both the confinement and ambulatory phases. There will be 30 subjects assigned to this arm with a randomization ratio of 1.
89280865|NCT06177392|Experimental|RADIAL|RADIAL ARTERY ACCESS AS SECONDARY ACCESS IN TAVI PROCEDURE
89280866|NCT06177392|Active Comparator|FEMORAL|FEMORAL ARTERY ACCESS AS SECONDARY ACCESS IN TAVI PROCEDURE
89280867|NCT06176495|No Intervention|Control Group|Patients with Diabetes and Family Member Caregivers who will receive no text messages over the designated period of the designated
89280868|NCT06176495|Other|Intervention Group|Patients with Diabetes and Family Member Caregivers who will receive Educational Text Messages via WhatsApp over the designated period of the intervention
89280869|NCT06172335|Experimental|Intervention (Cetoleic acid)|6 x capsules intervention oil (oil = mix of fish oils, olive oil, high-oleic sunflower oil and rapeseed oil) with high content of cetoleic acid (1780 mg/day, estimated: 29,76%) every morning for 4 weeks.
89280870|NCT06172335|Placebo Comparator|Control oil|6 x capsules control oil (oil= mix of fish oils, olive oil, high-oleic sunflower oil and rapeseed oil) with low content of cetoleic acid (35 mg/day, estimated 0.58%) every morning for 4 weeks.
89280871|NCT06161753|Experimental|Cognitive Functional Therapy|The Cognitive Functional Therapy arm will be subject to receiving the intervention, as described in the intervention section.
89280872|NCT06159088|Experimental|Feihe Investigational Formula|"Feihe Investigational Formula~With the highest probiotic content~Containing 2' -fucosyl lactose~Add hydrolyzed whey protein~Comprehensive nutrition: OPO, lactoferrin, CPP, nucleotide, choline, inositol, taurine, L-carnitine, GOS, lutein"
89280873|NCT06159088|Active Comparator|Control Formula|Control formula contains comparable macronutrients and micronutrients, but does not contain probiotics fortified with hydrolyzed whey protein
89280874|NCT06159088|Other|Breastfeeding|breastmilk-feeding
89280875|NCT06158659|Experimental|Feihe Investigational Formula|"Feihe Investigational Formula~With the highest lactoferrin content (more than blue)~Contains 2 kinds of HMOs~Double probiotic combination~Comprehensive nutrition: OPO, DHA&ARA, CPP, nucleotide, choline, inositol, taurine, L-carnitine, GOS, lutein"
89280876|NCT06158659|Active Comparator|Control Formula|Control formula contains comparable macronutrients and micronutrients, but does not contain Lactoferrin fortified with HMO
89280877|NCT06158659|Other|Breastfeeding|breastmilk-feeding
89280878|NCT06154421||Rheumatoid Arthritis finger joint destruction|Patients with rheumatoid arthritis who received a metacarpophalangeal joint prostheses system after 01.01.2014
89280879|NCT06154421||Osteoarthritis finger joint destruction|Patients with post-traumatic wrist osteoarthritis who received a metacarpophalangeal joint prostheses system after 01.01.2014
89280880|NCT06148272|Experimental|LY3971297 (Part A)|Single ascending doses of LY3971297 administered subcutaneously (SC) in healthy participants
88805650|NCT01100255|Active Comparator|Group A|0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes
88805651|NCT01100255|Active Comparator|Group B|IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes
88805652|NCT03012347|Experimental|Sunscreen Users|Subjects will participate in a 2-Day study involving three applications of a single test article each day. The first application will be followed by an exposure of 30 minutes in a hot room.
89280881|NCT06148272|Experimental|LY3971297 (Part B)|Multiple ascending doses of LY3971297 administered SC in healthy participants
89280882|NCT06148272|Experimental|LY3971297 (Part C)|Multiple ascending doses of LY3971297 administered SC in healthy Chinese participants
89280883|NCT06148272|Experimental|LY3971297 (Part D)|Multiple ascending doses of LY3971297 administered SC in participants with obesity and hypertension
89280884|NCT06148272|Experimental|LY3971297 (Part E)|Multiple ascending doses of LY3971297 administered SC in healthy Japanese participants
89280885|NCT06148272|Placebo Comparator|Placebo|Placebo administered SC
89280886|NCT06138951|Placebo Comparator|Nonexercised rested day|Athlete will not exercise on trial day.
89280887|NCT06138951|Experimental|Recovery from 10KM run|Athlete will run 10km on trial day.
89280888|NCT06138951|Experimental|Recovery from 20KM run|Athlete will run 20km on trial day.
89280889|NCT06132724||Healthy Volunteers|"Subjects who will agree to participate to the study will be healthy subject with no particular antecedents.~Subjects will be enroled for two sessions with a 20 min monitoring phase in each session, to coect physiological data with non invasive sensors."
89280890|NCT06131281|Experimental|E-TORe|Participants in this arm received the E-TORe procedure
89280891|NCT06131281|Active Comparator|c-TORe|"Participants in this arm received the classical or c-TORe procedure"
89280892|NCT06118086|Experimental|REM-422|"Dose Escalation: Participants will receive escalating doses of REM-422 to determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)-422, oral capsule administered once daily~Dose Expansion: Participants will receive REM-422 at the identified RP2D~Treatment will continue until disease progression, therapy intolerance, or participant withdrawal~Safety evaluation will continue until 30 days of last administration of REM-422"
89280893|NCT06109909|Experimental|Neurofeedback|Half of the participants will be blindly assigned to receive 12 sessions of LIP-tES intervention over 6 weeks. A subset of these participants will also complete a resting-state MRI scan during the initial session (prior to LIP-tES intervention) and after their final LIP-tES intervention.
89280894|NCT06109909|Sham Comparator|Sham Treatment|Half of the participants will be blindly assigned to receive 12 sessions of a sham intervention that will mirror all aspects of the LIP-tES intervention except that no neurofeedback pulses will be delivered. A subset of these participants will also complete a resting-state MRI scan at the beginning of the initial session and at the end of the 12th session.
89280895|NCT06108141|Experimental|Resident Education And Counseling on Household (REACH) Firearm Safety|Resident participants will complete a modified online self-guided American Academy of Pediatrics (AAP) Safer curriculum. Next, residents will complete REACH individually with a trained facilitator.
89280896|NCT06108141|Active Comparator|Modified AAP Safer|Resident participants will complete a modified online self-guided American Academy of Pediatrics (AAP) Safer curriculum.
89280897|NCT06108076|Experimental|Ketone Ester administration|"Monitored administration of oral Ketone monoester at 400mg/kg dosed twice on visit 2 (cardiac MRI day)~Self administered oral β-hydroxybutyrate (BOHB) at 400mg/kg/day for a period of 6 days"
89280898|NCT06106984|Experimental|Intervention|Veterans will trial the Graded Motor Imagery mobile application.
89280899|NCT06105151|Experimental|Part Ⅰ - Single Ascending Dose (SAD) study: Experimental|Subjects will receive VV119 orally for single dose.
89280900|NCT06105151|Experimental|Part Ⅰ - Single Ascending Dose (SAD) study: Placebo|Subjects will receive VV119 placebo orally for single dose.
89280901|NCT06105151|Experimental|Part Ⅱ - Food Effect (FE) study: Experimental|Subjects will receive VV119 orally for single dose.
89280902|NCT06101238|Experimental|Iron Supplementation|
89280903|NCT06101238|No Intervention|Standard of Care|
89280904|NCT06101043|Experimental|PECS II block group|
89280905|NCT06101043|No Intervention|No PECS II block group|
89280906|NCT06090669|Experimental|Dose Escalation|Escalating doses of imatinib to determine the MTD
89280907|NCT06090669|Experimental|Dose Expansion|Imatinib at the MTD
89280908|NCT06090669|No Intervention|No Treatment|Collection of blood or marrow only. No treatment.
89280909|NCT06078436|Experimental|Pulmonary artery catheter monitoring group|Within 8 hours of random allocation, a pulmonary artery catheter will be inserted to monitor hemodynamic parameters.
89280910|NCT06078436|Active Comparator|No pulmonary artery catheter monitoring group|After random allocation, a pulmonary artery catheter will not be inserted during cardiogenic shock management.
89280911|NCT06075589||Arm 1|Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.
89280912|NCT06075589||Arm II|Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
89280913|NCT06073067|Experimental|Fractionated grid radiation therapy|Subjects with resectable extremity soft tissue sarcoma received neoadjuvant grid radiation therapy (GRID), followed by standard-of-care conventional radiotherapy (XRT) and tumor resection.
89280914|NCT06064981|No Intervention|Control|Participants in the control arm receive usual care. In this case they receive naloxone training only. The training involves a 1-hour in-person overdose recognition and reversal course, which addressed the following topics: the scope and nature of the opioid overdose epidemic nationally and locally in Philadelphia, signs of opioid overdose, strategies for approaching or interacting with a person who is suspected to have overdosed, administration of naloxone in its nasal spray formulation, what to expect after administering naloxone, legal considerations and Good Samaritan protection, and how and where to acquire naloxone.
89280915|NCT06064981|Experimental|Text message nudges|Participants in this arm receive text message nudges with salient messaging around overdose and naloxone. They also receive naloxone training.
89280916|NCT06064981|Experimental|Commitment contract|Participants in this arm receive sign a commitment contract agreeing to obtain or carry naloxone. They also receive naloxone training.
89280917|NCT06064604|Experimental|Stroke Survivors|"This study will be divided into 2 sessions that will occur on 2 separate days: 1) Hip Exoskeleton session and 2) Ankle Exoskeleton session. In each session, subjects will undergo two conditions in which they complete the outcomes measures 1) while wearing the exoskeleton and 2) in a baseline condition without the exoskeleton. Order of condition and session will be randomized.~Prior to the exoskeleton condition, subjects will be allowed time to acclimate to the device during a walking session on the treadmill. Subjects will complete several timed walking tests both indoors and outdoors. Measurements of energy expenditure may also be recorded along with patient reported outcomes data to assess participant perception of their performance with and without the devices."
89280918|NCT06052293|Experimental|ANG003 Dose Level 1|Single administration starting dose contains lipase, protease and amylase.
89280919|NCT06052293|Experimental|ANG003 Dose Level 2|Single administration dose contains 2x lipase, 2x protease and 2x amylase starting dose.
88805653|NCT03012737|Other|MPV arm|Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.
89280920|NCT06052293|Experimental|ANG003 Dose Level 3|Single administration dose contains 4x lipase, 2x protease and 2x amylase starting dose.
89280921|NCT06052293|Experimental|ANG003 Dose Level 4|Single administration dose contains 6x lipase, 3x protease and 3x amylase starting dose.
89280922|NCT06051357|Experimental|Treatment group A|
89280923|NCT06051357|Experimental|Treatment group B|
89280924|NCT06046209|Experimental|Control Lens, then Test Lens|Participants will wear the Control Lens for 90 minutes, then crossover to the Test Lens for 90 minutes.
89280925|NCT06046209|Experimental|Test Lens, then Control Lens|Participants will wear the Test Lens for 90 minutes, then crossover to the Control Lens for 90 minutes.
89280926|NCT06038227||Robotic Assisted Thoracic Surgery|Participants will undergo robotic assisted thoracic surgery (RATS) for segmentectomy or lobectomy.
89280927|NCT06038227||Video Assisted Thoracic Surgery|Participants will undergo video assisted thoracic surgery (VATS) for segmentectomy or lobectomy.
89280928|NCT06036927|Experimental|TQC2731 injection 210 mg|TQC2731 injection 210 mg combined with Mometasone Furoate Aqueous Nasal Spray, 28 days as a treatment cycle.
89280929|NCT06036927|Experimental|TQC2731 injection 420 mg|TQC2731 injection 420 mg combined with Mometasone Furoate Aqueous Nasal Spray, 28 days as a treatment cycle.
89280930|NCT06036927|Placebo Comparator|TQC2731 matching placebo|TQC2731 matching placebo combined with Mometasone Furoate Aqueous Nasal Spray, 28 days as a treatment cycle.
89280931|NCT06033898|Experimental|12-hr trial|Participants will go through a 48-hr physical activity control phase with 10,000 steps taken every 24 hours (9 pm to 9 pm the next day). This phase will be followed with a 12-hour physical inactive phase (9 pm to 9 am the next morning). Less than 1,000 steps during this 12 hours (mostly night time) will be required. The 1-hr cycling session will take place from 8 pm to 9 pm the same day when inactive phase starts. A high fat tolerance test that lasts 5 hours will take place at 9 am the last day.
89280932|NCT06033898|Experimental|24-hr trial|Participants will go through a 48-hr physical activity control phase with 10,000 steps taken every 24 hours (9 am to 9 am the next morning). This phase will be followed with a 24-hour physical inactive phase (9 am to 9 am the next morning). During this 24 hours, from 9 am to 9 pm (mostly daytime), less than 1,500 steps is required, and from 9 pm to 9 am the next morning (mostly night), less than 1,000 steps is required. The 1-hr cycling session will take place from 8 pm to 9 pm on the day when inactive phase starts. A high fat tolerance test that lasts 5 hours will take place at 9 am the last day.
89280933|NCT06033898|Experimental|36-hr trial|Participants will go through a 48-hr physical activity control phase with 10,000 steps taken every 24 hours (9 pm to 9 pm the next day). This phase will be followed with a 36-hour physical inactive phase (9 pm - 9 am on the high fat tolerance day). During the inactive phase, it includes two 12 hours that mostly at night (9 pm - 9 am the next day) and one 12 hours (9 am to 9 pm the same day) that mostly in the day. Less than 1,500 steps is required for 9 pm - 9 am periods, and less than 1,000 steps is needed for 9 am - 9 pm (same day) phase. The 1-hr cycling session will take place from 8 pm to 9 pm the second last day in the trial. A high fat tolerance test that lasts 5 hours will take place at 9 am the last day.
89280934|NCT06023862|Experimental|Group A|Dostarlimab monotherapy
89280935|NCT06023862|Experimental|Group B|Dostarlimab + Bevacizumab combination therapy
89280936|NCT06023862|Active Comparator|Group C|General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)
89280937|NCT06008782|Experimental|Immediate treatment|immediate treatment
89280938|NCT06008782|Placebo Comparator|Delayed treatment|1 month delayed treatment
89280939|NCT06008080||Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System|The Navitor valve is available in four valve sizes to cover annulus diameters from 19 mm to 27 mm. The FlexNav delivery system is available in two sizes, small and large. The Navitor loading system is an accessory used to compress and load the Navitor valve onto the FlexNav delivery system and is available in two sizes, small and large.
89280942|NCT06000046|Experimental|MRI for prostate cancer|Biopsy-naive men undergoing MRI for suspected prostate cancer via the Norwegian standardized care pathway. The MRI images will then be evaluated by the radiologist and a machine-learning based diagnosis and detection system.
89280943|NCT05996198|Experimental|Patients with History of Stroke|"Individuals with history of stroke more than 6 months prior to enrollment.~Participants will complete 3 blocks of 54 trials in a single session. Block 1 is a baseline phase where subjects will perform reaches without any loads applied via the exoskeleton devices. Block 2 is the intervention block where bilateral exoskeletons apply gravity assistance to the impaired arm for stroke survivors and gravity resistance to the non-impaired arm. Block 3 is a retention block, where tested procedures are identical to block 1."
89280944|NCT05996198|Experimental|Healthy Controls|"Healthy age and gender-matched control participants.~Participants will complete 3 blocks of 54 trials in a single session. Block 1 is a baseline phase where subjects will perform reaches without any loads applied via the exoskeleton devices. Block 2 is the intervention block where bilateral exoskeletons apply gravity assistance to the non-dominant arm and resistance is applied to the dominant arm in healthy controls. Block 3 is a retention block, where tested procedures are identical to block 1."
89280946|NCT05981794|Experimental|Heating Pad heated|An electrical heating pad will be applied prior to the cystoscopy or urodynamic procedure
89280947|NCT05981794|Placebo Comparator|Placebo heating pad|An electrical heating pad that is not heated will be applied prior to the cystoscopy or urodynamic procedure
89280948|NCT05981703|Experimental|Dose Escalation|Phase 1a: Sequential cohorts of increasing dose levels of BGB-26808 will be evaluated as monotherapy and in combination with tislelizumab.
89280949|NCT05981703|Experimental|Dose Expansion|Phase 1b: The recommended dose for expansion (RDFE) for BGB-26808 (alone or in combination with tislelizumab) from Phase 1a will be evaluated.
89280950|NCT05964569|Active Comparator|Standard treatment plan|Model-based NTCP is calculated after plan approval, however, no further adjustments are to be made to the approved treatment plan
89280951|NCT05964569|Experimental|Optimized treatment plan|"Allocated to Control Calculation of normal tissue complication probability (NTCP) Model-guided replanning. Replanning is performed with Raysearch Raystation. Optimizations objectives are:~the optimization objectives that control the maximum dose in the target volume employ a variable, LETd-dependent model for RBE that allows us to include the RBE-variations predicted by the NTCP model~the periventricular volume, defined as the volume closer than 4 mm to the ventricular wall, is included into the optimization with a constraint on its Equivalent Uniform Dose (EUD) and with the variable RBE model described above. Thereby, the combined effect of the RBE variation and increased sensitivity of the periventricular volume, as predicted by the NTCP model, is included.~The effectiveness of the re-planning is verified by a second NTCP computation."
89280952|NCT05962125|Experimental|periodic alveolar recruitment maneuvers (PARM) alone|Alveolar recruitment maneuvers [ARM] repeated every 30 min after tracheal intubation and after any disconnection from the ventilator.
89280953|NCT05962125|Active Comparator|positive end-expiratory pressure (PEEP) alone|PEEP was routinely set at 6 cm H2O. If it was in a state of Trendelenburg position or carbon dioxide pneumoperitoneum, PEEP was set to 8 cm H2O.
89280954|NCT05962125|Active Comparator|a combination of PEEP and PARM|Alveolar recruitment maneuvers [ARM] repeated every 30 min after tracheal intubation and after any disconnection from the ventilator. PEEP was routinely set at 6 cm H2O. If it was in a state of Trendelenburg position or carbon dioxide pneumoperitoneum, PEEP was set at 8 cm H2O.
89280955|NCT05948878|Active Comparator|Retrograde Directional Test|Subjects during the Retrograde Directional Test will have the three taping methods placed on their left and/or right antecubital fossa region to superficially secure an IV catheter (i.e., the catheter will be placed on top of the participant's skin and not in the vein but will be taped as if the catheter was placed intravenously). Six total measurements will be obtained of which three will be using the Retrograde Directional Test (i.e., each taping method will undergo testing for each directional method). The order of placing the different taping methods and the direction testing will be randomized.
89280956|NCT05948878|Active Comparator|90 Degrees Directional Test|Subjects during the 90 Degrees Directional Test will have the three taping methods placed on their left and right antecubital fossa region, superficially taping an IV catheter (i.e., the catheter will be placed on top of the participant's skin and not in the vein but will be taped as if the catheter was placed intravenously). Six total measurements will be obtained of which three will be using the 90 Degrees Directional Test (i.e., each taping method will undergo testing for each directional method). The order of placing the different taping methods and the direction testing will be randomized.
89280957|NCT05947149||Cohort A Survivors|about 80 patients with at least a 5 year follow up with head and neck, skull base and brain tumors and no evidence of progressive disease.
89280958|NCT05947149||Cohort B|100 patients with histological and/or radiological diagnosis of head and neck tumors enrolled at baseline
89280959|NCT05940012|Experimental|Manual therapy treatment|Manual therapy treatments will consist of global soft tissue stretching of the upper trapezius, occipital muscles, levator scapula, and scalene muscles as the patient lies in supine. Non-thrust manipulation will consist of unilateral or central posterior-anterior accessory movements (PAIVMs) to the cervical and upper thoracic segments (in prone) at the most symptomatic levels. Passive physiological intervertebral movements of rotation will be performed in supine, as a mechanism to reduce pain and increase range of motion. Individuals with chronic neck pain randomized to the manual therapy arm, will be assigned a HEP twice daily that will consist of cervical rotations with belt or equivalent, side flexion with belt or equivalent, self-stretching exercises that are designed to target the upper thoracic musculature, and corner wall stretches.
89280960|NCT05940012|Active Comparator|Resisted exercise treatment|"In-clinic exercises will consist of chin retractions in sitting, supine clock isometric resistance, supine anterior neck flexion exercises that target the deep neck flexors, prone neck extensor exercises (with concurrent chin retraction), and lateral neck raises (bilaterally). The study team will also target the mid and upper thoracic region by performing upright rows, supine chest raises that target the mid-scapular muscles and the paraspinal muscles, prone I, T, and Y exercises, and proprioceptive neuromuscular facilitation exercises using a bar or a cane. Individuals randomized to the resistance exercise arm will be assigned a HEP twice daily that will consist of chin retractions in sitting, supine anterior neck flexion exercises, and elastic band rows that replicate the upright rows performed in the clinic."
89280961|NCT05935098|Experimental|Phase 1a Part A: Dose Escalation (BGB-A3055 Monotherapy)|Different groups of participants will receive increasing doses of BGB-A3055 alone to determine the most appropriate dosage levels.
89280962|NCT05935098|Experimental|Phase 1a Part B: Dose Escalation (BGB-A3055 + tislelizumab)|Different groups of participants will receive increasing doses of BGB-A3055 in combination with tislelizumab to determine the most appropriate dosage levels.
89280963|NCT05935098|Experimental|Phase 1b (Dose Expansion):|Participants will receive the recommended dose for expansion phase (RDFE) of BGB-A3055 in combination with tislelizumab to provide additional information on the safety, tolerability, and potential benefits of the recommended dose.
89280964|NCT05932446|Experimental|LY3819469 (Reference)|LY3819469 administered subcutaneously (SC).
89280965|NCT05932446|Experimental|LY3819469 (Test)|LY3819469 administered SC.
89280966|NCT05909280||Observational arm|Patients on VA-ECMO, eligible for weaning
89280967|NCT05906836|Experimental|Rosuvastatin + Selpercatinib|Rosuvastatin administered orally on day 1 followed by rosuvastatin administered with selpercatinib on day 5 orally.
89280968|NCT05904496|Experimental|Phase 1a: Dose Escalation Part A: BGB-30813 Monotherapy|
89280969|NCT05904496|Experimental|Phase 1a: Dose Escalation Part B: BGB-30813 + Tislelizumab|
89280970|NCT05904496|Experimental|Phase 1b: Dose Expansion BGB-30813 in Combination with Tislelizumab|
89280971|NCT05900570|Experimental|Urodynamic testing and LLP with and without pudendal nerve stimulation|Commercially available stimulation needles will be inserted into the peri-urethral space targeting the perineal branch of the pudendal nerve. An external neurostimulator settings will be adjusted to deliver acute stimulation. Urodynamic testing will be completed by filling the bladder to a set volume and observing for urinary leakage. The assessment will be completed with stimulation turned on and off. The neurostimulator device settings will be adjusted by the investigator to stay within safe and comfortable levels for each individual study participant.
89280972|NCT05889715|Experimental|Green Wellness Program: Plants-2-Plate|The Green Wellness Program:Plants-2-Plate is an established program focusing on whole food plant-based predominant eating pattern in academic primary care setting.The dietary approach includes vegetables, fruits, legumes, whole grains, seeds, nuts in small portion, elimination of all or most of animal foods, and reduction of processed foods. Participants will eat ad libitum. In addition, they will receive support to manage stress, improve quality of sleep, and increase physical activity during the SMA.
89280973|NCT05878717|Experimental|Belimumab|Participants will receive belimumab in addition to standard therapy.
89280974|NCT05878717|Placebo Comparator|Placebo|Participants will receive placebo in addition to standard therapy.
89280975|NCT05877508|Experimental|AER002|AER002 1200mg administered once by IV
89280976|NCT05877508|Placebo Comparator|Placebo|Placebo administered once by IV
89280977|NCT05875896||Rheumatoid Arthritis wrist destruction|Patients with rheumatoid arthritis who received an APTUS wrist fusion system after 01.01.2014
89280978|NCT05875896||Osteoarthritis wrist destruction|Patients with post-traumatic wrist osteoarthritis who received an APTUS wrist fusion system after 01.01.2014
89280979|NCT05875493|Experimental|A-JAB-21822|Dosing in the fasted state followed by fed dosing
89280980|NCT05875493|Experimental|B-JAB-21822|Dosing in the fed state followed by fasted dosing
89280981|NCT05871307|Experimental|Experimental Arm A (Preoperativ SRS)|Preoperative stereotatic radiosurgery following resection of brain metastases after 1-7 days
89280982|NCT05871307|Experimental|Experimental Arm B (Intraoperativ SRS)|Intraoperative stereotactic radiotherapy after resection of brain metastases
89280983|NCT05871307|Active Comparator|Standard Treatment Arm C (Posoperativ SRS)|Resection of brain metastases following stereotactic radiotherapy after 2-6 weeks
89280984|NCT05859412|Experimental|Neurodynamic exercises|6-weeks home exercise programme of nerve and tendon gliding exercises
89280985|NCT05859412|Active Comparator|Steroid injection Steroid injection (Depomedrone 40mg)|Single steroid injection into Carpal Tunnel (positive control group)
89280986|NCT05859412|Other|Advice|The advice group will receive advice but no additional intervention during the 6 week intervention period (negative control group)
89280987|NCT05851547|Experimental|Prostate SBRT with Focal Boost and Androgen Deprivation Therapy|Stereotactic body radiotherapy to 27 Gy in 3 fractions to uninvolved regions of the prostate glad and up to 39 Gy in 3 fractions to mpMRI-defined intraprostatic lesions, with concurrent/adjuvant androgen deprivation therapy (6 months for intermediate risk, 24 months for high risk)
89280988|NCT05837975|Experimental|FREE Walk Exoskeleton vs Traditional Rehabilitation for Stroke Patients|Participants in this arm will receive one month of traditional rehabilitation followed by one month of using the exoskeleton at home.
89280989|NCT05837975|Experimental|Traditional Rehabilitation vs FREE Walk Exoskeleton for Stroke Patients|Arm Description: Participants in this arm will receive one month of using the exoskeleton at home followed by one month of traditional rehabilitation.
89280990|NCT05833087|Experimental|Schema therapy|The participants in this arm will receive up to 30 individual, weekly sessions of consecutive Schema Therapy (ST). A treatment manual for ST has been written for the study, based on former studies of ST on chronic depression as well as the manual for a major clinical trial on ST for avoidant personality disorder.
89280991|NCT05833087|Active Comparator|Treatment as Usual|Patients with moderate-severe depression in the Danish secondary psychiatric sector are treated according to standard 'treatment packages', in the 'Main Function' offering from 6 to 16 weekly sessions of psychotherapy, in group or individually, typically Cognitive Behavioral Therapy, psychodynamic or interpersonal therapy or other evidence-based therapies.
89280992|NCT05824871|Experimental|Sudapyridine arm|
89280993|NCT05824871|Active Comparator|Bedaquiline arm|
89280994|NCT05823142|Experimental|CB-sleep|Initial instruction for the CB-sleep intervention will occur 60-minute telehealth session. The initial action planning session with a sleep report and booster sessions will be interactive and stage matched. The intervention will include an interactive PowerPoint with the participant's clinician sleep report with personalized feedback. They will be encouraged to systematically extend their time in bed by 1 hour and maintain the extension on both weekends and weekdays. Weekly titration will occur according to the following parameters: if sleep efficiency is ≥ 85%, time in bed is increased by 15 minutes per week until a total of a 1 hour increase in time in bed is achieved, if sleep efficiency is <85%, time in bed remains the same. There will be weekly follow-ups (email, phone, text, video chat) and telehealth 4-week booster sessions. Sleep reports generated by the baseline actigraphy report will be shared with participants with brief action planning and goal setting.
89280995|NCT05823142|No Intervention|Attention Control Enhanced Usual Care arm|After baseline, the RA assigned to this condition will schedule a 60-minute telehealth appointment to provide instruction for enhanced usual care at the initial consultation visit via contact at T1 (60-minute telehealth session in a private location). The time-balanced follow-up sessions will remain neutral and focused on health perceptions, current plan of care, and relationship building as opposed to the CB-sleep condition's focus on sleep promotion and extension. The RA assigned to the control condition will ask participants to (a) describe how they are doing and (b) ask how confident they are in achieving the goals they have set for themselves. These calls will help to build a relationship with participants to promote study retention. The investigators recognize that participants may obtain self-initiated diabetes self-management in this group, which will vary and will use a Diabetes Self-Management Tracking Form to monitor weekly information acquisition.
89280996|NCT05799872|Experimental|Positive Affect Treatment for Anorexia Nervosa (PAT-AN):|
89280997|NCT05799872|Active Comparator|Psychoeducational and Behavioral Therapy (PBT):|
89280998|NCT05799586|Experimental|traditional Chinese medicine health preservation group|"The participants in the traditional Chinese medicine health preservation group will attend six traditional Chinese medicine health preservation courses (2h each per one, for 6 weeks) to learn and experience traditional Chinese medicine health preservation from a registered traditional Chinese medicine practitioner in a classroom at the School Nursing, the Hong Kong Polytechnic University.~Each class will be conducted in a small group of 4 to 6 participants to enhance interaction and ensure the quality of teaching. Participants will then practice traditional Chinese medicine health preservation at home for 6 weeks."
89280999|NCT05799586|No Intervention|Waitlist control group|Participants in the waitlist control group will receive usual care during the 6-week waitlist period of intervention, and 6-week waitlist period of follow-up. After the follow-up assessment, they will be provided an equivalent traditional Chinese medicine health preservation for depression.
89281000|NCT05799495|Experimental|Arm 1: low dose|
89281001|NCT05799495|Experimental|Arm 2: medium dose|
89281002|NCT05799495|Experimental|Arm 3: high dose|
89281003|NCT05799495|Placebo Comparator|Arm 4: Placebo|
89281004|NCT05793255|Experimental|Treatment group|
89281005|NCT05770102|Experimental|Treatment Arm 02: Atezolizumab|This atezolizumab treatment arm is for adult, TYA and paediatric participants with cancers with high TMB or high MSI or proven (previously diagnosed) CMMRD.
89281006|NCT05770037|Experimental|Treatment Arm 01: Alectinib|This alectinib treatment arm is for adult, teenage/young adult (TYA) and paediatric participants with ALK-positive cancers.
89281007|NCT05767658|Experimental|Safe Sleep|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for infant safe sleep and b) an online community and social network of other pregnant WIC clients and new parents
89281008|NCT05767658|Experimental|Breastfeeding|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for breastfeeding and b) an online community and social network of other pregnant WIC clients and new parents
89281009|NCT05767658|Experimental|Safe Sleep and Breastfeeding|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for infant safe sleep and breastfeeding, and b) an online community and social network of other pregnant WIC clients and new parents
89281010|NCT05767658|Active Comparator|Early Brain Development and Parent -Child Relationships|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for early brain development and parent-child interactions (control intervention) and b) an online community and social network of other pregnant WIC clients and new parents.
89281011|NCT05762198|Active Comparator|Rezūm|
89281012|NCT05762198|Active Comparator|TURP|
89281013|NCT05755386|Experimental|iptacopan 200mg b.i.d|iptacopan 200mg b.i.d
89281014|NCT05755386|Placebo Comparator|Placebo to iptacopan 200mg b.i.d.|Placebo to iptacopan 200mg b.i.d.
89281015|NCT05750056|Experimental|Lidocaine group|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the surgery.
89281016|NCT05750056|Placebo Comparator|Placebo group|Patients received a perioperative 0.9% saline infusion at the same rate as the lidocaine infusion.
89281017|NCT05732831|Experimental|Dose Escalation|Participants with MTAP-deleted solid tumors (excluding primary CNS) will receive escalating doses of TNG462 to estimate the MTD
89281018|NCT05732831|Experimental|Dose Expansion in NSCLC|Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG462 at the identified RP2D
89281019|NCT05732831|Experimental|Dose Expansion in Mesothelioma|Participants with MTAP-deleted mesothelioma will receive TNG462 at the identified RP2D
89281020|NCT05732831|Experimental|Dose Expansion in Pancreatic Ductal Adenocarcinoma|Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG462 at the identified RP2D
89281021|NCT05732831|Experimental|Dose Expansion in Sarcoma|Participants with MTAP-deleted sarcoma (soft tissue or bone) will receive TNG462 at the identified RP2D
89281022|NCT05732831|Experimental|Dose Expansion in Solid Tumors|Participants with other MTAP-deleted solid tumors will receive TNG462 at the identified RP2D
89281023|NCT05731973|Experimental|Intercostal nerve cryoablation|When a patient is allocated to the intercostal nerve cryoablation group, cryoablation will be performed prior to bar placement. In brief, cryoablation will be performed at the level of the bar and two levels above and below, bilaterally. For this, a second portal access will be placed for video guidance on the contralateral side, and the cryoprobe (cryoICE, Atricure, Masion, OH, USA) will be inserted through the thoracic incisions that are already made for bar placement. The probe will be placed at the inferior aspect of the ribs, posterior to the midaxillary line, directly on the neurovascular bundle. One freezing cycle takes 2 minutes, and a temperature of -60 ⁰C will be applied. The probe will be warmed to room temperature before removing it from the pleura to prevent additional trauma. Furthermore, intercostal nerve cryoablation will be combined with single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks placed just anterior to the side of the cryoablation.
89281024|NCT05731973|Active Comparator|Thoracic epidural (local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Prior to surgery, an anesthesiologist will place the thoracic epidural at T5-T6 or T6-T7 interspace in the awake patient. After correct placement, a local continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml) will be started. At the third postoperative day, thoracic epidural analgesia will be ceased and transitioned to oral pain medication at discretion of the pain management team. In general, opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours as needed) will be provided 12 hours before thoracic epidural analgesia is ceased.
89281025|NCT05724615|No Intervention|Usual care|Participants will receive usual care only, and no additional intervention from this study.
89281026|NCT05724615|Experimental|Outreach + Bulk ordering|Participants will receive a standard mailed letter about lipid panel screening signed by Penn Primary Care, similar to birthday letters that are currently sent to some practices. These letters or messages will describe the importance of getting a lipid panel, their eligibility for a lipid panel, and information about fasting implications of getting the test. This letter will be complemented by a lipid panel order on behalf of their primary care provider, with a signed laboratory slip/order for lipid panel screening. Laboratory orders will be generated through bulk ordering in the electronic health records for all patients by a designated practice representative and the primary care provider as the authorizing clinician. Participants in Arm 2 will be asked to take the laboratory order to the laboratory of their choice to complete their test within the next 6 weeks.
89281027|NCT05724615|Experimental|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will receive a standard mailed letter, a signed laboratory slip/order, and text-based outreach. It will provide the patient information on walk-in hours in a partnering lab / or ask the patient to schedule an appointment with one of the listed Penn Labs with instructions on how to do so. Patients with an active MyPennMedicine account will be asked to schedule an appointment via MPM. Other patients will be sent a list with the contact of nearby available labs and opening hours and asked to call to schedule an appointment. Up to 2 reminder text messages with the deadline for the lab order will be sent to patients for which no appointment has been scheduled on MyPennMedicine at 2 weeks intervals. Enrollment in the text messaging platform will be opt-out. All results for lipid panel testing will be routed to the patients' primary care provider
89281028|NCT05721248|No Intervention|Cohort 1: Observational Continue Anti-HER2 Therapy|"Participants will have scans 30 days prior to starting study then undergo clinical follow-up 4-6 weeks after study initiation, at 12 weeks, and every 12 weeks thereafter. Visits will include interval history, physical exam, concomitant medications and blood draw for tumor marker assessment and research blood.~Participants will undergo restaging scans every 12 weeks (+/- 2 weeks)."
89281029|NCT05721248|Experimental|Cohort 2: - Stop Anti-HER2 Therapy|"Participants will have scans 30 days prior to starting study. Week 1 participants will stop anti-HER2 therapy then undergo clinical follow-up every 4-6 weeks, at 12 weeks, and every 12 weeks thereafter. Visits will include interval history, physical exam, concomitant medications and blood draw for tumor marker assessment and research blood.~Participants will undergo restaging scans every 12 weeks (+/- 2 weeks). Participants remaining progression-free after one year off treatment, may continue off anti-HER2 therapy indefinitely, with imaging surveillance suggested to be every 3-6 months at the discretion of the treating oncologist and will be followed up to 10 years Participants with disease progression after stopping anti-HER2 therapy, treatment is at discretion of the treating physician but resuming the pre-study regimen is strongly encouraged."
89281030|NCT05718583|Experimental|RA Patients who are Inadequate Responders to Current RA Treatment|Oral butyrate will be taken at 1000 mg three times daily with meals by RA patients who have active disease and are currently taking methotrexate (MTX) at prescriber's recommended dose. There will be no dose escalation of the study supplement. Clinical data to assess for adverse events, stool, urine samples and peripheral blood will be collected at baseline, 1 month, and with an optional 2-month time-point.
89281031|NCT05688111|Active Comparator|Tranexamic acid group|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
89281032|NCT05688111|Placebo Comparator|Glucose water group|Participants will receive 30 mL of 5% glucose water slowly intravenously immediately during the attack of the bleeding, twice daily for 48 hours. Accompanied with the usual expectant management care.
89281033|NCT05687344|Experimental|Intervention arm|Intervention group - intensive postpartum BP control with Nifedipine initiation at SBP≥140 mmHg or DBP≥90 mmHg and maintaining BP at <140/90 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.
89281034|NCT05687344|Active Comparator|Active control arm|Active control group - a group of usual care that follows ACOG recommendations with Nifedipine initiation at SBP≥150 mmHg or DBP≥100 mm Hg and maintaining BP at <150/100 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.
89281035|NCT05678634|Experimental|Children with developmental language disorder|
89281036|NCT05677269||Colorectal endometriosis patients|Subfertile women between 21 and 40 years with colorectal endometriosis facing the choice between IVF/ICSI or laparoscopic resection of (colorectal) endometriosis.
89281037|NCT05654220|No Intervention|Active Control|Participants in the control group will receive a summary flyer providing contact information for benefits enrollment navigators at BenePhilly, which includes a unique study phone line provided by Benefits Data Trust. Currently, the standard of care is for ED patients to receive no information about public benefits. Therefore, the flyer represents an augmentation of usual care for patients randomized to the control group.
89281038|NCT05654220|Experimental|Intervention|Participants in the intervention arm will receive a summary flyer providing contact information for benefits enrollment navigators at BenePhilly and will be instructed that study personnel will contact them one-day post-discharge to help connect them to a BDT enrollment navigator to help them submit their applications for public benefits. At Day 1 post-discharge, participants in the intervention group will receive a text message to prompt them to call the BDT enrollment navigators to complete their applications for public benefits they screened for while in the ED. On Day 3, patients will receive a follow-up message to assess whether they have contacted BDT. Those participants who indicate they have not yet connected with BDT on Day 3 will receive reminder text messages at Day 7 and 14 post-discharge.
89281039|NCT05654116|Experimental|CIP training group|Participants assigned to the CIP training group will receive either an individual 5-week CIP training or a pairwise 6-week CIP training, both with weekly sessions.
89281040|NCT05654116|No Intervention|Waiting-list control group|Participants assigned to the waiting-list control group will receive no intervention while data collection is ongoing; after data collection is finished they will also receive the CIP training.
89281041|NCT05643235|Other|Patients initiated on Bruton tyrosine kinase inhibitors, consenting to installment of ILR|Patients free of documented arrhythmia initiating treatment with a BTK inhibitor who consent to monitoring using the Medtronic LINQ-2 implanted cardiac monitoring device (ILR) prior to initiating BTK inhibitor therapy.
89281042|NCT05643066|Experimental|0.1 mg/kg esketamine group|Procedure sedation was induced using intravenous 0.1 mg/kg esketamine and propofol 1 mg/kg. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
89281043|NCT05643066|Experimental|0.2 mg/kg esketamine group|Procedure sedation was induced using intravenous 0.2 mg/kg esketamine and propofol 1 mg/kg. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
89281044|NCT05643066|Placebo Comparator|Placebo group|Procedure sedation was induced using intravenous 0.9% saline and propofol 1 mg/kg. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
89281045|NCT05642000|Experimental|SASEA HUB|Access to online COVID-19 information tool hub to support testing access
89281046|NCT05642000|No Intervention|Control|
89281047|NCT05632757|Experimental|Psychological assessments|
89281048|NCT05632575|Other|Single Arm: Virtual Promotoras Intervention|Single-arm study. Pre and post intervention. Observational. Behavioral
89281049|NCT05627232|Experimental|Part I (tazemetostat, CPX-351)|Patients receive tazemetostat PO BID on days -1 to 6, and CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients also undergo bone marrow aspiration and biopsy and blood sample collection during screening and on study.
89281050|NCT05627232|Experimental|Part II (palbociclib, CPX-351)|Patients receive palbociclib PO QD on days -3 to -1, and CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients also undergo bone marrow aspiration and biopsy and blood sample collection during screening and on study.
89281051|NCT05592223|Active Comparator|BCG Challenged-Isoniazid Treated|Will receive INH in the dose of 300 mg for three days post BCG injection.
89281052|NCT05592223|Placebo Comparator|BCG Challenged-Isoniazid Untreated|Will not receive any INH or RIF dose.
89281053|NCT05592223|Active Comparator|BCG Challenged-RIF Treated|Will receive RIF in the dose of 600 mg for seven days post BCG injection.
89281054|NCT05590689|Experimental|Radiodynamic therapy (RDT)|All patients will be treated with RDT. Patients are devided into cohorts which differs in the total amount and frequence of RDT.
89281055|NCT05588102|Experimental|Selective Serotonin Reuptake Inhibitor（SSRIs）combined with Electronic cognitive training|SSRIs（Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）combined with Electronic cognitive training (60min, once a day)
89281056|NCT05588102|Placebo Comparator|SSRIs antidepressants combined with blank control Electronic training for 52 weeks|SSRIs drug treatment （Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）combined with the blank control Electronic training(subjects were allowed to use electronic products to browse the web and watch the news for 1 hours every day)
89281057|NCT05582811|Experimental|Dose Riociguat 2,5 or 5mg|Riociguat dose finding pilot experiment, 2,5mg and 5mg
89281058|NCT05582811|Active Comparator|Riociguat|Riociguat orally
89281059|NCT05582811|Placebo Comparator|Placebo|Placebo orally
89281060|NCT05562934|Experimental|Dose 1|Lowest dose
89281061|NCT05562934|Experimental|Dose 2|Dose 2
89281062|NCT05562934|Experimental|Dose 3|Dose 3
89281063|NCT05562934|Experimental|Dose 4|Highest dose
89281064|NCT05562934|Placebo Comparator|Dose 5|Placebo
89281065|NCT05562245|Experimental|Intervention arm|"1st hour after cesarean section Pre-tests and motivational interviewing-based breastfeeding education~Postpartum 5-7th Day: When the mothers come to the hospital for control, a second motivational interviewing session will be held in the breastfeeding room and breastfeeding will be supported when necessary and a second measurement will be made.~Postpartum 6th Week: The third motivational interviewing session will be held by going to the mothers' homes, breastfeeding will be supported when necessary and a third measurement will be made.~Postpartum 3rd Month: In order to end the motivational interviewing, the fourth motivational interviewing session will be held by going to the mothers' homes and the fourth measurement will be made."
89281066|NCT05562245|No Intervention|Control arm|1st hour after cesarean section will be made pre-tests and routine breastfeeding training of the hospital will be given to mothers in the control group. Mothers will be followed up 5-7th days postpartum, postpartum 6th week, and postpartum 3rd month
89281067|NCT05560750|Experimental|Frenotomy|Patients who will have frenotomy soon after randomisation, on the same or next day
89281068|NCT05560750|Active Comparator|Oral physiotherapy|Patients whose parents are guided to give the child oral physiotherapy for 1 month
89281069|NCT05560750|No Intervention|Follow-up|Patients whose frenotomy appointment will be set at 1 month age
89281070|NCT05554627|Experimental|Esketamine|Intranasal spray of esketamine. Administered twice weekly for first 4 weeks, reduced to once weekly until week 12, then dosage will be determined by response and treating prescriber.
89281071|NCT05554627|Active Comparator|Aripiprazole|Participants will be randomized in a 1:1 ratio of equal allocation to either adjunctive ARI (n=470) or adjunctive IN ESK (n=470), stratified by participating site.
89281072|NCT05550714|Experimental|General anesthesia|
89281073|NCT05550714|Active Comparator|Conscious sedation|
89281074|NCT05537753|Experimental|Encore PFO closure device|
89281075|NCT05537753|Active Comparator|Any FDA-approved PFO closure device chosen by the investigator|
89281076|NCT05503056|Experimental|Intervention|Engage in six art therapy sessions
89281077|NCT05503056|Placebo Comparator|Control|Engage in usual activities
89281078|NCT05496374|Placebo Comparator|Double Blind: Placebo|Participants will receive matching placebo 4 capsules, orally once daily (QD) for 56 days.
89281079|NCT05496374|Experimental|Double Blind: SPR720 500 mg|Participants will receive SPR720 500 milligrams (mg) [250 mg × 2 capsules and 2 matching placebo capsules, orally QD for 56 days.
89281080|NCT05496374|Experimental|Double Blind: SPR720 1000 mg|Participants will receive SPR720 1000 mg [250 mg × 4 capsules], orally QD for 56 days.
89281081|NCT05496374|Experimental|Open-label: SPR720 1000 mg|Participants will receive SPR720 1000 mg [250 mg × 4 capsules], orally QD for 56 days.
89281082|NCT05496374|Experimental|Open Label: SPR720 500 mg|Participants will receive SPR720 500 mg [250 mg × 2 capsules], orally twice daily (BID) for 56 days.
89281083|NCT05487768|Experimental|Anterior cruciate ligament reconstruction group|Patients that underwent an anterior cruciate ligament reconstruction
89281084|NCT05487768|Active Comparator|Control group|Healthy matched controls
89281085|NCT05467891|Experimental|Investigational Group|"The drug ribociclib will be taken orally at a dose of 600 mg daily for 21 days out of a 28-day cycle. Ribociclib will be used in combination with ET per physician choice.~Physician's choice of endocrine therapy includes:~500 mg of fulvestrant received intramuscularly. This will be taken on Day 1 and Day 15 of Cycle 1 and on Day 1 of Cycle 2 and beyond.~1 mg of anastrozole taken orally daily of the 28 day cycle.~2.5 mg of letrozole taken orally daily of the 28 day cycle.~25 mg of exemestane taken orally daily of the 28 day cycle.~Concomitant use with tamoxifen is not allowed.~Premenopausal subjects must also be treated with ovarian suppression according to institutional standards or have undergone bilateral oophorectomy."
89281086|NCT05458882|Experimental|educational Booklet|Receive intervention- educational booklet describing the day to day social activities and eating out habits of children with established food allergy in Ireland
89281087|NCT05458882|Active Comparator|Routine education|This group will receive routine education in the allergy group.
89281088|NCT05442203|Other|AF Cohort|Will be comprised of 500 participants predicted to be increased risk for Atrial Fibrillation (AF) will receive a 2-week ECG patch monitor to wear (up to 3 times over 12 months),
89281089|NCT05442203|Other|SHD Cohort|Will be comprised 500 participants at increased risk for Structural Heart Disease (SHD) will be referred for a single echocardiogram.
89281090|NCT05417100|Active Comparator|Methadone bolus during surgery|Patients will be administered methadone 0.2 mg/kg (max 20 mg).
89281091|NCT05417100|No Intervention|No Methadone during surgery|No Methadone during surgery
89281092|NCT05413486||SCH, OB|People with obesity (BMI > 30 kg/m2) and a medical diagnosis of schizophrenia spectrum disorder.
89281093|NCT05413486||BD, OB|People with obesity (BMI > 30 kg/m2) and a medical diagnosis of bipolar spectrum disorder.
89281094|NCT05413486||Control, OB|Control group with obesity. People with obesity (BMI > 30 kg/m2) without psychiatric disease or sleep disorders.
89281095|NCT05413486||Control, non-OB|Normal weight (BMI 18.5 - 25kg/m2) control group without psychiatric disease.
89281101|NCT05398744|Experimental|Virtual group aerobic training program|16-week, virtual group aerobic training program led by exercise physiologist. Duration: 24 weeks. Four weeks recording of baseline activity through activity monitor; 16-week virtual group aerobic training program, 3 times per week for 30 minutes; and four weeks of follow-up.
89281102|NCT05393388||PET/CT|PET.CT using the radiotracer [18F]AV-1451
89281103|NCT05384470|Other|Exhaled Breath Samples|Quantitative detection of marijuana, morphine or fentanyl through exhaled breath
89281104|NCT05384444|Experimental|Fasting mimicking diet|The cyclic FMD diet consists of a 5 day regimen: day 1 diet of the diet supplies ~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
89281105|NCT05384444|No Intervention|regular diet|regular diet
89281106|NCT05378633|Experimental|Experimental Treatment Arm|Best Supportive Care + Stereotactic Radiotherapy of all Brain Metastases
89281107|NCT05378633|Other|Standard Treatment Arm|Best Supportive Care ± Whole Brain Radiotherapy
89281108|NCT05369819|Experimental|Group M|Patients of the Group M will be treated with midazolam premedication.
89281109|NCT05369819|Placebo Comparator|Group S|Group S patients are treated with 3 cc normal saline.
89281110|NCT05358587|Experimental|PENG (20 mL)|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %)
89281111|NCT05358587|Experimental|PENG (30 mL)|In this group, US guided PENG block will be performed with 30 ml of Bupivacaine solution (0.25 %)
89281112|NCT05357729|Experimental|MultiSense® remote monitoring|The patients included will be equipped with the MultiSense® solution prior to the hospital discharge. The device will be used for 6 days from the date of actual deployment.
89281113|NCT05348486|Experimental|Dose escalation|Dose escalated radiotherapy protocol: 75,9 - 79,2 Gy in 33 fractions GTV hypoxic or any hypoxic LN > 2cm - PTV (0mm): dose 75,9 - 79,2 Gy/33 (Contours must be subtracted and reduce by 3mm in case of close relation to the skin, bones or large blood vessels) GTV primary - CTV - PTV (5+5mm): for dose 70 Gy/33 LN low risk (for elective irradiation) - CTV - PTV (3mm-5mm): for dose 54 Gy/33
89281114|NCT05348486|No Intervention|Standard fractionation|Standard fractionation regimen: 70 Gy/54 Gy in 33 fractions GTV primary - CTV - PTV (5+5mm): for dose 70 Gy/33 GTV LN bulky (> 3cm) - PTV (5mm): for dose 70 Gy/33 LN low risk (for elective irradiation) - CTV - PTV (3mm-5mm): for dose 54 Gy/33
89281115|NCT05342597|Experimental|Group A|A single oral dose of MT-1186 with fasted condition in period 1, meal 1 condition in period 2, meal 2 condition in period 3, meal 3 condition in period 4, and meal 4 condition in period 5.
89281116|NCT05342597|Experimental|Group B|A single oral dose of MT-1186 with meal 1 condition in period 1, meal 2 condition in period 2, meal 3 condition in period 3, fasted condition in period 4, and meal 4 condition in period 5.
89281117|NCT05342597|Experimental|Group C|A single oral dose of MT-1186 with meal 2 condition in period 1, meal 3 condition in period 2, fasted condition in period 3, meal 1 condition in period 4, and meal 4 condition in period 5.
89281118|NCT05342597|Experimental|Group D|A single oral dose of MT-1186 with meal 3 condition in period 1, fasted condition in period 2, meal 1 condition in period 3, meal 2 in period 4, and meal 4 condition in period 5.
89281119|NCT05322226|Other|Adults undergoing pre- liver transplant assessment|All patients included in the study will have blood and urinary test from their registration on the transplant list and during their classic follow-up with their hepatologist for 12 months to quantify the biological markers of alcoholism (every 3 months). Additional tubes and urine will be collected in order to measure these markers (urinary ethylglucuronide and blood phosphatidylethanol).
89281120|NCT05321550||Fibromyalgia patients|Fibromyalgia patients diagnosed according to the 2010 ACR-criteria
89281121|NCT05321550||Neck pain patients|"Patients with non-specific, idiopathic neck pain complaints~Patients with neck pain complaints of traumatic origin type whiplash grade 1 (pain, stiffness or tenderness of the neck and no objective physical abnormalities) and grade 2 (neck complaints and musculoskeletal disorders such as reduced range of motion and tender pain points) according to the Quebec Task Force on Whiplash Associated Disorders"
89281122|NCT05321550||Low back pain patients|Patients with non-specific, idiopathic back pain complaints
89281123|NCT05321550||Healthy controls|Age, sex and BMI-matched healthy controls
89281124|NCT05315947|Experimental|Treatment A-B|Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence A-B at pre-specified timepoints.
89281125|NCT05315947|Experimental|Treatment B-A|Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence B-A at pre-specified timepoints.
89281126|NCT05308875|Experimental|PD1-BCMA-CART|Each subject will accept one of the following dosages of PD1-BCMA-CART cells intravenously (IV) on day 0: 0.5-2*10^6/KgBW.
89281127|NCT05300256|Experimental|Peripheral Heating|Peripheral Heating
89281128|NCT05300256|Sham Comparator|Sham|Sham
89281129|NCT05296096|Active Comparator|Standard protein and exercise|All enrolled patients randomized to this arm will receive a baseline nutrition and nurse-driven mobility pathway and other evidence-based bundled strategies as standard of care.
89281130|NCT05296096|Experimental|High protein plus exercise|"High protein nutrition: To achieve the prescribed age-appropriate high protein target, dietitians will use EN preferentially, or if EN is contraindicated, PN may be used. High-protein EN formulas and/or protein supplements (powder or liquid) will be added to formula/breast milk feedings or administered separately in divided bolus doses. Dietitians routinely employ and customize these solutions in their scope of practice. When EN is insufficient to meet protein targets, PN may be prescribed to make up the deficit on or after the end of PICU day 3. Energy and protein delivery adequacy (% of prescribed goal) will be monitored daily by the study team.~Patients in this arm will also be prescribed the age-appropriate highest-level of mobility by the rehabilitation team with a goal of 30 minutes duration, twice daily."
89281131|NCT05286242||Healthy control|Healthy controls Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.
89281132|NCT05286242||Disease control|"Disease controls (individuals with a qualifying autoimmune condition, but not treated with any immunomodulator).~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
89281133|NCT05286242||B-cell depleted|"Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with B-cell depleting anti-CD20 monoclonal antibodies.~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
89281134|NCT05286242||Other immunomodulator|"Individuals with autoimmune disease (multiple sclerosis or autoimmune blistering disease) who are treated with a non-CD20 monoclonal antibody immunomodulator to treat their disease.~Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design."
89281135|NCT05282758|Experimental|Interdisciplinary team treatment + add on Intervention - Free Movement Dance|Interdisciplinary team treatment + add on Intervention - Free Movement Dance as a physiotherapy intervention
89281136|NCT05282758|Active Comparator|Interdisciplinary team treatment + add on Modified person-centered progressive resistance exercise|Interdisciplinary team treatment + add on Control group - modified person-centered progressive resistance exercise as a physiotherapy intervention
89281137|NCT05273827||neoadjuvant immunotherapy group|Anti-PD-1 monoclonal antibody (Nivolumab，Pembrolizumab, Sintilimab, or Sugemalimab) 200 mg intravenously in combination with cis-platinum and paclitaxel/pemetrexed
89281138|NCT05273827||control group|platinum-containing dual-agent chemotherapy(cis-platinum and paclitaxel/pemetrexed)
89281139|NCT05265520|Active Comparator|His-CRT implantation|His-CRT implantation includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular lead, and an endocardial His-bundle pacing leads directly pacing the intrinsic conduction system.
89281140|NCT05265520|Active Comparator|BIV-CRT implantation|BIV-CRT implantation includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
89281141|NCT05265169|Experimental|Microwave ablation with margin confirmation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) of 1-3 colorectal cancer metastases with any FDA cleared/CE Marked Microwave Ablation System in accordance with the study site's standard-of-care (SOC) practices.
89281142|NCT05240677|Placebo Comparator|Group 1|Chronic kidney diseases patients with iron deficiency anemia and eGFR ≥ 60 ml/min/1.73 m2
89281143|NCT05240677|Experimental|Group 2|Chronic kidney diseases patients with iron deficiency anemia and eGFR < 60 ml/min/1.73 m2.
89281144|NCT05238740|Active Comparator|Intervention group 5-5.4 cc ViviGen®|Biological: 5-5.4 cc ViviGen®The stand-alone ALIF L5/S1 fusion patients assigned to this group will receive 5-5.4 cc ViviGen®
89281145|NCT05238740|Active Comparator|Control group 4-6mg rhBMP-2|Biological: 4-6mg rhBMP-2The stand-alone ALIF L5/S1 fusion patients assigned to this group will receive 4-6mg rhBMP-2
89281146|NCT05237453|Experimental|MR-guided adaptive radiotherapy|Patients receive Photon radiotheray as an MR-guided adaptive radiotherapy
89281147|NCT05227924||SYMBOL medical devices|Patients undergoing total hip arthroplasty with at least one medical device from the SYMBOL range
89281148|NCT05223868|Experimental|Group 1: JNJ-77242113 Dose 1 Once Daily (QD) and Placebo|Participants will receive JNJ-77242113 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
89281149|NCT05223868|Experimental|Group 2: JNJ-77242113 Dose 2 QD and Placebo|Participants will receive JNJ-77242113 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
89281150|NCT05223868|Experimental|Group 3: JNJ-77242113 Dose 3 QD and Placebo|Participants will receive JNJ-77242113 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
89281151|NCT05223868|Experimental|Group 4: JNJ-77242113 Dose 1 Twice Daily (BID) and Placebo|Participants will receive JNJ-77242113 Dose 1 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
89281152|NCT05223868|Experimental|Group 5: JNJ-77242113 Dose 3 BID and Placebo|Participants will receive JNJ-77242113 Dose 3 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
89281153|NCT05223868|Placebo Comparator|Group 6: Placebo|Participants will receive placebo BID from Week 0 through Week 16.
89281154|NCT05223647|Experimental|Chemo-immunotherapy plus thoracic radiotherapy|"Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.~Thoracic radiotherapy of 30 Gy/10 fractions between 2nd and 3rd carboplatin/etoposide/durvalumab course."
89281155|NCT05223647|Active Comparator|Chemo-immunotherapy|Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
89281156|NCT05218057|Active Comparator|Thulium-fibre laser (TFL)|The laser used in this group for surgical procedure ureteroscopic lithotripsy will be the Olympus SOLTIVETM Premium SuperPulsed laser system with a 365micron laser fibre. The laser pulse setting will be 1J x 10Hz, short pulse duration (adjusted up to 600microseconds).
89281157|NCT05218057|Active Comparator|Holmium: yttrium-aluminum-garnet (Ho: YAG)|The laser used in this group for surgical procedure ureteroscopic lithotripsy will be the Lumenis VersaPulse® PowerSuiteTM 100W laser system with a 365micron laser fibre. The laser pulse setting will be 1J x 10Hz. Pulse duration is not adjustable in this machine (up to 600microseconds).
89281158|NCT05215262|Experimental|T.A.K.E. Steps Motivational Interviewing Intervention|Four MI intervention sessions, 1:1 with participant and health coach.
89281159|NCT05215262|Active Comparator|Standard of Care|Standard of Care control visit with primary care physician (PCP)
89281160|NCT05198843|Experimental|Treatment (icosapent ethyl, dasatinib)|Patients receive icosapent ethyl PO BID and dasatinib PO QD in each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89281161|NCT05186415|Experimental|diagnostic arm|The echocardiography team will perform baseline echocardiographic views of the right ventricle without contrast. The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations. Dosages and timing of administration as well as patient size and transducer type will be recorded for each patient. The total cumulative dose of Lumason from the clinical study and the research study will not exceed the maximum recommended dose by the manufacturer, 4.8 mL. A single injection will not exceed the maximal FDA-recommended dose of 2.4 mL per single injection. These echocardiographic views of the right ventricle with ultrasound enhancing agent will be compared to the measurements made without the use of ultrasound enhancing agents, and the measurements made in MRI.
89281162|NCT05185037||Caesarian Section Patient|Obstetric patient
89281163|NCT05184556|Experimental|Family-based treatment|Families will complete 2-6 hours of therapy per week for 10 - 32 weeks, on average, determined by clinical need in conjunction with insurance specifications related to coverage of home-based care
89281164|NCT05184556|Active Comparator|Integrative family therapy|Families will complete 2-6 hours of therapy per week for 10 - 32 weeks, on average, determined by clinical need in conjunction with insurance specifications related to coverage of home-based care
89281165|NCT05180344|Experimental|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
89281166|NCT05180318|Placebo Comparator|0.9% saline preadministration group|0.9% saline will be given intravenously 24-36 hours before operation and immediately after operation
89281167|NCT05180318|Experimental|Esketamine preadministration group|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
89281168|NCT05169437|Experimental|Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations|
89281169|NCT05161819|Experimental|High-frequency rTMS at left DLPFC|Receive an rTMS course with high-frequency stimulation at left DLPFC
89281170|NCT05161819|Sham Comparator|High-frequency sham stimulation at left DLPFC|Receive an sham rTMS course with high-frequency stimulation at left DLPFC with the sham coil
89281171|NCT05155111|Experimental|Telemedicine arm|Neonates will have telemedicine consultation to evaluate symptoms of neonatal encephalopathy
89281172|NCT05151328|Experimental|Plecanatide group(n=320)|The investigational products are administrated orally, each patient will take one table (Plecanatide 3.0mg) Once daily(QD) in the day before 18:00 with approximately of water. If the investigational product is not taken in the day before 18:00 then skip the dose on that day and take the next dose on the next regular time. The duration of treatment is 12 weeks.
89281173|NCT05151328|Placebo Comparator|Placebo group (n=320)|The investigational products are administrated orally, each patient will take one table (Placebo 3mg) QD in the day before 18:00 with approximately of water. If the investigational product is not taken in the day before 18:00 then skip the dose on that day and take the next dose on the next regular time. The duration of treatment is 12 weeks.
89281174|NCT05146830||Participants with Cystinosis Disease|This is a long-term follow-up study of participants who previously received CTNS-RD-04 (single dose administration). No investigational product will be administered in this study.
89281175|NCT05145452|Experimental|Intervention Group|Subjects randomized to n-3 PUFA will receive a total of 4.2 g/d of fish oil.
89281176|NCT05145452|Placebo Comparator|Placebo Group|Subjects randomized to placebo will receive 4.2 g/d sunflower oil.
89281177|NCT05145452|No Intervention|Control group|Subjects assigned to the control group will be tested once
89281178|NCT05138510||Stage 0|Ductal carcinoma in situ. Timing: start of endocrine therapy
89281179|NCT05138510||Stages I-III Surgery first|Invasive cancer. Surgery first Timing: start of endocrine therapy
89281180|NCT05138510||Stages I-III, neoadjuvant chemotherapy first|Invasive cancer. Neoadjuvant chemotherapy first Timing: during neoadjuvant chemotherapy
89281181|NCT05138510||Stage IV|Metastatic cancer, chemotherapy only, no invasive surgery Timing: 2 months into treatment
89281182|NCT05138510||Survivors|Timing: any time
89281183|NCT05096442|Experimental|Genoss® DCB|Paclitaxel Coated PTCA Balloon Catheter
89281184|NCT05096442|Active Comparator|SeQuent® Please NEO|Paclitaxel Coated PTCA Balloon Catheter
89281185|NCT05090709|Experimental|Experimental A - Mobilisation Intervention|Participants receive 4 separate treatment sessions of the 30 minute spinal mobilisation intervention.
89281186|NCT05090709|Active Comparator|Experimental B - General Massage|Participants receive 4 separate treatment sessions of the 30 minute general massage.
89281187|NCT05087875|Experimental|TRAC: Tracking and Reducing Alcohol Consumption|"The TRAC intervention focuses on increasing motivation and building skills to reduce alcohol use and involves 4, 30-minute sessions with an interventionist done via video chat or phone.~Participants will complete smartphone-based self-monitoring of alcohol use. Each morning, participants complete a mobile survey indicating if they drank the previous day and if so, how many drinks they had. Surveys will be programmed using REDcap and sent via a link in the reminder text message. Additionally, participants will be prompted each evening and asked to complete a breathalyzer reading using a mobile app to determine blood alcohol content (BAC). If safety concerns are identified (e.g., BAC ≥0.30; blackouts), the interventionist will refer the AYA to a licensed provider with expertise in substance use treatment."
89281188|NCT05087875|Active Comparator|Control|Participants in the control group will receive educational materials regarding alcohol consumption and its link to cancer . They will also participate in smartphone monitoring of alcohol use on the same schedule as participants in the intervention group. This will allow us to compare daily alcohol use data between the two conditions and evaluate the added component of weekly counseling in TRAC.
89281189|NCT05073237|Experimental|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. Recommended and only FDA approved dosage is one CE/BZA tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications.
89281190|NCT05073237|Placebo Comparator|Placebo|Participants assigned to placebo will receive a daily tablet. To assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication. Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about CE/BZA and its potential side effects and contraindications, again to maintain the blind.
89281191|NCT05057858|Experimental|Perfect Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC once daily (7 doses per week).
89281192|NCT05057858|Experimental|Moderate Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet 4 times per week (Monday, Tuesday, Thursday, Friday)
89281193|NCT05057858|Experimental|Poor Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet twice per week(Monday and Tuesday)
89281194|NCT05056415|Active Comparator|Treatment as Usual (TAU)|"In the involved municipalities, TAU mainly consists of short-term efforts, such as Occupational Therapist (OT) prescribing technical aids, often initiated by the housing staff (HS). Daily support provided by HS varies, depending on the approach and commitment of individual staff and the norms that prevail in different housing units, as well as variations between municipalities. Co-planning on long-term rehabilitation efforts does not exist or is weak, and collaboration between OT and HS is, as described by staff from both parties, difficult to achieve.~After a control-period of 6 month, house facilities within the TAU-group will also be offered ELR."
89281195|NCT05056415|Experimental|Everyday Life Rehabilitation (ELR) plus TAU|"ELR is a model for long-term, outreach, and personalized rehabilitation for persons with SPD living in sheltered or supported housing facilities, in close collaboration between resident, OT, and HS.~ELR includes personcentred, motivational-, recovery- and activity-based methods, built on certain process steps. The focus is to promote personal recovery, while targeting meaningful daily activities, through person-driven goals, negotiated expectations, exploration and activity-training in real-life situations, and a maintenance phase. ELR includes a web-based educational package, and devices for reflective collaborative learning.~ELR consists of a weekly session with an OT, followed by regular collaboration with HS, who support the resident on a daily basis, in line with guidance given by the OT and input shared from the HS. The intervention period will last for 6 months.~Prior to the intervention, OT, HS, and HM will partake in web-based training, with associated manuals, and tools."
89281196|NCT05055050|Experimental|UGN-201 Pre Radical Cystectomy|UGN-201 200 mg/50ml
89281197|NCT05047055||Single Group - 4 months moxifloxacin group|"Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), Moxifloxacin (M)~Isoniazid, rifampicin, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by isoniazid, rifampicin, ethambutol and moxifloxacin daily for 2 months (2 HRZEM daily / 2HREM daily) - Duration 4 months~Drug dosages The Fixed-dose Combination (FDC) for HRZE(75/150/400/275mg) used under NTEP according to weight category will be used.~The patients enrolled in the study will receive an additional tablet of moxifloxacin(M) 400mg (body weight <64 Kg) / 600mg (body weight >65 Kg) along with the FDC both in the intensive and continuation phase."
89281198|NCT05031897|Experimental|Radiation-Based Cohort (fludarabine, TBI, infusion)|Patients receive fludarabine IV on days -11, -10, -9, and -8, undergo TBI BID on days -10 and -9, undergo DLI on day -6, and receive cyclophosphamide IV on days -3 and -2. Patients begin tacrolimus and mycophenolate mofetil IV on day -1. Patients then undergo HSCT on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
89281199|NCT05031897|Experimental|Chemotherapy-Based Cohort (fludarabine, melphalan, TBI)|Patients receive fludarabine IV on days -11, -10, -9, and -8 and melphalan IV on days -10 and -9. Patients undergo TBI and DLI once on day -6. Patients receive cyclophosphamide IV on days -3 and -2 and begin tacrolimus and mycophenolate mofetil on day -1. Patients undergo hematopoietic stem cell transplant on day 0.
89281200|NCT05028205|Experimental|Prevention Plus|Child's energy balance behavioral goals will be to consume < 3 sugar-sweetened beverages (e.g., regular carbonated soft drinks, sports drinks, lemonades, ice teas, flavored milk, juice drinks < 100% juice, and punches) servings /wk, ≥1 1/2 cups/day of whole vegetables and ≥ 1 cup/day of whole fruit, engage in ≥ 60 minutes/day of moderate- to vigorous-intensity physical activity, and reduce TV viewing to < 2 hours/day. The caregiver's energy balance behavioral goals will be to consume < 3 sugar-sweetened beverage servings/wk, ≥ 2 1/2 cups/day of whole vegetables and ≥ 1 1/2 cups/day of whole fruit, engage in ≥ 150 minutes of moderate- to vigorous-intensity physical activity per week and reduce TV viewing to < 10 hours/wk.
89281201|NCT05027880|Experimental|Single-session Intervention of Growth Mindset for Anxiety (SIGMA)|The SIGMA intervention group adapts the SSI-GP protocol in two ways: (a) by introducing the growth mindset of negative emotions rather than personality and (b) providing experiential process of negative emotion change. SIGMA consists of five components: (a) an introduction to emotions and the brain for conveying a scientific understanding of emotion and growth mindset of negative emotions; (b) stories and testimonials from high-school-aged youths who described their beliefs that people's negative emotion states (e.g., anxiety, depression, and stress) are malleable, and how these mindsets influence their coping with anxiety; (c) emotion changing experience induced by short videos; (d) common questions and misconceptions about growth mindset; and (e) self-persuasion writing exercises in which the participants write notes to younger students about the growth mindset of negative emotion.
89281202|NCT05027880|Experimental|Single-session Intervention on growth mindset of personality (SSI-GP)|The SSI-GP intervention group uses the intervention protocol of Project Personality. Two bilingual native English and Chinese speakers translated it into Chinese and made adaptations to better fit the local context. The SSI-GP consist of five components: (a) an introduction to the brain about the potential of neuroplasticity and behavioural change; (b) written testimonials from older, high-school-aged youths of their belief in change of personality; (c) additional vignettes written by older youths about how growth mindset of personality helped them succeed following setbacks; (d) overview of common questions and misconceptions about growth mindset; and (e) an exercise of writing notes to younger students about the malleability of people's personal traits.
89281203|NCT05027880|Active Comparator|Active control group: Support therapy (ST)|The control condition is a structurally similar web-based session of supportive therapy. The goals of supportive therapy are to encourage the client to identify and express feelings and to share their emotions-both positive and negative-with close others. The ST group does not teach or emphasize specific skills or beliefs. The active control group includes the same number of activities as do the SIGMA and SSI-GP interventions. Also, to mirror the intervention groups as closely as possible, supportive therapy includes vignettes written by similar school-aged youths, who describe times when they benefited from sharing their feelings with friends or family members.
89281204|NCT05027880|Experimental|SIGMA-BOOSTER|The SIGMA-BOOSTER group receives the same intervention as the SIGMA group, the only difference is that the SIGMA-BOOSTER group receives booster messages with core intervention content every 2 weeks between the 2-week post-test and the 2-month follow-up survey, that is, a total of 5 weekly booster messages are sent to the SIGMA-BOOSTER group, which will help us determine the most effective way of implementing the intervention.
89281205|NCT05027711|Experimental|A|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
89281206|NCT05027711|Experimental|B|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT), if a biologically effective dose (BED) of ≥ 100 Gy is achievable using an ITV
89281207|NCT05027711|Experimental|C|Magnetic Resonance-guided Stereotactic Body Radiotherapy (MRgSBRT). If a BED of ≥ 100 Gy cannot be achieved using an ITV concept (e.g. due to OAR constraints), patients will be treated in arm C using MRgSBRT with the highest achievable dose as deemed appropriate by the treating radiation oncologist
89281208|NCT05020587|Other|Open Pilot Trial|Open pilot trial of a group therapy manual.
89281209|NCT05015439|Experimental|Cannabidiol|Participants will receive cannabidiol, starting at 100 mg twice daily, and increased to 200 mg twice daily by week 3. This arm will last six weeks.
89281210|NCT05015439|Placebo Comparator|Placebo|Participants will receive six weeks of placebo.
89281211|NCT05006521|Experimental|KN-002 for SAD (Part 1)|Up to 6 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
89281212|NCT05006521|Placebo Comparator|Placebo for SAD (Part 1)|Up to 6 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
89281213|NCT05006521|Experimental|KN-002 for MAD (Part 2)|Up to 4 cohorts with 6 of 8 subjects per cohort randomised to receive KN-002
89281214|NCT05006521|Experimental|Placebo for MAD (Part 2)|Up to 4 cohorts with 2 of 8 subjects per cohort randomised to receive placebo
89281215|NCT05006521|Experimental|KN-002 for Part 3|Single cohort with up to 18 of 24 subjects randomised to active treatment
89281216|NCT05006521|Experimental|Placebo for Part 3|Single cohort with up to 6 of 24 subjects randomised to placebo treatment
89281217|NCT05006521|Experimental|KN-002 for Part 4|Single cohort with up to 18 of 24 subjects randomised to active treatment
89281218|NCT05006521|Experimental|Placebo for Part 4|Single cohort with up to 6 of 24 subjects randomised to placebo treatment
89281219|NCT05004727|Experimental|Guselkumab + Topicals (GUS)|
89281220|NCT05004727|Placebo Comparator|Placebo + Topicals (PBO)|
89281221|NCT05004727|No Intervention|Standard-of-Care Therapy (SOC)|"In this third, non-randomized arm, patients would continue treatment with topical therapy or UVB, as part of our ongoing natural history of disease registries. This arm will include participants fulfilling RM-PsASon criteria but also those that do not (to serve as negative controls)."
89281222|NCT04998305|Experimental|Treatment sequence TJ-68-Placebo-Placebo-TJ-68|"Employing an N-of-1, crossover design, each participant in the TJ-68 clinical trial will serve as his/her control. The participation will last for 11 weeks - four, 2-week treatment periods with 1-week washout (WO) period between each treatment period. Participants (n=13) will be randomized to the following treatment sequences:~TJ-68, placebo, placebo, TJ-68 (1 week WO between each treatment period)"
89281223|NCT04998305|Experimental|Treatment sequence Placebo-TJ-68-TJ-68-Placebo|"Employing an N-of-1, crossover design, each participant in the TJ-68 clinical trial will serve as his/her control. The participation will last for 11 weeks - four, 2-week treatment periods with 1-week washout (WO) period between each treatment period. Participants (n=13) will be randomized to the following treatment sequences:~placebo, TJ-68, TJ-68, placebo (1 week WO between each treatment period)"
89281224|NCT04994938|Experimental|Peer led diet and exercise intervention|participation in two-times per week diet and exercise peer led interventions.
89281225|NCT04986046|Active Comparator|Fruit and vegetable prescription|Fruit and vegetable incentive program
89281226|NCT04986046|Experimental|Fruit and vegetable prescription + Home Plate Lite|Fruit and vegetable incentive program + asynchronous, electronic resources delivered over six weeks
89281227|NCT04986046|Experimental|Fruit and vegetable prescription + Virtual Home Plate|Fruit and vegetable incentive program + 45-minute, virtual, small-group classes twice weekly for six weeks
89281228|NCT04984889|Experimental|TAK-662 80 IU/kg|TAK-662 80 international unit (IU)/kg, single intravenous infusion over 15 minutes on Day 1. In the extension part, dose of TAK-662 will be modified per participants. TAK-662 is Protein C Concentrate, which is a lyophilized, sterile concentrate of human protein C.
89281229|NCT04983251||U3 Women|Women in under-studied, under-represented, and under-reported (U3) populations.
89281230|NCT04983238|Experimental|BYON5667 & SYD985|BYON5667 eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)
89281231|NCT04983238|Placebo Comparator|Placebo & SYD985|Placebo eye drops should be self-administered daily during waking hours. SYD985, every 3 weeks (Q3W)
89281232|NCT04970368|Experimental|Sentinel Node Surgical Staging|
89281233|NCT04970368|Experimental|Selective Surgical Staging|
89281234|NCT04969315|Experimental|Multiple Ascending Dose|3+3 Dose escalation until MTD and/or R2PD of TT-10 is determined
89281235|NCT04969146|Experimental|Modified Cognitive Behavioral Therapy Intervention Dyadic|The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. The patient and caregiver will complete the assessment at 3- and 6 months follow up.
89281236|NCT04969146|Experimental|Modified Cognitive Behavioral Therapy Intervention Patient Only|The patient in the patient only intervention arm will receive 5 sessions of Modified CBTi. The patient and caregiver will complete the assessment at 3- and 6 months follow up
89281237|NCT04946357|Experimental|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm A: Protons, 39 Gy (RBE) in 13 fractions (single dose 3.0 Gy(RBE))
89281238|NCT04946357|Experimental|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))|Arm B: Carbon ions, 39 Gy(RBE) in 13 fractions (single dose 3.0 Gy(RBE))
89281239|NCT04925583|Experimental|Level 0|Total dose 50 Gy, (10 x 5 Gy single dose)
89281240|NCT04925583|Experimental|Level 1|Total dose 55 Gy, (10 x 5.5 Gy single dose)
89281241|NCT04925583|Experimental|Level 2|Total dose 60 Gy, (10 x 6 Gy single dose)
89281242|NCT04925583|Experimental|Level 3|Total dose 65 Gy, (10 x 6.5 Gy single dose)
89281243|NCT04919330|Experimental|ACT Group|One four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP) and routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation.
89281244|NCT04919330|Other|Wait-list Control Group|Routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation
89281245|NCT04909411|Other|Exposed arm|child infected with chikungunya virus during childbirth
89281246|NCT04909411|Other|Non-exposed arm|child not infected with the chikungunya virus at the time of childbirth, verifying the matching criteria specified
89281247|NCT04887792|Active Comparator|Acetazolamide|acetazolamide capsules
89281248|NCT04887792|Active Comparator|Placebo|Identical gelatin capsules
89281249|NCT04880031|Experimental|Cohort A1: BOS-580 Dose 1 or placebo (PBO)|
89281250|NCT04880031|Experimental|Cohort A2: BOS-580 Dose 2 or PBO|
89281251|NCT04880031|Experimental|Cohort A3: BOS-580 Dose 3 or PBO|
89281252|NCT04880031|Experimental|Cohort A4: BOS-580 Dose 4 or PBO|
89281253|NCT04880031|Experimental|Cohort A5: BOS-580 Dose 5 or PBO|
89281254|NCT04880031|Experimental|Cohort B: BOS-580 Dose 1 or PBO|
89281255|NCT04857905|Other|Microsurgical Resection of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after counseling~-> Patients who after counseling decide for microsurgical resection of their brain metastasis"
89281256|NCT04857905|Other|Radiosurgery of larger Brain Metastasis|"Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after study counseling~-> Patients who after counseling decide for dose-staged radiosurgical treatment of their brain metastasis"
89281257|NCT04855786|Experimental|Thoracic Duct Drainage|This is the main study group of patients with thoracic duct drainage
89281258|NCT04851873|Experimental|OAV101|Participants received a single IV dose administration of OAV101
89281259|NCT04822688||Basic Science (Biospecimen collection)|Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.
89281260|NCT04816721|Experimental|EDP-938|EDP-938, oral suspension, once daily for 5 days
89281261|NCT04816721|Placebo Comparator|Placebo|Matching placebo, orally, once daily for 5 days
89281262|NCT04814446|Experimental|Gardasil 9®|Nonavalent HPV vaccine
89281263|NCT04814446|Placebo Comparator|Placebo|NaCl 0.9 % solution for injection
89281264|NCT04807803|Experimental|Patients with compensated cirrhosis and portal hypertension|
89281265|NCT04805736|Experimental|Microwave Ablation alone|Microwave Ablation+ Breast Surgery
89281266|NCT04805736|Experimental|Camrelizumab alone|Camrelizumab+ Breast Surgery
89281267|NCT04805736|Experimental|Microwave Ablation & Camrelizumab|Microwave Ablation + Camrelizumab + Breast Surgery
89281268|NCT04805554|Experimental|Joint Insights Decision Aid|Participants view the entire Joint Insights decision aid for knee osteoarthritis including: Education Module with information about knee osteoarthritis and risks and benefits of various treatment options, Preferences and Values elicitation questions, and Personalized Risk/Benefit Report.
89281269|NCT04805554|Active Comparator|Education Module Only|Participants view the Joint Insights Education Module only
89281270|NCT04793776|Experimental|Manage Emotions to Reduce Aggression (MERA)|MERA is 3 individual 90-minute sessions delivered over 3 weeks.
89281271|NCT04793776|Active Comparator|Present Centered Psychotherapy (PCT)|PCT delivered in 3 individual 90-minute sessions over 3 weeks.
89281272|NCT04783558|Experimental|Adapted NAS tool Intervention|Pregnant women in this condition will receive the adapted mobile-based NAS instructional tool and TAU. Women in this condition will go through the NAS instructional tool at least once during pregnancy, with their choice of going through the modules gradually while waiting at the OAT clinic to receive their dose, or by scheduling a time to review the modules. Participants will have free online access to the tool throughout their third trimester as well as through 12-weeks postpartum so they can access the modules at any time, and as many times as desired, including after giving birth.
89281273|NCT04783558|No Intervention|Treatment-as-Usual (TAU)|Pregnant women in this condition will receive care as usual that involves continued enrollment in OAT and continued obstetric care. We will also provide them with a printed handout containing information on NAS and local resources. Participants in the TAU condition will not receive iPads with accompanying modules, however the handout constitutes more information than they normally receive.
89281274|NCT04777799|Experimental|URGOnight|Use of the URGOnight neurofeedback training headband and its associated application
89281275|NCT04769739|Active Comparator|CO2 insufflation|Colonoscopy will be performed in the traditional fashion, with minimal insufflation required to aid insertion. Cleaning in the CO2 group will be performed entirely during withdrawal.
89281276|NCT04769739|Active Comparator|WE with water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual decal debris, predominantly during insertion.
89281277|NCT04769739|Experimental|WE with 50% saline|Residual air in the colon will be removed, 50% salline (1:1 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
89281278|NCT04769739|Experimental|WE with 25% saline|Residual air in the colon will be removed, 25% saline (1:3 mixture of saline and water) will be infused to guide insertion through an airless lumen. Infused saline will be removed by suction, along with residual decal debris, predominantly during insertion.
89281279|NCT04761783||Prospective arm|Patients will receive SIGNATERA™ test results and the immunotherapy treatment regimen, dosing schedule, duration of treatment, number of cycles, and modifications during treatment will be at the discretion of the HCP. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
89281280|NCT04761783||Control arm|Control cases must have undergone immunotherapy treatment and have follow-up data available in their medical record at the participating site for two years following initiation of immunotherapy or death.
89281281|NCT04760288|Experimental|Arm A (Pralsetinib)|Participants will receive pralsetinib at a dose of 400 milligrams (mg) orally once daily (PO QD) in 28-day cycles.
89281282|NCT04760288|Active Comparator|Arm B (SOC: Cabozantinib/Vandetanib)|Adult participants will receive investigator's choice of SOC MKI therapy with either 140 mg cabozantinib PO QD or 300 mg vandetanib PO QD in 28-day cycles. Adolescents participants (≥ 12 and < 18 years of age) will receive vandetanib, PO QD or every other day, in 28-day cycles depending on the body surface area (BSA), at a dose determined according to the dosing nomogram available in the E.U. Vandetanib SmPC.
89281283|NCT04752280|Experimental|Arm A: Proton irradiation|Irradiation applied with protons
89281284|NCT04752280|Active Comparator|Arm B: Photon IMRT|Photon irradiation applied as intensity-modulated radiotherapy
89281285|NCT04751942|Experimental|Non-compressive Bioactive Garment|The non-compressive bioactive garment is a commercially available garment that is designed to reflect infrared waves generated by the wearer back into the soft tissue surrounded by the garment. The reflection of the infrared waves is intended to improve pain and swelling at the site. Patients following Total knee replacement are intended to wear morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks.
89281286|NCT04751942|Active Comparator|Thrombo-Embolic Deterrent|a gradient compression stocking that is currently the gold standard for deterring thromboembolic events and assisting with post-operative swelling after total knee replacements. Patients following Total knee replacement are intended to wear the TED hose morning and night for the first 2 weeks post-operatively, and then as tolerated for 4 weeks afterwards. The patients will then discontinue use of the sleeve after 6 weeks.
89281287|NCT04750278|Experimental|FP-025 100 mg|Low dose for patient treatment.
89281288|NCT04750278|Experimental|FP-025 300 mg|High dose for patient treatment.
89281289|NCT04750278|Placebo Comparator|Placebo|Dose without any study drug, to make it a controlled study.
89281290|NCT04746924|Experimental|Arm A: Tislelizumab plus Ociperlimab|Participants will receive tislelizumab 200 milligrams (mg) intravenously followed by ociperlimab 900 mg intravenously once every 3 weeks.
89281291|NCT04746924|Active Comparator|Arm B: Pembrolizumab plus Placebo|Participants will receive pembrolizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
89281292|NCT04746924|Placebo Comparator|Arm C: Tislelizumab plus Placebo|Participants will receive tislelizumab 200 mg intravenously followed by placebo intravenously once every 3 weeks.
89281293|NCT04743362||Participants with muco-cutaneous lesions|Participants will have muco-cutaneous lesions for non-invasive evaluation (including normal skin or mucosa and benign lesions) and will be identified by their physicians or fellows during routine clinical care.
89281294|NCT04732429|Experimental|Active Drug|Part B is the 6-month, randomized, double-blind (Subject/Investigator/Sponsor), placebo-controlled, 2-period crossover study consisting of 2 intervention periods of 12 weeks each to evaluate the safety and efficacy of the optimal dose of HST5040 in PA and MMA subjects ≥ 2 years old (N = minimum 12) in addition to SoC determined in Part A (within-subject dose escalation).
89281295|NCT04732429|Experimental|Placebo|Placebo in addition to standard of care.
89281296|NCT04731610|Other|Post-operative radiotherapy|Tumour resection followed by radiotherapy.
89281297|NCT04731610|Other|Surveillance after tumour resection|Tumour resection
89281298|NCT04728607|Experimental|Participants|Individuals requiring ring removal.
89281299|NCT04721665||SLD patients|No intervention
89281300|NCT04716686|Experimental|Niraparib as maintenance therapy for Endometrial Serous Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
89281301|NCT04716686|Experimental|Niraparib as recurrent therapy for Endometrial Carcinoma|For patients with baseline weight ≥ 77 kg and baseline platelets ≥ 150000/uL, a starting dose of 300 mg QD will be given; other patients will be given a starting dose of 200 mg QD. One treatment cycle is 28 days; follow-up and evaluation will be conducted every 2 cycles until the disease progression or patients cannot tolerate.
89281302|NCT04714164|Experimental|Teletherapy Group CBT participants|Patients over the age of 65 with either a Major Depressive Disorder or Generalized Anxiety Disorder who will be participating in a Group CBT delivered by Teletherapy
89281303|NCT04706208|Other|One time testing - able-bodied healthy adults|"Participants in this arm will be able-bodied healthy adults who will not receive an intervention.~This is just a one time testing of clinical assessments (over zoom), one MRI scan, and an optional blood draw test."
89281304|NCT04706208|Experimental|Usual Care, then Cognitive Multisensory Therapy - adults with spinal cord injury + neuropathic pain.|This is a cross-over study for participants with spinal cord injury and neuropathic pain. Participants in this arm will first receive usual care and then switch over to the experimental cognitive multisensory therapy training.
89281305|NCT04706208|Experimental|Cognitive Multisensory Therapy, then Usual Care - adults with spinal cord injury + neuropathic pain.|This is a cross-over study for participants with spinal cord injury and neuropathic pain. Participants in this arm will first receive the experimental cognitive multisensory therapy training and then switch over to usual care.
89281306|NCT04702776|Experimental|Arm 1; Humylub Ofteno® PF|Humylub Ofteno® PF (sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) ophthalmic solution applied QID for 30 days.
89281307|NCT04702776|Active Comparator|Arm 2; Hyabak®|Hyabak® PF (sodium hyaluronate 0.15%) ophthalmic solution applied QID for 30 days.
89281308|NCT04702776|Active Comparator|Arm 3; Lagricel Ofteno® PF|Lagricel Ofteno® PF (sodium hyaluronate 0.4%) ophthalmic solution applied QID for 30 days.
89281309|NCT04696822|Experimental|Adults with seasonal allergic rhinitis|Single administration of 1.6mg or 3.2 mg Epinephrine powder nasal spray, with or without allergenic challenge, and single IM 0.3 mg Epinephrine without allergenic challenge.
89281310|NCT04694586|Experimental|High-dose rifampicin and pyrazinamide|"rifampicin 35 mg/kg for 4 months provided as a combination of fixed drug combination tablets (HRZE for 8 weeks and HR Week 9-16) and single drug tablets of rifampicin (R)~AND~pyrazinamide 40 mg/kg the first 2 months provided as a combination of fixed drug combination tablets (HRZE) and single drug tablets of pyrazinamide (Z)~fixed drug combination tablets are: isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 16 (total treatment duration 4 months)"
89281311|NCT04694586|No Intervention|Standardized TB treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9-26 (total treatment duration 6 months)
89281312|NCT04690348|Active Comparator|Resection without brachytherapy|Patients will undergo craniotomy.
89281313|NCT04690348|Experimental|Resection plus brachytherapy|Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.
89281314|NCT04685928|Experimental|MRI arm|MRI prostate with contrast, followed by MRI-guided biopsy under local anaesthesia only if MRI show suspicious lesion. Men with non-suspicious MRI will not receive a biopsy.
89281315|NCT04685928|Active Comparator|TP-arm Systematic biopsy|24-core Systematic transperineal prostate biopsy under local anaesthesia
89281316|NCT04684797|Experimental|Intervention group|Each participant will undergo two sessions, consisting of performing the virtual T-maze task, scalp-EEG recording and/or intracranial video-EEG recording.
89281317|NCT04672681|Experimental|Intervention group|The intervention group will receive a 6-month play-based physical activity intervention with daily play and movement activities starting from treatment initiation.
89281318|NCT04672681|No Intervention|Standard care|"The control group will receive standard treatment and physiotherapy if needed.~For ethical reasons, after the primary study end-point at six months, the participants and parents allocated to this group will be offered the same inspirational material and the possibility to participate in the group-based physical activity as the participants and parents allocated to the intervention group, but they will not receive education and supervision play-based physical activity with their child in the hospital room."
89281319|NCT04668872||Participants with colorectal cancer liver metastases|The study population is represented by patients with colorectal cancer liver metastases that have been deemed clinically appropriate/eligible to receive Y90 TARE for the management of their liver metastases.
89281320|NCT04661137|Experimental|Carfilzomib-containing Regimen|"Carfilzomib 56 mg/m2 on days 1, 8 and 15. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 80 mg on days 1, 8 and 15."
89281321|NCT04661137|Experimental|Pomalidomide-containing Regimen|"Pomalidomide 4 mg po daily for 21 days. Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 60 mg on days 1, 8 and 15."
89281322|NCT04661137|Experimental|Exploratory/Daratumumab-containing Regimen|"Daratumumab on current schedule (16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on).~Dexamethasone 20 mg if ≥ 75 years old and 40 mg if < 75 years old on days 1, 8, 15 and 22.~Selinexor 100 mg on days 1, 8, 15 and 22."
89281323|NCT04649385|Experimental|Phase 1a: Dose Escalation|"Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 7 increasing doses~Part B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy )"
89281324|NCT04649385|Experimental|Phase 1b: Dose Expansion|Phase 1b dose expansion will begin based upon the recommended doses for expansion (RDFE) for BGB-15025 alone or in combination with tislelizumab, and with or without chemotherapy as determined from Phase 1a
89281325|NCT04633330|Experimental|Study Arm|AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
89281326|NCT04633330|Placebo Comparator|Control Arm|Simulation of AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
89281327|NCT04625465|No Intervention|No Intervention, No Intervention (AA)|Participants do not receive text messages during Interval 2 or Interval 3.
89281328|NCT04625465|Active Comparator|No Intervention, Attention-Control Texts (AB)|Participants do not receive text messages during Interval 2. Participants receive attention control text messages during Interval 3.
89281329|NCT04625465|Experimental|No Intervention, CBT Texts (AC)|Participants do not receive text messages during Interval 2. Participants receive CBT text messages during Interval 3.
89281330|NCT04625465|Active Comparator|Attention-Control Texts, No Intervention (BA)|Participants receive attention control text messages during Interval 2. Participants do not receive text messages during Interval 3.
89281331|NCT04625465|Active Comparator|Attention-Control Texts, Attention-Control Texts (BB)|Participants receive attention control text messages during Interval 2. Participants receive attention control text messages during Interval 3.
89281332|NCT04625465|Experimental|Attention-Control Texts, CBT Texts (BC)|Participants receive attention control text messages during Interval 2. Participants receive CBT text messages during Interval 3.
89281333|NCT04625465|Experimental|CBT Texts, No Intervention (CA)|Participants receive CBT text messages during Interval 2. Participants do not receive text messages during Interval 3.
89281334|NCT04625465|Experimental|CBT Texts, Attention-Control Texts (CB)|Participants receive CBT text messages during Interval 2. Participants receive attention control text messages during Interval 3.
89281335|NCT04622696||Prospective - Performance Cohort|Subjects will undergo an ultrasound-guided breast biopsy procedure with placement of HydroMARK Breast Biopsy Site Marker per site standard of care and will return to the office at 6-12 weeks post-implant for ultrasound imaging to evaluate device visibility.
89281336|NCT04622696||Retrospective - Safety Cohort|Device-related adverse events will be collected via retrospective medical chart review for a minimum of 90 days post-HydroMARK Breast Biopsy Site Marker implant (unless the subject was exited according to the medical records due to the implant being removed/explanted or subject death).
89281337|NCT04603898|Experimental|Controlled Dietary Study|Subjects will consume a controlled diet (low in oxalate and ascorbic acid) for six days. After two days of equilibration, subjects will provide a blood sample and ingest an oral load of ascorbic acid (1 mg/kg) with breakfast on Day 3. The following day (Day 4), serial blood and urine collections will occur. On Days 5 through 7, subjects will complete a 24-hr urine collection and blood draw.
89281338|NCT04598529|Active Comparator|A2 milk|A2 milk, organic, 200ml, twice daily
89281339|NCT04598529|Placebo Comparator|Conventional milk|Pasteurized semi-skimmed milk, organic, 200ml, twice daily
89281340|NCT04597437|Experimental|Zanamivir|In the treatment group, participants weighing less than 50 kg will receive 12 mg/kg and those weighing 50 kg and above will receive 600 mg as the initial dose intravenously every twelve hours for 5 days adjusted for renal function.
89281341|NCT04597437|Placebo Comparator|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
89281342|NCT04592627||Simulated home environment visit with the dyad participants|The cohort consists of six stroke survivor-informal caregiver (e.g., spouse or family member) dyads. Individual dyads will participate in the simulated home environment visit while the investigative team collects the data.
89281343|NCT04574882||Case|Patients ages 30-74 with and without CHD (IICD 10: I63, I20-I25 ) within the last 5 years.
89281344|NCT04574882||Control|Patients aged 30-74 who have non-cardiovascular-related history
89281345|NCT04565899|Experimental|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
89281346|NCT04542733|Active Comparator|mTORi with reduced-dose tacrolimus|Patient will received everolimus with target trough concentration of 3-6 ng/mL and tacrolimus with target trough concentration of 2-4 ng/mL. Duration for this regimen would be at least 3 months.
89281347|NCT04542733|Active Comparator|reduced-dose tacrolimus|Patient will receive tacrolimus with target concentration of 3-6 ng/mL with or without leflunomide 100 mg/day loading dose for 5 days, followed by 40 mg/day thereafter. Duration for this regimen would be at least 3 months.
89281348|NCT04540900|Active Comparator|KB301|non-integrating HSV-1 vector expressing human type III collagen
89281349|NCT04540900|Placebo Comparator|Placebo|sterile isotonic saline
89281350|NCT04527315||COVID-19 ICU Patients|
89281351|NCT04527315||Control|
89281352|NCT04520126|Active Comparator|olive extract 1 - olivomed|15 patients will be randomized to receive two Olivomed soft capsules bid for one month (5 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another one month.
89281353|NCT04520126|Placebo Comparator|placebo 1|15 patients will be randomized to receive two placebo soft capsules bid for one month. Then they will be crossed over to receive two Olivomed soft capsules bid for oen month (5 mg hydroxytyrosol po twice daily)
89281354|NCT04520126|Active Comparator|olive extract 2 - olivomedSmart|15 patients will be randomized to receive two soft capsules containing OL:HT:OC (2:1:3) bid for one month (5 mg hydroxytyrosol po twice daily) and then they will be crossed over to treatment placebo for another one month.
89281355|NCT04520126|Placebo Comparator|placebo2|15 patients will be randomized to receive two placebo soft capsules bid for one month. Then they will be crossed over to receive two soft capsules containing OL:HT:OC (2:1:3) bid for one month (5 mg hydroxytyrosol po twice daily) bid for one month.
89281356|NCT04506866|Other|Overactive Bladder Cohort|Subjects with overactive bladder will be treated with InterStim Micro Therapy and followed-up regarding their overactive bladder symptoms.
89281357|NCT04506866|Other|Fecal Incontinence Cohort|Subjects with fecal incontinence will be treated with InterStim Micro Therapy and followed-up regarding their fecal incontinence symptoms.
89281358|NCT04506866|Other|Non-Obstructive Urinary Retention Cohort|Subjects with non-obstructive urinary retention will be treated with InterStim Micro Therapy and followed-up regarding their non-obstructive urinary retention symptoms.
89281359|NCT04493853|Experimental|Capivasertib + Abiraterone|Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
89281360|NCT04493853|Placebo Comparator|Placebo + Abiraterone|Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
89281361|NCT04479605||Patients with advanced cancer|Patient and caregiver coaching is facilitated by a booklet titled Our Cancer Care (Appendices E & F) that includes a Question Prompt List (QPL) and resources for a Values Affirmation Exercise (Appendices G & H). The QPL and Values Affirmation Exercises will be provided with a cover letter (Appendix I). The QPL consists of example questions to discuss with oncologists about diagnosis, prognosis, treatments, symptom management, transitions in care, self-care, family needs, and life goals. Patients and caregivers meet over video-conferencing with a study interventionist for one hour to review the QPL. The interventionist makes three follow-up phone calls to each dyad bi-weekly to evaluate use of the QPL.
89281362|NCT04479605||Caregivers|Caregivers will participate in three 45-minute sessions with the interventionist over the telephone or video-conferencing (per caregiver preference) approximately bi-weekly. These sessions take place while the patient and caregiver are completing the three follow-up dyadic sessions. Efforts will be made to schedule the caregiver support sessions during weeks that fall between dyadic coaching sessions to minimize intervention burden on caregivers (i.e., avoiding scheduling two sessions for the caregiver in the same week).
89281363|NCT04479605||Oncologists|The Oncologist training will be conducted online using Bridge, an internet-based platform designed to facilitate communication between instructors and learners. The training includes written information on and videos demonstrating target communication skills (Table 1) and knowledge acquisition checks. Five of the online modules are required and the remaining six modules are optional. The required modules are estimated to take oncologists approximately one hour to complete; the optional modules are estimated to take 90 minutes total (i.e., for all modules) to complete. Oncologists' logging history will be tracked in Bridge.
89281364|NCT04465838||Psoriasis|This is a non-interventional study (NIS). All the patients diagnosed as psoriasis by the dermatologists in the clinic are included in this study no matter what kind of treatment they adopt.
89281365|NCT04450914|Other|Health Systems - First Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the first step, health systems will be assigned to usual care (passive implementation of CV Prevention Choice).
89281366|NCT04450914|Other|Health Systems - Second Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions. In the second step, health systems (in an order to be determined by randomization and staggered over time) will move into active implementation.
89281367|NCT04450914|Other|Health Systems - Third Step|Each health system will consist of clinicians who are affiliated with primary care practices and patients who are eligible for CV primary prevention discussions.In the third step, all health systems will move to maintenance implementation.
89281368|NCT04448678|Experimental|HIEP intervention|Participants will be randomized to receive the insurance navigation intervention from patient navigators, which includes four, one hour long, educational learning sessions. Randomization will be done by age at diagnosis and site.
89281369|NCT04448678|Active Comparator|Usual Care|"Participants will be randomized to receive standard navigation provided by patient navigators (usual care)."
89281370|NCT04437030|Active Comparator|Patient|Patient with Head and neck cancer
89281371|NCT04437030|Other|Healthy subjects|Healty subjects with not history of Tumor disease in the Head and neck region
89281372|NCT04428866||Participants with post-bariatric hypoglycemia|Individuals with history of Roux-en-Y gastric bypass surgery, who have a history of hypoglycemia will be recruited from the Joslin Hypoglycemia Clinic.
89281373|NCT04428866||Asymptomatic participants with Roux-en-Y gastric bypass (RYGB)|Individuals with history of RYGB, without a history of or symptoms of hypoglycemia will be recruited from local postoperative surgical clinics and from the community.
89281374|NCT04428866||Control group|Individuals without a history of bariatric surgery will be recruited by local advertisement.
89281375|NCT04428723||Hypoglycemia, no upper gastrointestinal (GI) surgery|Males or females with hypoglycemia with neuroglycopenia, but no history of upper GI surgery, diabetes or prediabetes
89281376|NCT04428723||Hypoglycemia, with history of upper GI surgery|Males or females with hypoglycemia with neuroglycopenia, with history of upper GI surgery
89281377|NCT04428723||Controls, without hypoglycemia or upper GI surgery|Males or females with no history of upper gastrointestinal surgery, hypoglycemia, or diabetes.
89281378|NCT04409288|Experimental|Group A|Apalutamide followed by Enzalutamide Study participants will receive 12 weeks of oral apalutamide (240mg) daily, followed by five weeks of washout period, and then 12 weeks of oral enzalutamide (160mg) daily.
89281379|NCT04409288|Experimental|Group B|Enzalutamide followed by Apalutamide Study participants will receive 12 weeks of oral enzalutamide (160mg) daily, followed by five weeks of washout period, and then 12 weeks of oral apalutamide (240mg) daily.
89281380|NCT04402125|Experimental|Intervention|Participants randomized to TEAM intervention for 6 months, then observed for 6 month follow up
89281381|NCT04402125|Other|Waitlist|Participants randomized to waitlist for 6 months, then offered the intervention for 6 months
89281382|NCT04401904|Experimental|Dapagliflozin|10 participants with pre-diabetes will be randomized to the experimental group to receive dapagliflozin 10mg by mouth daily for 12 weeks.
89281383|NCT04401904|Other|Nutritional Counseling|10 participants with pre-diabetes will be randomized to receive nutritional counseling weekly for 12 weeks
89281384|NCT04394637||PROSe-ICD|PROSe-ICD [NCT00733590/ Institutional Review Board (IRB) NA_00045142], a large prospective cohort study of patients who received an ICD for primary prevention.
89281385|NCT04394637||Reynolds study|Functional Energetics (Reynolds study, NA_00037404), a study with conventional contrast-enhanced 1H MRI to determine ventricular geometry, global and regional function, as well as infarct size characteristics following delayed contrast enhancement.
89281386|NCT04384757|Active Comparator|Open distal gastrectomy|An incision of 15~20 cm length is made in the abdominal midline . Standard distal gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, proper hepatic artery) . As a general rule, Billroth II method was used for gastric reconstruction for most cases
89281387|NCT04384757|Experimental|Laparoscopic distal gastrectomy|"5 trocar were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.~The right gastroepiploic vein was divided and the right gastroepiploic and the inferior pyloric artery were vascularized and cut at their origin from the gastroduodenal artery, just above the pancreatic head, to dissect group 6.~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.~The left gastric vein was prepared and separately divided and then the left gastric artery was vascularized to remove group 7.~The dissection was continued upward along the proximal branches of splenic vessels to remove group 11p and along the lesser curvature to remove group 1,3.~As a general rule, Billroth II method was used for gastric reconstruction for most cases"
89281388|NCT04381936|No Intervention|Standard Care|Patient receives usual hospital care
89281389|NCT04381936|Active Comparator|Low dose corticosteroids|"First (main) randomisation part A~[This arm is now closed to recruitment]"
89281390|NCT04381936|Active Comparator|Hydroxychloroquine|"First (main) randomisation part A~[This arm is now closed to recruitment]"
89281391|NCT04381936|Active Comparator|Lopinavir-Ritonavir|"First (main) randomisation part A~[This arm is now closed to recruitment]"
89281392|NCT04381936|Active Comparator|Azithromycin|"First (main) randomisation part A~[This arm is now closed to recruitment]"
89281393|NCT04381936|Active Comparator|Convalescent plasma|"First (main) randomisation part B~[This arm is now closed to recruitment]"
89281394|NCT04381936|Active Comparator|Tocilizumab|"Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment.~(Children with COVID-19 pneumonia are not eligible for this comparison).~[This arm is now closed to recruitment]"
89281395|NCT04381936|Active Comparator|Intravenous Immunoglobulin|"First (main) randomisation part A (children only)~[This arm is now closed to recruitment]"
89281396|NCT04381936|Active Comparator|Synthetic neutralising antibodies|"First (main) randomisation part B.~[This arm is now closed to recruitment]"
89281397|NCT04381936|Active Comparator|Aspirin|"First (main) randomisation part C~[This arm is now closed to recruitment]"
89281398|NCT04381936|Active Comparator|Colchicine|"First (main) randomisation part A~[This arm is now closed to recruitment]"
89281399|NCT04381936|Active Comparator|Baricitinib|"First (main) randomisation part D~[This arm is now closed to recruitment]"
89281400|NCT04381936|Active Comparator|Anakinra|"Randomisation for children only with PIMS-TS~(Children with COVID-19 pneumonia are not eligible for this comparison).~[This arm is now closed to recruitment]"
89281401|NCT04381936|Active Comparator|Dimethyl fumarate|"First (main) randomisation part A (UK adults only; early phase assessment)~[This arm is now closed to recruitment]"
89281402|NCT04381936|Active Comparator|High Dose Corticosteroids|First (main) randomisation part E
89281403|NCT04381936|Active Comparator|Empagliflozin|"First (main) randomisation part F~[This arm is now closed to recruitment]"
89281404|NCT04381936|Active Comparator|Sotrovimab|First (main) randomisation part J
89281405|NCT04381936|Active Comparator|Molnupiravir|"First (main) randomisation part K~[This arm is now closed to recruitment]"
89281406|NCT04381936|Active Comparator|Paxlovid|"First (main) randomisation part L~[This arm is now closed to recruitment]"
89281407|NCT04381936|Active Comparator|Baloxavir marboxil|Randomisation part G (influenza)
89281408|NCT04381936|Active Comparator|Oseltamivir|Randomisation part H (influenza)
89281409|NCT04381936|Active Comparator|Low-dose corticosteroids: Dexamethasone (influenza arm)|Randomisation part I (influenza)
89281410|NCT04381936|Active Comparator|Low-dose corticosteroids: Dexamethasone (pneumonia arm)|Randomisation part M (community-acquired pneumonia)
89281411|NCT04379830|Experimental|Very Low Energy Diet|VLED in its entirety is composed of the following for 3-weeks preoperatively: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
89281412|NCT04370301|Experimental|Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)|"JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation.~CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1 or day -1 and day 0.~TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.~GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is > 1,500/mm^3.~All patients undergo MRI, CT, bone marrow biopsy and aspiration and blood sample collection throughout the trial. Patients also undergo ECHO or MUGA on the trial."
89281413|NCT04356612||Achilles Tendon Rupture|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
89281414|NCT04355897|Experimental|Convalescent COVID 19 Plasma|Subjects will receive and intravenous infusion of 500 mls of Convalescent COVID 19 Plasma.
89281415|NCT04354467||Neonates exposed to Nephrotoxic Medications|Neonates exposed to Nephrotoxic Medications as defined by the NINJA inclusion criteria
89281416|NCT04348045|Experimental|ARM A - olaparib|Olaparib tablets at 300 mg orally twice daily until PD (RECIST 1.1) or unacceptable toxicity.
89281417|NCT04348045|Experimental|ARM B - durvalumab plus selumetinib|"Durvalumab plus selumetinib until PD (RECIST 1.1 and/or iRECIST), unacceptable toxicity, withdrawal of consent, or death.~Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle,~Selumetinib administered as 75 mg twice daily dose for 21 days on and 7 days off (a 28-day cycle)."
89281418|NCT04348045|Active Comparator|ARM C - FOLFIRI|FOLFIRI FOLFIRI (irinotecan 180 mg/m2 IV on day 1, folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2 every 2 weeks) until PD (RECIST 1.1) unacceptable toxicity, withdrawal of consent, or death.
89281419|NCT04343534||Original Shared Decision Making Process scale|Patients receive the original version of the Shared Decision Making Process scale.
89281420|NCT04343534||Revised Shared Decision Making Process scale|This group completes a new version of the scale with different wording for several items.
89281421|NCT04337710|Experimental|Exclusive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 60-80 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
89281422|NCT04337710|Active Comparator|Progressive Enteral Nutrition|This group will receive enteral feeding volumes at a rate of 20-30 ml/kg/day starting within the first 24 hours after birth. Volumes will increase by 20-30 ml/kg/day until intake is 150ml/kg/day.
89281423|NCT04317274|Experimental|High Cholesterol Good Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see good video first and poor video second.
89281424|NCT04317274|Experimental|Colorectal Cancer Good Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see good video first and poor video second.
89281425|NCT04317274|Experimental|High Cholesterol Poor Video First|Participants see videos of a conversation around taking medications (statins) for high cholesterol. Patients see poor video first and good video second.
89281426|NCT04317274|Experimental|Colorectal Cancer Poor Video First|Participants see videos of a conversation around screening for colorectal cancer. Patients see poor video first and good video second.
89281427|NCT04296409||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Deglutition Handicap Index, and Turkish version of the Eating Assessment Tool.
89281428|NCT04291612||Part 1|Participants will have endometrioid adenocarcinoma histological diagnosis with planned surgical treatment including hysterectomy in combination with SLN biopsy.
89281429|NCT04291612||Part 2|Participants will have undergone surgery and bilateral sentinel lymph node mapping (negative for malignancy)
89281430|NCT04270019|Experimental|Experimental|This group will receive polyethylene glycol (50% weight/volume) applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
89281431|NCT04270019|Placebo Comparator|Control|This group will receive normal saline applied to the nerve coaptation site during primary repair of peripheral nerve injury in the hand.
89281432|NCT04257773|Experimental|Immediate Treatment|Participants in this group will receive treatment/intervention immediately.
89281433|NCT04257773|Experimental|Delayed Treatment|Participant in this group will receive treatment/intervention 2-week later.
89281434|NCT04249843|Experimental|Phase 1a: Dose Escalation|BGB-3245 administered orally (PO)
89281435|NCT04249843|Experimental|Phase 1b, Group 1: Dose Expansion|BGB-3245 administered orally (PO)
89281436|NCT04247958||Robotic-assisted colorectal resection|Subjects with either a suspected or confirmed benign or malignant disease of the colon and rectum who are scheduled to undergo a robotic-assisted resection of the colon or rectum.
89281437|NCT04245176|Experimental|Quantitative Genetic Counseling|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:~-- Quantitative genetic counseling: Discussion is guided by tables and graphs."
89281438|NCT04245176|Active Comparator|STANDARD GENETIC COUNSELING|"The research study procedures include screening for eligibility and study interventions including evaluations and follow up visits - After receiving genetic testing, participants will be placed into one of two counseling methodology groups:~-- Standard genetic counseling: Standard of care discussion"
89281439|NCT04239703||Kidney transplant biopsies for cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care.
89281440|NCT04224987|Active Comparator|Azithro 1-11|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-11 months old and oral placebo or no intervention to children 12-59 months old
89281441|NCT04224987|Active Comparator|Azithro 1-59|Biannual age, weight- or height-based dose of oral azithromycin suspension to children 1-59 months old
89281442|NCT04224987|Placebo Comparator|Placebo|Biannual weight- or height-based dose of oral placebo to children 1-59 months old
89281443|NCT04219202|Active Comparator|Proton Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Proton Treatment
89281444|NCT04219202|Experimental|Carbon Ion Treatment|Patient receive 39 Gy (in 13 fractions (SD 3,0 Gy) Carbon Ion Treatment
89281445|NCT04218019|Experimental|Early Tumor Treating Fields (TTFields, Optune®) treatment|TTF will be started together with hypofractionated radiotherapy (+/- 5 days) with or without Temozolomide (according to the standard and local physician's decision). Chemoradiotherapy with temozolomide and hypofractionated radiotherapy is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator.
89281446|NCT04218019|Active Comparator|Late TTF treatment|Patients will be treated with hypofractionated radiotherapy with or without temozolomide (according to the local standard and physician's decision). Radiotherapy and treatment with temozolomide is regarded as standard therapy and not part of the intervention. In case of chemoradiotherapy temozolomide will be applied according to the standard of the participating trial center. Use of antiemetic and infection prophylaxis will be at the discretion of the investigator. Late TTFields treatment will start 4 weeks after the end of radiotherapy.
89281447|NCT04214119||Control|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and does not have a diagnosis of Barrett's esophagus or esophageal/gastric malignancy.
89281448|NCT04214119||Barrett's esophagus|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and diagnosed with Barrett's esophagus via pathology.
89281449|NCT04214119||Esophageal carcinoma|Patients age 18 or greater who have diagnosis of primary esophageal carcinoma.
89281450|NCT04214119||Gastric cancer|Patients age 18 or greater who have diagnosis of primary esophageal cancer.
89281451|NCT04213469|Experimental|PD1-CD19-CART|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CART infusion. A dose of PD1-CD19-CART will be infused on day 0.
89281452|NCT04211480|Experimental|γ-globin reactivated autologous hematopoietic stem cells|each subject will accept one dose of γ-globin reactivated autologous hematopoietic stem cells
89281453|NCT04205630|Experimental|SYD985|SYD985, Intravenous, every 3 weeks (Q3W)
89281454|NCT04199104|Experimental|Pembrolizumab with Lenvatinib|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
89281455|NCT04199104|Active Comparator|Pembrolizumab with Placebo|Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months).
89281456|NCT04197492|Experimental|HSRT With Anlotinib|"Hypofractionated stereotactic radiotherapy using CyberKnife 25Gy/5fx, 5 days a week for 1 week.~Anlotinib once daily (12mg/d) orally administered on days 1-14 of a 21-day cycle until disease progression or treatment intolerance."
89281457|NCT04194268|Experimental|Interventional arm|Carbon Ion Radiation 12 x 4 Gy (RBE) within 2 weeks
89281458|NCT04188678|Other|Interventional Arm- Bone Marrow Transplant|"Study visits will include the performance of assessments prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. Assessments include:~Physical function assessments~questionnaires about general health and current health compared to health one year ago~assessments that measure cognition, attention and memory~assessments regarding personality and psychological and social stressors~Physiological measures including~blood tests- 160 mL of blood during evaluations, and 90mL of blood at the day 180 visit.~bone marrow aspirate collected during standard of care bone marrow biopsies pre-transplant and at day 180~Saliva collections pre-transplant~ACTH Stimulation Test~Oral Glucose Tolerance Test~Holter Monitor- to record hear rate variability~MRI pre-transplant and at Day 180 in a subset of 10 subjects"
89281459|NCT04185974|Experimental|C12 irradiation|Evaluation of Safety and Toxicity of C12 ion reirradiation
89281460|NCT04185974|Active Comparator|Photon irradiation|Evaluation of Safety and Toxicity of photon re-irradiation
89281461|NCT04171089|Experimental|Child-Safety Plan Intervention|A Child Safety Plan to prevent suicidal behavior will be developed with the children and their parents. The parents and child will complete feasibility and acceptability questionnaires.
89281462|NCT04165772|Experimental|Cohort 1|Patients with clinical Stage II or Stage III MRI-staged, MSI-H or dMMR, solid tumors will receive up to 6 months (9, 21-day cycles) of PD-1 blockade followed by radiological and surgical restaging of the tumor. If subject exhibits complete clinical response, non-operative management will be followed. If a complete clinical response is not reached after 6 months of PD-1 blockade, the participant will proceed with standard chemoradiation. After completing chemoradiation participant will be assessed for response if complete CR is not obtained then the participant will proceed with disease specific surgical resection or standard of care therapy.
89281463|NCT04165772|Other|Cohort 2|The plan is to enroll six patients with MSI, regardless of their primary cancer diagnosis. This cohort will serve to generate hypothesis and initial data to plan a larger study. All analyses from this cohort will be exploratory
89281464|NCT04140708|Experimental|Exercise--Rock Steady Boxing class|Participants will be going twice a week to a Rock Steady Boxing class for an hour/class. Participants will be going to this class for a total of three months.
89281465|NCT04107831|Experimental|Pulmonary rehabilitation|Participants who are participating in a 6-week pulmonary rehabilitation program are enrolled in the study.
89281466|NCT04094454|Experimental|Tampon with extended vaginal dilatation|Patients in arm A will use a special tampon with extended vaginal dilatation during radiotherapy
89281467|NCT04094454|Active Comparator|Commercially available tampon|Patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
89281468|NCT04084431|Active Comparator|WBRT (10 x 2 Gy) + OSC|Whole brain radiotherapy will be applied with a total dose of 20 Gy in 10 fractions (single dose of 2 Gy). OSC as needed.
89281469|NCT04084431|Experimental|Optimal Supportive Care (OSC) alone|Symptomatic treatment including steroids, pain medication, nutritional support, etc
89281470|NCT04084366|Experimental|OBI-999 Escalation phase|Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).
89281471|NCT04084366|Experimental|OBI-999 Expansion Phase|Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.
89281472|NCT04083937|Active Comparator|70.0/ 2.0 Gray (RBE)|Normofractionated radiotherapy with photons (70.0/ 2.0 Gray)
89281473|NCT04083937|Experimental|57.0/ 3.0 Gray (RBE)|Hypofractionated radiotherapy with photons (57.0/ 3.0 Gray)
89281474|NCT04083937|Experimental|57.0/ 3.0 (RBE)|Hypofractionated radiotherapy with protons (57.0/ 3.0 Gray relative biological effectiveness [RBE]).
89290238|NCT03635008|Experimental|Anodal tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA."
89281475|NCT04060303|Active Comparator|ENRICH-US Implementation- early|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
89281476|NCT04060303|Active Comparator|ENRICH-US Implementation- mid|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
89281477|NCT04060303|Active Comparator|ENRICH-US Implementation- late|"Baseline, pre-intervention data will be collected. This phase consists primarily of individual-level patient (ages 10-18 years undergoing elective GI surgery) data collection. This phase involves abstraction of existing electronic health records data by the Site Coordinator about current, standard perioperative care received by patients. Patients and parents will complete web-based HRQoL assessments preoperatively, and 5 days and 4-6 weeks post-operatively. Site-specific barriers and facilitators to implementation will be assessed by semi-structured, telephone interviews, conducted by each Site's PI and Coordinator.~Intervention phase will span 12 months with an implementation curriculum. Sites will be randomized to this implementation phase based on stepped-wedge cluster assignment. A sustainability phase will collect post intervention data."
89281478|NCT04053062|Experimental|LIGHT-PSMA-CART|Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -6 to -4. Patients receive LIGH-PSMA-CART IV at split doses from day 0 on.
89281479|NCT04007055|Experimental|Experimental: screening/treating for HPR|Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
89281480|NCT04007055|No Intervention|Control: guideline based therapy|Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.
89281481|NCT03995173|Active Comparator|active|active rTMS
89281482|NCT03995173|Placebo Comparator|placebo|placebo rTMS
89281483|NCT03974503|Experimental|Exposure, Relaxation, and Rescripting Therapy (ERRT)|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately one hour per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, sleep behavior modification, Progressive Muscle Relaxation, diaphragmatic breathing, exposure to the trauma-nightmare, rescription, and treatment maintenance planning.
89281484|NCT03974503|Active Comparator|Sleep and Nightmare Management|This treatment protocol has amounts of therapist contact, handouts, and homework between sessions equivalent to those in ERRT. The protocol contains psychoeducation about sleep disturbances and trauma-related nightmares, including their distressing nature, chronicity, and impact on sleep and daytime functioning. Additionally, basic sleep behavior modification are presented. No nightmare content or rescripting will be explicitly discussed, and the diaphragmatic breathing techniques will be omitted from this protocol.
89281485|NCT03954236|Experimental|topical ruxolitinib BID to left side of face/body|And topical moisturizer BID to right side of face/body.
89281486|NCT03954236|Experimental|topical ruxolitinib BID to right side of face/body|And topical moisturizer BID to left side of face/body.
89281487|NCT03949127|Experimental|Exercise Group|The group who will exercise to manage pain.
89281488|NCT03949127|No Intervention|Control Group|The group who will not take part in any exercises and only have to do assessments.
89281489|NCT03933826||Patients who have selected radical cystectomy|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected radical cystectomy as their second-line treatment
89281490|NCT03933826||Patients who have selected medical management|Patients with a diagnosis of recurrent high-grade NMIBC that failed first-line BCG and who have selected medical management as their second-line treatment
89281491|NCT03917238|Other|Patients with T1D|gallium-68-exendin followed by a PET/CT scan (twice)
89281492|NCT03915769|Experimental|0.46 mg ozanimod oral capsule once daily (QD)|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.46 mg ozanimod.
89281493|NCT03915769|Experimental|0.92 mg ozanimod oral capsule QD|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.92 mg ozanimod.
89281494|NCT03915769|Placebo Comparator|Placebo oral capsule QD|It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with a placebo capsule, followed by 3 days of treatment with two placebo capsules, followed by two placebo capsules.
89281495|NCT03913949|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
89281496|NCT03910972|Experimental|Part A, Group A (Sm-TSP-2/Alhydrogel 10 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
89281497|NCT03910972|Experimental|Part A, Group B (Sm-TSP-2/Alhydrogel 10 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 10 mcg dose
89281498|NCT03910972|Experimental|Part A, Group C (Sm-TSP-2/Alhydrogel 30 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
89281499|NCT03910972|Experimental|Part A, Group D (Sm-TSP-2/Alhydrogel 30 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 30 mcg dose
89281500|NCT03910972|Experimental|Part A, Group E (Sm-TSP-2/Alhydrogel 100 mcg)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
89281501|NCT03910972|Experimental|Part A, Group F (Sm-TSP-2/Alhydrogel 100 mcg + AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine plus AP 10-701, delivered by IM injection on study days 0, 56, and 12; 100 mcg dose
89281502|NCT03910972|Active Comparator|Part A, Group G (HBV)|Hepatitis B Vaccine
89281503|NCT03910972|Experimental|Part B, Group H (Sm-TSP-2/Alhydrogel +/- AP 10-701)|Sm-TSP-2/Alhydrogel Schistosomiasis Vaccine, with or without AP 10-701, dose and formulation determined in Part A
89281504|NCT03910972|Active Comparator|Part B, Group I (HBV)|Hepatitis B Vaccine
89281505|NCT03910166|Experimental|DCB group|use DEB catheter(trade name:Orchid/Dhalia) to treat the stenosis or occlusion in Vertebral Artery Ostium Stenosis of experimental arm
89281506|NCT03910166|Active Comparator|BMS group|use Intracranial artery stent system(trade name:Apollo) to treat stenosis or occlusion in Vertebral Artery Ostium Stenosis of control group
89281507|NCT03907566||Adult patients with swallowing disorders|Swallowing function will be evaluated with the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals, and Turkish version of the Eating Assessment Tool.
89281508|NCT03906708||Premature Infants|Premature infants born between 24+0 and 36+6 weeks of gestation.
89281509|NCT03891732||MRI pathway|Plain biparametric MRI prostate applied to men with elevated PSA, on top of standard screening pathway using PSA and Prostate Health Index
89281510|NCT03891732||Standard screening pathway|Intervention: Using blood tests PSA and Prostate Health Index to screen men at risk of prostate cancer
89281511|NCT03875911|Active Comparator|Preoperative Subconjunctival injection of MMC|Subconjunctival injection of 0.1 ml of Mitomycin-C 0.002% at the site of future trabeculectomy surgery (2 - 4 weeks preoperatively).
89281512|NCT03875911|Active Comparator|Intraoperative subconjunctival injection of MMC|Intraoperative subjconjunctival injection of 0.1 mL of Mitomycin-C 0.01% (0.1mg/mL) to the site of trabeculectomy
89281513|NCT03875911|Active Comparator|Intraoperative topical application of MMC|Topical application of Mitomycin-C intraoperatively by applying a sponge soaked in 1mL of Mitomycin-C 0.02 mg/mL for 1 minute to the site of trabeculectomy
89281514|NCT03854019|Experimental|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), then Placebo|Dextromethorphan/quinidine (DM/Q) 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
89281515|NCT03854019|Placebo Comparator|Placebo, then Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|Placebo one capsule once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
89281516|NCT03838419|Active Comparator|BCS + WBI|breast conserving surgery followed by whole breast irradiation
89281517|NCT03838419|Experimental|BCS + IORT|Breast conserving surgery incl intraoperative radiotherapy
89281518|NCT03836053|Experimental|AMG 420|Single Arm Design
89281519|NCT03804788|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for six (6) weeks.
89281520|NCT03804788|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants.
89281521|NCT03803904|Experimental|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
89281522|NCT03803904|Active Comparator|Control|Participants in the control group will be equalized (frequency and duration) to the Spin group for contact and monitoring. As such they will report to the same facility and interact with the same experienced interventionist; however instead of progressive Spin exercise they will participate in sessions focused on balance and stretching. Similar to the aerobic intervention, these exercises will take place in a group setting and heart rate will be consistently monitored during each session to verify heart rate does not reach 50% HRR.
89281523|NCT03728673|Experimental|Escitalopram|This is an open-label study. Escitalopram will be administered to all participants as 10 mg capsules to be taken by mouth daily for 90 days.
89281526|NCT03711058|Experimental|Phase I - Copanlisib and Nivolumab (De-Escalation)|
89281527|NCT03711058|Experimental|Phase II /Arm A-P13K mutation/Copanlisib and Nivolumab|
89281528|NCT03711058|Experimental|Phase II/Arm B -P13K wild type /Copanlisib and Nivolumab|
89281529|NCT03704480|Experimental|Amended ARM A|"One cycle equals 4 weeks (D1=D28);~Durvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.~Tremelimumab: 300 mg by IV infusion on D1 at cycle 1 only."
89281530|NCT03700203||Early cardiac arrest patients|Cases will be consecutive adult patients with EMS-treated OHCA and transport to the 14 emergency departments of participating hospitals. A prospective OHCA patient cohort will be developed and all survived OHCA cases will be followed at 1-month and 6-month after ED discharge by telephone. During the study period, the investigators aim to recruit a total 1,780 cases (200 cases between September 2017 and August 2018, 600 cases between September 2018 and August 2020, 80 cases between September 2020 and December 2020, and 900 cases between January 2021 and December 2023).
89281531|NCT03700203||Matched community-based controls|Matched community-based controls (2:1 matching) will be selected from two health screening centers. Controls are those who visit the participating health screening centers for their annual routine physical examinations. During the study period, the investigators aim to recruit a total 3,560 controls (400 controls between September 2017 and August 2018, 1200 controls between September 2018 and August 2020, 160 controls between September 2020 and December 2020, and 1800 controls between January 2021 and December 2023).
89281532|NCT03697876|Experimental|PRO-165|Dose: one drop of gel, 4 times a day during the waking period, in the bottom of the right eye sac
89281533|NCT03697876|Active Comparator|1. Artelac® Nightime Gel|Dose: one drop of gel, 4 times a day during the waking period, in the bottom of the right eye sac
89281534|NCT03695315||OSA with hypoxia|People with obstructive sleep apnea and hypoxia before and after treatment with continuous positive airway pressure
89281535|NCT03695315||OSA without hypoxia|People with obstructive sleep apnea and without hypoxia before and after treatment with continuous positive airway pressure
89281536|NCT03678545|Active Comparator|Dupilumab|
89281537|NCT03678545|Placebo Comparator|Placebo|
89281538|NCT03670069|Experimental|Treatment (itacitinib)|Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89281539|NCT03656549|Experimental|Impaired renal function|patients will be treated with pemetrexed, with dosing based on renal function.
89281540|NCT03651752|Other|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
89281541|NCT03647137||Parkinson's disease without FoG|Subjects with Parkinson's disease that do not have freezing of gait observed during motor assessment while both on or off dopaminergic medication who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
89281542|NCT03647137||Parkinson's disease with FoG only while off-meds|Subjects with Parkinson's disease that have freezing of gait observed during motor assessment only while off dopaminergic medication who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
89281543|NCT03647137||Parkinson's disease with FoG worse while off-meds|Subjects with Parkinson's disease that have freezing of gait observed during motor assessment while both on and off dopaminergic medication, but greater severity of FoG under off-med, who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
89281544|NCT03647137||Parkinson's disease with FoG equivalent between on and off meds|Subjects with Parkinson's disease that have freezing of gait observed during motor assessment while both on and off dopaminergic medication, with no apparent effect of dopaminergic medication on FoG, who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid).
89281545|NCT03623113|Experimental|BCC intervention|The BCC program consists of three group sessions and is delivered by two trained dietitians. In addition to the BCC program, the participants receive regular medical care in the diabetes clinic
89281546|NCT03623113|Experimental|ABC-ACC intervention|The ABC-ACC program consists of one group session and two individual follow-up sessions and is delivered by trained dietitians with supervision by a medical doctor. In addition to the ABC-ACC program, the participants receive regular medical care in the diabetes clinic
89281547|NCT03623113|Active Comparator|Standard dietary education|The routine outpatient dietary care consists of three individual consultations delivered by a trained dietitian. The individual guidance is based on the overall treatment goal(s), the defined personal dietary goals for behavioral change which will be in accordance with the patient's needs and preferences. In addition to the dietary counselling, the participants receive regular medical care in the diabetes clinic
89281548|NCT03615326|Experimental|Pembrolizumab +Trastuzumab + Chemotherapy|Participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
89281549|NCT03615326|Active Comparator|Placebo +Trastuzumab + Chemotherapy|Participants receive matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
89281550|NCT03599635|Experimental|liposomal bupivacaine|These patients will receive liposomal bupivacaine for a pectoralis block infiltration by the anesthesiologist.
89281551|NCT03599635|Active Comparator|bupivacaine|These patients will receive incisional bupivacaine infiltration by the surgeon.
89281552|NCT03540420|Experimental|Atezolizumab|atezolizumab after completed chemo-radiotherapy and non-progression
89281553|NCT03540420|No Intervention|Observation|standard care after completed chemo-radiotherapy and non-progression
89281554|NCT03527485|Other|Opiate Use Disorder (OUD)|30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
89281555|NCT03527485|Other|Cocaine Use Disorder (CUD)|30 subjects meeting cocaine dependence criteria 11UCB-J PET Scan.
89281556|NCT03527485|Other|Healthy Controls (HC)|30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.
89281557|NCT03519464|Other|ICL and Healthy Volunteers|Biological/Vaccine
89290239|NCT03635008|Placebo Comparator|sham tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the sham tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be started but the intensity will decrease and stop in 30 seconds."
89290240|NCT01126164|Experimental|parent handbook|parent handbook
89281558|NCT03500731|Experimental|Lung and Bone Marrow Transplantation|"All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.~Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.~Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved."
89281559|NCT03498638|Experimental|Couples Therapy|Couples Therapy
89281560|NCT03498638|Placebo Comparator|Control|Couples Therapy after an 8 week waiting period
89281561|NCT03465644|Experimental|Tailored arm|early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone) strategy
89281562|NCT03465644|Active Comparator|Conventional arm|clopidogrel + aspirin for 12months
89281563|NCT03454893|Experimental|Single Assignment AVR-RD-01|AVR-RD-01 is an autologous CD34+-enriched cell fraction transduced with LV/AGA containing an RNA transcript that, after reverse transcription, results in codon-optimized cDNA that, upon its integration into the human genome, encodes for functional human AGA.
89281564|NCT03408613|Experimental|Positive Airway Pressure (PAP)|A registered polysomnographic technologist will perform a titration starting at 4 cm water (H2O) and adjust this value as needed to identify the optimal pressure to achieve an Apnea Hypopnea Index (AHI) <5 (including rapid eye movement sleep in the supine position). After PAP titration, subjects will be instructed to use the machine at the optimal pressure every night for 3 months. Compliance will be defined as: ≥4 hours use on 70% of nights and average use ≥6 hours per night.
89281565|NCT03408613|Experimental|Supplemental Oxygen (O2)|Subjects randomized to night-time supplemental oxygen will complete an overnight oxygen titration protocol in the clinical research unit. Initially, subjects will receive 0.5 liters oxygen (O2)/min; the delivery rate will then be increased by 0.5 l/min until oxygen saturation (SaO2) is ≥88%. The optimal O2 delivery rate determined during this study will be used for the intervention. The oxygen concentrators used at home will record cumulative hours of use to provide an objective measure of adherence (monitored weekly). Compliance will be defined as ≥6 h average use per night..
89281566|NCT03408613|Sham Comparator|Sham|Subjects in the sham treatment group will complete the oxygen titration protocol described for the night-time supplemental oxygen group, except that their oxygen concentrator will have been covertly modified to deliver room air at a rate of 0.5 l/min.
89281567|NCT03408613|No Intervention|Controls|Subjects without OSA will be recruited and complete all testing for primary outcome measures, but will not undergo any intervention.
89281568|NCT03406351||Asthma|
89281569|NCT03406351||Healthy|Matched controls
89281570|NCT03404193|Experimental|Treatment (decitabine, venetoclax)|Participants receive decitabine IV over 1 hour on days 1-10 and may also receive decitabine on days 1-5 after achieving complete remission/complete remission with incomplete count recovery during consolidation/maintenance. Participants also receive venetoclax PO daily on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles. Treatment repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89281571|NCT03381183|Experimental|Phase 1 - Dose Escalation|Six patients will be enrolled at Dose Level 1 with IRX-2 230 units/day in combination with cyclophosphamide and durvalumab and treated sequentially at least 1 week apart. If less than 2 out of 6 patients have DLTs in Dose Level 1, the dose will be escalated to administration of IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab as Dose Level 2. If 2 of 6 patients have DLTs, stop accrual and re-evaluate. In the next safety phase, six patients at IRX-2 460 Units/day in combination with cyclophosphamide and durvalumab will be enrolled and treated sequentially (at least 1 week apart). If DLT occurs in less than 2 of 6 patients during the first 6 weeks of treatment, enrollment can continue in the dose expansion phase at Dose Level 2. If DLT is observed in 2 of 6 patients, accrual will be stopped and Dose Level 1 will resume in the dose expansion phase.
89281572|NCT03381183|Experimental|Phase 2 - Dose Expansion|14 patients will be enrolled at the recommended dose level from the dose finding phase for a total enrollment of 20 patients; however, investigators will replace patients with any missing tumor sample collection and continue enrollment until there are at least 20 pre- and post-treatment paired tumors (i.e. minimum 2 of 3 tumors per patient). The 6 patients treated at the recommended dose in the dose finding phase of the study will be counted as a part of the dose expansion patient population,
89281573|NCT03379792||Type 1 Diabetes: BMI Classified as Lean|Participants with type 1 diabetes with a BMI between 18.0-24.9 kg/m^2.
89281574|NCT03379792||Type 1 Diabetes: BMI Classified as Overweight|Participants with type 1 diabetes with a BMI between 25.0-29.9 kg/m^2.
89281575|NCT03379792||Type 1 Diabetes: BMI Classified as Obese|Participants with type 1 diabetes with a BMI between 30.0-39.9 kg/m^2.
89281576|NCT03379792||Control: BMI Classified as Lean|Control participants without diabetes with a BMI between 18.0-24.9 kg/m^2.
89281577|NCT03379792||Control: BMI Classified as Overweight|Control participants without diabetes with a BMI between 25.0-29.9 kg/m^2.
89281578|NCT03379792||Control: BMI Classified as Obese|Control participants without diabetes with a BMI between 30.0-39.9 kg/m^2.
89281579|NCT03371407||Parkinsonian patient under dopaminergic medication|
89281580|NCT03371407||Parkinsonian patient without dopaminergic medication|
89281581|NCT03371407||Control participants|
89281582|NCT03370133|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 52 weeks.
89281583|NCT03370133|Active Comparator|Ustekinumab cohort|Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
89281584|NCT03370133|Placebo Comparator|Placebo|Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
89290241|NCT01126164|Experimental|peer basics|peer delivered basics
89290242|NCT01126164|Experimental|parent handbook and peer basics|parent handbook and peer basics
89281585|NCT03304717|Experimental|TDF/FTC then Placebo|This is a double-blind, placebo-controlled, 2 arm, cross-over trial involving 34 children with clinical findings and molecular confirmation of Aicardi Goutieres Syndrome, who also have an abnormal interferon signature. For arm 1, half of the patients will receive TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for the first 6 months of the study. There will be a one month washout period before starting on placebo for 6 months.
89281586|NCT03304717|Experimental|Placebo then TDF/FTC|For arm 2, half of the patients will receive placebo for the first 6 months of the study. There will be a one month washout period before starting on TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for 6 months.
89281587|NCT03297788|Experimental|Arm A: SRS|Patient receive stereotactic radiosurgery (SRS), dose prescription according to the size of radiated brain metastases
89281588|NCT03297788|Active Comparator|Arm B: WBRT|Patients receive whole brain radiotherapy (WBRT)
89281589|NCT03242161|Experimental|LabPatch-alcohol|All subjects will be administered alcohol and then monitored by a non-invasive alcohol sensor
89281590|NCT03240614|Active Comparator|BMI <30 no lung disease|Patients with a BMI <30 with no lung disease
89281591|NCT03240614|Active Comparator|BMI <30 with lung disease|Patients with a BMI <30 with lung disease
89281592|NCT03240614|Active Comparator|BMI 30-35 with no lung disease|Patients with a BMI between 30 and 35 with no lung disease
89281593|NCT03240614|Active Comparator|BMI 30-35 with lung disease|Patients with a BMI between 30 and 35 with lung disease
89281594|NCT03240614|Active Comparator|BMI >35 with no lung disease|Patients with a BMI> 35 with no lung disease
89281595|NCT03240614|Active Comparator|BMI >35 with lung disease|Patients with a BMI> 35 with lung disease
89281596|NCT03227991|Active Comparator|Safety Planning Intervention|SPI is a personalized approach that focuses on early identification of warning signs and execution of systematic steps to manage suicidal thoughts, created collaboratively by the patient and clinician.
89281597|NCT03227991|Active Comparator|Risk factors and Warning signs|Patients will receive a generic suicide risk factors and warning signs information handout.
89281598|NCT03227757|Experimental|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm.
89281599|NCT03221517|Experimental|Cohort 1|Shift workers receive a standardized meal with a glucose challenge test
89281600|NCT03221517|Experimental|Cohort 2|Matched healthy controls receive a standardized meal with a glucose challenge test
89281601|NCT03182296|Experimental|Gestational diabetes|Women with a history of gestational diabetes
89281602|NCT03182296|Active Comparator|Control|Women without a history of gestational diabetes
89281603|NCT03157674||HNC patients|"HNC patients who have been diagnosed with HNC between~01-Jan-2013 and 30-Sep-2016."
89281604|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Escalation|Dose escalation and determination
89281605|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Determination|Additional enrollment into previously cleared monotherapy dose levels
89281606|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Expansion|Dose expansion
89281607|NCT03149549|Experimental|CX-2009 Monotherapy: 14-Day Dosing Regimen-Expansion|Dose escalation and determination in selected tumor types
89281610|NCT03058796|Active Comparator|CCFES Therapy|CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.
89281611|NCT03058796|Experimental|CCFES Video Game Therapy|CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.
89281612|NCT02994121||People with Multiple Sclerosis or Related Disorders|Individuals must be 7 years or older, diagnosed with multiple sclerosis or related disorders, including a first central nervous system demyelinating episode with a positive MRI scan or abnormal MRI scans characteristic of MS but no clinical symptoms of the disease
89281613|NCT02994121||People without Multiple Sclerosis or Related Disorders|Control participants must be 7 years or older, have no known personal history of multiple sclerosis or related disorders, no other chronic disease, and can be a family member, unrelated household control, or control from the general population.
89281614|NCT02984735||Evaluation of children with spastic CP|Children with a diagnosis of spastic CP aged 2 to 12 years who were referred due to chewing/swallowing problems by pediatric neurologists were included. The inclusion criteria were above the age of 24 months, and had complaints about chewing function. Children under the age of 24 months, requiring tube feeding or taking any oral nutritional supplements, and used any medicine and/or oral appliances that could affect the chewing performance, were excluded.
89281615|NCT02931695|Other|pregnant women|"Women during third trimester of pregnancy and in the first trimester of post partum~ECG~circulating sex hormones levels"
89281616|NCT02931695|Other|women in the first trimester of post partum|"Women (same in first arm) in the first trimester of post partum~ECG~circulating sex hormones levels"
89281617|NCT02918435|No Intervention|Usual Care-Control|Participants in the usual care group will receive standard pediatric care.
89290243|NCT01361230|Experimental|Protocol|Using sedation monitoring and protocol
89290244|NCT01361230|No Intervention|Control|Standard practice
89281618|NCT02918435|Experimental|On-site WE CARE implementation arm|"WE CARE will be implemented in the study site using a facilitated on-site strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via an on-site team which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room."
89281619|NCT02918435|Experimental|Self-directed web-based WE CARE implementation arm|WE CARE will be implemented in the study site using a web-based implementation strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via web-based tools (e.g., web-based seminar) which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room
89281620|NCT02914899|Active Comparator|Pilot RCT Control Group|Eligible NYC Chinese livery drivers will receive written materials only
89281621|NCT02914899|Experimental|Pilot RCT CHW Intervention Group|Eligible NYC Chinese livery drivers will receive written materials and navigation for shared decision making (SDM) and lung cancer screening (LCS).
89281622|NCT02914899|Experimental|Focus Group|The investigators conducted a series of 4-6 focus groups with Chinese livery drivers who (currently, or in the past) smoke.
89281623|NCT02914899|Experimental|In-Depth Interview Group|12-15 in-depth interviews with livery base management and staff, and with 12-15 primary care physicians (PCPs), clinic directors, hospital CFOs, heads of financial services and counseling, and heads of radiology facilities serving the Chinese community.
89281624|NCT02914899|Experimental|Pre-pilot Group|Approximately 10 Chinese livery drivers who smoke or who quit smoking with the past 15 years and have a 30 pack-year history of smoking
89281625|NCT02909127||Cerebral palsied children|The inclusion criteria are age above 18 months, fed orally, referred due to parent complaints about their child's swallowing function and not admitted a swallowing center before. Swallowing evaluation will be performed. The Functional Independence Measure and PEDI-EAT-10 will be filled.
89281626|NCT02909127||Healthy children|Healthy children above the age of 18 months with no medical history of voice, swallowing, reflux, airway, neurologic, rheumatologic, or neoplastic disorders will be included for normative data generation. The PEDI-EAT-10 will be filled.
89281627|NCT02883530||Biomarker optimised patients|Optimised biomarker/Th2 low n=40
89281628|NCT02883530||non -optimised/Th2 low patients|Patients identified in clinic with FeNO <30 ppb. Those who at screening demonstrate FeNO <30 ppb and blood eosinophil count ≤0.20 x109/L will be considered to be non-optimised biomarker-low patients (Th2-low) and will proceed to bronchoscopy n=80
89281629|NCT02883530||corticosteroid-resistant biomarker|Patients identified in clinic with FeNO >45 ppb who have failed to suppress their FeNO during FeNO suppression testing. These patients are considered adherent to inhaled corticosteroids. Those who at screening also demonstrate blood eosinophils of >0.3x109/L n=40
89281630|NCT02879617|Experimental|durvalumab|1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.
89281631|NCT02874365|Experimental|Crohn disorder|arm composed by 30 patients with Crohn disorder
89281632|NCT02874365|Experimental|FAP (familial adenomatous polyposis )|arm composed by 30 patients with FAP disorder
89281633|NCT02874365|Experimental|ulcerative colitis|arm composed by 30 patients with ulcerative colitis
89281634|NCT02874365|Sham Comparator|witness|arm composed by 30 patients with no intestinal disorders
89281635|NCT02836067|Other|Smokers|"HIV-positive smokers will be enrolled in a smoking cessation program including the following procedures:~Counseling Smoking cessation drugs Questionnaires Blood Draw Bronchoscopy"
89281636|NCT02836067|Other|Non-Smokers|"HIV-positive non-smokers will be enrolled as a comparison group to HIV-positive smokers and will have the following procedures:~Questionnaires Blood Draw Bronchoscopy"
89281637|NCT02831335||Group 1|normal 21-35 years old participants
89281638|NCT02831335||Group 2|normal 36-50 years old participants
89281639|NCT02831335||Group 3|normal 51-65 years old participants
89281640|NCT02831335||Group 4|normal 66- 80 years old participants
89281641|NCT02823262|Experimental|Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~The Decision Aid Group (workbook and CD) explains each treatment including its benefits and risks.~-- The DA asks women 10 questions about their health;the response to each question is associated with a point value and women are asked to tally their points. The DA groups women into 4 health categories based on their health score.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
89281642|NCT02823262|Active Comparator|No Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~Participant will receive Usual Care assistance when making treatment decisions.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
89281643|NCT02785120|Experimental|High dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
89281644|NCT02785120|Experimental|Middle dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
89281645|NCT02785120|Experimental|Low dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
89281646|NCT02780492||Ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
89281647|NCT02780492||Non-ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
89281648|NCT02780492||Healthy volunteers and Disease controls|A set of assessment tools (upper limb function tests, MRI, blood analyses) will be performed
89281649|NCT02777281|Other|Shoulder pain and SCI|Manual wheelchair users with SCI
89281650|NCT02777281|Other|Shoulder pain and able bodies|No SCI or wheelchair use but presence of shoulder pain
89281651|NCT02773498|Active Comparator|conventional TESE|Conventional multiple TESE is performed under general or locoregional anesthesia. Through a small vertical incision in the median scrotal raphe, the skin, dartos muscle, and tunica vaginalis are opened to expose the tunica albuginea. The tunica albuginea is ordinarily incised for about 4 mm at the medium region of the testis. A similar biopsy will be systematically performed in the contralateral testis. The biopsy is analyzed by the biologist in the theatre in order to precise if sufficient spermatozoa is retrieved.
89281652|NCT02773498|Experimental|micro TESE|Microdissection TESE is also performed under general or locoregional anesthesia. After the tunica albuginea is opened widely along the antiepididymal border, direct examination of the testicular parenchyma is performed under the operating microscope. An attempt is made to identify individual seminiferous tubules that are larger, more opaque and whiter than other tubules in the testicular parenchyma, which are considered to contain spermatozoa. The extracted tubules are analyzed by the biologist in the theatre. The procedure is terminated when sperm are retrieved or further biopsy is thought likely to jeopardize the blood supply of the testis. If all tubules are seen to have an identical morphological appearance, at least three samples (upper, middle, and lower) are obtained. A similar microTESE will be systematically performed in the contralateral testis
89281653|NCT02764138|Experimental|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.~These children also complete pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments."
89281654|NCT02764138|No Intervention|Comparison|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments. No intervention.
89281655|NCT02749552|Experimental|Acceptance and Commitment Therapy|ACT intervention
89281656|NCT02734602|No Intervention|Single PET scan|Subjects will participate in 1 PET scan (up to 2 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan.
89281657|NCT02734602|Active Comparator|PET scans and ketamine administration|"Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.~Bipolar subjects will not participate in any ketamine arms."
89281658|NCT02734602|No Intervention|PET scans for subjects undergoing ketamine treatment|"For subjects currently undergoing treatment with ketamine. Subjects will participate in 1-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. Baseline scan will occur prior to initiation of ketamine treatment. Subsequent scans will occur after several treatments with ketamine and after completion of treatment.~Bipolar subjects will not participate in any ketamine arms."
89281659|NCT02710435||Arm 1 - Prospective|"Includes eligible subjects in the prospective arm who undergo baseline testing followed by the Reducer System implant procedure~Arm 1 has been closed to enrollment-March 2023"
89281660|NCT02710435||Arm 2 - COSIRA|Includes subjects who were previously enrolled and treated with the Reducer System during the COSIRA study and agree to participate in this long term follow up study
89281661|NCT02710435||Arm 3 - CE Mark|"Includes subjects who received a Reducer System under CE Mark (unrelated to the COSIRA study), and agree to participate in this long term follow up study~Arm 3 has been closed to enrollment-June 2017"
89281662|NCT02706561|Experimental|Standard care plus the ACT intervention (ACT-ED)|SC + ACT-ED-Group A uses Acceptance and Commitment Therapy (ACT). In this group, men focus on: long-term goals of rehabilitation; acceptance of the frustration related to ED; identifying and overcoming barriers; and committing to an erectile rehabilitation program. All participants will be asked to complete a set of questionnaires (baseline). The participants can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. You will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes)
89281663|NCT02706561|Experimental|SC plus nurse Enhanced Monitoring and Education (EME)|SC + EME-Group B uses enhanced monitoring and education. This group focuses on answering questions about the rehabilitation program, manage technical issues related to injections, and the dose titration of injection medication. Participants in this group will also receive education on the side effects and impact of prostate cancer surgery, and strategies for restarting sexual activity. All participants will be asked to complete a set of questionnaires (baseline). You can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. The participant will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes).
89281664|NCT02681328||Afirma GEC|single molecular test GEC of collected tissue
89281665|NCT02681328||ThyroSeq v.2|single molecular test ThyroSeq v.2 of collected tissue
89281666|NCT02681328||Afirma GSC|single molecular test GSC of collected tissue
89281667|NCT02681328||ThyroSeq v.3|single molecular test ThyroSeq v.3 of collected tissue
89281668|NCT02627092|Experimental|Copper linen exposure|"Subjects will use copper linens during their hospital stay, consisting of copper hospital gowns, copper bed sheets (top and bottom sheets), and copper pillow covers.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
89281669|NCT02627092|No Intervention|Non-copper linen exposure|"Subjects will not have exposure to copper linens during their hospital stay. They will use the usual hospital linens provided by hospital, not containing copper.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
89281670|NCT02566668||Asthmatic|1 year observational follow-up
89281671|NCT02566668||Non-Asthmatic|1 year observational follow-up
89281672|NCT02555280|Other|The coflex® Interlaminar Technology|The coflex device was designed to address the clinical needs of spinal stenosis patients by providing stabilization of the affected level without fusion. The coflex is an interspinous process functional dynamic implant designed to impart a stabilizing effect at the treated level(s). The coflex device was approved by FDA in 2012.
89281673|NCT02555280|Active Comparator|Decompression|Lumbar decompression back surgery is when a small portion of the bone over the nerve root and/or disc material from under the nerve root is removed to give the nerve root more space and provide a better healing environment.
89281674|NCT02425592||Men on Active Surveillance|This study will include men between age 30-80 with Gleason 6 prostate cancer, prostate specific antigen (PSA) <20, clinical stage <cT3, and a life expectancy of at least ten years. To be eligible, men must have undergone an MRI-USG fusion prostate biopsy for an elevated PSA or abnormal prostate examination that demonstrates Gleason 6 prostate cancer. If a man is already on active surveillance, the MRI-USG fusion biopsy may be negative or confirm Gleason 6 prostate cancer. Eligible men will be approached at their post fusion-biopsy visit to discuss the biopsy results and offered enrollment in the trial.
89281675|NCT02316340|Experimental|Study Arm - VOR with HCQ|Patients will be given vorinostat 400 mg daily and hydroxychloroquine 600 mg daily in 4 week cycles.
89281676|NCT02316340|Active Comparator|Control Arm - Regorafenib|Patients will be given oral RGF 160 mg daily for 3 weeks in 4 week cycles.
89281677|NCT02260505|Experimental|Imatinib maintenance|Maintenance of Imatinib at the last dose routinely taken by the patient in the 3 years period prior to randomization (either 300 or 400 mg/day). Increase dose up to 800 mg/day if relapse according to RECIST 1.1 criteria. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib Specific Product Characteristics (SPC).
89281678|NCT02260505|No Intervention|Imatinib Interruption|Treatment corresponding to standard practice : interruption of Imatinib from the day of randomization. Reintroduction of Imatinib at 400 mg/day after first relapse according to RECIST 1.1 criteria; Then increase dose to 800 mg/day after 2d relapse. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib SPC.
89281679|NCT02207114|No Intervention|Observational|9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.
89281680|NCT02207114|Experimental|Biomarker Algorithm Intervention|"The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics.~The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs."
89281681|NCT02143401|Experimental|Treatment (navitoclax, sorafenib tosylate)|Patients receive navitoclax PO QD on days 1-21 (days 1-28 cycle of 1 only) and sorafenib tosylate PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89281682|NCT02063724|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
89281683|NCT01976715||HIV-1|Subjects (greater than or equal to 18 years) with human immunodeficiency virus type 1 (HIV-1) who have documented virologic failure.
89281684|NCT01972919|Experimental|Radiation therapy plus chemotherapy|MR guided dose escalated radiation therapy plus concurrent chemotherapy in unresectable non-metastatic pancreas cancer. Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction and concurrent Gemcitabine or Capecitabine.
89281685|NCT01969188||SpA in RA|Patients with SpA with psoriatic arthritis (PsA), ankylosing spondylitis (AS), no biologic therapy for 3 months, over 18 yrs old.
89281686|NCT01782599|Experimental|Dual nicotine patch and electronic cigarette|Nicotine patch and the electronic cigarette will be administered.
89281687|NCT01758328|Experimental|Pts with Mutiple myeloma|Patients will undergo a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor. Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. The administration of WT1-specific cytotoxic T cells (WT1 CTLs) post transplantation is integrated to induce complete remissions in patients with residual disease and to decrease the rate of relapse following the allogeneic transplant.
89281688|NCT01746849|Experimental|palifermin with Lupron|All patients undergo total body irradiation (TBI) on days -9 to -6 & receive thiotepa intravenously (IV) over 2-4 hours on days -5 to -4, cyclophosphamide IV over 30-60 minutes on days -3 to -2, & anti-thymocyte globulin infused over 12 hours on days -3 to -2 Pts undergo T-cell depleted allogeneic hematopoietic stem cell transplant on day 0. Pts will receive a three month depot dose of Lupron 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Pts will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 & no more than 48 hours prior to the start of cytoreduction. Pts will receive three additional daily doses of palifermin the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 & d+2. Pts will receive a further 3-month depot injection of Lupron approximately 3 months (+/- one week) post the first dose.
89281689|NCT01746849|Experimental|palifermin with Degarelix|Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.
89281690|NCT01722266|Placebo Comparator|Placebo|Daily Injection
89281691|NCT01722266|Active Comparator|Liraglutide 1.8mg|Daily Injection
89281692|NCT01722266|Active Comparator|Liraglutide 1.2mg|Daily injections
89281693|NCT01722266|Active Comparator|Liraglutide 0.6 mg|Daily injection
89281694|NCT01468896|Experimental|Treatment (cetuximab and recombinant interleukin-12)|Patients receive cetuximab IV over 1-2 hours on day 1 and recombinant interleukin-12 SC on days 2 and 5 beginning in course 2. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving clinical response or stable disease may continue with therapy until disease progression.
89281695|NCT01425866|Experimental|2 years self management education|Long-term program including initial self-management education program (1 to 7 sessions, based on individual assessment), and follow-up group sessions maintained for 2 years (4-monthly assessment, empowerment, and contextual action planning; facultative additional specific thematic sessions being delivered if needed).
89281696|NCT01425866|Active Comparator|Initial self-management education|Initial self-management group education: 1 to 7 sessions (< 3 months), based on individual assessment.
89281697|NCT01261728|Experimental|Gemcitabine and Cisplatin|This is a Phase II Study of Gemcitabine and Cisplatin (GC) as neoadjuvant chemotherapy in patients with upper tract high-grade urothelial carcinoma who are candidates for radical nephroureterectomy or distal ureterectomy.
89281698|NCT01166321|Experimental|Carbon Ion Radiotherapy Boost|Carbon Ion Boost to the Macroscopic Tumor visible on contrast-enhanced MR-Imaging
89281699|NCT00953771|Experimental|Danazol, Plex, Steroids|Everyone will receive Danazol with plasma exchange and corticosteroids
89281700|NCT00953771|No Intervention|Historic Control|
89281701|NCT00711490|Experimental|Sirolimus|The study eye was treated with sirolimus.
89281702|NCT00673816|Experimental|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
89281703|NCT00589654||1|
89281704|NCT00582257||High Genetic Risk:|"Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.~Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.~Relative - Relatives of participants eligible for the High Genetic Risk Cohort will be eligible for participation. These relatives may also be at high risk of developing gastric cancer. These individuals will fall under the Cancer Cohort. Eligible relatives will be defined as someone having a relative who meets criteria for either the Early Onset Cancer Cohort or the Familial Gastric Cancer Cohort, or having a family history of a genetic mutation known to be associated with gastric cancer."
89281705|NCT00582257||Low Genetic Risk: Closed to Accrual|"Sporadic Gastric Cancer - gastric cancer that appears to have occurred by random or sporadic mutation. Specifically, a patient with gastric cancer not eligible for either High Genetic Risk cohort.~Control (closed to accrual) - A participant that is not a blood relative of a patient or relative participant, without gastric cancer and without a family history of a CDH1 gene mutation. Select MSK participants with Hereditary Diffuse Gastric Cancer with identified CDH1 germline genetic mutation will be invited by MSKCC only to complete the onetime Pre-implantation Genetic Diagnosis (HDGC PGD) survey. These patients may be verbally consented over the telephone."
89281706|NCT00582231||1|Participants that are starting penile injections therapy.
89281707|NCT00533117|Experimental|Dialectical Behavior Therapy Fluoxetine|Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy (CBT) targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period,and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
89281708|NCT00533117|Placebo Comparator|Dialectical Behavior Therapy placebo|Dialectal behavior therapy and placebo Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period, and placebo for fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
89281709|NCT00533117|Experimental|Supportive therapy Fluoxetine|Supportive psychotherapy and fluoxetine Supportive therapy is a manualized psychotherapy aimed at strengthening coping skills and is delivered over a 12 month period, and fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
89281710|NCT00533117|Active Comparator|Supportive therapy placebo|Supportive psychotherapy and placebo See above for descriptions.
89281711|NCT00033137||Family Members|A relative of a patient with a confirmed or suspected diagnosis of BHD (related by blood)
89281712|NCT00033137||Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis(Spouses have been removed from the inclusion criteria for this study. This closed cohort has been created for spouses previously enrolled on study.)
89281713|NCT00033137||Patients|Patients with phenotype or genotype suggestive of Birt Hogg Dub(SqrRoot)(Copyright) and/or Renal tumor histology consistent with BHD
89290245|NCT03009838|Active Comparator|letrozole|letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day
89281714|NCT00026312|Active Comparator|Arm I (isotretinoin) (closed to accrual as of 4/16/2009)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive isotretinoin PO BID for 14 days. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients may cross over to Arm II provided they have not experienced disease progression and have not received any further anti-neuroblastoma therapy following completion of isotretinoin therapy.
89281715|NCT00026312|Experimental|Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive immunotherapy comprising sargramostim SC or IV over 2 hours on days 0-13 during courses 1, 3, and 5 and dinutuximab IV over 10-20 hours on days 3-6 of courses 1-5. Patients also receive aldesleukin IV continuously on days 0-3 and 7-10 during courses 2 and 4. Immunotherapy repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity. Patients also receive isotretinoin as in Arm I beginning on day 11 of immunotherapy.
89281716|NCT00005917||Chediak-Higashi Syndrome|Confirmed or suspected patients with Chediak-Higashi Syndrome.
89281717|NCT01587794||retinal detachment group|Patients who were diagnosed with unilateral rhegmatogenous retinal detachment involving only the superior or inferior half of the retina and who underwent successful scleral buckling procedure or vitrectomy by a single surgeon between January 1, 2008 and April 1, 2010 were included in the study sample.
89281718|NCT03280264|Experimental|KHK7580|oral administration
89281719|NCT01094418||IGT group|IGT diagnosed by endocrinologist
89281720|NCT01094418||DM group|DM diagnosed by endocrinologist and whose primary NCS screening shows SNAP amplitudes of sural and superficial peroneal nerves greater than 10mA DM patients with no previous diagnosis of peripheral polyneuropathy
89281721|NCT01094418||Normal healthy participants|Normal health participants with no previous history of DM, IGT, thyroid disorder, hypercholesterolemia, or other condition associated with peripheral polyneuropathy
89281722|NCT01291238|Experimental|Healthy lifestyle habits|Increased physical activity and healthy food with decreased sugar and fat content
89281723|NCT01089348|Experimental|Lactofiltrum|
89281724|NCT01089348|Active Comparator|Control|
89281725|NCT01291316|Experimental|clobazam|
89281726|NCT01291316|Active Comparator|clonazepam|
89281727|NCT01291316|Placebo Comparator|tolterodine|
89281728|NCT01587872|Experimental|DBC|Double balloon colonoscopy will be attempted in cases where conventional colonoscopy failed due to technical difficulties such as looping or redundant colonic segments.
89281729|NCT01093248||Heroin-addicted Patients|Heroin-addicted outpatient department (OPD) patients who seek help for methadone maintenance treatment
89281730|NCT01287728|Experimental|treatment BY METROMIDAZOLE|
89281731|NCT03855176|Active Comparator|1-dose group|Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
89281732|NCT03855176|Experimental|2-dose group|Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
89281733|NCT00060840|Active Comparator|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO) at 40 parts per million (ppm)
89281734|NCT00060840|Placebo Comparator|Nitrogen|Nitrogen (N2) administered at 40 ppm.
89281735|NCT03854864||Oncologists|French oncologists
89281736|NCT01185860|Active Comparator|A|
89281737|NCT01185860|Experimental|B|
89281738|NCT01185860|Placebo Comparator|C|
89281739|NCT01089426|Other|Historical controls|A subset of patients previously seen, who have had at least 2 consecutive direct bilirubin levels > 2 mg/dL, who depended on parenteral nutrition for at least 90 days after surgical therapy for congenital or acquired intestinal diseases
89281740|NCT01089426|Experimental|Omegaven™|
89281741|NCT01290302|Experimental|Luitpold Azacitidine|
89281742|NCT01290302|Active Comparator|Vidaza®|
89281743|NCT01089660|Experimental|Study Group 1|Swine-origin A/H1N1 Vaccine Low-dose
89281744|NCT01089660|Experimental|Study Group 2|Swine-origin A/H1N1 Vaccine High-dose
89281745|NCT03861104|Active Comparator|group watched video|"patients will watch the medical video before filling out the spielberger state anxiety inventory at the time of nasal packing removal.~intervention is watching informative video."
89281746|NCT03861104|No Intervention|group without video|patients will fill out the spielberger state anxiety inventory without watching the video at the time of nasal packing removal
89281747|NCT03280108|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
89281748|NCT03280108|Active Comparator|Monofocal IOL|AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
89281749|NCT01093404|Experimental|Thrombus aspiration|Thrombus aspiration is then followed by standard balloon angioplasty (PCI).
89281750|NCT01093404|Active Comparator|Standard balloon angioplasty (PCI)|
89281751|NCT01182662|Experimental|Human umbilical cord-derived MSCs and cyclosporin|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle and CsA 5mg/kg po for 12 months
89281752|NCT01182662|Active Comparator|cyclosporine A|cyclosporine A at a dose of 5 mg CsA/kg
89281753|NCT01291082||Breast cancer patients|Breast cancer patients
89281754|NCT01185938|Active Comparator|Rosuvastatin|
89281755|NCT01185938|No Intervention|Control|
89281756|NCT03855098|Other|Fruit and Vegetable biomarkers|Each participant will consume the test foods over different weeks
89281757|NCT00059202|Placebo Comparator|Placebo|Placebo tablet that is identical (size, color, etc) to experimental ursodeoxycholic acid tablet.
89281758|NCT00059202|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid 28-30 mg/kg/day
89281759|NCT01177358|Experimental|Botulinum Toxin A injection|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 Units (0.1 mL) of Botulinum Toxin A will be injected at three sites along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy."
89281760|NCT01177358|Placebo Comparator|Saline|0.1 mL of normal saline in a placebo vial containing 2 mL of normal saline will be injected along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy.
89281761|NCT03854942|Other|First Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET followed by 7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
89281762|NCT03854942|Other|Second Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET - 7 days naltrexone intake (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) - injection of physiological saline solution (0,9%) - PET
89281763|NCT03854942|Other|Third Arm|7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET - 7 days naltrexone (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
89281764|NCT03854786|Active Comparator|Oxyjun|Oxyjun- 400 mg OD after breakfast
89281765|NCT03854786|Placebo Comparator|Methyl Crystalline Cellulose|Methyl Crystalline Cellulose- 400 mg OD after breakfast
89281766|NCT03956472|Experimental|Osteopathic group|LCS Drainage before altitude exposure
89281767|NCT03956472|Experimental|PEEP 10 cmH2O|10 min at rest
89281768|NCT03956472|Sham Comparator|Control group|Sham PEEP and fake osteopathic protocol
89281769|NCT03278626|Other|Nivolimumab+Carboplatin/paclitaxel+Radiation|240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks and radiation
89281770|NCT01182740||glidescope|
89281771|NCT01182740||storz c-mac|
89281772|NCT01182740||mcgrath vl|
89281773|NCT01182740||ambu pentax aws|
89281774|NCT01182740||macintosh laryngoscope|
89281775|NCT01182740||others|
89281776|NCT01327092|No Intervention|Literacy Group|Families in the Literacy Group (control group)will receive a program which seeks to promote literacy by providing developmentally appropriate books and other reading-related materials to children and encouraging mothers to develop an interest in reading with their child. After enrollment and randomization, CHIP staff will visit these control group homes, assess the mother's interest in and barriers to reading with her child, council mothers about the importance of literacy and reading books to their child, and children will be given age appropriate books and other materials to promote literacy.
89281777|NCT01327092|Experimental|Injury Intervention Group|Injury Intervention Group: In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq ft) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1 meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years
89281778|NCT03856736|Experimental|MIAT|Composite of the execution of moderated-intensity aerobic training (MIAT) twice week.
89281779|NCT03856736|Experimental|Control|Consisting of two session per week of different activities, such as body relaxation, low-intesity/volume of aerobic exercise to mimic sham group.
89281780|NCT01177436|Experimental|Patients treated for prostatic pathology|Patients treated for prostatic pathology (benign or malign)in the hospital department.
89281781|NCT03277846|Experimental|Accept ECT - TES|Accept ECT where subject is randomized to TES
89281782|NCT03277846|Placebo Comparator|Accept ECT - SHAM|Accept ECT where subject is randomized to a SHAM condition
89281783|NCT03277846|Experimental|Reject ECT - TES|Reject ECT where subject is randomized to TES
89281784|NCT03277846|Placebo Comparator|Reject ECT - SHAM|Reject ECT where subject is randomized to SHAM
89281785|NCT01186094|Active Comparator|Cypher|Sirolimus-eluting stent
89281786|NCT01186094|Active Comparator|Endeavor Resolute|Zotarolimus-eluting Stent
89281787|NCT04902976|Active Comparator|CPC+Zn|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride associated with 0.28% zinc lactate solution.
89281788|NCT04902976|Active Comparator|CPC|patients submitted to mouth rinse with 0.075% Cetylpyridinium Chloride solution.
89281789|NCT04902976|Placebo Comparator|Negative Control|patients submitted to mouth rinse with distilled water.
89281790|NCT01182818||Observation|all adult patients (18 - 60 years of age) with an acute cerebrovascular event of any etiology
89281791|NCT05571436|Experimental|Intervention group|iCan Diabetes Self-Management and Prevention Program
89281792|NCT01287806|Sham Comparator|blank control group|
89281793|NCT01287806|Experimental|ulinastatin group|ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine
89281794|NCT01186172|Experimental|Ethanol-lock|Treatment with a combination of ethanol-lock and parenteral therapy
89281795|NCT01186172|Active Comparator|Antibiotic lock|Treatment with a combination of antibiotic-lock and parenteral therapy
89281796|NCT03861182|Other|Adult Healthy Volunteers|
89281797|NCT03861182|Other|Neonates|
89281798|NCT03860948|Experimental|Savolitinib Test Preparation|The subjects in this arm will receive Test preparation (T). T is dry granulation savolitinib tablets.
89281799|NCT03860948|Experimental|Savolitinib Reference Preparation|The subjects in this arm will receive Reference preparation(R). R is wet granulation savolitinib tablets.
89281800|NCT03854708|Experimental|3 pmol/kg*min pancreatic polypeptide|3 pmol/kg*min of pancreatic polypeptide was intravenously infused.
89281801|NCT03854708|Experimental|10 pmol/kg*min pancreatic polypeptide|10 pmol/kg*min of pancreatic polypeptide was intravenously infused.
89281802|NCT03854708|Placebo Comparator|Placebo|0.9 % saline solution was intravenously infused.
89281803|NCT03861260|Other|Rigid Cystoscopy and Urethral dilatation|Rigid cystoscopy, performed under General Anaesthetic, followed by intervention of urethral dilatation with Hagar dilators.
89281804|NCT03861260|Other|Flexible cystoscopy and Glycosaminoglycan Layer replacement|Flexible cystoscopy, under Local Anaesthetic, followed by the intervention, which is 6 installations of Ialuril (a Glycosaminoglycan Layer replacement)
89281805|NCT03860870|Experimental|Clenbuterol|Subjects ingest 80 micrograms of clenbuterol tablets
89281806|NCT03860870|Placebo Comparator|Placebo|Subjects ingest placebo tablets
89281807|NCT01177514|Experimental|GABAPENTIN|Group of patients treated with oral gabapentin
89281808|NCT01177514|Placebo Comparator|PLACEBO|Group given the placebo capsules
89281809|NCT00073008|Other|lapatinib|Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.
89281810|NCT01186484|Experimental|001|JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
89281811|NCT01182974|Active Comparator|paracetamol treatment|
89281812|NCT01182974|Active Comparator|control- dypirone treatment|
89281813|NCT03856502|Experimental|group that received dexamethasone (DLSA)|The study group of 30 patients ASA status 2 or 3 received 8 mg of dexamethasone with 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
89281814|NCT03856502|Active Comparator|group without dexamethasone (LSA)|The control group of 30 patients ASA status 2 or 3 received 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
89281815|NCT03960684|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System
89281816|NCT01094652|Experimental|Whole grain diet|Participants in this group will be given whole grain snacks on school days and food packages consisting of whole grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
89281817|NCT01094652|Active Comparator|Refined grain diet|Participants in this group will be given refined grain snacks on school days and food packages consisting of refined grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
89281818|NCT01287884|No Intervention|Venous Blood Gas|All subjects have an ABG and VBG drawn. No intervention.
89281819|NCT03741192|Experimental|Treatment Group|SPEAC System
89281820|NCT03741192|No Intervention|Standard of Care|
89281821|NCT03856346||Phaco-vitrectomy|
89281822|NCT01583478|Active Comparator|incobotulinumtoxinA 20 units|Three patients will be randomly assigned to receive 20 units total of incobotulinumtoxinA to the glabellar region.
89281823|NCT01583478|Active Comparator|incobotulinumtoxinA 40 units|Three patients will be randomly assigned to receive 40 units total of incobotulinumtoxinA to the glabellar region.
89281824|NCT01583478|Active Comparator|incobotulinumtoxinA 60 units|Three patients will be randomly assigned to receive 60 units total of incobotulinumtoxinA to the glabellar region.
89281825|NCT01583478|Active Comparator|incobotulinumtoxinA 80 units|Three patients will be randomly assigned to receive 80 units total of incobotulinumtoxinA to the glabellar region.
89281826|NCT01583478|Active Comparator|incobotulinumtoxinA 100 units|Three patients will be randomly assigned to receive 100 units total of incobotulinumtoxinA to the glabellar region.
89281827|NCT01183052|Other|Training|20 sessions of training
89281828|NCT01327014|Placebo Comparator|Placebo group|
89281829|NCT01327014|Experimental|1,200 mg/day of XZK group|
89281830|NCT01327014|Experimental|2,400 mg/day of XZK group|
89281831|NCT03854630|Active Comparator|Standard dose (20µg)|Three doses of 20µg HBV vaccine given intramuscularly at week 0, 4, 24.
89281832|NCT03854630|Experimental|Double dose (40µg)|Three doses of 40µg HBV vaccine given intramuscularly at week 0, 4, 24.
89281833|NCT01093560|Experimental|young women with MetS|"Saturated fat (control)~n-3 Polyunsaturated fat (experimental)~monounsaturated fat"
89281834|NCT01177592|Experimental|Guided Therapy|Subjects on chronic clopidogrel therapy (≥ 5 days maintenance or loading within 4 hours of PCI) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing
89281835|NCT01177592|No Intervention|Standard Therapy|Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study.
89281836|NCT03955848|Experimental|ARM 1|NK cell infusion
89281837|NCT03955848|No Intervention|ARM 2|Follow up without treatment
89281838|NCT01089738|Experimental|Dosing|Ascending Doses
89281839|NCT03854396|Active Comparator|Intravaginal prasterone insert|Nightly intravaginal prasterone insert for 24 weeks
89281840|NCT03854396|Placebo Comparator|Intravaginal placebo insert (Witepsol H-15)|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks
89281841|NCT03956160|Experimental|Intervention group|"For 12 months from the return home, patients in the intervention group will benefit from telephone support by a trained case-manager (number and frequency of contacts defined according to the patient's needs) and access to an Internet platform.~The intervention aims to improve the patient's ability to manage his or her situation and meet his or her needs upon return home, including identifying and requesting the necessary health or social resources."
89281842|NCT03956160|No Intervention|Control group|"Patients randomized to the control group will receive the usual practices. As part of the study, they will be contacted for data collection upon their return home, at 6 months and 12 months by a clinical research associate.~Access to the internet platform and an interview with the case-manager will be offered at the end of the study to patients in the control group."
89281843|NCT01183130|Experimental|Compliance monitoring in real time|Patients get their opioid substitution medications in electronic compliance monitoring devices and send information of their medication intakes with mobile phone to the clinic every day during the two month study period.
89281844|NCT01183130|Active Comparator|Compliance monitoring|Patients get their opioid substitution medications in electronic compliance monitoring devices. Information of their medication intakes will be reviewed during the weekly visits to the clinic.
89281845|NCT01093638|Experimental|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with premature infant formula
89281846|NCT01093638|Placebo Comparator|Oral Formulation of Placebo|Oral formulation of placebo fed concomitantly with premature infant formula
89281847|NCT03856034|Experimental|Fetoscopic repair|
89281848|NCT01183208|Experimental|Cohort 1 active treatment and placebo|Active treatment and placebo
89281849|NCT01183208|Experimental|Cohort 2 - Active treatment and placebo|Active treatment and placebo
89281850|NCT01183208|Experimental|Cohort 3 Active Treatment and placebo|Active treatment and placebo
89281851|NCT01287962|Experimental|Apatinib|750 mg，po，QD； 28 days every cycle
89281852|NCT01287962|Placebo Comparator|Placebo|
89281853|NCT03855956|Experimental|KB174 Arm|KB174 is a novel mixture of oligosaccharides.
89281854|NCT03855956|Other|Maltodextrin Arm|Maltodextrin is a commercially available easily digestible polysaccharide.
89281855|NCT00058422|Experimental|R-CHOP and Ibritumomab Tiuxetan (Zevalin)|"Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.~Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
89281856|NCT01183286|Active Comparator|CFFONE|
89281857|NCT01183286|Placebo Comparator|CF website|
89281858|NCT03854240|Active Comparator|Classic block (Group C)|In group C, classic technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and multifidus muscles. Between these muscles, block needle will be inserted within in plane technique in a lateral-to-medial direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
89281859|NCT03854240|Active Comparator|Modified block (Group M)|In group M, modified technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
89281860|NCT03956628|Experimental|experimental group|participants in experimental group receive intervention and experimental group consists of two sub groups, teachers and students.
89281861|NCT03956628|No Intervention|control group|participants in control group does not receive intervention and control group consists of two sub groups, teachers and students.
89281862|NCT01186718||Control Group|Control group = functional symmetric cervical motion.
89281863|NCT01186718||Experimental subject group|Experimental subject group = asymmetric cervical motion
89281864|NCT01089816||All|Anyone presenting with influenza-like-illness
89281865|NCT01288040|Experimental|Treadmill exercise|Split-belt treadmill training
89281866|NCT02530866|Active Comparator|Standard care|Women in this arm will target fasting blood glucose values <95 mg/dL and 1 hour post-prandial values <140 mg/dL
89281867|NCT02530866|Experimental|Intensive therapy|Women in the arm will target fasting blood glucose values <90 mg/dL and 1 hour post-prandial values <120 mg/dL.
89281868|NCT01186952|No Intervention|Optimized usual care|participants will attend one visit with the dietician (30mn) and the physical activity specialist (30mn) when they will be given Canadian guidelines pamphlets for physical activity and food consumption. They will also receive a phone call once a month to discuss about issues in guidelines following.
89281869|NCT01186952|Active Comparator|Diet intervention alone|Participants will attend one visit with the physical activity specialist (30mn) when they will receive the physical activity guidelines. Monthly phone call will be make to discuss about issues in physical activity guidelines following.These individuals will also be enrolled in a supervised caloric restriction program. They will have to visit the dietician once a week for the first months and then twice a month for 3 months. The diet intervention will focus on a low fat diet. At each session participants will be weighed and taken the blood pressure.
89281870|NCT01186952|Active Comparator|diet intervention and exercise program|"Participants will attend diet intervention as described for group 2. They will also follow a supervised exercise program three days per week for 4 months. The exercise training is an interval high intensity aerobic (85-90% heart rate reserve) program with resistance exercises (15RM, 2-3 repetitions). Each session will last one hour. At the end of month 1, 2, and 3, all participants will receive the SWA armband for 7 days to record physical activity and estimate energy expenditure.~At the end of Month 4, all participants will attend a study visit for repeat baseline testing."
89281871|NCT01089894||18F-FLT 1|18F-FLT in differentiating benign from malignant pulmonary nodules
89281872|NCT01089894||18F-FLT 2|18F-FLT in evaluating therapeutic response of platinum-based chemotherapy (The chemotherapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
89281873|NCT01089894||18F-FLT 3|18F-FLT in evaluating therapeutic response of EGFR tyrosin kinase inhibitors (The target therapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
89281874|NCT01291472|Other|ketorolac|Ketorolac will be given to all patients as a part of routine medical care
89281875|NCT03960528|Active Comparator|Under direct vision erector spinae plane block|"20 ml bupivacaine 0,25%+ lidocaine 1% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
89281876|NCT03960528|Sham Comparator|Control group|"20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.~Participants will receive morphine iv PCA in the postanesthesia care unit( 0.5mg / ml 2cc bolus 8 min lock time 2cc/h infusion)"
89281877|NCT03854162|Active Comparator|FREEHAND|For these cases, the regular protocol of the study site is observed. The operator has the plan at their disposal projected on a screen in the operating theater. The preparation of the bony bed and the insertion of the implant are performed freehand, without any guidance. The positions and directions are determined with the naked eye, observing the plan projected on the screen. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
89281878|NCT03854162|Active Comparator|PILOT|The SMART Guide surgical template is applied only in the initial phase of the operation. After having prepared soft tissue access, the template is placed, and only one drilling is performed through its sleeve, with the so-called pilot drill. The resulting borehole serves as directional guidance for the drills applied later in the process. Further drilling and implant insertion are both performed freehand. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
89281879|NCT03854162|Active Comparator|PARTIAL GUIDE|The only non-guided step is implant insertion, that is, all drilling happens through the SMART Guide surgical template. After having prepared soft tissue access, the guide is placed, and all drillings are performed through it, according to the surgical protocol. Here the depth of the bony bed is also determined, as the sleeve does not allow the drill to move any deeper than planned. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
89281880|NCT03854162|Active Comparator|FULL GUIDE|"The SMART Guide surgical template is used for all steps of the operation, including the insertion of the implant. Apart from this, the procedure is exactly the same as described under partial guide."
89281881|NCT02530632|Active Comparator|Sevoflurane anesthesia|Anesthesia maintained with inhalational sevoflurane
89281882|NCT02530632|Experimental|Propofol anesthesia|Anesthesia maintained with intravenous propofol continuous infusion
89281883|NCT01183364|Experimental|STA-9090 and Docetaxel|STA-9090 (ganetespib) and Docetaxel
89281884|NCT00072384|Experimental|Treatment (chemotherapy, surgery)|Patients receive liposomal vincristine sulfate IV over 1 minute on day 1 and carboplatin IV over 1 hour and etoposide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 3 and continuing until blood counts recover. Patients receive subtenon carboplatin to each group C or D eye on day 0 or 1prior of courses 2-4 only. Treatment repeats every 28 days for 6 courses in the absence of occurrence of extraocular retinoblastoma or a second malignancy. Beginning with course 3 of systemic chemotherapy, patients undergo local ophthalmic therapy comprising local laser surgery and/or cryosurgery on day 1.
89281885|NCT01183442|Active Comparator|vitamin D (Oleovit®)|vitamin D drops
89281886|NCT01183442|Placebo Comparator|Placebo|placebo drops
89281887|NCT02525120|Experimental|Triojection System for ozone injection|Triojection is a system including a single-use sterile syringe cartridge and an accessory console. The console is interfaced to a supply of medical oxygen and uses this supply to fill the syringe with oxygen. Ozone is produced by applying a high voltage to electrodes physically located within the syringe. When a concentration of 35µg/ml is reached, the cartridge is removed from the console. The sterile syringe, containing the gas, is extracted from the protective housing and the gas is administered directly to the center of the herniated disc through a spinal needle.
89281888|NCT02525120|Active Comparator|Surgical discectomy|The surgical group will be receive a standard surgical discectomy to remove the herniated disc material.
89281889|NCT01183598|Experimental|Single Arm|
89281890|NCT01095042|Experimental|Control group|30 Asymptomatic Healthy Volunteers Intervention : Observation of emotional behavior in asymptomatic healthy volunteers subjected to stress.
89281891|NCT01095042|Experimental|Experimental group|"Persons reached by digestive pathologies (SII or IBD). Group SII : 30 patients Group IBD: 60 patients (30 patients RCH and 30 patients CD)~Intervention : Observation of emotional behavior in person affected by digestive pathologies subjected to stress."
89281892|NCT01187108|Placebo Comparator|Placebo pills|
89281893|NCT01187108|Active Comparator|Acetazolamide alone|
89281894|NCT01187108|Active Comparator|N-acetylcysteine alone|
89281895|NCT01187108|Active Comparator|Combination of N-acetylcysteine and acetazolamide|
89281896|NCT01187888|Active Comparator|Rasagiline|
89281897|NCT01187888|Placebo Comparator|Sugar pill|
89281898|NCT01187186|Experimental|Moderate Hepatic Impairment|Subjects with Moderate Hepatic Impairment
89281899|NCT01187186|Experimental|Normal Hepatic Function|Subjects with Normal Hepatic Function
89281900|NCT00054132|Experimental|Treatment (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89281901|NCT01291550||Nerodegenerative diseases|Patients with parkinsonism and patients with dementia
89281902|NCT01291550||Controls|
89281903|NCT01291550||ADHD|Subjects diagnosed with ADHD
89281904|NCT01093716|Experimental|rTMS|Compare the change in craving parameters following high frequency rTMS stimulation of right and left DLPFC in patients with alcohol dependence
89281905|NCT01588340|Active Comparator|MRI|The patient will have a rapid noncontrast MRI (magnetic resonance imaging) that will take approximately 15 minutes to complete.
89281906|NCT01588340|Active Comparator|Ultrasound exam|A noncontrast ultrasound examination
89281907|NCT03853850|Experimental|Intervention|Participating mothers will receive mobile phone text messages during their babies' first 6 months of life. Messages will educate mothers on breastfeeding and proper infant feeding.
89281908|NCT01187264|Active Comparator|methotrexate 10 mg|oral methotrexate 10 mg once weekly
89281909|NCT01187264|Active Comparator|methotrexate 25mg|oral methotrexate 25 mg once weekly
89281910|NCT03854084|Experimental|Intervention group|The cranial osteopathic techniques
89281911|NCT03854084|Sham Comparator|control group|Control group
89281912|NCT01183676|Experimental|Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Mylan Pharmaceuticals Inc
89281913|NCT01183676|Active Comparator|Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
89281914|NCT03856112|Experimental|Arm I (ixazomib, venetoclax, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, venetoclax PO QD on days 1-28 and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89281915|NCT03856112|Active Comparator|Arm II (ixazomib, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89281916|NCT03856112|Experimental|Arm III (ixazomib, venetoclax, dexamethasone)|PI-refractory patients receive ixazomib citrate, venetoclax and dexamethasone as Arm I.
89281917|NCT01183754||patients receiving drug-eluting stents|
89281918|NCT01290380|Experimental|ASA 404 + standard chemotherapy|ASA 404 in combination with in combination with standard chemotherapy (paclitaxel + carboplatin or docetaxel) and a cocktail of caffeine, diclofenac, simvastatin and omeprazole
89281919|NCT01183832||Concomitant|In this group, anastrazole is concomitant to the radiotherapy
89281920|NCT01183832||Sequential|In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)
89281921|NCT03854006|Active Comparator|Freeze cycle: 240 s - TTI <75 s or 2x240 s - >75 s|"In the first group freeze duration is 240s if TTI (time-to-isolation) is < 75 s. In case of TTI>75s a 240s bonus freeze is applied.~If no TTI could be documented, a single 240 s freeze cycle is applied in this group in case of balloon temperature -40°C (degrees Celsius) after 60 s."
89281922|NCT03854006|Active Comparator|Freeze cycle: TTI+120 s|In the second group freeze duration is TTI (time-to-isolation) +120 s. If no TTI could be documented, a single 180 s freeze cycle is applied in this group in case of balloon temperature -40 °C after 60 s.
89281923|NCT03853928|Experimental|Probiotics|50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .
89281924|NCT03853928|Placebo Comparator|Placebo|5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly). Duration of treatment Continuous, 1 cycle per month. Continuous treatment will be carried out from randomization to the development of the primary event or until the end of the study.
89281925|NCT01187420||EEG and Cerebral Vasospasm|Cerebral Vasospasm and role of BIS vista monitor in Subarachnoid Hemorrhage (SAH) patients
89281926|NCT05167682||Prehabilitation|25 patients scheduled for tumor-esophagectomy (Ivor-Lewis) who are capable and have given consent to participate in a smartphone-based prehabilitation program.
89281927|NCT05167682||Historical Cohort|Patients ≥ 65 years of age who have undergone tumor-related esophagectomy at the University Hospital of Cologne between 05/2016 and 04/2020, who have not participated in any form of prehabilitation procedures
89281928|NCT01187576|Experimental|Intervention|Multi-professional team intervention with PAR, lifestyle brochure
89281929|NCT01187576|Active Comparator|Conventional treatment|Ordinary recommendations on health behaviours, lifestyle brochure
89281930|NCT01187576|No Intervention|retrospective med history comparison|Treatment as usual (retrospective data collection)
89281931|NCT01188044||Study group|Healthy children
89281932|NCT01183910|Placebo Comparator|Calcium carbonate placebo pill|Placebo medication to treat the appearance of the skin in patients with senile purpura
89281933|NCT01183910|Active Comparator|Nutraceutical|Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura
89281934|NCT01588574|Active Comparator|BOTOX (registered trade mark)|
89281935|NCT01588574|Experimental|MT10109|
89281936|NCT03852914|Experimental|Experimental: Sodium Hyaluronate 2%|Each patient will receive a single injection of SH2%
89281937|NCT01184066|Experimental|ACTS Intervention|The intervention arm are the women who received the ACTS Intervention. It is a 45 minute intervention provided by a breast cancer survivor. The intervention includes a discussion of the patient's attitudes towards chemotherapy, communication strategies with providers, the recommended treatment in accordance with tumor size and tumor characteristics
89281938|NCT01184066|Active Comparator|Usual Care|This group receives care as usual.
89281939|NCT03853538|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
89281940|NCT03853538|Active Comparator|Women_Hemiface Vaseline|Adult women receive the test product randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
89281941|NCT03853382|Experimental|Cognitive Analytic Informed Brief Therapy|
89281942|NCT03853382|No Intervention|Treatment As Usual|
89281943|NCT01188122|Experimental|AnapnoGuard|
89281944|NCT01187654|Experimental|AC133 recipients|intra coronary injection of bone marrow derived AC133+ cells
89281945|NCT01187654|Experimental|MNC recipients|intra coronary injection of bone marrow derived MNC
89281946|NCT01187654|Active Comparator|control|injection of autologous serum
89281947|NCT04938284|Experimental|PAS and VNS|
89281948|NCT04938284|Active Comparator|PAS and sham VNS|
89281949|NCT04938284|Active Comparator|PAS|
89281950|NCT04938284|Active Comparator|VNS|
89281951|NCT01290458|Experimental|Vitamin|
89281952|NCT01290458|Placebo Comparator|Control|
89281953|NCT01184144|Experimental|pioglitazone|Pioglitazone study drug
89281954|NCT01184144|No Intervention|No drug|"Placebo like comparitor"
89281955|NCT03853460|Active Comparator|epidural group|ULTRASOUND GUIDED thoracic epidural at T 12 WILL BE INSERTED before anaesthesia induction
89281956|NCT03853460|Active Comparator|quadus lumborum group|bilateral ultrasound guided quadratus lumborum catheter will be inserted before anaesthesia induction
89281957|NCT01188200|Experimental|Nutritional Formula #M979|nutritional formula
89281958|NCT01188200|Active Comparator|Regular standard meal|standard meal
89281959|NCT01291628|Experimental|socks containing copper-oxide fibers|
89281960|NCT04934462|Other|non-surgical treatment|All participants will undergo 6 months of non-surgical treatment.
89281961|NCT04934462|Other|arthroscopic treatment|Those participants with failed non-surgical treatment at 6 months will undergo arthroscopic treatment.
89281962|NCT00053898|Active Comparator|Group 1|tamoxifen 20 mg/day and an anastrozole look-alike placebo for 5 years
89281963|NCT00053898|Experimental|Group 2|anastrozole, 1 mg/day and an tamoxifen look-alike placebo for 5 years
89281964|NCT03855488|Experimental|Standard cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively
89281965|NCT03855488|Experimental|Imagery enhanced cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively while engaging in imagery
89281966|NCT03855488|Placebo Comparator|Neutral Control Condition|Listen to descriptions of neutral scenarios
89281967|NCT01187732|Experimental|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
89281968|NCT01187732|Active Comparator|Traditional soap and water bath|The control intervention is the traditional bathing assistance as performed in care dependent patients by using tap water, a bowl, towels, washcloths and soap.
89281969|NCT01291706||Mild TBI with mild lesions on CT scan|Negative predictive value of transcranial doppler for patients with mild to moderate traumatic brain injury and mild brain lesions on initial CT scan (TCDB II)
89281970|NCT03849950|Experimental|SMARTCare|"Training in self-management support (SMS) strategies for ambulatory nursing staff~A web-based self-management education (I-Can-Manage Cancer) for patients~Telephone-based, nurse-led health coaching~Optional end of study patient interview (sub-study)"
89281971|NCT03849950|Active Comparator|Control|1. Training in self-management support (SMS) strategies for ambulatory nursing staff
89281972|NCT01293656||CD and UC participants|All participants with CD or UC visiting their physician over a period of one year, newly and already diagnosed, regardless of treatment pattern.
89281973|NCT01293734|Experimental|cold type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in cold type
89281974|NCT01293734|Experimental|heat type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in heat type.
89281975|NCT01293734|Experimental|Asthenia type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in Asthenia type.
89281976|NCT01293734|Active Comparator|Western medicine control group|
89281977|NCT03855644||Pelvic fracture patients|(1) 1<Age<80, and Chinese residents living in China more than 3 years; (2) Hemoglobin value less than 100g/L during hospitalization; Not suffered from pelvic fracture within 3 months; Not suffer from pathological fractures of the pelvis caused by malignant tumors; without chronic anemia and coagulopathy; accept blood transfusion
89281978|NCT01184300|Experimental|Rapid Genotyping|Patients randomized to the Rapid Genotyping arm will have their CYP2C19*2 carrier status determined at the time of percutaneous coronary intervention with subsequent alteration in anti-platelet therapy for *2 carriers.
89281979|NCT01184300|No Intervention|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping at the time of percutaneous coronary intervention. All patients will receive clopidogrel 75 mg daily for 1 week. At the end of the 1 week period, their CYP2C19*2 carrier status will be verified.
89281980|NCT03849872|Experimental|Part 1 Absolute Bioavailability|Single oral dose of 10 mg ONO-5788 capsule followed by iv infusion 100 μg/ 41 kBq (1.1 μCi) [14C]-ONO-5788 in 6 healthy male subjects.
89281981|NCT03849872|Experimental|Part 2 Mass Balance|Single oral dose of 10 mg [14C]-ONO-5788 capsule containing 4.1 MBq (111 μCi) [14C]-radioactivity in 6 healthy male subjects.
89281982|NCT03138538|Experimental|M8891 7 mg|Participant received M8891 at dose of 7 milligrams (mg) orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
89281983|NCT03138538|Experimental|M8891 12 mg|Participant received M8891 at dose of 12 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
89281984|NCT03138538|Experimental|M8891 20 mg|Participant received M8891 at dose of 20 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
89281985|NCT03138538|Experimental|M8891 35 mg|Participant received M8891 at dose of 35 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
89281986|NCT03138538|Experimental|M8891 60 mg|Participant received M8891 at dose of 60 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
89281987|NCT03138538|Experimental|M8891 80 mg|Participant received M8891 at dose of 80 mg orally with first dose in Cycle 1 Day 1 and consist of consecutive 21-day cycles of continuous once daily M8891 monotherapy under fasting conditions until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
89281988|NCT01188278||Patients in CP-CML treated with 2G TKI|Patients in CP-CML treated with 2G TKI (nilotinib or dasatinib) post imatinib failure
89281989|NCT01184378|Placebo Comparator|control formula|formula containing only vegetable fats
89281990|NCT01184378|Experimental|new formula|new formula with dairy lipids and soluble milk proteins
89281991|NCT04325230|Experimental|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
89281992|NCT03852602||Group Control|Analgesic application15 minutes before the end of the treatment will constitute the control group.
89281993|NCT03852602||Group preemptive|Patients who underwent analgesic 15 minutes after the induction of general anesthesia .
89281994|NCT02459392|Other|Epiduroscopy mechanical lysis - failed back surgery syndrome|Epiduroscopy only mechanical lysis
89281995|NCT02459392|Experimental|Epiduroscopy combination - failed back surgery syndrome|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
89281996|NCT02459392|Other|Epiduroscopy mechanical lysis - chronic low back pain without previous spine surgery|Epiduroscopy only mechanical lysis
89281997|NCT02459392|Experimental|Epiduroscopy combination - chronic low back pain without previous spine surgery|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
89281998|NCT03852368|Experimental|The Effects of Light Exercise in Executive Functions|The effects of light exercise in executive functions of adolescents
89281999|NCT03852368|Experimental|The Effects of Moderate Exercise in Executive Functions|The effects of moderate exercise in executive functions of adolescents
89282000|NCT03852368|Experimental|The Effects of Heavy Exercise in Executive Functions|The effects of heavy exercise in executive functions of adolescents
89282001|NCT02417272|Experimental|Total disc replacement (TDR)|Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
89282002|NCT02417272|Experimental|Anterior Cervical Decompression and Fusion (ACDF)|Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
89282003|NCT02359084|Experimental|Family Navigation|Families will work one-on-one with the navigator who provides off-site support - e.g. home visits or accompanying families to appointments. The goal of FN during the diagnostic evaluation period is to ensure timely completion of the evaluation. The focus of these interactions is to understand the structure and purpose of the evaluation, gather and complete required materials, and address logistic barriers related to the diagnostic visit. The navigator will continue to work with the family after the diagnostic evaluation to access recommended services and support the family's engagement in treatment.
89282004|NCT02359084|Active Comparator|Conventional Care Management|Families will be assigned to a care manager for the diagnostic evaluation and for 100 days thereafter. Consistent with a high quality medical home, the care manager will be responsible to ensure that the referral for the diagnostic evaluation has been made. She is also available for family-initiated support. The care manager will be responsible for ensuring that referrals are made and continue to provide family-initiated, clinic-based support to families for up to 100 days after the completion of diagnostic evaluation.
89282005|NCT01095198|Active Comparator|2nd Reminder Letter|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
89282006|NCT01095198|Experimental|Offer of Vaginal Self Collection|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
89282007|NCT03855722|Experimental|RIPC|RIPC will consist of setting a tourniquet to donor thigh and inflating it to 300mmHg four times 5 minutes with 5 minutes deflating in between each. RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
89282008|NCT03855722|Sham Comparator|Sham-RIPC|Sham-RIPC will consist of setting a tourniquet to donor thigh without inflating it and keeping it in place for 35 min. Sham-RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
89282009|NCT03955926|No Intervention|Control group|kept fasted from midnight until surgery
89282010|NCT03955926|Experimental|NO-NPO group|drink carbohydrate beverage until 2 h before surgery
89282011|NCT01293812|Experimental|sucrose po|"88% sucrose solution (Syrup B.P.). The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution."
89282012|NCT01293812|Placebo Comparator|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
89282013|NCT01191164|Experimental|Study Arm|
89282014|NCT03256552|Active Comparator|GP MDI 28.8 micrograms|Glycopyrronium Metered Dose Inhaler 28.8 micrograms
89282015|NCT03256552|Active Comparator|GP MDI 14.4 micrograms|Glycopyrronium Metered Dose Inhaler 14.4 micrograms
89282016|NCT03256552|Active Comparator|GP MDI 7.2 micrograms|Glycopyrronium Metered Dose Inhaler 7.2 micrograms
89282017|NCT03256552|Placebo Comparator|Placebo MDI|Placebo Inhalation Aerosol
89282018|NCT03852446|Experimental|Part 1: Single Ascending Dose|
89282019|NCT03852446|Experimental|Part 2: Bioavailability and Food Effect|"Single dose of Indoximod HCL (F2) formulation under fasting conditions~Single dose of Indoximod HCL (F2) formulation under fed conditions~Single dose of Indoximod base formulation under fasting conditions"
89282020|NCT01293890||COPD patients with hospital admission for exacerbation|
89282021|NCT05111236|Active Comparator|RPT Group|"Routine physical therapy comprising stretching of spastic muscles, Strengthening of weak muscles, positioning ( how to make sitting and standing postures at home) and posturing strategies. This whole regimen will be practiced fives times a week for a period of twelve weeks.~Other Names:~• Routine Physical Therapy"
89282022|NCT05111236|Experimental|Massage Group|"Traditional massage of thirty minutes duration ( five minutes of massage will be provided to all four limbs, front and back of trunk area) prior to routine physical therapy. Routine physical therapy comprising stretching of spastic muscles, Strengthening of weak muscles, positioning ( how to make sitting and standing postures at home) and posturing strategies.~Other Names:~• Routine physical therapy and Traditional massage"
89282023|NCT03849560|Experimental|Grippol® Quadri|"Grippol® Quadri, a quadrivalent inactivated subunit influenza vaccine. Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Yamagata lineage) influenza virus antigen 5 µg;~type B (Victoria lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
89282024|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Yamagata lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Yamagata lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Yamagata lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
89282025|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Victoria lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Victoria lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Victoria lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
89282026|NCT00071058|Experimental|Surgery plus chemotherapy|"Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.~Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3."
89282027|NCT01089972||20 gauge group|
89282028|NCT01089972||22 gauge group|
89282029|NCT03637582|Active Comparator|Anesthesia Arm|"Participants randomized to this arm will undergo uroflow studies then be given an hour rest. Five ml of 4% lidocaine gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of 4% lidocaine gel. The subject will then perform the second uroflow study.~Complex urodynamics with the use of lidocaine hydrochloride 4% will then be performed. The lidocaine gel will have been placed in and around the urethra. We are using lidocaine gel in an FDA approved manner (for anesthesia)."
89282030|NCT03637582|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given an hour rest. Five ml of plain aqueous gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of plain aqueous gel. Urodynamic testing without anesthesia (standard of care) will then be performed.
89282031|NCT03849482||Parotid Gland Neoplasms|"Preoperative Assessment of Parotid Gland Neoplasms with:~Clinical Evaluation;~Fine Needle Aspiration Cytology;~Multiparametric Magnetic Resonance Imaging.~Postoperative Collection of Final Histopathological Diagnosis"
89282032|NCT02258594|No Intervention|Baseline - Usual Care|"Usual Care on two Medical Intensive Care Units units~Usual Care on four Oncology units"
89282033|NCT02258594|Experimental|Post-Implementation - Intervention Units|"PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two MICU units~PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two Oncology units"
89282034|NCT02258594|No Intervention|Post-Implementation - Usual Care|Usual Care on two Oncology Units
89282035|NCT00053352|Experimental|Arm I|"Patients enrolled with gonadal tumors of stage II or greater or extragonadal tumors of any stage receive cisplatin IV over 90 minutes & etoposide IV over 90 minutes days 1-3 and bleomycin sulfate IV over ≥ 10 minutes day 1. Treatment repeats every 3 weeks, 3 courses (weeks 0,3 & 6).~After completion of compressed induction chemotherapy, patients with no change in disease status or disease progression are removed from study. Patients with no evidence of disease receive no further therapy. Patients with a partial response or abnormal tumor markers proceed to conventional surgery (second-look) and/or 3 more courses of compressed consolidation chemotherapy.~After surgery, patients with pathologic complete response and have normal tumor markers receive no further therapy. Patients who remain with a partial response after surgery receive compressed consolidation chemotherapy.~Patients receive cisplatin, etoposide, and bleomycin as induction chemotherapy in weeks 10,13, & 16."
89282036|NCT00053352|No Intervention|Arm 2|"Patients who are enrolled with stage I gonadal tumors receive no further anticancer therapy until evidence of tumor recurrence or the diagnosis of a second malignant neoplasm.~Observation only for recurrence or development of an SMN"
89282037|NCT03637504|Experimental|Interventional|web-based, mobile medication management application [MedActionPlan® (MAP) and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
89282038|NCT03637504|No Intervention|Control|usual care and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
89282039|NCT03637504|Other|Optional Extension|web-based, mobile medication management application [MedActionPlan® (MAP)]
89282040|NCT01193816|Experimental|loxapine|loxapine
89282041|NCT01193816|Placebo Comparator|Placebo|Placebo
89282042|NCT05571202||Anorectal surgery patient under general anesthesia plus local infiltration|Anorectal surgery patient under general anesthesia plus local infiltration
89282043|NCT05571202||Anorectal surgery patient under spinal anesthesia|Anorectal surgery patient under spinal anesthesia alone
89282044|NCT03847688||Treatment resistant Major Depressive Disorder|
89282045|NCT05671250|Experimental|PRP gel and SOC-treatment|platelet-lysate loaded lyophilized gel in addition to standard of care
89282046|NCT05671250|Experimental|Trigel and SOC-treatment|Erythropoietin/isosorbide dinitrate loaded cryogel scaffold in addition to standard of care
89282047|NCT05671250|Active Comparator|standard of care alone|sharp debridement, saline washing and saline dressing
89282048|NCT03245398|Active Comparator|Single dose of mebendazole|In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
89282049|NCT03245398|Active Comparator|Multiple dose of mebendazole|In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).
89282050|NCT01291940|Experimental|Pediatric Moisturizer Intervention|Apply one of four moisturizers to one arm daily for four weeks.
89282051|NCT01291940|Experimental|Adult Moisturizer Intervention|Apply moisturizer to one arm once a day for four weeks.
89282052|NCT01291940|No Intervention|Adult Control|No intervention.
89282053|NCT01294124||No Tinnitus|The absence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
89282054|NCT01294124||Tinnitus|The presence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
89282055|NCT01188434|Experimental|Integrated Behavioral Treatment|Combined substance abuse, parenting skills, and basic needs intervention
89282056|NCT01188434|Active Comparator|casework treatment as usual|services as usual as referred by child welfare
89282057|NCT03244618|Experimental|CSSP Toothpaste|Toothpaste containing Calcium Silicate and Sodium Phosphate
89282058|NCT03244618|Placebo Comparator|Fluoride Toothpaste|Toothpaste containing Sodium monofluorphosphate
89282059|NCT00052962|Other|Arm 1 Surgery + post op chemotherapy|"Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~Post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-fluorouracil (5-FU), every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
89282060|NCT00052962|Other|Arm 2 Surgery + HIPEC|"Arm 2 Surgery + Continuous hyperthermic peritoneal perfusion (CHPP/HIPEC) + post op dwell + post op chemotherapy~Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.~followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin~post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluorouracil (5FU) 800 mg/m^2 and paclitaxel 125 mg/m^2~post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-FU, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
89282061|NCT01193894|Experimental|Profermin|
89282062|NCT01193894|Active Comparator|Fresubin|
89282063|NCT03852212|No Intervention|Control Group|The control group did not received any treatment
89282064|NCT03852212|Experimental|Manipulation|Experimental group received the osteopathic maneuver and the blood value were measured at baseline, after 2,5 and 10 minutes.
89282065|NCT01194050||Cohort|
89282066|NCT01294280||Ancillary-Correlative (IHC)|Previously collected tissue samples are analyzed by IHC.
89282067|NCT03849404|Experimental|AVT02 100mg/mL (Adalimumab Biosimilar)|Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48
89282068|NCT03849404|Experimental|EU-Humira 100mg/mL (Adalimumab Originator)|Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48
89282069|NCT04226794|Experimental|a-tDCS and nutritional counseling|a-tDCS and nutritional counseling
89282070|NCT04226794|Active Comparator|s-tDCS and nutritional counseling|s-tDCS and nutritional counseling
89282071|NCT04226794|Active Comparator|a-tDCS|a-tDCS
89282072|NCT04226794|Active Comparator|Nutritional counseling|Nutritional counseling
89282073|NCT01188512|Experimental|BPZE1 - Low dose|1,000 colony forming units (cfu) of BPZE1
89282074|NCT01188512|Experimental|BPZE1- middle dose|100,000 colony forming units (cfu) of BPZE1
89282075|NCT01188512|Experimental|BPZE1 - High dose|10,000,000 colony forming units (cfu) of BPZE1
89282076|NCT01188512|Placebo Comparator|Placebo|Formulation buffer
89282077|NCT00051636|Experimental|Zoledronic Acid and Placebo to Risedronate|Participants received zoledronic acid 5 mg intravenous infusion one dose, 60 days of oral placebo to risedronate, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
89282078|NCT00051636|Active Comparator|Risedronate and Placebo to Zoledronic Acid|Participants received 60 days of oral risedronate 30 mg, one intravenous infusion of placebo to zoledronic acid, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
89282079|NCT01188590||Patients undergoing heart surgery|
89282080|NCT01294826|Experimental|AUY922 plus Cetuximab|
89282081|NCT03956004|Experimental|Experimental|Full decision aid, consisting of education on osteoarthritis and treatment options, preferences and values elicitation, and personalized risk/benefit estimates based on patient's response to patient-reported outcome measures.
89282082|NCT03956004|Active Comparator|Control|Education component of the decision aid only.
89282083|NCT03847922|Placebo Comparator|Control group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection plus self-administered room air
89282084|NCT03847922|Experimental|Study group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection + self-administered Pro-Nox 50% nitrous oxide/50% oxygen.
89282085|NCT03955770|Experimental|HFOT first then LFOT|
89282086|NCT03955770|Experimental|LFOT first then HFOT|
89282087|NCT01095276|Placebo Comparator|Nebulized saline|patients on mechanical ventilation who were randomized to receive a placebo comparator (vehicle solution for dornase alpha)
89282088|NCT01095276|Active Comparator|dornase alpha|patients on mechanical ventilation who were randomly assigned to receive dornase alpha by in-line nebulization
89282089|NCT01096758||PKU patients|
89282090|NCT01096758||healthy controls|
89290246|NCT03009838|Active Comparator|laparoscopic drilling|laparoscopy will be performed using three-puncture technique. Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle
89290247|NCT01215552|Experimental|HT-0712|
89290248|NCT01123902|Experimental|hand-held fan|
89282091|NCT01194128|Experimental|Psychoeducatioinal Support|The intervention is comprised of three modules (see Table 6), each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
89282092|NCT01194128|Active Comparator|INformation only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. This packet will contain several fact sheets from a nationally-recognized expert source in caregiving (the Family Caregiver Alliance's National Center on Caregiving) and a national information and advocacy group (the National Citizens' Coalition for Nursing Home Reform). The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition."
89282093|NCT01096836|Experimental|Diet counseling|Outcomes of the study may enhance diet counseling
89282094|NCT01096836|Experimental|exercise training|
89282095|NCT01194206|Experimental|Arm I|Patients undergo 3 fractions of stereotactic body radiation therapy in 3 fractions delivered within 14 days in the absence of disease progression or unacceptable toxicity.
89282096|NCT01096914|Active Comparator|Radiofrequency|patients treated with percutaneous radiofrequency ablation
89282097|NCT01096914|Active Comparator|laser|Patients treated with percutaneous laser ablation
89282098|NCT03847532|Other|Patients with mutations in the MutYH-gene|Patients with established diagnosis of MutYH-associated polyposis with monoallelic and biallelic mutations in the MutYH-gene
89282099|NCT03847532|Other|Patients with multiple colon polyps|Number of polyps from 4+
89282100|NCT03847532|Other|Control sample|Patients who did not have colon polyps
89282101|NCT03953430||study group|Patients with clubfoot recurrence undergoing Tibialis Anterior tendon transfer with a minimum age of three years from a prospective, consecutive database of patients with clubfoot treated with the Ponseti method.
89282102|NCT03953430||control group|healthy children of employees of our hospital
89282103|NCT01194284||High-grade osteosarcoma patients|
89282104|NCT03255382|Experimental|Risankizumab|Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
89282105|NCT03255382|Active Comparator|Fumaderm|Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.
89282106|NCT03960450|Experimental|Part A: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
89282107|NCT03960450|Placebo Comparator|Part A: Vehicle cream|Daily application of vehicle cream
89282108|NCT03960450|Experimental|Part B: BOS-475|Daily application of BOS-475 0.5%, 1%, or 2%
89282109|NCT03960450|Placebo Comparator|Part B: Vehicle cream|Daily application of vehicle cream
89282110|NCT03847454|Experimental|Intervention REACH group|The intervention REACH consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity. The participants will receive 30 min training every day during 3 weeks. 3 times a week the standard training will be replaced with the intervention. The training is conducted/ supervised by a physiotherapist.
89282111|NCT03847454|Active Comparator|Control group (Standard of care)|The participants will receive the standard of care as intervention which consists of 30 min training every day during 3 weeks. The training is conducted by a physiotherapist.
89282112|NCT01095354||Asthma Patients|Spirometry. Bronchodilator with Salbutamol. Induced sputum in > 10 years of age using Sodium Chloride Inhalation. Multiple Breath Washout (MBW).
89282113|NCT03847298||Pacemaker|
89282114|NCT03847298||Control|
89282115|NCT03955692|Active Comparator|Active tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will be used for 15 mins for a session.
89282116|NCT03955692|Sham Comparator|Sham tDCS|Cathodal tDCS will be applied over the left DLPFC (F3) according to the 10-20 EEG electrode systems and the anode will be placed over the right supraorbital (Fp2), using rectangular saline-soaked sponge pads 35 cm2. The current intensity of 1.5 mA will flow continuously only 120 seconds. The electrode will be attached until the end of stimulation even the current flows only at the beginning.
89282117|NCT01194518|Experimental|Lifestyle Intervention Program|
89282118|NCT01296386|Experimental|IC84, 75 µg w/ Alum|75 µg w/ Alum (microgram with Alum)
89282119|NCT01296386|Experimental|IC84, 75 µg w/o Alum|75 µg w/o Alum (microgram without Alum)
89282120|NCT01296386|Experimental|IC84, 200 µg w/ Alum|200 µg w/ Alum (microgram with Alum)
89282121|NCT01296386|Experimental|IC84, 200 µg w/o Alum|200 µg w/o Alum (microgram without Alum)
89282122|NCT03960294|Experimental|DOZE Users|Adolescents and young adults (AYAs) using DOZE for sleep disturbance.
89282123|NCT01294904||renal transplant patients|Patients undergoing transplantation
89282124|NCT01294904||dialysis patients|hemodialysis patients and peritoneal dialysis patients. Before and after a dialysis session
89282125|NCT01294904||patients with renal insufficiency|outpatient patients with chronic kidney disease stage 2, 3 and 4
89282126|NCT01294904||Chronic kidney disease|outpatient cohort. Those with mild renal insufficiency
89290249|NCT01123902|Placebo Comparator|wristband|
89290250|NCT01215630||Healthy subjects|Men Women Age; 18-75
89290251|NCT01375894|Active Comparator|depresive patients|30 patients suffering from depression
89290252|NCT01375894|Experimental|Schizophrenia patients|30 Schizophrenia patients
89282127|NCT03849170|Experimental|Psychological Intervention|Six session intervention, each session 20-25 minutes in length. Stress inoculation technique-based intervention. Participants will be taught stress coping skills and relaxation skills such as self-efficacy statements, imagery, relaxation breathing, relaxation scripts, thought stoppage, cognitive reframing, positive self-talk, goal setting, event planning, and preparing for competition
89282128|NCT03849170|Placebo Comparator|Health Intervention|Six session intervention, each session 20-25 minutes in length. Participants will be taught relevant health and nutrition guidelines and practice using a food diary app (MyFitnessPal). Nutrition and health content will include such topics as reading Canadian food labels, vitamins and supplements, effects of alcohol on performance and recovery, vegetarian vs. omnivore diets, and hydration & performance.
89282129|NCT03849014|Active Comparator|Dynamic Hip Screw|Dynamic Hip Screw is used for internal fixation of fractures of the certain types of hip fractures. The implant assembly consisting of a lag screw, a side plate, and cortical screws that fix the side plate to the proximal femoral shaft.
89282130|NCT03849014|Active Comparator|Proximal Femoral Nail|The Proximal Femoral Nail offers osteosynthesis for the several types of hip fractures. It consists of an anatomically curved nail, double neck screw, and two locking screws for distal end.
89282131|NCT01294982|Experimental|1.6 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
89282132|NCT01294982|Experimental|3.2 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
89282133|NCT01294982|Placebo Comparator|Placebo|Matching Placebo Capsules
89282134|NCT01191554|Experimental|High dosage|A loading dose of 30 mg/kg and a maintenance infusion of 16 mg/kg through out the operation, and 2 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
89282135|NCT01191554|Experimental|Low dosage|A loading dose of 10 mg/kg and a maintenance infusion of 1 mg/kg through out the operation, and 1 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
89282136|NCT01188746|Experimental|Questionnaire or interview|A pre-experimental design was chosen to examine changes in QoL following a palliative intervention.
89282137|NCT01296464|Experimental|Stalevo|levodopa/carbidopa/entacapone
89282138|NCT01296464|Placebo Comparator|Placebo|
89282139|NCT02524340||Juvenile Idiopathic Arthritis|Children diagnosed with Juvenile Idiopathic Arthritis
89282140|NCT01079728||ischemic stroke patients|patients with an ischemic stroke in the anterior (ACA, MCA) and posterior flow area (PCA, BA) of any severity in the last 36h
89282141|NCT05146466|Other|E-MATVR (intervention)|
89282142|NCT05146466|Other|E-MATEE (control)|
89282143|NCT03254602|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart.
89282144|NCT02524262|Experimental|Slow-release L-cysteine|Oral intake of slow-release L-cysteine 200 mg before challenge with ethanol.
89282145|NCT02524262|Placebo Comparator|Placebo|Oral intake of identically-looking placebo capsules
89282146|NCT00038142|Experimental|Arm A: VACdxr With ImmTher|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) intravenous (IV), Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days. Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin). ImmTher 900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
89282147|NCT00038142|Active Comparator|Arm B: VACdxr|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) IV. Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days, Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin).
89282148|NCT00366899|Experimental|1|13-valent pneumococcal conjugate vaccine
89282149|NCT00366899|Active Comparator|2|7-valent pneumococcal conjugate vaccine
89282150|NCT01090128|Experimental|All patients|All participants enrolled.
89282151|NCT01292174|Experimental|Group 1 - lowest dosage|120 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
89282152|NCT01292174|Experimental|Group 2 - middle dosage level|240 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
89282153|NCT01292174|Experimental|Group 3 - highest dosage level|480 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
89282154|NCT01090206|Other|Hemophilia, Vitamin D deficiency|"Hemophilia, Rickets - Vitamin D per endocrine consult~Hemophilia, Vitamin D deficient - Vitamin D 2000 units daily plus calcium~Hemophilia, Normal Vitamin D - no intervention - observation only"
89282155|NCT05570890|Experimental|Sham stimulation on stable surface|The participant will not receive stimulation and will stand on flat ground.
89282156|NCT05570890|Experimental|Noise stimulation on stable surface|The participant will receive stimulation with intensity set at 90% of their sensory threshold and will stand on flat ground.
89282157|NCT05570890|Experimental|Sham stimulation on unstable surface|The participant will not receive stimulation and will stand on foam.
89282158|NCT05570890|Experimental|Noise stimulation on unstable surface|The participant will receive stimulation with intensity set at 90% of their sensory threshold and will stand on foam.
89282159|NCT01296620|Experimental|Experimental 1|
89282160|NCT01296620|Experimental|Experimental 2|
89282161|NCT01296620|Placebo Comparator|Placebo|
89282162|NCT04728646|Experimental|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
89282163|NCT04728646|Other|Dissolvable intracanalicular plug|All patients will receive Dextenza insert in one eye and a regular dissolvable intracanalicular plug in the fellow-eye (randomized).
89282164|NCT03637192|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
89282165|NCT03637192|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
89282166|NCT01296776|Active Comparator|whole-body electromyostimulation|20 min of whole-body electromyostimulation with sequences of 6 sec of current and 4 sec at 85 Hz performed during low-intensity/low amplitude movements. 3 sessions / 14 days for 12 months
89282167|NCT01296776|Placebo Comparator|wellness control group|Low intensity, low frequency exercise that focus on well being. 1 session/week for 10 weeks. 10 blocks of exercise with intermittent periods of 100 weeks of rest
89282168|NCT04674826|Experimental|TR (Test-Reference)|Treatment period 1: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T) Treatment period 2: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R)
89282169|NCT04674826|Experimental|RT (Reference-Test)|Treatment period 1: 300 mg tralokinumab, subcutaneous dose, 2 × Y mL Device B (Reference treatment, R) Treatment period 2: 300 mg tralokinumab, single subcutaneous dose, 1 × X mL Device A (Test treatment, T)
89282170|NCT01295138|Experimental|Lactulose group|Group receives 48 hours of lactulose post Caesarean section.
89282171|NCT01295138|No Intervention|Non-lactulose group|Group receives no lactulose post Caesarean section.
89282172|NCT01049165|Active Comparator|Arm 1 (BMS-813160 or placebo)|
89282173|NCT01049165|Active Comparator|Arm 2 (BMS-813160 or placebo)|
89282174|NCT01049165|Active Comparator|Arm 3 (BMS-813160 or placebo)|
89282175|NCT01049165|Active Comparator|Arm 4 (BMS-813160 or placebo)|
89282176|NCT01049165|Active Comparator|Arm 5 (BMS-813160 or placebo)|
89282177|NCT01049165|Active Comparator|Arm 6 (BMS-813160 or placebo)|
89282178|NCT01049165|Active Comparator|Arm 7 [14C] BMS-813160|
89282179|NCT01049165|Active Comparator|Arm 8 (BMS-813160 or placebo)|
89282180|NCT01049165|Active Comparator|Arm 9 (BMS-813160 or placebo)|
89282181|NCT03849092|Experimental|Financial incentive|3 municipalities will receive 120.000 DKK for financial incentives.
89282182|NCT03849092|Experimental|Campaigns|3 municipalities will receive 120.000 DKK for campaigns.
89282183|NCT03849092|No Intervention|Control|"6 clean control municipalities perform their smoking cessation activities as usual. They wont receive any financial resources. These muncipalities have not been randomly selected but have been matched (by number of smokers attending the smoking cessation groups in the municipality in 2017, the year before the intervention). 3 of them are Campaing Control group and 3 are Finacial Incentives Control group."
89282184|NCT04647604|Active Comparator|Omega|Omegaven® (2 mL/kg/day, equivalent to 6 g Docosahexaenoic Acid (DHA)+Eicosapentaenoic Acid (EPA) in a 70 kg individual) once daily for 5 days
89282185|NCT04647604|Placebo Comparator|Sodium chloride (NaCl)|2 mL/kg/day) once daily for 5 days
89282186|NCT01188824|Active Comparator|Cilostazol|Pletaal® (Cilostazol) 100 mg, bid p.o.
89282187|NCT01188824|Placebo Comparator|placebo|"Placebo~1 tablet, bid p.o."
89282188|NCT01060475|Experimental|A|Low dose LIM-0705 and tacrolimus.
89282189|NCT01060475|Experimental|B|High dose LIM-0705 and tacrolimus.
89282190|NCT01060475|Experimental|C|Placebo LIM-0705 and tacrolimus.
89282191|NCT01060475|Experimental|D|High dose LIM-0705 and placebo tacrolimus.
89282192|NCT01191632|Active Comparator|Radiation 0,5Gy|"Radiation: one time Radiation with an intensity of 0.5 Gy Group A~Beginning on a weekday 48 hours before surgery"
89282193|NCT01191632|Active Comparator|No radiation|Control group with 0Gy radiation
89282194|NCT01191632|Active Comparator|Radiation 2Gy|"Radiation: one time Radiation with an intensity of~2.0 Gy Group B~Beginning on a weekday 48 hours before surgery"
89282195|NCT01191632|Active Comparator|Radiation 5Gy|"Radiation: one time Radiation with an intensity of~5 Gy Group C Beginning on a weekday 48 hours before surgery"
89282196|NCT01060631||patients with frontal or frontotemporal brain tumor.|
89282197|NCT01060631||patients without supratentorial brain tumor.|
89282198|NCT01296854|No Intervention|Standard|The patients randomized into this arm of the study will not have spa therapy.
89282199|NCT01296854|Experimental|Spa Therapy|The patients randomized into this arm of the study will have 3 weeks of spa therapy
89282200|NCT03851978|Experimental|Pharmacist Vaccine Education|
89282201|NCT03254134||Atrial Fibrillation|patients with atrial fibrillation
89282202|NCT01188902|Experimental|walnut|western type diet with 48 g walnut per day
89282203|NCT01188902|No Intervention|control|
89282204|NCT00037830|Active Comparator|Early-Start Group|Subjects were randomized to receive GM1 ganglioside for 24 weeks.
89282205|NCT00037830|Placebo Comparator|Delayed-Start Group|Subjects were randomized to receive placebo for 24 weeks.
89282206|NCT00037830|No Intervention|Comparison Group|A separate group of Parkinson's disease patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This comparison group was not compared statistically to the treatment groups since they were not randomized.
89282207|NCT05282810||cartilage tympanoplasty|use cartilage in tympanoplasty for recuurent perforation
89282208|NCT05282810||temporalis fascia graft in tympanoplasty|use temporalis fascia as a graft in tympanoplasty for recuurent perforation
89282209|NCT05179642||Control group|"This is a randomized, cluster stepped wedge study. The cluster will be made up of coordinating physicians grouped together according to the geographical area of their EHPAD.~Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group."
89282210|NCT05179642||Tool OPTIM-EHPAD|"This is a randomized, cluster stepped wedge study. The cluster will be made up of coordinating physicians grouped together according to the geographical area of their EHPAD.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
89282211|NCT05568862||spinal cord injury|patient with spinal cord injury
89282212|NCT05568862||no spinal cord injury|patient without spinal cord injury
89282213|NCT03848936||adult cerebral palsy patients|>18 age cerebral palsy diagnosed patients evaluated with a survey.
89282214|NCT03953196|Experimental|Cohort 1: Vaccine Challenge Imvanex|Participants will receive single dose of Imvanex subcutaneously on Day 1. Participants will also be included in the DREEM EEG substudy.
89282215|NCT03953196|Experimental|Cohort 2: Vaccine Challenge Shingrix|Participants will receive single dose of Shingrix intramuscularly on Day 1. Participants will also be included in the DREEM EEG substudy.
89282216|NCT03953196|Experimental|Cohort 3: Antigen Challenge Lipopolysaccharides (LPS)|Participants will receive a single dose of LPS intravenously (IV) on Day 1. Participants will also be included in the DREEM EEG substudy and vital patch physIQ platform substudy.
89282217|NCT03953196|Experimental|Cohort 4: Antigen Challenge Candin|Participants will receive one single injection of Candin and one single injection of saline control intradermally on Day 1. Participants will also be included in the DREEM EEG substudy.
89282218|NCT03953196|Experimental|Cohort 5: Skin Wounding Challenge|3 punch biopsies will be performed per standard dermatologic practice guidelines. Lower abdomen tissue biopsy specimens will be collected on Day 1.
89282219|NCT05179564|Experimental|iohexol plasma clearance|"a weight-dependent dose of iohexol will be injected as an intravenous bolus in 100 patients~2,5 -9kg = 1ml; 10-19kg = 2ml; 20-29kg = 3ml; 30-39kg = 4ml; ≥ 40kg = 5ml"
89282220|NCT03848624|Experimental|Cycling Group|Intention driven motor-assisted voluntary cycling with electrical stimulation
89282221|NCT03851900|Experimental|Teethmate Desensitizer (TM)|Calcium phosphate biomimetic material that forms hydroxyapatite from tetracalcium phosphate and dicalcium phosphate anhydrous and plug the dentin tubules causing remineralization and dentin hypersensitivity relief.
89282222|NCT03851900|Active Comparator|Clearfil SE Bond 2 (SE)|Two-step self etch adhesive resin treating dentin hypersensitivity b covering a film layer after light-curing.
89282223|NCT03851900|Placebo Comparator|Distilled water|Distilled water with no desensitizing components.
89282224|NCT01097070|Experimental|Bevirimat 200 mg twice daily, 15 days|
89282225|NCT01097070|Experimental|Bevirimat 300 mg once daily, 15 days|
89282226|NCT01097070|Experimental|Bevirimat 400 mg once daily, 15 days|
89282227|NCT05179252|Experimental|SFI intervention group|shenfu injection used during surgery, day one and two after surgery, 50ml,iv drop.
89282228|NCT05179252|Sham Comparator|Control group|same volume of normal saline used during surgery, day one and two after surgery, 50ml,iv drop.
89282229|NCT01295294|Experimental|tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with tranexamic acid
89282230|NCT01295294|Experimental|mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with mefenamic acid
89282231|NCT01295294|Placebo Comparator|placebo + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive placebo
89282232|NCT04502914|Experimental|The experimental group|The experimental group will consist of wounds treated with the open-to-air strategy.
89282233|NCT04502914|Other|The control group|The control group will consist of wounds treated with traditional closed-wound management with dressings soaked in topical antimicrobial solutions.
89282234|NCT01191710|Experimental|Antagonist group|Antagonist protocol for IVF
89282235|NCT01191710|Active Comparator|Agonist group|Long Agonist protocol for IVF
89282236|NCT04367740||Serum Antibodies|Blood samples to be obtained assess for IgG antibodies against SARS-CoV2
89282237|NCT03846986|Active Comparator|Apple Juice1|100% Apple Juice
89282238|NCT03846986|Experimental|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
89282239|NCT03846986|Placebo Comparator|Raw Apple|Raw Apple
89282240|NCT05565040|Experimental|Phallopexy group|phallopexy only
89282241|NCT05565040|Experimental|Dartos excision group|complete circumferential dissection and excision of dartos fascia only
89282242|NCT05565040|Experimental|Combined phallopexy and dartos excision group|phallopexy as in patients of group A but after complete dissection and excision of dartos fascia
89282243|NCT03852056|Placebo Comparator|MFP Fluoride toothpaste|Commercially available, monofluorophosphate (MFP) toothpaste. Fluoride level is 0.76%
89282244|NCT03852056|Experimental|Stannous Fluoride Toothpaste|New toothpaste containing 0.454% stannous fluoride.
89282245|NCT03242434|Other|Healthy controls|Approximately 15 healthy participants of age 18 years or above will be included in the study and will receive STM intermittently via oral route. The total duration of study for healthy participants will be approximately 2 weeks.
89282246|NCT03242434|Other|Thermal injury participants|Approximately 25 thermally injured participants having TBSA more than or equal to 15 percent and who are co-consented to the SIFTI-2 and HESTIA studies will be included in the study and will receive STM intermittently via oral route. The total duration of study for thermal injury participants will be approximately 6 months.
89282247|NCT03848702|Experimental|Healthy volunteers|All volunteers wore the DRFB
89282248|NCT03848702|Experimental|Patients with DRF|All patients wore the DRFB
89282249|NCT01191866||Diabetes mellitus|All children and adolescents with type 1 diabetes mellitus attending Assaf Harofeh Pediatric Diabetes Clinic
89282250|NCT01188980||NoBE (control)|
89282251|NCT01188980||BE without dysplasia|
89282252|NCT01188980||BE with dysplasia|
89282253|NCT04222426|Experimental|89Zr-atezolizumab PET scan|All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. The 89Zr-atezolizumab PET scan will be performed 4 days after tracer injection. Procedures within the ImaGelato study will be completed after the two 89Zr-atezolizumab PET scans, but patients will continue treatment with carboplatin combined with atezolizumab in the GELATO trial.
89282254|NCT03852134|Experimental|MOCC Group|The OB provider will hold the baby at/below the placenta, provide warmth, stimulate the baby and suction the mouth/nose for 30 secs.S/He will then clamp and cut the cord about 5 cm from the the introitus (vaginal deliveries) or from the abdominal incision (C-Sections) before handing the baby with the long-cut cord to the neonatal team to resuscitate/ stabilize the baby. A member of the neonatal team will milk the long-cut cord slowly 1 time from the cut end toward the infant over 10 secs before clamping and cutting the cord 1-2 cm from the umbilical stump. The neonatal team will provide PPV to the baby (during the milking process) if the baby is not breathing. If the baby is breathing during the milking process the team will continue the stabilization as per standard NRP practice.
89290253|NCT01124058|Experimental|Loading|1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose
89290254|NCT01124058|Active Comparator|Maintenance|Re-start same dose as previously stable on
89290255|NCT01375972|Experimental|SP treatment|S-1 plus cisplatin combination chemotherapy
89290256|NCT01375972|Active Comparator|GP treatment|Gemcitabine plus Cisplatin combination chemotherapy
89282255|NCT03852134|Active Comparator|DCC group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
89282256|NCT01292408|Experimental|Daily HCQ|Between tumor biopsy and surgery, during 2-3 weeks, breast cancer patients will take daily HCQ, an anti-malaria and anti-rheumatic drug that precludes tumor cells from surviving hypoxia by inhibiting the process of autophagy in these cells
89282257|NCT03637426|Placebo Comparator|GPLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
89282258|NCT03637426|Experimental|Gn-HAP|In this group a desensitizing gel containing 20% of nano-hydroxyapatite, 9000 ppm of sodium fluoride and 5% of potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) was applied to the hypersensitive dentin. The GnHAP volunteers will be submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications.
89282259|NCT03637426|Experimental|GLASER|"In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil) was applied in hypersensitive dentine.~GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours."
89282260|NCT03637426|Experimental|GLASERnHAP|In this group the laser + nano-hydroxyapatite was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, São Carlos, SP, Brazil) and a gel containing 20% nanohydroxyapatite, 9000 ppm sodium fluoride 5% potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) in hypersensitive dentin. GLASERnHAP first named a laser application and then an application of nanohydroxyapatite according to the manufacturer's recommendations.
89282261|NCT01295372|Experimental|Zicronapine|
89282262|NCT01295372|Active Comparator|Risperidone|
89282263|NCT05179174||patients with uveal melanoma|51 patients with a diagnosed with uveal melanoma; of both sexes, aging more than 18 years. The exclusion criteria are: a) subjects with autoimmune diseases, tumors, diseases kidney, atherosclerosis; b) subjects undergoing anti-inflammatory therapies.
89282264|NCT05179174||healthy controls|51 age sex matched controls, patients with diagnosed with cataracts; of both sexes, aging more than 18 years. The exclusion criteria are: a) subjects with autoimmune diseases, tumors, kidney diseases, atherosclerosis; b) subjects undergoing anti-inflammatory therapies.
89282265|NCT05179096|Experimental|Mindfulness|Participants in the experimental group will undergo an 8-week mindfulness training program with weekly 60-minute group sessions
89282266|NCT05179096|No Intervention|Control|The control group will follow routine daily school activities
89282267|NCT05283278|Active Comparator|Lactoferrin Bovine group|Group A (20 preterm neonates) which will receive lactoferrin (100mg/day)
89282268|NCT05283278|Active Comparator|Lactoferrin Bovine with probiotics group|Group B (20 preterm neonates) which will receive lactoferrin (100mg/day) in combination with the probiotic
89282269|NCT05283278|Placebo Comparator|Placebo group|Group C (40 preterm neonates) which is a placebo group.
89282270|NCT05179018||SLE patients group|The study will include 50 patients suffering from SLE, all patients with SLE should fulfill 2012 SLICC criteria
89282271|NCT05179018||Healthy control group|Control group of 40 healthy volunteers with age and gender-matched with SLE patients.
89282272|NCT01295450|Active Comparator|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
89282273|NCT01295450|Experimental|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
89282274|NCT05178394|Experimental|Male recreational weightlifters|
89282275|NCT01297010|Placebo Comparator|Dexamethasone|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg) at the beginning of the procedure.
89282276|NCT01297010|Placebo Comparator|Dexamethasone and ondasetron|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling) and ondansetron (0.1 mg / kg dose of 4mg ceiling)at the beginning of the procedure.
89282277|NCT03851432|Experimental|Janagliflozin 25 mg plus metformin|Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
89282278|NCT03851432|Experimental|Janagliflozin 50 mg plus metformin|Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
89282279|NCT03851432|Placebo Comparator|Placebo/Janagliflozin plus metformin|In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.
89282280|NCT01194986|Experimental|Pilot panel|[11C]AZ12807110 distribution and kinetics
89282281|NCT01194986|Experimental|Main panel|Histamine receptor occupancy reached by AZD5213
89282282|NCT01297088|Experimental|Arm 1|
89282283|NCT03846908|Experimental|MCT|subjects start with MCT fat load
89282284|NCT03846908|Experimental|SFA|subjects start with SFA fat load
89282285|NCT03846908|Experimental|MUFA|subjects start with MUFA fat load
89282286|NCT01192490|Experimental|Lidocaine Arm|This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.
89282287|NCT01192490|Placebo Comparator|Lubricant|Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.
89282288|NCT01295528||Blood Pressure, Heart Rate, Monitor|
89282289|NCT01295606|No Intervention|Cefazolin, antibiotic prophylaxis|All included patients will received iv cefazolin
89282290|NCT01292564|Active Comparator|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
89282291|NCT01292564|Placebo Comparator|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
89282292|NCT01192646|Active Comparator|Home based life saving skills training|Home based life saving skills will done in one the study group and in the control group no training will be done
89282293|NCT01192646|No Intervention|NO HBLSS|No intervention will be given to the control clusters
89282294|NCT03848546|Experimental|PDA|Intervention group: receives the personalized dietary advice
89282295|NCT03848546|Active Comparator|Control|Receives the general advice (two flyers containing information about fiber intake)
89282296|NCT01189058|Experimental|rTMS and CIMT|This group will receive both rTMS and CIMT.
89282297|NCT01189058|Experimental|rTMS and no CIMT|This group will receive rTMS only.
89282298|NCT01189058|Experimental|Sham and CIMT|This group will receive CIMT and sham rTMS.
89282299|NCT01189058|No Intervention|Sham and no CIMT|This group will receive sham rTMS and no CIMT.
89282300|NCT01192724|Active Comparator|Triple antiplatelet therapy (TAPT) group|3-month use of cilostazol in addition to dual antiplatelet agent
89282301|NCT01192724|Active Comparator|Dual antiplatelet therapy (DAPT) group|Aspirin and clopidogrel (dual antiplatelet therapy, DAPT) for 1 year
89282302|NCT01192802|Active Comparator|1 dose, Albendazole , tablet|
89282303|NCT01192802|Active Comparator|2 doses, albendazole, tablet|1 tablet of 400 mg of albendazole per day for two consecutive days
89282304|NCT01192802|Active Comparator|3 doses albendazole, 400mg, tablet|
89282305|NCT01195142||PCOS-CSAT|Women with PCOS
89282306|NCT01195142||Control-CSAT|Control population consisting of women without PCOS, matched for age and BMI with the PCOS cohort
89282307|NCT01292720|Placebo Comparator|Placebo|Placebo (herbal oil)
89282308|NCT01292720|Experimental|Vitamin D|
89282309|NCT01193036||Interview|
89282310|NCT01193036||Symptom Inventory Assessment|
89282311|NCT02939014|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
89282312|NCT05601518||Single Group Assignment|
89282313|NCT03851354|Other|Ultrasound meal accomodation test|ultrasound guided gastric dynamics test for tolerance of enteral feeding, 500 ml of water with protein (glutamine or casseinate) wil be administrated
89282314|NCT05178160|Active Comparator|Group A|All the patients undergo to helmet-CPAP setting PEEP at 10 cmH2O and performing a blood gas analysis after 2 hours
89282315|NCT05178160|Experimental|Group B|All the patients undergo to helmet-CPAP. PEEP was increased from 5 to 7.5 and 10 cmH20 in 30-minute steps during which lung ultrasound and blood gas analyses were repeated. The best PEEP was setted as the PEEP value before the appearance of lung pulse and with a PaO2/FiO2 levels stable or major than 20% in comparison to the basal value
89282316|NCT01195220|Active Comparator|HIV-T|"Group 1, the control, will be the current standard of care, consenting video and testing for HIV alone (HIV-T).~This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test"
89282317|NCT01195220|Experimental|STI/HIV-T|"Group 2 will add routine STI testing for CT and GC, (STI/HIV-T).~This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED."
89282318|NCT01195220|Experimental|STI/HIV-Plus|"Group 3, in addition to combined STI/HIV testing, will add a behavioral video encouraging safer sex, which is chosen for participants based on their answers to a brief measure on stage of change (STI/HIV-PLUS).~This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes"
89282319|NCT05177926|Other|antiviral prophylaxis with Tenofovir Alafenamide Fumarate (TAF)|All participants will receive oral Tenofovir Alafenamide Fumarate 25mg, daily, at gestational 27-29 week until delivery.
89282320|NCT03848390|Experimental|Modified Time-restricted Feeding|
89282321|NCT03848390|Active Comparator|Conventional diet|
89282322|NCT01193192||Arm #1 (Test Group)|100 subject administered Neevo® or NeevoDHA® daily
89282323|NCT01193192||Arm #2 (Control group)|100 subject administered a prenatal vitamin daily
89282324|NCT01313962|Experimental|Flufirvitide-3|
89282325|NCT01313962|Placebo Comparator|Placebo|
89282326|NCT01193270|Experimental|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate (Aquasol E®) 50 IU/kg.
89282327|NCT01193270|Placebo Comparator|Placebo|Sterile water in volume equal to that of the comparator drug.
89282328|NCT01193426||Cirrhosis patient|All consecutive patients with cirrhosis admitted to the five participating center Patients were hospitalized or treated in an ambulatory setting for treatment of ascites or complications of cirrhosis. Ascitic fluid was obtained by paracentesis according to the usual clinical management for these patients.
89282329|NCT01189214|Experimental|Memantine|
89282330|NCT01193504|Active Comparator|Pred Forte|Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
89282331|NCT01193504|Active Comparator|Lotemax|patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
89282332|NCT01295684|Placebo Comparator|placebo|Base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage.
89282333|NCT01295684|Experimental|Cranberry Juice|Base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day.
89282334|NCT03848468|Active Comparator|CH(conventional Hemorrhoidectomy)|conventional hemorrhoidectomy
89282335|NCT03848468|Experimental|LH (Ligasure Hemorrhoidectomy)|Ligasure hemorrhoidectomy
89282336|NCT01295762|Other|Type of neuroblastoma|Neonatal stages I Localized immediately resectable stages Localized immediately unresectable stages High-risk neuroblastoma Relapsed neuroblastoma
89282337|NCT03848780|Experimental|Desflurane Group|Thirty minutes before initiation of ischemia the surgeon was instructed to notify the anesthesiologist. At this single time point, propofol infusion was stopped and substituted with the volatile anesthetic desflurane to achieve a Minimum Alveolar Concentration of 1. The procedure included a 5-minute induction of desflurane, a 20-minute preconditioning and a 5-minute washout period when propofol was reintroduced and desflurane stopped.
89282338|NCT03848780|No Intervention|Control Group|No pharmacological preconditioning was implemented
89282339|NCT05599802|Experimental|1A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have not received any COVID-19 vaccines will vaccinate two doses of study vaccine with 28 days apart.
89282340|NCT05599802|Experimental|1B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have not received any COVID-19 vaccines will vaccinate two doses of study vaccine with 28 days apart.
89282341|NCT05599802|Experimental|2A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 inactivated vaccines will vaccinate 1 doses of study vaccine.
89282342|NCT05599802|Experimental|2B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 inactivated vaccines will vaccinate 1 doses of study vaccine.
89282343|NCT05599802|Experimental|3A: 50μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 mRNA vaccines will vaccinate 1 doses of study vaccine.
89282344|NCT05599802|Experimental|3B: 100μg SARS-CoV-2 variant mRNA vaccine|Participants who have received 2 dose of COVID-19 mRNA vaccines will vaccinate 1 doses of study vaccine.
89282345|NCT00051558|Experimental|A|Teriparatide 20 micrograms/day injection plus oral placebo, 36 months
89282346|NCT00051558|Active Comparator|B|Alendronate 10 mg/day oral plus injection placebo, 36 months
89282347|NCT03848234|Experimental|A Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
89282348|NCT03848234|Placebo Comparator|B Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
89282349|NCT05671640|Experimental|DragonFly-T Transcatheter Tricuspid Valve Repair System|The experimental group is allocated to use a novel tricuspid valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd.
89282350|NCT01295918|No Intervention|Placebo, antibiotic, diarrhea|
89282351|NCT01295918|Placebo Comparator|L. reuteri, Antibiotic, diarrhoea|L. reuteri will be ingested by patients on antibiotic therapy, effect of probiotic on AAD will be assessed.
89282352|NCT03851276|Other|Patients with 3-vessels diseased referred to CABG surgery|Patients with 3-vessel disease (with or without left main involvement) for which the regular and conventional Heart Team has made already the decision to refer the patient for CABG treatment.
89282353|NCT03846752|Active Comparator|7 Fr. radial access|radial artery access for complex PCI
89282354|NCT03846752|Active Comparator|7 Fr. femoral access|femoral artery access for complex PCI
89282355|NCT03848078|Other|Optical Coherence Tomography arm|In the intervention arm, OCT imaging is performed which will take about 3 minutes. The decision on the most adequate treatment strategy will be based directly on the OCT diagnosis, but only when there is certainty about the presence of BCC and BCC subtype according to the OCT diagnosis. A 'safety' biopsy will be performed after the OCT scan. In patients where the OCT diagnosis leaves doubt or it is certain that there is no BCC, a biopsy will be taken anyway and the treatment decision will be based on the result of this punch biopsy.
89282356|NCT03848078|No Intervention|Regular care arm|In patients assigned to regular care, the result of punch biopsy will always be used to decide which treatment is most adequate. Therefore, a next consultation will be planned to discuss the outcome of the biopsy and the intended treatment strategy.
89282357|NCT01296074|Experimental|Corticosteroid|Methylprednisolone will be given during cardiopulmonary bypass.
89282358|NCT03851042|Experimental|Virtual Reality Head set in PACU|Use of VR Headset in PACU post hysterectomy for up to 4 hours.
89282359|NCT03851042|Active Comparator|No intervention|Routine PACU care post hysterectomy for up to 4 hours
89282360|NCT01193738|Active Comparator|active osteopathic compression|osteopathic compression of Pterygopalatine node
89282361|NCT01193738|Placebo Comparator|placebo osteopathic compression|placebo osteopathic compression
89282362|NCT01189448|Active Comparator|Pyrimethamine/Sulfadiazine|Women who are enrolled and randomised in Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
89282363|NCT01189448|Active Comparator|Spiramycine|Spiramycin group : spiramycin 1g tid orally
89282364|NCT03848156||CRSwNP AERD allergic|Patients suffering from chronic rhinosinusitis with nasal polyps, allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
89282365|NCT03848156||CRSwNP AERD non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
89282366|NCT03848156||CRSwNP non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy - biopsy for RNA sequencing
89282367|NCT03848156||CRSwNP allergic|Patients suffering from chronic rhinosinusitis with nasal polyps with allergy - biopsy for RNA sequencing
89282368|NCT05671328||Patients with suspected ventilator-associated pneumonia|
89282369|NCT01195376|Experimental|BEZ235 Dose Escalation once daily|oral BEZ235 once daily (q.d.)
89282370|NCT01195376|Experimental|BEZ Dose escalation twice daily|oral BEZ235 twice daily (b.i.d.)
89282371|NCT01189526|Experimental|IVRI|IVRI : intravitreal ranibizumab (0.5mg) injection
89282372|NCT01189526|Active Comparator|Laser|Laser : macular laser photocoagulation
89282373|NCT01296230|Experimental|Hormone/semen measurements before and after varicocelectomy|We will measure sex-hormone and semen quality in patients both before and after varicocelectomy. The purpose is to asses if preoperative hormone levels are predictive for who will have improved semen quality after surgery.
89282374|NCT01296308||type 2 diabetics with neuropathy|
89282375|NCT01189682|Active Comparator|Tegaderm HP|
89282376|NCT01189682|Placebo Comparator|Tegaderm|
89282377|NCT01189682|Active Comparator|Tegaderm CHG|
89282378|NCT03846206|Experimental|mediterranean diet|Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
89282379|NCT03846206|No Intervention|Usual diet|Patients do usual diet for three months
89282380|NCT01196780||Cohort|
89282381|NCT03845972|No Intervention|before SSFTB|
89282382|NCT03845972|Experimental|after SSFTB|
89282383|NCT05388266|Experimental|Paratracheal pressure|After the induction of anesthesia, paratracheal pressure is applied during mask ventilation.
89282384|NCT05388266|Active Comparator|No pressure|After the induction of anesthesia, no pressure is applied during mask ventilation.
89282385|NCT05671016||Patient aged 65 or older receiving radiotherapy treatment for a newly diagnosed GBM|Patients aged 65 or older who have been newly diagnosed with a Glioblastoma (either through histological confirmation or confirmed by a consultant radiologist in a multidisciplinary team meeting setting) who are planned to be treated with radiotherapy. There is only 1 arm in this study, there is no randomisation. All participants will undertake questionnaires (as described in detail elsewhere in the form) and if the required MRI sequences are not available on their diagnostic imaging then they will undertake a trail specific MRI scan.
89282386|NCT01580696|Active Comparator|Non-vaccine clinically matched control group|HLA-A2-negative patients and HLA-A2+ patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression.
89282387|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
89282388|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
89282389|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
89282390|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
89282391|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
89282392|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
89282393|NCT03846518|Active Comparator|Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
89282394|NCT03846518|Experimental|mini Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the mini Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
89282395|NCT03846440||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
89282396|NCT01197014|Experimental|Amlodipine plus Losartan|
89282397|NCT01197014|Active Comparator|Amlodipine, Losartan|
89282398|NCT01197092|Active Comparator|Verum|
89282399|NCT01197092|Experimental|Control|
89282400|NCT01195454|Experimental|Insulin glargine / New insulin glargine formulation|"Period 1: Insulin glargine~Period 2: New insulin glargine formulation~Period 3: New insulin glargine formulation~Period 4: New insulin glargine formulation~Duration of treatment: 1 day at each period"
89282401|NCT01195532||Gliclazide/2|60 mg*1 for T 30 mg*2 For R
89282402|NCT01195532||Reference and test drug|Reference: 30 mg *2 Test: 60 mg *1
89282403|NCT03851666|Placebo Comparator|12 weeks daily administration Placebo|Intervention: 12 weeks daily administration. The placebo is a powder: microcrystalline cellulose. The daily dose administrated is 15 grams.
89282404|NCT03851666|Experimental|12 weeks daily administration Cereal 1|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 1).~The daily dose administrated is 15 grams."
89282405|NCT03851666|Active Comparator|12 weeks daily administration Cereal 2|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 2).~The daily dose administrated is 15 grams."
89282406|NCT03846596||Evaluated|An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis
89282407|NCT01187966|Placebo Comparator|Placebo|Drug: Placebo
89282408|NCT01187966|Experimental|High Dose (100mg/day)|
89282409|NCT01187966|Experimental|Low dose (50mg/day)|
89282410|NCT01292954|Active Comparator|Low dose blueberry|
89282411|NCT01292954|Active Comparator|medium dose blueberry|
89282412|NCT01292954|Active Comparator|high dose blueberry|
89282413|NCT01292954|Placebo Comparator|control|
89282414|NCT01195610|Experimental|New Nordic Diet|New Nordic Diet
89282415|NCT01195610|Experimental|Average Danish Diet|Average Danish Diet
89282416|NCT01197170|Experimental|Anastrozole|1 mg PO (by mouth) daily for 28 days.
89282417|NCT01197170|Experimental|Anastrozole + Bevacizumab|Anastrozole 1 mg PO daily and Bevacizumab starting dose 10 mg IV Day 1 of 21 day cycle. Expansion group added when MTD dose of Anastrozole + Bevacizumab found.
89282418|NCT01197170|Experimental|Anastrozole + Everolimus|Anastrozole 1 mg PO daily and Everolimus starting dose 5 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Everolimus found.
89282419|NCT01197170|Experimental|Anastrozole + Sorafenib|Anastrozole 1 mg PO daily and Sorafenib starting dose 200 mg PO twice a day for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Sorafenib found.
89282420|NCT01197170|Experimental|Anastrozole + Erlotinib|Anastrozole 1 mg PO daily and Erlotinib starting dose 75 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Erlotinib found.
89282421|NCT05670860||Anti-epileptic prophylaxis|The first group consists of patients treated between January 2019 and late 2020 who were given systematic prophylaxis
89282422|NCT05670860||NO Anti-epileptic prophylaxis|Patients from the second group were treated between 2021 and 2022 and did not receive any prophylaxis
89282423|NCT05382572||Patients|An individual diagnosed with PF or ILD, including those who are post lung transplant.
89282424|NCT05382572||Family Members|A family member (defined as biological parent, full or half-sibling, or biological child) of an individual with PF or ILD.
89282425|NCT05382572||Caregivers|An individual who has cared (currently or in the past) for an individual with PF or ILD.
89282426|NCT01189838||Low Cyr61|Low Cyr61 immunohistochemical stain in patients' TCC tumor
89282427|NCT01189838||High Cyr61|High Cyr61 immunohistochemical stain in patients' TCC tumor
89282428|NCT01197248|Active Comparator|Cystocele Plication|Placement of sutures over the pubocervical fascia during cystocele repair.
89282429|NCT01197248|Experimental|No Plication|Avoid sutures over pubocervical fascia during cystocele repair
89282430|NCT01197404|Active Comparator|General Health Promotion|
89282431|NCT01197404|Experimental|Affect Management|
89282432|NCT01195688|Experimental|BI 638683|1 single dose per subject as oral solution
89282433|NCT01195688|Placebo Comparator|Placebo solution|1 single dose per subject as oral solution
89282434|NCT05516966|Experimental|Group A|Participants receive low dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
89282435|NCT05516966|Experimental|Group B|Participants receive medium dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
89282436|NCT05516966|Experimental|Group C|Participants receive high dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection
89282437|NCT05516966|Active Comparator|Group D|Participants receive Dulaglutide 1.5 mg by multiple subcutaneous injection
89282438|NCT01195766|Experimental|Ofatumumab|Ofatumumab in addition to ESHAP therapy
89282439|NCT03850886|Experimental|Niacinamide group|Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea
89282440|NCT03850886|Active Comparator|Control group|diabetes management including metformin or Sulphonylurea
89282441|NCT03251482|Experimental|Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
89282442|NCT03251482|Experimental|Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
89282443|NCT03251482|Experimental|Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
89282444|NCT03251482|Experimental|Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
89282445|NCT03251482|Experimental|Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
89282446|NCT03251482|Experimental|Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
89282447|NCT03251482|Experimental|Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
89282448|NCT03251482|Experimental|Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
89282449|NCT03251482|Experimental|Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
89282450|NCT03251482|Experimental|Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
89282451|NCT03251482|Experimental|Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg|Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.
89282452|NCT05355584|Active Comparator|10-minute Cryotherapy Application|A cold application will be made on the shoulder for 10 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
89282453|NCT05355584|Active Comparator|15-minute Cryotherapy Application|A cold application will be made on the shoulder for 15 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
89282454|NCT05355584|Active Comparator|20-minute Cryotherapy Application|A cold application will be made on the shoulder for 20 minutes. Before and after the application, individuals will be evaluated in terms of muscle strength, flexibility, endurance and balance. The values before and after the application will be compared.
89282455|NCT01196000|Active Comparator|Arm I|Patients undergo standard conventional laparoscopic resection.
89282456|NCT01196000|Experimental|Arm II|Patients undergo robotic-assisted laparoscopic resection.
89282457|NCT01189916|Experimental|Transrectal NOTES appendectomy|These patients will undergo an experimental surgical procedure that uses flexible endoscopic instruments (i.e., inserted through the rectum).
89282458|NCT01189994|Experimental|Acupuncture|Patients will receive acupuncture treatment in addition to standard care, coming to twelve weekly acupuncture sessions
89282459|NCT01189994|Active Comparator|Orientation|Patients will receive standard care only, coming to three monthly orientation sessions
89282460|NCT03249454|Experimental|Anode, then Cathode, then Anode, then Sham, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282461|NCT03249454|Experimental|Sham, then Cathode, then Anode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282462|NCT03249454|Experimental|Anode, then Cathode, then Sham, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282463|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Anode, then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282464|NCT03249454|Experimental|Anode, then Anode, then Sham, then Cathode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282465|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Cathode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282466|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Sham, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282467|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282468|NCT03249454|Experimental|Cathode, then Cathode, then Sham, then Anode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282469|NCT03249454|Experimental|Anode, Then Cathode, Then Anode, Then Cathode Then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282470|NCT03249454|Experimental|Sham, Then Anode, Then Anode, Then Cathode, Then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
89282471|NCT03732248|Active Comparator|Rapamycin (sirolimus) 15mg|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
89282472|NCT03732248|Placebo Comparator|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
89282473|NCT01586000|Experimental|10 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
89282474|NCT01586000|Experimental|20 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
89282475|NCT01586000|Experimental|40 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
89282476|NCT03898648|Experimental|Depressed patients with history of suicide attempt|Depressed patients with a lifetime history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
89282477|NCT03898648|Experimental|Depressed patients without any history of suicide attempt|Depressed patients without history of suicide attempt will be evaluated regarding their behavioral adaptation toward negative social cues.
89282478|NCT05124548||Post-COVID condition|
89282479|NCT05124548||Healthy controls|
89282480|NCT00310037|Experimental|Arm A maintenance therapy|Patients receive bortezomib 1.6 mg/m^2 IV on days 1, 8, 15, and 22 once daily for 4 weeks. There will be a 4 week rest period. One cycle is a total of 8 weeks. A total of 10 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
89282481|NCT00310037|Experimental|Arm B consolidation therapy|Patients receive bortezomib 1.3 mg/m^2 IV on days 1, 4, 8, and 11 once daily for 3 weeks. One cycle is a total of 3 weeks. A total of 4 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
89282482|NCT03708094||molecular diagnosis confirmed|Whole exome sequencing is applied to children and the molecular diagnosis was identified before renal transplantation.
89282483|NCT03708094||molecular diagnosis unconfirmed|Whole exome sequencing is applied to children and the molecular diagnosis was not identified before renal transplantation.
89282484|NCT05670626|Other|non comparative interventional study|patients with high refractive error will do phakic ICL after preoperative assessment of anterior segments parameters and post-operative ICL vault will be measured using pentacam
89282485|NCT03631654|Placebo Comparator|Control|
89282486|NCT03631654|Experimental|Intervention|
89282487|NCT03477916|Other|Control (Placebo FMT and cellulose)|
89282488|NCT03477916|Experimental|FMT only (FMT followed by cellulose)|
89282489|NCT03477916|Other|Prebiotic only (Placebo FMT and prebiotic fiber)|
89282490|NCT03477916|Experimental|FMT + prebiotic fiber|
89282491|NCT01196234|Experimental|Paclitaxel/Carboplatin/Gefitinib|Paclitaxel/Carboplatin/Gefitinib
89282492|NCT01196234|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel/Carboplatin
89282493|NCT02937376|Experimental|N-acetyl Cystein|NAC supplementation (10 mg/kg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
89282494|NCT02937376|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
89282495|NCT01196468||Anal/cervical dyplasia|Any patient presenting for care with any degree of anal or cervical dysplasia
89282496|NCT01196468||STI|Any patient presenting for care with any non-HIV sexually transmitted infection
89282497|NCT01196468||Lymphoma|Any patient presenting for care with malignant lymphoma of any histological type
89282498|NCT01196468||Seborrhoeic dermatitis/exanthema|Any patient presenting for care with seborrhoeic dermatitis/exanthema
89282499|NCT01196468||Thromobocytopaenia/Leucopaenia, or hypergammaglobulinaemia|Any patient presenting for care with unexplained thromobocytopaenia/leucopaenia of more than four weeks duration, or with hypergammaglobulinaemia
89282500|NCT05324930|Placebo Comparator|Control group|After conventional therapy consisting of debridement, infection control and offloading, patients received a saline-moistened gauze dressing (control group) for wound care.
89282501|NCT05324930|Experimental|Experimental group|After conventional therapy consisting of debridement, infection control and offloading, patients received the piscean collagen dressing (the study group) for wound care.
89282502|NCT00309959|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89282503|NCT03845192|Other|ORI measurement by Radical-97|"In this arm ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®"
89282504|NCT03238924|Experimental|Oxytocin|40 IU intranasal oxytocin spray
89282505|NCT03238924|Placebo Comparator|Placebo|Placebo is matching saline nasal spray
89282506|NCT01190384|Experimental|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
89282507|NCT01190384|Active Comparator|Couscous plus Fiber|Soup with added fiber; has a low ORAC value. Subject serving is isocaloric to the experimental Bean soup.
89282508|NCT01190384|Active Comparator|Couscous plus Grape Seed Extract|Control for ORAC value of the Bean soup; for examining the effect of fiber in the bean soup.
89282509|NCT02532413|Experimental|HBeAg(+):Poly IC+Entecavir|"45 subjects(HBeAg-positive chronic hepatitis B). Combination therapy will last 24 weeks from 0 week.~Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
89282510|NCT02532413|Active Comparator|HBeAg(+):Entecavir|45 subjects(HBeAg-positive chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
89282511|NCT02532413|Experimental|HBeAg(-):Poly IC+Entecavir|"45 subjects(HBeAg-negative chronic hepatitis B). Combination treatment will last 24 weeks from 0 week.~Drug: Enticavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
89282512|NCT02532413|Active Comparator|HBeAg(-):Entecavir|45 subjects(HBeAg-negative chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
89282513|NCT03844958|Experimental|Red Furu|Volunteer was randomized into group red furu
89282514|NCT03844958|Experimental|Fresh Tofu|Volunteer was randomized into group tofu
89282515|NCT05253248|Experimental|Healthy adults|"We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days. Supplementation will provide the daily dietary recommendations of micronutrients, as these are established by the Department of Health, on top of the participant's free diet. Supplementation aims to correct any subclinical deficiencies the participants might have particularly those which are common in the general community. In the UK, a typical example is Vitamin D, due to lack of sunshine and selenium (a geochemical) whose content in the UK soil is depleted and therefore intake is often below the recommendations.~Fasted blood and urine samples will be collected before, and again two-to-three days, post-supplementation."
89282516|NCT02918500|No Intervention|Placebo|Participants will receive 3 weeks of inactive NRT patches.
89282517|NCT02918500|Active Comparator|Active|Participants will receive 3 weeks of active NRT patches
89282518|NCT03850652|Active Comparator|Prebiotic (Synergy-1)|Prebiotic (Synergy-1) + Iron supplement
89282519|NCT03850652|Placebo Comparator|Maltodextrin|Placebo (Maltodextrin) + Iron Supplement
89282520|NCT01190540|Active Comparator|OSS Phase 1|Thirty-six sites will receive the On Site Support service (OSS) activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 1
89282521|NCT01190540|Active Comparator|OSS Phase 2|Thirty-six sites will receive the OSS activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 2 that will serve as a control group in phase 1 and receive OSS nine months later.
89282522|NCT01293188||Biopresthetic aortic valve replacement.|
89282523|NCT03963622|Active Comparator|Control|Standard ventilation strategy.
89282524|NCT03963622|Experimental|Respiratory Mechanics|The goal of this arm is to individualize tidal volume (VT) and PEEP according to respiratory mechanics.
89282525|NCT01198184|Experimental|Treatment (temsirolimus and RO4929097)|Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89282526|NCT00333359|Experimental|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
89282527|NCT03844880|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
89282528|NCT03844880|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
89282529|NCT03246724|Experimental|Cataract Procedures|"The following ocular procedures will fall under this arm of the study:~• Cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
89282530|NCT03246724|Experimental|Retina Procedures|"The following ocular procedures will fall under this arm of the study:~Pars plana vitrectomy~Pars plana vitrectomy with cataracts, epiretinal membrane peel, pars plana lensectomy, and/or endolaser, silicone oil removal~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
89282531|NCT03246724|Experimental|Cornea Procedures|"The following ocular procedures will fall under this arm of the study:~Descemet Stripping Endothelial Keratoplasty (DSEK)~Cataracts with Descemet Stripping Endothelial Keratoplasty (DSEK)~Descemet Membrane Endothelial Keratoplasty (DMEK)~Cataracts with Descemet Membrane Endothelial Keratoplasty (DMEK)~Conjunctival and/or corneal lesion excisions~Pterygium~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
89282532|NCT03246724|Experimental|Glaucoma Procedures|"The following ocular procedures will fall under this arm of the study:~Ahmed valve~Ahmed valve with cataracts~Trabeculectomy~Trabeculectomy with cataracts~Baerveldt~Baerveldt with cataracts~Endocyclophotocoagulation~Endocyclophotocoagulation with cataracts~Istent~Cataracts with istent~Kahook~Cataracts with kahook~Cypass~Cypass with cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
89282533|NCT05484440|Experimental|Group cognitive-behavioral intervention plus individual Motivational Interviewing|Group participants will participate in six individual sessions based on Motivational Interviewing techniques (60 minutes each) and then in 18 group sessions based on psychoeducational and cognitive-behavioral techniques (90 to 120 minutes each). Groups will be composed of 6 to 10 participants. The intervention will be delivered weekly.
89282534|NCT05484440|Experimental|Group cognitive-behavioral intervention|Group participants will participate in 18 group sessions based on psychoeducational and cognitive-behavioral techniques (90 to 120 minutes each). Groups will be composed of 6 to 10 participants. The intervention will be delivered weekly.
89282535|NCT05484440|No Intervention|Treatment as usual (TAU)|Group participants will receive the usual treatment delivered by different institutions (e.g., correctional services, probation services, child protection services) as the participants of this study are justice-involved individuals (i.e., perpetrators of intimate partner violence).
89282536|NCT03984227||SLE patient group|SLE diagnosed patients between (18- 60) years old will be enrolled. All participants should met at least four of the American College of Rheumatology criteria (Hochberg, 1997). Disease activity will be assessed in accordance with the SLE Disease Activity Score (SLEDAI 2000 (SLEDAI-2K) (Ward et al., 2000).
89282537|NCT03984227||control group|The control group will include age and sex matched healthy volunteers
89282538|NCT01196546|Experimental|Vildagliptin/metformin|
89282539|NCT01196624|Active Comparator|TMS TO RT DLPF WITH EXPOSURE|TMS TO RIGHT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
89282540|NCT01196624|Active Comparator|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE
89282541|NCT01196624|Active Comparator|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
89282542|NCT01196624|Active Comparator|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE
89282543|NCT04609228||Blood-transfusion non-acceptors|Blood-transfusion non-acceptors
89282544|NCT04609228||Blood-transfusion acceptors|Blood-transfusion acceptors
89282545|NCT01293266|Active Comparator|Propofol|Anesthesia is changed from Sevoflurane to Propofol after obtaining baseline blood gas analysis from the heart catheterisation sheath.
89282546|NCT01293266|No Intervention|Sevoflurane|Sevoflurane anesthesia is maintained after obtaining a baseline blood gas analysis.
89282547|NCT03246646|Experimental|Coaching + VA CRAFT|Telephone coaching along with web-based CRAFT course
89282548|NCT03246646|Other|Treatment as usual|Treatment as usual matched comparison
89282549|NCT03948646|Experimental|Active|Sofpironium bromide, 15% gel, once per day
89282550|NCT03948646|Placebo Comparator|Vehicle|Vehicle gel, once per day
89282551|NCT01198340|Active Comparator|With basal local anesthetics|
89282552|NCT01198340|Experimental|Without basal local anesthetics|
89282553|NCT05670548||Abnormal postpartum glucose metabolism|GDM with positive OGTT results at 6-12 weeks postpartum
89282554|NCT05670548||Control|GDM with negative OGTT results at 6-12 weeks postpartum
89282555|NCT01347112|Active Comparator|Varenicline|varenicline 1.0 mg twice daily for 12 weeks
89282556|NCT01347112|Placebo Comparator|Sugar Pil|Varenicline look alike sugar pill twice daily for 12 weeks
89282557|NCT05083598||Adult patients undergoing major surgery|Patients aged 70 or older undergoing major non cardiac surgery, with expected surgical duration > 2 hours.
89282558|NCT05572216|No Intervention|conventional group|Robot-Assisted Partial Nephrectomy without 3D navigation
89282559|NCT05572216|Experimental|3D IGRAPN GROUP|Robot-Assisted Partial Nephrectomy with 3D navigation
89282560|NCT01293344|Experimental|Men and Mediterranean diet|Men who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
89282561|NCT01293344|Experimental|Women and Mediterranean diet|Women who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
89282562|NCT00308711|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg over 24h
89282563|NCT00308711|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg over 24h
89282564|NCT00308711|Active Comparator|Cervidil 10 mg vaginal insert|Cervidil 10 mg over 24h
89282565|NCT05170568|Experimental|T cell injection targeting CD7 chimeric antigen receptor|
89282566|NCT01190696|Other|hip spica casting|Patients in the spica cast group treated with skeletal traction and spica cast applied for them
89282567|NCT01190696|Other|titanium elasting nailing|For patients in the Titanium Elasting Nailing group, the nail applied retrogradely in femoral shaft fracture
89282568|NCT04655716|Experimental|Sodium bicarbonate|Intravenous sodium bicarbonate infusion
89282569|NCT04655716|No Intervention|Standard care|Standard of care by the clinical team
89282570|NCT01198418|Experimental|Internet-based counseling|Completes surveys monthly about their sexual and drug use behaviors as well as receives information designed to help reduce the chances of getting an STI.
89282571|NCT01198418|No Intervention|Survey Alone|Completes surveys monthly about their sexual and drug use behaviors
89282572|NCT04653688|Experimental|Parkinsonian syndromes patients|
89282573|NCT04653688|Sham Comparator|healthy subjects|
89282574|NCT02532725||Lean|Men aged 35-55 years, having <20% body fat
89282575|NCT02532725||Obese|Men aged 35-55 years, having >29% body fat
89282576|NCT03844490|Other|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivery)
89282577|NCT03844490|Experimental|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontaneous pulsation stops.~At this time, cord clamping will be made."
89282578|NCT00308555|Other|Cannabis|
89282579|NCT05153044|Other|sickle cell children group|sickle cell children group
89282580|NCT05153044|Other|sickle cell adult group|sickle cell adult group
89282581|NCT05153044|Other|control children group|control children group
89282582|NCT05153044|No Intervention|Vaccinated patients|Vaccinated patients
89282583|NCT01198496|Experimental|Blood pressure|"The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: less than 120/80 mmHg* than in a standard BP control group having BP target less than 140/90 mmHg or less than 130/80 mmHg for current DM/CKD/old MI in patients with hypertension.~This study uses BP target: less than 120/80 mmHg that is sat up for this study rather than the BP target recommended in the Guidelines for the management of hypertension, Japanese Society of Hypertension 2009.~BP management is strongly recommended in patients with hypertension, DM, and/or CKD for prevention of recurrent stroke in the Japanese guidelines for the management of stroke 2009."
89282584|NCT01066013|Experimental|Prospective Antimicrobial de-escalation arm|Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).
89282585|NCT01066013|No Intervention|Restrospective control arm|The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.
89282586|NCT01198652||Belfort-Dildy Obstetric Tamponade Tx|Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort.
89282587|NCT01066091|Placebo Comparator|mashed potatoes|Mashed potatoes is composed of potatoes and Skim milk powder.
89282588|NCT01066091|Experimental|Mashed potatoes + Oleic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 75% of Oleic Acid
89282589|NCT01066091|Experimental|Mashed potatoes + Palmitic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 39% of saturated fat with 32% of palmitic acid.
89282590|NCT05073848||BfitBwell Participants|Individuals in the BfitBwell Cancer Exercise Program complete a FACIT-Fatigue questionnaire at their baseline assessment. This will be screened for all incoming BfitBwell participants and those meeting the inclusion criteria of a score of 48 or less will be approached for interest in participating. The primary research activities beyond recruitment, screening, and informed consent are the collection of EMA fatigue assessments via smartphone application and PA assessment via actigraphy.
89282591|NCT03846284|Placebo Comparator|Bupivacaine (B group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion 50 cm saline with rate 10-20 ml/h according to child weight."
89282592|NCT03846284|Experimental|Magnesium sulfate caudal (MC group)|"caudal block with bupivacaine 0.25% 1mg/kg + Magnesium sulfate 50 mg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion of 50 cm saline with rate 10-20 ml/h according to child weight."
89282593|NCT03846284|Experimental|Magnesium sulfate I.V (M V group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
89282594|NCT01066169||Healthy volunteers|Healthy subjects without HIV, vaccinated with Pandemic Influenza A/H1N1
89282595|NCT01066169||HIV-infected patients|HIV-infected patients, vaccinated with Pandemic Influenza A/H1N1
89282596|NCT05572060|Active Comparator|Group C: (n=25) control.|patients will receive standardized protocol without receiving metformin.
89282597|NCT05572060|Active Comparator|Group D: (n=25) diabetic patients.|diabetic patients will receive standardized protocol and receiving metformin 500 mg every 8 hours since admission regardless of their random blood sugar with measurement of random blood sugar every hour and dextrose 25% infusion will be used if needed and also insulin infusion will be used when appropriate with target random blood sugar 140-180 in diabetic patients.
89282598|NCT05572060|Active Comparator|Group ND: (n=25) non-diabetic patients.|patients will receive standardized protocol and receiving metformin 500 mg every 8 hours since admission regardless of their random blood sugar with measurement of random blood sugar every hour and dextrose 25% infusion will be used if needed and also insulin infusion will be used when appropriate with target random blood sugar 100-140 in non diabetic patients.
89282599|NCT05431244|Other|Antiviral treatment in combination with low-dose gemcitabine|"For 1st & 2nd cycle D1, 8, 15 Gemcitabine 30-300mg/m2 IV over 30 minutes D8-28 Valganciclovir 900mg qd Every 4 weeks~For 3rd ~ 6th cycle D1, 8, 15 Gemcitabine 30-300mg/m2 IV over 30 minutes D1-28 Valganciclovir 900mg qd Every 4 weeks"
89282600|NCT05571982|Experimental|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
89282601|NCT05571982|Active Comparator|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
89282602|NCT01314040|Other|Run in|
89282603|NCT01314040|Experimental|High meat protein diet|
89282604|NCT01314040|Experimental|High dairy protein diet|
89282605|NCT01314040|Experimental|High grain protein diet|
89282606|NCT03850184||Mental Health Professionals|Psychiatrists, Psychologists, Nurses working with patients with mental disorders
89282607|NCT04923308||Intervention group|
89282608|NCT04923308||Control group|
89282609|NCT03182972|Experimental|Intervention arm|"Seminar presentation will be done using the followings:~Power point presentation on the following topics as it relates to medication reconciliation:~Communication skill (with patients and also with other members of the healthcare team)~Documentation of pharmaceutical care activities~Medication history taking~Drug therapy problems~Medication reconciliation practice~Case studies on medication reconciliation~Role plays on medication reconciliation"
89282610|NCT03182972|No Intervention|Control arm|Control group
89282611|NCT05571826||telerehabilitation|Assessments, no specific intervention
89282612|NCT05072288|Experimental|Remote activity program|Activity program based on objective evaluation. Possibility of 35 different programs primarily targeting impairments (lower limb, upper limb or balanced)
89282613|NCT04916912||CABG-1|A group of non-obese patients (BMI less than 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
89282614|NCT04916912||CABG-2|A group of obese patients (BMI over 30 kg / m2) who underwent isolated coronary artery bypass grafting for chronic ischemic heart disease
89282615|NCT03850106|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose)
89282616|NCT03850106|Active Comparator|Indus810|Indus810 ( 500mg/d)
89282617|NCT01199432|Experimental|Group B(CEF)|
89282618|NCT01199432|Experimental|Group A(CEFci)|
89282619|NCT01199432|Active Comparator|Group C(EC)|
89282620|NCT05064020||Polypharmacy|"Polypharmacy: patient is using five or more medications will be considered polypharmacy.~Subjects having polypharmacy condition with taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]"
89282621|NCT05064020||Nonpolypharmacy|"Nonpolypharmacy: patient is using less than five medications will be considered nonpolypharmacy~Nonpolypharmacy Subjects taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]"
89282622|NCT05058560|Experimental|BACE+Tislelizumab|BACE was performed on the first day of the first cycle, and the first 200 mg of tislelizumab was given 3-5 days later.
89282623|NCT01293422|Experimental|Rifampicin|
89282624|NCT01190774|Experimental|Dentist behaviour|Patient completes the MDAS which is handed to receptionist who then gives the information to the dentist with patient knowledge
89282625|NCT01190774|Experimental|Dentist behaviour and patient expectancy|Patient completes the MDAS and hands to the dentist
89282626|NCT03850262||patients with posterolateral corner trauma of the knee|
89282627|NCT01198886|Placebo Comparator|Successful Aging Program|
89282628|NCT01198886|Experimental|Exercise-Nutrition Program|
89282629|NCT01198964||Epileptic Patients|The population of patients with medically refractory epilepsy will already have been recommended clinically for electrode grid placement on the brain and high-level stimulation to map brain function.
89282630|NCT01566656|Experimental|TLI and anti-thymocyte globulin|
89282631|NCT01566734|Experimental|Cefazolin|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
89282632|NCT01566734|Experimental|Normal Saline|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients
89282633|NCT01566734|No Intervention|Control|
89282634|NCT00050778|Active Comparator|Interferon Beta-1a|
89282635|NCT00050778|Experimental|Alemtuzumab 12 mg|
89282636|NCT00050778|Experimental|Alemtuzumab 24 mg|
89282637|NCT05670392|Active Comparator|Arm 1: laser and HITS treatment|Laser and magnetic chair Treatment
89282638|NCT05670392|Other|Arm 2: laser (without HITS treatment)|Laser treatment
89282639|NCT01199510|Experimental|Standard of Care plus FID 112903|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
89282640|NCT01199510|Active Comparator|Standard of Care only|Post Cataract Standard of Care Regimen
89282641|NCT01199588|Experimental|Nexagon® High Dose|Weekly applications of Nexagon® high dose in addition to compression dressings.
89282642|NCT01199588|Placebo Comparator|Nexagon® Vehicle|Weekly applications of Nexagon® Vehicle in addition to compression dressings.
89282643|NCT01199588|No Intervention|No Investigational Product|Weekly application of compression dressings.
89282644|NCT01199588|Experimental|Nexagon® Low Dose|Weekly applications of Nexagon® low dose in addition to compression dressings.
89282645|NCT04153682|Active Comparator|Antimicrobial stewardship (= AMS)|Management of HAP according to current practice, including intervention of the AMS team.
89282646|NCT04153682|Experimental|Antimicrobial Stewardship + Rapid Diagnostic Testing|Management of HAP including rapid diagnostic testing (FA-PP) and intervention of the AMS team.
89282647|NCT01199120|Experimental|Omega 3|
89282648|NCT00050622|Placebo Comparator|No Treatment|No Medication, No Behavior Modification (BMOD)
89282649|NCT00050622|Active Comparator|Low Dose Medication Only|0.15 mg/kg methylphenidate (MPH), No BMOD
89282650|NCT00050622|Active Comparator|Medium Dose Medication Only|0.3 mg/kg MPH, No BMOD
89282651|NCT00050622|Active Comparator|Higher Dose Medication Only|0.6 mg/kg MPH, No BMOD
89282652|NCT00050622|Active Comparator|Low Intensity BMOD Only|Placebo, Low Intensity BMOD
89282653|NCT00050622|Active Comparator|Low Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, Low Intensity BMOD
89282654|NCT00050622|Active Comparator|Low Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, Low Intensity BMOD
89282655|NCT00050622|Active Comparator|Low Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, Low Intensity BMOD
89282656|NCT00050622|Active Comparator|High Intensity BMOD Only|Placebo, High Intensity BMOD
89282657|NCT00050622|Active Comparator|High Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, High Intensity BMOD
89282658|NCT00050622|Active Comparator|High Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, High Intensity BMOD
89282659|NCT00050622|Active Comparator|High Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, High Intensity BMOD
89282660|NCT00308087|Active Comparator|Rituximab|
89282661|NCT00308087|Experimental|Rituximab + Sargramostim|
89282662|NCT04942184|Experimental|Group 1- 15 Mild AD and 15 MCI due to AD|In Group 1, for the first 2 weeks participants will be taught memory strategies and reminded to use them each day from week 0 to week 2. Weeks 3-4, participants will be advised to keep using the strategies both on the tablet and in their daily life even though they will not be reminded each time they start the task.
89282663|NCT04942184|Active Comparator|Group 2- 15 Mild AD and 15 MCI due to AD|"In Group 2, for the first 2 weeks participants will be reminded to try hard to remember the items although they will not be given any specific strategies. At week 2 the subjects will be taught memory strategies and reminded to use them each day from week 2 to week 4."
89282664|NCT01090284||Heavy weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene heavy weight mesh.
89282665|NCT01090284||Light weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene light weight mesh.
89282666|NCT01202006|Experimental|Intervention|General practitioners of patients in the intervention group will receive detailed instructions on uptitration of ACE-inhibitors and beta-blockers before the inclusion of participants.
89282667|NCT01202006|No Intervention|Control|Patients in the control group receive care-as-usual. Their general practitioner will not be trained in applying the uptitration protocol.
89282668|NCT00307931|Experimental|Certolizumab pegol|certolizumab pegol 400 mg
89282669|NCT01097148|Active Comparator|Atracurium, TBW|Dose of atracurium 0.5 mg/kg based on total body weight
89282670|NCT01097148|Active Comparator|Atracurium IBW|dose 0.5 mg/kg based on ideal body weight
89282671|NCT01097226|Experimental|Apple flavanols|
89282672|NCT01095432||Main Study Group|All subjects who are undergoing a standard of care colonoscopy for flexible sigmoidoscopy and have a history of UC and agree to participate will be in the main study group.
89282673|NCT03844724|Experimental|Group A|subjects using the drug-eluting PTA balloon dilatation catheter
89282674|NCT03844724|Active Comparator|Group B|subjects using the peripheral balloon dilatation catheter
89282675|NCT01199276|Experimental|Xenon|60%(1MAC)in oxygen (FiO2 = 0.35-0.45)
89282676|NCT01199276|Active Comparator|Sevoflurane|1.1-1.4% (1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air
89282677|NCT03955380|Active Comparator|Active Comparator: Contraloid 160 mg|160 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
89282678|NCT03955380|Active Comparator|Active Comparator: Contralod 320mg|320 mg Contraloid/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
89282679|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 160 mg|160 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
89282680|NCT03955380|Placebo Comparator|Placebo Comparator (for Contraloid) 320 mg|320 mg placebo/participant administered orally (for 14 days in the first cohort and for 28 days in the second cohort) as a single daily dose.
89282681|NCT01199666|Experimental|Text message reminders|
89282682|NCT01199666|Active Comparator|standard of care for MMR, letter reminder for Hep A|MMR: automated phone call appointment reminder Hep A: recall letter, automated phone call appointment reminder
89282683|NCT01202084|Experimental|Formoterol/Fluticasone Eurofarma|formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks
89282684|NCT01202084|Active Comparator|Foraseq®|formoterol + budedonide (12/400 mcg) twice a day per 12 weeks
89282685|NCT01202084|Active Comparator|Fluticasone|fluticasone (500 mcg) twice a day per 12 weeks
89282686|NCT03842072|No Intervention|No post-operative bracing|patients in this arm will not be prescribed a cervical collar following anterior cervical discectomy and fusion surgery
89282687|NCT03842072|Active Comparator|Post-operative bracing|Patients in this arm will be prescribed a cervical collar following anterior cervical discectomy and fusion surgery.
89282688|NCT03839264||Graft stenosis and thrombosis|Diagnostic performance for stenosis at angiography of non invasive screening tools (duplex ultrasound, access blood flow (Qa), dynamic and static dialysis machine venous pressures, dynamic dialysis machine arterial pressure, and monitoring) and incipient thrombosis (within 4-month period) of the presence and degree of stenosis at angiography, non invasive screening techniques and acute hypotensive episode/s during the follow-up
89282689|NCT04133792|Experimental|Simvastatin|Simvastatin 40 mg administered orally daily for 5 years.
89282690|NCT04133792|Placebo Comparator|Placebo|Placebo for Simvastatin 40 mg administered orally daily for 5 years.
89282691|NCT01204034|Other|Inuvair|
89282692|NCT01202240|Experimental|Tasocitinib (CP-690,550) plus Ketoconazole|
89282693|NCT01204112|Experimental|Tasocitinib (CP-690,550) plus Rifampin|
89282694|NCT05670314|Placebo Comparator|Placebo arm|The participants in the placebo/control arm (N=30) will be required to take 10g of maltodextrin for the same period of 6 weeks.
89282695|NCT05670314|Experimental|Diet only Arm|The participants in the dietary intervention arm will be required to take 20g of inulin (N=30) for a period of 6 weeks.
89282696|NCT05670314|Experimental|Exercise only arm|Joint Academy An app-based exercises platform (Joint Academy®) will be used as an intervention given to the treatment arm. The programme consists of a mixture of open and close chain exercises, a combination of concentric, eccentric and focusing on the global strength of legs including the muscles around the hips and knee joints as well as balance enhancement exercises. The intervention also includes educational sessions integrated into the programme covering the basics of OA, its treatment, self-managing symptoms of OA and the benefits of maintaining a healthy lifestyle. The exercise intervention focuses on core stability and performance, neuromuscular leg strengthening and balance enhancement.
89282697|NCT05670314|Experimental|Diet + exercise intervention arm|The participants in this arm will be required to take 20g of inulin (N=30) for a period of 6 weeks and doing exercise at the same time.
89282698|NCT05670002|Other|Intervention|Taking milk supplement
89282699|NCT01204190|Experimental|Arm 1|
89282700|NCT01204190|Experimental|Arm 2|
89282701|NCT01204190|Experimental|Arm 3|
89282702|NCT01204268|No Intervention|Propofol group|Patients will receive the total intravenous anesthesia with propofol infusion during the surgery.
89282703|NCT01204268|Active Comparator|Sevo-C group|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
89282704|NCT01204268|Experimental|Sevo-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
89282705|NCT02965898|Active Comparator|Vitamin D 100ug|The highest safest dose. Expected to lower risk of chronic pancreatitis after acute pancreatitis.
89282706|NCT02965898|Placebo Comparator|Vitamin D 10ug|Placebo dose. Minimal recommended dose
89282707|NCT03843866|Active Comparator|Suture & steri-strips|
89282708|NCT03843866|Active Comparator|Adhesive Glue|
89282709|NCT01204346|Experimental|MBT group|mentalization based treatment program
89282710|NCT01204346|Active Comparator|Treatment as usual group|treatment as usual group
89282711|NCT01567202|Experimental|Arm DC|In this arm, the patients will receive DC vaccination in addition to the standard therapy, including Surgery, Chemotherapy, and Radiotherapy.
89282712|NCT01567202|Placebo Comparator|Arm Placebo|In this arm, the patients will receive blank placebo instead of the DC vaccination in addition to the standard therapy.
89282713|NCT02796170|Active Comparator|Dapagliflozin|Participants underwent 6 weeks of Dapagliflozin or placebo (washout period for 2 weeks) and then crossed over to 6 weeks of placebo or Dapagliflozin.
89282714|NCT02796170|Active Comparator|Placebo|Participants underwent 6 weeks of Dapagliflozin or placebo (washout period for 2 weeks) and then crossed over to 6 weeks of placebo or Dapagliflozin.
89282715|NCT02725658|Other|DOSI|
89282716|NCT03844178|Active Comparator|The right eyes with compensation for Pupil centroid shift|
89282717|NCT03844178|Active Comparator|The left eyes without compensation for Pupil centroid shift|
89282718|NCT03843788|Experimental|Post-CS TENS|The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site. Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
89282719|NCT03843788|Experimental|Opioid Addicted Post-CS TENS|Subjects will be targeted on the basis of opioid addiction and usage of methadone maintenance. The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site). Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
89282720|NCT03843788|No Intervention|Post-CS Routine Care|Routine pharmacologic care will be provided.
89282721|NCT03843788|No Intervention|Opioid Addicted Post-CS Routine Care|Routine pharmacologic care will be provided.
89282722|NCT04702724|Experimental|Experimental group|
89282723|NCT03841994||Preterm infant cohort|Preterm infants who were born <28 weeks of gestational age
89282724|NCT02670902|Experimental|Critical Time Intervention-Residential|CTI-R is a 9-month, assertive outreach and linkage program.
89282725|NCT02670902|Active Comparator|Enhanced Usual Discharge-Residential|The enhanced usual discharge condition includes usual discharge services plus enhanced transition services.
89282726|NCT00049842|Experimental|PEG-Intron (peginterferon alfa-2b) 0.5 µg/kg Weekly (QW)|PEG-Intron 0.5 µg/kg Weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up
89282727|NCT00049842|No Intervention|Untreated Control|
89282728|NCT00307151|Experimental|Coh I: NVP|Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.
89282729|NCT00307151|Experimental|Coh I: LPV/r|Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.
89282730|NCT00307151|Experimental|Coh II: NVP|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen
89282731|NCT00307151|Experimental|Coh II: LPV/r|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen
89282732|NCT03979157|Experimental|Healthy Volunteers|Multispectral Optoacoustic Tomography (MSOT) of proximal and distal leg muscles (total of 12 sites: left and right, 3 measurement points of Musculus quadriceps, and 3 measurement points of Musculus triceps surae) before and after the 6-Minute-Walk-Test by to independent investigators. Repetition of the same protocol after 14 days.
89282733|NCT03978923||the drill-inserted implants (G1)|
89282734|NCT03978923||the ultrasonic device- inserted implants (G2)|
89282735|NCT03981029||FACT High-dose folic acid treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily high-dose folic acid supplementation during pregnancy.
89282736|NCT03981029||FACT Placebo treatment group|Consenting study participants who, through their participation in FACT (NCT01355159) are randomized to receive daily placebo supplementation during pregnancy.
89282737|NCT02654132|Experimental|Elotuzumab Arm|"Biological:Elotuzumab (BMS-901608; HuLuc63)~Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)~Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)~Drug: Pomalidomide~•Capsules,Oral,4 mg,once daily, on Days 1-21~Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~•Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Subjects > 75 years old:~•Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Other Names:~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak"
89282738|NCT02654132|Active Comparator|Control Arm|"Drug: Pomalidomide~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22~Subjects > 75 years old:~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,~Other Names:~Decadron~Dexamethasone Intensol~Dexpak~Taperpak"
89282739|NCT01064141|Experimental|Group 1: Dengue Vaccine Group|Participants will receive CYD Dengue vaccine as Visits 1 and 2.
89282740|NCT01064141|Active Comparator|Group 2: Control Group|Participants will receive Control Vaccines. (Varicella at Visit 1 and Hepatitis A at Visit 2)
89282741|NCT01064141|Experimental|Group 3: Co-administration Group|Participants will receive CYD Dengue vaccine and childhood vaccines at Visit 1 and CYD Dengue vaccine at Visit 2.
89282742|NCT01064141|Experimental|Group 4: Sequential Administration Group|Participants will receive CYD Dengue vaccine and a Placebo vaccine at Visit 1 and CYD Dengue vaccine at Visit 2.
89282743|NCT03241342|Active Comparator|1 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
89282744|NCT03241342|Active Comparator|3 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
89282745|NCT03241342|Placebo Comparator|matching placebo|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
89282746|NCT02532803|Experimental|Novel pelvic MRI scan assessment|All patients with rectal tumours of 20-50mm in size who consent to enter the trial will receive novel staging report for their pelvic MRI scan.
89282747|NCT03837470|Experimental|Saline Loading and Diuretic Challenge|Subjects receive intravenous infusion of 0.9% Sodium Chloride, followed by diuretic challenge with bolus injection of Furosemide 40 mg
89282748|NCT04614844|Experimental|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
89282749|NCT04614844|Active Comparator|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
89282750|NCT04572646|Other|NRT proposition and exhaled CO measurement|
89282751|NCT03837236|Experimental|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
89282752|NCT03636880|Experimental|Brief treatment for insomnia|Brief Behavioral Treatment for Insomnia (BBTI) is a manualized, individual intervention designed to modify sleep patterns to reduce insomnia and improve sleep quality and efficiency. Participants complete two in-person meetings and two booster telephone calls over a four-week period.
89282753|NCT03636880|Active Comparator|Sleep Monitoring|Sleep Monitoring is an active comparator condition where participants track their sleep patterns for two weeks prior to the baseline and post-intervention assessments. They receive no contact from study staff during the intervening four-week period, except for a reminder call to begin completing the second sleep diary and to schedule the post-intervention assessment.
89282754|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -8 hours prior to OGTT|
89282755|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -12 hours prior to OGTT|
89282756|NCT01199900|Active Comparator|(Part 1) 5 mg Prednisone|5 mg prednisone tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
89282757|NCT01199900|Experimental|(Part 2) 3 mg PF-04171327|
89282758|NCT01199900|Experimental|(Part 2) 10 mg PF-04171327|
89282759|NCT01199900|Active Comparator|(Part 2) 5 mg Prednisone|
89282760|NCT01199900|Active Comparator|(Part 2) 20 mg Prednisone|
89282761|NCT03841838|Experimental|Energy drink|Two 12 oz bottles of energy drink
89282762|NCT03841838|Placebo Comparator|Placebo|Two 12 oz bottles of placebo drink
89282763|NCT01200056|Active Comparator|Atorvastatin 10mg low dose|Atorvastatin 10mg daily for 6 months and compared to atorvastatin 40mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
89282764|NCT01200056|Active Comparator|Atorvastatin 40mg moderate dose|Atorvastatin 40mg daily for 6 months and compared to atorvastatin 10mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
89282765|NCT01204502|Experimental|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~dose 1 5x104 cells/kg~dose 2 5x105 cells/kg"
89282766|NCT02473874||Skin Spect dermoscope|Skin mole
89282767|NCT02473874||Spatially modulated quantitative|Skin mole
89282768|NCT01200134|Experimental|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
89282769|NCT01200212|Experimental|A|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22 + 1800 mg/m2 Capecitabine day 1-14 q22
89282770|NCT01200212|Active Comparator|B|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22
89282771|NCT00306995|Experimental|SB218352_15 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
89282772|NCT00306995|Experimental|SB218352_8 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
89282773|NCT00306995|Experimental|SB218352_4 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
89282774|NCT00306995|Experimental|SB218352_2 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
89282775|NCT00306995|Experimental|SB218352_8AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
89282776|NCT00306995|Experimental|SB218352_4AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
89282777|NCT00306995|Experimental|SB218352_2AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
89282778|NCT00121108|Placebo Comparator|Placebo|Participants will receive IM dose of placebo matched to motavizumab every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
89282779|NCT00121108|Active Comparator|Motavizumab|Participants will receive IM dose of motavizumab 15 milligram/Kilogram (mg/kg) every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
89282780|NCT03978845|Experimental|Phrenic Nerve Blockade|All patients will be submitted to bilateral phrenic nerve block on its cervical portion.
89282781|NCT02387996|Experimental|Nivolumab|Nivolumab intravenous infusion as specified
89282782|NCT03841370||endodontic|"The color of anterior (incisors and canines) and posterior (premolar) teeth treated at a private clinic in the city of Pelotas will be evaluated. Data will be collected regardless of technique, treatment time and sealer used.~The ΔE00 will be evaluated using the measurements obtained in the homologous tooth (without endodontic treatment) versus the measurement obtained from the tooth treated endodontically.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
89282783|NCT01204580|Experimental|Amaryl-M (Glimepiride + Metformin)|"Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets.~Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test."
89282784|NCT01566812|Experimental|Breast feeding optimization|
89282785|NCT01566812|Active Comparator|Usual/routine care|
89282786|NCT04673708|Other|Hashim Talib Hashim|It is a video with +18 different contents to know the effect of much video than the others.
89282787|NCT04673708|Experimental|Mustafa Ahmed Ramadhan|Is is an assessment of the vital signs among the participants and the change with the showing of videos.
89282788|NCT05181514|Placebo Comparator|Normal Saline|Participants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of normal saline
89282789|NCT05181514|Experimental|20% Intralipid|Participants will undergo a dual labeled, 3-h oral glucose tolerance test (OGTT) during i.v. infusion of Intralipid 20%.
89282790|NCT04662398|Active Comparator|Case (Testes shocker device)|The shocker will be used in delivering the current gradually on the testes and penis to improve the blood flow and stimulates the sexual activity among males.
89282791|NCT04662398|Sham Comparator|Control (non testes shocker device)|These groups will not given the shocks, shame device will be used instead and then compare the two results.
89282792|NCT05253976||Patients who received the NexGen TM Augmentation Patella|
89282793|NCT03841786|Placebo Comparator|Control diet|Participants will be asked to consume a normal diet supplemented with sodium chloride (sodium chloride tablets, USP, 1 gram; 3 tablets per day) and potassium chloride (Klor-Con, 8 mEq; 0.5 tablets per day) for 1 week.
89282794|NCT03841786|Experimental|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet with supplemental phosphorus (K-Phos Neutral tablets, 250 mg; 4 tablets a day) for 1 week.
89282795|NCT04644614|Active Comparator|Group 1: Magnetic Stimulation|Patients will be instructed to sit in a magnetic coil chair. Magnetic flux is generated in this field. This current stimulates the nerve or muscle of the pelvic floor. To administer MS, a stimulation amplitude of 200 μs and a repetition of 10 Hz for 10 minutes, 2 minutes rest in between, 50 Hz for 10 minutes (20 minutes total), 5 seconds on / 5 seconds off, in accordance with device literature will be adjusted to produce maximum stimuli with the cycle. During each treatment session, the device will be adjusted to receive patients the current intensity gradually increasing, reaching the maximum stimulation intensity.
89282796|NCT04644614|Sham Comparator|Group 2: Sham Magnetic Stimulation|"The Sham MS treatment program will be the same as active MS in terms of duration, frequency, current duration, current intensity and general patient experience. The same magnetic chair will be used for both groups. Sham therapy application will be applied by the coordinator of the study by placing a thin deflector lead / aluminum coated plate on the magnetic coil of the magnetic chair that prevents the magnetic flux from penetrating into the patient.~During both applications, the patients will be exposed to the same sound, vibration sensation and lighting of the device."
89282797|NCT05181202||Hypersensitivity reaction group|The patients get hypersensitivity after Pegylated liposomal doxorubicin injection.
89282798|NCT05181202||None hypersensitivity reaction group|The patients do not get hypersensitivity after Pegylated liposomal doxorubicin injection.
89282799|NCT02016248|Experimental|Low Risk Cohort|"The low risk cohort will receive:~Stereotactic Ablative Body Radiotherapy as Monotherapy on the CyberKnife System"
89282800|NCT02016248|Experimental|High Risk Cohort|"The high risk cohort will receive:~28 treatments of external beam radiation therapy followed by Stereotactic Ablative Body Radiotherapy as a Boost on the CyberKnife System and hormonal therapy as indicated."
89282801|NCT03212326|Experimental|Definity|Perflutren echo contrast is infused to enhance intracardiac echo imaging recorded during catheter ablation of ventricular tachycardia. We will compare areas that appear to be myocardial scar on ultrasound with areas of abnormal electrical signals obtained by direct catheter mapping.
89282802|NCT03833882|Experimental|MAF1217/Cationorm|
89282803|NCT03833882|Experimental|Cationorm/MAF1217|
89282804|NCT03834194|Experimental|Lottery + Monthly Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
89282805|NCT03834194|Experimental|Lottery + Overall Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
89282806|NCT03834194|Experimental|Lottery + Overall Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
89282807|NCT03834194|Experimental|Lottery + Monthly Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
89282808|NCT03834194|Experimental|Loss + Monthly Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
89282809|NCT03834194|Experimental|Loss + Overall Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
89282810|NCT03834194|Experimental|Loss + Overall Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
89282811|NCT03834194|Experimental|Loss + Monthly Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
89282812|NCT03229486|Experimental|Sugammadex Injection [Bridion]|reversal of neuromuscular blockade with sugammadex
89282813|NCT03229486|Active Comparator|Neostigmine+Glycopyrronium|reversal of neuromuscular blockade with neostigmine & glycopyrrolate
89282814|NCT03833648|No Intervention|Arm 1 - Usual Care|No intervention, patients will receive treatment as usual. Patients will download the UControl Pain app on their personal cell phones and will complete the four study surveys via the app or via REDCap.
89282815|NCT03833648|Experimental|Arm 2 - UControl Pain App with Education|Patients will install the UControl Pain app on their personal cell phones. The app will include educational information about pain management, e.g., using acetaminophen and NSAIDs for pain, as well as information on addiction and safe storage of medications. Subjects will also complete the four study surveys via the app or via REDCap.
89282816|NCT03833570|Experimental|Melatonin therapy|"Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks~Symptomatic treatment dose: Three times a day for six weeks"
89282817|NCT03833570|Active Comparator|Conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Dose: Three times a day for six weeks"
89282818|NCT01779050|Active Comparator|Arm I (definitive therapy)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel"
89282819|NCT01779050|Experimental|Arm II (definitive therapy, trastuzumab)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~Patients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy. Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity."
89282820|NCT01200446|Placebo Comparator|Placebo Docosahexaenoic Acid (DHA)|Eight subjects will take 8 placebo DHA capsules per day for 3 weeks.
89282821|NCT01200446|Experimental|Active Docosahexaenoic Acid (DHA)|Eight subjects will take 8 active DHA capsules per day for 3 weeks.
89282822|NCT03841136|Experimental|anlotinib combined with EP|anlotinib combined with etoposide and platinum
89282823|NCT05669768|Experimental|pamiparib+tamoxifen|
89282824|NCT03843398|Experimental|Minilaparotomy Group|Participants in this arm undergo colorectal cancer resection via minilaparotomy.
89282825|NCT03843398|Active Comparator|Laparoscopy Group|Participants in this arm undergo laparoscopic colorectal cancer resection.
89282826|NCT03843320||SAVR|"Patients with aortic stenosis undergoing surgical aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~INSPIRIS RESILIA;~EDWARDS INTUITY;~Carpentier-Edwards PERIMOUNT Magna-Ease."
89282827|NCT03843320||TAVR|"Patients with aortic stenosis undergoing transcatheter aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~SAPIEN 3;~SAPIEN XT."
89282828|NCT00306527|Active Comparator|cTIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
89282829|NCT00306527|Active Comparator|cTIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
89282830|NCT00306527|Active Comparator|cTIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
89282831|NCT00306527|Active Comparator|cTIV\TIV (elderly)|Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
89282832|NCT00306527|Active Comparator|TIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
89282833|NCT00306527|Active Comparator|TIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
89282834|NCT00306527|Active Comparator|TIV\TIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
89282835|NCT00306527|Active Comparator|TIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
89282836|NCT05669378|Experimental|Intervention group|The experimental group will receive the Appetite to Play + intervention which is a capacity-building intervention that support childcare providers in implementing the best practices for active play. It includes a 3 e-learning online modules and then the are supported with weekly . bi-weekly emails.
89282837|NCT05669378|Other|Standard of care waitlist control|The standard of care waitlist control group will receive the intervention at 3-months post-randomization. The standard of care group has access to the Appetite to Play materials which are available to everyone. The site includes resources that childcare providers can use.
89282838|NCT03832166|Experimental|Fruits and Vegetables Only|This group will receive a prescribed amount of free fruits and vegetables (F & V) for 6 weeks through pick-up at a farm stand, or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 18 weeks with minimal contact
89282839|NCT03832166|Experimental|Fruits and Vegetables and Cook|"In addition to the prescribed amount of free F&V, participants will receive 6 weekly, group nutrition and cooking education classes based on The Happy Kitchen curriculum. Participants will also receive free ingredients to complete the recipe from each weekly session at home."
89282840|NCT01066247|Active Comparator|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
89282841|NCT01066247|Active Comparator|Morphine|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
89282842|NCT03980951|Active Comparator|combined spinal epidural group|Bupivacaine 2.5 mg
89282843|NCT03980951|Active Comparator|dura puncture epidural group|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
89282844|NCT03980951|Active Comparator|epidural|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 20 mL load over 5 min
89282845|NCT03980795|Experimental|Intervention|The intervention (I) group received monthly exercise physiologist consultations, exercise prescription (resistance and aerobic exercise program using exercise bands) and weekly phone calls over 12 weeks.
89282846|NCT03980795|No Intervention|Control|Usual care
89282847|NCT03978455||Patients Who Smoke|"This group will consist of up to 100 English-speaking adult smokers recruited from their primary care clinic who are willing to complete a brief phone-based interview about their experience in using the Learn, Connect, and Quit (LCQ) tablet-based mobile application. The LCQ app presents smoking and cessation-related educational and motivational content in an easily accessible manner (i.e., via videos) and provides avenues for smokers to connect to evidence-based treatment."
89282848|NCT03978455||Clinic Staff|"Rooming staff and physicians from the primary care clinic (where Patients Who Smoke group participants are recruited) will be asked to participate in interviews about the feasibility of implementing the LCQ app including implementation burden, impact on clinical workload, and clinical utility of the app (i.e., Did patients ask more questions about smoking treatment? How challenging was it to try to give all smokers the app to explore?)."
89282849|NCT01066325|Experimental|NET|This arm will receive two 20-minutes sessions of NET 1 week apart. NET (Neuro Emotional Technique) is a non-invasive stress reduction technique.
89282850|NCT01066325|Active Comparator|Active Controls|This arm will receive two 20-minute sessions of stretching instructions 1 week apart.
89282851|NCT01066325|No Intervention|Inactive Controls|This arm will receive no intervention and no instructions.
89282852|NCT02532491|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
89282853|NCT02532491|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
89282854|NCT01066403|Experimental|Pergolide|Patients will be randomly assigned to a sequence of treatments of either pergolide or placebo p.o. under continuous concomitant atypical neuroleptic therapy (stable at least 2 weeks prior trial begin).
89282855|NCT01064219|Experimental|intrauterine hCG|intrauterine injection of 100 hCG followed by endometrial biopsy
89282856|NCT03980639||abatacept|patients with abatacept prescription
89282857|NCT03980639||others bDMARDs|patients with at least one bDMARD prescriptions
89282858|NCT03978299||Positive PSA result|"Men with a positive PSA test defined as:~Serum total PSA concentration is over 10 ng/ml.~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is under 25%, in at least in two determinations."
89282859|NCT03978299||Negative PSA result|"Men with a negative PSA test defined as:~Serum total PSA concentration is under 10 ng/ml.~Serum total PSA between 4 and 10 ng/ml if the value of the free PSA/total PSA fraction is over 25%."
89282860|NCT03978221|Experimental|diaphragmatic tissue doppler evaluation|A tissue Doppler evaluation, using a sectorial probe, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration randomly assessed in spontaneous breathing with Venturi Mask and in Non-invasive ventilation with a helmet or facial mask
89282861|NCT03978143|Other|Sequence 1|Receive treatments in the following order from Periods 1-6: A, B, C, D, E, G
89282862|NCT03978143|Other|Sequence 2|Receive treatments in the following order from Periods 1-6: A, C, B, D, E, G
89282863|NCT03978143|Other|Sequence 3|Receive treatments in the following order from Periods 1-6: B, A, C, D, E, G
89282864|NCT03978143|Other|Sequence 4|Receive treatments in the following order from Periods 1-6: B, C, A, D, F, H
89282865|NCT03978143|Other|Sequence 5|Receive treatments in the following order from Periods 1-6: C, A, B, D, F, H
89282866|NCT03978143|Other|Sequence 6|Receive treatments in the following order from Periods 1-6: C, B, A, D, F, H
89282867|NCT00294671|Active Comparator|Diflunisal|Diflunisal 250 mg po bid
89282868|NCT00294671|Placebo Comparator|Placebo|Placebo 1 po bid
89282869|NCT01064453||Group 1|
89282870|NCT01064609|Active Comparator|2. Biopsy with cryoprobes|Transbronchial cryobiopsy with a cryoprobe.
89282871|NCT01064609|Active Comparator|2.Biopsy with forceps|Transbronchial lung biopsy with conventional forceps.
89282872|NCT03980327|Experimental|probiotic|Lactobacillus rhamnosus (5 billion colony forming units per day) and Lactobacillus johnsonii (200 million colony forming units per day) given orally or through a gastrostomy tube daily for 3 months
89282873|NCT03980327|Placebo Comparator|control|1 mL of pure medium chain triglyceride oil given orally or through a gastrostomy tube daily for 3 months
89282874|NCT03980249|Experimental|Carvedilol + Standard Treatment|Subjects will receive carvedilol starting at 6.25 mg orally (PO) twice daily for 1-2 weeks and if tolerated will then be increased to 12.5 mg PO twice daily starting on day 1 of concurrent chemoradiotherapy and continue daily until the end of adjuvant cycle 6 of temozolomide and Tumor Treated Fields.
89282875|NCT01495598|Experimental|Phase 1 Pomalidomide 5mg Daily|Up to six subjects will initially be treated with for 21 days of a 28 day cycle
89282876|NCT01495598|Experimental|Phase 2 Pomalidomide 5mg Daily|15 human immunodeficiency virus (HIV) positive and 10 HIV negative subjects evaluable for response will be treated with Pomalidomide 5mg daily for 21 days of a 28 day cycle
89282877|NCT01204892|Active Comparator|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
89282878|NCT01204892|Active Comparator|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
89282879|NCT01202396||ulcerative colitis patients with a pouch|"ulcerative colitis patients undergoing proctocolectomy with an ileal pouch anal anastomosis~comparing patients with versus those without pouchitis~no intervention"
89282880|NCT05668130|Experimental|Sacrospinous Ligament Fixation Arm|Women randomized to this arm will undergo sacrospinous ligament fixation for apical suspension procedure during pelvic organ prolapse surgery.
89282881|NCT05668130|Experimental|Uterosacral Liganemt Suspension Arm|Women randomized to this arm will undergo uterosacral ligament suspension for apical suspension procedure during pelvic organ prolapse surgery.
89282882|NCT01204970||COPD|COPD Gold class 1-4
89282883|NCT01204970||Transplant|Lung transplant recipients
89282884|NCT01204970||Control|Patients with normal spirometric data
89282885|NCT01297166|Experimental|LEO 27989 ointment|
89282886|NCT03843476||Surgical with Rod|The patient is being treated with the patient specific rod with a surgery date planned
89282887|NCT01202474|Experimental|insulin glulisine and insulin glargine|insulin glulisine and insulin glargine basal/bolus regimen in accordance with the summary of product characteristics and titrated to Plasma glucose target as defined by American Diabetes Association (ADA) recommendations age-specific goals (12)
89282888|NCT05667818|Experimental|Amlodipine besylate controlled-release tablets|Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
89282889|NCT05667818|Active Comparator|Amlodipine besylate tablets (trade name: Norfloxacin ®）|Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
89282890|NCT01205204|Active Comparator|BF25 (Control)|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
89282891|NCT01205204|Experimental|BC15(Study 1)|GROUP BC15 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
89282892|NCT01205204|Experimental|BC30(Study 2)|GROUP BC30 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
89282893|NCT01205204|Experimental|BC60 (Study 3)|GROUP BC60 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
89282894|NCT01205282|Experimental|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). There will be 14 weeks of active treatment.
89282895|NCT01205282|Placebo Comparator|Placebo|
89282896|NCT05666414|Experimental|computer guided sandwich interpositional bone grafting|patient specific cutting guide were fabricated to perform the osteotomies ( and another patient specific guide was then fabricated to start the fixation of the cut bony segment a full digital intervention for sandwich interpositional grafting in patients with vertically atrophied mandible (bilateral split mouth study)
89282897|NCT05666414|Active Comparator|conventional sandwich osteotomy interpositional bone grafting|conventional interpositional bone grafting was done for patients with vertically atrophied mandibles (bilateral split mouth study)
89282898|NCT01205360|Active Comparator|Bupivacaine-Fentanyl (3-15)|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
89282899|NCT01205360|Experimental|Bupivacaine-Fentanyl (4-20)|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
89282900|NCT01205360|Experimental|Bupivacaine-Fentanyl (6-30)|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
89282901|NCT01200914|Active Comparator|'PTA without use of the GORE VIABAHN'|Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
89282902|NCT01200914|Experimental|PTA with covered stent|Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .
89282903|NCT04533308|Experimental|VR intervention|Participants will have a session in VR for 20-30 minutes each working day. They can choose natural 360-degrees scenes from different locations in the world with or without interactions with animals. The equipment will include HTC Vive (HTC Corporation).
89282904|NCT04533308|No Intervention|Control|Patients in the control group will not receive any psychological interventions.
89282905|NCT01297556|No Intervention|Control group|Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
89282906|NCT01297556|Experimental|Treatment|Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
89282907|NCT01205516|Experimental|Methadone|
89282908|NCT01205516|Active Comparator|Controlled Release Morphine|Controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
89282909|NCT01297634|Other|Botulinum Toxin Type-A 1U|
89282910|NCT01297634|Other|Botulinum Toxin Type-A 2U|
89282911|NCT01297634|Other|Botulinum Toxin Type-A 3U|
89282912|NCT01201070|No Intervention|control group|
89282913|NCT01201070|No Intervention|no treatment|
89282914|NCT01201070|Active Comparator|TREATMENT WITH ANTITHROMBIN|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
89282915|NCT01205594|Experimental|ITPR device|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
89282916|NCT02937454|Active Comparator|ferric carboxymaltose|The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
89282917|NCT02937454|Placebo Comparator|normal saline 0.9%|The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
89282918|NCT01205672|Experimental|Metformin|Metformin 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
89282919|NCT01205750|Experimental|Glucose clamp|
89282920|NCT01297712|Active Comparator|Hi Line|This arm is examined with latest generation HDTV colonoscopes
89282921|NCT01297712|No Intervention|Classic Line|control group undergoing colonoscopy with older generation scope currently in use in most centers
89282922|NCT01297790||Asthma|Subjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
89282923|NCT01297790||Chronic obstructive pulmonary disease|Subjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
89282924|NCT01297790||Healthy Volunteers|Healthy non smoking adults.
89282925|NCT01297790||Healthy smokers|Current smokers with normal breath tests (spirometry)
89282926|NCT01297790||Chronic cough|Subjects with idiopathic chronic cough.
89282927|NCT03843086|Active Comparator|720 Low Intensity shockwave therapy|Five daily sessions within a week, Monday thru Friday, in which 720 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
89282928|NCT03843086|Active Comparator|600 Low Intensity shockwaves therapy|"Three weekly sessions for 2 consecutive weeks, Monday-Wednesday-Friday, in which 600 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor in terms of type and dose of drug, for the remainder of study duration."
89282929|NCT03012386|Experimental|Sildenafil citrate|Sildenafil citrate 20 mg three times a day
89282930|NCT01202552|Experimental|group 1|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
89282931|NCT01202552|Experimental|group 2|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site
89282932|NCT01202552|Experimental|group 3|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
89282933|NCT01205906|Experimental|Internet-based guided self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
89282934|NCT01205906|Experimental|Cognitive-behavior group therapy|This well-established, cognitive-behavior group therapy was developed by Hiller and Haerkötter (2005) and consists of 10 weekly group sessions of 90 minutes. The strictly manualized program includes the following components focusing on the special needs of chronic tinnitus patients: Education, relaxation techniques, cognitive restructuring, the role of attentional processes for tinnitus perception, analysis of avoidance behaviors, tinnitus and the health care system as well as relapse prevention. For each session participants receive written materials, exercises and homework assignments to enhance understanding and to transfer the new information into the daily routine.
89282935|NCT01205906|Active Comparator|Discussion forum group|To the participants of the control group the group therapy or the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
89282936|NCT01202630|Experimental|Probiotic|BIO-K+ CL1285
89282937|NCT01202630|Placebo Comparator|Placebo|Placebo
89282938|NCT01205984|Active Comparator|oral methylprednisolone|
89282939|NCT01205984|Placebo Comparator|placebo|
89282940|NCT03842852||LTEPR|Patients who underwent inguinal hernia repair laparoscopic extra-peritoneal repair under general anesthesia.
89282941|NCT03842852||OPHSR|Patients that underwent inguinal hernia repair open using prolene hernia system mesh under general or regional anesthesia.
89282942|NCT05282576|Active Comparator|Experimental Group|We applied neurophysiological facilitation techniques in addition to conventional rehabilitation.
89282943|NCT05282576|Other|Control Group|Critical ill patients was applied their conventional physiotherapy
89282944|NCT01297868||exercise group|
89282945|NCT01297946|Placebo Comparator|Open-loop|Conventional continuous subcutaneous insulin infusion (CSII) therapy
89282946|NCT01297946|Experimental|Dual-hormone closed-loop|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. The infusion rates are based on continuous glucose sensor reading and a control algorithm.
89282947|NCT04475978|Experimental|IVUS group|
89282948|NCT04475978|Placebo Comparator|Angio group|
89282949|NCT01202786||miRview mets Disclosed|Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results
89282950|NCT01202786||Control|Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results
89282951|NCT04451798|Experimental|Intervention|Impella implantation and hemodynamic measurement
89282952|NCT03829904|Experimental|VGH-BPH1 group|VGH-BPH1 includes Ji Sheng Shen Qi Wan 2.5g, Sangpiaoxiao powder 1.0g, Wuyao 0.3g, Yizhiren 0.3g, Danshen 0.3g, Yinyanghuo 0.3g, Fupenzi 0.1g, Huangbo 0.25g and Zhimu 0.25g, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
89282953|NCT03829904|Placebo Comparator|Control group|Placebo includes corn starch plus caramel coloring, and added 1/100 VGH-BHP1 compound, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
89282954|NCT03211858|Experimental|SAR341402|SAR341402 subcutaneous (SC), before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
89282955|NCT03211858|Active Comparator|NovoLog/NovoRapid|NovoLog/NovoRapid SC, before meals intake on top of QD Insulin Glargine, up to Week 52.
89282956|NCT01298102|Experimental|influenza vaccine|Pandemrix vaccine (Influenza A/H1N1 2009)to be injected to renal transplant patients, haemodialyzed patients, and controls
89282957|NCT01202864||Cases|3000 Cases
89282958|NCT01202864||Controls|3000 Controls
89282959|NCT01206218|Active Comparator|Group A|FLOT Regimen
89282960|NCT01206218|Experimental|Group B|FLO Regimen or FLOT Regimen
89282961|NCT01298180|Experimental|SPW|Children presenting a Prader-Willi Syndrome
89282962|NCT01298180|Experimental|GHD|Patient deficient in Growth Hormone
89282963|NCT01298180|Experimental|SPW-B|Patient with Prader-Willi Syndrome who has Biopsy
89282964|NCT01298180|Experimental|T|Patient Control
89282965|NCT01298180|Experimental|SPW-GH-B|Patient with Prader-Willi Syndrome taking growth Hormone and who has biopsy
89282966|NCT03211156|Placebo Comparator|Placebo arm|Placebo 2 capsules PO twice a day for 7 days, n=49
89282967|NCT03211156|Experimental|Treatment arm|Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49
89282968|NCT01298258|Placebo Comparator|placebo|control group
89282969|NCT01298258|Experimental|Aliskiren|Aliskiren 150 mh
89282970|NCT01298336|Experimental|Clarithromycin|
89282971|NCT01298336|Experimental|Moxifloxacin|
89282972|NCT01201148|Experimental|Oscillating or intermittent tDCS|
89282973|NCT04472494|Experimental|Abatacept + Standard of care|
89282974|NCT04472494|Placebo Comparator|Placebo infusion + Standard of care|
89282975|NCT04568200|Experimental|durvalumab and neoadjuvant therapy|durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
89282976|NCT04568200|Placebo Comparator|normal saline and neoadjuvant therapy|normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy
89282977|NCT04419506|Placebo Comparator|Placebo, Antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.
89282978|NCT04419506|Experimental|BI 1015550, Antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.
89282979|NCT04419506|Placebo Comparator|Placebo, Non-antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
89282980|NCT04419506|Experimental|BI 1015550, Non-antifibrotics at baseline|Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
89282981|NCT03842774|Experimental|Test group|taken 3 tablets of Gelidium elegans extract (1000 mg/day) once a day for 12 weeks
89282982|NCT03842774|Placebo Comparator|Control group|taken 3 tablets of placebo once a day for 12 weeks
89282983|NCT03236506|Experimental|Daily observed therapy|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
89282984|NCT03236506|Active Comparator|Fortnightly pick-up|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
89282985|NCT03236506|Active Comparator|Fortnightly pick-up +psych intervention|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.
89282986|NCT01201226|No Intervention|Patients|Perimenopausal women, who will undergo oelvic organ surgery, and will allow harvest of about half an oary for the study purpose
89282987|NCT01201304|Experimental|Interoceptive exposure|Repeated trials of voluntary hyperventilation intended to reduce fears of arousal-related body sensations.
89282988|NCT01201304|Placebo Comparator|Expressive writing|Expectancy control intervention.
89282989|NCT04933708|Experimental|Labor Podcast Group|"1) Labor Podcast Group - Women randomized to this arm will receive access to a link to download six HUP physician created labor podcasts in addition to usual care during labor, delivery, and postpartum~o Podcast topics: Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth~LAS-10 and Birth Satisfaction survey - Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)~EPDS - Women will receive this survey on postpartum day 7 via method they desire"
89282990|NCT04933708|No Intervention|Usual Care|"2. Usual care Women randomized to this arm will receive usual care during labor, delivery, and postpartum with the following exceptions:~LAS-10 and Birth Satisfaction survey Women will be sent these surveys on postpartum day 2 via method they indicated they desire (either email or text message)~EPDS Women will receive this survey on postpartum day 7 via method they desire"
89282991|NCT01201382|Experimental|IPT-AST|Interpersonal Psychotherapy-Adolescent Skills Training
89282992|NCT01201382|Active Comparator|Group Counseling|Group Counseling
89282993|NCT01201460||Glucose testing|Patients participating in this study may be alerted to possible presence of (DM) or pre-(DM) or to inadequate glycemic control. In such a case, they were advised to follow-up with their physician for definitive diagnosis and treatment. Early diagnosis and improved glycemic control may be of significant benefit to the patients' health.
89282994|NCT04421404|Experimental|COVID-19 Convalescent Plasma|Subjects in the COVID-19 convalescent plasma group will receive a single infusion of 250 ml anti-SARS-CoV-2 convalescent fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
89282995|NCT04421404|Placebo Comparator|Placebo|Subjects in the placebo group will receive a single infusion of 250 ml of standard fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
89282996|NCT03227692|Experimental|Persona with iASSIST Knee|Having total knee arthroplasty (Persona Knee System) surgery with the use of a navigation system iASSIST Knee.
89282997|NCT03227692|Active Comparator|Persona without iASSIST Knee|Having total knee arthroplasty surgery (Persona Knee System) with the use of conventional surgical instruments, and without a navigation system iASSIST Knee.
89282998|NCT01298726|Other|PHARMACEUTICAL CARE|
89282999|NCT01298726|Other|HEALTH USUAL CARE|
89283000|NCT01298804|Experimental|Problem Solving Education|
89283001|NCT01298804|No Intervention|Control|
89283002|NCT05180578|Experimental|Tolerability of goat milk consumption in patients with EOE triggered by milk allergy|Elimination of cow milk from diet . Goat milk containing diet.
89283003|NCT01298882|Experimental|Diacerein|
89283004|NCT01298882|Placebo Comparator|Placebo|
89283005|NCT05180266|Experimental|Therapeutic Touch Group|In order to examine the effects of therapeutic touch on menopausal symptoms, sleep and quality of life, women will be given therapeutic touch for 15 minutes, once a week for four weeks.Therapeutic touchis a form of descriptive treatment that lasts approximately 15-20 minutes, in which hands are used on or near the body to correct abnormalities in the person's energy field and to achieve healing, and the energy in the universe is transferred from the practitioner's hands to the applied individual.
89283006|NCT05180266|Experimental|Music Listening Group|The women were asked to listen to the relaxation music included in the relaxation exercises CD prepared by the Turkish Psychological Association every day for four weeks in a comfortable environment at home for 30 minutes before bedtime.
89283007|NCT05180266|Other|Control Group|No action will be taken on the control group for four weeks.
89283008|NCT03828500|Experimental|Experimental Arm|encouraged by Research Assistant to drink clear fluids up to 2 hour limit. Arm 2 - standard of care
89283009|NCT03828500|No Intervention|Control Arm|
89283010|NCT05281250|Experimental|Supervised physical exercise|Supervised exercise (aerobic + strength + flexibility) depending on the functional capacity of each patient, during hospitalization
89283011|NCT05281250|No Intervention|Control|Patients will receive recommendations about exercising during hospitalization.
89283012|NCT03210220|Experimental|pecs group|Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .
89283013|NCT03210220|No Intervention|control group|There is no block.
89283014|NCT03842540|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
89283015|NCT03842540|Active Comparator|PartyWise Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
89283016|NCT03209518||Leuprorelin acetate|Usually, for adults, 22.5 mg of Leuprorelin acetate was subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants received Leuprorelin as part of routine medical care.
89283017|NCT01201538|Experimental|Single arm|
89283018|NCT03646214|Experimental|Midline traction oral appliance|Subjects will wear the oral appliance nightly for 4 weeks. Must snore or have other evidence of sleep disordered breathing.
89283019|NCT03646214|No Intervention|Control|Subjects who do do not wish to wear the oral appliance will have their sleep monitored in parallel to the experimental subjects for 4 weeks.
89283020|NCT03725852|Experimental|GLPG1205 100 mg|Participants will receive GLPG1205 100 milligrams (mg) (2 capsules x 50 mg), orally once daily for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
89283021|NCT03725852|Placebo Comparator|Placebo|Participants will receive GLPG1205 matching placebo, orally once daily (as 2 capsules) for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
89283022|NCT01202942|Experimental|Quest|Participants smoke Quest cigarettes level 1 for 10 days, followed by level 2 for 10 days, and finally by level 3 for 10 days.
89283023|NCT01202942|No Intervention|Preferred brand|Participants smoke their preferred brand of cigarettes for the duration of the study.
89283024|NCT03840512|Experimental|Oral CBD 75 BID|
89283025|NCT03840512|Experimental|Oral CBD 150 BID|
89283026|NCT03840512|Experimental|Oral CBD 300 BID|
89283027|NCT03842462|Active Comparator|nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-8 cmH2O) by pure CPAP system , with FiO2 (0.21～0.40)adjusted to target SpO2 from 89% to 94%
89283028|NCT03842462|Active Comparator|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec (according to clinicians'evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
89283029|NCT03842462|Experimental|NHFOV|"- neonates assigned to NHFOV will be started with the following boundaries, according to available physiological and mechanical data, as suggested elsewhere:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 89%-94%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-15Hz). c)Inspiratory time 50% (1:1).[ d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2O); amplitude will be titrated according to PaCO2."
89283030|NCT04284410|Experimental|CLASP-PE arm|
89283031|NCT03840590|Experimental|AI-assisted Colonoscopy|Participants in this arm undergo AI-assisted colonoscopy using CSK AI system.
89283032|NCT03840590|Active Comparator|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy.
89283033|NCT05282420|Active Comparator|Ranibizumab group|Ranibizumab injection monthly for 3 successive months
89283034|NCT05282420|Active Comparator|Aflibercept group|Aflibercept injection monthly for 3 successive months
89283035|NCT01566968||Healthy Volunteers|Adults between ages of 18-75 inclusive who have never smoked and have no history of any respiratory disease for which they are on regular treatment.
89283036|NCT01566968||Asthma|Adults between the ages on 18-75 inclusive who have a physician diagnosis of asthma and have no smoking history or minimal smoking history (less than 10 pack years or in other words less than 20 cigarettes per day for 10 years).
89283037|NCT01566968||COPD|Adults between the ages of 18-75 inclusive who have previously been smokers (at least 20 pack years) and have physician diagnosis and spirometry evidence of COPD.
89283038|NCT01566968||Healthy smokers|Adults between the ages of 18-75 inclusive who are currently smokers (at least 10 pack years history)but have no history of any respiratory disease and no evidence of COPD on spirometry.
89283039|NCT01566968||Chronic cough|Adults between ages of 18-75 inclusive who have history of dry cough for at least 8 weeks and have a normal chest x ray and no smoking history or minimal smoking history (less than 10 pack years).
89283040|NCT04241510|Active Comparator|Facilitation Tape|Diaphragm and Intercostal muscles will be taped with facilitation technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
89283041|NCT04241510|Active Comparator|Mechanical Correction Tape|Thorax will be taped with mechanical correction technique. After 30 minutes of application patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea.
89283042|NCT04241510|No Intervention|No Tape|Patients will be evaulated for pulmonary parameters, functional exercise capacity and dyspnea with no tape.
89283043|NCT01298960|Experimental|rGH Group|
89283044|NCT01298960|No Intervention|Non rGH group|
89283045|NCT01206686|Experimental|1 Hour Planning Prompt|
89283046|NCT01206686|Experimental|2 Hour Planning Prompt|
89283047|NCT01206686|Experimental|1 Day Planning Prompt|
89283048|NCT01206686|Experimental|Default Planning Prompt|
89283049|NCT01206686|Active Comparator|Control|
89283050|NCT00304031|Active Comparator|Conventional adjuvant TMZ|Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.
89283051|NCT00304031|Experimental|Dose-dense adjuvant TMZ|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.
89283052|NCT00304031|Other|No adjuvant TMZ (not randomized )|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.
89283053|NCT01567046||Correlative studies|Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
89283054|NCT01206842|Experimental|social cognition training|
89283055|NCT01206842|No Intervention|treatment as usual|
89283056|NCT01201616|Experimental|High fat, low carbohydrate diet|Fats intake 55% , Protein 17% and carbohydrate 28% of total energy
89283057|NCT01201616|Active Comparator|Low fat, high carbohydrate diet|Fat intake 20%, Protein 17% and carbohydrate 63% of total energy intake
89283058|NCT01567124|Other|Olanzapine|Participants taking olanzapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
89283059|NCT01567124|Other|Clozapine|Participants taking clozapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
89283060|NCT01299194|Active Comparator|ATORVASTATIN|Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
89283061|NCT01299194|Placebo Comparator|PLACEBO|Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily
89283062|NCT03827408|Active Comparator|Midazolam group (MDZ)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.5 mg/kg Midazolam.
89283063|NCT03827408|Experimental|Dexmedetomidine group (DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 5µg/kg Dexmedetomidine.
89283064|NCT03827408|Experimental|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.
89283065|NCT01206998|Experimental|Vaginal progesterone gel|
89283066|NCT01206998|Placebo Comparator|Placebo vaginal gel|
89283067|NCT00331799|Active Comparator|1|Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.
89283068|NCT01207076|Experimental|receiving AHN-12 and 90Y-AHN-12|Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).
89283069|NCT01299350|No Intervention|Usual|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged according to routine clinical practice based on symptoms, physical examination and other data that the cardiologist deems appropriate, except for Nt-proBNP.
89283070|NCT01299350|Experimental|Nt-proBNP guided|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
89283071|NCT03826940|Experimental|NF1 - experimental|
89283072|NCT03826940|Placebo Comparator|NF1 - control|
89283073|NCT03826940|Experimental|ASD - experimental|
89283074|NCT03826940|Placebo Comparator|ASD - control|
89283075|NCT04177238|Placebo Comparator|Placebo|Identical in taste and colour to the supplement juice, but with no anthocyanin content
89283076|NCT04177238|Experimental|Cherry juice|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
89283077|NCT04177238|Experimental|Blueberry|30 mL of tart juice concentrate, which will be diluted with 100 mL of water - taken twice per day,
89283078|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Group|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
89283079|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Expansion|Following finding of MTD surface-controlled water soluble curcumin, escalating dose levels
89283080|NCT01201928||Technosphere Insulin Inhalation Powder|
89283081|NCT01201928||Comparator|Based on parent trial
89283082|NCT01299428|Active Comparator|cerebral oxygenation|
89283083|NCT01299506||Trabectedin|The administration of chemotherapy regimen with trabectedin will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
89283084|NCT01299506||Conventional care|This includes other palliative chemotherapy or biological therapy or best supportive care.
89283085|NCT01203176|Active Comparator|Post-menopausal symptomatic women|
89283086|NCT01203176|Experimental|Post-menopausal asymptomatic women|
89283087|NCT00303719|Experimental|High Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
89283088|NCT00303719|Experimental|Standard Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
89283089|NCT01207154||BIS guidance|Sedation guided according to a predetermined BIS level
89283090|NCT01207154||Clinical sign guided|Sedation guided by clinical signs
89283091|NCT01207232|Experimental|Time Plan Condition|A basic reminder mailing prompted each subject to write down a planned date and time for getting their flu shot.
89283092|NCT01207232|Experimental|Date Plan Condition|A basic reminder mailing prompted each subject to write down a planned date for getting their flu shot.
89283093|NCT01207232|Active Comparator|Control Condition|A basic reminder mailing prompted each subject to receive a flu shot.
89283094|NCT01064765||Heart failure|Outpatients with heart failure, age 75 or less, left ventricular ejection fraction 40% or less, english speaking with no known dementia
89283095|NCT01207310|Experimental|Pager Arm|Participants in the Pager Arm will be provided with alphanumeric pagers and will receive therapeutic messages on these pagers for 3 months in addition to individual smoking cessation counseling and nicotine patches.
89283096|NCT01207310|Active Comparator|Control Arm|Participants in the Control Arm will receive individual smoking cessation counseling and nicotine patches.
89283097|NCT00331409|Experimental|Everolimus and Imatinib Mesylate|Everolimus: 2.5 mg daily by mouth Imatinib Mesylate: 600 mg daily by mouth
89283098|NCT03820778|Experimental|Study Arm|Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
89283099|NCT01203254|Placebo Comparator|Placebo|
89283100|NCT01203254|Active Comparator|Cholestagel|
89283101|NCT01064843||4 Imtec mini-dental implants (MDI)|4 Imtec MDI
89283102|NCT03826394|Experimental|Exercise Intervention|Exercise intervention with the aim of incrementally increasing physical activity to meet the national recommendation of 150 minutes a week of moderate-vigorous physical activity, reducing BMI and improving overall health.
89283103|NCT03826394|Experimental|Dietary Intervention|Staged dietary intervention with the aim of improving eating behaviours, reducing BMI and improving overall health.
89283104|NCT01064921|Experimental|Arm I|Patients receive oral vorinostat on days 0-2 and cisplatin IV on days 7, 21 and 35. Patients undergo radiation therapy 5 days a week beginning on day 7. Patients also receive concurrent oral vorinostat along with the radiotherapy to be given 3 days per week (Monday, Tuesday, and Wednesday). Optional repeat tumor and normal mucosal biopsies will be performed and blood will be drawn for correlative studies.
89283105|NCT05623826|Experimental|Experimental|Experimental (receiving EMA and Imager EMI)
89283106|NCT05623826|No Intervention|Control|Control (receiving EMA only)
89283107|NCT01299662|Experimental|Poly ICLC|One 1.6 mg subcutaneous injection of the adjuvant, poly ICLC, in the upper arm.
89283108|NCT00303485|Experimental|Ibandronate|Participants received Ibandronate 150 mg tablet once-monthly along with a combination dietary supplement containing vitamin D 200 international units (IU) and elemental calcium 500 mg twice daily with meals for 6 months.
89283109|NCT00303485|Placebo Comparator|Placebo|Participants received a matching placebo tablet to Ibandronate once-monthly along with a combination dietary supplement containing vitamin D 200 IU and elemental calcium 500 mg twice daily with meals for 6 months.
89283110|NCT01299740|Other|Control Group|Treatment as usual
89283111|NCT01299740|Experimental|Research Group|Participation in the DBT skills group
89283112|NCT03818906|Active Comparator|Control Group|Patients with first or second molars where the extractions will be performed in a conventional way without any additional local treatment to be done in the alveolus. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
89283113|NCT03818906|Experimental|Test Group 1|Patients with first or second molars where the extractions will be performed in a conventional way and after extraction will be performed aPDT inside the alveolus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
89283114|NCT03818906|Experimental|Test Group 2|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia, the fresh socket will receive local application of infrared in the outer vestibular portion. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
89283115|NCT03818906|Experimental|Test Group 3|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia the approaches from the previous groups (Test Group 1 and 2 (aPDT + infrared) will be done. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
89283116|NCT03983915|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
89283117|NCT03983915|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
89283118|NCT01300754|Active Comparator|Dextrose|
89283119|NCT01300754|Active Comparator|Lidocaine|
89283120|NCT01300754|Active Comparator|Usual Care|
89283121|NCT01203332||Alternative Venue Testing (AVT)|Participants recruited for testing through the AVT recruitment method.
89283122|NCT01203332||SSNIT - Index Recruiter|Participants recruited for HIV testing and to bring members of their social and sexual network to the study.
89283123|NCT01203332||SSNIT - Network Member|Participants recruited by someone in their social or sexual network to participate in the study, including HIV testing.
89283124|NCT03825848|Experimental|Left Portal Vein Branch|Shunt left portal vein branch during the trans jugular intrahepatic portal systemic shunt
89283125|NCT03825848|Experimental|Right Portal Vein Branch|Shunt right portal vein branch during the trans jugular intrahepatic portal systemic shunt
89283126|NCT03825614|Experimental|training gruop|The plates exercise program is concerned with the following main principles: efficient breathing, mental concentration, relaxation, correct spine elongation and posture, correct abdominal muscle control over spine stability and mobility, correct function of each upper and lower limb, precision, lowing integrated movement, and achieving muscle strength and stamina.
89283127|NCT03825614|Active Comparator|training group|Therapeutic exercise program was designed according to the American Collage of Sports Medicine's recommendations for healthy people. The exercise program was conducted using low- to moderate-intensity therapeutic exercises. These therapeutic exercises included a short educational talk that provided information on proper body mechanics, the benefits of exercise, realistic goal-setting, and overcoming common barriers (such as fear) when developing an exercise routine.
89283128|NCT03825614|No Intervention|Control group|Participants in the control group have no exercise in this study.
89283129|NCT03825770|Experimental|"The PEP Program"|"The PEP (Personal Energy Planning) Program"
89283130|NCT03825770|Active Comparator|General Education|General Education about Kidney Disease
89283131|NCT03235726|Experimental|Cohort A, Part 1: Active|60 milligrams (mg) single dose of CCI15106 will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered twice daily (BID) on Days 6-19 to healthy subjects.
89283132|NCT03235726|Placebo Comparator|Cohort A, Part 1: Placebo|60 mg single dose of placebo will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered BID on Days 6-19 to healthy subjects.
89283133|NCT03235726|Experimental|Cohort B, Part 1: Active|60 mg of CCI15106 BID will be administered by inhalation route for 14 days to healthy subjects.
89283134|NCT03235726|Placebo Comparator|Cohort B, Part 1: Placebo|60 mg of placebo BID will be administered by inhalation route for 14 days to healthy subjects.
89283135|NCT03235726|No Intervention|Cohort C, Part 1: bystanders|Healthy subjects will be enrolled to follow bystander exposure and will be studied concomitantly with Cohort B.
89283136|NCT03235726|Experimental|Cohort A, Part 2: Active|60 mg single dose of CCI15106 will be administered by inhalation route to subjects with COPD.
89283137|NCT03235726|Placebo Comparator|Cohort A, Part 2: Placebo|60 mg single dose of placebo will be administered by inhalation route to subjects with COPD.
89283138|NCT03235726|Experimental|Cohort B, Part 2: Active|60 mg BID dose of CCI15106 will be administered by inhalation route for 14 days to subjects with COPD.
89283139|NCT03235726|Placebo Comparator|Cohort B, Part 2: Placebo|60 mg BID dose of placebo will be administered by inhalation route for 14 days to subjects with COPD.
89283140|NCT00303953|Experimental|Arm I|"Patients will receive an infusion of PXD101 once a day for 5 days. Treatment may repeat every 3 weeks for up to 2 years. Some patients will also undergo core biopsy and blood collection for laboratory studies before and after treatment.~After finishing treatment, patients will be evaluated every 3-6 months for up to 3 years."
89283141|NCT01203410||Cohort 1|Term infants >2500g birthweight.
89283142|NCT03823820||Cesarean section|Women attending for elective CS.
89283143|NCT03823820||Induction of labour|Women admitted for induction of labour and expected to stayed in hospital for more than 24 hours.
89283144|NCT03823820||pregnancy complication group|"Maternal condition that could affect body fluid including:~Pre-eclampsia requiring hospital admission.~Hyperemesis gravidarum.~Major postpartum haemorrhage."
89283145|NCT03823820||control|Gestational age matched controls.
89283146|NCT03840122|Experimental|A - ACB + IPACK with injection|50 arms: ACB + IPACK block with injection of local anesthetic of Ropivacaine, Epinephrine, Ketorolac, Clonidine and saline
89283147|NCT03840122|Active Comparator|B - ACB + IPACK without injection|50 arms: ACB + IPACK block without injection of local anesthetic
89283148|NCT04385758|Experimental|Diabetes-REM Program|
89283149|NCT04375462|Experimental|AspireAssist|"Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days, and the AspireAssist group will have a clinic visit at 7 days to have the skin-port placed.~All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube"
89283150|NCT04375462|Active Comparator|Standard PEG|Gastrostomy tubes will be placed 1-2 days after enrollment. Questionnaires will be completed at 7 and 30 days All participants will be placed on a diet consisting of liquids and soft foods to prevent clogging of the gastrostomy tube
89283151|NCT01314274|Experimental|bevacizumab|submucosal intranasal bevacizumab on day 0
89283152|NCT01314274|Placebo Comparator|placebo|0.9% NaCl intranasal submucosal on day 0
89283153|NCT01299818||spinal surgery|patients who undergo spinal surgery
89283154|NCT03818984|Experimental|Safer Conception Intervention|Men will participate in 3 counseling sessions with a lay counselor. In the first session, the counselor will share information on the various safer conception strategies and help the participant think about developing a healthy plan. In the following 2 sessions, the counselor and the participant will work together to develop a healthy baby plan using motivational interviewing and problem solving. In the 2 booster sessions, the counselor and the participant will check in to evaluate the success of the plan and make changes as necessary.
89283155|NCT03840044|Other|Healthy volunteers|Healthy volunteers will perform the same protocol as foreseen for asthmatic patients. Both will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
89283156|NCT03840044|Other|Asthmatic subjects|Asthmatic patients will perform the same protocol as foreseen for healthy volunteers. They will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
89283157|NCT05620550|Experimental|ozonated oil|treatment of scar area with ozonated oil
89283158|NCT05620550|Sham Comparator|non ozonated oil|treatment of scar area with non ozonated oil
89283159|NCT01299974|Other|Parents and Residents in Session|Parents and Residents in Session
89283160|NCT02935894|Experimental|Single group|"All subjects will participate in 4 study day visits in the same order.~compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).~compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).~collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).~collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen."
89283161|NCT03818750|Experimental|Experimental arm|"Patients (60) will be selected from the Alcohol Use Disorders Identification Test (AUDIT-C) :~light drinkers (score between 1 to 3)~heavy drinkers (score between 4 to 7) Two clinical visits will be realized in less than 4 weeks"
89283162|NCT01300130|Experimental|low docosahexaenoic acid formula|
89283163|NCT01300130|Experimental|medium docosahexaenoic acid formula|
89283164|NCT01300130|Experimental|high docosahexaenoic acid formula|
89283165|NCT01300130|Active Comparator|human milk|
89283166|NCT05669300||Yilmaz Technique|the patients underwent ceserean section and uterus closed with Yilmaz Technique
89283167|NCT05669300||single layer continue locked suturation|the patients underwent ceserean section and uterus closed with single layer continue locked suturation
89283168|NCT03224182|Experimental|Qapzola|Participants were randomized to receive a single dose of Qapzola 8 mg by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
89283169|NCT03224182|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of Qapzole-matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
89283170|NCT03821480|Experimental|Fluconazole 50 mg, Manufacturer: Amboise|Test drug
89283171|NCT03821480|Active Comparator|Fluconazole 50mg, Manufacturer:West Ryde|Reference drug
89283172|NCT05623436|Experimental|Experimental|"Ventrogluteal injection training given by virtual reality technology is effective in increasing the knowledge and skill levels of students. It also has an impact on students' motivation and anxiety levels.~Intervention: Behavioral: Education"
89283173|NCT05623436|No Intervention|Control|Ventrogluteal injection training given by virtual reality technology doesn't effective in increasing the knowledge and skill levels of students. It also hasn't an impact on students' motivation and anxiety levels.
89283174|NCT01203488|Experimental|Experimental|Vitamin A group.
89283175|NCT01203488|Sham Comparator|Control|Sham procedure Control group.
89283176|NCT02935192|Experimental|Vaccine Arm|Seasonal trivalent split, inactivated influenza vaccine
89283177|NCT02935192|Placebo Comparator|Placebo Arm|Phosphate buffered saline
89283178|NCT03819998||PCOS group|women who have PCOS
89283179|NCT03819998||control group|women who donnot have PCOS
89283180|NCT03819920|Placebo Comparator|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
89283181|NCT03819920|Active Comparator|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
89283182|NCT01314352|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
89283183|NCT01314352|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
89283184|NCT01567280||Controlled patients|Asthmatic patients with controlled asthma (according to ACQ score)
89283185|NCT01567280||Partly controlled/Uncontrolled patients|Patients with partly controlled or uncontrolled asthma (according to ACQ score)
89283186|NCT03636802||EXPERIMENTAL GROUP|Patient with respiratory failure and on a lung transplant waiting list
89283187|NCT03818282|Experimental|Paclitaxel for injection (albumin-bound)|
89283188|NCT03818126|Experimental|del Nido cardioplegia|
89283189|NCT03818126|Active Comparator|cold blood cardioplegia|
89283190|NCT01300910|Active Comparator|1|One group of men will undergo a circumcision using the Shang Ring and men are to return for regular follow-up visits to evaluate pain and wound healing. . The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 60 days.
89283191|NCT01300910|Active Comparator|2|One group of men will undergo a conventional circumcision using a WHO recommended surgical technique, either the forceps-guided method or the dorsal slit method. Men are to return for regular follow-up visits to evaluate pain and wound healing, with the last scheduled follow-up visit at 60 days.
89283192|NCT03722264|Experimental|OpalSeal|"OpalSeal will be applied~to the buccal surfaces of to-be-extracted teeth on one side of the mouth which will be determined randomly for each participant during bonding of orthodontic brackets, or~to the proximal surfaces following IPR in accordance to manufacturer instructions. Since OpalSeal has fluoride releasing capability, this would be experimental arm"
89283193|NCT03722264|Placebo Comparator|Transbond XT|"TransbondXT will be applied~to the buccal surfaces of to-be-extracted teeth on the other side of the mouth which will be determined based on which side received OpalSeal for each participant during bonding of orthodontic brackets, or~to the proximal surfaces following IPR in accordance to manufacturer instructions. Transbond XT does not have fluoride and hence would be considered as a placebo."
89283194|NCT05623202|Experimental|Capacity-oriented behavior-change intervention|
89283195|NCT01300364|Placebo Comparator|sugar pill|
89283196|NCT01300364|Active Comparator|reboxetine (NRI)|
89283197|NCT01300364|Active Comparator|citalopram (SSRI)|
89283198|NCT03722030|Experimental|Strength-Training Intervention|Following baseline measures, participants will receive an initial in-person instructional session, instructional material and resistance training equipment, support and feedback via video coaching, mid-point assessment, and an in-person study visit to collect post study measures. Intervention will be 10 weeks, with a 5 week follow up period.
89283199|NCT03722030|Placebo Comparator|Waitlist Control|Following baseline measures, participants will provide mid-point measures, and in-person post-study measures with no 10-week strength training intervention.
89283200|NCT05617352||2F Group|Patients with Two-field Lymphadenectomy
89283201|NCT05617352||3F Group|Patients with Three-field Lymphadenectomy
89283202|NCT05623124||Dementia|Participants have cognitive impairment and difficulty in daily activity.
89283203|NCT05623124||Mild cognitive impairment|Participants have cognitive impairment, but no difficulty in daily activity.
89283204|NCT05623124||cognitively normal|Participants do not have cognitive impairment.
89283205|NCT03221842|Experimental|C1-INH|C1-esterase inhibitor
89283206|NCT03221842|Placebo Comparator|Placebo|Excipients of C1-INH plus albumin
89283207|NCT01203566|Active Comparator|Conventional 3-port laparoscopic appendectomy|Laparoscopic appendectomy will be performed with the standard 3-port technique. The laparoscope is introduced via a 10mm subumbilical port. Dissection will be performed with a 5mm LLQ port and a 5mm RLQ port. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
89283208|NCT01203566|Active Comparator|LESS appendectomy|Two 5 mm ports and a 10mm port will be inserted through a 13mm transumbilical incision. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. Retraction of the appendix would be performed with a flexible curved forceps. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
89283209|NCT01300442|Experimental|Control|The transcutaneous electrical diaphragmatic stimulation will be applied in healthy and COPD subjects.
89283210|NCT01300442|Experimental|Chronic Obstructive Pulmonary Disease|The intervention will be the TEDS in patients with Chronic Obstructive Pulmonary Disease (COPD)
89283211|NCT01300520|No Intervention|Target Tape|Including target tape in the procedure
89283212|NCT01300520|Other|Control|Without target tape in the procedure
89283213|NCT05369000|Experimental|LAVA-1207|"In part 1 (dose escalation) LAVA-1207 will be administered via intravenous infusion with dose escalation~In part 2 (dose expansion) patients will receive LAVA-1207 at the dose established in part 1 of the study"
89283214|NCT03819608|Experimental|real APT+ real iTBS|real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
89283215|NCT03819608|Active Comparator|real APT + placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
89283216|NCT03819608|Active Comparator|placebo APT+ real iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
89283217|NCT03819608|Active Comparator|placebo APT+ placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
89283218|NCT03364738|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter [mg/dL]). Once a participant achieves a stable ACSC (2-2.25 mmol/L [8.0-9.0mg/dL]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (>) 2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be administered.
89283219|NCT05622890|Experimental|treatment|All patients will receive single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W).
89283220|NCT00303329|Experimental|Deferasirox|Deferasirox daily oral dose between 5-40 mg/kg/day
89283221|NCT01300988|Active Comparator|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
89283222|NCT01300988|Placebo Comparator|Placebo|Aprepitant (Emend®) placebo for 14 days
89283223|NCT01064999|Experimental|High intensity group|(RT 55Gy + CapOx) + a cycle of Xelox + Surgery
89283224|NCT01064999|Active Comparator|Low instensity group|(RT 50Gy + CapOx) + Surgery
89283225|NCT03818048|Experimental|Group Propofol|propofol infusion
89283226|NCT03818048|Experimental|Group Sevoflurane|inhalation with sevoflurane
89283227|NCT01325519|No Intervention|no intervention control group|control subjects
89283228|NCT01325519|Experimental|experimental intervention group|video decision aid viewed by subjects
89283229|NCT05614388|Experimental|Study participants|The study procedure is universal to all the participants from both the institutes. There are no control arms defined separately. The groups within the participants include - include health care workers, non-medical hospital staff and medical students at ZMC; and faculty, students and supporting staff at the Pacchunga University College.
89283230|NCT01301924|Active Comparator|High dose|High dose: 20 days of 20 mg/kg/day meglumine antimoniate
89283231|NCT01301924|Experimental|Low dose|Low dose: 30 days of 5 mg/kg/day meglumine antimoniate
89283232|NCT00329849|Experimental|MenACWY-CRM|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)
89283233|NCT00329849|Active Comparator|MenACWY-PS|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS)
89283234|NCT05655806|Active Comparator|group A|will receive aminophylline loading dose 5mg/kg on a 50 cm syringe using syringe pump over 5 minutes and maintenance dose 1.5 mg/kg/hr as a continuous infusion half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5 cm syringe of saline will be given over 5 minutes
89283235|NCT05655806|Active Comparator|group B|will receive a 50 cm syringe of saline using syringe pump over 5 minutes and maintenance continuous infusion of saline half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5cm syringe of aminophylline bolus 5mg\kg will be given over 5 minutes
89283236|NCT05655806|Placebo Comparator|group C|will receive a 50 cm syringe of saline using syringe pump over 5 minutes and maintenance continuous infusion of saline half an hour before discontinuation of isoflurane, and after discontinuation of isoflurane a 5 cm syringe of saline will be given
89283237|NCT02934178|Experimental|Cohort 1: WRSS1 3 x 10³ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10³ colony-forming units (CFU) of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
89283238|NCT02934178|Experimental|Cohort 2: WRSS1 3 x 10⁴ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁴ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
89283239|NCT02934178|Experimental|Cohort 3: WRSS1 3 x 10⁵ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁵ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
89283240|NCT02934178|Experimental|Cohort 4: WRSS1 3 x 10⁶ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁶ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
89283241|NCT02934178|Placebo Comparator|Cohort 1: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10³ WRSS1 approximately 4 weeks apart.
89283242|NCT02934178|Placebo Comparator|Cohort 2: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁴ WRSS1 approximately 4 weeks apart.
89283243|NCT02934178|Placebo Comparator|Cohort 3: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁵ WRSS1 approximately 4 weeks apart.
89283244|NCT02934178|Placebo Comparator|Cohort 4: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁶ WRSS1 approximately 4 weeks apart.
89283245|NCT05050058||Neonates born to diabetic mothers|
89283246|NCT05050058||Neonates born to non-diabetic mothers (control)|
89283247|NCT03983759|Experimental|treatment group|"phlebotomation 50ml 1-7 days before chemotherapy for culture of R-CIK cells chemotherapeutic regimen EP or EC as follows: VP-16 100mg/m2 D1-3 plus cisplatin 75mg/m2 D1 or VP-16 100mg/m2 D1-3 plus carboplatin AUC=5 D1 R-CIK cells were transfused back to the patients 2-7 days after the end of chemotherapy, and the amount of R-CIK cells returned each time was about 5×109 three weeks each cycle efficacy evaluated every two cycles patients with the efficay is CR, PR or SD after 4-6 cycles enter the sintilimab maintenance therapy for one year or until the progression of disease, or occurrence of intolerable adverse events.~the dose of sintilimab is fixed dose of 200mg every three weeks"
89283248|NCT01300676|Active Comparator|Tualang Honey|Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
89283249|NCT01300676|No Intervention|Group 2|Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
89283250|NCT03814694|Experimental|CRHP Diet|Hypo-energetic carbohydrate-reduced high-protein (CRHP) dietary intervention with a controlled 5-7% loss in body weight.
89283251|NCT03814694|Active Comparator|CD Diet|Hypo-energetic conventional diabetes (CD) dietary intervention with a controlled 5-7% loss in body weight.
89283252|NCT01560338||Pediatric after Cardiac Arrest|Pediatric patients greater than 3 kg. and less than 18 years suffering cardiac arrest who have been given or currently receiving morphine and/or midazolam and receiving hypothermia.
89283253|NCT00329303|Experimental|Certolizumab Pegol (CZP) 200 mg|Subcutaneous injections of 400 mg initial dose at Week 0 with 200 mg every 2 weeks thereafter.
89283254|NCT00329303|Experimental|Certolizumab Pegol (CZP) 400 mg|Subcutaneous injections of 400 mg every 2 weeks.
89283255|NCT03806816|Experimental|HYPOTHERMIA / MELATONIN group|HIE infants who will receive melatonin in addition to the routine cooling treatment
89283256|NCT03806816|Experimental|HYPOTHERMIA / PLACEBO group|HIE infants who will not receive melatonin in addition to the routine cooling treatment
89283257|NCT01301222|Experimental|octreotide|octreotide arm 100mcg for 5 days. control has no octreotide
89283258|NCT03817658|Experimental|SHR-1210|SHR-1210
89283259|NCT03817658|Placebo Comparator|placebo|placebo
89283260|NCT01301300|Active Comparator|Glenbrook Hospital|Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
89283261|NCT01301300|Active Comparator|Evanston, Highland Park, Skokie Hospitals|"Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months.~Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)"
89283262|NCT02532569|Other|Japanese encephalitis vaccine|After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC
89283263|NCT03817424|Experimental|Cohort 1: VIB7734 Dose 1|Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
89283264|NCT03817424|Experimental|Cohort 2: VIB7734 Dose 2|Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
89283265|NCT03817424|Experimental|Cohort 3: VIB7734 Dose 3|Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
89283266|NCT03817424|Placebo Comparator|Placebo|Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
89283267|NCT04535596|Experimental|Conventional Exercises|12 week long strength training exercise with the higher loading (%70-80 of 1 Repetitive Maximum)
89283268|NCT04535596|Experimental|Blood Flof Restriction Exercises|12 week long strength training exercise with the lower loading (%20-30 of 1 Repetitive Maximum) by using cuff around the thigh
89283269|NCT01302002|Experimental|Metformin Pre-Surgery|Patients will take metformin twice a day for three weeks prior surgery
89283270|NCT03817346|Active Comparator|Experimental GT-002 SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
89283271|NCT03817346|Placebo Comparator|Experimental Placebo oral capsule SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
89283272|NCT03216850||Patients in ICU requiring parenteral nutrition|
89283273|NCT03814772||Liver transplant|"18 years to 65~48h preoperative biochemical indicators, blood general indicators, coagulation test complete"
89283274|NCT01303250|Experimental|Group 1|A balanced hydroxyethyl starch 130/0.4 will be used
89283275|NCT01303250|Active Comparator|Group 2|A balanced crystalloid will be used
89283276|NCT01303328|Experimental|Treatment group|
89283277|NCT01303328|Placebo Comparator|Placebo group|
89283278|NCT03817034|Experimental|Multimodal Analgesia|
89283279|NCT03814616|Experimental|Arm Pyramax 3 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for three days (Arm A)
89283280|NCT03814616|Experimental|Arm Pyramax 2 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for two days (Arm B)
89283281|NCT03814616|Experimental|Arm Pyramax 1 day|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for one day (Arm C)
89283282|NCT03814460||Control Group|A control group of healthy subjects with no previous history of neurological disorders or conditions. This group pf participants will be selected in a similar population based-cohort than the other two study groups.
89283283|NCT03814460||Acute Stroke Group|In this group, participants who suffered a previous stroke within 3 months before data collection will be included.
89283284|NCT03814460||Chronic Stroke Group|In this group, only participants who have suffered a previous stroke of more than 3 months duration before data collection will be included.
89283285|NCT01303484|Placebo Comparator|MDn|Maltodextrin
89283286|NCT01303484|Active Comparator|B-GOS|Prebiotic
89283287|NCT00302159|Experimental|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
89283288|NCT03814226|Experimental|PACAP-38 infusion|According to main hypothesis PACAP-38 is expected to induce headache. PACAP-38 causes marked vasodilation visible to investigator. PACAP38 (10 pmol/kg/min) is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
89283289|NCT03814226|Active Comparator|VIP infusion|According to main hypothesis VIP is not expected to induce headache. VIP also causes marked vasodilation visible to investigator, which is why VIP is chosen as an active comparator. VIP (10 pmol/kg/min) is infused over 20 minutes. VIP is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
89283290|NCT03804320|Other|Patients with small renal masses|Active surveillance
89283291|NCT00302081|Active Comparator|PEG2b 1.5/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks
89283292|NCT00302081|Experimental|PEG 2b 1.0/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks
89283293|NCT00302081|Experimental|PEG2b 1.5/R (16 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks
89283294|NCT01060709||elective colonoscopy and requiring sedation|
89283295|NCT00302003|Experimental|Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim|Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 & 2, Vincristine sulfate IV (1.4 mg/m2 [max 2.8 mg]) Days 1 & 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 & 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.
89283296|NCT00036270|Experimental|exemestane|
89283297|NCT00036270|Experimental|tamoxifen + exemestane|
89283298|NCT03951324||Expert Endoscopists|Experienced Endoscopists with significant user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
89283299|NCT03951324||None-Expert Endoscopists|Experienced Endoscopists with non-significant or beignner user experience with Volumetric Laser Endomicroscopy for bile duct/pancreatic duct strictures
89283300|NCT01097382|Experimental|AMBIEN CR|AMBIEN CR 12.5 mg once daily immediately before bedtime or in elderly/hepatically impaired patients: 6.25 mg once daily immediately before bedtime
89283301|NCT00301067|Experimental|Cohort 1 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.2 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
89283302|NCT00301067|Experimental|Cohort 2 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.3 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
89283303|NCT00301067|Experimental|Cohort 3 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
89283304|NCT00301067|Experimental|Expansion - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
89283305|NCT02530086|Active Comparator|Placement of a Nasogastric tube|Placement of a Nasogastric tube
89283306|NCT02530086|Experimental|No placement of a Nasogastric tube|No placement of a Nasogastric tube
89283307|NCT03979859|Experimental|WCK 4873|200 and 400 mg tablets Dosage form : Oral tablets Doses : To be determined based on the safety, tolerability and PK results of the single dose and food effect study
89283308|NCT03979859|Placebo Comparator|Placebo|Visually matching placebo
89283309|NCT03955458|Experimental|FICB with EXPAREL|Group 1: Suprainguinal Fascia Iliaca Compartment Block (FICB) with EXPAREL and bupivacaine HCl
89283310|NCT03955458|Active Comparator|FICB with Standard of Care: ropivacaine|Suprainguinal FICB with continuous infusion of local anesthetic (ropivacaine) via catheter placed in the FIC.
89283311|NCT00007020|Other|Cholic Acid|
89283312|NCT03955536|Active Comparator|Group A|Routine cardiac rehabilitation program (RCRP)atient education
89283313|NCT03955536|Experimental|Group B|routine cardiac rehabilitation program + virtual reality
89283314|NCT03955536|Experimental|Group C|RCRP + inspiratory muscle training
89283315|NCT03952884|Active Comparator|Leucine|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g leucine powder dissolved in 250 mL of water.
89283316|NCT03952884|Experimental|Leucine Peptide (Dileucine)|Participants will be allocated to an exercise or non-exercise group. After resistance exercise (or equivalent time point for non-exercise group), participants will consume 2g protein peptide powder dissolved in 250 mL of water.
89283317|NCT01097538|Active Comparator|Body-weight supported treadmill training|Supported treadmill walking
89283318|NCT01097538|Experimental|Total body recumbent stepper training|Recumbent stepper exercise training
89283319|NCT03955224|Active Comparator|Basic Oral Care + active LLLT (experimental arm)|
89283320|NCT03955224|Placebo Comparator|Basic oral Care + inactive LLLT (control arm)|
89283321|NCT03955224|Other|Basic Oral Care (control arm)|
89283322|NCT01100970||Unipolar electric needle|
89283323|NCT01100970||Bipolar electric needle|
89283324|NCT01100970||Control|Infants who were born in a vaginal birth
89283325|NCT00300755|Active Comparator|1|Arm 1- Low Dose pantoprazole
89283326|NCT00300755|Active Comparator|2|Arm 2- Medium Dose pantoprazole
89283327|NCT00300755|Active Comparator|3|Arm 3- High Dose pantoprazole
89283328|NCT00033540|Experimental|Capecitabine + Gemcitabine|Capecitabine 650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days; Gemcitabine 1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1, 8, every 21 days
89283329|NCT00300365|Experimental|Active Pioglitazone + Open-Label Niacin|Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day
89283330|NCT00300365|Placebo Comparator|Placebo +Open-Label Niacin|Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin
89283331|NCT03980015||erythema migrans|patients with erythema migrans
89283332|NCT01101048|Placebo Comparator|A|Two (2) women in each of cohorts 1 and 4, and two (2) men in cohort 2 will receive placebo every 2 weeks for a total of 6 doses. Two (2) women in each of cohorts 3 and 5, and two (2) men in cohort 6 will receive placebo every 4 weeks for a total of 3 doses. Six (6) women in cohort 7 will receive placebo every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of placebo; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
89283333|NCT01101048|Active Comparator|B|Six (6) women in each of cohorts 1 and 4, and six (6) men in cohort 2 will receive AMG 167 every 2 weeks for a total of 6 doses. Six (6) women in each of cohorts 3 and 5, and six (6) men in cohort 6 will receive AMG 167 every 4 weeks for a total of 3 doses. Eighteen (18) women in cohort 7 will receive AMG 167 every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of AMG 167; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
89283334|NCT01095588|Experimental|Avanafil|
89283335|NCT01095588|Placebo Comparator|Placebo|
89283336|NCT03951246|Experimental|Training Group|"Training Group recieved cognitive and Motor training included 6 sessions using the following training devices.~Dynavision D2 ® (USA) (https://products.dynavisioninternational.com/products/d2) presents a panel with 64 bulbs which take the form of five circles. The task of a participant is to press the bulb that is glowing as quick as possible. In the trial 8 modes will be used; they have different instructions which are aimed at visual-motor co-ordination, processing speed, inhibition, and shifting.~Fitlight Trainer ® (Canada) (https://www.fitlighttraining.com) consists of 7 clickers, and the tasks are similar to Dynavision ones.~NeuroTracker ® (Canada) (https://neurotracker.net) includes a task of multiple object training for working memory and attention enhancement."
89283337|NCT03951246|No Intervention|Control Group|Control Group didn't recieved any cognitive and motor training. They visited swimming pool and physical therapy.
89283338|NCT01097772|Other|Ovation Abdominal Stent Graft System|Implant of Ovation Abdominal Stent Graft System
89283339|NCT03951168|Other|Routine Management|The patients were divided into routine diabetic health education management model group. Patients who meet the criteria for admission and discharge.
89283340|NCT03951168|Experimental|Standardized Management|The patients were divided into standardized diabetes health education management model group. Patients who meet the criteria for admission and discharge.
89283341|NCT00048048|Experimental|Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) at a dose of 0.15 microgram per kilogram (mcg/kg) subcutaneously (SC) once every week to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283342|NCT00048048|Experimental|Cohort 2 (RO0503821, 0.3 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every week to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283343|NCT00048048|Experimental|Cohort 3 (RO0503821, 0.6 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283344|NCT00048048|Experimental|Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every two week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283345|NCT00048048|Experimental|Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every two week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283346|NCT00048048|Experimental|Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.2 mcg/kg SC once every two week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283347|NCT00048048|Experimental|Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.45 mcg/kg SC once every three week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283348|NCT00048048|Experimental|Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)|Eligible participants will be receiving RO0503821 at a dose of 0.9 mcg/kg SC once every three week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283349|NCT00048048|Experimental|Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.8 mcg/kg SC once every three week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
89283350|NCT01327170|Active Comparator|Subthreshold diode micropulse laser|Subthreshold diode micropulse laser in patients with chronic central serous chorioretinopathy
89283351|NCT01327170|Sham Comparator|Sham|Sham group simulating the laser treatment
89283352|NCT03953118|Placebo Comparator|Placebo|
89283353|NCT03953118|Active Comparator|Azithromycin|
89283354|NCT01101126|Experimental|Disease Management|Comprehensive care delivered by designated nurses and pulmonologists, in collaboration with the primary practitioners and other healthcare professionals in the community
89283355|NCT01101126|Active Comparator|Unual care|Care delivered by the primary practitioner with the advice of a consultant pulmonologist
89283356|NCT01097850|Other|Right|Application of henna paste to right hand/foot plus CeraVe moisturizer
89283357|NCT01097850|Other|Left|Application of henna paste to the left hand/foot plus CeraVe moisturizer
89283358|NCT01095744||EOAD typical AD|this cohort is constituted with early onset typical AD.
89283359|NCT01095744||LOAD typical|this group is constituted with late onset typical AD
89283360|NCT01095744||atypical AD|this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.
89283361|NCT01095744||young controls|under 65
89283362|NCT01095744||old controls|over 65
89283363|NCT01101204|Active Comparator|M1000 S10 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 10mg
89283364|NCT01101204|Active Comparator|M1000 S10 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 10mg
89283365|NCT01101204|Active Comparator|M1000 S40 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 40mg
89283366|NCT01101204|Active Comparator|M1000 S40 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 40mg
89283367|NCT01101204|Active Comparator|M2500 S10 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 10mg
89283368|NCT01101204|Active Comparator|M2500 S10 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 10mg
89283369|NCT01101204|Active Comparator|M2500 S40 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 40mg
89283370|NCT01101204|Active Comparator|M2500 S40 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 40mg
89283371|NCT01101204|Placebo Comparator|Therapeutic Lifestyle Change|Only therapeutic lifestyle change
89283372|NCT01095822|Active Comparator|Aliskiren|25 patients with recently diagnosed hypertension and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
89283373|NCT01095822|Experimental|Aliskiren + Valsartan|25 patients with recently diagnosed hypertension, and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
89283374|NCT01095900||LIS group)|
89283375|NCT01095900||BT group|
89283376|NCT03954912|Active Comparator|MAKO robotic assisted UKA|image base (MAKO) robotic assisted UKA
89283377|NCT03954912|Active Comparator|NAVIO robotic assisted UKA|imageless (NAVIO) robotic assisted UKA
89283378|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Unfed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Unfed.
89283379|NCT03954600|Other|NPT520-34 - SAD Cohort 1, Dose 1 (Fed)|Single ascending dose of orally administered capsule(s) NPT520-34: 125 mg OR Single dose of orally administered placebo capsule(s) to match dose. Fed.
89283380|NCT03954600|Other|NPT520-34 - SAD Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT520-34: 250 mg OR Single dose of orally administered placebo capsule(s) to match dose.
89283381|NCT03954600|Other|NPT520-34 - SAD Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT520-34: 500 mg OR Single dose of orally administered placebo capsule(s) to match dose.
89283382|NCT03954600|Other|NPT520-34 - SAD Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT520-34: 1000 mg OR Single dose of orally administered placebo capsule(s) to match dose.
89283383|NCT03954600|Other|NPT520-34 - MAD Cohort 1, Dose 1|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
89283384|NCT03954600|Other|NPT520-34 - MAD Cohort 2, Dose 2|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
89283385|NCT03954600|Other|NPT520-34 - MAD Cohort 3, Dose 3|Multiple ascending dose of orally administered capsule(s) NPT520-34: TBD mg OR Single dose of orally administered placebo capsule(s) to match dose.
89283386|NCT00300053|Experimental|CLBS14: Low-Dose Group|10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 1 x 10^5 (=100000) cells/kg bodyweight
89283387|NCT00300053|Experimental|CLBS14: High-Dose Group|10 intramyocardial injections of 0.2 mL each of auto-CD34+ cells at a dose of 5 x 10^5 (=500000) cells/kg bodyweight
89283388|NCT00300053|Placebo Comparator|Placebo injection|10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma
89283389|NCT01098084|Experimental|Decitabine|
89283390|NCT01101282|No Intervention|'Usual care'|"Participants will receive 'usual medical care' consisting of the following:~Medical management: Bronchodilators, corticosteroids, antibiotics and supplemental oxygen will be provided (where appropriate) in accordance with Australian and New Zealand COPD management guidelines (COPDX guidelines).~Non-invasive ventilation: if clinically indicated and prescribed in accordance with standardised hospital guidelines.~Physical rehabilitation: Participants will be assessed by a physiotherapist and prescribed appropriate exercises to facilitate a safe and timely discharge. Participants will perform physical rehabilitation according to a standardised protocol with an aim of maximising physical function at discharge.~Other allied health (e.g. occupational therapy, speech pathology, dietician) assessments and interventions, as required."
89283391|NCT01101282|Experimental|'Usual care' plus PEP mask therapy|"This will comprise:~'Usual care'~PEP mask therapy"
89283392|NCT01101360|Active Comparator|Matrix RF followed by Pulse Dye Laser|
89283393|NCT03952572|Experimental|CDOP regimen|cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) administered in 3 week cycles for 6 cycles.
89283394|NCT03952572|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
89283395|NCT00299975|Experimental|MaZiRenWan (MZRW) Low dose|MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
89283396|NCT00299975|Experimental|MaZiRenWan (MZRW) Median dose|MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
89283397|NCT00299975|Experimental|MaZiRenWan (MZRW) High dose|MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
89283398|NCT03951090|Experimental|GARRT Arm|Participants in this arm complete an brief geriatric assessment, and the results of these assessments are given to providers with recommendations to address deficits identified by the geriatric assessment
89283399|NCT03951090|Active Comparator|Control Arm|Providers of participants of this group will not receive the results of the brief geriatric assessments. These participants will receive standard of care treatment
89283400|NCT03954522|Experimental|Expérimental|psychologist interview and psychometrics scales
89283401|NCT01065155||Median central blood pressure|Median central blood pressure, lower median group 1 and higher group 2.
89283402|NCT00004980|Experimental|active rTMS|1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
89283403|NCT00004980|Placebo Comparator|sham stimulation|Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
89283404|NCT03954756|Experimental|apatinib and PD-1|Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect
89283405|NCT00326963|Experimental|Enfuvirtide+PI+ARV's|"Eligible participants received Fuzeon® (enfuvirtide) 90 milligram (mg) subcutaneously (SC) two times a day (bid) for 24 weeks plus new protease inhibitor (PI) (darunavir/ritonavir) plus other investigator-choice antiretrovirals (ARVs). Participants selected their preferred injection device among the following three options: 27 gauge (G) ½ needle/syringe, 31G 8 millimeter (mm) needle/syringe or Biojector 2000 (B2000) needle-free injection device (NFID)."
89283406|NCT03983525|Experimental|Goji berry|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0 SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with either a 45-day supply of goji berries and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
89283407|NCT03983525|Active Comparator|Lutein + zeaxanthin supplementation|The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
89283408|NCT01065233||alcoholic cirrhosis with viral infection|patient with alcoholic cirrhosis with viral infection (300 patients)
89283409|NCT01065233||alcoholic cirrhosis without viral infection|patient with alcoholic cirrhosis without viral infection
89283410|NCT00326885|Experimental|Catumaxomab|
89283411|NCT01065311|Experimental|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of certain aspects of cognitive behavioral therapy for depression (Beck et al., 1979) and components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
89283412|NCT01065311|Active Comparator|CBASP|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions.
89283413|NCT01065311|Active Comparator|Treatment-as-usual|"Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
89283414|NCT03979703|Experimental|Intervention group|Intervention will be a 12 week yoga class
89283415|NCT03979703|No Intervention|Control group|Control group will not participate in the 12 week yoga class but will participate in Surveys, 6 minute walking test, lung function test, and biomarker analysis. Furthermore, they will be offered a yoga class after the study.
89283416|NCT00326495|Experimental|BAY 43-9006 & Cetuximab|BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID). Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2, followed by 250 mg/m^2 weekly starting on week 3
89283417|NCT03983447|Experimental|School-based intervention to promote Physical Activity (PA)|"This intervention included :~Physical (Environmental) adaptation of playground~Time adaptation of lunch breaks~Curriculum-based program of children~Workshops and newsletters for parents~Meetings for teachers"
89283418|NCT03983447|No Intervention|Control|Nothing has changed in the school.
89283419|NCT00326417|Experimental|Cyclophosphamide 150mg|Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)
89283420|NCT00326417|Experimental|Cyclophosphamide 100mg|Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)
89283421|NCT00326417|Experimental|Cyclophosphamide 50mg|Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)
89283422|NCT00326417|Experimental|Fludarabine|Fludarabine only (no Cyclophosphamide administered)
89283423|NCT01060787||Fluocinolone Acetonide 0.59 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 0.59 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
89283424|NCT01060787||Fluocinolone Acetonide 2.1 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 2.1 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
89283425|NCT01065389|Experimental|Prgressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
89283426|NCT01065389|Active Comparator|Unstructured Resistance Exercise|Unstructured Resistance Exercise thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
89283427|NCT01065467|Experimental|Treatment|LBH589
89283428|NCT01065545|Experimental|Clofarabine|
89283429|NCT01065623|Experimental|Arm 1|
89283430|NCT03979469|Experimental|opiod free general anesthesia|In group A opioid free anesthesia is administered. Anesthesia and analgesia were achieved with ketamine(1mg/kg, bolus), dexmedetomidine(1mcg/kg, over 10 minutes), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg). Anesthesia induction with ketamine(1mg/kg), propofol 1% 2-3mg/kg, rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
89283431|NCT03979469|Active Comparator|opioid based general anesthesia|In group B opioid based anesthesia is administered.Anesthesia and analgesia were achieved with remifentanil(0.3mcg/kg/minute), local anesthetic(ropivacaine 2mg/kg 0.75% wound infiltration), paracetamol(15mg/kg), non steroid analgesics(diclofenac 1mg/kg).Anesthesia induction with propofol 1% 2-3mg/kg,fentanyl(2mcg/kg), rocuronium 1mg/kg. Anesthesia maintenance with propofol 1% 10mg/kg/hour. Reversal of rocuronium with sugammadex 2mg/kg.
89283432|NCT01060865|Experimental|Aliskiren|only one arm with the experimental drug [aliskiren]
89283433|NCT01065701|Active Comparator|1mcg/kg|1mcg/kg intranasal dexmedetomidine administered 45 minutes befoe anesthesia induction
89283434|NCT01065701|Active Comparator|2mcg/kg|2mcg/kg intranasal dexmedetomidine given 45 minutes prior to anesthetic induction
89283435|NCT03825341|Active Comparator|Arm 1 Liquid Hydroxyurea|In Arm 1 of this study, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be ~20 mg/kg/day or the infant's usual daily dose.
89283436|NCT03825341|Active Comparator|Arm 2 Hydroxyurea Oral Capsule|In Arm 2, n=30 children who range in age from 2 to 18 years will be administered oral capsule HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg
89283437|NCT01060943|Active Comparator|KOKEN(collagen)|atelocollagen filler
89283438|NCT01060943|Experimental|TheraFill|atelocollagen filler
89283439|NCT01065857|Experimental|Citrafleet|The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.
89283440|NCT01065857|Active Comparator|Klean Prep|The day prior to the colonoscopy from 16:00h to 20:00h.
89283441|NCT01065857|Experimental|Citrafleet Exploratory|The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.
89283442|NCT01061021|Experimental|Integrated Intervention|Five small group + 2 individual counseling behavioral intervention to simultaneously address HIV transmission risk reduction and HIV treatment adherence in men and women living with HIV/AIDS.
89283443|NCT01061021|Active Comparator|Comparison Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
89283444|NCT00297479|Experimental|Mindfulness-Based Treatment Group (MBAT)|MBAT is 6 weeks of nicotine patch therapy; a Self-help guide; and In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence.
89283445|NCT00297479|Active Comparator|Standard Care Group|Standard Care Group (ST) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
89283446|NCT00297479|Active Comparator|Usual Care Group|Usual Care (UC) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
89283447|NCT01069367|Experimental|Arm:1|
89283448|NCT01069445|Active Comparator|Diet advices|will receive the Optimal Diet for Elderly
89283449|NCT01069445|Experimental|Diet advices + VSL-3|will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
89283450|NCT01069445|Experimental|Diet advices + 5203-L|will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
89283451|NCT01069445|Experimental|Diet advices + Argan oil|will receive the Optimal Diet for Elderly + Argan oil
89283452|NCT00688870|Experimental|1|13vPnC
89283453|NCT00688870|Active Comparator|2|7vPnC
89283454|NCT00297167|Experimental|EUR-1008 (APT-1008) First, Then Placebo|
89283455|NCT00297167|Experimental|Placebo First, Then EUR-1008 (APT-1008)|
89283456|NCT02532335|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
89283457|NCT02532335|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
89283458|NCT02532335|Active Comparator|Healthy Volunteers OCA|Obeticholic acid Obeticholic acid 25 mg/day in three weeks
89283459|NCT02532335|Placebo Comparator|Healthy volunteers Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
89283460|NCT03216226|Experimental|dasiglucagon (ZP4207)|Repeated single fixed doses (s.c.injection) of dasiglucagon
89283461|NCT03216226|Experimental|GlucaGen|Repeated single fixed doses (s.c.injection) of GlucaGen
89283462|NCT03215758|Active Comparator|QAW039|QAW039 once daily
89283463|NCT03215758|Placebo Comparator|Placebo|Placebo once daily
89283464|NCT00290771|Experimental|Imatinib 600 mg + hydroxyurea 1000 mg|Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.
89283465|NCT00290771|Experimental|Imatinib 1000 mg + hydroxyurea 1000 mg|Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.
89283466|NCT01069601|Experimental|transplanted adults|male and female adults who have previously undergone solid organ transplantation or allogeneic or autologous BMT
89283467|NCT00274625|Experimental|1|Surgisis Gold Graft
89283468|NCT00274625|Active Comparator|2|Control
89283469|NCT01325597|Experimental|Combined training|Training with functional electrical stimulation added by inspiratory muscle training.
89283470|NCT01325597|Experimental|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
89283471|NCT01325597|Experimental|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
89283472|NCT01325597|No Intervention|Control group|No intervention.
89283473|NCT00290693|Experimental|CapTere (Capecitabine + Docetaxel)|Capecitabine + Docetaxel (Taxotere)
89283474|NCT03214666|Experimental|GTB-3550 TriKE® (Phase I: Dose Finding Component)|Patients receive a single course of GTB-3550 TriKE® at their assigned dose as 3 weekly treatment blocks. Each block consists of four consecutive 24 hour continuous infusions (over approximately 96 hours) of GTB-3550 TriKE® followed by a 72 hour break after Block #1 and #2. All treatment is given as an inpatient. The assigned dose will be calculated on a weight obtained within 5 days prior to or on day of the 1st dose. The dose is not be recalculated for subsequent treatment blocks.
89283475|NCT03214666|Experimental|GTB-3550 TriKE® Only (Phase II: Extended Component)|The treatment schedule is identical to the dose finding component. The extended component uses a Simon's MiniMax two-stage design for continued enrollment using the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
89283476|NCT06292156|Experimental|Theta treatment group|In active tACS, the target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks.
89283477|NCT06292156|Active Comparator|Alpha active control group|In active tACS, the target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 10 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks.
89283478|NCT06292156|Sham Comparator|Sham control group|In sham group, Sham stimulation lasted 30 s (15 s of ramp- up and 15 of ramp-down) .
89283479|NCT06292143|Other|Advance Care Planning toolkit|"Provision of access to the digital ACP platform to patients and caregivers, baseline assessment with the ACP digital platform on day 0.~Information to guide decision making around care and treatment preferences are accessed by patients and carers on days 1 to 7. Where desired, care and treatment preferences are recorded.~Evaluation of usefulness and burden of the digital platform for ACP on day 7. Content stored on digital platform for ACP shared across care settings to those involved in care of participant on day 8 to 29.~Evaluation of usefulness and burden of the digital platform for ACP, participant and carer experience of completion. Initial exploration of impact on communication between health and social care professionals, access to timely information to inform clinical decision making, and efficiency savings (e.g. reduction in paper forms and duplication, less time chasing information) on day 90."
89283480|NCT06292130|Experimental|App users|All participants will be provided with access to the intervention app (refresh).
89283481|NCT06292104||POTS|Patients meeting clinical criteria for postural orthostatic tachycardia syndrome who meet other criteria for inclusion.
89283482|NCT06292104||Healthy matched controls|Age and sex matched controls
89283483|NCT06292078|Experimental|Wave 1 Instructional Skill-Building Learning Approach (ISLA)|Following a baseline year for data collection, school staff in 15 schools will be trained and supported in implementing ISLA schoolwide for two consecutive years.
89283484|NCT06292078|No Intervention|Wave 1 Waitlist Control|These 15 schools will receive no intervention while wave 1 intervention schools undergo training and coaching on ISLA.
89283485|NCT06292078|Experimental|Wave 2 Instructional Skill-Building Learning Approach (ISLA)|Delayed one year after wave 1: Following a baseline year for data collection, school staff in 15 schools will be trained and supported in implementing ISLA schoolwide for two consecutive years.
89283486|NCT06292078|No Intervention|Wave 2 Waitlist Control|These 15 schools will receive no intervention while wave 2 intervention schools undergo training and coaching on ISLA.
89283487|NCT06292052||Neoadjuvant immunochemotherapy NSCLC group|NSCLC patients who received neoadjuvant immunochemotherapy and underwent surgery.
89283488|NCT06292026|Experimental|Treatment with ProgenaMatrix|application of ProgenaMatrix daily for 12 weeks
89283491|NCT06291948|Active Comparator|Humira® (adalimumab) AC Pen [Reference Product]|A single subcutaneous dose of 40 mg of the Reference Product- Humira® AC Pen [Reference Product]
89283492|NCT06291948|Active Comparator|Adalimumab Richmond [Test Product]|A single subcutaneous dose of 40 mg of the Test Product- Adalimumab Richmond [Test Product]
89283493|NCT06291935|Experimental|VG901|Participants will receive a single dose of intravitreal injection of VG901 in most affected eye at Day 0.
89283494|NCT06291922|Experimental|Exercise Intervention|The exercise intervention focuses on walking and strengthening exercises with a standardized protocol to guide exercise prescription and exercise progression based on data obtained from the activity tracking watch and smartphone app.
89283495|NCT06291922|Other|Usual Care|The usual care group will be encouraged to increase daily walking activity as they tolerate, while complying with any activity restrictions from their clinical team. The Physical Activity Guidelines for Americans recommend increasing daily walking activity as tolerated to an average of 30 minutes daily, 5 times a week.
89283496|NCT06291870||COVID+|Patients with post-acute sequelae of SARS-COV-2 infection (PSAC) and obstructive sleep apnea (OSA)
89283497|NCT06291870||Control|Patients with obstructive sleep apnea and no history of COVID-19
89283498|NCT06291831||Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)|Adult COVID-19 patients' Healthcare Resource Utilization (HRU) within the 30-day period following nirmatrelvir, ritonavir prescription.
89283499|NCT06291831||Controls|Adults COVID-19 patient HRU within 30 days period following nirmatrelvir/ritonavir prescription
89283500|NCT06291818|Other|Assess the performance of this novel eyelid closure device in vivo|The primary goal of this study is to determine the feasibility and success of a temporary magnetic system for tarsorrhaphy (MST) to provide adequate closure of the eyes for ultimate use in conditions causing lagophthalmos (a disorder in eyelid closure). In this disorder, people are unable to sufficiently cover their cornea (the front of the eye), which can lead to dryness, infection, scarring and even blindness. Current therapies are invasive, involving local anesthesia and surgeries, and have a negative cosmetic impact.
89283501|NCT06291805||wtATTR-CM patients (n = 100)|"Clinical history, physical examination, ECG, advanced echocardiography, blood and urine samples, cardiac magnetic resonance imaging (CMRI), and QoL questionaires (KCCQ, EQ-5Q-5L and ATTR-QoL)).~Subgroup with these patient (n = 10): A endomyocardial biopsy."
89283502|NCT06291805||Control (n = 20)|Blood and urine samples. To rule out cardiac disease: clinical history, physical examination, ECG and advanced echocardiography.
89283503|NCT06291792|Experimental|Telerehabilitation Otago Exercise Group (TOEG)|"The use of Otago Exercise Program in the home environment using the telerehabilitation method. Telerehabilitation was performed with video and audio interviews 3 times a week for 45 minutes.~The study will take 12 weeks. An 8-week treatment protocol will be applied. 4 weeks after the treatment protocol, the last measurement will be made and the study will be terminated."
89283504|NCT06291792|Experimental|Face to face Otago Exercise Group (FOEG)|"Otago Exercise Program was applied in a face-to-face clinical setting. Interviews were held 3 times a week for 45 minutes.~The study will take 12 weeks. An 8-week treatment protocol will be applied. 4 weeks after the treatment protocol, the last measurement will be made and the study will be terminated."
89283505|NCT06291779||Pancreatic cancer group|scheduled for curative surgery for pancreatic cancer
89283506|NCT06291779||Control group|group included healthy individuals as well as patients with benign diseases
89283507|NCT06291766|Other|Continous glucose measurement|Use of FreeStyle Libre 3, with Libre Link app and Glooko app for measurement and review of glucose measurements.
89283508|NCT06291766|No Intervention|Capillary glucose measurement|Standard care, including capillary glucose measurements and Glooko app for review of glucose measurements.
89283509|NCT06291740|Experimental|Continuous nebulization|continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min
89283510|NCT06291740|Active Comparator|intermittent nebulization|intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour
89283511|NCT06291727|Active Comparator|Mepivacaine|Standard dose of mepivacaine anesthesia (1.5% or 2%) for total knee arthroplasty procedure
89283512|NCT06291727|Active Comparator|Bupivacaine|Standard dose of hyperbaric bupivacaine anesthesia (0.75%) for total knee arthroplasty procedure
89283513|NCT06291701||Other|adolescent tennis player
89283514|NCT06291688|Experimental|Game group|An educational game regarding common EGFR-related cutaneous adverse drug reactions on a mobile APP
89283515|NCT06291688|Placebo Comparator|Text group|An educational text regarding common EGFR-related cutaneous adverse drug reactions on a mobile APP
89283516|NCT06291675||Transgender women|Transgender women included in this study receive estrogen, either transdermally (Estrogel-Gel®, Estradot® or Estramon®) or orally (Estrofem®). If needed, the treatment can be supplemented by cyproterone acetate (Androcur®), and/or an alpha-5-reductase inhibitor (Finasterid Actavis/Arcana/Aurobindo®). The GAHT of our probands is prescribed and managed independently of the study, and the study has no effect on the treatment.
89283517|NCT06291675||Transgender men|The cohort of transgender men are persons who receive testosterone either intramuscularly (Nebido®) or transdermally (Testogel® or Testavan®). The GAHT of our probands is prescribed and managed independently of the study, and the study has no effect on the treatment.
89283518|NCT06291662|Experimental|Pelvic bone neoplasm|Patients with primary tumor of the pelvic bone; Primary meta-diaphysial tumor of the long bones; squamous cell carcinoma of the oral cavity involving the maxillary upper and/or lower.
89283519|NCT06291662|Experimental|Sarcoma pediatric patients|Patients with primary sarcoma of bone and soft parts involving the scapula, the pelvis and upper and lower limbs; brain tumor.
89283520|NCT06291662|Experimental|Intracranial oncologic pathology|Patients with intracranial oncologic pathology with bone involvement and lesions of the skull theca primary or secondary.
89283521|NCT06291623|Experimental|Pre disinfection (30% H2O2, followed by 2.5% NaOCl) NaOCl inactivated with 5% sodium thiosulfate.|sample was taken before pre disinfection protocol (30% H2O2, followed by 2.5% NaOCl) NaOCl will be inactivated with 5% sodium thiosulfate.
89283522|NCT06291623|Experimental|Post disinfection (30% H2O2, followed by 2.5% NaOCl) NaOCl inactivated with 5% sodium thiosulfate.|sample was taken after pre disinfection protocol, to check the sterility of the disinfected tooth surface and access
89283523|NCT06291623|Experimental|Group 1 (n = 10): Ca(OH)2|3 samples was taken before and after the treatment. Sample 1 was taken before Chemomechanical procedures Sample 2 was taken immediately after Chemomechanical procedures, intracanal medication was placed for 1 week Sample 3 was taken immediately after intracanal medication was removed
89283524|NCT06291623|Experimental|Group 2 (n = 10): Glycyrrhizin|3 samples was taken before and after the treatment. Sample 1 was taken before Chemomechanical procedures Sample 2 was taken immediately after Chemomechanical procedures, intracanal medication was placed for 1 week Sample 3 was taken immediately after intracanal medication was removed
89283525|NCT06291610|Other|Decision intervention group|The decision intervention will be tested in one arm (group)
89283526|NCT06291597||Daily electronic cigarette users|Participants must use their vaping device everyday at time of enrollment.
89283527|NCT06291571||Liver diseases|Patients with documented liver diseases
89283528|NCT06291571||Control|Healthy volunteers without evidence of liver disease
89283529|NCT06291558|Experimental|Face to face Exercise Group|In the face-to-face exercise group called Group 1, students will implement an exercise program of respiratory exercises and resistance exercises with the physiotherapist. Exercises will be held for 8 weeks
89283530|NCT06291558|Experimental|Telehealth Exercise Group|In the online (telehealth) exercise group, group 2 will be applied by the students with the help of the physiotherapist. Exercises will be held for 8 weeks
89283531|NCT06291558|No Intervention|Control Group|In the control group called Group 3, students will not be given any exercise program.
89283532|NCT06291532|Experimental|Experimental Group (EG)|The group consists of patients diagnosed with autism spectrum disorder and intellectual disability who underwent treatment with VRRS
89283533|NCT06291519|Experimental|Experimental Group 1|In this group, the mother applied multiple sensory stimuli. In this group, the mothers of the babies to be vaccinated applied multiple sensory stimuli such as breastfeeding, mother's voice, touch-light massage, and eye contact. The mother breastfed her baby for a total of 20 minutes. Breastfeeding was terminated before vaccination. Other applications were applied for 5 minutes before vaccination and 5 minutes after vaccination. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
89283534|NCT06291519|Experimental|Experimental Group 2|In this group, the nurse applied multiple sensory stimuli. In this group, the mothers of the babies to be vaccinated breastfed the baby for 20 minutes. The mother stopped breastfeeding before the vaccination procedure. The nurse started to give multisensory stimuli. The nurse administered multisensory stimuli including soft tone of voice, touch-light massage, and eye contact 5 minutes before the vaccination. Other applications were applied 5 minutes before and 5 minutes after vaccination. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
89283535|NCT06291519|Experimental|Experimental Group 3|In this group, the mother breastfed her baby for 20 minutes before vaccination. Breastfeeding was terminated before vaccination. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
89283536|NCT06291519|No Intervention|Control Group|Babies in this group did not receive any treatment. A light touch was applied for ethical reasons. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
89283537|NCT06291506|Experimental|Pulmonary veins isolation plus linear left atrial ablation.|
89283538|NCT06291506|Active Comparator|Pumonary veins isolation only.|
89283539|NCT06291480|Experimental|Music Therapy + Care as Usual|9 music therapy sessions within 2-5 weeks during stroke rehabilitation, in addition to care as usual.
89283540|NCT06291480|No Intervention|Care as Usual|2-5 weeks of care as usual, without music therapy
89283541|NCT06291467|Experimental|Suicide attempters|patients hospitalized for suicide attempt within the last 72 hours
89283542|NCT06291467|Active Comparator|Affective controls|patients hospitalized for current major depressive episode according to DSM-5 criteria and without any lifetime history of suicide attempt
89283543|NCT06291441||Women's single sample|"INSTRUMENTS:~UI Survey: A survey, written in Italian by the authors, will collect women's socio-demographic, economic and clinical characteristics~Italian version of International Consultation of Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ UI-SF)~Italian version of Incontinence Impact Questionnaire-7 (IIQ-7)"
89283544|NCT06291428||Raman spectroscopy|Patients with acute lymphoblastic leukemia, in assessment for measure residual disease.
89283545|NCT06291428||flow citometry|Patients with acute lymphoblastic leukemia, in assessment for measure residual disease.
89283546|NCT06291376|Experimental|Ravulizumab IV q8w|"Participants will receive a weight-based loading dose on Day 1 followed by weight-based maintenance dosing initiated on Day 15, and then administered every 8 weeks (q8w).~Participants in the exploratory group will receive open-label weight based loading dose on Day 1 followed by open label weight based maintenance dose on Day 15 and q8weeks after."
89283547|NCT06291376|Placebo Comparator|Placebo IV q8w|Participants will receive a weight-based loading dose on Day 1 followed by weight-based maintenance dosing initiated on Day 15, and then administered q8w.
89283548|NCT06291337|Experimental|Treatment of sweet taste receptors with Ibuprofen oral rinse|Participants were tested for sweetness perception without and with an oral rinse of ibuprofen.
89283549|NCT06291337|Experimental|Treatment of sweet taste receptors with naproxen oral rinse|Participants were tested for sweetness perception without and with an oral rinse of naproxen.
89283550|NCT06291311||NIPP treatment|Treatment with cold physical Plasma
89283551|NCT06291311||Control group|No treatment with cold physical Plasma
89283552|NCT06291298|Experimental|COGMUSE-AUT|Participants will complete the computerized cognitive training intervention for 60 minutes per day, 3 times per week for 6 weeks at home totaling to 18 hours.
89283553|NCT06291285|Experimental|Formulation A followed by Formulation B|Participants will receive a single oral dose of decitabine and tetrahydrouridine (THU) immediate release tablets (Formulation A) on Day 1 of treatment period 1 followed by a single oral dose of decitabine and THU delayed release capsules (Formulation B) on Day 1 of treatment period 2. A washout period of 7- 21 days will be maintained between the two treatment periods.
89283554|NCT06291285|Experimental|Formulation B followed by Formulation A|Participants will receive a single oral dose of decitabine and THU delayed release capsules (Formulation B) on Day 1 of treatment period 1 followed by a single oral dose of decitabine and THU immediate release tablets (Formulation A) on Day 1 of treatment period 2. A washout period of 7- 21 days will be maintained between the two treatment periods.
89283555|NCT06291272|Experimental|Psyllium|375 ml containing 15g inulin made up in 375 ml water with 15 g psyllium husk
89283556|NCT06291272|Experimental|Methylcelulose|375 ml containing 15g inulin made up in 375 ml water with 15g modified methylcellulose
89283557|NCT06291272|Placebo Comparator|Maltodextrin|375 ml containing 15g inulin made up in 375 ml water with maltodextrin powder (placebo)
89283558|NCT06291259||Confirmed positive for mpox|Participants with laboratory test results confirming the diagnosis of Mpox. This includes the total number of unique participants who complete the main part 1 study, those who complete the baseline visit only, those who agree to frequent sampling, and those who only participate in part 2.
89283559|NCT06291259||Confirmed negative for mpox|Participants in whom the clinician feels that the diagnosis of Mpox has been clearly ruled out.
89283560|NCT06291246|Experimental|Family Navigation|Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.
89283561|NCT06291246|Active Comparator|Educational Materials|"The comparison condition (Educational Materials) consists of providing the participant's caregivers with individualized recommendations for intervention for their child at the time of the diagnosis of autism spectrum disorder."
89283562|NCT06291233|Experimental|Virtual Interview Training|
89283563|NCT06291233|Active Comparator|Services-as-usual|
89283564|NCT06291220|Experimental|Part A: Cohort 1.1 ABBV-453 Dose A|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose A is achieved, during the 5 year study duration.
89283565|NCT06291220|Experimental|Part A: Cohort 1.2 ABBV-453 Dose B|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose B is achieved, during the 5 year study duration.
89283566|NCT06291220|Experimental|Part A: Cohort 1.3 ABBV-453 Dose C|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose C is achieved, during the 5 year study duration.
89283567|NCT06291220|Experimental|Part A: Cohort 1.4 ABBV-453 Dose D|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose D is achieved, during the 5 year study duration.
89283568|NCT06291220|Experimental|Part A: Cohort 1.5 ABBV-453 Dose E|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose E is achieved, during the 5 year study duration.
89283569|NCT06291220|Experimental|Part B: Cohort 2.1 ABBV-453 Dose E|Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose E is achieved, during the 5 year study duration.
89283570|NCT06291220|Experimental|Part B: Cohort 2.2 ABBV-453 Dose E|Participants will no participate in the debulking period and receive escalating doses of ABBV-453, until the dose E is achieved, during the 5 year study duration.
89283571|NCT06291181|Experimental|cases group|wound infected patients
89283572|NCT06291168|Experimental|Chiropractic Manipulation (CM) Group|Sacroiliac joint manipulation and manipulations to be applied to the lumbar region will be applied twice a week for 8 weeks in the side lying position.
89283573|NCT06291168|Experimental|Yoga-based Exercise (YBE) Group|"Yoga treatment includes exercise, respiration, balance and coordination, and stretching and will be performed by a physiotherapist with yoga certification.~Yoga exercises will be practiced with the classical yoga program, divided into groups of 3-4 people, for 8 weeks, 2 days a week, 60 minutes a day."
89283574|NCT06291168|Experimental|Conventional Exercise (Control) Group (CG)|Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week under the supervision of a physiotherapist. Individuals will be called to the hospital two days a week for 8 weeks and will be advised to continue the exercises during the follow-up period. At the end of the 12th week, the exercises will be repeated and progressed with the physiotherapist.
89283575|NCT06291155|Other|SGLT2i Arm|
89283576|NCT06291129|Other|Hematological and Periodontal Parameters|Hematological parameters were recorded - fasting blood glucose and glycosylated hemoglobin - to confirm the allocation of each participant between the groups: diabetic (DM) and control (NDM). The clinical periodontal parameters, including plaque index (PI) and bleeding on probing (GI) full mouth (Ainamo & Bay 1975), and plaque index (PI), probing depth of pocket (PPD), gingival recession (GR) and clinical attachment level (CAL). Gingival biotype clinical parameters were evaluated by three aspects: Gingival transparency to probing, Height of keratinized mucosa and Gingival thickness on permanent incisors and molars. For the periodontal parameters' examination, a periodontal probe PCP15 (PCP-UNC15, Hu-Friedy, Chicago, IL) was used, excluding third molars and erupting teeth. The intraexaminer agreement of the categorical variables (CAL) using the kappa calculation was 7.64, at the tooth level.
89283577|NCT06291129|No Intervention|Orthodontic Parameters|The clinical orthodontic parameters were recorded by the Angle's Classification, witch evaluated occlusion of right and left canines and molars, and the Dental Aesthetic Index (DAI) that evaluates the prevalence of malocclusions, its severity and the need for treatment. DAI aspects evaluated were: upper teeth loss, lower teeth loss, crowding, spacing, diastema, maxillary misalignment, mandibular misalignment, anterior maxillary overjet, anterior mandibular overjet, anterior open bite, molar relationship.
89283578|NCT06291116|Experimental|experimental|Experimental group: standard care + rotigotine at 4 mg/24 hours for 24 months.
89283579|NCT06291116|Active Comparator|Control|Control group: standard care for 24 months.
89283580|NCT06291103|Experimental|Experimental|- Experimental arm: conversion to Belatacept CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
89283581|NCT06291103|Active Comparator|Control|- Control arm: Standard of care treatment (SOC regimen) with Tacrolimus Tacrolimus will be continued until kidney graft survival with objective of whole blood through levels between 6 and 8 ng/mL
89283583|NCT06291077|Experimental|Belatacept group|Belatacept group
89283584|NCT06291077|Active Comparator|anticalcineurin group|anticalcineurin group
89283585|NCT06291064|Experimental|Treatment Arm|Participants will receive epirubicin and cyclophosphamide every three weeks for a total of 12 weeks followed by 3-weekly docetaxel for 12 weeks and carboplatin every three weeks for a total of 12 weeks. All premenopausal participants will receive luteinizing hormone-releasing hormone (LHRH) agonist goserelin (Zoladex) for contraception and fertility preservation.
89283586|NCT06291051|Experimental|Electrical spinal cord stimulation in Parkinson's patients presenting with painful camptocormia|
89283587|NCT06291038|Experimental|Glutamine|• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks.
89283588|NCT06291038|Placebo Comparator|Protifar|• Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
89283589|NCT06291025|Experimental|PEX-FREE|Replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
89283590|NCT06291012|Experimental|Short arm|Antibiotic therapy for 3 to 5 days depending on response
89283591|NCT06291012|Active Comparator|Long arm|Antibiotic therapy for 5 to 7 days depending on response
89283592|NCT06290999||patient with pulsatile tinnitus|
89283593|NCT06290986|Active Comparator|Pyrocardan® implant|
89283594|NCT06290986|Active Comparator|Ligament reconstruction and tendon interposition (LRTI)|
89283595|NCT06290947|Experimental|Blood-Flow Restriction Walk Training (BFRw)|"Participants in this group will engage in a Blood-Flow Restriction Walk Training (BFRw) program designed to evaluate the efficacy of BFRw in enhancing insulin sensitivity and aerobic capacity.~Activities:~Participants will attend three weekly supervised walking sessions for eight weeks, each integrating specialized BFR cuffs calibrated to a precise pressure to restrict blood flow during exercise partially.~Purpose:~This arm is crucial for testing the study's primary hypothesis by measuring the intervention's effects against a control group."
89283596|NCT06290947|Active Comparator|Control Group Walk Training|"Participants in this group will engage in a conventional walking training program without applying BFR cuffs.~Activities:~Participants will attend three weekly supervised walking sessions for eight weeks without using BFR cuffs.~Purpose:~This group will serve as a benchmark to ascertain the effectiveness of the intervention, providing a baseline for the comparative analysis of the results obtained from the intervention group."
89283597|NCT06290908||RPE-P/TLIF|The clinical manifestation is intermittent claudication accompanied by lower back pain. Patients with lumbar spinal canal stenosis indicated by MRI and/or CT, and instability of the responsible segment of the lumbar spine shown by X-ray in the over extension and over flexion position, with severe symptoms that affect daily life and work, and poor conservative treatment effect, should undergo RPE-P/TLIF single or double segment surgical treatment.
89283598|NCT06290895||In-vitro fertilization (IVF) cycle using artificial oocyte activation (AOA)|
89283599|NCT06290895||In-vitro fertilization (IVF) cycle without artificial oocyte activation (AOA)|
89283600|NCT06290843||Scoliosis|Children with idiopathic scoliosis
89283601|NCT06290843||Control|Children without idiopathic scoliosis
89283602|NCT06290817|Experimental|Orelabrutinib combined with R-CDOP regimen|Participants will receive 150 mg of oral orelabrutinib once daily with R-CDOP on day 1 of each cycle (21 days)
89283603|NCT06290804|Other|Children aged 60-72 months-before|"As a data collection tool, two separate questionnaires were prepared for parents and children by utilizing the literature. The questionnaire form prepared for children consists of 3 parts. The first part includes some variables thought to be related to climate change and sustainability, the second part includes the questions '' Environmental Sustainability Scale for 60-72 Month-old Children and the third part includes questions about health effects of climate change.~The questionnaire form prepared before the intervention will be applied to children who agree to participate in the study."
89283604|NCT06290804|Other|Children aged 60-72 months-after|In the intervention phase, the effectiveness of the training program and training videos to be applied to children will be evaluated in terms of sustainable behaviors towards the environment and awareness of the health effects of climate change in 60-72 month old children.
89283605|NCT06290791|Experimental|group A (with one drain)|
89283606|NCT06290791|Active Comparator|the group B (with two drains)|
89283607|NCT06290765|Experimental|Ropeginterferon alfa-2b group|Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), target optimal dose of 500 µg. Phlebotomy should be conducted when Hct ≥ 45%.
89283608|NCT06290765|Other|Control group|Phlebotomy only and should be conducted when Hct ≥ 45%.
89283609|NCT06290739||Intrahepatic cholangiocarcinoma patients who underwent lymph nodes dissection|
89283610|NCT06290739||Intrahepatic cholangiocarcinoma patients who didn't undergo lymph nodes dissection|
89283611|NCT06290713|Experimental|Tadalafil and Exercise Arm|Participants receive tadalafil weight-dependent dosage to take daily for 6 months (26 weeks).
89283612|NCT06290713|Placebo Comparator|Placebo and Exercise Arm|Participants receive a tadalafil placebo tablet matching the tadalafil weight-dependent dosage to take daily for 6 months (26 weeks).
89283613|NCT06290700|Experimental|İntervational group|Neonatal care education given to primiparous pregnant women affect their postpartum maternal function Neonatal care education given to primiparous pregnant women affect their postpartum quality of life?
89283614|NCT06290700|No Intervention|Control group|All pregnant women, those in the control group, were provide with standard
89283615|NCT06290661|Experimental|Participants receiving active electrostimulation after implantation procedure|Twenty-eight participants (anticipated) from different 4 hospital in China whose mean VAS scores decreased more than 30% compared with baseline scores after electrode implantation. They will still receive electrostimulation therapy during randomized withdrawal period.
89283616|NCT06290661|Placebo Comparator|Participants receiving placebo electrostimulation after implantation procedure|Twenty-eight participants (anticipated) from different 4 hospital in China whose mean VAS scores decreased more than 30% compared with baseline scores after electrode implantation. The electrostimulation of them will be turned off during randomized withdrawal period.
89283617|NCT06290648|Experimental|Experimental: Forging New Paths + Usual Care|The experimental condition receives Forging New Paths in addition to community based mental health services as determined by their treatment providers.
89283618|NCT06290648|No Intervention|Control: Usual Care Alone|The control condition receives community based mental health services as determined by their treatment providers.
89283619|NCT06290635||All Participants|Participants include IPF and F-ILD including progressive pulmonary fibrosis phenotype
89283620|NCT06290609|Experimental|Vibrotactile Coordinated Reset stimulation|Participants will receive vCR stimulation, involving vibratory stimulation of the fingertips, with the Stanford CR Glove on a daily or weekly basis.
89283621|NCT06290570||Hypertrophic Cardiomyopathy (HCM)|Subjects with clinically validated diagnoses of HCM will be enrolled and have a clinically indicated 12-Lead ECG obtained as well as ECG tracings collected using an Apple Smart Watch (single-lead) and AliveCor KardiaMobile (6-Lead).
89283622|NCT06290570||Athlete's Heart|Subjects with clinically validated diagnoses of Athlete's Heart will be enrolled and have a clinically indicated 12-Lead ECG obtained as well as ECG tracings collected using an Apple Smart Watch (single-lead) and AliveCor KardiaMobile (6-Lead).
89283623|NCT06290544|Other|Single arm study|Subjects with type 1 diabetes mellitus who meet all the inclusion and none exclusion criteria
89283624|NCT06290531|Experimental|Buzzy device (cold and vibration)|
89283625|NCT06290531|Experimental|Buzzy device (vibration only)|
89283626|NCT06290531|Experimental|Precooling|
89283627|NCT06290531|Active Comparator|Flavored Benzocaine topical anesthetic gel 20%|
89283628|NCT06290518|Experimental|Probiotic group|All women in the probiotic group consume (oral route) a daily capsule with ~50 mg of freeze-dried probiotic (9.5 log10 CFU of L. salivarius CECT5713; excipient: maltodextrin) during the 6 months prior to the fertility treatment and during the first IVF cycle (estimated 1-2 months). In case of pregnancy, the woman will continue the treatment until 12 weeks of gestation.
89283629|NCT06290518|Placebo Comparator|Placebo group|All women in the placebo group consume (oral route) a daily capsule with ~50 mg of maltodextrin during the 6 months prior to the fertility treatment and during the first IVF cycle (estimated 1-2 months). In case of pregnancy, the woman will continue the treatment until 12 weeks of gestation.
89283630|NCT06290505|Experimental|Treatment|Participants will receive 2 weeks of therapy with concurrent hypofractionated radiotherapy (30Gy/10#), weekly carboplatin (AUC2), weekly paclitaxel (50mg/m2) and durvalumab (1500mg) intravenously every 4 weeks, followed by durvalumab monotherapy continuing at 1500mg intravenously every 4 weeks until disease progression or 24 months of therapy. A single metastasis will be treated with stereotactic radiotherapy (24Gy/3#) 4 weeks after the completion of the chemoradiotherapy to the primary tumour. Monitoring of adherence to treatment will be done by attendance at booked appointments
89283631|NCT06290492|Active Comparator|real stimulation|Participants will receive active HD-tDCS daily for 10 consecutive days. The anode electrode was placed on the DMPFC (Fz) surrounded by four cathodes with a 1cm diameter (FPz, F3, Cz, and F4). The stimulation direct current magnitude was set at 2 mA with a 30-s immediate decline at the beginning and end of each phase.
89283632|NCT06290492|Sham Comparator|sham stimulation|In the sham intervention phase, the sensation was simulated by applying a 30-s rising current until 2 mA was reached, with a 30-s immediate decline at the beginning and end of each phase.
89283633|NCT06290479|Experimental|Air Up® Peach Pod|Participants in this arm will use the air up® drinking system with a peach-flavored pod. The intervention aims to test if the flavored scent encourages increased water intake, which will be assessed by self-reported questionnaires and hydration-related health outcomes over 12 weeks.
89283634|NCT06290479|Experimental|Air Up® Orangeade Pod|Participants in this arm will use the air up® drinking system with an orangeade-flavored pod. Similar to Arm 1, the intervention will assess the impact of the flavored scent on water consumption and health outcomes, using the same methods of evaluation.
89283635|NCT06290479|No Intervention|Control - Unscented Pod|Participants in this control arm will use the air up® drinking system with an unscented pod. This group will serve as the control to evaluate the effectiveness of the scented pods in comparison to a baseline with no added scent.
89283636|NCT06290466|Experimental|FCN-437c capsule|fasting oral, single dose.Specification :100mg
89283637|NCT06290466|Placebo Comparator|FCN-437c capsule Placebo|fasting oral,single dose.Specification :100mg
89283638|NCT06290453||Multiple sclerosis patients (MS)|"included 40 patients with newly discovered MS (duration of the disease is 3 years or less) and diagnosed according to the revised McDonald criteria. The patients will be recruited from the neurology department of Assiut University Hospital.~MS patients will be further subdivided into two subgroups: 20 patients with RRMS and 20 patients with Progressive MS group."
89283639|NCT06290453||Control (C)|Group II: included 20 healthy individuals who will be age- and sex-matched as a control group, with no history of any neurological or autoimmune disease.
89283640|NCT06290427|Active Comparator|DaVinci system|Robot-assisted partial nephrectomy is performed using the DaVinci platform
89283641|NCT06290427|Experimental|Hugo RAS system|Robot-assisted partial nephrectomy is performed using the Hugo RAS platform
89283642|NCT06290427|Experimental|Versius system|Robot-assisted partial nephrectomy is performed using the Hugo RAS platform
89283643|NCT06290401|Active Comparator|Active Treatment|SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
89283644|NCT06290401|Placebo Comparator|Control Condition|Participants randomized to SCHealthED will receive usual care plus 7 text messages consisting of SCD educational facts to ensure the care is uniform across sites.
89283645|NCT06290375|Experimental|HSK21542 tablet 2mg|
89283646|NCT06290375|Experimental|Placebo|
89283647|NCT06290349|Experimental|DA5221-T1 + DA5221-R2 + DA5221-B1 + DA5221-B2|
89283648|NCT06290349|Experimental|DA5221-R1 + DA5221-T2 + DA5221-B1 + DA5221-B2|
89283649|NCT06290349|Placebo Comparator|DA5221-R1 + DA5221-R2 + DA5221-B1 + DA5221-B2|
89283650|NCT06290336|Experimental|Intervention group|Pre-operative exercise therapy and education before knee replacement surgery
89283651|NCT06290336|Other|Control group|Standard care
89283652|NCT06290323|Other|Placebo|Patients in the first group are the control group and after spinal anesthesia, the sensory block is formed, the lithotomy position will be taken for the surgical procedure. Patients will be monitored for 48 hours for postoperative pain (Numarating Raiting Scala: NRS) and side effects. On the post-operative 7th day, the patients' pain level will be assessed with NRS and the DJS connected sub-urinary system septomas will be evaluated with the ureteral stent discomfort questionnaire (with the stent inserted). In our clinic, approximately 1 month after URS operations, control cystoscopy is performed and ureteral stents are removed. After 5 days of removal of the ureteral stent, the symptoms of the lower urinary system will be questioned with the ureteral stent discomfort questionnaire (after removal of the stent).
89283653|NCT06290323|Active Comparator|Quadratus lumborum|After the posterior quadratus lumborum block was made in the lateral decubitus position, the patient was taken to the lithotomy position for surgery. Patients will be monitored for 48 hours for postoperative pain (Numarating Raiting Scala: NRS) and side effects. On the post-operative 7th day, the patients' pain level will be assessed with NRS and the DJS connected sub-urinary system septomas will be evaluated with the ureteral stent discomfort questionnaire (with the stent inserted). In our clinic, approximately 1 month after URS operations, control cystoscopy is performed and ureteral stents are removed. After 5 days of removal of the ureteral stent, the symptoms of the lower urinary system will be questioned with the ureteral stent discomfort questionnaire (after removal of the stent).
89283654|NCT06290310||mechanically ventilated patients|Invasively or non-invasively ventilated patients.
89283655|NCT06290297|Experimental|Children with neurodevelopmental disabilities|Children aged 4 to 18 with cognitive, motor and/or speech-language impairments
89283656|NCT06290284|Experimental|Long Peripheral Catheter|The procedure to place a LPC includes these steps: before inserting the catheter, the nurse will perform routine preliminary (non sterile) inspection of the arm to identify an insertion site. After selecting the insertion site, the nurse will release the tourniquet, with non-sterile gloves, and disinfect the skin around the insertion site. While allowing the antiseptic to act, the nurse will apply the tourniquet, and pull lightly with the thumb of the non-dominant hand to keep the vein from moving. After the needle has been inserted in the vein lumen, the guide wire is advanced and the catheter is inserted using the catheter wings. As the catheter is being inserted, the sheath (housing) is removed and then the wings. Before attaching the catheter to an extension without a needle or to a 3-way stopcock, it should be connected to a statlock to ensure it is safely fixated. A transparent, semi-permeable dressing will allow for daily visual inspection of the insertion site.
89283657|NCT06290284|Active Comparator|Peripheral Intra-Venous Catheter|The procedure to place a PIVC includes these steps: before inserting the catheter, the nurse will perform routine preliminary (non sterile) inspection of the arm to identify an insertion site. After selecting the insertion site, the nurse will release the tourniquet, with non-sterile gloves, and disinfect the skin around the insertion site. While allowing the antiseptic to act, the nurse will apply the tourniquet, and pull lightly with the thumb of the non-dominant hand to keep the vein from moving. The needle will be inserted at a 10-30 degree angle about 1-2 cm distal from the catheter insertion site. Holding the needle firmly, the nurse will advance the cannula for its entire length into the lumen, remove the needle, and connect the cannula via an extension to a 3-way stopcock. A transparent, semi-permeable dressing will allow for daily visual inspection of the insertion site.
89283658|NCT06290271||Passive Group|The cerebral blood flow pattern normalizes after the recanalization of the occluded artery
89283659|NCT06290271||Active Group|The overall major cerebral blood flow increases after the recanalization of the occluded artery
89283660|NCT06290258|Experimental|Fecal microbiota transplantation|Children with autism spectrum disorder will receive fecal microbiota transplantation after evaluation. After the first intervention, the second transplantation will be arranged 6 months later.
89283661|NCT06290245|Experimental|study group|the participants will receive combined PEP Buddy plus the same exercise protocol as in the control group three times per week for eight weeks
89283662|NCT06290245|Active Comparator|control group|the participants will perform an aerobic exercise in the form of cycling three times per week for eight weeks
89283663|NCT06290219|Experimental|platelet-rich plasma combined with hyaluronic acid nasal injection|a nasal injection of platelet-rich plasma combined with hyaluronic acid at the first day of the treatment. At the same time, one tablet of zinc gluconate (10mg) three times a day for 12 weeks and traditional olfactory training with 4 separate bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil. Patients were told to sniff each odorant for 10 seconds, twice a day for 12 weeks.
89283664|NCT06290219|Active Comparator|Control|one tablet of zinc gluconate (10mg) three times a day for 12 weeks and traditional olfactory training with 4 separate bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove. Patients were told to sniff each odorant for 10 seconds, twice a day for 12 weeks.
89283668|NCT06290193|Experimental|Acute Normovolemic Hemodilution (ANH) Arm|
89283669|NCT06290193|No Intervention|Standard Intraoperative Management Arm|
89283670|NCT06290180|Experimental|Healing Lodge First Face Training Evaluation Study|All participants in this evaluation will be assigned to the First Face for Mental Health training condition. The investigators will use a pre-post design to measure change in relevant outcomes from pre-training, to post-training, to 3-months post-training.
89283671|NCT06290167|Experimental|360° media|All participants will be randomly assigned to 360° media or TAU condition
89283672|NCT06290167|Active Comparator|Treatment As Usual (TAU)|All participants will be randomly assigned to TAU or 360° media condition
89283673|NCT06290167|Other|In hospital sessions|all participants will perform session in hospital
89283674|NCT06290167|Other|at home sessions|all participants will perform session at home
89283675|NCT06290167|Other|Mild Cognitive Impairment|half of the patients will have MCI
89283676|NCT06290167|Other|Subjective Memory Complain|half of the patients will have SMC
89283679|NCT06290102|Experimental|Sequence 1|
89283680|NCT06290102|Experimental|Sequence 2|
89283681|NCT06290102|Experimental|Sequence 3|
89283682|NCT06290102|Experimental|Sequence 4|
89283683|NCT06290102|Experimental|Sequence 5|
89283684|NCT06290102|Experimental|Sequence 6|
89283685|NCT06290089|Other|ETEC strain|Each enrolled subject will receive a single administration of the challenge dose
89283686|NCT06290076||Severe Complications Group|Patients with severe complications (including symptomatic intracranial hemorrhage and malignant cerebral edema) occurred within 72 hours after endovascular thrombectomy are classified into severe complications group.
89283687|NCT06290076||Non-Severe Complications Group|Patients without severe complications (including symptomatic intracranial hemorrhage and malignant cerebral edema) occurred within 72 hours after endovascular thrombectomy are classified into non-severe complications group.
89283688|NCT06290063|Experimental|Full-Spectrum Hemp-Derived CBD (fsCBD)|8 weeks of use of a daily dose of cannabis (200mg CBD/4mg THC)
89283689|NCT06290063|Experimental|Broad-Spectrum Hemp-Derived CBD (bsCBD)|8 weeks of use of a daily dose of cannabis (200mg CBD)
89283690|NCT06290063|Placebo Comparator|Placebo|
89283691|NCT06290037|Other|Elderly drivers|Individuals over the age of 65 who are currently driving
89283692|NCT06290024||Patients with neuropathic pain|With prospective and longitudinal research design, patients with neuropathic pain that meet the entry/displacement standards will be included in the group and receive the routine diagnosis and treatment of the pain department. At the same time, the patients admitted to the group will be clinical observation and studied. After the diagnosis and treatment, follow-up will be carried out until 3 months after joining the group.
89283693|NCT06290011||Pain key group|mixed real pain treatment software, pain treatment scenarios in MR
89283694|NCT06290011||Sham MR group|TV screen 2D treatment scene with the same content provided
89283695|NCT06289998|Active Comparator|Tamibarotene Group|
89283696|NCT06289998|Placebo Comparator|Placebo Group|
89283697|NCT06289985|Other|Endovascular Therapy (EVT) Indication Expansion Domain: Low NIHSS Strata|"Adult patients with acute cerebral ischemia within 24 hours of last known well who have large vessel occlusion (LVO) and mild deficits/low NIHSS (NIHSS 0-5) will be randomized to receive one of two strategies:~Endovascular Therapy (EVT)~Medical Management (MM)"
89283698|NCT06289985|Other|Endovascular Therapy (EVT) Indication Expansion Domain: Medium/Distal Occlusions Strata|"Adult patients with acute cerebral ischemia within 24 hours of last known who have Medium Vessel Occlusion (MVO) with Non-dominant/Co-dominant M2 occlusion or Distal Medium Vessel Occlusion (DMVO) patients with M3,4 or A1,2,3 or P1,2,3 occlusion will be randomized to receive one of two strategies:~Endovascular Therapy (EVT)~Medical Management (MM)"
89283699|NCT06289959|Active Comparator|Group1（Plasma cfDNA-negative patients）|Continue to receive monotherapy with rituximab （375mg/m2 q3w）for 2 cycles
89283700|NCT06289959|Experimental|Group2（plasma cfDNA-positive patients）|Continue monotherapy with rituximab （375mg/m2 q3w）for 2 cycles
89283701|NCT06289959|Experimental|Group3（plasma cfDNA-positive patients）|Receive the original regimen for 2 cycles（R-CHOP like）
89283702|NCT06289946|Placebo Comparator|Placebo arm|Subject will get placebo
89283703|NCT06289946|Experimental|Nitro arm|Subject will get Nitrobid
89283704|NCT06289933|Experimental|BR3005|
89283705|NCT06289933|Active Comparator|BR3005-1+BR3005-2|
89283706|NCT06289920|Experimental|BR3005|
89283707|NCT06289920|Active Comparator|BR3005-1+BR3005-2|
89283708|NCT06289907|Active Comparator|Active group|Dietary supplement containing a proprietary botanical blend with NK3R antagonistic activity
89283709|NCT06289907|Placebo Comparator|Placebo group|"Placebo capsule containing:~Microcrystalline cellulose~Silicon dioxide micronized~Magnesium stearate"
89283710|NCT06289894|Experimental|BRY805|
89283711|NCT06289881|Experimental|Experimental: Sequence 1-Sildenafil test product and then reference product|Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Sildenafil 100 mg tablets test product, treatment 2= Nebivolol tablets 5 mg reference product.
89283712|NCT06289881|Experimental|Experimental: Sequence 2-Sildenafil reference product and then test product|Participants will receive treatment 2 in period 1 and treatment 1 in period 2. Where treatment 1= Sildenafil 100 mg tablets test product, treatment 2= Nebivolol tablets 5 mg reference product.
89290257|NCT03933150|Other|ultrasoun guided caudal epidural injection|A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.
89283713|NCT06289868||At-risk and/or signs and symptoms patients of HAV infection and/or HAV test ordered patients|"Frozen leftover serum samples from adult and pediatric patients:~From subjects exhibiting either jaundice or elevated total bilirubin or elevated serum ALT enzymes and one or more primary signs and symptoms of hepatitis infection, and/or~From subjects at-risk of HAV infection, and/or~From subjects for whom laboratory testing for hepatitis A was ordered by their healthcare providers."
89283714|NCT06289868||Known anti-HAV IgM positive patients|"Frozen serum or EDTA retrospective known anti-HAV IgM positive leftover samples procured from sample vendors .~These samples are known Positive for HAV IgM AND at least one of the following :~Positive HAV PCR result (within the last 28 days) OR~Jaundice (clinical assessment OR Total bilirubin result >3.0 mg/dL) OR~Elevated ALT result (> 200 IU/L)"
89283715|NCT06289868||HAV Pre- and post-vaccinated patients|Frozen serum leftovers. A first sample was collected, and the US licensed and CE-marked vaccination series administered. A second sample was collected four (4) to ten (10) weeks after the complete vaccination series has been administered according to vaccine dosing instructions.
89283716|NCT06289842|Active Comparator|Unipolar depressed patients with suicidality|The participants will receive iTBS (intermittent theta burst stimulation) to the left dorsolateral prefrontal cortex (LDLPFC) determined using Beam method for 1800 pulses with an intertreatment interval of fifty minutes. Stimulation was at 120% of resting motor threshold. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
89283717|NCT06289842|Active Comparator|Bipolar depressed patients with suicidality|The participants will receive iTBS (intermittent theta burst stimulation) to the left dorsolateral prefrontal cortex (LDLPFC) determined using Beam method for 1800 pulses with an intertreatment interval of fifty minutes. Stimulation was at 120% of resting motor threshold. Patients received ten sessions every day for five consecutive days for a total of fifty sessions (90,000 pulses).
89283718|NCT06289829|Other|Remifentanil|Ambu Auragain inserted after general anesthesia induced with remimazolam and remifentanil
89283719|NCT06289803|Experimental|patients who accept the scan of pCLE|
89283720|NCT06289790|Active Comparator|ESP block group|under general anaesthesia, preoperative ultrasound(USG) guided ESP blockade at Th5, single shot of 30 ml 0,3 % bupivacaine (not exceeding the maximum dose of 2 mg/kg of bupivacaine) with adrenaline 5 µg/ml and dexamethasone 0,15 mg/kg intravenously, post-operative infusion of 0,9% NaCl for 6 hours, infusion rate set as if it were lignocaine 1,5 mg/kg/h
89283721|NCT06289790|Active Comparator|Lignocaine infusion group|pre-induction lignocaine bolus of 1,5 mg/kg i.v. and dexamethasone 0,15 mg/kg intravenously, intraoperative infusion of lignocaine 2 mg/kg i.v., post-operative infusion of lignocaine 1,5 mg/kg i.v. for 6 hours
89283722|NCT06289764|Placebo Comparator|Sweet almond oil|Premenstrual symptom scale will be applied to the participants who volunteered to participate in the study. Aromatherapy will be applied to people with a premenstrual symptom score exceeding 110. 3 groups will be formed from people with pms symptoms. 1st group will receive Bergamot essential oil, 2nd group will receive Grapefruit essential oil, 3rd group (placebo group) will receive sweet almond oil. Selected women will be allowed to smell 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. The aromatic oil will be put 3 drops on a cotton ball and the participants will smell it. Participants will be allowed to inhale the scent for 30 minutes in the fowler position at a distance of 15 cm.
89283723|NCT06289764|Experimental|Bergamot essential oil|Premenstrual symptom scale will be applied to the participants who volunteered to participate in the study. Aromatherapy will be applied to people with a premenstrual symptom score exceeding 110. 3 groups will be formed from people with pms symptoms. 1st group will receive Bergamot essential oil, 2nd group will receive Grapefruit essential oil, 3rd group (placebo group) will receive sweet almond oil. Selected women will be allowed to smell 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. The aromatic oil will be put 3 drops on a cotton ball and the participants will smell it. Participants will be allowed to inhale the scent for 30 minutes in the fowler position at a distance of 15 cm
89283724|NCT06289764|Experimental|Grapefruit essential oil|Premenstrual symptom scale will be applied to the participants who volunteered to participate in the study. Aromatherapy will be applied to people with a premenstrual symptom score exceeding 110. 3 groups will be formed from people with pms symptoms. 1st group will receive Bergamot essential oil, 2nd group will receive Grapefruit essential oil, 3rd group (placebo group) will receive sweet almond oil. Selected women will be allowed to smell 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. The aromatic oil will be put 3 drops on a cotton ball and the participants will smell it. Participants will be allowed to inhale the scent for 30 minutes in the fowler position at a distance of 15 cm
89283725|NCT06289751|Experimental|Neoadjuvant chemoimmunotherapy for ⅠB2 cervical cancer|neoadjuvant chemotherapy + Cadonilimab + Radical hysterectomy/Extrafascial hysterectomy
89283726|NCT06289738|Experimental|Experimental|Takayasu Arteritis patients between the ages of 18-65
89283727|NCT06289647|Active Comparator|Azithromycin Continuation|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment. Study drug will be distributed by health extension workers and organized by PNSO. Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
89283728|NCT06289647|No Intervention|Azithromycin Discontinuation|In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
89283729|NCT06289634|Experimental|Man-made sounds|Participants who listen to man-made sounds (music)
89283730|NCT06289634|Experimental|Natural sounds|Participants who listen to natural sounds (e.g., ocean, birds, rain)
89283731|NCT06289608||Self-reported Bruxism|Those dental patients responding positively to at least 2 of the 6 items of the Pintado et al Self-reported Bruxism Inventory
89283732|NCT06289595||PBM|PBM = Use of PBM Ortho device
89283733|NCT06289595||Control|Did not receive any photobiomodulation treatment.
89283734|NCT06289582|Experimental|Prodromal and manifest (PD) participants|
89283735|NCT06289582|Experimental|Healthy participants|
89283736|NCT06289569|Experimental|Tele Rehabilitation|Telerehabilitation therapy Occupational therapist prescribed hand/arm exercises will continue for 90 minutes per day with adequate rest periods for 4 weeks, followed by telerehabilitation with the application for 4 weeks, when subjects will perform the tasks at home with the guidance of the treatment app. Detailed records of each subject's motor tasks, number of repetition and level of performance will be kept. Treatment will be performed Monday-Friday for approximately 4 weeks. Treatment times can be broken up into multiple treatment periods to accommodate patient and caregiver preferences.
89283737|NCT06289543|No Intervention|Starvation|Fasting for 6-8 hours before the operation
89283738|NCT06289543|Active Comparator|Water|drink 400ml of water 2 hours before the operation
89283739|NCT06289543|Active Comparator|oral carbohydrate|drink 400ml of solution 2 hours before the operation
89283740|NCT06289517|Experimental|68Ga-Her2-affibody|Subjects with suspected or confirmed breast cancer will receive an intravenous injection of 68Ga-Her2-affibody followed by PET imaging.
89283741|NCT06289491|Experimental|Hydrus Microstent|
89283742|NCT06289491|Experimental|Incisional goniotomy|
89283743|NCT06289491|Experimental|Excisional goniotomy|
89283744|NCT06289478|Experimental|Retrograde Intraarticular Injection via Drain Tube|Tranexamic acid will be injected retrograde to the joint via drain tube after surgical wound closure
89283745|NCT06289478|Experimental|Topical Soaking of Tranexamic Acid|Tranexamic acid will be placed to soak the intramedullary canal of the femur and surgical area after sheath closure for 5 minutes and completely remove by sunction
89283746|NCT06289478|Placebo Comparator|Standard procedure (placebo)|Standard wound irrigation
89283747|NCT06289465||Seasonal Workers (Experimental group)|"Criteria:~Volunteering to participate in the study.~To be between the ages of 18-34.~Having worked as a seasonal worker in Giresun for at least 1 month during the hazelnut harvest period."
89283748|NCT06289465||Controls (Control group)|"Criteria:~Volunteering to participate in the study.~To be between the ages of 18-34.~Not having worked in any agricultural work during the summer period.~Living in the same socioeconomic environment as the group working as seasonal workers"
89283749|NCT06289400|Experimental|Study Group|Conventional treatment+ Magnetic field application
89283750|NCT06289400|Active Comparator|Control Group|Conventional treatment
89283751|NCT06289010|Experimental|Depressed Group|20 children with depression and their parents (40 participants total) will undergo a 12-session course of FFT-CD.
89283752|NCT06288906||Symptomatic deep vein thrombosis (DVT) patients|
89283753|NCT06288893|Active Comparator|SHEN211 Tablets|A total of 20 subjects were randomized to the test group
89283754|NCT06288893|Placebo Comparator|Placebo for SHEN211 Tablets|10 subjects randomized to placebo
89283755|NCT06288815|Experimental|Oral fluid|"NPO (8hr for food, 2hr for water)~Intraoperative IV fluid at least 1 liter~Post operative (Off IV fluid, allow oral fluid as protocol at least 24hr)"
89283756|NCT06288815|Active Comparator|IV fluid|"NPO (8hr for food, 2hr for water)~Intraoperative IV fluid at least 1 liter~Post operative (IV fluid as protocol at least 24hr, allow oral fluid as usual)"
89283757|NCT06288516|Experimental|Benralizumab Arm A|Benralizumab (30mg) administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks.
89283758|NCT06288516|No Intervention|No intervention Arm B|No intervention. Standard of care as treatment.
89283759|NCT06288191|Experimental|Neoadjuvant Treatment|Nivolumab and relatlimab will be administered in a fixed dose combination (FDC). The dose and dosing regimen for this study is nivolumab 480 mg and relatlimab 160 mg - 2 vials per infusion. All patients are scheduled to receive two doses of nivolumab and relatlimab FDC prior to surgery on days 1 and 29. Patients without a complete pathological response to neoadjuvant therapy may receive standard of care radiotherapy per multidisciplinary team meeting discussion.
89283760|NCT06287567|Experimental|Lusutrombopag|Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and titrated to a maximum dose of 6 mg during week 5 and week12 based on the platelet count (PLT)
89283761|NCT06287515|Experimental|SRS hypophysectomy|Once the radiation plan is ready, you will be brought to the radiation treatment room and positioned for treatment. You will be lying on your back on the treatment table during the radiation treatment. You will not see, hear, or feel the radiation during the treatment. The treatment time varies but may range from 1-3 three hours. Once the treatment is completed, the headframe/mask will be removed and you will be brought to a recovery area.
89283762|NCT06287502|Experimental|Intervention|Subjects received resistance, aerobic, flexibility and balance exercise training; and nutritional supplement containing β-hydroxy β-methylbutyrate (HMB) during the 12-week study period.
89283763|NCT06287502|No Intervention|Wait-list control|The waitlist control group would receive 12 weeks of conventional care. After the study period, they would receive the same intervention.
89283764|NCT06286826||Patients with oesophageal atresia minithoracotomy|Patients with oesophageal atresia who underwent a minithoracotomy between 2011-2021
89283765|NCT06286826||Patients with oesophageal atresia postero-lateral thoracotomy|Patients with oesophageal atresia who underwent a postero-lateral thoracotomy between 2011-2021
89283766|NCT06286397|Experimental|Clascoterone Treatment|Participants will apply 1% clasocterone cream to the affected area twice daily got a total of 12 weeks with assessment visits at weeks 0, 4, 8, and 12. At assessment visits participants will have medical photography of the diseased area, be administered a dermatology-specific quality of life questionnaire, and be assessed for any side effects.
89283767|NCT06286397|Placebo Comparator|Placebo Treatment|Participants will apply a vehicle cream matched in texture, appearance, and odor to clacoterone to the affected area twice daily got a total of 12 weeks with assessment visits at weeks 0, 4, 8, and 12. At assessment visits participants will have medical photography of the diseased area, be administered a dermatology-specific quality of life questionnaire, and be assessed for any side effects.
89283768|NCT06286371|Experimental|Study Group|This study has only one group, the group includes patients with laparoscopic endometriosis surgery (douglasectomy).
89283769|NCT06286293||bvYOD|Neuropsychological assessment and driving simulator task.
89283770|NCT06286293||non-bvYOD|Neuropsychological assessment and driving simulator task.
89283771|NCT06286293||Patients with frontal brain damage|Neuropsychological assessment and driving simulator task.
89283772|NCT06286293||Healthy controls|Neuropsychological assessment and driving simulator task.
89283773|NCT06286202|Experimental|Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR)|NEAR consists of using carefully selected computer cognitive games to restore cognitive functioning through rehearsal and strategy learning. It will be delivered 3 times a week for 12 weeks at the center. The duration of each session within the week is as follows: 1) First session: 45 min computer-assisted cognitive exercises + 30 min bridging group; 2) Second session: 30 min computer-assisted cognitive exercises + 45 min bridging group; 3) Third session: 45 min computer-assisted cognitive exercises. Computer-assisted cognitive exercises are sessions where participants engage in cognitive games that target different cognitive domains. In addition, the Multicontext Treatment Approach to strategy learning will be carried out. The metacognitive framework of self-evaluation and activity mediation will also be utilized. Bridging groups are conducted twice a week, to aid transfer of learning from the computer game sessions to the participants' everyday life.
89283774|NCT06286202|Other|Standard Psychiatric Rehabilitation at Anglican Care Centers|Participants in the control arm will attend their scheduled activities at their respective Anglican Care Centers. The Anglican Care Centers run a variety of activities to provide psychosocial rehabilitation for clients with serious mental illness. These may include vocational training such as training in a retail shop or café, instrumental activities of daily living training (eg: taking public transport, money management), psychoeducation, social skills training etc. Participants in the control arm will not be enrolled into the cognitive remediation.
89283775|NCT06285890|Experimental|Dose Escalation|If you are found to be eligible to take part in this study, you will be assigned to a dose level of HC-7366 based on when you join this study. Participants enrolled will receive HC-3766 single agent during cycle 1. HC-3766 will be taken once daily while fasting, 1 hour before or 2 hours after a meal, on days 1-28. Cycles 2 and beyond: Participants will receive HC-3766 single agent during cycle 1. HC-3766 will be taken once daily while fasting, 1 hour before or 2 hours after a meal, on days 1-28. Azacitidine will be administered either intravenously or subcutaneously on days 1-7 of each cycle. Venetoclax will be taken on daily with water and a meal on days 1-28.
89283776|NCT06285760||Hospitalized heart failure patients|Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied.
89283777|NCT06285422|Experimental|SC262 Plus Chemotherapy Regimen|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC262
89283778|NCT06285331|Active Comparator|Automatic Bed|PLR will be performed by adjusting the automatic bed the patients stay on.
89283779|NCT06285331|Placebo Comparator|Manual|PLR will be performed by the investigators by their hands.
89283780|NCT06284837|Active Comparator|Radial secondary access|
89283781|NCT06284837|Active Comparator|Femoral secondary access|
89283782|NCT06284434|Experimental|LB Treatment Arm|Patients on the treatment arm will receive liposomal bupivacaine mixed with epinephrine (ratio of 1:100,000), which is not considered the standard of care.
89283783|NCT06284434|Active Comparator|Bupivacaine Control Arm|Patients on the control arm will follow the current standard of care, which is traditional bupivacaine mixed with epinephrine (1:100,000).
89283784|NCT06284408|Other|Centralized Screening Unit (CSU)|"The CSU intervention will shift workflow by leveraging EMR data to direct automated messages to LCS-eligible patients, inviting them to connect with the CSU. The CSU incorporates evidence-based strategies for active outreach to inform patients about LCS and to offer support from lay navigators. Patients are identified through meaningful use of medical records data"
89283785|NCT06284408|No Intervention|No Intervention Yet Started|"Standard of Care during the no intervention period"
89283786|NCT06284369|Experimental|Loss-framed message|Loss-framed message. This 54-second video advertisement employs a loss-framed message, highlighting the detrimental costs associated with continued smoking, including the severe negative health impacts such as increased vulnerability to complications from COVID-19 and the likelihood of ICU hospitalization. The main focus of the ad is a well-known young male Mongolian singer, who serves as the central figure conveying the message.
89283787|NCT06284369|Experimental|Gain-framed message|Gain-framed message. In this 59-second video advertisement, the emphasis is on highlighting the gains associated with quitting smoking. The narrative follows a female protagonist who, one year after quitting, meets with her physician. The physician highlights the client's improved lung X-ray and blood test results compared to the previous year, offering congratulations on the decision and celebrating the positive health outcome. Encouraged by this progress, the client is motivated to continue making positive lifestyle choices.
89283788|NCT06283758|Experimental|Stage 1: Intervention group|"This arm is combined with 3 groups and a total of 30 participants will be 1:1:1 allocated (each group with 10 participants).~Single treatment group: receive treatment once after enrollment; Consecutive treatment group A: receive 3 consecutive treatments, each with an interval of 3 days; Consecutive treatment group B: receive 3 consecutive treatments, each with an interval of 7 days. In Stage 1, the investigators will select optimal treatment strategy and proceed to Stage 2."
89283789|NCT06283758|Active Comparator|Stage 2: Intervention group|Participants will receive optimal treatment strategy selected formerly in Stage 1
89283790|NCT06283758|Sham Comparator|Stage 2: Sham-control group|In sham control group, participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
89283791|NCT06281938|Experimental|3D camera weight estimation|TBW, LBW and IBW will be automatically estimated using the 3D camera system. All relevant medical care will be based on this weight for the first 72 hours
89283792|NCT06281938|Placebo Comparator|Standard care weight estimation|TBW, LBW and IBW will be estimated using standard care processes. All relevant medical care will be based on this weight for the first 72 hours
89283793|NCT06281418|Placebo Comparator|Control arm|2 ml IP normal saline (0.9 % NaCl)
89283794|NCT06281418|Experimental|Intervention arm|2ml IP granisetron (1 mg/mL)
89290258|NCT03933150|Other|fluoroscopy guided caudal epidural injection|B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor
89290259|NCT05129644|Experimental|P1101 24 mcg|A total of 6 subjects received single dose of 24 mcg P1101
89283795|NCT06280911|Experimental|Date fruit group|"Pregnant women were asked to consume 6 (about 65 gr) per day of dry date (Medjoul species) provided by the researcher until the birth of the 37th gestational age.~Dry date fruit provided by the researcher was given to the women to consume (42 pieces per week).~It has been stated that pregnancies should end the consumption of dates when actual uterine contractions begin.~Within the first 24 hours of labor, information on labor was recorded in the delivery file and structured information form."
89283796|NCT06280911|Experimental|Nipple group|"The pregnancies are requested to stimulate a nipple (three minutes a day, one minute in the morning, one noon, one minute in the evening) and three minutes in the other nipple (one minute morning, one noon, one minute evening) with naked fingures and moderate pressure by pulling and rounding.~The pregnancies were stated to terminate the nipple stimulation when the actual uterine contractions onset.~Within the first 24 hours of labor, information on labor was recorded in the labor file and structured information form."
89283797|NCT06280911|No Intervention|Control group|"• Within the first 24 hours of labor, information on labor was recorded in the delivery file and structured information form."
89283798|NCT06280846|Experimental|Experimental high-intensity laser acupuncture and an exercise therapy program.|The patients will receive high-intensity laser acupuncture and an exercise therapy program.three times a week for four weeks.
89283799|NCT06280846|Experimental|Experimental low-intensity laser acupuncture and an exercise therapy program.|The patients will receive low-intensity laser acupuncture and an exercise therapy program.three times a week for four weeks.
89283800|NCT06280846|Sham Comparator|sham laser acupuncture and an exercise therapy program.|The patients will receive a sham laser acupuncture and an exercise therapy program three times a week for four weeks.
89283801|NCT06280495|Active Comparator|FOLFOX only group|Oxaliplatin: 85 mg/m2 IV on day 1 Fluorouracil (FU): 400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours Leucovorin: 200 mg/m2 IV on day 1 This treatment regimen is repeated every two weeks for a total of 6 cycles.
89283802|NCT06280495|Experimental|Serplulimab + Bevacizumab + FOLFOX|Serplulimab: 200 mg IV infusion on day 1 Bevacizumab: 5 mg/kg IV infusion on day 1 Oxaliplatin, FU, and Leucovorin as per the control arm The experimental arm follows the same treatment schedule as the standard FOLFOX regimen, with the addition of Serplulimab and Bevacizumab for the first 3 cycles only.
89283803|NCT06280391|Experimental|Itepekimab Q2W|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
89283804|NCT06280391|Experimental|Itepekimab Q4W|SC administration of Itepekimab every 4 weeks (Q4W) with alternating placebo administration at the 2week interval between active IMP as SC injection for up to 52 weeks
89283805|NCT06280391|Placebo Comparator|Placebo|SC administration of matching placebo Q2W for up to 52 weeks
89283806|NCT06277830||Adults with autoimmune myasthenia gravis|Existing patients at MassGeneral Hospital's MG clinic, ages 18-80, with autoimmune, AChR or MuSK antibody positive generalized myasthenia gravis.
89283807|NCT06277713|Active Comparator|Exercise after prolonged sitting (SIT)|All participants will be instructed to complete two working days (8h) where they perform seated desk-work throughout the day. At the end of the second day, they will perform a supervised exercise bout at the research facility.
89283808|NCT06277713|Experimental|Exercise after sitting with standing breaks (WBR)|All participants will be instructed to complete two working days (8h) where they alternate seated desk-work with standing desk-work hourly throughout the day. At the end of the second day, they will perform a supervised exercise bout at the research facility.
89283809|NCT06277713|Other|Non-exercise control (NEX)|In this control group all participants will be instructed to complete two working days (8h) where they perform seated desk-work throughout the day.
89283810|NCT06276348|Experimental|Enrollees|Enrolled infants will receive 3 tests (DWGS, BeginNGS, and WES). DWGS will be performed in a standard manner. BeginNGS and WES will be performed in a batch after completion of enrollment. The diagnostic sensitivity and specificity of BeginNGS and WES will be compared to DWGS (a standard clinical test compliant with the Clinical Laboratory Improvement Amendments Act).
89283811|NCT06274944||Infants|Infants admitted to the University of Minnesota Masonic Children's Hospital neonatal intensive care unit.
89283812|NCT06257290||Venous ThromboEmbolic (VTE) patients|a diagnosis of Venous ThromboEmbolic (VTE) less than 72 hours old at inclusion, with a follow-up of 3 to 6 months
89283813|NCT06257056|Experimental|Randomized Discontinuation Period: OFF then ON DBS|"Subjects randomized to this arm are initially OFF DBS after the open label period then gradually decreased in their optimized setting's amplitude for 8 weeks and then ON DBS for 8 weeks."
89283814|NCT06257056|Experimental|Experimental: Randomized Discontinuation Period: ON then OFF DBS|"Subjects randomized to this arm are initially ON DBS with optimized stimulation settings for 8 weeks after the open label period and then OFF DBS with gradually decreasing amplitude for 8 weeks."
89283815|NCT06249503|Active Comparator|Activated PRP|PRP is activated by adding 200μl of 0.025 calcium chloride and used in hydrodissection.
89283816|NCT06249503|Active Comparator|Non-Activated PRP|PRP is used directly in hydrodissection.
89283817|NCT06249503|Active Comparator|Steroid group|Hydro dissection using a combination of steroid (Triamcinolone 40mg), local anesthetics and dextrose.
89283818|NCT06246565|Experimental|HS-10383 50mg|HS-10383 oral dose 50 mg once a day.
89283819|NCT06246565|Experimental|HS-10383 100mg|HS-10383 oral dose 100 mg once a day.
89283820|NCT06246565|Experimental|HS-10383 200ng|HS-10383 oral dose 200 mg once a day.
89283821|NCT06246565|Placebo Comparator|Placebo|Matching Placebo for HS-10383 oral dose once a day
89283822|NCT06246110|Experimental|Cohort A - Participants with non-squamous NSCLC|Participants in this arm will receive EIK1001 + Standard of Care (SOC).
89283823|NCT06246110|Experimental|Cohort B - Participants with squamous NSCLC|Participants in this arm will receive EIK1001 + Standard of Care (SOC).
89283824|NCT06246058||Survey Group 1 - Support|Receives a vignette with partner support component before answering AA-Med response items.
89283825|NCT06246058||Survey Group 2 - Control|Receives a vignette without partner support component before answering AA-Med response items.
89283826|NCT06246058||Recruitment Group 1 - Casual|Recruited by staff wearing casual attire.
89283827|NCT06246058||Recruitment Group 2 - Formal|Recruited by staff wearing formal (clinical) attire
89290260|NCT05129644|Experimental|P1101 48 mcg|A total of 6 subjects received single dose of 48 mcg P1101
89283828|NCT06239012|Experimental|position measurement with BePoW device compared with MCPAA scale measurements|Each patient will have position measurement with BePoW device and, at the same time, will have MCPAA scale measurements
89283829|NCT06232772||patients with clinically defined PD|Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
89283830|NCT06232772||patients with clinically probable PD|Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
89283831|NCT06232772||MSA group|Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
89283832|NCT06232772||PSP group|Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
89283833|NCT06232772||healthy subjects of equal age and sex without any risk or prodromal factor for PD|control group Using an ELISA kit and α- Synuclein Ultrafine Fluorescence Detection Method to analyze the skin and body fluids of the included subjects α- synuclein level detection.
89283834|NCT06230588|Experimental|TQH3906 capsule|TQH3906 capsule for oral administration as a single or multiple dose for 7days.
89283835|NCT06230588|Placebo Comparator|TQH3906 placebo capsule|TQH3906 placebo capsule for oral administration as single dose or multiple dose for 7days.
89283836|NCT06229834|Experimental|Chiropractic Care|4 sessions of chiropractic care (6 sessions of chiropractic care over 3 weeks followed by 8 sessions of chiropractic care over 12 weeks); participants will be allowed to continue usual care throughout the study.
89283837|NCT06229834|Other|Headache Health Education (HHE)|Participants randomized to Headache Health Education (HHE) will receive 14 interactive 15-minute education sessions delivered via videoconference.
89283838|NCT06229405||Nonfunctioning adrenal adenoma|Incidentally detected adrenal mass without hormone production
89283839|NCT06229405||Mild autonomous cortisol secretion|Adrenal tumors that do not meet the criteria for adrenal Cushing's syndrome but are not suppressed to below 1.8 µg/dL after the dexamethasone suppression test
89283840|NCT06229405||Adrenal Cushing syndrome|Adrenal diseases characterized by biochemical hypercortisolism accompanying with overt Cushingoid features.
89283841|NCT06229405||Primary aldosteronism|"Adrenal diseases characterized by the excessive production of the hormone aldosterone and suppressed renin.~Diagnostic criteria are as the following:~Plasma aldosterone level of ≥6 ng/dL after a seated saline infusion test~Plasma aldosterone level of ≥13 ng/dL after a captopril challenge test."
89283842|NCT06229405||Pheochromocytoma and paraganglioma|Chromaffin-originated tumors in the adrenal gland and others, characterized by catecholamine excess
89283843|NCT06229405||Adrenal cortical carcinoma|Malignant tumors originated from the adrenal cortex, which was confirmed by biopsy or pathology results
89283844|NCT06227975|Experimental|[14C]-BMS-986368|
89283845|NCT06216938|Experimental|Vusolimogene oderparepvec (RP1)|Patients will receive 3 doses of RP1 (1.0 mL/injection; 10e6 PFU/mL for the first dose, and 10e7 mL for the subsequent 2 doses). The drug will be injected into the skin at the tumor biopsy site at baseline (day 1), day 15, and day 21, 4-5 weeks prior to SOC WLE and SLNB. Definitive surgery will occur up to 28-35 (± 2 days) days from first injection, to avoid treatment delay.
89283846|NCT06216249|Experimental|Arm I (177Lu-PSMA-617)|"Patients receive 177Lu-PSMA-617 IV once every 6 weeks on study. Beginning with the third cycle, treatments may be postponed beyond the 6 weeks interval based on defined response criteria (treatment holiday period). Treatment repeats every 6 weeks for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients receive 68Ga-PSMA-11 IV and undergo PSMA PET/CT throughout the trial. Patients also undergo SPECT/CT, PET/CT, or CT on the trial."
89283847|NCT06216249|Active Comparator|Arm II (177Lu-PSMA-617)|Patients receive 177Lu-PSMA-617 IV once every 6 weeks on study. Treatment repeats every 6 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients receive 68Ga-PSMA-11 IV and undergo PSMA PET/CT throughout the trial. Patients also undergo SPECT/CT, PET/CT, or CT on the trial.
89283848|NCT06214494|Experimental|Interventional Cohort|Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion 2x weekly for 16 Sessions totaling a minimum of 75 minutes weekly.
89283849|NCT06214494|Active Comparator|Control Cohort|High-Intensity Treadmill Training 2x weekly for 16 Sessions totaling a minimum of 75minutes weekly.
89283850|NCT06206811|Experimental|Part 1 - Single Ascending dose|To assess the safety and tolerability of single ascending doses of OD-07656 administered as an oral capsule
89283851|NCT06206811|Experimental|Part 2 - Multiple Ascending dose|To assess the safety and tolerability of multiple ascending doses of OD-07656 administered as an oral capsule
89283852|NCT06206811|Experimental|Part 3 - Food effect and relative bioavailability between dose forms|To assess the safety and tolerability of OD-07656 administered as an oral capsule or tablet
89283853|NCT06206811|Experimental|Part 4 - Pharmacokinetic drug interaction between midazolam and OD-07656|To assess the safety and tolerability of OD-07656 administered as an oral capsule or tablet following administration of midazolam
89283854|NCT06205121|Experimental|Active Arm|Subjects will receive OATD-01 as 25mg film-coated tablets for oral administration once daily for 12 weeks
89283855|NCT06205121|Placebo Comparator|Placebo Arm|Subjects will receive placebo as film-coated tablets for oral administration once daily for 12 weeks
89283856|NCT06201897|Other|Treatment Arm|Children receiving ACTH therapy for West Syndrome
89283857|NCT06200207|Active Comparator|Ziltivekimab|Participants will receive ziltivekimab administered subcutaneously (s.c.) once-monthly and added to standard of care for 12 months.
89283858|NCT06200207|Placebo Comparator|Placebo|Participants will receive placebo matched to ziltivekimab administered s.c. once-monthly and added to standard of care for 12 months.
89283859|NCT06198972|Active Comparator|Control Group|strength exercise training
89283860|NCT06198972|Experimental|Study Group|pnf exercise training
89283861|NCT06192758|Experimental|TheraSphere PCa Dose Escalation|"Participants will be treated in cohorts of three across three sequential dose levels:~Dose Level 1 (or starting dose) = 175 Gy; however, a provisional lower dose level, Dose Level -1 = 150 Gy, may be utilized in case de-escalation is warranted at Dose Level 1.~Dose Level 2 = 200 Gy~Dose Level 3 = 225 Gy"
89290261|NCT05129644|Experimental|P1101 90 mcg|A total of 6 subjects received single dose of 90 mcg P1101
89283862|NCT06191562|Experimental|Posterior Tympanostomy Tube Left|Patients in whom the left ear is randomized to receive a tympanostomy tube in the posterior-inferior quadrant (new location).
89283863|NCT06191562|Experimental|Posterior Tympanostomy Tube Right|Patients in whom the right ear is randomized to receive a tympanostomy tube in the posterior-inferior quadrant (new location).
89283864|NCT06184529|Experimental|Virtual Reality Group|Participants in this group will receive the virtual reality simulation for up to 6 weeks.
89283865|NCT06182306||Trial Cohort|Patients with advanced or metastatic triple negative breast cancer, due to start a new line of systemic therapy (targeted drug or immunotherapy)
89283866|NCT06175390|Experimental|Cohort A: early Triple Negative Breast Cancer|"Patients will receive neoadjuvant therapy with four cycles of 1200 mg of atezolizumab and 600 mg of Tiragolumab every 3 weeks in combination with nab-paclitaxel 100 mg/m2 on days 1, 8, and 15, every 3 weeks plus carboplatin AUC 5 on days 1 every 3 weeks then four cycles of 1200 mg of atezolizumab (Tecentriq®, Roche) and 600 mg of Tiragolumab (Roche) every 3 weeks in combination with Doxorubicin 60 mg/m2 plus Cyclophosphamide 600 mg/m2.~After surgery, patients will receive adjuvant treatment with atezolizumab plus tiragolumab every 3 weeks for up to nine cycles (in patients with germline BRCA1/2 mutation eligible to adjuvant olaparib, tiragolumab and atezolizumab will not be resumed after surgery)."
89283867|NCT06175390|Experimental|Cohort B: metastatic Triple Negative Breast Cancer|"Patients will receive atezolizumab 1680 mg administered by IV infusion Q4W, plus tiragolumab 840 mg administered by IV infusion Q4W, plus nab-paclitaxel 100 mg/m2 administered by IV infusion d1, d8, d15 of every 28-day cycle.~Treatments will be administered until disease progression or limiting toxicity."
89283868|NCT06173674|Experimental|Music intervention|The music intervention will consist of three components, including 1) playlist composition, 2) music intervention delivery, and 3) cleaning or disinfection of the equipment.
89283869|NCT06166225|Experimental|Internet-based weight loss program + Iyengar yoga|Participants randomized to this group will receive a 12-month automated weight loss program which is delivered via the Internet and will also receive a 9-month Iyengar yoga intervention (delivered during months 4-12). Yoga classes will be delivered live (via Zoom) and participants will be instructed to attend two classes per week for the first 14 weeks and one class per week thereafter. They will also be asked to do self-guided yoga practice on their own and report their yoga practice on the study website.
89283870|NCT06166225|Active Comparator|Internet-based weight loss program + health and wellness classes|Participants randomized to this group will receive a 12-month automated weight loss program which is delivered via the Internet and will also receive a 9-month health and wellness intervention (delivered during months 4-12). Health and wellness classes will be delivered live (via Zoom) and participants will be instructed to attend two classes per week for the first 14 weeks and one class per week thereafter. Classes will consist of lectures, videos, and discussions and will provide education around a variety of lifestyle topics.
89283871|NCT06163859|Experimental|Intervention Group|Female Community Health Volunteers (FHPC) implementation strategy
89283872|NCT06163859|No Intervention|Control Arm|Routine hypertension care
89283873|NCT06157255|Experimental|AZD4604|In Part 1, one 30 ug dose of [14C]AZD4604 Solution for Infusion 6 ug/mL (NMT 37.0 kBq/5 mL) and one 3 mg dose of AZD4604 Inhalation Powder, 1 mg (as 3 x 1 mg). In Part 2, one 4 mg dose of [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq).
89283874|NCT06156462||Adults|>18 yo
89283875|NCT06156462||Adolescents|<16 yo
89283876|NCT06156436||Paediatric Patients|
89283877|NCT06149156|Experimental|Healthy Minds Program (HMP) intervention|Participants will receive access to the 4-week HMP Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
89283878|NCT06149156|Active Comparator|Waitlist Control|Participants will receive a list of well-being resources. They will be given access to HMP at the end of the study.
89283879|NCT06138691|Experimental|Ketamine Infusion|
89283880|NCT06138691|Experimental|Radically Open Dialectical Behavior Therapy (RO DBT)|
89283881|NCT06135506|Experimental|control group|conventional ridge splitting with conventional simultaneous implant placement.
89283882|NCT06135506|Experimental|study group|computer guided ridge splitting assisted by artificial intelligence with simultaneous computer guided implant placement.
89283883|NCT06131554|Experimental|batch 1 of MCV4|1 dose of Menhycia on Day 0
89283884|NCT06131554|Experimental|batch 2 of MCV4|1 dose of Menhycia on Day 0
89283885|NCT06131554|Experimental|batch 3 of MCV4|1 dose of Menhycia on Day 0
89283886|NCT06131554|Active Comparator|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|1 dose of Menactra on Day 0
89283889|NCT06129721|Experimental|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
89290262|NCT05129644|Experimental|P1101 180 mcg|A total of 6 subjects received single dose of 180 mcg P1101
89290263|NCT05129644|Experimental|P1101 225 mcg|A total of 6 subjects received single dose of 225 mcg P1101
89290264|NCT05129644|Experimental|P1101 270 mcg|A total of 6 subjects received single dose of 270 mcg P1101
89290265|NCT05129644|Active Comparator|Pegasys 180 mcg|A total of 12 subjects received single dose of 180 mcg Pegasys
89290266|NCT01220544|Experimental|HaploTransplant with NK cells|Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2
89290267|NCT00255047|Experimental|Study Group 1: DAPTACEL®, ActHIB®, and IPOL®|Participants will receive 3 doses of DAPTACEL®, ActHIB®, and IPOL® at Months 2, 4, and 6, respectively
89283890|NCT06126874|Experimental|Patient education, Pelvic floor muscle training, Aerobic and Resistance exercise trainings|"Patient Education: Individuals in both study groups will be provided with patient education through verbal and visual presentations.~Pelvic Floor Muscle Training (PFMT): In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program.~Aerobic Exercise Training: Aerobic exercise training will be planned 3 days a week, 1 day on the routine clinic day with a treadmill ergometer and 2 days as a home program in the form of brisk walking outside the clinic (e.g. outdoors or in a suitable environment).~Resistance Exercise Training: Resisted exercise training will be planned 2 days a week, 1 day in the clinic and 1 day outside the clinic as a home program, and 12 different exercises for large muscle groups with dumbbells and weight sets, resistance bands (therabands) will be used in the training."
89283891|NCT06126874|Active Comparator|Patient education and Pelvic floor muscle training|"Patient Education: Individuals in both study groups will be provided with patient education through verbal and visual presentations.~Pelvic Floor Muscle Training (PFMT): In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program."
89283892|NCT06115759|Experimental|T-REX Twente|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
89283893|NCT06115759|Active Comparator|Usual care|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
89283894|NCT06113380|Experimental|Rehabilitation by rehabilitation robot|"Rehabilitation therapists will determine the training mode based on the subject's movement ability.~Passive training mode Active-assistive training mode"
89283895|NCT06113380|Active Comparator|Traditional rehabilitation|Traditional upper limb physical therapy is performed by the therapist.
89283896|NCT06108219|Experimental|Experimental|Patients who meet the entry criteria for study CORT118335-862 will be enrolled to receive 100 mg of miricorilant, twice a week for 48 weeks.
89283897|NCT06108219|Placebo Comparator|Placebo|Patients who meet the entry criteria for study CORT118335-862 will be enrolled to receive a matching placebo twice a week for 48 weeks.
89283898|NCT06107426||Cohort A: ABBV-951|Participants naïve to ABBV-951 will receive ABBV-951 as prescribed by their physician according to the local label.
89283899|NCT06107426||Cohort B: ABBV-951|Participants transitioning from the Open-Label Extension studies M15-737 and M20-098 will continue to receive ABBV-951.
89283900|NCT06107387|Experimental|Binge Eating Self-help for Teens|Participants will have 16 guided self-help sessions (4 months; weekly sessions for adolescents with parents joining monthly). Participants will complete daily self-monitoring of eating behaviors (timing of meals and snacks; whether or not a binge occurred) throughout treatment. Treatment sessions involve a self-help component, which includes brief videos that participants watch at home. Treatment sessions also involve a guidance component (brief consultation), which is 15-30 minutes on a secure videoconferencing platform (e.g., Zoom) between the therapist and the participant. These sessions focus on clarifying material, reviewing self-monitoring and looking for patterns, and problem-solving maladaptive thinking patterns and binge behaviors.
89283901|NCT06106139|No Intervention|Normal diet group|"This group of patients follows the Dietary Guidelines for Chinese Residents (2022) to ensure balanced nutrition, with daily calorie intake ranging from 1600 to 2400 kcal."
89283902|NCT06106139|Experimental|Strict ketogenic diet group|the patients ate ketogenic biscuits or ketogenic foods provided by the researchers every day. During the study, the patients were not allowed to drink any drinks or eat other foods except drinking water, so as to ensure that the daily intake of calories was roughly the same as that of the normal diet group.
89283903|NCT06106139|Experimental|Cyclic ketogenic diet group|"the patients took 7 days as a cycle, and 7 days of strict ketogenic diet+7 days of normal diet as a cycle. During the strict ketogenic diet, the patient should eat the ketogenic biscuit or ketogenic food provided by the researcher every day, and should not drink any beverage or eat other food except drinking water; During the normal diet period, patients followed the Dietary Guidelines for Chinese Residents (2022) to ensure nutritional balance. During the study period, patients were guaranteed to eat approximately the same amount of calories per day as the normal diet group."
89283904|NCT06106139|Experimental|Autonomous ketogenesis group|Patients choose ingredients for cooking and consumption under the guidance of researchers, ensuring that the nutritional composition is about 90% fat, 10% protein, and can contain a small amount of carbohydrates (10%). The daily calorie intake is around 1600~2400 kcal.
89283905|NCT06105996|Experimental|Interoceptive training|Participants will undergo 6 sessions of cardiac interoceptive training.
89283906|NCT06105996|No Intervention|Treatment as usual arm|Participants will undergo treatment as usual.
89283907|NCT06094647|Experimental|Altitudes Condition|Approximately 30 individuals whose loved ones are experiencing FEP and receiving services from two of the five FEP clinics (OASIS and SHORE) will be recruited to participate in a digital platform, Altitudes, for 6 months as part of an adjunct service to the clinic's services. Participants will have access to and encouraged to use the educational and therapeutic content as well as the moderated online community network during their time engaging with the platform. They will be asked to complete a battery of measures at baseline, 3-months, and 6 months.
89283908|NCT06094647|No Intervention|Treatment as Usual|Approximately 30 individuals whose loved ones are experiencing FEP and receiving services from three of the five FEP clinics (Encompass, Eagle, and AEGIS) will be recruited to participate in treatment as usual offered by their respective clinic. Participants will then be asked to complete the same battery of measures as the experimental group at baseline, 3-months, and 6 months.
89283909|NCT06094010|Experimental|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).
89283910|NCT06091098|Experimental|Dynamic CO2 within Drive-Dependent OSA|During sleep, before ~30 distinct respiratory events, we will administer ~2% CO2 for ~3-4 breaths.
89283911|NCT06091098|Active Comparator|Dynamic CO2 within Classic OSA|During sleep, before ~30 distinct respiratory events, we will administer ~2% CO2 for ~3-4 breaths.
89283912|NCT06091098|Sham Comparator|Sham CO2 within Drive-Dependent OSA|During sleep, Sham CO2 (air) will be administered for ~3-4 breaths before respiratory events.
89283913|NCT06091098|Sham Comparator|Sham CO2 within Classic OSA|During sleep, Sham CO2 (air) will be administered for ~3-4 breaths before respiratory events.
89283914|NCT06091085|Experimental|Acetazolamide|Acetazolamide administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
89283915|NCT06091085|Placebo Comparator|Placebo|Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
89283916|NCT06080594|Experimental|Exercise leg|High-intensity exercise training for one leg
89283917|NCT06080594|No Intervention|Control leg|No exercise training for the controlateral leg
89283918|NCT06079203|No Intervention|No intervention|No intervention, serving as a usual care control group
89283919|NCT06079203|Experimental|Single intervention: Emergency Care Redesign (ECR)|
89283920|NCT06079203|Experimental|Single intervention: Nurse-led Telephonic Care (NLTC)|
89283921|NCT06079203|Experimental|Single intervention: Community Paramedic-led Transitions Intervention (CPTI)|
89283922|NCT06079203|Experimental|Two intervention: ECR and NLTC|
89283923|NCT06079203|Experimental|Two interventions: ECR and CPTI|
89283924|NCT06079203|Experimental|Two interventions: NLTC and CPTI|
89283925|NCT06079203|Experimental|All interventions: ECR, NLTC, and CPTI|
89283926|NCT06076863|Experimental|Pharmacist Care|Pharmacists on a regional team will manage requests for Paxlovid placed by patients via e-visits using a standard protocol.
89283927|NCT06076863|Active Comparator|Adult and Family Medicine Physician Pool Care|Adult and family medicine physicians serving in pools will manage requests for Paxlovid placed by patients via e-visits using a standard protocol.
89283928|NCT06076018|Active Comparator|intrathecal morphine|In spinal anesthesia, 12 mg hyperbaric bupivacaine and 20 mcg fentanyl, 120 mcg intrathecal morphine (ITM) will be administered intrathecally.
89283929|NCT06076018|Placebo Comparator|intrathecal fentanyl|Intrathecal 12 mg hyperbaric bupivacaine and 20 mcg fentanyl in spinal anesthesia, ITM will not be applied
89283930|NCT06073054|Experimental|Research Pharmacist Monitoring|The pharmacist will help the mother find a primary care physician if she doesn't have one, obtain health insurance if she doesn't have any, and discuss any health-related information about herself or her child, as needed. These pharmacist interactions will occur 7 days after baseline and again 1 month later (the participant will be asked to measure and text their blood pressure again 1 time per day for 3 days during the follow-up month). If the participant's blood pressures become elevated, the pharmacist will provide behavioral and lifestyle interventions to attempt to lower the blood pressure. They may also recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed, as necessary.
89283931|NCT06067893|Experimental|Dexmedetomidine|Patient receives low dose dexmedetomidine infusion in addition to normal post-operative pain management protocol
89283932|NCT06067893|Placebo Comparator|Control|Patient receives normal saline infusion in addition to normal post-operative pain management protocol
89283933|NCT06063083|Experimental|"Tell Me More (Dime Mas) group"|"Participants will get the Tell Me More (Dime Mas) program within up to 6 months."
89283934|NCT06063083|Experimental|"Peer Ambassador Stories [Listen Miami (Oye Miami)] group"|"Participants will get the Peer Ambassador Stories [Listen Miami (Oye Miami)] within up to 6 months."
89283935|NCT06063083|Active Comparator|Standard Community Outreach group|Participants will receive standard community outreach within up to 6 months.
89283936|NCT06062368|No Intervention|Standard Duration|The participant will undergo an MRI scan using the manufacturer's rate of entry into and exit from the MRI machine. This rate of entry and exit is 20 seconds.
89283937|NCT06062368|Experimental|1-minute entry|The participant will undergo an MRI scan using a slower rate of entry than that specified by the manufacturer. This rate of entry is one minute (60 seconds).
89283938|NCT06062368|Experimental|2-minute entry|The participant will undergo an MRI scan using a slower rate of entry than that specified by the manufacturer. This rate of entry is two minutes (120 seconds).
89283939|NCT06062368|Experimental|3-minute entry|The participant will undergo an MRI scan using a slower rate of entry than that specified by the manufacturer. This rate of entry is three minutes (180 seconds).
89283940|NCT06052423|Experimental|HS-20093|All subjects will receive HS-20093 at 10mg/kg
89283941|NCT06049329|Experimental|NNC0487-0111|Once-daily oral administration - 1 of 3 different doses
89283942|NCT06049329|Placebo Comparator|Placebo|Once-daily oral administration - 1 of 3 different doses
89283943|NCT06046482|Experimental|Cohort A|Participants will receive magrolimab and cetuximab along with pembrolizumab.
89283944|NCT06046482|Experimental|Cohort B|Participants will receive magrolimab and cetuximab along with docetaxel.
89283945|NCT06046157|Experimental|Breast milk-scented PIOMI|During PIOMI application, the baby will be smelled his/her own breast milk.
89283946|NCT06046157|Experimental|Breast milk-tasting PIOMI|During PIOMI application, the baby will be able to taste his own breast milk. The finger on which PIOMI was applied will be immersed in breast milk.
89283947|NCT06046157|No Intervention|Control|Only PIOMI application will be made.
89283948|NCT06042608|Active Comparator|Active intercostobrachial nerve block|Patient will receive local anesthetic injected around their intercostobrachial nerve in the axilla (armpit). They will still receive an active interscalene nerve block (gold standard) that helps with the rest of the shoulder pain.
89283949|NCT06042608|Placebo Comparator|Sham intercostobrachial nerve block|Patient will receive saline injected around their intercostobrachial nerve in the axilla (armpit). This is a sham intercostobrachial nerve block because saline is not an active medication. They will still receive an active interscalene nerve block (gold standard) that helps with the rest of the shoulder pain.
89283950|NCT06038344|Experimental|Standard of Care + Gluten-free food guide teaching|45-minute dietary counselling session using the novel gluten-free food guide conducted by a researcher over Zoom. This occurs after standard of care dietary education by an RD. The gluten free teaching session in the study protocol focuses on the GF plate model, the rationale for the GF plate model, and addressing the individual participants dietary needs based on a dietary intake assessment by a trained investigator using specific educational materials that are present in the guide.
89283951|NCT06038344|No Intervention|Standard of Care|45-minute group session on the gluten-free diet conducted by registered dietitians over Zoom. The registered dietitian's dietary education included a virtual group class focusing on gluten literacy, meal planning, food label reading and dietary intake based on Canada's Food Guide to Healthy Eating (2019).
89283952|NCT06032013|Experimental|Cardiac Rehabilitation intervention|Outpatient intervention with participants after a cardiac event who fulfil the inclusion criteria.
89283953|NCT06025513|Experimental|embrace patch treatment|Insulin PK/PD before and after treatment with embrace patch
89283954|NCT06020014|Experimental|Arm 1|AZD4604
89283955|NCT06020014|Placebo Comparator|Arm 2|Placebo
89283956|NCT06006247|Experimental|CVN424 150 mg|Participants will be administered with CVN424 150 mg.
89283957|NCT06006247|Placebo Comparator|Placebo|Participants will be administered with placebo.
89283958|NCT05998018|Experimental|pdSTIM System Therapy|
89283959|NCT05998018|No Intervention|Standard of Care|
89283960|NCT05987852|Experimental|Hyperbaric Oxygen Therapy|"Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days."
89283961|NCT05987852|Sham Comparator|Sham Hyperbaric Air|"This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days."
89283962|NCT05979844|Experimental|Non-medicine sessions of bCBCT + Medicine Sessions with 3,4-methyllenedioxymethamphetamine (MDMA)|"bCBCT Non-medicine sessions: 8 sessions~MDMA Medicine sessions:~Initial Dose 1: 80 mg MDMA HCl (~68 mg MDMA) Supplementary Dose 1: 40 mg MDMA HCl (~34 mg MDMA) Initial Dose 2: 100 mg MDMA HCl (~84 mg MDMA) Supplementary Dose 2: 40 mg MDMA HCl (~34 mg MDMA)"
89283963|NCT05977361|Active Comparator|Resiting Epidural Catheter|
89283964|NCT05977361|Active Comparator|Intrathecal catheter placement|
89283965|NCT05976464|Active Comparator|erector spinae plane block|Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.
89283966|NCT05976464|Experimental|magnesium sulfate as an adjuvant in erector spinae plane block|Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine and magnesium sulfate into interfacial plane below erector spinae muscle.
89283967|NCT05974878|Experimental|Treatment Group|"Participants in this group are going to be in physiotherapy program, which is created specific to diabetic patients, contains;~Exercises for stability, flexibility and strength,~Exercises which improves wrist proprioception,~Exercises for sensation recovery,~Mirror therapy and motor imagination~Physiotherapy program will be changed in every 3 weeks. Participant will be informed about their disease, about process of healing and will check by phone calls 2 times a week. They will be given recommendations about disease management. Home exercises will be given to this group and will be added new exercises every 3 weeks while physiotherapy program continues."
89283968|NCT05974878|Experimental|Control Group|Control group will take conventional physiotherapy as in the literature. Diabetic individuals in routine takes aerobic exercise recommendation and resistive exercises. In our study control group will continue 12 sessions of resistive exercise program focused on upper extremity, also aerobic exercise recommendation.
89283969|NCT05966480|Experimental|ESK-001 Dose Level 1|ESK-001 administered as an oral tablet
89283970|NCT05966480|Experimental|ESK-001 Dose Level 2|ESK-001 administered as an oral tablet
89283971|NCT05966480|Experimental|ESK-001 Dose Level 3|ESK-001 administered as an oral tablet
89283972|NCT05966480|Placebo Comparator|Placebo|Placebo administered as an oral tablet
89283973|NCT05964413|Experimental|vilobelimab|Patients will be treated with vilobelimab IV, Q2W for 26 weeks
89283974|NCT05964413|Placebo Comparator|Placebo|Patients will receive placebo IV in the same schedule as patients in Arm 1
89283975|NCT05964140|Experimental|Group A|Group A: One induction IV dose
89283976|NCT05964140|Experimental|Group B|Group B: One induction IV dose and 2 further postoperative IV doses
89283977|NCT05964140|Active Comparator|Group C|Group C: One IV dose of antibiotics on induction and 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy
89283978|NCT05959070||Risankizumab|Participants will receive risankizumab as prescribed by their physician according to local label.
89283979|NCT05945485|Experimental|Arm 1|Healthy adults, 18 to 49 years of age will receive 10 mcg of DCVC H1 HA mRNA Vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. N = 10
89283980|NCT05945485|Experimental|Arm 2|Healthy adults, 18 to 49 years of age will receive 25 mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A dose escalation safety evaluation will occur to ensure the safety data support proceeding to the higher dose group. N = 10
89283981|NCT05945485|Experimental|Arm 3|Healthy adults, 18 to 49 years of age will receive 50 mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. A safety evaluation will occur to ensure the safety data support proceeding to the optimal dose group. N = 10
89283982|NCT05945485|Experimental|Arm 4|Healthy adults, 18 to 49 years of age will receive a selected dose mcg of DCVC H1 HA mRNA vaccine administered intramuscularly to the upper arm/deltoid at days 1 and 29. The DCVC H1 HA mRNA vaccine dose for Arm 4 will be selected based on interim analysis of safety and immunogenicity data from Arms 1-3. N = 10
89283983|NCT05945485|Active Comparator|Arm 5|Healthy adults, 18 to 49 years of age will receive 60 mcg of Licensed quadrivalent inactivated influenza vaccine (IIV4), Fluzone Quadrivalent, administered intramuscularly to the upper arm/deltoid at days 1 and 29. N = 10
89283984|NCT05932745|Experimental|Non-menthol, nicotine 59mg/ml (1)|Flavor without menthol with 59mg/ml nicotine
89283985|NCT05932745|Experimental|Low menthol, nicotine 59mg/ml (1)|Flavor with low menthol concentration with 59mg/ml nicotine
89283986|NCT05932745|Experimental|High menthol, nicotine 59mg/ml (1)|Flavor with high menthol concentration with 59mg/ml nicotine
89283987|NCT05932745|Experimental|Non-menthol, nicotine 59mg/ml (2)|Flavor without menthol with 59mg/ml nicotine
89283988|NCT05932745|Experimental|Low menthol, nicotine 59mg/ml (2)|Flavor with low menthol concentration with 59mg/ml nicotine
89283989|NCT05932745|Experimental|High menthol, nicotine 59mg/ml (2)|Flavor with high menthol concentration with 59mg/ml nicotine
89283990|NCT05932745|Experimental|Non-menthol, nicotine 59mg/ml (3)|Flavor without menthol with 59mg/ml nicotine
89283991|NCT05932745|Experimental|Low menthol, nicotine 59mg/ml (3)|Flavor with low menthol concentration with 59mg/ml nicotine
89283992|NCT05932745|Experimental|High menthol, nicotine 59mg/ml (3)|Flavor with high menthol concentration with 59mg/ml nicotine
89283993|NCT05932693|Experimental|WS-3 (1), no nicotine|WS-3 block: 0.1%
89283994|NCT05932693|Experimental|WS-3 (2), no nicotine|WS-3 block: 0.25%
89283995|NCT05932693|Experimental|WS-3 (3), no nicotine|WS-3 block: 0.5%
89283996|NCT05932693|Experimental|WS-3 (4), no nicotine|WS-3 block: 1.0%
89283997|NCT05932693|Experimental|WS-3 (5), no nicotine|WS-3 block: 2.0%
89283998|NCT05932693|Experimental|Menthol (1), no nicotine|Menthol block: 0.1%
89283999|NCT05932693|Experimental|Menthol (2), no nicotine|Menthol block: 0.25%
89284000|NCT05932693|Experimental|Menthol (3), no nicotine|Menthol block: 0.5%
89284001|NCT05932693|Experimental|Menthol (4), no nicotine|Menthol block: 1.0%
89284002|NCT05932693|Experimental|Menthol (5), no nicotine|Menthol block: 2.0%
89284003|NCT05931380|Experimental|Orforglipron Dose 1|Participants will receive orforglipron orally.
89284004|NCT05931380|Experimental|Orforglipron Dose 2|Participants will receive orforglipron orally.
89284005|NCT05931380|Experimental|Orforglipron Dose 3|Participants will receive orforglipron orally.
89284006|NCT05931380|Placebo Comparator|Placebo|Participants will receive placebo.
89284007|NCT05925036|Experimental|Experimental Cohort|MSC
89284008|NCT05925036|Placebo Comparator|Validation Cohort|Placebo
89284009|NCT05924685|Active Comparator|Continue immunosuppressive therapy with MMF/MPA|Kidney transplant recipients with maintenance therapy, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).
89284010|NCT05924685|Active Comparator|Replace immunosuppressive therapy with MMF/MPA by everolimus|Kidney transplant recipients replacing MMF/MPA by everolimus for at least six weeks, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).
89284011|NCT05919849|Experimental|Expressive Writing|Participants in the expressive writing (EW) condition will be instructed to write in a free-form manner about the most stressful aspects of being a parent of an SGMY, following standard EW procedures.
89284012|NCT05919849|Experimental|Attachment-Based Writing|Participants in the attachment-based writing (ABW) condition will respond to distinct prompts created for the condition based on components of attachment-based family therapy (ABFT).
89284013|NCT05919849|Other|Neutral Writing|Participants in the control condition will be asked to write about what they have done since waking up that morning.
89284014|NCT05919823|Experimental|KarXT|
89284015|NCT05919823|Placebo Comparator|Placebo|
89284016|NCT05915299||OCS Heart Transplant Recipients|All heart transplant recipients who are transplanted with an OCS perfused donor heart are eligible for this registry. Up to 5,000 subjects will be enrolled.
89284017|NCT05910775|No Intervention|Treatment as usual (TAU)|Participants receive TAU
89284018|NCT05910775|Experimental|Intervention + TAU|"Participants receive a presentation prior to the first treatment and receive a follow up session within 24 hours after the first treatment in addition to treatment as usual"
89284019|NCT05908656|Other|Persons with electronic health records suggestive of Gaucher disease|
89284020|NCT05905250|Experimental|Intervention|The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
89284021|NCT05905250|Active Comparator|Attention Control|Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.
89284022|NCT05900388||Pediatric patients with VTE|Pediatric patients under two years who initiate an anticoagulation therapy with rivaroxaban oral suspension or Standard of care (SOC) following a VTE diagnosis.
89284023|NCT05884554|Experimental|Cohort 1|No hepatic impairment
89284024|NCT05884554|Experimental|Cohort 2|Mild hepatic impairment
89284025|NCT05884554|Experimental|Cohort 3|Moderate hepatic impairment
89284026|NCT05884554|Experimental|Cohort 4|Severe hepatic impairment
89284027|NCT05878405|Active Comparator|Standard of Care Mouthwash Group|Patients receive standard of care mouthwash as needed on study.
89284028|NCT05878405|Experimental|Methylene Blue Mouthwash Group|Patients receive Methylene Blue mouthwash as needed on study.
89284029|NCT05877287|Experimental|mindfulness-based stress reduction program|The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
89284030|NCT05877287|No Intervention|control group|No application will be made.
89284031|NCT05875207|Experimental|Evidence based physical therapy combined with mindfulness (Low-Intensity)|"Physical therapists randomized to this arm will receive a manual on how to integrate MORE; mindfulness, mindful reappraisal, and mindful savoring savoring into routine outpatient physical therapy for patients with chronic musculoskeletal pain and long-term opioid treatment.~After 4 weeks to review the manual, the physical therapist's competency will be assessed during mock patient encounters using trained actors as standardized patients.~Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about pain and opioid use before, and after treatment. We plan on enrolling 2 patients for each physical therapist."
89284032|NCT05875207|Other|Standard physical therapy|"Physical therapists randomized to this arm will deliver routine treatment for someone with chronic musculoskeletal pain and long-term opioid treatment.~Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about pain and opioid use before, during and after treatment. We plan on enrolling 2 patients for each physical therapist."
89284033|NCT05875207|Experimental|Evidence based physical therapy combined with mindfulness (High-Intensity)|"Physical therapists randomized to this arm will receive 13 hours of training. The first 6 hours consists of prerecorded didactic lectures that the physical therapist can view on their own time. After viewing the lectures, participants will attend 6.25 hours of live experiential instruction to promote trainee competence in providing mindfulness, mindful reappraisal, and mindful savoring after which the participating physical therapist's competency will be assessed during mock patient encounters using trained actors as standardized patients. .~Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about pain and opioid use before, and after treatment. We plan on enrolling 2 patients for each physical therapist."
89284034|NCT05872555||Patients with psychiatric diagnosis/prescribed psychiatric medications|"Diagnosed with schizophrenia/schizoaffective disorder/bipolar disorder/depression/dementia/diagnosed with other psychiatric disorders, or not diagnoses with any disorder, and registered in the Clalit database.~First exposure to antipsychotics/antidepressants/benzodiazepines/mood stabilizers above the age of 16 years, regardless of the presence of having a psychiatric diagnosis. We will include patients treated with these medications also if they do not have a psychiatric diagnosis.~Prescription of these psychiatric medications between 2001-2024"
89284035|NCT05872555||Control individuals|"The control groups will differ according to the analysis performed, and will be clearly described in the publication.~Depending on the analysis, will not include person prescribed antipsychotics, antidepressants, benzodiazepines, mood stabilizers.~Matched for age, sex and socio-economic status and other potential confounders, depending on the disease studied."
89284036|NCT05862285|Experimental|Ipatasertib|Participants will continue to receive Ipatasertib monotherapy or in combination with other agent(s) or comparator agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participants non-compliance, if local access becomes available or study termination by the Sponsor, whichever occurs first.
89284037|NCT05855694|Experimental|Intervention Arm - Therapeutic Setting|Photobiomodulation Helmet, Therapeutic setting, 35mW/cm2 = 42J/cm2, 3 x Sessions per week for 6 weeks
89284038|NCT05855694|Sham Comparator|Control Arm - Non-Therapeutic Setting|Photobiomodulation Helmet, Non-Therapeutic setting, 0mW/cm cm2 = 0J/cm2, 3 x Sessions per week for 6 weeks
89284039|NCT05854212|Experimental|Behavioral economics-enhanced user interface|Food agencies will see the behavioral economics (BE)-enhanced interface by default; food items will be sorted with green-labeled items listed first, followed by yellow, then red. If users search for a specific item type (e.g., chicken) the results returned for that item type will also be sorted so that green-labeled items are listed first. At any time during the ordering episode, users will have the option to switch from the BE-enhanced default to an alternate sorting or filtering choice, such as alphabetical or cost. Users will be shown the percent of items (by weight) that are labeled green in a prominent location on the ordering screen. The percent green-labeled items in the order will appear alongside messaging reporting the average percent green-labeled items ordered by GBFB pantries that rank in the top 10% based on this metric.
89284040|NCT05854212|No Intervention|Usual user interface|When agency staff log on to the food bank platform, by default, foods are listed in alphabetical order. If they wish, users can change how items are sorted or filtered using pull-down menus and check-boxes, including the ability to have items sorted or filtered based on traffic light labels. As orders are created, an information section at the top of the page is updated with details on the order weight and cost.
89284041|NCT05852223|Experimental|experimental arm A|N° 20 patients: patients will receive pembrolizumab 200 mg Every Three Weeks (Q3W) for 2 courses, followed by thyroidectomy +/- radioiodine according to the risk class
89284042|NCT05852223|No Intervention|control group B|N° 5 patients: patients will be treated for clinical practice with upfront thyroidectomy followed by +/- radioiodine according to the risk class
89284043|NCT05828511|Experimental|Phase 1 cohort|Linvoseltamab dose escalation (part A) and dose expansion (part B) for participants with NDMM who are treatment-naïve.
89284044|NCT05828511|Experimental|Phase 2 - transplant ineligible cohort|Transplant-ineligible participants, enrolled in dose expansion, will receive selected Linvoseltamab regimen until disease progression as per protocol.
89284045|NCT05828511|Experimental|Phase 2 - transplant eligible cohort|Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol
89284046|NCT05815537|Experimental|Low-Reverberation|Participants perform psychoacoustic tasks under a low-reverberant environment and a control environment without reverberation.
89284047|NCT05815537|Experimental|High-Reverberation|Participants perform psychoacoustic tasks under a high-reverberant environment and a control environment without reverberation.
89284048|NCT05810129|Active Comparator|standard physical therapy|Men with clavicle fracture immobilized for 6 weeks + standard physical therapy for 12 weeks
89284049|NCT05810129|Experimental|concentric-eccentric strength training|Men with clavicle fracture who perform concentric-eccentric strength training on the uninjured limb during the 6-week immobilization period + Posterior Standard PhysicalTherapy.
89284050|NCT05810129|Experimental|eccentric strength training|Men with clavicle fracture who perform eccentric strength training on the unaffected limb during the 6-week period of immobilization + Posterior Standard Physical Therapy.
89284051|NCT05809986||Cohort 1: Early treatment arm|All patients who initiated Ofatumumab within 3 years after MS diagnosis (can be treatment-naive or switch).
89284052|NCT05809986||Cohort 2: Late treatment arm|All patients who initiated Ofatumumab with more than 3 years of MS diagnosis.
89284053|NCT05806814|Experimental|Extended course of Sipuleucel-T treatment|
89284054|NCT05797168|Experimental|Module 1: AZD5335 Monotherapy|AZD5335 Monotherapy
89284055|NCT05797168|Experimental|Module 2: AZD5335 + AZD5305|AZD5335 + AZD5305
89284056|NCT05790486|Experimental|The Intervention: Take a Break plus Nicotine replacement therapy (NRT) Sampling|Motivational text messages, challenge quizzes, goal-setting, coping mini-games, and recognition & rewards. Nicotine lozenges will be given to all participants in both randomized groups.
89284057|NCT05790486|Active Comparator|The Comparison: Nicotine replacement therapy (NRT) Sampling without Take a Break|Nicotine lozenges will be given to all participants in both randomized groups. The goal of the comparison group is to isolate the effect of the Take a Break experience.
89284058|NCT05790486|Experimental|The Enhanced Program: Community Paramedicine Standard Plus Enhanced Implementation Program|The Enhanced Program will include strategies described in the Standard Program plus training of local champions.
89284059|NCT05790486|Active Comparator|The Standard Program: Community Paramedicine Standard Implementation Program|The standard program will include training, resources, and access to the e-refer tool.
89284060|NCT05788432||Coronary Artery Disease (CAD)|
89284061|NCT05787821||Cohort 1|Cementless Femur Cementless Tibia
89284062|NCT05787821||Cohort 2|Cementless Femur Cementless Tibia
89284063|NCT05787821||Cohort 3|Cemented Femur Cemented Tibia
89284064|NCT05787821||Cohort 4|Cemented Femur Cemented Tibia
89284065|NCT05787821||Cohort 5|Cementless Femur Cemented Tibia
89284066|NCT05787821||Cohort 6|Cementless Femur Cemented Tibia
89284067|NCT05787821||Cohort 7|Cementless Femur Cemented Tibia
89284068|NCT05787821||Cohort 8|Cementless Femur Cemented Tibia
89284069|NCT05787821||Cohort 9|Cementless Femur Cementless Tibia
89284070|NCT05787821||Cohort 10|Cementless Femur Cementless Tibia
89284071|NCT05787821||Cohort 11|Intended to capture on-label configurations of newly cleared components not captured in cohorts 1-10.
89284072|NCT05787704||Multiple Sclerosis|People with Multiple Sclerosis, 18 years or older
89284073|NCT05780151|Active Comparator|Conventional|"In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.~The conventional arm is modelled after a previous clinical trial with a similar indication and intervention and aims to represent current state-of-the art clinical trial conduct."
89284074|NCT05780151|Active Comparator|Hybrid|"In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.~The hybrid trial design is defined as a trial containing conventional trial elements, such as site-based recruitment and screening visits, as well as decentralised trials elements, such as a remote follow-up period and data collection"
89284075|NCT05780151|Active Comparator|Remote|"In RADIAL, the main study intervention is a methodological intervention with patients being recruited into three arms with different level of decentralization. Additionally, participants in all arms are switching from their previously used basal insulin to Toujeo®, which is the clinical intervention, in the protocol defined as the study drug.~The remote arm is fully decentralised and aims to represent future decentralised clinical trial practice using a decentralised recruitment model, intervention period and data collection."
89284076|NCT05776277|Experimental|Iltamiocel|
89284077|NCT05776277|Placebo Comparator|Placebo|
89284078|NCT05774002|No Intervention|standard of care control groups no psychological intervention|standard of care control groups no psychological intervention
89284079|NCT05774002|Experimental|psychological intervention ADAPT|The psychological intervention plan is based on the Aim to Decrease Anxiety and Pain Treatment (ADAPT) model.
89284080|NCT05771558|Experimental|Tailored Lighting Intervention (TLI)|"The TLI will be performed for 2 hours each day over an 8-week period~During the last week of the lighting, participants will be asked to wear the actigraph and light meter again for 7 days"
89284081|NCT05769478|Experimental|Amifampridine will be orally administered to study participants|Amifampridine will be orally administered to study participants following completion of the baseline SFEMG. Post-dose SFEMG will commence at 30 minutes following dosing and will be completed within 30 minutes. The participant will remain under observation in the Diagnostic Neurology suite for 2 hours after dosing so it is estimated that the entire protocol including monitoring will be completed within 2-3 hours.
89284082|NCT05761951|Experimental|DKN-01|Participants will receive DKN-01 by vein over about 30 minutes to 2 hours on Day 1 of each cycle, as well ason Day 15 of Cycle 1.
89284083|NCT05761951|Experimental|Pembrolizumab|Participants will receive pembrolizumab by vein over about 30 minutes on Day 1 of each cycle for up to 24 months.
89284084|NCT05759585|Experimental|Person-centered lifestyle intervention group|"Intervention group: Volunteers who were diagnosed with RA by a rheumatologist according to the 2010 criteria of the American College of Rheumatology (ACR)/European Rheumatology Association (ACR/EULAR) will be included in the study.~Person-centered lifestyle intervention in individuals with rheumatoid arthritis is planned as 2 sessions per week, for a total of 4 weeks."
89284085|NCT05759585|Experimental|Control group|"Control group: Volunteers who were diagnosed with RA by a rheumatologist according to the 2010 criteria of the American College of Rheumatology (ACR)/European Rheumatology Association (ACR/EULAR) will be included in the study.~For the control group, they will be called twice a week for 4 weeks and inquired about their general condition."
89284086|NCT05757414|Experimental|Tailored Lighting intervention (TLI)|"The TLI will be performed for 2 hours each day over a 4-week period.~During the last week of the lighting, participants will be asked to wear the actigraph and light meter again for 7 days"
89284087|NCT05755984|Experimental|Arm 1: 3D printed model|a 3-D printed model of your breast will be created and discussed with participants during your surgical consultation.
89284088|NCT05755984|No Intervention|Arm 2: No 3D printed model|Participants will have a standard-of-care surgical consultation using traditional breast imaging.
89284089|NCT05753137|Experimental|Ophthalmic Acupoint Treatment Group|"Ophthalmic acupoint treatment group will receive a total of 6 courses of treatment, once a week, a total of six weeks, 20 minutes each time.~Acupuncture points: Fengchi(GB20), Cuanzhu(BL2), Sibai(ST2), Taiyang(EX-HN5), Hegu(LI4), Taichong(LR3), a total of six acupoints."
89284090|NCT05753137|Placebo Comparator|Non-ophthalmological Acupoint Control Group|"Non-ophthalmological acupoint control group will receive a total of 6 courses of treatment, once a week, a total of six weeks, 20 minutes each time.~Acupuncture points: Yinlingquan(SP9), Liangqiu (ST34),Xiajuxu(ST39), Yanglingquan (GB34), Shousanli(LI10), Sanyangluo(TE8), a total of six acupoints. The Non-ophthalmological acupoint control group points are not indicated for the treatment of ophthalmological related pathologies, and are not reported to improve ophthalmological function."
89284091|NCT05743595|Experimental|Cohort A: Personalized neoantigen DNA vaccine + retifanlimab|"Cohort A will receive the personalized neoantigen DNA vaccine via electroporation mediated IM injection alone during the first two priming doses, then concurrently with retifanlimab during the subsequent boosting doses (Doses 3 through 6)~The personalized neoantigen DNA vaccine will be given once every 28 days for up to 6 doses. Retifanlimab is given at a fixed dose of 500 mg every 28 days.~Patients may receive up to 6 doses of personalized neoantigen DNA vaccine and up to 12 months total of retifanlimab"
89284092|NCT05743595|Experimental|Cohort B: Personalized neoantigen DNA vaccine + retifanlimab|"Cohort B will receive the personalized neoantigen DNA vaccine via electroporation mediated IM injection plus concurrent retifanlimab beginning with Dose 1 and continuing for a total of 6 doses.~The personalized neoantigen DNA vaccine will be given once every 28 days for up to 6 doses. Retifanlimab is given at a fixed dose of 500 mg every 28 days.~Patients may receive up to 6 doses of personalized neoantigen DNA vaccine and up to 12 months total of retifanlimab"
89284093|NCT05739955|Experimental|Sani24|Application of a 24-hour continuously acting quaternary ammonium salt disinfectant: Sani24 (PDI Healthcare Inc.) by study team
89284094|NCT05739955|Experimental|Standard EPA-registered disinfectant|Application of standard EPA-registered disinfectant by study team
89284095|NCT05739955|Active Comparator|Control|Routine disinfection completed by hospital staff
89284096|NCT05730075||Phase 1 HBCC providers|This group will include up to 9 Spanish-speaking HBCC providers, who will receive the Spanish version of the provider questionnaire.
89284097|NCT05730075||Phase 1 families|This group will include up to 9 Spanish speaking families and up to 9 English speaking families who will each receive the family questionnaire and who will participate in cognitive interviews.
89284098|NCT05730075||2 HBCC providers|This group will include 150 purposively selected providers from diverse backgrounds who will each complete the provider questionnaire and will also be asked to recruit one or more families to complete the family questionnaire.
89284099|NCT05730075||Phase 2 families|This group will include up to 150 purposively selected families who will each receive the family questionnaire.
89284100|NCT05727163|Experimental|HAI group|"FOLFOX given via Hepatic Artery Infusion (HAI) in Combination With intravenous Irinotecan With or Without Bevacizumab.~Dexamethasone 25 mg via HAI (Pre-chemotherapy) Anisodamine (654-2) 10 mg HAI (Pre-chemotherapy) Oxaliplatin 85 mg/m2 via HAI over 3 hours Leucovorin 200 mg/m2 via HAI FU 400 mg/m2 via HAI FU 2.4g/m2 via HAI over 48 hours Irinotecan 150 mg/m2 intravenously Bevacizumab 5 mg/kg intravenously~The above regimen was given on Day 1 and repeated after 14 days. Patients will typically receive a maximum of 12 courses (preoperative and/or postoperative) unless disease progression is detected, intolerable adverse effects, or the patient refuses further treatment."
89284101|NCT05727163|Active Comparator|Systemic Chemotherapy group|"Systemic FOLFOXIRI With or Without Bevacizumab~Irinotecan 150mg/m2 intravenously Oxaliplatin 85 mg/m2 intravenously over 3 hours Leucovorin 200 mg/m2 intravenously FU 400 mg/m2 intravenously 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours Bevacizumab 5 mg/kg intravenously~Note: (UGT*28 7/7, UGT*6 A/A, UGT*28 6/7 and UGT*6 A/G patients, Irinotecan dosage was reduced to 130 mg/m2)~The above regimen was given on Day 1 and repeated after 14 days. Patients will typically receive a maximum of 12 courses (preoperative and/or postoperative) unless disease progression is detected, intolerable adverse effects, or the patient refuses further treatment."
89284102|NCT05722873|Experimental|Fasting|Subjects will fast one-day per week for 12 weeks
89284103|NCT05722873|Experimental|Fasting with weight maintenance|Subjects will fast one-day per week for 12 weeks and maintain body weight
89284104|NCT05722873|Placebo Comparator|Counseling|Subjects will be counseled on optimal diet and activity recommendations to maintain/achieve a normal BMI (standard of care)
89284105|NCT05721950||Brigatinib 90 mg/180mg|Participants with ALK positive locally advanced or metastatic NSCLC will be observed ambispectively (retrospective plus prospective) after receiving recommended dose of brigatinib, 90 mg orally once daily for first 7 days followed by 180 mg once daily for up to 36 months as their first line of treatment as part of routine medical care up to approximately 16 months. Data will be collected every 3 months after their first dose until the 36 month or participant death, loss to follow-up, or withdrawal from the study for any reason in the real-world setting from September 1, 2022 and December 31, 2026.
89284106|NCT05721222|Experimental|PRO1160|PRO1160 monotherapy in escalating doses in Part A and at the recommended phase 2 dose in Part B
89284107|NCT05719558|Experimental|ASP1002 Dose Escalation (Part 1)|Participants will be assigned to sequentially escalating doses of ASP1002. Each dose level will open sequentially based upon sponsor review of emerging data.
89284108|NCT05719558|Experimental|ASP1002 Dose Expansion (Part 2) non-small cell lung cancer (NSCLC)|Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
89284109|NCT05719558|Experimental|Experimental: AS1002 Dose Expansion (Part 2) urothelial carcinoma (UC)|Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
89284110|NCT05719558|Experimental|Experimental: ASP1002 Dose Expansion (Part 2) colorectal cancer (CRC)|Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
89284111|NCT05710640|Experimental|Blinded phase|Participants will receive 5 minutes of active tcVNS or sham tcVNS daily for 8 weeks.
89284112|NCT05710640|Experimental|Open-Label phase|Participants will receive 5 minutes of stimulation via the active tcVNS for 8 weeks after a double-blind, sham-controlled 8- week period.
89284113|NCT05706558||Circumferential resection margin (CRM)|Participants will have a diagnosis of esophageal carcinoma and residual tumor >1 mm from the CRM
89284114|NCT05706558||Circumferential resection margin (CRM)-close|Participants will have a diagnosis of esophageal carcinoma and residual tumor >0-1 mm from the CRM
89284115|NCT05706558||Circumferential resection margin (CRM)+|Participants will have a diagnosis of esophageal carcinoma and residual tumor at the surgical CRM
89284117|NCT05701514|No Intervention|Conservative arm|Children assigned to this treatment arm will be conservatively managed, and will continue to be followed until the age of 5 years (end of study inclusion).
89284118|NCT05701514|Active Comparator|Surgical arm|Children assigned to this treatment arm will undergo elective surgical resection at the age of 6-9 months, and will continue to be followed until the age of 5 years (end of study inclusion).
89284119|NCT05694286|Experimental|Infraorbital Filler|Receives 1-2mL injection of approved filler in infraorbital region
89284120|NCT05690295|Experimental|CLIMHEALTHY|All postmenopausal women without breast cancer will be subjected to 12 weeks of full body resistance exercise training (3 times per week)
89284121|NCT05690295|Experimental|CLIMCANCER|All postmenopausal women survivors of breast cancer without or with Hormone Therapy (pecifically Aromatase Inhibitor or Tamoxifen) will be subjected to 12 weeks of full body resistance exercise training (3 times per week)
89284122|NCT05689515|Experimental|Mobile Health App group|Mobile health app to increase rates of engagement in care in youths living with HIV
89284123|NCT05689515|No Intervention|Control group|Standard of care for youths living with HIV
89284124|NCT05687032|Experimental|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
89284128|NCT05675345|Active Comparator|HFNC only|
89284129|NCT05675345|Experimental|HFNC + CNEP10|
89284130|NCT05675345|Experimental|HFNC + CNEP20|
89284131|NCT05675345|Experimental|HFNC + CNEP30|
89284132|NCT05672186|Sham Comparator|Waitlist control|Participants in low-income neighborhoods and/or adjacent to low-income housing randomized to the control group will be placed on a waitlist to receive market service after follow- up data collection is complete.
89284133|NCT05672186|Experimental|Experimental group|Participants in low-income neighborhoods and/or adjacent to low-income housing randomized to the intervention group will receive the full-service market intervention following randomization.
89284134|NCT05666921||Pediatric patients|The group is made up of pediatric patients, and an accompanying caregiver, belonging to the functional chronic pain clinic of Pain Therapy and Palliative Care, to the Gastroenterology and Nutrition Unit, to the Bronchopneumology Unit and Medical Pediatrics as well as to the Pediatric Psychology Unit, who present with somatic symptom disorders.
89284135|NCT05666921||Control group|The population of the control group, recruited through informal channels according to a sampling of convenience, will be enrolled on the basis of the expected inclusion criteria.
89284138|NCT05664256|Experimental|policy intervention group|The group will receive the policy intervention package.
89284139|NCT05664256|No Intervention|policy control group|The group will follow the usual guidelines for food procurement policy at the canteen. After three months, the group will receive the policy intervention package.
89284140|NCT05659264|Experimental|SAD Stage: mRNA-0184|Participants will receive a single dose of mRNA-0184.
89284141|NCT05659264|Experimental|MAD Stage: mRNA-0184|Participants will receive up to 4 doses of mRNA-0184 administered over a treatment period of up to 16 weeks.
89284142|NCT05659264|Placebo Comparator|MAD Stage: Placebo|Participants will receive placebo matching to mRNA-0184 administered over a treatment period of up to 16 weeks.
89284143|NCT05652777||Pregnant women|Pregnant women attending antenatal care clinic during routine community outreach activities in Lusaka, Zambia.
89284144|NCT05650879|Experimental|Phase 1a Monotherapy Dose Escalation|ELVN-002 will be administered either once or twice daily. Each cohort of patients will receive a higher dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
89284145|NCT05650879|Experimental|Phase 1a Monotherapy Dose Exploration|ELVN-002 will be administered either once or twice daily. A maximum of 60 patients will enroll in this arm. A maximum of 10 patients may be enrolled at a single dose or tumor type. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
89284146|NCT05650879|Experimental|Phase 1b Monotherapy Dose Expansion|"ELVN-002 will be administered either once or twice daily. A maximum of 40 patients will enroll in this arm. Patients will be randomized 1:1 to one of two dose levels.~ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason."
89290268|NCT00255047|Experimental|Study Group 2: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
89284147|NCT05650879|Experimental|Phase 1a Combination Dose Escalation with T-DXd|ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DXd once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
89284148|NCT05650879|Experimental|Phase 1a Combination Dose Escalation with T-DM1|ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 3.6 mg/kg of intravenous T-DM1 once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
89284150|NCT05640648|Active Comparator|Standard Implementation Strategy Period|During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
89284151|NCT05640648|Experimental|Enhanced Contact Investigation Intervention Period|"The enhanced contact investigation strategy includes 4 implementation facilitation tools and 3 continuous quality improvement techniques and will be delivered as a branded package named for an inspirational Luganda phrase that is translated as We are together with you. Implementation facilitation tools include 1) a TB education pamphlet, 2) a contact identification algorithm, 3) an instructional video on sputum collection, and 4) community health riders who transport clients, community health workers, and sputum samples by motorcycle. The continuous quality improvement techniques delivered as the community of practice package include 1) community of practice meetings, 2) audit and feedback reports and 3) a group chat application."
89284152|NCT05640102||Cohort 1: MYD88 L265P mutation|Arm A: Treatment-naïve (TN); Arm B: Relapsed/refractory (R/R)
89284153|NCT05640102||Cohort 2: Non-L265P MYD88 mutation(s) and MYD88 wildtype|Arm C: TN and R/R
89284154|NCT05637788||HCC Patients Submitted Surgery|"For the retrospective data collection, the planned number of subjects that will be enrolled will be almost 150/year. Considering the study-period (2010-2020), it is estimated a total of 1500 patients.~For the prospective observational data collection, the estimation of patients'enrolment is based on the number of patients treated per year in the participating centers (globally 150/year). Since the observational nature, patients will be evaluated for their enrolment consecutively. The prospective data collection will be prosecuted for 2 years, leading to a prospective cohort of 300 patients. The whole study is planned to be ended in December 2023. Inclusion and exclusion criteria will be the same among the retrospective and the prospective parts of the study."
89284155|NCT05634369|Experimental|Treatment|"Part 1: Enrollment of 5 patients in each cohort (osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and non-rhabdomyosarcoma).~Part 2: Enrollment of 2 cohorts in 2 stages for a total of 40 patients."
89284156|NCT05630872|Experimental|Adults with HIV and newly diagnosed DS-TB not currently on ART|"Participants will receive daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide for 8 weeks followed by daily rifapentine-moxifloxacin plus isoniazid for 9 weeks (referred to as 2HPZM/2HPM) for anti-tuberculosis (anti-TB) therapy at study entry.~DTG-based ART at 50 mg twice daily (BID) will be started after 6 weeks of TB therapy and will be continued for 2 weeks after completion of TB therapy.~Two weeks after completion of TB therapy DTG will be reduced to standard dose 50 mg once daily (QD)."
89284157|NCT05630677|Experimental|Treatment A|Subjects will receive AZD5055 solution as a 20-minute infusion in overnight fasted state on Day 1 in Period 1.
89284158|NCT05630677|Experimental|Treatment B|Subjects will receive oral suspension of AZD5055 in an overnight fasted state on Day 1 in Period 1.
89284159|NCT05630677|Experimental|Treatment C|Subjects will receive AZD5055 film-coated tablet in overnight fasted state on Day 1 (Study Day 4) in Period 2.
89284160|NCT05630677|Experimental|Treatment D|Subjects will receive a standardized high-fat breakfast 30 minutes before film-coated tablet of AZD5055 administered as On Day 1 (Study Day 8) in Period 3.
89284161|NCT05630677|Experimental|Treatment E|Subjects will receive rabeprazole twice daily on Day 10. On Day 1 (Study Day 13), AZD5055 film-coated tablet will be administered, under fasted conditions, together with rabeprazole and rabeprazole dosing will continue twice daily in Period 4.
89284162|NCT05630677|Experimental|Treatment F|Subjects will receive a low-fat breakfast 30 minutes before AZD5055 film-coated tablet administered together with rabeprazole on Day 17. Rabeprazole will continue twice daily, the last dose is on the evening of Study Day 18 in Period 5.
89284163|NCT05630066|Experimental|Part 1 Adult Alogabat High Dose (aged 15-17)|In Part 1 of the study, participants will receive age-adjusted dose 60 mg QD alogabat
89284164|NCT05630066|Experimental|Part 1 Age adjusted high dose (age 10-14)|In Part 1 of the study, participants will receive age-adjusted dose 60 mg QD alogabat.
89284165|NCT05630066|Experimental|Part 1 Age Adjusted Low Dose (age 5-9)|In Part 1 of the study, participants will receive age-adjusted dose 20 mg QD alogabat.
89284166|NCT05630066|Experimental|Part 2 Cohort 1|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
89284167|NCT05630066|Experimental|Part 2 Cohort 2|In Part 2 of the study, the dosing will depend upon the results of Part 1, with age-adjusted dose equivalents of up to 100 mg being administered.
89284168|NCT05630066|Experimental|Part 1 Optional Cohort|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, additional participants may be recruited in any of the of the 3 age-groups in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2."
89284169|NCT05630066|Experimental|Part 2 Optional Cohort|"If dose adjustments (e.g., increase or decrease in dose) are required, particularly due to uncertainty of the clearance estimates (e.g., due to high variability) or over-/underprediction of the pediatric clearance versus adult clearance, participants from any of the 3 age-groups may enroll in order to confirm the exposure equivalence.~A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2."
89284170|NCT05626322|Experimental|Phase 1b|Participants will be allocated to sequential dose levels of maplirpacept (PF-07901801), administered in combination with standard doses of tafasitamab and lenalidomide, to select two doses for further evaluation in Phase 2. Approximately 20 participants will be enrolled.
89284171|NCT05626322|Experimental|Phase 2|Participants will be randomized to 1 of 2 different dose levels of maplirpacept (PF-07901801) which will be administered in combination with standard doses of tafasitamab and lenalidomide. Approximately 50 participants will be enrolled (25 per dose).
89284172|NCT05625269|Experimental|Education and follow-up group|Patients in the intervention group will be given training on the procedure and home care process on the first day of hospitalization and the day before discharge. Afterwards, patients will be followed up by phone at intervals of two weeks. The purpose of telephone monitoring is to question adherence to treatment, to identify and change barriers, to apply counseling and to control symptoms.
89284173|NCT05625269|No Intervention|Control group|The control group will be given the standard care applied in the clinic, and the patients of this group will be given training after the research is completed.
89284174|NCT05624554|Experimental|Nemtabrutinib|Administered daily via oral tablet.
89284175|NCT05624554|Active Comparator|FCR or BR|Investigator's choice of fludarabine plus cyclophosphamide plus rituximab (FCR) OR bendamustine plus rituximab (BR). Participants will receive either rituximab or specified approved rituximab biosimilar.
89284176|NCT05623085|Experimental|Aerobic Exercise|Aerobic exercise group with 8 weeks of individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
89284177|NCT05623085|Active Comparator|Yoga Exercise|Yoga exercise group with 8 weeks of individualized exercise program. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
89284178|NCT05621317|Experimental|PVX108 50 nmol in adolescents|Twelve 4-weekly intradermal (ID) doses of PVX108 at 50 nmol in adolescents (Cohort 1)
89284179|NCT05621317|Placebo Comparator|Placebo in adolescents|Twelve 4-weekly ID doses of placebo matching PVX108 in adolescents (Cohort 1)
89284180|NCT05621317|Experimental|PVX108 5 nmol in children|Twelve 4-weekly ID doses of PVX108 at 5 nmol in children (Cohort 2)
89284181|NCT05621317|Experimental|PVX108 50 nmol in children|Twelve 4-weekly ID doses of PVX108 at 50 nmol in children (Cohort 2)
89284182|NCT05621317|Placebo Comparator|Placebo in children|Twelve 4-weekly ID doses of placebo matching PVX-108 in children (Cohort 2)
89284183|NCT05617313|Experimental|Experimental Group|"Pembrolizumab will be given intravenously on Day 1 of the 21 day cycle (For all cycles).~GT103 dose will be determined by the safety lead in prior to the study. Dosing calculations should be based on actual body weight where applicable. It will be taken intravenously on Day 1 of the 21 day cycle (For all cycles)."
89284184|NCT05608564|Experimental|Local antibiotic group|A combination of Piperacillin and Tazobactam in gel form is applied using a syringe and a flexible blunt needle into the periodontal pockets 24 hours after the non-surgical periodontal therapy. After administration, the dry field should be maintained for 5 minutes and the patient should not rinse the oral cavity for 15 minutes.
89284185|NCT05608564|Active Comparator|Systemic antibotic group|Amoxicillin (500mg, 3 times a day, 7 days) and Metronidazole (400mg, 3 times a day, 7 days) per os at the beginning of non-surgical treatment.
89284186|NCT05592379|Experimental|2-minute IV Psilocybin/Placebo Infusion - Asleep|Participants will receive 2mg of IV psilocybin over 2 minutes while asleep during an overnight visit and 10 mL of placebo (saline) over 2 minutes while asleep during another overnight visit. The order of administration will be determined by the study protocol.
89284187|NCT05592379|Experimental|2-minute IV Psilocybin/Placebo Infusion - Awake|Participants will receive either 2mg of IV psilocybin or 10 mL of IV saline (placebo) over 2 minutes during an overnight visit while awake.
89284188|NCT05592379|Experimental|10-minute IV Psilocybin/Placebo Infusion - Asleep|Participants will receive 2mg of IV psilocybin over 10 minutes while asleep during an overnight visit and 10 mL of placebo (saline) over 10 minutes while asleep during another overnight visit. The order of administration will be determined by the study protocol.
89284189|NCT05592379|Experimental|10-minute IV Psilocybin/Placebo Infusion - Awake|Participants will receive either 2mg of IV psilocybin or 10 mL of IV saline (placebo) over 10 minutes during an overnight visit while awake.
89284190|NCT05588570|Experimental|CAT|Participants will receive behavioral treatment for anxiety.
89284193|NCT05577702|Experimental|Arm 1A: Tislelizumab Monotherapy|Tislelizumab on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days)
89284194|NCT05577702|Experimental|Arm 1B: Tislelizumab and Ociperlimab|Tislelizumab + ociperlimab on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days)
89284195|NCT05577702|Experimental|Arm 1C: Tislelizumab and LBL-007|Tislelizumab + LBL-007 on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days)
89284196|NCT05577702|Experimental|Arm 2A: Tislelizumab and Chemotherapy|"Tislelizumab + chemotherapy on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days); Platinum-based doublet chemotherapy options may include:~Cisplatin/carboplatin + pemetrexed (nonsquamous)~Cisplatin/carboplatin + paclitaxel (squamous)"
89284197|NCT05577702|Experimental|Arm 2C: LBL-007 and Tislelizumab and Chemotherapy|"LBL-007 + tislelizumab + chemotherapy on a 3-week cycle for 2 to 4 cycles, followed by surgical resection (each cycle is 21 days); Platinum-based doublet chemotherapy options may include:~Cisplatin/carboplatin + pemetrexed (nonsquamous)~Cisplatin/carboplatin + paclitaxel (squamous)"
89290269|NCT00255047|Experimental|Study Group 3: DTaP-IPV and ActHIB®|Participants will receive 3 doses of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively
89284198|NCT05577312|Experimental|BRL-101|BRL-101 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of BRL-101.
89284199|NCT05574478||Patients and Caregivers|Participants will include patients diagnosed with metastatic breast cancer and caregivers for patients diagnosed with metastatic breast cancer. Participants will be recruited from the UNC Medical Center breast oncology group as well as other practices identified by the Principal Investigator based on existing professional networks (referring physicians, other UNC oncology entities, collaborative groups).
89284200|NCT05568459||Cohort 1|Male participants with hemophilia B on current FIX Replacement Therapy prophylaxis or a documented genotype known to produce severe hemophilia B
89284201|NCT05561309|Experimental|dose 1|"Experimental: HR18034 190mg (10ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 50mg (10mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
89284202|NCT05561309|Experimental|dose 2|"Experimental: HR18034 285mg (15ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 75mg (15mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
89284203|NCT05561309|Experimental|dose 3|"Experimental:HR18034 380mg (20ml)~Intervention: Drug: HR18034~Active Comparator: Ropivacaine Hydrochloride Injection~Ropivacaine Hydrochloride Injection 100mg (20mL)~Intervention: Drug: Ropivacaine Hydrochloride Injection"
89284204|NCT05558358|Experimental|1|Randomized sham-controlled crossover design - participants have baseline assessments/evaluation, 1 week detoxification, surgery, 30 days residential care, then begin DBS stimulation, 12 weeks IOP/CM and are followed for 52 weeks.
89284205|NCT05558358|Experimental|2|Randomized sham-controlled crossover design - participants have baseline assessments/evaluation, 1 week detoxification, surgery, 30 days residential care, then begin DBS stimulation, 12 weeks IOP/CM and are followed for 52 weeks.
89284206|NCT05556824|Active Comparator|Drug Product|Panosyl-isomaltooligosaccharide (PIMO) liquid 1 g (1.5 ml) per day for 8 weeks
89284207|NCT05556824|Placebo Comparator|Placebo|Placebo liquid (1.5 ml) per day for 8 weeks
89284208|NCT05549037||morning group|The immunotherapy infusion is before 15:00 p.m
89284209|NCT05549037||afternoon group|The immunotherapy infusion is after 15:00 p.m
89284210|NCT05546866|Experimental|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
89284211|NCT05546476|Experimental|Double-Blind ponsegromab Treatment low dose followed by Open Label ponsegromab Treatment|ponsegromab low dose subcutaneous injection every 4 weeks
89284212|NCT05546476|Placebo Comparator|Double-Blind Placebo Treatment followed by Open-Label ponsegromab Treatment|Match placebo subcutaneous injection every 4 weeks
89284213|NCT05546476|Experimental|Double-Blind ponsegromab Treatment medium dose followed by Open Label ponsegromab Treatment|ponsegromab medium dose subcutaneous injection every 4 weeks
89284214|NCT05546476|Experimental|Double-Blind ponsegromab Treatment high dose followed by Open Label ponsegromab Treatment|ponsegromab high dose subcutaneous injection every 4 weeks
89284215|NCT05535387|Experimental|FamilyNet smart speaker/mobile application|In a 4- to 6-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans.
89284216|NCT05531786|Experimental|Arm 2 - Low-dose|Expansion dosing to evaluate the efficacy of pacritinib 100 mg PO BID
89284217|NCT05531786|Experimental|Arm 3 - High-dose|Expansion dosing to evaluate the efficacy of pacritinib 200 mg PO BID
89284218|NCT05531786|Experimental|Escalating doses of treatment|Escalating doses of pacritinib to confirm safety in cGVHD
89284219|NCT05519449|Experimental|Dose Escalation|IV dosing during 21- or 28-day cycles. Dosage per cohort will increase to determine the maximum tolerable dose.
89284220|NCT05519449|Experimental|Backfill Expansion|IV dosing during 21- or 28-day cycles. Subjects will be dosed at levels previously declared tolerable.
89284221|NCT05519449|Experimental|Expansion|IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose (RP2D).
89284222|NCT05509296|Experimental|SINOMED CBC|Cutting balloon catheter (Sino Medical Sciences Technology Inc.)
89284223|NCT05509296|Active Comparator|NSE Coronary Dilatation Catheter|NSE Coronary Dilatation Catheter (Goodman Co.,Ltd)
89284224|NCT05496998|Experimental|Medtronic Intrepid™ TMVR TF System|Medtronic Intrepid™ TMVR TF System
89284225|NCT05496868|Experimental|Reparixin + Standard of care|Reparixin tablets 1200 mg TID (2 tablets x 600 mg TID) as add-on to the standard of care (SoC).
89284226|NCT05496868|Placebo Comparator|Placebo + Standard of care|Placebo tablets with the same schedule of reparixin, as add-on to the standard of care (SoC)
89284227|NCT05488639||Football players at the FIFA U-20 Women's World Cup 2022.|"Upper age limit: all players must be a maximum of 20 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or after 1 January 2002).~Lower age limit: all players must be at least 16 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or before 31 December 2006)."
89284228|NCT05488639||Football players at the FIFA U-17 Women's World Cup 2022.|"Upper age limit: all players must be a maximum of 17 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or after 1 January 2005).~Lower age limit: all players must be at least 15 years old by the end of the calendar year in which the World Cup 2022 is played (i.e. all players of the teams were born on or before 31 December 2007)."
89284229|NCT05480306|Experimental|Treatment|DKN-01 + FOLFIRI or FOLFOX + bevacizumab
89284230|NCT05480306|Active Comparator|Control|FOLFIRI or FOLFOX + bevacizumab
89284231|NCT05471596||NeuWave Microwave Ablation System|Patients who underwent a Microwave Ablation at a participating institution and a NeuWave generator was utilized.
89284232|NCT05470920|Experimental|Electronic decision aid arm|Receive decision aid followed by an appointment with their oncologist.
89284233|NCT05470920|Active Comparator|Genetic counselor Arm|Receive pretest counseling with a genetic counselor.
89290270|NCT00255047|Experimental|Study Group 4: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
89284234|NCT05467371|Experimental|Parenting Action Plan|The parenting action plan is a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby. Maternal caregivers will receive the booklet via mail and a trained research staff member will virtually go over the booklet using motivational interviewing strategies
89284235|NCT05467371|Active Comparator|Safe Kids Home Safety Checklist|The Safe Kids Home Safety Checklist is a handout with information that focuses on home safety for parents of young children. Maternal caregivers will receive the handout via mail and a trained research staff member will virtually go over the handout with the parent using educational strategies.
89284236|NCT05464420|Experimental|V116 Lot 1|Participants will receive a single 0.5 mL intramuscular (IM) dose of V116 Lot 1 on Day 1.
89284237|NCT05464420|Experimental|V116 Lot 2|Participants will receive a single 0.5 mL IM dose of V116 Lot 2 on Day 1.
89284238|NCT05464420|Experimental|V116 Lot 3|Participants will receive a single 0.5 mL IM dose of V116 Lot 3 on Day 1.
89284239|NCT05464420|Active Comparator|PPSV23|Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
89284240|NCT05464121|Experimental|Blended intervention for AjD.|Blended intervention for AjD. Main components: psychoeducation, techniques for regulating emotions, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention.
89284241|NCT05461794|Experimental|Arm A: Sitravatinib + Tislelizumab|Sitravatinib administered orally and tislelizumab administered intravenously
89284242|NCT05461794|Experimental|Arm B: Sitravatinib|Sitravatinib administered orally
89284243|NCT05461794|Experimental|Arm C: Investigator-chosen Chemotherapy|Docetaxel or Irinotecan
89284244|NCT05459207|Experimental|Moderate Fat Meal, Followed by High Fat Meal Group|Participants will receive a moderate fat meal, followed by a high fat meal approximately seven days apart.
89284245|NCT05459207|Experimental|High Fat Meal, Followed by Moderate Fat Meal Group|Participants will receive a high fat meal, followed by a moderate fat meal approximately seven days apart.
89284246|NCT05455619|Experimental|Evexomostat|Each subject will receive repeat doses (C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
89284247|NCT05455489||FUNCTIONAL MR|Patients with symptomatic severe secondary MR (3-4+, according to the multiparametric study algorithm), both ischemic or non-ischemic etiology, on optimal medical therapy
89284248|NCT05455489||DEGENERATIVE MR|Patients with symptomatic severe primary MR (3-4+, according to the multiparametric study algorithm)
89284249|NCT05448105|Experimental|My Diabetes Care (MDC) Mobile|Patients have access to a patient web portal embedded with the My Diabetes Care (MDC) intervention.
89284250|NCT05437250||CLL patients treated with acalabrutinib at their physician's discretion|In each center, all patients meeting the inclusion criteria and no exclusion criteria will be offered to participate in this study.
89284251|NCT05435352||Early TNBC patient Cohort A|"Early TNBC patients receiving neoadjuvant therapy and providing core needle biopsy.~Any approved neoadjuvant therapy can be used based on physician's choice."
89284252|NCT05435352||Early TNBC patient Cohort B|"Early TNBC patients receiving neoadjuvant therapy and providing core needle biopsy and blood.~Any approved neoadjuvant therapy can be used based on physician's choice."
89284253|NCT05427929|Experimental|NVR 4mm Edi Catheter|
89284254|NCT05426265|Experimental|MEL-T01|MEL-T01 is a game-based digital-therapeutics (DTx) medical software device that implements personalised cognitive training to alleviate MDD symptoms and improve cognitive performance in MDD subjects.
89284255|NCT05426265|Active Comparator|MEL-S01|MEL-S01 is an active comparator similar to MEL-T01 but without personalized cognitive training elements.
89284256|NCT05426265|No Intervention|TAU|Treatment-as-usual.
89284257|NCT05424562||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label.
89284258|NCT05417737||Ozone group|Patients treated with ozone as adjuvant palliative therapy. The procedure of ozone administration, dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
89284259|NCT05413850|Experimental|Phase 1, Cohort A|Subjects with PSMA positive disease will receive 5.55GBq of 177Lu-rhPSMA-10.1 (maximum of 3 cycles).
89284260|NCT05413850|Experimental|Phase 1, Cohort B|Subjects with PSMA positive disease will receive 7.4GBq of 177Lu-rhPSMA-10.1 (maximum of 3 cycles).
89284261|NCT05413850|Experimental|Phase 2, Cohort 1, post-chemotherapy mCRPC|Subjects with PSMA positive disease will receive up to 6 cycles of the Therapeutic IMP at the Recommended Phase 2 dose [RP2D]
89284262|NCT05413850|Experimental|Phase 2, Cohort 2, Taxane-naïve mCRPC|Subjects with PSMA positive disease will receive up to 6 cycles of the Therapeutic IMP at the Recommended Phase 2 dose [RP2D] .
89284263|NCT05411367|Experimental|SI-614|
89284264|NCT05411367|Placebo Comparator|Vehicle|
89284265|NCT05401097|Experimental|Arm A (IDHi+Aza followed by Ven+aza)|For IDH1 mutated AML patients randomized to first-line therapy with IDHi+aza, patients will receive Ivosidenib 500mg po orally daily on Days 1-28 of each 28 day cycle. For IDH2 mutated AML patients randomized to first-line therapy with IDHi+aza, patients will receive Enasidenib 100mg po orally daily on Days 1-28 of each 28 day cycle. Azacitidine will be given to both groups intravenously or subcutaneously at 75mg/m2 daily on days 1-7 or 1-5/8-9 of each 28 day cycle. Subsequent cycles after CR/CRi/CRh/MLFS achievement may be adjusted in timing and dosing.
89284266|NCT05401097|Experimental|Arm B (Ven+aza followed by IDHi+aza)|For both IDH1 and IDH2 mutated AML patient randomized to first-line therapy with Ven+aza, patients will receive venetoclax dosing with the ramp-up and dosing per the FDA-label (based off of concurrent drug interactions). Azacitidine will be given intravenously at 75mg/m2 daily on days 1-7 of each 28-day cycle. Subsequent cycles after CR/CRi/CRh/MLFS achievement may be adjusted in timing and dosing.
89284267|NCT05399992||Inclisiran cohort|Participants prescribed inclisiran in combination with Standard of Care (SoC)
89284268|NCT05399992||SoC cohort|Participants prescribed standard of Care (SoC) only. Patients can be treated with maximum tolerated dose of statins and/or with add-on therapy with ezetimibe, PCSK9 inhibitors (alirocumab or evolocumab), fibrates, bempedoic acid or bile acid sequestrants, but not inclisiran.
89290271|NCT01220622|Active Comparator|Nimodipine|
89290272|NCT01220622|Placebo Comparator|Placebo|
89284269|NCT05399485|Experimental|Rimegepant|Randomization Phase: one 75 mg rimegepant (BHV3000) oral disintegration tablet every other day until Week 12
89284270|NCT05399485|Placebo Comparator|Placebo|Randomization Phase: one matching placebo every other day until week 12
89284271|NCT05394285|Experimental|hetrombopag Olamine tablets|"The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were <50*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is >100*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days."
89284272|NCT05394285|Other|rhTPO|"The first chemotherapy cycle (single center, open label, randomized controlled):~Start using rh-TPO 15000 units/day (subcutaneous injection) when platelets are less than 50*109/L. When the platelet count is more than 100*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days."
89284273|NCT05393739|Experimental|Intermittent theta burst|The total TBS time is about 1 to 3 minutes and the subjects have to look at at a visual stimulus on a computer monitor while receiving TBS and continue the visual training until 20 minutes after the treatment. In iTBS group, the subjects look at the visual stimulus with amblyopic eye while in cTBS group, subjects look at visual stimulus with non-amblyopic eye. The subjects will receive three times of stimulations in one week. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
89284274|NCT05393739|Experimental|Continuous theta burst|The total TBS time is about 1 to 3 minutes and the subjects have to look at at a visual stimulus on a computer monitor while receiving TBS and continue the visual training until 20 minutes after the treatment. In iTBS group, the subjects look at the visual stimulus with amblyopic eye while in cTBS group, subjects look at visual stimulus with non-amblyopic eye. The subjects will receive three times of stimulations in one week. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
89284275|NCT05393739|Sham Comparator|Sham theta burst|The stimulus intensity in sham group is about half of that in iTBS/cTBS groups, and the subjects receive a placebo stimulation with the coil orientation tilted to 90°. The visual function evaluation includes BCVA, contrast sensitivity and stereoacuity. Visual functions will be evaluated right after TBS session (t1). Participant will receive same type of treatment for another 2 times within one week followed by visual function tests (t2). To evaluate the long-term effect, participants will be followed for another visual function tests (t3) after 2 weeks.
89284276|NCT05393648|Experimental|Active iTBS|Patients will receive unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
89284277|NCT05393648|Placebo Comparator|Sham iTBS|Patients will receive sham unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
89284278|NCT05388370||Base Cohort|The Base Cohort includes all enrolled patients aged 3 to < 18 years.
89284279|NCT05388370||Nested Prospective Cohort|The Nested Prospective Cohort will include the subset of Base Cohort patients aged 8 to < 18 years who have not reached Tanner Stage V on the index date
89284280|NCT05387096|Sham Comparator|Control: standard pharmaceutical care|Patients in the control arm (standard pharmaceutical care) will receive a sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire
89284281|NCT05387096|Active Comparator|trained physician-implemented intervention|The definitive multi-faceted intervention delivered by a trained physician.
89284282|NCT05387096|Active Comparator|clinical pharmacist-implemented intervention|The definitive multi-faceted intervention delivered by a trained pharmacist.
89284283|NCT05384249|Placebo Comparator|Group 1: Placebo subcutaneous once weekly|Participants will receive placebo every week to week 51.
89284284|NCT05384249|Experimental|Group 2: Izokibep subcutaneous once weekly|Participants will receive izokibep every week to week 51.
89284285|NCT05372601|Experimental|Relax+|Relax+ consists of a powder containing a blend of two prebiotics.
89284286|NCT05372601|Placebo Comparator|Placebo|The placebo contains maltodextrin.
89284287|NCT05353257|Experimental|Serplulimab + carboplatin/cisplatin-etoposide + radiotherapy|Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus Serplulimab 300 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
89284288|NCT05353257|Placebo Comparator|placebo + carboplatin/cisplatin-etoposide + radiotherapy|Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus placebo every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
89284289|NCT05353166|Experimental|Group A|Randomized 1:1; limited to participants with heart failure with reduced ejection fraction (HFrEF) not taking sacubitril/valsartan
89284290|NCT05353166|Experimental|Group B|Randomized 1:1; limited to participants with HFrEF taking sacubitril/valsartan
89284291|NCT05353166|Experimental|Group C|Randomized 1:1; limited to participants with heart failure with preserved ejection fraction (HFpEF) not taking sacubitril/valsartan
89284292|NCT05348330|Experimental|Thoracic intervertebral foramen block|Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain.
89284293|NCT05348330|Active Comparator|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain.
89284294|NCT05347238||Dopamine Units|Units who have standardized their practice with the use of Dopamine as a first line agent.
89284295|NCT05347238||Norepinephrine Units|Units who have standardized their practice with the use of Norepinephrine as a first line agent.
89284296|NCT05339412|Experimental|Technology Based Training Tool Only|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
89284297|NCT05339412|Experimental|Technology Based Training Tool plus Live Supervision|Participants randomized to this condition will receive (in addition to the training tool described above) access to live supervision delivered remotely via commercially available video conferencing software (Zoom). Facilitators-in-training will complete two mock roleplays of curriculum activities, which can be conducted live via Zoom with PHAT Life trainers (either Dr. Floyd or Dr. Snow-Hill) or can be recorded and submitted via the app. Trainers will review for fidelity and provide feedback. During the supervision sessions, participants will have the opportunity to clarify content, ask questions, roleplay group sessions to practice difficult parts of the group sessions, and review feedback on role plays.
89284298|NCT05335252|Experimental|Dronabinol|Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
89284299|NCT05335252|Placebo Comparator|Placebo|Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
89284300|NCT05331300|Experimental|LASN01|
89284301|NCT05331300|Placebo Comparator|Placebo|
89284302|NCT05327270|Experimental|Nivolumab|Nivolumab will be given as an injection directly into an oral lesion.
89284303|NCT05321420|Placebo Comparator|Placebo|Placebo oral administration
89284304|NCT05321420|Active Comparator|pirfenidone 801 mg TID|pirfenidone 801 mg TID oral administration
89284305|NCT05321420|Experimental|LYT-100 550 mg TID|LYT-100 (Deupirfenidone) 550 mg TID oral administration
89284306|NCT05321420|Experimental|LYT-100 825 mg TID|LYT-100 (Deupirfenidone) 825 mg TID oral administration
89284307|NCT05315713|Experimental|Subcutaneous (SC) Mosunetuzumab in Combination with Intravenous (IV) Tiragolumab|Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
89284308|NCT05315713|Experimental|Mosunetuzumab SC in Combination with Tiragolumab IV and Atezolizumab IV|Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
89284309|NCT05307640|Experimental|CG-Well|CG-Well is a web & phone based psychosocial intervention that teaches caregivers how to obtain information, education & support
89284310|NCT05307640|Placebo Comparator|Information Support and Referral|Attention control group that receives phone calls and modules from the Brain Injury Association of America.
89284311|NCT05298254|Experimental|Non-adjuvanted HSV formulation 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 1 vaccine, one at Day 1 and one at Day 29.
89284312|NCT05298254|Experimental|Non-adjuvanted HSV formulation 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 2 vaccine, one at Day 1 and one at Day 29.
89284313|NCT05298254|Experimental|Non-adjuvanted HSV formulation 3 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the non-adjuvanted HSV formulation 3 vaccine, one at Day 1 and one at Day 29.
89284314|NCT05298254|Experimental|HSV formulation 1 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 1 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
89284315|NCT05298254|Experimental|HSV formulation 2 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 2 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
89284316|NCT05298254|Experimental|HSV formulation 3 with adjuvant 1 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 3 with adjuvant 1 vaccine, one at Day 1 and one at Day 29.
89284317|NCT05298254|Experimental|HSV formulation 1 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 1 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
89284318|NCT05298254|Experimental|HSV formulation 2 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 2 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
89284319|NCT05298254|Experimental|HSV formulation 3 with adjuvant 2 - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of the HSV formulation 3 with adjuvant 2 vaccine, one at Day 1 and one at Day 29.
89284320|NCT05298254|Placebo Comparator|Placebo - Part I Group|Participants enrolled in Part I of the study who receive 2 doses of Placebo, one at Day 1 and one at Day 29.
89284321|NCT05298254|Experimental|HSVTI formulation (F) 1 - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of the formulation of the HSVTI_F1 selected from Part I of the study, one at Day 1 and one at Day 29.
89284322|NCT05298254|Experimental|HSVTI_F2 - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of the HSVTI_F2 selected from Part I of the study, one at Day 1 and one at Day 29.
89284323|NCT05298254|Placebo Comparator|Placebo - Part II Group|Participants enrolled in Part II of the study who receive 2 doses of Placebo, one at Day 1 and one at Day 29.
89284324|NCT05297305|Active Comparator|Onlay Component-Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
89284325|NCT05297305|Active Comparator|Inlay Component-Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
89284326|NCT05295173|Experimental|experimental group|Recombinant human tissue plasminogen kinase derivatives(r-PA) for injection: the first intravenous bolus injection of 18mg, after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time. Subjects were closely monitored during the treatment period and within 24 hours after administration.
89284327|NCT05295173|Active Comparator|comparative group|Recombinant human tissue plasminogen activator (rt-PA) for injection: 0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours after administration.
89284328|NCT05293886|Active Comparator|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
89284329|NCT05293886|Experimental|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
89284330|NCT05286307|Experimental|Participants receiving IPACK block|Patients in this study group will receive the standard of care adductor canal block composed of 15 mL of Bupivacaine (0.25%). And receive the additional IPACK block performed using 20 mL of Bupivacaine (0.25%) injected into the interspace between the popliteal artery and capsule of the knee.
89284331|NCT05286307|No Intervention|Standard of care group|Patients in the control group will receive the standard of care adductor canal block composed of 15 mL of Bupivacaine (0.25%).
89284332|NCT05258929||Hematological patients who underwent allograft|Patients who underwent allograft and then relapsed
89284333|NCT05254990|Experimental|Reparixin + standard of care|"Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) TID (6 tablets daily) for up to 21 days.~The three daily doses will be administered maintaining an interval between doses of about 8 hours."
89284334|NCT05254990|Placebo Comparator|Placebo + standard of care|Placebo tablets are identical in appearance to the active formulation. Placebo will be administered with the same treatment schedule.
89284335|NCT05247398|Experimental|Dynamic Stability Exercise Program|Involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults. The intervention focuses on enhancing mobility and strength of the thumb for use during daily activities.
89284336|NCT05240469|No Intervention|Standard sperm selection|In the control group the oocytes will be injected with sperm that is selected by embryologists using conventional methods in the IVF lab.
89284337|NCT05240469|Experimental|Automated sperm selection|The only intervention is the additional sperm selection step using software immediately prior to ICSI.
89284338|NCT05237505|Experimental|Oxygen|OVS subjects will receive treatment with oxygen during night time for 6 months
89284339|NCT05237505|Experimental|Bi-level positive pressure non invasive ventilation|OVS subjects will receive treatment with bi-level PAP therapy during night time for 6 months
89284340|NCT05232344|Experimental|Estradiol / Progesterone treatment|Estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) Vaginal progesterone (400 mg, Progestan®, evening and morning, ie 800 mg per day).
89284341|NCT05222906|Experimental|Venglustat|Venglustat
89284342|NCT05222906|Active Comparator|Cerezyme|Cerezyme
89284343|NCT05210439|Experimental|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment from the date of the last positive blood culture
89284344|NCT05210439|Active Comparator|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment from the date of the last positive blood culture
89284345|NCT05198934|Experimental|Arm A: Sotorasib 960 mg QD + panitumumab|
89284346|NCT05198934|Experimental|Arm B: Sotorasib 240 mg QD + panitumumab|
89284347|NCT05198934|Active Comparator|Arm C : Investigator's choice|Participants will be administered trifluridine and tipiracil, or regorafenib
89284348|NCT05194462|Active Comparator|Pelvic Floor Physical Therapy (PFPT)|6 sessions of PFPT over a 12 week period with planned home exercises as per physical therapist's recommendation.
89284349|NCT05194462|Active Comparator|Biofeedback device|Pericoach® by Analytica is a vaginal device with recommendation for daily use during the 12 week period.
89284350|NCT05193552|No Intervention|Control Group|11 subjects will be treated for 6 months at their current dose of Hizentra
89284351|NCT05193552|Experimental|Treatment Group|11 subjects will have their level of immunoglobulin replacement therapy increased by the equivalent of 0.05 gm/kg in dose per 4 weeks, adjusted for bioavailability as per manufacturer's instructions. On average, rounded up to the nearest gram, this will typically increase their dose of Hizentra by 2 gm per week.
89284352|NCT05184881|Active Comparator|Group medial branch block|cervical medial branch block will done at the affected dermatomal level using 1 mL of a mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml).
89284353|NCT05184881|Active Comparator|Group retrolaminar block|cervical retrolaminar block was done using 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) for each affected dermatomal level.
89284354|NCT05173012|Placebo Comparator|SAGE-324 Matched Placebo|"Participants will receive SAGE-324 matched placebo, stratified by baseline propranolol use.~Monotherapy:~Participants will receive SAGE-324 matched placebo, oral tablets, once daily (QD), in the evening, from Day 1 to Day 90 in a double-blind treatment period.~Adjunct therapy:~Participants will receive SAGE-324 matched placebo, oral tablets, QD, in the evening, from Day 1 to Day 90 along with a stable dose of up to 320 milligrams (mg) of propranolol from 3 months prior to Screening up to Day 90 in a double-blind treatment period."
89290273|NCT05123170|Active Comparator|Group I|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) alone diluted with normal saline 0.9% to make the final volume 30 ml
89284355|NCT05173012|Experimental|SAGE-324 15 mg|"Participants will receive SAGE-324, 15 mg, stratified by baseline propranolol use.~Monotherapy:~Participants will receive SAGE-324, 15 mg, oral tablets, QD, in the evening, from Day 1 to Day 90 in a double-blind treatment period.~Adjunct therapy:~Participants will receive SAGE-324, 15 mg, oral tablets, QD, in the evening, from Day 1 to Day 90 along with a stable dose of up to 320 mg of propranolol from 3 months prior to Screening up to Day 90 in a double-blind treatment period."
89284356|NCT05173012|Experimental|SAGE-324 30 mg|"Participants will receive SAGE-324, 30 mg, stratified by baseline propranolol use.~Monotherapy:~Participants will receive SAGE-324, 30 mg, oral tablets, QD, in the evening, from Day 1 to Day 90 in a double-blind treatment period.~Adjunct therapy:~Participants will receive SAGE-324, 30 mg, oral tablets, QD, in the evening, from Day 1 to Day 90 along with a stable dose of up to 320 mg of propranolol from 3 months prior to Screening up to Day 90 in a double-blind treatment period."
89284357|NCT05173012|Experimental|SAGE-324 60 mg|"Participants will receive SAGE-324: 15 mg, 30 mg, 45 mg, and 60 mg, stratified by baseline propranolol use.~Monotherapy:~Participants will receive SAGE-324, 15 mg from Day 1 to 14, followed by up-titration to 30 mg from Day 15 to 28, then to 45 mg from Day 29 to 42, and then to 60 mg from Day 43 to 90, oral tablets, QD, in the evening, from Day 1 to Day 90 in a double-blind treatment period.~Adjunct therapy:~Participants will receive SAGE-324, 15 mg from Day 1 to 14, followed by up-titration to 30 mg from Day 15 to 28, then to 45 mg from Day 29 to 42, and then to 60 mg from Day 43 to 90, oral tablets, QD, in the evening, from Day 1 to Day 90 along with a stable dose of up to 320 mg of propranolol from 3 months prior to Screening up to Day 90 in a double-blind treatment period."
89284358|NCT05171907|No Intervention|Control Group|Patients into the control group will receive the same assessments as patients in the intervention group, for the same time (in 1th, 8th, 24, and 48 weeks), but they will not receive nutritional teleconsultation.
89284359|NCT05171907|Other|Intervention Group|Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
89284360|NCT05171777|Experimental|Treatment A|Participants will receive atezolizumab SC followed by atezolizumab IV.
89284361|NCT05171777|Experimental|Treatment B|Participants will receive atezolizumab IV followed by atezolizumab SC.
89284362|NCT05170464|Experimental|Acute Exercise|20 minutes of moderate intensity acute exercise (treadmill speed to achieve ⅔ of maximum heart rate).
89284363|NCT05170464|Active Comparator|Caffeine Ingestion|1.2mg/kg of powdered caffeine (Caffeine powder, ReagentPlus® from Sigma-Aldrich) dissolved in 1 cup of water then sitting for 20 minutes.
89284364|NCT05155605|Experimental|Participants 50 years of age or older|The study will aim to enroll a diverse participant population generally representative of the US population with respect to race, ethnicity, and sex. The target age categories of 60-69 years and 70-79 years will be enriched to increase the number of cancer events that are observed during the study.
89284365|NCT05155098||secukinumab|Patients receiving secukinumab in real world practice
89284366|NCT05147662|Experimental|Main study (Part A) and the extension study (Part B)|Part A will last for 6 months. After completing Part A participants will continue in the extension study for another 18 months.
89284367|NCT05144503|Experimental|SpherePVI™ Catheter|Subjects treated with the SpherePVI™ Catheter
89284368|NCT05131646||Cohort 2 (Low-mid Dose) Extension|Subjects who were administered by suprachoroidal injection 0.10 mg CLS-AX in cohort 2 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
89284369|NCT05131646||Cohort 3 (High-mid Dose) Extension|Subjects who were administered by suprachoroidal injection 0.50 mg CLS-AX in cohort 3 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
89284370|NCT05131646||Cohort 4 (High Dose) Extension|Subjects who were administered by suprachoroidal injection 1.0 mg CLS-AX in cohort 4 of the parent study, CLS1002-101, will be followed for an additional 12 weeks following exit from the Parent study. No intervention will be administered in this extension study.
89284371|NCT05124002|Experimental|H101+HAIC|"Recombinant Human Adenovirus Type 5 (H101): intratumorally injected 3 days before HAIC. 1 vial (5.0 × 10^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10^12 vp) if the maximum diameters of lesion is > 10 cm.~HAIC (FOLFOX): Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium"
89284372|NCT05123586|Experimental|LY3361237|Participants are administered LY3361237 subcutaneously (SC) and standard of care (SOC)
89284373|NCT05123586|Placebo Comparator|Placebo|Placebo administered SC and SOC given at matching intervals
89284374|NCT05122650|Experimental|10 milligram (mg) JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.
89284375|NCT05122650|Experimental|20 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.
89284376|NCT05122650|Experimental|30 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.
89284377|NCT05122650|Placebo Comparator|Placebo|Participants will receive placebo from Day 1.
89284378|NCT05119140|Experimental|Mesalamine and Hydroxychloroquine|All participants will be on Mesalamine and Hydroxychloroquine
89284379|NCT05116202|Active Comparator|Cohort 1: Nivolumab + Ipilimumab|Cohort 1 participants in the nivolumab plus ipilimumab arm will receive treatment for 2 cycles (6 weeks) on Day 1 of each cycle (cycle length 21 days) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
89284380|NCT05116202|Experimental|Cohort 1: RO7247669 2100 mg|Cohort 1 participants in the RO7247669 arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
89284381|NCT05116202|Experimental|Cohort 1: + Atezolizumab + Tiragolumab|Cohort 1 participants in the atezolizumab plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
89284382|NCT05116202|Experimental|Cohort 1: RO7247669 2100 mg + Tiragolumab|Cohort 1 participants in the RO7247669 plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
89284383|NCT05116202|Experimental|Cohort 2: RO7247669 2100 mg + Tiragolumab|Cohort 2 participants in RO7247669 plus tiragolumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
89284384|NCT05116202|Experimental|Cohort 1: RO7247669 600 mg|Cohort 1 participants in the RO7247669 arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
89284385|NCT05116202|Experimental|Cohort 1: RO7247669 600 mg + Tiragolumab|Cohort 1 participants in the RO7247669 plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
89284386|NCT05115214|Experimental|SpherePVI™ Catheter|Subjects treated with the SpherePVI™ Catheter
89284387|NCT05112965|Experimental|Atezolizumab Monotherapy|Participants will continue to receive atezolizumab monotherapy as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
89284388|NCT05112965|Experimental|Combined Agents with Atezolizumab|Participants will continue to receive atezolizumab with other agent(s) as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
89284389|NCT05112965|Active Comparator|Comparator Treatment|Participants will continue to receive comparator agent(s) as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
89284390|NCT05105152|Experimental|DARIC-33|
89284391|NCT05103280|Experimental|Progressive improvement in walking performance|A total of ten patients with peripheral artery disease will be enrolled for this arm and wear the assistive tennis shoes for three-months as an intervention.
89284392|NCT05101018|Experimental|Romosozumab Baseline to Month 11 followed by Denosumab Month 12 to Month 24|"Of the forty (40) individuals with subacute spinal cord injury (SCI) enrolled in this study, twenty (20) participants will be randomly selected to receive romosozumab (210mg SQ) once a month for 12 months.~After 12 months the same twenty (20) individuals will receive denosumab (60mg SQ) at month 12 and 18."
89284393|NCT05101018|Active Comparator|Denosumab Baseline to Month 24|Of the forty (40) individuals with subacute spinal cord injury (SCI) enrolled in this study, twenty (20) participants will be randomly selected to receive denosumab (60 mg SQ) at baseline and 6, 12, and 18 months.
89284394|NCT05091684|Experimental|Fibrinogen|Patients with refractory thrombocytopenia, following intensive chemotherapy, and presenting grade ≥ 2 hemorrhagic symptoms, will receive adjuvant fibrinogen administration and platelet transfusions.
89284395|NCT05083403|Experimental|HPI Arm|AcumenTM HPI Software Feature to guide hemodynamic management in cardiac surgery post-CPB
89284396|NCT05083403|Placebo Comparator|Non-HPI Arm|Non-protocolized standard of care management per clinician and provider judgement.
89284397|NCT05062044||Multivitamins usage in pregravidal preparation|Participants start use of Elevit multiple micronutrient (MMN) before pregnancy.
89284398|NCT05062044||Multivitamins usage during pregnancy|Participants start use of Elevit multiple micronutrient (MMN) in the first trimester of pregnancy.
89284399|NCT05062044||Folic acid usage during pregnancy|Participants use folic acid in accordance with clinical guidelines.
89284400|NCT05060016|Experimental|Part 1: Tarlatamab Low Dose|Participants will receive the low dose of Tarlatamab.
89284401|NCT05060016|Experimental|Part 1: Tarlatamab High Dose|Participants will receive the high dose of Tarlatamab.
89284402|NCT05060016|Experimental|Part 2: Dose Expansion|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1.
89284403|NCT05060016|Experimental|Part 3: Modified Monitoring Substudy|Participants will receive the selected target dose of Tarlatamab based on findings in Part 1 with reduced Cycle 1 monitoring requirements.
89284404|NCT05059236|Experimental|Darolutamide+ADT|Participants will receive darolutamide plus ADT in the ARASEC treatment arm. The control arm for the study will be derived from the participants treated with ADT alone in the CHAARTED trial using a matching approach
89284405|NCT05058755|Experimental|TALE regimen|tislelizumab plus azacytidine and lenalidomide
89284406|NCT05058755|Experimental|TEPA regimen|tislelizumab plus etoposide and pegaspargase
89284407|NCT05050110|Other|chronic kidney disease patients|Evaluation of Increased fruits and vegetables consumption in chronic kidney disease patients maintaining normokalemia with patiromer
89284408|NCT05047250|Experimental|Atezolizumab|Participants will receive IV infusion of atezolizumab on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
89284409|NCT05047068||OCS DBD Heart Primary Analysis Population|"200 adult primary heart transplant recipients of OCS perfused DBD donor hearts that meet the FDA-approved indication for use except for the following recipient exclusion criteria:~Concurrent (multi-organ transplant) or previous solid organ or bone marrow transplant; or~On renal dialysis at time of transplant"
89284410|NCT05047068||OCS DCD Heart Primary Analysis Population|"150 adult primary heart transplant recipients of OCS perfused DCD donor hearts that meet the FDA-approved indication for use except for the following recipient exclusion criteria:~Concurrent (multi-organ transplant) or previous solid organ or bone marrow transplant; or~On renal dialysis at time of transplant~Transplanted with DCD heart with warm ischemic time > 30 minutes (warm ischemic time is defined as: Time from when mean systolic blood pressure (SBP) is < 50 mmHg or peripheral saturation < 70% to aortic cross-clamp and administration of cold cardioplegia in the donor)."
89284411|NCT05047068||Other OCS Heart Analysis Population|Any/all other recipients of OCS Heart perfused donor hearts outside of the DBD and DCD indications above will be collected in the respective arm of this registry until the enrollment of the PAP of that arm is completed (200 for DBD and 150 for DCD).
89284412|NCT05039177|Experimental|Dose Escalation (Parts A1a, A2a, or A3a): ERAS-007 in combination with encorafenib and cetuximab|ERAS-007 will be orally administered in combination with encorafenib and cetuximab to study participants with BRAFm CRC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
89284413|NCT05039177|Experimental|Dose Escalation (Parts B1a, B2a, B3a or B4a): ERAS-007 in combination with palbociclib|ERAS-007 will be orally administered in combination with palbociclib to study participants with KRASm or NRASm CRC and KRASm PDAC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
89284414|NCT05039177|Experimental|Dose Expan (Parts A1b, A1c, A2b, A2c, A3b, or A3c): ERAS-007 in combo with encorafenib & cetuximab|ERAS-007 will be orally administered at the recommended dose (as determined from Parts A1a, A2a or A3a) in combination with encorafenib and cetuximab to study participants with BRAFm CRC.
89284415|NCT05039177|Experimental|Dose Expansion (Parts B1b, B2b, B3b, and B4b): ERAS-007 in combination with palbociclib|ERAS-007 will be orally administered at the recommended dose (as determined from Parts B1a, B2a, B3a or B4a) in combination with palbociclib to study participants with KRASm or NRASm CRC.
89284416|NCT05038202|Experimental|Bencycloquidium Bromide|Bencycloquidium Bromide Nasal Spray (90μg per spray)：1 spray on each nostril, 4times per day, continuous treatment for 4 weeks (28days).
89284417|NCT05038202|Active Comparator|Mometasone Furoate Aqueous|Mometasone Furoate Aqueous Nasal Spray (50μg per spray)：2 sprays on each nostril, 1 time per day, continuous treatment for 4 weeks (28days).
89284418|NCT05038202|Experimental|Bencycloquidium Bromide with Mometasone Furoate Aqueous|Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray: For Bencycloquidium Bromide Nasal Spray(90μg per spray), 1 spray on each nostril, 4times per day. For Mometasone Furoate Aqueous Nasal Spray (50μg per spray), 2 sprays on each nostril, 1 time per day. If there is an overlap between the two drugs, use Bencycloquidium Bromide Nasal Spray first, and then mometasone furoate nasal spray should be used after an interval of more than 30 minutes.
89284419|NCT05021835|Experimental|Ziltivekimab|Participants will receive 15 milligrams (mg) of either Ziltivekimab B or Ziltivekimab C subcutaneously using single-use pre-filled DV3430-C1 manual syringe or single-dose DV3430-C3 pen-injector respectively once monthly for up to 4 years.
89284420|NCT05021835|Placebo Comparator|Placebo|Participants will receive 15 mg of either placebo (Ziltivekimab B) or placebo (Ziltivekimab C) subcutaneously using single-use pre-filled DV3430-C1 manual syringe or single-dose DV3430-C3 pen-injector respectively once monthly for up to 4 years.
89284421|NCT05020015|Experimental|Part 1: Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 200×10^6 anti-CD19 chimeric antigen receptor (CD19-CAR+) viable NK cells, single-dose, intravenously, once on Day 0.
89284422|NCT05020015|Experimental|Part 1: Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells|Participants will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 800×10^6 CD19-CAR+ viable NK cells, single-dose, intravenously, once on Day 0.
89284423|NCT05020015|Experimental|Part 1: Dose Expansion: Cohort 1A (LBCL 3L+): TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ viable NK cells, single-dose, intravenously, once on Day 0 to determine RP2D.
89284424|NCT05020015|Experimental|Part 1: Dose Expansion: Cohort 2A (iNHL 3L+): TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Indolent Non-Hodgkin Lymphoma (iNHL) will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 200×10^6/ 800×10^6 CD19-CAR+ viable NK cells, single-dose, intravenously, once on Day 0 to determine RP2D.
89284425|NCT05020015|Experimental|Part 1: Dose Expansion: Cohort 1B (LBCL 3L+): TAK-007- 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 800×10^6 CD19-CAR+ viable NK cells, intravenously, once on Days 0, 7 and 14 to determine RP2D.
89284426|NCT05020015|Experimental|Part 1: Dose Expansion: Cohort 1C (LBCL 2L): TAK-007- 800×10^6 CD19-CAR+ Viable NK Cells|Participants with r/r Large B-cell Lymphoma (LBCL) will receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 - 800×10^6 CD19-CAR+ viable NK cells, intravenously, once on Days 0, 7 and 14 to determine RP2D.
89284427|NCT05020015|Experimental|Part 2: Cohort 1- LBCL|Participants with LBCL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 at the RP2D, intravenously.
89284428|NCT05020015|Experimental|Part 2: Cohort 2- iNHL|Participants with iNHL will be enrolled in this cohort to receive lymphodepleting chemotherapy per day intravenously for 3 days followed by TAK-007 at the RP2D, intravenously.
89284429|NCT05017935|Experimental|Renal Denervation|
89284430|NCT05009342|Experimental|Below-knee soft resin cast|"Below-knee soft resin cast is administered to participants in emergency department. Investigator puts three layers of jersey supplemented by strips of soft resins to be unrolled along the leg after immersion in warm water~Duration to ankle immobilization with soft resin boot : 21 days."
89284431|NCT05009342|Other|Below-knee rigid resin cast|"Below-knee soft resin cast is administered to participants in emergency department. Investigator puts one layer of jersey and then one layer of foam composed by strips of cotton wool to be unrolled supplemented by strips of rigid resins to be unrolled along the leg after immersion in warm water.~Duration to ankle immobilization with soft resin boot : 21 days."
89284432|NCT04995523|Experimental|Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC)|Rilvegostomig Intravenous (IV) monotherapy
89284433|NCT04995523|Experimental|Dose Expansion Part B: CPI experienced NSCLC|Rilvegostomig IV monotherapy
89284434|NCT04995523|Experimental|Dose Expansion Part C: CPI Naive NSCLC|Rilvegostomig IV monotherapy
89284435|NCT04995523|Experimental|Dose Expansion Part D: CPI Naive NSCLC|Rilvegostomig IV monotherapy
89284436|NCT04968821|Experimental|Physical Activity|Participants randomized to the physical activity intervention will receive usual postoperative care and a tele-health physical activity intervention.
89284437|NCT04968821|Other|Usual Care|Participants randomized to usual care will receive postoperative care as determined by their treating surgeon.
89284438|NCT04962477||Pregnant|
89284439|NCT04962477||Non-pregnant|
89284440|NCT04935879|Experimental|inclacumab, 30 mg/kg|Participants will receive inclacumab 30 mg/kg administered IV every 12 weeks
89284441|NCT04935879|Placebo Comparator|placebo|Participants will receive placebo administered IV every 12 weeks.
89284442|NCT04930159|No Intervention|Enhanced usual care|Written materials in an appealing package.
89284443|NCT04930159|Active Comparator|Facilitated group support|Weekly group gatherings.
89284444|NCT04930159|Active Comparator|1:1 Peer Support|Individual peer support calls.
89284445|NCT04929223|Experimental|Inavolisib + Cetuximab|"Participants will receive 9 milligrams (mg) of inavolisib by mouth once daily (QD) on Days 8-28 of Cycle 1, then QD on Days 1-28 from Cycle 2 onwards (1 cycle=28 days).~Participants will also receive cetuximab intravenous (IV) infusion 400 mg/m2 body surface area on Day 1 of Cycle 1. All subsequent weekly (QW) doses will be 250 mg/m2 each."
89284446|NCT04929223|Experimental|Inavolisib + Bevacizumab|Participants will receive 9 mg of inavolisib by mouth QD combined with bevacizumab 15 milligram/kilogram (mg/kg) IV once every three weeks (Q3W) on Day 1 of each cycle (1 cycle=21 days).
89284447|NCT04929223|Experimental|Atezolizumab + Tiragolumab + Bevacizumab|Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle, combined with tiragolumab at a dose of 600 mg IV infusion on Day 1 of each cycle and bevacizumab IV infusion at a dose of 15 mg/kg on Day 1 of each cycle. (Cycle length=21 days)
89284448|NCT04929223|Experimental|Atezolizumab + Tiragolumab|Participants in this randomized cohort will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle combined with tiragolumab 600 mg IV infusion on Day 1 of each cycle. (Cycle length=21 days)
89284449|NCT04929223|Experimental|Atezolizumab + SY-5609|"Participants will receive 1680 mg of atezolizumab by IV infusion on Day 1 of each cycle Q4W in repeated 28-day cycles combined with SY-5609 at a dose of 3, 4, 5, 6, 7 or 10 mg by mouth for 7 days, followed by 7 days off. (Cycle length=28 days) Open in the United States only.~Enrollment is closed."
89284450|NCT04929223|Experimental|Divarasib + Cetuximab + FOLFOX|Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFOX on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days)
89284451|NCT04929223|Experimental|Divarasib + Cetuximab|Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days)
89284452|NCT04929223|Experimental|Divarasib + Cetuximab + FOLFIRI|Participants will receive cetuximab IV 500 mg/m2 body surface area on Days 1 and 15 and FOLFIRI on Days 1 and 15 with divarasib PO QD on Days 1-28. (Cycle length=28 days)
89284453|NCT04895358|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg administered by intravenous infusion (IV) on Day 1 of each 21-day cycle (Q3W) PLUS one of four chemotherapy regimens: 1) paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle (Q4W), 2) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8, and 15 Q4W, 3) liposomal doxorubicin 50 mg/m^2 IV on Day 1 Q4W, OR 4) capecitabine 1000 mg/m^2 by oral administration (PO) twice a day (BID) on Days 1-14 Q3W for up to 35 administrations.
89284454|NCT04895358|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline or dextrose) IV on Day 1 Q3W PLUS one of four chemotherapy regimens: 1) paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 Q4W, 2) nab-paclitaxel 100 mg/m^2 IV on Days 1, 8, and 15 Q4W, 3) liposomal doxorubicin 50 mg/m^2 IV on Day 1 Q4W, OR 4) capecitabine 1000 mg/m^2 PO BID on Days 1-14 Q3W for up to 35 administrations.
89284455|NCT04867343|Experimental|HR020602 injection|
89284456|NCT04867343|Active Comparator|fentanyl injection + remifentanil injection|
89284457|NCT04867317|Active Comparator|Growth Hormone Replacement Therapy|Recombinant Human Growth Hormone
89284458|NCT04867317|Placebo Comparator|Placebo|Placebo
89284459|NCT04865289|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
89284460|NCT04865289|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
89284461|NCT04858854|Active Comparator|BSE group (Broccoli sprout group)|The BSE Group will receive 50 µmmol/day of sulforaphane administered by BSE (Lantmännen®) from week 0 to week 4. If no side-effects are reported, the sulforaphane dose will increase to 100 µmmol/day from week 5 to week 8 and in the absence of side-effects, the dose will increase to 150 µmmol/day from week 9 to week 12.
89284462|NCT04858854|Placebo Comparator|Control group|The Control Group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for 12 weeks.
89284463|NCT04851964|Experimental|Tezepelumab|Tezepelumab subcutaneous injection, in an accessorized pre-filled syringe.
89284464|NCT04851964|Placebo Comparator|Placebo|Placebo subcutaneous injection, in an accessorized pre-filled syringe.
89284465|NCT04850300|Experimental|Total knee prosthesis 1|prosthesis with medial condylar stabilization
89284466|NCT04850300|Active Comparator|Total knee prosthesis 2|traditional prosthesis with central pivot stabilization
89284467|NCT04829760|Experimental|Psyllium|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to at least 8 ounces (240 mL) of cold water or a beverage that is typically consumed. Participants will ingest the intervention each morning and evening for eight weeks.
89284468|NCT04829760|Experimental|Coarse wheat bran|10 g per day. Participants will be instructed to divide the 10 g into 2 doses and ingest by adding the product to a food they normally eat.
89284469|NCT04829760|Placebo Comparator|Maltodextrin|Volume equivalent to the psyllium. Participants will be instructed to divide the daily dose into 2 doses and ingest by adding the product to a food or to 8 ounces (240 mL) of a beverage that is typically consumed.
89284470|NCT04824547|Active Comparator|Stabilization exercise group|"Spinal stabilization exercise will be applied all patients accompanied by physiotherapist.~Sessions will be included selected exercises according to motor learning phases."
89284471|NCT04824547|Active Comparator|yoga group|Yoga program will be applied all patients in this group accompanied by physiotherapist. Sessions will be included selected breathing exercises, warm up, asana and relaxation.
89284472|NCT04795336|Active Comparator|Knee cohort|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
89284473|NCT04795336|Placebo Comparator|Knee cohort control|In the cohort of patients undergoing primary elective knee arthroplasty, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
89284474|NCT04795336|Active Comparator|Hip cohort|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into intervention group. Intervention group will receive a 5mg Melatonin prescription for 14 days
89284475|NCT04795336|Placebo Comparator|Hip cohort control|In the cohort of patients undergoing primary elective total hip, participants are recruited from those who are willing to consent and participate in the study, and will be randomly recruited into placebo group. Control group will receive a placebo pill for 14 days
89284476|NCT04789681|Experimental|Prevention (canakinumab)|Patients receive canakinumab SC on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89284477|NCT04784442|Experimental|ETC-1002 180mg|
89284478|NCT04784442|Experimental|ETC-1002 120mg|
89284479|NCT04784442|Experimental|ETC-1002 60mg|
89284480|NCT04784442|Placebo Comparator|Placebo|
89284481|NCT04780217|Experimental|Phase 1|T3011 Single Agent Dose Escalation in participants with solid tumors
89284482|NCT04752826|Experimental|Phase I, Part A - Dose escalation and safety of BI-1808 alone|Dose escalation with repeated administrations of BI-1808 infusions as a single agent, in patients with advanced malignacy.
89284483|NCT04752826|Experimental|Phase I, Part B - Dose escalation and Safety of BI-1808 in combination with pembrolizumab|Dose escalation and safety with repeated administrations of BI-1808 infusions in combination with infusions of pembrolizumab in patients with advanced malignacy.
89284484|NCT04752826|Experimental|Phase IIa - Part A Expansion cohorts of BI-1808 alone|Repeated administrations of BI-1808 infusions as a singel dose in 3 cohorts of patients with defined advanced malignacy : ovarian cancer, non-small cell lung cancer , Cutaneous T-cell lymphoma (Sézary Syndrome and Mycosis Fungoides).
89284485|NCT04752826|Experimental|Phase IIa, Part B - Expansion cohorts of BI-1808 in combination with pembrolizumab|Repeated administrations of BI-1808 infusions in combination with infusions of pembrolizumab in 2 cohorts of patients with defined advanced malignacy : ovarian cancer, non-small cell lung cancer.
89284486|NCT04751487|Experimental|Itepekimab Q2W in former smokers|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
89284487|NCT04751487|Experimental|Itepekimab Q4W in former smokers|SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
89284488|NCT04751487|Placebo Comparator|Placebo in former smokers|SC administration of matching placebo Q2W for up to 52 weeks
89284489|NCT04751487|Experimental|Itepekimab Q2W in current smokers|SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
89284490|NCT04751487|Placebo Comparator|Placebo in current smokers|SC administration of matching placebo Q2W for 52 weeks
89284491|NCT04731922|Experimental|TAK-510: Part 1|TAK-510 at starting dose of 5 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1. Staggered dosing will be done in the first cohort of Part A (Cohort 1). Staggered dosing in subsequent Cohorts (Cohorts 2-12 and 21-25) will be used based on emerging safety, tolerability, and PK data from Cohort 1 as determined in the dose escalation meeting.
89284492|NCT04731922|Experimental|TAK-510: Part 2|TAK-510 to be decided (TBD) or placebo-matching solution, subcutaneously, once daily from Day 1 through Day 5. Dose of MRD Cohorts (Cohorts 13-17 and 26-28) of Part 2 will be determined based on emerging safety, tolerability, and available PK data from Part 1 (SRD) and any available PK data from Part 2 as determined in the dose escalation meeting.
89284493|NCT04731922|Experimental|TAK-510: Part 3|TAK-510 TBD or placebo-matching solution, subcutaneously, once daily from Days 1 to 7. Dose of dose titration and redosing Cohorts (Cohorts 18-20) of Part 3 will be based on emerging safety, tolerability, and available PK data from Part 1 (SRD) and Part 2 (MRD) as determined in the dose escalation meeting. Single redosing will be performed on Day 14 after 7 days of washout period following the 7 days treatment period.
89284494|NCT04731246|Experimental|Parkinson's disease (mild to moderate stage)|
89284495|NCT04725071|Experimental|Immunonutrition|Participants will consume a 6oz immunonutrition drink 2 times daily for 7 days and then once a day for remaining hospital stay.
89284496|NCT04725071|Active Comparator|Conventional Supplement|Participants will consume a 6oz conventional supplement drink 3 times daily for 7 days and then once a day for remaining hospital stay.
89284497|NCT04680052|Experimental|Arm A : tafasitamab + rituximab + lenalidomide|Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
89284498|NCT04680052|Placebo Comparator|Arm B : placebo+rituximab+lenalidomide|Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
89284499|NCT04673851|Experimental|FEP Clients|Approximately 90 first episode psychosis (FEP) clients recruited from First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in the online platform Horyzons for 3 months (cohort 1) or 6 months (cohort 2) as a part of their care plan. Participants will be encouraged to use both the therapeutic content and the moderated online community throughout their time in the study.
89284500|NCT04673851|Other|FEP Clinicians|Approximately 40 providers (clinicians and peer support specialists) affiliated with First Episode Clinics in North Carolina (OASIS, Encompass, Eagle, and SHORE) will participate in a focus group discussing the implementation and integration of Horyzons into their care routine with clients who participated in the study.
89284501|NCT04639050|Experimental|Part 1 (Dose Finding) Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
89284502|NCT04639050|Placebo Comparator|Part 1 (Dose Finding) Cohort 1: Placebo|Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.
89284503|NCT04639050|Experimental|Part 1 (Dose Finding) Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284504|NCT04639050|Placebo Comparator|Part 1 (Dose Finding) Cohort 2: Placebo|Participants will receive matching placebo to dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284505|NCT04639050|Experimental|Part 1 (Dose Finding) Cohort 3: Dose Level 3 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284506|NCT04639050|Placebo Comparator|Part 1 (Dose Finding) Cohort 3: Placebo|Participants will receive matching placebo to dose level 3, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284507|NCT04639050|Experimental|Part 1 (Dose Finding) Cohort 4: Dose Level 4 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284508|NCT04639050|Placebo Comparator|Part 1 (Dose Finding) Cohort 4: Placebo|Participants will receive matching placebo to dose level 4, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284509|NCT04639050|Experimental|Part 2 (Expansion) Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284510|NCT04639050|Placebo Comparator|Part 2 (Expansion) Cohort 1: Placebo|Participants will receive matching placebo to dose level 1, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284511|NCT04639050|Experimental|Part 2 (Expansion) Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284512|NCT04639050|Placebo Comparator|Part 2 (Expansion) Cohort 2: Placebo|Participants will receive matching placebo to dose level 2, Q4W, for 28 weeks followed by a 28-week safety follow-up period.
89284513|NCT04639050|Experimental|Part 3 (Dose/Frequency/Pharmacodynamic (PD) Relationship): Dose Level 1: RO7126209|Participants will receive multiple doses of RO7126209 in an open-label treatment period at dose level 1, Q4W, for 24 weeks followed by a 28-week safety follow-up period.
89284514|NCT04639050|Experimental|Part 3 Dose/Frequency/PD Relationship: Dose Level 2: RO7126209|Participants will receive multiple doses of RO7126209 in an open-label treatment period at dose level 2, Q12W, for 24 weeks followed by a 28-week safety follow-up period.
89284515|NCT04639050|Experimental|Part 4: Open Label Extension (OLE) phase: RO7126209|Participants who completed Part 1, 2, or 3 and have reached amyloid negativity (≤ 24 centiloids) in either of the Study Parts or at the OLE baseline visit will receive RO7126209 Q12W. Those who are amyloid positive (≥24 centiloids) will receive RO7126209 Q4W for 12 weeks and will have to reach amyloid negativity (≤ 24 centiloids) before they can switch to Q12W dosing in an open-label treatment period of 101 weeks followed by a 28-week safety follow-up period.
89284516|NCT04638231|Active Comparator|Text Message Group|This group will receive daily supportive messages through Short Messaging Service (SMS) on their mobile phones in addition to standard care
89284517|NCT04638231|Experimental|Email Message Group|This group will receive same supportive message as the Text Message group but through their email addresses, in addition to receiving standard care
89284518|NCT04622007|Experimental|A1 Tomi + Current Pembro|Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert will receive tomivosertib in addition to pembrolizumab.
89284519|NCT04622007|Placebo Comparator|Pbo + Current Pembro|Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert, will receive matching placebo in addition to pembrolizumab.
89284520|NCT04622007|Experimental|B1 Tomi + Pembro|Subjects will initiate pembrolizumab as first-line therapy and receive tomivosertib.
89284521|NCT04622007|Placebo Comparator|Pbo + Pembro|Subjects will initiate pembrolizumab as first-line therapy and receive matching placebo.
89284522|NCT04622007|Experimental|C1 Tomi + Pembro + Pemetrexed (Non-sqamous) or Tomi + Pembro (Squamous)|Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive tomi plus pembrolizumab and pemetrexed (non-squamous NSCLC) or tomi plus pembro as a single agent (squamous) in accordance with the package insert.
89284523|NCT04622007|Placebo Comparator|Pbo + Pembro + Pemetrexed (Non-sqamous) or Pbo + Pembro (Squamous)|Subjects who have completed 4 to 6 cycles of platinum-based chemotherapy doublet will receive placebo plus pembrolizumab and pemetrexed (non-squamous NSCLC) or placebo plus pembro as a single agent (squamous) in accordance with the package insert.
89284524|NCT04621890|Experimental|LOAN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary deductions from a virtual bank of $210 for missed doses of insulin at mealtimes. According to the methodology for calculating BOLUS(1) breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will deduct $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus missed (maximum -$1.50/day). Youth can also lose an additional amount of up to $5.00/week for weeks during which they don't achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will deduct the virtual account up to $2.00 per week for failing to share their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum deduction of $24.00). Maximum total deductions is $210.
89284525|NCT04621890|Experimental|COIN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary incentives for dosing insulin at mealtimes. Mealtimes will be defined based on hour of the day and the presence of a carbohydrate entry associated with the insulin bolus. Breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will reimburse youth up to $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus completed (maximum $1.50/day). We will offer the opportunity for youth to earn a bonus reimbursement of up to $5.00/week for weeks during which they achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will pay youth up to $2.00 per week for sharing their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum $24.00). Therefore, maximum total incentive available is $210.
89284526|NCT04621890|No Intervention|Control|This group will engage have usual diabetes care without intervention. They will fill out all questionnaires, attend clinic visits and provide A1C samples at the same times as the participants in the other groups.
89284527|NCT04613492|Experimental|Single dose MEDI9253, sequential Durvalumab|Various dose level cohorts for single dose MEDI9253 with sequential Durvalumab dosing
89284528|NCT04613492|Experimental|Multiple dose MEDI9253, sequential Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with sequential Durvalumab dosing;
89284529|NCT04613492|Experimental|Multiple dose MEDI9253, concurrent Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with concurrent Durvalumab dosing.
89284530|NCT04603183|Experimental|Interventional Arm (Arm A)|Abemaciclib 150 mg orally twice daily (BID) during each 28 day cycle combined with ET (2.5 mg letrozole, orally administered and taken daily during each 28-day cycle, or 500 mg fulvestrant, by intramuscular [IM] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter.
89284531|NCT04603183|Active Comparator|Control Arm (Arm B)|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
89284532|NCT04587778|Experimental|Esketamine ((S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.~In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan."
89284533|NCT04587778|Experimental|Racemic ketamine ((R,S)-Ketamine)|"Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms.~In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan."
89284534|NCT04587778|Experimental|Pilot study II: Esketamine ((S)-Ketamine)|In a cross-over study design, esketamine will be administered during the first scan and placebo during the second scan.
89284535|NCT04566042|Experimental|ACT video game|
89284536|NCT04560452||Prostate cancer|according to the doctor's decision, have prescribed and agreed to start taking at least one dose of Olaparib
89284537|NCT04560452||Ovarian cancer|At least take one tablet of olaparib before enrolment for OC cohort
89284538|NCT04545736|Experimental|Metformin|Oral administration of metformin
89284539|NCT04539548|Experimental|Dextenza|1 dosing group - 37 eyes treated with Dextenza
89284540|NCT04539548|Active Comparator|Prednisolone|1 dosing group - 32 eyes treated with Prednisolone
89284541|NCT04526795|Experimental|Treatment (pegcrisantaspase, fludarabine, cytarabine)|"INDUCTION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-11 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive pegcrisantaspase IV over 60 minutes on days 1 and 15, and fludarabine IV over 15-30 minutes and cytarabine IV over 2 hours on days 8-10. Treatment repeats every 5 weeks for up 3 cycles in the absence of disease progression or unacceptable toxicity."
89284542|NCT04520217|Experimental|4% Imipramine Cream on UVB-Treated Areas|"2g of 4% imipramine cream will be applied to the UVB-treated areas on volar forearm and back.~2g of base cream will be applied to the UVB-treated areas on volar forearm and back.~No cream will be applied to a UVB-treated area on the back"
89284543|NCT04501614|Experimental|Ponatinib|Ponatinib tablet or age appropriate formulation (AAF) [i.e., capsules with ponatinib minitablets], based on age and weight, in combination with chemotherapy backbone, orally, once daily in both reinduction block and consolidation block (35 days each including 29 days of treatment followed by rest period from chemotherapy for a minimum of 6 days consisting of daily ponatinib only) in Phase 1 to determine RP2D. In Phase 2 participants will receive ponatinib at RP2D in combination with chemotherapy backbone.
89284544|NCT04495946|Experimental|Sepsis Transition and Recovery (STAR) Program|Virtual sepsis navigation delivered across the peri-hospital discharge interval
89284545|NCT04495946|Active Comparator|Usual Care|Standard of care received through Atrium Health facilities for patients hospitalized with sepsis. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
89284546|NCT04490057|Experimental|12 wks NRT+CM / 12 wks NRT+CM|Nicotine replacement therapy combined with contingency management. Responders remain on same treatment for second 12 weeks.
89284547|NCT04490057|Experimental|12 wks NRT+CM/ 12 wks VAR or bupropion+CM|Nicotine replacement therapy combined with contingency management. Non-responders switch to varenicline or bupropion combined with contingency management for second 12 weeks.
89284548|NCT04490057|Experimental|12 wks NRT+CM/12 wks NRT+CM plus|Nicotine replacement therapy combined with contingency management Non-responders switch to nicotine replacement therapy combined with intensified contingency management for second 12 weeks.
89284549|NCT04490057|Experimental|12 wks NRT/ 12 wks NRT|Nicotine replacement therapy alone. Responders remain on nicotine replacement therapy.
89284550|NCT04490057|Experimental|12 wks NRT/ 12 wks VAR or bupropion|Nicotine replacement therapy alone. Non-responders switch to varenicline or bupropion alone for second 12 weeks.
89284551|NCT04490057|Experimental|12 wks NRT/ 12 wks NRT+CM|Nicotine replacement therapy alone. Non-responders switch to nicotine replacement therapy combined with contingency management for second 12 weeks.
89284552|NCT04464980|Experimental|Retention: SL-BUP standard dose + MM|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
89284553|NCT04464980|Experimental|Retention: SL-BUP high dose + MM|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
89284554|NCT04464980|Experimental|Retention: XR-BUP + MM|Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
89284555|NCT04464980|Experimental|Retention: XR-NTX + MM|Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
89284556|NCT04464980|Experimental|Retention: SL-BUP standard dose + MMR|Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.
89284557|NCT04464980|Experimental|Retention: SL-BUP high dose + MMR|High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
89284558|NCT04464980|Experimental|Retention: XR-BUP + MMR|Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
89284559|NCT04464980|Experimental|Retention: XR-NTX + MMR|Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
89284560|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with SL-BUP + MM|Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
89284561|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with XR-BUP + MM|Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
89284562|NCT04464980|Experimental|Discontinuation: Discontinue XR-BUP with XR-BUP + MM|Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
89284563|NCT04464980|Experimental|Discontinuation: Discontinue XR-NTX with XR-NTX + MM|Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
89284564|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with SL-BUP + MMD|Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
89284565|NCT04464980|Experimental|Discontinuation: Discontinue SL-BUP with XR-BUP + MMD|Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
89284566|NCT04464980|Experimental|Discontinuation: Discontinue XR-BUP with XR-BUP + MMD|Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
89284567|NCT04464980|Experimental|Discontinuation: Discontinue XR-NTX with XR-NTX + MMD|Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
89284568|NCT04456699|Experimental|Olaparib + bevacizumab|Participants will receive olaparib (300 mg twice daily [BID] oral) + Bevacizumab (5 mg/kg intravenous [IV] once every 2 weeks [Q2W]) until progressive disease or end of study.
89284569|NCT04456699|Experimental|Olaparib|Participants will receive olaparib (300 mg BID) oral, until progressive disease or end of study.
89284570|NCT04456699|Active Comparator|Bevacizumab + chemotherapy|Participants will receive investigator's choice of either bevacizumab (7.5 mg/kg IV once every three weeks (Q3W)) + capecitabine (1000 mg/m^2 BID for 14 days, then 7 days off, Q3W) or bevacizumab (5 mg/kg IV Q2W) + 5-FU (2400 mg/m2 IV over 46 to 48 hours Q2W; bolus 5-FU (400 mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion). Leucovorin or levoleucovorin 400 mg/m^2 (leucovorin) or 200 mg/m^2 (levoleucovorin) Q2W IV infusion may be added per investigator's discretion. Treatment will continue until progressive disease or end of study.
89284571|NCT04446975|No Intervention|BPA Off|No best-practice alert (BPA) message is displayed to providers.
89284572|NCT04446975|Experimental|BPA On|BPA message is displayed to providers based on patient opioid intake as reported in the electronic health record (EHR).
89284573|NCT04442269|Experimental|dupilumab|Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)
89284574|NCT04442269|Experimental|Placebo|Matching dupilumab without active substance
89284575|NCT04424316|Experimental|RSVpreF vaccine|RSVpreF
89284576|NCT04424316|Placebo Comparator|Placebo dose|Placebo
89284577|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-40 BIW)|Participants will receive fixed dose of 40 milligram (mg) of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet twice weekly (BIW) on Days 1, 3, 8, 10, 15, 17, 22, and 24 of each 28-day cycle.
89284578|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-100 QW)|Participants will receive fixed dose of 100 mg of Selinexor oral tablet followed by 40 mg of low-dose Dexamethasone oral tablet once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone may be given as 20 mg on days 1 and 2 of each week).
89284579|NCT04414475|Experimental|Selinexor + Low-dose Dexamethasone (Sd-80 BIW)|Participants will receive fixed dose of 80 mg of Selinexor oral tablet followed by 20 mg of low-dose Dexamethasone oral tablet BIW on Days 1, 3, 8, 10,15, 17, 22, and 24 of each 28-day cycle.
89284580|NCT04414475|Experimental|Selinexor + Bortezomib + Dexamethasone (SVd)|Participants will receive fixed dose of 100 mg of Selinexor oral tablet on Days 1, 8, 15, 22, and 29 followed by 1.3 milligram per square-meter (mg/m^2) of Bortezomib subcutaneous (SC) injection on Days 1, 8, 15, and 22 and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, 22, and 29 of each 35-day cycle (Dexamethasone dose may be split to 20 mg on days 1 and 2).
89284581|NCT04414475|Experimental|Selinexor + Pomalidomide + Dexamethasone (SPd)|Participants will receive fixed dose of 40 mg of Selinexor oral tablet on Days 1, 8, 15, and 22 of each 28-day cycle followed by Pomalidomide 4 mg PO on Days 1 through 21 of each 28-day cycle and followed by 40 mg of low-dose Dexamethasone oral tablet on Days 1, 8, 15, and 22 of each 28-day cycle. (Dexamethasone dose 20 mg QW for those of >75 years old at the Investigator's discretion, before QW dosing of Selinexor; it may be divided over 1 to 4 days at the Investigator's discretion).
89284582|NCT04409080|Experimental|Part A|Part A: Single ascending dose (SAD) escalation cohorts
89284583|NCT04409080|Experimental|Part B|Part B: Multiple REGN7257 dosages.
89284584|NCT04402645||Chronic pulmonary hypertension|Diagnosis on echocardiography at 36 weeks CGA using standard criteria (flat interventricular septal motion or right ventricular dilatation)
89284585|NCT04402645||No chronic pulmonary hypertension|Confirmed on echocardiography at 36 weeks CGA
89284586|NCT04399239|Experimental|AuriNovo|AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
89284587|NCT04384848|Experimental|Chronic myeloid leukemia (CML) patients|CML patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy
89284588|NCT04370054|Experimental|PF-07055480 (giroctocogene fitelparvovec)|Single administration of PF-07055480
89284589|NCT04334889||Chronic low back pain (CLBP)|All CLBP patients should present with non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months.
89284590|NCT04334889||Asymptomatic controls|Asymptomatic participants should have had no history of LBP requiring medical attention during the last two years and no other concomitant pain or condition that could compromise the evaluation of lumbar kinematics.
89284591|NCT04314843|Experimental|Lenzilumab and Axicabtagene Ciloleucel|Phase 1: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab and axicabtagene ciloleucel on Day 0 to determine a recommended Phase 2 dose (RP2D) of lenzilumab. Phase 2: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab, at the RP2D, and axicabtagene ciloleucel on Day 0.
89284592|NCT04314531|Experimental|Arm A|
89284593|NCT04314531|Placebo Comparator|Arm B|
89284594|NCT04299893|Experimental|Ozone Group|"Drug: Ozone Ozone Group: Usual treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.~Other Names: O3"
89284595|NCT04299893|Placebo Comparator|Control Group|"Drug: Oxygen Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.~Other Names: O2"
89284599|NCT04288726|Experimental|Treatment Phase|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.~Dose Level 1: 4 × 107 CD30.CAR-EBVST cells~Dose Level 2: 1 × 108 CD30.CAR-EBVST cells~Dose Level 3: 4 × 108 CD30.CAR-EBVST cells"
89284600|NCT04288375|Experimental|extremity soft tissue sarcoma (STS)|Postoperative radiation therapy to the primary site with a reduction in radiation dose and volume. Specifically, the tumor bed plus a margin of 2cm craniocaudally and 1.5cm radially will be utilized to create the clinical target volume. The total dose will consist of 50 Gy in 25 fractions.
89284601|NCT04282018|Experimental|Part A: BGB-10188 Monotherapy Dose Escalation|BGB-10188 capsules administered orally once daily (QD) in 5 cohorts of escalating doses
89284602|NCT04282018|Experimental|Part B: BGB-10188 + Zanubrutinib Dose Escalation|BGB-10188 capsules administered orally QD at the latest cleared dose of BGB-10188 monotherapy (Part A) in combination with zanubrutinib 160mg (2*80mg capsules) administered orally twice daily (BID)
89284603|NCT04282018|Experimental|Part C: BGB-10188 + Zanubrutinib Dose Expansion|BGB-10188 capsules administered orally QD at RDFE of part B in combination with zanubrutinib 160mg (2*80mg capsules) administered orally BID
89284604|NCT04282018|Experimental|Part D: BGB-10188 + Tislelizumab Infusion Dose Escalation|BGB-10188 capsules administered orally QD in up to 6 cohorts of escalating doses in combination with tislelizumab 200mg IV infusion administered every 3 weeks (Q3W)
89284605|NCT04282018|Experimental|Part E: BGB-10188 + Tislelizumab Infusion Dose Expansion|BGB-10188 capsules administered orally QD at two doses in combination with tislelizumab 200mg IV infusion administered Q3W
89284606|NCT04281381||Desmoid Fibromatosis|Participants will have a clinical diagnosis of desmoid fibromatosis, either new or newly recurrent
89284607|NCT04280029|Experimental|SELUTION SLR™ DEB|
89284608|NCT04280029|Active Comparator|Control Treatment|POBA or DES
89284609|NCT04266795|Active Comparator|Venetoclax 100/200/400 mg + Azacitidine 75 mg/m^2|Venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 (cycle length= 28 days) and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Following the confirmation of remission in Cycle 1 or thereafter, venetoclax 400 mg was administered on Day 1 through 21 or 28 as per Investigator's discretion, plus azacitidine 75 mg/m^2 intravenous (IV) or subcutaneous (SC) dosing on Days 1 through 7 or Days 1 through 5, Days 8, and 9 in each cycle up to primary completion date: 06 September 2022.
89284610|NCT04266795|Experimental|Pevonedistat 20 mg/m^2 + Venetoclax 100/200/400 mg + Azacitidine 75 mg/m^2|Pevonedistat 20 mg/m^2 as a 60-minute IV infusion on Days 1, 3, and 5 in each 28-day cycle plus venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Day 3 through Day 28 in Cycle 1 (cycle length= 28 days) and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Following the confirmation of remission in Cycle 1 or thereafter, venetoclax 400 mg was administered on Day 1 through 21 or 28 as per Investigator's discretion, plus azacitidine 75 mg/m^2 IV or SC dosing on Day 1 through 7 or Days 1 through 5, Days 8, and 9 in each cycle up to primary completion date: 06 September 2022.
89284611|NCT04256733|Experimental|Supra-threshold capsaicin|Participants will be exposed to progressively increasing concentrations of aerosolized capsaicin (the ingredient in chili peppers that makes them spicy, and a known cough stimulant) to stimulate an urge-to-cough. Participants will be coached to implement cough suppression strategies following each exposure.
89284612|NCT04256733|Placebo Comparator|Sub-threshold capsaicin|Participants will be exposed repeatedly to a single sub-threshold dose of aerosolized capsaicin through a nebulizer during treatment. This sub-threshold dose will elicit minimal or no urge-to-cough.
89284613|NCT04253275|Other|Ischemic stroke patients|Patients with ischemic stroke diagnosed on clinical presentation and cerebral imaging
89284614|NCT04253275|Other|hemorragic stroke patients|Patients with hemorragic stroke diagnosed on clinical presentation and cerebral imaging
89284615|NCT04253275|Other|healthy controls|Stroke-free
89284616|NCT04227301||Hyponatremic patients|Patients hospitalized at the University Hospital of Basel and presenting with hyponatremia will be screened for the study
89284619|NCT04207710|Experimental|Microbial growth on wrist after application of Gebauer's Ethyl Chloride|An area of skin on the wrist will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Gebauer's Ethyl Chloride topical refrigerant spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
89284620|NCT04207710|Experimental|Microbial growth on lower back after application of Gebauer's Ethyl Chloride|An area of skin on the lower back will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Gebauer's Ethyl Chloride topical refrigerant spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
89284621|NCT04207710|Experimental|Microbial growth on wrist after application of Gebauer's Pain Ease|An area of skin on the wrist will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Gebauer's Pain Ease topical refrigerant spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
89284622|NCT04207710|Experimental|Microbial growth on lower back after application of Gebauer's Pain Ease|An area of skin on the lower back will be swabbed before and after Chloraprep application, and then each area will be swabbed again after application of Gebauer's Pain Ease topical refrigerant spray. The bacterial growth prior to and after numbing spray application will be evaluated, based on the number of colony forming units that are present.
89284623|NCT04205786|Active Comparator|Control - Standard of Care|"Day 0:~Baseline questionnaires: FACT-ES, BPI-SF, Assessment of AI Adherence, Demographics, CRF, and Supplemental Agents Reporting Form~Blood collection~Continue Usual Care~Day 45:~Repeat of baseline questionnaires with addition of vitamin B12 supplements form and investigational agent accountability record~Blood collection~Continue Usual Care~Day 90:~-Repeat of day 45"
89284624|NCT04205786|Experimental|Study Medication Group (B12)|"Day 0:~Baseline questionnaires: FACT-ES, BPI-SF, Assessment of AI Adherence, Demographics, CRF, and Supplemental Agents Reporting Form~Blood collection~Oral intake of Vitamin B12 Daily in the morning~Day 45~Repeat of baseline questionnaires with addition of investigational agent accountability record~Blood collection~Oral intake of Vitamin B12 Daily in the morning~Day 90:~-Repeat of day 45 without additional study drug intake."
89284625|NCT04199520|Experimental|surgery combined with systemic therapy|surgery combined with systemic therapy
89284626|NCT04199520|Active Comparator|systemic therapy|systemic therapy
89284627|NCT04181333||TRASTUZUMAB BS|Unresectable Advanced/Recurrent HER2-Overexpressing Gastric Cancer patients injected TRASTUZUMAB BS
89284628|NCT04175834|Other|diphenhydramine|25 mg diphenhydramine capsule, generic, sourced from Major Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
89284629|NCT04175834|Active Comparator|cetirizine|10 mg cetirizine tablet, generic, sourced from Mylan Pharmaceuticals will be give orally 30-60 minutes prior to ocrelizumab infusion.
89284630|NCT04173273|Experimental|Etrasimod Dose A|
89284631|NCT04173273|Experimental|Etrasimod Dose B|
89284632|NCT04173273|Placebo Comparator|Placebo|
89284633|NCT04158583|Experimental|Part A: Cohort 1 RO7296682 0.3 mg Q3W|Participants with non-small cell lung cancer (NSCLC), melanoma (MEL), head and neck squamous cell carcinoma (HNSCC), ovarian cancer (OvC), triple-negative breast cancer (TNBC), and esophageal carcinoma (EsC) received RO7296682 0.3 milligram (mg) intravenous (IV) infusion on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, every 3 weeks (Q3W). Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284634|NCT04158583|Experimental|Part A: Cohort 2 RO7296682 1 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 1 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284635|NCT04158583|Experimental|Part A: Cohort 3 RO7296682 2 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 2 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284636|NCT04158583|Experimental|Part A: Cohort 4 RO7296682 6 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 6 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284637|NCT04158583|Experimental|Part A: Cohort 5 RO7296682 18 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 18 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284638|NCT04158583|Experimental|Part A: Cohort 6 RO7296682 35 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 35 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284639|NCT04158583|Experimental|Part A: Cohort 7 RO7296682 70 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 70 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284640|NCT04158583|Experimental|Part A: Cohort 8 RO7296682 100 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 100 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284641|NCT04158583|Experimental|Part A: Cohort 9 RO7296682 165 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 165 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284642|NCT04158583|Experimental|Part A: Cohort 10 RO7296682 20 mg Q3W|Participants with NSCLC, MEL, HNSCC, OvC, TNBC, and EsC received RO7296682 20 mg, IV infusion, on Day 1 of Cycle 1 (1 cycle=21 days), and at subsequent cycles, Q3W. Participants experiencing toxicities fulfilling the definition of a DLT (e.g: skin toxicities; Grade >=4, IRR; Grade >=4, immune-mediated adverse events; Grade >=4) were discontinued from study treatment.
89284643|NCT04152863|Experimental|IV Gebasaxturev + Pembrolizumab|Participants receive gebasaxturev at a dose of 1 X 10^9 TCID50 by IV infusion on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Gebasaxturev will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
89284644|NCT04152863|Experimental|ITu Gebasaxturev + Pembrolizumab|Participants receive gebasaxturev at a dose of 3 X 10^8 TCID50 by ITu injection on Days 1, 3, 5, and 8 of Cycle 1 (28-day cycle) and Day 1 of Cycles 2-8 (21-day cycles) plus pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Gebasaxturev will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
89284645|NCT04152863|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by IV infusion on Day 8 of Cycle 1 (28-day cycle) and Day 1 of each subsequent 21-day cycle. Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
89284646|NCT04145349|Experimental|Ramucirumab + Cyclophosphamide + Vinorelbine|Ramucirumab given intravenously (IV), Cyclophosphamide given orally and vinorelbine given IV.
89284647|NCT04145349|Active Comparator|Cyclophosphamide + Vinorelbine|Cyclophosphamide given orally and vinorelbine given IV.
89284648|NCT04141826|Experimental|Hydrolysed whey|Hydrolysed whey
89284649|NCT04141826|Active Comparator|Intact whey|Intact whey
89284650|NCT04141826|Placebo Comparator|Caseinate|Caseinate
89284651|NCT04140279|Experimental|Latanoprostene Bunod|Participants will receive LBN ophthalmic solution 0.024% in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
89284652|NCT04140279|Placebo Comparator|Placebo|Participants will receive Renu MultiPlus Lubricating and Rewetting Drops (placebo) in the applicable eye identified during randomization. The first dose will be instilled in the morning (AM) at approximately 11 AM on Day 1 and the remaining 6 doses will be instilled once per day in the evening at approximately 8 PM.
89284653|NCT04138953|Experimental|TMS over premotor cortex|Noninvasive brain stimulation in the premotor cortex
89284654|NCT04138953|Experimental|TMS over primary motor cortex|Noninvasive brain stimulation in the motor cortex
89284655|NCT04138953|Sham Comparator|Sham TMS over premotor cortex|Sham brain stimulation in the premotor cortex
89284656|NCT04134325|Experimental|Arm 1: Relapse After Prior CD30 CAR-T Therapy|Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.
89284657|NCT04134325|Experimental|Arm 2: Relapse with no Prior CD30 CAR-T Therapy|Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have not received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.
89284658|NCT04104945|Experimental|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
89284659|NCT04101916|Experimental|Paired Associative Stimulation|
89284660|NCT04101916|Sham Comparator|Sham|
89284661|NCT04098666|Experimental|metformin users|Extended release metformin 500 mg tablets up to 2,000 mg (4 tablets) a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
89284662|NCT04098666|Placebo Comparator|metformin non-users|Placebo tablets identical to extended release metformin 500 mg tablets up to 4 tablets a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.
89284663|NCT04088318|Experimental|OQL011 Dose I|OQL011, Dose I, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
89284664|NCT04088318|Experimental|OQL011 Dose II|OQL011, Dose II, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
89284665|NCT04088318|Experimental|OQL011 Dose III|OQL011, Dose III, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
89284666|NCT04088318|Other|Vehicle Ointment|Vehicle ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
89284667|NCT04084496|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
89284668|NCT04075526|Experimental|Povidone iodine and vancomycin powder|
89284669|NCT04075526|Experimental|Povidone iodine alone|
89284670|NCT04075526|Active Comparator|Vancomycin powder alone|
89284671|NCT04075526|Active Comparator|Conventional|neither povidone iodine, vancomycin powder, nor polymyxin/bacitracin irrigation
89284672|NCT04061967|Other|HPV self sampling test ordered|An invitation to order a HPV self sampling test through an online application will be sent by SMS or electronic letter.
89284673|NCT04059406|Experimental|Sapablursen Dose Level 1 (Cohort A)|A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.
89284674|NCT04059406|Experimental|Sapablursen Dose Level 1 (Cohort B)|A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.
89284675|NCT04059406|Experimental|Sapablursen Dose Level 1 (Cohort C)|A single injection of sapablursen at multiple dose levels, administered subcutaneously every 4 weeks.
89284676|NCT04058028|Experimental|Rozibafusp Alfa, Dose A|Investigational product solution in vial
89284677|NCT04058028|Experimental|Rozibafusp Alfa, Dose B|Investigational product solution in vial
89284678|NCT04058028|Experimental|Rozibafusp Alfa, Dose C|Investigational product solution in vial
89284679|NCT04058028|Placebo Comparator|Placebo for Rozibafusp Alfa|Placebo Investigational product solution in vial
89284680|NCT04050683|Experimental|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Right Atrial Pressure (RAP) ≥ 15mmHg or change in RAP ≥ 10 mmHg or Peak Systolic Right Ventricular (PSRV) Pressure ≥ 46 mmHg
89284681|NCT04050683|Active Comparator|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Normal hemodynamic parameters
89284682|NCT04046094|Experimental|IV Ascorbic Acid|IV Ascorbic Acid 25 grams (g) infused 2 times a week for 4 weeks
89284683|NCT04036188|Experimental|Triamcinolone Cream + Vitamin D3|This arm will continue to take Vitamin D3 at Week 16 to Week 28.
89284684|NCT04036188|Placebo Comparator|Triamcinolone Cream + Placebo|Starting at Week 16, this arm will be given Vitamin D3 to take until Week 28.
89284685|NCT04031989|Other|Enrolled Subjects (PSR)|Patients who meet the study's entrance criteria and provide written informed consent, will undergo signal acquisition prior to their scheduled right heart catheterization (RHC) on the day of the procedure.
89284692|NCT04025879|Experimental|Neoadj. Nivo+ Pt-based Doublet Chemo followed by Adj. Nivo|
89284693|NCT04025879|Placebo Comparator|Neoadj. Plac. + Pt-based Doublet Chemo followed by Adj.Plac.|
89284694|NCT04008368|Other|1|patients with HLA-matched sibling donors
89284695|NCT04008368|Other|2|patients with haploidentical donors
89284696|NCT03981523|Experimental|BZN-60|150 mg twice a day for 60 days.
89284697|NCT03981523|Experimental|BZN-30|150 mg once a day for 30 days.
89284698|NCT03981523|Experimental|BZN-90|150 mg once a day for 90 days.
89284699|NCT03981523|Experimental|NFX-60|240 mg twice a day for 60 days.
89284700|NCT03981523|Experimental|NFX-30|240 mg twice a day for 30 days.
89284701|NCT03981523|Experimental|NFX-90|240 mg once a day for 90 days.
89284702|NCT03981380||MESA study participants|Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study
89284703|NCT03969212|Experimental|Baloxavir Marboxil|Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.
89284704|NCT03969212|Placebo Comparator|Placebo|Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.
89284705|NCT03954223|Experimental|LSC + blinded CGM|Group 1) Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)
89284706|NCT03954223|Experimental|LSC+TLE + blinded CGM|Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM
89284707|NCT03954223|Experimental|LSC+TLE+ real time feedback via CGM|Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).
89284708|NCT03946202|Experimental|Radiotherapy + radiation sensitiser|Patients randomised to the test group will receive standard radiotherapy for breast cancer + a radiation sensitiser
89284709|NCT03946202|No Intervention|Radiotherapy alone|Patients randomised to the control group will receive standard radiotherapy for breast cancer alone
89284710|NCT03932682|Experimental|Seqirus QIVc|Cell-derived Quadrivalent Influenza Vaccine
89284711|NCT03932682|Active Comparator|Comparator|Non-influenza Comparator (NesiVac-C)
89284712|NCT03906253|Experimental|Factionated Laser Resurfacing - Right Arm|Right forearm treatment of fractionated laser resurfacing.
89284713|NCT03906253|Experimental|Factionated Laser Resurfacing - Left Arm|Left forearm treatment of fractionated laser resurfacing.
89284714|NCT03904498|Experimental|Tolcapone then Placebo|Participants in this arm will receive tolcapone during the first medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8), and placebo during the second medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8).
89284715|NCT03904498|Experimental|Placebo then Tolcapone|Participants in this arm will receive placebo during the first medication period (1 capsule on study days 1 and 2; 3 capsules on study days 3-8), and tolcapone during the second medication period (1 capsule containing 200 mg tolcapone on study days 1 and 2; 3 capsules containing a total of 600 mg tolcapone on study days 3-8).
89284716|NCT03884101|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
89284717|NCT03884101|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
89290274|NCT05123170|Active Comparator|Group II|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.25 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml.
89290275|NCT05123170|Active Comparator|Group III|Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.5 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml
89290276|NCT01215708|Active Comparator|Nifedipine|nifedipine retard 20mg daily
89290277|NCT01215708|Active Comparator|tamsulosin|tamsulosin 0,4mg
89290278|NCT01215708|Placebo Comparator|placebo|placebo capsule
89284718|NCT03878524|Experimental|Treatment (biospecimen collection, 2 drug combination)|"TUMOR BIOPSY: Patients undergo collection of tissue samples. Clinical analytics are performed on the samples and analyzed by a clinical tumor board to recommend a treatment option based on those analytics.~SMMART-PRIME TREATMENT: Patients receive a combination of 2 drugs (Drug A and Drug B, selected from interventions below). Doses will be escalated within individual patients over time. As described in detail below, escalation will occur monthly and is anticipated to occur as follows: first month - 100% FDA approved dose Drug A + 25% FDA approved dose Drug B; second month -- 100% dose Drug A + 50% dose Drug B; third month -- 100% dose Drug A + 100% dose Drug B. All dose-escalations will be reviewed and approved by an independent consultant outside of Oregon Health & Science University (OHSU).~Treatment will continue for up to the end of 6 treatment cycles (cycle length is between 21-28 days) in the absence of disease progression or unacceptable toxicity."
89284719|NCT03875378|Experimental|Transdermal estrogen/progesterone|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) patch applied weekly for 18 months
89284720|NCT03875378|Placebo Comparator|Placebo|Placebo patch applied weekly for 18 months
89284721|NCT03869190|Active Comparator|Atezolizumab for mUC Cohort (Stage 1)|"Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.~Enrollment is closed."
89284722|NCT03869190|Experimental|Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284723|NCT03869190|Experimental|Atezolizumab + Niraparib for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Niraparib (Nira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284724|NCT03869190|Experimental|Atezolizumab + Magrolimab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and magrolimab (Hu5F9-G4) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284725|NCT03869190|Experimental|Atezolizumab + Tiragolumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284726|NCT03869190|Experimental|Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284727|NCT03869190|Experimental|Atezolizumab + Tocilizumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Tocilizumab (TCZ) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284728|NCT03869190|Experimental|Atezolizumab + RO7122290 for mUC Cohort (Stage 1)|Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284729|NCT03869190|Experimental|Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 2)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284730|NCT03869190|Experimental|Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 2)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status. Enrollment is closed.
89284731|NCT03869190|Active Comparator|Atezolizumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 1|Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.
89284732|NCT03869190|Experimental|Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 2|Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.
89284733|NCT03869190|Active Comparator|Atezolizumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 1|Participants will receive Atezolizumab for 3 cycles pre-surgery and 14 cycles post-surgery.
89284734|NCT03869190|Experimental|Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 2|Participants will receive Atezolizumab and Tiragolumab (Tira) for 3 cycles pre-surgery and 14 cycles post-surgery.
89284735|NCT03869190|Active Comparator|Cisplatin-eligible MIBC Cohort 3 Arm 1|Participants will receive 3 cycles of Atezolizumab, Cisplatin, and Gemcitabine pre-surgery and 14 cycles of Atezolizumab only post-surgery.
89284736|NCT03869190|Experimental|Cisplatin-eligible MIBC Cohort 3 Arm 2|Participants will receive Atezolizumab, Tiragolumab (Tira), Cisplatin and Gemcitabine for 3 cycles pre-surgery and 14 cycles of Atezolizumab and Tiragolumab (Tira) post-surgery.
89284737|NCT03863288|Placebo Comparator|Intranasal Spray Placebo|Nasal spray of placebo liquid solution as a single dose. fMRI scan pre and post-administration.
89284738|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 8 International Unit (IU)|Nasal spray of Oxytocin 8 International Unit (8IU) liquid solution as a single dose. fMRI scan pre and post administration.
89284739|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 24 International Unit (IU)|Nasal spray of Oxytocin 24 International Unit (24IU) liquid solution as a single dose. fMRI scan pre and post administration.
89284740|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 48 International Unit (IU)|Nasal spray of Oxytocin 48 International Unit (48IU) liquid solution as a single dose. fMRI scan pre and post administration.
89284741|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 80 International Unit (IU)|Nasal spray of Oxytocin 80 International Unit (80IU) liquid solution as a single dose. fMRI scan pre and post-administration.
89284742|NCT03833154|Experimental|SoC SBRT + Durvalumab Therapy (Main Cohort)|"SBRT~Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met."
89284743|NCT03833154|Placebo Comparator|SoC SBRT + Placebo Therapy (Main Cohort)|"SBRT~Placebo (matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met."
89284744|NCT03833154|Experimental|SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, separate cohort)|"SBRT~Osimertinib 80mg every day [qd] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT"
89284745|NCT03820986|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
89284746|NCT03820986|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
89284747|NCT03816683||Single cohort (registry) of MCL patients|Patients diagnosed with MCL who have initiated a novel therapy meeting inclusion/exclusion criteria in the past 6 months and treatment is ongoing at the time of enrollment.
89284748|NCT03773991||Maintenance Hemodialysis Patients|"Patients on chronic hemodialysis therapy due to end-stage renal disease.~Proton Lung MRI~Sodium MRI of the leg~Chest CT~Transthoracic Echocardiography~Fractional Exhaled Nitric Oxide~Six-Minute Walk Test~Pulmonary Function Tests~Blood sampling~Self-administered dyspnea questionnaires"
89284749|NCT03757910|Experimental|DPPOS Exposed to Metformin|DPPOS participants with exposure to metformin will be scanned with 18F-MK-6240 and 11C-PIB.
89284750|NCT03757910|Active Comparator|DPPOS Exposed to Placebo|DPPOS participants with no exposure to metformin but only placebo will be scanned with 18F-MK-6240 and 11C-PIB.
89284751|NCT03747042|Experimental|Treatment|"Drug: letrozole Take by mouth at a dose of 2.5 mg on days 7-30~Other: Blood Collection Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction~Procedure: biopsy/lumpectomy/mastectomy Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis"
89284752|NCT03739619|Experimental|Gemcitabine, bendamustine, nivolumab|Patients receive gemcitabine IV over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive nivolumab IV over 60 minutes on day 1. Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89284753|NCT03737981|Active Comparator|Arm I (ibrutinib, obinutuzumab)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Treatment repeats every 28 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 15, patients receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity.
89284754|NCT03737981|Experimental|Arm II (ibrutinib, obinutuzumab, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Beginning cycle 3, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity. All patients will then receive a 15th cycle of ibrutinib. Beginning cycle 16, patients who do not achieve a BM MRD negative CR, receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a BM MRD negative CR undergo observation every 3 cycles for 6 years, then every 6 cycles thereafter.
89284755|NCT03729739|Experimental|QFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by Quantitative flow ratio (QFR).~Revascularization is indicated if QFR≤0.80. Treatment is performed according to standard clinical practice."
89284756|NCT03729739|Active Comparator|FFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by fractional flow reserve (FFR).~Revascularization is indicated if FFR≤0.80. Treatment is performed according to standard clinical practice."
89284757|NCT03721640||Preterm neonates (< 33 weeks GA)|Preterm neonates requiring in the first week of life, an elective tracheal intubation for surfactant administration by INSURE or LISA methods.
89284758|NCT03710772|Experimental|Group I (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as described in part I.~COMBINATION CHEMOTHERAPY: Patients receive rituximab IV over 6 hours on day 1, dexamethasone PO or IV on days 1-4, cyclophosphamide IV over 3 hours BID on days 2-4, and doxorubicin hydrochloride IV over 24 hours and vincristine sulfate IV over 15-30 minutes on day 5 of odd-numbered cycles (1 and 3). Patients also receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours BID on days 3-4 of even-numbered cycles (2 and 4). Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib and venetoclax PO QD on days 1-28, and rituximab IV over 4-8 hours on day 1 of every other month. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
89284759|NCT03710772|Experimental|Group II (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as in part I.~Patients receive combination chemotherapy as in group I. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive maintenance therapy as in group I."
89284760|NCT03710772|Experimental|Group III (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib, rituximab, venetoclax as in part I. Patients then receive maintenance therapy as in group I.
89284761|NCT03705351|Experimental|Treatment|Patients will receive trimodal therapy consisting of tumor treating fields therapy with the Optune device concurrent with temozolomide and radiation therapy.
89290279|NCT05114278|Experimental|Oral Iron + IV Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year.
89284762|NCT03678753|Experimental|Cenobamate|Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks. The adolescent subjects will follow the same regimen in an oral suspension adolescent equivalent dose based on weight.
89284763|NCT03678753|Placebo Comparator|Placebo|Matching placebo
89284764|NCT03672864|Experimental|Immediate Group|The intervention is intensive exercise, delivered over 12 weeks beginning on admission to the study. The group will then be followed for 9 months post intervention.
89284765|NCT03672864|No Intervention|Delay Group|The group will be followed for 6 months with no intervention. After 6 months the group will be given the opportunity to receive the same intensive exercise intervention as the Immediate group. The group will be followed for 3 months following the intervention.
89284766|NCT03672292|Experimental|SCY-078 plus Voriconazole|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral SCY-078 tablets (loading dose of 500 mg BID on Days 1 and 2 followed by maintenance dose of 500 mg QD from Day 3 onwards). Treatment duration = minimum 6 weeks/Max 13 weeks"
89284767|NCT03672292|Placebo Comparator|Voriconazole mono-therapy|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral Placebo Tablets matching SCY-078 tablets (loading dose of 2 tablets given BID on Days 1 and 2 followed by maintenance dose of 2 tablets given QD from Day 3 onwards).~Treatment duration = minimum 6 weeks/Max 13 weeks"
89284768|NCT03659916|Experimental|A4250|"Capsules for oral administration (40 or 120 µg/kg) once daily for 72 weeks, or 40 µg/kg/day for the first 12 weeks followed by 120 µg/kg/day for the remaining 60 weeks"
89284769|NCT03630354|Experimental|Arm I (supervised exercise together)|Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting remotely for 6 months.
89284770|NCT03630354|Experimental|Arm II (supervised exercise separately)|Survivors and partners perform exercise routines over 1 hour, 2 days per week separately in a supervised group setting remotely for 6 months.
89284771|NCT03630354|Experimental|Arm III (unsupervised exercise separately)|Survivors and partners undergo 2 training sessions remotely over 1 hour with an exercise trainer and then perform exercise routines over 1 hour, 2 days per week unsupervised at home or a facility following an instructional DVD.
89284772|NCT03548779|Experimental|Pre-visit prep / usual care + exome seq|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care and will be offered research exome sequencing."
89284773|NCT03548779|Experimental|Pre-visit prep / usual care|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care."
89284774|NCT03548779|Experimental|No prep / usual care + exome seq|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care and will be offered research exome sequencing."
89284775|NCT03548779|No Intervention|No prep / usual care|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care."
89284776|NCT03539419||Patients with plaque psoriasis on apremilast|Adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice.
89284777|NCT03500757||360-degree Display of solid tumors|Evaluate the feed back of using the HoloLens headset to have a 360 degree visualization of patient tumors during percutaneous liver tumor ablation
89284778|NCT03478514|Experimental|Single Arm|"All patients will receive palbociclib at 100 mg oral once a day for 21 days, followed by 7 days off.~Ibrutinib will be administered at 560 mg oral continuously."
89284779|NCT03442465||Regenerative Osseous Surgery|Participants undergoing osseous reconstructive surgery (RegOS) for bone neoplasm. Study visits for post-op assessments will be annually after month-36.
89284780|NCT03442465||Other Reconstructive Surgery|Participants undergoing other reconstructive surgery for bone neoplasm. Study visits for post-op assessments will be annually after month-36.
89284781|NCT03441737|Experimental|Exercise|Aerobic exercise intervention
89284782|NCT03441737|Active Comparator|Non-Exercise|Non-aerobic exercise intervention
89284783|NCT03439059|Experimental|intervention- reducing SB|prompted to do 10min of light physical activity 3x/day
89284784|NCT03439059|No Intervention|Control|go about their normal daily living
89284785|NCT03436797|Experimental|AK002-IV|AK002 given as monthly intravenous infusions at up to 3 mg/kg.
89284786|NCT03434730|Experimental|Adult Participants With High Risk Hematologic Malignancies|
89284787|NCT03400423|Experimental|Non-caffeine exercise|Exercise cognition score
89284788|NCT03400423|Active Comparator|Non-caffeine cognition|Caffeine cognition score
89284789|NCT03400423|Experimental|Caffeine consumption exercise|Exercise cognition score
89284790|NCT03400423|Active Comparator|Caffeine consumption cognition|Caffeine cognition score
89284791|NCT03400423|Experimental|Deprived Caffeine consumers exercise|Exercise cognition score
89284792|NCT03400423|Active Comparator|Deprived caffeine consumers cognition|Caffeine administration cognition score
89284793|NCT03399539|Experimental|Treatment (venetoclax, ixazomib citrate, dexamethasone)|Patients receive venetoclax PO daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89284794|NCT03389100|Experimental|18F-MK6240 injection|intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), IV, total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
89284795|NCT03384589|Active Comparator|Group 1: 3 doses of PCV13|PCV13, 0.5ml intramuscular at 2, 4 and 12 months of age
89284796|NCT03384589|Experimental|Group 2: 2 doses of PCV13|PCV13, 0.5ml intramuscular at 2 and 12 months of age
89284797|NCT03377361|Experimental|Part 1 Cohort 1 3rd Line (3L): nivolumab + trametinib|
89284798|NCT03377361|Experimental|Part 1A Cohort 2 2nd Line (2L): nivolumab + ipilimumab + trametinib|
89284799|NCT03377361|Experimental|Part 1A Cohort 3 (2L): nivolumab + ipilimumab + trametinib|
89284800|NCT03377361|Experimental|Part 2 Cohort 4 (3L): nivolumab + ipilimumab + trametinib|
89284801|NCT03377361|Experimental|Part 2 Cohort 5 (3L): Regorafenib|
89284802|NCT03377361|Experimental|Part 1B Cohort 6 (2L): nivolumab + ipilimumab + trametinib|
89284803|NCT03360721|Experimental|Treatment (abiraterone acetate, apalutamide, prednisone)|Participants receive abiraterone acetate PO once daily QD, apalutamide PO QD, and prednisone PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89284804|NCT03330847|Active Comparator|Olaparib monotherapy|All randomized patients will receive Olaparib monotherapy 300 mg twice daily (BD).
89284805|NCT03330847|Active Comparator|Olaparib+Ceralasertib|All randomized patients will receive Olaparib 300 mg twice daily+Ceralasertib 160 mg once daily (OD).
89284806|NCT03330847|Active Comparator|Olaparib+adavosertib|All randomized patients will receive Olaparib 200 mg BD +adavosertib 150 mg BD. Following the discontinuation of adavosertib+olaparib treatment arm on 18 April 2019, patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
89284807|NCT03319537|Experimental|Pevonedistat|
89284808|NCT03319537|Experimental|pevonedistat in combination with pemetrexed and cisplatin|
89284809|NCT03282695||Surgery|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.~These patients will receive standard pain treatment until the planned surgery."
89284810|NCT03282695||Ozone|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.~These patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.~These patients will receive standard pain treatment until the planned surgery."
89284811|NCT03263572|Experimental|Treatment (blinatumomab, chemotherapy, ponatinib)|Patients receive blinatumomab IV nonstop on days 1-28 of cycles 1-5, and methotrexate and cytarabine intrathecally (by spinal tap) on days 1, 15, and 29 of cycles 1-4. Patients also receive ponatinib PO daily. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89284812|NCT03258580|Experimental|Substudy 1: All participants|Measuring facial response to painful stimulation.
89284813|NCT03258580|No Intervention|Substudy 2: Healthy volunteers|Measuring pain assessment accuracy
89284814|NCT03258580|No Intervention|Substudy 3: Control|Subjects will judge stimuli with the same instructions as Sub-Study 2 (which provides a test of replication).
89284815|NCT03258580|Experimental|Substudy 3: Feedback Group|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
89284816|NCT03220347|Experimental|CC-90010 in patients with solid tumors and NHL|Subjects will be administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data.
89284817|NCT03217266|Experimental|Step 1 (tumor tissue testing, navtemadlin)|Patients undergo tumor tissue testing for p53 gene status and receive navtemadlin PO on day 2, days 2 and 4, days 2-4, days 2-5, or days 1-5 of weeks 1 to 5 in the absence of disease progression or unacceptable toxicity.
89284818|NCT03217266|Experimental|Step 2, Group I (navtemadlin, radiation therapy)|Patients receive navtemadlin as in Step 1 and undergo radiation therapy daily on weeks 1-5 in the absence of disease progression or unacceptable toxicity.
89284819|NCT03217266|Experimental|Step 2, Group II (radiation therapy)|Patients undergo radiation therapy daily on weeks 1-5 in the absence of disease progression or unacceptable toxicity.
89284820|NCT03195608|Experimental|Intervention|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, the lane change assistance system will be introduced and participants will be taught how to use it. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world. They will drive this new route with the assistive technology. One to two weeks after the post-test, participants will be invited to participate in a follow-up assessment (battery of tests and simulator assessment).
89284821|NCT03195608|Active Comparator|Control|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, participants will drive the scenario and receive feedback from a trained evaluator regarding their live performance. No lane change assistance system will be utilized. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world.
89284822|NCT03195478|Experimental|Nivo/Ipi Combination Therapy A|
89284823|NCT03195478|Experimental|Nivo/Ipi Combination Therapy B|
89284824|NCT03195478|Experimental|Nivo/Ipi Combination Therapy C|
89284825|NCT03195478|Experimental|Nivo/Ipi Combination Arm D|
89284826|NCT03183713|Active Comparator|Comparison Group|Patients with a zero risk score will serve as a comparison group (N=20).
89284827|NCT03183713|Active Comparator|Sham Treatment|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
89284828|NCT03183713|Active Comparator|CBT|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
89284829|NCT03157128|Experimental|LOXO-292|Phase 1 - Multiple doses of LOXO-292 (selpercatinib) Phase 2 - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
89284830|NCT03155061|Experimental|Part A (Dose Escalation Part): ONO-4578 monotherapy|ONO-4578 specified dose on specified days in advanced or metastatic solid tumors
89284831|NCT03155061|Experimental|Part B: ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in advanced or metastatic solid tumors
89284832|NCT03155061|Experimental|Part C (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent gastric cancer
89284833|NCT03155061|Experimental|Part D (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent colorectal cancer
89284834|NCT03149081|Experimental|Boswellia|Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.
89284835|NCT03142958|Other|Integra® Cadence™ Total Ankle System|
89284836|NCT03132948|Experimental|Physical Activity|Single arm study where patients choose from physical activities after baseline assessment by PT. Activities include the following: Nintendo WII fit console, Xbox Kinect fit console and other sport activities.
89284837|NCT03078010|Active Comparator|Piperacillin-tazobactam|
89284838|NCT03078010|Experimental|cefepime|
89284839|NCT03070327|Experimental|BCMA Targeted CAR T Cells with or without Lenalidomide|
89284840|NCT03069326|Experimental|Cohort A: Ruxolitinib and Thalidomide|After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
89284841|NCT03069326|Experimental|Cohort B: Ruxolitinib and Thalidomide|"A cohort expansion, for patients with baseline thrombocytopenia, will enroll 35 additional patients~After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs."
89284842|NCT03045744|Experimental|incomplete SCI patients|
89284843|NCT03008408|Experimental|Arm I (ribociclib, everolimus, letrozole)|Patients receive ribociclib PO QD, everolimus PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89284844|NCT03008408|Experimental|Arm II (everolimus, letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89284845|NCT03003572||patients with primary Sjögren's syndrome|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA) in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria.
89284846|NCT02997501|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
89284847|NCT02992015|Experimental|Gemcitabine|The entire therapy on this study is one dose of gemcitabine. No intrapatient dose modifications are necessary. Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure.
89284848|NCT02986048||Proton Beam Therapy|All patients treated with proton beam therapy at the UH Proton Therapy Center who consent to have their health information recorded, including whether the cancer was cured and if any complications occur ed due to treatment
89284849|NCT02983578|Experimental|Treatment (danvatirsen, durvalumab)|Patients receive danvatirsen IV over 1 hour on days 7, 5 and 3 prior to cycle 1, then on days 1, 8, 15 and 22. Patients also receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89284850|NCT02981966|Active Comparator|T2DM individuals on Dapagliflozin|Individuals with type 2 diabetes mellitus - dapagliflozin
89284851|NCT02981966|Placebo Comparator|T2DM individuals on Placebo|Individuals with type 2 diabetes mellitus on placebo
89284852|NCT02981966|Active Comparator|Normal Glucose Tolerance (NGT) on Dapagliflozin|Individuals with normal glucose tolerance - dapagliflozin
89284853|NCT02981966|Placebo Comparator|Normal Glucose Tolerance (NGT) Placebo|Individuals with normal glucose tolerance - on placebo
89284854|NCT02922036|Experimental|Treatment|WiSE System therapy ON with Guideline Directed Medical Therapy
89284855|NCT02871258|Other|The MetaNeb® System Treatment|Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
89284856|NCT02870985|Experimental|BIOTRONIK Orsiro SES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the experimental arm will be implanted with BIOTRONIK sirolimus eluting coronary stent(Orsiro).
89284857|NCT02870985|Active Comparator|Abbott Xience Prime™ EES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the comparator arm will be implanted with Abbott everolimus eluting coronary stent(Xience Prime™).
89284858|NCT02851615|Other|SCThrive|SCThrive Intervention for Adolescents with SCD - 6 week self-management group
89284859|NCT02851615|No Intervention|Attention Control|6 weekly 15-20 minute individual phone calls on educational topics. No interventions are included in this arm.
89284860|NCT02735343|Active Comparator|Standard treatment arm|compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously
89284861|NCT02735343|Experimental|Research arm|Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously
89284862|NCT02697383|Experimental|Ixazomib (MLN9708) and Dexamethasone|Patients with high risk SMM will be enrolled on the pilot study and treated with 2 drug combination (Cycles 1-12 Ixazomib at 4 mg weekly on days 1, 8 and 15, and dexamethasone on days 1, 8, 15 and 22 of 28 day cycle); the dexamethasone dose will be 40 mg/week the first 4 cycles, thereafter 20 mg/week.
89284863|NCT02692872||1|We plan to perform genetic screening of up to 2,000 individuals of African ancestry, an ethnic group with a high prevalence of alpha thalassemia.
89284864|NCT02687906|Experimental|Single dose IV meropenem-vaborbactam|"Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours~Cohort 1 (n=8): 12 to < 18 years of age (40 mg/kg)~Cohort 2 (n=8): 6 to < 12 years of age (40 mg/kg)~Cohort 2b (n=4): 6 to < 12 years of age (60 mg/kg)~Cohort 3 (n=8): 2 to < 6 years of age (60 mg/kg)~Cohort 4 (n=8): 3 months to < 2 years of age (60 mg/kg)~Cohort 5 (n=24): Birth to < 3 months of age (dose TBD)~Group A: Gestational Age (GA) < 32 weeks, Postnatal Age (PNA) < 2 weeks (n=6)~Group B: GA < 32 weeks, PNA > 2 weeks (n=6)~Group C: GA > 32 weeks, PNA < 2 weeks (n=6)~Group D: GA > 32 weeks, PNA > 2 weeks (n=6)~Cohort 6 (n=7): 2 to < 12 years of age and ≤ 35 kg of weight (80 mg/kg)"
89284865|NCT02685358|Experimental|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consisted of 4 brief sessions over 8 weeks.
89284866|NCT02685358|Active Comparator|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
89284867|NCT02570672|Experimental|Metformin|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated)
89284868|NCT02570672|Placebo Comparator|Placebo|Subjects will be randomized to metformin (titrated up to 1000 mg twice daily, as tolerated) vs. placebo.
89284869|NCT02540330|Active Comparator|Intramuscular Fulvestrant|500mg fulvestrant administered intramuscularly
89284870|NCT02540330|Experimental|Intraductal Fulvestrant|up to 500mg fulvestrant administered intraductally
89284871|NCT02520791|Experimental|Treatment (MEDI-570)|Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89284872|NCT02475681|Active Comparator|Arm A - Obinutuzumab in Combination with Chlorambucil|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 1 Day 1. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.
89284873|NCT02475681|Experimental|Arm B - Acalabrutinib in Combination with Obinutuzumab|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 2 Day 1. Acalabrutinib (ACP-196) will be orally administered starting on Cycle 1 Day 1. Daily administration of Acalabrutinib (ACP-196) will continue until disease progression or unacceptable toxicity.
89284874|NCT02475681|Experimental|Arm C - Acalabrutinib Monotherapy|Acalabrutinib (ACP-196) will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.
89284875|NCT02470260||Diabetes|Defined by clinical history or HbA1c criteria (HbA1c greater of equal to 6.5%)
89284876|NCT02470260||Pre-diabetes|Defined by HbA1c criteria (5.7 to 6.4%)
89284877|NCT02470260||Normal glucose tolerance|Defined by HbA1c criteria (< 5.7%)
89284878|NCT02441686|Experimental|Lenalidomide, subcutaneous Bortezomib, Dexamethasone|"Lenalidomide (R): 25 mg on days 1-14 orally Subcutaneous Bortezomib (sqV): 1.3 mg/m^2 on days 1, 4, 8 and 11 Dexamethasone (d): 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 Stem cell mobilization occurs at the end of Cycle 4. Participants may elect to stop treatment at the end of Induction Cycle 4 and proceed to autologous stem cell transplant (ASCT) with melphalan 200 mg/m^2 conditioning, or receive a full 8 cycles of RsqVd induction therapy. RsqVd cycle duration is 21-days.~Maintenance follows with the specific regimen determined by risk category. High-risk participants defined as those with International Staging System (ISS) stage II or stage III disease and/or high-risk cytogenetics including t(4;14), t(4; 16), del(17p) receive sqV of 1.3 mg/m^2 on days 1 and 15 in addition to R 10mg (15mg after cycle 3 if tolerated) on days 1-21 of 28-day cycle. Standard-risk participants receive R monotherapy."
89284879|NCT02428205|Experimental|Propranolol arm|Propranolol will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session. To minimize risk, the bodyweight adjusted minimum dose of propranolol used safely for test anxiety in healthy adults (10mg) will be used: participants weighing > 30 kg will be given 4 mg, participants weighing 22.5 - 30 kg will be given 3 mg, participants weighing 15 - 22.5 kg will be given 2 mg. Participants weighing < 15 kg will be excluded for safety reasons.
89284880|NCT02428205|Placebo Comparator|Placebo arm|Placebo will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session.The same bodyweight adjusted doses specified in the propranolol arm will be used for this arm.
89284881|NCT02415712||Fomepizole Intravenous Infusion|Fomepizole Intravenous Infusion
89284882|NCT02375841||Physicians, Patients, and Caregivers|This is a longitudinal study of patients with GBM with recurrent or multi-recurrent disease as determined by their neuro-oncologist (on the basis of clinical and/or radiological findings). Patients will indicate a single caregiver who will consent separately and perform separate assessments. The study assessments will evaluate the content of the discussion in which this change in disease status was communicated, as well as include patient-reported and caregiver-reported outcomes. We intend to accrue 160 total participants (80 patients and 80 caregivers) with complete post-discussion visit follow-ups over 18-24 months.
89284884|NCT02308982|Active Comparator|Intravenous immunoglobulin|Intravenous immunoglobulin: 1g/kg per day for 2 consecutive days
89284885|NCT02308982|Placebo Comparator|Placebo|Equivalent volume to 1g/kg of IVIG per day for 2 consecutive days
89284886|NCT02280356|Experimental|radiation therapy in combination with brachytherapy|Patients will undergo low dose rate (LDR) prostate brachytherapy using Pd-103 followed approximately 4 weeks later with hypofractionated image-guided external beam radiation therapy (25Gy in 5 fractions; 5Gy x 5 fractions every other day) to the prostate & seminal vesicles. Both brachytherapy as well as external beam will be performed according to our current standards of practice using the same equipment, techniques, & treatment planning procedures. Pts will be followed post-treatment at 1, 3, 6 (+/- 4 weeks) & every 6 months (+/- 4 weeks) thereafter until 36 months. During the post-treatment followup, pts will be evaluated for urinary, bowel/rectal & sexual toxicity. Baseline measures of these domains will be obtained prior to treatment at the time of enrollment. Serum PSA levels will be drawn on the same schedule as clinical followup. Post-treatment prostate biopsies will be obtained once between 24-36 months post-treatment to evaluate pathologic response to therapy
89284888|NCT02179853|Experimental|Anakinra|This is a dose escalation study (4 mg/kg, 6 mg/kg and 8 mg/kg).
89284889|NCT02143466|Experimental|AZD6094|AZD9291 in combination with AZD6094
89284890|NCT02143466|Experimental|Selumetinib|AZD9291 in combination with selumetinib
89284891|NCT02143466|Experimental|MEDI4736|AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
89284892|NCT02143466|Experimental|AZD6094 (monotherapy)|AZD6094 in monotherapy (for Japan only)
89284893|NCT02134301|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
89284894|NCT02102789|Experimental|Systemic chemotherapy|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
89284895|NCT02102789|Experimental|Systemic chemotherapy combined with HAI|"Patients will receive mFOLFOX6+HAI every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15. 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
89284896|NCT01881373|Experimental|CHL program|Multiple component environmentally focused intervention designed with a community engagement process.
89284897|NCT01881373|Other|Delayed Optimized CHL program|Comparison community that participated in community engagement process and received delayed optimized program.
89284898|NCT01881373|No Intervention|Temporal|Communities assessed for temporal trends in anthropometry.
89284899|NCT01865929|Active Comparator|Robotic hysterectomy|Minimally invasive hysterectomy by robotic surgery
89284900|NCT01865929|Active Comparator|Vaginal or laparoscopic hysterectomy|Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
89284901|NCT01805609|Experimental|Working with the Caregiving Family (WCF) training|This is a new training curriculum for inpatient oncology providers called Working with the Caregiving Family (WCF) training, a program designed to teach MSKCC inpatient staff to address family-level concerns during acute hospitalization. The WCF training will teach staff to recognize and inquire about areas of family distress that are likely to impact the caregiving process; to provide brief, supportive interventions, and/or to transition families to specialized support services when needed. We will provide staff with skills to address especially challenging family situations (e.g., noncompliance with medical care, conflict, poor communication) in collaborative and compassionate ways. We will teach clinicians to intervene and respond more effectively when problematic relationships develop within families or between families and larger systems (e.g., medical team, institutional programs).
89284902|NCT01781949|Other|A: Nontargeted rapid HIV screening|Eligible patients randomized to this arm will be offered rapid HIV screening without assessment of risk. HIV testing will occur on a 24-hour basis as part of routine ED care.
89284903|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions regarding HIV risk using the Denver HIV Risk Score (DHRS), an empirically-developed clinical prediction instrument for assessing HIV risk, to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
89284904|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions related to HIV risk using a traditional behavioral risk screening tool to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
89284905|NCT01774409|Experimental|Blood and tumor samples|
89284906|NCT01149850|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks and oral temozolomide on days 1-5. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
89284907|NCT01120184|Experimental|Trastuzumab + Taxane (docetaxel or paclitaxel)|
89284908|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab|
89284909|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab placebo|
89284910|NCT01087320||Genetic Disorders|Patients or family probands with genetic cause of disorders that are intractable or difficult to identify with existing technique.
89284911|NCT00872495||1|"Bladder Cancer Group:~Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue.~Two urine samples collected at the time of the scheduled procedure:~One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection."
89284912|NCT00872495||2|Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.
89284913|NCT00867048|Experimental|Early ART|Initiate ART immediately following randomization
89284914|NCT00867048|Active Comparator|Deferred ART|Defer ART until the CD4+ count declines to <350 cells/cu mm or AIDS develops
89284915|NCT00567580|Active Comparator|PBRT Alone|Prostate bed radiotherapy (PBRT) begins within 6 weeks (+/- 2 weeks) after registration.
89284916|NCT00567580|Experimental|PBRT + STAD|Prostate bed radiotherapy (PBRT) and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before radiotherapy (RT), and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
89284917|NCT00567580|Experimental|PLNRT + PBRT + STADT|Pelvic lymph node radiotherapy (PLNRT), prostate bed radiotherapy (PBRT), and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before RT, and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
89284918|NCT00407654|Experimental|Arm I|Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
89284919|NCT00067054||1|Sample collection only
89284920|NCT00274469|Experimental|1|Fulvestrant
89284921|NCT00274469|Active Comparator|2|Anastrozole
89284922|NCT03214588|Placebo Comparator|Placebo|TAK-831 placebo-matching tablets, orally, twice daily for up to 12 weeks.
89284923|NCT03214588|Experimental|TAK-831 75 mg|TAK-831 75 mg, tablets, orally, twice daily for up to 12 weeks.
89284924|NCT03214588|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, twice daily for up to 12 weeks.
89284925|NCT01556776|Experimental|Lenalidomide|lenalidomide maintenance following firstline treatment with FCR, BR, FR, or FC(if Rituximab is contraindicated)
89284926|NCT01556776|Placebo Comparator|Placebo|placebo
89284927|NCT05425810|Experimental|Transtibial patient|All the recruited participants will be included in this arm and will go through the socket manufacturing, fitting, and testing procedure.
89284928|NCT03166618|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.
89284929|NCT03166618|No Intervention|Control_No Treatment|No treatment is administered.
89284930|NCT02810236|Active Comparator|No ultrasound|No ultrasound recommended. Discussion with radiologist.
89284931|NCT02810236|Active Comparator|Ultrasound|Ultrasound recommended.
89284932|NCT05353036||Adolescents|Patients 12-21 years undergoing anesthetic care
89284933|NCT05294614|Other|A B B B B B B B B C C C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A B B B B B B B B C C C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
89284934|NCT05294614|Other|A A B B B B B B B B C C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A A B B B B B B B B C C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
89284935|NCT05294614|Other|A A A B B B B B B B B C C C C|"Considering the study design of a closed cohort study, the design of this study is composed by 3 sequences (3 different starts of the treatment phase). In this case, the following arm is established as de first arm of the study: A A A B B B B B B B B C C C C.~In this sequence A represent the control phase, B the treatment phase and the C the maintenance phase."
89284936|NCT05225818|Experimental|Experimental: PLAN - Home|Trained NPs will deliver the PLAN-Home to the enrolled participants, which consists of home-based dementia evaluation, education, and care planning for older adults with probable dementia.
89284937|NCT05225818|No Intervention|No intervention: Control Group|The control group will receive a copy of the publicly available educational material on 10 warning signs and symptoms of Alzheimer's disease and action steps prepared by Alzheimer's Association.
89284938|NCT02599558|Experimental|Cytosponge-directed food reintroduction|Subjects will follow the six-food elimination diet per clinical protocol. The cytosponge will be used to monitor the diet at certain timepoints during food reintroduction
89284939|NCT01314976|Experimental|Metronidazole|Active treatment.
89284940|NCT01314976|Placebo Comparator|Placebo|Passive treatment.
89284941|NCT04504942|Experimental|Leronlimab 525mg|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
89284942|NCT04466800|Experimental|Intervention group_rehabilitation program|multidisciplinary and personalized rehabilitation program
89284943|NCT04466800|No Intervention|Control group|Usual care of each site, including delivery of an information sheet concerning recommended physical activity (based on WHO recommendations) and nutrition. One month after inclusion, patients of this group will be offered a rehabilitation program (as described in the intervention group, but with only one session with a physical activity educator at home) and one dietitian consultation.
89284944|NCT01882816|Experimental|IMRT and doxorubicin|All patients will undergo radiation treatments using IMRT with concurrent low-dose radiosensitizing doxorubicin at 10 mg/m2 will be administered.
89284945|NCT03162796|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
89284946|NCT03162796|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
89284947|NCT03162796|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
89284948|NCT03162328|Placebo Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers. After 2 nights in the lab in the sham condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
89284949|NCT03162328|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night. After 2 nights in the lab in the stim condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
89284950|NCT00272987|Experimental|Cohort 1|Participants received: paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily
89284951|NCT00272987|Experimental|Cohort 2|Participants received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily.
89284952|NCT00272987|Experimental|Cohort 3|Participants in this arm received 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 750 mg PO
89284953|NCT01069757|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
89284954|NCT01070927|Experimental|cohort 1|
89284955|NCT01070927|Experimental|cohort 2|
89284956|NCT03976271|Active Comparator|T1DM poor glycaemic control|patients with type 1 diabetes and poor glycaemic control (HbA1c >8% / >64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
89284957|NCT03976271|Active Comparator|T1DM impaired awareness|patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
89284958|NCT03976271|Active Comparator|T1DM Normal awareness|patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
89284959|NCT03976271|Active Comparator|T2DM + Insulin|patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
89284960|NCT03976271|Active Comparator|Healthy control T2DM|healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
89284961|NCT03976271|Active Comparator|Healthy control T1DM|Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
89284962|NCT01069835||1|Non-small cell lung cancer patients
89284963|NCT01069913|Active Comparator|BG00012|BG00012 Standard Formulation
89284964|NCT01069913|Active Comparator|BG00012 API|BG00012 API
89284965|NCT01730950|Active Comparator|Bevacizumab|Bevacizumab every 2 weeks
89284966|NCT01730950|Experimental|Bevacizumab + RT|Radiation therapy with bevacizumab every 2 weeks
89284967|NCT01069991|Experimental|Patient education group|Patient education program delivered to high school students with persistent asthma.
89284968|NCT01069991|Experimental|Wait list control group|Control students received no intervention until the one year follow up period was completed.
89284969|NCT00271505|Experimental|Avastin + Docetaxel + Carboplatin|Avastin 15 mg/kg intravenously (IV) every 3 weeks. Docetaxel 75 mg/m2 IV every 3 weeks. Carboplatin AUC 6 IV every 3 weeks.
89284970|NCT01642186|Experimental|Arm A everolimus|"Everolimus will be administered at the following doses:~Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
89284971|NCT01642186|Experimental|Arm B letrozole plus leuprolide|"Day 1 of Cycle 1: Leuprolide 7.5 mg IM will be administered by a nurse in clinic.~Letrozole will be dispensed and will be taken at home. Patients will be instructed to take letrozole at the same time each day, consistently with food or without food, and swallowed whole with a glass of water. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
89284972|NCT01642186|Experimental|Arm C combination everolimus, letrozole and leuprolide|"Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. Leuprolide 7.5 mg IM will be given every 4 weeks (+/- 7 days). Everolimus and letrozole will be administered continuously using the same dose, schedule and administration. Everolimus, letrozole and leuprolide should be administered concurrently at all times."
89284973|NCT03953352|Other|Radiotherapy treatment|
89284974|NCT03546322||Registry|Head and neck cancer patients monitored on registry
89284975|NCT01413802|Experimental|Thyroid surgery.|Patients who undergo thyroid surgery during which intra operative continuous nerve monitoring will be used.
89284976|NCT03635944||Group A|Infants born in Lyon (France)
89284977|NCT03635944||Group B|Infants born in Stockholm (Sweden)
89284978|NCT01264510|Other|patients implanted with a Bone-anchored hearing aid(Baha)|
89284979|NCT01315054|Other|Control arm|Using currently practiced methadone dosage prescription methods
89284980|NCT01315054|Experimental|MMT provider dosage training|Intensive health care provider training on prescribing methadone dosage based on national guidelines
89284981|NCT01315054|Experimental|MMT provider dosage training/counseling|Intensive health care provider training on prescribing methadone dosage, plus providing on-site psychosocial counseling services and peer support to clients .
89284982|NCT00423514|Experimental|cytoreduction regimen & stem cell transplant|This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).
89284983|NCT01329874|No Intervention|Gow gates ,conventional block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
89284984|NCT01329874|No Intervention|Buccal infiltration, Lingual infiltration|
89284985|NCT01329952||Current intravenous drug users|Those who were actively injecting drugs at the time of their hepatitis C treatment.
89284986|NCT01329952||Past drug users|Those who stopped injecting drugs intravenously at least 6 months prior to the start of treatment for hepatitis C
89284987|NCT00289991|Active Comparator|Itraconazole|
89284988|NCT00289991|Experimental|Voriconazole|
89284989|NCT00289913|Experimental|VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
89284990|NCT00289913|Experimental|PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
89284991|NCT00289913|Experimental|VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.~Week 24: The second dose of VAQTA™ was administered."
89284992|NCT00289913|Experimental|PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ was administered.~Week 4: The first dose of VAQTA™ was administered.~Week 28: The second dose of VAQTA™ was administered."
89284993|NCT00289913|Experimental|VAQTA™/VAQTA™ (Stage 2)|"Day 1: The first dose of VAQTA™ was administered.~Week 24: The second dose of VAQTA™ was administered."
89284994|NCT01325675|Experimental|Interval training|Interval training
89284995|NCT01325675|No Intervention|Control|Live as usual
89284996|NCT01325753|Experimental|Treatment (cryoablation)|Patients undergo CT-guided CA.
89284997|NCT00270413|Experimental|1|sutent
89284998|NCT00270413|No Intervention|2|
89284999|NCT01325831|Experimental|transcranial magnetic stimluation|
89285000|NCT01325831|Sham Comparator|rTMS_sham|
89285001|NCT00289289|Active Comparator|On-Off|Subjects have intervention pacing features turned On according to randomization assignment in the first crossover period then Off in the second period.
89285002|NCT00289289|Active Comparator|Off-On|Subjects have intervention pacing features turned Off according to the randomization assignment for the first crossover period and then On in the second period.
89285003|NCT00289289|No Intervention|Non-randomized|Subjects that did not have device recorded episodes of atrial tachycardia/atrial fibrillation during the 3 month observation period post-implant did not qualify for randomization but were continued to be followed in the study. There were no programming requirements and symptom activations were not collected.
89285004|NCT00270257|Experimental|Long term medication assisted treatment (LT-MAT)|Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
89285005|NCT00270257|Experimental|Short term medication assisted treatment (ST-MAT)|Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
89285006|NCT00269633|Placebo Comparator|Red Light Box 657 nm|Red Light Box 657 nm
89285007|NCT00269633|Active Comparator|Blue Light Box 467 nm|Blue Light Box 467 nm
89285008|NCT00269477|Experimental|Menactra® Vaccine Group 1|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
89285009|NCT00269477|Experimental|Menactra® Vaccine Group 2|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination
89285010|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 3|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
89285011|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 4|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination.
89285012|NCT00269399|Experimental|Rifaximin Treatment Arm|rifaximin 400mg taken 3 times a day
89285013|NCT00269399|Active Comparator|Vancomycin Comparator Arm|vancomycin 125mg taken 4 times a day
89285014|NCT00289133|Active Comparator|GVF|Gamma Vacuum Foil polyethylene tibial insert
89285015|NCT00289133|Active Comparator|P.F.C.|Cross-linked polyethylene tibial insert
89285016|NCT00288587|Active Comparator|Ultrafiltration|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
89285017|NCT00288587|Active Comparator|Usual & Customary|Patients treated with conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
89285018|NCT00268463|Active Comparator|Arm 1: Capecitabine + Oxaliplatin|Within 4-6 weeks after surgery and/or ablation, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
89290280|NCT05114278|Active Comparator|Oral Iron only|Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
89290281|NCT01222026|Active Comparator|Strontium Ranelate|Receiving Strontium Ranelate + Ca/Vitamin-D
89290282|NCT01222026|Placebo Comparator|Placebo|Receiving Placebo + Ca/Vitamin D
89285019|NCT00268463|Experimental|Arm 2: Floxuridine + Oxaliplatin + Capecitabine|Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.
89285020|NCT00288509|Experimental|Dysport|250-1000 units
89285021|NCT03975023||hockey players|"During each study visit, the participants will undergo the following procedures:~NeuroCatch Platform (NCP) assessment (only if participant meets NCP-specific criteria)~RightEye's eye-tracking battery~Highmark Interactive's EQ application~Cambridge Brain Science's neuropsychological tests"
89285022|NCT03741803|Active Comparator|Delayed cord clamping|
89285023|NCT03741803|Active Comparator|Early cord clamping|
89285024|NCT01070147|Experimental|Control|The control group will receive a paper-based printed asthma guideline.
89285025|NCT01071005|Experimental|Test|Lorelin Depot - Bergamo
89285026|NCT01071005|Active Comparator|comparator|Lupron Depot® - Abbott
89285027|NCT00266825|Experimental|DHA capsules|DHA capsules
89285028|NCT00266825|Placebo Comparator|Placebo capsules|Placebo capsule
89285029|NCT03976037|Active Comparator|Vaginal Misoprostol in combination with foley bulb|"Women in the vaginal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of misoprostol per vagina along with the insertion of a16F Foley catheter with a stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~Vaginal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
89285030|NCT03976037|Active Comparator|Buccal Misoprostol in combination with foley bulb|"misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
89285031|NCT00265889|Experimental|Poor Risk|Primary progressive, recurrent, or resistant relapse patients
89285032|NCT00265889|Experimental|Good Risk|First recurrence patients
89285033|NCT01333696|Experimental|Pemetrexed|500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity
89285034|NCT01333774||Group 1|
89285035|NCT01333852|Active Comparator|Paclitaxel, placebo|Paclitaxel 175mg/m² q21d until disease progression, unacceptable toxicity or consent withdrawal
89285036|NCT01333852|Experimental|Paclitaxel plus metformin|Paclitaxel 175mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
89285037|NCT01333930|Experimental|Test product (Active O2)|
89285038|NCT01333930|Placebo Comparator|Placebo (Adelholzener Mineralwasser)|
89285039|NCT01334164|Experimental|Recovery Management Checkup (RMC)|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
89285040|NCT01334164|Active Comparator|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own.
89285041|NCT01334242|Experimental|LX4211|400 mg of LX4211 administered orally
89285042|NCT01334242|Placebo Comparator|Placebo|Nonidentical placebo administered orally
89285043|NCT01334320|Experimental|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
89285044|NCT01334320|No Intervention|wait and see|patient underwent primary tumor excision transorally as initial treatment, and without a cervical intervention
89285045|NCT01334398||Initial Treatment Group|
89285046|NCT01334398||Deferred Treatment Group|
89285047|NCT03209362|Experimental|SI-613|
89285048|NCT03209362|Placebo Comparator|Placebo|
89285049|NCT05151406|Active Comparator|medical students|5th year undergraduate medical students
89285050|NCT05151406|Active Comparator|nursing students|4th year undergraduate nursing students
89285051|NCT02932462|Experimental|DSXS 1535|DSXS 1535 topical product
89285052|NCT02932462|Placebo Comparator|Placebo|Vehicle
89285053|NCT03206788|Experimental|Losartan group|Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
89285054|NCT03206788|Placebo Comparator|Placebo group|Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.
89285055|NCT03356392||stroke patients|acute stroke patients treated with endovascular treatment combined with or without
89285056|NCT03205150|Experimental|LIK066 30 mg|Film coated tablet of LIK066 30 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
89285057|NCT03205150|Experimental|LIK066 150 mg|Film coated tablet of LIK066 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
89285058|NCT03205150|Experimental|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
89285059|NCT02932306|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
89285060|NCT02932306|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
89285061|NCT04936984|Experimental|Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
89285062|NCT04936984|Experimental|Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
89285063|NCT04936984|Experimental|Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
89285064|NCT04936984|Experimental|Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min|Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).
89285065|NCT04886050|Active Comparator|LC350189 Formulation A (Tablet)|Each subject will be administered a single LC350189 200mg (QD) Tablet on Day 1 and Day 5, respectively.
89285066|NCT04886050|Active Comparator|LC350189 Formulation B (Capsule)|Each subject will be administered two LC350189 100mg (QD) Capsules (2 x 100-mg capsules) on Day 1 or Day 5, respectively.
89285067|NCT02932228|Experimental|ImPACT|Patients in ImPACT receive intensive outpatient care from the ImPACT team. The ImPACT team augments existing PACT primary care with intensive services delivered by a multidisciplinary team (including a physician, nurse practitioner, social worker, recreational therapist, and program coordinator). ImPACT program elements include a comprehensive patient assessment, identification and tracking of patients' goals and priorities, care management for medical and social service needs, co-attendance at specialty care appointments, and coordination of care with VA and non-VA providers, including during and after hospitalization.
89285068|NCT02932228|No Intervention|PACT|Patients in PACT receive usual VA primary care through the VA's Patient Centered Medical Home. VA primary care is delivered by PACT teamlets that comprise a primary care provider, nurse, clinical associate, and administrative associate who are supported by social work, pharmacy, and behavioral health services.
89285069|NCT02931838|Experimental|BMS-986165 Dose 1|Specified dose of BMS-986165 on specified days.
89285070|NCT02931838|Experimental|BMS-986165 Dose 2|Specified dose of BMS-986165 on specified days.
89285071|NCT02931838|Experimental|BMS-986165 Dose 3|Specified dose of BMS-986165 on specified days.
89285072|NCT02931838|Experimental|BMS-986165 Dose 4|Specified dose of BMS-986165 on specified days.
89285073|NCT02931838|Experimental|BMS-986165 Dose 5|Specified dose of BMS-986165 on specified days.
89285074|NCT02931838|Placebo Comparator|Placebo|Specified dose of Placebo for BMS-986165 on specified days.
89285075|NCT03201562|Experimental|Aceclidine+tropicamide combination|Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution)
89285076|NCT03201562|Active Comparator|Aceclidine|Aceclidine single dose
89285077|NCT03201562|Sham Comparator|Vehicle|Vehicle single dose
89285078|NCT03321916|Experimental|Subthreshold Photothermal Therapy|
89285079|NCT03321916|Sham Comparator|Sham|
89285080|NCT04693390|Experimental|Acupuncture|The acupuncture will be applied at points LI4, ST36, HT7, in association with auriculotherapy point Master Cerebral, immediately after induction of anesthesia for 20 minutes
89285081|NCT04693390|No Intervention|Standard care group|The patients will follow the standard procedure
89285082|NCT03200860|Active Comparator|Empagliflozin|Empagliflozin 10 mg daily, oral, 30 days
89285083|NCT03200860|Placebo Comparator|Placebo|Matching Placebo 10 mg daily, oral, 30 days
89285084|NCT04520932|Experimental|RFA treatment efficacy|PNETs ablation by radiofrequency treatment (1 to 3 sessions)
89285085|NCT04501432||Cardiac Rehabilitation|Participants will be recruited from a group of patients who regularly attended group-based cardiac rehabilitation exercise training at the study site until COVID-19 restrictions (national lockdown) came into force on 16th March 2020.
89285086|NCT03198754|Experimental|PEI Experimental Light|Ambient light fixture installed in the patient's hospital room
89285087|NCT03198754|Active Comparator|Comparison Light|Ambient light fixture installed in the patient's hospital room
89285088|NCT03198520|Other|Polymer Removable Partial Denture|Evaluate the change in patient Oral Health-related Quality of Life while wearing the Solvay Dental 360™ polymer Removable Partial Denture (RPD)
89285089|NCT01314508|Other|All patients will be treated with IGF-1 factors|Patients will serve as their own control.
89285090|NCT03194464|Experimental|Task-failure, Extended Session|Repeated sub-maximal gripping exercise with the less affected hand to task-failure - followed by repeated measurements (5) during recovery period
89285091|NCT04040920|Experimental|Ozone therapy|Ozone application before pits and fissure sealants
89285092|NCT04040920|Active Comparator|Pits and fissure sealants|
89290283|NCT05095168|Experimental|Single Ascending Dose (SAD)|In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). Additional subjects may be added in any cohort if necessary.
89285093|NCT03192904|Experimental|Energy Instruments Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
89285094|NCT03192904|Experimental|Stapling Device Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
89285095|NCT03912532|Experimental|NGM282 Dose 1|Administered by subcutaneous injection
89285096|NCT03912532|Experimental|NGM282 Dose 2|Administered by subcutaneous injection
89285097|NCT03912532|Experimental|NGM282 Dose 3|Administered by subcutaneous injection
89285098|NCT03912532|Placebo Comparator|Placebo|Administered by subcutaneous injection
89285099|NCT01314586|Placebo Comparator|placebo|placebo pill, diet counseling to comply with NCEP Step I diet
89285100|NCT01314586|Experimental|150 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 150 mg secoisolariciresinol (SDG) per day for 12 weeks
89285101|NCT01314586|Experimental|300 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 300 mg secoisolariciresinol (SDG) per day for 12 weeks
89285102|NCT03188536||Multiple Myeloma (MM) Participants|Adult participants with a diagnosis of MM who received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
89285103|NCT03187756|Experimental|Cyclophosphamide|
89285104|NCT03022708|Experimental|Xeltis Bioabsorbable Pulmonary Valved Conduit|"The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.~The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~In addition, the PV conduit can be used for the following indications:~replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).~Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve."
89285105|NCT02926924|Active Comparator|Wound Vac|Wound vac
89285106|NCT02926924|Active Comparator|Standard Dressing|Standard Dressing
89285107|NCT03187132|Experimental|Digital Pain Reduction Kit|Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
89285108|NCT03187132|Active Comparator|Active Control|Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.
89285109|NCT03184558|Experimental|Bemcentinib (BGB324) + pembrolizumab|Participants received Bemcentinib (BGB324) capsules orally once daily as a loading dose of 400 milligram (mg) on Days 1, 2, and 3. A dose of 200 mg pembrolizumab was given by intravenous infusion over 30 minutes every 3 weeks in all participants. Dosing of both drugs commenced on Day 1. On days when both BGB324 and pembrolizumab were given, pembrolizumab was given first and participants were observed for 1 hour after the end of infusion before BGB324 was administered. From Day 4 onward, participants received a daily maintenance dose of 200 mg along with Pembrolizumab 200 mg intravenous (IV) infusion over 30 minutes every 3 weeks until disease progression, until an unacceptable toxicity occurred that required treatment withdrawal or withdrawal of consent or until 106 weeks had passed.
89285110|NCT03183778|Experimental|Patiromer + Research Diet|"During the first phase (week 2), participants will be transitioned to a plant-rich renal diet, which contains moderate protein (10-15% of kcal), restricts dairy products (less than or equal to 1 serving/day), and eliminates high-potassium fruits and vegetables.~During the second phase (weeks 3 and 4), the diet will be altered to provide at-least half of fruits and vegetables from high-potassium sources."
89285111|NCT03182686|Experimental|AMPION™ 4 mL dose|4 mL injection of Ampion
89285112|NCT03182686|Placebo Comparator|Placebo 4 mL dose|4 mL injection of Placebo
89285113|NCT03181594|Experimental|Treatment with the ClariFix Device|Bilateral ablation of nasal tissue for treatment of chronic rhinitis
89285114|NCT03180736|Experimental|Daratumumab+Pomalidomide+Dexamethasone|Daratumumab at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
89285115|NCT03180736|Active Comparator|Pomalidomide + Dexamethasone|Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
89285116|NCT05240092|Experimental|Haptonomy Group|A home visit was made to the experimental group, and haptonomy was applied for at least 30 minutes, once a week, for 7 weeks (with the researcher for 3 weeks, with the husband by providing the training brochure and video that will help the practice for the next 4 weeks).
89285117|NCT05240092|No Intervention|Standard of care Group|The control group did not receive any treatment.
89285118|NCT03178942|Active Comparator|Reference: Elimite™ Cream|Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
89285119|NCT03178942|Experimental|Test: Permethrin Cream, 5%|Test: Permethrin Cream, 5% (Encube Ethicals)
89285120|NCT05239702|Experimental|Crohn Disease|
89285121|NCT05239702|Experimental|Ulcerative Colitis|
89285122|NCT05239702|Experimental|Dermatomyositis|
89285123|NCT05239702|Experimental|Still Disease|
89285124|NCT05239702|Experimental|Autoimmune Diseases|
89285125|NCT03175198||Patients with nonvalvular atrial fibrillation (NVAF)|Patients with nonvalvular atrial fibrillation (NVAF) taking daily oral dose of Prazaxa® Capsules (Dabigatran etexilate). Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg [as 2 capsules of 75 mg] twice a day (b.i.d)) or 220 mg (110 mg [as 1 capsule of 110 mg] b.i.d) for a treatment duration of 52 weeks.
89285126|NCT03087448|Experimental|Ceritinib + Trametinib|"PHASE 1 Standard 3+3 dose escalation starting at dose level 1. Patients with ALK-rearranged, or ROS-1 rearranged NSCLC. 6-18 patients will be enrolled.~Ceritinib dose: 300-450mg orally, once daily over 28 day cycles. Trametinib dose: 1.5mg-2.0mg orally, once daily over 28 day cycles.~PHASE II The study was terminated before Phase II was initiated. The study did not open Phase II for enrollment."
89285127|NCT03175120|Experimental|Insulin degludec/liraglutide|
89285128|NCT03175120|Active Comparator|Insulin degludec|
89285129|NCT03172702|Experimental|Sodium Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
89285130|NCT02795182|Other|Zanubrutinib abd Tislelizumab|Based on results of the dose escalation cohorts and the identified recommended Phase 2 dose, all patients will receive zanubrutinib at 160 mg orally twice daily in combination with intravenous infusion of tislelizumab 200mg given every 21 days, to be continued until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination
89285131|NCT05213182|Experimental|Intervention|The intervention arm (n=104 adolescent mothers) participated in the 12 in-person peer support group sessions and completed sociodemographic, base-, mid-, and end-line surveys.
89285132|NCT05213182|No Intervention|Control|The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys.
89285133|NCT05206162|Active Comparator|continuous theta burst stimulation|cTBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s.
89285134|NCT05206162|Active Comparator|intermittent theta burst stimulation|iTBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in an intermittent train of 190s for iTBS, with repeated cycles of 2s stimulation and 8s pause.
89285135|NCT05206162|Sham Comparator|sham stimulation|Sham stimulation over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s using a plastic spacer (25mm thickness) between coil and scalp, preventing effective cortical stimulation.
89285136|NCT03054766|Experimental|Ranibizumab only|"Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Sham macular laser"
89285137|NCT03054766|Experimental|Ranibizumab combined macular laser|"Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation"
89285138|NCT05068570|Experimental|EXPERMINTAL GROUP|start with cycle at a pace of 15-25 cycles per minute without resistance and end with cycle 45cycles per minute
89285139|NCT05068570|No Intervention|CONTROL GROUP|selected respiratory exercise program
89285140|NCT03036748|Experimental|TX control|Kidney transplant recipients with urinary albumin/creatinin-ratio < 30mg/g
89285141|NCT03036748|Experimental|TX Proteinuria|Kidney transplant recipients with urinary albumin/creatinin-ratio > 300mg/g
89285142|NCT04933786|Experimental|Digital Health Nudging|During 12-week intervention period participants receive daily text messages via WhatsApp on their smartphone to encourage them to be physically active in their daily lives.
89285143|NCT04933786|No Intervention|Control|During 12-week control period participants receive no text messages.
89285144|NCT04935736|Experimental|CORTISOMOL SP|Zinc oxide/Eugenol-type sealer containing 1% Prednisolone Acetate. The sealer is used in combination with gutta percha points for the permanent obturation of root canals.
89285145|NCT04935736|Active Comparator|SEALITE REGULAR|The Zinc oxide/Eugenol-type sealer is used in combination with gutta percha points for the permanent obturation of root canals.
89285146|NCT03167242|Experimental|Part A - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 400 mg and LUM-SDF 960 mg
89285147|NCT03167242|Experimental|Part A - Cohort 2: KAF 800 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 800 mg and LUM-SDF 960 mg
89285148|NCT03167242|Experimental|Part A - Cohort 3: KAF 400 mg and LUM 960 mg QD for 2 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 2 days
89285149|NCT03167242|Experimental|Part A - Cohort 4: KAF 200 mg and LUM 480 mg QD for 3 days|Participants received KAF156 200 mg and LUM-SDF 480 mg once daily via oral administration for 3 days
89285150|NCT03167242|Experimental|Part A - Cohort 5: KAF 400 mg and LUM 480 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 480 mg once daily via oral administration for 3 days
89285151|NCT03167242|Experimental|Part A - Cohort 6: KAF 400 mg and LUM 960 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 3 days
89285152|NCT03167242|Active Comparator|Part A - Cohort 7: Coartem|Participants received Coartem twice daily via oral administration for 3 days
89285153|NCT03167242|Experimental|PK Run-in Cohort: KAF 200 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 200 mg and LUM-SDF 960 mg
89285154|NCT03167242|Experimental|Part B - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 day|Participants received a single oral dose of KAF156 400 mg and LUM-SDF 960 mg
89285155|NCT03167242|Experimental|Part B - Cohort 2: KAF 400 mg and LUM 960 mg QD for 2 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 2 days
89285156|NCT03167242|Experimental|Part B - Cohort 3: KAF 400 mg and LUM 960 mg QD for 3 days|Participants received KAF156 400 mg and LUM-SDF 960 mg once daily via oral administration for 3 days
89285157|NCT03167242|Active Comparator|Part B - Cohort 4: Coartem|Participants received Coartem twice daily via oral administration for 3 days
89285158|NCT02964052||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
89285159|NCT04780828||GROUP I|Group I will include cases classified as normal weight (healthy) with a body mass index of 18.5-24.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined for this group will be made. Since this group was not considered as obese, it was determined as the control group.
89285160|NCT04780828||GROUP II|Group II will include cases classified as overweight and having a body mass index of 25.0-29.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
89285161|NCT04780828||GROUP III|Group III will include cases classified as class I obese, with a body mass index of 30.0-34.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
89285162|NCT04780828||GROUP IV|Group IV will include cases classified as class II obese, with a body mass index of 35.0-39.9 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
89285163|NCT04780828||GROUP V|Group V will include cases classified as class III (morbid) obese, with a body mass index of 40 kg / m2 as a result of the classification made by the World Health Organization. All parameter and evaluation measurements determined in this group will be made.
89285164|NCT05438056|Experimental|providing training to mothers of premature babies with a mobile application|providing training with mobile application to mothers discharged home with their premature babies +standard education prior to discharge
89285165|NCT05438056|No Intervention|standard education prior to discharge control group; standard education prior to discharge|standard education prior to discharge
89285166|NCT03636334|Experimental|Computer-based decision support system|Computer-based decision support system for BP management, with appropriate training of local PHC doctors.
89285167|NCT03636334|No Intervention|Control|After site randomization, physicians at the control sites will manage their patients with hypertension by usual care.
89285168|NCT03636178|Other|1st group|20 patients out of 40 will be enrolled into the study including males and females above 18 years old
89285169|NCT03636178|Other|2nd group|20 patients out of 40 will be enrolled in the study including males and females above 18 years old
89285170|NCT05432050||Remimazolam anesthesia|General anesthesia will be induced and maintained by remimazolam and the depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
89285171|NCT01330186||Anal cancer|
89285172|NCT01330264||Dyad|
89285173|NCT01330342||HIV patients without lymphoma|HIV-infected subjects on cART without a diagnosis of lymphoma
89285174|NCT01330342||HIV patients with lymphoma|HIV seropositive individuals with lymphoma
89285175|NCT01330498||Tysabri (natalizumab) infusing|Patients with relapsing forms of MS who participated in 001-001-TY and are currently still infusing with Tysabri (natalizumab).
89285176|NCT02026414|Experimental|PrimaVie Exercise|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
89285177|NCT01330654|Active Comparator|Beta blocker|These patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery
89285178|NCT01330654|No Intervention|Control|This arm will receive no additional treatment prior to surgery
89285179|NCT01330732||1|Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.
89285180|NCT01330810|Active Comparator|C3 tablet|4g C3 tablet
89285181|NCT01330810|Active Comparator|Meriva|2g Meriva powder
89285182|NCT01330888||Group 1|ARNG Chaplains
89285183|NCT01331044|Experimental|RUTF|Ready to use Therapeutic Food (RUTF) Plumpy nut.
89285184|NCT01331044|Active Comparator|Khichuri - Halwa|Cereal Legume
89285185|NCT01331122|Experimental|droxidopa|Northera (2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-DOPS L-threo-dihydroxyphenylserine Droxidopa SM-5688
89285186|NCT01331122|Placebo Comparator|placebo|placebo
89285187|NCT01320280|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) 50mg daily continuously (oral medication)
89285188|NCT01331278|Active Comparator|Custom Cutting Blocks|
89285189|NCT01331278|Active Comparator|Computer Assisted Surgery|
89285190|NCT01331356|Experimental|Injection of botulinum toxin type A|
89285191|NCT01331590|Experimental|G-CSF + Ifosfamide + Etoposide + Dexamethasone + Mesna|"G-CSF = 10 mcg/kg/d SQ starting on day 1 and continuing until ANC >=1000/mcL x 2 days~Ifosfamide = 3330 mg/m2/d CIVI over 24 hours on Days 4-6~Etoposide = 150 mg/m2 IV over 2 hours BID on Days 4-6~Dexamethasone = 5 mg/m2 PO or IV BID on Days 4-10~Mesna = 2660 mg/m2/d continuous IV infusion over 24 hours on Days 4-6. 2000 mg/m2 continuous IV infusion over 12 hours on Day 7 to be started immediately after completion of ifosfamide."
89285192|NCT01331746|Experimental|APD515|Active APD515 treatment 20 mg qds for 7 days
89285193|NCT01331746|Placebo Comparator|Placebo|
89285194|NCT03635866|Experimental|prior negative MRFTB of PI-RADS 4 and 5 lesions|Diagnosed withing 12 months of initial diagnostic cancer biopsy
89285195|NCT01331902|Experimental|Adenosine Followed by Nicorandil|
89285196|NCT01331902|Experimental|Nicorandil Followed by Adenosine|
89285197|NCT01331980||cystic fibrosis|children aged 6-12 years of age and Tanner stage 1 with a diagnosis of cystic fibrosis
89285198|NCT01331980||healthy controls|children ages 6-12 years and Tanner stage 1 without cystic fibrosis or other chronic disease that affects bone health
89285199|NCT01332058|Experimental|Motivational Interviewing (MI)|
89285200|NCT04261972||CHARM|Patients identified with hereditary breast and ovarian cancer syndrome (germline BRCA1 or BRCA2 carrier) or Lynch syndrome (germline variant in EPCAM, MLH1, MSH2, MSH6, or PMS2).
89285201|NCT01332136||Endoscopic sinus surgery|Patients electing endoscopic sinus surgery for chronic rhinosinusitis
89285202|NCT01332136||Medical management|Continued medical management for symptoms of chronic rhinosinusitis
89285203|NCT01332214|Experimental|AZD2820|
89285204|NCT01332214|Placebo Comparator|Placebo|
89285205|NCT01332370||Adults with Type 2 Diabetes|Subjects with a diagnosis (ICD-9 code) of diabetes
89285206|NCT01332448||Orlistat 120|Orlistat 120mg tid
89285207|NCT01332448||Orlistat 60|Orlistat 60 mg tid
89285208|NCT01332448||Placebo|No active drug
89285209|NCT03617848||Cohort|A cohort of participants with suspected stable HFpEF will be recruited from the primary care setting. HFpEF diagnosis will be confirmed as per the 2016 European Society of Cardiology (ESC) guidelines for diagnosing HFpEF. All participants will undergo a series of assessments including but not limited to pulse wave velocity, 6 minute walk test, blood tests including natriuretic peptides (NT-Pro-BNP), ECG, physical assessments and a series of questionnaires. Those with confirmed HFpEF will be followed up at 6 and 12 months.
89285210|NCT03552094||Hemochromatosis or polycythemia patients|"Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.~Blood bag (volume of blood: from 450 to 500 mL)."
89285211|NCT03552094||Healthy donors|Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
89285212|NCT01332526||Patients with BMI> 30 and metabolic syndrome ( ATP III).|Patients with BMI> 30 and metabolic syndrome ( ATP III).
89285213|NCT01332526||Patient with BMI> 30 without metabolic syndrome.|Patient with BMI> 30 without metabolic syndrome.
89285214|NCT01332526||Normal healthy control|healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).
89285215|NCT01332526||Patients with CKD stage III and uric acid < 7 mg/dl|"Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
89285216|NCT01332526||Patients with CKD stage III and uric acid > 7 mg/dl|"Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
89285217|NCT01332526||Patient with asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
89285218|NCT01332526||Hemodialysis patients|"Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.~CKD: nondiabetic nephropathy~duration hemodialysis 3-48 months~Hb-11-13 g/dl~well controlled hypertension ( < 140/90 mmHg)~without ACEi, ARB, allopurinol treatment~residual diuresis will be estimated for last 48 hours-between mid and next dialysis"
89285219|NCT04484428|Experimental|Treatment Arm A|K-285
89285220|NCT04484428|Active Comparator|Treatment Arm B|Menthol
89285221|NCT01332604|Experimental|A|
89285222|NCT01332604|Experimental|B|
89285223|NCT01332760|Active Comparator|narrow diameter heavy dental tool|periodontal tools for dental scaling and cleaning provided that have a narrow diameter (8mm) made of heavy material (steel).
89285224|NCT01332760|Experimental|light large diameter dental tool|periodontal tools for scaling and tooth cleaning provided with large diameter (11mm) handle made of light weight material
89285225|NCT01332838|Experimental|Sigvaris special compression stocking|
89285226|NCT01332838|Active Comparator|Standard Compression|
89285227|NCT01332916|Experimental|patients aged 45 and over group|patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
89285228|NCT01332916|Active Comparator|healthy volunteers (controls) aged 45 and over|healthy volunteers (controls) aged 45 and over
89285229|NCT03286426|Experimental|Vision/Eye Screening|Image of back of each eye along with color vision and visual acuity assessment if able.
89285230|NCT03127696|Experimental|FMT + LMP|FMT and lifestyle modification program
89285231|NCT03127696|Experimental|FMT alone|Fecal Microbiota Transplantation
89285232|NCT03127696|Sham Comparator|Sham + LMP|Sham and lifestyle modification program
89285233|NCT01333150|Experimental|Propranolol|
89285234|NCT01333150|Experimental|Placebo|
89285235|NCT01333228|Experimental|Endothelial Progenitors Cells|Autologous bone marrow-derived endothelial progenitor cells
89285236|NCT01333306|Experimental|tDCS and cognitive training|
89285237|NCT02972008||Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
89285238|NCT02972008||No Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
89285239|NCT02972008||patients with constitutional von Willebrand factor (vWF) deficiency|
89285240|NCT02913664|Experimental|Aerobic Exercise (Ex)|Aerobic exercise training; blood and cholesterol management will be standard-care by participant's regular doctor.
89285241|NCT02913664|Experimental|Intensive Reduction of Vascular Risk Factors (IRVR)|Lowering SBP < 130 mmHg, administration of atorvastatin 80 mg daily, and stretching exercise.
89285242|NCT02913664|Experimental|IRVR+Ex|A combination of IRVR and aerobic exercise training.
89285243|NCT02913664|Placebo Comparator|Usual Care|Blood and cholesterol management will be standard-care by participant's regular doctor, and stretching exercise.
89285244|NCT01333462|Placebo Comparator|Phosphate Buffered Saline (PBS) IN|
89285245|NCT01333462|Active Comparator|Fluzone 4 mcg HA IN|
89285246|NCT01333462|Active Comparator|Fluzone 15 mcg HA IM|
89285247|NCT01333462|Experimental|NB-1008 4 mcg HA 5% W805EC|
89285248|NCT01333462|Experimental|NB-1008 4 mcg HA 10% W805EC|
89285249|NCT01333462|Experimental|NB-1008 4 mcg HA 15% W805EC|
89285250|NCT01333462|Experimental|NB-1008 4 mcg HA 20% W805EC|
89285251|NCT01333462|Active Comparator|Fluzone 10 mcg HA IN|
89285252|NCT01333462|Experimental|NB-1008 10 mcg HA 5% W805EC|
89285253|NCT01333462|Experimental|NB-1008 10 mcg HA 10% W805EC|
89285254|NCT01333462|Experimental|NB-1008 10 mcg HA 15% W805EC|
89285255|NCT01333462|Experimental|NB-1008 10 mcg HA 20% W805EC|
89285256|NCT02818582|Active Comparator|GS-5734 100mg given intravenously daily for 5 days|Male Ebola survivors with persistent Ebola virus in their semen were given GS-5734 100mg intravenously daily for 5 days
89285257|NCT02818582|Placebo Comparator|Normal saline intravenously for 5 days|Male Ebola survivors with persistent Ebola virus in their semen were given normal saline intravenously daily for 5 days
89285258|NCT02728258|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89285259|NCT01333618|Experimental|curving introducer|
89285260|NCT01333618|Placebo Comparator|straight introducer|
89285261|NCT05186506|Experimental|Ensatinib|225 mg administered once daily orally for two years.
89285262|NCT05186506|Active Comparator|Platinum-Based Chemotherapy|Patients in the chemotherapy group were allowed to cross into the Ensatinib treatment group after the disease progressed.
89285263|NCT01337440|Active Comparator|UDCA pretreatment|"Ursodeoxycholic Acid (UDCA) for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
89285264|NCT01337440|Active Comparator|Sitagliptin pretreatment|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
89285265|NCT01337518|Experimental|EZN-4176|
89285266|NCT05186194|Experimental|Experimental (Treatment) Group|Oral vitamin D1000IU, 1/day, calcium 1200mg, 1/day, for 8 weeks.
89285267|NCT05186194|Placebo Comparator|Control Group|Oral placebo, for 8 weeks.
89285268|NCT01337830|Experimental|Ariva® Silver Wintergreen|Subjects allow study product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
89285269|NCT01337830|Active Comparator|Silver Wintergreen|Subjects allow comparator product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
89285270|NCT01338064||exposed workers|At least six months of occupational exposure to Caesar stone
89285271|NCT04446676|Active Comparator|Stem stabilization|Group of patients with stem endoprosthesis stabilization
89285272|NCT04446676|Active Comparator|Sleeve stabilization|Group of patients with sleeve endoprosthesis stabilization
89285273|NCT01338142|Placebo Comparator|CCC|Crystalline calcium carbonate (CCC)
89285274|NCT01338142|Experimental|ACC|Amorphous calcium carbonate (ACC)
89285275|NCT01338376|Experimental|Structured Education Group|Subjects received structured diabetes education
89285276|NCT01338376|Active Comparator|Conventional Care Group:|Subjects received conventional diabetes education
89285277|NCT05186038||Population of children and adolescents between 2 and 18 years old|Population of children and adolescents between 2 and 18 years old who are diagnosed with celiac disease or are suspected to suffer the disease.
89285278|NCT04442152|Experimental|Intervention|See intervention description
89285279|NCT04442152|No Intervention|Control|Participants who were randomized into the control arm were and will be surveyed at the same time point as intervention participants, but did not receive any intervention.
89285280|NCT01338454|Active Comparator|tranexamic acid|TA administered intravenously over a 5 min period at delivery of the anterior shoulder
89285281|NCT01338454|No Intervention|saline|10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder
89285282|NCT01338532|Active Comparator|Supervised exercise + patient education|
89285283|NCT01338532|Active Comparator|Patient education|
89285284|NCT02882152|Experimental|femoral blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve"
89285285|NCT02882152|Active Comparator|Morphine|intrathecal morphine
89285286|NCT05185804|Experimental|Group DD217|Study drug Dimolegin - DD217, 60 mg orally, 1 time per day
89285287|NCT05185804|Active Comparator|Group Clexane|Reference drug Clexane, 40 mg subcutaneously, 1 time per day
89285288|NCT01338688||Td ,Td and TIG|
89285289|NCT01338766|Experimental|Surgery|Decompression using the iO-Flex® system
89285290|NCT05185648|Experimental|post-training scores|evaluating qualities of trauma care after standard trauma traning
89285291|NCT01338844|Experimental|D-Chiro-inositol|Patients will receive 1.2g/day of D-chiro-inositol
89285292|NCT01338844|Active Comparator|Myo-inositol|Patients will receive 4g/day of myo-inositol
89285293|NCT01338922|Experimental|Insulin pump therapy (CSII)|Continuous subcutaneous insulin infusion therapy using different devices with marketing approval and different insulins
89285294|NCT01338922|Active Comparator|Multiple daily injection therapy (MDI)|Multiple daily injection therapy using different devices with marketing approval and different insulin types
89285295|NCT05185414|Other|RNA sequencing in genetically solved lissencephaly cases|RNA expression patterns in lissencephalies. RNA sequencing will be applied to the genetically solved lissencephaly cases. The acquired information on RNA expression patterns will be implemented in unsolved lissencephaly cases.
89285296|NCT05185414|Other|RNA sequencing in genetically unsolved lissencephaly cases|Obtain a genetic diagnosis in unsolved lissencephaly cases by implementation of RNA expression patterns obtained in arm 1.
89285297|NCT01315522|Active Comparator|ComVi stent|ComVi stent (Niti-S stent, ComVi type, Taewoong Medical Inc, Korea)
89285298|NCT01315522|Active Comparator|Uncovered SEMS|uncovered nitinol metal stent (HANAROSTENT, M.I. Tech Co., Ltd., Korea)
89285299|NCT01339156|Experimental|P3914|
89285300|NCT01339156|Placebo Comparator|Placebo|
89285301|NCT01339234|Experimental|Body-weight supported treadmill training|
89285302|NCT01339312|Experimental|VRVg Vaccine Group 1|Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
89285303|NCT01339312|Experimental|VRVg Vaccine Group 2|Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
89285304|NCT01339312|Active Comparator|Verorab Vaccine Group 1|Participants aged 18 years or older will receive Verorab Vaccine
89285305|NCT01339312|Active Comparator|Verorab Vaccine Group 2|Participants aged 10 to 17 years will receive Verorab Vaccine
89285306|NCT01339468|Experimental|Arm 1|Intravenous Prograf therapy followed by oral Advagraf therapy
89285307|NCT01339468|Active Comparator|Arm 2|Intravenous Prograf therapy followed by oral Prograf therapy
89285308|NCT01339624|Active Comparator|NASAL FENTANYL,|
89285309|NCT01339624|Active Comparator|KETOROLAC + MORPHINE|
89285310|NCT05184946|Experimental|Anti-PD1 combined with SOX|Camrelizumab will be administered one day before SOX regimen.
89285311|NCT01339702||"Pre-implementation cohort (before)"|This cohort is a combination of retrospective and some prospective severe TBI patients cared for in the EMS systems of Arizona BEFORE implementation of the national prehospital TBI management guidelines
89285312|NCT01339702||"Post-implementation cohort (after)"|"This cohort is a comprised of prospective severe TBI patients cared for in the EMS systems of Arizona AFTER training EMS providers in the implementation of the national prehospital TBI management guidelines. It is intended that these patients will receive the bundle of care specified in the TBI Guidelines."
89285313|NCT01339780|Experimental|Breast Cancer|
89285314|NCT01339780|Experimental|Prostate Cancer|
89285315|NCT01340092|Active Comparator|Family Navigator|Family navigation
89285316|NCT01340092|No Intervention|Standard Care|standard care
89285317|NCT01340170|Experimental|Soft bone drilling protocol|A soft bone drilling protocol will be used in bone quality 3 and 4
89285318|NCT01340170|Active Comparator|Standard drilling protocol|A standard drilling protocol will be used in bone quality 1 and 2
89285319|NCT01340248|Experimental|Dilatrend 64mg capsule|"* Randomized, open-label, single dose, two-period, two-way, crossover study~group : Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~group : Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
89285320|NCT01340326|Active Comparator|Valsartan,high dose|high dose group (valsartan up to 320 mg/day)
89285321|NCT01340326|Other|Valsartan, usual dose|usual dose group (valsartan 80 mg/day)
89285322|NCT05184322|Experimental|Cohort 1|Cohort 1 will enroll 10 healthy participants, doses ranging from 2mg to 7mg.
89285323|NCT05184322|Experimental|Cohort 2|Cohort 2 will enroll 10 healthy participants, doses ranging from 2mg to 15mg.
89285324|NCT05184322|Experimental|Cohort 3|Cohort 3 will enroll 10 healthy participants, doses ranging from 7mg to 30mg.
89285325|NCT05184322|Experimental|Cohort 4|Cohort 4 will enroll 10 otherwise 'healthy' participants with obesity, doses ranging from 7mg to 30mg.
89285326|NCT05184322|Experimental|T2026 tablet|Tablet containing no ecnoglutide but T2026 2 participants receiving T2026 tablet will be enrolled in each cohort.
89285327|NCT05184322|Placebo Comparator|Placebo tablet|placebo containing no ecnoglutide or T2026 2 participants receiving placebo tablet will be enrolled in each cohort.
89285328|NCT01340404|Experimental|Stem Cell Transplantation|
89285329|NCT01340404|Active Comparator|Transfusion program|
89285330|NCT05184010|Experimental|arthroscopic release with ulnar nerve mini open release|
89285331|NCT05184010|Placebo Comparator|arthroscopic release alone without ulnar nerve mini open release|
89285332|NCT01340638|Active Comparator|Cookgas|This group will be assigned to use cookgas mask
89285333|NCT01340638|Active Comparator|LMA mask|This group will be assigned to use LMA mask
89285334|NCT01340716|Active Comparator|stretching exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style.
89285335|NCT01340716|Experimental|Tai Chi Chuan exercise|patients in this group held weekly classes of two stretching for 12 weeks.
89285336|NCT01315834||Couples coping with CHD|The target group will be 127 male patients and their partners. The couples will be recruited during the patients' first hospitalization for ACS. The participants will complete questionnaires during the hospitalization and again six months later. The patients will also be asked to be weighed and have their blood drawn and at the six-month follow-up for measurement of blood Cholesterol level. Relevant data will be obtained from their medical files.
89285337|NCT01315834||control group|The control group will be 100 couples who are not coping with a life threatening illness. The couples will complete self report questionnaires at one point of time.
89285338|NCT00286091|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
89285339|NCT00286091|Experimental|Denosumb|Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
89285340|NCT01340950|Active Comparator|Better-Penetrating ART|zidovudine 300 mg orally every 12 hours lamivudine 300 mg orally daily nevirapine 200 mg orally every 12 hours
89285341|NCT01340950|Active Comparator|Worse-Penetrating ART|tenofovir disoproxil fumarate 300 mg orally daily lamivudine 150 mg orally every 12 hours efavirenz 600 mg orally daily
89285342|NCT01341028|Active Comparator|Roux-en-Y gastric bypass (LRYGBP)|Twelve subjects underwent laparoscopic Roux-en-Y gastric bypass
89285343|NCT01341028|Experimental|LRYGBP plus gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass plus gastric fundus resection
89285344|NCT01341106|Experimental|Treatment Arm|Patients will be treated with entecavir
89285345|NCT01341184|Experimental|Group 1|16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
89285346|NCT01341184|Experimental|Group 2|16 subjects: TMC207 400mg orally on days 1 and 29, rifampin 600mg orally, every day on day 20-41
89285347|NCT00285857|Experimental|Lovastatin 80 mg/day|Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.
89285348|NCT05183386|No Intervention|Control Group|The dental socket heals spontaneously
89285349|NCT05183386|Experimental|Experimental group|Distinct bone graft regeneration strategies (PRGF, Autologous bone and DFDBA)
89285350|NCT03975101|Experimental|VSEL Max|A mean volume of 5.5 mL platelet-rich plasma containing approximately 120,000 cells were prepared and injected into the selected knee of the patient
89285351|NCT03975101|Experimental|VSEL Medium|A mean volume of 5.5 mL platelet-rich plasma containing approximately 90,000 cells were prepared and injected into the selected knee of the patient
89285352|NCT03975101|Experimental|VSEL Mini|A mean volume of 5.5 mL platelet-rich plasma containing approximately 60,000 cells were prepared and injected into the selected knee of the patient
89285353|NCT03975101|No Intervention|Control|A mean volume of 5.5 mL platelet-rich plasma containing no VSELs injected into the selected knee of the patient
89285354|NCT01341340|Experimental|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
89285355|NCT01341418|Active Comparator|Suprapatellar approach|surgical approach for intramedullary nailing of the tibia
89285356|NCT01341418|Active Comparator|Infrapatellar approach|surgical approach for intramedullary nailing of the tibia
89285357|NCT01341496|Experimental|1|autologous tumor vaccine plus chemotherapy
89285358|NCT05183074|Experimental|MR-linac group|Pts received ultra-hypofractionated RT for primary w/o adjacent oligo-metastatic diseases on 1.5-Tesla MR-Linac
89285359|NCT05182996|Other|smoking education|smoking education
89285360|NCT00284141|Experimental|aflibercept 4.0 mg/kg|Participants with metastatic non-small-cell lung adenocarcinoma administered 4.0 mg/kg Aflibercept every 2 weeks until a study withdrawal criterion was met.
89285361|NCT05182684|Experimental|Single arm|Electrocardiograms were measured by VP-100 for more than 6 hours and transmitted to a central server.
89285362|NCT05182138|Placebo Comparator|Unfortified potato plus placebo|Volunteers given potato with no fortified zinc and a placebo
89285363|NCT05182138|Active Comparator|Zinc Biofortified potato plus placebo|Volunteers given potato biofortified with zinc and a placebo
89285364|NCT05182138|Active Comparator|Unfortified potato plus zinc supplement|Volunteers given potato with no fortified zinc and a zinc supplement
89285365|NCT03975257|Experimental|Preventive application of EHT02|application of one Ectoin Lozenge before SLIT-initiation
89285366|NCT03975257|Experimental|Therapeutic application of EHT02|application of one Ectoine Lozenge after SLIT-initiation
89285367|NCT03975257|No Intervention|No application of EHT02|SLIT-Initiation without Ectoin Lozenge
89285368|NCT02531945|Experimental|Intervention|"The device used in this research to the topography examination is three-dimensional morphometry device of AXS Medical society : the BIOMOD L.~'Use of Biomod device' for all the patient in addition to the conventional X-ray examination."
89285369|NCT01341808|Experimental|IBD patients|"Patients diagnosed with IBD~-> receive Epaxal Berna (virosomal hepatitis A vaccine)"
89285370|NCT03975725|Experimental|witcard|
89285371|NCT04597528||Elective induction group|Nulliparous singleton gestations undergoing elective induction between 39weeks and 0days -39weeks and 6 days based on clinical information and evaluation of the earliest ultrasound as described in Gestational Age
89285372|NCT01314196|Active Comparator|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers
89285373|NCT01314196|Experimental|progressive resistance training biceps|therapeutic exercises for the shoulder and scapula stabilizers and biceps resistance training.
89285374|NCT01315990|Experimental|FOLFIRI + Cetuximab|
89285375|NCT00265343|Experimental|1|asenapine
89285376|NCT00265343|Active Comparator|2|olanzapine
89285377|NCT01341886|Active Comparator|metformin|patients who receive metformin in addition to levothyroxine
89285378|NCT01341886|Placebo Comparator|levothyroxine|patients who receive only levothyroxine
89285379|NCT03975881|Experimental|Open Label|Patients aged 15 to 35 who made a suicide attempt and went through the emergency departments of the participating hospitals (Nantes, Angers, Rennes and Poitiers).
89285380|NCT05162950||SW CAH|Patients with 21-hydroxylase deficiency, salt wasting form.
89285381|NCT05162950||SV CAH|Patients with 21-hydroxylase deficiency, simple virilising form.
89285382|NCT05162950||NC CAH|Patients with 21-hydroxylase deficiency, non-classic form.
89285383|NCT05162950||Carrier CAH|Healthy individuals, heterozygous carriers a mutation in the CYP21A2 gene. Recruited among parents of patients with CAH.
89285384|NCT05162950||Control|Healthy sex and age matched controls
89285385|NCT03637114|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
89285386|NCT03637114|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
89285387|NCT00283595|Active Comparator|1|Treatment with rHGH
89285388|NCT00283595|Placebo Comparator|2|Treatment with Placebo
89285389|NCT01342042|Active Comparator|Metformin|
89285390|NCT01342042|Active Comparator|exenatide-4|
89285391|NCT00265109|Other|open label|Open-label trial; all participants received levetiracetam
89285392|NCT03637036|Other|Control Condition|A general communication intervention will occur inviting staff to take up the influenza vaccination, without a specific authority or social norm designated.
89285393|NCT03637036|Other|Authority Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority but not a social norm designated.
89285394|NCT03637036|Other|Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a social norm but not a specific authority designated.
89285395|NCT03637036|Other|Authority + Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority and a social norm designated.
89285396|NCT01342120||Quetiapine|Quetipine users
89285397|NCT01342120||All other atypical antipsychotics|All other atypical antipsychotics users
89285398|NCT01342120||Risperidone|Risperidone users
89285399|NCT01342120||Olanzapine|Olanzapine users
89285400|NCT01342198|Experimental|1|Single Dose Pregabalin Controlled Release
89285401|NCT01342198|Experimental|2|Single Dose Pregabalin Controlled Release with Multiple Doses of Erythromycin
89285402|NCT01342276|Experimental|vHFC|Patients will get to participate in the interactive heart failure website (vHFC).
89285403|NCT01342276|No Intervention|Usual Care|Patients will not get to participate in the interactive heart failure website (vHFC).
89285404|NCT01342354|Experimental|Stereotactic Radiation|Escalating doses of SBRT in three doses over ten days.
89285405|NCT04806022|Experimental|Mental Fatigue Task first|"First appointment :~Pre-fatigue assessment~mental fatigue task~post-fatigue assessment~7 resting days~second appointment~Pre-fatigue assessment~Muscle fatigue task~post-fatigue assessment"
89285406|NCT04806022|Experimental|Muscle fatigue task first|"First appointment :~Pre-fatigue assessment~Muscle fatigue task~post-fatigue assessment~7 resting days~second appointment~Pre-fatigue assessment~mental fatigue task~post-fatigue assessment"
89285407|NCT03235024|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day."
89285408|NCT03235024|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day."
89285409|NCT01342432|Experimental|Balance reeducation plus exercise|exercises that challenge postural control are performed in addition to general exercises for stretch and strength of abdominal and paraspinal muscles
89285410|NCT01342432|Other|General exercise only|general exercise for stretch and strength of paraspinal and abdominal muscles
89285411|NCT05155774|Active Comparator|Control group, controlled every 6th week|"This group was controlled every 6th week, in accordance with what is deemed to be golden standard for treatment with a Twin Block orthodontic appliance."
89285412|NCT05155774|Experimental|Test group, controlled every 4th week|This group was controlled every 4th week, testing if a more frequent control interval would increase compliance with a Twin block orthodontic appliance.
89285413|NCT01342588|Experimental|Electrical stimulation|Only arm of the study, the experimental
89285414|NCT01342744|Experimental|Metformin|Metformin (850mg) 1 tab oral twice a day
89285415|NCT01342744|Placebo Comparator|Placebo|Placebo 1 tab oral twice a day
89285416|NCT01342822||PROMUS Element™|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987)
89285417|NCT01342822||Xience™ Prime stent|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987) versus the Xience™ Prime Stent (N=993).
89285418|NCT05150782|Experimental|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin(2%), boswellia serrata (1,5%) and ascorbic acid (6%).
89285419|NCT01342900|No Intervention|standard care|The data from the InSPectra Monitor in the Control group will be inaccessible for the Investigator since this is not a part of their daily medical practice
89285420|NCT01342900|Active Comparator|Treatment group,|The data given by the monitor will be available for the Investigator and used to apply the optimization protocol
89285421|NCT05251246|No Intervention|Without recovery management program|
89285422|NCT05251246|Experimental|Trained in the recovery management program|Half of the included volunteered participants are randomized in the intervention group
89285423|NCT03760120|Active Comparator|PEP standard|
89285424|NCT03760120|Sham Comparator|PEP sham|
89285425|NCT01316068|Experimental|sequencial use of sulodexide|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks. Then patients will receive 1000 LSU per day orally for 50 weeks.
89285426|NCT01316068|Active Comparator|oral use of sulodexide|Patients allocated to oral group will received 1000 LSU per day orally for 52 weeks
89285427|NCT03233308|Experimental|Netarsudil Ophthalmic Solution 0.02%|Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
89285428|NCT03233308|Placebo Comparator|Placebo Comparator|Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye
89285429|NCT05250934|Experimental|Robotic group|In the robotic group, each patient undergoes 20 upper limb robotic telerehabilitation sessions, each session lasting 1 hour. The frequency is 5 sessions/week. Each session is performed at the patient's home, with direct supervision of a caregiver and remote supervision of a physical therapist, using three webcams able to show (a) the frontal and (b) the sagittal plane of the patient, as well as (c) the monitor of the robot.
89285430|NCT04391686||COVID intensive care unit|
89285431|NCT04391686||intensive care unit|
89285432|NCT04391686||obesity|
89285433|NCT05117320|Experimental|AI support|
89285434|NCT05117320|No Intervention|Non-AI support|
89285435|NCT00283439|Experimental|Single Arm: AMG 531 Dose-Escalating Cohort Study|
89285436|NCT05114824|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy
89285437|NCT05114824|No Intervention|Control Group|Control group
89285438|NCT03233230|Placebo Comparator|Placebo|
89285439|NCT03233230|Experimental|M2951 25 mg QD|
89285440|NCT03233230|Experimental|M2951 75 mg QD|
89285441|NCT03233230|Experimental|M2951 50 mg BID|
89285442|NCT00283049|Experimental|Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)|Arm 1: Insulin glargine administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
89285443|NCT00283049|Experimental|Insulins + Metformin (MET) + Thiazolidinedione (TZD)|Arm 2: Insulin glargine administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
89285444|NCT00283049|Experimental|Insulins + Metformin (MET) + Sulfonylurea (SU)|Arm 3: Insulin glargine administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added arms after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
89285445|NCT04645108|Experimental|Coached|
89285446|NCT04645108|Active Comparator|No Coach|
89285447|NCT00264875|Experimental|1|
89285448|NCT04897672||case|case: Children aged 6 to 17 years old reffered to the pediatric cardiology consultation with a chronic renal disease and renal insufficiency
89285449|NCT04897672||control|control : Children aged 6 to 17 years old reffered to the pediatric cardiology consultation who were classified in the control group after a completely normal check-up, including physical examination, electrocardiogram, and echocardiography
89285450|NCT05069662||Patients treated with oral anticancer drugs|Patients treated with oral anticancer drugs followed in the Oncoral program
89285451|NCT05250700||Adults (40-70yrs)|
89285452|NCT03152110|Experimental|HIIT|Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
89285453|NCT03635398|Experimental|Intranasal Midazolam by SipNose device|
89285454|NCT03635398|Active Comparator|Intranasal Midazolam by MAD (Mucosal Atomization Device)|
89285455|NCT03635398|Active Comparator|oral administration of midazolam|
89285456|NCT04832074|Experimental|Dry Needling|"Dry needling will be performed with 'solid filiform needles'. The procedure is as follows: The participant will lie in the prone position. The overlying skin will be cleaned with antiseptic spray. The taut band and MTrP, will be localized manually.~After measuring the Pain Pressure Thresholds in this location and the control (located 3 cm lateral to the MTrP), the needle within its plastic guide tube will be placed over the MTrP. After a tapping movement to insert the needle, the needle will be moved to the muscle around the bundle and moved forward and backward to the tissue to elicit a small muscle twitch. After eliciting LTR, needling will be stopped. If no twitch were elicited, needling will stopped after two or three stellate movements"
89285457|NCT04832074|Sham Comparator|Sham Dry Needling|"The same approach will be used with the exception of piercing the skin. The guide tube will press against the tissue and the sham needle will be allowed to drop against the skin. The handle will be tapped briskly but not breaking the skin. The sham needle will stay within the guide tube and will be pressed against the skin twice so as to mimic the quick in and out technique."
89285458|NCT04812652|Experimental|Intervention group: Digitally distributed yoga|"Type of yoga: Physical yoga sequences that through scientific evaluation have proven to be effective and relevant for the target group. There will be 3 different programs during the 12-week-intervention Dose: twice weekly for 12 weeks; one yoga class live broadcasted and digitally distributed to the patient's computer or mobile device, and one class pre-recorded video for self-training.~Sequences: The yoga class will be 60 minutes including 10 minutes of final relaxation. Thereafter, a 5 minutes reflection will be offered.~Home Training: Instructions for yoga home practice will be standardized. The three yoga programs will be distributed in video-links for the participants to view at a time-point that suits them during the week. The recommendation will be to yoga at home once a week in addition to the digital yoga class in real time.~Participants are expected to use their own computer or mobile device."
89285459|NCT04812652|No Intervention|Control group: Regulare care|Receive regular care, including written standardized information about the importance of physical activity by their contact nurse or physiotherapist, when discharged from the hospital accordingly to the routines at the clinic.
89285460|NCT03151408|Experimental|Pracinostat plus AZA|60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
89285461|NCT03151408|Placebo Comparator|Placebo plus AZA|1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
89285462|NCT05250232|Experimental|onlays conservative|conservative onlays preparation with partial cusp coverage only defective cusps
89285463|NCT05250232|Active Comparator|onlays conventional|onlays preparation design conventional as all cusps covered with shoulder finish line preparation
89285464|NCT05226442|Experimental|Argatroban|Continuous infusion of 0,3μg/kg/min to target an aPTT of 50-70sec and/or Hemoclot of 0,60 - 0,80 µg/mL
89285465|NCT05226442|Active Comparator|Unfractionated Heparin|Continuous infusion of Unfractionated Heparin to target an aPTT of 50-60 seconds and/or Anti-Xa level between 0.20 and 0.30 IU/ml and/or thrombin time >20sec.
89285466|NCT01316458|Experimental|imatinib mesylate|
89285467|NCT04391452|Experimental|Dietary supplement group|Group 1:50 stressed subjects who will have a 28-day intake of dietary supplement. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam. Dietary supplement is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg).
89285468|NCT04391452|Placebo Comparator|Placebo group|Group 2 (Placebo comparator (lactose)): 50 stressed subjects who will have a 28-day intake of placebo. Of the 50 stressed subjects, 20 subjects will participate in the fMRI exam.
89285469|NCT01316536|Experimental|With Music|This randomized group will receive music
89285470|NCT01316536|Placebo Comparator|Control Arm|Will not receive music but will receive audio loop of recorded ICU sounds
89285471|NCT05198128|Experimental|Calcium intravenous infusion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
89285472|NCT05198128|Placebo Comparator|saline|0.9 % saline intravenous infusion
89285473|NCT01316848|Experimental|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
89285474|NCT01316848|Experimental|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
89285475|NCT02121184|Active Comparator|Group A|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. Oxytocin management will continue as per the routine oxytocin protocol
89285476|NCT02121184|Experimental|Group B|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
89285477|NCT01485874|Experimental|Doxil + BIBF 1120|
89285478|NCT05159128|Experimental|Part 1: Single Ascending Dose (SAD) Cohorts|Healthy Japanese participants will receive JNJ-75105186 or matching placebo orally in Cohorts 1-3.
89285479|NCT05159128|Experimental|Part 2: Single Dose (SD) Cohort|Healthy Chinese participants will receive JNJ-75105186 or matching placebo orally in Cohort 4.
89285480|NCT04786756|Active Comparator|Lateral Approach of Costoclavicular Block|US-guided lateral approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
89285481|NCT04786756|Active Comparator|Medial Approach of Costoclavicular Block|US-guided medial approach costoclavicular block with 1 mg/kg Bupivacaine (%0,25)
89285482|NCT00546754|Experimental|1|Drug Arm
89285483|NCT00546754|Active Comparator|2|active comparator
89285484|NCT04768426|Experimental|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day cycles
89285485|NCT04473508|Experimental|Treated|active treatment (Local anaesthetic): Local administration of ropivacaine 30 mL (5mg/mL)
89285486|NCT04473508|Placebo Comparator|Control|Local administration of Placebo ( Saline Solution)
89285487|NCT04471402||All subjects recruited|"All subjects recruited will be given 3mcg/kg intranasal Precedex through an atomiser, divided equally between two nostrils. They will be observed and sedation score will be recorded every 5 minutes according to the University of Michigan Sedation Scale (UMSS). Pulse oximetry and Blood pressure cuff will be applied whenever they accept these monitoring.~A buccal swab sample will be taken from all children and the identified genes will be analysed and compared between the different responders (fast, normal, slow or non-responders)."
89285488|NCT00282347|Experimental|Rituximab|Participants received rituximab 1000 mg intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
89285489|NCT00282347|Placebo Comparator|Placebo|Participants received placebo intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
89285490|NCT01334632|Active Comparator|Continuous interscalene block|Continuous interscalene block with bolus ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2% 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
89285491|NCT01334632|Placebo Comparator|PCA morphine|Patients with iv self-administration of morphine, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
89285492|NCT00405964|Experimental|5-mg Desloratadine tablet|
89285493|NCT00405964|Placebo Comparator|Placebo tablet|
89285494|NCT04379206||Men who have sex with men|MSM receiving a self-test kit with optional assistance
89285495|NCT00264797|Active Comparator|Methylphenidate|
89285496|NCT00264797|Placebo Comparator|Methylphenidate (Placebo)|
89285497|NCT03148756|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
89285498|NCT03148756|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
89285499|NCT00282113|Active Comparator|ProBioPlus|
89285500|NCT00282113|Active Comparator|Culturelle|
89285501|NCT00282113|Placebo Comparator|Placebo|
89285502|NCT01343680|Active Comparator|10U/l heparin|
89285503|NCT01343680|Experimental|normal saline|
89285504|NCT04502836|Experimental|preliminary psychological intervention|Participants in this group will receive a psychological intervention providing knowledge and tools for problems solving one hour prior to the ACTH LRH test.
89285505|NCT04502836|No Intervention|control group|Participants in this group will not receive any psychological intervention prior to the test.
89285506|NCT01343758|Active Comparator|5% dextrose in normal saline|This group will receive a bolus of normal saline that contains 5% dextrose
89285507|NCT01343758|No Intervention|Normal Saline Bolus|
89285508|NCT01343836|Experimental|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte implantation) injection with eccentric exercises
89285509|NCT01343836|Placebo Comparator|Saline injection|Intratendinous saline injection with eccentric exercises
89285510|NCT00281957|Experimental|Arm I (sorafenib, temsirolimus)|Patients receive oral sorafenib twice daily on days 1-28 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
89285511|NCT00281957|Experimental|Arm II (sorafenib, tipifarnib)|Patients receive oral sorafenib as in arm I and oral tipifarnib twice daily on days 1-21
89285512|NCT01071161|Experimental|Azithromycin|
89285513|NCT01071161|Placebo Comparator|Placebo|
89285514|NCT03975335|Experimental|Intervention group|Health education on NCDs and behavioral risk factors was delivered through motivation and observational learning session.
89285515|NCT03975335|Placebo Comparator|Control group|Control group received session on carrier guidance.
89285516|NCT03975413||N=1 MS patient|"Single-Arm, Non-Randomized, Time Series, Single-Subject Study. Observational study of the FMT intervention.~Single subject studies are based on repeated observations within an individual over time and are acknowledged as an important research method for generating scientific evidence about the health or behavior of an individual. This design is desirable when the available patient pool is limited and thus it is not optimal to randomize participants to a control arm. The subject serves as his/her own control, rather than using another individual/group.These designs are used primarily to evaluate the effect of a variety of interventions in early stage clinical research development."
89285517|NCT03974633|Placebo Comparator|Control|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, without administering any type of non-invasive analgesic
89285518|NCT03974633|Experimental|Vibration|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, while applicating a vibrating device on the skin below the injection site, before and during injection.
89285519|NCT03974633|Experimental|Cold|A subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a bag of 50mL of frozen physiologic saline covered with a plastic glove on the injection site for 50 seconds
89285520|NCT03974633|Experimental|Anesthetic cream|subcutaneous injection of 0,1mL saline (0,9%NaCl) was administered in a part of the forehead, after applicating a uniform thickness of 2mm of the anesthetic cream EMLA covered with an adhesive transparent plastic dressing for 30 minutes
89285521|NCT01070225|Experimental|Hydrocortisone and Propranolol|Participant administered 10 or 20mg propranolol orally. Participants meeting the parameters are randomised to receive 400mg Hydrocortisone intravenously. Participant then receives Histamine PC10 challenge, Administered 5mg Salbutamol via nebuliser, administered 500mcg Ipratropium Bromide via nebuliser; visit end
89285522|NCT01070225|Placebo Comparator|Placebo and propranolol|identical to other arm but participant receive placebo injection as opposed to hydrocortisone
89285523|NCT00281099|Active Comparator|VVI 40 pacing|Backup ventricular pacing (VVI) at 40 beats per minute
89285524|NCT00281099|Active Comparator|MVP pacing|Managed ventricular pacing (MVP) at 60 beats per minute
89285525|NCT01070459|Placebo Comparator|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
89285526|NCT01070459|Experimental|Aerobic exercise group|The patients continues their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heart rate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week training programme 4 information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
89285527|NCT01070459|Experimental|Follow-up first aerobic exercise group|
89285528|NCT01070459|Placebo Comparator|Follow-up control group|
89285529|NCT01070459|Experimental|Follow-up second aerobic exercise group|
89285530|NCT00262925|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"INDUCTION THERAPY: Patients receive methotrexate IV; vincristine IV and asparaginase IM ; oral dexamethasone ; and alemtuzumab SC.~CONSOLIDATION THERAPY: Patients receive methotrexate IV and asparaginase IM.~CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV; leucovorin calcium IV; and oral dexamethasone.~MAINTENANCE THERAPY: Patients receive oral mercaptopurine; oral methotrexate; vincristine IV; and oral dexamethasone."
89285531|NCT01581515|Active Comparator|P-E group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
89285532|NCT01581515|Active Comparator|X-P group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
89285533|NCT01581671||Patients having a first time angiogram|Patients who are coming to the Cardiac Cath Lab to have an angiogram for the first time
89285534|NCT03720470|Experimental|PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg|Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 100 mg from Week 16 to Week 20
89285535|NCT03720470|Experimental|PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg|Once-daily oral PF-04965842 200 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 200 mg from Week 16 to Week 20
89285536|NCT03720470|Active Comparator|Dupilumab Injection + Oral Placebo followed by Oral Placebo|Dupilumab injected subcutaneously once every 2 weeks + once-daily oral Placebo from Day 1 until Week 16 followed by once-daily oral Placebo from Week 16 to Week 20
89285537|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 100 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 100 mg PF-04965842 from Week 16 to Week 20
89285538|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 200 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 200 mg PF-04965842 from Week 16 to Week 20
89285539|NCT00262847|Active Comparator|Arm I (placebo, paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
89285540|NCT00262847|Experimental|Arm II (placebo, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
89285541|NCT00262847|Experimental|Arm III (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive bevacizumab alone IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
89285542|NCT03803930|Other|Arm 22G+SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
89285543|NCT03803930|Other|Arm 22G+MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
89285544|NCT03803930|Other|Arm 20G+SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
89285545|NCT03803930|Other|Arm 20G+MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
89285546|NCT05329532|Experimental|Patients with TNBC, advanced/unresectable SCCHN, high grade serous ovarian carcinoma, or RCC|
89285547|NCT05329532|Experimental|Patients with SCCHN eligible for curative intent resection surgery (neoadjuvant cohort; monotherapy)|
89285548|NCT05329532|Experimental|Patients with SCCHN eligible for curative intent resection surgery (neoadjuvant cohort; combination)|
89285549|NCT01303562|Placebo Comparator|Placebo muffin made with no whole grains|
89285550|NCT01303562|Active Comparator|Test muffin made with whole oats|
89285551|NCT01303562|Active Comparator|Test muffin made with whole barley|
89285552|NCT03814070|Active Comparator|Non-reinforced full arch acrylic restorations|
89285553|NCT03814070|Experimental|full arch acrylic restorations with fiber-reinforced framework|
89285554|NCT01303640|Active Comparator|Biolimus-eluting stent|Biolimus-eluting stent
89285555|NCT01303640|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent
89285556|NCT03817268|Experimental|Capecitabine monotherapy group|
89285557|NCT03817268|No Intervention|Control group|
89285558|NCT00280397|Experimental|1|
89285559|NCT03817112|Active Comparator|Dexmedetomidine|Infusion of dexmedetomidine
89285560|NCT03817112|Active Comparator|Propofol|Propofol infusion
89285561|NCT03816722|Experimental|intervention|Patients starting the cross over with 6 weeks of high flow treatment with Airvo2 in addition to usual care
89285562|NCT03816722|Experimental|control|Patients starting the cross over in the usual care Group but after 6 weeks receiving High Flow treatment with Airvo2
89285563|NCT00262301|Experimental|"100 IU/kg rhC1INH"|100 IU/kg recombinant human C1 inhibitor
89285564|NCT00262301|Placebo Comparator|Saline|Saline solution
89285565|NCT03814148|Experimental|LENINGRADO 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Leningrado 5 association and 1 tablet Natrilix® SR placebo."
89285566|NCT03814148|Active Comparator|Natrilix® SR|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Natrilix® SR 1,5 mg and 1 tablet Leningrado 5 association placebo."
89285567|NCT03816566|Experimental|Wearable Device and PSG|The device under investigation (the patch) will be used in patients undergoing overnight polysomnography simultaneously, to compare the accuracy of the investigational device against the gold standard for the diagnosis of sleep apnea.
89285568|NCT03801824|Active Comparator|Standard Nutrition Therapy|Subjects in this group receive a standard nutrition therapy based on local guidelines that is usually high in fibre with moderate to high glycemic index food
89285569|NCT03801824|Experimental|Low Glycemic Index|Subjects in this group receive intervention on low glycemic index foods
89285570|NCT03813914|Experimental|Sineos|Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months
89285571|NCT03813914|Placebo Comparator|Placebo comparator|placebo 2 pills/day for 3 months
89285572|NCT01303718|Experimental|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
89285573|NCT01303718|Active Comparator|Standard of Care|Usual care (no CardioFit System implant)
89285574|NCT03800888|Experimental|Arm A|Participants in Arm A will receive a Wisepill device for Real- time monitoring plus Daily SMS reminders plus Social Supporter notifications (for 3 months) sent according to participant's preferred time and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
89285575|NCT03800888|Experimental|Arm B|Participants in Arm B will receive a wisepill device for Real-time monitoring plus Weekly SMS reminders plus Social support notifications (for 3 months) sent according to participant's preferred time and date and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
89285576|NCT03800888|No Intervention|Arm C|Participants in Arm C will receive only the Wise pill device (No SMS)
89285577|NCT00279305|Experimental|Rituximab Intravenous Infusion|Participants will receive active rituximab (anti-CD20 monoclonal antibody) as an intravenous infusion, with 4 administrations at weeks 0, 1, 2, and 3 at a dose of 375mg/m2
89285578|NCT00279305|Placebo Comparator|Placebo Intravenous Infusion|Participants will receive placebo given as an intravenous infusion with 4 administrations at weeks 0, 1, 2, and 3.
89285579|NCT03800810|Experimental|Control|Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
89285580|NCT03800810|Experimental|Intervention 1|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
89285581|NCT03800810|Experimental|Intervention 2|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
89285582|NCT03800810|Experimental|Intervention 3|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
89285583|NCT01325909|Active Comparator|Exercise|
89285584|NCT01325909|No Intervention|No Exercise|
89285585|NCT03799796|Experimental|Flash Glucose Monitoring with Online Peer Support|Pre-Test-Post-Test
89285586|NCT01301378|Active Comparator|KeraSys Tissue Patch Graft|20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft
89285587|NCT01301378|Active Comparator|Tutoplast tissue patch graft|20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft
89285588|NCT05030402|Experimental|Maitland group|31 patients receives tens, SW, Maitland, and exercises. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
89285589|NCT05030402|Active Comparator|Control group|32 receives tens, SW, conventional physiotherapy and exercises as treatment. An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
89285590|NCT03799640|Experimental|Standard Yoga|Yoga will be performed using linear forward and backward movements.
89290284|NCT05095168|Placebo Comparator|placebo|In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). In higher dose levels, subjects will be randomized to receive the treatment or placebo.
89285591|NCT03799640|Experimental|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses. .
89285592|NCT03799640|Experimental|Educational Control|Lectures on Health and Wellness
89285593|NCT00278993|Active Comparator|1|With stratification
89285594|NCT03816800|Placebo Comparator|Placebo-Allergic|Over the course of 6 months allergic participants receive twice daily a placebo tablets.
89285595|NCT03816800|Active Comparator|Active-Allergic|Over the course of 6 months allergic participants receive twice daily a dietary supplement containing whey protein-bound, chelated iron.
89285596|NCT03974867|Experimental|Oral Prednisone Group|36 participants in Group 1 will receive oral prednisone 1mg/kg/d (maximum daily dosage is no more than 60mg) for 7 days, followed by a 7-day taper.
89285597|NCT03974867|Experimental|Intratympanic Methylprednisolone Group|36 participants in Group 2 will receive 7 intratympanic 40mg/ml methylprednisolone injections in 14 days, one injection every other day.
89285598|NCT03816410|Experimental|LAA amputation group|
89285599|NCT03816410|No Intervention|No LAA amputation group|
89285600|NCT03799406|Active Comparator|Intervention group|cholecalciferol at dose of 100 IU/Kg/day
89285601|NCT03799406|Placebo Comparator|Placebo group|placebo
89285602|NCT05270876|Experimental|Investigational|Recipients of cochlear implant or suitable for implantation
89285603|NCT05270876|Active Comparator|Standard of Care|Recipients of cochlear implant or suitable for implantation
89285604|NCT03799172||Echinocandin group|Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
89285605|NCT03799172||Triazole group|Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
89285606|NCT03799094|Experimental|Experimental group|75 patients received a weekly intravenous Vitamin C injection (dose: 30 g / time, once a week, treatment termination when the disease progress is confirmed) in combination with daily taking tyrosine kinase inhibitor.
89285607|NCT03799094|Experimental|Control group|75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)
89285608|NCT00277355|Experimental|Minocycline|Minocycline (3:1 randomization) 100 mg capsules taken by mouth twice daily, 200 mg per day total for 18 months treatment duration.
89285609|NCT00277355|Placebo Comparator|Matching placebo|Sugar pill manufactured to mimic minocycline, 1 capsule taken by mouth twice daily for 18 months treatment duration.
89285610|NCT03799250|Experimental|Goal Directed Hemodynamic Therapy|"The GDT (Goal Directed Therapy) group will not receive any maintenance fluid. Fluid boluses will be given according to the flowchart attached.~Baseline MAP and HR will be measured in the pre-anesthetic clinic or if not available will be recorded according to community medical record.~Measurements of hemodynamic variables including heart rate and automatic non-invasive blood pressure measurements as well pulse oximetry as routine procedures will be recorded and stored by Metavision system (iMDsoft company) at regular intervals, all according to standard clinical practice.~Blood gases measurement will be performed upon admission and at discharge. Urine output will be measured and recorded every hour.~Other laboratory exams will be taken based on the physician discretion unrelated to the participation in the study."
89285611|NCT03799250|Active Comparator|Control Group|The control group will receive standard care which includes fluid maintenance program as dictated by the operating room anesthesiologist and as needed boluses through the PACU (Post Anesthesia Care Unit) stay.
89285612|NCT03974399|Other|study enrollment|all participants will take dietary supplement, Bacopa Monnieri, daily for 3 months
89285613|NCT00262223|Active Comparator|1) Seeking Safety + Sertraline|Seeking Safety + Sertraline
89285614|NCT00262223|Placebo Comparator|2) Seeking Safety + Placebo|Seeking Safety + Placebo;
89285615|NCT05575700|Experimental|Ibuprofen|Participants received ibuprofen 400 mg tablet administered orally three times daily, with eight hour intervals, for eight days after surgery.
89285616|NCT05575700|Placebo Comparator|Placebo|Participants received identical placebo tablet administered orally three times daily, with eight hour intervals, for eight days after surgery.
89285617|NCT00276419|Experimental|Placebo First, then Diclofenac (Arm A)|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks, then compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks.
89285618|NCT00276419|Experimental|Diclofenac First, then Placebo (Arm B)|Compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks, then placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks.
89285619|NCT03975569|Experimental|vulvovaginitis patients- lactobacillus gel|Daily use of vaginal gel containing lactobacilli by patients. Probiotic vaginal gel.
89285620|NCT05569070|Experimental|Guided Young United Parents! (YUP!) Website Intervention|The Guided YUP! website intervention is the confirmatory contrast, which will involve two months of directed use of the YUP! website.
89285621|NCT05569070|Sham Comparator|Nutrition Website|The nutrition website is the control counterfactual condition.
89285622|NCT03813680|Active Comparator|PVM group|This group included 30 participants. Passive vertebral mobilization was given along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
89285623|NCT03813680|Active Comparator|PNF group|This group included 30 participants. PNF exercise in the form of diagonal pattern neck movements was along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
89285624|NCT03813680|Active Comparator|RPT(Routine Physiotherapy) group|This group included 30 participants.Routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care.
89285625|NCT03798548|Experimental|Brief Bedside CBT|
89285626|NCT03798548|No Intervention|Treatment As Usual|
89285627|NCT03798470|Experimental|Cohort|Intervention with FAVOR peer recovery coaching. Patients identified in the ED as opioid overdose and enrolled in the current study.
89285628|NCT03798392|Active Comparator|SP group|
89285629|NCT03798392|Active Comparator|Baska group|
89285630|NCT03816020|Active Comparator|NR Group|Participants receiving Nicotinamide Riboside capsules, 500mg BI'D for 30 days
89285631|NCT03816020|Placebo Comparator|Placebo Group|Participant receiving Placebo BIDfor 30 days
89285632|NCT03813758||finger after digital nerve cut|
89285633|NCT03813758||healthy finger|
89285634|NCT01301534||T-Con|1. Nurse initiated Telephone Consult (T-Con)
89285635|NCT01301534||Mail-Out|2. Mail-0ut Letter to the patient
89285636|NCT01301534||Education|3. Provider, Nurse and Technician Education with point-of-care patient referrals , Exam Room Flyer
89285637|NCT01301534||Control group|4. Control group (i.e. usual care)
89285638|NCT03815864||D2SA+|Median fluoresce intensity > or = 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
89285639|NCT03815864||D2SA-|Median fluoresce intensity < 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
89285640|NCT03798236|Experimental|PBF-1650 40mg|
89285641|NCT03798236|Experimental|PBF-1650 80mg|
89285642|NCT03798236|Experimental|PBF-1650 120mg|
89285643|NCT03798236|Experimental|PBF-1650 240mg|
89285644|NCT03798236|Placebo Comparator|Placebo|
89285645|NCT03815942|Experimental|Intermediate risk prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.
89285646|NCT03815942|Experimental|Advanced metastatic prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
89285647|NCT03813602|Experimental|Cannabis sativa|a 750 mg cannabis cigarette with 12.5% THC
89285648|NCT01303874|Experimental|Combination Therapy|Methotrexate & Etanercept
88805654|NCT01100723|Experimental|Computer directed dosing decisions|This study will be an open-label, non-randomized, single arm design. Patients will have their mineral and bone disorders managed by the computer directed algorithm. The computer algorithm will make recommendations for dosing active vitamin D and cinacalcet. The doses of these medications recommended by the algorithm will then be prescribed to the subjects participating in the study unless overridden by the patients primary attending nephrology for other clinical or safety concerns. At any time in the study, subjects may be on neither, one, or both of these medication depending on their laboratory results and the output recommendations of the algorithm.
88805655|NCT01101971|Experimental|first year medical students|
88805656|NCT05306405|Active Comparator|vaginal misoprostol|only vaginal misoprostol 25 μg tablets will be applied for induction of laour
88805657|NCT05306405|Active Comparator|combined vaginal misoprostol and estradiol|vaginal misoprostol 25 μg (Vagiprost) tablets with vaginal estradiol 150 ml cream will be applied for induction of laour
89285649|NCT01303874|Placebo Comparator|Single-agent therapy|Methotrexate (MTX)
89285650|NCT04093076|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device.
89285651|NCT04093076|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit.
89285652|NCT04093076|Placebo Comparator|Placebo Group C|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device.
89285653|NCT04093076|Placebo Comparator|Placebo Group D|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit..
89285654|NCT01560494|Experimental|STAC curriculum|
89285655|NCT01560494|No Intervention|Conventional Curriculum|
89285656|NCT01301612|Active Comparator|Radiation therapy and Cisplatin|Cisplatin, 40 mg/m2, IV - Weekly doses for 6 weeks Pelvic radiation therapy, 45 Gy External, Fractions of 1.8 Gy per day, 5 days a week Dose boosts,15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week Brachytherapy (if indicaed), 40 Gy at spot A(low dose rate), Intracavitary 1 or 2 separate fractions for 1 to 3 weeks. 28 Gy at spot A, (high dose rate) Intracavitary,4 fractions of 7.0 Gy once or twice a week.
89285657|NCT01301612|Experimental|Nimotuzumab and|"Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks.~Nimotuzumab, 200 mg, Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes, Weekly doses for 14 weeks.~Pelvic radiation therapy, 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts, 15 Gy ± 5%, External,Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week~Brachytherapy (In case there is indication, should it be performed, not to be longer than the expected 70 days for the entire radiation therapy), 40 Gy at spot A (low dose rate) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks 28 Gy at spot A (high dose rate), Intracavitary, 4 fractions of 7.0 Gy once or twice a week."
89285658|NCT03815630|Experimental|PD-1 and dc-cik treatment group|
89285659|NCT03815786|Experimental|CKD patients|CKD patients stage 3b-4 will follow a 2-months supplementation of either symbiotic or placebo
89285660|NCT03815786|Other|Controls|Healthy volunteers will follow a 2-months supplementation of either symbiotic or placebo
89285661|NCT03813134|Active Comparator|Immediate PCI with medical therapy|"Group 1 will receive immediate revascularisation with Percutaneous Coronary Intervention (PCI) to the culpirit lesion only) + standard care (pharmacological support titrated to attain SBP >90mmHg).~No mechanical support device allowed."
89285662|NCT03813134|Experimental|Immediate PCI with early VA-ECMO|Group 2 will receive immediate PCI plus standard pharmacological support with early peripheral veno-arterial ECMO.
89285663|NCT03798002|Experimental|Neuro-muscular exercise training Group|Neuro-muscular exercise training will be administer to Knee OA patients.
89285664|NCT03798002|Active Comparator|quadriceps training program|quadriceps stretching and strengthening exercises will be administer to Knee OA patients.
89285665|NCT03812978|No Intervention|Control|Standard treatment
89285666|NCT03812978|Experimental|Intervention|Standard treatment and intervention (Smart phone application)
89285667|NCT01303952|Experimental|Eculizumab|
89285668|NCT03970616|Experimental|Tivozanib in Combination with Durvalumab|Tivozanib in Combination with Durvalumab
89285669|NCT01304030|Experimental|Experimental Group|The experimental group receives Empathy Training. The control Group receives residency training as usual
89285670|NCT01304030|Active Comparator|Control Group|The control group receives residency training as usual
89285671|NCT01301690||Neck masses|Neck mass received US and US-FNA
88805658|NCT03012893|Experimental|Ultrasound transverse scan|Transvers scan by identifying the C7 transvers process using vertebral artery and absence of anterior tubercle as a landmark and then scan back following articular process, lamina and then find out the spinous process of C7
89285672|NCT03815552|Experimental|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with type 1 Diabetes.The System will be set to provide realtime glucose information, including alarms and alerts in the home settings für 180 days.
89285673|NCT01301768|Experimental|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
89285674|NCT01301768|No Intervention|Usual care|Women in the control group receive the usual care during the pregnancy
89285675|NCT03812900|Experimental|Formulation A|Echinacea purpurea alcoholic extract lozenges (novel formulation)
89285676|NCT03812900|Experimental|Formulation B|Echinacea purpurea alcoholic extract spray (novel formulation)
89285677|NCT03812900|Active Comparator|Formulation C|Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
89285678|NCT03812900|Active Comparator|Formulation D|Echinacea purpurea alcoholic extract, drops (basic formulation, reference)
89285679|NCT03815474|Experimental|anlotinib & epirubicin& ifosfamide|interventions:Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
89285680|NCT03797846|Active Comparator|Corneal Suture|intraoperative fixation with the suture in clear cornea qualified to the combined glaucoma surgery
89285681|NCT03797846|Active Comparator|Muscle Suture|intraoperative fixation with the bridle suture for superior rectus muscle qualified to the combined glaucoma surgery
89285682|NCT01304108|Experimental|Order Set|"Insertion of VTE-P Order Set tollgate in all active admission and transfer orders."
89285683|NCT01304108|Experimental|Clinical Decision Support Pop-up|Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
89285684|NCT01304108|Active Comparator|Usual Care|Usual care, without the experimental additions
89285685|NCT01304186|Experimental|Tailored Information|Participants in this arm receive the computer-based tailored information application that focuses on improving health literacy related to treatment of HIV infection.
89285686|NCT05644730|Experimental|FUSION closed loop glucose control system|All subjects will be treated with the FUSION closed loop glucose control system for up to 24 hours
89285687|NCT03797768|Experimental|Intervention|
89285688|NCT03797768|No Intervention|Control|
89285689|NCT01301846||Wheelchair users|People who have a wheelchair for home and community use.
89285690|NCT03812822|Experimental|Insole Group|Gait and foot posture analysis with and without the insole.
89285691|NCT03812822|No Intervention|Control Group|Gait and foot posture analysis.
89285692|NCT03797612|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the active treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
89285693|NCT03797612|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal injection of placebo as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
89285694|NCT03880292|Other|Intraoperative Maneuvers|To document intraoperative maneuvers performed in repsonse to alerts
89285695|NCT01302236|Experimental|Eplerenone|
89285696|NCT03861806|Experimental|PAS true|Participants will receive paired associative stimulation therapy with a modulatory inter-stimulus interval.
89285697|NCT03861806|Sham Comparator|PAS sham|Participants will receive paired associative stimulation therapy with a non modulatory inter-stimulus interval.
89285698|NCT03797534|No Intervention|Standard anticoagulant group|
89285699|NCT03797534|Experimental|Bayesian model group|
88805659|NCT03012893|Experimental|Ultrasound sagittal scan|Sagittal scan by identifying the first and second ribs and scan medially to depict the C7 transvers process.
88805660|NCT03012893|Active Comparator|Floroscopic technique|Fluoroscopy image will do on lateral view including all cervical spines and upper thoracic spines. C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
88805661|NCT04352621|Experimental|Ketamine plus rTMS|Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.
88805662|NCT02246855|Experimental|Vigam® Liquid infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
88805663|NCT02246855|Experimental|Gammaplex® infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
89285700|NCT01304264||combination topical glaucoma treatment|timolol or dorzolamide add on latanoprost monotherapy
89285701|NCT03797300|Experimental|Primary|
89285702|NCT01304342|Active Comparator|Remifentanil|Remifentanil 1 microgram/kg/h along with propofol infusion
89285703|NCT01304342|Active Comparator|Fentanyl|Fentanyl 200 micrograms intranasally
89285704|NCT01304342|Placebo Comparator|Normal saline|Normal saline intravenously and intranasally
89285705|NCT01560026||ovarian preservation|endometrial cancer with ovarian preservation
89285706|NCT01560026||oophorectomy|endometrial cancer without ovarian preservation
89285707|NCT03815318|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
89285708|NCT03815084|Experimental|PD-1 and DC-NK treatment group|
89285709|NCT03812744|Experimental|WCCE|
89285710|NCT03812744|Placebo Comparator|Placebo|
89285711|NCT03653546|Experimental|AZD3759 Group|AZD3759 group will receive a 200 mg twice daily dose of AZD3759
89285712|NCT03653546|Active Comparator|Erlotinib or Gefitinib Group|SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
89285713|NCT05143190|Experimental|PTR-01|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg once monthly for a total of 5 doses.
89285714|NCT03812432|Experimental|near-infrared cholecystocholangiography|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence. Once the fundus is grasped and retracted, a needle-tipped cholangiogram catheter is introduced through the skin, adjacent to gallbladder. The catheter, guided by a grasping or dissecting instrument, is used to puncture the infundibulum of the gallbladder. Nine milliliters of bile is aspirated from the gallbladder into a syringe and and a indocianine green solution is injected into the gallbladder. The catheter is removed and the puncture site pinched closed with a grasper. Dissection is then performed under either ambient light or near-infrared mode. The surgical view of the gallbladder dissection is toggled back and forth between the two viewing.
89285715|NCT01302314|Experimental|cognitive rehabilitation|
89285716|NCT03812354|Active Comparator|THRIVE 2L/kg/min using OptiFlow|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
89285717|NCT03812354|Experimental|THRIVE 4L/kg/min using OptiFlow|"After apnea sets in and mask ventilation is successfully established, randomization envelopes are opened and according to group allocation, the following oxygen delivery system is applied.~High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand."
89285718|NCT03812120|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
89285719|NCT03812120|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
89285720|NCT03796910|Experimental|SPR720 for SAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
89285721|NCT03796910|Placebo Comparator|Placebo for SAD|2 out of 8 subjects per cohort will be randomized to receive placebo
89285722|NCT03796910|Experimental|SPR720 for MAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
89285723|NCT03796910|Placebo Comparator|Placebo for MAD|2 out of 8 subjects per cohort will be randomized to receive placebo
89285724|NCT01302470|Active Comparator|Robotic placement of CS lead|CS leads placed epicardially in the area of increased dyssynchrony as demonstrated by low dose dobutamine stress testing.
89285725|NCT01302470|Active Comparator|Transvenous placement of CS lead|CS lead will be placed transvenously
89285726|NCT03796520||Patients suspected for epilepsy|The cohort includes patients referred to the participating centers on suspicion of epilepsy, provided their seizure onset was at 10 years of age or older.
89285727|NCT03812042||Screen population|The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
89285728|NCT03795974|Active Comparator|MNC & MSC with Control|One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity
89285729|NCT03795974|Experimental|MNC & MSC|Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients
88805664|NCT02246855|Experimental|Gammaplex® infused at up to 6mL/min|Gammaplex® (Human Normal Immunoglobulin)
88805665|NCT05272397|Active Comparator|Drug Session|"In this arm of the study participants receive the drug (Methylphenidate - 20mg), administered prior to completion of the primary and secondary tasks for the study.~Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized."
88805666|NCT05272397|Placebo Comparator|Placebo Session|"In this arm of the study participants receive the a placebo, administered prior to completion of the primary and secondary tasks for the study.~Electroencephalography (EEG) is measured for the duration of the primary and secondary tasks. Participants complete both arms of the study, and the order in which participants are assigned to this and the other arm of the study is randomized."
89285730|NCT03812198|Active Comparator|Group 1-1|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 modified release tablet; LEO 32731 blend, hard capsule; LEO 32731 API hard capsule (reference formulation).
89285731|NCT03812198|Active Comparator|Group 1-2|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 soft capsule; LEO 32731 gastro-resistant capsule; LEO 32731 API hard capsule (reference formulation).
89285732|NCT03812198|Experimental|Group 2-1|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
89285733|NCT03812198|Experimental|Group 2-2|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
88805667|NCT05272397|Other|Intake Session|In this arm of the study participants are screened for suitability to participate in the experiment based on specified inclusion and exclusion criteria. They also complete some baseline tasks to assess working memory capacity, impulsiveness, and subjective mood.
88805668|NCT01125605||Adults > 12 years|adult patients and patients older than 12 years
88805669|NCT01125605||Children 6-12 years|children between 6 and 12 years
88805670|NCT01125605||Children 1-6 years|children between 1 and 6 years
89285734|NCT03812198|Experimental|Group 2-3|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
89285735|NCT03812198|Placebo Comparator|Group 3-1|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
89285736|NCT03812198|Placebo Comparator|Group 3-2|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
89285737|NCT03796052|Experimental|Avena Sativa Skincare Regimen|Avena sativa-containing body wash, body cream, and anti-itch balm
89290285|NCT00225251|Experimental|bupropion XL|Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
89285738|NCT03796130|Experimental|(A)Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomlyallocated intotwo groups.~In group (A): myomectomy will be performed before ART~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
89285739|NCT03796130|No Intervention|(B) No myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (B):women will have their trial of ART without myomectomy"
89285740|NCT03796286|Placebo Comparator|Control bar (0 g fiber)|Each subject will be randomly assigned to consume a control sports bar-type product (0 grams of fiber) at one treatment visit.
89285741|NCT03796286|Experimental|Medium-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 10 grams of fiber) at one treatment visit.
89285742|NCT03796286|Experimental|High-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 20 grams of fiber) at one treatment visit.
89285743|NCT03795896|Experimental|Optic nerve sheath diameter|The intracranial pressure will be measured by optic nerve sheath diameter while the patient in supine position with 30 -degree bed position .The linear probe in the two -dimensional mode will be placed gently on the upper eyelid without pressure .In linear horizontal orientation for both right and left optic nerve sheath will be measured
89285744|NCT03793322|Experimental|Indocyanine-Green(ICG) injection group|
89285745|NCT03793244||Experimental: TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
89285746|NCT03793244||Active Comparator: TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
89285747|NCT03811730|Experimental|TEE group|Eligible patients would be conducted TEE examination by researcher A,The examination results are judged by A and provided to the physician of this patient,
89285748|NCT03811730|Active Comparator|TTE group|Eligible patients would be conducted TTE examination by researcher B,The examination results are judged by B and provided to the physician of this patient,
89285749|NCT03795584||Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The participants underwent SOM before, immediately after EST, and 3 weeks after EST with endoclip papilloplasty. The participants were followed for 3 days during hospitalized.
89285750|NCT05078918|Experimental|Comprehensive care program|Intervention group receiving newly developed comprehensive care program pre- and post-operatively.
89285751|NCT05078918|Active Comparator|Usual care|Control group receiving usual care
89285752|NCT01304576|Experimental|patient with right parietal lesions|
89285753|NCT01304576|Active Comparator|patient with left parietal lesions|
89285754|NCT03795662||Community-acquired pneumonia|Adults over 18 years old admitted with confirmed community-acquired pneumonia.
89285755|NCT03792776|Active Comparator|Air|Endotracheal tube cuff inflation with air
89285756|NCT03792776|Experimental|Lidocaine 1%|Endotracheal tube cuff inflation with Lidocaine 1%
89285757|NCT03792776|Experimental|Lidocaine 2%|Endotracheal tube cuff inflation with Lidocaine 2%
89285758|NCT01302626||1: Surgery alone or combined with (chemo)radiotherapy|"Fresh frozen tumor tissue and normal tissue;~Recording of clinical characteristics, imaging, surgery features.~After treatment: FU at 2-3 weeks post surgery, 3,6,12,24 and 36 months post-surgery"
89285759|NCT01302626||2: Radiotherapy alone|"(including stereotactic radiotherapy)~Before start RT (during staging):Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Day 0 (before start RT): Recording of clinical characteristics, imaging, and radiotherapy features;~Day 8-12 (during RT): Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
89285760|NCT01302626||3: Sequential chemotherapy and radiotherapy|"Day -30 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
89285761|NCT01302626||4: Concurrent chemoradiotherapy with induction chemotherapy|"Day -30 until-18 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
89285762|NCT01302626||5: Concurrent chemoradiotherapy without induction chemotherapy|"Day 0 (before start CRT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, chemotherapy features, and radiotherapy features.~Day 8-12 (during CRT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
89285763|NCT01302626||6: Stage IV lungcancer, any systemic therapy & supportive care|"Day 0:~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, surgery or any systemic (MoAb) features.~After treatment: FU at 2-3 weeks post treatment, 3,6,12,24 and 36 months post-treatment"
89285764|NCT03795740|Experimental|Precise|precise PEA therapy with the guide of 3-D imaging techniques
89285765|NCT03795740|Placebo Comparator|Placebo|traditional PEA therapy solely by surgical probe and traditional CT scanning/pulmonary angiography method
89285766|NCT03795272|Experimental|Rucaparib|Patients will be treated with active oral drug, Rucaparib twice daily for 24 months
89285767|NCT03795272|Placebo Comparator|Placebo|Patients will be treated with oral placebo twice daily for 24 months
89285768|NCT03794960|Experimental|TOL-3021|
89285769|NCT03794960|Placebo Comparator|TOL-3021 Placebo|
89285770|NCT01304654||ALI/ARDS oncologic patients|Consecutively admitted patients at GRAACC's PICU with malignancy diagnosis according to IDC-10, in a 24mo consecutive period, under mechanical ventilation for over 24h and with ALI/ARDS criteria, not younger than 29 days or older than 17 years 11 months
89290286|NCT00225251|Placebo Comparator|Placebo|Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day
89285771|NCT00956930|Experimental|Arm I (radioembolization)|Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
89285772|NCT00956930|Experimental|Arm II (transarterial chemoembolization [TACE])|Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
89285773|NCT03792698|Experimental|Aidcube utilization|"Aidcube is a fully customizable, commercially available digital app-based platform to deliver home-based pulmonary rehabilitation for patients. On the patient-facing side, patients can view their daily exercise prescription, descriptions and videos demonstrating correct execution of the exercises, document completion of exercises, and message their health-care provider. On the provider-facing side, from over 150 available exercises, surveys, and activities, providers can design a fully-customized exercise prescription. Based on real-time patient feedback, the exercise prescription can be progressed (i.e., advanced and/or modified) by adding repetitions or time to specific exercises or adding new activities. The provider can also message the patient from within the Aidcube environment."
89285774|NCT05625386|Other|Real Stimulation|The continuous theta burst stimulation (iTBS) protocol lasted 10 min and consisted of 1800 pulses. In the iTBS session, this 10min protocol was repeated for ten times (18000 pulses in total) separated by 50 min breaks (controlled by a stopwatch). MRI dataset should be acquired before the first iTBS session and after the last iTBS session.
89285775|NCT03794804|Active Comparator|ColdZyme|"ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
89285776|NCT03794804|Placebo Comparator|Placebo|"Water based mouth spray manufactured to be similar to ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
89285777|NCT03811652|Experimental|NSCLC-Sq/HNSCC|Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
89285778|NCT03811652|Experimental|Small Cell Lung Cancer|Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.
89285779|NCT03811652|Experimental|Colorectal Cancer|Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.
89285780|NCT03811652|Experimental|Pancreatic Ductal Adenocarcinoma|Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.
89285781|NCT03811652|Experimental|Metastatic Castration-Resistant Prostate Cancer|Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
89285782|NCT03811652|Experimental|Other advanced/metastatic target expressing solid tumors|Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies
89285783|NCT03181412||Patients with suspected ischemic stroke|The cohort will be constituted of patients treated for a stroke suspicion after calling emergency medical services of the Rhone and presenting a symptom-onset (the last time the patient was seen without deficit) less than 6 hours.
89285784|NCT03794648|Experimental|Intervention Group|
89285785|NCT03794648|No Intervention|Control Group|
89285786|NCT03792620|Experimental|Cyclo Thal Dex Daratumumab|"Eligible patients will be enrolled and treated according to the following elicited schema: Cyclo Thal Dex- Daratumumab (cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week (28 days cycle)- 4 cycles. ) + Daratumumab 16mg/Kg every week on cycles 1 and 2 and every other week at cycles 3 and 4- (total of 12 doses). Then Daratumumab 16mg/Kg after D+30, every other week as pre consolidation until starts full consolidation D+90-120 every other week (total of 4 doses) + thal100mg D1-28 during sixteen weeks as full consolidation. Follow by Daratumumab 16mg/Kg once a month as maintenance until progression or limiting adverse event (total of 28 planning doses).~Total scheme Daratumumab doses= 50 doses = PROTOCOL MAXDARA."
89285787|NCT03792542|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
88805671|NCT01127087|Experimental|RYGB CaOx Stone Formers|"Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB).~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
89290287|NCT01220700|Experimental|Triclosane|triclosan coated suture material
89285788|NCT03811418|Experimental|Kanjinti/Pertuzumab plus Vinorelbine|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus vinorelbine.
89285789|NCT03811418|Active Comparator|Kanjinti/Pertuzumab plus Docetaxel|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus docetaxel.
89285790|NCT03794570|Sham Comparator|Control|Patients in this group will have BFR tourniquet applied but inflated to only minimal pressure.
89285791|NCT03794570|Experimental|Blood Flow Restriction (BFR) Therapy|Patients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure
89285792|NCT03811496||GD-PD|Patients and carriers of Gaucher disease with confirmed mutations in GBA gene who have developed Parkinson's disease symptoms
89285793|NCT03811496||GD-nonPD|Patients with Gaucher disease but no known Parkinson's symptoms
89285794|NCT03811496||nonGD-nonPD|Non-Gaucher disease/healthy controls
89285795|NCT03014336|No Intervention|Control|Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
89285796|NCT03014336|Experimental|memsorb|Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
89285797|NCT03794492|Experimental|Mycophenolate mofetil|One arm: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
89285798|NCT01304810||NicVAX|NicVAX vaccine
89285799|NCT01304810||Placebo vaccine|Placebo vaccine
89285800|NCT05625074||CHUP Angiology and Vascular Surgery Service|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
89285801|NCT05625074||CHUSJ Angiology and Vascular Surgery Service CHUSJ|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
89285802|NCT05625074||CHUC Angiology and Vascular Surgery Service CHUSJ|"A transversal study, recruiting consecutive patients undergoing great saphenous vein saphenectomy by stripping technique.~Evaluation and Qol Questionnaires performed at the 30th day of the postoperative period (acceptable scope - 25 to 45 days)"
89285803|NCT03792230|Experimental|Video|This group received educatıon via video material
89285804|NCT03792230|Experimental|Brochure|This group received education via written material (brochure)
89285805|NCT03792230|No Intervention|Control|This group received standart clinical education
89285806|NCT03811106|Active Comparator|NMES + PT|NMES will be applied to the back muscles with the chattanooga intelect advanced device. In addition, conventional physiotherapy and rehabilitation applications will be made.
89285807|NCT03811106|Other|PT|Conventional physiotherapy and rehabilitation practices will be carried out.
89285808|NCT03792152|Experimental|rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd(15mg If creatinine clearance is between 30-49 ml/min ).
89285809|NCT03792152|Active Comparator|Warfarin|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
89285810|NCT03792386|Active Comparator|Ultrasound guidance with fluoroscopic confirmation|Patients in which the intervention will be performed using ultrasound guidance with fluoroscopic confirmation
89285811|NCT03792386|Active Comparator|Fluoroscopic guidance with ultrasonographic confirmation.|Patients in which intervention will be performed using fluoroscopic guidance with ultrasonographic confirmation.
89285812|NCT00262067|Experimental|Bevacizumab + chemotherapy|Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
89285813|NCT00262067|Placebo Comparator|Placebo + chemotherapy|Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
89285814|NCT05624762|Active Comparator|LIFU group|receive LIFU therapy
89285815|NCT05624762|Sham Comparator|Control group|receive sham LIFU therapy
89285816|NCT01304888|Experimental|Food basket w/o nutrition education|
89285817|NCT01304888|Experimental|Food basket + nutrition education|
89285818|NCT01304888|Experimental|Control|
89285819|NCT01304888|Experimental|Cash + health and nutrition education|
89285820|NCT03794102|Active Comparator|Ureteroscopy with water irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Water will be used as the irrigation fluid during the ureteroscopy.
89285821|NCT03794102|Active Comparator|Ureteroscopy with saline irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Saline will be used as the irrigation fluid during the ureteroscopy.
89285822|NCT03974165|Experimental|Cereal-legume product 1|Treatment with cereal-legume product-1
89285823|NCT03974165|Experimental|Cereal-legume product 2|Treatment with cereal-legume product-2
89285824|NCT03974165|Experimental|Cereal product|Treatment with cereal product
89285825|NCT03974165|Active Comparator|Reference food|Treatment with reference food
89285826|NCT00275561|Experimental|Fluticasone|Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks
89285827|NCT00275561|Placebo Comparator|Placebo|Placebo inhaler swallowed bid for 6 weeks
89285828|NCT02802020|Experimental|WallFlex FCSEMS Recipients|"The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent. Patients who meet all eligibility criteria will receive the WallFlex Pancreatic stent for up to 6 months stent indwell and 6 months follow-up after stent removal. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study."
89285829|NCT01071473|Other|Exercise Group|Survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy will participate in a 12 week exercise intervention.
89285830|NCT01070849|Active Comparator|a) educational booklet|
89285831|NCT01070849|Active Comparator|b) IRENA|
89285832|NCT01070849|Experimental|c) RÜCKGEWINN|
89285833|NCT03792308|Experimental|SPR206|"SAD Cohorts: Subjects will receive single doses of SPR206 via IV infusion over one hour. Planned doses to be studied are: 10, 25, 50, 100, 200, 300, 350 and 400mg. If the 300 mg dose is not deemed safe and well-tolerated, a dose of 250 mg will be used.~MAD Cohorts: Subjects will receive SPR206 via IV infusion over one hour q8h for 7 consecutive days (Cohorts 9 - 12) and over one hour q8h for 14 consecutive days (Cohort 13). Up to five dose groups will be studied. Planned doses will be 25 mg, 50 mg, 100 mg and 150 mg with dosing occurring q8h for 7 consecutive days (Cohorts 9 - 12) and q8h for 14 consecutive days (Cohort 13). Cohort 13 participants will be dosed at a dose deemed safe and tolerable, not to exceed the maximum dose tested in previous MAD dose cohorts.~."
89285834|NCT03792308|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD Cohorts: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over one hour.~MAD Cohorts: Subjects will receive q8h infusions of placebo over 1 hour for 7 consecutive days (Cohorts 9 - 12) and q8h infusions of placebo over 1 hour for 14 consecutive days (Cohort 13)."
89285835|NCT03810872|Other|Open label|Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2
89285838|NCT03794180|Experimental|TJ003234|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion
89285839|NCT03794180|Placebo Comparator|Placebo|0 mg/kg via single IV infusion
89285840|NCT05669144|Experimental|exosome therapy|"a) Intracoronary and intra-myocardial injection of exosomes (5 patients)~1 mL of exosomes containing 100 micrograms of exosomes"
89285841|NCT05669144|Experimental|mitochondria therapy|"b) Intracoronary and intra-myocardial injection of mitochondria (5 patients)~1 mL of exosomes containing 10 million mitochondria"
89285842|NCT05669144|Experimental|co-transplantation of mitochondria and exosome therapy|"c) co-transplantation Intracoronary and intra-myocardial injection of exosomes and mitochondria (5 patients)~1 mL of exosomes containing 100 micrograms of exosomes~1 mL of exosomes containing 10 million mitochondria"
89285843|NCT05669144|Placebo Comparator|placebo|1 mL of placebo solution
89285844|NCT00274937|Experimental|Stratum I (radiotherapy, chemoprotective agent)|Patients undergo radiotherapy 5 days a week for 8 weeks. Patients also receive amifostine subcutaneously on the same days they undergo radiotherapy.
89285845|NCT00274937|Experimental|Stratum II (chemotherapy, chemoprotective agent, radiotherapy)|Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiotherapy and receive amifostine as in stratum I. Patients also receive 3 courses of cisplatin as before.
89285846|NCT03791996|No Intervention|"Late cranioplasty"|Subjects undergoing cranioplasty within 3 months after craniectomy.
89285847|NCT03791996|Experimental|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
89285848|NCT04914728|Experimental|mini-invasive lumbar arthrodesis|"The patient will be admitted to the hospital on the morning of the surgery, operated on the same morning by either the posterior or anterior mini-invasive approach.~The choice of the approach depends on the specificity of the pathology leading to the arthrodesis procedure and the surgeon's experience. It is the surgeon who decides this in agreement with the patient. The patient will be discharged in the evening after agreement of the anaesthetist and the surgeon."
89285849|NCT01305122|Other|OMS grade II glioma|neurocognitive tests
89285850|NCT03811184||MemScreen|Each participants will undergo MemScreen : a screening tool on smartphone for detecting mild cognitive impairment.
89285851|NCT01582217||SA + 5mg prasugrel|Prasugrel 5 mg group: Patients with Intermediate or high bleeding risks and PRU ≥ 230 are Prescribed 5mg of prasugrel daily along with aspirin.
89285852|NCT01582217||ASA + 10 mg prasugrel|Prasugrel 10 mg group: Patients with Low bleeding risk and high ischemia risk and PRU ≥ 230 are prescribed 10 mg of prasugrel daily along with aspirin.
89285853|NCT01582217||ASA + 75 mg clopidogrel daily|Clopidogrel 75 mg group (control): PRU ≤ 230; high bleeding risk or high ischemic risk; patients with active malignancy, age >75; Wt< 60kg with previous CVA or TA are prescribed 75 mg of clopidogrel daily along with aspirin.
89285854|NCT03794414|Experimental|fluid responder|patients with 10% or more increase in stroke volume after fluid challenge. Both arms receive PEEP challenge.
89285855|NCT03794414|Experimental|fluid non-responder|patients with no increase or less than 10% increase in stroke volume after fluid challenge. Both arms receive PEEP challenge
89285856|NCT01582295|Experimental|Treatment Arm|Cabozantinib ( XL 184)
89285857|NCT03793946|Experimental|AB-assistant|Use of the AB-assistant app by physicians in intervention wards.
89285858|NCT03793946|No Intervention|Standard antimicrobial stewardship|Physicians on these wards will use conventional ways to assess local guidelines to prescribe antimicrobials.
89285859|NCT01071551|Experimental|Lifestyle and health promotion|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
89285860|NCT01071551|Active Comparator|Physical activity only|Children allocated to this group will attend physical activity classes only.
89285861|NCT03793790|Experimental|Group 1|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
89285862|NCT03793790|Experimental|Group 2|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
89285863|NCT03793790|Experimental|Group 3|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
89290288|NCT01220700|Active Comparator|Control|ordinary suture material
89285864|NCT03793790|Experimental|Group 4|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
89285865|NCT03793790|Sham Comparator|Group 5|Sham conditioning of nocebo effects on pain (induction) and extinction (attenuation).
89285866|NCT03794258|Experimental|SOF+DCV+CDI-31244|Subjects will receive two weeks of sofosbuvir, daclatasvir, and CDI-31244 if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
89285867|NCT03794258|Experimental|SOF+DCV+CDI-31244+ASV|Subjects will receive two weeks of sofosbuvir, daclatasvir, CDI-31244 and asunaprevir if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
89285868|NCT03792074|Experimental|SCT510 combined paclitaxel and carboplatin|SCT510 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
89285869|NCT03792074|Active Comparator|Bevacizumab combined paclitaxel and carboplatin|Bevacizumab 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
89285870|NCT01305590|Other|Survey|"We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
89285871|NCT00251693|Experimental|Dexlansoprazole MR 60 mg QD|
89285872|NCT00251693|Experimental|Dexlansoprazole MR 90 mg QD|
89285873|NCT00251693|Active Comparator|Lansoprazole 30 mg QD|
89285874|NCT03791918|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89285875|NCT03791918|Active Comparator|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
89285876|NCT03793712|Experimental|Lu AF11167 low dose|
89285877|NCT03793712|Experimental|Lu AF11167 high dose|
89285878|NCT03793712|Placebo Comparator|Placebo|
89285879|NCT01305278|No Intervention|Control|No Wii balance gaming undertaken
89285880|NCT01305278|Active Comparator|Wii during vestibular rehab only|To start Wii Balance Gaming from the beginning of vestibular rehabilitation.
89285881|NCT01305278|Active Comparator|Wii whilst on waiting list and rehab|Wii Balance Gaming whilst on waiting list for vestibular rehabilitation. To continue with Wii Balance Gaming until end of vestibular rehabilitation.
89285882|NCT03793868|Experimental|Low dose|Perampanel 4mg PO x1
89285883|NCT03793868|Placebo Comparator|Placebo|Receiving placebo
89285884|NCT03793868|Experimental|High dose|Perampanel 8 mg PO x1
89285885|NCT01303016|Experimental|Nutrition supplement|Receives a month's supply of the nutrition supplement, Chispuditos, in addition to a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month.
89285886|NCT01303016|No Intervention|Control|Receives a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month. Participants in the control group will receive the nutrition supplement, Chispuditos, for one year after the study is complete.
89285887|NCT03974477|Experimental|Intervention|"The intervention will last for 8 weeks, an individual session of presentation of SALT CONTROL H will be carried out, with explanation of how the equipment works in the culinary preparation with an adequate salt content (will be used an illustrative video and recipes with an adequate salt content); use of SALT CONTROL H at home by the participant to control the use of salt during the cooking process; supervision and enhancement of the use of equipment; daily occurrence log; and the application of a satisfaction questionnaire on the use of SALT CONTROL H. A leaflet will also be delivered about The new Food Wheel, a guide to the daily food choice!."
89285888|NCT03974477|No Intervention|Control|"No intervention will be carried out except the provision of a leaflet on The new Food Wheel, a guide to the daily food choice! to the participants."
89285889|NCT01305434|Other|Placebo then mulberry leaf|These patients receive placebo for two weeks, then 1 week washout, then two weeks of mulberry leaf extract.
89285890|NCT01305434|Other|Mulberry leaf then placebo|These patients receive mulberry leaf extract for two weeks, then 1 week washout, then two weeks of placebo.
89285891|NCT01305512|Experimental|SPARC1028|
89285892|NCT03793634|Experimental|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect.
89285893|NCT03793634|Active Comparator|Topical Triamcinolone Acetonide|topical triamcinolone acetonide is the gold standard treatment of oral lichen planus.
89285894|NCT00250835|Experimental|Chemotherapy, Celecoxib, and Radiation|"Oxaliplatin weekly at 50 mg/m2 given intravenously over two hours for the duration of radiation.~Capecitabine: on the days of radiation at 850 mg/m2 orally twice a day [1700 mg/m2/day] (Monday through Friday during radiation therapy).~Celecoxib at 200 mg orally twice a day throughout the duration of radiation without a break."
89285895|NCT01817504|Active Comparator|Study group|The study group corresponds to systematic transplantectomy under immunosuppressive therapy within two months after return to dialysis,
89285896|NCT01817504|Other|Control group|The control group corresponds to progressive reduction of immunosuppression without systematic transplantectomy after return to dialysis
89285897|NCT05624216|Experimental|BTL-084 Treatment|Radiofrequency and targeted pressure energy devices for the treatment of cellulite
89285898|NCT03810716|Experimental|Interactive Platform|Tha participants in this group will see the interactive platform and answer a survey before and after the intervention. Their clinical health records will be checked one month ago.
89285899|NCT03810716|No Intervention|Control|The participants in this group will answer the survey. Their clinical health records will be checked one month ago.
89285900|NCT01303094|Other|Continuation of Trabectedin|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity
89285901|NCT01303094|Other|"Drug holiday therapy"|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge
89285902|NCT04869644|Experimental|Intervention: Behavioral Change Techniques to encourage Habit Formation|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps 5 days per week. Participants will be enrolled for a baseline period lasting 2 weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will be asked to generate a walking plan with the goal of walking an additional 2,000 steps above their baseline activity level on 5 days per week. This walking plan will include details about day of the week, time of day, and location of walking. Once participants have completed their walking plan, they will receive daily texts based on the 5 identified BCTs for the duration of the 10-week intervention. All BCTs will be delivered daily. The goal of the text messages will be to encourage habit formation for walking behavior.
89285903|NCT03791684|Active Comparator|Accelerated Cross Linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 18mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 5 min, delivering a dose of 5.4 J/cm2.
89285904|NCT03791684|Active Comparator|Standard Cross linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 3mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 30 min, delivering a dose of 5.4 J/cm2.
89285905|NCT03791762|Experimental|WaveOne Gold|Root canal preparation with WaveOne Gold instrumentation system in a reciprocating manner
89285906|NCT03791762|Experimental|Reciproc Blue|Root canal preparation with Reciproc Blue instrumentation system in a reciprocating manner
89285907|NCT03791762|Experimental|ProTaper Next|Root canal preparation with ProTaper Next instrumentation system in a rotating manner
89285908|NCT03791372|Placebo Comparator|Placebo|0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
89285909|NCT03791372|Experimental|Cord Blood Mononuclear Cells(CBMNC)|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells>1*10^7/kg). The infusion speed is 1ml/min.
89285910|NCT03788954|Active Comparator|Kinesiotaping on FCU|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. flexor carpi ulnaris.
89285911|NCT03788954|Active Comparator|Kinesiotaping on ECR|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. extensor carpi radialis.
89285912|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on FCU|Same kinesiotape used on m. flexor carpi ulnaris without any taping techniques.
89285913|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on ECR|Same kinesiotape used on m. extensor carpi radialis without any taping techniques.
89285914|NCT04663568|Other|Levonorgestrel-releasing intrauterine system|
89285915|NCT03810326|Experimental|Intervention|
89285916|NCT05669066|No Intervention|Control|This group will undergo a standardized conventional intra-operative and postoperative analgesia regimen. Anesthetic type and postoperative analgesia will be standardized.
89285917|NCT05669066|Experimental|Mindful meditation|Start the MM program 2 weeks preoperatively and continue for 30 days post operatively. Study subjects will meet with the meditation instructor for 30 minutes once, 2 weeks prior to surgery, and daily during hospital admission following total joint replacement (TJR). Throughout the intervention period, subjects will be asked to practice daily 15 minutes twice a day, and record their daily meditation experience. Upon discharge from hospital, subjects will receive telephone follow up sessions with the research assistant weekly until 30 days have elapsed. Subjects will be required to show compliance by recording their daily meditation experience in the Daily Meditation Diary (Post-op). At the end of the meditation intervention period, subjects will be asked to provide their feedback in the Patient Satisfaction Survey. Will undergo a standardized, conventional intra-operative postoperative analgesia regimen in addition to the meditation intervention. Anesthetic type will be standardized
89285918|NCT03788876|Active Comparator|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge and the protocol of physiotherapy by the physiotherapists of HCPA twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
89285919|NCT03788876|Sham Comparator|Conventional care|The protocol of physiotherapy by the physiotherapists of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
89285920|NCT03789032|Experimental|Rabeprazole and Vadadustat|Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6
89285921|NCT03788798|No Intervention|Standard clinical pathway|A standard clinical pathway for TKA has been compulsively implemented for medical cost containment and quality assurance to meet with the Taiwan Diagnosis-Related Groups (TW-DRGs) payment system since 1997. The clinical pathway for TKA undertakes with preadmissions, anesthetic, surgery, and physiotherapy assessment. Medical, nursing, and physiotherapy assessment were put down for each postadmission day. The time from admission to surgery, the use of intravenous antibiotics injection and intravenous fluid were all assessed. Discharge criteria were active knee flexion to 90 degrees, having the ability to walk with aids and clean wound condition with any infection sign. The pathway was initially set for a 6-day postoperative length of stay.
89285922|NCT03788798|Experimental|Patient Infotainment Terminal|Patients who have additional access to an integrated infotainment system and are cared by a standard clinical pathway. The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
89285923|NCT03788720|Experimental|Suture|Women undergoing suturing of the ovarian cortex after laparoscopic enucleation of endometriomas.
89285924|NCT03788720|Sham Comparator|No suture|Women undergoing laparoscopic enucleation of endometriomas without subsequent suture of the ovarian cortex.
89285925|NCT03788486|Experimental|2-3 Joule light device for MGD/Dry eye|patients who qualify for the study will receive interventional in office treatments with the light treatment device in the upper and lower lids for defined periods of time twice weekly for a total of one month. Non-invasive tear break up, subjective questionnaires and corneal fluorescein staining will be measured through the course of the study.
89285926|NCT01306370|Experimental|Tranexamic acid|Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.
89285927|NCT01306370|Experimental|Fibrin glue BSTC|It is homologous fibrin glue from a single blood donor.
89285928|NCT01306370|Experimental|Tissucol|It is fibrin glue commercialized from multiple donors.
89285929|NCT01306370|Other|Habitual haemostasis|Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)
89285930|NCT01305668||Emphysema phenotype|
89285931|NCT01305668||No-Emphysema phenotype|
89285932|NCT03791528|Active Comparator|Kinesio-taping Treatment Group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the sacroiliac joint (SIJ), and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
89285933|NCT03791528|No Intervention|Control Group|Without Kinesio-taping treatment evaluated at baseline and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
89285934|NCT03716024|Experimental|PTK 0796|
89285935|NCT03716024|Active Comparator|Linezolid|
89285936|NCT01305746|Experimental|A-623 high dose weekly|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
88805672|NCT01127087|Experimental|Idiopathic Hyperoxaluria CaOx Stone Formers|"Subjects with idiopathic hyperoxaluria.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
89285937|NCT01305746|Experimental|A-623 low dose weekly|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
89285938|NCT01305746|Experimental|A-623 high dose every 4 weeks|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
89285939|NCT00250679|Active Comparator|Formoterol 12 ųg 2x/day|
89285940|NCT00250679|Experimental|Arformoterol 15 ųg 2x/day|
89285941|NCT00250679|Experimental|Arformoterol 25 ųg 2x/day|
89285942|NCT05620706|Experimental|Treatment group|GCP3 CAR-T cells
89285943|NCT03791294|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
89285944|NCT03791294|No Intervention|Control|No treatment
89285945|NCT01567358|Experimental|NI-071|
89285946|NCT01567358|Active Comparator|Remicade|
89285947|NCT04603430||Physical Therapy Students|Students will be participating in a focus group and completing a survey.
89285948|NCT04603430||Senior STEPS Participants|Seniors will be participating in a focus group, completing a survey, and researchers will be conducting a retrospective chart review on relevant documented health outcomes of the STEPS program.
89285949|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 30mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg +Placebo of AD-35 30mg, once daily in the second 26 weeks (oral)
89285950|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 60mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg x two tablets, once daily in the second 26 weeks (oral)
89285951|NCT03790982|Experimental|AD-35 30 mg+Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, once daily for 52 weeks (oral)
89285952|NCT03790982|Experimental|AD-35 60 mg|AD-35 60 mg AD-35 30 mg× two tablets, once daily for 52 weeks (oral)
89285953|NCT03790826|Experimental|Cystoscopic Inspection|"Comparison of bladder damage with traditional Foley catheter and the Kohli Atraumatic catheter.~Interventions: cystoscopy"
88805673|NCT00271154|Placebo Comparator|CRT OFF|Cardiac Resynchronization Therapy (CRT) turned OFF in conjunction with optimal medical therapy
88805674|NCT00271154|Active Comparator|CRT ON|Cardiac Resynchronization Therapy (CRT) turned ON in conjunction with optimal medical therapy
89285954|NCT01306448|Experimental|vibrating capsule|
89285955|NCT03790904|Active Comparator|Co. mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
89285956|NCT03790904|Placebo Comparator|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
89285957|NCT03790904|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
89285958|NCT03790748|Experimental|Conventional Epidural Technique|Procedure: Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L4-5 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
89285959|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|Procedure: 25G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
89285960|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 27G Whitacre needle|Procedure: 27G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
89285961|NCT03788408|Experimental|Intensive Psychotherapy Case Management|Treatment group received Intensive Psychotherapy and Case Management (IPCM) delivered by psychotherapists and social worker with expertise in refugee trauma and mental health.
89290289|NCT01376128||Subjects prescribed PAXIL|Pediatric subjects with panic disorder prescribed PAXIL during study period
89290290|NCT01220778|Experimental|Exercise|
89290291|NCT01220778|No Intervention|Control|
89285962|NCT03788408|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual group received ongoing care from their primary care providers without the involvement of CVT (except for the collection of outcomes). TAU patients could be referred to a full range of outpatient and community-based behavioral health services by their primary care physician.
89285963|NCT03809858|Experimental|Klue App Use then Usual Care|Subjects will use the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will discontinue Klue App use and will continue the final 6 weeks without the product.
89285964|NCT03809858|Experimental|Usual Care then Klue App Use|Subjects will begin the study without using the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will begin the use of the Klue App and will continue the final 6 weeks with the product.
89285965|NCT05566652|Experimental|NPS|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing Neural Pressure Support Ventilation.
89285966|NCT05566652|Sham Comparator|PSV|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing Pressure Support Ventilation.
89285967|NCT01306526||Moderate to Severe OSA|
89285968|NCT05693870|Experimental|Group I (B&L)|13 Band and loop (B&L) appliance were included in group one
89285969|NCT05693870|Experimental|Group II (Ssb&l)|13 Single-sided Band and loop (SsB&L) appliance were included in group two
89285970|NCT05693870|Experimental|Group III (DBW)|13 Direct Bonded Wire (DBW) appliance were included in group three
89285971|NCT05693870|Experimental|Group IV(T&L)|13 Tube and Loop (T&L) appliance were included in group four
89285972|NCT03788330|Experimental|Fresh air system with filtration|A fresh air ventilation system combined with PM2.5 filtration is applied in one primary school classroom.
89285973|NCT03788330|Placebo Comparator|Fresh air system with no filtration|A fresh air ventilation system with no PM2.5 filtration is applied in a parallel classroom.
89285974|NCT03788330|No Intervention|Natural ventilation|Natural ventilation system was applied in the 3rd classroom as normal.
89285975|NCT03790592|Experimental|trifocal IOL|patients implanted with a trifocal intraocular lens
89285976|NCT00261833|Experimental|Zemaira®|
89285977|NCT00261833|Placebo Comparator|Placebo|
89285978|NCT01308242|Experimental|Treatment|Patients enrolled will receive Renvela for a 3 month time frame.
89285979|NCT01306682|Active Comparator|Trivalent Influenza vaccine|0.5ml of TIV will be administered into deltoid muscle of non dominant arm
89285980|NCT01306682|Placebo Comparator|Normal saline|0.5ml of normal saline administered into deltoid muscle of non dominant arm
89285981|NCT03973463|Sham Comparator|Low fat diet,12 weeks low oil balance 1200 kcal / day|12 weeks low oil balance 1200 kcal / day
89285982|NCT03973463|Experimental|12-week resistance exercise 3 times a week|12-week stretch with resistance exercise, 3 times a week
89285983|NCT03973463|Experimental|12 weeks low oil balance and resistance exercise|12 weeks low oil balance 1200 kcal / day and 12-week stretch with resistance exercise, 3 times a week
88805675|NCT00136214||Interferon Treated Group|Group treated with PEG-Interferon and ribavirin and undergoing MR brain and neuropsychiatric tests
89285984|NCT01308320|Placebo Comparator|saline|control group
89285985|NCT01308320|Active Comparator|F1 group|F1 group : fentanyl 1 mcg/kg
89285986|NCT01308320|Active Comparator|F1.5 group|F1.5 group : fentanyl 1.5 mcg/kg
89285987|NCT01308320|Active Comparator|F2 group|F2 group : fentanyl 2 mcg/kg
89285988|NCT01072253||eye amputated|lost an eye
89285989|NCT01306760|Experimental|Ketamine|Ketamine used as the anaesthetic during ECT.
89285990|NCT01306760|Active Comparator|Propofol|Propofol, the standard anaesthetic, used during ECT.
89285991|NCT05693714||1|One group who have adenovirus infection
89285992|NCT03788252|Active Comparator|Renamezin|oral treatment duration: three times a day, 7 capsules (2g) once, for 48 weeks
89285993|NCT03788252|No Intervention|Non-Renamezin|no use of Renamezin
89285994|NCT03788096|Experimental|PS-PICS Peer Support Intervention|ICU mentors will be responsible for providing support to survivor participants randomized to the PS-PICS peer support intervention. Mentors will be trained in motivational interviewing techniques to engage mentees in goal setting and emotional management that is not readily accessible as part of discharge planning.
89285995|NCT03788096|Placebo Comparator|Usual Care Group|A control intervention will be used to provide comparison data consistent with usual care (absence of structured peer support telephone intervention) to evaluate the impact of the PS-PICS peer support intervention.
89285996|NCT03787940|Active Comparator|Standard INH for Non-rapid acetylators|Participant with slow or intermediate acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid)
89285997|NCT03787940|Active Comparator|Standard INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid )
89285998|NCT03787940|Experimental|High dose INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with high dose isonized treatment (3 months HRZE followed by 9 months HRE with high dose isoniazid)
88805676|NCT00136214||Non-treated cohort control|Group undergoing MR brain and neuropsychiatric tests
88805677|NCT01127321|Placebo Comparator|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
89285999|NCT01306838|Experimental|Treatment|The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.
89286000|NCT01306838|Active Comparator|Control Group|Routine care
89286001|NCT03788018|Experimental|Effect of IV lidocaine and dexmedetomidine on PONV|
89286002|NCT03788018|Experimental|Effect of IV saline on PONV|
89286003|NCT01306916||Group 1 of 1|diagnosis of primary and secondary hyperparathyroidism scheduled to undergo parathyroid resection.
89286004|NCT03790202||single cohort of up to 30 patients|patients with acute or chronic lower limb wounds to be treated with the VistaCare® device
89286005|NCT05585060|Experimental|PEEP titration for mechanical ventilated AECOPD patients|Pre- and post-self-controlled trials for invasive mechanical ventilated AECOPD patients during PEEP titration.
89286006|NCT01305902|No Intervention|walking recommendations|Participants assigned to this condition will be instructed to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. Each week, they will be congratulated if they walked the target goal on any days, and encouraged to meet the goals for the upcoming week. However, they will not receive any tangible reinforcement for walking. The meetings will be brief (about 15 minutes) and will include discussions and handouts related to the health benefits of walking.
89286007|NCT01305902|Experimental|contingency management for walking|Participants assigned to this condition will be asked to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. The meeting duration and structure will be similar to that in the standard treatment condition including the handouts, with one exception. Participants in this condition will earn tangible reinforcement in the form of prizes for walking the target number of steps per day.
89286008|NCT01307072||Never-treated group|The patients who had no previous ophthalmic examination until the first visit when vitreous surgery was prescribed
89286009|NCT01307072||The non-compliant group|The patients with a history of missing ophthalmic examination over a one year period
89286010|NCT01307072||The compliant group|The patients who had ophthalmic examinations at least once a year
89286011|NCT03785990||preterms with enterostomy|GA 23±0/7 - 31±6/7 with clinically indicated operations because of NEC (necrotising enterocolitis) or FIP (focal intestinal perforation). Operation after birth (within 14 days) and at term (enterostomy closure) Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)
89286012|NCT03785990||preterms without enterostomy|"GA 23±0/7 bis 31±6/7 with a clinically indicated operation (e.g. herniotomy) at term, without any abdominal problems.~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
89286013|NCT03785990||term infants|"GA ≥34±0/7 with a clinically indicated operation directly after birth (within 14 days) (e.g. gastroschisis).~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
89286014|NCT05693636||Total Wrist Fusion|Patients with end-stage wrist arthritis treated with total wrist fusion.
89286015|NCT05693636||Total Wrist Arthroplasty|Patients with end-stage wrist arthritis treated with total wrist arthroplasty of the fourth generation
89286016|NCT01307150||Before and after treatment|SCORAD of each patient before and after treatment.
89286017|NCT03785756|Experimental|Prolonged Release Group|Ibuprofen 300 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
89286018|NCT03785756|Active Comparator|Immediate Release Group|Ibuprofen 200 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
89286019|NCT03785756|Placebo Comparator|Placebo Group|Placebo of IR tablet Placebo of PR tablet
89286020|NCT01307228|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~database (Health Systems Evidence) access;~monthly e-mail alerts; and~full-text article availability."
89286021|NCT01307228|Active Comparator|Self-serve evidence service|"Participants allocated to the self-serve evidence service will receive only database access, which is already publicly available at www.healthsystemsevidence.org"
89286022|NCT03788174|Experimental|Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
89286023|NCT03787550||Model building group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to six blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
89286024|NCT03787550||Model validation group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to three blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
89286025|NCT03787784|Experimental|AI visible group|
89286026|NCT03787784|No Intervention|AI invisible group|
89286027|NCT05694806||patients with symptomatic Mediastinal mass syndrome|patients with symptomatic Mediastinal mass syndrome at diagnosis or at relapse of a patient with haematological malignancy admitted to the Intensive Care unit
89286028|NCT03787394|Experimental|FAAA-enriched|food products enriched with FAAA-conjugates
89286029|NCT03787394|Placebo Comparator|Plain|Food products without FAAA-conjugates
89286030|NCT03790514|Experimental|Heat Wrap Group|
89286031|NCT03790514|Placebo Comparator|Control Group|
89286032|NCT03789890|Experimental|Healthy men|Healthy male adults from Germany receiving BAY1902607 during study period 1 (length = 6 days) and BAY1902607 + Itraconazole during study period 2 (length = 15 days), separated by a washout phase.
89286033|NCT03787706|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
89286034|NCT03787706|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
89286035|NCT01308554|Placebo Comparator|Sterile normal saline|Control group will receive sterile normal saline in the block
89286036|NCT01308554|Active Comparator|Marcaine|Study group will receive a bilateral TAP block using 20 ml of Marcaine 2,5 mg/ml on each side.
88805678|NCT01127321|Experimental|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
89286037|NCT03787238|Experimental|non-invasive Vagus Nerve Stimulation|nVNS (non-invasive vagus nerve stimulation) treatment with the gammaCore Sapphire device and standard of care
89286038|NCT03787238|No Intervention|Standard of Care|Standard of Care treatment
89286039|NCT05693402||Group 1 consisting of treated patients using OFA|Group 1 consisted of 56 (Mean age was 54±14 years)
89286040|NCT05693402||Group 2 consisting of treated patients using NOFA|Group 2 consisted of 60 patients (Mean age was 51±12 years)
89286041|NCT05694728|Experimental|The Group of Investigational Vaccine|"For Mid-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg#40μg#60μg#40μg#20μg#20μg#20μg#20μg and 20μg respectively, totaling 270μg of antigens.~For High-dosage group, 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30μg#40μg#80μg#60μg#30μg#30μg#30μg#30μg and 30μg respectively, totaling 360μg of antigens."
89286042|NCT05694728|Active Comparator|The Group of Active Control Vaccine|0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens.
89286043|NCT01307540|Experimental|Active light therapy|oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)
89286044|NCT01307540|Placebo Comparator|Inactive light therapy|Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.
89286045|NCT05694572||Pacemaker system|Patients implanted with ENO or ALIZEA family pacing systems
89286046|NCT05694572||ICD system|Patients implanted with ULYS family ICD systems
89286047|NCT05694572||CRT-D system|Patients implanted with GALI family CRT-D systems
89286048|NCT03787316|Experimental|Experimental group|4-weeks use of specially produced shock absorbing insoles and the daily home exercise program during this 4 weeks. Daily exercises include M. gastrocnemius, soleus, tibialis anterior, tibialis posterior stretching, strengthening of the anterior, lateral, posterior compartmental and foot intrinsic muscles of the foot, eccentric exercise of gastrocnemius and soleus.
89286049|NCT01306136|Experimental|Prolonged Exposure|
89286050|NCT01306136|Active Comparator|Usual care|
89286051|NCT03789734|Experimental|BLS-M22 or Placebo 500mg group|Single Ascending Dose (SAD): BLS-M22 500mg or Placebo 500mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
89286052|NCT03789734|Experimental|BLS-M22 or Placebo 1,000mg group|Single Ascending Dose (SAD): BLS-M22 1,000mg or Placebo 1,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
89286053|NCT03789734|Experimental|BLS-M22 or Placebo 2,000mg group|Single Ascending Dose (SAD): BLS-M22 2,000mg or Placebo 2,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
89286054|NCT03789734|Experimental|Multiple Ascending Dose group|Multiple Ascending Dose (MAD): BLS-M22 2,000mg or Placebo 2,000mg(n=10; BLS-M22=8 or Placebo=2) Oral Administration
89286055|NCT01308632|Experimental|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
89286056|NCT03789812|Active Comparator|Manual Toothbrush with Superfloss|Patients in this group will receive Manual Toothbrush (Oral B) and Superfloss (Oral B) and will be instructed to use them three times a day.
89286057|NCT03789812|Experimental|Electric Toothbrush with Superfloss|Patients in this group will receive Electric Toothbrush (JETPIK) and Superfloss (Oral B) and will be instructed to use them three times a day.
89286058|NCT03789812|Experimental|Manual Toothbrush with Water Flosser|Patient in this group will receive Manual Toothbrush and Dental Water Jet and will be instructed to use them three times a day.
89286059|NCT03789812|Experimental|Electric Toothbrush with Water Flosser|Patient in this group will receive Electric tooth brush (JETPIK) and water flosser and will be instructed to use them three times a day.
89286060|NCT03789578|Experimental|Semaglutide plus insulin 287|Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
89286061|NCT03789578|Experimental|Semaglutide alone|Participants will get a single dose of semaglutide (treatment B) alone.
89286062|NCT03789578|Experimental|Insulin 287 alone|Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
89286063|NCT03713684|Placebo Comparator|Placebo|Participants received placebo (matched to efpeglenatide) subcutaneous (SC) injection once weekly up to Week 56 on top of basal insulin alone or in combination with oral antidiabetic drugs (OADs).
89286064|NCT03713684|Experimental|Efpeglenatide 2 mg|Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs.
88805679|NCT01127321|Experimental|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
88805680|NCT01127321|Experimental|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
89286065|NCT03713684|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and maintained at the 4 mg dose through-out the treatment duration up to Week 56.
89286066|NCT03713684|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 4 and later up-titrated to 6 mg and maintained at the 6 mg dose through-out the treatment duration up to Week 56.
89286067|NCT03785522||Tresiba®|Patients with type 2 diabetes in Saudi Arabia are to receive Tresiba® (Insulin degludec) for 26 weeks.
89286068|NCT05694416|Experimental|Etoposide Plus Cisplatin group|Etoposide 100mg/m2 d1-5 Cisplatin 20mg/mCisplatin d1-5
89286069|NCT05694416|No Intervention|Temozolomide group|Temozolomide 150-200mg/m2 d1-5
89286070|NCT03787160|Active Comparator|CDH Group|10 patients after surgical closure of CDH will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity). Thereafter patients will receive probiotic treatment with OmniBiotic6 (R) (Allergosan, Graz, Austria) 1 sachet daily for 3 months (probiotic treatment). Three months after discontinuing probiotic treatment VOC testing (VOC probiotics), fecal microbiome sampling (fecal microbiome probiotics) and deep induced sputum testing (pulmonary microbiome probiotics) will be repeated and compared to the results of the initial tests.
89286071|NCT03787160|Other|Control Group|10 healthy controls (age and sex matched) will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity).
89286072|NCT01560650|Experimental|high dose (35ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 35 mL/kg/h.
89286073|NCT01560650|Experimental|low dose (25ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 25 mL/kg/h.
89286074|NCT03785444||Intensive Care Patients|Postoperative patients who have been admitted to intensive care
89286075|NCT03785444||Non-Intensive Care Patients|Postoperative patients who have not been admitted to intensive care but to the normal ward
89286076|NCT03789344|Experimental|Acupuncture treatment|
89286077|NCT03789344|Active Comparator|Psychotherapy|
89286078|NCT03789344|Placebo Comparator|blank control|
89286079|NCT03789422|Active Comparator|Association drugs|levocetirizine 10mg/day + tranexamic acid (AT) 2g/day for a month
89286080|NCT03789422|Active Comparator|one drug|Levocetirizine 20 mg/day for a month
89286081|NCT03789266|Experimental|Drain ablation - Non Aspiration mode|Drain ablation will be done in non Aspiration mode
89286082|NCT03789266|Other|Drain ablation - Aspiration mode|Drain ablation will be done in Aspiration mode
89286083|NCT03786848|Experimental|MiniPDX Group|Patients medication plan based on MiniPDX drug sensitivity test.
89286084|NCT03787004|Experimental|Part 1 Cohort 1 (Single Dose)|Single 100 mg oral dose of CNTX-6970 (film-coated tablet or enteric-coated tablet)
89286085|NCT03787004|Experimental|Part 1 Cohort 2 (Single Dose)|Single 100 mg oral dose of CNTX-6970 film-coated tablet
89286086|NCT03787004|Experimental|Part 2 (Multiple Ascending Dose)|100 mg, 300 mg, and 600 mg CNTX-6970 oral tablet
89286087|NCT03787004|Placebo Comparator|Part 2 Placebo|Placebo oral tablet
89286088|NCT03785132||cardiac surgery|Patients who underwent cardiac surgery with cardiopulmonary bypass
89286089|NCT03785054|Experimental|Cohort 1|6 subjects receiving a single dose of 1 mg capsule HTL0014242 and 2 subjects receiving matching placebo oral capsule
89286090|NCT03785054|Experimental|Cohort 2|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
89286091|NCT03785054|Experimental|Cohort 3|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
89286092|NCT03785054|Experimental|Cohort 4|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
89286093|NCT03785054|Experimental|Cohort 5|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
89286094|NCT03785054|Experimental|Cohort 6|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
89286095|NCT03785054|Experimental|Cohort 7|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
89286096|NCT03785054|Experimental|Cohort 8|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
89286097|NCT03785054|Experimental|Cohort 9|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
88805681|NCT01127321|Experimental|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
89286098|NCT04703348|Other|Healthy patients|Healthy patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
89286099|NCT04703348|Other|Complex regional pain syndrome patients|Complex regional pain syndrome patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
89286100|NCT04703348|Other|Musculoskelettal disorders patients|Musculoskelettal disorders patients take the MIQ-RS during about 40 minutes : about 20 minutes for the assessment of the right side and about 20 minutes for the left side
89286101|NCT01307852|Experimental|In Vivo Dosimetry|Modified endorectal device capable of real-time dose measurement during prostate radiation therapy
89286102|NCT03784976|Experimental|Intervention|Patients in the intervention group will first undergo 3 months of regular care and then 3 months of biweekly yoga classes. Participants will complete surveys at baseline, 3 months (after of control care), 6 months (after 3 months of biweekly yoga classes), and 12 months (after 6 months of observation and optional yoga practice).
89286103|NCT03784976|No Intervention|Control|The study lasts 12 months for the intervention and 9 months for the control group with an optional 3 month yoga therapy session offered at the end
89286104|NCT03782012|Experimental|Knowledge Supported|Students will have 30 seconds to view pictures of the knowledge base items and discuss relations among items.
89286105|NCT03782012|Experimental|Knowledge Not Supported|Students will be provided 30 seconds to view pictures of the knowledge base items.
89286106|NCT05690048|Experimental|Vancomycin + A/B + FMT|"Atezolizumab 1200mg i.v. & Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).~Vancomycin orally (125 mg 4xd, day -3 to 0) for reduction of original patient gut microbiota.~Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21."
89286107|NCT05690048|Placebo Comparator|Placebo Vancomycin + A/B + Placebo FMT|"Atezolizumab 1200mg i.v. & Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).~Placebo Vancomycin orally (125 mg 4xd, day -3 to 0) for reduction of original patient gut microbiota.~Placebo Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21."
89286108|NCT01560806|No Intervention|Conventional Healthcare services|People with high blood pressure detected during screening survey or opportunistically during study period will be referred to receive the conventional health care services for hypertension at district hospital or local commune health station
89286109|NCT01560806|Experimental|Commune Hypertension Management|People with high blood pressure were managed in commune-based hypertension management programme
89286110|NCT01308866|No Intervention|Control|Usual care
89286111|NCT01308866|Experimental|Intervention|Intervention arm using a share-decision tool for cardiovascular patients
89286112|NCT01308086|Active Comparator|FOLFOX 4 - 6months or XELOX -6months|
89286113|NCT01308086|Experimental|FOLFOX4 -3months or XELOX -3months|
89286114|NCT03786458|Experimental|Cancer and Fertility Decision making|Cancer and Fertility Decision aid
89286115|NCT05694026|Experimental|IPL+|Participants in the IPL+ group used DQS 1 drop 6 times/per day for four weeks along with 2 sessions of IPL, 2 weeks apart.
89286116|NCT05694026|Experimental|IPL|IPL treatment sessions were administered once at 2- weeks interval to all participants for 4 weeks.
89286117|NCT05694026|Experimental|DQS|DQS group will be administered one drop of 3% DQS (Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan) six times per day for 4 weeks.
89286118|NCT03786302|Experimental|TAMP bioglass|Tailored amorphous multiporous bioglass (TAMP-BG) of 70% SiO2 / 30% CaO was prepared according to Wang et al. (2011, 2013) in the tissue engineering lab, Faculty of Dentistry, Alexandria University as follows: Scaffolds were grounded to 180- to 300-μm particle size and sterilized at 180°C for 2 hours. The resulting powder was mixed with distilled water to obtain a putty like consistency that was carried to the pulp chamber and condensed lightly on the pulp stumps.
89286119|NCT03786302|Active Comparator|Biodentine ™|Biodentine ™ (BD) pre-dosed capsule were gently tapped on a hard surface to diffuse the powder. Five drops of the liquid from the single dose dispenser were poured into the capsule and mixed for 30 seconds at 4,200 rpm in an amalgamator according to manufacturer's instructions to obtain putty- like consistency. (Powder-liquid system). It was then be carried to the pulp chamber and condensed lightly on the pulp stumps. Final restoration was applied after 12 minutes, allowing Biodentine ™ to set.
89286120|NCT03782090|Active Comparator|Control|Endobronchial intubation using conventional technique with left-sided double-lumen endotracheal tube (Shiley®, Covidien, Mansfield, MA, USA)
89286121|NCT03782090|Experimental|Experimental|Endobronchial intubation using novel left-sided double-lumen endobronchial tube (Ankor®,Insung Medical, Wonjou, S. Korea)
89286122|NCT05443802|Experimental|Experimental|Reduced dose of rapid-acting insulin of 0.05 IU/kg/h from randomization until resolution of DKA
89286123|NCT05443802|Other|Control|Rapid-acting insulin dose of 0.10 IU/kg/h in accordance with usual recommendations until resolution of DKA
89286124|NCT01311284|Active Comparator|Macintosh|
89286125|NCT01311284|Active Comparator|Mcgrath|
89286126|NCT01311284|Active Comparator|Airtraq Nasotracheal|
89286127|NCT01308164|Experimental|MD logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
89286128|NCT01308164|No Intervention|Control Group|Regular treatment, no change will be made in the insulin pump setting during the study (unless there is a medical need or any safety concern) Only segment 2 of the study, which is conducted as RCT (randomized controlled trial) , will include control group
89286129|NCT01308944|Experimental|Arm 1|"Propranolol 40mg po orally twice daily to begin at least 48 hours prior to surgical debulking. This will ideally be titrated in order to maintain a heart rate between 60 and 80 without hypotension.~After surgery, the patient will resume the propranolol once tolerating clear liquids in the hospital and will remain on them until completion of chemotherapy.~After completion of chemotherapy, the patient will be weaned off the medication over the following two weeks."
89286130|NCT01311596||No icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the first 2 weeks of the study period~Lab -Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the first 2 weeks of the study period"
89286131|NCT01311596||Icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the last 2 weeks of the study period~Lab - Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the last 2 weeks of the study period"
89286132|NCT03784664|Active Comparator|Arterial blood gas|
89286133|NCT03784664|Experimental|Veinous blood gas|
89286134|NCT03781856|Experimental|La Vida Buena Program|Administered in a group setting over the course of 8 weeks in a community setting.
88805682|NCT00272168|Experimental|Arm 1: MPROVE|The Maryland Program for Vocational Effectiveness (MPROVE)
88805683|NCT00272168|Active Comparator|Arm 2: Control|Supportive Treatment for SMI (control)
88805684|NCT00185900|Active Comparator|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate.
88805685|NCT00185900|Active Comparator|Nifedipine|Preterm labor treatment with Nifedipine.
88805686|NCT00186056|Experimental|Mifepristone|Patients received mifepristone for 6 days
88805687|NCT00186056|Placebo Comparator|placebo|Patients received placebo for 6 days
88805688|NCT00186446|Experimental|Bupropion|
89286135|NCT03781856|Active Comparator|Brief educational session|Administered one on one or in a group setting in a one-hour session at the clinic
89286136|NCT03781622|Experimental|WOLF Thrombectomy Device Arm|Patients enrolled in the study who received the treatment and who met all Inclusion and Exclusion Criteria
88805689|NCT01899638|Experimental|UMEC/VI 125/25 mcg|Combination in high dose
88805690|NCT01899638|Experimental|UMEC/VI 62.5/25 mcg|Combination in low dose
88805691|NCT01899638|Experimental|UMEC 125 mcg|LAMA mono in high dose
89286137|NCT03777488|Experimental|Tranexamic acid Group 1|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Intramuscular Third Dose: Oral"
89286138|NCT03777488|Experimental|Tranexamic acid Group 2|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Oral Third Dose: Intramuscular"
89286139|NCT03777488|Experimental|Tranexamic acid Group 3|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Intravenous Third Dose: Oral"
89286140|NCT03777488|Experimental|Tranexamic acid Group 4|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Oral Third Dose: Intravenous"
89286141|NCT03777488|Experimental|Tranexamic acid Group 5|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intravenous Third Dose: Intramuscular"
89286142|NCT03777488|Experimental|Tranexamic acid Group 6|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intramuscular Third Dose: Intravenous"
89286143|NCT03777566||group A|35 patients with an indication for hysterectomy without gross uterine pathology
89286144|NCT03777566||group B|150 infertile patients in the childbearing age without gross uterine pathology
89286145|NCT03784742|Active Comparator|Nitrate-rich Beetroot juice|Nitrate-rich beetroot juice equivalent to 3.7 mg nitrate per kg body weight daily for 8 weeks.
89286146|NCT03784742|Placebo Comparator|Placebo beetroot juice|Placebo beetroot juice (equivalent volume to the amount of nitrate-rich beetroot juice consumed) daily for 8 weeks.
89286147|NCT03777254|Experimental|RC28-E|"·Experimental:RC28-E 0.25mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 0.5mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 1.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 2.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E"
89286148|NCT03711266|Experimental|PE-PC|Eligible participants who present to participating CHCs and screen positive for PTSD will be offered PE-PC via telepsychiatry.
89286149|NCT01561352|Experimental|Factor VII|
89286150|NCT01312298|Experimental|General Anesthesia|Patients allocated to this arm will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml in a Target Controlled Infusion (TCI)
89286151|NCT01312298|Active Comparator|Regional anesthesia|Patients will receive intrathecal anesthesia
89286152|NCT01560884|Active Comparator|Group B|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
89286153|NCT01560884|Active Comparator|Group C|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
89286154|NCT01560884|Active Comparator|Group D|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
89286155|NCT01560884|Active Comparator|Group A|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
89286156|NCT05111132|Experimental|7.5 ml/kg|Group 1, receiving a fluid challenge of 7,5 ml/kg in 5 minutes
89286157|NCT05111132|Experimental|12.5 ml/kg|Group 2, 12.5 ml/kg of fluid challenge in 5 minutes
89286158|NCT01318226|Placebo Comparator|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
89286159|NCT01318226|Experimental|ATx08-001 2.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg, twice a day approximately every 12 hours over an 8 day period.
89286160|NCT01318226|Experimental|ATx08-001 7.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
89286161|NCT03776708|Experimental|Spinal manipulation|The spinal manipulation is located between the fifth and eighth thoracic vertebrae, on a level and a side pain-free to a light palpation. The maneuver is of high velocity and low amplitude, oriented posterior to anterior, on the transverse process area of the chosen thoracic vertebrae.
89286162|NCT03776708|Sham Comparator|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires."
89286163|NCT03776786|Experimental|Safety Arm - 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
88805692|NCT01899638|Experimental|UMEC 62.5 mcg|LAMA mono in low dose
89286164|NCT03776786|Placebo Comparator|Safety Arm - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
89286165|NCT03776786|Experimental|Safety Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes.
89286166|NCT03776786|Experimental|Safety Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
89286167|NCT03776786|Experimental|Safety Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes.
89286168|NCT03776786|Experimental|Safety Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes.
89286169|NCT03776786|Experimental|Efficacy Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
89286170|NCT03776786|Placebo Comparator|Efficacy Arm - 2 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
89286171|NCT03776786|Experimental|Efficacy Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
89286172|NCT03776786|Placebo Comparator|Efficacy Arm - 5 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
89286173|NCT03776786|Experimental|Efficacy Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
89286174|NCT03776786|Placebo Comparator|Efficacy Arm - 10 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
89286175|NCT03776786|Experimental|Efficacy Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
89286176|NCT03776786|Placebo Comparator|Efficacy Arm - 20 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
89286177|NCT01560962|Other|PI vs no intervention|In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI twice daily for 10 days and the other eye with no intervention.
89286178|NCT01560962|Other|PI vs hygiene|In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive warm soaked eyelid wash.
89286179|NCT01560962|Other|PI vs azasite|In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days.
89286180|NCT01560962|Other|PI vs tobradex|In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive tobradex ointment applied to the lid margin.
89286181|NCT03784508||Bariatric surgery|200 consecutive patients that will undergo bariatric surgery as a routinary procedure at our site
89286182|NCT05401058|Experimental|Experimental group|Droperidol 1.25mg/0.5ml
89286183|NCT05401058|Placebo Comparator|Placebo group|Normal saline 0.5ml
89286184|NCT03781466|Active Comparator|Cervical cerclage|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm
89286185|NCT03781466|Active Comparator|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
89286186|NCT03781466|Active Comparator|Cervical cerclage plus vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm plus Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
88805693|NCT01899638|Experimental|VI 25 mcg|LABA mono
88805694|NCT04104230||Individuals Affected With Pancreatic Cancer|Individuals affected with pancreatic adenocarcinoma, with or without a family history of pancreatic adenocarcinoma.
89286187|NCT03781310|Experimental|Dose reduction|Reduce the Tocilizumab dose at the baseline visit (week 0) and maintain that dose until 20 weeks of follow-up. The reduced dose is dependent of the tocilizumab serum concentration, measured at the screening visit, and is calculated according to the pre-defined dose-reduction algorithm.
89286188|NCT03781310|Active Comparator|Maintain dose|Maintain the original dose at baseline visit (week 0) until 20 weeks of follow-up.
89286189|NCT03781076|Experimental|Sleep Intervention|1-hour brief behavioral intervention to improve sleep consolidation and nocturnal sleep duration.
89286190|NCT03781076|No Intervention|Control|"In this care as usual arm, no specific behavioral sleep intervention is provided."
89286191|NCT03150862|Experimental|Arm A (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
89286192|NCT03150862|Experimental|Arm B (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
88805695|NCT04104230||Individuals Affected with Related Cancer|Individuals affected with bile duct cancer, ampullary cancer, duodenal cancer or gallbladder cancer.
89286193|NCT03150862|Experimental|Arm A (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
89286194|NCT03150862|Experimental|Arm C (Dose Escalation)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
88805696|NCT04104230||Individuals Affected With Pancreatic Neoplasm|Individuals affected with pancreatic neoplasm, cyst or pre-cancerous lesion, with or without a family history of pancreatic adenocarcinoma.
88805697|NCT04104230||High-Risk Individuals|Individuals at high lifetime risk of pancreatic adenocarcinoma due to familial pancreatic cancer or hereditary cancer predisposition.
89286195|NCT03150862|Experimental|Arm C (Dose Expansion-Cohorts C1 and C2)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
89286196|NCT01318928|Placebo Comparator|Periodontal intervention, sugar pill|Group 1: metronidazole + mechanical treatment in one day, Group 2: Placebo + mechanical treatment in one day Group 3: metronidazole + mechanical treatment on day 1 and 21 Group 4: Placebo + mechanical treatment on day 1 and 21
89286197|NCT03784352|Experimental|Virtual Reality (VR)|The intervention will consist of standard of care (SOC) in addition to the use of virtual reality. SOC consists of the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device) Patients assigned to the VR group will interact with VR through mobile-based VR googles.
89286198|NCT03784352|No Intervention|No Virtual Reality (VR)|This arm will receive regular standard of care (SOC), the same that would be received if they were not enrolled in the study. SOC will include the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device)
89286199|NCT03781232|Experimental|RSP-09-01|Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic. A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
89286200|NCT03781232|Experimental|RSP-09-02|Enrolled subjects will measure at home for 26 six days and visit the clinic two times. During home measurements, 6 measurement sessions will be performed by the subject a day. A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3. On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
89286201|NCT01309178|Active Comparator|Amitriptyline|After the experience with the treatment of 18 CF-patients phase IIa study), the medication will be therefore 25 mg daily in two doses (2 x 12,5 mg). Because of a higher rate of side effects (tiredness, dry mucous membrane) the higher dose of 50 mg (2 x 25 mg) is not chosen first, but will be adapted after 2 weeks of treatment.
89286202|NCT01309178|Placebo Comparator|Mannite|The placebo will be given 25 mg daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
89286203|NCT05382260|Experimental|Disorders of consciousness(DOC)|The participants in this arm are disorders of consciousness, containing of vegetative state(VS) and minimally conscious state(MCS).
89286204|NCT05382260|Other|Health control|They are health people with normal hearing, acting as a control for DOC group.
89286205|NCT01343914||Cohort|
89286206|NCT05346068|Experimental|Study Device|
89286207|NCT05346068|Active Comparator|Control Device|
89286208|NCT03780998||Group-1 (n: 50): Healthy cases|Control group
89286209|NCT03780998||Group-2 (n:50): Grade 1 hemorroid|With perianal examination diagnosed of grade 1 hemorroidal disease
89286210|NCT03780998||Group-3 (n:50): Grade 2 hemorroid|With perianal examination diagnosed of grade 2 hemorroidal disease
89286211|NCT03780998||Group-4 (n:50): Anal fissure cases|With perianal examination diagnosed of anal fissure cases
89286212|NCT03780998||Group-5 (n:50): Simple perianal fistula|With perianal examination diagnosed of uncomplicated, simple perianal fistula cases
89286213|NCT01343992|Active Comparator|Bedrest|Patients will rest in bed ten minutes after the embryo transfer.
89286214|NCT01343992|Experimental|No bed rest|Patients will not rest after the embryo transfer.
89286215|NCT01344070|Active Comparator|Reference formulation of each drug|Innovator formulation
89286216|NCT01344070|Active Comparator|generic formulation a|one of the several generic formulations in the market, randomly selected for each drug
89286217|NCT01344070|Active Comparator|generic formulation b|second of the several generic formulations in the market, randomly selected for each drug
89286218|NCT01344070|Active Comparator|generic formulation c|third of the several generic formulations in the market, randomly selected for each drug
89286219|NCT01319162||Women with PCOS|All obese women between 18 and 50 years diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
89286220|NCT01319162||Women without PCOS|All obese women between 18 and 50 years not diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
89286221|NCT01317238|Experimental|CJ Vaccination arm|healthy vaccinia-experienced volunteers who received CJ smallpox vaccine
89286222|NCT01319474|Other|Ultrasound for suspected DVT|Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
89286223|NCT01344148|Experimental|Anti- TB therapy HAART|
89286224|NCT03784196||Acute Whiplash Associated Disorders|People suffering from acute WAD at the time of recruitment.
89286225|NCT03784196||Healthy controls|Participants with no neck pain during the past 6 months, chronic pain or other medical disorders relevant to this study.
89286226|NCT01335100||ambulatory CP|ambulatory children with cerebral palsy undergoing Botulinum toxin injections to lower limbs
89286227|NCT01335100||controls|age and gender matched sibilings
89286228|NCT01335178|Experimental|Intervention|Participants received the behavioral intervention, which was designed to motivate parents to protect their children from tobacco smoke exposure
89286229|NCT04942964|Experimental|ASP0367: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
88805698|NCT04104230||Healthy Controls|Healthy individual at general population lifetime risk of pancreatic cancer and related cancers.
88805699|NCT00136760|Experimental|1|Contingent reinforcement plus bupropion
89286230|NCT04942964|Experimental|ASP0367: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
89286231|NCT04942964|Experimental|ASP0367: Normal Hepatic Function|Participants with normal hepatic function will receive a single dose of ASP0367 under fasting conditions on day 1.
89286232|NCT04231942|Experimental|Group 1 (experimental): continuous using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS (at least 8 hours per day) for both lower extremities every day for 12 months, while change of GCS for the new one should be carried out at 6 months or early in case of stocking deterioration;"
89286233|NCT04231942|Experimental|Group 2 (experimental): intermittent using of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~In addition to lifestyle correction and exercises, patients will be recommended to use Class 1 (RAL GZ 387) below-knee GCS on both limbs during physical activity and long stasis events: any kind of sport activities, air travel of any duration, traveling on vehicles for more than 4 hours, walking for more than 2 hours, standing work for more than 4 hours) for 12 months, while change of GCS for the new one should be carried in case of stocking deterioration;"
89286234|NCT04231942|No Intervention|Group 3 (control): no use of GCS|"At 30-45 days after the intervention for VVs treatment patients without objective signs (C0-1) and subjective symptoms (intensity of 30% and less) of CVD, without any need for long-term using of GCS and/or vein-active drugs will receive appropriate recommendations on lifestyle correction (avoiding long static activities, maintaining an active lifestyle, the correction of excess weight and constipation, a diet with enough fiber and vitamins) and physical activity (visiting the pool, exercises that improve venous outflow).~The use of GCS will be possible on-demand when symptoms or risk factors appear after appropriate coordination with the Investigator"
89286235|NCT01561118|Experimental|Bicycle-Ergometer Training Group|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions).~In the second part of the study intervention will be prolonged for another 12 weeks."
89286236|NCT01561118|Other|Control|"No intervention during hemodialysis during the first 12 weeks of the study.~In the second part of the study a training program, according to that of the intervention group, will be performed with a performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions)."
89286237|NCT01335256|Experimental|Arm 1|
89286238|NCT03784274||Stakeholders|Key stakeholders involved program and policy making
89286239|NCT01309256||R-robot group|retrospective robot group
89286240|NCT01309256||P-robot group|prospective robot group
89286241|NCT01309256||P-laparoscopic group|prospective laparoscopic group
89286242|NCT01071629|Active Comparator|Combined interval and strength training|CHF Pts randomly designed at the combined interval and strength training group
89286243|NCT01071629|Active Comparator|Aerobic interval training|CHF Patients that randomly designed to participate at the interval training group
89286244|NCT01335412||IXIARO exposed group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of IXIARO
89286245|NCT01335412||Comparison group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of JE-VAX
89286246|NCT03776084||Patients SAHS with CPAP|Continuous Positive Airway Pressure treatment
89286247|NCT01072487|Experimental|Capnography|Arm with capnographic monitoring
89286248|NCT01072487|No Intervention|Standard|Standard monitoring.
89286249|NCT01344304|No Intervention|Standard therapy|The patients are treated with 5HT3-receptor antagonist + dexamethasone during the first course, then treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone
89286250|NCT01344304|Experimental|Aprepitant / Fosaprepitant therapy|The patients are treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone during first and second courses.
89286251|NCT02532101|Experimental|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 3 months
89286252|NCT01072565|Active Comparator|SMBG Only|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
89286253|NCT01072565|Active Comparator|SMBG and CGM|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.
89286254|NCT03776006||TPLA|
89286255|NCT03775616|Experimental|Supportive (financial navigation program)|Participants receive financial navigation program intervention consisting of a financial navigation video, monthly one-one financial counselling session, monthly phone or email consultation with patient navigators for 6 months and complete surveys at baseline, 3, 6, and 12 months.
89286256|NCT01320020|Experimental|catumaxomab|
89286257|NCT00260429|Experimental|AA4500 0.58 mg|
89286258|NCT00260429|Placebo Comparator|placebo|
89286259|NCT01313468|Experimental|4 x 4 Interval|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
89286260|NCT01313468|Experimental|1 4 minutes interval|1 x 4 minutes intervals at 90-95% of HR max
89286261|NCT01313468|Experimental|Moderate continuous Training|47 minutes of Moderate continuous Training
89286262|NCT00379288|Experimental|MF/F 200/10 mcg BID|
89286263|NCT00379288|Experimental|MF/F 400/10 mcg BID|
89286264|NCT00379288|Active Comparator|F/SC 250/50 mcg BID|
89286265|NCT00379288|Active Comparator|F/SC 500/50 mcg BID|
89286266|NCT03784040|Experimental|(Arm A) OTSGC-A24 + nivolumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14 each 28 day cycle (q28d) for up to 24 months.
89286267|NCT03784040|Experimental|(Arm B) OTSGC-A24 + nivolumab + ipilimumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 …) of each 28 day cycle for up to 24 months.
89286268|NCT00243503|Experimental|A|
88805700|NCT00136760|Experimental|2|Contingent reinforcement plus placebo
88805701|NCT00136760|Experimental|3|Non-contingent reinforcement plus bupropion
89286269|NCT03780686|Active Comparator|Dopamine and norepinephrine infusion|Infusion doppamine (2-5mcg/kg/min) and norepinephrine (3mcg/kg/h) with restricted fluid
89286270|NCT03780686|Active Comparator|Norepinephrine|Infusion norepinephrine (3mcg/kg/h) with restricted fluid.
89286271|NCT03780686|No Intervention|Standard fluid management|Standard fluid managements.
89286272|NCT04725136|Experimental|High-dose repeat administration group|FURESTEM-AD Inj 1.0 x 10^8 cells /body 3 repeated subcutaneous injection at 4 week intervals
89286273|NCT04725136|Experimental|High-dose single administration group|FURESTEM-AD Inj 1.0 x 10^8 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
89286274|NCT04725136|Experimental|Low-dose repeat administration group|FURESTEM-AD Inj 5.0 x 10^7 cells /body 3 repeated subcutaneous injection at 4 week intervals
89286275|NCT04725136|Experimental|Low-dose single administration group|FURESTEM-AD Inj 5.0 x 10^7 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals
89286276|NCT04725136|Placebo Comparator|Placebo|Normal saline(0.9% NaCl) 3 repeated subcutaneous injection at 4 week intervals
89286277|NCT03780764|Active Comparator|Conventional fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch."
89286278|NCT03780764|Experimental|Self ligating fixed appliance|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side."
89286279|NCT01561196|Active Comparator|Ultrasound guided arterial cannulation|The arterial needle is placed using ultrasound monitoring for guiding the operator.
89286280|NCT01561196|Active Comparator|Conventional cannulation|the arterial needle is placed using the traditional method and lidocaine. The operator decides where to place the needle in the forearm
89286281|NCT03775772|Other|Oral Health - Test Group|- study population is randomly assigned to control and test group
89286282|NCT03775772|Other|Bite Force/Chewing Efficacy-Test Group|- study population is randomly assigned to control and test group
89286283|NCT00239837|Experimental|Middle School Success Intervention (MSS)|Middle School Success Intervention (MSS): Participants receive the preventative intervention
89286284|NCT00239837|No Intervention|Foster Care Services as Usual|Foster Care Services as Usual: Participants continue with usual foster care
89286285|NCT03775928|Experimental|Apatinib + Capecitabine|Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
89286286|NCT03775928|Active Comparator|Capecitabine|capecitabine 1000mg/m2 bid d1-14, q21d
89286287|NCT03775538|Experimental|CDNF mid-dose (400 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to mid-dose (400 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
89286288|NCT03775538|Experimental|CDNF high-dose (1200 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to high-dose (1200 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
89286289|NCT03884920||Group A Pre-diabetic placebo|Group of pre-diabetics receiving placebo BD for six weeks
89286290|NCT03884920||Group B Pre-diabetic test|Group of Pre-diabetic receiving polyherbal / test candidate 900mg in two divided doses for six weeks
89286291|NCT03884920||Group C Diabetic test|Early onset of Diabetes mellitus receiving polyherbal formulation 1800mg in two divided doses for six weeks
89286292|NCT01320098|Experimental|Home-Based Parenting Program|
89286293|NCT01320098|Experimental|Clinic-Based Parenting Program|
89286294|NCT01320098|Other|Wait-List Control Group|
89286295|NCT01335490|Experimental|Biolite Cook Stove|Provision of two cook stoves to each subject. Each stove burns wood fuel, but more efficiently than a traditional three stone fire.
89286296|NCT01335490|Experimental|LPG Cook Stove|Provision of a two-burner liquified petroleum gas stove to each subject, along with fuel needed for the family during the follow up period.
89286297|NCT01335490|No Intervention|Control|
89286298|NCT01335568|Experimental|surgery|chronic liver insufficiency, cirrhosis
89286299|NCT01315444|Active Comparator|PPI abrupt cessation|Abrupt cessation
89286300|NCT01315444|Active Comparator|PPI gradual step down cessation|Gradual cessation
89286301|NCT01320176|Experimental|Group A|Subjects received dose A of the investigational HIV vaccine
89286302|NCT01320176|Experimental|Group B|Subjects received dose B of the investigational HIV vaccine
89286303|NCT01335646|Active Comparator|Surgery|
89286304|NCT01335646|Active Comparator|Non-operative|
89286305|NCT01309412|Experimental|Siltuximab|Siltuximab 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
89286306|NCT01320254|Experimental|Cisplatin, Gemcitabine and Panitumumab|Experimental Arm with cisplatin 25mg/sq.m. at day 1 + 8, gemcitabine 1000mg/ sq.m.at day 1 + 8 and panitumumab 9mg/kg BW at day 1. Cycle will be repeated every 3 weeks.
89286307|NCT01320254|Active Comparator|Cisplatin and Gemcitabine|Cisplatin 25mg/sq.m. at day 1 + 8 and Gemcitabine 1000 mg/sq.m. at day 1 + 8. Cycle will be repeated every 3 weeks.
88805702|NCT00136760|Placebo Comparator|4|Non-contingent reinforcement plus placebo
89286308|NCT01335802||Subclinical hypothyroidim|Women having subclinical hypothyroidism and/or TPOab-positive.
89286309|NCT01335802||Controls|Women having normal levels of TSH and TPOab-negative.
89286310|NCT03780218||Experimental Group:Respiratory function|Patients with burn injury will be included in this study. Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed on the discharge week.
89286311|NCT03780218||Control Group:Respiratory function|Healthy subjects will be included in this study.Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed.
89286312|NCT01344694||patient with liver fat|30 patients with liver fat
89286313|NCT01344694||excess of visceral fat|50 pts. with excess of visceral fat
89286314|NCT01344694||control|30 control subjects
89286315|NCT01344772|Active Comparator|Internal fixation|Displaced femoral neck fracture treated with internal fixation using two parallel cannulated screws.
89286316|NCT01344772|Active Comparator|Total hip replacement|Displaced femoral neck fracture treated with total hip replacement through a posterior approach.
89286317|NCT03783728||Untreated Latent Tuberculosis Infection|Isoniazid 900 mg orally + Rifapentine 600 mg orally + Pyridoxine 50 mg orally once a week for 12 weeks
89286318|NCT03620422|Other|Healthy Controls|Mannitol-Induced Cough Challenges on Visit 2 and 3. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
89286319|NCT03620422|Placebo Comparator|Mild Allergic Asthmatics (Saline)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized placebo (Sodium Chloride 0.9% Inhl 3Ml) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
89286320|NCT03620422|Active Comparator|Mild Allergic Asthmatics (Salbutamol)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
89286321|NCT03775226|Experimental|Single are|This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.
89286322|NCT04228354|Experimental|Semaglutide 0.68 mg/mL|Semaglutide administered with the PDS290 pen-injector
89286323|NCT04228354|Experimental|Semaglutide 1.0 mg/mL|Semaglutide administered with the PDS290 pen-injector
89286324|NCT03780374|Active Comparator|Sound Processing Principle 1|Sound Processing Principle 1 will be applied in the hearing aid.
89286325|NCT03780374|Experimental|Sound Processing Principle 2|Sound Processing Principle 2 will be applied in the hearing aid.
89286326|NCT03780374|Experimental|Sound Processing Principle 3|Sound Processing Principle 3 will be applied in the hearing aid.
89286327|NCT01344928|Experimental|HIT training|
89286328|NCT01344928|Active Comparator|Aerobic exercise training|
89286329|NCT03775148|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
89286330|NCT03775148|No Intervention|CAU Group|Care-As-Usual group
89286331|NCT01309490|Experimental|Ribavirin, nucleoside analog|
89286332|NCT04883840|Placebo Comparator|Placebo|
89286333|NCT04883840|Experimental|Rosuvastatin 10 mg|
89286334|NCT01345084|Experimental|Radiation therapy, cisplatin and nimotuzumab|"Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.~Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week~Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)"
89286335|NCT01345084|Active Comparator|Radiation therapy and cisplatin|"Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week~Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)"
89286336|NCT01320332|Experimental|ASP3291 low dose|
89286337|NCT01320332|Experimental|ASP3291 high dose|
89286338|NCT01320332|Placebo Comparator|Placebo|
89286339|NCT04074772||Healthy Controls|This group will consist of healthy controls between the ages of 18 and 70-years-old. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be used to train a neural network to identify points of interest in a generalized patient population.
89286340|NCT04074772||Movement Disorder Patients|This group will consist of movement disorder clinic patients between the ages of 18 and 70-years-old with a diagnosed or putative movement disorder. Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
89286341|NCT04074772||Age-Matched Controls|This group will consist of relatives of movement disorder clinic patients that are visiting with them to serve as age-matched controls (within 10 years of patient's age). Following consent, they will complete a simplified motor physical exam while being filmed from three angles. This video data will be analyzed with the neural network trained on the healthy controls.
89286342|NCT03780530|Active Comparator|subcuticular suturing|
89286343|NCT03780530|Active Comparator|surgical glue|
89286344|NCT03780530|Active Comparator|adhesive steri-strip tape|
89286345|NCT01309568||Investigational testing|Pending the outcome of culture, the subject may be treated with an approved antiviral medication at the doctors discretion.
89286346|NCT03774836|Active Comparator|Tramadol 50 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
89286347|NCT03774836|Active Comparator|Morphine 4 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
89286348|NCT03774836|Placebo Comparator|Placebo|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
89286349|NCT03774680|Active Comparator|Cetuximab nanoparticles goup|A group of volunteers infected colon cancer or colorectal cancer received cetuximab in the formulated nanoparticles
89286350|NCT03774680|Placebo Comparator|Oral approved anticancer drug|A group of volunteers infected with colon cancer or colorectal cancer received placebo anticancer drug.
89286351|NCT03783650|Experimental|Cohort 1|0-6 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist, Registry & BP measurement 7-12 months: QIC with Subspecialist to improve communication and standardize, 13-18 months: Hub and Spoke co-management QIC with Primary care and Subspecialist 19-24 months: Sustainability of changes
89286352|NCT03783650|Active Comparator|Cohort 2|0-6 months: Control condition Usual Care and Registry & BP measurement, 7-12 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist 13-18 months: QIC with Subspecialist to improve communication and standardize 19-24 months: Hub and Spoke co-management QIC with Primary care and Subspecialist
89286353|NCT03774602|Experimental|MCSP package of interventions|MCSP package of interventions for health promotion and provision of RMNCH services
89286354|NCT03783806||Osteoarthrosis (OA)|Patients with primary osteoarthrosis, waiting for a total hip replacement. Determination of functional status, posturography measurements, postural tests.
89286355|NCT03783806||Rheumatoid arthritis (RA)|Patients with rheumatoid arthritis affecting hip joint. Determination of functional status, posturography measurements, postural tests.
89286356|NCT03783806||Control (C)|The healthy reference group was matched with the patient groups for age, gender and body mass index (BMI). Determination of functional status, posturography measurements, postural tests.
89286357|NCT03783338|Active Comparator|Physical therapy group|Group A will consist of 15 children and will receive the conventional physical therapy program only. This group will be used to compare the results of the other two groups.
89286358|NCT03783338|Experimental|Physical therapy and aerobic exercises group|Group B will consist of 15 children and will receive the conventional physical therapy program and aerobic exercises.
89286359|NCT03783338|Experimental|Physical therapy, aerobic exercises and vitamin D group|Group C will consist of 15 children and will receive the conventional physical therapy program, aerobic exercises and an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) .
89286360|NCT03774524|Active Comparator|Misoprostol with TA|400 μg of sublingual misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
89286361|NCT03774524|Active Comparator|Misoprostol with placebo to TA|400 μg of sublingual misoprostol (two tablets) plus 110 ml saline by iv rout
89286362|NCT03774524|Placebo Comparator|placebo to Misoprostol with placebo to TA|placebo to misoprostol plus placebo to tranexamic acid
89286363|NCT03774290|Experimental|PBF-680 10 mg|10 mg of PBF-680 once a day
89286364|NCT03774290|Placebo Comparator|Placebo oral capsules|Placebo once a day
89286365|NCT03774212|Experimental|Group A|On study night 1, participants will receive standard care (no headphones provided). On study night 2, these patients will wear Active Noise Cancelling headphones playing white noise.
89286366|NCT03774212|Experimental|Group B|Patients will spend night 1 wearing Active Noise Cancelling headphones playing white noise. On Study night 2, these patients will receive standard care (no headphones provided).
89286367|NCT04775420||Group 1|Ascetic patients without spontaneous bacterial peritonitis
89286368|NCT04775420||Group 2|Ascetic patients with spontaneous bacterial peritonitis
89286369|NCT03780296|Experimental|Real-Time Action Observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
89286370|NCT01314326||Perimetric Glaucoma (PG)|Patients with clinically confirmed abnormal VF and glaucomatous ONH or NFL defect
89286371|NCT01314326||Glaucoma Suspects and Pre-Perimetric Glaucoma (GSPPG) Group|Patients who are at high risk to develop perimetric glaucoma
89286372|NCT01314326||Normal Group|Volunteers with healthy eyes
89286373|NCT01314560|Experimental|1|experimental
89286374|NCT03779750||End Stage Renal Disease Patients|complete blood picture blood urea s.creatinine urine analysis calcium phosphorus parathyroid hormone. 4- Hepatitis BsAg,HCV-Abs and HIV.
89286375|NCT03774368|Other|Website about emergency contraception|Subjects are randomly assigned to view an existing website about emergency contraception. The website contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
89286376|NCT03774368|Other|Video about emergency contraception|Subjects are randomly assigned to view an existing video about emergency contraception. The video is two minutes in length and contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
89286377|NCT03773900|Experimental|Chitin-Glucan supplementation|
89286378|NCT03773900|Placebo Comparator|Placebo supplementation|
89286379|NCT03783260|Experimental|Single|All participating subjects will undergo two, 2-day Mediterranean diet feeding periods separated by a 14-day period of Canadian diet
89286380|NCT03774056|Experimental|dose group|Drug name L:HC-1119 Dosage: 40 mg, 80 mg, 160 mg, and 200 mg
89286381|NCT03783104|Experimental|250μg of vitamin B12 supplementation|Group 1 (Intervention) will receive 250μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
89286382|NCT03783104|Active Comparator|50μg of vitamin B12 supplementation|Group 2 (Control) will receive 50μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
89286383|NCT01309724|No Intervention|Control|No measurements are made on the control group.
89286384|NCT01309724|Experimental|USCOM|Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.
89286385|NCT03773744|Experimental|Arm 1: Intravenous Dosing|Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort.
89286386|NCT03773744|Experimental|Arm 2: Intravenous followed by Intratumoral Dosing|A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6).
89286387|NCT03779516|Active Comparator|Group C|In Control Group, 4 mL of saline solution was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
89286388|NCT03779516|Active Comparator|Group L|In Lidocaine Group 4 mL of 4% lidocaine was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
89286389|NCT03779594|Experimental|treatment group|patients who met the inclusion criteria will be allocated to the treatment group, and will receive acetazolamide from time of diagnosis until shunt surgery (2-6 weeks).
89286390|NCT04503590|Experimental|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
89286391|NCT03779672|Active Comparator|Memantine Hydrochloride 10 mg Placebo|"Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.~Dose regimen:~Memantine Hydrochloride~Week #1: 5 mg id (am), 1 caps~Week #2: 5 mg bid (am and pm), 2 caps~Weeks #3-6: 5 mg am & 2x 5 mg pm, 3 caps~Washout (Weeks #7-8)~Placebo~Week #9: id (am), 1 caps~Week #10: bid (am and pm), 2 caps~Weeks #11-14: 1 caps am & 2 caps pm, 3 caps"
89286392|NCT03779672|Placebo Comparator|Placebo Memantine Hydrochloride 10 mg|"Placebo~Week #1: id (am), 1 caps~Week #2: bid (am and pm), 2 caps~Weeks #3-6: 1 caps am & 2 caps pm, 3 caps~Washout (Weeks #7-8) Memantine Hydrochloride~Week #9: 5 mg id (am), 1 caps~Week #10: 5 mg bid (am and pm), 2 caps~Weeks #11-14: 5 mg am & 2x 5 mg pm, 3 caps"
89286393|NCT03779282||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving ketodex
89286394|NCT03779282||study|pediatric patients undergoing outpatient strabismus surgery, and receiving ketodex
89286395|NCT03773588|Active Comparator|Closed-Loop propofol Target control infusion|Closed loop target controlled infusion(TCI) TIVA with propofol using BD TCI pumps guided by entropy and SPI
89286396|NCT03773588|Active Comparator|Open-loop propofol target control infusion|Open-loop target controlled infusion of propofol using BD TCI pumps based on Schnider effect site algorithm
89286397|NCT03773510|Active Comparator|Trabectedin continuation|All the patients who will complete 6 cycles of trabectedin without disease progression, will continue trabectedin until progressive disease, unacceptable toxicity, patient or investigator decision
89286398|NCT03773510|Experimental|Trabectedin discontinuation|"All the patients who will complete 6 cycles of trabectedin without disease progression , will discontinue trabectedin.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
89286399|NCT03773432|Other|Men|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
89286400|NCT03773432|Other|Women|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
89286401|NCT01320644||vaginal mesh placement|
89286402|NCT01314950|Active Comparator|Best practices primary care|Best practices primary care encompasses the collaborative care intervention tested in a prior clinical trial (Callahan CM et al. JAMA 2006).
89286403|NCT01314950|Experimental|Home based occupational therapy|The intervention group receives all of the components of best practice primary care in addition to a home-based intervention designed to slow functional decline.
89286404|NCT03779360|Active Comparator|Subjects 1-6|7 day treatment of erythromycin and clindamycin twice daily on indicated skin areas prior to Clobetasol treatment; randomized either on the left or right arm for 2 days.
89286405|NCT03779360|Experimental|Subjects 7-24|7 day treatment of erythromycin and clindamycin twice daily on indicated skin area prior to 4 Lipopolysaccharide injections and Clobetasol treatment; randomized either on the left or right arm for 2 days.
89286406|NCT03779360|Active Comparator|Subjects 25-30|0.5mg/kg prednisolone two days prior to Lipopolysaccharide injections
89286407|NCT03782948|Active Comparator|Controls|"In each session, the group will undergo standard gait training on BART without pelvic perturbations, i.e.,~walk a virtual track on the BART without pelvic perturbations (i.e., the pelvic brace of the BART device will be set to follow the patient's motion) for 10 minutes;~practise gait symmetry and take-off using visual feedback without pelvic perturbations in two 10-minute sessions."
89286408|NCT03782948|Experimental|Experimental|"In each session, the group will undergo robotised gait training with BART with pelvic perturbations, i.e.,~walk a virtual track on the BART with pelvic perturbations during virtual uphill walk and virtual curved walk for 10 minutes;~practise gait symmetry and take-off using visual feedback with pelvic perturbations for 10 minutes;~practise dynamic gait balance using pelvic perturbations during treadmill walking for 10 minutes."
89286409|NCT01560728|Experimental|Trauma-Focused CBT|Adapted or modified Trauma-Focused Cognitive Behavioral Therapy
89286410|NCT01560728|No Intervention|Wait list|Monitored while waiting for intervention
89286411|NCT05271734|Experimental|Single arm -lid retractor placement|Placement of a lid retractor the find out if the corneal limbus is exposed to 360 degrees
89286412|NCT01320800|Active Comparator|Expert-led CBT|Expert SASS is the Skills for Academic and Social Success protocol delivered by a postdoctoral fellows.
89286413|NCT01320800|Experimental|School Counselor-led CBT|"School Counselor SASS is the Skills for Academic and Social Success protocol delivered by School Counselors.~Intervention: Behavioral: Skills for Social and Academic Success"
89286414|NCT01320800|Active Comparator|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors. Intervention: Behavioral: Skills for Life
89286415|NCT01309958||intervention|design instruments and test feasibility of an intervention aimed at increasing the proportion on non-invasive treatment for early caries
89286416|NCT01320878|Active Comparator|iloprost low dose group|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
89286417|NCT01320878|Active Comparator|iloprost high dose group|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
89286418|NCT01320878|Placebo Comparator|placebo group|distilled water 2 ml per session
89286419|NCT01321034|Other|Niacin/Laropiprant|Subjects with normal Lp(a) will be use as comparative group for the other two groups, so no placebo group is required is this study
89286420|NCT03779438|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
89286421|NCT03779438|Placebo Comparator|placebo to 17-OHPC|patients received weekly placebo to 17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
89286422|NCT03778814|Experimental|TCR-T cell therapy group|Appropriate lung cancer or other solid tumor patients who could benefit from immunotherapy will be treated with targeting TCR-T cells.
89286423|NCT03773354|Experimental|Intervention|There is no control group for this study, and all participants receive the intervention. Although a few participants will be asked to give additional information during the intake and after the study concludes for quality improvement purposes. Effects of these additional interview questions will be considered during analysis
89286424|NCT03782714|Experimental|Low-level laser therapy group|This group of teeth received laser irradiation after amputation of coronal pulp
89286425|NCT03782714|No Intervention|Formocresol group|This group of teeth received the gold standard medication (formocresol) after coronal pulp amputation
89286426|NCT01321112|Experimental|Conversion arm|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
89286427|NCT03773042|Experimental|HSK3486|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg
89286428|NCT03773042|Active Comparator|Propofol|1.0mg/kg, 2.0mg/kg
89286429|NCT03778892|Experimental|Novel Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
89286430|NCT03778892|No Intervention|Standard Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
89286431|NCT01310348|Placebo Comparator|Very low magnitude vibration|Very low magnitude vibration
89286432|NCT01310348|Experimental|Training|The whole-body vibration (WBV) training
88805703|NCT00136838|Experimental|Neutral Cue first, then Active Cue|"Each participant receives two consecutive interventions.~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue."
89286433|NCT03782480|Active Comparator|Intrarosa|Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks
89286434|NCT03782480|Placebo Comparator|Placebo|Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks
89286435|NCT03778970|Experimental|Pain Neuroscience Education + Exercises|The PNE will follow the principles established by Explain Pain, addressing reconceptualization of pain, emphasizing modern neuroscience concepts. The PNE workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic.
89286436|NCT03778970|Active Comparator|Self-Management Education + Exercises|"The Self-Management Education (SME) strategy will be aligned with the Back Book concepts, focused on behavior change and encouraging participants to be active despite of the pain. The SME workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic."
89286437|NCT03712280|Experimental|Group A: MNK6106 2 grams (tid)|Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days
89286438|NCT03712280|Experimental|Group B: MNK6106 4 grams (bid)|Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days
89286439|NCT03712280|Experimental|Group C: MNK6106 4 grams (tid)|Participants receive 4 tablets of MNK6106 tid for 5 days
89286440|NCT03712280|Active Comparator|Group D: Rifaximin 550 mg (bid)|Participants receive 1 tablet of rifaximin bid for 5 days
89286441|NCT01561508|Experimental|GABA|2/3 of participants will be randomized to the GABA treatment group. Dosage will be based on body weight and will be adjusted at each study visit.
89286442|NCT01561508|Placebo Comparator|Placebo|1/3 of participants will receive placebo.
89286443|NCT03772886|Experimental|Peanut Ball Arm|Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
89286444|NCT03772886|No Intervention|Control Arm|Study participants randomized to the Control Arm will labor without the peanut ball.
89286445|NCT03772808|Experimental|Lycocomfort|The once-daily supplement LycoComfort™ is a combination of lycopene and beta-sitosterol, a chemically defined extract of phytosterols with beta-sitosterol as the main component,
89286446|NCT01321190||Low Back Pain|Individuals who experience bothersome low back pain.
89286447|NCT01321190||Headache|Individuals who experience bothersome headaches.
88805704|NCT00136838|Experimental|Active Cue first, then Neutral Cue|"Each participant receives two consecutive interventions.~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue.~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue"
88805705|NCT00189098|Placebo Comparator|placebo|
88805706|NCT00189098|Active Comparator|Sulfamethoxazole-trimethoprim|
89286448|NCT01321190||Fibromyalgia|Individuals who experience bothersome fibromyalgia-related pain.
89286449|NCT01561664|Active Comparator|volunteers|not overweight Volunteers responding to the study criteria
89286450|NCT01561664|Experimental|overweight patients insulin sensitive|overweight patients insulin sensitive responding to the study criteria
89286451|NCT01561664|Experimental|overweight insulin resistant|overweight patients insulin resistant responding to the study criteria
89286452|NCT03772496|Experimental|circulating tumor cells|circulating tumor cells test and FNAB will be performed at the same time
89286453|NCT03769610|Active Comparator|Inpatient Foley catheter|Subjects will be admitted to a room on labor and delivery and will be monitored with the external fetal monitor (EFM) and tocometer (a device to monitor contractions). If she is contracting less than every 2 minutes, intravenous (IV) Pitocin will be started at 2 milliunits/minute and increased per hospital protocol. While on pitocin, she will remain on continuous EFM and tocometer. She will also be kept on a clear liquid diet with intravenous fluids per standard protocol. If the Foley catheter has not been expulsed in 24 hours, it will be removed. After expulsion or removal of the Foley catheter, induction may proceed as deemed clinically appropriate by the managing physician. No further cervical ripening will be performed after the Foley catheter is expulsed/removed, or after 24 hours.
88805707|NCT00145418|Experimental|1|Oxaliplatin + Docetaxel as first line therapy of Stage IV or IIIB unresectable non-small cell lung cancer. The primary objective of the trial is to determine the response rate by RECIST criteria to the combination of oxaliplatin and docetaxel in patients with previously untreated NSCLC.
88805708|NCT04751474|Experimental|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
88805709|NCT04751474|No Intervention|Control group|The control group did not receive any intervention.
88805710|NCT04751318|Experimental|Duloxetine Test Produc|Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
88805711|NCT04751318|Active Comparator|Duloxetine Referent Product|Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a feeding condition.
88805712|NCT01105247|Experimental|PCI-32765|
89286454|NCT03769610|Experimental|Outpatient Foley catheter|Subjects are asked to return to the hospital ~12 hours after placement. Subjects are to return to the hospital if they develop heavy vaginal bleeding, decreased fetal movement, rupture of membranes, or increasingly painful or frequent contractions requiring an epidural or pain relief. Once admitted, subjects will be evaluated for expulsion of the catheter. If the catheter is in place IV Pitocin will be started. If the catheter has been expulsed, the induction will proceed as deemed clinically appropriate. After 24 hours, if the Foley catheter is still in the cervix it will be removed and the induction will proceed as deemed clinically appropriate.
89286455|NCT03772418|Placebo Comparator|Cream base|A group of volunteers receiving placebo medications without natural extracts of ginkgo biloba and Pomegranate.
89286456|NCT03772418|Active Comparator|Pomegrante and Ginkgo biloba group|A group of volunteers with the aging state receiving natural extracts of ginkgo biloba and Pomegranate in different topical dosage forms.
89286457|NCT03772262|Experimental|Control|Study subjects will be administered a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one rosuvastatin tablet (10 mg) by mouth. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
89286458|NCT03772262|Experimental|Treatment|Study subjects will be administered goldenseal 2 capsules (500 mg each) three times daily for 5 days. On day 6, subjects will be administered goldenseal 2 capsules (500 mg each), a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one tablet (10 mg) rosuvastatin. Goldenseal 2 capsules (500 mg each) will be administered approximately 4 and 8 hours later. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
89286459|NCT03772340|Experimental|Tradipitant|
89286460|NCT03772340|Placebo Comparator|Placebo|
89286461|NCT03772106|Experimental|Group P|Group P : Propolipid 1% dose : variable to keep BIS between 40 and 60
89286462|NCT03772106|Experimental|Group S|Group S : Sevoflurane dose : variable to keep BIS between 40 and 60
89286463|NCT03778736|Experimental|Cumulase denudation|
89286464|NCT03778736|No Intervention|Hyaluronidase denudation|
89286465|NCT03778346|Experimental|CAR-T therapy in multiple myeloma|In order to assess the safety and validity of using the Fourth Genenation of CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD38-CART , Integrin β7-CART or 10 different combinations ,subjects will receive 10^6-10^7/Kg transduced CAR-T cells at one time.
89286466|NCT03771950|Experimental|Intervention group|Early team based neuro-rehabilitation after Traumatic Brain Injury
89286467|NCT03771950|No Intervention|Control group|Treatment as usual.
89286468|NCT03771794|Active Comparator|Active Comparator: ReguRate RR2 active|Device: ReguRate neurostimulation device
89286469|NCT03771794|Sham Comparator|Sham Comparator: ReguRate RR2 sham.|Device: Sham ReguRate neurostimulation - mock sham stimulation mode
88805713|NCT01107665|Experimental|Pazopanib and Paclitaxel|Treatment on study will be administered in 4-week cycles. Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
88805714|NCT05272007||Acute cholecystitis|
89286470|NCT03771872|Experimental|Virtual Prism Adaptation Therapy|This group will be provided with real virtual prism adaptation therapy. In the real therapy session, the hand trajectory will deviate to the right side in the virtual reality. The deviation angle will be adjusted according to the subject's adaptation. 20min-session will be provided twice a day for 5 days, then the total 10 sessions of therapy will be provided.
89286471|NCT03771872|Sham Comparator|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
89286472|NCT01316588|Experimental|Plastic adesive drape|Intraoperative: Plastic adhesive drape on the chest and bare skin on the leg
89286473|NCT01316588|Experimental|Microbial Sealant|Intraoperative: Microbial Sealant on the leg and bare skin on the chest
89286474|NCT04141592||Healthy Control|non-obese individuals without fatty liver disease
89286475|NCT04141592||Obese wihtout non-alcoholic steatohepatitis|Body mass index greater than 30 without liver histological evidence of non-alcoholic fatty liver disease
89286476|NCT04141592||Obese Non-alcoholic steatohepatitis|Body mass index greater than 30 with liver histological evidence of non-alcoholic fatty liver disease
89286477|NCT03778268|Experimental|Undergoing sentinel lymph node biopsy|This group of patients will undergo sentinel lymph node biopsy.
89286478|NCT01345240|Experimental|RTS,S Regimen A Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286479|NCT01345240|Experimental|RTS,S Regimen A Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. In addition, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
88805715|NCT03012659|Experimental|Intervention Arm|Full-day contraceptive counseling training for health center staff
89286480|NCT01345240|Experimental|RTS,S Regimen A Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286481|NCT01345240|Experimental|RTS,S Regimen B Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286482|NCT01345240|Experimental|RTS,S Regimen B Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286483|NCT01345240|Experimental|RTS,S Regimen B Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286484|NCT01345240|Experimental|RTS,S Regimen C Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286485|NCT01345240|Experimental|RTS,S Regimen C Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286486|NCT01345240|Experimental|RTS,S Regimen C Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
88805716|NCT03012659|No Intervention|Control Arm|Usual care
89286487|NCT01345240|Active Comparator|Engerix B Regimen A Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen A. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™ at Weeks 0, 4 and 8, and 2 doses of Rotarix™, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286488|NCT01345240|Active Comparator|Engerix B Regimen B Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen B. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™ vaccine, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
89286489|NCT03771638|Experimental|DOT Diary Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
89286490|NCT03771638|Other|DOT Diary Control|Standard of care for Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
89286491|NCT03771404|Other|Operable (stages I-IIIA) NSCLC|For Operable (stages I-IIIA) NSCLC Patients, blood sampling and tissue samples of the primary tumor as well as the regional involved lymph nodes and, in selected patients, from biopsies from metastasis
89286492|NCT03771482|Active Comparator|Opioid module first then fluid|The providers in this arm will first receive daily information and questions related to opioid use for eight weeks and then daily information and questions related to intravenous fluid prescribing for five weeks.
89286493|NCT03771482|Active Comparator|Fluid module first then opioid|The providers in this arm will first receive daily information and questions related to intravenous fluid prescribing for five weeks and then daily information and questions related to opioid use for eight weeks.
89286494|NCT03771248|Active Comparator|Co-cr telescopic partial denture|A removable partial denture, that gains retention from a telescopic crown made of cobalt chromium
89286495|NCT03771248|Experimental|PEEK telescopic partial denture|A removable partial denture, its attachment is a telescopic crown made of PEEK
89286496|NCT01335880|Active Comparator|Promotion I|Three month time horizon
89286497|NCT01335880|Experimental|Promotion II|One week time horizon
89286498|NCT03771170|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
89286499|NCT03771170|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
89286500|NCT03280732|Experimental|Lung Ultrasound|Bedside lung ultrasound will be performed by a paediatrician with specific LUS expertise and blinded to clinical and radiological data.
89286501|NCT03769064|Experimental|Qualification Phase (Part A)|Placebo/Methylphenidate (60 mg) on days 1 and 3
89286502|NCT03769064|Experimental|Qualification Phase (Part B)|Methylphenidate (60 mg)/Placebo on days 1 and 3
89286503|NCT03769064|Experimental|Treatment Phase Sequence 4213|Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg
89286504|NCT03769064|Experimental|Treatment Phase Sequence 2134|Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg
89286505|NCT03769064|Experimental|Treatment Phase Sequence 1342|Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo
89286506|NCT03769064|Experimental|Treatment Phase Sequence 3421|Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo
89286507|NCT03771092|Experimental|Patients with non-severe anemia treated with SunActive®Fe|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized
89286508|NCT03771092|Experimental|Patients with non-severe anemia treated with Lipofer®|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with Lipofer®
89286509|NCT03771092|Experimental|Patients with severe anemia with Lipofer®|Patients with severe anemia (Hb <10 g/dl) treated respectively with Lipofer®
89286510|NCT03771092|Experimental|Patients with severe anemia with SunActive®Fe|Patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized
89286511|NCT03771092|Experimental|Patients with severe anemia with intravenous ferric gluconate|Patients with severe anemia (Hb <10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols
89286512|NCT03771326|Experimental|obese men|To the 7 obese men, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
89286513|NCT03771326|Experimental|Normal men|To the 7 normal BMI mean, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
89286514|NCT03778034||Female with forward head posture|post-pubertal females suffering from (FHP) with Craniovertebral angle (CVA) less than 49 degrees(study group)
89286515|NCT03778034||healthy female without (FHP)|post-pubertal females expected to exhibit an average normal CVA within 10degrees range from 49 to 59 (control group)
89286516|NCT04026646|Experimental|Proprioceptive Neuromuscular Facilitation stretching exercises|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
89286517|NCT04026646|Experimental|Static stretching exercises|Passive Static Stretching exercises will be performed 2 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.
89286518|NCT03768908|Active Comparator|Treatment with artesunate + amodiaquine|Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children <12months <10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day.
89286519|NCT03768908|Active Comparator|Treatment with artemether-lumefantrine (Coartem®)|Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children <60 months, 5-14kg: 1 tab/dose; Children <60 months >14kg: 2 tabs/dose.
89286520|NCT03777878|Active Comparator|Carbetocin plus placebo to TA and placebo to oxytocin|100 μg carbetocin ampoule or separate placebo ampoule was diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby plus two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion
89286521|NCT03777878|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1gm TA in 100ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
89286522|NCT03777878|Active Comparator|oxytocin plus placebo to TA and placebo to carbetocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
89286523|NCT01345396|Experimental|Education|
89286524|NCT01345396|No Intervention|No education|
89286525|NCT04008004|Experimental|EDP-514 HV SAD Cohorts|EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration
89286526|NCT04008004|Experimental|EDP-514 HV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days
89286527|NCT04008004|Placebo Comparator|EDP-514 HV SAD Placebo Cohort|Matching placebo, orally, once daily in one single administration
89286528|NCT04008004|Placebo Comparator|EDP-514 HV MAD Placebo Cohort|Matching placebo, orally, once daily for 14 days
89286529|NCT04008004|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days
89286530|NCT04008004|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days
89286531|NCT03620344|Experimental|ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support."
89286532|NCT03620344|Sham Comparator|No ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure."
89286533|NCT03707912|Experimental|Anaferon|"1 tablet per administration. Day 1: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals through the rest of the day.~Days 2-5: 1 tablet 3 times a day. The drug is taken out of the meal (in the interval between meals or 15-30 minutes before eating), keep the tablet in the mouth, without swallowing, until completely dissolved."
89286534|NCT03707912|Placebo Comparator|Placebo|Placebo using Anaferon regimen until the end of the study.
89286535|NCT03246958|Experimental|Nivolumab alone for two weeks|Ipilimumab will be administered via IV infusion, starting two weeks after Nivolumab
89286536|NCT03246958|Experimental|Ipilimumab alone for two weeks|Nivolumab will be administered via IV infusion, starting two weeks after Ipilimumab
89286537|NCT03157960|Experimental|Blueberry drink|Participant will receive a blueberry drink containing 18 g of fructose and 14 g of glucose.
88805717|NCT01447225|Experimental|MM-121 plus Gemcitabine|escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
89286538|NCT03157960|Experimental|Blueberry and pizza|Participant will receive a blueberry drink and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
89286539|NCT03157960|Experimental|Soft beverage|Participant will receive a Soft beverage (Coca-cola containing 17,5 g fructose and 17,5 g glucose)
89286540|NCT03157960|Experimental|Soft beverage and pizza|Participant will receive a Soft beverage and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
89286541|NCT03157960|Experimental|Fructose|Participant will receive a drink containing 35 g of fructose
89286542|NCT03157960|Experimental|Fructose and pizza|Participant will receive a drink containing 35 g of fructose and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
89286543|NCT01321268|Experimental|dietary supplement for cellulite|PUFA, resveratrol, lycopene, beta carotene, lutein
89286544|NCT01321268|Active Comparator|Control|Vitamin E
89286545|NCT03768830|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
89286546|NCT03768830|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
89286547|NCT03768830|Experimental|Healthy Exercise|Healthy individuals that will exercise-group (HE). Intervention is exercise training.
89286548|NCT03768830|No Intervention|Healthy Control (no-Exercise)|Healthy individuals that will not exercise (HC).
89286549|NCT03988270|Experimental|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
89286550|NCT03988270|No Intervention|Control|Participants in the control group will not receive any pre-surgical instructions for exercise in the access arm
89286551|NCT02883244|Experimental|Soft-Picks Advanced|Device: Curved Soft-Picks
89286552|NCT02883244|Active Comparator|Floss|Device: Waxed tape floss
89286553|NCT05162066|Other|C3G cohort|Approximately 14 eligible participants with C3G will be enrolled.
89286554|NCT05162066|Other|IgAN cohort|Approximately 14 eligible participants with IgAN will be enrolled.
89286555|NCT05162066|Other|PMN cohort|Approximately 14 eligible participants with PMN will be enrolled.
89286556|NCT01316666||Neurogenic Hypotension|Patients with neurogenic hypotension, which includes those with Pure Autonomic Failure (PAF), Multiple System Atrophy (MSA) and Parkinson Disease (PD)
89286557|NCT01335958|Experimental|A|
89286558|NCT03768674||Inpatient cohort (Target group)|"Inpatient at mental health centre/ psychiatric hospital due to severe self-harm. Duration > 4 weeks and/or > five admissions last year.~Assessment of diagnoses, functioning and health services"
89286559|NCT03768674||Outpatient comparison cohort|"Admitted to treatment within Norwegian Network of personality-focused treatment during 2017-2018.~Assessment of diagnoses, functioning and health services"
89286560|NCT01561274|Active Comparator|2 ml bupivacaine|2 ml of 0.75% hyperbaric bupivacaine, for a total of 15 mg of bupivacaine.
89286561|NCT01561274|Active Comparator|1.5 ml bupivicaine.|1.5 ml of 0.75% hyperbaric bupivacaine, for a total of 12.5 mg of bupivacaine.
89286562|NCT02882854|Experimental|Guanfacine|Guanfacine 1 mg capsule by mouth, one time prior to surgery.
89286563|NCT02882854|Placebo Comparator|Placebo|Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
89286564|NCT04469348|Experimental|Healthy volunteers|"Healthy volunteers will be included. They will have nasal swab at the inclusion visit to detect contamination of S. Aureus.~If contamination of S. Aureus: they will have 12 follow-up visits (1 per month)~If no contamination of S. Aureus: their participation stops"
89286565|NCT03707522|Experimental|Growth mindset + MRF Information|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
89286566|NCT03707522|Experimental|Control + MRF information|Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes
89286567|NCT03707522|Experimental|Control + Growth mindset|Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)
89286568|NCT03707522|Placebo Comparator|Control + Control|2 doses online daily activity scheduling interactive article (control)
89286569|NCT03770936|No Intervention|Control group|No intervention
89286570|NCT03770936|Active Comparator|Candesartan|Candesartan 8 mg/day
89286571|NCT03770936|Active Comparator|Ramipril|Ramipril 1.25 mg/day
89286572|NCT03150082|Experimental|Treatment sequence: A/B|Eligible subjects will be randomized to receive a single dose of Treatment A (GR37547 500 mg tablet) followed by Treatment B (ciprofloxacin 500 mg reference tablet) administered orally on Day 1 in each treatment period. The washout period will be of at least 7 days and not more than 14 days.
89286573|NCT03150082|Experimental|Treatment sequence: B/A|Eligible subjects will be randomized to receive a single dose of Treatment B (ciprofloxacin 500 mg reference tablet) followed by Treatment A (GR37547 500 mg tablet) administered orally. The washout period will be of at least 7 days and not more than 14 days.
89286574|NCT01321346|Experimental|Leukemia Patients|Patients with ALL and AML will be treated in one arm of the study.
89286575|NCT01321346|Experimental|Lymphoma Patients|Patients with NHL or HD will be treated in one arm of the study.
89286576|NCT02600182|Experimental|Bilevel Positive Airway Pressure (BiPAP)|The routine physical therapy will be performed in two groups (control and BiPAP). The BiPAP group will receive two daily sessions of 20 minutes, with positive expiratory pressure of 10cmH2O and inspiratory of 15cmH2O.
89286577|NCT02600182|No Intervention|Control|Routine physical therapy will be performed.
89286578|NCT02118610|Experimental|l-tetrahydropalmatine|l-tetrahydropalmatine (30 mg BID)
89286579|NCT02118610|Placebo Comparator|Sugar Pill|
89286580|NCT01561742|Experimental|Minocycline|
89286581|NCT01561742|Placebo Comparator|Placebo|
89286582|NCT03770702|No Intervention|Control group|No intervention
89286583|NCT03770702|Active Comparator|Angiotensin receptor blockers|ARB ( Angiotensin receptor blockers) + Traditional therpy.
89286584|NCT03770702|Active Comparator|Statins|Statin + Traditional therapy.
89286585|NCT03768596|Experimental|Nudge|receiving nudge and form
89286586|NCT03768596|Active Comparator|No nudge|receiving the same form without nudge (only questions about their opinion/attitudes about vaccination)
89286587|NCT03768596|No Intervention|No intervention|receiving no nudge nor form
89286588|NCT04332224|Experimental|Non-shivering cooling group|Cooling devices
89286589|NCT01345864|Other|Cohort A|Parallel design with 5 unique treatment groups Donepezil tablets and matching placebo tablets may be overencapsulated as needed.
89286590|NCT04320602|Experimental|Ravulizumab|Participants will receive eculizumab during the 3-month Screening Period. Participants will then switch over to and receive weight-based doses of ravulizumab for the duration of the study Treatment Period (351 days).
89286591|NCT03948022|Active Comparator|intramuscular progesterone|progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.
89286592|NCT03948022|Active Comparator|vaginal progesterone|crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.
89286593|NCT03948022|Experimental|oral dydrogesterone|oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)
89286594|NCT03777644|Experimental|TPVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
89286595|NCT03777644|Placebo Comparator|placebo TPVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with morphine
89286596|NCT04345666|Experimental|Testosterone group|20 patients will receive a 200 mg testosterone cyprionate intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
89286597|NCT04345666|Placebo Comparator|Placebo group|20 patients will receive a sterile saline intramuscular injection weekly with the first dose started two weeks prior to surgery and the last dose injected at 6 weeks after surgery (9 doses).
89286598|NCT03770624|Experimental|200 mg QD|Tablet QL-007 will be administered orally daily (200 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
89286599|NCT03770624|Experimental|400 mg QD|Tablet QL-007 will be administered orally daily (400 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
89286600|NCT03770624|Experimental|600 mg QD|Tablet QL-007 will be administered orally daily (600 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
89286601|NCT03770624|Experimental|100 mg BID|Tablet QL-007 will be administered orally daily (100 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
89286602|NCT03770624|Experimental|200 mg BID|Tablet QL-007 will be administered orally daily (200 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
89286603|NCT03770624|Active Comparator|TDF 300 mg QD|TDF will be administered orally daily (300 mg QD) over the 28 days not request fast .
89286604|NCT01336192|No Intervention|Best supportive care|Best supportive care
89286605|NCT01336192|Experimental|Maintenance gemcitabine|Maintenance therapy of gemcitabine alone
89286606|NCT01567592|Experimental|Active Shockwave Therapy|Treatment group. Patients in this group receive actual shockwave therapy.
89286607|NCT01909570|Experimental|Elective single embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer would be of a single embryo followed by the cryotransfer or a single embryo in case of no fresh conception
89286608|NCT01909570|Active Comparator|Double embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer woub be of two fresh embryos
89286609|NCT04607200|Experimental|Monotherapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks for up to 24 months
89286610|NCT04607200|Experimental|Combination Therapy|AGEN2034 - dose of 3 mg/kg IV every 2 weeks + AGEN1884 - dose of 1 mg/kg IV every 6 weeks (following AGEN2034 infusion), for up to 24 months
89286611|NCT03770156||Subjects who contacted CUMP by phone|Subjects who contacted CUMP (Medical Psychological Emergency Cell) by phone from Paris November 13th, 2015, London 11th,2017 ; Barcelone 17-18th, 2017 ; Strasbourg 11th, 2018.
89286612|NCT03770234|Experimental|Treatment A: Transtec patch application for 96 hours|Transtec 35 µg/hour transdermal patch wearing period of 96 hours, with application of patch on Study Day 1 and removal on Study Day 5.
89286613|NCT03770234|Experimental|Treatment B: Transtec patch application for 72 hours|Transtec 35 µg/hour transdermal patch wearing period of 72 hours, with application of patch on Study Day 1 and removal on Study Day 4.
89286614|NCT01336270||MELANOMA 10mm|patients with a melanoma larger than 10mm or with cutaneous metastasis
89286615|NCT01336270||STAGE III MELANOMA|stage III melanoma patients who shall undergo a regional lymph node dissection
89286616|NCT01336270||SENTINEL NODE PROCEDURE|retrospective study of patients who underwent a sentinel node procedure
89286617|NCT01336270||STAGE IV MELANOMA|stage IV patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment(processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases
89286618|NCT01336348|Experimental|prasugrel|Prasugrel 60 mg loading dose
89286619|NCT01336348|Active Comparator|Tirofiban|Tirofiban will be at a bolus only of 25uM or followed by 2 hour infusion
89286620|NCT01345942|Experimental|A food|
88805718|NCT01447225|Experimental|MM-121 plus Carboplatin|carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
89286621|NCT01345942|Experimental|B without food|
89286622|NCT01346020||CLL|
89286623|NCT01346098|Experimental|GROUP B|At the time of surgery the surgeon will directly assess pancreatic consistency and the pancreatic duct size. In the presence of a soft pancreas and a small duct (diameter <3 mm), the patient will be randomly assigned to receive either a pancreaticoduodenectomy with pancreatic anastomosis (group A) or a total pancreatectomy with IAT (group B).
89286624|NCT01346098|Active Comparator|GROUP A|
89286625|NCT01346254|Experimental|Vildagliptin|16 patients randomized into this arm will receive vildagliptin (Galvus) 50mg orally once daily
89286626|NCT01346254|Experimental|Pioglitazone|16 patients randomized into this arm will receive pioglitazone (Actos) 30mg orally once daily
89286627|NCT01346254|Placebo Comparator|Placebo|16 patients randomized into this arm will receive placebo medication orally once daily
89286628|NCT03142750|Experimental|Enrolled subjects|There is only one arm to this study. The intervention includes providing one week supply of each of two gastrostomy tube dressing prototypes to try at home.
89286629|NCT04592536|Experimental|CVL-865|High dose CVL-865 (25mg) Low dose CVL-865 (7.5mg)
89286630|NCT04592536|Active Comparator|Alprazolam|Active Comparator Alprazolam with extended release oral tablets; 1 tablet BID
89286631|NCT04592536|Placebo Comparator|Placebo|Placebo Comparator matching oral tablets for CVL-865, capsule for Alprazolam
89286632|NCT01346332||Anesthetization|
89286633|NCT01336582|Experimental|docetaxel|
89286634|NCT01336582|Active Comparator|Taxotere|Docetaxel-PM 75 mg/m2 (70 mg/m2 for age of ≥ 65) Taxotere 75mg/m2 (70 mg/m2 for age of ≥ 65)
89286635|NCT03149848|Experimental|Treatment A|Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
89286636|NCT03149848|Experimental|Treatment B|Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
89286637|NCT01346644|Active Comparator|No probiotics|Infant formula with no probiotics
89286638|NCT01346644|Experimental|Probiotic|Infant formula supplemented with probiotic
89286639|NCT01346800|Experimental|Prasugrel 10mg po|
89286640|NCT01346800|Experimental|Prasugrel 10mg po + ritonavir 100mg po|
89286641|NCT03902314|Active Comparator|Lidocaine|Lidocaine infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
89286642|NCT03902314|Placebo Comparator|Saline|Saline infusion at 2 mg/kg/hr will be started in the operating room and continue in the recovery period for 60 minutes.
89286643|NCT01336660|Experimental|Equine F(ab')2 antivenom|Intensive care support and Equine F(ab')2 antivenom
89286644|NCT01336660|Placebo Comparator|Placebo|Intensive care support plus placebo
89286645|NCT03706040|Placebo Comparator|Placebo|Participants randomized to receive placebo for 16 weeks in Period A followed by either risankizumab 150 mg or risankizumab 300 mg for 36 weeks in Period B.
89286646|NCT03706040|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg for 16 weeks in Period A followed by risankizumab 150 mg for 36 weeks in Period B.
89286647|NCT03706040|Experimental|Risankizumab 300 mg|Participants randomized to receive risankizumab 300 mg for 16 weeks in Period A followed by risankizumab 300 mg for 36 weeks in Period B.
89286648|NCT01321970|Other|Severe coronary artery disease|Patients in this group have coronary artery disease with a stenosis of >70%.
89286649|NCT01321970|Other|Coronary artery disease|Patients in this group have coronary artery disease with stenosis < 70%.
89286650|NCT03770000|Experimental|Tenalisib+Romidepsin|Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15
89286651|NCT03770312|Active Comparator|Low intensity statin group|Taking low intensity statin
89286652|NCT03770312|Active Comparator|Moderate intensity statin group|Taking moderate intensity statin
89286653|NCT03770078|Experimental|Study period|First the subjects will use the comparator (SenSura Mio) and then the test products (Test Product A)
89286654|NCT01561820|Active Comparator|Buddy|Participant will be assigned a buddy that will meet with them at the gym for each of their exercise sessions. This person will serve as a source of support and motivation for them and will also help them remember and stick to the goals set for you. This person will also help them maintain their exercise logs and ensure they are correct. The buddy will not be exercising with them, but will just be there with them while you exercise.
89286655|NCT01561820|Placebo Comparator|Non Buddy|Participants will not be assigned a buddy (and are not allowed to bring someone with them as a buddy). They will be asked to exercise on their own and remember the goals set for them. They will also be responsible for filling out their own exercise logs and ensuring they are correct.
89286656|NCT03158272|Experimental|Monotherapy|Cabiralizumab administered as a single agent intravenous formulation
89286657|NCT03158272|Experimental|Combination Therapy|Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation
89286658|NCT03763292|Experimental|Information brochure|Intervention: The parents are given a specific information brochure that describes the procedures that the child is going through during anesthesia when it has been decided that the child is going to have the surgery.
89286659|NCT03763292|No Intervention|Information as usual|Information as usual, i.e. oral information about the procedures to parents when they arrive at the hospital with the child that is going to have the surgery.
89286660|NCT03705494|Active Comparator|Home-based peer counselling intervention|Women planning to breastfeed who meet the study's inclusion criteria
89286661|NCT03705494|No Intervention|Standard usual care|Women planning to breastfeed who meet the study's inclusion criteria
89286662|NCT01336816|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
89286663|NCT01336816|Placebo Comparator|Placebo Wintergreen|Subjects allow study placebo lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
89286664|NCT03768362|Experimental|Undergoing plication strabismus surgery|
89286665|NCT03768362|Active Comparator|Undergoing resection strabismus surgery|
89286666|NCT03763214|Experimental|Stenting with PTFE-coated stent (HILZO)|The bile duct is stented with a PTFE-coated stent by duodenoscopy to allow bile duct flow
89286667|NCT03763214|Active Comparator|Stenting standard silicone coated stent|The bile duct is stented with a standard silicone-coated stent by duodenoscopy to allow bile duct flow
89286668|NCT01431508|Experimental|Losartan 50 mg / HCTZ 12.5 mg|Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.
89286669|NCT01321424||Aqueous Dificiency Dry Eye|20 Participants
89286670|NCT01321424||Meibomian Gland Disease Dry Eye|20 Participants
89286671|NCT01321424||Normal Eye|20 Participants
89286672|NCT03769922|Experimental|Extensive mesenteric resection|Mesenteric is resected avoiding the root region, i.e. 1 cm from the root of ileocolic artery and vein.
89286673|NCT03769922|Active Comparator|Limited mesenteric excision|"Mesentery is retained, i.e. Close shave or 3 cm from the border of bowel (using whatever approach - clips, or haemostatic vessel sealing device)."
89286674|NCT01347190|Experimental|Liquid API|
89286675|NCT01347190|Placebo Comparator|Placebo|
89286676|NCT03847402|Experimental|GDD intervention|The early integrated intervention for GDD
89286677|NCT03847402|Active Comparator|GDD non-intervention|Community intervention for GDD
89286678|NCT03847402|Experimental|ASD intervention|The early integrated intervention for ASD
89286679|NCT03847402|Active Comparator|ASD non-intervention|Community intervention for ASD
89286680|NCT03847402|Experimental|ADHD intervention|The early integrated intervention for ADHD
89286681|NCT03847402|Active Comparator|ADHD non-intervention|Community intervention for ADHD
89286682|NCT03825172||Group I|Caudal Epidural Ultrasonography will be performed in patients aged between 1-24 months
89286683|NCT03825172||Group II|Caudal Epidural Ultrasonography will be performed in patients aged between 25-48 months
89286684|NCT03825172||Group III|Caudal Epidural Ultrasonography will be performed in patients aged between 49-84 months
89286685|NCT03788512||AICVD patients with CoCCA|acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.
89286686|NCT01347268|Experimental|withdrawing GnRH agonists|
89286687|NCT01347268|Experimental|GnRH antagonist administration|
89286688|NCT02402504|Placebo Comparator|Extruded snack control|100% corn flour
89286689|NCT02402504|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
89286690|NCT02402504|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
89286691|NCT02402504|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
88805719|NCT01447225|Experimental|MM-121 plus Pemetrexed|pemetrexed at 500 mg/m2 with escalating doses of MM-121 on Day 1 of every 3 week cycle
88805720|NCT01447225|Experimental|MM-121 plus Cabazitaxel|escalating doses of MM-121 and cabazitaxel on Day 1 of every 3 week cycle
88805721|NCT01447849|Active Comparator|Lubiprostone 24 mcg Twice a day|Both controls and patients with chronic constipation will receive 1 week of therapy with lubiprostone and one week of placebo.
88805722|NCT01447849|Placebo Comparator|Placebo|Both controls and patients with chronic constipation will receive placebo pills twice daily for one week in cross over design
88805723|NCT00277394|Experimental|innohep®|innohep® 175 anti-Xa IU/kg once daily
88805724|NCT00277394|Active Comparator|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
88805725|NCT01450189|Active Comparator|Standard Counseling Arm|The SC arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
88805726|NCT01450189|Active Comparator|Behavioral Intervention Arm only|Behavior- BI: Information-Motivation-Behavioral Skills Model the Information-Motivation-Behavioral Skills (IMB) Model. The 5 sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
89286692|NCT02402504|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
89286693|NCT02402504|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
89286694|NCT05187052||Group 1 (REI group)|Group 1 included patients that were intubated using rigid endoscope-assisted orotracheal intubation (REI) (0°, 45°, and 70°), 18-cm rigid telescope (Storz, Germany), full-HD camera (Olympus, USA), and Macintosh blade.
89286695|NCT05187052||Group 2 (V-MAC Group)|Group 2 included patients that underwent endotracheal intubation using a V-MAC (Besdata, China) videolaryngoscope and Magill forceps.
89286696|NCT05187052||Group 3 (FFEI group)|Group 3 included patients that underwent flexible fiberoptic endotracheal intubation (FFEI Group, Storz, Germany).
89286697|NCT02385890|Experimental|Bagel control|100% wheat flour
89286698|NCT02385890|Experimental|Bagel with pea flour|Pea flour
89286699|NCT02385890|Experimental|Bagel with pea fibre|Pea fibre
89286700|NCT02385890|Experimental|Bagel with pea protein|Pea protein
89286701|NCT02385890|Experimental|Bagel with pea flour + pea protein|Pea flour + pea protein
89286702|NCT02385890|Experimental|Bagel with pea fibre + pea protein|Pea fibre + pea protein
89286703|NCT04538560|Experimental|Polar body biopsy group|The study group will undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
89286704|NCT04538560|No Intervention|Control group|The control group will undergo routine culture and the transfer priority is determined according to the morphological score only.
89286705|NCT01337206|Experimental|Stenting Arm|Stenting Arm
89286706|NCT01337206|Active Comparator|Dilation Arm|Dilation Arm
89286707|NCT03758846|Experimental|Cognitive-motor Exergaming|A total of 6 Wii-fit games: Bubble balance, Table Tilt, Tightrope walking, Soccer head, Basic Run and Basic Step. A total of 6 cognitive tasks namely Digit recall, repeated letter, word list generation (category and alphabets), mental arithmetic, analogies. Each session was divided into 3 sub-sessions. Every Wii-fit game was played with any 3 cognitive tasks. The combination of games with cognitive tasks was randomized in such a manner that all the cognitive tasks were played with the Wii-fit games in that session. Breaks were provided after each sub-session or when the participant demanded one or when the research personnel noticed any discomfort of the participant.
89286708|NCT03758846|Active Comparator|Conventional balance Training for people with Chronic stroke|The sessions were divided into 10 minutes of warm-up that involved active movements of the body (arm movements, trunk twists, lunges). Next 15 minutes consisted of functional strengthening exercises like high stepping, lunges, squats, resistance training using therabands and weights. Following 35 minutes included balance training exercises like one leg standing, tandem standing, sit to stand exercises, reach outs and step-ups. Last 10-15 minutes were spent treadmill walking. Breaks were provided in between the exercise training as and when needed by the participant.
89286709|NCT03758846|Experimental|Dance Therapy for Stroke|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
89286710|NCT03758846|Experimental|Dance Therapy for Older Adults|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
89286711|NCT03758846|Active Comparator|Conventional therapy - Home education for Older adults|Participants received a one-hour education on conventional physical exercises and fall prevention.
89286712|NCT01347424|Experimental|Test group|
89286713|NCT01347424|Active Comparator|control group|
89286714|NCT02288702||Normal|This is the group with no neurological problems or syndrome
89286715|NCT02288702||Down syndrome|This is the group with Down syndrome
89286716|NCT01347502||HCPs with smartphone|healthcare providers in MICU who have smart cellular phones
89286717|NCT01347502||HCP with non-smart phones|healthcare providers in MICU who have non-smart cellular phones
89286718|NCT01322438|Experimental|Arm 1|
89286719|NCT01347658|Experimental|Etravirine + echinacea|etravirine + root of Echinacea purpurea
89286720|NCT03762980|Experimental|Right hemiplegic patients|
89286721|NCT03762980|Experimental|Left hemiplegic patients|
89286722|NCT03768050|Active Comparator|Advanced care for frail elderly|Integrated care program for frail elderly covering Home Hospitalization/Early Discharge; geriatric residences and; home-based case management done by dedicated teams specialised in geriatric medicine
89286723|NCT03768050|No Intervention|Standard care|Usual care at the community and geriatric residences by primary care physicians
89286724|NCT00654628|Experimental|1|Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks
89286725|NCT03767972|Experimental|Rejuvenation|Adults requiring rejuvenation of either the face, neck/décolletage, hands, upper and lower extremities, trunk and/or vagina will receive energy-based treatment (Fraxel Restore, Helios III, PicoWay, Halo, ThermiVa or DiVa) based on the investigators' assessment and discretion. The treating physician will decide which energy-based device is best-suited to addressing the patients' aging concerns; although patient preference will be taken into account, ultimately the treating physician will be responsible for the correct assessment of patients' rejuvenation needs and use of appropriate energy-based devices for the final treatment.
89286726|NCT00536380|Experimental|5-mg Desloratadine|5-mg Desloratadine once daily
89286727|NCT00536380|Experimental|10-mg Desloratadine|10-mg Desloratadine once daily
89286728|NCT00536380|Experimental|20-mg Desloratadine|20-mg Desloratadine once daily
89286729|NCT05186896||Residents of areas at high risk of environmental crisis|1000 adult males and females living in areas declared at high risk of environmental crisis in the areas of Caltanissetta (Italy) and Tunis (Tunisia).
89286730|NCT01337362|Active Comparator|Patients with hypoglycemia awareness|Patients who have symptoms when the blood sugar level is low
89286731|NCT01337362|Experimental|patients with hypoglycaemic unawareness.|Patients who do not feel any symptoms when the blood sugar levels are low
89286732|NCT03758768|Experimental|Blue monochromatic light|Three consecutive mornings of one hour exposure to monochromatic light (20 lx, irradiance = 49.65 µW/cm2) with peak wavelength of 455 nm (blue light), with equal photon flux as the control condition.
89286733|NCT03758768|Active Comparator|Full spectrum light control condition|"Three consecutive mornings of one hour exposure to full spectrum light (2500 Kelvin, irradiance = 37.72 µW/cm2) with equal photon flux as the blue light.~We will adjust the light intensity to make sure that the photon energy is the same across the two conditions."
89286734|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated patients|Patients with different inflammatory rheumatic diseases are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
89286735|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated controls|Healthy controls are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
89286736|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
89286737|NCT03762824|Active Comparator|PCV13 to previous PPV23-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PPV23 within another study (see VACCIMIL), are immunized with one dose PCV13 0.5 ml i.m.
89286738|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated controls|Healthy controls previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
89286739|NCT03762746|Active Comparator|Active|Intervention with transcranial magnetic stimulation (TMS) low frequency 1 Hz , 1000-pulse train, 20 minutes, 90% motor threshold in left temporo-parietal cortex for 10 consecutive days for 20 schizophrenia patients with auditory hallucination
89286740|NCT03762746|Sham Comparator|Control|Control group is received treatment as usual
89286741|NCT03767816|Experimental|Group R : Rectus sheath block group|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision
89286742|NCT03767816|Active Comparator|Group RE: Rectus sheath block and erector spinae plane block|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision and ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml
89286743|NCT03762434|Active Comparator|mobile app|Mobile app: The participants will receive a Life style Modification Program with the support of mobile application (MetS app). The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area of the Mets app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the app installment and briefing.
89286744|NCT03762434|Active Comparator|booklet|The participants will receive the Life Style Modification programme with the support of a Hong Kong version Metabolic Syndrome (MetS) booklet to take home and use for 3 months. The booklet had been modified from a booklet of a Life Style Intervention Programme (LIP) in China and the principal investigator of this proposal was the core team members of the previous project . The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management . The major component of the booklet for the change is the language translated from simplified Chinese to traditional Chinese and slight adjustment about the advice on vegetable choice due to difference in type of available vegetables in Hong Kong.
89286745|NCT05260346|Placebo Comparator|Placebo|Cranberry flavored drink, once daily, in a 8fl oz bottle. Identical in appearance and taste compared with the treatment.
89286746|NCT05260346|Active Comparator|Cranberry juice|100% cranberry juice, once daily, in a 8fl oz bottle.
89286747|NCT03758690|Experimental|Treatment Group|Treatment with the investigational device - High-Intensity Focused Electromagnetic (HIFEM) Field Device
89286748|NCT00496834|Experimental|1|Losartan or Losartan/HCTZ
89286749|NCT00496834|Active Comparator|2|Carvedilol or Carvedilol/HCTZ
89286750|NCT05244122|Experimental|Feedback X Prevalence Using Dermatology Stimuli|"In this experiment, observers (Os) completed blocks of 80 trials. On each trial, they saw an image of a spot on the skin. They classified this as a melanoma (cancer) or a nevis (benign). Blocks could be of low prevalence (20% cancer cases, 16 images) or high prevalence (50%, 40 images). Os either did received trial by trial Feedback about their performance accuracy, or they did not. Thus, there were four types of block.~Low prevalence, No Feedback Low prevalence, Feedback High prevalence, No Feedback High prevalence, Feedback Each of these four types of block was made available to Os on each of 6 days. Os could elect to view each of the four blocks each day. Our particular interest was in the effect of performing one block on performance on an immediately subsequent block."
89286751|NCT03758612|Active Comparator|Cohort 1 (sentinel group) - Active|Single dose of TBI-223 50 mg (n=2) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
89286752|NCT03758612|Placebo Comparator|Cohort 1 (sentinel group) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
89286753|NCT03758612|Active Comparator|Cohort 1 (remainder of cohort) - Active|Single dose of TBI-223 50 mg (n=4).
89286754|NCT03758612|Placebo Comparator|Cohort 1 (remainder of cohort) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1).
89286755|NCT03758612|Active Comparator|Cohort 2 - Cohort 7 - Active|Single dose of TBI-223 100, 300, 600, 1200, 2000, 2600 mg; n=3 per dosing group.
89286756|NCT03758612|Placebo Comparator|Cohort 2 - Cohort 7 - Placebo|Single dose of matching Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg, n=1 per dosing group.
89286757|NCT03758612|Active Comparator|Cohort 3b - Active - Oral Capsule|Single dose of 300 mg in oral enteric capsule, n=4 per dosing group.
89286758|NCT03758612|Placebo Comparator|Cohort 3b - Placebo - Oral Capsule|Single dose of placebo for 300 mg in oral enteric capsule, n=1 per dosing group.
89286759|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 1|Single dose of TBI-223 sustained-release (SR) tablet prototype 1, 3 x 600 mg, n=6 per cohort.
89286760|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 2|Single dose of TBI-223 SR tablet prototype 2, 3 x 600 mg, n=6 per cohort.
89286761|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 3|Single dose of TBI-223 SR tablet prototype 3, 2 x 900 mg, n=6 per cohort.
89286762|NCT03758612|Active Comparator|Cohort 8 - IR Tablet fasted|Single dose of TBI-223 immediate-release (IR) tablet prototype 4, 2 x 1000 mg, n=6 per cohort; fasted prior to dose.
89286763|NCT03758612|Active Comparator|Cohort 9 - IR Tablet with meal|Single dose of TBI-223 immediate-release (IR) tablet, 2 x 1000 mg, n=6 per cohort; fed prior to dose.
89286764|NCT00189280|Experimental|imiqimod 5% cream|
89286765|NCT01352494|Experimental|docetaxel/gemcitabine|All the patients are locally advanced breast cancer. Patients with a measurable lesion at chest CT. (at least 1 measurable lesion)
89286766|NCT05217602|Experimental|AC+ARwdC|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; Weekly text message reminders during the intervention period to reinforce the use of their anchoring plan; In-kind rewards only if they meditate using their anchoring plan on at least 8 days out of every 2 weeks (i.e., 14 days) during the 8 week intervention period (i.e., eligible for 4 prizes); $20 incentive for completing the baseline, week 8, and week 16 surveys
89286767|NCT05217602|Experimental|AC+RwdC|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; Weekly text message reminders during the intervention period to reinforce the use of their anchoring plan; In-kind rewards if they meditate on at least 8 days out of every 2 weeks (i.e., 14 days) during the 8 week intervention period (i.e., eligible for 4 prizes); $20 incentive for completing the baseline, week 8, and week 16 surveys
89286768|NCT05217602|Active Comparator|Usual Calm Control (UC)|Prescribed Calm usage = 10 minutes a day; Personalized anchoring plan for initiating any available meditation; $20 incentive for completing the baseline, week 8, and week 16 surveys
89286769|NCT01347736|Experimental|Treatment (pain therapy)|Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
89286770|NCT03758456|Placebo Comparator|HAL-MRE1 0 AUeq|15 subjects will receive placebo. Subjects will receive 7-9 incremental weekly injections. All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
89286771|NCT03758456|Experimental|HAL-MRE1 5,000 AUeq|10 subjects will receive HAL-MRE1 5,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 5,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
89286772|NCT03758456|Experimental|HAL-MRE1 10,000 AUeq|10 patients will receive HAL-MRE1 10,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 10,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
89286773|NCT03758456|Experimental|HAL-MRE1 20,000 AUeq|10 patients will receive HAL-MRE1 20,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 20,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 year). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
89286774|NCT01347892||DeNovo NT Subject|Subjects who have received or who are scheduled to receive a DeNovo NT Graft for repair of a cartilage lesion in the ankle.
89286775|NCT01348048|Experimental|Specialised palliative care (SPC) group|Patients continue with their standard treatment (typically they receive treatment in one or more hospitals departments and from their GP). In addition, they are offered a consultation in the SPC out-patient clinic (or at home if the patient cannot attend the hospital) as soon as possible and no more than one week after randomization. If possible, each patient will have at least two contacts to the SPC in the trial period.
89286776|NCT01348048|No Intervention|Standard care group|Patients continue with their standard treatment. They are instructed to contact either their GP or their hospital department if they feel that additional treatment or care is needed.
89286777|NCT01348126|Active Comparator|Single agent docetaxel|
89286778|NCT01348126|Experimental|Combination of ganetespib and docetaxel|
89286779|NCT01348204|Experimental|quercetin|health food supplement
89286780|NCT00166504|Experimental|Vytorin|Ezetimibe 10 mg/Simvastatin 20 mg
89286781|NCT00166504|Active Comparator|Atorvastatin|Atorvastatin 10 mg
89286782|NCT01342978||oropharyngeal cancer case|208 oropharyngeal cancer cases were enrolled
89286783|NCT01342978||partner or spouse of case|110 partners of patients with oropharyngeal cancer were enrolled
89286784|NCT01342978||control|A convenience group of 106 non-cancer controls were enrolled at some study sites at cancer screening events
89286785|NCT01348282|Experimental|Lithium|Lithium group: Patients who will initiate therapy with lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
89286786|NCT01348282|Active Comparator|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
89286787|NCT01348282|No Intervention|Control group|Patients who will not initiate treatment
89286788|NCT03137992|Experimental|Test Product (tiotropium bromide inhalation powder)|Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness).
89286789|NCT03137992|Active Comparator|Reference Product (Spiriva®)|Single dose of reference product (Spiriva®) 18 mcg
89286790|NCT03137992|Placebo Comparator|Placebo|Single dose of placebo inhalation powder
89286791|NCT04501588|Experimental|Parent Learning Style 1|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
89286792|NCT04501588|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
89286793|NCT04501588|Active Comparator|Learning Style 1 (Parent)|Mothers with Learning Style 1 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
89286794|NCT04501588|Active Comparator|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to receive the responsive intervention with video feedback or without video feedback.
89286795|NCT04470778|Experimental|BMS-986256|
89286796|NCT04470778|Experimental|BMS-986256 + Famotidine|
89286797|NCT01352572|Experimental|antidepressant response|antidepressant response are refered the patients having a 50 ≤ Decrease rate(%) of HAM-D score
89286798|NCT01352572|Active Comparator|antidepressant non-response|antidepressant non-response are refered the patients having a 50 > Decrease rate(%) of HAM-D score
89286799|NCT01352650|Active Comparator|Cohort 1A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5
89286800|NCT01352650|Active Comparator|Cohort 1B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
89286801|NCT01352650|Active Comparator|Cohort 2A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5
89286802|NCT01352650|Active Comparator|Cohort 2B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 2 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 4 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
89286803|NCT01352650|Active Comparator|Cohort 3A|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5
89286804|NCT01352650|Active Comparator|Cohort 3B|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10
89286805|NCT03762278|Experimental|Immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the uni-laterally immobilised leg.
89286806|NCT03762278|Active Comparator|Non-immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the non-immobilised leg.
89286807|NCT03762278|Placebo Comparator|Immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the uni-laterally immobilised leg.
89286808|NCT03762278|Placebo Comparator|Non-immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the non-immobilised leg.
89286809|NCT01352728|Experimental|TACE+Axitinib|
89286810|NCT01348360||NOBORI stent|
89286811|NCT03704636|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.
89286812|NCT01348438|Other|Single arm study|
89286813|NCT01348516|Experimental|KM-023|
89286814|NCT01348516|Placebo Comparator|Placebo for KM-023|
89286815|NCT03761966||Pregnant women|"Pregnant women older than 18 years old atended at the Mónica Pretelini Sáenz Maternal-Perinatal Hospital (HMPMPS), Health Institute of the State of Mexico (ISEM)."
89286816|NCT01352806|Experimental|fluoroscopy, palpation, ultrasound|in the same subject we will compare the accuracy of identifying the intralaminar space by three technique, fluoroscopy, ultrasound, palpation.
89286817|NCT03761888||Labetalol|Patients who will receive labetalol in IV route in first intention
89286818|NCT03761888||Nicardipine|Patients who will receive nicardipine in IV route in first intention
89286819|NCT04470388|Experimental|EDP-514 HBV MAD Cohorts|EDP-514 capsule Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days.
89286820|NCT04470388|Placebo Comparator|EDP-514 HBV MAD Placebo Cohort|Matching placebo, orally, once daily for 28 days.
89286821|NCT01343134||Retinal detachment cohort|
89286822|NCT03982160|Experimental|L-arginine|Intravenous infusion of L-arginine (250-350 mg/kg) will be performed for 30 minutes.
89286823|NCT03982160|Placebo Comparator|Saline|Saline will be infused for 30 minutes
89286824|NCT03689920|Active Comparator|WaveWriter Settings|WaveWriter Programming
89286825|NCT03689920|Active Comparator|Conventional Settings|Conventional Programming
89286826|NCT01348594||Vitamin D deficient|
89286827|NCT01348594||Vitamin D sufficient|
89286828|NCT01321580|Experimental|Group A|
89286829|NCT01343212||newly diagnosed HCC|"Subjects with newly diagnosed untreated hepatocellular carcinoma (HCC) will be enrolled.~Subjects with the following conditions will be excluded:~liver cancer other than HCC, treated HCC, post major abdominal surgery, contraindications to liver tumor biopsy, contraindications to local percutaneous treatment of liver tumors, low quality ARFI measurement"
89286830|NCT03767660|Experimental|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
89286831|NCT03689608|Experimental|Intermittent Fasting (IF)|3 days fasting per week
89286832|NCT03689608|Experimental|Daily Restriction (DR)|daily energy restriction
89286833|NCT03689608|Other|standard care (SC)|usual care
89286834|NCT03761654||"Patients with a non-severe subarachnoid hemorrhage"|
89286835|NCT01348672||1. ARMD Study arm|"The ARMD study arm (n=150) consists of 3 groups. The groups are organised according to established risk criteria for clinical progression (AREDS, 2003).~Group 1A (n=50); Early stage ARMD with low risk of progression; several small drusen, or a few medium-sized drusen, in one or both eyes. One eye will be randomly selected for the study.~Group 2A (n=50); Intermediate ARMD with high risk of progression to advanced ARMD; many medium-sized drusen, or one or more large drusen, in one or both eyes. More severely affected eyewill be selected for the study.~Group 3A (n=50); In one eye only, either a break-down of light-sensitive cells and supporting tissue in the central retinal area (i.e. geographic atrophy), or abnormal and fragile blood vessels under the retina (i.e. choroidal neovascular membrane formation). The fellow eye is at high risk of progression to advanced ARMD. The fellow eye will be selected for the study."
89286836|NCT01348672||2. POAG study arm|"Patient groups are organised according to established risk criteria for clinical progression (EMGT, 2003).~Group 1P (n=36); Stable, early to moderate, treated patients with POAG. Early to moderate POAG is defined as having an untreated IOP prior to treatment of >21mmHg and a repeatable visual field defect with a Mean Deviation of <12dB and/or documented but stable ONH appearance, consistent with a diagnosis of glaucoma.~Group 2P (n=36); Early to moderate, treated patients with normal tension glaucoma (NTG). Normal Tension Glaucoma is defined using the same criteria as POAG but with an untreated IOP of <21mmHg throughout the day. This group has NTG and is thought to be at increased risk of vascular dysfunction due to loss of ONH perfusion.~Group 3P (n=36); Early to moderate, treated patients with POAG or NTG with recurrent disc hemorrhage (indicative of progression)."
89286837|NCT01348672||3. DR study arm|"DR patient groups are organised according to established risk factors for the clinical progression of DR (increasing from Groups 1 A to 3 A, ETDRS, 1991). We will recruit 41 patients per group (Klein et al, 1984).~Group 1D (n=41); Type 2 diabetic patients with no, or minimal, clinically visible DR. These patients are at low risk of developing sight-threatening DR.~Group 2D (n=41); Type 2 diabetic patients with microaneurysms and / or hard exudates within 2 disc diameters of the fovea and no clinical evidence of retinal thickening. These patients are at increased risk of developing DME.~Group 3D (n=41); Type 2 diabetic patients with the typical features of moderate-to-severe DR i.e. venous beading, intra-retinal microvascular abnormalities (IRMA) and dark blot intra-retinal haemorrhages. These patients are at a much increased risk of developing proliferative DR and/or ischemic maculopathy."
89286838|NCT03767504|Experimental|Musclin|Thymol based dietary supplement
89286839|NCT01352884|Experimental|Stage 1|Stage 1 will identify the recommended Stage 2 dose using a dose-escalation process. Dose-escalation will continue until either a maximum tolerated dose is established, or a therapeutic dose is reached.
89286840|NCT01352884|Experimental|Stage 2|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood specimens will be evaluated for pharmacodynamic markers/activity at specified timepoints throughout the study.
89286841|NCT03767270|Experimental|MRT5201|Single Ascending Low, Mid, and High doses of MRT5201
89286842|NCT03767270|Placebo Comparator|Placebo|Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
89286843|NCT01343290|Experimental|001|Canagliflozin Type = 1 unit = mg number = 300 form = tablet route = oral use. Single tablet taken with or without a meal during 2 treatment periods
89286844|NCT03761342|No Intervention|Control|A control arm that mirrors a traditional web-grocery store with no but with no FOP labels.
89286845|NCT03761342|Experimental|Multiple Traffic Light Labels|Similar to Arm 1, with Multiple Traffic Light labels displayed on all products FOP. A 60-second introductory video briefly explaining the MTL scheme will be shown before each shop in this Arm.
89286846|NCT03761342|Experimental|Nutri-Score|Similar to Arm 2, with Nutri-Score labels instead of MTL labels displayed on all products FOP. A 60-second introductory video briefly explaining the NS scheme will be shown to shoppers in this condition.
89286847|NCT03761264|Experimental|Intra-canal Odontopaste®|Single visit placement of Odontopaste®
89286848|NCT03761264|Active Comparator|Intra-canal Pulpdent|Single visit placement of Pulpdent
89286849|NCT03761264|Active Comparator|Oral Amoxicillin|Amoxicillin 15mg/kg tds for 5 days
89286850|NCT05096312|Active Comparator|Zinc gluconate group|"interventions: Zinc gluconate (200g/capsule) one capsule once in the morning after breakfast for 60 days.~Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days."
89286851|NCT05096312|Placebo Comparator|Placebo group|interventions: Placebo capsule, one capsule once in the morning after breakfast for 60 days. Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days.
89286852|NCT03758378|Experimental|Dietary intervention|
89286853|NCT03758300|Experimental|Radiofrequency group|In this group patients will receive in a sterile fashion continuous radiofrequency for 4 minutes to the 3 genicular nerves in the operative knee as well as Pulsed Radiofrequency at 42 degrees celsius, for 4 minutes (60-70 volts) to the saphenous nerve and the nerve to the Vastus Medialis, at the level of the adductor canal. The procedure is done under local anesthesia on an ambulatory basis. After the radiofrequency, Ropivacaine 0.5% 5 ml is injected to each one of the nerves, along with 5 milligrams of Methylprednisolone to each nerve. Once the procedure is completed (takes about 20 minutes), patients will be observed in the preoperative program facility for 30 minutes and then discharged home.
89286854|NCT03758300|Sham Comparator|Control (Sham Radiofrequency) group|In this group patients will receive injections of the local anesthetic and steroids in the same anatomical locations, without activating the radiofrequency generator.
89286855|NCT05088668|Experimental|Agumented Reality combined with scapular exercises|Scapular exercises performed with glasses of augmented reality during sessions at clinic, and without glasses at home.
89286856|NCT05088668|Active Comparator|Scapular exercises|Scapular exercises performed all the time without glasses.
89286857|NCT03767192|Experimental|Active Stimulation|Device: The Ischemic Stroke System SPG stimulation and standard of care
89286858|NCT03767192|Sham Comparator|Sham Stimulation|Device: Sham control Sham stimulation and standard of care
89286859|NCT03767114|Experimental|cases of psoriasis|group of 25 cases of psoriasis subjected to skin biopsy for detection of lesional and non lesional expression of ERAP1 by RT-PCR
89286860|NCT03767114|Experimental|normal controls|group of 30 age and sex matched healthy controls o subjected to skin biopsy from normal skin for detection of expression of ERAP1 by RT-PCR
89286861|NCT03767036|Active Comparator|Tramadol|Each participant received an oral dose of tramadol hydrochloride 25 mg (A1, one capsule) under fasting conditions with 250 milliliters (mL) of water.
89286862|NCT03767036|Active Comparator|Ketorolac|Each participant received an oral dose of ketorolac 10 mg (A2, one tablet) under fasting conditions with 250 mL of water.
89286863|NCT03767036|Experimental|Tramadol and ketorolac|Each participant received an oral dose of tramadol hydrochloride 25 mg and ketorolac 10 mg simultaneously (A3 = one capsule of A1 + one tablet of A2, test medication) under fasting conditions with 250 mL of water.
89286864|NCT03758144|Active Comparator|study|
89286865|NCT03758144|No Intervention|CONTROL GROUP|
89286866|NCT03760874||Non Vitamin K Oral Anticoagulant|Dabigatran, Rivaroxaban, Apixaban, Edoxaban
89286867|NCT03760874||Vitamin K Oral Anticoagulant|Warfarin, Acenocoumarol.
89286868|NCT01322126|Experimental|ultrasound ,without ultrasound|ultrasound group will be passed the neuraxial anesthesia with ultrasound,the secoud group will be passed the neuraxial anesthesia without ultrasound .
89286869|NCT03766880|Experimental|Single arm study|Participants will receive MR imaging, transjugular HVPG measurement, and analysis per protocol.
89286870|NCT04908488|Other|P1fA, then AMfA|Verofilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
89286871|NCT04908488|Other|AMfA, then P1fA|Etafilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
89286872|NCT03766802|Active Comparator|Wearable watch training group.|"Aerobic exercises Strengthening exercises Stretching exercises Balance exercises Dose was increased as person is able to tolerate. Form:intervention is trackable and notifiable if patients don't exercise with smartwatch.~Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
89286873|NCT03766802|Active Comparator|Mobile application training group.|"Aerobic exercises Strengthening exercises Stretching exercises~Balance exercises Form:intervention is trackable and notifiable if patients don't exercise with smartphone Dose was increased as person is able to tolerate. Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
89286874|NCT03766802|Sham Comparator|Supervised exercise training group|Aerobic exercises Strengthening exercises Stretching exercises supervised by a physical therapist
89286875|NCT04876274|Experimental|Intervention group|Patients in the intervention group received Taipei Medical University (TMU) line-oriented video education and care in addition to usual care
89286876|NCT04876274|No Intervention|Control group|Patients in the control group received usual care
89286877|NCT03766724|Experimental|Group A|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
89286878|NCT03766724|Experimental|Group B|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
89286879|NCT03766724|Experimental|Group C|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
89286880|NCT03766724|Experimental|Group D|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
89286881|NCT04865354|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
89286882|NCT04865354|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 days in a daily disposable modality.
89286883|NCT04860518|Experimental|IV IFN beta-1a|Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
89286884|NCT04860518|Active Comparator|IV Dexamethasone|Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.
89286885|NCT03110380|Experimental|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet + dolutegravir (DTG) placebo tablet + emtricitabine/tenofovir alafenamide (F/TAF) placebo tablet administered without regard to food for at least 48 weeks.
89286886|NCT03110380|Active Comparator|DTG + F/TAF|DTG 50 mg tablet + F/TAF FDC tablet + B/F/TAF placebo tablet administered without regard to food for at least 48 weeks.
89286887|NCT03110380|Experimental|Open-label Phase B/F/TAF from B/F/TAF|Participants who received B/F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
89286888|NCT03110380|Experimental|Open-label Phase B/F/TAF from DTG + F/TAF|Participants who received DTG + F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
89286889|NCT03473366|Experimental|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
89286890|NCT03473366|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
89286891|NCT01322204|Experimental|1|Neonates 0-30 days, no more than 2,000 grams, receiving mechanical ventilation.
89286892|NCT01353040|Experimental|AVI-6003|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
89286893|NCT01353040|Placebo Comparator|Placebo|Normal saline
89286894|NCT03766568|Experimental|Diagnostic with JGG endoscope|
89286895|NCT01348750|Other|Group A|This group receives 6 Healing Touch & Guided Imagery treatments in addition to standard medical care.
89286896|NCT01348750|No Intervention|Group B|This group receives standard medical care but NO Healing Touch and Guided Imagery.
89286897|NCT04851314|Active Comparator|ICU certified ventilator|Participants assigned to receive ventilation with the ICU certified ventilator
89286898|NCT04851314|Active Comparator|Non-ICU certified ventilator|Participants assigned to receive ventilation with the Non-ICU certified ventilator
89286899|NCT01348906|Experimental|Intermittent normoxia|Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
89286900|NCT03757754|Experimental|HPPH 2.5 mg/m2|HPPH 2.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
89286901|NCT03757754|Experimental|HPPH 3 mg/m2|HPPH 3 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
89286902|NCT03757754|Experimental|HPPH 3.5 mg/m2|HPPH 3.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
89286903|NCT03757754|Experimental|HPPH 4 mg/m2|HPPH 4 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
89286904|NCT03757754|Experimental|HPPH 5 mg/m2|HPPH 5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
89286905|NCT03757754|Experimental|HPPH 6 mg/m2|HPPH 6 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
89286906|NCT03675724|Experimental|Treatment|Fisetin 20mg/kg/day, orally for 2 consecutive days
89286907|NCT03675724|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
89286908|NCT03757676|Experimental|No Play|This 'no play' group functioned as the control group.
89286909|NCT03757676|Experimental|At Will Play|This group functioned as 1 of the 2 play groups.
89286910|NCT03757676|Experimental|Goal Oriented Play|This group functioned as 1 of the 2 play groups.
89286911|NCT01343446||Patients with Diabetes|Patients with diabetes suffer from sleep impairment or not
89286912|NCT03766490|Experimental|Anlotinib Hydrochloride plus gefitinib or icotinib|
89286913|NCT03645070|No Intervention|No probe|Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
89286914|NCT03645070|Active Comparator|Single probe thermometer|Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
89286915|NCT03645070|Active Comparator|Multi-probe|Twenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
89286916|NCT01348984|Active Comparator|group 1|group 1 = transdermal fentanyl patch
89286917|NCT01348984|Placebo Comparator|group 2|placebo patch
89286918|NCT01567670|Active Comparator|Naloxone|nasal spray before binging, naloxone dose 2 mg, maximum daily dose 4 mg
89286919|NCT01567670|Placebo Comparator|nasal spray|nasal placebo (h2o) spray before binging, max sprays / day
89286920|NCT01349062|Other|"Kallunk oxide (Immunotherapy)"|"The participants will be received a daily regimen of Kallunk oxide(Immunotherapy) ."
89286921|NCT03100240|Experimental|Experimental group|Modified Supper Long Protocol
89286922|NCT03100240|No Intervention|control group|long protocol
89286923|NCT04848662|Experimental|A/B - Treatment with BDA MDI (PT027) 160/180 μg followed by treatment with Pulmicort Respules 1mg|Subjects randomized to receive a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 μg at Visit 2, and a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 3.
89286924|NCT04848662|Experimental|B/A - Treatment with Pulmicort Respules 1 mg followed by treatment with BDA MDI (PT027) 160/180 μg|Subjects randomized to receive a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 2, and a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 μg at Visit 3.
89286925|NCT03766412||School start time 8:30 AM or later|These are high schoolers with migraine who attend a school that begins at 8:30 AM or later (i.e. follows AAP recommendation re: high school start time).
89286926|NCT03766412||School start time earlier than 8:30|These are high schoolers with migraine who attend a school that begins earlier than 8:30 AM (i.e. does not follow AAP recommendation re: high school start time).
89286927|NCT03757598|No Intervention|Paper Partograph|The comparison group used the standard WHO Standard Paper Partograph approved in Kenya to monitor labor. Copies of the partograph were made available to the facilities.
89286928|NCT03757598|Experimental|ePartogram|ePartogram use by skilled birth attendant providers in health facilities. The intervention arm used the novel ePartogram or electronic partogram. The interface was of the same WHO approved partograph on an Android tablet. There were reminders to spur provider actions and alerts that were programmed in an algorithm.
89286929|NCT03757520|Active Comparator|Regular user group|Their number: 300; female and male students, will earn 39 points or less of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
89286930|NCT03757520|Active Comparator|Heavy user group|Their number: 300; female and male students, will earn 40 points or more of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
89286931|NCT03701516|Experimental|TEST/CONTROL|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Test/Control sequence.
89286932|NCT03701516|Experimental|CONTROL/TEST|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Control/Test sequence.
89286933|NCT04351256|Experimental|Arm A (HYPO group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles~Thoracic radiation therapy (TRT): hypofractionated thoracic radiotherapy consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks (+9 days)"
89286934|NCT04351256|Active Comparator|Arm B (CON group)|"Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles~Thoracic radiation therapy (TRT): conventional fractions of 30 x 2 Gy (60 Gy) within 6 weeks (+9 days)"
89286935|NCT03700892|Experimental|Cinnamaldehyde, then PG/VG|Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
89286936|NCT03700892|Experimental|PG/VG, then Cinnamaldehyde|Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.
89286937|NCT03700892|No Intervention|Healthy Controls|Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.
89286938|NCT03700736|Active Comparator|Facebook|"Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via a private (secret) Facebook group. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. A study counselor will facilitate discussions about the topics posted in the Facebook group. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to download the MyFitnessPal app to track daily diet."
89286939|NCT03700736|Active Comparator|Traditional|Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via in-person 90-minute group sessions (weekly in months 1-4, every other week in months 5-6). The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. Intervention components will be introduced in the format of handouts, group discussions, and lists of existing resources. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
89286940|NCT03760172||Prevalence of NAFLD in patients with IMID|To analyze the global prevalence of NAFLD in patients with an immune-mediated inflammatory disease IMID
89286941|NCT03760172||Prevalence of High-risk NASH in patients with IMID|To evaluate the prevalence of high-risk NASH (NASH with advanced fibrosis) in patients with IMID through clinical, radiological and histological evaluation
89286942|NCT03760172||Immunophenptypic characterization|To investigate the existence of common and differential immunophenotypes between the subjects with NASH with and without IMID, and patients with IMID without liver involment
89286943|NCT03760172||Genetic and Molecular characterization|Liver molecular characterization of NASH associated to IMID
89286944|NCT03766256|Experimental|Shared decision-making with pharmacists|Pharmacist-coordinated shared decision making about treatment for history of gestational diabetes mellitus (lifestyle change and/or metformin), using a decision tool
89286945|NCT03760094|Experimental|Study group|patients with lymphadenopathy
89286946|NCT01322282|Experimental|ODT with Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water
89286947|NCT01322282|Experimental|ODT Without Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water
89286948|NCT01322282|Active Comparator|FCT with Water|Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water
89286949|NCT03757364||19 patients with Ps|19 patients with Ps with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
89286950|NCT03757364||13 patients with PsA|13 patients with PsA with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
89286951|NCT03757286|Experimental|FSF with CAD\CAM customized cutting guide|Maxillary reconstruction using free scapular flap with CAD/CAM customized osteotomy guide.
89286952|NCT03757286|Active Comparator|FSF without customized cutting guide|maxillary reconstruction using free scapular flap without customized osteotomy guide. CAD/CAM 3D model for maxilla will be used.
89286953|NCT03766178|Experimental|Nimotuzumab + SHR-1210|Nimotuzumab + SHR-1210
89286954|NCT04737278|Experimental|Cunermuspir|Cunermuspir (Copper Niacin Chelate) 6.06mg per capsule. Non--medicinal ingredients: Organic evaporated cane juice powder, hypromellose, titanium dioxide Two doses per day: one with the morning meal and the other with a mid afternoon snack. The study duration was 28 days.
89286955|NCT04737278|Placebo Comparator|Placebo|Organic evaporated cane juice powder, hypromellose, titanium dioxide. Same dosing as Cunermuspir arm
89286956|NCT03759860|Experimental|Selective Retina Therapy and ranibizumab combination therapy|"Perform R:GEN laser (SRT) on the 6,000 microns diameter region including macular edema, while excluding the 500 microns diameter region from the fovea, with the appropriate treatment energy determined.~Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) injection into the vitreous cavity at 3.5-4.0 mm posterior to the corneal limbus, towards the center of the eye, avoiding horizontal meridians. Then, 0.05 mL of the injection solution is slowly injected.~In study group and the control group, ranibizumab is administered 5 times in total from the baseline to month 4."
89286957|NCT03759860|Sham Comparator|Sham Selective Retina Therapy and ranibizumab monotherapy|"For the participants assigned to the control group, sham procedures are performed in Sham Mode. All procedures except for the absence of laser light emission at the laser irradiation stage are the same with the study group.~Sham SRT is performed three times in total, one time for each visit for month 1, 3, and 5. At the time of month 1 and 3, Sham SRT should be performed before administration of ranibizumab."
89286958|NCT03766100|Experimental|Intervention group|Cognitive Behavioural Therapy for Insomnia (CBT-i).
89286959|NCT03766100|No Intervention|Control group|Insomnia is untreated.
89286960|NCT03759782|Experimental|Group 1|Tenofovir (TDF) 300 mg po once a day (OD)
89286961|NCT03759782|Active Comparator|Group 2|Tenofovir 300 mg po OD + Ribavirin 400 mg twice a day (BID) if <70kg / 600 mg every (q) in the morning (AM) and 400 mg q in the evening (PM) if ≥70kg
89286962|NCT03757208|No Intervention|Fasting group|
89286963|NCT03757208|Active Comparator|Carbohydrate rich drink (CHD) group|
89286964|NCT01322750||With CTCs|Those individuals whom are identified with CTCs
89286965|NCT01322750||Without CTCs|Those individuals whom present and did not have CTCs
89286966|NCT04725500|Experimental|Auto-titrating EPAP|ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.
89286967|NCT03757052|Experimental|Skin testing and Graded Oral Challenge|Penicillin skin testing as described in the intervention section, followed by amoxicillin graded oral challenge as described in the intervention section
89286968|NCT03759704||Hyperpolarized 13CPyruvate and gadolinium|Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.
89286969|NCT03176108|Experimental|CBT Group|"The CBT group benefits of an intervention based on the program Better manage its anger and its frustrations of 15 sessions for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
89286970|NCT03176108|Sham Comparator|Control Group|"The control group participates in an intervention of body mediation (theatre) of 15 session for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
89286971|NCT03765944|Active Comparator|NPC-12 granule|NPC-12 granules (1.0g: 2mg sirolimus)
89286972|NCT03765944|Active Comparator|NPC-12T tablet|NPC-12T 2 tablets (2mg sirolimus)
89286973|NCT03756974|Experimental|BX-1 (dronabinol)|BX-1
89286974|NCT03756974|Placebo Comparator|Placebo|Placebo of BX-1
89286975|NCT03765866|No Intervention|Massive Transfusion Protocol Guided|Clinicians will only transfuse patients according to standard massive transfusion protocol (MTP)
89286976|NCT03765866|Experimental|Thromboelastometry guided transfusion|Clinicians will transfuse patients according to ROTEM results.
89286977|NCT04694066|Experimental|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (followup; 8 hours). The sessions will be supervised by an experienced qigong master.
89286978|NCT04694066|Active Comparator|Light flexibility exercise|The control group will practice light flexibility exercise only, with the same duration and frequency of supervised sessions identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
89286979|NCT04684394|Experimental|SoC + GEM103|Participants were administered SoC therapy defined as aflibercept (2 milligram [mg]/50 microliter [mcL]) first, followed by GEM103 (500 microgram [mcg]/50mcL) 15 minutes later. Administration occurred every other month (EOM) for a total of 6 doses during the 12-month study period.
89286980|NCT04684394|Sham Comparator|SoC + Sham|Participants were administered SoC therapy defined as aflibercept (2mg/50mcL) first, followed by the Sham injection 15 minutes later. Administration occurred EOM for a total of 6 doses during the 12-month study period.
89286981|NCT03759626|Active Comparator|pupils benefiting from the impulsive intervention|Secondary school pupils from general secondary schools
89286982|NCT03759626|Active Comparator|pupils benefiting from the reflective intervention|Second year students from general high schools.
89286983|NCT03759548||Breast Cancer|Breast Cancer's patients undergoing pharmacological treatments prior or after surgery.
89286984|NCT03759548||Colorectal Cancer|Colorectal Cancer's patients undergoing pharmacological treatments prior or after surgery.
89286985|NCT03759470||Evaluation of different methods for diagnosis of meningitis|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperaturetemperature.Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with ~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit.."
89286986|NCT01322828|Active Comparator|Single incision repair of distal bicep tendon rupture|In this treatment arm patients will have a single incision technique used to repair their distal bicep tendon rupture
89286987|NCT01322828|Active Comparator|Double incision repair of distal bicep tendon rupture|In this treatment arm, patients will have a double incision technique used to repair their distal bicep tendon rupture.
89286988|NCT03765554|Experimental|PF-06700841: IR followed by MR|Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR)
89286989|NCT03765554|Experimental|PF-06700841: MR followed by IR|Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR)
89286990|NCT04675346||Questionnaire|The EUNASS Study Questionnaire is an electronic questionnaire (using the Qualtrics programme) designed to assess management after diagnosis of melanoma and during follow-up, health status, fear of melanoma recurrence, melanoma-specific supportive care needs, sun protection behaviour, views and habits about SSE and standard socio-demographic details.
89286991|NCT04675346||Interviews|A qualitative researcher will undertake 25-30 semi-structured interviews with participants who have volunteered their contact details in the final section of the EUNASS Study Questionnaire. A purposive sampling approach will be taken for participant recruitment to this part of the study.
89286992|NCT04674644|Other|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals|Dental professionals
89286993|NCT04668950|Experimental|Fluvoxamine|Start fluvoxamine 50mg capsule once, then 100mg twice daily. May reduce dose for tolerability reasons. Will be followed in the RCT for approximately 15 days.
89286994|NCT04668950|Placebo Comparator|Placebo|Start placebo one capsule, twice daily. May reduce dose for tolerability reasons. Will be followed in RCT for approximately 15 days.
89286995|NCT03078478|Experimental|IDeg 200 U/mL|
89286996|NCT03078478|Active Comparator|IGlar 300 U/mL|
89286997|NCT01343524||all subjects|all subjects who are enrolled in an industry-sponsored study that utilizes a sponsor-supplied spirometer.
89286998|NCT01353352|Other|Cervical spine injury|We enrolled consecutive alert adults who were in stable condition and who presented with potential cervical spine injury after acute blunt trauma, including patients with posterior neck pain and those presenting by ambulance with immobilization of the cervical spine.
89286999|NCT04423822||Firefighter|Firefighter with high cardiovascular risk
89287000|NCT01353430||VCP families|Patients with a personal or family history of VCP associated disease.
89287001|NCT01349218|Experimental|Blood sample drawn from a vein and from a heel stick|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis. A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
89287002|NCT01349296|Experimental|BIBF 1120 + RAD001|
89287003|NCT04422964|Experimental|Intervention group (3D protective obturator)|Patients enrolled in the intervention group will have an intraoral scan of the palate, alveolar arch, and upper vestibular area before surgery. Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer, in cooperation with the Faculty of Mechanical Engineering (Department of Mechanics of Bodies, Mechatronics and Biomechanics) of Brno University of Technology. For the production of the obturator, a silicone certified for use in the oral cavity will be used.
89287004|NCT04422964|No Intervention|control group|The standard procedure without the 3D obturator.
89287005|NCT01343602|Experimental|mod. Constraint-Induced Movement Therapy|CIMT at home is applied in the patients' home over the course of four weeks including (i.e. 20 consecutive days) 2 hours of daily training together with an instructed non-professional coach (e.g. family member) applying shaping techniques.
89287006|NCT01343602|Other|Therapy as usual|Patients in this arm will receive usual care dose-matched to the intervention group (250-300 minutes).
89287007|NCT03522844|Experimental|Mindfulness-Based Stress Reduction (MBSR)|
89287008|NCT03522844|Active Comparator|Escitalopram|
89287009|NCT02879578|Experimental|Valbenazine (Children)|Children (6 to 11 years of age) received valbenazine 10 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 20 mg or continue with the participant's current dose for the remainder of the treatment period.
89287010|NCT02879578|Experimental|Valbenazine (Adolescents)|Adolescents (12 to 17 years of age) received valbenazine 20 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 40 mg or continue with the participant's current dose for the remainder of the treatment period.
89287011|NCT02879578|Experimental|Valbenazine (Adults)|Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.
89287012|NCT01317628|Other|Lifestyle counseling|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
89287013|NCT01349374|Experimental|Group1|healthy volunteers
89287014|NCT01349374|Experimental|group2|Unaffected siblings of MODY patients
89287015|NCT01349374|Experimental|Group3|Type2 Diabetic patients
89287016|NCT01349374|Experimental|Group4|MODY patients
89287017|NCT02982538|Other|Standard PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE.
89287018|NCT02982538|Other|Extended PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE and will receive expert PE case consultation on two PE training cases via weekly phone consultation.
89287019|NCT00045942|Experimental|PKC412 (Core)|Participants received 75 mg PKC412 three time daily (tid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
89287020|NCT00045942|Experimental|FLT3 mutated PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
89287021|NCT00045942|Experimental|FLT3 mutated PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
89287022|NCT00045942|Experimental|FLT3 wild type PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
89287023|NCT00045942|Experimental|FLT3 wild type PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
89287024|NCT00045942|Experimental|FLT3 mutated PKC412 dose escalation|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
89287025|NCT00045942|Experimental|FLT3 mutated PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
89287026|NCT00045942|Experimental|FLT3 wild type PKC412 dose escalation (E2)|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
89287027|NCT00045942|Experimental|FLT3 wild type PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
89287028|NCT04386616|Placebo Comparator|All Placebo|Participants randomized to this arm received one intravenous (IV) infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo on Day 1. A second IV infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo (same placebo as the first infusion) was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
89287029|NCT04386616|Experimental|MSTT1041A|Participants randomized to this arm received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
89287030|NCT04386616|Experimental|UTTR1147A|Participants randomized to this arm received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.
89287031|NCT00045708|Experimental|Group A [Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
89287032|NCT00045708|Experimental|Group B [No Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.~Pharmacological Study Phase 1"
89287033|NCT00045708|Experimental|Group C [MTD-Phase 2)|"Maximum tolerated Dose (MTD-Phase 2) - subjects treated at dose determined by Group B~Drug: ixabepilone~Other Names:~BMS-247550 epothilone B lactam Ixempra Given IV"
89287034|NCT01349452|Experimental|Ganciclovir|
89287035|NCT01349452|Sham Comparator|Artificial tear|
89287036|NCT03488524|Experimental|AMX0035|AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA
89287037|NCT01349530|Experimental|Anticoagulation clinic care|Monitoring by CREATIF
89287038|NCT01349530|Active Comparator|Usual care|Monitoring by GP.
89287039|NCT00045630|Experimental|Gemcitabine, Paclitaxel, Carboplatin|Gemcitabine, Paclitaxel, Carboplatin followed by surgery
89287040|NCT01357252|Experimental|vildagliptin|
89287041|NCT01357252|Placebo Comparator|placebo|
89287042|NCT01349608|Experimental|Health coaching|
89287043|NCT01349686|Experimental|Oral intake of fluids|Intake of oral fluids during labour.
89287044|NCT01349686|Placebo Comparator|Fasting|No intake of oral fluids during labour.
89287045|NCT01098552||High-risk radical prostatectomy patients|
89287046|NCT01098552||Primary external beam radiotherapy patients|
89287047|NCT01098552||Primary prostate brachytherapy patients|
89287048|NCT01098552||Hormone refractory prostate cancer patients|
89287049|NCT01098552||Active Surveillance|
89287050|NCT01098552||Prostate biopsy patients|
89287051|NCT01098630||Group I (limited participation)|Patients do not complete any questionnaires at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
89287052|NCT01098630||Group II (full participation)|Patients complete the Patient Registration Survey and Patient Questionnaire at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
89287053|NCT01349764||No vitamin D replacement|The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
89287054|NCT01349764||Vitamin D3 tabs|The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.
89287055|NCT02924272|Experimental|Ixazomib|Ixazomib capsule, orally, at same dose and schedule that participants were receiving in the parent study until disease progression, clinical deterioration in the investigator's judgment, experience an unacceptable toxicity, withdraw consent, pursue an alternative therapy, meet other study-specified reasons for discontinuation of study drug, or until the participant is transitioned to ixazomib through commercial channels, including reimbursement for the participant's indication, whichever is sooner. Participants who were receiving a combination therapy with ixazomib and another medication(s) will continue to receive the combination regimen.
89287056|NCT01353742|Active Comparator|Lamivudine and Adefovir dipivoxil|One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet
89287057|NCT01353742|Experimental|Fixed dose combination|One capsule (100mg lamivudine and 10mg adefovir dipivoxil)
89287058|NCT01357330|Experimental|Dose Escalation|Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg)
89287059|NCT01317862|Active Comparator|Transcervical foley catheter|
89287060|NCT01317862|Active Comparator|Prostaglandins|
89287061|NCT01349842|Experimental|Circulating Tumor Cells|Centralized determination of CTC by CellSearch® technology (Veridex), the only technology currently validated in clinical practice for the early evaluation of response to chemotherapy of breast cancers. This evaluation is performed by blood sampling comparing the CTC level before the first injection of each new line of chemotherapy. Chemotherapy can only be continued in the case of a positive CTC response. Discontinuation of chemotherapy can also be decided by the clinician on the basis of other clinical or radiological arguments.
89287062|NCT01349842|Other|Clinical and radiological criteria|Management of chemotherapy according to the usual clinical and radiological criteria adopted by the patient's attending physician.
89287063|NCT00003702|Experimental|Arm I (methotrexate)|Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
89287064|NCT00003702|Experimental|Arm II (dactinomycin)|Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
89287065|NCT01318720|Experimental|Manipulation|The experimental group is receiving thoracic spine thrust manipulation and cervical spine non-thrust manipulation.
89287066|NCT01350076|Active Comparator|control group|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
89287067|NCT01350076|Experimental|study group|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
89287068|NCT01098786||Healthy|
89287069|NCT01350154|Experimental|Sildenafil (Revation) 20 mg|This arm will receive sildenafil for 4 weeks followed by 2 weeks washout and 4 weeks placebo.
89287070|NCT01350154|Experimental|Placebo|This arm will receive placebo for 4 weeks followed by 2 weeks washout and 4 weeks sildenafil
89287071|NCT00031590|Experimental|Study Treatment|"All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatment is completed, all subjects will begin 9 cycles (each cycle lasts 6 weeks) of maintenance chemotherapy which will be given as 2 different drug combinations, Regimen A (Lomustine, Vincristine, and Cisplatin) and Regimen B (Cyclophosphamide, given with Mesna, and Etoposide [IV and oral]) which will be given in the following order: AABAABAAB (total of 54 weeks)."
89287072|NCT01350310|Experimental|Intramyocardial Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
89287073|NCT01350310|Active Comparator|Intracoronary Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Patients will undergo myocardial perfusion scintigraphy and CD34+ cells will be injected intracoronary in the artery supplying segments of reduced viability. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
89287074|NCT01350310|Active Comparator|Ischemic heart disease|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure
89287075|NCT03412786|Experimental|Arm A: IM followed by IP|Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
89287076|NCT03412786|Experimental|Arm B: IP followed by IM|Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
89287077|NCT01318096|Experimental|A:Raltegravir + tenofovir+lamivudine|
89287078|NCT01318096|Active Comparator|B:Efavirenz+tenofovir+lamivudine|
89287079|NCT01098942||Surgical|Roux-en-Y gastric bypass surgery
89287080|NCT01098942||Non-surgical|Non-surgical lifestyle weight management
89287081|NCT02530320|Experimental|Palbociclib (PD0332991)|Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
89287082|NCT01353820|Active Comparator|1 = Tested product|
89287083|NCT01353820|Sham Comparator|2 = Control product|
89287084|NCT01357408||REVEAL XT device|Subjects implanted at time of admission for HF or to be implanted within 14 days of discharge from HF hospitalization for clinical indications>
89287085|NCT03954054||Former therapeutic education participants|Semi-structured interviews with people who already completed the TPE programme
89287086|NCT03954054||Intervention group (current therapeutic education participants)|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
89287087|NCT03954054||Control AUD (Alcohol Use Disorder) patients|"A face-to-face interview and a telephone interview at treatment initiation (M0) and 6 months after programme initiation (M6)~Administration of socio-economic questionnaires and a Brief Evaluation of Alcohol-Related Neuropsychological Impairment (BEARNI) before, and 6 months after inclusion in the therapeutic education programme."
88805727|NCT01450189|Active Comparator|Behavioral Intervention plus ARV|The BIA arm consists of the behavioral intervention plus antiretroviral drugs (ARVs) with raltegravir (400 mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg daily) orally for 12 weeks.
88805728|NCT00278876|Experimental|imatinib mesylate|patients receiving adjuvant imatinib mesylate
89287088|NCT00239681|Experimental|Rosuvastatin|Rosuvastatin 20 mg once daily
89287089|NCT00239681|Placebo Comparator|Placebo|Placebo once daily
89287090|NCT02878330|Placebo Comparator|Placebo|Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
89287091|NCT02878330|Experimental|MEDI8897 50 mg|Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
89287092|NCT01354054|Experimental|High frrequency TENS|100 Hz TENS, 100 usec
89287093|NCT01354054|Experimental|Low frequency TENS|4 Hz, 100 usec TENS
89287094|NCT01354054|Experimental|Placebo TENS|100 Hz, 100 usec, set at motor minus 10% then ramps to off in 45 sec, 40 minutes
89287095|NCT01354054|No Intervention|Control|Age matched controls, no intervention
89287096|NCT01354288|Experimental|Therapeutic education|
89287097|NCT01354288|No Intervention|Classical management|
89287098|NCT01354366||Control|Marketed hypoallergenic infant formula containing a probiotic
89287099|NCT01354366||Experimental 1|An investigational hypoallergenic infant formula with a different protein content, containing the same probiotic as the control
89287100|NCT01354366||Experimental 2|An investigational hypoallergenic infant formula with a different protein content, without a probiotic
89287101|NCT00238433|Experimental|Filgrastim/Melphalan/Thiotepa|"Biological/Vaccine: filgrastim~5mcg/kg intravenous piggyback (IVPB) will be administered beginning on day +5 and continued until absolute neutrophil count (ANC) > 1500 for 2 consecutive days.~Drug: busulfan~3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.~Drug: melphalan~50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.~Drug: thiotepa~250 mg/m2/day/iv on days -3 and -2 Procedure/Surgery: bone marrow ablation with stem cell support~The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.~Procedure/Surgery: peripheral blood stem cell transplantation~Performed 36-48 hours following last chemotherapy dose."
89287102|NCT02532023|Active Comparator|omega 3 fatty acid supplementation|patients with migraine receive 2 capsules 1000 mg omega3, 2 times a day, for 2 months.
89287103|NCT02532023|Active Comparator|curcumin supplementation|patients with migraine receive 2 capsules 1000 mg curcumin, 2 times a day, for 2 months.
89287104|NCT02532023|Placebo Comparator|omega 3 fatty acid Placebo|patients with migraine receive 2 capsules of omega 3 fatty acid placebo for 2 months.
89287105|NCT02532023|Placebo Comparator|curcumin placebo|patients with migraine receive 2 capsules of curcumin placebo for 2 months.
89287106|NCT01354522|Active Comparator|TAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
89287107|NCT01354522|Experimental|TCX|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
89287108|NCT01072721|Other|Fibrosis group|a single arm with the two interventions (elastometry and biopsy)
89287109|NCT00045162|Active Comparator|1|
89287110|NCT00045162|Active Comparator|2|
89287111|NCT04289038|Experimental|Autogenic Relaxation|Autogenic Relaxation: It is an exercise program consisting of standard sentences that describe the body's absolute comfort and calm features.
89287112|NCT04289038|Experimental|Virtual Reality|Virtual reality: Playing games via smart phone with virtual reality glasses and headset.
89287113|NCT04289038|Other|Control Group|Routine nursing care and kidney function narration
89287114|NCT01072799|Experimental|Low dose H1N1|
89287115|NCT01072799|Experimental|Mid dose H1N1|
89287116|NCT01072799|Experimental|High dose H1N1|
89287117|NCT01072799|Placebo Comparator|Placebo|
89287118|NCT02748616|Experimental|Ursodiol|Subjects will begin to take 300 mg Ursodiol following Visit #1 and continue for a total of 8 (eight) weeks.
89287119|NCT01582373|Experimental|Cognitive-behavioral couple therapy|The goals of CBCT are to enable participants to: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of their sexual functioning, reduce their sexual distress and increase their sexual satisfaction; (5) consolidate skills.
89287120|NCT01354600|Other|Energy Balance|
89287121|NCT01354600|Other|Positive Energy Balance|
89287122|NCT01354678|Active Comparator|group of bone marrow cell therapy|
89287123|NCT01354678|Sham Comparator|group of sham therapy|
89287124|NCT01354756||bariatric population|obese patients in whom a bariatric surgery is planified
89287125|NCT01350466||FESS patients|
89287126|NCT01350466||Controls|
89287127|NCT00238121|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89287128|NCT03386968|Experimental|Video gaming|A child's usual physical therapy session will be replaced with a session utilizing Active video games and the Rutger's V-step.
89287129|NCT03386968|Active Comparator|Usual care|Children will receive their usual care in the physical therapy program at Blythedale.
89287130|NCT03635242|Active Comparator|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
89287131|NCT03635242|Experimental|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
89287132|NCT03139552|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
89287133|NCT03139552|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
89287134|NCT03139552|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
89287135|NCT01096134|Experimental|HPV Vaccine|Eligible girls were offered 3 doses of the HPV vaccine
89287136|NCT03954288||chronic otitis media|patients with chronic otitis media without cholesteatoma
89287137|NCT03954288||cholesteatoma|patients with chronic otitis media whose cholesteatoma
89287138|NCT03954288||control|patients scheduled to operation with diagnosis of other causes
89287139|NCT01350622|Experimental|Pennsaid|Active Pennsaid and oral placebo
89287140|NCT01350622|Active Comparator|Oral Diclofenac|Oral diclofenac and placebo lotion (2.3% DMSO solution)
89287141|NCT01096212|Experimental|generic sevoflurane|
89287142|NCT01096212|Active Comparator|origianl sevoflurane|
89287143|NCT03804918|Experimental|Interventional group: All participants|Given access to a selected breaking bad news mobile learning resource (VitalTips application).
89287144|NCT03139240|Experimental|Gestational age <7 weeks|Women with a gestational age <7 weeks will be randomized to oxycodone 10mg oral vs placebo
89287145|NCT03139240|Experimental|Gestational age 7-10w0d|Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo
89287146|NCT01099098||Patients with TB sequelae|
89287147|NCT01099098||People without TB sequelae|
89287148|NCT01327404||Depressed|Patients with Major Depressive Disorder
89287149|NCT01327404||Diabetic|Patients with Type 2 Diabetes
89287150|NCT01327404||Diabetic/Depressed|Patients with both diabetes and major depressive disorder
89287151|NCT01327404||Healthy Controls|
89287152|NCT01350700||Patients that were treated in MW2004-011-02 study with Debrase|
89287153|NCT01350700||Patients that were treated in MW2004-011-02 with SOC|
89287154|NCT01584180|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
89287155|NCT01584180|Active Comparator|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad (Emergency Medical Cooling Systems AG, Wien, Austria)
89287156|NCT01350778||Biomatrix stent|patients treated with Biomatrix stent
89287157|NCT00237809|Experimental|Drug and control CRT|D-serine/control
89287158|NCT00237809|Experimental|Drug and CRT|D-serine/cog rehab
89287159|NCT00237809|Experimental|Placebo Drug and Placebo CRT|Placebo/control
89287160|NCT00237809|Experimental|Placebo Drug and CRT|Placebo/cog rehab
89287161|NCT01350856|Active Comparator|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
89287162|NCT01350856|Experimental|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
89287163|NCT02530398|Experimental|cinobufacini group|48 patients(half males and half females) will be in the group.Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc.
89287164|NCT01351012|Placebo Comparator|Corn and safflower oil|
89287165|NCT01351012|Active Comparator|Canola oil|
89287166|NCT01351012|Active Comparator|High oleic acid canola oil|
89287167|NCT01351012|Active Comparator|DHA enriched high oleic acid canola oil|
89287168|NCT01351012|Active Comparator|Flax and safflower oil|
89287169|NCT03973775|Experimental|Test Drug Treatment Arm|Permethrin Cream 5%, Saptalis Pharmaceuticals, LLC
89287170|NCT03973775|Active Comparator|Reference Drug Treatment Arm|Elimite™ (Permethrin Cream 5%), Prestium Pharma, Inc.
89287171|NCT01351168|Placebo Comparator|Sugar pill|
89287172|NCT01351168|Active Comparator|Levodopa|
89287173|NCT01351168|Experimental|Zolpidam second dose|
89287174|NCT01351168|Experimental|Zolpidam first dose|
89287175|NCT00003498|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89287176|NCT01351246|Experimental|Intervention|
89287177|NCT01096524|Other|Control group standard physiotherapy|Standard pathway of care pre-and post-TKA without using NMES.
89287178|NCT01096524|Experimental|Kneehab|Kneehab on the quadriceps of the affected leg, 20 minutes, twice per day, 5 days per week over 12-week intervention (6 weeks pre-op, 6 weeks post op).
89287179|NCT01351324|Experimental|SFA|Oral dose of palmitic acid (SFA) given as a chocolate-flavoured drink every 30 min (0-390 min) with a continuous infusion of heparin (60-390 min).
89287180|NCT01351324|Experimental|SFA + LC n-3 PUFA|Oral dose of palmitic acid and DHA-rich fish oil (SFA + LC n-3 PUFA) given as a chocolate-flavoured drink every 30 min (0-390 min) together with a continuous infusion of heparin (60-390 min).
89287181|NCT03952026||isolated pelvic fracture|Patients with an isolated pelvic fracture
89287182|NCT03952026||combined abodominal/pelvic injury|Patients with a combined injury of a pelvic fracture and an abdominal injury.
89287183|NCT03952104|Experimental|Experimental-Low Intensity Strength Training|Strength training (low intensity)
89287184|NCT03952104|Experimental|Experimental-Moderate Intensity Strength Training|Strength training (moderate intensity)
89287185|NCT03952104|Experimental|Experimental-High Intensity Strength Training|Strength training (high intensity)
89287186|NCT03952104|No Intervention|Control|No intervention
89287187|NCT01351558|No Intervention|Control|No intervention for 12 weeks
89287188|NCT01351558|Active Comparator|Knee muscle strengthening exercises|
89287189|NCT01351558|Active Comparator|Upper extremity strengthening exercises|
89287190|NCT01351558|Active Comparator|Cardiovascular fitness exercises|
89287191|NCT01351636|Experimental|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride
89287192|NCT01351636|Placebo Comparator|Non arotinolol group|Antihypertensive medications without arotinolol hydrochloride
89287193|NCT00003492|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89287194|NCT01351714|Other|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
89287195|NCT01101672|Experimental|Single-port laparoscopic colectomy|
89287196|NCT01101672|Active Comparator|Conventinal laparoscopic colectomy|
89287197|NCT01351792|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
89287198|NCT01351792|Active Comparator|Symbicort® Turbohaler®|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
89287199|NCT03952260|Active Comparator|Fasting clear fluid for 1 hour prior to anaesthesia|Fasting clear fluid for 1 hour prior to anaesthesia
89287200|NCT03952260|No Intervention|Fasting clear fluid for 2 hours prior to anaesthesia|Fasting clear fluid for 2 hours prior to anaesthesia
89287201|NCT01351948|Experimental|Group 1|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
89287202|NCT01351948|Experimental|Group 2|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
89287203|NCT01351948|Experimental|Group 3|AdCh63 AMA1 + AMA1-C1/Alhydrogel®
89287204|NCT01351948|Experimental|Group 4|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
89287205|NCT01351948|Experimental|Group 5|AdCh63 AMA1 + MVA AMA1
89287206|NCT01099176|Experimental|Atorvastatin|10mg of Atorvastatin
89287207|NCT01099176|Experimental|Fenofibrate|267mg of Fenofibrate
89287208|NCT01099176|Experimental|Fenofibrate and atorvastatin|10mg of Atorvastatin and 267mg of fenofibrate
89287209|NCT01099176|Placebo Comparator|Therapeutic Lifestyle Change|Placebo and Therapeutic Lifestyle Change
89287210|NCT01317706|Active Comparator|Bishop score|
89287211|NCT01317706|Active Comparator|transvaginal ultrasound|
89287212|NCT01352026|Experimental|Metformin|
89287213|NCT03136198|Experimental|LUS-guided strategy-of-care|Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
89287214|NCT03136198|Placebo Comparator|Usual care|Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
89287215|NCT00042666|Experimental|LY317615|500 milligrams (mg), oral, daily (QD), up to six (6) 28-day cycles
89287216|NCT01357486|Experimental|A|patients receiving sorafenib 400 mg - twice a day
89287217|NCT01357486|Experimental|B|patients receiving pravastatin 40 mg - once a day
89287218|NCT01357486|Experimental|C|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
89287219|NCT01357486|Other|D|patients receiving best supportive care
89287220|NCT01318564||Group 1: Unit-dose - Pill Bottle|Unit-dose (blister) packages used first week, followed second week by pill bottles usage.
89287221|NCT01318564||Group 2: Pill Bottle - Unit Dose|Pill bottle usage the first week followed second week by Unit-dose (blister) packages.
89287222|NCT01352104|Experimental|waiting-intervention-course|
89287223|NCT01352260||Cardiac Disease|Total Aortic Arch Replacement
89287224|NCT00042432|Experimental|cinacalcet (AMG 073)|
89287225|NCT00042432|Placebo Comparator|Placebo|
89287226|NCT03225820||Overall Pharmacogenomics|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
89287227|NCT03225820||Warfarin Sub-Study|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
89287228|NCT01352338|Experimental|lenalidomide, endoxan, prednisone|"lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.~Lenalidomide is combined with endoxan and prednisone"
89287229|NCT01599520|Experimental|Spanish-Language Self-Administered Training + Usual Care|Participants randomized to this arm will receive Spanish-Language Self-Administered Training + Usual Care.
89287230|NCT01599520|Active Comparator|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
89287231|NCT01361386||1|
89287232|NCT00003474|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89287233|NCT01099332|Active Comparator|Gastro-retentive zinc cysteine tablet|Once daily administration by mouth of a gastro-retentive, sustained-release preparation of zinc cysteine with excipients, all G.R.A.S., with adequate water.
89287234|NCT01099332|Placebo Comparator|Identical appearance of placebo with active comparator|Once daily administration of placebo of identical physical appearance to that of active comparator with similar amount of water.
89287235|NCT01354834||hMG|
89287236|NCT01099410||Group 1|volunteer subjects
89287237|NCT01099488|Other|All subjects|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received a GSK2231392A vaccine, were enrolled for blood withdrawal to support the development of CD8+ T cell immunological detection assays.
89287238|NCT01542736|Experimental|Reduced radiation with concurrent chemotherapy|Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
89287239|NCT01099566|Experimental|Prasugrel|
89287240|NCT01099566|Placebo Comparator|pills consisting of lactose-starch|
89287241|NCT01099722|Active Comparator|Inhaler|
89287242|NCT01099722|Active Comparator|inhaler|Symbicort
89287243|NCT01346410|Experimental|A|Stereotactic Radiation to Pancreas
89287244|NCT03953586||bubble suction test and peristalsis in hydrosalpnix|. Group A: Women with unilateral or bilateral blockage of the distal end of the fallopian tubes with tubal distension.
89287245|NCT03953586||bubble suction test and peristalsis in normal tubes|Group B: Women with normal appearance of the fallopian tubes by HSG.
89287246|NCT01361542|Experimental|Anti TNF|Anti TNF alpha therapy including either infliximab or etanercept with data obtained before and after the study duration.
89287247|NCT00003456|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89287248|NCT03950778|Active Comparator|Septic patients receiving albumin replacement|Septic patients receiving albumin replacement 20 ml Inj Human Albumin 20% -3x100 ml- 3 day
89287249|NCT03950778|No Intervention|Septic patients not receiving albumin replacement|
89287250|NCT03953664|Experimental|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups.
89287251|NCT03953664|Experimental|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
89287252|NCT03953664|Experimental|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
89287253|NCT03950700|Experimental|Bupivacaine solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
89287254|NCT03950700|Placebo Comparator|Saline solution|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
89287255|NCT01355146||Fabry's Disease under Replagal|
89287256|NCT00237185|Experimental|imatinib mesylate 400 mg|400 mg once daily
89287257|NCT00237185|Experimental|imatinib mesylate 600 mg|600 mg once daily
89287258|NCT01357798|Active Comparator|Btx-A: Active Comparator|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
89287259|NCT01357798|Placebo Comparator|Placebo Comparator|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
89287260|NCT00003222|Experimental|Peptides pulsed on dendritic cells|4 melanoma peptides pulsed on monocyte-derived dendritic cells
89287261|NCT00003222|Experimental|Peptides in GMCSF-in-adjuvant|4 melanoma peptides administered as an emulsion with GM-CSF and Montanide ISA-51 adjuvant.
89287262|NCT01361698|Experimental|IMR program|The program is organised into 11 curriculum topic areas: recovery strategies, practical facts about mental illness, the stress-vulnerability model, building social support, using medication effectively, drug and alcohol use, reducing relapses, healthy lifestyle, coping with stress, coping with problems and symptoms, and getting your needs met in the mental health system. In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
89287263|NCT01361698|No Intervention|Treatment as usual|Patients randomised to the control group will get 'treatment as usual' only. This means individual adapted interdisciplinary treatment including medication, individual support, occupational therapy, psycho-education and group therapy.
89287264|NCT01581827||Study population|People at high risk of heart failure (from SCREEN-HF study)
89287265|NCT01357876|Other|Type two diabetics|Type two diabetics
89287266|NCT03973307||Participants with bladder cancer|50 participants with histologically confirmed evidence of malignancy for bladder cancer following routine cystoscopy and biopsy.
89287267|NCT03973307||Participants without bladder cancer|50 participants with negative biopsy for bladder cancer following routine cystoscopy and biopsy.
89287268|NCT05626062|Experimental|Intervention group|30 adults with learning disabilities with incontinence will be offered a 12-week personalised toilet training plan, which promotes prompted voiding in a toilet
89287269|NCT01581983|Experimental|Internet Mindfulness Meditation|
89287270|NCT01581983|Experimental|Individual Mindfulness Meditation|
89287271|NCT02877082|Experimental|Tacrolimus, bortezomib, thymoglobulin|Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
89287272|NCT03951558|Experimental|Diet for calciuria prevention|placebo capsules and a strict eating plan will be given. The placebo will look similar to that of hydrochlorothiazide and will be prepared in the Nephrology Research Laboratory by Biol. Ana María Hernández Sánchez and Quim Lourdes Ortiz.
89287273|NCT03951558|Placebo Comparator|hydrochlorothiazide for calciuria prevention|recommendations for water intake and decrease in salt intake will be given.
89287274|NCT01319578|Active Comparator|Chewing Arm 1|
89287275|NCT01319578|Placebo Comparator|Chewing Arm 2|
89287276|NCT01319578|Active Comparator|Chewing Arm 3|
89287277|NCT01319578|Active Comparator|Chewing Arm 4|
89287278|NCT01099800||Mexican/Mexican American families|Parents and children who self-identify as being of Mexican heritage whether US-born or Mexican-born
89287279|NCT01099800||Puerto Rican families|Parents and children who self-identify as Puerto Rican whether US-born or island-born.
89287280|NCT01361776|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
89287281|NCT01361776|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
89287282|NCT01361776|Active Comparator|TBE vaccinte at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
89287283|NCT01361776|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
89287284|NCT04847128|Experimental|Arm I|Participants receive exercise intervention 3 times weekly for 8 weeks.
89287285|NCT04847128|No Intervention|Arm II|Participants keep sedentary life without exercise for 8 weeks.
89287286|NCT01361932|Experimental|Video of ED Discharge Instructions|
89287287|NCT01361932|No Intervention|Control (usual standard of care)|
89287288|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 4%|Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.
89287289|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 1%|Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.
89287290|NCT01362010|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Once daily, evening
89287291|NCT01362088||CVVH patients|
89287292|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
89287293|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
89287294|NCT02875834|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
89287295|NCT01099878|Active Comparator|Cycling Exercise with Functional Electrical Stimulation|Cycling Exercise with Functional Electrical Stimulation
89287296|NCT01099878|Placebo Comparator|Cycling Exercise|Cycling Exercise
89287297|NCT01099956||diabetes group|
89287298|NCT01099956||control group|
89287299|NCT02875366|Placebo Comparator|Placebo|Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.
89287300|NCT02875366|Experimental|LUM/IVA|LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.
89287301|NCT01362400|Active Comparator|ARM 1: IPI 504 + Docetaxel|Drug: IPI-504 plus Docetaxel
89287302|NCT01362400|Placebo Comparator|Placebo + Docetaxel|Placebo plus Docetaxel
89287303|NCT01362478||Case group|
89287304|NCT01362478||Control group|
89287305|NCT00002850|Experimental|Ciprofloxacin or ofloxacin|"Quinolone:~Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours."
89287306|NCT00002850|Experimental|TMP-SMX|TMP-SMX: 160 mg trimethoprim and 800 mg sulfamethoxazole every 12 hours
89287307|NCT00002850|No Intervention|No prophylaxis|The patient will receive no prophylactic antibiotics.
89287308|NCT01362556|Placebo Comparator|Sodium Chloride|Group receiving sodium chloride 0.9% after arterial blood gas analysis in cardiac arrest.
89287309|NCT01362556|Active Comparator|Sodium Bicarbonate|Group receiving targeted sodium bicarbonate 8% therapy after arterial blood gas analysis in cardiac arrest.
89287310|NCT01102920|Experimental|Tailored behavioural treatment and CPAP|Tailored behavioural treatment targeting physical activity and eating habits.
89287311|NCT01102920|Active Comparator|CPAP-treatment|CPAP-treatment as usual. Advice about benefits of physical activity and weight loss.
89287312|NCT01362634|Experimental|CAPI Intervention|an interviewer-administered comprehensive health and social risk assessment intervention
89287313|NCT01362634|Experimental|ACASI Intervention|self-administered comprehensive health and social risk assessment intervention
89287314|NCT01362634|No Intervention|Control|waitlist control condition
89287315|NCT04234906|Active Comparator|Stage 1, Group 1 - Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
89287316|NCT04234906|Active Comparator|Stage 1, Group 2- Magnesium|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
89287317|NCT04234906|Active Comparator|Stage 2, AMIODARONE|AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
89287318|NCT04234906|Active Comparator|Stage 2, PROCAINAMIDE|PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
89287319|NCT04470232||Patients with coxofemoral pathologies|"For the transcultural validation, a french version of the 2 self-assessment questionnaires, SUSHI-score and the HOOs-12 score will be produced.~For the psychometric validation, 120 patients with coxofemoral pathologies will pass the two questionnaires. The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
89287320|NCT01363024|Experimental|A|
89287321|NCT01363102|No Intervention|Control group|Group will undergo usual mobilization per standard SICU care
89287322|NCT01363102|Experimental|Study Group|Patient mobilization discussed on rounds, SOMS score goal created, specific attempt to mobilize patient and achieve goal throughout day.
89287323|NCT00002766|Experimental|"ARA-C/High-Dose Mitoxantrone(All-2)"|See detail description
89287324|NCT00002766|Active Comparator|"Standard Vincristine/Prednisone (L-20)"|See detail description
89287325|NCT02636530|Experimental|Ground Reaction Forces|Participants will have an individualized exercise program that includes walking, jogging, stair climbing, and box jumping.
89287326|NCT02636530|Experimental|Joint Reaction Forces|Participants will have an individualized exercise program that includes weight lifting and aerobic rowing.
89287327|NCT01355380||Group 1|Drug (incl. Placebo)
89287328|NCT01102998||Brain Tumor Survivors|Brain tumor survivors ages 8 to 18 years who are at least 5 years post diagnosis and at least 2 years post active therapy or observation and their parents/guardians will be approached to participate during clinic visits.
89287329|NCT01355536||Preterm birth group|Women with prior preterm birth
89287330|NCT01355536||Term birth group|Women with prior term birth
89287331|NCT01103076|Active Comparator|Polyamide 210 H|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
89287332|NCT01103076|Experimental|HCO 1100|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
89287333|NCT01355614|Experimental|QAX576|
89287334|NCT01355614|Other|Infliximab|
89287335|NCT01584414||normal samples|
89287336|NCT01584414||premalignant/carcinoma samples|
89287337|NCT01355692|Experimental|Laser therapy|
89287338|NCT01584492|Experimental|Treatment A|CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic
89287339|NCT01584492|Experimental|Treatment B:|CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic
89287340|NCT01584492|Experimental|Treatment C|CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
89287341|NCT01584492|Active Comparator|Treatment D|formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
89287342|NCT01584492|Placebo Comparator|Treatment E|placebo pMDI with spacer, 6 inhalations in the morning at the clinic
89287343|NCT01355848|Experimental|Brief Intervention|The brief intervention consists of stepped care protocol, including building rapport, functional analysis of suicidal behavior, and crisis planning
89287344|NCT01355848|No Intervention|care as usual|Patients randomized to the care as usual arm will not receive the brief intervention.
89287345|NCT01355926|Experimental|Flexible Fiber-based CO2 Laser|In the CO2 excised group, the resection will be performed at 15W, at a distance of 1cm from the tissue. Here too, if required, the bipolar will be used to achieve hemostasis The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
89287346|NCT01355926|Experimental|electrocautery resection|In the electrocautery excised group, the cut and coagulation modes used will be each at 25 Malis power setting. First, cut mode will be used to mark out the lesion. Subsequently, coagulation mode will be used for excision. Bipolar cautery will then be used at 25 Malis for hemostasis. The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
89287347|NCT02306122|Experimental|Default patient default doctor|Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
89287348|NCT02306122|Experimental|Information patient default doctor|Patient nonadherence information sent to physician
89287349|NCT02306122|No Intervention|Control patient default doctor|Control - no intervention
89287350|NCT02306122|Experimental|Choice patient choice doctor|Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
89287351|NCT02306122|Experimental|Information patient choice doctor|Patient nonadherence information sent to physician
89287352|NCT02306122|No Intervention|Control patient choice doctor|Control - no intervention
89287353|NCT02306122|Experimental|Information patient information doctor|Patient nonadherence information sent to physician
89287354|NCT02306122|No Intervention|Control patient information doctor|Control - no intervention
89287355|NCT02306122|Experimental|Information doctor|Physician receives nonadherence information, but there is no opportunity for pharmacist action
89287356|NCT02306122|Experimental|Choice doctor|Physician receives nonadherence information, and can choose to request pharmacist action
89287357|NCT02306122|Experimental|Default doctor|Physician receives nonadherence information; pharmacist action will be triggered unless physician cancels action
89287358|NCT00001962|Experimental|Daclizumab in participants with a bone marrow failure syndrome|daclizumab, 1 mg/kg, will be given for a total of 5 intravenous infusions. These subjects may be diagnosed with moderate aplastic anemia, pure red cell aplasia, Diamond Blackfan anemia, relapse and refractory severe aplastic anemia will receive treatment. The subjects will be seen and receive the daclizumab infusion biweekly during the treatment period.
89287359|NCT01356004|Experimental|chicken pox vaccine, efficacy|
89287360|NCT01356004|Placebo Comparator|saline, efficacy|
89287361|NCT03951714|Other|Reference|Control experience using marketed application to record medication intake without reminders from the app
89287362|NCT03951714|Experimental|Intervention|Full experience using marketed application, with all functionalities enabled
89287363|NCT01356082||Arterial blood pressure line|Patients receiving an arterial blood pressure line
89287364|NCT01584570|Active Comparator|Control|fentanyl 1 mcg/kg before induction
89287365|NCT01584570|Experimental|D 0.5 group|Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium
89287366|NCT01584570|Experimental|D 1.0 group|Dexmedetomidine 1.0 ug/kg + Propofol + Sevoflurane+ Vecuronium
89287367|NCT01101984|Experimental|DE-089|DE-089 ophthalmic solution
89287368|NCT01101984|Active Comparator|HA|0.1% sodium hyaluronate ophthalmic solution
89287369|NCT01103154|Active Comparator|Carvedilol|carvedilol 6.25mg per day
89287370|NCT01103154|Active Comparator|N+I|nadolol 40mg per day, ISMN 10 mg per day
89287371|NCT01103310|Experimental|Arm 1|Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT
89287372|NCT01103310|Experimental|Arm 2|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood
89287373|NCT01100190|Experimental|NUVANCE Facial Rejuvenation System|
89287374|NCT03950388|No Intervention|Treatment as Usual|
89287375|NCT03950388|Experimental|Intervention|
89287376|NCT01327248||affected patients|20 Patients suffering from bronchiolitis obliterans
89287377|NCT01327248||non-affected patients|20 matched controls not suffering from bronchiolitis obliterans
89287378|NCT01103388|Experimental|Rituximab|
89287379|NCT01103388|No Intervention|No Rituximbab|
89287380|NCT01102062|Experimental|Orange Juice|1 glass (=200mL) of orange juice
89287381|NCT01327326|Active Comparator|TMD patients|"Intervention:~Drug: Naltrexone~Drug: placebo"
89287382|NCT01327326|Active Comparator|Healthy controls|"Intervention:~Drug: Naltrexone~Drug: placebo"
89287383|NCT03950544|Experimental|only meropenem therapy,|this group is only meropenem therapy as a single antibiotic treatment
89287384|NCT05625672|Experimental|Intervention|Five modules of training on hemovigilance were given in 5 hours. A pre-test was applied at the beginning of the training. The final test was done at the end of the training. One month later, the same test was applied again to measure the permanence of the training.
89287385|NCT05625672|No Intervention|Control|No training was provided. Only the pretest was administered one week after the posttest.
89287386|NCT00028002|Experimental|Arm I|Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
89287387|NCT03949998|Experimental|Dry Needling|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals.
89287388|NCT03949998|Active Comparator|Dry Needling + Manual Therapy|Participants will receive dry needling of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals IN ADDITION TO manual therapy of the above muscles and/or cervical joint traction and/or mobilization as indicated.
89287389|NCT03949998|Active Comparator|Manual Therapy|Participants will receive manual therapy of the following muscles as indicated: upper fibres trapezius, levator scapulae, cervical multifidus, suboccipitals and/or cervical joint traction and/or mobilization as indicated.
89287390|NCT00256997|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
89287391|NCT00256997|Active Comparator|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
89287392|NCT00027846|No Intervention|GTR1 Differentiated Histology Supratentorial (Group 1)|Patients undergo observation.
89287393|NCT00027846|Experimental|Radiation (Group 2)|Supratentorial Anaplastic Ependymoma (GTR1, GTR2, NTR) and Anaplastic or Differentiated Infratentorial Ependymoma (GTR1, GTR2, NTR) and Supratentorial Differentiated Ependymoma(GTR2, NTR). Patients undergo conformal radiation therapy to the brain once daily 5 days a week for 6-6½ weeks.
89287394|NCT00027846|Experimental|Sub-Total Resection Any Histology or Location (STR) (Group 3)|Patients receive an initial course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously or IV beginning on day 3 and continuing until blood counts recover. Patients then receive a second course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and oral etoposide on days 1-21. After completion of chemotherapy, patients are evaluated for second therapeutic conventional surgery. Patients who have unresectable disease undergo conformal radiation therapy. Patients who have resectable disease undergo second surgery followed by conformal radiotherapy.
89287395|NCT00027378|Experimental|1|fluoxetine plus Treatment As Usual (TAU)
89287396|NCT00027378|Placebo Comparator|2|placebo plus Treatment As Usual (TAU)
88805729|NCT01474213|Active Comparator|dexmedetomidine|a loading dose (1.5mcg/kg) infused over10 min followed by a continuous infusion of 0.7 μg/kg/h
88805730|NCT01474213|Active Comparator|remifentanil|The initial target was 3.0 ng/ml and the TCI was adjusted by 0.5 ng/ml after the target concentration at the effect site had equilibrated with the plasma concentration, until the desired level of sedation was acheived.
89287397|NCT01103544||Patients with advanced / metastatic TCCU after CDDP-failure|
89287398|NCT03949062|Experimental|iR2|Participants received six 21-day cycles of ibrutinib, lenalidomide, and rituximab (iR2) treatment (21-day cycles).
89287399|NCT00235391|Experimental|Deferasirox|Deferasirox was administered orally once a day, 30 minutes prior to breakfast. Dosage was based on participant's body weight. Starting dose was determined by the frequency of blood transfusions and recommended initial daily dose of deferasirox is 20 mg/kg body weight for patients receiving blood transfusion, 10 mg/kg for patients receiving less frequent transfusion/exchange transfusion and 30 mg/kg for patients receiving more frequent blood transfusions.
89287400|NCT01103622|Experimental|1|twice daily Day 1 to Day 7; digoxin on day 4
89287401|NCT01103622|Placebo Comparator|2|twice daily Day 1 to Day 7; digoxin on day 4.
89287402|NCT01100424|Experimental|Contact lens wearers|Contact lens wearers experienced three currently available contact lens/contact lens care combinations in randomized order: balafilcon A + Optifree RepleniSH, balafilcon A + ReNu MultiPlus, and balafilcon A + Unisol 4 saline.
89287403|NCT01100424|No Intervention|Non-lens wearers|Non-lens wearers completed one study visit and served as the control group.
89287404|NCT01102296|Active Comparator|male homosexuals|HIV-uninfected male homosexuals will be provided 2 doses of HAV vaccine, which will be administered at baseline and 6th month of follow-up.
89287405|NCT01102296|Active Comparator|HIV-infected male homosexuals, group1|HIV-infected male homosexuals will be provided 3 doses of HAV vaccine, which will be administered at baseline, 1st, and 6th month of follow-up.
89287406|NCT01102296|Active Comparator|HIV-infected male homosexuals, group 2|HIV-infected male homosexuals will be provided 2 doses of hepatitis A vaccine, which will be administered at baseline and 6th month of follow-up.
89287407|NCT01072955|Experimental|heparin of bovine origin|5.000UI/mL bottle with 5mL
89287408|NCT01072955|Active Comparator|heparin of porcine origin|5000 USP Heparin Units / mL vial with 10 mL vial
89287409|NCT01102452|Placebo Comparator|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
89287410|NCT01102452|Experimental|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
89287411|NCT01326143||ORM Narval MRD|
89287412|NCT02981108|Experimental|Escalation Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
89287413|NCT02981108|Experimental|Escalation Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
89287414|NCT02981108|Experimental|Escalation Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
89287415|NCT02981108|Experimental|Escalation Cohort 4|Oral Once-Daily Administration of HS-10296 260mg
89287416|NCT02981108|Experimental|Expansion Cohort 1|Oral Once-Daily Administration of HS-10296 55mg
89287417|NCT02981108|Experimental|Expansion Cohort 2|Oral Once-Daily Administration of HS-10296 110mg
89287418|NCT02981108|Experimental|Expansion Cohort 3|Oral Once-Daily Administration of HS-10296 220mg
89287419|NCT02981108|Experimental|Phase 2 Extension|Oral Once-Daily Administration of HS-10296 110mg (RP2D)
89287420|NCT00234533|Experimental|NutropinAq 10 mg/2 mL (30 IU)|"Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:~GHD patients: 0.025 - 0.035 mg/ kilogram (kg) bodyweight~TS patients: up to 0.05 mg/kg bodyweight~CRI patients: up to 0.05 mg/kg bodyweight~Patients visited the study clinic for a baseline visit and for 2 other visits every 3 months (Weeks 12 and 24). Additional home assessments were made at Weeks 21, 22 and 23.~The investigator determined the dose administered to each patient, and it was recommended to perform the injection in the evening."
89287421|NCT03759236|Experimental|Health Messaging via SMS|Clinics randomized to this arm will receive the health messaging via SMS intervention. Flyers and information cards will be made available in all exam rooms and the waiting room, which contain information about the health messaging program. Patients must voluntarily elect to enroll in the program using their mobile device. Patients who enroll will receive a variety of health messages on topics including HPV Vaccine, Cervical Cancer screening, Birth Control options, Menstrual Problems, diet and exercise. Text messages are sent out using a third party interface, Twilio, at a frequency of 2 times each week for a duration of 1 year. These are one-way messages which only allow for texts to be sent to the participant.
89287422|NCT03759236|Active Comparator|CDC Pamphlets|The clinic randomized to this control arm will receive standard Center for Disease Control health pamphlets about the HPV Vaccine. Flyers are posted in the clinic waiting room and exam room.
89287423|NCT00026208|Experimental|Stanford V-C + Low-dose Radiotherapy|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.~Radiotherapy = 20 Gy modified involved field radiotherapy"
89287424|NCT00026208|Experimental|Stanford V-C only|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide."
89287427|NCT00025662|Experimental|RFT5-SMPT-dgA Isolex system|RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin used in allogeneic stem cell transplantation (SCT) in older patients with hematologic malignancies using a graft manipulation process
89287428|NCT03765398|Experimental|VR Cognitive-motor-balance training|Virtual reality based cognitive-motor balance (VR-CogMoBal) training will be delivered using the commercially available Wii-Fit Nintendo in conjunction with cognitive training. All participants will undergo 12 sessions of training in a tapering manner for four weeks with 90 minutes of training per session, i.e., 5 sessions for the first week, 3 sessions for the second week, and 2 sessions for the third and fourth week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
89287429|NCT02935478|Experimental|HCC-Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
89287430|NCT03759158|Experimental|NAC Arm|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
89287431|NCT03759158|Placebo Comparator|Placebo|
89287432|NCT03756584|Experimental|Intermittent theta-burst stimulation|iTBS will be performed on the left lateral parietal cortex
89287433|NCT03756584|Active Comparator|Control stimulation|iTBS will be performed on the vertex
89287434|NCT03765086|Active Comparator|Karydakis procedure|Karydakis Procedure: In this procedure the pilonidal sinus will be excised by semilunar incision so that the incision line closure will be away from midline.
89287435|NCT03765086|Active Comparator|Limberg Flap|Limberg Flap: In this procedure the pilonidal sinus will be excised by diamond shaped incision and the defect will be closed by random pattern flap.
89287436|NCT00025506|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89287437|NCT03756428|Experimental|Deep dry needling in tibialis posterior|Deep dry needling will be applied in the tibialis posterior myofascial trigger point
88805731|NCT04752410|Experimental|Selective Brachial plexus block|Selective brachial plexus block will be done under ultrasound guidance to patients scheduled for upper extremity surgeries. Local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 25ml) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anesthetize the whole upper limb.
88805732|NCT03008863|Experimental|Education Intervention|"The investigators will use an electronic learning (E-learning) curriculum with an educational video and a user-centered checklist for anesthesia residents. This E-learning curriculum will cover how to care for geriatric patients in the preoperative, intraoperative and postoperative settings, and specific interventions that have been shown to improve postoperative outcomes in older patients.~The checklist will be user-centered. It will remind providers of what they learned in the video and online curriculum, and how to apply these lessons in real-time while they are caring for older patients."
89287438|NCT03756428|Placebo Comparator|Sham technique in tibialis posterior|Placebo tibialis dry needling
89287439|NCT05461040|Experimental|Optic capture of Intraocular lens without anterior vitrectomy (Group 1)|
89287440|NCT05461040|Experimental|in-the-bag implantation of Intraocular lens with anterior vitrectomy (Group 2).|
89287441|NCT00024258|Experimental|Arsenic Trioxide|"Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2-3 months for 1 year and then annually thereafter."
89287442|NCT03756272|Experimental|Stellate ganglion bupivacaine block|Nervus Sympathicus block. Stellate ganglion anaesthetic block in which 7 ml of 0.5% bupivacaine will be injected next to the stellate ganglion
89287443|NCT03756272|Placebo Comparator|Placebo ganglion block|Sham Nervus Sympathicus block. Stellate ganglion sham anaesthetic block using 7 ml of 0.9 % natrium chloride (NaCl)
89287444|NCT01321658|Experimental|Geriatric intervention|
89287445|NCT01321658|No Intervention|Control|
89287446|NCT03756194|Experimental|Experimental|"Participants will utilize the socially-assistive robot with a CARESSES cultural competence solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
89287447|NCT03756194|Other|Control arm 1|"Participants will utilize the socially-assistive control robot with an alternative CARESSES solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
89287448|NCT03756194|No Intervention|Control arm 2|"Participants will be receiving conventional human care with no robot intervention.~Baseline assessments will be conducted as soon as participants are recruited and allocated to the study arm. Follow-up assessments will be conducted in two weeks after the baseline data collection."
89287449|NCT03759080|Active Comparator|intervention of PNF|PNF group: 30 individuals, these subjects received proprioceptive neuromuscular facilitation training.
89287450|NCT03759080|Experimental|MP|PNFMP group:30 individuals, these subjects received mental practice.
88805733|NCT03008863|No Intervention|Control|Residents randomized to this group will receive the current, standard education provided for all Duke Anesthesiology residents.
88805734|NCT00147212|Experimental|1|ET-743
89287451|NCT03765008|Active Comparator|High Water intake|5-days of High water intake according to IOM guidelines
89287452|NCT03765008|Experimental|Low Water Intake|5-days of Low water intake of 500 mL/day
89287453|NCT03756116|Experimental|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
89287454|NCT03756116|Active Comparator|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope; followed by octreotide.
89287455|NCT00023712|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89287456|NCT00023322|Experimental|Peginterferon Alpha-2a|Patients with hepatitis D virus (HDV) infection are treated with pegylated alpha interferon therapy for 3 years. The dose of the drug is 180 mcg/week.
89287457|NCT04640168|Experimental|Remdesivir plus Baricitinib|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and dexamethasone placebo administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
89287458|NCT04640168|Experimental|Remdesivir plus Dexamethasone|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 10-day total course; baricitinib placebo administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course; and 6 mg of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course.
89287459|NCT00022698|Experimental|Cohort 1,Initial Regimen:(Capecitabine + Irinotecan )|Participants will receive capecitabine (Xeloda) 1000 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
89287460|NCT00022698|Experimental|Cohort 2,Amended Regimen:(Capecitabine + Irinotecan)|Participants will receive capecitabine 900 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
88805735|NCT01474915|Active Comparator|Aprepitant|"Aprepitant is given orally, along with an oral or PO placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy 40mg Aprepitant PO + IV placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
88805736|NCT01474915|Active Comparator|Ondansetron|"Ondansetron is given via IV, along with an oral or IV placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication (25mg promethazine, 10mg dexamethasone, and either 4mg ondansetron or 40mg aprepitant) plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy~4mg Ondansetron IV + PO placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
88805737|NCT00280826|Experimental|Efalizumab|
89287461|NCT03951402|Experimental|CG5503 PR 100 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 100 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 1 tablet CG5503 PR and 1 placebo-tablet, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin 400 mg.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
89287462|NCT03951402|Experimental|CG5503 PR 200 mg twice daily (tapentadol hydrochloride)|"Each participant received a morning and an evening dose of 200 mg CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
89287463|NCT03951402|Placebo Comparator|Placebo|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); additionally at each dosing each participant received 2 placebo-capsules, matching moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
89287464|NCT03951402|Active Comparator|Moxifloxacin 800 mg single dose|"Each participant received a morning and an evening dose of placebo to CG5503 PR on days 1 and 2 and a morning dose on Day 3 (each dose: 2 tablets placebo, matching CG5503 PR); and 2 placebo-capsules, matching moxifloxacin on days 1 and 2; In the morning of Day 3, each participant received additionally 2 capsules each containing 1 tablet moxifloxacin.~The participants received 2 tablets and 2 capsules at each dosing with approximately 150 ml water."
89287465|NCT03948828|Other|Conventional treatment group|GnRHa combained with reverse addition therapy
89287466|NCT03948828|Experimental|Conventional treatment and Autologous NK cells therapy|GnRHa combained with reverse addition therapy and NK cell combined treatment group
89287467|NCT03948750||Patients with Ocular Toxoplasmosis|
89287468|NCT03948750||Patients without Ocular Toxoplasmosis|
89287469|NCT03755960|Experimental|acupuncture plus routine care|12 session of semistandardized acupuncture together with pharmacological routine care
89287470|NCT03755960|Active Comparator|routine care alone|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
89287471|NCT03948594|Placebo Comparator|plain water|subject drink 250cc plain water
89287472|NCT03948594|Active Comparator|resource|subject drink 1 packet resource(237ml)
89287473|NCT03759002||Patients|Children with end stage renal disease
89287474|NCT03759002||Controls|Healthy sex- and age adjusted children
89287475|NCT01100580|Active Comparator|water therapy|"The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)."
88805738|NCT01899794|Active Comparator|TVT-O|mid-urethral sling
89287476|NCT01100580|Experimental|low salt diet + water therapy|low salt diet refers to a salt intake of 4 g/day
89287477|NCT03948360|Experimental|LIMB Phototherapy with SOC|Arm I: The first 3 participants enrolled will receive standard of care therapy under the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device.
89287478|NCT03948360|Experimental|LIMB Phototherapy without SOC|Arm II: The subsequent participants will receive only the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device without standard of care.
88805739|NCT01899794|Active Comparator|Oxytrol|medication
89287479|NCT03949608|Experimental|BASIC|"mon cœur, mon BASIC video viewing and installation in the own smartphone or tablet of the patient"
89287480|NCT03949608|No Intervention|Control|Usual care
89287481|NCT01100736|Experimental|Bosentan|Bosentan 125mg twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of bosentan therapy
89287482|NCT01100736|Experimental|Sitaxsentan|Sitaxsentan 100mg once daily + placebo tablet will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of sitaxsentan therapy
89287483|NCT01100736|Placebo Comparator|Placebo|Placebo tablet twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of placebo therapy
89287484|NCT03947268|Experimental|Short-course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation technique.
89287485|NCT01584726|Other|magnesium sulfate arm|magnesium sulfate with standard therapy
89287486|NCT01584726|No Intervention|placebo arm|placebo with standard therapy
89287487|NCT01584804|Active Comparator|Monotherapy|Monotherapy with Su-Huang antitussive capsule
89287488|NCT01584804|Placebo Comparator|Sugar pill|Monotherapy with placebo
89287489|NCT06159582|Active Comparator|eSTEP Treatment Group|Treatment group participants will be given access to eSTEP (Electronic Support to Engage with PrEP), an mHealth intervention to promote engagement on the full PrEP care continuum tailored to the unique needs of transgender women (TW) and gay, bisexual, and other men who have sex with men (GBMSM), in addition to the usual HIV testing and PrEP clinical care.
89287490|NCT06159582|Placebo Comparator|Control Arm|Usual HIV testing and PrEP clinical care
89287491|NCT06159530|Experimental|PEEK framework veneered with nanocomposite resin(visio-lign)|patients recieved 4 implants according to All on 4 concept then peek framework was delivered and veneered with nano-composite resin (visio-lign) as an occlusal material
89287492|NCT06159530|Experimental|PEEK framework veneered with zirconia crowns|patients recieved 4 implants according to All on 4 concept then peek framework was delivered and veneered with zirconia crowns as an occlusal material
89287493|NCT06159504|Active Comparator|Arm 1 - simplified care model|Arm 1 will receive DAA medication at the second appointment following the return of RNA HCV results. They will receive sofosbuvir (400mg) and velpatasvir (100mg).
89287494|NCT06159504|Experimental|Arm 2 - short read time|Arm 2 will begin DAA treatment after the first appointment following a shortened RDT read time of 5 minutes rather than 20 minutes. They will receive sofosbuvir (400mg) and velpatasvir (100mg).
89287495|NCT06159491|Experimental|Pacritinib in combination with Azacitidine|Participants will take pacritinib 200 mg BID for each 28 day cycle, azacitidine 75mg/m2 will be administered IV or SQ QD D1-7 of each 28 day cycle
89287496|NCT06159452|Experimental|Group A|SAR153191 - P3 drug product concentration 1 dose 1
89287497|NCT06159452|Experimental|Group B|SAR153191 - P2 drug product concentration 2 dose 2
89287498|NCT06159452|Experimental|Group C|SAR153191 - P3 drug product concentration 2 dose 2
89287499|NCT06159452|Experimental|Group D|SAR153191 - P3 drug product concentration 3 dose 3
89287500|NCT06159452|Experimental|Group B'|SAR153191 - P2 drug product concentration 2 dose 3
89287501|NCT06159452|Experimental|Group C'|SAR153191 - P3 drug product concentration 2 dose 3
89287502|NCT06159452|Active Comparator|Group E'|SAR153191 - CIF3 drug product concentration 2 dose 3
89287503|NCT06159439|Experimental|Participants with CKD having MRI and CEUS|10 participants with CKD will have an MRI scan and a contrast enhanced ultrasound scan. The two scans will be done within 7 days of each other.
89287504|NCT06159348||Healthy adults|Participants will be adults aged 18-70, male or female
89287505|NCT06159322||First-line treatment group|This group will consist of 20 patients with schizophrenia or schizoaffective disorder who are primarily prescribed olanzapine. Treatment will be carried out by the physicians within their circle of care, however, we will record their symptoms as they continue treatment.
89287506|NCT06159322||Treatment-resistant group|This group will consist of 20 patients with schizophrenia or schizoaffective disorder who are primarily prescribed clozapine due to poor treatment response to first-line antipsychotic agents. Treatment will be carried out by the physicians within their circle of care, however, we will record their symptoms as they continue treatment.
89287507|NCT06159296|Other|Treatment-Placebo arm|The participants in this arm are given a machine that produces hydroxy gas in the first three weeks. In the final three weeks of the study, they will use a machine that produces a placebo gas.
89287508|NCT06159296|Other|Placebo-treatment arm|The participants in this arm are given a machine that produces a placebo gas in the first three weeks. In the final three weeks of the study, they will use a machine that produces hydroxy gas.
89287509|NCT06159270||Cohort of patients presenting infectious diseases|
89287510|NCT06159257|Other|Steatohepatitis (NASH)|
89287511|NCT06159244|Experimental|sAH patients|the recruitment of patients with sAH will be carried out from the Hepatogastroenterology Service of the University Hospital of Amiens.
89287512|NCT06159244|Experimental|Alcohol controls without liver complications|the recruitment of alcohol controls will concern patients followed for alcohol addiction without sAH in the antecedents or evolutionary. It will be carried out by the Hospital of Roye-Montdidier. The total number of controls will be equivalent to the number of sAH patients, matched for age and sex.
89287513|NCT06159244|Active Comparator|Healthy non-alcoholic witnesses|the general population will be called with a matching on age
89287514|NCT06159218|Active Comparator|Omeprazole|Patients with active EoE who have been started on omeprazole as treatment
89287515|NCT06159218|Active Comparator|Budesonide|Patients with active EoE who have been started on budesonide as treatment
89287516|NCT06159205|Experimental|Group 1: SE Group|SE: standard exercises During the follow-up period, only the interventions included in the standard exercise program were applied to the SE Group.
89287517|NCT06159205|Experimental|Group 2: SE + CSE Group|CSE: core stability exercises During the follow-up period interventions included in both the standard and core stability program were applied to the SE + CSE group.
89287518|NCT06159140|Experimental|Healthy subjects|MRI and neuropsychological evaluation
89287519|NCT06159114|Experimental|Ningmitai Capsule Group|Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules and celexcoib placebo, 0.2 g/ capsule, 1 capsule, qd each time, after meals, for 6 weeks.
89287520|NCT06159114|Active Comparator|Celecoxib Capsule Group|Patients take celexcoib capsule, 0.2 g/capsule, qd, 1 capsule and Ningmitai placebo, 0.38 g/ capsule, 4 cpsule, tid each time, after meals, for 6 weeks.
89287521|NCT06159114|Experimental|Combined Group|Patients take Ningmitai capsule, 0.38 g/capsule, tid, 4 capsules and celexcoib capsule, 0.2 g/ capsule, 1 capsule, qd each time, after meals, for 6 weeks.
89287522|NCT06159101|Experimental|HLX13 group|Recombinant anti-CTLA-4 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.
89287523|NCT06159101|Active Comparator|CN-sourced ipilimumab group|CN-sourced ipilimumab
89287524|NCT06159101|Active Comparator|EU-sourced ipilimumab group|EU-sourced ipilimumab
89287525|NCT06159101|Active Comparator|US-sourced ipilimumab group|US-sourced ipilimumab
89287526|NCT06159036|Experimental|Group 1|Strength training in inertial machines for 2 days and around 12 weeks.
89287527|NCT06159036|Active Comparator|Group 2|Control group developed conventional strength training with squats, deadlifts, hip thrust jumps for 2 days and around 12 weeks.
89287528|NCT06159023|No Intervention|Thick scope + BAL|In this arm, participants with suspected pulmonary TB will be received bronchoscopic procedure using thick (5.9mm diameter) conventional bronchoscope and bronchoalveolar lavage (BAL).
89287529|NCT06159023|Experimental|Thin scope + BW|In this arm, participants with suspected pulmonary TB will be received bronchoscopic procedure using thin (4.0mm diameter) bronchoscope and bronchial washing (BW).
89287530|NCT06158997|Experimental|EyePeace+Heated eye mask group|Participants will received the HEM therapy for 10 minutes according to the manufacturer's instructions. This was followed immediately by 10 gentle squeezes of the eyelid massage device on one eye
89287531|NCT06158997|Active Comparator|Heated Eye Mask group|Participants in Heated Eye Mask group will use heated eye mask once.
89287532|NCT06158932|Experimental|Myo Inositol and D-Chiro Inositol Supplement|Participants must take 4 capsules per day, with water. The product should be taken with the last meal of the day.
89287533|NCT06158919|Experimental|PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy|"Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sindilizumab: 200mg iv.gtt d1, q3w SOX: Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sindilizumab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable.The longest duration of PD-1 inhibitor treatment is 24 months."
89287534|NCT06158893|Experimental|salbutamol|children will receive 0.15 milligram per kilogram of salbutamol diluted with normal saline to a total volume of 4 ml by inhalation 20 minutes preoperatively
89287535|NCT06158893|Active Comparator|budesonide|children will receive 0.5 milligram per kilogram of budesonide diluted with normal saline to a total volume of 4 ml by inhalation 20 minutes preoperatively
89287536|NCT06158893|Placebo Comparator|normal saline|children will receive 0.4 ml of normal saline 0.9 by inhalation 20 minutes preoperatively
89287537|NCT06158854|Experimental|Dose Escalation: ABBV-383 Dose A|Participants will receive ABBV-383 dose A during the approximately 2 year study duration.
89287538|NCT06158854|Experimental|Dose Escalation: ABBV-383 Dose B|Participants will receive ABBV-383 dose B during the approximately 2 year study duration.
89287539|NCT06158854|Experimental|Dose Escalation: ABBV-383 Dose C|Participants will receive ABBV-383 dose C during the approximately 2 year study duration.
89287540|NCT06158854|Experimental|Safety Expansion: ABBV-383 Expansion A|Participants will receive ABBV-383 expansion dose A during the approximately 2 year study duration.
89287541|NCT06158854|Experimental|Safety Expansion: ABBV-383 Expansion B|Participants will receive ABBV-383 expansion dose B during the approximately 2 year study duration.
89287542|NCT06158828|Experimental|Recipient, Myeloablative Conditioning (MAC)|Patients will undergo Myeloablative Conditioning (MAC) consisting of rabbit antithymocyte globulin (rATG), Busulfan, Fludarabine, and Thiotepa. All agents are administered intravenously. rATG is administered from days -9 to -7, followed by Busulfan and Fludarabine from days -6 to -3, and Thiotepa on day -2. On Day 0, patients will undergo infusion of the ex vivo TCRαβ/CD19+ depleted haploidentical HPC graft. On Day +7, patients will undergo infusion of the memory-like NK (ML NK) cells, followed by IL-2 subcutaneously 4 hours after the ML NK infusion. IL-2 will continue every other day through Day +19 for a maximum of 7 doses.
89287543|NCT06158828|Experimental|Recipient, Reduced Intensity Conditioning (RIC)|Patients will undergo Reduced Intensity Conditioning (RIC) consisting of rabbit antithymocyte globulin (rATG), Fludarabine, Melphalan, and Thiotepa. All agents are administered intravenously. rATG is administered from days -9 to -7. Fludarabine is administered from day -8 to day -5, followed by Thiotepa on day -4 and Melphalan on days -3 and -2. On Day 0, patients will undergo infusion of the ex vivo TCRαβ/CD19+ depleted haploidentical HPC graft. On Day +7, patients will undergo infusion of the memory-like NK (ML NK) cells, followed by IL-2 subcutaneously starting 4 hours after the ML NK infusion. IL-2 will continue every other day through Day +19 for a maximum of 7 doses.
89287544|NCT06158828|Other|Donor|Donors will undergo 2 leukapheresis collections. First, patients will be mobilized using G-CSF for 5 days followed by leukapheresis on the day prior to planned stem cell transplant. The second collection will occur on Day +6 after stem cell transplant and will be non-mobilized.
89287545|NCT06158815|No Intervention|control group|Participants in the control group will be placed on a waiting list without any intervention during the 6-week study period.
89287546|NCT06158815|Experimental|exercise group|Participants in the exercise group will have face-to-face Proprioceptive Neuromuscular Facilitation Exercises during the 6-week study period.
89287547|NCT06158789|Experimental|Focused ultrasound treatment group|
89287548|NCT06158763|Experimental|Experimental Group|In the experimental group, a web-based application intervention will be provided.
89287549|NCT06158763|No Intervention|Control Group|In the control group, the patients screened for depression or anxiety received treatment as usual (TAU). TAU consisted of standard care under the responsible family physician. TAU in low-income countries largely consists of pharmacological treatment with anti-depressant medication and follow-up in an outpatient clinic.
89287550|NCT06158750|Experimental|Test group|Patients can be included in the study if they meet all of the inclusion and none of the exclusion criteria and have provided written informed consent, intent to use Flow modulation device to treat intracranial aneurysm.
89287551|NCT06158737|Experimental|Experimental: JS010 injection|
89287552|NCT06158737|Placebo Comparator|Placebo|
89287553|NCT06158724||Simplified PPE group|Surgical mask, standard non sealing goggles, use of protective gown while in direct contact with patients.
89287554|NCT06158724||Standard COVID-19 PPE|"FFP2 mask, goggles and face shield, protective gown for COVID-19 ward.~FFP 3 mask or filter gas mask, sealing goggles, face shield or hazmat suit, protective gown, gloves and surgical cap."
89287555|NCT06158711||single drug group, two drugs group, three drugs group and four drugs group|single drug group, patients with heart failure only took one sort of drugs two drugs group, patients with heart failure took two sorts of drugs three drugs group, patients with heart failure took three sorts of drugs four drugs group, patients with heart failure took four sorts of drugs
89287556|NCT06158685|Active Comparator|control group|The control group subjects were applied with 15 sessions of conventional physiotherapy consisting of hotpack, ultrasound, and TENS.
89287557|NCT06158685|Experimental|study group|The study group subjects received 15 sessions of McKenzie hyperextension exercises in addition to the conventional physiotherapy program.
89287558|NCT06158672|Experimental|Emotional freedom technique group|Emotional freedom technique will be applied to menopausal women in the emotional freedom technique group.
89287559|NCT06158672|Placebo Comparator|Sham Emotional freedom technique group|Menopausal women in the sham emotional freedom technique group will receive sham emotional freedom technique.
89287560|NCT06158672|No Intervention|Control group|Menopausal women in the control group will not receive any intervention.
89287561|NCT06158646|Experimental|patients with kinematic aligned knee prosthesis|
89287562|NCT06158646|Active Comparator|patients with biomechanic aligned knee prosthesis|
89287563|NCT06158633||Active Intervention|All subjects will be in the active treatment group and receive the study intervention. The study intervention is Prevora.
89287564|NCT06158607|Experimental|Intervention|
89287565|NCT06158607|Active Comparator|Standard of care treatment|
89287566|NCT06158529|Active Comparator|spinal cord stimulation|
89287567|NCT06158529|Experimental|high frequency spinal cord stimulation|
89287568|NCT06158516|Experimental|Surufatinib|
89287569|NCT06158516|Placebo Comparator|Placebo|
89287570|NCT06158425||OA group|Data for consecutive OA patients with knee pain who underwent primary TKA by one senior surgeon between August 2021 and July 2023 at a single institution were analyzed retrospectively. A total of 273 patients underwent long-leg radiographs. The following 27 patients were excluded from this study: prior total hip arthroplasty, 2; obvious bony deficiency of the femur or tibia, 10; simultaneous flexion of the knee and rotation of the leg on radiographs, 15. CPAK distribution of the remaining 246 cases(unilateral, 15; bilateral, 231; totally 477 knees) was examined.
89287571|NCT06158425||healthy group|Data for consecutive visitors at outpatient clinic who underwent long-leg radiographs but without any sign of cartilage degeneration or medical history of low extremity between January 2023 and July 2023 at the same institution were analyzed retrospectively. A total of 136 visitors were recruited. The following 18 visitors were excluded from this study: extra-articular deformity of the femur or tibia, 15; simultaneous flexion of the knee and rotation of the leg on radiographs, 13; poor quality image, 1. CPAK distribution of the remaining 107 cases(214 knees) was examined.
89287572|NCT06158373|Experimental|Infant Massage Group|infant massage
89287573|NCT06158373|Experimental|Safe Swaddling Group|safe swaddling
89287574|NCT06158373|Sham Comparator|Control Group|control group
89287575|NCT06158347|Experimental|HBOT group|Hyperbaric oxygen therapy allows the patient to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied while gradually increasing the atmospheric pressure from normal atmospheric pressure to 1.5 atmospheres absolute (ATA). If the intensity acceptable to the clinical research subject is lower than 1.5 ATA, maintain it at the point acceptable to the research subject and record that value.
89287576|NCT06158347|No Intervention|control group|The control group will receive systemic education in dermal care and will be under the instruction of usual self-care.
89287577|NCT06158334||Minor and major surgeries of patients with haemophilia A treated with Elocta®|Description of all surgical data (minor and major) on Elocta® (all dosage and treatment regimens)
89287578|NCT06158334||Minor and major surgeries of patients with haemophilia B treated with Alprolix®|Description of all surgical data (minor and major) on Alprolix® (all dosage and treatment regimens)
89287579|NCT06158321|Sham Comparator|M1 or DLPFC sham stimulation|Participants will receive M1 or DLPFC sham stimulations.
89287580|NCT06158321|Experimental|M1 rTMS|Participants will receive high-frequency rTMS over M1.
89287581|NCT06158321|Experimental|DLPFC rTMS|Participants will receive low-frequency rTMS over DLPFC.
89287582|NCT06158308||Laparoscopic Appendicectomy|
89287583|NCT06158308||Open Appendicectomy|
89287584|NCT06158269|Experimental|DVRd group|Daratumumab combined with bortezomib, lenalidomide and dexamethasone
89287585|NCT06158243||0-2|children aged 0 to 2 years
89287586|NCT06158243||2-4|children aged 2 to 4 years
89287587|NCT06158243||4-6|children aged 4 to 6 years
89287588|NCT06158243||6-8|children aged 6 to 8 years
89287589|NCT06158243||8-10|children aged 8 to 10 years
89287590|NCT06158230|Active Comparator|Amitriptyline-Propranolol|"Combination of amitriptyline and propranolol.~Initial 2 weeks:~Amitriptyline 10 mg at bedtime Propranolol 20mg twice daily~Next 2 weeks:~Amitriptyline 25 mg at bedtime Propranolol 20mg three times daily~Next 8 weeks:~Amitriptyline 25 mg at bedtime Propranolol 40mg twice daily"
89287591|NCT06158230|Experimental|Pizotifen|"Pizotifen~Initial 2 weeks:~Pizotifen 0.5 mg at bedtime~Next 2 weeks:~Pizotifen 1 mg at bedtime~Next 8 weeks:~Pizotifen 1.5 mg at bedtime"
89287592|NCT06158191|Experimental|Intervention group|Lifestyle modification program focused on physical activity and diet. Diet recommendations in line with the AHA's guidelines focusing on foods rather than nutrients. Emphasis will be placed on awareness of the risk of overeating associated with the consumption of energy-dense foods (fat, added sugar or both). Dieticians will closely interact with participants and will not recommend a daily energy deficit greater than 500 kcal. Participants will have constant access to the dieticians and bi-monthly appointment will be required for the first year of the study to tailor recommendations to the participants. The physical activity/exercise component will be under the supervision of a kinesiologist and will aim at 160 minutes per week of moderate intensity endurance-exercise (mainly brisk walking) tailored to the participants' preferences and habits. Following the first year, participants will meet a dietician and a kinesiologist every month for the next two years (maintenance period).
89287593|NCT06158191|No Intervention|Control group|Usual behavior
89287594|NCT06158139|Experimental|CAR-T Cell Therapy|Single Arm Subjects with Refractory Pancreatic Ductal Adenocarcinoma (PDAC) cancer will receive iC9.CAR.B7-H3 T cells manufactured from their collected blood sample.
89287595|NCT06158087|Experimental|Test group|Patients can be included in the study if they meet all of the inclusion and none of the exclusion criteria and have provided written informed consent, intent to use pEGASUS stent system assisted to treat intracranial aneurysm.
89287596|NCT06158074|Experimental|EPNS group|
89287597|NCT06158074|Active Comparator|SNM group|
89287598|NCT06158061|Active Comparator|patient group|Patients with acne vulgaris ≥ 18 years old, both male and female patients will be included.
89287599|NCT06158061|Active Comparator|control group|healthy controls without acne vulgaris or other dermatological diseases like psoriasis, vitiligo, DLE
89287600|NCT06158048|Experimental|Norepinephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89287601|NCT06158048|Experimental|Phenylephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89287602|NCT06158035|Experimental|Norepinephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89287603|NCT06158035|Experimental|Phenylephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89287604|NCT06158022|Experimental|Norepinephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89287605|NCT06158022|Experimental|Phenylephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89287606|NCT06158009|Experimental|Norepinephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89287607|NCT06158009|Experimental|Phenylephrine group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89287608|NCT06157996|Experimental|Intensive treatment of lenvatinib and tislelizumab plus CapeOX chemotherapy|Efficacy of lenvatinib and tislelizumab plus CapeOX as first-line treatment
89287609|NCT06157996|Active Comparator|Conventional treatment of tislelizumab plus CapeOX chemotherapy|Efficacy of tislelizumab plus CapeOX as first-line treatment
89287610|NCT06157970||Block Group|After intubation, the plastic part of the 18G angioket is placed transnasally into both nostrils in the supine position of the patients who will undergo sphenopalatine ganglion block, with the head in 15-20° extension and is advanced until it contacts the posterior mucosa. After contact, withdraw 1 mm and apply 0.5% bupivacaine 2 ml by dropping into the postnasal space within 1 minute.
89287611|NCT06157970||Control Group|Group of patients who did not undergo sphenopalatine gangion block
89287612|NCT06157918|Experimental|Group 1-sequence ABC|Participants will sequentially receive SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A), followed by SYHA1813 oral solution (20ml:200mg) fasted (Treatment B), and SYHA1813 oral solution (2.0g:25mg) fed (Treatment C).
89287613|NCT06157918|Experimental|Group 2-sequence BCA|Participants will sequentially receive SYHA1813 oral solution (20ml:200mg) fasted (Treatment B), followed by SYHA1813 oral solution (2.0g:25mg) fed(Treatment C), and SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A).
89287614|NCT06157918|Experimental|Group 3-sequence CAB|Participants will sequentially receive SYHA1813 oral solution (2.0g:25mg) fed (Treatment C), followed by SYHA1813 oral solution (2.0g:25mg) fasted (Treatment A), and SYHA1813 oral solution (20ml:200mg) fasted (Treatment B).
89287615|NCT06157905|Experimental|Patients of Extensive alopecia areata|Patients of either gender, age between 18-60 years, having extensive alopecia areata (SALT>24)
89287616|NCT06157879|Experimental|WVI-MIS-01-2022|Healthy volunteers
89287617|NCT06157853|Active Comparator|Active Post-Procedure Cream|"Dosage Form: reverse emulsion (water in oil) cream containing bioactive ingredients, botanical actives, peptides, and antioxidants.~Frequency of Dosage: Twice daily (morning and evening). Subjects will be asked to massage 2 to 3 pumps of test material onto face, forehead, under eyes, cheeks, upper lips, chin, nose, and neck.~Study duration: 14 days. Active Post-Procedure Cream duration 7-days."
89287618|NCT06157853|Other|Comparator Anhydrous Cream|"Dosage Form: anhydrous cream containing peptides, and antioxidants.~Frequency of Dosage: Twice daily (morning and evening). Subjects will be asked to massage 2 to 3 pumps of test material onto face, forehead, under eyes, cheeks, upper lips, chin, nose, and neck.~Study duration: 14 days. Comparator Anhydrous Cream duration 7-days."
89287619|NCT06157814|Experimental|STOMA Care|Patients and the caregivers accessing the full MORE program on the secured Website. The patients and caregivers will be instructed on how to complete the 1 week (or upon discharge) and 4 week surveys via REDCap or through the RC. This group has additional requirements in the 4-week survey to assess the helpfulness of the Stoma Care app.
89287620|NCT06157814|Active Comparator|Usual Care|Patients and caregivers will NOT be given access to the web-based app and outpatient clinic will provide ostomy care if requested by all patients with ostomies per their regular care.
89287621|NCT06157775||Healthy Individuals|
89287622|NCT06157762|Experimental|ESPB performed by surgeon|The transverse process of the vertebra will be observed by the surgeon intraoperatively. Local anesthetic medication will be applied between the transverse process and the ESP muscle group.
89287623|NCT06157762|Active Comparator|Erector spinae plane block|The ultrasound-guided erector spinae plane block will be applied preoperatively.
89287624|NCT06157723||Knee osteoarthritis participants|Participants who are registered in the Health system electronic database, with a clinical and radiographic diagnostic of knee osteoarthritis. Approximately a total of 400 participants will be enrolled in the study.
88805740|NCT00147446|Experimental|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
89287625|NCT06157710|Experimental|Procrastinate digital programme|"8-week unternet-based CBT for procrastination~Behavioural Module: Introduction~Behavioural Module: Goal setting techniques~Behavioural Module: Motivation~Behavioural Module: Barriers to action~Behavioural Module: Managing maladaptive thoughts and beliefs~Behavioural Module: Value clarification~Behavioural Module: Moving forward"
89287626|NCT06157710|No Intervention|Waitlist control|"Wait-list control group. They do not receive the weekly modules though they are asked to complete 4-week and 8-week online surveys.~They will be allowed to revive the intervention after 8 weeks."
89287627|NCT06157684|Experimental|Postprandial Ambulation|Participants are counseled to walk for 20 minutes within 2 hours following meals daily.
89287628|NCT06157684|No Intervention|Routine exercise counseling|Participants are counseled on routine ADA recommendations for 30 minutes of low-impact exercise 5 times a week
89287629|NCT06157645|No Intervention|Group A|"Good preparation of the patient preoperative~Performing an opening in the skin surrounding the stoma 3-4 mm from the muco-cutaneous junctions.~Separate the bowel loop away from its attachment to the abdomen wall.~Cut out a rim of 0.3-0.4 cm of scarred bowel edges exposes healthful tissue.~Avoid any spillage or soiling~Closing of bowel defect can be made by double layer of 3-0 vicryl interrupted.~Once the tissue is of poor quality for simply closing, we expand the incision in the abdomen wall and resect a section. An end-to-end anastomosis is created using the conventional 2-layers suture method.~Reduction of the bowel into the abdomen are carried out.~irrigation the surgical field with a dilute anti-biotics or antiseptics and closure of the defect by continuous sutures using vicryl or prolene sutures~Closure of the wound"
89287630|NCT06157645|Experimental|Group B|"Good preparation of the patient preoperative~Performing an opening in the skin surrounding the stoma 3-4 mm from the muco-cutaneous junctions.~Separate the bowel loop away from its attachment to the abdomen wall.~Cut out a rim of 0.3-0.4 cm of scarred bowel edges exposes healthful tissue.~Avoid any spillage or soiling~Closing of bowel defect can be made by double layer of 3-0 vicryl interrupted.~Once the tissue is of poor quality for simply closing, we expand the incision in the abdomen wall and resect a section. An end-to-end anastomosis is created using the conventional 2-layers suture method.~Reduction of the bowel into the abdomen are carried out.~irrigation the surgical field with a dilute anti-biotics or antiseptics and closure of the defect by continuous sutures using vicryl or prolene sutures~mesh is simply fixed over the defect as a tension-free patch (onlay)~Closure of the wound"
89287631|NCT06157632|Other|Patients with thyoid nodules|Patients with thyroid nodules that will do thyroidectomy
89287632|NCT06157619||Formulation of Vitrification medium #1|Hydroxypropyl cellulose (HPC), Ethylene glycol, Dimethyl sulfoxide (DMSO) y trehalose
89287633|NCT06157619||Formulation of Vitrification medium #2|Human serum albumin (HSA), Ethylene glycol, Dimethyl sulfoxide (DMSO) & sucrose
89287634|NCT06157593|Experimental|NAVA|
89287635|NCT06157593|No Intervention|SIMV|
89287636|NCT06157580|Other|History of a preeclampsia|Women who had preeclampsia in their most recent pregnancy
89287637|NCT06157580|Other|History of a healthy pregnancy|Women who had an uncomplicated pregnancy
89287638|NCT06157554|Experimental|Intervention group|Respiratory exercises will be applied in addition to conventional treatment for frozen shoulder patients.
89287639|NCT06157554|Other|Control Group|For frozen shoulder patients, 15 conventional treatment programs will be applied.
89287640|NCT06157528|Experimental|ovarian endometriomas|Patients received a single dose of 1OOmg abarelix injection with slow absorption, Cmax of (43.4±32.3)ng/mL, Tmax of (3.0±2.9) days. AUC0-∞ is (500 ±96) ng·d/mL, t1/2 is (13.2±3.2) days, CL/F is (208±48) L/d
89287641|NCT06152861|Experimental|Travoprost Ophthalmic Topical Cream low-dose|Travoprost Ophthalmic Topical Cream low-dose administered once-daily in the evening for 28 days
89287642|NCT06152861|Experimental|Travoprost Ophthalmic Topical Cream mid-dose|Travoprost Ophthalmic Topical Cream mid-dose administered once-daily in the evening for 28 days
89287643|NCT06152861|Experimental|Travoprost Ophthalmic Topical Cream high-dose|Travoprost Ophthalmic Topical Cream high-dose administered once-daily in the evening for 28 days
89287644|NCT06152861|Active Comparator|Timolol maleate ophthalmic solution, 0.5%|Timolol maleate ophthalmic solution, 0.5% administered twice daily, morning and evening, for 28 days
89287645|NCT06152861|Active Comparator|Travoprost ophthalmic solution, 0.004%|Travoprost ophthalmic solution, 0.004% administered once daily in the evening for 28 days
89287646|NCT06152406|Active Comparator|Right Ventricular Only Pacing|All study participants will have an RV lead inserted, but this arm will have an RV lead only.
89287647|NCT06152406|Other|HIS Bundle Pacing|Participants in this group will have HIS bundle pacing, but in addition will have an RV lead inserted that will serve as a backup alternative in the event HIS bundle pacing is not effective.
89287648|NCT06152211|Experimental|Choir|For each choir session, the choir director will be supported by an accompanist who will provide the music accompaniment for the songs and four section leaders who will provide musical leadership for choral sections (soprano, alto tenor & bass). At the beginning of each choir group, participants will be asked about their favorite songs to help ensure that the music will be appropriate for the participants' interest and cultural background. Each choir group will rehearse once a week for two hours with a short break in the middle for snacks for a total of 16 consecutive weeks. The choir rehearsals will follow a general routine, beginning with announcements and warm-ups, work on the repertoire, a break, additional work on the repertoire in sections, and a short group practice at the end. Participants will also be given at-home activities, in the form of pre-recorded videos and music theory exercises to complete outside of class for an estimated 1.5 hours per week.
89287649|NCT06152211|Active Comparator|Music Listening|Over the course of 16-weeks, the group will meet for two hours per week to talk about a set of musical recordings. Recorded music will be previously assigned and provided as a playlist via a web platform to track the time duration of engagement. Regular attendance will be required. The discussion group will meet as a full group each week to listen to a subset of that week's recordings, with a guided and brief discussion after each of the six selected songs. The group will then pause for a brief break and will divide into four smaller discussion groups where a volunteer facilitator from that group would guide a discussion about the selected music, to include personal reflections, its cultural context, and ideas around societal impacts.
89287650|NCT06151782|Active Comparator|Wheat gluten|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
89287651|NCT06151782|Experimental|Barley gluten|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
89287652|NCT06151782|Experimental|Low dose barley gluten|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
89287653|NCT06151782|Experimental|Low dose hydrolyzed barley gluten|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
89287654|NCT06150976|Experimental|MAAT-YS Group|This group will be treated with the MAAT-YS cognitive-behavioral therapy.
89287655|NCT06150430|Experimental|Training with APO|All participants are assigned to the training group with the APO
89287656|NCT06150105||sprint-trained|Sprint-trained athletes: 6 male and 6 female, aged average 15 y.,
89287657|NCT06150105||endurance-trained|Endurance-trained athletes: 6 male and 6 female, aged average 15 y.,
89287658|NCT06147986|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of ST-elevation Myocardial Infarction.
89287659|NCT06147986|Other|standard treatment|Standard-of-care for ST-elevation Myocardial Infarction
89287660|NCT06147167|Experimental|indvidualized iTBS|In this arm of the study, participants undergo individualized intermittent theta burst stimulation (iTBS) subsequent to encephalography (EEG) testing. Three electrodes are strategically positioned on the first dorsal interosseous (FDI) hotspot to record the resting theta frequency, which is subsequently utilized as the theta frequency for theta burst stimulation (TBS). The participants receive this treatment regimen once daily, five times a week, over a total duration of three weeks.
89287661|NCT06147167|Active Comparator|standard iTBS|In this particular arm of the study, participants also undergo an initial electroencephalography (EEG) procedure. Subsequently, intermittent theta burst stimulation (iTBS) is administered using the standard theta burst stimulation frequency of 5Hz. The participants receive this treatment once daily, five times a week, over a total duration of three weeks.
89287662|NCT06147167|Sham Comparator|sham iTBS|In this arm, the treatment procedure is similar to the standard iTBS unless the coil is perpendicular to the scalp.
89287663|NCT06144164|Experimental|Participants with Breast Cancer|Participants will have a diagnosis of breast cancer and may undergo axillary lymph node dissection.
89287664|NCT06132880|Experimental|Intervention group|Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip quaquedie (QD) for 10 days.
89287665|NCT06132880|Other|Control group|Conventional therapy of acute ischemic stroke after based on Chinese guidelines.
89287666|NCT06127043|Experimental|Rosnilimab SC Dose 1|This arm will receive High dose Rosnilimab SC
89287667|NCT06127043|Experimental|Rosnilimab SC Dose 2|This arm will receive low dose Rosnilimab SC
89287668|NCT06127043|Placebo Comparator|Placebo|This arm will receive Placebo SC
89287669|NCT06125535||Hypoinflammatory|By means of latent class analysis, a sub-phenotype of LUTX recipients with down-regulated inflammatory biomarkers
89287670|NCT06125535||Hyperinflammatory|By means of latent class analysis, a sub-phenotype of LUTX recipients with up-regulated inflammatory biomarkers
89287671|NCT06114875|No Intervention|Control|Half of RallyPoint's active users will comprise the control group. The control group will not be shown the intervention flags and will see posts displayed as usual.
89287672|NCT06114875|Experimental|Intervention|Participants will not be actively recruited for this intervention. Rather, about half of active RallyPoint users (approximately 40,000 users; 80,000 users total) will be randomized to see the Intervention #1 psychoeducational pop-ups. The investigators will work with RallyPoint collaborators who will only display the distress flags to participants in the intervention group. RallyPoint users will not see flags appear on their own concerning posts, if they make any. The intervention will last up to six months (i.e., flags will be visible on concerning posts made over a six month period).
89287673|NCT06114849|Active Comparator|Control|Participants will be identified using a machine learning risk algorithm developed by the investigators that will automatically identify concerning posts (e.g., those mentioning suicidal thoughts or behaviors). RallyPoint members whose posts are flagged will randomly be assigned to the intervention group or the control group.
89287674|NCT06114849|Experimental|Intervention|Participants will be identified using a machine learning risk algorithm developed by the investigators that will automatically identify concerning posts (e.g., those mentioning suicidal thoughts or behaviors). RallyPoint members whose posts are flagged will randomly be assigned to the intervention group or the control group.
89287675|NCT06111651|Experimental|Intervention|parents will participate in a multicomponent parenting intervention
89287676|NCT06111651|No Intervention|Control|parents will receive information about healthy eating habits
89287677|NCT06111131|Active Comparator|Ancora-SB Overtube|Enteroscopy with Ancora-SB Balloon Overtube
89287678|NCT06111131|Active Comparator|Olympus ST-SB1 Overtube|Enteroscopy with Olympus ST-SB1 Overtube
89287679|NCT06110754|Experimental|I-STRONG for SCD|Adolescents with sickle cell disease and their parents participating in a multi-component intervention that includes mind-body, cognitive-behavioral, and neuromuscular movement training.
89287680|NCT06108011|Experimental|Lollipop|Given lollipop 6 hours after operation, sucking of lollipop at least 20mins every 4 hours after operation until feeding is resumed.
89287681|NCT06108011|No Intervention|No Lollipop|No placebo would be given
89287682|NCT06107582||Pediatric Primary Immune Thrombocytopenia|Immune thrombocytopenia (ITP) : defined according to the international working group criteria
89287683|NCT06106737||previous calculation formula|
89287684|NCT06106737||modified calculation formula|
89287685|NCT06106204|Experimental|ROAD Home Intervention|Hospitals randomized to receive the ROAD Home Intervention will receive an implementation intervention that includes external facilitation to support them in selecting and implementing evidence-based antibiotic stewardship strategies based on local context and the ROAD Home framework (https://academic.oup.com/cid/article/74/9/1696/6374407).
89287686|NCT06106204|No Intervention|Stewardship as Usual|Hospitals randomized to the control group will continue usual antibiotic stewardship activities. Although control hospitals are part of the HMS collaborative, during the intervention period they will not receive any of the ROAD Home Intervention components including analysis of their baseline data or needs assessment, customized suite of stewardship strategies, supported decision-making in selecting ROAD Home strategies to implement, an implementation blueprint, adaptable stewardship tools, or external facilitation from study investigators.
89287687|NCT06094881|Experimental|Intervention (Obinutuzumab)|60 enrolled subjects: one infusion
89287688|NCT06085573||Dexmedetomidine Hydrochloride|"Pediatric patients (1 month to < 18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation of non-intubated pediatric patients for non-invasive procedures and tests"
89287689|NCT06085313|Experimental|CAI: Web App-based, individualized coaching and support program for cancer pain|Web App-based information and coaching/support program for cancer pain management with the individual optimization functionality
89287690|NCT06085313|Active Comparator|CAPA: Web App-based information and coaching/support program for cancer pain|Web App-based information and coaching/support program for cancer pain management
89287691|NCT06078475|Active Comparator|Group M-TAPA (Modified Perichondral Approach Thoracoabdominal Nerve block group)|In group M-TAPA, M-TAPA block will be performed with patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine(Buvasin %5 flakon) (total 40 ml for both sides) will be injected bilaterally.
89287692|NCT06078475|Active Comparator|Group C (Control group)|In the control group, analgesics will be administered according to the protocol in postoperative analgesia management.
89287693|NCT06077331|Experimental|HS-10374 Dose 1|
89287694|NCT06077331|Experimental|HS-10374 Dose 2|
89287695|NCT06077331|Active Comparator|Placebo|
89287696|NCT06071884|Experimental|Bridge Percutaneous Nerve Field Stimulator|The case group (n = 15) will receive an activated Bridge device after surgery and continuing wearing the device until post-operative day (POD) 7.
89287697|NCT06070194|Experimental|Time restricted eating (TRE)|Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks.
89287698|NCT06070194|No Intervention|Habitual eating duration|Subjects randomized to this arm will be asked to continue habitual eating duration of >14h/day for 4 weeks.
89287699|NCT06066996|Experimental|Transdermal Nicotine Patch|Participants assigned to this condition will receive a blinded nicotine patch and will wear the patch on their upper arm, per the manufacturer's instructions.
89287700|NCT06066996|Placebo Comparator|Transdermal Placebo Patch|Participants assigned to this placebo nicotine patch condition will receive a blinded patch containing 0mg of nicotine, and will wear the patch on their upper arm, per the manufacturer's instructions.
89287701|NCT06066996|No Intervention|No Patch|Participants assigned to this condition will not receive a patch.
89287702|NCT06064110|Experimental|Intervention arm|
89287703|NCT06052098|Experimental|Transbronchial group|Subjects receive bronchoscopy-guided RFA and undergo follow-up.
89287704|NCT06052098|Experimental|Transthoracic group|Subjects receive CT-guided RFA and undergo follow-up.
89287705|NCT06038240|Experimental|Savoring Meditation|A 4-session meditation intervention in which participants are trained to generate positive emotional states and focus their awareness on those states throughout the meditation.
89287706|NCT06038240|Other|Pain Self-Management and Education|Education Control
89287707|NCT06035081|Experimental|Prednisolone first, then placebo|Prednisolone 12.5 mg twice daily for 5 days. Placebo twice daily for 5 days
89287708|NCT06035081|Experimental|Placebo first, then prednisolone|Placebo twice daily for 5 days Prednisolone 12.5 mg twice daily for 5 days.
89287709|NCT06034925|Active Comparator|Control|valganciclovir 900mg once daily
88805741|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
89287710|NCT06034925|Experimental|Intervention|maribavir 400mg twice daily
89287711|NCT06031454|Experimental|Experimental 1|"All participants will receive the following oral doses of study drugs following an overnight fast in the fixed-sequence below:~Period 1: 1 × 15-mg Midazolam tablet ,1 ×20-mg omeprazole tablet ,1×10-mg rosuvastatin tablet~Period 2: 6 × 400-mg Leritrelvir tablet+1 × 15-mg Midazolam tablet, 1 ×20-mg omeprazole tablet ,1×10-mg rosuvastatin tablet"
89287712|NCT06031454|Experimental|Experimental 2|"All participants will receive the following oral doses of study drugs following an overnight fast in the fixed-sequence below:~Period 1: 1 × 400-mg Leritrelvir tablet~Period 2: 5 × 240-mg verapamil tablet+1 × 400-mg Leritrelvir tablet~Period 3: 8 × 600-mg rifampin capsule +1 × 400-mg Leritrelvir tablet"
89287713|NCT06029517|Other|Aim 1 - interview, focus group|Participants complete interviews over 60 minutes and attend focus groups over 90 minutes in support of intervention adaptation and refinement
89287714|NCT06029517|Experimental|Aim 2 - Indigenous SIPin|Participants receive the Indigenous SIPin intervention over 6 months, which includes in-person and/or virtual educational sessions weekly over 30 minutes for 12 weeks and text message communications BIW for 12 weeks and then monthly thereafter up to month 6.
89287715|NCT06029075|Experimental|"tACS Sham, tACS 10Hz, tACS 20Hz experimental order"|"tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns.~tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns."
89287716|NCT06029075|Experimental|"HD-tACS 20Hz, HD-tACS 10Hz, HD-tACS Sham experimental order"|"tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns.~tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns."
89287717|NCT06029075|Experimental|"HD-tACS 10Hz, HD-tACS 20Hz, HD-tACS Sham experimental order"|"tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns.~tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns."
89287718|NCT06029062|Experimental|tACS Sham, tACS 10Hz, tACS 20Hz|"tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns.~tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns."
89287719|NCT06029062|Experimental|HD-tACS 20Hz, HD-tACS 10Hz, HD-tACS Sham|"tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns.~tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns."
89287720|NCT06029062|Experimental|HD-tACS 10Hz, HD-tACS 20Hz, HD-tACS Sham|"tACS Sham is a temporary non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for up to 30 second, it is not designed to entrain neuronal activity into any external regulatory frequency patterns.~tACS 10Hz is a 10Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp or 20 or 40 minutes to entrain neuronal activity into 10Hz frequency patterns.~tACS 20Hz is a 20Hz non-invasive electrical stimulation that applies a weak oscillatory current to the brain through the scalp for 20 or 40 minutes to entrain neuronal activity into 20Hz frequency patterns."
89287721|NCT06028698|Experimental|Positive emotion music fatigue group|After mental fatigue inducement, participants will be instructed listening to music pieces for inducing positive emotion music.
89287722|NCT06028698|Placebo Comparator|Fatigue control group|After mental fatigue inducement, participants will be instructed to sit and relax for the same duration as intervention group.
89287723|NCT06028698|Placebo Comparator|No Fatigue positive emotion music group|participants will not be induced mental fatigue, but will be instructed listening to music pieces for inducing positive emotion music.
89287724|NCT06028698|No Intervention|No fatigue control group|participants will not be induced mental fatigue. Also, participants will not receive music intervention，just sit and relax.
89287725|NCT06024928|Experimental|Automated Insulin Delivery in the Basal Insulin Titration Phase|Participants will use Automated Insulin Delivery (AID) for 10 days in the Basal Insulin Titration (BIT) Phase. This group will then return to their original home therapy (basal insulin using pen) using the new setting in the Maintenance Phase (MP) with a blinded CGM. The total daily insulin (TDI) requirement during the BIT Phase will be translated to a basal insulin dose.
88805742|NCT01475305|Placebo Comparator|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
89287726|NCT06024928|No Intervention|Standard Care with Study Continuous Glucose Monitor|Participants will use a study Continuous Glucose Monitor (CGM) along with their original home therapy and will be contacted by a study physician as per standard care to adjust their insulin doses if needed. This group will then transition into a 10-day Maintenance Phase (MP) using a blinded CGM, where the basal dose will be maintained.
89287727|NCT06018883|Experimental|Ascorbate|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 900 mg/day, three times a day, orally.
89287728|NCT06018883|Other|Control|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
89287729|NCT06017388|Active Comparator|Control|The control group will simply receive a reading of the mystical experience suggestion without hypnosis.
89287730|NCT06017388|Experimental|Experiemental|The experiemental group will receive a suggestion of the mystical experience in hypnosis.
89287731|NCT06006884||Sequelae group|COVID-19 convalescents that recover from prior severe acute diseases requiring hospitalization and who will be at high risk of chronic lung sequelae (with an estimate of >50% having moderate to severe sequelae based on current literature)
89287732|NCT06006884||Recovery group|Age and gender matched individuals who had mild SARS-CoV-2 infection and experienced complete resolution of symptoms
88805743|NCT01475305|Experimental|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
89287733|NCT06005545|Active Comparator|Passive Ultrasonic Irrigation group (PUI)|Arm 1: Passive ultrasonic irrigation group (PUI); shaping up to WL with 25.06,
89287734|NCT06005545|Experimental|Endoclean group (EC)|Arm 2: Endoclean (EC) group; shaping up to WL with 20.06; EC application tip kept 3mm short of WL, irrigation protocol with NaOCl (sodium hypochlorite)
89287735|NCT06005545|Active Comparator|Conventional Group|Arm 3: Conventional group; shaping up to WL of 25.06, irrigation protocol with NaOCl (sodium hypochlorite)
89287736|NCT06005272||Cases|Recently pregnant women/people who have experienced baby loss during pregnancy, labour or shortly after birth between 20-28 weeks of pregnancy
89287737|NCT06005272||Controls|Individuals still pregnant at same gestational age
89287738|NCT06004219|Experimental|Peer Support Group|Patients will be asked to complete a health-related quality of life (HRQOL) survey at enrollment, 3 months, and end of the study. Participants will complete the VascuQoL-6 and PROMIS in several domains of HRQOL (including global physical function, global mental function, fatigue, depression, sleep disturbance, pain behavior, and social satisfaction). Each participant will complete the PROMIS CAT tool on an iPad App and the data will be stored in the secure REDCap
89287739|NCT06004219|No Intervention|Usual Care Group|Subjects in this group will not participate in the peer group.
89287740|NCT06003946|Experimental|Intervention group (BreLax)|BreLax: midwife-led antenatal education class
89287741|NCT06003946|Active Comparator|Control group (Standard care)|Midwife-led antenatal education class
89287742|NCT06003166|Experimental|4AP then placebo (Group A)|Subjects randomized to this group will receive the study drug (4AP) followed by the placebo.
89287743|NCT06003166|Experimental|Placebo then 4AP (Group B)|Subjects randomized to this group will receive the placebo first followed by the study drug (4AP)
89287744|NCT06002685|Experimental|Attachment and Biobehavioral Catch-up (ABC) program|The ABC program consists of 10 1 -hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic.
89287745|NCT06002685|Active Comparator|Home-Based Book-of-the-Week (HBOW) program|The HBOW program consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. A trained RA will utilize a standard set of questions to ask about the mother's and child's well-being.
89287746|NCT05996900|Active Comparator|TBS via direct electrical stimulation|
89287747|NCT05996900|Active Comparator|TBS via transcranial magnetic stimulation|
89287748|NCT05996900|Sham Comparator|Sham TBS via direct electrical stimulation|
89287749|NCT05996900|Sham Comparator|Sham TBS via transcranial magnetic stimulation|
88805744|NCT02103218|Experimental|Risky sex prevention|education, activities, empowerment, racial pride building
89287750|NCT05986552|Active Comparator|Individual Schema Therapy (IST)|IST will follow the revised protocol described by Arntz & van Genderen. In the first year, 2 sessions (of 50-60 minutes each) per week will be provided, with at least one day in between. In the second year, the frequency will be reduced to once a week for the first 6 months, for the next 3 months to once every two weeks, and for the last 3 months three (booster) sessions will be offered. Therapists need to be trained at least at the junior level of the Dutch ST Association, or of the International ST society (ISST), or having successfully completed the basic IST training and delivering the trial treatments under supervision of a recognized ST supervisor.
89287751|NCT05986552|Active Comparator|Combined Individual-Group Schema Therapy (IGST)|"In IGST individual sessions (45-60 min) are provided weekly in the first year, and once every 2 weeks in the first three quarters of the second year, after which 3 monthly booster sessions are offered. Group sessions take place once per week for 1.5 years. After 1.5 years, patients leave the group but continue with IST during the last .5 year. If slots are available, new patients can enter the ST group every 10 weeks.~GST is provided as semi-closed group format developed from the closed format as developed by Farrell & Shaw. IST is based on Arntz & van Genderen, with the addition that IST and GST are coordinated at weekly peer supervision meetings, and that problems related to the patient's participation in the group are put on the IST agenda.~GST therapists don't need to be IST therapist of their patients. The same training requirements hold as in the IST arm. Additionally, GST-therapists completed GST training and receive(d) at least 10 GST supervisions."
89287752|NCT05983432|Experimental|BL-B01D1 administered Day 1 and Day 8 per cycle|BL-B01D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks
89287753|NCT05983432|Experimental|BL-B01D1 administered Day 1 per cycle|BL-B01D1 will be administered on Day 1 via by intravenous infusion every 3 weeks
89287754|NCT05981469||Induction of labour|
89287755|NCT05980117|Experimental|Intervention|Patients assigned to the study group will receive Remimazolam.
89287756|NCT05980117|Active Comparator|Control|Patients assigned to the control group will receive Midazolam.
89287757|NCT05971407|Active Comparator|Remote Ischaemic Preconditioning|RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks.
89287758|NCT05971407|Sham Comparator|Sham remote ischaemic preconditioning|Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks
89287759|NCT05952180|Experimental|Virtual reality and Cycloergometer|The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.
89287760|NCT05952180|Active Comparator|Standard cycloergometer|"For the standard cycloergometer intervention, the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. No virtual reality is used. The session last 30 minutes in the participant's room"
89287761|NCT05952076|Experimental|Bi-26 supplementation|Bi-26 administered daily.
89287762|NCT05952076|Placebo Comparator|Placebo|Maltodextrin: Placebo administered daily
89287763|NCT05951023|Experimental|Eszopiclone|Subjects will be asked to take their study drugs nightly at bedtime and use their CPAP during sleep as much as possible
89287764|NCT05951023|Placebo Comparator|Placebo|Subjects will be asked to take their study drugs nightly at bedtime and use their CPAP during sleep as much as possible
89287765|NCT05949203||All participants|All participants will receive standard-of-care through the tele-PrEP program and home infusion pharmacy.
89287766|NCT05948748||Anxiety levels|pre-surgical anxiety levels in patients undergoing minimally invasive osteoarticular foot surgery
89287767|NCT05947838|Experimental|Circulating tumoral DNA directed neoadjuvant therapy arm|Participants will have their circulating tumoral DNA levels measured at the onset of neoadjuvant chemotherapy and during their neoadjuvant treatment to direct the duration of therapy provided.
89287768|NCT05945784||Minimal to moderate upper extremity deficits|"Individuals aged 18 years to 55 years.~Minimal to moderate upper extremity deficits, including but not limited to limited mobility or dexterity impairments.~Regular users of beauty products.~Able to understand and communicate in the language of the study."
89287769|NCT05942365|Experimental|The DDI of ZSP1273 ,Warfarin and Midazolam|Warfarin and midazolam will be co-administered alone and in combination with ZSP1273.
89287770|NCT05938712|Experimental|Semaglutide|Semaglutide Subcutaneous 0.25mg once weekly for 4 weeks, then 0.5mg once weekly for 4 weeks, then 1mg once weekly for 4 weeks.
89287771|NCT05938712|Experimental|Dapagliflozin|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
89287772|NCT05923229|Experimental|Mindfulness-Based Walking Therapy (MBWT)|Participants will receive the MBWT intervention.
89287773|NCT05923229|Placebo Comparator|Freezing of Gait (FOG) Education|Participants will receive educational materials about FOG and track their usual care.
89287774|NCT05923060|Experimental|Standard PDT + topical aminolevulinate + red light illumination|Standard PDT using topical aminolevulinate followed by red light illumination for actinic keratosis. A region of interest (ROI) on the skin of the arms, hands, legs, or feet will be selected for monitoring. This ROI will be marked and baseline measurements will be taken. The topical drug Levulan (ALA) will be applied to the ROI and other areas being treated, and covered with plastic wrap. Prior to red light illumination, post topical measurements and baseline values will be performed to measure PpIX and sO2. Red light illumination will follow, and sO2 phosphorescence will be recorded continuously from the ROI. After, a post-PpIX measurement will be taken.
89287775|NCT05907174|No Intervention|Enhanced Treatment as Usual (Healthcare Workers)|Monitoring of treatment as usual (i.e., routine interactions between healthcare workers and patients). Treatment as usual will be enhanced by providing healthcare workers with a substance use psychoeducation and screening training.
89287776|NCT05907174|Experimental|Siyakhana - P (Healthcare Workers)|Providers working with PRC. Siyakhana - P healthcare workers will also receive a substance use psychoeducation and screening training, and a workshop for healthcare workers to get to know the PRC and learn more about the PRC role.
89287777|NCT05907174|No Intervention|Enhanced Treatment as Usual (Patients)|Monitoring of treatment as usual (i.e., routine interactions between healthcare workers and patients). Treatment as usual will be enhanced by providing healthcare workers with a substance use psychoeducation and screening training.
89287778|NCT05907174|Experimental|Siyakhana - P (Patients)|Patients seen by the team of health care workers with an integrated PRC. Patients will have the opportunity to meet with the PRC for about 3-months after their baseline assessment. Siyakhana - P healthcare workers will also receive a substance use psychoeducation and screening training, and a workshop for healthcare workers to get to know the PRC and learn more about the PRC role.
89287779|NCT05896579|Experimental|COPD with pulmonary artery enlargement|Participants will complete testing to identify patterns of right ventricular dysfunction. If a participant decides to participate in the optional exercise training program, the participant will complete exercise training followed by repeat testing to determine the impact of exercise training on right ventricular dysfunction.
89287780|NCT05893459|Experimental|Debrief|Following exposure to a laboratory stressor, participants in this arm will debrief their experience with a friend for 5 minutes while their psychophysiological reactivity is recorded using an electrocardiogram (ECG). Their interaction will be audio and video recorded for later observational coding of their friend's validating and invalidating behaviors during the conversation.
89287781|NCT05893459|No Intervention|No Debrief|Following exposure to a laboratory stressor, participants in this arm will sit by themselves while their psychophysiological reactivity is recorded using an electrocardiogram (ECG).
89287782|NCT05872399||Physiotherapy students|The group will consist of Greek physiotherapy undergraduate students.
89287783|NCT05872243|Experimental|WMN group|Active rTMS will be delivered to the tailored stimulation site within the working memory network.
89287784|NCT05872243|Experimental|DMN group|Active rTMS will be delivered to the tailored stimulation site within the default mode network.
89287785|NCT05872243|Sham Comparator|sham WMN group|Sham rTMS will be delivered to the tailored stimulation site within the working memory network.
89287786|NCT05872243|Sham Comparator|sham DMN group|Sham rTMS will be delivered to the tailored stimulation site within the default mode network.
89287787|NCT05872191||Upper extremity functional impairment due to chronic stroke|Spanish-native speakers with functional impairment of the upper extremity after stroke in chronic phase.
89287788|NCT05870761|Experimental|Treatment (dostarlimab, niraparib)|Patients receive dostarlimab IV and niraparib PO on study. Patients also undergo MRI/CT and collection of blood samples throughout the trial.
89287789|NCT05862844|Experimental|The single-arm trial with a pre- and post-test design|The Intervention Arm in the Promise Women Project evaluates a specific educational intervention program for Muslim women to promote cervical cancer prevention. It involves a one-time, 90-minute culturally and religiously tailored educational session with 20 participants. The session covers perceived risks of Human Papilloma Virus (HPV) infection, cervical cancer, and benefits of early screening and vaccination. Pre- and post-intervention surveys measure changes in participants' knowledge. This experimental arm assesses the intervention's effects on knowledge and acceptance of cervical cancer prevention.
89287790|NCT05854836|Experimental|CHOICES-PLEAS|Participants in the experimental arm will receive the motivational interviewing intervention, CHOICES-PLEAS which consists of three one-on-one sessions and one family planning referral visit during incarceration and one booster session at one month after release from jail.
89287791|NCT05854836|No Intervention|Control condition|Participants in the active comparator will receive a control condition that consists of a booklet with general information about healthy lifestyle for women as well as a referral guide to local resources.
89287792|NCT05850455|Experimental|Group A|will receive local anesthesia with dexmedetomidine infusion
89287793|NCT05850455|Experimental|Group B|will receive epidural analgesia
89287794|NCT05850455|Experimental|Group Con|will receive general anesthesia
89287795|NCT05849727|Experimental|TQH3821 tablets 200 mg|Oral administration of TQH3821 tablets 200 mg, twice a day for 24 weeks.
89287796|NCT05849727|Placebo Comparator|TQH3821 tablets matching placebo|The placebo group was taken orally until the end of week 12. At the end of week 12, the placebo group was switched to the oral administration of TQH3821 tablets 200 mg until the end of week 24.
89287797|NCT05849168|Experimental|Veterans with respiratory symptoms|
89287798|NCT05848752|Experimental|Environmental Feature Experiment|
89287799|NCT05848089|Other|Treatment as usual (TAU) + EMA|Participants will receive TAU and be prompted to complete 4x/day smartphone-based EMA surveys of negative emotion and STBs.
88805745|NCT02103218|Active Comparator|Healthy behaviors|General health education, activities
88805746|NCT01451983||ASD with PTEN|Individuals with autism spectrum disorder who are also found to have a PTEN mutation.
88805747|NCT01451983||ASD no PTEN macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation with a large head circumference.
89287800|NCT05848089|Experimental|Experimental intervention + TAU|Participants will receive TAU plus 3 brief sessions of CBT skills, one discretionary post-discharge skills booster session, and 4x/day EMA and prompted EMI, which guides in-the-moment CBT skills practice.
89287801|NCT05842382|Experimental|IV Vitamin C (12g/day)|IV Vitamin C 3g diluted with dextrose 5% into 50ml, given every 6 hourly (12g/day), infused over 30 minutes under close monitoring, until successful extubation (minimum 16 doses, maximum 40 doses).
89287802|NCT05842382|Placebo Comparator|Placebo|IV dextrose 5% 50ml, given every 6 hourly, infused over 30 minutes under close monitoring, until successful extubation (minimum 16 doses, maximum 40 doses).
89287803|NCT05837819|Active Comparator|Active Lighting Intervention|Lighting intervention designed to effect the circadian system then will receive the control lighting intervention.
89287804|NCT05837819|Placebo Comparator|Control Lighting Intervention|Lighting intervention using low light levels designed to not effect the circadian system
89287805|NCT05834881|Experimental|CM combined with Vocational/educational Coaching from Coaches without Lived Experience|This group will receive contingency management (CM) combined with vocational/educational coaching from paraprofessional coaches without lived experience in community settings.
89287806|NCT05834881|Active Comparator|CM combined with Vocational/educational Coaching from Coaches with Lived Experience|This group will receive contingency management (CM) combined with vocational/educational coaching from paraprofessional coaches with lived experience in community settings.
89287807|NCT05832359|Experimental|Children diagnosed with childhood rheumatic disease|
89287808|NCT05832359|Experimental|Healthy children|
89287809|NCT05829733|Experimental|SYNOLIS VA 80/160|Single guided intra-articular injection of SYNOLIS VA 80/160
89287810|NCT05820906|Experimental|Cadonilimab+rego+Gem/Cis|
89287811|NCT05819476|Other|Part 1: Visit 1 (No treatment) followed by Visit 2 (OLP intervention)|In Part 1, participants will receive one injection (administration of open-label placebo injections without any active ingredient (5 ml 0.9% saline)) at twenty minutes after start of the experiment during the intervention visit 2. Visit 1 (No treatment) will be the control of the study intervention.
89287812|NCT05819476|Other|Part 1: Visit 1 (OLP intervention) followed by Visit 2 (No treatment)|In Part 1, participants will receive one injection (administration of open-label placebo injections without any active ingredient (5 ml 0.9% saline)) at twenty minutes after start of the experiment during the intervention visit 1. Visit 2 (No treatment) will be the control of the study intervention.
89287813|NCT05819476|Other|Part 2/ Group A: 1x OLP (Control)|In Part 2, the Group A (Control) receives just one single OLP injection and no repetition.
89287814|NCT05819476|Other|Part 2/ Group B: 2x OLP; booster time fixed|"In Part 2, Group B participants will receive two injections, the first at twenty minutes after start of the experiment, and the second at a time point derived from Part 1 (if data is inconclusive; at 100 minutes).~For every subsequent OLP administration, patients will be reminded of the inertness of the injection and that this injection might help with regulating pain."
89287815|NCT05819476|Other|Part 2/ Group C: 2x OLP; booster on- demand|"In Part 2, Group C participants will receive two injections, the first at twenty minutes after start of the experiment, and the second on demand.~For every subsequent OLP administration, patients will be reminded of the inertness of the injection and that this injection might help with regulating pain."
89287816|NCT05812118|No Intervention|Control group|Control group
89287817|NCT05812118|Experimental|Experimental group|Physical active learning intervention
89287818|NCT05798390||Bempedoic acid and/or fixed-dose combination with ezetimibe|Participants with primary hypercholesterolemia or mixed dyslipidemia who received bempedoic acid and/or its fixed-dose combination with ezetimibe.
89287819|NCT05796388|Sham Comparator|Sham VR|Patients in the sham Virtual Reality group will receive the same brand of head mounted device (Oculus Quest 2), but will only have access to sham content. Both groups will receive standard of care linaclotide treatment 290 mcg.
89287820|NCT05796388|Active Comparator|Immersive VR|Patients in the immersive Virtual Reality group will receive a head mounted VR device Oculus Quest 2, and will receive active immersive content. Both groups will receive standard of care linaclotide treatment 290 mcg.
89287821|NCT05786404|Experimental|Experimental: PRIM-DJ2727 - FROZEN|
89287822|NCT05786404|Experimental|Experimental: PRIM-DJ2727 - CAPSULES|
89287823|NCT05776836|Experimental|FASY|Subjects will be consecutively included to receive FASY F in cheeks and nasolabial folds and FASY P in periorbital areas.
89287824|NCT05755997|Other|Study group 1|Cerebrolysin - Placebo
89287825|NCT05755997|Other|Study group 2|Placebo - Cerebrolysin
89287826|NCT05754593|Experimental|MS patients|Diagnosis of multiple sclerosis based on McDonald Criteria 2017
89287827|NCT05754593|Active Comparator|Controls|Healthy controls
89287828|NCT05752305|Experimental|Methylprednisolone group|Preoperative administration of 40mg of methylprednisolone via submucosa
89287829|NCT05752305|Experimental|Dexamethasone group|Preoperative administration of 8mg of dexamethasone via submucosa
89287830|NCT05752110|Active Comparator|Ketamine|Received 0.5mg/kg IV single dose ketamine in addition to propofol and fentanyl anesthesia at induction period of anesthesia.
89287831|NCT05752110|Placebo Comparator|Control|Received 0.05ml/kg IV % 0.9 saline in addition to propofol and fentanyl anesthesia at induction period of anesthesia.
89287832|NCT05741892|Experimental|3D fracture reposition guide group|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
89287833|NCT05727644|Active Comparator|Participants with normal renal function|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
89287834|NCT05727644|Experimental|Participants with impaired renal function|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
89287835|NCT05709678|Placebo Comparator|Control|Group Education (General nutrition and sport nutrition)
89287836|NCT05709678|Active Comparator|Treatment|Group Education (General nutrition and sport nutrition with athlete testimonials on impacts of RED-S on health)
89287837|NCT05709639|Experimental|Responder|Increased carbohydrate intake (top 50%) vs moderate to regression in carbohydrate intake (lower 50%)
89287838|NCT05702879||Ulcerative colitis patients|Patients with a flare of ulcerative colitis who meet the inclusion criteria. 120 patients will be included.
89287839|NCT05702879||Controls|For each patient, enrollment of a healthy control individual who shares the same living conditions (e.g., spouse or roommate) is attempted
89287840|NCT05699551|Experimental|Exercise treatment group|This group will serve as both their own controls and study subjects for the experimental intervention. They will take surveys to record bladder symptoms and quality of life before undergoing exercise. They will then take the same surveys after exercise and their scores will be compared.
89287841|NCT05699239|Experimental|10 mg bid|Patients receive TS-172 10 mg bid.
89287842|NCT05699239|Experimental|30 mg bid|Patients receive TS-172 30 mg bid.
89287843|NCT05699239|Experimental|60 mg bid|Patients receive TS-172 60 mg bid.
89287844|NCT05699239|Experimental|20 mg tid|Patients receive TS-172 20 mg tid.
89287845|NCT05699239|Placebo Comparator|Placebo|Patients receive placebo.
89287846|NCT05696418|Experimental|Mobile Bearing Design TKA|Patients who were randomized to receive the PFC Sigma Mobile Bearing TKA system
89287847|NCT05696418|Experimental|Fixed Bearing Design TKA|Patients who were randomized to receive the PFC Sigma Fixed Bearing TKA system
89287848|NCT05695911|Experimental|Limb Load Biofeedback Training Intervention|The limb-load biofeedback training focuses on altering habitual movement patterns to promote proper prosthetic limb loading with an emphasis on between-limb loading symmetry. Participants randomized to the EXP group will receive 12 biofeedback training sessions (1 in-person, 11 telehealth) tapered over 40 weeks.
89287849|NCT05695911|Placebo Comparator|Attention Control Intervention|The CTL group intervention will include the same standard of care rehabilitation sessions as the EXP group and receive the same computer tablets for telehealth sessions as the EXP group. The CTL group will also have attention control educational sessions at the same frequency, timing, and duration as the EXP group limb-load biofeedback sessions (12 total sessions) with the first session being an in-person session at the Week 24. There will be no biofeedback training intervention in the CTL group. As such, there will be no behavioral intervention or wearable sensors provided to the CTL group. The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group.
89287852|NCT05683756|Active Comparator|Brief Parent Behavioral Intervention|A brief parent behavioral intervention with evidenced based strategies for treatment of ADHD.
89287853|NCT05683756|Experimental|Sleep-Focused Parent Behavioral Intervention|A modified version of the brief parent behavioral intervention that specifically targets sleep disrupting behaviors.
89287854|NCT05682365|Experimental|prevANS intervention|In this arm, participants will receive an online personalized intervention to prevent anxiety disorders based on a risk predictive algorithm (predictA).
89287855|NCT05682365|No Intervention|Control group|In this arm, participants will continue receiving the usual care from their health providers. However, they will not receive any intervention, but they will fill out the same questionnaires as in the intervention group.
89287856|NCT05680012|Experimental|Gluten challenge group|Diagnosis of celiac disease by intestinal biopsy and serology for at least 12 months
89287857|NCT05680012|No Intervention|Gluten de-challenge group|Suspected celiac disease either showing typical symptoms or positive celiac disease serology
89287858|NCT05680012|No Intervention|Control group|No history or symptoms of celiac disease
89287859|NCT05662384||Patients hospitalized with small bowel obstruction|Patients hospitalized with a certain diagnosis during a certain period of time
89287860|NCT05657548||Child with Cerebral Palsy|Children and adolescents from 4 to 17 years old with cerebral palsy GMFCS III, IV or V followed in the Physical Medicine and Rehabilitation Department, Children's Rehabilitation Unit of the University Hospital of Nîmes (Carémeau Hospital)
89287861|NCT05648097|No Intervention|Standard of Care|Patients exposed to a patient with COVID-19 isolated at the site - standard of care
89287862|NCT05648097|Active Comparator|Baldachin-Intervention|Patients exposed to a patient with COVID-19 isolated at the site - under Baldachin
89287863|NCT05628376||Cohort A|300 participants with early stage resectable I-IIIB NSCLC
89287864|NCT05628376||Cohort B|200 participants with unresectable late stage IIIB-IIIC or de novo metastatic (stage IV) NSCLC.
89287865|NCT05628376||Cohort C|50-100 participants with stage I-IV SCLC or pleural mesothelioma.
89287866|NCT05618431|Other|pregnant women|Pregnant woman 18 and 50 years oldbetween 10 and 40 weeks of pregnancy
89287867|NCT05602779|Experimental|tVNS Program|Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.
89287868|NCT05602779|Experimental|Phone App Program|Adolescents will use a specially designed phone app to communicate with peers to help them cope with emotions, and to foster connection with peers to establish social connections. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey. The phone app will not be monitored during the night. If your adolescent needs immediate care during the night, please call 911 or your doctor's emergency contact number.
89287869|NCT05602779|Experimental|tVNS and Phone App Program|Adolescents will self-administer 30-minute tVNS (i.e., nerve stimulation) sessions daily for 30 days. They will receive a daily text message on their phone to remind them about their session. In addition, they will answer a 2-3 minute self-report survey on their current thoughts, feelings, and behaviors once a day for 30 days. They will receive a text message with a link to Qualtrics, a secure online platform where they will complete the survey.
89287870|NCT05602779|Sham Comparator|Enhanced Treatment as Usual|Enhanced TAU participants will be referred to and have access to available services within the community and, in addition to reports of their daily experiences via the sham app, will be called weekly to complete risk assessments during the active 30-day intervention stage.
89287871|NCT05600452|Active Comparator|Traditional heat acclimation|The traditional heat acclimation programme will consist of daily 75-minute heat exposures for eight consecutive days
89287872|NCT05600452|Experimental|Condensed heat acclimation|The condensed heat acclimation programme will consist of two consecutive days with four, 75-minute heat exposures undertaken on each day
89287873|NCT05576194||TauroPace irrigation group|every consecutive CIED placement, revision, extraction conducted with TauroPace
89287874|NCT05576194||antiseptic irrigation group|every procedure conducted with adjunct antiseptic irrigation, which could be Taurolidine, TauroPace or Hydrogen Peroxide 3%
89287875|NCT05574413|Placebo Comparator|Resting (no exercise) control|Resting (no exercise) control condition
89287876|NCT05574413|Experimental|Moderate intensity continuous exercise (MICE)|Experimental session involving an acute bout of moderate intensity continuous exercise (MICE; continous cycling expending 350 kcal at 70% of lactate threshold)
89287877|NCT05574413|Experimental|High intensity continuous exercise (HICE)|Experimental session involving an acute bout of high intensity continuous exercise (HICE; continuous cycling expending 350 kcal at 10% of the difference between lactate threshold and VO2peak)
89287878|NCT05574413|Experimental|High intensity interval exercise (HIIT)|Experimental session involving an acute bout of high intensity interval exercise (HIIT; cycling intervals expending 350 kcal at 10% of the difference between lactate threshold and VO2peak)
89287879|NCT05568914|Experimental|Assessments|"In this single-arm trial, each participant undergoes the following measurements/assessments:~Physical: Body weight (before and after dialysis), length Biophysical: NRS2002, GLIM, Bio-electrical Impedance Analysis Metabolic: Indirect Calorimetry Nutritional: dietary anamnesis, 3-days nutritional diary"
89287880|NCT05563298|Active Comparator|Active Neuro Rx Device|The active device will deliver light for the 20 minutes session duration.
89287881|NCT05563298|Sham Comparator|Sham Neuro Rx Device|The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
89287882|NCT05562323||MKP vaccination for pre-exposure prophylaxis (HIV positive)|HIV positive individuals who receive MKP vaccination for pre-exposure prophylaxis
89287883|NCT05562323||MKP vaccination for pre-exposure prophylaxis (seronegative individuals)|HIV seronegative individuals who receive MKP vaccination for pre-exposure prophylaxis
89287884|NCT05555355|Placebo Comparator|Group 1 (control)|Retrospective control of patients who did not use Prevena following spine surgery.
89287885|NCT05555355|Active Comparator|Group 2 (Prevena)|Prospective group of patients receiving spine surgery who will have Prevena applied to incision area.
89287886|NCT05554549||UK Biobank|UK Biobank. There are no interventions in this observational cohort study.
89287887|NCT05551780|Experimental|SoundBite Crossing System - PAD|Use of the SoundBite Crossing System to cross calcified chronic total occlusions (above-the-knee or below-the-knee)
89287888|NCT05551780|Experimental|SoundBite Crossing System - BTK|Use of the SoundBite Crossing System to cross calcified chronic total occlusions (below-the-knee)
89287889|NCT05541211|Active Comparator|Coeliac plexus neurolysis (CPN)|Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).
89287890|NCT05541211|Experimental|Splanchnic nerve neurolysis (SNN)|Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
89287891|NCT05539534|Experimental|Training|This is a one-arm trial. The intervention group receives a training on suicide prevention.
89287892|NCT05532943|Experimental|UMSC01|UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis.
89287893|NCT05532943|Sham Comparator|Placebo|For IV administration, normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis. For IT administration, sham puncture procedure will partially penetrate without reaching subarachnoid space, and no spinal fluid will be drawn.
89287894|NCT05532722|Experimental|ABC008 Dose Level 1 Cohort|"0.25 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
89287895|NCT05532722|Experimental|ABC008 Dose Level 2 Cohort|"0.75 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
89287896|NCT05532722|Experimental|ABC008 Dose Level 3 Cohort|"1.5 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
89287897|NCT05532722|Experimental|ABC008 Dose Level 4 Cohort|"3.0 mg / kg ABC008 Subjects receive ABC008 every 8 weeks OR 1.5 mg / kg Subjects receive ABC008 every 4 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
89287898|NCT05532722|Experimental|ABC008 Dose Level 5 Cohort|"3.0 mg / kg ABC008 Subjects receive ABC008 every 4 weeks.~Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose."
89287899|NCT05530499|Experimental|Almond|Participants in this group will be instructed to consume 57 grams of whole almonds every day for six weeks.
89287900|NCT05530499|Active Comparator|Cookie|Participants in this group will be instructed to consume cookies equivalent to the energy content of 57 grams of whole almonds every day for six weeks.
89287901|NCT05515718|Active Comparator|Standard pain management|"Patients receive a standard analgesic treatment, in accordance with the latest international guidelines :~if pain EN is ≥ 3: Paracetamol 1g every 6 hours (age <75 years) or every 8 hours (# 75 years) and/or Tramadol 50 mg every 8 hours ;~and/or if verbal EN for pain is ≥ 7: intravenous morphine titration according to local protocol: 3 mg bolus if weight > 60 kg and age ≤ 80 years; Bolus of 2 mg if weight ≤ 60 kg and age ≤ 80 years ; Bolus of 1 mg if age>80 years, regardless of weight ; This bolus is repeated every 5 minutes until an EN≤ 3 is obtained."
89287902|NCT05515718|Experimental|Femoral nerve block|"Patients receive a standard analgesic treatment, in accordance with the latest international guidelines 5,13,45: - if pain EN is ≥ 3:~Paracetamol 1g every 6 hours (age <75 years) or every 8 hours (# 75 years) and/or Tramadol 50 mg every 8 hours; - and/or if verbal EN for pain is ≥ 7: intravenous morphine titration according to local protocol: 3 mg bolus if weight > 60 kg and age ≤ 80 years; Bolus of 2 mg if weight ≤ 60 kg and age ≤ 80 years ; Bolus of 1 mg if age>80 years, regardless of weight ; This bolus is repeated every 5 minutes until an EN≤ 3 is obtained."
89287903|NCT05513274|Experimental|Pain Psychology Neuroscience+ Written Emotional Disclosure|Pain Neuroscience Education exercise followed by Written Emotional Disclosure
89287904|NCT05513274|Active Comparator|Pain Psychology Neuroscience + Healthy Habits Disclosure|Pain Neuroscience Education followed by Healthy Habits writing
89287905|NCT05513274|Active Comparator|Health Behavior + Written Emotional Disclosure|Health behavior education followed by written emotional disclosure
89287906|NCT05513274|Placebo Comparator|Health Behavior + Healthy Habits Disclosure|Health behavior intervention followed by healthy habits writing
89287907|NCT05489406|Active Comparator|Single-dose DTG 30 mg|Healthy volunteers receiving a single-dose DTG 30 mg as 6X5 mg dispersible tablets (DT) as a dispersed suspension in a fasted state. Samples will be taken pre-dose (t=0) and 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, and 48 hours post ingestion.
89287908|NCT05489406|Active Comparator|Single-dose F/TAF 180/22.5 mg|Healthy volunteers receiving a single-dose F/TAF 180/22.5 mg as 3X60/7.5 mg TOS as a dispersed suspension in a fasted state. Samples will be taken pre-dose (t=0) and 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, and 48 hours post ingestion.
89287909|NCT05489406|Experimental|Single-dose DTG 30 mg and F/TAF 180/22.5 mg|Healthy volunteers receiving a single-dose F/TAF 180/22.5 mg as 3X60/7.5 mg TOS + DTG 30 mg as 6X5 mg DT as a co-dispersed suspension in a fasted state. Samples will be taken pre-dose (t=0) and 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, and 48 hours post ingestion.
89287910|NCT05488509|Experimental|20mg THC|Participants will inhale vapor from .17 grams of cannabis containing 11.86% THC (20mg THC total).
89287911|NCT05488509|Experimental|40mg THC|Participants will inhale vapor from .34 grams of cannabis containing 11.86% THC (40mg THC total).
89287912|NCT05488509|Placebo Comparator|Placebo|Participants will inhale vapor from a placebo product.
89287913|NCT05486689|Experimental|Standard Program|Pulmonary Rehabilitation
89287914|NCT05480930|Active Comparator|paper-based clinical decision support tool|Providers at the TMDS will use the existing paper-based clinical decision support tools to consult/examine patients.
89287915|NCT05480930|Experimental|digital clinical decision support (dCDS) tool|Providers at the TMDS will use the new digital clinical decision support (dCDS) tool to consult/examine patients.
89287916|NCT05478902|Experimental|Exercise Therapy|"This group will receive the Shape Up My Shoulders (SUMS) protocol and it will be led by a physiotherapist trained in therapeutic exercise. It will last 12 weeks and it will be divided in 3 stages.~Stage I- Early-stage rehabilitation exercises (i.e., breathing and relaxation exercises, ball rolling exercises, hand gripping exercises, mental imagery and contralateral side exercises) and Shoulder Symptom Modification Procedure (SSMP). This stage typically lasts 1 to 2 weeks.~Stage II - Isometric, eccentric and heavy slow resistance exercises. The final part of Stage II is a progression from eccentric only to eccentric and concentric contractions.~Stage III - Functional program. This stage starts in week 5 or 6 and progressed to week 12. Involves pushing, pulling, throwing, lifting, carrying, and precision (sensory-motor control) exercises."
89287917|NCT05478902|Active Comparator|Extracorporeal Shockwave Therapy|This group will receive high energy Extracorporeal Shockwave Therapy (ESWT) applied by an experienced physiotherapist. ESWT will be applied on the most tender point of the shoulder, located by palpation. The dose will be 1500 impulses per session without anaesthesia and an intensity between 0.15 and 0.30 mJ/mm2 depending on patient tolerance. A total of 4 treatment sessions (1 session per week) with 1 week of rest between sessions will be implemented. Patient's position during the treatment will be seated in supine position with shoulder hyperextension and internal rotation with the hand placed below the contralateral glute with the palm touching the table.
89287918|NCT05478902|Active Comparator|Ultrasound-Guided Percutaneous Irrigation|This intervention will be performed by an experienced interventionist radiologist in two sessions. The shoulder position will be with hyperextension and internal rotation with the hand behind the back. One 20 mL syringe with saline solution, one with an anaesthetic with 20 mg/mL of mepivacaine 2% and another syringe with a corticoid injection with 40 mg/mL of triamcinolone acetonide will be prepared before the intervention. Firstly, the anaesthetic will be injected directed to the calcification. Then, the procedure will consist of injecting saline solution and aspiring the calcific deposits until it is neither possible to aspire more inside the syringe nor to detect any calcifications with ultrasound imaging. After that, a corticoid will be injected to the bursa to prevent the appearance of subacromial bursitis. Finally, an anaesthetic will be injected during the extraction of the needle.
89287919|NCT05478902|No Intervention|Wait and Watch group|The wait and see group will not receive any intervention and will serve as a control group to determine the natural history of RCCT. If one treatment proves to be more effective then participants in the other groups will be offered that treatment after 12 months, or before, if the investigation finishes early due to an obvious group difference and a need to break randomisation codes.
89287920|NCT05470881|Experimental|PRO-201|A total of 29 anticipated healthy volunteers will be exposed to the investigation product.
89287921|NCT05467774|Experimental|Training group|Participants receive 24 sessions of operant H-reflex conditioning of the rectus femoris.
88805748|NCT01451983||ASD no PTEN no macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation without a large head circumference.
88805749|NCT01451983||Siblings|Siblings of individuals with autism spectrum disorders.
88805750|NCT01391299|Active Comparator|botulinum toxin Type A (40 Units)|Botulinum toxin Type A 40 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
88805751|NCT01391299|Active Comparator|botulinum toxin Type A (30 Units)|Botulinum toxin Type A 30 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
88805752|NCT01391299|Placebo Comparator|placebo (Normal saline)|Placebo (Normal saline) injected into bilateral forehead and frown line areas on Day 1.
88805753|NCT02099084|Experimental|Teduglutide First, then Placebo|Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days, followed by a 14-day washout period, and placebo administered subcutaneously for 7 days.
88805754|NCT02099084|Placebo Comparator|Placebo First, then Teduglutide|Placebo administered subcutaneously for 7 days, followed by a 14-day washout period, and Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days.
88805755|NCT02099786|Experimental|COMP-VA|Hearing testing at each treatment and at 1 month following treatment.
88805756|NCT02099786|Experimental|Usual Care|Hearing testing done according to Audiology Clinic protocol
88805757|NCT02100410|Experimental|Iteration 2-87-1|Delefilcon A toric contact lenses T1 and T2 worn contralaterally (1 in each eye) for approximately 30 minutes
89287922|NCT05463250|Experimental|Smart Watch, then no intervention|Physicians will be asked to wear a Smartwatch for 6 months, and then will be monitored for the following 6 months without wearing a Smartwatch. Physicians will complete surveys about their experiences
89287923|NCT05463250|Experimental|No intervention, then Smart Watch|Physicians will be monitored for the first 6 months without wearing a Smartwatch, and then will be asked to wear a Smartwatch for the following 6 months. Physicians will complete surveys about their experiences
89287924|NCT05441384|Experimental|CBT/Existential Group Therapy for Fear of Cancer Recurrence|Participants will receive 7 weekly group therapy sessions consisting of psychoeducation on fear of cancer recurrence, relaxation training, CBT, and evidenced-based tips to decrease avoidance and anxiety surrounding fear of cancer recurrence.
89287925|NCT05441384|No Intervention|Wait-list Control Group|Participants assigned to this arm wait about 3-months to receive the intervention.
89287926|NCT05440188||COPD|Patients over 65 years old diagnosed with COPD in GOLD II state or higher who uses Breath Detect Platform for monitoring their respiratory health status.
89287927|NCT05439330|Experimental|Application of a dental-dedicated MRI|MRI of conditions related to teeth and surrounding structures
89287928|NCT05429658|Experimental|Thrombectomy|Aspiration of clot with large bore catheter in acute ischemic stroke patients
89287929|NCT05423444|Experimental|Trauma-focused cognitive behavioral therapy (TF-CBT)|Trauma-focused Cognitive Behavioral Therapy (TF-CBT) is an evidence-based psychotherapy that is considered the gold-standard treatment for trauma in youth. The TF-CBT model is flexible but it follows a specific order of phases and components, including psychoeducation, emotion regulation skills, processing the trauma narrative, and safety planning. Sessions are provided weekly for 18-weeks.
89287930|NCT05423444|Active Comparator|Treatment As Usual (TAU)|Treatment as usual (TAU) consists of the standard-of-care psychotherapy as provided by licensed clinicians at a local clinic. The order and choice of techniques is based on the knowledge and preferences of the clinicians. Sessions are provided weekly for 18-weeks.
89287931|NCT05422144|Experimental|Treatment|Antimicrobial Skin & Wound Cleanser and Antimicrobial Wound gel will be subsequently administered to the wound during the 28 day study duration.
89287932|NCT05421676|Experimental|FETO with GOLDBAL2|A balloon will be placed in the airway of the fetus during the FETO procedure.
89287933|NCT05416905|Experimental|STN-DBS|The patients in this group will be treated with STN-DBS.
89287934|NCT05416905|Active Comparator|GPi-DBS|The patients in this group will be treated with GPi-DBS.
89287935|NCT05412602|Experimental|Intervention|experimental group will receive 36 chiropractic treatments designed to correct vertebral subluxation over ~12 weeks
89287936|NCT05412602|No Intervention|waitlist control|waitlist control will receive no chiropractic interventions and will be reminded that to successfully complete their condition, they do not seek alternative chiropractic treatments
89287937|NCT05409287|Experimental|Immediate Implant Loading|A provisional single implant crown will be mounted on an implant, placed 16 weeks post tooth extraction, immediately after implant placement. Occlusion will be adjusted, so that there is no occlusal contact with the 8 µm Shim Stock foil (Hanel Shim Stock Foil; Coltène/Whaledent AG, Altsätten, Switzerland), but contact with 40µm occlusion foil (Hanel Articulating Paper, Coltène/Whaledent AG, Altsätten, Switzerland) during static occlusion. All dynamic contacts will be eliminated by intraoral grinding with a diamond bur, and the occlusal surface will be polished afterward. The screw access channel will be sealed by a Teflon strip and a provisional light-polymerizing resin (Telio CS, Ivoclar Vivadent AG, Schaan, Liechtenstein). In case of a mini-flap on the buccal aspect, the flaps will then be sutured around the implant healing cap or the implant provisional with single interrupted sutures. Finally, a periapical radiograph will be taken, using the customized x-ray tray.
89287938|NCT05409287|Active Comparator|Early Implant Loading|A provisional single implant crown will be mounted on an implant, placed 16 weeks post tooth extraction, 4 weeks after implant placement. Occlusion will be adjusted, so that there is no occlusal contact with the 8 µm Shim Stock foil (Hanel Shim Stock Foil; Coltène/Whaledent AG, Altsätten, Switzerland), but contact with 40µm occlusion foil (Hanel Articulating Paper, Coltène/Whaledent AG, Altsätten, Switzerland) during static occlusion. All dynamic contacts will be eliminated by intraoral grinding with a diamond bur, and the occlusal surface will be polished afterward. The screw access channel will be sealed by a Teflon strip and a provisional light-polymerizing resin (Telio CS, Ivoclar Vivadent AG, Schaan, Liechtenstein). In case of a mini-flap on the buccal aspect, the flaps will then be sutured around the implant healing cap or the implant provisional with single interrupted sutures. Finally, a periapical radiograph will be taken, using the customized x-ray tray.
89287939|NCT05404373|Placebo Comparator|Low flow oxygen group|patients were randomized into the Low flow oxygen group and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
89287940|NCT05404373|Experimental|NBO group (2h)|patients were randomized into the NBO group (2h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 2 hours.
89287941|NCT05404373|Experimental|NBO group (4h)|patients were randomized into the NBO group (4h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
89287942|NCT05404373|Experimental|NBO group (6h)|patients were randomized into the NBO group (6h) and immediately given 100% oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 10L/ min using a oxygen storage mask and keep giving oxygen for 6 hours.
89287943|NCT05394493||patients with advanced renal cell carcinoma|
88805758|NCT02100410|Experimental|Iteration 2-87-2|Delefilcon A toric contact lenses T3 and T4 worn contralaterally (1 in each eye) for approximately 30 minutes
88805759|NCT02100410|Experimental|Iteration 2-87-3|Delefilcon A toric contact lenses T5 and T6 worn contralaterally (1 in each eye) for approximately 30 minutes
88805760|NCT01477567|Experimental|0.3 mg LY3009385|LY3009385: 0.3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
88805761|NCT01477567|Experimental|1 mg LY3009385|LY3009385: 1 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
88805762|NCT01477567|Experimental|3 mg LY3009385|LY3009385: 3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
88805763|NCT01477567|Experimental|9 mg LY3009385|LY3009385: 9 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
88805764|NCT01477567|Experimental|22 mg LY3009385|LY3009385: 22 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
88805765|NCT01477567|Experimental|54 mg LY3009385|LY3009385: 54 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
89287944|NCT05393232|Experimental|Dietitian-Assisted DASH groceries|Participants will order groceries sufficient to meet their caloric needs each week for 12 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions. During the remainder of the study (months 4-12), participants will be asked to apply what they learned without the provision of groceries.
89287945|NCT05393232|Active Comparator|Self-directed shopping (referent assignment)|Participants will receive a monthly stipend over a 3 month period and some basic information about healthy eating. The stipend is not restricted to foods. During the remainder of the study (months 4-12), participants will be asked to continue their typical shopping without the provision of the monthly stipend.
89287946|NCT05390580|Experimental|Stimulation with Transcutaneous Auricular Vagal Nerve Stimulator|All patients will be fitted with the device, the investigator will attach adhesive contacts to the left ear. Stimulation sessions will occur for 20 minutes twice daily during the inpatient period, the investigator will stimulate the auricular branch of the vagus nerve. Patients' will be treated with the following parameters: frequency 20 Hz, pulse width 250 µm, and and a fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation.
89287947|NCT05390580|Sham Comparator|Control - Transcutaneous Auricular Vagal Nerve Stimulator - Sham|All patients will be fitted with the device, the investigator will attach adhesive contacts to the left ear. Stimulation sessions will occur for 20 minutes twice daily during the inpatient period. Patients assigned to the controls arm will have electricity applied to the the great auricular nerve (cervical nerve branch), the lobule of the ear. The investigator will stimulate the lobule of the ear. Patients' will be treated with the following parameters: frequency 20 Hz, pulse width 250 µm, and and a fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation.
89287948|NCT05385913||"Placebo"|AB high group; SUVR >1.11
89287949|NCT05385913||"Treatment"|AB low group; SUVR ≤1.11
89287950|NCT05385913||Study Partners|Each participant will also have a stud partner that will be enrolled.
89287951|NCT05364099|Experimental|Suprascapular Nerve Block in Participants with Spinal Cord Injuries (SCI) Group|Participants in this group will receive standard of care (SOC) suprascapular nerve block using a mixture of Lidocaine and Triamcinolone.
89287952|NCT05358821|Experimental|SAGE-718|Participants will receive SAGE-718 1.2 mg softgel lipid capsule orally once daily in the morning for up to 28 days.
89287953|NCT05358821|Placebo Comparator|Placebo|Participants will receive SAGE-718-matching placebo capsule orally once daily in the morning for up to 28 days.
89287954|NCT05355025|Experimental|Intervention|Participants will be provided with a personal login code for the study web portal via automated email and encouraged to complete the initial components of the intervention which seek to determine participants' current support and management strategies and help them to understand their specific antidepressants. They will then complete the third component which contains three sub-sections to assist in creating a personal plan to help them cease their ADs: i) Management strategies for withdrawal symptoms and opportunities to discuss the plan with their GP or trusted Mental health worker; ii) Selecting a start time to begin tapering; iii) Print out of the personalised action plan to keep and share with supportive family and/or friends. Participants will also be required to complete a daily check-in through the portal which will check current symptoms and highlight any negative changes in emotional wellbeing, they will also receive texts reminders to complete these tasks.
89287955|NCT05355025|Experimental|Usual care - Attention Control|Participants allocated to the treatment as usual group will receive usual care plus attention control which comprises a link to the AD factsheet within the BeyondBlue website. This provides education material relevant to the participants' enrolment in the study but they will not be advised to cease or continue with their medication. GPs will not be advised of the participants allocated to this treatment arm.
89287956|NCT05344326|Experimental|CAT-GSH|Participants, who provide informed consent, will be provided an assessment session, six fortnightly CAT-GSH sessions, and one follow-up session.
89287957|NCT05340478||AF-CBT|Adjunctive Family -CBT for family members of Veterans with anxiety
89287958|NCT05334901|Experimental|High intensity light cure|High intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
89287959|NCT05334901|Active Comparator|Low intensity light cure|Conventional light curing (1200 mw/cm2) for long exposure time (20 seconds) to achieve the slower rate of conversion allowing for a better flow of the material, which decreases contraction stress in the filling material
89287960|NCT05332145|Experimental|Intervention development and testing|"Phase 1 participants (N=12) will complete the MAP to Health online interview and rate the ease of use, usefulness, intention to use, and theoretical fidelity of the intervention.~Phase 2 participants (N=35) will participate in a proof-of-concept pilot trial via a double-pretest single group design. Participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 week period."
89287961|NCT05331456|Other|Alveolar cleft repair using autologous bone from the mandibular symphysis|Control group
89287962|NCT05331456|Other|Alveolar cleft repair using a biphasic clacium phosphate putty|Study group
89287963|NCT05318287|Experimental|PeriGrief|A brief four-module intervention delivered via computer or mobile device. Modules utilize mindfulness and cognitive behavioral therapy strategies to reduce distress following perinatal loss.
88805766|NCT01477567|Placebo Comparator|Placebo|Placebo: saline, subcutaneous (SC) injection, single dose on Day 1
88805767|NCT01391611|Experimental|Pazopanib arm|
88805768|NCT00281918|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
89287964|NCT05316922|Experimental|TSH suppression during irradiation|"From 14 days beforehand and throughout their RT, patients in the experimental arm will receive L-thyroxine in the morning, starting with 1-2 μg/kg, and adjusting the dose every 3 days to ensure TSH < 0.3 μIU/mL before RT beginning. The 0.3 μIU/mL threshold is just below normal range not causing hyperthyroidism, and is defined as mild TSH suppression. Based on hormone status, L-thyroxine doses will be gradually increased to patients' individual minimum TSH-suppressive dose before starting RT, maintained throughout the treatment, then rapidly tapered off and stopped. During radiation treatment course will be checked twice a week for serum FT3, FT4, TSH assays in order to maintain TSH < 0.3 μIU/mL, possibly without exceeding normal levels of FT3 and FT4. Once a week patients will also have a full visit and any other blood examination according to protocol in use and Institutional practice."
89287965|NCT05316922|No Intervention|Any TSH suppression during irradiation|Patient in the standard arm will perform radiotherapy treatment without any TSH suppression. At the end of radiation they will do serum FT3, FT4, TSH assay and then, after one year from RT, thyroid ultrasound + serum FT3, FT4, TSH assay.
89287966|NCT05310799|No Intervention|Current Best Practice|"Physicians randomized to this arm will provide current care and treatment decisions with patients will be made in accordance with current best practices. Will not engage in structured shared decision making (SDM) discussion and will not have access to PERSON-JIA Reports.~Patients will be consented to enroll in the CAPRI Registry at the clinic visit when they are diagnosed. Registry enrollment will allow collection and input of clinical data into the Registry.~Clinic visit and discussion will remain unchanged for physicians, patients and their families. Questionnaires will be collected at enrollment, at the second visit and a 6-month and 12-month follow-up visits."
89287967|NCT05310799|Experimental|Shared Decision Making (SDM)|"Physicians will use the PERSON-JIA Report to guide discussions with the newly diagnosed patient and family. The intervention will not dictate the use of specific medications or treatment strategies, only facilitate better informed treatment choices according to patient circumstances.~The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis. Discussion is guided by the PERSON-JIA Report, which is generated in real time, on the physician's smart phone.~Patients newly-diagnosed with JIA will be consented to both enrollment in the CAPRI Registry and enrollment in the PERSON-JIA trial.~Clinic visit and discussion between the physician, patient and family will be facilitated by the PERSON-JIA report to support a shared decision making process. Questionnaires will be collected at enrollment, at the second visit and at 6-month and 12-month follow-up visits."
89287968|NCT05297838|Active Comparator|Ice Bath then VR and Bike During Ice Bath (Ice Bath vs VR Bike)|"Participants will immerse hand in ice bath and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first, while utilizing a VR headset. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.~After a washout period of 5 minutes, patients will immerse hand in ice bath keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first, while utilizing a VR headset.Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.~This occurred for both dominant and non-dominant hand. Randomization of dominant and non-dominant hands to the study conditions occurred prior to initiating the intervention."
89287969|NCT05297838|Active Comparator|VR with Ice Bath then Bike with VR During Ice Bath (VR vs VR Bike)|"Patients will immerse hand in ice bath keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first, while utilizing a VR headset.Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.~After a washout period of 5 minutes, Participants will immerse hand in ice bath while utilizing stationary bike and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first, while utilizing a VR headset. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.~This occurred for both dominant and non-dominant hand. Randomization of dominant and non-dominant hands to the study conditions occurred prior to initiating the intervention."
89287970|NCT05286983||K0 - baseline cohort|45 preterm infants and their parents (average number of patient admissions per 6 months during the last 5 years)
89287971|NCT05286983||K1 - 1st intervention cohort|All preterm infants and their parents enrolled during the first 6 months period after completion of the baseline cohort and who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287972|NCT05286983||K2 - 2nd intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287973|NCT05286983||K3 - 3rd intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287974|NCT05286983||K4 - 4th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
88805769|NCT00281918|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
88805770|NCT00201734|Experimental|Arm I|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, carboplatin IV over 1-2 hours on day 1, and capecitabine PO BID on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88805771|NCT01898468|Active Comparator|Intracostal Closure Technique|Closure involves drilling four evenly spaced holes using a 5-mm bit attached to the end of a Stryker drill into the bed of the sixth rib.
88805772|NCT01898468|Active Comparator|Pericostal Closure Technique|Closure involves placing sutures around the ribs in the standard pericostal fashion
88805773|NCT04752956|Active Comparator|Grup1|Nasal steroid spray only (NS) (Each dose contains 27.5 micrograms of fluticasone furoate; administered single dose per day as 1 puff through both nostrils)
88805774|NCT04752956|Active Comparator|Grup 2|NS + administered ambient temperature normal saline (NSS) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (NSS; 0,09% NaCl, pH:4-5)
89287975|NCT05286983||K5 - 5th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287976|NCT05286983||K6 - 6th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287977|NCT05286983||K7 - 7th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287978|NCT05286983||K8 - 8th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287979|NCT05286983||K9 - 9th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287980|NCT05286983||K10 - 10th intervention cohort|All preterm infants and their parents enrolled during the 6 months period after the previous 6 months period who are treated according to prespecified Family Centred Care interventions implemented as Potentially Better Practices.
89287981|NCT05267132|Experimental|Kindness to Others with Reflection|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others and will also complete a reflection component. They will be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day. At the end of each intervention week, they will be asked to reflect upon their experience of performing kind acts for others.
89287982|NCT05267132|Active Comparator|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They will be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
89287983|NCT05267132|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
89287984|NCT05262517|Experimental|BHV3000 (rimegepant)|One dose of rimegepant 75 mg ODT
89287985|NCT05262517|Placebo Comparator|Matching Placebo|One dose of matching placebo
89287986|NCT05261126|Experimental|MK-0616 6 mg|Participants will receive 6 mg of MK-0616 orally QD for 8 weeks
89287987|NCT05261126|Experimental|MK-0616 12 mg|Participants will receive 12 mg of MK-0616 orally QD for 8 weeks
89287988|NCT05261126|Experimental|MK-0616 18 mg|Participants will receive 18 mg of MK-0616 orally QD for 8 weeks
89287989|NCT05261126|Experimental|MK-0616 30 mg|Participants will receive 30 mg of MK-0616 orally QD for 8 weeks
89287990|NCT05261126|Placebo Comparator|Placebo|Participants will receive MK-0616-matching placebo orally QD for 8 weeks
89287991|NCT05258448||COLA 1: Locally advanced non-small-cell lung cancer|Patients with locally advanced non-small-cell lung cancer treated with radiotherapy alone or in combination with chemotherapy with curative intent. Patients are included before initiation of the treatment. A Cardiac MR and ECG are performed at the beginning of the treatment, and at 6, 12, and 24 months after radiotherapy.
89287992|NCT05258448||COLA 2 Locally advanced non-small-cell lung cancer|Patients with locally advanced non-small-cell lung cancer treated with radiotherapy alone or in combination with chemotherapy with curative intent. Patients not included in COLA 1 cohort are offered one cardiac MR and ECG between 12-24 months after radiotherapy treatment.
89287993|NCT05247203|Experimental|Telitacicept Arm 1|Telitacicept 80mg, once a week for 24 weeks plus standard therapy
89287994|NCT05247203|Experimental|Telitacicept Arm 2|Telitacicept 160mg, once a week for 24 weeks plus standard therapy
89287995|NCT05247203|Experimental|Telitacicept Arm 3|Telitacicept 160mg, once a week for 12 weeks followed by once every two weeks for another 12 weeks plus standard therapy
89287996|NCT05247203|Experimental|Telitacicept Arm 4|Telitacicept 240mg, once a week for 24 weeks plus standard therapy
89287997|NCT05247203|Experimental|Telitacicept Arm 5|Telitacicept 240mg, once every two weeks for 24 weeks plus standard therapy
89287998|NCT05245006|Experimental|Cohort A: 89Zr-DFO-YS5|Participants receive one dose of 89Zr-DFO-YS5 up to 3 millicurie (mCi), and undergo a whole body PET performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total. The optimized scan time will be used for imaging in cohorts B and C. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
89287999|NCT05245006|Experimental|Cohort B: 89Zr-DFO-YS5, YS5 antibody|Participants receive either a 20mg or 50mg dose of YS5 prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a single whole body PET scan at the optimal time determined in Cohort A. The optimal dose of unmodified YS5 antibody will be used in the following cohorts C & D. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
89288000|NCT05245006|Experimental|Cohort C: 89Zr-DFO-YS5, Optimal dose YS5 antibody|Participants receive optimal dose of YS5 antibody prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a single whole body PET scan at the optimal time determined in Cohort A. Participants have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
89288001|NCT05245006|Experimental|Cohort D: 89Zr-DFO-YS5, Optimal dose YS5 antibody, Multiple Scans|Participants will receive optimal dose of YS5 prior to imaging and administration of one dose of up to 3 millicurie (mCi) 89Zr-DFO-YS5 and then complete a series of whole body PET scans performed at 1-4 hours, approximately 20-28 hours, 48-96 hours, and 120-168 hours post injection for up to 4 scans total. Participants in have the option to receive a repeat 89Zr-DFO-YS5 PET at the time of disease progression.
89288002|NCT05235659|Experimental|Condition 1|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
89288003|NCT05235659|Experimental|Condition 2|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
89288004|NCT05235659|Experimental|Condition 3|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
89288005|NCT05235659|Experimental|Condition 4|"Component 1 (Watch out!): off, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
89288006|NCT05235659|Experimental|Condition 5|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
89288007|NCT05235659|Experimental|Condition 6|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
89288008|NCT05235659|Experimental|Condition 7|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
89288009|NCT05235659|Experimental|Condition 8|"Component 1 (Watch out!): off, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
89288010|NCT05235659|Experimental|Condition 9|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
89288011|NCT05235659|Experimental|Condition 10|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
89288012|NCT05235659|Experimental|Condition 11|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
89288013|NCT05235659|Experimental|Condition 12|"Component 1 (Watch out!): on, Component 2 (You are safe here): off, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
89288014|NCT05235659|Experimental|Condition 13|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): off"
89288015|NCT05235659|Experimental|Condition 14|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): off, Component 4 (My coach): on"
89288016|NCT05235659|Experimental|Condition 15|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): off"
89288017|NCT05235659|Experimental|Condition 16|"Component 1 (Watch out!): on, Component 2 (You are safe here): on, Component 3 (Who am I and where do I belong?): on, Component 4 (My coach): on"
89288018|NCT05234632|Experimental|PICO 14 Any Wound|Any wound treated with PICO 14. For closed Surgical incisions this will be for 14 days post surgery and with a 30 day follow up. For chronic and dehisced wounds this will be for up to 28 days therapy and no follow-up.
89288019|NCT05234632|Experimental|PICO 14 Closed Incisions|Any Closed incision treated with PICO 14, for closed Surgical incisions this will be for 14 days post-surgery and with a 30 day follow up.
89288020|NCT05234632|Experimental|PICO 14 Chronic/Dehisced Surgical Wounds|Any Chronic/Dehisced Surgical wound treated with PICO 14, for chronic and dehisced wounds this will be for up to 28 days therapy and no follow-up.
89288021|NCT05231265||Patients with Low Back Pain|
89288022|NCT05225688||PASC patients|Non-hospitalized covid-19 patients with Post-acute Sequelae of COVID-19
89288023|NCT05225688||Healthy controls|Non-hospitalized covid-19 patients without residual symptoms
89288024|NCT05225688||ME/CFS patients|Patients with ME/CFS
89288025|NCT05224063|Experimental|Individualized CEN-targeted rTMS|Individualized CEN-targeted rTMS will combine neuronavigated rTMS and single pulse TMS-EEG to identify the region of the dlPFC making the strongest connection with the parietal node of the CEN. First, regions of the dlPFC strongly connected to the parietal CEN will be identified by applying single TMS pulses in grid-like fashion to ROIs within the dlPFC. For each anatomical dlPFC subunit probed with TMS, the TMS-EEG response will be quantified in the parietal region of the CEN. The dlPFC subunit that demonstrates the strongest TMS-EEG response in parietal cortex will be chosen for rTMS. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
89288026|NCT05224063|Active Comparator|Neuronavigated rTMS|Neuronavigated rTMS will be delivered using neuro-navigation based on participants' own MRI images to target the dlPFC. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
89288027|NCT05224063|Active Comparator|Scalp-targeted rTMS|Scalp-targeted rTMS will be delivered using standard BEAM F3 targeting methodology to target the dlPFC. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
89288028|NCT05224063|Sham Comparator|Sham rTMS|Sham rTMS will be delivered for one session to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
89288029|NCT05217680|Experimental|PRO-169|Bevacizumab 1.25 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
89288030|NCT05217680|Active Comparator|Lucentis ®|Ranibizumab 0.5 mg / 0.05mL for intravitreal injection. All patients in this arm will be exposed to one monthly injection for the first four months. During the rest of the study, during the monthly visits, it will be decided if injections are to be continued or postponed. The maximum amount of intravitreal injections to be administered are 12.
89288031|NCT05210374|Experimental|DSF/Cu|"A 3+3 dose escalation design will be used to determine the recommended phase 2 dose (RP2D) of DSF/Cu in combination with liposomal doxorubicin. There will be a 7 day lead-in week of Disulfiram (DSF)/Copper Gluconate (Cu). The disulfiram and the copper gluconate will be dosed once a day. Disulfiram in the morning and copper gluconate in the evening. Same total daily dose every 4 week (28 days) administration of liposomal doxorubicin (Doxil) 30mg/m2/dose IV~Cycle length: 28 days Maximum 12 cycles"
89288032|NCT05189769|Experimental|CP/No REACT|Traditional Coping Power for 7th graders, no school wide REACT training
89288033|NCT05189769|Experimental|CP/REACT|Traditional Coping Power for 7th graders and school wide REACT training
89288034|NCT05189769|Experimental|CP+/No REACT|New, adapted Coping Power for 7th graders intervention with no school wide REACT training
89288035|NCT05189769|Experimental|CP+/REACT|New, adapted Coping Power for 7th graders, school wide REACT training
89288036|NCT05188287|Experimental|HealthyCells|"The HealthyCells app will have the following features:~Smoking status assessments with facial recognition: Participants will initiate a smoking status assessment and CO breath sample submission using the iCOquit® Smokerlyzer® TWICE per day. To verify the participant's identity while they complete their CO breath sample, we will use Microsoft Face API.~Daily step counter and sedentary behavior prompts: A Google OS smartwatch will be used to monitor participants' activity, and the HealthyCells app will deliver an activity prompt when they have been sedentary for 30 minutes, which will be experienced as noise and vibration on the phone and watch. Also, a text-based reminder message will appear on the phone and watch along with a personalized tip for reducing sedentary time.~Motivational messages for smoking cessation and physical activity. TWICE per day, the HealthyCells app will send messages to encourage users to remain quit and become more active."
89288037|NCT05180591|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
89288038|NCT05180591|Placebo Comparator|Saline Injection|2 placebo injections spaced 4 weeks apart at the beginning of the trial
89288039|NCT05179083|Experimental|High-impact Exercise|
89288040|NCT05179083|Active Comparator|Low-impact Exercise|
89288041|NCT05172934|Experimental|Intra-arterial Tenecteplase|Participants will receive intra-arterial Tenecteplase after achieving mTICI 2b or 2c reperfusion with standard of care MT.
89288042|NCT05166811|Active Comparator|75 mg/kg|Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 75 mg/kg arm, this will be accomplished by mixing 37.5 mL of IVMg (80 mg/mL) with 2.5 mL of sterile water for a final concentration of 75 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
89288043|NCT05166811|Active Comparator|50 mg/kg|Doses for each IVMg arm will be prepared in identical manner, by drawing a specified volume of IVMg from the commercial container using sterile technique and mixing in a polyvinylchloride container with a specified volume of sterile water. For the 50 mg/kg arm, this will be accomplished by mixing 25 mL of IVMg (80 mg/mL) with 15 mL of sterile water for a final concentration of 50 mg/mL and volume of 40 mL. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
89288044|NCT05166811|Placebo Comparator|Placebo|For the placebo arm, 40 mL of 0.9% sodium chloride solution will be drawn into a polyvinylchloride container identical in appearance to the containers used for the IVMg arms. After randomization the institutional pharmacist will draw equivolumetric dosages (1 mL/kg, with max of 40 mL) from previously prepared vials. The dose will be delivered by the clinical nurse over 20 minutes through a peripheral IV.
89288045|NCT05165940|Active Comparator|TAU|Treatment As Usual with a VA mental health treatment coordinator
89288046|NCT05165940|Experimental|New Health Services Intervention|Novel health services intervention with a VA mental health treatment coordinator
89288047|NCT05165472|Experimental|Intervention|Real transcranial magnetic stimulation applied
89288048|NCT05165472|Sham Comparator|Sahm-control|Sham transcranial magnetic stimulation applied
89288049|NCT05161325||Cohort 1|Participants with untreated advanced or recurrent non-small cell lung cancer (NSCLC) receiving first-line nivolumab plus ipilimumab with or without chemotherapy
89288050|NCT05147584|Experimental|Interventional/Observational|The internal and external oxygen sensors will be used to record fetal oxygen during active labor and these will be be compared to the CTG retrospectively.
89288051|NCT05143138||fEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a fenestrated stent graft to allow endovascular aneurysm repair
89288052|NCT05143138||bEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a branched stent graft to allow endovascular aneurysm repair
89288053|NCT05143138||fEVAR and bEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a branched and fenestrated stent graft to allow endovascular aneurysm repair
89288054|NCT05141487||Conditional SNM|This group receives conditional sacral neuromodulation, applied intermittently based on sensor data describing bladder activity.
89288055|NCT05141487||Continuous SNM|This group receives continuous SNM, applied constantly throughout the bladder filling cycle.
89288056|NCT05140954|Experimental|Perfect Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC once daily (7 doses per week).
89288057|NCT05140954|Experimental|Moderate Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC 4 times per week
89288058|NCT05140954|Experimental|Poor Adherence|Cisgender women will receive a single tablet of coformulated 25 mg TAF/ 200mg FTC twice per week
89288059|NCT05138848|Experimental|Time in Bed Restriction|Time in Bed (TIB) restriction of 85% of habitual TIB.
89288060|NCT05138848|Active Comparator|Control|Participants will follow their typical sleep schedule consistent with measured average sleep and wake times.
89288061|NCT05136859|Experimental|preserve|preserve the perivascular fat of the target cephalic vein
89288062|NCT05136859|No Intervention|remove|remove from perivascular fat of the target cephalic vein
89288063|NCT05121337|Experimental|Dietitian-Assisted DASH groceries|Participants will order groceries sufficient to meet their caloric needs each week for 12 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions. During the remainder of the study (months 4-12), participants will be asked to apply what they learned without the provision of groceries.
89288064|NCT05121337|Active Comparator|Self-directed shopping (referent assignment)|Participants will receive a monthly stipend over a 3 month period and some basic information about healthy eating. The stipend is not restricted to foods. During the remainder of the study (months 4-12), participants will be asked to continue their typical shopping without the provision of the monthly stipend.
89288065|NCT05116683|Experimental|ATX-101|Patients will be treated with ATX-101 60 mg/m2 IV weekly in continuous 21 day cycles. Patients will receive premedication prior to the ATX-101 infusion to reduce the risk of infusion-related reactions.
89288066|NCT05113069|Experimental|Treatment group|SHR-A1912
89288067|NCT05111925||Pilot Cohort|Active duty Service members with no recent history of musculoskeletal injury, no history of musculoskeletal related surgery, and no restrictions on physical activity participation.
89288068|NCT05111925||Uninjured Cohort - Initial Assessment|Active duty Service members who are not currently receiving healthcare for a musculoskeletal injury and who have no physical activity participation restrictions.
89288069|NCT05111925||Injured Cohort - Initial Assessment|Active duty Service members who are receiving conservative treatment for a musculoskeletal injury of the low back or lower extremity.
89288070|NCT05111925||Uninjured Cohort - Optimized Assessment|Active duty Service members who are not currently receiving healthcare for a musculoskeletal injury and who have no physical activity participation restrictions.
89288071|NCT05111925||Injured Cohort - Optimized Assessment|Active duty Service members who are receiving conservative treatment for a musculoskeletal injury of the low back or lower extremity.
89288072|NCT05105633|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
89288073|NCT05105633|Active Comparator|Standard Care (which may include intravenous Alteplase)|Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour).
89288074|NCT05102929|Experimental|active, then sham Intermittent Theta Burst Stimulation (iTBS) over DLPFC|This arm will first receive active iTBS stimulation and then sham iTBS over the left dorsolateral prefrontal cortex (DLPFC).
89288075|NCT05102929|Experimental|sham, then active intermittent Theta Burst Stimulation (iTBS) over DLPFC|This arm will first receive sham iTBS (i.e., with the TMS coil in the placebo orientation) and then active iTBS stimulation over the left dorsolateral prefrontal cortex (DLPFC).
89288076|NCT05102578|No Intervention|Standard Care|Usual care. Consultation with pharmacist with no decision aid tool.
89288077|NCT05102578|Experimental|Digital Decision Aid Tool|Consultation with pharmacist using the digital decision aid tool.
89288078|NCT05102383|Experimental|All participants|All participants have habitual Comfilcon A Toric lenses optimized for wear over 2 weeks. Then all participants are fit with the Verofilcon A study daily disposable lenses with water surface treatment for astigmatism.
89288079|NCT05099393|Experimental|subject with obesity|composed of subject with obesity (Body mass index > 30)
89288080|NCT05099393|Experimental|lean subject|composed of healthy volunteers (Body mass index < 30)
89288081|NCT05099367|Other|Group 1 : healthy subject|15 healthy subject without diabetes
89288082|NCT05099367|Other|Group 2 : diabetes without ulcer|15 patients with diabetes type II and without foot ulcer
89288083|NCT05099367|Other|Group 3 : diabetes with ulcer active or <2 years|15 patients with diabetes type II and with foot ulcer (active or <2years)
89288084|NCT05099367|Other|Group 4 : Patients with type 2 diabetes, neuropathy and DFU undergoing lower limb|Patients with type 2 diabetes and neuropathy and DFU undergoing lower lunb surgery for skin ulcer
89288085|NCT05090033||Part I study cohort|Retrospective data analysis of up to 1500 de-identified participants contributing onboarding and adherence data via the MSGo Kesimpta Patient App.
89288086|NCT05090033||Part II study cohort|Up to 100 participants responding to PROs via the MSGo Patient App
89288087|NCT05084053|Experimental|Cohort 1: TAK-771 for CIDP Participants|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
89288088|NCT05084053|Experimental|Cohort 2: TAK-771 for MMN Participants|TAK-771 includes IGI 10% and rHuPH20. Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
89288089|NCT05076643||University students|University students in Universiti Tunku Abdul Rahman Sungai Long Campus
89288090|NCT05072613||Pregnant women|Pregnant women attending Antenatal Care Services
89288091|NCT05072613||School children|Children attending Primary Schools
89288092|NCT05070260|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to thrombolysis +/- mechanical thrombectomy
89288093|NCT05070260|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to thrombolysis +/- mechanical thrombectomy
89288094|NCT05066984|Experimental|structured, multidisciplinary and personalized post-ICU care|structured, multidisciplinary and personalized post-ICU care
89288095|NCT05066984|No Intervention|Ususal care|Usual care
89288096|NCT05052333||Examining the psychosocial impacts of COVID-19 in Pakistan.|This is exploratory research and data will be obtained on a set of measures using a bilingual (Urdu-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
89288097|NCT05052333||Examining the psychosocial impacts of COVID-19 in Iraq.|This is exploratory research and data will be obtained on a set of measures using a bilingual (Arabic-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
89288098|NCT05052333||Examining the psychosocial impacts of COVID-19 in Türkiye.|This is exploratory research and data will be obtained on a set of measures using a unilingual (Turkish) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
89288099|NCT05052333||Examining the psychosocial impacts of COVID-19 in Iran.|This is exploratory research and data will be obtained on a set of measures using a Bilingual (Persian-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
89288100|NCT05052333||Examining the psychosocial impacts of COVID-19 in Malaysia.|This is exploratory research and data will be obtained on a set of measures using a bilingual (Malay-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
89288101|NCT05052333||Examining the psychosocial impacts of COVID-19 in Indonesia.|This is exploratory research and data will be obtained on a set of measures using a unilingual (Indonesian) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
89288102|NCT05052333||Examining the psychosocial impacts of Covid-19 in Somaliland.|This is exploratory research and data will be obtained on a set of measures using a unilingual (Somalia) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
89288103|NCT05047913|Experimental|18F-FTX|The radioactive tracer (FAZA)
89288104|NCT05042388|Experimental|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Group intervention comprised of didactics and trainings in cognitive behavioral therapy relapse prevention skills and mindfulness meditation.
89288105|NCT05042388|Active Comparator|Treatment-As-Usual (TAU)|Standard procedure for residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on issues related to mental health and substance use disorders; and medication counseling. No aspect of the treatment-as-usual services provided entails mindfulness training or components of mindfulness training.
89288106|NCT05025657|Experimental|Program|
89288107|NCT05025657|Placebo Comparator|Control|
89288108|NCT05014165||Ancillary-Correlative (Cord Blood collection)|Accrue patients with ALL and AML who indicate having banked cord blood at birth through the COG Project:EveryChild (APEC14B1)
89288109|NCT05012865||Patients with metastatic renal cell carcinoma|Patients with metastatic renal cell carcinoma
89288110|NCT05011903|Experimental|PFI+CDF with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) and Cross-tailored Dynamic Feedback (CDF) related to alcohol use and related sexual behavior. They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
89288111|NCT05011903|Experimental|PFI+GHI with diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior, and generic health information (GHI). They also complete weekend diary surveys in which they are asked to self-report on weekend behaviors.
89288112|NCT05011903|Experimental|PFI-only with no diary surveys|Participants in this condition receive a Personalized Feedback Intervention (PFI) related to alcohol use and related sexual behavior. They do not complete weekend diary surveys.
89288113|NCT05011903|No Intervention|Control|Participants in this condition get no intervention and do not complete weekend diary surveys.
89288114|NCT04987528||Patients with pulmonary fibrosis|"All ICU patients for which one of the non-invasive criteria of pulmonary fibrosis is reached :~Typical CT scan patterns (reticulation and/or bronchiectasia)~Serum PIIINP above 16 µg/L~BAL PIIINP above 9 µg/L"
89288115|NCT04987528||Patients without pulmonary fibrosis|All ICU patients for which none of the non-invasive criteria of pulmonary fibrosis are reached.
89288116|NCT04985357||Carcinoma-Associated Malignant Fluid|Diagnosis of any kind of carcinoma with a malignant fluid (pleural effusion or ascites) where drainage is clinically indicated as part of SOC, and a new course of treatment is upcoming.
89288117|NCT04985357||Carcinoma Solid Tissue Specimen|Diagnosis of any kind of carcinoma where a needle biopsy or tissue resection is clinically indicated as part of SOC, and a new course of treatment is upcoming.
89288118|NCT04985357||Multiple Myeloma|Diagnosis of relapsed multiple myeloma where bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
89288119|NCT04985357||Acute myelogenous leukemia (AML)|Diagnosis of acute myelogenous leukemia where a blood draw or bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
89288120|NCT04985357||Triple Negative Breast Cancer (TNBC)|Diagnosis of Stage IV Triple Negative Breast Cancer where a needle biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
89288121|NCT04985357||Peripheral Blood Cell Immune Competency|Diagnosis of any cancer where a blood draw is clinically indicated as part of SOC, a new course of treatment is upcoming, and checkpoint inhibitor therapy being considered for next line of treatment.
89288122|NCT04975815||Non-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores0 will place the participants in Non-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
89288123|NCT04975815||Pre-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores1-2 will place the participants in Pre-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
89288124|NCT04975815||Frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores3-5 will place the participants in Frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
89288125|NCT04972565|Experimental|Usual Care plus Inspiratory Muscle Training (IMT)|"Participants will attend the standard of care rehabilitation program offered to hEDS and HSD patients at the University Health Network. The program consists of i) an individualized home-based rehabilitation and exercise program (twelve weeks of aerobic, neuromotor, and resistance-based exercises), ii) a self-management education intervention, and iii) a community resource engagement plan. Furthermore, patients attend four on-site sessions (a baseline assessment and three follow-up visits).~Participants in this group will also be provided with a personalized prescription for an IMT program for eight weeks to be performed in the home environment (two daily IMT sessions of 30 breaths, five days per week). Participants will be virtually supervised by the study team weekly with any adverse events closely monitored. Participants will receive instructions and feedback on how to optimize their home training efforts with direct observation of their IMT practice."
89288126|NCT04972565|No Intervention|Usual Care|Participants will participate in the standard of care rehabilitation program offered to hEDS and HSD patients at the University Health Network.
89288127|NCT04970771|Experimental|Solving Wellness Platform Group|Participants will receive a 1-year membership to the Solving Wellness virtual platform containing interactive wellness resources.
89288128|NCT04968912|Placebo Comparator|Group 1: Placebo|Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
89288129|NCT04968912|Experimental|Group 2: Nipocalimab Dose 1|Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
89288130|NCT04968912|Experimental|Group 3: Nipocalimab Dose 2|Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).
89288131|NCT04905212|Experimental|Telitacicept 160mg|Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses
89288132|NCT04905212|Experimental|Telitacicept 240mg|Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses
89288133|NCT04905212|Placebo Comparator|Placebo|Placebo subcutaneous injection once weekly, and a total of 24 doses
89288134|NCT04903106||Meniscal Tear|Subject requires a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
89288135|NCT04903106||Meniscal Insufficiency|Subject requires a MAT for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed.
89288136|NCT04892797||Covid-19+|Hospitalized patients with Covid-19 infection confirmed by PCR test
89288137|NCT04884165|Experimental|Intervention|Remote monitoring using SRETT (CE marked device) + home mechanical ventilation (non-invasive ventilation, NIV) and usual care.
89288138|NCT04884165|Active Comparator|Control|Home mechanical ventilation (non-invasive ventilation, NIV) with usual care.
89288139|NCT04877275|Experimental|Arm I: Selinexor+Pegylated liposomal doxorubicin +Dexamethasone|Arm I is given XDd regimen (ATG-010(Selinexor) 80mg/d QW, Pegylated liposomal doxorubicin 25mg/m2, d1and Dexamethasone 40mg/d QW) in approximately 25 subjects. 4 weeks per cycle and include a total of 12 cycles.
89288140|NCT04877275|Experimental|Arm II: Selinexor+Cyclophosphamide+Dexamethasone|Arm II is given XCd regimen (ATG-010 100mg/d QW, Cyclophosphamide 300mg/m2, d1and Dexamethasone 40mg/d QW). 4 weeks per cycle and include a total of 12 cycles.
89288141|NCT04873830|Experimental|Group I (VCMX)|includes 10 patients where implant placement will be performed followed by volume stable collagen matrix placement to augment the buccal defect.
89288142|NCT04873830|Experimental|Group II (control)|Will include 10 patients where implant placement will be performed followed by connective tissue grafting to augment the buccal defect.
89288143|NCT04850534||EGD+NSBB|Patients receiving both endoscopic therapy and non-selective beta-blockers for treating high-risk esophagogastric varices
89288144|NCT04850534||EGD|Patients receiving mono endoscopic therapy for treating high-risk esophagogastric varices
89288145|NCT04825483|Experimental|Weight loss and exercise|In addition to the physiotherapist-prescribed exercise program, participants in the weight loss and exercise group will also undergo six consultations with a dietitian. They will undergo a ketogenic very low-calorie diet (VLCD) including meal replacements, with an intensive weight loss phase and weight maintenance phase. The exercise component will be the same as that provided for the exercise only comparator. All dietitian and physiotherapy consultations will be delivered online by video-conference platform.
89288146|NCT04825483|Active Comparator|Exercise only|Participants will undergo five consultations (30-45 minutes) with a physiotherapist over 6 months for prescription of a home-based strengthening exercise program and physical activity plan (to be conducted independently at home), as well as OA education. All consultations will be conducted remotely via video-conference.
89288147|NCT04809987|Experimental|Virtual Gait and Physical Exercise|
89288148|NCT04809987|Sham Comparator|Documental projection and Physical Exercise|
89288149|NCT04809987|Experimental|Virtual Gait|
89288150|NCT04809987|Sham Comparator|Documental Projection|
89288151|NCT04802317||Control|Health people without any respiratory diseases
89288152|NCT04802317||Bronchial asthma|Patients with asthma
89288153|NCT04802317||COPD|Patients with chronic obstructive pulmonary disease
89288154|NCT04787679||Osteoporotic patients|Osteoporotic patients, age > 18 years old
89288155|NCT04787679||Non osteoporotic patients|Non osteoporotic patients, age > 18 years old
89288156|NCT04765111|Experimental|Treatment (acalabrutinib, rituximab)|Patients receive acalabrutinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 3-4 hours on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2-12, 14, 18, 20, 22, and 24. Cycles repeats every 28 days for up to 24 months or until complete remission is achieved in the absence of disease progression or unacceptable toxicity.
89288157|NCT04764253|Experimental|Modified Sodium Watcher Program + Digital Self-Monitoring|
89288158|NCT04764253|Active Comparator|Usual care + Digital Self-Monitoring|
89288159|NCT04752319|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
89288160|NCT04752319|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
89288161|NCT04751526|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
89288162|NCT04751526|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
89288163|NCT04750564|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
89288164|NCT04750564|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
89288165|NCT04750551|Experimental|BreEStim|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation.
89288166|NCT04750551|Experimental|EStim|EStim is transcutaneous electrical nerve stimulation.
89288167|NCT04750538|Experimental|BreEStim 120, then BreEStim 240|"BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. 120 vs 240 BreEStim electrical stimuli will be compared to examine the impact of different stimuli dose on pain reduction in this experiment."
89288168|NCT04750538|Experimental|BreEStim 240, then BreEStim 120|"BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. 120 vs 240 BreEStim electrical stimuli will be compared to examine the impact of different stimuli dose on pain reduction in this experiment."
89288169|NCT04750525|Experimental|BreEStim 120, then EStim 120|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. EStim is transcutaneous electrical nerve stimulation.
89288170|NCT04750525|Experimental|EStim 120, then BreEStim 120|BreEStim is voluntary breathing controlled transcutaneous electrical nerve stimulation. EStim is transcutaneous electrical nerve stimulation.
89288171|NCT04743024||Household|Household carer-child pairs will be included according to age and consent criteria
89288172|NCT04742803|Other|Straberi Epistamp Needling Treatment|Non-Randomized treatment for patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production using Straberi Epistamp needling treatment
89288173|NCT04742803|Other|No Treatment|Non-Randomized patients who seek improvement for elastin, fine lines, deep wrinkles, and collagen production.
89288174|NCT04740268|Other|Patiant without treatment|Non-Randomized patients with atrophic acne skin conditions
89288175|NCT04740268|Other|Straberi Microneedling Treatment|Non-Randomized treatment for patients with atrophic acne skin conditions using the Straberi Microneedling device.
89288176|NCT04740255|Other|Straberi Epistamp Needling Treatment|Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Straberi Epistamp needling.
89288177|NCT04740255|Other|No Treatment|Non-Randomized patients with Postinflammatory Hyperpigmentation (PIH)
89288178|NCT04709861||Retrospective 6 week Weight-Bearing|Delayed weight-bearing 6 weeks after total ankle replacement
89288179|NCT04709861||Prospective 2 week Weight-Bearing|Early weight-bearing 2 weeks after total ankle replacement
89288180|NCT04706390||Health care workers|500-1000 health care workers prioritized for early vaccination
89288181|NCT04706390||prioritized patient populations|2000 individuals in patient populations prioritized for vaccinations
89288182|NCT04706000||Study group|endometrial polyp
89288183|NCT04706000||Control group|normal endometrium
89288184|NCT04704518|Experimental|Group 1; Lagricel® Ofteno PF|Lagricel® Ofteno PF, multidose presentation (sodium hyaluronate 0.4%) Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
89288185|NCT04704518|Active Comparator|Group 2; Thealoz® Duo|Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
89288186|NCT04678232|Experimental|receive PATH therapy|PATH includes six 60-90 min, weekly sessions, with two booster sessions for partial responders. Session 1 provides the PATH rationale and a review of life events (PATH of life: negative and positive). A rationale for an explicit focus on positive events/emotions will be provided. Sessions 2-4 focus on a verbal narrative of the destabilizing life event, reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. Sessions 5 focuses on constructive processing and provides opportunity for integration and consolidation of learning. Session 6 focuses on future negative and positive events to promote application of new learning and resilience. Booster sessions focus on positive and negative life events since the last session and adaptive processes (constructive processing, approach, and reward). All sessions will include cultivation and elaboration of positive emotions to promote engagement and to build on the benefits of positive emotions.
89288187|NCT04667468|Experimental|Cold-stored Platelet (CSP)|early infusion of one apheresis unit urgent release cold stored platelets (CSP)
89288188|NCT04667468|Active Comparator|Standard Care|resuscitation, blood and blood component transfusion per site standard care
89288189|NCT04633369|Experimental|Fructo-oligosaccharide|Fructo-oligosaccharide 20g
89288190|NCT04633369|Experimental|Arabinogalactan|Arabinogalactan 12g
89288191|NCT04633369|Experimental|Glucomannan|Glucomannan 4g
89288192|NCT04617015|Experimental|Ipratropium bromide|All subjects will receive ipratropium bromide HFA and will have spirometry performed before and after ipratropium.
89288193|NCT04616547|Experimental|Supportive care (tin Sn 117m DTPA)|Patients receive tin Sn 117m DTPA IV over 5-10 minutes on day 1. Treatment repeats every 8 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive tin Sn 117m DTPA for an additional 2 cycles if pain recurs within 6 months after a 16-week pain observation period and no disease progression on bone scans, or evidence of clinical progression.
89288194|NCT04616248|Experimental|Cohort A (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89288195|NCT04616248|Experimental|Cohort B (immunomodulators, radiation therapy)|Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody IT and IV over 90 minutes and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89288196|NCT04613076|Experimental|"Me cuido y me siento mejor"|Patients in the primary care clinics assigned to the intervention will receive eight sessions of a computer-assisted, psycho-educational intervention delivered by trained therapists; structured telephone calls by social worker to monitor clinical progress and treatment adherence; usual medical care for chronic diseases; and access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles. Study therapists will receive biweekly and monthly supervision by psychologist and psychiatrist, respectively. A monthly meeting will be held between the PCC team and a member of the research team to ensure continuity of care.
89288197|NCT04613076|Active Comparator|Enhanced Usual Treatment|The patients in the primary care clinics assigned to the comparator will receive the usual treatment for depression and their physical conditions -all the guaranteed interventions for people with depression, hypertension, and/or diabetes in primary care, according to the Clinical Guidelines for the Treatment of Depression- and their associated basket of health benefits included in the Regime of Explicit Health Care Guarantees. They will have access to the project's website, which will be populated with information about the project's aims, the research team, and contact data, along with educational material related to depression, diabetes and hypertension, and healthy lifestyles.
89288198|NCT04611022|Experimental|Patients Eligible for HPV Vaccine|
89288199|NCT04607616|Experimental|3 baselines sessions Treatment As Usual (TAU)|Patients received 3 baseline sessions before interactive guidance therapy
89288200|NCT04607616|Experimental|4 baselines sessions TAU|Patients received 4 baseline sessions before interactive guidance therapy
89288201|NCT04607616|Experimental|5 baselines sessions TAU|Patients received 5 baseline sessions before interactive guidance therapy
89288202|NCT04607616|Experimental|6 baselines sessions TAU|Patients received 6 baseline sessions before interactive guidance therapy
89288203|NCT04607616|Experimental|7 baselines sessions TAU|Patients received 7 baseline sessions before interactive guidance therapy
89288204|NCT04607616|Experimental|8 baselines sessions TAU|Patients received 8 baseline sessions before interactive guidance therapy
89288205|NCT04602572||Non-surgical group.|Patients will be offered a standardized program comprised of individual consultations by a trained nurse every 3 months over 2 years, participation in a lifestyle course with 13 group sessions focusing on healthy diet and physical activity, and pharmacotherapy.
89288206|NCT04602572||Surgical group|After completing the systematic work-up and the lifestyle course, eligible subjects will be offered bariatric surgery. The surgical procedure will be chosen at the surgeon's discretion taking into consideration the target weight, comorbidities, risk of complications, the patient's ability to cope with side effects and complications, and the patient's motivation.
89288207|NCT04601779|Other|Cluster I|Cluster I is randomized to start the VIPP-PUF intervention phase May 1, 2022
89288208|NCT04601779|Other|Cluster II|Cluster II is randomized to start the VIPP-PUF intervention phase November 1, 2022
89288209|NCT04601779|Other|Cluster III|Cluster IiI is randomized to start the VIPP-PUF intervention phase March 1, 2023
89288210|NCT04599556|Experimental|T-ALL/LBL|
89288211|NCT04599556|Experimental|T-NHL|
89288212|NCT04599556|Experimental|AML|
89288213|NCT04597372|Experimental|Tamsulosin|"10 capsules will be distributed to subjects to be taken daily. Each capsule contains 0.4mg of Tamsulosin. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
89288214|NCT04597372|Placebo Comparator|Placebo|"10 capsules will be distributed to subjects to be taken daily. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
89288215|NCT04587674|Other|Spinal Cord Stimulation|
89288216|NCT04585815|Experimental|Sub-Study A|Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.
89288217|NCT04585815|Experimental|Sub-Study B|Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.
89288218|NCT04570436|Experimental|gabapentin 600 mg|single dose
89288219|NCT04570436|Active Comparator|diazepam 20 mg|single dose
89288220|NCT04570436|Placebo Comparator|placebo|single dose
89288221|NCT04570436|Experimental|gabapentin 1200 mg|single dose
89288222|NCT04570436|Experimental|gabapentin 1800 mg|single dose
89288223|NCT04563845|Placebo Comparator|Part 1: Participants receiving placebo|Participants will receive a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
89288224|NCT04563845|Experimental|Part 1: Participants receiving GSK3640254 500 milligrams (mg)|Participants will receive a single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.
88805775|NCT04752956|Active Comparator|Grup 3|NS + administered ambient temperature hyaluronic acid (HA) through both nostrils by means of nasal douche device twice a day 15 minutes before NS. (Nasorinse plus pediatric® Ingredients: water, sodium chlorine, sodium bicarbonate, and HA; pH balanced)
89288225|NCT04563845|Experimental|Part 2: Main QTc Study|Participants will be randomized to 1:1:1:1 ratio to receive Treatment T- Therapeutic dose of GSK3640254 (100 mg QD) on Days 1 through 7 or Treatment ST- Supratherapeutic dose of GSK3640254 (to be determined from Part 1) on Days 1 through 7 or Treatment P- Placebo for GSK3640254 on Days 1 through 7 or Treatment M- Moxifloxacin (GSK3640254 placebo Days 1 through 6 and a single dose of Moxifloxacin [400 mg] on Day 7 in 4 treatment periods. There will be at least 7 days wash out period between each period.
89288226|NCT04555161|Experimental|Aria CV Pulmonary Hypertension System|Treatment with the Aria CV Pulmonary Hypertension System
89288227|NCT04551040|Experimental|Primary Cohort|Titrating doses of terazosin starting at 1mg daily and increasing to 5mg daily on a weekly basis for five weeks.
89288228|NCT04537650||COVID-19 Ventilated|Participants who were diagnosed with COVID-19 prior to October, 2021 who required hospitalization in an ICU with mechanical ventilation during their illness.
89288229|NCT04537650||COVID-19 Non-Ventilated|Participants who were diagnosed with COVID-19 prior to October, 2021 who did not require mechanical ventilation during their illness.
89288230|NCT04531644|Experimental|Study|the patients in this group will be treated with double stimulation
89288231|NCT04531644|Active Comparator|Control|the patients in this group will be treated with conventional ovarian stimulation
89288234|NCT04475354||Cervical cancer patients and their partners|520 cervical cancer patients will complete questionnaires, online food diary and wear a fitbit after diagnosis, after 6 months, and after 1, 2, 5 and 10 years. In addition, a subsample (n=116) will donate blood samples and a scalp hair sample after diagnosis and 6, 12 and 24 months. We expect 312 partners of cervical cancer patients to included in the study and complete questionnaires after diagnosis, after 6 months, and after 1, 2, 5 and 10 years
89288235|NCT04473430|Experimental|Real-time Dexcom CGM, then Point-Of-Care Blood Glucose Group (Intervention-Control Group)|Patients with type 2 DM treated with insulin and receiving hemodialysis will use a real-time/personal CGM for 4 weeks (Intervention-Control Group), then 2 weeks of wash-out period, and cross over to use POC BG for 4 weeks.
89288236|NCT04473430|Experimental|Point-Of-Care Blood Glucose (Control) then Real-time Dexcom CGM Group (Control-Intervention Group)|Patients with type 2 DM treated with insulin and receiving hemodialysis will use POC BG for 4 weeks, then 2 weeks of wash-out period, and cross over to use a real-time/personal CGM for 4 weeks (Control-Intervention Group).
89288237|NCT04452864|Experimental|Study Intervention|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by AD. This training will be performed for three months (each day for 20 minutes). After three months this group will continue the training at home for six months and meet monthly for group sessions (i.e. booster sessions) on site.
89288238|NCT04452864|Active Comparator|Active Control Group|This control study arm will watch documentaries at home for three months (each day for 20 minutes) , instead of performing the CCT and serve as active control group. This group will also train with the CCT tasks after these three months.
89288239|NCT04452864|Other|Wait-List Control|This control study arm will start with the CCT with a delay of three months and serve as wait-list control group.
89288240|NCT04439370||Aim 1: Postmenopausal Women|Participants in this group are postmenopausal women.
89288241|NCT04439370||Aim 1: Premenopausal Women|Participants in this group are premenopausal women.
89288242|NCT04439370||Aim 2: Premature/Early Menopause|Participants in this group women who experienced premature or early menopause.
89288243|NCT04439370||Aim 2: Typical-Age Menopause|Participants in this group are women who experienced menopause at a typical age.
89288244|NCT04433767|Experimental|Transdermal Nicotine Patch|Participants will wear open label transdermal nicotine patch daily for 12-15 weeks. They will apply study patch each morning and remove at bedtime. Dosage will begin at 3.5mg patch / day, increasing to a possible maximum of 21mg patch / day.
89288245|NCT04427592|Experimental|pregnant women with placenta accreta spectrum|The participants were subjected to ultrasound to diagnose placenta accreta spectrum followed by new conservative surgical technique.
89288246|NCT04419467|Experimental|CSL346 (low dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
89288247|NCT04419467|Experimental|CSL346 (high dose)|Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions
89288248|NCT04419467|Placebo Comparator|Placebo|Administered as a single IV loading dose followed by SC infusions
89288249|NCT04382326|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
89288250|NCT04382326|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
89288251|NCT04379739|Experimental|camrelizumab + apatinib|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; apatinib 250 mg, qd, p.o. 3 weeks per cycle, 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
89288252|NCT04379739|Experimental|camrelizumab + platinum-based chemotherapy|"Neoadjuvant treatment stage: camrelizumab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (squamous: carboplatin AUC5, gemcitabine 1000mg/m2; non-squamous: carboplatin AUC5, pemetrexed 500mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery 3-4 weeks after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
89288253|NCT04372797|Experimental|Mild Traumatic Brain Injury Participants|Males and females from 18-50 years of age who present to a recruitment site within 10 days of injury with a diagnosed concussion that meets all of the following criteria: 1) clear mechanism of injury (i.e., direct or indirect impact to head), 2) Glasgow Coma Scale= 13-15, 3) observed or reported signs (e.g., loss of consciousness, amnesia, or confusion) or symptoms (e.g., headache, dizziness, nausea), and 3) neurosensory symptoms.
89288254|NCT04372797|Active Comparator|Control Participants|Age- and sex-matched control subjects with minor, non-surgical injuries (e.g., sprains, strains) not requiring hospital admission and no history of mild traumatic brain injury will be recruited from the same study sites.
89288255|NCT04369911|Experimental|Low Dose|Acupuncture treatment once per week for 5 weeks. Five total acupuncture treatments completed.
89288256|NCT04369911|Experimental|High Dose|Acupuncture treatment twice per week for 5 weeks. Ten total acupuncture treatments completed.
89288257|NCT04362488|Experimental|Patients with chronic post-traumatic lateral ankle instability|"The study population consists in patients affected by chronic post-traumatic lateral ankle instability who must undergo surgical intervention of ankle external ligament reconstruction.~The patients will be analyzed pre and postoperatively using differents tests, questionnaires, instrument and clinical evaluation:~Delos system (computerized oscillating platform)~Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
89288258|NCT04359901|Active Comparator|Standard of care plus subcutaneous sarilumab|Standard of care as directed by the treating clinicians, plus sarilumab 400 mg subcutaneous injection. Sarilumab is provided in prefilled syringes/pens containing 200 mg each as is used clinically, and both injections will be given as soon as is convenient after the patient has decided to enroll.
89288259|NCT04359901|No Intervention|Standard of care|Standard of care as directed by the treating clinicians.
89288260|NCT04358289|No Intervention|Arm 1: Control group|For commune health center and community
89288261|NCT04358289|Other|Arm 2: Basic antimicrobial stewardship education|For commune health center and community
89288262|NCT04358289|Other|Arm 3: 3. Basic AS education + community education|For commune health center and community
89288263|NCT04358289|Other|Arm 4: Education + participatory action research|For commune health center and community
89288264|NCT04358289|Other|Hospital intervention|For hospital: The hospital interventions will use quality improvement using a participatory action research approach to improve antibiotic stewardship. These activities will be evaluated through a before and after knowledge, attitudes and practice (KAP) survey, to assess whether or not the engagement activities had a measurable impact on knowledge and behaviour. There are not sufficient hospitals in the area to conduct a cluster randomized evaluation, so we will conduct a before and after survey, patient record review, and overall antibiotic use data from the Pharmacy Department
89288265|NCT04349826|Active Comparator|Azithromycin+Cefixime|Azithromycin 20mg/kg/day oral dose once daily (maximum 1gm/day) AND Cefixime 20-30mg/kg/day oral dose in two divided doses (maximum 400mg bd) for 7 days.
89288266|NCT04349826|Placebo Comparator|Azithromycin+placebo|Azithromycin 20mg/kg/day oral dose once daily (Max 1gm/day) for 7 days AND Cefixime-matched placebo for 7 days.
89288267|NCT04338685|Experimental|Part A1-1 mg RO7119929|Participants received 1mg RO7119929 every week in 3-week cycles.
89288268|NCT04338685|Experimental|Part A1-3 mg RO7119929|Participants received 4 mg RO7119929 every week in 3-week cycles
89288269|NCT04338685|Experimental|Part A1 - 6 mg RO7119929|Participants received 6 mg RO7119929 every week in 3-week cycles
89288270|NCT04338685|Experimental|Part A1 -9 mg RO7119929|Participants received 9 mg RO7119929 every week in 3-week cycles
89288271|NCT04338685|Experimental|Part B1-5 mg RO7119929|Participants with both available and evaluable tumor biopsy samples received 5 mg RO7119929 on Cycle 1 Day 1 to month 12
89288272|NCT04338685|Experimental|Part A2- 2/5/5 mg RO7119929|Participants received RO7119929 QW with step-up dosing of 2/5/5 mg during Cycle 1.
89288273|NCT04338685|Experimental|Part A2- 2/5/6 mg RO7119929|Participants received RO7119929 QW with step-up dosing of 2/5/6 mg during Cycle 1.
89288274|NCT04338685|Experimental|Part A3-4 mg RO7119929|Participants received tocilizumab pre-treatment on Cycle 1 Day 1, approximately 2 hours prior to RO7119929 administration and 4 mg RO7119929 every week in 3-week cycles
89288275|NCT04327180||patients suspected of infection with COVID-19.|Patients included with positive PCR and patients with negative PCR included
89288276|NCT04324229|Active Comparator|liraglutide|
89288277|NCT04324229|Placebo Comparator|placebo|
89288278|NCT04259983||Patients with CF with normal obstruction severity|In CF children with normal obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
89288279|NCT04259983||Patients with CF with mild obstruction severity|In CF children with mild obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
89288280|NCT04259983||Patients with CF with moderate obstruction severity|In CF children with moderate obstruction severity will be subjected to the same maximal exercise test, endothelial dysfunction and arterial stiffness assessments.
89288281|NCT04251585|Experimental|Low Insulin|Regular insulin (Novolin-R) 20 international units (10 units) in one nostril twice daily for 21 days, 100 µl volume.
89288282|NCT04251585|Experimental|Medium Insulin|Regular insulin (Novolin-R) 40 international units (10 units) in each nostril twice daily for 21 days, 100 µl volume.
89288283|NCT04251585|Experimental|High Insulin|Regular insulin (Novolin-R) 80 international units (10 units) in each nostril twice daily for 21 days, 200 µl volume.
89288284|NCT04251585|Placebo Comparator|Placebo|0.9% sodium chloride in each nostril twice daily for 21 days, 100 µl volume.
89288285|NCT04250025|Experimental|EXPERIMENTAL GROUPE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
89288286|NCT04250025|No Intervention|CONTRO GROUPE|60 patients benefit from standard treatment for 6 months i.e elastic compression and anticoagulation if needed. Notably, if patients were no longer on anticoagulant treatment at the time of screening and inclusion, this treatment will not be reintroduced.
89288287|NCT04247334|No Intervention|Cautious Participants|Participants who have low scores on a self-report of inhibitory control abilities (BRIEF-Inhibit).
89288288|NCT04247334|Experimental|Impulsive Participants- Active Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to active stimulation.
89288289|NCT04247334|Sham Comparator|Impulsive Participants- Sham Stimulation|Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to sham stimulation.
89288290|NCT04241978|Experimental|Intervention group|The participants will complete the baseline assessment and will be asked to read the project information sheet. Then, patients allocated to the intervention group will review the PtDA accompanied by the researcher and will complete the questionnaires assessing the outcome measures, in the same web interface.
88805776|NCT00203216|Experimental|Levatiracetam|Subject titrated open-label study drug to maximally tolerated dose: maximum: 3000 mg. per date. (minimum allowed daily dose to remain in study: 1000)
89288291|NCT04241978|Active Comparator|Control group|Patients in the control group will follow the same procedure, but they will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
89288292|NCT04225520|Active Comparator|Treatment recommendation based on guidelines|Treatment of the patient assigned to this arm will be based on the current guidelines for CRT implantation, as issued by the European Society of Cardiology. All patients will receive CRT implantation, with bi-ventricular pacing ON.
89288293|NCT04225520|Experimental|Treatment recommendation based on mechanical dyssynchrony|Treatment of the patients assigned to this arm will be based on the presence of mechanical dyssynchrony. All patients will receive CRT implantation. Bi-ventricular pacing will be either turned ON or OFF, based on respectively the presence or absence of mechanical dyssynchrony.
89288294|NCT04224272|Experimental|ZW25 (zanidatamab) + palbociclib + fulvestrant|ZW25 (zanidatamab) plus palbociclib, fulvestrant
89288295|NCT04223856|Experimental|Arm A|Enfortumab vedotin + pembrolizumab
89288296|NCT04223856|Active Comparator|Arm B|Gemcitabine + cisplatin or carboplatin
89288297|NCT04223856|Experimental|Arm C (Not Recruiting)|Enfortumab vedotin + pembrolizumab + Cisplatin or carboplatin
89288298|NCT04223284|Active Comparator|Experimental1|"During the Cross-Over study, patients will be randomly assigned to one of the arms:~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with D-Limonene at visit 2 and olfactory Stimulation with lavender oil (SLVO) at visit 3"
89288299|NCT04223284|Active Comparator|Experimental2|"During the Cross-Over study, patients will be randomly assigned to one of the arms:~Treatment sequence: Placebo at the baseline visit, olfactory Stimulation with SLVO at visit 2 and olfactory Stimulation with D-Limonene at visit 3"
89288300|NCT04218864|Experimental|Strength for U in Relationship Empowerment (SURE)|Theory-driven and derived from empirical support
89288301|NCT04218864|Active Comparator|Attention, time, and information matched control|Well-validated
89288302|NCT04207307|Experimental|Multimodal exercise intervention|Behavioral: Multimodal exercise intervention with machine-based resistance, coordination and endurance training, 1-2 times per week for 30-45 min (increasing amount of training).
89288303|NCT04207307|Sham Comparator|Usual Care|General recommendations for healthy ageing, usual physical activity. No machine-based strength training intervention.
89288304|NCT04203017|Experimental|AutoHSCT + FMT|AutoHSCT with reduced intensity condition regimen (RIC). FMT starting D+60 up to D+120 via po capsules: 30 capsules with fecal transplant divided in two consecutive days (more accurate capsules amount is according to patients body weight)
89288305|NCT04193956||POINTING|
89288306|NCT04190394||Patients following the CONT program|"In the  CONT continuous training group, the control group, the patient benefits from a retraining program according to the continuous mode (see details in section 3.4) for 8 weeks, with three 40-minute sessions per week."
89288307|NCT04190394||Patients following the IT program|"In the IT intermittent training group, group, (the experimental group), the patient benefits from a retraining program according to the intermittent mode (see details in section 3.4) for 8 weeks, with three 45-minute sessions per week."
89288308|NCT04185558|Experimental|ActiGraft|Whole blood clot (WBC) gel
89288309|NCT04185558|Active Comparator|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
89288310|NCT04149457|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
89288311|NCT04149457|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
89288312|NCT04142320|Experimental|Closed-loop rTMS|Closed-loop rTMS will be delivered to determine the target engagement compared to open-loop rTMS. Closed loop rTMS will be applied for two consecutive days for 30 minutes to determine dose response. Closed- loop rTMS will be delivered using neuro-navigation based on participants' own MRI images. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
89288313|NCT04142320|Active Comparator|Open-loop rTMS|A series of open-loop rTMS protocols will be delivered to determine the most effective standard and individualized rTMS. Active rTMS will be delivered using neuro-navigation based on participants' own MRI images. For each clinically-utilized rTMS protocol (1Hz, 5Hz, 10Hz, 20Hz), 3000 pulses will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
89288314|NCT04142320|Placebo Comparator|Sham rTMS|Sham rTMS will be delivered for two consecutive sessions to mimic active rTMS conditions. To maximize sham validity, both 1) a direction- sensor TMS coil will alert the operators to flip the coil if the wrong side is being used, and 2) low-intensity electrical stimulation to match the active rTMS frequency will be applied to scalp electrodes under the coil for sham and placed but not activated in the active arm. The rTMS coil will be positioned using neuro-navigation based on participants' own MRI images, mimicking active rTMS. Sham rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the sham rTMS session for adverse events and/or side effects.
89288315|NCT04120298|Experimental|Supervised exercise group|"The intervention group will participate in a 9-month exercise intervention. The exercise program will start with a 6-month period, where patients participate in a supervised multimodal exercise program twice a week supplemented with unsupervised exercises. The multimodal exercise program comprises aerobic-, resistance- and balance components. After completing the initial six-month period, one supervised session will be replaced by one unsupervised session until month nine.~Unsupervised exercises will be supported by an activity tracker (FitBit) and an exercise App specifically designed for the EFFECT trial"
89288316|NCT04120298|No Intervention|Control group|Patients randomized to the control group will also receive an activity tracker (like the intervention group). We will advice control patients to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150min/week in line with the current exercise guidelines.
89288317|NCT04109586|Experimental|Personalized nutrition therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
89288318|NCT04109586|No Intervention|Standard treatment|Standard treatment includes dietitian-led group session on nutrition after SCI and patient visits / consultations on request from doctor.
89288319|NCT04100408||Ancillary-Correlative (biospecimen collection)|LCH patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal brushing will be sequenced, genotyped, and analyzed.
89288320|NCT04084080|Experimental|Exchange transfusion plus standard of care|Randomized to standard of care and automated exchange blood transfusion every 3-6 weeks for 12 months.
89288321|NCT04084080|Active Comparator|Standard of care|Randomized to standard of care
89288322|NCT04080739|Experimental|Experimental Group|US-guided ipsilateral sciatic nerve block for fibula free flap patients utilizing ropivacaine 0.2% at 2-8 cc/hr for fibula free flap patients; US-guided infraclavicular brachial plexus nerve block for forearm free lap patients utilizing ropivacaine 0.2% at 2-8cc/hr for forearm free flap patients.
89288323|NCT04080739|No Intervention|Control Group|No regional anesthetic of any kind during the surgical procedure.
89288324|NCT04075903|Experimental|Intervention|"Storytelling A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
89288325|NCT04075903|No Intervention|Control|Usual Care
89288326|NCT04074954||Cataracts present, no surgery|Adult patients undergoing bilateral cataract surgery
89288327|NCT04074954||Cataracts present, yes surgery|adult patients who have cataracts but are not undergoing cataract surgery
89288328|NCT04074096|Experimental|Encorafenib + binimetinib + pembrolizumab|Encorafenib 450 mg oral route (PO) once daily (QD) + binimetinib 45 mg PO twice daily (BID) + pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W).
89288329|NCT04074096|Experimental|SRS followed by encorafenib + binimetinib + pembrolizumab|Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm); followed by encorafenib 450 mg PO QD + binimetinib 45 mg PO BID + pembrolizumab 200 mg IV Q3W. The treatment should be started more than 24 hours and less than 8 days (excluded) after the SRS
89288330|NCT04059068||NASH (non-alcoholic steatohepatitis)|Patients diagnosed with non-alcoholic steatohepatitis.
89288331|NCT04059068||NAFLD (non-alcoholic fatty liver disease)|Patients diagnosed with non-alcoholic fatty liver disease.
89288332|NCT04059068||Control|Patients with normal liver tissue.
89288333|NCT04059068||obese / high WAT inflammation and fibrosis|Patients who are obese with inflammed white adipose tissue and evidence of fibrosis.
89288334|NCT04059068||obese / low WAT inflammation and fibrosis|Patients who are obese with no evidence of inflammed white adipose tissue and no evidence of fibrosis.
89288335|NCT04059068||non- obese controls|Patients who are not obese.
89288336|NCT04046575|Experimental|IMRT + Carboplatin + Paclitaxel|Concurrent chemoradiation will consist of hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) for 3 weeks with carboplatin and paclitaxel for 3 cycles every 7 days. Endoscopy and (optional) PET/CT within 6-8 weeks post-completion of chemoradiation.
89288337|NCT04026581||Assessment|A comprehensive AAC assessment collecting clinical and personal data required to select a speech-generating device (SGD) is conducted along with a trial of three AAC technology solutions, followed by a trial for BCI access to an AAC system.
89288338|NCT04026581||Training and Treatment|AAC training and treatment services will be provided and communication performance outcomes monitored over the course of studying clinical treatment services. At monthly home visits the SLP gathers clinical and personal data on communication performance outcomes and user satisfaction of their AAC system and any alternative access methods.
89288339|NCT04022915|Experimental|Acute pulmonary embolism|Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.
89288340|NCT03995238|Experimental|Error-augmentation training|A 4-week, 8 session, treadmill-based gait training program, with error-augmentation of step asymmetry delivered on a split-belt treadmill. Each training session will adhere to the same schedule. During the training blocks on the treadmill, the belt under the limb with the shorter step length will be set at 3/4 of the pre-intervention over-ground self-selected walking speed while the belt under the limb with the longer step length will be set to 1/2 of the fast belt speed (2:1 ratio between belts).
89288341|NCT03995238|Experimental|Error-correction training|A 4-week, 8 session, treadmill-based gait training program, with error-correction of step asymmetry delivered with an auditory metronome signal while walking on a treadmill. During each training block, the metronome will be set to overcorrect stance time asymmetry through use of asymmetrical metronome tones, 2:1 ratio.
89288342|NCT03995238|Active Comparator|Supervised waking|A 4-week, 8 session, treadmill-based supervised walking program. The active comparator group will participate in a supervised treadmill walking program of the same frequency and duration, to the two experimental groups.
89288343|NCT03984422||Raynaud phenomenon|Use of smartphone application
89288344|NCT03973931|No Intervention|Usual Care|This group will not receive an intervention. We have included a usual care group to demonstrate the impact of the text messaging interventions above and beyond usual care given that many prior medication adherence interventions have demonstrated small to negligible effects.
89288345|NCT03973931|Experimental|Generic Nudge|A generic reminder text will be delivered to patients to refill their medication at days 1, 3, 5, 7 and 10 after they been labeled as non-adherent.
89288346|NCT03973931|Experimental|Optimized nudge|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1, 3, 5, 7 and 10 after they have been labeled as non-adherent.
89288347|NCT03973931|Experimental|Optimized nudge plus AI Chat Bot|An optimized nudge text will be delivered to patients to remind them to refill their medications at days 1 and 3 after they have been labeled as non-adherent. If the patient has not filled their medication on days 5 and 7, in addition to receiving an optimized nudge text, an AI will conduct interactive chat via a chat bot to assess barriers filling the medication as described in Aim 1 above. If they still have not filled the medication, they will receive another message on day 10.
89288348|NCT03959163|Other|DMSA/Quick MRI|All participants will go through DMSA and Quick MRI scan to help determine the validity of the Quick Renal MRI in pediatric kidney disease.
89288349|NCT03957954|Experimental|Cultivated Limbal Stem-Cells (cLSC)|One dose of cultivated limbal stem-cells (cLSC), size between 7.6 to 15 mm in the average diameter.
89288350|NCT03957954|Active Comparator|Scleral Contact Lens Device (SCL)|Scleral contact lens device (SCL) will be fitted to stabilize and improve ocular surface.
89288351|NCT03953898|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood throughout the study.
89288352|NCT03951298||Wolfram Syndrome Patients|Participant has confirmation of a WFS1 mutation OR Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old
89288353|NCT03951298||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
89288354|NCT03937921||Group 1 - Dotarem|Group 1 (n=30) will receive the clinically approved gadoterate meglumine (Dotarem, 0.1mmol/kg) as the contrast agent for their clinical perfusion study
89288355|NCT03937921||Group 2 - Gadavist|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as the contrast agent.
89288356|NCT03920774||Familial Dysautonomia|Patients diagnosed with familial dysautonomia, a genetic disorder that affects the development and survival of nerve cells in the autonomic nervous system. It primarily affects neurons that control involuntary actions like regulation of blood pressure and breathing. It also affects the sensory nervous system and the perception of pain, heat and cold.
89288357|NCT03890484|Experimental|New Peers|Participants will drink with two new peers (i.e. strangers), who they did not know prior to the study and their Peer Type.
89288358|NCT03890484|Experimental|Close Friends|Participants will recruit and drink with two of their close friends and their Peer Type
89288359|NCT03885349|Experimental|SBIP+ ADAPs-IMP|Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
89288360|NCT03885349|Active Comparator|SBIP+IMP|Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
89288361|NCT03880240|Experimental|2 weeks of daily tACS sessions|10 daily (Monday-Friday) 1-hour sessions of tACS stimulation
89288362|NCT03880240|Experimental|4 weeks of daily tACS sessions|20 daily (Monday-Friday) 1-hour sessions of tACS stimulation
89288363|NCT03880240|Experimental|4 weeks of twice daily tACS sessions|20 days (Monday-Friday) of 1-hour sessions of tACS twice per day
89288364|NCT03880240|Sham Comparator|2/4 weeks of Sham tACS sessions|10/20 days (Monday-Friday) of 1-hour sessions of tACS once/twice per day
89288365|NCT03839706|Experimental|PET MRI Arm|Patient enrolled in the study will have a PET MRI exam scheduled before transplant
89288366|NCT03799835|Active Comparator|Arm A : control arm|"BCG therapy only~BCG therapy will be administered in two phases:~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1)."
89288367|NCT03799835|Experimental|Arm B: experimental arm|"BCG therapy + administration of atezolizumab~BCG therapy will be administered in two phases:~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).~atezolizumab is administered by IV infusion every 3 weeks (21 [± 2] days) for 1 year (18 cycles as a maximum)."
89288368|NCT03778554|Experimental|Beta blocker treatment|"Treatment with beta blockers plus standard of care. Type and dosage according to treating cardiologist choice~Bisoprolol up to a total dose of 10 mg daily~Carvedilol up to a total dose of 50 mg daily~Metoprolol succinate up to a total dose of 200 mg daily~Nebivolol up to a total dose of 10 mg daily"
89288369|NCT03778554|No Intervention|No beta blocker treatment|Standard care without beta blocker treatment
89288370|NCT03752333|Experimental|Pembrolizumab|All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
89288371|NCT03744676|Experimental|Lisocabtagene maraleucel|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel. During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control. Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.
89288372|NCT03742921||Relapsed or Refractory T-Cell Lymphoma patients with Istodax|Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance
89288373|NCT03736538|Experimental|Nitrous Oxide|"Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive inhaled nitrous oxide."
89288374|NCT03736538|Placebo Comparator|Placebo Gas|"Placebo gas given at 50% nitrogen [inert]/50% oxygen.~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive placebo gas."
89288375|NCT03736343|Active Comparator|Young Adult Heavy Drinkers Group 1|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
89288376|NCT03736343|Active Comparator|Young Adult Heavy Drinkers Group 2|Young adult heavy drinkers, aged 21-30, will be administered varying doses of oral alcohol.
89288377|NCT03718546||Sibling pediatric donors|Donors who are donating to a sibling
89288378|NCT03718546||Sibling recipients and caregivers|Recipients who are receiving a transplant from a sibling
89288379|NCT03718546||Non-donor sibling|From the donor-recipient families
89288380|NCT03718546||Non-donor siblings|Of patients receiving unrelated transplants
89288381|NCT03718546||Healthy comparison|A matched sample
89288382|NCT03718546||Parents|Parent/caregiver of study participating donor.
89288383|NCT03656081|Placebo Comparator|Itraconazole & inhaled placebo|Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
89288384|NCT03656081|Experimental|Itraconazole & inhaled Ambisome®|Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
89288385|NCT03620032|Other|Standard treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
89288386|NCT03620032|Experimental|Experimental treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
89288387|NCT03615495||Flourish device|The Flourish Pediatric Esophageal Atresia device is indicated for use in lengthening atretic esophageal ends and creating an anastomosis with a non-surgical procedure in pediatric patients.
89288388|NCT03605667|Experimental|BHV-4157|troriluzole, 280 mg (2 x 140 mg) capsules, QD
89288389|NCT03605667|Placebo Comparator|Placebo|matching 280 mg (2 x 140 mg) placebo capsules, QD
89288390|NCT03600350|Experimental|Treatment Group|"Nivolumab 240 mg IV every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12~pTVG-HP (100 µg) administered intradermally (i.d.) every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12~rhGM-CSF (208 µg) administered intradermally (i.d.) every two weeks x 4 beginning week 4, then every four weeks x 9 beginning week 12 NOTE: Only administered to patients for whom serum PSA obtained week 4 > serum PSA obtained at day 1."
89288391|NCT03597165|Experimental|Incidental Genomic Sequencing Results|"Patients in Intervention will receive GS results related to primary indication (cancer) and will be offered the option learning their incidental results, categorized into five bins based on a framework by Berg et al."
89288392|NCT03597165|Active Comparator|Primary Indication only|Patients in the control will receive the intervention GS results for Primary Indications only.
89288393|NCT03582033|Experimental|Parts A and B: SEA-BCMA Monotherapy|SEA-BCMA
89288394|NCT03582033|Experimental|Part C: SEA-BCMA + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone
89288395|NCT03582033|Experimental|Part D: SEA-BCMA + Pomalidomide + Dexamethasone Combination Therapy|SEA-BCMA + dexamethasone + pomalidomide
89288396|NCT03580083|Experimental|Dose 1; 1x10^10 GC/g brain mass of RGX-111|
89288397|NCT03580083|Experimental|Dose 2; 5x10^10 GC/g brain mass of RGX-111|
89288398|NCT03573791||Complete response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging ypT0N0 as complete response.
89288399|NCT03573791||Poor response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging >ypT1-2N0 as poor response.
89288400|NCT03569657|Other|A positive psychology workshop|The group intervention implements a manualized treatment protocol outlining the content of each of the four 90 minute sessions. The sessions will include topics such as mindfulness, self-compassion, gratitude and forgiveness, grief and growth, utilizing one's strengths, and resilience; with each session including homework exercises to be practiced between sessions. To assess the outcome measures, participants complete a baseline survey, a survey after the second session (2 weeks), a survey after the final session (4 weeks), and a follow-up survey 3 months after the workshop has ended (4 months).
89288401|NCT03533595|No Intervention|Standard Suture|Standard suture for thoracolumbar fusion will be used per standard of care.
89288402|NCT03533595|Active Comparator|Stratafix Barbed Suture|Stratafix Barbed Suture for thoracolumbar fusion will be used.
89288403|NCT03521804|Other|SoundBite™ Crossing System-Coronary|Crossing of coronary chronic total occlusions.
89288404|NCT03513952|Experimental|Group 1 (CYT107, atezolizumab)|Patients receive CYT107 IM on days 1, 8, 15, and 22, and atezolizumab IV over 60 minutes on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study.
89288405|NCT03513952|Active Comparator|Group 2 (atezolizumab)|Patients receive atezolizumab IV over 60 minutes on cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study.
89288406|NCT03498066|Experimental|Discontinuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..
89288407|NCT03498066|Active Comparator|Continuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.
89288408|NCT03495011||Cohort A|Patient with recently identified calcifications on mammography requiring biopsy. Patients will undergo a quantitative, multiparametric breast MRI as part of their clinical care. MRI will not change need for biopsy, but could identify additional suspicious sites. Only patients diagnosed with pure DCIS at biopsy and eventual surgical excision will receive Oncotype DX DCIS score testing.
89288409|NCT03495011||Cohort B|Patient with recent diagnosis of biopsy-proven DCIS would complete a research quantitative, multiparametric breast MRI as part of their clinical care. Only patients diagnosed with pure DCIS at surgical resection will receive Oncotype DX DCIS score testing.
89288410|NCT03469609|Experimental|Perioperative mucous fistula refeeding|Perioperative mucous fistula refeeding between enterostomy creation and enterostomy closure
89288411|NCT03469609|No Intervention|No mucous fistula refeeding|No perioperative mucous fistula refeeding
89288412|NCT03428477|Experimental|Icosapent Ethyl (EPA-EE)|Soft gelatin capsules containing 1g pure EPA-EE equivalent to 914mg EPA-FFA. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
89288413|NCT03428477|Placebo Comparator|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
89288414|NCT03417960|Experimental|iTBS|accelerated iTBS to Left DLPFC
89288415|NCT03413501|No Intervention|Treatment as usual|Receives treatment as usual at the clinic
89288416|NCT03413501|Experimental|MUD-PI|Receives multi-disciplinary pain intervention, agroup-based, multi-disciplinary treatment
89288417|NCT03385226|Experimental|Pembrolizumab with radiotherapy|"All patients will receive~single 200mg pembrolizumab IV infusions given 3-weekly until 2 years post study entry, termination of treatment, disease progression or unacceptable toxicity~radiotherapy, 12Gy in 3 fractions"
89288418|NCT03301792|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration.
89288419|NCT03301792|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a six session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 2-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by a health educator and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
89288420|NCT03299179||Natural cycle|15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.
89288421|NCT03299179||Anti-conception|15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.
89288422|NCT03254381|Experimental|Resistance Training|Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
89288423|NCT03254381|Experimental|Balance and Tone Training (Control)|Exercises will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.
89288424|NCT03252808|Experimental|TBI-1401(HF10) + Gem/nab-PTX|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel injected by intravenous infusions.
89288425|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
89288426|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary and meta)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
89288427|NCT03250325|Experimental|Split dose of 5x10^9 TBI-1301|Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.
89288428|NCT03246230|No Intervention|NO VACCINES AT BIRTH|These will be newborns who will not receive any vaccines at birth and will have delayed immunization with catch-up (i.e., HBV, BCG and polio vaccine) by Day of Life 7.
89288429|NCT03246230|Other|HBV VACCINE AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) at birth (Day of Life (DOL)-0) with catch up immunization (i.e., BCG and polio vaccine) at DOL-1, -3, or -7.
89288430|NCT03246230|Other|BCG VACCINE AT BIRTH|Participants in this arm will receive licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life(DOL)-0) with catch up immunization (i.e., HBV and polio vaccine) at DOL-1, -3 or- 7.
89288431|NCT03246230|Other|(HBV + BCG) VACCINES AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) and licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life (DOL- 0) with catch up immunization (i.e., polio vaccine) at DOL-1, -3, or -7.
88805777|NCT00204932|Active Comparator|CLA treatment|The group randomized to Conjugated Linoleic Acid (CLA) treatment at 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA; and 22% safflower oil for 6 months
88805778|NCT00204932|Placebo Comparator|Placebo|The group randomized to control received 4 g/d of safflower oil.
88805779|NCT00206336|Experimental|topiramate|Topiramate open label
89288432|NCT03229278|Experimental|Treatment (trigriluzole, nivolumab, pembrolizumab)|Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
89288433|NCT03217058|No Intervention|Pre-implementation|The pre-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services prior to implementation of computerized screening and behavioral intervention in the clinics.
89288434|NCT03217058|Experimental|Post-implementation|The post-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services after computerized screening and behavioral intervention have been implemented in the clinics.
89288435|NCT03201445|Experimental|Filgotinib|Participants received filgotinib up to Week 13 in the DB phase (Part A). At Week 13, participants who were IBD responders, without meeting pre-specified sperm decrease thresholds, continued DB treatment up to Week 26 (Part B). Participants who were IBD non-responders at Week 13 or had disease worsening after Week 13 and prior to Week 26, and whose sperm parameters did not meet a prespecified decrease threshold, entered the OL Phase and received OL filgotinib for up to Week 13. At Week 26/OL Week 13, participants who were IBD responders and who had not experienced disease worsening, and whose sperm parameters did not meet a prespecified decrease threshold, continued receiving the same study drug they were responding to as part of the LTE for up to 195 weeks. Participants who met pre-specified sperm decrease threshold(s) at any postbaseline visit discontinued study drug and switched to a standard of care (SOC) regimen selected by the investigator and entered the MP for up to 52 weeks.
89288436|NCT03201445|Placebo Comparator|Placebo|Participants received placebo (matched to filgotinib) up to Week 13 in the DB phase (Part A). At Week 13, participants who were IBD responders, without meeting pre-specified sperm decrease thresholds, continued DB treatment up to Week 26 (Part B). Participants who were IBD non-responders at Week 13 or had disease worsening after Week 13 and prior to Week 26, and whose sperm parameters did not meet a prespecified decrease threshold, entered the OL Phase and received OL filgotinib for up to Week 13. At Week 26/OL Week 13, participants who were IBD responders and who had not experienced disease worsening, and whose sperm parameters did not meet a prespecified decrease threshold, continued receiving the same study drug they were responding to as part of the LTE for up to 195 weeks. Participants who met pre-specified sperm decrease threshold(s) at any postbaseline visit discontinued study drug and switched to SOC regimen selected by the investigator and entered the MP for up to 52 weeks.
89288437|NCT03193333|Experimental|PRO-122 group|"To validate the 3 flasks of the triple therapy will be used 1 bottle with the three active principles (PRO-122) and two placebos and thus comply with the masking.~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL. preservative free.~Pharmaceutical form: Ophthalmic solution~Made by: Laboratorios Sophia, S.A. de C.V.~Posology: 1 drop every 12 hours for 90 days~Description of the solution: clear, visibly particle free, slightly yellow solution, preservative free~Package description: 5 m multidose dropper bottle.~Placebo (for~Two pieces of approved placebo. Administered in 2 multidose dropper bottles.~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
89288438|NCT03193333|Active Comparator|Concomitant triple therapy group|"Imot Ofteno~Drug substance: Timolol 5 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by Laboratorios Sophia S.A. de C.V.~Alphagan~Drug substance Brimonidine 2 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by: Allergan, Inc.~Trusopt~Drug substance: Dorzolamide 20 mg/mL~Pharmaceutical form: Ophthalmic solution~Made by: Merck Sharp and Dohme Corp.~Posology: 1 drop every 12 hours for 90 days"
89288439|NCT03193333|Active Comparator|Krytantek Ofteno Group|"To validate the three flasks of the triple therapy will be used 1 bottle with the three active principles (Krytantek) and two placebos and thus comply with the masking.~Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL.~Pharmaceutical form: Ophthalmic solution~Made by: Laboratorios Sophia, S.A. de C.V.~Posology: 1 drop every 12 hours for 90 days~Description of the solution: clear, visibly particle free, slightly yellow solution Package description: 5 m multidose dropper bottle.~Placebo (for two pieces of approved placebo. Administered in 2 multidose dropper bottles.~Posology: 1 drop of each dropper bottle every 12 hours for 90 days"
89288440|NCT03189914|Experimental|RX-3117 + Abraxane|"RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle.~Abraxane: 75 - 125 mg/m^2, infused once per week for 3 weeks. 1 washout week/ cycle."
89288441|NCT03160794|Experimental|[18F] DCFPyL PET/MRI|"[18F] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.~Lesions identified through [18F] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery."
89288442|NCT03155191|Experimental|Dose Level -1 to 2|"0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.~cohort -1: 3×10^5 cells/kg cohort 1: 1×10^6 cells/kg cohort 2: 3×10^6 cells/kg."
89288443|NCT03142802|Experimental|Patients with testicular germ cell cancer|Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
89288444|NCT03112044|Experimental|HCV+ lung transplant to HCV- recipients|HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
89288445|NCT03087487||NVAF patients on Warfarin|NVAF patients newly initiated with Warfarin. Non-Interventional.
89288446|NCT03087487||NVAF patients on Apixaban|NVAF patients newly initiated on Apixaban. Non-Interventional.
89288447|NCT03087487||NVAF patients on Dabigatran|NVAF patients newly initiated with Dabigatran. Non-Interventional.
89288448|NCT03087487||NVAF patients on Rivaroxaban|NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
89288449|NCT03066297||Lobectomy|Lobectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
89288450|NCT03066297||Segmentectomy|Segmentectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
89288451|NCT03066297||Wide wedge resection|Wide wedge resection will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
89288452|NCT03018041|Experimental|Marine n-3 PUFAs|3 capsules of Omacor 1000 mg daily, corresponding to a dose of 2.5 g / day of marine n-3 PUFAs (EPA plus DHA).
89288453|NCT03018041|Placebo Comparator|Placebo|Corresponding placebo oral capsules with olive oil, three capsules daily.
89288454|NCT03015974||corticosteroid|pediatric IgA nephropathy treated with only corticosteroid
89288455|NCT03015974||corticosteroid and cyclophosphamide|pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide
89288456|NCT03015974||corticosteroid and mycophenolate mofetil|pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil
89288457|NCT03011372|Experimental|Pemigatinib|
89288458|NCT03006354|Experimental|nHFOV|"Ventilator-derived nHFOV will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.~When nHFOV failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
89288459|NCT03006354|Active Comparator|nCPAP|"Ventilator-derived nCPAP will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.~When nCPAP failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
89288460|NCT02960230|Experimental|Stratum A: Newly Diagnosed DIPG|Newly diagnosed children with diffuse intrinsic pontine glioma who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid (TT) peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
89288461|NCT02960230|Experimental|Stratum B: Newly Diagnosed Glioma (non-DIPG)|Newly diagnosed children with gliomas other than DIPG who are positive for HLA-A2 and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks.
89288462|NCT02960230|Experimental|Stratum C: Newly Diagnosed DIPG or other Midline Glioma|Newly diagnosed children with DIPG or other midline gliomas (excluding primary spinal cord tumors) who are positive for HLA-A2 (02:01) and the H3.3K27M mutation that underwent radiation therapy will receive the specific H3.3K27M peptide vaccine, combined with the tetanus toxoid peptide, emulsified in Montanide. Poly-ICLC, which is a synthetic nucleic acid, will be given concurrently to improve the therapeutic effects of the vaccine. Nivolumab will also be given via IV. Vaccine will be given every 3 weeks for the first 24 weeks, then if there is stable or improved disease, will be given every 6 weeks for a total treatment period of 96 weeks. Nivolumab will continue to be given every 3 weeks throughout all of treatment.
89288463|NCT02942368|Experimental|tDCS|Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks. Treatments will take place daily, 5 days per week.
89288464|NCT02935686|Experimental|Group 1: Ad26.Mos4.HIV + Clade C gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12, followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminium phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
89288465|NCT02935686|Experimental|Group 2: Ad26.Mos4.HIV + Clade C gp140 + Mosaic gp140|Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + combination of 125 mcg Mosaic gp140 and 125 mcg Clade C gp140 mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants who receive all 4 vaccinations and are negative for HIV infection at Week 72 can consent to be included in a long-term extension (LTE) phase (approximately 3 years after Week 72).
89288466|NCT02935686|Placebo Comparator|Group 3: Placebo|Participants will receive a single placebo injection at Weeks 0 and 12, followed by two placebo injections at Weeks 24 and 48.
89288467|NCT02935686|Experimental|Group 1b: Ad26.Mos4.HIV + gp140 HIV Bivalent Vaccine|Participants enrolled in the LTE phase will receive late boost vaccination Ad26.Mos4.HIV and bivalent gp140 within 4 weeks prior to Week 192 until 4 months after Week 192 (that is, approximately 3 years after the 4th vaccination of the primary vaccination series).
89288468|NCT02935686|Placebo Comparator|Group 2b: Placebo|Participants will receive placebo injection at Week 192 -4 weeks/+4 months, that is, approximately 3 years after the 4th vaccination of the primary vaccination series.
89288469|NCT02923206|Experimental|Phase 0 - healthy volunteers|Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
89288470|NCT02923206|Experimental|Phase A - preeclampsia patients|Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
89288471|NCT02923206|Experimental|Phase B - preeclampsia patients|Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.
89288472|NCT02918253|Experimental|Tumour visible on MRI|Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose
89288473|NCT02918253|Active Comparator|No tumour visible on MRI|Whole-gland HDR Brachytherapy
89288474|NCT02907866||Patients undergoing bronchoscopy|All patients presenting for bronchoscopy (These patient are expected to have normal pleural sliding sign identified by ultrasound)
89288475|NCT02907866||Patients with pneumothorax|Patients with pneumothorax requiring chest tube(This group of patient is expected to have residual pneumothorax for identification of absence of lung sliding, B lines and lung point)
89288476|NCT02907866||Patients on mechanical ventilation|Patients with respiratory failure on mechanical ventilation(This group of patient is expected to have alveolo-interstitial findings such as B lines)
89288477|NCT02839720|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a volume decrease in the target cutaneous neurofibromas may continue treatment for 12 additional cycles.
89288478|NCT02834637|Active Comparator|3 doses 2valent|3 doses of bivalent HPV vaccine (Cervarix) given at M0, M1 and M6
89288479|NCT02834637|Active Comparator|2 doses 2valent|2 doses of bivalent HPV vaccine (Cervarix) given at M0 and M6
89288480|NCT02834637|Active Comparator|1 dose 2valent|1 dose of bivalent HPV vaccine (Cervarix) given at M0
89288481|NCT02834637|Active Comparator|3 doses 9valent|3 doses of nonavalent HPV vaccine (Gardasil9) given at M0, M2 and M6
89288482|NCT02834637|Active Comparator|2 doses 9valent|2 doses of nonavalent HPV vaccine (Gardasil9) given at M0 and M6
89288483|NCT02834637|Active Comparator|1 dose 9valent|1 dose of nonavalent HPV vaccine (Gardasil9) given at M0
89288484|NCT02798783||Diagnosed with EVA|Self-reported Enlarged Vestibular Aqueduct (EVA), or, when available, radiological diagnosis of EVA will be used to define the cohort.
89288485|NCT02773407|Active Comparator|Group A|Azithromycin tablets 20mg/kg/day for 7 days (Maximum dose 1000mg/day)
89288486|NCT02773407|Active Comparator|Group B|Co-trimoxazole tablets (Trimethoprim 10 mg/kg+Sulphamethoxazole 50 mg/kg) in two divided doses everyday for 7 days (maximum 3000mg/day)
89288487|NCT02763683||Parkinsons Disease|Individuals with Parkinsons Disease
89288488|NCT02763683||Healthy Controls|Individuals without Parkinsons Disease
89288489|NCT02709343|Experimental|Bone-marrow derived MSCs|4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks
89288490|NCT02709343|Placebo Comparator|Placebo|Placebo product manufactured to look like MSCs
89288491|NCT02708914|Other|UB-851|
89288492|NCT02708914|Other|Eprex then UB-851|
89288493|NCT02696239|Active Comparator|V-lock suture|V-lock absorbable Wound Closure Device, by Covidien
89288494|NCT02696239|Active Comparator|Vicryl suture|Vicryl suture by Ethicon
89288495|NCT02696239|Active Comparator|Lapra-Ty II|Lapra-Ty II, Absorbable Suture Clip, by Ethicon
89288496|NCT02649647|Active Comparator|Conventional Resection|Patients receive conventional resection with standard proximal excision margin. The sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
89288497|NCT02649647|Experimental|Proximally Extended Resection|Patients receive proximally extended resection. The whole sigmoid colon and rectum proximal to the tumor is removed, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
89288498|NCT02643095|Experimental|Lens fitting/evaluation|This study will be done with subjects who already habitually wear scleral contact lenses. The study lens is made with a material that is already widely available and has a new design. It will be fit by the investigators and will be assessed and at one week and 1 month.
89288499|NCT02642042|Experimental|Treatment (trametinib, docetaxel)|Patients receive trametinib PO on days 1-21. Patients also receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89288500|NCT02608268|Experimental|Phase I Dose escalation: MBG453 Q2W ROW|Sabatolimab every 2 weeks (Q2W) in Phase I Dose Escalation Part in rest of the world (ROW) patients
89288501|NCT02608268|Experimental|Phase I Dose escalation: MBG453 Q2W Japan|Sabatolimab Q2W in Phase I Dose Escalation Part in Japanese patients
89288502|NCT02608268|Experimental|Phase I Dose escalation: MBG453 Q4W ROW|Sabatolimab every 4 weeks (Q4W) in Phase I Dose Escalation Part in ROW patients
89288503|NCT02608268|Experimental|Phase I Dose escalation: MBG453 Q4W Japan|Sabatolimab Q4W in Phase I Dose Escalation Part in Japanese patients
89288504|NCT02608268|Experimental|Phase Ib Dose Escalation: MBG453 Q2W + PDR001 Q2W|Sabatolimab Q2W in combination with spartalizumab Q2W in Phase Ib Dose Escalation Part
89288505|NCT02608268|Experimental|Phase Ib Dose Escalation: MBG453 Q4W + PDR001 Q4W|Sabatolimab Q4W in combination with spartalizumab Q4W in Phase Ib Dose Escalation Part
89288506|NCT02608268|Experimental|Phase Ib Dose Escalation: MBG453 + Decitabine|Sabatolimab in combination with decitabine in Phase Ib Dose Escalation Part. This arm was not opened for enrollment.
89288507|NCT02608268|Experimental|Dose Ranging Part: MBG453 Q4W|Sabatolimab Q4W in Dose Ranging Part
89288508|NCT02608268|Experimental|Phase II: MBG453 + PDR001|Sabatolimab Q4W in combination with spartalizumab Q4W in non-small cell lung carcinoma (NSCLC) and melanoma
89288509|NCT02608268|Experimental|Phase II: MBG453|Sabatolimab alone in Phase II. This arm was not opened for enrollment.
89288510|NCT02596802|Experimental|FETO therapy|Intervention name: FETO therapy
89288511|NCT02595879|Experimental|Treatment (triapine, chemoradiation)|Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.
89288512|NCT02523716|Experimental|Hypoxia|Mild hypoxia of 15% oxygen, equivalent altitude of 2440m over a period of 7 days
89288513|NCT02523716|Sham Comparator|Normoxia|Exposure to normal, sea-level air
89288514|NCT02510261|Experimental|Prior Placebo Group of Study 004|Participants who received placebo and completed parent study ALN-TTR02-004 (NCT01960348) were enrolled to receive 0.3 milligrams per kilogram (mg/kg) patisiran intravenously (IV) once every 3 weeks (Q3W) up to 65.5 months.
89288515|NCT02510261|Experimental|Prior Patisiran Group of Study 004|Participants who received patisiran and completed parent study ALN-TTR02-004 (NCT01960348) were enrolled to receive 0.3 mg/kg patisiran IV Q3W up to 66.9 months.
89288516|NCT02510261|Experimental|Prior Patisiran Group of Study 003|Participants who received patisiran and completed parent study ALN-TTR02-003 (NCT01961921) were enrolled to receive 0.3 mg/kg patisiran IV Q3W up to 61.4 months.
89288517|NCT02506192|Experimental|Modified-Release Prednisone|Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm
89288518|NCT02506192|Placebo Comparator|Placebo|Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm
89288519|NCT02476825|Active Comparator|Inhaled fluticasone|Inhaled fluticasone propionate (via dry powder inhaler [Accuhaler]), 500 micrograms b.i.d. for 4 weeks
89288520|NCT02476825|No Intervention|Observational|Observation
89288521|NCT02453984|Experimental|1|89Zr-MPDL3280A-PET scan
89288522|NCT02424123||The study population|The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).
89288523|NCT02413606|Experimental|Intervention|reduced follow-up schedule: 4 follow-up visits, after 3, 12, 24 and 36 months
89288524|NCT02413606|No Intervention|control|regular follow-up schedule according to the guideline, 10-13 visits during 5 years
89288525|NCT02408757||All study participants|The study population consists of consecutive patients undergoing clamping of EVD/LD treated at the Departments of Neurosurgery or Intensive Care Medicine at the University Hospital Bern
89288526|NCT02395666|Experimental|DFMO twice daily|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
89288527|NCT02339220|Experimental|Standard CI Therapy Group|This group will receive Constraint-Induced Movement Therapy (CIMT) with the Standard Transfer Package (sTP).
89288528|NCT02339220|Experimental|Enhanced CI Therapy Group|This group will receive CIMT with the enhanced Transfer Package (eTP).
89288529|NCT02339220|Active Comparator|Standard Fitness Training Group|This group will receive Lakeshore Enriched Fitness Training (LEFT) with the standard Transfer Package (sTP).
89288530|NCT02339220|Active Comparator|Enhanced Fitness Training Group|This group will receive LEFT with the enhanced Transfer Package (eTP)
89288531|NCT02323464||Before surgery|patients scheduled for surgery of colorectal cancer
89288532|NCT02323464||Open surgery for colorectal cancer|investigated after open surgery of colorectal cancer
89288533|NCT02323464||Laparoscopic or robotic surgery|investigated after laparoscopic or robot surgery of colorectal cancer
89288534|NCT02323464||Control subjects|Controls from the population without colorectal cancer
89288535|NCT02245321|Placebo Comparator|Letter Group- No information|Receive a thank you letter after each blood donation.
89288536|NCT02245321|Experimental|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
89288537|NCT02245321|Placebo Comparator|Ferrous gluconate- 0 mg|Receive pills to take daily that contain no iron (a placebo or inert pill).
89288538|NCT02245321|Experimental|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
89288539|NCT02245321|Experimental|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
89288540|NCT02223819|Experimental|Crizotinib|Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
89288541|NCT02194530||Peanut allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
89288542|NCT02194530||Allergic/atopic individuals (not peanut)|Subjects should not be allergic to peanut. 20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
89288543|NCT02194530||Non-allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
89288544|NCT02030067|Experimental|RX-3117|All subjects will receive RX-3117.
88805780|NCT00210470|Experimental|IRX-2 Regimen|The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin, zinc supplementation, and omeprazole.
88805781|NCT00212264|Experimental|Behavioral Therapy|Behavioral Therapy (Pelvic floor muscle training, bladder control strategies)
88805782|NCT00212264|Experimental|Behavioral Therapy Plus Technologies|Behavioral therapy plus technologies (home pelvic floor electrical stimulation and biofeedback)
88805783|NCT00212264|Placebo Comparator|Placebo Comparator|No treatment control
88805784|NCT01108445|Active Comparator|RAD001|Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
88805785|NCT01108445|Active Comparator|Sunitinib|Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
88805786|NCT01607892|Experimental|selinexor|
88805787|NCT01108757|Experimental|Drug|
88805788|NCT01108757|Placebo Comparator|Placebo|
89288545|NCT02027935|Experimental|Treatment (T cells, chemo, aldesleukin, ipilimumab)|Beginning 48 to 72 hours prior to T cell infusion, patients receive cyclophosphamide IV over 30-60 minutes. Patients then receive autologous CD8+ melanoma-specific T cells IV over 30-60 minutes on day 0, aldesleukin SC BID on days 0-13 and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
89288546|NCT02017366|No Intervention|Control|Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
89288547|NCT02017366|Active Comparator|Enteral feeding|Treatment group: start jejunostomy feeds from day 1, with target of 1000ml = 1000kCal (= 40cc/hour). To equilibrate energy intake during build up fase, Glucose 20% is given at a total cumulative dose taking into account the dose of j-drip, cumulative not exceeding 40cc/hr. Oral feeds are started at the same time as in the control group (reg. day 5) Jejunostomy feeds are then continued for 6 weeks together with oral intake with a continuous energy administration of 1000kCal, and then stopped. After this time, patients should be on regular full diet in both groups. If failure and step-back needed, temporary switch to Glc 20% is done to maintain fluid and calory administration.
89288548|NCT01866540|Experimental|Fluenz vaccine|LAIV vaccine
89288549|NCT01811394|Experimental|protons|16x4GyE protons
89288550|NCT01811394|Experimental|Carbon ions|16x4GyE carbon ions
89288551|NCT01788020|Experimental|DRC+Bortezomib|"Induction experimental arm (Arm B):~Cycle 1:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5~Cycle 2-6:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
89288552|NCT01788020|Active Comparator|DRC|"Induction standard arm (Arm A)~Cycle 1:~Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5;~Cycle 2-6:~Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
89288553|NCT01708941|Experimental|Arm A (higher dose ipilimumab, HDI)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
89288554|NCT01708941|Experimental|Arm B (higher dose ipilimumab)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
89288555|NCT01708941|Experimental|Arm C (lower dose ipilimumab + HDI)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
89288556|NCT01708941|Experimental|Arm D (lower dose ipilimumab)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
89288557|NCT01652235|Experimental|Endovascular|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft
89288558|NCT01580826|No Intervention|raw milk|Infants who were assigned to the raw group received fresh or thawed milk from their own mother, cultured weekly with a semi-quantitative analysis. Raw milk was withheld if it contained any Gram-negative organisms, S. aureus or enterococci.
89288559|NCT01580826|Active Comparator|pasteurized milk|Infants who were assigned to pasteurization received own mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
89288560|NCT01514669||No treatment|No Tx, this is observational
89288561|NCT01495676|Active Comparator|Radiotherapy + cisplatin|
89288562|NCT01495676|Experimental|Radiotherapy + cisplatin + gemcitabine|
89288563|NCT01113697||Clinical Investigator Collaborative (CIC) Asthma study cohort|Participants will be healthy volunteer research subjects with allergic asthma who will have an allergen inhalation challenge at CIC sites across Canada.
89288564|NCT01113697||Western Red Cedar Asthma study cohort|Participants will be volunteer research subjects with Western Red Cedar asthma, who will have a plicatic acid inhalation challenge at The Lung Centre at Vancouver General Hospital.
89288565|NCT01113697||Environmental Exposure Unit (EEU), Kingston General Hospital|Subjects will be over 19 years of age so that they qualify for studies involving allergen challenge.
89288566|NCT01052350||Parkinson disease|individuals with Parkinson disease
89288567|NCT01052350||healthy control|individuals without Parkinson disease
89288568|NCT00915122|Experimental|IMRT in prostate cancer|
89288569|NCT00890006|Experimental|MRI + CBCT in prostate cancer|
89288570|NCT00791115|Experimental|prostatectomy after radiotherapy|
89288571|NCT00762645|Experimental|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
89288572|NCT00762645|Active Comparator|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
89288573|NCT00165256|Experimental|Observation (omission of RT)|Wide excision of DCIS; no radiotherapy (RT).
89288574|NCT03949686|Sham Comparator|Saline + Placebo|Ultrasound guided 0.5 ml/kg saline injection to erector spinae plane
89288575|NCT03949686|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound guided 0.5 ml/kg % 0.250 bupivacaine injection to erector spinae plane
89288576|NCT03946956|Active Comparator|Prebooking|Participants randomised to this arm receives a prebooked appointment to screening
89288577|NCT03946956|Placebo Comparator|Web based booking|Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office.
89288578|NCT03946956|Active Comparator|Pictured invitation|Participants randomised to this arm receives a pictured invitation to screening
89288579|NCT03946956|Placebo Comparator|Texted invitation|Participants randomised to this arm receives a classical texted invitation to screening
89288580|NCT01105572|Experimental|Intel Home Health Guide|Participants in the intervention group will receive the use of the Intel Healthguide, an Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback when transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager. Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
89288581|NCT01105572|No Intervention|Case Management Only|All participants in the comparison group, are identified for outreach and assistance by a nurse case manager. Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
89288582|NCT04061382||Randomised selection of population - Group 1|Group 1 will be focusing on COVID-19, diphtheria and group C invasive meningococcal disease. The investigators are aiming to recruit around 2300 individuals and the investigators are aiming to ensure that sample is broadly representative of the region according to IMD (Index of Multiple Deprivation scores). PHE have generated a list of all postcodes in recruiting regions and determining the quintiles of IMD within that region. Participants interested in taking part in the study will contact sites to arrange a visit. Basic demographic characteristics will be collected by questionnaire and/ or case report form (CRF) and will include: DOB, gender, GP details, Ethnic group, association with communities of special interest, household income and vaccination history.The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.
89288583|NCT04061382||Group 2|"Group two will focus on 0-19 year olds only. They will not be restricted to the post code sampling. Instead this will include standard recruitment methods such as social media advertisements within the normal recruiting regions for each site. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients. The questionnaire will gather information regarding potential COVID-19 symptoms both in the participant and the participant's household.~A proportion of participants from this group from selected sites will also provide up to a maximum of three blood samples for separation of peripheral blood mononuclear cells (PBMCs) to evaluate T cell responses. These participants can be either seronegative or seropositive at their Visit 1."
89288584|NCT04061382||Group 3|Group three will consist of up to 300 participants aged 0-19 from the Black, Asian and Minority ethnic population aged 0-19 years. They will not be restricted to the post code sampling and will be recruited at a sub-set of sites depending on capacity and the demographic profile of the local population. Recruitment will be by multiple approaches, including mail outs, radio and advertising in community (e.g. community centres, religious establishments) or Pharmacies and GP practices where we have ethics approval for them to act as PICs. These can vary according to each site's experience and their contacts within their local community on how is best to approach the BAME community. Other methods of recruitment are identification of potential participants by the local study team, staff communication channels and inpatients or outpatients clinics as long as potential participants are not patients.
89288585|NCT03949842|Experimental|Subjects who inhaled non-ELLIPTA MITT|Subjects with moderate or severe exacerbation in the past year and history of use of inhaled non-ELLIPTA MITT of ICS/LABA/LAMA within a routine clinical practice setting in the 52-week retrospective pre-switch period.
89288586|NCT03949842|Experimental|Subjects receiving TRELEGY ELLIPTA SITT|Subjects will receive FF/UMEC/VI (100 microgram [mcg]/62.5 mcg/25 mcg), inhalation powder, once daily, in a single device (TRELEGY ELLIPTA) in the 52-week prospective post-switch period.
89288587|NCT01584960|Experimental|Prostate cancer, endurance training|Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
89288588|NCT01103856|Experimental|Patient Mentor Intervention|The patient mentor intervention from TSHC has been adapted to the inpatient setting. Participants randomized to that arm will receive 2 sessions with a patient mentor during their hospitalization, as well as 5 phone call sessions over the 10 weeks after discharge and a brief meeting between the subject and the mentor when the subject attends their first outpatient visit at TSHC after discharge.
89288589|NCT01103856|Placebo Comparator|HIV transmission risk reduction|Participants randomized to the control arm will receive an attention control intervention delivered by a patient educator who is not an HIV patient mentor. We will use a modified version of the RESPECT intervention for our attention control group. Similar to the active intervention, these patients will receive 2 sessions in the hospital and 5 phone calls over 10 weeks after discharge.
89288590|NCT01102608|Experimental|1|
89288591|NCT01105728|Experimental|Study arm|Endoscopic resection
89288592|NCT01105806||cardiopulmonary resuscitation (CPR) video|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative script in advance directive (AD) completion over a 1 month time frame post intervention.
89288593|NCT01105806||cardiopulmonary resuscitation (CPR) narrative script|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative in advance directive (AD) completion over a 1 month timeframe post intervention.
89288594|NCT01102686|Experimental|Pyrimethamine|
89288595|NCT03949296|Active Comparator|Mindfulness Intervention|Mindfulness-Based Treatment for Insomnia intervention led by a certified instructor. It is adapted from the Mindfulness-Based Stress Reduction Curriculum developed by the Center for Mindfulness in Medicine, Health Care, and Society at the University of Massachusetts Medical School. It introduces the concept of mindfulness and provides the opportunity to practice it within sessions and during home practice. Participants learn about stress, and explore habitual behavioral, physical, emotional and cognitive patterns, as well as more effective responses to challenges and demands of everyday life. Each class includes mindfulness practice, group discussions, and practices and exercises related to the class topics. Participants receive home assignments with guided meditation and yoga practices.
89288596|NCT03949296|Placebo Comparator|Sleep Hygiene|Control group participants attend a 30-minute group counseling session on sleep hygiene. The session includes a handout from the Centre for Clinical Intervention in Australia that provides 15 sleep hygiene tips.
89288597|NCT05499468|Other|Popular-Opinion Leader-led workshops & conversations to encourage utilization of support resources|Physicians identified by programwide Qualtrics survey item asking housestaff who in their program they respect and trust most, personally and professionally. Identified POLs were invited to join this health promotion effort as a POL to improve the culture of wellness and psychological safety among housestaff and encourage them to utilize resources at a time when they may benefit significantly. POLs were trained to endorse the benefits of mental health promotion coaching or therapy for residents training at Stanford.
89288598|NCT05499468|No Intervention|Standard Training Program Curriculum and Access to Existing Support Resources|All residents and fellows continued to have the same access to coaching and psychotherapy resources available through Stanford WellConnect, along with other educational activities in their usual training.
89288599|NCT03949374|Active Comparator|10mg of the generic formulation (rosuvastatin, ROVASRO®)|Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)
89288600|NCT03949374|Active Comparator|10mg of the reference formulation (rosuvastatin, CRESTOR®)|Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)
89288601|NCT05626374|Active Comparator|Basic case management|Basic case management with bi-weekly meetings between case manager and trainees that includes check-ins, frequent visits to construction sites and monitoring of feedback forms from mentors. Case managers attempt to connect trainees with external support services as needed.
89288602|NCT05626374|Experimental|Basic case management supplemented by self-reporting distress tool (DT)|Basic case management plus access to the self-report daily distress tool. The trainees are provided web-based access to the daily distress tool and report their distress levels using a validated visual analog scale (Distress Thermometer), along with reporting their risk of missing work/class or dropping out of the program. The case manager responds to the distress tool by coordinating external support services as needed.
89288603|NCT05626374|Experimental|Basic case management supplemented by rapid access healthcare services|Basic case management supplemented by a fit-for-purpose rapid referral process for trainees with active mental health and/or substance use disorders affecting their program participation.
89288604|NCT05626374|Experimental|Basic case management supplemented by DT and rapid access healthcare services|Basic case management supplemented by both the self-report distress tool and rapid referral process for those trainees at-risk of program absence or drop-out from either mental health or addictions issues.
89288605|NCT01104012||All patients|Allergy patients, asthma and rhinitis
89288606|NCT01104168||Nursing home residents with diabetes|
89288607|NCT03949530|Experimental|IDL-2965 Oral Capsule|IDL-2965 oral capsule, single and multiple doses
89288608|NCT03949530|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single and multiple doses
89288609|NCT05626140|Placebo Comparator|Diclofenac plus placebo|Oral tablet diclofeanc sodium 50 mg was given with tab folic acid 5 mg as placebo ,12 hourly for 15 days
89288610|NCT05626140|Active Comparator|Diclofenac plus codeine|Oral tablet diclofeanc sodium 50 mg was given with tab codeinephosphate 30 mg ,12 hourly for 15 days
89288611|NCT05626140|Experimental|Diclofenac plus lacosamide|Oral tablet diclofeanc sodium 50 mg was given with tab lacosamide 50 mg as placebo ,12 hourly for 15 days
89288612|NCT03949452|Active Comparator|Subcostal Transversus Abdominis Plane catheter|This group includes patients who will receive subcostal Transversus abdominis plane block analgesia
89288613|NCT03949452|Placebo Comparator|Epidural catheter|This group includes patients who will receive epidural analgesia using a catheter technique
89288614|NCT03764774|Experimental|LY3463251 Single dose|Single dose of LY3463251 administered subcutaneously (SC)
89288615|NCT03764774|Placebo Comparator|Placebo Single dose|Single dose of placebo administered SC
89288616|NCT03764774|Experimental|LY3463251 Multiple Dose|Multiple doses of LY3463251 administered SC
89288617|NCT03764774|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered SC
89288618|NCT03944850|Experimental|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.The one time intervention takes approximately 45 minutes to complete.
89288619|NCT04878042|Experimental|Active|Mouth wash and nasal spray containing a diluted solution of hydrogen peroxide
89288620|NCT04878042|Placebo Comparator|Placebo|Mouth wash and nasal spray not containing a diluted solution of hydrogen peroxide
89288621|NCT04813614|Experimental|STYLAGE M Lidocaine|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into and/or around the lip mucosa by linear threading injection, multipoint injection, or a combination of both techniques with needle or cannula.~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
89288622|NCT04813614|Active Comparator|Active control group|"The first injection is performed at visit 1 (V1) on Day 0 (D0). D0 is considered as the baseline. The maximum volume to be injected is 2 mL in total for lower and upper lips. The exact volume per lip will be determined by the physician/injector in order to reach optimal volume correction and/or lips' redefinition, as well as the injection technique(s) to be used. Injection is done into the submucosal layer of the lip by linear threading injection or serial puncture techniques injection with needle or cannula.~One optional touch-up injection is allowed at visit 2 (V2) on Month 1 (M1), with a maximum volume to be injected of 1 mL in total for lower and upper lips. No other touch-up injection is allowed until the end of the study.~A total maximum volume of 2.5 mL is recommended for both initial and touch-up injections combined (upper and lower lips)."
88805789|NCT04352153|Experimental|Single-use group|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
89288623|NCT01106118||Group 1|
89288624|NCT01327872|Experimental|Treatment A|
89288625|NCT01327872|Experimental|Treatment B|
89288626|NCT01327872|Experimental|Treatment C|
89288627|NCT01327872|Experimental|Treatment D|
89288628|NCT03944694||Delirious|Patients were delirious if CAM-ICU was positive within 24 hours from admission due to acute ischemic stroke.
89288629|NCT03944694||Non-delirious|Patients were delirious if CAM-ICU was negative within 24 hours from admission due to acute ischemic stroke.
89288630|NCT01108692|Experimental|Active|Patients will be followed by telecardiology.
89288631|NCT01108692|Active Comparator|Control|Patients will be followed in the conventional manner. They will be equipped with telecardiology but data will not be used for patient surveillance.
89288632|NCT01108770||HED affected males|
89288633|NCT01108770||Unaffected male controls|
89288634|NCT00234065|Experimental|1|cilostazol
89288635|NCT00234065|Active Comparator|2|Aspirin
89288636|NCT04730076|Active Comparator|Standard Balloon Dilation|Patients in this group will receive standard balloon dilation therapy.
89288637|NCT04730076|Experimental|Progressive Balloon Dilation|Patients in this group will receive progressive balloon dilation therapy.
89288638|NCT03948126||travel medicine|Healthy adults originating from Sub-Saharan Africa, South America and the Caribbean and attending a travel medicine and international vaccination consultation in France.
89288639|NCT02531711|Experimental|Diet A|Dietary intervention: Dietary fats are adjusted. Key study foods and oils are provided for 12 weeks. Participants learn which foods to eat and which to avoid.
89288640|NCT02531711|Active Comparator|Diet B|Dietary intervention: This diet also adjusts dietary fats, and provides key study foods and oils for 12 weeks.
89288641|NCT01108848||Berinert|Patients requiring treatment with Berinert®
89288642|NCT01106196||MI plus respiratory illness|Patients with an incident myocardial infarction who also have a record of a visit to primary care with a respiratory tract infection
89288643|NCT04696458|Experimental|EXPERIMENTAL PROBIOTIC|1 Multistrain Probiotic Capsule
89288644|NCT04696458|Placebo Comparator|Placebo|1 Identical Placebo Capsule
89288645|NCT04660188|Experimental|Multidisciplinary collaborative care arm|Post-treatment clinical follow-up visits will be staggered between the oncologist and a dedicated PCP. A patient navigator will be assigned to each study participant to conduct follow-up sessions over the phone regularly at an approximate interval of 3 months.
89288646|NCT04660188|No Intervention|Attentional control arm|BCS will receive follow-up care by their oncologists and any other healthcare providers under existing usual care practices at NCCS.
89288647|NCT00233987|Experimental|High-dose therapy plus tandem transplant|Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.
89288648|NCT01108926|Experimental|All Subjects|All Subjects will receive the same intervention
89288649|NCT03946644|Active Comparator|EVLA with keeping of security distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
89288650|NCT03946644|Experimental|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
89288651|NCT03947970|Experimental|[14C] CR845|Subjects will receive a single dose of [14C] CR845 IV solution administered as an IV bolus on Day 1.
89288652|NCT01106508|Experimental|LEQ506|
89288653|NCT04623242|Experimental|Gantenerumab|
89288654|NCT04623242|Experimental|Solanezumab|
89288655|NCT04623242|Placebo Comparator|Matching placebo (Gantenerumab)|
89288656|NCT04623242|Placebo Comparator|Matching Placebo (Solanezumab)|
89288657|NCT03946722|Other|Standard downregulation with GnRH analogue|"Participants in this arm will be assigned to the routine IVF protocol currently being used in the investigators' IVF unit, as outlined below, with one week of downregulation. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Start progesterone (Norethisterone 5mg twice daily orally) on day 14 of downregulation cycle and continue for 11 days. Start GnRH analogue (Buserelin 0.5ml subcutaneously once daily) on day 21 of downregulation cycle and reduce to 0.2ml on day 1 of bleed. Baseline scan on day 1 - 5 of bleed and start oestrogen (Progynova 2mg three times daily orally). Serial scanning from day 10 until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
89288658|NCT03946722|Experimental|Prolonged downregulation with GnRH analogue|"Participants in this arm will be exposed to an additional five weeks of downregulation using a GnRH analogue. Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Baseline scan on day 1-5 of bleed and administer GnRH analogue (Leuprorelin acetate 3.75 mg subcutaneously single injection). 28 days later administer second dose of GnRH analogue (Leuprorelin acetate 1.875 mg subcutaneously), and 21 days later start oestrogen (Progynova 2 mg three times daily orally). Serial scanning from day 10 of oestrogen until endometrial thickness more than 8mm. Once endometrial thickness more than 8mm start progesterone (Cyclogest 400mg twice daily vaginally/rectally and Lubion 25mg twice daily subcutaneously) and proceed to embryo transfer on appropriate day for embryo age."
89288659|NCT01071707||Confirmed Diagnosis of IPF|Subjects in this cohort will continue beyond the screening visit(s) for longitudinal follow up visits for a minimum of 48 weeks and maximum of 80 weeks.
89288660|NCT01071707||No diagnosis of IPF|Subjects that complete screening visits and do not obtain a confirmed diagnosis of IPF will conclude the study at screening, at the time point where IPF is ruled out as a diagnosis.
89288661|NCT03947658|Experimental|Six weeks group|Prosthetic restoration started 6 weeks after surgical crown lengthening
89288662|NCT03947658|Experimental|Fourteen weeks group|Prosthetic restoration started 14 weeks after surgical crown lengthening
89288663|NCT01073033|Experimental|oral supplement1|Oral supplement for pregnant and lactating mothers
89288664|NCT01073033|Active Comparator|oral supplement 2|Oral supplement for pregnant and lactating mothers
89288665|NCT01073033|No Intervention|Reference|No oral supplementation during pregnancy and lactating.
89288666|NCT03973073|Experimental|camouflage group|Topical applications and/or NB-UVB plus Capulin TM on-demand treatment period
89288667|NCT03973073|Other|blank group|Topical applications and/or NB-UVB on-demand treatment
89288668|NCT01104714||All patients|As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.
89288669|NCT03972761|Active Comparator|Group exposed to cognitive remediation|Computerized cognitive remediation program. Program performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
89288670|NCT03972761|Placebo Comparator|Group not exposed to cognitive remediation|Standard remediation performed during inclusion in the EPIREMED patient study (Clinical trial number NCT02757794)
89288671|NCT01147666|Experimental|Cohort A-1 (Roxadustat 1.0 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.0 milligrams (mg)/kg, administered orally 3 times weekly (TIW) in the morning of the day after dialysis (interdialytic days) for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 grams [g]/deciliter [dL]) will be based upon regular monitoring of Hb.
89288672|NCT01147666|Experimental|Cohort A-2 (Roxadustat 1.5 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288673|NCT01147666|Experimental|Cohort A-3 (Roxadustat 2.0 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288674|NCT01147666|Experimental|Cohort A-4 (Roxadustat 1.8 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-85 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288675|NCT01147666|Experimental|Cohort A-5 (Roxadustat 1.8 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 85-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.8 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288676|NCT01147666|Experimental|Cohort A-6 (Roxadustat 1.3 mg/kg TIW)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.3 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288677|NCT01147666|Experimental|Cohort A-7 (Weight Tiered Roxadustat 70-100-150 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.3 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 100 mg, and 150 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288678|NCT01147666|Experimental|Cohort A-8 (Weight Tiered Roxadustat 70-120-200 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288679|NCT01147666|Experimental|Cohort A-9 (Roxadustat 2.0 mg/kg)|Normoresponsive participants (with baseline epoetin alfa dosage 85-150 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288680|NCT01147666|Experimental|Cohort A-10 (Weight Tiered Roxadustat 70-120-200 mg)|Normoresponsive participants (with baseline epoetin alfa dosage 25-115 IU/kg/dose at study entry) will receive tiered, weight-based initial doses of roxadustat (approximately 1.5 mg/kg/dose TIW). Low weight (40 to 60 kg), medium weight (>60 to 90 kg), and heavy weight (>90 to 140 kg) participants will receive roxadustat 70 mg, 120 mg, and 200 mg, respectively, administered as oral capsules for 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288681|NCT01147666|Active Comparator|Cohorts A (Epoetin Alfa)|Normoresponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort A. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
89288682|NCT01147666|Experimental|Cohort B-1 (Roxadustat 1.5 mg/kg TIW)|Hyporesponsive participants (with baseline epoetin alfa dosage 125-400 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 1.5 mg/kg, administered orally TIW for 6 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288683|NCT01147666|Experimental|Cohort B-2 (Roxadustat 2.0 mg/kg TIW)|Hyporesponsive participants (with baseline epoetin alfa dosage >115 IU/kg/dose at study entry) will receive roxadustat capsules at a dose of 2.0 mg/kg, administered orally TIW for 6 weeks. Participants who have not completed 6-week treatment at the time of Amendment 2, will continue treatment for up to 19 weeks. Dose adjustment to achieve correction and subsequent maintenance of target Hb values (11.0-13.0 g/dL) will be based upon regular monitoring of Hb.
89288684|NCT01147666|Active Comparator|Cohort B (Epoetin Alfa)|Hyporesponsive participants will receive IV epoetin alfa treatments on Day 1, at their prestudy dose and according to their prestudy dosing schedule (TIW). Epoetin alfa dosing will occur on dialysis days in each Cohort B. Dose adjustment will be per local standard of care (exclusive of IV iron) for routine maintenance of stable Hb levels on dialysis participants.
89288685|NCT01147666|Placebo Comparator|Cohort B (Placebo)|Hyporesponsive participants will receive placebo matched to roxadustat, administered orally TIW for 19 weeks.
89288686|NCT01073111|Active Comparator|zotarolimus-eluting stents (ENDEAVOR®)|
89288687|NCT01073111|Active Comparator|sirolimus-eluting stents (CYPHER SELECT® PLUS)|
89288688|NCT01073111|Active Comparator|everolimus-eluting stents (PROMUS®)|
89288689|NCT01325987|Placebo Comparator|sugar pill|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
89288690|NCT01325987|Experimental|vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
89288691|NCT03464604||Group 1 Control group|Patients randomized into this group will follow normal standard of care in Nova Scotia
89288692|NCT03464604||Group 2 Active group|"Patients randomized into this group will be part of the active arm of the study. They will be pre-screened and asked the following questions:~Sign an Information and Authorization form~Demographic data: gender, date of birth, ethnicity~Health history (duration of lesion, changes in lesion, specific changes, who identified the lesion, measurement in two greatest dimensions radially and color."
89288693|NCT03947502|Experimental|Intervention Group with|Educational intervention in neurobiology of pain
89288694|NCT03947502|No Intervention|Control group|The control group is treated with usual medication for fibromyalgia, anxiolytics, antidepressants, analgesics, ... Depending on the medical needs and criteria of patients´s primary care physician.
89288695|NCT00256295|Experimental|Gemcitabine plus Oxaliplatin|Gemcitabine given 1000 mg/m2 IV over 100 minutes Every 21 days. Oxaliplatin given 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days.
89288696|NCT03944460|Active Comparator|Contraloid 4 mg|4 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288697|NCT03944460|Active Comparator|Contraloid 12 mg|12 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288698|NCT03944460|Active Comparator|Contraloid 36 mg|36 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288699|NCT03944460|Active Comparator|Contraloid 108 mg|108 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288700|NCT03944460|Active Comparator|Contraloid 320 mg|320 mg Contraloid/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288701|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 4 mg|4 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288702|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 12 mg|12 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288703|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 36 mg|36 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288704|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 108 mg|108 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288705|NCT03944460|Placebo Comparator|Placebo (for Contraloid) 320 mg|320 mg placebo/participant in a single oral dose with a staggered dose for sentinels followed by the rest of the cohort
89288706|NCT01356238|Experimental|MRC media|Use MRC media in the human IVF-ET program
89288707|NCT01356238|Active Comparator|Sydney IVF media|Use Sydney IVF media in the human IVF-ET program
88805790|NCT04352153|Experimental|Research group|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
88805791|NCT05215067|Experimental|AK104 plus Docetaxel|AK104 RP2D + Docetaxel 75mg/m^2 every 3 weeks until progressive disease or unacceptable toxicity.
88805792|NCT05214833|Experimental|Real neurofeedback|The first arm will receive real neurofeedback.
88805793|NCT05214833|Sham Comparator|Sham neurofeedback|The second arm will receive sham neurofeedback.
88805794|NCT01162733|Active Comparator|Study Drug 1|Vancomycin 15mg/kg
89288708|NCT01106664|Placebo Comparator|P|
89288709|NCT01106664|Experimental|E|
89288710|NCT02877004|Active Comparator|Laser for 4 weeks|3 Low-Level Laser Therapy Treatments Weekly
88805795|NCT01162733|Active Comparator|Study Drug 2|Vancomycin 30mg/kg
88805796|NCT02530242|Other|End-tidal Carbon Monoxide Subjects|Children between 1-18 years old with Sickle Cell Anemia
88805797|NCT02530242|Other|End-tidal Carbon Monoxide Controls|Healthy children age matched with subjects.
88805798|NCT05444010|Experimental|mental health|The effect of mandala painting on mental health. Mental health-related anxiety, depression, well-being, distress and death anxiety and depression will be measured.
88805799|NCT01131065|Experimental|Hepatitis B immune globulin|Treatment group (newly liver transplanted subjects due to HBV induced liver disease)
88805800|NCT00214526|Experimental|Alair Group|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
89288711|NCT02877004|Active Comparator|Laser for 6 weeks|2 Low-Level Laser Therapy Treatments Weekly
89288712|NCT02877004|Active Comparator|Laser for 12 weeks|1 Low-Level Laser Therapy Treatment Weekly
89288713|NCT04602156|Experimental|Group T|Patients will be randomized to undergo PC catheter placement (8-French) using the trocar method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
89288714|NCT04602156|Active Comparator|Group S|Patients will be randomized to undergo PC catheter placement (8-French) using the Sellinger method under US guidance while receiving local anesthesia and opioid analgesic, in a bedside setting, either in the US room or in the ICU.
89288715|NCT04587882|Experimental|Telehealth|Participants will be provided with a smartwatch, have access to activity tracking and goal setting through the VALENTINE app, receive micro-randomized, contextually tailored notifications, and receive weekly activity summaries via email, which will be provided to participants and to their exercise physiologist while enrolled in cardiac rehabilitation.
89288716|NCT04587882|Active Comparator|Control|Participants will continue to receive usual care and a smartwatch but without access to the micro-randomized notifications or weekly activity summaries.
89288717|NCT01356316|Experimental|AdimFlu-S Influenza Vaccine|
89288718|NCT01363180||Control|
89288719|NCT01363180||Trauma-exposed without PTSD|
89288720|NCT01363180||Trauma-exposed with PTSD|
89288721|NCT04422262||Moli-sani Study sub-cohort|A sample of 2,500 men and women from the Moli-sani Study cohort (2005-2010) who were re-examined in 2017-2020. Participants will be contacted by telephone by researchers of the Moli-sani Study recruitment team in order to collect dietary, lifestyle and psychosocial information and assess potential changes possibly occurred during Phase 1 lockdown.
89288722|NCT04422262||Italian general population|The project will retrospectively collect data through a web-based survey using Google form. The questionnaire consists of the same items used for the Moli-sani sub-cohort. The project aims at including as many subjects' records as possible.
89288723|NCT03946566||Acupuncture group|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
89288724|NCT03946566||Basic treatment group|Use basic treatments, such as western medicine.
89288725|NCT01318798||Patients with post-operative ARF|"Patients developing acute renal failure (ARF) following liver surgery~ARF was defined according to the RIFLE criteria as an absolute increase in serum-creatinine of more than 0.3 mg/dl above baseline, or an increase of more than 1.5 times the pre-operative baseline value within 48 hours after surgery, or a reduction of urinary output less than 0.5 ml/kg/h for at least 6 hrs."
89288726|NCT01318798||Patients without post-operative ARF|Patients with normal kidney function (without acute renal failure (ARF)) following liver surgery
89288727|NCT01104948|Experimental|DA-8031|
89288728|NCT01104948|Placebo Comparator|Placebo|
89288729|NCT04410562|Experimental|Hydroxychloroquine|Participants will be then randomized in a 1:1 ratio to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days)
89288730|NCT04410562|Placebo Comparator|Placebo|Participants will be then randomized in a 1:1 ratio to placebo (2 tablets for three days, followed by one tablet for 11 days).
89288731|NCT01109160|Experimental|Azithromycin|Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
89288732|NCT01363336||Group 1|
89288733|NCT01105026|Experimental|bioactive glass|
89288734|NCT01363414|Experimental|Artificial tear|One drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
89288735|NCT01363414|Placebo Comparator|Control|one drop of sterile 0.9% sodium chloride solution in the other eye
89288736|NCT03946410|Active Comparator|Screening|Invitation to cardiovascular screening
89288737|NCT03946410|Placebo Comparator|Control|No invitation to cardiovascular screening
89288738|NCT01105104|Other|MedMinder System|
89288739|NCT01105104|Other|MedMinder System - deactivated|
89288740|NCT02223520|Active Comparator|Mupirocin and Chlorhexidine|Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
89288741|NCT02223520|Placebo Comparator|Placebo ointment and placebo cloths|Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.
89288742|NCT03343470||Cushing Syndrome (active phase)|Patients displaying biochemical and clinical features of active Cushing's syndrome
89288743|NCT03343470||Cushing Syndrome (during remission)|Patients at 3-6 months from remission with cortisol levels in the normal range
89288744|NCT01357954|Experimental|Targeted Training|
88805801|NCT00214526|Active Comparator|Control Group|Conventional therapy with ICS+LABA.
89288745|NCT01357954|Other|Control|
89288746|NCT01356472|No Intervention|Linezolid alone|the control group is designed for linezolid alone treated MRSA VAP (standard treatment).
89288747|NCT01105182||Radiofrequency Ablation|
89288748|NCT01106742|Experimental|AndoSan, UC|AndoSan as a supplement to 10 UC patents
89288749|NCT01106742|Experimental|AndoSan, CD|AndoSan as a supplement to 10 CD patients.
89288750|NCT02122198|Placebo Comparator|Placebo|Monthly placebo injections for 6 months under parent study (FAME) protocol (NCT01712230)
89288751|NCT02122198|Active Comparator|GnRH agonist|"Monthly injections of leuprolide acetate 3.75mg for 9 months; first 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study protocol.~Weekly application of estradiol patch 0.075mg/d months 6-9.~Daily medroxyprogesterone acetate 5mg by mouth for 12 days at week 30."
89288752|NCT04617860|Experimental|WVE-120102 (Dose A)|
89288753|NCT03944226|Experimental|Beetroot|16 patients confirmed with a diagnosis of invasive ductal carcinoma who will undergo wide local excision surgery or mastectomy. All patients in the single arm will undergo a 5 day intervention drinking concentrated beetroot juice and 2 magnetic resonance imaging scan sessions pre and post intervention. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
89288754|NCT01106820|Active Comparator|Resistance training|
89288755|NCT01106820|Active Comparator|Relaxation training|
89288756|NCT01363570|Other|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
89288757|NCT04608500|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
89288758|NCT04608500|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
89288759|NCT01105260||control|group with classical rehabilitation program
89288760|NCT01105260||training|group with an 8 weeks interval training program on wheelchair independence
89288761|NCT01109082||Adolescents with idiopathic scoliosis|Adolescents with idiopathic scoliosis
89288762|NCT01363648|Experimental|Choline alfoscerate|choline alfoscerate 400mg, 3 times a day, for 12 weeks.
89288763|NCT01363648|Placebo Comparator|placebo (for choline alfoscerate )|placebo tablet, 3 times a day, for 12 weeks.
89288764|NCT01107054|Experimental|PF-00610355 450 µg|An orally inhaled dose of PF-00610355 450 µg
89288765|NCT01107054|Experimental|PF-00610355 1200 µg|An orally inhaled dose of PF-00610355 1200 µg
89288766|NCT01107054|Active Comparator|moxifloxacin 400 mg|A single oral dose of moxifloxacin 400 mg on Day 4.
89288767|NCT01107054|Placebo Comparator|placebo|A single oral dose of non-matched placebo on Day 4.
89288768|NCT01363726||2|Jewish and Bedouin children < 5 years of age in southern Israel
89288769|NCT03944070|Active Comparator|Intensive Treatment|The participants will receive x1 intraoperative and 3 postop monthly injections. Subsequently, they will follow the treat and extend protocol.
89288770|NCT03944070|Active Comparator|Standard Treatment|The participants will continue their preoperative treat and extend protocol .
89288771|NCT01363804|Experimental|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
89288772|NCT01363882|Active Comparator|Standard NIV|Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of <50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.
89288773|NCT01363882|Experimental|Sleep study titrated NIV|ALS subjects in this arm, who are offered NIV for Forced Vital Capacity (FVC) <50% as per AAN Practice Parameters, will have their initial level of NIV determined polysomnographically. They will be followed with sleep studies at 1 month, 3 months and 6 months to reassess NIV efficacy and NIV will be adjusted as necessary to optimize parameters of oxygenation and ventilation.
89288774|NCT03764462|Experimental|Raloxifene 60mg to AD-101 45mg|Period 1: Raloxifene 60mg, 1 tab, QD, Per oral / Period 2: AD-101 45mg, 1 tab, QD, Per oral
89288775|NCT03764462|Experimental|AD-101 45mg to Raloxifene 60mg|Period 1: AD-101 45mg, 1 tab, QD, Per oral / Period 2: Raloxifene 60mg, 1 tab, QD, Per oral
89288776|NCT03758924|Experimental|Active arm|Week 0-7: Take 1 ml orally of the product daily (solution of ANAVEX2-73)
89288777|NCT03758924|Placebo Comparator|Placebo arm|Week 0-7: Take 1 ml orally of the product daily (placebo)
89288778|NCT05460728|Experimental|Dry needling|
89288779|NCT04585646|Experimental|Orion then Gemini|Subjects will be randomized to wear Orion daily disposable contact lens then Gemini daily disposable contact lens for 2 weeks in this randomized, cross-over bilateral dispensing study.
89288780|NCT04585646|Experimental|Gemini then Orion|Subjects will be randomized to wear Gemini daily disposable contact lens then Orion daily disposable contact lens for 2 weeks in this randomized, cross-over bilateral dispensing study.
89288781|NCT04074928|Experimental|QIVc|Cell-derived Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
89288782|NCT04074928|Active Comparator|Comparator QIV|Comparator Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
89288783|NCT04584788|Experimental|Healthy Adult Volunteers|Controlled hypoxia will be induced and Masimo O3 regional oximeter-derived tissue oxygen saturation (rSO2) readings of somatic tissue will be measured. The readings will be compared with blood reference oxygen saturation values.
89288784|NCT05460572|Other|Patients undergoing PVI procedure and who are treated with peripheral parental nutrition|Patients undergoing elective PVI procedure who will receive peripheral parental nutrition before start of the procedure.
89288785|NCT01363960||neonates with retinopathy of prematurity|"all neonates meet the criteria:~a BW of less than 1501 gram (g)~born at a GA of 34 weeks (wk) or less and~selected infants with an unstable clinical course were included"
89288786|NCT03764306|Active Comparator|Carotid Artery Stenting|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent with a proximal protection system Mo.Ma
89288787|NCT03764306|Active Comparator|Endarterectomy carotid artery|Subjects will undergo carotid endarterectomy
89288788|NCT03949504||General population|Male and Female subjects (n=1000) over 34 years of age randomly recruited from the participants to the recall phase of the Moli-sani study
89288789|NCT03949504||Patients with type 2 Diabetes|Male and Female patients with type 2 diabetes (n=550) without (n=200) or with cardiovascular (n=200) or neurological (n=150) complications consecutively admitted to the IRCCS Neuromed
89288790|NCT05460416|Experimental|Treatment by acetylsalicylic acid|
89288791|NCT05460416|No Intervention|No treatment|
89288792|NCT01364194|Active Comparator|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
89288793|NCT01364194|Placebo Comparator|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
89288794|NCT03755648|Experimental|Treadmill training|Group A: received treadmill training along with traditional physiotherapy.. The motorized treadmill was used keeping treatment parameters as 50 Hertz, 10 Ampere and 220 Volts The treadmill training was provided by giving instructions first and then warm up was given for 5 minutes prior to the training. The children were upright with the feet flat on treadmill platform. The height of handrails was adjustable according to every child thus keeping their gaze forward. The training was ended at cool down period of 5 minutes
89288795|NCT03755648|Other|traditional physical therapy|Traditional therapy includes use of hot packs for 15 minutes and stretching for 20 minutes which will be applied to both groups prior to actual intervention
89288796|NCT03755648|Experimental|Delorme Resistance exercise|Group B received delorme resistance exercise with traditional physiotherapy. Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
89288797|NCT03753464||Peri-implantitis|Patients undergoing surgical treatment for peri-implantitis. Gingival and blood samples will be collected during the treatment for peri-implantitis.
89288798|NCT03753464||Healthy|Healthy patients undergoing treatment for either wisdom tooth extraction or gingivectomy. Gingival and blood samples will be collected during either wisdom tooth extraction or gingivectomy.
89288799|NCT01321814|Experimental|Cognitive behavioural therapy (CBT)|Patients receiving 6 sessions of CBT conducted by a licensed psychologist. Sessions include psychoeducation, exposure treatment, behavioral activation and applied relaxation.
89288800|NCT01321814|No Intervention|Waiting list|Patient waits for CBT treatment for 6 months.
89288801|NCT03906994|Experimental|Subjects with Amblyopia|Adult amblyopia subjects will play the video game Mario Kart Wii
89288802|NCT03753386|Experimental|Healthy subjects|Subjects not presenting any pulmonary pathology that will follow the intervention Oxygen therapy simulation.
89288803|NCT01364350||TODAY cohort|The cohort of participants diagnosed with type 2 diabetes ages 10 to <18 and obese at time of diagnosis who participated in the TODAY clinical trial are recruited, consented and followed.
89288804|NCT03753308||1a, HBV patients / no scheduled biopsy|"Intervention : Blood Sampling~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~HBsAg positive for more than 6 months~known status of HBeAg (positive or negative)~Treated or not with an antiviral"
89288805|NCT03753308||1b, HBV patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~HBsAg positive for more than 6 months~known status of HBeAg (positive or negative)~Treated or not with an antiviral~Patient with a liver biopsy indication as part of the treatment within 3 months."
89288806|NCT03753308||2, NASH patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~The existence of at least one element of metabolic syndrome~Steatosis detected by non-invasive tests (echo, CAP, MRI)"
89288807|NCT03753308||3, Blood samples from healthy donors|"No subject will be included in this group, the samples have been already collected at EFS from healthy donors who had previously given their informed consents for using their blood samples in the research.~The blood samples have been collected in sufficient quantity to carry out the analyzes (20mL from each donor)."
89288808|NCT01364506|Experimental|Water exercise|
89288809|NCT01364506|No Intervention|Control|
89288810|NCT04575038|Experimental|Brequinar 100 mg|Brequinar oral capsules 100 mg x 5 days
89288811|NCT04575038|Placebo Comparator|Placebo|Placebo for Brequinar capsules x 5 days
89288812|NCT03066622|Active Comparator|Standard of Care|IV Morphine or any medication per attending decision
89288813|NCT03066622|Experimental|Olanzapine|oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
89288814|NCT03764228|Experimental|hAECs|Infusion of hAECs at the day before HSCT and 7th days after HSCT. The dose is 1×10^6, 2×10^6, 5×10^6 cell/kg, successively.
89288815|NCT05372120|Experimental|ICP-192|20 mg once daily
89288816|NCT01364818||Placebo Comparator: Placebo|No treatment/ performance of somatosensory task (cortical metrics) without any intervention. The somatosory task will be performed before any intervention/at the midpoint/ and finally at the end.
89288817|NCT01364818||Active Comparator: Active Medication|Treatment (memantine, lurasidone)/ performance of somatosensory task (cortical metrics) with intervention. The somatosory task will be performed before any intervention has started/at the midpoint/ and finally at the end.
89288818|NCT03764150||PaCO2> 45 mmHg|Diurnal hypercapnia defined by PaCO2> 45 mmHg
89288819|NCT03764150||PaCO2 <45 mmHg|PaCO2 diurnal within the limits of normal (PaCO2 <45 mmHg)
89288820|NCT03029104|Active Comparator|Group 1|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
89288821|NCT03029104|Active Comparator|Group 2|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
89288822|NCT03029104|Active Comparator|Group 3|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.
89288823|NCT03753230|Experimental|EEG Device 1|Participants are listening to music while their neural activity is recorded with Emotiv Epoc+
89288824|NCT03753230|Experimental|EEG Device 2|Participants are listening to music while their neural activity is recorded with g.tec
89288825|NCT03753230|Active Comparator|High density EEG|Participants are listening to music while their neural activity is recorded with high density 256 electrodes EEG Geodesic
88805802|NCT02537574|Experimental|NTX/BUP|Oral naltrexone + sublingual buprenorphine
89288826|NCT03763916|Active Comparator|Intra operative ureteric dissection|midline abdominal incision extending supraumbilical, incision of the SC tissue, dissection and splitting of the recti, classic midline incision of the uterus [above the site of placental insertion], delivery of the fetus , avoid traction of the placenta, quick closure of the uterus [in presence of the placenta] in one layer, clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
89288827|NCT03763916|Active Comparator|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy [Karl storz] is done to identify the ureteric orifices. ureteric catheters [Roche] are inserted followed by the insertion of Foley's urethral catheter.
89288828|NCT01364974|Experimental|Group A|low dose, all male
89288829|NCT01364974|Experimental|Group B|medium dose, all male
89288830|NCT01364974|Experimental|Group C|high dose, all male
89288831|NCT01364974|Experimental|Group D|medium dose, all female
89288832|NCT01364974|Placebo Comparator|Placebo|
89288833|NCT05323214|Other|Control group|Normal saline 2 ml will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
89288834|NCT05323214|Other|Fentanyl group|Fentanyl 2 ml (100 μg) will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
89288835|NCT05323214|Other|Dexmedetomidine group|Dexmedetomidine 1 ml (100 μg) plus 1 ml normal saline will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.
89288836|NCT02369536|Active Comparator|nutraceutical mixture|Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)
89288837|NCT02369536|Placebo Comparator|placebo|Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)
89288838|NCT03753152|Experimental|Investigational medical device|Neuramis® Deep Lidocaine
89288839|NCT03753152|Active Comparator|Comparator device|YVOIRE® Volume Plus
89288840|NCT05283746|Experimental|Open Label|All subjects in Cohorts 1-4 receive 500 mg epetraborole once; Subjects on Cohort 5 receive 500 mg epetraborole twice
89288841|NCT01936480|Experimental|Moxifloxacin group|Healthy volunteers with QT genotype score in the highest or lowest quintile
89288842|NCT01936480|Placebo Comparator|Placebo group|Healthy volunteers with QT genotype score in the highest or lowest quintile
89288843|NCT05460260||GLUCODAY21|Study subjects for 21-day study
89288844|NCT03755258|Experimental|GCK 100 mg group|GCK 100 mg+ Placebo 200 mg GCK tablet 100 mg + Placebo tablet 100 mgX2 tablets, once daily for 12 weeks (oral)
89288845|NCT03755258|Experimental|GCK 200 mg group|GCK 200 mg + Placebo 100 mg GCK tablet 100 mg X 2 tablets+ Placebo tablet 100 mg once daily for 12 weeks (oral)
89288846|NCT03755258|Experimental|GCK 300 mg group|GCK tablet 300 mg GCK tablet 100 mgX3 tablets once daily for 12 weeks (oral)
89288847|NCT03755258|Placebo Comparator|Placebo of GCK group|Placebo 300 mg Placebo tablet 100 mgX3 tablets, once daily for 12 weeks (oral)
89288848|NCT01575886|Experimental|Smoking cessation intervention|This group receives the teachable moment communication process intervention focused on smoking cessation and contributes data at baseline (Time 1) and post intervention (Time 2).
89288849|NCT01575886|Other|Delayed intervention group|This group serves as the comparison group for the evaluation of the smoking cessation intervention at Time 1 and Time 2 data collection to complete the group randomized trial. This group of clinicians then has Time 3 data collection focused on weight management receives a revised intervention focused on teachable moment communication for weight management and has Time 4 data collected to evaluate the teachable moment for weight management training as a pre-post design.
89288850|NCT03755180|Experimental|Group 1|Exercise Group
89288851|NCT03755180|Active Comparator|Group 2|Compression Group
89288852|NCT01356550|Experimental|Healthy subjects|
89288853|NCT01356550|Experimental|Hepatic impairment|
89288854|NCT03755024||normal group|fetuses with normal growth
89288855|NCT03755024||Growth retardation group|fetuses with retarded growth
89288856|NCT01356706||CRLM|patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study)
89288857|NCT01321892||Squamous cell carcinoma|Patients included in this study will be receiving surgical treatment for their biopsy-proven squamous cell carcinoma.
89288858|NCT01356784|Experimental|Tailored Physical Activity|
89288859|NCT01356784|Active Comparator|"Chronic Pain Self-management Programme"|
89288860|NCT01356784|Other|Health Counselling|
89288861|NCT01356862|Experimental|PASIREOTIDE|INTRAMUSCULAR INJECTION OF PASIREOTIDE 60 MG
89288862|NCT01356862|Placebo Comparator|PLACEBO|INTRAMUSCULAR INJECTION OF PLACEBO
89288863|NCT03763760|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
89288864|NCT03763760|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
89288865|NCT01357018||patients with rheumatoid arthritis|
89288866|NCT01357018||patients with ankylosing spondylitis|
89288867|NCT03763682|Experimental|Genio(TM) system therapy|Genio(TM) bilateral hypoglossal nerve stimulation system
89288868|NCT01357096|No Intervention|Comparison group|
89288869|NCT01357096|Experimental|Integrated health care team|
89288870|NCT01357174||All Participants|Infants who were vaccinated with ROTATEQ™
89288871|NCT01365442||Consenting, eligible participants|All consenting eligible participants in the study area will receive the oral cholera vaccine
89288872|NCT04501952|Experimental|Remdesivir (RDV)|Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.
89288873|NCT04501952|Placebo Comparator|Placebo|Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.
89288874|NCT00321100|Active Comparator|Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab|Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
89288875|NCT00321100|Active Comparator|Cetuximab, Oxaliplatin, Capecitabine|Cetuximab 400 mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly of each 21 day cycle; Oxaliplatin 130mg/m2 IV day 1 of each 21 day cycle; Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
89288876|NCT01365520|Experimental|N8|
89288877|NCT05191732|Experimental|PRP augmentation ACL reconstruction group|Platelet-rich plasma (PRP) (Dosage form: APA-15)
89288878|NCT05191732|Experimental|PRP+BMC augmentation ACL reconstruction group|Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
89288879|NCT05191732|No Intervention|Traditional ACL reconstruction group|No intervention
89288880|NCT05191654||with Congenital heart diseases|
89288881|NCT05191654||without Congenital heart diseases|
89288882|NCT02930122|Experimental|Anakinra|Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury
89288883|NCT02930122|Placebo Comparator|Placebo Control|Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury
89288884|NCT01365598|Placebo Comparator|Placebo|Non-active drug
89288885|NCT01365598|Experimental|Low dose primaquine (PQ1)|Lowest experimental dose of primaquine base: 0.1mg/kg
89288886|NCT01365598|Experimental|Intermediate dose primaquine (PQ2)|Intermediate experimental dose of primaquine base: 0.4mg/kg
89288887|NCT01365598|Active Comparator|Reference dose primaquine (PQ-R)|WHO-recommended dose of primaquine base: 0.75mg/kg
89288888|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
89288889|NCT01365676|Active Comparator|GAMALINE® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
89288890|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 45-55 years old|Climacteric women with PMS symptoms
89288891|NCT01365676|Active Comparator|GAMALINE® 45-55 years old|Climacteric women with PMS symptoms
89288892|NCT01365208||advanced nasopharyngeal carcinoma|
89288893|NCT01358032|Experimental|Cognitive behavioral program|an in-home cognitive behavioral program on managing concerns about falling and associated activity avoidance in frail community-dwelling older people facilitated by trained community nurses.
89288894|NCT01358032|No Intervention|Control group|no program, only care as usual
89288895|NCT01365286|Active Comparator|Ivabradine-Placebo|
89288896|NCT01365286|Active Comparator|Placebo-Ivabradine|
89288897|NCT01365364|Active Comparator|PLM group|Individuals with increased periodic leg movement index (>5)
89288898|NCT01365364|Active Comparator|Non-PLM group|Individuals with PLM index <5
89288899|NCT03697460|Experimental|INCB018424|INCB018424 Cream
89288900|NCT05191498|Experimental|Study patients|All patients receive intratumoral holmium microsphere injections.
89288901|NCT03754712|Active Comparator|Intervention Vitamin D3 along with SSRIs|One tablet of vitamin D3 (2000IU) per day for 8 weeks
89288902|NCT03754712|No Intervention|SSRIs|Patients treated with SSRIs
89288903|NCT01318954||Subjects on allergen immunotherapy|Measurements of Nitric Oxide by NIOX MINO. This device is now FDA approved.
89288904|NCT03752606|Active Comparator|TACHOSIL GROUP|Surgical procedures were performed by four doctors with extensive experience in oncological gynecology. A TachoSil® absorbable patch of 4.8x4.8 cm was attached, once, intraoperatively to one side of the obturator fossa (study group). Specific drainage of the retroperitoneum was performed.
89288905|NCT03752606|No Intervention|GROUP WITHOUT TACHOSIL|The same patient constituted also control group, because no TachoSil® absorbable patche was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed.
89288906|NCT05191342||Rheumatoid arthritis|Patients with rheumatoid arthritis (n=25).
89288907|NCT05191342||Rheumatoid arthritis complicated atrial fibrillation|Patients with rheumatoid arthritis complicated atrial fibrillation (n=25).
89288908|NCT05191342||healthy volunteers|Healthy volunteers (n=25).
89288909|NCT01365754|Active Comparator|A|A - Fusion
89288910|NCT01365754|Active Comparator|B|B - Dynamic (new)
89288911|NCT01370044|Experimental|Verum|Verum arm receiving Carbogen
89288912|NCT01370044|Placebo Comparator|Placebo|Placebo arm receiving oxygen
89288913|NCT00070018|Experimental|CHOP + RT + Zevalin|Patients first receive 3 cycles (21 days each) of CHOP, consisting of: cyclophosphamide 750 mg/m^2 on day 1, doxorubicin 50 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 1, and prednisone 100 mg on days 1-5. Patients receive 4000-5000 cGy of radiation therapy in 25 fractions, starting 3 weeks after completion of CHOP. 3-6 weeks after completing RT, patients receive Zevalin, which consists of: rituximab 250 mg/m^2 on days 1 and 7, 8 or 9; In-111 ibritumomab tiuxetan 5 mCi within 4 hours after rituximab on day 1; and Y-90 ibritumomab tiuxetan 0.4 mCi/kg within 4 hours after rituximab on day 7, 8 or 9.
89288914|NCT03750812|Active Comparator|Highly fit older adults - Exercise|This will receive an aerobic exercise intervention
89288915|NCT03750812|Active Comparator|Poorly fit older adults - Exercise|This arm will receive an aerobic exercise intervention
89288916|NCT03750812|Active Comparator|Highly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
89288917|NCT03750812|Active Comparator|Poorly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
89288918|NCT03750812|Active Comparator|Highly fit older adults - TV|This arm will sit at rest and watch television
89288919|NCT03750812|Active Comparator|Poorly fit older adults - TV|This arm will sit at rest and watch television
89288920|NCT03750812|Active Comparator|Highly fit young adults - TV|This arm will sit at rest and watch television
89288921|NCT03750812|Active Comparator|Poorly fit young adults - TV|This arm will sit at rest and watch television
89288922|NCT03750734||Idiopathic bronchiectasis|Idiopathic bronchiectasis participants
89288923|NCT03750734||Healthy volunteers|Healthy volunteers
89288924|NCT00231413|Active Comparator|HPV-16/18 Group|Female subjects who received 3 doses of the HPV-16/18 L1 AS04 vaccine intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
89288925|NCT00231413|Experimental|HPV-TETRA A Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 1 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
89288926|NCT00231413|Experimental|HPV-TETRA B Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 2 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
89288927|NCT00231413|Experimental|HPV-TETRA C Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 3 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
89288928|NCT00231413|Experimental|HPV-TETRA D Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 4 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
89288929|NCT00231413|Experimental|HPV-TETRA E Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 5 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
89288930|NCT00231413|Experimental|HPV-TETRA F Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 6 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
89288931|NCT01370122||Subjects exposed to radiation|
89288932|NCT01370122||Subjects not exposed to radiation|
89288933|NCT03752372||HSCT cohort|IL10RA-deficient patients who received hematopoietic stem cell transplantation
89288934|NCT04494646|Experimental|Bardoxolone Methyl|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
89288935|NCT04494646|Placebo Comparator|Placebo|Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo
89288936|NCT03634774|Experimental|Step 1 CHOICE+|Receives the intervention first
89288937|NCT03634774|Other|Step 2 CHOICE+|Received intervention four months after baseline
89288938|NCT03634774|Other|Step 3 CHOICE+|Receives intervention eight months after baseline
89288939|NCT01073189|Experimental|Intra-Renal Fenoldopam|Intra-Renal Fenoldopam: Patients randomized to this wing will undergo placement of Angiodynamics Benefit catheter and receive intra-renal infusion of fenoldopm mesylate
89288940|NCT01073189|Active Comparator|Diuretic Control|Patients in the control group will be randomized to receive intra-venous diuretics as a comparator control
89288941|NCT05191186|Active Comparator|grass pollen extract treatment|participants receive 3 injections with Alutard phleum pratense, ALK, grass pollen extract
89288942|NCT05191186|Placebo Comparator|Placebo|Participants receive 3 injections with saline (NaCl 0.9%)
89288943|NCT01358110|Experimental|Early palliative care consultation|Early palliative care consultation for ED patients with advanced cancer.
89288944|NCT01358110|Other|Care as usual|Care as usual, may or may not receive palliative care consultation
89288945|NCT00231179|Experimental|Home visiting Intervention|Home visiting intervention group.
89288946|NCT00231179|Placebo Comparator|Control|Control condition did not receive any services.
89288947|NCT05459714|Experimental|MCE for obese patients|After a standardized gastrointestinal preparation, the patient will undergo MCE examination. After completing the MCE procedure, the patient is evaluated for examination comfort and can then leave the hospital on his or her own and watch for capsule excretion.
89288948|NCT01071785|No Intervention|usual diet|no dietary or drug intervention. Patients followed their usual diet.
89288949|NCT01071785|Experimental|guar gum|guar gum
89288950|NCT03750656|Active Comparator|Hyoscyamine|Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort
89288951|NCT03750656|Active Comparator|Tamsulosin|0.4 mg tab orally daily
89288952|NCT01370200|Active Comparator|4% citrate|4% trisodium citrate, starting infusion rate 180 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
89288953|NCT01370200|Active Comparator|15% citrate|15% trisodium citrate, starting infusion rate 50 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
89288954|NCT03752294|Active Comparator|Dabigatran|Participants will receive 150mg dabigatran daily for a total of 9-months.
89288955|NCT03752294|Placebo Comparator|Placebo|Participants will receive placebo daily for a total of 9-months.
89288956|NCT03752294|Active Comparator|Open Label|All study participants are assigned to receive 150mg dabigatran daily for a total of 12 months (study month 9 through month 21)
89288957|NCT03750578|Experimental|Virtual Reality Group|Patients in this group will be offered virtual reality distraction through the use of OR in addition to standard of care.
89288958|NCT03750578|No Intervention|Standard of care group|Patients in this group will receive standard care, including the proposition to use topical anesthetic cream prior to venipuncture attempt, usual distraction and positioning proposed by the treating nurse.
89288959|NCT03135028|Experimental|ENTO monotherapy (Group A)|Participants with relapsed or refractory hematologic malignancies will receive ENTO twice daily of every 28-day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit.
89290547|NCT03931044|Experimental|Image-Guided Robotic Gastrectomy|"The day before surgery, the ICG will be injected endoscopically into the submucosa of the four quadrants around the tumor (1.25mg/mL, 0.6mL x 4).~A modified total D2 gastrectomy - including the following lymph node stations: 1 - 7 + 8a, 9, 11p, 12a - will be performed in each patient.~The lymph node dissection will be performed using the Da Vinci Xi robotic system and the assistance of the near infrared technology to detect ICG fluorescence.~Even the resulting fluorescent lymph nodes outside the standard dissection plane will be retrieved. The lymph node stations will be sent to the pathologist in different containers and further subdivided according to fluorescence."
89288960|NCT03135028|Experimental|ENTO + cytarabine + daunorubicin (Group B)|"Lead-in (Cycle 0): Participants with previously untreated AML will receive ENTO twice daily for 14 days.~Induction (Up to 2 cycles): ENTO in combination with daunorubicin and cytarabine for up to two 28-day cycles.~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants (who have achieved complete remission [CR] or morphologic complete remission with incomplete blood count recovery [CRi] and do not require or cannot proceed to allogeneic stem cell transplantation [SCT] and participants who are awaiting a donor or transitioning to allogeneic SCT per investigator discretion) will have the option to receive post-remission chemotherapy with ENTO twice daily in combination with high-dose cytarabine (Hi-DAC) for up to four 28-day cycles."
89288961|NCT03752138|Experimental|Group 1 Part 1 TK216: Days 1-7|Patients receive TK216 IV continuously on days 1-7 every 21 days.
89288962|NCT03752138|Experimental|Group 2 Part 1 TK216: Days 1-7 and 15-28|Patients receive TK216 IV on days 1-7 and 15-21 every 28 days.
89288963|NCT03752138|Experimental|Part 2 TK216 + Decitabine 10mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
89288964|NCT03752138|Experimental|Part 2 TK216 + Decitabine 20 mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
89288965|NCT03752138|Experimental|Expansion Phase: TK216 + Decitabine|All patients in the expansion cohort will receive the RP2D of TK216 and Decitabine.
89288966|NCT01370434|No Intervention|VAD combination|"vincristine 0.4mg iv on D1-4~doxorubicin 9mg/m2 iv on D1-4~dexamethasone 40mg/d po on D1-4,9-12,17-20~Many physicians use vincristine, doxorubicin, and dexamethasone (VAD) for three to four months as induction therapy (Alexandrian et al, 1990). VAD produces partial response (PR) in about 50% patients, with complete response (CR) observed in 5%-10% patients (Kyle et al, 2004)."
89288967|NCT03754478||overweight subjects|Overweight male and females referred to a physical activity program by their primary care physician Intervention is being included in a 3-month physical activity training program
89288968|NCT01370668|Experimental|Functional remediation|"Patients assigned to the experimental treatment will receive standard psychiatric care and will be enrolled in the neurocognitive intervention program composed of 21 sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 8-to-10 patient group conducted by 2 experienced neuropsychologists. with previous experience with bipolar patients (at least 3 years) and specific training on patients' group management."
89288969|NCT01370668|Active Comparator|Psychoeducation|The group psychoeducation is a tested (Colom et al, 2003) and manualized intervention (Vieta and Colom, 2006) consisting on 21 sessions of 90 minutes, aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences and lifestyle regularity. The program will be performed in an 8-10 patient group conducted by 2 experienced psychologists with previous experience with bipolar patients and specific training on patients' group management. The structure of each session consists of a 30 to 40 minute speech on the topic of the day, followed by an exercise related to the issue (eg. drawing a life chart, writing a list of potential triggering factors) and a discussion.
89288970|NCT01370668|Active Comparator|Treatment as Usual|This arm will not receive any sort of add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
89288971|NCT03754400|Experimental|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
89288972|NCT03754400|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment.
89288973|NCT00228917|Experimental|ACAC_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study ( NCT00317187) are boosted in the current study with one dose of the same vaccines at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
89288974|NCT00228917|Experimental|ACHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
89288975|NCT00228917|Experimental|HibACPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
89288976|NCT00228917|Experimental|HibHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of the same vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
89288977|NCT00228917|Experimental|ACAC_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccines at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
89288978|NCT00228917|Experimental|ACHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
89290548|NCT03931044|No Intervention|Robotic Gastrectomy|Data from patients undergoing the same surgery without the ICG imaging procedure will be collected during the same study period.
89288979|NCT00228917|Experimental|HibACPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
89288980|NCT00228917|Experimental|HibHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
89288981|NCT05190952|Active Comparator|Group 1|Control Group (Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure).
89288982|NCT05190952|Active Comparator|Group 2|Ketamine Group (In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes).
89288983|NCT05190952|Active Comparator|Group 3|Dexamethasone Group (In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes).
89288984|NCT01365832|Experimental|Sleep apnea|"Participants with Obstructive Sleep Apnea (OSA).This arm will undergo a pre-treatment blood draw, six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw 3 and 6 months later.~Intervention: Procedure: Continuous Positive Airway Pressure (CPAP)"
89288985|NCT04523870|Experimental|Botanical extract|
89288986|NCT04523870|Experimental|Major compound of the extract|
89288987|NCT04523870|Placebo Comparator|Placebo|
89288988|NCT01071863||Rheumatoid Arthritis (RA) Patient Group|Patients with RA who have been refered for biological drug treatment
89288989|NCT01071863||Control Group|20 people of same age and sex as the RA patient cohort
89288990|NCT05189626|Experimental|Group A|Muscle energy technique
89288991|NCT05189626|Experimental|Group B|Kaltonborn mobilizations
89288992|NCT03754166|Experimental|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
89288993|NCT03754166|No Intervention|Usual care|Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.
89288994|NCT03972683|Experimental|Handgrip Exercise Training Intervention|"Participants will visit the lab for baseline measurements designed to evaluate signaling mechanisms that regulate blood flow. A physician will place a catheter in the brachial artery for pharmacological infusions. The following drugs will be administered to each participant: acetylcholine, adenosine triphosphate, atropine, phenylephrine, and sodium nitroprusside (see Interventions for further details regarding each drug). The order of infusions will be randomized and blood flow will be allowed to return to baseline between each infusion (~15 min) with the exception of atropine, which will be administered last owing to its longer half-life.~Following baseline measurements, participants will complete a 7 week handgrip exercise training intervention, then they will return to the laboratory for post-training measurements. The post-training assessments will be performed in the same manner as the baseline visit; thus, the same drugs will be infused as described above."
89288995|NCT01370746||Cross-Sectional Study Group|Cross-sectional comparison of perceived barriers to adherence to post-transplant immunosuppressant regimens in parents/legal guardians of children 0-11 years versus adolescents 12-21 years
89288996|NCT01370746||Longitudinal Study Group|Subset of Cross-Sectional Study Group to evaluate whether perceived barriers to adherence increase with time during the first year following transplantation
89288997|NCT01319032||I. Top-level swimmers|
89288998|NCT01319032||II. Control|Other swimmers
89288999|NCT00227903|Experimental|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
89289000|NCT00227903|Active Comparator|Brief Advice|Advice and education
89289001|NCT01370824||Basal cell carcinoma|"- Population: Eligible are patients (men and women) ≥18 years of age who visit the outpatient department of dermatology of the Maastricht University Medical Centre because of a clinically suspected BCC.~- Inclusion criteria: All patients aged 18 years or older, otherwise healthy, with ≤ three primary (no previous treatment) clinically determined BCC.~- Exclusion criteria: Patients using immunosuppressive drugs. Genetic skin cancer disorders. Earlier treatments at the same site. Age under 18 years. More than 3 clinical suspected BCCs. Not capable of informed consent."
89289002|NCT04420546|Active Comparator|Control (volitional help sheet)|"Participants read a brief statement designed to encourage them to be more physically active (We want you to plan to increase your level of physical activity). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted not to be physically active and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
88805803|NCT02537574|Active Comparator|NTX/PBO-B|Oral naltrexone + sublingual placebo
88805804|NCT02537574|Placebo Comparator|PBO-N/PBO-B|Oral placebo naltrexone + sublingual placebo buprenorphine
88805805|NCT05098925|Experimental|Intervention|Study of Thermoregulatory Processes in Ultra-endurance Runners in a Hot and Humid Environment
89290549|NCT01228266|Experimental|autologous mesenchymal stem cell|A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months
89289003|NCT04420546|Experimental|Intervention (volitional help sheet)|"Participants read a brief statement designed to encourage them to avoid self-harming (We want you to plan to avoid self-harming). Participants are presented with a table with two columns and ten rows. Ten 'high risk' situations (temptations) are presented in the left hand column and 10 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to self-harm and identifying ways to overcome those temptations had been shown to help people change their behaviour.~Participants in this condition are asked to form implementation intentions by linking critical situations with appropriate responses by choosing an appropriate response from a drop down menu for each critical situation."
89289004|NCT01358188||Gaucher disease group|Subjects will include individuals with GD
89289005|NCT01358188||Control group|Controls will include healthy individuals and individuals with primary immune dysfunction
89289006|NCT04411628|Experimental|LY3819253|Participants received single doses of 700 milligrams (mg), 2800 mg or 7000 mg LY3819253 administered as intravenous infusion.
89289007|NCT04411628|Placebo Comparator|Placebo|Participants received single dose of Placebo as intravenous infusion.
89289008|NCT01370902|Experimental|Single-dose (SD) trial part (i.v.)|
89289009|NCT01370902|Experimental|Single-dose (SD) trial part (s.c.)|
89289010|NCT01370902|Experimental|Multiple-dose (MD) trial part (s.c.)|
89289011|NCT03973619|Active Comparator|Labial|Patients who received a labial graft as replacement of urethral tissue
89289012|NCT03973619|Active Comparator|Jugal|Patients who received a jugal (inner cheek) graft as replacement of urethral tissue
89289013|NCT03754010|Placebo Comparator|Scaling and root planning (SRP)|Under local anesthesia, full-mouth SRP was performed within 24 h in a single or two sessions using ultrasonic and hand instruments (Gracey, Hu-Friedy, Chicago, IL, USA) by a single investigator (DA). Immediately after the SRP, HA gel (Gengigel, Hyaluronic acid, gingival gel, Ricefarma S.R.L, Italy) or mouthrinse was performed according to the groups' procedure. In Group 1, the periodontal sulcus was irrigated with saline solution after SRP.
89289014|NCT03754010|Experimental|Hyaluronic acid gel (HA) and SRP|Group 2, after SRP was performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA was applied intrasulcular.
89289015|NCT03754010|Experimental|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse (Gengigel, Hyaluronic acid, Hydrogel moutrinse for gums, Ricefarma S.R.L, Italy) were used as an irrigator after SRP.
89289016|NCT03754010|Experimental|HA mouthrinse+gel and SRP|In Group 4, after SRP was performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel was applied.
89289017|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 3 weeks|
89289018|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 4.5 weeks|
89289019|NCT04364854|Experimental|SET (Speech Entrainment Therapy) 6 weeks|
89289020|NCT04364854|Other|No Therapy 6 weeks|
89289021|NCT01366066|Active Comparator|TMNS treatment - Stress incontinence|Women with stress incontinence treated with active TMNS (vibration)
89289022|NCT01366066|No Intervention|No treatment - stress incontinence|Women with stress incontinence NOT treated with TMNS (vibration)
89289023|NCT01366066|Active Comparator|TMNS treatment - Urge incontinence|Women with stress incontinence treated with TMNS (vibration)
89289024|NCT01366066|No Intervention|No treatment - urge incontinence|Women with urge incontinence NOT treated with TMNS (vibration)
89289025|NCT05668910||malignant group|patients diagnosed with high grade Intraepithelial neoplasia or GC (> 50% of patients in stage I and II)
89289026|NCT05668910||non-malignant group|healthy individuals and patients with non-atrophic gastritis, gastric ulcer, gastric polyp or other benign gastric diseases
89289027|NCT00227591|Experimental|Treatment (lenalidomide, prednisone)|For courses 1 and 2, patients receive oral lenalidomide once daily and oral prednisone once daily on days 1-28. For course 3, patients receive oral lenalidomide once daily on days 1-28 and oral prednisone once on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Patients with stable or responding disease after course 3 receive oral lenalidomide alone once daily on days 1-28 for courses 4-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89289028|NCT01358344|Experimental|Standard Percentage|
89289029|NCT01358344|Experimental|High Percentage|
89289030|NCT03750422|Active Comparator|Stratacel|medical grade silicone gel following Picoway Laser treatment
89289031|NCT03750422|Sham Comparator|Vehicle|Clear ultrasound gel following Picoway Laser treatment
89289032|NCT01366222|Placebo Comparator|Placebo|
89289033|NCT01366222|Active Comparator|Food concentrates (FC)|Food concentrates (FC) was including fruit and vegetable, fish and probiotics.
89289034|NCT03752060|Experimental|Resistance Training Group|These participants will participate in a progressive resistance training program three times per week on non-consecutive days for 16 weeks. During each session, participants will perform the following exercises: supine bench press, lat pulldown, lateral raise, seated row, leg press, leg extension, leg curl, biceps curl, and triceps extension. The exercises will be completed such that upper body and lower body exercises are alternated throughout each session. During the Weeks 1-4 of training, the subjects will complete two sets of 15 repetitions for each exercise at approximately 50% of their one-repetition maximum (1RM). During Weeks 5-8 of training, the subjects will complete three sets of 12 repetitions at approximately 60% 1RM. During Weeks 9-12, the subjects will complete four sets of 12 repetitions at approximately 60% 1RM. During Weeks 13-16 of training, the subjects will complete 4 sets of 10 repetitions at approximately 70% 1RM.
89289035|NCT03752060|Active Comparator|Aerobic Training Group|Women randomized to the AT group will engage in aerobic exercise training that complies with ACSM recommendations10. Specifically, women will complete walking or stationary cycling sessions 5 times per week for 16 weeks. Heart rate data from the pre-intervention VO2peak tests (described below) will be used to estimate each participant's target training heart rate. Like the RT regimen, the AT intervention will be progressive in nature. During the first half of the intervention period, duration will increase by 5 minutes every 2 weeks, from 30 min to 45 min. In the second phase of the intervention, duration will remain constant at 45 min, but intensity will increase from 50% to 65% of heart rate reserve (HRR). Exercise sessions will take place on a treadmill and/or cycle ergometer.
89289036|NCT03752060|No Intervention|Control Group|The control group will complete all baseline and post-testing, but will not complete any training for the 16 weeks between the baseline and post-testing sessions. These participants will also be instructed to maintain their current dietary and physical activity habits (see Lifestyle Controls section). All participants in the control group will also be provided an opportunity to come to the laboratory for two weeks after they have completed the study to receive instruction regarding resistance and/or aerobic training exercise prescription, and to complete supervised resistance and/or aerobic exercise training.
89289037|NCT01366300|Active Comparator|Intravenous lidocaine infusion|Intravenous lidocaine infusion during total intravenous anesthesia with propofol administered by target controlled infusion
89289038|NCT01366300|Placebo Comparator|Intravenous 0.9% saline infusion|Intravenous 0.9% saline infusion during total intravenous anesthesia with propofol administered by target controlled infusion
89289039|NCT03751982|Active Comparator|Open-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is not synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
89289040|NCT03751982|Experimental|Closed-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
89289041|NCT05190796||women with history of recurrent pregnancy loss.|100 women who had history of recurrent pregnancy loss.
89289042|NCT05190796||women without history of recurrent pregnancy loss.|50 women who had given birth at term (>37 weeks of gestation) to healthy infants (control group)
89289043|NCT03753698|Experimental|eCoin|Neuromodulation of posterior tibial nerve
89289044|NCT04512482|Experimental|Experimental: Bromelain, Then Placebo|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of bromelain that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the placebo rinse (powdered sugar), following the same protocol and series of intraoral photographs.
89289045|NCT04512482|Placebo Comparator|Experimental: Placebo, Then Bromelain|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of powdered sugar that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the bromelain rinse, following the same protocol and series of intraoral photographs.
89289046|NCT05456204|Other|Refralone group|Patients with recurrent AF/AFL after catheter interventions to restore SR will be cardioverted with refralon
89289047|NCT00226811|Experimental|A|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
89289048|NCT03751904|Other|AcoustiCare|Single Arm
89289049|NCT04903496||Group A: Diabetic patients with CVD, CKD or at risk|The group A includes all Patients with diagnosis of diabetes, and with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk.
89289050|NCT04903496||Group B: Diabetic patients without CVD, CKD or at risk|The group B includes all patients with diagnosis of diabetes, but not with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk.
89289051|NCT04903496||Group C: Non-diabetic patients with CVD, CKD or at risk|The group C includes all patients with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk, but not with diagnosis of diabetes.
89289052|NCT04903496||Group D: Non-diabetic patients without CVD, CKD or at risk|The group D includes all patients without diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk, and without diagnosis of diabetes.
89289053|NCT05261516|Active Comparator|Propofol|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given.~In patients in the propofol group, anesthesia will be induced and maintained with a total intravenous anesthesia pump following the model of Schnider et al, at a targeted effect-site concentration of 4 +/- 1 mcg/ml.~In patients in all groups, after induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital."
89289054|NCT05261516|Experimental|Isoflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: isoflurane in this group."
89289055|NCT05261516|Experimental|Desflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: desflurane in this group."
89289056|NCT05261516|Experimental|Sevoflurane|"In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital.~The anesthesia will be maintained with the agent specified by randomization: sevoflurane in this group."
89289057|NCT03748004|Experimental|Adults living in the DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
89289058|NCT03748004|Placebo Comparator|Individuals 19 yrs or older settled in DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
89289059|NCT00226655|Experimental|I|All patients will receive hCRF (XERECEPT) 2mg/day
89289060|NCT03750344|Experimental|ChroniSense Polso Respiratory Rate|
89289061|NCT03777410||Vanguard|(CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
89289062|NCT03777410||Relapsed/Refractory MM|BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.
89289063|NCT03751826|Experimental|Incentivised network delivery HIV-ST|Peer-navigators will use respondent-driven sampling to distribute HIV-ST kits through 'seeds'. Each 'seed' (female aged 18-24 years) will receive a session on HIV prevention, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. Seeds will be asked to recruit females aged 18-24 years and given 5 uniquely numbered incentivized recruitment coupons with HIV-ST kits to pass on to their peers. Individual who return the coupons will undergo the same procedure as the seeds above and the individual who handed out the coupon will receive a sum of $1.5 in airtime per friend who returns the coupon. The packs include referral slips with information on how to link to HIV community-based confirmatory testing, HIV treatment and PrEP.
89289064|NCT03751826|Experimental|Peer Navigator distributed HIV-ST|Peer navigators will directly distribute HIV-ST kits to females aged 18-24 years over a period of six months. Each person recruited will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV-ST. The packs include referral slips with information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
89289065|NCT03751826|Active Comparator|Standard of care|Peer navigators will encourage females aged 18-24 years to test for HIV at clinics, and link to services/care. Each female aged 18-24 approached by a peer navigator will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. They will then be given a referral slip for HIV testing through the clinic. The referral slips include information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
89289066|NCT03672344|Active Comparator|Lookware TM|Lookware TM computer-based video game that requires the subject to engage in social skills related exercises during simulated social interactions with game characters.
89289067|NCT03672344|Placebo Comparator|Lookware TM Control Module|Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises.
89289068|NCT03747770|No Intervention|Cross-sectional baseline survey|This are will collect behavioral questionnaire and urine in Grade 10 high school and Year 1 vocational school and Grade 12 high school and Year 3 Vocational school female students
89289069|NCT03747770|Active Comparator|Single Dose HPV vaccination|Grade 8 female students from Udon Thani Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Single Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
89289070|NCT03747770|Active Comparator|Two-dose HPV vaccination|Grade 8 female students from Buriram Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Two-Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
89289071|NCT03747770|No Intervention|Cross-sectional survey at Year 2|This arm will collect behavioral questionnaire, urine and blood in Grade 10 high school and Year 1 vocational school female students
89289072|NCT03747770|No Intervention|Cross-sectional survey at Year 4|Cross-sectional survey at Year 4 post vaccination
89289073|NCT03747692|Experimental|study group|patient put in dorsal postion , insertion of a speculum , sterilization of the cervix then intracervical injection of 5 ml mepicaine hydrochloride a local anasthetic as Carbocaine3%54 mg at site 3 and 9 using a 10 cm syringe
89289074|NCT03747692|Placebo Comparator|control group|patient receives one tablet of NSAIDs (diclofenac sodium 50 mg )15 minutes before procedure then 5 ml of normal saline will be injected intracervical using 10 cm syringe then wait for 5 minutes before the procedure
89289075|NCT04520412|Experimental|GV-971|
89289076|NCT04520412|Placebo Comparator|Placebo|
89289077|NCT03751748|Sham Comparator|Control arm|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
89289078|NCT03751748|Experimental|AFR arm|Implantation of Occlutech atrial flow regulator (AFR) device
89289079|NCT03124108|Placebo Comparator|Placebo|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
89289080|NCT03124108|Active Comparator|Elafibranor 80 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
89289081|NCT03124108|Active Comparator|Elafibranor 120 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
89289082|NCT03946488|No Intervention|Inactive neuroprosthesis|
89289083|NCT03946488|Experimental|Active neuroprosthesis|
89289084|NCT04465812|No Intervention|Standard health counseling at baseline|Standard health counseling at baseline
89289085|NCT04465812|Experimental|Self-monitoring and personalized feedback on smartphone app|"Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index > 15 to assess detail clinical status and recommend outpatient visit if necessary;~Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS>49 or SDS>52 to assess detail clinical status and recommend outpatient visit if necessary;~Patients will complete cognitive training games every week on app;~Medical staff will send health information on app"
89289086|NCT04475588|Experimental|Arm A - Itolizumab + BSC|
89289087|NCT04475588|Active Comparator|Arm B - Best supportive care (BSC)|
89289088|NCT03946254|Experimental|Intervention|THE EXPERIMENTAL GROUP WILL DEVELOP 20 WEEKS OF TRAINING TO IMPROVE THE MUSCLE CAPACITY. FOR THIS, FORCE EXERCISES WILL BE DEVELOPED IN GUIDED MACHINES.
89289089|NCT03946254|Experimental|Control|THE CONTROL GROUP WILL DEVELOP 20 WEEKS OF BALANCE AND BREATHING EXERCISES.
89289090|NCT03946020|Active Comparator|Augmentation with autologous bone + DBBM|A layer of autogenous bone chips was placed on the implant surface. On top of this a layer of DBBM (Bio-Oss™, Geistlich®, Wolhusen, Switserland) was placed, thereafter covered with a collagen membrane.
89289091|NCT03946020|Experimental|Augmentation with DBBM|A layer of DBBM was placed on the implant surface and thereafter covered with a collagen membrane. Care was taken to make both augmentations as comparable as possible by weighting the used amount of graft material.
89289092|NCT03750032|Experimental|Stapler appendectomy|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using a stapler.
89289093|NCT03750032|Experimental|Endoloop|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using endoloop.
89289094|NCT03750032|Experimental|Hem-O-Lock|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using Hem-O-Lock.
89289095|NCT04287556||Population in risk of MH|Patient with hypermetabolic response of skeletal musculature by causes related with Malignant Hyperthermia in the literature.
89289096|NCT03947580|Experimental|Use of the Dvectis Single pad|The Dvectis Single Dynamic-directional pad is a basic model of the Dvectis product range that provides full functionality based on the dynamic-directional seating principle. The Dvectis Single pad is designed to steer muscle tension during sitting in deep-seated muscles. The Dvectis Single pad is intended to eliminate chronic lumbar spine pain by strengthening the stabilizing muscles.
89289097|NCT03947580|Experimental|Use of the Dvectis Double pad|The Dvectis Double Dynamic-directional pad is based on the Dvectis Single model, but in addition to its dual-chamber design, it provides seating with a more balanced load and a higher dynamic-directional effect. The Dvectis Double pad is designed to create and route muscle tension during sitting in deep-seated muscles. The Dvectis Double is also suitable for soft substrates (sofa, soft chair, etc.). The Dvectis Double Pad is intended to remove chronic lumbar spine pain by strengthening the stabilizing muscles.
89289098|NCT03947580|No Intervention|Use of no pad|Description is not needed
89289099|NCT01371058|Active Comparator|routine dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically； clopidogrel 75mg/d for 1year.
89289100|NCT01371058|Experimental|high maintenance clopidogrel|aspirin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 150mg/d for 1 month followed by 75mg/d for at least 1 year.
89289101|NCT01371058|Experimental|policosanol plus dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 75mg/d for at least 1 year; Policosanol 40mg/d for 6months.
89289102|NCT03751592|Experimental|Chlorogenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
89289103|NCT03947736||patients with positive HER2 amplification|
89289104|NCT03947736||patients with negative HER2 amplification|
89289105|NCT01371136|Experimental|Curricular Trained|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
89289106|NCT01371136|No Intervention|conventional residency training|These residents proceed through surgical residency training as usual
89289107|NCT01105338|Active Comparator|Green tea drink|Green tea drink
89289108|NCT01105338|Active Comparator|Green tea capsules|Green tea capsules
89289109|NCT01105338|Placebo Comparator|Green tea placebo capsules|Green tea placebo capsules
89289110|NCT01105338|Active Comparator|Lycopene capsules|Lycopene capsules
89289111|NCT01105338|Placebo Comparator|Lycopene placebo capsules|Lycopene placebo capsules
89289112|NCT01105338|Active Comparator|Tomato rich diet|Tomato rich diet
89289113|NCT01371214|Experimental|Group 1|PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
89289114|NCT01371214|Active Comparator|Group 2|Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
89289115|NCT03747614|Experimental|Dry eye group|The recruitment of subjects met the criteria of DEWS. Each subject received treatment based on increasing severity according to the expert consensus for the treatment of DE inflammation. For moderate levels of severity, topical anti-inflammatory agents (0.1% Fluorometholone) were administered twice daily and then gradually less frequently until inflammation was controlled. For severe DE, the approach was similar to that of the moderate level but with an increased concentration and treatment frequency of the anti-inflammatory agents (0.1% Fluorometholone, 4 times daily). Topical 0.05% tacrolimus twice daily when DE was extremely severe. Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
89289116|NCT03747614|Experimental|Control group|Normal health subject without drug intervention, Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
89289117|NCT05206656|Placebo Comparator|Eribulin mesylate|"Metastatic breast cancer patients receive eribulin mesylate injection alone. The dosage is 1.4mg/m2 for one cycle. Injection is performed on Day 1 and Day 8 of a treatment cycle. Patients receive Eribulin untill progression.~Patients were observed for at least 6 months but no longer than 18 months."
89289118|NCT05206656|Experimental|Eribulin mesylate combined with Anlotinib|"Metastatic breast cancer patients receive Eribulin mesylate combined with Anlotinib. The dosage of Eribulin mesylate is 1.4mg/m2 for one cycle. Injection is performed on Day 1 and Day 8 of a treatment cycle.~Anlotinib dosage is 12mg per day for consecutive 14 days (21 days per cycle). Patients receive Anlotinib untill progression.~Patients were observed for at least 6 months but no longer than 18 months."
89289119|NCT05347004|Experimental|BI 425809 fed state (Test, T) then BI 425809 fasting state (Reference, R)|
89289120|NCT05347004|Experimental|BI 425809 fasting state (Reference, R) then BI 425809 fed state (Test, T)|
89289121|NCT01371292|Experimental|Transformational teaching condition|Teachers allocated to this condition will receive the transformational teaching intervention.
89289122|NCT01371292|Active Comparator|Standard practice control condition|Teachers allocated to this condition will not receive the transformational teaching intervention. Instead they will take part in a parallel workshop offered by their respective school board (unrelated to transformational leadership training).
89289123|NCT04353596|Experimental|Stopping/replacing ACEI/ARB|Chronic treatment with ACEI or ARB will be stopped or replaced.
89289124|NCT04353596|No Intervention|Control|No intervention, which means further treatment with ACEI or ARB.
89289125|NCT05107596|Active Comparator|Post ST Elevation Myocardial Infarction/ Heart Attack|Image patients who have had a heart attack
89289126|NCT05107596|Active Comparator|Sarcoidosis|Image patients who have Sarcoidosis
89289127|NCT05107596|Active Comparator|Myocarditis|Image patients with Myocarditis
89289128|NCT05107596|Active Comparator|Cardiomyopathy|Image patients with cardiomyopathy
89289129|NCT05107596|Active Comparator|Infected Cardiovascular Implantable Electronic Devices|Image patients with cardiovascular implanted medical devices
89289130|NCT05107596|Active Comparator|Healthy Volunteers|Image healthy volunteers
89289131|NCT01358422||In Patients|
89289132|NCT03749954||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
89289133|NCT01105416|Placebo Comparator|Enhanced Standard Care (ESC)|Standard emergency department care plus informational brochures
89289134|NCT01105416|Experimental|Brief Prevention Intervention (BPI)|Brief Prevention Intervention in the Pediatric ED
89289135|NCT01366378|Experimental|Arm 1|methylnaltrexone (MNTX)
89289136|NCT03747536|Experimental|Intervention|ipratropium bromide administered via metered dose spray (21 micrograms per spray). 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
89289137|NCT03747536|Placebo Comparator|Placebo|normal saline administered via metered dose spray. 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
89289138|NCT01366456|Active Comparator|Shingigu|Treat with Shingigu
89289139|NCT01366456|Active Comparator|Charcoal|Treat with Charcoal
89289140|NCT03921580|Placebo Comparator|Control Canned Tuna|Control Canned Tuna
89289141|NCT03921580|Experimental|Enriched Canned Tuna Variety 1|Enriched Canned Tuna Variety 1: Wakame fiber
89289142|NCT03921580|Experimental|Enriched Canned Tuna Variety 2|Enriched Canned Tuna Variety 2: Polyphenols
89289143|NCT04350788|Placebo Comparator|Survivorship Care Plan (SCP)|The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
89289144|NCT04350788|Experimental|Enhanced SCP (ESCP)|ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
89289145|NCT05096286|Experimental|Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy|"A diagnostic MRI-only, simulation-free plan will be generated from diagnostic brain MRI imaging, using a semi-automated, AI-assisted plan template within the Ethos Therapy system.~The radiation prescription dose twill be 3.0 Gy daily over approximately 2 weeks for a total of 30.0 Gy (10 fractions)."
89289146|NCT03852316|Experimental|Click Device|Each subject (females 14 years of age and older) will perform a self-collection vaginal swab for the Click device and be randomized to a particular order for three vaginal swab collections (performed by Health Care Providers (HCP) as defined by state/local regulatory authorities) for comparator methods. N=1750
89289147|NCT05062200|Experimental|Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])|Japanese participants will receive single oral dose 1 of JNJ-77242113 (immediate-release [IR] tablet) or matching placebo on Day 1 in Cohort 1 of Part 1.
89289148|NCT05062200|Experimental|Cohort 2: JNJ-77242113 or Placebo (SAD)|Japanese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 2 of Part 1.
89289149|NCT05062200|Experimental|Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])|Chinese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 3 of Part 2.
89289150|NCT05062200|Experimental|Cohort 4: JNJ-77242113 or Placebo (SD)|Japanese participants will receive single oral dose 3 of JNJ-77242113 (delayed-release [DR] tablet) with absorption enhancer (AbE) or matching placebo on Day 1 in Cohort 4 of Part 3.
89289151|NCT01358500|Experimental|Fentanyl|
89289152|NCT05225870|Other|patients with colorectal carcinoma|patients with colorectal carcinoma will undergo colectomy. their colectomy specimens will be sectioned, tissue blocks will be prepared from tumor and adjacent normal mucosa. sections will be stained immunohistochemically by antibody against cortactin.
89289153|NCT03724942|Experimental|Brexpiprazole|
89289154|NCT01327794||Group 1|Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a national, multi-center, double-blind phase III study that randomly assigned patients (1:1) with advanced pancreatic cancer to gemcitabine plus bevacizumab vs gemcitabine plus placebo. Blood samples were collected from consenting participants in CALGB 80303 at the time of study registration at respective institutions and shipped to the CALGB Pathology Coordinating Office for storage (Columbus, OH).Baseline serum 25-hydroxyvitamin D (25[OH]D) levels were measured and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test.
89289155|NCT01371370|Experimental|Resistance exercise training|Lower-body exercises 3 times per wk for 12 wk
89289156|NCT01371370|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
89289157|NCT01371370|Experimental|Resistance exercise training & diet|Lower-body exercise training and diet
89289158|NCT01371370|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
89289159|NCT03751514|Experimental|Phase A - SI|"Phase A aims to determine a 'standard inoculum' dose (SI), which results in safe colonisation of 70% of volunteers.~The SI will be identified in a dose escalating or de-escalating experiment commencing at 10-3 colony forming units B. pertussis administered intranasally. Each group of volunteers will be inoculated at half log-fold increasing/decreasing doses until the endpoint is reached. The experiment will be continued until the SI yields 10 subjects who are colonised at day 14.~Intervention to be administered: Bordetella Pertussis B1917"
89289160|NCT03751514|Experimental|Phase B Inoculum|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence. The final protocol for phase B will be presented as a protocol amendment, it will be based on the SI and colonisation period identified in Phase A.~The SI determined in phase A will be used for all volunteers and eradication therapy will be given after the colonisation period based on the data of phase A. Approximately 30 individuals will receive the intranasal SI and will be treated with azithromycin for three days at the end of the colonisation period.~Intervention to be administered: Bordetella Pertussis B1917"
89289161|NCT03751514|Experimental|Phase B Sham|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence.~Approximately 15 individuals will not receive the Bordetella Pertussis B1917, instead they will be given an intranasal sham of sterile saline and will be treated with azithromycin 500mg for three days at the end of the 'colonisation' period."
89289162|NCT03621358|Placebo Comparator|Control Gummy|Control gummy with free flavour (without encapsulating)
89289163|NCT03621358|Experimental|Gummy Variety 1|Experimental gummy with 50% free/50% encapsulated flavour
89289164|NCT03621358|Experimental|Gummy Variety 2|Experimental gummy with 100% encapsulated flavour
89289165|NCT03615664|Experimental|BGD therapy|Bendamustine, Gemcitabine, Dexamethasone
89289166|NCT04335812|Experimental|R-ICBT|The intervention offered is a guided relaxation-based CBT offered via the Internet. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules provided will focus on applied relaxation only.
89289167|NCT04335812|Active Comparator|F-ICBT|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules are a mixture of applied relaxation, Cognitive Behavioral Therapy and advice addressing common problems
89289168|NCT05189548|Experimental|Adsorbed a cell-free whitening break (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine.
89289169|NCT01562522|Experimental|Intervention group|
89289170|NCT01562522|No Intervention|Control group|
89289171|NCT03513250|Experimental|hyoscine-n-butylbromide group|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
89289172|NCT03513250|Placebo Comparator|control group|the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
89289173|NCT01107132||Diabetic Retinopathy|T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME)
89289174|NCT03749876|Active Comparator|Study Group 1|Study Group 1 will begin the first treatment period with the provided Unfiltered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Filtered Cigarette intervention for two weeks.
89289175|NCT03749876|Experimental|Study Group 2|Study Group 2 will begin the first treatment period with the provided Filtered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Unfiltered Cigarette intervention for two weeks.
89289176|NCT03634618|Experimental|Mirror Therapy|Mirror Therapy program for 2 weeks and convantional physiotherapy for 4 weeks. Exercises Frequency: 5 days/week; 2 days with the physiotherapist, other days as home program; 2 weeks in total. Exercises Duration: 20 minutes. Exercises Repetation: 20 repetation for each exercise.
88805806|NCT03011801|Experimental|Behavioral: Interpersonal Therapy|Individual psychotherapy that includes an initial engagement session and a total of 8 sessions. IPT focuses on psychoeducation and interpersonal skill building to decrease interpersonal conflict and increase interpersonal support and competence.
89289177|NCT03634618|Experimental|Convantional Physiotherapy|Convantional physiotherapy for 6 weeks. Exercises Frequency: 3 times a day, 4 weeks in total. Exercises Duration: 15-20 minutes. Exercises Repetation: 10 repetation for each exercise.
89289178|NCT01107210||stroke patients|50 patients recruited in the stroke rehabilitation unit in the University Hospital, Leuven, Belgium will be included
89289179|NCT03945942|Other|Pediatric liver transplant patients|Using somatic and cerebral Near infrared spectroscopy devices
89289180|NCT01366690|Experimental|Peer Support|Peer supporter assigned to participant.
89289181|NCT01366690|No Intervention|Standard of Care|No peer assigned. Current standard of care.
89289182|NCT03749798|Experimental|Intraoperative wavefront measurement|Patients will be measured with an intraoperative wavefront device during cataract surgery
89289183|NCT01107288|Experimental|Intervention group|Randomized to receive the intervention first
89289184|NCT01107288|Other|Delayed intervention control group|Randomized to wait-list control first
89289185|NCT05190250||Study group - women with idiopathic infertility|Endometrial biopsy during implantation window Blood analysis
89289186|NCT05190250||Control group - women with naturally conceived offspring|Endometrial biopsy during implantation window Blood analysis
89289187|NCT01327950||Superficial Femoral Lesions|Patients undergoing percutaneous treatment of Superficial Femoral Artery lesions
89289188|NCT01366768|Experimental|Oral amino acid mixture|Oral administration of amino acid mixture in healthy volunteers
89289189|NCT01366768|Experimental|Intravenous amino acid administration|Intravenous infusion of amino acid mixture in healthy volunteers
89289190|NCT01358656|Active Comparator|Single Bundle Reconstruction|Subjects will undergo single bundle acl reconstruction
89289191|NCT01358656|Active Comparator|Double bundle reconstruction|Subjects will undergo double bundle acl reconstruction
89289192|NCT03946176|Experimental|Symbiotic|HD patients with 7 weeks symbiotic administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
89289193|NCT03946176|Placebo Comparator|Placebo|HD patients with 7 weeks placebo administration + 1 week overlapping with the 3 dialytic sessions with the DVB cartridge
89289194|NCT01358812|Experimental|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
89289195|NCT05258942||Heart Failure Patients Scheduled for Coronary Artery Bypass Graft (CABG) Surgery|Heart Failure Patients Scheduled for Coronary Artery Bypass Graft (CABG) Surgery
89289196|NCT05258942||Heart Failure Patients Scheduled for Percutaneous Coronary Interventions (PCI)|Heart Failure Patients Scheduled for Percutaneous Coronary Interventions (PCI)
89289197|NCT05258942||Heart Failure Patients Scheduled for Aortic Valve Replacement (AVR) Surgery|Heart Failure Patients Scheduled for Aortic Valve Replacement (AVR) Surgery
89289198|NCT05258942||Heart Failure Patients Scheduled for Mitral Valve Replacement (MVR) Surgery|Heart Failure Patients Scheduled for Mitral Valve Replacement (MVR) Surgery
89289199|NCT05258942||Heart Failure Patients Scheduled for Transcatheter Aortic Valve Replacement (TAVR)|Heart Failure Patients Scheduled for Transcatheter Aortic Valve Replacement (TAVR)
89289200|NCT05258942||Heart Failure Patients Scheduled for Transcatheter Mitra Clip|Heart Failure Patients Scheduled for Transcatheter Mitra Clip
89289201|NCT05258942||Heart Failure Patients Scheduled for Ventricular Tachycardia Ablation|Heart Failure Patients Scheduled for Ventricular Tachycardia Ablation
89289202|NCT05258942||Heart Failure Patients Scheduled for Stellate Gangliectomy|Heart Failure Patients Scheduled for Stellate Gangliectomy
89289203|NCT05258942||Heart Failure Patients Scheduled for Mechanical Circulatory Support (MCS) Surgery|Heart Failure Patients Scheduled for Mechanical Circulatory Support (MCS) Surgery
89289204|NCT05258942||Heart Failure Patients Scheduled for Heart Transplantation (HTx) Surgery|Heart Failure Patients Scheduled for Heart Transplantation (HTx) Surgery
89289205|NCT01371448||Patients prescribed PAXIL for long-term use|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
89289206|NCT03983070|Active Comparator|Control Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 80% maximal Watts, and deadlifts at 60% of one-repetition maximum.
89289207|NCT03983070|Experimental|Blood Flow Restriction and Exercise Group|Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include the application of blood flow restriction during two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 40% maximal Watts, and deadlifts at 30% of one-repetition maximum. Blow flow restriction will be applied at 80% occlusion during both exercise modalities.
89289208|NCT01371526|Experimental|Synacthen|active treatment
89289209|NCT03945708|Experimental|Treatment|Addition of whole blood adsorber to CPB circuit
89289210|NCT03945708|No Intervention|Control|Standard treatment
89289211|NCT05189392|No Intervention|21 patients with opsite visible|application of visible opsite plaster on the surgical wound after hip arthroplasty
89289212|NCT05189392|Experimental|21 patients with PICO|application of PICO on the surgical wound after hip arthroplasty
89289213|NCT03943992|Experimental|YYD601 40mg|Esomeprazole magnesium Dihydrate.
89289214|NCT03943992|Active Comparator|Nexium 40mg|Esomeprazole magnesium trihydrate, a substituted benzimidazole.
89289215|NCT01371604|Experimental|IDX184 50 mg + Peg-IFN/RBV|IDX184 50 mg and matching placebo once daily plus peginterferon alfa-2a (Peg-IFN) weekly and ribavirin (RBV) daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
89289216|NCT01371604|Experimental|IDX184 100 mg + Peg-IFN/RBV|IDX184 100 mg once daily plus Peg-IFN weekly and RBV daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
89289217|NCT01107600|Experimental|Nobel Active®|Immediate implant and socket preservation
89289218|NCT01107678|Experimental|YMCA PAN|YMCA PAN (Physical activity and nutrition)- Consists of organized physical activity and controlled serving sizes of healthy low fat snacks
89289219|NCT01107678|Experimental|YMCA Standard CAre|YMCA standard care - Follow the standard care of the YMCA after school Y-Care program for physical activity and nutrition
89289220|NCT01371682|Other|Session 1|Ropinirole manufactued at Crawley will be compared to that manufactured at Aranda
89289221|NCT01371682|Other|Session 2|Ropinirole manufactured at Crawley will be compared to that manufactured at Aranda.
89289222|NCT01107756|Experimental|TAXOTERE (Docetaxel) + GRANOGYTE 34 (Lenograstim)|Taxotere (Docetaxel) is given as background treatment and should be administered by the treating physician in accordance with the prescribing information outlined in the package insert + Granocyte 34 (lenograstim)
89289223|NCT01371760|Experimental|Intervention|The patients will undergo PTA of the extracranial cerebral veins
89289224|NCT01371760|Sham Comparator|Controls|The patients will undergo sham procedure
89289225|NCT01208844||Posttraumatic Stress|
89289226|NCT01208844||Depression|
89289227|NCT01208844||Healthy|
89289228|NCT03127384|Experimental|No-treatment control|
89289229|NCT03127384|Experimental|Treatment|Intradermal injection Restylane Lidocaine
89289230|NCT03942900||Cohort LAND|Patients enrolled in OPTIMANAL clinical trial
89289231|NCT01366924|No Intervention|Muscle protein turnover and intracellular signaling at rest|Muscle protein turnover and intracellular signaling are measured at rest for comparison to post-exercise muscle metabolism.
89289232|NCT01366924|Active Comparator|Muscle metabolism after endurance exercise|Post-exercise muscle protein metabolism was measured to determine if endurance exercise affects muscle metabolism compared to rest.
89289233|NCT01366924|Experimental|Muscle Metabolism after endurance exercise|Muscle metabolism response to endurance exercise with essential amino acid supplementation
89289234|NCT01366924|Experimental|Muscle anabolism after endurance exercise|Muscle anabolism after endurance exercise with essential amino acid supplementation.
89289235|NCT01111500|Active Comparator|external rotation immobilization|Patient will wear an external rotation brace to immobilize the injured arm.
89289236|NCT01111500|Active Comparator|internal rotation immobilization|Patient will wear an internal rotation brace to immobilize the injured arm.
89289237|NCT01111578||New enteral feeding tube|
89289238|NCT03945630|Experimental|anterior Quadratus Lumborum Block (QLB)|"Anterior QLB will be performed in the sitting position. This block is also known as TQL- Transmuscular QLB or QLB 3. A convex transducer will be placed in a transverse position, in the posterior axillary line and tilted caudad until the 'shamrock sign' at L4 level will be obtained. An 80-110 mm SonoTAP (PAJUNK Medizintechnologie, Geisingen, Germany) will be inserted in-plane from the lateral end of the transducer and advanced until the needle tip will be inside the interfascial plane between the Quadratus Lumborum and the Psoas muscles. The successful needle placement will be confirmed by observing the spread of 5 mls 0,9%NaCl. Subsequently, 30 ml 0.5% ropivacaine with 100 mcg dexmedetomidine and adrenaline 1:200,000 will be injected. Satisfactory interfascial spread will be assessed by longitudinal probe orientation.~Following QLB, a spinal anaesthetic will be sited and a THA via posterior approach will be performed."
89289239|NCT03945630|Active Comparator|Standard of Care (no QLB)|A spinal anaesthetic will be sited and a THA via posterior approach will be performed.
89289240|NCT04212598|Experimental|Definitive concurrent chemoradiotherapy or radiotherapy arm|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
89289241|NCT01109472|Experimental|Patient Tailored Magazine|Patient responses from computer assisted telephone interviews will be used to develop a patient tailored educational magazine.
89289242|NCT01358890|Experimental|B|Subjects will be supplied with low carbohydrate diet for 12 weeks.
89289243|NCT01358890|Experimental|A|Subjects will be supplied with calories restricted diet for 12 weeks
89289244|NCT01111656|Active Comparator|1|Interferon beta-1b 250ug subcutaneously every other day
89289245|NCT01111656|Experimental|2|Interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
89289246|NCT02819752|Experimental|HPV-ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
89289247|NCT02819752|Experimental|HPV+ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
89289248|NCT03943524|No Intervention|DrApp Without Interax-AI|There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, before the implementation of the drug interactions detection module.
89289249|NCT03943524|Experimental|DrApp With Interax-AI|"There are approximately 100 outpatients in whom the indications were registered through the use of DrApp, AFTER the implementation of the drug interactions detection module (Interax-AI).~Intervention: Device: Medication Interaction System of Dr App (Interax-AI)"
89289250|NCT05189158|Other|HVS-|subjects with no complaint AND a Nijmegen questionnaire score of < 23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS-)
89289251|NCT05189158|Other|HVS+|subjects with complaints AND a Nijmegen questionnaire score of ≥23/64 AND a negative hyperventilation provocation test (criteria revised in 2021) (HVS+)
89289252|NCT03942978|Active Comparator|Longitudinal Equity Action Plan (LEAP)|Heart failure patients admitted with a principal diagnosis of heart failure to general medicine service and admitted to a general medicine pod that is randomized to the intervention arm.
89289253|NCT03942978|No Intervention|Standard Care|Heart Failure patients admitted to a general medicine pod at our institution, which is not randomized to intervention arm. Patients will be treated for their heart failure as per standard of care while admitted to the hospital.
89289254|NCT02567578|Experimental|YH12852 0.1 mg|twice daily for 4 weeks
89289255|NCT02567578|Experimental|YH12852 0.25 mg|twice daily for 4 weeks
89289256|NCT02567578|Experimental|YH12852 0.5 mg|twice daily for 4 weeks
89289257|NCT02567578|Placebo Comparator|Placebo|twice daily for 4 weeks
89289258|NCT01328028||Group A|Subjects diagnosed with invasive cervical cancer
89289259|NCT03943602|Experimental|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
89289260|NCT02523274|Placebo Comparator|Placebo + exercise|Placebo capsules will be taken orally daily in combination with exercise
89289261|NCT02523274|Experimental|Resveratrol 500 mg/day + exercise|500 mg/day resveratrol taken orally in combination with exercise
89289262|NCT02523274|Experimental|Resveratrol 1000 mg/day + exercise|1000 mg/day resveratrol taken orally in combination with exercise
89289263|NCT03945474|Experimental|OMT|Patients will receive a standardized protocol of: condylar decompression, Still's technique for the sternocleidomastoid, hyoid rebalancing and thoracic inlet myofascial release.
89289264|NCT03945474|Sham Comparator|Sham|Patient will be treated in the supine position, with hands gently applied without pressure to the four areas: occiput, lateral cervical spine, hyoid area and thoracic inlet.
89289265|NCT01107990||Single right ventricles|
89289266|NCT01107990||Single left ventricles|
89289267|NCT02432560||Everolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
89289268|NCT02432560||Sirolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
89289269|NCT01111734|Experimental|Treatment Group|The study consists of eight weeks of open label N-Acetylcysteine. All eligible study subjects will be treated with 600mg of N-Acetylcysteine twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks. weeks. Subjects will be seen every two weeks during the 8-week study. Efficacy and safety assessments will be performed at each visit.
89289270|NCT01111734|Experimental|Control|40 healthy age-matched peers with undergo the same baseline testing as the NAC subjects as well as baseline fMRI. They will not engage in any follow up visits.
89289271|NCT01111812||weight measurements|This study include 1000 weight measurements of children and adolescence, boys and girls, ages 5-18, that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center.
89289272|NCT01698138|Placebo Comparator|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
89289273|NCT01698138|Active Comparator|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
89289274|NCT03942822|Experimental|Chia supplemented group|8 weeks of 25 g/day of milled chia supplemented-isocaloric diet
89289275|NCT01111890|Experimental|Azarga|Azarga (brinzolamide 1% / timolol 0.5%)
89289276|NCT01111890|Active Comparator|Cosopt|Cosopt (dorzolamide 2% / timolol 0.5%)
89289277|NCT01111968|Experimental|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
89289278|NCT01111968|Experimental|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
89289279|NCT01111968|Experimental|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
89289280|NCT01111968|Experimental|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
89289281|NCT01111968|Experimental|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
89289282|NCT01111968|Experimental|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
89289283|NCT01111968|Experimental|pandemic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
89289284|NCT01111968|Experimental|pandemic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
89289285|NCT01111968|Experimental|pandemic vaccine 13|15µg of A/H1N1 with no adjuvant
89289286|NCT01111968|Placebo Comparator|placebo group 14|placebo
89289287|NCT03942666|Experimental|Treatment A|Single administration of CHF 6532 Dose #1
89289288|NCT03942666|Experimental|Treatment B|Single administration of CHF 6532 Dose #2
89289289|NCT03942666|Experimental|Treatment C|Single administration of CHF 6532 Dose #3
89289290|NCT03942666|Experimental|Treatment D|Single administration of CHF 6532 Dose #4
89289291|NCT03942666|Placebo Comparator|Treatment E|Single administration of CHF 6532 Placebo
89289292|NCT03942666|Other|Treatment F|Part II: Administration of tablet of CHF 6532 b.i.d. for 10 days at one dose.
89289293|NCT04398134|Experimental|ABI-H2158 plus ETV|ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
89289294|NCT04398134|Placebo Comparator|Placebo plus ETV|Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
89289295|NCT01112046|Experimental|Endoscopic submucosal dissection|
89289296|NCT01112046|Active Comparator|Laparoscopic resection|
89289297|NCT04281342|Experimental|Aprocitentan 25 mg|Therapeutic dose level
89289298|NCT04281342|Experimental|Aprocitentan 100 mg|Supratherapeutic dose level
89289299|NCT04281342|Placebo Comparator|Matching placebo|
89289300|NCT04281342|Other|Moxifloxacin|
89289301|NCT01207362||Young adult|
89289302|NCT01207362||Older adult|
89289303|NCT01108146|Experimental|Arm 1|"Drug: Hydrocortisone 10 mg~Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo-1 week hydrocortisone 10 mg/d -1 week placebo - 1 week hydrocortisone 30 mg/d"
89289304|NCT01108146|Experimental|Arm 2|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
89289305|NCT01207518|Experimental|Intervention Group|For the intervention group, there will be a Guide facilitator provided by the project team, normally the Project Manager or their delegate. The role of the Guide facilitator will be to provide basic information about the Guide and to facilitate the use of the web-based tools.
89289306|NCT01207518|Active Comparator|Control Group|The Control Group will be asked to provide immunization rates for the base year and two years of the study, and will be asked about their influenza immunization campaign activities to use as a comparator. They will receive the Guide and web-based tools following completion of the study.
89289307|NCT01108224|Experimental|Psychosocial support|
89289308|NCT01108224|No Intervention|Control group|
89289309|NCT01109628|Experimental|Protein drink|
89289310|NCT01109628|Placebo Comparator|Placebo drink|
89289311|NCT01108302|No Intervention|PPH Treatment only|Auxilliary nurse midwives will be able to treat for PPH only, not provide Oxytocin in Uniject
89289312|NCT01108302|Experimental|Oxytocin in Uniject|Auxilliary Nurse Midwives will provide 10IU Oxytocin in Uniject device IM immediately after delivery
89289313|NCT01108380|Experimental|1. CD34|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell)~In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed."
89289314|NCT01108380|Active Comparator|2. Mononucelar cell|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed."
89289315|NCT01108380|Other|3. Control|Without infusion of G-CSF, patients will be performed just right portal vein embolization
89289316|NCT03122860|Experimental|0.03 mg SM04690|Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle
89289317|NCT03122860|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
89289318|NCT03122860|Experimental|0.15 mg SM04690|Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle
89289319|NCT03122860|Experimental|0.23 mg SM04690|Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle
89289320|NCT03122860|Placebo Comparator|Placebo|Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle
89289321|NCT03122860|Sham Comparator|Sham|Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle
89289322|NCT05175586|Experimental|Group 1|15 patients in the experimental group of percutaneous neuromodulation together with orthopaedic manual therapy (Maitland and Mulligan)
89289323|NCT05175586|Active Comparator|Group 2|15 patients in the experimental group of orthopaedic manual therapy (Maitland and Mulligan).
89289324|NCT01319188|Active Comparator|0.5 mg of ranibizumab|
89289325|NCT01319188|Active Comparator|injection + photodynamic therapy|
89289326|NCT01319188|Sham Comparator|Sham injection|
89289327|NCT05167162|Active Comparator|Group 1: Compression technique|20 participants make up the compression technique group.
89289328|NCT05167162|Active Comparator|Group 2: Massage techniques|20 participants make up the massage technique group.
89289329|NCT05167162|Active Comparator|Group 3: Hydromassage|20 participants make up the hydromassage technique group.
89289330|NCT05167162|Active Comparator|Group 4: Active recovery technique.|20 participants make up the active recovery technique group.
89289331|NCT01367314|Experimental|NVC-422 Dermal Gel, 1.5%|
89289332|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.5%|
89289333|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.1%|
89289334|NCT05167084|Experimental|Metyrapone And Hydrocortisone|During one of the study periods, subjects receive hydrocortisone 19.9 mg/d subcutaneously via a pump in a pulsed fashion (eight times/day) and metyrapone per os (starting with a dose of 500 mg/d, then the dose will be increased the next days until 2500mg/d is achieved).
89289335|NCT05167084|Placebo Comparator|Placebo|During the other study period, subjects receive placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion and the same dose of placebo tablets p.o instead of metyrapone.
89289336|NCT03798366|Experimental|GLPG1690 600 mg|Participants received GLPG1690 600 milligrams (mg), orally once daily for 24 weeks.
89289337|NCT03798366|Placebo Comparator|Placebo|Participants received GLPG1690 matching placebo, orally once daily for 24 weeks.
89289338|NCT00867178|Experimental|Treatment (vorinostat, isotretinoin, chemotherapy)|See Detailed Description
89289339|NCT01209156|Experimental|Assess [18F] PBR111 and PET imaging|Evaluation of PET imaging with [18F]PBR111 in HV and AD subjects (Proof of Mechanism)
89289340|NCT01209312|Experimental|full bolus -20|Will administer full insulin bolus 20 minutes prior to meal
89289341|NCT01209312|Experimental|Full bolus, T0|Will administer full meal bolus at the start of the meal
89289342|NCT01209312|Experimental|1/2 bolus, T-20|Will only give half the insulin dose 20 minutes before meal
89289343|NCT01209312|Experimental|1/2 bolus T0|Will give half the amount of insulin at the time of the meal
89289344|NCT03945006||Multiple Sclerosis Patients with Incontinence|Multiple Sclerosis with incontinence 24-58 years of age and being volunteered.
89289345|NCT03945006||Multiple Sclerosis Patients without incontinence|Multiple Sclerosis without incontinence 24-58 years of age and being volunteered.
89289346|NCT01109706||patient treated by statines|
89289347|NCT01109706||patient without normolipidemic treatment|
89289348|NCT03945396|Experimental|Multidisciplinary intervention + homeopathic medication|"Multidisciplinary intervention (diet, exercise program, motivational support) and Calcarea carbonica ostrearum 30c.~A single dose of Calcarea carbonica ostrearum 30C dissolved in a 30 ml bottle of 30% alcohol-distilled water. Patients will receive 8 drops PO three times per day prior agitation."
89289349|NCT03945396|Active Comparator|Multidisciplinary intervention + homeopathic placebo|"Multidisciplinary intervention (diet, exercise program, motivational support) and placebo.~Placebo will be prepared with 30% alcohol-distilled water only, in the same 30 ml bottle. Patients will receive 8 drops PO three times per day prior agitation."
89289350|NCT01209390||Osteochondral lesions|Patients with osteochondral lesions in the knee, the ankle, or other joint
89289351|NCT01109784|Experimental|prasugrel|prasugrel per os 10mg/day
89289352|NCT01109784|Active Comparator|clopidogrel|clopidogrel per os 150mg/day
89289353|NCT01112280|Experimental|cap-assisted chromoendoscopy|To the tip of the colonoscope, transparent cap is fitted and applied. In addition, panchromoendoscopy using indigocarmine solution is preformed in this group.
89289354|NCT01112280|No Intervention|Standard colonoscopy|Neither transparent cap nor chromoendoscopy is applied in this group and standard colonoscopy is performed.
89289355|NCT01328262|Experimental|Hemoglobin dose|Intervention: Calculated red blood cell transfusion
89289356|NCT01328262|Active Comparator|Standard treatment|Intervention: Standard red blood cell transfusion
89290550|NCT01131234|Experimental|Treatment (cediranib maleate and RO4929097)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17 (days 1-3, 8-10, 15-17 22-24, 29-31, and 36-38 of course 1 only) and cediranib maleate PO QD on days 1-21 (days 22-42 course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
89289357|NCT04327388|Experimental|Sarilumab 200 mg|"Sarilumab 200 milligrams (mg), single dose of intravenous (IV) injection on Day 1. Participants could receive a second dose of sarilumab 200 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in fraction of inspired oxygen (FiO2) requirement or~Required vasopressors, extracorporeal membrane oxygenation (ECMO) or development of multi-organ dysfunction."
89289358|NCT04327388|Experimental|Sarilumab 400 mg|"Sarilumab 400 mg, single dose of IV injection on Day 1. Participants could receive a second dose of sarilumab 400 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in FiO2 requirement or~Required vasopressors, ECMO or development of multi-organ dysfunction."
89289359|NCT04327388|Placebo Comparator|Placebo|"Placebo (for sarilumab), single dose of IV injection on Day 1. Participants could receive a second dose of placebo (for sarilumab) 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in FiO2 requirement or~Required vasopressors, ECMO or development of multi-organ dysfunction."
89289360|NCT01112436|Placebo Comparator|control group (group C)|control group will receive no medication preoperatively and during operation
89289361|NCT01112436|Active Comparator|periarticular injecion group (group I)|patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.
89289362|NCT03741114|Active Comparator|Foley's Catheter plus TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
89289363|NCT03741114|Active Comparator|Foley's Catheter plus placebo to TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
89289364|NCT01328340|Active Comparator|High-speed power training|Volunteers randomized into SHPT will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
89289365|NCT01328340|Active Comparator|Slow-speed strength training|Volunteers randomized into STR will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
89289366|NCT01328340|No Intervention|Control|Volunteers randomized into CON will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
89289367|NCT03796728|Experimental|Juvéderm® VOLIFT™ with Lidocaine|Initial treatment with Juvéderm® VOLIFT™ with Lidocaine injectable gel to augment the lips on Day 1, with an optional touch-up treatment 14 days later, if applicable. Volume was determined by the Investigator not to exceed 3.0 milliliters (mL).
89289368|NCT04323800|Experimental|High titer anti-SARS-CoV-2 plasma|Participants with High titer anti-SARS-CoV-2 plasma.
89289369|NCT04323800|Active Comparator|SARS-CoV-2 non-immune plasma|Participants with SARS-CoV-2 non-immune plasma.
89289370|NCT01328418|Other|Achondroplasia lengthening|
89289371|NCT01108536|Experimental|adaptive trans-tibial socket|subjects are fitted with experimental sockets.
89289372|NCT04112862|Experimental|Intervention|three GLUT1DS patients with drug resistant epilepsy who tried the ketogenic diet without any benefits.
89289373|NCT03942276|Placebo Comparator|Control|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks without perform exercise training.
89289374|NCT03942276|Experimental|Alternative training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of high intensity interval training.
89289375|NCT03942276|Experimental|Conventional training|Hypertensive post menopausal women, who will do the evaluations before the beginning and after 12 weeks of moderate intensity continuous training
89289376|NCT01328106|Experimental|1|
89289377|NCT01209468|Active Comparator|oral appliance 2|Patients in treatment arm/group B will have a customized twinblock OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized monobloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the monobloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
89289378|NCT01209468|Experimental|oral appliance 1|Patients in treatment arm/group A will have a customized monobloc OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized twin-bloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the twin-bloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
89289379|NCT01371916||ESAT-6 positive|
89289380|NCT01371916||ESAT-6 negative|
89289381|NCT01109862|Experimental|THA|Total hip arthroplasty
89289382|NCT01109862|Active Comparator|HAP|Bipolar Hemiarthroplasty
89289383|NCT04321460|Experimental|LRG-002|LRG-002 once daily for 14 days
89289384|NCT04321460|Placebo Comparator|Placebo|Placebo once daily for 14 days
89289385|NCT03943212|Experimental|Blood Flow Rate Reduction|Participants will have their hemodialysis blood flow rate reduced on their regular schedule.
89289386|NCT03943212|Sham Comparator|Control|Participants will continue to receive regularly-scheduled hemodialysis without any changes to the prescription.
89289387|NCT01209546|Active Comparator|Flutter group|In Flutter group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland).
89289388|NCT01209546|Active Comparator|PEP group|In PEP group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland) without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1.
89289389|NCT01209546|Placebo Comparator|control group|In placebo patients were assessed as pulmonary function, respiratory muscle strength and transport properties of respiratory secretions
89289390|NCT01209546|Sham Comparator|Group Sham|Exercise with Flutter®VRP1 without the ball inside
89289391|NCT03122548|Experimental|CRS-207 + Pembrolizumab|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
89289392|NCT03942510|Experimental|High intensity eccentric training|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
89289393|NCT03942510|Experimental|High intensity eccentric training with blood flow restriction|high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) will be performed during 6 weeks, 3 times a week.
89289394|NCT03942510|Experimental|Low intensity eccentric training|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
89289395|NCT03942510|Experimental|Low intensity eccentric training with blood flow restriction|A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure)will be performed during 6 weeks, 3 times a week.
89289396|NCT03749642|Experimental|trazodone/gabapentin 2.5/25 mg|One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
89289397|NCT03749642|Experimental|trazodone/gabapentin 5/50 mg|One capsule, three times a day, for 8 weeks.
89289398|NCT03749642|Experimental|trazodone/gabapentin 10/100 mg|One capsule, three times a day, for 8 weeks.
89289399|NCT03749642|Placebo Comparator|placebo|Two capsules, three times a day, for 8 weeks.
89289400|NCT03749642|Active Comparator|Gabapentin|"according to the following scheduling dosage regimen:~100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1);~300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1);~400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1);~300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2)."
89289401|NCT01359124||Water Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a water-based treadmill.
89289402|NCT01359124||Land Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a land-based treadmill.
89289403|NCT01359124||Exercise Cycle|These subjects will participate in three monitored exercise sessions per week for 8 weeks using an upright exercise cycle.
89289404|NCT01108614|Experimental|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
89289405|NCT01108614|No Intervention|Usual|Routine HIV prevention, including health education, counseling and testing, condom promotion.
89289406|NCT03751358|Experimental|Unilateral Erector spinae plane block|Thoracic unilateral Erector spinae plane block performed on the volunteer and analyse of the spread of local anesthetic by magnetic resonance imaging
89289407|NCT05193292|Experimental|Camrelizumab combined with trastuzumab and chemotherapy|Camrelizumab: 200mg, iv, 21d for a treatment cycle Trastuzumab: 8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle Chemotherapy will either be XELOX, mFOLFOX6, FOLFIRI, mXELIRI or mIRIS
89289408|NCT03943056|Experimental|Single Ascending Dose (SAD): Cohort 1A|Participants will receive dose level 1 of BIIB091 or placebo, orally, while fasting on Day 1.
89289409|NCT03943056|Experimental|(SAD): Cohort 2A|Participants will receive dose level 2 of BIIB091 or placebo, orally, while fasting on Day 1.
89289410|NCT03943056|Experimental|(SAD): Cohort 3A|Participants will receive dose level 3 of BIIB091 or placebo, orally, while fasting on Day 1, then again following a 7 day washout and high-fat meal.
89289411|NCT03943056|Experimental|(SAD): Cohort 4A|Participants will receive dose level 4 of BIIB091 or placebo, orally, while fasting on Day 1.
89289412|NCT03943056|Experimental|(SAD): Cohort 5A|Participants will receive dose level 5 of BIIB091 or placebo, orally, while fasting on Day 1.
89289413|NCT03943056|Experimental|Multiple Ascending Dose (MAD): Cohort 1B|Participants will receive dose level 1 of BIIB091 or placebo, orally, twice daily (BID) for 13 days, and a single dose on Day 14.
89289414|NCT03943056|Experimental|(MAD): Cohort 2B|Participants will receive dose level 2 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
89289415|NCT03943056|Experimental|(MAD): Cohort 3B|Participants will receive dose level 3 of BIIB091 or placebo, orally, BID for 13 days, and a single dose on Day 14.
89289416|NCT05193214|Experimental|609A UPS|The 609A single-drug regimen (200mg Q3W) was used to treat unresectable or advanced undifferentiated pleomorphic sarcoma to evaluate the safety and effectiveness of 609A.
89289417|NCT01367392|Experimental|interventional procedure|The patients undergo the required interventional procedure, biopsy or ablation
89289418|NCT02529774|Experimental|Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)|
89289419|NCT02529774|Active Comparator|Systemic Chemotherapy|
89289420|NCT04459598|Experimental|Efavirenz 600 mg + Quizartinib 60 mg|Participants who received efavirenz 600 mg once daily (QD) for 34 days and a single, oral dose of quizartinib 60 mg on Day 15 concurrently with efavirenz.
89289421|NCT04459598|Active Comparator|Quizartinib 60 mg|Participants who received a single, oral dose of quizartinib 60 mg on Day 1.
89289422|NCT01207830|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
89289423|NCT05167006|Experimental|Group A:|Participants will be treated with routine physical therapy for 20 minutes, five days a week for 12th weeks. Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation.
89289424|NCT05167006|Active Comparator|Group B|The participants will be treated with Perfetti's method and routine physical therapy for 35 minutes, five times a week for 12th weeks. Each participant will receive his/her arms training therapy.
89289425|NCT01114230|Experimental|Dose Level 1|
89289426|NCT01114230|Experimental|Dose Level 2|
89289427|NCT01114230|Experimental|Dose Level 3|
89289428|NCT01114230|Experimental|Dose Level 4|
89289429|NCT01114230|Experimental|Dose Level 5|
89289430|NCT01114230|Experimental|Dose Level 6|
89289431|NCT01114230|Experimental|Dose Level 7|
89289432|NCT01114230|Experimental|Dose Level 8|
89289433|NCT01114230|Experimental|Dose Level 9|
89289434|NCT01367470|Active Comparator|VSL#3 probiotic preparation|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) 1 sachet per day of probiotics (VSL#3) during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet before meal).
89289435|NCT01367470|Placebo Comparator|Placebo VSL#3|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) a placebo comparable to VSL#3 during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet/day, before meal)
89289436|NCT03942354|Experimental|Intervention arm|A total of 72 intervention arm trial patients (from TB-PRACTECAL trial) are anticipated across all three sites: South Africa, Belarus, and Karakalpakstan.
89289437|NCT03942354|Active Comparator|Standard therapy|72 standard therapy trial patients (from TB-PRACTECAL trial) will be recruited across all three sites. Patients will complete measures at baseline, 3 months, 6 months and 12 months.
89289438|NCT05165992|Active Comparator|Nebulized Fentanyl|Intervention group (n=100): Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
89289439|NCT05165992|Placebo Comparator|Nebulized 0.9% Saline Solution|Control group (n=100): Administration of nebulized 0.9% saline solution (5 ml of normal saline), over 15 minutes, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
89289440|NCT01359202|Active Comparator|Niastase RT|Niastase RT 80ug/kg IV bolus
89289441|NCT01359202|Placebo Comparator|Placebo|saline IV bolus
89289442|NCT03942432|Experimental|Patients with dysmetabolic iron overload syndrome|
89289443|NCT01367548|Experimental|Arm 1|
89289444|NCT01367548|Placebo Comparator|Arm 2|
89289445|NCT01110018|Active Comparator|Period 1|20μg intravenous infusion administered over 30 minutes
89289446|NCT01110018|Active Comparator|Period 2|1000μg Oral dose
89289447|NCT01110018|Active Comparator|Period 3|50μg Intravenous infusion administered over 30 minutes
89289448|NCT01110018|Active Comparator|Period 4|1000μg Inhaled dose
89289449|NCT01110018|Active Comparator|Period 5|100μg Intravenous infusion administered over 30 minutes
89289450|NCT01367626|Active Comparator|letrozole|2.5 mg tablet
89289451|NCT01367626|Active Comparator|Fermara|2.5 mg tablet
89289452|NCT05118412|Experimental|Lucerne protein concentrate|Lucerne protein concentrate powder presented in the form of a shake.
89289453|NCT05118412|Experimental|Whey protein concentrate|Whey protein concentrate powder presented in the form of a shake.
89289454|NCT01110096|Experimental|Group A - family camp|Obese families participate in a two week camp with two years follow-up.
89289455|NCT01110096|Other|Group B - family lifestyle school|Families participate in a four day practical course about lifestyle.
89289456|NCT05192902|Experimental|Student-administered|
89289457|NCT05192902|Placebo Comparator|Dentist-administered|
89289458|NCT01211808|Experimental|Treatment A (BMS-914832)|
89289459|NCT01211808|Experimental|Treatment B (BMS-914832 + diltiazem)|
89289460|NCT05192824|No Intervention|Single-vision glasses|Subjects wearing single-vision glasses CR-39
89289461|NCT05192824|Experimental|Orthokeratology lenses group 1|Subjects wearing orthokeratology lenses of 5mm optical zone.
89289462|NCT05192824|Experimental|Orthokeratology lenses group 2|Subjects wearing orthokeratology lenses of 5.5mm optical zone.
89289463|NCT05192824|Experimental|Orthokeratology lenses group 3|Subjects wearing orthokeratology lenses of 6mm optical zone.
89289464|NCT05192824|Experimental|Orthokeratology lenses group 4|Subjects wearing orthokeratology lenses of 6mm optical zone and the increased height of peripheral reverse curve.
89289465|NCT03943134||Avive® Soft Tissue Membrane|Subjects with utilization of Avive® Soft Tissue Membrane on an impacted but intact nerve during a surgical procedure for one of the following targeted acute upper extremity traumas (selected injuries): Spaghetti Wrist, Distal Radius Fracture, Medial Epicondyle Fracture, Flexor Tenolysis at Wrist, and Ballistic Injuries in the Forearm and/or Hand.
89289466|NCT03943134||Standard Surgical Procedures - Control Arm|Subjects who have undergone surgical procedures for the same selected injuries, but without placement of a surgical implant on an impacted but intact nerve.
89289467|NCT05192746|Experimental|"group A Control group"|"Twenty two patients will receive conventional treatment hot pack and exercise (control group).~."
89289468|NCT05192746|Experimental|"group BExtracorporeal shock wave group:"|Twenty two patients will receive Radial Extra corporeal Shock Wave Therapy plus conventional treatment hot pack and exercise.
89289469|NCT05192746|Experimental|"Group CHigh power pain threshold ultrasound group:"|Twenty two patients will receive High-Power Pain Threshold Ultrasound therapy plus conventional treatment hot pack and exercise
89289470|NCT05192668|Experimental|Quiet time care|Reduce noise and centralize medical or nursing operations in the NICU
89289471|NCT05192668|No Intervention|Routine nursing care|Perform routine nursing care for the VLBWIs in the NICU
89289472|NCT01211964|Experimental|LEO 22811 oral solution 1.5 mg (fasted state)|
89289473|NCT01211964|Experimental|LEO 22811 single tablet 1.5 mg (fasted state)|
89289474|NCT01211964|Experimental|LEO 22811 single tablet 1.5 (fed state)|
89289475|NCT03940638||Patients with septic non-union of the tibia|
89289476|NCT05192278|Active Comparator|Group 20 ml|receive ESB with 1mL of methylprednisolone 40mg/mL with 10 mL of 0.5% bupivacaine and 2mL of nonionic contrast in 7 ml saline 0.9% (total 20 ml with bupivacaine 0.25%).
89289477|NCT05192278|Active Comparator|Group 30 ml|receive ESB with 1mL of methylprednisolone 40mg/mL with 15 mL of 0.5% bupivacaine and 2mL of nonionic contrast in 12 ml saline 0.9% (total 30 ml with bupivacaine 0.25%).
89289478|NCT01207986|Other|CT screening|CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre
89289479|NCT01114386||COPD patients, CHF patients|COPD and CHF patients with smoking history (> 10 pack/years), male and female, older than 50 years, referred to Hospital for dyspnea and chronic cough.
89289480|NCT01372072|Active Comparator|Humidification|Patients in this arm of the trial will receive humidification with the non-invasive ventilation.
89289481|NCT01372072|No Intervention|NIV without humidifivation|As per usual practice patients in this arm will not have humidification with their NIV
89289482|NCT01208064|Experimental|Pazopanib|2 weeks at 600mg and then maintenance at 800mg
89289483|NCT01208064|Placebo Comparator|Placebo|placebo match 2 weeks at 600mg and then maintenance at 800mg
89289484|NCT05192044|Experimental|Group A|Fast track Care (Enhanced recovery after)pancreatico-duodenectomy
89289485|NCT05192044|Active Comparator|Group B|Conventional Care pancreatico-duodenectomy.
89289486|NCT01114464||young women with breast cancer|
89289487|NCT03634462|Experimental|Patients with Lipedema|Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
89289488|NCT03634462|Experimental|Patients with secondary leg lymphedema|Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females. These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
89289489|NCT01209858|Experimental|Experimental 1|
89289490|NCT01209858|Experimental|Experimental 2|
89289491|NCT05191888|Active Comparator|14-day vonoprazan high-dose two-in-one therapy|vonoprazan 20mg bid and amoxicillin 750mg qid
89289492|NCT05191888|Active Comparator|14-day vonoprazan triple therapy|vonoprazan 20mg bid and amoxicillin 1gm bid and clarithromycin 500mg bid
89289493|NCT05191888|Active Comparator|14th Rabeprazole reverse mixed therapy|first 7 days rabeprazole 20mg bid and amoxicillin 1gm bid and clarithromycin 500mg bid and metronidazole 500mg bid Next 7 days rabeprazole 20mg bid and amoxicillin 1gm bid
89289494|NCT02529618||Football Athlete Group|"All football athlete participants in this arm will take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test. Participants who sustain a concussion during the football season will complete the iDETECT test and a standing balance test (BESS assessment) four times after injury. Participants in this arm are eligible to receive the Riddell High Impact Technology (HIT) System or the i1 Biometrics Vector Mouth Guard.~NOTE: Football athletes who sustain a concussion during the football season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
89289495|NCT02529618||Non-Collision Sport Athlete Group|"Non-collision sport athletes who are active in a school's Fall athletic program will be take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test, standing balance test (BESS assessment), and complete a questionnaire at the beginning of the sport season. Participants will be asked to take the iDETCT test up to 5 more times during the season. Participants who sustain a concussion during the athletic season will be asked to take additional iDETECT tests four times after the injury.~NOTE: Non-collision sport athletes who sustain a concussion during the season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
89289496|NCT05170906|Experimental|Experimental Group|"The subject will be placed on a stretcher with the torso uncovered. Once the spectroscopy helmet is in place, a recording of the resting activity will be started, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation on the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure on the pectoral area in the pattern of the reflex swing locomotion complex in its first phase. For this, the subject will be placed in supine decubitus aligned with respect to the axial axis, with the arms alongside the body, the lower extremities in extension and the head extended with a rotation of approximately 30º to one side of the stimulation. Manual stimulation pressure will be exerted in the space between the 6th-7th or 7th-8th ribs below the mammary line, with a force of about 2 kg."
89289497|NCT05170906|Sham Comparator|Control Group|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg"
89289498|NCT01112826|Experimental|Capecitabine|Capecitabine 650 mg/m2 bid
89289499|NCT01112826|No Intervention|Standard treatment|Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
89289500|NCT01367782|Active Comparator|Active repetitive Transcranial Stimulation|Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
89289501|NCT01367782|Sham Comparator|Sham Stimulation|The control arm group will receive sham stimulations in identical treatment and maintenance schedules.
89289502|NCT01359280|Experimental|Adherence Counseling + Text Messages|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
89289503|NCT01359280|Experimental|Adherence Counseling Only|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building.
89289504|NCT01359280|Placebo Comparator|General Health Counseling Only|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building.
89289505|NCT01359280|Placebo Comparator|General Health Messages + Text Messages|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
89289506|NCT01210014|Placebo Comparator|A|Patients with Recurrent aphthous stomatitis
89289507|NCT01210014|Active Comparator|B|Patients with Recurrent aphthous stomatitis
89289508|NCT03940794|Experimental|Verbal instruction|"The participants will be instructed to contract the pelvic floor muscle with the following verbal instruction: (1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.Those who will not be able to contract will be taught by the ultrasound as biofeedback."
89289509|NCT01208142|Active Comparator|Standard of care|25 Control subjects will only receive SOC (a weekly standardized physical therapy and daily wear of an AFO).
89289510|NCT01208142|Experimental|Dynasplint|25 Patients will receive the standard of care as well as an Ankle Flexion Dynasplint
89289511|NCT05118256|No Intervention|No intervention - standard of care|A group of patients with PMF will be treated per standard of care on site
89289512|NCT05118256|Experimental|Experimental - Pirfenidone plus standard of care|A group of patients with PMF will be treated with pirfenidone plus standard of care on site
89289513|NCT03940716|Experimental|IntERact|"Participants randomized to this condition will receive behavioral therapy comprised of motivational interviewing, cognitive behavioral skills therapy, and care management. Youth will receive a total of six sessions, one delivered in the emergency department at the time of recruitment and five delivered over the five subsequent weeks after the ED visit (i.e., baseline). Participants will also receive a smartphone APP that will deliver intervention content between therapy sessions, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
89289514|NCT03940716|No Intervention|Enhanced Usual Care Condition|Participants randomized to this condition will receive a pamphlet with violence, mental health, and substance use resources.
89289515|NCT01114542|Experimental|IDeg 0.4 U/kg|
89289516|NCT01114542|Experimental|IDeg 0.6 U/kg|
89289517|NCT01114542|Experimental|IDeg 0.8 U/kg|
89289518|NCT01114542|Active Comparator|IGlar 0.4 U/kg|
89289519|NCT01114542|Active Comparator|IGlar 0.6 U/kg|
89289520|NCT01114542|Active Comparator|IGlar 0.8 U/kg|
89289521|NCT01367938||OMNI Apex Ultracongruent Knee Device|
89289522|NCT01210092||Macintosh #3 Laryngoscope|
89289523|NCT01210092||Glidescope|
89289524|NCT01210092||Ambu Pentax AWS|
89289525|NCT01210092||McGrath|
89289526|NCT01210092||Airtraq|
89289527|NCT01210092||Storz C-MAC|
89289528|NCT05121220|Experimental|fixed mandibular lingual rectangular retainer 0.673 x 0.268 mm|0.673 x 0.268 mm 8-stranded wire Bond A Braid (Reliance Orthodontic Products, USA) will be bonded in mandible canine to canine on each tooth using Filtek flowable composite (Ivoclar Vivadent, Lichtenstein) and Multilink adhesive (3M, USA).
89289529|NCT05121220|Experimental|fixed mandibular lingual round retainer 0.40 mm|0.40 mm round 6-stranded wire (Forestadent, Germany) will be bonded on 6 mandibular frontal teeth, canine to canine on each tooth using Filtek flowable composite (Ivoclar Vivadent, Lichtenstein) and Multilink adhesive (3M, USA).
89289530|NCT05121220|Active Comparator|removable mandibular retainer|Group without fixed retainer will be wearing removable thermoplastic vacuum-formed Essix retainer
89289531|NCT02529540|Other|Group 1|Self-refraction with adjustable glasses
89289532|NCT02529540|Other|Group 2|Subjective refraction by an expert refractionist after auto refraction and receiving custom standard glasses
89289533|NCT02529540|Other|Group 3|Subjective refraction by an expert refractionist after auto refraction and receiving ready-made glasses
89289534|NCT05188924|Experimental|DKF-306|During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
89289535|NCT05188924|Placebo Comparator|Placebo|During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
89289536|NCT05045014||Patient group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task. In addition, X-ray images taken during routine follow-ups will be used to determine the location, type of curvature and Cobb angle of the scoliosis. The degree of rotation will be measured with a mobile application called Scoliodetector. Quality of life is planned to be evaluated with the Scoliosis Research Society-22 questionnaire.
89289537|NCT05045014||Control group|Romberg test and single leg standing test will be used in balance assessment. The presence of vestibular dysfunction will be evaluated with the Utenberger test. Under the name of visual-spatial perception, spatial memory will be evaluated with the mobile application called Corsi Block Tapping, and navigation performance will be evaluated with the triangle completion task.
89289538|NCT05009290|Experimental|Treatment group：SHR3680 + ADT|
89289539|NCT05009290|Placebo Comparator|Treatment group : Placebo + ADT|
89289540|NCT01208298|Experimental|# 1727|Cold sore Patch
89289541|NCT01359436|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
89289542|NCT03942198|Experimental|Oral Chinese medicine|Participants in experimental group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
89289543|NCT03942198|Placebo Comparator|Oral Chinese medicine placebo|Participants in placebo group will receive Taodan granule two times daily after meals three times per week for 8 weeks.
89289544|NCT01359514|Active Comparator|Duloxetine|
89289545|NCT01359514|Active Comparator|Pregabalin|
89289546|NCT01208376||unexplained chronic ALT elevation|Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation
89289547|NCT01208376||always normal ALT|Control patients: HIV-infected, always normal ALT values
89289548|NCT01368016|Experimental|Experimental NRT|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits.
89289549|NCT01368016|Active Comparator|Nicotine GUM|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits.
89289550|NCT01114776||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
89289551|NCT01114776||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
89289552|NCT01114776||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
89289553|NCT01114776||Controls|
89289554|NCT01208454|Experimental|Treatment (isotretinoin and vorinostat)|"Patients receive isotretinoin PO BID on days 1-14, PO suspension* of vorinostat QD on days 1-4 of course 1, and capsules of vorinostat PO QD on days 1-4 and 8-11 of course 2 and subsequent courses. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~EXPANSION COHORT 1 (=< 21 years of age): Once the MTD has been determined, patients are treated at that dose level as above.~EXPANSION COHORT 2 (22-30 years of age): Patients receive isotretinoin as above and vorinostat at the MTD on days 1-3 and 8-10."
89289555|NCT01368094|Active Comparator|Standard drainage|
89289556|NCT01368094|Experimental|Short drainage|
89289557|NCT05188846|Experimental|SDF|
89289558|NCT05188846|Active Comparator|SDF + ART ( SMART technique )|
89289559|NCT01110486|Experimental|Monotherapy, once daily|
89289560|NCT01110486|Experimental|Combination with carboplatin|
89289561|NCT01110486|Experimental|Combination with docetaxel|
89289562|NCT01110486|Experimental|Monotherapy, twice daily|
89289563|NCT01110486|Experimental|IV Monotherapy, once daily|
89289564|NCT01372306|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's
89289565|NCT01372306|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
89289566|NCT01114854|Other|Topiramate IR followed by Topiramate ER|Dosing with IR followed by dosing with ER
89289567|NCT01359670|Experimental|Tadalafil|
89289568|NCT01359670|Experimental|Sildenafil|
89289569|NCT03942588|Experimental|High-intensity interval training|Twice-weekly supervised high-intensity interval treadmill training in a laboratory setting for 10 weeks.
89289570|NCT03942588|No Intervention|Control|Usual activities for 10 weeks
89289571|NCT04784806|Experimental|Consumption of ground beef|Consuming 106g of cooked ground beef (85% lean) to deliver 20g of protein.
89289572|NCT04784806|Experimental|Consumption of ground pork|Consuming 118g of cooked ground pork (72% lean) to deliver 20g of protein.
89289573|NCT04784806|Experimental|Consumption of tofu burger|Consuming 113g of cooked tofu to deliver 20g of protein.
89289574|NCT04784806|Experimental|Consumption of Beyond Meat burger|Consuming 113g of Beyond Meat burger to deliver 20g of protein.
89289575|NCT01114932||BMI-I|Patients with BMI values between 18.5-24.9
89289576|NCT01114932||BMI-II|Patients with BMI values between 25-29.9
89289577|NCT01114932||BMI-III|Patients with BMI values between 30-49.9
89289578|NCT04688944||patients|(1) age ≥ 45 years, (2) diagnosed LSS through a combination of clinical history, physical examination and radiological changes showing spinal canal stenosis on magnetic resonance imaging
89289579|NCT04688944||healthy people|(1) age ≥ 45 years; (2) without chronic low back pain (LBP)
89289580|NCT01115010|Experimental|Stiffening wire only if difficulty|Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
89289581|NCT01115010|Experimental|Stiffening wire #1 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #1 is introduced on entry of the tip of the colonoscope into the transverse colon.
89289582|NCT01115010|Experimental|Stiffening wire #2 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #2 is introduced on entry of the tip of the colonoscope into the transverse colon.
89289583|NCT01368172|Experimental|Physical Activity Guidelines|Participants randomized to this arm received training/guidance on following the physical activity guidelines for adults with spinal cord injury
89289584|NCT01368172|No Intervention|Control|
89289585|NCT05188768|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
89289586|NCT05188768|Active Comparator|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
89289587|NCT01110564||1|COPD patients
89289588|NCT01368328|Placebo Comparator|Placebo|
89289589|NCT01368328|Active Comparator|Chromium nicotinate 50 mcg|
89289590|NCT01368328|Active Comparator|Chromium nicotinate 200 mcg|
89289591|NCT01210326|Experimental|aspiration|90 patients with non-obstructive azoospermi undergo testicular sperm aspiration
89289592|NCT01210326|Experimental|extraction|90 patients with non-obstructive azoospermi undergo testicular sperm extraction
89289593|NCT01212120||All patients|All patients
89289594|NCT03940404||experiment|The patients whose treatment strategy containing anlotinib.
89289595|NCT03940248|Experimental|Early Stage Breast Cancer|Patients to be treated with Accelerated Partial Breast Irradiation utilizing pencil beam scanning proton therapy. Treatment will be delivered twice a day, at least 6 hours apart, over 5 treatment days.
89289596|NCT01113060||CAD patients|Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention
89289597|NCT01110642|Experimental|Lovastatin solution|All patients will receive lovastatin solution
89289598|NCT01212198||Korean type 2 diabetic patients|
89289599|NCT01212198||Koreans at high risk for diabetes|
89289600|NCT01212198||Korean gestational diabetic patients|
89289601|NCT01115088|Experimental|Aspartame|Food or beverages containing Aspartame in comparison to Stevia or Sucrose
89289602|NCT01115088|Experimental|Sucrose|Food or beverages containing Sucrose in comparison to Aspartame or Stevia
89289603|NCT01115088|Experimental|Stevia|Food or beverages containing Stevia in comparison to Aspartame or Sucrose
89289604|NCT02929498|Experimental|Arm A: GSK2879552 monotherapy|Subjects will receive GSK2879552 2 milligrams (mg) once daily in each 28 day cycle.
89289605|NCT02929498|Experimental|Arm B: GSK2879552+Azacitidine combination therapy|Subjects will receive GSK2879552 starting at 1 mg once daily in each 28 day cycle and Azacitidine 75 mg/square meter (m2) from Day 1 to Day 7 of each 28 day cycle.
89289606|NCT01110720|Experimental|Davunetide 30 mg BID|
89289607|NCT01110720|Placebo Comparator|Placebo|
89289608|NCT04645186||Calcium Phosphate Cement (CPC)|Evaluation of CPC in long bone & extremities
89289609|NCT01359826|Experimental|Milnacipran|Patients administered milnacipran will receive a dose escalation to 50 mg twice a day over 12 days and continued at this dose until week 6. If tolerated and a 15% improvement in fatigue from baseline is achieved by assessment on the FSS, then patients will continue taking 50 mg twice a day until the end of the study on day 98 (week 14). Otherwise, the dose of milnacipran will be titrated upward to 100 mg twice a day over 12 days and continued at this dose until day 98 (week 14).
89289610|NCT01359826|Placebo Comparator|Placebo|Placebo tablets administered orally twice a day for 14 weeks.
89289611|NCT04576936|Experimental|AIRVO Device|All participants are assigned to this single-arm: Enrolled participants will be given a MyAIRVO2 Device and device stand, and asked to use their device daily, for 12 months
89289612|NCT04535674|No Intervention|Standard of Care|
89289613|NCT04535674|Experimental|Standard of Care + Asunercept 25 mg|
89289614|NCT04535674|Experimental|Standard of Care + Asunercept 100 mg|
89289615|NCT04535674|Experimental|Standard of Care + Asunercept 400 mg|
89289616|NCT03792672|Experimental|TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
89289617|NCT03792672|Experimental|TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
89289618|NCT03792672|Experimental|TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
89289619|NCT03792672|Experimental|TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
89289620|NCT03792672|Experimental|Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
89290551|NCT03924726|Other|Control and experimental (4 weeks MOP)|This is a split mouth study. At the experimental site in group 1, three Micro-osteoperforation (MOP) were made directly at the buccal cortical bone of extracted first premolars sites, at equidistance from the canine and second premolar under local anaesthesia. This group received four sessions of MOPs at an interval of 4 weeks.
89289621|NCT03792672|Experimental|Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
89289622|NCT01372540|Experimental|Treatment (filanesib and carfilzomib)|Patients receive filanesib IV over 1 hour on days 1, 2, 15, and 16 and carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 8 courses of therapy, patients may continue with dosing of carfilzomib on days 1, 2, 15, and 16 and filanesib as tolerated. If patient progresses on carfilzomib maintenance with administration on days 1, 2, 15, and 16 they may increase the intensity and add in days 8 and 9 dosing.
89289623|NCT01368484|Placebo Comparator|Sunflower oil|
89289624|NCT01368484|Experimental|Docosahexanoic acid|
89289625|NCT04394884||COVID-19 -|will receive BTK therapy for other reasons
89289626|NCT04394884||COVID-19 + BTK|will receive BTK therapy
89289627|NCT04394884||COVID-19 + No BTK|will not receive BTK therapy
89289628|NCT01110954|Active Comparator|PD L 506 2nd dose|Different dosage
89289629|NCT01110954|Experimental|PD L 506|
89289630|NCT01113138|No Intervention|Baseline|
89289631|NCT01113138|Active Comparator|Mablet|
89289632|NCT01113138|Active Comparator|Magnesium sulfate|
89289633|NCT01210404|Experimental|1.0|
89289634|NCT03940170||vistacam|
89289635|NCT03940170||ICDAS II|
89289636|NCT03940170||Fissurotomy|
89289637|NCT01115322|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
89289638|NCT01115322|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
89289639|NCT01115322|Experimental|Tazarotene Foam with UVA , UVB, and visible light irradiation|Subjects will be exposed to Tazarotene Foam with UVA and UVB and visible light irradiation
89289640|NCT01115322|Placebo Comparator|Vehicle Foam without irradiation|Subjects will be exposed to Vehicle Foam Patch without irradiation
89289641|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
89289642|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB and visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
89289643|NCT01115322|Sham Comparator|No Treatment without irradiation|Subjects will be exposed to a Blank Patch without irradiation
89289644|NCT01115322|Sham Comparator|No Treatment with UVA and UVB irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB irradiation
89289645|NCT01115322|Sham Comparator|No Treatment with UVA and UVB and visible light irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB and visible light irradiation
89289646|NCT01368640||healthy adults|The study will cover 130 healthy adults. 65 men and 65 women in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
89289647|NCT01359982|Experimental|RRx-001|
89289648|NCT01111032||Treadmill test|
89289649|NCT05188534||BOLD-fMRI|Identifying the language functional cortex in glioma patients with BOLD-fMRI
89289650|NCT05188534||ZOOMit-fMRI|Identifying the language functional cortex in glioma patients with ZOOMit-fMRI
89289651|NCT01111188|Experimental|all subjects|Subjects will receive PD 0332991 plus bortezomib. The dose of each agent will be dependent on the time point the subject enters the trial.
89289652|NCT04231396|Other|HA and CI Users using Audiobooks for Hearing Loss for Auditory Training|"study participants will be seen weekly for 12 weeks and will use the Audiobooks for HL App for the final 6 weeks using the App at least two hours per week on their own. The researcher will conduct 12 weekly in-home visits where the following will be done:~First 6 weeks:~• Partial BKB-SIN will be administered~Final 6 weeks:~Partial BKB-SIN will be administered~Conduct a comprehension test.~Address any usability issues the participant brings up.~Review and set new weekly goals Final session: Conduct Final Usability survey"
89289653|NCT01210482||Temsirolimus|Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)
89289654|NCT01113294|Experimental|ablation|
89289655|NCT01360060||Group N|parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia
89289656|NCT01360060||Group P|parturients who had undergone Cesarean section under the diagnosis of preeclampsia
89289657|NCT03741036|Active Comparator|autogenous bone graft as a space filling material|Autogenous bone from sub mental bone had been grafted in jumping gap between implant and freshely extracted socket
89289658|NCT03741036|Active Comparator|deproteinized bovine as a space filling material|Granules of deproteinized bovine bone of 0.25-1.0 mm diameter were used to fill the remaining defect when the distance of the defect wall to the implant surface was > 3 mm.
89289659|NCT03741036|Active Comparator|nano-hydroxyapatite alloplast as a space filling material|The patient was treated using alloplast material mixed with a nano-bone graft to fill gap between implant and freshely extracted socket
89289660|NCT04154644|Experimental|Cervical Cytology|100 women with abnormal cervical cytology will receive cryotherapy with the experimental CryoPop device
89289661|NCT01210638|Active Comparator|Oxymorphone Hydrochloride|Tablet
89289662|NCT01210638|Active Comparator|Opana|Tablet
89289663|NCT03120676|Experimental|Atezolizumab|Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.
89289664|NCT01115478|Active Comparator|Vitamin A|
89289665|NCT01115478|Active Comparator|Zinc|
89289666|NCT01115478|Active Comparator|Vitamin A + Zinc|
89289667|NCT01115478|Placebo Comparator|Placebo|
89289668|NCT01360138|Active Comparator|midline approach|cervical epidural steroid injection with 18G Touhy epidural needle by midline approach
89289669|NCT01360138|Active Comparator|paramedian approach|cervical epidural steroid injection with 18G Touhy epidural needle by paramedian approach
89289670|NCT01212276|Experimental|Cohort 1|MORAb-028 0.1 mg/kg intravenous
89289671|NCT01212276|Experimental|Cohort 2|MORAb-028 0.2 mg/kg intravenous
89289672|NCT01212276|Experimental|Cohort 3|MORAb-028 0.5 mg/kg intravenous
89289673|NCT01212276|Experimental|Cohort 4|MORAb-028 1.0 mg/kg intravenous
89289674|NCT03634384||Derivation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as derivation cohort."
89289675|NCT03634384||Validation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as validation cohort."
89289676|NCT01111344|Experimental|Glizigen + Viusid|
89289677|NCT01111344|Placebo Comparator|Placebo|
89289678|NCT01208688|Experimental|FES Therapy|FES Therapy
89289679|NCT01208688|Active Comparator|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
89289680|NCT05365204|Experimental|Voluven diluted indocyanine green|This arm participants uses Voluven diluted ICG for sentinel lymph node mapping.
89289681|NCT05365204|Active Comparator|Distilled-water diluted indocyanine green|This arm participants uses Distilled-water diluted ICG for sentinel lymph node mapping.
89289682|NCT01212354|Experimental|A - experimental|7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
89289683|NCT01212354|Active Comparator|B - control|7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
89289684|NCT01368796|Active Comparator|Trivalent Influenza vaccine subunit|The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.
89289685|NCT01368796|Active Comparator|Adjuvanted Tri-valent Influenza Vaccine|The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.
89289686|NCT01368796|Active Comparator|Intradermal Tri-valent Influenza vaccine|(Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.
89289687|NCT01368796|Active Comparator|Trivalent Split-virion Influenza vaccine|Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.
89289688|NCT01368952|Active Comparator|Pure Prone Positioning|Sleeping in prone position by pure prone positioning device, which consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
89289689|NCT01368952|No Intervention|Baseline|No intervention for sleep position
89289690|NCT01111422|No Intervention|Control|Age and sex matched peritoneal dialysis patients
89289691|NCT01111422|Experimental|N-acetylcysteine|N-acetylcysteine in stable peritoneal dialysis patients
89289692|NCT05188378|Experimental|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
89289693|NCT05188378|Active Comparator|EU-approved RoActemra|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
89289694|NCT05358730|Experimental|IASTM + Standard Exercise Group|Patients were applied IASTM in combination with standard exercise program two days a week for six weeks. The IASTM technique was performed using six titanium-plated instruments in different sizes, shapes and treatment styles. ROM, crutch, roller, scapulothoracic and stretching exercises were given as home exercises during the treatment.
89289695|NCT05358730|Active Comparator|Standard Exercise Group|Patients were given a standard exercise program two days a week for six weeks. ROM, crutch, roller, scapulothoracic and stretching exercises were given as home exercises during the treatment.
89289696|NCT03939702|Active Comparator|Non-Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
89289697|NCT03939702|Active Comparator|Bile Collection|On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12
89289698|NCT05188300|Experimental|Dorsal intercostal artery (DICA) perforator flaps|Retrograde dissection of free style perforator arising from DICA according to region of dorsal spine and identification of paraspinal muscle where perforator vessel was found
89289699|NCT05188300|Experimental|Trapezius musculocutaneous perforator flaps|Retrograde dissection of a free style perforator arising as a trapezius myocutenous perforator where the trapezius muscle is identified and a perforator vessel was isolated.
89289700|NCT05188300|Experimental|Lumbar artery perforators flaps|Retrograde dissection of free style perforator arising from lumbar artery according to region of lumbar spine and identification of lumbar fascia where perforator vessel was found
89289701|NCT01115634|Experimental|Fibroblast|Injection of autologous cultured fibroblast
89289702|NCT01360216|Experimental|LARC education and training|Clinicians and contraceptive educators practicing in clinics assigned to this arm receive a special half-day Continuing Medical Education (CME/CEU) accredited LARC education and training session.
89289703|NCT01360216|No Intervention|Standard practice- control|Clinicians and contraceptive educators practicing in clinics assigned to this arm do not receive special LARC training and education session. Standard practice will be followed at clinics assigned to the control arm.
89289704|NCT03938064|Active Comparator|Group Early start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries from the day of ovum retrieval (OR).
89289705|NCT03938064|Placebo Comparator|Group Late start|group will include 260 women with POR undergoing a trial of IVF/ICSI. This group will receive vaginal micronized progesterone pessaries 2 days after OR.
89289706|NCT01213368|Experimental|dronedarone 300 mg|Dronedarone, 100mg + 200mg tablets twice daily, administered with food.
89289707|NCT01213368|Experimental|dronedarone 400 mg|Dronedarone, 400mg tablets twice daily, administered with food.
89289708|NCT01213368|Experimental|dronedarone 600 mg|Dronedarone, 400mg + 200mg tablets twice daily, administered with food.
89289709|NCT01213368|Placebo Comparator|placebo|Matching placebo tablets twice daily, administered with food.
89289710|NCT01212510|Other|Tumor markers|measurement of tumor markers ( blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA )
89289711|NCT05336110||Patient with a positive preoperative SARS-CoV-2 test|Patient with a positive preoperative SARS-CoV-2 test
89289712|NCT01210950|Experimental|cell and RPR recepients|mesenchymal cells and plasma reach protein are injected to the callus center of short limb
89289713|NCT03938142||patients with chronic pain|
89289714|NCT01211028|Other|Autologous ASCs|Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells.
89289715|NCT01369186|Active Comparator|Morphine|Vendal 5 mg i.v. bolus injection
89289716|NCT01369186|Placebo Comparator|Placebo|Sodium chloride 0.9% i.v. bolus injection
89289717|NCT01115712|Active Comparator|Pioglitazone 30 mg|Pioglitazone 30 mg
89289718|NCT01115712|Placebo Comparator|Placebo|Placebo
89289719|NCT01360294||Asthma with small airway disease|
89289720|NCT01360294||Asthma without small airway disease|
89289721|NCT01369264|Experimental|True Left High Frequency|True left high frequency repetitive transcranial magnetic stimulation
89289722|NCT01369264|Placebo Comparator|Passive sham left high frequency|Passive sham left high frequency repetitive transcranial magnetic stimulation
89289723|NCT03939936|Active Comparator|Test Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients before treatment and after 8 weeks.~Intervention: Non-surgical periodontal treatment was performed and the Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
89289724|NCT03939936|Placebo Comparator|Control Group|"Psoriatic measurements and saliva samples were taken from periodontal disease patients at the baseline and after 8 weeks without the periodontal treatment.~Intervention: Psoriasis Area and Severity Index (PASI) was filled, saliva samples were taken."
89289725|NCT01117662|Experimental|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
89289726|NCT01117662|Placebo Comparator|Control|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
89289727|NCT01319266|Experimental|Normal Renal Function|Subjects with normal renal function
89289728|NCT01319266|Experimental|Mild Renal Impairment|Subjects with mild renal impairment (defined by an estimated creatinine clearance of > 50 and up to 80 mL/min)
89289729|NCT01319266|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment (defined by an estimated creatinine clearance of 30-50 mL/min)
89289730|NCT01319266|Experimental|Severe Renal Impairment|Subjects with severe renal impairment (defined by an estimated creatinine clearance of less than 30 mL/min)
89289731|NCT01319266|Experimental|End Stage Renal Disease (ESRD)|Subjects with ESRD (defined as being on hemodialysis for at least 6 months prior to enrollment and be receiving standard in-center dialysis treatments three times a week)
89289732|NCT01115790|Experimental|Prexasertib|
89289733|NCT01115868|Experimental|Group 2 - 2 doses of Prevascar and placebo|
89289734|NCT01115868|Experimental|Group 1 - 2 doses of Prevascar and placebo|
89289735|NCT01115868|Experimental|Group 3 - 2 doses of Prevascar and placebo|
89289736|NCT01115868|Experimental|Group 4 - 2 doses of Prevascar and placebo|
89289737|NCT01115946|Experimental|single-add first group|single administration first, then concomitant administration
89289738|NCT01115946|Experimental|combi-add first group|concomitant administration first, then single administration
89289739|NCT01113372|Experimental|Clopidogrel 3 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 3 months.
89289740|NCT01113372|Active Comparator|Clopidogrel 12 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 12 months.
89289741|NCT03120520|Experimental|Plecanatide 0.5 mg|Taken orally once daily in the morning for 8 weeks
89289742|NCT03120520|Experimental|Plecanatide 1.0 mg|Taken orally once daily in the morning for 8 weeks
89289743|NCT03120520|Experimental|Plecanatide 1.5 mg|Taken orally once daily in the morning for 8 weeks
89289744|NCT03120520|Placebo Comparator|Matching placebo|Taken orally once daily in the morning for 8 weeks
89289745|NCT03941340|Experimental|[14C]-AST2818 80mg (oral solution)|Volunteers will receive 80 mg [14C]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.
89289746|NCT01117740||Thoracoscopy Group|
89289747|NCT01117740||Indwelling Pleural Catheters|
89289748|NCT01372852||T2DM patients|newly diagnosed T2DM patients and untreated with any drugs.
89289749|NCT01372852||Non-diabetic Control Group|
89289750|NCT01117818|Active Comparator|A: AFFITOPE AD02|
89289751|NCT01117818|Active Comparator|B: AFFITOPE AD02|
89289752|NCT01117818|Active Comparator|C: AFFITOPE AD02|
89289753|NCT01117818|Active Comparator|D: Placebo control|
89289754|NCT01372930|Experimental|Etanercept|
89289755|NCT01372930|Placebo Comparator|saline|
89289756|NCT01117896|Experimental|Adult vs Pedi manikin CC quality|"The primary objective is to determine whether chest compression deterioration occurs at the same rate in pediatric and adult manikins. The primary endpoint will be the difference in mean number of effective compressions per minute in each manikin at times 1, 2, 5 and 10 minutes.~Another objective is to identify the correlation between the anaerobic threshold and the deterioration of compressions in each manikin. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each manikin."
89289757|NCT01117896|Experimental|Stepstool use|A third main objective is to determine the effect of the stepstool use on the quality of chest compressions and metabolic demand. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each experimental group.
89289758|NCT01328652|Experimental|Proton Pump Inhibitor|Treatment with dexlansoprazole 60 mg once daily for 3 months
89289759|NCT01373008|Experimental|Inhaled QVAR|Inhaled QVAR 100 mic via aerochamber twice daily until 3 month post discharge
89289760|NCT01373008|Placebo Comparator|Inhaled placebo|Inhaled nonmedicated MDI [metered dose inhaler] in a similarly marked aerosol chamber using the same delivery technique, obtained from the drug manufacturer
89289761|NCT01116180|Active Comparator|Candesartan|
89289762|NCT01116180|Placebo Comparator|Placebo|
89289763|NCT01117974|Experimental|Liposuction|
89289764|NCT05008744||Patients presenting with TTTS|Pregnant persons between 16 and 36 weeks of pregnancy with a diagnosis of twin to twin transfusion syndrome
89289765|NCT01116258|Experimental|1|
89289766|NCT01116258|Placebo Comparator|2|
89289767|NCT01113528|Experimental|Regenerative therapy|
89289768|NCT01113528|Placebo Comparator|Sugar pill|
89289769|NCT01213446|Experimental|Biostate|
89289770|NCT01113606|Active Comparator|Obagi Nu-Derm System (ONDS)|
89289771|NCT01113606|Active Comparator|Standard of Care|
89289772|NCT01369576|Placebo Comparator|Placebo|Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©
89289773|NCT01369576|Experimental|zopiclone|Sleep apnea OSR Medical Treatment plan ©
89289774|NCT01113762|Experimental|resurfacing|a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint
89289775|NCT01113762|Experimental|large head THA|a standard stemmed THA but with a large metal head, and a metal-metal articulation
89289776|NCT01113762|Active Comparator|28 mm ceramics-polyethylene|a standard 28 mm head uncemented THA
89289777|NCT01113762|Active Comparator|28 mm metal-polyethylene THA|a standard stemmed uncemented THA
89289778|NCT03939780|Experimental|Cohort 1|Subjects will be scanned twice (once with each of the tracers [18F]RO-948 and [18F]MK-6240)
89289779|NCT03939780|No Intervention|Cohort 2A|No PET scans will be done. Previous [18F]AV-1451 scans of selected aged matched older cognitively healthy controls (OC) subjects from the Baltimore Longitudinal Study of Aging (BLSA) study (IRB00047185) will be reanalyzed.
89289780|NCT03939780|Experimental|Cohort 2B1 - AD [18F]RO-948 and [18F]AV-1451|Alzheimer's Disease (AD) subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
89289781|NCT03939780|Experimental|Cohort 2B2 - AD [18F]MK-6240 and [18F]AV-1451|AD subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with AD will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
89289782|NCT03939780|Experimental|Cohort 2B3 - OC [18F]RO-948 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]RO-948 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
89289783|NCT03939780|Experimental|Cohort 2B4 - OC [18F]MK-6240 and [18F]AV-1451|OC subjects who show high binding to the choroid plexus by a visual analog scale (high, low, and none) will be studied. Subjects with OC will be scanned twice: once with [18F]MK-6240 and a second scan with [18F]AV-1451 in randomized order and within one month of each other.
89289784|NCT01212666|Experimental|Adductor-Canal-Block, Ropivacain|25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.
89289785|NCT01212666|Placebo Comparator|Adductor Canal Block, Placebo (saline)|25 patients. ACB. 30 mL Saline. Ultrasound-guided application.
89289786|NCT01213602||Femoral block preoperative|In one group (T1) with performance of femoral block before general anesthesia and administration of bolus of local anesthetic through stimulating catheter (combined anesthesia)
89289787|NCT01213602||Femoral block postoperative|In second group (T2) with a administration of local anesthetic through stimulating femoral catheter until awareness of patient (balanced anesthesia).
89289788|NCT01116336|Experimental|Erlotinib and Green Tea Polyphenon E|Patients will receive erlotinib, at pre-defined dose level, with polyphenon E.
89289789|NCT01116492|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
89289790|NCT01116492|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
89289791|NCT03941418|Experimental|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
89289792|NCT03941418|Placebo Comparator|Placebo|Patients will be administered with placebo as an addition to their standard therapy.
89289793|NCT03941028|Experimental|bone defects caused by trauma|Large bone defects (>6cm) caused by trauma
89289794|NCT03941028|Experimental|bone defects caused by infection|Large bone defects caused by chronic osteomyelitis
89289795|NCT03941028|Experimental|bone defects caused by tumor|Large bone defects caused by benign tumor
89289796|NCT01213680|Active Comparator|1000 mg iron isomaltoside as intravenous infusion|
89289797|NCT01213680|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
89289798|NCT01113840|Placebo Comparator|Control|Control group continues with their daily activity as they were prior to randomization. Receive bi-weekly follow-up phone calls to assess health status and encourage adherence with protocol.
89289799|NCT01113840|Active Comparator|Exercise|Exercise classes three times per week in a controlled, supervised environment.
89289800|NCT01113918||Obsity PCOS Women|"Polycystic ovary syndrome (PCOS) was diagnosed according to the European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM) case definition which requires presentation of signs and/or symptoms of a minimum of 2 of the following 3 criteria: polycystic ovary morphology (PCOM), oligomenorrhea or amenorrhea (Oligo-An), androgen excess (HA).~Body mass index (BMI) was defined as body weight in kilograms divided by body height in meters squared (kg/m2). Obesity was defined as BMI≥25 kg/m2, according to the Asia-Pacific definition."
89289801|NCT01113918||Non-obesity PCOS Women|The subjects BMI were less than ≥25 kg/m2 and out of criteria of PCOS by European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM).
89289802|NCT01116570|Experimental|Physical training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
89289803|NCT01116570|Other|control|None intervention
89289804|NCT01213758||Liver tumors|Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
89289805|NCT01113996|No Intervention|Standard treatment - usual care|
89289806|NCT01113996|Experimental|Protein supplementation|
89289807|NCT01113996|Experimental|Protein supplementation and strength training|
89289808|NCT03937518|Other|strontium ranelate|included 15 patients who received oral strontium ranelate and physiotherapy program. The age of the patients ranged from 50 to 62 years,
89289809|NCT03937518|Other|physiotherapy|included 15 patients who received physiotherapy program. The age of the patients ranged from 50 to 62 years
89289810|NCT01211496|Active Comparator|High-speed power training|Volunteers randomized into High-speed power training (HSPT) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
89289811|NCT01211496|Active Comparator|Slow-speed strength training|Volunteers randomized into Slow-speed strength training (SSST) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
89289812|NCT01211496|No Intervention|placebo exercise (control group)|Volunteers randomized into the control group (CON) will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
89289813|NCT01114074||Factor XII deficiency|Patients deficient in coagulation factor XII
89289814|NCT01114074||Factor XI Deficiency|Patients deficient in coagulation factor XI
89289815|NCT01114074||Prekallikrein deficiency|Patients deficient in prekallikrein
89289816|NCT01114074||HMWK deficiency|Patients deficient in high molecular weight kininogen (HMWK)
89289817|NCT01114074||Control group|Healthy controls
89289818|NCT01116726|Experimental|Motivational interviewing and enhanced community services|Motivational interviewing sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries, provided shortly after childbirth, and at 6, 12, and 18 months. Enhanced community services will involve development of culturally appropriate messages related to the mitigation of risk factors for ECC through public service announcements and brochures.
89289819|NCT01116726|Active Comparator|Enhanced community services|Enhanced community services will involve development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
89289820|NCT01118208|Experimental|Blister Packaging|Patients will receive all prescription medications on blister pack cards.
89289821|NCT01118208|Active Comparator|Dispense as Usual|Patients will receive all prescription medications in standard pill bottles.
89289822|NCT03937440|Experimental|Deep neuromuscular block group|
89289823|NCT03937440|Experimental|Moderate neuromuscular block group|
89289824|NCT01114152|Experimental|1|Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8)
89289825|NCT01114152|Placebo Comparator|2|placebo given (2 subjects in each dose group)
89289826|NCT01211574|Experimental|peer coach|Participants will be coached by a peer between treatment visits.
89289827|NCT01211574|Experimental|mentor|Participants will be coached by a mentor between treatment visits
89289828|NCT01211574|Experimental|Professional|Participants will be coached by an interventionist between treatment visits
89289829|NCT01118286||Group 1|
89289830|NCT01211652||1|
89289831|NCT03940014||Pulmonary arteriovenous malformations|"Patients with hereditary haemorrhagic telangiectasia (HHT)-related Pulmonary Arteriovenous Malformations (PAVMs). For all patients, the final diagnosis of certain HHT the diagnosis can be made depending on the presence of four criteria known as the Curaçao criteria: 1) Spontaneous recurrent epistaxis 2) Multiple telangiectasias in typical locations 3) Proven visceral Arteriovenous Malformations (AVM) (lung, liver, brain, spine) 4) First-degree family member with HHT. If conditions three or four are met, a patient has definite HHT, while condition two is considered as possible HHT. All patients had a molecular diagnosis and all follow-up clinical assessments were available in the database."
89289832|NCT01118364|Experimental|cigarette with cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)"
89289833|NCT01118364|Other|cigarette without cannabis|"a cigarette tobacco trade mark Drum"
89289834|NCT03939468||Observational Cohort|Patient with diffuse CAD disease treated with hybrid strategy (DES+DCB)
89289835|NCT01585506||Questionnaire responders|
89289836|NCT03787212|Experimental|MiBo ThermoFlo / Bruder mask|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
89289837|NCT03787212|Experimental|Bruder Mask / MiBo ThermoFlo|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
89289838|NCT01585350|Experimental|Cohort 1|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
89289839|NCT01585350|Experimental|Cohort 2|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
89289840|NCT03937674|Experimental|HeartSteps Intervention|For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not.
89289841|NCT01121640|Other|CA125 every screen, HE4 at confirmatory screen.|CA125 will be used at every screen. Women with a parametric empirical Bayes (PEB) longitudinal algorithm score above the 90th percentile will be asked to return for early recall screening. Women with a PEB score above the 95th percentile will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
89289842|NCT01121640|Other|CA125 and HE4 at every screen.|CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
89289843|NCT01118598|Placebo Comparator|placebo arm|this group will receive placebo as per protocol
89289844|NCT01118598|Active Comparator|tredaptive|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
89289845|NCT01121718|Experimental|ICG Intervention|Intraoperative NIR fluorescence imaging was performed after injection of 1.0 ml of 100 µM, 250 µM or 500 µM of ICG:HSA in four quadrants around the primary lesion. (The intervention to be administered is the ICG.)
89289846|NCT03939546|No Intervention|Control|The Control Arm will not receive any study intervention or placebo. The infants in this arm will receive standard NICU care.
89289847|NCT03939546|Active Comparator|B. infantis EVC001|Infants in the B. infantis arm will receive a once daily enteral feed of Evivo with MCT oil (8B CFU B. infantis EVC001) from Study Day 0 (by Day 10 of life) to hospital discharge, except on days when the infant is NPO.
89289848|NCT03937362||Clinical Response Evaluation|"Patients with operable esophageal squamous cell carcinoma who are planned to undergo neoadjuvant chemoradiotherapy according to the CROSS regimen (intravenous carboplatin AUC 2 mg/mL/min and intravenous paclitaxel 50 mg/m2 on days 1, 8, 15, 22 and 29 with concurrent 41.4 Gy radiotherapy given in 23 fractions of 1.8 Gy on 5 days per week) followed by surgery.~Patients will undergo a first clinical response evaluation (CRE-1) 4-6 week after completion of nCRT. In patients without histological evidence of residual tumor surgery will be postponed another 6 weeks. A second clinical response evaluation (CRE-2) will be performed 10-12 weeks after completion of nCRT. Immediately after CRE-2 all patients without evidence of distant metastases will undergo esophagectomy."
89289849|NCT01215864|Experimental|TCD-717|
89289850|NCT01118754|Experimental|DE-101 ophthalmic suspension high dose|
89289851|NCT01118754|Experimental|DE-101 ophthalmic suspension low dose|
89289852|NCT01118754|Placebo Comparator|DE-101 ophthalmic suspension vehicle|
89289853|NCT01216020|Experimental|cetuximab plus radiotherapy|Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
89289854|NCT01216020|Active Comparator|cisplatin plus radiotherapy|CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)
89289855|NCT01212978|No Intervention|Delayed Intervention|These subjects will neither receive a pedometer or access to the motivational software until completion of the study.
89289856|NCT01212978|Active Comparator|Pedometer only|Participants in the this arm will receive a pedometer with instructions to reach a goal of 10,000 steps/day but will not receive access to the motivational software.
89289857|NCT01212978|Experimental|Pedometer + Motivational Software|In this arm, subjects will receive access to both a pedometer and motivational software
89289858|NCT01118910|Experimental|Vusion ointment|
89289859|NCT03939078||Vaginal Laser Intervention|Patients will be submitted to vaginal biopsy before and after three laser sections, and therefore will be their own comparative group to see the improvement associated with the laser effects.
89289860|NCT01121796|Active Comparator|Vitamin D|
89289861|NCT01121796|Placebo Comparator|Placebo|
89289862|NCT01121796|Active Comparator|Unique vehicle for Vitamin D supplementation|
89289863|NCT01121874|Active Comparator|LRTI|These patients will undergo ligament reconstruction with tendon interposition (LRTI) surgery. They will serve as a control group, against which to compare the investigational surgical technique.
89289864|NCT01121874|Experimental|Suture fixation system|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system.
89289865|NCT01121874|Experimental|Suture fixation system + 2 week immobilization|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system, and with a decreased immobilization time from 6 to 2 weeks post-surgery.
89289866|NCT01121952|Placebo Comparator|Placebo|Single high-velocity, low-amplitude (HVLA) thrust manipulation towards Tibia, not affecting the dysfunctional talo-crural joint
89289867|NCT01121952|Experimental|Treatment|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation on dysfunctional talo-crural joint
89289868|NCT01116960||Faculty; MD|Full time Faculty members working with the Department
89289869|NCT01116960||CRNAs|Full time CRNAs working within the department
89289870|NCT01116960||Residents|Residents working within the department
89289871|NCT03937284||Parkinson's patients|Patients with Parkinson disease evaluated in agreement with UK Brain Bank criteria
89289872|NCT03937284||Control group|Subject matched for sex, age and BMI
89289873|NCT01119144|Experimental|Polycaprolactone / Tricalcium Phosphate|Polycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant
89289874|NCT01119144|Active Comparator|Control|Control group with titanium mesh
89289875|NCT01117038|Experimental|enalapril and avanafil|
89289876|NCT01117038|Experimental|amlodipine and avanafil|
89289877|NCT01216098|Experimental|Experimental arm - D|Experimental arm - Women randomized to this arm will receive doula support alongside standard care.
89289878|NCT01216098|No Intervention|No intervention - ND|No intervention - Women randomized to this arm will receive standard care alone.
89289879|NCT01119300|Active Comparator|Standard care|Standard care
89289880|NCT01119300|Experimental|Genotype-guided dosing algorithm|Genotyping for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.
89289881|NCT01216254|Active Comparator|Classic electrocoagulation|Arm of the study where the classic low-frequency electrocoagulation is used during the operation
89289882|NCT01216254|Experimental|High Frequency electrocoagulation|Arm of the study where the tested high-frequency electrocoagulation is used during the operation
89289883|NCT03938844||TLH with BURCH Colposuspension|the patients who underwent simultaneous burch copying with TLH was evaluated. In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
89289884|NCT03938844||TLH with Transobturatuar Tape (TOT)|In cases of simultaneous toting with TLH; In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
89289885|NCT01213056|Active Comparator|Mindfulness Based Cognitive Therapy * (MBCT)|Mindfulness based cognitive therapy aimed to improve coping with, and managing chronic headache pain.
89289886|NCT01213056|No Intervention|Delayed Treatment Control * (DT)|
89289887|NCT01119378|Experimental|Post Menopausal|post menopausal women between the ages 50-70 yrs.
89289888|NCT01213914|Experimental|High-volume hemofiltration at 70ml/kg/hr|Paired randomization into four groups via central randomization center. Group 1: age 18-65 and <40%TBSA Group 2: age 18-65 and >40%TBSA Group 3: age >65 and <40%TBSA Group 4: age >65 and >40%TBSA
89289889|NCT01213914|Active Comparator|Control group|Contemporary care via consideration of the Burn-Specific Sepsis Bundle adapted form the most recent Surviving Sepsis campaign recommendations and specifically modified to our patient population.
89289890|NCT03938766|Other|PSMA PET/CT|Repeat PSMA PET/CT after ADT
89289891|NCT01119534|Experimental|Transpulmin|Suppository composed by guaiacol, eucalyptol, menthol and camphor
89289892|NCT01119534|Active Comparator|Comparator 1|Suppository composed by guaiacol
89289893|NCT01119534|Active Comparator|Comparator 2|Syrup composed by guaifenesin
89289894|NCT01117116|Active Comparator|fluticasone propionate and salmeterol|
89289895|NCT01117116|Active Comparator|budesonide and formoterol|
89289896|NCT01117194|Experimental|shoulder training, rehabilitation robot|
89289897|NCT01117194|No Intervention|control group|
89289898|NCT01122186|Experimental|Intervention Condition|Eight sessions of Motivational Interviewing and Cognitive Behavioral Skills Training, adapted to target both MA use and medication adherence, as well as sexual risk behaviors and polydrug use.
89289899|NCT01122186|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition. The content will be as follows: 3 sessions focusing on medication adherence; 3 sessions focusing on the dangers of methamphetamine use; 1 session addressing sexual risk; and 1 session addressing poly-substance use.
89289900|NCT01119612|Active Comparator|Iron|
89289901|NCT01119612|Placebo Comparator|Placebo|
89289902|NCT03937206|Experimental|Low Dose|Low Dose (300mg TG Omega-3) - 1 capsule containing 1000mg NutriterraTM per capsule + 3 capsules containing 1000mg corn oil per capsule
89289903|NCT03937206|Experimental|Mid Dose|Mid Dose (600mg TG Omega-3) - 2 capsules containing 1000mg NutriterraTM per capsule + 2 capsules containing 1000mg corn oil per capsule
89289904|NCT03937206|Experimental|High Dose|High Dose (1200mg TG Omega-3) - 4 capsules containing 1000mg NutriterraTM per capsule
89289905|NCT03937206|Placebo Comparator|Placebo|Placebo (0mg TG Omega-3) - 4 capsules containing 1000mg corn oil per capsule
89289906|NCT01216488|Active Comparator|40 ml of Xylocaine|
89289907|NCT01216488|Experimental|25 ml of Xylocaine|
89289908|NCT01119690|Active Comparator|Rapeseed oil|
89289909|NCT01119690|Active Comparator|Milk fat|
89289910|NCT01122342|Experimental|Vaginal Testosterone|Daily application of vaginal testosterone for 28 days.
89289911|NCT03935802||primary non-metastatic breast cancer|primary non-metastatic breast cancer
89289912|NCT01213212|Experimental|Caloric restriction|Caloric restriction
89289913|NCT01213212|Sham Comparator|"Diet ad libitum"|"Diet ad libitum"
89289914|NCT01119924|Active Comparator|Mirtazapine|Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks
89289915|NCT01119924|Placebo Comparator|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
89289916|NCT01117272||PCOS group|Who met the 2003 Rotterdam criteria.
89289917|NCT01117272||Mild hyperprolactinaemia group|Who were diagnosed with prolactin levels above the upper limit of normal (24.29 ng/ml) and under 100 ng/ml.
89289918|NCT01117272||Control group|Without PCOS and with normal prolactin levels.
89289919|NCT01216566|Experimental|I. Patients with chronic neck pain|
89289920|NCT01120002|Placebo Comparator|Placebo pill|
89289921|NCT01120002|Active Comparator|Tamibarotene|
89289922|NCT03935490||e-TREPP|Patients with strangulated inguinal hernia treated with e-TREPP
89289923|NCT01213992|Active Comparator|Monofer® 500 mg|500 mg iron isomaltoside 1000
89289924|NCT01213992|Active Comparator|Monofer® 1000 mg|1000 mg iron isomaltoside 1000
89289925|NCT02529384||malignant group|The lesion which is malignant tumors in breast
89289926|NCT02529384||begin group|The lesion which is begin lesion in breast
89289927|NCT02529384||The control group|Patient's ipsilateral or contralateral normal breast parenchyma were collected as a control group
89289928|NCT01216644|Experimental|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
89289929|NCT01216644|Active Comparator|ECF|Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP
89289930|NCT01213290|Active Comparator|EUS-FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
89289931|NCT01213290|Active Comparator|EUS-FNA without stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
89289932|NCT03125200|Experimental|ADCT-502|"Part 1 (dose escalation): Participants received an infusion of ADCT-502, at escalating doses. Part 1 continued until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion were determined.~Part 2 (expansion): Participants were due to be assigned to the recommended dose level of ADCT-502 as identified in Part 1 by the Dose Escalation Steering Committee."
89289933|NCT03938376||Potential Prostate Cancer|Biopsy naïve patients with rising Prostate Specific Antigen (PSA) results referred by their Urologist for a standard of care (SOC) biopsy.
89289934|NCT01216722|Experimental|Resistance Strengthening|Body weight antigravity positioning and elastic resistance bands are used to provide resistance for strengthening in supine, sitting, and standing in subjects post liver transplant.
89289935|NCT01216722|No Intervention|Usual Care Control|Subjects perform the usual care of progressive ambulation and increased activity post liver transplant
89289936|NCT01369654|Experimental|Computerized decision aid|
89289937|NCT01214070|Active Comparator|Arm 1|Group 1 - Combination Treatment
89289938|NCT01214070|Active Comparator|Arm 2|Group 2 - Combination Treatment
89289939|NCT01214070|Active Comparator|Arm 3|Group 3 - Combination Treatment
89289940|NCT01214070|Active Comparator|Arm 4|Group 4 - Combination Treatment
89289941|NCT01214070|Active Comparator|Arm 5|Group 5 - Monotherapy Treatment
89289942|NCT01214070|Active Comparator|Arm 6|Group 6 - Monotherapy Treatment
89289943|NCT01214070|Active Comparator|Arm 7|Group 7 - Monotherapy Treatment
89289944|NCT01369810||1|All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
89289945|NCT05188066||Normal, pathological IVG|We will use placenta and fetal memebranes collected from first trimester termination of pregnancy. This will constitute group IVG.
89289946|NCT05188066||Normal and pathological term|We will also use the same specimens collected from third trimester pregnancies . We will call this group normal and pathological..... à finaliser
89289947|NCT01214148|Other|ORSIRO|
89289948|NCT03936972||ilizarov circular frame|46 participants with open tibia fracture Gustillo type III only
89289949|NCT03936972||Ex. Fix|47 participants with open tibia fracture Gustillo type III only
89289950|NCT04959760|Experimental|BinaxNow Covid-19 Antibody test|The BinaxNOW™ Antibody Tests measure SARS-CoV-2 S-IgG antibodies.
89289951|NCT03935334|Experimental|Eptacog alfa, biosimilar (AryoSeven)|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
89289952|NCT03935334|Active Comparator|Novoseven|Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
89289953|NCT04934566|Experimental|patients|patients receiving temporary veno-arterial assistance whose weaning, or transfer to a heart transplant, or to long-term assistance or discontinuation is envisaged.
89289954|NCT01122420|Experimental|Goal-Setting Tool|
89289955|NCT01122420|Active Comparator|Health Web Sites|
89289956|NCT01373320|Experimental|Early Intervention|Participants in this group are nested in churches which were randomly assigned to the treatment group.
89289957|NCT01373320|No Intervention|Delayed Intervention|Participants in this group are nested in churches which were randomly assigned to the wait-list control group. They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.
89289958|NCT01214226|Active Comparator|Pentoxifylline + Prednisolone|"Pentoxifylline 400 mg prolonged-released tablets 3 time a day [1200 mg/day]~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
89289959|NCT01214226|Placebo Comparator|Placebo + Prednisolone|"Placebo prolonged-release tabled 3 time a day~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
89289960|NCT01360372|Active Comparator|Methylnaltrexone|
89289961|NCT01360372|Placebo Comparator|saline placebo injection|
89289962|NCT01360528||Extremely low birth weight|Extremely low birth weight under 1000 gram
89289963|NCT01360528||Very low birth weight|Between 1000-1500 gram babies
89289964|NCT01360528||Low birth weight|Between 1500-2500 gram
89289965|NCT01219062|Placebo Comparator|control|The patient will be performed spinal anesthesia alone, with postoperative PCA
89289966|NCT01219062|Active Comparator|Morphine|The patient will received intrathecal Morphine for 0.1 mg. in Isobaric bupivacaine in spinal anesthesia and postoperative PCA
89289967|NCT01219062|Active Comparator|bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
89289968|NCT04812262|Experimental|Group A1 - Single Ascending Dose|DD01 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection
89289969|NCT04812262|Experimental|Group A2, Single Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection
89289970|NCT04812262|Experimental|Group A3, Single Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection
89289971|NCT04812262|Experimental|Group A4, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
89289972|NCT04812262|Experimental|Group B2 - Multiple Ascending Dose|DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
89289973|NCT04812262|Experimental|Group B3 - Multiple Ascending Dose|DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
89289974|NCT04812262|Experimental|Group B4 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
89289975|NCT04812262|Experimental|Group B5 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
89289976|NCT04812262|Experimental|Group B6 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
89289977|NCT04812262|Experimental|Group A5, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
89289978|NCT04812262|Experimental|Group A6, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
89289979|NCT04812262|Experimental|Group A7, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
89289980|NCT04812262|Experimental|Group A8, Single Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection
89289981|NCT04812262|Experimental|Group B7 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
89289982|NCT04812262|Experimental|Group B8 - Multiple Ascending Dose|DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks
89289983|NCT01120158|Experimental|1|Paclitaxel/Bevacizumab
89289984|NCT01219140|Experimental|2 POMx Capsules|2 POMx Capsules daily
89289985|NCT01219140|Placebo Comparator|2 placebo Capsules|2 placebo Capsules daily
89289986|NCT01124526|Experimental|Rituximab, Fludarabine, ciclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2)"
89289987|NCT01122498|Experimental|1|
89289988|NCT01122498|Experimental|2|
89289989|NCT01122498|Experimental|3|
89289990|NCT01120314|Experimental|Severe renal impairment population|
89289991|NCT01120314|Experimental|Moderate renal impairment population|
89289992|NCT01120314|Experimental|Mild renal impairment population|
89289993|NCT01120314|Experimental|Healthy population|Healthy matched subjects
89289994|NCT03633994|Experimental|Heparin Bladder Instillation|At the completion of the scheduled benign hysterectomy, intravesicular bladder instillation containing 40,000U of heparin (40mL of 10,000U heparin/10mL) will be administered be introduced in a retrograde fashion by gravity via Foley catheter. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
89289995|NCT03633994|Placebo Comparator|Normal Saline Bladder Instillation|Patients randomized to the control group will undergo intravesical instillation with 40mL of normal saline. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
89289996|NCT01328886|Experimental|Omalizumab|
89289997|NCT01120392|Experimental|Treatment group - Nintendo wii.|
89289998|NCT01120392|Active Comparator|conventional - Physical Therapy|
89289999|NCT01374022|Experimental|ART Strategy|maximum alveolar recruitment plus PEEP titration
89290000|NCT01374022|Active Comparator|ARDSNet Strategy|standard strategy (ARDSNet)
89290001|NCT01214304|Placebo Comparator|Lavender Scent|Patients will receive aromatherapy with a fake lavender scent (placebo) which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
89290002|NCT01214304|Experimental|Essential Lavender Oil|Patients will receive essential Lavender Oil which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
89290003|NCT04624984|Experimental|PD-1 Inhibitor or PD-1 Inhibitor with GVD|"All patients receive PD-1 Inhibitor on day 1. Treatment cycles repeat every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET/CT confirmed CR or PR receive PD-1 Inhibitor for another 3 cycles. Patients with PD or SD receive PD-1 Inhibitor plus GVD (gemcitabine, vinorelbine and doxorubicin liposome) regimen every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients with PET/CT confirmed CR after 6 cycles of PD-1 Inhibitor treatment can receive radiotherapy or ASCT, which is determined by investigators. Patients with PR receive 2-4 cycles of PD-1 Inhibitor plus GVD regimen. Patients with PD or SD receive 4 cycles of PD-1 Inhibitor plus GVD regimen.~Patients with confirmed CR or PR after PD-1 Inhibitor plus GVD regimen can receive radiotherapy or ASCT, which is determined by investigators. Patients with PD or SD quit the trial."
89290004|NCT01219218|Experimental|A|Treatment group. Patients in this group receive actual shockwave therapy.
89290005|NCT05187754|Experimental|Intervention Group|
89290006|NCT05187754|No Intervention|Control Group|
89290007|NCT01214382|Experimental|Sertraline|
89290008|NCT01373476|Experimental|Qideng Mingmu capsule|High dosage group,Middle dosage group,Low dosage group.
89290009|NCT01373476|Placebo Comparator|Placebo|Placebo group
89290010|NCT01216956|Experimental|Extended release nicotinic acid|
89290011|NCT01216956|Placebo Comparator|Placebo|
89290012|NCT03132220|Active Comparator|Book Club Active Control|"The subject will participate in 16 in-person hours that are broken into sessions for the book club active control intervention. This club will be facilitated by 1-2 instructors. The club will be described as a fun activity to do outside of work to help reduce work-related stress. The club will be structured similarly to the intervention with respect to time, and homework expectations. Nurses will be prohibited from talking about work stress."
89290552|NCT03924726|Other|Control and experimental ( 8 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 8 weeks.
89290553|NCT03924726|Other|Control and experimental (12 weeks MOP)|This is a split mouth study. This group received 2 sessions of Micro-osteoperforation (MOP) at an interval of 12 weeks.
89290626|NCT03923712|No Intervention|Control Group|Participants randomly assigned to control group will be instructed to maintain their normal life habits with respect to physical activity and diet. During the 5 months of intervention participants from this group will receive at least one call from the researchers to be interested in their health status and inform them about the next evaluation appointment, as well as, an objectively evaluation of the main behaviours in the middle of intervention. Investigators will inform about the relevance of attending the full process and respecting the condition and rule as control. Participants from the control group will be freely offered the possibility to get involve in a similar intervention protocol at the end of the study in order to benefit from the potential positive effect of exercise.
89290627|NCT03923712|Experimental|Supervised exercise programme|5 months of supervised physical exercise program. The individualized and progressive Health periodization model will be applied establishing an initial individualizing period, as well as identifying any need or adaptation to apply during the exercise program. The physical exercise program will be applied in a period of progressive increase whose initial objective will be to reach the volume and intensity established by the international recommendations of physical activity (http://www.health.gov/paguidelines/) for this population. Briefly, a volume of 150 min/week of moderate-vigorous physical activity (60% -85% reserve heart rate) spread over a maximum of 5 days and including force work 2-3 days/week. The training load will progressively increase with a wave and flexible periodization.
89290628|NCT03102034|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants received a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
89290629|NCT03102034|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
89290630|NCT03774576|Experimental|RO7017773|Single dose of RO7017773
89290631|NCT03774576|Experimental|RO7017773 and Itraconazole|Single dose of RO7017773 and multiple doses of itraconazole
89290632|NCT03923634|Experimental|Princess® RICH|"Eligible subjects will be injected with Princess® RICH (this is an open-label study).~Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids."
89290633|NCT05415436|No Intervention|Group A- propofol given at FDA approved administration speed|
89290634|NCT05415436|Experimental|Group B- propofol given over 120 seconds|
89290635|NCT01227408|Experimental|Metronomic Chemotherapy|Doxorubicin will be administered as an intravenous bolus, careful intravenous injection. PPX will be administerd as an intravenous 10 mins. infusion. Capecitabine and methotrexate will be taken orally twice a day. Cyclophosphamide will be taken orally once a day.
89290636|NCT01130220||Brain Tumor Patient|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
89290637|NCT01130220||Health Care Provider|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
89290638|NCT02928952|Experimental|Diabetes Self Management Education (DSME) + Mind-STRIDE|Will receive routine diabetes self-management education + the Mind-STRIDE intervention
89290639|NCT02928952|No Intervention|DSME alone|Usual care control
89290640|NCT03773796|Other|Treatment Group|Assessment of long-term efficacy and safety of nabilone 0.25 mg - 2 mg
89290641|NCT02927938|Other|Evaluable Cohort - Transplant Arm|"Other - Standard of Care Consolidation (HCT)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT); HMA-based induction subjects: Are candidates for (as determined by the investigator) and receive HCT"
89290642|NCT02927938|Other|Evaluable Cohort - Consolidation Chemo Arm|"Other - Standard of Care Consolidation (cytarabine-based chemo)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT)"
89290643|NCT02927938|No Intervention|Observational Cohort 1|Enrolled subjects who do not achieve a CR to induction therapy, regardless of diagnostic phenotype. Following completion of induction therapy and remission bone marrow aspirate, if a subject is determined to not have achieved a complete remission to induction therapy, he or she would be included in observational cohort 1.
89290644|NCT02927938|No Intervention|Observational Cohort 2|"Enrolled subjects who achieve a CR to induction therapy but meet one or more of the following criteria:~Lack the immunophenotype of interest,~Cytarabine based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit or refusal)] and do not receive consolidation therapy (cytarabine-based chemotherapy or HCT)~HMA-based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit, lack of donor, refusal)] and do not receive HCT~Final investigator determination of fit-ness can occur at any time until the start of consolidation therapy.~HMA-based induction subjects will not receive consolidation cytarabine-based chemotherapy as part of the evaluable cohort if they do not receive HCT."
89290645|NCT01224522|Experimental|Visionaire|the group who will be operated by the use of Visionaire patient matched cutting blocks
89290646|NCT01224522|Active Comparator|Standard Surgical technique|The group who will be operated by means fo standard surgical technique
89290647|NCT01227486||Obese patients for planned surgery and endotracheal intubation|
89290648|NCT01227642|Experimental|pre-implant transrectal ultrasound images and planning|Transrectal ultrasound session will be performed at a separate session prior to the implant.
89290649|NCT03863860|Experimental|Fluzoparib capsules, 50mg per capsule|Fluzoparib capsules, PO
89290650|NCT03863860|Placebo Comparator|Placebo capsules, 50mg per capsule|Placebo capsules, PO
89290651|NCT01224600||1|patient with newly diagnosed PAD (< 1 year)
89290652|NCT03794206|Experimental|Treatment Arm|Single-arm of subjects who receive treatment with Vesair Balloon
89290653|NCT03923478|Experimental|ABI-M201|"Cohort A: 1 capsule one time a day~Cohort B: 1- 5 capsules one time a day"
89290654|NCT03923478|Placebo Comparator|Placebo|"Cohort A: 1 capsule one time a day~Cohort B: 1-5 capsules one time a day"
89290655|NCT03690466|Experimental|Study device treatment|Transcutaneous non-invasive ultrasound will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
89290656|NCT03690466|Sham Comparator|Sham device treatment|Sham treatment will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
89290657|NCT03923166|Experimental|pyrotinib+ capecitabine|
89290658|NCT03923244|Experimental|cohorte 1|"Normal patient consultation schedule for cataract surgery with:~Preoperative appointment scheduled for the patient~Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
89290659|NCT05332210|Experimental|HBM9161 Drug Product (680mg)|"HBM9161 680mg: subcutaneous injection, 6 times per treatment cycle, once a week; the second cycle of treatment may start 4 weeks after the last dose of the previous treatment cycle; if the disease state is still stable 4 weeks after the last dose, the observation can be continued until the disease activity is aggravated (improvement of MG-ADL < 3 points compared with the previous treatment cycle), and the next treatment cycle can start.~The dose may be reduced to 340 per investigator's discretion. Return to the dose of 680 mg is not permitted after a dose reduction is made."
89290660|NCT01224756|Experimental|Tinoridine HCl 100 mg (2 capsules) TID|
89290661|NCT01224756|Placebo Comparator|Placebo TID|
89290662|NCT03392428|Experimental|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
89290663|NCT03392428|Active Comparator|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
89290664|NCT01228812||RA patients|Patients with Rheumatoid Arthritis
89290665|NCT01228812||Healthy subjects|Healthy subjects matched for age and sex
89290666|NCT05308732|Experimental|Copaiba arm|It will consist of the group of patients who will use copaiba mouthwash. It will be subdivided into 6 consecutive cohorts.
89290667|NCT03926832|Experimental|Patients with Sarcoidosis|Participants with Sarcoidosis. This arm will complete baseline questionnaires assessing daytime sleepiness (Epworth Sleepiness Scale - ESS) and fatigue (Fatigue Assessment Scale - FAS). All participants will perform home polygraphy and will be treated with CPAP for three months if moderate-to-severe OSA has been diagnosed and re-assessed with the same questionnaires along with a complete analysis of CPAP adherence by analyzing the compliance report of the device.
89290668|NCT01224834|Placebo Comparator|1|
89290669|NCT01224834|Experimental|2|
89290670|NCT03222856|Experimental|Pembrolizumab + eribulin|All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle. Treatment with MK3475 (pembrolizumab) and eribulin will continue based on physician criteria. No maximum duration of treatment is specified. Study follow-up will be performed 12 months after last study dose.
89290671|NCT01130298|Experimental|1|
89290672|NCT01227720|Experimental|A NSL2L|Experimental Nicotine Replacement Therapy (NRT)(L) 2 mg
89290673|NCT01227720|Active Comparator|B Lozenge|Marketed Nicotine Lozenge 2 mg
89290674|NCT01227720|Experimental|C NSL4M|Experimental NRT (M) 4 mg
89290675|NCT01227720|Active Comparator|D Lozenge|Marketed Nicotine Lozenge 4 mg
89290676|NCT01227720|Experimental|E NSL4L|Experimental NRT (L) 4 mg
89290677|NCT01227720|Experimental|F NSL4H|Experimental NRT (H) 4 mg
89290678|NCT03175978|Experimental|IGF/MTX|This arm will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, as assessed after 2 cycles, unacceptable toxicity, or patient refusal.
89290679|NCT03923088|Experimental|jacobson's progressive muscle relaxation technique|
89290680|NCT03923088|Experimental|audiovisual distraction technique|
89290681|NCT03923088|No Intervention|conventional|
89290682|NCT01224912|Experimental|Internet Deliviered CBT for Insomnia|Cognitive behavioral self-help method for insomnia via the Internet
89290683|NCT03923010|Experimental|Itraconazole|Participants with Tinea cruris or Tinea corporis infection that have been prescribed itraconazole 200 milligram (mg) daily by their treating physician will be enrolled in this study. Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
89290684|NCT01227798|Placebo Comparator|Placebo|100 mM sodium Chloride and 25 mM sodium phosphate at pH 7.0 +/- 0.2
89290685|NCT01227798|Active Comparator|Infergen|15mcg subcutaneous injection at fill volume of 0.5mL
89290686|NCT01329354|Experimental|Autologous effector lymphocytes|
89290687|NCT03926676|Experimental|Grandio blocks|Nano hybrid composite blocks
89290688|NCT03926676|Active Comparator|E max|ceramic blocks
89290689|NCT01130376|Experimental|Vaccine and cytokines|"Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection."
89290690|NCT01130376|Active Comparator|Vaccine alone|"Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.~Day 42: GTU-MultiHIV B clade vaccine as day 0.~Day 84: GTU-MultiHIV B clade vaccine as day 0."
89290691|NCT01130376|Active Comparator|Cytokines alone|"Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC."
89290692|NCT03740178|Experimental|Donepezil + MK-4334|Oral MK-4334 60/120 mg QD and open-label, oral donepezil 10 mg QD.
89290693|NCT03740178|Placebo Comparator|Donepezil + Placebo|Placebo to MK-4334 QD and open-label, oral donepezil 10 mg QD.
89290694|NCT01128348|Experimental|patient advocate|"Patient advocate works with patient before, during, and after a visit to asthma doctor.~Patient receives video of asthma education materials"
89290695|NCT01128348|Active Comparator|asthma education|Patient receives video of asthma education materials
89290696|NCT03926442|Experimental|Active1|Italian Herb in active breakfast meal
89290697|NCT03926442|Experimental|Active2|Cinnamon in active breakfast meal
89290698|NCT03926442|Experimental|Active3|Pumpkin Spice Mix in active breakfast meal
89290699|NCT03926442|Placebo Comparator|Placebo Comparator|Placebo Breakfast
89290700|NCT03867552|Experimental|Altered gas (86% CO2, 10% N2O, 4% O2)|Surgery with the use of the altered insufflation gas (86% CO2, 10% N2O, 4% O2)
89290701|NCT03867552|Active Comparator|Standard gas (100% CO2)|Surgery with the use of the standardized gas (100% CO2)
89290702|NCT02529306||two parallel group|group with inflammatory markers high levels and control group with inflammatory normal levels markers.
89290703|NCT01131468|Experimental|N-acetylcysteine|N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
89290704|NCT01131468|No Intervention|Controls|Vancomycine and/or amikacin alone
89290705|NCT03930108||Mortality outcome|
89290706|NCT01225224|Experimental|ASP015K Single Japanese Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
89290707|NCT01225224|Experimental|ASP015K Single Caucasian Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
89290708|NCT01225224|Placebo Comparator|Placebo Single Japanese Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
89290709|NCT01225224|Placebo Comparator|Placebo Single Caucasian Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
89290710|NCT01225224|Experimental|ASP015K Multiple Group|Participants will receive ASP015K in three stages, each stage corresponding to a different dosage level. ASP015K will be administered at 12-hour intervals after breakfast and dinner for seven days.
89290711|NCT01225224|Placebo Comparator|Placebo Multiple Group|Participants will receive placebo in three stages, each stage corresponding to a different dosage level. Placebo will be administered at 12-hour intervals after breakfast and dinner for seven days.
89290712|NCT01131546|Experimental|Levamlodipine besylate (2.5mg)|
89290713|NCT01131546|Experimental|Levamlodipine besylate (5mg)|
89290714|NCT01131546|Active Comparator|Amlodipine maleate (5mg)|
89290715|NCT01225302|Experimental|Arm A|
89290716|NCT01225302|Experimental|Arm B|
89290717|NCT03922152|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation and 2D-technique.
89290718|NCT03922230||Early esophageal cancer group|Pathological examination diagnosed as Early esophageal cancer.The ratio of male to female is 3:1, and the age is between 50 and 70 years old.
89290719|NCT03922230||Middle and advanced ES group|Pathological examination diagnosed as Middle and advanced esophageal cancer.
89290720|NCT03922230||Normal group|Confirmed as the normal by health checkups.
89290721|NCT01131624|Active Comparator|Ferric carboxymaltose|"Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.~subjects with bw <66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening"
89290722|NCT01131624|Active Comparator|Oral Iron|Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.
89290723|NCT03926286|Experimental|FMT for Sjogrens|FMT- active ingredient coming from participant's screening stool
89290724|NCT03926364||Patients|Referred pain
89290725|NCT01128582|Active Comparator|Rozerem|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
89290726|NCT01128582|Placebo Comparator|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology
89290727|NCT01130454|Active Comparator|SCIO Test Group|
89290728|NCT01130454|Placebo Comparator|SCIO Placebo Group|
89290729|NCT01228890|Experimental|CATCH-IT 2-R Arm|Primary care/Internet based depression prevention intervention (CATCH-IT 2-R) with a family component.
89290730|NCT01228890|Active Comparator|Attention Monitoring Psycho-education (AMPE) Arm|
89290731|NCT03929484|Experimental|Group A|Each patient will receive oxygen for 1 hour using a novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 1), followed by a 1-hour period of continued use of the standard nasal cannula alone (Period 2).
89290732|NCT03929484|Experimental|Group B|Each patient will receive oxygen for 1 hour using a standard nasal cannula alone (Period 1), followed by a 1-hour period of continued use of the novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 2).
89290733|NCT01229046|Active Comparator|ticarcillin-clavulanate|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
89290734|NCT03929406|Experimental|Brain Tissue Imprint|Evaluation and validation of the samples collected during the brain tissue imprint procedure using a CE marked Medical Device in patients presenting one of the following five disorders: Parkinson's disease (PD), essential tremor (ET), dystonia (DYS), Obsessive compulsive disorder (OCD) and Tourette Syndrome (TS).
89290735|NCT03922074|Experimental|Non-anesthesiologist administered propofol|Sedation directed by an endoscopist in which the intravenous drugs are propofol and fentanyl . Target level sedation: moderate - deep.
89290736|NCT03922074|Active Comparator|Monitored anesthesia care|Sedation directed by an anesthesiologist in which the used intravenous drugs and target level sedation are chosen by the anesthesiologist.
89290737|NCT01225458|Placebo Comparator|exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
89290738|NCT01225458|Experimental|geriatric follow-up|"250 patients will be included and randomized in the geriatric follow-up arm. They will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients.~About geriatric evaluation Patients randomized in this arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
89290739|NCT03921684|Experimental|Neoadjuvant Treatment|All subjects will receive chemoradiation followed by chemotherapy and nivolumab as neoadjuvant treatment
89290740|NCT03929094|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
89290741|NCT01228032|Experimental|Intervention|
89290742|NCT01228032|No Intervention|Control|referral only
89290743|NCT01131702|Experimental|Ranitidine Tablets, 300 mg|Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited
89290744|NCT01131702|Active Comparator|Zantac Tablets, 300 mg|
89290745|NCT03921762|Experimental|Artis Active IOL|Artis Active IOLs (Artis Active Mid, Artis Active Plus) will be implanted in patients eyes during cataract surgery
89290746|NCT03921762|Experimental|AT Lara IOL|AT Lara IOLs will be implanted in patients eyes during cataract surgery
89290747|NCT03921918|Other|Evaluation of Fluid Expression Technology|This study aims to provide important insights with respect to the safety, performance, and real-life usability of pumping technology
89290748|NCT03740022|Active Comparator|ACL plasty|The surgical procedure consists of a ligamentoplasty of the antero crusader ligament (ACL) with the patellar tendon according to a conventional arthroscopic procedure.
89290749|NCT03740022|Experimental|ACL + ALL plasty|The surgical procedure consists of a hamstring ligamentoplasty (DIDT) of the antero crusader ligament (ACL) and anterolateral ligament (ALL) according to a published arthroscopic procedure.
89290750|NCT01128660||RSD-citizens|Residents of Southern Denmark, who filed more than 9 prescriptions during 2009.
89290751|NCT03925896|Experimental|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
89290752|NCT03929328|No Intervention|Spontaneous breathing trial with T-piece|Patients were randomized to undergo a spontaneous breathing trial with T-piece that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
89290753|NCT03929328|Experimental|Spontaneous breathing trial with high flow oxygen therapy|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
89290754|NCT01228110|Active Comparator|Corticosteroid group|This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days
89290755|NCT01228110|Placebo Comparator|Placebo group|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).
89290756|NCT02528994|Experimental|Serine 6g daily|Randomized participants will take 6g daily of dietary serine supplement
89290757|NCT02528994|Experimental|Serine 12g daily|Randomized participants will take 12g daily of dietary serine supplement
89290758|NCT02528994|Experimental|Serine 24g daily|Randomized participants will take 24g daily of dietary serine supplement
89290759|NCT02528994|Experimental|Serine 48g daily|Randomized participants will take 48g daily of dietary serine supplement
89290760|NCT01225536|Experimental|ARQ 736|
89290761|NCT03925818|Experimental|B.I.D. TMPPI + Lactobacillus-10|pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days
89290762|NCT03925818|Active Comparator|B.I.D. Bismuth|pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days
89290763|NCT03925740|Experimental|MI Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Remineralization protocol, group one will be treated with MI varnish according to the manufacture instructions in first visit and each follow up visits.
89290764|NCT03925740|Experimental|PreviDent Varnish Group|The teeth will be cleaned, plaque will be removed, placement of wedge/separator and teeth will be dried with the aids of light, mouth mirror and dental probe following ICDAS score. Group two will receive PreviDent varnish according to the manufacture instructions in the first visit and each follow up visits.
89290765|NCT03925740|Active Comparator|1.23% APF Control Group|Regular application of APF for 4 minutes with high volume suction to the whole mouth.
89290766|NCT01130688|Experimental|single arm of experimental drug combination|
89290767|NCT03928938|Experimental|Electronic follow-up|Follow-up of cancer patients treated with immune checkpoint inhibitor therapy using electronic patient reported outcomes-tool
89290768|NCT03925662|Active Comparator|Folfox with avastin|Folfox with avastin only
89290769|NCT03925662|Experimental|Mebendazole|Folfox with avastin with mebendazole
89290770|NCT03921450|Experimental|Inhibitory repetitive transcranial magnetic stimulation (rTMS)|1 Hz stimulation of 17 mins over the supplementary motor area (SMA), 1000 pulses at 110% resting motor threshold intensity total of 15 sessions in 3 weeks
89290771|NCT03921450|Active Comparator|Facilitatory intermittent theta burst stimulation (iTBS)|"Intermittent theta burst stimulation of 50 Hz over the supplementary motor area (SMA) with 600 pulses in 2 sec trains every 10 seconds for 190 seconds total. Two iTBS stimulations will be administered with 15 mins pause in between.~total of 15 sessions in 3 weeks"
89290772|NCT03921450|Placebo Comparator|Placebo|1 Hz stimulation of 17 mins over the supplementary motor area (SMA) without any magnetic emission using a placebo-coil that looks identical and makes identical sounds as the real TMS coil total of 15 sessions in 3 weeks
89290773|NCT03921450|No Intervention|Waiting group|This group will receive no intervention for 3 weeks. Afterwards they will receive the inhibitory rTMS protocol as in the first arm
89290774|NCT01225614|Experimental|bipap ventilation|
89290775|NCT01225614|Active Comparator|Standard care|Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
89290776|NCT03921606|Experimental|Experimental group|The experimental group will receive a brief MI via WhatsApp/WeChat on a smartphone during the study period. The brief MI messages will be delivered more intensively as preferred by the subject (usually not less than once every 2 to 3 days and no more than 2 times per day) for the first 6 months. The frequency of delivering the messages via WhatsApp/WeChat will be interactive, depending on the subjects' actions and responses, and may take several sessions of chats within several days or weeks. However, the total time spent by the interventionist will not be more than that for a traditional MI with several long sessions. After 6 months, minimal messages will be provided to the subjects by merely following their progress of behavioural changes and responding to their questions to maintain contact until the 1-year follow-up. The total time spent will be recorded and analysed.
89290777|NCT03921606|Other|Control group|The control group will receive individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese) in SOPCs. A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs. The subjects in this group will receive the same schedule of follow-ups as in the intervention group, but they will not receive any follow-up booster intervention.
89290778|NCT01229202|Active Comparator|standard of care|standard of care for trabeculectomy surgery
89290779|NCT01229202|Active Comparator|bevacizumab arm|
89290780|NCT03928860|Experimental|OMT Session and Doppler Ultrasonography|"OMT Session Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.~Doppler Ultrasonography Femoral artery diameter and flow evaluated by radiologist.~In the evaluation, the wall contour characteristics of the vessel to be examined were evaluated and the diameter was measured. Color doppler examination was performed to determine whether the vessel contained color filling, patency, flow direction and turbulence.~Peak systolic and end diastolic flow rates and flow pattern and flow rate were measured by spectral examination"
89290781|NCT03921372|Experimental|Normal Tension Glaucoma (NTG)|Patients with diagnosed NTG
89290782|NCT03921372|Experimental|Healthy Control Subjects|Subjects with no sign of glaucoma, Age and sex matched
89290783|NCT01329510|Experimental|methylphenidate|
89290784|NCT01229280|Experimental|Darisec(R) 7.5 mg|
89290785|NCT01229280|Active Comparator|Enablex(R) 7.5 mg|
89290786|NCT03929172|Experimental|AAVLP-HPV Vaccine Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
89290787|NCT03929172|Placebo Comparator|Placebo Arm|Subjects will receive a total of 3 vaccinations: a prime on Day 1, and boosts on Day 57 (± 2 days) and Day 180 (± 1 week).
89290788|NCT01229358|Experimental|Silver Eluting Dressing|Acticoat Absorbant™ applied as post-operative dressing
89290789|NCT01229358|Active Comparator|Standard Guaze|Standard dry gauze applied as post-operative dressing
89290790|NCT03921138||Benign laparoscopic hysterectomy|Patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy
89290791|NCT01130766|Experimental|stereotactic radiosurgery (SRS)|
89290792|NCT01130766|No Intervention|observation|
89290793|NCT03920124|Experimental|High intensity interval exercise|Completion of four separate step and walk-based high intensity interval exercise sessions, followed by completion of six week unsupervised (at home) high intensity interval exercise intervention
89290794|NCT03920046||Effects of passive smoking on children|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents smoking.
89290795|NCT03920904||Bupivacaine dosage in PIFB block|The pharmacokinetics of bupivacaine 0.25% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following a PIFB block will be determined by the collection of blood samples at predetermined time points.
89290796|NCT03919890|Experimental|ONO-7684 Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
89290797|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A1|Single ascending doses of ONO-7684 or placebo orally under fasted conditions
89290798|NCT03919890|Experimental|ONO-7684 Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
89290799|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part A2|Single doses of ONO-7684 or placebo orally under fed conditions
89290800|NCT03919890|Experimental|ONO-7684 Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
89290801|NCT03919890|Placebo Comparator|ONO-7684 Placebo Part B1|Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
89290802|NCT01132092||Normal hearing (experimental 1)|76 Normal hearing subjects, male and female, adults, , evaluated by new device
89290803|NCT01132092||Normal hearing (experimental 2)|15 Normal hearing subjects, male and female, adults, , evaluated by new device
89290804|NCT01132092||Hearing loss (experimental 3)|15 hearing loss subjects, male and female, adults, evaluated by new device
89290805|NCT01132092||Gold standard 1|15 Normal hearing subjects, male and female, adults, evaluated by gold standard device
89290806|NCT01132092||Gold Standard 2|15 hearing loss subjects, male and female, adults, evaluated by gold standard device
89290807|NCT03920748||Difficult laryngoscopy (Group D)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 3-4 are classified as difficult laryngoscopy ( Group D).
89290808|NCT03920748||Easy laryngoscopy (Group E)|Glottic structures appearing during laryngoscopy are graded according to Cormack-Lehane (CL) Classification. According to this classification, patients are divided into two groups, patients with grade 1-2 are classified as easy laryngoscopy ( Group E).
89290809|NCT01131780|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
89290810|NCT01131780|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
89290811|NCT01131858|Placebo Comparator|Placebo|Placebo
89290812|NCT01131858|Active Comparator|Vitamin D|Vigantol (cholecalciferol) 4000 IE/day
89290813|NCT01130922|Experimental|Moxifloxacin IV|
89290814|NCT01130922|Active Comparator|Moxifloxacin oral|
89290815|NCT01131000|Experimental|Ibuprofen|
89290816|NCT01131000|Placebo Comparator|Saline|Normal Saline
89290817|NCT01132170|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
89290818|NCT01132170|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
89290819|NCT03925428|Experimental|Treatment (entinostat, molibresib)|Patients receive entinostat PO on days 1, 8, 15, and 22 and molibresib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89290820|NCT01228188|Experimental|Idiopathic Full Thickness Macular Hole|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um.
89290821|NCT01229514||Exposure to anesthesia|
89290822|NCT01229514||Normal controls|
89290823|NCT03920592|Experimental|Video watching|"All participants will watch 4 videos of potential everyday school situations, adapted for boys and girls.~Videos contain different levels of bullying (presence/absence) and virtual reality (presence/absence).~Every pupil will watch the 4 types of video content randomly."
89290824|NCT03920514|Active Comparator|GROUP 1|IUI 24 hours after hCGadminstration
89290825|NCT03920514|Active Comparator|GROUP 2|IUI 36 hours after hCG adminstration
89290826|NCT03920514|Active Comparator|GROUP 3|IUI 48 hours after hCG adminstration
89290827|NCT03920514|Active Comparator|GROUP 4|IUI at time of hCG adminstration
89290828|NCT03919812|Experimental|Vitamin D supplementation according to baseline Vitamin D|The intervention provided according to the participants' state of vitamin D sufficiency. vitamin D sufficient participants received 800 IU cholecalciferol (syrup containing 400 IU cholecalciferol per measuring spoon, Gracia Pharmindo, Indonesia) daily for 8 weeks, while those who had insufficient or deficient vitamin D level consumed 2000 IU daily. Compliance was systematically monitored using drug monitoring diary evaluated by researchers. Blood samples for the study objectives were taken at enrollment and after eight weeks of cholecalciferol supplementation during routinely scheduled visits to the clinic.
89290829|NCT03919656|Experimental|Dapagliflozin|Dapagliflozin 10 mg daily (orally)
89290830|NCT03919656|Placebo Comparator|Placebo|Matching placebo for dapagliflozin daily (orally). Does not contain active ingredient
89290831|NCT01132248|Experimental|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
89290832|NCT01132248|Placebo Comparator|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
89290833|NCT01229592|Experimental|Ethanol|Every three day lock using Ethanol in all the lumen of the Catheter
89290834|NCT01229592|Active Comparator|Heparine|Every three day lock using Heparine in all the lumen of the Catheter
89290835|NCT01131936|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
89290836|NCT01131936|Active Comparator|Norvasc Tablets, 10 mg|
89290837|NCT05402670||Dermatomyositis group|patient with dermatomyositis
89290838|NCT05402670||control group|health check-up population
89290839|NCT01231776|No Intervention|control group|
89290840|NCT01231776|Active Comparator|acupuncture preoperative|acupuncture before operation for one week
89290841|NCT01231776|Active Comparator|acupuncture in hospital|acupuncture all the time in hospital
89290842|NCT01132404|Experimental|TAK-448 Dose 1|
89290843|NCT01132404|Experimental|TAK-448 Dose 2|
89290844|NCT01132404|Active Comparator|Leuprorelin|
89290845|NCT01134354||TEFTOM|Patient outcome measure
89290846|NCT01229670|Experimental|aerobic intermittent group|aerobic intermittent group
89290847|NCT01229670|Experimental|aerobic continuous group|aerobic continuous group
89290848|NCT01229670|No Intervention|control|home exercise group
89290849|NCT03919500|Experimental|Erythropoietin|Infants in the EPO group are given EPO 500IU/kg dissolved in 2 ml saline intravenously every other day for 2 weeks starting within 72 hours after birth.
89290850|NCT03919500|Placebo Comparator|Normal saline|Infants in the control group are given normal saline intravenously with the same volume as EPO every other day for 2 weeks.
89290851|NCT01229904|Experimental|Arm 1|patients with PTSD are randomized to either entering immediately a 6 week treatment with music therapy, or being in the delay group that enters the treatment arm after 6 weeks. This is a delayed entry RCT.
89290852|NCT01229748|Experimental|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth.(Liddle, 2002) considered in the U.S. and abroad as an empirically supported Best Practice treatment for teen substance abuse and delinquency (USDHHS 2002; Drug Strategies 2003; NIDA 1999; Rigter et al 2004).
89290853|NCT01229748|Experimental|Family Motivational Interviewing|Motivational Interviewing (MI; Miller 1983; Miller & Rollnick 1991), is a client-centered treatment designed to strengthen clients' commitment and empower them to change their substance use behavior (Miller & Rollnick 2002).
89290854|NCT01229748|Other|Standard Care|The standard care condition will represent typical services for teens with alcohol problems in the community: assessment and referral for treatment
89290855|NCT01231854|Active Comparator|Ciclosporingroup|
89290856|NCT01231854|Active Comparator|Alitretinoingroup|
89290857|NCT03920436|Experimental|Infrared water group|This group takes drinking water using a tumbler that emits far infrared rays at room temperature for 8 weeks.
89290858|NCT03920436|Sham Comparator|sham group|This group takes drinking water using a tumbler at room temperature for 8 weeks.
89290859|NCT01132638|Active Comparator|Magnesium Pantoprazole|
89290860|NCT01132638|Active Comparator|Magnesium Esomeprazole|
89290861|NCT01233180|Active Comparator|Gua Sha|Single Gua Sha treatment of the neck and shoulder region.
89290862|NCT01233180|Active Comparator|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region.
89290863|NCT05483946|Experimental|CPM#1|Compartment compressibility ratio measurement using the CPM#1 device
89290864|NCT05402124|Other|ASA 81mg|Acetylsalicylic acid delayed release tablets (81mg), single tablet taken once per day for 90 days.
89290865|NCT01134432|Experimental|Prednisolone + Rituximab|
89290866|NCT01134432|Active Comparator|Prednisolone|
89290867|NCT01232010|Experimental|Healthy Volunteers|
89290868|NCT01232010|Experimental|Patients with severe renal impairment|
89290869|NCT03919110||Genetically Undiagnosed SAID Patients (guSAID)|"adults and children, with different SAID of unknown pathogenesis, for which no specific mutations is identified and whose pathogenic mechanism remains unknown:~Still Disease,~Recurrent pericarditis,~Neutrophilic dermatosis,~Schnitzler,~Vasculitis (Kawasaki disease, Behçet disease, Takayasu arteritis),~Inflammation of unknown origin,~Chronic/recurrent osteitis."
89290870|NCT03919110||Parents of guSAID patients|Enrollment of parents of guSAID patients is justified by the TRIO genomic analysis (patient plus two parents) of the guSAID patients without known mutations. Indeed, the TRIO based whole-exome sequencing helps to facilitate the interpretation of genotypes and improve genetic explorations
89290871|NCT03919110||Monogenic SAID patients (mSAID)|This group of patients will serve as positive control to classify other diseases and encompass the following diseases: FMF, TRAPS, HIDS, and CAPS. Investigators aim at recruiting 50 patients per disease entity.
89290872|NCT03919110||Patient Free of inflammatory disorders control subjects|In order to set a reference / baseline for the identification of biomarkers the study will need non-inflammatory samples.
89290873|NCT05402046|Experimental|ProRodinki application test|Patients scheduled for excisional biopsy of skin lesion(s) will be invited to participate in this study. Photo-documentation of the skin neoplasm(s) in the ProRodinki application will be performed, and the generated report will be sent for evaluation by artificial intelligence. Following this procedure, an excisional biopsy of the lesion(s) will be scheduled. From the moment of inclusion in the study until the excisional biopsy, an interval of no more than 2-4 weeks is allowed. After excisional biopsy of the skin neoplasm(s), a routine intravital pathological examination with hematoxylin and eosin staining will be performed, if necessary, immunohistochemical and molecular genetic tests will be performed. The selected biosamples (paraffin blocks) will then be analyzed centrally by a morphologist.
89290874|NCT05401812|No Intervention|Control|Standard care without glucocorticoid therapy.
89290875|NCT05401812|Experimental|Low dose and long treatment duration|Methylprednisolone equivalent dose 0.5 mg/kg/day for 5 days, followed by 0.25 mg/kg/day for 5 days.
89290876|NCT05401812|Experimental|Low dose and short treatment duration|Methylprednisolone equivalent dose 0.5 mg/kg/day for 4 days,, followed by 0.25 mg/kg/day for 3 days.
89290877|NCT05401812|Experimental|Moderate dose and long treatment duration|Methylprednisolone equivalent dose 1 mg/kg/day for 5 days, followed by 0.5 mg/kg/day for 5 days.
89290878|NCT05401812|Experimental|Moderate dose and short treatment duration|Methylprednisolone equivalent dose 1 mg/kg/day for 4 days, followed by 0.5 mg/kg/day for 3 days.
89290879|NCT01134588|Active Comparator|Reference group|This group will fill out paper questionnaires.
89290880|NCT01134588|Experimental|Experimental group|This group will fill out touch-screen questionnaires.
88821037|NCT05249465|Experimental|Condition 4|Core + Track Diet
89290881|NCT05401734||Cohort 1|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
89290882|NCT05401734||Cohort 2|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
89290883|NCT05401734||Cohort 3|Approximately 10 persons with a SCI will be included in the study. All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre. The recruitment will be performed by word of mouth. Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study. Participation will be strictly voluntary
89290884|NCT01137552|Experimental|A|Dose Escalation
89290885|NCT01137552|Experimental|B|Dose Expansion
89290886|NCT01137630|Experimental|K40a|K40a is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
89290887|NCT01137630|Experimental|K40b|K40b is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
89290888|NCT01137630|Placebo Comparator|Placebo|Placebo is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
89290889|NCT01137708|Experimental|Treatment Sequence 1|
89290890|NCT01137708|Experimental|Treatment Sequence 2|
89290891|NCT03765138|Experimental|PE/Pramipexole|Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.
89290892|NCT01233414|Experimental|Parent Training|
89290893|NCT01233414|Active Comparator|Psychoeducation|
89290894|NCT01137864|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
89290895|NCT01137864|No Intervention|Control|Patients not receiving infectious disease specialist advice
89290896|NCT01134744||Chest trauma|chest x-ray applied for patients with chest trauma and the manifestations compared with clinical examination
89290897|NCT03739788|Experimental|BMS-986165|Oral and intravenous administration
89290898|NCT01134822||Idiopathic pulmonary fibrosis (IPF)|
89290899|NCT03918954|Active Comparator|Physical sensory room|In the inpatient ward there is a specifically designed room for calming down which a patient can request access to. In the room there is calming music, soft mats, nature themed wallpaper and calming visual lighting.
89290900|NCT03918954|Experimental|Virtual sensory room|The patients will have access to wireless virtual reality glasses during a session. The glasses will have a specially made protection that will be disinfected between each user, all users will also have the opportunity to choose a disposable cover for the glasses. The VR glasses are adjustable and adaptable to all types of head sizes and can be used with regular glasses. The application accessable in the VR glasses is called Calm Place, a virtual natural environment with day and night cycles, dynamic weather and associated soundscapes.
89290901|NCT01134978|Experimental|Practice Schedules|Subjects are randomly assigned to either a blocked or random practice schedule when learning three 3-D computer mazes. A blocked practice schedule is created when the tasks to be learned are presented in a predictable order, while a random practice schedule has tasks presented in a nonsequential, unpredictable order. Neural activity and behavioral measures will differ for the two practice schedules. For memory and transfer, it is predicted that random practice will be better than blocked practice.
89290902|NCT01230138|Experimental|FP187 - TID|FP187 250mg TID (total daily dose of 750mg)
89290903|NCT01230138|Experimental|FP187- BID|FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
89290904|NCT01230138|Experimental|FP187-LD-BID|FP187 250mg BID (total daily dose of 500mg)
89290905|NCT01230138|Placebo Comparator|Placebo|Placebo treatment
89290906|NCT01230138|Experimental|Open, flexible dosing treatment arm|Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
89290907|NCT05401500|Experimental|familial aortopathy|
89290908|NCT01137942||H. pylori eradication failure|Those who eradicated Helicobacter pylori with appropriate antibiotic therapy and those who did not.
89290909|NCT01135056|Active Comparator|Sorafenib, Multikinase Inhibitor, Tablet|"Sorafenib tosylate:~Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation.~Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma."
89290910|NCT01135056|Active Comparator|SIR-Spheres, Microspheres, Device|"SIR-Spheres:~SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value.~SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver."
89290911|NCT01132794|Placebo Comparator|Placebo|Intranasal nasal saline
89290912|NCT01132794|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine
89290913|NCT01135212|Active Comparator|Fimasartan 60mg|Take one tablet of Fimasartan 60mg once a day in the morning
88821422|NCT04191174||Adults undergoing lung resection for lung cancer|
89290914|NCT01135212|Active Comparator|Fimasartan 120mg|Take one tablet of Fimasartan 120mg once a day in the morning
89290915|NCT01135212|Active Comparator|Candesartan 8mg|Take one tablet of Candesartan 8mg once a day in the morning
89290916|NCT01138176|No Intervention|Standard care|
89290917|NCT01138176|Experimental|Cooling|Reduction of rectal temperature to 33.5 C for 72 hours
89290918|NCT01233570|Experimental|Topical tacrolimus|Once daily topical application
89290919|NCT01132950|Active Comparator|Didactic Educational Counseling|
89290920|NCT01132950|Experimental|Motivation Interviewing|Participant will receive two sessions of personalized motivational interviewing.
89290921|NCT01135290|Other|B|
89290922|NCT01135290|Active Comparator|A|
89290923|NCT01230216|Active Comparator|intensive blood pressure control|systolic blood pressure less than 120 mmHg
89290924|NCT01230216|Active Comparator|standard blood pressure control|systolic blood pressure less than 140 mmHg
89290925|NCT01138254|No Intervention|control group|ESRD patients will not receive FIR therapy in this study.
89290926|NCT01138254|Experimental|Far infrared therapy|Patients will receive far infrared therapy 40 minutes three times weekly (TIW) for 6 months.
89290927|NCT03918174|Experimental|Dart Splint orthosis|The Dart-Splint orthosis allows oblique wrist motion along the Dart Throwing Motion (DTM) plane, thus inhibiting movement of the healing structures following surgery around the distal radius. This is a hinged orthosis that permits selective midcarpal mobilization along the plane of the DTM is a novel orthotic device that was developed in order to facilitate protected midcarpal motion.
89290928|NCT03918174|Experimental|The conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions.
89290929|NCT01232088||Data collection group: ICU physicians|Online survey for ICU physicians (members of the European Society of Intensive Care Medicine (ESICM)).
89290930|NCT01230294||control|participants without structural heart disease
89290931|NCT01230294||CHF|patients with chronic heart failure of the left ventricle affecting the right heart
89290932|NCT01230294||PAH|patients with pulmonary arterial hypertension without left ventricular dysfunction
89290933|NCT05401422|Active Comparator|Pulsed dye laser|Laser
89290934|NCT05401422|Active Comparator|Doxycycline|Drug
89290935|NCT05401422|Active Comparator|Brimonidine gel 0.33%|Topical drug
89290936|NCT01135446|Experimental|dapagliflozin (0.001 mg)|Cohort 1
89290937|NCT01135446|Experimental|dapagliflozin (0.01 mg)|Cohort 2
89290938|NCT01135446|Experimental|dapagliflozin (0.1 mg)|Cohort 3
89290939|NCT01135446|Experimental|dapagliflozin (0.3 mg)|Cohort 4
89290940|NCT01135446|Experimental|dapagliflozin (1 mg)|Cohort 5
89290941|NCT01135446|Experimental|dapagliflozin (2.5 mg)|Cohort 6
89290942|NCT03739632|Experimental|10 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10mg/day Study,5mg tablet is to be given orally, twice daily, for 6 weeks
89290943|NCT03739632|Experimental|20 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 20mg/day Study,10mg tablet is to be given orally, twice daily, for 6 weeks
89290944|NCT03739632|Experimental|40 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 40mg/day Study,20mg tablet is to be given orally, twice daily, for 6 weeks
89290945|NCT03739632|Placebo Comparator|comparator|Placebo tablets is to be given orally, twice daily, for 6 weeks
88813138|NCT03837080|No Intervention|Control|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care. Patients will receive all treatments (e.g. physical therapy) except the nutrition education.
89290946|NCT01230450|Experimental|Single-incision Mini-slings (SIMS- Ajust)|AjustTM has polypropylene fixing anchors (one is fixed and the other adjustable) which are anchored onto the obturator membrane. The pulley like system enables adjustment of the tension once the arms have been anchored. Once in place, the anchors rest at right angles to insertion which is claimed to reduce the chances of anchor dislodgment
89290947|NCT01230450|Other|standared med urethral sling (SMUS)|standard med urethral sling (SMUS)TVT-O, was done as originally described by Deleval et al.
89290948|NCT01138410|Experimental|SCIB1|
89290949|NCT01135602|Experimental|Topiramate|1 group
89290950|NCT01133028|Experimental|Combined|This represents a combination of the tolerance training and behavioral management interventions together.
89290951|NCT01133028|Active Comparator|Behavioral management|This represents the behavioral contingency management intervention only.
89290952|NCT05401344||dry nose patients|
89290953|NCT05401344||normal controls|
89290954|NCT05401188|Active Comparator|hospitalization group|Patients in the hospitalization group, once the surgical intervention was finished, were transferred to the postoperative recovery unit and later they were discharged to the usual hospital ward. Patients received adequate intravenous fluid resuscitation based on their individual hemodynamic parameter and fluid balance, and they received analgesia according to personal requirement. In the hospital ward, the usual patient management protocols were followed until a complete recovery and consequently discharged according to the usual criteria.
89290955|NCT05401188|Experimental|outpatient group|Patients in the outpatient group , once operated, were transferred to the surgery unit without admission and were later discharged home if they met the ALDRETE criteria in less than 23 hours after the intervention (following the surgery criteria without admission stages). If the patient was operated during the night shift, following the advice of major outpatient surgery where overnight stays are allowed, the patient was admitted to the post-anesthetic recovery unit and discharged the next day, always in less than 23 hours. In case of being discharged after 23 hours or not meeting ALDRETE criteria, it was considered a failure of the outpatient treatment.
89290956|NCT05308212|Experimental|FLU-M Tetra w/p|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (with preservative) intramuscularly
89290957|NCT05308212|Experimental|FLU-M Tetra w/o/p|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (without preservative) intramuscularly.
89290958|NCT05308212|Active Comparator|Ultrix|211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Ultrix vaccine.
89290959|NCT01133106|Experimental|In-person behavioral intervention|behavioral counseling plus antidepressant treatment prescribed by participant's own provider; consisted of orientation session plus 6 counseling sessions in person with a psychosocial nurse practitioner
89290960|NCT01133106|Experimental|Telephone behavioral intervention|This arm is identical to the in-person Arm except that the intervention is delivered by telephone instead of in-person.
89290961|NCT01133106|Active Comparator|Standard care|participants have orientation to the study with the same written materials given those in the experimental arms. Keep a medication log and keep appointments with their own post-stroke provider
89290962|NCT01138488|Experimental|NN5401|
89290963|NCT01232166|Experimental|Endobronchial Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
89290964|NCT01232166|Active Comparator|Endobronchial Intubation, Observation|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
89290965|NCT01232166|Active Comparator|Endobronchial intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
89290966|NCT01232166|Active Comparator|Endobronchial intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
89290967|NCT01232166|Experimental|Endotracheal Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the trachea, 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
89290968|NCT01232166|Active Comparator|Endotracheal Intubation, observation|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5-3cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
89290969|NCT01232166|Active Comparator|Endotracheal intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5 - 4 cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
89290970|NCT01232166|Active Comparator|Endotracheal intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
89290971|NCT01135680|Placebo Comparator|Arm 1|"Cohort A: 9 mL HPN-100 or placebo~Cohort B: 12 mL HPN-100 placebo"
89290972|NCT01135680|Placebo Comparator|Arm 2|"This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.~Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days~Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3~Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days~Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days"
89290973|NCT01135758|Experimental|ketamine 0.5 mg/kg i.v.|Single administration of ketamine 0.5 mg/kg i.v.
89290974|NCT01138566||ESBL- and/or AmpC-(+) or (-)|
89290975|NCT05401032|Active Comparator|Control arm|tamsulosin 0.4mg (once a day) for 6 months.
89290976|NCT05401032|Experimental|Experimental arm|5-hidroxitriptophan 100 mg (3 times a day) for 6 months.
89290977|NCT01135836|Experimental|pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
89290978|NCT01135836|Experimental|intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity
89290979|NCT01135836|Placebo Comparator|Control group|CO2 was removed by passive exsufflation through the port site.
89290980|NCT03768726|Experimental|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
89290981|NCT01585740|Active Comparator|Normal Saline|250 patients in this arm assigned to receive normal saline as the study fluid
89290982|NCT01585740|Active Comparator|Ringer's Lactate|250 patients in this arm assigned to receive Ringer's Lactate as the study fluid
88821038|NCT05249465|Experimental|Condition 5|Core + Track Weight + Track Steps
89290983|NCT01138878||Patient pre-study group|A set of all 16-65 yr olds (not know already to be HIV-positive) accessing the healthcare setting prior to the introduction of the HIV testing pilot programme
89290984|NCT01138878||Staff pre-study group|A set of staff working within the healthcare setting prior to the introduction of the HIV screening programme
89290985|NCT01138878||Patient intra-study group|A set of patients, aged 16-65 and known not to be HIV-positive, who access the healthcare setting during the HIV testing pilot programme
89290986|NCT01138878||Post-study staff group|A set of staff who worked within the healthcare setting for the duration of the HIV testing pilot programme
89290987|NCT01138956|Experimental|Group 1|Pentavalent antimonial, 20mg/kg/day, 28 days, IV, plus N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po.
89290988|NCT01138956|Active Comparator|Group 2|Pentavalent antimonial, 20mg/kg/day, 28 days
89290989|NCT01139034|Experimental|shoulder FES treatment|
89290990|NCT01136070||Burn Trauma Patients|
89290991|NCT03917706||Congenital Heart Disease|Adults suffering from congenital heart disease, followed within the CHU Brugmann hospital, operated during childhood.
89290992|NCT05287542|Experimental|Hypnotic suggestion|During the first phase of the study, two groups will receive identical hypnotic inductions followed by targeted suggestion for one group and non-targeted suggestion for the other. The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
89290993|NCT05287542|Active Comparator|Mindfulness|The targeted procedure consists of suggestions about enhancing WM functions through the instantiation of preinjury WM ability in the present using age regression and visualizations of brain plasticity.
89290994|NCT05287542|No Intervention|No treatment|The passive control group receives no intervention
89290995|NCT01232244||Healthy young males|
89290996|NCT03917862|No Intervention|Control|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques.
89290997|NCT03917862|Active Comparator|TDM-621|This group include patients which will be undergone to conventional ascending aortic surgery, according to stablished techniques and will receive the TDM-621 for complementary hemostasis.
89290998|NCT05400876|Experimental|TQB2618 injction+penpulimab injection|TQB2618 injection with penpulimab injection, 21 days as a treatment cycle
89290999|NCT01232322||Pulmicort Respules|Those with an exposure
89291000|NCT05192538|Experimental|Endoscopic endoloop pre-test treatment|Endoscopic endoloop pre-test treatment is a less invasive reversible endoscopic treatment to predict whether the gastroesophageal reflux can be alleviated in order to ultimately decide whether to undergo irreversible surgery or endoscopic treatment.
89291001|NCT03917784|Experimental|Curcumin and bioperine|This group will receive curcumin 500 mg and bioperine 5 mg oral dosing every 12 hours for 3 months
89291002|NCT03917784|Placebo Comparator|Placebo|This group will receive placebo (starch) 500 mg oral dosing every 12 hours for 3 months
89291003|NCT01133496|Experimental|Alendronate Sodium|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's
89291004|NCT01133496|Active Comparator|Fosamax|Fosamax Tablets 70 mg of Merck & Company. Inc., USA.
89291005|NCT01233804|No Intervention|Opting in|Currently, pregnant women have to sign a consent stating that they want the influenza vaccine (at the clinics where the study is being conducted). Therefore, this group is the same as usual care. However, women will then be asked if they would like to take part in parts 2 and 3 of the study.
89291006|NCT01233804|Experimental|Opting Out|Women will sign a consent form only if they do not want to receive the flu vaccine.
89291007|NCT01233882|Experimental|Healthy Volunteers|
89291008|NCT01233882|Experimental|Mild Renal Impairment|
89291009|NCT01233882|Experimental|Moderate Renal Impairment|
89291010|NCT01233882|Experimental|Severe Renal Impairment|
89291011|NCT01139346|Experimental|oral darinaparsin|open label, single arm, dose escalation
89291012|NCT01232400|Experimental|esmolol|Esmolol will be used preferentially to control hypertension.
89291013|NCT01232400|No Intervention|Standard care|Standard care for SAH includes other hypertensives such as nicardipine.
89291014|NCT01136148|Experimental|A Medical and Mental Health Unit|A specialist unit for cognitively impaired older patients admitted as a medical emergency to the acute hospital.
89291015|NCT01136148|Active Comparator|Standard care wards|The standard care provided by the acute hospital for cognitively impaired older patients admitted as a medical emergency.
89291016|NCT01232478|Experimental|Comprehensive Adherence Program (CAP)|The comprehensive adherence program emphasizes the patient's active, collaborative role in identifying adherence barriers and solving them to improve adherence to prescribed treatment regimens. Problem-solving sessions will be used to address barriers to adherence that are identified by the adolescent. The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re-instruction/re-training of skills needed to perform daily treatments.
89291017|NCT01232478|Experimental|Standard Care (SC)|Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
89291018|NCT01230606||overnight|Subjects that stay overnight at the hospital.
89291019|NCT01230606||Next Day Discharge|Subjects that are discharged on the same day of the procedure.
89291020|NCT01230684|Other|Endoleak imaging|In the single arm all participants are recieving both imaging techniques; CEUS and CTA
89291021|NCT01136304||Adults with Type 1 Gaucher disease (GD1)|Adults with GD1 who are cared for at one of the participating research sites whether treatment naive or treated in past or currently with imiglucerase enzyme replacement treatment.
89291022|NCT01136460||Primary congenital glaucoma|Primary congenital glaucoma patients and their immediate relatives
89291023|NCT02528760|Experimental|Metaclopromide group|
89291024|NCT02528760|Experimental|Erythromycin group|
89291025|NCT02528760|Placebo Comparator|Placebo group|
89291026|NCT05594472|Experimental|Ozonated olive oil|ozonated oil will be applied to on one lesion followed by gauze for 5 consecutive days.
89291027|NCT05594472|Active Comparator|Topical garamycin cream|conventional topical treatment will be applied to a comparable lesion followed by gauze for 5 consecutive days.
89291028|NCT01139424|Experimental|open label treatment arm|endoscopic suturing
89291029|NCT05205018|Experimental|Motivational Interviewing Arm|This Arm will receive a remote intervention (via videacalls) based on motivational interviewing to improve self-care. The intervention will be delivered seven time over 12 months.
89291030|NCT05205018|No Intervention|Standard care Arm|This Arm will receive the standard of care.
89291031|NCT01139502|Active Comparator|Work rehab with cognitive therapy|Work rehabilitation based on the cognitive therapeutical model
89291032|NCT01139502|Active Comparator|Work rehab with cognitive training|Work rehabilitation with the addition of weekly training of concentration, memory, and executive function
89291033|NCT01230762|Experimental|001|dapoxetine 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
89291034|NCT01136538|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
89291035|NCT01136538|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
89291036|NCT03917550|Experimental|Recovery (Transdiagnostic & self)|A longitudinal study conducted before has shown that self-compassion, unconditional self-acceptance, self-esteem and self concept clarity could be considered risk factors for the severity of the clinical symptoms in anxiety and depression. This is the main reason why this arm consists of the Transdiagnostic intervention program for emotional disorders plus a number of intervention techniques targeting the self-concepts mentioned before. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms. Moreover, additional intervention techniques targeting self-concepts will be used to improve participants' self.
89291037|NCT03917550|Active Comparator|Transdiagnostic|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
89291038|NCT01133574|Experimental|A1|Part A, Parallel design Arm 1
89291039|NCT01133574|Experimental|A2|Part A, Parallel design Arm 2
89291040|NCT01133574|Experimental|A3|Part A, Parallel design Arm 3
89291041|NCT01133574|Experimental|A4|Part A, Parallel design Arm 4
89291042|NCT01133574|Experimental|A5|Part A, Parallel design Arm 5
89291043|NCT01133574|Experimental|A6|Part A, Parallel design Arm 6
89291044|NCT01133574|Experimental|A7|Part A, Parallel design Arm 7
89291045|NCT01133574|Experimental|A8|Part A, Parallel design Arm 8
89291046|NCT01133574|Placebo Comparator|A9|Part A, Parallel design Arm 9
89291047|NCT01133574|Experimental|B1-1|Part B, Cross-over design, Arm 1
89291048|NCT01133574|Experimental|B1-2|Part B, Cross-over design, Arm 2
89291049|NCT01133574|Experimental|B2-1|Part B, Cross-over design, Arm 3
89291050|NCT01133574|Experimental|B2-2|Part B, Cross-over design, Arm 4
89291051|NCT01133574|Placebo Comparator|B3|Part B, Cross-over design, Arm 5
89291052|NCT03917628|Experimental|SCT630|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing SCT630
89291053|NCT03917628|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
89291054|NCT01232634||All Subjects|
89291055|NCT01230840|Placebo Comparator|placebo|Control cookies will contain no wheat dextrin and will be taken 3 times daily for 2 weeks.
89291056|NCT01230840|Experimental|wheat dextrin|wheat dextrin (formulated according to the supporter's established method), will be baked in cookies providing three doses per day (≈5 gram of wheat dextrin in each dose)for 2 weeks.
89291057|NCT01230918|Experimental|Diagnostic Imaging|A single dose of 800 to 1100 mBq of 99mTc-NC100692 radiopharmaceutical will be injected. Serial cardiac nuclear imaging will be done over a 3 hour period.
89291058|NCT01136616||Nasal Fracture|"67 patients admitted for facial fractures and who undergo routine CT scans of the face are to be studied. CT scans are evaluated to assess the position, comminution and displacement of the 5 said buttresses.~The buttresses are graded Grade 1 Simple fracture without displacement Grade 2 Simple fracture with displacement Grade 3 Comminuted fracture without displacement Grade 4 Comminuted fracture with minimal displacement Grade 5 Comminuted fractured with displacement~The septum is graded from Grade 0 Septum is straight Grade 1 Septum is deviated by less than 1 half the distance from the midline to the nasal turbinate Grade 2 Septum is deviated by more than 1 half the distance from the midline to the nasal turbinate Grade 3 Septum is almost touching the nasal turbinate"
88813139|NCT03836456|Experimental|Experimental Intervention|Mindfulness Based Stress Resilience Training: This approach will be conducted with study participants for 4 weeks. One evening per week.
89291059|NCT01329588|Placebo Comparator|Sugar pill|
89291060|NCT01329588|Experimental|Treatment arm|
89291061|NCT01136694||RA patients who are new bDMARD users|
89291062|NCT01136694||RA patients who are existing DMARD users|
88821039|NCT05249465|Experimental|Condition 6|Core + Track Weight + Track Diet
89291063|NCT01136850|Active Comparator|SP, chloroquine treatment; bed net|Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net
89291064|NCT01136850|Experimental|3 x SP plus azithromycin; bed nets|Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.
89523302|NCT05152121|Other|carb counting|Patients using insulin infusion pumps will be placed CGMS for 2 days before starting the study to check whether they are within the target blood glucose levels and normoglycemia will be provided. The content of the first day of the study; The test meal, which is 80 g carbohydrate (29.3%), 70.2 g fat (57.9%), 34.7 g protein (12.7%), will be consumed in the evening meal and normal bolus insulin will be given according to carbohydrate counting. On the second day of the study, instead of the normal bolus for the test meal, the additional insulin for fat-protein by dual wave bolus that.The data obtained will be analyzed by evaluating the CGMS data of all patients by a pediatric endocrinologist experienced in diabetes, CGMS and insulin infusion pump therapy.
89523303|NCT03378791|Experimental|Group A|Iron bisglycinate (27mg of elemental iron)
89291065|NCT05054244||control group|The patients in control group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires: visual analogue scale, McGill Pain questionnaire, Wound Quality of Life Index, Health Quality of Life Questionnaire, Beck depression and Beck anxiety inventory.
89291066|NCT05054244||HBOT group|"The patients in HBOT group will be evaluated upon enrolment, after 2, 4, 6 weeks, 3, 6, 9, and 12 months, to evaluate the wound characteristics, clinical healing rate and indicators of biofilm and/or infection. The patients will be treated with standard treatment (dressings, debridement, antibiotics and infection control). The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with granulation tissue.~The HBOT sessions will be performed 5 days a week in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2. The patient related outcome measures will be evaluated assessing intensity and pain characteristics, quality of life, depression, and anxiety by means of standardized questionnaires as in control group."
89291067|NCT01133652|Active Comparator|VeinViewer|The Veinviewer machine will be used to guide intravenous access.
89291068|NCT01133652|Active Comparator|Ultrasound|The Ultrasound will be used to guide intravenous access.
89291069|NCT01133652|Active Comparator|Conventional IV placement|IV will be placed using conventional technique
89291070|NCT01234116|Active Comparator|Kaletra|Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.
89291071|NCT01234116|Active Comparator|Raltegravir|Arm 2: Raltegravir 400 mg, one pill twice a day + Truvada one pill once a day.
89291072|NCT01136928|Experimental|American ginseng and efavirenz|This is a sequential study. Healthy volunteers will receive efavirenz alone for 14 days followed by efavirenz plus American ginseng for an additional 14 days.
89291073|NCT03917004|Experimental|hypotension group (group H )|particcipants in hypotension group are received controlled hypertension in the operation.
89291074|NCT03917004|No Intervention|control group (group C )|participants in cotrol group are received no controlled hypertension in the operation
89291075|NCT01232712|Experimental|ImMucin|Treatment with ImMucin and rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)
89291076|NCT01139736|Experimental|Probiotics|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks. VSL#3 was selected for use in this study because (a) it contains three different Bifidobacteria strains (in addition to lactobacilli and streptococci) and the limited evidence available Bifidobacteria as the most effective probiotics in IBS .
89291077|NCT01133730|Experimental|Active treatment group|Ultrasound-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
89291078|NCT01133730|Placebo Comparator|Placebo arm|Ultrasound-guided TFP block with 20ml of 5% dextrose solution
89291079|NCT01230996|Experimental|Dose escalation study|This is a dose escalation study of IMRT for women with locally advanced cervical cancer. Three dose levels will be investigated, (although, the first dose level is considered to be the equivalent to a standard pelvic dose with parametrial boost). Before moving to the next dose level it must be confirmed by the Chief Investigator that the Maximum Administrable Dose (MAD) has not been met in the previous dose level (see section 6.3). If MAD is reached before dose level 3 the study will stop. All patients enrolled on the study will undergo the same procedures at the same time points, regardless of the dose level they are being given (see section 5).
89291080|NCT01137084|Active Comparator|a steroid immunosuppression protocol|
89291081|NCT01137084|Active Comparator|a steroid-free immunosuppression protocol|without steroid
89291082|NCT01133886|Experimental|Decitabine|
89291083|NCT01137240||Children with mitochondrial disorders|suffering from gastrointestinal dysfunction
89291084|NCT01140126|Experimental|Antibody (UB-421)|
89291085|NCT01231074|Experimental|Psychotropic/metformin (PIW)|"Inclusion Criteria:Psychotropic/metformin (PIW) Cohort: Children aged 10-17 years on psychotropic* medication with reported weight gain defined by 1 of the following: 1. >5% weight increase from the start of medication to 3 months on medication 2. Crossing into the 95th percentile for BMI 3. Crossing into the 85-95th percentile plus one obesity related complication~The subject will have to be on one of these medications in addition to the criteria above to be eligible for the study: haloperidol, perphenazine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, thioridazine, fluphenazine, loxapine, mesoridazine, thiothixene or trifluoperazine"
89291086|NCT01231074|Experimental|Obese/metformin (OME)|Obese/metformin (OME) cohort: Children 10-17 years old with BMI >95th percentile and fasting insulin level>21.7U/L
89291087|NCT03917394||rHuEPO monotherapy group|rHuEPO was administrated during hospitalization period.
89291088|NCT03917394||iron sucrose monotherapy group|Iron sucrose was administrated during hospitalization period.
89291089|NCT03917394||rHuEPO combined with iron sucrose group|rHuEPO combined with iron sucrose was administrated during hospitalization period.
89291090|NCT03917394||control group|Subjects didn't be administrated with rHuEPO and/or iron sucrose during hospitalization period.
89291091|NCT01133964|Experimental|milk|skim milk
89291092|NCT01133964|Experimental|casein drink|
89291093|NCT01133964|Experimental|whey drink|
89291094|NCT01133964|Sham Comparator|water|
89291095|NCT04938726|Experimental|Ketone Monoester|The ketone used is from KetoneAid and is commercially available as KE4 and will be consumed at 30 mL twice daily (15 g / dose)
89291096|NCT04938726|Placebo Comparator|Placebo|A placebo is being manufactured by KetoneAid to match the taste and other characteristics of the ketone supplement for blinding purposes
89291097|NCT03769896|Active Comparator|Treatment Group|Nabilone 0.25 mg
89291098|NCT03769896|Placebo Comparator|Placebo Group|Placebo (corn starch)
89291099|NCT01234194|Active Comparator|Group 1|
89291100|NCT01234194|Active Comparator|Group 2|
89291101|NCT04913922|Experimental|Combination therapy|"5-azacitidine 75 mg/m2 body surface area s.c. for 7 days nivolumab 480mg i.v. day 1 relatlimab 80-160mg i.v. day 1~repeat day 28"
89291102|NCT01233024|Placebo Comparator|Low fiber control|no treatment dinner bar, no treatment breakfast bar
89291103|NCT01233024|Experimental|Promitor soluble corn fiber|12g in dinner bar, 11g in breakfast bar
89291104|NCT01233024|Experimental|FiberSym resistant starch|12g in dinner bar, 11g breakfast bar
89291105|NCT01233024|Experimental|Orafti P95 fructooligosaccharide|12g in dinner bar, 11g in breakfast bar
89291106|NCT01233024|Experimental|Orafti HPX inulin|12g in dinner bar, 11g in breakfast bar
89291107|NCT05495256|Other|MDI Training|All participants are led through the MDI training with the Respimetrix Device. Protocol is within groups design.
89291108|NCT01585818|Active Comparator|standard dietary intervention (SDI) arm|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre
89291109|NCT01585818|Experimental|LGI intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI. Participants will be provided with a list of low GI carbohydrates to consume during the intervention period and in addition, they will be provided with a supply of the staples for the same period
89291110|NCT01137318|Experimental|Cognitive remediation and Behavioral Intervention|
89291111|NCT01137318|Placebo Comparator|Low Level Cognitive Remediation and Behavioral Parent Traning|
89291112|NCT02528682|Experimental|Single arm|MiHA-loaded PD-L-silenced DC Vaccination
89291113|NCT01233102|Active Comparator|Conserved Therapy|Conserved Therapy
89291114|NCT01233102|Experimental|Interventional Therapy|"Patients with liver cirrhosis will be randomly divided into three groups.~1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared."
89291115|NCT01140282|Active Comparator|Arm I (Control)|Patients refrain from increasing physical activity levels for 16 weeks.
89291116|NCT01140282|Experimental|Arm II (Exercise)|Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.
89291117|NCT03739944|Active Comparator|Laparotomic radical hysterectomy|
89291118|NCT03739944|Active Comparator|Laparotomic radical trachelectomy|
89291119|NCT03739944|Active Comparator|Laparoscopic radical hysterectomy|
89291120|NCT03739944|Active Comparator|Laparoscopic radical trachelectomy|
89291121|NCT01134120|Experimental|LY2784544|
89291122|NCT01234272|Experimental|ITM-IVPCA|ITM-IVPCA:intrathecal morphine and IV-fentanyl patient controlled analgesia
89291123|NCT01234272|Active Comparator|PCEA|PCEA:epidural PCA(patient controlled analgesia)
89291124|NCT01231308|Active Comparator|Lifestyle modification|Intensive nutritional/exercise counseling for weight loss by lifestyle modification in addition to optimum medical treatment.
89291125|NCT01231308|Experimental|Roux-en-Y-Gastric Bypass|A laparoscopic gastric bypass will be performed in the treatment of type 2 diabetes in Overweight-to-Moderately Obese Patients
89291126|NCT01140438|Active Comparator|Metformin + NPH Insulin|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization insulin treatment will be added in the form of injections of NPH insulin in the evenings.
89291127|NCT01140438|Active Comparator|Metformin + sitagliptin +/-repaglinid|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization sitagliptin tablets will be added.If HbA1c after 6 months of treatment is > 10 % above the upper limit of normal,then treatment with repaglinide tablets tree times daily at mealtimes will be added.
89291128|NCT01234506|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 0.8g/day of BeneFlax containing 300 mg SDG. 1000 IU vitamin D as standard of care.
89291129|NCT01234506|Placebo Comparator|Placebo|An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
89291130|NCT03916536|Active Comparator|Holmium Laser|holmium laser enucleation of the prosteate
89291131|NCT03916536|Active Comparator|Thulium Laser|Thulium laser enucleation of the prosteate
89291132|NCT03916536|Active Comparator|Bipolar Enucleation|Bipolar enucleation of the prosteate
89291133|NCT01234584|Experimental|Group A|23 implants using SPK Abutments
89291134|NCT01234584|Active Comparator|Group B|implants using CPK Abutments
89291135|NCT04751604|Experimental|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide [1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)] for 4 weeks
89291136|NCT04751604|Placebo Comparator|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
89291137|NCT02528604|Active Comparator|Catheter Ablation|Left atrial catheter ablation for persistent atrial fibrillation and implantable loop recorder.
89291138|NCT02528604|Active Comparator|Pacemaker and AV node ablation|Participants will have a permanent pacemaker implant followed by AV node ablation
89291139|NCT02528604|Active Comparator|DC cardioversion|Participants will have electrical cardioversion with concomitant anti-arrhythmic therapy and implantable loop recorder.
89291140|NCT01231542|Experimental|Arm 1|Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects enrolled in Arm 1 will receive GSK1349572 50 mg once daily for 7 days, GSK1348572 50 mg twice daily for 7 days, and GSK1349572 50 mg twice daily in combination with rifampin 600 mg once daily for 14 days.
89523304|NCT03378791|Active Comparator|Group B|Ferrous fumarate (115mg of elemental iron)
89523305|NCT03383003|Experimental|High dose dual therapy|Esomeprezole (Nexium)40 mg tid. and amoxicillin (Amolin) 750 mg qid. for 14 days
89291141|NCT01231542|Experimental|Arm 2|Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects in Arm 2 will receive GSK1349572 50 mg once daily for 7 days and GSK1349572 50 mg once daily in combination with rifabutin 300 mg once daily for 14 days.
89291142|NCT01234428|Other|surgery|
89291143|NCT04849104||COPD high-risk patients|age <70 years old, long-term smoker (≥10 pack years), CT without macroscopic airway abnormalities and/or mild or moderate emphysema, air retention or bronchial thickening, normal lung function
89291144|NCT04849104||Early-stage COPD patients|"those who are younger than 70 years old, long-term smokers (≥10 pack years) and have any of the following abnormalities:~Forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) <lower limit of normal value (LLN, 80%);~CT abnormalities: abnormal airway and/or emphysema, air retention or bronchial wall thickening;~FEV1 drops rapidly (≥60 mL/year);"
89291145|NCT04849104||patients with mild to moderate COPD|Patients with mild to moderate COPD: age <75 years, FEV1/FVC<70%, FEV1 predicted value ≥50%
89291146|NCT01234662|Active Comparator|Group 1|Spinal anesthesia + intrathecal opioid bolus (SPA)
89291147|NCT01234662|Active Comparator|Group 2|CSE + epidural opioid bolus (CSE)
89291148|NCT01234662|Experimental|Group 3|CSE + continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs (CSEPCEA)
89291149|NCT01140672|Experimental|Cohort 1 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
89291150|NCT01140672|Experimental|Cohort 2 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
89291151|NCT01140672|Experimental|Cohort 3 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 30 mg per day for 14 days. (2 placebo: 8 active)
89291152|NCT01140672|Experimental|Cohort 4 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 100 mg per day for 14 days. (2 placebo: 8 active)
89291153|NCT01140672|Experimental|Cohort 5 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 300 mg per day for 14 days. (2 placebo: 8 active)
89291154|NCT01140672|Experimental|Cohort 6 (N=10) Optional cohort|Placebo-controlled, multiple doses of PF-04634817 up to 300 mg per day for 14 days. (2 placebo: 8 active)
89291155|NCT01231698|Experimental|esmolol|
89291156|NCT01231698|Other|control|
89291157|NCT01142778|Experimental|Trastuzumab, Docetaxel, and Bevacizumab|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel along with bevacizumab in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the bevacizumab infusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
89291158|NCT01142778|Active Comparator|Trastuzumab and Docetaxel|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
89291159|NCT01142778|Active Comparator|Trastuzumab and Docetaxel (Standard Regimen)|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of >/=70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
89291160|NCT01237938|Experimental|Low Glycemic Diet|
89291161|NCT03750708|Other|Ara® KOLIBREE toothbrush|The Ara® KOLIBREE tooth brush is given to the child at the usual consultation one month before alveolar bone graft.
89291162|NCT03750708|No Intervention|Without Ara® KOLIBREE tooth brush|Usual consultation one month before alveolar bone graft.
89291163|NCT01142934|Other|TegaDerm CHG|TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).
89291164|NCT04722978|Active Comparator|Experimental group|Gemcitabine combined with carboplatin plus moxifloxacin
89291165|NCT04722978|Placebo Comparator|Control group|Gemcitabine combined with carboplatin plus placebo
89291166|NCT03739398|Experimental|LUTRONIC GENUS laser with LASEMD laser|
89291167|NCT03739398|Active Comparator|LUTRONIC GENUS laser without LASEMD laser|
89291168|NCT01140828|Active Comparator|Rabeprazole|Rabeprazole
89291169|NCT01140828|Placebo Comparator|Rabeprazole Placebo|Rabeprazole Placebo
89291170|NCT01234740|Experimental|Arm I|Patients undergo intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily for 1 day. Beginning at least 2 weeks after surgery, patients continue to receive oral bafetinib twice daily in the absence of disease progression or unacceptable toxicity.
89291171|NCT01238016|Other|device|Device implant and EEG recording
89291172|NCT01234818|Experimental|LNG-IUS, endometrial hyperplasia|
89291173|NCT01143012|Active Comparator|Group eczema education session|One group will attend a group eczema education session. All subjects will answer quality of life questions two times.
89291174|NCT01143012|Active Comparator|Control group|The other group will not attend the group eczema education session. Both groups will be asked quality of life questions two times.
89291175|NCT03714594|Active Comparator|Dapagliflozin 10mg|Dapagliflozin inhibits SGLT2 promoting the excretion of glucose in the urine,and lowers the plasma glucose concentration. This class of drugs has been shown to effectively reduce the HbA1c at all stages of T2DM and can be used in combination of all other anti-diabetic agents including insulin.
89523306|NCT03383003|Active Comparator|Non-bismuth quadruple therapy|Esomeprezole (Nexium) 40 mg bid.,clarithromycin (Klaricid) 500 mg bid., amoxicillin (Amolin) 1 g bid. and metronidazole (Flagyl) 500 mg bid. for 7 days
89291176|NCT03714594|Active Comparator|Saxagliptin 5mg|Saxagliptin is a DPP4 inhibitor.In patients with type 2 diabetes,administration of saxagliptin led to inhibition of DPP4 enzyme activity.After an oral glucose load,this DPP4 inhibition resulted in a increase in circulating levels of active incretin hormones include GLP-1 and GIP, decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness,which resulted in higher insulin and C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
89291177|NCT03714594|Active Comparator|Saxagliptin 5 mg + dapagliflozin 10 mg|Please see Arm 1 and 2
89291178|NCT01144884|Other|Single arm trial|"Education:To standardize, treatment education will consist of counsel to stay active. Details will be given to subjects verbally & reinforced in the home booklet.~Posture:Facilitation of proper posture has been show to increase recruitment of the lumbar multifidus & deep neck flexors. Instruction will be given verbally & in writing.~Stretching:Stretching exercises will be targeted to address these common impairments. Patients will be introduced to proper stretching procedures. Each stretch will be held for 30s & repeated two times,each side as applicable. The following stretches will be performed:~Upper trap Anterior/medial Scalene Suboccipital Pectoralis~Muscular Performance: Muscle performance will be trained incorporating components of strength, endurance and motor control. Each of the exercises listed below are outlined based on progressions.~Isometric Cervical Extension Craniocervical flexion Seated Row Seated T Palms Up Seated Side Arm Raises"
89291179|NCT04624776|Active Comparator|Methylprednisolone|A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.
89291180|NCT04624776|Placebo Comparator|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
89291181|NCT01234896|Experimental|Nicotine Gum 6|6 mg Nicotine medicated gum
89291182|NCT01234896|Active Comparator|Nicotine Gum 4|4 mg Nicotine Gum
89291183|NCT01234896|Active Comparator|Nicotine Gum 2|2 mg Nicotine Gum
89291184|NCT01234896|Active Comparator|Nicotine Lozenge|4 mg Nicotine Lozenge
89291185|NCT02528838||Patients receiving Revlimid according to clinical practice|
89291186|NCT02528916||Primary Knee Arthroplasty Patients|Patients who consented, met inclusion and exclusion criteria, had plasma and synovial fluid samples drawn as described in the included protocol. No interventions were completed. No changes to standard of care treatment completed.
89291187|NCT01238094|Experimental|FOLFIRI or XELIRI/simvastatin|FOLFIRI or XELIRI/simvastatin
89291188|NCT01236612|Experimental|Immunization + bloodstage challenge|
89291189|NCT01236612|Active Comparator|Immunization + mosquito challenge|
89291190|NCT01236612|Placebo Comparator|Control - Bloodstage challenge|
89291191|NCT01236612|Placebo Comparator|Control - Mosquito challenge|
89291192|NCT03633630|Experimental|Amla (Emblica Officinalis)|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days.
89291193|NCT03633630|Placebo Comparator|Placebo|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days
89291194|NCT01234974|Experimental|Pasireotide|Pasireotide 60 mg day 1 every 28 days
89291195|NCT01144962|Sham Comparator|Control group|Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
89291196|NCT01144962|Active Comparator|Cohort 1|10x10^6 MSC
89291197|NCT01144962|Active Comparator|Cohort 2|30x10^6 MSC
89291198|NCT01144962|Active Comparator|Cohort 3|90x10^6 MSC
89291199|NCT04578288|Active Comparator|Standard Blood Pressure management|The standard blood pressure management is maintenance of intraprocedural pre-recanalization SBP between 140-180 mmHg for all patients who receive endovascular thrombectomy for acute ischemic stroke in anterior circulation.
89291200|NCT04578288|Experimental|Individualized Blood Pressure management|The study intervention would be maintaining the intraprocedural pre-recanalization blood pressure in individualized SBP target ranges depending on the systolic blood pressure of the patient at presentation (=baseline SBP or bSBP).
89291201|NCT01140984|Experimental|treatment|
89291202|NCT01145040||Partition 1|Overt primary hypothyroidism
89291203|NCT01145040||Partition 2|"Hypothyroidism with full dose levothyroxine substitution therapy (more than 1.75 µg per kg of body mass)"
89291204|NCT01145040||Partition 3|Overt primary hyperthyroidism
89291205|NCT01141062|Experimental|Treated leiomyomas|Philips MR-guided HIFU
89291206|NCT01235052|Experimental|TEP with 18F-FMISO|TEP with 18F-FMISO
89291207|NCT01145430|Experimental|Treatment (veliparib and liposomal doxorubicin hydrochloride)|Patients receive veliparib PO BID on days 1-14 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89291208|NCT01141140|Other|M-NO-NR|Men (M) non-obese (NO) and non-restrained (NR).
89291209|NCT01141140|Other|M-NO-R|Men (M) non-obese (NO) and restrained (R).
89291210|NCT01141140|Other|M-O-NR|Men (M) overweight or obese (O) and non-restrained (NR).
89291211|NCT01141140|Other|M-O-R|Men (M) overweight or obese (O) and restrained (R).
89291212|NCT01141140|Other|W-NO-NR|Women (W) non-obese (NO) and non-restrained (NR).
89291213|NCT01141140|Other|W-NO-R|Women (W) non-obese (NO) and restrained (R).
89291214|NCT01141140|Other|W-O-NR|Women (W) overweight or obese (O) and non-restrained (NR).
89291215|NCT01141140|Other|W-O-R|Women (W) overweight or obese (O) and restrained (R).
89291216|NCT03389724|Experimental|Group capoten (Intervention arm)|Patients will receive prophylactic ACE-I(Capoten®) at day 1 of initiation of chemotherapy and is to be continued for 1 year after the end of treatment. Patients will remain on this arm until they experience any of the study primary or secondary end-point where they will be off-study and will receive cardiotoxicity treatment independently.
89291217|NCT03389724|No Intervention|Group standard treatment (Control arm)|Patients will not receive ACE-I as prophylaxis, and will be monitored and evaluated for first signs of cardiotoxicity based on the above mentioned end-points.
89291218|NCT05382000|Other|Intervention|"Inclusion in the study will be proposed to all patients who come to the Emergency Department of the Gynecology and Obstetrics Service~The planned procedures for this group are as follows:~Obtaining informed consent.~Sequential triage - Patients will be evaluated sequentially using the MAT system according to standard practice. Next, another professional from the center, trained in the use of the Mediktor Hospital ® tool, will perform the advanced triage in the same space, both professionals being blind to the result of each of the tools.~Once the sequential triage is finished, the patient's care will be carried out according to usual clinical practice, following the triage assessment carried out with the MAT system.~Retrieval and introduction of data in DRF - Data of the study variables will be retrieved from the emergency report issued in the Gynecology and Obstetrics Emergency area and will be entered into an electronic DRF for subsequent analysis and processing."
89291219|NCT01585974||Group 1|
89291220|NCT01586052|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
89291221|NCT01141218||Never-smokers with lung cancer|
89291222|NCT01145586|Experimental|Lactase EUF|1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
89291223|NCT01145586|Active Comparator|Lactase Ref|1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days
89291224|NCT05796739|Experimental|Routine stress testing|In this group, the preselected functional stress testing (exercise electrocardiography, stress echocardiography, nuclear imaging, or stress cardiac magnetic resonance imaging) will be performed within three months (± 2 months) according to the practice pattern of each participating center.
89291225|NCT05796739|Active Comparator|As-needed stress testing|In this group, optimal medical treatment will be performed by current guidelines without further testing. A stress test will be performed only when new symptoms (exertional chest pain or dyspnea) occur that may clinically suggest significant coronary artery disease.
89291226|NCT05796726||Capmatinib Patients|Patients who received first- or second-line treatment with capmatinib in Study GEOMETRY mono-1
89291227|NCT05796726||Standard of Care Patients|Patients who received appropriate comparative therapy (ACT) defined by the German HTA agency G-BA or standard of care (SoC) practiced in German routine care
89291228|NCT05796700|Active Comparator|Microwave Ablation|According to the shape, size and location of each patient's tumor, as well as the adjacent relationship with the surrounding organs, the individual MWA scheme was pre-established. Contrast-enhanced CT (CE-CT) or contrast-enhanced magnetic resonance imaging (CE-MRI) was used to evaluate complete ablation within 3 to 5 days after ablation. If radiography suggested incomplete ablation, supplementary ablation was performed as soon as the patient's condition permitted. A cooled-shaft MW system (KY-2000, Kangyou Medical, China) was used in the procedure.
89291229|NCT05796700|Active Comparator|Laparoscopic Hepatectomy|The optimal surgical procedure for each patient depends on the characteristics of the tumor. Patients were placed in French position and a laparoscopic-assisted partial hepatectomy was performed under CO2 pneumoperitoneum pressure 12-14 mmHg (1 mmHg =0.133 kPa). In most cases, a 4-well or 5-well method was used under general anesthesia.
89291230|NCT05796635|Experimental|Herpecin L|Participants will use Herpecin L Everyday Protection lip balm.
89291231|NCT05796635|No Intervention|Controlled Arm|Participants will not use any cold sore products or lip balms.
89291232|NCT05796622|Experimental|HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)|Promote and implement HIV self-testing (HIVST) services with real-time counselling provided by a fully-automated artificial intelligence Chatbot (HIVST-Chatbot)
89291233|NCT05796622|Active Comparator|HIVST-OIC (HIV self-testing services with counseling provided by administrators)|Promote and implement HIV self-testing (HIVST) services with real-time counselling provided by trained administrators)
89291234|NCT05796596|Experimental|Virtual Reality (VR) distraction|Distraction intervention using a virtual environment
89291235|NCT05796596|Active Comparator|Distraction by the book|Distraction intervention using a book visualization
89291236|NCT05796596|No Intervention|Usual care|Control group receiving usual care and no distraction.
89291237|NCT05796466|Experimental|How-to Parenting Program|The How-to Parenting Program is a highly structured and skill-based program. It is manualized, teaches 30 concrete, specific, easy-to-grasp (e.g., taught using comic strips), and readily applicable skills. It also optimizes learning with exercises (e.g., perspective taking; role-playing) and practice, and addresses parents' readiness and motivation to change. The program is delivered over six consecutive 2-hour weekly sessions (12 hours in total).
89291238|NCT05796466|Active Comparator|Nobody's Perfect Program|Based on andragogy principles, parents following the Nobody's Perfect curriculum will learn how to solve problems with their child and engage in theme-related activities meant to increase awareness of parents' own needs, child behaviors, development, health, and safety. There is no pre-determined order for themes and time devoted to each one varies according to parents' needs. The program is delivered over six consecutive 2-hour weekly sessions (12 hours in total).
89291239|NCT05796362|Active Comparator|Reference Azithromycin Tablet (Zithromax)|250 mg azithromycin (Zithromax) tablet to be taken once orally.
89291240|NCT05796362|Experimental|Oral Oleogel|250 mg azithromycin/ 15 ml oral oleogel (16.67 mg/ml) to be dosed once orally.
89291241|NCT05796362|Experimental|Rectal Oleogel|250 mg azithromycin/ 15 ml rectal oleogel (16.67 mg/ml) to be dosed once rectally.
89291242|NCT05796349||healthy group|The healthy group included 16 individuals (male, age 40.25±11.18). No history of brain disease and no abnormalities were seen on plain CT scans of their brains.
89291243|NCT05796349||patient group|The patient group included 8 patients with brain diseases (7 males, age 59±10.46). Obvious lesions were visible on the patients' CT or MRI images, including 6 patients with intracranial hemorrhage, 1 patient with cerebral ischemia, and 1 patient with cerebral edema
89291244|NCT05796323||Methodist Health System Employees|All MHS employees, clinical and non-clinical.
89291245|NCT05796310||Autism Spectrum Disorder Patients|This group is comprised of 3-17 years children with an expert clinical diagnosis of autism spectrum disorders.
89291246|NCT05796310||Siblings of children with Autism Spectrum Disorders|This group is comprised of 3-17 years old siblings, with typical development, of a child with an expert clinical diagnosis of autism spectrum disorders.
89291247|NCT05796310||Typical Development children|This group is comprised of 3-17 years children with typical development.
89291248|NCT05796284|Experimental|Breast pressure relief intervention at the end of pregnancy|"The Breast Compression Intervention at the End of Pregnancy group is expected to start after the 36th week of pregnancy and continue until three months after delivery. In addition to routine care, breast relaxation methods of different intensities during pregnancy and postpartum will be provided in stages."
89291249|NCT05796284|Active Comparator|Routine care group|Cases in the routine care group receive routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery, including breastfeeding posture and skills, hand expression, and breast milk storage methods, etc.
89291250|NCT05796219|Other|Low dose mammogram|Low dose mammo to compare with standard mammo
89291251|NCT05796193|Experimental|Py-PBO LLIN|Veeralin is a long-lasting net of 130 deniers containing the pyrethroid insecticide alpha-cypermethrin 6.0 g/kg (216 mg/m2) and the synergist piperonyl butoxide (PBO) 2.2 g/kg (79.2 mg/m2) and manufactured by VKA polymers.
89291252|NCT05796193|Experimental|Py-CFP LLIN|Interceptor® G2 is a long-lasting dual insecticide treated nets of 100 deniers combining Alpha-cypermethrin 2.4 g/kg (100 mg/m2) and Chlorfenapyr 4.8 g/kg (200 mg/m2) manufactured by BASF
89291253|NCT05796193|Active Comparator|Py LLIN|MAGNet® is a long-lasting net of 150 deniers containing the pyrethroid insecticide alpha-cypermethrin 5.8 g/kg (261 mg/m2) only and manufactured by VKA polymers.
89291254|NCT05796154|Other|ear blood pressure monitor|
89291255|NCT05796128|Active Comparator|LISA with NCPAP|In this group, infants will receive NCPAP during LISA procedure.
89291256|NCT05796128|Experimental|LISA with NIPPV|In this group, infants will receive NIPPV during LISA procedure.
89291257|NCT05796115|Active Comparator|Antibiotic prophylaxis for EOS|
89291258|NCT05796115|Experimental|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|
89291259|NCT05796076|Other|Control group|Participants in the control group will be received standard care
89291260|NCT05796024||Derivation Cohort|The derivation cohort will correspond to approximately 70% of the total sample to be analyzed in the study. The Ex-Care II risk model will build upon it. It is composed of patients operated in the participating institutions.
89291261|NCT05796024||Validation Cohort|Composed of the remaining 30% of the sample. It will be used for the external validation of the Ex-Care II model
89291262|NCT05796011||Age-related hearing loss patients with hearing aid(s)|Age-related hearing loss patients who were fitted with at least one hearing aid.
89291263|NCT05796011||Age-related hearing loss patients without an hearing aid|Age-related hearing loss patients who were treated without hearing intervention.
89291264|NCT05796011||Elderly healthy control|healthy elderly with normal hearing tested by pure tone audiometry.
89291265|NCT05795946|No Intervention|Diet Only Group|Diet only: guided diet
89291266|NCT05795946|Experimental|Combination Group|Combination of whole food-based B and D vitamins
89291267|NCT05795946|Experimental|B Only Group|Whole food-based B vitamins
89291268|NCT05795920|Experimental|Patients with advanced pancreatic cancer that is inoperable and not suitable for local treatment|Patients with advanced pancreatic cancer that is inoperable and not suitable for local treatment
89291269|NCT05795907|Experimental|SAR443820|Single dose oral ascending dose (parts 1a and 1b) and multiple ascending oral dose (part 2) of SAR443820
89291270|NCT05795907|Placebo Comparator|Placebo|Single dose oral ascending dose (part 1a) and multiple ascending oral dose (part 2) of matching placebo
89291271|NCT05795868|Experimental|Compression stockings group|Pregnant women in the compression stockings group will wear the socks given for 3 weeks.
89291272|NCT05795868|Placebo Comparator|Placebo sock group|Pregnant women in the placebo socks group will wear the socks given for 3 weeks.
89291273|NCT05849428|Other|Measuring Arm|Participants will wear 2 Freestyle Libre 3 sensors on each arm, 1 on the left and 1 on the right for 2 consecutive weeks (total of 14 days).
89291274|NCT05849402|Active Comparator|Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
89291275|NCT05849402|Sham Comparator|Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
89291276|NCT05849376|Experimental|EMIT Intervention|Immediate access to EMIT intervention
89291277|NCT05849376|Other|Waitlist Control|Delayed access to EMIT intervention
89291278|NCT05849324|Experimental|Straight needle|25 gauge straight chiba needle
89291279|NCT05849324|Active Comparator|Bent needle|25 gauge bent chiba needle
89291280|NCT05849285||TLC Patient|Patients of the TLC program with CP/SB/DD
89291281|NCT05849285||Control Patient|Adults with CP/SB/DD that are not patients of the TLC Program
89291282|NCT05849285||TLC Caregiver|Caregiver of Patients of the TLC program with CP/SB/DD
89291283|NCT05849285||Control Caregiver|Caregiver of Adults with CP/SB/DD that are not patients of the TLC Program
89291284|NCT05849285||Healthcare Providers|Healthcare Providers who care for patients in the TLC clinic
89291285|NCT05849246|Experimental|tusamitamab ravtansine + sintilimab|Sintilimab dose will be administered intravenously prior to intravenous administration of tusamitamab ravtansine dose every 3 weeks.
89291286|NCT05849246|Experimental|Tusamitamab ravtansine + Sintilimab + carboplatin/ cisplatin + pemetrexed|Sintilimab dose will be administered intravenously prior to intravenous adminstration of tusamitamab ravtansine dose every 3 weeks. Pemetrexed will be infused over 10 minutes after tusamitamab ravtansine infusion on Day 1 and then Q3W. Carboplatin / cisplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
89291287|NCT05849246|Placebo Comparator|Sintilimab + carboplatin/ cisplatin + pemetrexed|Pemetrexed will be infused over 10 minutes after Sintilimab infusion on Day 1 and then Q3W. Carboplatin/ cisplatin will be infused over 15 to 60 minutes immediately after pemetrexed infusion on Day 1 and Q3W for the first 4 cycles.
89291288|NCT05849220|Experimental|Dapagliflozin+Standard of Care|Dapagliflozin
89291289|NCT05849220|Active Comparator|Standard of Care|Standard of Care
89291290|NCT05849116||High flow nasal cannula|preterms infants who are connected to high flow nasal cannula
89291291|NCT05849116||Continuous positive airway pressure|preterms who are connected to continuous positive airway pressure
89291292|NCT05848934||CAD（coronary heart disease ）surgical treatment|
89291293|NCT05848934||CAD（coronary heart disease ）conservative treatment|
89291294|NCT05848934||HC （Healthy controls）|
89291295|NCT05848921||CAS-CN|Carotid Artery Stenosis with cognitive normality
89291296|NCT05848921||CAS-MCI|Carotid Artery Stenosis with mild cognitive impairment
89291297|NCT05848921||HC|Healthy controls
89291298|NCT05848635|Experimental|Experimental: Lung tumor ablation using hydromorphone for pain control and anaesthesia|"Premedication:hydromorphone is started 15min before surgery with a single subcutaneous injection of 2mg.~Intraoperative administration:NRS（Numeric Rating Scale）≥7 during operation, 2mg hydromorphone is injected intravenously and slowly pushed for 2-3 minutes.~Postoperative administration:The drug is administered as needed according to the patient's postoperative pain, 2mg/time."
89291299|NCT05848635|Active Comparator|Active Comparator:Lung tumor ablation using morphine for pain control and anaesthesia|"Premedication:morphine is started 15min before surgery with a single subcutaneous injection of 10mg.~Intraoperative administration:NRS（Numeric Rating Scale）≥7 during operation, 10mg morphine is injected intravenously and slowly pushed for 2-3 minutes.~Postoperative administration:The drug is administered as needed according to the patient's postoperative pain, 10mg/time."
89291300|NCT05848609|Other|Older patients with colorectal cancer|Patients undergo geriatric assessment including evaluation of cognitive function, functional status and quality of life
89291301|NCT05848531|No Intervention|Morphine|Standard Morphine PCIA
89291302|NCT05848531|Experimental|Clonidine and Morphine|Morphine Associated with Clonidine PCIA
89291303|NCT05848505|Experimental|Dexmedetomidine group|Intranasal dexmedetomidine 2 mcg/kg administered before surgery
89291304|NCT05848505|Placebo Comparator|Control group|Intranasal saline 0.02 mL/kg administered before surgery
89291305|NCT05848492|Experimental|Prophylactic Fluconazole|12 mg/Kg loading dose of fluconazole given intravenously followed by 6 mg/Kg every 48 hours till 14 days of life, and then 6 mg/kg/day thereafter, for a total duration of 6 weeks (42 days).
89291306|NCT05848492|Placebo Comparator|placebo group|Normal Saline 2cc given intravenously
89291307|NCT05848466|Experimental|A/ Accelerated titration 0.8mg/kg of BAT8010|Drug: BAT8010, Dosage: 0.8mg/kg, Frequency: once every 3 weeks, Duration: 1year
89291308|NCT05848466|Experimental|B/ Standard 3+3 1.2mg/kg of BAT8010|Drug: BAT8010, Dosage: 1.2mg/kg, Frequency: once every 3 weeks, Duration: 1year
89291309|NCT05848466|Experimental|C/ Standard 3+3 2.4mg/kg of BAT8010|Drug: BAT8010, Dosage: 2.4mg/kg, Frequency: once every 3 weeks, Duration: 1year
89291310|NCT05848466|Experimental|D/ Standard 3+3 3.6mg/kg of BAT8010|Drug: BAT8010, Dosage: 3.6mg/kg, Frequency: once every 3 weeks, Duration: 1year
89291311|NCT05848466|Experimental|E/ Standard 3+3 4.8mg/kg of BAT8010|Drug: BAT8010, Dosage: 4.8mg/kg, Frequency: once every 3 weeks, Duration: 1year
89291312|NCT05848466|Experimental|F/ Standard 3+3 6.0mg/kg of BAT8010|Drug: BAT8010, Dosage: 6.0mg/kg, Frequency: once every 3 weeks, Duration: 1year
89291313|NCT05848466|Experimental|G/ Standard 3+3 7.2mg/kg of BAT8010|Drug: BAT8010, Dosage: 7.2mg/kg, Frequency: once every 3 weeks, Duration: 1year
89291314|NCT05848466|Experimental|H/ Standard 3+3 8.4mg/kg of BAT8010|Drug: BAT8010, Dosage: 8.4mg/kg, Frequency: once every 3 weeks, Duration: 1year
89291315|NCT05848401|Experimental|Treatment Group|The treatment group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. The principal investigator will schedule two Biosound Therapy sessions per week for four weeks for all treatment group participants. The treatment sessions will not occur on consecutive days. All participants in the treatment group will listen to identical playlists. At the beginning of the BTS session, the participant will complete a session of HeartMath biofeedback. Next, the participant will receive approximately 30-40 minutes of music containing binaural beats synchronized with sound massage.The session will finish with gratitude-based video content.
89291316|NCT05848401|No Intervention|Control Group|The control group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. Control group participants were given a complimentary Biosound Therapy session and a ten dollar gift card upon completion of their final assessments.
89291317|NCT05848388||1|older than 9-year-old patients, with panoramic radiographic images showing the first permanent molars
88821040|NCT05249465|Experimental|Condition 7|Core + Track Steps + Track Diet
89291318|NCT05848362|Other|SINGLE GROUP|This is a quasi-experimental study with a single group and simultaneous (matched) sample will conduct with the purpose of to determine whether glucose values are different for a bedside glucose meter compared to the main clinical laboratory and whether the blood sampling site has a significant effect on glucose values.
89291319|NCT05848336|Experimental|Gluten Free Casein Free Diet|Foods containing gluten (pasta, bread, etc.), casein (unfermented dairy products), and their disguised sources have been eliminated from the nutrition program. Also, packaged foods (chocolate, crackers, etc.) containing additives such as artificial preservatives, food coloring, and sweeteners that create a tendency to consume in children were avoided from the nutrition program. Goat milk contains type A2 casein, and most of the casein is digested in fermented dairy products. In order to increase calcium intake, the consumption of some foods (dill, kale, spinach, chard, arugula, broccoli, parsley, legumes, nuts, tahini, etc.) has been increased. Elimination was done gradually, considering nervousness, anxiety, etc., due to the effects of opioid mechanisms of action and gastrointestinal system symptoms.
89291320|NCT05848284|Experimental|VDyne System Treatment Arm|Device
89523307|NCT03378713|Experimental|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.
89291321|NCT05848245|Experimental|low suction|It is a small and narrow in diameter help to remove saliva , blood and debris and provide a clear vision to healthcare worker. It will be used as conventional way; low suction will be hanged on patient mouth and moved it thoroughly as needed it, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand.
89291322|NCT05848245|Active Comparator|intraoral suction|Intraoral suction is attached to high volume excavation hose and provide continuous suction with a bite block, tongue, and oral pathway protection.It will be used as conventional way; intraoral suction will be hanged on patient mouth and moved it thoroughly as needed it, high suction will be moved with scaler, and extraoral suction where on right hand side of patient, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand.
89291323|NCT05848245|Experimental|high & low suction|"Low section is a small and narrow in diameter help to remove saliva , blood and debris and provide a clear vision to healthcare worker.~High section is a large tube designed to suction large amount of air volume and droplet. It will be used as conventional way; low suction will be hanged on patient mouth and moved it thoroughly as needed it, high suction will be moved with scaler, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand."
89291324|NCT05848245|Experimental|extra-oral suction & low suction|"EOS is used to remove aerosol and droplet that arising from patient mouth and filtering air. The device starts from air volume level 1 to level 10.~Low section is a small and narrow in diameter help to remove saliva , blood and debris and provide a clear vision to healthcare worker. It will be used as conventional way; low suction will be hanged on patient mouth and moved it thoroughly as needed it, and extraoral suction where on right hand side of patient, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand."
89291325|NCT05848245|Experimental|extra-oral suction and intraoral suction|"EOS is used to remove aerosol and droplet that arising from patient mouth and filtering air. The device starts from air volume level 1 to level 10.~High section is a large tube designed to suction large amount of air volume and droplet. It will be used as conventional way; intraoral suction will be hanged on patient mouth and moved it thoroughly as needed it, and extraoral suction where on right hand side of patient, power will be turned on to level 10, and suction cone will be facing patient mouth and it was away from its around 10 -15 cm based on the manufacturer instruction and to allow comfortable movement of the dental hygienist's hand."
89291326|NCT05848219||Dabrafenib + trametinib (dab/tram)|Patients with a first diagnosis of metastatic melanoma, who received dab/tram in the United States
89291327|NCT05848219||Encorafenib + binimetinib (enco/bini)|Patients with a first diagnosis of metastatic melanoma, who received enco/bini in the United States
89291328|NCT05848206||Primary LAAD Cohort|Patients with ≥1 SAC/VAL transactions from plans of interest identified in LAAD
89291329|NCT05848206||Secondary LAAD Cohort|Patients with SAC/VAL abandonment or rejection identified in LAAD
89291330|NCT05848102|Experimental|Dapagliflozin arm|In the Dapagliflozin arm, participants with functional mitral regurgitation of more than moderate and left ventricular ejection fraction of more than 40% will add oral drug of Forxiga (Dapagliflozin, specification: 10mg) of 10 mg per day on the basis of regular guideline directed medical therapy for functional mitral regurgitation for 6 months.
89291331|NCT05848102|No Intervention|GDMT arm|In the guideline directed medical therapy (GDMT) arm, participants with functional mitral regurgitation of more than moderate and left ventricular ejection fraction of more than 40% will continue to maintain the original treatment of GDMT for 6 month.
89291332|NCT05848037|Experimental|cymactive catheter device arm|All participants will receive background local standard of care therapy according to participating institutions/hospitals regardless of the study group to which they belong. 60 participants will be recruited to this study. 30 patients in the CCD arm and 30 patients in the FTD.
89291333|NCT05848037|Active Comparator|Foley-type device arm|All participants will receive background local standard of care therapy according to participating institutions/hospitals regardless of the study group to which they belong. 60 participants will be recruited to this study. 30 patients in the CCD arm and 30 patients in the FTD.
89291334|NCT05847972|Experimental|Experimental Group|A will undergo MWM and have their moulds taken in phenolic foam immediately after the musculoskeletal manipulation.
89291335|NCT05847972|Placebo Comparator|Control Group|Participants will undergo MWM and moulds will be taken one week after the musculoskeletal manipulation.
89291336|NCT05847959|Active Comparator|intervention group|The intervention group will receive not only Western medicine, but also XK-I. The therapeutic drugs used in the control group will be according to the European Society of Cardiology's 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure.
89291337|NCT05847959|No Intervention|The control group|The control group will receive Western medicine.The therapeutic drugs used in the control group will be according to the European Society of Cardiology's 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure.
89291338|NCT05847907|Experimental|BA Surface test group|"Common procedures: Implants placement in subjects with type 2 diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation.~Test procedure: use of implant with BA surface in type 2 diabetic patients."
89291339|NCT05847907|Active Comparator|SA Surface control group|Common procedures: Implants placement in subjects with type 2 diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. Control procedure: use implant with SA surface in type 2 diabetic patients
89291340|NCT05847868|Experimental|Device Feasibility|Device feasibility will be performed in this single arm study.
89291341|NCT05847855||pNETs|Patients with pancreatic neuroendocrine tumors (pNETs).
89291342|NCT05847855||Healthy|Healthy volunteers.
89291343|NCT05847842|Active Comparator|Group Q|Anterior quadratus lumborum block
89291344|NCT05847842|Active Comparator|Group T|Transversus abdominis plane block
89291345|NCT05847842|Active Comparator|Group L|Local infiltration
89291346|NCT05847816|Experimental|Experimental group: infrared vascular imaging|The patient's vital signs, skin color and skin turgor will be evaluated and recorded in the peripheral intravenous chemotherapy application registration form. After the tourniquet is attached, the stopwatch will be started and the catheter intervention process will be started when the vein visibility reaches the level where the nurse can insert the catheter. The stopwatch will be terminated at the stage of advancing the branule into the vein and fixing it with a plaster. If the catheterization application is successful or unsuccessful in the first attempt, it will be recorded. The pain and arm comfort levels in the form will be evaluated on a scale ranging from 0 to 10, with 0: none, 10: many, before and after the application (at the 5th, 30th, and 60th minutes).
89291347|NCT05847816|Experimental|Experimental group: isometric hand exercise|The patients to be included in this group will have applied isometric hand squeeze exercise, which lasted for twenty minutes a day, five days a week, before the PIVK procedure. On the fifth day, the patient's vital signs, skin color and skin turgor will be evaluated and recorded in the peripheral intravenous chemotherapy application registration form. Patients will be told how to use the stress ball 5 minutes before and during the PIVK procedure before the procedure. Patients will be taught to count from one to three and tighten and loosen the stress ball once, and they will be told to continue squeezing and loosening the stress ball in this way until the procedure is over. Focus their attention on the stress ball during the procedure.
89291348|NCT05847816|No Intervention|Control group: no intervention|The patient's vital signs, skin color and skin turgor will be evaluated and recorded in the peripheral intravenous chemotherapy application registration form. After the tourniquet is attached, the stop watch will be started and the catheter intervention process will be started when the vein visibility reaches the level where the nurse can insert the catheter. If the PIVC application is successful or unsuccessful in the first attempt, it will be recorded. PIC success will be evaluated according to whether the branule is placed in the vein. The pain and arm comfort levels in the form will be evaluated on a scale ranging from 0 to 10, with 0: none, 10: many, before and after the application (at the 5th, 30th, and 60th minutes).
89291349|NCT05847764|Experimental|Arm 1: RC48+PD-1/PD-L1 inhibitor|
89291350|NCT05847764|Experimental|Arm 2: RC48+Furmonertinib, 1L|
89291351|NCT05847764|Experimental|Arm 3: RC48+Furmonertinib, 2L+|
89291352|NCT05847738||Group A: (left side of the patient|prepared 2 sizes larger than the IBF, to size 35#/.04 mesial canals and 40#/.04 distal canals.
89291353|NCT05847738||Group B (right side of the patient|prepared 3 sizes larger than the IBF, to size 40#/.04 mesial canals and 45#/.04 distal canals.
89291354|NCT05846685||ED Patients Scheduled and Completed Falls Clinic Visit|Patients age 65 and Older identified by the automated system as being high-risk of future falls, and subsequently referred to the UW Health Mobility and Falls Clinic by the ED provider at discharge
89291355|NCT05846685||ED Patients Declined or Did Not Complete Falls Clinic Visit|Patients age 65 and Older identified by the automated system as being high-risk of future falls, and subsequently referred to the UW Health Mobility and Falls Clinic by the ED provider at discharge
89291356|NCT05846685||ED Patients Likely to be Discharged|Patients aged 65 and older who are in the emergency department and likely to be discharged.
89291357|NCT05846607|Experimental|experiment|"The data will be collected in two phases. Firstly, after a fasting period of eight hours, the participants received ultrasound scan by expert doctor with the objective of measuring the fasting gastric antrum area in supine and right lateral decubitus(RLD)position(phase 1).Then the expert made the grading according to the ultrasound image.~In phase 2, the participant will ingest 0 to 400ml of the study drink described below randomly. The individual will be immediately positioned in the supine position and another ultrasound scan will be carried out. Again in the RLD position."
89291358|NCT05846555||general anesthesia|patients observed under general anesthesia
89291359|NCT05846555||spinal anesthesia|patients observed under spinal anesthesia
89291360|NCT05846503|Other|Intervention|Cluster of clinics receiving the five investigational interventions
89291361|NCT05846503|No Intervention|Control|Standard of care
89291362|NCT05846490|Experimental|Continuous positive airway pressure (CPAP)|Standard OSA treatment + BP adjustments with anti-hypertensive therapy
89291363|NCT05846490|Active Comparator|Usual Care|BP adjustments with anti-hypertensive therapy
89291364|NCT05846477||MySpine MC|spinal stabilization via cortical bone trajectory with the support of patient specific guide (MySpine MC technology)
89291365|NCT05846477||MySpine STD|spinal stabilization via standard pedicle screw positioning with the support of patient specific guide (MySpine std technology)
89291366|NCT05846464|Experimental|Virtual Reality to Enhance Upper Extremity Physical Therapy and Recovery|This is a descriptive study assessing the feasibility of using VR rehabilitation with unilateral (or bilateral) impairment of the arm, wrist, and or hand resulting in reduced range of motion, dexterity, and/or strength of the hand. Phase I: Typical Home Exercise Program, Phase II: Use of VR headset in conjunction with current Home Exercise Program. Intervention sessions include the baseline, midpoint and final visits.
89291367|NCT05846438|Experimental|Showering 48 hours after Surgery|Group 1 will be allowed to shower 48 hours after surgery with drain tubes still in place.
89291368|NCT05846438|No Intervention|Showering after drain tubes are removed|Group 2 will not be allowed to shower until drain tubes are removed.
89291369|NCT05846412|Experimental|Rhythm Control by Catheter Ablation:|Patients randomized to rhythm control with CA will undergo CA of AF.
89291370|NCT05846412|Active Comparator|M-TEER (Control):|Patients randomized to the M-TEER group will undergo M-TEER with the MitraClip or PASCAL device to reduce FMR severity.
89291371|NCT05846386|Experimental|Aerobic and resistance training|aerobic exercises (intervention) on arm ergometer and resistance training using weights for post valve replacement surgery patients for 4 weeks, 3 times/week for the duration of 45-70 min/ session.
89291372|NCT05846386|Active Comparator|Aerobic training|aerobic exercises (intervention) on arm ergometer for post valve replacement surgery patients for 4 weeks, 3 times/week for the duration of 30-55 min/ session.
89291373|NCT05846373|Active Comparator|Nicotinic Acid Extended-release tablet 500 mg arm|This arm includes 22 Migraine patients receiving beta blocker
89291374|NCT05846373|Active Comparator|Nicotinic Acid Extended-release tablet 1000 mg arm|This arm includes 22 Migraine patients receiving beta blocker
89291375|NCT05846373|Placebo Comparator|Control arm|This arm includes 22 Migraine patients receiving beta blocker
89291376|NCT05846334|Experimental|Intervention group|
89291377|NCT05846334|No Intervention|Control group|
89291378|NCT05846282|Experimental|STRIVE|Based on the Learning to BREATHE (L2B) curriculum (Broderick, 2013), the STRIVE intervention is a mindfulness-based program designed to facilitate the development of emotion regulation for middle to high school students. Goals of the program include helping students understand their thoughts and feelings, learning how to use mindfulness-based skills to manage emotions, and providing opportunities for guided group mindfulness meditation practice. Delivered in twelve 60-minute group sessions, the intervention will be include the core components of the L2B program (i.e. body awareness; understanding and working with thoughts; understanding and working with feelings; integrating awareness of thoughts, feelings, and bodily sensations; reducing harmful self-judgments, and integrating mindful awareness into daily life) with content framed around the needs of high achieving, college-bound BIPOC students with the goal of offsetting the costs of resilience.
89291379|NCT05846282|Placebo Comparator|Study Skills|The attention control condition will incorporate face-valid content to support college readiness and achievement in twelve 60- minute group sessions. Twelve sessions will cover the SOAR study skills curriculum (Kruger, 2017), including goal-setting, organization and time-management, and study skills for reading comprehension, writing papers, note-taking, and test-taking.
89291380|NCT05846269||2023 Clinical Cohort|Students in the Doctor of Nursing Practice (DNP) nurse practitioner specialties and certificate programs in the clinical year of their programs during 2023.
89291381|NCT05846256||Infertile male|Men with unexplained infertility
89291382|NCT05846256||Donors (control)|Fertile sperm donors
89291383|NCT05846243|Experimental|Group 1 (The first stage): VAC∆6 (10⁷ PFU), Live Smallpox Vaccine (2 months after the vaccination)|"15 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal VAC∆6 dose of 1x10⁷ PFU/0.2ml. Live smallpox vaccine was administered by scarification 2 months after the vaccination.~(The first stage is an open comparative study of the safety, reactogenicity, immunological activity and protective efficacy of VAC∆6 vaccine in two parallel groups)."
89291384|NCT05846243|Experimental|Group 2 (The first stage): VAC∆6 (10⁶ PFU), Live Smallpox Vaccine (1 month after the vaccination)|"15 volunteers aged 18 to 60 who met the inclusion criteria and who received two intradermal VAC∆6 doses of 10⁶ PFU/0.2ml (given 28 days apart). Live smallpox vaccine was administered by scarification one month after the full vaccination series.~(The first stage is an open comparative study of the safety, reactogenicity, immunological activity and protective efficacy of VAC∆6 vaccine in two parallel groups)."
89291385|NCT05846243|Experimental|Group 3 (The second stage): two intradermal VAC∆6 (10⁶ PFU/0.2 ml) given 28 days apart.|"76 volunteers aged 18 to 60 who met the inclusion criteria and who received two intradermal VAC∆6 doses of 10⁶ PFU/0.2 ml (given 28 days apart).~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
89291386|NCT05846243|Placebo Comparator|Group 4 (The second stage): two intradermal placebo doses of 0.2 ml (given 28 days apart).|"76 volunteers aged 18 to 60 who met the inclusion criteria and who received two intradermal placebo doses of 0.2 ml (given 28 days apart).~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
89291387|NCT05846243|Experimental|Group 5 (The second stage) in the FGBUZ MSCH-163: a single intradermal VAC∆6 (10⁷ PFU/0.2 ml).|"60 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal VAC∆6 dose of 10⁷ PFU/0.2 ml.~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
89291388|NCT05846243|Placebo Comparator|Group 6 (The second stage) in the FGBUZ MSCH-163: a single intradermal placebo dose of 0.2 ml.|"60 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal placebo dose of 0.2 ml.~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
89291389|NCT05846243|Experimental|Group 7 (The second stage) in the Hospital No. 1: a single intradermal VAC∆6 (10⁷ PFU/0.2 ml).|"16 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal VAC∆6 dose of 10⁷ PFU/0.2 ml.~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
89291390|NCT05846243|Placebo Comparator|Group 8 (The second stage): in the Hospital No. 1: a single intradermal placebo dose of 0.2 ml.|"16 volunteers aged 18 to 60 who met the inclusion criteria and who received a single intradermal placebo dose of 0.2 ml.~(The second stage is a Double-blind, Comparative, Randomized, Placebo-controlled study on Immunogenicity, Reactogenicity, and Safety of the VAC∆6 Vaccine in Parallel Groups)."
89291391|NCT05846217|Experimental|PBMT Group|"In PBMT group, we choose 9 points on the affected face, include Mastoid, Preauricular, Temple, Frontalis muscle, Zygomatic muscle, Buccinator muscle, Masseter, Orbicularis oris and Depressor angulli oris. Based on clinical experience, we choose 7 acupoints, including LI4 (HeGu), LI11(QuChi), ST25 (TianShu), ST36 (ZuSanLi), SP6 (SanYinJiao), KI3 (TaiXi), LR3 (TaiChong). All the acupoint were applied bilaterally.~Laser divice directly contacts the points. All those points near the superficial roots of facial nerve. At each point, we treated for 1min, 1500 Hz, 50% laser intensity. And patients in PBMT group wore safety glasses to prevent eye damage during the laser sessions. All treatments were performed in the outpatient clinic by the same physician."
89291392|NCT05846217|Sham Comparator|Control Group|Patients in the control group received no intervention but were free to pursue therapies if desired.
89291393|NCT05846191|Other|serum pentraxin 3 and high sensitive CRP|female with gestational diabetes mellitus in 2nd trimester
89291394|NCT05846165|Experimental|Bladder tumours|Participants with muscle-invasive and non-muscle invasive bladder tumours of at least 3 cm in diameter will undergo one FCI scan.
89291395|NCT05846152|Experimental|WoundCare medical device|Unique arm. The patients undergo all interventions planned in the study.
89291396|NCT05846139|Experimental|PerioTabs® brushing solution|At baseline, patients were given instructions for the home use of PerioTabs® for daily gum and toothbrushing for 10 consecutive days, according to the product's directions for use. The procedure consisted of brushing the teeth and gums for 2 minutes in the evening during a 10-day period. After one week, one-stage full-mouth disinfection was performed with the use of ultrasonic devices on each quadrant. In addition, two cycles of 90 seconds ozone-therapy were carried out.
89291397|NCT05846139|Active Comparator|Chlorhexidine 0.2% mouth rinse|At baseline, patients were given instructions for the home use of toothbrush with chlorhexidine 0.12 % toothpaste for 15 days toothbrushing twice daily (morning and evening). Also, a chlorhexidine 0.2% mouth rinse had to be used every evening for the course of the 15 days. After two weeks, the one-stage full-mouth disinfection was performed in the same way as in Group 1.
89291398|NCT05846100|Placebo Comparator|standard group|Fictional ultrasound identification Screen device shut down Intervertebral space identified using the standard palpation
89291399|NCT05846100|Active Comparator|ultrasound group|pre-puncture ultrasound-guided neuraxial anesthesia group
89291400|NCT05846061||Prevalence study population|prevalence study population
89291401|NCT05845983|Placebo Comparator|Control group|The patient received conventional treatment and Maltodextrin treatment (placebo) for three months after surgery.
89291402|NCT05845983|Experimental|LA treatment group|The patient received conventional treatment and Lactobacillus acidophilus treatment for three months after surgery.
89291403|NCT05845957|Experimental|Digital Education Group|"All participants in this group were given the Safe pediatric intravenous drug administration knowledge test prepared by the researchers as a pre-test.~The participants of this group, who were determined by randomization, were given training prepared using the digital storytelling method. The training took 25 minutes.~After the training, the Safe intravenous drug administration knowledge test was applied as a post-test."
89291404|NCT05845957|No Intervention|Control Group|"No intervention was made. All participants in this group were given the Safe pediatric intravenous drug administration knowledge test prepared by the researchers as a pre-test.~Afterward, theoretical information on the subject was given. After theoretical information, the Safe intravenous drug administration knowledge test was applied as a post-test."
89291405|NCT05845944|Experimental|Video-supported education group|"All participants in this group were given the Knowledge Test on Nasogastric Tube Feeding in Pediatric Patients prepared by the researchers as a pre-test.~The participants of this group, who were determined by randomization, were given education prepared using the video-supported education method. The education took 35 minutes. After the training, the Knowledge Test on Nasogastric Tube Feeding in Pediatric Patients was applied as a post-test."
89291406|NCT05845944|No Intervention|Control Group|"No intervention was made. All participants in this group were given the Knowledge Test on Nasogastric Tube Feeding in Pediatric Patients prepared by the researchers as a pre-test.~Afterward, theoretical information on the subject was given. After theoretical information, the Knowledge Test on Nasogastric Tube Feeding in Pediatric Patients was applied as a post-test."
89291407|NCT05845892|Experimental|Intervention|"Patients will be given written and oral consent by explaining the purpose of the study. Patients with fistula and non-grafted arms will be asked to fill out data collection forms at the first interview. Patients will then be asked to squeeze the stress ball 15 minutes before the start of hemodialysis treatment and for 15 minutes during hemodialysis treatment. This treatment will be performed during (nine) hemodialysis treatments. After the last session, data collection forms will be filled out again.~Use of stress Ball~1) place a stress ball in one hand (which hand will be left to the patients' wishes.) 2.squeeze the ball in your hand for 2-3 seconds after receiving it and then loosen it.~3.perform this application for a total of 30 minutes before and during hemodialysis treatment."
89291408|NCT05845892|No Intervention|Control|"No intervention will be given to the control group other than standard treatment. Data collection forms will be completed before the first dialysis session and after the eighth session.~Before the first dialysis session and after the ninth session, the individual Introduction form, the Visual Analog scale (VAS) for stress level, the Beck anxiety scale and the hemodialysis comfort scale will be filled out."
89291409|NCT05845853|Experimental|interventinal group|28 subject will receive a program of scapular motor control exercises using PNF technique in addition to the conventional treatment for 18 sessions (3 sessions per week for six weeks)
89291410|NCT05845853|No Intervention|control group|28 subject will receive conventional physical therapy program (heat-TENS) for 18 sessions (3 sessions per week for six weeks)
89291411|NCT05845723|Experimental|Tocilizumab+GCS for VBS|Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
89291412|NCT05845723|Experimental|Tofacitinib+GCS for VBS|Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with oral tofacitinib 5mg twice a day for 24 weeks of treatment.
89291413|NCT05845723|Experimental|Cyclophosphamide+GCS for VBS|Participants randomized to this arm will receive prednisone 1mg/kg/d, gradually tapered to 10mg/d at week 12, combined with intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
89291414|NCT05845606|Experimental|CBT + BZ-TP|Participants in this condition will receive telehealth-delivered Cognitive Behavioral Therapy (CBT) in addition to the benzodiazepine taper (BZ-TP) treatment.
89291415|NCT05845606|Active Comparator|HE + BZ-TP|Participants in this condition will receive telehealth-delivered health education in addition to the benzodiazepine taper (BZ-TP) treatment.
89291416|NCT05845528|Placebo Comparator|Respondres placebo effect|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~The patients will receive tDCS stimulation treatment prefrontal cortex dorso lateral~According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.~Placebo stimulation uses a 2 milliamperes current during in the first minutes, in the 10 min and in 19 minutes."
89291417|NCT05845528|Active Comparator|No respondres placebo effect|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~The patients will receive tDCS stimulation treatment prefrontal cortex dorso lateral~According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.~Active stimulation uses a 2 milliamperes current during 20 minutes."
89291418|NCT05845515|Active Comparator|laparoscopic orchiopexy|laparoscopic orchiopexy group
89291419|NCT05845515|Active Comparator|open orchiopexy|open orchiopexy group
89291420|NCT05845502|Experimental|SZ003 CAR-NK|
89291421|NCT05845463|Experimental|Endoscopists with AI feedback|This will be the group of endoscopists who will have AI feedback during the endoscopy
88819282|NCT01546454|Experimental|Contraceptive effects|Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.
89291422|NCT05845463|Active Comparator|Endoscopists without AI feedback|This will be the group of endoscopists without AI feedback during the endoscopy to assess their baseline site detection rate. Both arms will cross over to see if AI improves endoscopy quality and if its removal decreases quality.
89291423|NCT05845424|Experimental|Aggressive treatment arm|In this group, high-intensity statin (rosuvastatin 20mg) combined with ezetimibe 10 mg will be prescribed regardless of patients' age, concomitant diabetes mellitus, or ASCVD risk.
89291424|NCT05845424|Active Comparator|Standard treatment arm|In this group, lipid lowering therapy will be followed according to the current guideline recommendation. A moderate-intensity statin (rosuvastatin 5 mg) will be prescribed for patients over 75 years of age or with diabetes mellitus. For non-diabetic patients aged 40-75 years, the use of statins will be determined by calculating the ASCVD risk score. (ASCVD risk <7.5%: no statin use, ≥7.5 - <20%: moderate-intensity statin [rosuvastatin 5mg], ≥ 20%: high-intensity statin [rosuvastatin 20mg])
89291425|NCT05845411|Experimental|Intervention|A group of 30 people will participate in 8 fortnightly virtual group sessions for 4 months, where the subject of Mindful Eating will be addressed. Participants will be encouraged to share their eating experiences, reflect and discuss the above, and engage in formal and non-formal mindfulness eating practices (meditation, eating slowly, observing thoughts, and being present at meal times) between sessions.
89291426|NCT05845411|Active Comparator|Control|A group of 30 people will have 8 fortnightly, virtual, and individual consultations for 4 months. They will receive a hypocaloric diet (reduction of approximately 500kcal per day in total energy expenditure) and food and nutrition education. The food plan will be monitored in each meeting, and a theme of food and nutrition education will be worked on, based on the Food Guide for the Brazilian Population, through expository content. A virtual folder of all subjects taught will be provided.
89291427|NCT05845385|Active Comparator|lumbar epidural analgesia|For postoperative analgesia; Lumbar epidural catheter inserted at L3-4 or L4-5 epidural space before anesthesia induction in the sitting position. After the end of surgery but approximately 20 minutes before extubation, 0.125% bupivacaine 20 ml administered through epidural catheter and the catheter was removed.
89291428|NCT05845385|Active Comparator|transversus abdominis plane block|For postoperative analgesia; After the end of surgery but before extubation, USD-guided TAP block was performed with 0.125% bupivacaine 20 ml to the anatomic neurofacial space between the internal oblique and transersus abdominis muscles, bilaterally (10 ml for each side).
89291429|NCT05845385|Active Comparator|wound infiltration|For postoperative analgesia; After the end of surgery but before extubation, 0.125% bupivacaine 20 ml administered to the surgical incision site.
89291430|NCT05845372||Stress Ulcer Prophylaxis|Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.
89291431|NCT05845372||Control Group|Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.
89291432|NCT05845346|Experimental|Group TENS|Experimental group 1 will undergo a physiotherapy treatment based on TENS-type analgesic currents and application of massage therapy for neck pain.
89291433|NCT05845346|Experimental|Group STRECHING|Experimental group 2 will undergo a physiotherapy treatment based on stretching and the application of massage therapy therapy for neck pain.
89291434|NCT05845346|No Intervention|Control Group|The control group will not undergo any physiotherapy treatment therapy for neck pain.
89291435|NCT05845294|Active Comparator|Control group|
89291436|NCT05845294|Experimental|Experimental group|
89291437|NCT05845268|Experimental|CRT+concurrent PD-1 inhibition|Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 8 of radiation therapy. TME surgery is scheduled in 10~13 weeks after completion of radiation.
89291438|NCT05845268|Active Comparator|CRT without PD-1 inhibition|Long-course chemoradiation plus PD-1 inhibition with no PD-1 inhibition. TME surgery is scheduled in 10~13 weeks after completion of radiation.
89291439|NCT05845242||Risk 0|Very low ulcer risk: No LOPS (loss of peripheral sensation) and No PAD (peripheral arterial disease)
89291440|NCT05845242||Risk 1|Low ulcer risk: LOPS or PAD
89291441|NCT05845242||Risk 2|Moderate ulcer risk: LOPS + PAD, or LOPS + foot deformity or PAD + foot deformity
89291442|NCT05845242||Risk 3|"High ulcer risk: LOPS or PAD, and one or more of the following:~history of a foot ulcer~a lower-extremity amputation (minor or major)~end-stage renal disease"
89291443|NCT05845229|Experimental|High-N-acylethanolamines meal|Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).
89291444|NCT05845229|Active Comparator|Low-N-acylethanolamines meal|Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
89291445|NCT05845203|Experimental|transcranial doppler and pulsatility measurements|"PATIENT and HEALTHY VOLUNTEERS:~The intervention consists of:~- perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere, and The ultrasound system used will be: ArtUS ultrasound system (Telemed, Vilnius, Lithuania), with transcranial probe P5-1S15-A6.~Two identical devices (ultrasound + probe) will be used, each scanning a cerebral hemisphere. They each carry the CE mark and will be used in accordance with the CE mark. https://www.pcultrasound.com/products/products_artus/"
89291446|NCT05845190|Experimental|aerobic exercises group (group A )|"20 male patients with diabetes mellites Attended the program of walking on treadmill for 12 weeks according to the following parameters.~Exercise prescription:~Intensity: started by 60-75% of target heart rate according to each patient response.~Duration: Each session consisted of five minutes warming up firstly then 25-30 minutes time of session ended by five minutes cool down exercises Frequency: Three times / week (day after day) for 12 weeks"
89291447|NCT05845190|Experimental|resistance exercises group (group B)|"20 male patients with diabetes mellites will participate in resistance training exercises 30-45 mins. The subject will warm up and cool down for at least five to seven minutes each, (before and after exercise) with initial load of 60% of 1 repetition maximum.~This program consists of 3 sets of 8 to 12 repetitions, then increasing load when subject was able to complete 12 repetitions. A rest period of 1.5 min was established between each set.~Mode: 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 leg exercises (leg press, extension, and flexion), abdominal crunches and back extensions. with the individualized workloads at 60% of 1RM.~Duration: 30 min-45 min (total session). Frequency: Three times / week (day after day). Intensity: increased load was established when subject was able to complete 12 repetitions."
89291448|NCT05845164|Experimental|Treatment|"The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory.~In order to help minimize the stinging feel of the treatment, we have chosen to ramp up time and frequency. For visits 2-6 (tDCS treatment visits), we will start with 0.5mA ramping up to 0.75mA for 5 minutes. Followed by a brief (8 sec) EEG recording. Then, we will apply 0.75mA to 1mA while watching the ACT video for 5 minutes. This will also be followed by 8 second EEG recording. The final application of current will be 1.0mA to 1.75mA for 10 minutes followed again by 8 second EEG recording."
89291449|NCT05845164|Sham Comparator|Sham|"The sham group will receive ramped up current from 0.0mA not to exceed 0.5mA for the first minute at the initiation of each of the three ramp-ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons."
89291450|NCT05845151|Experimental|LN Patients group|
89291451|NCT05845125|Active Comparator|Physiotherapy alone|"Physiotherapy alone after diagnosis of hemiplegic shoulder pain with a capsular pattern. The physiotherapy will focus on stretching and range of motion of the shoulder.~(This is a self-controlled study. The participants' clinical evolution with physiotherapy alone will be compared to their evolution after physiotherapy coupled with the injection.)"
89291452|NCT05845125|Experimental|Physiotherapy with mild arthrographic distension|"Physiotherapy continues after the participant receives a mild arthrographic distension with corticosteroid of the shoulder.~(This is a self-controlled study. The participants' clinical evolution with physiotherapy alone will be compared to their evolution after physiotherapy coupled with the injection.)"
89291453|NCT05845112||Cameroon: Primary healthcare clinics|Country with a high burden of HIV associated TB with recruitment to the study occurring at the PHC.
89291454|NCT05845112||Cameroon: District Hospital|Country with a high burden of HIV associated TB with recruitment to the study occurring at the District Hospital.
89291455|NCT05845112||Cameroon: Informal settlements/rural poor active case finding (ACF)|Country with a high burden of HIV associated TB with recruitment to the study occurring through ACF in rural areas and informal settlements.
89291456|NCT05845112||Cameroon: children|Country with a high burden of HIV associated TB with recruitment to the study occurring only in children, an under represented cohort in TB studies.
89291457|NCT05845112||Nigeria: Primary healthcare clinics|Country with a high burden of drug resistant TB infections with recruitment to the study occurring at the PHC.
89291458|NCT05845112||Nigeria: District Hospitals|Country with a high burden of drug resistant TB infections with recruitment to the study occurring at the District Hospital.
89291459|NCT05845112||Nigeria: Nomads|Country with a high burden of drug resistant TB infections with recruitment to the study occurring through ACF targeting Nomad populations.
89291460|NCT05845112||Nigeria: Internally displaced people (IDP)/refugees|Country with a high burden of drug resistant TB infections with recruitment to the study occurring through ACF targeting Internally displaced people (IDP)/refugees.
89291461|NCT05845112||Kenya: Primary healthcare clinics|Country with a high burden of HIV associated TB with recruitment to the study occurring at the PHC.
89291462|NCT05845112||Kenya: District Hospital|Country with a high burden of HIV associated TB with recruitment to the study occurring at the District Hospital.
89291463|NCT05845112||Bangladesh: Primary healthcare clinics|Country with a high TB burden in the general population with recruitment to the study occurring at the PHC.
89291464|NCT05845112||Bangladesh: District Hospitals|Country with a high TB burden in the general population with recruitment to the study occurring at the District Hospital.
89291465|NCT05845112||Bangladesh: Informal settlements active case finding|Country with a high TB burden in the general population with recruitment to the study through active case finding targeting informal settlements.
89291466|NCT05845112||Brazil: Primary healthcare clinics Aracaju|Country with a high burden of HIV associated TB with recruitment to the study occurring at the Primary healthcare clinics in Aracaju.
89291467|NCT05845112||Brazil: Primary healthcare clinics Maceio|Country with a high burden of HIV associated TB with recruitment to the study occurring at the Primary healthcare clinics in Maceio.
89291468|NCT05845112||Viet Nam: Primary healthcare clinics|Country with a high burden of drug resistant TB infections with recruitment to the study occurring at Primary healthcare clinics.
89291469|NCT05845112||Viet Nam: Informal settlements active case finding|Country with a high burden of drug resistant TB infections with recruitment to the study occurring through ACF targeting informal settlements.
89291470|NCT05845112||Viet Nam: Children|Country with a high burden of drug resistant TB infections with recruitment to the study occurring only in children, an under represented cohort in TB studies.
89291471|NCT05845112||Malawi: Primary healthcare clinics|Country with a high burden of HIV associated TB with recruitment to the study occurring at the Primary healthcare clinics in Blantyre, Malawi.
88821041|NCT05249465|Experimental|Condition 8|Core + Track Weight + Track Steps + Track Diet
88821042|NCT05248984||Ketorolac 30 mg|Participants will receive single dose of intravenous (IV) Ketorolac 30mg
88821043|NCT05248984||Ketorolac 60 mg|Participants will receive single dose of intravenous (IV) Ketorolac 60mg
88821044|NCT05248230|Experimental|4D-710 Dose Exploration Cohort 1|Single inhalational administration of 4D-710 Dose 1
88821045|NCT05248230|Experimental|4D-710 Dose Exploration Cohort 2|Single inhalational administration of 4D-710 Dose 2
88821046|NCT05248230|Experimental|4D-710 Dose Exploration Cohort 3|Single inhalational administration of 4D-710 Dose 3
88821047|NCT05248230|Experimental|4D-710 Dose Exploration Cohort 4|Single inhalational administration of 4D-710 Dose 4
88821048|NCT05248230|Experimental|4D-710 Dose Expansion Cohort|Single inhalational administration of 4D-710 at the selected dose
89291472|NCT05845034|Experimental|With additional SPEs ablation|Patients who undergo PVI + SPEs ablation using ThermoCool SmartTouch catheter.
89291473|NCT05845034|Active Comparator|Control Group|Patients who undergo PVI alone using ThermoCool SmartTouch catheter.
89291474|NCT05844930|Active Comparator|Intra-articular Injection of Corticosteroid Plus Lidocaine|Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc).
89291475|NCT05844930|Experimental|Intra-articular Injection of ActiveMatrix Plus Lidocaine|Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc).
89291476|NCT05844917|Experimental|50 character|
89291477|NCT05844800|Experimental|Pectus Excavatum|Patients included in the study after preoperative examination underwent the Nuss surgery procedure - a minimally-invasive repair technique of Pectus Excavatum (MIRPE)
89291478|NCT05844800|No Intervention|Healthy Control|Healthy control group with no posture defects
89291479|NCT05844787|Experimental|SAD Phase|"SAD Phase: including Food Interaction - Blinding and Randomization: This is a randomized, double-blind, placebo-controlled, sentinel design, dose-escalating study with 40 healthy volunteers. Subjects will be assigned to 1 of up to 5 cohorts and will be randomized within each cohort to MT101-5 or placebo, as follows:~cohort 1: 100 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)~cohort 2: 150 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)~cohort 3: 300 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)~cohort 4: 450 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)~cohort 5: 600 mg (8 subjects total; 6 receiving MT101-5, 2 receiving placebo)"
89291480|NCT05844787|Experimental|Food Interaction Phase|Food Interaction Phase: Following the completion of the SAD phase, if study stopping criteria (SSC) is not met, then subjects in cohort 5 will cross-over to the fed part of the study following a 7 day washout period. If SSC is achieved in the SAD phase, then the previous dose will be in the Food Interaction phase.
89291481|NCT05844787|Experimental|MAD Phase|MAD Phase; Blinding and Randomization: This is a randomized, double-blind, placebo-controlled study in approximately 8 elderly healthy volunteers. If study stopping criteria (SSC) is not met in the SAD phase, then subjects will be assigned to the cohort 5 dose. If SSC is achieved in the SAD phase, then the previous dose will be used as the cohort in the MAD phase
89291482|NCT05844774|Experimental|HPI-intervention algorithm|In the intervention group the HemoSphere screen is visible and the anesthesiologist and PACU personal are instructed to follow the algorithm (chapter 4) in case of a HPI >85%. The purpose of the alarm at 85% and the presented algorithm is to prevent hypotension. If hypotension occurs, it should be treated as according to the standard of care.
89291483|NCT05844774|Other|Control group|Patients in the control group are connected to the HemoSphere monitor to evaluate the TWA of hypotension in this group. The screen is not visible to the anesthesiologist or PACU personal and the alarm is set silent. It will be explained to the anesthesiologist and PACU personal that the patients are included to this study and that a blood pressure with a MAP of 65 mmHg should be monitored.
89291484|NCT05844748|Experimental|diabetes education with motivational interview technique|A face-to-face motivational interview session was applied to each participant in the experimental (intervention) group by the researcher once a week in the 1st month and once in 15 days in the 2nd month. The interviews were held in 6 sessions in total, and each interview was completed in approximately 45-60 minutes.
89291485|NCT05844722|Experimental|MBCT group|The intervention group were involved in MBCT intervention in addition to usual care. MBCT intervention was designed to consist of eight 1.5-hour group sessions over 6 consecutive weeks.
89291486|NCT05844722|Active Comparator|Control group|Received usual care (standard multidisciplinary stroke care) over 6 weeks.
89291487|NCT05844709||Control group|The infants will be divided into 200 in the control group. Eligible hospitalized preterm infants that met the inclusion criteria from January 2017 to December 2019 were selected for the control group by retrospective cohort.
89291488|NCT05844709||Experimental group|The infants will be divided into 30 in the experimental group.
89291489|NCT05844683|Experimental|Chlorhexidine Bath|All patients in the randomized to the intervention arm will receive baths using a 2% chlorhexidine digluconate solution
89291490|NCT05844683|Active Comparator|usual bath|All patients in the randomized to the intervention arm will receive baths using soap and water according to the current practice
89291491|NCT05844670|Experimental|Vincristine|A dose advice for vincristine will be given based on vincristine concentrations in blood samples and toxicity monitoring.
89291492|NCT05844605|Experimental|Prehabilitation|Adult patients affected by Brain Tumour and candidated for surgical treatment.
89291493|NCT05844592|Placebo Comparator|A|Dose A
89291494|NCT05844592|Placebo Comparator|B|Dose B
89291495|NCT05844592|Placebo Comparator|C|Dose C
89291496|NCT05844592|Placebo Comparator|D|Dose D
89291497|NCT05844592|Placebo Comparator|E|Dose E
89291498|NCT05844553||Exhaled breath measurement|Patient inhales from device
89291499|NCT05844540|Other|harvesting and augmentation of bone block|autogenous bone block was harvested from the symphysis, trimmed to L-shape and used to augment the anterior maxilla or mandible horizontally and vertically.
89291500|NCT05844514||Control group - 470 patients|Symptomatic patients who are attending for a planned colonoscopy referred under the two-week wait pathway. Any patients who is found to have histology proven CRC on colonoscopy will be analysed as part of the CRC group.
89291501|NCT05844514||CRC group - 250 patients|Patients who are scheduled to undergo elective resection of histologically confirmed colorectal adenocarcinoma.
89291502|NCT05844488||Blood based biomarker group|Subjects who consent to having a blood based biomarker performed
89291503|NCT05844397|Active Comparator|LASIK using Contoura with Phorcides|LASIK using Contoura with Phorcides in one eye.
89291504|NCT05844397|Active Comparator|SMILE|small incision lenticule extraction (SMILE) refractive surgery on the contralateral eye.
89291505|NCT05844384|Experimental|Nanodroper|"Patients are given a Nanodropper to use with their IOP-lowering eyedrops.~Patient returns for a safety check 1 month following the start of Nanodropper use.~At 3 months, the patient returns for clinical assessment and starts using IOP-lowering eyedrops without Nanodropper for 3 months.~The patient returns at 6 months for final clinical assessment"
89291506|NCT05844384|Active Comparator|Regular Dropper|"Patient continues using current IOP-lowering eyedrops without Nanodropper adaptor.~At 3 months, the patient returns for clinical assessment and starts using IOP-lowering eyedrops with Nanodropper for 3 months.~Patient returns for a safety check 1 month following the start of Nanodropper use.~The patient returns at 6 months for final clinical assessment"
89291507|NCT05844371|Experimental|study group|chemotherapy with oxaliplatin + heroda regimen (oxaliplatin 130mg / m2 D1, heroda tablets 1000mg / m2 bid d1-14, 21d repeated), during which tirelizumab (200mg, q3w) was used. After 6 cycles of chemotherapy, monotherapy with tirelizumab (200 mg, q3w) was maintained until 1 year.
89291508|NCT05844371|Active Comparator|Control group|6 cycles of oxaliplatin + heroda regimen chemotherapy.
89291509|NCT05844319|Experimental|intervention|"Following the completion of the evaluations of the cases, the following 6-step program will be applied to cope with the pain:~Informative education about the disease~Teaching relaxation positions for pain management~Relaxation exercises with breathing exercises~Training on ergonomic approaches in daily life (correct sitting, lying, working, carrying, etc.)~Education of principles of joint protection~Creating and training a personalized physical activity and exercise plan"
89291510|NCT05844306|Experimental|Device ([18F]-FDG PET-CT, X1 RMRS PET-CT)|Patients receive [18F]-FDG injection and undergo SOC [18F]-FDG PET-CT on study. Patients with at least one PET avid lesion then undergo X1 RMRS PET-CT imaging-only session on study.
89291511|NCT05844254|Experimental|NORD group|After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. NORD group will undergo NORD flap for root coverage. Patients will be followed up after 1 month,6, 12 and 15 months. Patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification.
89291512|NCT05844254|Active Comparator|Sub epithelial connective tissue group|After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Sub epithelial connective tissue group will receive sub epithelial connective tissue graft. Patients will be followed up after 1 month,6, 12 and 15 months. Patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification.
89291513|NCT05844215||Non-Severe|Non-severe groups consisted of mild and moderate severity of COVID-19. Mild-degree are patients with symptoms of COVID-19 but do not require oxygen with normal X-ray images. Moderate-degree are patients with symptoms of COVID-19 that require a low oxygen flow rate with minimal pneumonia on chest X-Ray.
89291514|NCT05844215||Severe|Severe groups consisted of Severe and Critical Ill of COVID-19. Severe-degree are patients that require high oxygen flow rate with diffuse lung infiltrates. Critical-Ill are COVID-19 patients that suffered shock sepsis or respiratory failure.
89291515|NCT05844202|Experimental|Low dose|0.5 mg Alveavax-v1.2 in one ID injection
89291516|NCT05844202|Experimental|Standard dose|2 mg Alveavax-v1.2 in one ID injection
89291517|NCT05844202|Experimental|High dose|8mg Alveavax-v1.2 in four ID injections
89291518|NCT05844202|Active Comparator|Comparator|0.5ml Janssen Ad26.COV2.S COVID-19 vaccine in one IM injection
89291519|NCT05844202|Experimental|Subcutaneous|8mg Alveavax-v1.2 in one SC injection
89291520|NCT05844189|Experimental|Treatment Group|CRMRF and physical therapy modalities on pelvic floor.
89291521|NCT05844189|Sham Comparator|Sham Group|Only physical therapy modalities on pelvic floor. In this Arm the CRMRF is off.
89291522|NCT05844163||Conservative treatment group|Patients in conservative treatment group receive optimal drug therapy including appropriate blood pressure control and other measures.
89291523|NCT05844163||Intracranial aneurysm clipping group|Patients in Intracranial aneurysm clipping group receive neurosurgical clipping.
89291524|NCT05844163||Coil embolization or stent-assisted coil embolization group|Patients in coil embolization or stent-assisted coil embolization group receive coil embolization or stent-assisted coil embolization according to individualized condition.
89291525|NCT05844163||Flow diversion group.|Patients in flow diversion group receive flow diverters.
89291526|NCT05844124|Active Comparator|Control group: Standard of care land-based walking exercise|"Participants enrolled in the land-based walking exercise program will complete a total of two community walking or normal treadmill (not LBPP) walking exercise sessions per week for a total of eight consecutive weeks (i.e. 16 exercise sessions in all).~Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing."
89291527|NCT05844124|Experimental|Intervention group 1: Lower-body positive-pressure supported low-load treadmill walking exercise|"Participants enrolled in the Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise will complete a total of two walking exercise sessions per week for a total of eight consecutive weeks (i.e. 16 exercise sessions in all). Each walking session will include 30-minute walking on a G-Trainer (AlterG Inc., Fremont, CA) under low-load walking conditions.~Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing."
89291528|NCT05844124|Experimental|Intervention group 2: Aquatic Walking exercise|"Participants enrolled in the aquatic exercise program will complete a total of two aquatic walking exercise sessions per week for a total of eight consecutive weeks (i.e. 16 exercise sessions in all). Each aquatic exercise program will include walking in the pool for 30 minutes at self-selected speeds under the guidance of an aquatic therapy instructor.~Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing."
89291529|NCT05844098|Experimental|With K-wire|arthroscopic assisted CC-stabilization with K-wire
89291530|NCT05844098|No Intervention|No K-wire|arthroscopic assisted CC-stabilization
89291531|NCT05844072|Active Comparator|Ankle dorsiflexion range of motion with inclinometer in standing|The Standing Ankle Dorsiflexion Screen (SADS) will be used as a categorical outcome measure which is a more functional way to measure ankle dorsiflexion and does not require the use of additional equipment. The participant will be instructed to stand in tandem stance, one foot directly in front of the other, and bend both knees as far as they can while keeping their heel in contact with the ground. The examiner will then use a ruler to align the posterior knee with the medial malleolus and determine the position of behind, within, or in front of the malleolus.
89291532|NCT05844072|Active Comparator|Weight bearing lunge test|The Weight Bearing Lunge Test (WBLT) will be used to measure closed chain dorsiflexion in participants. A bubble inclinometer will be placed 15 cm below the tibial tuberosity for measurement during the WBLT. Participants will place their foot on a line on the floor which is perpendicular to the wall to help maintain alignment. The participant's heel will be stabilized by an examiner, and they will then be instructed to lunge forward so that their knee reaches a vertical line on the wall. The measurement will then be taken using the inclinometer placed at 15 cm below the tibial tuberosity. The examiner stabilizing the heel will hold the inclinometer in place, while another examiner ensures proper placement of the inclinometer and takes the reading. The WBLT will be completed twice and the average of the two measurements will be taken.
89291533|NCT05844059||Patients undergoing instillation therapy with BCG|All patients that undergo therapy with BCG after diagnosis of non-muscle-invasive bladder cancer
89291534|NCT05844059||Patients undergoing instillation therapy with Mitomycin C|All patients that undergo therapy with Mitomycin C after diagnosis of non-muscle-invasive bladder cancer
89291535|NCT05843929|Experimental|Group with Laser speckle contrast imaging technique (LSCI) and 3D foot creator use|"The proposed solution is based on the process synthetized in, and hereafter described:~A technician delivers a service at the home of the diabetic patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:~the piezoelectric insole that replaces missing pain sensation;~Laser speckle contrast imaging technique (LSCI) that measures the blood flow;~the multi points temperature device.~Data collected by the technician are sent via internet to the reference Hospital or Primary Care Unit where a specialist physician evaluates the acquired information;~On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole"
89291536|NCT05843929|No Intervention|Group not use laser speckle contrast imaging technique (LSCI) and not use 3D foot creator use|"The patients of this group will be visited in the hospital:~An assessment of the patient's risk of presenting problems due to diabetic foot will be carried out.~In this group, the control measures will be established within the usual practice in consultations.~No visits will be made to the patient's home. You will always visit the doctor's office.~If any problem is detected, the patient will be visited by health personnel and the usual treatments in these patients at present will be applied."
89291537|NCT05843903|Experimental|Peer Health Coaching|Young adult (18- to 25-years), postpartum, Black women enrolled in WIC will undergo paid training in health coaching.
89291538|NCT05843903|Experimental|#BabyLetsMove|There are four digital components to the intervention including Fitbit activity tracker, interactive self-monitoring and tailored feedback text messages, tailored skills training text messages and materials, and peer health coaching.
89291539|NCT05843851|Experimental|Tested newborns|Tested for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
89291540|NCT05843825|Active Comparator|(BOS-G) Block out spacer group|(BOS-G)(Control group) : Patients who would be delivered mandibular overdenture retained by three locator attachments picked up using block out spacer .
89291541|NCT05843825|Active Comparator|(WBOS-G) Without block out spacer group|(WBOS-G) (Study group): Patients who would be delivered mandibular overdenture retained by three locator attachments picked up without using block out spacer .
89291542|NCT05843812||Magnesium sulphate|Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
89291543|NCT05843812||No Magnesium sulphate|Patients who did not receive preoperative magnesium sulfate infusion as part of their anesthetic management
89291544|NCT05843760||undergraduate students|Hacettepe University Faculty of Physical Therapy and Rehabilitation undergraduate students
89291545|NCT05843734|Experimental|Equia forte HT (glass-hybrid) group|This study planned to investigate the clinical performance of Equia Forte HT (permanent glass hybrid restorative) in the treatment of anterior class III restorations. This arm of the study is the group whose effectiveness was investigated. The results will be evaluated by comparing with a traditional anterior resin composite in terms of functional, biological and aesthetic properties.
89291546|NCT05843734|Active Comparator|"G-Aenial anterior"|"This group will serve as a control. Equia forte HT (glass-hybrid) restorations will compare with the G-Aenial anterior anterior resin composite restorations."
89291547|NCT05843682|Other|Avatr|"In the inclusion visit, it will be install the Avatr App in the mobile device of the patients. The patients will give an evaluation to perform by the medical and nursing staff, where clinical data (office blood pressure, weight, height, abdominal circumference) will be collected and will answer questionnaires on quality of life, anxiety, sleep quality, food intake and therapeutic adherence. They will receive an automatic blood pressure measurement device to make household blood pressure measurement according to nursing guidance. Also, the patients will collected blood samples to further analysis for biochemical profile and 24-hour urine collection sample for urinary sodium dosage.~The patients will take four in person visits after the initial visit, with the final visit after 12 months."
89291548|NCT05843682|No Intervention|Control|"The patients will perform the same initial evaluation and answer the same questionnaires as described above for the Intervention Group. In this evaluation they will receive guidance regarding the adoption of life habits by the multidisciplinary team. The Control Group will receive reinforcement of guidance only in face-to-face visits.~The patients will take four in person visits after the initial visit, with the final visit after 12 months."
89291549|NCT05843656|Experimental|Slow-wave-like transcranial direct current stimulation (tDCS)|tDCS during sleep
89291550|NCT05843656|Experimental|Spindle-like transcranial alternating current stimulation (tACS)|tACS during sleep
89291551|NCT05843656|Sham Comparator|Sham stimulation during sleep|Sham
89291552|NCT05843656|Active Comparator|Wake in case participants could not take a nap|Active Comparator (with stimulation), in case participants could not take a nap
89291553|NCT05843630||Training cohort|Model construction based on training cohort
89291554|NCT05843630||Validation cohort 1|Model validation in an independent validation cohort 1
89291555|NCT05843630||Validation cohort 2|Model validation in an independent validation cohort 2
89291556|NCT05843617|Experimental|Liposomal Vitamin C (Liposovit-C)|Single oral dose of liposomal vitamin C formulation
89291557|NCT05843617|Active Comparator|Traditional Vitamin C|Single oral dose of traditional vitamin C formulation
89291558|NCT05843591||Aerobic Exercise group|Participants in the aerobic exercise (AE) group were asked to perform moderate to high intensity regular aerobic exercise. Exercise was required 3 times per week for at least 1 hour each time. At the beginning of the exercise, they were required to sign in at the research personnel, and at the end of the exercise, they were also required to sign out at the research personnel. However, there was no restriction on the type of exercise, which could be running, basketball, badminton, table tennis, tennis, rope skipping, dancing, etc.; there was no restriction on the form of exercise, which could be individual or group exercise; there was no restriction on the period of exercise start, which could be any time of the day to start exercise.
89291559|NCT05843591||Tai Chi Chuan group|Participants in the Tai Chi Chuan (TCC) group attended an 8-week Tai Chi training program, which consists of 24-form Tai Chi and Bafa Wubu of Tai Chi. Certified instructors administer and guide Tai Chi Chuan activities. We set up 6 Tai Chi Chuan classes each week, and participants in the Tai Chi Chuan group can participate in any 3 of the 6 classes each week to be considered as completing the task. Each 1-hour training session consists of a brief warm-up stretching session followed by standard Tai Chi routine activities.
89291560|NCT05843591||Wait-List Control group|Participants in the wait-list control (WLC) group received no intervention in addition to their usual physical education classes.
89291561|NCT05843526|Active Comparator|Titanium abutment|Titanium (Ti) grade 5 titanium abutment
89291562|NCT05843526|Experimental|Dental resin abutment|Dental resin (Re) Optibond ™ FL, Kerr Dental abutment
89291563|NCT05843526|Experimental|Polyetheretherketone abutment|Polyetheretherketone (PEEK) Polyetheretherketone abutment
89291564|NCT05843487||Carotid plaque length|Patients underwent carotid ultrasonography and first coronary angiography simultaneously
89291565|NCT05843422|Experimental|part 1-0.8% QY211 Gel or placebo（10%BSA）|6 subjects use 0.8% QY211 Gel，2 subject uses 0.8% QY211 placebo ，11days（Day1 QD,Day4-Day10 BID,Day11 QD ）.
89291566|NCT05843422|Experimental|part 1-1.5% QY211 Gel or placebo（10%BSA）|6 subjects use 0.8% QY211 Gel，2 subject uses 0.8% QY211 placebo ，11days（Day1 QD,Day4-Day10 BID,Day11 QD ）.
89291567|NCT05843422|Experimental|part 1-1.5% QY211 Gel or placebo（20%BSA）|6 subjects use 0.8% QY211 Gel，2 subject uses 0.8% QY211 placebo ，11days（Day1 QD,Day4-D10 BID,Day11 QD ）.
89291568|NCT05843422|Experimental|part 2-0.1% QY211 Gel or placebo|6 subjects use 0.1% QY211 Gel，2 subject uses 0.1% QY211 placebo ，29days（Day1-Day28 BID,Day29 QD）.
89291569|NCT05843422|Experimental|part 2-0.3% QY211 Gel or placebo|6 subjects use 0.3% QY211 Gel，2 subject uses 0.3% QY211 placebo ，29days（Day1-Day28 BID,Day29 QD）.
89291570|NCT05843422|Experimental|part 2-0.8% QY211 Gel or placebo|6 subjects use 0.3% QY211 Gel，2 subject uses 0.3% QY211 placebo ，29days（Day1-Day28 BID,Day29 QD）.
89291571|NCT05843422|Experimental|part 2-1.5% QY211 Gel or placebo|6 subjects use 0.3% QY211 Gel，2 subject uses 0.3% QY211 placebo ，29days（Day1-Day28 BID,Day29 QD）.
89291572|NCT05843396|Active Comparator|Neonatal Massage Received|
89291573|NCT05843396|No Intervention|No Massage Received|
89291574|NCT05843344|Active Comparator|ropivacaine and morphine group|erector spinae plane block with a combination of ropivacaine and morphine
89291575|NCT05843344|Active Comparator|ropivacaine and dexmedetomidine group|erector spinae plane block with a combination of ropivacaine and dexmedetomidine
89291576|NCT05843344|Active Comparator|ropivacaine group|erector spinae plane block with ropivacaine only
89291577|NCT05843331|Active Comparator|posterior vertical implants|the anterior implants were inserted in the canine/lateral incisor area bilaterally to each other's following the contour of the alveolar bone of the premaxilla. The posterior implants were inserted vertically just anterior to the maxillary sinus (in the area of second premolars) .
89291578|NCT05843331|Active Comparator|posterior inclined implants|The anterior implants were inserted in the canine/lateral incisor area bilaterally to each other's and will be inclined 15o labially following the contour of the alveolar bone of the premaxilla. The posterior implants were inserted just anterior to the maxillary sinus (in the area of second premolars) and inclined 15o distally .
89291579|NCT05843305|Experimental|Dose Escalation|Oral tablets taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-452080 administered once daily.
89291580|NCT05843305|Experimental|Dose Expansion|"Oral tablets administered at MTD/RP2D defined dose. Each treatment cycle will be 21 days in duration with BPI-452080 administered once daily.~Cohort 1: Locally Advanced or Metastatic ccRCC Cohort 2: VHL disease associated RCC Cohort 3: Other Advanced Solid Tumors"
89291581|NCT05843292|Experimental|Short-term Sintilimab in Combination With Taxane and Carboplatin|Prior to surgery: 2 cycles of sintilimab, in combination with 4 cycles of taxane and carboplatin
89291582|NCT05843201|Experimental|Patients are hospitalized with chronic heart failure symptoms and fluid overloaded|"Phase 1: 'In Hospital' Phase: chronic heart failure (CHF) patients are enrolled in the study when admitted to the hospital with fluid overload.~Study procedures performed, alongside diuretic therapy, in the hospital. Phase 2: 'At Home' Phase: Upon investigator's decision at discharge, the patients are enrolled in the second phase of the study for additional treatment sessions at home."
89291583|NCT05843162|Experimental|Telmisartan|Telmitrend Tab.(Telmisartan) 40mg(80mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg
89291584|NCT05843162|Active Comparator|Losartan|Cozaar Tab.(Losartan) 50mg(100mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg
89523308|NCT03378713|Active Comparator|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
89523309|NCT03378713|Active Comparator|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
89291585|NCT05843136|Experimental|Intervenction|"We used the SONOPULSE II device from the manufacturer IBRAMED, the electrodes measuring nine centimeters in length and five centimeters in width, from the manufacturer ARKTUS, of the adhesive plate type.~According to the IBRAMED manual (2011, p. 47), the application is produced by two medium frequency currents through four electrodes, quadripolar method. The current type is tetrapolar interferential and the stimulation mode is automatic vector; the carrier frequency of 4000HZ, AMF modulation frequency of 50HZ, and the sweep frequency of SWEEP will be 20HZ. SWEEP sweep modes with 6 seconds of rise from the modulation frequency to the threshold the sweep frequency upon reaching the threshold immediately decays over the next 6 seconds. The positioning of the four-leaf clover type electrodes and the intensity of the strong current, however comfortable, according to the patient's report."
89291586|NCT05843136|Active Comparator|Control Group 01|he treatment is based on non-invasive methods, highlighting manual therapy techniques, especially joint manipulation therapy. Manual therapy techniques are adjustments in lumbar rotation. Joint adjustment is a controlled lever-like force with direction, amplitude, and speed that is applied to specific, tissue-adjacent joints. While joint mobilization is manual therapy without the impulse, the joint remains within the physiological range of motion (SILVA et al., 2012). Therefore, a high-velocity, low-amplitude (HVA) manual maneuver was applied. The thrust (impulse) is carried out in the para-physiological environment, between the physiological and anatomical barriers. preload phase before the manipulation, thrust phase where the maneuver is performed with high speed and low amplitude and the resolution phase where the manipulation ends. The maneuver is detailed by the authors Bergmann & Peterson (2010).
89291587|NCT05843136|Active Comparator|Control Group 02|The procedure adopted in this group was based on the guidelines and recommendations for non-pharmacological treatment of the Associação Médica Brasileira AMB (RACHED, R.D.V.A. et al, 2013) use of 1 MHZ Ultrasound with a power of 1W/cm2, continuous IBRAMED device for 10 minutes, Wave Diathermy Short for 15 minutes/day, HTM brand, TENS 50 HZ and 50 ms intensity phase according to the patient's threshold, 30 minutes, IBRAMED brand
89291588|NCT05843123|Active Comparator|Pressure control (PC)|In PC physicians set the inspiratory pressure and time, the respiratory rate and the PEEP while the ventilator measures tidal volume and the actual respiratory rate
89291589|NCT05843123|Active Comparator|Pressure regulated volume control (PRVC)|In PRVC physicians set a target tidal volume and the respiratory rate. An algorithm delivers pressure using a decelerating flow pattern to reach the target tidal volume based on the lung compliance measured during previous breaths.
89291590|NCT05843110|Other|Decision-making process|1 arm with 25 couples who had an isolated CCA announcement during pregnancy and who decided to continue the pregnancy and 25 couples who had an isolated CCA announcement during pregnancy and who decided to terminate the pregnancy
89291591|NCT05843058|Experimental|laughter yoga|The psychological well-being scale was filled in at the first encounter with the patient. Then, 12 sessions of laughter yoga were performed and after 12 sessions, the psychological well-being scale was applied again.(Laughter yoga was practiced twice a week for 6 weeks)
89291592|NCT05843058|No Intervention|Standard care|The psychological well-being scale was filled in at the first encounter with the patient. Then, 6 weeks later, the psychological well-being scale was applied again.
89291593|NCT05843006||STEMI + PCI|18 subjects referred for coronary angiography/PCI due to ST-segment elevation myocardial infarction (STEMI)
89291594|NCT05843006||Diagnostic coronary angiography without a resulting intervention (PCI)|6 subjects undergoing a diagnostic coronary angiography without a resulting intervention (PCI)
89291595|NCT05842980||sepsis|sepsis patients
89291596|NCT05842850|Experimental|LBW individuals with NAFLD|LBW individuals with NAFLD
89291597|NCT05842850|Placebo Comparator|NBW controls without NAFLD|Age-, gender- and body mass index-matched NBW controls without NAFLD
89291598|NCT05842811||Disease Cohort|Observational
89291599|NCT05842811||Engaged Cohort|Observational
89291600|NCT05842798|Experimental|Cohort 1: TNM002 35 μg/kg or placebo|Eight subjects will be randomly assigned to receive either TNM002 35 μg/kg or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo)
89291601|NCT05842798|Experimental|Cohort 2: TNM002 100 μg/kg or placebo|Eight subjects will be randomly assigned to receive either TNM002 100 μg/kg or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo)
89291602|NCT05842798|Experimental|Cohort 3：TNM002 250 μg/kg or placebo|Eight subjects will be randomly assigned to receive either TNM002 250 μg/kg or placebo at a 3:1 ratio (i.e. 6 subjects receive TNM002 and 2 with placebo)
89291603|NCT05842785|Experimental|Phase I Dose escalation|100 microgram (μg), 200 μg, 400 μg, 800 μg, 1600 μg, and 3200 μg of TSN222 as a single agent in subjects with advanced solid tumors or lymphomas.
89291604|NCT05842785|Experimental|Phase II-HNSCC|Patients with advanced squamous cell carcinoma of head and neck (HNSCC).
89291605|NCT05842785|Experimental|Phase II-Advanced melanoma|patients with the advanced melanoma.
89291606|NCT05842785|Experimental|Phase II-solid tumors or lymphomas.|patients with advanced other types of solid tumors or lymphomas.
89291607|NCT05842772|Experimental|Intervention group|The DESIRE intervention which includes training of health professionals, a conversation with patients and their relatives, and a patient decision aid.
89291608|NCT05842772|Active Comparator|Control group|Usual care
89291609|NCT05842746|Placebo Comparator|Stupp Protocol|Patients receive maximal safe tumor resection, concurrent radiochemotherapy with TMZ, and adjuvant TMZ (the Stupp Protocol). Placebo that has the same appearance and flavor with Elemene is given 20ml orally, three times a day for 28 consecutive days (as one cycle) for 6 cycles, during the phase of adjuvant TMZ administration.
89291610|NCT05842746|Experimental|Ele-Stupp Protocol|Patients receive maximal safe tumor resection, concurrent radiochemotherapy with TMZ, and adjuvant TMZ (the Stupp Protocol). Elemene is given 20ml:176mg orally, three times a day for 28 consecutive days (as one cycle) for 6 cycles, during the phase of adjuvant TMZ administration.
89531693|NCT05705427|Experimental|Tenofovir disoproxil fumarate (TDF) arm|140 pregnant women in the experimental arm will receive tenofovir disoproxil fumarate (TDF) 300 milligrams (mg) daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine.
88813140|NCT03836456|Active Comparator|Active Control Intervention|Health Enhancement Program: This is a validated active comparator used in Mindfulness-based training studies. It will be conducted with the participants one evening per week for 4 weeks.
89291611|NCT05842720|Active Comparator|retrospective|Consecutive patients with ASA score≥3 that underwent unsedated colonoscopy from May 2021 to August 2022 at Sheba medical center were identified by search of the computerized endoscopy database). Following an informed consent, patients were interviewed over the phone using a structured questionnaire. To assess their satisfaction, a standard Likert scale between 1 (unsatisfied) to 5 (very satisfied) was administered. Additional assessment included the maximum level of pain experienced at any point during the procedure (between 1-no pain) to 5-severe pain), and whether they would choose to perform future procedures without sedation in the future. Patients were also asked if they were able to return on the same day to their routine daily function and activities
89291612|NCT05842720|Active Comparator|prospective|"High risk patients scheduled for an anesthesiologist-assisted sedated-colonoscopy in Sheba medical center, were contacted during their clinic visit or by phone to receive explanation about the option to enroll in this unsedated colonoscopy study.~After obtaining informed consent, patients' Anxiety trait was assessed with the help of State-Trait Anxiety Inventory (STAI) questionnaire [8] in order to assess their level of anxiety and to investigate its predictive utility for their success in undergoing the unsedated procedure. Upon completion of the procedure in the same satisfaction questionnaire was administered, as detailed above for the retrospective part"
89291613|NCT05842707|Experimental|Part 1 (dose escalation) and Part 2 (dose expansion)|"Part 1 (dose escalation)~the dose of dualCAR-NK19/70 participants receive will depend on when you join this study. Up to 3 dose levels of dualCAR-NK19/70 will be tested. About 3-6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level of dualCAR-NK19/70. Each new group will receive a higher dose of dualCAR-NK19/70 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of dualCAR-NK19/70 is found.~Part 2 (dose expansion)~Participants will receive dualCAR-NK19/70 at the recommended dose that was found in Part 1."
89291614|NCT05842681|Active Comparator|Conventional therapy group|Patients will receive conventional treatment for acute exacerbation of IPF, including pulse corticosteroid therapy and supportive treatment, and oxygen therapy.
89291615|NCT05842681|Active Comparator|Add-on Azithromycin|Patients will receive conventional therapy and Add-on Azithromycin 500 mg single daily dose for five days
89291616|NCT05842655|Experimental|Patients thats were chosen in order to rehabilitate partial edentulism by dental implants.|
89291617|NCT05842629||Patients with an adnexal lesion in the Central Denmark Region|
89291618|NCT05842616|Experimental|Transcranial doppler pulsatility index guided protocol|Norepinephrine titration that will be guided by Transcranial doppler (TCD) pulsatility index.
89291619|NCT05842616|Active Comparator|Mean arterial blood pressure guided protocol|Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
89291620|NCT05842590|Experimental|Direct Composite Veneer|This is a single-arm study. Direct composite veneer restoration will be performed to all patients.
89291621|NCT05842564|Experimental|Crohn's Disease Group|Patients followed for a Crohn's Disease in consultation or in day hospital aged between 6 and 18 years old.
89291622|NCT05842564|Other|Control Group|Patients followed for functional abdominal disorders
89291623|NCT05842486||Real-world cohort|The real-world cohort consists of patients with diagnosis of paroxysmal nocturnal hemoglobinuria and anemia initiating anti-C5 therapy.
89291624|NCT05842447|Experimental|367 mg Pomanox group|One capsule daily with 367 mg of Pomanox®P30 for 12 weeks
89291625|NCT05842447|Experimental|700 mg Pomanox group|One capsule daily with 700 mg of Pomanox®P30 for 12 weeks
89291626|NCT05842447|Placebo Comparator|Control group|One capsule daily with maltodextrin for 12 weeks
89291627|NCT05842421|Experimental|Intervention group|After clinical examination, each lesion that is suspicious for non-melanoma skin cancer and/or its precursor, is examined with dermoscopy, optical coherence tomography, in vivo reflectance confocal microscopy and each patient gets 3D total body photography. Afterwards, decision for management of each lesion is made (excision, biopsy, local treatment or no treatment). Surgeons are blinded to the groups but get the planning of surgery of the investigator. Pathologists are blinded to the groups.
89291628|NCT05842421|No Intervention|Control group|After clinical examination, each lesion that is suspicious for non-melanoma skin cancer and/or its precursor, is examined with dermoscopy as is the standard of care. Afterwards, decision for management of each lesion is made (excision, biopsy, local treatment or no treatment). Surgeons are blinded to the groups but get the planning of surgery of the investigator. Pathologists are blinded to the groups.
89291629|NCT05842408|Experimental|DA-5212|administered once daily for 4weeks
89291630|NCT05842408|Other|DA-5212-R|administered once daily for 4weeks
89291631|NCT05842395|Experimental|Participants with distal radius fractures taking vitamin c supplementation.|Participants who give informed consent and successfully pass the eligibility criteria will take 1g of oral vitamin C daily for three months.
89291632|NCT05842395|Placebo Comparator|Participants with distal radius fractures taking a placebo.|Participants who give informed consent and successfully pass the eligibility criteria will take a placebo daily for three months.
89291633|NCT05842187|Experimental|Organoid generation|All patients will be included in a single-arm. Participants will undergo biopsy of tumor tissue for subsequent organoid generation
89291634|NCT05842109||ABO HDN|positive in diagnosis of ABO-HDN
89291635|NCT05842109||non ABO HDN|negative in diagnosis of ABO-HDN
89291636|NCT05841862|Experimental|2C-QD|Single-dose intravitreal injection
89291637|NCT05841862|Sham Comparator|Sham 2C-QD|Single-dose intravitreal injection
89291638|NCT05841108|Experimental|experimental group|
89291639|NCT05841108|Active Comparator|control group|
89291640|NCT05840848|Active Comparator|Control plus Placebo|B-carotene supplement (15 mg) consumed in the morning after a >10 hour overnight fast.
89291641|NCT05840848|Experimental|Control plus iron Supplement|B-carotene supplement (15 mg) and iron sulphate supplement (25 mg) consumed in the morning after a >10 hour overnight fast.
88813141|NCT01839032|Experimental|Vinorelbine cisplatin radiotherapy|Induction period + radio chemotherapy
89291642|NCT05840848|Experimental|Control plus zinc Supplement|B-carotene supplement (15 mg) and zinc sulphate supplement (30 mg) consumed in the morning after a >10 hour overnight fast.
89291643|NCT05840835|Experimental|IMX-110 in Combination With Tislelizumab|Patients with advanced solid tumors will be administered a combination of IMX-110 with Tislelizumab
89291644|NCT05840562|Experimental|Experimental Arm|"The capsaicin 179 mg patch should be applied to the most painful extremities.~Application:~Capsaicin patches must be applied to intact, dry and non-irritated skin and allowed to remain in place for 30 minutes for the feet and maximum 60 minutes for hands depending on immediate tolerance.~If all the areas to be treated cannot be treated in once, a second session will be organised between 3 and 7 days later. Further sessions can be held within 15 days of the 1st session (up to 4 sessions in total). All sessions will be considered as one application.~1 application may require several treatment sessions.~The patch, which may be cut to shape, was used within 2 h of opening the foil pouch.~After the first treatment session, treatment may be repeated every 2 months (at weeks 9, 17, 25) as warranted by the persistence or return of pain."
89291645|NCT05840562|Active Comparator|Control Arm|"Duloxetine should be initiated at an initial dose of 30 mg orally for 1 week followed by a maintenance dose of 60 mg per day, given either once a day or 30 mg orally 2 times a day.~After W6, in case of insufficient response to the 60 mg dose, the dosage may be increased to the maximum dose of 120 mg."
89291646|NCT05839938|Experimental|Treatment group|Vitamin D (2000IU/day) for 6 months
89291647|NCT05839938|Placebo Comparator|Control group|placebo
89291648|NCT05839496|Experimental|Cervical Stabilization Training Group|The Cervical Stabilization Training Group applied cervical stabilization training three times a week for 8 weeks. Each session was completed in 45 minutes.
89291649|NCT05839496|No Intervention|Control Group|Control Group continued their medical treatment and they did not participate in any treatment for eight weeks.
89291650|NCT05839106|Experimental|PM1032 monotherapy|PM1032 0.3mg/kg-12mg/kg
89291651|NCT05839093|Active Comparator|Inferior Alveolar Nerve Block Group|A standard Inferior Alveolar Nerve Block (IANB) injection with a conventional dental injector and a 27-G needle to achieve pulpal anesthesia in mandibular molar teeth.
89291652|NCT05839093|Experimental|Intraligamentary Injection Group|An intraligamentary injection that performed with a special pressure injection syringe (Sopira Citoject, Kulzer, Hanau, Germany) and a 30-G needle.
89291653|NCT05838638|Experimental|Intervention|This intervention is a serious game which allows older adults under treatment for cancer to practice making self-care decisions for an avatar that is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with the research assistant about choices related to managing nausea and vomiting at home
89291654|NCT05838638|Active Comparator|Control|The control group will receive standard education related to managing nausea and vomiting and will have the opportunity to participate in the intervention at the end of the study
89291655|NCT05837728||Older adults ≥75 living at home|Older adults ≥75 years living at home applying for a municipal health and care service for an estimated period of more than two weeks.
89291656|NCT05837611|Active Comparator|Monitoring Group Only|Individuals in the Monitoring only group will be required to put down a 200$ deposit but will earn it back non-contingently by attending the weekly study meetings. They will be monitored using the Transdermal Alcohol Monitoring device, but will not be required to meet any Alcohol reduction goals to earn their deposit back.
89291657|NCT05837611|Experimental|Deposit Contract Group|Individuals in the Deposit COntract group will be required to put down a 200$ deposit but will earn it back, as well as a bonus, contingently for meeting alcohol reduction requirements. For this study, this is counted as having a Transdermal Alcohol COntent below equal to .02 g/dl. They will be monitored using the Transdermal Alcohol Monitoring device.
89291658|NCT05837546|Experimental|Real dog|presence of a real dog, contact with participant for 5 minutes
89291659|NCT05837546|Active Comparator|replica dog|presence of a replica dog, contact with participant for 5 minutes
89291660|NCT05837546|Active Comparator|plant|presence of a plant, contact with participant for 5 minutes
89291661|NCT05835414|Experimental|Adjunctive eTMS treatment (no delay)|6 weeks (30 sessions) of daily eTMS as an adjunct to standard of care TSRD treatment
89291662|NCT05834816|Experimental|Behavioral|Negative Affect Task
88806141|NCT01790204|Experimental|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
89291663|NCT05831865||DLBCL patients achieving CR or CMR during interim evaluation|During the interim evaluation, patients achieving complete response (CR) as determined by computed tomography (CT), or complete metabolic response (CMR) as determined by positron emission tomography-computed tomography (PET-CT), will be followed up for up to two years after completing the R-CHOP regimen followed by ASCT.
88821423|NCT04179552|Experimental|PAAG-OA|All subjects receive treatment with PAAG-OA
89291664|NCT05831865||DLBCL patients achieving PR or PMR during interim evaluation|During the interim evaluation, patients achieving partial response (PR) as determined by CT, or partial metabolic response (PMR) as determined by PET-CT, and who are willing to receive Pola-R-CHP as the following treatment regimen followed by ASCT with Pola-BEAM as conditioning regimen, will also be followed up for up to two years.
89291665|NCT05830903|Experimental|Mild ED/NS|10 patients with mild or none executive function impairment and mild or none negative symptoms.
89291666|NCT05830903|Experimental|Mild ED/Severe NS|10 patients with mild or none executive function impairment and severe or moderate negative symptoms.
89291667|NCT05830903|Experimental|Severe ED/Mild NS|10 patients with severe or moderate executive function impairment and mild or none negative symptoms.
89291668|NCT05830903|Experimental|Severe ED/NS|10 patients with severe or moderate executive function impairment and severe or moderate negative symptoms.
89291669|NCT05829577|Experimental|Executive function treatment|Patient will receive Individual DLS and SI/SP training combined with EF strategies
89291670|NCT05829577|Active Comparator|Treatment as usual|patient will receive Individual DLS and SI/SP training.
89291671|NCT05829499|Experimental|Eyedrops treatment arm|
89291672|NCT05827809|Experimental|Unified Protocol (UP-C/A) for children and youth with anxiety disorders and/or depression|A within group design where one clinical manualised intervention, the Unified protocol based on the third-wave of Cognitive Behavior Therapy (CBT), is offered in a 11 session group format to children and adolescents. Parent training is at the same time also offered in a group format. Therapists are trained in the method and receive regular supervision adhering to the evidence-based manual. The group treatment and parent training is delivered face-to- face.
89291673|NCT05825573|Active Comparator|Reference treatment|
89291674|NCT05825573|Experimental|Direct Oral Anticoagulant|
89291675|NCT05825352|Experimental|Eyedrops treatment arm|
89291676|NCT05824494|Experimental|Cadonilimab plus nab-paclitaxel|"Drug: Cadonilimab 10mg/kg,every 3 weeks,IV infusion~Drug: Nab paclitaxel~≤260mg/m2,every 3 weeks,IV infusion"
89291677|NCT05824000|Experimental|Eyedrops treatment arm|
89291678|NCT05823506|Active Comparator|Medication group|PDE5 inhibitor tadalafil in dosage 5 mg daily by 1 month
89291679|NCT05823506|Experimental|Combination group|PDE5 inhibitor tadalafil in dosage 5 mg daily by 1 month plus Device BTL-6000 fSWT: 6 sessions with EFD 0,09 mJ/mm2 by 5000 impulses per session in 5 points in corpora cavernosa penis
89291680|NCT05823129|No Intervention|Standard Group|"Usual clinical protocol is followed, the caregiver is given verbal training and assistive instructions by therapists and clinicians before patient discharge. Brief pamphlets are provided on post-operative care of patients. Patients are encouraged to perform rehabilitative exercises according to what they have learned during the in-patient stay.~Remote-TUG app is only used in the first and final assessment at day 30."
89291681|NCT05823129|Experimental|Intervention Group|"A recruitment assessment videoconference is scheduled at the 1st post-discharge week providing clear instructions on how to perform daily TUG test. The TUG test is to be performed at least twice in the morning and twice afternoon and complimented by other specific training exercises as specified in HSH1. Training instructions and assessment is performed by videoconference to ascertain that both the patient and the caregiver can follow instructions in using the remote-TUG smartphone app and safety measures are understood and applied when assisting the patients in exercises. Clear video instructions and multimedia for review will be provided. Interim videoconference will be conducted again after week 2 to ascertain adherence. Non-adherence can be immediately detected by remote data collection from the remote-TUG server interface. Non-adherence will trigger phone calls and videoconferences serving as reminders and performing troubleshooting."
89291682|NCT05822895||Computer-aided polyp detection|patients undergoing colonoscopy with CADe enabled programme
89291683|NCT05822895||without CADe|patients undergoing colonoscopy without CADe enabled programme
89291684|NCT05822817|Experimental|sevoflurane|Anesthesia is maintained with sevoflurane.
89291685|NCT05822817|Experimental|propofol|Anesthesia is maintained with continuous infusion of propofol.
89291686|NCT05821335|Experimental|Leap motion assisted rehabilitation|Individuals who will participate in the study will be treated 2 days a week for 5 weeks with Leap Motion sensor-supported games aimed at increasing patient-specific wrist flexion, wrist extension, ulnar and radial deviation of the wrist, flexion, extension and abduction of the fingers. Each training period will last 30 minutes.
89291687|NCT05821335|Experimental|Traditional program|They will be included in traditional rehabilitation training consisting of stretching exercises, strengthening exercises and functional exercises including activities of daily living for 2 days a week for 5 weeks.
89291688|NCT05820555|Experimental|Group A: 1 hour of tablet use in the hour before bed|"During week 1, children will maintain a sleep schedule within 30 minutes +/- of their habitual bedtime. This bedtime will be maintained throughout the 3 weeks of the study except on nights when dim light melatonin onset is assessed in the lab.~During week 2, participants will be asked to reframe from screen use in the 3 hours before bed time for 6 evenings.~During week 3, participants will be exposed to 1 hour of tablet use (Standard bright setting), 1 hour before bedtime for 6 evenings."
89291689|NCT05820555|Experimental|Group B: 1 hour of tablet use 2 hours before bed|"During week 1, children will maintain a sleep schedule within 30 minutes +/- of their habitual bedtime. This bedtime will be maintained throughout the 3 weeks of the study except on nights when dim light melatonin onset is assessed in the lab.~During week 2, participants will be asked to reframe from screen use in the 3 hours before bedtime for 6 evenings.~During week 3, participants will be exposed to 1 hour of tablet use (Standard bright setting), 2 hours before bedtime (and no screen use in the hour before bed) for 6 evenings."
89291690|NCT05820555|Active Comparator|Control Condition|"During week 1, children will maintain a sleep schedule within 30 minutes +/- of their habitual bedtime. This bedtime will be maintained throughout the 3 weeks of the study except on nights when dim light melatonin onset is assessed in the lab.~During week 2, participants will engage no screen use for the 3 hours before bedtime for 6 evenings.~During week 3, participants will be asked to engage in no screen use in the 3 hours before bedtime for 6 evenings."
89291691|NCT05818462||Patients who received EBRT to the pelvis.|Childhood cancer survivors who were treated with chemotherapy and radiation therapy to the pelvis, with or without surgical intervention. This group will consist of both primary pelvic sarcomas as well as patients who received whole abdominal radiation that included bladder exposure.
89291692|NCT05818462||Control cohort.|Childhood cancer survivors who have been treated for a sarcoma who did not receive pelvic radiation, and were treated with chemotherapy, with or without surgical intervention or radiation therapy (outside of the pelvis). These patients will be matched as closely as possible to Group 1 to match chemotherapy regimens, and sex.
89291693|NCT05817903|Experimental|ARM A|Axitinib (starting dose 5 mg BID orally) in addition to nivolumab (lat dose of 480 mg IV every four weeks as per standard clinical practice)
88806142|NCT00250484|Active Comparator|Transcranial Magnetic Stimulation|Active treatment with TMS for 10 days.
88806143|NCT00250484|Sham Comparator|Sham Transcranial Magnetic Stimulation|Patients will receive no active TMS/treatment.
88813142|NCT00906776|Active Comparator|Emdogain PLUS|Straumann Emdogain in combination with Straumann BoneCeramic
89291694|NCT05817903|Active Comparator|ARM B|Nivolumab (flat dose of 480 mg IV every four weeks as per standard clinical practice) after nivolumab plus ipilimumab induction as per standard clinical practice
89291695|NCT05814406|Experimental|JW0201+C2202+C2204|Experimental group, Treatment period for 24 weeks
89291696|NCT05814406|Placebo Comparator|C2202+C2204|Placebo group, Treatment period for 24 weeks
89291697|NCT05812196||Post-COVID|Patients with COVID-19 infections.
89291698|NCT05812196||Control|Patients without earlier diagnosis of COVID-19.
89291699|NCT05810896|Experimental|AF at Home|All recruited participants will participate in the AF at Home educational intervention.
89291700|NCT05808218|Experimental|CLTS|This arm will receive a standard community-led total sanitation) intervention).
89291701|NCT05808218|Experimental|CLTS Plus|Includes all activities in the CLTS arm with the addition of village-level Care Groups for sanitation and hygiene promotion.
89291702|NCT05808218|No Intervention|Control|
89291703|NCT05807061|Experimental|EmBARK|Parents receive a narrated training program about children's racial biases and read books that are focused on race with their children.
89291704|NCT05807061|Experimental|Popular guidance|Parents receive interesting popular press articles about children's racial biases and read books that are focused on race with their children.
89291705|NCT05807061|Experimental|Practice first|Parents practice discussing books about animals with their children first, and then receive a narrated training program about children's racial biases and read books that are focused on race with their children.
89291706|NCT05805605|Experimental|Cy/Flu/TBI + Post transplant CY|
89291707|NCT05805072|Experimental|Selinexor+HAAG±HMA|
89291708|NCT05801666|Experimental|Acupuncture group|Acupuncture points: ST36 (Zusanli), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Neiguan), and LI4 (Hegu) Liv 3(Taichung).
89291709|NCT05801666|Sham Comparator|Control group|Acupuncture on the sham points: ST36 (Zusanli), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Neiguan), and LI4 (Hegu) Liv 3(Taichung)(Sham 1~5). Those points are not indicated to treat digestion in Chinese medicine and in a location of 1 cm lateral/medial and 1 cm distal/proximal to those points there is no acupuncture point.
89291710|NCT05801081||Active group|Participants will be divided into two groups according to their physical activity level using the International Physical Activity Scale. Individuals with high physical activity levels will be included in this group.
89291711|NCT05801081||Inactive Group|cipants will be divided into two groups according to their physical activity level using the International Physical Activity Scale. Individuals with low physical activity levels will be included in this group.
89291712|NCT05800119|Experimental|Brain-level condition|Participants assigned to this condition received a brief reading passage (126 words) that provided psychoeducation about how psychotherapy can change the brain of those with depression, and specifically how psychotherapy can change the functioning of the prefrontal cortex and the amygdala, and affect neurotransmitters.
89291713|NCT05800119|Active Comparator|Mind-level condition|Participants assigned to this condition received a brief reading passage (115 words) that provided psychoeducation about the effectiveness of psychotherapy for depression, and specifically how psychotherapy can improve maladaptive thought processes and teach people with depression how to regulate negative emotions.
89291714|NCT05800119|No Intervention|Control condition|Participants assigned to this condition received no additional materials.
89291715|NCT05799001|Experimental|experimental|4 months of dance workshop with a Professional dance teacher
89291716|NCT05799001|Other|Control|First, patients will have usual activities for 4 months and in a second time, they will have 4 months of dance class with a nurse previously trained by the dance teacher
89291717|NCT05798416|Active Comparator|Exercise under inhalation of CO2|Subjects will perform shuttle walk test under inhalation of low concentration of CO2 supplied by a novel device at high altitude.
89291718|NCT05798416|Placebo Comparator|Exercise under inhalation of ambient air|Subjects will perform shuttle walk test under inhalation of ambient air at high altitude.
89291719|NCT05797090|Experimental|crystalloid cardioplegia with modified del Nido cardioplegia|To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
89291720|NCT05796843|Experimental|360 Degrees Virtual Reality-based Mirror Therapy Group|The group which will receive 360 Degrees Virtual Reality-based Mirror Therapy Group
89291721|NCT05796843|Active Comparator|Traditional Mirror Therapy Group|The group which will receive traditional mirror therapy using a conventional mirror
89291722|NCT05796843|Active Comparator|Conventional Physical Therapy Group|The group which will receive conventional rehabilitation for upper extremity
89291723|NCT05794932|Experimental|Stress test|All patients will undergo a stress test before and after venous recanalization.
89291724|NCT05792891||Covid-19 patients|
89291725|NCT05792891||No Covid-19 patients|
89291726|NCT05787444||symptomatic|Subject is currently exhibiting fever, or one or more symptoms associated with COVID-19 or influenza (such as, but not limited to, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea) and must present within 6 days of symptom onset. Subject must still be exhibiting symptoms on the day of sample collection.
89291727|NCT05784701|Active Comparator|TSCV (Full-strength)|Full-strength GMP formulation of Trivalent Salmonella Conjugate Vaccine (TSCV)
88813143|NCT00906776|Active Comparator|Autogenous bone|Autogenous bone from the patient
89291728|NCT05784701|Active Comparator|TSCV (Half-strength)|Half-strength GMP formulation of TSCV
89291729|NCT05784701|Active Comparator|Typbar-TCV|Licensed Monovalent Typbar-TCV
89291730|NCT05784701|Placebo Comparator|Placebo|PBS
89291731|NCT05783245|Experimental|Experimental Ice Therapy|Postoperative care with experimental ice therapy
89291732|NCT05783245|Active Comparator|Standard of Care Ice Therapy|Postoperative care with standard of care ice therapy
89291733|NCT05782283|No Intervention|Usual Care Group|Primary care providers will treat subject per standard of care
89291734|NCT05782283|Experimental|Electrocardiogram AI Group|The ACE (AI-Cirrhosis-ECG) 2.0 will be used to alert primary care providers to the likelihood of advanced liver disease with a recommendation for laboratory tests.
89291735|NCT05778877|Experimental|Cohort 1 - Adolescents|IV infusion of MMA-101 in the first patient on Day 1 IV infusion of SEL-302 in the second and third patient on Day 1, followed by two repeat doses of SEL-110 on Day 28 and Day 56 Adolescents ages ≥12 and <18
89291736|NCT05778877|Experimental|Cohort 2 - Children|IV infusion of SEL-302 in all patients on Day 1, followed by two repeat doses of SEL-110 on Day 28 and Day 56 Children ages ≥3 and <12
89291737|NCT05776511|Other|suggestive demyelinating disease|White matter lesions suggestive demyelinating diseases
89291738|NCT05776511|Other|no suggestive demyelinating diseases|White matter lesions not suggestive demyelinating diseases
89291739|NCT05776511|Other|Controls|patients controls
89291740|NCT05776199|Experimental|Ischemic Compression group|IC group with conservative technique in trigger points in levator scapulae muscle
89291741|NCT05776199|Active Comparator|Dry needling group|Dry needling group with invasive technique in trigger points in levator scapulae muscle
89291742|NCT05773079|Experimental|Toripalimab|Toripalimab 240mg, VD, Q3W (treatment time: maintain for 1 year or until disease progression or intolerance requires drug withdrawal)
89291743|NCT05772364|Experimental|Low-calcium water first, then high-calcium water|Participants drink 1.5 L of the designated water
89291744|NCT05770180|Experimental|low dose test group|one dose, Day 0
89291745|NCT05770180|Experimental|high dose test group|one dose, Day 0
89291746|NCT05770180|Active Comparator|control group 1|one dose, Day 0
89291747|NCT05770180|Active Comparator|control group 2|one dose, Day 0
89291748|NCT05765682|Active Comparator|Mepivacaine Spinal|Mepivacaine (60 mg: 3ml of 2%) or will be injected into the intrathecal space.
89291749|NCT05765682|Active Comparator|Bupivacaine Spinal|Isobaric bupivacaine (10mg: 2ml or 0.5%) will be injected into the intrathecal space.
89291750|NCT05765604|Experimental|test group|low dose and high dose, only one dose at day 0
89291751|NCT05765604|Active Comparator|control group|one dose at day 0
89291752|NCT05762575||control group|The volunteers in control group study traditional knotting technology,
89291753|NCT05762575||new knotting group|The volunteers in experimental group study new knotting technology.
89291754|NCT05760820|Experimental|Intervention Group|Access to the digital intervention post-baseline questionnaire and randomization.
89291755|NCT05760820|No Intervention|Control Group|Control group will gain access to the digital intervention after the 3-month follow-up.
89291756|NCT05757076||Screening Cohort|"This is a prospective specimen collection cohort study aimed to increase the detection of primary aldosteronism (PA) in patients with hypertension.~Study samples will be obtained longitudinally. One collection of plasma will be obtained. Blood draw may need to be repeated in some subjects after washout period. Study will continue for a period or 1 year, with plan to enroll around 50 subjects."
89291757|NCT05752136|Experimental|Neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Name: KN053~Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure: TME surgery, total mesorectal excision The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient."
89291758|NCT05752136|No Intervention|Neoadjuvant chemoradiotherapy and total mesorectal excision|"Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure: TME surgery, total mesorectal excision The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient."
89291759|NCT05745389||Alopecia Areata|Pts presenting to enrolling sites across the US are invited to enroll if eligible
89291760|NCT05742828|Active Comparator|Virtual Seating Coach|The Virtual Seating Coach is a context-aware reminding system that when set up by a clinician, directly benefits a user by reminding him or her to change position with the chair's power seating function.. Regular position changes increase independent function, reduce the risk of pressure ulcers, manage pain, and reduce swelling.
89291761|NCT05742828|No Intervention|Non Virtual Seating Coach|power wheelchairs that tilt, recline, and have leg elevation for maximal pressure management and to encourage repositioning to reduce the risk of skin breakdown/pressure injury as well as decrease pain.
89291762|NCT05740384|Experimental|Sonotubometry Assessment|All participants will be measured 8 times using sonotubometry. 2 times without applying any sound and 2 times while applying sound. This is done for both the left and right ear.
89291763|NCT05738005|Other|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|MyFitnessPal smartphone application is used to track daily dietary intake and herbal/alternative supplements.
89291764|NCT05737797|Experimental|Endometrial cancer patients|Endometrial cancer patients Cervical cytology during surgical intervention.
89291765|NCT05733728||Uveal Melanoma|
89291766|NCT05731908|Experimental|BI 690517 mild hepatic impairment (Child-Pugh A)|
89291767|NCT05731908|Experimental|BI 690517 normal hepatic function|control group
89291768|NCT05731908|Experimental|BI 690517 moderate hepatic impairment (Child-Pugh B)|
89291769|NCT05731440||Healthy participants|"Drug: [18F]-Fluselenamyl. A dosage range of 10 mCi +/- 20% of Fluselenamyl will be injected by a PET certified medical professional followed by 10 ml 0.9% sodium chloride (normal saline) flush.~Drug: [11C]-Pittsburgh Compound ([11C]PIB) A dosage range between 6.0-20.0 mCi is planned. A PET certified professional will prepare and administer the [11C]-PIB tracer. Participants will receive the PIB injection followed by 10 ml 0.9% sodium chloride (normal saline) flush."
89291770|NCT05731440||Participants with mild cognitive impairment|"Drug: [18F]-Fluselenamyl. A dosage range of 10 mCi +/- 20% of Fluselenamyl will be injected by a PET certified medical professional followed by 10 ml 0.9% sodium chloride (normal saline) flush.~Drug: [11C]-Pittsburgh Compound ([11C]PIB) A dosage range between 6.0-20.0 mCi is planned. A PET certified professional will prepare and administer the [11C]-PIB tracer. Participants will receive the PIB injection followed by 10 ml 0.9% sodium chloride (normal saline) flush."
89291771|NCT05724498|Active Comparator|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Compare two behavioral interventions for insomnia
89291772|NCT05724498|Active Comparator|Standard Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Standard VA 6 session version of CBT-I
89291773|NCT05718596|Experimental|Sweeps laser|use of sweeps laser irrigation activation
89291774|NCT05718596|Experimental|pasif ultrasonic irrigation (PUI)|Pasif ultrasonic irrigation (PUI) -VDW Ultra
89291775|NCT05712434|Experimental|Long CHG Intervention|2 months of iodine protocol, followed by 4 months of CHG protocol, followed by 6 months of CHG plus protocol.
89291776|NCT05712434|Experimental|Mid-length CHG Intervention|4 months of iodine protocol, followed by 4 months of CHG protocol, followed by 4 months of CHG plus protocol.
89291777|NCT05712434|Experimental|Short CHG Intervention|6 months of iodine protocol, followed by 4 months of CHG protocol, followed by 2 months of CHG plus protocol.
89291778|NCT05712421|Experimental|North Star|
89291779|NCT05712421|Active Comparator|Levothyroxine|
89291780|NCT05712226|Other|Sleepiz One+ vs. gold standard|Each enrolled participant will undergo a simultaneous recording with the Sleepiz One+, Capnography device and cardiorespiratory polygraphy with reduced number of channels (ECG and REB only) to measure respiration rate at and heart rate at rest, while sitting and lying down on a bed.
89291781|NCT05707117|Experimental|Group A: Tendon neuroplastic training (TNT)|the strength training of the wrist extensors are being done with the help of an externally pace device
89291782|NCT05707117|Active Comparator|Group B: Conventional treatment|static stretching and myofascial release on wrist extensors
89291783|NCT05705323|Experimental|Internet-delivered cognitive behavioral therapy for tinnitus|An 8-week modular cognitive behavioral therapy
89291784|NCT05705323|Experimental|Internet-delivered mindfulness-based therapy for tinnitus|An 8-week mindfulness-based stress reduction.
89291785|NCT05705323|No Intervention|Waiting-list control|The waiting list for 8 weeks.
89291786|NCT05704673|Active Comparator|group (1)|who given intrathecal morphine thin IV nalbuphine and asize of 80 patients
89291787|NCT05704673|Placebo Comparator|group (2)|who given intrathecal morphine onInguinal hernia druing spinal anathesia
89291788|NCT05699265||Fabry Disease Follow-Up Patients|
89291789|NCT05698667|Experimental|Oropharynx Ultrasound|Transoral and transcervical ultrasound of the oropharynx, including the tonsils and tongue base.
89291790|NCT05697835|Experimental|Behavioral activation and medication optimization|"Behavioral activation (BA) will begin perioperatively and will span across 3 months postoperatively, with sessions approximately weekly or biweekly, depending on patient preference & health condition.~Medications will be reviewed by a team of interventionists to minimize brain-toxic medications and optimize doses of antidepressants and other mental health medications. In-hospital and after discharge, the interventionists' role will include coordinating with the care teams to ensure that medication changes that were introduced preoperatively are maintained."
89291791|NCT05697835|Other|Control (treatment as usual)|Participants in control arm will continue care as usual. They will receive printed resources for supporting sleep hygiene, stress reduction, cognitive and mental health exercises, as well as community resources for older adults.
89291792|NCT05690763|Experimental|XP-endo Finisher|use of XP-endo Finisher
89291793|NCT05690763|Experimental|EndoActivator|use of EndoActivator
89291794|NCT05689944|No Intervention|Control group|Patients in the control group will not participate in any art-therapy or yoga interventions. They will be asked to complete pain and sleep diaries, questionnaires and pain, fatigue and mood scales at the same times and for the same duration as the other groups.
88806144|NCT03549650|Experimental|Pentosan Polysulfate Na 100Mg Cap|Drug intervention of Pentosan Polysulfate Na 100Mg Cap (ELMIRON) thrice daily PO for 6 weeks, after meeting the eligibility criteria during the the two-week Screening period.
89291795|NCT05689944|Experimental|Dance-therapy group|Patients in the dance-therapy group will attend a weekly session of dance-therapy between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
89291796|NCT05689944|Experimental|Art-therapy group|Patients in the art-therapy group will attend a weekly session of art-therapy (drawings, collages…) between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
89291797|NCT05689944|Experimental|Yoga group|Patients in the yoga group will attend a weekly session of Vinyasa yoga between weeks 1 and 15 of the protocol (15 sessions). They will be asked to complete daily pain and sleep diaries at weeks W0, W5, W16, W20 and W28 as well as questionnaires (kinesiophobia, anxiety, catastrophizing, fear of pain, quality of life, body image/self-perception). They will also be asked to assess their pain, fatigue and mood levels at the end of each week between W1 and W15.
89291798|NCT05686837||People infected with NTM isolates identified in a cluster|All people with CF infected with NTM respiratory isolated identified in a cluster based on whole genome sequencing of the core genome will undergo epidemiologic investigation and home of residence watersheds will be mapped.
89291799|NCT05686837||People infected with NTM isolates not identified in a cluster|All people with CF infected with NTM respiratory isolated not identified in a cluster based on whole genome sequencing of the core genome will undergo epidemiologic investigation and home of residence watersheds will be mapped.
89291800|NCT05683041|Experimental|intrauterine gel application|Application of Hyalobarrier intrauterine after myomectomy.
89291801|NCT05683041|No Intervention|no intra-uterine gel application|No application of Halobarrier intrauterine after myomectomy.
89291802|NCT05681689|Experimental|Indication for H. pylori testing|Patients who have been treated for H. pylori and need to undergo eradication confirmation testing. Patients will be enrolled for this study if all acceptance criteria are met. Patients will undergo 13C Urea Breath Test in addition to non-invasive diagnostic comparators (H. pylori Stool Testing and Comparator Breath Test) OR invasive diagnostic comparator (Endoscopy for Rapid Urease Testing and Histology).
89291803|NCT05681520|Experimental|peer specialist|Work with a peer specialist for six 30-minute sessions
89291804|NCT05678400|Experimental|Hypopressive abdominal techniques|All subjects were instructed by a registered physiotherapist on how to correctly perform the hypopressive abdominal techniques (HAT) in two familiarisation sessions of 45 minutes each before any action was taken. After the two sessions, all subjects who did not learn the exercise correctly were dropped from the study. The HAT training consisted of asking subjects in a standing position to perform a spinal elongation with neutral pelvis and scapular muscle activation for three normal respiratory cycles with slow and deep exhalation, and on the last breath, an expiratory apnoea with rib expansion and elevation was requested. In this session, following the guidelines described in the familiarisation sessions, two series of four dynamic HATs in standing position were performed: dynamic HATs in right tilt, dynamic HATs in left tilt, dynamic HATs in right rotation and dynamic HATs in left rotation.
89291805|NCT05678400|Active Comparator|Stretching of proprioceptive neuromuscular facilitation|The therapist straddled that leg, and raised the other leg by placing the heel on the shoulder. The therapist then flexed the participant's hip, maintaining knee extension, to the point of discomfort indicated by the patient or the therapist's perceived end of range. In this position the leg was held straight for 10 seconds and immediately afterwards the participant was asked to perform a maximum isometric contraction for 5 seconds using the therapist's shoulder as counter resistance, thus keeping the leg straight at the same point. As soon as the contraction stops, the therapist flexes the hip again until a new range limit is reached, repeating the same protocol again. The total duration is 60 seconds, consisting of 4 passive stretches of 10 seconds each and 4 isometric contractions against resistance of 5 seconds each.
89291806|NCT05678205|Experimental|Phase 1 Dose Confirmation|Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression
89291807|NCT05678205|Experimental|Phase 2 Cohort A|AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC ≥2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available
89291808|NCT05678205|Experimental|Phase 2 Cohort B|AB-201 given to patients with advanced/unresectable or metastatic breast cancer with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) that is relapsed to, refractory to, or intolerant of previous trastuzumab deruxtecan (T-DXd) based therapy
89291809|NCT05678205|Experimental|Phase 2 Cohort C|AB-201 given to patients with advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression (IHC ≥ 2+) that is refractory to or intolerant of standard treatment, or for which no standard treatment is available
89291810|NCT05675527|Experimental|Low-dose PRP|Patients will receive a single injection of 6 ml low-dose platelet-rich plasma (PRP) into the glenohumeral joint. Low-dose is defined as a platelet yield of 3X (i.e., 3-fold increase in platelets in PRP compared to whole blood).
89291811|NCT05675527|Experimental|High-dose PRP|Patients will receive a single injection of 6 ml high-dose platelet-rich plasma (PRP) into the glenohumeral joint. High-dose is defined as a platelet yield of 12X (i.e., 12-fold increase in platelets in PRP compared to whole blood).
89291812|NCT05675527|Placebo Comparator|Saline control|Patients will receive a single injection of 6 ml saline into the glenohumeral joint.
89291813|NCT05671562|Experimental|Lycopene|Capsules containing 7mg of lycopene. 2 capsules are swallowed once per day with water for 12 weeks. Looks identical to placebo capsule.
89291814|NCT05671562|Placebo Comparator|Placebo|Placebo capsules containing an inactive ingredient. 2 capsules are swallowed once per day with water for 12 weeks. Looks identical to lycopene capsule.
89291815|NCT05670756||Medication allergy|Patients who have a medication allergy listed in their electronic medical record.
89291816|NCT05654818|Experimental|Vitamin D|
89291817|NCT05654818|Placebo Comparator|Control|
89291818|NCT05637047|Experimental|pulsed radiofrequency|
89291819|NCT05637047|Active Comparator|Dry needling|
89291820|NCT05636800|Experimental|Microwave Treatment (Swift System)|3-4 Watts applied locally for up to a 3 second burst to each AK lesion, repeated 3 times per lesion. Burst is defined as a single delivery of microwave energy. There will be approximately 20 seconds between each repeat dose.
89291821|NCT05636800|No Intervention|No Treatment|No Treatment administered
89291822|NCT05636696|Experimental|couple eMBCT|The couple eMBCT has nine sessions, takes 15-20 weeks, can be followed from home and will be supervised remotely by a trained therapist. Consistent with the original (patient-only) eMBCT, the couple eMBCT aims to change the patient's behavioral and cognitive reactions to fatigue and other cancer-related stressors. Couple eMBCT includes information for partners each session, the possibility for partners to perform exercises and one session specifically dedicated to the couple's mutual relationship and mindful communication about CCRF. Couples can determine themselves to which degree the partner is involved in the therapy.
89291823|NCT05634252|Experimental|Education + Action Plan + UV Photo + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
89291824|NCT05634252|Experimental|Education + Action Plan + UV Photo|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, and receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system.
89291825|NCT05634252|Experimental|Education + Action Plan + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
89291826|NCT05634252|Experimental|Education + Action Plan|Students in this intervention will receive education on skin cancer and prevention strategies and complete an individualized sun protection and tanning worksheet for situations in which they receive UVR exposure.
89291827|NCT05634252|Experimental|Education + UV Photo + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies, receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system, and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
89291828|NCT05634252|Experimental|Education + UV Photo|Students in this intervention will receive education on skin cancer and prevention strategies and receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system.
89291829|NCT05634252|Experimental|Education + MC1R Test|Students in this intervention will receive education on skin cancer and prevention strategies and provide a saliva sample using an Oragene® clinical-grade saliva kit and receive individualized results following MC1R sequencing.
89291830|NCT05634252|Experimental|Education|Students in this intervention will receive education on skin cancer and prevention strategies.
89291831|NCT05634213|Experimental|saline injection|After the patient is placed on cardiopulmonary bypass, the surgeon will inject a saline into the atria.
89291832|NCT05634213|No Intervention|standard of care|The patient will be placed on cardiopulmonary bypass as usual and the surgery will proceed without an attempt to inject saline into the atrial tissue.
89291833|NCT05632068|Experimental|Xian-Hua-Cha (XHC) group|Xian-Hua-Cha (XHC) 520 mL, twice a day will be given with diet education/monitoring program for this group for 3 months, followed by one-month wash-out period and a 3-month period with diet education/monitor program alone.
89291834|NCT05632068|No Intervention|Control group|Diet education/monitoring program (500 kcal lower than estimated total energy expenditure of each subject) will be given to each subject for 3 months first, followed by one month wash-out period and a 3-month period of Xian-Hua-Cha (XHC) 520 mL, twice a day, intervention course.
89291835|NCT05631561|Experimental|The endovascular denervation (EDN) group|Receive endovascular denervation (EDN)
89291836|NCT05625009|Experimental|Experimental: Transversus Abdominis Plane Block (TAPB)|patients received TAPB postoperatively
89291837|NCT05625009|Experimental|Experimental: Erector Spinae Plane Block (ESPB)|patients received ESPB postoperatively
89291838|NCT05624398|Experimental|Treatment Group|Subjects implanted with the Vivity IOL undergoing concurrent implantation of the Hydrus Microstent
89291839|NCT05617443|Active Comparator|selective laser melting (SLM) CO-Cr metal surgical-guides|
89291840|NCT05617443|Experimental|digital light processing (DLP) resin surgical-guides|
89291841|NCT05613205|Experimental|Step 1a low dose without adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP04A Low Dose without adjuvant investigational vaccine, administered at Day 1 and Day 169.
89291842|NCT05613205|Active Comparator|Step 1a control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
89291843|NCT05613205|Experimental|Step 1b low dose with adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP03A Low Dose adjuvanted investigational vaccine, administered at Day 1 and Day 169.
89291844|NCT05613205|Active Comparator|Step 1b control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
89291845|NCT05613205|Experimental|Step 2 full dose without adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP04B Full Dose without adjuvant investigational vaccine, administered at Day 1 and Day 169.
89291846|NCT05613205|Experimental|Step 2 full dose with adjuvant Group|Participants 18 to 50 years of age randomized to receive 2 doses of TYP03B Full Dose adjuvanted investigational vaccine, administered at Day 1 and Day 169.
89291847|NCT05613205|Active Comparator|Step 2 control Group|Participants 18 to 50 years of age randomized to receive 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine at Day 1 and 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine at Day 169.
89291848|NCT05610046|Sham Comparator|Non-heated sauna session|The test days will consist of sitting in an infrared sauna cabin (HM-LSE-3 Professional edition, Health Mate, Belgium). Participants will sit in an infrared sauna at 21° Celsius for a total of 40 minutes.
89291849|NCT05610046|Experimental|Heated sauna session|The test days will consist of sitting in an infrared sauna cabin (HM-LSE-3 Professional edition, Health Mate, Belgium). Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
89291850|NCT05609786|Experimental|myPlan Kenya|myPlan Kenya web-based application
89291851|NCT05599412||Korean patients with Metastatic ALK+ Non small cell lung cancer|
89291852|NCT05596591|Experimental|Intervention|Participants will receive four sessions over four consecutive weeks (one per week) of focused extracorporeal shockwave therapy.
89291853|NCT05596591|No Intervention|Control|Participants will receive the conventional treatment for bone marrow lesions, which includes avoidance of weight bearing and anti-inflammatory medications.
89291854|NCT05593510|Experimental|No prep ready-to-eat meals|
89291855|NCT05593510|Active Comparator|Ingredient bundles (e.g. meal kits)|
89291856|NCT05592730||Study Group|Patients with Unexplained İnfertility
89291857|NCT05592730||First Control Group|Healthy Multiparous Women
89291858|NCT05592730||Second Control Group|A: Patients with male infertility B: Patients with tubal factor
89291861|NCT05583877|Experimental|Intervention - Diabetes BOOST|Intervention group participants will complete a baseline survey, receive a referral to DSMT from the research team, a mailed welcome letter and self-care education sent via a series of personalized patient portal secure messages, text messages, and video call. They will be sent text messages with information about one of the American Association of Diabetes Educators 7 self-care behaviors and will receive encouragement to author their own self-management behavioral goals. Participants will also complete a telehealth training video call with research staff to review the functionality of their patient portal and refine diabetes-related goals. The participant will then be encouraged to send a patient portal message to their DSMT CDCES that includes their personalized goals prior to their scheduled DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.
89291862|NCT05583877|Active Comparator|Usual Care|Comparison Group participants will complete a baseline survey, receive a DSMT referral request from research team to their primary care provider and a mailed welcome letter. The mailed letter will welcome the participant to the study and contain general information about diabetes self-care behaviors and goal setting. They will complete a DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.
89291863|NCT05581927|Experimental|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure.
89291864|NCT05581927|Active Comparator|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia.
89291865|NCT05577351|Experimental|Treatment Arm|Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove thrombus in the neuro-vasculature using the RapidPulseTM (feasibility) device.
89291866|NCT05567874||SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the first period|SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in April 2021
89291867|NCT05567874||SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the second period|SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville from June to September 2021
89291868|NCT05567874||SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the third period|SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in December 2021
89291869|NCT05562349|Experimental|Clavulanic Acid|Participants may receive 500 mg of CLAV at baseline. Subjects who are using cocaine once per week or more and who can tolerate 500 mg/day for 4 weeks, will have a dose escalation to 750 mg/day. If tolerated, 750mg/day will be maintained for 8 weeks, otherwise the dose will decrease to 500mg/day.
89291870|NCT05562349|Placebo Comparator|Placebo|"Participants may receive placebo and serve as a control group. They will be blinded to their condition and will have a dose escalation at the same time as the experimental group, and be given additional placebo pills to match the number given to the experimental group."
89291871|NCT05556603||Cancer arm|Participants with new diagnosis of pancreatic cancer, from whom a blood sample will be collected.
89291872|NCT05556603||Benign disease arm|Participants with benign pancreatic diseases, from whom a blood sample will be collected.
89291873|NCT05556603||Healthy arm|Participants with no known presence of malignancies or benign diseases, from whom a blood sample will be collected.
89291874|NCT05556603||High risk for pancreatic cancer arm|Participants with high risk for pancreatic cancer, from whom a blood sample will be collected.
89291875|NCT05550181||with hypocapnia|We will use the intraoperatively collected etCO2 levels to classify patients as either 'with hypocapnia' or 'without hypercapnia', using the cutoff of 35 mmHg. A patient is considered 'hypocapnic' if the etCO2 was < 35 mm Hg at any point during surgery, from start of the study till end of the study
89291876|NCT05550181||without hypocapnia|We will use the intraoperatively collected etCO2 levels to classify patients as either 'with hypocapnia' or 'without hypercapnia', using the cutoff of 35 mmHg. A patient is considered 'hypocapnic' if the etCO2 was < 35 mm Hg at any point during surgery, from start of the study till end of the study, and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
89291877|NCT05536713||Federally Qualified Health Center 1|Patients who received an order for colorectal cancer screening, either using a stool-based test or colonoscopy, but failed to complete the screening after six months will be recruited to participate in the study.
89291878|NCT05536713||Federally Qualified Health Center 2|Patients who received an order for colorectal cancer screening, either using a stool-based test or colonoscopy, but failed to complete the screening after six months will be recruited to participate in the study.
89291879|NCT05536713||Federally Qualified Health Center 3|Patients who received an order for colorectal cancer screening, either using a stool-based test or colonoscopy, but failed to complete the screening after six months will be recruited to participate in the study.
89291880|NCT05529706|Experimental|Brain Health Program|A multimodal educational and interactive diet, exercise and computerized cognitive exercise public health program.
89291881|NCT05524233|Experimental|Transcranial Direct Stimulation|Subjects will receive an active electrical stimulation device (tDCS) to use up to 20 minutes daily for 4 weeks. To deliver tDCS subjects will place a strap around their forehead area.
89291882|NCT05520541|Experimental|Clinical Group|This group will receive clinical-based LSVT-BIG training
89291883|NCT05520541|Active Comparator|Home Group|This group will receive home-based LSVT-BIG training
89291884|NCT05516459||Three doses of vaccination|Subjects received three pfizer BNT162b2 vaccination at least four month before recruitment
89291885|NCT05516459||Four doses of vaccination|Subjects received three pfizer BNT162b2 vaccination at least four month before recruitment and decided to receive another dose at time of recruitment or followup
89291886|NCT05508763||PGx-guided dosing|This group will be genotyped for 14 pharmacogenes at the start of the study.
89291887|NCT05508763||Standard of care|This group will be genotyped for 14 pharmacogenes at the end of the study.
89291888|NCT05505617||Lung diffusing capacity measurements|Participants will be randomly allocated to perform single-breath lung diffusing capacity measurements on both devises during a single study visit.
89291889|NCT05500274|Active Comparator|Education Arm|The Education condition will include COVID-19 prevention messaging and an interactive activity reinforcing the messages. Testimonial videos will be played including those that describe the testing experience and motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors.
89291890|NCT05500274|Active Comparator|Motivational Arm|Study participants randomized to the Motivational Intervention will receive the intervention using a social network diffusion approach. This is a Type I network intervention that includes specific training on mobilization of network members. The Motivational intervention will be based upon a previous workshop divided into four learning and practice modules.
89291891|NCT05497531|Experimental|ctDNA collection from draining and peripheral veins|Patient with suspected primary hepatobiliary or pancreatic cancer undergoing a diagnostic work-up with a percutaneous or trans-jugular biopsy (standard of care) and will undergo a sampling of the cancer draining vein during their biopsy procedure with a collection of an additional 10mL of blood.
89291892|NCT05496231|Experimental|Human Papilloma Virus 9-valent (HPV9) High Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-High formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
89291893|NCT05496231|Experimental|Human Papilloma Virus 9-valent (HPV9) Med Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-Medium formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
89291894|NCT05496231|Experimental|Human Papilloma Virus 9-valent (HPV9) Low Group|Healthy females aged 16 to 26 years receive 3 doses of the HPV9-Low formulation of the investigational adjuvanted HPV vaccine on Day 1, Month 2, and Month 6.
89291895|NCT05496231|Active Comparator|Gardasil 9 (Gar9) Group|Healthy females aged 16 to 26 years receive 3 doses of the marketed HPV vaccine on Day 1, Month 2, and Month 6.
89291896|NCT05494255|Active Comparator|Group RM|One single recruitment maneuver will be applied in this group at the end of the surgery and before the extubation
89291897|NCT05494255|No Intervention|Group NoRM|Usual care will be applied in this group
89291898|NCT05493358||Open distal gastrectomy|An incision of 15~20 cm length is made in the abdominal midline . Standard distal gastrectomy and omentectomy will be performed with D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, proper hepatic artery) . As a general rule, Billroth I, Billroth II or Roux en Y method was used for gastric reconstruction.
89291899|NCT05493358||Laparoscopic distal gastrectomy|"5 trocar were used. The gastrocolic ligament was divided along the border of the transverse colon. ligating the left gastroepiploic vessels to remove group 4sb.~The right gastroepiploic vein was divided and the right gastroepiploic and the inferior pyloric artery were vascularized and cut at their origin from the gastroduodenal artery, just above the pancreatic head, to dissect group 6.~The dissection was continued along the hepatoduodenal ligament to removed group 5 and group 12a and along the common hepatic artery to remove group 8a and along the celiac axis to remove group 9.~The left gastric vein was prepared and separately divided and then the left gastric artery was vascularized to remove group 7.~The dissection was continued upward along the proximal branches of splenic vessels to remove group 11p and along the lesser curvature to remove group 1,3.~As a general rule, Billroth I, Billroth II or Roux en Y method was used for gastric reconstruction."
89291900|NCT05490316|Placebo Comparator|Placebo tablet|
89291901|NCT05490316|Experimental|IBI353 (Orismilast) dose 2|
89291902|NCT05490316|Experimental|IBI353 (Orismilast) dose 1|
89291903|NCT05485428|Experimental|Exercise|High-intensity interval training plus usual care
89291904|NCT05485428|No Intervention|Usual care|Usual care / treatment. Usual physical activity.
89291905|NCT05484466|Experimental|Group A:ZM-H1505R 50 mg QD + Baraclude 0.5 mg QD|"The treatment regimen is as follow:~Group A: ZM-H1505R 50 mg QD + Baraclude 0.5 mg QD 48weeks After 48 weeks of treatment with the corresponding regimen, subjects will continue to take Baraclude 0.5 mg QD, as a monotherapy for a 12-week ."
89291906|NCT05484466|Experimental|Group B:ZM-H1505R 100 mg QD + Baraclude 0.5 mg QD|"The treatment regimen is as follow:~Group B: ZM-H1505R 100 mg QD + Baraclude 0.5 mg QD 48weeks After 48 weeks of treatment with the corresponding regimen, subjects will continue to take Baraclude 0.5 mg QD, as a monotherapy for a 12-week ."
89291907|NCT05484466|Placebo Comparator|Group C:ZM-H1505R placebo QD + Baraclude 0.5 mg QD|"The treatment regimen is as follow:~Group C: ZM-H1505R placebo QD + Baraclude 0.5 mg QD 48weeks After 48 weeks of treatment with the corresponding regimen, subjects will continue to take Baraclude 0.5 mg QD, as a monotherapy for a 12-week ."
89291908|NCT05479383||Tobacco users|"Tobacco users~Never smokers (reference group) will be compared with former smokers, occasional smokers and daily smokers.~Never snus users (reference group) will also compare with never users, former users and current users."
89291909|NCT05474352|Experimental|ALLON System|The ALLON system water garment, is like a large apron that covers your body. There are tubes that run throughout the water garment, which allow warm liquid to flow so that the garment keeps the participant warm. The ALLON system water garment will be filled with warm water.
89291910|NCT05469334|Experimental|Experimental: DeStress for Health Program Participants|Rural residents 18 years and older of Granville and Vance counties (n=40) will be recruited to participate.
89291911|NCT05466747|Experimental|Part A: RYMPHYSIA 60 mg/kg|Participants will receive 60 mg/kg RYMPHYSIA, intravenous (IV) infusion, once every week for up to 104 weeks.
89291912|NCT05466747|Active Comparator|Part A: Another Available A1PI 60 mg/kg|Participants will receive 60 mg/kg of another available A1PI, IV infusion, once every week for up to 104 weeks.
89291913|NCT05466747|Experimental|Part B: RYMPHYSIA 60 mg/kg|Participants will receive 60 mg/kg RYMPHYSIA, IV infusion, once every week for up to 104 weeks.
88806145|NCT03549650|Placebo Comparator|Placebo oral capsule|Participants will receive Placebo oral capsule, similar to (ELMIRON 100mg) thrice daily PO for 6 weeks, , after meeting the eligibility criteria during the the two-week Screening period.
88806146|NCT00252512|Experimental|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are negative, they receive a chance to draw tokens from a bowl. Some tokens are social reinforcement. Others have monetary value.
89291914|NCT05466747|Experimental|Part B: RYMPHYSIA 120 mg/kg|Participants will receive 120 mg/kg RYMPHYSIA, IV infusion, once every week for up to 104 weeks.
89291915|NCT05463874|Experimental|Mindful Self-Compassion Arm|Participants in this arm will participate in an 8-week virtual mindful self-compassion program.
89291916|NCT05463874|No Intervention|Wait-list Control Arm|Participants in this arm will receive usual clinical care and will have the opportunity to participate in the mindful self-compassion program at the end of the study.
89291917|NCT05463705|Experimental|Intervention to address diffusion of responsibility|PCPs will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. Specifically, these elements will be adapted from interventions that mitigate diffusion of responsibility in other contexts, including: (1) assigning responsibility to individuals or smaller groups, (2) increased perceived harm of the situation to be addressed (3) highlighting competence to act, and (4) modeling the desired behavior. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer.
89291918|NCT05463705|Experimental|Intervention to address diffusion of responsibility + simplification of prescribing|"PCPs will receive the same contact addressing diffusion of responsibility as in the Intervention to address diffusion of responsibility arm, but will additionally have access to an experienced administrative team for diabetes medication insurance authorization support, by routing their clinic note through the EHR. PCPs will be informed, suing the same email outreach, how to access the administrative team, which consists of medical and administrative assistants and currently supports prescribing within the endocrinology division. The team will follow up with the pharmacy to determine coverage, complete prior authorizations, determine alternate covered options, and track progress."
89291919|NCT05463705|No Intervention|Usual care|PCPs in this arm will receive no additional outreach or resources than standard MGH primary care practice.
89291920|NCT05462561|Experimental|Treatment (VCBA)|Patients undergo robotic VCBA transplantation.
89291921|NCT05460754|Experimental|Organic grass-fed beef, then conventional-fed beef|Participants receive an organic grass-fed steak meal in the morning. After a washout period of at least 7 days, they then receive the alternative meal, conventional-fed steak meal in the morning.
89291922|NCT05460754|Experimental|Conventional-fed beef, then organic grass-fed beef|Participants receive a conventional-fed steak meal in the morning. After a washout period of at least 7 days, they then receive the alternative meal, an organic grass-fed steak meal in the morning.
89291923|NCT05459454|Experimental|Digital intervention group|"Participants will be instructed to download the Sidekick Health app and receive a code to access the 14-week digital intervention in addition to standard of care, as is defined for the control arm.~Beyond this, all patients in the interventional arm will also receive standard of care as defined for the control arm."
89291924|NCT05459454|No Intervention|Standard of Care|The control arm will receive standard of care treatment. Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
89291925|NCT05456607|Active Comparator|Control|Online Mood Monitoring for 12 weeks
89291926|NCT05456607|Experimental|Single Insomnia Treatment|Cognitive-behavioral therapy for insomnia delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access for 12 weeks.
89291927|NCT05456607|Experimental|Single Depression Treatment|Cognitive-behavioral therapy for depression delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access for 12 weeks.
89291928|NCT05456607|Experimental|Sequenced Depression and Insomnia Treatment|Cognitive-behavioral therapy for depression followed by cognitive-behavioral therapy for insomnia each delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access to the depression treatment only for 4 weeks after which the access to the insomnia treatment is also made available. Total duration of access for 12 weeks.
89291929|NCT05456607|Experimental|Sequenced Insomnia and Depression Treatment|Cognitive-behavioral therapy for insomnia followed by cognitive-behavioral therapy for depression each delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access to the insomnia treatment only for 4 weeks after which the access to the depression treatment is also made available. Total duration of access for 12 weeks.
89291930|NCT05452733|Experimental|Sleepwalking patient|
89291931|NCT05452733|Active Comparator|Non sleepwalking patient|
89291932|NCT05433298|Experimental|Treatment|Patient: Intravenous infusion of single-dose of Mesenchymal stem cells (MSCs)
89291933|NCT05433298|Placebo Comparator|Placebo|Intravenous infusion of single-dose of Ringer's lactate, albumin and heparin solution
89291934|NCT05411393|Experimental|Experimental arm|Research participants in this arm will receive the ADL-enhanced program and usual home health care rehabilitation. The ADL-enhanced program consists of six home visits delivered by a study occupational therapist.
89291935|NCT05411393|Other|Control arm|Research participants in this arm will receive usual home health care rehabilitation.
89291936|NCT05409807|Experimental|Classic Ultrasound Guided|Ultrasound guided interscalene nerve block
89291937|NCT05409807|Experimental|Smart Glasses Assisted|Ultrasound guided smart glasses assisted interscalene nerve block
89291938|NCT05408988||Patients with subarachnoid haemorrhage|Patients aged 18 or older hospitalized in the Intensive Care Unit with Subarachnoid Haemorrhage.
89291939|NCT05406362|Experimental|30 mg|30 mg VAD044
89291940|NCT05406362|Experimental|40 mg|40 mg VAD044
89291941|NCT05406362|Placebo Comparator|Placebo|Placebo
89291942|NCT05404581|Sham Comparator|Control|Subjects who respond favorably to test/trial stimulation of the insula will be implanted with DBS devices. In an outpatient clinical trial, each subject will receive 3 months of active stimulation and 3 months of sham stimulation. The assignment for stimulation will be randomized and blinded to the subject and to the outcome assessors.
89291943|NCT05404581|Active Comparator|DBS of the insula|Subjects who respond favorably to test/trial stimulation of the insula will be implanted with DBS devices. In an outpatient clinical trial, each subject will receive 3 months of active stimulation and 3 months of sham stimulation. The assignment for stimulation will be randomized and blinded to the subject and to the outcome assessors.
89291944|NCT05399654|Experimental|TAC-001 Single-Agent Dose-Escalation Cohorts|
89291945|NCT05393791|Experimental|Experimental group|In the experimental group, treatment will be paused if there is a >50% decline in baseline PSA. AA/ENZ will be restarted if the PSA rises to the same level or higher than the pre-treatment PSA. AA/ENZ treatment will be paused again after the PSA declines >50% from the baseline. This pause/restart cycle of adaptive therapy will be repeated presuming consent, tolerance and safety. Patients who do not have a >50% decline of their baseline PSA level after restarting AA/ENZ remain on treatment until the criteria for treatment failure are met.
89291946|NCT05393791|Active Comparator|Control group|In the control group, patients will receive the standard continuous treatment with abiraterone or enzalutamide (AA/ENZ) until criteria for treatment failure are met.
89291947|NCT05388773|Experimental|Arm S (Low Risk)|"Low risk patients are defined as T1-T2 AND 0 or 1 metastatic lymph nodes AND <3 cm AND clear (≥3mm) margins AND no extracapsular extension (ECE) AND no perineural invasion AND no lymphovascular invasion.~Patients will undergo transoral surgical resection of the oropharyngeal tumor."
89291948|NCT05388773|Experimental|Arm RT (Intermediate Risk)|"Intermediate risk patients are defined as having any of the following features: One or more close (<3mm) margins, OR minimal ≤1 mm ECE OR 1 or more metastatic lymph nodes >3 cm in diameter OR 2-4 lymph nodes positive (≤ 6 cm in diameter), OR perineural invasion OR lymphovascular invasion~Patients will undergo transoral surgical resection of the oropharyngeal tumor. Following surgery, patients will receive low-dose IMRT five times a week for 3 weeks."
89291949|NCT05388773|Experimental|Arm CRT (High Risk)|"High risk patients are defined as having any of the following features: One or more positive margins OR >1 mm ECE OR ≥ 5 metastatic lymph nodes.~Patients will undergo transoral surgical resection of the oropharyngeal tumor. Following surgery, patients will receive low-dose IMRT six times a week and a weekly chemotherapy infusion (cisplatin or carboplatin) during radiation therapy.~Patients will receive 2 Gy/fraction, 6 fractions per week with at least a 6-hour interfraction interval between each treatment:~PTV-P50 or PTV-N50: 50 Gy in 25 fractions (2 Gy/fx)~PTV-N45: 45 Gy in 25 fractions (1.8 Gy/fx) with simultaneous integrated boost to the PTV-P50 volume.~PTV-P30 or PTV-N30: 30 Gy in 15 fractions (2 Gy/fx)"
89291950|NCT05386537|Experimental|MyoPro-VR/HM group|Receive 18 sessions (in 6 weeks) of wrist/hand/UE rehabilitation using the MyoPro wearable robotic orthosis combined with VR-video games and Haptics.
89291951|NCT05386537|Active Comparator|MyoPro group|Receive 18 sessions (in 6 weeks) of wrist/hand/UE rehabilitation using the MyoPro wearable robotic orthosis only.
89291952|NCT05386537|Active Comparator|VR/HM group|Receive 18 sessions (in 6 weeks) of wrist/hand/UE rehabilitation using VR-video games only.
89291953|NCT05386537|Other|control|Receive 18 sessions (in 6 weeks) of conventional UE therapy at a rehabilitation facility.
89291954|NCT05385952|Experimental|GATT-Patch|Hemostatic patch
89291955|NCT05385952|Active Comparator|TachoSil|Hemostatic patch
89291956|NCT05384808|Experimental|No dog present|Conventional psychotherapy with no dog being present.
89291957|NCT05384808|Experimental|Dog present and active part of therapeutic narrative.|The dog is actively integrated into the therapeutic narrative.
89291958|NCT05384808|Experimental|Dog present but not active part of therapeutic narrative.|The dog is present but not actively integrated into the therapeutic narrative.
89291959|NCT05383521|Experimental|Tinidazole 56|Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
89291960|NCT05383521|Experimental|Tinidazole 42|Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
89291961|NCT05378854|Experimental|LifeChamps Platform|Participants will be asked to use the LifeChamps platform and will be provided with the study equipment.
89291962|NCT05376683|No Intervention|Control|
89291963|NCT05376683|Active Comparator|Telemonitoring group|
89291964|NCT05376683|Active Comparator|AI. + Telemonitoring group|
89291965|NCT05372289|Experimental|Supplemented patients|
89291966|NCT05372289|No Intervention|Standard of care|
89291967|NCT05368506|Experimental|Treatment (wee1 inhibitor ZN-c3)|Patients receive Wee1 inhibitor ZN-c3 PO QD on days 1-21. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
89291968|NCT05364437|Active Comparator|Dietary Fibres Supplement|Dietary fibre mix comprising of inulin, pectin and oat beta-glucan. The mix comes in a powdered form which can be added to participants' food.
89291969|NCT05364437|Placebo Comparator|Placebo|Placebo comprising of cellulose which will come in a powdered form that can be added to participants' food.
89291970|NCT05361850|Active Comparator|Awake Extubation|Removal of the endotracheal tube while the patient is no longer under general anesthesia
89291971|NCT05361850|Active Comparator|Deep Extubation|Removal of the endotracheal tube while the patient is under general anesthesia
89291972|NCT05358938|Experimental|Adjuvant Arm with Exercise|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting. Adjuvant participants will receive 1 year [currently 9-18 cycles] of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab or relatlimab, or currently approved standard of care treatment, either alone or in combination. Participants also will complete 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles. Blood samples will be collected at 1) baseline (upon arrival to clinic), 2) post-exercise, and 3) post-infusion. Blood samples will be obtained on the first, third, midpoint, and final infusion dates.
89291973|NCT05358938|Active Comparator|Adjuvant Arm without Exercise|Participants will receive clinical care following Moffitt standards for the patients disease type and therapeutic setting. Adjuvant participants will receive one year [currently 9-18 cycles] of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab, relatlimab, or currently approved standard of care treatment, either alone or in combination. Blood samples will be collected at 1) baseline (upon arrival to clinic) and 2) post-infusion. Blood samples will be obtained on the first, third, midpoint, and final infusion dates.
89531147|NCT02497625|Active Comparator|Usual Care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
89291974|NCT05358938|Experimental|Neoadjuvant Arm with Exercise|Participants will complete 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles. Neoadjuvant participants will receive up to 4 cycles of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab, or relatlimab, or currently approved standard of care treatment, either alone or in combination. Blood samples will be collected at 1) baseline (upon arrival to clinic), 2) post-exercise, and 3) post-infusion. Blood samples will be obtained on the first and third infusion dates.
89291975|NCT05358938|Active Comparator|Neoadjuvant Arm without Exercise|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting. Neoadjuvant participants will receive up to 4 cycles of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab, or relatlimab, or currently approved standard of care treatment, either alone or in combination. Participants also will complete 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles. Blood samples will be collected at 1) baseline (upon arrival to clinic), 2) post-exercise, and 3) post-infusion. Blood samples will be obtained on the first and third infusion dates.
89291976|NCT05354713|Experimental|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
89291977|NCT05354713|Active Comparator|NVP-1805-R1 and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
89291978|NCT05353400|Experimental|(Intervention group): self-removal of transurethral catheter on POD 1|Subjects will self-remove transurethral catheter at home on postop day 1
89291979|NCT05353400|Active Comparator|(Standard practice group): self-removal of transurethral catheter on POD 3|Subjects will self-remove transurethral catheter at home on postop day 3
89291980|NCT05352399|Experimental|Intervention (NeuViCare AI)|An anticipated 55 participants will be part of the Intervention arm participants and will engage with NeuViCare AI, including all variations of its 5 components described further below.
89291981|NCT05349526||stenotic carotid|patients with a stenotic carotid
89291982|NCT05349526||non stenotic carotid|patients with non stenotic carotid
89291983|NCT05349474|Experimental|Metformin Treatment|Metformin 500 mg tablets up to 2,000 mg (4 tablets) a day divided into two doses. Patients will start on 500 mg Qday and a titration to maximum dose will be attempted during the first 30 day period of the study.
89291984|NCT05349474|Placebo Comparator|Placebo Treatment|Placebo tablets identical to metformin 500 mg tablets divided into two doses. Patients will be started on 1 tablet a day and a titration to maximum dose (4 tablets) will be attempted during the first 30 day period of the study.
89291985|NCT05349097|Experimental|SAD cohort 1|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of 30mg IMG-004 oral capsule(s) or a single dose of matching placebo. Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
89291986|NCT05349097|Experimental|SAD cohort 2|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
89291987|NCT05349097|Experimental|SAD cohort 3|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
89291988|NCT05349097|Experimental|SAD cohort 4|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
89291989|NCT05349097|Experimental|SAD cohort 5|Each participant who meets confirmation of eligibility and completion of the screening phase will be randomized to receive either a single dose of IMG-004 oral capsule(s) or a single dose of matching placebo.Participants will be admitted to the clinic on Day -1 ,remain domiciled until Day 8 and complete the safety follow-up on Day15.
89291990|NCT05345093|Experimental|Ialuxid Gel|twenty-two patients affected by acne vulgaris; twenty-two patients affected by impetigo; twenty-two patients affected by folliculitis.
89291991|NCT05343481|Experimental|Experimental: Group 1 ChAdOx1-HBV, MVA-HBV and nivolumab|Day 1: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 29: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
89291992|NCT05343481|Experimental|Experimental: Group 2 ChAdOx1-HBV, MVA-HBV and nivolumab, MVA-HBV and nivolumab|Day 1: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 29: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion Day 85: MVA-HBV 1 x 10^8 pfu IM injection + nivolumab 0.3 mg/kg IV infusion
89291993|NCT05343481|Experimental|Experimental: Group 3 ChAdOx1-HBV, MVA-HBV, nivolumab, MVA-HBV|Day 1: ChAdOx1-HBV 1 x 2.5 10^10 vp IM injection Day 29: MVA-HBV 1 x 10^8 pfu IM injection Day 36: Nivolumab 0.3 mg/kg IV infusion Day 85: MVA-HBV 1 x 10^8 pfu IM injection
89291994|NCT05340764|Active Comparator|2-hour infusion of infliximab|2 hour infusion of infliximab
89291995|NCT05340764|Experimental|1-hour infusion of infliximab|1 hour infusion of infliximab
89291996|NCT05327361|Active Comparator|Control Group|Participant will receive sunscreen in the morning and at the beginning of the afternoon for 3 months.
89291997|NCT05327361|Experimental|Liftactiv B3|Participants will undergo a wash out phase of two weeks where they regularly apply a moisturizer (Hydreane Legere) in the morning and a sunscreen in the morning and at the beginning of the afternoon. On the 3rd week, participants will apply Liftactiv B3 serum daily in the morning before sunscreen and in the evening (two applications daily) on half face for 3 months.
89291998|NCT05326529|Active Comparator|Traditional Cardiac Rehabilitation (Hospital based programme)|Traditional Cardiac Rehabilitation will involve 8 hospital-based exercise sessions, and one virtual education day over 8 weeks, supervised by CR health care professionals.
88806147|NCT00252512|Placebo Comparator|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
89291999|NCT05326529|Experimental|Traditional combined with Web-based Cardiac Rehabilitation|Traditional combined with Web-based Cardiac Rehabilitation. Patients will attend 8 hospital-based exercise sessions and one virtual education day over 8-weeks with access to additional web-based (MyHeart app) exercise and educational information.
89292000|NCT05326529|Experimental|Web-based Cardiac Rehabilitation|Web-based Cardiac Rehabilitation, using MyHeart app introduced during a pre-CR assessment, will follow an 8-week individualised self-managed platform, allowing contact with the CR health professionals via app messages only (no direct contact for web-based CR).
89292001|NCT05324085|Experimental|Exercise intervention group|Participants will undergo supervised treadmill exercise three times each week for eight weeks, in addition to treatment as usual (TAU).
89292002|NCT05324085|Other|Control group|Participants will undergo TAU. The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.
89292003|NCT05323864|Experimental|Normobaric hypoxia|Normobaric hypoxia equivalent to 3800m terrestrial altitude. The chamber located on the campus of the University of Innsbruck's Department of Sport Science. The chamber dimension is 5 x 3m.
89292004|NCT05323864|Sham Comparator|Sham hypoxia|The chamber located on the campus of the University of Innsbruck's Department of Sport Science. The chamber dimension is 5 x 3m.
89292005|NCT05309369|Experimental|Preferred Music - Visit 1, Nature Sounds - Visit 2|
89292006|NCT05309369|Placebo Comparator|Nature Sounds - Visit 1, Preferred Music - Visit 2|
89292007|NCT05305014||Patient with conversive motor disorder|Patients with paralysis, motor weakness or abnormal movements meeting the DSM-IV criteria of conversive motor disorder consulting the SAU or the Neurology departments of the CHU of Nîmes and Montpellier included in the HYCORE parent study (RCB ID 2014-A01159-38, NCT02329626)
89292008|NCT05300451|Experimental|AMR Treatment Group|Subjects with antibody mediated cardiac allograft rejection (AMR) and cardiac allograft dysfunction will receive daratumumab/hyaluronidase-fihj.
89292009|NCT05300451|Experimental|HLA Desensitization Group|Subjects awaiting cardiac transplantation with high levels of circulating Human Leukocyte Antigen (HLA) antibodies will receive daratumumab/hyaluronidase-fihj.
89292010|NCT05298631|Experimental|Treatment group 1: stabilization exercises|"stabilization exercises~Chin tuck~Cervical extension~Shoulder shrugs~Shoulder rolls~Scapular retraction (15 repetitions 1 set) with TENS(10 mins before each session for 10 min at the back of the neck), stretching of trapezius, Pectorals minor, sternocleidomastoid, levator scapulae (5 rep 10 sec hold 1 set in both sides ) and cold pack (10 min at the back of neck at the end of each session)"
89292011|NCT05298631|Active Comparator|Treatment group 2: dynamic exercises|"dynamic exercises~Cervical extension-dynamic isometric.~Cervical Flexion-Dynamic isometric.~Chest flies exercises (15 repetitions 1 set) with TENS(10 mins before each session for 10 min at the back of the neck), stretching of trapezius, Pectorals minor, sternocleidomastoid, levator scapulae (5 rep 10 sec hold 1 set in both sides ) and cold pack (10 min at the back of neck at the end of each session)"
89292012|NCT05296122|Experimental|Single arm|MR-Guided Laser Thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG ® Thermoguide Workstation.
89292013|NCT05293834|Experimental|VRAPT intervention group|"Data collection process:~Pre-intervention (t0): patients self-reports and staff observation;~VRAPT: 8-16 weeks;~Post-intervention (t1): patients self-reports, staff observations, and qualitative interview with participants and VRAPT therapists conducted by research staff;~Follow-up 12 weeks after completion of the intervention (t2): patients self-reports and staff observations."
89292014|NCT05288803||Control cohort|The investigators will collect outcomes for 100 Veterans treated with usual care rehabilitation after total knee arthroplasty. Data will be collected at all participating clinical locations. Data collection for these Veterans will precede data collection for the intervention cohort.
89292015|NCT05288803||Intervention cohort|The investigators will implement the clinical decision support tool in all participating clinic locations. We will collect outcomes for 100 Veterans treated in rehabilitation with use of the clinical decision support tool. Data collection for these Veterans will occur after data collection is complete for the Control cohort.
89292016|NCT05285904||Ofatumumab|Population under routine medical care prescribed Ofatumumab in an early Relapsing Multiple Sclerosis
89292017|NCT05283083|Experimental|Dexmedetomidine|"Patients will receive dexmedetomidine infusion according to the protocol plus the usual care.~We will evaluate patients for inclusion in the study after 6 hours on NE infusion, given stabilization of the MAP > 65 mmHg. In the DEX group, we will commence DEX infusion at the rate of 0.2 mcg.kg-1.h-1 without a loading dose, then titrate DEX infusion to maintain the HR from 60 to 90 bpm.~Titration of the DEX infusion rate will not be more than 0.1 mcg.kg-1.h-1 every 30 minutes at any time. The maximum DEX infusion rate will be 0.7 mcg.kg-1.h-1.~We aim to continue DEX infusion for 48 hours. After 48 hours of DEX infusion, we will taper the DEX infusion over one hour.~According to our protocol, DEX infusion would trigger either STOP events or hemodynamic assessment events:"
89292018|NCT05283083|No Intervention|Usual care without dexmedetomidine infusion|The patients in this group will receive the usual care.
89292019|NCT05279157|Experimental|ADASCs Group|5 patients, who will receive adipose tissue mesenchymal stem cells in a single dose as study treatment
89292020|NCT05279157|Experimental|Acellular laminas group|5 patients, who will receive decellularized corneal laminas as treatment medication
89292021|NCT05279157|Experimental|ADASCs recellularized laminas group|5 patients, who will receive adipose tissue mesenchymal cells combined with decellularized corneal laminas as study treatment in a single intervention
89292022|NCT05276557|Experimental|Indication for H. pylori testing|Walk in basis: Symptomatic patients of H. pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test (a single dose of 13C urea at 75mg in powder form, to be dissolved in potable water as the kit indicates) in addition to stool antigen test comparison.
89292023|NCT05265637||Implantation of the Visian ICL|Visian implantable collamer lens (ICL)
89292024|NCT05265624|Experimental|Early Genetic Results Disclosure|Early disclosure group receives results of genetic testing at Month 1
89292025|NCT05265624|Active Comparator|Late Genetic Results Disclosure|Late disclosure group receives results of genetic testing at Month 12
89292026|NCT05260736|Active Comparator|Group Costoclavicular Lateral (CL)|Patients anesthetized with costoclavicular lateral infraclavicular brachial plexus block.
89292027|NCT05260736|Active Comparator|Group Costoclavicular Medial (CM)|Patients anesthetized with costoclavicular medial infraclavicular brachial plexus block.
89292028|NCT05260736|Active Comparator|Group Lateral Sagittal (LS)|Patients anesthetized with lateral sagittal infraclavicular brachial plexus block.
89292029|NCT05260645|Experimental|Experimental group|Intervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
89292030|NCT05260645|No Intervention|Control group|I declare that I will not change my lifestyle during the study process.
89292031|NCT05257733||CIDP associated with systemic diseases|Patients with CIDP associated with systemic diseases
89292032|NCT05257733||CIDP without systemic diseases|Patients with CIDP without other systemic diseases
89292033|NCT05252403|Experimental|CARCIK-CD19|
89292034|NCT05248321|Experimental|Extra treatment (ET) group|In the extra treatment (ET) group, standard endoscopic therapy will be performed to the bleeding peptic ulcer by local injection of diluted epinephrine 1:10 000 in combination with either heater probe coagulation, hemoclipping and/or rubber band ligation. Afterwards, we will apply 1.25g tranexamic acid powder via the endoscopy to the peptic ulcer before the end of endoscopic exam. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores <6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
89292035|NCT05248321|No Intervention|standard treatment (ST) group|In the standard treatment (ST) group, the endoscopic exam ends after standard endoscopic therapy. After the first endoscopy, the patient will receive a 3-day continuous high-dose (8 mg/h) PPI infusion and Rockall score assessment as current guideline's recommendation. In patients with Rockall scores ≥6, after 3-day intravenous PPI infusion, we will apply oral twice-daily PPI for 11 days followed by once-daily PPI after then. In patients with Rockall scores <6, we will apply once-daily PPI after 3-day intravenous PPI infusion. A second-look esophagogastroduodenoscopy (EGD) will be performed 2-3 days after the initial endoscopy, aiming to survey if major SRH of peptic ulcer persists.
89292036|NCT05245357|Experimental|Lentil, then Control|Participants first received a meal with 140 g of lentils in the morning. After a washout period of at least 7 days, they then received a meal with 0 g of lentils in the morning.
89292037|NCT05245357|Experimental|Control, then Lentil|Participants first received a meal with 0 g of lentils in the morning. After a washout period of at least 7 days, they then received a meal with 140 g of lentils in the morning.
89292038|NCT05241106|Experimental|HYML-122 treatment|HYML-122 tablets, 200mg spec, 28 days for each cycle. The first eligible three enrolled subjects will be administrated with 600mg bid dose regimen for 28 consecutive days ( 1 treatment cycle). The Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of these three subjects and make decision whether the regimen need to be adjusted (increasing/decreasing administration dosing or adjusting dosing frequency).
89292039|NCT05241093|Experimental|HYML-122 plus cytarabine|"The first three eligible enrolled patients will be treated with initial dosing of HYML-122 400mg bid daily and cytarabine 100mg/m2 intravenously by using 3+3 escalating design to explore RP2D. the Data Monitoring Committee (DMC) will evaluate the safety, efficacy and PK data of the phase 1 subjects and establish the combined regimen recommended dose. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgement of the investigator, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria, whichever occurs first."
89292040|NCT05240573|Experimental|SKI App|
89292041|NCT05240573|Active Comparator|CMUH Dialysis Care App|
89292042|NCT05240144|Experimental|IHG group|Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% Maximal Voluntary Contraction (MVC) on both hands with the frequency of 3 days per week for a period of 6 weeks.
89292043|NCT05240144|Active Comparator|Aerobic training group|Aerobic Exercises include walk for 50 min with the frequency of 3 days per week. This exercise will be done for a 6-week period.
89292044|NCT05240144|Sham Comparator|IHG + Aerobic exercises group|"Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% MVC on both hands with the frequency of 3 days per week for a period of 6 weeks.~Isometric handgrip exercises will be performed in 4 sets for 2 min at 30% MVC on both hands with the frequency of 3 days per week for a period of 6 weeks."
89292045|NCT05240144|Sham Comparator|Sham IHG group|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period.
89292046|NCT05236556|Experimental|Intervention|Receive best practice advisory (BPA)
89292047|NCT05236556|No Intervention|Control|Does not receive best practice advisory (BPA)
89292048|NCT05233163|Experimental|Study Drug Arm|Subjects will take empagliflozin 10 mg oral daily for 12 weeks.
89292049|NCT05231083|Experimental|Arm A - 20Hz Stimulation|Transcutaneous stimulation of the genital nerves at 20Hz
89292050|NCT05231083|Experimental|Arm B - 60Hz Stimulation|Transcutaneous stimulation of the genital nerves at 60Hz
89292051|NCT05229991|Experimental|Intervention Group|Lonafarnib 50mg co-administered with ritonavir 200 mg
89292052|NCT05227105|Active Comparator|Physical Activity intervention|Five physical activity coaching calls with MoveLine and weekly physical activity. Objective tracking of activity with an accelerometer will occur at baseline, after 12 months, and after 24 months.
89292053|NCT05227105|Placebo Comparator|Delayed intervention|Objective tracking of activity with an accelerometer will occur at baseline, after 12 months, and after 24 months.
89292054|NCT05213884|Experimental|Camrelizumab plus chemoradiotherapy|Induction camrelizumab therapy at least one cycle (every 3 weeks) followed by definitive concurrent chemoradiotherapy. After 4~6 weeks of the completion of radiotherapy, adjuvant camrelizumab therapy will begin every 3 weeks for 16 cycles (1 year) or continue until progression or unacceptable toxicity.
89292055|NCT05211024||Aim 1: Group A|Children and adolescent who are prior GOAL participants who have a normal echocardiogram at the 2 year endpoint and are no receiving secondary antibiotic prophylaxis
89292056|NCT05211024||Aim 1 Group B|Children and adolescent who have a normal echocardiogram at the start of the study
89292057|NCT05211024||Aim 2|Children and adolescent who are prior GOAL participants who have persistent latent RHD on echocardiogram at the 2 year endpoint.
89292058|NCT05185271|Experimental|Dyad- focused strategy training intervention|"The dyad-focused strategy training intervention protocol will be developed to help dyads manage the needs that they have as transitioning to the community.~The following theoretical frameworks and guidelines will be used to guide the development of the intervention: (1) the strategy training guideline outlined by Skidmore et al; (2) Bodenmann's framework of dyadic coping; and (3) Self-efficacy theory."
89292059|NCT05176080|Experimental|Treatment group|Famitinib Plus SHR6390 and Endocrine therapy
89292060|NCT05165082|Experimental|Timolol plus cryotherapy|Apply topical timolol solution twice daily (since the beginning of the allocation and continue for 8 weeks) and cryotherapy with liquid nitrogen once every other week (on the allocation day, at the 2nd week, 4th week and 6th week after the beginning of the trial).
89292061|NCT05165082|Placebo Comparator|Placebo plus cryotherapy|Apply placebo (normal saline) twice daily (since the beginning of the allocation and continue for 8 weeks) and cryotherapy with liquid nitrogen once every other week (on the allocation day, at the 2nd week, 4th week and 6th week after the beginning of the trial).
89292062|NCT05159531|Experimental|Standard model of care|Delivery of PrEP care through the local standard of care.
89292063|NCT05159531|Active Comparator|mHealth model of care|Delivery of PrEP care through the Freddie® mobile Health (mHealth) platform.
89292064|NCT05144893|Experimental|Virtual Mindfullness-Based Support Group|The virtual mindfulness-based intervention with social support groups will meet once a week for 4 weeks, each session will be 60 minutes. Each group will have 3-8 participants. The groups will be closed, meaning the same group of participants meet with the same instructor (unless a backup instructor is needed due to unavoidable reasons). Groups will be completed using the video conferencing application.
89292065|NCT05144282||premature baby without ROP (Group 1)|ROP: retinopathy of prematurity
89292066|NCT05144282||ROP without treatment (Group 2)|ROP: retinopathy of prematurity
89292067|NCT05144282||ROP with anti-VEGF treatment (Group 3)|ROP: retinopathy of prematurity
89292068|NCT05144282||ROP with laser photocoagulation treatment (Group 4)|ROP: retinopathy of prematurity
89292069|NCT05132543|Experimental|Wireless µECoG Prosthesis for Speech|
89292070|NCT05132257||PM No-ROP|Premature without retinopathy of prematurity. Prematurity was defined as birth at < 37 weeks gestation.
89292071|NCT05132257||Mild ROP|Prematurity with mild retinopathy of prematurity. ROP not needing treatment. Prematurity was defined as birth at < 37 weeks gestation.
89292072|NCT05132257||Severe ROP|Prematurity with type 1 retinopathy of prematurity. Prematurity was defined as birth at < 37 weeks gestation.
89292073|NCT05132257||Fullterm|Heathal fullterm.
89292074|NCT05129995|Experimental|Passive heat treatment|Infrared sauna bathing
89292075|NCT05128955|Active Comparator|Active Comparator: Splenic artery embolization with vascular embolic coils|Device: Splenic artery embolization with vascular embolic coils
89292076|NCT05128955|Active Comparator|Active Comparator: Splenic artery embolization with vascular embolic plugs|Active Comparator: Splenic artery embolization with vascular embolic plugs
89292077|NCT05128071|Active Comparator|Progesterone Arm|Randomized to receive progesterone
89292078|NCT05128071|Placebo Comparator|Placebo Arm|Randomized to receive placebo
89292079|NCT05126225|Experimental|Protocol group|The intervention is modularized to eight weekly sessions of 2-hour group discussions. The facilitator applies the principle of Cognitive Behavior Therapy and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques. In five sessions, participants are introduced to the general cognitive-behavioral model of HIV stigma and are encouraged to track their thoughts, feelings, and behavioral responses when encountering external stigma or adverse events. The participants further learn to differentiate helpful and non-helpful coping strategies and practice applying helpful coping skills to effectively reduce their HIV stigma. In the other three sessions, participants further discuss more specific stigma that intersects with HIV stigma, including stigma in healthcare settings, access to social support, and available resources on the society levels.
89292080|NCT05121324|Experimental|Intervention|This arm will be exposed to the study intervention: a standardized seizure protocol.
89292081|NCT05121324|Active Comparator|Control|This arm will be exposed to the emergency medical services (EMS) agency's existing seizure protocol; this is the control arm
89292082|NCT05113056|Experimental|Non-randomized|All subjects will be ablated using the Acutus Medical Pulsed Field Ablation System (PFA System) in the management of their atrial fibrillation.
89292083|NCT05109611|Active Comparator|Nitric Oxide Releasing Solution|"Nasal spray with nitric oxide releasing solution (NORS) delivered up to 3 times daily morning, mid-day, and evening.~Maximum volume delivered: 0.56 mL NORS @ 0.11ppm*hrs"
89292084|NCT05109611|Placebo Comparator|Placebo|"Nasal spray with isotonic saline delivered up to 3 times daily morning, mid-day, and evening.~Maximum volume delivered: 0.56 mL Saline @ 0.9%"
89292085|NCT05108987|Experimental|Exercise Morning|If subjects are randomly assigned to this group, they will participate in exercise training in the morning at a moderate to hard intensity. Subjects will be asked to regularly engage in morning exercise while supervised for about 2 weeks.
89292086|NCT05108987|Active Comparator|Exercise Afternoon|If subjects are assigned to this group, they will participate in the same exercise program but after in the afternoon.
89292087|NCT05106153|Experimental|Qualification Phase: Treatment Sequence YXZ|Participants will receive a single oral dose of suvorexant (Treatment Y) in qualification period 1, followed by single oral dose of placebo (Treatment X) in qualification period 2 and then single oral dose of zolpidem (Treatment Z) in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
88806148|NCT00252590|Experimental|Health Motivational Feedback|Personalized health-related feedback
88806149|NCT00252590|Active Comparator|Health Education|Non-personalized didactic health-related education
89292088|NCT05106153|Experimental|Qualification Phase: Treatment Sequence ZYX|Participants will receive Treatment Z in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
89292089|NCT05106153|Experimental|Qualification Phase: Treatment Sequence XZY|Participants will receive Treatment X in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
89292090|NCT05106153|Experimental|Qualification Phase: Treatment Sequence YZX|Participants will receive Treatment Y in qualification period 1, followed by Treatment Z in qualification period 2, and then Treatment X in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
89292091|NCT05106153|Experimental|Qualification Phase: Treatment Sequence ZXY|Participants will receive Treatment Z in qualification period 1, followed by Treatment X in qualification period 2, and then Treatment Y in qualification period 3 on Day 1 during qualification phase. Each treatment will be separated by washout of at least 3 days.
89292092|NCT05106153|Experimental|Qualification Phase: Treatment Sequence XYZ|Participants will receive Treatment X in qualification period 1, followed by Treatment Y in qualification period 2, and then Treatment Z in qualification period 3 on Day 1 during each qualification phase. Each treatment will be separated by washout of at least 3 days.
89292093|NCT05106153|Experimental|Treatment Phase: Treatment Sequence ABFCED|Participants will receive a single oral dose of placebo (Treatment A) in treatment period 1, followed by single oral dose of suvorexant (Treatment B) in treatment period 2, single oral Dose 3 of seltorexant (Treatment F) in treatment period 3, single oral dose of zolpidem (Treatment C) in treatment period 4, single oral Dose 2 of seltorexant (Treatment E) in treatment period 5 and then a single oral Dose 1 of seltorexant (Treatment D) in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
89292094|NCT05106153|Experimental|Treatment Phase: Treatment Sequence BCADFE|Participants will receive Treatment B in treatment period 1, followed by Treatment C in treatment period 2, Treatment A in treatment period 3, Treatment D in treatment period 4, Treatment F in treatment period 5 and then Treatment E in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
89292095|NCT05106153|Experimental|Treatment Phase: Treatment Sequence CDBEAF|Participants will receive Treatment C in treatment period 1, followed by Treatment D in treatment period 2, Treatment B in treatment period 3, Treatment E in treatment period 4, Treatment A in treatment period 5 and then Treatment F in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
89292096|NCT05106153|Experimental|Treatment Phase: Treatment Sequence DECFBA|Participants will receive Treatment D in treatment period 1, followed by Treatment E in treatment period 2, Treatment C in treatment period 3, Treatment F in treatment period 4, Treatment B in treatment period 5 and then Treatment A in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
89292097|NCT05106153|Experimental|Treatment Phase: Treatment Sequence: EFDACB|Participants will receive Treatment E in treatment period 1, followed by Treatment F in treatment period 2, Treatment D in treatment period 3, Treatment A in treatment period 4, Treatment C in treatment period 5 and then Treatment B in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
89292098|NCT05106153|Experimental|Treatment Phase: Treatment Sequence FAEBDC|Participants will receive Treatment F in treatment period 1, followed by Treatment A in treatment period 2, Treatment E in treatment period 3, Treatment B in treatment period 4, Treatment D in treatment period 5 and Treatment C in treatment period 6 on Day 1 during each treatment phase. Each treatment will be separated by washout of at least 5 days.
89292099|NCT05096923||UNC-CAYACC|Children, adolescents, and young adults diagnosed with cancer before the age of 40 enrolled at any point during the diagnosis-treatment-survivorship continuum.
89292100|NCT05093829|Experimental|Vaccination at 9 months of age with NmCV-5|Infant participants randomized to receive the NmCV-5 meningococcal vaccination at 9 months of age, while receiving the current Mali EPI schedule of vaccines.
89292101|NCT05093829|Active Comparator|Vaccination at 9 months of age with MenACWY-TT|Infant participants randomized to receive the MenACWY-TT meningococcal vaccination at 9 months of age, while receiving the current Mali EPI schedule of vaccines.
89292102|NCT05093829|Experimental|Vaccination at 15 months of age with NmCV-5|Infant participants randomized to receive the NmCV-5 meningococcal vaccination at 15 months of age, while receiving the current Mali EPI schedule of vaccines.
89292103|NCT05093829|Active Comparator|Vaccination at 15 months of age with MenACWY-TT|Infant participants randomized to receive the MenACWY-TT meningococcal vaccination at 15 months of age, while receiving the current Mali EPI schedule of vaccines.
89292104|NCT05093686|Experimental|RUBIES|RUBIES provides paraeducators in training on behavioral strategies based on principles of applied behavior analysis to target student disruptive behaviors in the classroom
89292105|NCT05093686|Active Comparator|Usual Care Treatment|Usual Care Treatment provides paraeducators with foundational psychoeducation on autism spectrum disorders.
89292106|NCT05080972|Experimental|in-the-kNOW mobile app.|Participants will be assigned to the in-the-kNOW mobile app for four (4) months.
89292107|NCT05080972|Active Comparator|Control condition.|Participants will be randomized to receive a one-time virtual women's health counseling session with a healthcare provider.
89531148|NCT02497625|Other|Control group|Patients will not receive intervention in the first mo nth of enrollment. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
89531149|NCT05054673|Experimental|intervention|PALFIQUE universal adhesive (Tokuyama self-cure universal adhesive)
89531150|NCT05054673|Active Comparator|control|3M™ ESPE™ single bond Universal Adhesive
89531151|NCT03340259||Newborn infants with enterostomy|Infants with enterostomy after surgery due to congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation
88806150|NCT00252590|Active Comparator|Control - treatment as usual|No added treatment control
88806151|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 1)|
88806152|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 2)|
89292108|NCT05080426|Experimental|Intervention Group|"Mangers in the intervention group will be asked to:~Complete an online survey;~Take the Family Supportive Supervisor Training online (FSST);~Take the Supervisor Support for Leave Use module;~Track their behaviors for two weeks;~Participate in a webinar and have the opportunity to ask questions and give comments;~Complete a post-training survey;~8-10 managers may also participate in the focus group.~Employees in the intervention group will be asked to:~1. Complete an online survey three times over the course of 6 months."
89292109|NCT05080426|No Intervention|Control Group|"Managers and employees in the control group will be asked to:~1. Complete an online survey three times over the course of 6 months."
89292110|NCT05074992|Experimental|Ipilimumab|3mg/kg Ipilimumab IV infusion (day 1) given as a 21 day cycle for 2 cycles.
89292111|NCT05072132|Experimental|Inefficient metabolizers|Participants will be selected based on being inefficient arsenic metabolizers. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. This intervention group will additionally be provided information on their arsenic metabolism efficiency (i.e., their genetic results indicating they are inefficient metabolizers and at increased risk for arsenic toxicities).
89292112|NCT05072132|Experimental|Efficient metabolizers|Participants will be selected based on being efficient arsenic metabolizers. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. This intervention group will additionally be provided information on their arsenic metabolism efficiency (i.e., their genetic results indicating they are efficient metabolizers and at decreased risk for arsenic toxicities).
89292113|NCT05072132|Active Comparator|Control group|The control group will consist of a random sample of HEALS participants. A standard informational intervention will be provided, reminding them of the effects of arsenic exposure and strategies to reduce their exposure. No information on arsenic metabolism efficiency will be provided during the study period (option to receive after the study)
89292114|NCT05067205|Sham Comparator|open release|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using open carpal tunnel release method with duration of 6 months estimated.
89292115|NCT05067205|Experimental|mini CTS releaser|A prospective, open-label, parallel-group to evaluate the postoperative outcome after carpal tunnel release by using mini CTS releaser method with duration of 6 months estimated.
89292116|NCT05063656|Experimental|Gabapentin Open-label treatment|8-week treatment with gabapentin
89292117|NCT05060237|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single photodynamic therapy (PDT)."
89292118|NCT05054829|Experimental|PEERS|
89292119|NCT05054829|Other|Controls|
89292120|NCT05047601|Experimental|PF-07321332/ritonavir (5 days)|Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 5 followed by Placebo every 12 hours from Day 6 through Day 10
89292121|NCT05047601|Experimental|PF-07321332/ritonavir (10-Day)|Participants will receive PF-07321332/ritonavir every 12 hours from Day 1 through Day 10.
89292122|NCT05047601|Placebo Comparator|Placebo|Participants will receive placebo every 12 hours from Day 1 through Day 10.
89292123|NCT05031208|Experimental|Vagus nerve stimulation|Invasive vagus nerve stimulation
89292124|NCT05031208|Experimental|Transcutaneous vagus nerve stimulation|Cymba concha stimulation
89292125|NCT05031208|Sham Comparator|Sham vagus nerve stimulation|No vagus nerve stimulation
89292126|NCT05025189|Active Comparator|Table Grape|Subjects will consume 4 weeks of (two servings) of standardized Freeze-Dried Whole Table Grape Powder
89292127|NCT05025189|Placebo Comparator|Beige Diet|Subjects will consume 4 weeks of a beige diet (low in fiber and low in polyphenols)
89292128|NCT05022329|Experimental|Patients who received two doses Pfizer-BioNTech vaccine, Arm 1|
89292129|NCT05022329|Experimental|Patients who received two doses MODERNA vaccine, Arm 2|
89292130|NCT05022329|Experimental|Patients who received two doses Pfizer-BioNTech vaccine ,Arm 3|
89292131|NCT05022329|Experimental|Patients who received two doses MODERNA vaccine, Arm 4|
89292132|NCT05011760|Experimental|PET|[C-11]NPA PET Scan
89292133|NCT05008146|Experimental|PET|[C-11]NOP-1A
89292134|NCT05006599|Experimental|Humulin® R U-100|Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of Humulin® R U-100 (40 IU) four times daily for 3 weeks.
89292135|NCT05006599|Placebo Comparator|Placebo|Twenty randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive intranasal administrations of placebo (insulin diluent) four times daily for 3 weeks.
89292136|NCT04998669|Experimental|Loncastuximab tesirine + Rituximab|"During the 12-week Induction Phase (Cycles 1 to 4), participants will receive loncastuximab tesirine on days 1 of each 3-week cycle for Cycles 1 through 4; and rituximab on days 1, 8, 15 of Cycle 1 and day 1 of Cycle 2.~Maintenance Phase 1 (Cycle 5) is 8 weeks: Participants achieving complete response (CR) or partial response (PR) during the Induction Phase will receive loncastuximab tesirine once every 3-weeks; and rituximab once during week 7 or 8. Participants achieving a response of Stable Disease (SD) or Progressive Disease (PD) will be taken off treatment.~Maintenance Phase 2 (Cycles 6 and 7) is 16 weeks:~Participants achieving CR during Maintenance Phase 1 receive rituximab once during week 7 or 8 of Cycles 6 and 7.~Participants achieving PR during Maintenance Phase 1 receive loncastuximab tesirine once every 3-weeks over each 8 week cycle; and rituximab once during week 7 or 8 of Cycles 6 and 7.~Participants achieving SD or PD will be taken off treatment."
89292137|NCT04978545|Experimental|calciumhydroxide|Participants received calciumhydroxide as an intracanal medicament for a one week period
89292138|NCT04978545|Experimental|chlorhexidine|Participants received chlorhexidine gel as an intracanal medicament for a one week period
89292139|NCT04968249||Gold 0|Participant must be ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted.
89292140|NCT04968249||Gold 1|Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 >= 80% predicted.
89292141|NCT04968249||Gold 2|Participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC < 0.70 and FEV1 50-79% predicted.
89292142|NCT04968249||Preserved Ratio Impaired Spirometry (PRISm)|Participant shall be between ages 30-55 years and have: ≥10 year smoking history, post-bronchodilator of FEV1 50-79% predicted and a predicted FEV1/FVC ≥ 0.70.
89292143|NCT04960384|Placebo Comparator|Placebo|
89292144|NCT04960384|Experimental|Human Fibroblast Growth Factor-2 (FGF-2)|
89292145|NCT04958811|Experimental|Tiragolumab plus atezolizumab and bevacizumab|Tiragolumab 600mg IV will be administered together with atezolizumab 1200mg IV and bevacizumab 15mg/kg IV every 3 weeks (q3w) until progressive disease or unacceptable toxicity.
89292146|NCT04950530|Experimental|Arm 1|"Biktarvy - one tablet once daily, orally administered for the first 28 days of the study.~No treatment for the last 44 days of the study."
89292147|NCT04950530|Experimental|Arm 2|No treatment for the first 28 days of the study. Biktarvy - one tablet once daily, orally administered for the last 28 days of the study (day 44-72).
89292148|NCT04940741|Experimental|VER-01|VER-01 is administered orally (b.i.d.) using a dosing syringe. One unit corresponds to 2.5 mg THC. The optimal dose is titrated on a patient-by-patient basis. The maximum daily dose should not exceed 13 dose units (32.5 mg THC).
89292149|NCT04940741|Placebo Comparator|Placebo|The Placebo is administered orally (b.i.d.) using a dosing syringe. The optimal dose is titrated on a patient-by-patient basis, analogous to VER-01.
89292150|NCT04937699|Active Comparator|Standard-DAPT of Ticagrelor plus aspirin (DAPT)|"Patients will receive Standard-DAPT of Ticagrelor plus aspirin for 1month after PCI and continue to receive standard-DAPT till 1 year in this arm after as followed:~Ticagrelor 90mg bid+Aspirin 100mg qd for 1month; Ticagrelor 90mg bid+Aspirin 100mg qd for another 11 months;"
89292151|NCT04937699|Experimental|Sequential monotherapy of Ticagrelor and Clopidogrel (SAPT)|"Patients will receive Standard-DAPT of Ticagrelor plus aspirin for 1month after PCI and switch to ticagrelor monotherapy in the following 5 months, and then further de-escalated to clopidogrel monotherapy till 1 year in this arm as followed:~Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month; Ticagrelor 90mg bid, for 5 months; clopidogrel 75mg qd, for 6 months."
89292152|NCT04931758||Patients with low back pain|
89292153|NCT04931758||Controls|
89292154|NCT04929756||Fixation PRL|Visual feedback will be provided at the the preferred retinal locus (PRL) to train subjects to attend to a fixation location. Feedback consists of a gaze-contingent ring whose size varies depending on task performance. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Gaze behavior will be measured with an eye tracker.
89292155|NCT04929756||Smooth Pursuit PRL|Visual feedback will be provided to train subjects to attend to a PRL for smooth pursuit eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on a drifting target. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Smooth pursuit tracking behavior will be measured with an eye tracker.
89292156|NCT04929756||Saccade PRL|Visual feedback will be provided to train subjects to attend to a PRL for saccadic eye movements. Feedback consists of a gaze-contingent ring whose size varies depending on the subject's ability to center the ring on an abruptly shifting dot. Training consists of 5 blocks of up to 50 trials, each block lasting approximately 10 minutes. Acuity and contrast sensitivity will be assessed at the PRL with forced choice psychophysical letter identification tasks. Saccadic eye movement behavior will be measured with an eye tracker.
89292157|NCT04929756||Scotoma Awareness PRL|Subjects are often unaware of their scotomas because they are filled in with the surrounding background texture. The investigators will exploit this filling in to increase awareness of the scotoma by surrounding the scotoma with a visible disk that will be perceptually completed across the scotoma, rendering the scotoma visible. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Scotoma Awareness Disk at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
89292158|NCT04929756||Meta-Guidance PRL|Oculomotor control can be promoted in the location around our hands. The investigators will exploit this meta-guidance advantage by asking subjects to move their hand and their PRL to an on-screen target. In a randomized within-subjects design, Acuity and contrast sensitivity will be assessed with and without a Hand Movement at a Fixation, Smooth Pursuit and Saccade PRL with forced choice psychophysical letter identification tasks. Oculomotor behavior will be measured with an eye tracker.
89292159|NCT04921683|Experimental|Treatment LIFUP|LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone to minimize bone absorption and refraction. Accurate aiming will be ensured using the Brain Sight neuronavigation device, customized for tracking our LIFUP transducer. Following LIFUP, the patient will undergo a second EEG session, except for the EEG cap being fit to the patient's head prior to the LIFUP session so that, as soon as LIFUP administration is complete, the EEG paradigm can be promptly administered. The patient will then be allowed to rest (~1h).The patient will then be administered a second dose of tracer in order to undergo a second PET measurement. Finally, at the end-of-day, the clinical coordinator will collect an Adverse Event Questionnaire and will fit the PSG device for night monitoring.
89531442|NCT06066268||1) Critical limb ischemia (CLI);|"1)Critical limb ischemia (CLI):~Patients suffering from CLI undergoing lower limb revascularization via subgenual femoropopliteal bypass. muscle biopsies willbe taken.~Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing thigh amputation. Muscle biopsies will be taken.~Patients suffering from terminal CLI and/or gangrene of the lower limb undergoing leg amputation. Muscle biopsies will be taken."
89531443|NCT06066268||2)Controls|2)Controls: patients affected by infrarenal abdominal aortic aneurysm (AAA) free from CLI, affected and not affected by type 2 diabetes mellitus, undergoing endovascular exclusion surgery of the AAA (EVAR), similar by age and sex to CLI patients. Sartorius muscle biopsies will be taken.
89531444|NCT06066242|Experimental|AZA+VEN|Two courses of azacitidine combined with venetoclax as induction regimen
88806153|NCT01791452||NAFLD|
88806154|NCT04751864|Experimental|Active Arm|Participants receive active device for the full 8 week study
88806155|NCT04751864|Sham Comparator|Sham Arm|Participants receive sham device for the first 4 weeks, and then at the week 5 cross over, receive the active device.
89292160|NCT04894396|Experimental|Prefabricated Orthotics with metatarsal pad|Participants in Group A will receive the Orthotic with the metatarsal pad (L 2305) according to participants shoe size (https://www.aetrex.com/search?q=l2305&search-button=&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities.
89292161|NCT04894396|Active Comparator|Prefabricated Orthotics without metatarsal pad.|Participants in Group B will receive the neutral Orthotic with a cupped heel (L 2300) according to participants shoe size (https://www.aetrex.com/search?q=l2300&search-button=&lang=en_US). When the investigators provide the Orthotics, an instruction sheet will also be provided, explaining how to use the Orthotic. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. Participants will be required to use the Orthotic wherever possible for a period of 6 weeks, whilst continuing with usual activities
89292162|NCT04894383|Experimental|Prefabricated Orthotics in shoes & indoor comfort sandals with built-in arch support|Participants from Group A will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420&search-button=&lang=en_US) and an Aetrex comfort sandal with built-in arch support (https://www.aetrex.com/aetrex-flips-black-L3000M.html?lang=en_US or https://www.aetrex.com/fiji-flips-women-watermelon-L7009W.html?lang=en_US) according to participants shoe size. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the orthotic/comfort sandal wherever possible.
89292163|NCT04894383|Active Comparator|Prefabricated Orthotics in shoes only|Group B will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420&search-button=&lang=en_US) alone. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the Orthotic wherever possible.
89292164|NCT04891068|Experimental|Single arm with previously untreated high risk early stage breast cancer|All participants will receive azacitidine 50mg/m2 SC daily for five consecutive days.
89292165|NCT04884789|Experimental|Post-Burn Face scar|Use of 3d printed TFO with silicone interface (COFIS 3D)
89292166|NCT04880499|Experimental|Intervention (group A)|Patients who are subjected to the intervention, being iron plus other cofactors for hematopoiesis, other than the standard of care.
89292167|NCT04880499|No Intervention|Control (group B)|Patients who are not subjected to the intervention and follow the standard of care.
89292168|NCT04879979|Experimental|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) designed for the treatment of Cancer-Related Cognitive Impairment (CRCI)
89292169|NCT04872816|Experimental|Continuous airway positive pressure|All participants in continuous airway positive pressure arm will use CPAP (model S10-Resmed®) with expiratory relief and nasal mask.
89292170|NCT04872816|Sham Comparator|SHAM continuous airway positive pressure|Individuals in SHAM continuous airway positive pressure arm will use CPAP (model S7-Resmed®) with expiratory relief and nasal mask. The Sham-CPAP consists of a modified CPAP so that the pressure in the mask was less than 1 cm H2O. In this study, the Sham-CPAP equipment includes an increase in the expiratory orifice of the CPAP mask to eliminate airflow resistance, and a resistor with a small orifice was placed between the CPAP and the circuit. The noise produced by the ventilator and the airflow through the mask will be very similar to that of the effective CPAP. The diameter of the expiratory orifice was 10 cm H2O, and a 4 mm diameter resistor was placed between the trachea and the CPAP flow generator.
89292171|NCT04855812|Experimental|MyoPro|Receiving MyoMo training in-clinic and at home for 6-weeks
89292172|NCT04855812|Active Comparator|Myo-SB|Receiving MyoMo training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
89292173|NCT04855812|Active Comparator|Control|Receiving conventional therapy/training in-clinic and using their prescribed static brace (or others) at home for 6-weeks
89292174|NCT04855799|Experimental|Aquamin®|
89292175|NCT04853719|Experimental|Vascular dose|Rivaroxaban 2.5 mg BID and aspirin 100 mg OD for 6 months
89292176|NCT04853719|Active Comparator|Aspirin|Aspirin 100 mg OD for 6 months
89292177|NCT04852484|Active Comparator|local anesthetic and morphine group|paravertebral block with local anesthetic and morphine, followed by a continuous infusion of local anesthetic and morphine in the paravertebral space
89292178|NCT04852484|Active Comparator|local anesthetic and ketamine group|paravertebral block with local anesthetic and ketamine, followed by a continuous infusion of local anesthetic and ketamine in the paravertebral space
89292179|NCT04852484|Active Comparator|local anesthetic group|paravertebral block with local anesthetic only, followed by a continuous infusion of local anesthetic only in the paravertebral space
89292180|NCT04850872|Experimental|Experimental|PLAYwithHEART Programme is a manualized mindfulness, acceptance, and compassionate-based group intervention for adolescent competitive athletes. It included 8 weekly group sessions, 45 minutes each, run in small groups (ranging from 8 to 12 participants). Participants of this group complete also self-report measures.
89292181|NCT04850872|No Intervention|Control|Participants of control group do not receive the intervention Programme (PLAYwithHEART), nor any other program, and only complete self-report measures.
89292182|NCT04845477|No Intervention|internal hip rotation pre measurement|with knee and hip flexion at 90º, internal hip rotation will be performed
89292183|NCT04845477|Experimental|internal hip rotation post experimental application measurement|with Magnetic tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
89292184|NCT04845477|Placebo Comparator|internal hip rotation post placebo application measurement|with Placebo tape Application with knee and hip flexion at 90º, internal hip rotation will be performed
89292185|NCT04842799|Experimental|Digital delivery of genetic pre-test information|Half of participants will be provided with genetic pre-test information via the BRCA-DIRECT digital platform.
89292186|NCT04842799|No Intervention|Genetic counselling telephone appointment to discuss genetic pre-test information|Half of participants will be provided with genetic pre-test information via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
89292187|NCT04842799|Experimental|Digital delivery of BRCA-gene testing results|97.5% of participant's with a negative (normal) result will receive their BRCA-gene testing result via the BRCA-DIRECT digital platform.
89292188|NCT04842799|No Intervention|Genetic counselling telephone appointment to discuss BRCA-gene testing results|2.5% of participants with a negative (normal) result and those with positive results will receive their BRCA-gene testing result via the normal standard pathway - a telephone consultation with a Genetic Counsellor.
89292189|NCT04840667|Experimental|REPLAGAL|Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight of intravenous (IV) infusion Every Other Week (EOW) for 104 weeks.
89292190|NCT04838223||Neuropathic Corneal Pain with Ocular Surface Discomfort|Participants diagnosed with neuropathic corneal pain with ocular surface discomfort
89292191|NCT04838223||Neuropathic Corneal Pain with Dry Eye Disease|Participants diagnosed with dry eye disease and neuropathic corneal pain
89292192|NCT04838223||NCP or Dry Eye in patients with ocular surface discomfort|Participants diagnosed with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort
89292193|NCT04835363|No Intervention|Control group|Usual care.
89292194|NCT04835363|Experimental|OT intervention.|Patients and their caregivers assigned to the experimental group are included in an early occupational therapy intervention program.
89292195|NCT04830761|Experimental|Habit - Motivation group|First: 2 weeks habit intervention; Second: 2 weeks motivation intervention
89292196|NCT04830761|Experimental|Habit - Social group|First: 2 weeks habit intervention; Second: 2 weeks social intervention
89292197|NCT04830761|Experimental|Habit - Habit group|4 weeks habit intervention
89292198|NCT04830761|Experimental|Motivation - Habit group|First: 2 weeks motivation intervention; Second: 2 weeks habit intervention
89292199|NCT04830761|Experimental|Motivation - Social group|First: 2 weeks motivation intervention; Second: 2 weeks social intervention
89292200|NCT04830761|Experimental|Motivation - Motivation group|4 weeks motivation intervention
89292201|NCT04830761|Experimental|Social - Habit group|First: 2 weeks social intervention; Second: 2 weeks habit intervention
89292202|NCT04830761|Experimental|Social - Motivation group|First: 2 weeks social intervention; Second: 2 weeks motivation intervention
89292203|NCT04830761|Experimental|Social - Social group|4 weeks social intervention
89292204|NCT04830267|Active Comparator|Camrelizumab alone|Camrelizumab 200mg IV every 2 weeks
89292205|NCT04830267|Experimental|Stereotactic body radiotherapy plus Camrelizumab|Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks
89292206|NCT04827147|Experimental|MPP first, FPP second|Participants in this arm will receive the MPP in the first period of the crossover and the FPP in the second period.
89292207|NCT04827147|Experimental|FPP first, MPP second|Participants in this arm will receive the FPP in the first period of the crossover and the MPP in the second period.
89292208|NCT04823975|Experimental|HIEP intervention|Participants will be given the health insurance intervention from Utah Health Policy Project staff, which includes four, 30 minute long, educational learning sessions.
89292209|NCT04815226|Other|Using Peristeen Transanal Irrigation|All participants in the trial will use Peristeen Transanal Irrigation. Eligible volunteers will be those patients who have failed conventional supportive bowel care, have neurogenic bladder, and use CIC (ClC: Clean Intermittent Catheterization) daily.
89292210|NCT04814953||Basal cell carinoma patients|Patients with basal cell carcinoma in history (up to 10 years before inclusion) with or without squamous cell carcinoma or actinic keratosis but no other skin cancers (melanoma or non-melanoma skin cancer)
89292211|NCT04814953||Squamous cell carcinoma patients|Patients with squamous cell carcinoma in history (up to 10 years before inclusion) with or without basal cell carcinoma or actinic keratosis but no other skin cancers (melanoma or non-melanoma skin cancer)
89292212|NCT04814953||Patients with actinic keratoses|Patients with actinic keratosis in history (up to 10 years before inclusion) with or without basal cell carcinoma or squamous cell carcinomas but no other skin cancers (melanoma or non-melanoma skin cancer)
89292213|NCT04811521|Active Comparator|Primary care follow-up|Enhanced primary care coordination
89292214|NCT04811521|Active Comparator|Online Cognitive Behavioral Therapy|Online Self-Administered Anxiety Management Program plus Peer Support Guidance
89292215|NCT04811521|Active Comparator|Therapist-Administered Cognitive Behavioral Therapy|Telehealth 8 one-hour sessions over the course of 8 to 10 weeks
89292216|NCT04801212|Experimental|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
89292217|NCT04801212|Active Comparator|core stability exercises alone|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention, both groups will be given a home exercise program consist of same exercises they have carried out in the clinic for the duration another 6 weeks. The participants will be asked to keep diaries of their exercises they have carried out each week.
89292218|NCT04789486|Experimental|AGUIX + SMART Phase 1|"Dose escalation of Activation and Guidance of Irradiation X (AGUIX) and SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).~Central lung tumor cohort will receive:~five fractions of stereotactic body radiation therapy (SBRT)~AGuIX Nanoparticle given on -7 or -14 day prior to radiation treatment, then with 1st fraction of radiation and for patients receiving radiation over a two (2) week period with the 4th fraction of radiation .~Locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC cohort, will receive:~five fractions of stereotactic body radiation therapy (SBRT)~AGuIX Nanoparticle given on -7 or -14 day prior to radiation treatment, then with 1st fraction of radiation."
89531445|NCT06066242|Experimental|DA/IA 3+7|Daunorubicin or Idarubicin ×3 days combined with cytarabine × 7 days as induction regimen
89292219|NCT04789486|Experimental|AGUIX + SMART Phase 2|Randomized participants will receive recommended phase 1 dose established for their disease group (central lung tumor or locally advanced/unresectable pancreatic ductal adenocarcinoma-LAPC) of Activation and Guidance of Irradiation X (AGUIX) and SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
89292220|NCT04789486|Experimental|SMART Phase 2|Randomized participants will receive standard of care SMART, magnetic resonance imaging (MR)-guided stereotactic body radiation therapy (SBRT).
89292221|NCT04786873|Active Comparator|standard GHST order randomized: arginine - clonidine|"At visit 2 (V2), all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at visit 3 (V3) and visit 4 (V4).~In this arm, those subjects will be presented which will have been randomized to the arginine GHST at V3 and the clonidine GHST at V4.~At visit 5 (V5) all subjects will perform the macimorelin GHST."
89292222|NCT04786873|Active Comparator|standard GHST order randomized: clonidine - arginine|"At V2, all subjects will perform the macimorelin GHST and will be randomized 1:1 to the order of the clonidine and arginine GHSTs at V3 and V4.~In this arm, those subjects will be presented which will have been randomized to the clonidine GHST at V3 and to the arginine GHST at V4.~At V5 all subjects will perform the macimorelin GHST."
89292223|NCT04781881||Entresto|Patients administered Entresto by prescription
89292224|NCT04779333|Experimental|LEAP Group|In addition to the components of the BMT group, the LEAP program includes an emphasis on supporting optimal physical activity, limiting screen time, and encouraging adequate sleep. The child and caregiver are also given a wrist-worn activity tracker and caregivers participate in a motivational Facebook group.
89292225|NCT04779333|Active Comparator|BMT Group|The BMT Group will take part in a family-based intervention within the context of evidence-based behavioral management training (BMT) for caregivers. Standard BMT represents the current standard of care for childhood ADHD.
89292226|NCT04773899|Other|Cohort C1|COVID19 (+) ICU patients with COVID19 pneumonia.
89292227|NCT04773899|Other|Cohort C2|COVID19 (-) matched ICU patients
89292228|NCT04773899|Other|Cohort C3|COVID19 (-) ASA 1 non-hospitalized patients
89292229|NCT04771728|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
89292230|NCT04771728|Experimental|Metronidazole vagianl and Probiotics(Umeta-mimi)|Metronidazole:Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) Probiotics:Oral Umeta-mimi( 5×109cfu per day,30 days）
89292231|NCT04767074|Experimental|Non-pharmacological Cough control therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management. Sessions will be designed to target participants' needs and expectations according to the semi-structured theme.~Session 1 General assessment Prescription of cough technique~Session 2 Cough principles of cough Cough control~Session 3 Breathing pattern retraining and laryngeal hygiene~Session 4 Reinforcement of cough control therapies"
89292232|NCT04763330|Active Comparator|Enhanced Usual Care (EUC)|Active comparator (EUC only).
89292233|NCT04763330|Experimental|Active treatment plus EUC|Veterans randomized to this condition received the treatment plus EUC.
89292234|NCT04761614|Experimental|Treatment (riluzole, mFOLFOX6, bevacizumab)|Patients receive riluzole PO BID on days 1-14. Patients also receive oxaliplatin via IVPB over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via IV push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
89292235|NCT04760860|Placebo Comparator|Placebo Control Arm|Participants in this arm will receive placebo during the trial for 15 weeks, the placebo will follow the same schedule as the Terazosin group; the placebo capsules will have the same appearance as the Terazosin capsules.
89292236|NCT04760860|Experimental|Terazosin Arm|Participants in this arm will receive Terazosin during the trial for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
89292237|NCT04750850|Experimental|Core stability exercises group|30 minutes of core stability exercises program at a light intensity and take a rest breaks if is necessary. They will be instructed in the use of the 4-5 points of the Borg 10 Rating of Perceived Exertion for self-monitoring of exercise intensity. The exercises will performed twice a day for 5 days a week during 5 weeks. A physiotherapist conducted an initial home visit to ensure correct execution of the exercises. He or she will teach the exercises and then the patient will perform them alone in your home. Once a week the physiotherapist will phone the patient and will ask her/him for doubts.
89292238|NCT04750850|Active Comparator|Control group|The patients to continue as normal and not change their routine in terms of exercise and physical activity during the period of study.
89292239|NCT04747587||Patients with stroke|
89292240|NCT04747587||Controls|
89292241|NCT04729933|Experimental|Treatment|V-Wave Shunt Placement
89292242|NCT04724902|Experimental|Compression Group|The volunteer must remain supine on a stretcher, with both legs extended and relaxed. The intervention will be performed with elastic bandages (Selecta® of 13cm x 160 cm, composed of 45% cotton, 20% elastodiene and 27% polyamide) involving the entire knee surface, positioned considering anatomical aspects: covering the femoral condyles and the anterior tibial tuberosity). The bandage will involve the knee from the distal to the proximal, respecting the blood flow of the venous return. The level of compression was defined according to recommendations in the literature on compression interventions in lymphedema and venous changes, and should be kept between 30 mmHg and 60 mmHg. Variations on stipulated values may be interfered according to the volunteer's self-report, which should indicate a level of moderate, comfortable and pain-free compression. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days.
89531446|NCT06066242|Experimental|DA/IA 2+5+VEN|Daunorubicin or Idarubicin ×2 days, cytarabine × 5 days combined with venetoclax as induction regimen
88806156|NCT03419702|No Intervention|Control|No almonds
88806157|NCT03419702|Experimental|Experimental|Almonds
88806158|NCT02097992|Experimental|SD placebo and MD roflumilast then MD placebo|Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.
88813144|NCT01457885|Experimental|CloBu4 regimen|After pre-conditioning with CloBu4 (Clofarabine/Busulfan x 4), subjects will receive a peripheral blood stem cell transplant
89292243|NCT04724902|Sham Comparator|Sham Group|For Sham application, the volunteer must remain supine on a stretcher, with both lower limbs extended and relaxed. Elastic bandages will be used (Selecta® of 13cm x 160 cm, composed of 45% cotton, 20% elastodiene and 27% polyamide) involving the entire knee surface, positioned considering anatomical aspects: covering the femoral condyles and the anterior tibial tuberosity) . The bandage will involve the knee from the distal (tibial tuberosity) to the proximal (femoral condyles), respecting the blood flow of the venous return. However, in this group, no compression force will be performed, maintaining the pressure at 00 mmHg according to a previous reliability study. The procedure will be carried out for 20 minutes, once a day, for 4 consecutive days.
89292244|NCT04724902|No Intervention|Control Group|The Control group will be composed of individuals with knee osteoarthritis, who make up the study's waiting list and will carry out evaluations at the same time intervals as the other groups, but will not receive any type of intervention and will be instructed not to start another treatment during their participation.
89292245|NCT04724096||Non-patient volunteers|5 non-patient volunteers for testing of protocol to allow for the ascertaining of good quality data prior to the scanning of patients.
89292246|NCT04724096||Patients|50 patients to be scanned with the oxygen enhanced MRI scan protocol prior to definitive curative intent therapy.
89292247|NCT04723719|Experimental|SIESTA training + treatment as usual for ADHD|We developed a cognitive behavioral therapy for sleep problems in adolescents with ADHD. This includes seven individual sessions with the adolescent and two individual sessions with the parent(s)/guardian(s). Participants receive this CBT training called SIESTA next to their treatment as usual for ADHD symptomatology (mostly ADHD-medication).
89292248|NCT04723719|Active Comparator|Treatment as usual for ADHD only|Participants continue their treatment as usual for ADHD (mostly ADHD-medication).
89292249|NCT04722458||Patients with Lower urinary tract sypmtoms|Patients with Lower urinary tract sypmtoms over 18 years old will be included to this study
89292250|NCT04710199|Experimental|Maraviroc experimental group|Maraviroc tablet combined with standard treatment
89292251|NCT04710199|Other|Standard treatment|It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
89292252|NCT04707781||prospective patient cohort|patients who will undergo the prospective ILD Screening algorithm
89292253|NCT04707781||retrospective patient cohort|patients with diagnosed ILD
89292254|NCT04699240|Active Comparator|Clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
89292255|NCT04699240|Active Comparator|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times + Lactobacillus Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
89292256|NCT04698460|Experimental|Hybrid coronary revascularization (HCR)|Patients with multi-vessel CAD randomized to hybrid coronary revascularization
89292257|NCT04698460|Active Comparator|Conventional coronary artery bypass grafting (CABG)|Patients with multi-vessel CAD randomized to conventional CABG
89292258|NCT04692168||Entire group|The group will be test prior and three months after a neurotoxic chemotherapy for gynecological cancer.
89292259|NCT04688658|Experimental|Duvelisib plus Nivolumab|"Phase 1: Duvelisib will be taken orally in doses from 15mg once a day, 25mg once a day or 25mg twice a day, 12 hours a part, to determine the recommended dose for the Phase II study when combined with nivolumab.~Nivolumab, 240mg, IV, every 2 weeks for the first four cycles; thereafter it may be switched to 480mg, IV, once every 4 weeks if deemed appropriate by the study doctor.~Phase II: The Recommended Phase II dosage of duvelisib administered will not be determined until Phase I is completed.~Nivolumab, 480mg, IV, every 4 weeks, for up to 1 year."
89292260|NCT04680130||Neurodegenerative symptoms|
89292261|NCT04679870|Experimental|GB2064|GB2064 will be administered orally as 4 x 250 mg tablets twice a day.
89292262|NCT04679441|Active Comparator|Healthy individuals Skills training only|These participants will receive CFSAT training only (n = 60). They will train for 24 hours over 12 weeks.
89292263|NCT04679441|Experimental|MCI, Skills training only|These participants will receive 24 hours of CFSAT training over 12 weeks following the same training protocol as the NC sample.
89292264|NCT04679441|Experimental|MCI, Combined treatment|Participants assigned to this condition will initially train for 3 weeks @ 60 minutes twice per week on CT (Posit Science). Participants will train 90 minutes on Double Decision and 30 minutes on Hawkeye. They can train on Hawkeye in 15- minute increments and intersperse it within the Double Decision training. They will then train CFSAT for 9 weeks at the recommended dosage. Each task will be trained twice before advancing to the next task
89292265|NCT04658784|Experimental|Intervention|Receives posterior colporrhaphy closure using standardized technique with 2-0 V-Loc 90TM, Medtronic
89292266|NCT04658784|Active Comparator|Control|Receives posterior colporrhaphy closure using standardized technique with conventional 2-0 PDS® Ethicon
89292267|NCT04657640|Experimental|weekly iron and folic acid supplementation (IFA)|
89292268|NCT04657640|Experimental|daily multiple micronutrient supplement (MMS)|
89292269|NCT04657640|No Intervention|control|
89523310|NCT04445675|Experimental|Experimental|The support for breastfeeding and the feeding of infants' with breast milk will be conducted in one stage for the experimental group. (1) breastfeeding support education. The content of the support for breastfeeding and the feeding of infants' with breast milk and the materials used were determined by the researchers in accordance with the literature. The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding. Breastfeeding support will be provided in the postpartum service and lactation outpatient clinic of the relevant hospital.
89292270|NCT04648072|Experimental|Periarticular Injection + Adductor Canal Block (Local Anesthestic)|"The experimental arm with receive both the periarticular injection and the adductor canal block.~The periarticular injection will be performed by the surgeon and will consist of 100 mL of injectate being distributed in the following manner: 30 mL to the posterior capsule, 10 mL to the medial collateral ligament, 10mL to the lateral collateral ligament (ensuring not to infiltrate common peroneal nerve), 20mL to the quadriceps and anterior capsule, and 30 mL to the subcutaneous tissue. The periarticular injection will consist of 250 mg of ropivacaine, 30 mg of ketorolac, and 0.5 mg of epinephrine.~The adductor canal block will be completed by the anesthesiologist after spinal anesthesia has been initiated, but before the surgery commences. The block will be completed using an aseptic technique under dynamic, in-plane US guidance. 20 mL of injectate consisting of 100mg of ropivicaine and 50 mcg of epinephrine will be injected around the hyperechoic saphenous nerve."
89292271|NCT04648072|Placebo Comparator|Periarticular Injection + Adductor Canal Block (Normal Saline)|"The control arm with receive a periarticular injection and a sham adductor canal block.~The periarticular injection will be carried out in the same manner as described for the experimental group. The technical aspects of the sham adductor canal block will be the same as for the experimental arm; however, the injectate will consist of 20 mL of normal saline."
89292272|NCT04644042|Experimental|Glenohumeral arthroscopy and arthroscopic subacromial decompression|The intervention group will receive a glenohumeral arthroscopy and ASAD. Participants are discharged with an arm sling and referred to 3 months physiotherapy in a municipally setting. Participants are given a rehabilitation program containing progressive exercises to guide the rehabilitation.
89292273|NCT04644042|Active Comparator|Glenohumeral arthroscopy and skin incision|The control group will receive a glenohumeral arthroscopy, but no treatment concerning the subacromial structures. To allow for the best possible blinding, a 7-10 mm incision, mimicking the one used for ASAD, is performed on the lateral side of the arm 2-3 distal to the acromion. Participants are discharged with an arm sling and referred to 3 months physiotherapy in a municipally setting. Participants are given a rehabilitation program containing progressive exercises to guide the rehabilitation.
89292274|NCT04635787||Healthy Adults|Adults 18 years or older
89292275|NCT04635787||COVID19|Adults 18 years or older diagnosed with COVID 19
89292276|NCT04634708||Pediatric patients on EXCOR VAD support|
89292277|NCT04629586||Individuals diagnosed with type 1 diabetes|"T1D Exchange Registry is currently looking for participants:~Of all ages, genders, races, and ethnic groups~Living in the United States~Diagnosed with type 1 diabetes~Currently taking insulin or have had a pancreatic or islet cell transplant"
89292278|NCT04628910|Active Comparator|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
89292279|NCT04628910|Experimental|Simulated Flotation Therapy|Participants will utilize the Zerobody dry flotation therapy.
89292280|NCT04622813|Placebo Comparator|Placebo group|Patients received sevoflurane-dexmedetomidine-based anesthesia with saline, ketoprofen and paracetamol for postoperative pain control,
89292281|NCT04622813|Experimental|Multimodal group|patients received sevoflurane-dexmedetomidine-based anesthesia with nefopam, ketoprofen, and paracetamol for postoperative pain control.
89292282|NCT04619056|Experimental|Cohort 1|CEB-01 with total SN-38 dose: 9 mg
89292283|NCT04619056|Experimental|Cohort 2|CEB-01 with total SN-38 dose: 18 mg
89292284|NCT04619056|Experimental|Cohort 3|CEB-01 with total SN-38 dose: 36 mg
89292285|NCT04616963|Other|FTC 200 mg / TDF 300 mg and FTC 200 mg / TAF 25 mg|"Phase I: Participants will continue or initiate F/TDF for PrEP for a minimum 12-week lead-in period prior to switching to F/TAF.~Phase II: Participants will be switched to study-provided F/TAF for PrEP until 48 weeks after initiation. Participants will receive study treatment for the duration of the study unless they meet criteria for discontinuation."
89292286|NCT04613921||Group 1|patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list (n=2,000)
89292287|NCT04613921||Group 2|patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD > 20) at the time of listing (n=500)
89292288|NCT04613921||Group 3|patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation (n=500)
89292289|NCT04612348||NJ tube fed|Critically ill children receiving nutrition via a nasojejunal feeding tube.
89292290|NCT04612348||NG tube fed|Critically ill children receiving nutrition via a nasogastric feeding tube.
89292291|NCT04611217|Experimental|High Fiber diet|Group receiving a high fiber diet
89292292|NCT04611217|Other|Low Fiber diet|Control group receiving a low fiber diet
89292293|NCT04610762||(Ex) Drug users recognized at-risk population of infection with Hepatitis C virus|
89292294|NCT04606394|Other|Open label treatment|All subjects receive Trelegy and Ventolin for 2 weeks
89292295|NCT04591782|Experimental|PomJuice (PJ)|8 oz of PJ
89292296|NCT04591782|Active Comparator|Sugar Water|8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it
89292297|NCT04591782|Other|Water|8 oz of water
89292298|NCT04588649|Other|THK-5351|Name: [18F]THK5351，(S)-6-[(3-Fluoro-2-hydroxy)propoxy]-2-(2-Methylaminopyrid-5-yl)-quinoline Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the tau protein Pharmacological category：Radio pharmaceutical
89292299|NCT04588649|Other|AV-45|Name: [18F]AV-45, (E)-4-(2-(6-(2-(2-(2-[18F]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the β- amyloid protein Pharmacological category：Radio pharmaceutical
89292300|NCT04586088|Experimental|Apatinib plus Camrelizumab arm|Subjects receive apatinib plus camrelizumab
89292301|NCT04585451||Chronic Pain Patients|
89292302|NCT04585451||Healthy Controls|
89292303|NCT04579510|Active Comparator|nOPV2 only|Participants in this arm will receive nOPV2 at 6, 10, and 14 weeks of age
89292304|NCT04579510|Active Comparator|nOPV2 and bOPV|Participants in this arm will receive both nOPV2 and bOPV at 6, 10, and 14 weeks of age
89292305|NCT04579510|Active Comparator|bOPV only|Participants in this arm will receive bOPV at 6, 10, and 14 weeks of age
89292306|NCT04579120||African American|African American participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
89292307|NCT04579120||Non-Hispanic White|Non-Hispanic White participants receiving [11C]-Pittsburgh Compound B ([11C]PiB) F 18 AV-1451 (Flortaucipir) for imaging.
89292308|NCT04574089|Experimental|Baofukang Suppository 7 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 7 days
89292309|NCT04574089|Experimental|Baofukang Suppository 14 days|Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 14days
89292310|NCT04572477|Other|[18F]THK-5351|"Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.~Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.~B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.~C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
89292311|NCT04572477|Other|[18F]AV-45|"Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.~Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.~B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.~C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD."
89292312|NCT04563078|Experimental|Transcranial Magnetic Stimulation (TMS)|TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
89292313|NCT04563078|Sham Comparator|Sham Transcranial Magnetic Stimulation (TMS)|Sessions of Sham Transcranial Magnetic Stimulation (TMS) will be conducted.
89292314|NCT04552990|Experimental|Tumor Excision, No Illumination|The first four patients will not receive illumination but have their tumors excised after jet-injection (AirGent2.0) of ALA (Levulan Kerastick), and 3h incubation; this will be done to assess biodistribution of ALA through fluorescence microscopy.
89292315|NCT04552990|Experimental|PDT treatment with jet-injections|Patient 5-16 will receive PDT treatment with jet-injections of ALA followed by 3h incubation under occlusion and thereafter illumination with red light (total dose 75 J/cm2). In patient 5-16, the PDT treatment will be repeated after 2 weeks.
89292316|NCT04550169||Intensive Care Coordination|Intensive Care Coordination along with Standard of Care
89292317|NCT04550169||Control|Standard of Care alone
89292318|NCT04549974|Experimental|Passive heat exposure|
89292319|NCT04536480|Experimental|Control: 12 hour eating period|Control: Habitual daily eating period (no meal time restrictions)
89292320|NCT04536480|Experimental|Time Limited Eating|Time Limited Eating: 8-hour eating period (16 hours of daily fasting).
89292321|NCT04534673|Experimental|Intervention group|Pegylated interferon lambda + Standard of care treatment
89292322|NCT04534673|No Intervention|Control group|Standard of care treatment
89292323|NCT04527900|Experimental|Concurrent chemoradiation|Concurrent carboplatin and paclitaxel and IMPT (Intensity Modulated Proton Therapy)
89292324|NCT04518397|Experimental|Theatre participants|Girls in this arm will participate in the theatre intervention.
89292325|NCT04518358|Experimental|Evaluation of Expert Guiding Technology|
89292326|NCT04549168|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.
89292327|NCT04549168|Placebo Comparator|Placebo|Participants will receive one placebo matched to lemborexant 10 mg tablet, orally, once daily for 30 consecutive nights on each night approximately 5 minutes before participants intends to try to sleep.
89292328|NCT04509050||Part A|Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
88813145|NCT03830138||Acute coronary syndrome patients:|One hundred patients with acute coronary syndrome.
89292329|NCT04509050||Part B|Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.
89292330|NCT04504955||Atopic Dermatitis|Pts presenting to enrolling sites across in North America and select European countries are invited to enroll if eligible
89292331|NCT04504682|Experimental|Ambulation|Participants in this arm will be encouraged to ambulate with epidural in place.
89292332|NCT04496544||Drug-Coated Devices|Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with drug-coated devices (drug-eluting stent ± drug-coated balloon, bare metal stent with drug-coated balloon, or drug-coated balloon alone)
89292333|NCT04496544||Non-Drug-Coated Devices|Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with non-drug-coated devices (bare metal stent ± percutaneous transluminal balloon angioplasty or percutaneous transluminal balloon angioplasty alone)
89292334|NCT04490642||Concomitant bladder and bowel Dysfunction|25 patients with concomitant bladder and bowel dysfunction.
89292335|NCT04490642||Those without concomitant bladder and bowel dysfunction|25 patients without concomitant bladder and bowel dysfunction.
89523311|NCT04445675|No Intervention|Control Groups|The infants in the control group will be followed up in routine service. No intervention will be made.
89292336|NCT04489693|Active Comparator|Ambulatory Care Coordinator Team (ACCT)|Patients randomized to ACCT receive care from different doctors in clinic and in the hospital. ACCT patients who have been hospitalized twice, had 4 emergency department (ED) visits in the last year or are referred by their primary care physician are offered ACCT care coordination services (ACCT-CC) from nurses and social workers who manage their care with the larger clinical team. Patients are graduated from ACCT if the ACCT team thinks they are no longer high risk.
89292337|NCT04489693|Active Comparator|Comprehensive Care Physician (CCP)|Patients randomized to the CCP group are assigned to a Comprehensive Care Physician and are asked to see their assigned CCP for their primary care. The patients receive their care from the same CCP in the outpatient clinic and also if they were to be hospitalized.
89292338|NCT04489693|Active Comparator|Comprehensive Care, Community & Culture Program (C4P)|Patients randomized to C4P receive care from a CCP in both the hospital and the clinic as well as the following: 1) systematic screening of 17 domains of unmet social needs, 2) access to a community health worker and 3) access to community-based arts and culture programming.
89292339|NCT04486755|Experimental|Dose Level 1|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 20 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
89292340|NCT04486755|Experimental|Dose Level 2|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 16 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
89292341|NCT04486755|Experimental|Dose Level 3|Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 12 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
89292342|NCT04486677|Other|Caring Cards Group|Group of Veteran card-makers.
89292343|NCT04486677|Other|Caring Cards Recipients|Group of Veteran card-recipients.
89292344|NCT04483921|Experimental|Exercise|Participants will complete a prescribed exercise bout.
89292345|NCT04483921|No Intervention|Sedentary|Participants will rest quietly in a seated position for the equivalent amount of time prescribed for the exercise condition.
89292346|NCT04470284|Active Comparator|SMBP_only|Standard treatment with SMBP
89292347|NCT04470284|Experimental|SMBP_mobile_app|SMBP with mobile App based feed-back algorithm
89292348|NCT04469803|Experimental|No nap, brief nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
89292349|NCT04469803|Experimental|No nap, longer nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with no nap first, undergo a 1-week minimum washout, then complete the protocol again with a longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
89292350|NCT04469803|Experimental|Brief nap, no nap, then longer nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a longer nap opportunity.
89292351|NCT04469803|Experimental|Brief nap, longer nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with brief nap first, undergo a 1-week minimum washout, then complete the protocol again with longer nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
89292352|NCT04469803|Experimental|Longer nap, brief nap, then no nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with a brief nap, then undergo a minimum 1-week washout, then return to complete the protocol again with no nap opportunity.
89292353|NCT04469803|Experimental|Longer nap, no nap, then brief nap|Participants will be monitored for 72 total hours, including a 12-hour simulated night shift. At baseline (consent), participants randomized to crossover study design with three study arms (No nap, brief nap, longer nap). In this sequence, participants will perform the 12-hour night shift with a longer nap first, undergo a 1-week minimum washout, then complete the protocol again with no nap, then undergo a minimum 1-week washout, then return to complete the protocol again with a brief nap opportunity.
89292354|NCT04460573|Active Comparator|Smart boot irremovable|Smart boot rendered irremovable with cohesive bandage; no feedback on adherence.
89292355|NCT04460573|Active Comparator|Smart boot removable|Smart boot, removable, without feedback on adherence.
89292356|NCT04460573|Experimental|Smart boot removable+reinforcement|Smart boot with, removable, with reinforcement of adherence via smart watch and smart phone as well as remote patient monitoring.
89292357|NCT04445714|Other|dapagliflozin and saxagliptin|Singe arm once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
89292358|NCT04445116|Experimental|Endeavor™ Action Video Game Treatment|25 participants will fill out questionnaires and complete a neuropsychological evaluation. During study participation, participants will target using Endeavor™ action video game to complete 25-30 minutes at-home sessions 5 days a week for a total of 8 weeks via an iOS application.
88813146|NCT03830138||Controls:|Fifty healthy control
89292359|NCT04443153|Experimental|De-escalation|Subjects randomized to this arm will proceed from DSS to PF to SAM
89292360|NCT04443153|Experimental|Escalation|Subjects randomized to this arm will proceed from SAM to PF to DSS
89292361|NCT04442100|Experimental|bioprosthesis|"prosthetics of heart valves with dentures MedEng-Bio"
89292362|NCT04437667|Experimental|Intervention Arm|Adolescents participants enrolled in the intervention arm will receive the intervention, Tumaini, loaded on a low-cost Android smartphone, during the long November-December school holidays for the first three years of the study.
89292363|NCT04437667|Active Comparator|Control Arm|Adolescent participants enrolled in the control arm will receive a commercially available age- and language-appropriate educational game or knowledge quiz loaded on a study-provided low-cost Android smartphone.
89292364|NCT04435704|Experimental|Oxytocin|Oxytocin will be administered at increasing and decreasing rates
89292365|NCT04431700|Experimental|Anti-inflammatory whole food|Included food items will include a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., curcumin), fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be permitted or encouraged. Recommended portions of complex carbohydrates (50% - 60%) and lean proteins (20% - 30%) will form the basis of weight-based caloric needs. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Vegetables with high insoluble fiber content will be cooked instead of eaten raw.
89292366|NCT04431700|Active Comparator|Regular Diet|Patients in the control diet arm will be counseled to continue their regular diets and focus on recording all food intake.
89292367|NCT04429971|Experimental|Immediate PreP initiation|"PreP screening program with immediate PrEP (iPrEP) initiation in the ED using a PrEP starter pack with facilitated linkage to care."
89292368|NCT04429971|Active Comparator|Out-patient care for PrEP initiation|PrEP screening program with referral to out-patient care for PrEP initiation
89292369|NCT04429971|Experimental|PreP Screening Program|Part 1: Targeted ED-based patients
89292370|NCT04427709|Other|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®) first then placebo injection.
89292371|NCT04427709|Other|Placebo, Then Oxytocin|Subjects in this arm will receive Intramuscular placebo injection first then oxytocin injection
89292372|NCT04422912|Experimental|DSG3-CAART|"Cohort A: Fractionated infusions of DSG3-CAART at increasing dose levels (6-9 groups) administered as a single cycle.~Cohort B: Consolidation of infusion of DSG3-CAART to fewer fractionations than in Cohort A using the selected dose from Cohort A (1 group) administered as a single cycle.~Cohort C: Infusion of final selected dose and fractionation of DSG3-CAART from Cohorts A and B (1 group) administered as a single cycle"
89292374|NCT04415476|Other|Sirolimus and Tacrolimus and prednisone|Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)
89292375|NCT04415476|Experimental|Standard of Care|"Arm1:) sirolimus and tacrolimus and prednisone group:~Tacrolimus, The patient will receive 0.1-0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 5-12 ng/ml.~Mycophenolate mofetil (NA )Stopped upon sirolimus initiation Sirolimus:1-5 mg/day PO if >40 kg / 1 mg/m²/day if <40 kg trough blood levels 5-12 ng/ml Prednisone:20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effects.~Arm 2) Standard Therapy Tacrolimus:0.1 to 0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 8-12 ng/ml Mycophenolate mofetil:750-1250 mg bid PO and adjust to tolerance (WBCs and GI side effects Sirolimus: NA Prednisone: Prednisone dose 20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effect"
89292376|NCT04390321|Experimental|Down Syndrome LLMcare|Individuals with Down Syndrome which are able to execute the LLMcare physical and cognitive training intervention
89292377|NCT04389567||Patients with COVID-19 taking Famotidine|Use of any dose of oral Famotidine during period of COVID-19
89292378|NCT04386967|Experimental|Dose expansion|Dose expansion trial comprises of 2 cohorts. In cohort 1, OH2 injection will be administered at 1x10e7CCID50/mL . In cohort 2, OH2 injection will be administered at 1x10e7CCID50/mL in combination with Keytruda injection, an anti-PD-1 antibody, and the first doses of the two anti-tumor agents will be administered on the same day.
89292379|NCT04378933|Experimental|Amber Glasses and Fixed Wake|Participants will wear glasses with amber lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will also be required to wake up at the same time (±30 mins).
89292380|NCT04378933|Active Comparator|Clear glasses and Free Wake|Participants will wear identically appearing glasses with clear lenses beginning 7 hours before average baseline mid-sleep time until the time of intended sleep onset or until a duration of 7 hours of use is reached. Participants will not be given instructions regarding sleep schedule.
89292381|NCT04372563||healthy|Healthy patients with normal aortic dimensions
89292382|NCT04372563||ascending aortic dilation 45-55, operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves operated on
89292383|NCT04372563||ascending aortic dilation 45-55, non operated on|patients with ascending aortic dilation 45-55, tricuspid aortic valves non operated
89292384|NCT04371536|Active Comparator|Arm A: Oral iron therapy|Arm A is standard oral iron therapy for 3 months.
89292385|NCT04371536|Experimental|Arm B: Oral iron therapy plus IRONCHILD web-based intervention|Oral iron therapy as per Arm A plus the IRONCHILD web-based intervention aimed at promoting oral iron adherence. This web-based intervention was developed specifically for caregivers of young children with nutritional iron deficiency anemia to promote oral iron adherence.
89292386|NCT04364568|Experimental|Symptomatic group at three month|"Rivermead Post-Concussion Syndrome >= 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
89523312|NCT04967963|Experimental|Transplantation of HAM|HAM was used after sequestrectomy in patients with stage-2 MRONJ
89292387|NCT04364568|Experimental|Asymptomatic group at three month|"Rivermead Post-Concussion Syndrome < 12 MRI and clinical exam and sociological interview at day 105 (+/-15 days) 6 months follow up : sociological interview~1 year follow up : psychological and sociological interview, Rivermead Post Concussion Syndrome questionnaire"
89292388|NCT04362982|Experimental|ADHD|In the first part of the clinical trials, ADHD cohorts are going to undergo a neuropsychological assessement. Moreover, they will interact with the serious game twice (30-45 minutes/each time). In the second part, participants will interact with game two or three times per week (30-45 minutes/each time). Finally, a neuropsychological assessment will be administered following the procedures of the first one.
89292389|NCT04362982|Active Comparator|non-ADHD|Non-ADHD group will follow the same procedures as the experimental one.
89292390|NCT04362189|Experimental|HB-adMSCs|Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.
89292391|NCT04362189|Placebo Comparator|Placebo|Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10.
89292392|NCT04350762|Experimental|Supplement + Fish Oil|"Participants will mix 5 scoops of powdered nutrition supplement with 8 oz of cold water (2x/day). The supplemental shake will be consumed on two separate occasions daily. Omega-3 fish oil supplement is in capsule form for intake once daily.~The NutraWell nutrition powder and OmegaRich fish oil supplement will be provided by and distributed from DoWell Laboratories (Irvine, CA - USA)."
89292393|NCT04350762|No Intervention|Control|No dietary supplements. Participants will continue current intake.
89292394|NCT04342624|Experimental|Cinnamon|Consume 4g of cinnamon capsules daily. Will be randomized, double blind, cross-over to other arm after.
89292395|NCT04342624|Placebo Comparator|Placebo|Consume 4g of placebo daily. Will be randomized, double blind, cross-over to other arm.
89292396|NCT04341259|Experimental|Ipatasertib as a Single Agent|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD). This study has three study periods: a screening period (up to 14 days in length), followed by a treatment period of up to approximately 2 years (Cycle 1 will be 35 days in length, all subsequent cycles will be 28 days in length) and a 28-day follow-up period after the treatment discontinuation or study completion.
89292397|NCT04341116|Experimental|TJ003234 Medium Dose|
89292398|NCT04341116|Experimental|TJ003234 Low Dose|Part 1 only
89292399|NCT04341116|Placebo Comparator|Placebo|
89292400|NCT04341116|Experimental|TJ003234 High Dose|Part 2 Phase 3 only
89292401|NCT04335188||In-patients with SARS-CoV-2 infection|"In-patients fulfilling the following criteria:~SARS-CoV-2 infection In-patient treatment Written informed consent for participation in observational study No explicit medical exclusion criteria are stated to avoid selection bias."
89292402|NCT04335006|Experimental|Experimental A|Subjects receive Carelizumab in combination with Nab-paclitaxel plus Apatinib,each 4-week cycle
89292403|NCT04335006|Experimental|Experimental B|Subjects receive Carelizumab in combination with Nab-paclitaxel,each 4-week cycle
89292404|NCT04335006|Active Comparator|Comparator C|Subjects receive nab-paclitaxel intravenously each 4-week cycle.
89292405|NCT04333108|Experimental|Masitinib & BSC|"Experimental Arm:~Masitinib (titration to 6.0 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC).~Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control."
89292406|NCT04333108|Placebo Comparator|Placebo & BSC|"Placebo Comparator:~Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)"
89292407|NCT04330001|Experimental|FAIOL|Implantation of FAIOL in the capsular bag in the posterior chamber of the eye. The IOL is intended to be used over the lifetime of the subject.
89292408|NCT04321876||NMG IM 211 E Chicago Ave|
89292409|NCT04321876||NMG IM ARKES|
89292410|NCT04321876||NMG IM 1460 N Halsted St|
89292411|NCT04321876||NMG IM 201 E Huron St|
89292412|NCT04321876||NMG Integrative Medicine 150 E Huron St|
89292413|NCT04321876||NMG IM 1776 N Milwaukee Ave|
89292414|NCT04321876||NMG IM 20 S Clark St|
89292415|NCT04321876||NMG IM FM 1704 Maple Ave|
89292416|NCT04321876||NMG IM 259 E Erie St|
89292417|NCT04321876||NMG IM 1135 S Delano Ct|
89292418|NCT04321876||NMG IM 1333 W Belmont Ave|
89292419|NCT04319120||questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed.
89292420|NCT04313088|Other|Experimental Group A|All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group A will take eluxadoline 100mg by mouth twice for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take matching placebo by mouth twice daily. Each participant in Group A will take 42 days of eluxadoline 100mg twice daily followed by 42 days of placebo over the course the study.
89292421|NCT04313088|Other|Experimental Group B|All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group B will take placebo by mouth twice daily for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take eluxadoline 100mg by mouth twice daily. Each participant in Group B will take 42 days of placebo followed by 42 days of eluxadoline 100mg twice daily over the course the study.
89523313|NCT03378323|Active Comparator|Multiple injection local anesthetic|Ultrasound guided axillary plexus block with multiple injections of local anesthetic
89523314|NCT03378323|Experimental|Single injection local anesthetic|Ultrasound guided axillary plexus block with a single injection of local anesthetic
89292422|NCT04301986|Experimental|TNE Followed by EGD|Subjects will undergo administration of a transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
89292423|NCT04301986|Experimental|Cytosponge, then TNE, followed by EGD|Subjects will undergo administration of Cytosponge and transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.
89292424|NCT04301531|Experimental|Arm 1 (intervention arm)|Arm 1 or the intervention arm will involve seven communities: 4-monthly mass screening, and treatment of those who test positive by CHWs will be conducted. Febrile cases will be tested and treated by CHWs any time
89292425|NCT04301531|Other|Arm 2 (control arm)|Arm 2 or the Control arm will involve 2 communities: mass screening and treatment only done at baseline and at evaluation. Febrile cases will be tested and treated by CHWs any time.
89292426|NCT04293276|Experimental|Treatment group|Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
89292427|NCT04292808|Other|Penthrox|Low Dose Methoxyflurane
89292428|NCT04276194|Experimental|Treatment (intensity modulated proton therapy)|Patients undergo intensity modulated proton therapy once daily over 30 fractions and also undergo MRI over 20 minutes during fractions 7, 13, 20, and 30 of radiation in the absence of disease progression or unacceptable toxicity.
89292429|NCT04267822|Experimental|RV521 Capsules|RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. They are a white, opaque capsule and administered orally.
89292430|NCT04267822|Placebo Comparator|RV521 Placebo Capsules|RV521 placebo capsules will contain mannitol and microcrystalline cellulose only. They are a white, opaque capsule and administered orally.
89292431|NCT04261777|Experimental|SPL-01-001|
89292432|NCT04259424|Experimental|Aerobic Exercise + Upper Extremity Rehabilitation|Subjects will receive a total of 18 intervention sessions. In each intervention session, subjects will perform 15 minutes of aerobic exercise on a stationary cycle followed by 200 repetitions of an upper extremity rehabilitation program.
89292433|NCT04258332|Other|High Salt Diet then Low Salt Diet|"The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure.~The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg)."
89292434|NCT04258332|Other|Low Salt Diet then High Salt Diet|"The low-salt diet is comprised of 7 days of freshly prepared frozen meals, snacks, and Na+ free water. All low-salt meals will be prepared in each site's Metabolic Kitchen, with standardization of diets across sites. The low-salt diet includes: 20 mEq Na+ (±2 mEq) (460 mg/day), 100 mEq potassium (±2 mEq), and 1,000 mg calcium (±50 mg).~The high-salt diet will be achieved through the supplementation of each participant's usual diet with Na+ bullion packets (2 packets per day). This will increase Na+ intake by approximately 2,200 mg (≈100 mEq Na+) to a total greater than 5,000 mg Na+ per day based on prior estimates of Na+ intake (see section C1.2). In addition, 1,000 mg of calcium carbonate (provided via Tums tablets) will be taken daily on the high Na+ diet to reduce the potential impact of changes in calcium intake on blood pressure."
89292435|NCT04242901||Colorectal cancer|Patients recently diagnosed colorectal cancer
89292436|NCT04239144|No Intervention|Medical therapy group|Arm 1 - 15 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming.
89292437|NCT04239144|Active Comparator|Catheter ablation|Intervention Arm 2 -15 patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).
89292438|NCT04239144|Experimental|Bilateral sympathectomy|Interventional Arm 3 - 15 patients allocated to this group will undergo bilateral sympathectomy, which will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers.
89292439|NCT04233190|Experimental|Formoterol + budesonide Eurofarma (12/400mcg e 6/200mcg)|Formoterol 12mcg + budesonide 400mcg / Formoterol 6mcg + budesonide 200mcg
89292440|NCT04233190|Active Comparator|Alenia® (12/400mcg e 6/200mcg)|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
89292441|NCT04231578|Experimental|Immediate Couple HOPES|Immediately assigned to receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
89523315|NCT03382691|Experimental|EXPERIMENTAL|Blood pressure check using mobile device and control device
89292442|NCT04231578|No Intervention|Delayed Intervention|Participants will not receive Couple HOPES for the first 8 weeks, and complete assessments at the beginning, middle, and end of this period. After this 8-week delay, participants will then receive seven modules of an Internet-delivered self-help intervention with paraprofessional coaching for PTSD completed at the participant's own pace within 8 weeks.
89292443|NCT04225507|Other|Lifestyle Intervention|Diet and exercise.
89292444|NCT04225507|Experimental|Lifestyle Plus CPAP Intervention|CPAP treatment, diet and exercise.
89292445|NCT04207281|Active Comparator|Honey|Raw honey (1.5 tablespoons)
89292446|NCT04207281|Placebo Comparator|Comparator|Honey comparator(1.5 tablespoons)
89292447|NCT04181788|Experimental|Arm A1 (Phase 1b)|
89292448|NCT04181788|Experimental|Arm B1 (Phase 1b)|
89292449|NCT04181788|Experimental|Arm A2 (Phase 2)|
89292450|NCT04181788|Experimental|Arm B2 (Phase 2)|
89292451|NCT04181684|Experimental|Experimental: LITT with Hypofractionated radiation therapy|Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 35Gy/10 fractions.
89292452|NCT04173221|Experimental|Intervention|
89292453|NCT04173221|Other|Control|
89292454|NCT04161118|Experimental|Tisagenlecleucel (CTL019)|All patients will receive a single target dose of 0.6 to 6.0 × 108 of autologous tisagenlecleucel (CTL019) transduced T-cells with a viability of at least 70% administered via IV infusion after optional bridging with chemo- or immunotherapy and lymphodepleting (LD) chemotherapy with cyclophosphamide and fludarabine.
89292455|NCT04159480|Experimental|Experimental - Cogito Companion|Those allocated to Experimental arm will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators. The Cogito mobile sensing platform passively gathers behavioral information through an individual's normal smartphone usage. Measurements of location, call, and text patterns are recorded.
89292456|NCT04159480|Active Comparator|Active Control|Participants randomized to the Active Control group will download MyCAP and have access to resources housed within this app for a three-month period post-consent. Participants will be provided information regarding the mHealth Tool apps, and provided basic information on how to download the apps. As noted above, participants will be provided biweekly surveys .
89292457|NCT04121897|Experimental|TEMPO|The Therapist Education and Massage for Parent-Infant Outcomes program (TEMPO) is a structured, therapist-led physical therapy program. TEMPO trains and supports parents to deliver physical therapy interventions including massage and developmental play during hospitalization and in the home setting.
89292458|NCT04120194|Experimental|NanoFlu|NanoFlu will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
89292459|NCT04120194|Active Comparator|Fluzone Quadrivalent|Fluzone Quadrivalent will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.
89292460|NCT04119570|No Intervention|No intervention|Participants will have their clinic visit as per usual care.
89292461|NCT04119570|Active Comparator|CKD Report Card|Participants will receive the CKD Report Card prior to the clinic visit.
89292462|NCT04119037|Experimental|Group I (cordotomy)|Patients undergo a cordotomy over 1-2 hours.
89292463|NCT04119037|Sham Comparator|Group II (morphine, fake cordotomy)|Patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours.
89292464|NCT04109937|No Intervention|Surgery Alone|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction but will not receive any post-operative radiation therapy.
89292465|NCT04109937|Active Comparator|Surgery and Post-Operative Radiation Therapy|Patients with lower extremity bone metastases will receive surgical fixation/reconstruction and will receive any post-operative radiation therapy.
89292466|NCT04108455||With Diabetes|Pregnant women with diabetes - either diagnosed beforehand or diagnosed during gestation
89292467|NCT04108455||Controls|Biobank samples will be obtained from similar age/BMI/ethnicity women who do not have evidence of diabetes.
89292468|NCT04103359|Experimental|MDS patients|MDS patients receiving blood transfusion
89292469|NCT04090853|Other|Patient Treatment Group|Up to three Diode and Radio Frequency treatments and up to three additional radio frequency treatments will be performed per patient at the discretion of the principal investigator. Diode treatments will be spaced six weeks apart while the radio frequency treatments will be spaced between 2-3 weeks apart.
89292470|NCT04089111|Experimental|1.1. ASV, MV target 100%|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
89292471|NCT04089111|Active Comparator|1.2. Volume control, MV target %100|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3 Ventilation frequency will be adjusted to reach the same volume target calculated in arm1.
89292472|NCT04089111|Experimental|2.1. ASV, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with ASV mode. Tidal volume, ventilation frequency, inspiratory duration will be automatically adjusted by the mechanical ventilator.
89292473|NCT04089111|Active Comparator|2.2. Volume control, MV target to reach PaCO2< 45 mmHg|Patients will be ventilated with volume control mode. A tidal volume of 6-8 ml/kg will be used. I:E ratio will be set as 1:3. Ventilation frequency will be adjusted to reach the target PaCO2 level
89292474|NCT04072809||All participants|All participants in the study will experience the same procedures.
89292475|NCT04071769|Experimental|Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF)|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
89292476|NCT04068896|Experimental|NGM120 Dose 1|NGM120 Subcutaneous Injection
89292477|NCT04068896|Experimental|NGM120 Dose 2|NGM120 Subcutaneous Injection
89292478|NCT04068896|Experimental|NGM120 Dose 3|NGM120 Subcutaneous Injection
89292479|NCT04068896|Experimental|NGM120 Dose 4|NGM120 Subcutaneous Injection
89292480|NCT04068896|Experimental|NGM120 Dose 5|NGM120 Subcutaneous Injection
88813147|NCT01839266||acute PE survivor, acute PE nonsurvivor|acute PE survivor, acute PE nonsurvivor (in-hospital death)
89292481|NCT04068896|Experimental|NGM120 Dose 6|NGM120 Subcutaneous Injection
89292482|NCT04068896|Placebo Comparator|Placebo|Placebo
89292483|NCT04068649|Experimental|Arm I (palliative RT)|Patients undergo 1, 3-5, 5-6, or 10 fractions of palliative RT deemed appropriate by the treating physician.
89292484|NCT04068649|Experimental|Arm II (SBRT)|Patients undergo single fraction SBRT.
89292485|NCT04057638|Experimental|Treatment group|There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
89292486|NCT04052568|Experimental|Experimental psilocybin|Participants will have up to four doses of psilocybin.
89292487|NCT04050670|Experimental|Tirzepatide - Upper Arm|Participants received 5mg Tirzepatide by subcutaneous injection on upper arm.
89292488|NCT04050670|Experimental|Tirzepatide - Thigh|Participants received 5mg Tirzepatide by subcutaneous injection on thigh.
89292489|NCT04050670|Active Comparator|Tirzepatide - Abdomen|Participants received 5mg Tirzepatide by subcutaneous injection on abdomen.
89292490|NCT04032106|Active Comparator|Group A (standard HPV information)|Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.
89292491|NCT04032106|Experimental|Group B (Outsmart HPV, unidirectional vaccine reminders)|Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).
89292492|NCT04032106|Experimental|Group C (Outsmart HPV, interactive vaccine reminders)|Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).
89292493|NCT04016714|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, and 4 (approximately 3, 5, and 12 months of age). As part of the study design, participants will also receive other pediatric vaccines, including Vaxelis™ (0.5 mL single dose at Visits 1, 2, and 4); M-M-R™II (0.5 mL single dose at Visit 4); and VARIVAX™ (0.5 mL single dose at Visit 4, except participants in Norway and Denmark, who will receive a second dose of VARIVAX™ at Visit 5, according to local vaccination requirements).
89292494|NCT04016714|Active Comparator|Prevenar 13™|Participants will receive a single 0.5 mL IM injection of Prevenar 13™ at Visit 1, 2, and 4 (approximately 3, 5, and 12 months of age). As part of the study design, participants will also receive other pediatric vaccines, including Vaxelis™ (0.5 mL single dose at Visits 1, 2, and 4); M-M-R™II (0.5 mL single dose at Visit 4); and VARIVAX™ (0.5 mL single dose at Visit 4, except participants in Norway and Denmark, who will receive a second dose of VARIVAX™ at Visit 5, according to local vaccination requirements).
89292495|NCT04009733|Experimental|Osteogenesis imperfecta type 1|Patients with OI type 1
89292496|NCT04009733|Experimental|Osteogenesis imperfecta type 3|Patients with OI type 3
89292497|NCT04009733|Active Comparator|Control population|The control population corresponds to a pre-existing serum collection of osteoarthritis cohorts (OFELY and MODAM for women, STRAMBO for men).
89292498|NCT03997578|Active Comparator|NIPSA|Patients will be treated with only NIPSA technique.
89292499|NCT03997578|Experimental|NIPSA plus Connective tissue graft|Patients will be treated with NIPSA technique associated to a connective tissue graft.
89292500|NCT03997435|Experimental|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy
89292501|NCT03997435|Experimental|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy
89292502|NCT03997409|Experimental|Low Carbohydrate Diet|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the LCD intervention will consume 25-35% of total daily intake from carbohydrates, 45-65% from fat and 10-30% from protein.
89292503|NCT03997409|Active Comparator|Standard Carbohydrate Diet|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the SCD intervention will consume 45-65% of total daily caloric intake from carbohydrates, 25-35% from fat and 10-30% from protein.
89292504|NCT03997409|No Intervention|No Dietary Recommendations|This group will serve as a control that receives the same number of education sessions as LCD and SCD group to teach general diabetes management but without specific dietary recommendations.
89292505|NCT03988530|Active Comparator|DPI-386 Nasal Gel|DPI-386 Nasal Gel (0.2 mg / 0.12 g)
89292506|NCT03988530|Placebo Comparator|Placebo Nasal Gel|placebo nasal gel (0.12 g)
89292507|NCT03981003||MS Patients|
89292508|NCT03978741|Experimental|Test Device|Yōni.Fit Test Device
89292509|NCT03978741|Active Comparator|Comparator Device|Yōni.Fit Comparator Device
89292510|NCT03948243|Experimental|G.Glabra|single arm
89292511|NCT03948035|Experimental|E-KRd/ Arm A|Induction/ Consolidation: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone (E-KRd), autologous stem cell transplant, Maintenance: Elotuzumab, Lenalidomide
89292512|NCT03948035|Active Comparator|KRd/ Arm B|Induction/ Consolidation: Carfilzomib, Lenalidomide, Dexamethasone (KRd), autologous stem cell transplant, Maintenance: Lenalidomide
89292513|NCT03946813|Experimental|Poor ovarian reserve|Infertile women with poor ovarian reserve
89292514|NCT03946124|Other|Fesoterodine|Subjects (irrespective of preference) will receive a 90-day supply of open label fesoterodine 4 mg per day. Medication will start 1 week after the baseline visit. After 2 weeks of treatment, dose may be increased to 8 mg over the telephone based on symptom report. This dosing regimen is direct alignment with clinical care. Change of prescription to another anti-cholinergic may occur during the study period, if determined necessary by the physician.
89292515|NCT03942224|Experimental|Arm I (DId)|"INDUCTION: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2 and on days 1 and 15 of cycles 3-8, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.~MAINTENANCE: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
89531447|NCT06066229||Lung transplant patients|Adult lung transplant patients followed at Hôpital Bichat (Paris) or Hôpital Foch (Suresnes)
89292516|NCT03942224|Experimental|Arm II (DVd, DId)|"INDUCTION CYCLES 1-3: Patients receive dexamethasone IV and PO on days 1, 8, and 15, daratumumab IV on days 1, 8, and 15, and bortezomib subcutaneously (SC) on days 1, 4, 8, and 11. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~INDUCTION CYCLES 4-8: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1 and 15, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.~MAINTENANCE: Patients receive dexamethasone IV on day 1, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
89292517|NCT03938701|Experimental|Fluorescence imaging of IBD with adalimumab-800CW|"Fluorescence imaging with adalimumab-800CW in inflammatory bowel disease (IBD). A non-randomised, non-blinded, prospective, feasibility study.~Administration of 4.5 mg, 15 mg or 25 mg of adalimumab-800CW in 15 patients."
89292518|NCT03938701|Experimental|Fluorescence imaging of RA with adalimumab-800CW|"Fluorescence imaging with adalimumab-800CW in rheumatoid arthritis (RA). A non-randomised, non-blinded, prospective, feasibility study.~Administration of 4.5 mg, 15 mg or 25 mg of adalimumab-800CW in 15 patients."
89292519|NCT03937323||Group 1: Pancreatitis group|Patients with biliary pancreatitis
89292520|NCT03937323||Group 2: Control group,|Healthy volunteers
89292521|NCT03922269||Transgender individual with a diagnosis of HIV|The participant self-identifies as transgender and/or has a current gender identity which differs from gender assigned at birth, is 18 years old or above, has a diagnosis of HIV infection and has been prescribed antiretroviral therapy.
89292522|NCT03912662|Other|Hernia prevention cohort|single arm safety study, no control arm
89292523|NCT03906435|No Intervention|Control Arm|Standard of care information given by NICU staff and Follow up Clinic staff, including information about health care, diagnosis, medications, daily cares, anticipatory guidance, and discharge prep information.
89292524|NCT03906435|Experimental|Intervention CBT Arm|In addition to Standard of care information that the control arm receives, this arm will also receive 5 CBT sessions focusing on past NICU trauma, emotional coping, parental perceptions of child vulnerability, and helpful parenting and emotional coping skills.
89292525|NCT03905356|Experimental|Exercise|"The exercise intervention will utilize the Moving Through Cancer: A Guide to Exercise for Cancer Survivors framework. A certified cancer exercise physiologist will work through this guide at radiation therapy visits, with at least 1 visit per week, per the study schema. The cancer exercise physiologist will teach participants proper: warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. The cancer exercise physiologist will tailor the instruction to convey special considerations for exercise based on treatment and cancer type. The patient will perform supervised exercise in the Exercise Medicine Unit under the guidance of the cancer exercise specialist. The exercise done will be educational in nature (i.e. learning about proper walking form, proper intensity for a warmup/cool down, proper techniques for resistance exercises)."
89292526|NCT03894553|Experimental|FUS Mesencephalotomy|Subjects will receive unilateral stereotactic focused ultrasound mesencephalotomy using the ExAblate Neuro device for severe, opioid-resistant pain associated with head and neck cancer.
89292527|NCT03881631|Experimental|Mindfulness Based Stress Reduction (MBSR) Program|The MBSR program is an eight-week-long course designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
89292528|NCT03881631|Active Comparator|Living Well (LW) Program|LW is an eight-week course of group presentations and discussions on topics related to the promotion of health and well-being in the context of dementia caregiving. LW is designed to teach participants how to improve their physical and emotional health as a complement to traditional medical treatments.
89292529|NCT03881631|No Intervention|Usual Care|The usual care arm is a no intervention group wherein participants experience their usual circumstances.
89292530|NCT03879798|Experimental|DS-3201b and Irinotecan|The first part of this study is a phase I trial to assess the safety and tolerability of DS-3201b in combination with fixed-dose irinotecan. The second part of this study will be an open label, single-arm phase II study of DS-3201b at the established recommended phase II dose (RP2D) in combination with fixed-dose irinotecan. Dose-Escalation, which enrolled a total of 12 patients at MSK, is completed. Phase 1 of this study determined that the highest and safest dose of DS-3201b in patients was 100 mg daily.
89292531|NCT03872206|Experimental|HPN536-2001 - Part 1 (Dose Escalation)|HPN536 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD is being determined.
89292532|NCT03872206|Experimental|HPN536-2001 - Part 2 (Dose Expansion)|HPN536 is IV administered once weekly for about 1 hour at the recommended phase 2 dose established in Part 1
89292533|NCT03870633||Observational (medical chart, interview)|Participants undergo medical chart abstraction within 1 week and complete telephone interview over 30-45 minutes within 8 weeks after registration.
89292534|NCT03856463|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay patient navigator who will provide information regarding early advance care planning, documentation of goals of care, and coordinating home-based care. The intervention arm will also receive usual care as provided by their local oncologists.
89292535|NCT03856463|Active Comparator|Control Group Arm|The control group will receive usual care as provided by their local oncologists.
89292536|NCT03852017|Experimental|Mindfulness Audio Program|Mindfulness Audio Program is a daily audio-session, which teaches emotional self-regulation skills through the adoption of mindful awareness practices into one's life
89292537|NCT03852017|Active Comparator|Music Audio Program|Music Audio Program is a daily audio session of peaceful and relaxing music
89292538|NCT03852004|Experimental|Osteopatic treatment|An osteopatic treatment will be realised by osteopath
89292539|NCT03852004|Placebo Comparator|simulated osteopathic treatment|A simulated ostepathic treatment will be realised by osteopath
89292540|NCT03826771|Experimental|POWER training|high velocity strength training
89292541|NCT03826771|Active Comparator|Stretching|Upper and lower body range of motion exercises
89292542|NCT03815578|Experimental|Rheumatoid Arthritis (RA) patients|RA according to the ACR/EULAR 2010 classification criteria
89292543|NCT03813472||Atopic Dermatitis|Evaluate sensor performance for hydration sensing.
89292544|NCT03813472||Healthy aged matched controls|Evaluate sensor performance for hydration sensing.
89292545|NCT03812029|Experimental|Vonafexor 100 mg BID|Oral dose twice daily for 12 weeks (84 days)
89292546|NCT03812029|Experimental|Vonafexor 200 mg QD|Oral dose once daily for 12 weeks (84 days)
89292547|NCT03812029|Experimental|Vonafexor 400 mg QD|Oral dose once daily for 12 weeks (84 days)
89292548|NCT03812029|Placebo Comparator|Placebo|Oral dose twice daily for 12 weeks (84 days)
89292549|NCT03812029|Experimental|Vonafexor 100 mg QD|Oral dose once daily for 12 weeks (84 days)
89292550|NCT03811301|Experimental|Interventional|Wireless Implantable Neurodevice Microsystem
89292551|NCT03808727|Experimental|Massed Cognitive Processing Therapy (MCPT)|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. MCPT will be delivered in an intensive outpatient setting (12 sessions in 5 days) composed of both group and individual sessions.
89292552|NCT03808727|Active Comparator|Standard Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Standard CPT will be delivered in 12 one-hour sessions over 6 weeks and involves only individual sessions.
89292553|NCT03801122|Experimental|Tranexamic acid 3g/day|Administration of tranexamic acid 3g/day, with 3 injections/8 hours.
89292554|NCT03801122|Experimental|Tranexamic acid 1.5g/day|Administration of tranexamic acid 1.5g/day, with 3 injections/8 hours.
89292555|NCT03801122|No Intervention|No treatment|No treatment (no administration of tranexamic acid)
89292556|NCT03800758|Experimental|Expressive Helping writing|"Writing sessions 1-3: Participants complete one 20-minute expressive writing session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.~Writing session 4: One 20-40 minute peer support writing session about 1 week after completion of writing session 3."
89292557|NCT03800758|Active Comparator|Factual Writing|"Writing sessions 1-3: Participants complete one 20-minute factual session at three time points: 1) after hospitalization but prior to transplant infusion, (2) approximately 3 days after hospital discharge, and (3) approximately 2 weeks after completion of writing session 2.~Writing session 4: One 20-40 minute factual writing session about 1 week after completion of writing session 3."
89292558|NCT03797066|Other|Single arm|"A phase 4, open label, non-randomised study, conducted in hostels and homeless shelters in London; as well as mobile clinics in collaboration with the Hep C trust and the NHS Find and Treat program.~Treatment: 12 or 16 weeks of Zepatier, based on genotypes; with Ribavarin for certain subtypes. The study drug is administered as a single tablet; which is a combination of 100 mg of grazoprevir and 50 mg of elbasvir; as outlined below:~Genotypes 1a/b and 4: once daily dose for 12 weeks, taken with / without food. Genotype 1a and 4: (HCV RNA> 800,000 iu/ml or baseline NS5A resistance): once daily dose for 16 weeks, taken with / without food.~NO dose modifications with the study drug."
89292559|NCT03789864|Other|Individuals undergoing SOC Gemcitabine Treatment for mycosis fungoides (MF) T-cell lymphoma|Standard of Care (SOC) treatment with gemcitabine in this setting is 1200 mg/m2 as a 30 minute infusion given intravenously on days 1, 8, and 15 of every 28-day treatment cycle. Standard dose reductions are expected in patients experiencing unacceptable toxic effects of treatment. All subjects will undergo standardized staging tests, with tumor stage defined according to established guidelines. For this study, three 6-mm x 4-mm dermal punch biopsies from one or more target lesions will be collected prior to treatment initiation and submitted for Biodynamic imaging (BDI). All patients will be considered off-study after completing cycle 2.
89292560|NCT03777020|Experimental|Service Dog Training Program (SDTP)|Veterans randomized to the SDTP will be paired with an experienced Warrior Canine Connection (WCC) Mission Based Trauma Recovery (MBTR)-Trainer (MBRT-T) and a service dog (SD). One hour training modules will be scheduled once a week for 8 weeks. Participants will come to WCC for all the weekly training modules. Participants will be paired with the same SD for the duration of the SDTP unless an unforeseen circumstance arises and the SD needs to be removed from the SDTP. The MBTR-T will deliver the prescribed SDTP modules created by WCC. Each session will be fully supervised by a WCC MBTR-T to address any concerns or safety issues that may arise.
89292561|NCT03777020|Other|Dog Training Education|Veterans randomized to Dog Training Education will participate in one hour online SD training modules (https://e-trainingfordogs.com) scheduled once a week for 8 weeks. The online training modules are delivered by experienced SD trainers and will employ parallel content to the WCC SDTP. Participants will come to the WCC site for all the weekly online training modules. Members of the WLCI group will have education about dog training, but NO interaction with a SD. The online training modules for the DTE group are intended to keep the veterans who are not immediately assigned to the SDTP engaged in the study. They will participate in the SDTP after conclusion of participation in the 8 week study.
89292562|NCT03771677|Active Comparator|Active Comparator:NAs group|"Active Comparator:nucleotide analogues(NAs)~patients continue to use NAs"
89292563|NCT03771677|Experimental|Experimental:PEG-IFN group|"Experimental: peg-interferon alfa-2a~patients use peg-interferon α-2a and nucleotide analogues(NAs)"
89292564|NCT03770767|Experimental|Intervention with insulin Fiasp|Women randomized to insulin Fiasp
89292565|NCT03770767|Active Comparator|Control (insulin Novorapid)|Women randomized to insulin NovoRapid
89292566|NCT03761875|Other|CHB patients|a blood sample is done during a follow-up visit
89292567|NCT03761875|Other|Control group|a blood sample
88806159|NCT02097992|Experimental|SD placebo and MD placebo then MD roflumilast|Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
88813148|NCT01460225|Experimental|Treatment|24 micrograms of lubiprostone twice daily for one week.
89292568|NCT03760926|Experimental|May Health Procedure|May Health Procedure performed with use of the May Health Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
89292569|NCT03753776|Placebo Comparator|Radium bromatum placebo group|Placebo group will receive placebo pills of Radium bromatum during radiotherapy
89292570|NCT03753776|Experimental|Radium bromatum group|Radium bromatum group will receive homeopathic Radium bromatum pills during radiotherapy
89292571|NCT03753776|Placebo Comparator|Radium bromatum/Apis mellifica/Belladonna placebo group|Placebo group will receive Radium bromatum/Apis mellifica/Belladonna placebo pills to treat grade 2 or higher radiodermatitis
89292572|NCT03753776|Experimental|Radium bromatum/Apis mellifica/Belladonna group|Radium bromatum/Apis mellifica/Belladonna group will receive homeopathic Radium bromatum/Apis mellifica/Belladonna pills to treat grade 2 or higher radiodermatitis
89292573|NCT03752892|Experimental|intervention -1-leg cycle training|Primary aerobic training component one-legged, partitioned, cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity one-legged exercise progressing to continuous duration of the target duration of 15 min for each leg and then restarting the cycle at a higher intensity.
89292574|NCT03752892|Active Comparator|usual care - 2-leg cycle training|Primary aerobic training component conventional two-legged cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity exercise progressing to continuous duration of 30 min and then restarting the cycle at a higher intensity.
89292575|NCT03747575|Experimental|Treatment|Participants will receive MSTT1041A
89292576|NCT03747575|Placebo Comparator|Placebo|Participants will receive placebo matched to MSTT1041A
89292577|NCT03747419|Experimental|Avelumab and Bladder-Directed Radiation|"Avelumab will be administered every 2 weeks intravenously for 6 doses unless there is unacceptable toxicity~Two radiation dose regimens are allowed, and the regimen selected is at the discretion of the treating radiation oncologist"
89292578|NCT03733145|Experimental|Participants on ACE inhibitors|Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group. Intervention: Drug: Angiotensin II.
89292579|NCT03733145|Experimental|Participants on ARBs|Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group. Intervention: Drug: Angiotensin II.
89292580|NCT03733145|Experimental|Other Classes of Antihypertensive Agents|Participants taking any other class of Antihypertensive Agents will be placed into this group. Intervention: Drug: Angiotensin II.
89292581|NCT03715972||Anemia Observation|The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients. Diamox (acetazolamide) will be administered during MRI.
89292582|NCT03715972||Anemia Intervention|"Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose.~non transfusion dependent sickle cell disease patients not already receiving hydroxyurea will be placed on hydroxyurea following their baseline exam and titrated to maximal tolerated dose. They will then undergo a repeat MRI within two months of reaching that dose and be given the option to continue on hydroxyurea or stop."
89292583|NCT03715972||Healthy Controls|40 control subjects recruited from first degree relatives of the sickle cell disease population. Diamox (acetazolamide) will be administered during MRI.
89292584|NCT03708731||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study.
89292585|NCT03702218|Experimental|Hep C Ab + NAT - Donor to Naïve Recipient|"HCV Ab and HCV NAT testing at 3 days, week 1, week 2 and monthly for 3 months, at 6 months and 1 year. In approximately 16% of the patients, active hepatis C infection will ensue. For these patients, treatment is as follows.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
89292586|NCT03702218|Experimental|Hep C Ab+ NAT+ Donor to Naïve Recipient|"HCV RNA levels, liver biochemistries, and renal function will be measured 3 days after transplant. HCV Genotype will be determined after HCV RNA is >1,000 IU/mL. HCV RNA levels will be measured weekly after transplant until HCV treatment is initiated.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
89292587|NCT03702218|Active Comparator|Hep C Ab- NAT - Donor to Naïve Recipient|Current standard of care for donor recipient infectious disease matching. No treatment necessary
89292588|NCT03699761|Experimental|Pelvic Peritonization|
89292589|NCT03699761|No Intervention|Without Pelvic Peritonization|
89292590|NCT03690050|Experimental|Diode Subthreshold Micropulse Laser|"DSML is a relatively new laser technology aimed at minimising damage (tissue-sparing) to choroid and retina but maintaining treatment efficacy by its selective effect on the retinal pigment epithelium (RPE). It is performed using laser that, instead of delivering a continuous-wave laser beam, as the standard laser, it provides very small, repetitive, low energy pulses of laser separated by a brief rest period. This rest period allows the tissue to cool down between laser pulses avoiding the increased tissue heat that would be produced by continuous laser and allowing the use of lower laser energy power to achieve an effect. The reduced heat produced in the tissue and the reduced energy power required for the treatment may reduce side effects."
89292591|NCT03690050|Active Comparator|Standard threshold laser (532 nm laser)|Green-yellow argon laser photocoagulation at threshold levels has been used for many years as the standard laser for the treatment of many retinal disorders including DMO. The ETDRS demonstrated the efficacy of laser in preventing visual loss in patients with DMO.
89292592|NCT03657043|Experimental|Safety Run-In (3Q4W Schedule)|28-day, 3 dose cycle
89292593|NCT03657043|Experimental|Part A: Tisotumab Vedotin|21-day, single dose cycle
89292594|NCT03657043|Experimental|Part A: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
89292595|NCT03657043|Experimental|Part B: Tisotumab Vedotin (3Q4W Schedule)|28-day, 3 dose cycle
89292596|NCT03646669|Experimental|Asthma education and PEF feedback|Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
89292597|NCT03646669|Placebo Comparator|Asthma education|No PEF feedback arm
89292598|NCT03646240|Experimental|Dosing arm|
89292599|NCT03637387|Experimental|BIIB074|Administered orally three times daily (TID)
89292600|NCT03637387|Placebo Comparator|Placebo|Placebo matching BIIB074
89292601|NCT03634540|Experimental|Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1)|Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time.
89292602|NCT03634540|Experimental|Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2)|Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time.
89292603|NCT03619876|Active Comparator|Non- Tumor necrosis factor (TNF) inhibitor arm|Treatment with abatacept will consist of weekly subcutaneous (SQ) injections at a dose of 125mg.
89292604|NCT03619876|Active Comparator|TNF inhibitor arm|Treatment with a adalimumab, as the TNF-inhibitor arm, will consist of every 2 weeks SQ injections at a dose of 40mg.
89292605|NCT03608280|Active Comparator|Autograft|Reconstructive surgery by autologous bone graft (bone autograft). It is the gold standard strategy.
89292606|NCT03608280|Experimental|3D implant|"Orbital reconstruction by 3D-printed porous titanium implant (PorousiTi®, laboratoire OBL/MATERIALISE).~The device is a custom-made porous titanium implant processed by selective laser melting (SLM technique)"
89292607|NCT03605901|Active Comparator|Standard dosing of methadone|Receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
89292608|NCT03605901|Experimental|Aliquots of methadone titrated to apnea|Receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals. The practitioner will continue to coach patient to take deep breaths. After reaching the apnea threshold as determined by respiratory rate less than 8 breaths/min, induction of general anesthesia and intubation will proceed.
89292609|NCT03584165|Experimental|BIIB111|Participants previously treated with sub-retinal injection of BIIB111 in antecedent studies 273CH301 (NCT03496012) and 273CH203 (NCT03507686) will be enrolled. Participants previously treated with this same sub-retinal injection (rAAV2-REP1) in antecedent studies 20150371 (NCT02553135), Pro00028599 (NCT02077361), THOR-TUE-01 (NCT02671539), CHM09/01 (NCT01461213) and REGEN2015 (NCT02407678) will also be invited for enrollment. This is a follow-up study, investigational product was administered in the previous study.
89292610|NCT03584165|Experimental|BIIB112|Participants previously treated with sub-retinal injection of BIIB112 in the antecedent study 274RP101 (NCT03116113) will be enrolled. This is a follow-up study, investigational product was administered in the previous study.
89292611|NCT03584165|No Intervention|Untreated|Untreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled. This is a follow-up study, participants will not be administered study medication nor receive a sham surgery.
89292612|NCT03579771|Experimental|Gemcitabine, cisplatin, nab-paclitaxel|Participants receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
89292613|NCT03578081|Experimental|Arm I (fosaprepitant dimeglumine, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, fosaprepitant dimeglumine IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89292614|NCT03578081|Active Comparator|Arm II (placebo, olanzapine)|Patients receive palonosetron hydrochloride IV over 30 seconds or ondansetron hydrochloride IV over 2-5 minutes or PO on day 1, dexamethasone PO on days 1-4, placebo IV over 20-30 minutes on day 1, and olanzapine PO on days 1-4. Treatment (with no placebo) may repeat every 4 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
89292615|NCT03563131|Active Comparator|Uncemented Persona® total knee arthroplasty|Uncemented TM Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
89292616|NCT03563131|Active Comparator|Cemented Persona® total knee arthroplasty|Cemented Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
89292617|NCT03552419||Level Red|A level red refers to a case with an immediate threat to the life of the fetus or mother and may not be delayed under any circumstance.
89292618|NCT03552419||Level Orange|A level orange case requires the patient to arrive in the OR within 30 minutes from the time of decision with the approximate estimated time of arrival determined by the obstetrician.
89292619|NCT03552419||Level Yellow|A level yellow case requires operative intervention, but there is no maternal and/or fetal compromise at the time of evaluation. Timing to the OR is agreed upon by both the anesthesiology and obstetrical providers. The case may be delayed if a level red or orange case is identified. Possible
89292620|NCT03552419||Level Green|A level green case is most dependent on the acuity of the OR suite and unit. The patient and/or fetus are stable with no threat to the health of either.
89292621|NCT03551262|Experimental|OTSC|Use of OTSC to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb, in first-line endoscopic haemostatic treatment.
89292622|NCT03551262|Active Comparator|TTS clip|Use of TTS clip to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb in first-line endoscopic haemostatic treatment
88821238|NCT04805333|Experimental|Dose 2 - 900mg Artemisia annua|Participants in this group will consume 2 cups of decaffeinated coffee (900 mg Artemisia annua).
89292623|NCT03536312|No Intervention|Surveillance Arm|Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
89292624|NCT03536312|Other|Surgery/Treatment Arm|Patients in the Operative Registry will have thoracic aortic surgery
89292625|NCT03527420|Active Comparator|Exercising|12 weeks of aerobic exercise training
89292626|NCT03527420|No Intervention|Non-exercising|standard of care
89292627|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen A."
89292628|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen B."
89292629|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen A."
89292630|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen B."
89292631|NCT03526861|Experimental|Placebo initial-> Placebo maintenance|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52 (maintenance period):~Placebo continuation SC injection regimen A."
89292632|NCT03526861|Experimental|Tralokinumab (Dose1) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
89292633|NCT03526861|Experimental|Tralokinumab (Dose2) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
89292634|NCT03526861|Experimental|Placebo initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
89292635|NCT03520322|Experimental|Mastoid Oscillator|patients with Menieres Disease
89292636|NCT03520322|Placebo Comparator|Control device|patients with Menieres Disease
89292637|NCT03517475|Experimental|Supervising for Home Safety modified|We will train caregivers to provide adequate levels of supervision to the 3-4 year-old children.
89292638|NCT03517475|Placebo Comparator|Services as Usual|Clients will receive home visiting services from Head Start
89292639|NCT03510884|Experimental|Placebo/Alirocumab Q2W|Participants received subcutaneous (SC) injection of placebo (matched to alirocumab) based on their body weight (BW) (less than [<] 50 kilograms [kg] or greater than or equal to [>=] 50 kg) Q2W for 24 weeks in DB treatment period added to stable LMT. After completion of DB treatment period, eligible participants entered into OL treatment period and received alirocumab 40 milligrams (mg) (for BW <50 kg) or 75 mg (for BW >=50 kg) Q2W from Week 24 up to an additional 80 weeks (i.e., up to Week 104) added to stable LMT. After Week 24, dose up-titrated from 40 mg to 75 mg when BW increased from <50 kg to >=50 kg. From Week 32 up to Week 104, based on participant LDL-C value, alirocumab dose was either up-titrated as 40 mg to 75 mg (for BW <50 kg) or 75 mg to 150 mg (for BW >=50 kg) or down titrated as 75 mg to 40 mg (for BW <50 kg) or 150 mg to 75 mg (for BW >=50 kg).
89292640|NCT03510884|Experimental|Alirocumab Q2W|Participants received SC injection of alirocumab 40 mg (for BW <50 kg) or 75 mg (for BW >=50 kg) Q2W for 24 weeks in DB treatment period added to stable LMT. Alirocumab dose was up-titrated to 75 mg or 150 mg Q2W from Week 12, when LDL-C level was >=110 milligrams per deciliter (mg/dL) (2.85 millimoles per liter [mmol/L]) at Week 8. After completion of DB treatment period, eligible participants entered into OL treatment period and received alirocumab 40 mg (for BW <50 kg) or 75 mg (for BW >=50 kg) from Week 24 up to an additional 80 weeks (i.e., up to Week 104) added to stable LMT. After Week 24, dose up-titrated from 40 mg to 75 mg when BW increased from <50 kg to >=50 kg. From Week 32 up to Week 104, based on participant LDL-C value, alirocumab dose was either up-titrated as 40 mg to 75 mg (for BW <50 kg) or 75 mg to 150 mg (for BW >=50 kg) or down titrated as 75 mg to 40 mg (for BW <50 kg) or 150 mg to 75 mg (for BW >=50 kg).
89292641|NCT03510884|Experimental|Placebo/Alirocumab Q4W|Participants received SC injection of placebo (matched to alirocumab) based on their BW (<50 kg or >=50 kg) Q4W for 24 weeks in DB treatment period added to stable LMT. After completion of DB treatment period, eligible participants entered into OL treatment period and received alirocumab 150 mg (for BW <50 kg) or 300 mg (for BW >=50 kg) Q4W from Week 24 up to an additional 80 weeks (i.e., up to Week 104) added to stable LMT. After Week 24, dose up-titrated from 150 mg to 300 mg when BW increased from <50 kg to >=50 kg. From Week 32 up to Week 104, based on participant LDL-C value, alirocumab dose was either up-titrated as 150 mg Q4W to 75 mg Q2W (for BW <50 kg) or 300 mg Q4W to 150 mg Q2W (for BW >=50 kg) or down titrated as 75 mg Q2W to 40 mg Q2W (for BW <50 kg) or 150 mg Q2W to 75 mg Q2W (for BW >=50 kg).
89523316|NCT03378245|Experimental|Telemedicine Intervention|Multidisciplinary telemedicine education of staff and providers on best practices for behavioral modification as well as education on best practices for pharmacologic therapies.
89523317|NCT03378089|Experimental|Music Therapy|Participants in the experimental group will be given choices about how to proceed with the session: active or passive, improvisation, re-creative or receptive songs, or receptive (relaxation). Three music therapy sessions will be completed, the first within 24 hours of admission, the second 24-96 hours of session 1, and the final session the day before stem cell infusion.
89292642|NCT03510884|Experimental|Alirocumab Q4W|Participants received SC injection of alirocumab 150 mg (for BW <50 kg) or 300 mg (for BW >=50 kg) Q4W for 24 weeks in DB treatment period added to stable LMT. Alirocumab dose was up-titrated to 75 mg or 150 mg Q2W from Week 12, when LDL-C level >=110 mg/dL (2.85 mmol/L) at Week 8. After completion of DB treatment period, eligible participants entered into OL treatment period and received alirocumab 150 mg (for BW <50 kg) or 300 mg (for BW >=50 kg) from Week 24 up to an additional 80 weeks (i.e., up to Week 104) added to stable LMT. After Week 24, dose up-titrated from 150 mg to 300 mg when BW increased from <50 kg to >=50 kg. From Week 32 up to Week 104, based on participant LDL-C value, alirocumab dose was either up-titrated as 150 mg Q4W to 75 mg Q2W (for BW <50 kg) or 300 mg Q4W to 150 mg Q2W (for BW >=50 kg) or down titrated as 75 mg Q2W to 40 mg Q2W (for BW <50 kg) or 150 mg Q2W to 75 mg Q2W (for BW >=50 kg).
89292643|NCT03497975|Experimental|Active|162 mg nalbuphine ER tablets, BID
89292644|NCT03497975|Placebo Comparator|Placebo|Matching placebo tablets
89292645|NCT03497975|Experimental|Open Label Extension|162 mg nalbuphine ER tablets, BID
89292646|NCT03491007|No Intervention|Placebo|Subjects will receive a one-time oral dose of PBO prior to initial brain imaging followed by sustained administration of PBO for 6 weeks.
89292647|NCT03491007|Placebo Comparator|DHEA|Subjects will receive a one-time oral dose of DHEA prior to initial brain imaging followed by sustained administration of DHEA for 6 weeks.
89292648|NCT03488472|Experimental|NovoTTF-200A device + Stereotactic Radiosurgery (SRS)|Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.
89292649|NCT03472664|Experimental|Modified Mediterranean Ketogenic Diet|"The MMKD is a low carbohydrate/high fat diet aimed at inducing ketosis, as the experimental diet in the proposed study. Participants on the MMKD will keep their daily carbohydrate consumption below 20 grams per day throughout the 4 month intervention.The MMKD group will be supplied with extra virgin olive oil during their in person visits to use as a source of fat in their diet, and will be encouraged to eat plentiful fish, lean meats, and nutrient rich foods that meet the requirement of <20 grams total carbohydrates per day.~Participants will receive a daily multivitamin (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet."
89292650|NCT03472664|Experimental|American Heart Association Diet|The American Heart Association Diet (AHAD), is a low fat/high carbohydrate diet (<40 grams/day) will be used as the control diet. Participants on the AHAD will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Participants will receive the same daily multivitamin supplement (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet.
89292651|NCT03456453|Experimental|NIDA Standard via Facebook|Participants will receive the NIDA Standard via Facebook
89292652|NCT03456453|No Intervention|Re-entry services as usual|Participants will receive standard re-entry services available in the community and through the criminal justice system
89292653|NCT03455829|Experimental|Part 1: Cohort 1 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
89292654|NCT03455829|Experimental|Part 1: Cohort 2 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
89292655|NCT03455829|Experimental|Part 1: Cohort 3 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
89292656|NCT03455829|Experimental|Part 1: Cohort 4 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
89292657|NCT03455829|Experimental|Part 1: Cohort 5 G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
89292658|NCT03454828|Experimental|obese carbohydrate diet|Obese adolescents with a body mass index (BMI) >95th percentile.
89292659|NCT03454828|Active Comparator|lean carbohydrate diet|Lean adolescents with a body mass index (BMI) <85th percentile.
89292660|NCT03453489|Experimental|Treatment (AMT-PET, telotristat etiprate)|Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate PO TID for 9-14 days.
89292661|NCT03442894|Active Comparator|Standard PT Treatment|"This group will receive manual therapy and exercise interventions provided by their physical therapist. The treatment will occur for 10 sessions over 6 weeks.~Interventions: Manual therapy interventions including mobilization and manipulation of the shoulder girdle spine and ribcage. Exercise interventions will include strengthening and flexibility exercises for rotator cuff and shoulder girdle musculature."
89292662|NCT03442894|Experimental|Standard PT Treatment plus DN|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits.
89292663|NCT03442894|Sham Comparator|Standard PT Treatment plus Sham DN|In addition to the standard PT treatment, patients in the sham DN group will receive 6 sessions of sham DN intervention.
89292664|NCT03441334|Experimental|High Frequency rTMS|The High Frequency rTMS group will receive real repetitive transcranial magnetic stimulation (rTMS) in 5Hz at 90% of resting motor threshold delivered to the bilateral motor areas via a figure of 8 air-filmed coil. The stimulation is structured as 24 10-second trains with a inter-train interval of 30 second.
89292665|NCT03441334|Sham Comparator|Sham rTMS|The Sham rTMS group will receive the same protocol but delivered via a sham coil which generates the same auditory and cutaneous feedback as the real stimulation. However, there will be no active stimulation.
89292666|NCT03439371|Experimental|HLA-mismatched micro-transplantation|HLA-mismatched micro-transplantation
89292667|NCT03437941|Experimental|Dose Determination Segment 1|Patients will be treated with enzalutamide monotherapy once daily for 28 days followed by combination treatment with CORT125281 at escalating dose levels and enzalutamide once daily in 28-day dosing cycles.
89292668|NCT03437941|Experimental|Dose Expansion - Abi-Resistant Cohort|Patients who have progressed during treatment with abiraterone and no other AR-blocking therapies will be treated with CORT125281 and enzalutamide.
89292669|NCT03437941|Experimental|Dose Expansion - Abi-Resistant Cohort Food Effect|Sub-Cohort (first 10 patients enrolled into Cohort A). Patients enrolled into this subcohort will receive a single dose of CORT125281 at Cycle 1 Day -7 and a single dose of CORT125281 at Cycle 1 Day 1 30 minutes after a standard breakfast to assess the effect of food on PK parameters. Patients will then begin CORT125281 in combination with enzalutamide on Cycle 1 Day 2 and continue in 28-day dosing cycles.
89292670|NCT03437941|Experimental|Dose Expansion - ARant-Resistant Cohort|Patients who progressed during treatment with enzalutamide or second-generation AR-blocking therapies will be treated with a daily dose of CORT125281 and enzalutamide.
89292671|NCT03437941|Experimental|Dose Determination Segment 2 (Double-Blind) - Arm A|Patients randomized to this cohort will receive enzalutamide and a titrated dose of CORT125281. Enzalutamide will be continued at the dose currently tolerated by the patient at screening.
89292672|NCT03437941|Experimental|Dose Determination Segment 2 (Double-Blind) - Arm B|Patients randomized to this cohort will receive enzalutamide, placebo, and CORT125281.
89292673|NCT03436615|Experimental|SB206 4%|SB206 4% topically twice daily
89292674|NCT03436615|Experimental|SB206 8%|SB206 8% topically twice daily
89292675|NCT03436615|Experimental|SB206 12%|SB206 12% topically once or twice daily
89292676|NCT03436615|Placebo Comparator|Placebo (vehicle gel)|Vehicle Gel topically once or twice daily
89292677|NCT03429244|Experimental|Prostate cancer- men being treated with radical prostatectomy|Men being treated for prostate cancer with radical prostatectromy were enrolled in this arm.
89292678|NCT03429244|Experimental|Prostate cancer- men undergoing cancer screening or active surveillance|Men undergoing cancer screening or active surveillance were enrolled in this arm.
89292679|NCT03429244|Experimental|Prostate cancer- focal therapy|Men undergoing focal therapy with high intensity focused ultrasound are in this group.
89292680|NCT03409133|Experimental|Stimulating nerve electrodes & intramuscular recording electrodes|"Fifteen subjects with lower limb amputation will have multi-contact stimulating nerve cuff electrodes implanted around the nerves in their residual limb. These electrodes will be connected to temporary percutaneous leads.~During experimental testing, a small amount of electrical current will be delivered to the nerves through multi-contact nerve cuff electrodes.~Participants also have the option to have recording electrodes implanted within muscles in their lower limb(s). These muscles are associated with prosthetic movement, and recordings from these muscles will be used to develop a controller for a robotic myoelectric prosthesis."
89292681|NCT03408587|Experimental|CVA21 / Ipilimumab|Subjects will receive up to 8 cycles (Day 155) of intravenous CVA21 and 4 doses of ipilimumab (Days 8, 29, 50 and 71).
89292682|NCT03392935|Experimental|All Subjects|All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.
89292683|NCT03389035|Experimental|CARCIK-CD19|
89292684|NCT03348748|Experimental|Study 1 (highest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the peripheral lung undergo highest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
89292685|NCT03348748|Experimental|Study 2 (lowest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the central lung undergo lowest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
89292686|NCT03348748|Experimental|Study 3 (lowest- or higher-dose of SBRT, surgery)|Patients with stage IIIA NSCLC in the any lung location undergo lowest- or higher-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
89292687|NCT03347539||Nexplanon|This group is participants who choose to receive the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of implant.
89292688|NCT03347539||Removal participants|This group is participants who choose to remove the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of removal. Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group.
89292689|NCT03314636|Experimental|PET-CT-positive patients|Carfilzomib 20/36mg/m2 days 1,2,8,9,15,16 Lenalidomide 25mg days 1-21 Dexamethasone 40mg days 1,8,15,22 28 day cycles 4 cycles
89292690|NCT03310541|Experimental|Prostate, Previously treated with Enzalutamide|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Enzalutamide 160 mg PO once daily
89292691|NCT03310541|Experimental|ER+ Breast, Previously treated with Fulvestrant|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Fulvestrant 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
89292692|NCT03310541|Experimental|Advanced Solid Tumors|28-DAY CYCLE AZD5363 480mg PO twice daily for 4 days on, 3 days off, every week
89292693|NCT03291756||Multiple Sclerosis|Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible
89292694|NCT03287765||Experimental 18F-AV-1451|
89292695|NCT03279861|Active Comparator|Entresto|First-line anti-hypertensive: sacubitril-valsartan, starting at 24-26 mg twice daily, increasing to maximum dose of 97-103 mg twice daily
89292696|NCT03279861|Active Comparator|Usual meds|First-line anti-hypertensive: valsartan, starting at 40 mg twice daily, increasing to a maximum dose of 160 mg twice daily
89292697|NCT03279445||African American|Patient of African American race
89292698|NCT03279445||Caucasian|Patient of Caucasian race
89292699|NCT03269149|Experimental|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period.
89292700|NCT03269149|Active Comparator|Educational Control|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks.
89292701|NCT03258463||Time Period 1|Women who obtained an abortion from January 1 2012-December 31 2012
89292702|NCT03258463||Time Period 2|Women who obtained an abortion from May 1 2014-April 30 2015.
89292703|NCT03250117|Experimental|Cohort 1|Requip; One Ropinirole Implant
89292704|NCT03250117|Experimental|Cohort 2|Requip; Two Ropinirole Implants
89292705|NCT03250117|Experimental|Cohort 3|Requip; Three Ropinirole Implants
89292706|NCT03250117|Experimental|Cohort 4|Requip; Four Ropinirole Implants
89292707|NCT03240341|Experimental|Patient Activation Measure (PAM)|completion of the PAM questionnaire
89292708|NCT03236935|Experimental|L-NMMA Plus Pembrolizumab|L-NMMA and pembrolizumab will be administered for 6 cycles. Cycle length will be 21 days. L-NMMA will be administered as a 2-hour intravenous (IV) infusion on Days 1-5 at each cycle. The dose levels of L-NMMA are as follows: Dose Level -1, 12.5 mg/kg; Dose Level 0 (starting dose), 15.0 mg/kg; and Dose Level 1, 20 mg/kg. L-NMMA dose will escalate/de-escalate based on the occurrence of dose-limiting toxicities. Pembrolizumab at a fixed dose of 200 mg will be IV infused over 30 minutes on Day 5 at each cycle. Pembrolizumab will be administered 1 hour after L-NMMA infusion on Day 5 at each cycle. Subjects without disease progression after 6 cycles of L-NMMA and pembrolizumab will continue pembrolizumab until disease progression or unacceptable AEs.
89292709|NCT03234335||Myeloma patients with severe renal impairment|Myeloma patients with severe renal impairment. Data collection will concern myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation.
89292710|NCT03233074||Acute Myeloid Leukemia patients|For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.
89292711|NCT03233074||Healthy donors|Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.
89292712|NCT03230838|Experimental|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum 1 g and 0.5 g/dose) administered intravenously (IV) every 8 hours for 7-14 days
89292713|NCT03230838|Active Comparator|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for 7-14 days
89292714|NCT03222102|Experimental|Phasix mesh|Phasix mesh will be affixed to the exposed fascia after closure of the Abdomen in the course of liver transplantation.
89292715|NCT03222102|No Intervention|Standard surgery|Surgery will be performed according to routine, without the use of Phasix mesh.
89292716|NCT03220945|No Intervention|Arm I (Control group)|Patients may receive yoga instruction for 1 week after post-test 2.
89292717|NCT03220945|Experimental|Arm II (Yoga group)|Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13.
89292718|NCT03217136|Experimental|Ceftolozane/Tazobactam + Metronidazole|Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum 1 g and 0.5 g/dose), plus metronidazole 10 mg/kg (maximum 1.5 g/day) administered intravenously (IV) every 8 to 12 hours for 5 to 14 days.
89292719|NCT03217136|Active Comparator|Meropenem + Placebo for Metronidazole|Meropenem 20 mg/kg (maximum 1 g/dose) plus placebo for Metronidazole administered IV every 8 hours for 5 to 14 days.
89292720|NCT03201939|Active Comparator|Active Medication (Intervention arm)|ACE-inhibitor lisinopril
89292721|NCT03201939|Placebo Comparator|Placebo comparator (Control arm)|Matched placebo
89292722|NCT03184922|Active Comparator|Fixed suspensory loop|Non-adjustable femoral cortical fixation device to be used
89292723|NCT03184922|Experimental|Adjustable suspensory loop|Adjustable femoral cortical fixation device to be used
89292724|NCT03179761|Experimental|Group I (HD-TIV)|Patients received HD-TIV intramuscularly once at baseline (day 0) and again between 28-42 days later.
89292725|NCT03179761|Active Comparator|Group 2(SD-QIV)|Patients received SD-QIV intramuscularly once at baseline (day 0) and again between 28-42 days later.
89292726|NCT03171493|Experimental|Intravesical MV-NIS therapy prior to radical cystectomy|MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
89292727|NCT03169634|Experimental|short or long stemmed rTKR cemented|
89292728|NCT03169634|Experimental|Cone with short stem|
89292729|NCT03169634|Experimental|Cone with long stem|
89292730|NCT03163030|Experimental|Therapy|Right Cervical Vagus Nerve Stimulation (VNS)
89292731|NCT03158064|Experimental|Duravalumab + Tremelimumab|"Duravalumab/Tremelimumab: Durvalumab and Tremelimumab will be administered by IV every 4 weeks for up to 4 doses/cycles, then Durvalumab by IV every 4 weeks starting at Week 16 for 9 doses (total treatment duration of 12 months).~Participants enrolled now will receive tremelimumab *300mg with durvalumab 1500mg for 1 cycle followed by 12 cycles of durvalumab 1500mg every 4 weeks or until lack of clinical benefit or unacceptable toxicity."
89292732|NCT03155841|Experimental|Life Skills Coaching|Participants in the experimental arm will receive access to HIV prevention and life skills content, including opportunities for goal setting, a directory of local resources in their community, and the ability to discuss their goals with Youth Navigators through a video-chat function.
89292733|NCT03155841|Active Comparator|Community Resources|Participants in the control arm will receive access to a directory of local resources in their community.
89292734|NCT03114891|Experimental|First Round: fMRI-guided Target/Video, Second Round: 6cm Target/Task|"First round: This site of stimulation will be created from participants' individualized resting connectivity data. We will identify a cortical target in the left prefrontal cortex (LPFC) that influences the subgenual anterior cingulate cortex (sgACC). Two daily sessions (~10min apart) of intermittent theta-burst stimulation will be administered to this fMRI-guided target for 10 consecutive weekdays. Between the two iTBS sessions, participants will watch a relaxing nature video.~Second round: After 3 weeks, participants will undergo another set of two daily iTBS sessions for 10 consecutive weekdays to their 'standard' target (6cm anterior of their hand knob). Between the two iTBS sessions, participants will complete a working memory task."
89292735|NCT03114891|Experimental|First Round: 6cm Target/Video, Second Round: fMRI-guided Target/Task|"First round: This 'standard' target will be identified by measuring 6cm anterior of the hand knob. Two daily sessions (~10min apart) of intermittent theta-burst stimulation will be administered to this to this target for 10 consecutive weekdays. Between the two iTBS sessions, participants will watch a relaxing nature video.~Second round: After 3 weeks, participants will undergo another set of two daily iTBS sessions for 10 consecutive weekdays to their fMRI-guided target (cortical target influencing sgACC). Between the two iTBS sessions, participants will complete a working memory task."
89292736|NCT03114891|Experimental|First Round: fMRI-guided Target/Task, Second Round: 6cm Target/Video|"First round: This site of stimulation will be created from participants' individualized resting connectivity data. We will identify a cortical target in the left prefrontal cortex (LPFC) that influences the subgenual anterior cingulate cortex (sgACC). Two daily sessions (~10min apart) of intermittent theta-burst stimulation will be administered to this fMRI-guided target for 10 consecutive weekdays. Between the two iTBS sessions, participants will complete a working memory task.~Second round: After 3 weeks, participants will undergo another set of two daily iTBS sessions for 10 consecutive weekdays to their 'standard' target (6cm anterior of their hand knob). Between the two iTBS sessions, participants will watch a relaxing nature video."
89292737|NCT03114891|Experimental|First Round: 6cm Target/Task, Second Round: fMRI-guided Target/Task|"First round: This 'standard' target will be identified by measuring 6cm anterior of the hand knob. Two daily sessions (~10min apart) of intermittent theta-burst stimulation will be administered to this to this target for 10 consecutive weekdays. Between the two iTBS sessions, participants will complete a working memory task.~Second round: After 3 weeks, participants will undergo another set of two daily iTBS sessions for 10 consecutive weekdays to their fMRI-guided target (cortical target influencing sgACC). Between the two iTBS sessions, participants will watch a relaxing nature video."
89292738|NCT03098511|Other|Neurological Diagnostic Evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to validate CT-perfusion as an accurate ancillary test for neurological diagnostic.
89292739|NCT03087708|Active Comparator|Group I (lower dose naloxegol, placebo)|Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
89292740|NCT03087708|Active Comparator|Group II (placebo, higher dose naloxegol)|Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
89292741|NCT03087708|Placebo Comparator|Group III (placebo)|Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
89292742|NCT03070132|Experimental|BIIB074|Optimized oral dose three times daily (TID)
89292743|NCT03070132|Experimental|Placebo|Administered orally TID
89292744|NCT03058783|Experimental|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
89292745|NCT03058783|Active Comparator|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
89292746|NCT03057847|Experimental|SOF/VEL|Sofosbuvir/Velpatasvir, One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
89292747|NCT03047161||High-risk pregnancy|abnormal fetal heart rate or rhythm or risk of abnormal fetal heart rate or rhythm
89292748|NCT03047161||Uncomplicated pregnancy|uncomplicated pregnancy
89292749|NCT03042143|Experimental|Human umbilical cord derived CD362 enriched MSCs|Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins
89292750|NCT03042143|Placebo Comparator|Placebo (Plasma-Lyte 148) infusion|Plasma-Lyte 148 infused over 30 to 90 mins
89292751|NCT03024424|Experimental|Early disclosure|Early disclosure group receives results of genetic testing at Week 4
89292752|NCT03024424|Active Comparator|Late disclosure|Late disclosure group receives results of genetic testing at final study visit (Month 12)
89292753|NCT03022773|Other|Carotenoid measurements|Subjects are asked to have carotenoid levels measured in the eye, skin and/or blood.
89292754|NCT03020797|Experimental|perampanel|perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks
89292755|NCT03020797|Placebo Comparator|placebo|placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks
89292756|NCT03002571|Experimental|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
89292757|NCT03002571|Active Comparator|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
89292758|NCT03001479|No Intervention|Standard: Liquid HMF and liquid protein|This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.
89292759|NCT03001479|Experimental|Intervention: HMF Hydrolyzed Protein Concentrated Liquid|One packet (5 mL) of Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. Feedings then continue to be advanced to full volume (160 ml/kg/d).
89292760|NCT02995681|Experimental|Pulmonary rehab and balance training|The intervention group will receive standard pulmonary rehab plus additional balance training.
89292761|NCT02995681|Active Comparator|Pulmonary rehab|The control group will receive pulmonary rehab only and a pulmonary rehab home program (walking and lower extremity resistance exercises) upon discharge from pulmonary. They will also receive the same monthly phone calls and three home visits at three, six and nine months to ensure proper technique and progression.
89292762|NCT02990572||Amish and Mennonite|"Agree to allow access to past, current, and future medical records~Provide a detailed family health history~Provide contact information that may be used for future approach regarding research studies"
88821239|NCT04805333|Experimental|Dose 3 - 1350mg Artemisia annua|Participants in this group will consume 3 cups of decaffeinated coffee (1350 mg Artemisia annua).
89292763|NCT02989025|Experimental|Experimental|To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
89292764|NCT02989025|No Intervention|Control|To determine how close the molecular markers are with 17 OHPC added to the management protocol.
89292765|NCT02988466|Experimental|Arm A: Haplo-HCT <55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients <55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2
89292766|NCT02988466|Experimental|CLOSED Arm B: Haplo-HCT ≥55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
89292767|NCT02988466|Experimental|Arm C: Haplo-HCT HCT-CI ≤2 aged ≥55 and < 65yo|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2 aged ≥55 and < 65 years old.
89292768|NCT02988466|Experimental|Arm D: Haplo-HCT aged ≥65 and ≤75yo OR any age HCT-CI ≥3|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients patients ≥65 and ≤75 years old OR any age group with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
89292769|NCT02980575|Experimental|Exercise with music|Participants will listen to music when they exercise
89292770|NCT02980575|Active Comparator|Exercise|Participants will not listen to music when they exercise
89292771|NCT02961322|Experimental|lobo isthmectomy|
89292772|NCT02946463|Experimental|Ravulizumab|"Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligram (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
89292773|NCT02946463|Active Comparator|Eculizumab|"Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
89292774|NCT02933008|Experimental|aNMT Biofeedback|Participants randomized to receive a neuromuscular training intervention that incorporates biofeedback training.
89292775|NCT02933008|Sham Comparator|Sham Biofeedback|Participants randomized to receive a neuromuscular training intervention with sham feedback training.
89292776|NCT02907944|No Intervention|Usual Care- Control|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The first phase for all clinics is a control phase where clinic staff and patients engage in usual care. The time to implementation is randomly assigned. Each clinic is then followed prospectively to determine their outcome status.
89292777|NCT02907944|Experimental|Implementation Facilitation|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The time to implementation in a stepped wedge design is randomly assigned. Clinics are then followed prospectively to determine their outcome status..
89292778|NCT02891759|Experimental|Group A: Alloderm RTU|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group A will receive Alloderm RTU~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
89292779|NCT02891759|Experimental|Group B: Cortiva 1mm Allograft Dermis|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group B will receive Cortiva 1mm Allograft Dermis~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
89292780|NCT02819024|Experimental|Treatment (dexamethasone, 18F-FLT PET)|Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
89292781|NCT02805530|Experimental|single arm|"Patients with synchronous metastases at Central Nervous System (CNS), evaluated in less than one week by the Multidisciplinary Committee at National Cancer Institute of Mexico to define the initial treatment. Patients with metastases at other sites than CNS will receive first line systemic treatment, in those EGFR-mutated with tyrosine kinase inhibitors (TKI) and in patients without a driver mutation with first line duplet of chemotherapy based on platin. The type of TKI or chemotherapy will be at discretion of the treating physician.~After 4 cycles of treatment, patients with stable disease or partial response will be evaluated by de Multidisciplinary Committee to establish the type of radical treatment to the primary and to the metastases, radiation therapy and chemoradiotherapy."
89531448|NCT06066229||Relatives of lung transplant patients|Close relatives of lung transplant patients (spouse; partner; first-degree parent) followed at Bichat Hospital (Paris) or Foch Hospital (Suresnes).
89292782|NCT02800785|Active Comparator|Antibiotics Therapy Arm|Patients in the antibiotics (abx) arm will receive a total of 10 days of abx, with a minimum of 24 hours using an IV abx formulation (administered in q8, q12, or q24 hour regimens with or without concurrent oral abx) followed by oral abx for the remainder of the 10 days. Patients will be offered a treatment regimen of abx based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. Any of the IV abx options (Single antibiotic-Cefoxitin, Ertapenem, Moxifloxicin, Tigecycline, Ticarcillin-Clavulanic Acid or Dual antibiotics-Metronidazole plus one of the following-Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, Levofloxacin) will be considered acceptable. After IV abx, a regimen of oral abx will be continued for a total treatment length of 10 days.
89292783|NCT02800785|Active Comparator|Appendectomy Arm|Patients in the appendectomy arm will have an appendectomy performed by an open or laparoscopic approach, depending on patient and surgeon preference. Prior to their operation, patients in this arm will receive one dose of antibiotics per currently accepted standards when appendicitis diagnosis is confirmed. Patients may also receive preoperative antibiotics per hospital standards for surgical infection prevention bundle.
89292784|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose A|Open label dose A once daily (QD)
89292785|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose B|Open label dose B QD
89292786|NCT02765854|Experimental|Arm B (ixazomib and dexamethasone)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
89292787|NCT02765854|Experimental|Arm C (ixazomib, dexamethasone, lenalidomide)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
89292788|NCT02765854|Active Comparator|Arm A (ixazomib and dexamethasone)|UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
89292789|NCT02761694|Experimental|Part 1: Vevorisertib 5 mg QD|Participants will receive vevorisertib 5 mg orally once a day (QD) until discontinuation or toxicity.
89292790|NCT02761694|Experimental|Part 1: Vevorisertib 10 mg QD|Participants will receive vevorisertib 10 mg orally QD until discontinuation or toxicity.
89292791|NCT02761694|Experimental|Part 1: Vevorisertib 20 mg QD|Participants will receive vevorisertib 20 mg orally QD until discontinuation or toxicity.
89292792|NCT02761694|Experimental|Part 1: Vevorisertib 25 mg QD|Participants will receive vevorisertib 25 mg orally QD until discontinuation or toxicity.
89292793|NCT02761694|Experimental|Part 1: Vevorisertib 25 mg QOD|Participants will receive vevorisertib 25 mg orally every other day (QOD) until discontinuation or toxicity.
89292794|NCT02761694|Experimental|Part 1: Vevorisertib 50 mg QD|Participants will receive vevorisertib 50 mg orally QD until discontinuation or toxicity.
89292795|NCT02761694|Experimental|Part 1: Vevorisertib 75 mg QD|Participants will receive vevorisertib 75 mg orally QD until discontinuation or toxicity.
89292796|NCT02761694|Experimental|Part 1: Vevorisertib 100 mg QD|Participants will receive vevorisertib 100 mg orally QD until discontinuation or toxicity.
89292797|NCT02761694|Experimental|Part 2: Vevorisertib 50 mg QD plus Paclitaxel|Participants will receive vevorisertib 50 mg orally QD plus paclitaxel 80 mg/m^2 via intravenous (IV) infusion on Days 1, 7, 15 followed by a week of rest of each 28-day cycle until discontinuation or toxicity.
89292798|NCT02761694|Experimental|Part 2: Vevorisertib 75 mg QD plus Paclitaxel|Participants will receive vevorisertib 75 mg orally QD plus paclitaxel 80 mg/m^2 via IV infusion on Days 1, 7, and 15 followed by a week of rest of each 28-day cycle until discontinuation or toxicity.
89292799|NCT02761694|Experimental|Part 2: Vevorisertib 50 mg QD plus Fulvestrant|Participants will receive vevorisertib 50 mg orally QD plus fulvestrant 500 mg via intramuscular (IM) injection on Days 1 and 15 of Cycle 1, and Day 1 of each 28-day cycle thereafter until discontinuation or toxicity.
89292800|NCT02761694|Experimental|Part 2: Vevorisertib 75 mg QD plus Fulvestrant|Participants will receive vevorisertib 75 mg orally QD plus fulvestrant 500 mg via IM injection on Days 1 and 15 of Cycle 1, and Day 1 of each 28-day cycle thereafter until discontinuation or toxicity.
89292801|NCT02760030|Experimental|Treatment (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15. Patients also receive palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89292802|NCT02728284|Active Comparator|Normal Cardiovascular System|70 with a history of heart or lung disease
89292803|NCT02728284|Active Comparator|Abnormal Cardiovascular System|30 without any history of heart or lung disease
89292804|NCT02710253|Experimental|Treatment (SBRT or EBRT)|Patients undergo either 4, 5, or 10 fractions of SBRT, or 5-15 fractions of EBRT to any site of metastatic disease daily for any time between 4 days and 3 weeks as determined by the treating radiation oncologist. Patients with at least SD after the second imaging evaluation may undergo additional SBRT in 4 fractions or EBRT in 3 fractions.
89292805|NCT02704351||Sugammadex group|sugammadex to reverse neuromuscular blockade following cardiac surgery
89292806|NCT02698111|Experimental|Donafeinib|donafenib 200mg,bid
89292807|NCT02697812|Experimental|slow sternal retraction|sternal retraction (which is required for exposure of the heart during coronary artery bypass graft surgery) will be performed gradually over 15 minutes
89292808|NCT02697812|No Intervention|standard sternal retraction|sternal retraction will be performed as per standard practice (sternum opened rapidly over 30 sec.)
89531449|NCT06066229||Physicians from lung transplant|Physicians from lung transplant centers in France, or French-speaking experts identified in the professional network of investigators
89531450|NCT06066229||Paramedical staff|Nurses, psychologists, physiotherapists, etc.) from the same French center or French-speaking centers whose primary focus is on caring for lung transplant patients
89531451|NCT06066164|Placebo Comparator|Control group|
89531452|NCT06066164|Active Comparator|Polysubstance use disorder patients|
89531453|NCT06066164|Active Comparator|Monosubstance use disorder patients|
89531454|NCT06066125|Experimental|AK111 regimen 1|
89531455|NCT06066125|Experimental|AK111 regimen 2|
89531456|NCT06066125|Placebo Comparator|Placebo|
89531694|NCT05705427|Placebo Comparator|Placebo arm|140 pregnant women in the placebo arm will receive a placebo pill daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine.
89292809|NCT02695680||Lung SBRT|Respiratory motion causes significant geometric and dosimetric errors in the administration of lung stereotactic radiotherapy (SBRT). The purpose of this study is to create and validate patient-specific motion models of the thoracic anatomy with high spatial and temporal resolution. These models will be used to develop novel four-dimensional (4D=3D+time) techniques for radiotherapy treatment planning and real-time motion-adaptive dose delivery.
89292810|NCT02641093|Experimental|Pembrolizumab|Pembrolizumab in combination with standard of care surgery followed by radiation therapy with or without cisplatin
89292811|NCT02614768|Experimental|Glucose Sensor|Continuous subcutaneous glucose monitoring using four different CGM systems in parallel will be performed throughout the study. Insulin therapy will be performed by the subjects themselves, as under daily life conditions. For the hypoglycaemia experiment an increased insulin bolus will be administered with meals (180% of the subject's calculated mealtime dose).
89292812|NCT02612454|Experimental|Body weight ≥60 kg|Administered every two weeks (Q2W)
89292813|NCT02612454|Experimental|Body weight 30 kg to <60 kg|Administered Q2W
89292814|NCT02612454|Experimental|Body weight 15 kg to <30 kg|Administered every 4 weeks (Q4W)
89292815|NCT02612454|Experimental|Body weight 5 kg to <15 kg|Administered Q4W
89292816|NCT02603237|Other|Glucose tolerance test|All participants will receive an oral standardized glucose tolerance test
89292817|NCT02603237|Other|Fat tolerance test|The same participants will receive an oral standardized fat load test
89292818|NCT02578732|Experimental|FOLFOXA|"Schema:~1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~Antiemetics will be administered as per standard institutional policy."
89292819|NCT02574481|Experimental|ELUVIA Stent Implantation|Percutaneous stent placement in the SFA/PPA
89292820|NCT02574481|Active Comparator|Zilver PTX Stent Implantation|Percutaneous stent placement in the SFA/PPA
89292821|NCT02530268||Ankylosing Spondylitis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
89292822|NCT02530268||Psoriatic Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
89292828|NCT02505984|Active Comparator|Oxytocin|Sub-group of participants receiving oxytocin nasal spray (Syntocinon)
89292829|NCT02505984|Placebo Comparator|Placebo|Sub-group of participants receiving placebo nasal spray
89292830|NCT02489214|Experimental|donafenib tosilate tablets|200mg bid
89292831|NCT02477280|Experimental|Methylphenidate|Methylphenidate 20 mg Tablet single-dose per os
89292832|NCT02477280|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
89292833|NCT02414347||Experimental F 18 T807|Participants will undergo a PET scan using the flortaucipir imaging tracer
89292834|NCT02408770|Experimental|treatment|ulipristal acetate 5mg daily for 3 months
89292835|NCT02385279|Experimental|MiStent®|Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.
89292836|NCT02385279|Active Comparator|XIENCE EES|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
89292837|NCT02376829|Experimental|The Invisalign System|Class II correction of malocclusions
89292838|NCT02368665|Experimental|AML 5mg|- Amlodipine 5mg, once a day for 8 weeks
89292839|NCT02368665|Experimental|AML 5mg / CC 16mg|- Amlodipine 5mg and Candesartan cilexetil 16mg, once a day for 8 weeks
89292840|NCT02368665|Experimental|AML 10mg / CC 16mg|- After 8 weeks of treatment period, Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
89292841|NCT02368652|Experimental|CC 16mg|Candesartan ceilexetil 16mg, once a day for 8 weeks
89292842|NCT02368652|Experimental|AML 10mg / CC 16mg|Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
89292843|NCT02332577|Experimental|Pristinamycin + Placebo|Pristinamycin: 500 mg tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days Amoxicillin Placebo: capsule, 2 capsules x 3 /day for 7 to 9 days.
89531695|NCT05693610|Experimental|Portable OSP|Outcomes will be assessed with the portable version of the OSP.
89292844|NCT02332577|Active Comparator|Amoxicillin + Placebo|Amoxicillin: 500 mg capsule, 2 capsules x 3/day for 7 to 9 days Pristinamycin Placebo: tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days.
89292845|NCT02330926|Experimental|multimodal intervention|standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)
89292846|NCT02330926|Active Comparator|standard care|standard palliative care
89292847|NCT02312245|Experimental|Arm A (Avatar-directed paclitaxel)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
89292848|NCT02312245|Experimental|Arm B (Avatar-directed gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89292849|NCT02312245|Experimental|Arm C (Avatar-directed liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89292850|NCT02312245|Experimental|Arm D (Avatar-directed topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 every 21 days or days 1, 8, and 15 every 28 days. Patients may also receive bevacizumab IV over 90 minutes on day 1 every 21 days or days 1 and 15 every 28 days. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
89292851|NCT02297438|Experimental|Palbociclib + Letrozole|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)
89292852|NCT02297438|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
89292853|NCT02297139|Experimental|Dasatinib|This is a continuation roll-over study for patients receiving benefit from prior dasatinib protocols. All subjects will receive dasatinib as per previous protocol
89292854|NCT02249624||Survivors of TTTS|Infants who have survived TTTS to hospital discharge, have an MRI at term, and return for nursery follow-up clinic.
89292855|NCT02247843|Experimental|βAS3-FB vector transduced peripheral blood CD34+ cells|This is a single arm study without randomization. All subjects will receive the intervention of BetaAS3 lentiviral vector-modified autologous peripheral blood stem cell transplant.
89292856|NCT02137759|Active Comparator|Std RT/TMZ (Cohort 1)|"Standard radiation therapy~Standard temozolomide"
89292857|NCT02137759|Experimental|Std RT/TMZ + belinostat (Cohorts 2a, 2b)|"Standard radiation therapy~Standard temozolomide~Belinostat"
89292858|NCT02137122|Experimental|Cognitive Training + Active tDCS|Participants will undergo up to 10 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The group will undergo active transcranial direct current stimulation.
89292859|NCT02137122|Sham Comparator|Cognitive Training + Sham tDCS|Participants will undergo up to 10 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The group will undergo sham transcranial direct current stimulation.
89292860|NCT02107573|Active Comparator|Rotator cuff repair without Suprascapular Nerve decompression|approximately 17 subjects in the study will receive traditional rotator cuff repair surgical intervention with no suprascapular nerve decompression surgical intervention
89292861|NCT02107573|Active Comparator|Rotator Cuff Repair with Suprascapular Nerve decompression|approximately 17 subjects in the study will undergo rotator cuff repair with arthroscopic suprascapular nerve decompression surgical intervention
89292862|NCT02100722|Active Comparator|FFR guided PCI|Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity (or Onyx) drug-eluting stent (DES) as per usual routine. If the FFR is >0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.
89292863|NCT02100722|Active Comparator|CABG|CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.
89292864|NCT02090998|Active Comparator|SPG Nerve Block with Lidocaine 5% gel|Sphenopalatine Ganglion Nerve Block (SPG Nerve Block) will be administed weekly for 4 weeks using 5% Lidocaine gel This intervention (a nerve block) will treat the headache for the time period investigated
89292865|NCT02090998|Active Comparator|Amitriptyline / Elavil|Amitriptyline / Elavil 10 mg once a day for one week then Amitriotyline 20 mg once a day for three weeks This intervention will treat the headache for the time period investigated
89292866|NCT02043665|Experimental|CVA21/pembrolizumab|CVA21/pembrolizumab
89292867|NCT02028988|Experimental|Enzalutamide with External Beam Radiation|"Enzalutamide~40 mg orally 4x daily for 6 (28 day +/-3 days) cycles.~External Beam Radiation Therapy (EBRT) - 7-10 weeks after beginning Enzalutamide~75.6 to 79.2 Gy in 1.8 Gy fractions for up to 11 weeks.~*Patients that are unable to complete enzalutamide therapy will still be treated with EBRT"
89292868|NCT02006511|Experimental|Incisional Neg Pressure Wound Therapy|Incisional negative pressure wound therapy dressings applied to the surgical site
89292869|NCT02006511|Active Comparator|Standard of care wound dressing|Standard of care wound dressing of gauze and tape or the equivalent applied to the surgical site
89292870|NCT02004236|Experimental|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
89292871|NCT02004236|Experimental|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
89292872|NCT02004236|Placebo Comparator|tRNS with sham|This group receive 35 sessions with sham
89292873|NCT01929005|No Intervention|Standard of Care|If patients are randomized to standard of care, they are not assigned to a Comprehensive Care Physician. They are asked to continue receiving their care as they normally would.
89292874|NCT01929005|Experimental|Comprehensive Care|Patients randomized to the Comprehensive Care group are assigned to a Comprehensive Care physician and are asked to see their assigned CCP for their primary care. The patients will receive their care by the CCP in the outpatient clinic and also if they were to be hospitalized.
89292875|NCT01912651|No Intervention|No antibiotic treatment|Withholding post-operative antibiotics following reconstructive surgery necessitating skin grafting for defects of the face or nose.
89292876|NCT01912651|Experimental|Antibiotics|All patients will receive peri-operative antibiotics per standard practice. This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week).
89292877|NCT01912625|Experimental|Treatment (trametinib, chemotherapy, radiation therapy)|"CONCURRENT CHEMOTHERAPY: Patients undergo IMRT or 3D-CRT QD 5 days a week for 6 weeks. Patients receive trametinib PO QD and carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients without disease progression after completion of chemoradiation proceed to consolidation chemotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning 3 weeks after completion of concurrent chemoradiation, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on days 1 and 22. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
89292878|NCT01894672|Experimental|LGX818|LGX818 capsules will be administered orally on a once -daily schedule (QD) dosing at a dose of 300 mg/day, 2 weeks on followed by a 2 week break. This schedule of 2 weeks on, followed by 2 weeks off, will continue for the duration of time the patients remains on the clinical trial. After the follow up visit patients will be contacted approximately every 12 weeks until they have received a subsequent therapy or until they have been off treatment for a year to monitor their survival.
89292879|NCT01814813|Experimental|Arm 1, HSPPC-96 + concomitant bevacizumab|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression. HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion. (1 cycle=14 days)~Note: If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression."
89292880|NCT01814813|Experimental|Arm 2, HSPPC-96 with bevacizumab at progression|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression. (1 cycle = 14 days)~NOTE: It is possible that HSPPC-96 vaccination may end prior to evidence of progression. In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab.~Upon confirmation of progression the patient should initiate bevacizumab within 7-42 days from the last dose of vaccine."
89292881|NCT01814813|Active Comparator|Arm 3, Bevacizumab|Bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days)
89292882|NCT01774071|Experimental|89Zr DFOMSTP2109A tracer Group 1|The first group of participants will include 6 participants whom will receive 10mg of 89Zr-DFO-MSTP2109A. A second group of 6 participants may receive twice the amount of antibody to determine if this results in better pictures of your tumors. Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2.
89292883|NCT01774071|Experimental|89Zr-DFO-MSTP2109A tracer Group 2|Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.
89292884|NCT01720836|Experimental|Stage IA or I/II NSCLC or neuroendocrine carcinoid tumor|Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
89292885|NCT01720836|Experimental|Stage IB/II/IIIA|Resection and adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
89292886|NCT01720836|Experimental|Stage IIIA or IIIB|Concomitant chemo-irradiation followed by 3 cycles of vaccine + PolyICLC.
89292887|NCT01680822||NTM patient|confirmed NTM patient
89292888|NCT01667120|Placebo Comparator|Placebo|Postoperative surgical neonates will receive an equivalent volume of 0.9% normal saline as placebo.
89292889|NCT01667120|Experimental|Ketorolac|Postoperative ketorolac 0.5mg/kg intravenously every 8 hrs for 72hrs will be administered.
89292890|NCT01642251|Experimental|Arm A (veliparib)|Patients receive veliparib PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89292891|NCT01642251|Active Comparator|Arm B (placebo)|Patients receive placebo PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89292892|NCT01607502||Patients of our outpatient clinic|Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing
89292893|NCT01606137|Experimental|GW-1000-02|Active treatment
89292894|NCT01532518|Experimental|Cohort 3|Nepadutant low dose (0.1mg/kg) for 7 days followed by Nepadutant high dose (1mg/kg) for additional 7 days
89292895|NCT01532518|Experimental|Cohort 2|Nepadutant medium dose (0.5mg/kg) for 7 days followed by Nepadutant high dose (1mg/kg) for additional 7 days
89292896|NCT01532518|Experimental|Cohort 1|Nepadutant low dose (0.1mg/kg) for 7 days followed by Nepadutant medium dose (0.5mg/kg) for additional 7 days
89292897|NCT01489813|Placebo Comparator|Sugar pill|Patients will be given placebo pills for 10 weeks.
89292898|NCT01489813|Experimental|Genistein supplement|30 mg of genistein supplement by mouth three times daily (PO TID) for 10 weeks.
89292899|NCT01489449|Placebo Comparator|Stent|Stent Implantation (DES or BMS), no further treatment
89292900|NCT01489449|Active Comparator|DCB|"DEBonly strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection"
89292901|NCT01420874|Experimental|FOLFOX6 & EGFRBi armed ATC Infusions|"FOLFOX6: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.~EGFRBi armed ATC Infusions: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion"
89292902|NCT01405521|Experimental|M01ZH09 vaccine|
89292903|NCT01405521|Placebo Comparator|Vaccine placebo|
89292904|NCT01405521|Other|Ty21a vaccine|Positive control
89292905|NCT01402661||Rheumatoid Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible.
89292906|NCT01246947|Active Comparator|Mitral surgery alone|Mitral valve surgery randomization for no repair of the moderate tricuspid regurgitation
89292907|NCT01246947|Active Comparator|Mitral surgery w/Tricuspid valve repair|Mitral valve surgery with randomization to repair the moderate tricuspid regurgitation
89292908|NCT01221389|Active Comparator|Colloid Control|Patients will receive 2 units of 250 ml of hydroxyethylated starch solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
89292909|NCT01221389|Active Comparator|Plasma|Patients will receive 2 units of AB+ plasma once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
89292910|NCT01099982||Advanced Heart Failure Therapy Group|Patients diagnosed with end stage heart failure undergoing either VAD implantation or heart transplantation.
89292911|NCT01099982||Normal Hearts Group|Control samples will be obtained from individuals undergoing other types of cardiac surgery during which it is routine to discard some tissue intraoperatively.
89292912|NCT01083030|Active Comparator|Conventional PTA|Angioplasty of SFA with uncoated balloon catheters
89292913|NCT01083030|Experimental|Drug coated balloon|Angioplasty of SFA with paclitaxel-coated balloon catheters
89292914|NCT01027000|Experimental|Treatment (Combination of chemotherapy and transplant)|See detailed description
89292915|NCT00949819||no treatment|Men with previously untreated, early stage prostate cancer.
89292916|NCT00935090|Experimental|3'-deoxy-3'-[18F]fluorothymidine|The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
89292917|NCT00880516||control|Adults with normal sinuses
89292918|NCT00880516||case|Adults with chronic sinusitis and positive findings on imaging.
89292919|NCT00861068|Experimental|1|
89292920|NCT00861068|Placebo Comparator|2|
89292921|NCT00844285||Cimzia Cohort:|Patients about to receive treatment with Cimzia® as part of pre-existing management plan for Crohn's disease or has already been receiving treatment with Cimzia® for ≤12 months. Patients must also receive a Cimzia dose within 2 months following enrollment.
89292922|NCT00844285||Comparison cohort|Patient must be about to receive treatment with any other medication as part of a pre-existing management plan for Crohn's disease or has already been receiving treatment (previous Cimzia® treatment is prohibited).
89292923|NCT00841789|Experimental|Arm 1 -Etanercept|Drug - Treatment with Etanercept as adjunct to standard treatment with IVIG and aspirin
89292924|NCT00841789|Placebo Comparator|2|Placebo
89292925|NCT00829972||1|children undergoing adenotonsillectomy
89292926|NCT00829972||2|children undergoing elective procedures other than adenotonsillectomy
89292927|NCT00711646|Experimental|Sativex|
89292928|NCT00711646|Placebo Comparator|Placebo|
89292929|NCT00702468|Experimental|Sativex|Sativex
89292930|NCT00702468|Placebo Comparator|Placebo|Placebo
89292931|NCT00681538|Experimental|Sativex|"Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations (THC 32.4 mg:CBD 30 mg) in 24 hours"
89292932|NCT00681538|Placebo Comparator|Placebo|Contains no active drug but colourants and excipients. Subjects received placebo delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations in 24 hours.
89292933|NCT00640133|Active Comparator|Active DBS|Participants will receive deep brain stimulation.
89292934|NCT00640133|Sham Comparator|Sham DBS|Participants will receive sham deep brain stimulation for several months and then active deep brain stimulation thereafter.
89292935|NCT00588250|Experimental|A|
89292936|NCT00588250|No Intervention|B|
89292937|NCT00582062||1|Positive controls will include patients who have positive cytology or positive biopsy of peritoneal metastases. Cell lines which over-express these tumor markers will also be used as positive controls. Sensitivity will be defined using serial dilutions of several established gastric and pancreatic tumor cell lines. The mRNA of the tumor markers will be normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA expression.
89292938|NCT00582062||2|Patients who are scheduled to undergo laparoscopy for benign disease (e.g., laparoscopic cholecystectomy, hernia repair, or prophylactic BSO) will be recruited as negative controls. A leukemia cell line which does not express epithelial cell markers will also be used as a negative control for the RT-PCR reactions.
89292939|NCT00523003|Experimental|1,|2.2 g protein/kg LBM/day high protein diet
89292940|NCT00523003|Placebo Comparator|2, standard protein|1.1 g protein/kg LBM/day standard protein diet
89292941|NCT00455351|Experimental|A I|Study drug
89292942|NCT00379340|Experimental|Treatment (chemotherapy, surgery, radiotherapy)|"REGIMEN DD4A (weeks 1-6): Patients receive dactinomycin IV; vincristine IV; and doxorubicin hydrochloride IV. Patients with pulmonary and extra-pulmonary metastases at diagnosis undergo radiotherapy.~Patients with initially unresectable or incompletely resected tumors are reevaluated at week 6, and if resectable, undergo surgery and then proceed to either regimen DD4A or regimen M.~REGIMEN DD4A (weeks 7-25): Patients receive dactinomycin IV; vincristine IV; and doxorubicin hydrochloride IV.~REGIMEN M (weeks 7-31): Patients receive cyclophosphamide IV; vincristine IV; and dactinomycin IV and doxorubicin hydrochloride IV. Patients with pulmonary metastases only who are SIR also undergo whole lung radiotherapy."
89292943|NCT00301808|Experimental|Cisplatin, Docetaxel & Radiation Therapy|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43; Docetaxel 75 mg/m2 on day 1 of each cycle; Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
89292944|NCT00289380||Nutrition support|Nutrition support cohort means accept nutrition support，it was defined as ≥15kal/kg/d and < 30kal/kg/d of non-protein calories (carbohydrate and/or fat) and amino acids or protein≥1g/kg/d for 5~28 consecutive days.
89292945|NCT00289380||Without nutritional support|Group received only intravenous 5 to 10% glucose and electrolyte infusions
89292946|NCT00138801|Active Comparator|1|Doxycycline
89292947|NCT00138801|Active Comparator|2|cephtriaxone
89292948|NCT00113659|Active Comparator|1|Participants in this arm will receive Lactobacillus GG.
89292949|NCT00113659|Placebo Comparator|2|Participants in this arm will receive a placebo.
89292950|NCT05795829|Experimental|Disposable Intravascular Ultrasound Ablation Catheter and Ultrasound Ablation Instrument|All subjects will receive treatment from the disposable intravascular ultrasound ablation catheter.
89292951|NCT05795803||SSD group|Adolescents with SSD diagnosis made within previously six months or before unless assessed and confirmed by a specialist within the last six months
89292952|NCT05795803||Without SSD group|Control group: adolescents without diagnosis of SSD, matched with the SSD group by age and sex
89292953|NCT05795725|Experimental|Colonoscopy|Fecal samples will be obtained from patients who are enrolled for colonoscopy procedures for the suspicion of colon cancer.
89292954|NCT05795673|Other|Group Peer support|Intervention of mentor to provide peer support
89292955|NCT05795673|No Intervention|Group Control|Usual practices of accompaniment of the pediatric-adult transition
89292956|NCT05795660|Experimental|Osteochondral lesions of the talus group|Patients will receive PRP injection.
89292957|NCT05795660|Placebo Comparator|Control group|Patients will receive saline injection.
89292958|NCT05795556||Home-dwelling geriatric outpatients|"Home-dwelling geriatric outpatients from the Falls Clinic at Gentofte Hospital .~Clinical assesment: Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles, screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)"
89292959|NCT05795543|Active Comparator|A|subtalar arthrodesis by single screw
89292960|NCT05795543|Active Comparator|B|subtalar arthrodesis by double screws
89292961|NCT05795478|Experimental|Combined group|Oxycodone+Pregabalin
89292962|NCT05795478|Other|Oxycodone group|Oxycodone+placebo capsules
89292963|NCT05795478|Other|Pregabalin group|NS+Pregabalin
89292964|NCT05795478|Placebo Comparator|Control group|NS+placebo capsules
89292965|NCT05795452||Adolescents from the Mothers and Newborns Cohort|
89292966|NCT05795400|Experimental|Dapagliflozine group|20 patients diagnosed with heart failure and amyloid cardiomyopathy, regardless of HF phenotype, are planned to be enrolled in the study. Patients with the edematous syndrome are allowed to participate in the study, but the condition of stable hemodynamics must be observed. Regardless of the group, patients will receive standard therapy for ADHF (diuretics and MRA). Patients will not receive beta-blockers/ACE-I/ARNI. In the treatment group the therapy will include the SGLT-2 inhibitor dapagliflozin, which will be prescribed during the first 24 hours after the hospitalization.
89292967|NCT05795400|Placebo Comparator|Control group|In the control group, patients will be treated with standard diuretic therapy without SGLT-2 inhibitors.
89292968|NCT05795387|Experimental|Experimental Add-on Intervention - Video-based self-regulated training|"The intervention consist of access to the video e-library on their e-learning platform.~The video e-library consists of 23 videos of brief patient interviews, mostly with inpatients, with adjoining MSE written by three faculty psychiatrists. Selected videos are used for demonstration of phenomena, and five videos will have audio explanation of the resulting MSE.~As well as the authentic patient videos on the e-library there are some pages with written theoretical instructions on the MSE, a brief animated movie and some simulated videos by an actor all regarding the MSE."
89292969|NCT05795387|Active Comparator|Non-video group|For the present trial, also the NV students will receive the same non-authentic patient material I.E written theoretical instructions on the MSE, a brief animated movie and some simulated videos by an actor all regarding the MSE. Ensuring it is the authentic patient video e-library and not the theoretical information responsible for the expected difference in scores.
89292970|NCT05795322||Tuning for Health|Community based group 'Tuning for Health' was set up to provide chronic condition self-management support to people. Trained, experienced therapist-led group used half an hour of sound healing in virtual session.
89292971|NCT05795283||Group A: Citalopram i.v. and p.o|Both intravenous and oral administration of citalopram
89292972|NCT05795283||Group B: Citalopram p.o|Oral administration of citalopram
89292973|NCT05795270||Sleep apnea syndrome with excessive daytime sleepiness|
89292974|NCT05795231||Gender Based|Male patients will be compared to female patients with regards to incidence of complications
89292975|NCT05795231||Age Based|Various age groups will be evaluated to determine vulnerable age groups
89292976|NCT05795088|Experimental|Patients with parkinson's disease|
89292977|NCT05795036|Experimental|Hope Clinic|Participants will be recruited from clients admitted to the Phase III CR program at Hope Clinic. An information sheet introducing this study will be provided to clients by the assigned therapist at the Hope clinic after admission.
89292978|NCT05794945||Breastfeeding mothers|In this study breastfeeding mothers will be included. Samples will be collected from breast-feeding mothers experiencing mastitis Samples will be collected from breast-feeding mothers after the mastitis episode is resolved Breastfeeding mothers will be sampled at each mastitis episode, and with the final sample collected after a maximum of 12 months
89292979|NCT05794919|Experimental|Calcium Hydroxybenzene Sulphonate Dispersible Tablets|The healthy subjects will be administered a single dose of Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g under fast or fed conditions.
89292980|NCT05794919|Active Comparator|Doxium®|The healthy subjects will be administered a single dose of Doxium® 250mg under fast or fed conditions.
89292981|NCT05794893|Experimental|Good Behavior Game|28 classes receiving Good Behavior Game intervention
89292982|NCT05794893|No Intervention|Service-as-usual|16 classes receiving usual classroom teaching
89292983|NCT05794867||Patients were randomly allocated in one of two groups each group contain 100 patients.|Group A considered control group. Those patients weaned from the ventilator by the conventional criteria of weaning
89292984|NCT05794867||100 patients|group B weaned from the ventilator by the ultrasound criteria of weaning. All patients weaned from both groups followed for six days for signs of failure of weaning ,signs of post-extubation respiratory failure. And number of patients who were re-ventilated and who discharged from ICU in both groups recorded and compared.
89292985|NCT05794854|Experimental|abdominal aerobic endurance exercise|Subjects were combining treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 d per wk for 10 weeks
89292986|NCT05794854|Active Comparator|Control group|Subjects performed only treadmill running (45 minutes) at 70% HRmax for 4 d per week for 10 weeks.
89292987|NCT05794841||Patients with digestive tract malignant tumors|Patients with malignant tumors of the esophagus, stomach or colon confirmed by pathology, have not received anti-tumor therapy, and have not had malignant tumors in the past.
89292988|NCT05794841||Healthy volunteer|Healthy individuals with no digestive tract malignancies confirmed by gastroscopy and colonoscopy.
89292989|NCT05794737||Participants|60 archived Formalin-fixed Paraffin-embedded tissue blocks of Colorectal Carcinoma will be obtained and sectioned. From each block; Two tissue sections will be prepared, one tissue section will be stained by Hematoxylin and Eosin to detect tumor phenotype and depth of invasion. Other tissue section will be immunohistochemically stained by Anti-Human INHBA.
89292990|NCT05794646|Other|Intervention|Community-based intervention with screening and treatment initiation for HCV elimination among PWUD
89292991|NCT05794607|Experimental|Study group|
89292992|NCT05794607|No Intervention|Control group|
89292993|NCT05794594||3D printed|3D printed personalized extendable prosthesis replacement for limb preservation in children with osteosarcoma
89292994|NCT05794594||amputation|patients had undergone amputation of the limbs
89292995|NCT05794529||Lung cancer patient|Lung cancer patients diagnosed a non-small cell lung carcinoma requiring resection surgery.
89292996|NCT05794451||Healthy controls|Adults aged 60 and above without cognitive impairment
89292997|NCT05794451||Mild cognitive impairment|Adults 60 and above with mild cognitive impairment
89292998|NCT05794451||Alzheimer's disease|Adults diagnosed with Alzheimer's disease
89292999|NCT05794373||Pre-Education group|Patients in this group undergo rehabilitation for back pain in a municipality setting with physiotherapists before the physiotherapists have participated in an educational intervention
89293000|NCT05794373||Post-Education group|Patients in this group undergo rehabilitation for back pain in a municipality setting with physiotherapists after they have participated in an educational intervention
89293001|NCT05794113|Active Comparator|Web-based notification arm|All participants randomized to the web-based notification arm received the following web-based CANVAS notifications [4,5]. Briefly, participants received an email notifying them of their registration in the study. Eight days following their influenza vaccine, participants received an email with the survey link asking them to complete their online influenza vaccine safety survey. Participants received a reminder email on day 11 if they did not complete their survey.
89293002|NCT05794113|Experimental|Mobile app arm|Participants randomized to the mobile app arm, received an email asking them to download the app and activate their account. Users who did not activate their account after 48 hours received a reminder email. Participants who activated their accounts, could spontaneously report an adverse event through the app, and were also notified of the day 8 survey through the app.
89293003|NCT05794100|Active Comparator|Test 1|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + Allulose provided at a dose of 1 serving equivalent
89293004|NCT05794100|Active Comparator|Test 2|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + Allulose provided at a dose of 1.75 serving equivalent
89293005|NCT05794100|Active Comparator|Test 3|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + Allulose provided at a dose of 2.5 serving equivalent
89293006|NCT05794100|Active Comparator|Test 4|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + FOS provided at a dose of 1 serving equivalent
89293007|NCT05794100|Active Comparator|Test 5|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + FOS provided at a dose of 1.75 serving equivalent
89293008|NCT05794100|Active Comparator|Test 6|No-sugar chewable candy containing Soluble Corn Fiber + Inulin + FOS provided at a dose of 2.5 serving equivalent
89293009|NCT05794100|Active Comparator|Test 7|No-sugar chewable candy containing Maltitol + Polydextrose provided at a dose of 1 serving equivalent
89293010|NCT05794100|Active Comparator|Test 8|No-sugar chewable candy containing Maltitol + Polydextrose provided at a dose of 1.75 serving equivalent
89293011|NCT05794100|Active Comparator|Test 9|No-sugar chewable candy containing Maltitol + Polydextrose provided at a dose of 2.5 serving equivalent
89293012|NCT05794100|Placebo Comparator|Test 10|Control chewable candy made with sugar and provided at a dose of 1 serving equivalent
89293013|NCT05793580|Other|VSB arm|longitudinal follow-up of VSB users preoperatively and at 1, 3, 6, 12 and 60 months post-implantation.
89523318|NCT03378089|Active Comparator|No Music Therapy|Participants randomized to the standard care group will be asked to rate the same symptoms as those in the experimental group. This will mark the beginning of a 45-minute control condition period during which the participants may fill the 45-minute time-period in whatever ways they choose.
89293014|NCT05793541|Experimental|Just-in-time intervention for promoting use of the safety plan or its components|"Completed surveys will be assigned to a risk level based on self-reported level of suicidal urge and intent. Participants will be micro-randomized to one of the available intervention options based on the survey's risk level. All interventions will include reminders to use the safety plan or its components. At high risk (intent >= 8 OR (urge >= 8 AND intent > 0)), participants will be randomized to either receive a phone call from a clinician, text messaging from a clinician, or automated interactive smartphone tool. At medium risk ((intent = 5-7) OR (urge = 5-7 AND intent < 8 but > 0) OR (urge >= 8 AND intent = 0)), participants will be randomized to receive an automated interactive smartphone tool, non-interactive pop-up messages, or no intervention. At low risk ((intent = 1-4) OR (urge = 1-4 AND intent < 5)), participants will be randomized to receive non-interactive pop-up messages or no intervention. No intervention will be given at no risk (intent=0 AND urge=0)."
89293015|NCT05791968|Active Comparator|DONATION GROUP|Participants will be measured before and after a standard blood bank donation (450 mL of whole blood withdrawal)
89293016|NCT05791968|Sham Comparator|CONTROL GROUP|Participants will be measured before and after a sham blood donation (0 mL of whole blood withdrawal)
89293017|NCT05791786||AFE|"participants of the AFE registry and biorepository include affected individuals diagnosed with AFE~All subjects or their next of kin must be able to provide a signed and dated informed consent form.~In the case of lethal AFE, the surviving family member or next of kin must be able to provide a signed and dated informed consent form with an accompanying death certificate and proof of legal kinship"
89293018|NCT05787132|Experimental|Group A (Balance Board Therapy)|30 minutes of Balance board therapy along with conventional physical therapy
89293019|NCT05787132|Experimental|Group B (Perceptual Motor Therapy)|30 minutes of Perceptual Motor therapy along with conventional physical therapy
89293020|NCT05783401||Cohort A: palliative care center|Patients from a palliative care center (Palliativzentrum Hildegard, Basel)
89293021|NCT05783401||Cohort B: mid-size cancer center|Patients from a mid-size cancer center (Tumorzentrum Baselland)
89293022|NCT05779579|Experimental|HS-10517 Dose 1|Dose level 1 of HS-10517 Tablets，Dose 1
89293023|NCT05779579|Experimental|HS-10517 Dose 2|Dose level 1 of HS-10517 Tablets，Dose 2
89293024|NCT05779579|Experimental|HS-10517 Dose 3|Dose level 1 of HS-10517 Tablets，Dose 3
89293025|NCT05779579|Experimental|HS-10517 Dose 4|Dose level 1 of HS-10517 Tablets，Dose 4
89293026|NCT05779579|Experimental|Placebo Comparator|Dose level A of placebo
89293027|NCT05768958|Experimental|Morning exercise|Study visit performed in the morning with 45 min exercise.
89293028|NCT05768958|Experimental|Morning control|Study visit performed in the morning with 45 min rest period.
89293029|NCT05768958|Experimental|Evening exercise|Study visit performed in the evening with 45 min exercise.
89293030|NCT05768958|Experimental|Evening control|Study visit performed in the evening with 45 min rest period.
89293031|NCT05763238|Experimental|Interventional Group|Preoperative Exercise therapy Patient Education, and post-operative conventional protocol.
89293032|NCT05763238|Active Comparator|Control group|Patient Education, and post-operative conventional protocol.
89293033|NCT05750225||690AD IOL|50 eyes /patients implanted with 690AD IOL
89293034|NCT05750225||690ADY IOL|50 eyes /patients implanted with 690ADY IOL
89293035|NCT05749913||Normal|"Participants living in the community.~No vision or hearing impairment.~No severe depression, or other neurological/mental disorders affecting cognitive function."
89293036|NCT05749913||Subjective Cognitive Decline, SCD|"The Montreal Cognitive Assessment (MoCA) score >22~Use two questions to screen: Compared with the previous situation, do you have memory problems?, Has your family or relatives ever thought that you have memory problems compared with the previous situation?, the answer to both questions is yes.~Geriatric Depression Scale-Short Form (GDS-S) score <8"
89293037|NCT05749913||Mild Cognitive Impairment, MCI|"MCI diagnosed by neurologists or psychiatrists: the diagnosis of MCI is mainly in accordance with the revised consensus version of the diagnostic criteria (Winblad et al., 2004), that is, memory function score is 1.5 standard deviations below the value for age- and education-related norms on the third edition of Wechsler Memory Scale.~MoCA: with a range of scores of 17-23(>17 , <23) (Trzepacz et al., 2015)~Geriatric Depression Scale-Short Form (GDS-S) score <8"
89293038|NCT05749913||Mild Dementia|"has met the criteria of dementia~at the early stages"
89293039|NCT05743790|Experimental|Group A: RS2 first|Crackers were provided during each of 3 treatment periods in a crossover design. The 3 types of crackers were matched for total carbohydrate content. Treatment period 1 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 2 (30g/day) for 7 days; Treatment period 2 (10 days): Participants received control crackers with 100% digestible starch; Treatment period 3 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 4 (30g/day) for 7 days. There were 5-day washout periods between the treatment periods.
89293040|NCT05743790|Experimental|Group B: RS4 first|Crackers were provided during each of 3 treatment periods in a crossover design. The 3 types of crackers were matched for total carbohydrate content. Treatment period 1 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 4 (30g/day) for 7 days; Treatment period 2 (10 days): Participants received control crackers with 100% digestible starch; Treatment period 3 (10 days): After a 3-day ramp up, participants received 120g of crackers/day containing resistant starch type 2 (30g/day) for 7 days. There were 5-day washout periods between the treatment periods.
89293041|NCT05734859|Experimental|EHARW Treatment group|The experimental group will drink a total amount of 20 mL/ kg body weight/day of EHARW for 4 weeks on an empty stomach according to the researcher's instruction.
89523319|NCT03378011|Active Comparator|UVA1 phototherapy|UVA1 phototherapy in acral vitiligo
89523320|NCT03378011|Active Comparator|Topical PUVA|Topical PUVA in acral vitiligo
89531554|NCT06062550|Experimental|High-dose group|Patient-controlled analgesia is established with esketamine 150 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
89531696|NCT05693610|Experimental|Cloud-based OSP|Outcomes will be assessed with the cloud-based version of the OSP.
89531697|NCT05692323|Experimental|Supervised Prehabilitation Exercise Program|
89293042|NCT05724394|Experimental|Ca-GBBB arm|The Ca-GBBB strongly focuses on enhancing participant's motivation and belief in their ability to change. The intervention will be comprised of 16-week training program delivered over four months. Sessions will be delivered weekly and each session will last about 45-50 minutes. All sessions will be delivered by master level psychologist. The manual will be translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios will be incorporated and a consensual view to addressing cultural factors such as gender role, financial difficulties will be taken into consideration. The time and venue of session will be decided prior according to participant convenience.
89293043|NCT05724394|No Intervention|Treatment As Usual|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4-month post-randomization.
89293044|NCT05712343|Experimental|valacyclovir group|"Patients (N=20) in the valacyclovir group will be received, at baseline, periodontal scaling + valacyclovir (500 mg, 3 times a day for 3 days) (Valacyclovir group)."
89293045|NCT05712343|Active Comparator|Control group|"Patients (N=20) in the control group will receive, at baseline, periodontal scaling + placebo medication, three times a day for 3 days (Control group)."
89293046|NCT05707130|Experimental|gaze stabilization exercises group|Experimental group will receive Vestibulo ocular reflex VOR / gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
89293047|NCT05707130|Active Comparator|control group|Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
89293048|NCT05704283|Experimental|Diagnostic (3D-US)|Patients undergo 3D-US on study. Patients who have an ALN clip placed and undergoing neoadjuvant chemotherapy undergo imaging of the clipped node before surgery.
89293049|NCT05703425|Experimental|Sulfasalazine|Pregnant persons will receive sulfasalazine daily with 500 mg/daily and increasing by 500 mg/day every week until they reach a therapeutic dose of 1,000 mg twice daily. Drug will be started at 24 weeks estimated gestational age and ended at 36 weeks or earlier if preterm birth occurs.
89293050|NCT05703425|No Intervention|Standard Care|Pregnant persons will receive standard care in pregnancy.
89293051|NCT05693220|Active Comparator|Density gradient centrifugation|Patients will undergo sperm preparation by density gradient centrifugation
89293052|NCT05693220|Active Comparator|Zymot sperm separation device|Patients will undergo sperm preparation by the Zymot sperm separation device
89293053|NCT05690503|Experimental|CI-581a+CI-581b|Administration of CI-581a at 0.8mg/kg during week 1. Administration of CI-581b at 0.025mg/kg during week 3.
89293054|NCT05690503|Experimental|CI-581b+CI-581a|Administration of CI-581b at 0.025mg/kg during week 1. Administration of CI-581a at 0.8mg/kg during week 3.
89293055|NCT05678309||patient library|Patient with pruritus sine materia
89293056|NCT05666141|Experimental|PES stimulation in volunteers|10 volunteers will receive PES stimulation. For healthy volunteers, the study protocol includes 1 stimulation trial. Each stimulation trial consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).
89293057|NCT05666141|Sham Comparator|Sham treatment in volunteers|10 volunteers will receive Sham treatment. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
89293058|NCT05666141|Experimental|PES stimulation + PES stimulation in patients|20 patients will receive PES stimulation twice. For patients, the protocol thus includes 2 stimulation trails. Each stimulation trial consists of 3 PES sessions, so they receive 6 PES sessions in total. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003).
89293059|NCT05666141|Other|PES stimulation + Sham treatment in patients|20 patients will receive PES stimulation and afterwards Sham treatment. During the first stimulation trial, they will receive 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters, as reported by Fraser et al. (2003). During the second stimulation trial, the same method and same device will be used. However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
89293060|NCT05666141|Sham Comparator|Sham treatment + Sham treatment in patients|20 patients will receive Sham twice. In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
89293061|NCT05661032||Covid Positive|Nasopharyngeal Swab
89293062|NCT05661032||Covid Negative|Nasopharyngeal Swab
89293063|NCT05659355|Experimental|Treatment Group|Constraint Induced Movement Therapy
89293064|NCT05659355|Experimental|Control Group|Mirror Therapy
89293065|NCT05658133|Other|Survey for student athletes|15 to 20 minute online questionnaire completed using Qualtrics
89293066|NCT05658133|Other|Survey for influencers of student athletes|15 to 20 minute online questionnaire completed using Qualtrics
89293067|NCT05653180|Experimental|IBI310+ sintilimab|All Subjects will be treated with : Sintilimab 200mg IV Q3W continuously and IBI310 2mg/kg IV single dose, 3 weeks later, IBI310 maintenance dose is 1mg/kg IV Q6W until progression (treatment duration up to 24 months).
89293068|NCT05649501|Experimental|proprioceptive neuromuscular facilitation techniques|Experimental group will receive proprioceptive neuromuscular facilitation stretching which include hold-relax and contract-relax for 6 sec hold, 10 repetitions and 2 min rest in between, for 5 day/week for 4 weeks along with conventional physical therapy.
89293069|NCT05649501|Active Comparator|traditional physical therapy|this group will receive conventional therapy (ROMs, stretching, strengthening).
89293070|NCT05647863|Experimental|F-CaST|The experimental group who will receive the Functional Cognitive and Sensory Treatment (F-CaST)- in which therapy is individually tailored for successful task performance and where the focus is on strategies for improving sensory and EF deficits.
89293071|NCT05647863|No Intervention|Standard Care|Standard care at the therapeutic community for SUD.
89293072|NCT05627180|Experimental|The Intervention Group|The intervention group will receive a tailored intervention based on each individuals health literacy needs. A project nurse with broad experience in cancer care will be trained in Motivational Interviewing techniques to provide follow-up for the patients in the intervention group in a period of 9 months.
89293073|NCT05627180|No Intervention|Usual care group|Usual care group will receive usual follow-up.
89293074|NCT05626361|Experimental|Specialized Dysphagia training|Power point presentation covering material related to nursing evaluation and caring of dysphagia patients. Stimulation session with nurses to practice screening skill
89293075|NCT05626361|Active Comparator|Reading material|Reading material covering information related to nursing evaluation and caring of dysphagia patient
89293076|NCT05624606|Experimental|Group 1: Quadrivalent Influenza mRNA Vaccine MRT5410 low dose|participants will receive a single dose (low) of QIV mRNA vaccine
89293077|NCT05624606|Experimental|Group 2: Quadrivalent Influenza mRNA Vaccine MRT5410 medium dose|participants will receive a single dose (medium) of QIV mRNA vaccine
89293078|NCT05624606|Experimental|Group 3: Quadrivalent Influenza mRNA Vaccine MRT5410 high dose|participants will receive a single dose (high) of QIV mRNA vaccine
89293079|NCT05624606|Active Comparator|Group 4: RIV4|participants will receive a single dose of RIV4 vaccine
89293080|NCT05624606|Active Comparator|Group 5: QIV-SD|participants will receive a single dose of QIV-SD vaccine
89293081|NCT05624606|Active Comparator|Group 6: QIV-HD|participants will receive a single dose of QIV -HD vaccine
89293082|NCT05591027|Experimental|Centella asiatica water extract product (CAP) 4g|A sachet of containing 4g dried hot water extract (CAW) of Centella asiatica combined with inactive ingredients (excipients) will be dissolved in water and orally consumed daily as a drink for six weeks. Assessments will be collected at baseline and after six weeks of daily intervention.
89293083|NCT05591027|Placebo Comparator|Placebo|A sachet of inactive ingredients (excipients) identical in composition to those found in the active arm will be be dissolved in water and orally consumed daily for six weeks. Assessments will be collected at baseline and after six weeks of daily intervention.
89293084|NCT05588648|Experimental|Single Arm|Single arm, open-label, no blinding or randomization procedure will be involved.
89293085|NCT05580796|Experimental|TCR-T cells|TCR-T cell injection
89293086|NCT05568472|Experimental|ARM I (ET, health education, symptom assessment)|Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients are asked 6 brief questions about symptoms weekly by email, text, or phone call for the first 6 months, then every 4 weeks for 12 months. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at baseline, 3, 12, and 18 months.
89293087|NCT05568472|Active Comparator|ARM II (ET, health education)|Patients receive ET and standard of care clinic visits with a cancer provider at 12, 24, 36, 48, 60, and 72 weeks, and phone visit at 80 weeks to access ongoing use ET medication. Patients also receive a list of websites with information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health. Patients have the option to submit blood specimen collection at 3, 12, and 18 months.
89293088|NCT05550194|Experimental|Treatment|Patients with Achalasia (phenotypes II and III) with VZV DNA in saliva. Patients will be treated with valacyclovir 3 times per day. Patients found to benefit from treatment with valacyclovir will be offered Shingrix vaccine (2 - 0.5mL doses)
89293089|NCT05547217|Experimental|Neurorehabilitation of the Hand|Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
89293090|NCT05545579|Experimental|circuit training|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes.
89293091|NCT05545579|Experimental|Trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
89293092|NCT05539833|Experimental|TCR-T cells|
89293093|NCT05532709|Experimental|Plyometric training|The plyometric training program progressed from level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
89293094|NCT05532709|Experimental|circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
89293095|NCT05518864|Experimental|Placebo - Intervention - Intervention|"Treatment period 1: placebo for 1x/week for 6 weeks, followed by two treatment periods of 6 weeks receiving GAG-therapy (Ialuril) 1x/week.~Finally this arm continues with unblinded GAG-therapy (Ialuril) instillations 1x/month for 6 instillations."
89293096|NCT05518864|Experimental|Intervention - Placebo - Intervention|"Treatment period 1: GAG-therapy (Ialuril) for 1x/week for 6 weeks, followed by treatment period 2: Placebo for 1x/week for 6 weeks and afterwards treatment period 3: GAG-therapy (Ialuril) for 1/x week for 6 weeks.~Finally, this arm continues with unblinded GAG-therapy (Ialuril) instillations 1x/month for 6 instillations."
89531555|NCT06060496|Experimental|Active cTBS and sham cTBS|There is only one arm in this study and all participants in this arm will receive 2 interventions: active and sham cTBS in a within subject blinded fashion. They will first receive active cTBS and then sham cTBS, separated by four weeks to minimize carryover effects.
89293097|NCT05518864|Experimental|Intervention - Intervention - Placebo|"Treatment period 1: GAG-therapy (Ialuril) for 1x/week for 6 weeks, followed by treatment period 2: GAG-therapy (Ialuril) for 1x/week for 6 weeks and afterwards treatment period 3: placebo for 1/x week for 6 weeks.~Finally, this arm continues with unblinded GAG-therapy (Ialuril) instillations 1x/month for 6 instillations."
89293098|NCT05515237|Experimental|Grade 2-5 CI Therapy + Sensory Components|All participants will receive CI Therapy + Sensory Components administered over the specific time frame of 2-3 weeks.
89293099|NCT05512312|Active Comparator|Test Group|Eight patients indicated for ECL were treated using digitally assisted crown lengthening utilizing 3D printed surgical stents.
89293100|NCT05512312|Active Comparator|Control Group|Eight patients indicated for ECL were managed by conventional crown lengthening.
89293101|NCT05477459|Experimental|Verum|Lysergic diethylamide tartrate (equivalent to 25 microgram LSD base), one dose every 3 days for 3 weeks (totalling 7 vials)
89293102|NCT05477459|Placebo Comparator|Placebo|Placebo vial looking like verum vial, one vial every 3 days for 3 weeks (totalling 7 vials)
89293103|NCT05469841|Experimental|Pupillometry|Pain will be evaluated via pupillometry with 3 successive measurements
89293104|NCT05461001|Experimental|Warm Up Exercises daily for Cardiorespiratory Fitness|Effect of warm up activities daily on cardiorespiratory fitness of Male Football Players
89293105|NCT05461001|Experimental|Endurance based Exercises for Cardiorespiratory Fitness|Effect of sports-specific endurance based exercises on cardiorespiratory fitness of Male Football Players
89293106|NCT05437406|Experimental|PBT-AC|PBT-AC includes the elements of family based behavioral treatment for obesity, delivered exclusively to caregivers as the agents of change, via telehealth.
89293107|NCT05437406|Active Comparator|Health Education|This program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress via telehealth.
89293108|NCT05426486|Experimental|ARX788 + pyrotinib maleate|ARX788 1.5 mg/kg intravenously (IV) every three weeks plus pyrotinib maleate 320 mg orally once daily for 6 cycles
89293109|NCT05426486|Active Comparator|trastuzumab + pertuzumab + docetaxel + carboplatin|Trastuzumab (8 mg/kg first dose, followed 6 mg/kg) puls pertuzumab (840 mg first dose, followed 420 mg) plus docetaxel (75 mg/m3) plus carboplatin (AUC6) IV every 3 weeks for 6 cycles
89293110|NCT05412134|Experimental|Active inspiratory muscle rehabilitation (IMR) group|"Each participant will be provided a PrO2™ device and trained on its use and its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed at Visit 1 and Visit 2 to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide a precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP."
89293111|NCT05412134|Active Comparator|SHAM|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
89293112|NCT05404971|Experimental|Joint integrity exercises|"Tactile stimulation with the various textures will be applied to the patients with three strokes followed by 3 sec rest period.~Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set."
89293113|NCT05404971|Active Comparator|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
89293114|NCT05404646|Experimental|Group A|Thoracic mobility exercises
89293115|NCT05404646|Experimental|Group B|Thoracic stretching exercises
89293116|NCT05399290|Active Comparator|100 mg standard dose doxycycline BID|Oral, 12 weeks
89293117|NCT05399290|Experimental|20 mg sub-antimicrobial dose doxycycline BID|Oral, 12 weeks
89293118|NCT05395078|Experimental|Group A|Thoracic extension exercises
89293119|NCT05395078|Experimental|Group B|Thoracic Stabilization exercises
89293120|NCT05393960|Experimental|Mobilization|Lumbosacral manual therapy mobilization
89293121|NCT05393960|Other|Stretching program|home based self strechings program
89293122|NCT05393323|Experimental|Distraction technique|conventional physical therapy with distraction technique
89293123|NCT05393323|Experimental|Traction technique|conventional physical therapy with traction technique
89293124|NCT05392517|Experimental|Group A|self-mobilization technique
89293125|NCT05392517|Other|Group B|: conventional treatment
89293126|NCT05392036|Experimental|Group A|shockwave therapy
89293127|NCT05392036|Other|Group B|therapeutic ultrasound
89293128|NCT05392023|Experimental|Group A|Scapular Stabilization exercise program
89293129|NCT05392023|Other|Group B|Relaxation Exercises of cervico- scapular region
89531556|NCT06060366||PE for CTEPH|CTEPH patients who were eligible for operation
89531557|NCT06060366||Medical treatment CTEPH|CTEPH patients who were not eligible for surgery of any reason and decided to follow up with medical treatment
89293130|NCT05379231|Experimental|Speech Intelligibility with CROS device|"The focus of this study is on Speech Intelligibility (SI), evaluated by the US Matrix Test, which measures a speech recognition threshold (SRT) in dB SNR (signal to noise ratio).~Therefore each participant will perform the tests with the experimental rechargeable CROS transmitter (CROS) in different interventions, like comparison to monaural fitting and unaided condition.~All participants will perform the same tests. The order of the intervention in the speech test is randomized, but will be performed in the same visit by each participant."
89293131|NCT05363488||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
89293132|NCT05355181|Experimental|Group A: scar mobilization and core stabilization exercises group|Group A will perform exercises for 3 weeks. Participants will perform core stabilization exercises as well as scar mobility exercises. All exercises will be performed in 3 sessions per week for a period of 3 weeks.
89293133|NCT05355181|Active Comparator|Group B: scar mobilization techniques group|"Group B will perform scar mobilization exercises for 3 weeks along with baseline treatment.~All exercises will be performed in 3 sessions per week for a period of 3 weeks."
89293134|NCT05352828|Experimental|Nivolumab and CD30.CAR-T|Study treatment will include 4 cycles of nivolumab and a single CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy of Fludarabine and Bendamustine).
89293135|NCT05347251|Experimental|Group A|Cervicothoracic mobility program
89293136|NCT05347251|Other|Group B|Conventional Treatment
89293137|NCT05318248|Experimental|Clonidin|pill 0,15 mg clonidin
89293138|NCT05318248|Placebo Comparator|Placebo|placebo pill
89293139|NCT05306249|Experimental|CBD LGP 50 group|Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
89293140|NCT05306249|Placebo Comparator|Control group|Patients will receive the MCT oil placebo without CBD until the end of week 12.
89293141|NCT05298397|Experimental|Intervention - EAT|This study has one arm (it is an open trial). All participants will receive the intervention (EAT-PTSD adapted for youth).
89293142|NCT05260034|Active Comparator|Otago Group|The control group will receive balance exercises adapted from the evidenced-based Otago Exercise program. Briefly, all eight sessions (~30 min) will involve balance exercises and strength exercises using ankle weights, and will progressively increase as performance improves by increasing resistance or the difficulty of the balance exercises (e.g., reducing base of support).
89293143|NCT05260034|Experimental|FAST Group|Participants randomized to the intervention arm will undergo the FAST program, a progressive safe-falling training based on the tuck and roll strategy. As part of the FAST program, participants will train 30 minutes twice a week for a period of four weeks under the supervision of a trained researcher. Participants will wear protective gear (knee, hip, head) and they will complete a 10-minute stretching exercise routine to minimize the risk of injury.
89293144|NCT05240209|Experimental|Education (Intervention) Group|In the pretest phase of the research;Education group, those who signed the Informed Voluntary Consent Form and agreed to participate in the research will fill out the questionnaire.Data collection will take approximately 20-25 minutes.Afterwards,the researcher will give training to the training group about skin cancer,skin self-examination and sun protection behaviors.The tutorials are planned as a PowerPoint demonstration.The duration of the trainings is planned to take approximately 40minutes.The content of the training was prepared in line with the literature review.As a method;It will be in the form of narration,question and answer,brainstorming.Materials used in education;Colorfulbrochures on the subject will be given to reinforce the slide show and post-training information.A follow-up period of four months will be expected after the training given.At the end of the follow-up period,the training group will have to fill out the post-test questionnaires during the post-test phase.
89293145|NCT05240209|No Intervention|Control Group|Control Group: In the pre-test phase of the study; control group parents, those who signed the Informed Consent Form and agreed to participate in the study will fill out the questionnaire. Data collection will take approximately 20-25 minutes. During the follow-up period (120 days), no intervention will be made on the control group. At the end of the follow-up period (120 days), the control group will have to fill out the post-test questionnaires during the post-test phase. Participants will be reminded of the purpose of the research. Approval of the Informed Consent Form will be received. Completing the post-test questionnaires will take approximately 20-25 minutes. A brochure training material will be distributed to the parents of the control group, in line with the principle of equality, immediately after the completion of the post-tests.
89293146|NCT05204862|Experimental|TU2218 Phase 1a|Escalating doses of TU2218 orally administered daily for two weeks followed by one week of rest for up to 21-day cycles
89293147|NCT05204862|Experimental|TU2218 Food Effect|TU2218 orally administered at a one dose level below MTD under fasting condition on -Day 2, followed by the same dose orally administered with meals on -Day 1 and then continued under fasted condition for two weeks followed by one week of rest for up to 21-day cycles
89293148|NCT05204862|Experimental|TU2218 + Anti-PD-1 antibody Phase 1b|Escalating doses of TU2218 in combination with anti-PD-1 antibody up to 21-day cycles
89293149|NCT05204862|Experimental|TU2218 Phase 2a|TU2218 at a RP2D orally administered daily for two weeks followed by on week of rest for up to 21-day cycles
89293150|NCT05204862|Experimental|TU2218 + Anti-PD-1 antibody Phase 2b|TU2218 at a RP2DC in combination with anti-PD-1 antibody up to 21-day cycles
89293151|NCT05203380||Part A|Assessed in a single visit and no study-related treatment will be given.
89293152|NCT05203380||Part B|Patients in Part A may also enroll in Part B provided they meet the eligibility criteria.
89293153|NCT05193851|Experimental|healthy subjects|12 healthy Chinese adult subjects, both male and female, are treated with ricolinostat
89293154|NCT05193318|Experimental|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
89293155|NCT05186493|Experimental|Locally advanced pelvic cancer that requires total pelvic exenteration|Adult patients (>18 years) with locally advanced pelvic cancer that require pelvic exenteration considered eligible for robot- assisted minimally invasive surgery by the respective multidisciplinary teams
89293156|NCT05183295|Experimental|Experimental: Nonessential Amino Acid Restriction (NEAAR) Medical Food|All subjects will receive NEAAR medical food
89293157|NCT05171868|Experimental|EMDR receiving group|EMDR is a psychotherapeutic approach that emphasizes the role of the brain's information processing system in perfecting the psychological consequences of distressing events. EMDR is an eight-phase treatment protocol, including procedure that focuses on the memories underlying current problems and those that must be specifically addressed to bring the client to a robust state of psychological health. One of its distinguishing aspects is its use of bilateral physical stimulation, such as side-to-side eye movements, alternating hand taps, or alternating auditory tones while the person undergoing treatment is mentally focusing on aspects of various life experiences.
89293158|NCT05171868|No Intervention|Waiting list Control Group|The control group will receive their routine care as usual. Once the trial is completed they will be invited for EMDR sessions
89293159|NCT05163041|Experimental|BT7480 monotherapy dose escalation|Participants will receive increasing doses of BT7480. It is expected that approximately 80 patients will participate in this dose escalation arm.
89293160|NCT05163041|Experimental|BT7480 and nivolumab dose escalation|Participants will receive increasing doses of BT7480 and standard dose of nivolumab. It is expected that approximately 12 patients will participate in this dose escalation arm.
89293161|NCT05163041|Experimental|BT7480 monotherapy dose expansion|Participants will receive a selected dose of BT7480. It is expected that approximately 45 patients will participate in this dose expansion arm in Phase 2.
89293162|NCT05163041|Experimental|BT7480 and nivolumab dose expansion|Participants will receive a selected dose of BT7480 and standard dose of nivolumab. It is expected that approximately 45 patients will participate in this dose expansion arm in Phase 2.
89293163|NCT05163041|Experimental|BT7480 monotherapy in patients with renal insufficiency|Participants will receive a selected dose of BT7480. It is expected that approximately 12 patients will participate in this dose confirmation arm.
89293164|NCT05133947||CIPN patient|Patient with CIPN symptom
89293165|NCT05133947||Healthy subject|Healthy subject
89293166|NCT05122559|Active Comparator|N-acetyl cysteine|N-acetyl cysteine (NAC) 1200mg t.i.d.
89293167|NCT05122559|Placebo Comparator|Placebo|Placebo 1200mg t.i.d.
89293168|NCT05113407||Coronary angioplasty performed using the Shockwave Medical C2 Coronary Lithotripsy System|
89293169|NCT05112679|Active Comparator|Proprio Foot|microprocessor-controlled prosthesis that regulates the angle of ankle dorsiflexion during the swing phase
89293170|NCT05112679|Active Comparator|Empower Ankle|a powered prosthesis that provides active propulsion in late stance to mimic the positive work performed by the ankle plantar-flexors in push-off. The Empower has been shown to improve affected leg kinematics (increased ankle range of motion and reduced knee flexion) on smooth flat ground, ramp ascent, and gravel
89293171|NCT05112666||Cancer patients with VTE|Adults diagnosed with active (primary or metastatic) cancer experiencing a hospitalization or emergency department admission or a primary care visit with an incident venous thromboembolism (VTE), being administered rivaroxaban or other direct-acting oral anticoagulants (DOACs) or a low molecular weight heparin (LMWH) will be included.
89293172|NCT05097027|Experimental|Blood flow restriction recovery (Experimental I)|Active recovery program with blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
89293173|NCT05097027|Experimental|Non-Blood flow restriction recovery (Experimental II)|Active recovery program without blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
89293174|NCT05092659|Other|patient interviews|Patient enrolled in a bariatric surgical pathway scheduled for visceral surgery.
89293175|NCT05091879|No Intervention|Standard of Care|A multigene pharmacogenomics test will not be ordered for patients in this study arm, as is the standard of care.
89293176|NCT05091879|Experimental|Pharmacogenomics Testing|Patients in the experimental arm will be ordered a multigene pharmacogenomics test. This DNA test requires a blood draw, with the results expected to be reported in the medical record approximately 7 to 14 calendar days after the blood draw. These results will be made available to Geisinger healthcare professionals that have a treatment relationship with study participants.
89293177|NCT05080764|Experimental|1h incubation BF-200 ALA|Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
89293178|NCT05080764|Experimental|3h incubation BF-200 ALA|Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
89293179|NCT05080764|Placebo Comparator|1h incubation vehicle|Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
89293180|NCT05080764|Placebo Comparator|3h incubation vehicle|Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
89293181|NCT05066581|No Intervention|Philips band|It is a medical device that collects, among other things, movement data by means of an accelerometer, from which it accelerometer, from which it estimates the total time of sleep (TTS) and wakefulness, and waking time, also offering the efficiency of the same (time asleep in relation to time in bed). time in bed). In addition, it collects data not related to sleep, such as energy expenditure (in kilocalories), energy expenditure (in kilocalories) (in kilocalories), heart rate, and daily activity (in steps), among others.
88806160|NCT02097992|Experimental|SD roflumilast and MD placebo then MD roflumilast.|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
89293182|NCT05066581|Active Comparator|Philips Band + Live chat|In the Intervention group, in addition to having the philips band, the subjects will interact through the live chat system that they will have to download to their mobile phones. This live chat offers the possibility to consult in real time, thus initiating a process of relationship between researcher/subject.
89293183|NCT05065151|Experimental|Stimulation|Patients will be getting standard clinically acceptable stimulation within already safety validated stimulation ranges through their Medtronic Percept PC device.
89293184|NCT05065151|Experimental|No Stimulation|Patients will have stimulation turned off through their Medtronic Percept PC device.
89293185|NCT05061537|Experimental|Monotherapy dose escalation (Part 1A)|Participants will receive PF-07263689 once a week for 4 doses
89293186|NCT05061537|Experimental|Combination dose escalation (Part 1B)|Participants will receive PF-07263689 intravenous (IV) once week for 4 doses in combination with sasanlimab subcutaneous (SC) once every 4 weeks
89293187|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm A|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
89293188|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm B|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
89293189|NCT05061537|Experimental|Dose expansion (Part 2) - Tumor specific Arm C|Participants will receive PF-07263689 IV once week for 4 doses in combination with sasanlimab SC once every 4 weeks
89293190|NCT05054725|Experimental|RMC-4630 and sotorasib, Safety Run-in|"Safety Run-In:~RMC-4630 and sotorasib"
89293191|NCT05054725|Experimental|RMC-4630 and sotorasib, Expansion|"Dose Expansion:~RMC-4630 and sotorasib"
89293192|NCT05046522|Experimental|Palmitoylethanolamide sold as Levagen +|Palmitoylethanolamide in capsule form - taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)
89293193|NCT05046522|Placebo Comparator|A comparator placebo capsule - Maltodextrin and microcrystalline cellulose mix|A comparator capsule taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)
89293194|NCT05046132|Experimental|Group 1: Setmelanotide 7 mg|SC setmelanotide 7 mg; oral placebo on Days 10 and 16
89293195|NCT05046132|Active Comparator|Group 2: Active placebo (Day 10)|SC placebo; oral moxifloxacin (positive control) on Day 10 and oral placebo on Day 16
89293196|NCT05046132|Active Comparator|Group 3: Active placebo (Day 16)|SC placebo; oral placebo on Day 10 and oral moxifloxacin on Day 16
89293197|NCT05030610|Experimental|Intervention Group|Participants, along with a support person, will complete 12 weekly sessions of the BeatIt-ASD intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.
89293198|NCT05026034||Training Cohort|Inpatients with HF requiring >24 hours IV diuretics
89293199|NCT05026034||Cohort A|Patients undergoing serial, clinically indicated RHC. To investigate if measures derived by the CPM wearable device correlate with invasive measures of cardiopulmonary haemodynamics (PCWP).
89293200|NCT05026034||Cohort B|Patients receiving haemodialysis. To investigate if changes in measures derived by the CPM wearable device correlate with B-lines on LUS and changes in B-lines before and after haemodialysis and with volume of fluid removed during haemodialysis
89293201|NCT05026034||Cohort C|Patients receiving inpatient intravenous diuretic treatment for heart failure. To investigate if changes in measures derived by the CPM wearable device system correlate with B-lines on lung ultrasound and weight before and after treatment for HF.
89293202|NCT04997954|Experimental|MediCabilis CBD Oil|MediCabilis CBD Oil to be taken no more than 7ml/day orally based from participants' individual 14 day titration period completed at the beginning of the trial. The frequency of the drug intake can range between once and three times a day depending on the outcome of the 14 day titration period. Titration period allows participants to gradually increase study drug intake in order to find appropriate dose for participants without or with minimal undesired side effects. The treatment will last no more than 6 months.
89293203|NCT04988893||Parturients with Normal Weight|Parturients undergoing elective caesarean delivery with a BMI <30 (control group)
89293204|NCT04988893||Parturients with Morbid Obesity|Parturients undergoing elective caesarean delivery with a BMI >40 (Study Group)
89293205|NCT04979858|No Intervention|Control Group|The subjects will choose their own mask and masking practices.
89293206|NCT04979858|Experimental|Treatment Group|The treatment group will receive and use the focal mask.
89293207|NCT04969718|Experimental|LEADS Plus educational posters|A total of six group sessions with students using presentations and videos.
89293208|NCT04969718|Experimental|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers (teachers). This includes both presentations and videos.
89293209|NCT04969718|Experimental|Screening by Professionals programme Plus educational posters|This is an indicated or selective intervention by health professionals who will review assessments (done using structured questionnaires) and refer students where necessary.
89293210|NCT04969718|Active Comparator|Educational poster|The control group will be exposed to the six educational posters.
89293211|NCT04969718|Experimental|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents). This includes both presentations and videos.
89293212|NCT04953728|Experimental|Subjects with IBS-C|All participants will receive all treatment options. Each participant will receive all of the following treatments; 100 Hz ST36, 100 Hz PC6, 25 Hz ST36, 25 Hz PC6, as well as the sham comparator. Each administration will be performed on different dates, between 1 and 3 weeks apart.
89293213|NCT04915482|Experimental|Combined use of TPO-RAs with low-dose anti-CD20 antibody|The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
89531558|NCT06055712|Active Comparator|One dose of IV cefazolin|Patients in group A will receive one dose of IV cefazolin and will have no further antibiotic administration.
89531559|NCT06055712|Active Comparator|24 hours IV cefazolin|Patients in group B will receive a dose of IV cefazolin every 8 hours for 24 hours (a total of 3 doses).
89531560|NCT06055712|Active Comparator|24 hours IV cefazolin plus 5 days oral cephalexin|Patients in group C will receive a dose of IV cefazolin every 8 hours for 24 hours (a total of 3 doses). Additionally, they will be instructed to take 5 days of oral cephalexin.
89531561|NCT06055478|Experimental|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using ropivacaine|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using each 0.75% ropivacaine 10mL when arthroscopic rotator cuff repair Patient Controlled Analgesia (PCA) at a low fixed dose: fentanyl-loading dose: 0.4㎍/kg, continuous dose: 0.2㎍/kg/h, nefopam-loading dose: 0.04mg/kg, continuous dose: 0.02mg/kg/h
89293214|NCT04915482|Active Comparator|The best available therapy other than combined use of TPO-RAs with low-dose anti-CD20 antibody|The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
89293215|NCT04897971||Spine implant associated infection cohort|Adult patients undergoing revision spine surgeries with suspected infection of previous instrumentation.
89293216|NCT04891263|Experimental|Suture-Septoplasty|Participants will receive suture-septoplasty technique, and will be followed for three months postoperatively.
89293217|NCT04857827|Experimental|QLS-101 ophthalmic solution 1.0%|Ophthalmic solution once daily (QD) dosing in both eyes (OU) for 14 days followed by 14 days of twice daily (BID) dosing.
89293218|NCT04857827|Active Comparator|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
89293219|NCT04857827|Experimental|QLS-101 ophthalmic solution 2.0%|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
89293220|NCT04841902|Experimental|Life Style Intervention Manual (Supervised)|Supervised Exercises with Life Style Intervention Manual (Dietary & Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of alternating light to moderate intensity aerobic exercises including warm up and rest interval
89293221|NCT04841902|Experimental|Life Style Intervention Manual (Home Based)|Home Based- Life Style Intervention Manual (Exercise, Dietary & Educational Component for 16 weeks. Subject will be asked to maintain a regular exercise and dietary diary to ensure adherence to the program
89293222|NCT04841902|Placebo Comparator|Control|Age matched Control Group followed for 16 weeks with General Advise to stay healthy and active
89293223|NCT04799197|Experimental|Kicking it with the Gurlz|This multicomponent intervention includes a violence and gender affirmation screening tool, a peer delivered adaptation of the group-level Seeking Safety Program, and individual-level peer navigation sessions.
89293224|NCT04796584||MS subjects who are being treated with ocrelizumab|Ocrelizumab's immunomodulating mechanisms of action is B-cell lytic. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
89293225|NCT04796584||MS subjects who are being treated with fingolimod|Fingolimod's immunomodulating mechanisms of action is to prevent mobilization of B and T cells from peripheral lymphoid organs. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
89293226|NCT04796584||MS subjects who are being treated with natalizumab|Natalizumab's immunomodulating mechanisms of action is to block transmigration of monocytes, and lymphocytes into the central nervous system. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
89293227|NCT04796584||MS subjects who are being treated with dimethyl fumarate/diroximel fumarate|Dimethyl Fumarate's immunomodulating mechanisms of action is to reduce inflammation-induced oxidative stress. Each consenting subject will provide approximately 30 mL of whole blood via venipuncture before and 45, 90 and 180 days after the first vaccine injection and 28-42 days after the booster vaccination (if applicable).
89293228|NCT04794621|No Intervention|Standard of Care Only|This will be group 1
89293229|NCT04794621|Experimental|SOC and PED-10 +Procellera|In group 2, in addition to SoC, the patients will apply the EDThi dressing (PED-10) on the wound(s) for the first 3 weeks following enrollment followed by Procellera® or EDTlo for additional 3 weeks. The use of dressings will be discontinued anytime if complete wound closure is achieved.
89293230|NCT04759976|Experimental|Robotic motor training|Participants will perform motor tasks (i.e. movements) with upper limb robotic devices applying different strategies (e.g. supporting or challenging the subject, or being fully compliant).
89293231|NCT04754126|Experimental|Intervention Group|Educators and students complete a baseline survey. Educators will implement 6 lessons, each 45 minutes, in the classroom. Educators are free to choose the time between lessons, so some can implement all in one week, others can choose to implement once per week. Educators are given a maximum of 6 weeks to implement the curriculum. Educators and students complete a post-program survey. Students complete a 6- and 12-month follow-up survey.
89293232|NCT04754126|No Intervention|Control Group|This group will only complete online surveys that match the time when intervention group is complete the surveys. There is a baseline survey and then a post-survey 6 weeks later for both educators and students. Additionally, students will complete a 6- and 12-month follow-up survey.
89293233|NCT04752592|Experimental|SeroSelectTB|The participants in this arm, after providing informed concent, will be tested using the SeroSelectTB rapid assay.
89293234|NCT04752592|No Intervention|Standard of Care|The participants in this arm, after providing informed consent, will receive the established standard of care.
89293235|NCT04752501|Experimental|Psychologically Informed Video Series|"This 3 part educational video series will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it); Simple methods of cognitive restructuring; and how to respond to activity-related pain."
89293236|NCT04752501|Active Comparator|Biomedical Education Video Series|Participants in the control (biomedical education) group will watch a series videos on the iPad equal in length to the psychologically informed video series. The control video will discuss basic anatomy of the knee and provide no psychosocial education or positive reinforcement about their condition, basic strengthening exercises and proper lower extremity mechanics
89293237|NCT04725149|Placebo Comparator|0 ml tart cherry concentrate|Still cherry-flavored beverage, similar in appearance, taste, aroma and calories to the 30 ml and 60 ml tart cherry concentrate beverages
89293238|NCT04725149|Experimental|30 ml tart cherry concentrate|"Low dose tart cherry concentrate beverage"
89293239|NCT04725149|Experimental|60 ml tart cherry concentrate|"High dose tart cherry concentrate beverage"
89293240|NCT04716075|Experimental|Acalabrutinib 2x100mg oral capsule +alloSCT|Acalabrutinib administered 2x100mg p.o. daily for 3-6 months before alloSCT +acalabrutinib administered 2x100mg p.o. daily for 9 months after alloSCT
89293241|NCT04701957|Experimental|Modified Atkins 2 :1 Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
89293242|NCT04701957|No Intervention|Control diet|
89293243|NCT04694924||Localized and locally advanced prostate cancer|Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.
89293244|NCT04691700|Active Comparator|Goreisan|Goreisan (TJ-17) will be added at a dose of 7.5g per day to standard treatment
89293245|NCT04691700|Active Comparator|No Goreisan|Standard treatment without Goreisan (TJ-17)
89293246|NCT04688931|Experimental|UGN-102 ± TURBT|6 weekly intravesical instillations of UGN-102 (75 mg mitomycin) starting on Day 1 + TURBT for patients who have a NCR at the 3-month Visit (3 months after the start of treatment with UGN-102).
89293247|NCT04688931|Active Comparator|TURBT Alone|TURBT on Day 1 + repeat TURBT for patients who have a NCR at the 3-month Visit (3 months after the initial TURBT).
89293248|NCT04630769|Experimental|Monotherapy: IP FT516 at 9 x 10^7 cells/dose on Day 1, 8, and 15|
89293249|NCT04630769|Experimental|Monotherapy: IP FT516 at 3 x 10^8 cells/dose on Day 1, 8, and 15|
89293250|NCT04630769|Experimental|Monotherapy: IP FT516 at 9 x 10^8 cells/dose on Day 1, 8, and 15|
89293251|NCT04630769|Experimental|Safe dose (MTD-1) from 1st 3 levels + IV enoblituzumab on Day -6|
89293252|NCT04630769|Experimental|Highest dose (MTD) from 1st 3 levels + IV enoblituzumab on Day -6|
89293253|NCT04610138|Experimental|Active treatment with 60 ml low-dose ZnAg|(Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours
89293254|NCT04610138|Experimental|Active treatment with 60 ml high-dose ZnAg|(Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours;
89293255|NCT04610138|Placebo Comparator|60 ml matching placebo|60 ml matching placebo, po q12 hours
89293256|NCT04581434|Experimental|Trauma-Focused Therapy|Patients randomized to Trauma Focused Therapy will receive either Prolonged Exposure (PE) or Cognitive Processing Therapy (CPT). According to standard VA practice, assignment will be determined according to which trauma-focused therapy the assigned provider is verified to provide; if the assigned therapist is verified in both PE and CPT, the provider will decide which treatment to deliver. PE and CPT are both recommended as frontline treatments by all published PTSD guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted.
89293257|NCT04581434|Experimental|Non-Trauma-Focused Therapy|"Those randomized to non-trauma-focused therapy will receive present centered therapy (PCT). Originally designed as a strong comparator for psychotherapy research that included the components of good therapy, PCT is now a bona-fide PTSD treatment suggested at the second tier in multiple clinical practice guidelines. The standard treatment length will be 12 weekly sessions; however, patients and providers can collaboratively agree to early completion or extension as warranted."
89293258|NCT04572659|Experimental|Group intervention|
88819283|NCT01546454|Experimental|Steroid effects|Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.
89293259|NCT04572659|Experimental|Couple intervention|
89293260|NCT04572659|No Intervention|No intervention|
89293261|NCT04571021|Experimental|I-DEPT|Novel triage. The triage nurse can adjust the triage category one level of urgency down or one or two levels up.
89293262|NCT04571021|Active Comparator|DEPT|Existing triage algorithm
89293263|NCT04543188|Experimental|PF-07284890 (Part A monotherapy)|Monotherapy dose escalation of PF-07284890
89293264|NCT04543188|Experimental|PF-07284890+binimetinib (Part A combo-therapy)|Combination dose escalation of PF-07284890 + binimetinib
89293265|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 1)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with asymptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
89293266|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 2)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with symptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
89293267|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 3)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with asymptomatic brain involvement, and prior BRAF inhibitor utilization
89293268|NCT04543188|Experimental|Expansion Phase (Part B, Cohort 4)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma, with symptomatic brain involvement, and prior BRAF inhibitor utilization
89293269|NCT04543188|Experimental|Expansion Phase (Part B Cohort 5)|PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors
89293270|NCT04543188|Experimental|Expansion Phase Drug-Drug Interaction Substudy (Part B Optional Cohort 6)|PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor
89293271|NCT04543188|Experimental|Expansion Phase (Part B Optional Cohort 7)|PF-07284890 (at the recommended dose for expansion when administered with food) plus binimetinib in participants with BRAF V600 solid tumor
89293272|NCT04534712||PROGRESSION|Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage
89293273|NCT04534712||NON PROGRESSION|Cohort B with those who improved by two points on the ordinal scale without any further progression
89293274|NCT04526067|Active Comparator|Cognitive Adaptation Training (CAT)|A home delivered adherence intervention used by managed care used to improve outcomes across multiple conditions.
89293275|NCT04526067|Active Comparator|Remote Cognitive Adaptation Training (R-CAT)|A primarily remotely delivered workable adherence intervention used by managed care used to improve outcomes across multiple conditions.
89293276|NCT04525027||survivors|
89293277|NCT04525027||non survivors|
89293278|NCT04506463|Experimental|Arm A|MM-II 1 ml
89293279|NCT04506463|Experimental|Arm B|MM-II 3 ml
89293280|NCT04506463|Experimental|Arm C|MM-II 6 ml
89293281|NCT04506463|Placebo Comparator|Arm 4|Placebo 1ml
89293282|NCT04506463|Placebo Comparator|Arm 5|Placebo 3ml
89293283|NCT04506463|Placebo Comparator|Arm 6|Placebo 6ml
89293284|NCT04477512|Experimental|Level 1: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 20 mg. Participants can continue to receive treatment for up to 2 years.
89293285|NCT04477512|Experimental|Level 2: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be 40 mg. Participants can continue to receive treatment for up to 2 years.
89293286|NCT04477512|Experimental|Expansion: Cabozantinib+Abiraterone acetate +Nivolumab|-Abiraterone acetate is an oral medication given at a dose of 1000 mg daily. Prednisone is an oral medication given at a dose of 5 mg daily. Nivolumab is given intravenously over 30 minutes on Day 1 of each 28-day cycle at a dose of 480 mg. Cabozantinib is an oral drug given daily; dosing will be dependent on recommended dose found in first part of study. Participants can continue to receive treatment for up to 2 years.
89293287|NCT04468841|Experimental|Prospective Group|Study participants with untreated, newly diagnosed follicular lymphoma will have blood collected for cfDNA testing before, during, and after their first-line treatment or observation period
89293288|NCT04468841|Experimental|Retrospective Group|Study participants who have received first-line treatment for follicular lymphoma and are in complete remission will have blood collected for cfDNA testing. In the retrospective cohort, MSKCC patients with CRs lasting ≥10 years after induction therapy will be studied. Initial tumor tissue (if available) will be collected to examine the status of s cfDNA in patients with long-term remissions. Blood samples will be collected once, if the patient has interesting results (e.g. positive cfDNA sample despite CR on imaging, etc.) then additional blood samples may be taken during follow up visits.
89293289|NCT04429061|No Intervention|SOC Arm|Standard of care (SOC): the sexual reproductive curriculum which is implemented by the schools as part of mandatory SRH education.
89293290|NCT04429061|Active Comparator|Enhanced Arm|The SKILLZ-Girl Curriculum, plus the graduation event (including HIVST + access to family planning) and home based delivery of commodities with subsequent encouragement to be involved with SKILLZ-Clubs at their school
89293291|NCT04407325|Experimental|AeoNose|the AeoNose will be compared with digital ChestXray and the conventional methods of establishing TB diagnosis
89293292|NCT04404465||Control Group|Participants undergoing electrophysiologic (EP) study or ablation for supraventricular tachycardia (SVT) with no history of AF and does not meet criteria of At Risk Group or AF Group
89293293|NCT04404465||At Risk Group|"Participants with no prior diagnosis of AF and have:~two or more of the following criteria:~Age >65 years of age~A diagnosis of hypertension~A diagnosis of diabetes~A diagnosis of sleep apnea~A body mass index (BMI) ≥30~Stable heart failure (HF) with preserved or reduced ejection fraction (New York Heart Association Class I, II or III)~Chronic kidney disease (CKD) not requiring dialysis~AND/ OR~More than 5% premature atrial complex (PAC) burden on ambulatory ECG monitoring (e.g. holter, ZioPatch, Lifewatch, etc.)"
89293294|NCT04404465||AF Group|Participants who have a history of non-valvular AF or Atrial Flutter (AFL) documented on ECG or ambulatory monitoring within 1 year of enrollment
89293295|NCT04362306|Experimental|Planned Intervention|Patients will be scheduled for CT (computed tomography ) simulation for radiation treatment planning. Prior to simulation, patients will be asked to complete anxiety and patient satisfaction questionnaires. Following completion of the questionnaires, each patient will receive the first intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic. The patient will then be asked to complete a second set of anxiety and patient satisfaction questionnaires and will then undergo the planned simulation.
89293296|NCT04362306|Active Comparator|No Planned Intervention|After patients are enrolled into this study, they will be scheduled for CT simulation for radiation treatment planning. Prior to simulation, patients will receive anxiety and patient satisfaction questionnaires to complete
89293297|NCT04349124|Other|Treatment Group|The treatment group will be provided with month supply of 30mg tablets of nifedipine extended release prior to discharge from the delivery admission. Dose increases in clinic will be at the discretion of providers, however a treatment algorithm will be provided for guidance.Treatment group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
89531698|NCT05688202|Active Comparator|Left face|The face's left side is treated with simultaneous combination therapy, in which fractional CO2 laser is performed immediately following subcision
89531699|NCT05688202|Placebo Comparator|Right face|The face's right side receives sequential combination therapy with fractional CO2 laser conducted two weeks after subcision.
88821240|NCT04805333|Experimental|Dose 5 - 1800mg Artemisia annua|Participants in this group will consume 4 cups of decaffeinated coffee (1800 mg Artemisia annua).
89293298|NCT04349124|No Intervention|Control Group|The control group will not receive any medications at discharge. Providers will be instructed to only prescribe new blood pressure medication at subsequent postpartum visits if the blood pressure is in the severe range (>/=160/110). The control group will be given a home blood pressure cuff prior to discharge with instructions for use. They will also be scheduled for a 1 week blood pressure check and 4 week postpartum clinic appointment which standard for these patients outside of this proposal.
89293299|NCT04348292|Experimental|Treatment (sirolimus, durvalumab)|Patients receive sirolimus PO QD on days 1-21 in the absence of disease progression or unacceptable toxicity. Starting on day 22, patients receive durvalumab IV over 1 hour. Treatment with durvalumab repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Within a 2-3 week period after the second dose of durvalumab, but not earlier than two weeks after the administration of durvalumab, patients undergo standard of care surgery.
89293300|NCT04341662|Experimental|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination & Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case."
89293301|NCT04341662|Active Comparator|Usual care|Usual care with dissemination of the current guidelines
89293302|NCT04324567||APR-open|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparotomy.
89293303|NCT04324567||APR-robot|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) with laparoscopic robot assisted technique.
89293304|NCT04313192|Experimental|Pulse rate 2Hz (hertz)|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
89293305|NCT04313192|Experimental|Pulse rate 10Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
89293306|NCT04313192|Experimental|Pulse rate 150Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
89293307|NCT04303494||Experimental1|preterm infants will be routinely immunised during primary hospitalisation
89293308|NCT04303494||Experimental2|preterm infants discharged and readmitted for immunisation during the 3-year period
89293309|NCT04303494||Control|healthy control infants
89293310|NCT04292600||BRH|Cohort recruited at Brandon Regional Hospital by Bay Area Consulting Telemedicine
89293311|NCT04276610|No Intervention|Healthy Control Participants|Older adults (65+) without impairments in vision or hearing. This groups will simply be followed for the study period (1 year), measured at 6 months intervals, to provide control comparison data for all outcome measures
89293312|NCT04276610|Experimental|Low Vision Participants|Older adults (65+) with impairments in vision but without hearing impairment. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
89293313|NCT04276610|Experimental|Dual Sensory Impairment Participants|Older adults (65+) with impairments in both vision hearing hearing. This groups will receive regular standard of low vision rehabilitation care and will be followed for the study period (1 year), measured at 6 months intervals.
89293314|NCT04257253|Experimental|Targeted exercise program|Targeted motor control and isolated lumbar extensor strengthening exercises. Supervised 12-week program, 2 times a week.
89293315|NCT04257253|Active Comparator|General exercise program|General exercise program including upper body and lower body strengthening and flexibility exercises. Supervised 12-week program, 2 times a week.
89293316|NCT04208243|Experimental|Oncology Patient|Any Oncology patient in the CCBD who has not previously received more than two sessions of CAT in the outpatient unit and who will be receiving approximately weekly infusions of at least one hour in the infusion center will be identified by a research assistant.
89293317|NCT04206449|Experimental|Infrared thermography system|Therapeutic decision taken with infrared thermography system, integrated in an expert diagnostic algorithm (TIS), to determine the sleep stages and Apnea-Hypopnea Index (AHI).
89293318|NCT04206449|Active Comparator|Standard Polysomnography (PSG)|Therapeutic decision taken with Standard Polysomnography (PSG), to determine the sleep stages and Apnea-Hypopnea Index (AHI)
89293319|NCT04192214|Active Comparator|BC 007|The treatment arm will comprise 20 randomly allocated β1-AAb positive dilative cardiomyopathy (DCM) patients. Participants will receive a continuous 75 minute infusion of 1350 mg BC 007 at day 1. The β1-AAb status will be monitored 10 days after treatment and every month. Treatment is repeated once up to month 11 if the participant's β1-AAbs were not neutralized after 1st dosing on day 1 or reoccur.
88806161|NCT02097992|Experimental|SD roflumilast and MD roflumilast then MD placebo|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily
88806162|NCT02098304|Other|Sound and Unsound Molars|Imaging of unrestored sound molars (ICDAS 0), and third Molars (ICDAS 1,2 or 3) with the Calcivis Caries Activity Imaging System
89293320|NCT04192214|No Intervention|Control|The control arm will comprise 10 randomly allocated β1-AAb positive DCM patients. Participants will receive standard therapy but no intervention. The β1- AAb status will be monitored every month.
89531700|NCT05686785||Chronic viral hepatitis|
88806163|NCT01392625|Active Comparator|Autologous hMSCs|Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
88806164|NCT01392625|Active Comparator|Allogeneic hMSCs|Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
89531701|NCT05670951|Active Comparator|ELGN-2112|
89531702|NCT05670951|Placebo Comparator|Placebo|
89293321|NCT04181047|Experimental|Virtual EMDR|Patients will receive 1 to 3 preparation sessions (which will include psychoeducation and preparation exercises before EMDR), followed by up to 12 EMDR sessions, delivered over encrypted Zoom videoconferencing. EMDR is an evidence based trauma therapy. These EMDR sessions will focus on the experiences, urges or negative thoughts associated with their suicidal thoughts. The sessions will be 90 minutes in length and occur twice per week. This group will also have access to usual psychiatric care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
89293322|NCT04181047|Active Comparator|Treatment as usual|This group will also have access to usual care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
89293323|NCT04131179|Experimental|Youth culturally adapted therapy (Y-CMAP)|Youth Culturally adapted manual assisted (Y-CMAP) psychological therapy
89293324|NCT04131179|No Intervention|Treatment as Usual|"TAU will be standard routine care delivered by local medical, psychiatric and primary care services according to clinical judgement. A record will be kept of any treatment received by each participant.~Assessment will be done at 3rd,6th,9th and 12 month after randomization along with TAU"
89293325|NCT04101487|No Intervention|Control|Participants in this arm will receive routine monthly visits along with survey administration and the regular package of health services provided at the facility level and at home by community health assistants
89293326|NCT04101487|Experimental|Cash Transfers|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants and unconditional cash transfers every month
89293327|NCT04101487|Experimental|Cash Transfers and Nutrition Education|Participants in this arm will receive routine monthly visits along with the regular package of health services provided at the facility level and at home by community health assistants, unconditional cash transfers every month, and structured nutrition education provided at household level by community health assistants based on a structured nutrition education handbook.
89293328|NCT04096560|Placebo Comparator|Part A, Cohorts A1a and Cohorts A1b and A2 (Optional), NT1 Participants: Placebo|TAK-994 placebo-matching tablets for 28 days, in participants with NT1.
89293329|NCT04096560|Experimental|Part A, Cohort A1a, NT1 Participants: TAK-994 TBD|TAK-994, tablets, dose level 1 for 28 days, in participants with NT1.
89293330|NCT04096560|Experimental|Part A, Cohort A1b, NT1 Participants: TAK-994|TAK-994 tablets, dose to be determined (TBD) based on safety, tolerability and/or efficacy in Cohort A1a participants with NT1.
89293331|NCT04096560|Experimental|Part A, Cohort A2 (Optional), NT1 Participants: TAK-994 TBD|TAK-994 tablets, TBD based on safety, tolerability and/or efficacy data of Cohort A1, for 28 days.
89293332|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 1|TAK-994 dose 1, tablets, for 56 days in participants with NT1.
89293333|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 2|TAK-994 dose 2, tablets, for 56 days in participants with NT1.
89293334|NCT04096560|Experimental|Part B, NT1 Participants: TAK-994 Dose 3|TAK-994 dose 3, tablets, 56 days in participants with NT1.
89293335|NCT04096560|Placebo Comparator|Part B, NT1 Participants: Placebo|TAK-994 placebo-matching tablets for 56 days in participants with NT1.
89293336|NCT04096560|Placebo Comparator|Part C, NT1 Participants in China: Placebo|TAK-994 placebo-matching tablets for 56 days, in participants with NT1 in China.
89293337|NCT04096560|Experimental|Part C, NT1 Participants in China: TAK-994|TAK-994 tablets, dose TBD based on safety and tolerability in Part B, for 56 days in participants with NT1 in China.
89293338|NCT04096560|Placebo Comparator|Part D, Cohort D1a, D1b and D2, NT2 Participants: Placebo|TAK-994 placebo-matching tablets for 28 days, in participants with NT2.
89293339|NCT04096560|Experimental|Part D, Cohort D1a, NT2 Participants: TAK-994|TAK-994 tablets, dose TBD based on safety, tolerability and/or efficacy in Part A , for 28 days in participants with NT2.
89293340|NCT04096560|Experimental|Part D, Cohort D1b, NT2 Participants: TAK-994|TAK-994 tablets, dose TBD based on safety and/or tolerability efficacy in Cohort D1a participants with NT2.
89293341|NCT04096560|Experimental|Part D, Cohort D2, NT2 Participants (Optional) : TAK-994 TBD|TAK-994 tablets, TBD based on safety, tolerability and/or efficacy data of Cohort D1, for 28 days.
89293342|NCT04054856|Other|Patients with Morbus Parkinson|
89293343|NCT04054856|Other|Healthy Subjects|
89293344|NCT04050501|Active Comparator|non-invasive Vagus Nerve Stimulation|non-invasive Vagus Nerve Stimulation on top of best medical practice
89293345|NCT04050501|No Intervention|Standard Care|Best medical practice alone
89293346|NCT04030598|Placebo Comparator|Part A: Placebo|Participants with hereditary angioedema type I/type II (HAE-1/HAE-2) received placebo subcutaneously (SC) every 4 weeks at Weeks 1, 5, 9, and 13.
89293347|NCT04030598|Experimental|Part A: Donidalorsen 80 mg|Participants with HAE-1/HAE-2 received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.
89293348|NCT04030598|Experimental|Part B: Donidalorsen 80 mg|Participants with hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.
89293349|NCT04028284|Active Comparator|Group 1|In Group 1 (control), the staff anesthesiologist will follow the traditional technique for US-guided thoracic epidural insertion. Briefly, the anesthesiologist will use the US to identify and mark the appropriate spot for placement of the thoracic epidural catheter. The US probe is then placed at rest and the anesthesiologist will proceed with thoracic epidural needle insertion following standard techniques.
89293350|NCT04028284|Active Comparator|Group 2|In Group 2 (intervention), the staff anesthesiologist will use the HoloLens tool to assist with the traditional technique as described above for Group 1. In combination with the US, a hologram image of the trajectory towards the epidural space will be generated, thereby mitigating the need to walk off the lamina. The holographic system will mark the appropriate spot for placement of the thoracic epidural catheter. Then, the needle will be inserted following the holographic trajectory overlaid on the patient's back.
89293351|NCT03994016|Experimental|WiseGuyz Participant|Individuals in this arm will receive the WiseGuyz program in their grade 9 year.
89293352|NCT03994016|No Intervention|Comparison Participant|Individuals in this arm will not receive any intervention in their grade 9 year, and will be used to create a matched comparison group for individuals in Arm 1 (WiseGuyz Participants).
89293353|NCT03991403|Experimental|Atezolizumab group|
89293354|NCT03991403|Active Comparator|Control group|
89293355|NCT03985930|Experimental|Distraction Group|Children between the ages of 3 and 5 years will be distracted using virtual reality content delivered through goggles.
89293356|NCT03985930|Active Comparator|Treatment as Usual|Children randomized to this group will receive the usual medical care.
89293357|NCT03973827|Experimental|Low dose|3 patients receiving low dose
89293358|NCT03973827|Experimental|Medium dose|3 patients receiving medium dose
89293359|NCT03973827|Experimental|High dose|3 patients receiving high dose
89293360|NCT03973827|Sham Comparator|Control|6 patients
89293361|NCT03970525||Venturi pump|This cohort will receive femtosecond laser cataract surgery with Venturi pump.
89293362|NCT03970525||Peristaltic vacuum pump|This cohort will receive femtosecond laser cataract surgery with peristaltic pump.
89293363|NCT03932760|Experimental|UPLIFT Program|Weekly one-hour group sessions for 10 weeks facilitated by a mental health professional.
89293364|NCT03932760|Active Comparator|Pregnancy Skills Group|Weekly one-hour group sessions for 10 weeks facilitated by a registered nurse.
89293365|NCT03930680|Experimental|Dexrazoxane 100mg/m2|one dose of 100mg/m2 dexrazoxane
89293366|NCT03930680|Experimental|Dexrazoxane 200mg/m2|one dose of 200mg/m2 dexrazoxane
89293367|NCT03930680|Experimental|Dexrazoxane 300mg/m2|one dose of 300mg/m2 dexrazoxane
89293368|NCT03930680|Experimental|Dexrazoxane 400mg/m2|one dose of 400mg/m2 dexrazoxane
89293369|NCT03930680|Experimental|Dexrazoxane 500mg/m2|one dose of 500 mg/m2
89293370|NCT03905369|Experimental|Decision aid, SDM booster and deliberation training|In the first arm, patients have COMBO, consisting of the decision aid, the SDM-booster, and the values deliberation training for physicians
89293371|NCT03905369|Active Comparator|Deliberation training|In the second arm, patients have the values deliberation training for physicians alone.
89293372|NCT03897439|Active Comparator|Usual Care (UC)|196 African American smokers will receive 12 weeks of smoking cessation counseling and 18 weeks of nicotine patch.
89293373|NCT03897439|Experimental|Optimized Care (OPT)|196 African American smokers will receive 12 weeks of smoking cessation counseling. They will receive the nicotine patch and up to two pharmacotherapy adaptations (VAR, BUP+NP) based on verified smoking status at Weeks 2 and 6 for a total of 18 weeks of pharmacotherapy.
89293374|NCT03883100|Experimental|HQP1351|
89293375|NCT03883087|Experimental|HQP1351|
89293376|NCT03882359|Active Comparator|Definity|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of DEFINITY® 100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
89293377|NCT03882359|Experimental|MVT-100|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of MVT-100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
89293378|NCT03878719|Experimental|Safety Run-in Phase|"binimetinib taken twice daily (BID) and~encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol."
89293379|NCT03878719|Experimental|Expansion Phase|"binimetinib taken twice daily (BID) and~encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol."
89293380|NCT03831698|Experimental|Omega-3, 2 grams|Omega-3 fatty acid ethyl esters (2 grams) orally (by mouth) once per day for 12 months
89293381|NCT03773302|Experimental|Infigratinib (BGJ398) 125 mg|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
89293382|NCT03773302|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib if certain criteria are met.
89293383|NCT03690791|Active Comparator|MediCabilis CBD Oil|
89293384|NCT03690791|Placebo Comparator|Placebo Oil|
89293385|NCT03592992|Experimental|Spinal Hydromorphone|For the intervention group, 75 mcg of hydromorphone will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
89293386|NCT03592992|Active Comparator|Spinal Morphine|For the control group,150 mcg of preservative-free morphine will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
89293387|NCT03536559|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
89293388|NCT03536559|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
89293389|NCT03536559|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatments.
89293390|NCT03522025|Active Comparator|GMK-UNI cemented fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
89293391|NCT03522025|Experimental|GMK-UNI cementless fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
89293392|NCT03490253|Active Comparator|Static Messaging|We will send patients a total of seven messages per week (one per day) at 10.00 am. For the physical health management messages we use messages from established topics in the Diabetes Prevention Program(23) content with the emphasis on physical activity and stress management. The final message, on the seventh day will ask patients to rate their mood on a scale from 1 to 9. Physical activity (step-count/day) will be passively monitored via the app on their smartphone.
89293393|NCT03490253|Experimental|Adaptive Messaging|Patients in the adaptive messaging arm will receive the daily messages of the static arm, and additionally receive daily messages within different categories of feedback and motivational messages that are chosen using a reinforcement learning (RL) algorithm. Physical activity (step-count/day) will be actively monitored via the app on their smartphone.
89293394|NCT03490253|No Intervention|Control Condition|Control patients will only install the app on their phone and will not receive any feedback messages. They will receive one message a week, on a fixed day, asking them to assess their mood in the previous week on a scale of 1 to 9. The message will be sent daily at 10:00 am. Non-responders will receive reminders to submit their mood self-assessments in two hour intervals.
89293395|NCT03489733|Experimental|Intervention Group|Infant Formula with hydrolyzed protein and breast milk until at least 120 days of life
89293396|NCT03489733|Experimental|Control Group|Infant Formula with intact protein and breast milk until at least 120 days of life
89293397|NCT03489733|No Intervention|Breast Fed Group|Exclusively breast ilk until at least 120 days of life
89293398|NCT03447808|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89293399|NCT03436602||Training cohort|Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
89293400|NCT03436602||Validation cohort|Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
89293401|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs|Single infusion of 200 million cells per patient.
89293402|NCT03406585|Placebo Comparator|Sham transplantation (placebo)|Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)
89293403|NCT03392584||APR|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR)
89293404|NCT03392584||APR with VRAM|Patients with locally advanced rectal cancer treated with neoadjuvant (chemo-) radiotherapy (CRT) and operated with abdominoperineal resection (APR) and subsequent reconstruction of the perineum with a vertical rectus abdominis myocutaneous flap (VRAM)
89293405|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, pemetrexed disodium)|Patients with non-squamous lung cancer receive nivolumab IV over 30 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity
89293406|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)|Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
89293407|NCT03301675|Experimental|Orange juice|Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
89293408|NCT03301675|No Intervention|Control|Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
89293409|NCT03299309|Experimental|PEP-CMV|Cytomegalovirus (CMV)-specific peptide vaccine (PEP-CMV)
89293410|NCT03292679||3D template|Subjects will have custom models of relevant portions of their facial skeleton printed and used as templates for bending and shaping plates for stabilizing the fracture(s).
89293411|NCT03258788||Non-Small Cell Lung Cancer|Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken.
89293412|NCT03256760|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
89293413|NCT03256760|Placebo Comparator|Placebo|Placebo
89293414|NCT03254927|Experimental|CDX-3379 and cetuximab|During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
89293415|NCT03238599|Experimental|Pedometer-based activity monitoring|The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
89293416|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (CAD)|
89293417|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (wAIHA)|
89293418|NCT03101826|Experimental|Filtered Music Intervention|All participants will participate in pre-intervention assessments (6 months, 1 week prior) and post-intervention assessments (1 week, 1 month post). The Filtered Music Intervention (i.e., Listening Project Protocol) will last for 1 hour per day, for 5 consecutive days.
89293419|NCT03100539|Experimental|Therapist treated massage (TT-M)|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
89293420|NCT03100539|No Intervention|Wait list control (WL-C)|Participants in the waitlist control will be instructed to continue their medical care as normal and to not begin any massage treatment during the 6 months of the study. At the competition of the final 6 month outcome, participants in the control arm will be eligible to attend a caregiver training session and receive a complementary massage session from a TOMCATT study therapist.
89293421|NCT03045757||Healthy Newborn|Healthy Newborn
88806165|NCT02114294|Experimental|Isolated hip strengthening|Isolated hip strengthening (abduction, external rotation, extension)
88806166|NCT02114294|Active Comparator|Quadriceps based training|Quadriceps based training (mini-squat, straight leg raising, terminal extensions)
88806167|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
89293422|NCT03045757||CHD Neonates|Neonates born with CHD before and after surgical repair
89293423|NCT03039036|Experimental|Early Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy within 1 hour of Foley catheter removal.
89293424|NCT03039036|Active Comparator|Delayed Amniotomy|Patients undergoing induction of labor with foley catheter, with or without concurrent use of misoprostol, will undergo amniotomy no sooner than 4 hours following removal of Foley catheter.
89531152|NCT05054205|Experimental|Experimental group|To the experimental group; motivational interview based self-management education was given for 30-45 minutes with groups of 5-8 people, COPD education guide was given, questions were shared with the question-answer method and group interaction was provided. After the self-management education, 3 motivational interviews were conducted 3 days apart with 30-45 minutes.The data were collected in three stages as pre-test, post-test and follow-up (after 30 day).
89293425|NCT03025880|Experimental|Single arm|"Eligible patients will be enrolled and treated with Pembrolizumab (P) at a dose of 200mg as an intravenous (IV) infusion on day 1 of each 21-day cycle in combination with Gemcitabine (G) at a dose of 1,250mg/m2 or 1,000mg/m2 (this dose will be explored in combination with P in the initial exploratory run-in-phase if necessary) as a IV infusion on day 1 and 8 of each 21-day cycle.~Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. An initial exploratory run-in-phase will be performed to test the safety of the combination and determine the Recommended Phase II Dose (RP2D) of G in combination with fixed doses of P."
89293426|NCT02962297|Experimental|treatment group|Vitamin E softgel,100mg,Tid,orally, 96 weeks. All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
89293427|NCT02962297|Placebo Comparator|placebo group|A similar appearing placebo softgel , Vitamin E -Placebo, Tid, orally, 96 weeks, All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
89293428|NCT02908308|Active Comparator|Normothermia|Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.
89293429|NCT02908308|Experimental|Hypothermia|Targeted temperature management to 33°C for up to 28h.
89293430|NCT02880163|Experimental|ResQFoam|ResQFoam in-vivo expandable foam
89293431|NCT02827617||TP53 mutated CLL|
89293432|NCT02750566|Experimental|Osteopathic Manipulative Treatment|A board certified NMM/OMM or FP/OMM physician will perform an osteopathic structural exam and osteopathic treatment for a 30 minute session. The investigators will follow a generalized protocol for diagnosis and treatment of the head, neck, spine, rib cage, and pelvis. The following techniques will be included in the treatment protocol, OA (Occipitoatlantal) decompression, V-Spread, venous sinus drainage, balanced membranous tension (BMT), cranial lifts, CV4, and a mix of balanced ligamentous tension (BLT), muscle energy techniques, facilitated positional release, articulatory techniques (ART), high-velocity low-amplitude, and counterstrain to address any somatic dysfunctions.
89293433|NCT02750566|Active Comparator|Counseling|"For the control group, an investigator will complete a 30-minute counseling session with the subject. The focus of discussion will be from the CDC's What to expect after a concussion article. Other resources that will also be used come from the American Academy of Family Physicians (AAFP), FamilyDoctor.org, and the Brain Care Center. Each counseling session will follow the same protocol. The counseling session will provide subject with similar face-to-face time with the OMT arm."
89293434|NCT02733601||Breast Cancer Patients|Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy
89293435|NCT02661646||Advanced Pneumatic Compression Group|All study participants will receive treatment using an advanced pneumatic compression device.
89293436|NCT02652078|Sham Comparator|Control|Sham treatment in identical format to treatment arm but without shockwave production
89293437|NCT02652078|Experimental|Shockwave|Active shockwave treatment to calf muscle bulk
89293438|NCT02518555|Experimental|Arm A (concurrent vaccines and ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 3 and 5 and trivalent influenza vaccine IM and DTaP vaccine IM on day 1 of course 4. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
89293439|NCT02518555|Experimental|Arm B (sequential vaccines and ibrutinib)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 1 and 3 and trivalent influenza IM and DTaP vaccine IM on day 1 of course 2. Beginning in course 4, patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity.
89293440|NCT02390414||Gets HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT and actually undergo HSCT.
89293441|NCT02390414||No HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT but do not undergo HSCT.
89293442|NCT02320266||Parkinson's Disease|Patients diagnosed with Parkinson's Disease undergoing DBS surgery.
89293443|NCT02320266||Control|Age matched controls without Parkinson's Disease and no history of mental illness.
89293444|NCT02320266||Essential Tremor|Patients diagnosed with Essential Tremor undergoing DBS surgery.
89293445|NCT02320266||Dystonia|Patients diagnosed with Dystonia undergoing DBS surgery.
89293446|NCT02320266||Obsessive-Compulsive disorder|Patients diagnosed with Obsessive-Compulsive disorder undergoing DBS surgery.
89293447|NCT02212262||Multiple Myeloma Patients|Patients with multiple myeloma will undergo a blood draw and a bone marrow aspirate. Extra bone marrow will be taken for study purposes only.
89293448|NCT02212262||Healthy subjects|Healthy subjects and multiple myeloma patients will undergo a blood draw
89293449|NCT02107638|Experimental|OMM treatment arm|Subject will receive osteopathic manipulative treatment protocol for Parkinson's disease (PARK-OMM), twice a week for 6 weeks.
88806168|NCT01454791|Experimental|Diclofenac Sodium Topical Gel first then Placebo|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
89293450|NCT02107638|Active Comparator|Counseling|Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
89293451|NCT02032940||Standard Sequence Imaging MRI|Patients requiring MRI. All Comers accepting study participation.
89293452|NCT02032940||Additional Pulse Sequence Increased|Patients requiring MRI. All comers accepting study participation and the run of additional pulse sequences during MRI procedure.
89293453|NCT02027376|Experimental|LDE225 (sonidegib) plus docetaxel|Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.
89531153|NCT05054205|No Intervention|Control group|Normal care was continued in the control group.
89531154|NCT02497547|Experimental|Oxytocin 400 IU|Oxytocin 400 IU vaginal gel (1 x 1mL/400 IU oxytocin daily for 12 weeks)
89293454|NCT02024542||Weight Loss Surgery - Healthy|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients do not have metabolic syndrome.
89293455|NCT02024542||Weight Loss Surgery - Metabolic Syndrome|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients have metabolic syndrome.
89293456|NCT02005289|Experimental|Cohorts 1-3Treatment (MOR00208, lenalidomide)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and lenalidomide PO daily on days 1-28 (days 9-28 of course 1 only). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
89293457|NCT02005289|Experimental|Cohort 4 Treatment (MOR00208, ibrutinib)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with ibrutinib on immune effector cell number and function.
89293458|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation|Active TMS (1)
89293459|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 2|Active TMS (2)
89293460|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 3|Active TMS (3)
89293461|NCT01879657|Experimental|68Ga-DOTATATE PET scans|"This is an open-label, single-dose diagnostic study using DOTATATE peptide, labelled with the 68Ga tracer. The radiation (imaging) dose will be 111-185MBq (3 - 5 mCi) ±25%. Imaging will start 90 ±30 minutes after injection.~The diagnostic sensitivity, specificity and accuracy of the study drug are being compared with a predefined standard of truth (SOT) parameters. A comparative conventional scan, such as anatomical imaging modalities CT, ultrasound, and MRI or functional imaging using 18F-FDG and NaF PET/CT or bone scan is being used to evaluate the diagnostic efficacy of 68Ga-DOTATATE."
89293462|NCT01683955|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
89293463|NCT01683955|Placebo Comparator|Placebo|100mL 0.9% sterile saline, applied topically
89293464|NCT01606436|Experimental|400 mg LY2140023|400 milligrams (mg) LY2140023 (5 x 80 mg tablets) administered orally as a single dose during 1 of 3 treatment periods separated by 2-day washout periods.
89293465|NCT01606436|Placebo Comparator|Placebo|Placebo tablets (5) matching LY2140023 administered orally as a single dose during 1 of 3 treatment periods separated by 2-day washout periods.
89293466|NCT01606436|Other|400 mg Moxifloxacin|Positive control, unblinded 400 milligrams (mg) moxifloxacin (1 x 400 mg tablet) administered orally as a single dose during 1 of 3 treatment periods separated by 2-day washout periods.
89293467|NCT01468246||Young Women|Young women with newly diagnosed breast cancer
89293468|NCT01453088|Active Comparator|Treatment A|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
89293469|NCT01453088|Experimental|Treatment Arm B|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
89293470|NCT01345175|Experimental|Pts receiving Rifaximin|This group will receive rifaximin 400mg bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
89293471|NCT01345175|Placebo Comparator|Pts receiving placebo|This group will receive a placebo bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
89293472|NCT01257139|No Intervention|dual-agent therapy or docetaxel alone|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, according to PS or age
89293473|NCT01257139|Experimental|dual-agent therapy or docetaxel or best supportive care|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, or best supportive care, allocated on the basis of a simplified geriatric scale, plus a more thorough geriatric evaluation if necessary
89293474|NCT01246739|No Intervention|Follow-up|Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.
89531155|NCT02497547|Experimental|Oxytocin 200 IU|Oxytocin 200 IU vaginal gel (1 x 1mL/200 IU oxytocin daily for 12 weeks)
89293475|NCT01246739|Experimental|Surgery|Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy
89293476|NCT01243190|Experimental|Ofatumumab|Loading dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
89293477|NCT01058018|Experimental|A - 100 mg per day RVX000222|Arm A: Treatment with RVX000222 at 50 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
89293478|NCT01058018|Experimental|B - 200 mg per day RVX000222|Arm B: Treatment with RVX000222 100 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
89293479|NCT01058018|Experimental|C - 300 mg per day RVX000222|Arm C: Treatment with RVX000222 150 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
89293480|NCT01058018|Placebo Comparator|D - Placebo|Arm D: Treatment with placebo for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
89293481|NCT00777712||Diabetics (HbA1c level >8%) with infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer with infection. N=50
89293482|NCT00777712||Normoglycemic- with infection|Non-Diabetic patients with wound(s) 4 weeks or longer with infection. N=50
89293483|NCT00777712||Diabetics (HbA1c level >8%) without infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer without infection. N=50
89293484|NCT00777712||Normoglycemic- without infection|Non-Diabetic patients with wound(s)4 weeks or longer without infection. N=50
89293485|NCT00777712||Diabetics (HbA1c level<8%) with infection|Patients with controlled diabetes with HbA1c level<8% who have wound (s) 4 weeks or longer and also with infection. N=50
89293486|NCT00777712||Diabetics (HbA1c level <8%) without infection|Patients with controlled diabetes with HbA1c level <8% who have wound (s) 4 weeks or longer and also without infection. N=50
89293487|NCT03843710|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89293488|NCT03843710|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89293489|NCT03843710|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89293490|NCT03843710|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
89293491|NCT00470639|Experimental|TMS|
89293492|NCT00470639|Sham Comparator|Sham|
89293493|NCT00442533|Experimental|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
89293494|NCT00186992|Other|Treatment|Eligible patients will be accessioned at the time of irradiation and undergo a pre-radiotherapy evaluation, treatment planning, image-guided radiotherapy delivery and intra-and post-irradiation evaluations.
89293495|NCT01235208|Experimental|Eurodiet treatment|
89293496|NCT01141296|Active Comparator|Fenofibrate|
89293497|NCT01141296|Placebo Comparator|sugar pill|
89293498|NCT01238328|Experimental|Transplantation|
89293499|NCT01238406|Experimental|MD-logic Artificial Pancreas (MDLAP) system|Use of the closed loop MD-logic Artificial Pancreas(MDLAP)System
89293500|NCT01238406|Active Comparator|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
89293501|NCT03724890|Experimental|Part A: M3814 + Avelumab|
89293502|NCT03724890|Experimental|Part B: M3814 + Avelumab + Radiotherapy (RT)|
89293503|NCT03724890|Experimental|Part FE: M3814 + Avelumab (fasted/fed state)|
89293504|NCT01145664|Active Comparator|Western therapy|
89293505|NCT01145664|Experimental|Herbal concentrate-granules plus western therapy|
89293506|NCT01145664|Experimental|Reduning Injection plus western therapy|
89293507|NCT01141452||IPDA FP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as fluticasone via metered dose inhaler
88806169|NCT01454791|Placebo Comparator|Placebo first then Diclofenac Sodium Topical Gel|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
89293508|NCT01141452||IPDA HFA-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as extra-fine hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
89293509|NCT01141452||IPDA CFC-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
89293510|NCT01141452||IPDI CFC-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
89293511|NCT01141452||IPDI HFA-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
89293512|NCT01141452||IPDI FP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as fluticasone propionate via metered dose inhaler
89293513|NCT01141530||Tissue Bank Samples|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study. All samples studied will be obtained through the UAMS Tissue Bank.
89293514|NCT01145742|Experimental|self-management support and BP telemonitoring|collaborative intervention involving home BP monitoring, home behavior change counseling to enhance self management, and intensification of treatment by primary care doctors
89293515|NCT01145742|No Intervention|usual care|usual primary care management of BP. lipids, and glucose
89293516|NCT01238484|Active Comparator|Control|Patients in the control group will be treated with the current standard of care including shoe modification and home stretching exercises.
89293517|NCT01238484|Experimental|Experimental|Patients assigned to the experimental group will receive the current standard of care as well as the Ankle Dorsiflexion Dynasplint.
89293518|NCT01145820|Experimental|Juice Plus|
89293519|NCT01145820|Placebo Comparator|Placebo|
89293520|NCT00219557|Active Comparator|Gemcitabine|
89293521|NCT00219557|Experimental|Axitinib [AG-013736] plus gemcitabine|
89293522|NCT01141764|Experimental|Study Group|"In our study, patients will be scanned with their DBS electrodes turned on and off.~Participation involves undergoing 2 separate PET scans on 2 separate days. The MRI and neuropsychological tests will either be performed on the same day as one of the PET scans or on a separate day.~Procedures performed in this study are not part of the standard management of epilepsy."
89293523|NCT01235286|Experimental|remote ischemic preconditioning|
89293524|NCT05282940|Experimental|Levonorgestrel and Ethinyl estradiol Test Product|Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
89293525|NCT05282940|Active Comparator|Levonorgestrel and Ethinyl estradiol Reference Product|Participants will receive two tablets of the test marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.
89293526|NCT01238562|Experimental|YPEG-Filgrastim, 10mcg/kg|
89293527|NCT01238562|Experimental|YPEG-Filgrastim, 20mcg/kg|
89293528|NCT01238562|Experimental|YPEG-Filgrastim, 30mcg/kg|
89293529|NCT01238562|Experimental|YPEG-Filgrastim, 45mcg/kg|
89293530|NCT01238562|Experimental|YPEG-Filgrastim, 60mcg/kg|
89293531|NCT01141842|Experimental|lung cancer|breath samples of patients with confirmed lung cancer
89293532|NCT01141842|Active Comparator|underlying lung disease|patients with underlying lung disease and impairment in lung function
89293533|NCT01141842|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
89293534|NCT05269056||Stage I-II gastric cancer|Cell-free DNA collected from plasma samples of 200 patients with stage I-II gastric cancer will undergo whole-genome sequencing
89293535|NCT05269056||Healthy controls|Cell-free DNA collected from plasma samples of 100 non-cancer individuals will serve as controls
89293536|NCT01329666|Experimental|50,000 IU Vitamin D3|
89293537|NCT01329666|Placebo Comparator|Placebo (inactive Vitamin D3)|
89293538|NCT01141920|Active Comparator|3-month counseling induction: routine care|Participants assigned to this condition will receive routine stepped-care treatment at ATS. Participants will begin in Step 2 (one counseling session per week), and be advanced to higher intensity care based on missed counseling sessions and drug-positive urine samples. Participants advanced to Step 3 will be scheduled to attend 2 group counseling sessions per week (in addition to individual counseling), and those advanced to Step 4 will be scheduled to attend 8 group counseling sessions per week (in addition to individual counseling). Time of methadone dosing will be based on step of care.
89293539|NCT01141920|Experimental|3-month counseling induction: low threshold|Participants assigned to this treatment arm will receive low threshold counseling. These participants will be scheduled to attend one counseling session per month with their individual counselor for the first 3-months. Participants can attend more counseling sessions if they desire, and they can meet with program supervisors to address crisis situations. They can receive methadone dosing any time during the clinic hours (7:30 am-1:15 pm and 4:00 pm - 6:00 pm)
89293540|NCT01236846|Placebo Comparator|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml) for 12 weeks
89293541|NCT01236846|Experimental|VDR Genotype (aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
89293542|NCT01236846|Experimental|VDR Genotype (AA)|Daily intake of yogurt drink fortified (500 ml) with 1000 IU vitamin D for 12 weeks
89293543|NCT01236846|Experimental|VDR genotype (Aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
89293544|NCT01141998|Placebo Comparator|Placebo|
89293545|NCT01141998|Active Comparator|Vitamin D administered orally|
89293546|NCT01141998|Experimental|Vitamin D administered via UVB|
89293547|NCT05632302|Experimental|TBI-ICP monitoring|Optical signals acquisition from the nICP probe stuck to the patient's forehead
89293548|NCT01142076|Placebo Comparator|placebo|Dose treatment group, 10%
89293549|NCT01142076|Active Comparator|Xinju Xiaogao Prescription|treatment group
89293550|NCT01235364|Experimental|Digital|The patient was randomized to digital insertion of the Foley catheter
89293551|NCT01235364|Experimental|Speculum|
88806170|NCT02099006|Experimental|Medications|Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.
89293552|NCT01236924|Experimental|Lifestyle counseling|
89293553|NCT01238718|Active Comparator|lidocaine|
89293554|NCT01238718|Placebo Comparator|normal saline|
89293555|NCT04284072|Experimental|All subjects|Single arm study with a device intervention for epileptic seizure monitoring in subjects with refractory focal impaired awareness, tonic-clonic, and/or typical absence seizures.
89293556|NCT01238796|Experimental|Normal renal function|Subjects with normal renal function
89293557|NCT01238796|Experimental|Severe renal impairment|Subjects with severe renal impairment
89293558|NCT01238796|Experimental|End stage renal disease|Subjects with end stage renal disease
89293559|NCT01238874|No Intervention|No intervention|Mostly observational study with 1 patient global assessment.
89293560|NCT01235520|Experimental|1|
89293561|NCT01235520|Experimental|2|
89293562|NCT01235520|Placebo Comparator|3|
89293563|NCT01143948|Active Comparator|15 patient sliding scale regular insulin|
89293564|NCT01143948|Active Comparator|15 patient BBI NPH plus regular insulin|
89293565|NCT01143948|Active Comparator|15 patients BBI Glargine plus Glulisine|
89293566|NCT01145976|Active Comparator|CY-ATG(Arm1)|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
89531156|NCT02497547|Placebo Comparator|Placebo|Placebo vaginal gel (1 x 1mL daily for 12 weeks)
89293567|NCT01145976|Experimental|Flu-ATG(Arm2)|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
89293568|NCT01142154|Experimental|oral, liquid solution|
89293569|NCT05667636|Experimental|single arm, non randomized|SBRT 30 Gy/ 5 fractions
89293570|NCT05667636|Experimental|radiation, SBRT|SBRT 30 Gy/5 fractions to the prostatic bed +/- 25 Gy/5 fractions to the pelvic lymphnodes
89293571|NCT01237002||Group 1|117 patients with cumulative clamping time between 60 and 120 minutes
89293572|NCT01237002||Group 2|72 patients with cumulative clamping time longer than 120 minutes
89293573|NCT01144104|Experimental|Public Service Announcements|Demographically targeted public service announcement
89293574|NCT01144104|Experimental|Interactive Multi-Media Computer Program|Personally tailored information about seeking care for depression based on respondent characteristics
89293575|NCT01144104|Active Comparator|Attention Control Video|Two-minute video focusing on common sleep disorders.
89293576|NCT05158998|Other|propofol group|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Propofol infusion will be stopped at the end of surgery.
89293577|NCT05158998|Other|sevoflurane group|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
89293578|NCT01235676|Experimental|Diet|Calorie restriction to reduce weight gain
89293579|NCT01235676|Experimental|Exercise|Exercise to reduce weight gain
89293580|NCT01239186||Oligozoospermia|infertile patients presenting a reduced sperm count (less than 20 Millions of spermatozoa/ml)
89293581|NCT05632380|Experimental|ASCT and C-CAR088|Patients will undergo ASCT followed by C-CAR088 single dose infusion.
89293582|NCT01237158||healthy controls|
89293583|NCT01237158||bipolar disorder type I|
89293584|NCT01144260|Experimental|Bafetinib|
89293585|NCT05667558||Study grup|
89293586|NCT03835260|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 2 or more cigarettes per day
89293587|NCT01235988||Eltrombopag & standard of care|
89293588|NCT01235988||Standard of care|
89293589|NCT01142544||Pediatric ALIEN|All children from 1 month to 18 years old meeting the American-European Consensus Conference definition of acute lung injury
89293590|NCT01237236|Experimental|LEE011|
89293591|NCT01237314||Glargine Group|After baseline titration of metformin, this group will take glargine along with metformin.
89293592|NCT01237314||Exenatide Group|After baseline titration of metformin, this group will take exenatide along with metformin.
89293593|NCT01237314||Glargine and Exenatide Group|After baseline titration of metformin, this group will take glargine and exenatide along with metformin.
89293594|NCT01239498|Experimental|Saline + Lidocaine/Adrenaline|
89293595|NCT01239498|Placebo Comparator|Lidocaine/Adrenaline only|
89293596|NCT01144572||1|Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
89293597|NCT00251927|Active Comparator|1|Surgery
89293598|NCT00251927|Experimental|2|Esomeprazole (NEXIUM) therapy
89293599|NCT01237392|Active Comparator|Contact Ultrasonic Debridement Device|
89293600|NCT01237392|Active Comparator|Standard Sharp Debridement|
89293601|NCT01236066||Study Group|Australian children aged < 5 years who have been vaccinated with RotaTeq or Rotarix from 2007 to 2009 as well as all children aged < 5 years hospitalised for all-cause gastroenteritis, rotavirus gastroenteritis or bronchiolitis.
89293602|NCT03971201|Experimental|Surgery plus sorafenib|surgical resection followed by adjuvant sorafenib
89293603|NCT03971201|Active Comparator|sorafenib only|sorafenib only
89293604|NCT01236144|Experimental|AC220 Intervention|
89293605|NCT01236144|Experimental|Plerixafor Intervention|
89293606|NCT01236144|Experimental|Ganetespib|
89293607|NCT03971435||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360)
89293608|NCT02528526|Experimental|Treatment|Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.
89293609|NCT01073735||Cancer Survivors|Examine the construct validity, short-term stability, internal consistency and item-response performance of a health-related needs assessment self-report instrument for adult childhood cancer survivors.
89293610|NCT01329744|Experimental|Treatment|Recombinant IGF-I
89293611|NCT01329744|Placebo Comparator|Placebo|
89293612|NCT00165503|Experimental|Surgery+Heated Cisplatin+Sodium Thiosulfate+Adjuvant CT|Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimta each given day 1 of a 21-day cycle for 3 cycles.
89293613|NCT01745796||Intubated ICU patients|
89293614|NCT03971123|Experimental|AC-SD-03 (for Part 1)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
89293615|NCT03971123|Experimental|AC-LMP-01 (for Part 1)|Tricaprilin LMP formulation, single dose (20g tricaprilin). Administered orally.
89293616|NCT03971123|Experimental|AC-SD-03P (for Part 1)|Placebo formulation, single dose. Administered orally
89293617|NCT03971123|Experimental|AC-1202 (for Part 2)|Tricaprilin SD formulation, single dose (20g caprylic triglyceride). Administered orally.
89293618|NCT03971123|Experimental|AC-SD-03 (for Part 2)|Tricaprilin SD formulation, single dose (20g tricaprilin). Administered orally.
89293619|NCT01144650|Placebo Comparator|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
89293620|NCT01144650|Experimental|Dapsone|Patients will receive either a single total dose of 250 mg IV and oral dosage
89293621|NCT00162773|Placebo Comparator|Placebo|water injection
89293622|NCT00162773|Experimental|Omalizumab|"Other Names:~Xolair 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE."
89293623|NCT00209339|Experimental|MitraClip|Percutaneous mitral valve repair (MitraClip Implant)
89293624|NCT03970889|No Intervention|Standard Care|Participants will be in their usual care, wearing a continuous glucose sensor and taking insulin by pump or by pens with memory
89293625|NCT03970889|Experimental|Klue|Subjects will wear an Apple watch on their dominant hand and receive alerts when eating behavior is detected by the Klue software.
89293626|NCT03968003|Experimental|Inulin|Group A (intervention group) will receive inulin 10 g.
89293627|NCT03968003|Placebo Comparator|Maltodextrin|Group B will receive placebo of isocaloric maltodextrin.
89293628|NCT03968003|Active Comparator|Dietary fiber|Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.
89293629|NCT03970577|Experimental|Rituximab treatment|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
89293630|NCT03970577|Active Comparator|Oral steroid treatment|"The patients will continue exclusive oral steroid treatment, that will be progressively tapered, for a total of 24 weeks (by taking into account the initial oral steroid therapy administered during 8 weeks and the oral steroid treatment given after randomization).~Each patient will be followed up until 18 months after randomization. The patient will have study visits at inclusion, 4 weeks and 8 weeks after inclusion. At the time of randomization, patients who will have reached CR of MCNS will be allocated in test or control group and will be followed up similarly: visits at 1, 4, 16, 24 weeks, 12 and 18 months after randomization."
89293631|NCT01073813|Active Comparator|Minocycline 100mg|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
89293632|NCT01073813|No Intervention|No treatment|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
89293633|NCT03970421||patients without anticoagulant and / or antiplatelet treatment|Patients older than 16yo with no anticoagulant or antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
89293634|NCT03970421||patients on antiplatelet therapy (ASA and / or clopidogrel|Patients older than 16yo on antiplatelet treatment attended at ED because of Head Injury and with a Head CT performed.
89293635|NCT03970421||patients on treatment with acenocoumarol and INR <2|Patients older than 16yo on acenocumarol and with INR <2 attended at ED because of Head Injury and with a Head CT performed.
89293636|NCT03970421||Others|patients on anticoagulant therapy with acenocoumarol and INR> = 2 or patients on treatment with direct thrombin inhibitors (dabigatran), or inhibitors of factor Xa (rivaroxaban, apixaban, edoxaban) or patients on treatment with low molecular weight heparins (LMWH) attended at ED because of Head Injury and with a Head CT performed.
89293637|NCT03823391|Experimental|ABBV-3373 Followed by Placebo|Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.
89293638|NCT03823391|Experimental|Adalimumab|Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.
89293639|NCT03970187|Experimental|Exposure|Phase 1 (visit 1): 60 minutes exposure-based eye contact training in VR Phase 2 (home training): 9 blocks of 20 minutes exposure-based eye contact training in VR, distributed over a total duration of maximally 2 weeks
89293640|NCT03970187|No Intervention|Control|"Phase 1 (visit 1): waitlist. In order to prevent systematic preparation for the subsequent PST, a 60 minutes virtual reality games with fear-unrelated content will serve as the control intervention.~Phase 2 (home training): waitlist"
89293641|NCT01075529|No Intervention|fluoxetine|
89293642|NCT01073891|Active Comparator|Arm 1|
89293643|NCT01073891|Experimental|Arm 2|
89293644|NCT01073891|Experimental|Arm 3|
89293645|NCT03970031|Active Comparator|MSDC-0602K|MSDC-0602K one tablet per day taken orally
89293646|NCT03970031|Placebo Comparator|Placebo|Placebo one tablet per day taken orally
89293647|NCT00209027|Experimental|schizophrenia subjects|Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
89293648|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Sacrificed|PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
89293649|NCT00208325|Active Comparator|PFC Sigma RP PCL Sacrificed|PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
89293650|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Retained|PFC Sigma Fixed Bearing Total Knee System with PCL Retained
89293651|NCT00208325|Active Comparator|PFC Sigma RP PCL Retained|PFC Sigma Rotating Platform Total Knee System with PCL Retained
89293652|NCT00160667|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day.
89293653|NCT00160667|Experimental|Brivaracetam 200 mg/day|Brivaracetam 200 mg/day (100 mg administered twice a day).
89293654|NCT00160667|Experimental|Brivaracetam 400 mg/day|Brivaracetam 400 mg/day (200 mg administered twice a day).
89293655|NCT00206375|No Intervention|1|Group 1 will be treated only with Synthroid.
89293656|NCT00206375|Experimental|2|Group 2 will be treated with Growth hormone, synthroid, and lupron.
89293657|NCT00206375|No Intervention|3|Group 3 will have acute hypothyroidism and will serve as controls.
89293658|NCT00160199|Experimental|1|
89293659|NCT00160199|Active Comparator|2|
89293660|NCT00157157|Experimental|Single Arm - All Participants|All subjects enrolled in the study who meet the eligibility criteria.
89293661|NCT00203411|Experimental|Bevacizumab Plus Capecitabine|Bevacizumab 7.5 mg/kg every 3 weeks will be administered interavenously (IV) to the enrolled patients. Oral capecitabine 1000 mg/m^2 twice daily for 14 days followed by 7 days off every 21 days. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of patient consent.
89293662|NCT00203021|Experimental|Glatiramer Acetate: Delayed Start|Participants who were originally randomized to the placebo group in the 01-9001 and/or the 01-9001E studies received glatiramer acetate 20 milligrams (mg) subcutaneous (SC) injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg three times weekly (TIW). The treatment continued for up to 288 months.
89293663|NCT00203021|Experimental|Glatiramer Acetate: Early Start|Participants who were originally randomized to the glatiramer acetate 20 mg group in the 01-9001 and/or the 01-9001E studies continued to receive glatiramer acetate 20 mg SC injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg TIW. The treatment continued for up to 288 months.
89293664|NCT00201851|Active Comparator|Immediate surgery|Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
89293665|NCT00201851|Experimental|Scheduled surgery|Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
89293666|NCT00201851|Other|Immediate Surgery - nonrandomized|Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
89293667|NCT03969485|Experimental|Hybrid Fractional Laser|Hybrid Fractional Laser Treatment
89293668|NCT01073969|Placebo Comparator|Control cereal|grain-based ready to eat cereal that does not contain active wheat bran extract
89293669|NCT01073969|Active Comparator|low dose|grain-based ready to eat cereal containing a low dose of wheat bran extract
89293670|NCT01073969|Active Comparator|High dose|grain-based ready to eat cereal that contains a high dose of wheat bran extract
89293671|NCT03967769|No Intervention|Standard Practice|Infants will have high Flow nasal cannulae placed into the nares before induction. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
89293672|NCT03967769|Experimental|Low Flow oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 0,2L/kg/min of oxygen flowing through the cannulae in this group during the study.
89293673|NCT03967769|Experimental|High Flow Oxygenation|Infants will have conventional nasal cannulae into the nares prior to induction of anesthesia. They will be removed from the nares at the end of the study when the airway has been secured. There will be 1L/kg/min of oxygen flowing through the cannulae in this group during the study.
89293674|NCT01074203|Experimental|Nitazoxanide arm|All patients will receive nitazoxanide
89293675|NCT03129100|Experimental|Ixekizumab (IXE) 80Q4W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
89293676|NCT03129100|Experimental|Ixekizumab (IXE) 80Q2W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
89293677|NCT03129100|Placebo Comparator|Placebo|Participants received subcutaneous dose of placebo.
89293678|NCT03101020|Experimental|Experimental Group|The participants will receive standard care physiotherapy plus active visceral manipulation
89293679|NCT03101020|Placebo Comparator|Control Group|The participants will receive standard care physiotherapy plus placebo visceral manipulation
89293680|NCT05294692|Experimental|Financial Health Incentives|"fter registration on the Caterpillar App, participants will be instructed to 'carry their phone' as much as possible during a 5-day baseline period to assess their daily step counts. In Month 1, participants will earn daily rewards (3¢ per day personalized daily step goal met; BE present bias). In Month 2, users will earn weekly rewards (25¢ per week goal met 5+ times; BE fresh start). In Month 3, users will earn team-based rewards (35¢ per week if 10+ goals are reached collaboratively with someone they know e.g., friend; BE herd mentality). Participants are expected to earn $1.25 CAD (or 0.75 British pounds) over the course of the 12-week intervention (about $5/person/yr). Rather than offer daily incentives indefinitely, Caterpillar will offer daily incentives as a temporary feature-moving to larger, less frequent, less certain (team-based) incentives as PA becomes habitual."
89293681|NCT03100006|Experimental|Nivolumab and Oregovomab|
89293682|NCT03030664|Active Comparator|L.reuteri|probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
89293683|NCT03030664|Placebo Comparator|Placebo|Same formulation as probiotics, without active substance. 5 drops per day will be delivered
89293684|NCT03100942|Experimental|Lanraplenib|Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.
89293685|NCT03100942|Experimental|Filgotinib|Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.
89293686|NCT03100942|Experimental|Tirabrutinib|Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.
89293687|NCT03100942|Placebo Comparator|Placebo, then active treatment|"Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48:~filgotinib + lanraplenib placebo + tirabrutinib placebo~lanraplenib + filgotinib placebo + tirabrutinib placebo~tirabrutinib + filgotinib placebo + lanraplenib placebo"
89293688|NCT05239780|Experimental|Participants with depression|Participants with depression to undergo brain stimulation
89293689|NCT02476474|Active Comparator|3 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 3 cm from pylorus (antrum).
89293690|NCT02476474|Active Comparator|6 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 6 cm from pylorus (antrum).
89531410|NCT06066931|Other|Group 1 of a simple method (Plastic surgery with local tissues) n=50|In group 1 patients (plastic surgery with local tissues), a simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.
89293691|NCT05211076|Experimental|Music Group|"In the selection of the music to be played,Rast,Uşşak,Kürdi,Muhayyer modes were chosen by taking expert opinion.Before starting the music application,the selected music will be sent to the mothers in this group by the researcher over the internet to the mother's phone and it will be ensured that the mother listens to the music transmitting the sound from her own phone in each session.~Music practice will take place in mothers' rooms or in the NICU.~The room will be quiet and your mother will be alone.~To make the mother listen to music;The mother will be asked to sit on the bed/seat in a comfortable position.~At the same time,the mother will be asked to close her eyes and be relaxed.~Later, music will be turned on from the mother's phone, allowing the mother to listen to music for 30 minutes~While the mother listening to the music,at the 16th minute of the music,researcher will manually express each breast separately for at least 15 minutes until no milk comes out"
89293692|NCT05211076|Experimental|Marmet Technique Group|Marmet Technique is one of the non-pharmacological methods used to increase milk production.The Marmet Technique is a combined method that includes breast massage and manual milking.The Marmet Technique will be performed in the mothers' rooms or in the Breastfeeding Room of the Neonatal Intensive Care Unit. It will be ensured that the mother is comfortable by paying attention to her privacy. Mothers will be manually milked into the hopper in their own milking set. In addition, the reservoir will be used after washing with hot water. This technique consists of two stages, these stages are emptying the milk ducts and stimulating the milk stroke reflex (massage).
89293693|NCT05211076|Experimental|control group|On the other hand, no application will be made to the control group, and the milking process will be carried out manually by the researcher for at least 15 minutes until the milk does not come.
89293694|NCT03099694|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) - as a primary mode of ventilation in premature infants with RDS
89293695|NCT03099694|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS
89293696|NCT03099538|Experimental|Ixekizumab|Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
89293697|NCT03099304|Experimental|Ruxolitinib cream 1.5% twice daily (BID)|Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
89293698|NCT03099304|Experimental|Ruxolitinib cream 1.5% once daily (QD)|Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
89293699|NCT03099304|Experimental|Ruxolitinib cream 0.5% QD|Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
89293700|NCT03099304|Experimental|Ruxolitinib cream 0.15% QD|Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if < 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
89293701|NCT03099304|Placebo Comparator|Vehicle BID|Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
89293702|NCT05127382||untreated patients with advanced EGFR positive non-small cell lung cancer|
89293703|NCT01518400||Eligible Population|Cancer Survivors of all ages (Must be diagnosed with cancer at 21 years or younger)
89293704|NCT05064904|Active Comparator|never received RAAS blockers or multidiscipline consultation before AKI.|The enrollees assigned to the control group should not receive RAAS blockers or AKD consultation at least in 180 days after index discharge. In addition, these multidiscipline consultation and administration of RAAS blockers are continuing, and results regarding them remain masked. All patients provided written informed consent.
89293705|NCT05064904|Active Comparator|had received RAAS blockers and multidiscipline consultation before AKI.|"All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, <130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.~Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D)."
89293706|NCT05060848||ADRD|"Participants in the ADRD group will have a score of greater than or equal to 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory.~Subgroups based on sex and race categories will also be examined."
89293707|NCT05060848||Control|Participants in the control group will have a score of less than 17 on the ADAS-cog, a paper and pencil test of cognitive function including memory
89293708|NCT03632512|Experimental|Hericium honey bolus|Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
89293709|NCT03632512|Placebo Comparator|Control group|Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
89293710|NCT05016856|Active Comparator|Reminder Only Condition|To promote adherence, participants will receive generic reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone.
89293711|NCT05016856|Experimental|Smart Adherence Support Condition|To promote adherence, participants will receive reminders when home-based cognitive training has not been completed. This will be in the form of a text message to participants' smart phone. In this condition, participants will receive adaptive and tailored reminders based on dynamic algorithms that deploy reminders in a way that considers participant preferences, days and times of previous successful assessments, the success of previous reminder attempts, and answers to brief questions contained within reminder prompts. Parameter weights for these variables will be adjusted dynamically over a 6-month assessment period to ensure that reminders are deployed when they are most likely to be acted upon.
88806171|NCT02099006|Placebo Comparator|Placebo|The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.
88806172|NCT01454947|Experimental|SA, AJ, PC|Participants are given all 3 interventions.
89293712|NCT05015530||Test Medical Device|Healsea Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
89293713|NCT00883480|Experimental|2|The rest of the patients who do not carry the Factor Receptor mutation of Epidermal Growth will receive chemotherapy treatment individualized based on BRCA 1 m RNA levels. Function of these levels, three different subgroups of treatment: Subgroup A with low BRCA1 mRNA levels will receive treatment with gemcitabine / cisplatin Subgroup B with intermediate levels of BRCA1 mRNA: will receive treatment with docetaxel / cisplatin Subgroup C with high levels of BRCA1 mRNA: will receive treatment with docetaxel
89293714|NCT00883480|Experimental|1|The group of patients carrying EGFR mutation will receive treatment with Erlotinib, a selective oral Receptor tyrosine kinase inhibitor Epidermal Growth Factor
89293715|NCT05418946||Treatment group|Patient in treatment with Dapagliflozin 10 mg/day
89293716|NCT05418790|Experimental|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
89293717|NCT03097588|Experimental|Supportive care (NEPA)|"Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.~Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies"
89293718|NCT05418166||pro-Evo|Patients regularly take Ticagrelor and Aspirin for five days.Platelet activity was test before inject Evolocumab.
89293719|NCT05418166||24h-Evo|Patients regularly take Ticagrelor and Aspirin for five days, then inject Evolocumab 140mg. Platelet activity was test 24h after inject.
89293720|NCT05418166||1w-Evo|Patients regularly take Ticagrelor and Aspirin for five days, then inject Evolocumab 140mg. Platelet activity was test 1 week after inject.
89293721|NCT05417542|Experimental|Exposition I|preterm neonates between 28 and 30 wGA Exposition to music during the NICU period
89293722|NCT05417542|Experimental|Exposition II|preterm neonates between 32 and 34 wGA Exposition to music during the NICU period
89293723|NCT05417542|Active Comparator|Control I|preterm neonates between 28 and 30 wGA
89293724|NCT05417542|Active Comparator|Control II|preterm neonates between 32 and 34 wGA
89293725|NCT05417542|Active Comparator|Control III|preterm neonates between 36 and 40 wGA
89293726|NCT04846036|Experimental|Sonlicromanol|Paediatric-equivalent dose (as determined by Physiologically Based Pharmacokinetics (PBPK) modelling and the results of the Adaptive PK study) of sonlicromanol twice daily administered as an oral liquid for 26 weeks
89293727|NCT04846036|Placebo Comparator|Placebo|Matching placebo twice daily orally for 26 weeks
89293728|NCT05417230|Experimental|RC48-ADC plus envafolimab|
89293729|NCT04713670|Experimental|(A) T-V14|
89293730|NCT04713670|Experimental|(B) T-V7|
89293731|NCT04713670|Experimental|(C) D-V14|
89293732|NCT04713670|Experimental|(D) HD-V14|
89293733|NCT04713670|Experimental|(E) BQ-V14|
89293734|NCT04713670|Experimental|(F) RH-V14|
89293735|NCT04713670|Experimental|(G) BQ-L14|
89293736|NCT04713670|Experimental|(H) T-L14|
89293737|NCT01631214|Active Comparator|Alendronate/Alendronate|Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
89293738|NCT01631214|Experimental|Romosozumab/Alendronate|Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.
89293739|NCT04684108|Experimental|SG301|SG301 monotherapy intravenous (IV) infusion
89293740|NCT01567774|Active Comparator|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
89293741|NCT01567774|Active Comparator|Rosuvastatin|Patients will receive randomly rosuvastatin (10 mg per day) for 30 days
89293742|NCT04619524|Experimental|A: Patients undergo cycle with the transfer of fresh embryos|In study group A the cervical mucus will be collected from patients undergoing the in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI)/embryo transfer (ET) cycle with the transfer of fresh embryos.
88806173|NCT01454947|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
89293743|NCT04619524|Experimental|B: Patients undergo cycle with the transfer of frozen embryos|In study group B cervical mucus will be sampled from patients undergoing treatment cycles with the transfer of cryopreserved embryos.
89293744|NCT05415280|Experimental|Mindfulness based stress reduction|mindfulness based stress reduction intervention was used to treat psychological and addiction problems of the individuals
89293745|NCT05415280|Other|Relaxation Exercise|the control group was provided with the relaxation technique.
89293746|NCT05413564|Other|optimized self-exclusion procedure A|optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months
89293747|NCT05413564|Other|standard procedure|standard self-exclusion procedure B
89293748|NCT05185986|Experimental|Home based Pilates exercises|This group will perform two weekly sessions of Pilates for eight weeks, completed with at least 48-hours between sessions, in their own home, supported by a DVD developed and previously implemented and evaluated by the lead researcher in a feasibility trial among people with Multiple Sclerosis. Each Pilates session will last approximately one hour and is comprised of seven Pilates warm-up exercises and fourteen mat-based beginner's level exercise. Four repetitions of each Pilates movement will be performed during sessions in the first two weeks, with intensity being self-regulated by the participant based on level of physical condition. Repetitions will gradually progress at biweekly intervals, resulting in ten repetitions being performed for the final two weeks of the trial (Weeks 7 and 8). Six post-training stretches will be maintained for a minimum of thirty seconds.
89531562|NCT06055478|Placebo Comparator|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using saline|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using each 0.9% saline 10mL when arthroscopic rotator cuff repair Patient Controlled Analgesia (PCA) at a low fixed dose: fentanyl-loading dose: 0.4㎍/kg, continuous dose: 0.2㎍/kg/h, nefopam-loading dose: 0.04mg/kg, continuous dose: 0.02mg/kg/h
89293749|NCT05185986|Experimental|Combination of Home-based Pilates exercises and Home-based Cognitive Rehabilitation exercises|In addition to performing home-based Pilates exercises described in arm 1, this group will also perform home-based cognitive rehabilitation exercises for 8 weeks and 3 sessions per week. The interval between each session is at least 48 hours and each session will take between 30 to 45 minutes. Cognitive rehabilitation exercises are in pen and paper and each session includes two exercises in the areas of planning, cognitive organization, cognitive flexibility and working memory. All exercises will be explained to the subjects by a cognitive rehabilitation specialist, and in addition, explanations of all the exercises in each session will be available for participants in the separate voices. During the intervention period, in addition to the Pilates specialist, the cognitive rehabilitation specialist contacts the group 2 participants on a weekly basis and monitors their rehabilitation exercises.
89293750|NCT05185986|Other|Waiting list group|This group is the waiting list group and acts as a control group and will be instructed to maintain their preintervention physical and cognitive activity levels during the intervention. After 8 weeks of intervention, Pilates exercises and cognitive rehabilitation exercises will be provided to the participants of this group for their own use.
89293751|NCT03758040|Experimental|Slips on Turns|Slips administered during walking on a curved paths of radii 1.0, or 2.0 meters in early, middle or late stance to the inside or outside foot.
89293752|NCT03758040|Experimental|Slips on Slopes|Slips administered during walking on sloped ground of 5.0 or 10.0 degrees mediolaterally or anteroposteriorly, or flat ground, in early middle or late stance. For mediolateral slopes, slips will be administered to the uphill or downhill foot.
89293753|NCT01142622|Experimental|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
89293754|NCT01142622|Active Comparator|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity before surgery
89293755|NCT01142700|Experimental|BMS-824393 (10mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
89293756|NCT01142700|Experimental|BMS-824393 (30 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
89293757|NCT01142700|Experimental|BMS-824393 (100 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
89293758|NCT01142700|Placebo Comparator|Placebo|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
89293759|NCT01142700|Other|Peginterferon alfa-2a plus Ribavirin|Weeks 13 - 48
89293760|NCT01236222|No Intervention|Control group|
89293761|NCT01236222|Experimental|Cycling to school|
89293762|NCT01146132|Other|Luxembourg diet + wine|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
89293763|NCT01146132|Other|conventional + wine|conventional Diet with red wine
89293764|NCT01146132|Other|conventional|conventional diet without wine
89293765|NCT01146132|Other|Luxembourg diet|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
89293766|NCT01237470|Experimental|Desarda group|Patients with primary inguinal hernia operated using the Desarda technique
89293767|NCT01237470|Experimental|Lichtenstein group|Patients with primary inguinal hernia operated using the Lichtenstein technique.
89293768|NCT04909242|Experimental|single oral dose of DZD9008|single dose of DZD9008 (50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)
89293769|NCT04909242|Placebo Comparator|single oral dose of placebo|single dose of placebo (matching placebo, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg, tablet)
89293770|NCT04909242|Experimental|single oral dose of DZD9008 (300 mg, tablet)|
89293771|NCT04909242|Experimental|single oral dose of DZD9008 (100 mg, tablet or suspension)|
89293772|NCT04545814|Experimental|Stereotactic Radiosurgery|SRS will be delivered utilizing gamma knife or linear accelerator-based techniques.
89293773|NCT01144728|Experimental|Single arm Glimepiride+metformin|Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
89293774|NCT04540354|Experimental|Optimal Medical Therapy without ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will not receive an ICD device
89293775|NCT04540354|Active Comparator|Optimal Medical Therapy with ICD device therapy|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive an ICD device
89293776|NCT04615026||COVID 19 patients|all patients with positive SARS-CoV 2 swap
89293777|NCT01239654|Active Comparator|everolimus|everolimus-eluting stent
89293778|NCT01239654|Active Comparator|zotarolimus|zotarolimus-eluting stent
89293779|NCT03093454|No Intervention|Control|No intervention patient will receive current standard of care treatment and will answer surveys to collect data.
89293780|NCT03093454|Experimental|Lavender Group|Patient will receive lavender essential oil topically and by inhalation during their hospital stay while at the same time receiving regular standard of care.
89293781|NCT01239810||Control group|Receiving no treatment
89293782|NCT01239810||hyaluronic acid|treatment group receiving intraarticular hyaluronic acid
89293783|NCT01568086||AFFITOPE AD03 with adjuvant|
89293784|NCT01568086||AFFITOPE AD03 without adjuvant|
89293785|NCT01239888|Active Comparator|Oxytocin|
89293786|NCT01239888|Active Comparator|Oxytocin and Tibolone|
89293787|NCT01239888|Placebo Comparator|Placebo|
89293788|NCT01318486|Active Comparator|Heparin free dialysis standard of care|Standard of care: can be either saline flushes or predilution (on-line or bags)
89293789|NCT01318486|Experimental|Heparin free dialysis with Evodial|
89293790|NCT04226586|Active Comparator|Treatment Group|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.~Children in the treatment (intervention) arm will receive essential amino acids (EAA) twice a day.~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
89531563|NCT06054646|Active Comparator|Amnion Collagen|The right side of the split-face was treated by micro-injection of Amnion Collagen
89531564|NCT06054646|Active Comparator|PRP|The left side of the split-face was treated by micro-injection of Platelet-rich plasma (PRP)
89293791|NCT04226586|Placebo Comparator|Placebo|"This is a double-blind study. Participants and the investigators will be blinded to the intervention.~Children in the placebo arm will receive placebo twice a day. EAA and placebo supplements will look and taste alike. The same flavoring ingredients (stevia blend, citric acid, malic acid, natural flavors, tartaric acid, fruit and vegetable juice for color) will be used in both products at the same amount.~Children 3 to 5 years of age will be asked to take either 8.5 g (1 serving) of EAA supplement or placebo at breakfast and at bedtime.~Children 6 to 11 years of age will be assigned to take either 17 g (2 servings) of EAA supplement or placebo at breakfast and at bedtime.~EAA and placebo dissolve easily in any liquid beverage and can be taken on empty versus full stomach."
89293792|NCT00950118||Congenital Diaphragmatic Hernia (CDH)|Humans affected with congenital diaphragmatic hernia (CDH)
89293793|NCT00950118||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
89293794|NCT01237548||All participants|Normal People who have smoked Water-pipe, at least once before.
89293795|NCT01374256||Combination therapy|Patients with Acinetobacter baumannii bacteremia treated with combination therapy of imipenem and sulbactam
89293796|NCT01374256||Not combination therapy|Patients with Acinetobacter baumannii bacteremia not treated with combination therapy of imipenem and sulbactam
89293797|NCT01144806|Active Comparator|Group 1|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
89293798|NCT01144806|Active Comparator|Group 2|Ready to use therapeutic food (RUTF / PlumpyNut)will be provided to parent/care givers of children with severe malnutrition in enrolled in this group
89293799|NCT03436108||PCOS group|patients who have PCOS
89293800|NCT03436108||control group|patients who donnot have PCOS
89293801|NCT02969824|No Intervention|Usual Care Group|Following a brief period of physical and cognitive rest (typically1-7 days, depending on symptom severity and timing of spontaneous symptom abatement), the physician advises participants to increase their activity levels gradually with minimal head movement (predominantly involving a stationary bike) and progressively increase levels of exertion while remaining under the threshold of symptom exacerbation. Subsequently, exercise progressed to include a progression of head movements, visual and cognitive burdens, sport-specific activities, and heavy resistance, in that order, all below the symptom exacerbation threshold.
89293802|NCT02969824|Experimental|Supervised Exercise Group|These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Two of the sessions (i.e., first and mid-point) will be an in-person exercise sessions at the lab with a member of the research team while the remaining six sessions will be home-based exercise sessions with remote communication by phone (i.e., call or text) with a member of the research team. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
89293803|NCT03633916|Experimental|Intervention|Classroom sensitization session (plus school-level sensitization activities)
89293804|NCT03633916|Active Comparator|Control|School-level sensitization activities only
89293805|NCT02870218|Active Comparator|0.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
89293806|NCT02870218|Active Comparator|1.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
89293807|NCT02870218|Active Comparator|2.50mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
89293808|NCT02870218|Active Comparator|5.60mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
89293809|NCT02870218|Active Comparator|16.9mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
89293810|NCT02870218|Experimental|Halo G6 & Tribeca e-liquid|"Difference detection assessments.~Nicotine discrimination thresholds"
89293811|NCT02870218|Experimental|Spectrum Research Cigarette|"Difference detection assessments.~Nicotine discrimination thresholds"
89293812|NCT02614690|Active Comparator|No split Cast of forearm fractures|"Patient will have a No split cast long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm."
89293813|NCT02614690|Active Comparator|Univalve Split Cast of forearm fractures|"Patients will have a Univalve Split Cast long arm cast applied after undergoing closed reduction of of forearm fractures. This is a cast that is split on only one side of the cast. 20 patients will be randomized to this arm"
89293814|NCT02614690|Active Comparator|Bivalve Split Cast of forearm fractures|"Patients will have a Bivalve Split Cast long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast."
89293815|NCT02414386||Acute Kidney Injury - CRRT|Multi-organ failure with acute kidney injury critically ill patients admitted to the critical care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
89293816|NCT02414386||Control|Multi-organ failure non acute kidney injury critically ill patients admitted to the critical care unit. Multi-organ failure is defined as a respiratory and circulatory failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
89293817|NCT01374724|Experimental|Ban & Informational Pamphlet|Following 8.5 weeks of cessation subjects are given an informational pamphlet on tobacco cessation and relapse prevention.
89293818|NCT01374724|Experimental|Ban & Tailored Pamphlet|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force
89293819|NCT01374724|Experimental|Ban & Tailored Pamphlet & Intervention|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force. In addition they are given a face to face relapse prevention intervention.
89293820|NCT02387398|Experimental|Interventional|Early Angiography with purpose of coronary revascularization within 120 minutes of admission to ED, post out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG
89293821|NCT02387398|No Intervention|Control Group|Standard of care treatment including therapeutic hypothermia in subjects post resuscitation, out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG.
89293822|NCT01442194||Fingolimod|non-interventional
89293823|NCT01442194||parallel cohort|non-interventional
89293824|NCT00468130|Experimental|Aripiprazole|Subjects in the experimental group will receive Aripiprazole
89293825|NCT00468130|Placebo Comparator|Placebo|Subjects in the control group will receive sugar pill
89293826|NCT01374880||Dyspnea cohort|Dyspnea cohort
89293827|NCT01374880||Stable chronic heart failure|Stable chronic heart failure
89293828|NCT01374880||Valvular heart disease|Valvular heart disease
89293829|NCT01374880||Ventricular assist device|Ventricular assist device
89293830|NCT01374880||Cardiac arrest|Cardiac arrest
89293831|NCT01374880||Cardiac rehabilitation|Cardiac rehabilitation
89293832|NCT05197738||High risk OSA|"Cohort of individuals found to sleep have scores categorized as High risk, on the Berlin questionnaire."
89293833|NCT05197738||Low risk OSA|"Cohort of individuals found to sleep have scores categorized as Low risk, on the Berlin questionnaire."
89293834|NCT05197738||Short sleepers|Cohort of individuals found to have average sleep duration of < 7 hours per night. Individuals who sleep on average less than 6 hours per night will further be sub-categorized as very short sleeprs.
89293835|NCT05197738||Long sleepers|Cohort of individuals found to have average sleep duration of >9 hours per night.
89293836|NCT05197738||Average lengths leepers|Cohort of individuals found to have an average sleep duration between 7 and 9 hours per night
89293837|NCT05197738||Regular sleepers|Cohort of individuals whose standard deviation of sleep duration falls within 1 standard deviation of their mean sleep duration.
89293838|NCT05197738||Irregular sleepers|Cohort of individuals whose standard deviation of sleep duration falls greater than 1 standard deviation of their mean sleep duration
89293839|NCT05197738||Severe insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as severe
89293840|NCT05197738||Moderate insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as moderate
89293841|NCT05197738||No insomnia risk|Cohort of individuals whose scores on the Insomnia Severity Index would be categorized as low
89293842|NCT05197738||Increased social jet lag|Individuals who are more than 1 hour less or more of sleep on weekdays compared to average weekend sleep.
89293843|NCT05197582|Active Comparator|Tele-monitoring group|The researchers called the patients in the experimental group on the first day of the quarantine and explained the topics covered in the COVID 19 patient education booklet to the patients. Patient education and follow-up in quarantine took approximately 25-30 minutes for each patient in the experimental group. The patients in quarantine were followed up by the researchers two more times, on the 5th and 9th days of the quarantine. On the 10th and last day of the quarantine, post-test online questionnaires were sent to the patients for the second time, and the data collection phase was ended.
89293844|NCT05197582|No Intervention|Plasebo group|The patients in the control group were called by the researchers on the first day of the quarantine and asked to fill in the online pre-test forms. On the 10th day, the last day of the quarantine, the patients were called and the online post-test forms were sent for the second time, and the data were collected. There was no telephone follow up in the control group and the patients received only routine care in the home
89293845|NCT05197114|Experimental|Intervention|There will be one arm to the study, and all participants will be receiving the intervention.
89293846|NCT05196802|Experimental|mHeart.4u|The mHEART.4U intervention includes the use of an online Clinical Decision Support System (CDSS) for remote patient monitoring. According to the patient needs and profile, the CDSS will suggest a monitoring plan for the patient. The mHEART.4U kit will include mobile apps and wearables, such as heart rate, blood pressure, peripheral oxygen saturation (SpO2), sleep and step trackers, symptoms, lifestyle self-monitoring tools, medication reminders or motivational resources. The intervention length will be 6 months and will take into account the most recent guidelines on Cardiac Rehabilitation.
89293847|NCT05196802|No Intervention|Standard care|This arm will receive treatment and care according to the prevailing practice at each of the cardiac hospital units.
89293848|NCT05196724|Experimental|Mentalization Based Therapy (MBT)|MBT for foster carers is a 12 session therapeutic intervention that will be offered to foster families by municipal foster care consultants
89293849|NCT05196724|Active Comparator|Usual care|the control group will receive the usual care offered to foster families such as supervision
89293850|NCT05196490||Micro-CT|Samples were scanned before and after air polishing with a high-resolution micro-CT device. The scanning conditions were 100 kVp; 100-mA, 0.5-mm Al/Cu filter; 13.1-μm pixel size; and rotation at 0.2 steps. According to the manufacturer's instructions, each sample was rotated 360°. The mean scanning time was around 1hour.
89293851|NCT05196490||CAD/CAM|The teeth surfaces were digitalized before and after air polishing with an intraoral scanner. The mean scanning time was around 10 second. The virtual images of the scanned teeth were saved in stereolithography (STL) format.
89531565|NCT06052969|Experimental|Group/Cohort|Subjects presenting to the emergency department with AIS, eligible for thrombolytic therapy, and with evidence of an occlusive clot by angiographic imaging will be considered for inclusion in the study. Post-thrombolytic therapy and mechanical thrombectomy eligible Subjects will receive the experimental NanoMED device.
89531566|NCT06042842||group 1|healthy control
89531567|NCT06042842||group 2|patient with hepatic cell carcinoma
89531568|NCT06042842||group 3|patient with non malignant liver diseased
89293852|NCT05196256|Experimental|Dural Puncture Epidural group (DPE)|Dural puncture with a 25 Gauge needle, then placement of the epidural catheter (Tuohy 18 Gauge). The medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL, both administered epidurally with a programmed intermittent bolus mode (PIB) and patient controlled epidural analgesia (PCEA). An initial fractionated bolus of 20 mL will be administered epidurally, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40min. PCEA pump will allow 10 mL every 20 min, all along the dilatation and expulsion period.
89293853|NCT05196256|Active Comparator|Epidural group (EP)|Placement of an epidural catheter through a 18 Gauge Tuohy needle. The medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL, both administered epidurally with a programmed intermittent boluses mode (PIB) and patient controlled epidural analgesia (PCEA); An initial fraction bolus of 20ml will be administered epidurally, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40 min. PCEA pump will allow 10 mL every 20 min, all along the dilatation and expulsion period.
89293854|NCT05196256|Active Comparator|Combined Spinal-Epidural group (CSE)|Spinal injection through a 25 Gauge needle of Levobupivacaine 2.5mg and Sufentanyl 2.5 mcg in a total volume of 2 mL, placing an epidural catheter through a Tuohy 18 Gauge needle. The epidural medication consists of Levobupivacaine 0.0625% and Sufentanyl 0.25 mcg/mL. The epidural medication is administered on a programmed intermittent bolus mode (PIB) and patient controlled epidural analgesia (PCEA). An initial fractioned bolus of 20 mL will be administered epidurally 30 min after the intrathecal injection, then automatic intermittent bolus of 10 mL will be administered, the first one after 30 min and then every 40 min. PCEA pump will allow 10 mL every 20min, all along the dilatation and expulsion period.
89293855|NCT05196178|Experimental|Spinal cord stimulation therapy|Spinal cord stimulation at the thoracic levels ranging from T10 to T12.
89293856|NCT01375270|Experimental|Glucotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood glucose."
89293857|NCT01375270|No Intervention|Control Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest and isocaloric meal feeding."
89293858|NCT01375270|Experimental|Lipotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood free fatty acids."
89293859|NCT05195554|Experimental|Intervention group|The intervention groups will involve a psycho-educational intervention and will consist of between 10 and 12 people led by two professionals, one of whom must be a psychologist, while the other may be any professional in the center (usually social workers).
89293860|NCT05195554|No Intervention|Control group|Participants in the control group will receive information on suicide and advice if the suicidal ideation increases.
89293861|NCT01375348|Active Comparator|Remifentanil|"Investigate the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle pain induced by the tourniquet pain model~cognitive tests~recording of brain activity by use of 64 channel cap"
89293862|NCT01375348|Placebo Comparator|Placebo infusion|"To blind the study and use as comparator in the investigation of the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle induced pain by the tourniquet pain model~cognitive tests~brain activity by use of a 64 channel cap"
89293863|NCT05195086||Cyc group|
89293864|NCT05195086||MMF group|
89293865|NCT03633760|Experimental|Bilastine 40mg single dose|12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine
89293866|NCT03633760|Experimental|Bilastine 20mg multiple dose|12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9
89293867|NCT05194852|Active Comparator|group 1|Group I received ultrasound-guided hydrodilatation with corticosteroid, saline, and local anesthetic via posterior intra-articular approach
89293868|NCT05194852|Experimental|group 2|group II received the same ultrasound-guided hydrodilatation via anterior rotator interval approach
89293869|NCT05194774||GT overgrowth group|pediatric patients with greater trochanter overgrowth
89293870|NCT05194150|Experimental|Rayone EMV|Patient will receive the non-diffractive monofocal IOL during cataract surgery
89293871|NCT05194150|Experimental|Acrysof IQ Vivity|Patient will receive the standard EDOF IOL during cataract surgery
89293872|NCT05193838||Allopurinol|we plan to follow up effect of Allopurinol on left ventricular function in children with dilated cardiomyopathy for 6 months
89293873|NCT01375504|Active Comparator|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
89293874|NCT01375504|Other|Mindfulness Training Program|The mindfulness training program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
89293875|NCT05186116|Experimental|LDLT recipients|Patients that undergo LDLT for CRLM in the study period
89293876|NCT01375738|Active Comparator|Gastroduodenostomy|Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer
89293877|NCT01375738|Experimental|Roux-en Y gastrojejunostomy|Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer
89293878|NCT05173558|Experimental|Uninterrupted motionless standing|20minutes of uninterrupted motionless standing
89293879|NCT05173558|Experimental|Uninterrupted motionless sitting|20 minutes of uninterrupted motionless sitting
89293880|NCT05173558|Experimental|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
89531569|NCT06041945|Active Comparator|Standard Arm CADe|Standard, high-definition colonoscopy with the use of CADe assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION ,NEC). All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
88806174|NCT01454947|Experimental|SA, PC|Participants receive the Suggested Alternative and Peer Comparison interventions, but not the Accountable Justification intervention.
89293881|NCT01375816|Active Comparator|FOLFIRI 1 or m FOLFIRI3-Bevacizumab|"FOLFIRI 1-Bevacizumab:~Day 1 H0 : Bevacizumab 5 mg/kg, 30-90 min infusion H+1: Irinotecan 180 mg/m² in 250 ml NaCl 0.9%, 1h infusion Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) over 2h H + 3: 5-FU bolus 400 mg/m², 15 min infusion H + 3.5: 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14~modified FOLFIRI3-Bevacizumab H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H+1:Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion H+1: Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) 2-h infusion H + 3: 5-FU continuous infusion 2400 mg/m² 46-h infusion Day 3 (H+49) H0 Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion End of cycle: day 14"
89293882|NCT01375816|Experimental|FUPEP-Bevacizumab|"Day 1 H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H +1 :PEP02 80 mg/m² , 1h30 infusion. The infusion time could be reduced to 1h from cycle 2 if no acute infusion reaction has occured in cycle 1.~H +1 : Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) , 2-h infusion H +3 : 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14"
89293883|NCT05172154||15 subjects testing themselves|15 subjects 14 years of age and older
89293884|NCT05172154||15 subjects testing someone else|15 adult subjects testing individuals ages 2-13
89293885|NCT05167552|Experimental|Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells|Group 1: Patients with allergic rhinitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
89293886|NCT05167552|Experimental|Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells|Group 2: Patients with chronic polypous rhinosinusitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
89293887|NCT05167552|Active Comparator|Patients with allergic rhinitis receiving standard treatment|Group 3: Patients with allergic rhinitis receiving standard treatment
89293888|NCT05167552|Active Comparator|Patients with chronic polypous rhinosinusitis receiving standard treatment|Group 4: Patients with chronic polypous rhinosinusitis receiving standard treatment
89293889|NCT03632824|Experimental|interventional arm|Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid
89293890|NCT03632824|Placebo Comparator|comparative group|expectant management, including admission to hospital, ultrasound examination at least twice a week, regular blood coagulation tests, fetal wellbeing , frequent ultrasound performing for placenta location ,betamethasone administration for whom delivery was suspected
89293891|NCT05603962|Active Comparator|Stop training group|Home-base prism training during week 1-6 --> then stop training during week 7-12 --> endpoint data collected at week 12
89293892|NCT05603962|Experimental|Continune training group|Home-base prism training during week 1-12 --> endpoint data collected at week 12
89293893|NCT05403892||Participant|"The participants must be teenage basketball players (12-17 years old).~The exclusion criteria are:~have suffered in the last 3 months of lower limb musculoskeletal disorders such as pain for more than 7 days (ankle distortion outcomes, leg/foot fractures, plantar heel pain, metatarsalgias, etc);~athletes who have undergone surgery on their lower limb."
89293894|NCT00911820|Active Comparator|Arm A: PCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally, on days 1 and 8 of each cycle, patients received cisplatin 30 mg/m2 IV over 30 minutes and then irinotecan 65 mg/m2 IV over 30 minutes of each 3-week cycle. Treatment could continue until disease progression or unacceptable toxicity.
89293895|NCT00911820|Active Comparator|Arm B: TPCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally on days 1 and 8 of each cycle, patients received docetaxel 30 mg/m2 IV over 30 minutes followed by cisplatin 25 mg/m2 IV over 30 minutes and then irinotecan 50 mg/m2 IV over 30 minutes of each 3-week cycle.
89293896|NCT05348122|Experimental|TG103, 15 mg,Q2W|TG103 (15 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
89293897|NCT05348122|Experimental|TG103, 22.5 mg,Q2W|TG103 (22.5 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
89293898|NCT05348122|Placebo Comparator|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
89293899|NCT05348122|Experimental|TG103, 7.5 mg,QW|TG103 (7.5 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
89293900|NCT05348122|Experimental|TG103, 15 mg,QW|TG103 (15 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
89293901|NCT05348122|Placebo Comparator|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
89293902|NCT05348122|Active Comparator|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
89293903|NCT05038618|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89293904|NCT01237704|Active Comparator|Traditional rehabilitation (TR)|
89293905|NCT01237704|Active Comparator|Transcutaneous electrical stimulation (ES)|
89293906|NCT05031052|Experimental|Normothermic machine perfusion (NMP)|End-ischemic NMP will be performed immediately after arrival of the allocated and static cold stored ECD kidney graft. The study protocol aims a duration of 4 hours. Machine perfusion will be performed with a combination of patient's blood group matched packed red blood cells (RBC) and a special manufactured solution with the currently only certified device in Europe (XVIVO - KidneyAssist®). After 4 hours of perfusion and viability assessment, the kidney allograft will be disconnected from the device immediately prior to transplantation and flushed with three litres of Custodiol HTK solution via the renal artery. Then transplantation will be performed in typical method.
89293907|NCT05031052|Active Comparator|Statical cold storage (SCS)|Conventional method kidney transplantation of statical cold stored and transported ECD kidney allograft. The allocated kidney allograft will be flushed with Custodiol HTK solution during back table preparation with the aim of immediate implantation into recipient.
89293908|NCT01244880|Experimental|Saline/PF-02545920|Treatments are co-administered
89293909|NCT01244880|Experimental|Ketamine/PF-02545920|Treatments are co-administered
89293910|NCT01244880|Placebo Comparator|Saline/Placebo|Treatments are co-administered
89293911|NCT01244880|Experimental|Ketamine/Placebo|Treatments are co-administered
89293912|NCT01244958|Active Comparator|Rituximab 1000 mg|Administration of 1000 mg Rituximab in Part I, followed by either re-treatment with 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
89293913|NCT01244958|Placebo Comparator|Placebo|Administration of Placebo in Part I followed by re-treatment with either 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
89293914|NCT01240434|Active Comparator|Fascia closure of the surgical trocars|Arm in which all the surgical trocar orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone)
89293915|NCT01240434|No Intervention|Trocar site without closure|All the orifices of the trocar site are left open, closing only the skin.
89293916|NCT01245348||Schizophrenia|Patient with schizophrenia
89293917|NCT01245348||Bipolar|Patient with bipolar disorder
89293918|NCT00603642|Placebo Comparator|AMG 531|Double blinded placebo-controlled study
89293919|NCT00603642|Placebo Comparator|Placebo|
89293920|NCT00246324|Experimental|Single Arm|Interferon beta 1a, oral doxycycline
89293921|NCT05507788|Experimental|Cushion|Three seating conditons (Quadtro Select 10cm, Starlock 10cm, and Starlock 13cm)
89293922|NCT00102336|Experimental|AMG 531|Active investigational product
89293923|NCT00102336|Placebo Comparator|Placebo|
89293924|NCT01146210||Ancillary-correlative|Previously collected cryopreserved cells are analyzed via western blot to identify patients with Fanconi anemia.
89293925|NCT01237782|Experimental|Propolis solution|A proprietary denture cleanser with propolis as the active agent.
89293926|NCT01237782|Placebo Comparator|Saline solultion|Physiologic saline solution.
89293927|NCT05152680|Experimental|[14C]-NV-5138|[14C]-NV-5138 oral solution
89293928|NCT03632668|Experimental|Sequence 1|Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
89293929|NCT04860726|Experimental|GROUP A|Joint mobilization
89293930|NCT04860726|Experimental|GROUP B|Myofascial release
89293931|NCT04860726|Experimental|GROUP C|Joint Mobilization & Myofascial release
89293932|NCT04876690||All Participants|Participants diagnosed with CD and CPF in the Portuguese routine clinical practice will be assessed. Retrospective data on healthcare resource utilization related with CPF management in the previous three years will be obtained from the medical records.
89293933|NCT01245660|Experimental|Patient|
89293934|NCT03693768|Experimental|Health coaching ARM|Participants in this ARM will undergo health coaching for 4 months.
89293935|NCT03686904|Placebo Comparator|SOC GROUP [Cohort A]|Debridement, SOC irrigation & SOC topical gel
89293936|NCT03686904|Active Comparator|SOC TOPICAL GEL & TORRENT X GROUP [Cohort B]|Debridement, benzalkonium irrigation & SOC topical gel
89293937|NCT03686904|Active Comparator|BLASTX and SALINE (SOC) GROUP [Cohort C]|Debridement, SOC saline irrigation & benzalkonium gel
89293938|NCT03686904|Active Comparator|BLASTX and TORRENTX GROUP [Cohort D]|Debridement, benzalkonium irrigation & benzalkonium gel
89293939|NCT04627168|Experimental|Spinal cord injured persons|Persons living with spinal cord injury presenting with constipation due to neurogenic bowel dysfunction.
89293940|NCT04627168|Experimental|Persons without neurogenic bowel dysfunction|Abled-bodied persons with chronic constipation.
89293941|NCT04461964|Experimental|treatment group|Eligible participants will be identified by their treating physician and referred to the study research coordinator for enrollment. NYU standard practice in relation to pre-operative and intra-operative imaging studies will be explained. The role of the MvIGS system in this study will then also be explained. In each subject, they will perform posterior instrumentation utilizing the MvIGS spine navigation system for pedicle screw guidance and record data for intraoperative study endpoints
89293942|NCT03913806|Experimental|Treatment group|Bevacizumab-IRDye800CW
89293943|NCT04807608||Healthy Users|Each subject will be provided with a wearable device (smartwatch EmbracePlus manufactured by Empatica), to be worn every day outside of work hours for a total of 6 weeks. After the 6 weeks of data collection the participant will be asked to fill an online questionnaire related to the system usability (max 20 min).
89293944|NCT04380922||Active IBD|"Active Inflammatory Bowel Diseases defined as :~For Crohn's disease :~Harvey Bradshaw Index ≥ 4~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy or in imaging within 3 months For Ulcerative colitis~Partial Mayo score ≥ 2~Associated with fecal calprotectin rate > 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy within 3 months"
89293945|NCT04380922||Non-active IBD|Non-active Inflammatory Bowel Diseases
89293946|NCT01146678|Experimental|Lantus(insulin glargine)/lixisenatide on-site mix|Single dose injection of an on site mix of Lantus U100 and lixisenatide (800µg/mL in Lantus U100) at one peri-umbilical site under fasting conditions
89293947|NCT01146678|Active Comparator|lixisenatide + Lantus (insulin glargine)|Single dose, separate injection simultaneous injections of Lantus U100 and lixisenatide (100µg/mL) at opposite peri-umbilical sites within 1 minute under fasting conditions
89293948|NCT01241526|Experimental|Disease management program|
89293949|NCT01241526|Active Comparator|Usual site management|
89293950|NCT05417464|Other|Management of conductive disorders after TAVR|Evaluation of efficacy and safety of a flowchart for screening, monitoring and management of conductive disorders after TAVR
89293951|NCT03913338|Other|Study group|LASIK followed by intraoperative application of riboflavin under the flap and crosslinking after reposition of the flap.
89293952|NCT03913338|Other|Control group|LASIK only
89293953|NCT03913494|Experimental|4 Week Snoozeal Use|Participants will take the device home and be required to use it for 20 minutes morning and night every day for at least 4 weeks. The SnooZeal records usage time to allow assessment of compliance.
89293954|NCT01250886|Placebo Comparator|Normal saline solution|Blood sample is obtained from patient in either forearm immediately before a Normal saline solution administered on the same site. The volume of fluid administration is calculated by means of Holliday and Segar formula.
89293955|NCT01250886|Active Comparator|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
89293956|NCT01250886|Active Comparator|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
89293957|NCT03632590|Experimental|Magnesium Citrate|450 mg of Magnesium Citrate per day
89293958|NCT03632590|Experimental|Magnesium Sulfate|450 mg of Magnesium Sulfate per day
89293959|NCT03632590|Experimental|Magnesium Oxide|450 mg of Magnesium Oxide per day
89293960|NCT03632590|Placebo Comparator|Placebo|
89293961|NCT05667480|Experimental|VR-based script training|
89293962|NCT05667480|Active Comparator|Conventional script training|
89293963|NCT01250964|Active Comparator|Wound-assisted lens injection|Wound-assisted lens injection is considered neither superior or inferior to wound-directed lens injection.
89293964|NCT01250964|Active Comparator|Wound-directed lens injection|Wound-directed lens injection is neither considered superior nor inferior to wound-assisted lens injection.
89293965|NCT03913416|Experimental|3D|Surgery with surgeon trained using a 3D printed model of the pulmonary malformation.
89293966|NCT03913416|Other|Control group|Conventional surgery without training using a 3D printed model of the pulmonary malformation.
89293967|NCT01242774|Experimental|Panobinostat|
89293968|NCT05630742||Interstitial Cystitis|patients with an existing diagnosis of BPS/IC. BPS/IC was confirmed by reviewing medical record.
89293969|NCT05630742||control group|patients with chronic non-neoplastic pain, suffering from fibromyalgia or other types of chronic pain (chronic arthralgia or lower back pain).
89293970|NCT04716192|Experimental|Positional release technique|Positional release technique, Mayofascial release technique and ultrasound
89293971|NCT04716192|Active Comparator|Mayofascial release technique and ultrasound|Mayofascial release technique and ultrasound
89293972|NCT01146444|Experimental|sunscreens with a low, medium, high SPF|sunscreens with a low, medium, and high SPF. UVA and UVB irradiation
89293973|NCT01146444|Experimental|vehicle|Intra-individual application of vehicle in random order; UVA and UVB irradiation
89293974|NCT01243086|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
89293975|NCT01243086|Active Comparator|Ranibizumab and OZURDEX|Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections. Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
89293976|NCT01243554|Experimental|Exercise training|Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
89293977|NCT01243554|No Intervention|Control|Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive
89293978|NCT01246830||3D cephalometric analysis|
89293979|NCT01246830||2D cephalometric analysis|
89293980|NCT01247376|No Intervention|No Cooling and compression|
89293981|NCT01247376|Experimental|Intervention with cooling and compression|
89293982|NCT03908814|Experimental|Drug: LDP|"This is a dose-escalation trial, all participants will receive treatment with LDP. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.~Cohort 1: 0.1 mg/kg Cohort 2: 0.3 mg/kg Cohort 3: 1 mg/kg Cohort 4: 3 mg/kg Cohort 5: 10 mg/kg Cohort 6: 10 mg/kg"
89293983|NCT01253382|Active Comparator|ecallantide|
89293984|NCT01253382|Placebo Comparator|placebo|phosphate buffered saline
89293985|NCT01147614|Active Comparator|specialty mental health care referral|
89293986|NCT01147614|Experimental|Brief Cognitive Behavioral Therapy|
89293987|NCT01148160||1|Patients with hematologic malignancies who were given voriconazole to treat invasive (pulmonary) aspergillosis at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
89293988|NCT03913572||REVOLVE|Patients that have agreed to be prospectively enrolled in the study and undergo Injection of adipose-derived stem cells into perianal fistula with the REVOLVE system
89293989|NCT03913572||Retrospective cohort|Patients that have undergone treatment of perianal disease without use of adipose-derived stem cell injection.
89293990|NCT03913260|Experimental|Part A: LY3375880 Formulation A|LY3375880 Formulation A administered subcutaneously (SC).
89293991|NCT03913260|Experimental|Part A: LY3375880 Formulation B|LY3375880 Formulation B administered subcutaneously SC.
89293992|NCT03913260|Experimental|Part A: LY3375880 Formulation C|LY3375880 Formulation C administered SC.
89293993|NCT03913260|Placebo Comparator|Part A: Positive Control|Positive Control (buffer matrix, only) administered SC.
89293994|NCT03913260|Experimental|Part B: LY3375880 Test 1|LY3375880 Test 1 Formulation administered SC.
89293995|NCT03913260|Experimental|Part B: LY3375880 Test 2|LY3375880 Test 2 Formulation administered SC.
89293996|NCT03913260|Experimental|Part B: LY3375880 Test 3|LY3375880 Test 3 Formulation administered SC.
89293997|NCT03908424||CONTROL|Parturients who gave birth to a normal birth and did not receive epidural anesthesia.
89293998|NCT03908424||Normal Epidural|Parturients who gave birth to a normal birth with epidural anesthesia without an unintentional dural puncture.
89293999|NCT03908424||PDPH conservative treatment|Parturients who gave birth to a normal birth with epidural anesthesia and had an unintentional dural puncture, these women were treated conservatively.
89294000|NCT03908424||PDPH treated with Blood Patch|. Parturients who had a normal birth with epidural anesthesia and had an unintentional dural puncture and were treated with a blood patch following PDPH.
89294001|NCT01251198||Acute coronary Syndrome|Patients affected are patients with acute coronary syndrome with ST segment elevation ST (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance, intensive care unit, cardiac catheterization lab).
89294002|NCT01147692|Experimental|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
89294003|NCT03913182|Experimental|apatinib group|apatinib：500mg po Qd
89294004|NCT02528292||Active Rheumatoid Arthritis|Patients with active Rheumatoid Arthritis with a DAS 28 score of greater than 5.1 and eligible for anti-TNF alpha therapy according to National Institute for Clinical Excellence guidelines will be recruited in this study
89294005|NCT05625750||Patients diagnosed with NAFLD|All subjects will receive the currently recognized routine test of NAFLD according to their disease and no additional intervention and treatment will be added for subjects
89294006|NCT03908190|No Intervention|Treatment As Usual|Participants will receive treatment as usual within the VHA Women's Wellness Clinic including any appropriate treatment or treatments for their medical and psychosocial concerns as determined by their primary care teams.
89294007|NCT03908190|Experimental|Treatment As Usual Plus Personalized Support for Progress|In addition to treatment as usual, women will receive the Personalized Support for Progress intervention.
89294008|NCT03913026|Experimental|Main intervention|Eligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved.
89294009|NCT02713386|Active Comparator|Arm I (paclitaxel and carboplatin)|See Detailed Description.
89294010|NCT02713386|Experimental|Arm II (ruxolitinib, paclitaxel, and carboplatin)|See Detailed Description.
89294011|NCT01253616|Experimental|VNS plus tones|
89294012|NCT01967238|Active Comparator|Biologic/Vaccine, Age 18-64 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
89294013|NCT01967238|Active Comparator|Biologic/Vaccine, Age 65-80 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
89294014|NCT01967238|Active Comparator|Vaccine, healthy adults|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
89294015|NCT05616000|Experimental|Acetyl-L-Carnitine group|Acetyl-L-Carnitine (2gm once a day), folic acid 5mg (once a day) 43 Patients with Primary Infertility will receive Acetyl-L-Carnitine (2gm once a day) orally& folic acid 5mg orally was given to all the participants of this group (once a day).
89294016|NCT05616000|Experimental|Control group|Coenzyme Q10 (400mg once a day) orally was given to all participants& folic acid 5mg (once a day) was also given orally to these participants 43 Patients with Primary Infertility will receive Coenzyme Q10 (400mg once a day), folic acid 5mg (once a day).
89294017|NCT03908112|Active Comparator|Standard Community Concussion Care (SC)|Standard concussion care consists of physical and cognitive rest immediately following the injury for a brief period of time to allow symptoms to abate, followed by a gradual reintroduction of academic and physical activities, restricting activities at high risk for repeat brain injury (such as contact or collision sports) until a graded return to play protocol has been completed in a symptom-free manner.
89294018|NCT03908112|Experimental|SC plus Simple Convergence Procedures (SC+)|In addition to the treatment described for SC, participants in this group will be asked to work with the Brock String, which is a popular and simple therapy technique designed to improve convergence. A 3-phase, graded Brock String procedure has been developed for ICONICC.
89294019|NCT03908112|Experimental|SC plus Office-based Vergence/Accommodative Therapy (SC+VAT)|Office-based vergence accommodative therapy (OBVAT) is administered by a study certified therapist at weekly intervals (60-minute office visits with 55 minutes of therapy time), combined with procedures to practice at home for 15 minutes, 5 times per week.
89294020|NCT01251432||chronic otitis media|adults who have had tympanostomy tube(s) inserted for chronic otitis media
89294021|NCT01251432||Eustachian tube dysfunction|adults who have had tympanostomy tube(s) inserted for the clinical diagnosis of Eustachian tube dysfunction
89294022|NCT01148238||Diabetes type 1 older than 10 years|Blood samples will be taken from 10 patients with diabetes type 1 older than 10 years and 10 healthy age-and sexmatched controls.
89294023|NCT01148238||Newly diagnosed type 1 diabetes|Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes and 10 healthy age-and sexmatched controls.
88806175|NCT01454947|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternative intervention.
88806176|NCT01454947|Experimental|Peer Comparison (PC)|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
89294024|NCT01148238||LADA|Blood samples will be taken from 10 patients with LADA and 10 healthy age-and sexmatched controls.
89294025|NCT03907722||Genotypic variants|AA, AG and GG genotype
89294026|NCT03912480|Experimental|Stem cells from human exfoliated teeth|"Basic treatment:~The original treatment regimen was maintained. During the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped or patients still had frequent hypoglycemia).~Stem cell therapy:~Dosage: Stem cells from human exfoliated teeth were calculated at 0.11IU/kg body weight .~Course of treatment: 3 times, Injections were administered at enrollment, 2 weeks after enrollment, and 6 weeks after enrollment.~Note: at 1 month follow-up (V5) after the last transplantation of several cells, the subjects were still unable to discontinue insulin, and then began the second course of stem cell therapy.After the second course of treatment, the follow-up plan was resumed."
89294027|NCT01248546||Digital mammography|
89294028|NCT03907956|Experimental|INTERVENTION|The subjects included in the intervention group will be treated with Dry Needling with Fascial Winding Technique according to the original Four-Pole Carpal Dry Needling approach, which has already been validated recently by means of a first ultrasound study.
89294029|NCT03907956|No Intervention|CONTROL|The individuals of the control group will remain within the normal course of their waiting list status for CTS surgery, without receiving any extraordinary treatment to what is normally practiced in this situation.
89294030|NCT03912714|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy in therapy refractory ulcerative colitis patients after pre-operative endoscopic biopsies of the appendix
89294031|NCT03912714|Active Comparator|Non-active UC|Patients with non-active ulcerative colitis planned for surveillance colonoscopy will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
89294032|NCT03912714|Active Comparator|Healthy control|'Healthy control' patients (i.e. patients planned for colonoscopy for polyps) will have additional endoscopic appendix biopsies to evaluate the histological characteristics of the appendix.
89294033|NCT03912402|Experimental|BCD-100|BCD-100 mg/kg Q3W
89294034|NCT03908034|No Intervention|Uncontrollable factor ABSENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5 (Hong Kong dollars). Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
89294035|NCT03908034|Experimental|Uncontrollable factor ABSENT; anticipated regret induced|"Same description as in the uncontrollable factor absent, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
89294036|NCT03908034|Experimental|Uncontrollable factor PRESENT; NO anticipated regret induced|"The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5. Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.~There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points."
89294037|NCT03908034|Experimental|Uncontrollable factor PRESENT; anticipated regret induced|"Same as the uncontrollable factor present, no anticipated regret induced arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease."
89294038|NCT01147770|Experimental|stop progesterone|
89294039|NCT01148316|Active Comparator|Fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
89294040|NCT01148316|Active Comparator|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
89294041|NCT01251510||Healthy adults|
89294042|NCT01251510||Type 2 diabetes|
89294043|NCT03912168|Experimental|Question Prompt List|
89294044|NCT03912168|Active Comparator|3 questions list|
89294045|NCT03916380|No Intervention|Group A|Tacrolimus Extended Release + Midazolam
89294046|NCT03916380|Active Comparator|Group B|Tacrolimus Extended Release + Midazolam + Grapefruit Juice
89294047|NCT03907254|Experimental|National Capital Region (NCR)|10-week longitudinal pre-post study, in which each participant will serve as their own control. Each participant will train a service dog using methods that facilitate a relationship between the trainer and dog for the gradual shaping of desired behavior. Self-report measures of behavioral symptoms will be given weekly throughout participation in this study. Biological measures, including blood collection, HR, BP, etc. will be collected at baseline, during the three-week training follow-up, during the six-week training follow-up, and at a three-month post-training follow-up. The researchers will also be collecting self-report assessments from the participant, observational reports from an Occupational Therapist (OT) and electronic health records to track healthcare utilization and social skills (i.e. communication).
89294048|NCT03915990|Other|control group|60 healthy pregnant women will be included
89294049|NCT03915990|Active Comparator|controlled diabetics|30 diabetic pregnant women with controlled Diabetes (i.e. HbA1C less than 6.5 %)
89294050|NCT03915990|Active Comparator|uncontrolled diabetics|30 diabetic pregnant women with uncontrolled Diabetes (i.e. HbA1C equal or more to 6.5 %)
89294051|NCT01249638|Experimental|Cap+Bev until PD followed by CAPIRI +Bev|"Capecitabine + Bevacizumab~In case of Progression Escalation to:~Capecitabine + Irinotecan + Bevacizumab"
89294052|NCT01249638|Active Comparator|Capiri + Bev|Capecitabine + Irinotecan + Bevacizumab
89294053|NCT01251666|Other|Magstream + Oc Sensor + Hemoccult II|"Each patient will perform all three tests:~Magstream: 2 samples (each on a different stool)~OC Sensor: 2 samples (each on a different stool)~Hemoccult II: 6 samples (2 samples per stool, on 3 different stools)~Each test will be considered as positive if at least one sample is positive (cutoff for Magstream 55 ng/ml and for OC Sensor 150 ng/ml).~Screening will be considered as positive if at least one of the three tests is positive, leading to a colonoscopy"
89294054|NCT03907098|Experimental|endostar + chemotherapy|"Endostar 15 mg per square of BSA, continuous intravenous infusion 24 hours a day, continuous administration for 7 days, every three weeks.~Chemotherapy regimens are selected by physicians based on regular clinical decision."
89294055|NCT03915756|Experimental|With drain|Participants who received a drain during surgery
89294056|NCT03915756|No Intervention|Without drain|Participants who did not receive a drain during surgery
89294057|NCT01148394|No Intervention|Traditional|Involves traditional management of patients with preoperative mechanical bowel preparation, no preoperative education, nasogastric tube, delayed feeding and mobilisation, use of drains
89294058|NCT01148394|Active Comparator|Multimodal rehabilitation|Involves preoperative patient education, no preoperative mechanical bowel preparation, no nasogastric tube, early oral feeding and mobilisation, physiotherapy
89294059|NCT03915834||endovascular treatment group|
89294060|NCT01251822|Experimental|PEG 3350|PEG 3350 plus electrolytes in solution plus placebo tablets
89294061|NCT01251822|Active Comparator|Prucalopride|Prucalopride tablets plus placebo solution
89294062|NCT01253694|Experimental|Patients with 3-5 consecutive Avastin injections|These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
89294063|NCT01253694|Experimental|Patients with 6 or more consecutive injections of Bevacizumab|Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.
89294064|NCT03911934|Active Comparator|Usual care|Usual care in the geriatric outpatient clinic.
89294065|NCT03911934|Experimental|Usual care plus polypharmacy intervention|Usual care in the geriatric outpatient clinic plus polypharmacy intervention. Polypharmacy intervention consists of a medication review by a physician from the Department of Clinical Pharmacology plus additional communication with patients' GPs before and after the visit in the outpatient clinic.
89294066|NCT03906864|No Intervention|Control group|Usual care consisted of 2 half hourly therapy sessions per day from Monday to Friday and medical ward rounds 3 times a week. Multidisciplinary rounds were conducted every 2 weeks. Any specific goals or interventions were at the discretion of the managing team.
89294067|NCT03906864|Experimental|Intervention group|Intervention group had structured assessments and checklists (as part of the integrated care pathway) in addition to usual care.
89294068|NCT03906942|Experimental|Fun For Wellness (FFW)|Participants assigned to the FFW group (i.e., FFW participants) will proceed through the pre-operative program provided by the center and will be given 4 weeks of 24 hr access to the FFW online intervention during data collection for this study. Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being and/or physical activity.
89294069|NCT03906942|No Intervention|Usual Care (UC)|Participants assigned to the UC group (i.e., UC participants) will proceed through the pre-operative weight management program provided by the center.
89294070|NCT03906786|Experimental|motivacional interviewing group|
89294071|NCT03906786|No Intervention|control group|
89294072|NCT01250106|Experimental|Probiotic capsule|
89294073|NCT01250106|Placebo Comparator|placebo capsule|
89294074|NCT01252056|No Intervention|Control|
89294075|NCT01252056|Active Comparator|Probucol|Probucol treatment
89294076|NCT01252056|Active Comparator|Combination|Probucol and Cilostazol
89294077|NCT03906552|Experimental|acupressure group|"2 neonates did not calm down before heel lancing; oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well.~Acupressure was performed when the mother was holding the neonate on her arm. For two minutes, acupressure was performed in the acupressure points (Kun Lun (UB60) and Taixi (K3). Each point was applied acupressure for 60 seconds, and heel lancing was performed right after this procedure. The acupuncture points that Kun Lun (UB60) and Taixi (K3) are on the side of the ankle."
89294078|NCT03906552|Experimental|masssage group|"oxygen saturation and heart rate values of 2 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).~Foot massage was performed when the mother was holding the neonate on her arm. Each neonate was given foot massage for two minutes, and heel lancing was performed right after the massage."
89294079|NCT03906552|No Intervention|control group|"oxygen saturation and heart rate values of 1 neonates could not be monitored because the pulse oximeter tool probe was not fastened well; heel lancing could not be performed at the first attempt (2 neonates).~No application was made to theneonates in the control group before heel lancing procedure"
89294080|NCT03906630||Shoulder patients|
89294081|NCT03906396|Experimental|Intervention Group|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant for 6 weeks, 3 times per week. Games use for the activity are Sports Kinect and Sports Kinect 2. The activity can be performed in solo or in pairs with another participant. The game activity will be played only at the site chosen for this study.
89294082|NCT03906396|No Intervention|Control Group|No standard activity is provided for the participants. The participants will continue with their normal daily life activities.
89294083|NCT01252212|Experimental|Receiving SMS alerts|The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
89294084|NCT01252212|Active Comparator|No SMS messages|The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
89294085|NCT03911544|Active Comparator|TIVA anesthesia with BIS monitoring|The depth of anesthesia will be adjusted with the help of BIS monitoring.
89294086|NCT03911544|No Intervention|TIVA anesthesia without BIS monitoring|The depth of anesthesia will adjusted as in standard practice (clinical signs of poor anesthesia such as increase in blood pressure and/or heart rate, tearing and profuse sweating)
89294087|NCT03911310|Experimental|PET/CT 1: [18F]PSMA-11, PET/CT 2: [68Ga]PSMA-11|Patients in this arm will first receive the experimental radiotracer [18F]PSMA-11 PET/CT followed by the [68Ga]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
89294088|NCT03911310|Active Comparator|PET/CT 1: [68Ga]PSMA-11, PET/CT 2: [18F]PSMA-11|Patients in this arm will first receive the experimental radiotracer [68Ga]PSMA-11 PET/CT followed by the [18F]PSMA-11 PET/CT after at least 4 days and maximum 3 weeks.
89294089|NCT01250262|Active Comparator|Standard care|Subjects will receive normal medical care and follow up during the four month study period if assigned to this group.
89294090|NCT01250262|Active Comparator|Isolated Lumbar Resistance Exercise Program|Lumbar extension exercise protocol to increase strength and reduce pain.
89294091|NCT01250262|Active Comparator|Total Body Resistance Exercise Program|Training protocol for 1 set for each exercise: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl
89294092|NCT02528448|Active Comparator|plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
89294093|NCT02528448|Active Comparator|0,9% saline|Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
89294094|NCT03915522|Experimental|Adductor Canal Block|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a single adductor canal block wiht 20cc of 0.5% Ropivacaine using ultrasound guidance .
89294095|NCT03915522|Placebo Comparator|Placebo Comparator|Patients will receive multi-modal analgesia (oral, intravenous and local infiltration anesthesia) for pain management following total knee arthroplasty and in the first postoperative day a sham adductor canal block with 2ml of 1% subcutaneous lidocaine at the level of the adductor canal using ultrasound guidance.
89294096|NCT03915600|Experimental|Quinoa|Personalized diet added with quinoa
89294097|NCT03915600|Experimental|Flaxseed|Personalized diet added with Flaxseed
89294098|NCT03915600|Experimental|Quinoa and Flaxseed|Personalized diet added with quinoa and flaxseed
89294099|NCT03915600|No Intervention|Normal diet|Personalized diet without dietary supplement
89294100|NCT03915288|Experimental|Group continuous training at moderate intensity|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity - MICT (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).~Regarding the MICT training, this was done with fast walk or jog in endless band with the floor tilted to reach the desired intensity. Also by bicycle, rowing and elliptical. During the entire intervention the participants was monitored by a Polar Multisport RS800CX, oximetry and with the Borg scale to avoid exceeding the training intensity (60-80% FCM, 6 to 8 Borg)."
89294101|NCT03915288|Experimental|Group high Intensity Interval Training|"Training program lasting 36 weeks with assistance 3 times a week with 70 minutes per intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60 -80% FCM), 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. And the last 10 minutes were for cooling (exercises coordination, balance, walking and breathing exercises).~Concerning the HIIT training, it consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group, which we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%)."
89294102|NCT03915288|Active Comparator|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities. It is highlighted that in the institutions where the patients of the 3 groups attended, there is not a physical training area supervised by a professional. Therefore, the intervention protocol was not excluded or denied to the participants of the control group, but continuity and supervision was given for investigative purposes to its process and treatment. In addition, none of the 3 groups stopped their medical treatment or that of the other professionals that make up the interdisciplinary team.
89294103|NCT01148472|Experimental|Escitalopram|
89294104|NCT01148472|Active Comparator|Duloxetine|
89294105|NCT01250340|Experimental|Aspirin|100 mg/day for 30 days
89294106|NCT01250340|Placebo Comparator|Placebo|1 cp /day for 30 days
89294107|NCT03914898|Experimental|Nurse led intervention group|"The program was four sessions; It took about 1.5-2 hours. The intervention group was divided into two groups. The author who administered the intervention previously led nurse support groups, is also an active educator in psychiatry and mental health nursing, and has training in cognitive behavioral therapy.~The group sessions were based on cognitive restructuring techniques."
89294108|NCT03914898|No Intervention|Control Group|No intervention was applied to the control group during the study.
89294109|NCT03915054|Active Comparator|AREG-TRIGGER|"Per case (6mL) 5940 µL Basal Medium~60 µL IVM MIX Do not need to filtrate media."
89294110|NCT03915054|Active Comparator|CONTROL-TRIGGER|Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
89294111|NCT03915132|Experimental|VMAT plus Nimotuzumab|Patients receive Nimotuzumab weekly during radiotherapy .
89294112|NCT01250574||Postoperative infections|
89294113|NCT01250574||Bacterial infections in the GI tract|
89294114|NCT01250652|Active Comparator|Levocetirizine|24 patients will received 20 mg Levocetirizine daily
89294115|NCT01250652|Experimental|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
89294116|NCT03911232|Experimental|Enhanced recovery|rocuronium 2 effective dose at anesthesia induction sugammadex after skin incision and before extubation (total 2 mg/kg iv)
89294117|NCT03911232|No Intervention|Conventional anesthesia|standard general anesthesia protocol (1 effective dose of rocuronium at anesthesia induction)
89294118|NCT01252368||RAS active drugs|ACE inhibitors and sartanes
89294119|NCT01252368||healthy participants|
89294120|NCT03910842|Experimental|CD19-TriCAR-T/NK（SILK）|CD19-TriCAR-T/SILK cells will be administered intravenously
89294121|NCT01252446||ADHD|The sample of 187 children and adolescent in the age of 6 to 17 years referred to the Child and Adolescent Clinic, Haugesund, Norway during the period of one year and diagnosed in ICD 10 system as ADHD.
88806177|NCT01454947|Experimental|Suggested Alternatives (SA)|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
88806178|NCT01454947|Experimental|Accountable Justification (AJ)|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
89294122|NCT03910608|Experimental|DLPFC+10 IPL|Stimulation of dorsolateral prefrontal cortex (DLPFC) 10 ms before inferior parietal lobule (IPL) presumes that the DLPFC to IPL input facilitates insula postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
89294123|NCT03910608|Experimental|IPL+10 DLPFC|Stimulation of IPL 10 ms before DLPFC presumes that the IPL to DLPFC input inhibits insula postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
89294124|NCT03910608|Experimental|IPL+4 DPLFC|Stimulation of IPL 4 ms before DLPFC is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula inhibits insula postsynaptic output by weakening the IPL to insula input, thereby impairing cognition response.
89294125|NCT03910608|Experimental|DLPFC+4 IPL|Stimulation of DLPFC 4 ms before IPL is presumed to be too brief for a corticocortical effect but presumes that the DLPFC input to insula potentiates insula postsynaptic output by strengthening the IPL to insula input, thereby improving cognition response.
89294126|NCT03910608|Experimental|DLPFC+4 MPFC|Stimulation of DLPFC 4 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
89294127|NCT03910608|Experimental|MPFC+4 DLPFC|Stimulation of MPFC 4 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
89294128|NCT03910608|Experimental|DLPFC+10 MPFC|Stimulation of DLPFC 10 ms before medial prefrontal cortex (MPFC) presumes that the DLPFC input facilitates MPFC postsynaptic output activity, thereby improving cognition response via a long term potentiation-like effect.
89294129|NCT03910608|Experimental|MPFC+10 DLPFC|Stimulation of MPFC 10 ms before DLPFC presumes that the DLPFC input inhibits MPFC postsynaptic output activity, thereby impairing cognition response via a long term depression-like effect.
89294130|NCT03906474|Experimental|Group 1|A third blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to two blood-stage challenges in the VAC063 trial. Group 1 will be challenged in parallel with Groups 2 (undergoing a second challenge) and 3 (malaria-naïve controls).
89294131|NCT03906474|Experimental|Group 2|A second blood-stage controlled human P. falciparum malaria infection will be administered to individuals who have previously been exposed to one blood-stage challenge in the VAC063 trial. Group 2 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 3 (malaria-naïve controls).
89294132|NCT03906474|Experimental|Group 3|Malaria-naïve controls will receive a primary blood-stage controlled human P. falciparum malaria infection. Group 3 will be challenged in parallel with Groups 1 (undergoing a third challenge) and 2 (undergoing a second challenge).
89294133|NCT03906084|Active Comparator|Corticotomy facilitated orthodontics.|Corticotomy is carried out under local anesthesia in right side.
89294134|NCT03906084|Experimental|Corticotomy and low level laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
89294135|NCT01253928|Active Comparator|Pioglitazone 45mg per day|Pioglitazone 45mg qd will be added to the current treatment
89294136|NCT01253928|Placebo Comparator|placebo|placebo qd will be added to current treatment
89294137|NCT03910686|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
89294138|NCT03910686|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
89294139|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
89294140|NCT03910686|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
89294141|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
89294142|NCT03910686|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
89294143|NCT03906006|Experimental|ABP-671, Cohort 1-|ABP-671, Cohort 1 participants received 50 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
89294144|NCT03906006|Experimental|ABP-671, Cohort 2-|ABP-671, Cohort 2 participants will receive 0.1 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
89294145|NCT03906006|Experimental|ABP-671, Cohort 3-|ABP-671, Cohort 3 participants will receive 0.5 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
89294146|NCT03906006|Experimental|ABP-671, Cohort 4-|ABP-671, Cohort 4 participants will receive 1.0 mg ABP-671 single agent or placebo during dose escalation (6 active: 2 placebo).
89294147|NCT01252524|Placebo Comparator|Placebo|A placebo tablet PO TID before each meal with 8 oz of water for 6 months.
89294148|NCT01252524|Experimental|Calcium polycarbophil|Calcium polycarbophil 625 mg PO TID before each meal with 8 oz of water for 6 months
89294149|NCT03914586||Septic patients with AKI|Patients with sepsis /septic shock ( Sepsis III ) and AKI submitted to Continuous Renal Replacement Therapy with the adsorbing membrane oXiris.
89294150|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured dairy|
89294151|NCT03914430|Experimental|Breakfast meal with granola cereal and cultured non-dairy|
89294152|NCT03914430|Experimental|Water|Energy-free control
89294153|NCT03905850|Experimental|Somapacitan 5/10/10 mg|One dose of somapacitan 5 mg/1.5 ml followed by two doses of somapacitan 10 mg/1.5 ml. Each dose will be followed by a 3 week observation period.
89294154|NCT03905850|Experimental|Somapacitan 10/5/10 mg|One dose of somapacitan 10 mg/1.5 ml followed by a 5 mg/1.5 ml dose followed by a 10 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
89294155|NCT03905850|Experimental|Somapacitan 10/10/5 mg|Two doses of 10 mg/1.5 ml somapacitan followed by a 5 mg/1.5 ml dose. Each dose will be followed by a 3 week observation period.
89294156|NCT03906162|Experimental|Motivational interviewing|Experimental content + base intervention
89294157|NCT03906162|Active Comparator|Control intervention|Base intervention
89294158|NCT03910374|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
89294159|NCT03910374|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
89294160|NCT03914352|Experimental|PD-1 antibody group|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
89294161|NCT03914352|Active Comparator|Controlled group|In this group entrolled patients were treated with TACE in the 30 days after hepatic resection.
89294162|NCT03914274|No Intervention|"Thermometer FTN Medisana, precision 0.18º C),"|"Temperatures were taken with an infrared thermometer FTN Medisana, precision 0.18º C.~The temperature will be taken into account to see if it will vary according to the socket used as the temperature is a favoring element of dermic injuries on the feet."
89294163|NCT03914274|No Intervention|Non-elastic tape measure|"Perimeter was measured with a flexible, non-elastic tape measure Lawton 18-0160, precision 1 mm.~The measurement of the feet perimeters will be taken into account to see if it will vary according to the socket used and related to injuries in the feet."
89294164|NCT03914274|No Intervention|Bascule|"Weight was measured using scales (Tanita UM-076, precision 0.1kg). The scale is used to control the weight of the participants in order to find out their body mass index since the weight can influence the appearance of lesions on the feet."
89294165|NCT03914274|No Intervention|Altimeter|"Height was measured using the weight rod of different scales SECA 704, precision 1 mm) The altimeter is used to measure the participants in order to find out their body mass index."
89294166|NCT03914274|Experimental|Socks|"Socks were of two types: technical socks, designed for high performance sports use Lurbel brand, models Tierra and Set, and non-technical socks for everyday use. The socks had different composition: Tierra:50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra; Set:75% cotton, 17% polyamide, 8% lycra and cotton: 98% cotton, 2% elastane.~Different socks were given to the participants to see if the different compositions influenced the appearance of injuries in a short route route and little difficulty"
89294167|NCT03914274|No Intervention|"Geographical Position System Garmin ETREX 20"|"The height range and the pace hikers were controlled with a Garmin ETREX 20X Geographical Position System"
89294168|NCT03914040|Experimental|IPSE program|IPSE is conceptually divided in two phases: 1) pre-immersion preparation, 2) immersion.
89294169|NCT03914040|No Intervention|Traditional course|Participants in the control group will receive the current face-to-face course.
89294170|NCT02528136|Experimental|Carbetocin|One minute injection of carbetocin 100 µg after the delivery of the baby
89294171|NCT02528136|Active Comparator|Oxytocin|One minute injection of oxytocin 2.5 U after the delivery of the baby
89294172|NCT01252602||Prenatally depressed|Women who tested positive for prenatal depression with a score of > 12 on the Edinburgh Postnatal Depression Scale
89294173|NCT01252602||Not Prenatally Depressed|Women who tested not depressed on the prenatal depression scale with a score < 13
89294174|NCT01252680|Experimental|Group 1: Healive+Healive|75 subjects to receive two doses of Healive 6 months apart
89294175|NCT01252680|Experimental|Group 2: Healive+Havrix|75 subjects to receive one dose of Healive and another dose of Havrix 6 months apart
89294176|NCT01252680|Experimental|Group 3: Havrix+Havrix|75 subjects to receive two doses of Havrix 6 months apart
89294177|NCT01252680|Experimental|Group 4: Havrix+Healive|75 subjects to receive one dose of Havrix and another dose of Healive 6 months apart
89294178|NCT05667402|Experimental|TBF group|The subjects receive TBF conditioning regimen.
89294179|NCT05667402|Active Comparator|Modified BuCY2 group|The subjects receive modified BuCY2 conditioning regimen.
89294180|NCT03910062||VA ECMO|Patients under VA-ECMO with a femoral reperfusion cannula.
89294181|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 1|
89294182|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 2|
89294183|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 3|
89294184|NCT01252758|Placebo Comparator|placebo|
89294185|NCT01252758|Active Comparator|Ventolin HFA dose 1|
89294186|NCT01252758|Active Comparator|Ventolin HFA dose 2|
89294187|NCT03913962|Experimental|Patient|Patients with juvenile idiopathic arthritis, type 1 diabete mellitus, inflammatory bowel diseases, anorexia nervosa, cancer survivor
89294188|NCT03913962|Active Comparator|Control|healthy children sex- and age-matched
89294189|NCT03913884|Experimental|Concentrated growth factor Group|Group I (test); in which CGF fibrin matrix was applied to the extraction socket
89294190|NCT03913884|Experimental|Non-Concentrated growth factor Group|Group II (control); in which CGF was not applied to the extraction socket
89294191|NCT01147224||ATEM|A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
89294192|NCT03909984|Other|Intervention|All participants will be monitored for 2 months.
89294193|NCT03905616|Experimental|healthy subjects|25 healthy subjects with a normal/corrected vision fitting to all of the inclusion/exclusion criteria. All the subjects will be tested on the same visual stimuli, leading to intrasubject comparison analyses of functional magnetic resonance imaging (fMRI) activity between conditions.
89294194|NCT03910140|Experimental|TILA-TACE group|
89294195|NCT03913650|Active Comparator|Nerve block(+)|patient accept nerve block for post-op pain control
89294196|NCT03913650|Sham Comparator|Morphine|patient received morphine for post-op pain control
89294197|NCT03905304|Experimental|Meditoxin|Meditoxin administered 200U~300U, single-dose administration.
89294198|NCT03905304|Active Comparator|Botox|Botox administered 200-300U, single-dose administration.
89294199|NCT03903510|Experimental|Virtual Reality|Participants will experience Virtual Reality during their cast removal
89294200|NCT03903510|No Intervention|Standard of care|Participants will receive their usual standard of care treatment during cast removal
89294201|NCT03909906|Active Comparator|Euphytose®|Euphytose® 2 tablets 3 times per day for 14 days
89294202|NCT03909906|Placebo Comparator|Placebo|Matched placebo 2 tablets, 3 times per day for 14 days
89294203|NCT05571540|Experimental|U-CAR-T Cells (LstCAR019)|Subjects who meet the enrollment conditions will receive intravenous infusion of U-CAR-T Cells (LstCAR019) after lymphodepletion.
89294204|NCT03909672|Experimental|Cupping therapy with 2 suctions|Participants in the intervention group will receive the application of cupping therapy with two acrylic type 1 cups with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally. This group will consist of the application of windsheets with 2 suctions for 10 minutes, once a week, for 10 weeks. The cups shall be secured by means of elastic bands.
89294205|NCT03909672|Placebo Comparator|Cupping Therapy sham|"The placebo group will receive the application of cupping therapy with 2 cups of acrylic type size 1 with a distance of 3 cm each cup, parallel to the vertebrae L1 to L5, bilaterally . This group will consist of applying the sham winds for 10 minutes, once a week for 10 weeks.~However, the cups will be made with small holes <2 mm in diameter to release the negative pressure in seconds. The cups will also be fixed by means of elastic bands."
89294206|NCT01149174|No Intervention|transurethral resection alone|Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
89294207|NCT01149174|Active Comparator|intravesical mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
89294208|NCT01149174|Experimental|electromotive mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection
89294209|NCT01252836|Placebo Comparator|Control|Treatment with Tegaderm
89294210|NCT01252836|Experimental|AWBAT-D|Application of AWBAT-D on donor site.
89294211|NCT01254084|Placebo Comparator|Placebo tea|Dietary Supplement: Placebo tea 3 gram twice daily, orally
89294212|NCT01254084|Active Comparator|Gynostemma pentaphyllum Tea|Gynostemma Pentaphyllum tea 3 grams twice daily, orally
89294213|NCT01252992||1:paradoxical reaction negative (RP-)|control group with tuberculosis but without paradoxical reaction
89294214|NCT01252992||1:paradoxical reaction negative (RP+)|group with tuberculosis and paradoxical reaction
89294215|NCT03903432|Other|45 participants, in one center - Assuta|Patients with chronic sinusitis who are scheduled to undergo ESS at Assuta will be recruited and patients will sign an informed consent form for performing MRI (new protocol-without gadolinium injection) in addition to the routine CT.
89294216|NCT03903276|No Intervention|Control|assessment of pain scale and functional capacity
89294217|NCT03903276|Experimental|Experimental|assessment of pain scale and functional capacity, TENS 30 minutes 3 sessions
89294218|NCT04711408|Experimental|Virtual reality|women allocated to undergo ultrasound for the diagnosis of endometriosis with Virtual reality System
89294219|NCT04711408|No Intervention|Standart care|women allocated to undergo ultrasound for the diagnosis of endometriosis without VR
89294220|NCT01148628|Experimental|RAD 001 in combination with CaelyxTM|"RAD001 will be given p.o. at increasing doses (no intra-patient)and CaelyxTM will be administered i.v. at a fixed dose.~At each dose level 3 to 6 patients will be entered, according to toxicities observed; the first 3 patients can be treated simultaneously; subsequent patients can be treated after the first 3 have been observed for at least one cycle (4 weeks).~The dose escalation process will be discontinued once the MTD has been achieved and the RD will be evaluated in a subsequent expansion part of the study."
89294221|NCT01254708|Active Comparator|Control|Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
89294222|NCT01254708|Experimental|liposomal amphotericin B (AmBisome ®)|Inhaled Liposomal preparation of Amphotericin B.
89294223|NCT01254786|Active Comparator|CPAP2 - HFPPV group|the non-dependent lung will be ventilated with CPAP of 2 cm H2O for 30 min followed with HFPPV for min.
89294224|NCT01254786|Active Comparator|HFPPV-CPAP2 group|the non-dependent lung will be ventilated with HFPPV for 30 min followed with CPAP of 2 cm H2O for 30 min.
89294225|NCT03909594|Experimental|Nerve Block with Bupivacaine an|Patients will receive an ultrasound guided regional nerve block with Bupivacaine (0.5% or 5 mg/ml) 2.5 mg/kg (max dose 175 kg) + Ketamine (50 mg/ml) 2 mg/kg. Each patient will be given a volume of 40 mL - this will be a mixture of Bupivacaine, Ketamine and 0.9% NS to make up the full 40 ml.
89294226|NCT03909594|Active Comparator|Nerve Block with Bupivacaine al|Patients will receive an ultrasound guided regional nerve block with Bupivacaine 0.5% only. Each patient will be given a volume of 40 ml - this will be a mixture of Bupivacaine and 0.9% NS to make up the full volume of 40 mL
89294227|NCT04636762|Experimental|Treatment (etoposide, cisplatin, carboplatin, radiation, Atezolizumab)|Participants receive EC/EP chemotherapy combined with Atezolizumab（ PD-L1 inhibitor）for 2 cycles, and the efficacy is evaluated 2 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent chemoradiotherapy with EC/EP(2 cycles) + Atezolizumab） will be initiated. After concurrent chemoradiotherapy+ Atezolizumab, Atezolizumab was maintained until PD or intolerance or for at most 2 years. Participants with brain metastases will receive radiotherapy forbrain metastases during the first 2 cycles of chemotherapy.
89294228|NCT04529980|Experimental|Lactobacillus rhanmosus GG(LGG®) Group|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health. As such, this dietary supplement is not reviewed and approved by the FDA. This study does not intend to investigate route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the dietary supplement. Patients in the treatment group will receive a standard dose of Lactobacillus rhamnosus GG capsule following their surgery while in the hospital until discharge.
89294229|NCT04529980|Placebo Comparator|Placebo Control Group|Patients in the placebo group will receive a placebo capsule following their surgery while in the hospital until discharge.
89294230|NCT03904992|No Intervention|Non-exposed|Subjects with access to nutritional counseling sessions every 30 days
89294231|NCT03904992|Experimental|Exposed|Subjects with access to the progressive web app in their smartphones.
89294232|NCT04492072|Experimental|Oxytocin with Mechanical Dilation|"If the patient is randomized to Cook Balloon and Oxytocin - The balloon inflated to 60cc will be placed and oxytocin 2 mu/min will be initiated, and increased incrementally by 2mu/min every 30 minutes. If the cook cannot be placed initially, it will be reattempted and placed within 6 hours of oxytocin starting. The Cook catheter will remain in place until spontaneously expelled, or if not, after 12 hours of placement.~If a Cook Balloon is not available, a Foley catheter can be used in its place as alternate and equivalent form of mechanical dilation."
89294233|NCT04492072|Active Comparator|Misoprostol with Mechanical Dilation|If the patient is randomized to Misoprostol and Cook balloon - she will be given 25mcg of misoprostol orally or buccal and a Cook Balloon inflated to 60cc will be placed. She will subsequently receive 50mcg oral or buccal misoprostol every 4 hours up to 4 doses. If regular contractions occur (three or more contractions in a 10-minute period), the patient will be switched to Oxytocin 2 mu/min, and increased incrementally by 2mu/min every 30 minutes. If the cook balloon cannot be placed initially, it will be reattempted and placed within 6 hours of induction start. The Cook catheter will remain in place until spontaneously expelled, or at the fourth misoprostol administration. At this point, oxytocin will be started if not already initiated and artificial rupture of membranes will occur
89294234|NCT03909516|No Intervention|Standard of Care|"Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded."
89294235|NCT03909516|Active Comparator|Standard of Care + iovera° Treatment|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded.~Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events.~Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
89294236|NCT03909360|Experimental|drainage|Placement of subhepatic drainage tube for laparoscopic cholecytetomy
89294237|NCT03909360|No Intervention|no drainage|no placement of subhepatic drainage tube for laparoscopic cholecytetomy
89294238|NCT03909126|Experimental|Montreal Region of Quebec|Vaccination with Boostrix at time of gestational diabetes screening in a hospital setting
89294239|NCT03909126|No Intervention|Montérégie|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
89294240|NCT03909126|Experimental|Maurice Region|Vaccination with Boostrix of pregnant women receiving routine care at high volume clinic
89294241|NCT03909126|No Intervention|National Capital|Vaccination with Boostrix of pregnant women receiving routine care at the CLSC or regular clinic
89294242|NCT03905382|Other|Qualitaitve|Qualitaitve
89294243|NCT01568164|Experimental|Device Treatment|Treatment with the investigational device.
89294244|NCT03909048|Experimental|Interactive Psycho-education|Interactive psycho-education using interactive dashboard.
89294245|NCT03909048|Placebo Comparator|Psycho-education|Non-interactive psycho-education not using interactive dashboard.
89294246|NCT04181008|Experimental|0.2 mg|
89294247|NCT04181008|Experimental|0.4 mg|
89294248|NCT04181008|Experimental|0.6 mg|
89294249|NCT03902886||cerebral palsy infants|gait analysis
89294250|NCT03902886||typically developed infants|gait analysis
89294251|NCT01254162|Experimental|Placebo Gel|
89294252|NCT04396132|Experimental|Virtual SVV|The subjects will be tested by virtual SVV. The deviation angle will be measured at 15, 30 and 45-degree head tilt to the left and right side while they are standing
89294253|NCT03905070||Study Group|The study group consisted of people who had undergone bariatric surgery and who had at least 6 months after the operation.
89294254|NCT03905070||Control Group|The control group will consist of asymptomatic individuals whose BMI is 18-25 kg / m2 and has not participated in any exercise program in the last one year.
89294255|NCT03902730|Other|Back Squat Variation One|In a randomized order, traditional back squat will be completed.
89294256|NCT03902730|Other|Back Squat Variation Two|In a randomized order, barefoot back squat will be completed.
89294257|NCT03902730|Other|Back Squat Variation Three|In a randomized order, box squat will be completed.
89294258|NCT03902730|Other|Back Squat Variation Four|In a randomized order, traditional back squat with chains will be completed.
89294259|NCT03632278|Experimental|Mindfulness psychoeducation programme|A MBPP will be conducted for 2 hours for each session, one a week for ten weeks, with 13-15 participants per group. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).
89294260|NCT03632278|No Intervention|Treatment as usual|"The usual care group will receive routine psychiatric outpatient services, including monthly psychiatric consultation and treatment by a psychiatrist, psychiatric nursing advice and brief education according to the patient's psychosocial needs. There will be community mental health services, social welfare or financial assistance supported by medical social workers, whenever necessary.~Participants in this control may be aware that they are receiving no extra treatment which may result in negative expectancies and inflation of the treatment effect (Stoney & Johnson, 2012). To eliminate the time effect and artificially inflated intervention effect, patients in the control group will receive telephone contact once a week to discuss their disease process and daily issues."
89294261|NCT03902496|Experimental|Avulux Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
89294262|NCT03902496|Sham Comparator|Sham Spectacles|Subjects will be instructed to use the spectacles for three weeks. They will be instructed to put the spectacles on at the first signs or symptoms of their migraine attacks. This could be their usual aura, or the first signs of their headache commencing, and to keep the spectacles on until their headache has resolved.
89294263|NCT03908658|Active Comparator|Inspiratory Muscle Training and Nasal High Flow|Inspiratory Muscle Training will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Nasal High Flow will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
89294264|NCT03908658|Active Comparator|Inspiratory Muscle Training and Venturi mask|IMT will start as soon as the patient wakes up and is cooperative, ventilated with support settings. Venturi mask will be applied immediately after extubation. IMT intervention will continue until patient's discharge from the ICU
89294265|NCT03904836|Experimental|Tobramycin|Subjects with end-stage renal disease who have been involved in an intermittent hemodialysis program and who have suspected or diagnosed Gram-negative rod-type infection
89294266|NCT04234984||Conventional radiofrequency (RF) treatment|All patients with chronic knee pain who qualify for a conventional RF treatment of the genicular nerves
89294267|NCT03908580|Experimental|Meditoxin®|Botulinum toxin type A was intramuscularly injected up to 360U and up to 4 sites, depending on the muscle size.
89294268|NCT01254240|Experimental|UVA/B phototherapy treatment|UVA/B phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
89294269|NCT01254240|Active Comparator|UVB phototherapy treatment|UVB phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
89294270|NCT05340400||Patients diagnosed with IBS|Collaborators will use Rome IV criteria for diagnosing IBS, and then divide participants into those with and without the disease.
89294271|NCT05340400||Patients not diagnosed with IBS|Collaborators will use Rome IV criteria for diagnosing IBS, and then divide participants into those with and without the disease.
89294272|NCT03904680|Active Comparator|Methotrexate|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week for 3 months.
89294273|NCT03904680|Active Comparator|Methotrexate and Vitamin D|15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week and Vitamin D intramuscular injections with the dose of 200,000 IU per month for 3 months.
89294274|NCT01150266|Experimental|Alteplase|Alteplase 0.9mg/kg (maximum 90mg), 10% IV bolus over 1 minute and the remainder over one hour infusion in patients with ischemic stroke after awaking.
89294275|NCT01256268|Experimental|Endometrial Cancer|Phase 1A + Cohort 1B - Recurrent or Metastatic Endometrial Cancer. Patients with recurrent or metastatic endometrial cancer with up to 1 prior chemotherapy. Ridaforolimus at the Phase 1A MTD and schedule will be administered with paclitaxel at the Phase 1A MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
89294276|NCT01256268|Experimental|Ovarian Cancer|Phase 1 A + Cohort 1B - Recurrent or Metastatic Ovarian Cancer. Patients with platinum-sensitive, recurrent ovarian cancer with up to 2 prior chemotherapy regimens. Ridaforolimus at the phase 1A MTD and schedule will be administered with paclitaxel at the phase 1 MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
89294277|NCT01256346||Babies|Preterm newborn infants thought to be 24-32 weeks gestational age.
89294278|NCT01149252|Placebo Comparator|Psoralait|
89294279|NCT01255020|Active Comparator|α-Keto Acid plus restricted protein diet|Participants randomized to this group will receive 12 months treatment of α-Keto Acid. The dose of α-Keto Acid is 100mg/kg per day and will divided into three times per day, and the α-Keto Acid will be asked to be taken during the meal. In addition, the participants will be asked to restrict the protein intake. The protein intake is restricted as 1g/kg/d.
89294280|NCT01255020|Placebo Comparator|Placebo plus restricted protein diet|All participants will receive 12 months treatment of placebo, at the same time they will be asked to restrict the protein intake.The dose of placebo is 100mg/kg per day, and the protein intake is restricted as 1g/kg/d.
89294281|NCT01148706|Experimental|ActiSight Needle Guidance System|
89294282|NCT01148784|Active Comparator|Quadrupled Hamstring Allograft|
89294283|NCT01148784|Active Comparator|Doubled Tibialis Anterior Allograft|
89294284|NCT03902106|Active Comparator|beta2-agonist and exercise|Subjects undergo exercise training with administration of salbutamol (800 microgram in 12 hours x 2)
89294285|NCT03902106|Sham Comparator|placebo and exercise|Subjects undergo exercise training with administration of sham placebo
89294286|NCT03902340|Experimental|TENS|Treatment by non-pharmacological transcutaneous electric nerve stimulation (TENS)
89294287|NCT03902340|Active Comparator|level 2 systemic analgesic treatments|Treatment by level 2 analgesic pharmacological treatment indicated in the treatment of chronic nociceptive pain of moderate to severe intensity.
89294288|NCT01149330|Experimental|Adapalene-BPO Gel|
89294289|NCT04365790||Patients with triple-negative breast cancer|Patients with histologically confirmed triple-negative breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
89294290|NCT04365790||Patients with HER2+ positive breast cancer|Patients with histologically confirmed HER2+ breast adenocarcinoma with high risk of recurrence. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.
89294291|NCT03901872||Acute Iliofemoral DVT|Suitable patients would be invited to take part in this trial as part of standard of care.
89294292|NCT03632122||Bothersome back pain|The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
89294293|NCT02527980||dual users|Individuals who at the point of study enrollment are using both electronic cigarettes (ecig) and commercial cigarettes (CCs)
89294294|NCT02527980||commercial cigarette (CC) only users|Individuals who at the point of study enrollment are using exclusively commercial cigarettes
89294295|NCT01568242|Experimental|Thermoprobe|Determination of vitreous temperature with a thermoprobe
89294296|NCT03898518|No Intervention|Control Group|The control group was in the facility for all jump rope exercise sessions but did not participate in the exercise intervention.
89294297|NCT03898518|Experimental|Experimental Group|The experimental group performed the jump rope exercise intervention.
89294298|NCT01150344|Active Comparator|Malarone|"Malarone (atovaquone + proguanil combination):~patients treated with Malarone®"
89294299|NCT01150344|Active Comparator|Riamet|"RIAMET (artemether + LUMEFANTRIN combination):~patients treated with Riamet®"
89294300|NCT02865070||2 infants (ages 1-6mo) non-NICU setting|
89294301|NCT02865070||10 babies (full term, ages 37-42 weeks)|
89294302|NCT02865070||5 babies (premature, ages 34-37 weeks)|
89294303|NCT02865070||5 babies (premature, ages 31-34 weeks)|
89294304|NCT02865070||5 babies (premature, ages 28-31 weeks)|
89294305|NCT02865070||5 babies (premature, ages 25-28 weeks)|
89294306|NCT02865070||5 babies (premature, ages 23-25 weeks)|
89294307|NCT02865070||30 babies (any gestational age under 6 months)|
89294308|NCT02865070||25 neonates (ages 24-29 weeks for sub-study)|
89294309|NCT01150422|No Intervention|Standard of care for post medical abortion follow-up|Standard of care includes a routine hospital visit two weeks after mifepristone administration. At the hospital visit, the woman will undergo a bimanual and vaginal ultrasound examination. In the event the woman fails to return for the follow-up visit, each hospital will follow their standard procedure for contacting women who fail to attend their follow-up visit, i.e. three efforts to contact the woman. Form 2a will document the results of any clinical examinations, any additional medical abortion-related care given and the abortion outcome. At the follow-up visit, women will also be asked about the acceptability of current medical abortion follow-up procedures and their future preferences.
89294310|NCT01150422|Active Comparator|Alternative follow-up|"At their first clinic visit, women will be asked to provide their phone number for contact purposes. Women will also be asked to complete a semi-quantitative pregnancy test in the clinic and the results of the test will be noted on a study form. After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist.~Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned date two weeks after mifepristone administration. The checklist will indicate that if the woman answers yes to any of the questions, then she should return to the clinic for a follow-up visit. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests."
89294311|NCT05759884|Experimental|anti-VEGF combined SML therapy group|The patients were treated with intravitreal injection of anti-VEGF drugs and SML therapy.
89294312|NCT05759884|Active Comparator|anti-VEGF single therapy group|Only intravitreal injection of anti-VEGF drugs was given to patients.
89294313|NCT01150578||Lexi-Echo pilot|Appropriate patients at University of Arizona Medical Center stress imaging laboratory who have a routine regadenoson SPECT nuclear scan will have simultaneous cardiac echo images obtained.
89294314|NCT05759806|Experimental|ADHF patients|ADHF patients with compromised response to diuretics treated with Nephronyx system
89294315|NCT01256580|Active Comparator|Monotherapy|Bevacizumab (Avastin; Genentech, Inc.)1.25 mg by intravitreal injection on day 0 and then prn (as-needed) based on ophthalmic examination and OCT findings
89294316|NCT01256580|Active Comparator|Combination therapy|Intravitreal injection of bevacizumab 1.25 mg (Avastin; Genentech, Inc.) combined with reduced fluence PDT(Visudyne®; Novartis,) and 200 ug of intravitreal dexamethasone(4mg/ml, American regent, Inc) on Day 0 and then monthly retreatment with bevacizumab as-needed and triple therapy every 3 months as-needed.
89294317|NCT01255098||Experimental Group|
89294318|NCT01255098||Control Group|
89294319|NCT03901794||With Clear Sight|record and observe the data including SVI, CI, SVR with clearSight during hemodialysis
89294320|NCT02658136|Other|1 arm study: CCT estimated right ventricular function.|By use of Cardiac computed tomography, the ejection faction of the right ventricle will be visualized and measured in all participants.
89294321|NCT03901716|Experimental|Sufentanil|Group S received sufentanil 0.1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
89294322|NCT03901716|Experimental|Fentanyl|Group F received fentanyl 1 mcg/kg and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
89294323|NCT03901716|Experimental|Remifentanil|Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml and midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
89294324|NCT04113538|Active Comparator|Standard|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed by an injection every 8 weeks until the end of the study
89294325|NCT04113538|Experimental|Treat and Extend|2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed and, until the end of the study, retreatment interval based on disease stability
89294326|NCT03904368|Active Comparator|Myomectomy group|women with intramural myoma not reaching endometrial cavity will undergo open myomectomy followed by ovarian stimulation for in vitro fertilization 6 months after the operation
89294327|NCT03904368|Active Comparator|Conservative group|women with intramural myoma not reaching endometrial cavity will undergo ovarian stimulation for in vitro fertilization
89294328|NCT03898206|Experimental|Prolonged sitting|Participants will remain seated for 5 h and instructed to reduce excessive movement, only rising from the chair to void.
89294329|NCT03898206|Experimental|Breaking up sitting with walking breaks|Participants will rise from the seated position every 30 min throughout the experimental period to walk on a motorised treadmill at a light intensity walking (as determined during the preliminary test) for 3 min. Participants will start walk on a treadmill at 30 min (so physical activity would be at 30-33 min), 60 min (physical activity will be at 60-63 min), 90 min (physical activity will be at 90-93 min), 120 min (physical activity will be 120-123 min), 150 min (physical activity will be at 150-153 min ), and 180 min (physical activity will be at 180-183 min) in the breakfast postprandial period and 30 min (physical activity will be 30-33 min), 60 min (physical activity will be at 60-63 min), and 90 min (physical activity will be at 90-93 min) in the lunch postprandial period. After performing walking activity, they will return to the seated position.
89294330|NCT03922750|Experimental|Insulin 287 (with 100% loading dose)|Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
89294331|NCT03922750|Experimental|Insulin 287 (without loading dose)|Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.
89294332|NCT03922750|Active Comparator|Insulin glargine U100|Participants will receive insulin glargine U100 once daily (OD).
89294333|NCT03903978|Experimental|CORE condition|CORE is a 6-week web-based prevention programme whose main objective is to teach coping skills and strategies to cope with stressful everyday situations in order to improve resilience, promote self-efficacy and increase well-being. The intervention consists of 6 interactive modules designed for weekly sessions and organized in 6 dimensions: autonomy, self-acceptance, environmental mastery, purpose in life, positive relationships, and personal growth. Each module includes exercises to practice the proposed skills. The program includes multimedia elements: videos, audios, vignettes, images.
89294334|NCT03903978|Active Comparator|Healthy lifestyle|This program will provide information to promote a healthy lifestyle, on issues related to physical and mental health and physical activity, as well as diet and sleep management. The components of psychoeducation are based on the intervention protocol for depression (Castro, et al. 2015) based on low intensity psychological intervention models for mild or moderate depressive symptoms in primary care (Garcia-Herrera et al 2011; NICE, 2009; Nieuwsma et al 2012).
89294335|NCT03903978|No Intervention|Waiting List Control|Participants assigned to the Waiting List control group will be evaluated and monitored at the start of the study, 4 weeks, 8 weeks and follow-ups at 3 months. After the last follow-up evaluation, they will be given access to CORE training.
89294336|NCT03897894|Experimental|Enhanced Service Package|"The enhanced service package provides 40 sequential sessions selected by CFS program staff in advance and implemented over a twelve-week period. Activities are meant to build upon and reinforce one another and are organized into seven psychosocial themes: 1) Building community: Our space together, 2) Emotional learning: My feelings, 3) Wellbeing and coping: Feeling good, 4) Social support: My friends and family, 5) Relating to others: Being a good friend, 6) Protection and boundaries: My safety, and 7) Building on strengths: All my supports. Each session takes approximately 1.5 - 2 hours to facilitate and will conclude with 1-1.5 hours unstructured free play time."
89294337|NCT03897894|Experimental|Basic Service Package|The basic service package offers a mixture of recreational and non-formal education activities over a twelve-week period. Each session lasts around 1.5 - 3 hours. Structured activities offered include basic literacy and numeracy lessons, life skills exercises, health and hygiene sessions, and traditional song and dance. Many activities are centered around various forms of play that enable expression and age-appropriate skill development. Unstructured free play and playground time is allocated throughout the daily session.
89294338|NCT03897894|No Intervention|Control|Waitlist control will receive delayed treatment of intervention after the primary assessment period.
89294339|NCT01150812|Experimental|1|
89294340|NCT01149408|Experimental|All patients|All participants enrolled.
89294341|NCT01255176|No Intervention|placebo group|not receive physical therapy intervention, there will only support the achievement of a handbook on the abdomen of the baby.
89294342|NCT01255176|No Intervention|control group|not receive any type of intervention, and infants remain at rest
89294343|NCT01255176|Experimental|Thoracoabdominal rebalancing|infants who receive physical therapy through the application of the handlings of the RTA.
89294344|NCT01568398|Experimental|TAK-438 20 mg QD|
89294345|NCT03631966|Experimental|BTX-A injection|
89294346|NCT03904212|Active Comparator|Adipose tissue injection|Patients will be treated with freshly harvested autologous adipose tissue
89294347|NCT03904212|Placebo Comparator|Placebo|Patients will be treated with saline
89294348|NCT03901326|Experimental|CTA/CT-FFR care group|If the subjects are randomly allocated to CTA/CT-FFR arm, they will be examined by DeepFFR for three major epicardial arteries. If CT-FFR value of one or more major coronary arteries is less than 0.75, ICA will be performed directly; if CT-FFR is 0.75-0.8 (including 0.8), physicians will decide whether to start intensive drug therapy or ICA; if CT-FFR value is more than 0.8, only drug therapy will be needed. The clinical management plan will be suggested including optimal medical therapy, ICA, PCI, CABG and other intervention according to the result of this non-invasive examination.
89294349|NCT03901326|No Intervention|routine clinically-indicated diagnostic care group|If the subjects are randomized to CID arm, attending physicians will decide next step of diagnosis and treatment, such as exercise ECG, stress cardiac echo, SPECT. According to the results of examination combined with risk factors assessment and clinical manifestations, physicians should provide recommendation whether the subjects would undergo ICA or not.
89294350|NCT03897972|Active Comparator|Non-personalised general diet advice|Control group to receive non-personalised dietary advice based on general public health dietary recommendations for Northern Europe. Advice will be delivered to the participant via the eNutri web application.
89294351|NCT03897972|Experimental|Personalised diet advice|Intervention group to receive personalised dietary advice generated by the eNutri app from their actual dietary intakes and tailored according to their body mass index and food preferences. Advice will be delivered to the participant via the eNutri app web application and will be generated based on their adherence to an 11-item diet quality score suitable for Northern European populations.
89294352|NCT01149018|Experimental|Tetrahydrocannabinol|
89294353|NCT01149018|Placebo Comparator|Placebo|
89294354|NCT03903900|Experimental|Intervention group|Adults with chronic pain (n=48) matching the inclusion and exclusion criteria will be included.
89294355|NCT03901248||Normoglycemia|Participant with normal blood glucose level with No Intervention
89294356|NCT03901248||Impaired Glucose Tolerance|Participants with Impaired Glucose Tolerance blood glucose level with No Intervention
89294357|NCT03901248||Type 2 Diabetes|Newly diagnosed type 2 diabetes patients with No Intervention
89294358|NCT03900936||Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
89531703|NCT05667038|Placebo Comparator|Placebo arm|The placebo sachets containing only the excipients, i.e., maize starch and maltodextrins, weights 3g. The placebo was indistinguishable in color, smell, and taste from the probiotic formulation.
89294359|NCT03904056|Active Comparator|ETDRS-PRP group|Patients with proliferative diabetic retinopathy submitted to panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
89294360|NCT03904056|Experimental|ISQ-RP group|Patients with proliferative diabetic retinopathy submitted to retinal photocoagulation targeted to ischemic retina combined with intravitreal injection of ranibizumab (IVR) if angluofluoresceinography demonstrated the presence of actively leaking retinal neovascularization or SD-OCT demonstrated a CSFT of more than 300 µm.
89294361|NCT01256736|Experimental|Tocilizumab 8mg/kg + DMARDs|
89294362|NCT03903588||Normal|Eyes judged as age-appropriate normal as determined by an Investigator and that meet applicable inclusion/exclusion criteria.
89294363|NCT03903588||Glaucoma|Eyes that have been diagnoses with Glaucoma
89294364|NCT03903588||Retinal Disease|Eyes that have been diagnoses with a Retinal Disease
89294365|NCT01256814|Experimental|Behaviorial Intervention|SystemCHANGE-HIV is a 10-week, small-group intervention that will promote behavior changes to improve the following: physical activity, sleep behaviors and mental wellness. S
89294366|NCT01256814|Active Comparator|Control|"The control group will receive the manual Symptom Management Manual: Strategies for People Living with HIV/AIDS."
89294367|NCT03897660|Active Comparator|TG form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acidsesterified in a reconstitute triglyceride form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
89294368|NCT03897660|Active Comparator|EE form of omega-3|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in ethyl esters form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
89294369|NCT03897660|Experimental|MaxSimil (MAG form of omega-3)|The participant will arrive fasted at he research center. After installing a cathether and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids in MaxSimil® form as a unique dose of 1.5 g EPA + DHA in TG form + 45 mg vitamin K2.The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma and a side effect questionnaire will be administered to monitor side effects.
89294370|NCT01256970||Polycystic Ovary Syndrome.|Polycystic ovary syndrome was diagnosed according to the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria: PCOM, chronic anovulation and hyperandrogenism.
89294371|NCT01256970||Normal Control|Normal control women were women who did not present with any of three PCOS criteria.
89294372|NCT03901170|Experimental|letrozole|patients with letrozole
89294373|NCT03901170|No Intervention|control|patients without letrozole
89294374|NCT03900858|Experimental|Isoniazid/ Rifapentine 3 times a week|Intervention：Isoniazid/ Rifapentine 3 times a week given by DOT oral Rifapentine (450mg) plus Isoniazid (400mg) for 12 doses
89294375|NCT03900858|No Intervention|No Intervention|No preventive treatment Follow up without intervention. Have already done.
89294376|NCT01149564|Placebo Comparator|IV ibuprofen|The first dose of either oral or IV ibuprofen will be given at the time the patient is randomized.The subsequent doses of indometacin or ibuprofen are also determined according to the echocardiographic PDA flow patterns at intervals of once every 24 hours from the last dose. The dosage of both oral ibuprofen (Ibuprofen suspension, 20 mg/ml, Yung Shing Co., Taiwan) and IV ibuprofen (PedeaR 20 mg/ml, developed by Orphan Europe and approved by the EMEA) are an initial dose of 10 mg/kg and then 5 mg/kg at 24-hour intervals as indicated by PDA flow pattern.
89294377|NCT01149564|Active Comparator|Oral ibuprofen|
89294378|NCT03900702|Active Comparator|Active Intervention|Gaze-driven games, played at home on PC with eye-tracker, to train resistance to attention distraction and speed of processing.
89294379|NCT03900702|No Intervention|Wait List Control|Wait list then cross over to active intervention.
89294380|NCT03894072|Active Comparator|HFHO-CPAP|This group will have HFHO before CPAP
89294381|NCT03894072|Active Comparator|CPAP-HFHO|This group will have CPAP and then HFHO
89294382|NCT01586286|Placebo Comparator|Ointment Base|Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).
89294383|NCT01586286|Active Comparator|Nifedipine Ointment|Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
89294384|NCT01257048|Placebo Comparator|1|Single Dose evaluation placebo (V5)
89294385|NCT01257048|Active Comparator|2|Single Dose evaluation formoterol (V5)
89294386|NCT03893994|Experimental|Stretching group|Posterior shoulder stretching exercises
89294387|NCT03893994|No Intervention|Control Group|No exercise will be applied
89294388|NCT03900390|Experimental|Cross Ischemic Preconditioning Group|the ascending aorta of the CIP group will be crossclamped to cease the blood supply for 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions
88806179|NCT01454947|No Intervention|Education Control|Participants do not receive any of the 3 interventions.
89294389|NCT03900390|No Intervention|Control Group|The recipients in the control group are to undergo routine cardiopulmonary bypass procedure of heart transplantation without Ischemic Preconditioning manoeuvre.
89294390|NCT03900780|Experimental|PGT-A group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
89294391|NCT03900780|Active Comparator|Control group|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
89294392|NCT03900312|Experimental|Intervention|The program consists of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices.
89294393|NCT03897504|Experimental|feminizing genitoplasty using inner surface of the prepuce|Feminizing genitoplasty will be done using the prepuce as a pedicled tubularized flap to create the new vagina, the new vagina which the investigators create it from the prepuce will be sutured above to the native vagina after its separation from the urogenital sinus, and the remaining part of the urogenital sinus will be used to create the urethra, the remaining part of the prepuce will create the labia minora, clitoroplasty will be attempted in all patients.
89294394|NCT01258218||Accent MRI Group|
89294395|NCT01150968|Experimental|Internal Medicine Residents|All UCSf Internal Medicine residents for 2009-2010
89294396|NCT01255254|Experimental|A: Scaling group|The experimental group will receive oral hygiene instruction (OHI) and full-mouth scaling using standard rigid Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, IL, USA) and ultrasonic instrumentation (EMS piezoelectric system, Electro Medical Systems, Nyon, Switzerland) at week 1-2 and at a second reinforcement visit at 6-8 weeks. Subjects will also be instructed to rinse with 10ml of Chlorhexidine 0.2% mouthrinse twice daily for 30 seconds for the duration of the study.
89294397|NCT01255254|No Intervention|B: Control group|The control group will receive no periodontal treatment during the study. After completion of the study, these patients will be given oral hygiene instruction and a full mouth scaling.
89294398|NCT03900234||Residents of the single rural settlement|No interventions will be administered
89294399|NCT01257126|Experimental|diclofenac potassium|
89294400|NCT01257126|Active Comparator|nimesulide|
89294401|NCT03897426|No Intervention|Standard-of-care arm|Patients randomized to the Standard-of-care-arm were provided 60 minutes of RD time for consultation through in person visits.
89294402|NCT03897426|Experimental|Intervention arm|"Mediterranean Diet - Remote Coaching using a Mobile App.~Patients randomized to the intervention arm were allotted 60 minutes of RD time through a Mobile App (for remote consultation), given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD. Remote coaching by RD was the intervention."
89294403|NCT03897738|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
89294404|NCT03897738|Placebo Comparator|Placebo|"Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~Placebo capsules are identical to Amberen and Smart B capsules."
89294405|NCT03893760||No Pulonary Hypertension|the presence of mean pulmonary pressures (PAPm) at the right heart catheterization < 25 mmHg
89294406|NCT03893760||Postcapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg and postcapillary wedge pressure (PCWP) >15 mmHg
89294407|NCT03893760||combined postcapillary/precapillary Pulmonary Hypertension|PAPm ≥ 25 mmHg, PAWP >15 mmHg and diastolic peak gradient (DPG - diastolic pulmonary pressure - PCWP) ≥7 mmHg and/or pulmonary vascular resistence (PVR) >3 WU, where available.
89294408|NCT03897114|Experimental|Cocoa group|The cocoa will be provided in sachets. The intervention will be carried out for 10 weeks. Cocoa is provided in a single daily dose of 5 g, which contains 83 mg of flavonoids per gram of cocoa (dose at which a prebiotic effect has been shown).
89294409|NCT03897114|Placebo Comparator|Placebo group|Maltodextrin will be supplied as a placebo, which will be provided in sachets. Athletes will take 5g of product per day.
89294410|NCT03900078|Active Comparator|Control group|After subcuticular skin suture, patients receive standard dressing with adhesive wound tapes.
89294411|NCT03900078|Experimental|Incisional negative pressure group|After subcuticular skin suture, patients receive an incisional negative pressure dressing for 5 days.
89294412|NCT03893604|Experimental|Anodal tDCS|Subjects will receive 20min anodal tDCS
89294413|NCT03893604|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham anodal tDCS
89294414|NCT02527824|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"intervention with triple combination chemotherapy with oxaliplatin, irinotecan, and S-1 Treatment will be delivered as a 2-week cycle.~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day 1-7"
89294415|NCT02528058||Myopic traction maculopathy|
89294416|NCT01149642|Experimental|Oral immunomodulatory solution|The oral supplement is a 74g sachet containing 302 kcal and 16.7g proteins as well as immunonutrients such as L-Arginine, ARN and omega-3.
89294417|NCT01149642|Placebo Comparator|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
89294418|NCT01586208|Active Comparator|40mg/kg intial valproate bolus|Patient receives a 40mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
89294419|NCT01586208|Active Comparator|20mg/Kg intial bolus valproate|Patient receives a 20mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
89294420|NCT03893526|Placebo Comparator|Placebo|Participants are subjected to a standardized meal
89294421|NCT03893526|Active Comparator|Entrestro|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
89294422|NCT03893526|Active Comparator|Sitagliptin|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
89294423|NCT03893526|Active Comparator|Entrestro + sitagliptin|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
89294424|NCT03893526|Active Comparator|Valsartan|206mg valsartan as one single dose followed by a standardized meal
89294425|NCT01149720|Experimental|ARQ 197 Capsule, oral|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
89294426|NCT01149720|Experimental|ARQ 197 Tablet, oral|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
89294427|NCT01149720|Experimental|ARQ 197 Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
89294428|NCT01149798|Experimental|Abraxane and Cisplatin combination|Abraxane and Cisplatin combination
89294429|NCT03896802|Experimental|Low PEEP|PEEP 5 cmH2O
89294430|NCT03896802|Experimental|High PEEP|PEEP 15 cmH2O
89294431|NCT02527590|Experimental|patient with neuropathic pain with allodynia|
89294432|NCT02527590|Experimental|healthy volunteers|
89294433|NCT01258452|Experimental|CHF 5074 (fed group)|oral tablet, single dose
89294434|NCT01258452|Experimental|CHF 5074 (fasting group)|oral tablet, single dose
89294435|NCT01151202|Experimental|AG NPP709 syrup|AG NPP709 contains Ivy leaf extract and coptis rhizoma extract
89294436|NCT01151202|Active Comparator|Ivy leaf extract syrup|
89294437|NCT05943054|Experimental|Patients carrying the Huntington's gene|"A long temporal perception task and a short temporal perception task"
89294438|NCT05943054|Experimental|Alzheimer's disease patients|"A long temporal perception task and a short temporal perception task"
88806180|NCT05266274|Experimental|The Treatment of Recurrent AML After Transplantation|
88806181|NCT03225404|Experimental|Experimental group|EPTE + EXER Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
88806182|NCT03225404|Experimental|Control group|
88806183|NCT05265962|Experimental|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
88806184|NCT01455181|Experimental|NPSP558|
89294439|NCT05943054|Active Comparator|Healthy Volunteers|"A long temporal perception task and a short temporal perception task"
89294440|NCT05943041|Experimental|GB104: Dose level 1|Dose escalation cohort includes patients with CRC who completed curative colectomy and planned therapy. 3 to 6 patients will be enrolled per escalating dose levels.
89294441|NCT05943041|Experimental|GB104: Dose level 2|Dose escalation cohort includes patients with CRC who completed curative colectomy and planned therapy. 3 to 6 patients will be enrolled per escalating dose levels.
89294442|NCT05943041|Experimental|GB104: Dose level 3|Dose escalation cohort includes patients with CRC who completed curative colectomy and planned therapy. 3 to 6 patients will be enrolled per escalating dose levels.
89294443|NCT05943028|Experimental|Control group|The preset EEG value of 36 in closed-loop target-controlled infusion is the baseline value of EEG closed-loop feedback guidance (obtained by the team's previous research results)
89294444|NCT05943028|Experimental|Experimental group|Due to the action of esketamine in closed-loop target-controlled infusion, the EEG preset value of 36+N is the baseline value of the new EEG closed-loop feedback guidance (pre-experiment and literature data, N value is 6-8)
89294445|NCT05943015|Active Comparator|Quadratus Lumborum Block II|Quadratus Lumborum Block II
89294446|NCT05943015|Active Comparator|Quadratus Lumborum Block III|Quadratus Lumborum Block III
89294447|NCT05943015|Active Comparator|Paravertebral Block|Paravertebral Block
89294448|NCT05942989|Experimental|Intervention group that given education|Reiki group
89294449|NCT05942989|No Intervention|Control group|Group with no intervention
89294450|NCT05942963|Experimental|Group A|SOC+ Empagliflozin + Pioglitazone
89294451|NCT05942963|Experimental|Group B|SOC +Empagliflozin
89294452|NCT05942963|Experimental|Group C|SOC+ Pioglitazone
89294453|NCT05942963|Active Comparator|Group D|SOC only
89294454|NCT05942924|Active Comparator|Selective stimulation|At the start of the study, selective tactile stimulation will be performed at each participating centre in accordance with international guidelines. Clinicians will gently rub the back, chest, extremities or soles of the feet if they consider the breathing of the infant to be insufficient or absent. All other procedures in the delivery room and NICU will be performed according to international and local guidelines.
89294455|NCT05942924|Experimental|Repeated stimulation|"For each centre, a lot will be drawn which indicates the month in which the protocol for tactile stimulation changes from selective stimulation to repetitive stimulation.~Repetitive stimulation is defined as gently rubbing the soles of the feet, back, chest, or extremities for 10 seconds. To prevent extinction of the stimulatory effect (reflex), every 10 second period of stimulation will be followed by 10 seconds rest (no stimulation). The repetitive stimulation will be performed for the first 5 minutes after birth, or longer if the breathing is still considered insufficient or absent. All other procedures in the delivery room and NICU will be performed according to international and local guidelines."
89294456|NCT05942872||NirAEs, grade ≥ 3 according to CTCAE|Patients treated with ICIs who developed neurologic syndromes consistent with NirAEs, of grade ≥ 3 according to the Common Terminology Criteria for Adverse Events (CTCAE)
89294457|NCT05942755||Subarachnoid haemorrhage with Fisher 3 or 4.|"HAS Group :~Adults~Hospitalized in the neurological intensive care unit for a Fisher 3 or 4 aneurysmal meningeal hemorrhage with external ventricular drain (EVD) and urinary catheter. This EVD allows the evacuation of 10-20ml/h of CSF into an external collector. CSF is usually removed daily.~With a catheter (arterial or venous) for repeated sampling. Blood samples are taken as part of routine care on arrival of patients and then every 24 hours if an arterial catheter is in place; otherwise, every Monday, Wednesday and Friday. Samples from the EVD will be taken on Day 0 and then every 24 hours. A urine ionogram is also performed every 24 hours as part of the usual management to regulate water, sodium and potassium intake by enteral or parenteral route.~In addition, clinical data will be collected every 24 hours on the basis of a computerized medical record without additional examination."
89294458|NCT05942755||Control group, normal pressure hydrocephalus|"Control group :~Adults~Performing a perfusion test in the operating room in the context of normal pressure hydrocephalus.~A lumbar puncture is performed in the operating room to evacuate the chronic CSF effusion in the ventricles (hydrocephalus), before performing an intrathecal perfusion test. 1ml of the CSF thus collected will be analyzed to determine the ionic composition and thus compare it to the CSF collected from patients with SAH."
89294459|NCT05942703||obese patients|Patients with a body mass index superior or equal at 30 and with a periodontitis
89294460|NCT05942703||non-obese (BMI<30) patients|Patients with a body mass index inferior at 30 with a periodontitis
89294461|NCT05942664|Sham Comparator|Normal sleep|Participants will be asked to sleep during their normal sleep times prior to this visit
89294462|NCT05942664|Active Comparator|Sleep deprivation|Participants will be asked to go to bed normally but wake up earlier, such that normal sleep duration is restricted by 60%. For example, if someone normally sleeps for 8 hours by falling asleep at 11 pm and waking up at 7 am, they will be asked to fall asleep normally (11 pm) and sleep for 3.2 hours, which results in a wake-up time of 2:12 am.
89294463|NCT05942573|Experimental|continuation of Serplulimab plus chemotherapy after first progression|"Serplulimab+Paclitaxel+Apatinib~Paclitaxel±Ramucirumab"
89294464|NCT05942547|Experimental|diosmin group|(Diosmin group; n = 24):will receive 600 mg twice daily
89294465|NCT05942547|Placebo Comparator|placebo group|placebo group n=24 :will receive placebo twice daily
89294466|NCT05942508|Experimental|TQB2450 Injection + Anlotinib Hydrochloride Capsules|TQB2450 injection: 1200 mg/time, intravenous drip, day 1, Q3W; Anlotinib Hydrochloride Capsules: 8 mg/dose, once daily (QD), continuously used for 2 weeks, stopped for 1 week, and taken orally before breakfast (the starting dose of Anlotinib Hydrochloride is 8 mg, and it is allowed to be increased to 10 mg after two cycles of use)
89294467|NCT05942456||sB7-H3 of treatment-naive osteosarcoma patients|Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
89294468|NCT05942456||sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients|After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
89294469|NCT05942443|Active Comparator|MCP blocking orthosis|Patients received the MCP blocking orthosis
89294470|NCT05942443|Experimental|RME orthosis|Patients received the RME orthosis for six weeks
89294471|NCT05942417|Active Comparator|Neuromodulation Percutaneous echoguided plus exercise|The experimental group will receive a EPNM in the common peroneal nerve of the affected ankle. . Three interventions will be carried out, in a dosage of 1 per week. Moreover, a 3-week of strength exercises will be carried out with two sessions per week. The strength program includes a protocol for the use of Theraband ® according to that described by Kaminsky et al. Moreover, the participants will have to do a balance exercises program.The EPNM will be applied prior to the exercise program session
89294472|NCT05942417|Placebo Comparator|Strength program|"The strength program includes a Theraband® use protocol as described by Kaminsky et al.~The balance exercise program will consist of performing a series of closed kinetic chain exercises in a weight-bearing standing position that will progress from bilateral to unilateral depending on the acceptance of the load."
89294473|NCT05942404|No Intervention|Group of no bowel preparation|none mechanical bowel preparation
89294474|NCT05942404|Active Comparator|Group of bowel preparation|mechanical bowel preparation
89294475|NCT05942391|Experimental|Brief-Intensive CBT|16 sessions in 2 weeks + 4 follow up sessions. The CBT consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks, + 4 sessions within 3 months.
89294476|NCT05942391|Active Comparator|weekly CBT|20 weekly CBT sessions within 5 to 6 months. The CBT consists of exposure therapy.
89294477|NCT05942378|Experimental|HRXG-K-1939 Combined with Adebrelimab|"Dose Escalation:~HRXG-K-1939 at escalated dosages with Adebrelimab Experimental: Dose Expansion HRXG-K-1939 at recommended dose with Adebrelimab"
89294478|NCT05942339|Experimental|Targeted Epidural Spinal Stimulation|"Single arm study: the participants that have undergone the STIMO study will be proposed to exchange their currently implanted system with selected components from the ARC-IM Lumbar system.~After the surgery, the participants will perform around 20 optimization sessions that may include rehabilitation to configure the neuromodulation system. Then the participants will use the ARC-IM Lumbar system independently during daily life activities until the end of the 36 months post-surgery. Assessments will be planned throughout the course of the study at the end of the optimization phase, after 12 and 24 months post-surgery and at the end of the study, with and/or stimulation."
89294479|NCT05942287|Experimental|Diet intervention|Diet intervention (in addition to standard clinical care)
89294480|NCT05942287|No Intervention|Standard clinical care|Standard clinical care only
89294481|NCT05942248|Other|Acne vulgaris|Inflammatory and non-inflammatory lesion counts
89294482|NCT05942248|Other|Rosacea|Inflammatory lesion count
89294483|NCT05942248|Other|Melasma|Pigment intensity and distribution with use of Melasma Area Severity Index
89294484|NCT05942248|Other|Seborrheic Dermatitis|Grading of seborrheic dermatitis with Seborrheic Dermatitis Area Severity Index score
89294485|NCT05942235||Control grup 1|"Among the students enrolled in the surgical diseases nursing course in the fall semester, 42 students will be selected using the research randomizer program. Then, students will be asked to fill in the Wound Healing Process and Care Information Form and the Student Information Form. Then, the wound healing process course will be given as a trainer presentation."
89294486|NCT05942235||Experimental 1|The population of the study will consist of students enrolled in the Surgical Diseases Nursing course in the fall and springs semester of the 2022-2023 academic year in the Department of Nursing at the Faculty of Health Sciences of Karadeniz Technical University. The students enrolled in the Surgical Diseases Nursing course in the fall semester will form the control group, while the students enrolled in the spring semester will form the experimental group.
89294487|NCT05942222|Active Comparator|Dupilumab week 0-24 300 mg/2 weeks|Normal dose and interval of Dupixent i.e. 300 mg s.c. every 2 weeks
89294488|NCT05942222|Active Comparator|Mepolizumab week 0-24 100 mg/4 weeks|Normal dose and interval of Nucala i.e. 100 mg s.c. every 4 weeks
89294489|NCT05942222|Active Comparator|Dupilumab week 24-48 300 mg/4 weeks|Increased dosage interval of Dupixent i.e. 300 mg s.c. every 4 weeks - for subjects on Dupixent who met the 24 weeks effect criteria
89294490|NCT05942222|Active Comparator|Dupilumab week 24-48 300 mg/2 weeks|Normal dose and interval of Dupixent i.e. 300 mg s.c. every 2 weeks but for subjects who have crossed over after 24 weeks due to unmet effect criteria.
89294491|NCT05942222|Active Comparator|Mepolizumab week 24-48 100 mg/4 weeks|Normal dose and interval of Nucala i.e. 100 mg s.c. every 4 weeks but for subjects who have crossed-over after 24 weeks due to unmet effect criteria.
89294492|NCT05942209||ECO-LEAK transvaginal ultrasound|A transvaginal ultrasound is performed with a transrectal enema performed routinely during 4th-6th post-operative day
89294493|NCT05942209||ECO-LEAK with other diagnostic method (Computed Tomography Scan or rectoscopy)|Women with colo-rectal anastomosis with a CT-SCAN (Computed Tomography Scan) or rectoscopy image test performed routinely during 4th-6th post-operative day and a transvaginal ultrasound
89294494|NCT05942209||CT-SCAN and/or rectoscopy|Women with colo-rectal anastomosis with a CT-SCAN or rectoscopy image test performed routinely during 4th-6th post-operative day
89294495|NCT05942170|Other|SLN/MRI|
89294496|NCT05942144|Experimental|Exercise-snacks group|"They will perform a exercise-snacks program and receive information about physical activity"
89294497|NCT05942144|No Intervention|Control group|They will maintain their usual lifestyle until the end of the study
89294498|NCT05942131|Experimental|Intervention Group (n:42)|Laughter yoga will be practiced to students in the intervention group
89294499|NCT05942131|No Intervention|Control Group (n:42)|"No intervention will be applied to the control group midwives and Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory will be applied when they are included in the study and again after 4-6 weeks."
89294500|NCT05942118||ROLL|Prior to surgery, an ultrasound-guided localization will be performed and albumin marked with Technetium 99m will be injected close to the tumor and in the subareolar area. During surgery, a specific probe will be used to locate the lesion and sentinel lymph node.
89294501|NCT05942118||SEED|During diagnostic biopsy or prior to surgery, a magnetic clip will be placed in the breast lesion; during surgery, localization will be performed using a specific probe, while sentinel lymph node localisation, when needed, will be performed even with indocyanine green dye (ICG) or methylene blue dye
89294502|NCT05942079||group receiving reiki|Individuals who will undergo Reiki for 12 weeks
89294503|NCT05942079||control group|control group
89294504|NCT05942053|Placebo Comparator|Group 1: Control group|"Non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b). Patients will be treated with ramipril 10 mg/day and a placebo match vitamin K2 capsules once per day. The dose of ramipril may be modified according to blood pressure control.~Participants will be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence for 6 months."
89294505|NCT05942053|Active Comparator|Vitamin K2 (menaquinone-7)|"Non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b).Patients will be treated with ramipril 10 mg/day and vitamin K2 capsules (menaquinone-7) 90 mcg/day. The dose of ramipril may be modified according to blood pressure control.~Participants will be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence for 6 months."
89294506|NCT05942027|Placebo Comparator|Group 1: Control group|"Non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b). Patients will be treated with ramipril 10 mg/day and a placebo match Coenzyme Q10 capsules once per day.The dose of ramipril may be modified according to blood pressure control.~Participants will be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence for 6 months."
89294507|NCT05942027|Active Comparator|Group 2: Coenzyme Q10|"Non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b).Patients will be treated with ramipril 10 mg/day and Coenzyme Q10 capsules (CoQ10) 200 mg/day.The dose of ramipril may be modified according to blood pressure control.~Participants will be followed-up by weekly telephone calls and monthly direct meetings to assess their adherence for 6 months."
89294508|NCT05942001|Experimental|HRS-5041|
89294509|NCT05941975|Experimental|PIRA|From the MS functional outcome database, identification of a cohort of patients with RMS experiencing progression independent of relapse (PIRA)
88806185|NCT00324896|Experimental|eszopiclone|eszopiclone. Those under 65yo received 3mg of eszoplicone ( or randomized to matching placebo)and those 65yo or older received 2mg of eszoplicone ( or randomized to matching placebo)taken each night at bedtime
89294510|NCT05941975|Active Comparator|N-PIRA|From the MS functional outcome database, identification of a cohort of patients with RMS not experiencing progression independent of relapse (N-PIRA)
89294511|NCT05941936|Experimental|Intravenous of LM103|≥5×10^9 cells (LM103) will be infused i.v. to patients after NMA lymphodepletion treatment with Cyclophosphamide for Injection and Fludarabine Phosphate for Injection.
89294512|NCT05941923|Experimental|Intervention group|The experimental group, who will receive specialized respiratory care from RCCN from the time they arrive in the emergency room until their discharge from the hospital
89294513|NCT05941923|No Intervention|Control group|No intervention group, who will receive only routine care without any intervention.
89294514|NCT05941910|Active Comparator|Q10|
89294515|NCT05941910|Placebo Comparator|Placebo|
89294516|NCT05941884||Schistosoma haematobium cystitis.|patient has symptoms suggestive of Schistosoma haematobium infection like terminal hematuria and burning micturition
89294517|NCT05941884||Healthy personnel.|as control group
89294518|NCT05941884||Schistosomal bladder cancer.|from patient undergone diagnostic cystoscopy and sampling and confirmed pathologically as Schistosomal bladder cancer.
89294519|NCT05941884||non Schistosomal bladder cancer.|from patient undergone diagnostic cystoscopy and sampling and confirmed pathologically as non Schistosomal bladder cancer.
89294520|NCT05941884||Schistosomal cystitis patients.|from patient undergone diagnostic cystoscopy and sampling and confirmed pathologically as Schistosomal cystitis
89294521|NCT05941884||healthy bladder tissue from tissue biopsy patient with benign prostatic hyperplasia.|as control group
89294522|NCT05941871|Experimental|Control|Group that will follow a low-calorie diet with a standard daily energy distribution for 4 months
89294523|NCT05941871|Experimental|Intervention|Group following a low-calorie diet with a different daily energy distribution according to their chronotype for 4 months
89294524|NCT05941845|Experimental|6-month interferon alfa treatment|
89294525|NCT05941806|Active Comparator|Group receiving Tamsulosin|Patients randomized to the intervention group will receive 0.4 mg tamsulosin capsules, administered orally, once a day for 5 days before surgery, the morning of surgery and the day after surgery. The steady-state plasma concentration of tamsulosin is reached after 4 to 5 consecutive doses, which justify the administration duration of 5 days preoperatively. The total duration of administration of tamsulosin was established at 7 days since the study of Patel et al. showed a significant reduction in POUR after 7 days of administration.
89294526|NCT05941806|Placebo Comparator|Group receiving Placebo|Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec.
89294527|NCT05941754|Experimental|high omega-3 group|A single dose of 4.0g EPA was given orally
89294528|NCT05941754|Experimental|low omega-3 group|A single dose of 2.0g EPA was given orally
89294529|NCT05941754|Placebo Comparator|placebo group|A single dose of 4.0g corn oil was given orally
89294530|NCT05941754|No Intervention|healthy control group|no intervention. assessement of cognitive performance twice.
89294531|NCT05941676||Head and neck carcinoma patients|Head and neck carcinoma patients will be enrolled in this study group.
89294532|NCT05941624|Experimental|Ha-330 Hemoperfusion Filter Hemodialysis|Participants underwent therapy using Ha-330 Hemoperfusion Filter Hemodialysis for 4 hours, 3 times a week, with two days apart between dialysis.
89294533|NCT05941624|Active Comparator|Conventional hemodialysis|Participants underwent therapy using Conventional Hemodialysis for 4 hours, 3 times a week, with two days apart between dialysis.
89294534|NCT05941611|Experimental|Partisipants|
89294535|NCT05941559|Other|Shortest baseline length|Intervention starting points are at day 15, 16, 17, 18 or 19.
89294536|NCT05941559|Other|Medium baseline length|Intervention starting points are at day 20, 21, 22, 23, and 24.
89294537|NCT05941559|Other|Longest baseline length|Intervention starting points are at day 25, 26, 27, 28, or 29.
89294538|NCT05941481|Experimental|neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody|"Immunotherapy combined with chemotherapy (2 cycles): Intravenous tislelizumab (200mg, d1, q21d) in combination with XELOX regimen (capecitabine 1000 mg/m2 bid*14d + oxaliplatin 130mg/m2, d1, q21d);~Concurrent radiotherapy: Within one week after the first initiation of chemo-immunotherapy, concurrent hypofractionated radiotherapy will be started: intensity modulated radiotherapy was given for tumors, total dose:30Gy/12f, 2.5Gy/f.~D2 resection will be received three to five weeks after the completion of neoadjuvant therapy."
89294539|NCT05941468|Experimental|AR group (EG-A)|Behavioral: AR intervention For the EG-A, the AR dental care training system will give to patients that 2 to 3 times tooth clean skill learning course (including Bass method of brushing and inter-dental toothbrush brushing technique) during non-surgical periodontal treatment period.
89294540|NCT05941468|Experimental|AR-health consulting group (EG-B)|"Behavioral: AR intervention For the EG-B, the AR dental care training system will give to patients that 2 to 3 times tooth clean skill learning course (including Bass method of brushing and inter-dental toothbrush brushing technique) during non-surgical periodontal treatment period.~The health counseling will also provide professional oral health related courses (including oral care for diabetes and periodontal disease, etc.)"
89294541|NCT05941468|No Intervention|Control group (CG)|the control group(CG) only have standard oral hygiene education
89294542|NCT05941455|Experimental|Venus-Neo group|Procedure: surgical aortic valve replacement
89294543|NCT05941429|Active Comparator|Silver Diamine Fluoride|"38% Silver Diamine Fluoride varnish~the affected tooth will be cleaned by a disposable micro-brush for 30 seconds and then will be dried using cotton gauze sponges.~No excavation will be done to the infected dentin tissue prior to the application of the agent.~Gum will be protected with petroleum jelly, and isolation will be achieved by using cotton rolls.~After isolation, a single drop SDF will be applied into the cavity by using a disposable micro-brush for at least two minutes. Then site of application will be covered with petroleum jelly.~Finally, parents will be instructed that children participating in the trial are not allowed to eat or drink for one hour after application of the agent"
89294544|NCT05941429|Experimental|Nano-Silver Fluoride|"Nano-Silver fluoride varnish preparation~the affected tooth will be cleaned by a disposable micro-brush for 30 seconds and then will be dried using cotton gauze sponges.~No excavation will be done to the infected dentin tissue prior to the application of the agent.~Gum will be protected with petroleum jelly, and isolation will be achieved by using cotton rolls.~After isolation, a single drop NSF will be applied into the cavity by using a disposable micro-brush for at least two minutes. Then site of application will be covered with petroleum jelly.~Finally, parents will be instructed that children participating in the trial are not allowed to eat or drink for one hour after application of the agent"
89294545|NCT05941403|Experimental|Enhanced Produce Prescription Implementation|The study team will develop an enhanced implementation blueprint to support uptake of the produce prescription (VeggieRx) intervention that is informed by advisory board input and includes multiple implementation strategies to address identified barriers to implementation.
89294546|NCT05941390|No Intervention|control|patients undergoing one of the procedures without using VR device
88806186|NCT00324896|Placebo Comparator|placebo|Those randomly assigned to matching placebo, took their dose each night at bedtime
89294547|NCT05941390|Active Comparator|VR without sound|patients undergoing one of the procedures using VR device without sound
89294548|NCT05941390|Active Comparator|VR with sound|patients undergoing one of the procedures using VR device with sound
89294549|NCT05941377|Experimental|standard blood pressure lowering (SBPL) group|
89294550|NCT05941377|Experimental|enhanced blood pressure lowering (EBPL) group|
89294551|NCT05941351|Other|Running|Group 1: Flap fixation after mastectomy with running sutures.
89294552|NCT05941351|Other|Individual|Group 2: Flap fixation after mastectomy with interrupted sutures.
89294553|NCT05941338|Experimental|Arm 1|Drug:Tirelizumab , Carboplatin,albumin-bound paclitaxel Patients receive Tirelizumab IV on day 1, albumin-bound paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2cycles in the absence of disease progression or unacceptable toxicity. Then surgery.
89294554|NCT05941325|Experimental|fruquintinib combined with envafolimab|
89294555|NCT05941312|Active Comparator|CONTROL GROUP (GROUP 1)|"Only open flap debridement (OFD):~Conventional OFD surgery was applied to patients in all groups which began with local anesthesia (4% articaine with 1:100 000 epinephrine) after the surgical area was disinfected. Defects were thoroughly debrided firstly by using periodontal curettes and then cleaned by piezoelectric ultrasonic scaler. For the control group, the defects were left without adding any products."
89294556|NCT05941312|Active Comparator|GROUP 2|Conventional OFD surgery was applied to patients in all groups which began with local anesthesia (4% articaine with 1:100 000 epinephrine) after the surgical area was disinfected. Defects were thoroughly debrided firstly by using periodontal curettes and then cleaned by piezoelectric ultrasonic scaler. After the operation area was washed thoroughly with saline, platelet-rich fibrine (PRF) was placed inside defects
89294557|NCT05941312|Active Comparator|GROUP 3|Conventional OFD surgery was applied to patients in all groups which began with local anesthesia (4% articaine with 1:100 000 epinephrine) after the surgical area was disinfected. Defects were thoroughly debrided firstly by using periodontal curettes and then cleaned by piezoelectric ultrasonic scaler. After the operation area was washed thoroughly with saline, Consantrated Growth Factor (CGF) was placed inside defects
89294558|NCT05941312|Active Comparator|GROUP 4|Conventional OFD surgery was applied to patients in all groups which began with local anesthesia (4% articaine with 1:100 000 epinephrine) after the surgical area was disinfected. Defects were thoroughly debrided firstly by using periodontal curettes and then cleaned by piezoelectric ultrasonic scaler. After the operation area was washed thoroughly with saline, autologous bone graft (ABG) was placed inside defects
89294559|NCT05941273|Experimental|Implanted Eye with SING IMT|The SING IMT is implanted in on eye and safety endpoints are aimed at following that eye over time post-implant
89294560|NCT05941234|Other|Patients cohort Fondazione Policlinico Gemelli|Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of artificial intelligence-based prognostic markers
89294561|NCT05941221|Experimental|study group|patients will receive pericapsular nerve group (PENG )block through ultrasound at the end of the surgery.
89294562|NCT05941195|Experimental|psychoeducation applied experimental group|The patients in the experimental group received a total of 5 weeks (9 sessions) of cognitive-behavioral-based psychoeducation, consisting of 45-60 minutes, 2 sessions per week and the first session preparation session. In the sessions, the topics determined by using learning activities such as lecture, discussion, summarization, role-play, question/answer and exercises were explained and discussed. At the end of each session, homework was given to facilitate the patient's cognitive and behavioral change between sessions.
89294563|NCT05941195|No Intervention|non-intervention control group|Control group: The control group continued to receive the routine care.
89294564|NCT05941182||Patient participants|"Participants who have been assigned to remote consultation follow up following a face-to-face appointment by their clinician.~Online Perceived Attributes of eHealth Technology online questionnaire before and after the remote consultation."
89294565|NCT05941182||Staff participants|Medical and administrative eye clinic staff at participating centres. Normalisation process (NOMAD) online questionnaire before and after the implementation period.
89294566|NCT05941169|Experimental|Cytoreductive Nephrectomy|Cytoreductive Nephrectomy within 6 months to 1 year after start systemic therapy for metastatic Renal Cell Carcinoma
89294567|NCT05941169|No Intervention|Standard of Care|Standard of Care for metastatic Renal Cell Carcinoma
89294568|NCT05941156|Experimental|CAR-T Cell Infusion|Pretreatment was initiated at -5 days prior to CAR T cell reinfusion, and CAR T cell therapy was performed 2 days after completion of chemotherapy. All patients were pretreated with FC regimen, fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day. Anti CD56-CAR T cells were transfused back 2 days after chemotherapy. The freeze-thawed cell product solution is injected back into the body as soon as the patient can accept it. The patient's vital signs should be closely monitored throughout the infusion, and oxygen saturation should be measured at 15-minute intervals before, at the end of, and after infusion, and continue until the patient is stable. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
89294569|NCT05941143|Experimental|mindfulness-based intervention|The intervention consist of 8 sessions in which participants learned three main different practices: body scan, sitting meditation, and yoga practice. Participants are instructed to regularly engage in home mindfulness practice of these new learned skills (45 minutes a day for 6 days a week). Home exercises include formal mindfulness practice (i.e., meditation and yoga) for about 30-35 minutes a day and informal practice focused on bringing mindful awareness to everyday activities for about 10-15 minutes a day. Mp3 audio of meditations proposed at each session are provided to guide personal practice.
89294570|NCT05941130|Experimental|Group A|Patients assigned into group A (NSAID) will receive only Ibuprofen 600mg (Mylan)
89294571|NCT05941130|Experimental|Group B|Patients assigned into group B (CORT + NSAID) will receive Ibuprofen 600mg (Mylan) with methylprednisolone (Medrol, 16mg Pfizer Laboratories)
89294572|NCT05941117|Active Comparator|weight bearing exercises group|20 patients were assigned to this group with bilateral knees osteoarthritis, they received TENS, stretching exercises and weight bearing strengthening exercises.
89294573|NCT05941117|Active Comparator|non-weight bearing exercises group|20 patients were assigned to this group with bilateral knees osteoarthritis, they received TENS, stretching exercises and Non-weight bearing strengthening exercises.
89294574|NCT05941104||Frail group|
89294575|NCT05941104||Non-frail group|
89294576|NCT05941091|Experimental|Intervention Group or HafifMod Group|The HafifMod Programme; It consists of modular education practice and a mobile application offered to HD patients.
89294577|NCT05941091|Active Comparator|Control group|"Prepared by a dietitian; As a result of the distribution of a printed material called Nutrition Guide for Dialysis Patients to the active control group, individuals will be informed about nutrition."
89294578|NCT05941078|Experimental|ICF-based post-stroke rehabilitation program group|The ICF-PSRP based on the ICF Core Set for Stroke targeted to facilitate patients' functional improvement, and community and social reintegration. Duration of the ICF-PSRP was eight or 12 weeks, comprising of 30 or 48 two-hour sessions depending on the patients' needs and progress.
89294579|NCT05941026|Experimental|Arms|Nursing students who were in the experimental group during the application phase of the study were given training to develop their intercultural sensitivity levels based on Leninger's Intercultural Nursing Theory. Data were collected at the beginning of the four-week online training, at the end of the training, and one month after the training.
89294580|NCT05941026|No Intervention|Control groups|No application was made to the control group within the scope of the research. Data were collected simultaneously with only the experimental group.
89294581|NCT05940987|Experimental|Intervention Group|"Participants in the intervention group will receive one 20-30 minutes 5A smoking cessation health consultation after enrollment; They will be given regular phone-based smoking cessation intervention once a week in the first month and once a month thereafter (15 times in total). Participants will be followed at 2, 6, 12 months, and cotinine urine test kits will be mailed to those who have self-reported smoking cessation at follow-up, which is used to confirm whether they have quitted smoking or not. (smoking cessation is defined as urine cotinine levels below 200 ng/mL)."
89294582|NCT05940987|No Intervention|Control Group|"Participants in the control group will receive one 20-30 minute 5A smoking cessation health consultation after enrollment; Phone-based smoking cessation intervention will not be regularly given after enrollment."
89294583|NCT05940519|Experimental|dynamic tape group|The dynamic tape group
89294584|NCT05940519|Sham Comparator|sham taping group|The sham tape group
89294585|NCT05940116|Experimental|HS-20117|Participants will receive IV infusion of HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)
89294586|NCT05939921|Experimental|Treatment|T2DM patients will be provided with metformin in a specified dose
89294587|NCT05939219|Experimental|3-month-old group|"Randomly inoculate 4 batches of 15-valent pneumococcal conjugate vaccine. Immunization program and dosage: Basic immunization at 0, 1, and 2 months, booster immunization at 12-15 months of age, a total of 4 doses administered.~Dosage form: water injection type"
89294588|NCT05939219|Experimental|7-11 month old experimental group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: Basic immunization for 0 and 2 months program; Strengthen one dose after 12 months of age; A total of 3 doses were administered.~Dosage form: water injection type"
89294589|NCT05939219|Active Comparator|7-11 month old control group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: Basic immunization for 0 and 2 months program; Strengthen one dose after 12 months of age; A total of 3 doses were administered.~Dosage form: water injection type"
89294590|NCT05939219|Experimental|12-23 months old experimental group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: Immunize 2 doses using the 0 and 2 month program, with a total of 2 doses administered.~Dosage form: water injection type"
89294591|NCT05939219|Active Comparator|12-23 months old control group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: Immunize 2 doses using the 0 and 2 month program, with a total of 2 doses administered.~Dosage form: water injection type"
89294592|NCT05939219|Experimental|2-5 year old experimental group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: 1 dose administered. Dosage form: water injection type"
89294593|NCT05939219|Active Comparator|2-5 year old control group|"The experimental group was vaccinated with the 15 valent pneumococcal conjugate vaccine, while the control group was vaccinated with the 13 valent pneumococcal polysaccharide conjugate vaccine, with a ratio of 2:1.~Immunization program and dosage: 1 dose administered. Dosage form: water injection type"
89294594|NCT05938647||Dengue hemorrhagic fever group 3|Risk factor (severity 3): no diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
89294595|NCT05938647||DHF group 4 (DSS);|Risk factor (group 4): no diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
89294596|NCT05938517|Experimental|Betahistine-dihydrochloride|Subjects received single dosages of Betahistine (24 mg, 48 mg, 96 mg) orally for pharmacokinetic serum draw with at least two days between the different dosages.
89294597|NCT05938517|Experimental|Betahistine-dihydrochloride and Selegiline-hydrochloride|Subjects were pre-treated with Selegiline (5 mg/day) orally for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) orally with at least two days between the different dosages.
89294598|NCT05937204|Experimental|one group pre- test post- test|
89294599|NCT05937022|Experimental|Right VLPFC tDCS|Participants who are assigned to the right VLPFC group will receive anodal tDCS over the right ventrolateral prefrontal cortex (VLPFC).
89294600|NCT05937022|Experimental|Left DLPFC tDCS|Participants who are assigned to the right VLPFC group will receive anodal tDCS over the left dorsolateral prefrontal cortex (DLPFC).
89294601|NCT05937022|Sham Comparator|Sham Control tDCS|For the sham protocol, the electrode positioning will be randomly allocated to be identical to either the left DLPFC or the right VLPFC group, but the active stimulation will be delivered for the first 30 seconds only.
89294602|NCT05935657|Experimental|Remimazolam Group|sedation with remimazolam
89294603|NCT05935657|Active Comparator|Dexmedetomidine group|sedation with dexmedetomidine
89294604|NCT05935072|Experimental|rest with fixed meal|
89294605|NCT05935072|Experimental|rest with ad libitum meal|
89294606|NCT05935072|Experimental|Exercise with fixed meal|
89294607|NCT05935072|Experimental|Exercise with ad libitum meal|
89294608|NCT05929846||In-Person|Participants will be assessed by a LiveWell specialist to assess functional goals and baseline capacity and design an individualized program. LiveWell specialist may also refer participants for an assessment with a physiotherapist based on a pre-defined criteria including redflag for serious conditions. Participants will engage in a 12-week program consisting of 45 minute sessions 3 times a week. Day 1 will include individualized program at the fitness center, Day 2 will include a group class exercises ending with mindfulness activities, action planning and education. Day 3 will consist of an independent day when participants can attend other classes at the YMCA or repeat the fitness center. In addition, there will be 12 virtual videos of education on self-management that will be discussed during the group activity day (Day 2) .
89294609|NCT05929846||e-Health|Participants will be assessed by a LiveWell specialist to assess functional goals and baseline capacity and provide recommendation on exercise modifications and the program. LiveWell specialist may also refer participants for an assessment with a physiotherapist based on a pre-defined criteria including redflag for serious conditions. Participants will engage in a 12-week program consisting of 45 minute sessions 3 times a week. They will be provided with 3 exercise videos (including 3 levels of exercises per video) and will also have access to the on-demand YMCA platform for additional videos. In addition, there will be 12 virtual videos of education on self-management that will be discussed during follow-up phone calls. Participants will also be provided with an action planning document to complete at home. All online participants will have a phone call with the LiveWell specialist at 3 and 7 weeks to discuss the program, action planning and the education materials.
89294610|NCT05924477|Active Comparator|Sulcus tube placement|Glaucoma drainage device (GDD) implantation with tube placement in the ciliary sulcus
89294611|NCT05924477|Active Comparator|Anterior chamber (AC) tube placement|Glaucoma drainage device (GDD) implantation with tube placement in the anterior chamber
89294612|NCT05923372||Patients with indolent systemic mastocytosis (IMS)|Patients with IMS, included in the CEREMAST registry and who have given their consent to participate
89294613|NCT05922982|Active Comparator|Standard care arm|MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol
89294614|NCT05922982|Experimental|Experimental arm (HPI-guided)|MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI<80) delivered by the Acumen IQ medical device.
89294615|NCT05922956|Experimental|patients with bipolar disorder 1|
89294616|NCT05922956|Experimental|patients with bipolar disorder 2|
89294617|NCT05922956|Active Comparator|healthy controls|
89294618|NCT05915559|Experimental|Tonsillectomy|
89294619|NCT05910840|Experimental|Support-t plus usual diabetes care|Access to the Support-t online training and peer support platform in addition to usual diabetes care for 18 months. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum. Health care providers from the pediatric diabetes clinics will receive Support-t training and will be encouraged to recommend the Support-t platform during routine care with their patients from the active arm.
89294620|NCT05910840|No Intervention|Usual diabetes care only|Usual diabetes care for 18 months, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians. Health care providers from the pediatric diabetes clinics will be instructed not to discuss or refer to the Support-t platform with patients from the control arm. Control arm participants will have the option to use the Support-t platform after the 18-month study.
89294621|NCT05910762|Experimental|Learning and consolidation in Associative Inference|The proposed functional magnetic resonance imaging study assesses the neural representations contributing to humans' ability to associate objects in the support of simple inferences and generalization. All participants will undergo the same procedure. Participants will learn about pairs of objects and then be asked to make judgments and inferences about the relationships between the objects. The order of presentation of the objects will be manipulated within subjects, as different learning theories make different predictions about how learning will unfold under different orderings. Participants will be brought back one week later for a second scan, to evaluate how the neural substrates of these processes change with consolidation.
89294622|NCT05910762|Experimental|Learning and consolidation in category learning|The proposed functional magnetic resonance imaging study assesses the neural representations contributing to humans' ability to learn new categories of objects. All participants will undergo the same procedure. Participants will learn about novel objects, each with several colored parts. Some parts are unique to individual objects and others are shared among the members of the category. The investigators will assess how different regions of the brain contribute to learning and remembering these different kinds of parts, and how the resulting representations support category understanding. Participants will be brought back one week later for a second scan, to evaluate how the neural substrates of these processes change with consolidation.
89294623|NCT05910762|Experimental|Manipulating replay during sleep using real-time EEG|In the proposed electroencephalography (EEG) study, all participants will undergo the same procedure. Participants will learn the visual features and spoken names associated with three categories of novel objects. Participants' memory for these objects and the objects' parts will be tested before and after a nap. The investigators will monitor brain activity during the nap in real time and, at optimal moments, quietly play the spoken names of the objects to encourage reactivation of particular objects in particular orders. The investigators will assess how this manipulation impacts memory for these objects.
89294624|NCT05907850|Active Comparator|Riboflavin Group|Riboflavin 100mg will be self administered by participants, one capsules prior to the long stage of the race followed by a second dose at the completion of the long stage.
89294625|NCT05907850|Placebo Comparator|Placebo/Control Group|Placebo will be self administered by participants, one capsule prior to the long stage of the race followed by a second dose at the completion of the long stage.
89294626|NCT05904730|Experimental|Axitinib is 5 mg BID administered orally|The starting dose of Axitinib 5 mg BID administered orally with food.
89294627|NCT05893173||Major Depressive Disorder|Ten individuals (aged 25-50) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging and waking EEG prior to and following approximately 30 hours of total sleep deprivation.
89294628|NCT05860270|Active Comparator|Treatment group|Patients will be given Cholecalciferol (produced by Xymogen Company) 4000 U (2 capsules) per day
89294629|NCT05860270|Placebo Comparator|Control group|Patients will receive placebo, 2 capsules per day.
89294630|NCT05855395|Experimental|Group A|Experimental group with standard of care combined with glucocorticoid（dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)
89294631|NCT05855395|No Intervention|Group B|Control group with standard of care（The clinical standard of care of COVID-19 includes general treatment, oral antiviral drugs, immunotherapy, oxygen therapy and respiratory support, etc.）
89294632|NCT05853354|Experimental|LY06006|to be administered 2 doses to the patients at the main treatment period and 1 dose at the transition period.
89294633|NCT05853354|Active Comparator|EU Prolia|to be administered 2 doses to the patients at the main treatment period and 1 dose at the transition period.
89294634|NCT05850260||Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
89294635|NCT05850260||McGrath Mac videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option
89294636|NCT05818293|Experimental|study group -control group|Group (A) (study group) will receive radiofrequency, medical standard care for insulin resistance and regular diet habits.
89294637|NCT05818293|No Intervention|control group|Group (B) (control group) will receive regular diet habits only.
89294638|NCT05808881|Experimental|Nalmefene|Nalmefene hydrochloride (HCl) injection
89294639|NCT05808881|Active Comparator|Naloxone|Naloxone hydrochloride (HCl) injection
89294640|NCT05802628|Experimental|Investigational group|
89294641|NCT05792930|Experimental|Experimental Group|The experimental group will receive cognitive-behavioral therapy (CBT) and biofeedback therapy.
89294642|NCT05792930|No Intervention|Control Group|The design of control group is waiting list control; their data will be collected without intervention during the observation period. After the observation period, psychotherapy (CBT and biofeedback, the same as intervention) will be arranged.
89294643|NCT05792423|Experimental|24 healthy adult volunteers|
89294644|NCT05775796|Experimental|Serplulimab plus platinum doublet chemotherapy|
89294645|NCT05775367|Experimental|Study Group|This group of children with single-sided deafness will receive a cochlear implant.
89294646|NCT05775367|No Intervention|Typical Hearing Control Group (THCG)|This group of five-year-old children will have typical hearing in both ears.
89294647|NCT05775367|No Intervention|Single-Sided Deafness Control Group (SSDCG)|This group of five-year-old children will have single-sided deafness and no cochlear implant.
89294648|NCT05767905|Experimental|Part 1: PF-06821497 Sequence 1|"Participants randomized to Sequence 1 will receive Treatments A, B, and C in Periods 1 through 3, respectively in the form of tablets by mouth.~Interventions:~Drug: Single dose of PF-06821497 Treatment A~Drug: Single dose of PF-06821497 Treatment B~Drug: Single dose of PF-06821497 Treatment C"
89294649|NCT05767905|Experimental|Part 1: PF-06821497 Sequence 2|"Participants randomized to Sequence 2 will receive Treatments B, A and C in Periods 1 through 3, respectively in the form of tablets by mouth.~Interventions:~Drug: Single dose of PF-06821497 Treatment A~Drug: Single dose of PF-06821497 Treatment B~Drug: Single dose of PF-06821497 Treatment C"
89294650|NCT05767905|Experimental|Part 2: PF-06821497 Sequence 1|"Participants randomized to Sequence 1 will receive Treatments D, E and F in Periods 1 through 3, respectively in the form of tablets by mouth.~Interventions:~Drug: Single dose of PF-06821497 Treatment D~Drug: Single dose of PF-06821497 Treatment E~Drug: Single dose of PF-06821497 Treatment F"
89294651|NCT05758727|Experimental|Home-based exercise group|This group will be asked to practise the 'exercise snacking and Tai-chi snacking' exercises once each and record the exercise bouts in a log book.
89294652|NCT05758727|No Intervention|Control group|Usual care control group
89294653|NCT05753761|Experimental|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS)|Additional to usual care, the experimental arm will undergo a theory-based behaviour change intervention to improve stepping time relative to reducing sedentary behaviour.
89294654|NCT05753761|Active Comparator|Usual care:|The control arm program will consist of usual inpatient care including therapeutic mobilization by the physical therapy team and general mobilization, as tolerated, by the nursing team.
88806187|NCT01479517|Experimental|Kovacaine Mist 0.1 mL x 4 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
88806188|NCT01479517|Experimental|Kovacaine Mist 0.2 mL x 2 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
88806189|NCT01479517|Experimental|Kovacaine Mist, 0.2 mL x 1 spray|Total dose: 6 mg tetracaine/0.1 mg oxymetazoline
88806190|NCT01480219||Any Voriconazole|
88806191|NCT01480219||No Voriconazole|
89294655|NCT05751187|Experimental|Pembrolizumab + Bevacizumab + Chemotherapy|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4-6 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
89294656|NCT05733637||Vascular Access|Patients undergo vascular access procedure.
89294657|NCT05723393|Experimental|20 ml T2 ESPB group|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
89294658|NCT05717803|Experimental|Segmentectomy|Segmentectomy is performed for ground glass-dominant invasive lung cancer with size of 2-3cm.
89294659|NCT05701241|Active Comparator|somatostatin analogs continuation|Somatostatin analog (octreotide long-acting release (LAR) 30 mg or lanreotide 120 mg) will be given every four weeks for a duration of 18 months.
89294660|NCT05701241|No Intervention|somatostatin analogs withdrawal|Somatostatin analog treatment (octreotide LAR 30 mg or lanreotide 120 mg) will be withdrawn for a duration of 18 months.
89294661|NCT05698979|Experimental|drug administration|Botox Injection
89294662|NCT05696483|Experimental|Active|Active OLX-07010 in single ascending and multiple ascending dose cohorts
89294663|NCT05696483|Placebo Comparator|Placebo|OLX-07010 placebo in single ascending and multiple ascending dose cohorts
89294664|NCT05676216|Active Comparator|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping
89294665|NCT05676216|Experimental|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping
89294666|NCT05676216|Experimental|Diphenhydramine with Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push
89294667|NCT05671380|Active Comparator|Enhanced Usual Care: Ask-Advice-Connect (AAC)|AAC participants will receive care through their primary care provider as usual (with the caveat that providers in the clinics will be trained to provide AAC). AAC includes enhanced access to State Quitline and Nicotine Replacement Therapy.
89294668|NCT05671380|Experimental|AAC + Longitudinal Proactive Outreach (LPO)|AAC+LPO participants will receive AAC plus an MI tailored outreach call at baseline and at 3, 6, and 9 months post-enrollment. AAC includes enhanced access to State Quitline and Nicotine Replacement Therapy.
89294669|NCT05657977|No Intervention|Pretest|"Pretest: The newborn connected to nCPAP will be placed in the supine position and slight extension position on the neck of the newborn to ensure airway patency. The first saliva sample will be taken to measure cortisol level in the 30th minute after the first cry from the newborn who is connected to nasal CPAP. Immediately after the saliva sample is taken in pretest group, the stress level determined by using the neonatal stress scale, vital signs (respiration, heart rate, oxygen saturation), saliva sample collection time will be recorded on the chart."
89294670|NCT05657977|Experimental|Posttest, swaddling|"Posttest: The swaddling method will be applied to the newborn after the first saliva sample is taken. A second saliva sample will be taken 30 minutes after swaddling to measure cortisol level. Immediately after the saliva sample is taken in posttest group, the stress level determined by using the neonatal stress scale, vital signs, saliva sample collection time will be recorded on the chart."
89294671|NCT05650073|Experimental|Immersive Soundscapes Environment|Subjects having venous ablation with Vascular Surgery at Mayo Clinic will have relaxing music and relaxing sounds played during the procedure.
89294672|NCT05650073|No Intervention|Control Environment|Subjects having venous ablation with Vascular Surgery at Mayo Clinic will have no music played during the procedure.
89294673|NCT05643287|Experimental|Periodontitis patients|Periodontitis patients receiving non-surgical periodontal treatment.
89294674|NCT05636423||Italian physiotherapists|The survey will take place through the administration of a questionnaire accessible via the website of the Italian Physiotherapy Association (AIFI), the Scientific Association of reference for the physiotherapists, registered since 2020 in the list of Scientific Societies recognized by the Italian Health Ministry.
89294675|NCT05635435||primary glioma patients|We collected the information of clinical characteristics, inflammatory factors and immune factors of patients with primary glioma.
89294676|NCT05630196|Experimental|LY3857210|Participants will receive LY3857210
89294677|NCT05630196|Placebo Comparator|Placebo|Participants will receive placebo
89294678|NCT05620563|Experimental|LY3857210|LY3857210 will be given orally
89294679|NCT05620563|Placebo Comparator|Placebo|Placebo will be given orally
89294680|NCT05617027|Experimental|actual tDCS|"The actual transcranial direct current stimulation (tDCS) intervention will be conducted by a physiotherapist who will perform 5 sessions of actual tDCS , 5 consecutive days, for 20 minutes of treatment for a total of 45 minutes at the clinic for each session.~The tDCS current will be 2 mA for the whole 20-minute session."
89294681|NCT05617027|Placebo Comparator|placebo tDCS|"The placebo transcranial direct current stimulation (tDCS) intervention will be conducted by a physiotherapist who will perform 5 sessions of placebo tDCS, 5 consecutive days, for 20 minutes of treatment for a total of 45 minutes at the clinic for each session.~The tDCS current will be 2 mA for 30 secondes, and then will strop for the rest of the 20-minute session (programming of the equipment)."
89294682|NCT05584449|Experimental|Supportive Care (group curriculum)|Participants attend an online group facilitated by two oncology social workers and receive information regarding coping with cancer survivorship as a young adult, as well as discuss survivorship issues/concerns with peers.
89531570|NCT06041945|Active Comparator|Standard Arm CADe/CADx|Standard, high-definition colonoscopy with the use of CADe/CADx assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION ,NEC). All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
89531571|NCT06041945|Experimental|Leave-In-Situ Arm|"Standard, high-definition colonoscopy with the use of CADe/CADx assistance (GI-GENIUS, Medtronic; CAD-EYE, Fujifilm; WISE VISION, NEC).~Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology."
89294683|NCT05573737|Experimental|Group Receiving Umbilical Cord Training|Oral umbilical care training will be given to the primiparous mothers who gave birth on odd days of the week and met the research criteria, and the training brochure will be printed out and given to the mothers. The training will be given face-to-face during the postpartum period when the mother is stabilized. In order to increase the effectiveness of the training, the content of the training will be reinforced by making mutual questions and answers.
89294684|NCT05573737|No Intervention|Group Without Umbilical Cord Training|The routine operation of the clinic will be carried out without any intervention for primiparous mothers who gave birth on even days of the week and met the research criteria.
89294685|NCT05571592|Experimental|Cannabidiol 400mg|Participants assigned to 200mg twice-daily (400mg/day) dose for 3 weeks.
89294686|NCT05571592|Experimental|Cannabidiol 800mg|Participants assigned to 400mg twice-daily (800mg/day) dose for 3 weeks.
89294687|NCT05571592|Placebo Comparator|Placebo|Participants assigned to twice-daily placebo dose for 3 weeks.
89294688|NCT05559905|Experimental|Panel A: Molnupiravir Prophylaxis|Participants receive molnupiravir 800 mg every 12 hours for 5 days beginning on Day -1, and are inoculated with RSV-A Memphis 37b on Day 0. Participants then receive placebo on the evening of Day 4 to the morning of Day 10.
89294689|NCT05559905|Experimental|Panel B: Molnupiravir Triggered Treatment|Participants receive placebo on Day -1, are inoculated with RSV-A Memphis 37b on Day 0, and continue to receive placebo until testing positive for RSV. Participants then receive molnupiravir 800 mg every 12 hours for 5 days.
89294690|NCT05559905|Placebo Comparator|Panel C: Matched Placebo|Participants receive placebo from Day -1 to Day 10, and are inoculated with RSV-A Memphis 37b on Day 0.
89294691|NCT05556759|Placebo Comparator|control group|patients will be operated on under general anesthesia
89294692|NCT05556759|Active Comparator|IPS group|patients will receive an ultrasound-guided anterior iliopsoas muscle space (IPS) block
89294693|NCT05556759|Active Comparator|Supra-iliac QL group|patients will receive an ultrasound-guided supra-iliac anterior quadratus lumborum (QL) block
89294694|NCT05538832|Experimental|Visual Perception Training|Contains targeted visual perception exercises from BrainHQ's suite of cognitive exercises. This training paradigm is designed to improve state estimation processes at the perceptual input level.
89294695|NCT05538832|Experimental|Visual Cognitive Control Training|Contains targeted visual cognitive control exercises from BrainHQ's suite of exercises. This training paradigm is designed to enhance state representation stability of visual information.
89294696|NCT05536791||Pediatric patients eligible for Dabigatran Etexilate (DE) VTE treatment and secondary VTE prevention|
89294697|NCT05529264|Experimental|Invasive EEG (electrodes are implanted in a participant's brain)|Patients with intracranial electrodes (electrodes are implanted in a participant's brain) undergoing pre-surgical evaluation for clinical reasons will be asked to participate in various study tasks with the recording of intracranial EEG (recording of brain waves via electrodes implanted in a participant's brain) during these tasks.
89294698|NCT05529264|Experimental|Scalp EEG (electrodes are placed on a participant's scalp)|Patients with non-invasive scalp electrodes who are admitted to the hospital for clinical reasons will be asked to participate in various study tasks with the recording of their EEG (recording of brain waves via electrodes attached to a participant's scalp) during these tasks.
89294699|NCT05529264|Active Comparator|Normal Controls|Normal controls will be recruited from family members of patients, from advertisements, or from online tools. There will be no EEG recordings obtained from these participants.
89294700|NCT05529264|Active Comparator|Online Controls|Certain control subjects will be recruited through Amazon Mechanical Turk. These participants will be given their task on the online platform using Qualtric survey function. The task design will be identical to normal controls who are recruited in-person, with the exception of identifiers. There will be no EEG recordings obtained from these participants.
89294701|NCT05522231|Experimental|Investigational arm|fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
89294702|NCT05522231|Active Comparator|Control arm (comparator)|axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion ;Everolimus, 10 mg, QD, PO, 3 weeks/cycle.
89294703|NCT05522231|Other|Fruquintinib monotherapy factorial study|fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
89294704|NCT05513833|Other|Sequence 1|"Standard School Screening: All counties in Sequence 1 will receive standard hearing screening in the control period, Year 1~Standard Referral: All counties in Sequence 1 will receive standard referral in control period, Years 1 and 2.~Enhanced mHealth screening component: Counties randomized to Sequence 1 will receive the enhanced mHealth screening in Years 2, 3, and 4.~Specialty telemedicine referral component: Counties randomized to Sequence 1 will receive the specialty telemedicine referral component in addition to the enhanced mHealth screening in Years 3 and 4."
89294705|NCT05513833|Other|Sequence 2|"Standard Hearing Screening: All counties in Sequence 2 will receive standard hearing screening in the control period, Years 1 and 2~Standard Referral: All counties in Sequence 2 will receive standard referral in control period, Years 1, 2 and 3.~Enhanced mHealth screening component: Counties randomized to Sequence 2 will receive the enhanced mHealth screening in Years 3 and 4.~Specialty telemedicine referral component: Counties randomized to Sequence 2 will receive the specialty telemedicine referral component in addition to the enhanced mHealth screening in Year 4."
89294706|NCT05507918|Experimental|Low fluid intake|0.5 L - 1.5 L fluid intake in the 24 hours prior to NPO status for surgery
89294707|NCT05507918|Experimental|Medium fluid intake|1.5 L - 3 L fluid intake in the 24 hours prior to NPO status for surgery
89294708|NCT05507918|Experimental|High fluid intake|3 L - 4.5 L fluid intake in the 24 hours prior to NPO status for surgery
89294709|NCT05484154|Active Comparator|10mg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
89294710|NCT05484154|Active Comparator|15mg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
89294711|NCT05484154|Active Comparator|30mg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
89294712|NCT05484154|Placebo Comparator|Placebo|Matching placebo, q12h for up to 5 doses
89294713|NCT05467306|Experimental|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
89294714|NCT05467306|No Intervention|Standard PrEP services|Standard PrEP services
89294715|NCT05459077|Other|Aim 3B|This aim will evaluate the feasibility and acceptability of the adapted health care delivery intervention to improve anti-hypertensive medication adherence and blood pressure control in persons living with HIV at 24 weeks.
89294716|NCT05450848|Experimental|StrataXRT|Patients allocated to receive StrataXRT will be provided with StrataXRT gel to apply twice daily to the irradiated area until any radiation dermatitis that may occur has resolved. In case the patient develops radiation dermatitis that results in moist desquamation, IntraSiteTM gel (Smith and Nephew, UK) and secondary dressings will be provided.
89294717|NCT05450848|Active Comparator|Standard of care|Patients allocated to receive standard care will be provided with aqueous cream to apply daily to the irradiated area until any radiation dermatitis that may occur has resolved. In case the patient develops radiation dermatitis that results in moist desquamation, IntraSiteTM gel (Smith and Nephew, UK) and secondary dressings will be provided.
89294718|NCT05441956|Experimental|TGRX-326|Subjects to be treated with the investigational drug TGRX-326
89294719|NCT05429112|Active Comparator|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
89294720|NCT05429112|Active Comparator|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
89294721|NCT05418894|No Intervention|EMU|Patient's behavioral and neural activity via computer tasks and questionnaires are monitored in the Epilepsy Monitoring Unit
89294722|NCT05418894|Experimental|TRD|
89294723|NCT05416489|Active Comparator|Traditional direct laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a traditional direct laryngoscopy technique.
89294724|NCT05416489|Active Comparator|C-MAC videolaryngoscope technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscope technique.
89294725|NCT05394714|Experimental|Magicell-NK|Magicell-NK Cohort 1: 2 x 108 cells x 6 infusions Cohort 2: 6 x 108 cells x 6 infusions Cohort 3: 18 x 108 cells x 6 infusions
89294726|NCT05382936|Experimental|QD Regimen|Patients in the QD regimen will take study medication once daily.
89294727|NCT05382936|Experimental|BID Regimen|Patients in the BID regimen will take study medication twice daily.
89294728|NCT05380414|Experimental|Metastatic/advanced PDAC Patients|Tumor samples
89294729|NCT05377424|Experimental|AIH + istradefylline (AIH+IST)|Participants enrolled in this study arm will ingest a 20mg tablet containing istradefylline. Four hours later, participants will receive acute intermittent hypoxia (AIH). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after AIH. Participants will breathe 15 episodes/session of acute low oxygen. Air concentrations will be monitored to ensure delivery of 1-minute episodes of low oxygen, with 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
89294730|NCT05377424|Active Comparator|Sham-AIH + istradefylline (sham+IST)|This is a sham counterpart to the low oxygen. Participants enrolled in this study arm will ingest a 20mg tablet containing istradefylline. Four hours later, participants will receive SHAM acute intermittent hypoxia (SHAM). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after SHAM. Participants will breathe 15 episodes/session of sham low oxygen, in which normal air is used. One-minute episodes of sham low oxygen are separated by 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
89294731|NCT05377424|Active Comparator|AIH + placebo (AIH+CON)|This is a placebo counterpart to the istradefylline drug. Participants enrolled in this study arm will ingest a 20mg tablet containing microcrystalline cellulose. Four hours later, participants will receive acute intermittent hypoxia (AIH). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after AIH. Participants will breathe 15 episodes/session of acute low oxygen. Air concentrations will be monitored to ensure delivery of 1-minute episodes of low oxygen, with 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
89294732|NCT05377424|Active Comparator|Sham-AIH + placebo (sham+CON)|This is a sham counterpart to low oxygen, and a placebo counterpart to the istradefylline drug. Participants enrolled in this study arm will ingest a 20mg tablet containing microcrystalline cellulose. Four hours later, participants will receive SHAM acute intermittent hypoxia (SHAM). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after SHAM. Participants will breathe 15 episodes/session of sham low oxygen, in which normal air is used. One-minute episodes of sham low oxygen are separated by 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
89294733|NCT05370833|Experimental|Standard protocol|5 tDCS sessions in 1 week
89294734|NCT05370833|Experimental|Enhanced protocol|11 tDCS sessions devised in 4 weeks
89294735|NCT05364853|Other|In-Person Testing|In this arm, participants will undergo the neuropsychological assessment of interest (DAYC-2) in-person.
89294736|NCT05364853|Other|Remote Testing|In this arm, participants will undergo the neuropsychological assessment of interest (DAYC-2) remotely over video/telehealth.
89294737|NCT05362747|Experimental|ProduceRx|Participants in the ProduceRx intervention group will be provided with BWL and produce vouchers for fresh fruits and vegetables.
89294738|NCT05362747|No Intervention|Waitlist Control|Participants in the WLC group with be asked to stay weight stable, not to make changes in their eating and physical activity behaviors, and not to seek treatment for weight or eating during the waiting period.
89294739|NCT05349981|Experimental|Lyric self-replacement|This cohort of experienced Lyric patients are required to meet the candidacy criteria to be eligible for the self-replacement procedure. They will also be required to demonstrate proficiency with the self-replacement procedure before proceeding with independent self-replacement.
89294740|NCT05338164|Experimental|Cerclage group|cervical cerclage between 14 and 20 weeks will be done by one of the three authors.
89294741|NCT05338164|No Intervention|No Cerclage group|Routine follow up without cerclage
89294742|NCT05334264|Experimental|Group A|cervical cerclage between 14 and 20 weeks will be done by one of the three authors. McDonald cervical cerclage.
89294743|NCT05334264|No Intervention|Group B|Routine antenatal care without cerclage
89294744|NCT05318989||Premenopausal women (PREM)|Control group
89294745|NCT05318989||Postmenopausal women (POSMA)|Test group A : postmenopausal women not treated with topical estrogens
89294746|NCT05318989||Postmenopausal women (POSMB)|Test group B: postmenopausal women treated with topical estrogens
89294747|NCT05292118||Coronary Artery Disease (CAD)|
89294748|NCT05286125|Active Comparator|erector spinae plane (ESP) block group ( (E) group)|Under aseptic conditions, a high frequency linear transducer will be placed on the spinous process at T8 level on the parasagittal plane and then slid 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle.
89294749|NCT05286125|Active Comparator|oblique subcostal transverse abdominis plane (TAP) block ( (T) group) )|Under aseptic conditions, the probe will be initially placed below the xyphoid process to view the linea alba, then directed obliquely down the costal margin while keeping the rectus abdominis muscle in view. The transverse abdominis muscle come into view below the rectus abdominis muscle. The probe will be advanced further until the semilunaris is viewed.
89294750|NCT05282927|Active Comparator|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in our prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
89294751|NCT05282927|Experimental|Enhanced REP|EnREP begins with the same activities as foundational REP. Sites that do not meet EBP-specific a priori benchmarks reflecting adoption within 6 months will continue with foundational REP and will receive higher intensity support for a period of 6 months (enREP). Additionally, sites randomized to enREP that met adoption benchmarks but did do not meet the sustainment benchmark, will also receive intensified implementation support for the remainder of the study period (3 months). The higher intensity support will include one-on-one calls approximately every 3 to 4 weeks between site implementation teams and a trained practice facilitator (from Function QUERI team). The facilitator will coach individual sites using techniques, processes, and activities to help teams make decisions and identify and solve problems. Facilitators? actions will depend on each site?s needs and clinical context.
89294752|NCT05273086|Experimental|Sleep intervention program|The Sleep Intervention program Group will be subdivided into two groups of 10 participants to receive the sleep quality improvement program. The program consists of 2 sessions of 90 minutes during one week.
89294753|NCT05273086|No Intervention|Control Group|The control group will continue with their usual routine.
89294754|NCT05262764||Patients with chronic heart failure (CHF)|
89294755|NCT05248737||Group 1 - DHA/EPA bioenhanced poultry (n=24)|Participants will be asked to consume two meals of chicken, one meal will contain chicken that has been fed omega-3 fatty acids so the chicken contains omega 3 (DHA/EPA) fatty acids and the other meal will consist of non enhanced chicken and a DHA supplement. Each participant will be asked to eat both of these forms of chicken in random order. Each study is expected to take 9-hours and the two visits will be separated by a period of two weeks. A total of 5 blood samples will be collected over a 9-h period.
89294756|NCT05248737||Group 2 - 25(OH)D bioenhanced poultry (n=36)|Participants will be asked to consume 1 serving of 25-hydroxyvitamin D (25(OH)D enhanced chicken or non-fortified chicken that does not contain additional 25(OH)D and a vitamin D supplement every day for 21 days. Your participation in the study is expected to last 3 weeks. On Monday-Friday you will be asked to eat lunch in the HMRU on the Cornell campus. On weekends you will be given packaged chicken to eat at home. At 4 timepoints over the 3-week study, a blood draw will be collected to measure vitamin D status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit should last about 30 minutes. The total time needed to complete study visits in the HMRU is 10 hours over the 21-day period.
89294757|NCT05248737||Group 3 - DHA/EPA and 25(OH)D bioenhanced poultry (n=24)|Participants will be asked to consume chicken that contains both omega3 (DHA/EPA) fatty acids and vitamin D (25(OH)D) for a 3week period. On the first day, you will be asked to spend around 9h in the HMRU, and will be fed a breakfast containing this chicken. A total of 5 blood samples will be collected over the 9h period. You will be asked to stay in the HMRU for this 9h study and will be fed breakfast, lunch and dinner. For the next 3w you will be asked to eat this chicken at lunch in the HMRU on the Cornell campus on weekdays (Monday-Friday). On weekends you will be given two packaged frozen chicken servings to eat at home (one serving per day). At 4 timepoints over the 3-week study, a blood draw will be collected to measure (25(OH)D) status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit to the HMRU should last about 30 minutes. The time needed to complete this study in the HMRU is 10 hours over the 3w period.
89294758|NCT05234567||Participants with Pediatric-onset HPP|Each participant will be followed for a minimum of 5 years or, if applicable, until early withdrawal. Biochemical, clinical, imaging (if clinically indicated), and functional/quality of life outcomes relevant to HPP will be assessed.
89294759|NCT05233579|Experimental|Sulforaphane 1 Tablet|Participants are taking 1 tablet per day. All participants will start with 1 tablet and continue with 1 tablet for 2 weeks before increasing dose.
89294760|NCT05233579|Experimental|Sulforaphane 2 Tablets|Participants will increase dosage to 2 tablets per day after 2 weeks from the start of study participation. Participants will continue to take 2 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 1 tablet.
89294761|NCT05233579|Experimental|Sulforaphane 3 Tablets|Participants will increase dosage to 3 tablets per day at 4 weeks from the start of study participation. Participants will continue to take 3 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 2 tablets.
89294762|NCT05233579|Experimental|Sulforaphane 4 Tablets|Participants will increase dosage to 4 tablets per day at 6 weeks from the start of study participation. Participants will continue to take 4 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 3 tablets.
89294763|NCT05233579|Experimental|Sulforaphane 5 Tablets|Participants will increase dosage to 5 tablets per day at 8 weeks from the start of study participation. Participants will continue to take 5 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 4 tablets.
89294764|NCT05233579|Experimental|Sulforaphane|Participants will increase dosage to 6 tablets per day at 10 weeks from the start of study participation. Participants will continue to take 6 tablets for 2 addiitonal weeks before increasing dose. If participants experience adverse side effects, participants will decrease dosage to 5 tablets.
89294765|NCT05227612|Experimental|Psilocybin + CBT|All participants will receive 12 sessions of cognitive-behavioral therapy (CBT) along with two psilocybin-drug sessions -- the first following the third CBT session (10mg of psilocybin, taken orally) and the second following the sixth CBT session (25mg of psilocybin, taken orally).
89294766|NCT05222893|Active Comparator|PEEP Pes|PEEP adjustment according to the pressure indicators in the lower third of the esophagus Pes (intervention group)
89294767|NCT05222893|Active Comparator|PEEP 5|PEEP constantly set at 5 cmH2O (control group)
89294768|NCT05208892|Experimental|SZMN Treatment Group|Patients randomized into the SZMN treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic per side.
89294769|NCT05208892|Experimental|SZMN+Dexmedetomidine Treatment Group|Patients randomized into the SZMN+Dexmedetomidine treatment group will receive bilateral single injection SZMN blocks under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthetic along with 0.25 mcg/kg (max 10 mcg) Dexmedetomidine on each side (total of 0.5 mcg/kg, total max 20 mcg).
89294770|NCT05208892|No Intervention|No Intervention: Control Group|Patients in this group will receive the standard of care for T&A procedures within the pediatric population.
89294771|NCT05198089|Experimental|Arm I (MyInspiration)|Patients use MyInspiration for spiritual and/or religious guidance for 30 days.
89294772|NCT05154955|Experimental|10XB-101 Solution for Injection, 2.0%|Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
89294773|NCT05154955|Experimental|10XB-101 Solution for Injection, 3.0%|Participants receive 10XB-101 Solution for Injection, 3.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
89294774|NCT05154955|Experimental|10XB-101 Solution for Injection, 4.5%|Participants receive 10XB-101 Solution for Injection, 4.5% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
89294775|NCT05154955|Placebo Comparator|10XB-101 Vehicle Solution for Injection|Participants receive 10XB-101 Vehicle Solution for Injection, via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
89294776|NCT05153369|Experimental|Level 1|At enrollment, participants will be categorized according to the following criteria related to suicidality, emotion dysregulation, risk behaviors, and participant preference: No lifetime suicidal behaviors on the Columbia-Suicide Severity Rating Scale (C-SSRS) AND no active suicidal ideations with method/plan/intent in the past month on the C-SSRS (cannot score 'yes' on items > 3) AND a score of < 73 on the Difficulties in Emotion Regulation Scale (DERS).
89294777|NCT05153369|Experimental|Level 2|At enrollment, participants will be categorized according to the following criteria related to suicidality, emotion dysregulation, risk behaviors, and participant preference: No non-suicidal self-injurious (NSSI) behaviors in the past 3 months on the C-SSRS AND no suicide attempts (actual, interrupted and/or aborted) in the past year on the C-SSRS AND a score of < 30 on the Suicidal Ideation Questionnaire (SIQ) AND a score of < 105 on the DERS OR participant preference.
89294778|NCT05153369|Experimental|Level 3|At enrollment, participants will be categorized according to the following criteria related to suicidality, emotion dysregulation, risk behaviors, and participant preference: NSSI behaviors in the past 3 months on the C-SSRS OR at least 1 suicide attempt in the past year (actual, interrupted, and/or aborted) on the C-SSRS OR a score of ≥ 30 on the SIQ OR a score of ≥ 105 on the DERS OR Meets youth threshold for at least 2 impulsive behavior categories on question #4 from the Structured Interview for DSM-IV Personality Disorders Borderline Personality Disorder (SIDP-IV) or 1 category is identified as severe OR participant preference during the course of treatment.
89294779|NCT05142605|Experimental|Cohort 1: Meaning-Centered Grief Therapy/MCGT|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
89294780|NCT05142605|Active Comparator|Group 2: Supportive Psychotherapy /SP|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
89294781|NCT05142605|Active Comparator|Group 3: Enhanced usual care/EUC|Participants will consist of parents who have lost a child to a cancer diagnosis within the last 6 months
89294782|NCT05138471|Experimental|tDCS Active vs TENS Active|
89294783|NCT05138471|Experimental|tDCS Active vs TENS Placebo|
89294784|NCT05138471|Placebo Comparator|tDCS Placebo vs TENS Placebo|
89294785|NCT05138120|Experimental|Common Elements Toolbox|
89294786|NCT05138120|No Intervention|Wait-list control|
89294787|NCT05136339|Experimental|Immediate Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions immediately after enrollment.
89294788|NCT05136339|Experimental|Delayed Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions approximately 12 months after enrollment.
89294789|NCT05129345||Aim 1|People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit including being consented electronically and complete a demographic survey, a photography training visit and an interview visit.
89294790|NCT05129345||Aim 2|People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit and be electronically consented to study and complete an electronic survey.
89294791|NCT05129345||Aim 3|Group composed of 10 willing participants recruited from the participating clinics and community based organizations and may include, HIV providers, nurses, pharmacists, people living with HIV who have cardiometabolic disorders, and representatives of the community advisory boards, and any other key stakeholders. There will be 3 one hour meetings over 3 months.
89294792|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
89294793|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
89294794|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
89294795|NCT05119920|Placebo Comparator|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
89294796|NCT05107362||Symptomatic Adult and Pediatric Subjects|Untrained lay user to collect throat swab specimen and perform investigational test.
89294797|NCT05102656||Group A (video call)|Patients receive standard of care via video call with treating physician.
89294798|NCT05102656||Group B (in-person)|Patients receive standard of care in-person physician visits.
89294799|NCT05092191|Experimental|CBD alone|"Dosage form : Softgel~Dosage & frequency : 40 mg /day of CBD up to 200 mg in two doses a day~Duration : 4 weeks of treatment followed by 12 additional weeks of follow up."
89294800|NCT05092191|Experimental|THC alone|"Dosage form : Softgel~Dosage & frequency : 4 mg /day of THC up to 20 mg in two doses a day~Duration : 4 weeks of treatment followed by 12 additional weeks of follow up."
89294801|NCT05092191|Experimental|THC and CBD combined|"Dosage form : Softgel~Dosage & frequency : 40 mg /day of CBD up to 200 mg and 4 mg /day of THC up to 20 mg in two doses a day~Duration : 4 weeks of treatment followed by 12 additional weeks of follow up."
89294802|NCT05092191|Placebo Comparator|Placebo|"Dosage form : Softgel~Dosage & frequency : caps of placebo twice a day~Duration : 4 weeks of treatment followed by 12 additional weeks of follow up."
89294803|NCT05064397|Experimental|Eptinezumab|Participants will receive 4 intravenous (IV) infusions with eptinezumab at Baseline (Day 0) and at the end of Weeks 12, 24, and 36.
89294804|NCT05057676|Experimental|Intervention Autoimmune Intervention Mastery Course (AIM) online course|This arm will begin the intervention immediately after randomization
89294805|NCT05057676|Other|Delayed Autoimmune Intervention Mastery Course|This is the control arm.
89294806|NCT05054868|Active Comparator|Group 1 (Control group) - Oxycodone only|Subjects randomized to this group will receive oxycodone for postop pain management (standard of care).
89294807|NCT05054868|Experimental|Group 2 (Treatment group) - Oxycodone and Ketorolac|Subjects randomized to this group will receive oxycodone and ketorolac for postop pain management.
89294808|NCT05048082|Experimental|Fluorescence imaging with pegsitacianine|Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.
89294809|NCT05046535||Smokers|Individuals with MS who are current tobacco smokers: Either cigarettes, hookah pipe, E-cigarettes or other forms of tobacco. This group will perform all the assessments including surveys about nicotine dependence and smoking behavior.
89294810|NCT05046535||Non-smokers|Individuals with MS who are non-smokers of any form of tobacco. This group will perform all the assessments except for the surveys related to nicotine dependence and smoking behavior.
89294811|NCT05024292||rapid local ischemic postconditioning (RL-IPostC) group|RL-IPostC is performed immediately after successful reperfusion with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation.
89294812|NCT05024292||control group|no intervention was provided after successful reperfusion
89294813|NCT05015504|Experimental|Time restricted feeding|The study will consist of three phases. In phase I all study subjects will be in the ad libitum feeding phase for one week followed by Phase II. In Phase II the subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week. For phase III (final week), patients will be returned to an ad libitum feeding. The first and third phases will serve as control phases, and the second phase will be the experimental phase
89294814|NCT05007977|Experimental|Treatment order: placebo, low dose, high dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
89294815|NCT05007977|Experimental|Treatment order: placebo, high dose, low dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
89294816|NCT05007977|Experimental|Treatment order: low dose, placebo, high dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
89294817|NCT05007977|Experimental|Treatment order: low dose, high dose, placebo|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
89294818|NCT05007977|Experimental|Treatment order: high dose, placebo, low dose|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
89294819|NCT05007977|Experimental|Treatment order: high dose, low dose, placebo|Subjects will receive a single administration of each treatment in this order during three consecutive clamps
89294820|NCT05000359|Other|AYA Text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
89294821|NCT04926805|Experimental|Mask A|Overnight CPAP using the participant's usual pressure settings and using Mask A. One night only.
89294822|NCT04926805|Active Comparator|Mask B|Overnight CPAP using the participant's usual pressure settings and using Mask B. One night only.
89294823|NCT04922827|Experimental|Infliximab + Standard of Care|
89294824|NCT04922827|Active Comparator|Standard of Care|
89294825|NCT04921930|Experimental|Artesunate|"Dose escalation of oral artesunate:~Step 1: 25 mg daily (1 tablet) during one week Step 2: 50 mg daily (2 tablets) during one week (if no effect on biomarker and no adverse reaction at step 1) Step 3: 75 mg daily (3 tablets) during one week (if no effect on biomarker and no adverse reaction at step 2) Step 4: 100 mg daily (4 tablets) duing one week (if no efficacy and no adverse reaction at step 3)"
89294826|NCT04909684|No Intervention|Standard of care|100% pembrolizumab
89294827|NCT04909684|Experimental|Intervention|75% pembrolizumab
89294828|NCT04893837||Standard care plus infrascans|"All participants will receive regular clinical neurological assessments as ordered by the clinical care team. In addition, a research team member will perform an infrascan. This process will be repeated hourly at the same timepoint as the clinical neurological assessments. If a patient's neurological status deteriorates at any time point, and the medical team orders an early (unplanned) CT scan, the neurological data collection will cease once the patient is sent to CT.~Infrascan results will not be shared with the clinical care team, and will not guide the participants' care in any way."
89294829|NCT04877457|Experimental|Ocrelizumab|Three courses of ocrelizumab will be administered over the course of the study.
89294830|NCT04877457|Placebo Comparator|Placebo|Three courses of placebo will be administered over the course of the study.
89294831|NCT04859205|Experimental|Intervention|"All participants partaking the SUPPORT-Pro study will receive the full intervention for 3 months which implies: (1) Full access to the platform (2) a newsletter sent by email every 2 weeks to inform them on the new blogs posted on the platform.~During the following 9 months, participants will still have access to the platform, but no newsletter will be sent (sustainability phase)."
89294832|NCT04820127|No Intervention|Control (usual care)|Patients in the control group will benefit from the usual care with a half-yearly visit by the specialist physician (geriatrician, neurologist or psychiatrist) according to AD French national management guidelines (HAS 2011 and HAS 2018).
89294833|NCT04820127|Experimental|Intervention (personalized care program)|Patients in the intervention group will benefit from personalized care preceded by a standardized assessment
89294836|NCT04725344|Experimental|ACTIV'DOS group|ACTIV'DOS is a smartphone application of self rehabilitation. There are 7 muscular exercices. Patients going to exercices during 15 minutes per day, during 6 weeks.
89294837|NCT04725344|Experimental|Control group|This group uses a sheet of paper for self-rehabilitation exercise. The self-rehabilitation program is the same as the ACTIV'DOS group. Patients have to exercise during 15 minutes per day, during 6 weeks.
89294838|NCT04720300|Active Comparator|MaaS app|The Mobility-as-a-Service (MaaS) App will be provided to students in the Intervention Group and is intended to facilitate their use of alternative transportation modes such as public transit, ride-hailing, walking, biking, bike share, and e-scooter share to get to campus. The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app. This means, for instance, that a student can plan a trip that includes driving to a train station, taking the train, and then walking from the alighting train station to their final destination. The app will be white label, i.e. it will have a customized look and feel specific to the participating south Florida colleges, and it will have personalization features so that students can tailor the app to their travel patterns. Students in a cluster assigned to the MaaS group will also receive information concerning housing options. Students complete surveys
89294839|NCT04720300|Placebo Comparator|No app|Students receive no app, no housing information, students complete surveys.
89294840|NCT04703322|Experimental|Pexidartinib|Participants with TGCT who will receive oral pexidartinib 800 mg (400 mg twice daily [BID]).
89294841|NCT04701515||Retrospective Cohort|Review electronic medical records of de-identified patients that tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until December 2022
89294842|NCT04684537|Active Comparator|Shockwave group|each subject will receive extracorporeal shockwave therapy
89294843|NCT04684537|Active Comparator|Injection group|each subject will receive ultrasound-guided piriformis corticosteroid injection
89294844|NCT04682730|Experimental|Deliberative Loop|28-page Context-Setting Document; 2-page addendum to Context-Setting Document; 90 minute Deliberative session; 8-page post-session survey
89294845|NCT04673370|Experimental|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
89294846|NCT04673370|Active Comparator|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
89294847|NCT04663646|Experimental|Intervention Group|
89294848|NCT04663646|Placebo Comparator|Control Group|
89294849|NCT04634253|Experimental|LY3462817 300 mg|Participants received Intravenous (IV) infusion of 300 mg LY3462817 solution.
89294850|NCT04634253|Experimental|LY3462817 700 mg|Participants received IV infusion of 700 mg LY3462817 solution.
89294851|NCT04634253|Placebo Comparator|Placebo|Participants received IV infusion of 0.9% sodium chloride solution (Placebo).
89294852|NCT04631510|Experimental|Critically ill patients|Administer gabapentin 300 mg PO at 8 PM for sleep
89294853|NCT04614441||Idiopathic Pulmonary Fibrosis (IPF)|
89294854|NCT04614441||Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
89294855|NCT04614441||Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)|
89294856|NCT04612257|Experimental|Insulin alone closed-loop|Insulin alone closed-loop algorithm in children with type 1 diabetes in a free-living study.
89294857|NCT04609956|Experimental|virtual reality|Experimental arm is a virtual reality headphones
89294858|NCT04609956|Other|standard|Control arm is a usual practice (hydroxyzine + patient music with headphones)
89294859|NCT04566003|Experimental|[18F]PI-2620 PET, then [18F]GTP1 PET|Participants will undergo one [18F]PI-2620 PET imaging session, then one [18F]GTP1 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of [18F]PI-2620 or 7mCi of [18F]GTP1.
89294860|NCT04566003|Experimental|[18F]GTP1 PET, then [18F]MK-6240|Participants will undergo one [18F]GTP1 PET imaging session, then one [18F]MK-6240 PET imaging session. Prior to each session, participants will be administered a bolus intravenous injection of approximately 5 millicurie (mCi) of [18 F]MK-6240 or 7mCi of [18F]GTP1.
89294861|NCT04559581||Patients newly initiating Nintedanib|
89294862|NCT04556734|Experimental|Etrasimod 2 mg|
89294863|NCT04556734|Experimental|Etrasimod 3 mg|
89294864|NCT04556734|Placebo Comparator|Placebo|
89294865|NCT04553640|Experimental|Group A/Intervention Curriculum|Virtual patient (VP) cases and feedback available through solving VP cases and participants' self-report on the diagnosis of dizzy patients in the emergency department.
89294866|NCT04553640|Active Comparator|Group B/Control curriculum|Online articles on dizziness AND regular emergency department clinical rotations
89294867|NCT04552119||HEALICOIL Knotless Suture REGENESORB|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless REGENESORB
89294868|NCT04552119||HEALICOIL Knotless PEEK|HEALICOIL™ Knotless Suture Anchor in Shoulder Rotator Cuff Tendon Repair using HEALICOIL Knotless PEEK
89294869|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM + Tech Detailing|
89294870|NCT04549259|Experimental|Social Support + Stigma Reduction + SBCM|
89294871|NCT04549259|Experimental|Social Support + Stigma Reduction + Technology Detailing|
89294872|NCT04549259|Experimental|Social Support + Stigma Reduction|
89294873|NCT04549259|Experimental|Social Support + SBCM + Technology Detailing|
89294874|NCT04549259|Experimental|Social Support + SBCM|
89294875|NCT04549259|Experimental|Social Support + Technology Detailing|
89294876|NCT04549259|Experimental|Social Support|
89294877|NCT04549259|Experimental|Stigma Reduction + SBCM + Technology Detailing|
89294878|NCT04549259|Experimental|Stigma Reduction + SBCM|
89294879|NCT04549259|Experimental|Stigma Reduction + Technology Detailing|
89294880|NCT04549259|Experimental|Stigma Reduction|
89294881|NCT04549259|Experimental|SBCM + Technology Detailing|
89294882|NCT04549259|Experimental|SBCM|
89294883|NCT04549259|Experimental|Technology Detailing|
89294884|NCT04549259|No Intervention|HIV Information Only|This arm will not receive any of the 4 intervention components but will receive information on successfully aging with HIV.
89294885|NCT04522050|Other|Induction chemotherapy + IMRT and concurrent gemcitabine|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m²,d1) every 3weeks for 2 cycles before radiotherapy, and then receive intensity modulated radiotherapy (IMRT) concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. Patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
89294886|NCT04494516||Pre-trial|This cohort of participants will be recruited preceding evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with design of the intervention and implementation strategy. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
89294887|NCT04494516||Post-trial|This cohort of participants will be recruited after evaluation of the community-based pediatric TB prevention intervention (CHIP-TB; NCT04369326) to assist with future scale up and dissemination of the intervention. Participants will include four stakeholder groups including: (1) policy makers, program managers, (2) nurse and physician clinicians, (3) community health team members, and (4) caregivers of child contacts from both South African and Ethiopian sites.
89294888|NCT04481048|Experimental|N-Acetylcysteine (NAC)|"Each subject will be dosed with approximately 70 mg/kg/day of NAC for 8 weeks. To facilitate drug compounding, three tiers of drug dose will be administered based on body weight as described in Table 3.~Table 3: NAC Dosing Participant's weight (kg) Dose (BID) < 20 700 mg 21-39 1050 mg > 40 1350 mg~*Max dose not to exceed 2700mg/day (1350mg BID)"
89294889|NCT04481048|Placebo Comparator|Placebo|Each subject will be dosed with placebo for 8 weeks.
89294890|NCT04481048|No Intervention|Single Visit/Non-Treatment Arm|"Based on preliminary data, an additional Single visit, non-treatment cohort will include 40 individuals with NF1 for a single biomarker study visit. These individuals will undergo motor function (PANESS) and brain-based measures (TMS, MRI-MRS, DTI) as biomarkers of impaired executive function (ADHD-RS; BRIEF-2; TOVA) but will not be assigned to receive NAC/Placebo."
89294891|NCT04479787|Active Comparator|Spinal Cord Stimulation (SCS)|An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
89294892|NCT04479787|Active Comparator|Conventional Medical Management (CMM)|CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
89294893|NCT04428580|Experimental|Online Training|10 lectures that are self-paced with a maximum of three months to complete with each lecture bundle comprising of 5-8 short (about 4 minutes in length), didactic videos that discuss the treatment model and provide mock therapy session video clips (modeling FBT with a typical adolescent AN case), as well as supplementary readings and videotaped role-plays. Enrollees complete each lecture bundle and complete the assignments as they move through the training at their own pace, but to have completed all within the 3-month time frame. When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
89531572|NCT06039007|Experimental|7-DAY FMD|The 7-DAY FMD by L-Nutra is a low-calorie and low-protein diet that provides all the necessary micronutrients to prevent malnutrition. This medically-designed dietary kit supplies food for 7 days, with Day 1 providing 1100 kcal, while days 2 to 5 provide 800 kcal per day. The diet consists of ingredients that are Generally Regarded As Safe (GRAS), selected for their fasting mimicking properties. Patients will take the 7-DAY FMD once every 60 days.
89531573|NCT06024538||Prospective part of the study|
89294894|NCT04428580|Active Comparator|Webinar Training|1-hour weekly webinar lectures that essentially is the FBT training that is conducted in person, just recorded. There will be lectures discussing the scientific evidence supporting FBT, how therapists set up treatment for FBT, main interventions used in FBT during each phase, and recorded role-plays illustrating interventions throughout the 3 phases. Enrollees watch each webinar video as it is released weekly over a 12 week (3 month period). When the training is completed, therapists will proceed to schedule post-online supervision for a minimum of 1 case and a maximum of 2 cases over the course of 3 months.
89294895|NCT04421989|Experimental|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
89294896|NCT04421989|Active Comparator|Support Group|Participants randomized to FBT + Support parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The parent support group facilitates parent discussion and support around a variety of topics central to treatment for pediatric AN including: understanding medical co-morbidities, levels of care for treatment, understanding expected body weight, navigating FMLA, and medications. The facilitator introduces each topic weekly and opens up discussion between parents. The facilitator's role is to ensure the group remains on topic and on time.
89294897|NCT04410133|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
89294898|NCT04395495||Neurofibromatosis 1 (NF1)|Individuals with a confirmed or suspected diagnosis of Neurofibromatosis Type 1 (NF1). Diagnosis may be made clinically and/or confirmed through genetic testing. Clinical (non-genetic) diagnosis requires that individuals meet the National Institute of Health's (NIH) clinical diagnostic criteria for NF1.
89294899|NCT04395495||Noonan Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
89294900|NCT04395495||Noonan Syndrome with Multiple Lentigines|Individuals with a confirmed or suspected diagnosis of Noonan Syndrome with Multiple Lentigines. Diagnosis may be made clinically and/or confirmed through genetic testing.
89294901|NCT04395495||Noonan Neurofibromatosis Syndrome|Individuals with a confirmed or suspected diagnosis of Noonan Neurofibromatosis Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
89294902|NCT04395495||Cardiofaciocutaneous Syndrome|Individuals with a confirmed or suspected diagnosis of Cardiofaciocutaneous Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
89294903|NCT04395495||Costello Syndrome|Individuals with a confirmed or suspected diagnosis of Costello Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
89294904|NCT04395495||Legius Syndrome|Individuals with a confirmed or suspected diagnosis of Legius Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
89294905|NCT04395495||Smith-Kingsmore Syndrome|Individuals with a confirmed or suspected diagnosis of Smith-Kingsmore Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.
89294906|NCT04395495||GATOR-1 Mutation|Individuals with a suspected or known mutation of GATOR-1.
89294907|NCT04395495||SYNGAP1-Related Intellectual Disability|Individuals with a suspected or known mutation of SYNGAP1.
89294908|NCT04395495||DLG4 Mutation|Individuals with a suspected or known mutation of DLG4.
89294909|NCT04395495||MAPK1 Gene Mutation|Individuals with a suspected or known mutation of MAPK1.
89294910|NCT04395495||MTOR Gene Mutation|"Individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.~Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway."
89294911|NCT04395495||RAS Mutation|"Individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing.~Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway."
89294912|NCT04392843|Other|Fasting|Subjects will remain fasted prior to insulin-induced hypoglycemia.
89294913|NCT04392843|Active Comparator|Feeding|Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
89294914|NCT04377971|Experimental|Ask-tell-ask method|Study team will provide participant education using the ask-tell-ask method. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
89294915|NCT04377971|Active Comparator|Standard of Care (SOC)|Participants will receive SOC education from the researcher. Participants will receive a post-operative instruction sheet containing detailed information regarding wound care for reference and will receive a phone call at 1 week to inquire about wound care adherence. Participants will come to clinic at 2 weeks to have wounds assessed in addition to answering surveys regarding wound care adherence and participant experience.
89531574|NCT06024226||Patients with lung carcinoma surgically treated by surgery only|
89531575|NCT06019624|Active Comparator|Cohort 1 Receipt of Food Box|Up to 80 individuals with diabetes or prediabetes with a history of food insecurity enrolled in a 6 month program offering free bimonthly fresh food boxes, nutrition education, and individualized support. Each enrolled individual will serve as their own control. The study will evaluate pre and post program changes in reported self-obtained home glucose levels, food security, and dietary intake.
89294916|NCT04357587|Experimental|Pembrolizumab|Experimental pembrolizumab and SOC external beam radiation and capecitabine
89294917|NCT04352244||Surgical Participants|Individuals undergoing abdominal surgery or radiologically-guided biopsies for clinical indications will be recruited prior to the planned procedures.
89294918|NCT04272723||VMP members of the SFMV|VMP (vascular medicine physicians) members of the SFMV (French Society of Vascular Medicine )
89294919|NCT04272723||VMP registered as willing to do medical research|VMP (vascular medicine physicians) registered as willing to do medical research
89294920|NCT04269408|Experimental|NicaPlant®|"10 NicaPlant® implants (total 40 mg nicardipine) will be placed after clip ligation into the basal cisterns in direct contact with the exposed cerebral blood vessel walls.~In addition patients will receive standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines."
89294921|NCT04269408|Other|Control|Standard of care for aneurysmal subarachnoid haemorrhage patients according to the treatment guidelines.
89294922|NCT04247620|Experimental|DiaBetter Together Intervention|Young Adult participants with type 1 diabetes (ages 17-25) who are approaching transfer from pediatric to adult care will be randomized to either the DiaBetter Together Intervention group or the Usual Care group. After randomization to the intervention group, young adults will be assigned a Peer Mentor. Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
89294923|NCT04247620|Other|Peer Mentors|Peer Mentors will deliver the DiaBetter Together intervention and will also be enrolled as study participants to permit assessment of their own outcomes from delivering this peer support intervention to younger people with diabetes. Peer Mentors will be experienced young adults with T1D who have transferred to adult diabetes care.
89294924|NCT04247620|No Intervention|Usual Care|Participants randomized to the comparison condition will receive usual diabetes care only, without additional intervention through the study. They will participate in all study activities related to data collection, but will not receive the Peer Mentor intervention. In both conditions, participation in this study will not impact participants' ability to contact the pediatric TCH diabetes care team or any other medical services to receive medical care.
89294925|NCT04247620|No Intervention|Research Supplement|Following completion of 12-month data collection, a subset of participants from the Usual Care group will have the opportunity to complete an optional and additional week (7 days) of follow-up data collection to characterize general and diabetes-specific sleep patterns.
89294926|NCT04225624|Experimental|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation.
89294927|NCT04225624|Active Comparator|Supportive Psychotherapy (SPT)|Individuals with repetitive negative thinking receiving Supportive Psychotherapy.
89294928|NCT04209634|Experimental|Active PLE|Patients aged 1 year and older with a clinical diagnosis of CD55-deficient PLE disease
89294929|NCT04184401|Experimental|Replacement with albumin|"Check drain amount every 4 hour after SICU admission~Replacement of 70% of drainage from previous 4 hours over next 4 hours~30% of the drainage with 5% albumin~40% of drainage with Hartmann's solution~If, serum K + level> 5mEq/L, replace with 0.9% saline instead of Hartmann solution~If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
89294930|NCT04184401|Active Comparator|Replacement with Hartmann's solution|"Check drain amount every 4 hour after SICU admission~Replacement of 70% of drainage from previous 4 hours with Hartmann's solution over next 4 hours~If, serum K + level> 5mEq/L, replace with 0.9% saline instead of Hartmann solution~If, serum albumin level is below 2.6 g/dL, inject 100mL of 20% albumin"
89294931|NCT04155723||Phase 1 group|During phase 1, Midlines are inserted only by doctors.
89294932|NCT04155723||Phase 2 group|During Phase 2, Midlines are preferentially inserted by ICU nurses, and if needed, by doctors.
89294933|NCT04126486|Other|Zio®XT Monitor Arm|
89294934|NCT04126486|No Intervention|Usual Care Arm|
89294935|NCT04126005||Cohort 1 (Age < 18 Months)|"Motor function assessments (remote or in-clinic) every 2 months~Clinic assessments every 6 months"
89294936|NCT04126005||Cohort 2 (Age ≥ 18 Months - 3 Years)|"Motor function assessments (remote or in-clinic) every 4 months~Clinic assessments every 6 months"
89294937|NCT04126005||Cohort 3 (Age > 3 - 5 Years)|"Motor function assessments (remote or in-clinic) every 6 months~Clinic assessments every 6 months"
89294938|NCT04126005||Cohort 4 (Age > 5 Years)|"Motor function assessments (remote or in-clinic) 12 months~Clinic assessments every 12 months"
89294939|NCT04126005||Cohort 5 (Deceased)|• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.
89294940|NCT04122170|Active Comparator|Bentracimab (PB2452)|PB2452 18 g Intravenous Infusion over a 16 hour duration.
89294941|NCT04122170|Placebo Comparator|Placebo|Placebo (0.9% Sodium chloride) intravenous Infusion over a 16 hour duration.
89294942|NCT04113499|Active Comparator|Direct Endoscopic Necrosectomy|The subject will have endoscopic drainage and necrosectomy at the time of the index intervention.
89294943|NCT04113499|Active Comparator|Step-up Endoscopic Interventions|The subject will only have endoscopic drainage of the pancreatic necrotic collection at the time of index intervention.
89294944|NCT04074252|Active Comparator|Lofstrand Crutches|This group is given a set of Lofstrand crutches.
89294945|NCT04074252|Active Comparator|Axillary Crutches|This group is given a set of axillary crutches.
89294946|NCT03997266|Active Comparator|Empiric antibiotics|Infants will receive standard antibiotic coverage of ampicillin and gentamycin at site approved dosing guidelines while completing an evaluation for early-onset neonatal sepsis.
89294947|NCT03997266|Placebo Comparator|Placebo|Infants will receive a volume matched placebo of normal saline while completing an evaluation for early-onset neonatal sepsis.
89294948|NCT03959293|Experimental|FOLFIRI plus durvalumab|"Durvalumab: 1500 mg by 1-hour IV infusion. Every 4 weeks until progression~FOLFIRI (1 course every 2 weeks, until progression):~Irinotecan: 180 mg/m² by 2-hour IV infusion,~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
89294949|NCT03959293|Experimental|FOLFIRI plus durvalumab plus tremelimumab|"Durvalumab: 1500 mg by 1-hour IV infusion - Every 4 weeks.~Tremelimumab: 75 mg by 1-hour IV infusion - Every 4 weeks (for only 4 cycles).~FOLFIRI (1 course every 2 weeks, until progression):~Irinotecan: 180 mg/m² by 2-hour IV infusion~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion~5-FU bolus: 400 mg/m² by 10-minutes IV bolus~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
89294950|NCT03952234|Other|Dose finding safety study|In this study, the highest acceptable dose of an amino acid called citrulline will be established in people who have a mitochondrial disorder. Previous research conducted by several groups including our center at Baylor College of Medicine has determined that there is a deficiency of a compound called nitric oxide in people affected with MELAS.
89294951|NCT03903705|Experimental|VEGFR cohort:|Fruquintinib
89294952|NCT03902873|No Intervention|usual compression|A group who get no real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
89294953|NCT03902873|Active Comparator|real-time audiovisual feedback|A group who get the real-time audiovisual feedback from the R Series® Monitor/Defibrillator (Zoll medical).
89294954|NCT03837392|Experimental|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) - participants in this arm will take part in an online ACT + psychoeducation intervention. The intervention will provide psychoeducation surrounding perinatal anxiety and depression as well as on engaging social support and coping strategies. The ACT portion of the intervention will focus on developing psychological flexibility, which is defined as behaviorally pursuing one's values even in the presence of barriers (e.g., thoughts, emotions). Following the online intervention, the participants will be contacted for two phone coaching calls -- each lasting about 30-45 minutes.
89294955|NCT03837392|Active Comparator|Supportive Psychoeducation|Control group - participants in this arm will take part in an online psychoeducation and support intervention. This intervention will focus on psychoeducation surrounding perinatal anxiety and depression, as well as on engaging social support and coping strategies. Following the online intervention, the participants will be contacted for two phone coaching calls -- each lasting about 30-45 minutes.
89294956|NCT03793621|Experimental|BI 730357|
89294957|NCT03793621|Placebo Comparator|Placebo|
89294958|NCT03782987|Experimental|BI 730357 + Itraconazole (T)|Participants were administered 50 mg BI 730357 tablet orally on Day 1 along with 20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
89294959|NCT03782987|Experimental|BI 730357 (R)|Participants were administered 50 mg BI 730357 tablet orally on Day 1 alone in treatment period 1 (R).
89294960|NCT03755102|Experimental|Cohort 1: Participants treated with dacomitinib alone|Participants in this cohort have a somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy.
89294961|NCT03755102|Experimental|Cohort 2: Participants treated with dacomitinib in combination with osimertinib|Participants in this cohort have a secondary acquired EGFR mutation in addition to the sensitizing mutation
89294962|NCT03725982|Experimental|With exoskeleton, then without exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) with the exoskeleton, then without the exoskeleton.
89294963|NCT03725982|Experimental|Without exoskeleton, then with exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) without the exoskeleton, then with the exoskeleton.
89294964|NCT03717727|Experimental|Exergame|Home-based exergame intervention and usual treatment.
89294965|NCT03717727|Experimental|Control|Home-exercise by standard protocol and usual treatment.
89294966|NCT03708770|Other|endoAVF|
89294967|NCT03673774|Experimental|cardiac impedancemetry|"Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for PH. Patients are included via the competence center of the PHP of the Midi Pyrenees region. The cardiac output is measured by impedance measurement at rest and during the walking test. The NO / CO coupled transfer measurement is performed at rest. The physician performing the consultation will not know the results of the IPC and these results will not influence the subsequent management.~The patient will be followed for 18 months as part of the research."
89294968|NCT03664011|Experimental|BI 730357 BS (C-14)|"All participants were administered an oral single dose of 50 milligram (mg) BI 730357 containing [C-14] BI 730357 base (BS) (pure 14C-labelled hot drug substance) and BI 730357 BS (unlabelled cold drug substance). This mixture corresponds to the warm substance BI 730357 BS (C-14) containing a radioactive dose of approximately 3.7 MegaBecquerel (MBq), (100 microcurie (µCi)), and was administered in a solution of 10 milliliter (mL) volume with 240 mL of water after an overnight fast of at least 10 hours (h)."
89294969|NCT03624023|Experimental|TWB-103|(Mixture of TWB-102 cell and TWB-103 hydrogel)
89294970|NCT03617562|Experimental|Superior Capsular Reconstruction|Patients will be treated with the new technique of superior capsular reconstruction with dermal allograft.
89294971|NCT03617562|Active Comparator|Partial Repair|Patients will have a partial repair with residual defect as an established standard procedure.
89294972|NCT03575403|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules one time daily.
89294973|NCT03575403|Experimental|Low Dose Duloxetine|Subjects will receive 30 mg oral duloxetine one time daily.
89294974|NCT03575403|Experimental|High Dose Duloxetine|Subjects will receive 60 mg oral duloxetine one time daily.
89294975|NCT03513497|Experimental|Periodontal Profile Class (PPC-A)|Periodontally healthy participants (PPC-A) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
89294976|NCT03513497|Experimental|Periodontal Profile Class (PPC-G)|Participants with severe periodontal disease (PPC-G) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
89294977|NCT03476187|Experimental|µCor wearers|Wear the µCor device
89294978|NCT03474029|Experimental|6 weeks of daily rifapentine (6wP)|Rifapentine daily for 6 weeks: 600 mg of Rifapentine (RPT) given once daily for 6 weeks
89294979|NCT03474029|Active Comparator|12-16 week rifamycin-based regimen|"A 12-16 week rifamycin-based regimen available at the participant's site:~Rifapentine and Isoniazid weekly for 12 weeks (3HP) or Rifampin and Isoniazid daily for 12 weeks (3HR) or Rifampin daily for 16 weeks (4R)"
89294980|NCT03457402|Experimental|Treatment|Participants in the Experimental arm will begin the Shaping Delay Tolerance behavioral intervention immediately after baseline, and this training will last for about 6 weeks.
89294981|NCT03457402|Active Comparator|Wait-list Control|After baseline, participants in the Wait-list Control arm will wait for about 6-weeks before entering the pre-treatment phase, which is a repeat of effortful control assessments and behavior questionnaires, and then they will begin training for with the Shaping Delay Tolerance behavioral intervention.
89294982|NCT03448692|Experimental|PF-06730512 Cohort 1|Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
89294983|NCT03448692|Experimental|PF-06730512 Cohort 2|Subjects in cohort 2 will receive dose 2 IV infusion.
89294984|NCT03448692|Experimental|PF-06730512 Cohort 3 (optional)|Subjects in cohort 3 will receive dose 3 IV infusion.
89294985|NCT03419195|Experimental|Type 2 diabetes|Men and women between the ages of 30-55 with well controlled type 2 diabetes (A1C <9%).
89294986|NCT03419195|Experimental|Healthy overweight controls|Men and women between the ages of 30-55 with BMI 25-40 and limited immediate family history of type 2 diabetes.
89294987|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EEC|300mg DKN-01 monotherapy in recurrent EEC
89294988|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EEC|300mg DKN-01+paclitaxel in recurrent EEC
89294989|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EOC|300mg DKN-01 monotherapy in recurrent EOC
89294990|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EOC|300mg DKN-01+paclitaxel in recurrent EOC
89294991|NCT03395080|Experimental|DKN-01 monotherapy in carcinosarcoma|600mg DKN-01 monotherapy in carcinosarcoma
89294992|NCT03395080|Experimental|DKN-01 +paclitaxel in carcinosarcoma|600mg DKN-01 +paclitaxel in carcinosarcoma
89294993|NCT03354273|Experimental|1|Flurpiridaz PET MPI (following off-study SPECT MPI)
89294994|NCT03319927|Experimental|Integrated pest management|The intervention consists of an integrated pest management (IPM) educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for child care center directors and providers on IPM policies and practices including the providers' practices and beliefs. The workshop includes IPM videos, IPM Toolkit, and IPM toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
89294995|NCT03319927|Active Comparator|Physical activity|The intervention consists of a physical activity educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for the child care center directors and providers on physical activities center policies and best practices over 7 months. The workshop includes a Physical Activity Toolkit and toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
89294996|NCT03304912||Women who inject drugs who are eligible for PrEP|Women who inject drugs who are eligible for PrEP are provided PrEP Education and option to accept a PrEP prescription.
89294997|NCT03267251|Active Comparator|Usual Clinic communication - HPV Vaccine|Standard Usual and Customary HPV Information - CDC pamphlet
89294998|NCT03267251|Experimental|Usual Care and Web App on HPV Vaccine|Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
89294999|NCT03217643|Experimental|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
89295000|NCT03006432|Active Comparator|FOLFOX|Cycles every 15 days until progression desease
89295001|NCT03006432|Experimental|TFOX|Cycles every 15 days until progression desease
89295002|NCT02917577|Active Comparator|Avaxim Pediatric®|2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
89295003|NCT02917577|Active Comparator|Avaxim ® (adult)|2 doses (0.5 mL each) six months apart of Avaxim ® (adult)
89295004|NCT02802176|Experimental|Intra-vaginal culture - INVOcell device|3 day intra-vaginal incubation using the INVOcell device
89295005|NCT02802176|Active Comparator|Traditional IVF culture|3 day traditional IVF incubation
89295006|NCT02759185|Experimental|High THC cannabis|Provided up to 1.8 g of cannabis per day with more tetrahydrocannabinol than cannabidiol
89295007|NCT02759185|Experimental|High CBD cannabis|Provided up to 1.8 g of cannabis per day of marijuana with more cannabidiol than tetrahydrocannabinol
89295008|NCT02759185|Experimental|THC/CBD cannabis|Provided up to 1.8 g of cannabis per day with an approximately equal amount of tetrahydrocannabinol and cannabidiol
89295009|NCT02759185|Placebo Comparator|Placebo cannabis|Provided 1.8 g of cannabis per day with very low levels of tetrahydrocannabinol and cannabidiol
89295010|NCT02685332|Experimental|Stereotactic Radiation|"Single Fraction Stereotactic Radiation. Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1 26.5~1 30"
89295011|NCT02436993|Experimental|Carboplatin+Paclitaxel+Bevacizumab (HER2-)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses
89295012|NCT02436993|Experimental|Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses
89295013|NCT02360579|Experimental|Cohort 1|Lifileucel (LN-144) without cryopreservation (Gen 1 infusion product) (Closed)
89295014|NCT02360579|Experimental|Cohort 2|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)
89295015|NCT02360579|Experimental|Cohort 3|Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).
89295016|NCT02360579|Experimental|Cohort 4|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
89531576|NCT06019624|Active Comparator|Cohort 2 Receipt of Food Box|Up to 80 individuals with diabetes or prediabetes with a history of food insecurity enrolled in a 6 month program offering free bimonthly fresh food boxes, nutrition education, and individualized support. Each enrolled individual will serve as their own control. The study will evaluate pre and post program changes in reported self-obtained home glucose levels, food security, and dietary intake.
89295017|NCT02244411|Experimental|Intervention group|Participants will be assigned an individual diet & physical activity counselor through Healthways at Hopkins. This counselor will stay with the participant for the 24 months. The primary communication with the counselor will be via website & email. Participants will be encouraged to consume a low-calorie, low-salt diet with 7-12 daily servings of fruits, vegetables & low-fat dairy products. Calorie goals are based upon weight at study entry & whether or not the weight loss goal has been met. Participants will gradually build to ≥ 180 minutes of moderate to vigorous physical activity per week, using the activity of their own choosing & gradually adding bouts of ≥ 10 minutes in length. Monitoring & Counselor Contacts: the first 3 months, the participants are encouraged to log into the web hub on a daily basis to record weight, food intake, & physical activity. Participants who decline or drop out of the intervention program will remain on-study doing home visits & questionnaires.
89295018|NCT02244411|Active Comparator|control group|Participants will receive general information brochures on healthy living and weight loss but will not have access to the Healthways at Hopkins website or counselors.
89295019|NCT02205840|Experimental|SI-614|
89295020|NCT02205840|Placebo Comparator|Placebo Vehicle|
89295021|NCT02193841|Active Comparator|C & P|Curettage with puncture (C & P) will be performed alone
89295022|NCT02193841|Active Comparator|C & P with Vitoss|A predetermined amount of Vitoss morsels will be injected following the curettage and puncture (C & P)
89295023|NCT02011971|Active Comparator|Low dose|Vinpocetine 10 mg Healthy subjects
89295024|NCT02011971|Active Comparator|Mid-dose 1|Vinpocetine 20mg Healthy subjects
89295025|NCT02011971|Placebo Comparator|Placebo|0 dose of vinpocetine Healthy and Epilepsy subjects
89295026|NCT02011971|Active Comparator|High Dose|Vinpocetine 60 mg single dose Healthy Subjects & 20mg tid Epilepsy Subjects
89295027|NCT01951339|Experimental|Sitagliptin plus placebo|100 mg sitagliptin plus 2 mg placebo once daily for three months
89295028|NCT01951339|Active Comparator|Glimepiride plus placebo|2 mg glimepiride plus 100 mg placebo once daily for three months
89295029|NCT01896479|Experimental|Cabozantinib (XL184) 140 mg|Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
89295030|NCT01896479|Experimental|Cabozantinib (XL184) 60 mg|Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
89295031|NCT01844518|Experimental|Short and Long Terms: Orencia|"Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months~Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months"
89295032|NCT01835041|Experimental|Treatment (6,8-bis[benzylthio]octanoic acid, mFOLFIRINOX)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 3. Patients also receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on day 1. Treatment repeats every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
89295033|NCT01833572|Experimental|Gefitinib|A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.
88806192|NCT01480297|Experimental|Salsalate|All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
88806193|NCT01480843|Experimental|Glargine|We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
89295034|NCT01809002|Experimental|Processed Nerve Allograft|Processed Nerve Allograft
89295035|NCT01809002|Active Comparator|Collagen Nerve Cuff|
89295036|NCT01793909|Other|Single Leg Exercise|Supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
89295037|NCT01713439|Experimental|Injection of allogeneic neuroblastoma cells|Retrovirally transduced allogeneic neuroblastoma cell lines secreting the human interleukin-2 and lymphotactin genes are frozen and, when needed, are thawed, mixed and irradiated. Relapsed or refractory patients are then treated with a course of four injections of their gene-modified tumor cells according to the following schedule: The first two injections will be given at week 1 and week 2. Patients will then have a two-week rest and the remaining two injections will be given at week 4 and week 5. A complete evaluation for evidence of toxicity and response will be performed at week 8 after a 3 week rest. At the 8 week evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
89295038|NCT01639690|Experimental|Autologous CD34+ cells transduced with TNS9.3.55|An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.
89295039|NCT01591577|Experimental|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
89295040|NCT01588665||Pregnant women and pregnant adolescents|
89295041|NCT01582802||Pregnant women carrying multiples|Healthy pregnant women carrying twins, triplets and quadruplets will be recruited.
89295042|NCT01521741||Breast Cancer|
89295043|NCT01509586|Experimental|PREP (Potentially Reduced Exposure Product) Group|
89295044|NCT01509586|No Intervention|cigarette group|
89295045|NCT01364584|Experimental|Exenatide|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of exenatide for 2.5 months
89295046|NCT01364584|Placebo Comparator|Placebo|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of placebo for 2.5 months
89295047|NCT01330121|Active Comparator|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
89295048|NCT01330121|No Intervention|Standard therapy|Standard therapy: Nurses distribute a education pamphlet on diabetes
89295049|NCT01088386||Patients|All patients who will be receiving Zyprexa Relprevv must be enrolled into the Zyprexa Relprevv Patient Care Program
89295050|NCT01044264|Active Comparator|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Test product
89295051|NCT01044264|Active Comparator|DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Reference product
89295052|NCT01044264|Placebo Comparator|Placebo|
89295053|NCT01039584|Placebo Comparator|Placebo|vehicle of the test product; applied intravaginally once within 48 hours of randomization
89295054|NCT01039584|Experimental|Test Product|Butoconazole Nitrate Vaginal Cream; applied intravaginally once within 48 hours of randomization
89295055|NCT01039584|Active Comparator|Reference Product|Gynazole 1 Vaginal Cream; applied intravaginally once within 48 hours of randomization
89295056|NCT00941759||Known or suspected Stage IV disease & an intact primary|Pt will be asked to undergo a research core needle biopsy of the primary tumor. If pts are not agreeable to a research biopsy then the original diagnostic biopsy material will be requested. They will also undergo a diagnostic biopsy of a metastatic site, if not already performed, and a blood draw as appropriate for correlative science studies. Additionally, patients will complete a general medical questions form at the time of enrollment.
89295057|NCT00941759||Unsuspected metastatic disease W/I 3 months of primary b|A blood sample will be collected and patients will complete a general medical questions form at the time of enrollment. Paraffin tissue from the prior surgical procedure will be obtained as Tissue sample. Paraffin tissue from the diagnostic biopsy of a metastatic site will also be obtained. In the event that fresh frozen tissue is available for either site this will also be requested.
89295058|NCT00920387|Experimental|Full Dose LSD (200 mcg)|200 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.
89295059|NCT00920387|Active Comparator|Active Placebo LSD (20 mcg)|20 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.
89295060|NCT00786019|Experimental|Ascorbic acid|All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.
89295061|NCT00692484|Experimental|1|Chlorhexidine gluconate 2%
89295062|NCT00692484|Active Comparator|2|Povidone iodine scrub and paint
89295063|NCT00679783|Experimental|1|"Triple negative breast Cancer with unknown BRCA mutation status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral"
89295064|NCT00679783|Experimental|2|"Known BRCA mutation positive breast cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) to be administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral"
89295065|NCT00679783|Experimental|3|"High grade serous/undifferentiated tubo-ovarian carcinoma with unknown BRCA status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral"
89295066|NCT00679783|Experimental|4|"Known BRCA mutation positive ovarian cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral"
89295067|NCT00490581|Experimental|Study group|These patients are assigned to the intervention of early supportive housing with case management integrated into the medical system. These subjects are offerred respite care/interim housing upon discharge from enrolling hospitalizations, followed by stable housing within 90 days. They have a case manager at each stage (hospital, respite/interim housing, and stable housing)
89295068|NCT00490581|No Intervention|Usual Care|These patients receive usual social services for hospital discharge planning.
89295069|NCT00367003|Experimental|Deep Brain Stimulation|Participants with treatment resistant depression will have a device implanted for deep brain stimulation.
89295070|NCT00152698|Active Comparator|Irbesartan|
89295071|NCT00152698|Placebo Comparator|Placebo|
89295072|NCT00074698|Experimental|FG-3019 Low Dose|Participants will receive a single intravenous (IV) infusion of FG-3019 low dose on Day 0.
89295073|NCT00074698|Experimental|FG-3019 Medium Dose|Participants will receive a single IV infusion of FG-3019 medium dose on Day 0.
89295074|NCT00074698|Experimental|FG-3019 High Dose|Participants will receive a single IV infusion of FG-3019 high dose on Day 0.
89295075|NCT01257516|Other|Pregabalin immediate release, 300 mg|Reference Treatment
89295076|NCT01257516|Experimental|Pregabalin controlled release, 330 mg|
89295077|NCT01149954|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
89295078|NCT01149954|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
89295079|NCT03900156|No Intervention|comparison group|The CG received no extra care.
89295080|NCT03900156|Experimental|Intervention Group|Intervention Group, goal-setting with follow-up, will have a structured goalsetting interview using the Bangor Goal-Setting Interview ; once goals are identified and clearly expressed in accordance with SMART principles (specific, measureable, achievable, realistic, and timed)
89295081|NCT03893292||Preoperative cooled radiofrequency ablation|Patients who undergo cooled radiofrequency ablation within 4-8 weeks of their scheduled total knee replacement.
89295082|NCT03899766||Animal Assisted Intervention|children interact and play with the expert of Animal Assisted Intervention (AAI) and his/her trained dog in the waiting room and then, are accompanied by a parent (as standard care) and the AAI in the venipuncture room during and immediately after the procedure
89295083|NCT03899766||Clowns|children interact and play with hospital clowns in the waiting room and then, are accompanied by a parent (as standard care) and the clown in the venipuncture room during and immediately after the procedure
89295084|NCT03899766||Musicians|children interact and play with a musician in the waiting room and then, are accompanied by a parent (as standard care) and the musician in the venipuncture room during and immediately after the procedure
89295085|NCT03899766||Non-clinical Conversation|children are accompanied by a parent in the waiting room and then in the venipuncture room during the procedure, thus receiving standard care
89295086|NCT01255332||C13-urea breath test: positive|lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days
89295087|NCT05098626||Individuals Working Remotely|Individuals aged between 18-60 and working remotely, who volunteered to participate in the study, will form the study group.
89295088|NCT03899610|Experimental|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"Neoadjuvant treatment:~Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~Interval debulking surgery~Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
89295089|NCT02527668|Experimental|Calcifediol Hy.D (25-hydroxyvitamin D)|20 μg Calcifediol Hy.D (25-hydroxyvitamin D) (one capsule) per day for 6 months
89295090|NCT02527668|Active Comparator|Vitamin D3 (cholecalciferol)|3200 IU Vitamin D3 (cholecalciferol) (one capsule) per day for 6 months
89295091|NCT02527668|Placebo Comparator|Placebo|1 Placebo capsule per day for 6 months
89295092|NCT03896412|Experimental|Detection of circulating tumor DNA|sampling of 20 ml of blood the day before surgery, the day after , 6 months after diagnosis and every 3 months thereafter until 18 months of follow up
89295093|NCT03893214|Experimental|intervention group|Virtual reality exposure for acrophobia - this arm receives the virtual reality exposure intervention in the initial phase and has a four-week follow-up assessment.
89295094|NCT03893214|Placebo Comparator|waitlist control group|This arm watches a movie in the initial phase in order to control for effects of behavioral approach test that is done before and after the intervention and for time effects. In the second phase after four weeks, this arm receives the virtual reality exposure after collection of outcome measures.
89295095|NCT03896490|Experimental|ACT|
89295096|NCT03896490|Placebo Comparator|Control|
89295097|NCT03896256|Experimental|Treatment Arm|Patients will be admitted to the hospital for a total of 5 full days from the time of admission until discharge. Ketamine infusion will be started on day 1. Adjustments to ketamine infusion will be made according to standard acute pain service protocol.
89295098|NCT03893136||Control group|The control group mainly consists of healthy volunteers. The whole blood is obtained and frozen to detect the corresponding biochemical markers in the futures. The vascular tissues are obtained from the deserted and free abdominal aorta conjugated to the renal artery in the kidney transplantation.
89295099|NCT03893136||sham TA group|In the TA cohort, patients are divided into two groups mainly, sham TA group and scramble TA group. The sham TA group is the TA group who is given the traditional and classical intervention or treatment and so on.
89295100|NCT03893136||scramble TA group|Compared to sham TA group in the cohort, scramble TA group refers to TA patients who are given novel drugs or new drugs which are safe to treat other autoimmune diseases but have not been used to treat TA yet, or some new interventions and so on.
89295101|NCT03899454|Experimental|Extract administration|administration of a mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
89295102|NCT03899454|Placebo Comparator|Control|Placebo
89295103|NCT01150032||Osteopenic women|Women with osteopenia: Bone Mineral Density T-score between -1.0 and -2.5 (for whom with clinical factor risk) or -3.0 (for whom without clinical factor risk)
89295104|NCT01258530|Experimental|Treatment A|Over-encapsulated oseltamivir 75 mg (1 capsule)
89295105|NCT01258530|Experimental|Treatment B|oseltamivir 75 mg (1 capsule)
89295106|NCT01255410|Experimental|Healthy Adults (Group 1)|Healthy adults will receive a single dose of 10^6 plaque forming unit (PFU) rHMPV-Pa vaccine intranasally.
89295107|NCT01255410|Experimental|Seropositive Children-Vaccine (Group 2)|Seropositive children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
89295108|NCT01255410|Placebo Comparator|Seropositive Children-Placebo (Group 2)|Seropositive children will receive a single dose of placebo vaccine intranasally.
89295109|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^5) (Group 3)|Seronegative infants and children will receive a single dose of 10^5 PFU rHMPV-Pa vaccine intranasally.
89295110|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 3)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
89295111|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^6) (Group 4)|Seronegative infants and children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
89295112|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 4)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
89295113|NCT01257672|Experimental|ondansetron|ondansetron, syrup, 0,15 mg/Kg of body weight, 1 dose
89295114|NCT01257672|Active Comparator|domperidon|domperidone, syrup, 0,5 mg/Kg of body weight, one dose
89295115|NCT01257672|Placebo Comparator|placebo|placebo, syrup, one dose
89295116|NCT01258686|Experimental|silymarin, treatment|
89295117|NCT01258686|Placebo Comparator|placebo|
89295118|NCT03896178||Firefighters|
89295119|NCT03896178||Pilots|
89295120|NCT03896178||Police|
89295121|NCT03896178||Military personnel|
89295122|NCT03896178||Controls|Control group matched for geographic location (county), and year of diagnosis. Consisting of all other workers than the four specified groups.
89295123|NCT03895944|Experimental|iv low dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with low dose (1x10^6) in Leukemia or Lymphoma patients
89295124|NCT03895944|Experimental|iv middle dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with middle dose (3x10^6) in Leukemia or Lymphoma patients
89295125|NCT03895944|Experimental|iv high dose|Autologous ET190L1-ARTEMIS™ T cells administered by intravenous (IV) infusion with high dose (10x10^6) in Leukemia or Lymphoma patients
89295126|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Autoimmune Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
89295127|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Orthopedic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
89295128|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Neurologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
89295129|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Urologic Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
89295130|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Cardiac Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiac conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
89295131|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Renal Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for renal conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
89295132|NCT03899298|Experimental|Amniotic and Umbilical Cord Tissue for Pulmonary Conditions|Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary conditions. Outcomes will be compared to the literature results of the current gold standard for several conditions.
89295133|NCT01258764|Active Comparator|Lisinopril|
89295134|NCT01258764|Active Comparator|Hydrochlorothiazide|
89295135|NCT03895788|Experimental|niraparib and brivanib|Subjects will be assigned into niraparib 100mg+brivanib 200mg, niraparib 200mg+brivanib 200mg, niraparib 200mg+brivanib 400mg, niraparib 200mg+brivanib 600mg dose group at the first day of the first cycle.
89295136|NCT01258842|Experimental|B. lactis HN019|
89295137|NCT01258842|Placebo Comparator|Placebo|
89295138|NCT01257828|Placebo Comparator|Placebo|Placebo medication and decompressive cervical spine surgery
89295139|NCT01257828|Experimental|Riluzole|Riluzole in dose 50mg BID for 14 days prior to surgery and 28 days after the decompressive spine surgery
89295140|NCT01150188|Active Comparator|Amino acids|Amino acid supplementation between meals for eight weeks
89295141|NCT01150188|Placebo Comparator|Placebo|Supplementation of placebo (inert components) between meals for eight weeks
89295142|NCT03899142|Experimental|human hepatitis B immunoglobulin|once, i.m.
89295143|NCT01255488|Experimental|EBN-Search (without full-text manuscripts)|In the intervention arm research subjects will be provided access to EBN-Search (a fictitious search engine) with nine abstracts relating to the clinical case but no full-text manuscripts.
89295144|NCT01255488|Active Comparator|EBN-Search (with full text manuscripts)|Research subjects will be exposed to 9 abstracts and corresponding full-text manuscripts related to the simulated clinical encounter.
89295145|NCT03892902|Experimental|Treatment A (50 mg ACT-541468)|1 tablet of ACT-541468 50 mg + 1 tablet of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period A.
89295146|NCT03892902|Experimental|Treatment B (100 mg ACT-541468)|2 tablets of ACT-541468 50 mg + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period B.
89295147|NCT03892902|Experimental|Treatment C (7.5 mg zopiclone)|2 tablets of ACT-541468 matching placebo + 1 capsule of zopiclone 7.5 mg administered in the evening on Days 1 and 4 of Treatment Period C. In the evenings of Days 2 and 3, subjects will receive placebo (i.e., 2 tablets of ACT-541468 matching placebo + zopiclone matching placebo).
89295148|NCT03892902|Experimental|Treatment D (placebo)|2 tablets of ACT-541468 matching placebo + zopiclone matching placebo administered in the evening on Days 1-4 of Treatment Period D.
89295149|NCT03895866||Group A|High-risk HPV persistent infection more than half a year and reversion
89295150|NCT03895866||Group B|High-risk HPV non-infection
89295151|NCT03895554||Normal volunteers|Normal, healthy volunteers with undergo cardiac PET stress testing.
89295152|NCT03892668|Experimental|tranexamic acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
89295153|NCT03892668|Active Comparator|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
89295154|NCT03892668|Placebo Comparator|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
89295155|NCT01255566||Medical therapy cohort|For patients electing continued medical therapy, medication was prescribed based on the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
89295156|NCT01255566||Surgical cohort|For patients electing ESS, surgery was performed by the enrolling rhinologist. In addition, medical management was administered in the perioperative and postoperative periods as dictated by the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
89295157|NCT01151982|Experimental|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
89295158|NCT01151982|No Intervention|Usual Care|The kind of care that general practitioners usually provide when not knowing the level and risk profile of depression of the patients
89295159|NCT01258920|Experimental|Paliperidone palmitate|Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
89295160|NCT03892590||Stable patient|Stable patients who admitted to ICU for observation.
89295161|NCT03898752|Experimental|Lifestyle intervention|Diet, omega-3 fish oil (1g daily), CoQ10 (100 mg/day) and a normal Multi-vitamin, Smoking cessation, weight loss, exercise,
89295162|NCT02527902|Experimental|IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) >90 ml/min/1.73 m2
89295163|NCT02527902|Experimental|IgAN with GFR 60-89 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2
89295164|NCT02527902|Experimental|IgAN with GFR 30-59 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2
89295165|NCT02527902|Experimental|IgAN with GFR 15-29 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2
89295166|NCT02527902|Experimental|IgAN with GFR < 15ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR < 15ml/min/1.73 m2.
89295167|NCT03898830|Experimental|eon™ FR 1064 nm device|Patient will be treated with the eon™ FR 1064 nm device
89295168|NCT01255644|Experimental|Antiviral drug|
89295169|NCT01259076||Group 1|Participants who are eligible for and have opted to undergo gastric bypass surgery
89295170|NCT01259076||Group 2|Participants who are eligible for but decided not to undergo gastric bypass surgery.
89295171|NCT01255800|Experimental|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.~Starting on Day 15 of the first cycle, Patients will take the study drug by mouth every day."
89295172|NCT03898674|Experimental|GDT feasibility|Patients undergoing microcirculatory goal directed therapy
89295173|NCT01257906|Experimental|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel Test Product
89295174|NCT01257906|Active Comparator|ZIANA®|Topical Gel Reference Product
89295175|NCT01257906|Placebo Comparator|Vehicle Control|Topical Gel Placebo
89295176|NCT03892512|Active Comparator|dexmedetomedine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex .Pfizer CO ) .
89295177|NCT03892512|Active Comparator|esmolol|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride . Baxter CO ).
89295178|NCT01152060||prednisone|
89295179|NCT01152060||prednisone and anti-virus|
89295180|NCT01257984|Experimental|Arm 1|
89295181|NCT01257984|Experimental|Arm 2|
89295182|NCT01152138|Active Comparator|Open Cell Stent|Open cell stent (Driver™ or Integrity™,Medtronic), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
89295183|NCT01152138|Active Comparator|Closed Cell Stent|Closed cell stent (Presillion Plus™, Cordis), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
89295184|NCT03895164|Placebo Comparator|Standard NE|Control Group will receive standard nutrition education package from primary health care.
89295185|NCT03895164|Experimental|Enhanced NE|Intervention Group will receive standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
89295186|NCT01258062|Experimental|of GelVac™ nasal powder H5N1 influenza vaccine.|
89295187|NCT01258062|Placebo Comparator|Placebo|
89295188|NCT03895398|Experimental|nutrition and psychosocial intervention arm|"12 selected ECE centers will be selected to be the intervention group. ECE teachers will be trained on psychosocial and nutrition care for children and expected to deliver the information and parenting class to mother.~Community health officers will be trained on how to monitored the activities regularly and providing technical assistance to ECE teachers if needed.~mothers will received weekly parenting class. in the parenting class mothers will be informed on how to provide appropriate feeding and psychosocial stimulus to their children. nutrient dense food supplementation in the form of liver and fish floss will be prepared together and distributed.~underfive children will received nutrient dense food supplementation in the form of liver and fish floss and expected to be eaten everyday for 6 months"
89295189|NCT03895398|No Intervention|control arm|no intervention is given to this arm
89295190|NCT01255878|Experimental|stabilization splint|
89295191|NCT01255878|Experimental|Gabapentine|
89295192|NCT01255956|Experimental|Rapamycin eluting stent|Patients treated with rapamycin eluting stent (n=100)
89295193|NCT01255956|Experimental|Paclitaxel eluting balloon catheter|Patients treated with paclitaxel eluting balloon catheter (n=100)
89295194|NCT01259154||RFITT+UPPP|
89295195|NCT01259154||UPPP|
89295196|NCT01258140|Active Comparator|1|Patients examined with normal-dose Computed tomography pulmonary angiography
89295197|NCT01258140|Active Comparator|2|Patients examined with low-dose Computed tomography pulmonary angiography
89295198|NCT03892434|Active Comparator|Bevacizumab|
89295199|NCT03892434|Active Comparator|Dexamethasone|
89295200|NCT01256112|Experimental|NAE + Behavioral Intervention|Parents of participants receive training in behavioral support at home, in addition to a standard nutrition and physical activity education (NAE) program.
89295201|NCT01256112|Active Comparator|Nutrition/Activity Education|Parents and participants receive a standard nutrition and physical activity education (NAE) program.
89295202|NCT03892356||Concussion Group|Participants (age group 18-60) who presents to the emergency department in the University Health Network within 7 days of concussion
89295203|NCT03892356||Healthy Controls Group|Participants (age group 18-60) with no previous history of concussions who are age, education and sex-matched to the patients' group will be recruited from the community.
89295204|NCT03895242|Experimental|Group 1:First supine position,then prone position|First group was supine position then prone position.
89295205|NCT03895242|Experimental|Group 2:First prone position, then supine position|Second group was first prone position, then supine position.
89295206|NCT01151514||nrHA-AKI patients|Patients with hospital-acquired acute kidney injury not referred to the nephrologists
89295207|NCT01151514||lrHA-AKI patients|Patients with hospital-acquired acute kidney injury whao are late referred to the nephrologists
89295208|NCT03895086|Experimental|Specific Physical Activity|Specific patient care in telephone coaching of fibromyalgia patients.
89295209|NCT03895086|Other|Classic Physical Activity|Classic patient care in common group of multipathological patients.
89295210|NCT03889626|Experimental|Apatinib|In this arm, patients will receive a daily oral treatment with Apatinib 500mg.
89295211|NCT03889626|Experimental|Capecitabine|In this arm , patients will receive capecitabine 1000mg/m2 twice for 14 days, and repeat every 3 weeks.
89295212|NCT03889626|No Intervention|Observation|In this arm, no additional treatment will be given, and patients will be followed up at regular time
89295213|NCT03895008||Cardia gastric cancer|Cardiac gastric cancer is defined as a cancer center lies arising 2-5 cm from the gastric mucosa distal to the esophagogastric junction.
89295214|NCT03895008||Non-cardia gastric cancer|Non-cardia gastric cancer is defined as tumors originated from the gastric mucosa distal to the cardia.
89295215|NCT03892122|Other|Propofol group|"Sleep endoscopy will be performed by a Target Controlled Infusion system (BRAUN perfusion system) using Schneider model in effect-site (cerebral) targeted infusion 50-ml prefilled syringe of 1% propofol. Schneider system is a complex pharmacokinetic/pharmacodynamic (PK/PD) model that allows to obtain different rates of drug from the values of age, height, weight and lean body mass of the patient~. The starting dose of propofol will be 2-2,5 mcg ml-1 and increments of 0.2 mcg ml-1 took place when the new cerebral concentration of propofol will be reached, and never before 5 minutes. In this way, the investigators will be realized a slow technique of TCI propofol infusion according to European working group"
89295216|NCT03892122|Other|Dexmedetomidine group|For the D-DISE group, dexmedetomidine will be administered with an IV infusion at 1 mcg/kg over 10 minutes, followed by a maintenance rate of 0,7 mcg/kg/h.
89295217|NCT03892278|Experimental|Aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and <85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and <85% of HRat for 1 minute.
89295218|NCT03892278|Experimental|Aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and <85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and <85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
89295219|NCT03892278|Active Comparator|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
89295220|NCT01589562|Active Comparator|Megace 800mg/20ml|Fed condition
89295221|NCT01589562|Experimental|DW-ES(B) 625mg/5ml|Fed condition
89295222|NCT01152372|Other|Arm 1|Beta cell function by frequently sampled intravenous glucose tolerance test
89295223|NCT01152372|Other|Arm 2|Modified glucose disposal test assessment of insulin sensitivity, endogenous glucose production and insulin secretion
89295224|NCT01152372|Other|Arm 3|Endogenous glucose production and insulin sensitivity by isotope dilution and isoglycemic, heperinsulinemic clamp
89295225|NCT01589640||Blink Tears|Blink Tears is an over the counter artificial tear
89295226|NCT01589640||Blink Gel Tears|Blink Gel Tears is an over the counter artifical tear product
89295227|NCT01589640||Systane Balance|Systane Balance is an over the counter artificial Tear product
89295228|NCT01259934|No Intervention|Arm A|Observation only - no therapy
89295229|NCT01259934|Experimental|Arm B Interferon 1 year|Interferon Therapy: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 12 months
89295230|NCT01259934|Experimental|Arm C Interferon 2 years|"Two year arm Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months"
89295231|NCT01153386|Experimental|0.5 mg treprostinil diethanolamine|0.5 mg treprostinil diethanolamine
89295232|NCT01153386|Experimental|2.5 mg treprostinil diethanolamine|2.5 mg treprostinil diethanolamine
89295233|NCT01153386|Experimental|1 mg treprostinil diethanolamine|1 mg treprostinil diethanolamine
89295234|NCT01260012|Experimental|praziquantel+antioxidant|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In additions, antioxidant suppliment will be given daily for a period of one year
89295235|NCT01260012|Active Comparator|Praziquantel +placebo 2mths then antioxidant for 10 months|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
89295236|NCT01260012|No Intervention|Praziquantel therapy with placebo supplement|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for a period of one year.
89295237|NCT03888924|Experimental|BCG treated patients|a single dose of Bacille Calmette-Guerin vaccine
89295238|NCT03888924|Placebo Comparator|Placebo treated patients|a single dose of placebo.
89295239|NCT03894930|Experimental|Metta meditation|Eight-week, guided metta meditation training that is administered online
89295240|NCT03894930|No Intervention|Wait-list|Eight-week wait-list control with no training
89295241|NCT03894852||AML|cases with denovo AML and t-AML
89295242|NCT03894852||MDS|cases with denovo MDS and t-MDS
89295243|NCT03891810|Experimental|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
89295244|NCT03891810|No Intervention|Control|This group was a wait list control group who received the treatment following the intervention period.
89295245|NCT03894774|Experimental|Intensive InPatient Psychotherapy Treatment Group (IG)|Intensive non-pharmaceutical inpatient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic frame where patients live over the whole treatment (approximately a 1:1-ratio caregiver per patient is given) of 6 to 8 month treatment duration.
89295246|NCT03894774|Active Comparator|Waiting Control Group (WCG)|"Treatment as usual (mostly combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy).~Duration: At least 3 month to a maximum of 6 month."
89295247|NCT03894774|No Intervention|Healthy Control Group (HCG)|"Matched Pairs design to control for gender, age and handedness. HCG measurements are planned and conducted according to the exact durations of their matched inpatient pair of the IG.~Mandatory to control for effects of factors such as brain maturation."
89295248|NCT01151670|Experimental|Arm I|Pioglitazone 22.5 mg once daily by mouth
89295249|NCT01151670|Experimental|Arm 2|Pioglitazone 45 mg once daily by mouth
89295250|NCT03888846|Other|Colchicine|Colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
89295251|NCT03888846|Experimental|Topical Pentoxifylline Gel and Colchicine|Topical Pentoxifylline Gel administration in addition to the colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
89295252|NCT03889236|Experimental|Fasting mimicking diet|5-day Fasting mimicking diet Prolon. In total 3 cycles of the FMD in three months.
89295253|NCT03889236|Experimental|Food supplement|4 capsules a day of the food supplement Endocalyx for 3 months.
89295254|NCT03889236|Placebo Comparator|Placebo|4 capsules a day of the placebo for 3 months.
89295255|NCT01153464|No Intervention|Treatment As Usual|In this arm, participants are not provided any intervention through the study, they are just followed for research purposes at 3m, 6m, 9m, and 12m post baseline as the comparison group.
89295256|NCT01153464|Experimental|Recovery Support Counseling|This group is eligible to receive the telephone based recovery support counseling from paraprofessionals based out of the City of Philadelphia's Department of Behavioral Health.
89295257|NCT03894228||Biologics exposed cohort|Children born from mothers treated with biologic drugs (with or without immunomodulators) at any time during pregnancy or the three months before conception. Biologic drugs are IgG monoclonal antibodies able to cross the placenta.
89295258|NCT03894228||Immunomodulators exposed cohort|Children born from mothers treated with immunomodulators (without biologics) during pregnancy or the three months before conception.
89295259|NCT03894228||Non-exposed cohort|Children born from mothers treated neither with biologic drugs nor with immunomodulators at any time during pregnancy or the three months before conception.
89295260|NCT03891420|Experimental|Galidesivir|Galidesivir IV infusion
89295261|NCT03891420|Placebo Comparator|Placebo|Placebo IV infusion
89295262|NCT01153542|Experimental|VX-770|
89295263|NCT01153542|Experimental|desipramine|
89295264|NCT01152606||Cohort|
89295265|NCT01259232||schizophrenia patients,untreated|
89295266|NCT01259232||schizophrenia relatives|
89295267|NCT01259232||controls|
89295268|NCT03888690|Active Comparator|With and then without VR|Virtual Reality with standardized procedures for first intervention, Standardized procedures for second intervention, without VR.
89295269|NCT03888690|Active Comparator|Without and then with VR|Standardized procedures without VR for first intervention, Virtual Reality with standardized procedures for second intervention.
89295270|NCT03888768|Active Comparator|ProPBM|Pre-operative: patient will be screened for iron deficiency and anemia and administered IV monofer Intra-operative:IV tranexamic Acid 1gm will be administered at the beginning of surgery and blood transfusion triggered by Allowable blood loss Post-operative: IV Iron monofer will be given to those with estimated blood loss >1L and subsequent post operative follow up till 6month
89295271|NCT03888768|No Intervention|Standard Care|patient will received standard hospital practise
89295272|NCT03894384||Group:1|Gastric cancer patients
89295273|NCT03894384||Group:2|Patients with benign gastric diseases
89295274|NCT01259310||Women with epilepsy|Women with epilepsy, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
89295275|NCT01259310||Women without epilepsy|Healthy women, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
89295276|NCT01155414|Experimental|Investigational infant formula A|Investigational Protein Hydrolysate formula
89295277|NCT01155414|Active Comparator|Hydrolysate based Infant Formula|
89295278|NCT01155414|Experimental|Investigational Infant Formula B|Investigational Protein Hydrolysate Formula
89295279|NCT01153776|Experimental|64-slice CT angiography|64-slice CT angiography
89295280|NCT01260168||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or an intact pre-malignant colorectal lesion large enough to require surgical excision or complex colonoscopic polypectomy.
89295281|NCT01153854|Experimental|ORS-Raceca In hospital Group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
89295282|NCT01153854|Placebo Comparator|ORS-Placebo in hospital group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and placebo in double blind assigned.
89295283|NCT01153854|Placebo Comparator|ORS-Placebo ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and placebo in double blind assigned and ambulatory (in home) bases.
89295284|NCT01153854|Experimental|ORS-Raceca ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned and ambulatory (in home) bases.
89295285|NCT03891498|Experimental|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
89295286|NCT03891342|Experimental|Patients with sepsis/septic shock|Comaprison of fast or slow fluid bolus administration in patients with sepsis/septic shock 48hours before admission to ICU requiring fluid challenge as assessed by clinical examination
89295287|NCT03891342|Experimental|Major surgical patients|Comaprison of fast or slow fluid bolus administration in patients undergoing major surgery requiring fluid challenge as assessed by clinical examination
89295288|NCT01260246|Experimental|sitagliptin|sitagliptin 100mg/daily for 6 months
89295289|NCT01260246|Placebo Comparator|placebo|placebo match for 6 months
89295290|NCT01262040|Experimental|pts having a thorascopic, laparoscopic or robotic procedure|The procedure will begin with washings (peritoneal) and two assessments of the extent of peritoneal disease. First, a four quadrant inspection of the peritoneal cavity under white light, this is the standard of care assessment. Then, a repeat four quadrant inspection of the peritoneal cavity under NBI will be done, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI. For those patients scheduled for thorascopic procedures: The procedure will begin with sampling of pleural effusions when clinically indicated. Then there will be two assessments of the pleural surfaces. First, an inspection of the pleural cavity under white light, this is the standard of care assessment. Then, a repeat inspection under NBI, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI.
89295291|NCT03886116|Active Comparator|Exercise|"Patient randomized are required to squeeze a soft ball 10 times for a set. They are required to perform 3 sets of 10 squeezes each at a 1 Minute interval.~3 sets of exercises to be performed twice in the Morning and Evening, for a total of 6 weeks."
89295292|NCT03886116|No Intervention|No Exercise|Patient is not required to do any exercise.
89295293|NCT03891108|Active Comparator|Treatment A: BMS-986231 Formulation A|Participants will be administered Treatment A: BMS-986231 Formulation A as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
89295294|NCT03891108|Experimental|Treatment B: BMS-986231 Formulation B|Participants will be administered Treatment B: BMS-986231 Formulation B as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
89295295|NCT03891108|Experimental|Treatment C: BMS-986231 Formulation C|Participants will be administered Treatment C: BMS-986231 Formulation C as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
89295296|NCT03891108|Experimental|Treatment D: BMS 986231 Formulation D|Participants will be administered Treatment D: BMS 986231 Formulation D as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
89295297|NCT03885882|Experimental|Cohort 1: E0302 Sustained Release (SR1) 1500 mcg|Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.
89295298|NCT03885882|Experimental|Cohort 2: E0302 Sustained Release (SR3) 1500 mcg|Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.
89295299|NCT03885882|Experimental|Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg|Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
89295300|NCT03885882|Experimental|Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg|Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
89295301|NCT03888534|Experimental|Ixazomib|Ixazomib, injection, intravenously, once on Days 1, 4, 8, and 11 in a single 29-day treatment cycle in combination with multiagent reinduction therapy. Participants >= 1 year will receive the starting dose of 1.0 milligram per square meter (mg/m^2) and <1 year will receive the starting dose of 0.03 milligram per kilogram (mg/kg). The dose escalation phase will determine the MTD or RP2D of Ixazomib. Dose of Ixazomib will be escalated based on the observed safety and tolerability data.
89295302|NCT01152684||HIV-Positive Latinos living in San Diego or Tijuana|This is an exploratory study of Latinos living with HIV in the San Diego-Tijuana US-Mexico border region.
89295303|NCT01155492||Subjects with Parkinson's disease|Male and female subjects with clinically diagnosed Parkinson's disease, Stage I-IV.
89295304|NCT01155492||Control subjects|Age- and gender-matched subjects who do not have Parkinson's disease
89295305|NCT01155492||Multiple system atrophy.|Men and women with clinically diagnosed multiple system atrophy.
89295306|NCT02527278||Laparoscopic tubal ligation (no pain)|Women who have laparoscopic tubal ligation, with no previous diagnosis of pain at baseline
89295307|NCT02527278||Laparoscopic tubal ligation (pain)|Women who have laparoscopic tubal ligation, with a previous diagnosis of pain at baseline
89295308|NCT02527278||Hysteroscopic sterilization (no pain)|Women who have hysteroscopic sterilization, with no previous diagnosis of pain at baseline
89295309|NCT02527278||Hysteroscopic sterilization (pain)|Women who have hysteroscopic sterilization, with a previous diagnosis of pain at baseline
89295310|NCT01260480|Experimental|[18F]-ML-10|
89295311|NCT03891186|Experimental|Experimental Group|"Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the treatment as usual (TAU)."
89295312|NCT03891186|Active Comparator|Control Group|The control group will not participate in the MCT program. In both groups will be maintained the TAU.
89295313|NCT01153932|Experimental|Continuous regimen; 6mg/kg once weekly|Once Weekly
89295314|NCT01153932|Experimental|Intermittent regimen; 6mg/kg twice weekly|Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle
89295315|NCT03886194|Active Comparator|Thrombolytic group|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip
89295316|NCT03886194|Experimental|Interventional treatment group|Interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
89295317|NCT03888456|Experimental|study|participants will receive a single touch intervention based on osteopathic assessment and treatment
89295318|NCT03888456|Sham Comparator|Control|participants will receive a single touch sham intervention mimicking the intervention
89295319|NCT03891030|Experimental|Checklist Based Box system|Pregnant mothers will receive scheduled person-centered health educations starting from: they are identified as suspected pregnant mother up to attending their third PNC visit. In between the first ANC and the third PNC drop out tracing mechanisms will be applied, for mothers who fail to utilize the recommended maternal health services.
89295320|NCT03891030|No Intervention|Routine maternal health care|Pregnant mothers in this arm will receive the usual routine maternal health care.
89295321|NCT05095584|Experimental|validity and reliability of 3 meter backward walking test|"This study was conducted as test-retest design and the psychometric properties of 3-m backward walk test were examined in LLA. The Rivermead Mobility Index, 3-m backward walk test, Berg Balance Scale, Timed Up and Go test were applied to the patients. An experienced physiotherapist performed all these tests. In order to measure test-retest reliability, the second evaluations (retest) were carried out by the same physiotherapist two days following the first evaluation (test). A same evaluator collected data in order to avoid the inter-rater variability error rate between the evaluations. The patient was evaluated at one time of the day for test and retest."
89295322|NCT03885570||Groups/Cohorts|"1) Patients undergoing mitral valve replacement surgery;2) Age 18-75 years old;3) 48h preoperative biochemical indicators, blood general indicators, coagulation indicators are complete."
89295323|NCT03890640|Experimental|Ultrasound-guided TECI|After assessment of the epidural space using the loss of resistance technique with saline under ultrasound guidance, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
89295324|NCT03885804|Sham Comparator|Quadratus lamborum dexmedetomidine intravenous group|Patients will receive quadratus lamborum block on the same surgical side.a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
89295325|NCT03885804|Active Comparator|Quadratus lamborum dexmedetomidine perineural group|Patients will receive quadratus lamborum block on the same surgical side. Patients will receive perineural dexmedetomidine of 1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
89295326|NCT03885258|Experimental|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
89295327|NCT01262196|Experimental|MP4OX|250-mL dose
89295328|NCT01262196|Placebo Comparator|Control|250-mL of normal saline solution
89295329|NCT03885180|Experimental|Extend anticoagulation group|Extended the duration anticoauglation to 12 months
89295330|NCT03885180|No Intervention|Stop anticoagulation group|Just stop oral anticoagulation like routine
89295331|NCT01154244||Drug naive type II DM|Newly diagnosed type II Diabetes Mellitus
89295332|NCT03888300|Experimental|Patient Group|Patients with obstructive pulmonary diseases receiving standard physiotherapy treatment
89295333|NCT03885414|Experimental|OST-VRET + in-vivo transition program|One-session treatment (OST) VRET on-location with clinical psychologist (3 hours), followed by a therapist-guided, four-week online program encouraging transition to real-world, in-vivo exposure exercises.
89295334|NCT01152762|Experimental|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy is the intervention in all selected patients
89295335|NCT03890562|Experimental|Auricular acupressure for NAS infants|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
89295336|NCT03888144|Active Comparator|Oxycodone group|Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.
89295337|NCT03888144|Experimental|Ketorolac group|Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.
89295338|NCT03890406|Experimental|Group D|Deep neuromuscular blockade
89295339|NCT03890406|Active Comparator|Group M|Moderate neuromuscular blockade
89295340|NCT03887832|Experimental|SBSI intervention|Mothers is this arm will download the SMBI intervention app onto their smartphone. They will be shown a video from the app and how to share videos with others. After hospital discharge, mothers will receive a weekly media package (video, associated prompt(s), and activity) via the SMBI for six months.
89295341|NCT03887832|Active Comparator|Infant standard of care|Mothers in this arm will receive the standard of care for newborn and infants including education and a list of resources.
89295342|NCT01154400|Experimental|Casein protein hydrolysates|15 g casein protein hydrolysates and 15 g maltodextrin
89295343|NCT01154400|Experimental|Whey protein hydrolysates|15 g whey protein hydrolysates and 15 g maltodextrin
89295344|NCT01154400|Experimental|Casein protein hydrolysates + LEU|15 g casein protein hydrolysates + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
89295345|NCT01154400|Experimental|Whey protein hydrolysates + LEU|15 g whey protein hydrolysates + 1.5 g LEU (40% of EAA content) + 15 g maltodextrin
89295346|NCT03884868|No Intervention|Control group|Regular nursing visit: 1. Explanation of the meaning of a positive result in the FIT. 2. Explanation of the need to perform a colonoscopy with sedation. 3. Anamnesis. 4. Agreement of the day and hour to perform the colonoscopy. 5. Explanation of the diet and delivery of preparation for the preparation of the colon.
89295347|NCT03884868|Experimental|Intervention group|In addition of the regular nursing visit: the nurse will use iconographies specially designed to communicate the risk of the different possible diagnoses and the complications of the colonoscopy. Because the risks are different according to sex and age, specific iconographies will be developed from the data available in the first screening round.
89295348|NCT01152840|Experimental|RAD001|RAD001 daily po medication
89295349|NCT01262274|Active Comparator|ANA|
89295350|NCT01262274|Experimental|ANA+UFT|
89295351|NCT03890796|Experimental|Dementia Care Education and Activity Scheduling Group (DE&AS)|Will received both dementia care education and activity scheduling
89295352|NCT03890796|Sham Comparator|Dementia Care Education Group (DE)|Will received dementia care education
89295353|NCT01155648|Experimental|PSV group.|Chest wall compression plus increase of 10 cmH2O of PSV.
89295354|NCT01155648|Active Comparator|chest wall compression group|Chest wall compression
89295355|NCT03890328|Experimental|RF group|radiofrequency-assisted spleen-preserving therapy group.
89295356|NCT03890328|No Intervention|CT group|Conventional Treatment of Blunt Splenic Injury group.
89295357|NCT01154478|Experimental|B group|Diet rich in omega-3 fatty acids
89295358|NCT01154478|Experimental|C group|Diet rich in polyphenols
89295359|NCT01154478|Experimental|D group|Diet rich in polyphenols and in omega-3 fatty acids
89295360|NCT01154478|Placebo Comparator|A group (control group)|diet with low content of omega-3 fatty acids and polyphenols
89295361|NCT01260558|Active Comparator|Arm 1|Sirolimus-Permanent-Polymer Eluting Stent
89295362|NCT01260558|Active Comparator|Arm 2|Sirolimus-Polymer-free Eluting Stent
89295363|NCT01152918|Experimental|Linkage-to-Care Component: Financial Incentive (FI)|HIV test sites will provide financial incentives to encourage linkage to HIV care.
89295364|NCT01152918|Active Comparator|Linkage-to-Care Component: Standard of Care (SOC)|HIV test sites will provide the standard-of-care to their patients for linkage to HIV care.
89295365|NCT01152918|Experimental|Viral Suppression Component: FI|HIV care sites will provide financial incentives to encourage viral load suppression.
89295366|NCT01152918|Active Comparator|Viral Suppression Component: SOC|HIV care sites will provide the standard-of-care to their patients for viral load suppression.
89295367|NCT01152918|Experimental|Prevention for Positives Component: Counseling and SOC|Participants will take part in a computerized HIV risk reduction counseling program and receive SOC for HIV infection.
89295368|NCT01152918|Active Comparator|Prevention for Positives Component: SOC|Participants will receive SOC for HIV infection.
89295369|NCT01260636|Experimental|MultiHance contrast agent|MultiHance administered at a dose of 0.1 mmol/kg (0.2 mL/kg)
89295370|NCT01260636|Active Comparator|Magnevist|Magnevist administered at a dose of 0.2 mmol/kg
89295371|NCT01260714|Experimental|Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)|Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.
89295372|NCT03890094||Sufentanil and Midazolam|Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 were included in this study.
89295373|NCT03887754|Active Comparator|The Hyperbaric oxygen therapy group|This group consists of twenty autistic children received forty sessions of HBOT, the time of the session is one hour. The sessions were done at pressure 1.5 ATA (atmosphere absolute) and with 100% oxygen concentration, either in multiplace or monoplace chamber. The number of sessions per week allowed is five sessions per week, all participants were required to complete forty sessions within two months. After six months from the last session, another forty sessions would be taken in the same manner
89295374|NCT03887754|Active Comparator|The Risperidone group|"This group consists of twenty autistic children received Risperidone (dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more) for eight months.~The medication schedule in the initial 2 months was based on the child's weight and clinical response. Adjusting the total daily dose according to response and/or adverse effects, at the end of these eight months of treatment we began the discontinuation phase. In this phase, gradual placebo substitution occurs. The discontinuation reduced the maintenance dose by 25% per week. Thus, the dose was 75% of the last week in the eight months for the first week, followed by 50% of the last week for the second week, 25% of the last week for the third week, and placebo only by the fourth week."
89295375|NCT03887754|Active Comparator|The HBOT and Risperidone group|This group consists of twenty autistic children received HBOT as the HBOT group in addition to Risperidone as the Risperidone group in the same manner and duration
89295376|NCT03887754|Placebo Comparator|The Control group|This group consists of twenty autistic children received placebo in the form of multivitamins
89295377|NCT01262430|Active Comparator|OtisMed|
89295378|NCT01262430|Active Comparator|Computer Assisted Surgery (CAS)|
89295379|NCT01259622|Placebo Comparator|placebo|
89295380|NCT01259622|Experimental|K201|intravenous K201
89295381|NCT03890016||snakebite victims|Victims of snakebite presenting to the Emergency Department of Jubilee Mission Medical College and Research Institute
89295382|NCT01155804|Other|Exercice|
89295383|NCT01155804|Other|non-exercice|
89295384|NCT01155882||Whipple Surgery at the Splenic Artery|Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
89295385|NCT01589874||acute ill patients|
89295386|NCT03887598||breast nodule|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of breast surgery or breast biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
89295387|NCT01154556||HIV1 positive, NNRTI exposure and failure|
89295388|NCT01260792||Children|Children between 5 and 18 years old.
89295389|NCT01260792||Adults|Parents of children between 5 and 18 years old
89295390|NCT01153074|Experimental|Occluder|The patients with bronchopleural fistulas treated with bronchoscopic deployment of the cardiac septal defects occluder.
89295391|NCT03884322|Experimental|Prepod Group|Premature Infants (31 to 32 weeks gestation on entry to program), healthy who wear a prepod or elastic knit fabric pod with snaps essentially 24 hrs a day with brief breaks for bathing, exams, or parent skin to skin time. The intervention lasts 4 weeks
89295392|NCT03884322|Active Comparator|Control Group|Premature infants (31 to 32 weeks of age on entry to program), healthy who receive a joint compression exercise program approximately 10 minutes a day 5 days a week. The intervention lasts 4 weeks
89295393|NCT03890172||study group|in this group the investigators will be managing diabetic wounds with platelet rich plasma treatment.
89295394|NCT03890172||control group|In this group patients will receive the standard treatment in form of debridement and dressing twice weekly
89295395|NCT03884244|Active Comparator|taking chewing gum patients|
89295396|NCT03884244|No Intervention|no chewing gum|
89295397|NCT01261026||Ectopic pregnancy, extra-uterine pregnancy|Ectopic pregnancy, control
89295398|NCT01261026||Abnormal intrauterine pregnancy|
89295399|NCT03889470|Active Comparator|200 microgram NTG|200 microgram NTG through the radial sheath
89295400|NCT03889470|Placebo Comparator|Saline|Saline infusion through the radial sheath
89295401|NCT01153230||poisoned patient|after patients died the pathological findings evaluated with autopsy
89295402|NCT01261104||Hearing impaired elderly|
89295403|NCT01261104||Hearing impaired adults|
89295404|NCT01262508||Risk Population|Patients being suspected to be at risk of hemodynamic instability due to medical history
89295405|NCT01259700|Experimental|High risk management|
89295406|NCT01259700|Experimental|Salt reduction|
89295407|NCT01259700|Experimental|high risk management and salt reduction|
89295408|NCT01259700|No Intervention|Usual care|
89295409|NCT01153308||Bariatric Surgery Patients|Bariatric Surgery patients at UMass Memorial Medical Center
89295410|NCT01262586|Experimental|Vildagliptin|
89295411|NCT01262586|Active Comparator|Glimepiride|
89295412|NCT03887364|Active Comparator|Group A-Diaphragmatic breathing exercise|Diaphragmatic breathing exercise
89295413|NCT03887364|Experimental|Group B-Icing and Airflow Stimulation|Icing and Airflow Stimulation
89295414|NCT03889392||polycystic kidney disease|Adult autosomal dominant polycystic kidney disease patients who received kidney transplantation at Asan Medical Center between 1994 and 2018
89295415|NCT01262664|Experimental|Prohibitin-TP01|Prohibitin-TP01 starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
89295416|NCT01261182|Experimental|In School Feeding|
89295417|NCT01261182|Experimental|Take Home Rations|
89295418|NCT01261182|No Intervention|Control|
89295419|NCT01157052|Active Comparator|Ca2+/Mg2+ pre & post cycle 1|Arm A:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1
89295420|NCT01157052|Active Comparator|Ca2+/Mg2+pre & post cycle 2|Arm B:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 2
89295421|NCT03887130|Experimental|Vinorelbine-Capecitabine (arm A)|oral vinorelbine (OV) with capecitabine (CAP)
89295422|NCT03887130|Active Comparator|Gemcitabine-Paclitaxel (arm B)|gemcitabine (GEM) in combination with paclitaxel (PAC)
89295423|NCT03887130|Active Comparator|Gemcitabine-Docetaxel (arm C)|gemcitabine (GEM) in combination with docetaxel (DOC)
89295424|NCT01154712|Active Comparator|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
89295425|NCT01154712|Sham Comparator|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
89295426|NCT01155960|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
89295427|NCT01155960|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
89295428|NCT03883932|Experimental|F3 Program|The F3 group will focus on the fatherhood role each session. The topic of children and parenting will be applied to each of the standard FVEP topics.
89295429|NCT03883932|Active Comparator|FVEP Program|A retrospective control group who received the standard FVEP will be included in this arm.
89295430|NCT03883776|Experimental|healthy volunteers and NET patients|"In the first part of the study, 6 healthy volunteers will receive a single intravenous single injection of Al18F-NOTA-octreotide, followed by whole-body PET/CT scans at various time points for an initial safety assessment and dosimetry study.~In the second part of the study, a single dose of Al18F-NOTA-octreotide will be intravenously injected in 6 patients with neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and initial efficacy assessment."
89295431|NCT01157130|Experimental|Intervention Group|Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.
89295432|NCT01157130|No Intervention|Control Group|The control group will receive basic information on physical activity but not be instructed.
89295433|NCT01157208|Experimental|Diet A|This diet is high in omega-3 fatty acids, low in trans fatty acids, and low in omega-6 fatty acids. Subjects are encouraged to eat fatty fish daily (e.g., salmon), to limit vegetable oil intake, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include salmon-salad sandwiches, hummus with olive oil, other bean dips and bean dishes, frozen and canned fish, and blueberry-flax muffins.
89295434|NCT01157208|Experimental|Diet B|This diet is low in trans fatty acids and low in omega-6 fatty acids. Subjects are encouraged to to limit vegetable oil intake, to replace meats and eggs with beans and lean fish/shellfish, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include hummus with olive oil, other bean dips and bean dishes, lean fish and shellfish,and blueberry muffins.
89295435|NCT03886896|Experimental|Group A - lidocaine group|Group A: children receiving standard general anesthesia with intravenous lidocaine infusion 1,5 mg/kg for 5 minutes before induction of anesthesia. After 5 minutes, lidocaine infusion continued at rate of 1.5 mg/kg/h during operation, and discontinued before move the patients to PACU.
89295436|NCT03886896|No Intervention|Group B - control group|Group B: children receiving standard general anesthesia (involving fentanyl and sevoflurane) without lidocaine infusion
89295437|NCT03881826|Experimental|Haematological patients|
89295438|NCT03881826|Active Comparator|Healthy volunteers|
89295439|NCT03881904|Active Comparator|OCP Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
89295440|NCT03881904|No Intervention|Control Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.
89295441|NCT01263678|Other|Non-Coaching|Usual care for patients with a diagnosis of spinal stenosis after viewing a DA and completing a survey.
89295442|NCT01263678|Other|Coaching|Patients randomized to coaching group will receive one week post viewing of Decisional Aid.
89295443|NCT03881592||R-Clb patients|Patients treated with the combination of Rituximab + chlorambucil
89295444|NCT03881592||R-B patients|Patients treated with the combination of Rituximab + bendamustine
89295445|NCT03881592||Obi-Clb patients|Patients treated with the combination of Obinutuzumab + chlorambucil
89295446|NCT05666934|Experimental|Home-based Augmented Reality Storybook Training Module|The children were entirely involved in this intervention program at home, with 20 minutes each time, 4 times a week for 8 weeks. The caregiver was required to perform the interactive picture book specified by the AR home training modules. During the process, the caregivers could directly contact the researcher by telephone and instant messaging for solving problems that occur during the interaction. The researcher and the caregiver consistently met once every two weeks. On the day of the meeting, the caregiver needs to prepare at least ten minutes of interactive video to discuss with the researcher. The researcher not only provides suggestions for caregiver interaction skills based on the video, in order to facilitate the child's interaction. The interaction strategies were also revised according to the interaction ability and special behavior problems of individual children.
89295447|NCT03883308|Experimental|Treatment|Treatment group will receive 6 months of online, computerized, multi-domain cognitive training at home.
89295448|NCT03883308|Active Comparator|Active Control|The Active Control group will receive 6 months of online, computerized cross-word puzzles at home using the same platform as for the Treatment group.
89295449|NCT01156038|Experimental|Atopy patch test|Atopy patches were applied on healthy volunteer's back for 48 hrs then the patches were removed. Reaction was evaluated 48 and 72 hrs after applying atopy patch test
89295450|NCT01157286||level of apnea|patients will be separated depending on the iah(apnea hypopnea index) in mild, moderate and severe
89295451|NCT05482776|Active Comparator|classic training group|The classic training group followed their routine of both physical and cognitive exercises that were recorded for their control. Balance exercises, strength and aerobic exercise. They were assessed at the beginning and at the end of the 10 weeks.
89295452|NCT05482776|Experimental|HIFT group|The experimental group performed 10-weeks training program consisted in Warm-up phase and HIFT training. They were assessed at the beginning and at the end of the 10 weeks.
89295453|NCT01261260|Placebo Comparator|Uridine|1g BID
89295454|NCT01262742|Active Comparator|Carbetocin 80mcg|
89295455|NCT01262742|Active Comparator|Carbetocin 90mcg|
89295456|NCT01262742|Active Comparator|Carbetocin 100mcg|
89295457|NCT01262742|Active Comparator|Carbetocin 110mcg|
89295458|NCT01262742|Active Comparator|Carbetocin 120mcg|
89295459|NCT03883464|Experimental|Low fat intake|Patients who underwent cholecystectomy and were instructed to have a low fat diet.
89295460|NCT03883464|No Intervention|Regular diet|Patients who underwent cholecystectomy and were instructed to have a regular diet.
89295461|NCT03883620|Experimental|Cohort 1 (Initial Safety Cohort) 1 mg/kg|4 participants will be administered Dengushield at 1 mg/kg body weight as Intravenous injection.
89295462|NCT03883620|Experimental|Cohort 2 Experimental 3mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
89295463|NCT03883620|Placebo Comparator|Cohort 2 Placebo 3 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo and enrolled.
89295464|NCT03883620|Experimental|Cohort 3 Experimental 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
89295465|NCT03883620|Placebo Comparator|Cohort 3 Placebo 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
89295466|NCT03883620|Experimental|Cohort 4 Experimental 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
89295467|NCT03883620|Placebo Comparator|Cohort 4 Placebo 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
89295468|NCT01261416||Infants with seizures|
89295469|NCT03617172|Experimental|Study Drug (Misoprostol)|
89295470|NCT03617172|Placebo Comparator|Placebo|
89295471|NCT01154790|Experimental|CG100649|By the amount of doses, the groups are classified
89295472|NCT01154790|Active Comparator|Naproxen|By the amount of doses, the groups are classified
89295473|NCT01154790|Placebo Comparator|Placebo|By the amount of doses, the groups are classified
89295474|NCT01261494|Experimental|GFT505 80mg|
89295475|NCT01261494|Placebo Comparator|Matching placebo|
89295476|NCT01157442|Experimental|cell phone sms messages|The experimental arm will receive the cell phone SMS text messaging intervention.
89295477|NCT01157442|No Intervention|Control|The control group will receive the standard of care but no SMS text messages.
89295478|NCT01261572|Experimental|High dose group|ASP3350 high dose
89295479|NCT01261572|Experimental|Low dose group|ASP3350 low dose
89295480|NCT01261650|Active Comparator|transcranial direct current stimulation|transcranial direct current stimulation of the primary motor cortex
89295481|NCT01261650|Sham Comparator|sham treatment|
89295482|NCT01156194|Active Comparator|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
89295483|NCT01156194|Active Comparator|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
89295484|NCT01156194|Placebo Comparator|Placebo|globules identical to true comparators
89295485|NCT03883698|Experimental|ESRD, alternate day dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 400 mg on alternate days. Total duration of treatment will be 12 weeks
89295486|NCT03883698|Experimental|ESRD, daily dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 200 mg daily doses. The total duration of treatment will be 12 weeks
89295487|NCT03883698|Active Comparator|Control|Participants with normal eGFR and hepatitis C virus infection and treated with sofosbuvir 400 mg daily dose. The total duration of treatment will be 12 weeks
89295488|NCT01263756||ASD group|Adolescents and adults with Autism Spectrum Disorders (ASDs).
89295489|NCT01157520||Cesarean|Women scheduled for elective Cesarean section under spinal anesthesia
89295490|NCT01263210|Active Comparator|Pneumococcal vaccine|Half of the children were randomized to receive heptavalent pneumococcal conjugate vaccine (before this vaccine was included in the national immunization programme).
89295491|NCT01263210|No Intervention|Control|Half of the children were randomized to no vaccination and functioned as controls.
89295492|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 400 IU|
89295493|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 1000 IU|
89295494|NCT01263288|Placebo Comparator|Placebo|
89295495|NCT01261806|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up: 10 session intervention in foster families' homes designed to enhance parental nurturance, synchrony, and provide skills such that parents can help children calm down when overwhelmed.
89295496|NCT01261806|Active Comparator|Developmental Education for Families|10 session intervention in foster families' homes that targets cognitive and motor skills of children
89295497|NCT01154868|Other|Healos|
89295498|NCT01261884|No Intervention|Routine prenatal care|
89295499|NCT01261884|Experimental|Exercise support|
89295500|NCT01261884|Experimental|Exercise intervention|
89295501|NCT03886428|Experimental|100% Portion Size|Test meal with portion size 100% of baseline
89295502|NCT03886428|Experimental|125% Portion Size|Test meal with portion size 125% of baseline
89295503|NCT03886428|Experimental|150% Portion Size|Test meal with portion size 150% of baseline
89295504|NCT03886428|Experimental|175% Portion Size|Test meal with portion size 175% of baseline
89295505|NCT03881280|No Intervention|Control group|Treatment as usual for 4 weeks
89295506|NCT03881280|Experimental|Intervention group|Education through the app for 4 weeks
89295507|NCT01156272||Replacement aortic heart valve|ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm
89295508|NCT01263834|Active Comparator|Mitomycin c|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
89295509|NCT01263834|Experimental|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
89295510|NCT01263366|Experimental|Norepinephrine|
89295511|NCT01263912|Active Comparator|LCPUFA Supplement|DHA/ARA supplement providing 200 mg/day docosahexaenoic acid (DHA) from DHASCO®-S oil and 200 mg/day arachidonic acid (ARA) from ARASCO® oil (DSM Nutritional Products).
89295512|NCT01263912|Placebo Comparator|A Placebo|400 mg/day corn oil
89295513|NCT01154946||DAC group|patients who show detrusor after-contraction during voiding cystometrography (CMG)
89295514|NCT01586520||Disease positive|Imaging or biopsy evidence of disease
89295515|NCT01586520||Disease negative|No evidence of disease
89295516|NCT03882606|Other|SML implantation|prospective study of a cohort of patients with age-related macular degeneration or myopic maculopathy treated with SML implantation
89295517|NCT01263990|No Intervention|Nexfin|Nexfin is used in all patients
89295518|NCT02527356|Experimental|ROC-Stand group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-stand).
89295519|NCT02527356|Active Comparator|ROC-Sit group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-sit)
89295520|NCT02527356|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for regular therapy.
89295521|NCT03882762|Experimental|Group I - Cebranopadol 200 μg tablet|"Mild Renal Impairment:~PK evaluable non-dialyzed patients with mildly impaired renal function (eGFR = 60-89 mL/min/1.73 m2)"
89295522|NCT03882762|Experimental|Group II - Cebranopadol 200 μg tablet|"Moderate Renal Impairment:~PK evaluable non-dialyzed patients with moderately impaired renal function (eGFR = 30-59 mL/min/1.73 m2)"
89295523|NCT03882762|Experimental|Group III - Cebranopadol 200 μg tablet|"Severe Renal Impairment:~PK evaluable non-dialyzed patients with severely impaired renal function (eGFR = 15-29 mL/min/1.73 m2)"
89295524|NCT03882762|Experimental|Group IV - Cebranopadol 200 μg tablet|"Normal Renal Function:~PK evaluable participants with normal renal function (eGFR greater than or equal to 90 mL/min/1.73 m2)"
89295525|NCT01261962|Experimental|Chemotherapy and zinc|Patients in adjuvant chemotherapy supplemented with zinc
89295526|NCT01261962|Placebo Comparator|Chemotherapy placebo|Patients in adjuvant chemotherapy with placebo
89295527|NCT01261962|Other|Control and zinc|Healthy patients supplemented with zinc
89295528|NCT01261962|Other|Control Placebo|Healthy volunteers received placebo
89295529|NCT03886662|Experimental|LB-100 for Intravenous administration|Phase Ib: Escalating doses of LB-100 administered. Phase 2: Safe dose of LB-100 from phase Ib administered.
89295530|NCT01264068|No Intervention|Insomnia control|
89295531|NCT01264068|Experimental|Suan Tsao Jen Tang|
89295532|NCT01264068|Experimental|Jia-Wey Shiau-Yau San|
89295533|NCT01155258|Experimental|Arm I|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89295534|NCT01157598|Active Comparator|BIS group|
89295535|NCT01157598|Placebo Comparator|non BIS group|
89295536|NCT01156584|Experimental|Single arm|Toca 511 vector/ Toca FC prodrug
89295537|NCT01264146|Active Comparator|calcaneal plating HBOT|Open reduction and internal fixation of calcaneal fracture + HBOT
89295538|NCT01264146|Placebo Comparator|calcaneal plating|Open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
89295539|NCT03879174|Experimental|Pembrolizumab + Tamoxifen|Pembrolizumab (200mg IV every three weeks) + Tamoxifen (20 mg OD)
89295540|NCT03882450|No Intervention|Neonates with congenital cardiac disease (retrospective)|Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
89295541|NCT03882450|Active Comparator|Neonates with congenital cardiac disease (prospective)|Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.
89295542|NCT03881202|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
89295543|NCT01263522|Experimental|Endurance training|
89295544|NCT01263522|Experimental|interval training|
89295545|NCT01263522|Experimental|strength endurance training|
89295546|NCT01263522|Placebo Comparator|control|
89295547|NCT01156662|Active Comparator|No aspiration|
89295548|NCT01156662|Active Comparator|Thrombus aspiration|
89295549|NCT01159470||bacterial infection|children with fever due to bacterial infection
89295550|NCT01159470||viral infection|children with fever due to viral infection
89295551|NCT01159548|No Intervention|Saline|
89295552|NCT01159548|Other|Promethazine 6.25 mg|
89295553|NCT01159548|Other|Promethazine 3 mg|
89295554|NCT03881358|Active Comparator|ortho-k lenses and thinner spectacles|participants using conventionally designed ortho-k lenses (target for 4.00D) and thinner spectacles during day time
89295555|NCT03881358|Experimental|newly designed ortho-k lenses|participants using newly designed ortho-k lenses for high myopia (target for full correction)
89295556|NCT03882684||Cancer patients|The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.
89295557|NCT03882684||Benign tumor and other disease patients|Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.
89295558|NCT03880890|Active Comparator|sphenoidotomy (group A)|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus
89295559|NCT03880890|Active Comparator|sphenoid nasalization (group B)|sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
89295560|NCT01156740|Active Comparator|Intramuscular benzathine Penicillin G|A single dose of intramuscularly administered intramuscular benzathine penicillin G (IM BPG). The dosing was as follows: IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg
89295561|NCT01156740|Active Comparator|Amoxicillin|A 10-day once daily dose of Amoxicillin was given in an oral form. The first dose was given at the time of randomization, and parents were instructed on giving the remaining doses. Dosing was as follows: 750 mg/QD
89295562|NCT03882138|Active Comparator|thin biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
89295563|NCT03882138|Active Comparator|thick biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
89295564|NCT01265628||Glaucoma|
89295565|NCT01265628||Retinitis pigmentosa (RP)|
89295566|NCT01265628||Anterior Ischemic Optic Neuropathy (AION)|
89295567|NCT03880812|Experimental|Cost group|These patients reviewed total societal costs associated with carpal tunnel release.
89295568|NCT03880812|No Intervention|No cost group|These patients did not review total societal costs associated with carpal tunnel release.
89295569|NCT01159626|Experimental|Single dose|
89295570|NCT01159626|Experimental|Multiple dose|
89295571|NCT03880968||inactive - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and assigned to sequential tapering group (A1).
89295572|NCT03880968||inactive - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and then assigned to discontinuation group (A2).
89295573|NCT03880968||low disease activity - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to sequential tapering group (B1).
89295574|NCT03880968||low disease activity - full dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to delayed tapering group (B2) with extra 12 weeks of full dose ETN.
89295575|NCT03880968||low disease activity - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to discontinuation group (B3).
89295576|NCT01159704|Experimental|Network plus HIV Counseling&Education|"Social network peer education model plus HIV testing and counseling; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
89295577|NCT01159704|Active Comparator|HIV Counseling and Education (C&E) only|"HIV testing and counseling C&E; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
89295578|NCT03880734|Experimental|study|Vitamin D.Generic name-Cholecalciferol (40,000 IU).Dose- 80,000. Dosage-2 capsule/week for consecutive 26 weeks
89295579|NCT03880734|Experimental|control|Placebo oral capsule.Dose 80,000.Dosage-2 capsules for consecutive 26 weeks
89295580|NCT01159782|Other|Asthma, Healthy|Asthmatics or Healthy Volunteers
89295581|NCT01157754|Experimental|OCP+GnRH antagonist|Microgynon 14 to 21 tablets starting COH on day 5 post pill, rFSH + GnRH antagonist
89295582|NCT01157754|Active Comparator|long GnRH agonist|daily triptorelin starting day 21st of previous cycle
89295583|NCT03879252|Experimental|Tooth brushing|
89295584|NCT03879252|Active Comparator|Mouthwash|
89295585|NCT01265862|Active Comparator|LMA-Fastrach® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach®, establishment of ventilation~Evaluation of glottic view through LMA-Fastrach® using fibrescope~Tracheal intubation with the GlideRite® tube through the LMA-Fastrach®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
89295586|NCT01265862|Experimental|I-gel® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel®, establishment of ventilation~Evaluation of glottic view through I-gel® using fibrescope~Tracheal intubation with the GlideRite® endotracheal tube through the I-gel®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
89295587|NCT01156818||Children|Age 8-21 years
89295588|NCT01156818||Adult|Age 21-80 years
89295589|NCT03881982|Experimental|PIMPERNEL Novel Electronic Log - intervention|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
89295590|NCT03881982|Other|PIMPERNEL Novel Electronic Log - control|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
89295591|NCT01156896|Experimental|Iron intervention|"All study subjects with malaria and all control subjects will receive an iron intervention (supplement or fortification dose of iron).~Control subjects will be studied on only one occasion.~Study subjects with malaria will receive the same iron intervention two weeks later, after the malarial episode has been successfully treated."
89295592|NCT01264224|Experimental|PAC-14028|
89295593|NCT01156974|Experimental|care guide|patients receive education about care goals and work with a care guide to achieve goals
89295594|NCT01156974|Active Comparator|no care guide|patients receive education about care goals and usual care to achieve goals
89295595|NCT03882216|Experimental|test group pouch technique|free connective tissue graft augmentation using pouch technique
89295596|NCT03882216|Experimental|test group modified pouch technique|free connective tissue graft augmentation using modified pouch technique
89295597|NCT01265940|Experimental|Pazopanib + Vinflunine|
89295598|NCT01159860|Active Comparator|Cryosurgery|One lesion on the patients' trunk or proximal extremities will be treated with cryosurgery.
89295599|NCT01159860|Active Comparator|Curettage|One lesion on one side of the patients' trunk or proximal extremities will be treated by curettage.
89295600|NCT01264302|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
89295601|NCT01264302|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
89295602|NCT03760146|Experimental|60 years and above 20vPnC/Saline|20vPnC and saline
89295603|NCT03760146|Active Comparator|60 years and above 13vPnC/PPSV23|13vPnC and PPSV23
89295604|NCT03760146|Experimental|50 through 59 years of age 20vPnC|20vPnC
89295605|NCT03760146|Experimental|18 through 49 years of age 20vPnC|20vPnC
89295606|NCT03760146|Active Comparator|50 through 59 years of age 13vPnC|13vPnC
89295607|NCT03760146|Active Comparator|18 through 49 years of age 13vPnC|13vPnC
89295608|NCT03877068|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Patients will wear a real-time Dexcom G6 CGM, which provide BG readings every 5 minutes for up to 10 days. In addition, patients will undergo POC testing before meals and bedtime per hospital protocol. Insulin therapy will be titrated based on daily CGM printouts, which will include BG readings, glycemic excursions, hypoglycemia and severe hyperglycemia values throughout the day. Patients will wear a CGM in the current approved insertion site, the abdomen, and in the upper arm.
89295609|NCT03877068|Active Comparator|POC BG - Point-of-Care Blood Glucose monitoring|Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded in the electronic medical record (EMR) system. The research team together with the PCP team will adjust daily insulin orders based on POC readings (standard of care). In addition, patients will wear a 'blinded' CGM where no results will be visualized by patients, nursing staff, primary care physician (PCP) or research teams.
89295610|NCT01266174|Experimental|Eltoprazine|eltoprazine pill 2.5mg bid, eltoprazine pill 5mg bid, eltoprazine 7.5mg bid
89295611|NCT01266174|Placebo Comparator|Placebo|placebo pill 2.5mg bid, placebo pill 5mg bid, placebo 7.5mg bid
89295612|NCT01266252|Experimental|Dexmedetomidine|
89295613|NCT03878940|Other|Primary care patients|All GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent.
89295614|NCT01266330|Active Comparator|Low Dairy|<0.5 standard dairy servings/day
89295615|NCT01266330|Experimental|Adequate dairy|3.5 standard dairy servings per day
89295616|NCT01161732|No Intervention|Conventional treatment|In the conventional treatment group, indications for aortic valve replacement surgery are development of symptoms, reduced left ventricular systolic function and an increase in aortic jet velocity > 0.5 m/sec during follow-up.
89295617|NCT01161732|Active Comparator|Early Surgery|Early surgery is performed within 2 months of randomization.
89295618|NCT01266408||DRSP/EE/metafolin|Women using oral contraceptives containing drospirenone, ethinylestradiol and metafolin
89295619|NCT01266408||Other OC users|Women using oral contraceptives containing other estrogen/progestogen combinations
89295620|NCT01264458||Traumatic Injury|Trauma patients arriving at Saint Mary's Emergency Department
89295621|NCT01264458||Control group|
89295622|NCT01266486|Experimental|Metformin|
89295623|NCT03879954|Other|OOP-IJV|Out of plane inetrnal jugular vein catetherization
89295624|NCT03879954|Other|IP-SSV|in plane supraclavicular subclavian vein catetherization
89295625|NCT01266564||Cohort|
89295626|NCT01267968|Experimental|Cohort 1|GSK2251052 1500 mg Single dose (i.v., 60 min)
89295627|NCT01267968|Experimental|Cohort 2|GSK2251052 1500 mg IV q12h x 5 doses infused over 60 minutes
89295628|NCT01160094||Patients|ErbB2+ metastatic breast cancer patients
89295629|NCT01157988|Experimental|ibritumomab tuixetan, response, toxicity|
89295630|NCT03760068|Active Comparator|MYL-1601D Product (100 U/mL)|
89295631|NCT03760068|Active Comparator|FlexPen NovoLog® (100 U/mL)|
89295632|NCT03759600|Experimental|Niraparib 300 mg|Niraparib 300 milligrams (mg), capsules, orally, once daily on Days 1 to 28 of each 28-day treatment cycle for up to 50 cycles.
89295633|NCT01158066|No Intervention|CT cardiac|the patient will undergo cardiac CT
89295634|NCT03876912|Experimental|GnRH antagonist|Administration of GnRH antagonist (subcutaneous injection, 240 mg) after baseline 18F-PSMA 1007 PET/CT.Then 18F-PSMA 1007 PET/CT is repeated 3 weeks after ADT and at development of CRPC
89295635|NCT01268124|Experimental|Treatment|
89295636|NCT01161966|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
89295637|NCT01161966|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
89295638|NCT01158144|Experimental|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
89295639|NCT01158144|Active Comparator|Conctrol|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
89295640|NCT01162044|No Intervention|No intervention|Subjects will be assessed, but no active intervention given
89295641|NCT01162044|Experimental|Computer game|Subjects will play with computer game while in the Emergency Room
89295642|NCT01264536|Experimental|Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
89295643|NCT01264536|Placebo Comparator|maltodextrin|Maltodextrin is an inert sugar.
89295644|NCT01160172|Experimental|Group A|
89295645|NCT01160172|Experimental|Group B|
89295646|NCT01160172|Experimental|Group C|
89295647|NCT01160172|Experimental|Group D|
89295648|NCT01160172|Placebo Comparator|Group E|
89295649|NCT01160172|Placebo Comparator|Group F|
89295650|NCT02527122|Experimental|Allergen extracts|"Skin prick test of 4 concentrations of D. pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of one forearm. Assessment of the wheal size after 15 minutes.~Skin prick test of 4 concentrations of D. farinae allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the other forearm. Assessment of the wheal size after 15 minutes."
89295651|NCT03878784|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigrane infusion (0.4 mg/min) for 10 mins"
89295652|NCT03878784|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
89295653|NCT01266720|Experimental|Phase 1 study|"Interventions:~Biological: VEGFR1, VEGFR2 Drug: Gemcitabine"
89295654|NCT01162200|Other|Stereotactic Body Radiation Therapy|SBRT dose per fraction
89295655|NCT03876756||PAUR (postpartum acute urinary retention)|patients presenting postpartum acute urinary retention.
89295656|NCT03876756||Control|patients without postpartum acute urinary retention. This group was selected randomly, respecting a 1:1 matching criteria, including the year of delivery and the age of the patient at delivery.
89295657|NCT01162278|Other|single fraction|Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 35Gy in one fraction. Subsequent cohorts of patients will receive an additional 5Gy per treatment to a maximum planned dose of 50Gy in one fraction.
89295658|NCT01162434||Patients|Up to 8 patients who have received Deep Brain Stimulation for Treatment Resistant Depression at Frenchay Hospital (UK) will be recruited.
89295659|NCT01162434||Healthy volunteers|Up to 16 healthy volunteers, matched to the DBS patients on age, sex, handedness, and education, will be recruited.
89295660|NCT01589952|Experimental|Pegylated Interferon, Entecavir|'Pegylated Interferon, Entecavir' arm will consist of 20 chronic hepatitis B patients who will receive Pegylated Interferon 90 micro gms subcutaneously once weekly in combination with entecavir 0.5 mg orally once daily for 24 weeks
89295661|NCT01266798|Experimental|Portal arm|
89295662|NCT01266798|No Intervention|Treatment as usal|
89295663|NCT01585896|Experimental|Self-help group|The facilitated self-help group, which represents an empirically supported intervention for hoarding (Frost et al., 2011).
89295664|NCT03876600|Experimental|conventional hospitalization management.|"The patients who are randomized to have a conventional hospitalization for the pacemaker replacement have conventional management.~In this management patient come to hospital one day before this surgical operation and he is operated next day"
89295665|NCT03876600|Active Comparator|ambulatory management|"The patients who are randomized to have a ambulatory surgery for the pacemaker replacement have ambulatory management.~In the ambulatory hospitalization patients come to hospital and have a surgical operation the same day"
89295666|NCT03876444|Experimental|Intervention arm|Pulse intravenous methylprednisolone (30 mg / kg for 3 days) followed by 1-week taper of oral prednisolone Day 1-3 Intravenous Methylprednisolone in dose of 30 mg/kg/day Day 4-6 Oral Prednisolone in dose of 2mg/kg/day Day 7-10 Oral Prednisolone in dose of 1mg/kg/day
89295667|NCT03876444|Active Comparator|Control|Oral prednisolone (4 mg/kg/day) for 2 weeks followed by tapering over 2 weeks Day 1-14 (2 weeks): dose 4mg/kg/day Day 15-21 (1 weeks): 2mg/kg/day Day 22-28 (1 weeks): 1mg/kg/day
89295668|NCT01162512|Experimental|Physical Activity|Participants will receive 7 weeks of weekly news letters and phone calls. The news letters and phone calls will include information about physical activity and ways to increase physical activity levels. This is in addition the standard medical care.
89295669|NCT01162512|No Intervention|Standard Medical Care|Participants will receive standard medical care
89295670|NCT01264692|Experimental|Treatment A|ACT-280778
89295671|NCT01264692|Placebo Comparator|Treatment B|Placebo
89295672|NCT01264692|Other|Treatment C|Amlodipine
89295673|NCT01162590|Experimental|Rotarix Group|Subjects will receive Rotarix™.
89295674|NCT01162590|Placebo Comparator|Placebo Group|Subjects will receive placebo.
89295675|NCT01266954|Experimental|Stage 1|Three to six patients on a medium dose of GSK2141795 for four weeks
89295676|NCT01266954|Experimental|Stage 2|Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks
89295677|NCT01160328|No Intervention|Control Group|Participants in this group will not receive any treatment.
89295678|NCT01160328|Experimental|Lupron Group|Participants in this group will receive leuprolide acetate (Lupron) treatment for 7 weeks resulting in temporary decreases in testosterone levels.
89295679|NCT01160328|Other|Lupron & Testosterone Group|Participants in this group will receive 7 weeks of leuprolide acetate (Lupron) treatment with testosterone gel (Androgel).
89295680|NCT03878238|Placebo Comparator|Placebo|
89295681|NCT03878238|Experimental|Probiotic|
89295682|NCT01162746|Experimental|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
89295683|NCT01162746|Active Comparator|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
89295684|NCT01268202|Experimental|Pravastatin|Pravastatin : 40mg/day during 12 months
89295685|NCT01160406||ischemic stroke, no atrial fibrillation|Patients who have suffered ischemic stroke or transient ischemic attack without known atrial fibrillation
89295686|NCT01264848|Experimental|Balloon angioplasty and/or stenting|Balloon angioplasty and/or stenting of stenosed internal jugular vein and/or azygous vein and/or brachiocephalic vein
89295687|NCT01268358|Experimental|Lamazym 6.25|
89295688|NCT01268358|Experimental|Lamazym 12.5|
89295689|NCT01268358|Experimental|Lamazym 25|
89295690|NCT01268358|Experimental|Lamazym 50|
88806194|NCT01392703|Other|Dasatinib, 100 mg as tablets + water|Treatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
88806195|NCT01392703|Other|Dasatinib, 100 mg as liquid + water|Treatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
88806196|NCT01392703|Other|Dasatinib, 100 mg as tablets in orange juice + water|Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
89295691|NCT01268358|Experimental|Lamazym 100|
89295692|NCT01162824|Other|No endothelial dysfunction|
89295693|NCT01162824|Other|Endothelial Dysfunction|Definition of abnormal epicardial and microvascular vasoreactivity Abnormal epicardial vasoreactivity is defined as a reduction of the baseline coronary diameter ≥75% after glyceryltrinitrate i.c. together with a reproduction of the angina symptoms reported by the patient and/or ischemic ECG-changes. Abnormal microvascular vasoreactivity is defined as the reproduction of the angina symptoms together with ischaemic ECG-changes, but without changes in epicardial vasomotion.
88806197|NCT01392859|Experimental|Initial Treatment: Levocetirizine(LCT)|Group 1 will begin with active Levocetirizine(LCT) 0.5 mg/ml oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and placebo will be provided for 5-8 days.
89295694|NCT01267032|Experimental|Arm 1|Integrated Care + Cognitive-Behavioral Treatment for Insomnia
89295695|NCT01267032|Sham Comparator|Arm 2|Integrated Care + Desensitization Treatment for Insomnia
89295696|NCT01264926||rotator cuff tear, pain|
89295697|NCT03877848||ACS and Non-ACS|"DAPT will be stopped at 30 days in non-ACS subjects while at ACS Patients it may be maintained for up to 3 months. In patients with ACS or with an ischemic event during the first 30 days, DAPT may be continued at the discretion of the investigator. In ACS patients DAPT should be continued for a maximum of 3 months. For patients with recurrent ischemic events duration of DAPT therapy will be at the discretion of the investigator.~Patients receiving long-term oral anticoagulation with either a Vitamin K inhibitor or a NOAC/DOAC will receive either single antiplatelet therapy with clopidogrel, or DAPT for 30 days (triple therapy) followed by single antiplatelet therapy with clopidogrel. Clopidogrel (75 mg QD) will be given to these patients post procedure for 6 months in stable patients and 12 months in ACS patients."
89295698|NCT01265004||Stitches, rupture of achilles tendon|Patients, in who the achilles tendon rupture was treated with tendon surgery including a special way of stitching to preserve the sliding ability of the tendon.
89295699|NCT01265004||Fibrin-glue, rupture of achilles tendon|Patients, who received a surgical treatment including a fixing of the tendon with fibrin-glue.
89295700|NCT01265004||Stiches and Fibrin-glue|Patients, in who the achilles rupture was treated with stitches and fibrin-glue.
89295701|NCT01586598|No Intervention|control group|No intervention will be given to this control group. Spontaneous recovery of mandibular nerve will be assessed for sensory function.
89295702|NCT01586598|Experimental|sensory retraining group|Sensory retraining protocol will be applied this group. Any facilitation of sensory function in mandibular nerve will be assessed.
89295703|NCT01162902|Experimental|Diltiazem treated group|Diltiazem 180mg treated group
89295704|NCT01162902|Active Comparator|Bisoprolol treated group|Bisoprolol 5mg treated group
89295705|NCT01162902|Active Comparator|Candesartan treated group|Candesartan 32mg treated group
89295706|NCT05666856|Experimental|CRAFT|Participants assigned to CRAFT will have access to a 12-module on-line CRAFT intervention and asked to complete one module weekly for 12 weeks. Modules introduce CRAFT concepts and provide workbooks to assist participants in learning and applying the concepts. The modules that are unlocked weekly include: 1) Introduction to CRAFT; 2) Communication Training; 3) Functional Analysis of Drug Using; 4) Positive Reinforcement; 5) Problem-solving; 6) Withdrawing Reinforcement; 7) Allowing Natural Consequences; 8) Life Enrichment; 9) Suggesting Treatment; 10) Recovery and Relapse; 11) Relationship; and 12) Recap of Skills. Two additional modules (domestic violence and opioid overdose precautions) are available at any time. CRAFT participants also attend weekly 60-minute online group sessions facilitated by a CRAFT-certified coach. During weekly group or individual sessions concepts are briefly reviewed, questions are answered, and skills are practiced through role-plays of common situations.
89295707|NCT05666856|Active Comparator|PEER|"Participants assigned to the PEER condition will participate in an online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs.~Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully."
89295708|NCT03876834|Experimental|study group (group A)|Group (A) included 30 leukemic patients receiving chemotherapy in addition to training by inspiratory muscle trainer(IMT) for 4 weeks, 5 sessions /week
89295709|NCT03876834|No Intervention|control group (B)|Group (B) included 10 leukemic patients receiving chemotherapy only
89295710|NCT03877536|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.
89295711|NCT02526888|Experimental|Sequence AB|During Period 1, subjects receive a single dose of ACT-541468 on Day 1. During Period 2, they receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4
89295712|NCT02526888|Experimental|Sequence BA|During Period 1, subjects receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4. During Period 2, they receive a single dose of ACT-541468 on Day 1
89295713|NCT01158612|Experimental|Growth hormone|The effect of Growth hormone on the collagen synthesis rate
89295714|NCT01158612|Placebo Comparator|Saline|
89295715|NCT01267110|Experimental|Intervention|
89295716|NCT01267110|Active Comparator|Control|
89295717|NCT02526966|Other|patient with primitive form of IgA nephropathy|
89295718|NCT01267188|Experimental|NBI-98854|Open-label, dose titration of active drug
89295719|NCT01158690|Experimental|resource card group|The intervention group will receive an envelope with a gift voucher and a resource card (wallet size card with on the one side safety measures and on the other side contact details of resources for violence).
89295720|NCT01158690|Active Comparator|control group|The control group will receive the same envelop with a gift voucher and a letter of thanks.
89295721|NCT01268436||Injectable pain medication|Patients who receive an injectable form of pain medication.
89295722|NCT01268436||Oral pain medication|Patients who receive oral pain medication only
89295723|NCT01158768||Violence, Comorbidity|
89295724|NCT03877692|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg, 80mg after each severe BP
89295725|NCT03877692|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg, 60mg after each severe BP
89295726|NCT03879720|Active Comparator|Standard Endotracheal Intubation (SEI)|the patient will be positioned supine on the gurney for intubation, with eventual position in the standard semi-prone ERCP position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed, Propofol and Succinylcholine will be administered per standard of care and intubation will be accomplished by direct laryngoscopy or glidescope, with confirmation of endotracheal tube placement by auscultation.
89295727|NCT03879720|Experimental|Endoscope assisted endotracheal intubation [EAEI]|the patients will position themselves in the semi-prone position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed and Propofol will be administered per standard of care. Succinylcholine will not be administered and therefore the patient will not be paralyzed. The endotracheal tube will be positioned on the mid-distal aspect of the ultra-slim endoscope and the ultra-slim endoscope will then be advanced into the trachea under direct endoscopic visualization to the level of the carina. The anesthesiologist will then advance the endotracheal tube over the endoscope into the trachea, and its position above the carina will be simultaneously confirmed endoscopically with the ultra-slim endoscope.
89295728|NCT03877614||Cardiovascular high-risk (disease) group|A. Coronary artery disease B. Congestive heart failure with reduced ejection fraction C. Hypertrophic cardiomyopathy D. Atrial fibrillation E. Pulmonary hypertension F. Fabry's disease
89295729|NCT03877614||Cardiovascular Low-risk (control) group|Patient with only risk factors with ASCVD score<10% will be recognized as the comparison group
89295730|NCT03878004|Experimental|Primary Group|135 people who will receive the vaccine in the therapeutic scheme
89295731|NCT03878004|Placebo Comparator|Placebo Group|45 people who will receive placebo in the therapeutic scheme
89295732|NCT01268592|Experimental|positive cancer diagnosis|female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes
89295733|NCT01158846|Active Comparator|prasugrel/bivalirudin|60 mg loading dose of prasugrel will be followed by maintenance dose of 10mg (or 5mg according to body weight and age). During primary PCI, Bivalirudin will be used as anticoagulant (bolus plus infusion), on a weight-adjusted dose.
89295734|NCT01158846|Active Comparator|clopidogrel/abciximab|600mg loading dose of clopidogrel will be followed by 75mg maintenance dose. During primary PCI abciximab (bolus plus infusion) will be used as anticoagulant.
89295735|NCT01268670|Active Comparator|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
89295736|NCT01268670|Active Comparator|Oxycodone|Subjects will receive topical LET and oral oxycodone.
89295737|NCT01268670|Placebo Comparator|Placebo|Subjects will receive topical LET and oral placebo.
89295738|NCT01265082||Patients in remission with pruritus|
89295739|NCT01265082||Patients in remission without pruritus|
89295740|NCT01160718|Active Comparator|Arm A: Fulvestrant / AZD6244|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days AZD6244 75 mg p.o. bid
89295741|NCT01160718|Placebo Comparator|Arm B: Fulvestrant / Placebo|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Placebo 3 caps p.o. bid (same appearance as AZD6244)
89295742|NCT01160796|Experimental|Lcr35®|
89295743|NCT01160796|Placebo Comparator|placebo|
89295744|NCT01160874|Experimental|TDA/H|
89295745|NCT01160874|Other|Sleep apnea patient|
89295746|NCT01160874|Other|Healthy volunteer|
89295747|NCT01159002||Critically ill ICU patients|ICU patients with brain injuries who will be receiving a feeding tube.
89295748|NCT01159080|Active Comparator|routine dose tacrolimus and less myfortic|
89295749|NCT01159080|Experimental|reduced dose tacrolimus and conventional myfortic|
89295750|NCT01160952|Other|long-term group|long-term group refers to prophylaxis by using itraconazole for up to 90 days
89295751|NCT01160952|Other|short term group|short term group refers to prophylaxis by itraconazole for 30 days
89295752|NCT01265160||the group of Jiangzhuo prescription|
89295753|NCT01265160||the group of fenofibrate|
89295754|NCT01265160||the group of placebo|
89295755|NCT01161030|Experimental|almonds|1-oz raw almonds: 173 kcal, 4.6 g carbohydrate, 14.6 g fat
89295756|NCT01161030|Placebo Comparator|Control|cheese stick
89295757|NCT01163370|Placebo Comparator|control and exercise|this is trained and receives placebo
89295758|NCT01163370|Experimental|creatine|this is non-exercise trained and receives creatine supplementation
89295759|NCT01163370|Experimental|exercise and creatine|this is exercised trained and receives creatine supplementation
89295760|NCT01163370|Placebo Comparator|placebo|this only receives placebo (dextrose)
89295761|NCT01163448|Experimental|High-Dose Single-Fraction Image-Guided Radiotherapy|This will assess the feasibility and safety of this approach in men at high-risk for extraprostatic prostate cancer undergoing RP. This initial trial has been designed in a manner intended to emphasize patient comfort and safety.
89295762|NCT01163526||neuroendocrine metastases|15 patients with neuroendocrine metastases
89295763|NCT01163526||colon cancer metastases|15 patients with colon cancer metastases
89295764|NCT01163526||HCC treated with cyberknife radiation and chemotherapy|15 patients with HCC treated with cyberknife radiation and chemotherapy
89295765|NCT01163526||HCC treated with Sirsphere embolization and chemotherapy|15 patients with HCC treated with Sirsphere embolization and chemotherapy
89295766|NCT01159158|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
89295767|NCT01159158|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
89295768|NCT01161108|Active Comparator|Group A: Fast Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
89295769|NCT01161108|Active Comparator|Group B: Timed Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
89295770|NCT01161186|Experimental|Nab-paclitaxel,Gemcitabine, and Capecitabine|
89295771|NCT01159236|Experimental|Group 1: ER-Positive|"Participants with Estrogen Receptor (ER)-Positive breast cancers receive Standard T/FAC or T/FEC chemotherapy before surgery.~T/FAC or T/FEC: Combination chemotherapy with sequential paclitaxel (80 mg/m2) weekly x 12 weeks followed by 5-fluorouracil (500 mg/m2), cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2) or epirubicin (100 mg/m2) (FAC or FEC) once every 3 weeks for 4 treatments."
89295772|NCT01159236|Experimental|Group 2: ER-Negative|Participants with ER-negative cancers (randomized between Group 2 & Group 3), Standard T/FAC or T/FEC chemotherapy before surgery.
89295773|NCT01159236|Experimental|Group 3: ER-Negative + Bevacizumab|Participants with ER-negative cancers (randomized between Group 2 & Group 3), T/FEC chemotherapy combined with 10 mg Bevacizumab every 2 weeks during first 3 treatments before surgery.
89295774|NCT01267344|Active Comparator|GEMOX|Intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks.
89295775|NCT01267344|Experimental|E-GEMOX|Arm A will receive E-GEMOX with additional intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above.
89295776|NCT01159314|Experimental|Arm A - Baerveldt 250 mm2|Patients receiving Baerveldt 250 mm2
89295777|NCT01159314|Experimental|Arm B - Baerveldt 350 mm2|Patients receiving Baerveldt 350 mm2
89295778|NCT03877302|Experimental|reflexology group|In addition to providing routine nursing/midwifery care, foot reflexology was applied by the researcher to the pregnant women in the experimental group in the active phase of labor (dilatation 4 cm). By giving appropriate position to the pregnant women, the massage was done to both feet for totally 10 minutes including 5 minutes for each foot starting from right foot under the supervision of a doctor. Whereupon, the reflexology technique was applied by stimulating the nerve points by applying pressure to reflex regions of each foot for 20 minutes as totally 40 minutes for both feet. As reflex points of the feet for manual pressure in labor pain; 1: Solar Plexus, 2: Hypothalamus, 3: Pituitary, 4: Spleen, 5: Thyroid Gland, 6: Adrenal, 7: Intestine, 8: Spinal Cord 9: Uterus, Vagina, Ovaries and Fallopian Tubes were studied.
89295779|NCT03877302|No Intervention|Control Group|The control group received only routine treatment, care, and practices of the hospital. Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI FORM TX-I) were evaluated 2 times as in active (4-7 cm) and transition (8-10 cm) phases in the pregnant women in the control group. After the delivery, the Birth Satisfaction Scale was applied to the women by the researcher.
89295780|NCT03875976|Active Comparator|Fast Track Protocol|Patients treated using Fast Track Care Protocol
89295781|NCT03875976|Active Comparator|Standard Protocol|Patients treated using Standard Care Protocol
89295782|NCT04997226|Active Comparator|tDCS over the left DLPFC with adaptive memory game|"The stimulation will be carried out using a battery-powered mobile device made by Neurocon with two 5 x 5 cm electrodes The anodal electrode will be positioned above the F3 region of a standard EEG cap that is parallel to the cortical DLPFC region. The return electrode will be placed over the right eyebrow. The electrodes will remain on the subjects head for 50 minutes - the entire duration of the session. 1mA stimulation will be given for 15 minutes, then a 20-minute break and again 15 minutes of 1 mA stimulation. This protocol has been shown to improve the duration of the stimulus effect (Monte-Silva et al., 2013)."
89295783|NCT04997226|Placebo Comparator|Sham tDCS over the left DLPFC with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 50 minutes, similar to the active tDCS arm.
89295784|NCT04997226|Active Comparator|tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but stimulation method will be employed at 2mA intensity for 20 minutes at theta-gamma coupling using a laplacian montage (Alekseichuk et al., 2016).
89295785|NCT04997226|Placebo Comparator|Sham tACS over the left DLPFC at theta-gamma coupling with adaptive memory game|As above but current will be operated for 1 minute - 30 seconds ramp up to 1 mA and 30 seconds ramp-down to initiate similar sensations to real stimulation. The electrodes will stay on the subjects heads for 20 minutes, similar to the active tACS arm.
89295786|NCT03879564|Placebo Comparator|control|0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
89295787|NCT03879564|Experimental|ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
89295788|NCT01581840|Experimental|5Fu-mitomycine-panitumumab + radiotherapy|5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10
89295789|NCT01161264|Experimental|18-60 YOA|
89295790|NCT01161264|Experimental|≥ 60 YOA|
89295791|NCT03879486|Experimental|PVPI intervention|rectal cleansing and disinfection of the needle tip at transrectal ultrasound guided prostate biopsy
89295792|NCT03879486|No Intervention|Control arm|controls at transrectal ultrasound guided prostate biopsy
89295793|NCT01159392||Brain injury plus acute lung injury|Patients with severe brain injury (Glasgow coma score<13) with acute lung injury (PaO2/FiO2 <300 mmHg)
89295794|NCT01163838|Placebo Comparator|Placebo|
89295795|NCT01163838|Experimental|RN316: 1 mg/kg every 2 weeks|
89295796|NCT01163838|Experimental|RN316: 2 mg/kg every 4 weeks|
89295797|NCT01163838|Experimental|RN316: 4 mg/kg every 4 weeks|
89295798|NCT01163838|Experimental|RN316: 4 mg/kg every 8 weeks|
89295799|NCT01163838|Experimental|RN316: 8 mg/kg every 8 weeks|
89295800|NCT01163838|Experimental|RN316: 12 mg/kg every 8 weeks|
89295801|NCT01269294|Experimental|001|TMC435 2 capsules of 75 mg once daily for 7 days in Treatment A
89295802|NCT01269294|Other|002|Placebo for TMC435 2 placebo capsules once daily for 7 days in Treatment A
89295803|NCT01269294|Other|003|Placebo for moxifloxacin 1 placebo tablet on Day 7 of Treatments A B and D
89295804|NCT01269294|Experimental|004|TMC435 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
89295805|NCT01269294|Other|005|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment C
89295806|NCT01269294|Other|006|Moxifloxacin 1 tablet of 400 mg on Day 7 of Treatment C
89295807|NCT01269294|Placebo Comparator|007|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment D
89295808|NCT03876210|Other|Sequence A|"Period 1: PK101-001, PK101-002 / Period 2: PK101~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
89295809|NCT03876210|Other|Sequence B|"Period 1: PK101 / Period 2: PK101-001, P101-002~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
89295810|NCT03875898|Experimental|150 g bread fortified (15 g mix fibre)|Volunteers will have to consume daily 150 g of a bread instead of usual bread during eight weeks
89295811|NCT03875898|Placebo Comparator|150 g unfortified bread|Volunteers will have to consume daily 150 g of an unfortified usual bread during eight weeks
89295812|NCT01163994|Active Comparator|MEM-ceftriaxone|
89295813|NCT01163994|Active Comparator|MEM-doxycycline|
89295814|NCT01163994|No Intervention|controls|
89295815|NCT01163994|Active Comparator|EM-doxycycline|
89295816|NCT01267578|Experimental|peptide vaccination|
89295817|NCT03874728||Older people at risk of falls|Older people at risk of falls
88806198|NCT01392859|Experimental|Initial Treatment: Placebo|Group 2 will begin with placebo oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and active Levocetirizine(LCT) 0.5 mg/ml will be provided for 5-8 days.
88806199|NCT01457521|Active Comparator|Therapeutic|Ibuprofen
89295818|NCT01161576|Experimental|Group A|The first dose cohort consists of 6 subjects who received AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (gc) total dose. This is equal to 900,000,000,000 molecules of the drug.
89295819|NCT01161576|Experimental|Group B|The second dose cohort consists of 10 subjects, who will receive AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (gc) total dose. This is equal to 285,000,000,000 molecules of the drug.
89295820|NCT01267734|Experimental|EECSS + DDAT|Promus Element stent + double-dose clopidogrel anti-platelet therapy
89295821|NCT01267734|Active Comparator|ZECSS + DDAT|Endeavor Resolute stent + double-dose clopidogrel anti-platelet therapy
89295822|NCT01267734|Experimental|EECSS + TAT|Promus Element stent + triple anti-platelet therapy
89295823|NCT01267734|Active Comparator|ZECSS + TAT|Endeavor Resolute stent + triple anti-platele therapy
89295824|NCT01268748|Other|4 ports laparoscopic cholecystectomy|
89295825|NCT01268748|Other|One port transumb. laparoscopic surgery|
89295826|NCT01164072||HIGH NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with 7.2 mg nicotine cartridges (high nicotine group).
89295827|NCT01268826||dosage of the urinary osmolality|dosage of the urinary osmolality
89295828|NCT01164306|Experimental|LifeSkills training|
89295829|NCT01164306|Active Comparator|Healthy Lifestyle Behaviors|
89295830|NCT01269450|Active Comparator|Utrogestan|
89295831|NCT01269450|Placebo Comparator|placebo|
89295832|NCT01269528||Born in 2007-2008|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
89295833|NCT01269528||Born in 2009-2010|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
89295834|NCT03877146|No Intervention|Usual Care Control Condition|As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure. Music options will include instrumental jazz, classical piano, harp and flute, and world music.
89295835|NCT03877146|Experimental|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing. The other 50% of the intervention will be spent listening to music, which is part of usual care. Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
89295836|NCT01164930|Experimental|Acceptance and Commitment Therapy group|8-week ACT group
89295837|NCT01164930|No Intervention|Wait-list control group|Participants will be offered treatment following wait-list data collection
89295838|NCT01167036|Experimental|FascialEdge tool|A massage tool used to loosen adhesions in the superficial fascia
89295839|NCT01167036|Placebo Comparator|Placebo|Detuned electric point stimulation over the upper trapezius trigger point
89295840|NCT01268904||Pediatric status epilepticus|
89295841|NCT01269606|Experimental|Treatment sequence 1 - IM treatment group|
89295842|NCT01269606|Experimental|Treatment sequence 2 - IM treatment group|
89295843|NCT01269606|Experimental|Treatment sequence 1 - IV treatment group|
89295844|NCT01269606|Experimental|Treatment sequence 2 - IV treatment group|
89295845|NCT03875430||Perimenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
89295846|NCT03875430||Postmenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
89295847|NCT03875742|Other|"Ultraplex 360"|"This group will execute the first TAP block using Ultraplex 360 (Braun) and the second TAP block using  STIMUPLEX D SH, 30° (Braun)"
89295848|NCT03875742|Other|" STIMUPLEX D SH, 30°"|"This group will execute the first TAP block using  STIMUPLEX D SH, 30° (Braun) and the second TAP block using Ultraplex 360 (Braun)"
89295849|NCT01268982|Experimental|preserved socket|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket.
89295850|NCT03875352|Experimental|Neutropenia patients|Patients with neutropenia were treated using the CHG and HMG technique.
89295851|NCT03875352|Experimental|No neutropenia patients|Patients with no neutropenia were treated using the CHG and HMG technique.
89295852|NCT03872232|Experimental|Ezetimibe/Rosuvastatin and Telmisartan|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin and Telmisartan for 8 weeks."
89295853|NCT03872232|Active Comparator|Ezetimibe/Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin for 8 weeks."
89295854|NCT03872232|Active Comparator|Telmisartan|"60 subjects will be assigned and the subjects will be administered Telmisartan for 8 weeks."
89295855|NCT03872076|Experimental|Plyometric exercises|The subjects included in the experimental group will carry out an intervention using plyometric exercises and isometric exercises with elastic band for the quadriceps muscle. Each session will last 15 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
89295856|NCT03872076|Active Comparator|Isometric exercises|The subjects included in the experimental group will carry out an intervention of isometric exercises with elastic bands for the quadriceps muscle. Each session will last 8 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
89295857|NCT01280214|Experimental|Triamcinolone|
89295858|NCT03871842|Active Comparator|active tDCS|20-minute of daily anodal stimulation (2mA) above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
89295859|NCT03871842|Sham Comparator|sham tDCS|20-minute of daily sham stimulation above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
88806200|NCT01457521|Active Comparator|Prophylactic|Ibuprofen
89295860|NCT01164462|Other|A 2|During the normal opening hours of five testing centers, clients with a rapid finger-stick blood specimen test
89295861|NCT01164462|Other|B group|During evenings and week-ends (i.e. when the centers are closed) only community based with rapid HIV testing
89295862|NCT01164462|Other|A1 group|During the normal opening hours of five testing centers, clients with a conventional test.
89295863|NCT01164540|Experimental|1|Oral Treatment
89295864|NCT01164540|Placebo Comparator|2|Oral treatment
89295865|NCT01269684|Experimental|1|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
89295866|NCT01164618|Experimental|Group 1|The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
89295867|NCT01164618|Experimental|Group 2|The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
89295868|NCT01280370||1|1.patients treated in a laparoscopic manner
89295869|NCT01280370||2.|2. patients treated in open operative manner
89295870|NCT01280448||Case Group|
89295871|NCT01280448||Control Group|
89295872|NCT03875196|Experimental|Biyofeedback|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes
89295873|NCT03875196|Experimental|Extracorporeal Magnetic Innervation|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes and the Extracorporeal Magnetic Innervation application was made for 20 minutes
89295874|NCT01165164|Experimental|FID 115958D|Lubricant eye drop
89295875|NCT01280526|Experimental|Romidepsin dose 10mg/m²|Romidepsin dose 10mg/m²
89295876|NCT01280526|Experimental|Romidepsin dose 12mg/m²|Romidepsin dose 12mg/m²
89295877|NCT01280526|Experimental|Romidepsin dose 14mg/m²|Romidepsin dose 14mg/m²
89295878|NCT01280526|Experimental|Romidepsin dose 8mg/m²|Romidepsin dose 8mg/m²
89295879|NCT01164696||Group 1|
89295880|NCT03874650|Experimental|Activity Planning Group|"Those in the Activity Planning group receive training and practice in identifying realistic and safe activities in everyday life that may be enjoyable or rewarding to complete. They gain practice in scheduling activities and identifying and overcoming barriers to completion, such as memory problems, avoidance, sticking to habitual patterns and physical and transport issues.~The intervention will consist of weekly 1 hour group sessions over 8 weeks, as below:~Introduction to Group Therapy Identifying Enjoyable Activities The Automatic Pilot and Planning Pleasurable Activities Goal Review and Balancing Enjoyable and Routine Activities Identifying Solutions to Goal Attainment Increasing Mastery and Managing Fatigue Active Approaches to Engagement Relapse Prevention"
89295881|NCT03874650|Experimental|Activity Engagement Group|"Individuals randomised to this arm will meet weekly for 8 weeks for 1 hour and engage in various potentially rewarding and meaningful social activities such as board games, crafting, and puzzles. Participants in this group will not receive specific training on activity scheduling or overcoming barriers to activity participation. Rather the aim is that participants gain experience of positive reinforcement from the activities and that this explicitly or implicitly challenges potentially negative predictions about such situations and encourages generalised increases in positive activity beyond the group setting. The group will cover activities such as board games, t-shirt making, puzzles, painting, pub quizzes, figurine painting, origami/paper-craft, and clay sculptures."
89295882|NCT03874650|Placebo Comparator|Waitlist Group|In consenting to the study, individuals understand that access to groups cannot always be immediate. In the design we take advantage of this by completing the outcome measures before and after an 8-week period in participants randomized to this condition. We do not ask participants in any condition to discontinue any clinical services that they currently receive, hence the waitlist forms a treatment as usual control arm against which to judge and effects of the two groups. At the end of the waitlist the participants will be invited to take part in the Activity Planning or Activity Engagement Group depending upon their initial randomisation..
89295883|NCT01269060|Experimental|Single incision sigmoidectomy|Single incision laparoscopic sigmoidectomy for sigmoid colon cancer
89295884|NCT03874962|Experimental|Routine oral cleaning and professional oral care group|"The subjects in Routine oral cleaning and professional oral care group were received about routine oral cleaning and professional oral care."
89295885|NCT03874962|No Intervention|Routine oral cleaning group|"The subjects in Routine oral cleaning group were received only routine oral cleaning, just maintain daily condition."
89295886|NCT01164774|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
89295887|NCT01164774|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
89295888|NCT01269138||Factor VII Deficient Patients|Patients affected by Inherited Factor VII deficiency undergoing treatment for bleeding episodes, surgery , prophylaxis.Any patient with levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by his/her treating physician can be enrolled.
89295889|NCT03871920||intervention|any kind of condition treated by physiotherapists, physical therapy treatment is chosen by treating physiotherapist
89295890|NCT03874572|Experimental|Allogeneic mesenchymal stem/stromal cell therapy|Treatment with intra-glandular Injections of allogeneic adipose derived stem cells
89295891|NCT02526810|Active Comparator|GROUP A|using continuous subcutaneous insulin injection with insulin lispro, Humalog, initiating with 0.5-0.8 IU/kg.
89295892|NCT02526810|Experimental|GROUP B|using glargine combined with oral drugs: insulin glargine, Lantus( initiating with 0.2 IU/kg) with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets, Diamicron modified release(MR) tablets 60mg qd.
89295893|NCT01269762|Experimental|LipoCol Forte|Subject will receive single dose of one, two and four 600 milligram (mg) red yeast rice capsules (LipoCol Forte)and multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days.
89295894|NCT01280760||Non invasive ventilation|Non-invasive ventilation after invasive mechanical ventilation weaning
89295895|NCT01165398||Residents, PAs, mid level providers|Lehigh Valley Health Network residents, physician assistants, and mid level providers who place central lines and attend the central lines simulation course
89295896|NCT01280838|Experimental|Theory-based behavioral intervention|Participants in this arm will receive a single-session, theory-based intervention (Hombre Seguro) at baseline that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and Motivational Interviewing (MI) to increase clients' use of condoms with FSWs. The intervention lasts approximately 45 minutes.
89295897|NCT01280838|Active Comparator|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
89295898|NCT01164852|No Intervention|Expectant management|Expectant management: refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.
89295899|NCT01164852|Active Comparator|Interventionist management|Interventionist management: in which blood pressure is stabilized, corticosteroids are given for acceleration of fetal maturity and delivery is planned within 48-72 hours.
89295900|NCT01269216|Active Comparator|5-FU with leucovorin|
89295901|NCT01269216|Active Comparator|TS-1 with Irinotecan|
89295902|NCT03874806|Experimental|single|local anesthetic is delivered as a single bolus
89295903|NCT03874806|Active Comparator|continuous|local anesthetic is delivered as a continuous infusion
89295904|NCT01280916|Experimental|Mind-body intervention|Mindful Awareness in Body-oriented Therapy
89295905|NCT01280916|No Intervention|Treatment as Usual|
89295906|NCT01165476|Active Comparator|manufacturer #1|treprostinil diethanolamine from manufacturer #1
89295907|NCT01165476|Experimental|manufacturer #2|treprostinil diethanolamine from manufacturer #2
89295908|NCT03871686|Experimental|Experimental Group|Participants will be asked to complete a brief online program over a 4 to 8-week period. Each week participants will be asked to complete one session of the program online. There are four sessions.
89295909|NCT03871686|No Intervention|Control Group|Participants will receive no intervention from the investigators. Participants may continue services as usual as provided by Children's Brain Tumor Foundation.
89295910|NCT01283100|Experimental|Treatment A|GSK1349572 50mg q24h x 7 days
89295911|NCT01283100|Experimental|Treatment B|GSK2248761 200mg q24h x 7 days
89295912|NCT01283100|Experimental|Treatment C|GSK1349572 50mg q24h x 7 days + GSK2248761 200mg q24h x 7 days
89295913|NCT01269996|Active Comparator|Metformin followed by gliclazide and protaphane|
89295914|NCT01269996|Active Comparator|Janumet followed by Lantus insulin injection|
89295915|NCT01283178|Experimental|Arm I|Patients undergo intensity-modulated image-guided adaptive radiotherapy once daily 5 days a week for 6 weeks. Patients also receive cisplatin IV on days 1 and 22. Treatment continues in the absence of disease progression or unacceptable toxicity.
89295916|NCT03869346||GG|wild-type homozygote (CYP3A4*1/*1, GG)
89295917|NCT03869346||GA|mutant heterozygote (CYP3A4*1/*1G, GA),
89295918|NCT03869346||AA|mutant homozygote (CYP3A4*1G/*1G, AA)
89295919|NCT01281150|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"DOSE-ESCALATION: Patients receive veliparib PO twice daily BID on days 1-5, 8-12, and 15-19 and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes in course 1 and 3 hours in subsequent courses on days 3, 10, and 17. After 4 courses, patients receive paclitaxel and carboplatin on days 3 and 10 only. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (Completed as of 12/2012)~EXPANSION COHORT: Patients receive veliparib PO BID on days 1-21 and paclitaxel IV over 1 hour and carboplatin IV over 3 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89295920|NCT03871218|Active Comparator|Test Group|Hyaluronic acid application group. After FGG was taken from the donor region in the TG, sterile gauze was applied with moderate pressure for 2 minutes, and HA was applied topically after the bleeding stopped. The cross-linked HA package containing 20 mg/ml Na-hyaluronate, stored at room temperature, was opened, and the protective cap of the syringe was removed.
89295921|NCT03871218|No Intervention|Control Group|In the control group (CG), HA was not applied to the recipient or the donor site.
89295922|NCT01281228|Experimental|exenatide|Infusion of exenatide; loading dose 50 ng/min during 30 min, followed by a maintenance dose 20ng/min for the rest of the tests.
89295923|NCT01281228|Experimental|exenatide + exendin (9-39)|exenatide infusion: loading dose 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the test. And infusion of exendin(9-39) 600pM/kg/min.
89295924|NCT01281228|Placebo Comparator|saline|saline infusion, with the same infusion speed
89295925|NCT01283256||Experimental|
89295926|NCT01270776|Experimental|Aqueous Chlorhexidine|The group received skin antisepsis using 2% aqueous chlorhexidine solution.
89295927|NCT01270776|Active Comparator|2% Chlorhexidine 70% isopropyl alcohol|The group will receive skin antisepsis with 2% chlorhexidine solution in alcohol.
89295928|NCT03874260|Experimental|statin / fenofibrate|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg)+ choline fenofibrate 178.8mg / once a day, P.O
89295929|NCT03874260|Placebo Comparator|statin / fenofibrate placebo|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
89295930|NCT03869424|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from rumination. They take the nasal spray once in the laboratory.
89295931|NCT03869424|No Intervention|No-treatment control group|Participants do not receive the nasal spray.
88806201|NCT00325442|Active Comparator|Active|Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.
89295932|NCT01281384|Active Comparator|Standard imaging (echocardiography)|Subjects will undergo their clinically indicated echocardiogram as ordered by their attending physician.
88806202|NCT00325442|Placebo Comparator|Placebo Arm|Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.
89295933|NCT01281384|Active Comparator|Advanced Imaging (Cardiac MRI)|Subjects will undergo their clinically indicated echo as ordered by their attending physician, plus a cardiac MRI, which will be scheduled within 14 days of the echo.
89295934|NCT01281540|Experimental|001|Cisapride one 10 mg tablet 4 times a day for 8 weeks
89295935|NCT01281540|Placebo Comparator|002|Placebo one placebo tablet 4 times a day for 8 weeks
89295936|NCT01283412|Active Comparator|Arm P|Placebo infusion
89295937|NCT01283412|Experimental|Arm D|Dexmedetomidine infusion
89295938|NCT01271478|Experimental|Telmisartan plus Captopril|captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)
89295939|NCT01271478|Experimental|Telmisartan plus Placebo|telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day
89295940|NCT01271478|Experimental|Captopril plus Placebo|patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
89295941|NCT01271478|Placebo Comparator|Placebo|2 tablets of placebo orally twice a day
89295942|NCT03871452|Active Comparator|ABS in external bleeding|Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
89295943|NCT03871452|Active Comparator|Repetition of ABS stopped bleeding|Repetition of ABS stopped bleeding
89295944|NCT01586832||ED Nurses|"Nurses in the emergency department (ED) providing patient care using supplies found in the stocking towers"
89295945|NCT01281618||Those with barrett's esophagus|Those with barrett's esophagus: no dysplasia or low grade dysplasia
89295946|NCT03871062|Active Comparator|topical anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
89295947|NCT03871062|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
89295948|NCT01281696|Experimental|Bevacizumab, etoposide, cisplatin (BEEP)|
89295949|NCT05835934|Experimental|Arms|2 μg/0.212 μCi/kg [14C]HSK21542
89295950|NCT05835817|Experimental|Adults|
89295951|NCT05835817|Experimental|full term neonates|
89295952|NCT05835817|Experimental|premature neonates|
89295953|NCT05835817|Experimental|pregnant women|
89295954|NCT05835739||Cohort A (Retrospective)|all consecutive women with a germline deleterious mutation in BRCA1-2 admitted to the participant Center since 1st of January 2010 until site activation will be enrolled
89295955|NCT05835739||Cohort B (Prospective):|all consecutive women with a germline deleterious mutation in BRCA1-2 admitted to the participant Center since site activation until September 2025 will be enrolled
89295956|NCT05835713|Experimental|Remimazolam besylate|Remimazolam group receive total intravenous anesthesia using remimazolam besylate and remifentanil during rigid bronchoscopy. Remimazolam group receive flumazenil during the emergence from anesthesia.
89295957|NCT05835713|Active Comparator|Propofol|Propofol group receive total intravenous anesthesia using propofol and remifentanil during rigid bronchoscopy.
89295958|NCT05835700|Other|Gasdermin-D levels in preterm labor (study group)|Maternal serum Gasdermin-D levels of pregnant women who were diagnosed with idiopathic preterm labor
89295959|NCT05835700|Other|Gasdermin-D levels in healthy pregnant women (control group)|Maternal serum Gasdermin-D levels of healthy pregnant women
89295960|NCT05835674||Cohort I|500 participants screened by history and interview with parents to assess if they are to proceed to cohort II. This will be assessed by steering committee.
89295961|NCT05835674||Cohort II|"Participants (n=300) who meet the inclusion criteria from Cohort I, is assessed at enrollment visit and will proceed to cohort III if they meet any two of the following criteria:~Neuroimaging predictive of a motor disability~GMA test with absent fidgety GMs at fidgety age~HINE scores <57 at 3months or <60 at 6months or <63 at 9 months or < 66 at 12 months~Infants will also be included if they meet both of the following criteria:~Unilateral brain injury on neuroimaging predictive of CP~Clinical signs of asymmetry~Studies/objectives related to Cohort II~Evaluation of MRI~GMA implementation - To assess the feasibility of GMA in a multi-center Danish hospital setting.~Prediction of CP - To determine the clinical utility of the MRI, HINE, HAI, and GMA to predict a confirmed diagnosis of CP at 24 months~GMA/HINE/MRI vs. HAI - To compare diagnostic accuracy of HAI and GMA/HINE/MRI."
89295962|NCT05835674||Cohort III|"Participants (n=160) will be included in cohort III if infants are considered CP or at high risk of CP Participants are followed at enrolment, and ages six, 12, 18 and 24 months. Blood sample for trio-whole genome sequencing is offered to participants with definite or high risk of CP.~Studies/objectives related to Cohort III~e) Evaluation of genetics f) GO-PLAY. To analyse the effect of the GO-PLAY intervention with early family-centred set-up for children with definite or high risk of CP.~g) Parents perspective on intervention. To explore parents' perspectives on barriers and facilitators involved in early intervention.~h) Parents perspectives of early diagnosis - To analyse interviews of parents' perspectives of gains and concerns when having an early diagnosis of high risk of CP."
89295963|NCT05835661||Observation on the application of nasopharyngeal airway|Patients eligible for inclusion were selected, and after fully explaining the advantages and disadvantages of the two ways of nasopharyngeal airway, the patients were allowed to choose to be enrolled by themselves, and then subsequent observation was started
89295964|NCT05835648|Experimental|Dietary fiber intervention group|On the basis of daily diet, dietary fiber supplement (Nutrasumma) was given once a day, 1 strip each time, before meals, and the intervention lasted for 3 months.
89295965|NCT05835622|Other|Arm A|8 weeks of using keeogo at home (experimental phase) followed by 8 weeks of wash-up and then followed by 8 weeks of recommended home practise (control phase).
89295966|NCT05835622|Other|Arm B|8 weeks of recommended home practise (control phase) followed by 8 weeks of wash-up and then followed by 8 weeks of using keeogo at home (experimental phase)
89295967|NCT05835609|Experimental|PM534|Patients will be included in cohorts of a minimum of three or six patients to receive PM534 at successively increasing dose levels.
88806203|NCT01791530||MV>48h|10-20 consecutive admissions with a predictive duration of intubation and mechanical ventilation > 48h.
88806204|NCT01393717|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses. Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving CR after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
88806205|NCT01459705|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
89295968|NCT05835596|Active Comparator|Access to MumCare app|Women will be randomized prospectively (before or after delivery) after they consent to participate in the study. These women are at increased risk of longterm cardiovascular disease due to hypertensive or gestational diabetes pregnancy complication. This group is randomized to have access to the MumCare app will, in addition to standard care, have access to the app for 18 months following giving birth. The MumCare app has 3 main parts (1. an educational part, 2. The patient's own health data (entered by the user herself) that represent modifiable risk factors for cardiovascular disease), and 3. The app will send push reminders for the woman to book a visit at her general practitioner according to recommended guidelines (that are usually not followed-up today).
89295969|NCT05835596|No Intervention|No access to MumCare app|Women will be prosepctively randomized (before or after delivery) after they consent to participate in the study. These women are at increased risk of longterm cardiovascular disease due to hypertensive or gestational diabetes pregnancy complication. Women randomized to NOT have access to the MumCare app will receive standard care, which includes being provided oral and written information according to delivery ward routines.
89295970|NCT05835583|Experimental|experimental|Members of the experimental group received routine home visits( by psychiatric mental nurses, and the nurse provided patients with answers to questions about medications or care and handling of life events), and plus a 1-hour theory based integrated program intervention for 12 times in the 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 15th, 17th, 19th, 21st, and 23rd weeks, and each patient received a total of 12 hours of intervention.
89295971|NCT05835583|No Intervention|control|The control group received routine home visits by psychiatric mental nurses, and the nurse provided patients with answers to questions about medications or care and handling of life events. The visits and intervention time frequency were the same as those in the experimental group.
89295972|NCT05835557|Experimental|Blood flow restriction with short interval training (BFR-ST)|9 sessions of high intensity short interval training with blood flow restriction.
89295973|NCT05835557|Sham Comparator|Sham altitude with short interval training (ST)|9 sessions of high intensity short interval training in an altitude chamber.
89295976|NCT05835401|Experimental|Experimental (Beetroot juice NO3)|Acute ingestion of beetroot juice rich in NO3 (800mg).
89295977|NCT05835401|Placebo Comparator|Placebo (Beetroot juice without NO3)|Acute ingestion of beetroot juice rich depleted in NO3.
89295978|NCT05835388||Primary Study|Community dwelling adults from the South Texas area who are interested in volunteering for research studies on aging. This will facilitate the inclusion of older adults and minority in research studies and help to increase the quantity and quality of research relating to them.
89295979|NCT05835388||KAPP Sen Tissue Mapping Study|The substudy KAPP Sen TMC will enroll eligible STARR participants to undergo repeat assessments over two years. KAPP Sen TMC is a collaborative effort between UT Health San Antonio, Jackson Laboratory for Genomic Medicine (JAX-GM), Brigham and Women's Hospital, Joslin Diabetes Center, UConn Health Center on Aging and Mayo Clinic to characterize cellular senescence in terms of its presence and heterogeneity in healthy human tissues, as well as its tissue burden, spatial distribution, and biological features in a diverse study population.
89295980|NCT05835362|Experimental|Question prompt list only group|"In the question prompt list group youth will be handed the youth ADHD prompt list, and the parent will be handed the parent ADHD prompt list, and will be told, Your provider wants you to ask any questions that you have about ADHD. Here are lists of questions that you may want to ask. Please spend some time reading through this and marking any questions you want to ask your provider during the visit. You can also write other questions you want to ask on the bottom."
89295981|NCT05835362|Experimental|Pre-visit video only group|Parents and youth in the pre-visit video only group will watch together a short educational video with six themes on an iPad encouraging families to ask questions and to be engaged during ADHD visits.
89295982|NCT05835362|Experimental|Combined question prompt list/video intervention group|"In the combined pre-visit video/question prompt list group youth will watch the video with the parent. Then, youth will be handed the youth ADHD prompt list, and the parent will be handed the parent ADHD prompt list, and will be told, Your provider wants you to ask any questions that you have about ADHD. Here are lists of questions that you may want to ask. Please spend some time reading through this and marking any questions you want to ask your provider during the visit. You can also write other questions you want to ask on the bottom."
89295983|NCT05835362|No Intervention|Control group|The control group will receive usual care.
89295984|NCT05835336|Experimental|Active|VIZO Glasses- personalized
89295985|NCT05835310|Experimental|Anifrolumab|Randomized participants will receive a single dose of Anifrolumab via IV infusion every 4 weeks
89295986|NCT05835310|Placebo Comparator|Placebo|Randomized participants will receive matching placebo via IV infusion
89531577|NCT06019624|Active Comparator|Cohort 3 Receipt of Food Box|Up to 80 individuals with diabetes or prediabetes with a history of food insecurity enrolled in a 6 month program offering free bimonthly fresh food boxes, nutrition education, and individualized support. Each enrolled individual will serve as their own control. The study will evaluate pre and post program changes in reported self-obtained home glucose levels, food security, and dietary intake.
89295987|NCT05835167|Experimental|Inferior part-sternotomy CABG|A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward. Left internal mammary artery (LIMA)-left anterior descending branch bypass is the first choice for all patients. Remaining coronary bypassing techniques are according to clinical practice and preference of the operator. If it is difficult to perform CABG via inferior part-sternotomy, the treatment strategy convert to full median sternotomy, which is deemed to be failed to achieve complete revascularization via inferior part-sternotomy.
89295988|NCT05835167|Active Comparator|Full median sternotomy CABG|A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw. Remaining coronary bypassing techniques are same in both groups according to clinical practice and preference of the operator.
89295989|NCT05835115||The training dataset|The training dataset was comprised of data from a school-based, prospective cohort (the Shanghai Time Outside to Reduce Myopia [STORM] trial) and data from another population-based, prospective study, the High Myopia Registration Study (SCALE-HM), with annual follow-up. Participants of the two studies were divided into a training set (70%), a tuning set (10%), and an internal test set (20%), which were not duplicated by each other at the participant level.
89295990|NCT05835115||The internal validation dataset|The internal validation dataset was comprised of data from a school-based, prospective cohort (the Shanghai Time Outside to Reduce Myopia [STORM] trial) and data from another population-based, prospective study, the High Myopia Registration Study (SCALE-HM), with annual follow-up. Participants of the two studies were divided into a training set (70%), a tuning set (10%), and an internal test set (20%), which were not duplicated by each other at the participant level.
89295991|NCT05835115||The external validation dataset|To test the extrapolation capabilities of the deep learning sysyem, two independent datasets, the Joint Five-site Fundus Test (JFFT) and the Hong Kong Children Eye Study (HKCES), were applied as external test sets. The JFFT study, a multi-site dataset, contains cross-sectional data from Shanghai, Yunnan, Inner Mongolia, Xinjiang and Guangzhou. HKCES, a population-based cohort study of eye conditions in children aged 6-8 years.
89295992|NCT05835102||Patients With SARS-CoV-2 Infection|Patients who test positive for SARS-CoV-2 nucleic acid or SARS-CoV-2 antigen
89295993|NCT05835089||children and adolescents with chronic kidney diseases|The serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels will be measured for all the study participants.
89295994|NCT05835089||control group of patients|The serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels will be measured for all the study participants.
89295995|NCT05834985|Active Comparator|group (1) endoscopic group|"For patients in EG, we began with assessment of the site & size of fistula . In this study, OTSC was used in 9 patients .We started deploying the clips perpendicular to the long axis of the defect. If needed, more than one clip was sequentially deployed, starting at edge of the defect towards the center. Standard clips were passed through-the-scope to achieve superficial tissue apposition engaging the mucosa and submucosa (with 1.2-mm-wide and 6-mm-long arms capable of an approximately 12-mm grasp) and were used in conjunction with thermal ablation or mechanical scraping of the tissue around the edges of the defect to achieve a more resilient seal.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
89295996|NCT05834985|No Intervention|group (2) surgical group|sigmoid resection after proper colonic preparation with primary anstomosis with circular stapler either open or laparoscopically
89295997|NCT05834933|No Intervention|Standard care (SC)|Participants received one-on-one breast cancer awareness education; one-on-one monthly Breast Self-Examination (BSE) training; general breast cancer screening recommendations; and general lifestyle modification recommendations
89295998|NCT05834933|Experimental|SC + Risk assessment and counselling|Participants received Standard care as described in the SC arm above in addition to individualized breast cancer risk assessment, individualized breast cancer risk counseling, and lifestyle risk reduction recommendations
89295999|NCT05834868|Experimental|THDB0206 Injection|
89296000|NCT05834868|Active Comparator|Insulin Lispro Injection|
89296001|NCT05834855|No Intervention|Ocrelizumab|The standard group will receive ocrelizumab (600 mg, the first dosage given in two infusion of 300 mg with a two week interval) following the current treatment protocol
89296002|NCT05834855|Experimental|Rituximab|The experimental group will receive rituximab (1000 mg). Rituximab will be given intravenously. To ensure blinding of treatment allocation two dosages of 500 mg with a two week interval will be given instead of one initial dosage of 1000 mg of rituximab to mimic the ocrelizumab protocol
89296003|NCT05834764|Experimental|Pyrotinib|pyrotinib 400mg orally daily for one year
89296004|NCT05834751|Experimental|experimental group|PEG-rhG-CSF
89296005|NCT05834751|Active Comparator|control group|rhG-CSF
89296006|NCT05834712|Experimental|Mobile Platform Intervention Group|The mobile platform is used to evaluate the nutrition of patients 2 weeks after the first course of induction chemotherapy, before radiotherapy, during radiotherapy, after radiotherapy, and 1 month after radiotherapy. The doctor pushes individualized nutrition education, oral advice, medication advice, etc. .
89296007|NCT05834712|Active Comparator|Non-mobile Platform Intervention Group|Nutritional assessment of patients was performed at 2 weeks after 1 course of induction chemotherapy, before radiotherapy, during radiotherapy, at the end of radiotherapy, and at 1 month after the end of radiotherapy.
89296008|NCT05834647|Experimental|Group P|Drug: prilocaine 2% Dosage : 50 mg prilocaine 2% (2.5 mL volume)
89296009|NCT05834647|Active Comparator|Group L|Drug: hyperbaric lidocaine 5% Dosage : 50 mg hyperbaric lidocaine 5% (1 mL volume)
89296010|NCT05834634||Group 1|Patients with parkinsonism
89296011|NCT05834634||Group 2|Healthy age and sex matched controls
89296012|NCT05834582|Experimental|Cohort1: Epirubicin+Cyclophosphamide|2 cycles of EC (Epirubicin+Cyclophosphamide) induced chemotherapy, if tumor response is CR or PR: Epirubicin+Cyclophosphamide for 2 cycles Fluzoparib+Paclitaxel for 2 cycles
89296013|NCT05834582|Experimental|Cohort2: Fluzoparib+Paclitaxel|2 cycles of EC (Epirubicin+Cyclophosphamide) induced chemotherapy, if tumor response is SD: Fluzoparib+Paclitaxel for 4 cycles
89296014|NCT05834556|Experimental|Prehabilitation group|Participants will engage in 4 virtual sessions with a physiotherapist, over a 3 week period. They will be prescribed an individual exercise program (based on assessment). Participants will complete the program 3x/week independently and diarize the exercise on provided documents. For participants living within Winnipeg, they will also diarize their accelerometer use/sleeping times during wear.
89296015|NCT05834543|Experimental|TQB2618 injection +Penpulimab injection+Chemotherapy|Experimental group in Cohort 1. TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin, 21 days as a treatment cycle. After 4~6 cycles, TQB2618 injection combined Penpulimab injection, 21 days as a treatment cycle.
89296016|NCT05834543|Active Comparator|Penpulimab injection+Chemotherapy|"Active comparator group in Cohort 1. Penpulimab injection, Paclitaxel, Cisplatin, 21 days as a treatment cycle.~After 4~6 cycles, Penpulimab injection 21 days as a treatment cycle."
89296017|NCT05834543|Experimental|TQB2618 injection +Penpulimab +TQB3617capsules|"Cohort 2. TQB2618 injection, Penpulimab injection, 21 days as a treatment cycle.~TQB3617 capsules are administered on Day 1 and Day 14, 21 days as a treatment cycle."
89296018|NCT05834530|No Intervention|Conventional Complete Denture|
89296019|NCT05834530|Experimental|3 D printed Complete Denture|
89296020|NCT05834517|Experimental|hyaluronic acid/ scaling|topical application of hyaluronic acid after scaling by 1 day
89296021|NCT05834517|Experimental|scaling|scaling only
89296022|NCT05834504|No Intervention|Control group|"The control group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 6-8 days of break in between training sessions until proficiency level is achieved."
89296023|NCT05834504|Experimental|Intervention Group|"The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved."
89296024|NCT05834452|Active Comparator|the Epley Maneuver|Treatment of BPPV with the Epley Maneuver in the TRV chair. No kinetic energy will be used.
89296025|NCT05834452|Active Comparator|the 360 Maneuver|Treatment of BPPV with the 360 Maneuver in the TRV chair.
89296026|NCT05834413|Experimental|chemotherapy plus TCM 1&ICIs plusTCM2 placebo|"Phase1： Chemotherapy：Proposed platinum-containing two-drug adjuvant chemotherapy, vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin within 8 weeks after surgery, according to CSCO guidelines (2022).~TCM1 granules：oral granules, HeWeiYangXueFang , twice a day, every 21 days for 4 cycles.~Phase 2： One of the following agents may be selected after chemotherapy ：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab.A total of 12 cycles will be performed or the patient will discontinue the drug due to intolerable toxic side effects.~TCM2 granules：oral granules, FeiPingFang , twice a day, every 21 days for 12 cycles."
89296027|NCT05834413|Placebo Comparator|chemotherapy plus TCM 1 placebo&ICIs plus TCM2 placebo|"Phase1： Chemotherapy：Proposed platinum-containing two-drug adjuvant chemotherapy, vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin within 8 weeks after surgery, according to CSCO guidelines (2022).~Placebo1 granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect , twice a day, every 21 days for 4 cycles.~Phase 2：One of the following agents may be selected after chemotherapy：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab.A total of 12 cycles will be performed or the patient will discontinue the drug due to intolerable toxic side effects.~Placebo2 granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, twice a day, every 21 days for 12 cycles."
89296028|NCT05834374|Experimental|Contextual variation|The contextual variation group alternate between six affordance conditions where the surface of the model i either half covered combined with no guide, a partial guide or a complete guide.
89296029|NCT05834374|Experimental|Maximum affordances|The maximum affordances group has half the surface model covered and a complete guide throughout the session.
89296030|NCT05834374|No Intervention|Minimum affordances|The control group has the whole surface uncovered and no guide throughout the session.
89296031|NCT05834361|Experimental|early administration of carboprost methylate|Shortening the vaginal administration time of carboprost methylate, approximately 20 minutes before the surgery. Carboprost methylate was given when patients enter the operation room area.
89296032|NCT05834361|Active Comparator|delayed administration of carboprost methylate|Delay the vaginal administration time of carboprost methylate, approximately 2 hours before the surgery. Carboprost methylate was given when patients were in the ward.
89296033|NCT05834283|Experimental|aerobic exercises|"This group will be received aerobic exercises 3 sessions per week for 8 weeks. Warm up phase: in which each participant will walk at 80 m/min at 0.0% grade for 5 mint.~Active phase: treadmill speed will be increased to 147 m/min and grade will be increased gradually untill reached 25% grade for 20 mint.~Cool down phase: in which the treadmil speed and grade will be decreased to 2.0miles/h and 0.0% grade during a cool down period consisted of 5 mint."
89296034|NCT05834283|Experimental|core stability exercises|"This group will be received core stability exercises 3 sessions per week for 8 weeks.~All participants in both groups will be evaluated before and after the treatment programs.~Lie on your back and place your feet on a wall so that your knees and hips are bent at 90 degrees angles. Tighten your abdominal muscles.~Raise your head and shoulders off the floor. Return to the start position and repeat."
89296035|NCT05834270|Active Comparator|Single dose tamsulosin 0.4mg|Single dose tamsulosin 0.4mg
89296036|NCT05834270|Active Comparator|Double dose tamsulosin 0.4mg|Double dose tamsulosin 0.4mg
89296037|NCT05834231|Active Comparator|Intervention|
89296038|NCT05834231|Placebo Comparator|Control|
89296039|NCT05834192|Experimental|Backward treadmill walking group|
89296040|NCT05834192|Active Comparator|Lower extremity cross training|
89296041|NCT05834179|Experimental|cold endotracheal tube (ETT)|Patients who were intubated with an ETT which kept in the fridge.
89296042|NCT05834179|No Intervention|Endotracheal tube (ETT) in the normal temperature|Patients who were intubated with an ETT which kept in the operation room.
89296043|NCT05834140|Active Comparator|Traditional physical therapy|TENS and Heating pads
89296044|NCT05834140|Experimental|Muscle Energy Technique|Muscle Energy Technique protocol in along with TENS and Heating pads
89296045|NCT05834101|Experimental|Myofacial Release|Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs
89296046|NCT05834101|Experimental|Dynamic Stretching|The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
89296047|NCT05833243|Experimental|Interventional Group|"Baseline measurement will be done in the rehabilitation center. Participants will receive modified diaphragmatic training using modified diaphragmatic training with increased load every week for strength training (60% from inspiratory muscle strength).~Weekly follow-up will be taken to reassure the respiratory muscle strength. Prescription for intervention will be determined based on the result of baseline measurement.~After 4 weeks post-intervention measurement will be taken."
89296048|NCT05833243|Active Comparator|Control Group|"Baseline measurement will be done in the rehabilitation center. Participants will receive standard diaphragmatic training using a sitting position.~Weekly follow-ups will be taken to remeasure the respiratory muscle strength and training procedure.~After 4 weeks post-intervention measurements will be taken."
89296049|NCT05833191|Experimental|Auricular vagus stimulation|Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid.
89296050|NCT05833191|Experimental|Tibial Nerve Stimulation|Transcutaneous tibial nerve stimulation (TTNS) is reported to be beneficial for fecal and urinary incontinence. A review of the literature showed that there are very few studies using TTNS that have been shown to be effective for constipation.
89296051|NCT05831306|Experimental|Diet A|Modified Diet A
89296052|NCT05831306|Experimental|Diet B|Modified Diet B
89296053|NCT05830890|Experimental|Sentinel Lymph Node Biopsy|The fluorescence laparoscope was used to visualize and locate the sentinel lymph node, which was then removed.
89296054|NCT05830162|Placebo Comparator|Placebo|"The Pharmacy of the main capital region provides the bioclavid (amoxicillin with Clavulanic acid) and placebo tablets for this study. They are responsible for the randomization and packing of the tablets. The randomization will be in randomly variating block sizes.~Women in the placebo arm will get 3 calcium tablets to take within the fist 24 hours of the delivery. The first tablet must be administrated within 6 hours of the delivery."
89296055|NCT05830162|Experimental|Antibiotics (bioclavid)|"The Pharmacy of the main capital region provides the bioclavid (amoxicillin with Clavulanic acid) and placebo tablets for this study. They are responsible for the randomization and packing of the tablets. The randomization will be in randomly varying block sizes.~Women in the antibiotic arm will get 3 tablets bioclavid (amoxicillin and Clavulanic acid) to take within the fist 24 hours of the delivery. The first tablet must be administrated within 6 hours of the delivery."
89296056|NCT05830149|Experimental|Cryoinsufflation|In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
89296057|NCT05830149|Active Comparator|Deroofing|Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
89296058|NCT05829941|Experimental|HabitAware condition|This group will receive the device which messages the participant after a passively detected binge-eating episode with CBT strategies.
89296059|NCT05829941|Placebo Comparator|Reminder Condition|This group will receive a device that vibrates randomly throughout the day as a reminder not to binge eat.
89296060|NCT05829707|Active Comparator|Diclofenac|All patients underwent quadrantectomy or mastectomy with axillary lymph node dissection. They received diclofenac 2 x 75 mg intravenously on the first day after surgery. During the 3 subsequent days, from day 2 to day 4 postoperatively patients were given 3 x 50 mg diclofenac tablets orally. The medicine was delivered by the nurse, and the patients drank tablets in front of her.
89296061|NCT05829707|Experimental|Levobupivacaine bolus analgesia|Group Levobupivacaine Bolus received 0.5 mg/kg 0.5% Levobupivacaine HCl every 8 h via wound catheter. The dose of levobupivacaine was prescribed by the doctor and the drug was delivered by the nurse.
89296062|NCT05829707|Experimental|Levobupivacaine PCA group|Group Levobupivacaine patient-controlled analgesia (PCA) received 0.05 mg/kg 0.5% Levobupivacaine HCl continuously via wound catheter delivered by CADD - Legacy® PCA Pump. These patients were allowed to add a dose of 7.5 mg 0.5% levobupivacaine in case of pain by pressing the patient's button on the PCA pump, with a lock-out period of 4 hours.
89296063|NCT05828290|Experimental|Yoga Group|"The Little Yogis Doing Yoga Program was started to be implemented by the researcher for 4 weeks, 2 days a week for 30 minutes, separately for each group, in a way to form 2 groups."
89296064|NCT05828290|No Intervention|Control Group|Children in the control group will continue their routine education at school.
89296065|NCT05826938|Experimental|Virtual reality|The intervention group receives stimuli in the form of Virtual Reality technology before and during oocyte retrieval. In addition, patients receive standard treatment
89296066|NCT05826938|No Intervention|Control|The control group, does not receive stimuli in the form of Virtual Reality technology, but only the standard treatment
89296067|NCT05826756||Patients|Individuals who have been diagnosed with lung cancer. Individuals with all stages of lung cancer and individuals who have reached no evidence of disease (NED).
89296068|NCT05826756||Caregivers|Family and friends who provide care for someone who has been diagnosed with lung cancer
89296069|NCT05819918||Calcifediol|
89296070|NCT05819918||Best therapy available|
89296071|NCT05818228|Experimental|Video with Childhood Maltreatment-Related Content|Participants will view a video of an actor describing the story of an individual who experienced childhood maltreatment and how they overcame its effects on their life.
89296072|NCT05818228|No Intervention|Video without Childhood Maltreatment Content|Participants will view a lifestyle video of an actor describing their day-to-day experiences, without any childhood maltreatment-related themes.
89296073|NCT05810883||Insulin Resistant Group|HOMA-IR score of ≥ 3.4
89296074|NCT05810883||Non-Insulin Resistant|HOMA-IR score of less than 3.4
89296075|NCT05807074|Experimental|TXA, Saline|Each participant will have one breast exposed to TXA in the breast pocket and the other to saline only prior to closure. During surgery and prior to wound closure, the wound surface will be moistened on one side with 20 cc of dilute TXA 25mg/ml solution, and the contralateral with 20cc of saline.
89296076|NCT05805202|Experimental|aHUS Patient|The study will include 110 patients consenting adult and pediatric patients with a diagnosis of atypical hemolytic uremic syndrome and carrying mutations in the MCP or DGKE genes. New patients will be selected through clinical and genetic screening of the inhabitants of a small island of South Italy (Linosa) with high incidence of patients affected by DGKE mutations and characterized by a high rate of endogamy
89296077|NCT05805202|Other|Healthy volunteer|2 healthy subjects will undergo urine analysis (multistick) and only subjects with normal parameters will be enrolled as controls.
89296078|NCT05780645|Experimental|Cohort 1|"Regimen A: Participants will receive Dose B (3 x Dose A) ALXN2050 IR Tablet orally under fasted conditions.~Regimen B: Participants will receive Dose C ALXN2050 MR Prototype Tablet orally under fasted conditions.~Optional Regimens C, D, E, and F"
89296079|NCT05780645|Experimental|Cohort 2|"Regimen G: Participants will receive Dose B (3 x Dose A) ALXN2050 IR Tablet orally under fasted conditions.~Regimen H: Participants will receive Dose C ALXN2050 MR Prototype Mini-Tablet orally under fasted conditions.~Optional Regimens: I, J, K, and L"
89296080|NCT05776576||Special needs children and adolescents with physical disabilities and their parents|"Project consists of three main stages as evaluation, education and experimentation. For evaluation, firstly physical activity levels of individuals with special needs, barriers in physical activity, and motivators will be determined with an interactive roundtable meeting with children, adolescents and their parents. Afterwards, posture analyzes of individuals with special needs will be performed by physiotherapists. For education, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after that posture and ergonomics education will be given to the participants individually. For experimentation, group exercises, dance therapy and technology-supported exercise educations will be implemented by physiotherapists, taking into account the previous evaluations."
89296081|NCT05775601|Experimental|18F-LY3950321 Whole Body Dosimetry|
89296082|NCT05772273|Experimental|Camrelizumab, Azacitidine and low-dose Donor lymphocyte infusion|Patients are given azacytidine for 7 days, followed by 4 DLI treatments on Days 10, 17, 24 and 31, with the dose of DLI and Camrelizumab adjusted according to the donor source. Camrelizumab infusions were given 3 hours after completion of the 1st and 3rd DLIs, respectively.
89296083|NCT05771376|Experimental|Intervention Group|Patients who performed the Qigong exercise program
89296084|NCT05771376|Experimental|Control Group|Patients who performed a home exercise program
89296085|NCT05769127|Experimental|Intervention|All subjects participating in the diabetes prevention program will be offered body composition analysis and liver fat analysis, before, during, and after the lifestyle intervention
89296086|NCT05753917|Experimental|Group A|"piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy). One or two implants were placed in each edentulous ridge along with an additional 3.3 x 8.5 mm implant, termed a study fixture, in an adjacent area"
89296087|NCT05753917|Active Comparator|Group B|"In Group B, all implant sites were prepared with conventional drills according to the manufacturer's protocol (Premium, Sweden & Martina, Due Carrare, Padova, Italy); similarly to group A, one or two implants were placed in each edentulous ridge, and an additional 3.3 x 8.5 mm study-fixture was placed in the adjacent area."
89296088|NCT05753098|Experimental|estrogen therapy in addition to clomiphene citrate|received clomiphene citrate 50 mg (Tecnovula®) orally twice daily from the 2nd to 7th day of the cycle and estrogen (Cyclopregnova® 2mg, white tablets, BAYER Schering pharma), one tablet every 12 hour from day 8th till triggering of ovulation.
89296089|NCT05753098|Experimental|sildenafil in addition to clomiphene citrate|received clomiphene citrate 50 mg (Tecnovula®) orally twice daily from the 2nd to 7th day of the cycle as and Sildenafil (Respatio® 20mg film coated tablets for 5 days) from last day of menstruation till reaching optimal size of follicle and endometrial thickness
89296090|NCT05753098|Other|clomiphene citrate alone|received clomiphene citrate 50 mg (Tecnovula®) orally twice daily from the 2nd to 7th day of the cycle as in the first and second groups in addition to placebo tablet.
89296091|NCT05726292|Experimental|Group 1: Participants Who Receive Study Drug (Relacorilant) with Hormone Therapy and Enzalutamide|All participants in this group will have surgery up to 4 weeks after receiving enzalutamide/relacorilant with hormone therapy. A radical prostatectomy (removal of the prostate and any surrounding tissue that the surgeon thinks may be affected by the cancer).
89296092|NCT05726292|Experimental|Group 1: Participants Who Receive Placebo (no study drug) with Hormone Therapy and Enzalutamide|All participants in this group will have surgery up to 4 weeks after receiving enzalutamide/placebo (sugar pill in the form of 2 softgel capsules) with hormone therapy. A radical prostatectomy (removal of the prostate and any surrounding tissue that the surgeon thinks may be affected by the cancer).
89296093|NCT05699811|Experimental|MSC-IFNα monotherapy|Subjects will be enrolled for safety evaluation of MSC-IFNα monotherapy. Subjects will receive MSC-IFNα infusion from a dose of 2×10^6 cells/kg 1-4 times every 4-6 weeks. All treatment-related adverse events(TRAE) will be recorded for at least 28 days after the cell infusion.
89296094|NCT05699811|Experimental|MSC-IFNα combined with immunochemotherapy|"Subjects will be enrolled and received MSC-IFNα combined with immunochemotherapy, namely nab-paclitaxel (125 mg/m2, 5 days before infusion), cyclophosphamide (200 mg/m2,4 days before infusion) and anti-PD-1 antibody (200mg, 7 days after infusion) for 4 cycles.~From the 5th cycle, subjects will receive MSC-IFNα combined with anti-PD-1 antibody every 4-6 weeks for another 4 cycles for efficacy consolation. From the 9th cycle, subjects will receive anti-PD-1 antibody alone every 3 weeks for another 4 cycles for efficacy maintenance."
89296095|NCT05692908|Experimental|STI-6129 infusion|Intravenous infusion to be given with prophylaxis for infusion reactions if necessary.
89296096|NCT05692843|Other|Start of Cyclosporin treatment|"Patients will receive the starting dose used in routine clinical practice (maximum dose of 3 mg/kg/day is standard practice in our center).~Once the patient is included in the clinical trial their therapeutic management will be carried out according to usual clinical practice, but additional procedures will be performed:~The frequency of follow-up visits will be increased in order to collect data related to clinical efficacy, safety and quality of life;~Biological samples will be obtained (blood and urine) for biochemical, kinetic, pharmacogenetic and immunological biomarker analysis to identify variables associated to CsA treatment."
89296097|NCT05692843|Other|Receiving or received cyclosporin|"If the patient is receiving cyclosporine therapy, a blood sample for pharmacogenetic analysis will be obtained at screening; also, at discretion of the treating physician, biological samples will be obtained (blood and urine) in this visit and in the follow-up visits to assess biochemical and kinetic variables. Clinical data (scales) will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.~If the patient received cyclosporine previously but is no longer under CsA therapy, a blood sample will be extracted at screening for pharmacogenetic analysis. Clinical data (scales) will be collected from clinical records."
89296098|NCT05679544|Experimental|Subjects occupationally exposed to PAHs|
89296099|NCT05669248||mid covid-19 patients|Participant is diagnosed with symptomatic COVID-19 by a positive PCR for SARS-CoV-2 or antigen quicktest and meet the standard of mild COVID-19
89296100|NCT05660616|Experimental|Gemcitabine + supportive care|Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care.
89296101|NCT05660616|Other|supportive care|best supportive care alone.
89296102|NCT05660291|Experimental|Early time-restricted eating|Subjects window for eating would be between 08:00 AM - 4:00 PM
89296103|NCT05660291|Experimental|Late time-restricted eating|Subjects window for eating would be between 12:00 PM (noon) and 8:00 PM
89296104|NCT05659810|Active Comparator|Preoperative oral gabapentin before spinal anesthesia|The participants will receive 900 mg of gabapentin before surgery in 2 divided doses; 300 mg 10 hours prior to surgery and 600 mg 2 hours before surgery.
89296105|NCT05659810|Placebo Comparator|Preoperative oral placebo before spinal anesthesia|The participants will receive 1 tablet 10 hours prior to surgery, and then 2 tablets 2 hours prior to surgery
89296106|NCT05658497||Diroximel Fumarate|Pregnant women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
89296107|NCT05658497||Disease Modifying Therapy (DMTs) Exposed|Pregnant women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries) at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
89296108|NCT05658497||DMTs Unexposed|Pregnant women who were unexposed to DMT which is defined as either never received a DMT or discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP or discontinued a non-Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP.
89296109|NCT05658497||Dimethyl Fumarate|Pregnant women with MS who were exposed to DMF at any time from 2 weeks after the first day of their LMP through the end of pregnancy.
89296110|NCT05658497||Women Without MS|Pregnant women with external, general population comparators.
89296111|NCT05650619||Enrolled participants prior to transplant|Participants will be consented.
89296112|NCT05650619||Enrolled participant after transplant|Participants will be consented.
89296113|NCT05650619||Retrospective participant data|Waiver of consent for secondary use of existing data.
89296114|NCT05639699|Experimental|Experimental group|Motivational interview will be done to the experimental group
89296115|NCT05639699|No Intervention|I Control group|No intervention will be applied to the control group
89296116|NCT05639699|No Intervention|II Control group|No intervention will be applied to the control group
89296117|NCT05622422|Experimental|Body Knowleging Program Pilot Study|There will be three groups of 10 participants with a chronic disease that will receive the Body knowledging Program. The intervention aims to activate patients' inherent resources and by this, facilitate empowerment, patient activation, and self-care management of their chronic disease. The participants will include people 18 years and older that have been diagnosed with a chronic disease. This pilot study will use a pre-post design. Some of the data will be collected initially, then the intervention will be provided in seven sessions the first three face-to-face at a local community center and then the last four sessions through video conferencing that will be facilitated by three researchers. Data collection will take place at the first session and then again at the seventh session. The participants will be invited back in week nine to attend a video conference focus group to obtain qualitative data. Both qualitative and quantitative data will be analyzed.
89296118|NCT05611138|Experimental|Isolated pea protein|Dietary supplementation with isolated pea protein powder. Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
89296119|NCT05611138|Experimental|Isolated whey protein|Dietary supplementation with isolated whey protein. Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
89296120|NCT05611138|Experimental|Concentrated pea protein|Dietary supplementation with concentrated pea protein Amount: 0.5 g of protein from the supplement per kilogram of body weight, taken in 3 portions during the day, for 4 weeks.
89296121|NCT05602090|Experimental|Growth Hormone adjuvant treatment|Growth hormone in this trial will use 4 IU of recombinant GH (Somatotropin, ) by day after day subcutaneous injection for 6 weeks before starting cycle. And on start day of induction ( Day 2 to 3) until the day of the human chorionic gonadotropin (hCG) trigger.
89296122|NCT05602090|No Intervention|control|standard controlled ovarian stimulation
89296123|NCT05599308|Active Comparator|Atrial fibrillation (AFib)|Patient with known history of AFib who are in AFib at the time of study screening.
89296124|NCT05599308|Active Comparator|Non-Afib|Patient with no known diagnosis of AFib
89296125|NCT05594680|Active Comparator|Cilostazol and Methotrexate|Participants in this arm will receive Cilostazol 50 mg twice daily with Methotrexate for rheumatoid arthritis for 12 weeks.
89296126|NCT05594680|Placebo Comparator|Placebo and Methotrexate|Participants in this arm will receive Placebo with Methotrexate for rheumatoid arthritis for 12 weeks.
89296127|NCT05591885|Experimental|Study product gruop|Nutrilite Memory Builder Ingredients (Cistanche deserticola extract, Ginkgo biloba extract, glucose, microcrystalline cellulose, corn starch, etc.) 60 Tablets / bottle
89296128|NCT05591885|Placebo Comparator|Placebo group|Ingredients (glucose, microcrystalline cellulose, corn starch, caramel pigment, etc.) 60 Tablets / bottle
89296129|NCT05567029|Experimental|Risankizumab Dose A|Participants will receive subcutaneous dose of risankizumab dose A.
89296130|NCT05567029|Experimental|Risankizumab Dose B|Participants will receive subcutaneous dose of risankizumab dose B.
89296131|NCT05564702|Experimental|Opt-IVF predicted drug dosage|In this arm, OPT-IVF will use the patient's age and day three serum day AMH and AFC levels to decide the starting dose for the patient's cycle. It will also use the first day and day 5 data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient. The dosage predicted by Opt-IVF will be used for the patient in this arm.
89296132|NCT05564702|Active Comparator|Traditional drug treatment|The current practice of Physician specified dosage will be used in this arm.
89296133|NCT05557643|Active Comparator|Mindfulness-Based Stress Reduction (MBSR)|Participants in the MBSR arm will complete an 8-week Mindfulness-Based Stress Reduction Curriculum involving a weekly 2 hour group meeting (either in person or virtual) as well as a 8 hour group mindfulness retreat in week 6-7 of the curriculum.
89296134|NCT05557643|Experimental|Mindfulness-Based Stress Reduction (MBSR) + Psilocybin-Assisted Psychotherapy (PAP)|Participants in the MBSR + PAP arm will complete an 8-week Mindfulness-Based Stress Reduction Curriculum involving a weekly 2 hour group meeting (either in person or virtual). They will additionally complete a psilocybin-assisted psychotherapy (PAP) intervention that involves three 2-hour group preparatory sessions, a single 8-hour group psilocybin administration session (done in place of the mindfulness retreat), and three 2-hour group integration sessions. All PAP intervention sessions will utilize a 1:1 therapist to participant ratio with an additional lead therapist present.
89296135|NCT05553795|Experimental|A - Early removal of chest drain|
89296136|NCT05553795|Other|B - Control|
89296137|NCT05542641|Experimental|real rTMS|verum rTMS to the DLPFC, 1500 1Hz pulses at 120% RMT, 25 minutes total
89296138|NCT05542641|Sham Comparator|sham rTMS|sham rTMS to the DLPFC, 1500 1Hz pulses at 120% RMT, 25 minutes total
89296139|NCT05540756||SCS|Patients undergoing a spinal cord stimulator trial who is planning to have intraoperative neuromonitoring performed during the procedure
89296140|NCT05531370|Experimental|Breathing Retraining (BR)|"Patients will receive three sessions (60 min, 30 min, 30 min) of breathing retraining (BR), 1-to-1 with a trained physiotherapist.~As preferred by the patient:~Hybrid delivery mode of BR (H-BR): First session on-site at hospital/clinic for initial assessment and introduction, and following sessions online (MedComs VDX platform or equal; participants access using web cam and sound on smart phone, tablet, or pc).~Ordinary delivery of BR: Three sessions on-site at hospital/clinic."
89296141|NCT05530473|Experimental|CTR Group|Eyes had a capsular tension ring (CTR) implanted into the capsular bag during the cataract surgery.
89296142|NCT05530473|No Intervention|NCTR Group|Eyes underwent cataract surgery without implanting a CTR.
89296143|NCT05526443||Patient with locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma|Patient with locally advanced inoperable and/or metastatic pancreatic ductal adenocarcinoma
89296144|NCT05518604|Experimental|Intervention Arm 1|Women in this arm will undergone dietary counseling in the first year postpartum in addition to close supervision of diet, exercise, and sleep.
89296145|NCT05518604|Experimental|Intervention Arm 2|Women in this arm will not have dietary counseling but will have close supervision of diet, exercise and sleep.
89296146|NCT05518604|No Intervention|Control|Women in this arm will undergo routine postpartum care.
89296147|NCT05507905|Experimental|Dance 3 Times Weekly (3xD)|Participants in this arm will attend classes 3 times a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.
89296148|NCT05507905|Experimental|Dance 2 Times Weekly (2xD)|Participants in this arm will attend classes 2 times a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.
89296149|NCT05507905|Experimental|Dance 1 Time Weekly (1xD)|Participants in this arm will attend a class 1 time a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.
89296150|NCT05507905|Active Comparator|Music Appreciation Classes (MAC)|In the MAC, the music associated with that dance form will be used as the subject for classes and will also change every 6 weeks.
89296151|NCT05467787|Experimental|Message-based psychotherapy (MBP)|
89296152|NCT05467787|Experimental|Video-chat psychotherapy (VCP)|
89296153|NCT05446389|Experimental|Intervention Group|Infants randomized in to the experimental group will receive the PAL intervention 2 times a week until the infant transitions to room air or < 2L high flow nasal cannula and is able to begin attempting feeds by mouth. The PAL is an FDA cleared medical device that has a sensor that will connect to the infant's pacifier and can read the infant's suck. Then, the device plays music as positive reinforcement to help improve sucking skills. This intervention typically lasts about 15 minutes and is implemented while the infant is receiving gavage feeds.
89296154|NCT05446389|No Intervention|Control Group|Infants randomized in to the control group will not receive music therapy intervention throughout NICU admission.
89296155|NCT05441111|Experimental|COMET + guided self-help bibliotherapy|"Participants are given access to a single session intervention the Common Elements Toolbox (COMET) and, a week after, are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Each participant is assigned an eCoach -- an undergraduate, post-baccalaureate, or graduate research assistant -- who will meet with the participant for a 60-minute welcome call describing the intervention and 3-6 sessions of guidance focused on promoting adherence to the manual and using skills in everyday life."
89296156|NCT05441111|Active Comparator|COMET + unguided self-help bibliotherapy|"Participants are given access to a single session intervention the Common Elements Toolbox (COMET) and, a week after, are given access to the World Health Organization's (WHO) Doing what matters in times of stress: An illustrated guide (https://www.who.int/publications/i/item/9789240003927) virtually (i.e., as a pdf) and/or in print. Participants are left to read the book on their own (i.e., without an eCoach)"
89296157|NCT05428904|Experimental|Intervention Group|Nursing undergraduate students participating in a virtual reality simulation program
89296158|NCT05428904|No Intervention|Control Group|Nursing undergraduate students receiving attention-matched training
89296159|NCT05428085||Caregivers whose children are currently receiving early treatment|Individual caregivers were interviewed through paper questionnaires to assess children's and families' digital media usage habits, children's activity levels, and parental stress. Pearson's Chi-Square test and liner regression was used for analysis.
89296160|NCT05416047||Frail and no frail|Frailty will be assessed using Rockwood Clinical Frailty Score
89296161|NCT05416047||Sarcopenia and no sarcopenia|Sarcopenia will be assessed using psoas muscle mass
89296162|NCT05396599|Experimental|Eyhance Toric II IOL|Model DIU
89296163|NCT05396599|Experimental|TECNIS Synergy Toric II|Model DFW
89296164|NCT05396599|Active Comparator|TECNIS Toric 1-Piece IOL|Model ZCT
89296165|NCT05378126|Other|Neurological cohort|All patients included in the study wil have a neurological examination
89296166|NCT05367804|Experimental|Isolated plant protein|Visit 1 to 8 participants will collect faecal samples. Visits 4 to 8 in addition to the faecal sample, urinary samples (24 h urine collection) will be collected by themselves, and blood sample will be collected at the hospital. For the visits with blood collection (visits 4 to 8), subjects will come to the study centre after 10 hours of overnight fast. Subjects will have anthropometry measurements taken in the visits 4, 5, 6, and 7 using a Tanita® full body composition. Subjects will respond to questionnaires about their physical activity (once a week), Gastrointestinal Symptom rating scale (GSRS - once a week) and track their intestinal habits using Bristol scale (every day). Subjects' diet will be assessed using a web-based 24-hour diet recall (interviewed so the participants learn how to use the tool regardless of where they are) followed by multiple day records (3 times a week).
89296167|NCT05354414|Experimental|VR followed by SOC|Participants will receive a 20-minute (min) VR session at the first nusinersen IT (IT1), followed by SOC (local anesthesia - lidocaine or intravenous sedation) at the subsequent nusinersen IT (IT2) during the main study, later followed by 20-min VR sessions at two subsequent nusinersen ITs (IT3 and IT4) during the extension period, for up to 450 days.
89296168|NCT05354414|Experimental|SOC followed by VR|Participants will receive SOC (local anesthesia - lidocaine or intravenous sedation) at nusinersen IT1, followed by a 20-min VR session at the subsequent nusinersen IT (IT2) during the main study, later followed by 20-min VR sessions at two subsequent nusinersen ITs (IT3 and IT4) during the extension period, for up to 450 days.
89296169|NCT05353218|Active Comparator|Group intermediate cervical plexus block (GI)|Patients anesthetized with intermediate cervical plexus block.
89296170|NCT05353218|Active Comparator|Group deep cervical plexus block (GD)|Patients anesthetized with deep cervical plexus block.
89296171|NCT05345925|Experimental|Experimental group|Eligible subjects instrumented for CNT testing
89296172|NCT05328648|Experimental|Community Score Card|In the Community Score Card approach, community members come together to document challenges they encounter when seeking services and develop a corresponding set of indicators that can be used to produce a validated facility score. The score is shared with the community and a collaborative process between key community members and facility staff takes place to develop feasible solutions and a strategic action plan.
89296173|NCT05328648|Experimental|Citizen Report Card|In the Citizen Report Card approach, individual-level feedback is collected from actual clients of target facilities, via a structured questionnaire, to assess facility performance and generate a public record of service quality. In addition to sharing the final report card with communities, engaged policymakers are invited to use the citizen feedback to improve service delivery.
89296174|NCT05328648|No Intervention|Control|Communities in the control arm will not receive an intervention.
89296175|NCT05325372|Experimental|Ultrasound guided axillary block|the Ultrasound probe with a linear high frequency (8-14 MHZ) transducer will be placed parallel to the anterior axillary fold at the axilla to identify the axillary artery and to identify the hyperechoic median, ulnar, and radial nerves in relation to the axillary artery. The musculocutaneous nerve which supplies the skin of the lateral side of the forearm had to be blocked also. It is found between the biceps brachii and coracobrachialis muscles. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe. The needle is inserted in-plane from the anterior aspect and directed toward the posterior aspect of the axillary artery. All four nerves in the axillary region will be blocked. A local anesthetic will be administered adjacent to each of the four nerves (at least 5 ml for each).
89296176|NCT05325372|Experimental|Ultrasound guided infraclavicular block block|The transducer is positioned in the parasagittal plane to identify the axillary artery. Surrounding the artery are the three cords of the brachial plexus: the lateral, posterior, and medial cords. The needle is inserted in-plane short-axis technique from the cephalad end of the probe, with the insertion point just inferior to the clavicle. A local anesthetic will be injected posterior to the axillary artery to achieve a U-shaped distribution around the artery (cephalad, caudad, and posterior).
89296177|NCT05322967|Active Comparator|Morning intake|Intake of antihypertensive medication in the morning
89296178|NCT05322967|Active Comparator|Bedtime intake|Intake of antihypertensive medication at bedtime
89296179|NCT05302141|Experimental|3D printing assistive device group|experimental (3D printing assistive device) groups for 4 weeks of treatment (thirty minutes a time, twice a week).
89296180|NCT05302141|Active Comparator|universal cuff groups|control (universal cuff) groups for 4 weeks of treatment (thirty minutes a time, twice a week).
89296181|NCT05281614|Experimental|Arm A|Arm A will receive 6 weeks of vedolizumab after 8 weeks of etanercept. Final study visit at 52 weeks.
89296182|NCT05281614|Experimental|Arm B|Arm B will receive 6 weeks of vedolizumab only. Final study visit at 52 weeks.
89296183|NCT05264636|Active Comparator|Sucrose|sucrose sweetened beverage 16 oz (473 ml) given daily for 28 days
89296184|NCT05264636|Experimental|Steviol glycosides|steviol glycosides sweetened beverage 16 oz (473 ml) given daily for 28 days
89296185|NCT05256680|Experimental|Gardening Activities|In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.
89296186|NCT05256680|Active Comparator|Control|No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home.
89296187|NCT05251805|Experimental|Costal bone marrow aspiration|10 NSCLC patients undergoing surgery from which blood samples, bone marrow aspirate and lung tumor tissue will be collected
89296188|NCT05228288|Active Comparator|CDL|Conventional direct laryngoscopy using a Macintosh blade
89296189|NCT05228288|Experimental|M-VAL|Video assisted laryngoscopy with a Macintosh-shaped blade
89296190|NCT05228288|Experimental|H-VAL|Video assisted laryngoscopy with a hyper-angulated blade
89296191|NCT05216861|Experimental|Experimental|The rehabilitation coordinators are trained in the intervention (0,5 day).
89296192|NCT05216861|Other|Active comparator|Participants in the experimental arm will be matched with controls from the Micro Data for the Analysis of Social Insurance register (MiDAS) from the Social Insurance Agency, Sweden.
89296193|NCT05214898||Immediate Start|"Investigators will use a quasi-experimental interrupted time series (ITS) design that allows for a continuous sequence of observations on a population, taken repeatedly over time (Bernal et al., 2017). ITS design provides an estimate of the causal effect of a discrete intervention; the design begins with measurements on a dependent variable and the intervention breaks (interrupts) this time series into preintervention and post-intervention time points. Data will be collected from two group an Immediate Start Group and a Delayed Start Group (who will serve as a control group for the ITS design)."
89296194|NCT05214898||Delayed-Start|"Investigators will use a quasi-experimental interrupted time series (ITS) design that allows for a continuous sequence of observations on a population, taken repeatedly over time (Bernal et al., 2017). ITS design provides an estimate of the causal effect of a discrete intervention; the design begins with measurements on a dependent variable and the intervention breaks (interrupts) this time series into preintervention and post-intervention time points. Data will be collected from two group an Immediate Start Group and a Delayed Start Group (who will serve as a control group for the ITS design)."
89296195|NCT05211492|Other|Chronic pain|
89296196|NCT05211492|Other|Acute pain|
89296197|NCT05211492|Other|Control group|
89296198|NCT05193955|Experimental|Intervention Group|undergraduate students who practice laughter yoga and simulation education together
89296199|NCT05193955|No Intervention|Control Group|undergraduate students who practice simulation education
89296200|NCT05185323|Experimental|Breastfeeding usual known aids and osteopathic treatment|The osteopathic treatment consists of manual listening without intention, without thrust. The hands follow the spontaneous movements of the patients. The end of the treatment is perceived by an overall relief and a feeling of balance for the baby and his mother
89296201|NCT05185323|Active Comparator|Breastfeeding usual known aids|Breastfeeding usual known aids in usual care
89296202|NCT05181345||Normal sleep first|"The night before the first heat exposure, the participants will have a normal night at home.~The night before the second heat exposure, the participants sleep will be restricted to 3 hours in bed."
89296203|NCT05181345||Reduced sleep first|"The night before the first heat exposure, the participants sleep will be restricted to 3 hours in bed.~The night before the second heat exposure, the participants will have a normal night at home."
89296204|NCT05180526|Experimental|Experimental|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
89296205|NCT05165706|Experimental|Mediterranean Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
89296206|NCT05165706|Experimental|Standard Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
89296207|NCT05165706|Experimental|Low Fat, Healthy Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
89296208|NCT05159947|Experimental|Test group (SPT-07A injection group)|
89296209|NCT05159947|Placebo Comparator|Control group (placebo group)|
89296210|NCT05145075|Experimental|Survey group|Patients are asked to fill in a survey.
89296211|NCT05132686|Experimental|Intermittent energy restriction (IER) + Mediterranean diet (MED) or IER+MED|The IER+MED group intervention will be to restrict 70% energy (25%, 45% and 30% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow a MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. This would be equivalent to an over-all 20% daily energy restriction. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
89296212|NCT05132686|Experimental|Mediterranean diet (MED) + daily energy restriction (DER) or MED/DER|The MED/DER group intervention will restrict 20% energy (25%, 45% and 30% distribution of protein, carbohydrate, and fat, respectively) continuously. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
89296213|NCT05060692||LONGCOVID|Patient with Long-COVID Syndrom
89296214|NCT05060692||CONTROLS|Healthy individials
89296215|NCT05051475|Active Comparator|radiofrequency ablation|Circumferential ablation with radiofrequency ablation will be performed for each segment of the BE starting from the proximal end with one ablation at 12J/cm2, followed by cleaning of mucosal slough with esophageal cap, patient extubation, cleaning of ablation device with wet gauze, and finally a second ablation at 12 J/cm2 (1 × 12J/cm2-clean-1 × 12 J/cm2). Focal ablations will be performed with three consecutive ablations at 12 J/cm2 without cleaning (simplified protocol).
89296216|NCT05051475|Active Comparator|hybrid argon plasma coagulation|Patients in the Hybrid argon plasma coagulation group will be treated with a single ablation per session with a power limitation of 60 W (pulsed mode (VIO® 300 D & APC 2, PULSED APC®, Effect 2). No scraping with the endoscope cap and second ablation will be performed.
89296217|NCT05030831|Experimental|INZ-701|"The study design during the Dose Evaluation Period is a MAD 3+3 with 3 dose cohorts. The planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly.~During the Extension Period, subjects will be administered INZ-701 at the dose and dose schedule assigned in the Dose Evaluation Period. However, the administered dose and dose schedule for a subject may change once the selected dosing regimen has been determined upon completion of the Dose Evaluation Period, at which time all subjects will be assigned to the selected dosing regimen."
89296218|NCT05025631|Experimental|Fruquintinib dose-optimization|Fruquintinib was administered orally on 21 consecutive days in a 28-day treatment cycle. All patients were dose-optimized for the first cycle of fruquintinib - oral fruquintinib 3 mg/day in the first week; if tolerated, oral fruquintinib 4 mg/day in the second week; if still tolerated, then the dose was increased to 5 mg/day in the third week. From the second cycle, patients were given the maximum dose that they have tolerated in the first cycle.
89296219|NCT04987047||Prescription with pharmacogenetics assistance|The participants randomized in this arm will received a prescription of antidepressants based on the results of pharmacogenetics analyses.
89296220|NCT04987047||Prescription without pharmacogenetics assistance|The participants randomized in this arm will received a prescription of antidepressants left to the discretion of the clinician without pharmacogenetics assistance.
89296221|NCT04983329|Other|Improvement in administration of surgical antibiotic prophylaxis.|The eight-month module will include a baseline phase, educational interventions, real-time guidance from a remote telemedicine center, regular feedback regarding adherence to protocols related to that module, and continued silent monitoring.
89296222|NCT04955938|Experimental|Arm A - Participants with IDH1 Mutations|"After genetic testing, if participants are found to have IDH1 Mutations (a genetic mutation) then they will be assigned to this group and will receive the following study drugs:~Single agent Phase (Cycles 1-3):~The initial phase of treatment will consist of 3 cycles (lasting 28 days) of ivosidenib 500mg daily x 28 days~Combination Phase (Cycle 4 onwards):~If a participant shows clinical benefit (including their disease stabilizing) following the first 3- cycle phase, he or she may go onto the combination phase. Combination treatment will consist of ivosidenib daily x 28 days along with fedratinib daily x 28 days."
89296223|NCT04955938|Experimental|Arm B - Participants with IDH2 Mutations|"After genetic testing, if participants are found to have IDH2 Mutations (a genetic mutation) then they will be assigned to this group and will receive the following study drugs:~Single agent Phase (Cycles 1-3):~The initial phase of treatment will consist of 3 cycles (lasting 28 days) of enasidenib 100mg daily x 28 days~Combination Phase (Cycle 4 onwards):~If a participant shows clinical benefit (including their disease stabilizing) following the first 3- cycle phase, he or she may go onto the combination phase.Combination treatment will consist of enasidenib 100mg daily x 28 days along with fedratinib daily x 28 days."
89296224|NCT04927650||Screening|Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer.
89296225|NCT04923347|Experimental|Participants receiving FF/UMEC/VI via ELLIPTA inhaler|
89296226|NCT04911023||Patients operated by fissurectomy|
89296227|NCT04911023||Patients operated by fissurectomy with anoplasty|
89296228|NCT04905745||Facial palsy|Adulthood facial palsy patients group who receive Korean integrative medicine.
89296229|NCT04901091||study group№ 1|patients who have left ventricular aneurysm without thrombosis
89296230|NCT04901091||study group№ 2|patients who have left ventricular aneurysm with thrombosis
89296231|NCT04901091||control group|patients who have not left ventricular aneurysm
89296232|NCT04880200|Experimental|POC NAT & Adherence Intervention|These participants will receive the POC NAT test during their study visit. The result will be conveyed to their provider, who will deliver the result and an adherence intervention.
89296233|NCT04880200|No Intervention|Standard of Care|These participants will receive the clinical standard of care during their visit.
89296234|NCT04879589|Experimental|SC ATRS-2002|3 different dosages [25mg (0.13mL) , 75mg (0.4mL) and 200mg (1.05mL)] will be tested as single SC injection into the abdomen.
89296235|NCT04879589|Active Comparator|Oral Abiraterone Acetate|A single dose of 1000mg of commercially available oral formulation of abiraterone acetate will be administered to enrolled participants in Cohort 4
89296236|NCT04872608|Experimental|Letrozole, Palbociclib, and Onapristone ER|This study has two stages: a dose-finding stage and a dose expansion stage. Stage 1 of the study will utilize a standard 3+3 dose de-escalation design with a total of three dose levels of onapristone ER, 30mg PO BID, 40mg PO BID, and 50mg PO BID given on a 28-day cycle. Onapristone ER will be given in addition to letrozole 2.5mg QD and each patient's pre-enrollment dose of palbociclib.
89296237|NCT04853641||Living Donor Liver Transplant Recipient|Patients who have received a living donor liver transplant.
89296238|NCT04853641||Deceased Donor Liver Transplant Recipient|Patients who have received either a Deceased by Circulatory Death or Deceased by Brain Death Liver Transplant
89296239|NCT04836624|Experimental|Co-designing personalised aids of daily living|Participants will be involved in up to 6 interactive sessions spread over 3 months with the researcher. Participants will work with the researcher to help develop their own assistive device to overcome challenges of daily living they experience.
89296240|NCT04831398|Placebo Comparator|Placebo|Placebo (PLA) is 10 sublingual sprays of a diluted (1 microliter/29ml filtered water) mint extract.
89296241|NCT04831398|Experimental|Melatonin|5mg commercially available melatonin (MEL) spray will be given sublingually.
89296242|NCT04824209||AP group|Healthy patients between 25-55 years with Apical Periodontitis
89296243|NCT04824209||Control Group|Healthy patients between 25-55 years without Apical Periodontitis
89296244|NCT04801849|Active Comparator|Vitamin E, 200 IU|200 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
89296245|NCT04801849|Active Comparator|Vitamin E, 400 IU|400 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
89296246|NCT04801849|Active Comparator|Vitamin E, 800 IU|800 IU of d-alpha tocopherol (vitamin E) taken once daily with breakfast
89296247|NCT04801849|Placebo Comparator|Placebo|matching placebo taken once daily with breakfast
89296248|NCT04791488|Experimental|Healthy individuals|
89296249|NCT04791488|Experimental|Decompression sickness patients|
89296250|NCT04784533|Experimental|Part A, Period 1 - Low dose|8 mg BID CTP-543 for 24 weeks
89296251|NCT04784533|Experimental|Part A, Period 1 - High dose|12 mg BID CTP-543 for 24 weeks
89296252|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from low dose|Dose reduction for a maximum of 24 weeks for those previously receiving 8 mg BID
89296253|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from low dose|Placebo for a maximum of 24 weeks for those previously receiving 8 mg BID
89296254|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from high dose|Dose reduction for a maximum of 24 weeks for those previously receiving 12 mg BID
89296255|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from high dose|Placebo for a maximum of 24 weeks for those previously receiving 12 mg BID
89296256|NCT04784533|Experimental|Part B - Low dose|8 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
89296257|NCT04784533|Experimental|Part B - High dose|12 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
89296258|NCT04770935|Experimental|efanesoctocog alfa (BIVV001)|A single IV dose of BIVV001 will be administered to each patient
89296259|NCT04764448|Experimental|Belcesiran Cohort 1|
89296260|NCT04764448|Placebo Comparator|Placebo Cohort 1|
89296261|NCT04764448|Experimental|Belcesiran Cohort 2|
89296262|NCT04764448|Placebo Comparator|Placebo Cohort 2|
89296263|NCT04764448|Experimental|Belcesiran Cohort 3|
89296264|NCT04764448|Placebo Comparator|Placebo Cohort 3|
89296265|NCT04746690|Active Comparator|Slider neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch on one nerve end and slackness on the other end.
89296266|NCT04746690|Active Comparator|Tensioner neurodynamic mobilization technique only|a neurodynamic mobilization technique of the sciatic nerve with stretch of both nerve ends.
89296267|NCT04746690|Active Comparator|Stretching exercises of back extensors, hamstrings and gastrocnemius muscles|Stretching exercises of back extensors, hamstrings and gastrocnemius to relief the pressure on the nerve.
89296268|NCT04724733|No Intervention|Control|The control group will receive incentives for study participation but will not be introduced to the Smoke Sense app.
89296269|NCT04724733|Experimental|Smoke Sense|
89296270|NCT04724733|Active Comparator|Smoke Sense Plus|
89296271|NCT04709796|Experimental|Intervention group: EmbryoGlue|Embryo transfer with EmbryoGlue®
89296272|NCT04709796|Active Comparator|Control group|Conventional embryo transfer
89296273|NCT04705038|Experimental|Educational Intervention|Participants in this arm undergo a short educational session about orchiectomy. They will also be asked to complete questionnaires.
89296274|NCT04705038|No Intervention|No Intervention|"Participants that decline the education session will continue with routine care of their cancer.~They will also be asked to complete questionnaires."
89296275|NCT04703413|Experimental|LoFric® OrigoTM or LoFric® SenseTM|Hydrophilic male (LoFric Origo) and female (LoFric Sense) urinary catheters for single use. Target subject population are subjects suffering from bladder voiding dysfunction and are experienced in intermittent catheterization (IC).
89296276|NCT04693936|Active Comparator|Nutraceuticals|Participants will receive a combination of nutraceuticals and will be instructed to follow a Mediterranean diet
89296277|NCT04693936|No Intervention|Control|Participants will follow usual diet
89296278|NCT04692480|Experimental|Breastfeeding Video Education|"Participants will view a breastfeeding educational video entitled Breastfeeding in the First Hour, It's in Your Hands."
89296279|NCT04692480|Other|Control|Participants will view a PDF of breastfeeding education materials available for inclusion in standard discharge paper work.
89296280|NCT04654260|Experimental|Behavioral Therapy for Irritability in Autism (BTIA)|BTIA consists of 15 ninety-minute weekly sessions that will be conducted with the teens and their parents by experienced therapists using a structured, detailed manual.
89296281|NCT04654260|Active Comparator|Psychoeducation and Supportive Therapy (PST)|PST consist of 15 weekly, ninety-minute sessions focused on learning about and discussing issues of diagnosis, treatment and educational services with an experienced therapist could be helpful to children on the autism spectrum and their families.
89296282|NCT04635839|Active Comparator|Standard Dosing|Standard dose of unfractionated heparin
89296283|NCT04635839|Active Comparator|Gestational Age-Based Dosing|Dose of unfractionated heparin based on trimester of pregnancy
89296284|NCT04599270|Experimental|Intervention group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.~If adolescent have not risk personality traits, the patient will go out of the study.~If adolescent have risk personality traits, other tests and scales will be performed to study the intensivity of dependance of substance use and the patient will be randomized.~If he is randomized in intervention group, the patient will follow PREVENTURE program (2 session of 90 min by videoconference), within 3 months after inclusion and will be contacted by phone by the psychologist at 1, 3, 6 and 12 month after sessions to answer the same tests and scales."
89296285|NCT04599270|Active Comparator|Control group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.~If adolescent have not risk personality traits, the patient will go out of the study.~If adolescent have risk personality traits, other tests and scales will be performed to study the severity of substance use disorders and the patient will be randomized.~If he is randomized in control group, the patient will follow routine care and will be contacted by phone by the psychologist at 1, 3, 6 and 12 month after inclusion to answer the same tests and scales."
89296286|NCT04594356||Patients with COVID-19 infection|"As part of this research, existing clinical data of patients infected with COVID-19 is collected from the patients' computerized medical records.~During the hospitalization of the patients, in addition to the clinical and laboratory data collected, the dosage of IL-6, apparently playing a central role in the worsening of the symptoms of COVID-19, was performed. The remainder of the contents of the tube used to perform this assay will allow further research by assaying the DNA-myeloperoxidase (DNA-MPO) complexes. These complexes reflect a phenomenon called netosis, most likely involved in the widespread inflammation that patients have suffered from."
89296287|NCT04590365|Experimental|Coldamaris plus|verum Coldamaris plus i.e. 0.12% Iota-Carrageenan plus 0.04% Kappa-Carrageenan in 0.5% saline
89296288|NCT04590365|Placebo Comparator|Coldamaris sine|Coldamaris sine i.e. 0.5% saline
89296289|NCT04560179|Experimental|Treatment Arm - 78mg|The phase 1 trial will begin with a dose of 78mg. All treatment arms will administer study drug every 12 hours for up to 14 days (28 doses). Up to 6 infants in this arm will receive the 78mg dose of tobramycin solution for inhalation administered via vibrating mesh nebulizer. During the trial, infants in each treatment arm will undergo blood and tracheal aspirate sampling and respiratory mechanics measurements at pre-specified time points to assess dose safety and potential efficacy. Continuous pulse oximetry monitoring for the duration of the trial will also occur. Clinical data will also be recorded daily throughout the trial in all participants.
89296290|NCT04560179|Experimental|Treatment Arm - 150mg|If tolerability is demonstrated in the 78mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
89296291|NCT04560179|Experimental|Treatment Arm - 216mg|If tolerability is demonstrated in the 150mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
89296292|NCT04560179|Experimental|Treatment Arm - 300mg|If tolerability is demonstrated in the 216mg treatment arm following the 3+3 trial design, up to 6 infants will then be enrolled and receive 150mg of tobramycin solution for inhalation every 12 hours. The same monitoring procedures will be performed in this treatment arm as in the prior.
89296293|NCT04560179|No Intervention|Observational Arm|Enrolled infants who are eligible to participate in the phase-1 trial may be enrolled in an untreated observational cohort at parental discretion. This cohort will undergo collection of clinical and respiratory mechanics data for 14 days after enrollment but will not receive the study drug.
89296294|NCT04555174||Orsiro Mission DES|All subjects will be implanted with the Limus Eluting Orsiro Mission Stent System and followed up until 60 months.
89296295|NCT04543799||A1|"Group A1 consists of patients with prostate cancer receiving ADT as part of their standard care for either locally advanced or metastatic disease.~Group A1 consists of a combination of two groups; B1, metastatic patients receiving ADT both with and without an oral AR targeted agent, and not receiving radiotherapy and B2, locally advanced patients receiving ADT alongside radiotherapy"
89296296|NCT04543799||A2|patients with localised prostate cancer receiving radiotherapy only
89296297|NCT04543799||YET|Breast cancer survivors receiving endocrine therapy
89296298|NCT04543799||NET|Breast cancer survivors not receiving endocrine therapy
89296299|NCT04536337|Experimental|ALG-000184|Oral tablet(s) of ALG-000184 in HV or CHB subjects once daily for up to 4 weeks
89296300|NCT04536337|Placebo Comparator|Placebo|Oral tablet(s) of placebo in HV or CHB subjects once daily for up to 4 weeks
89296301|NCT04536337|Active Comparator|Entecavir in combination with ALG-000184|
89296302|NCT04518267||Civilian group|Participants with civilian status
89296303|NCT04518267||Military group|Participants with military status
89296304|NCT04515836|Experimental|Treatment Arm|Olaparib will be given orally to patients in 28-day cycles. Patients will attend the clinic on days 1 (first day of treatment) and 15 of the first cycle following the beginning of study treatment and then every 4 weeks (day 1 of every cycle) until discontinuation of treatment.
89296305|NCT04514744|Experimental|Unilateral Immobilization|One leg will undergo 14 days of single-leg immobilization, by means of a removable knee brace.
89296306|NCT04514744|Experimental|Unilateral Resistance Exercise|One leg will undergo 4 sessions of unilateral resistance exercise, over the course of 8 days. Specifically, participants will be asked to perform leg press and leg extension.
89296307|NCT04493502|Experimental|LY3041658|Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W).
89296308|NCT04493502|Placebo Comparator|Placebo|Placebo administered IV. Participants will switch to 600 mg LY3041658 administered IV after week 16.
89296309|NCT04453293|Experimental|BCG vaccine|Freeze-dried Glutamate Bacillus Calmette-Guérin (BCG) (Tokyo 172) vaccine
89296310|NCT04453293|Placebo Comparator|Placebo|Vaccine diluent [sodium glutamate]
89296311|NCT04408001||Symptomatic individuals|"Hospital staff identified by the COVID-19 case census cell :~who have been infected (confirmed by a positive RT-PCR result on a nasopharyngeal swab)~OR who have displayed clinical signs compatible with COVID-19 despite a negative RT-PCR result."
89296312|NCT04408001||Asymptomatic individuals|Hospital staff who have not been identified by the COVID-19 case census cell.
89296313|NCT04390672|Experimental|SUPRAFLEX Cruz|Percutaneous Coronary Intervention with the SUPRAFLEX Cruz Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
89296314|NCT04390672|Active Comparator|SYNERGY|Percutaneous Coronary Intervention with the SYNERGY EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with an bioabsorbable polymer coating.
89296315|NCT04373551|Experimental|Cultural adaptation of a patient-provider communication tool|Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.
89296316|NCT04354909||Biological samples|levels of s-CD95-L (ELISA test)
89296317|NCT04348006|Experimental|Induction Therapy|Bortezomib will be administered as part of VCD or VRD protocols
89296318|NCT04339790||New study participant|Individuals who respond to study website or advertisements for the study who have not previously been a NIMH study participant
89296319|NCT04339790||NIMH Study Participant|Individuals who have previously consented for a NIMH study
89296320|NCT04313972|Experimental|Low-dose naltrexone|2mg low-dose naltrexone capsules
89296321|NCT04313972|Placebo Comparator|Placebo|Placebo capsules
89296322|NCT04306237|Experimental|IMB-1018972|Participants will receive IMB-1018972 (200 mg) MR tablets twice daily for 16 weeks
89296323|NCT04306237|Placebo Comparator|Placebo|Participants will receive matching placebo tablets twice daily for 16 weeks
89296324|NCT04304599|Experimental|LoFric Elle|New hydrophilic female urinary catheter for single use. Ready-to-Use.
89296325|NCT04295863|Experimental|standard interval dosing|
89296326|NCT04295863|Experimental|extended interval dosing|
89296327|NCT04287608||Patients with qualifying conjunctivitis events|
89296328|NCT04287608||Patients with no clinical signs of eye inflammation|
89296329|NCT04281537||Patient with Fabry Disease on ERT (agalsidase alfa)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase alfa)
89296330|NCT04281537||Patient with Fabry Disease on ERT (agalsidase beta)|Patients with Fabry Disease receiving Enzyme Replacement Therapy (agalsidase beta)
89296331|NCT04281537||Caregiver|Caregiver of patient with Fabry Disease on ERT
89296332|NCT04276805|Active Comparator|tVNS group|Participants will undergo cognitive training with tVNS
89296333|NCT04276805|Sham Comparator|Sham group|Participants will undergo cognitive training with earlobe sham
89296334|NCT04262544|Experimental|mHealth|Intervention group
89296335|NCT04262544|Active Comparator|Usual Care|Control group
89296336|NCT04244162||Study Group|brain scans, cognitive tests, blood biomarkers
89296337|NCT04231526|Experimental|ARM A - Pembrolizumab + Surgery|
89296338|NCT04231526|Active Comparator|ARM B - Surgery|
89296339|NCT04227535||Rheumatoid arthritis - Interstitial lung disease patients|"Assessment are as follows :~Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic: chest HRCT scan~Genetic: DNA, mRNA~Biologic: serum"
89296340|NCT04227535||Rheumatoid arthritis - no Interstitial lung disease patients|"Assessment are as follows :~Clinical: Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic:Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic: chest HRCT scan~Genetic: DNA, mRNA~Biologic: serum"
89296341|NCT04201873|Experimental|Group A (pembrolizumab, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
89531704|NCT05667038|Experimental|Probiotic arm|Drug being used is Hexbio sachet containing 3g / 90 billion CFU. this drug is a formulation containing six microorganism strains (Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120).
89296342|NCT04201873|Active Comparator|Group B (placebo, ATL-DC, poly ICLC)|Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
89296343|NCT04173117|Experimental|Intervention|Low energy meal replacement plan 12 weeks
89296344|NCT04158492|Active Comparator|Standard diagnostic tests|Patients who will undergo only the standard diagnostic procedures
89296345|NCT04158492|Experimental|Experimental + standard diagnostic tests|Patients will undergo described standard diagnostic procedures and in addition, real-time multiplex Protein Chain Reaction (PCR, FilmArray Pneumonia panel Plus ™, Biofire, BioMérieux).
89296346|NCT04147858|Experimental|NYX-2925 50 mg|NYX-2925 50 mg administered orally.
89296347|NCT04147858|Experimental|NYX-2925 100 mg|NYX-2925 100 mg administered orally.
89296348|NCT04147858|Placebo Comparator|Placebo|Placebo administered orally.
89296349|NCT04146896|Experimental|NYX-2925|NYX-2925 50 mg
89296350|NCT04146896|Placebo Comparator|Placebo|Placebo
89296351|NCT04146285|Experimental|BAT4406F|
89296352|NCT04120480|Experimental|Testing|Participants randomized to this arm will be sent a kit to collect a genetic sample from a swab of their mouths. The kit will have instructions on how to collect the genetic sample and how to send it in a postage-paid envelope to the testing laboratory (OneOme). OneOme will process the sample and The study pharmacist will scan the results and enter any related information into the participant's KPCO electronic health record. If any changes to the participant's medication(s) are recommended (for example: a dose decrease or increase, stop taking your current medication and start another), the study pharmacist will contact the participant's KPCO prescriber directly to discuss the recommendations. The prescriber may contact the participant to change the participant's medication(s).
89296353|NCT04120480|No Intervention|Usual Care|Participants randomized to this arm will NOT be tested. They will receive usual care and the research will not involve study visits or in-person contact.
89296354|NCT04092504|No Intervention|Control group|Standard care at the unit
89296355|NCT04092504|Experimental|Gero-Erat|New care pathway that is built on the concept of ERAS and CGA
89296356|NCT04080232|Experimental|Lung MRI|lung MRI concordance as compared to chest CT-scan for the description of morphological abnormalities necessary for the diagnosis of BOS after HSCT. It will be evaluated using lung MRI performed after inclusion (D0) using a standardized procedure
89296357|NCT04072887|Experimental|QBW251 450 mg|QBW251 was orally administered 450 mg b.i.d for 24 weeks
89296358|NCT04072887|Experimental|QBW251 300 mg|QBW251 was orally administered 300 mg b.i.d for 24 weeks
89296359|NCT04072887|Experimental|QBW251 150 mg|QBW251 was orally administered 150 mg b.i.d for 24 weeks
89296360|NCT04072887|Experimental|QBW251 75 mg|QBW251 was orally administered 75 mg b.i.d for 24 weeks
89296361|NCT04072887|Experimental|QBW251 25 mg|QBW251 was orally administered 25 mg b.i.d for 24 weeks
89296362|NCT04072887|Placebo Comparator|Placebo|Placebo was orally administered b.i.d for 24 weeks
89296363|NCT04028609|Experimental|Intervention|Subjects receive an intervention with 4 components: development of a personal health plan; review and support for medication adherence; connection with primary care provider within 30 days; and education about clinical indicators that call for immediate intervention.
89296364|NCT04028609|Active Comparator|Services as Usual|Subjects receive medical services as usual.
89296365|NCT03972813|Experimental|cervical cancer - sexually transmitted (STD) - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
89296366|NCT03972813|Experimental|cervical cancer - STD - 12 years old (y.o.)|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
89296367|NCT03972813|Experimental|cervical cancer - STD - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
89296368|NCT03972813|Experimental|cervical cancer - infectious - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
89296369|NCT03972813|Experimental|cervical cancer - infectious - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
89296370|NCT03972813|Experimental|cervical cancer - infectious - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
88806206|NCT01459705|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
88806207|NCT01459705|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
89296371|NCT03972813|Experimental|cervical cancer - blank - standard|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
89296372|NCT03972813|Experimental|cervical cancer - blank - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
89296373|NCT03972813|Experimental|cervical cancer - blank - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
89296374|NCT03972813|Experimental|many cancers - STD - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
89296375|NCT03972813|Experimental|many cancers - STD - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
89296376|NCT03972813|Experimental|many cancers - STD - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
89296377|NCT03972813|Experimental|many cancers - infectious - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
89296378|NCT03972813|Experimental|many cancers - infectious - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
89296379|NCT03972813|Experimental|many cancers - infectious - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
89296380|NCT03972813|Experimental|many cancers - blank - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
89296381|NCT03972813|Experimental|many cancers - blank - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
89296382|NCT03972813|Experimental|many cancers - blank - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
89296383|NCT03947697|Placebo Comparator|Control|Participants will receive stimulation only up to sensory level.
89296384|NCT03947697|Experimental|NMES|Participants will receive stimulation up to maximum tolerable level.
89296385|NCT03947697|Placebo Comparator|Resistance Training|Participants will receive exercise training with stimulation up to sensory level.
89296386|NCT03947697|Experimental|Resistance Training + NMES|Participants will receive exercise training with stimulation up to maximum tolerable intensity.
89296387|NCT03930342|Experimental|Native CHOICES Intervention|Native-CHOICES will comprise usual care plus 2 MI sessions delivered over 4 weeks; a contraception counseling session at a local clinic; and 3 months of electronic messaging to boost the effects of MI and counseling by increasing perceptions of social connection and social support for behavior change. Contraception counseling will be completed within 2 weeks after the second MI session, so the maximum duration of MI and counseling for each participant will be 6 weeks. Electronic messaging will include positive motivational content consistent with alcohol and contraception use goals set in the MI sessions.
89296388|NCT03930342|No Intervention|Wait-list Control Group|The control condition will comprise usual care for the 6-month study period, with a wait-list design that offers women the Native- CHOICES program after they have completed the 6-month data collection.
89296389|NCT03914794|Experimental|Treatment: Pemigatinib|Patients will receive pemigatinib for 4 to 6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
89296390|NCT03880513||Longitudinal study|Patients during overt and after cure of endogenous Cushing's syndrome.
89296391|NCT03880513||Cross-sectional study|Patients with proven endogenous Cushing's syndrome (overt or subclinical).
89296392|NCT03865667||Primary Total Hip Arthroplasty|Single-arm, single-center, prospective follow-up study with consecutively enrolled newly or previously implanted subjects with the PROFEMUR® Preserve Femoral Stem(s) and CoCr (cobalt-chromium) Modular Neck combined with other Wright Medical Technologies (WMT) or MPO (MicroPort) THA (Total Hip Arthroplasty) components including acetabular shells, acetabular liners and femoral heads.
89296393|NCT03861195||Da Vinci Robotic Surgical System|
89296394|NCT03861195||conventional laparoscopic surgery|
89296395|NCT03836300|Experimental|Infants with a rare neurogenetic condition and their parent/primary caregiver(s)|PIXI
89296396|NCT03785678|Experimental|Tenecteplase|Patients in this arm will receive Tenecteplase (0.25 mg/kg, maximum 25 mg) administered as a single bolus injection over 5 seconds.
89296397|NCT03785678|Placebo Comparator|Placebo|Patients in this arm will receive placebo administered as a single bolus injection over 5 seconds.
89296398|NCT03774719|Experimental|Hand-carried ultrasound arm|This is the only arm of the study. It will be comprised of 154 inpatients who had a renal ultrasound ordered or performed within the past 4 hours. The intervention will be performing hand-carried ultrasound to evaluate for presence and degree of hydronephrosis.
89296399|NCT03729804|Experimental|KRD Arm|Patients assigned to this group will receive a combination of carfilzomib, lenalidomide, and dexamethasone in 28 day cycles. Doses will vary
89296400|NCT03729804|Experimental|VRD Arm|Patients assigned to this group will receive a combination of Bortezomib, lenalidomide and dexamethasone in 21-day cycles. Doses will vary
89296401|NCT03705000|Experimental|Slit Stent II|The Slit Stent II (investigational) device is created by modifying an existing FDA cleared lacrimal stent (BIKA, manufactured by FCI Opthalmics) by adding additional 3 mm and 35 mm long slits of equal depth.
89296402|NCT03705000|Active Comparator|BIKA for DCR|The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device.
89296403|NCT03697564|Experimental|gemcitabine +nivolumab + cabiralizumab|
89296404|NCT03690011|Experimental|CD7.CAR/28zeta CAR T Cells|Three dose levels will be evaluated. The T cells will be administered following lymphodepleting chemotherapy with cyclophosphamide and fludarabine.
89296405|NCT03662126|Experimental|Part A Cohort 1|KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
89296406|NCT03662126|Experimental|Part A Cohort 2|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
89296407|NCT03662126|Experimental|Part A Cohort 3|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
89296408|NCT03662126|Experimental|Part A Cohort 4b|KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
89296409|NCT03662126|Experimental|Part B Arm 1 KRT-232|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
89296410|NCT03662126|Active Comparator|Part B Arm 2 Best Available Therapy|Best available therapy at the discretion of the investigator, on a 28-day cycle.
89296411|NCT03658616|Experimental|WO3970|Formulation containing WO3979 for topical application
89296412|NCT03658616|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
89296413|NCT03500445|Experimental|Treatment Arm (D-KRd)|
89296414|NCT03494530|Other|Early initiation of edoxaban|Participants will be initiated on edoxaban within ≤ 5 days following ischemic stroke
89296415|NCT03494530|Other|Delayed initiation of edoxaban|Participants will be initiated on edoxaban within 6-14 days following ischemic stroke
89296416|NCT03466736||cognitively intact older adults|Each subject will receive an amyloid PET scan with [18F]flutemetamol
89296417|NCT03466736||Mild Cognitive Impairment|Each subject will receive an amyloid PET scan with [18F]flutemetamol
89296418|NCT03466736||Alzheimer's disease|Each subject will receive an amyloid PET scan with [18F]flutemetamol
89296419|NCT03440047|Experimental|Fuji Flim Processor VP-7000|Screening or surveillance colonoscopy using Fuji Flim Processor VP-7000, Light Source BL-7000
89296420|NCT03397134|Experimental|Roluperidone 64 mg|Roluperidone 64 mg for entire study
89296421|NCT03397134|Experimental|Roluperidone 32 mg|Roluperidone mg for entire study
89296422|NCT03397134|Placebo Comparator|Placebo-1|Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension
89296423|NCT03397134|Placebo Comparator|Placebo-2|Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension
89296424|NCT03357562|Experimental|lung MRI|lung MRI without contrast injection
89296425|NCT03324672|Active Comparator|TRIGGER|
89296426|NCT03324672|Experimental|TRIGGER+CURETAPE|
89296427|NCT03275194|No Intervention|Control group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure will be finished.
89296428|NCT03275194|Experimental|HIPEC group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.
89296429|NCT03238976|Experimental|Nature sounds exposure|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~Patients in the nature sounds group will be exposed to continuous nature sounds during the core needle biopsy (CNB) procedure.~The CNB procedure will continue as planned with nature sounds playing instead of the supportive dialogue. All sounds will be played out of a speaker situated in the corner of the room."
89296430|NCT03238976|No Intervention|Standard care (supportive dialogue)|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~The CNB procedure will continue as planned with supportive dialogue which will be played out of a speaker situated in the corner of the room. This group follows the current standard of care."
89296431|NCT03225547|Experimental|Cohort 1|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with hormone receptor positive, hormone refractory advanced breast cancer will be enrolled in cohort 1. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
89296432|NCT03225547|Experimental|Cohort 2|Enrollment will be paused after the first 10 patients are enrolled in the study for a safety evaluation. Once safety is confirmed, patients with triple-negative advanced breast cancer will be enrolled in cohort 2. Regardless of cohort, all eligible patients will be treated with pembrolizumab (on day 1 of every 21 day cycle), and mifepristone (administered daily starting the week prior to pembrolizumab).
89296433|NCT03122119|Experimental|Platelet Rich Plasma Joint Injection|Venous blood will be drawn from the patient receiving injection treatment. It will be spun down to form PRP and reinjected back into the SI joint.
89296434|NCT02990533|Placebo Comparator|Placebo|Placebo Supplement Placebo Injection
89296435|NCT02990533|Experimental|Testosterone|Placebo Supplement Testosterone Injection
89296436|NCT02990533|Experimental|Protein Supplement|Protein Supplement Placebo Injection
89296437|NCT02990533|Experimental|Protein Supplement + Testosterone|Protein Supplement Testosterone Injection
89296438|NCT02969837|Experimental|E-KRd regimen|Participants will receive elotuzumab, carfilzomib, lenalidomide, and dexamethasone.
89296439|NCT02969837|Experimental|E-Rd Regimen|Participants will receive elotuzumab, lenalidomide, and dexamethasone.
89296440|NCT02850809||patients|Treated by percutaneous image-guided radiofrequency for renal tumor
89296441|NCT02815462|Experimental|Intervention|FAM-FACE-SG risk score + decision making algorithm
89296442|NCT02815462|Active Comparator|Control|Usual Care
89296443|NCT02776917|Experimental|Cirmtuzumab + Paclitaxel|"Cirmtuzumab 600 mg is administered intravenously on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Paclitaxel 80 mg/m^2 is administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle."
89296444|NCT02751255|Experimental|daratumumab--> daratumumab + ATRA|In part A of the study patients will be treated with daratumumab as a single agent. In case patients have progressive disease after cycle 1, or in case patients achieve less than minimal response after cycle 2, or patients achieve less than PR after cycle 3, or in case patients experience progression during daratumumab therapy after having obtained a response, then ATRA will be added to daratumumab (part B).
89296445|NCT02748941|Experimental|symptomatic and asymptomatic patients|
89296446|NCT02747303|Active Comparator|Stereotactic Radiosurgery to 2 mm GTV to PTV margins|
89296447|NCT02747303|Experimental|Stereotactic Radiosurgery to 0 mm GTV to PTV margins|
89296448|NCT02707666|Experimental|Pembrolizumab+Surgery+Chemotherapy|Neoadjuvant pembrolizumab, followed by surgery, followed by adjuvant pemetrexed and cisplatin
89296449|NCT02678273|Experimental|Intervention group|Intervention
89296450|NCT02678273|No Intervention|Control group|Standard care when patient is in the hospital. At discharge, patients may be referred to community services as deemed necessary by the hospital team. This is not restricted.
89296451|NCT02659293|Active Comparator|Lenalidomide (Control)|Treatment with lenalidomide only
89296452|NCT02659293|Experimental|Experimental Combination Regimen|Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
89296453|NCT02656511|Experimental|Dolutegravir+Emtricitabine/Tenofovir|Dolutegravir 50 mg PO daily plus Emtricitabine 200 mg/Tenofovir alafenamide 25 mg
89296454|NCT02613169|Experimental|Isoniazid|Isoniazid (INH) ~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.
89296455|NCT02613169|No Intervention|No Isoniazid|No INH will be administered to this arm.
89296456|NCT02611102|Experimental|MCT oil + Butter in Coffee|This group will be provided with MCT oil and butter to add to their daily coffee intake.
89296457|NCT02611102|Placebo Comparator|Low calorie coffee|This group will continue to drink their normal daily coffee with < 50kcal of creamer and/or sweetener.
89296458|NCT02572323|Active Comparator|Immediate group|1.4mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months
89296459|NCT02572323|Placebo Comparator|Deferred group|No treatment is given for 6 months, then 1.4mg of tesamorelin is injected once a day for 6 months
89296460|NCT02441491|Experimental|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, will be given by vein once every day to try to help your blood cells grow faster."
89296461|NCT02437526|Experimental|Treatment interruption|Antiretroviral therapy will be discontinued under close laboratory monitoring and clinical supervision.
89296462|NCT02431988|Experimental|CAR19 T-cells|"Patients will receive a single infusion of CAR19 T-cells following standard pre-conditioning with cyclophosphamide and fludarabine.~The CAR19 T-cells are to be administered on day 0."
89296463|NCT02399371|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.
89296464|NCT02389517|Experimental|Arm I (ixazomib citrate, lenalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
89296465|NCT02389517|Active Comparator|Arm II (lenalidomide)|Patients receive lenalidomide PO as in Arm I.
89296466|NCT02366819|Experimental|Treatment (mFOLFIRINOX, surgery)|"PREOPERATIVE THERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo conventional surgery.~POST-OPERATIVE THERAPY: Beginning 5-10 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 more courses in the absence of disease progression or unacceptable toxicity."
89296467|NCT02281838|Experimental|Target systolic BP <140mmHg|Systolic blood pressure will be reduced to <140 mmHg within 1 hour of randomization.
89296468|NCT02281838|Active Comparator|Target systolic BP <180mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
89296469|NCT02213913|Experimental|Treatment (lenalidomide, DA-EPOCH-R)|"INDUCTION PHASE: Patients receive lenalidomide PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months."
89296470|NCT02004561||Gastric Banding|Patients chose Gastric banding
89296471|NCT02004561||Gastric Bypass|Patients chose gastric bypass surgical operation
89531578|NCT06019624|Active Comparator|Cohort 4 Receipt of Food Box|Up to 80 individuals with diabetes or prediabetes with a history of food insecurity enrolled in a 6 month program offering free bimonthly fresh food boxes, nutrition education, and individualized support. Each enrolled individual will serve as their own control. The study will evaluate pre and post program changes in reported self-obtained home glucose levels, food security, and dietary intake.
89531579|NCT06014957|Experimental|spinal group|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF),immediately positioned supine with one pillow supporting the head and shoulders.
89296472|NCT01974765|Experimental|Enzalutamide|"After signing a screening consent, patients archival tissue will be evaluated for degree of AR positivity by AR staining. Patients with no archival tissue available will undergo a biopsy (using the modality deemed most appropriate by the patient's physician) for collection of tumor tissue for AR positivity by IHC. Only AR+ patients, defined as ≥5 % positivity by IHC, will be included. All IHC testing will be performed in the MSKCC Clinical CLIA approved laboratory.~All enrolled patients will be treated with enzalutamide 160 mg by mouth QD until progression of disease (POD), unacceptable toxicity or withdrawal from study. All treatments will be administered in the outpatient setting."
89296473|NCT01953159||Patients with severe neuropathy|Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.
89296474|NCT01953159||Patients without neuropathy|Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity
89296475|NCT01914094|No Intervention|Standard care|Received current standard care.
89296476|NCT01914094|Experimental|Prehab|Received pre-operative exercise therapy plus education classes concerning management of their risk factors for coronary artery disease at a local medical fitness facility.
89296477|NCT01725217|Experimental|MenACWY-CRM|MenACWY-CRM
89296478|NCT01706432||All participants|"Patients will undergo standard of care radiation therapy and have research blood samples collected at following time points:~pre-treatment~3-4 weeks post-treatment~every 9-12 weeks post-treatment for 1 year"
89296479|NCT01665794|Experimental|PdC Group|Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
89296480|NCT01665794|Experimental|PdC + Dara Group|Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
89296481|NCT01369212|Experimental|Tenofovir|Tenofovir 192 weeks
89296482|NCT01369212|Experimental|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks
89296483|NCT01344057|Other|Sub unit, Inactivated, MF59C.1 Adjuvanted Influenza Vaccine|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
89296484|NCT01017055||Voice and Swallowing Evaluations|
89296485|NCT00977119||Capecitabine|Women with breast cancer receiving capecitabine as treatment for their breast cancer.
89296486|NCT00886782|Experimental|Cdc7-inhibitor|
89296487|NCT00800215|Experimental|1|
89296488|NCT00800215|Placebo Comparator|2|
89296489|NCT00800215|Experimental|3|
89296490|NCT00800215|Placebo Comparator|4|
89296491|NCT00795028|Active Comparator|1|Standard Care for people after a hip fracture
89296492|NCT00795028|Experimental|2|Standard Care + exercise intervention
89296493|NCT00583024|Experimental|Adenovirus/PSA Vaccine|Participants will receive three injections of 0.16 ml. (0.125 ml. vaccine + 0.035 ml. Gelfoam) of the Ad/PSA subcutaneously
89296494|NCT00337649|Experimental|Phase I - Epothilone D Dose Escalation|
89296495|NCT00337649|Experimental|Phase II - Epothilone D Maximum Tolerated Dose|
89296496|NCT00071084|Experimental|HuMax-CD4 280 milligrams (mg)|
89296497|NCT00071084|Experimental|HuMax-CD4 980 mg|
89296498|NCT00057304|Experimental|RO 205-2349 2 mg QD|RO 205-2349 2 mg was taken once daily (QD) for 16 weeks during the double-blind treatment period.
89296499|NCT00057304|Experimental|RO 205-2349 5 mg QD|RO 205-2349 5 mg was taken once daily (QD) for 16 weeks during the double-blind treatment period.
89296500|NCT00042406|Placebo Comparator|Placebo|
89296501|NCT00042406|Experimental|HuMax-CD4 80 milligrams (mg)|
89296502|NCT00042406|Experimental|HuMax-CD4 160 mg|
89296503|NCT01281774|Experimental|CSL112|Multiple ascending intravenous doses of CSL112
89296504|NCT01281774|Placebo Comparator|Placebo|Multiple intravenous infusions of placebo
89296505|NCT01170078|Experimental|Arm A: Epoetin Hospira administered IV for three doses|
89296506|NCT01170078|Active Comparator|Arm B: Epogen administered IV for three doses|
89296507|NCT01283490|Active Comparator|DASD Group|Benzocaine 20% will be placed using the DASD for one minute. Immediately after DASD application a needle puncture with a 27 gauge needle to the depth of 3 millimeters will be performed.
89296508|NCT01283490|Sham Comparator|Sonic Vibration (SV)|A modified tooth brush which only allows sonic vibration (SV), that has the appearance and sound of the DASD will be used to apply the benzocaine 20% for one minute. Following application with the SV a needle puncture with a 27 gauge needle to the depth of 3millimeters.
89296509|NCT01283568||1 - Gamaline+Hipericin - fertile women|
89296510|NCT01283568||2- Gamaline+Hipericin - climateric women|
89296511|NCT01283568||3- Gamaline- control - fertile women|
89296512|NCT01283568||4 - Gamaline control - climateric women|
89296513|NCT01283646|Experimental|Apevitin BC|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
89296514|NCT01283646|Active Comparator|Vitamin B Complex + Vitamin C|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
89296515|NCT01283724|Experimental|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
89296516|NCT01586442|Active Comparator|Spironolactone|spironolactone 12.5mg once daily titrated to 25mg once daily
89296517|NCT01586442|Experimental|Eplerenone|Eplerenone 25mg once daily titrated to 50mg once daily
89296518|NCT01587066|Active Comparator|Quetiapine fumarate|
89296519|NCT01587066|Active Comparator|Divalproex sodium|
89296520|NCT03873948||Control|Healthy patients
89296521|NCT03873948||Periodontitis|Patients with periodontal disease
89296522|NCT03873948||Cardiovascular|Patients with cardiovascular disease
89296523|NCT03873948||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
89531705|NCT05656976|Experimental|A Self sampling device (SSD) provided by the general practitioner (GP)|A self sampling device will be provided by the GP.
89296524|NCT01587144|Placebo Comparator|Placebo|Participants will receive a matching placebo as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
89296525|NCT01587144|Active Comparator|Lucanthone|Participants will receive Lucanthone as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
89296526|NCT03870984|Experimental|wNUTS, low-caloric diet plus nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
89296527|NCT03870984|Other|w/oNUTS, low-caloric diet without nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
89296528|NCT01587222|Experimental|Albumin, Midodrine, Octreotide|
89296529|NCT01170234||Eosinophilic esophagitis (EoE)|Treatment-naïve EoE patients, age 7 -65
89296530|NCT01167660||Healthy newborn babies|Healthy newborn babies immediately after birth.
89296531|NCT01167660||Sick newborn babies|Sick newborn babies whose medical condition indicates performing coagulation tests.
89296532|NCT01167738|Experimental|PEXG regimen + metformin|cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
89296533|NCT01167738|Active Comparator|PEXG regimen|cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15
89296534|NCT01272726||ADHD|Women with symptoms of ADHD. Women who either think they may have ADHD or have been previously diagnosed with ADHD but have not been treated for it.
89296535|NCT01167816|Experimental|azacitabine|
89296536|NCT01167894|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
89296537|NCT01167894|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
89296538|NCT03870828||Study group IPAF|"Patients with IPAF which is defined according to the Work Group of the European Respiratory Society/American Thoracic Society.~The interventions to be administered include:bronchoalveolar lavage and taking bronchial mucosa samples lung function tests,6 minute walk test, use of cough and dyspnea scales, transthoracic echocardiography, blood testing, arterial blood gas and pulse oximetry"
89296539|NCT03870828||Control group CTD-ILD|Patients with connective tissue disease associated intestitial lung disease: rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM, dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjögren's syndrome - SjS, mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE, diagnosed according to diagnostic criteria issued by European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR)
89296540|NCT03870828||Control group ILD|Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF, nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP, acute interstitial pneumonia - AIP; respiratory bronchiolitis associated interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP, lymphocytic interstitial pneumonia - LIP).
89296541|NCT01167972||1|
89296542|NCT01283802||IOCUS|
89296543|NCT03868878|Experimental|Capoeira training group|The experimental protocol for Capoeira program lasted 12 weeks and was performed twice a week with duration of 60 minutes each with warm-up, basic movements in the modality, and 20 minutes with theoretical instructions related to Capoeira and musicality.
89296544|NCT03868878|Sham Comparator|Control group|While the Capoeira group performed the entire class, the Control group performed only the final part (20 minutes) with musicality - singing and touch of typical instruments - and theoretical instructions related to Capoeira.
89296545|NCT03869112|Experimental|Physical activity intervention|Physical activity group will be given a FitBit device to monitor their PA, especially steps count Step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home based intervention.
89296546|NCT03869112|Experimental|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
89296547|NCT03869112|No Intervention|Usual care|Usual care group will have the standard follow up care by rehabilitation clinic without being in any physical intervention.
89296548|NCT01168050|Experimental|Nilotinib|
89296549|NCT01170312|Active Comparator|Autologous conditioned plasma|
89296550|NCT01170312|Placebo Comparator|Normal saline|
89296551|NCT01165710||001|Patients with Atrial Fibrillation (AF) Treatment patterns of AF according to patient demographics clinical factors risk stratification and geographic regions.
89296552|NCT03870594||diabetic|patients suffer from diabetes mellitus
89296553|NCT03870594||non diabetic|patients free from diabetes with normal blood glucose level
89296554|NCT01165788||autologous BMT recipients|Lymphoma patients who received an autologous BMT as adults
89296555|NCT01165866|Active Comparator|Treatment 1.|Metoclopramide 0.3 mg/kg max 10 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline as a single intravenous dose. Complete blood count,serum electrolytes,renal function,HCO3 level will be requested.Oral fluid will be started thereafter and increased gradually until patient discharge.
89296556|NCT01165866|Other|Treatment2.|Ondansetron 0.15 mg/kg max 4 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline to be given over 10 minutes,then patient will be kept NPO for one hour after completion of the anti emetic infusion and last episode of vomiting . Oral fluid will be started thereafter and increased gradually until fully tolerated and the patient is ready for discharge
89531580|NCT06014957|Experimental|saddle block group|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF),placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders.
89531581|NCT06014346|No Intervention|Control group|EFS usual standard practices for the whole blood donation
89531706|NCT05656976|Experimental|B Self sampling device provided by letter|A self sampling device will be provided by letter.
89296557|NCT02504697||Longitudinal Cohort|For this longitudinal screening cohort, we will enroll 800 participants who currently or historically smoked and who have a 10 year Bach risk model of lung cancer > 2.5% (5). We will include participants 50 to 79 years old, with ≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less. In order to further enrich for lung cancer risk, participants also will have COPD/emphysema or at least one first-degree relative with a diagnosis of lung cancer. We will exclude patients previously diagnosed with lung cancer. These patients will be followed for a total of 4 years with annual follow-up visits. Biosamples from airway and blood and images will be collected.
89296558|NCT01168128|Experimental|Tailored Action Plan|A Tailored Action Plan is an intervention selected to overcome barriers identified before the design and delivery of the intervention.
89296559|NCT01170468|Experimental|Vitamin D3|Vitamin D3 5000 IU daily
89296560|NCT01170468|Placebo Comparator|Placebo|Placebo daily
89296561|NCT01273584|Active Comparator|Metformin|"Tablet Metformin 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
89296562|NCT01273584|Placebo Comparator|Placebo|"Tablet Placebo 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
89296563|NCT03868800|Other|SDM-DC|All adult patients with kidney failure referred to a department of renal medicine at one of the four hospitals from the 1st of October 2016 to the 31st of May 2018 were offered the intervention and invited to participate in the study. The inclusion criterion was an estimated glomerular filtration rate below 20 ml/min and based on a clinical judgement made by the contact doctor and/or the contact nurse about the decline in the Estimated glomerular filtration rate to continue. Exclusion criteria were patients who had decided on conservative management, patients with a living donor and a set date for transplantation and patients not able to participate in the intervention due to cognitive impairment. The use of an interpreter was not an exclusion criterion.
89296564|NCT03868644|Experimental|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
89296565|NCT03868644|Experimental|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
89296566|NCT03868644|Experimental|VCT and Condoms|Youth are offered both VCT and condoms.
89296567|NCT03868644|No Intervention|Control|No intervention is provided (beyond the standard available HIV prevention services within the area)
89296568|NCT01168206|Placebo Comparator|Placebo|
89296569|NCT01168206|Experimental|TK3|1 capsule, 3 times per day.
89296570|NCT01168362||High risk group|positive cardiovascular risk group
89296571|NCT01168362||Low risk group|negative cardiovascular risk group
89296572|NCT01274052||Gestational Diabetes Mellitus|Women with Gestational Diabetes Mellitus
89296573|NCT01274052||Normal Glucose Tolerance|Women with Normal Glucose Tolerance
89296574|NCT01281852|Experimental|Treatment (paclitaxel, cisplatin, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IV over 1 hour on day 2, and veliparib PO on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89296575|NCT01170780|Placebo Comparator|Placebo|Saline
89296576|NCT01170780|Active Comparator|Dexamethasone|Corticosteroid (Fortecontin 8 mg)
89296577|NCT01274208||Gaucher Disease with Hepatitis C|
89296578|NCT01165944|No Intervention|Standard diabetes therapy|Standard diabetes therapy with either oral agents or insulin injections
89296579|NCT01165944|Active Comparator|Oral diabetic agents and pramlintide|
89296580|NCT01165944|Active Comparator|Insulin injection with pramlintide|
89296581|NCT03870516|Placebo Comparator|Valve replacement according to guideline parameters|One group will be referred for surgery according according to indications for mitral valve replacement in European guidelines for valvular heart diseases published in 2017 and will have speckle tracking echocardiography before surgery and 6 months later for comparison.
89296582|NCT03870516|Active Comparator|Early valve replacement|The other group will include patients with severe asymptomatic mitral regurgitation who have left atrial or left ventricular dysfunction according to speckle tracking echocardiography and will be referred to surgery, then speckle tracking echo will be performed 6 months later.
89296583|NCT01166022|Experimental|Exercise|Muscle strengthening program using weights and resistance bands in combination with a home based cycle ergometry program. The home-based exercise program will be performed up to 5 times weekly.
89296584|NCT01166022|No Intervention|Typical Activity|Subjects in this group will be asked to maintain their typical daily activity. Those assigned to this arm will be given the opportunity to join the intervention arm seven months after their screening visit.
89296585|NCT01281930|Experimental|Wick placement into abscess cavity|
89296586|NCT01281930|Active Comparator|Full packing of abscess cavity|
89296587|NCT01282008||Focus Groups|Focus Groups about smoking messages
89296588|NCT01170858|Experimental|Icodextrin group|7.5% icodextrin dialysis solution
89296589|NCT01170858|Active Comparator|glucose solution group|2.5% or 4.25% glucose dialysis solution
89296590|NCT01170936|Experimental|Canakinumab|
89296591|NCT03868488|Experimental|Visual imagery tasks group|During the intervention, each participant of this group will be asked to create visual mental images.
89296592|NCT03868488|Experimental|Auditory imagery tasks group|During the intervention, each participant of this group will be asked to create auditory mental images.
89296593|NCT01171014|Experimental|High dose probiotic|Bifidobacterium lactis HN019, 10 billion cfu/day
89296594|NCT01171014|Experimental|Low dose probiotic|Bifidobacterium lactis HN019, 1 billion cfu/day
89296595|NCT01171014|Placebo Comparator|Placebo|Placebo
89296596|NCT01274832||Late-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease > 10 years
89296597|NCT01274832||Early-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease <7 years
89296598|NCT01276392||Heparin|10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
89296599|NCT01276392||CiCa|10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
88806208|NCT01460875|Experimental|Treatment (interferon therapy)|Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
88806209|NCT01481545|Experimental|preoperative chemoradiotherapy|Preoperative radiation therapy and combination chemotherapy plus bevacizumab
89296600|NCT01171092|Experimental|bortezomib and G-CSF|
89296601|NCT01171170|Active Comparator|carboplatin-paclitaxel-bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
89296602|NCT01171170|Experimental|standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
89296603|NCT03868176||Experimental: reminder SMS before appointment|SMS before appointment detailing the date of consultation and exams to be performed before
89296604|NCT03868176||Active comparator: standard of care|
89296605|NCT01282320|Experimental|Increased Physical Activity|Individually tailored training one hour, 2-3 sessions per week.
89296606|NCT01282320|No Intervention|"Activity as usual (Buisness as usual)"|
89296607|NCT03873324|Experimental|CPL500036|"PART A: 7 cohorts are to receive single dose of IMP. Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
89296608|NCT03873324|Placebo Comparator|Placebo|PART B: 2 Participants from 4 cohorts (total of 8 people) are to receive masking placebo capsules once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
89296609|NCT01166100|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
89296610|NCT01166100|Active Comparator|Prozac ® weekly TM|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
89296611|NCT01166256|Experimental|High-flow nasal cannula|In this arm,patients with acute hypoxemic respiratory failure were treated with high-flow nasal cannula system(Optiflow, Fisher & Paykel, Auckland, New Zealand) to achieve SpO2 >92% or PaO2 >65 mmHg.
89296612|NCT01166256|Active Comparator|Non-invasive ventilation|In this arm, patients with acute hypoxemic respiratory failure is treated with the bi-level positive airways pressure mode (BiPAP Vision, Respironics Inc., Murrysville, PA) S/T mode to achieve SpO2 >92% or PaO2 >65 mmHg.
89296613|NCT03870282|Experimental|9h 15m Goal|
89296614|NCT03870282|Experimental|"9h 15m Goal | Texts B"|
89296615|NCT03870282|Experimental|"9h 15m Goal | Texts A"|
89296616|NCT03870282|Experimental|"9h 15m Goal | Texts A&B"|
89296617|NCT03870282|Experimental|"9h 15m Goal | Incentive B"|
89296618|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts B"|
89296619|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A"|
89296620|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A&B"|
89296621|NCT03870282|Experimental|"9h 15m Goal | Incentive A"|
89296622|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts B"|
89296623|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A"|
89296624|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A&B"|
89296625|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B"|
89296626|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts B"|
89296627|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts A"|
89296628|NCT03870282|Experimental|"9h 15m Goal | Incentives A&B | Texts A&B"|
89296629|NCT03870282|Experimental|Personal Goal|
89296630|NCT03870282|Experimental|"Personal Goal | Texts B"|
89296631|NCT03870282|Experimental|"Personal Goal | Texts A"|
88806210|NCT01482091|Placebo Comparator|Intranasal Saline|
88806211|NCT01482091|Experimental|Intranasal Fentnayl|
88806212|NCT00325598|Experimental|Cohort 1 (36 Gy)|36 Gy in 9 fractions BID x 4 1/2 treatment days
88806213|NCT00325598|Experimental|Cohort 2 (40 Gy)|40 Gy in 10 fractions BID over 5 treatment days
88806214|NCT05265884|Experimental|Group A (Kinesio taping group)(Experimental group):|This group includes 30 patients who will receive Kinesiotaping, in additional to traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
88806215|NCT05265884|Active Comparator|Group B (control group)|This group includes 30 patients who will receive traditional treatment only (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for 1 month.
89296632|NCT03870282|Experimental|"Personal Goal | Texts A&B"|
89296633|NCT03870282|Experimental|"Personal Goal | Incentive B"|
89296634|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts B"|
89296635|NCT03870282|Experimental|"Personal Goal | Incentive B | Text A"|
89296636|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts A&B"|
89296637|NCT03870282|Experimental|"Personal Goal | Incentive A"|
89296638|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts B"|
89296639|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A"|
89296640|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A&B"|
89296641|NCT03870282|Experimental|"Personal Goal | Incentive A&B"|
89296642|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts B"|
89296643|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts A"|
89296644|NCT03870282|Experimental|"Personal Goal | Incentives A&B | Texts A&B"|
89296645|NCT03870126|Placebo Comparator|Flavored Beverage Mix 1|Flavored still beverage
89296646|NCT03870126|Experimental|Flavored Beverage Mix 2|Flavored still beverage with polyphenols, concentration 1
89296647|NCT03870126|Experimental|Flavored Beverage Mix 3|Flavored still beverage with polyphenols, concentration 2
89296648|NCT03870126|Experimental|Flavored Beverage Mix 4|Flavored still beverage with caffeine
89296649|NCT03868098|Active Comparator|Crisaborole 2% (application rate A, B, C)|Crisaborole (Marketed drug)
89296650|NCT03868098|Placebo Comparator|Placebo ointment (vehicle)|Placebo
89296651|NCT01171248||type 1 diabetes|
89296652|NCT01171248||non-diabetics|
89296653|NCT01166334|Active Comparator|WebQuit study group|Intervention arm 1 (identity and description withheld to protect integrity of study)
89296654|NCT01166334|Active Comparator|WebQuit control group|Intervention arm 2 (identity and description withheld to protect integrity of study)
89296655|NCT01277016|No Intervention|MDex:|"MDex:~Administration of oral melphalan (M) at 0.22 mg/kg and dexamethasone (Dex) at 40 mg daily for 4 consecutive days every 28 days (MDex) until end of therapy"
89296656|NCT01277016|Experimental|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
89296657|NCT01168752|Experimental|schedule A|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
89296658|NCT01168752|Experimental|schedule B|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as a daily schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
89296659|NCT01277250|Other|Usual Care|Standard smoking cessation information provided to all hospitalized patients as part of discharge packet.
89296660|NCT01277250|Experimental|Smoking Cessation Program|"Web-based program tailored to patients who smoke and are hospitalized. Program is tailored to participant's specific hospital experience and other characteristics. E-messages, social support and a transition coach are provided to each participant in this condition."
89296661|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 4%|Minocycline Foam FXFM244 - 4%
89296662|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 1%|Minocycline Foam FXFM244 - 1%
89296663|NCT01171404||1|Patients, older than 18, hospitalized within 24 hours of onset of symptoms and diagnosed with UA, STEMI or NSTEMI
89296664|NCT01171482|Experimental|The FM group|Patients in the FM group will be administered 5-FU plus mitomycin
89296665|NCT01171482|Active Comparator|The sorafenib group|Patients in the sorafenib group will be administered sorafenib
89296666|NCT01171560|Active Comparator|EZ Blocker|Patients assigned to the EZ group will be intubated using a conventional tube in an adequate size as it is standard of care and single lung ventilation will be provided using the EZ-Blocker.
89296667|NCT01171560|Active Comparator|Double lumen tube|"The patients assigned to the double lume tube group will be intubated using the double lume tube in an adequate size as it is standard of care."
89296668|NCT01171638||Critical Controls|"Critically injured patients with NO severe traumatic lower extremity injuries to provide normative data for the critically injured physiological status upon arrival at study site"
88806216|NCT03111758|Active Comparator|Geko Device|Neuromuscular Stimulator
89296669|NCT01171638||Investigational cohort|"Soldiers with severe traumatic lower extremity injuries in stable or critical physiological status presenting to a participating study site within 12 hours of their injury, to provide data on the acute post-injury phase. This cohort will be made up of:~Patients meeting inclusion criteria for investigational cohort, who have UNILATERAL severe lower extremity injuries~Patients meeting inclusion criteria for investigational cohort, who have BILATERAL severe lower extremity injuries.~Patients meeting inclusion criteria for investigational cohort, who have been clinically diagnosed by the treating provider using that treating providers standards for diagnosing ACS and the patient in addition to be diagnosed with ACS undergoes four-compartment leg fasciotomy."
89296670|NCT01171716|Other|Dietary Protein Intake|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
89296671|NCT01284036|Other|PF-05230905|9 subjects will participate in each dose cohort. 6 subjects will receive investigational product (PF-05230905) and 3 subjects will receive placebo
89296672|NCT01168830|Experimental|Investigational device|
89296673|NCT01282398|Experimental|simvastatin|The experimental group will take simvastatin 40mg for at least two years.
89296674|NCT01282398|Placebo Comparator|placebo|the control group wiil take placebo pills for at least two years.
89296675|NCT01169142|Active Comparator|Immediate Vitamin D3|Will start Vitamin D3 immediately
89296676|NCT01169142|Active Comparator|Three month delay|Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
89296677|NCT01169220|Experimental|Split prep|
89296678|NCT01169220|Active Comparator|Whole prep|
89296679|NCT01169298|Experimental|Lenalidomide|Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
89296680|NCT01169454||Monitor then drain|Subjects who are treated with intermittent CSF drainage
89296681|NCT01169454||Drain then monitor|Subjects who are treated with continuous CSF drainage at set pressure thresholds
89296682|NCT03867942|Active Comparator|monolayer group|monolayer of Gemigliptin/Rosuvastatin
89296683|NCT03867942|Experimental|bilayer group|bilayer of Gemigliptin/Rosuvastatin
89296684|NCT01277484|Experimental|Decitabine, MDS treatment, IV injection|For the patients who achieve remission after allogeneic BMT and meet the enrollment criteria, decitabine will be given at a dose of 5mg/kg/day ~ 15mg/kg/day iv over 1 hour for 5 consecutive days starting 42-90 days after transplantation. The drug will be repeated every 4 weeks for up to 12 cycles.
89296685|NCT01282632|Experimental|Risperidone|Commence at 0.5 mg once daily Increase, blindly, to 1 mg and then by 1 mg at discretion of clinicians through weeks 1-4 to a maximum of 3 mg.
89296686|NCT01282632|Experimental|Olanzapine|Commence at 2.5 mg once daily Increase to 5.0 mg, blindly, and then by 5 mg at the discretion of the clinician through weeks 1 - 4 to a maximum of 15 mg
89296687|NCT03873090|Experimental|SBRT in 4 fraction|Selected intermediate risk prostate cancer patients treated with 4 fraction SBRT
89296688|NCT03867786|Experimental|Exercise Condition|Participants will undergo a 40 minute exercise protocol
89296689|NCT03867786|Active Comparator|Video Control Condition|Participants will view a 40 minute nature video
89296690|NCT01172028|Experimental|Alimta and Taxotere|Alimta and Taxotere given in combination with dose modifications.
89296691|NCT02525952|Experimental|Hepatectomy with NDR 0-2|Surgical removal of all lesions for patients with a NDR score 0-2 according to the NDR scoring system
89296692|NCT02525952|Active Comparator|TACE with NDR 0-2|Transarterial chemoembolization for patients with a NDR score 0-2 according to the NDR scoring system
89296693|NCT02525952|Experimental|Hepatectomy with NDR >2|Surgical removal of all lesions for patients with a NDR score more than 2 according to the NDR scoring system
89296694|NCT02525952|Active Comparator|TACE with NDR >2|Transarterial chemoembolization for patients with a NDR score more than 2 according to the NDR scoring system
89296695|NCT01166490|Experimental|1|ASG-5ME
89296696|NCT01282788|No Intervention|Traditional Diet|Infants in communities randomized to the traditional diet arm will not receive food supplements.
89296697|NCT01282788|Experimental|Cereal|All infants in communities randomized to the Cereal Arm will receive caterpillar cereal from 6-18 months of age.
89296698|NCT01278186|Experimental|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun)
89296699|NCT01278186|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent
89296700|NCT01282944|Experimental|Combined Financial Incentive & Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Subjects connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. Participants also receive weekly feedback regarding which participants in the peer group achieved their walking goals during the previous week.~Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200.~Financial incentive and peer network terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
89296701|NCT01282944|No Intervention|Active Control|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or peer networks in this group."
89296702|NCT01282944|Experimental|Financial Incentive Arm|Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 2 months.
89296703|NCT01282944|Experimental|Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period.~Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant will be given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. All participants in a peer network will receive a list of ways in which his or her new network could support each individual's walking goals. Participants will also receive weekly feedback regarding which participants in the peer group were successful in achieving their walking goals during the previous week.~Peer network is terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
89296704|NCT02526108|Experimental|HIFT|High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions.
89296705|NCT01172106|Placebo Comparator|Encouragement on drug compliance|The intervention for the placebo comparator will be encouragement on drug compliance
89296706|NCT01172106|Experimental|Family psychoeducation|The experimental group will receive weekly sessions of psychoeducation for 12 weeks in addition to receiving drug compliance encouragement
89296707|NCT01284192|Experimental|ASP3026|Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)
89296708|NCT02526732|Experimental|individual training program|Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.
89296709|NCT03872934||Turkish music group|Turkish music group (Saba or rast makam)
89296710|NCT03872934||classical western music|classical western music (vivaldi)
89296711|NCT03872934||soft rock music|soft rock music (elvis)
89296712|NCT03872934||control group (group not listening music)|control
89296713|NCT01284270|Other|All Patients|All patients undergo the same study procedures
89296714|NCT01278264|Active Comparator|iTAP-group|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
89296715|NCT01278264|Active Comparator|aTAP-group|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
89296716|NCT03867864|Experimental|Group A|Group A participants will wear the necklace with essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace without essential oil for last 4 weeks (the sixth to ninth weeks).
89296717|NCT03867864|Other|Group B|The group B will wear the necklace without essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace with essential oil for last 4 weeks (the sixth to ninth weeks).
89296718|NCT03867708||patients with residual shunt|patient with residual left to right shunt detected by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
89296719|NCT03867708||patients without residual shunt|patient without residual left to right shunt by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
89296720|NCT01172574|Experimental|Motor control exercise|Subjects of the exercise group underwent a 3-month (13-week) treatment program directed on 3-weekly 1-hr one-to-one sessions by the researcher who had experience in the specific exercise treatment of the spinal region. During the next 3 months, the subjects were urged to perform the exercises alone at home at least once a day, and compliance was monitored by the activity quota chart given to them at the beginning of each study-month.
89296721|NCT01172574|No Intervention|Control group|The control group underwent treatment throughout a 6-month period, directed by each patient's medical practitioner. This consisted of the patients carrying out regular weekly general exercises (walking and swimming). Three of them regularly attended other treatment providers involving group general exercise programs. Two patients received the application of local pain-relieving methods such as heat, massage, laser and ultrasound and one did nothing except for receiving osteoporotic medication.
89296722|NCT01172652|Experimental|ziprasidone|
89296723|NCT01172652|Placebo Comparator|Placebo|
89296724|NCT01278732||untreated persons with suspected hypertension|
89296725|NCT03867630||Runoff Group|Runoff group are the patients whose images were shown root shadow by contrast media.
89296726|NCT03867630||Nonrunoff-Transforaminal group|Nonrunoff-Transforaminal group are the patients whose images are not shown root shadows by contrast media, so additional transforaminal blocks are done.
89296727|NCT03867630||Nonrunoff-NonTransforaminla group|Nonrunoff-NonTransforaminal group are the patients whose images are not shown root shadows by contrast media, but no additional transforaminal blocks are done.
89296728|NCT02526030|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day, during study duration
89296729|NCT02526030|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
89296730|NCT02526030|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
89296731|NCT03867474|Experimental|Intervention (MBSR)|Mindfulness-Based Stress Reduction (MBSR) - Intervention Arm
89296732|NCT03867474|No Intervention|Control - Usual Care|Control
89296733|NCT01172730||Ultrasound scanning|
89296734|NCT01278888|Active Comparator|PLEACE 1|Anterolateral vs. posterolateral thoracotomy
89296735|NCT01278888|Active Comparator|PLEACE 2|Video assisted thoracic surgery (VATS) vs. anterolateral thoracotomy
89296736|NCT01172262||Bothered Tinnitus|Either responds with a Global Tinnitus Scale of Moderately or Severely Bothered. Score >30 on the Tinnitus Handicap Index (THI).
89296737|NCT03872622|Other|CD patients|New onset Crohn's disease patients
89296738|NCT03872622|Other|Healthy controls|Patients' family members and healthy subjects undergoing colonoscopy for non-research purposes
89296739|NCT01172340|Experimental|Behavioral and support intervention|one individual counseling session with diet and exercise recommendations plus 16 weeks of group sessions, plus 8 weeks of phone followup
89296740|NCT01172340|Placebo Comparator|wait-listed control group|Controls receive individual counseling session and recommendations, mailed health information, and after post-test measures are offered an abbreviated group-based intervention
89296741|NCT03867240|Experimental|Gabapentin|Gabapentin is a common neuropathic medication used in the treatment of chronic pain. Gabapentin will be given preoperative and continued for 5 days postoperatively.
89296742|NCT03867240|Placebo Comparator|Placebo|Control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group.
89296743|NCT03468660|Experimental|Experimental group|Auditory training with feedback
89296744|NCT03468660|No Intervention|Passive control group|Pre-post testing only; no training
89296745|NCT03468660|Active Comparator|Active Control group|Listening task with no feeback
89296746|NCT01172964|Experimental|Arm I|Patients undergo debulking craniotomy and receive injections of HB1.F3.CD neural stem cells directly into brain tissue on day 0. Patients then receive oral 5-fluorocytosine every 6 hours on days 4-10 in the absence of disease progression or unacceptable toxicity.
89296747|NCT03866928|Experimental|Stiripentol|
89296748|NCT03435354|Experimental|Intervention|Physical activity counselling during cardiac clinic visit with additional supports for community physical activity and access to a kinesiologist.
89296749|NCT03435354|No Intervention|Usual Care|Cardiac clinic visit with usual care but no physical activity counselling
89296750|NCT03866694|Experimental|BRIGHT|Building Resilience through Intervention: Growing Healthier Together (BRIGHT) weekly home-based intervention from the third trimester of pregnancy through 6 months postpartum. A licensed clinician meets with mother and infant to promote attunement and optimal parent-child interactions. Additionally, the mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic
89296751|NCT03866694|Active Comparator|STAR/TAU+|The mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic.
89296752|NCT02526576|Experimental|Stromal Vascular Fraction|Subjects will receive stromal vascular fraction assisted fat transfer.
89296753|NCT02526576|Active Comparator|Biopsy for Control -regular fat transfer|Subjects will receive regular fat transfer. A biopsy procedure will analyzes the different between experimental and control groups.
89296754|NCT01172496|Experimental|1 mg tablet; 1mg solution|
89296755|NCT01172496|Experimental|1mg solution; 1mg tablet|
89296756|NCT01279824|Active Comparator|Usual Care|Patients will receive behavioral swallowing therapy comprising combination's of treatment strategies / exercises chosen from an approved hierarchy. This formulation of treatment will be designed and applied by the treating clinician.The treatment will be provided daily for a one-hour over a consecutive 3-week period.
89296757|NCT01279824|Placebo Comparator|sham NMES|Patients will receive behavioral swallowing therapy comprising combinations of treatment strategies / exercises chosen from an approved hierarchy with the addition of non stimulating electrodes. A faux NMES device will be utilized with an active current display and non stimulating electrodes. The treatment will be provided daily for a one-hour over a consecutive 3-week period.
89296758|NCT01279824|Experimental|NMES therapy|Patients will receive a protocol of standardized behavioral swallowing intervention combined with NMES. This formulation of treatment will be prescribed from a standard protocol and will be applied daily for one-hour over a consecutive 3-week period.
89296759|NCT03863886|Experimental|Crohn's Disease|20 patients with Crohn's disease with at least colonic involvement will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
89296760|NCT03863886|Experimental|Ulcerative Colitis|20 patients with ulcerative colitis will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
89296761|NCT03863886|Experimental|Non-IBD Controls|20 patients without inflammatory bowel disease (controls) will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
89296762|NCT01284582|Experimental|ATH03 Group A|ATH03, 10 µg, 0.2% Alum
89296763|NCT01284582|Experimental|ATH03 Group B|ATH03, 30 µg, 0.2% Alum
89296764|NCT01284582|Experimental|ATH03 Group C|ATH03, 100 µg, 0.2% Alum
89296765|NCT01166880||Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
89296766|NCT01284660|Active Comparator|I. DHA|Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel).
89296767|NCT01284660|Placebo Comparator|II. Placebo|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
89296768|NCT01175070|Experimental|Pegaptanib|Participants receiving 6-weekly treatment with pegaptanib sodium (Macugen [TM]) for ischaemic diabetic macular oedema over a 30 week period.
89296769|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 minutes|Blood test
89296770|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 7 minutes|Blood test
89296771|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 15 minutes|Blood test
89296772|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 30 minutes|Blood test
89296773|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1 hour|Blood test
89296774|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1.5 hours|Blood test
89296775|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2 hours|Blood test
89296776|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2.5 hours|Blood test
89296777|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 hours|Blood test
89296778|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3.5 hours|Blood test
89296779|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4 hours|Blood test
89296780|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4.5 hours|Blood test
89296781|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 5 hours|Blood test
89296782|NCT01280136|Experimental|It's Your Game Tech|An interactive web-based HIV, sexually transmitted infection (STI), and pregnancy prevention program for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
89296783|NCT03863652||Snuffboxer|Patients undergoing percutaneous coronary intervention via snuffbox approach
89296784|NCT01178034|Experimental|pharmacogenetic warfarin dose|Warfarin maintenance dose on the basis of demographic/pharmacogenetic data
89296785|NCT01286298|Experimental|Laser gingivectomy|
89296786|NCT03863418|Experimental|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG (10 billion Colony Forming Units/CAPSULE)
89296787|NCT03863418|Placebo Comparator|placebo|maltodextrin
89296788|NCT01286376|Active Comparator|symbiotic|
89296789|NCT01286376|Placebo Comparator|placebo|
89296790|NCT01175304||Workers in a Barcelona tertiary hospital|Workers attending annual medical checkups
89296791|NCT01286532||1|Children (male or female) aged 5 to 11 years inclusive on step 3 asthma combination therapy with ICS(inhalation glucocorticosteroids) and LABA ( long-acting b2-agonist) who have completed at least one valid CACT assessment after the study entry
89296792|NCT01284738|Active Comparator|TM patients|thalassemia major (TM) Need transfusion for survive
89296793|NCT01284738|Active Comparator|TI patients|thalassemia intermedia (TI) Patients with TI have a milder clinical phenotype than those with TM
89296794|NCT01284816|Other|severely obese patients|35 patients addressed for severe obesity in the Endocrinology department of Marseille North Hospital before (V1) and 6 months (V2) after bariatric surgery
89296795|NCT01173198|Active Comparator|WAVEFRONT GUIDED LASIK|
89296796|NCT01173198|Active Comparator|WAVEFRONT OPTIMIZED|
89296797|NCT03866304|Experimental|Picosecond Laser|Treatment with investigational wavelengths of the S2 laser for tattoo removal.
89296798|NCT03866616|Active Comparator|Control (usual care)|"Behavioral: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
89296799|NCT03866616|Experimental|Intervention (group sessions)|Behavioral: Brain Builders Parenting Class-intervention (BBPC). Participants who are selected via the lottery to participate in the BBPC program will be asked to attend six, 1-hour classes, every other week over a 12 week period of time.
89296800|NCT01284894|Other|Conventional manometry|
89296801|NCT01284894|Experimental|High resolution manometry|
89296802|NCT01288170|Other|Nebcinal Tobi|crossover design
89296803|NCT01288170|Other|Tobi Nebcinal|crossover design
89296804|NCT01178112|Experimental|Trientine + Carboplatin MTD Group|Trientine starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group.
89296805|NCT01178112|Experimental|MTD Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group
89296806|NCT01178112|Experimental|Carboplatin PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
89296807|NCT01178112|Experimental|Trientine PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
89296808|NCT01173354|Experimental|COPD patients only|Free balanced amino acid mixture or free essential amino acid mixture
89296809|NCT01175460|Experimental|Chemoradiotherapy|Thoracic radiation 60Gy over 30 fractions.Concurrently, nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 was given on Days 1-14,repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
89296810|NCT01175538|Experimental|Lactulose|
89296811|NCT03860688|Experimental|Teduglutide + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
89296812|NCT01173432|Active Comparator|continuous positive airway pressure|using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)
89296813|NCT01173432|No Intervention|control|observation for the study period (4 weeks, no CPAP)
89296814|NCT01288248|Experimental|Airway laryngeal mask classic|Ventilation with Airway laryngeal mask classic during surgery
89296815|NCT01288248|Active Comparator|endotracheal tube|Ventilation with endotracheal tube during surgery
89296816|NCT01288326||A|
89296817|NCT01173510|Experimental|Raltegravir plus tenofovir/emtricitabine|
89296818|NCT01173510|Active Comparator|Efavirenz/Emtricitabine/Tenofovir|
89296819|NCT01173588|Experimental|Yogurt+fiber+probiotic|Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
89296820|NCT01173588|Placebo Comparator|regular yogurt|yogurt YR had no additional fiber or bifidobacterium
89296821|NCT01284972||HINTEGRA|Patient Implanted with the HINTEGRA Total Ankle Prosthesis more than 2 years ago
89296822|NCT01175616|Experimental|Creatine|Open-Label Active Treatment with Creatine 5 grams daily for 8 weeks.
89296823|NCT03863340|Experimental|short interruptions of work tasks|randomly start with or without short interruptions on the first experimental day and without or with them on the second experimental day
89296824|NCT01286610|Other|vibration therapy and electrical muscle stimulation|
89296825|NCT01178190||lung cancer|
89296826|NCT03860454||Lamin DCM (LMNA+)|Adults with known pathogenic lamin (LMNA+) gene mutation.
89296827|NCT03860454||Wild types DCM (DCMwt)|Adults with heart muscle failure but normal (wild-type) LMNA gene (DCMwt).
89296828|NCT03860454||Healthy Volunteers (HV)|Matched healthy volunteers (HV).
89296829|NCT03435640|Experimental|NKTR-262 + bempegaldesleukin or + bempegaldesleukin with nivolumab|Phase 1: NKTR-262 in escalating doses, combined with bempegaldesleukin. The goal of this dose escalation part of the study is to establish a recommended Phase 1b dose for NKTR-262 + bempegaldesleukin with nivolumab, followed by a dose-confirmation cohort.
89296830|NCT01175694|Active Comparator|Brachytherapy|Interstitial multicatheter brachytherapy
89296831|NCT03860298|Experimental|NaviFUS System|FUS treatment for 10 minutes
89296832|NCT01175772|Experimental|Metronomic Chemoterapy|Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy
89296833|NCT01173666|Placebo Comparator|Drug therapy|Patients will be treated by standard medical therapy.
89296834|NCT01173666|Experimental|Drug therapy + stenting angioplasty|Patients will be treated by standard medical therapy + stenting angioplasty of renal artery.
89296835|NCT01536964|Experimental|Morphine|the effect of morphine on prasugrel absorption will be tested
89296836|NCT01536964|Placebo Comparator|Saline|
89296837|NCT01288404|Placebo Comparator|Control|topical 0.1% fluorometholone eye drops
89296838|NCT01288404|Active Comparator|Bevacizumab group 1|Bevacizumab 1.25 mg/0.05mL
89296839|NCT01288404|Active Comparator|Bevacizumab group 2|Bevacizumab 2.5 mg/0.1mL
89296840|NCT01288404|Active Comparator|bevacizumab group 3|bevacizumab 3.75 mg/0.15mL
89296841|NCT01285206|Experimental|Routine practice|
89296842|NCT01307878|Experimental|arm A|Pre-PTR, chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
89296843|NCT01307878|No Intervention|arm B|Upfront PTR, then chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
89296844|NCT03860220|Active Comparator|NEWSTATIN TS|Triple therapy (Telmisartan + Amlodipine + Rosuvastatin 40/5/10mg)
89296845|NCT03860220|Placebo Comparator|CADUET|Dual therapy (Amlodipine + Atorvastatin 5/10mg)
89296846|NCT01568476|Active Comparator|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
89296847|NCT01568476|Active Comparator|Interneural|sciatic nerve blockade at the site of bifurcation
89296848|NCT01173744|Experimental|Gamma-3 Nail|
89296849|NCT01173744|Active Comparator|DHS|
89296850|NCT01285284|Experimental|Music|A previously defined list of songs will be administered by headphones to these patients during the colonoscopy.
89296851|NCT01285284|Sham Comparator|Control|These patients will receive an MP3 device (and headphones) which will be functioning but without volume.
89296852|NCT03862872|Experimental|Anti-Aging Formula|4 capsules daily of high-EPA fish oil, borage oil, zeaxanthin, lutein and vitamin D providing 1050 mg of Eicosapentaenoic acid (EPA) and 350 mg of Docosahexaenoic acid (DHA), 120 mg of Gamma-linolenic acid (GLA), 2.5 mg of zeaxanthin, 5 mg of lutein and 25 μg (1000 IU) of vitamin D3 for 90 days.
89296853|NCT03862872|Active Comparator|Control Fish Oil|4 capsules daily of 1,106 mg each of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil providing 816 mg EPA and 572 mg DHA total for 90 days.
89296854|NCT03862872|Placebo Comparator|Inert Placebo|4 capsules daily of 1040 mg each of corn oil for 90 days.
89296855|NCT03862794|Experimental|high total and high broad spectrum prescribing letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
89296856|NCT03862794|Active Comparator|high total and high broad spectrum prescribing control|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
89296857|NCT03862794|Experimental|high total prescribing only intervention letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
89296858|NCT03862794|Active Comparator|high total prescribing control letter|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
89296859|NCT03862794|Experimental|moderate total prescribing and high broad spectrum letter|social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
89296860|NCT03862794|No Intervention|moderate total prescribing and high broad spectrum control|GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.
89296861|NCT03859986|Experimental|ALX-101 Gel 5%|ALX-101 Gel 5% applied topically twice daily for 56 days
89296862|NCT03859986|Placebo Comparator|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle applied topically twice daily for 56 days
89296863|NCT01175928|Experimental|Peristaltic Pulse PCD|Peristaltic Pulse Pneumatic Compression Device (NormaTec PCD)
89296864|NCT01175928|Sham Comparator|Sham Device|Sham Pneumatic Compression Device (looks and sounds like real device, but applies no compression)
89296865|NCT02525640|Experimental|Hearing Aid|CROS hearing aid
89296866|NCT01178346|Experimental|NicVAX|Experimental vaccine
89296867|NCT01178346|Placebo Comparator|Placebo|Placebo vaccine
89296868|NCT01173822|Experimental|Treatment group|Ultra filtration of residual blood.
89296869|NCT01173822|No Intervention|Control|The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.
89296870|NCT01286688|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
89296871|NCT01286688|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
89531582|NCT06014346|Experimental|Test Group 1|"A psychological strategy is added to EFS standard practices before the whole blood donation~flyer given at the interview presenting the 4 most frequent fears as well as a description of the recommended muscular and breathing exercises,~followed by a training of these exercises and their execution"
89296872|NCT01178424|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of mindfulness skills taught in the program.
89296873|NCT01178424|Active Comparator|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
89296874|NCT03859518||patients with Vitiligo|
89296875|NCT03859518||control|
89296876|NCT03863028||Novice|Residents with no individual experience in TUR-B defined as no prior hands-on surgical experience in TURB
89296877|NCT03863028||Intermediates|Residents who have performed 10 to 30 TURBs.
89296878|NCT03863028||Experienced|Consultants with experience in the procedure defined as more than 100 TURBs.
89296879|NCT01176084|Experimental|low carbohydrate diet|
89296880|NCT01176084|Experimental|diet & exercise|
89296881|NCT01173900|Other|Class-based delivery|All girls attending standard 6 in schools selected for class-based vaccine delivery
89296882|NCT01173900|Other|Age-based delivery|All girls born in 1998 attending schools selected for age-based delivery
89296883|NCT03866070|Experimental|Experimental|The subjects that are part of the experimental group will carry out the intervention thought the performance of strengthening exercises of the shoulder and scapula, and capsular stretches.
89296884|NCT03866070|Active Comparator|Control|Subjects that are part of the control group will perform shoulder strengthening exercises exclusively.
89296885|NCT01288482|Experimental|Asthma Subjects|
89296886|NCT03859830|Experimental|Artis Dialysis System|One midweek HDF session for a duration of 4 hours.
89296887|NCT03859830|Active Comparator|AK200 Ultra S|One midweek HDF session for a duration of 4 hours.
89296888|NCT01286766|Active Comparator|DCS|DCS: docetaxel with cisplatin with TS-1
89296889|NCT01286766|Active Comparator|DCF|DCF : docetaxel with cisplatin with 5-FU
89296890|NCT01286844|Experimental|Cohort 1|Subjects ≥4 and< 12 years. First 6 subjects included, ≥8 and< 12 yrs and weigh ≥21kg, receive 1 SD (10mg) and an 8 day RD period (100mg). Remaining subjects in cohort: Subjects < 21kg receive 2 SD periods (10mg and 50mg), Subjects > 21kg receive 2 SD periods (10mg and 50mg) and an 8 day RD (100mg)
89296891|NCT01286844|Experimental|Cohort 2|Subjects ≥1 and< 4 years, receive 2 SD (5mg and 25mg)
89296892|NCT01288638|Experimental|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
89296893|NCT01288638|Placebo Comparator|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
89296894|NCT03862638|Experimental|Yoga Therapy|Yoga therapy session lasted for 60 minutes consisting physical posture, Breath work, Relaxation, guided meditation, chants and combination techniques for groups sessions.
89296895|NCT02525484|Experimental|Pirfenidone ACBD treatment sequence|Participants will be given 801 milligrams (mg) single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 1 and in fasted state (treatment C) on Day 4, 801-mg tablet in fed state (treatment B) on Day 7 and in fasted state (treatment D) on Day 10.
89296896|NCT02525484|Experimental|Pirfenidone BADC treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fed state (treatment B) on Day 1, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 4, 801-mg tablet in fasted state (treatment D) on Day 7 and capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 10.
89296897|NCT02525484|Experimental|Pirfenidone CDAB treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 1, 801-mg tablet in fasted state (treatment D) on Day 4, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 7 and 801-mg tablet in fed state (treatment B) on Day 10.
89296898|NCT02525484|Experimental|Pirfenidone DBCA treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fasted state (treatment D) on Day 1 and in fed state (treatment C) on Day 4, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 7 and in fed state (treatment A) on Day 10.
89296899|NCT01173978|Experimental|No intervention|Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
89296900|NCT01173978|Experimental|Intervention|Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
89296901|NCT03865758|Experimental|IN2L enhanced therapy|The intervention to be delivered is the use of the IN2L computer system to deliver video, music, and exercises to patients receiving physical and occupational therapy. Therapists will select the specific IN2L that will be most appropriate given each person's rehabilitation goals and personal preferences.
89296902|NCT03865758|No Intervention|Usual OT and PT services without IN2L|The intervention to be delivered is physical therapy and occupational therapy to improve functioning.
89296903|NCT01174056|Experimental|Pioglitazone+zileuton placebo|Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days
89296904|NCT01174056|Experimental|Zileuton+pioglitazone placebo|Sugar pill qD for 2 weeks plus Zileuton 600 mg q6hr for 5 days
89296905|NCT01174056|Sham Comparator|Pioglitazone placebo+zileuton placebo|Sugar pill qD for 2 weeks plus Sugar pill q6hr for 5 days
89296906|NCT01174134|Placebo Comparator|Milk-based beverage w/out DHA|
89296907|NCT01174134|Experimental|Milk-based beverage with DHA|
89296908|NCT01174134|Experimental|Milk-based beverage containing DHA at a higher level|
89296909|NCT03859596||MGB/OAGB|Consequent group of patients who underwent MGB/OAGB
89296910|NCT01174212|Experimental|Experimental|Patients receiving antibiotics approximately 1 hour prior to incision are considered to be in the experimental group of this study.
89296911|NCT01174212|Other|Control|Control group is to receive no antibiotics until the intraoperative cultures have been obtained.
89296912|NCT01174290|Experimental|Haloperidol 1mg IV q6h|
89296913|NCT01174290|Placebo Comparator|D5W 0.2mL IV q6h|
89296914|NCT03859440|Experimental|DSiHy (test lens)|
89296915|NCT03859440|Active Comparator|Silicone hydrogel soft contact lens CE-marked for daily use|
89296916|NCT01176162||"Group < 28"|• Gestational Age < 28 weeks
89296917|NCT01176162||"Group 28 - < 33"|• Gestational Age : 28 - < 33 weeks
89296918|NCT01176162||"Group 33- < 37"|Gestational Age : 33- < 37 weeks
89296919|NCT01176162||"Group > 37"|Gestational Age > 37 weeks
89296920|NCT03862560|Experimental|Experimental group|Female soccers that perform a strength training
89296921|NCT03862560|No Intervention|Control group|Female soccers that do not perform a strength training
89296922|NCT03862404|Placebo Comparator|Control group|Patients in this group receive Normal Saline injection in the inter pleural space
89296923|NCT03862404|Experimental|Experimental group|Patients in this group receive Bupivacaine 0.25% + Epinephrine 5 mcg/ml injection in the inter pleural space
89296924|NCT01285440||Diagnostic Imaging|
89296925|NCT03865680|Experimental|MI varnish|MI Fluoride varnish: 5% sodium fluoride varnish water based, sugar free containing RecaldentTM (CPP-ACP) (GC AMERICA INC.3737 West 127th Street, Alsip, IL 60803 U.S.A). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
89296926|NCT03865680|Active Comparator|Duraphat Fluoride varnish|Duraphat Fluoride: varnish 5% sodium fluoride varnish (Colgate, New York, N.Y.). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
89296927|NCT01288716|Placebo Comparator|Placebo|
89296928|NCT01288716|Active Comparator|Arbaclofen|
89296929|NCT03862248|Experimental|High-Dose Isoniazid|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
89296930|NCT03862248|Experimental|High-Dose Rifampicin|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
89296931|NCT03862248|Active Comparator|World Health Organisation (WHO) regimen|WHO levofloxacin-strengthened regimen (6EHRZLfx)
89296932|NCT00655876|Experimental|Chemoradiation + Cetuximab|External beam radiation therapy (RT) with concurrent weekly paclitaxel, cisplatin, and cetuximab
89296933|NCT00655876|Active Comparator|Chemoradiation|External beam radiation therapy with concurrent weekly paclitaxel, and cisplatin
89296934|NCT01176318|Experimental|erdosteine|standard care plus erdosteine for 10 days
89296935|NCT01176318|Placebo Comparator|placebo|Standard care for exacerbation of COPD plus placebo
89296936|NCT01178658|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
89296937|NCT01178736||Cancer Screening and Diagnosis|Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.
88806217|NCT03111758|Active Comparator|IPCS|Intermittent Pneumotic Compression Stocking
88806218|NCT05261360|Experimental|SF-MSC-EX Treatment Group (Experimental group's left knees)|The left knee will receive 1 million cells/kg SF-MSC-EX (Synovial fluid mesenchymal stem cell-derived exosome) by intra-articular injection method.
89296938|NCT03862326|Other|Group Training|Group Training of the women with incontinence - with 5-8 women in each group. This is also Usual Care
89296939|NCT03862326|Experimental|Individual training|Individual pelvic floor exercises one-to-one with the physiotherapist
89296940|NCT03862326|Experimental|Individual training with biofeedback|Individual pelvic floor exercises one-to-one with the physiotherapist but with ultrasound used as biofeedback, and to check if the women are contracting the right muscles.
89296941|NCT00585832|Experimental|DASH-4-Teens Intervention|DASH-4-Teens Intervention is described in detail in Couch, SC et al. Hypertension 2021: 77:241-251.
89296942|NCT00585832|Other|Routine Care|Routine Care is described in detail in Couch, SC et al. Hypertension 2021: 77:241-251.
89296943|NCT03092752||Patients with T2DM|
89296944|NCT03750552|Experimental|ampreloxetine|Participants randomized to ampreloxetine will receive a single, oral, daily dose of active drug for 4 weeks.
89296945|NCT03750552|Placebo Comparator|Placebo|Participants randomized to Placebo will receive a single, oral, daily dose of placebo for 4 weeks.
89296946|NCT03750240|Experimental|Triple Negative Breast Cancer Patients|scanned 4 times to assess breast cancer response to NACT with the proposed method.
89296947|NCT01174524|Experimental|gestoden and ethinylestradiol|"Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.~The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients."
89296948|NCT01178892|Placebo Comparator|Placebo|
89296949|NCT01178892|Experimental|Omega-3|
89296950|NCT01178892|Experimental|Yoga|
89296951|NCT01178892|Experimental|Exercise|
89296952|NCT01178892|Other|Usual Activity 1|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
89296953|NCT01178892|Other|Usual Activity 2|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
89296954|NCT03865368|Experimental|Active Whole Body Vibration Training|Exercises were taught during the first session, active training was done in the second session, and acute evaluations were made during the third session. Both groups performed the dynamic exercises, under supervision, on the whole body vibration device with 10-second rest intervals. Throughout the WBVT session, the vibration amplitude was set to 2 mm and exercise frequency 30 Hz.
89296955|NCT03865368|Active Comparator|Control Group|The same exercises as the aWBVT group were performed on the vibration platform, with the vibration application turned off
89296956|NCT01287234|Other|All Patients|All patients will have an echocardiogram and SonR sensor readings completed.
89296957|NCT03859284|Active Comparator|flowable resin-composite|"3M flowable composite is a conventional restoration to treat anterior carious cervical lesions. considered to be the gold standard of the flowable composites.~other names: ''flowable composite ''"
89296958|NCT03859284|Experimental|self-adhering flowable|intervention one is moist bonding self adhering flowable composite that binds to tooth without an adhesive system
89296959|NCT03859284|Experimental|self-adhering flowable with adhesive|intervention two moist bonding self adhering flowable composite that binds to tooth with the aid of adhesive system to improve the clinical performance
89296960|NCT02525328||CT subjects|blood or saliva specimen
89296961|NCT02525328||subjects without CT|blood or saliva specimen
89296962|NCT02525172|Experimental|ITT|immune modulation therapy
89296963|NCT01176396|Active Comparator|Caries prevention active intervention|Patients receive CAMBRA related products like CHX, 5000ppm F-toothpaste etc according to their risk level
89296964|NCT01176396|Placebo Comparator|control treatment|Patients receive treatment according to standard of care
89296965|NCT03865134||Laser Group|Children with premature retinopathy treated with Laser therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
89296966|NCT03865134||Anti-VEGF Group|Children with premature retinopathy treated with anti-VEGF therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
89296967|NCT03865134||Regrese Group|Children with premature retinopathy haven't applied any invasive treatment method. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
89296968|NCT01285674|Experimental|Intra-tympanic steroid injection|
89296969|NCT01179126|Experimental|complete multivessel revascularization|
89296970|NCT01179126|Active Comparator|stress echo guided revascularization|
89296971|NCT01285752|Experimental|1|
89296972|NCT01285752|Experimental|2|
89296973|NCT01285752|Active Comparator|3|
89296974|NCT03865056|Experimental|High-Flow Nasal Cannula|
89296975|NCT03865056|Experimental|Noninvasive ventilation|
89296976|NCT01568554||Group 1|Group 1 will include subjects 15 years of age or older who are a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP), and have not had any previous genetic testing for porphyria themselves.
89296977|NCT01568554||Group 2 (Not Yet Enrolling)|Group 2 will consist of subjects 15 years of age or older who have a history of clinical features suggestive of acute porphyria, such as such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity, and an increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins.
89296978|NCT01568554||Group 3|"Subjects in Group 3 will participate in the Follow Up Sub-Study. This group will include individuals who have been seen by one of the Porphyria Consortium physicians/investigators for suspicion of porphyria 10 or more years prior to study initiation, but were not given a diagnosis of porphyria at the time of their initial visit."
89296979|NCT01179204||Patiens operated with TKA|
89296980|NCT03365596||Subacute stroke|
89296981|NCT01174602|Experimental|Exposure Therapy for AN (AN-EX/RP)|Exposure Therapy and Ritual Prevention (AN-EX/RP) includes 12 sessions of confronting feared eating situations without the use of anxiety reducing behaviors.
89296982|NCT01174602|Active Comparator|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT)
89296983|NCT03300804|Active Comparator|20-herb formulation|Active herb
89296984|NCT03300804|Placebo Comparator|Placebo|Placebo herb formulation
89296985|NCT05598892|Experimental|Robot-assisted Rehabilitation|Participants will receive rehabilitation based on hand robotic exosqueleton (ROBHAND, ITAP Valladolid, Spain) Patients will perform upper limb exercises assisted by the device. Training involve 16 sessions, 2 sessions per week for 8 weeks, each lasting about 60 minutes.
89296986|NCT01287390|Active Comparator|standard radiotherapy treatment|These patients receive the normal standard treatment.
89296987|NCT01287390|Experimental|adaptive radiotherapy|These patients receive the adaptive image-guided intensity-modulated radiotherapy (IMRT) for head and neck cancer.
89296988|NCT03336112|Experimental|Intervention group|5 weeks guided internet-delivered cognitive behavioral therapy program The program consists of psychoeducation, exposure to physical activity, and awareness (mindfulness) training.
89296989|NCT03336112|Active Comparator|Control group|Information program delivered by the Internet during 5 weeks.
89296990|NCT01179282|Placebo Comparator|PLACEBO|PLACEBO NASAL SPRAY
89296991|NCT01179282|Active Comparator|DUST MITE ALLERGEN|Subjects will use dust mite Dermatophagoides pteronyssinus (Dp) extract or placebo nasal spray at home for 2 weeks, with a 1 month washout period followed by 2 weeks of the other nasal spray.
89296992|NCT03859362|Experimental|Ertapenem in urosepsis|Ertapenem PK studies were carried out on the 3rd dose of ertapenem administration. Blood samples (3 mL) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the start of ertapenem administration. All blood samples were added to a heparinized tube and centrifuged at 1,000 g for 10 min at 4°C within 5 min.
89296993|NCT01287468||Experimental Group|
89296994|NCT01287468||Control Group|
89296995|NCT01287546|Experimental|LY2875358|
89296996|NCT01287546|Experimental|LY2875358 + erlotinib|
89296997|NCT01287546|Experimental|LY2875358 at Part A highest dose|
89296998|NCT01287546|Experimental|LY2875358 at Part A highest dose + trametinib|
89296999|NCT05598268|Experimental|T3011 Herpes Virus Injection|
89297000|NCT03182166|Experimental|Patients treated with golimumab|"The optimization procedure is:~For patients treated at 50 mg of golimumab every 4 weeks (less than 80 kg) will have an increase dose of golimumab: 100 mg every 4 weeks for 8 weeks. They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies.~For patients treated at 100 mg of golimumab every four weeks (more than 80 kg) will have an increase dose of golimumab: treated at 100 mg every 2 weeks for 4 weeks.~They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies."
89297001|NCT01285830|Placebo Comparator|Placebo|
89297002|NCT01285830|Active Comparator|Lactobacillus reuteri|
89297003|NCT03091738|Experimental|Ramelteon Pill|Patients given ramelteon and re-evaluated after 15 days of therapy
89297004|NCT01179360||Imaging group|
89297005|NCT03631888||patients scheduled for elective laparoscopic surgery|
89297006|NCT01174680|Experimental|patients with stable angina pectoris|stable patients, who have been admitted to one of the participating centres for an elective coronary angiography
89297007|NCT03859050|Experimental|LPS arm|
89297008|NCT03193216|Experimental|Alginate group|Patients in this group will be taking the study medication -- alginate solution in addition to standard of care twice daily proton pump inhibitor therapy
89297009|NCT03864822|Experimental|Active tDCS|30s ramp to 2mA with 20 minute session of active High-Definition Transcranial Direct Current Stimulation at 2mA
89297010|NCT03864822|Placebo Comparator|Sham tDCS|30s ramp to 2mA with High-Definition Transcranial Direct Current Stimulation, then device stops stimulating for 20 minutes
89297011|NCT03864978|Experimental|Rifaximin-EIR 800 mg BID for 10 days|2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
89297012|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 30 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days
89297013|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 10 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
89297014|NCT03864978|Placebo Comparator|Two placebo tablets BID for 30 days|2 x placebo tablets twice a day for 30 days
89297015|NCT05597956|Experimental|white defects|Evaluate the infiltration of the defects.
89297016|NCT05597956|Experimental|yellow defects|Evaluate the infiltration of the defects.
89297017|NCT05597956|Experimental|Brown defects|Evaluate the infiltration of the defects.
89297018|NCT03862092|Experimental|Patients with acute abdominal pain|Salivary VZV-DNA PCR was performed in patients who visited the emergency room due to acute abdominal pain.
89297019|NCT01568788|Experimental|Inactivated Influenza Vaccine|15μg HA/strain/0.5ml/syringe, Hualan Biologicals
89297020|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of Pasteur|15ug HA/strain/0.5ml/syringe, Sanofi Pasteur
89297021|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of GSK|15ug HA/strain/0.5ml/syringe, GSK
89297022|NCT01287624|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin)
89297023|NCT01287624|Active Comparator|Gemcitabine, Paclitaxel|GT (gemcitabine and paclitaxel combination)
89297024|NCT05597800|Experimental|Cohort A: HBV and HCV patients|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections, such as HBV and HCV in cohort A.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
89297025|NCT05597800|Experimental|Cohort B: HIV patients|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections such as HIV in cohort B.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
89531583|NCT06014346|Experimental|Test Group 2|A physiological strategy is added to EFS standard practices before the whole blood donation : - Ingesting a salty snack.
89531584|NCT06014346|Experimental|Test group 3|"The both psychological and physiological strategies are added to EFS standard practices before the whole blood donation~flyer given at the interview presenting the 4 most frequent fears as well as a description of the recommended muscular and breathing exercises,~followed by a training of these exercises and their execution Ingesting a salty snack."
89531585|NCT06013163|Active Comparator|Xenical - EMP22 part 1 crossover blinded|After a 5-day diet run-in period, orlistat in its conventional form (Xenical®, 120 mg orlistat) will be taken 3 times daily (ter in die [TID]) together with the 3 main daily meals for a 9-day treatment period. After a 4-to-14-day wash-out period; EMP22 (120 mg modified release orlistat) will be taken TID together with the 3 main daily meals for a 9-day treatment period.
89297026|NCT05597800|Experimental|Cohort C: Long COVID syndrome|"Participants (≥ 18 years) must have histologically confirmed metastatic or unresectable non-small cell lung cancer (both non-squamous and squamous), without sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations, with chronic viral infections such as Long Covid syndrome in Cohort C.~Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2 Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m2."
89297027|NCT01176552|Experimental|Study group: GM-CSF, IFN, IL-2|
89297028|NCT05597644|Experimental|females with adenomyosis|
89297029|NCT01287702|Experimental|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
89297030|NCT01287702|Active Comparator|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL.
89297031|NCT05597566||Elderly depression patients with suicidal ideation|Conformity: Age 60-85 years old; meet DSM-5 diagnostic criteria for major depressive disorder; currently in acute phase, HDRS-17 ≥ 24; history of suicide attempt in this depressive episode; current suicidal ideation, SIOSS ≥ 12.Exclusions: Patients with unstable physical diseases; patients currently suffering from acute inflammatory infection or chronic inflammatory disease; participated in another interventional clinical study within the past 1 month; previous or current diagnosis of other psychiatric diseases by DSM-IV ; abuse of alcohol and active drugs within 12 months, except for nicotine; severe aphasia, visual and hearing impairment, etc. unable to complete the scale evaluation; MECT treatment contraindications; pregnant, lactating women or planning pregnancy; allergic to propofol and succinylcholine chloride.
89297032|NCT03859206|Experimental|empyema patients having medical thoracoscopy|"patients having empyema will undergo medical thoracoscopy as follow :~With the closed biopsy forceps, step by step, fibrinous septae will be perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken & If no lesion, biopsy from parietal pleura was obtained from any sites.~the intervention : is breaking the septation within the loculated empyema"
89297033|NCT03859206|No Intervention|tube thoracostomy in patients with empyema|after confirmation of diagnosis of empyema Following , a chest tube (gauge 26-28) will be introduced and connected to underwater seal. The wound was then closed around the tube by stitches to fix it in position.
89297034|NCT01285986|Experimental|Vein collar at distal anastomosis|Vein collar at the distal anastomosis
89297035|NCT01285986|Experimental|No vein collar at the distal anastomosis|No vein collar at the distal anastomosis
89297036|NCT03864666|Other|Sequence 1|Treatment RTRT
89297037|NCT03864666|Other|Sequence 2|Treatment TRTR
89297038|NCT01174758||Parkinson's disease|Individuals participating in the study have been diagnosed with idiopathic Parkinson's disease.
89297039|NCT03858972|Experimental|Tesetaxel (oral) and capecitabine (oral)|"Cohort 1: Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle.~Cohort 2: On Cycle 1, Day -1, either a single morning dose of capecitabine at 825 mg/m2 (Cohort 2A) or 1,250 mg/m2 (Cohort 2B). On Cycle 1, Day 1, a single dose of tesetaxel (27 mg/m2), followed 2 hours later by capecitabine (825 mg/m2), followed by an evening dose of capecitabine (825 mg/m2). Capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the morning dose on Day 2 through evening dose on Day 14 of Cycle 1. Starting with Cycle 2, tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle."
89297040|NCT03091348|Experimental|SQ - IM|Subcutaneous testosterone injection followed by intramuscular testosterone injection
89297041|NCT03091348|Experimental|IM - SQ|Intramuscular testosterone injection followed by subcutaneous testosterone injection
89297042|NCT02525016|Experimental|assessment of plasmatic lidocaine rate|Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine
89297043|NCT01179594|Placebo Comparator|A|
89297044|NCT01179594|Experimental|B|
89297045|NCT01179594|Placebo Comparator|C|
89297046|NCT01179594|Experimental|D|
89297047|NCT03751098|Other|1-TR/PE, 2-Placebo, 3-Placebo|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye.
89297048|NCT03751098|Other|1-Placebo, 2-Placebo, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the designated treatment in each eye.
89297049|NCT05595226|Experimental|RT3D-TEE-guided mitral valve repair|Two experienced surgeons and two experienced echocardiography technicians jointly formulated the plan for the TEE-guided mitral valve repair.
89297050|NCT05595226|No Intervention|Control|
89297051|NCT05576428|Active Comparator|DIET& EXERCISE|diet plan & daily 20 minutes brisk walking.
89297052|NCT05576428|Experimental|N Acetylcysteine WITH DIET & EXERCISE|NAC 200mg BD along with diet plan & exercise.
89297053|NCT03751020|Experimental|Expressive Writing (EW)|Expressive Writing (EW) prompts individuals to write about personally stressful events, potentially enabling cognitive processing of unresolved, psychological and physiological stressors.
89297054|NCT03751020|Experimental|Self-Affirmation (SA)|Self-Affirmation (SA) interventions prompt individuals to write advice to a (hypothetical) similarly stigmatized person regarding how best to cope with stigma-related stress. By affirming one's own stigmatized identity through the process of helping another similarly stigmatized person.
89297055|NCT03751020|Placebo Comparator|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days.
89297056|NCT01176708|Experimental|Liver transplanted|10 Liver transplanted patients
89297057|NCT01176708|Experimental|Kidney transplanted|10 kidney transplanted individuals
88806219|NCT05261360|Experimental|SF-MSC Treatment Group (Experimental group's right knees)|The right knee will receive 1 million cells/kg SF-MSC (Synovial fluid-derived mesenchymal stem cell) by intra-articular injection method.
89297058|NCT01176708|Experimental|Healthy controls|10 healthy controls
89297059|NCT01288794|Active Comparator|Standard medical treatment plus albumin|The patients will receive standard medical treatment (diuretics) plus weekly albumin infusion
89297060|NCT01288794|Other|Standard medical treatment|The patients will receive the standard medical treatment (diuretics), but non albumin for the therapy of ascites
89297061|NCT03861546|Experimental|Healthy lifestyle Shared Medical Appointment (SMA) program|South Asian (SA) adults with prediabetes and Type 2 Diabetes (T2D) that are 'information rich' and have variation in background characteristics will be identified. Dyads (spouses, parent/adolescent or young adult child, peers) will participate in a 16-week culturally-tailored, community-informed pre-post SMA intervention to improve health behaviors.
89297062|NCT01288872|Experimental|Praziquantel|45 women in 3 cohorts (15 early pregnancy: 12-16 weeks gestation; 15 late pregnancy: 30-36 weeks gestation; and 15 lactating nonpregnant women who are 5-7 months (inclusive) postpartum) given praziquantel (PZQ), 60 mg/kg orally in split dose (30 mg/kg each) separated by 3 hours.
89297063|NCT01286064|Experimental|patient with colo-rectal cancer|fluorescence spectra will be mainly characterized by the presence of an emission peaking at 620-630 nm
89297064|NCT01286064|Active Comparator|patient without colo-rectal cancer|fluorescence spectra will be characterized by the absence of an emission peaking at 620-630 nm
89297065|NCT03864354||Participants|Participants were adults with a diagnosis of asthma, treated using a standardized Osteopathic Manipulative Treatment protocol.
89297066|NCT03864588|Placebo Comparator|Control|Anesthesiologist preforms ultrasound guided adductor canal block post-operatively
89297067|NCT03864588|Experimental|Intervention|Surgeon preforms inter-operative adductor canal block
89297068|NCT03861312|Experimental|Neck Laterality|It was done with 20 images of necks and 4 seconds for each image in the Vanilla program of the tablet application.
89297069|NCT03861312|Experimental|Foot Laterality|It was done with 20 images of feet and 4 seconds for each image in the Vanilla program of the tablet application.
89297070|NCT01176864|Active Comparator|Double-balloon enteroscopy|DBE for suspected or known small-bowel bleeding
89297071|NCT01176864|Active Comparator|Single-balloon enteroscopy|SBE for suspected or known small-bowel bleeding
89297072|NCT03858660||Elderly|Healthy elderly No intervention.
89297073|NCT01176942|Experimental|Probiotic|
89297074|NCT01176942|Placebo Comparator|Placebo|
89297075|NCT03090100|Experimental|Group I: Guselkumab Plus Placebo|Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
89297076|NCT03090100|Active Comparator|Group II: Secukinumab|Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
89297077|NCT03864432|Experimental|25mg SAD|
89297078|NCT03864432|Experimental|50mg SAD|
89297079|NCT03864432|Experimental|100mg SAD|
89297080|NCT03864432|Experimental|50mg Multiple dosing|
89297081|NCT01288950|Experimental|Vitamin D3|
89297082|NCT01288950|No Intervention|Placebo|
89297083|NCT01174914|Experimental|Naltrexone Low-dose 3mg capsule|Each person in this arm 1 of the study had never received any ARV drugs and in this study received only one Low-Dose Naltrexone 3mg capsule nightly for 9 months (no placebo).
89297084|NCT01174914|Active Comparator|Naltrexone Low Dose + ARVs|In this Arm 3, Patients were on ARV's plus being given Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months.
89297085|NCT01174914|Placebo Comparator|ARV's (continued,standard) plus Placebo|In this arm 2, patients were started or continued on their standard ARV drugs plus placebo capsule once daily at bedtime; in the 2nd and 3rd arms patients did not know whether they were taking Low-Dose Naltrexone or a placebo.
89297086|NCT03858738||group A: women aged 25-49 years|"Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5.~Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device."
89297087|NCT03858738||Group B: Women aged 25-49 years or 50 ≥|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 1 or 2.Thermography examination was performed with the use of Braster device.
89297088|NCT03858738||Group C: Woman aged 50 years or over|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5. Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device.
89297089|NCT01177020||Placentas after delivery or abortion|
89297090|NCT01179750|No Intervention|No Ultrasonic Coagulating Shears group|the one arm: operated group without using Ultrasonic coagulation shears during gastrectomy;
89297091|NCT01179750|Experimental|ultrasonic coagulation shears group|the other arm: operated group using ultrasonic coagulation shears during gastrectomy
89297092|NCT03102892|Active Comparator|Scaling Root Planing|Treatment by scaling and root planing. Repetition after 7 and 14 days.
89297093|NCT03102892|Experimental|Antimicrobial Photodynamic Therapy|Scaling and root planing and Antimicrobial photodynamic therapy with red laser (658 nm, 0.1 Watts, 2229 J/cm², 10s per point) and methylene blue dye (10mg/ml). Repetition after 7 and 14 days.
89297094|NCT01177176|Other|Standard Care|Standard tobacco counseling provided to hospital inpatients as part of routine, clinical-guideline compliant care in the study hospital. No post-discharge treatment is offered in this arm.
89297095|NCT01177176|Experimental|Extended Care Management|In addition to Standard Care, subjects in this arm receive Extended Care Management intervention to facilitate the continued use of smoking cessation treatment (counseling and medication use) after hospital discharge. This consists of 3 months of telephone-based contact after discharge.
89297096|NCT03089944|Experimental|Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
89297097|NCT01286142||Influenza treatment with oseltamivir|Patients 24 months of age and younger initially presenting with confirmed or presumed influenza A or B infection treated with oseltamivir.
89297098|NCT01286142||Influenza prophylaxis with oseltamivir|Patients 24 months of age and younger prescribed oseltamivir for influenza prophylaxis
89297099|NCT01286142||Influenza patients with no antiviral treatment|A comparator group of patients 24 months of age and younger presenting with confirmed or presumed influenza A or B and not treated with any influenza antiviral.
89297100|NCT03864198|Other|Genante (Tm)|Genante tablets One tablet in the morning and one tablet in the evening for 3 months
89297101|NCT01174992|Experimental|Evicel|
89297102|NCT01174992|Other|Sutures only|
89297103|NCT01287780|Active Comparator|Collagen-gentamicin sponges|Two sponges of collagen-gentamicin will be inserted into the hip immediately before closure of the wound. Each sponge (10 by 10 cm) contains 280 mg of collagen and 130 mg of gentamicin.
89297104|NCT01287780|No Intervention|No intervention|
89297105|NCT05546632||Critically ill patients|Patients included in this study will have blood sampling using EDTA tube and nex generation Cyto-Chex BCT tubes in order to compare compare the expression of mHLA-DR with these two types of tubes
89297106|NCT01179828|Active Comparator|1|Oxycodone 15mg
89297107|NCT01179828|Active Comparator|2|Clobazam 20mg
89297108|NCT01179828|Active Comparator|3|Imipramine 75mg
89297109|NCT01179828|Placebo Comparator|4|Tolterodine 1mg
89297110|NCT01179906|Experimental|Lifestyle intervention-exercise & diet|Subjects trained for 48 weeks with a personal trainer
89297111|NCT05437588|Other|MDD Participant|Participants with MDD will return at six weeks for a second blood draw and assessments
89297112|NCT01177332|Experimental|Fasted|Two-hour cycling test, fasted condition
89297113|NCT01177332|Other|Glucose-fed|Two-hour cycling test, glucose-fed condition
89297114|NCT01286220|Active Comparator|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
89297115|NCT01286220|Placebo Comparator|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
89297116|NCT01180062|Active Comparator|Arm 1|Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
89297117|NCT01180062|Active Comparator|Active Comparator - Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
89297118|NCT01180062|Active Comparator|Active Comparator - Arm 3|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
89297119|NCT03857958|Experimental|FCSEMS|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In FCSEMS group, patients are inserted with Fully covered self-expandable metal stent (FCSEMS) bilaterally for malignant hilar biliary stricture via endoscopic retrograde cholangio-pancreatography.
89297120|NCT03857958|Active Comparator|Plastic stent|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In plastic stent group, patients are inserted with plastic stents bilaterally for malignant hilar biliary stricture.
89297121|NCT01180920||Periodontal disease|11 patients with periodontal disease, specifically generalized chronic or aggressive periodontitis will be selected. In general, the disease group will be comprised of subjects that need an open flap procedure.
89297122|NCT01180920||Healthy periodontium|11 patients without periodontal disease will be selected. In general, the healthy group will be comprised of subjects that are requiring a gingivectomy or crown lengthening procedure.
89297123|NCT01289106|Active Comparator|Arm A|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
89297124|NCT01289106|Experimental|Arm B|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
89297125|NCT01289106|Experimental|Arm C|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
89297126|NCT02637492||ICCMI|Patient hospitalized for lower limb arterial disease and suspected to have critical ischaemia
89297127|NCT01177488|Experimental|BATE-T|Behavioral Activation Therapeutic Exposure done while the patient is at home via videoconferencing technology
89297128|NCT01177488|Active Comparator|BATE-IP|Behavioral Activation Therapeutic Exposure done in the therapist's office
89297129|NCT03860766|Sham Comparator|Sham Group (G-S)|The LED will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
89297130|NCT03860766|Experimental|50J Infrared LED Group (G-50J)|The LED with a wavelength of 940nm, 50J power, will be applied throughout the quadriceps and hamstrings bilaterally, just before the strength training protocol.
89297131|NCT03860766|Experimental|240J Infrared LED Group (G-240J)|The LED with a wavelength of 940nm, 240J power, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
89297132|NCT03860766|Experimental|Progressive dose infrared LED group (G-50-240J)|The LED with a wavelength of 940nm, initial energy of 50J with an increment of 38J each week to the final energy of 240J, will be applied throughout extension of the quadriceps and hamstrings bilaterally, immediately prior to the performance of the strength training protocol
89297133|NCT03858582|Experimental|Arm A|Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles.
89297134|NCT03858582|Experimental|Arm B|Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles.
89297135|NCT03858582|Experimental|Arm C|Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles.
89297136|NCT01287858|Placebo Comparator|Placebo|Placebo
89297137|NCT01287858|Active Comparator|AC430|AC430
89297138|NCT01180140|No Intervention|1|without seamguard
89297139|NCT01180140|Experimental|2|with seamguard
89297140|NCT01177566|Active Comparator|pimecrolimus (Elidel)|pimecrolimus twice daily to a chosen target lesion on one side of body
89297141|NCT01177566|Active Comparator|topical medical device cream (Eletone)|topical medical device cream three times daily to a chosen target lesion on one side of the body
89297142|NCT01181154|Placebo Comparator|equivalent volume total (=1000 ml)|Placebo : equivalent volume total (=1000 ml)
89297143|NCT01181154|Experimental|rituximab (Mabthera®)|rituximab (Mabthera®), 1000 mg at day 1 and day 15
89297144|NCT03101566|Experimental|Gemcitabine + Cisplatin + Nivolumab|"Drug: Gemcitabine 1000 mg/m2 IV on days 1,8 every 3 weeks~Drug: Cisplatin 25 mg/m2 IV on days 1,8 every 3 weeks~Drug: Nivolumab 360 mg IV on day 1 every 3 weeks~If there is continued benefit after 6 months, then:~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
89297145|NCT03101566|Experimental|Nivolumab + Ipilimumab|"Drug: Ipilimumab~1 mg/kg IV on day 1 every 6 weeks~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
89297146|NCT01289496|Experimental|Peg-interferon alpha-2a, Ribavirin|"Adult patients with chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin(non-response or relapse).~This is a pilot study with no control group."
89297147|NCT01383772|Experimental|Visual fields|One arm study. All patients will receive laser treatment following visual field testing.
89297148|NCT03739866|Experimental|Part A: Lenacapavir 20 mg|Participants will receive single dose of lenacapavir 20 mg on Day 1 followed by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as per standard-care therapy starting on Day 10 through Day 225.
89297149|NCT03739866|Experimental|Part A: Lenacapavir 50 mg|Participants will receive single dose of lenacapavir 50 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
89297150|NCT03739866|Experimental|Part A: Lenacapavir 150 mg|Participants will receive single dose of lenacapavir 150 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
89297151|NCT03739866|Experimental|Part A: Lenacapavir 450 mg|Participants will receive single dose of lenacapavir 450 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
89297152|NCT03739866|Experimental|Part A: Lenacapavir 750 mg|Participants will receive single dose of lenacapavir 750 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
89297153|NCT03739866|Placebo Comparator|Part A: Placebo|Participants will receive single dose of placebo matched to lenacapavir on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
89297154|NCT03739866|Experimental|Part B: TAF 200 mg|Participants will receive a single dose of TAF 200 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
89297155|NCT03739866|Experimental|Part B: TAF 600 mg|Participants will receive a single dose of TAF 600 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
89297156|NCT03857724|Experimental|prolapse surgery|
89297157|NCT03857802|Experimental|Sleep hygiene intervention|In the experimental group will proceed to the explanation of sleep hygiene measures to improve the quality of sleep. After 3 months, at the next health check, the quality of sleep questionnaire will be carried out together with the blood extraction.
89297158|NCT03857802|No Intervention|No sleep hygiene intervention|In the no intervention group, the same follow-up visits and the same blood extractions will be carried out, but no educational activity on sleep will be carried out.
89297159|NCT01181232|Experimental|MR low-dose group|
89297160|NCT01181232|Experimental|MR high-dose group|
89297161|NCT01181232|Active Comparator|IR group|
89297162|NCT01177644|Experimental|Active|
89297163|NCT01587534|Experimental|pancreatic enzyme replacement therapy|The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
89297164|NCT01587534|No Intervention|Placebo|The placebo will match the active drug in appearance, taste, and weight and contained pharmacologically inactive substances.
89297165|NCT01288014||Edlerly Recipients of Zoster Vaccine|Blood samples are collected before and after vaccination in people age 60 or more, who are getting the zoster vaccine as part of their routine health care.
89297166|NCT03860532|Active Comparator|HMPL-011 tablets|A sigle total oral dose of 1200 mg tablets (600 mg tablet X 2)
89297167|NCT03860532|Active Comparator|HMPL-011 capsules|A sigle total oral dose of 1200 mg capsules (200 mg tablet X 6)
89297168|NCT01181310|Experimental|A, B, D, E, C|Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.
89297169|NCT01181310|Experimental|B, C, E, A, D|Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.
89297170|NCT01181310|Experimental|C, D, A, B, E|Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.
89297171|NCT01181310|Experimental|D, E, B, C, A|Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.
89297172|NCT01181310|Experimental|E, A, C, D, B|Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.
89297173|NCT01181310|Experimental|A, C, B, E, D|Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.
89297174|NCT01181310|Experimental|B, D, C, A, E|Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.
89297175|NCT01181310|Experimental|C, E, D, B, A|Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.
89297176|NCT01181310|Experimental|D, A, E, C, B|Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.
89297177|NCT01181310|Experimental|E, B, A, D, C|Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.
89297178|NCT01289184||control|
89297179|NCT01289184||exposure 2-3 years|
89297180|NCT01289184||exposure 3-5 years|
89297181|NCT01289184||exposure 5-10 years|
89297182|NCT01289184||exposure >15 years|
89297183|NCT03858036|Active Comparator|Epi-OFF CXL|The Epi-ON treatment will be performed without removal of the corneal epithelium. Ricrolin+will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-ON treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-ON treatment.
89297184|NCT03858036|Active Comparator|Epi-ON CXL|The Epi-OFF treatment will be performed with removal of the corneal epithelium before the first dose of riboflavin is administered. Ricrolin+ will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-OFF treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-OFF treatment.
89297185|NCT02525250|Experimental|Acute myeloïd leukemia|Realization of 3 blood samples at day 0, day 15 and day 28.
89297186|NCT01288092|Experimental|BEZ235|
89297187|NCT03858504|Experimental|Yoga Group|The yoga program will include breathing exercises, different postures, and meditation. The yoga will be performed in groups. The program will be supervised a physical therapist for two times in a week for eight weeks . A session will be fifty minutes (5-10 minutes: warming-up, 20-25 minutes: postures, 10-15 minutes: cooling down).
89297188|NCT03858504|Active Comparator|Home Exercise Group|Home exercise program will consist of trunk strengthening exercises. The patients will be asked to check the exercise days. Patients will be contacted with telephone once a week.
89297189|NCT03858426||Children with eosinophilic esophagitis|"Inclusion criteria:~Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus > 15 eos / CGA)~And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids~Exclusion criteria:~Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)~Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids)."
89297190|NCT01289262|Active Comparator|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture.
89297191|NCT01289262|Active Comparator|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked closure technique.
89297192|NCT02524782|Experimental|MEDI-4166|MEDI-4166 administered subcutaneously
89297193|NCT02524782|Placebo Comparator|Placebo|Placebo administered subcutaneously
89297194|NCT01290744|Placebo Comparator|Placebo group|These patients will receive placebo for 12 months after completion of MDT.
89297195|NCT01290744|Experimental|Clofazimine for 12 months after MDT|Patients will be given clofazimine (100mg daily) for 12 months after completion of MDT.
89297196|NCT01181388|Active Comparator|intra-guide-catheter infusion of tirofiban|
89297197|NCT01181388|Experimental|intra-thrombus-aspiration-catheter infusion of tirofiban|
89297198|NCT01180452|Other|Single group open label|Prospective Cohort
89297199|NCT03857568|Experimental|SHR0410 group|SHR0410 will be dosed
89297200|NCT03857568|Experimental|Placebo|Placebo will be dosed
89297201|NCT01181544|Experimental|Heparin dose titration|
89297202|NCT01184586|Active Comparator|Intervention arm - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (STORZ DUOLITH, 1000 impulses, 0.55-0,8mJ/mm2)
89297203|NCT01184586|Sham Comparator|Control - SHAM ESWT STORZ DUOLITH [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave with modified probe without shockwave transduction (1000 impulses)
89297204|NCT02524860|Experimental|MRI-ultrasound fusion device|Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging
89297205|NCT01184664|Experimental|Varenicline + Active Patch|Participants will use varenicline (1mg BD) + an active, 15mg/16hr Nicotine Patch
89297206|NCT01184664|Placebo Comparator|Varenicline + Placebo Patch|Participants will use varenicline (1mg BD) + a Placebo Nicotine Patch
89297207|NCT01181700|Experimental|Treatment A|
89297208|NCT01181700|Experimental|Treatment B|
89297209|NCT01181700|Experimental|Treatment C|
89297210|NCT01181700|Active Comparator|Treatment D|
89297211|NCT01181700|Active Comparator|Treatment E|
89297212|NCT01181700|Active Comparator|Treatment F|
89297213|NCT01181700|Active Comparator|Treatment G|
89297214|NCT03858192|Experimental|Elective colorectal surgery|Patients who are expected to undergo a major colorectal surgery procedure will be recruited to this study preoperatively and followed-up until three months postoperatively.
89297215|NCT03858192|Experimental|Emergency abdominal surgery|Patients who are admitted as an emergency and undergo abdominal surgery will be recruited from general surgery wards either preoperatively or within 48 hours of surgery. They will be followed-up until three month postoperatively.
89297216|NCT03858192|Experimental|Medical patients|Patients admitted under general medicine with an infection will be recruited from general medicine wards within 48 hours of admission. They will be followed-up until three month post-admission
89297217|NCT05668494|Other|immediate loading|Immediate loading of implants by means of one definitive abutment on one side and temporary abutment on the other side of the posterior mandible restored by provisional crown-split mouth design
89297218|NCT01184820|Experimental|Arm 1|
89297219|NCT01184820|Experimental|Arm 2|
89297220|NCT01289652||HCV + HIV|
89297221|NCT01289652||HCV|
89297222|NCT03858270|Experimental|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
89297223|NCT03858270|Placebo Comparator|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week placebo will be administered at 10 mg tablet twice/day for 51 weeks.
89297224|NCT01180530||A|
89297225|NCT01289730|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice a week
89297226|NCT01289340||Polymem (R)|superficial burns treated with Polymem wound dressing until complete wound healing
89297227|NCT01289340||Biaten IBU|burns treated with Biaten IBU until complete wound healing.
89297228|NCT01289340||Hartmen dressing|burns treated with hartman or saline wet dressing until wound healing
89297229|NCT05666544|Active Comparator|Written health education leaflets|Using written health education leaflets to conduct education.
89297230|NCT05666544|Experimental|Web-based patient decision aid|Using web-based patient decision aid of renal replacement therapy.
89297231|NCT01290900|Experimental|CXL104|2000 mg NXL104 + 1500 mg Ceftaroline (IV)
89297232|NCT01290900|Experimental|CAZ104|Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
88806220|NCT05261360|No Intervention|Control Group|Participants who received no treatment were defined as the control group.
88806221|NCT05242094|Active Comparator|Group 1|Traditional Pulmonary Rehabilitation
88806222|NCT05242094|Experimental|Group 2|Pulmonary Rehabilitation in Virtual Reality
89297233|NCT01290900|Active Comparator|Moxifloxacin|Moxifloxacin 400mg (1 tablet)
89297234|NCT01290900|Placebo Comparator|Placebo|Placebo Infusion (saline)
89297235|NCT01184976|Experimental|0.6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
89297236|NCT01184976|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 2mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
89297237|NCT01184976|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
89297238|NCT01180608|Active Comparator|Pregabalin|
89297239|NCT01180608|Placebo Comparator|placebo + pregabalin|
89297240|NCT01185054|Experimental|Fluids as Tolerated (FAT) Group|The FAT group will receive ½ strength apple juice and will form the experimental group in this study.
89297241|NCT01185054|Active Comparator|Electrolyte Maintenance Solution (EMS)|The EMS group will form the control group as solutions such as Pediatric Electrolyte® are routinely recommended for use in children with gastroenteritis.
89297242|NCT03855306|Experimental|A Test|Test drug (Glibesyn) 1 tablet contains 5 mg Glibenclamide
89297243|NCT03855306|Active Comparator|B Reference|Reference drug (Daonil) 1 tablet contains 5 mg Glibenclamide
89297244|NCT03855384|Experimental|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
89297245|NCT03855384|Placebo Comparator|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
89297246|NCT01185132|Experimental|IMRT|Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
89297247|NCT01185132|Active Comparator|3D-CRT|Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
89297248|NCT01181856|Experimental|Group A|Intramuscular immunisation
89297249|NCT01181856|Experimental|Group B|Intradermal immunisation
89297250|NCT01181934|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
89297251|NCT01181934|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
89297252|NCT01181934|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
89297253|NCT01180686|Active Comparator|Multiple thrust Impulse instrument|This instrument automatically delivers 12 thrusts at the same intensity over the joint involved.
89297254|NCT01180686|Active Comparator|Single impulse Activator IV instrument|This is a manual spring loaded device that delivers one thrust to the joint involved
89297255|NCT01289808|Experimental|glucose 25%|"180 healthy babies born term in the Baruch Padeh Medical Center, Poriya.~There will be three study groups:~Study Group: 60 newborn infants who will receive 1cc 25% Glucose, 2-3 minutes prior red-reflex examination.~Base line (control) Group 1: 60 newborn infants who will receive 1cc Water for Injection (WFI), 2-3 minutes prior red-reflex examination.~Base line (control ) Group 2: 60 newborn infants who will not receive neither glucose nor Water for Injection (WFI), 2-3 minutes prior red-reflex examination"
88806223|NCT00326924|Experimental|Biological|PRBCs that are less than 7 days old are considered 'fresh'.
88806224|NCT00326924|Experimental|Standard PRBCs|PRBCs 'stored' as per hospital policy.
88806225|NCT00328016|Experimental|Device Guided Breathing|Individual breathing rate was determined from an expandable band around the torso connected to a commercially available device (RESPeRATE, Lod, Israel) that presented distinctive tones via earphones.
89297256|NCT03858114|Experimental|Mild-to-moderate physical activity|Three sessions/week, for 12 weeks, of mild-to-moderate physical activity, of mixed type (aerobic-anaerobic), supervised by expert and qualified personnel (physical education instructors) and performed in a gym.
89297257|NCT03858114|Active Comparator|Cultural group program|Cultural group program with thematic meetings and one visit/week to places of historical and artistic interest in the city of Cagliari, Sardinia, accompanied by expert guides (accredited tour guides).
89297258|NCT01180764|Experimental|Lovaza|Lovaza 4g po qd
89297259|NCT01180764|Placebo Comparator|Placebo|Matching placebo
89297260|NCT01182012|Experimental|Lifestyle counseling|Adjust drug treatment to control cardiovascular factor risks. A nurse will implement a lifestyle counseling in order to improve compliance of treatment and a healthy lifestyle.
89297261|NCT01289886|Other|Arm A|BR-A-657 20mg or placebo
89297262|NCT01289886|Other|Arm B|BR-A-657 60mg or placebo
89297263|NCT01289886|Other|Arm C|BR-A-657 120mg or placebo
89297264|NCT01289886|Other|Arm D|BR-A-657 240mg or placebo
89297265|NCT01289886|Other|Arm E|BR-A-657 480mg or placebo
89297266|NCT04986618|Experimental|One-way Nordic Exercise Group|
89297267|NCT04986618|Experimental|Two-way Nordic Exercise Group|
89297268|NCT04986618|No Intervention|Control Group|
89297269|NCT01180842|Other|Alternative Treatment|The CF Patient Population receiving the specific yoga study treatment
89297270|NCT01187862|Other|Basel cocktail|
89297271|NCT01289964|No Intervention|Waiting list control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
89297272|NCT01289964|Active Comparator|Treatment group|Received the 5 cupping treatments, application twice a week, non standardised application - individual determinations of trigger points
89297273|NCT01290042|Active Comparator|Placebo arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
89297274|NCT01290042|Active Comparator|Active arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
89297275|NCT03852732|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
89297276|NCT01291680||Pre - delivery pregnant women|Participants in the study will be pregnant women attending the obstetric ER for routine term followup. This evaluation is generally conducted at week 39-41 of pregnancy. The current study will focus on women attending a regular followup, not considered to be at high risk.
89297277|NCT03857412|Sham Comparator|Non capsular polishing|No capsular polishing taking place during cataract surgery
89297278|NCT03857412|Active Comparator|Capsular polishing|Capsular polishing taking place during cataract surgery
89297279|NCT01187940|Experimental|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
89297280|NCT01187940|No Intervention|Placebo|Will receive managment as usual from their local educational and NHS services
89297281|NCT01182090|Active Comparator|Prolapse repair by open approach|Correction of urogenital prolapse by open surgery approach
89297282|NCT01182090|Active Comparator|Prolapse repair by laparoscopic approach|Correction of urogenital prolapse by laparoscopic approach
89297283|NCT03739242|Experimental|Nutraceutical combination|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
89297284|NCT03739242|Placebo Comparator|Placebo|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
89297285|NCT01185444|Experimental|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
89297286|NCT01185444|Active Comparator|Hyalgan|the control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
89297287|NCT01188018|Active Comparator|Brief Advice|
89297288|NCT01188018|Experimental|Motivational Interviewing|
89297289|NCT01188018|Active Comparator|Health Education|
89297290|NCT03857334|Experimental|Arm A|
89297291|NCT03857334|Active Comparator|Arm B|
89297292|NCT01587690||Healthy subjects|Self-explanatory
89297293|NCT01587690||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
89297294|NCT01587690||Treated Patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Interferon-beta-1a prior to enrollment
89297295|NCT01185678||Group1|
89297296|NCT01185756|Experimental|ICD implantation|"MIBG for diagnostic purpose:~MIBG scintigraphy for diagnostic purpose"
88806226|NCT00328016|Placebo Comparator|Control Group|Control group were instructed to sit in the same manner passively attend to their breathing, and silently repeat 'one' during each exhalation. If other thoughts came to mind, they were instructed to calmly attend to their breathing.
88806227|NCT01791608|Active Comparator|Zinc sulphate|Preschool children healthy enrolled in FAN Foundation of Medellin, which will be supplied with zinc sulphate
88806228|NCT01791608|Experimental|Zinc Amino Acid Chelate|Preschool children healthy enrolled in FAN Foundation of Medellin , which will be supplied with zinc amino acid chelate
88806229|NCT01791608|Placebo Comparator|Milk without fortification|Milk without zinc
89297297|NCT01188174|Experimental|Clofarabine|
89297298|NCT01588002|Active Comparator|A danoprevir+ritonavir|
89297299|NCT01588002|Active Comparator|B efavirenz|
89297300|NCT01588002|Experimental|C combination|
89297301|NCT01291212|Active Comparator|Testosterone and FSHr|
89297302|NCT01291212|Active Comparator|testosterone and FSHr-LHr|
89297303|NCT01291290|No Intervention|Control treatment|Usual transfusion regime to patients with rAAA
89297304|NCT01291290|Experimental|Thrombocyte|Early thrombocyte administration to patients with rAAA
89297305|NCT01182168|Experimental|gemcitabine and cisplatin plus Everolimus|This is a single-institution phase I study of gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) in patients with advanced urothelial cancer.
89297306|NCT01182246|Experimental|AXP107-11|
89297307|NCT01182402|Experimental|Electronic compliance monitoring|Suboxone treated patients in Kuopio city area get their unsupervised Suboxone doses in electronic compliance monitoring devices during the 4 month study.
89297308|NCT03852420|Experimental|Treatment with the LUMINIZE RF Balloon Catheter|Subjects undergoing cardiac ablation procedure LUMINIZE™ RF Balloon Catheter System.
89297309|NCT01182558|Other|Activation of Hypothenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
89297310|NCT01182558|Other|Activation of Thenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
89297311|NCT01182558|Other|Activation of Extensor Digitorum Brevis|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
89297312|NCT01182558|Placebo Comparator|Maintain Relaxation of the Opposite Side|While the muscle of the right side is activated periodically and the compound muscle action potential is tested frequently, the muscle on the left side is maintained at rest and the compound muscle action potential is tested infrequently.
89297313|NCT02524470|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
89297314|NCT01188252|Experimental|Roniciclib|
89297315|NCT03855072|Experimental|Customized plate fixation|"Customized Plate fixation of Vertical Ramus Osteotomy after Mandibular Setback~- intervention:~All cases will undergo one surgery under general anesthesia.~Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~The customized fixation plate is positioned to fix the proximal and distal segment together"
89297316|NCT03855072|Active Comparator|maxillomandibular fixation|"Mandibular Setback by Vertical Ramus Ostotmy fixed with Maxillomandibular fixation~- intervention:~All cases will undergo one surgery under general anesthesia~incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint"
89297317|NCT01588626|Experimental|AZD6140|single administration of 90 mg dose of AZD6140
89297318|NCT01291758||GWI|Veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
89297319|NCT01291758||HC|Healthy veterans of the 1990-1991 Persian Gulf War
89297320|NCT03857022|Experimental|Enhanced External Counterpulsation|"Subjects of Heart failure with 'Enhanced External Counterpulsation therapy"
89297321|NCT03857022|No Intervention|"No 'Enhanced External Counterpulsation"|"Subjects of Heart failure without 'Enhanced External Counterpulsation therapy"
89297322|NCT01290198|Placebo Comparator|Vehicle without ANESDERM (lidocaine, prilocaine)|
89297323|NCT01290198|Active Comparator|Vehicle with ANESDERM (lidocaine, prilocaine)|
89297324|NCT01290198|Active Comparator|Fluconazole without ANESDERM (lidocaine, prilocaine)|
89297325|NCT01290198|Active Comparator|Fluconazole with ANESDERM (lidocaine, prilocaine)|
89297326|NCT01290276|Experimental|Ond-PR1 followed by (Ond-PR1 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
89297327|NCT01290276|Experimental|Ond-PR2 followed by (Ond-PR2 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
89297328|NCT01185912||Cardiomyocyte apoptosis|Elective aortic valve replacement patience
89297329|NCT03852654|Experimental|treatment|
89297330|NCT01185990||Tinnitus subjects|Subjects with chronic, moderate to severe unilateral tinnitus.
89297331|NCT01185990||Healthy control subjects|
89297332|NCT03854994|Experimental|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-5x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes Frequency: total one time
89297333|NCT01588080|Placebo Comparator|SiPAP|
89297334|NCT01588080|Experimental|Neurally Adjusted Ventilatory Assist|
89297335|NCT03857100|Active Comparator|Intervention|Receives letter and report
89297336|NCT03857100|No Intervention|Control|Does not receive letter and report
89297337|NCT03856866|Experimental|Hydroxychloroquine|Hydroxychloroquine: liquid suspension, 4mg/kg/day by mouth, divided bid for 84 days.
89297338|NCT03856866|Placebo Comparator|Placebo|Liquid suspension compounded to mimic the taste, appearance and texture of the investigational agent.
89297339|NCT01587768||Patients with a definite case of acute liver injury|"The information recorded in the patients' medical record met all the criteria to be classified as idiopathic acute liver injury and the patient presents with at least with one of the following conditions (A+B or A+C):~A - A diagnosis of liver injury (codes listed in tables 1a, 1b, 1c) with a referral to a specialist or hospital.~Together with B - An increase of more than two times the upper limit of the normal range in alanine aminotransferase (ALT) or C - A combined increase in aspartate aminotransferase (AST), alkaline phosphatase (AP) and total bilirubin provided one of them is twice the upper limit of the respective normal range."
89297340|NCT01587768||Patients with a probable case of acute liver injury|The information recorded in the patients' medical file was compatible with idiopathic acute liver injury, but not fulfilling all conditions and criteria to be defined as definite case. For example, patients identified with a READ or ICPC code for acute liver injury with a hospitalization or visit to a specialist but without complete laboratory criteria or patients identified with a READ or ICPC code for acute liver injury without a referral to a hospital/specialist, and with or without complete laboratory data.
89297341|NCT01587768||Non-cases|Any potential or probable case that was excluded in one of the previous steps and those with insufficient data to determine their case status. Patients presenting normal liver function tests (LFTs), alcohol related problems, gallbladder disease, pancreatic disease, or other liver diseases with clear aetiology such as viral, alcoholic or autoimmune, or presence of other well defined pathology known to cause acute liver injury will be considered non-cases.
89297342|NCT01188330|Experimental|WITH Comprehensive Geriatric assessment|Conventional haematological management of patients and Comprehensive Geriatric assessment (CGA) at diagnosis followed by interventions according to disabilities detected and planned monthly follow up by a nurse practitioner during 6 months.
89297343|NCT01188330|Active Comparator|Conventional|Conventional haematological management of patients
89297344|NCT01186068|Experimental|V-101 Cream 0.01% Concentration|Low dose
89297345|NCT01186068|Experimental|V-101 Cream 0.06% Concentration|Mid-dose
89297346|NCT01186068|Experimental|V-101 Cream 0.1% Concentration|Mid-dose
89297347|NCT01186068|Experimental|V-101 Cream 0.15% Concentration|High dose
89297348|NCT01186068|Placebo Comparator|Vehicle|Cream without an active ingredient
89297349|NCT01182636|Experimental|Investigational Test Product|Adapalene Topical Gel, 0.1%
89297350|NCT01182636|Active Comparator|Reference Listed Drug|Differin® (adapalene 0.1%) Topical Gel
89297351|NCT01182636|Placebo Comparator|Placebo|Gel base only
89297352|NCT01290354|Experimental|lapatinib|unlabelled, administered orally
89297353|NCT01188408|Experimental|Liposome Entrapped Docetaxel (LE-DT)|Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
89297354|NCT01182714|Other|removal of catheter|
89297355|NCT01186146|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
89297356|NCT01186146|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
89297357|NCT01291992||Continuous EEG Monitoring|Immediately after surgery, while still sedated and in the cardiac surgery recovery unit, 9 sticker electrodes applied to the skin just below the hairline, which record brain activity onto a computer. The EEG will be recorded for 24 hours. This brain activity (EEG) will later be interpreted by a neurologist who will be looking for evidence of seizure activity in the brain waves. Other relevant information: age, sex, the nature of other health problems, drugs used, complications and whether or not seizures are found will be stored on our computer for further evaluation.
89297358|NCT01182792|Experimental|Antioxidant|
89297359|NCT01182792|Placebo Comparator|Control|
89297360|NCT01188486|Experimental|pulmonary interstitial lymphography|stereotactic body radiation therapy & pulmonary interstitial lymphography
89297361|NCT01186302|Other|Midlevel provider|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
89297362|NCT01186302|Other|Physician arm|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
89297363|NCT01186380||TEE Procedure|patients requiring TEE procedure by their physician
89297364|NCT03856554|Experimental|Patients indicated for TLIF|Patients with lumbar degenerative spondylolisthesis, indicated for TLIF surgery
89297365|NCT03852186|Active Comparator|Cognitive behavioral therapy|Manualized group-based cognitive behavioual therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
89297366|NCT03852186|Experimental|Acceptance and commitment therapy|Manualized group-based Acceptance and Commitment therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
89297367|NCT01182870|Experimental|cholecalciferol|cholecalciferol in doses 800-6000 IU per day
89297368|NCT01182870|Placebo Comparator|placebo|placebo identical looking as cholecalciferol capsules
89297369|NCT01182948|Experimental|Aerobic Exercise|The aerobic training group will use cardiovascular training devices.
89297370|NCT01182948|Experimental|Resistance Exercise|The resistance training group will perform exercises on weight machines and free weights.
89297371|NCT01183182|Experimental|Needle Guidance|Lung biopsies performed with the needle guidance system.
89297372|NCT03854760|Experimental|anesthesiologist with limited experiment|Anesthesiologists with limited experiment of bronchoscopy.
89297373|NCT04979286|Experimental|Kinesiotaping Group|Y strip kinesiotaping will be applied to both the gastrocnemius muscles with approximately 20% tension.
89297374|NCT04979286|Placebo Comparator|Placebo Group|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
89297375|NCT03854292||Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopic electrocoagulating roller ball
89297376|NCT03854292||Laparoscopic tubal disconnection|Coagulation of the mid isthmus region of the affected Fallopian tube, with the bipolar forceps. using direct current that was no greater than 25 Watts.
89297377|NCT01186536|Experimental|Whey protein supplementation|Daily whey protein supplementation
89297378|NCT01186536|Experimental|Soy Protein supplementation|Daily soy protein supplementation
89297379|NCT01186536|Experimental|Placebo|Daily carbohydrate placebo supplementation
89297380|NCT01188720|No Intervention|Baseline|Assessment only baseline
89297381|NCT01188720|Experimental|Acute exercise|Exercise immediately before sexual activity, three times per week.
89297382|NCT01188720|Active Comparator|General exercise|Exercise not immediately before sexual activity, three times per week.
89297383|NCT01183494|Experimental|UGT1A1*1/*1|Participants with UGT1A1*/*1 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
89297384|NCT01183494|Experimental|UGT1A1*1/*28|Participants with UGT1A1*1/*28 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
89297385|NCT01183572|Active Comparator|Folic Acid and Iron|0.4mg of folic acid and 30 mg elemental iron taken daily for 6 months
89297386|NCT01183572|Placebo Comparator|Folic Acid|0.4mg of folic acid taken daily for 6 months
89297387|NCT01183572|Active Comparator|Multivitamins, Folic Acid, and Iron|A multivitamin and micronutrient supplement that constitutes 1 RDA of Vitamins A (2500 IU), B1 (1.4 mg), B2 (1.4 mg), B6 (1.9 mg), B12 (2.6 ug), niacin (18 mg), C (70 mg), E (10 mg), and folic acid (0.4 mg)along with 30 mg of elemental iron taken daily for 6 months.
89297388|NCT02524548|Experimental|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor
89297389|NCT02524548|No Intervention|Standard care|Routine care
89297390|NCT01291446|Sham Comparator|High flatulogenic diet|3-day diet containing fermentable residues
89297391|NCT01186614|Experimental|Novel treatment paradigm|treatment protocol including - mechanical CPR, therapeutic hypothermia, ECMO, coronary intervention
89297392|NCT02524236|Active Comparator|Botox 50 IU|"Intervention: Botox 50 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
89297393|NCT02524236|Active Comparator|Botox 100 IU|"Intervention: Botox 100 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
89297394|NCT03856008|Experimental|Exercises focused on flexor muscles.|Flexor cervical stabilization exercises will be applied.
89297395|NCT03856008|Experimental|Exercises focused on extensor muscles.|Extensor cervical stabilization exercises will be applied.
89297396|NCT03856008|No Intervention|Control.|No intervention will be applied.
89297397|NCT03855930||micturition induced PLP|"10 Patients with chronic post amputation micturition induced PLP.All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.~All patients will go through functional MRI study"
89297398|NCT03855930||non micturition induced PLP|10 Patients with chronic post amputation with PLP and without post amputation micturition induced PLP All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.All patients will go through functional MRI study
89297399|NCT03855930||healthy volunteers|10 healthy volunteers. All patients will go through functional MRI study
89297400|NCT03856242|No Intervention|No intervention|It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
89297401|NCT03856242|Active Comparator|Tamsulosin|This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
89297402|NCT03856242|Active Comparator|TURP|This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).
89297403|NCT01186926|Experimental|HGNS Treatment|
89297404|NCT03851874|Active Comparator|Gastric bypass bariatric surgery|Patients in this arm underwent Roux-en-Y gastric bypass bariatric surgery for the treatment of morbid obesity
89297405|NCT03851874|Active Comparator|Sleeve gastrectomy bariatric surgery|Patients in this arm underwent sleeve gastrectomy bariatric surgery for the treatment of morbid obesity
89297406|NCT01187082|Experimental|bladdertraining group|Cognitive training in groups at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
89297407|NCT01187082|Active Comparator|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
89297408|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 400-500 calorie|
89297409|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
89297410|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, bedtime|
88806230|NCT04346030|Experimental|steroid and hydrodissection|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
89297411|NCT01291524|Other|Pregabalin immediate release, 300 mg|Reference Treatment
88806231|NCT04346030|Active Comparator|steroid only|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine)
88806232|NCT05095844||Vaccinated|All individuals who have received a vaccine dose.
89297412|NCT03855852|Active Comparator|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
89297413|NCT03855852|Experimental|Xenograft and A-PRF|Placing the implant with xenograft and A-PRF at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
89297414|NCT01183806|Experimental|Rivastigmine and exercise program|Experimental group: Rivastigmine and exercise program: All patients will monthly receive Rivastigmine (Exelon patch). The exercise training program consists of two 40-minute sessions per week for six months and includes aerobic, strength, flexibility and balance training
89297415|NCT01183806|Active Comparator|Rivastigmine|Control group : Rivastigmine All patients will monthly receive Rivastigmine (Exelon patch)
89297416|NCT01188954|Active Comparator|Doxycycline|Doxycyline, family of tetracycline antibiotics, used to scleroses the lymphatic vessels that may have transected during dissection.
89297417|NCT01188954|Placebo Comparator|Normal Saline/Water|The standard care is wetting and suctioning fluids followed with suturing of the groin.
89297418|NCT01183962|Other|Vitamin D|Subject receives daily dose of Vitamin D
89297419|NCT01183962|Other|No medicine|Subject does not receive medication
89297420|NCT01184040|No Intervention|(A) Non-contingent control|Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
89297421|NCT01184040|Experimental|VIP CM|Participants assigned to Increasing Variable Interval Prize (VIP) Reinforcement group will be scheduled for the same study visits as those in the Control group, but will also earn chances to win prizes if they have walked more than 10,000 steps in the past 4 days.
89297422|NCT01187160|Experimental|Transoral robotic surgery (TORS)|da Vinci® Robotic Surgical System
89297423|NCT03851718|Experimental|Acupuncture Procedure|Acupuncture is a type of Traditional Chinese Medicine (TCM) therapeutic approaches involving the insertion and manipulation of fine needles in specific points. Mothers in acupuncture group will be given three standardized sessions of acupuncture within 5 weekdays, preferably on 3 consecutive days.
89297424|NCT03851718|Active Comparator|Power pumping|Power pumping is a pumping strategy that mimics normal infant cluster feedings by repeatedly emptying mother's breast very frequently in an effort to increase breast milk supply. As there is no standardized protocol of power pumping, one of the most popular recommendations will be adapted as the study power pumping instruction. It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days.
89297425|NCT01187238|No Intervention|Arm1-radical radiotherapy alone group|Arm1-radical radiotherapy alone group, the eligibility patients will received radical intensity-modulated radiotherapy alone
89297426|NCT01187238|Experimental|Arm2-concurrent chemoradiotherapy group|Arm2-concurrent chemoradiotherapy group, the eligibility patients will received radiotherapy the same as radical radiotherapy arm,and also will received the concurrent chemotherapy wiht the regimen consist of cisplatin 40mg/m2, weekly for 7weeks.
89297427|NCT01588314|Active Comparator|gabapentin|
89297428|NCT01588314|Placebo Comparator|placebo|
89297429|NCT03853980|Experimental|Rotational fractional resection (RFR)|Single treatment of skin resection (removal of loose skin)
89297430|NCT01290432|Experimental|Inofolic Plus|Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
89297431|NCT01290510|Experimental|hyaluronic acid sodium salt|
89297432|NCT01184196|Active Comparator|Arm 1|Subjects randomized to Arm 1 will receive Betadine surgical scrub at the time of primary total knee arthroplasty.
89297433|NCT01184196|Active Comparator|Arm 2|Subjects in Arm 2 will receive ChloraPrep surgical scrub prior to elective primary total knee arthroplasty.
89297434|NCT01292382|Sham Comparator|rTMS versus Sham|rTMS: active coil Sham: inactive coil
89297435|NCT01292382|Active Comparator|rTMS versus sham|rTMS group: active coil Sham group: inactive coil
89297436|NCT01292460|Active Comparator|Preservative-free timolol|
89297437|NCT01292460|Experimental|Preservative-free FDC and placebo|
89297438|NCT01292460|Active Comparator|Preservative-free tafluprost|
89297439|NCT01292460|Experimental|Preservative-free FDC|
89297440|NCT03851952|Other|Optilume DCB|Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada
89297441|NCT03855540||Study group|Adult patients with documented paroxysmal, nonvalvular atrial fibrillation with CHA2DS2-VASc score > 2 (for females > 3) and sinus rhythm at the time of inclusion. In total 100 patients will be included.
89297442|NCT03855540||Control group|"Patients without a history of palpitations or irregular heart rhythm. AFib will be excluded with the help of 7 days ECG Holter and ECG event recorder monitoring. In total 100 patients will be included.~Propensity matching according to the:~CHA2DS2-VASc parameters~LVEF: preserved (<40%), mid-range (40-49%) and reduced (>50%)~Presence of diastolic dysfunction~Glomerular filtration rate: (≥1,5 ml/s), (1,4-1 ml/s) and (0,9-0,5 ml/s)~Drugs: ACE-I/ARB, betablockers, digoxin, amiodarone~BMI: (<30kg/m2), (30-39kg/m2) and (≥40kg/m2)~Smoking (>5 cigarettes per day)"
89297443|NCT01184352||PCI patients treated with Glider Device|
89297444|NCT03855462|Experimental|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with silicon oil medium-chain triglycerides (MCT) as tamponade agent :~Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~MCT ablation after 4 to 6 weeks (after effective retinopexy)"
89297445|NCT01187316|Experimental|TENS|
89297446|NCT01187316|Active Comparator|Massage therapy and muscle stretching|
89297447|NCT01292694|Experimental|Losartan|Angiotensin II AT1 receptor antagonist which blocks the actions of angiotensin II
89297448|NCT01292694|Experimental|Captopril|ACE inhibitor which blocks the formation of angiotensin II
89297449|NCT01292694|Placebo Comparator|Placebo Tablet|A placebo tablet will be provided by the Vanderbilt Investigational Drug Service for these studies.
89297450|NCT01184430|Active Comparator|advanced hemodynamic monitoring|advanced hemodynamic monitoring with pulse contour analysis ( LiDCO rapid) and goal-directed therapy
88806233|NCT05087264|Experimental|Indocyanine green injection|43 cases received preoperative intravenous injection of indocyanine green and radical resection of q-mc1 cervical cancer under pelvic autonomic nerve fluorescence development
88806234|NCT05087264|No Intervention|Not Indocyanine green injection|43 cases underwent routine surgery，not indocyanine green injection
88806235|NCT05075330|Experimental|Intervention|Participants who live in the Orange Mound community of Memphis. Billboards targeting stigma reduction were posted in the community for one month.
88806236|NCT05075330|No Intervention|Control|Participants who live in the Frayser community of Memphis. No billboards (intervention) were placed here.
88806237|NCT05005286||Group A|Lactating women with vaginal infection during pregnancy as confirmed by past medical records
89297451|NCT01184430|No Intervention|standard monitoring|hemodynamic monitoring based on the standard operating procedures of our clinic
89297452|NCT03853668|Active Comparator|aerobic exercise group|"aerobic exercises (intervention) on treadmill for 10 weeks, 3 times/week for duration of 30-45 min/session.~Exercise intensity is 50-65%of maximal heart rate (MHR)"
89297453|NCT03853668|Experimental|aerobic and resisted exercise|combined resisted and aerobic exercises (intervention) for 10 weeks (circuit weight training and treadmill training respectively) 2 times/week for a duration of 30-45 min/session Exercise intensity is 50-65%of maximal heart rate (MHR) for aerobic part and 50% of 1 repetition maximum (1RM) for resistance part.
89297454|NCT03855774|Other|Polymorphisms|Classification of sleep disorders prevalence through polymorphisms
89297455|NCT03851562|Experimental|Alprostadil 20 micrograms|1 μg / kg patient weight up to a maximum of 60 μg
89297456|NCT03851562|Placebo Comparator|Placebo (physiological saline solution)|Placebo (physiological saline solution)
89297457|NCT02524704||Healthy controls|Subjects between the ages of 2 and 21 with healthy lungs. Electrical impedance tomography data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, and during FEV1 and FEF 25-75 spirometry maneuvers for subjects over age 8.
89297458|NCT02524704||CF patients scheduled for a CT scan|Subjects with CF between the ages of 2 and 21 who are either clinically indicated for a CT scan of the lungs or are scheduled for a pulmonary CT scan as part of their routine care. Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during forced expiratory volume in 1 second (FEV1) and forced expiratory flow (FEF) 25-75 spirometry maneuvers for subjects over age 8, and immediately before or after pulmonary CT scanning.
89297459|NCT02524704||CF patients with pulmonary exacerbation|"Subjects with CF between the ages of 8 and 21 who are being started on intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation.~Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during FEV1 and FEF 25-75 spirometry maneuvers upon admission for a pulmonary exacerbation and following 7 to 14 days hospitalized treatment including IV antibiotics. Further data will be collected at the same time with CT scanning if the scan is part of the patient's standard of care."
89297460|NCT01293630|Experimental|Cohort - 1 through 5|AVE8062 combined with paclitaxel and carboplatin will be administered once every 3 weeks
89297461|NCT01191060|Experimental|lenalidomide, bortezomib with ASCT|"RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)~Autologous stem cell transplant:~Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)"
89297462|NCT01191060|Experimental|lenalidomide, bortezomib without ASCT|RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
89297463|NCT03853824|Other|Intervention arm|Patients randomised to increased postoperative surveillance.
89297464|NCT03853824|Other|Control arm|Patients randomised to usual postoperative care.
89297465|NCT02524392|Experimental|Independent medical evaluation|Independent medical evaluation (IME) of another doctor than the treating general practitioner.
89297466|NCT02524392|No Intervention|Treatment as usual|Treatment as usual by the treating general practitioner. There will be one randomized control group in one county. Sick-listed in other counties serve as an extra control group.
89297467|NCT01291602|Experimental|NXL104|Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
89297468|NCT01291602|Placebo Comparator|Placebo|Three Japanese subjects to receive placebo IV doses
89297469|NCT01291602|Experimental|Ceftazidime NXL104 (CAZ104)|Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
89297470|NCT03853590|Active Comparator|Laparoscopic Adjustable Gastric Band|Subjects who elected to undergo Laparoscopic Adjustable Gastric Band intervention were examined prior to surgery and at 2, 3, 6 months after operation.
89297471|NCT03853590|Experimental|Roux-en-Y gastric bypass surgery|Subjects who elected to undergo Roux-en-Y gastric bypass surgery were examined prior to surgery and at 2, 3, 6 months after operation.
89297472|NCT01187628|Experimental|Arm 1|
89297473|NCT01293708||Hospital Cohort|All 80+ year old that had had an ICU stay of >=24 hrs. Followed until hospital d/c
89297474|NCT01293708||Longitudinal Cohort|All 80+ year old that had had an ICU stay of >=24 hrs. Followed for 12 months
89297475|NCT03851172|Experimental|Nepafenac and cyclopentolate|Nepafenac 1 mg eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
89297476|NCT03851172|Experimental|Ketorolac and cyclopentolate|Ketorolac 0.5% eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
89297477|NCT03851172|Placebo Comparator|Cyclopentolate and saline 0.9%|Cyclopentolate eye drops two times before surgery and saline 0.9% eye drops two times before cataract surgery
89297478|NCT03853512|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
89297479|NCT03853512|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
89297480|NCT03849924|Experimental|Self-affirmation|Participants assigned to the self-affirmation intervention condition will undergo a self-affirmation intervention in the form of a questionnaire at time point one (one week after the intervention). This is a brief intervention that involves forming self-affirming implementation intentions. Implementation intentions are formulated plans that encourage one to link critical situations with appropriate behavioural responses. In this study participants are encouraged to write out the stem and their response to the stem from the four options.
89297481|NCT03849924|Experimental|Self-affirmation 'booster'|Participants assigned to this condition will undergo the self-affirmation intervention described above twice, in comparison to just once, in the form of a questionnaire at time points one (one week after the intervention) and two (two weeks after the intervention).
89297482|NCT03849924|No Intervention|Control|Participants assigned to the control condition will not undergo a self-affirmation intervention. Instead they will still complete the same questionnaire as participants in the intervention conditions but without the self-affirmation intervention included (normally included on the last page of the questionnaire).
89297483|NCT01189188|Experimental|With ultrasound guidance|In this group of patients, ultrasound guidance will be used when drawing blood from the radial artery.
89297484|NCT01189188|Active Comparator|Without ultrasound guidance|In this group of patients, no ultrasound guidance will be used when drawing blood from the radial artery.
89297485|NCT03849846||Adults with low socio-economic status|Four focus groups will be conducted with adults with low socioeconomic status recruited through community centres in the Québec City area.
89297486|NCT01293786||Kidney transplant recipients|
89297487|NCT01293786||Chronic kidney disease|
89297488|NCT03849612|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
89297489|NCT03853278|Experimental|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls.These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
89297490|NCT03853278|No Intervention|No intervention control group|The control group will receive health education leaflets.
89297491|NCT01189344|Experimental|Not surgical group|The Nos surgical (NS) group includes 15 patients for whom bariatric surgery is planned. Body mass index (BMI) of this group of patients is ≥40 Kg/m2.
89297492|NCT01189344|Experimental|Surgical group|The Surgical (S) group includes 15 patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study
89297493|NCT01187706||gynecological cancer survivors|"Criteria for including: (1)Been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment. (2)Age from 20 - 70 years old. (3) Agreed to participate in this study.~Criteria for exclusion: Combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients."
89297494|NCT01187706||healthy controls|Criteria for including: (1)Not those who suffer from cancer.(2)20-70 years old.(3)Agreed to participate in this study.Criteria for exclusion:Had undergone gynecologic surgical removal of ovaries or uterus were.
89297495|NCT01191138|Other|Infracolic Anastamosis|The gastrojejunal anastamosis is done in the infracolic compartment
89297496|NCT01191138|Other|Supracolic Anastamosis|The gastrojejunal anastamosis is done in the supracolic compartment
89297497|NCT01189578||Recreational cocaine users|Individuals who have used cocaine in the past 3 months, but do not meet DSM-IV-TR diagnostic criteria for Cocaine Dependence.
89297498|NCT03853200|Experimental|Group I|QMix the solution under investigation which includes CHX EDTA and detergent QMix Root Canal Irrigant
89297499|NCT03853200|Active Comparator|Group II|it involves use of two irrigant solutions, 17%EDTA+2%Chlorhexidine
89297500|NCT03853200|Active Comparator|Group III|17% EDTA with no antibacterial activity . the control group
89297501|NCT01187784|Active Comparator|CBT|Coping Cat cognitive-behavioral therapy protocol
89297502|NCT01187784|No Intervention|Waitlist Control|Treatment as usual
89297503|NCT01293942|Experimental|IXO+A|IXO regimen with Avastin
89297504|NCT01189656|Experimental|Vaccine+Lamivudine group|Subjects assigned into the experimental and the controlled groups with randomization and double-blindness by a ratio of 2:1
89297505|NCT01189656|Placebo Comparator|Placebo+Lamivudine group|
89297506|NCT01292850||Healthy Volunteers|15 healthy volunteers were recruited
89297507|NCT01581138|Experimental|12 week treatment|
89297508|NCT01581138|Experimental|16 week treatment|
89297509|NCT01191216|Experimental|Arm I|Patients receive oral 1-methyl-d-tryptophan twice daily on days 1-21 and docetaxel IV over 1 hour on day 1 (in course one patients receive 1-methyl-d-tryptophan once daily on days 1 and 3-21).
89297510|NCT01580358|Active Comparator|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
89297511|NCT01580358|Placebo Comparator|starch|Starch in the same granule as intervention group for this double-blind trial
89297512|NCT05671614||Critically ill patients|Critically ill patients with sudden onset of disease receiving mechanical ventilation, to be enrolled within 72 hours of admission, who are likely to need 7 days or more of ICU stay.
89297513|NCT05671614||Volunteers with a very good to excellent performance status|Elective hip surgery patients with a very good to excellent performance status, only limited to joint pain (ECOG 0)
89297514|NCT01193946||Single-arm design|There is currently considerable debate regarding the accuracy of the estimated average requirement (EAR) and the recommended dietary allowance (RDA) for older people. Very limited data obtained from older individuals are available to support the assumption that age does not affect protein requirement. Existing method like nitrogen balance has inherent limitations that diminish it from being considered a reference method. Indicator amino acid oxidation technique is emerging as an alternative method to measure dietary protein requirement. It is more accurate and less demanding. The current study will be the first time this technique is used with elderly adults and will provide an important foundation for geriatric nutrition research
89297515|NCT01194024||Intubated within 24hrs of admission|All patients that are admitted to a participating burn center and intubated within 24 hours
89297516|NCT01191294|Experimental|Medical Students|3rd year medical students during their primary care clerkship
89297517|NCT01294176|Active Comparator|Oral Lipoic Acid|Lipoic acid is a natural antioxidant available as an oral dietary supplement. A higher than average dose of 1200mg will be administered in this trial.
89297518|NCT01294176|Placebo Comparator|Avicel™|The placebo is Avicel™ (microcellulose crystal) and 4.3 mg quercetin (a bioflavanoid).
89297519|NCT01191372|Placebo Comparator|saline for injection|
88806238|NCT05005286||Group B|Lactating women without any vaginal infection during pregnancy
89297520|NCT01191372|Experimental|ARC19499 Low Dose|
89297521|NCT01191372|Experimental|ARC19499 Mid Dose|
89297522|NCT01191372|Experimental|ARC19499 High Dose|
89297523|NCT01189734|Placebo Comparator|laparoscopic common bile duct exploration|
89297524|NCT01189734|Active Comparator|laparoscopic cholecystectomy with intraoperative ES|
89297525|NCT01294254|Experimental|experimantal: wound site will be treated with Oleogel-S10|"The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.~Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg~Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg~Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)~Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site"
89297526|NCT01294254|Active Comparator|Moist wound healing dressing alone|Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
89297527|NCT03847818|Experimental|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|
89297528|NCT03847584||Adults-low socioeconomic status|Survey completed by adults with low socioeconomic status
89297529|NCT03847584||Adults-middle/high socioeconomic status|Survey completed by adults with middle/high socioeconomic status
89297530|NCT01194102|Experimental|Stroke Community Wellness Program|"Participants with stroke will attend a 12 week Community Wellness Program. The program consists of a Community Based Exercise Program at the YMCA (2x 1 hour exercise sessions per week with specially trained fitness instructors). They will also attend a 1 hour long Living with Stroke education session one time per week and an independent exercise session in the fitness centre one time per week."
89297531|NCT01194102|Active Comparator|Regular YMCA membership|"The control group will have access to YMCA facilities to use at their discretion but will not attend the Community Based Exercise Program for stroke survivors or the Living with Stroke education program. YMCA staff working with the control group will not receive specialized training in exercise and education for stroke survivors but will be trained on important safety precautions and contraindications to exercise after stroke."
89297532|NCT03850938|Experimental|Conventional Kyphoplasty|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration. Then, the cement is injected into the cavity created by the balloon.
89297533|NCT03850938|Active Comparator|Kyphoplasty with Rotary Cutter|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration, which may induce a cavity with barriers pushed by balloon dilatation. Then, the structure of the cavity is destroyed by a rotary cutter. Finally, the cement is injected, which may effectively interdigitates with the healthy cancellous bone.
89297534|NCT01294410|Experimental|Cohort 1: Induction|Placebo or Anti-IP-10 Antibody
89297535|NCT01294410|Experimental|Cohort 2: Induction|Placebo or Anti-IP-10 Antibody
89297536|NCT01294410|Experimental|Cohort 3: Induction|Placebo or Anti-IP-10 Antibody
89297537|NCT01294410|Experimental|Maintenance|Placebo or Anti-IP-10 Antibody
89297538|NCT01294410|Other|Open Label|
89297539|NCT01191450|Active Comparator|Higroton®|Chlorthalidone 25mg - one oral tablet a day in the morning
89297540|NCT01191450|Experimental|Diupress®|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning
89297541|NCT01194180|Experimental|Group A|"BCG-naive subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
89297542|NCT01194180|Experimental|Group B|"BCG-naïve subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
89297543|NCT01194180|Experimental|Group C|"BCG-experienced subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
89297544|NCT01194180|Experimental|Group D|"BCG-experienced subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
89297545|NCT01294488|Experimental|Phone Consultation|Therapists receive phone consultation for 6 months during the course of the project.
89297546|NCT01294488|Experimental|Remote Real-Time Consultation|Therapists receive consultation for 6 months via polycommunication technology.
89297547|NCT01189968|Experimental|Carboplatin and Pemetrexed plus demcizumab|Carboplatin and Pemetrexed plus demcizumab
89297548|NCT01189968|Experimental|Pemetrexed plus demcizumab|Pemetrexed plus demcizumab
89297549|NCT01294566|Experimental|Cohort 1|GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects)
89297550|NCT01294566|Experimental|Cohort 2|GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects)
89297551|NCT01194336||Huperzine A: 100 ug|
89297552|NCT01194336||Huperzine A: 200 ug|
89297553|NCT01194336||Donepezil: 2.5 mg|
89297554|NCT01194336||Donepezil: 5 mg|
89297555|NCT01194336||Galantamine: 4 mg|
89297556|NCT01194336||Galantamine: 8 mg|
88806239|NCT01793558|No Intervention|Control; passive insulation|The mothers will receive passive temperature insulation by a cotton blanket (standard procedure) after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the cotton blanket (also passive insulation without active warming) for 20 min after birth (bonding period).
89297557|NCT01194336||Placebo|
89297558|NCT01194492|Other|Albumin kinetics|
89297559|NCT03850470||Patients with Musculoskeletal Pain|Subjects reporting for care with complaints of musculoskeletal pain will be examined and a diagnosis and plan of care will be established. The accuracy of the clinical examination will be compared to pathology detected by MRI
89297560|NCT03849222|Active Comparator|Ca(OH)2 Apexification|Apexification was performed with calcium hydroxide. calcium hydroxide dressing was applied directly against the open apex .The canals were back filled with Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
88806240|NCT01793558|Experimental|Active Warming|The mothers will receive active warming by a forced-air warming blanket after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the warming blanket for 20 min after birth (bonding period).
88806241|NCT02108288|Experimental|OPC-1085EL ophthalmic solution|Once daily
88806242|NCT02108288|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
89297561|NCT03849222|Experimental|Ca(OH)2 Apexification with apical matrix|Treated by condensation of calcium hydroxide dressing against an internal matrix , a piece (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy) was gently compacted toward the apex before insertion of Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
89297562|NCT03849222|Active Comparator|MTA Apexification|Apexification was performed with MTA as apical plug. A 3-5 mm thickness of MTA using a hand plugger was applied as apical plug and verified radiographically. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
89297563|NCT03849222|Experimental|MTA Apexification with apical matrix|An internal (apical) matrix was used as a base for condensation of MTA apical plug, a pieces of (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy)were compacted toward the apex with premeasured suitable size schilder plugger. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
89297564|NCT01190046|Other|Resistance exercise training|Exercise is being used as an experimental tool to determine if remediation of muscle disuse counteracts cellular/molecular defects in muscle structure/function.
89297565|NCT01190202|Experimental|Overall Study Group (Survey 1)|Subjects at least 6 months of age at the time of Survey 1, conducted at Year 1 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
89297566|NCT01190202|Experimental|Overall Study Group (Survey 2)|Subjects at least 6 months of age at the time of Survey 2, conducted at Year 2 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
89297567|NCT01190202|Experimental|Overall Study Group (Survey 3)|Subjects at least 6 months of age at the time of Survey 3, conducted at Year 3 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
89297568|NCT01190202|Experimental|Overall Study Group (Survey 4)|Subjects at least 6 months of age at the time of Survey 4, conducted at Year 4 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
89297569|NCT02849626|Experimental|Perampanel|Perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension
89297570|NCT03849144|Experimental|Therapy dog activity|Interact with visiting therapy dogs for 15 minutes on two Fridays
89297571|NCT03849144|Active Comparator|Low impact physical activity|Participate in 15-minute low impact physical activity on two Fridays
89297572|NCT01989624||Pancreatic Adenocarcinoma|
89297573|NCT02833792|Experimental|Stem Cells|Stem cells
89297574|NCT02833792|Placebo Comparator|Placebo|Lactated Ringer's Solution
89297575|NCT02660710|Experimental|R-CHOP|We will enroll 40 adult patients age 18-60 years (20 HIV-infected with CD4 count ≥ 100 cells/µL, 20 HIV-uninfected) who will receive a maximum of 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) over 18-24 weeks
89297576|NCT01294878|Experimental|treatment with omalizumab|Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used
89297577|NCT01296438|Experimental|Treatment sequence 1|
89297578|NCT01296438|Active Comparator|Treatment sequence 2|
89297579|NCT01190280||AC - operation|Patients admitted with acute cholecystitis randomized to operation
89297580|NCT01190280||AC - observation|Patients admitted with acute cholecystitis randomized to observation
89297581|NCT01190280||SGBS - operation|Patients admitted with uncomplicated gallstone disease randomized to operation
89297582|NCT01190280||SGBS - observation|Patients admitted with uncomplicated gallstone disease randomized to observation
89297583|NCT01190280||1983 - stones|Patients that in 1983 were diagnosed with gallstones in a population screening
89297584|NCT01190280||1983 - operation|Patients that were operated for gallstone disease at Haukeland University Hospital, Bergen, Norway, in 1983
89297585|NCT01190280||1983 - controls|Patients that were shown not to have gallstones in a 1983 population screening
89297586|NCT01190280||Gallstone patients|Patients with symptoms from gallstone disease
88806243|NCT02108288|Active Comparator|Latanoprost ophthalmic solution|Once daily
89297587|NCT03850548||Prosthetic joint infection with Cutibacterium acnes|Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
89297588|NCT03850626||Immunotherapy Trees|Patients allergic to tree pollen
89297589|NCT03850626||Immunotherapy Grass|Patients allergic to grass pollen
89297590|NCT03850626||Immunotherapy Mites|Patients allergic to HDM
89297591|NCT01296516|Placebo Comparator|Control Group|A group matched for age and BMI will be selected to serve as control subjects in this study.
89297592|NCT01296516|Active Comparator|Face-to-face group|Participants randomized to the face-to-face intervention will attend motivational meetings held once per week in Phase I and biweekly in Phase II. Behavioral sessions will be led by a trained interventionist and will take place at Pennington Biomedical Research Center.
89297593|NCT01296516|Active Comparator|Telehealth Group|Participants randomized to the Telehealth intervention will receive behavioral counseling through Trestletree, phone system.
89297594|NCT01294956|Experimental|FID 115958D|Lubricant Eye Drop
89297595|NCT01294956|Active Comparator|Refresh Liquigel|Lubricant Eye Drop
89297596|NCT01190358|Placebo Comparator|Placebo|Sugar pill
89297597|NCT01190358|Active Comparator|Grape seed extract|300mg of grape seed extract.
89297598|NCT01296594|Active Comparator|Usual Care|
89297599|NCT01296594|Experimental|usual care with cell phone monitoring and CM|In the CM condition, patients will carry a cell phone and record and send in time- and date-stamped self videos of medication ingestion.
89297600|NCT01293162||placebo|
89297601|NCT01296750|Active Comparator|Early Physiotherapy|Physiotherapy to begin within 1 day post op.
89297602|NCT01296750|No Intervention|Late Physiotherapy|Physiotherapy to start 6 weeks post op
89297603|NCT01296828||MOUTH BREATHING CHILDREN|
89297604|NCT01296906|Experimental|Population-based Reminder/Recall|Recall is performed centrally by public health departments for all children in need of immunizations in a geographic area.
89297605|NCT01296906|Experimental|Practice-based Reminder/Recall|Reminder/Recall is performed by individual private practices for their patients who appear in need of immunizations.
89297606|NCT01191606|Active Comparator|Group A|the exchange of ventilatory mode from volume controlled ventilation to pressure controlled ventilation
89297607|NCT01191606|Active Comparator|Group B|the exchange of ventilatory mode from pressure controlled ventilation to volume controlled ventilation
89297608|NCT05671536|Experimental|Motivational interview|Patients on intervention group will receive 4 sessions of motivational interview at least 20 minutes and once a month. Resilience of patients will be evaluated at the beginnig of the study and five months after the beginning of the study.
89297609|NCT05671536|No Intervention|Control|Patients on control group will receive standard care. Resilience of patients will be evaluated at the beginnig of the study and five months after the beginning of the study.
89297610|NCT01190592|Experimental|Milk|
89297611|NCT01190592|Experimental|Juice|
89297612|NCT01190592|Placebo Comparator|Water|
89297613|NCT01211418|Experimental|Integrative Meditation|
89297614|NCT01211418|Active Comparator|Nondirective Therapy|
89297615|NCT03735498|Experimental|Psychological Intervention|"Qualitative interview will be conducted~7-item Generalized Anxiety Disorder measure will be completed by participants via mail correspondence or online~A psychoeducational component to address preparedness, manage expectations, and develop caregiving skills~A psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~A self-care component to promote caregiver health and well-being"
89297616|NCT01194648|Other|High Intensity Focused Ultrasound|HIFU, the Intervention
89297617|NCT01293318||Acute pancreatitis|
89297618|NCT01190670|Experimental|Part 1, Group 1|ASP015K, low dose followed by high dose, with oral tacrolimus
89297619|NCT01190670|Experimental|Part 1, Group 2|ASP015K, high dose followed by low dose, with oral tacrolimus
89297620|NCT01190670|Experimental|Part 2|ASP015K high dose with intravenous tacrolimus
89297621|NCT01194882|Experimental|Insuman Implantable|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
89297622|NCT01194882|Active Comparator|Insuplant|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
89297623|NCT01296984||Extralevator APR|The perineal part of the APR is done with the intent to create a cylindrically shaped specimen thus removing part of or the entire levator muscle with the specimen.
89297624|NCT01296984||Traditional APR|The perineal part of the APR is performed with the intent to remove the tumour with CRM free of tumour and the levator left in place.
89297625|NCT01295190||Propofol|Patients receiving Propofol during cardiopulmonary bypass.
89297626|NCT01295190||Sevoflurane|Patients receiving sevoflurane during cardiopulmonary bypass
89297627|NCT03848598||Responders|Patients suffering from patellar tendinopathy who have complete pain resolution after performing isometric exercises.
89297628|NCT03848598||Non-responders|Patients suffering from patellar tendinopathy who do not have complete pain resolution after performing isometric exercises.
89297629|NCT01191684|Experimental|Treatment (vaccine therapy)|Patients receive MVAp53 subcutaneously on days 0, 21, and 42 in the absence of unacceptable toxicity.
89297630|NCT02659540|Experimental|Cohort A (Conventional RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a conventional total palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each.
89297631|NCT02659540|Experimental|Cohort B (Hypofractionated RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a hypofractionated high-dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each.
89297632|NCT01295268|Active Comparator|Emu Oil|
89297633|NCT01295268|Placebo Comparator|inert oil|
89297634|NCT03850392|Active Comparator|ice|"16 knee arthritis patients treated by local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - twice within one single day).~Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle."
89297635|NCT03850392|Active Comparator|CO2|16 knee arthritis patients treated by local hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-applied twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle.
89297636|NCT03850392|No Intervention|contralateral non-treated knees|16 contralateral arthritic knees : the synovial fluid was collected and analysed according to the same procedure but no cold treatment was applied (while the corresponding contralateral arthritic knees were treated by ice) : At 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.
89297637|NCT01383694|Experimental|Piperine Dose 1|Piperine 1 mM
89297638|NCT01383694|Experimental|Piperine Dose 2|Piperine 150 microM
89297639|NCT03850158|Experimental|Interventional Arm, ICG and NIR imaging|NIR fluorescence imaging is performed after white light laparoscopy. 0.3mg/kg bodyweight of ICG is administered i.v. All suspected lesions are removed and labeled whether they are seen in WL or NIR imaging or both. Evaluation is performed after the histological analysis of the lesions.
89297640|NCT01295346||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
89297641|NCT02558764|No Intervention|Control|No intervention; basic wound contact absorbent dressings will be used as per current standard of care.
89297642|NCT02558764|Other|PICO|PICO device will be used for prevention of wound complications. This is a portable negative pressure wound treatment device. Patients will have the device for 7 days after undergoing kidney transplant surgery.
89297643|NCT01191918|Experimental|donepezil|donepezil plus Lithium
89297644|NCT01191918|Placebo Comparator|Control|Placebo plus Lithium
89297645|NCT02544802|Experimental|ADMSCs|Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection
89297646|NCT03850314|Experimental|Glycine|Glycine total daily dose of 150mg/kg divided three times daily with meals (powder dissolved in 1 cup of water) for 12 weeks.
89297647|NCT03850080|Experimental|Autologous Conditioned Serum|Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.
89297648|NCT01097746|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab)|Participants receive paclitaxel IV over 3 hours on days 1, 8 and 15 and carboplatin IV over 1 hour on day 1. Beginning course 2, participants also receive bevacizumab IV over 1.5 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89297649|NCT01191996|Experimental|MIS416|MIS416, immunomodulating microparticle, given intravenously weekly
89297650|NCT01190748|Experimental|A|Galantamine 4 mg Tablet, single dose
89297651|NCT01190748|Active Comparator|B|Reminyl 4 mg Tablet, single dose
89297652|NCT01383538|Experimental|FOLFIRINOX Plus IPI-926|
89297653|NCT01192074||Ultrasound of the spine|Pregnant women receiving labor epidural analgesia or spinal anesthesia for cesarean delivery
89297654|NCT01383460|Active Comparator|G-CSF+EPO|
89297655|NCT01383460|Placebo Comparator|Placebo|
89297656|NCT05420116|Experimental|Intervention group|"Physical Activity: Prescription in physical activity include to perform 1 session a week of exercice led by a sports professional, and 2 sessions of authonomus exercice at 60-80% of participants maximum heart rate.~Nutritional: Visits and checks every 2 months with a nutritionist with the aim of improving healthy eating habits.~Positive Mental Health: There are 4 group psycho-emotional sessions based on improving self-esteem, self-control, proactive social attitude and conflict resolution"
89297657|NCT05420116|No Intervention|Control group|Participants follow the habitual controls in nursing consultation. Recomendations of physical activity and diet.
89297658|NCT01190826|Experimental|ASM-024 10 mg|ASM-024 administered once by inhalation at a target dose of 10 mg
89297659|NCT01190826|Experimental|ASM-024 100 mg|ASM-024 administered once at a target dose of 100 mg
89297660|NCT01190826|Placebo Comparator|Placebo|Placebo administered once by inhalation
89297661|NCT05419414|Active Comparator|Adenomyosis|Patients who were diagnosed with adenomyosis according to pelvic MRI were examined with transvaginal ultrasound. Certain ultrasonographic features of adenomyosis ( asymmetrical uterine wall thickening, myometrial cysts, fan shaped lines and shadows, presence of irregular junctional zone, presence of clue sign, global enlargement) were recorded. Then the patients were examined with shear wave elastography. Maximum and minimum median shear wave values were recorded through the selected regions of interest.
89297662|NCT05419414|Active Comparator|Uterine Fibroid|Patients who were diagnosed with myoma uteri according to pelvic MRI were examined with transvaginal ultrasound. Then the patients were examined with shear wave elastography. Maximum and minimum median shear wave values were recorded through the selected regions of interest.
89297663|NCT01195194|Experimental|A- negative pre-transplant ELISPOT|Sirolimus: Start at 5 mg/day as soon as treatment allocation arrives to obtain targeting levels to 8 -15 ng/ml (immunoassay) in the first 3 months, followed by trough levels of 5-10 ng/ml.
89297664|NCT01195194|Experimental|B- Positive pre-transplant ELISPOT|Tacrolimus 0.1 mg/kg/12h starting as soon as treatment allocation arrives to obtain targeting troughs levels of 8-15 ng/ml the first 3 months, followed by trough levels of 5-10 ng/ml until the end of the study.
89297665|NCT01190904||Coronary Artery Disease (≥50%) with or without PCI|We propose to investigate four specific aims using 1,143 diabetic men who have CAD (≥50%) lesion in at least one major epicardial vessel with or without PCI.
89297666|NCT05416840|Experimental|Clonidine|Patients will receive clonidine controlled-release patch (2.5 mg), once a week
89297667|NCT05416840|Active Comparator|Amlodipine|Patients will receive amlodipine (5 mg), once daily
89297668|NCT01192308|Experimental|40mg QD dose intervention|40mg QD dose intervention during 4 weeks in patients with CYP2D6 variant allele or using CYP2D6 inhibitor.
89297669|NCT01190982|Experimental|LEP-ETU|All patient will have baseline to confirm disease status. The disease progression/response is assessed inaccordance to the RECIST guidelines
89297670|NCT03631186||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
89297671|NCT03631108||Normal Population|"Normal population with different gender, different age different, different blood pressure, different ocular pressure, etc.~All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
89297672|NCT03631108||Patients with common ophthalmic diseases|"(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
89297673|NCT03631108||Patients using eye drops|"(1) conjunctivitis patients treated with levofloxacin antibiotics; (2) glaucoma patients treated with prostaglandins, adrenaline or receptor blockers drugs; (3) childhood myopia patients treated with atropine drugs; (4) uveitis patients treated with hormones treatment. (5) diabetic retinopathy patients treated with vasodilator.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after eyedrops."
89297674|NCT03631108||Ocular surgery patients|"(1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitrectomy.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after surgery."
89297675|NCT00176436|Active Comparator|active|Atomoxetine titrated up to 120 mg/day by week 8 and continues at 120 mg/day through week 24. Diet support group, group counseling and exercise.
89297676|NCT00176436|Placebo Comparator|Placebo|Placebo medication, diet support group, group counseling and exercise
89297677|NCT05282784|Experimental|Hyperthermia group|Hyperthermia Radiotherapy
89297678|NCT05282784|Active Comparator|Control|Radiotherapy
89297679|NCT03846960|Experimental|preterm infants|A prospective study to assess the safety and efficacy of surfactant administration via thin catheter using a specially adapted VNscope, originally used for endotracheal intubation and adapted for the administration of surfactant without the placement of an endotracheal tube. A feasibility study of 10 preterm infants 30-36 gestational age at birth, that requires surfactant administration for the indication of respiratory distress syndrome, and do not require immediate intubation
89297680|NCT05410756||FIBROMYALGIA GROUP|Patients diagnosed with Fibromyalgia Syndrome (n=25) who volunteered to be undergone voice analysis.
89297681|NCT05410756||HEALTHY CONTROL GROUP|Healthy volunteers (n=25) without any chronic disease not under any medication volunteered to be undergone voice analysis.
89297682|NCT01293474||glaucoma patients|patients with diagnosis of primary open angle glaucoma
89297683|NCT01293474||control group|age matched healthy controls
89297684|NCT05409508|Experimental|Patients with mindfulness meditation care|
89297685|NCT05409508|Active Comparator|Patients without mindfulness meditation care|
89297686|NCT05370664||Female COPD|
89297687|NCT05370664||Male COPD|
89297688|NCT01196754|Other|sevoflurane|
89297689|NCT05208580|Experimental|On-line education|Virtual educational activities
89297690|NCT05208580|Experimental|Contact education|Live educational classes
89297691|NCT05208580|No Intervention|Control group|Regular perioperative care without additional educational activities
89297692|NCT01295424||Single group study|
89297693|NCT01383226|Other|Thoracic endosonography|Thoracic endosonography, either endobronchial or esophageal ultrasound controlled needle aspiration, is a minimally invasive diagnostic technique.
89297694|NCT01295502|Experimental|Treatment (radiation, cisplatin, paclitaxel, carboplatin)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
89297695|NCT05207644|Other|Letrozole followed by misoprostol|There is only one arm in this study.
89297696|NCT03631030|Other|Cooled radiofrequency ablation|This is a single arm study. Patients who will be undergoing cooled radiofrequency ablation for the treatment of arthritis in the cervical facet joints, thoracic facet joints, lumbar facet joints, sacroiliac (SI) region, hip and knee.
89531586|NCT06013163|Active Comparator|EMP22 - Xenical part 1 crossover blinded|After a 5-day diet run-in period, EMP22 (120 mg modified release orlistat) will be taken 3 times daily (ter in die [TID]) together with the 3 main daily meals for a 9-day treatment period. After a 4-to-14-day wash-out period; orlistat in its conventional form (Xenical®, 120 mg orlistat) will be taken TID together with the 3 main daily meals for a 9-day treatment period.
89297697|NCT03846102|Experimental|Levobupivacaïne|"Fascia Iliaca Compartment Block with Levobupivacaine Hydrochloride (weight based dosage and volume)~Ideal Body Weight : Levobupivacaïne dose (mg) : Dose/kilogram (mg/kg) : Total volume (ml)~[<64 kg : 100 mg : 2.0 mg/kg : 40 ml]~[65-74 kg : 125 mg : 1.9 mg/kg : 45 ml]~[≥ 75 kg : 150 mg : 2.0 mg/kg : 50 ml]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
89297698|NCT03846102|Placebo Comparator|Placebo|"Fascia Iliaca Compartment Block with placebo (Sodium Chloride 0.9%), similar volume to experimental arm.~Ideal Body Weight : Total volume (ml)~[<64 kg : 40 ml]~[65-74 kg : 45 ml]~[≥ 75 kg : 50 ml]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
89297699|NCT01383148|Experimental|Arm 1 - TG4010 + first line therapy|First-line therapy and maintenance therapy
89297700|NCT01383148|Active Comparator|Arm 2 : Placebo + first line therapy|First-line therapy and maintenance therapy
89297701|NCT05671068||DYT-SGCE|Patients with myoclonus dystonia (DYT-SGCE)
89297702|NCT05671068||Healthy volunteers|Control group
89297703|NCT05123716|Experimental|Experimental: Placebo Then MDMA|Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 100 mg MDMA.
89297704|NCT05123716|Experimental|Experimental: MDMA Then Placebo|Participants first receive 100 mg MDMA at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive placebo.
89297705|NCT03845868||Egang hospital physical examination center|
89297706|NCT03845868||Ezhou CDC physical examination center|
89297707|NCT01383070|No Intervention|Lactational Conseling|The existing staff of the hospitals will be provided training in IYCF by BPNI. They will be encouraged to set up their own systems to continue counseling during the ante natal period, at delivery and during the immunization visits. The participants will be asked to come for the same schedule of visits as in the intervention group where their data will be collected.
89297708|NCT01383070|Experimental|Lactation Counseling by Cell Phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
89297709|NCT01195350||stroke|
89297710|NCT01382992||Early Stage|
89297711|NCT01382992||Late Stage|
89297712|NCT01196910|Active Comparator|Stimulation over the left dorsolateral prefrontal cortex|Group A (fifteen subjects) - treatment by HLPFC coil high-frequency stimulation over the left dorsolateral prefrontal cortex (DLPFC).
89297713|NCT01196910|Active Comparator|stimulation over the right DLPFC|Group B (fifteen subjects) - Treatment by HLPFC coil high-frequency stimulation over the right DLPFC.
89297714|NCT01196910|Placebo Comparator|Treatment with HLPFC coil simulator mode|Group C (fifteen subjects) - Treatment with HLPFC coil simulator mode (sham).
89297715|NCT04945174|Active Comparator|Exercise|12 weeks of supervised cardiorespiratory exercise twice a week (6 weeks at the hospital and 6 weeks in the local municipality) combined with patient education and individual follow-up sessions
89297716|NCT04945174|No Intervention|Usual care|The usual care group is encouraged to perform home-based aerobic exercise on their own
89297717|NCT01382914|Experimental|chlorhexidine 0.12 %|
89297718|NCT01382836||Black inner city children with persistent asthma|
89297719|NCT01382836||Black inner city non-atopic healthy children|
89297720|NCT03997318|Experimental|AMDC-USR|AMDC-USR is the study product (Autologous Muscle Derived Cells for Urinary Sphincter Repair).
89297721|NCT03997318|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
89297722|NCT03992092|Experimental|C-Mac VS|Intubation using the C-MAC Video Stylet
89297723|NCT03992092|Active Comparator|FB|Intubation using the Flexible Bronchoscope
89297724|NCT01195428|Active Comparator|Simvastatin|Simvastatin 40 mg daily.
89297725|NCT01195428|Placebo Comparator|Placebo|Placebo
89297726|NCT03718780|Experimental|A1: Patient in intensive care|"Patient in intensive care (n=10):~in patients in the intensive care unit of the Centre Hospitalier Metropole Savoie (Chambéry, France), where repeated arterial blood gas analysis is routinely performed (Patients equipped for their usual care with an arterial catheter, enabling repeated arterial blood gas determination ).~PaCO2 and Pt CO2 will be measured simultaneously at rest, and during conditions inducing PaCO2 modifications (ventilator settings modifications, or exercise as per routine rehabilitation) Comparison will be done between arterial PaCO2 and PtCO2"
89297727|NCT03718780|Experimental|A2: Healthy subjects|"Healthy subjects performing a voluntary hyperventilation, in the laboratory room where routine exercise testing is usually done.~Comparison will be done between arterialized PaCO2 and PtCO2, at rest, and during an induced voluntary hyperventilation."
89297728|NCT03718780|Experimental|B1: Healthy subject|"Subjects, referred for exercise diagnostic testing, and whose results indicate normal cardiac and pulmonary exercise physiology.~Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points."
89297729|NCT03718780|Experimental|B2: Chronic Obstructive Pulmonary Disease|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
89297730|NCT03718780|Experimental|B3: Interstitial Lung Disease (ILD)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
89297731|NCT03718780|Experimental|B4: Chronic heart failure (CHF)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
89297732|NCT03718780|Experimental|B5: Pulmonary Arterial Hypertension (PAH)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
89297733|NCT03718780|Experimental|B6: inappropriate hyperventilation syndrome|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
89297734|NCT03846648|Active Comparator|Cypep-1|"CyPep-1 cream 1% (w/w) will be applied once daily on a 5x5 cm healthy skin area on the upper back and on 1 to max 3 common warts on the (dorsal/palmar) side of the hand.~In Part 1 the dosing will be performed once daily for 7 days. The dose of 200 μL CyPep-1 cream will be applied on a 5x5 cm on the back by clinical staff. In addition, up to 3 common warts will be treated with 20 μL of the CyPep1 cream per day.~In Part 2 subjects will administer 20-30 mg CyPep-1 cream once daily at home after instruction by clinical staff. The total treatment period will be 28 days, possibility of a maximum extension of three days is allowed."
89297735|NCT03846648|Placebo Comparator|Placebo|Placebo cream (the same as that of the drug product CyPep-1 1% (w/w) but without the active substance) will be applied once daily on the same areas as described above.
89297736|NCT04903392|Experimental|Backward Walking Group|Conventional therapy + Backward Walking Training
89297737|NCT04903392|Other|Forward Walking Group|Conventional therapy + Forward Walking Training
89297738|NCT01192932||COPD|COPD patients aged 40 or more, with a smoking history of > 10 pack-years, a post-bronchodilator FEV1/VC < 0.7 and an optimal treatment according to GOLD guidelines will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5 years.
89297739|NCT01193166|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 12 months
89297740|NCT01193166|Active Comparator|002|olanzapine flexible dosing as prescribed by the study doctor for 12 months
89297741|NCT01193166|Active Comparator|003|paliperidone flexible dosing as prescribed by the study doctor for 12 months
89297742|NCT01193166|Active Comparator|004|aripiprazole flexible dosing as prescribed by the study doctor for 12 months
89297743|NCT01193166|Active Comparator|005|haloperidole flexible dosing as prescribed by the study doctor for 12 months
89297744|NCT01193166|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 12 months
89297745|NCT01193166|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 12 months
89297746|NCT01193166|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 12 months
89297747|NCT03848520||Total Knee Arthroplasty|Internal Registry of Patients having a TKA and with a high (>=9) activity-scale score at anytime between preoperatively and now.
89297748|NCT01197144|Active Comparator|Adalimumab|Treatment with adalimumab 40 mg sc eow for 4 weeks
89297749|NCT01197144|Placebo Comparator|Placebo|Treatment with placebo s c eow for 4 weeks
89297750|NCT01197144|No Intervention|Healthy Controls|"Healthy volunteers, age ≥18. Will perform all the same pain assessments, blood sampling and baseline fMRI as RA patients~Exclusion criteria:~For fMRI - left handedness and all forms of metallic implants.~Fulfilling ACR criteria for fibromyalgia.~Severe ischemic heart disease.~Concurrent treatment for depression/anxiety with antidepressant drugs.~Concurrent neurological disease.~Other reason as evaluated by the P.I."
89297751|NCT01193400|Experimental|Clofarabine-Cytarabine|Induction therapy with a combination of clofarabine and low-dose cytarabine followed by consolidation therapy with clofarabine and low-dose cytarabine
89297752|NCT03904888|Other|l-TAPP without local anesthetics|These patients will undergo a laparoscopic surgery without local anaesthetics.
89297753|NCT03904888|Other|l-TAPP with local anesthetics|These patients will undergo a laparoscopic surgery with local anaesthetics.
89297754|NCT03904888|Other|r-TAPP without local anesthetics|These patients will undergo a robot-assisted surgery without local anaesthetics.
89297755|NCT03904888|Other|r-TAPP with local anesthetics|These patients will undergo a robot-assisted surgery with local anaesthetics.
89297756|NCT05670834||control group (GroupA)|normal healthy non-cataractous volunteers aged ≥21 years
89297757|NCT05670834||Group B (experimental group 1)|cataractous patients aged >50 years and diagnosed with senile cataract.
89297758|NCT05670834||Group C (experimental group 2)|cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract
89297759|NCT01197222|Active Comparator|EndoClear used|The EndoClear device is used during a laparoscopic abdominal surgery.
89297760|NCT01197222|No Intervention|Control|EndoClear Lens Cleaning Device not used during a laparoscopic abdominal surgery.
89297761|NCT03846258|Active Comparator|Low bicarbonate arm (22 mmol/L)|PHOXILLUM solutions are used as a replacement solution in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 22 mmol/L.
89297762|NCT03846258|Active Comparator|High Bicarbonate (32 mmol/L)|PrismaSATE is another replacement solution used in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 32 mmol/L.
89297763|NCT03763318|Experimental|EQ001 Dose Escalation (Part A)|Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses.
89297764|NCT03763318|Experimental|EQ001 (Part B)|EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses.
89297765|NCT03763318|Placebo Comparator|EQ001 Placebo (Part B)|Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses.
89297766|NCT01193478|Active Comparator|Cohort 1|GS-5885 (3 mg), once daily or matching placebo, once daily
89297767|NCT01193478|Active Comparator|Cohort 2|GS-5885 (10 mg), once daily or matching placebo, once daily
89297768|NCT01193478|Active Comparator|Cohort 3|GS-5885 (30 mg), once daily or matching placebo, once daily
89297769|NCT01193478|Active Comparator|Cohort 4|GS-5885 ( up to 90 mg), once daily or matching placebo, once daily
89297770|NCT01193478|Active Comparator|Cohort 5|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
89297771|NCT01193478|Active Comparator|Cohort 6 (optional)|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
89297772|NCT01193634|Experimental|Paradym RF ICD|Active implantable defibrillators range
89297773|NCT02930590|Experimental|Low Pressure mattress|Alternating Low Pressure mattress with low air loss function (IsoAir, stryker, USA)
89297774|NCT02930590|Experimental|Reactive support surface|Gel mattress (IsoGel, stryker, USA)
89297775|NCT02930590|Active Comparator|Standard mattress|basic foam
89297776|NCT03848442|Experimental|UPART intervention group|A 1-group pretest-posttest design was conducted. Outcomes were evaluated on four occasions; twice during baseline separated by six weeks and immediately following a 12-week 'uptime' participation intervention and after a further 12 weeks (follow-up).
89297777|NCT01295658||Cancer Survivors|"This is a broad observational study conducted online at www.cancerexperienceregistry.org, or via pen and paper survey obtained by calling the cancer support helpline at 888-793-9355~Any individual who has ever received a cancer diagnosis, regardless of disease type, stage, treatment, and time since diagnosis, can take part in this study."
89297778|NCT01295736|Active Comparator|Actif arm|Sildenafil 20mg TID during 90 days
89297779|NCT01295736|Placebo Comparator|Sugar pill|Placebo pills TID during 90 days
89297780|NCT01195740|Experimental|Attachment Based Family Therapy|
89297781|NCT01195740|Active Comparator|Enhanced Usual Care|
89297782|NCT01195818|Experimental|RAS Inhibitors|RAS Inhibitors
89297783|NCT03733470|Experimental|Nonsusceptible Smokers (NS)|8 subjects recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
89297784|NCT03733470|Experimental|Susceptible Smokers (SS)|11 subjects recruited to study non-contrast imaging at TLC and 20% VC and with contrast using DECT to assess pefused blood volume. For the intervention the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
89297785|NCT03058276|Experimental|Exposure|Exposure to a 5 minutes video related to alcohol consumption (updating/retrieval), followed by 10 minutes of the alcohol- AAT(Approach Avoidance Task) (extinction), during 4 days of training (2 weeks).
89297786|NCT03058276|Active Comparator|No exposure|Exposure to a 5 minutes video with neutral content (no retrieval) followed by 10 minutes of the alcohol- AAT (Approach Avoidance Task) , during 4 days of training.
89297787|NCT03058276|Experimental|Active rTMS|Each session (5 sessions along 2 weeks), patients receive active stimulation with repetitive transcraneal magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex.
89297788|NCT03058276|Sham Comparator|SAM|Pacients receiving a sham stimulation (SAM), with a similar procedure to the experimental condition
89297789|NCT03845478|Active Comparator|Control Group (CG)|Education, modifying diet and physical activity
89297790|NCT03845478|Experimental|Intervention Group (IG)|Education and modifying diet and physical activity with prescription and goal setting
89297791|NCT05351710|Experimental|Exposure-Based Treatment for Perfectionism|This arm consists of a 2-week computerized, exposure-based intervention. Treatment sessions are completed every 2 days at home (8 treatment sessions total).
89297792|NCT05351710|Active Comparator|Stress Management Condition|This arm consists of a 2-week, computerized, stress-management condition in which participants watch videos of health habits (e.g., nutrition, exercise, sleep) and relaxation videos. These sessions are completed every 2 days at home (8 sessions total).
89297793|NCT01195974|Experimental|Period 1|YASMIN + 200 mg GSK2248761 or Placebo
89297794|NCT01195974|Experimental|Period 2|YASMIN + 200 mg GSK2248761 or Placebo
89297795|NCT01195974|Other|Run In Period|YASMIN
89297796|NCT03268356|Other|AGN1 Treatment|Subjects who have suffered a fragility hip fracture in one hip, sign the consent form and meet the inclusion and none of the exclusion of the study will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) in the non-fractured hip.
89297797|NCT04731376|Experimental|Arm I (testosterone cypionate)|Patients with low testosterone levels receive testosterone cypionate IM QW for 3 months.
89297798|NCT04731376|Active Comparator|Arm II (best practice)|Patients with normal testosterone levels receive standard peri-operative care.
89297799|NCT05281354|No Intervention|standard care|Follow-up according to standard practice
89297800|NCT05281354|Experimental|multimodal intervention|Addition of a treatment to normalise resting energy expenditure according to the observed abnormalities
89297801|NCT01295892|Placebo Comparator|placebo|placebo (transdermal gel)
89297802|NCT01295892|Experimental|Estrogen|1mg of 17B-estradiol/day (transdermal gel)
89297803|NCT05257720||Remission|Patient with schizophrenia in remission
89297804|NCT05257720||treatment resistant|patient with treatment resistant schizophrenia
89297805|NCT05257720||controls|healthy controls
89297806|NCT01295970|Active Comparator|Radiosurgery (SRS)|
89297807|NCT01295970|Active Comparator|Surgery|
89297808|NCT01193712|Other|on-table non-responder|patients who do not show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
89297809|NCT01193712|No Intervention|on-table responders|patients who do show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
89297810|NCT03848130|Active Comparator|Knee Taping with Home Exercises (Group 1)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into knee taping group.Each subject in first group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
89297811|NCT03848130|Active Comparator|Lateral wedge insoles with Home Exercises (Group 2)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into lateral wedge insole group.Each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
89297812|NCT03848130|Active Comparator|Traditional Physiotherapy with Home Exercises (Group 3)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into traditional physiotherapy group.Each subject in third group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
89297813|NCT03631576|Experimental|Arm 1|CD123/CLL1 CAR-T Cells treat
89297814|NCT01296048||Body Analysis|
89297815|NCT05136118|Active Comparator|Group MS|The modified surgeon assisted approach for TAPB Before the closure of the peritoneum, TAPB will be performed; at the level of the umbilicus 8 to 10cms from the midline bilaterally. A sterile 100-mm 22-G insulated needle will be inserted perpendicular to the skin slightly directed towards the ipsilateral anterior superior iliac spine. After feeling the 2 pops of the external and the internal oblique aponeurosis by the anesthesiologist, the surgeon will confirm proper needle placement by his hand inside the abdominal cavity. The LA will be injected after negative aspiration and a bleb will be palpated by the surgeon as the injection continues. The same procedure will be repeated on the other side.
89297816|NCT05136118|Active Comparator|Group US|The ultra-sound guided approach for TAPB. After abdominal wall closure, the linear probe of the ultra- sound will be placed perpendicular to the skin at the mid-axillary line between the iliac crest and the costal margin; the TAP will be located between the internal oblique and the transversus abdominis muscle. A sterile 100-mm 22-G insulated needle will be inserted perpendicular to the skin and the 2 pops of the external and the internal oblique aponeurosis will be also felt. The LA will be injected after negative aspiration and its spread in the plane will be observed. The same procedure will be repeated on the other side.
89297817|NCT01196286|Experimental|MFG and CR|Subjects provided with both multifamily psychoeducation (MFG) and cognitive remediation (CR)
89297818|NCT01196286|Active Comparator|MFG|Subjects provided with only multifamily group psychoeducation (MFG)
89297819|NCT01196364|Experimental|Sedentary activity, noncaloric beverage|
89297820|NCT01196364|Experimental|Sedentary activity, glucose beverage|
89297821|NCT01196364|Experimental|Exercise activity, noncaloric beverage|
89297822|NCT01196364|Experimental|Exercise activity, glucose beverage|
89297823|NCT01197768|Experimental|Nutrition Intervention|The intervention group will receive a full nutrition assessment and a nutrition intervention.
89297824|NCT01197768|No Intervention|Control|This group will receive the nutrition assessment but no intervention from a Registered Dietician. If participant appears to be in danger due to BMI or Caloric intake status, their primary care physician will be notified.
89297825|NCT03732534|Experimental|NBI-98854|NBI-98854 administered once daily for up to 96 weeks
89297826|NCT04983472||Observational Group|Individuals diagnosed with Chronic Obstructive Pulmonary Disease by the Department of Pulmonology of the Faculty of Medicine of Bolu Abant Izzet Baysal University will be referred to the Department of Physiotherapy and rehabilitation of the Faculty of Health Sciences of Bolu Abant Izzet Baysal University
89297827|NCT02998450|Experimental|Cohort 1|"4 Subjects will receive a single low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
89297828|NCT02998450|Experimental|Cohort 2|"4 Subjects will receive a single low-mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
89297829|NCT02998450|Experimental|Cohort 3|"4 Subjects will receive a single mid-low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
89297830|NCT02998450|Experimental|Cohort 4|"4 Subjects will receive a single mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
89297831|NCT02998450|Experimental|Cohort 5|"4 Subjects will receive a single mid-high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
89297832|NCT02998450|Experimental|Cohort 6|"4 Subjects will receive a single high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
89297833|NCT01296204|Experimental|BB4 antibody-Iodine 131|
89297834|NCT03846336|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
89297835|NCT03846336|Other|Healthy individuals|20 healthy volunteers with matching ages and genders.
89297836|NCT01197846|Experimental|Quetiapine|Quetiapine 300 mg or 600 mg
89297837|NCT01197846|Placebo Comparator|Placebo|
89297838|NCT03631498||Healthy individuals|Gingival biopsies of healthy individuals who were never-smokers and had no systemic or oral disease or condition.
89297839|NCT03631498||periodontitis patients|Gingival biopsies of periodontitis patients who were never-smokers and had no systemic disease or condition.
89297840|NCT03631498||Healthy smokers|Gingival biopsies of healthy individuals who were smokers but no systemic or oral disease or condition.
89297841|NCT03631498||Smokers with periodontitis|Gingival biopsies of periodontitis patients who were smokers but no systemic disease or condition.
89297842|NCT01586754||With Metabolic Syndrome|
89297843|NCT01586754||Without Metabolic Syndrome|
89297844|NCT03847740|Experimental|Right Isometric Thumb Force (ITF) handle|
89297845|NCT03847740|Experimental|Left Isometric Thumb Force (ITF) handle|
89297846|NCT01193790|Experimental|Coblation|
89297847|NCT03087058|Experimental|Cohort 1|Patiromer for age 12 to < 18 years
89297848|NCT03087058|Experimental|Cohort 2|Patiromer for age 6 to < 12 years
89297849|NCT03087058|Experimental|Cohort 3|Patiromer for age 2 to < 6 years
89297850|NCT01296282||Heart failure patients|
89297851|NCT01196520||BL Cases|Children from East Africa diagnosed with BL
89297852|NCT01196520||HCII Controls|Matched controls from the local health clinics
89297853|NCT01196520||Population Controls|Matched controls from the geographic region
89297854|NCT01192854|Experimental|1|
89297855|NCT01192854|Active Comparator|2|
89297856|NCT03846180||Terlipressin group|Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
89297857|NCT03846180||Somatostatin/Octreotide group|Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
89297858|NCT05487690|Experimental|3D printing guide plate group|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries.
88813883|NCT03403868|Other|Conductance catheter|Contractility-measurement with conductance catheter (pressure-volume-catheter)
89297859|NCT05487690|Active Comparator|Conventional guidance group|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
89297860|NCT01199406|Placebo Comparator|normal saline|80 mL 0.9% NaCl
89297861|NCT01199406|Experimental|Levobupivacaine|80mL 0.125% levobupivacaine
89297862|NCT01197924||healthy volonteer children|paired for the sex and the age
89297863|NCT01197924||older children followed for a médulloblastome cérébelleux|children followed for a médulloblastome treaty by surgery, radiotherapy and chemotherapy
89297864|NCT03846414||PEG-rhG-CSF group|This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle. The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
89297865|NCT03846414||rhG-CSF group|This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
89297866|NCT01196598|Active Comparator|PFMT group|Women who undergo to three months of a pelvic floor muscle training program.
89297867|NCT01196598|Active Comparator|HE + PFM group|Women who undergo to three months of a hypopressive exercises plus pelvic floor muscle contraction program.
89297868|NCT01196598|Active Comparator|HE group|Women who undergo to three months of a hypopressive exercises program.
89297869|NCT01196598|Active Comparator|Control|Women who undergo to a session for lifestyle advice.
89297870|NCT02729116|Experimental|Sitafloxacin group|Sitafloxacin 100 mg oral twice daily
89297871|NCT02729116|Active Comparator|Ertapenem group|Ertapenem 1 gm IV every 24 h
89297872|NCT01196676|Experimental|1|AZD4451
89297873|NCT01196676|Placebo Comparator|2|Placebo
89297874|NCT04903236||Non-patient healthy volunteer|Undertake MR Imaging to enable development of sequences.
89297875|NCT04903236||Patient|Provide weekly blood and urine samples during period of radiotherapy as well as additional MR images.
89297876|NCT03844230|Other|Inhibition Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
89297877|NCT03844230|Other|Stimulation Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Stimulation, Experimental I- Stimulation, Experimental II -Stimulation). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
89297878|NCT05467410|Experimental|COG-AM|30-minute morning session of a computerized cognitive training intervention (Lumosity), delivered between the hours of 09:00 AM - 12:00 PM, in addition to UC
89297879|NCT05467410|Experimental|COG-PM|30-minute afternoon/evening session of a computerized cognitive training intervention (Lumosity), delivered between the hours of 15:00 PM - 18:00 PM, in addition to UC
89297880|NCT05467410|No Intervention|UC|Standard post-ICU inpatient care/usual care
89297881|NCT05457270|Experimental|Sequence 1 (Formulation A + Formulation B)|Participants will receive a single oral dose of Treatment 1: Formulation A followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 2: AZD4831 Formulation B.
89297882|NCT05457270|Experimental|Sequence 2 (Formulation B + Formulation A)|Participants will receive a single oral dose of Treatment 2: Formulation B followed by a washout period of at least 14 days from first dose of AZD4831. After the washout period, participants will receive a single oral dose of Treatment 1 Formulation A.
89297883|NCT01382758||Acute kidney injury|The group of patients who develop acute kidney injury as defined by the pediatric RIFLE criteria.
89297884|NCT01382758||No acute kidney injury|The patients who do not develop acute kidney injury
89297885|NCT03844152|Experimental|Fermented whey concentrate|Volunteers will receive the premixed water and fermented whey in weekly deliveries in 1.5L bottles and a drinking glass with a clear indication of the required 200ml volume. Participants will be asked to drink 200 ml of the supplemented water twice daily for the active intervention period.
89297886|NCT01199562||Arm I|Patients receive standard antiviral infection prophylaxis and management comprising ganciclovir, valganciclovir, or foscarnet sodium for 2 weeks or until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on subsequent CMV reactivations.
89297887|NCT05289258|Active Comparator|Neuropsychological treatment|Combination of different neuropsychological rehabilitation programs
89297888|NCT05289258|Experimental|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED).
89297889|NCT05289258|Other|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
89297890|NCT03845322|Experimental|Curcumin pills group|24 Patient will receive Curcumin (CC) pills, within 24 hours post-operatively (as long as they are able to take oral medication). It will then be continued TID
89297891|NCT03845322|Placebo Comparator|Placebo group|24 Patient will receive Placebo pills, within 24 hours post-operatively (as long as they are able to take oral medication. It will then be continued TID.
89297892|NCT04889976|Experimental|Double-active|Active portable transcranial electrical stimulation (ptES) and active internet-based behavioral therapy (iBT).
89297893|NCT04889976|Active Comparator|ptES-only|Active portable transcranial electrical stimulation (ptES) and sham internet-based behavioral therapy (iBT).
89297894|NCT04889976|Sham Comparator|Double-sham|Sham portable transcranial electrical stimulation (ptES) and sham internet-based behavioral therapy (iBT).
89297895|NCT01199640|Experimental|MLN1202|
89297896|NCT01198080|Experimental|femoral osteonecrosis patients|patientswith femoral head osteonecrosis
89297897|NCT03844932|Experimental|ST-0529 18.75 mg*|"ST-0529: 18.75 mg orally twice daily (BID)~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
89297898|NCT03844932|Experimental|ST-0529 37.5 mg*|"ST-0529: 37.5 mg orally twice daily (BID)~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
89297899|NCT03844932|Experimental|ST-0529 75 mg|ST-0529: 75 mg orally twice daily (BID)
89297900|NCT03844932|Placebo Comparator|Matching Placebo|Placebo: matching placebo orally twice daily (BID)
89297901|NCT03726996|Experimental|Children with INAD|Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
89297902|NCT01201980||1|Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
89297903|NCT01202058|Experimental|NEVO™ SES|"Design Protocol Am3.0 - safety follow-up:~The study population consists of 103 subjects with atherosclerotic coronary artery disease treated with the NEVO™ SES. Candidates for the initial NEVO II Study must have met ALL inclusion criteria and NO exclusion criteria.~Design Original Protocol~Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System."
89297904|NCT01202058|Active Comparator|XIENCE V®/XIENCE PRIME™/PROMUS®|Subjects randomized to treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System
89297905|NCT04136418|Active Comparator|Usual care|Patients currently self-manage their condition using antibiotics and steroids when their disease symptoms match the criteria in information provided by a clinician
89297906|NCT04136418|Experimental|Mobile App device|Patients enter their health status onto an App which is relayed to the healthcare team, who can then provide further information or clinical intervention should they so choose
89297907|NCT03844308|Experimental|Group 1|Participants will be asked to complete Isha Kriya meditation twice daily for a total of six weeks in phase 1.
89297908|NCT03844308|Active Comparator|Group 2|Participants will be asked to refrain from meditating for the first 6 weeks (phase 1) and then asked to complete Isha Kriya meditation for another 6 weeks (phase 2)
88813884|NCT01725620|Experimental|Group 1|Enbrel, LBEC0101
88813885|NCT01725620|Experimental|Group 2|LBEC0101, Enbrel
89297909|NCT05670054|Active Comparator|palbociclib + fulvestrant|Arm A includes patients who receive palbociclib 125 mg tab/day for 3 weeks and 1 week rest+ Fulvestrant 500 mg IM injection d1, d15, d29 1st cycle then every month
89297910|NCT05670054|Active Comparator|Ribociclib + fulvestrant|Arm B includes patients who receive ribociclib 200 mg 3 tabs/day for 3 weeks and 1 week rest+ Fulvestrant 500 mg IM injection d1, d15, d29 1st cycle then every month
89297911|NCT04777656|Experimental|CDED/Modulen™IBD®|Strategy combining CD exclusion diet plus Modulen™IBD® on top of ongoing maintenance therapy.
89297912|NCT04777656|Active Comparator|Unrestricted food access|Stop CDED and Modulen™IBD®, but continue maintenance therapy with unrestricted food access.
89297913|NCT04777656|Other|Not randomized|Patient not in remission at M2 or refusing randomisation
89297914|NCT05670600|Experimental|intervention group|The intervention group received training by sending foot and ankle exercise videos to their mobile phones via WhatsApp.
89297915|NCT04776564||Intensive courses|Participants on courses delivered within four days
89297916|NCT04776564||Long courses|Participants on courses delivered over minimum four weeks
89297917|NCT04776564||Clinical|Participants attending G7P courses delivered within the specialist health care setting
89297918|NCT04776564||Internett|Participants attending G7P courses delivered as an online course
89297919|NCT04776564||Professional|Participants attending G7P courses wihere professional health care personell are delivering the teaching
89297920|NCT04776564||Non-professional|Participants attending G7P courses wihere no professional health care personell are delivering the teaching
89297921|NCT04776564||Control group|A sample of couples from the public that do not at the moment participate in couple therapy or any couple enhancement programs
89297922|NCT01202136||Pancreatic cysts|patients referred to Johns Hopkins Hospital for evaluation and or treatment for 1 or more pancreatic cysts
89297923|NCT03844854|No Intervention|Control Group|Without intervention.
89297924|NCT03844854|Experimental|Research Group|With providing stabilization occlusal splint and manual therapy.
89297925|NCT03842046|Active Comparator|phenylephrine infusion|phenylephrine infusion (30 mL/h corresponding to 50 μg/min)
89297926|NCT03842046|Active Comparator|norepinephrine infusion|norepinephrine infusion (30 mL/h corresponding to 4 μg/min)
89297927|NCT01198314|Experimental|LT, withdrawal of immunosuppression|
89297928|NCT01198314|Active Comparator|LT, maintenance of immunosuppression|
89297929|NCT01199718|Experimental|CX-4945|CX-4945 oral formulation
89297930|NCT01202214|Experimental|Active drug|
89297931|NCT01202214|Placebo Comparator|Placebo|
89297932|NCT03841734|Experimental|Treatment bosentan|
89297933|NCT01202292|Experimental|Lifestyle counseling|
89297934|NCT05212740|Experimental|Corticosteroid|The participants will receive prednisolone for four weeks.
88806244|NCT02108522|Experimental|Multivirus Specific T cells|"Partially HLA-matched multivirus specific T cells (VSTs) will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team.~If after the first treatment there is persistent infection, there is an option to receive more treatments. These additional treatments might be with cells from the same donor or another donor whose cells are also thought to be a good match for the patient and effective against their virus. This second product will be administered at the same dose level 28 days after the initial infusion, and subsequent infusions should be at least 14 days apart."
89297935|NCT05212740|Active Comparator|Exercise|The participants will receive joint mobilization techniques, stretching and home exercise.
89297936|NCT03841968|Active Comparator|Dynamic needle tip positioning|Dynamic needle tip positioning
89297937|NCT03841968|Active Comparator|Conventional long-axis|Conventional long-axis
89297938|NCT04103502||MicroPort Medial Pivot|Subjects will have been implanted with the MicroPort Medial Pivot TKA
89297939|NCT04103502||DePuy Attune|Subjects will have been implanted with the DePuy Attune PCR TKA
89297940|NCT04707300|Experimental|Human T Lymphoid Progenitor (HTLP) injection|HTLP cellular product obtained after 7 days of culture of immune-selected CB
89297941|NCT03843996|Experimental|Treatment left|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
89297942|NCT03843996|Experimental|Treatment right|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
89297943|NCT04084392|Active Comparator|Usual Care|Participants randomized to this arm will receive care as usual.
89297944|NCT04084392|Active Comparator|Bridge Clinic|Participants randomized to this arm will be referred to the Bridge Clinic to facilitate identification and referral to an outpatient provider for addiction treatment.
89297945|NCT05174754|Experimental|Inflammatory Bowel Disease Exercise Group|The exercise group will be randomized to a 20-week physician-prescribed exercise programme following the principles of Frequency, Intensity, Time, and Type (FITT) in addition to best medical therapy with the aim of increasing physical fitness levels, inflammatory response, quality of life/fatigue improvements and favorable body composition changes.
89297946|NCT05174754|Other|Inflammatory Bowel Disease Control Group|The IBD control group will be randomized to best medical therapy alone.
89297947|NCT05174754|No Intervention|Healthy Control Group|A group of healthy controls without inflammatory bowel disease will be included in the study for comparison of inflammatory markers including cytokine analysis and body composition.
89297948|NCT03841890|Experimental|Intubation with the Clarus Video System as a video stylet|
89297949|NCT03841890|Experimental|Intubation with the Clarus Video System as a lightwand|
89297950|NCT03841890|Active Comparator|Intubation with direct laryngoscope|
89297951|NCT03052218|Experimental|single arm study|pupillometry, CYP2D6 genotyping and phenotyping
89297952|NCT01199874|Active Comparator|Primary 1: Rotavirus vaccine 6 and 10 weeks|EPI vaccines + rotavirus vaccine at 6 and 10 weeks
89297953|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 6, 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks
89297954|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 10 and 14 weeks
89297955|NCT01199874|Experimental|Primary 2: Rotavirus vaccine withholding breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks withholding breastfeeding
89297956|NCT01199874|Experimental|Primary 2: Rotavirus vaccine with immediate breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks with immediate breastfeeding
89297957|NCT01199874|No Intervention|Baseline seroconversion for rotavirus|EPI vaccines
89297958|NCT05670444|Active Comparator|kelavit|The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
89297959|NCT05670444|Placebo Comparator|placebo|Patients from the placebo group received three similar pills
89297960|NCT01200108|Experimental|Budesonide high dose via AKITA (1mg/2ml)|
89297961|NCT01200108|Experimental|Budesonide low dose via AKITA (0.5mg/2ml)|
89297962|NCT01200108|Active Comparator|Budesonide high dose via conventional nebulizer (1mg/2ml)|
89297963|NCT01200108|No Intervention|Placebo via AKITA|
89297964|NCT01200186||Group 1|
89297965|NCT01200186||Group 2|
89297966|NCT03841578|Experimental|Healthy|10 participants (matched per gender), aged 25-35 years old who accepts the consumption of dark chocolate plus a 'NutriDrink' previous to signing an informed consent and providing authorization to the handling of their personal data
89297967|NCT03841812|Experimental|Propofol|5mg/kg/h Propofol continue infusion during the maintain of anesthesia during the maintain of anesthesia.
89297968|NCT03841812|Experimental|Propofol & Sevoflurane|2mg/kg/h Propofol & 1% Sevoflurane group continue infusion(Balance anesthesia) during the maintain of anesthesia
89297969|NCT03882970|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
89297970|NCT03882970|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
89297971|NCT03882970|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
89297972|NCT03882970|Active Comparator|Insulin Degludec|Insulin degludec administered SC once a day.
89297973|NCT05111808|Experimental|Methyl Blue|This group will receive intraoperative IV methyl blue
89297974|NCT01566786|Experimental|activated recombinant human factor VII|
89297975|NCT01566786|Placebo Comparator|Placebo|
89297976|NCT01198392|Experimental|S-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
89297977|NCT01198392|Active Comparator|5-Fu plus cisplatin|5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
89297978|NCT03844542|Experimental|Therapeutic plasma exchange|Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
89297979|NCT03844542|No Intervention|Standard care alone for sepsis|Standard care for patients with sepsis induced multi-organ failure
89297980|NCT03843684|Experimental|Knee osteoarthritis patients|
89297981|NCT05759650|Experimental|Analyses of Kinematic and Kinetic parameters of movement|
89297982|NCT01200264|Experimental|apremilast for all subjects|
89297983|NCT04818970|Experimental|Phototherapy of narrow band ultraviolet Light B-Band NB-UVB|Daavlin Series 1 Phototherapy Unit that emits UVB light between 280nm and 320nm.
89297984|NCT04818970|Placebo Comparator|Placebo - Light|Daavlin Series 1 Phototherapy Unit that does not emit UVB light between 280nm and 320 nm.
89297985|NCT03841344|Active Comparator|Healthy volunteers|MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
89297986|NCT03841344|Active Comparator|Treatment naive patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH initiating PAH therapy for the first time"
89297987|NCT03841344|Active Comparator|Treatment change patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH, currently on PAH therapy who are undergoing an escalation of PAH therapy"
89297988|NCT03841344|Active Comparator|Stable patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients with PAH who are NOT undergoing changes in their treatment regime"
89297989|NCT04811872|Experimental|Intact umbilical cord milking (I-UCM)|
89297990|NCT04811872|Experimental|Cut-umbilical cord milking(C-UCM)|
89297991|NCT04811872|Experimental|Delayed Cord Clamping (DCC )|
89297992|NCT03841500|Active Comparator|Aperture (biocomposite screw) fixation|"16 patients in this arm underwent ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw (BioComposite Screw, Arthrex, North Naples, FL; or MILAGRO screw, DePuy Mitek, Raynham, MA, USA).~Intervention: ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw."
89297993|NCT03841500|Active Comparator|Suspensory (endobutton) fixation|"17 patients in this arm underwent ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button (TightRope, Arthrex, North Naples, FL, USA).~Intervention: ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button."
89297994|NCT03843346||Cohort 1: Postoperative group|"Consists of 75 patients who have completed definite surgery for their primary breast cancer as determined by a Consultant Surgeon and have been referred to a Medical Oncologist for consideration of adjuvant chemotherapy.~Tumours of any size will be eligible~Between 1 and 3 lymph nodes involved by tumour as assessed by Consultant Pathologist~Micro metastases (<=0.2mm) will be eligibile~Isolated tumour cells only (node negative i+/i-) are excluded"
89297995|NCT03843346||Cohort 2: Preoperative group|"Consists of 75 patients who have been referred by a Consultant Surgeon to a Medical Oncologist for consideration of neoadjuvant (preoperative) chemotherapy.~Min tumour size 2.1mm (T2)~Histological proof of involvement of at 1 lymph node, including micrometastases (<=0.2mm)"
89297996|NCT01200420|Experimental|miravirsen|Dose escalation study with review of safety data following each cohort.
89297997|NCT01200420|Placebo Comparator|saline|Dose escalation study with review of safety data following each cohort.
89297998|NCT01198704||HCC patients|Patients notified on the national waiting list for hepatic transplant
89297999|NCT01202370|Experimental|AR-67|Phase 1 study
89298000|NCT01200576||1|healthy volunteers
89298001|NCT04720378|Experimental|Cohort 1|0.1 ml/kg IV ST266 once a day for 5 days
89298002|NCT04720378|Experimental|Cohort 2|0.25 ml/kg IV ST266 once a day for 5 days
89298003|NCT04720378|Experimental|Cohort 3|0.5 ml/kg IV ST266 once a day for 5 days
89298004|NCT04720378|Experimental|Cohort 4|1.0 ml/kg IV ST266 once a day for 5 days
89298005|NCT01382680|Active Comparator|Classic guidewires|Conventional guidewires used in combination as preferred by the investigating ERCP specialist
89298006|NCT01382680|Active Comparator|New guidewire (G240)|Primary use of the new guidewire (G240)
89298007|NCT04703140|Experimental|nasopharyngeal swabs|One patient will have 2 nasopharyngeal for PCR and COVIDISC
89298008|NCT03843606|Experimental|diet 1|60% fat, 15% protein, 25% carbohydrates
89298009|NCT03843606|Experimental|diet 2|70% fat, 15% protein, 15% carbohydrates
89298010|NCT03843606|Experimental|diet 3|80% fat, 15% protein, 5% carbohydrates
89298011|NCT03630952|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
89298012|NCT03630952|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
89298013|NCT03630952|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
89298014|NCT01198782|Experimental|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
89298015|NCT05282160|No Intervention|Control Group|The control group (G1) will be composed of puerperal women over 18 years of age attended by Lucila Balalai Municipal Maternity in Londrina. Recruitment will be done through a chart review, which will include single-fetus primiparous that delivered on full term without intercurrence (between 37 and 42 weeks).
89298016|NCT05282160|Experimental|Epino Group|The study group (G2) will be composed of women over 18 years of age, primigravidae, between 30 and 32 weeks of gestation attended by the Basic Health Units of the central region of Londrina. Only those who agree to participate in the study and sign the free and informed consent form will be included.
89298017|NCT05032638|Experimental|Experimental Group|Subjects with motor impairment will work closely with an occupational therapist to identify a goal and select activities that they will work on at home to improve the function of their affected arm.
89298018|NCT03763240|Active Comparator|BSE|Sulforaphane-containing broccoli sprout extract (BSE). The study product is BSE with standardized amounts of sulforaphane. BSE contains a mixture of maltodextrin as a bulking agent and copper chlorophyllin (E 141) as a food additive. BSE is a dried powder of an aqueous extract of broccoli sprouts that provides a consistent and stable source of sulforaphane.
89298019|NCT03763240|Placebo Comparator|Placebo|A mixture of maltodextrin and copper chlorophyllin will be used as placebo. The active compound and the placebo are the same except BSE. The placebo will look similar to the BSE-containing mixture.
89298020|NCT03840954|Experimental|Neuromuscular Electrical Stimulation|The experimental group will receive the application of NMES associated with conventional physiotherapy. After the NMES application, conventional physiotherapy will be performed. The exercises performed will be according to the patient's physical condition, and the conducts will always be performed seeking the maximum possible functional performance for the patient. The conducts adopted according to the standard routine of the HCPA stroke unit are: passive, active, assisted and / or active exercises; muscle stretching; selective hip extension; trunk stabilization training in sedestation; orthostasis training and walking training.
89298021|NCT03840954|No Intervention|Group Control|The control group will only receive conventional physiotherapy, composed of the same exercises performed in the experimental group.
89298022|NCT03752866|Experimental|Portico™ Valve, Delivery System(s) and Loading Systems(s)|Implantation of the Portico ™ Valve using the Portico Delivery and Loading Systems
89298023|NCT03752866|Experimental|Portico™ Valve, FlexNav Delivery and Loading System(s)|Implantation of the Portico ™ Valve using the FlexNav Delivery and Loading Systems
89298024|NCT03841188|Other|Nutritional Orientation|The patients received a nutritional orientation with emphasis in food rich in calcium
89298025|NCT05759494||A|50 patients before use rapid diagnostic test (multiplex PCR filmArray)
89298026|NCT05759494||B|50 patients after use rapid diagnostic test (multiplex PCR filmArray)
89298027|NCT01202448|Active Comparator|DLBCL with risk factor|Patients have any of risk factors for secondary CNS involvement
89298028|NCT03730480|Experimental|Subjects with and without Diabetes test Contour Next and Contour TV3|All subjects test CONTOUR NEXT BGMS and CONTOUR TV3 BGMS
89298029|NCT01200654|Experimental|MRSA Infections|Methicillin-Resistant Staphylococcus aureus Infections
89298030|NCT05008380|Experimental|Standard of care + prone positioning|Standard of care. Prone-positioning cycles as the following: 3-6 hours of prone-positioning twice a day.
89298031|NCT05008380|No Intervention|Standard of care|Standard of care
89298032|NCT01200732|Active Comparator|Tadalafil|
89298033|NCT01200732|Placebo Comparator|placebo|
89298034|NCT01198938|Active Comparator|Melatonin|
89298035|NCT01566708|Experimental|treatment group|
89298036|NCT01566708|Active Comparator|waiting list group|
89298037|NCT01566708|Active Comparator|control group|
89298038|NCT03841032|Experimental|Sunscreen Lotion|Subjects with rosacea will apply the test sunscreen lotion to the face for 4 weeks
89298039|NCT01201044|Experimental|Gemcitabine, Nedaplatin,BAI plus 3DCRT|"Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year.."
89298040|NCT01201044|Other|Gemcitabine, Nedaplatin, IV Plus 3DCRT|"Gemcitabine 100mg/m2, D1 & D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month.~for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year."
89298041|NCT04525872|Experimental|Premature infants|Premature infants who are expected to receive TPN for a minimum of 5 days and infants with gastrointestinal surgical problems (e.g., ileal atresia, gastroschisis), expected to receive TPN for a minimum of 5 days
89298042|NCT05282082||Patients at the moment of their admission to the hospital in one of the three cities|Swabs will be taken from patients who are willing to participate.
89298043|NCT05282082||"Healthy volunteers living in high-risk areas in one of the three cities."|Swabs will be taken from healthy volunteers who are willing to participate.
89298044|NCT01202526||RYGB patients with type 2 diabetes|Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery
89298045|NCT01202526||RYGB patients without type 2 diabetes|Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery
89298046|NCT01202604||Outpatients with bipolar disorder I or II (as per DSM-IV)|The percentage of patients who experience a relapse episode during the first 9 months after a mood event (manic or depressive).
89298047|NCT01199094||Patients with mutation in the Lrp5 gene|Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
89298048|NCT03843060|Experimental|Single AZD9977|During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
89298049|NCT03843060|Experimental|Itraconazole + AZD9977|During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
89298050|NCT03842904|Experimental|Trimbow pMDI|Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation solution.
89298051|NCT03842904|Active Comparator|Fostair pMDI|Fostair 100/6 micrograms per actuation pressurised inhalation solution.
89298052|NCT04427904|Experimental|Bupivacaine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
89298053|NCT04427904|Active Comparator|Lidocaine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
89298054|NCT03842748||Retrospective study group|200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fibrosis have been identified for pathological diagnosis of liver histology and without other liver diseases. Before liver biopsy were performed, liver function, coagulation function, renal function, blood glucose, blood lipids, liver elasticity measurement, imaging indicators and demographic data were detected and recorded. To evaluate diagnostic ability of current non-invasive diagnostic model of NAFLD fibrosis and adaptability of model indicators to diagnosis of these patients, and correct the indicators including discarding unsuitable and incorporating new indicators and adjusting the diagnostic score. Establish a non-invasive diagnostic model for liver fibrosis in Beijing based on NAFLD.
89298055|NCT03842748||Prospective observational study group|100 patients without other liver diseases and ultrasound-tested fatty liver were enrolled, and histopathological diagnosis of liver were included , and liver function, coagulation function, renal function, blood glucose, and non-invasive model analysis, blood lipids, liver elasticity measurements and imaging indicators were examined and demographic data were collected. Adjusted the index of non-invasive diagnostic model to further revise and improve the diagnostic efficacy of diagnostic model. Long-term follow-up observations were performed in the prospective observation cohort. To explore the correlation and predictive ability of noninvasive diagnostic models for long-term outcomes of disease. Finally, a model for predicting the outcome of progression of liver fibrosis in NAFLD was established.
89298056|NCT03769038|Other|Chronic Total Occlusion and Restenosis|contemporary antegrade or retrograde dissection and re-entry (ADR or RDR) to open CTO
89298057|NCT01202838||Composite Implant|Subject receiving composite implant
89298058|NCT03840798||Pretest/Baseline period|
89298059|NCT03840798||Posttest/go-live period|
89298060|NCT03840876|Experimental|Group J|Jet ventilation was achieved via supraglottic jet oxygenation and ventilation with WEI NASAL JET (WNJ).
89298061|NCT03840876|No Intervention|Group I|Patients were ventilated with a small size endotracheal tube.
89298062|NCT01202916||Congenital Heart Disease|
89298063|NCT01202916||Healthy children|
89298064|NCT01201122|Experimental|Weight based Mesalamine: Once daily|
89298065|NCT01201122|Experimental|Weight based Mesalamine: Twice daily|
89298066|NCT05670366|Other|Physically active participants|There is only one study arm, namely all participants are subjected to the same interventions.
89298067|NCT03668808|Experimental|Insulin Degludec|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.
89298068|NCT03668808|Active Comparator|Insulin Glargine U100|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Glargine U100 and the LANTUS® SOLOSTAR® INSULIN PEN during a long-haul flight and randomized to this arm first or second.
89298069|NCT05281926|Experimental|Poly-ICLC|Hiltonol is a poly-ICLC developed by the Oncovir, Inc. A phase I study of hiltonol monotherapy in solid tumors was completed (NCT01984892). Clinical trials of hiltonol plus ICIs are undergone in various type cancers (NCT03721679, NCT02834052).
89298070|NCT03641118||Lower gastrointestinal cancer|All lower gastrointestinal neoplasms including rectal
89298071|NCT03641118||Upper gastrointestinal cancer|All upper gastrointestinal neoplasms
89298072|NCT03641118||Hepatobiliary cancers|All liver, pancreas, biliary cancer
89298073|NCT03840330|Experimental|High-intensity interval training group|Frequency: 2 days/weeks; Intensity: 16-18 Börg/85-100%VO2max; Recovery: Active; Duration: 1 hour.
89298074|NCT03840330|Experimental|Moderate-intensity interval training group|Frequency: 2 days/weeks; Intensity: 12-14 Börg/60-70% VO2max; Recovery: Active; Duration: 1 hour.
89298075|NCT03840330|No Intervention|Control group|Maintain their normal daily activities throughout the sixteen-week experimental period.
88806245|NCT02106494|Experimental|APF530 500 mg SC|APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC
88806246|NCT02106494|Active Comparator|ondansetron 0.15 mg/kg IV|Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1
88806247|NCT01931852|Experimental|CMR-guided care|Participants in this group will receive a cardiac MRI
89298076|NCT01199172|No Intervention|Control|
89298077|NCT01199172|Experimental|voice hygiene|Subjects will receive training in voice hygiene
89298078|NCT01199172|Experimental|VH + VP|
89298079|NCT05282472|Experimental|with surgical mask|all participants who were applied CPET with surgical mask
89298080|NCT05282472|Active Comparator|without surgical mask|all participants who were applied CPET without surgical mask
89298081|NCT03844776|Active Comparator|Co-Amoxiclav postoperatively alone|• Treatment 1: 0.9% normal saline irrigation immediately after the surgery with course of Co-Amoxiclav 625 mg 0.2% chlorhexidine mouthwash following the surgery for 5 days (control group)
89298082|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with Metronidazole postoperatively|• Treatment 2: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of Metronidazole 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
89298083|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with amoxicillin postoperatively|• Treatment 3: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of amoxicillin 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
89531587|NCT06013163|Active Comparator|EMP16 - Xenical part 2 sequential open label|Single dose of EMP16 (120 mg orlistat/40 mg acarbose) will be taken together with breakfast during one PK study day. After a 4-to-14-day wash-out period, Xenical® (120 mg orlistat) will be taken together with breakfast during one PK study day.
89298084|NCT04358328|Experimental|Intervention group|The patients in the intervention arm will receive the same care and treatment as is provided to all patients in the clinical setting, including the ERAS-concept. In addition to this they will be individually assessed by a physician with geriatric profile, dietician, physiotherapist and nurse and thereafter undergo appropriate interventions (CGA and care). The intervention team will have weekly meetings regarding the patients included in the study to evaluate how long the intervention should continue before surgery, a maximum time of eight weeks will be allowed for the intervention.
89298085|NCT04358328|Active Comparator|Control group|The patients in the control group will standard care and treatment which include assessment of surgeons, anaesthesiologists and, if needed, other specialized physicians. They will be treated according to the ERAS-concept in the pre- peri- and post operative phase.
89298086|NCT01201200||Group 1 - Obstructive Sleep Apnea (OSA)|Fifty-six patients with Obstructive Sleep Apnea
89298087|NCT01201200||Group 2 - Non-OSA Controls|Fifty individuals without OSA with similar age, gender and body mass index (BMI)
89298088|NCT01201200||Group 3 - Treatment|Fifteen patients with moderate and severe sleep apnea from group 1 underwent treatment with continuous positive airway pressure
89298089|NCT01201200||Group 4 - Placebo|Fifteen patients with moderate/severe sleep apnea underwent to placebo
89298090|NCT01566864|Experimental|Behavioral: Improve clinic based measurement of blood pressur|
89298091|NCT01566864|Experimental|Behavioral: Provider education system to promote patient-cent|
89298092|NCT01566864|Experimental|Behavioral: Introduce care management system in clinics|
89298093|NCT03840564||Group point of care (POC)|All the analyzes will be done in delocalized
89298094|NCT03840564||control group|the analyzes will be done at the central laboratory
89298095|NCT01566942|Active Comparator|FOLFOX|In this group, the patients will receive the adjuvant chemotherapy with mFOLFOX6.
89298096|NCT01566942|Experimental|FOLFIRI|in this arm, patients will receive adjuvant chemotherapy with FOLFIRI regimen for about 8 cycles
89298097|NCT01201278|Experimental|Nasal insulin 8 IU|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
89298098|NCT01201278|Experimental|Nasal insulin 16 IU|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
89298099|NCT01201278|Active Comparator|Subcutaneous insulin lispro 8 U|Subcutaneous insulin lispro (Humalog®) 8 U
89298100|NCT01201434|Experimental|Probiotics, Treatment, Food Additive|
89298101|NCT03549624||Intervention group|"All adult (>18y) patients with the need of an acute laparotomy (within 6 hours) at NÄL.~Patients will be treated with an perioperative regime/protocol consisting of:~Early so called NEWS-monitoring (measuring of standard physiological parameters);~Early start of antibiotics;~Rapid (within 6 hours) start of operation;~Goal-directed fluid therapy;~Intensified post-operative monitoring;~The presence of both surgical and anesthesiological specialists in the early care of the patients."
89298102|NCT03549624||Control group|All patients operated with an acute laparotomy at NÄL the years prior to the study will be retrospectively collected using the hospitals operation management database (Orbit©). Medical data will be collected from the patients' medical charts and outcome data (i.e. mortality, length of hospital stay, surgical complications, ICU-management etc.) will be registered
89298103|NCT01201512||Temporomandibular disorders|
89298104|NCT01199250||Basic science (biomarker analysis)|Previously collected samples are analyzed for biomarker and other laboratory analyses.
89298105|NCT01199328|Active Comparator|1|Aspirin 81 mg
89298106|NCT01199328|Active Comparator|2|Esomeprazole 20mg/aspirin 81mg
89298107|NCT03842514|Experimental|High-emulsifier to Low-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days high-emulsifier (soya lecithin) low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate"
89298108|NCT03842514|Experimental|Low-emulsifier to High-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days high-emulsifier( soya lecithin) low-calorie diet at 100% resting metabolic rate"
89298109|NCT03428490|Experimental|Fully Integrated Treatment|Evidence-based substance use treatment combined with Cognitive Behavioral Therapy (CBT) for Social Anxiety Disorder Intervention name: Fully integrated treatment
89298110|NCT03428490|Active Comparator|Usual Intensive Outpatient Care|Evidence-based substance use disorder treatment Intervention name: Stand-alone Intensive Outpatient Program
89298111|NCT03134742||Control Group|Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison
89298112|NCT03134742||CT Scan only|Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment.
89298113|NCT03134742||DEXA Scans only|Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
89298114|NCT03134742||CT and DEXA Scans|Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
89298115|NCT05281848|Active Comparator|Smoker-Periodontitis; Non-surgical periodontal treatment|
89298116|NCT05281848|Active Comparator|Nonsmoker-Periodontitis;Non-surgical periodontal treatment|
89298117|NCT05281848|No Intervention|Healthy|
89298118|NCT03134586|Other|trial participant|All participants undergoes the same diagnostic imaging
89298119|NCT02982954|Experimental|ccRCC KPS ≥ 70%|Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
89298120|NCT02982954|Experimental|Non-ccRCC, KPS ≥ 70%|Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
89298121|NCT02982954|Experimental|RCC with non-active Brain Mets, KPS ≥70%|Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
89298122|NCT02982954|Experimental|any RCC with KPS 50%-60%|Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
89298123|NCT03840408|Experimental|Mitochondrial therapy with radiofrequency ablation|
89298124|NCT03840408|Active Comparator|Surgery|
89298125|NCT01203150|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
89298126|NCT01203150|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
89298127|NCT02970864|Experimental|Polynerve|Participants found to have a nerve gap of at least 5 mm and no greater than 20mm will undergo repair with the Polynerve.
89298128|NCT01203228|Active Comparator|A|Myeloablative conditioning
89298129|NCT01203228|Experimental|B|Reduced Intensity Conditioning
89298130|NCT01203696|Active Comparator|non-amlodipine|For patient with suboptimal angina control: anti-anginal agent excluding calcium channel blocker
89298131|NCT01203696|Active Comparator|non - amlodipine|For patient with suboptimal BP control: anti-hypertensive agent excluding calcium channel blocker
89298132|NCT01204008|Experimental|CS|conservative discectomy
89298133|NCT01204008|Active Comparator|AS|
89298134|NCT01203306|Experimental|Drugs: bevacizumab + octreotide LAR + capecitabine|bevacizumab + octreotide + metronomic capecitabine
89298135|NCT03840018|No Intervention|Control|Sending doctors the lists of patients that meet the inclusion criteria to have their treatment reviewed
89298136|NCT03840018|Other|Letter by post to patients|Patients were sent a letter explaining the risks of using PPIs at long-term high doses and encouraging them to visit their doctor
89298137|NCT03839316|Active Comparator|tDCS group|"Sixteen stroke patient receiving bihemispheric tDCS in addition to a conventional physiotherapy (PT) and occupational therapy (OT) program for five consecutive days per week for a three week period (a total of fifteen sessions).~The one hour long conventional PT sessions will include an upper extremity range of motion, strengthening and neurofacilitation exercise program. The one hour long OT sessions will include task specific exercises chosen according to the patient's functional status, including activities aimed at improving gross and fine motor function of the upper extremities.~The tDCS application will be applied at the beginning of each OT session and will be continued for a total of thirty minutes at 2 mA."
89298138|NCT03839316|Sham Comparator|Sham group|Sixteen stroke patient receiving a conventional PT and OT program and sham tDCS for 5 consecutive days per week for a 3 week period ( a total of 15 sessions). The one hour long conventional PT and OT sessions will be the same as in the tDCS group. For sham tDCS, electrode application and positioning will be the same as the intervention group and will be applied at the beginning of each OT session as previously described. The current will initially be increased up to 2 mA, so to provide the typical initial tingling sensation, and slowly decreased over 30 seconds and consequently switched off. The electrodes will be removed after a total of thirty minutes.
89298139|NCT01201668||Persistent Tooth Pain|
89298140|NCT01203384|Experimental|CHF5074 1x|oral tablet, multidose
89298141|NCT01203384|Experimental|CHF5074 2x|oral tablet, multidose
89298142|NCT01203384|Experimental|CHF5074 3x|oral tablet, multidose
89298143|NCT01203384|Placebo Comparator|Placebo|placebo, oral tablet, multidose
89298144|NCT05669508|Experimental|Treatment Arm|Participants will receive closed-loop transcutaneous spinal cord stimulation via the RISES-T System while completing functional task practice in occupational therapy sessions.
89298145|NCT03724968|Experimental|Arm A|Nivolumab and Relatlimab
89298146|NCT03724968|Experimental|Arm B|Nivolumab and Ipilimumab
89298147|NCT03724812|Experimental|Portico valve and FlexNav™ Delivery System|Portico valve implantation with the second-generation FlexNav Delivery system
89298148|NCT01204086|Experimental|venlafaxine|
89298149|NCT01204086|Experimental|fluoxetine|
88806248|NCT01931852|Active Comparator|Invasive-based guideline-adherent care|Participants will receive care adherent with current ACC/AHA guideline recommendations. ( ACC/AHA Guideline adherent care )
88806249|NCT00333710|Experimental|Individual face-to-face contact|Individual face-to-face contact treatment
89298150|NCT03840096|Experimental|Quadriceps NMES using Breg Flex|
89298151|NCT03840096|No Intervention|Control|
89298152|NCT03840252|Active Comparator|PD patients: Parkinson's disease group|"Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Movement Disorder Society (MDS)-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
89298153|NCT03840252|Active Comparator|PSP patients|"Application of the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of probable PSP, evaluation of PSP rating scale, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis;MDS-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
89298154|NCT03840252|Active Comparator|HC: healthy control group|"Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Behavioral: PD-Mild Cognitive Impairment (MCI)-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
89298155|NCT01567176|Other|Single Arm|
89298156|NCT03842280||Prolonged mechanical ventilation|Prolonged mechanical ventilation with tracheostomy
89298157|NCT03842202|Experimental|Semaglutide|Participants will receive increasing doses of semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
89298158|NCT03842202|Placebo Comparator|Placebo (Semaglutide)|Participants will receive placebo (semaglutide). The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
89298159|NCT01201746|Experimental|Periodontal Therapy|Scaling Root planing and oral hygiene instructions
89298160|NCT01201746|Placebo Comparator|Delayed treatment|Scaling Root planing and oral hygiene instructions
89298161|NCT01201824|Other|1|
89298162|NCT01201902|Experimental|Group 1 : Low dose with adjuvant|Group 1: 18 ~ 64 years old subjects
89298163|NCT01201902|Experimental|Group 1: High dose with adjuvant|Group 1: 18 ~ 64 years old subjects
89298164|NCT01201902|Active Comparator|Group1 : Plain vaccine|Group 1: 18 ~ 64 years old subjects
89298165|NCT01201902|Experimental|Group 2 : Low dose with adjuvant|Group 2: greater than or equal to 65 years of age
89298166|NCT01201902|Experimental|Group 2 : high dose with adjuvant|Group 2: greater than or equal to 65 years of age
89298167|NCT01204164|Experimental|TG02 in AL|Single agent TG02 citrate in acute leukemia patients
89298168|NCT01204164|Experimental|TG02 in MM|Single Agent TG02 citrate in multiple myeloma patients
89298169|NCT01204164|Experimental|TG02 + CFZ in MM|TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients
89298170|NCT01204164|Experimental|TG02 + CFZ + DEX in CFZ refractory MM|TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients
89298171|NCT01203462|Experimental|Bifidobacterium supplemented yogurt|Bifidobacterium supplemented (minimum dosage of 1E+10cfu/serving) vanilla flavored yogurt containing starter cultures: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
89298172|NCT01203462|Placebo Comparator|Placebo Yogurt|Vanilla flavored yogurt containing starter cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
89298173|NCT03837912|Experimental|Patient reported safety experiences fed back to PC providers|The intervention will consist in gathering patient-reported experiences and outcomes of the safety of the healthcare patients received in their PC centres during the previous 12 months. This information will be processed and fed back to their healthcare professionals to help them identify potential safety problems, and then target improvements based on problematic areas.
89298174|NCT03837912|No Intervention|Patient reported safety experiences not fed back to providers|Waiting list: the practices allocated to the control group will receive the intervention (feedback report) after the trial finished (i.e., after post-intervention data collection has been completed).
89298175|NCT01206114||Vaccinated persons|The participants have taken one or more doses of 2009 H1N1 vaccine, either as a monovalent vaccine or as a part of a trivalent seasonal 2010-2011 influenza vaccine
89298176|NCT01206114||Not (yet) vaccinated persons|The participants do not want to take any 2009 H1N1 vaccine or have not received any yet
89298177|NCT03722784|Experimental|Invigor A (test)|Subjects will be randomized to wear Invigor A (test) for one month of daily wear during the study.
89298178|NCT03722784|Active Comparator|Invigor B (Control)|Subjects will be randomized to wear Invigor B (Control) for one month of daily wear during the study.
89298179|NCT01206192||Abused Chinese women|
89298180|NCT01204320|Experimental|Paclitaxel-coated Balloon|Paclitaxel-coated Balloon Angioplasty
89298181|NCT01204320|Active Comparator|Paclitaxel-eluting Stent|Paclitaxel-eluting Stent Implantation
89298182|NCT01298154|Experimental|Intact Pea Protein (20 g)|
89298183|NCT01298154|Experimental|Hydrolyzed Pea Protein (20 g)|
89298184|NCT01298154|Experimental|Intact Whey Protein|
89298185|NCT01298154|Experimental|Hydrolyzed Whey Protein|
89298186|NCT01298154|Experimental|Water|
89298187|NCT03722238|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Tablets|Ibuprofen 600 mg Immediate Release/Extended Release Tablets
89298188|NCT02725554|Active Comparator|Delayed Continuation Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the delayed continuation group will have their systems deactivated until their 3 months follow-up visit. After this visit the stimulation will be reactivated.
88806250|NCT00333710|Experimental|Individual telephone contact|Individual telephone contact treatment
88806251|NCT00333710|No Intervention|Control condition/treatment as usual|Control condition/treatment as usual
88806252|NCT00335504|Experimental|Arm I (atorvastatin calcium)|Patients receive oral atorvastatin once daily.
88806253|NCT00335504|Experimental|Arm II (sulindac)|Patients receive oral sulindac twice daily.
89298189|NCT02725554|Experimental|Continued Stim Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the continued stim group will continue with active stimulation and monitored at defined intervals for data collection and device reprogramming, if needed.
89298190|NCT01203540|Experimental|Naaga in ABAK system|
89298191|NCT01203540|Placebo Comparator|Saline solution|
89298192|NCT03819036|Experimental|Patients|Questionnaires for patients requiring dental emergencies care
89298193|NCT05622786|Experimental|High-Intensity Treadmill Gait Training (HIGT)|High-intensity walking physical therapy with some low intensity therapy.
89298194|NCT05622786|Active Comparator|Low Intensity Physical Therapy|Low-intensity gait activities, exercises (such as lower extremity strength training with or without weights or electrical stimulation, sit to stands from a chair, mat exercises for upper/lower extremities and core strength, etc.), stretches, balance training activities, and other therapeutic activities (such as transfers, bed mobility training, etc.).
89298195|NCT01298232|No Intervention|EMAT-guided therapy|electromechanical activation time (EMAT, obtain by phonocardiogram, Audicor, USA)
89298196|NCT01298232|No Intervention|Symptomatic-guided therapy|HF therapy guided by clinical symptoms
89298197|NCT01206270|Experimental|Testosterone|Testosterone undecanoate 1000mg injection at baseline (0-week), 6-week, 18-week, 30-week
89298198|NCT01206270|Placebo Comparator|Placebo|Injection 4 ml of castor oil at baseline (week-0), week-6, week-18, week-30
89298199|NCT01298310|Active Comparator|Xylocaine_1mg|1 injection of Xylocaine (1 mg/mL)
89298200|NCT01298310|Active Comparator|Xylocaine_10mg|1 injection of Xylocaine (10 mg/mL)
89298201|NCT01298310|Placebo Comparator|Placebo|1 injection of placebo
89298202|NCT01298466|Experimental|Pregabalin|Open label study. All patients fulfilling the protocol inclusion/exclusion criteria will receive pregabalin in a flexible-dosing regimen.
89298203|NCT01206348|Experimental|Open Label Combination|Solodyn, Ziana, Triaz FC
89298204|NCT01298622||controls|
89298205|NCT01298622||OCD patients|
89298206|NCT01298622||OCD parents|
89298207|NCT03818958||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
89298208|NCT03818958||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
89298209|NCT03818958||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
89298210|NCT03818958||fibromyalgia|subjects with fibromyalgia
89298211|NCT03836820|Experimental|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
89298212|NCT03836820|Experimental|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
89298213|NCT03836820|Experimental|Clinical pilates and Aerobic exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
89298214|NCT05622240|Experimental|99mTc-MIRC213 Dosimetry study|about 6 patients were injected with 11.1-14 (MBq) per kilogram body weight of 99mTc-MIRC213 in one dose intravenously and underwent wholebody scan at 5min、20min、40min、60min、90min、120min、180min、240min, then analysis of dosimetric distribution of radiopharmaceuticals in human body by HERMES software.
89298215|NCT05622240|Experimental|99mTc-MIRC213 wholebody and SPECT/CT scan|About 30 patients were injected with 11.1-14 (MBq) per kilogram body weight of 99mTc-MIRC213 in one dose intravenously and underwent wholebody scan 1 \2\3h later and underwent SPECT/CT scan at 2h.
89298216|NCT01300806||myHERO SBIRT|
89298217|NCT01300806||clinician administered SBIRT|
89298218|NCT03818568|Experimental|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
89298219|NCT03818568|Active Comparator|Control|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).
89298220|NCT01204476|Experimental|Treatment (cixutumumab, octreotide acetate, everolimus)|Patients receive cixutumumab IV over 60-90 minutes and octreotide acetate IM on day 1 and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
89298221|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) 150mg|ACE-083 150 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
89298222|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
89298223|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA bilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
89298224|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) 150 mg|ACE-083 150 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
89298225|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) 200 mg|ACE-083 200 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
89298226|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) 240 mg|ACE-083 240 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
89298227|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Tibialis Anterior (TA)|"Part 2, double-blind (DB) placebo-controlled (PC). Placebo TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
89298228|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
89298229|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Biceps Brachii (BB)|"Part 2, double-blind placebo-controlled. Placebo BB bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
89298230|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
89298231|NCT03633292|Active Comparator|Clorhexidine|- Clorhexidine Gel (LACER®, Barcelona, Spain) 0.12%, application 2 times / days for 1 month. The gel will be applied two times/day each 12 hours to the gingiva and mucosa.
88806254|NCT00335504|Experimental|Arm III (oligofructose-enriched inulin)|Patients receive oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.
89298232|NCT03633292|Experimental|Aloe Vera|"- 80% Aloe vera gel, application 2 times / day for 1 month~Master formula of 80% aloe vera gel Aloe Vera extract, obtained from the central part of the caudal leaves of plants with more than 8 years of life, eliminating its bark. Formulated with carbopol, hydrophilic crosslinked polymer of acrylic acid and vitamin C. The mixture is presented in containers that serve as a container for preparation and will be dispensed in the canister format with applicator tube."
89298233|NCT01382524||Stabilization system A|A commercialized stabilization dressing using a winged PIV catheter.
89298234|NCT01382524||Stabilization System B|A commercialized stabilization device using a non-winged PIV catheter
89298235|NCT03688672|Other|Apioc Lens|All subjects will wear the same, Apioc Contact Lens design.
89298236|NCT04630210|Experimental|A: Letrozole|Letrozole 2.5 mg/day oral until surgery
89298237|NCT04630210|Experimental|B: Letrozole + atezolizumab|Letrozole 2.5 mg/day oral until surgery and Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
89298238|NCT04630210|Experimental|C: Atezolizumab|Atezolizumab 840 mg IV single-dose 14 days (+/- 4 days) before surgery
89298239|NCT04630210|No Intervention|D: Observation|Observation until surgery
89298240|NCT04613752|Experimental|experimental group|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
89298241|NCT02051374|Active Comparator|Decompression alone|Posterior approach with decompression will be performed. The decompression will be done after microsurgical principles, and the midline structures will be preserved. The surgeons will either use microscope or magnifying glasses.
89298242|NCT02051374|Active Comparator|Decompression followed by fusion with instrumentation|Posterior approach with decompression will be performed, followed by posterolateral pedicle screw fixation with or without an additional cage. The surgeons will either use microscope or magnifying glasses.
89298243|NCT01382368|Experimental|Sildenafil|
89298244|NCT04563442||covid 19|complications and comorbidities
89298245|NCT04546828|Experimental|Gemcitabine, Cisplatin, and Nab-Paclitaxel|"Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days"
89298246|NCT01382134|Placebo Comparator|Placebo group|Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
89298247|NCT01382134|Active Comparator|Aspirin group|Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
89298248|NCT01298856|Active Comparator|hydrotherapy|hydrotherapy and ankle taping and land based exercise
89298249|NCT01298856|Active Comparator|land-based|land-based and ankle taping program
89298250|NCT03829176|No Intervention|Standard-of-Care|Participants who are randomized to not have whole genome sequencing performed on their sample. These participants will have standard-of-care genetic testing only (ordered by their clinical provider) and will not receive genetic results as part of this study.
89298251|NCT03829176|Experimental|Whole Genome Sequencing|Participants who are randomized to have their genome sequenced and receive a whole genome sequencing report. Results disclosure sessions will include a discussion of the whole genome sequencing report, how the results compare to their standard-of-care genetic testing report, and any potential relevant recommendations. Participants in this arm will receive a copy of their whole genome sequencing report accompanied by a summary letter written by a study genetic counselor.
89298252|NCT05077488|Experimental|Juvéderm® VOLIFT™ with Lidocaine|Intradermal injection (deep dermis) in marionettes lines and/or forehead by a specialist injector
89298253|NCT05668572|Experimental|The Group of Investigational Vaccine|
89298254|NCT05668572|Active Comparator|The Group of Active Control Vaccine|
89298255|NCT03828240|Other|Enhanced rehabilitation|
89298256|NCT02410980|Experimental|Tretinoin cream 0.1%|Assessment of the skin change
89298257|NCT03818490|Experimental|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes at the start of their medical office visit.
89298258|NCT03818490|No Intervention|Control|Patients in this group did not experience an intervention.
89298259|NCT01298934|Experimental|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
89298260|NCT02374476|Experimental|Bipolar Ablation|All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.
89298261|NCT02374476|Active Comparator|Registry|Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful
89298262|NCT01300884||healthy volunteers|
89298263|NCT01300884||patients with fecal incontinence|
89298264|NCT01300884||patients with constipation|
88806255|NCT00335504|Placebo Comparator|Arm IV (placebo)|Patients receive an oral placebo twice daily.
88806256|NCT01183169|Experimental|Treatment A: ALV 600 mg QD|Alisporivir (ALV) 600 mg once daily (QD) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) for up to 48 weeks
88806257|NCT01183169|Experimental|Treatment B: ALV 800 mg QD|Alisporivir (ALV) 800 mg QD with PEG and RBV for up to 48 weeks
88806258|NCT01183169|Experimental|Treatment C1: ALV Placebo - 600 mg QD|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR) after 12 weeks of treatment may switch to active ALV 600 mg QD with PEG and RBV.
88806259|NCT01183169|Experimental|Treatment C2: ALV Placebo - 400 mg BID|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR after 12 weeks of treatment may switch to active ALV 400 mg twice daily (BID) with PEG and RBV.
88806260|NCT01183169|Experimental|Treatment D: ALV 400 mg BID|Alisporivir (ALV) 400 mg twice daily BID with PEG and RBV for up to 48 weeks
89298265|NCT02169726||Musculoskeletal injuries|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
89298266|NCT02155920|Experimental|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
89298267|NCT01981902||Dehydration|Non-Invasive Optical Spectroscopic monitoring method for dehydration
89298268|NCT01301040|Active Comparator|Epirubicin/Cyclophosphamide|Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles
89298269|NCT01301040|Active Comparator|docetaxel/cyclophosphamide|Treatment Arm 2: TC - docetaxel (Taxotere) (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
89298270|NCT03818334|Experimental|Post Cyclophosphamide|Cyclophosphamide 50 mg/Kg on days +3 and +4 AND Calcineurin Inhibitor from day +5 AND Mycofenolate Mofetil from day +5 until day +35
89298271|NCT03818334|Active Comparator|Thymoglobulin (ATG)|Thymoglobulin (ATG) total dose 5 mg/Kg from day -4 until day -1 AND Calcineurin Inhibitor from day +5 AND Methotrexate on days +1, +3, +6 and +11
89298272|NCT03817788|Active Comparator|polyethylene glycol group (group P)|For all patients of this group, polyethylene glycol solution should be taken orally for colonic cleansing of colonoscopy
89298273|NCT03817788|Experimental|sodium phosphate group (group S)|For all patients of this group, sodium phosphate solution should be taken orally for colonic cleansing of colonoscopy
89298274|NCT01206972|Experimental|Arm 1|
89298275|NCT01206972|Experimental|Arm 2|
89298276|NCT01206972|Experimental|Arm 3|
89298277|NCT01206972|Active Comparator|Arm 4|
89298278|NCT03833232|Experimental|omentopexy and cyanoacrilate glue|Apposition of omentum with cyanoacrilate glue after gastric section
89298279|NCT03833232|No Intervention|gastrectomy without omentopexy|Gastric section without omentopexy
89298280|NCT01299246|Experimental|improving self-care|
89298281|NCT01301196|Experimental|Behaviour change|Attendance at 3-h workshop
89298282|NCT03833076|Experimental|GROUP A: Medical Device Procto|"Medical device Procto presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
89298283|NCT03833076|Placebo Comparator|GROUP B: Matching placebo|"Investigational Product (IP) placebo presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
89298284|NCT03817476|Experimental|T1-T2-R|
89298285|NCT03817476|Experimental|T1-R-T2|
89298286|NCT03817476|Experimental|T2-T1-R|
89298287|NCT03817476|Experimental|T2-R-T1|
89298288|NCT03817476|Experimental|R-T1-T2|
89298289|NCT03817476|Experimental|R-T2-T1|
89298290|NCT01299324|Experimental|BMAC Infusion|Infusion of autologous bone marrow aspirate concentrated nucleated sells into the coronary sinus
89298291|NCT01299324|No Intervention|Control|Standard of care only. No infusion
89298292|NCT01299402|Experimental|Soulera Herbal Blend|
89298293|NCT01299402|Placebo Comparator|Placebo Blend|
89298294|NCT02918292|Experimental|Haplo Bone Marrow HSCT|Patients will be treated with a preparative regimen of Antithymocyte Globulin (ATG) (4.5 mg/kg), fludarabine (150 mg/m^2), cyclophosphamide (29 mg/kg), and low dose total body irradiation (TBI) (200 cGy) before undergoing the haplo HSCT. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). G-CSF will be administered post-transplant.
88813886|NCT03004157|Experimental|Two finger technique|Two finger technique TFT: the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant CPR by international CPR guidelines
89298295|NCT01207128|Active Comparator|Voriconazole, Micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV) Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
89298296|NCT01207128|No Intervention|Voriconazole+Micafungin or Voriconazole+Placebo|Voriconazole+Micafungin or Voriconazole+Placebo
89298297|NCT01204866|Experimental|Stage I|Three (3) healthy male or female volunteers aged 18-59 years, not previously exposed to Valortim and who do not have pre-existing allergies
89298298|NCT01204866|Experimental|Stage II|Up to 4 healthy male or female volunteers aged 18-59 previously exposed to intravenous (IV) Valortim in PharmAthene Study #0036-08-05
89298299|NCT01299558|Other|Treatment period 1|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder given once daily in the morning on Day 1 of Treatment period 1
89298300|NCT01299558|Other|Treatment Period 2|Single IV dose of FF (250mcg) given over 20 mins on Day 1 of Treatment period 2
89298301|NCT01299558|Other|Treatment Period 3|Single IV dose of GW642444M (55mcg) given over 60 mins on Day 1 of Treatment period 3
89298302|NCT03826758|Other|E-DYNAMIC CDS|E-DYNAMIC clinical decision support (CDS) retrieves near-real time patient data from the electronic health record to help primary care providers identify patients with stage 3-5 CKD, present ASCVD risk, statin use and clinical recommendations for ASCVD risk reduction at point of care. E-DYNAMIC directs referrals to nurses for CKD education and to dietitians for MNT. Providers are also nudged to prescribe statin medications and address hypertension management.
89298303|NCT03826758|No Intervention|Standard care|No change in their clinical practice.
89298304|NCT03826680|Active Comparator|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by an ENT physician by flexible fiberoptic laryngoscopy before the surgery
89298305|NCT03826680|Active Comparator|Direct laryngoscopy|The same patients evaluated by flexible fiberoptic laryngoscopy will be evaluated by an anesthesiologist by direct laryngoscopy during surgery under general anesthesia
89298306|NCT01301352|No Intervention|Nasojejunal feeding (control)|
89298307|NCT01301352|Experimental|Nasogastric feeding (intervention)|
89298308|NCT01207284|Experimental|Physical Therapy|Foot and ankle passive and active stretching, muscle strengthening, proprioception training and gait training.
89298309|NCT01207284|No Intervention|Control|
89298310|NCT01299636|Experimental|PM060184|
89298311|NCT03826290|Experimental|Intervention arm|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated diabetes dashboard).
89298312|NCT03826290|No Intervention|Control arm|When patients are seen in clinics in this arm, the clinical providers will not have access to the intervention (EHR-integrated diabetes dashboard). The providers will have access to the usual decision support tools and information sources.
89298313|NCT03817242|Active Comparator|tympanoplasty with tragal cartilage|Tympanoplasty was performed using tragal cartilage graft
89298314|NCT03817242|Active Comparator|tympanoplasty with temporalis fascia|Tympanoplasty was performed using temporalis fascia graft
89298315|NCT03817164|Active Comparator|Active Treatment|Active stimulation pulsed current delivered over 15 minutes.
89298316|NCT03817164|Sham Comparator|Control Treatment|Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.
89298317|NCT03816930|Active Comparator|Mechanical cord usage|Mechanical retraction
89298318|NCT03816930|Active Comparator|Chemical contained retraction usage|Chemical retraction
89298319|NCT03816930|Active Comparator|MZ-6 laser tip used throughing|Laser retraction
89298320|NCT05604144|Other|Active Treatment|As a Proof of Concept Study, 5 subjects will follow the same protocol, with one cryoanalgesic treatment (iovera°®) with a 6 month clinical follow-up.
89298321|NCT03720210|Experimental|RFA group|RFA
89298322|NCT03719586|Experimental|A|Remdesivir plus optimized Standard of Care (oSOC)
89298323|NCT03719586|Experimental|B|MAb114 plus optimized Standard of Care (oSOC)
89298324|NCT03719586|Experimental|C|REGN-EB3 plus optimized Standard of Care (oSOC)
89298325|NCT03719586|Experimental|Control|Zmapp plus optimized Standard of Care (oSOC)
89298326|NCT05624034||Healthy group|Subjects with no previous medical history (healthy volunteers) will be assessed for eligibility criteria.
89298327|NCT05624034||Idiopathic Gastroparesis|Patients with symptoms of Gastroparesis based on ROME IV criteria and not having a known cause of gastroparesis like endocrine, neurological, rheumatological disorder.
89298328|NCT05624034||Diabetic Gastroparesis|Patients with symptoms of Gastroparesis based on ROME IV criteria and Diabetes mellitus of any duration.
89298329|NCT01297140|Experimental|questionary|
89298330|NCT03816540|Experimental|FXTAS-affected|FXTAS-affected participants will receive HRV and respiratory coherence biofeedback training for 20 sessions.
89298331|NCT03816540|Active Comparator|FXTAS-unaffected|FXTAS-unaffected participants will be assessed to compare the effects of biofeedback based on FXTAS status. This arm will receive HRV and respiratory coherence biofeedback training for 20 sessions.
89298332|NCT03830502||Salpingectomy|Women who gave consent for opportunistic prophylactic bilateral salpingectomy during cesarean section as a Surgical sterilization procedure
89298333|NCT03830502||Tubal ligation|Women who refused salpingectomy and gave consent for tubal ligation during cesarean section as a Surgical sterilization procedure
89298334|NCT05623644||TD-PD patients undergoing MRgFUS thalamotomy|The imaging data from patients with tremor dominant PD underwent MRgFUS thalamotomy. Their clinical and imaging data were also collected.
89298335|NCT05623644||MR-ET patients undergoing MRgFUS thalamotomy|The imaging data from patients with medication-resistant ET underwent MRgFUS thalamotomy. Their clinical and imaging data were also collected.
89298336|NCT03825276|Experimental|Mango consumption|
89298337|NCT01205022|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes once every 2 weeks. Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes once in weeks 3 and 9.Treatment continues in the absence of disease progression or unacceptable toxicity.
89298338|NCT01297218|Experimental|NEUROSTEM®-AD|
89298339|NCT03824574|Experimental|Treatment arm|Subjects receiving the clear mandibular advancement appliance
89298340|NCT01205100|Active Comparator|Biofeedback|Patients will be taught to control abdominal and diaphragmatic muscles by bio-feedback using EMG recordings.
89298341|NCT01205100|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
89298342|NCT03823560|Experimental|GROUP A: medical device Celegyn®|"Medical device Celegyn® presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
89298343|NCT03823560|Placebo Comparator|GROUP B: matching placebo|"Investigational Product (IP) placebo presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
89298344|NCT05623566|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
89298345|NCT05583396|Other|Acute exercise|Pulmonary diffusing capacity using the DLCO/NO technique is assessed at rest and during exercise (60% of maximal workload on a bicycle ergometer)
89298346|NCT01205178|Active Comparator|Tafenoquine|Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria.
89298347|NCT01205178|Active Comparator|Chloroquine|Dose for first 3 days for Part B & C of the study
89298348|NCT01205178|Active Comparator|Primaquine|once daily for first 14 days
89298349|NCT01205256|Experimental|Methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
89298350|NCT03816384|Active Comparator|Standard of Care|Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
89298351|NCT03816384|Experimental|Drain Line Clearance (DLC) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
89298352|NCT03816384|Experimental|Drain Line Clearance and Silver (DLCS) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
89531707|NCT05656976|No Intervention|C (control arm) Recommendation letter|"Following the usual care procedure, a random sample of 1125 Flemish women who meet the same inclusion criteria as in arm A and B and are not included in one of the latter arms is drawn by Centrum voor Kankeropsporing (CvKO) from Heracles, the database of the Flemish screening program."
89531708|NCT05653908|Experimental|Daily monitoring|
89298353|NCT03823170|Experimental|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW (Therapy EC, DMC) will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
89298354|NCT03823170|Active Comparator|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish (Duraphat), with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
89298355|NCT03823170|Experimental|Laser therapy and fluorotherapy|The teeth will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
89298356|NCT03823482|Experimental|Lidocaine group|Participants in lidocaine group, following induction to general anesthesia, will have lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation. Maximum dosage of lidocaine won't exceed 400 mg.
89298357|NCT03823482|No Intervention|Control group|Participants in control group will have general anesthesia without lidocaine administration.
89298358|NCT01299870|Active Comparator|AED treatment plus placebo|
89298359|NCT01299870|Experimental|Keishibukuryogan|
89298360|NCT01567254|Experimental|guided imaginary|7 children receiving auditory guided imagery disk
89298361|NCT01567254|Active Comparator|music|6 children receiving music disk
89298362|NCT03816306||Single group study|
89298363|NCT03816072|Active Comparator|Propofol|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with intravenous anaesthesia (propofol).
89298364|NCT03816072|Active Comparator|Sevoflurane|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with inhalational anaesthesia (sevoflurane).
89298365|NCT05560698|Other|Control|Standard reporting method
89298366|NCT05560698|Other|Intervention|Web based motivation-enhancing app
89298367|NCT01207050|Experimental|Rozerem (Ramelteon)|The primary drug of interest is a melatonin agonist for the treatment of insomnia.
89298368|NCT01207050|Placebo Comparator|Sugar pill|Control condition.
89298369|NCT01299948|Active Comparator|prednisolone|5 mg prednisolone per os daily administration
89298370|NCT01299948|Placebo Comparator|placebo|The placebo is designed to the equal look like the study medication.
89298371|NCT01300026|Experimental|Part II Dose Expansion|Dose selected from Part I dose exploration
89298372|NCT01300026|Experimental|Part I Dose Exploration|The AMG 319 doses proposed for this study are 25, 50, 100, 200, 300 and 400 mg administered by mouth once daily.
89298373|NCT01300104|Experimental|Exercise and whole grain rye|
89298374|NCT01300104|Active Comparator|No prescriptions|
89298375|NCT01297374|Experimental|dietetic counseling|
89298376|NCT01297374|Experimental|physical activities|
89298377|NCT01297374|Experimental|Lifestyle counseling|
89298378|NCT03815760|Experimental|Exercise with Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~The BFR cuff will be applied to the upper arm. Arterial occlusion will be set to 50%.~Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps. The occlusion will be maintained for the 8 min treatment period."
89298379|NCT03815760|Active Comparator|Exercise without Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~This group will not have BFR applied. Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps."
89298380|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered with paclitaxel + carboplatin on both a 21-day cycle with growth factor support (Group 1)
89298381|NCT01297452|Experimental|BKM120 (days 1 - 28, ) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).
89298382|NCT01297452|Experimental|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|EXPANSION COHORT A BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT A.
89298383|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B|Expansion Cohort B will be restricted to patients with tumors known to harbor PTEN mutation or homozygous deletion. The regimen in Expansion Cohort B will be the same regimen established in Group 1 of the protocol, with BKM120 (now called buparlisib) at 100 mg/day per oral + paclitaxel (175 mg/m2) + carboplatin (AUC 5), both given intravenously (IV) on day 1 of a 21-day cycle
89298384|NCT01301586|Active Comparator|Oral antibiotic plus soy extract|
89298385|NCT01301586|Active Comparator|Oral antibiotic|
89298386|NCT01297530|Experimental|Arm 1|
89298387|NCT01297608|Experimental|treatment|
89298388|NCT01297608|Placebo Comparator|placebo|
89298389|NCT03815994|Experimental|Experimental: group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
89298390|NCT03815994|Sham Comparator|group 2|Decubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.
89298391|NCT03815838|Experimental|PET imaging|18F-FDOPA and 18F-Fallypride PET imaging
89298392|NCT01300182|Experimental|Whole body vibration therapy|Whole body vibration therapy on top of conventional physiotherapy treatment.
89298393|NCT01300182|Active Comparator|Control|Conventional post-operative physical therapy rehabilitation exercises.
89531709|NCT05649098|Experimental|Open-Label Dupilumab|
89298394|NCT01205412||Assessed Cohort|Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
89298395|NCT03819972|Placebo Comparator|Control|Participants will ingest a drink containing 25 g whey protein hydrolysate (227 mg of total calcium ingested)
89298396|NCT03819972|Active Comparator|Dose 1|Participants will ingest a drink containing 25 g whey protein hydrolysate and 3179 mg Capolac (984 mg of total calcium ingested)
89298397|NCT03819972|Active Comparator|Dose 2|Participants will ingest a drink containing 25 g whey protein hydrolysate and 6363 mg Capolac (1742 mg of total calcium ingested)
89298398|NCT03819972|Active Comparator|Dose 3|Participants will ingest a drink containing 25 g whey protein hydrolysate and 9547 mg Capolac (2500 mg of total calcium ingested)
89298399|NCT03815526|Experimental|Dynamic tape|
89298400|NCT03815526|Experimental|Kinesio tape|
89298401|NCT03815526|Experimental|Sport tape|
89298402|NCT01205724|Experimental|A|
89298403|NCT01205724|Experimental|B|
89298404|NCT01205724|Experimental|C|
89298405|NCT03819894|Experimental|Intervention|The intervention is the introduction of a lower female threshold. In cluster-randomized trials, the cluster (i.e., hospital) is the unit of randomization.
89298406|NCT03819894|No Intervention|Control|The control phase will be standard of care, with the use of an overall population hs-cTn T and I threshold, for both men and women, to identify those with myocardial injury/infarction.
89298407|NCT01205802|Active Comparator|PTFE group|MHV reconstruction with ringed Goretex
89298408|NCT01205802|Placebo Comparator|Homograft group|MHV reconstruction with homograft
89298409|NCT05623332||Maraciclatide imaging group|Women referred to the endometriosis clinic for suspected endometriosis undergoing a maraciclatide imaging scan
89298410|NCT05623332||Control|Control group (samples but no scan) - Women undergoing surgery for any other condition than endometriosis
89298411|NCT01301820|Other|ARM A|maintenance study treatment: azacitidine sc 75 mg/m²/d (d1- d7) in first cycle: months 1,3,5,7,9 ,11 then lenalidomide 10mg/d (d1- d21) months 2,4,6,8,10,12
89298412|NCT01301820|Other|ARM B|maintenance study treatment: lenalidomide 10mg/d (d1- d21)in first cycle and months 1,3,5,7,9 ,11 then azacitidine sc 75 mg/m²/d (d1- d7) months 2,4,6,8,10,12
89298413|NCT01560000|Other|fiber|
89298414|NCT01297686|Experimental|Exercise|Multi-element exercise protocol involving static and dynamic stretches, deep massage, and balance training.
89298415|NCT01297686|Active Comparator|Standard of Care|This arm will consist of a single injection of a corticosteroid, followed by stretching exercises for the calf.
89298416|NCT01205880|Active Comparator|vectical ointment and clobex spray|patients were assigned to apply vectical ointment first then clobex spray on one target lesion and also apply clobex spray first then vectical ointment on a different target lesion on the opposite side of the body.
89298417|NCT05652114|Experimental|Child play of Mightier|Ad lib child biofeedback video game play in home
89298418|NCT03819738|Experimental|fMRI intervention|
89298419|NCT01205958|Active Comparator|medication(Zaltoprofen)|
89298420|NCT01205958|Active Comparator|Acupuncture|
89298421|NCT01205958|Active Comparator|Zalprofen plus Acupuncture|
89298422|NCT05623098||Dietary fiber was not added to enteral nutrition preparation|Dietary fiber was not added to enteral nutrition preparation
89298423|NCT05623098||Dietary fiber was added to enteral nutrition preparation|Dietary fiber was added to enteral nutrition preparation
89298424|NCT03830268|Experimental|MCT intake in young participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.~Interventions:~No MCT intake with breakfast, no lunch (i.e. CTL)~No MCT intake with lunch, no breakfast (i.e CTL inverted)~10g of Betaquik with breakfast, no lunch (i.e BQ10)~20g of Betaquik with breakfast, no lunch (i.e BQ20)~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
89298425|NCT03830268|Experimental|MCT intake in older participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.~Interventions:~No MCT intake with breakfast, no lunch (i.e. CTL)~No MCT intake with lunch, no breakfast (i.e CTL inverted)~10g of Betaquik with breakfast, no lunch (i.e BQ10)~20g of Betaquik with breakfast, no lunch (i.e BQ20)~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
89298426|NCT01300416||With Gastro-Intestinal (GI) symptoms|
89298427|NCT01300416||Without GI symptoms|
89298428|NCT01297842|Experimental|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
89298429|NCT01297842|Active Comparator|Meropenem or Imipenem|Meropenem or Imipenem o.5 or 1 gram 3 to 4 times a day for 7 to 14 days
89298430|NCT01297998|Experimental|gemcitabine , cisplatin|
89298431|NCT03819582|Experimental|Intraocular lens|Subjects implanted with the EyeCee One Intraocular lens
89298432|NCT05458206|Experimental|diaphragmatic release, and conventional|"Diaphragmatic release:~The patients will be positioned in the supine position. The therapist stood at the head of the patient. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and the last three fingers. During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist will deepen hand contact toward the inner coastal margins for 5 to 7 minute conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
89298433|NCT05458206|Experimental|mulligan SNAG mobilization, and conventional|"mulligan snag: Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement and then sustains it at the end range position for a few seconds. (3 sets,10 repetitions) conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
89531710|NCT05641116|Experimental|Lyme Borreliosis with physical activity program|Referral of the patient to the sport-health center of his department by the investigating physician (in connection with the attending physician for the prescription of Adaptive Physical Activity): for 24 sessions of APA for 3 months at a rate of 2 sessions/week at the sport and health center + 9 sessions of Therapeutic Patient Education in telecare
89298434|NCT05458206|Experimental|mulligan SNAG mobilization, diaphragmatic release, and conventional|"Diaphragmatic release:~The patients will be positioned in the supine position. The therapist stood at the head of the patient. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and the last three fingers. During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist will deepen hand contact toward the inner coastal margins. (5 to 7 minutes) mulligan snag: Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement and then sustains it at the end range position for a few seconds(3 sets,10 repetitions) conventional therapy: the patient will receive chin-in, interscapular exercises, and pectoralis stretch"
89298435|NCT05458206|Active Comparator|the conventional therapy|the patient will receive chin-in, inter-scapular exercises, and pectoralis stretch (3 sets,10 repetitions)
89298436|NCT01298076|Active Comparator|AVASTIN|intravitreal bevacizumab
89298437|NCT01298076|Active Comparator|OZURDEX|intravitreal dexamethasone
89298438|NCT03814902|Experimental|Electronic Tracking Device|Participants will be given a wearable electronic tracking device (ETD) to use for their child with autism spectrum disorder (ASD) for 6 weeks.
89298439|NCT03819504|Experimental|4-D navigated stereotactic radiosurgical ablation|Patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias will undergo 4-D navigated stereotactic radiosurgical ablation
89298440|NCT03814824|Active Comparator|VLE without IRIS, followed by VLE with IRIS|VLE (Volumetric laser endomicroscopy) performed alone, followed by IRIS (Intelligent real-time image segmentation) imaging.
89298441|NCT03814824|Active Comparator|VLE with IRIS, followed by VLE without IRIS|VLE (Volumetric laser endomicroscopy) performed with IRIS (Intelligent real-time image segmentation) imaging, followed by VLE alone.
89298442|NCT03821298|Experimental|Standard of Care|short thumb orthoses during ADL, joint reeducation for hand used, radial nerve gliding exercises and thumb proprioception exercises
89298443|NCT03819270|Experimental|LY3372689|Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
89298444|NCT03819270|Placebo Comparator|Placebo|Matching placebo administered orally in healthy participants in one of three study periods
89298445|NCT03814980|Experimental|Pilot Study|Participants will be shown how to use a mindful breathing software application. The software will be used for 1 week. At the end of the week, participants will evaluate the software.
89298446|NCT03814668|Experimental|Probiotic powder|One sachet of Probiotic powderwill be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
89298447|NCT03814668|Active Comparator|Lactase|One sachet of Lactase powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
89298448|NCT03814668|Placebo Comparator|Placebo|One sachet of placebo powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
89298449|NCT03819348||TSM of HIV-negative Host|Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
89298450|NCT03819426|Experimental|High Intensity Interval Training|Participants will be shown the appropriate techniques and intensity (high intensity; i.e., 70-90% of maximum heart rate (220-age) with a verified online youtube video. Participants will be provided with this video and other options that can be followed to complete 15 minute HIIT interventions at home. Interventionist will observe participant engaging in HIIT for 15 minutes. HIIT intervention (for 15 minutes) will also be observed during Session 4 and 8.
89298451|NCT03819426|Experimental|Walking|This intervention will be demonstrated during Session 1. Participants will be shown the appropriate walking intensity (low intensity; i.e., approximately 50% of maximum heart rate (220-age) or lower) by interventionist. Interventionist will observe participant engaging in walking at appropriate intensity level for 15 minutes. Walking intervention (for 15 minutes) will also be observed during Session 4 and 8.
89298452|NCT03814512|Experimental|Extended Sleep Intervention (ES)|Participants will receive a Standard Care Diet and Physical Activity Education Intervention (SC) and an Extended Sleep Intervention (ES). For the SC, participants will have their diet, physical activity, and screen time assessed by study interventionist. Prescribed goals will be determined collaboratively through discussion with participants and parents. For the ES, participants will subsequently be prescribed a sleep schedule that allows them to obtain 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively.
89298453|NCT01560312|Experimental|Renal denervation|Renal denervation (Symplicity® Catheter System™) + conventional antihypertensive medical treatment without spironolactone (spironolactone can be taken only if started before randomization)
89298454|NCT01560312|No Intervention|Medical treatment|"Conventional antihypertensive treatment including spironolactone (if not contraindicated).~One year after randomization, renal denervation can be performed according to the physician's decision based on the BP levels and if patient desires the procedure."
89531711|NCT05641116|Other|Lyme Borreliosis patients with physical activity at home|routine clinical practice : encouragement by the attending physician to modify lifestyle habits with advice on resuming regular physical activity independently and combating sedentariness. At home, in autonomy for 3 months.
88806261|NCT01183481|Experimental|Aprepitant and Granisetron|Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the Palliative radiation therapy.
88806262|NCT01183559|Other|Vandetanib|Vandetanib 100 mg (6 patients) or 200 mg (3 patients) orally daily during the conventional 3D-guided conformal radiation therapy plus chemotherapy with carboplatin (AUC 5) on days 1 and 29, paclitaxel 50 mg/m2 i.v. weekly on days 1, 8, 15, 22, 29; and continuous infusion of 5-fluorouracil at 225 mg/m2 for 96 hours Monday-Friday during the radiation.
88806263|NCT01184417|Active Comparator|Phenobarbital group|10 mg/kg IV phenobarbital in 100 ml saline
88806264|NCT01184417|Placebo Comparator|Placebo group|100 ml saline
88806265|NCT01159067|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
88806266|NCT01221857|Experimental|NiCord|
89298455|NCT01560390|Other|Rémifentanil + Kétamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
89298456|NCT01560390|Other|Rémifentanil + Placebo|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
89298457|NCT05400798|Experimental|Adipose Derived Regenerative Cells|a single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
89298458|NCT05400798|Active Comparator|Corticosteroid|a single corticosteroid injection into the subacromial space of the index arm
89298459|NCT01301898|Experimental|GC1111_0.5mg/kg|
89298460|NCT01301898|Experimental|GC1111_1.0mg/kg|
89298461|NCT01301898|Active Comparator|Elaprase_0.5mg/kg|
89298462|NCT03815136|Active Comparator|Chewing Gum|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy. Subjects chewed one piece of gum for approximately 15 min every 30 min at the first hour of the examination.
89298463|NCT03815136|Placebo Comparator|Control|The control group will not chew chewing gum while undergoing capsule endoscopy.
89298464|NCT03808194|Active Comparator|Optimized ART linkage package|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART.
89298465|NCT03808194|Experimental|Conditional lottery incentive|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART and will be entered into a lottery each time they meet the following conditions: visited the clinic by month 1, initiated treatment by month 3, and achieved viral suppression by month 6
89298466|NCT03807882|Experimental|Test group|Bilateral Maintenance ECT (B/L M-ECT)
89298467|NCT03807882|Active Comparator|Control group|Clozapine monotherapy. Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
89298468|NCT03814434|Experimental|Smokers with Periimplantitis group|Heavy smokers patients with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
89298469|NCT03814434|Experimental|Type 2 Diabetes with Periimplantitis group|Patients diagnosed with Type 2 Diabetes with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
89298470|NCT03814434|Experimental|Chronic Periodontitis with Periimplantitis group|Patients diagnosed with Chronic Periodontitis and periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
89298471|NCT03814434|Experimental|Control with Periimplantitis group|Systemically healthy patients with periimplantitis will be included in this group. Patients will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
89298472|NCT05647434|No Intervention|group C|conventional ventilation
89298473|NCT05647434|Active Comparator|group SI|Sustained inflations done after ultrasound during capnoperitoneum every 20 min.
89298474|NCT01303146|Experimental|Enzyme replacement therapy|intravenous infusion 100U/kg every other week for 18 months
89298475|NCT03806946||group1|ADHD with normal EEG
89298476|NCT03806946||group 2|ADHD with abnormal EEG
89298477|NCT03806946||group 3|Epilepsy
89298478|NCT03806946||group 4|Healthy control group
89298479|NCT03806946||group 5|ADHD and epilepsy
89298480|NCT03806322|Experimental|Cold-pack Group|One group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs
89298481|NCT03806322|Experimental|Intermittent Pneumatic Compression|The second group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression
89298482|NCT03805854|Experimental|Transcranial alternating current stimulation (tACS)|
89298483|NCT03796494|Active Comparator|Control Group|The control group is considered, using the company's classic multi-position straight anti-rotational abutment
89298484|NCT03796494|Experimental|Test group|The test group is considered, where the new multi-position straight esthetic anti-rotational slim abutment is used
89298485|NCT03814278|Experimental|Complete bed rest|Participants on complete bed rest group kept antepartum confinement to bed with toileting restricted to bedpan use. Participants in this group received prophylactic subcutaneous enoxaparin (40mg/day).
89298486|NCT03814278|Experimental|Activity restriction group|Activity restriction group had motion limited to bathroom privileges and walks to the ward canteen four times per day.
89298487|NCT04368858|Experimental|Cohort 1 : experimental group|Participants will be involved in an evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 1 year with evaluations (occurrence of fall) taking place at 6 months and at 1 year.
89298488|NCT03813810||Normal|People without any chronic pulmonary diseases.
89298489|NCT03813810||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease.
88813887|NCT03004157|Experimental|Two thumb technique|Two thumb technique TTHT: the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
89298490|NCT03813810||Asthma|Patients with asthma
89298491|NCT03813810||Idiopathic pulmonary fibrosis|Patients with idiopathic pulmonary fibrosis
89298492|NCT03814122|Experimental|ABCR Treatment Group|Group that is immediately administered action-based cognitive remediation intervention.
89298493|NCT03814122|Active Comparator|Waitlist Control Group|Group that is waitlisted (i.e., receives treatment-as-usual) and after approximately 8 weeks received action-based cognitive remediation intervention
89298494|NCT01303302|Active Comparator|GCM stimulation|The patient will be implanted with a gastric contractility modulation (GCM) stimulation system using the TANTALUS System for treatment of type 2 diabetic patients.
89298495|NCT01303302|Sham Comparator|Device off|The TANTALUS System is implanted but is off
89298496|NCT01303458|Experimental|Intervention arm|Study subjects will receive the Basic Needs Surveillance (BNS) intervention.
89298497|NCT01303458|No Intervention|Control arm|Study subjects in the control arm will receive the standard of care.
89298498|NCT03795948|Other|PROM Evaluation for stroke patients|Patient will be enrolled and PROMs will be collected.
89298499|NCT01304472|Experimental|Prasugrel|Prasugrel 10mg per day
89298500|NCT01304472|Active Comparator|Clopidogrel|
89298501|NCT03447210|Experimental|Assisted Partner Services|All participants in this arm will be offered assisted partner services (APS) which involves outreach to sexual partners and to individuals with whom they use injection drugs. When partners are contacted they are offered HIV and HCV testing. There is no comparison arm.
89298502|NCT03795792|Experimental|Curcumin|Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
89298503|NCT03795792|Placebo Comparator|Hydrollased collagen|Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
89298504|NCT03813888|Experimental|Arsha Vidya Group|After school, children joined regular sessions in Arsha Vidya study centre to practice, vedic chants, vedanta reading, yoga and group activities within the ashram.
89298505|NCT03813888|Other|Usual Activity Group|After school, control group were asked to conitue their usual routine.
89298506|NCT03795636|Experimental|Garlic extracts root canal irrigation group|"Experimental group treated with garlic extract~A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water"
89298507|NCT03795636|Active Comparator|Sodium hypochlorite root canal irrigation group|Control group which treated conventionally using .5 ml of 5.25% NaOCl (COLTENE®ENDO, Switzerland)
89298508|NCT01303536|Experimental|obsessive compulsive disorder|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
89298509|NCT01303614|Active Comparator|Lidocaine-Prilocaine cream|
89298510|NCT01303614|Placebo Comparator|Placebo|purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid
89298511|NCT03795714||Intravascular Imaging and Physiologic Assessment|330 patients with suspected ischemic heart disease and who underwent IVUS or OCT assessment and invasive physiologic assessment.
89298512|NCT03342378||Oropharynx Cancer Patients|Patients with OPSCC will be treated with comprehensive head and neck RT to 70 Gy in 33 fractions with concurrent weekly cisplatin at 40 mg/m2 and at the University of Wisconsin.
89298513|NCT03813732|Other|orbital fracture|using the trans-conjunctival approach with lateral canthotomy
89298514|NCT03795480|Experimental|MOOD|"The online program MOOD is based on methods of cognitive behavior therapy (KVT) and contains elements of mindfulness and metacognition. Participants can contact a moderator (trained psychologists) if they have any questions. However, this function is optional. The program consists of nine interactive modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention."
89298515|NCT03795480|No Intervention|Control|The wait-list control group does not receive additional treatment. However, previously started therapies (psychotherapy/ psychopharmacotherapy) may be continued during the study. Individuals of the wait-list control group receive access to MOOD after completion of the post-assessment.
89298516|NCT03795090|Active Comparator|Regular Patient privacy curtain|Control arm is a regular patient privacy curtain, washed and dried in hospital laundry using commercially available sodium hypochlorite and hydrogen peroxide.
89298517|NCT03795090|Experimental|Antimicrobial Coated Curtains|Treatment arm is an antimicrobial coated curtains, which is obtained by dipping the hospital laundered curtains into the antimicrobial coating. The curtains are then dried and provided to the nursing/supporting staff.
89298518|NCT03802578|Experimental|EXERCISE GROUP|Patients in the exercise group performed a program of strengthening, stretching and resistance upper limbs exercises (Hand exercise), of 30 minutes duration daily, for 12 weeks in addition to medical care.
88816736|NCT05588778|Experimental|BAILAMOS™ @home/en casa|The BAILAMOS™ @home/en casa dance program is provided twice weekly for 24 weeks. Each month a new dance style is introduced by a professional dance instructor.
89298519|NCT03802578|No Intervention|CONTROL GROUP|Patients in the control group continued their usual medical care.
89298520|NCT03802422|Experimental|Vitamin B12 hydrodissection|Ultrasound-guided hydrodissection with Vitamin B12 between carpal tunnel and median nerve.
89298521|NCT03802422|Placebo Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
89298522|NCT03813576|Other|All participants|Only 1 arm in the study. All women will undergo both self-collected swab and clinician-collected swab
89298523|NCT03813498|Experimental|intervention group|
89298524|NCT03813498|Other|control group|
89298525|NCT01303692||A|Total of 250 prostate cancer patients receiving GnRH agonist
89298526|NCT01303692||B|Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent
89298527|NCT03813264|Experimental|preliminary arm|pairs of patients and their therapists
89531712|NCT05633238|Experimental|Within-Subjects Attentional Information|Within-Subjects, all participants receive all interventions
89531713|NCT05630950|Experimental|Smoking cessation application|
89531714|NCT05630950|Active Comparator|Written smoking cessation information|
89298528|NCT03801564|Experimental|Platelet Rich Plasma Group (PRP)|Platelet Rich Plasma Treatment Group (PRP): The blood is drawn from the antecubital vein to the 10cc line of EasyPRP syringe consisted 1.5ml of anticoagulant. The syringe is centrifuged at a rate of 1200 g for 2 minutes. Then the syringe is rotated and the lower chamber filled with erythrocytes is discharged. The connector is inverted and the air gap is discharged. The injector is again centrifuged at 1200G for 10 minutes. Then the injector is rotated in the direction of the arrow, the lower stopper is removed. The application injector of 3cc with connector is placed in the EasyPRP injector. 1 ml of the PRP containing Buffycoat is separated for content analysis, the remaining 2 ml of the string is injected. Injection is repeated one month interval
89298529|NCT03801564|Experimental|Hyaluronic acid Group (HA)|Hyaluronic Acid Treatment Group (HA): 2 ml HA (32mg / ml) containing 1.6% sodium hyaluronate is injected intraarticular. The molecular weight is 800 - 1200 K Dalton. The viscosity is 20 pascal / s. The pH of the product is 7-7.5.Injection is repeated one month interval.
89298530|NCT03795324|Experimental|Redlove Apple|"Redlove Apple intervention~This product is a biofortified cultivar apple with anthocyanins."
89298531|NCT03795324|Experimental|Green Apple|"Green Apple intervention~This product is a common cultivar apple without anthocyanins."
89298532|NCT03795324|Experimental|Aronia Drink|"Aronia drink intervention~This product is an infusion of aronia fruit extract rich in anthocyanin."
89298533|NCT03795402||Group A|Three microneedle device samples will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1. Two skin biopsies of 4 millimeter (mm) will be performed on Day 1. No investigational drug product will be administered during this study.
89298534|NCT03795402||Group B|One microneedle device sample will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1 and at Weeks 2 and 4. Two skin biopsies of 4 mm will be performed on Day 1. No investigational drug product will be administered during this study.
89298535|NCT03813186|Experimental|ASTX727 + Day 2 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 2 of Cycle 1.
89298536|NCT03813186|Experimental|ASTX727 + Day 4 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 4 of Cycle 1.
89298537|NCT01304628|Experimental|PL-3994 (4 escalating doses)|
89298538|NCT01304628|Placebo Comparator|Placebo|
89298539|NCT03795012|Active Comparator|Eribulin monotherapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle
89298540|NCT03795012|Active Comparator|eribulin plus endocrine therapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, in combination with endocrine therapy (aromatase inhibitor). AI must be identical to the last AI administered to the patient, whether in the adjuvant or metastatic setting.
89298541|NCT03353350|Experimental|Efpeglenatide 2mg|Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
89298542|NCT03353350|Experimental|Efpeglenatide 4 mg|Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
89298543|NCT03353350|Experimental|Efpeglenatide 6 mg|Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
89298544|NCT03353350|Placebo Comparator|Placebo|Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
88817032|NCT03291067|Experimental|MT-8554 5mg|
88817033|NCT03291067|Experimental|MT-8554 10mg|
88817034|NCT03291067|Placebo Comparator|Placebo|
89298545|NCT03800238|Experimental|Telehealth Delivery Format|This group will participate in the Powerful Tools for Caregivers program using a telehealth delivery method.
89298546|NCT03800238|Active Comparator|Standard Delivery Format|This group will participate in the Powerful Tools for Caregivers program in person.
89298547|NCT03799848|Experimental|Vadadustat|Group 1: Subjects with moderately impaired hepatic function (Child-Pugh Class B) Group 2: Normal healthy volunteers Group 3: Subjects with mildly impaired hepatic function (Child-Pugh Class A)
89298548|NCT01382056|Experimental|Mixed beans (higher amount)|Participants may be randomized to foods containing 0.6 cup of mixed beans daily 5 times per week for 8 weeks
89298549|NCT01382056|Experimental|Mixed beans (lower aomunt)|Participants may be randomized to foods containing 0.3 cup of mixed beans daily, 5 times per week for 8 weeks.
89298550|NCT01382056|Active Comparator|Control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
89298551|NCT03799692|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, Carboplatin AUC=2, iv, d1, 8, 15, 4 cycles (21 days per cycle).
89298552|NCT03281824|Experimental|ALT-P7|"8 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.2 mg/kg, 4.5 mg/kg, 4.8 mg/kg,~Administration: Day 1 of each 3-week cycle"
89298553|NCT03799536|Experimental|Sequence AB|Subjects assigned to sequence AB will receive a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 1 and a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89298554|NCT03799536|Active Comparator|Sequence BA|Subjects assigned to sequence BA will receive a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 1 and a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89298555|NCT03812796|Experimental|Domatinostat plus Avelumab|This is a multicentre open-label, phase II non-randomised clinical trial domatinostat plus avelumab (two separate cohorts in phase IIB part of trial).
89298556|NCT03633214|Active Comparator|Training module (Intervention)|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later
89298557|NCT03633214|No Intervention|No training module (Control)|
89298558|NCT01381822|Experimental|TH-302 Dose escalation|The initial dose of TH-302 will be 240 mg/m2. A Dose Level minus 1 and 2 will be built into the study in the event that subjects experience excessive toxicity at Dose Level 1. Dose escalation will continue with approximately 40% increases from the previous dose level; however lower dose increases of 20-39% may be implemented after consultation between the Investigators, Medical Monitor and Sponsor with the percent increase dependent on the current dose level and the cumulative safety data.
89298559|NCT03794934|Placebo Comparator|Control|Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply
89298560|NCT03794934|Active Comparator|Intervention|provide structured education when applying CGM for 3 months
89298561|NCT01381744|Experimental|Group 3: 6 mcg Flagellin/F1/V|12 subjects will receive 6 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
89298562|NCT01381744|Experimental|Group 4: 10 mcg Flagellin/F1V|12 subjects will receive 10 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
89298563|NCT01381744|Experimental|Group 2: 3 mcg Flagellin/F1/V|12 subjects will receive 3 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
89298564|NCT01381744|Experimental|Group 1: 1 mcg Flagellin/F1/V|12 subjects will receive 1 microgram (mcg) of Flagellin/F1/V or placebo on Day 0 and Day 28.
89298565|NCT04403464|Experimental|HABIT-ILE with REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities with an interactive device
89298566|NCT04403464|Active Comparator|HABIT-ILE without REAtouch®|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities
89298567|NCT01384318||Cuffed ETT|Patients intubated with cuffed endotracheal tubes.
89298568|NCT01384240|Experimental|Proflavine Hemisulfate|
89298569|NCT04357600|Experimental|intravenous injection of UC-MSC|The dosage of the intravenous route is 100 million MSCs for each subject.
89298570|NCT04332640|Experimental|Next Generation Phaco System|VERITAS Vision System
89298571|NCT01381588||Post menopausal women|Post menopausal women between 50 to 80
89298572|NCT03032068|Experimental|At-Home Monitoring|Patients will follow-up in clinic postoperatively at 4, 8, and 12 weeks and their recovery will also be monitored using sensors and communication devices while they are at home after surgery.
89298573|NCT04293796|Experimental|TNBC group|A group with TNBC in neoadjuvant therapy will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then 12 cycles of neoadjuvant polychemotherapy according to the paclitaxel 60-100 mg / m² scheme in 1 day + carboplatin AUC 2 1 p in 7 days. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
89298574|NCT04293796|Experimental|HER2-positive breast cancer group|ER + - / HER2 + will receive 4 cycles of neoadjuvant polychemotherapy according to the AC regimen (doxorubicin 60 mg / m2, cyclophosphamide 600 mg / m2) once every 21 days, then docetaxel 75-100 mg / m² on the 1st day + trastuzumab 6 mg / kg (loading dose of 8 mg / kg) on the 1st day + pertuzumab 420 mg (loading dose of 840 mg) on the 1st day; 4 cycles, 1 time in 21 days and surgical treatment. In adjuvant therapy, a group of patients with HER2-positive breast cancer will receive trastuzumab for up to one year and hormone therapy with an antiestrogen (tamoxifen) or aromatase inhibitors in ER + / HER2 + tumors. VAB with SLNB and radiation therapy on the remaining breast tissue with cCR and pCR patients. Patients with residual breast cancer undergo standart surgery procedure.
89298575|NCT01381510||Adherent BPH patients|Patients with benign prostatic hyperplasia (BPH) who are adherent to 5-alpha reductase inhibitor (5ARI) therapy based on a medication possession ratio (MPR). Analyses will be conducted with threshold adherence levels of 70%, 75% and 80%
89298576|NCT01381510||Non-adherent BPH patients|Patients with BPH who are not adherent to 5ARI therapy based on an MPR and threshold levels of less than 70%, less than 75% and less than 80%
89298577|NCT04258072|Experimental|open label,single arm|Vactosertib* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours
89298578|NCT03923452|Experimental|MBSR: Mindfulness-based stress reduction|Participants will be exposed to the 9-week MBSR program, facilitated by a trained MBSR facilitator. Due to COVID-19, the program will be held virtually.
89298579|NCT03923452|No Intervention|WLC: Wait list Control|Participants will be asked to log their self-care activities every week.
89298580|NCT03631342|Experimental|VCV20|Volume-controlled ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
89298581|NCT03631342|Experimental|VCV40|Volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
88813888|NCT03004157|Experimental|new two-thumb technique|new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90 degrees to the chest while closing the fingers of both hands in a fist
88817035|NCT03265379||patients with an isolated recurrence in the chest wall|
89298582|NCT03631342|Experimental|PCV|Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
89298583|NCT03631342|Experimental|PCV+Tins|Pressure controlled ventilation mode and inspiratory pressure was increased every 5cmH2O, until the maximum pressure of 40 cmH2O was reached. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
89298584|NCT03631342|Experimental|PSV|Pressure support ventilation mode, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
89298585|NCT02984800|Experimental|Group I|Patients will receive one PVB injection at L1-L2 .
89298586|NCT02984800|Experimental|Group III|Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.
89298587|NCT04210414|Experimental|Day 3 transfer|Transfer on day 3 when only one embryo is available
89298588|NCT04210414|Experimental|Day 5 transfer|Transfer on day 5 when only one embryo is available
89298589|NCT04188730|Experimental|Lofexidine (granules for reconstitution), fasted|Participants will be administered lofexidine granules for reconstitution following an overnight fast of at least 10 hours.
89298590|NCT04188730|Active Comparator|LUCEMYRA (lofexidine) tablets, fasted|Participants will first be administered LUCEMYRA (lofexidine) tablets following an overnight fast of at least 10 hours
89298591|NCT04188730|Experimental|Lofexidine (granules for reconstitution), fed|Participants will first be administered lofexidine granules for reconstitution, 30 minutes following a standardized breakfast preceded by an overnight fast of at least 10 hours.
89298592|NCT01381432||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the lung transplantation
89298593|NCT01381354|Experimental|Combined intervention|Combination intervention consisting of the following: structured modified paleolithic diet, Progressive Exercise, Neuromuscular Electrical Stimulation designed to facilitate the adoption of multiple therapeutic lifestyle behaviors associated with superior health outcomes.
89298594|NCT01381276|Experimental|Cassava Treatment 1|Single meal containing bio-fortified, high carotenoid cassava without oil.
89298595|NCT01381276|Experimental|Cassava Treatment 2|Single meal containing bio-fortified, high carotenoid cassava with oil.
89298596|NCT01381276|Active Comparator|Cassava Treatment 3|Single meal containing low carotenoid cassava with oil and retinyl palmitate.
89298597|NCT01569178|No Intervention|standard care|optimal standard care post myocardial infarction
89298598|NCT01569178|Experimental|Intracoronary Reinfusion of Cells|Bone marrow-derived progenitor cells aspiration and Intracoronary reinfusion of the cells
89298599|NCT02674516|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo 3 sessions of anodal bilateral transcranial direct stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) on three consecutive days. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the DLPFC bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 2mA (1mA at each DLPFC site) will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
89298600|NCT02674516|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
89298601|NCT01569334|Other|HTC with Cardiac allograft vasculopathy|HTC:heart transplanted recipients
89298602|NCT01569334|Other|HTR without Cardiac allograft vasculopathy|
89298603|NCT01569334|Other|untransplanted|
89298604|NCT01381198|Active Comparator|Distal rectus femoris transfer|Single-event multilevel surgery with a concomitant distal rectus femoris transfer
89298605|NCT01381198|No Intervention|No distal rectus femoris transfer|Single-event multilevel surgery without distal rectus femoris transfer
89298606|NCT05758870||Research Group|surgical stabilization of low rib fracures by internal fixation
89298607|NCT05758870||Controls Group|conservative treatment of low rib fractures
89298608|NCT03633136|No Intervention|standard education|Standard of care education provided at each transplant center
89298609|NCT03633136|Experimental|electronic video education|Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
89298610|NCT02463448|Experimental|Autologous Muscle Derived Cells|Autologous Muscle Derived Cells are obtained by needle biopsy from the subject's own thigh muscle. These cells are sent to a special lab for growth and processing. When ready the cells are sent to the treatment location for injection into the bladder wall.
89298611|NCT01380964||DMD patients|DMD Patients
89298612|NCT01380964||Control patients|Control patients
89298613|NCT01569256|Active Comparator|Cabergoline administered group|"The patients in this group will have cabergoline (Dostinex tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days) for prevention of OHSS.~All patients were administered long luteal protocol for ovulation induction."
89298614|NCT01569256|No Intervention|Control arm|"The patients in the control group had no manipulation for prevention of OHSS and age-, BMI-matched with the active comparator group.~All patients were administered long luteal protocol for ovulation induction."
89298615|NCT01384162|Experimental|sNN0029, ICV infusion|
89298616|NCT01384084|Experimental|POP repair plus mini-sling|Patients affected by urogenital prolapse and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy plus anti-incontinence procedure (mini-sling).
89298617|NCT01384084|Active Comparator|pelvic organ prolapse repair|Patients affected by urogenital prolapsed and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy alone.
89298618|NCT01380886|Experimental|Infant formula, alternate protein source|Experimental infant formula with alternate protein source
89298619|NCT01380886|Active Comparator|Infant formula powder|Infant formula powder
89298620|NCT03794544|Experimental|Durvalumab 1500 mg|Participants will receive durvalumab 1500 mg intravenously (IV) every 4 weeks (Q4W; on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
89298621|NCT03794544|Experimental|Durvalumab 1500 mg + Oleclumab 3000 mg|Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and oleclumab 3000 mg IV every 2 weeks (Q2W; on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
89298622|NCT03794544|Experimental|Durvalumab 1500 mg + Monalizumab 750 mg|Participants will receive durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and monalizumab 750 mg IV Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
89298623|NCT03794544|Experimental|Durvalumab 1500 mg + Danvatirsen 200 mg|Participants will receive danvatirsen 200 mg IV on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period), followed by durvalumab 1500 mg IV Q4W (on Week 1 Day 1) and danvatirsen 200 mg IV every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period. Surgical resection will be planned between Day 29 and Day 42. After surgical resection, participants will be followed up to Day 105 (starting from Week 1 Day 1).
89298624|NCT01380808|Experimental|experimental arm|capecitabine and pseudomonas aeruginosa combination
89298625|NCT01380652|Experimental|rehabilitation with vibration training|
89298626|NCT01380652|No Intervention|rehabilitation without vibration training|
89298627|NCT03799224|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for recurrent and refractory acute leukemia at the time of HLA-mismatched HSCT~Details:~The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2"
89298628|NCT03799224|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD (minimal residual disease) at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3."
89298629|NCT03794622||Bone marrow concentration group|Consecutive patients receive intramedullary nail fixation with bone marrow concentration.
89298630|NCT03794622||Historical control group|Previous age- and gender-matched patients who receive intramedullary nail fixation only.
89298631|NCT01384006||Control|standard pancreas allograft recipients
89298632|NCT01384006||Study|recipients of extended donor criteria pancreas allografts
89298633|NCT03799068|Active Comparator|suprazygomatic maxillary nerve block|the group were given a bilateral suprazygomatic maxillary nerve block with 0.125% bupivacaine, 2 ml on each side, the total dose of bupivacaine not exceeding 2 mg/kg.
89298634|NCT03799068|Active Comparator|surgical site infiltraion|the group were given peri-incisional infiltration with 0.125% bupivacaine, 2 ml on each side. In all cases the block was given by the anaesthetist and the infiltration by the surgeon.
89298635|NCT03812406|Experimental|FAUCS|Patients undergoing a cesarean section using the FAUCS technique
89298636|NCT03812406|Active Comparator|Control|Patients undergoing a cesarean section using the traditional (Misgav-Ladach) technique
89298637|NCT03798990||users of French roads|all road users circulating on French roads outside over-seas
89298638|NCT03631264|Experimental|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
89298639|NCT03631264|No Intervention|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
89298640|NCT01383850|Active Comparator|NCPAP + standard air|
89298641|NCT01383850|Experimental|NCPAP + Heliox|
89298642|NCT03798912|Active Comparator|Intravenous octreotide group|Octreotide 100 mcg will be injected intravenously and serial blood samples will be collected for PK analysis
89298643|NCT03798912|Experimental|RaniPill A group|In 20 subjects, a RaniPill with a small balloon size will be administered and serial blood samples will be collected for PK analysis
89298644|NCT03798912|Experimental|RaniPill B group|In 20 subjects, a RaniPill with a larger balloon size will be administered and serial blood samples will be collected for PK analysis
89298645|NCT03798912|Experimental|RaniPill C group|In 20 subjects, a RaniPill with a different size will be administered and blood samples will be collected for the presence of drug
89298646|NCT03666832|Experimental|Arm1|TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.
89298647|NCT03812640|Experimental|Vicryl|Vicryl suture
89298648|NCT03812640|Active Comparator|Nylon|Nylon suture
89298649|NCT01804270|Active Comparator|Part 1 Active|Blinded, active repetitive transcranial magnetic stimulation
89298650|NCT01804270|Sham Comparator|Part 1 Sham|Blinded, sham repetitive transcranial magnetic stimulation
89298651|NCT01560468|Experimental|ITX 5061|Subjects will receive ITX 5061 for 28 days beginning at the time of liver transplantation for hepatitis C virus. 300mg will be administered on the day of surgery and for one week post transplant, followed by 150mg for an additional 21 days.
89298652|NCT03798834|Experimental|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
89298653|NCT03798834|Placebo Comparator|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
89531715|NCT05625061|Experimental|Core Behavioral Weight Loss (BWL) Intervention|Behavioral weight loss core intervention, includes activity tracker, wireless scale, daily self-weighing, and smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback summary, and daily weight-related behavioral goals. Core intervention component is combined with each of the 7 intervention messages to be tested repeatedly over time.
89298654|NCT01304784|Experimental|Arm 1|"Regimen follows a 3-week treatment cycle.~Cisplatin 80mg/m2 given on day 1 by IV infusion over two hours every three weeks.~Capecitabine 1000 mg/m2 given orally twice daily for fourteen days each 3-week cycle.~Up to six 3-week cycles of Cisplatin and Capecitabine to be administered. Trastuzumab given as 8 mg/kg loading dose at week 1 over 90 minutes followed by 6 mg/kg every 3 weeks over 30-90 minutes.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Trastuzumab (every 3 weeks) and MM-111 (weekly) will continue until disease progression, unacceptable toxicity, or withdrawal of consent."
89298655|NCT01304784|Experimental|Arm 2|"Regiment follows a 4-week treatment cycle.~The following Lapatinib and Trastuzumab regimen will be given in combination with MM-111 in the following order:~Trastuzumab 4 mg/kg loading dose week 1 over 90 minutes~Followed by Trastuzumab 2 mg/kg weekly thereafter~Lapatinib 1000 mg by mouth (PO) daily~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
89298656|NCT01304784|Experimental|Arm 3|"Regimen follows a 4-week treatment cycle Paclitaxel dosing should begin first dose on cycle 1 day 1. Paclitaxel will be administered at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab will be administered via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
89298657|NCT01304784|Experimental|Arm 4|"4-week treatment cycle. Lapatinib given orally. Paclitaxel dosing on cycle 1 day 1. Paclitaxel given at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab given via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 given over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
89298658|NCT01304784|Experimental|Arm 5|"Docetaxel, trastuzumab and MM-111 3-week treatment cycles with therapies given in the following order: 1) docetaxel, 2) trastuzumab, and 3) MM-111~Docetaxel given as an IV infusion over 60 minutes every three weeks. The infusion should be prepared as directed in the Docetaxel package insert and any institutional guidelines. All patients receiving Docetaxel should be pre-medicated as per the local institutional guidelines.~The first dose of trastuzumab is a loading dose of 8 mg/kg administered over 90 minutes followed by every three week dosing at 6 mg/kg over 60 minutes via IV infusion.~The first dose of MM-111 given over 90 minutes followed by 3 week dosing over 60 minutes in the absence of infusion-related reactions"
89298659|NCT03107026|Experimental|dasotraline 4mg|dasotraline 4mg once daily
89298660|NCT03107026|Experimental|dasotraline 6mg|dasotraline 6mg once daily
89298661|NCT03107026|Placebo Comparator|Placebo|Placebo, once daily
89298662|NCT05574972|Experimental|Timing Carotid Stent|
89298663|NCT05574972|Active Comparator|Carotid Wallstent|
89298664|NCT03798600||Critically ill patients|"20 patients consecutively admitted in the ICU with severe sepsis or septic shock requiring caspofungin therapy will be considered for this observational study.~Inclusion Criteria:~Adult ICU patients (>18 yrs) with severe sepsis or septic shock undergoing caspofungin therapy based on clinical judgement (empiric therapy) or microbiological result (targeted therapy).~Exclusion criteria:~Concomitant ciclosporin or rifampicin therapy. Pregnancy Continuous renal replacement therapy Severe Liver failure (Child Pugh score > 6)"
89298665|NCT03798522|Experimental|erector spinae plane block group (ESPB) n=14|Bilateral ultrasound guided erector spinae plane block will be performed in the lateral position at T7 vertebrae and before induction of GA. 20 ml of local anesthetic solution (20 ml bupivacaine (Sunnypivacaine, Sunny pharmaceutical, Egypt) 0.25%) will be injected in-plane into the ESP. This procedure will be repeated on the other side taking care not to exceed the maximum recommended doses (2 mg/kg of IBW for bupivacaine) and then GA will be conducted .
89298666|NCT03798522|Active Comparator|general anesthesia group (GA) n= 14|these patients will receive iv nalbuphine in dose of 2mg /kg according to ideal body weight after induction of GA
89298667|NCT03812484|Experimental|SCF Parole|Parolee supervised under the SCF Supervision model
89298668|NCT03812484|Active Comparator|Parole-As-Usual|Parolees are supervised under standard parole supervision practice in New Jersey.
89298669|NCT01308034|Experimental|association sunitinib radiotherapy|
89298670|NCT03798444||Bone mineral denstiy|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry in all subjects.Accroding to The World Health Organization, we defined osteoporosis as a T-score ≤-2.5,and the non osteoporosis as T-score>-2.5.
89298671|NCT03798444||Vertebral fractures|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray. A visual semi-quantitative method was used, with fractures defined as a vertebral height ratio <0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra.
89298672|NCT01302210||Intervention|Active surveillance testing for MRSA and decolonization of positive subjects
89298673|NCT01302210||control|Usual standard of care
89298674|NCT01303770|Experimental|Cognitive intervention group|Cognitive rehabilitation program designed to be tested in this study
89298675|NCT01303770|Active Comparator|Control group|
89298676|NCT03717480|Experimental|TCR α/β Reagent System|"The stem cell apheresis product will be depleted of TCRαβ T cells by negative selection using the automated CliniMACS® Plus device.~CD34+ stem cell counts will be obtained before and after processing with the Miltenyi ClinicMACs device"
89298677|NCT03798210|Placebo Comparator|Placebo|Look and taste-alike placebo tablets in white plastic vials.
89298678|NCT03798210|Experimental|Lactobacillus reuter's|Lactobacillus reuteri tablets in white plastic vials.
89298679|NCT00005044|Experimental|TAS x 8 weeks|Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
88817036|NCT03265379||distant metastatic disease is present but who undergo FTCWR|
89298680|NCT00005044|Experimental|TAS x 28 weeks|TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
89298681|NCT03800082|No Intervention|Control|Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
89298682|NCT03800082|Experimental|Treatment|Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention. The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check. A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness. Participants will be directed to the PC for technical problems.
89298683|NCT01303848||Healthy probands|Healthy probands, age between 18 and 40 years
89298684|NCT03811938|Active Comparator|Pulmonary Vein Isolation|Historical control from cases performed in year 2017 at Hammersmith Hospital. Intervention: Pulmonary vein isolation.
89298685|NCT03811938|Experimental|Low voltage ablation|Active arm, Intervention: Standard pulmonary vein isolation and Low Voltage Ablation.
89298686|NCT03794232|Experimental|Test group|NIUCHANG（Soluble dietary fiber + prebiotics）：Oral, 1 bag (15g) once a day, taking 24 weeks
89298687|NCT03794232|Placebo Comparator|Control group|Placebo（inactive drug ingredient）：Oral, 1 bag (15g) once a day, taking 24 weeks
89298688|NCT03794154|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
89298689|NCT03794154|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg as Cymbalta by mouth on Day 1 of period 1 or 2
89298690|NCT05090202||"HFrEF  Heart failure with reduced ejection fraction"|"chronic heart failure with echocardiographic finding of LVEF Left ventricular ejection fraction equal or less than 40%"
89298691|NCT05090202||"HFmrEF Heart failure with mildly reduced ejection fraction"|chronic heart failure with echocardiographic finding of LVEF between 41% and 49%
89298692|NCT05090202||"HFpEF  Heart failure with preserved ejection fraction"|chronic heart failure with echocardiographic finding of LVEF equal or more than 50%
89298693|NCT01305018|Experimental|Exercise and BCAA|
89298694|NCT01305018|Experimental|Exercise and Leucine|
89298695|NCT01305018|Placebo Comparator|Exercise and Placebo|
89298696|NCT03811860|Active Comparator|Once Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium once daily at bedtime. After 4-6 days, a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (twice daily dosing, if they have not already done so). Frequency of selected medication use is noted.
89298697|NCT03811860|Active Comparator|Twice Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium divided into two daily doses. After 4-6 days a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (once daily dosing, if they have not already done so).Frequency of selected medication use is noted.
89298698|NCT03811782|Experimental|Single-task Training Group|Single-task walking group
89298699|NCT03811782|Experimental|Dual-task Training Group|Dual-task walking group
89298700|NCT03811782|Experimental|Analogy Training Group|Analogy walking group
89298701|NCT02722668|Experimental|No ATG|Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
89298702|NCT02722668|Experimental|ATG|Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
89298703|NCT03799926|Experimental|Stratum 1: 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
89298704|NCT03799926|Experimental|Stratum 1: 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
88817037|NCT03265379||patient with primary tumor, no distant ds, failed conventional|
89298705|NCT03799926|Experimental|Stratum 1: placebo of 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
89298706|NCT03799926|Experimental|Stratum 1: placebo of 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
88817038|NCT03265379||patients refusing to undergo surgery|
88820362|NCT06189768||Children with hyperpigmentation disorder|Children aged 0 to 15 with hyperpigmentation due to any cause presenting to Dermatology Outpatient Department of Kanti Children's Hospital
89298707|NCT03799926|Experimental|Stratum 2: 8.4 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
89298708|NCT03799926|Experimental|Stratum 2: 16.8 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
89298709|NCT03799926|Experimental|Stratum 3: 8.4 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
89298710|NCT03799926|Experimental|Stratum 3: 16.8 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
89298711|NCT03797976|Experimental|Parkinson's Disease Group|MIP and MEP Respiratory Function Test Strength Test
89298712|NCT01303926|Active Comparator|Cisplatin and Pemetrexed|
89298713|NCT01303926|Active Comparator|Carboplatin paclitaxel bevacizumab|
89298714|NCT01304004|Experimental|Experimental drinking yogurt|
89298715|NCT01304004|Placebo Comparator|Placebo drinking yogurt|
89298716|NCT01305096|Experimental|Yoga group|Participants in this group will take part in six to eight weeks of yoga classes. The classes will be held once a week and each class will be approximately one hour long. The classes will consist of yoga inversions, sun salutations and other yoga postures with deep breathing.
89298717|NCT01305096|No Intervention|Control group|Matched control
89531716|NCT05625061|Experimental|Core BWL Intervention + BCT 1 Message (Action Planning)|"Core BWL Intervention + Message testing the Behavior Change Technique Action Planning"
89531717|NCT05625061|Experimental|Core BWL Intervention + BCT 2 Message (Discrepancy)|"Core BWL Intervention + Message testing the Behavior Change Technique Discrepancy Between Current Behavior and Goal"
89298718|NCT01305174|Active Comparator|Balloon expandable stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted"
89298719|NCT01305174|Active Comparator|Selfexpanding stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter."
89298720|NCT05069844|Experimental|Gum chewing for 2 minutes|Patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
89298721|NCT05069844|Experimental|Gum chewing for 4 minutes|Patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
89298722|NCT05069844|No Intervention|Control group|Patients will be asked to swallow 2 times only.
89298723|NCT01302600|Experimental|Olesoxime|100 patients in this arm. liquid suspension
89298724|NCT01302600|Placebo Comparator|Placebo|50 patients enrolled in this arm. liquid suspension
89298725|NCT03793764|Active Comparator|Group T|At the end of the surgery USG guided TAP block will be performed with 20 mL of 0.25% isobaric bupivacaine.
89298726|NCT03793764|Active Comparator|Group Q|At the end of the surgery USG guided QL block will be performed with 20 mL of 0.25% isobaric bupivacaine.
89298727|NCT03793764|No Intervention|Group C|In this group no intervention will be performed after the end of operation.
89298728|NCT01304160|Experimental|strereotactic radiotherapy, gemcitabine|stereotactic radiotherapy (30Gray in 5 fractions) followed by gemcitabine
89298729|NCT03811704|Experimental|Experimental group|Hepatectomy procedures were performed under Laparoscopic surgical navigation system and Indocyanine Green guidance.
89298730|NCT03084796|Experimental|Treatment A|CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose [TDD] of CHF 5259 12.5 μg)
89298731|NCT03084796|Experimental|Treatment B|CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)
89298732|NCT03084796|Experimental|Treatment C|CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)
89298733|NCT03084796|Experimental|Treatment D|CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)
89298734|NCT03084796|Placebo Comparator|Treatment E|Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;
89298735|NCT03084796|Active Comparator|Treatment F|Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)
89298736|NCT03717012|Active Comparator|Nintedanib treatment alone|
89298737|NCT03717012|Experimental|Nintedanib with a pulmonary rehabilitation program|
89298738|NCT03793686|Experimental|Experimental|PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
89298739|NCT03793686|Placebo Comparator|Placebo|Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
89298740|NCT02501148||Carotid artery stenting|Symptomatic and asymptomatic subjects requiring carotid artery stenting, post-dilation performed using the Paladin System with integrated embolic protection
89298741|NCT01305486||XenMatrix|
89298742|NCT03793530|Experimental|Bone marrow concentration group|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
89298743|NCT03793530|Active Comparator|Control group|Transforaminal lumbar interbody fusion with local bone graft
89298744|NCT01848912||Bone Marrow Transplant Patients|
89298745|NCT04893252|Experimental|vactosertib in combination with durvalumab|single arm study
89298746|NCT04863300|Experimental|Intervention group|Participants in the intervention group will receive a collaborative stepped care programme provided by registered social workers and trained Peer Supporters from aged care service units - the Districts Elderly Community Centres (DECC), and mental health service units - the Integrated Community Centre on Mental Wellness (ICCMW), all are local NGOs. In the collaborative stepped care model (see attachment Table 1), older persons are matched to the intervention module that most suits their current needs. The person does not have to start at the lowest level of intervention to progress to the next level of intervention. Rather, they enter the service with the intervention level aligned to their needs, e.g., level of risks, symptom severity (measured by the Patient Health Questionnaire, PHQ-9), and intervention response. Home visits or other format of contact will be delivered by trained Peer Supporters employed by the NGOs to detect and engage hidden cases.
89298747|NCT03797742||NC|Patients without heart failure.
89298748|NCT03797742||DCM|Dilated cardiomyopathy patients.
89298749|NCT03797742||ICM|Ischemic cardiomyopathy patients.
89298750|NCT03797664|Experimental|Experimental: CDX-6114|7.5, 15.0 and 22.5g
89298751|NCT03797664|Placebo Comparator|Placebo Comparator: Placebo|Phosphate Buffer Diluent Solution
89298752|NCT03797508|Other|threatened miscarriage|ultrasound ,CA125,progesterone
89298753|NCT03797118|Experimental|FFRct|Patients will receive cCTA, ICA, FFRct, and FFRinv per protocol.
89298754|NCT03797352|No Intervention|Control|Receive healthy ageing advice every 3 months for the duration of 12 months
89298755|NCT03797352|Experimental|Intervention|To participate in supervised Multicomponent exercise (combined exercise and cognitive activity) up to three times a week for 6 months and receive healthy ageing advice
89298756|NCT03811548|Experimental|Janagliflozin 25mg|Each patient will receive 25 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
89298757|NCT03811548|Experimental|Janagliflozin 50mg|Each patient will receive 50 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
89298758|NCT03811548|Experimental|Placebo/Janagliflozin|In the core period, each patient will receive placebo once daily for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin once daily until Week 52.
89298759|NCT03793296|Experimental|Paravalvular leak|After transcatheter- or surgical valve replacement
89298760|NCT03811626|Experimental|Intervention|Patient who underwent cognitive-behavioral rehabilitation
89298761|NCT03811626|No Intervention|Comparator|Patient with no specific management
89298762|NCT01380496|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
89298763|NCT01380496|Active Comparator|C|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
89298764|NCT01380496|Experimental|A|Subjects received the Par formulated product
89298765|NCT03793374||Axillary osmidrosis patients|Patients with axillary malodor and require surgical intervention. The subcutaneous apocrine glands shaving were used.
89298766|NCT03797040|Experimental|4 million PLX-R18 cells/kg-up to a maximal dose of 400 million|
89298767|NCT01380418||Study group|Obese BMI>30 18-85 years old
89298768|NCT01304316|Experimental|Kovacaine Nasal Spray|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 6 sprays of 0.1 mL - total of 18 mg tetracaine HCl and 0.3 mg oxymetazoline HCl followed by 12 sprays of 0.1 mL - total of 36 mg tetracaine HCl and 0.6 mg oxymetazoline HCl
89298769|NCT01301430|Experimental|H-1 parvovirus (H-1PV)|
89298770|NCT03792828|Active Comparator|Control|Duloxetine HCl 30mg is not used.
89298771|NCT03792828|Experimental|Duloxetine|One capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.
89298772|NCT01304394|Other|parenteral nutrition solution|
89298773|NCT01379326|Experimental|Mebendazole|
89298774|NCT00541294||B|M.tb unexposed HIV-infected and uninfected children <15 years of age
89298775|NCT00541294||A|M.tb exposed HIV-infected and uninfected children <15 years of age
89298776|NCT00791466|Experimental|1|
89298777|NCT00791466|Placebo Comparator|2|
89298778|NCT05748574|Experimental|"Sleep Well Sachet Treatment"|"Sachet of Sleep Well direct granulate (2.0 g)~1 sachet contains: 190 mg standardized dry extract of Melissa officinalis leaf , 75 mg dried pressed juice of fresh Lactuca sativa herb, 0.41 g Magnesiumdicitrate, 0.12 g L-Tryptophan, excipients and natural flavors."
89298779|NCT01560546|Active Comparator|Testim|
89298780|NCT01560546|Placebo Comparator|Placebo|Placebo for 24 weeks
89298781|NCT01380340|Experimental|Seniors early intervention driving group|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
89298782|NCT01380340|No Intervention|Matched comparison group|The subjects will be recruited from a parallel service and will be paired with similar subjects in the experimental group.
89298783|NCT03811392|Active Comparator|Hernioraphy/Caudal block|patients will receive a caudal block after induction of general anaesthesia.
89298784|NCT03811392|Active Comparator|Hernioraphy/Quadratus Lumborum block|patients will receive ultrasound guided quadrates lumborum block (QL )
89298785|NCT04921254|Experimental|BSG005|Active antifungal drug
89298786|NCT04921254|Placebo Comparator|Placebo|Will be a 5% glucose infusion
89298787|NCT01380262||Low Dose Doxycycline|Patients with metastatic colorectal cancer, qualified to either cetuximab or panitumumab based systemic treatment (either monotherapy or with chemotherapy) receiving a 100 mg of doxycycline daily
89298788|NCT03630874|Experimental|Experimental arm|
88814625|NCT01612793||AlphaCore device|AlphaCore device group will consist of subjects enrolled into the study with chronic obstructive pulmonary disease and receive an electrical stimulation to the vagus nerve to help open the subjects airways during the subjects stay in the hospital.
88814626|NCT01613339|Experimental|Body awareness therapy|
89298789|NCT03630874|No Intervention|Control arm|"Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (without the tool) the right prescription of ATs by answering a multiplechoice question, with the number, type, duration and dosage of AT provided."
89298790|NCT03792984|Placebo Comparator|Metformin + Placebo|
89298791|NCT03792984|Experimental|Calcium carbonate + Vitamin D3 + Metformin|
89298792|NCT05422456||Chronic pain group|children are diagnosed with chronic headache by pediatric neurologist
89298793|NCT05422456||Health group|children without chronic pain
89298794|NCT04914546|Experimental|LY3819469 (Part A)|Single ascending doses of LY3819469 administered subcutaneously (SC).
89298795|NCT04914546|Experimental|LY3819469 (Part B)|Single doses of LY3819469 administered SC in Japanese Participants.
89298796|NCT04914546|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
89298797|NCT04914546|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
89298798|NCT05200234|Experimental|Intervention group|Nattokinase + standard medical treatment
89298799|NCT05200234|Placebo Comparator|Control group|Placebo + Standard medical treatment
89298800|NCT05669196||standard thoracotomy group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with standard thoracotomy
89298801|NCT05669196||muscle sparing thoracotomy group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with muscle sparing thoracotomy
89298802|NCT05669196||VATS group|Individuals who are between the ages of 18-75 and lung cancer patient, underwent lobectomy with video-assisted thoracic surgery
89298803|NCT03792906|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
89298804|NCT03792906|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion.
89298805|NCT04884126||One stage dental implants placement|
89298806|NCT04884126||Second stage dental implants placement|
89298807|NCT02613286|Experimental|Extrafascial Hysterectomy|Type A hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
89298808|NCT02613286|Active Comparator|Modified radical hysterectomy|Type B2 hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
89298809|NCT03792594||Bone marrow concentration group|The patients receive arthroscopic repair with bone marrow concentration.
89298810|NCT03792594||Historical control group|The patients receive arthroscopic repair only
89298811|NCT05200078||Radiotherapy at free-breathing|breast/chest wall+-RNI 43.5Gy/15f/3w（tumor bed 49.5Gy/15f/3w) delivered at free-breathing
89298812|NCT05200078||Radiotherapy at deep inspiration breath-hold|breast/chest wall+-RNI 43.5Gy/15f/3w（tumor bed 49.5Gy/15f/3w) delivered at deep inspiration breath-hold
89298813|NCT03810846|Experimental|Exercise|Walking football exercise program
89298814|NCT05625048|Experimental|Intervention group|The intervention group receives same treatment as the control groups and in addition transperinal ultrasound guided instruction in pelvic floor muscle training at 2nd and 3rd session.
89298815|NCT05625048|No Intervention|Control group 1|The patients recieve standard care including three physiotherapist sessions; within one week preoperatively, one week postoperatively at catheter removal, and six weeks postoperatively
89298816|NCT05625048|No Intervention|Control group 2|The patients recieve standard care including three physiotherapist sessions; within one week preoperatively, one week postoperatively at catheter removal, and six weeks postoperatively
89298817|NCT04152382|Experimental|LY3462817 - Intravenous (IV)|LY3462817 administered as IV infusions.
89298818|NCT04152382|Placebo Comparator|Placebo - IV|Placebo administered as IV infusions.
89298819|NCT04152382|Experimental|LY3462817 - Subcutaneous (SC)|LY3462817 administered as SC injections. (SC administration is discretionary/optional.)
89298820|NCT04152382|Placebo Comparator|Placebo - SC|Placebo administered as SC injections. (SC administration is discretionary/optional.)
89298821|NCT04152382|Experimental|LY3509754|LY3509754 administered orally.
89298822|NCT04152382|Placebo Comparator|Placebo|Placebo administered orally.
89298823|NCT03792204||PD patients with wearing-off effect|"people who have been clinically diagnosed with Parkinson's disease (PD) and have received anti PD therapy would be recruited into the study. The anti -PD treatment would not be changed in the population of the participants.~We would use the tool of 'Wearing-off 9 questionnaire' to determine the prevalence of Wearing-off phenomenon in Parkinson's patients in Shanghai"
89298824|NCT05421442||Abatacept Group|Participants with established rheumatoid arthritis (RA) or psoriatic arthritis (PsA) and receiving abatacept
89298825|NCT05421442||Non-targeted Disease Modifying Anti-rheumatic Drug (DMARD) Group|Participants with established RA or PsA and not previously treated with any targeted disease modifying anti-rheumatic drugs (DMARDs) and who start treatment with a non-targeted DMARD
89298826|NCT05421442||Targeted DMARD Group|Participants with established RA or PsA and previously treated without abatacept who start treatment with targeted DMARDs
89298827|NCT01379248|Experimental|thrombus aspiration|Manual thrombus aspiration with dedicated catheter (Export, Medtronic Inc. Minneapolis, Minnesota, USA)
89298828|NCT01379248|No Intervention|no thrombus aspiration|
89298829|NCT03078556|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
89298830|NCT03078556|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
89298831|NCT03078556|Experimental|Subjects receiving high fat meal: Part 1|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
89298832|NCT03078556|Experimental|Treatment sequence A/C: Part 2|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
89298833|NCT03078556|Experimental|Treatment sequence C/A: Part 2|Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
89298834|NCT03078556|Experimental|Subjects receiving high fat meal: Part 2|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
89298835|NCT01377688||Diabetics with PKD|Diagnoses of diabetes type 2 with progressive kidney disease (slope of eGFR decline between -15 to -3 ml/min/1.73m2 per year, estimated by calculating an eGFR for each creatinine using the 4-variable Modification of Diet in Renal Disease Study [MDRD] equation and conducting a simple ordinary least squares regression from these values to evaluate changes over time to derive each individuals' slope of eGFR, annualized using test dates)
89298836|NCT03949894|Experimental|tolvaptan|
89298837|NCT02299648|Other|Single arm|molecular profiling, patient derived cells
89298838|NCT03714672|Experimental|Tramadol/Diclofenac 50/50|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
89298839|NCT03714672|Experimental|Tramadol/Diclofenac 25/25|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
89298840|NCT03714672|Active Comparator|Tramadol 50|Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
89298841|NCT03714672|Active Comparator|Diclofenac 50|Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
88814627|NCT01613339|No Intervention|Control|
89298842|NCT03083470|Experimental|SOR007 0.15%|SOR007 Ointment 0.15% applied to the face twice daily for 28 days
89298843|NCT03083470|Experimental|SOR007 0.3%|SOR007 Ointment 0.3% applied to the face twice daily for 28 days
89298844|NCT03083470|Experimental|SOR007 1.0%|SOR007 Ointment 1.0% applied to the face twice daily for 28 days
89298845|NCT03083470|Experimental|SOR007|SOR007 Ointment 2.0% applied to the face twice daily for 28 days
89298846|NCT03083470|Sham Comparator|Ointment Vehicle|SOR007 Ointment vehicle applied to the face twice daily for 28 days
89298847|NCT01306188||Breast cancer|Metastatic breast cancer
89298848|NCT01306188||Lung cancer|Metastatic lung cancer
89298849|NCT01377610|Active Comparator|Buprenorphine|Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
89298850|NCT01377610|Active Comparator|Oral naltrexone|The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.
89298851|NCT05669118||Autotransplantation|Patients who receive one tooth autotransplanted.
89298852|NCT03811080|Experimental|DWP14012 A mg|DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks
89298853|NCT03811080|Experimental|DWP14012 B mg|DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks
89298854|NCT03811080|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
89298855|NCT05421286||PLWH ≥50 years old|
89298856|NCT01302990|Experimental|5 micrograms H1 VLP|
89298857|NCT01302990|Experimental|13 micrograms H1 VLP|
89298858|NCT01302990|Experimental|28 micrograms H1 VLP|
89298859|NCT01302990|Active Comparator|45 micrograms Fluzone|
89298860|NCT01302990|Placebo Comparator|Placebo|
89298861|NCT05624970|Experimental|group (A)|"Group (A):~This group will consist of 30 patients who will receive the medical treatment (oral hypoglycemic drugs), aerobic training, tobacco cessation program and nutritional advices for 12 weeks."
89298862|NCT05624970|Experimental|group (B)|"Group (B):~This group will consist of 30 patients who will receive the medical treatment (oral hypoglycemic drugs), tobacco cessation program and nutritional advices for 12 weeks."
89298863|NCT05624892|Experimental|Experimental Group|Application of mirror therapy to the experimental group with virtual reality application
89298864|NCT05624892|No Intervention|Control Group|Application of classical mirror therapy to the control group
89298865|NCT01379950||periodontitis|patients diagnosed with periodontal disease
89298866|NCT03788772|Experimental|Adults patients hospitalized in ICU|Adult patients hospitalized in the intensive care unit (ICU) for severe infections (sepsis and septic shock) or or non-septic shock (cardiogenic or hemorrhagic shock)
89298867|NCT03810976|Experimental|eribulin+gemcitabine|The dose is 1.4 mg/m2 for 5 minutes intravenously. If necessary, the dose may be diluted in up to 100 mL of saline solution prior to intravenous administration. Gemcitabine doses 1000 mg/m2 intravenously for 30 minutes. After completion of the eribulin injection, intravenously inject gemcitabine. One cycle is 3 weeks, and the treatment is carried out on the 1st day and the 8th day for each cycle.
89298868|NCT05405244|Other|Bromocriptine, then Placebo|During the first intervention visit, participants receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Following a 2-week washout period, participants return for the second intervention visit, where they receive 2 capsules of placebo (sugar free calcium supplement) matched in shape (circle) and color (white) to bromocriptine. Both bromocriptine and placebo are administered orally.
88806267|NCT01159535|Active Comparator|MBRP|The Mindfulness Based Relapse Prevention (MBRP) intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include mindfulness practices targeting craving, Negative affect, and reactivity, as well as discussion about how to implement practice into high-risk situations and in daily life.
88806268|NCT01159535|Active Comparator|Relapse Prevention (RP)|The RP intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include discussions of personal high-risk situations, coping skills assessment, and exercises to evaluate expectancies, self-efficacy, and craving.
89298869|NCT05405244|Other|Placebo, then Bromocriptine|During the first intervention visit, participants receive 2 capsules of placebo (sugar free calcium supplement). Following a 2-week washout period, participants return for the second intervention visit, where they receive a single dose of 1.6mg of bromocriptine (2 0.8mg capsules). Both bromocriptine and placebo are administered orally.
89298870|NCT05420974|Experimental|NIR fluorescence|The included patients will be subdivided in four equal subgroups in order to evaluate alteration of NIR fluorescence signal during arthroscopy in combination with a (temporary) tourniquet and irrigation pump system.
89298871|NCT01379872||Study Protocol A - IMRT Post Prostatectomy|"Prospective TROG 08.03 (RAVES) Participants~Prospective Participants (NOT participating in TROG 08.03 (RAVES))~Retrospective TROG 08.03 (RAVES) Participants~Participating in dosimetric evaluation and toxicity/QoL study~Participating in dosimetric evaluation only"
89298872|NCT01379872||Study Protocol B - IMRT Anal Cancer|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)"
89298873|NCT01379872||Study Protocol C - IMRT Nasopharynx|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)~Post-Treatment Prospective Participants (toxicity/QoL and cost study)"
89298874|NCT01379872||Study Protocol D - IGRT Intact Prostate|"Patients with prostate cancer~- A sample of 30 patients from at least 10 centres that are to be treated for intermediate risk prostate cancer will be enrolled. The sample will be selected to comprise at least 10 patients that will undergo non-IGRT, 10 that will undergo IGRT with fiducials and planar imaging, and 10 that will undergo IGRT with volumetric imaging."
89298875|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 1|mRNA-3704
89298876|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 2|mRNA-3704
89298877|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 3|mRNA-3704
89298878|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 4 (optional)|mRNA-3704
89298879|NCT03810690|Experimental|Dose Expansion Phase: mRNA-3704|
89298880|NCT03762460|Experimental|Online eHealth Tool|Participants randomized to this group will use a personally-owned smartphone, tablet, or computer to access the online eHealth tool.
89298881|NCT03762460|Placebo Comparator|Informational website (control)|Participants randomized to this group will receive information about online resources for mental health
89298882|NCT03789006|Active Comparator|ATG|Induction with antithymocyte immunoglobulin (Rabbit) (Grafalon) and maintenance with tacrolimus, azathioprine and prednisolone
89298883|NCT03789006|Active Comparator|BAS|Induction with interleukin 2 receptor antagonist (basiliximab) and maintenance with tacrolimus, mycophenolate mofetil and prednisolone
89298884|NCT01379170|Experimental|Type 2 diabetes, de novo hypothyrodism treatment|Type 2 diabetic patients with de novo hypothyroidism will be included in this arm and will receive 3 months of treatment with Euthyrox (standard protocol).
89298885|NCT01306266|Active Comparator|rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo
89298886|NCT01306266|Placebo Comparator|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg
89298887|NCT05624814||Experimental group|Patients with chronic pain which failed standard therapies and with an implanted Spinal Cord Stimulator
89298888|NCT05624814||Comparison group|Patients with chronic pain following traditional therapies, i.e. pharmacological, psychological, physical and occupational therapies or surgery.
89298889|NCT05624814||Control group|Healthy volunteers matched for age and schooling to those included in the experimental group
89298890|NCT05416684||PEEK Group|
89298891|NCT05416684||Titanium Mesh Group|
89298892|NCT05624736||Glioblastoma Group|Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.
89298893|NCT05624736||Astrocytoma Group|Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.
89298894|NCT05624736||Oligodendroglioma Group|Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.
89298895|NCT03630796|Active Comparator|Sevoflurane|"Anesthetic induction with sevoflurane by mask 3-8% and fresh gas flow 2-8 l/min (FiO2 50-100%) followed by ketamine 1-2 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and sevoflurane 1-3% (end-tidal concentration) before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg and pancuronium 0,1 mg/kg will be administered and the sevoflurane sustained 1-3% in a specific sevoflurane vaporizer included in the CPB machine.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
89298896|NCT03630796|Other|Intravenous anesthetics (TIVA)|"Anesthetic induction with ketamine 1-3 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg after preoxygenation with FiO2 between 50-100% and fresh gas flow 4-8 l/min.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and continuous infusion of midazolam and ketamine 0,2-0,8 mg/kg/h and 1-2 mg/kg/h respectively before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg, midazolam 0,1-0,5 mg/kg and pancuronium 0,1 mg/kg will be administered.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
89298897|NCT05388162|Other|coposcopy|patients undergoing colposcopy will have images taken of the cervix with a standard colposcope and the Mobile colposcope. de-identified images from both devices will then be entered into a custom colposcopic image evaluation program. Images will then be randomly evaluated by expert colposcopists as normal, abnormal or cannot evaluate. On abnormal images, the most abnormal point on the images will be marked as teh recommended biopsy site. Scoring for images from the standard colposcope will be compared with that for the Mobile Colposcope.
89298898|NCT01379092|Experimental|Breast biopsy specimen imaging & comparison of image quality|Each subject's explanted tissue will serve as both the control (standard analysis) and the experimental analysis of the quality of the images.
89298899|NCT01306344||Patients|Heterogeneous groups of patients (age, gender)
89298900|NCT01306344||Nurses|Heterogeneous groups of nurses (age, gender, working experience)
89298901|NCT01306344||Physicians|Heterogeneous groups of physicians (age, gender, working experience)
89298902|NCT03810300|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
89298903|NCT03810300|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
89298904|NCT03810300|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
89298905|NCT03810300|Experimental|Cash transfer + nutrition BCC|1500 taka ($18.75) per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
89298906|NCT03810300|Experimental|Food transfer + nutrition BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
89298907|NCT03810300|Experimental|Control|No transfer, no behavior change communication
89298908|NCT05202964||Tolerance and adherence to oral antibiotics in patients managed for BJI|Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery
89298909|NCT01567332|Experimental|rTMS active|
89298910|NCT01567332|Placebo Comparator|rTMS inactive (sham)|
89298911|NCT01346722|Other|Group A|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with conventional rice-based diet (Diet- CR)
89298912|NCT01346722|Other|Group B|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with a rice-based diet plus zinc fortificant (Diet-CR+Z)
89298913|NCT01139866||Group 1: SABER™-Bupivacaine|Received 5.0 mL SABER™-Bupivacaine in previous C803-017 trial
89298914|NCT01139866||Group 2: SABER™-Placebo|Received 5.0 mL SABER™-Placebo in previous C803-017 trial
89298915|NCT01096966|Experimental|Bupivacaine TTS|
89298916|NCT01096966|Placebo Comparator|Placebo patch|
89298917|NCT01379638||cardiac output|Adult patients undergoing cardiac surgery with normothermic cardiopulmonary bypass
89298918|NCT01379560|Experimental|unoprostone isopropyl (2 drop)|
88814628|NCT01653509|Experimental|Test patch|Patch containing acyclovir applied to cold sore
88814629|NCT01653509|Placebo Comparator|Placebo patch|Patch without acyclovir applied to cold sore
89298919|NCT01379560|Experimental|unoprostone isopropyl (3 drop)|
89298920|NCT01379482|Experimental|Multimodal treatment|Neoadjuvant systemic chemotherapy followed by cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy
89298921|NCT03791892|Experimental|Shoulder mobilization Group|Kaltenborn mobilization will be applied to patient in experimental group only.
89298922|NCT03791892|Active Comparator|Conventional treatment Group|Application of conventional treatment that includes stretching and strengthening exercises of shoulder.
89298923|NCT05462002||plantar fasciitis group|Distance runners with plantar fasciitis
89298924|NCT05462002||asymptomatic control group|Distance runners without plantar fasciitis
89298925|NCT05624424|Experimental|Remimazolam Besylate|Induction of anesthesia Slowly inject Remimazolam Besylate 0.3~0.5 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS<60, if the degree of sedation is insufficient, additional Remimazolam Besylate (0.05 mg/kg each time) is allowed. After the LoC, sufentanil 0.3~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
89298926|NCT05624424|Active Comparator|Propofol|Induction of anesthesia Slowly inject Propofol 2~2.5 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS<60, if the degree of sedation is insufficient, additional Propofol (0.5 mg/kg each time) is allowed. After the LoC, sufentanil 0.3~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
89298927|NCT05624424|Active Comparator|Sevoflurane|Induction of anesthesia Slowly inject Etomidate 0.03 mg/kg (about 1 minute) until loss of consciousness (LoC) and BIS<60, if the degree of sedation is insufficient, additional etomidate (0.03 mg/kg each time) is allowed. After the LoC, sufentanil 0.3~0.5 ug/kg and cisatracurium besilate 0.2-0.3 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.
89298928|NCT05461846|Experimental|Group (A)|The integrated neuromuscular inhibition technique (INIT) is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
89298929|NCT05461846|No Intervention|Group (B)|control group
89298930|NCT05461690|Experimental|Niraparib group|200mg once a day for patients with body weight <77kg or baseline platelet count <150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
89298931|NCT05461612|Experimental|SRT Pacing|SRT sensing and pacing of the left atrium to detect AF and restore sinus rhythm.
89298932|NCT05461534|Experimental|Intervention group: mindfulness yoga|an 8-week structured mindfulness yoga program
89298933|NCT05461534|No Intervention|Waiting-list control group|provided the 8-week structured mindfulness yoga upon their completion of the study
89298934|NCT01306422|Placebo Comparator|Stage 2: Placebo|Placebo product, twice-daily, 65 minutes before breakfast and dinner
89298935|NCT01306422|Active Comparator|Stage 2: H.g.PE 1110 mg b.d.|Hoodia gordonii Purified Extract (H.g.PE) formulated product (1110 mg), twice-daily, 65 minutes before breakfast and dinner
89298936|NCT01306422|Placebo Comparator|Stage 1: placebo, breakfast & dinner|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
89298937|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/dinner|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
89298938|NCT01306422|Placebo Comparator|stage 1: Placebo breakfast/lunch|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
89298939|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/lunch|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
89298940|NCT03630094|Experimental|FEP-ZID via intravenous|total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
89298941|NCT01305642|Experimental|Individualized fortification of breast milk|
89298942|NCT01569490|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
89298943|NCT01569490|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
89298944|NCT01308216|Experimental|Transcranial low level laser therapy|Transcranial laser therapy is applied by automatic scanning over both hemispheres and the patients undergoing also a standard rehabilitation program based on therapeutic exercises.
89298945|NCT01308216|Active Comparator|Control|The patients undergoing only a standard rehabilitation program based on therapeutic exercises.
89298946|NCT05456230||Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
89298947|NCT05456230||Non-Midazolam|Midazolam was not given during the operation.
89298948|NCT03792048|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
89298949|NCT03792048|No Intervention|Manual Anastomosis|Manual Anastomosis for bilioenteric anastomosis and pancreaticojejunostomy
89298950|NCT05764174|Active Comparator|Factual messages|Participants in the arm with factual messages will listen to actual data on vaccination.
89298951|NCT05764174|Active Comparator|Narrative message|Participants the narrative messages will listen to messages appealing to emotions that were explored in a qualitative study conducted earlier.
89298952|NCT05764174|Active Comparator|Mixed messages|The mixed arm will combine both factual and narrative messages.
89298953|NCT05764174|No Intervention|Control arm|Participants in the control arm will not be provided with a message and will only be asked for whether they participant got vaccinated in the last two weeks.
89298954|NCT03791814|Experimental|Zepatier treatment|Open-label Zepatier (grazoprevir 100 mg and elbasvir 50 mg) will be administered in this study. Daily treatment of Zepatier for a 12-week duration will be administered.
89298955|NCT05426122|Experimental|Barley rice protein|Barley rice protein powder presented as a shake
89298956|NCT05426122|Experimental|Pea protein|Pea protein powder presented as a shake
89298957|NCT05426122|Experimental|Whey protein|Whey protein powder presented as a shake
89298958|NCT03792126|No Intervention|Standard Care|
89298959|NCT03792126|Experimental|Implicit Learning Approach|
89298960|NCT01306500|Experimental|Gastric lavage Group|In neonates randomized to intervention Group (gastric lavage group) gastric lavage was done in the labor room after initial stabilization
89298961|NCT01306500|No Intervention|No gastric lavage|Neonates randomized to 'No gastric lavage group' will receive supportive treatment as per standard unit protocol.
89298962|NCT01379014|Experimental|Decision Aid Tool|Intervention group - receives the decision aid tool in booklet form and is introduced to it by an investigator.
89298963|NCT01379014|No Intervention|Control|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
89298964|NCT01377376|Experimental|ARQ 197|ARQ 197 and Erlotinib
89298965|NCT01377376|Placebo Comparator|Placebo|Placebo and Erlotinib
89298966|NCT03788538|No Intervention|group 1 with no dexmedetomidine|
89298967|NCT03788538|Experimental|group 2 with dexmedetomidine 0.25μg/kg/h|
89298968|NCT03788538|Experimental|group 2 with dexmedetomidine 0.5μg/kg/h|
89298969|NCT05364814||Obese Group|A single sample group . Anthropometric measurements were taken at the beginning of all patients. Yogurt with probiotic added to medical nutrition therapy was applied for 2 weeks.Anthropometric measurements were taken at the beginning of all patients. Yogurt with probiotic added to medical nutrition therapy was applied for 2 weeks. At the end of each week, food consumption records and scales were applied. During the wash out period, all patients were asked to comply with their diet only. After the wash out period, a different diet was started and the same procedures were repeated.During the wash out period, all patients were asked to comply with their diet only. After the wash out period, a different diet (with the addition of probiotic yogurt) was changed and the same procedures were repeated.
89298970|NCT03494920|Other|Direct endovascular clot retrieval|Endovascular clot retrieval (ECR) within 4.5 hours stroke
89298971|NCT03494920|Other|Bridging thrombolysis followed by ECR|Intravenous tPA (at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour) followed by ECR
88806269|NCT01159535|Active Comparator|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
89298972|NCT01306578|Active Comparator|IVIG group|20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day
89298973|NCT01306578|Active Comparator|Plasma Exchange|21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days
89298974|NCT05343754|Active Comparator|Hyperbaric Oxygen Therapy|Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80 minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
89298975|NCT05343754|Active Comparator|Control group|In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.
89298976|NCT03788304|Active Comparator|Non invasive ventilation|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O.~Pressure support (PS): 12-20 cmH2O.~FiO2 will be adjusted to achieve a SpO2 at least 95%"
89298977|NCT03788304|Experimental|High flow nasal cannula|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C~Flow rate 30: 50 L/min.~FiO2 will be adjusted to achieve a SpO2 at least 95%"
89298978|NCT03785886|Experimental|Walking group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
89298979|NCT03785886|Experimental|Chinese Square Dancing group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
89298980|NCT03785886|Experimental|Control group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
89298981|NCT03297190|Active Comparator|SMS|Participants will receive SMS messages on nutrition and health related topics
89298982|NCT03297190|Active Comparator|Interpersonal|Participants will receive interpersonal counselling on nutrition and health related topics
89298983|NCT03297190|Active Comparator|SMS + Interpersonal|Participants will receive SMS messages on nutrition and health related topics as well as interpersonal counselling on nutrition and health related topics
89298984|NCT03297190|No Intervention|Usual Care|
89298985|NCT05320120|Experimental|first 56mg esketamine (2x Spravato® 28 mg nasal spray), then placebo|
89298986|NCT05320120|Experimental|first placebo (0.9% saline solution nasal spray), then ketamine|
89531718|NCT05625061|Experimental|Core BWL Intervention + BCT 3 Message (Feedback on Outcome of Behavior)|"Core BWL Intervention + Message testing the Behavior Change Technique Feedback on Outcome of Behavior"
89298987|NCT01306734||Gradient cooling group|Study group receiving gradient cooling during the procedure using extracorporeal circulation (ECC). The procedure is used routinely in the department and is not an experimental procedure. A maximum of 10 degrees celsius is allowed between the measured nasopharyngeal body temperature and the heater-cooler unit of the ECC-machine, when cooling or rewarming.
89298988|NCT01306734||Crash cooling group|Study group receiving rapid cooling using extracorporeal circulation. The protocol for rapid cooling is using routinely in the department and is not an experimental procedure. When cooling, the investigators aim for maximal difference in temperature between the heater-cooler unit of the ECC-machine.
89298989|NCT01567410|Other|traditional Classroom training|one group of nurses receive traditional classroom training to learn about the braden scale and pressure ulcer classification
89298990|NCT01567410|Other|e-learning|one group of nurses receive e-learning as a training method to learn about the braden scale and classification of pressure ulcer
89298991|NCT03074500|Experimental|Kinesiotaping|Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
89298992|NCT03074500|Sham Comparator|Sham taping|Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
89298993|NCT03074500|Other|Control|Stretching and strengthening exercises of wrist
89298994|NCT03791502|Experimental|Pilates Method Exercises - lower volume|The prescription will consist of 18 exercises, performed in a single series of seven to 10 repetitions, 60 seconds rest between exercises. Each week the exercises will be changed and the same exercise can only be repeated every three weeks. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises, but without modifying the repetitions. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
89298995|NCT03791502|Experimental|Pilates Method Exercises - higher volume|The participants will conduct a Pilates exercise program based on the recommendations of the American College Medicine of Sports. The prescription will consist of 12 exercises, performed in three sets of seven to ten repetitions and 60s of rest between sets. Every four weeks the exercises will be changed. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
89298996|NCT03791502|No Intervention|Group control|The subjects allocated in the control group will remain with their usual activities, and after the reevaluation will be offered the intervention that presents the greater size of effect.
89298997|NCT05621070|Experimental|JS002 150mg Q2W|JS002 150mg Q2W SC for 52 weeks
89298998|NCT05621070|Placebo Comparator|JS002 450mg Q4W|JS002 450mg Q4W SC for 52 weeks
89298999|NCT05621070|Placebo Comparator|Placebo Q2W|Placebo Q2W SC for 12 weeks, then switch to JS002 150mg Q2W SC for 40 weeks
89299000|NCT05621070|Placebo Comparator|Placebo Q4W|Placebo Q4W SC for 12 weeks, then switch to JS002 450mg Q4W SC for 40 weeks
89299001|NCT03715530|Experimental|Pregnant subjects|These are pregnant women that are admitted to Labor &Delivery (L&D) or an outpatient in the Women's Health Clinic that are being evaluated for rupture of membranes.
89299002|NCT03715530|Active Comparator|Pregnant controls|These women will be found primarily in the Women's Health Clinic, when being seen for their routine antepartum appointments. Most of them will be recruited at about 36 weeks, since they will be having a pelvic exam at this time, as part of their routine antepartum care.
89299003|NCT03715530|Sham Comparator|Non pregnant controls|These women will be found in the Women's Health Clinic, when being seen for gynecology appointments. Nursing staff and the dashboard will help to identify those patients who will be having a pelvic exam.
89299004|NCT01308372||1|For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;
89299005|NCT01378936|Experimental|MI plus IOC group intervention|
89299006|NCT01378936|Experimental|Motivational Interview only|
89299007|NCT03077698|Experimental|Sodium Cridanimod & progestin therapy|Sodium Cridanimod and progestin therapy (megestrol acetate) combination
89299008|NCT01377298|Experimental|Pazopanib|Single arm study, pazopanib
89299009|NCT03788460||childrens population with lack of Factor VI|"We will check PT levels, we will concentrate the data in the table, along with personal information such as age and gender.~We will try to conduct a statistical relationship between the PT values and Factor VII levels, to look for statistical significance, we will try to find a model for predicting the level of factor VII based on PT"
89299010|NCT05059366|Experimental|Expert participants randomized to MVG followed by 2VE|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the Manual ventilation grip device (MVG) first followed by the standard 2VE technique alone.
89299011|NCT05059366|Experimental|Expert participants randomized to 2VE followed by MVG|Expert participants (Anesthesiology residents and attendings with at least 2 or more years of clinical experience) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG).
89299012|NCT05059366|Experimental|Novice participants randomized to MVG followed by 2VE|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) first followed by the standard technique (2VE) alone
89299013|NCT05059366|Experimental|Novice participants randomized to 2VE followed by MVG|Novice participants (Current medical students or residents with no prior experience in hand mask ventilation techniques) randomized to perform the ventilation on a manikin using the standard technique (2VE) alone first followed by Manual ventilation grip device (MVG)
89299014|NCT03791580|Experimental|Commitment nudge|Primary care clinicians in the practice assigned to this arm will receive only the commitment nudge.
89299015|NCT03791580|Experimental|Justification nudge|Primary care clinicians in the practice assigned to this arm will receive only the justification nudge.
89299016|NCT03791580|Experimental|Commitment + Justification nudges|Primary care clinicians in the practice assigned to this arm will receive both the commitment nudge and the justification nudge.
89299017|NCT03791580|No Intervention|Non-participating|Primary care clinicians in Northwestern-affiliated practices other than the 3 pilot-participating practices will not receive any study interventions.
89299018|NCT03791658|Other|Asthmatics|"From the patients file the following information will be collected by the investigators:~Age~Sex~FEV1 derived from the last spirometry (including spirometry performed on day of study visit).~GINA step (Global Initiative for Asthma).~Number of exacerbations in the year prior to the study.~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.~FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).~Patients will fill out:~The 12-question TAI-questionnaire (test for the adherence to inhalers)~The Asthma Control Test (ACT)"
89299019|NCT03791658|Other|COPD-patients|"From the patients file the following information will be collected by the investigators:~Age~Sex~Pack Years~GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)~Number of exacerbations in the year prior to the study.~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.~Patients will fill out:~The 12-question TAI-questionnaire (test for the adherence to inhalers)~The COPD Assessment Test (CAT)"
89299020|NCT03079102|Experimental|inhaled nitric oxide (iNO)|20 ppm iNO delivered via mechanical ventilator connected to the iNO ventilator delivery system (iNOvent). Drug will be started as soon as possible after return of spontaneous circulation (ROSC) but no later than 4h after ROSC. Study drug will be dosed for 12h then tapered off over 1h.
89299021|NCT03079102|Placebo Comparator|Placebo|Nitrogen carrier gas delivered by identical system with similar dose/taper.
89299022|NCT03791424|Experimental|Midazolam|Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.
89299023|NCT03791424|Placebo Comparator|Control|Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
89299024|NCT03788226|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
89299025|NCT03788226|Active Comparator|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
89299026|NCT01378780|Active Comparator|Intervention for diet, exercise|This group will receive the educational intervention for healthy diet and increased physical activity
89299027|NCT01378780|Other|Control|This group will get a skin cancer awareness educational message. At the end of the study this group will also receive the diet and exercise intervention but outcomes will not be measured after the crossover.
89299028|NCT03787992|Experimental|Alflutinib Mesylate (AST2818) +placebo|AST2818 (80 mg or 40 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule
89299029|NCT03787992|Active Comparator|Gefitinib + placebo AST2818|Gefitinib (250 mg orally, once daily) + placebo AST2818 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
89299030|NCT04913194|Experimental|Immediate Treatment|Participants in this arm will receive the intervention within 2 weeks of completing the intake session.
89299031|NCT04913194|Other|Waitlist Control|Participants in this arm will not receive any intervention for two weeks. Participants will complete the treatment after 4-6 weeks of being on the waitlist after their intake session.
89299032|NCT04755426||Patients with severe aortic stenosis|Adults with severe aortic stenosis who either have faced or are facing a decision about valve replacement (depending on the phase of the research)
89299033|NCT04755426||Health care providers|HCPs who guide decisions about managing AS, including interventional cardiologists, cardiac surgeons and advanced practice providers (APPs), including nurse practitioners and physician assistants.
89299034|NCT03785808|Experimental|Diet A (low carbohydrate)|Dietary Intervention A will be a low-carbohydrate/high fat, ketogenic-type diet. The diet will include salads, leafy green and non-starchy vegetables, nuts and seeds, eggs, fish and shellfish, and meats in most meals. Grains and added sugars will be excluded, and starchy vegetables, fruits, berries, and legumes will be limited to below 10% of total calorie intake. In addition full fat yogurt, cheeses, and butter will be allowed in moderate amounts. Participants will be encouraged to eat freely from whole-foods rich in fats such as avocados, nuts, seeds, olives, coconut and to use coconut, medium-chain triglyceride (MCT), olive, and avocado oils for cooking and baking on that diet. Participants will aim to fulfill at least 65% of their total calorie requirements from fats.
89299035|NCT03785808|Experimental|Diet B (low fat)|Dietary Intervention B will be low-fat, high carbohydrate whole-foods, plant-based diet. Most animal products and concentrated plant-based protein sources (such as soy isolates) will be excluded. Whole grains, particularly in their cooked form, legumes, vegetables, and fruits will be encouraged while excluding added sugars and refined grains. Added fats and oils will be discouraged on this diet as dietary fat should comprise less than 10% of total energy. Participants can eat freely from all types of fruits, vegetables, and cooked whole grains. Legumes will be emphasized as a replacement for meat and dairy products. Proteins similar to beef, pork, poultry, and dairy products, should be strictly limited, while lean proteins such as eggs, fish, and shellfish may be included occasionally.
89531719|NCT05625061|Experimental|Core BWL Intervention + BCT 4 Message (Social Support)|"Core BWL Intervention + Message testing the Behavior Change Technique Social Support"
89531720|NCT05625061|Experimental|Core BWL Intervention + BCT 5 Message (Social Comparison)|"Core BWL Intervention + Message testing the Behavior Change Technique Social Comparison"
89531721|NCT05625061|Experimental|Core BWL Intervention + BCT 6 Message (Social Reward)|"Core BWL Intervention + Message testing the Behavior Change Technique Social Reward"
88806270|NCT02980055|Experimental|Test: collagen matrix|Root coverage using collagen matrix
89299036|NCT03785808|Active Comparator|Diet C (USDA control)|The control dietary intervention will be based on the 2015 USDA Dietary Guidelines for Americans, with a slightly higher amount of protein than recommended for the general population, and will be comprised of grains (of which ~50% should be consumed as whole grains), 3 servings per day of non-fat or low-fat dairy, legumes, fruit, vegetables, fish, vegetable oils and margarines, and limited quantities of meat, eggs, added sugars, nuts/seeds. Participants will be encouraged to reduce sodium intake to less than 2300 mg (1500 mg for participants over 51 yrs. old) per day, and to consume less than 10% of calories from saturated fat.
89299037|NCT04804306||Diagnostic Test: CBC-Diff Monocyte Volume Width Distribution|MDW measurement used to detect sepsis as part of the CBC-Diff ordered by ED Physician as part of the Institution's Standard of Care. Results will not be used to manage patients
89299038|NCT01305798|Experimental|Control Arm|The control arm will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment.
89299039|NCT01305798|Experimental|Active Choice and Default Option Arm|The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email.
89299040|NCT01305798|Experimental|Active Choice Only Arm|The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
89299041|NCT02434354|Experimental|neo-adjuvant/adjuvant pembrolizaumab 200 mg IV|All subjects will receive 1 cycle neo-adjuvant pembrolizumab 200mg IV followed by complete surgical resection followed by pembrolizumab Q3weeks for 1 year
89299042|NCT05553210|Experimental|Intervention group|The intervention group will get a 6-week therapist-guided online stress recovery intervention with an intervention plan.
89299043|NCT05553210|Experimental|Control group|The control group will get a 6-week therapist-guided online stress recovery intervention without an intervention plan. The control group will participate in the program at the same time as the intervention group.
89299044|NCT01377142||Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
89299045|NCT01377142||Vaginal mesh hysteropexy|Vaginal Mesh Hysteropexy using the Uphold device which includes Sacrospinous Ligament Fixation
89299046|NCT01377064|Experimental|Physical activity group|Subjects will participant in physical activity program
89299047|NCT01377064|Active Comparator|Standard care group|This group will not receive a physical activity intervention
89299048|NCT05549700|Experimental|Common fibular nerve group|The subjects of this group will receive electric nerve stimulation on the sciatic nerve through a lateral approach to stimulate the behavior corresponding to the common fibular nerve
89299049|NCT05549700|Experimental|Tibial nerve group|The subjects of this group will receive electric nerve stimulation on the sciatic nerve through a lateral approach to stimulate the behavior corresponding to the tibial nerve
89299050|NCT04783480|Active Comparator|Birthly plus standard of care|Women will receive a code to sign up for childbirth education classes through the Birthly platform. They will also participate in childbirth education at their own discretion.
89299051|NCT04783480|Placebo Comparator|Standard of Care|Women will not receive a code for the 3 Birthly courses. They will participate in childbirth education at their own discretion.
89299052|NCT03791268||Group A|Gastric Cancer Patients who underwent Chemotherapy and will have gastric cancer surgery.
89299053|NCT05764018|Placebo Comparator|Normoxia-Placebo|Participants will be breathing room air, and ingest a flavoured drink containing only a trivial amount of maltodextrin.
89299054|NCT05764018|Experimental|Normoxia-Caffeine|Participants will be breathing room air, and ingest a flavoured drink containing a trivial amount of maltodextrin and 6 mg/kg body mass caffeine.
89299055|NCT05764018|Placebo Comparator|Hypoxia-Placebo|Participants will be breathing a 13% oxygen gas mixture, and ingest a flavoured drink containing only a trivial amount of maltodextrin.
89299056|NCT05764018|Experimental|Hypoxia-Caffeine|Participants will be breathing a 13% oxygen gas mixture, and ingest a flavoured drink containing a trivial amount of maltodextrin and 6 mg/kg body mass caffeine.
89299057|NCT01308528|Experimental|Sodium enoxaparin|Endocris - 40 mg/0,4mL
89299058|NCT01308528|Experimental|sodium enoxaparin Clexane|Clexane - 40 mg/ 0,4mL
89299059|NCT03785652|Experimental|LY03005 extended-release tablets|LY03005 extended-release tablets at 4 doses 40 mg, 80mg, 120mg or 160mg
89299060|NCT03785652|Placebo Comparator|Placebo|Placebo tablet
89299061|NCT03076996|Experimental|Online support group|Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
89299062|NCT03785496|Experimental|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
89299063|NCT01307124|Active Comparator|standard dose|Arm 1:LPV/r Standard dose BW 25-35 kg 300/75 mg BW >35-50 kg 400/100 mg
89299064|NCT01307124|Experimental|low dose|Arm 2:Low dose BW 25-35 kg 200/50 mg BW >35-50 kg 300/75 mg
89299065|NCT03078868|Experimental|Single-point intervention|magnetic resonance scanner
89299066|NCT01378702|Experimental|Iscucin populi strength F, G and H|1 ampoule two times/week subcutaneously. Week 1-4: strength F. Week 5-8: strength G. Week 9-12: strength H.
89299067|NCT01378702|Experimental|Viscum Mali e planta tota D3, D2, 2%|1 ampoule two times a week subcutaneously. Week 1-4: D3. Week 4-8: D2. Week 9-12: 2%.
89299068|NCT01378702|Placebo Comparator|Placebo|1 ampoule two times a week subcutaneously
89299069|NCT03785418|Experimental|Experimental Arm|Multicomponent Risk Factor Modification Intervention focused on healthy eating, regular exercise and behavioural therapy
89299070|NCT03785418|No Intervention|Control Arm|Standard Clinical Practice
89299071|NCT01376986|Experimental|Activation|All those determined fit for service or who are granted postponement will be included in the activation intervention. The physical activation intervention will be implemented between the call-up and start of military service. The activation group utilises an ICT platform that will be developed.
89299072|NCT01376986|No Intervention|control|no access to the activation platform
89299073|NCT01307202|Experimental|Gabapentin|Gabapentin 600 mg will be given per oral two hours preoperatively and 200 mg three times daily after surgery (600 mg/day).
89299074|NCT01307202|Placebo Comparator|Placebo|Placebo will match the the gabapentin pill and will be given orally.
89299075|NCT03791190|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.
89299076|NCT03791190|Experimental|Regional citrate anticoagulation|"Patients accepted regional citrate anticoagulation. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.~Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+.~Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level."
89299077|NCT01307280|Experimental|Basic HEALTH|Participants received the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
89299078|NCT01307280|Experimental|Interactive Internet|Intervention intensity increased in RCT2, which included bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments.
89299079|NCT01307280|Experimental|Behavioral Counseling|RCT3 included bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
89299080|NCT05693376||Intervention group|Subjects who meet the following inclusion criteria: 1) Severe aortic stenosis. 2) Age > 65 years for male and >70 years for female. 3) Increased left ventricular wall thickness ≥14 mm. 4) Blood pressure ≤ 140/90 mmHg and at least 1 major or ≥ 2 minor criteria. Major criteria: a) Carpal tunnel syndrom; b) Non-traumatic rupture of the biceps tendon; c) NT-proBNP > 1000 pg/ml; d) hs Troponin value above the 99th percentile without dynamic changes (≤ 20%). Minor criteria: a) Diastolic dysfunction (at least grade 2, E' < 10 cm/s); b) Sinus bradycardia/AV block/pacemaker; c) Atrial fibrillation.
89299081|NCT05693376||Control group|Subjects who meet the following inclusion criteria: 1) Severe aortic stenosis. 2) Age > 65 years for male and >70 years for female. 3) Increased left ventricular wall thickness ≥14 mm. 4) Blood pressure ≤ 140/90 mmHg.
89299082|NCT03790722|Experimental|Higher Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
89299083|NCT03790722|Experimental|Lower Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
89299084|NCT03787914|Experimental|Intervention arm|Intervention arm patients were served by outreach mobile teams for oral anti-TB treatment under DOTS at the place of their convenience by health care professionals
89299085|NCT03787914|Active Comparator|Control arm|Control arm patients were given the traditional facility based DOTS treatment. Control arm was not served by the outreach mobile teams.
89299086|NCT01308606|Experimental|001|TMC435 gelatin capsule Single intake of one 150-mg capsule without food
89299087|NCT01308606|Experimental|002|TMC435 HPMC capsule Single intake of one 150-mg capsule without food
89299088|NCT01308606|Experimental|003|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food
89299089|NCT01308606|Experimental|004|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast
89299090|NCT01308606|Experimental|005|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast
89299091|NCT04637386|Active Comparator|TAP block group|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
89299092|NCT04637386|Active Comparator|LAWI group|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
89299093|NCT01307358|Experimental|Manual Toothbrush + Sonicare Interproximal Cleaning Prototype|Manual Toothbrush + Sonicare Interproximal (IP) Cleaning Prototype
89299094|NCT01307358|Active Comparator|Manual Toothbrush|Manual Toothbrush
89299095|NCT01307358|Active Comparator|Manual Toothbrush + Floss|Manual Toothbrush + Floss
89299096|NCT01307358|Active Comparator|Manual Toothbrush + Waterpik Ultra Water Flosser|Manual Toothbrush + Waterpik Ultra Water Flosser
89299097|NCT01308684|Experimental|1|
89299098|NCT01308684|Experimental|2|
89299099|NCT03629860|Active Comparator|ascending ramus group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The ascending ramus is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from ascending ramus to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures.~after atrophic maxillary alveolar ridge augmentation,sub mucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7 days"
89299100|NCT03629860|Active Comparator|Chin Group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The chin is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from chin to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures~after atrophic maxillary alveolar ridge augmentation,submucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7days"
89299101|NCT05613114|Experimental|Medication|Dalfampridine plus physiotherapy
89299102|NCT05613114|Placebo Comparator|No Medication|Placebo plus physiotherapy
89299103|NCT01378624|Experimental|Bronchoscopy|
89299104|NCT03630406||Laser treatment|Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment.
89299105|NCT03790566|Experimental|Erector spinae plane block|With the patient in lateral decubitus position (surgical side up), the transverse processes of T10-T12 vertebrae and erector spinae (ES) fascia are visualized 1-2 cm lateral to the vertebral spine using a linear ultrasound probe. A 22G peripheral block needle is introduced with in-plane technique under the ES muscle and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
89299106|NCT03790566|Active Comparator|Transversus abdominus plane block|With the patient in supine position, three layers of abdominal muscle are visualized using the linear ultrasound probe held with the long axis on the mid-axillary line above the iliac crest. 22G peripheral block needle is introduced in-plane into the fascia between the internal oblique and transversus abdominus muscles and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
89299107|NCT05763940|Experimental|OmegaBoost (QD)|Participants assigned the study supplement OmegaBoost, taken once daily (QD).
89299108|NCT05763940|Experimental|OmegaBoost (BID)|Participants assigned the study supplement OmegaBoost, taken twice daily (BID).
89299109|NCT05763940|Active Comparator|Nature Made (soft gel)|Participants assigned the Nature Made (soft gel), taken twice daily.
89299110|NCT05763940|Active Comparator|Nature Made (gummy)|Participants assigned the Nature Made (gummy), taken twice daily.
89299111|NCT04436224|Experimental|hydromorphone|NS 40ML+ hydromorphone(10mg , 2mg:2ml），IV-Pump，maintenance dose 0.50mg/h
89299112|NCT04436224|Active Comparator|fentanyl|NS 40ML+ fentanyl(0.5mg, 0.1mg:2ml），IV-Pump，maintenance dose 0.08-0.2mg/h
89299113|NCT04436224|Active Comparator|Butorphanol|NS 40ML+ butorphanol(10mg, 1mg:1ml），IV-Pump，maintenance dose 0.7-10mg/kg/h
89299114|NCT01307436|Experimental|Group A|Epaxal + concomitant administration of DTPaHibIPV, MMR, OPV
89299115|NCT01307436|Experimental|Group B|Epaxal, with administration of DTPaHibIPV, MMR, OPV one month later
89299116|NCT01307436|Active Comparator|Group C|Havrix 720 + concomitant administration of DTPaHibIPV, MMR
89299117|NCT03787524||Dysphagia group|Acute stroke patients who will be diagnosed dysphagia according to VFSS results.
89299118|NCT03787524||No dysphagia group|Acute stroke patient who showed no dysphagia according to VFSS results.
89299119|NCT04255108||Men/Women who meet the inclusion/exclusion criteria|
89299120|NCT03785184|Experimental|Venetoclax + Lenalidomide + Dexamethasone|Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).
89299121|NCT03790176|Other|A - patients on automated peritoneal dialysis|each of n=8 patients will receive one single intravenous infusion of ceftazidime/avibactam (CAZ/AVI) 2g/0.5g over two hours. Subsequently, PK of CAZ/AVI will be determined in plasma and peritoneal dialysis fluid (and urine, if applicable) at protocol-defined time points over 24 hours.
89299122|NCT03790176|Other|B - critically ill patients with pneumonia|following one intravenous dose of 2g/0.5g CAZ/AVI (which patients will receive based on clinical indication by their treating physician), PK of CAZ/AVI will be determined at protocol-defined time points over one dosing interval in plasma and in epithelial lining fluid (ELF).
89299123|NCT04524598|Experimental|Limbix Spark|A 5 week CBT-based intervention
89299124|NCT04524598|Active Comparator|Psychoeducation|5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention
89299125|NCT01305876|Experimental|one group with yoga intervention|one group with yoga intervention
89299126|NCT03784950|Experimental|Rating tool only|Rating eConsults from peer specialists in first phase
89299127|NCT03784950|Experimental|Feedback only|Receiving feedback from peer specialists in first phase
89299128|NCT03784950|Experimental|Rating Tool plus Feedback|Both rating and feedback in second phase.
89299129|NCT03784794|Experimental|Thromboelastometry|Decision to treat will be guided with thromboelastometry results, for fribrinogen deficiency the investigators will treat with fibrinogen concentrate (human), for correction of factor deficiency Prothrombin Complex Concentrates, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
89299130|NCT03784794|Active Comparator|STANDARD COAGULATION TEST ALGORITHM|Decision to treat will be guided by standard cogulation lab test (Thrombine time, Active Thromboplastine time, Clauss fibrinogen, platelets count etc) for fribrinogen deficiency the investigators will treat with cryoprecipitates, for correction of factor deficiency fresh frozen plasma, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
89299131|NCT05074446|Experimental|intensivist in the experimental group|Stereotype threat manipulation will be performed on the intensivist in the experimental group just before they are taken into the testing room.
89299132|NCT05074446|No Intervention|intensivist in the control group|The intensivist in the control group will not be given any prior information.
89299133|NCT05074446|Experimental|non-intensivist in the experimental group|Stereotype threat manipulation will be performed on the non-intensivist in the experimental group just before they are taken into the testing room.
89299134|NCT05074446|No Intervention|non-intensivist in the control group|The non-intensivist in the control group will not be given any prior information.
89299135|NCT04247308|Experimental|experimental group|"Sensory stimulations (ATVV) will be consisting of Soft lullaby between of 30-40 dB for Auditory, Gentle stroking massage in supine position(upper and lower limb)for Tactile, Visual Stimulations with Black and white card (distance of 8-10 in), gentle rocking (vertical and horizontal direction) for the stimulation of vestibular system and oral stimulation including stocking cheeks, lips, jaw and tongue, rubbing gum.Each stimulation will be given for 3 minutes.~Movement therapy will include: Guided range of motion: flexion-extension movements of lower limb (bicycle riding pattern). Hand should be placed around knee joint. Care must be taken as PI consist the cartilaginous joints at wrist and ankle. Anti gravity movements in prone (neck and spinal extension), Anti gravity movements in sitting (supported) and Upright positioning for 3min each"
89299136|NCT04247308|Active Comparator|control group|receives routine care from the nursing team as well as daily maternal care, such as being held in the mother's arms
89299137|NCT05688384|No Intervention|Control arm (LA)|Patients in this arm will undergo SVP insertion in local anesthesia (LA)
89299138|NCT05688384|Active Comparator|Study arm (LA+PCS)|Patients in this arm will undergo SVP insertion in local anesthesia and PCS (LA+PCS)
89299139|NCT03075904|Experimental|Cohort 1: ALXN1830|Participants received 5 doses of ALXN1830 10 mg/kg administered weekly.
89299140|NCT03075904|Experimental|Cohort 2: ALXN1830|Participants were to receive 3 doses of ALXN1830 30 mg/kg administered weekly (loading) followed by 5 doses of ALXN1830 10 mg/kg administered every other week or 10 weekly doses of ALXN1830 IV (maintenance).
89299141|NCT03790410|Active Comparator|Control group-Complex pulmonary rehab.|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings."
89299142|NCT03790410|Active Comparator|Inspiratory muscle training group|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.~Inspiratory muscle training~The training program contains strengthening exercises on the diaphragm muscle."
89299143|NCT03630250|Experimental|Challenge Volunteer - 4BN1|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4BN1 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4BN1."
89299144|NCT03630250|No Intervention|Contact Volunteer|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A single dose of an antibiotic (Ciprofloxacin) will be administered on Day 90 regardless of colonisation with modified N. lactamica.
89299145|NCT03630250|Experimental|Challenge Volunteer - 4YB2|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4YB2 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4YB2"
89299146|NCT01378468||Patients with first ischemic stroke|
89299147|NCT01378390|Experimental|ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million cells in case of incomplete fistula closure following week 12 assessment.
89299148|NCT01378390|Sham Comparator|Placebo|Instillation of saline solution into the fistulous tract, following identical tract preparation process as for the investigational treatment group.
89299149|NCT03790020|Active Comparator|transversus abdominis plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
89299150|NCT03790020|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
89299151|NCT03790020|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the appendix excision area-periappendiciall area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periappendicial area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
89299152|NCT03790020|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
89299153|NCT05763784|Experimental|Pelvic Tightrope fixation|Theses patients will be treated with Tightrope for their traumatic pubic symphysis diastasis
89299154|NCT01308996|Experimental|INFUSE® Bone Graft|
89299155|NCT01308996|Active Comparator|Autogenous bone graft|
89299156|NCT01378312|Placebo Comparator|Placebo Arm|
89299157|NCT01378312|Active Comparator|AERAS 402 Arm|
89299158|NCT03787446||Multiple Sclerosis (MS) patients|3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy
89299159|NCT03787446||Healthy Controls (HC)|3 Healthy volunteers aged between 18-60 years of age
89299160|NCT04409470||Indication for blood gas sampling|To be eligible, patients will need to be classified as critically ill and there has to be a clear clinical indication for an arterial blood gas sampling. Enrollment will be performed in a consecutive manner at all hours.
89299161|NCT03789942|Active Comparator|1. Local anaesthesia for oral surgery|Administration of local anesthesia, 40mg.epinephrine once. Oral surgery procedures Suturing End of procedure
89299162|NCT03789942|Active Comparator|2. Local anesthesia with Midazolam|"Administration of 40mg. epinephrine once, and Oral Sedation with Midazolam 0,5 mgr per kilo once.~Oral surgery procedures Suturing End of procedure"
89299163|NCT03789942|Active Comparator|3. Local anesthesia and sedation|"Administration of 40mg. epinephrine once, and Inhalation Sedation by Nitrous Oxide / Oxygen.~Nitrous oxide sedation Oral surgery procedures Suturing End of procedure Reduce nitrous oxide concentration"
89299164|NCT03789708|Experimental|A|Patients will receive 10 g of Gum Arabic supplementation daily for four weeks. Gum Arabic is provided in the form of easily soluble granules. Participants are asked to dissolve it in water or juice and drink it.
89299165|NCT03789708|Placebo Comparator|B|Patients will receive 5 g of maltodextrin supplementation daily for four weeks. Maltodextrin is an easily digested polysacharide provided in the form of soluble whitish powder that has no taste or odor. Participants are asked to dissolve it in water or juice and drink it.
89299166|NCT03789708|Experimental|C|Patients will receive 20 g of Gum Arabic supplementation daily for four weeks
89299167|NCT03789708|Experimental|D|Patients will receive 40 g of Gum Arabic supplementation daily for four weeks
89299168|NCT03073798|Active Comparator|Medication|Roflumilast. 500 mcg of Roflumilast daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of placebo.
89299169|NCT03073798|Placebo Comparator|Placebo|Placebo. 500 mcg of Placebo daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of Roflumilast
89299170|NCT04083274|Active Comparator|Group E = ESPB group|In group E, ESPB will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
89299171|NCT04083274|Sham Comparator|Group S = Sham block group|In group S, sham block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T2 transvers process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted caudo-cranial direction and then for correction of the needle 5 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml normal saline will be administered for block.
89299172|NCT03787056|Other|Cancer patients|420 patients affected by different types of cancer and treated in a curative or a palliative intent. In total 17 cohorts will be open, including: breast cancer, head and neck carcinomas, renal cell carcinoma, prostate carcinoma, lung carcinoma, hepatocellular carcinoma, colorectal carcinoma, thyroid cancer, pancreatic adenocarcinoma, ovarian adenocarcinoma, glioblastoma, endometrial adenocarcinoma, bladder carcinoma, oesophago-gastric carcinoma, B-cell lymphoma, gastric carcinomas. Patients enrolled in curative intent treatment cohorts will never have been previously treated for their cancer. Patients enrolled in non-curative intent treatment cohorts will have never been treated for their metastatic cancers previously, or have developed advanced/metastatic diseases as relapses of localized cancers previously treated with curative intent therapeutic strategies. Other cohort will be open (stability cohorts) : nychtemer cohort and post-operative kinetic cohort.
89299173|NCT03786978|Experimental|Structured pharmaceutical care|Patients receive a structured pharmaceutical care until one year after hospital discharge
89299174|NCT03786978|Active Comparator|Comparator group|Patient received a single phone call 30 days after basal hospital discharge.
89299175|NCT03784638|Experimental|lingually-based triangle flap design|In the experimental group, an incision will be made adjacent to the distal surface of the mandibular second molar, and extended along the sulcus to the distobuccal corner of the mandibular second molar. An oblique vestibular incision will made and extended into the vestibular fornix of the mandible, aligned with the mesiobuccal cusp of the second molar. It was continued posterosuperiorly towards the anterior border of mandibular ramus. The lingually-based triangle flap design will be used.
89299176|NCT03784638|Placebo Comparator|buccally based triangle flap design|In the control group, an incision will be made from the anterior border of the mandibular second molar. It will be extended along the sulcus to the distobuccal corner of the second molar crown. The incision will be continuous with vertical incision. The buccally based triangle flap design will be used.
89299177|NCT03786822|Experimental|Non-fluoroscopic Cryoballoon PVI|"Observation of pressure waveform change at the tip of the cryoballoon catheter from left atrial pressure to pulmonary vein pressure waveform.~Intracardiac echocardiography (ICE) imaging with no Doppler color evidence of peri-balloon high velocity leaks.~Intracardiac echo imaging showing no evidence of leak during agitated saline contrast injection into cryoballoon catheter positioned at pulmonary vein ostium."
89299178|NCT03786822|Active Comparator|Fluoroscopic Cryoballoon PVI|Standard cryoballoon PVI using radio opaque contrast pulmonary vein angiography
89299179|NCT03789552|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 8 weeks."
89299180|NCT03789552|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~Subjects in this group will use four T89 capsules each time by oral administration twice daily for 8 weeks."
89299181|NCT03789552|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 8 weeks.
89299182|NCT03784560||study group|anesthesia residents with 24 hours working shift
89299183|NCT03784404|Active Comparator|Non surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
89299184|NCT03784404|Active Comparator|Surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
89299185|NCT03075826|Other|Open Label-Single Arm|This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity
89299186|NCT04116970|Experimental|Diagnostic (bronchoscopy with EBUS-TBNA with/without vacuum)|Patients undergo bronchoscopy with EBUS-TBUA first without and then with applied vacuum.
88806271|NCT02980055|Active Comparator|Control: connective tissue graft|Root coverage using connective tissue graft
89299187|NCT03630484|Active Comparator|Expiratory Rib Cage Compression|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
89299188|NCT03630484|Active Comparator|Compression + Ventilator Hyperinflation|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same.
89299189|NCT01378234|Experimental|EDPP Intervention|Receive EDPP transitional care intervention from social worker upon hospital discharge
89299190|NCT01378234|No Intervention|Usual Care|Receive usual care upon hospital discharge
89299191|NCT05694390|Experimental|Experimental group: The group applied sterile transparent film dressing|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed.
89299192|NCT05694390|No Intervention|Control group: The group applied fixed with a tape (blaster)|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the control group, the catheter was fixed with a tape (blaster), routinely used in the clinic, and was monitored hourly until the catheter was removed.
89299193|NCT01569412|Experimental|Ertumaxomab|Ertumaxomab administration during two treatment cycles will follow a predefined dose escalation scheme, consisting of 5 ascending doses per cycle with each infusion lasting 3 hours.
89299194|NCT03786588||Group A|Vaginal microbiota in gestation CPP women without HPV infection
89299195|NCT03786588||GroupB|Vaginal microbiota in gestation women without CPP and HPV infection
89299196|NCT01378156|Experimental|JS7 plasmid DNA and MVA62B vaccines|All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
89299197|NCT03786510|Active Comparator|Active control|The control group received Community Center for Dementia's usual care of regular health check-up.
89299198|NCT03786510|Experimental|Intensive + Maintenance program|The INT+MNT group participated in a 4-week intensive program followed by a 20-week maintenance program
89299199|NCT03786510|Experimental|Intensive program only|The INT only group participated in a 4-week intensive program
89299200|NCT01378078|Sham Comparator|sham|patients receive sham tDCS stimulation
89299201|NCT01378078|Active Comparator|active|active transcranial direct current stimulation
89299202|NCT03784092|No Intervention|control|
89299203|NCT03784092|Experimental|feedback|
89299204|NCT04108234|Experimental|Treatment group A|HR071603,nasal spray,dose escalation.
89299205|NCT04108234|Placebo Comparator|Treatment group B|Placebo, nasal spray
89299206|NCT01307826|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
89299207|NCT01307826|Active Comparator|classical massage|In this group of patients 10 classical massage sessions were applied
89299208|NCT01378000||UFH,once a day|
89299209|NCT01378000||heparin Calcium,every 12 hours|
89299210|NCT01378000||dextran,Salviae,once a day|
89299211|NCT01378000||UFH,continuous intravenous infusion,|
89299212|NCT01307904|Active Comparator|dates|Each healthy and diabetic subjects received 50 grams equivalent of carbohydrates of the tested dates, On five separate days.
89299213|NCT01307904|Active Comparator|sugar|Each healthy and diabetic subjects received 50 grams of glucose
89299214|NCT01310634|Experimental|Comprehensive intervention|Parents of hospitalized neonates received Comprehensive intervention program.
89299215|NCT01310634|Other|Conventional treatment|Usual educational program
89299216|NCT03821896|Experimental|Conversation Cards for Adolescents and Goal-Setting|Adolescents in the experimental arm will receive the tool 15 minutes prior to their appointment with their primary care provider. They will be instructed to familiarize themselves with the tool and to select the top 3 factors that resonate most with them in their attemps to change their lifestyle habits. They will then proceed to their clinical appointment to set one S.M.A.R.T. goal based on their selections and in collaboration with their primary care provider.
89299217|NCT03821896|Active Comparator|Goal-Setting|Adolescents in the control arm will not complete the tool activity, but will still set a S.M.A.R.T. goal with their primary care provider.
89299218|NCT03687814|Experimental|Low FODMAP diet plus PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax).
89299219|NCT03687814|Sham Comparator|Sham diet plus PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax).
89299220|NCT03782220|Experimental|Kinesio taping group|"Kinesio taping group~Application of kinesio taping to sternocleidomastoid, upper trapezium, levator scapulae muscles.~Once a week , for 4 weeks"
89299221|NCT03782220|Placebo Comparator|Shame taping group|"Shame taping group~Application of kinesio band to same muscles except for the defined method which is considered to be ineffective.~Once a week , for 4 weeks"
89299222|NCT03786276|Experimental|Exercise-Only|Exercise-Only condition, 12 exercise sessions on a stationary recumbent bicycle over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
89299223|NCT03786276|Experimental|VR-WMR-Only|Virtual Reality Working Memory Retraining-Only condition, 12 working memory retraining sessions over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
89299224|NCT03786276|Experimental|Active VR-WMR|After 4 weeks in one of the first two arms, the participants will have a 1-week washout followed by the Active VR-WMR arm. Participants will complete 12 Active VR-WMR sessions on a stationary recumbent bicycle over 4 weeks.
89299225|NCT05694234||sugammadex group|patients who administered sugammadex
89299226|NCT05694234||AChEI group|patients who administered pyridostigmine-glycopyrrolate or neostigmine-glycopyrrolate
89299227|NCT03266068||Post Infectious IBS Case|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have developed some symptoms that might be suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
89299228|NCT03266068||Post Infectious with no IBS Control|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have not developed symptoms suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
89299229|NCT03266068||Healthy Control|Healthy volunteers; subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
89299230|NCT01307982|Active Comparator|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
89299231|NCT01307982|Active Comparator|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
89299232|NCT03784170|Experimental|Treatment|FemPulse System at one device setting
89299233|NCT03784170|Sham Comparator|Control|FemPulse System at a different device setting
89299234|NCT05763472||Patients with germline BRCA1/2 patitents|Women with germline BRCA-1/2 mutations, previously treated or undergoing treatment with platinum-based chemotherapy and/or PARP inhibitors for ovarian cancer, who have developed breast cancer, subjected to genomic profiling of breast and ovarian tumor samples.
89299235|NCT05763394|Experimental|Polarized workout|
89299236|NCT05763394|Experimental|High intensity workout|
89299237|NCT01569724|Experimental|bexarotene|
89299238|NCT03781908|Experimental|Silver Nitrate Pleurodesis|Patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%
89299239|NCT03781908|Active Comparator|Indwelling Pleural Catheter|Catheters will be inserted in an outpatient setting under local anaesthesia.The typical drainage schedule is every other day using disposable plastic bottles (550 mL to 1 L)
89299240|NCT03781830|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
89299241|NCT05764486|Other|treatment plan|Treatment plan performed by Hitachi's Heavy Ion Beam Therapy System HyBEAT will be designed to suit the particular needs of each subject and the course of treatment will differ for each subject depending on the type of tumor, varying from 1 day to 4 weeks. All subjects will be monitored for 12 weeks after receiving the last treatment.
89299242|NCT05694078|Experimental|Lumbrical Injured Climbers|6-weeks relative motion splinting protocol, while pain-free sport activities are permitted
89299243|NCT03427528|Experimental|FAB Pilot Study (Father/Male Participants)|"Fathers (male partners) received Fathers and Babies (FAB). FAB is a 12-session intervention with content that mirrors content found in MB, but was father-centric.~The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session."
89299244|NCT03427528|Experimental|MB 1-on-1 Plus TEXT (Mother/Female Participants)|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT) while her partner received Fathers and Babies in parallel. MB 1-on-1 is 12-sessions and is a postpartum depression preventive intervention. MB includes an introductory module followed by three cognitive-behavioral therapy modules: (1) pleasant activities, (2) thoughts, and (3) contact with others. After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
89299245|NCT05694000|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on."
89299246|NCT05694000|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off."
89299247|NCT05622396|Experimental|MBSR program adapted|8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews
89299248|NCT03781596|Experimental|Fluticasone and omeprazole|These patients will be prescribed swallowed fluticasone and omeprazole to be taken together for the 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
89299249|NCT03781596|Placebo Comparator|Fluticasone and placebo|These patients will be prescribed swallowed fluticasone and a placebo medication that appears identical to omeprazole to be taken together for an 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
89299250|NCT04074148|Experimental|Diabetes Prevention Education Program|Diabetes Prevention Education Program
89299251|NCT04074148|Experimental|control|Diabetes Prevention Education brochure
89299252|NCT03781674|Active Comparator|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg(4 tablets) daily beginning at 18-22 weeks gestational age
89299253|NCT03781674|Active Comparator|progesterone 200mg plus placebo to progesterone 200 mg|Women received vaginal progesterone suppositories in a dose of 200 mg(2 tablets) daily beginning at 18-22 weeks gestational age plus 2tablets placebo to vaginal progesterone
89299254|NCT03781674|Placebo Comparator|placebo to progesterone 400 mg|Women received 4 tablets placebo to vaginal progesterone suppositories
89299255|NCT03166930|Experimental|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
89299256|NCT03166930|Active Comparator|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management.
89299257|NCT03786120||1|First 25 subjects
89299258|NCT03786120||2|Second cohort of 25 subjects
89299259|NCT03783858|Other|Single|
89299260|NCT01308138|Experimental|ExerciseTr|
89299261|NCT01308138|Experimental|Remote ischemic preconditioning group|
89299262|NCT01308138|No Intervention|Control patient group|
89299263|NCT03781518|Experimental|ridge splitting|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic mandible and splinting with screws
89299264|NCT03781518|Active Comparator|khoury shell technique|bone block is taken from the ramus to augment deficient posterior mandible and splinting with screws
89299265|NCT01561014|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD, 5 days a week and receive fluorouracil IV continuously and erlotinib hydrochloride PO QD on days 1-38. Patients also receive oxaliplatin IV over 2 hours on days 1, 15, and 29.~SURGERY: Within 4-8 weeks after completion of chemoradiotherapy, patients with potentially resectable disease (i.e., complete response, partial response, or stable disease) undergo surgery to remove the tumor.~CONSOLIDATION CHEMOTHERAPY: Within 2-4 weeks after surgery, patients with tumors that demonstrate positive immunohistochemistry for EGFR and/or cyclin D1 (in the pretreatment biopsy or in the residual tumor in the esophagectomy specimen) receive consolidation chemotherapy comprising erlotinib hydrochloride PO QD for 12 weeks."
89299266|NCT01561092|Active Comparator|Escitalopram|
89299267|NCT01561092|Placebo Comparator|Non active drug|
89299268|NCT01561326|Experimental|Cognitive-affective barriers counseling delivered by phone|Standard care plus cognitive-affective barriers counseling delivered by phone , i.e., culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence
89299269|NCT01561326|Experimental|cognitive-affective barriers counseling via brochure|Standard care plus cognitive-affective barriers counseling delivered via mail-home print material
89299270|NCT01561326|Active Comparator|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
89299271|NCT01316874|Experimental|AD32 (valrubicin)|800mg, once weekly for 6 weeks
89299272|NCT01309542|Experimental|DVS|
89299273|NCT03777150|Experimental|Group ICU|Group ICU:patients are admitted directly into the ICU for postoperative care
89299274|NCT03777150|Experimental|Group Ward|Group Ward:patients are admitted directly into the standard ward for postoperative care
89299275|NCT01309620|Placebo Comparator|Placebo|
89299276|NCT01309620|Experimental|Zinc supplement|
89299277|NCT03783312|Placebo Comparator|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
89299278|NCT03783312|Active Comparator|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
89299279|NCT03783312|Active Comparator|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
89299280|NCT01317108|No Intervention|A|Low uPA/PAI-1: Observation
89299281|NCT01317108|No Intervention|B2|High uPA/PAI-1: Observation
89299282|NCT01317108|No Intervention|B3|High uPA/PAI-1: refused randomization
89299283|NCT01317108|Active Comparator|B1|High uPA/PAi-1: CMF chemotherapy
89299284|NCT03776916|Experimental|Group 1|"Simethicone administration 20-30 min before the procedure:~Patients intake simethicone solution 20-30 min before the procedure."
89299285|NCT03776916|Experimental|Group 2|"Simethicone administration 31-60 min before the procedure:~Patients intake simethicone solution 31-60 min before the procedure."
89299286|NCT03776916|Experimental|Group 3|Simethicone administration >60 min before the procedure; Patients intake simethicone solution >60 min before the procedure.
89299287|NCT03783390|No Intervention|Orientation|Informed consent, height, weight, and blood pressure measurement. A link to an online survey the participant and their parent can fill out at home about the participant's medical history will be given.
89299288|NCT03783390|No Intervention|Measurement session Pre/Post Intervention|Questionnaires completed, blood draws, and fixed and ad lib meals completed to measure appetite and hormones. DXA completed.
89299289|NCT03783390|No Intervention|Home Assessments Pre/Post intervention|24-hour dietary recalls. Physical activity measured by monitors (Actigraph, ActivPAL).
89299290|NCT03783390|No Intervention|Physical Activity Session Pre/Post intervention|DXA, and Fitness testing to measure VO2submax and VO2max. Cognitive assessments will be administered.
89299291|NCT03783390|No Intervention|fMRI Session Pre/Post intervention|The participant will have an fMRI completed and answer questions related to 60 food and activity images while in and out of the fMRI machine.
89299292|NCT03783390|Experimental|Exercise Intervention/Newsletter|After completion of the initial fMRI session the participant will be randomly assigned to intervention for 3 months and then complete another round of assessments described as above (except for the orientation session).
89299293|NCT01317342|Active Comparator|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour
89299294|NCT01317342|No Intervention|Control group: no intervention|Conventional cold storage (IGL-1)
89299295|NCT01317576|Experimental|Healthy control|This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.
89299296|NCT01317576|Experimental|Non-alcoholic fatty liver disease|This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group
89299297|NCT01317576|Experimental|Type 2 diabetes patients|This group will exist of patients that suffer from type 2 diabetes
89299298|NCT01560702|Active Comparator|Autologous blood|Patients will be injected by autologous blood at the edge of actively bleeding ulcer
89299299|NCT01560702|Other|Epinephrine injection|Patients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
89299300|NCT03776838|Experimental|SoC+NOL analgesia guided fentanyl administration|"A bolus of 2 mcg/kg of IV Fentanyl will be given at the induction of the anesthesia. A bolus of 1 mcg/kg of IV Fentanyl will be given at the time of incision. During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administered following a pre determinate algorithm based on NOL index + heart rate + mean arterial blood pressure variations.~Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery."
89299301|NCT03776838|Active Comparator|SoC analgesia guided group|"A bolus of IV Fentanyl at the discretion of a physician will be given at the induction of the anesthesia. A bolus of IV Fentanyl at the discretion of a physician will be given at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.~Intervention will be here to use Heart rate and blood pressure to administer intraoperative intravenous fentanyl."
89299302|NCT03781206|No Intervention|Standard of Care (SOC)|After stoma reversal, patients of SOC group will be treated as for normal clinical practice, using a simple adhesive wound dressing.
89299303|NCT03781206|Experimental|Negative Pressure Wound Therapy (NPWT)|PICO™ 7 will be applied after stoma reversal
89299304|NCT03781284|Experimental|PET/MRI with bowel purgation|
89299305|NCT03781284|Experimental|PET/MRI without bowel purgation|
89299306|NCT03781050|Experimental|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
89299307|NCT01561170||Chronically venous ulcer|A group of 36 patients
89299308|NCT01313130||blast-related TBI|100 active duty US military personnel identified clinically as having suffered blast-related TBI
89299309|NCT01313130||non-blast-related TBI|100 active duty US military personnel identified clinically as having suffered non-blast-related TBI. TBI caused by other mechanisms such as motor vehicle crashes, falls, struck by blunt objects etc.
89299310|NCT01313130||other blast-related injuries|100 active duty US military personnel with blast-exposure and other blast-related injuries but no clinical evidence of TBI
89299311|NCT01313130||other non-blast injuries|100 active duty US military personnel with other non-blast injuries and no clinical evidence of TBI
89299312|NCT01317654||Survivors of TBM trial 2001-2005|
89299313|NCT02865850|Experimental|Vadadustat|
89299314|NCT02865850|Active Comparator|Darbepoetin alfa|
89299315|NCT03711162|Experimental|GLPG1690 600 mg|Participants received GLPG1690 (ziritaxestat) 600 mg, film-coated tablets orally once daily (mean GLPG1690 exposure was up to 325.3 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
89299316|NCT03711162|Experimental|GLPG1690 200 mg|Participants received GLPG1690 (ziritaxestat) 200 mg as film-coated tablet for oral use once daily (mean GLPG1690 exposure was up to 356.0 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
89299317|NCT03711162|Placebo Comparator|Placebo|Participants received GLPG1690 (ziritaxestat) matching placebo tablets for oral use once daily (mean GLPG1690 exposure was up to 353.4 days) in addition to local standard of care. Standard of care included either pirfenidone or nintedanib at a stable dose for at least 2 months before screening, and during screening; or neither pirfenidone or nintedanib (for any reason).
89299318|NCT02347618|Experimental|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
89299319|NCT01309698|Experimental|Treatment Sequence 1|
89299320|NCT01309698|Experimental|Treatment Sequence 2|
89299321|NCT01309698|Experimental|Treatment Sequence 3|
89299322|NCT01309698|Experimental|Treatment Sequence 4|
89299323|NCT01309698|Experimental|Treatment Sequence 5|
89299324|NCT01309698|Experimental|Treatment Sequence 6|
89299325|NCT01142284|Placebo Comparator|Placebo|Placebo
89299326|NCT01142284|Experimental|Cilostazol|cilostazol
89299327|NCT01142284|Experimental|Probucol|probucol
89299328|NCT01142284|Experimental|Cilostazol + Probucol|cilostazol and probucol
89299329|NCT03783156|Other|hot snare|polypectomy with hot snare
89299330|NCT03783156|Other|cold snare|polypectomy with cold snare
89299331|NCT05762848||Researcher|Patients will have their Head circumference measured with a tape and with the mobile phone app.
89299332|NCT05762848||Parent|Patients will have their Head circumference measured with a tape and with the mobile phone app.
89299333|NCT01309776|Experimental|Tianeptine|
89299334|NCT01309776|Active Comparator|Escitalopram|
89299335|NCT00498160|Experimental|Living or Deceased Donor Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same living donor. Recipients with the need for a deceased donor kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same deceased donor
89299336|NCT03782766|Experimental|piezosurgery|group 1 consisted of 18 molars (13 molars from patients with bilateral first molar extraction space and 5 molars from patients with unilateral first molar extraction space) where piezocesion was performed immediately before molar protraction
89299337|NCT03782766|No Intervention|No piezocision|group 2 consisted of 21 molars (13 from patients with bilateral first molar extraction space and 8 molars from patients with unilateral first molar extraction space) where molar protraction was performed with no piezocesion
89299338|NCT03782766|Other|Late piezocision|group 3 consisted of 21 molars (group 2 subjects where piezocession was carried on after 3 months of molar protraction with no piezocesion.
89299339|NCT02772328|Experimental|Peer Mentor|Individuals in this arm will be trained in communication skills to promote HIV and HCV testing to their social network members, linkage to care and risk reduction behaviors.
89299340|NCT02772328|No Intervention|Neighborhood Matters|Participants in this arm will view a 15-20 minute video on issues in neighborhoods such as crime and violence, restoring communities and incarceration and discuss their reactions and thoughts.
89299341|NCT03780582|Experimental|Probabilistic Classification|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan."
89299342|NCT03780582|Experimental|Classification Plus Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. They also see ROIs identified by the AI that represent lung nodules."
89299343|NCT03780582|Experimental|Classification With Delayed Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. After identifying their own ROIs, the radiologist then can see ROIs identified by the AI that represent lung nodules before making final decisions."
89299344|NCT02684422||Cystic Fibrosis with MRSA infection|"Cystic Fibrosis patients that are admitted to the hospital for IV therapy targeting MRSA will give a sputum sample and complete symptom diaries at the beginning and end of therapy. There will be no intervention administered.~Inclusion criteria are ability to produce sputum and having a chronic i.e. > 2 years of positive respiratory cultures, MRSA CF lung infection."
89299345|NCT03783000|Experimental|All subjects|Treatment T followed by Treatment R
89299346|NCT02344420|Other|Single Arm|As it is not a randomize trial there is only one study arm. Described interventions as echocariography, six minute walk test, Quality of Life test or self assessment score should be done in all patients.
89299347|NCT03780738||Control|Chinese Han people to do physical examination in physical examination center of Guangdong Provincial People's Hospital
89299348|NCT03780738||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Guangdong Provincial People's Hospital
89299349|NCT02235142|Experimental|Localised prostat cancer and androgen deficiency|
89299350|NCT01309854|Experimental|pioglitazone|
89299351|NCT01309854|Experimental|pioglitazone and fostamatinib|
89299352|NCT03776604|Experimental|PEG-rhG-CSF|"Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were <45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
89299353|NCT03776526||Postoperative Hip fracture patients|The target population will include patients aged 65 years or older admitted with hip fracture to the orthopedic ward at the Juravinski Hospital, a site of Hamilton Health Sciences Corporation in Ontario, Canada.
89299354|NCT05074212|Experimental|Complex Linear Closure|The study participant will receive two layers of sutures to close the wound.
89299355|NCT05074212|Experimental|Second Intention Healing|The study participant will not have any sutures placed.
89299356|NCT03776994|Experimental|Group 1A 2 µg VEE Vaccine Alone|"Subgroup 1A, 2 µg VEE VLP Vaccine Alone Venezuelan equine encephalitis VLP Vaccine candidate~Vaccinations on Day 0, Day 28, and Day 140"
89299357|NCT03776994|Experimental|Group 2A 10 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 2A, 10 µg VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
89299358|NCT03776994|Experimental|Group 3A 20 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 3A, 20 µg VEE VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
89299359|NCT03776994|Experimental|Group 1B 2 µg VEE Vaccine and Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 1B, 2 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
89299360|NCT03776994|Experimental|Group 2B 10 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 2B, 10 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
89299361|NCT03776994|Experimental|Group 3B 20 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 3B, 20 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
89299362|NCT05073510||BlueDop Vascular Expert (BVE)|PAD assessment with BVE
89299363|NCT03780192||Treatment|Bifurcation lesion treatment using provisional stent technique
89299364|NCT05305560|Experimental|Active IMP|
89299365|NCT05305560|Placebo Comparator|Placebo|
89299366|NCT03780348|Experimental|New Method|'New' weight-for-height method will be used to assess children assigned to this arm
89299367|NCT03780348|Active Comparator|Existing Method|'Existing' weight-for-height method will be used to assess children assigned to this arm
89299368|NCT03780348|Experimental|Health Extension Workers|Health Extension workers will do weight-for-height assessment using the new method
89299369|NCT03782922|Experimental|Exercise Training Program|
89299370|NCT03782922|No Intervention|Control|
89299371|NCT03782844|Experimental|Conventional fixed CPAP and simple CPAP|Participants in this group were manually titrated . They were treated with conventional fixed pressure CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
89299372|NCT03782844|Experimental|Auto CPAP and simple CPAP|Participants in this group after being manually titrated were treated with Auto RemStar CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
89299373|NCT01310088|Experimental|Lifestyle counseling|Treatment protocol The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
89299374|NCT01310088|No Intervention|Control|Healthy age and gender matched control subjects. Recruited from school visits.
89299375|NCT01319058|Active Comparator|Electrocautery tonsillectomy|Children undergoing tonsillectomy and adenoidectomy for obstructive sleep apnea
89299376|NCT01319058|Active Comparator|Debrider tonsillotomy|Children undergoing debrider tonsillotomy + adenoidectomy for obstructive sleep apnea.
89299377|NCT01319058|Active Comparator|Laser tonsillotomy|Children undergoing laser tonsillotomy + adenoidectomy for obstructive sleep apnea.
89299378|NCT03776448|Experimental|Sativa Nigra oil arm|A total of 15 subjects randomly allocated to the treatment arm will receive 2000mg a day of 'Sativa Nigra oil' softgels for 30 consecutive days. The total daily dose is divided in 4 doses taken 6 hourly (each softgel contains 500mg). This supplement is manufactured by [Bioextract Ltd, Sri Lanka] and is available commercially.
89299379|NCT03776448|Placebo Comparator|The charcoal arm|Subject randomly allocated to the control arm will receive 1040mg a day of activated charcoal softgels for 30 consecutive days. The total daily dosage is divided in 4 doses taken 6 hourly (each softgel contains 260mg). This supplement is manufactured by [Arkopharma Pharmaceutical Laboratories] and is available commercially.
89299380|NCT03780270|Active Comparator|Control|"Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application at Day 0 and Day180.~=> Group: Fluoride Varnish"
89299381|NCT03780270|Experimental|Test1|"Single application of Curodont Repair (P11-4) at Day 0 followed by a Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application. Another fluoride Varnish application at Day180.~=> Group: Curodont Repair + Fluoride Varnish"
89299382|NCT03780270|Experimental|Test2|"Single application of Curodont Repair (P11-4) at Day 0. Curodont Protect (tooth gel containing P11-4 matrix) is handed out and subjects are asked to apply it 2x weekly at home after regular teeth cleaning in the evening for the whole study period (Day 360).~=> Group: Curodont Repair + Curodont Protect"
89299383|NCT05669040|Active Comparator|Patient experience|
89299384|NCT05669040|Active Comparator|Adherence to drug treatment|
89299385|NCT05669040|Active Comparator|Positive mental health|
89299386|NCT03780036|Experimental|porous collar|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous, to allow for bone ingrowth and stabilization of the implant.
89299387|NCT03780036|Experimental|porous collar with hydroxyapathite|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous and covered with hydroxyapathite particles, to allow for bone ingrowth and stabilization of the implant.
89299388|NCT03782454||intensive care patients with sepsis|Adult patients with verified or suspected sepsis admitted to the intensive care department from the emergency department
89299389|NCT03779802|Experimental|CRT device|Patients implanted with a CRT device who will undergo a non-invasive hemodynamic evaluation of different pacing modes
89299390|NCT04531254|Experimental|Masking at all times|Children in this group will be asked to wear a face mask/covering in the classroom and common areas during the simulation
89299391|NCT04531254|No Intervention|No mask/masking when physical distancing is not maintained|Children in this group will not be asked to wear a mask (JK-Grade 4) or only asked to wear a mask when physical distancing in the classroom cannot be maintained (Grade 5-Grade 12) during the simulation
89299392|NCT03072160|Experimental|Cohort 1: Participants that had an immune stimulating cancer vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 1: cancer vaccine"
89299393|NCT03072160|Experimental|Cohort 2: Participants that have had no vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 2: had no previous vaccine"
89299394|NCT05517486|Experimental|50 mg GTX-101|
89299395|NCT05517486|Experimental|100 mg GTX-101|
89299396|NCT05517486|Experimental|200 mg GTX-101|
89299397|NCT05517486|Active Comparator|Bupivacaine subcutaneous injection|
89299398|NCT01019356|Experimental|Rosiglitazone|Lean and obese PCOS women
89299399|NCT01019356|Active Comparator|Acarbose|Obese PCOS women
89299400|NCT01019356|No Intervention|Control|Obese and lean healthy women evaluated only at baseline
89299401|NCT03776292||supine position group= Group (S)|1st group of 20 patients will undergo urinary bladder cystectomy and orthotopic urinary diversion lying supine with ring abdominal retractors
89299402|NCT03776292||lateral position group = Group (L)|2nd group of 20 patients will undergo surgical open nephrectomy lying lateral position with self retaining abdominal retractors
89299403|NCT01314066|Experimental|Bevacizumab 5 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
89299404|NCT01314066|Experimental|Bevacizumab at 10 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
89299405|NCT01314066|Placebo Comparator|Placebo|In addition to receiving the best standard supportive care for both diagnosis and treatment for individuals diagnosed with severe sepsis, they will receive an IV saline solution.
89299406|NCT00407602|Other|Implant of Argus II Retinal Prosthesis|This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator.
89299407|NCT01314300|Experimental|Efficacy of Lidocaine 5% plaster|Treatment of pain by Lidocaine 5% plaster
89299408|NCT05202652|Placebo Comparator|Control Group|The control group received a three month supply of 90 vegetal capsules of hydroxypropyl methylcellulose, each of them containing 455mg of the carrier substance (magnesium stearate)
89299409|NCT05202652|Active Comparator|HealthSpan(HS) Group|The HS group received a three month supply of 90 vegetal capsules of hydroxypropyl methylcellulose, each of them containing the 455mg of the mixture of the active compounds along with the carrier.
89299410|NCT03773640|Experimental|The study group|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
89299411|NCT03773640|Active Comparator|The control group|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
89299412|NCT03779958||Study Group|All patients will be given information about a mobile app to use during the recovery period to assist with hand therapy activities
89299413|NCT01314768|Active Comparator|Brief intervention|Behavioural brief intervention delivered by GP
89299414|NCT01314768|Placebo Comparator|Business as usual|Business as usual according to individual GP
89299415|NCT01314768|Other|Chronic headache control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
89299416|NCT01314768|Other|Population control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
89299417|NCT03776058|Experimental|Cinacalcet|Participants received 65 mg cinacalcet orally twice a day for 4 weeks.
89299418|NCT03776058|Placebo Comparator|Placebo|Participants received placebo to cinacalcet orally twice a day for 4 weeks.
89299419|NCT05202574|Active Comparator|dexamethasone|
89299420|NCT05202574|Active Comparator|ondanestrone|
89299421|NCT05202574|Placebo Comparator|control group|
89299422|NCT05202496|Experimental|Experimental: oral vitamin D supplementation during orthodontic treatment|"The biological methods include using various chemicals like parathyroid hormone, thyroid hormone, prostaglandins, corticosteroids, relaxin and vitamin D.~Due to its important role in bone remodeling, vitamin D is hypothesized to play an important role in accelerating orthodontic tooth movement.~experimental group subjects with serum vitamin D levels in the range of 30-40 ng/ml are enrolled"
89299423|NCT05202496|Active Comparator|control : Orthodontic treatment with no intervention|control group subjects with serum vitamin D levels in the range of (30-40 ng/ml) are enrolled
89299424|NCT01320540||Breast Center Patients|Patients newly diagnosed with breast cancer who did or did not have genetic testing (retrospectively and prospectively).
89299425|NCT01320540||Staff from the Lynn Sage Comprehensive Breast Cancer Center|Members of the Northwestern staff to include but not limited the Lynn Sage Comprehensive Breast Cancer Center and/or Breast Cancer Genetics Program provider staff (including physicians, nurses, schedulers, physician assistants and/or genetic counselors).
89299426|NCT03779568|Experimental|Dose adjustment of bupivacaine|Patient will receive isobaric bupivacaine based on previous patient experience.
89299427|NCT05201560|Experimental|Butorphanol tartrate|Butorphanol tartrate on the patients with mechanical ventilation
89299428|NCT05201560|Active Comparator|fentanyl|fentanyl on the patients with mechanical ventilation
89299429|NCT05201326|Experimental|Treatment arm|irinotecan + bevacizumab + Re-radiotherapy
89299430|NCT05762458|Experimental|Ammoxetine group-cohort 1|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo.
89299431|NCT05762458|Experimental|Ammoxetine group-cohort 2|The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo.
89299432|NCT05762458|Placebo Comparator|Placebo group|The eligible subjects will receive placebo to Ammoxetine.
89299433|NCT03779256||Women with bowel endometriosis.|"Women with symptomatic bowel endometriosis scheduled for surgical treatment investigated with 2D transvaginal ultrasound before surgery at Hospital St John of God, Vienna, Austria; Oslo university hospital, Oslo, Norway and Nepean Hospital, Sydney, Australia.~The women recruited at Oslo university hospital, Norway will also have a magnetic resonance imaging (MRI) of the abdomen and pelvis before surger."
89299434|NCT03775668|Experimental|1 µCi of 14C-AAI101 + 500 mg AAI101|14C-AAI101 + 500 mg AAI101 iv infusion
89299435|NCT05762380|Active Comparator|Ferrous sulfate (FeSO4)|FeSO4 supplements containing 54 mg elemental iron
89299436|NCT05762380|Experimental|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|Ao iron supplements containing 54 mg elemental iron
89299437|NCT04928430|Experimental|XAV-19|XAV-19
89299438|NCT04928430|Placebo Comparator|Placebo|
89299439|NCT01561404|Experimental|Everolimus|Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)
89299440|NCT03775824||MTX start|Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
89299441|NCT03775824||TNF start|Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
89299442|NCT03775590|Active Comparator|Water|Subjects will bathe at least twice a week in a water bath for 6 months and keep a record of their bathing regimen
89299443|NCT03775590|Active Comparator|Bleach|Subjects will bathe at least twice a week in a water + dilute bleach bath for 6 months and keep a record of their bathing regimen
89299444|NCT03775590|Active Comparator|Acetic acid|Subjects will bathe at least twice a week in a water bath + vinegar for 6 months and keep a record of their bathing regimen
89299445|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, Future, and Risk"
89299446|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, and Future"
89531722|NCT05625061|Experimental|Core BWL Intervention + BCT 7 Message (Focus on Past Success)|"Core BWL Intervention + Message testing the Behavior Change Technique Focus on Past Success"
89299447|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Scenarios, and Risk"
89299448|NCT04661566|Experimental|Education+Narratives+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Scenarios"
89299449|NCT04661566|Experimental|Education+Narratives+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, Future, and Risk"
89299450|NCT04661566|Experimental|Education+Narratives+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Future"
89299451|NCT04661566|Experimental|Education+Narratives+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Skills, and Risk"
89299452|NCT04661566|Experimental|Education+Narratives+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Skills"
89299453|NCT04661566|Experimental|Education+Narratives+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives. Scenarios, Future, and Risk"
89299454|NCT04661566|Experimental|Education+Narratives+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Scenarios, and Future"
89299455|NCT04661566|Experimental|Education+Narratives+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Scenarios, and Risk"
89299456|NCT04661566|Experimental|Education+Narratives+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Scenarios"
89299457|NCT04661566|Experimental|Education+Narratives+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives, Future, and Risk"
89299458|NCT04661566|Experimental|Education+Narratives+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Future"
89299459|NCT04661566|Experimental|Education+Narratives+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives and Risk"
89299460|NCT04661566|Experimental|Education+Narratives|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Narratives"
89299461|NCT04661566|Experimental|Education+Skills+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, Future, and Risk"
89299462|NCT04661566|Experimental|Education+Skills+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, and Future"
89299463|NCT04661566|Experimental|Education+Skills+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Scenarios, and Risk"
89299464|NCT04661566|Experimental|Education+Skills+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills and Scenarios"
89299465|NCT04661566|Experimental|Education+Skills+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills, Future, and Risk"
89299466|NCT04661566|Experimental|Education+Skills+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills Future"
89299467|NCT04661566|Experimental|Education+Skills+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills and Risk"
89299468|NCT04661566|Experimental|Education+Skills|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Skills"
89299469|NCT04661566|Experimental|Education+Scenarios+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios, Future, and Risk"
89299470|NCT04661566|Experimental|Education+Scenarios+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios and Future"
89299471|NCT04661566|Experimental|Education+Scenarios+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios and Risk"
89299472|NCT04661566|Experimental|Education+Scenarios|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Scenarios"
89299473|NCT04661566|Experimental|Education+Future+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Future and Risk"
89299474|NCT04661566|Experimental|Education+Future|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Future"
89299475|NCT04661566|Experimental|Education+Risk|"Participants will receive a version of the Mission Wellness app (intervention) that includes the static educational component and the following components:~Risk"
89299476|NCT04661566|Experimental|Education|Participants will receive a version of the Mission Wellness app (intervention) that only includes the static educational component.
89299477|NCT03775746|Experimental|Clopidogrel with Rivaroxaban|Clopidogrel 75mg o.d. and Rivaroxaban 2.5mg b.i.d.
89299478|NCT03775746|Active Comparator|Clopidogrel|Clopidogrel 75mg o.d.
89299479|NCT03775746|Active Comparator|Ticagrelor|Ticagrelor 90mg b.i.d.
89299480|NCT03779412|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Happiness Trap by Harris (2008), a self-help book based on acceptance and commitment therapy.
89299481|NCT03779412|Active Comparator|MBSR self-help book condition|Participants in this condition will be assigned to read A Mindfulness-Based Stress Reduction Workbook by Stahl and Goldstein (2010), a self-help book based on Mindfulness-Based Stress Reduction.
89299482|NCT01561248|No Intervention|SOC-treatment|Patients with EHEC associated bloody diarrhoea (n=12) receiving standard of care treatment, consisting of intravenous fluids (2-3 liters/daily), analgetics, including paracetamol and metamizol and metoclopramid, if required.
89299483|NCT01561248|Experimental|PEG-Solution, daily bowel lavage|Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.
89299484|NCT01315080||Saline|Percutaneous drainage and saline solution irrigation
89299485|NCT01315080||Triamcinolone|Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone
89299486|NCT05171218|Experimental|Music & Auditory Beat Stimulation|Participants listened to calm music with theta auditory beat stimulation for 24 minutes
89299487|NCT05171218|Active Comparator|Music Alone|Participants listened to calm music for 24 minutes
89299488|NCT05171218|Active Comparator|Auditory Beat Stimulation|Participants listened to theta auditory beat stimulation for 24 minutes
89299489|NCT05171218|Sham Comparator|Pink Noise|Participants listened to pink noise for 24 minutes
89299490|NCT03773172|Placebo Comparator|Placebo Control Group|Subjects will receive placebo treatment to mimic active treatment.
89299491|NCT03773172|Active Comparator|Active treatment|IV push loading dose of 300 mg MEDI6012 followed by a 150 mg maintenance dose of MEDI6012 at 48 hours.
89299492|NCT03779178|Experimental|Landiolol group|Landiolol perfusion in incremental doses (range 0.5 to 10 µg/kg/min) over 2 hours
89299493|NCT03779178|Placebo Comparator|Placebo group|Placebo perfusion in incremental doses (range 0.03 to 0.6 mL/kg/h) over 2 hours
89299494|NCT05091892|Experimental|Water Group|Neurodevelopmental treatment
89299495|NCT05091892|Experimental|Land Group|Lonqitudinal, transversal and compined rotation in a hydrotherapy programm
89299496|NCT05084326||Mohamedabosena|
89299497|NCT05070286||Young people with MS and NMOSD|"Young people aged 10-25 years, who were diagnosed with MS or NMOSD prior to the age of 18.~Semi-structured interviews."
89299498|NCT05070286||Parents of young people with MS and NMOSD|"Parents of young people aged 10-25 who were diagnosed with MS or NMOSD prior to the age of 18.~Semi-Structured Interviews"
89299499|NCT05070286||Clinicians|Health care practitioners from medical, nursing and AHP backgrounds with at least two years' experience in NMOSD and MS.
89299500|NCT05762224|Experimental|Effect of kinesio taping on upper limb lymphedema|Kinesio taping was applied 2 times a week for 3 weeks to the KT group. KT improves fluid movement by widening the distance between connective tissues like skin and fascia,fascia and muscles and skin and muscles.
89299501|NCT05762224|Active Comparator|Effect of pressure garments on upper limb lymphedema|PG group received pressure garments ( 20-60 mmHg)for at least 15 to 18 hours per day for 3 weeks.
89299502|NCT04889508|Experimental|Socio-emotional mental training|The socio-emotional intervention will consist of 10 weeks of daily Affect Dyad practice with a partner.
89299503|NCT04889508|Experimental|Mindfulness-based mental training|The intervention will consist of 10 weeks of daily individual Breathing Meditation practice.
89299504|NCT04889508|Other|Retest Control Group (Waitlist control)|"The retest control group, which is also a waitlist control group, will first not undergo an intervention, but will be tested prior to and after the 10-week period at Pre- and Post-test wherein other groups undergo the interventions.~In a second step, the waitlist control group will then also undergo a 10-week period of socio-emotional intervention.~During the first 10-week intervention period, this group will only be tested serving as a re-test control group. After Post-test, however, they will be given the chance to also enroll in a 10-week socio-emotional mental training with the exact same protocol as the socio-emotional intervention experimental group above.~Both the experimental intervention arm groups will be given the possibility to continue their daily assigned practices (respective socio-emotional and mindfulness-based training exercises) after post-test for the duration of the 10-weeks during which the waitlist control group undergoes the socio-emotional intervention."
89299505|NCT05214508|Active Comparator|COPD patient|COPD patients diagnosed based on spirometry, PFT and history
89299506|NCT05214508|No Intervention|Control|Healthy volunteers
89299507|NCT01320852|Active Comparator|Milan Criteria|Patients meeting the Milan Criteria
89299508|NCT01320852|Other|No Milan Criteria|Patients not meeting the Milan Criteria
89299509|NCT01320930|Active Comparator|Pulmonary rehabilitation|A standardized 7 week rehabilitation program, including physical training and education.
89299510|NCT01320930|Placebo Comparator|Control|Conventional care
89299511|NCT05214352||young population with cerebral palsy-Families-Therapist and researchers|The principal group is designed by all people who composed the research and who will work together in the intervention manual elaboration on the participation in the community.
89299512|NCT03775434|Experimental|B244|B244 suspension in 30ml/bottle
89299513|NCT03779100|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89299514|NCT05213494|Active Comparator|Low-dose inulin|3-5 years old: 3g of fiber/day from inulin mixed in a beverage 6-9 years old: 5g of fiber/day from inulin mixed in a beverage
89299515|NCT05213494|Experimental|Low-dose soluble corn fiber|3-5 years old: 3g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 5g of fiber/day from soluble corn fiber mixed in a beverage
89299516|NCT05213494|Active Comparator|High-dose inulin|3-5 years old: 6g of fiber/day from inulin mixed in a beverage 6-9 years old: 8g of fiber/day from inulin mixed in a beverage
89299517|NCT05213494|Experimental|High-dose soluble corn fiber|3-5 years old: 6g of fiber/day from soluble corn fiber mixed in a beverage 6-9 years old: 8g of fiber/day from soluble corn fiber mixed in a beverage
89299518|NCT05213494|No Intervention|Baseline|3-9 years old: pre-intervention.
89299519|NCT01321086|Active Comparator|Motivational Interviewing|Motivational Interviewing (MI) is an effective counseling method in individuals who are less ready to change their behavior. 9 MI sessions will be conducted over the course of the six month intervention.
89299520|NCT01321086|Active Comparator|PACE|Patient-centered Assessment and Counseling for Exercise (PACE) is a protocol that targets known modifiable determinants of behavior change to motivate participants to increase their physical activity (walking).
89299521|NCT01321086|No Intervention|Control|
89299522|NCT03778866|Experimental|Bicarbonate-buffered Medium|
89299523|NCT03778866|No Intervention|HEPES-MOPS-buffered Medium|
89299524|NCT05711212|Experimental|Xanthohumol|single dose of 172 mg of micellar solubilized Xanthohumol
89299525|NCT05711212|Placebo Comparator|Placebo|
89299526|NCT01320228|Placebo Comparator|Control|Alli treatment plus placebo (rice flour)
89299527|NCT01320228|Experimental|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
89299528|NCT01320228|Experimental|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
89299529|NCT01320228|Experimental|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
89299530|NCT05212636|Experimental|MDD patient with HRSD score of at least 18|MDD patients who meet the DSM-5 diagnostic criteria of MDD and their current episode show a 17-Item Hamilton Rating Scale for Depression (HRSD) score of at least 18
89299531|NCT03775278|Experimental|Experimental|PHP-303, multiple oral dose, up to 5 ascending dose cohorts
89299532|NCT03775278|Placebo Comparator|Placebo|Placebo, multiple oral dose, up to 5 ascending dose cohorts
89299533|NCT05212558|Placebo Comparator|Placebo group|This group received a conventional respiratory retraining program plus unloaded (placebo) respiratory muscle training
89299534|NCT05212558|Active Comparator|Inspiratory muscle training group|This group received a conventional respiratory retraining program plus inspiratory muscle training only
89299535|NCT05212558|Experimental|Combined training group|This group received a conventional respiratory retraining program plus inspiratory and expiratory muscle training in the same respiratory cycle.
89299536|NCT03775122|Placebo Comparator|Group 1 sedation group|"Elderly patients under colonoscopy with sedation, but no real TAES neiguan(pc6)~sedation is using the typical protocol for the following: Slowly peripheral intravenous injection(0.5ml/s) of fentanyl 50μg, then followed with 1.5-2.5mg/kg propofol until loss of eyelash reflex, the Observer's Assessment of Alertness/Sedation Scale (OAAS) score Level3-5."
89299537|NCT03775122|Experimental|Group 2 sedation+TAES group|"Elderly patients under colonoscopy both have TAES neiguan(pc6) and sedation.~sedation is begun followed TAES. sedation is same as group2 do. TAES is same as group3 do."
89299538|NCT05212324||widening|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
89299539|NCT03773094|Experimental|Guava leaves extract|A natural product that is prepared as a mouthwash
89299540|NCT03773094|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
89299541|NCT01320306||Subarachnoid hemorrhage|A group of patients suffering aneurismal subarachnoid hemorrhage will participate in a fMRI study.
89299542|NCT01320306||Prophylactic surgical treatment of un-ruptured aneurysms|A retrospective follow-up study of patients who have received prophylactic surgical treatment of un-ruptured aneurysms
89299543|NCT01320306||Conservative treatment|A retrospective follow-up of patients receiving conservative (life stile etc.) treatment of un-ruptured aneurysms.
89299544|NCT01320306||Control group of healthy subjects|Control group of healthy subjects
89299545|NCT03057496|Experimental|Intervention|Participants will use the collision warning device as much as possible for about one month during everyday activities, when walking indoors and outdoors.
89299546|NCT03775356|No Intervention|1 - Blinded|EEG and Entropy will be blinded. The anesthesiological management will be performed by the anesthetist according to clinical standard operations.
89299547|NCT03775356|Active Comparator|2 - Unblinded|EEG and Entropy will be unblinded. The intervention starts with the start of a positive burst suppression rate. In the case of a concurrent hypotension the anesthetist treats the hypotension according to clinical standard operations in the first step. Hypotension means blood pressure values blow the baseline value which is defined by the lowest, preoperatively measured value. If after this treatment and a reevaluation of the BSR, BSR remains positive, the anesthetist is going to reduce the concentration of anesthetics in a second step. In case of positive BSR and a blood pressure value ≥ the baseline value, the concentration of anesthetics will be reduced as a first measure. The aim is to figure out whether one or both of these interventions can reduce to total, cumulative BSR.
89299548|NCT05211934||The group with delirium|
89299549|NCT05211934||The group without delirium|
89299550|NCT01315548||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histologicalconfirmation
89299551|NCT01315548||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
89299552|NCT05211778|No Intervention|Control Group|This group will continue to receive the routine standard of care during their treatment journey.
89299553|NCT05211778|Experimental|Digital Education Group|In addition to the standard of care, this group will complete an audiovisual digital education module during their postoperative stay in hospital.
89299554|NCT03779022||Sensitive|Sensitive group was defined ad complete response (CR) and/or partial response (PR). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
89299555|NCT03779022||Resistant|Resistant group was defined ad progression disease (PD) and/or stable disease (SD). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
89299556|NCT05211622|Experimental|Group I, OZOCLO|"• Group I, OZOCLO~alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days~ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks~chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks"
89299557|NCT05211622|Placebo Comparator|Group II, OBC|• Group II, OBC Sodium bicarbonate 5% solution - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 3 weeks
89299558|NCT05211622|Active Comparator|Group III, CHX|• Group III, CHX Chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks
89299559|NCT05211622|Active Comparator|Group IV, AAL-OZ|"• Group IV, AAL-OZ~alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days~ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks"
89299560|NCT01321164|Active Comparator|Fumaric acid esters|Fumaric acid esters monotherapy
89299561|NCT01321164|Experimental|fumaric acid esters plus narrow band UVB|Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)
89299562|NCT03778788|Active Comparator|App group|Participants will receive the MetS mobile application (MetS app) instalment and briefing by a research assistant (RA2) after the educational talk. They will be able view the booklet content in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting for their exercise plan and exercise record.
89299563|NCT03778788|Active Comparator|Booklet group|The participants will additionally receive a Hong Kong version Lifestyle Intervention Programme (LIP) booklet to take home and use for 20 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
89299564|NCT03778788|Active Comparator|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 20 weeks.
89299565|NCT05211544|Active Comparator|intervention group 1|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
89299566|NCT05211544|Active Comparator|intervention group 2|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
89299567|NCT05211544|Active Comparator|control group|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
89299568|NCT03778632|Experimental|Study Group|Intensive stuttering group therapy which was included individualized desensitization exercises was applied with the study group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
89299569|NCT03778632|Active Comparator|Control Group|Standard intensive stuttering group therapy was applied with the control group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
89299570|NCT05210686|Experimental|subgingival re-instrumentation + gel containing PDRN and HA|subgingival re-instrumentation + gel containing PDRN and HA
89299571|NCT05210686|Active Comparator|subgingival re-instrumentation|subgingival re-instrumentation
89299572|NCT01316328||BC patients after SSPBI|breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery
89299573|NCT05210452|Experimental|Patients with alopecia receiving standard treatment and follicular stem cells|Patients with alopecia receiving standard treatment and autologous follicular stem cells
89299574|NCT05210452|Active Comparator|Patients with alopecia receiving standard treatment|Patients with alopecia receiving standard treatment
89299575|NCT05210218|Experimental|mildly hypocaloric diet + CC 300 mg +WS 150 mg tid|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK) to be taken three times a day. All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
89299576|NCT05210218|Placebo Comparator|mildly hypocaloric diet + placebo tid|Each patient took the placebo (i.e., the same amount of cellulose). All patients received a mildly hypocaloric diet (i.e., -20% of the usual caloric intake as assessed by a 24-hour dietary recall).
89299577|NCT05499312|Experimental|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
89299578|NCT05499312|Placebo Comparator|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
89299579|NCT03772860||Healthy volunteers|Healthy volunteers will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
89299580|NCT03772860||Left headache|Migraine patients with mostly left sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
89299581|NCT03772860||Right headache|Migraine patients with mostly right sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
89299582|NCT03772860||Bilateral headache|Migraine patients without a dominant side headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
89299583|NCT03778398|Experimental|Neurologic music therapy|Patients will receive 2 days of 40 minutes per week, total 3 months of customized piano training. Each session will be started with finger warming exercises, then with the right hand, left handed and with both hands, a simple pentatonic array will be played. In the following lessons, notes will be marked with colors and simple songs will be taught.
89299584|NCT03778476|Experimental|Isometric Exercise|Participants will perform a submaximal voluntary contraction of the quadriceps muscle to task failure.
89299585|NCT03778476|No Intervention|Quiet Rest|Participants will sit quietly for a period of time that mimics the exercise.
89299586|NCT03778320|Experimental|CTP-692|
89299587|NCT03778320|Active Comparator|D-Serine|
89299588|NCT04872348||Eyes receiving OMNI intervention after medication washout|
89299589|NCT04872348||Eyes receiving OMNI intervention without medication washout|
89299590|NCT05190406|Experimental|Pulpotomy|complete pulpotomy will be done till the level of root canal orifice.
89299591|NCT05190406|Active Comparator|Root canal treatment|Single visit root canal treatment will be done according to standard protocol.
89299592|NCT03774966|Active Comparator|Adductor Canal Block + Catheter|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine
89299593|NCT03774966|Experimental|Adductor Canal Block + Catheter & IPACK|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine, IPACK block: 15 ml of 0.25% ropivacaine.
89299594|NCT01320384|Active Comparator|O2 conventional : standard low flow therapy|in order to obtain a SpO2>92%
89299595|NCT01320384|Experimental|O2-HNF : high flow nasal oxygen therapy|set between 30 to 50 l/min,adjusted in order to obtain a SpO2 >92%.
89299596|NCT01320384|Experimental|O2-HFN/NPPV|cycling of NIV and O2-HDN
89299597|NCT03773016|Experimental|Art apps - Group 1 (A-B)|Cross-over use of two different visual art apps on touchscreen tablets (App A and App B)
89299598|NCT03773016|Experimental|Art apps - Group 2 (B-A)|Cross-over use of two different visual art apps on touchscreen tablets (App B and App A)
89299599|NCT05087524|Experimental|BinaxNOW Surveillance|Participants will agree to the performance of nasal swabs samples to be used for diagnosis or screening. Samples will be obtained by research staff in the school setting. Madison Metropolitan School District (MMSD) has obtained a Clinical Laboratory Improvement Amendments (CLIA) waiver for collection of samples. When there is a positive test, a saliva sample will be collected for testing with a standard polymerase chain reaction (PCR) method. The standard PCR samples will be processed at University of Wisconsin (UW) Clinical Laboratory.
89299600|NCT05032144|Experimental|Cohort 1:2mg/kg|All participants (fasted) received either 2mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89299601|NCT05032144|Experimental|Cohort 2:5mg/kg|All participants (fasted) received either 5mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89299602|NCT05032144|Experimental|Cohort 3:10mg/kg|All participants (fasted) received either 10mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89299603|NCT05032144|Experimental|Cohort 4:20mg/kg|All participants (fasted) received either 20mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89299604|NCT05032144|Experimental|Cohort 5:30mg/kg|All participants (fasted) received either 30mg/kg of STSA-1002 as a single dose or dose-matched placebo.
89299605|NCT04908436|Experimental|Normal renal function|Healthy participants with creatinine clearance (CLCR) >80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
89299606|NCT04908436|Experimental|Mild renal impairment|Participants with CLCR 50-80 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
89299607|NCT04908436|Experimental|Moderate renal impairment|Participants with CLCR 30-<50 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
89299608|NCT04908436|Experimental|Severe renal impairment|Participants with CLCR <30 mL/min received single oral dose of 10 mg BAY94-8862 as an IR tablet under fasting conditions.
89299609|NCT03774498|Active Comparator|Sensodyne repair and protect|NovaMin & fluoride toothpaste
89299610|NCT03774498|No Intervention|Sensodyne Daily Care Toothpaste 0.315%|Sodium fluoride toothpaste
89299611|NCT04877392|No Intervention|Control (usual measures to control pain)|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure.
89299612|NCT04877392|Experimental|Case (usual measures to control pain plus inhaled lavender essential oil)|The neonate was taken to the neonatal unit and monitored with a pulse-oximeter before, during and after the procedure. The neonate was swaddled, administered 1 mL of oral sucrose, and allowed to suck for 2 minutes prior to the procedure. The neonate also had a 7 x 7 cm gauze pad with 1 drop (43.75 mg) of 100% pure LEO (Pranarôm España S.L.) placed 2 cm under their nose for 2 minutes prior to starting the frenotomy and for the duration of the procedure.
89299613|NCT03778008|Experimental|Recombinant bovine basic fibroblast growth factor|
89299614|NCT03778008|Active Comparator|Quadruple mixture|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
89299615|NCT04864678||Young people who are experiencing or at risk of homelessness|Young people aged 15-24 years who have accessed a homeless youth service, refuge, or flexible learning center in Melbourne, Australia.
89299616|NCT04801576|Placebo Comparator|Placebo mouthrinse|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse without flouride for 28 days; toothpaste with 1050 ppm F and mouthrinse without flouride for 28 days; toothpaste with 1450 ppm F and mouthrinse without flouride for 28 days.
89299617|NCT04801576|Experimental|Fluoride in mouthrinses|Group that uses just toothpaste without fluoride for 28 days; toothpaste without flouride and mouthrinse with 450 ppm F for 28 days; toothpaste with 1050 ppm F and mouthrinse with 450 ppm F for 28 days; toothpaste with 1450 ppm F and mouthrinse with 450 ppm F for 28 days.
89299618|NCT03778086||cataractous eyes|eyes of children with unilateral or bilateral cataract
89299619|NCT03778086||fellow eyes|fellow eyes of children with unilateral cataract
89299620|NCT03777852|Experimental|Pre-surgery First Breast Q|Women with proven breast cancer diagnosis. Respond to the First Breast Q questionnaire..
89299621|NCT03777852|Active Comparator|Post-surgery Second Breast Q|The Second Breast Q questionnaire will be applied to this group that will be composed of the women of the first group submitted to reconstructive breast cancer surgery.
89299622|NCT05697328|Experimental|Pseudoephedrine|over the counter pseudoephedrine
89299623|NCT05697328|Placebo Comparator|Placebo|pharmacy created placebo capsule
89299624|NCT03628378|No Intervention|Non-Sensor Group|Patients will undergo standard total knee replacement surgery without Verasense assisted balancing technology.
89299625|NCT03628378|Experimental|Sensor Group|Patients will undergo total knee replacement surgery with Verasense assisted balancing technology.
89299626|NCT04476576|Experimental|Aerobic|3 months program, 3 times/week aerobic ambulatory program.
89299627|NCT04476576|Active Comparator|Flexibility|3 months program, 3 times/week flexibility ambulatory program
89299628|NCT04668586|Experimental|Holmium:YAG laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Holmium:YAG laser machine.
89299629|NCT04668586|Experimental|Thulium Fiber laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Thulium Fiber laser machine.
89299630|NCT03777930|Experimental|chemotherapy group|the patients were recepted chemotherapy alone
89299631|NCT03777930|Experimental|chemotherapy combined with TH and MG group|the patients were recepted chemotherapy combined with thalidomide and megestrol
89299632|NCT03777930|Experimental|the best supportive treatment group|the patients were recepted the best supportive without chemotherapy
89299633|NCT03777930|Experimental|the best supportive treatment combined with TH and MG group|the patients were recepted the best supportive combined with thalidomide and megestrol without chemotherapy
89299634|NCT03777774|Active Comparator|No subgaleal drains|Drains will be placed during closing stage of craniectomy but will be clamped so that no drainage takes place. Drains can be opened if needed
89299635|NCT03777774|Active Comparator|Passive subgaleal drains|Passive non-vacuum drains will be placed during closing stage of craniectomy
89299636|NCT03777774|Active Comparator|Vacuum subgaleal drains|Active vacuum drains will be placed during closing stage of craniectomy
89299637|NCT04630054|Experimental|Mask Intervention|"Communities and individuals randomized to the intervention arm will be given masks and behavior change communication to motivate proper mask use.~In the community experiment, every adult in communities randomized to the intervention arm will be encouraged to wear a mask when outside their housing compound and around other people.~In the individual experiment, individuals randomized to the intervention arm will not be asked to recommend masks to others, but will also not be discouraged from recommending mask use to others."
89299638|NCT04630054|No Intervention|Control|Control individuals will receive no masks or behavior change communication.
89299639|NCT03777696|Active Comparator|Misoprostol with TA|400 μg of buccal misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
89299640|NCT03777696|Active Comparator|Misoprostol with placebo to TA|400 μg of buccal misoprostol (two tablets) plus 110 ml saline by iv rout
89299641|NCT03777696|Placebo Comparator|placebo to Misoprostol and TA|placebo to misoprostol plus placebo to tranexamic acid
89299642|NCT04627714|Experimental|Early Fencing|"patients of the Early Fencing arm will start adapted fencing practice (1h30/week) within 4 weeks after the breast surgery and for a duration of 3 months"
89299643|NCT04627714|Experimental|Delayed Fencing|"patients of the Delayed Fencing arm will start adapted fencing practice (1h30/week) 3 months after the breast surgery and for a duration of 3 months"
89299644|NCT03777540||Age; timing of gastric resection|Patients 80-85 years; Patients > 85 years; Elective and urgent surgery.
89299645|NCT04611880|Other|Single Arm Study|Single arm study: crizanlizumab will be supplied in single use vials containing 10 mL at a concentration of 10 mg/mL for administration by IV infusion. Each patient will receive one dose of crizanlizumab on day 1 of Week 1, day 1 of Week 3, day 1 of Week 7, and then day 1 of every 4-week cycle. On infusion day, the pharmacist or designated personnel will prepare individual doses of crizanlizumab for subjects on a milligram per kilogram basis (5 mg/kg) in a 100 mL infusion bag in accordance with the Pharmacy Manual. Crizanlizumab will be administered over 30 minutes by IV infusion
89299646|NCT03769740||CPR Group|
89299647|NCT03774342||CABG-patients|We will study one group of patients all scheduled for a Coronary Artery Bypass Grafting-procedure. This observational study consists of one group.
89299648|NCT04581148||M6|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M6) with residual blood samples.
89299649|NCT04581148||M12|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M12) with residual blood samples.
89299650|NCT04581148||M15|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M15) with residual blood samples.
89299651|NCT04581148||M19|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M19) with residual blood samples.
89299652|NCT04581148||M21|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M21) with residual blood samples.
89299653|NCT04581148||M22|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M22) with residual blood samples.
89299654|NCT04581148||M23|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M23) with residual blood samples.
89299655|NCT04581148||M24|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M24) with residual blood samples.
89299656|NCT04581148||M25|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M25) with residual blood samples.
89299657|NCT04581148||M26|All inpatient and outpatient patients of the Department of Pediatric- and Adolescent medicine of the University Hospital Erlangen in 4 weeks (M26) with residual blood samples.
89299658|NCT03942094|Experimental|Nilotinib|
89299659|NCT04478812|Experimental|Single Group Assignment|
89299660|NCT03708744|Experimental|Treatment A|Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
89299661|NCT03708744|Experimental|Treatment B|Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
89299662|NCT03708744|Experimental|Treatment C|Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
89299663|NCT03708744|Active Comparator|Treatment D|Treatment D: Intranasal zolmitriptan 2.5 mg
89299664|NCT03747328|Experimental|ABI-009|nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))
89299665|NCT01320462|Experimental|Smoking cessation group|Counselling, Pharmacotherapy and Smokers Help Line
89299666|NCT01320462|Other|Control group|Brief informatin about quitting and smokers help line
89299667|NCT03774030|Experimental|hearing impaired participants|Hearing impaired participants with mild or severe hearing loss
89299668|NCT03774108|Experimental|Metformin Experimental Arm|Metformin 850mg/12 hours, oral, 8 weeks
89299669|NCT03774108|Placebo Comparator|Placebo Comparator Arm|Placebo pills/12hours, oral, 8 weeks
89299670|NCT03769662|Experimental|High dose from study XT-150-1-0201|Open label administration of the highest dose in the earlier study, in which all doses were well tolerated
89299671|NCT03547726|Active Comparator|Physical Therapy|This group of patients will receive a predetermined physical therapy regimen with guidance from a physical therapist.
89299672|NCT03547726|Experimental|Self-Rehab|This group of patients will be provided with a list of actions not to perform during the stages of their rehab (to avoid injury), and allowed to rehab their shoulder at their own pace.
89299673|NCT03772938|Active Comparator|Stem/progenitor cells transplantation|Intervention: A single intravitreal injection of autologous bone marrow-derived stem/progenitor cells will be performed.
89299674|NCT03772938|Sham Comparator|Standard treatment of degenerative disease of retina|Symptomatic treatment of degenerative disease of retina without biologic cell-based treatment
89299675|NCT03438526|Experimental|Melatonin (Circadin ®)|
89299676|NCT03438526|Placebo Comparator|Placebo|
89299677|NCT01561638|Active Comparator|group p|pulse radiofrequency lesioning
89299678|NCT01561638|Placebo Comparator|sham group|Controlled, conventional
89299679|NCT01561638|Active Comparator|group C|Pulse dose radiofrequency
89299680|NCT03773718||Russkoe pole|400 patients
89299681|NCT03322384|Experimental|Experimental|All patients will begin epacadostat on day 1 of radiotherapy, which will consist of three threatments over one week. Epacadostat will continue until disease progression or intolerance occurs. On days 1, 8, 15, 22, 29, intralesional injectinons of SD101 will be given to patients.
89299682|NCT03772470|No Intervention|Control|No airtime incentive was given for completing the survey
89299683|NCT03772470|Experimental|1X Incentive|1X airtime incentive
89299684|NCT03772470|Experimental|2X incentive|2X airtime incentive
89299685|NCT03772470|Experimental|Lottery Incentive|Lottery airtime incentive given to one in 20 participants
89299686|NCT02977624|Experimental|Tele-CO-OP|The intervention included weekly videoconferencing sessions using the Cognitive Orientation to Daily Occupational Performance approach (tele-CO-OP) over a period of three months. Participant identified five functional goals, of which three were directly addressed.
89299687|NCT02977624|No Intervention|Waitlist control|The waitlist control group did not receive the intervention during the same time period
89299688|NCT03769428|Active Comparator|group B:ESP block|"Patients in the experimental arm will receive an erector spinae plane block prior to induction of general anesthetic :- 150 mg of Ropivacaine : 40cc of Ropivacaine (3.75mg/cc)~An intravenous patient controlled analgesia device will be given to the patients postoperatively"
89299689|NCT03769428|Placebo Comparator|group P: Sham ESP block|"Patients allocated to the placebo-control arm will receive a sham erector spinae plane block .they will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block:- 40 cc of normal saline will be injected~-An intravenous patient controlled analgesia device will be given to the patients postoperatively"
89299690|NCT02575144|Experimental|BiRd|"Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows:~Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min. Patients with a calculated creatinine clearance of <60 cc/min will receive 15 mgs PO daily on days 1-21 of a 28 cycle.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle."
89299691|NCT02575144|Active Comparator|Rd|"Subjects on the Rd arm will receive Revlimid, and dexamethasone in 28-day cycles. Dosing is as follows:~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up. Vomited doses will not be made up.Patients with renal failure will recived an ajusted dose.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle. Missed or vomited doses will not be made up. If subject cannot tolerate oral dexamethasone, it will be given intravenously. In patients over 75 years old, dexametasona oral will be given at dose of 20mg on days 1, 8, 15, 22 ."
89299692|NCT03769272||Echocardiographic targeting|
88820363|NCT06189391|Experimental|Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in need of systemic therapy
88820364|NCT06189170|Experimental|Cohort 1|KP405_dose 1, single dose
88820365|NCT06189170|Experimental|Cohort 2|KP405_dose 2, single dose
88820366|NCT06189170|Experimental|Cohort 3|KP405_dose 3, single dose
88820367|NCT06189170|Experimental|Cohort 4|KP405_dose 4, single dose
88820368|NCT06189170|Experimental|Cohort 5|KP405_dose 5, single dose
88820369|NCT06189170|Experimental|Cohort 6|KP405_dose 6, single dose
88820370|NCT06189170|Experimental|Cohort 7|KP405_dose 1, multiple dose
88820371|NCT06189170|Experimental|Cohort 8|KP405_dose 2, multiple dose
88820372|NCT06189170|Experimental|Cohort 9|KP405_dose 3, multiple dose
89299693|NCT03769272||Electrogram targeting|
89299694|NCT04092114|Other|Control|Receives Standard of Care (SOC) services established in accordance with the South African Department of Health (DoH) PrEP (Pre-exposure Prophylaxis) guidelines.
89299695|NCT04092114|Experimental|CHARISMA Intervention|"Receives SOC (Standard of care) per control arm plus provider-administration of HEART (HEAlthy Relationship Assessment Tool) and provider-administration of CHARISMA (the Community Health clinic model for Agency in Relationships and Safer Microbicide Adherence) counseling modules, as applicable:~Module A: General Partner Communication and Relationship Skills~Module B: Partner Disclosure and Communication around PrEP Use~Module C: Responding to Intimate Partner Violence and Safety Planning"
89299696|NCT03768882|Experimental|Paracetamol|Experimental: Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 102 patients
89299697|NCT03768882|Experimental|dexketoprofen|Dexketoprofen Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay-Menarini,Turkey) intravenous (IV) was given 98 patients
89299698|NCT02574286|Experimental|Velaglucerase alfa 60 U/kg|Participants will receive 60-minute intravenous infusion of 60 units per kilogram (U/kg) velaglucerase alfa every other week (EOW) and an oral daily dose of 800 IU vitamin D for 24 months (101 weeks).
89299699|NCT01321944|No Intervention|Usual clinical care|Usual clinical care provided by health care system
89299700|NCT01321944|Experimental|DTS intervention|Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP that encourages the smoker to quit, and offers a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC), free nicotine patches, and referral to additional treatment resources including the state's free telephone quitline.
89299701|NCT03771846|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin
89299702|NCT03771846|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and oxaliplatin
89299703|NCT03768804|Other|SyncAV algorithm on|"Device randomised to have SyncAV on, with delta programmed to the value which gives the narrowest QRS duration at rest and pseudo left ventricular (LV) only pacing"
89299704|NCT03768804|Other|SyncAV algorithm off|"Device randomised to have SyncAV off, with a fixed sensed atrioventricular (AV) delay of 120ms or shorter if necessary to prevent fusion, and biventricular (BiV) pacing"
89299705|NCT01321242||achieving resting HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
89299706|NCT01321242||non-achieving HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
89299707|NCT04068480||Capsule endoscopy patients|Patients swallowed the capsules in left lateral position, leaning on their left forearms and elbows, while we were positioning the magnet tightly against their backs. With the magnetic field vector X,Y,Z axis 180, -90 and 90, respectively. After swallowing the capsules with a small amount of water, they remained in this left lateral decubitus position.
89299708|NCT03763344|Experimental|Cohort C|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~the first cognitive assessment (Baseline),~intervention is fourteen sessions of Perceptual Cognitive Training (PCT) for seven weeks,~a post-treatment cognitive assessment (Week 7), and~a follow up cognitive assessment (Week 11)"
89299709|NCT03763344|No Intervention|Cohort D|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~the first cognitive assessment (baseline),~seven weeks of no intervention,~a post-treatment cognitive assessment (week 7), and~a follow up cognitive assessment (week 11)"
89299710|NCT03763266|Experimental|1 day low residue diet|Patients are instructed to complete a low residue diet exclusively one day prior the colonoscopy.
89299711|NCT03763266|Active Comparator|3 days low residue diet|Patients are instructed to complete a low residue diet three days prior the colonoscopy.
89299712|NCT03763188||the group BEFORE|Retrospective group. The daily urinary urea excretion was unknown.
89299713|NCT03763188||the group AFTER|Prospective group. Use the daily urinary urea excretion to guide the renal replacement therapy weaning.
89299714|NCT03771690|No Intervention|Control 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
89299715|NCT03771690|No Intervention|Control 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
89299716|NCT03771690|Experimental|Standardised meal 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
89299717|NCT03771690|Experimental|Standardised meal 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
89299718|NCT03763110|Experimental|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye [named photosensitizer PS] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
89299719|NCT03763110|Active Comparator|Antibiotic paste|Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation
89299720|NCT03772002|Experimental|HCV screening|
89299721|NCT03771924|Experimental|inorganic phosphate|"Experimental intervention:~Single dose of orally administered 700 mg inorganic phosphate as sodium phosphate in combination with a standardized meal and blood sampling"
89299722|NCT03771924|Placebo Comparator|Placebo|Single dose of Sodium chloride in combination with a standardized meal and blood sampling
89299723|NCT03771768|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide 0.1% 5 gm adhesive paste 4 times / day for 1 month.
89299724|NCT03771768|Experimental|Diode laser|Diode laser 980 nm & 100mWatt.
89299725|NCT01567566|Active Comparator|Local lumbopelvic stabilizers|
89299726|NCT01567566|Experimental|Local lumbopelvic plus hip stabilizers|
89299727|NCT03772080|Experimental|Early counseling of prematurity in high-risk pregnancies|
89299728|NCT03772080|No Intervention|Standard counseling of prematurity in high-risk pregnancies|
88820373|NCT06189170|Experimental|Cohort 10|KP405_dose 4, multiple dose
88820374|NCT06189170|Experimental|Cohort 11|KP405_dose 5, multiple dose
89531723|NCT05623345|Experimental|Group 1|Placebo from Day 1/Week 0 to Week 15, then izokibep from Week 16 to Week 51
89531724|NCT05623345|Experimental|Group 2|Izokibep Dose 1 from Day 1/Week 0 to Week 51
89531725|NCT05623345|Experimental|Group 3|Izokibep Dose 2 from Day 1/Week 0 to Week 51
89299729|NCT03771378|Experimental|Effective of rhTPO|After enrollment, all subjects receive rhTPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
89299730|NCT03771378|Active Comparator|Effective of eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
89299731|NCT04379700|Experimental|Embolization Group|23 participants who are aged between 30 to 75 years old, with grade 2 or 3 knee OA on the most recent knee radiographs obtained within 6 months of intervention. Each individual participant will be enrolled for approximately 13 months to complete all study visits from the initial screening visit to last follow up at 12-months post intervention.
89299732|NCT03762798|Experimental|Treatment|All participants will receive the Bridge device.
89299733|NCT03762720|Experimental|Physium treatment|Patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for a month
89299734|NCT03762642||Mastectomy|
89299735|NCT03762642||Breast-Conserving Surgery|
89299736|NCT03771300|Experimental|Mindfulness condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
89299737|NCT03771300|Experimental|Mindfulness condition complemented by VR|This condition is equivalent to the mindfulness condition (group sessions, held once a week over a space of 6 weeks and offered as an extra-curricular activity), unlike the time of each session, which is reduced from 90 to 75 minutes of duration.
89299738|NCT03771300|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extra-curricular activity.
89299739|NCT03771222|Experimental|Prophylactic DLI|The scheduled time of the first prophylactic DLI was +30 ~ +60 days after transplantation for HLA-matched sibling donors (MSD)-PBSCT recipients and +60 ~ +90 days after transplantation for HLA-haploidentical sibling donors (HID)-PBSCT recipients.
89299740|NCT03771222|No Intervention|No prophylactic DLI|
89299741|NCT03770988|Experimental|poziotinib single arm study|Single Arm study
89299742|NCT03762486|Active Comparator|TENS to around the incision|The Patient Controlled Analgesia infusion was started right after the surgery. TENS was applied to around the incision.
89299743|NCT03762486|Active Comparator|TAES to the acupuncture points|The Patient Controlled Analgesia infusion was started right after the surgery. TAES was applied to acupuncture points.
89299744|NCT03762486|No Intervention|No stimulation|No stimulation was performed to the patients in the control group.
89299745|NCT03762408|Experimental|ENKO 1|ENKO 1 administered by single intra-articular injection.
89299746|NCT03762408|Active Comparator|Durolane|Durolane administered by single intra-articular injection.
89299747|NCT03770910|Placebo Comparator|Placebo+placebo|Saline infusions
89299748|NCT03770910|Active Comparator|GIP+placebo|GIP(1-42), receptor agonist
89299749|NCT03770910|Experimental|GIP+dose 1|GIP(1-42) and lowest dose of GIP(3-30)NH2
89299750|NCT03770910|Experimental|GIP+dose 2|GIP(1-42) and dose of GIP(3-30)NH2
89299751|NCT03770910|Experimental|GIP+dose 3|GIP(1-42) and dose of GIP(3-30)NH2
89299752|NCT03770910|Experimental|GIP+dose4|GIP(1-42) and highest dose of GIP(3-30)NH2
89299753|NCT03771066|Experimental|Diet plus bisphenol A|Participants will receive a 4-day diet plus bisphenol A at 50 ug/kg body weight.
89299754|NCT03771066|Placebo Comparator|Placebo|Participants will receive a 4-day diet plus no bisphenol A.
89299755|NCT03627754|Experimental|Moderate Hepatic Impairment Group|Subjects with Child-Pugh Classification B (score 7-9)
89299756|NCT03627754|Experimental|Severe Hepatic Impairment Group|Subjects with Child-Pugh Classification C (score 10-15)
89299757|NCT03627754|Experimental|Normal Hepatic Function Group|Healthy subjects with normal hepatic function
89299758|NCT03762330|Active Comparator|COPD structured self-management plan|Participants will receive usual care for COPD and in addition, a structured self-management education plan.
89299759|NCT03762330|No Intervention|Usual care|COPD participants receiving only usual care
89299760|NCT03762252|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the scalene muscles
89299761|NCT03762252|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the scalene muscles
89299762|NCT03627676|Experimental|Intervention|
89299763|NCT03761940||Disease free|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires are disease free.
89299764|NCT03761940||Local recurrences|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with local recurrence and may be undergoing treatment for this.
89299765|NCT03761940||Distant disease|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with distant disease and may be undergoing treatment for this.
89299766|NCT03761940||Mastectomy|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have undergone a mastectomy.
89299767|NCT03768024|Experimental|Treatment A: GRT0151Y 100 mg|Treatment A: GRT0151Y 100 mg free base: 2 × GRT0151Y 50 mg capsules and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
89299768|NCT03768024|Experimental|Treatment B: GRT0151Y 200 mg|Treatment B: GRT0151Y 200 mg free base: 4 × GRT0151Y 50 mg capsules and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
89299769|NCT03768024|Experimental|Treatment C: GRT0151Y 400 mg|Treatment C: GRT0151Y 400 mg free base: 8 × GRT0151Y 50 mg capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
89299770|NCT03768024|Experimental|Treatment D: Matching placebo|Treatment D: Matching placebo to GRT0151Y and hydromorphone IR: 8 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
89299771|NCT03768024|Experimental|Treatment E: Hydromorphone IR 4 mg|Treatment E: Hydromorphone IR 4 mg: 1 × hydromorphone IR 4 mg tablet (encapsulated) and 7 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
89299772|NCT03768024|Experimental|Treatment F: Hydromorphone IR 8 mg|Treatment F: Hydromorphone IR 8 mg: 2 × hydromorphone IR 4 mg tablet (encapsulated) and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
89299773|NCT03768024|Experimental|Treatment G: Hydromorphone IR 16 mg|Treatment G: Hydromorphone IR 16 mg: 4 × hydromorphone IR 4 mg tablet (encapsulated) and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
89299774|NCT01567644|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
89299775|NCT03767790|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting. During AID use, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
89299776|NCT03767790|No Intervention|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting. During these 2 weeks, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
89299777|NCT03999684|Experimental|Tretinoin|-Participants will receive Tretinoin orally divided over two daily doses for days 1 through 14 of a 28-day cycle
89299778|NCT02083354|Experimental|Arm 1|All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure
89299779|NCT03761862||Control|The control group with bilateral tubal ligation
89299780|NCT03761862||Neural Therapy|The treatment group
89299781|NCT04230486|Experimental|Experimental Group Virtual Reality (VR) Treatment|Visual Auditory Virtual Reality rehabilitation for visual hemianopia
89299782|NCT01399918|Experimental|everolimus and bevacizumab|This is a single-institution, single-arm phase II trial of everolimus in combination with bevacizumab in patients with advanced non-clear cell RCC, who have not received prior VEGF-.or mTOR-targeted therapy. A separate cohort of patients with non-clear cell RCC with papillary features will be enrolled in order to gather information regarding the efficacy given the rarity of these entities.
89299783|NCT03770754|Experimental|Control group|"Control Group (n= 15): the root canals were prepared manually with K-files (Dentsply-Maillefer, Ballaigues, Switzerland) and step back technique up to size #35."
89299784|NCT03770754|Experimental|Group 1|Group 1 (n= 15): the root canals were instrumented with rotary LightSpeed LSX instruments (Discus Dental, Culver City, CA, USA). They were used to complete the canal preparation to a size #50 for the anteriors and molar teeth to size #40.
89299785|NCT03770754|Experimental|Group 2|Group 2 (n= 15): root canals were instrumented with ProTaper Next (Dentsply Maillefer, Ballaigues, Switzerland) using X1, X2 to X3. 0.5% NaOCl was used for irrigation.
89299786|NCT01073410||Healthy, non-asthmatic controls|People who are non-asthmatic and non-smokers.
89299787|NCT01073410||Asthmatics|People who have been diagnosed with asthma.
89299788|NCT03761628|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of VVC.
89299789|NCT01034254|Experimental|influenza vaccine|Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
89299790|NCT01034254|Placebo Comparator|saline placebo|Pregnant women assigned to the control group will receive one dose of placebo (normal saline).
89299791|NCT03761472|Active Comparator|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2 ml solution, once initially.
89299792|NCT03761472|Active Comparator|Platelet-rich plasma injection|Platelet-rich plasma 5 ml, once initially
89299793|NCT03761472|No Intervention|Unaffected side Hyaluronic acid|Unaffected sides of the patients will be controls for hyaluronic acid group, no intervention.
89299794|NCT03761472|No Intervention|Unaffected side Platelet-rich plasma|Unaffected sides of the patients will be controls for Platelet-rich plasma group, no intervention.
89299795|NCT03767556|No Intervention|Control|This group will not receive intervention
89299796|NCT03767556|Experimental|Inspiratory Muscle Training|This group, for inspiratory muscle training, will use the Powerbreathe® K5 device. This device will be adjusted with a load of 55% of previously assessed MIP. The volunteer will be instructed to inhale with sufficient force to overcome the resistance of the equipment and subsequently perform a normal expiration. During the 4-week period of respiratory muscle training volunteers will be instructed to perform 2 sets with 30 inspiratory efforts, 5 days a week. The training load will be readjusted on the first day of training each week, after a new reassessment of the PIMax in order to guarantee the overload during inspiratory muscle training.
89299797|NCT03767400||Group A - Young skin (18 - 30 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
89299798|NCT03767400||Group B - Aged skin (55 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
89531726|NCT05623345|Experimental|Group 4|Izokibep Dose 3 from Day 1/Week 0 to Week 51
89299799|NCT03767400||Group C - Atrophic acne scars (18 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
89299800|NCT03767322|Active Comparator|Allopurinol group|The intervention group will receive 300 mg of allopurinol 12 hours before and 12 hours after the coronary intervention.
89299801|NCT03767322|Placebo Comparator|Placebo group|The placebo group will receive 300 mg of placebo 12 hours before and 12 hours after the coronary intervention.
89299802|NCT03767322|Active Comparator|Febuxostat group|The intervention group will receive 80 mg of febuxostat 12 hours before and 12 hours after the coronary intervention
89299803|NCT01561872||intervention group|"Rooms of the patient of the intervention group will be equipped of cameras"
89299804|NCT01561872||reference group|"Patient in the non-equipped group will have usual care"
89299805|NCT01321320|Experimental|Active stimulation|This group will receive active muscle stimulation for 1 week to the quadriceps muscle - the leg will be randomly assigned.
89299806|NCT03770520|Experimental|QFR-guided|This group will be performed a CABG surgery based on CAG and QFR, whether graft the moderate stenosis vessels will be based on the result of QFR.
89299807|NCT03770520|Active Comparator|Angio-guided|This group will be performed a CABG surgery only based on CAG, the final surgery strategy will be decided after the discussion of heart team.
89299808|NCT03767088|Active Comparator|WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 8 muscle groups (legs, gluteal region, core, arms) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
89299809|NCT03767088|Active Comparator|partial WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 2 muscle groups (legs, gluteal region; lower extremities) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
89299810|NCT03767088|Sham Comparator|control|active sham comparator: 1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session performing slight eccentric pronounced physiological movement patterns
89299811|NCT03761316||FBSS patients|patients with Failed Back Surgery Syndrome, eligible for SCS
89299812|NCT03761238|Experimental|Standard medical treatment + MARS|Patients assigned to the control arm will receive standard medical treatment (SMT) and liver dialysis using Molecular Adsorbent Recirculating System (MARS).
89299813|NCT03761238|Active Comparator|Standard medical treatment|Patients assigned to the control arm will receive standard medical treatment (SMT) as specified in the study protocol.
89299814|NCT03570996|Active Comparator|Transversus abdominis plane catheter|Transversus abdominis plane catheter (TAP) for pain control in esophagectomy operations. TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine.
89299815|NCT03570996|Active Comparator|epidural|Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
89299816|NCT03770442|Experimental|Cycling with FES|"Ten sessions of 14 days in patients consented within 48 hours of arriving in critical care who are sedated and mechanically ventilated with a diagnosis of sepsis from any source.~Sessions last a maximum of 30 minutes (with an ideal minimum of 20 minutes), using the Restorative Therapies (RT) 300 Supine with the Sage 12-channel stimulator. Stimulation will provided to the quadriceps, hamstrings, calves and abdomen. Both legs and both sides of the abdomen will be stimulated. Stimulation current settings are individualised for each patient and each muscle group.~These patients will also receive their routine physiotherapy that they would have received if they were in the control group (or not in the trial at all)."
89299817|NCT03770442|Active Comparator|Control - routine physiotherapy|Usual daily physiotherapy, consisting of limb care and mobilisation, and respiratory care and exercises as appropriate.
89299818|NCT03761004|Experimental|WD-1603 single dose|"WD-1603 single dose:~A single WD-1603 tablet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
89299819|NCT03761004|Experimental|WD-1603 BID dose|"WD-1603 BID dose:~A single WD-1603 tablet after breakfast, and a second WD-1603 tablet approximately 3 hours after completing lunch.~Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 4.5, 5, 6, 7, 7.25, 7.5, 7.75, 8, 8.5, 9, 10, 10.5 11, 12, 16 and 24 hours post-dose."
89299820|NCT03761004|Active Comparator|Sinemet single dose|"Sinemet single dose:~A single oral dose of Sinemet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
89299821|NCT03766932||Blood culture candida positive group|
89299822|NCT03766932||Tracheal aspiration candida culture positive group|
89299823|NCT03766932||Urine candida culture positive group|
89299824|NCT03766932||Other aseptic humoral candida positive group|
89299825|NCT03770208|Placebo Comparator|Control: Standard Care + Placebo|"Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV placebo (Lactated Ringers). Lactated Ringers will be delivered as a initial bolus and then run as a continuous infusion to mimic the volume (as per Kg) of study drug for 72-96 hours. Standard care will be determined by the care team with no limitations introduced by the research team. Medications utilized and dosing regimes will be recorded after the intervention."
89299826|NCT03770208|Experimental|Intervention: Lidocaine|Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV lidocaine. IV lidocaine will be administered as a bolus dose of 2 mg/kg (maximum dose 100 mg) followed by a 2 mg/kg/hr infusion for 72-96 hrs.
89299827|NCT03766854|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic (PK) sampling where subjects are treated with once daily (OD) insulin glargine.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
89299828|NCT03766854|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.~After insulin glargine treatment, participants will receive insulin 287 OW for 8 weeks and subsequent 4 weeks of terminal PK sampling."
89299829|NCT03766776|Experimental|Anlotinib Arm|
89299830|NCT03760848|Other|Midazolam, Atorvastatin / Aramchol, Midazolam, Atorvastatin|Midazolam 2 mg -atorvastatin 40 mg /Aramchol 600mg -midazolam 2 mg-atorvastatin 40 mg (MA/MAA)
89299831|NCT01567488|Experimental|Everolimus + Octreotide LAR treatment|
89299832|NCT03760770|Experimental|Riboflavin at 4ºC|patients treated with Riboflavin at 4ºC in crosslinking (cases).
89299833|NCT03760770|Experimental|Riboflavin at room temperature|patients treated with Riboflavin at room temperature in crosslinking (controls)
89299834|NCT01561794|Experimental|Ciprofloxacin|
89299835|NCT03766542|Active Comparator|CPAP|Oronasal CPAP therapy applied as per current international guidelines
89299836|NCT03766542|Experimental|Bi-level|Oronasal Bi-level therapy + supplemental oxygen (if necessary) applied as per current international guidelines
89299837|NCT01321398||Critically Ill patients receiving HFO|
89299838|NCT03760614|Experimental|Entinostat + FOLFOX|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks. Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle. Entinostat dose will vary between 2mg and 5mg depending on time of enrollment and observed toxicities. Dosing will begin at 3mg.
89299839|NCT03760536||16-week Exercise Program|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
89299840|NCT03769974|Experimental|Motor imagery|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-person kinesthetic motor imagery training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of motor imagery will be 2 series of 30 seconds for each of the 12 manual positions to remember
89299841|NCT03769974|Experimental|Action observation|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-personaction observation training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of action observation will be 2 series of 30 seconds for each of the 12 manual positions to remember in video format.
89299842|NCT03769974|Placebo Comparator|Placebo group|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which an imagery training and placebo observation, inspired by a rural landscape, will be given for four consecutive days. This group will carry out the observation and imagination of a landscape during 2 series of 30 seconds for each manual motor sequence to remember.
89299843|NCT00112840|Experimental|CCI-779 and bevacizumab|Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
89299844|NCT03766308|Experimental|Highland barley diet|highland barley diet(20g, thrice-daily) +Metformin sustained-release tablets(500mg, thrice-daily)
89299845|NCT03766308|Active Comparator|ADA diet|ADA diet + Metformin sustained-release tablets(500mg, thrice-daily)
89299846|NCT03769818|Active Comparator|bupivacaine and dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
89299847|NCT03769818|Active Comparator|bupivacaine and placebo to dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
89299848|NCT03769818|Placebo Comparator|control group|Bilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
89299849|NCT05223244|Active Comparator|dimethyl sulfoxide (DMSO)|Six weekly bladder instillations with 50mL of DMSO and 1mL of triamcinolone (10mg/mL)
89299850|NCT05223244|Experimental|bupivacaine, triamcinolone, and heparin (BTH)|Six weekly bladder instillations with 30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
89299851|NCT03627598|Active Comparator|standard group|NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.
89299852|NCT03627598|Experimental|HFNC group|NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.
89299853|NCT03766152|Other|Adhear|Patients will be fitted with an adhesive bone conduction device for three weeks
89299854|NCT05222698|Active Comparator|Group A|Segmental free latissimus muscle trasfer to the face.
89299855|NCT05222698|Active Comparator|Group B|Free gracillis muscle trasfer to the face.
88820375|NCT06189066|Experimental|Ultrasound Group|
89299856|NCT05222074||CVP ≥ 12|central venous pressure ≥12 mmHg
89299857|NCT05222074||CVP ≥ 16|central venous pressure ≥16 mmHg
89299858|NCT05222074||CVP ≥ 20|central venous pressure ≥20 mmHg
89299859|NCT05222074||MAP ≤ 55 mmHg|mean arterial pressure ≤55 mmHg
89299860|NCT05222074||MAP ≤ 65 mmHg|mean arterial pressure ≤65 mmHg
89299861|NCT05222074||MAP ≤ 75 mmHg|mean arterial pressure ≤75 mmHg
89299862|NCT03760380|Experimental|Phase 1 Short Term|Participants will serve as their own control. Questionnaires and gait measures will be collected during an initial visit using the experimental shoe device. All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)
89299863|NCT03760380|Experimental|Phase 2 Long Term|Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
89299864|NCT03760302||Patient given analgesics or hypnotics|All patients treated with any kind of analgesics or hypnotics are analyzed and compared.
89299865|NCT03323892|Active Comparator|'normal' abstinence duration|Patients follow the normal abstinence duration as asked by the physician (2-7 days). This sperm will be used to inject half of the oocytes Intervention = second sperm sample
89299866|NCT03323892|Experimental|short abstinence duration|"Patients will be asked to produce a second sperm sample, 2 hours after the first. This sperm will be used to inject the other half of the oocytes.~Intervention = second sperm sample"
89299867|NCT01322256|Experimental|Included patients|"Patients included in the study according to stated inclusion and exclusion criteria~Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork"
89299868|NCT02301858|Other|Study arm|Genome analysis of tissue samples.
89299869|NCT03766074|Experimental|Intervention|vitamin D supplement every other week
89299870|NCT03766074|Placebo Comparator|control|Placebo every other week
89299871|NCT05221216||patients in Intensive Care unit|patients in Intensive Care unit with infection treated with cotrimoxazole will be included. Data will be collected of medical record.
89299872|NCT03765840||POCD group|patients occur cognitive decline after surgery according to scores in this group.
89299873|NCT03765840||NO POCD group|patients do not occur cognitive decline after surgery according to scores in this group.
89299874|NCT05221138|Experimental|VV116 after High-fat meal intake|a single oral after High-fat meal intake
89299875|NCT05221138|Experimental|VV116 after Fasting+Standard diet|a single oral after Fasting
89299876|NCT05221138|Experimental|VV116 after Standard meal intake|a single oral after Standard meal intake
89299877|NCT03758820|Experimental|BCT group|"Intervention : Behavorial Cognitive Therapy (BCT) will be delivered by two psychologists at six once-weekly sessions of 90 minutes (with homework activities between the sessions) + 4 booster sessions at week 6, 12, 18 and 36 after the end of the programme.~It was designed for groups of 8 to 10 people. The programme is standardised: PowerPoints presentations support each session and a detailed facilitator manual and companion patient workbook. accompany the programme."
89299878|NCT03758820|No Intervention|Control group|Usual local practice
89299879|NCT03765606|Placebo Comparator|Cocoa Flavanol beverage mix|Cocoa Flavanol beverage mix (flavanols, 566mg; caffeine, 11mg & theobromine, 93mg)
89299880|NCT03765606|Experimental|De-xanthinated Cocoa Flavanol beverage mix|De-xanthinated Cocoa Flavanol beverage mix (flavanols, 583mg; caffeine, 0.6mg & theobromine, 0.2mg)
89299881|NCT05220592|Experimental|Internet-based recovery training program (n=35)|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week.
89299882|NCT05220592|No Intervention|Wait-list control group (n=34)|Wait-list control group received equal and parallell assessment and eligibility procedure as the experimental conditions. Wait-list control group gained access to iCBT/W-iCBT program after the six months follow-up.
89299883|NCT03759990|Active Comparator|insertion time|
89299884|NCT03759990|Active Comparator|intubation time|
89299885|NCT05220436|Experimental|DISCOVER workshop programme|"As this is a case series study, all participants will receive the intervention (i.e. no other arms to the study design).~The DISCOVER workshop programme includes: 1:1 mental health and emotional well-being assessment session with a Clinical Psychologist, a group workshop day, follow-up supportive phone calls and a closing follow-up 1:1 mental health and emotional well-being session with a Clinical Psychologist."
89299886|NCT05220124|Experimental|Immunotherapy with Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)|420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 3-4 treatment cycles,21 days per cycle.
89299887|NCT05220124|No Intervention|Immunotherapy without Probiotics|control group, Immunotherapy without Probiotics
89299888|NCT05197660||- cataract surgery|
89299889|NCT05197660||- hip arthoplasty|
89299890|NCT05197660||- knee arthoplasty|
89299891|NCT05197660||- coronary angioplasty|
89299892|NCT05197660||- definitive cardiac stimulation (pacemaker)|
89299893|NCT03849274|Experimental|Smart Scar Care Pad+Pressure Garment|For experiment group, subject will be intervened by SSCP plus PG
89299894|NCT03849274|Active Comparator|Pressure Garment|For control group, subject will be intervened by conventional PG only
89299895|NCT03849274|No Intervention|Non-eligible patients (with VSS less than 4)|Non-eligible subjects with VSS less than 4 will be followed up for 6 months and assessment results will be recorded.
89299896|NCT05173636|Experimental|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
89299897|NCT05173636|Experimental|thoracic mobilization|A posteroanterior unilateral pressure will be applied over the transverse processes at T2-T5 on the ipsilateral side of pain in prone position.
89299898|NCT05168644|Experimental|Drug: Niclosamide Inhalation Powder|"PART A (SAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 0.5 mg, Cohort 2: 2 mg, Cohort 3: 6 mg.~PART B (MAD): Niclosamide Inhalation Powder will be supplied as one to six capsules. Each capsule contains either 0.25 mg or 1 mg of Niclosamide Inhalation Powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~MAD subjects will receive Niclosamide Inhalation Powder BID for a total of 9 doses. Subjects in Cohort 4 will receive 3 mg BID, Cohort 5: 6 mg BID."
89299899|NCT05168644|Placebo Comparator|Drug: Placebo|"PART A (SAD): Placebo will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~SAD subjects (Part A) will receive a single dose of Placebo.~PART B (MAD): Placebo inhalation powder will be supplied as one to six capsules. Each capsule contains Placebo inhalation powder and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 20-minute period.~MAD subjects (Part B) will receive Placebo inhalation powder BID for a total of 9 doses."
89299900|NCT03627520|Other|[14C]Sulfatinib|This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.
89299901|NCT02197572|Experimental|Sapanisertib|Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).
89299902|NCT05139862|Experimental|Active iTBS|Active intermittent theta-burst stimulation (iTBS) rTMS session on the left dorsolateral prefrontal cortex (L-DLPFC)
89299903|NCT05119738||Three doses of BNT162b2.|Cancer patients on active cytotoxic treatment who received three doses of BNT162b2.
89299904|NCT05119738||Two doses of Coronavac and one of BNT162b2.|Cancer patients on active cytotoxic treatment who received two doses of Coronavac and one dose of BNT162b2.
89299905|NCT05088694|Experimental|Intervention|Classrooms assigned to the intervention group will receive the Peaceful Coexistence (middle school) or Anti-extremism (high school) curricula.
89299906|NCT05088694|No Intervention|No intervention|Classrooms assigned to the No intervention group will receive general information during their sessions.
89299907|NCT02174406||women scheduled for breast screening|"Each patient will have the following:~Screening whole breast ultrasound~DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM."
89299908|NCT05059990|Experimental|Low Intensity Aerobic Exercises Group|stationary cycle for aerobic exercise
89299909|NCT05059990|Active Comparator|Active Exercises Group|Upper and lower limb range of Motion (ROM) & stretching exercises uses in active exercise group
89299910|NCT05412888|Placebo Comparator|Supplemented population 300mg|Supplemented population 300mg/24h CoQ10 - 25 participants
89299911|NCT05412888|Experimental|Training and IPC preconditioning|Group subjected to training and preconditioning by ischemia (IPC training) - 25 participants,
89299912|NCT05412888|Placebo Comparator|Control group (placebo)|Control group to CoQ10 supplementation (placebo)- 25 participants
89299913|NCT05412888|Sham Comparator|IPC control group|IPC control group - 25 participants
89299914|NCT03759756||AI visible group|the endoscopic novices analyzing the images can see the automatic diagnosis of AI during the process
89299915|NCT03759756||AI invisible group|the endoscopic novice analyzing the images can not see the automatic diagnosis of AI during the process
89299916|NCT03765294|Experimental|Treatment A: ACT-541468|50 mg once daily from Day 1 to Day 5 of Period A
89299917|NCT03765294|Placebo Comparator|Treatment B: Placebo|Matching placebo once daily from Day 1 to Day 5 of Period B
89299918|NCT03765216|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
89299919|NCT03765216|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
89299920|NCT03626896|Experimental|NaviFUS System|NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB
89299921|NCT01322334|Experimental|Singing exercises|
89299922|NCT05087212|Experimental|plerixafor|Participants will receive the first dose of plerixafor by subcutaneous (SC) injection on the evening of Day 4 (10 to 11 hours (± 1 hour) prior to the start of next day's apheresis). For a maximum of 4 days, patients will continue to receive daily plerixafor in the evening, followed by a morning dose of G-CSF and apheresis for up to a maximum of 4 apheresis or until ≥ 6×106 Cluster of differentiation 34 (CD34) + cells/kg were collected.
89299923|NCT01617642||Control group|Healthy control group, matched for age and gender
89299924|NCT01617642||Acute intermittent porphyria|Patients with acute intermittent porphyria.
89531747|NCT05569798|Experimental|Standard care + the INSIGHT intervention|Thirty patients will receive standard care + the INSIGHT intervention. The INSIGHT intervention is described in detail in section 5.7.1. INSIGHT scans will be performed by staff trained in the INSIGHT Training and Competency Programme on days 1 (0-36 hours), 3 (72-96 hours) and 7 (6 to 8 days) from ICU admission. Scans will only be performed at these timepoints if the patient is still admitted to the ICU.
89299925|NCT03765060|Experimental|Small Stitch|"Patients requiring an urgent emergency laparotomy. The Small Stitch closure technique will be perform using a Monomax® 2/0 HR26 (Half-circle Round body):~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle (Half-circle Round body).~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
89299926|NCT03765060|Active Comparator|Large Stitch|"The intervention will be the classic large Stitch closure technique using a Monomax® 1 HR48 (Half-circle Round body).~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle (Half-circle Round body).~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
89299927|NCT01532310||Pregnant women taking belimumab|Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
89299928|NCT01532310||Infants|Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
89299929|NCT05070910|Experimental|NDT|Therapy will be provided 2 days to 4 days per week for one-hour sessions
89299930|NCT01423734||MRI|Patients will be consented for a second MRI without additional intravenous contrast, referred to from now on as 'research MRI', to be performed later on the same day as their clinical liver MR examination, on one of two 3.0 Tesla MR 750 GE scanners at the Breast and Imaging Center. The research MRI will consist only of the localizer and diffusion weighted imaging (DWI) sequences, with acquisition parameters identical to our clinical MRI. The reproducibility of DWI is best assessed in separate MR imaging sessions, although the examinations can be performed the same day.
89299931|NCT03758586|Active Comparator|Study group|Surgical residents undergoing spatial skill training.
89299932|NCT03758586|Sham Comparator|Control group|Surgical residents not undergoing spatial skill training.
89299933|NCT03764826|Experimental|CAABT|CAABT(Cochleural Alternating Acoustic Beam Therapy) is an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
89299934|NCT03764826|Active Comparator|TMT|TMT(tinnitus masking therapy) is a traditional tinnitus intervention. The masking sound is mainly white noise, and the intensity just covers tinnitus.
89299935|NCT03764748|Experimental|mini-FMT|Participants will receive 200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.
89299936|NCT01321788||STUDY GROUP|will receive the study drug Innohep ® for 14 days
89299937|NCT01321788||CONTROL|The group that will receive placebo for 14 days
89299938|NCT05053828||Non-diabetic controls on clopidogrel|Non-diabetic patients prescribed clopidogrel
89299939|NCT05053828||Diabetic patients on clopidogrel|Diabetic patients on clopidogrel
89299940|NCT05053828||Diabetic patients on antiplatelet drugs other than clopidogrel|Diabetic patients on antiplatelet drugs other than clopidogrel
89299941|NCT05038306|Active Comparator|Chinese Medicine|
89299942|NCT05038306|Placebo Comparator|Placebo|
89299943|NCT03759444||women with eating disorders|"women with eating disorders (age: M = 26.88; SD = 5.82)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
89299944|NCT03759444||healthy female controls.|"healthy female controls (age: M = 24.27; SD = 6.49)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
89299945|NCT03759132|Experimental|Anodal tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes"
89299946|NCT03759132|Sham Comparator|Sham tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes (30s ON)"
89299947|NCT05019040|Experimental|PA1010 5 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 5 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
89299948|NCT05019040|Experimental|PA1010 10 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 10 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
89299949|NCT05019040|Experimental|PA1010 20 mg|Twelve subjects will be randomly assigned at a 3: 1 ratio to receive either 20 mg of PA1010 tablets or 300 mg of TDF tablets, once daily for 28 days.
89299950|NCT03764436|Experimental|LEAPS-NCHD Program - Group 1|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
89299951|NCT03764436|Experimental|LEAPS-NCHD Program - Group 2|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
89299952|NCT03764436|Experimental|LEAPS-NCHD Program - Group 3|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
89299953|NCT05552482||Patients with ESRD with early AVF failure|Patients with ESRD who underwent AVF access creation surgery with early AVF failure
89299954|NCT05552482||patients with ESRD without early AVF failure|Patients with ESRD who underwent AVF access creation surgery without early AVF failure
89299955|NCT03764358|Active Comparator|Arteriovenous fistula|
89299956|NCT03764358|Experimental|Tunneled Cuffed Catheter|
89299957|NCT04920838|Active Comparator|Paracetamol|Patients in this arm will receive paracetamol during 14 days
89299958|NCT04920838|Experimental|Nitazoxanide and Ciclésonide|Patients in this arm will receive the combination of ciclezonide (Alvesco® 160 µg ) / nitazoxanide (Netazox® 500 mg) during 14 days
89299959|NCT04920838|Experimental|Telmisartan|Patients in this arm will receive telmisartan (Micardis® 20 mg) during 10 days
89299960|NCT04920838|Experimental|Fluoxétine and Budésonide|Patients in this arm will receive the combination of Fluoxétine (Fluoxétine Arrow® 40 mg ) / Budésonide (Budecort® 2*400 mcg) during 7 days
89299961|NCT03764280|No Intervention|MDI with Physician Adjusted Basal-Bolus Parameters|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Participants will undergo their conventional multiple daily injection (MDI) therapy.
89299962|NCT03764280|Experimental|MDI with Basal-Bolus Optimization Algorithm|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Once daily, the data from the glucose sensor and injection information will be entered into a computer and the optimization algorithm will be run. Once daily, participants' parameters may be changed based on the algorithm's recommendations.
89299963|NCT01322412||Arm A : physical activity program|Arm A : physical activity program (aerobic and strength training) during the 27 weeks of treatment (chemotherapy and radiotherapy) and conventional follow-up during 27 weeks
89299964|NCT01322412||Arm B : conventional management|Arm B : conventional management during and after treatment
89299965|NCT02666586|Placebo Comparator|Control smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
89299966|NCT02666586|Experimental|Faba Bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder.
89299967|NCT02666586|Experimental|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
89299968|NCT02666586|Experimental|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
89299969|NCT02666586|Experimental|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
89299970|NCT03626818||NCF group|The patients have received 10 daily fractions of 3 Gy WBRT. Following WBRT treatment, subjects were assessed at each visit for NCT according to the Hopkins Verbal Learning Test-Revised(HVLT-R),Mini-Mental Status Examination(MMSE) and Quality Of Life measurements(QOL,Questionnaire-QLQC30).These tests was administered by trained and certified nurses or clinical research associates at baseline,6th week, 3rd, 6th, 9th, 12th month, and every 6 months until PS> 2 or intracranial tumor progression.
89299971|NCT02654964|Experimental|Treatment Arm|"A Drug Combination Treatment will be determined through High Throughput Screening. The classes of drugs this combination therapy will be comprised from are:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
89299972|NCT03764202|Other|CSEA，1μg/kg•d|"The puerpera received combined spinal epidural anesthesia~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
89299973|NCT03764202|Other|CSEA，1.5μg/kg•d|"The puerpera received combined spinal epidural anesthesia~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
89299974|NCT03764202|Other|GA，1μg/kg•d|"The puerpera received general anesthesia~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
89299975|NCT03764202|Other|GA，1.5μg/kg•d|"The puerpera received general anesthesia~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
89299976|NCT03764202|Other|CSEA，Epidural analgesia|"The puerpera received combined spinal epidural anesthesia~Postoperative analgesia was performed with epidural analgesia~Speed of epidural analgesia pump ：6ml/h（0.1% ropivacaine , 0.5μg/ml sufentanil）"
89299977|NCT02627196|Experimental|Device and Medical Management|Subjects will be implanted with the BAROSTIM NEO System and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
89299978|NCT02627196|Active Comparator|Medical Management|Subjects will receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
89299979|NCT03626740|Experimental|TheraCal|Indirect pulp capping with TheraCal
89299980|NCT03626740|Active Comparator|Mineral trioxide aggregate (MTA)|Indirect pulp capping with MTA
89299981|NCT05123196|Experimental|MT-8554|MT-8554 will be started from a low dose, and gradually increase the dose in order.
89299982|NCT05123196|Placebo Comparator|Placebo|
89299983|NCT04678492|Experimental|High-dose esomeprazole and amoxicillin dual therapy|Esomeprazole 40 mg and amoxicillin 1000 mg by mouth，three time daily for 14 days
89299984|NCT04678492|Active Comparator|Bismuth-containing quadruple therapy|Tetracycline 500mg three time daily for 14 days，furazolidone 100 mg, esomeprazole 40 mg, and Bismuth 220mg by mouth, twice daily for 14 days.
89299985|NCT03758430||Combined Diabetes Management Data|Participants with type 1 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their continuous glucose monitor and insulin pump. Combined data will be used for diabetes management.
89299986|NCT04266366|Active Comparator|Face-to Face rehabilitation program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience. This program will be developed in the rehabilitation service of the study health centers. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
89299987|NCT04266366|Experimental|Telemedicine Program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 8 weeks, with a total of 24 sessions
89299988|NCT03176784|Experimental|Varenicline + Patch Standard Duration|"Standard Condition Varenicline: 0.5 mg pill once daily (QD) on Days -7 to -5; 0.5 mg pill twice daily (BID) Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Nicotine Patches:~Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24"
89299989|NCT03176784|Experimental|Varenicline Only Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
89299990|NCT03176784|Experimental|Varenicline + Patch Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Nicotine Patches:~14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit."
89299991|NCT03176784|Experimental|Varenicline Only Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
89299992|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Single dose|One drop in the study administered one time only for one day
89299993|NCT03049852|Placebo Comparator|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
89299994|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Multidose|One drop in the study administered three times daily (TID) for 4 weeks
89299995|NCT05091528|Experimental|SBT6050 + T-DXd (5.4 mg/kg)|SBT6050 plus trastuzumab deruxtecan
89299996|NCT05091528|Experimental|SBT6050 + T-DXd (6.4 mg/kg)|SBT6050 plus trastuzumab deruxtecan
89299997|NCT05091528|Experimental|SBT6050 + Tucatinib + Trastuzumab + Capecitabine|SBT6050 plus tucatinib, trastuzumab, and capecitabine
89299998|NCT05091528|Experimental|SBT6050 + Tucatinib + Trastuzumab|SBT6050 plus tucatinib and trastuzumab
89299999|NCT04236258|Active Comparator|Nifedipine|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start nifedipine extended release 30 mg daily as their starting antihypertensive.
89300000|NCT04236258|Active Comparator|Enalapril|This arm will be postpartum women with high blood pressure who need an antihypertensive and have been assigned to start enalapril 10 mg daily as their starting antihypertensive.
89300001|NCT01317004|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
89300002|NCT01317004|Active Comparator|Multiple Sclerosis Disease Modifying Treatment (MS DMT)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
89300003|NCT01343056|Active Comparator|Office Staff follow up education|"A designee in the office staff shall be assigned to follow up with the patient for for behavioral goal setting attainment. The office staff will call patients monthly to monitor goal attainment. It will be suggested that they phone the participant monthly but researchers will observe how and if they provide follow up.~The intervention is the follow up goal attainment and office staff have been trained on elements of goal attainment."
89300004|NCT01343056|Active Comparator|Peer follow up education|"A person with diabetes trained as a peer shall meet the participant at their 6 week follow up visit and then call the participant monthly to monitor behavioral goal attainment.The intervention is the follow up goal attainment and peers have been trained on elements of goal attainment."
89300005|NCT01343056|Active Comparator|Usual Care|ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education. This one phone call will be made by the diabetes educator. The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
89300006|NCT01343056|Active Comparator|Educator support follow up|A diabetes educator will provide follow up support and make monthly call to the patient to ascertain behavioral goal setting attainment. The diabetes educator uses behavioral goal setting as an education intervention. The educator calls patient to determine goal attainment. That is the intervention.
89300007|NCT01316692|Experimental|MLN8237|Patients receive oral Aurora A kinase inhibitor MLN8237 every 12 hours on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89300008|NCT05536102|Experimental|Experiment group|Pegylated Liposomal Doxorubicin + Oxaliplatin + Capecitabine + Tislelizumab; reapt every 21 days.
89300009|NCT03626584||Cardiac Amyloidosis Patients|Patients with established diagnosis of cardiac amyloidosis.
89300010|NCT03626584||Healthy Volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
89300011|NCT05524714|Experimental|solubilized Xanthohumol low dose|single dose of 86 mg micellar solubilized Xanthohumol
89300012|NCT05524714|Experimental|solubilized Xanthohumol high dose|single dose of 172 mg micellar solubilized Xanthohumol
89300013|NCT05524714|Active Comparator|native Xanthohumol low dose|single dose of 86 mg native Xanthohumol
89300014|NCT05524714|Active Comparator|native Xanthohumol high dose|single dose of 172 mg native Xanthohumol
89300015|NCT05692804||Group with Sevoflurane|The Sevoflurane used for maintenance of general anesthesia
89300016|NCT05692804||Group with Propofol|The Propofol (IV) used for maintenance of general anesthesia
89300017|NCT01316380|Experimental|tiotropium 5 mcg|once daily delivered via Respimat inhaler
89300018|NCT01316380|Experimental|tiotropium 2.5 mcg|once daily delivered via Respimat inhaler
89300019|NCT01316380|Placebo Comparator|placebo|once daily delivered via Respimat inhaler
89300020|NCT05692648|Experimental|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
89300021|NCT05692648|Experimental|Hourly position change group:|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
89300022|NCT05692648|Other|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation.
89300023|NCT05692570|Experimental|Single-sequence, 3-period|Period 1: single dose of PBI-200; Period 2: daily dosing of ritonavir with a single dose of PBI-200 co-administered once ritonavir steady state reached; Period 3: daily dosing of cobicistat with a single dose of PBI-200 co-administered once cobicistat steady state reached.
89300024|NCT05692414|Experimental|Preoperative carbohydrate loaded patients|
89300025|NCT05692414|No Intervention|Conventional fasting protocol|
89300026|NCT05692336|Experimental|vestibular training|balance training that focus on vestibular system stimulation like when the eyes are folded while standing on a balance board or walking on swinging boards
89300027|NCT05692336|Experimental|dual task training|The children received special balance training in the form of dual-task training performing balance activities as a basic task in conjunction with second task that includes upper limb activity using basketball and long rings shaft or cognitive task like telling a story during balance training .
89300028|NCT05692258|Experimental|Acupuncture therapy + basic therapy|"Acupuncture treatment-Selected acupoints: Dazhui (GV14) , Feishu(BL13), Dingchuan(EX-B1), Tiantu(CV22), Danzhong(RN17), Quchi(LI11), Kongzui(LU6), Neiguan(PC6), Yinlingquan(SP9), Fenglong(ST40), Qihai(cv6). Once a day for 10 consecutive times.~Western medicine treatment (basic treatment) : According to the Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial 10th Edition) issued by the General Office of the National Health Commission and the General Department of the National Administration of Traditional Chinese Medicine, patients are arranged to be quarantined in hospitals for treatment. Conventional Western medicine treatment includes supportive treatment, antiviral therapy, immunotherapy, anticoagulant therapy, antibiotic therapy, etc."
89300029|NCT05692258|Sham Comparator|sham acupuncture + basic therapy|sham acupuncture. Acupoint selection, body position, intervention time and course of treatment are the same as those in acupuncture treatment group. After acupoint disinfection, fixed pad is pasted on the acupoint, and 1.5 blunt needle will be used to Pierce directly through the sham instrument to fix pad to the skin surface without piercing the skin, and do not require Deqi. Western medicine treatment (basic treatment) is the same as the acupuncture group.
89300030|NCT05691946|Experimental|Kinesiology Taping Group|Kinesiology Taping Group
89300031|NCT05691946|Placebo Comparator|Placebo Control Group|Placebo Taping Group
89300032|NCT05691556||Children CP|Children with cerebral palsy with motor impairment of the upper limb(s), seen in consultation and included in a HABIT-ILE therapeutic program and/or botulinum toxin injections
89300033|NCT01316224||Moderate or severe plaque psoriasis|Participants with moderate or severe plaque psoriasis treated with adalimumab
89300034|NCT05688826|Experimental|Sugar load|Sugar dissolved in water will be ingested during 5 minutes
89300035|NCT03619720|Experimental|Participants|
89300036|NCT05679076||Fabry patients|Fabry patients
89300037|NCT05663554|Experimental|WW Intervention|Participants in the intervention arm will be contacted by a WW Coach and will receive a voucher code that provides 12 months of access to the WW program and instructions for redeeming the code. The program will include access to weekly Virtual Workshops and the WW App. WW is a widely available, commercial behavioral weight management program that encourages healthy habits in the areas of food, activity, mindset, and sleep, with topics specific to diabetes.
89300038|NCT05663554|Active Comparator|Usual Care|Patients in the Usual Care Arm will continue to receive routine medical care by their healthcare provider. In addition, at the baseline visit, participants in the Usual Care Arm will receive one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments, based on current recommendations of the American Diabetes Association
89300039|NCT05417308|Active Comparator|Arm I (topical minoxidil)|Patients apply minoxidil foam topically to affected areas of the scalp QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
89300040|NCT05417308|Experimental|Arm II (orally minoxidil)|Patients receive minoxidil PO QD for up to 12 months in the absence of disease progression or unacceptable toxicity.
89300041|NCT05606848|Active Comparator|Control product|Nutrition Emulsion (TPF-T) is a tumor-specific enteral nutrition therapy
89300042|NCT05606848|Experimental|Study prodcut|Foods for special medical purposes [FSMP] for patients with tumors
89300043|NCT05601856||Alzheimer's Patient|"patients with AD whose clinical dementia rating (CDR) is > 1 Age 65-90 with none of the criteria below:~Familial Alzheimer's Disease (AD)~Severe cardiovascular disease~Severe respiratory system disease~Severe liver disease~Severe kidney disease~Severe central nervous system diseases~Having a lifespan of fewer than 3 months~History of psychiatric illness~Major neurological diseases other than AD~Current use of corticosteroids, antibiotics, or bowel motility modification agents~Any history of Alcoholism or illicit drug dependence~Previous inclusion in this study~Difficulty with follow-up or poor compliance~Severe hearing impairment~Severe vision impairment"
89300044|NCT05601856||Spousal Caregiver to Alzheimer's Patient|"Spousal Caregiver to Alzheimer's Patient group, Age 65-90 with none of the criteria below:~Familial Alzheimer's Disease (AD)~Severe cardiovascular disease~Severe respiratory system disease~Severe liver disease~Severe kidney disease~Severe central nervous system diseases~Having a lifespan of fewer than 3 months~History of psychiatric illness~Major neurological diseases other than AD~Current use of corticosteroids, antibiotics, or bowel motility modification agents~Any history of Alcoholism or illicit drug dependence~Previous inclusion in this study~Difficulty with follow-up or poor compliance~Severe hearing impairment~Severe vision impairment"
89300045|NCT05601856||Healthy adult control|"Age-matched to Spousal Caregiver to Alzheimer's Patient group Age 65-90 with none of the criteria below:~Familial Alzheimer's Disease (AD)~Severe cardiovascular disease~Severe respiratory system disease~Severe liver disease~Severe kidney disease~Severe central nervous system diseases~Having a lifespan of fewer than 3 months~History of psychiatric illness~Major neurological diseases other than AD~Current use of corticosteroids, antibiotics, or bowel motility modification agents~Any history of Alcoholism or illicit drug dependence~Previous inclusion in this study~Difficulty with follow-up or poor compliance~Severe hearing impairment~Severe vision impairment"
89300046|NCT05578846|Experimental|Treatment sequence ABC|Participants will be administered Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions), Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) and Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
89300047|NCT05578846|Experimental|Treatment sequence ACB|Participants will be administered Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions), Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
89300048|NCT05578846|Experimental|Treatment sequence BAC|Participants will be administered Treatment B (single Dose A of ALXN2050 tablet under fasted conditions), Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
89300049|NCT05578846|Experimental|Treatment sequence BCA|Participants will be administered Treatment B (single Dose A of ALXN2050 tablet under fasted conditions), Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal) and Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
89300050|NCT05578846|Experimental|Treatment sequence CAB|Participants will be administered Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal), Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) and Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
89300051|NCT05578846|Experimental|Treatment sequence CBA|Participants will be administered Treatment C (single Dose A of ALXN2050 tablet with a high-fat meal), Treatment B (single Dose A of ALXN2050 tablet under fasted conditions) and Treatment A (3 X Dose B of ALXN2050 tablet under fasted conditions) on Day 1 of each treatment period. Washout period of at least 4 days between the ALXN2050 dose in each treatment period.
89300052|NCT03619642|Other|persons with Multiple Sclerosis (MS)|25 persons with MS Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
89300053|NCT03619642|Other|stroke patients|25 stroke patients Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
89300054|NCT03619642|Other|healthy controls|50 healthy controls Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
89300055|NCT05393362|Experimental|Cardiac Rehabilitation Program (CR)|The CR program will consist of aerobic exercise sessions and strength exercise sessions. The exercises will be individualized after assessing short effort capacities (strength exercise) and long efforts (aerobic exercise). It will be done four days a week, with a minimum of 48 hours between sessions of the same type of exercise. To make progress will be taking a clinical criterion into account, determined by the absence of symptoms derived from HF at the current intensity, and a temporary criterion where provided that the clinical criterion is met, the intensity will be increased every two-three weeks.
89300056|NCT05393362|Active Comparator|Control Group (CG)|The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
89300057|NCT04315298|Experimental|Sarilumab 200mg IV (P2)|Phase 2
89300058|NCT04315298|Experimental|Sarilumab 200mg IV (P3:C1)|Phase 3: Cohort 1
89300059|NCT04315298|Experimental|Sarilumab 400mg IV (P2)|Phase 2
89300060|NCT04315298|Experimental|Sarilumab 400mg IV (P3:C1)|Phase 3: Cohort 1
89300061|NCT04315298|Experimental|Sarilumab 800mg IV (P3:C2)|Phase 3: Cohort 2
89300062|NCT04315298|Experimental|Sarilumab 800mg IV (P3: C3)|Phase 3: Cohort 3
89300063|NCT04650542|Experimental|HBI-3000 alone (Period 1) followed by HBI-3000 with Paroxetine (Period 2)|"HBI-3000: 350 mg, 50 mL intravenous infusion (IV) over 30 minutes on Day 1 of Period 1 and approximately 15 days later on Day 1 of Period 2~Paroxetine: 20 mg dose twice a day on Days 1 and 2 of Period 2, and once a day on Days 3 through 7 inclusive of Period 2"
89300064|NCT03747224|Experimental|ARO-ANG3|
89300065|NCT03747224|Placebo Comparator|Placebo|
89300066|NCT04621058|Experimental|D VITAMIN GROUP|"The administration of vitamin D will be carried out using the following treatment scheme:~If vitamin D deficiency (< 30 ng/ml) treatment with 2 capsules of 0.266 mg If vitamin D deficiency (< 40 ng/ml): treatment with 1 capsule of 0.266 mg~Blood levels of vitamin D will be determined on day 1, 4, 7 and 14. Based on the results from day 14, a new determination is recommended 4 weeks after starting treatment with the primary care physician who will decide whether to continue or interrupt the treatment. This phase will be carried out outside of the study.~In addition, the product should only be administered, if blood calcium and phosphorus levels are within normal limits, as well as if the creatinuria/calciuria ratio is within normal ranges."
89300067|NCT04621058|Placebo Comparator|PLACEBO GROUP|The procedure will be the same as in the experimental group but instead of the active component, patients will take placebo capsules exactly the same as above but without the active component.
89300068|NCT04308668|Experimental|Treatment|Participants in this arm will receive the study drug.
89300069|NCT04308668|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
89300070|NCT01562600||Nexium|
89300071|NCT04451330|Experimental|Trifarotene Cream + Doxycycline|Participants were applied with Trifarotene (CD5789) 50 micrograms per gram (mcg/g) cream topically on the face once daily in the evening for 12 weeks and received doxycycline 120 milligrams (mg) tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.
89300072|NCT04451330|Placebo Comparator|Trifarotene Vehicle + Doxycycline Placebo|Participants were applied with vehicle CD5789 topically on the face once daily in the evening for 12 weeks and received doxycycline matching placebo tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.
89300073|NCT02493426|Placebo Comparator|Placebo|Saline Nasal spray designed to look and feel like the drug intervention
89300074|NCT02493426|Experimental|Intranasal Oxytocin|Oxytocin nasal spray designed to look as seem exactly like Placebo
89300075|NCT03747068||anti-TNF|UC patients treated with maintenance anti-TNF therapy who underwent IPAA surgery
89300076|NCT03747068||CONTROL GROUP|UC patients who were not exposed to anti-TNF therapy
89300077|NCT03758898|Experimental|Treatment|Chest physiotherapy and mobilisation were applied on the patients for 4 days. The treatment of the patients was started on the first postoperative day and continued until the postoperative 4th day.
89300078|NCT03758898|Placebo Comparator|Group 2|only mobilisation was applied to the patients in the second group
89300079|NCT03758352|Experimental|intervention group (rIC)|The rIC procedure will be applied on seated patients, who have been resting for at least five minutes. The active rIC procedure consists of four five-minute inflations of a pneumatic tourniquet to 100 mmHg above the patient's systolic blood pressure separated by five-minute periods of complete deflation. Placement of the pneumatic tourniquet will be unilaterally on a lower limb (right thigh)
89300080|NCT03758352|Other|control group (non-rIC)|The control group will be a retrospective group, who have undergone a liver transplantation and meet the inclusion criteria.
89300081|NCT03756636|Other|"Underwater mucosectomy"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
89300082|NCT03756558|Experimental|Cross-Seal System|The Cross-Seal System will be used in all subjects enrolled in the study
89300083|NCT01321866|Experimental|Experimental arm|Patients in this arm will have angioplasty of a fistula stenosis using a cutting balloon
89300084|NCT01321866|Active Comparator|Standard arm|Patients in this arm will have angioplasty of a fistula stenosis using a non-cutting balloon.
89300085|NCT03763812|Other|Endovascular Aneurysm Repair (EVAR)|Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.
89300086|NCT03763812|Other|Endovascular Aneurysm Sealing (EVAS)|Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.
89300087|NCT04448756|Experimental|M5049 50 mg|
89300088|NCT04448756|Experimental|M5049 100 mg|
89300089|NCT04448756|Placebo Comparator|Placebo|
89300090|NCT03763734|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
89300091|NCT03763734|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
89300092|NCT05053932||Patients included in Drepagreffe 1 study (NCT01340404)|biological collection
89300093|NCT03763500|No Intervention|Care as usual|"Regular care at participating hospitals:~Extended written information and education of patients with atrial fibrillation."
89300094|NCT03763500|Active Comparator|Internet-based education|Patients randomized in this arm receive an Internet-based educational program in addition to extended written information. This includes 6 steps with detailed information on background, symptoms, investigations, treatment options, life-style as well as one part with guides to self management.
89300095|NCT03749486|Experimental|ArcScan|High resolution immersion ultrasound measurement before Cataract surgery
89300096|NCT04274192|Experimental|Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with synchronized)|Subjects will first receive HFNC synchronized to his/her own efforts via NAVA at 6 LPM followed by continuous HFNC at 6 LPM and then HFNC synchronized to his/her own efforts via NAVA at 8 LPM followed by continuous HFNC at 8 LPM
89300097|NCT04274192|Active Comparator|Alternating between Synchronized and Continuous HFNC at 6 and 8 LPM (starting with continuous)|Subjects will first receive continuous HFNC at 6 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 6 LPM. Next, subjects will receive continuous HFNC at 8 LPM followed by HFNC synchronized to his/her own efforts via NAVA at 8 LPM.
89300098|NCT03753594||H group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.5% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests at 5 min were assessed before the block and at 5-min intervals till 30 min after the block.
89300099|NCT03753594||L group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.25% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests were assessed at 5 min before the block and at 5-min intervals till 30 min after the block.
89300100|NCT03756324|Experimental|CHPM (Chinese Herbal Patent Medicine )|"CHPM (Chinese Herbal Patent Medicine ): Pugongying (Herba Taraxaci) Granules, 15g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
89300101|NCT03756324|Experimental|CHPM & Antibiotics Cefdinir Capsules|"CHPM (Chinese Herbal Patent Medicine): Pugongying (Herba Taraxaci) granules, 15g/tid for 3 days, follow-up for 7 days.~Antibiotics: Cefdinir Capsules, 0.1g/tid for 2 days, follow-up for 7 days.~Education, basic medical order."
89300102|NCT03756324|Active Comparator|Antibiotics Cefdinir Capsules|"Antibiotics: Cefdinir Capsules, 0.1g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
89300103|NCT03751202|Experimental|Test product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89300104|NCT03751202|Active Comparator|Reference product|ADVAIR DISKUS® 500/50
89300105|NCT03749408|Active Comparator|bupivacaine plus mannitol|0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol
89300106|NCT03749408|Experimental|bupivacaine alone|0.5% bupivacaine with 1:200,000epinephrine alone
89300107|NCT04387136|Experimental|Sublingual Sufentanil|Participants in this arm will receive the intervention.
89300108|NCT04387136|No Intervention|Control|Participants in this arm will not receive an intervention.
89300109|NCT04252586|Experimental|GWP42003-P|100 milligrams per milliliter (mg/mL) GWP42003-P oral solution, taken twice daily (morning and evening).
89300110|NCT03753516|Active Comparator|Laparoscopic - Vaginal Cuff Closure|
89300111|NCT03753516|Active Comparator|Vaginal - Vaginal Cuff Closure|
89300112|NCT04985370|Experimental|Pain neuroscience education plus exercise|Three sessions of pain neuroscience education plus exercise.
89300113|NCT04985370|Active Comparator|Exercise alone|Exercise alone without pain neuroscience education.
89300114|NCT04247828|Experimental|Experimental and Generic Communication Interfaces for AAC|Receives both Experimental and Generic AAC systems to communicate. Each participant will receive both devices, with Experimental AAC presented first (Day 1) and Generic AAC presented second (Day 2; reference).
89300115|NCT04507776||Patients with spondyloarthropathies|Patients with spondyloarthrosis that received Etanercept as treatment for disease
89300116|NCT04386902||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
89300117|NCT04357262|No Intervention|Control|No other non-standard of care activities will be performed
89300118|NCT04357262|Experimental|Intervention|Will be signed up for the automated text messaging program (StreaMD)
89300119|NCT04232540|Experimental|Patient participants|Patient and provider will view and discuss results of the MedViewer test.
89300120|NCT04232540|Experimental|Provider participants|Patient and provider will view and discuss results of the MedViewer test.
89300121|NCT04504032|Experimental|Rivaroxaban|
89300122|NCT04504032|Placebo Comparator|Placebo|
89300123|NCT03746834|Experimental|Treatment arm|Patients are given NASHA/Dx as a perianal injection
89300124|NCT03756246|Experimental|Depression Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
89300125|NCT03756246|Active Comparator|Healthy Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
89300126|NCT03758196|Experimental|Renal sympathetic denervation from the adventitia|Renal sympathetic denervation from the adventitia of renal artery and optimized medication regimen
89300127|NCT03758196|No Intervention|optimized medication regimen|optimized medication regimen
89300128|NCT04439240|Experimental|Treatment (AZD4547)|Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89300129|NCT05460858|Experimental|N-acetyl cystein|Seventy participants who randomly assigned in the intervention group, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction, will be received 1200 (2×600) mg of effervescent tablets of NAC daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles. Also, we will measure severity of dysmenorea by visual analogue scale (VAS) technique.
89300130|NCT05460858|Placebo Comparator|effervescent placebo|Seventy participants who randomly assigned to the control group, during 6 weeks simultaneous to start the standard long agonist protocol, or antagonist induction, will be received 1200 (2×600) mg of effervescent placebo tablets daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval, in addition to, follicular fluid will be obtained from the mature follicles. Also, we measure severity of dysmenorrhea by visual analogue scale (VAS) technique.
89300131|NCT04660032|Experimental|Nudge|Obstetric care providers will receive electronic prompts (nudge) for participants in this arm
89300132|NCT04660032|No Intervention|Usual care|Usual postpartum follow-up with visit at 4-12 weeks postpartum
89300133|NCT03753438||Intragastric Balloon|Intragastric Balloon will be placed for 6 months
89300134|NCT05359224|Active Comparator|Clopidogrel|Using a randomization program, the test group (203 patients; Aspirin 100 mg + Prasugrel 5 mg) and control group (203 patients; Aspirin 100 mg + Clopidogrel 75 mg) are classified. Prescribe the above drugs according to the assigned group, and take them 5 days before the procedure.
89300135|NCT05359224|Active Comparator|prasugrel|Using a randomization program, the test group (203 patients; Aspirin 100 mg + Prasugrel 5 mg) and control group (203 patients; Aspirin 100 mg + Clopidogrel 75 mg) are classified. Prescribe the above drugs according to the assigned group, and take them 5 days before the procedure.
89300136|NCT03753282||Population 1|Patients with a first AVN-related contact (initial or confirmed diagnosis) at the Universitätsspital Basel (USB) or Kantonsspital Basel-Liestal (KSBL) in the years between 1999-2006 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
89300137|NCT03753282||Population 2|Patients with a THA because of AVN in the years 2000-2007 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
89300138|NCT04919928|Experimental|Bimodal solution with cochlear implant and hearing aid (CI+HA)|"This Arm will serve as the intervention group. Patients referred for evaluation of cochlear implant candidacy at Odense University Hospital will be screened for eligibility in this study and invited to participate. All patients receive new replacement HAs that can later be fitted with the CI in a bimodal solution. The patients will use the new replacement HAs for one month and are then randomized to either the intervention group with CI+HA or to the control group with continuous use of HA+HA (bilateral) for another two months. Patients randomized to the intervention group CI+HA will undergo surgery as soon as possible after randomization.~Patients with the bimodal solution CI+HA will undergo follow-up one, three, six and twelve months after CI fitting."
89300139|NCT04919928|Experimental|Bilateral new replacement Hearing Aids (HA+HA)|This Arm will serve as the control group. The patients in the control group will use the new replacement HAs for one month like the intervention group and then for another three months, if they complete the study. The control group using the new replacement HAs for three months after randomization, will be offered the bimodal solution with CI to the poorer hearing ear and have the same follow-up period as the intervention group after a total of four months with new replacement HAs.
89300140|NCT03756090|Experimental|Experimental group|Arm I: Palbociclib combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
89300141|NCT03756090|Placebo Comparator|Control group|Arm II: Placebo combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
89300142|NCT03753126|Other|Cardiac CT imaging|
89300143|NCT03753048|Active Comparator|Y-Graft|The group includes patients who underwent CABG in Y-Graft Configuration.
89300144|NCT03753048|Active Comparator|In-Situ|The group includes patients who underwent CABG in In-Situ Configuration.
89300145|NCT04605588|Active Comparator|Active Study Drug|5 day dosing of Nitazoxanide, Ribavirin & Hydroxychloroquine sulfate
89300146|NCT04605588|Placebo Comparator|Placebo|5 day dosing of placebo
89300147|NCT04885296|Experimental|Test/Control|Eligible subjects will be randomized into one of two possible lens wear sequences, Test/Control.
89300148|NCT04885296|Experimental|Control/Test|Eligible subjects will be randomized into one of two possible lens wear sequences, Control/Test.
89300149|NCT04602000|Experimental|CT-P59 40 mg/kg group (Part 1)|CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
89300150|NCT04602000|Experimental|CT-P59 80 mg/kg group (Part 1)|CT-P59 (regdanvimab), 80 mg/kg by IV infusion once
89300151|NCT04602000|Placebo Comparator|Placebo group (Part 1)|Placebo, matching in volume of CT-P59 80 mg/kg by IV infusion once
89300152|NCT04602000|Experimental|CT-P59 40 mg/kg group (Part 2)|CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
89300153|NCT04602000|Placebo Comparator|Placebo group (Part 2)|Placebo, matching in volume of CT-P59 40 mg/kg by IV infusion once
89300154|NCT05053230|Experimental|IM@Home|Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, or breast cancer
89300155|NCT05053230|Placebo Comparator|Enhanced usual care|Participants with head and neck tumors, thoracic tumors, gynecological tumors, melanoma, or breast cancer
89300156|NCT05361018|Experimental|Whole Body Vibration exercise - WBV|The vibration exercises take place on a tri-planar vibration platform (Power Plate) according to the initially determined setting for each individual (highest, though feasible neuromuscular response). . Each session lasts for about 15-30 min in total, leaving sufficient time for regeneration. Training consists of at least four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions and adherence are documented by the exercise supervisor. Adverse events are documented, and patients asked to give feedback regarding the feasibility and subjective impression of each individual setting. All training sessions will be supervised. The participants rating of perceived exertion (RPE) will be assessed immediately after each set of exercise.
89300157|NCT05361018|Active Comparator|Conventional Aerobic and Resistance exercise - CAR|exercise sessions commence with 20 min of moderate intensity continuous aerobic exercise at a rating of perceived exertion (RPE) of 13-15 on the Borg scale. Participants complete both resistance exercises and high intensity intermittent aerobic exercises during each session. The resistance training regimen consists of 8 exercises (leg press, biceps curls, triceps extensions, bench press, shoulder press, standing row, sit ups/Russian weighted abdominal twist, and prone lying back extensions. Participants complete 2 sets of 8-12 repetitions at an initial intensity of 70 % of their estimated 1 repetition maximum (1-RM) strength and increase to 80 % of estimated 1-RM when more than 12 repetitions can be correctly performed by the participant
89300158|NCT03757962|Experimental|Dietary intervention|
89300159|NCT03752736|Active Comparator|Extended intervention|"Upon completion of the two-week baseline period and two-week standard intervention period, the two classrooms assigned to the Extended intervention condition will receive the I wear sunscreen everyday song-based video intervention daily for two additional weeks."
89300160|NCT03752736|No Intervention|Maintenance|"The two classrooms assigned to the Maintenance condition will continue to receive a two- minute window for sunscreen application, but no I wear sunscreen everyday song-based video instruction.~Change trajectories from Time 3-Time 4 (two-week follow up) will be compared by follow-up assignment condition and will provide preliminary information about dosing and maintenance effects."
89300161|NCT03041116|Experimental|Fosmetpantotenate|Administered as powder for reconstitution.
89300162|NCT03041116|Placebo Comparator|Placebo|Administered as powder for reconstitution.
89300163|NCT04860258|Experimental|CVnCoV Vaccine|Participants will be vaccinated with CVnCoV 12 µg mRNA on Day 1 and Day 29.
89300164|NCT03752658||Tenofovir alafenamide (TAF)|Male or female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with anti-HBV agents.
89300165|NCT03752580|Experimental|Arm|Experimental: User Instructions of a Novel Nasal Mask Participants to interpret user instructions in a one hour daytime visit.
89300166|NCT03041038|Experimental|Secukinumab|Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
89300167|NCT03041038|Placebo Comparator|Placebo|Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
89300168|NCT05460546|Experimental|Jincaopian Tablets high-dose group|Patients receive high dose Jincaopian Tablets 0.6g/day for 12 weeks.
89300169|NCT05460546|Experimental|Jincaopian Tablets low-dose group|Patients receive low dose Jincaopian Tablets 0.3g/day for 12 weeks.
89300170|NCT05460546|Placebo Comparator|Placebo group|Patients receive a matching placebo for 12 weeks.
89300171|NCT04382066|Experimental|Experimental 1|Plitidepsin 1.5 mg / day x 3 consecutive days
89300172|NCT04382066|Experimental|Experimental 2|Plitidepsin 2.0 mg / day x 3 consecutive days
89300173|NCT04382066|Experimental|Experimental 3|Plitidepsin 2.5 mg / day x 3 consecutive days
89300174|NCT03757884|Experimental|Virtual Pod|Mindfulness breathing, privacy screen, noise cancelling headphones, diagnostic checklist, diagnostic support on-line application
89300175|NCT03752502|Experimental|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
89300176|NCT03752502|Experimental|Combined stimulation|"Active transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
89300177|NCT03752502|Sham Comparator|Sham cerebral stimulation|"Sham transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes (30s ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
89300178|NCT03752502|Experimental|Peripheral stimulation|"Active peripheral electrical stimulation (PES).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
89300179|NCT03757728|Other|open haemorrhoidectomy|Open haemorrhoidectomy is performed using an anal retractor, exposed haemorrhoids at 3 - 7- 11 hours are excised using cautery. The arteries are ligated or cauterized. Open or closed technique is used (the choice of the surgeon). The Spongostan plug is then introduced
89300180|NCT03757728|Other|Haemorrhodal pedicle ligation|Haemorrhodal pedicle ligation is performed using operating proctoscope. The pedicle of symptomatic haemorrhoid is suture ligated with absorbable Vycril 2/0. Mucopexy is performed simultaneously if the prolapse is noticed. No tissue removal is performed
89300181|NCT03757728|Other|Intrahaemoroidal laser coagulation|Intrahaemoroidal laser coagulation is performed using disposable THD kit [Biolitec Co]. The haemorrhoidal pedicle is sutured. 1mm opening is created at the external haemorrhoid (skin level). Laser is then introduced up to pedicle and coagulation performed. This is repeated to all the piles. The procedure is finished with placing Spongostan plug into anal canal
89300182|NCT03752424|Active Comparator|Silver nanoparticles group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Topical silver nanoparticles in different dosage forms.
89300183|NCT03752424|Placebo Comparator|Topical approved anti-microbial gel|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo cream.
89300184|NCT03755778|Experimental|EDP-938 and itraconazole interaction (Part 1)|
89300185|NCT03755778|Experimental|EDP-938 and rifampin interaction (Part 2)|
89300186|NCT03755778|Experimental|EDP-938 and quinidine interaction (Part 3)|
89300187|NCT05266378|Experimental|Block group|The group undergoing PECs block
89300188|NCT05266378|Placebo Comparator|Control group|The group not receiving PECs block
89300189|NCT04435184|Experimental|Crizanlizumab|Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
89300190|NCT04435184|Active Comparator|Placebo Saline|0.9% saline 100 ml IV once.
89300191|NCT03755700|Placebo Comparator|Placebo|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with the placebos of both vitamin E and NAC (i.e. the placebo of vitamin E as a soft gel capsule and the placebo of NAC as an effervescent tablets along with a glass of water with the same consumption order used in the groups 2 and 3, respectively).
89300192|NCT03755700|Active Comparator|Vitamin E|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention plus the placebo of NAC with a consumption order similar to group 3.
89300193|NCT03755700|Active Comparator|NAC|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention plus the placebo of vitamin E with the consumption order similar to group 2.
89300194|NCT03755622|Active Comparator|Group C (Conventional)|Group C consists of patients who receive Transplatal Arch (TPA) fabricated from conventionally made stone working model.
89300195|NCT03755622|Experimental|Group 3D ( Three Dimensional)|Group 3D consists of patients who receive Transpalatal Arch (TPA) made from 3D recontructed model.
89300196|NCT03619486|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
89300197|NCT03619486|Experimental|Low energy shock wave|Low energy shock wave treatment (shock wave probe w/ energy)
89300198|NCT03757650|Active Comparator|HP eradication therapy positive-HP positive|who has HP positive endoscopic biopsy will take HP eradication therapy one month before the surgery
89300199|NCT03757650|Active Comparator|HP eradication therapy negative-HP positive|who has HP positive endoscopic biopsy and will not take any medication about HP
89300200|NCT03757650|No Intervention|HP negative-Control group|who has HP negative endoscopic biopsy and will not take any medication. (control group)
89300201|NCT03752346|No Intervention|control group|Control group maintained their regular lifestyle and received the routine care
89300202|NCT03752346|Experimental|exercise group|Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home. Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
89300203|NCT03751046|Experimental|Intervention group. Trial-Based Cognitive Therapy|Participants with therapeutic failure. Fourteen sessions of psychotherapy in group format, using Trial-Based Cognitive Therapy. Frequency: Bi-weekly meetings for seven months. Intervention arm comprises 10 psychotherapy groups with five participants in each group.
89300204|NCT03751046|Experimental|Control group. Standard healthcare.|Participants with therapeutic failure, receiving standard healthcare in the HIV/AIDS Program, which includes at least half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each). The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV.
89300205|NCT03693404|Experimental|Spinal Anesthesia|Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
89300206|NCT03693404|Active Comparator|General Anesthesia|The control group will receive no injection into area surrounding the fracture site
89300207|NCT03746678||C-Care Mobile Application|
89300208|NCT03696108|Experimental|Gefapixant 15 mg BID|Participants will receive gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg twice daily (BID) during the study period (52 weeks).
89300209|NCT03696108|Experimental|Gefapixant 45 mg BID|Participants will receive gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the study period (52 weeks).
89300210|NCT04219358|Active Comparator|Placebo & Standard Treatment|
89300211|NCT04219358|Experimental|Imiquimod 5% & Standard Treatment|
89300212|NCT04219358|Experimental|Imiquimod 0.05% & Standard Treatment|
89300213|NCT04219358|Experimental|Imiquimod nanoencapsulated 0.05% & Standard Treatment|
89300214|NCT03757572|Experimental|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Alginate dressings with silver and high-G cellulose, which combine increased absorption properties, antimicrobial action and high coherence will be used. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials for latent breathing of the skin with dressing dimensions based on the wound size, will be also placed.~Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
89300215|NCT03757572|Active Comparator|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Wound care will be performed with the application of simple gauze dressings. Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
89300216|NCT04218110|Experimental|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
89300217|NCT04218110|Experimental|Project X 10.5ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
89300218|NCT04218110|Experimental|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
89300219|NCT04218110|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.
89300220|NCT03752268|No Intervention|Enhancing Cancer Pain Management Part 1|"Will collect information from participants via self-report assessment at two time points: at baseline (i.e. study enrollment) and approximately 8 weeks post-baseline~Will then use MEMS to monitor LA opioid intake over approximately 8 weeks~A subset of enrolled participants (n=20) will be invited to participate in an optional one-time qualitative exit interview with a study staff member trained in conducting qualitative interviews"
89300221|NCT03752268|Experimental|Enhancing Cancer Pain Management Part 2|"Enhancing Cancer Pain Management will consist of 3 individual manualized sessions~The 3 individual manualized sessions will be conducted (approximately 20 minutes each), led by a nurse practitioner, to provide sufficient dose for change in adherence behaviors.~Learning and practicing skills for managing cancer-related pain and adhering to prescribed LA opioid regimens.~Study staff will provide participants with MEMS caps and bottles at time of enrollment, to monitor LA opioid intake over approximately 14 weeks."
89300222|NCT03752190|Experimental|Intravenous and intramuscular administration|Subjects will receive intravenous and intramuscular ACTH on different days
89300223|NCT04214600|Experimental|Cognitive Behavioral Therapy|This group will receive four CBT sessions twice a month for two months
89300224|NCT04214600|No Intervention|Control|This group will be scheduled the same number of visits as a follow up for diabetes
89300225|NCT04210310|Experimental|high-dose intranasal oxytocin|Subjects will be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). Subjects will take 4 sprays daily of oxytocin for the entire study.
89300226|NCT04210310|Placebo Comparator|Nasal spray|Subjects swill be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). The spray can be taken with or without food. Subjects will take 4 sprays daily of the placebo for the entire study.
89300227|NCT03755466|Active Comparator|BARI|
89300228|NCT03755466|Active Comparator|Bio|
89300229|NCT03755466|Active Comparator|Tofa|
89300230|NCT04209530|Experimental|Buttock & Posterolateral Thigh|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
89300231|NCT04349098|Experimental|Selinexor 20 mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
89300232|NCT04349098|Placebo Comparator|Placebo|Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
89300233|NCT04208750|Experimental|R-Refraction|
89300234|NCT04208750|Active Comparator|S-Refraction|
89300235|NCT03755310|Experimental|Suvorexant|10mg tabs during the first week, 10-20 mg tabs on the second week.
89300236|NCT03755310|Placebo Comparator|Placebo|Equivalent dosage, route of administration and dose regimen.
89300237|NCT03755232|Experimental|scFOS treatment #1|Phase 1: 10g of scFOS Phase 2: 50g dextrose +15g scFOS Phase 3: 50g avCHO from white bread +15g scFOS
89300238|NCT03755232|Experimental|scFOS treatment #2|Phase 1: n/a Phase 2: 35g Dextrose +15g scFOS Phase 3: 35g avCHO from white bread +15g scFOS
89300239|NCT03755232|Active Comparator|Control #1|Phase 1: Water control (negative control) Phase 2: 35g Dextrose control 1 Phase 3: 35g avCHO from white bread (control 1)
89300240|NCT03755232|Active Comparator|Control #2|Phase 1: 10g Dextrose (positive control) Phase 2: 50g Dextrose control 2 Phase 3: 50g avCHO from white bread (control 2)
89300241|NCT04381988|Experimental|Hydroxychloroquine|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of hydroxychloroquine 400mg daily.
89300242|NCT04381988|Placebo Comparator|Placebo|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of placebo 400mg daily.
89300243|NCT04333498|Experimental|Receiving Feedback From DBS|This arm of participants will receive monthly feedback from medical providers on their adherence measured through DBS.
89300244|NCT03355664|Active Comparator|ACT|Artemether-lumefantrine for 3 days plus primaquine at hour 24
89300245|NCT03355664|Experimental|TACT|Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24
89300246|NCT03668392|Experimental|Patients on Oncospar|
89300247|NCT04216576|Active Comparator|Standard of Care|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care
89300248|NCT04216576|Experimental|Standard of Care + Intervention|Participants will have a diagnosis of breast cancer and will be taking Palbociclib. Participants will receive standard of care + unidirectional text messaging intervention
89300249|NCT04170686|Experimental|Immediate Treatment|Participants will have immediate access to the self-help app. They will take 8 weeks to work through the content at their own pace.
89300250|NCT04170686|No Intervention|Waitlist Control|"Participants in the waitlist will receive no intervention for 8 weeks, other than a few check in emails from study personnel. At the end of 8 weeks, they will be crossed over to the active treatment group and will be given access to the app."
89300251|NCT03661372|Active Comparator|Face-to-Face|Face-to-Face Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A face-to- face standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
89300252|NCT03661372|Active Comparator|Robot|Robot Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A robot (telesimulated) standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room via a robot to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
89300253|NCT05668832|Experimental|oral intake of UVB-exposed mushrooms|Daily intake of 500 g of UVB-exposed button mushrooms over 7 days (provided as mushroom cream soup) and blood sampling (at baseline, 3 h postprandial, 6 h postprandial and at day 8)
89300254|NCT05668832|Placebo Comparator|oral intake of non-UVB-exposed mushrooms|Daily intake of 500 g of non-UVB-exposed button mushrooms over 7 days (provided as mushroom cream soup) and blood sampling (at baseline, 3 h postprandial, 6 h postprandial and at day 8)
89300255|NCT03695094|Experimental|Cohort 1|Cohort 1 (Inducers): Study participants on stable therapy with oxcarbazepine (OXC) either as monotherapy or adjunctive to levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). OXC may be used as monotherapy or in combination with 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) will be dosed to steady state and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
89300256|NCT03695094|Experimental|Cohort 2|Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
89300257|NCT04101526|No Intervention|Pre-Intervention Qualitative Interviews|Qualitative interviews will be conducted with breast cancer survivors, survivors' caregivers, cancer support group leaders and clinicians regarding sleep disturbance in breast cancer survivors and preferences for an intervention for sleep disturbance.
89300258|NCT04101526|Experimental|Videoconference Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I)|Behavioral: New Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference
89300259|NCT04101526|No Intervention|Waitlist control group|No intervention until 6 weeks after the baseline assessment, at which point participants complete a follow-up assessment and then are offered the new CBT-I intervention.
89300260|NCT04497948|Other|Single Arm|Single Arm
89300261|NCT04495374|Placebo Comparator|Group P(0) - Placebo|Patients were randomly allocated to Group P(0) - Placebo by a double blind randomized study. Group P(0) received two placebo tablets as medication, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
89300262|NCT04495374|Experimental|Group P(1) - Pregabalin 300mg|Patients were randomly allocated to Group P(1) - Pregabalin 300mg by a double blind randomized study. Group P(1) received two tablets of pregabalin 150mg, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
89300263|NCT04805008|Experimental|Intervention|Lactation cookies
89300264|NCT04805008|Placebo Comparator|Control|Control cookies
89300265|NCT03752112|Experimental|Cefixime|cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection.
89300266|NCT03752112|Other|Benzathine penicillin|To benchmark the performance of benzathine penicillin in the study population being used for cefixime, the investigators will include a contemporary arm of participants that will receive standard of care treatment with benzathine penicillin according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.
89300267|NCT04650646|Experimental|Hypoglycaemic clamp i combination with exercise|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with an exercise session. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
89300268|NCT04650646|Experimental|Hypoglycaemic clamp in combination with bed rest|A 180 minutes hyperinsulinaemic euglycaemic-hypoglycaemic clamp in combination with bed rest. The participants will be monitored with Holter-ECG throughout the entire clamp and plasma glucose will be measured every 5 minutes. Blood samples will be drawn and analysed for changes in electrolytes, counterregulatory hormones, coagulation status, inflammation, endothelial damage and oxidative stress.
89300269|NCT04800666|Experimental|Facial Nerve Block Group|Facial Nerve Block and oral Mecobalamin Tablets
89300270|NCT04800666|Experimental|Stellate Ganglion Block Group|Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets
89300271|NCT04800666|Experimental|D Group|Facial Nerve Block
89300272|NCT04800666|Other|C Group|control
89300273|NCT04794270|Experimental|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
89300274|NCT04794270|Experimental|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
89300275|NCT04567186|Experimental|Test/Control/Control|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Test/Control/Control).
89300276|NCT04567186|Experimental|Control/Test/Test|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Control/Test/Test).
89300277|NCT05460156|Experimental|NM Bridges|Receive NM Bridges supportive care from trained personnel
89300278|NCT04561102||COVID-19 asymptomatic population|COVID-19 asymptomatic Rollins College community
89300279|NCT03757494|Experimental|Use of Alpha Stim|Use of Alpha Stim Device
89300280|NCT03751956|Experimental|HSK3486|0.8 μCi/0.4 mg/kg of [14C]HSK3486 emulsion injection
89300281|NCT03757416||Flexor tenosynovectomy surgery|Adult patients who will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome and who have already undergone primary carpal tunnel release surgery.
89300282|NCT03751878|Experimental|Intervention arm|Evaluation of reporting inconsistencies between the CONSORT checklist and the information reported in the manuscript. Feedback is provided to authors.
89300283|NCT03751878|Other|Control arm|Standard peer review process.
89300284|NCT03757338|Active Comparator|Fingolimod Reference Formulation|0.5 mg Fingolimod capsule (manufactured by Novartis, Batch No. S0099), orally administered as a single dose of 3 x 0.5 mg capsules.
89300285|NCT03757338|Experimental|Fingolimod Test Formulation|0.5 mg Fingolimod capsule (manufactured by manufactured by Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), orally administered as a single dose of 3 x 0.5 mg capsules.
89300286|NCT03629548|Active Comparator|early amniotomy plus dinoprostone|10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
89300287|NCT03629548|Experimental|foley balloon catheter plus dinoprostone|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix
89300288|NCT03757260|Experimental|Treatment Group|Antimicrobial photodynamic therapy with methylene blue applied to test site after mechanical debridement.
89300289|NCT03757260|Placebo Comparator|Placebo Group|Photodynamic therapy laser is not activated with saline water in the test site after mechanical debridement.
89300290|NCT03754998|Experimental|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
89300291|NCT05761990|Experimental|POST ISOMTERIC RELAXATION TECHNIQUES|"Participants in Group A will instruct to perform the PIR techniques~These steps are taken when using the PIR approach:~Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~Starting with this new barrier, the procedure is carried out two or three more times."
89300292|NCT05761990|Experimental|NOVEL STRETCHING|"The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
89300293|NCT04483908||Cohort 1|"Disease survivors with a positive polymerase chain reaction (PCR) test > 12days (d) ago and no symptoms (~250 participants).~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
89300294|NCT04483908||Cohort 2|"Disease survivors with a positive PCR test 7 - 12d ago and no symptoms (~100 participants).~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
89300295|NCT04483908||Cohort 3|Subjects with PCR negative test > 5d (~100 participants). Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates.
89300296|NCT04483908||Cohort 4|"Anonymised blood sera from the Serumbank at the Kantonsspital Basel-Land (KSBL) taken during last years influenza period (~100 participants).~Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates."
88806272|NCT01222091|Active Comparator|Propranolol, Then Placebo|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
88806273|NCT01222091|Placebo Comparator|Placebo, Then Propranolol|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
88806274|NCT01225055|Experimental|Teriparatide|Teriparatide alone with sham vibration
88806275|NCT01225055|Experimental|Vibration|Vibration alone with placebo-teriparatide
89300297|NCT05761912||Ultrasound fusion targeted biopsy|Prostate ultrasound had abnormal echo and radiomics analysis showed high scores
89300298|NCT05761912||mpMRI cognitive fusion targeted biopsy|PI-RADS score ≥ 3
89300299|NCT04168190|Experimental|Phase 1: V116 0.5 mL|Participants will receive a single intramuscular (IM) 0.5 mL vaccination on Day 1 of Phase 1
89300300|NCT04168190|Experimental|Phase 1: V116 1.0 mL|Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 1
89300301|NCT04168190|Active Comparator|Phase 1: Pneumovax™23|Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 1
89300302|NCT04168190|Experimental|Phase 2: V116|Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 2
89300303|NCT04168190|Active Comparator|Phase 2: Pneumovax™23|Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 2
89300304|NCT01322724|Active Comparator|Warm water|Body temperature (95-100 degrees F) water
89300305|NCT01322724|Experimental|Cool water|Room temperature (68-73 degrees F) water
89300306|NCT03649672|Experimental|Awake calibration|The dominant arm of the patient
89300307|NCT03649672|Active Comparator|Asleep calibration|The non dominant arm of the patient
89300308|NCT05460000|Experimental|Arm A (3 cycles of chemotherapy + maintenance therapy with niraparib)|3 cycles carboplatin + paclitaxel maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
89300309|NCT05460000|Active Comparator|Arm B (6 cycles of chemotherapy + maintenance therapy with niraparib)|6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
89300310|NCT03754920|Experimental|prolonged fasting|Participants fast for five days, without any food, except unlimited mineral water, and do some fitness regimen(such as meditation and mild physical exercise ).
89300311|NCT05668962|Experimental|SELPERCATINIB + I-131|"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~Participants will be treated with Selpercatinib for 4 weeks.~In the fourth week of treatment, participants will receive a therapeutic dose of I-131.~Those participants in whom radioiodine uptake has been restored may be offered a second 4-week course of selpercatinib plus I-131 treatment"
89300312|NCT04732338|Experimental|Study arm - Osteopathic Manipulative Therapy|"Standard of care including physical therapy, occupational therapy and over the counter medication AND OMT as described below:~Musculoskeletal examination of the cervical spine. Testing will be comprised of :~Range of motion testing involving cervical rotation, lateral side bending, flexion and extension.~Muscular palpation of the cervical paraspinals for hypertonicity of the muscles and/or tenderness.~Patient placed supine on the examination table.~Treatment sessions lasting 5-10 minutes each. OMT techniques: cervical muscle energy, myofascial release of the cervical paraspinals and a suboccipital release.~Assessment with Headache Impact Test (HIT-6) at baseline and follow-up visit and change in pain scores between baseline and post treatment."
89300313|NCT04732338|No Intervention|Control - Standard of care|Standard of care including physical therapy, occupational therapy and over the counter medication.
89300314|NCT03754842|Placebo Comparator|Placebo|
89300315|NCT03754842|Experimental|Nicotinamide Riboside + Pterostilbene|
89300316|NCT04194008|Experimental|Nerivio device treatment|Treatment with active Nerivio device
89300317|NCT03463330|Experimental|Intervention Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
89300318|NCT03463330|Sham Comparator|Control Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
89300319|NCT03751644|Experimental|Electrical stimulation|After local antisepsis, 4 electrodes will be placed at the proximal and distal extremities of the lateral and vastus medialis muscles of dominant limb. A positive, single-phase pulsating (intermittent) current with a rectangular waveform will be delivered with a duty cycle of 10 to 15 seconds shutdown at a frequency of 60 Hertz with a pulse width of 400 microseconds for 30 minutes. To control the degree of muscle activation, electrical stimulation will be administered at an intensity that will consistently produce a target torque equal to 15% of maximal voluntary contraction, as monitored in real time through torque output. The desired intensity of stimulation and intensity adjustments throughout the treatment will be evaluated in all patients.
89300320|NCT03751644|No Intervention|Placebo|Patients will not submitted to electrical stimulation.
89300321|NCT01569802||screening|
89300322|NCT03751566|Active Comparator|Regimen A|Regimen A (control regimen): standard support treatment of adverse events of the radiotherapy.
89300323|NCT03751566|Experimental|Regimen B|Regimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.
89300324|NCT05761834||Partecipants with Fabry Desease (FD)|"For each patient, at the time of enrollment, a blood sample will be collected and plasma levels of markers of inflammation, oxidative stress and cardiac remodeling will be determined (C-reactive protein, interleukin [IL]-6, IL-1β, IL-2, soluble vascular cell adhesion molecule, tumor necrosis factor [TNF], TNF receptor 1 and 2, Myeloperoxidase, calprotectin, uric acid, asymmetric dimethyl arginine, symmetric dimethyl arginine, matrix metalloprotease [MMP]-2, MMP-8 and MMP-9, galectin-1, galectin-3, B-type natriuretic peptide, midregional pro-atrial natriuretic peptide, monocyte chemoattractant protein-1).~Serum proteomic analysis and transcriptomic analysis on peripheral blood mononuclear cells, investigating molecular mediators involved in inflammatory pathways will be also performed.~Patients enrolled will also undergo a comprehensive 2D-echocardiography with Doppler, Tissue Doppler (TD) and speckle tracking analysis and 12-leads electrocardiogram."
89523321|NCT03382613||Quality Improvement (QI) Program|Hospitals assigned to the QI program arm will begin the 4-month Preparatory Phase which is designed to introduce the institutional baseline reporting tools and materials related to performance improvement, and gain insight into their gaps in treatment, followed by 15 month Implementation Phase, which will consist of education, process, and engagement activities that are targeted at the hospital and healthcare provider level and then the Measurement Period at which time hospitals will complete a final survey to document specific interventions that were successfully implemented and perform a final retrospective chart review on selected patients.
89300325|NCT05761834||Partecipants with hypertrophic cardiomyopathy (HCM) systemic inflammation|"For each patient, at the time of enrollment, a blood sample will be collected and plasma levels of markers of inflammation, oxidative stress and cardiac remodeling will be determined (C-reactive protein, interleukin [IL]-6, IL-1β, IL-2, soluble vascular cell adhesion molecule, tumor necrosis factor [TNF], TNF receptor 1 and 2, Myeloperoxidase, calprotectin, uric acid, asymmetric dimethyl arginine, symmetric dimethyl arginine, matrix metalloprotease [MMP]-2, MMP-8 and MMP-9, galectin-1, galectin-3, B-type natriuretic peptide, midregional pro-atrial natriuretic peptide, monocyte chemoattractant protein-1). Serum proteomic analysis and transcriptomic analysis on peripheral blood mononuclear cells, investigating molecular mediators involved in inflammatory pathways will be also performed.~Patients enrolled will also undergo a comprehensive 2D-echocardiography with Doppler, Tissue Doppler (TD) and speckle tracking analysis and 12-leads electrocardiogram."
89300326|NCT03757104|Experimental|micro-incentives|micro-incentives only (8 communities)
89300327|NCT03757104|Experimental|EPIC-HIV|Empowered through informed choice for HIV [male sensitive HIV specific decision support app] (males only in 8 communities)
89300328|NCT03757104|Experimental|micro-incentive and EPIC-HIV|micro-incentives as well as EPIC [male sensitive HIV specific decision support app] (8 communities)
89300329|NCT03757104|No Intervention|control|standard of care
89300330|NCT01562210|Experimental|Olaparib, radiation +/- Cisplatin|Olaparib and radiotherapy with or without Cisplatin
89300331|NCT02341534|Other|BioMonitor arm|BioMonitor group (implantation with investigational device + transfer of information via Home Monitoring)
89300332|NCT02341534|No Intervention|Control arm|Control group (standard of care)
89300333|NCT04189952|Experimental|Acalabrutinib + R-ICE|Acalabrutinib in combination with rituximab, ifosfamide, carboplatin and etoposide (R-ICE). All participants will receive combination treatment for 3 cycles. Each cycle lasts 21 consecutive days. Combination treatment includes twice daily dose of Acalabrutinib, Rituximab on Day 1 of each cycle, Ifosfamide and Carboplatin on Day 2 of each cycle, and Etoposide on Days 1-3 of each cycle.
89300334|NCT04716426|Experimental|Tetracycline hydrochloride 3%|4 drops of tetracycline hydrochloride 3% (APT™ T3X) applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
89300335|NCT04716426|Placebo Comparator|Placebo|4 drops of placebo applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.
89300336|NCT02335606||Patients treating with Abatacept|Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept
89300337|NCT03694548|Other|Part A Survey: Group 1 Adolescent Patients with SCD|Adolescent patients with SCD and chronic pain completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
89300338|NCT03694548|Other|Part A Survey: Group 2 Parents of Adolescent Patients with SCD in Part A|Parents of adolescent patients with SCD and chronic pain from Group 1 completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
89300339|NCT03694548|Experimental|Part B Yoga Program|Participants from Part A Group 1 had the opportunity to enroll in Part B to receive eight in-person instructor-led group yoga sessions.
89300340|NCT01747096|Experimental|68-Ga-DOTANOC|
89300341|NCT04166630|Experimental|ICU Acquired Weakness Group|Participants with a score less than 48 on the Medical Research Council (MRC) Scale will be classified as having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
89300342|NCT04166630|Experimental|No ICU Acquired Weakness Group|Participants with a score of 48 or greater on the Medical Research Council (MRC) Scale will be classified as not having ICU acquired weakness. All participants will have their skeletal muscles tested with a clinical electrical stimulator.
89300343|NCT05234736|Experimental|CBL-514|All 10 participants enrolled in the study will receive a single course of treatment with CBL-514 800 mg (unit dose: 2.0 mg/cm^2) on the abdomen (administered as multiple subcutaneous injections) on Day 1 only.
89300344|NCT04164758|Experimental|Drug - pimavanserin|Pimavanserin 34 mg provided as 2 x 17 mg encapsulated tablets
89300345|NCT04164758|Placebo Comparator|Placebo|Placebo encapsulated tablet
89300346|NCT04164758|Active Comparator|Quetiapine|Immediate release Quetiapine encapsulated tablets
89300347|NCT03754686|Active Comparator|Oseltamivir|best medical care and oral oseltamivir 75 mg twice daily for five days.
89300348|NCT03754686|Active Comparator|Paracetamol|best medical care and oral paracetamol twice daily for five days.
89300349|NCT05200884|Active Comparator|: A (Lidocaine 2%)|"20 children will be injected with 1 ml of lidocaine 2% with epinephrine. each one received lidocaine2% at his\her ﬁrst or second visit.~Half of the total number of injections for 20 children i.e. 20 injections will be distributed randomly to the two drugs using the randomization table"
89300350|NCT05200884|Experimental|B (Articaine 4%)|"20 children will be injected with 1 ml of Articaine 4% with epinephrine. each one received articaine 4% at his\her ﬁrst or second visit.~Half of the total number of injections for 20 children i.e.20 injections will be distributed randomly to the two drugs using the randomization table"
89300351|NCT04178720|Experimental|LID018869|Lehfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
89300352|NCT04178720|Active Comparator|Biofinity|Comfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
88806276|NCT01225055|Experimental|Teriparatide and vibration|Teriparatide with vibration applied in conjuction
89300353|NCT03757026|Active Comparator|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
89300354|NCT03757026|Experimental|Slip training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine intervention sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
89300355|NCT03757026|Experimental|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
89300356|NCT03746444|Active Comparator|General Anesthesia|"The patients in this group will undergo unilateral total knee arthroplasty under general anesthesia. Following vascular access and monitorization (non-invasive blood pressure, saturation, electrocardiography).~Epidural chateterisation will be performed and test dose will be applied. Induction will be carried out using propofol (3mg/kg), fentanyl (1cmg/kg) and rocuronium (0.6 mg/kg). Maintenance will be carried out using sevoflurane (%2-3) and 50-50% mixture of nitrous oxide and oxygen. Epidural analgesia will be initiated after the end surgery."
89300357|NCT03746444|Active Comparator|Regional Anesthesia|The patients in this group will undergo unilateral total knee arthroplasty under combined spinoedpidural anesthesia . Following vascular access and monitorization (noninvasive blood pressure, oxygen saturation and electrocardiography), spinal anesthesia will be performed using 12,5 mg marcaine given to the subarachnoid space and epidural analgesia will be initiated at the end of surgery following negative test dose. The patients will be given nasal oxygen supplementation.
89300358|NCT03749096|Active Comparator|Intravenous immunoglobulin|IVIg dose will be 2g/kg ideal body weight every 4 weeks (in 2 divided doses on consecutive days) for 12 weeks (3 cycles total).
89300359|NCT03749096|Placebo Comparator|Placebo|
89300360|NCT03748940|Placebo Comparator|Part A: Placebo|Placebo administered subcutaneously (SC)
89300361|NCT03748940|Experimental|Part A: LY3074828|LY3074828 administered SC
89300362|NCT03748940|Placebo Comparator|Part B: Placebo|Placebo administered SC
89300363|NCT03748940|Experimental|Part B: LY3074828|LY3074828 administered SC
89300364|NCT03748940|Experimental|Part B: LY900021|LY900021 (LY3074828 + LY9999QS) administered SC
89300365|NCT04177862|Experimental|Sublingual Sufentanil|Single dose of sublingual sufentanil for acute pain.
89300366|NCT04177862|Active Comparator|IV Fentanyl|single dose of IV fentanyl for acute pain.
89300367|NCT03748862||Cases|"Patients who were receiving high-dose, long-term opioid therapy at study entry and achieved a sustained taper during the follow-up period.~A Taper Plan is a plan to reduce or discontinue use of opioids discussed with the primary care provider. Evidence of a taper plan is found in the prescription notes or medical encounter notes in the electronic health record."
89300368|NCT03748862||Controls|Patients who were receiving high-dose, long-term opioid therapy at study entry and didn't achieve a sustained taper during the follow-up period.
89300369|NCT04173572|Experimental|Walking Group|Participants will be walking two times a week in supervised virtual walking groups on a secure online platform (Zoom) and will also participate in independent walks done at a location of their own choosing outside group participation.
89300370|NCT04173572|Active Comparator|Fitbit Alone|Participants will be provided with a Fitbit wristband and instructed how to use it. Participants will also be given information on current recommended physical activity guidelines and told that study staff may be contacting them on a weekly basis if it looks like participants are not wearing their Fitbit for a certain number of days or to troubleshoot any issues.
89300371|NCT03746366|Experimental|Alcohol use disorders|[C-11]Pittsburgh Compound B (PiB) PET scan
89300372|NCT03746366|Experimental|Healthy controls|[C-11]Pittsburgh Compound B (PiB) PET scan
89300373|NCT04157738|Experimental|Fixed Group|Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.
89300374|NCT04157738|Active Comparator|Insulin to carbohydrate ratio (ICR) Group|Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen
89300375|NCT04156646|Experimental|Treatment sequence ABC|In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
89300376|NCT04156646|Experimental|Treatment sequence BAC|In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
88820680|NCT05795634|Other|Trier Social Stress Test|All participants in the study will get undergo the same stress procedure
89300377|NCT03751488|Experimental|LY03010 351mg|LY03010 at 351 mg
89300378|NCT03751488|Experimental|LY03010 156 mg|LY03010 at 156 mg
89300379|NCT03751488|Experimental|LY03010 117mg|LY03010 at 117mg
89300380|NCT03751488|Active Comparator|INVEGA SUSTENNA|INVEGA SUSTENNA 156mg
89300381|NCT01562288||Observational|Previously collected serum and DNA from peripheral blood mononuclear cell samples are analyzed for HER2-specific antibodies and FcγR genotype by ELISA and PCR.
89300382|NCT03746288|Experimental|Treatment Group|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
89300383|NCT03746288|Active Comparator|Control Group|The dose is 2.0 Gy/d, 5 times/week, with a total planned radiation dose of 36 Gy.
89300384|NCT05070702|Experimental|CT-1500 Active (SAD)|6 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of CT-1500 between 5 mg and 120 mg
89300385|NCT05070702|Placebo Comparator|Placebo (SAD)|2 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of matching placebo
89300386|NCT05070702|Experimental|CT-1500 Active (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of CT-1500 between 5 and 45 mg
89300387|NCT05070702|Placebo Comparator|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of matching placebo
89300388|NCT04150250|Experimental|iOWH032|On Day 1, participants were challenged with 10^6 colony-forming units (CFU) of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral iOWH032 500 mg tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
89300389|NCT04150250|Placebo Comparator|Placebo|On Day 1, participants were challenged with 10^6 CFU of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral matching iOWH032 placebo tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
89300390|NCT04537806|Placebo Comparator|Placebo|Participants receiving mechanical ventilation as standard of care were randomized to receive a 60-hour single continuous intravenous (IV) infusion of brexanolone-matching placebo.
89300391|NCT04537806|Experimental|Brexanolone|Participants receiving mechanical ventilation as standard of care were randomized to receive a 60-hour single continuous IV infusion of brexanolone at 70 micrograms per kilogram per hour (mcg/kg/h) for 58 hours followed by a 2-hour taper of brexanolone at 35 mcg/kg/h.
89300392|NCT03756948|Active Comparator|Usual Care (Before)|No Thromboelastometry No Synthetic Factor Concentrates Usual Care
89300393|NCT03756948|Experimental|Thromboelastometry-Guided Therapy (After)|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
89300394|NCT04015232|Experimental|INTP5 biosimilar product|INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
89300395|NCT04015232|Active Comparator|US Neulasta reference product|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
89300396|NCT04533204|Experimental|Mnemonic strategy training|Training using mnemonic strategies
89300397|NCT04533204|Active Comparator|Spaced retrieval training|Training using spaced retrieval
89300398|NCT03744884|Experimental|CP intervention group|Force efforts with haptic feedback in virtual reality for participants with CP.
89300399|NCT03744884|No Intervention|CP control group|Regular activity control group, for participants with CP.
89300400|NCT03744884|Experimental|TD intervention group|Force efforts haptic feedback in virtual reality. The intervention will be the same as the CP intervention group but for typically developing participants.
89300401|NCT03744884|No Intervention|TD control group|Regular activity control group, same as CP no intervention group, but for typically developing participants.
89300402|NCT04465422|Experimental|Intervention Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~The research at this stage is based on the theoretical framework of the MOHO model and the clinical practice of OTPF-3. Clinical experts are requested to assist in providing relevant suggestions as a reference for modifying intervention activities. Design OT@tcpc service model for occupational therapy intervention activities. The event design is based on the 4 systems of determinationl, habits, performance and environment, and 2 events are designed for each to be carried out in a group. Each activity includes 4 parts: warm-up, activity, feedback and homework. Each activity group will be explained separately so that the occupational therapist of the group can complete it under the guidance."
89300403|NCT04465422|Active Comparator|Control Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~This study was approved by the Institutional Review Board of Taipei City Hospital. After informed consent, the patients signed the consent form for this study and became the participant of this study.~Each activity group will be explained separately so that the participants of each group can complete it under the guidance. The group description includes: activity title, activity time (location), MOHO theory system, group purpose, activity content, equipment or materials, precautions, etc."
89300404|NCT01322802|Experimental|Treatment (pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine)|Patients receive pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine ID monthly for 3 months.
89300405|NCT04676256|Experimental|Early Vitrectomy|Experimental arm will be treated with early vitrectomy early vitrectomy 7 days after vitreous hemorrhage diagnosis
89300406|NCT04676256|Active Comparator|Comparator|"Active comparator arm will have fundus and ultrasound observation. Late vitrectomy may be indicated after 3 months of follow-up if needed.~Late vitrectomy will be performed in case of persistant vitreous hemorrhage after 3 months of folllow-up"
89300407|NCT04014062|Experimental|INTP5 Period I Crossover|"Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta."
89300408|NCT04014062|Active Comparator|US Neulasta Period I Crossover|"Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5."
89300409|NCT03744806||treated with intravitreal bevacizumab.|
89300410|NCT03744806||control group|
89300411|NCT01562366|Experimental|Group 1|
89300412|NCT01562366|Active Comparator|Group 2|
89300413|NCT04531098|Experimental|Sci-B-Vac-SciGen|The 3-antigen HepB vaccine, Sci-B-Vac-SciGen (SciGen Israel Ltd., produced in a new production facility located in Rehovot, Israel) contains three recombinant proteins of hepatitis B virus (HBV) envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-SciGen was supplied in a final volume of 1.2 ml vials
89300414|NCT04531098|Active Comparator|Engerix-B|The single antigen HepB vaccine, Engerix-B (GSK), contains the small S recombinant protein. Engerix-B was supplied in 1.0 ml vials.
89300415|NCT04531098|Experimental|Sci-B-Vac-BTG|The 3-antigen HepB vaccine, Sci-B-Vac-BTG (Bio-Technology General (BTG) Ltd., Rehovot, Israel.) contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac-BTG was supplied in a final volume of 1.2 ml vials
89300416|NCT03744650|Experimental|"Care4Heart programme"|The single group pretest and repeated posttest longitudinal study design is adopted in the main study. All the recruited participants received the study intervention
89300417|NCT04142450|Experimental|CoolSculpting® System|Participants underwent a single CoolSculpting® treatment session on Day 1 that was comprised of timed segments of cooling followed by 2 minutes of manual massage. Each treated arm had up to two timed segments (or cycles) in the treatment session, each treated thigh had one timed segment (or cycle) in the treatment session.
89300418|NCT04529850|Experimental|Open Label Active Arm|90mg GC4419 by IV
89300419|NCT04225676|Experimental|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients > 50 kg body weight."
89300420|NCT04142216|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum for three months.
89300421|NCT04142216|No Intervention|Control group|The patients will not chewing gum during three months.
89300422|NCT04140890|Experimental|Treatment|Participants in the treatment group will be asked to meet with an occupational therapist in their home weekly over 12 weeks. Each session takes an hour. In the first session, the occupational therapist will introduce the program. In session 2, the therapist will discuss pain and pain management with the participant. In session 3-12, the therapist will help the participant to develop physical activity and healthy eating habits. In each session the participant will pick two healthy behaviors to turn them into a habit. The therapist will give the participant a workbook and teach the participant to track his/her progress. The focus of session 3-5 will be physical activity, and session 6-11 will be healthy eating. In the last session (session 12), the therapist will wrap up the program and help the participant to develop a maintenance plan.
89300423|NCT04140890|Placebo Comparator|Control|Participants in the control group will receive newsletters focused on general healthy aging topics over 12 weeks. With the exception of two, 1-page handouts covering PA and dietary recommendations, the weekly content will not overlap with the treatment content. Within 4 days of mailing the newsletter, a trained research assistant (RA) will call the participant, verify receipt of the newsletter, and ask them if they have any questions about the materials. The phone call will last ~15 minutes. Control condition participants receive no further intervention.
89300424|NCT03700320|Active Comparator|Oral SOC Migraine Preventive Medication|Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.
89300425|NCT03700320|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet taken orally, once daily for 52 weeks.
89300426|NCT03744416|Experimental|Intervention group|Counseling based on Epstein's active decision making on birth plan
89300427|NCT03744416|No Intervention|Control group|The standard midwife's advice on birth plan during prenatal care.
89300428|NCT03744338||Group 1|
89300429|NCT04223258|Experimental|Automatic Oxygen Control|Infants randomized to this arm will be monitored using automatic oxygen control system on the ventilator. When infants oxygen saturation are out of the target range the ventilator will adjust the oxygen delivery depending on the saturation of the infant to bring the saturation int he target range.
89300430|NCT04223258|Active Comparator|Manual oxygen control|Infants randomized to this arm will be receive oxygen delivery adjustments manually by the nursing and medical team taking care of the infants. When the infants oxygen saturation are out of the target range, the staff will manually adjust the oxygen delivery.
89300431|NCT01561950|Experimental|Factor VII|
89300432|NCT01561950|Placebo Comparator|Placebo|
89300433|NCT04139018|Experimental|Timolol Gel Arm|Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
89300434|NCT04139018|Placebo Comparator|Placebo Gel Arm|Participants in the placebo gel arm will receive the gel itself with no active medication.
89300435|NCT03748628|Experimental|Single arm EDP-305|
89300436|NCT05206318|Experimental|20 participants with topical cysteamine cream|Participants with post-inflammatory hyperpigmentation will apply topical cysteamine cream for a 16 weeks period.
89300437|NCT05206318|Sham Comparator|20 participants with topical vehicle control cream|Participants with post-inflammatory hyperpigmentation will apply topical vehicle-control cream for a 16 weeks period.
89300438|NCT04527978|Other|PRECISION1, then Biotrue ONEday|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
89300439|NCT04527978|Other|Biotrue ONEday, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
89300440|NCT04136444|Experimental|Healthy participants|Participants will receive assigned single and multiple doses of padsevonil.
88820681|NCT05790304|Other|Group 1|Matched-control healthy participants with normal hepatic function.
89300441|NCT04136444|Experimental|Hepatically impaired participants|Participants will receive assigned single and multiple doses of padsevonil.
89300442|NCT05206006|Other|Control Group|As routine care, the choice of the initial antibiotic regimen will be let to the discretion of the emergency physician.
89300443|NCT05206006|Experimental|computerized decision support app (CDSA) Group|
89300444|NCT03754608||Diabetics/No cognitive impairment|These are individuals with diabetes who do not have vascular cognitive impairment as determined by VASCOG criteria.
89300445|NCT03754608||Diabetics with vascular cognitive impairment|These are individuals with diabetes who have vascular cognitive impairment as determined by VASCOG criteria.
89300446|NCT03754530|Experimental|Icotinib|icotinib is administered orally three times per day. Until emerge the progression of the intracranial disease, then is given radiotherapy(>3 with WBRT or <=3 with SRS) after PD
89300447|NCT03754530|Experimental|Icotinib plus radiation therapy|Standard whole brain radiotherapy (WBRT) is given with 30GY/10 times(>3), or SRS(<=3) plus concurrent icotinib, which was administered orally three times per day. Until the disease progresses.
89300448|NCT05761678||Transgender people|Whether they have transitioned or not, with or without reassignment surgery.
89300449|NCT05205694||Late COVID-19 and PERIO|Participants in the late convalescent stage of COVID-19 with diagnosed periodontitis
89300450|NCT05205694||PERIO non COVID-19|Participants with diagnosed periodontitis and no history of COVID-19
89300451|NCT05205694||Late COVID-19 non PERIO|Participants in the late convalescent stage of COVID-19 without periodontitis
89300452|NCT05205694||Non PERIO non COVID-19|Participants with no history of COVID-19 and without periodontitis
89300453|NCT03751332|Other|Conversion from either CSA or TAC|Tacrolimus with modified galenic (tacrolimus MR4; Advagraf®) once daily. In patients treated with ciclosporin A, the initial dose will be 0.1 - 0.12 mg tacrolimus MR4 per kg of body weight per day with oral morning administration. In patients who are already treated with Prograf, the conversion to Advagraf will be performed in a 1:1 ratio.
89300454|NCT04425252|Other|Standard of Care|Subjects are hospitalized for COVID-19 and will receive all supportive/interventional care per institutional guidelines.
89300455|NCT04425252|Experimental|Brequinar|Subjects will receive standard of care plus brequinar 100 mg daily (Study Days 1-5).
89300456|NCT03751254|Experimental|Myopic patients|In myopic patients with axial length over 25.0 mm during surgery of the first eye the Stellaris platform will be used and during surgery of the second eye the Stellaris Elite platform will be used
89300457|NCT01569958|Active Comparator|tDCS|
89300458|NCT01569958|Sham Comparator|sham|
89300459|NCT05204914|Other|Supra glottic airway devices|
89300460|NCT03696576|Active Comparator|PhoRTE|This group will undergo standard PhoRTE therapy.
89300461|NCT03696576|Experimental|PhoRTE + EMST|This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.
89300462|NCT05459610||group for training the algorithm|This group of images is used for training the algorithm of the artificial intelligence
89300463|NCT05459610||group for testing the algorithm|This group of images is used for testing the algorithm of the artificial intelligence
89300464|NCT04003610|Experimental|Pemigatinib + Pembrolizumab|Combination of pemigatinib (13.5 milligrams [mg] once a day orally) plus pembrolizumab (200 mg every 3 weeks [Q3W] intravenously [IV])
89300465|NCT04003610|Experimental|Pemigatinib|Pemigatinib (13.5 mg once a day orally) alone
89300466|NCT04003610|Active Comparator|Standard of Care|Either gemcitabine plus carboplatin or pembrolizumab as standard of care. Gemcitabine 1000 mg/meters squared (m^2) IV over 30 minutes on Days 1 and 8, followed by carboplatin (dosed to target area under the concentration-time curve [AUC] of 5 mg/milliliters [mL]/minute [min] or 4.5 mg/mL/min if required per local guidelines) on Day 1 or 2 of each 3-week cycle. Pembrolizumab 200 mg IV on Day 1 of each 21-day treatment cycle for up to 35 cycles or disease progression.
89300467|NCT03754296||CATCHVIEW stent retriever|
89300468|NCT03744182|Experimental|HM15211|
88820682|NCT05790304|Other|Group 2|Participants with moderate hepatic impairment (CP Class B, score of 7 to 9).
88820683|NCT05790304|Other|Group 3|Participants with severe hepatic impairment (CP Class C, score of 10 to 15).
89300469|NCT03744182|Placebo Comparator|Placebo|
89300470|NCT03999554|Experimental|Low dose Sing2016 M2SR|Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29
88820684|NCT05788601|Placebo Comparator|Placebo (4 mg and 6 mg)|Abdominal s.c. self-administration of placebo content once weekly for 12 weeks. To ensure double-blinding, the placebo arm is divided into a 4-mg and 6-mg arm. But both placebo arms are pooled during data analysis.
89300471|NCT03999554|Experimental|Medium dose Sing2016 M2SR|Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29
89300472|NCT03999554|Experimental|High dose Sing2016 M2SR|High dose Sing2016 M2SR will be administered intranasally on days 1 and 29
89300473|NCT03999554|Active Comparator|Low dose Bris10 M2SR|Low dose Bris10 M2SR will be administered intranasally on days 1 and 29
89300474|NCT03999554|Placebo Comparator|Placebo|Saline will be administered intranasally on days 1 and 29
89300475|NCT04129346|Experimental|Fit2ThriveMB|Participants assigned to the Fit2ThriveMB will receive the Fit2ThriveMB smartphone app, Fitbit, and coaching calls.
89300476|NCT04129346|Active Comparator|Healthy Living Control|Participants in the healthy living group will receive the American Society of Cancer Oncologists smartphone app, cancer.net. They will also receive calls during the intervention period and the Fitbit following completion of 12 week assessments
89300477|NCT05280626|Experimental|A: PD-1+R-CHOP|After one cycle of standard R-CHOP chemotherapy, Group A uses Sindilizumab + R-CHOP, with Sindilizumab administered on day 10 post-chemotherapy, scheduled for 5 cycles. After 5 cycles, CR patients in group A continue Sindilizumab treatment for 8 times, once every 21 days.
89300478|NCT05280626|Active Comparator|B: R-CHOP|After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP and plans for 5 cycles. CR patients in group B are followed up for observation.
89300479|NCT04526574|Active Comparator|Coadministration Group|Participants receive injections of pneumococcal vaccine (20vPnC) and influenza vaccine at the same visit, and then receive an injection of saline 1 month later.
89300480|NCT04526574|Active Comparator|Separate Administration Group|Participants receive injections of saline and influenza vaccine at the same visit, and then receive an injection of 20vPnC 1 month later.
89300481|NCT03993392|Experimental|TM buprenorphine followed by SUBLOCADE 300 mg|Participants with a diagnosis of OUD stopped use of their current opioid prior to coming to the clinic to be assessed for withdrawal symptoms. If confirmed to be in withdrawal, participants were administered 4 mg transmucosal (TM) buprenorphine. If tolerated without sensitivity, clinical signs of sedation, or precipitated withdrawal, 300 mg SUBLOCADE was administered. Following SUBLOCADE administration, participants remained in the clinic for approximately 48 hours and were assessed for safety and tolerability, as well as for any signs of precipitated withdrawal. Participants returned to the clinic weekly, until the end-of-treatment (EOT) visit (28 days after SUBLOCADE administration).
89300482|NCT04422990|Experimental|LID018869|Lehfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
89300483|NCT04422990|Active Comparator|Biofinity|Comfilcon A silicone hydrogel contact lenses worn in both eyes during waking hours only. Lenses will be worn for a total of 3 months, with monthly planned replacement over the course of the study duration. CLEAR CARE will be used for nightly contact lens cleaning and disinfection.
89300484|NCT03743948|Experimental|Expectant couple at risk of transmitting a monogenic disease.|Expectant couple (pregnant woman from 9 weeks of gestation and spouse) at risk of transmitting a monogenic disease among the genes included in the trusight one expanded sequencing kit (Illumina).
89300485|NCT03751176|Experimental|FOLFIRI + panitumumab|"Patients received panitumumab plus FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI:~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
89300486|NCT03751176|Active Comparator|FOLFIRI|"Patients received FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
89300487|NCT04377308|No Intervention|Treatment As Usual|Participants may choose to not take fluoxetine and remain in the study
89300488|NCT04377308|Active Comparator|Fluoxetine|Participants will take fluoxetine 20 mg initially, increasing as tolerated to a maximum of 60 mg until symptoms abate, then will be tapered by 20 mg per week off the fluoxetine Participants will be on fluoxetine for 2 weeks to 2 months depending on symptom duration
89300489|NCT01562912|Active Comparator|Control|Radiofrequency Ablation Procedure. Subjects who are undergoing AF ablation with traditional ablation technology at the same centers by the same operators. Control patients will be enrolled in a 1:2 ratio compared to the PVAC cohort. Intervention is the use of Radiofrequency Ablation.
89300490|NCT01562912|Experimental|PVAC Ablation Procedure|Intervention is the use of PVAC technology. The PVAC is deployed in the left atrium over a 0.032-inch guidewire inside the PV and advanced until it is wedged within the antrum proximal to the ostium. Energy is delivered through selected electrode pairs with local potentials as well as adjacent electrode pairs, allowing bipolar current to flow to the target electrode(s) from both sides. Each application lasts for 60 seconds. When the temperature does not rise above 50°C within 15 seconds, the application should be discontinued to improve position. The PVAC may be manipulated within the antrum to ablate in a pattern of overlapping circular lesions.
89300491|NCT04447404|Experimental|DUR-928|
89300492|NCT04447404|Placebo Comparator|Placebo|
89300493|NCT03743870||levobupivacaine cohort|125 pregnant patients that will have to undergo spinal anesthesia with Levobupivacaine for elective caesarean section.
89300494|NCT03743870||bupivacaine cohort|Historical control group made of 125 patients underwent spinal anesthesia with Bupivacaine for elective cesarean section during the period between April 2017 and April 2018.
89300495|NCT01562106|Experimental|ICG Dye|Fluorescence-guided sentinel lymph node detection
89300496|NCT03988166|Other|Chronic Total Occlusion Percutaneous Coronary Intervention|CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.
89300497|NCT03988088|Experimental|Lasmiditan|Participants with lower body weight (15 to ≤40 kilograms (kg)) received single oral dose of 100 milligrams (mg) Lasmiditan in Cohort 1 and higher body weight (>40 to ≤55 kg) participants received single oral dose of 200 mg Lasmiditan in Cohort 2.
89300498|NCT03987932|Experimental|NEAT!2|Participants will be asked to use the NEAT!2 app for 3 months after randomization. App use between 4-6 months is optional.
89300499|NCT03987932|Experimental|NEAT!2+Calls|Participants will be asked to use the NEAT!2 app for 3 months after randomization. In addition, participants will receive bi-weekly coaching calls over 3 months. App use between 4-6 months is optional.
89300500|NCT03987932|Other|Delayed NEAT!2|Participants will receive the NEAT!2 app to use between 3 and 6 months.
89300501|NCT03987620|Experimental|Ibrexafungerp (SCY-078)|300 mg BID for one day
89300502|NCT03987620|Placebo Comparator|Placebo|Matching Placebo
89300503|NCT03746132|Active Comparator|Transdermal Continuous Oxygen Therapy|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the Treatment arm which provides Transdermal Continuous Oxygen Treatment (TCOT) (as delivered by EPIFLO device), in addition to standard of care for the surgical wound
89300504|NCT03746132|No Intervention|Control|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the control arm which provides standard of care for the surgical wound.
89300505|NCT04376060|Experimental|Study population|Fifteen patients (1 male, 14 females) aged between 27 and 64 years old
89300506|NCT05204758|Experimental|Study arm|Patients receive afatinib and TCM. TCM recipe was chosen from three essential TCM formulas, including Bai He Gu Jin Tang (yin nourishing), Wen Dan Tang (phlegm reducing), and Qing Shang Fang Fen Tang (heat clearing). The packages contained 1.6 g TCM preparations, which were manufactured in powder form by Sun Ten Pharmaceutical (Taichung, Taiwan) according to the good manufacturing practice requirements. Patients were instructed to intake three packages of TCM preparations with each meal three times a day, for a total of nine packages per day. Administration of TCM was initiated at the same time as afatinib and continued for a total of three months.
89300507|NCT05204758|Placebo Comparator|Control arm|Patients receive afatinib and placebo. Placebo without the medical ingredients was prepared to be similar to the weight, color, smell, taste, and packaging of the TCM formulas. The packages contained 1.6 g placebo preparations, which were manufactured in powder form by Sun Ten Pharmaceutical (Taichung, Taiwan) according to the good manufacturing practice requirements. Patients were instructed to intake three packages of placebo preparations with each meal three times a day, for a total of nine packages per day. Administration of placebo was initiated at the same time as afatinib and continued for a total of three months.
89300508|NCT05204524|Experimental|Subjected arm|"temozolomide for injection (once a day, with a fixed dose of 200 mg (body surface area ≤1.7m2) or 300 mg (body surface area > 1.7 m2), for 5 days, with 21 days as a cycle) combined with epirubicin (60 mg/m2 21-day scheme).~Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months."
89300509|NCT05204056|Experimental|Group A|Twenty patients who were given intraoperative joint cavity infusion therapy using 20ml tranexamic and 40ml iced normal saline.
89300510|NCT05204056|Experimental|Group B|Twenty patients who were given 20ml of iced normal saline, 20ml of iced cocktail and 20ml of tranexamic
89300511|NCT05204056|Active Comparator|Control group|Twenty patients were given joint cavity infusion therapy with 20ml tranexamic only as the control group
89300512|NCT05203744|Experimental|Standard Dose (200 mg)|Participants will receive the standard 200 mg tafenoquine dose (200 mg daily for 3 days) followed by 200 mg weekly for two weeks to check for tolerability and adverse effects.
89300513|NCT05203744|Experimental|Low Monthly Dose (600 mg)|"The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose."
89300514|NCT05203744|Experimental|High Monthly Dose (800 mg)|The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose
89300515|NCT04413552|Experimental|Part I: INDV-2000|Participants will receive a single dose of INDV-2000. The starting dose is 1 mg with dose escalation dependent upon observed clinical safety, tolerability and pharmacokinetics.
89300516|NCT04413552|Placebo Comparator|Part I: Placebo|Participants will receive a single dose of matching placebo.
89300517|NCT04413552|Experimental|Part II: INDV-2000 Fasted/Fed|Participants will receive a single dose of INDV-2000 orally on Day 1 under fasted conditions and a single dose of INDV-2000 after a high-fat breakfast on Day 8. Dose to be determined based on a well-tolerated dose studied in Part I.
89300518|NCT03987074|Experimental|Semaglutide|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks
89300519|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks
89300520|NCT03987074|Experimental|Semaglutide + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks
89300521|NCT03987074|Experimental|Semaglutide + Cilofexor 100 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks
89300522|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks
89300523|NCT05761366|Experimental|Al18F-PSMA-BCH PET/CT|Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors.（including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.）
89300524|NCT05203666||degenerative lumbar spinal stenosis|All patients treated in 2019 with a percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
89300525|NCT05302466|Active Comparator|gymnastic (control group)|"usual care home gymnastics programme for 12 weeks, which consists of three different 3-minute sequences to be performed daily."
89300526|NCT05302466|Experimental|gymnastic plus dental bite pads (intervention group)|Identical home gymnastics programme for 12 weeks, which consists of three different 3-minute sequences to be performed daily plus dental bite pads during exercise. The dental bite pads are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise.
89300527|NCT05203588|Experimental|Experimental group|Patients in this group are received denosumab (60 mg) subcutaneously at one week and 26 weeks after the lumbar fusion surgery, combined with receiving daily calcium (≥1·0 g) and vitamin D (≥400 IU).
89300528|NCT05203588|Sham Comparator|Control group|Patients in this group are only received daily calcium (≥1·0 g) and vitamin D (≥400 IU) after the lumbar fusion surgery.
89300529|NCT05203354|Active Comparator|NB-UVB group|Patients who receive Narrowband ultraviolet B phototherapy
89300530|NCT05203354|Active Comparator|Acitretin group|Patients who receive acitretin
89300531|NCT05203354|No Intervention|Control group|It includes apparently healthy people who will be compared to patients in the measurement of Omentin-1 level
89300532|NCT04439214|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89300533|NCT05203042||prediabetes|
89300534|NCT05203042||diabetes|
89300535|NCT05761210||cases; subjects with steatosis|
89300536|NCT05761210||controls; subjects without steatosis|
89300537|NCT03754062|Placebo Comparator|Placebo|Placebo control
89300538|NCT03754062|Experimental|Haloperidol 3mg|Haloperidol
89300539|NCT03754062|Experimental|L-Dopa 150 mg & Domperidone 10mg|L-Dopa
89300540|NCT05202886|Experimental|Liver from deceased donors|This study included all consecutive subjects with chronic liver disease who underwent LT for the first time with a deceased donor liver
89300541|NCT05185960|Experimental|ALLSWEET®|ALLSWEET® will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
89300542|NCT05185960|Experimental|ALLSWEET® consumed with sucrose|ALLSWEET® and sucrose will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
89300543|NCT05185960|Active Comparator|Sucrose|Sucrose will be mixed with 250ml of water and an additional 125ml of water. Fingerprick blood samples will be taken for 2 hours following consumption of beverage in order to assess the glycemic response.
89300544|NCT03696342|Experimental|PRO-157|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
89300545|NCT03696342|Active Comparator|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
89300546|NCT05184244||Participants with CP|Children with CP
89300547|NCT03753984|Experimental|Healthy group|The protocol consists of Low-level laser therapy (LLLT) application in the dominant side brachialis muscle in healthy subjects prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, electromyography associated with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration by means of the lactimeter, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
89300548|NCT03753984|Experimental|Post stroke group|The protocol consists of Low-level laser therapy (LLLT) application in the hemiparetic side brachialis muscle post stroke individuals prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, surface electromyography with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
89300549|NCT03753906|Experimental|Osmed® hydrogel expander implantation|Implantation of Osmed® hydrogel expander was done in subperiosteal positions using the pouch technique in the mandibular anterior region.
89300550|NCT05761132|Experimental|Neoadjuvant pembrolizumab|"Patients receive pembrolizumab, 200 mg IV Q3W for a total of 2 administrations per patient over a period of 6 weeks prior to surgery.~Responders have the option to fall into an extension cohort and, after consultation with the multidisciplinary team, will be treated with adjuvant pembrolizumab from week 16 until week 58 (400 mg IV, Q6W, 7 times)."
89300551|NCT05761054|Experimental|A|
89300552|NCT04411680|Experimental|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
89300553|NCT04411680|Active Comparator|Control Arm|Standard of care for COVID-19
89300554|NCT03629392|Experimental|Low met/cys diet|Dietary intervention
89300555|NCT03629392|Experimental|Moderate met/cys diet|Dietary intervention
89300556|NCT03629392|Active Comparator|High met/cys diet|Dietary intervention
89300557|NCT05098756|Experimental|Art therapy group|Experimental group received 8-week art therapy. Art therapy uses different themes and materials to art-making.
89300558|NCT05098756|No Intervention|No intervention group|No intervention group maintain the institution's original daily routine and participation in activities.
89300559|NCT05760976|Experimental|Age range of 18 to 44 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
89300560|NCT05760976|Experimental|Age range of 45 to 59 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
89300561|NCT05760976|Experimental|Age range of 60 to 80 years olds|The initial dose of cisatracurium for pre-injection was set at 0.015mg/kg according to previous literature and preliminary test results. The dose of cisatracurium was according to the patients' fasciculation level. If there is no fasciculation (negative reaction), the dose of cisatracurium in the next patient will be reduced until the patient has fasciculation. If there is fasciculation (positive reaction), the dose of cisatracurium will be increased in the next patient until the patient has no fasciculation.
89300562|NCT04974346|Experimental|study arm|"External beam radiotherapy:~Pelvic and para-aortic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.~Concurrent chemotherapy:~Weekly cisplatin 40mg/m2 during external beam radiotherapy.~Brachytherapy:~High dose rate(HDR) Brachytherapy. The dose of high-risk clinical target volume(HR CTV) D90 or Point A should be 85Gy+/-10%. The dose of intermediate-risk clinical target volume(IR CTV) D98 should be 60Gy at least."
89300563|NCT04974346|Active Comparator|control arm|"External beam radiotherapy:~Pelvic radiotherapy 45-50.4Gy/25-28 fractions. PET-CT positive lymph node should be boost to a dose of 60Gy or higher. Parametrium(both) should be boost to a dose from 50Gy to 60Gy.~Concurrent chemotherapy:~Weekly cisplatin 40mg/m2 during external beam radiotherapy.~Brachytherapy:~HDR Brachytherapy. The dose of HR CTV D90 or Point A should be 85Gy+/-10%. The dose of IR CTV D98 should be 60Gy at least."
89300564|NCT04410198|Experimental|Roxadustat|Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 24 weeks. If a participant requires roxadustat <60 milligrams (mg)/week to maintain Hb levels, the dose frequency will be reduced in a stepwise manner, for example, to BIW, and then QW. For participants converted from CERA, the initial roxadustat dose will be based on the average prescribed CERA dose in the last 8 weeks prior to conversion. For participants with <6 weeks of prior CERA use, the initial roxadustat dose will be based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations will be made every 4 weeks and doses will be titrated based on Hb level and rate of Hb change. The prescribed dose will not exceed the maximum allowable dose of 3.0 mg/kilogram (kg)/dose or 400 mg per dose, whichever is lower.
89300565|NCT04947202||Safil Mesh|
89300566|NCT04887766|Active Comparator|Active|GS300: Three (3) GS300 capsules [approximately 0.65 grams (g)] two (2) times per day ingested 10 minutes (min) before meals (i.e., lunch and dinner) - total of 3.9 g per day
89300567|NCT04887766|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day 10 min before meals (i.e., lunch and dinner)
89300568|NCT05457114||Pulmonary artery catheter group|Patients who received pulmonary artery catheter insertion and hemodynamic monitoring by PAC-derived parameters
89300569|NCT05457114||Non-pulmonary artery catheter group|Patients who did not received pulmonary artery catheter insertion and were monitored with Flo-Trac FloTrac Vigileo
89300570|NCT05280678|Experimental|SH2018-10 miniscrew side|"We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews, randomly assigned to either left or right side. To do so, our nurse divided both miniscrew types into two halves and assigned symbols appropriate for blinding the intervention. Thus, two combinations of miniscrew sets aroused: 1. SH1514-08R and SH2018-10L or 2. SH1514-08L and SH2018-10R, which were placed separately in opaque packages marked consecutively from 1 to 100 and stored on the tray with dividers. One hundred cards, labeled accordingly, were placed in an envelope, from which the nurse blindly pulled the card just before the miniscrew insertion, this way assigning the set number to every patient. Thus both: the placement side and the screw size were random for clinician."
89300571|NCT05280678|Experimental|SH1514-08 miniscrew side|"We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews, randomly assigned to either left or right side. To do so, our nurse divided both miniscrew types into two halves and assigned symbols appropriate for blinding the intervention. Thus, two combinations of miniscrew sets aroused: 1. SH1514-08R and SH2018-10L or 2. SH1514-08L and SH2018-10R, which were placed separately in opaque packages marked consecutively from 1 to 100 and stored on the tray with dividers. One hundred cards, labeled accordingly, were placed in an envelope, from which the nurse blindly pulled the card just before the miniscrew insertion, this way assigning the set number to every patient. Thus both: the placement side and the screw size were random for clinician."
89300572|NCT04876300||Menotropin Cohort|
89300573|NCT03750474|Experimental|patient with chronic low back pain|magnetic resonance elastography and shear wave elastography of the back muscles
89300574|NCT03750474|Other|healthy controls|magnetic resonance elastography and shear wave elastography of the back muscles
89300575|NCT05760040|Experimental|Virtual Reality (VR)|During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.
89300576|NCT05760040|Experimental|Control group|Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
89300577|NCT03753672||preload responsive|defined as an increase in Velocity time integral of the sub-aortic flow greater or equal to 10%
89300578|NCT03753672||preload unresponsive|defined as an increase in Velocity time integral of the sub-aortic flow lower than 10%
89300579|NCT03750396|Experimental|Endocrine and local treatments|"Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.~Endocrine options included aromatase inhibitors, aromatase inhibitors with CDK4/6 inhibitors, fulvestrant, fulvestrant with CDK4/6 inhibitors, everolimus with exemestane, tamoxifen. For premenopausal women, agents for ovarian function suppression using GnRH agonists or surgical ovarian ablation including bilateral salpingo-oophorectomy are allowed.~Local treatments for metastatic lesions will be added in this group.~Local treatments include modalities described below:~i) Surgical resection: the achievement of tumor-free margin is not obligatory. ii) Stereotactic body radiotherapy iii) Radiofrequency ablation"
89300580|NCT04670848|Experimental|Patients suspected of suffering from sleep apnea|
89300581|NCT04670848|Experimental|Healthy volunteers|
89300582|NCT04660864|Experimental|Rhinochill|Treatment with nasal cavity cooling 10 minutes during three consecutive migraine attacks.
89300583|NCT03750942|Experimental|Adhesix® monofilament polypropylene mesh (Bard Davol) group|The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.
89300584|NCT03750942|No Intervention|Control group|The control group will not receive a mesh and the stoma will be created according local protocol.
89300585|NCT03747978|Experimental|Perindopril and Amlodipine|Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
89300586|NCT03747978|Active Comparator|Perindopril-Indapamide|Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks
89300587|NCT04603846|Experimental|Combined treatment group|All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel 260mg/m2 d1，q3w；
89300588|NCT03750162|Experimental|Passive Ultrasonic irrigation|Irrigation solution was ultrasonically activated in the canal for 1 minute by using IrriSafe tip coupled to an ultrasonic device with VDW Ultra .
89300589|NCT03750162|Experimental|Manuel dynamic activation|Irrigation solution was activated with a well-fitting a ProtaperNext X3 gutta-percha point placed to working length was then moved in push - pull motions at a rate of 100 strokes/per minute
89300590|NCT03750162|Experimental|Photodynamic Therapy|Root canal was filled by 0.5 mL of 0.01% methylene blue (MB) solution for 5 minutes, then radiated by the light supply of a diode laser AMD picasso with a wavelength of 810 nm for 40 seconds (0.2 W).
89300591|NCT03747900|Experimental|BTX-A|Patients underwent 200 U BTX-A injections in biceps brachii muscle.
89300592|NCT03747900|Active Comparator|BTX-A+Dry needling|Dry needling was administered for 4 times in total after the BTX-A injection.
89300593|NCT04578106|Experimental|Omission of surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Adjuvant period: If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB,patients will be eligible to omit loco-regional surgery. Whole breast radiotherapy without nodal radiotherapy will then be performed. Trastuzumab and pertuzumab FDC will be continued to complete 1 year of treatment and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
89300594|NCT04578106|No Intervention|Surgery|Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Surgery: If invasive tumor cells and/or in situ disease are identified, patients will undergo surgery. Adjuvant period: All patients will continue with Trastuzumab-emtansine (T-DM1) completing 1 year of treatment (14 cycles) and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.
89300595|NCT03747822|Active Comparator|autogenous fat|autogenous fat augmentation in deficient chin will be harvested from lower abdomen,inner or outer thigh
89300596|NCT03747822|Active Comparator|PEEK|Will use onlay PEEK augmentation in deficient chin.Virtual planning will be done using mimics software. A virtual osteotomy of the chin will be performed at the inferior border of the mandible same alignments as sliding genioplasty, then segmentation of the chin area will be done and according to the soft tissue analysis adjustment will be performed.
89300597|NCT03747822|Other|Osseous sliding genioplasty|Under general anesthesia, the preparation and the incision line will be performed same as PEEK augmentation .After complete exposure of the bone repositioning of the chin will be performed. Finally fixation will be obtained using x shape titanium plate.
89300598|NCT04472182|Experimental|Fluoride varnish with xylitol coated calcium and phosphate|
89300599|NCT04472182|Active Comparator|Conventional Fluoride varnish|
89300600|NCT04423744|Experimental|Intervention ABCD|"Intervention A:~Day 1 and 2: Supra-therapeutic dose of BAY1817080, three times daily (tid) Day 3: Supra-therapeutic dose of BAY1817080 and placebo to moxifloxacin, once~Intervention B:~Day 1 and 2: therapeutic dose of BAY1817080 and placebo to BAY1817080, tid Day 3: therapeutic dose of BAY1817080, placebo to BAY1817080 and placebo to moxifloxacin, once~Intervention C:~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and moxifloxacin, once~Intervention D:~Day 1 and 2: Placebo to BAY1817080, tid Day 3: Placebo to BAY1817080 and placebo to moxifloxacin, once~Subjects will receive intervention A, B, C and D sequentially. The washing-out period between each intervention is at least 14 days"
89300601|NCT04423744|Experimental|Intervention BCDA|Subjects will receive intervention B, C, D and A sequentially. The washing-out period between each intervention is at least 14 days
89300602|NCT04423744|Experimental|Intervention CDAB|Subjects will receive intervention C, D, A and B sequentially. The washing-out period between each intervention is at least 14 days
89300603|NCT04423744|Experimental|Intervention DABC|"Subjects will receive intervention D, A, B and C sequentially. The washing-out period between each intervention is at least 14 days~Note: the intervention sequences in this and above arms are examples, the actual order of intervention may differ from these examples"
89300604|NCT01562652|Experimental|Research|
89300605|NCT04884204|Experimental|Symptom management with Lee Symptom Scale|Participants will receive disease specific questionnaires electronically, cGVHD-PRO (Lee Symtpom Scale), one week prior to their scheduled visit in the outpatient clinic. The participants will be asked to answer the questionnaire from home without any involvement from clinicians. Afterwards the PRO data will be used during the scheduled clinical consultations as an instrument to discover symptoms on chronic GVHD and systematically to monitoring symptoms developing over time.
89300606|NCT05759416|Active Comparator|Gp I(Melatonin gp)|Group I: included 20 chronic periodontitis patients, treated by conventional periodontal therapy SRP combined with intra- pocket application of Melatonin gel once weekly for 1 month begin application at the second week after initial therapy.
89300607|NCT05759416|Placebo Comparator|Gp II(placebo gp)|Group II: included 20 chronic periodontitis patients, treated by SRP combined with the injection of placebo, weekly for one month
89300608|NCT04386538|Experimental|Low Starch Diet (LSD)|Participants will receive the low starch diet program: restricts the daily amount of ingested rich starch food, to a reduction of at least 40% compared to usual daily individual starch intake.
89300609|NCT04386538|Active Comparator|Control|Participants will receive dietary counselling based on general recommendations for healthy eating.
89300610|NCT03746340||Anesthetic|Sevoflurane Group Propofol Group
89300611|NCT04873206||Functional/ Cyclical Endometrial group.|cases of normal endometrium will be obtained from hystrectomy specimens done for causes other than hyperplasia or adenocarcinoma, for example; uterine fibroids, uterine prolapse.
89300612|NCT04873206||Hyperplastic Endometrial group.|cases of endometrial hyperplasia obtained by D&C or hystrectomy will be stained by H&E stain and categorized into typical or atypical hyperplasia.
89300613|NCT04873206||Primary Endometrial Adenocarcinoma group.|cases of primary endometrial adenocarcinoma obtained by D&C or hystrectomy operations
89300614|NCT05758480|Experimental|Patients with Long COVID|
89300615|NCT05758480|Active Comparator|COVID-19 recovered patients (Control)|
89300616|NCT04222816|Active Comparator|Lithium carbonate|Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.
89300617|NCT04222816|Experimental|Add-on Sodium chloride|Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.
89300618|NCT04161144|Active Comparator|Rapamycin 15mg (sirolimus)|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
89300619|NCT04161144|Placebo Comparator|Placebo|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
89300620|NCT03747744|Experimental|CD1c (BDCA-1)+ myDC|CD1c (BDCA-1)+ myDC
88820688|NCT05786508|Active Comparator|Key to Wellbeing program|adults with chronic neck or back pain from populations that experience health disparities due to race/ethnicity or socioeconomic status
89300621|NCT04823364|Active Comparator|Medically healthy adults diagnosed with ADHD|Medically healthy adults diagnosed with ADHD (men and women) ages 18-40 years (N= 35), treated with Amphetamines (Mixed Amphetamine salts (Attent) or short-acting methylphenidate (Ritalin)
89300622|NCT04823364|No Intervention|Control|HCS (N= 25) volunteers ages 18-40 years, who did not report ADHD or any other illness or medical conditions, and who do not take chronically medications, will be enrolled from the general population.
89300623|NCT03984812|Experimental|Part 1,Cohort 1:Subjects receiving blinded GSK3732394 10mg/PBO|GSK3732394 10 milligram (mg) or PBO will be administered by subcutaneous (SC) injection to the subjects.
89300624|NCT03984812|Experimental|Part 1,Cohort 2:Subjects receiving blinded GSK3732394 40mg/PBO|GSK3732394 40 mg or PBO will be administered by SC injection to the subjects. This is projected dose, dose will be based on PK/PD results from preceding dosing cohorts.
89300625|NCT03984812|Experimental|Part1,Cohort 3:Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 3 will be based on PK/PD results from preceding dosing cohorts.
89300626|NCT03984812|Experimental|Part1,Cohort 4:Subjects receiving blinded GSK3732394 350mg/PBO|GSK3732394 350 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
89300627|NCT03984812|Experimental|Part1,Cohort5: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
89300628|NCT03984812|Experimental|Part1,Cohort6: Subjects receiving blinded GSK3732394 800mg/PBO|GSK3732394 800 mg or PBO will be administered by SC injection to the subjects. This is a projected dose and will be given if necessary. The dose administered in Part 1, Cohort 6 (if necessary) will be based on PK/PD results from preceding dosing cohorts.
89300629|NCT03984812|Experimental|Part2,Cohort1: Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The dose administered in Part 2, Cohort 1 will be based on PK/PD results from preceding dosing cohorts.
89300630|NCT03984812|Experimental|Part2,Cohort2: Subjects receiving blinded GSK3732394 400mg/PBO|GSK3732394 400 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 2 will be based on PK/PD results from preceding dosing cohorts.
89300631|NCT03984812|Experimental|Part2,Cohort3: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 3 will be based on PK/PD results from preceding dosing cohorts and will not exceed the maximum exposure observed in SAD (Part 1).
89300632|NCT01562730||No previous cardiovascular disease|Individuals without any history of cardiovascular disease
89300633|NCT01562730||Previous cardiovascular disease|Individuals with history of cardiovascular disease
89300634|NCT03743714|Experimental|males|healthy, sedentary males
89300635|NCT03743714|Experimental|females|healthy, sedentary females
89300636|NCT04764630|Experimental|A. Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min)
89300637|NCT04764630|Experimental|B. Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
89300638|NCT04764630|Active Comparator|C. Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
89300639|NCT03745976||Group 1|a new long-term total articular prosthesis follow-up strategy by simple questionnaire and radiography (questionnaire and Xray for all patients)
89300640|NCT03748394|Experimental|Work-directed rehabilitation|Work-directed, person-centered plan using modules of occupational therapy and physical therapy
89300641|NCT03748394|Active Comparator|Physical activity|Physical activity according to national health recommendations
89300642|NCT04153188|Experimental|Pulsed Dye Laser & Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream for 4 weeks prior to 1st of 3 monthly Vbeam® Prima PDL treatments. Subjects will continue with once daily application of Oxymetazoline HCL 1% Cream during the 6-month post-baseline study with a 3-day washout of cream prior to each of the 3 PDL treatments.
89300643|NCT04153188|Active Comparator|Oxymetazoline HCL 1% Cream|Once daily application of pea-sized amount to face of Oxymetazoline HCL 1% Cream during the 6-month study.
89300644|NCT04113746|Experimental|Asthma and Exercise Lifestyle Change|Participants receive asthma and lifestyle change education related to exercise
89300645|NCT04113746|Placebo Comparator|Asthma Education|No lifestyle change education
89300646|NCT03747666|Experimental|Locking miniplate|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
89300647|NCT03747666|Experimental|Non-locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 two non-locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
89300648|NCT03611010|Experimental|Cohort 1|Cohort 1 = Baseline daily dose of 10 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
89300649|NCT03611010|Experimental|Cohort 2|Cohort 2 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
89300650|NCT03611010|Experimental|Cohort 3|Cohort 3 = Baseline daily dose of 40 mg oral atorvastatin during lead-in, then IV study drug for up to 15 days
89300651|NCT03611010|Experimental|Cohort 4|Cohort 4 = Baseline daily dose of 20 mg oral atorvastatin during lead-in, then SC study drug for up to 15 days
89300652|NCT03749850|Experimental|Study treatment|"LTLD in combination with MR-HIFU induced hyperthermia and cyclophosphamide~Single arm study"
89300653|NCT01562496|Experimental|Exercise|Twente patients will perform Aerobic exercise 3 times a week for at least 30 min
89300654|NCT01562496|No Intervention|Control|Fifteen patients will be listed as a control group and will be instructed to continue their previous level of activity throughout the study
89300655|NCT04357782|Active Comparator|Mild hypoxemia|S/F ratio >250 prior to Vitamin C infusion
89300656|NCT04357782|Active Comparator|Severe Hypoxemia|S/F ratio ≤250 prior to Vitamin C infusion
89300657|NCT03749772|Experimental|Cognitive|The participants of the COGNITIVE group performed cognitive training during 12 sessions during the 3 months of hypocaloric treatment. The training was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
89300658|NCT03749772|No Intervention|Control|As a control group, we used nutrition education sessions of approximately the same duration (30 min) where we simply reinforced the knowledge that was already provided during the sessions with the patient, such as concepts about the balanced diet, nutrient composition and micronutrients, etc. The objective of this control group was to avoid the effect of time with the researcher.
89300659|NCT03980522|Experimental|KPL-914: Part 1 Participants|Part 1 enrolls symptomatic participants with recurrent idiopathic pericarditis (RIP) with an elevated marker of systemic inflammation (C-reactive protein [CRP] > 1mg/dL).
89300660|NCT03980522|Experimental|KPL-914: Part 2 Participants|Part 2 enrolls symptomatic participants with RIP with CRP ≤1 mg/dL which, in the opinion of the Investigator, can be attributed to concomitant medications (e.g., corticosteroids) and with pericardial inflammation present on cardiac magnetic resonance imaging (MRI) confirmed by the imaging core lab.
89300661|NCT03980522|Experimental|KPL-914: Part 3 Participants|Part 3 enrolls participants with corticosteroid-dependent RIP not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
89300662|NCT03980522|Experimental|KPL-914: Part 4 Participants|Part 4 enrolls symptomatic participants with recurrent post pericardiotomy syndrome (PPS) with an elevated marker of systemic inflammation (CRP > 1mg/dL).
89300663|NCT03980522|Experimental|KPL-914: Part 5 Participants|Part 5 enrolls participants with corticosteroid-dependent recurrent PPS not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
89300664|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose A|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose A
89300665|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose B|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose B
89300666|NCT04402866|Experimental|Part 1: TD-0903 - MAD Dose C|6 out of 8 subjects per cohort will be randomized to receive TD-0903 MAD Dose C
89300667|NCT04402866|Experimental|Part 1: Placebo for MAD|2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo
89300668|NCT04402866|Experimental|Part 2: TD-0903|99 subjects will be randomized to receive TD-0903
89300669|NCT04402866|Experimental|Part 2: Placebo|99 subjects will be randomized to receive Placebo
89300670|NCT04400682|Experimental|FAVIRA then AVIGAN|Participants first received Favira 200 mg FT manufactured by Novelfarma in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
89300671|NCT04400682|Experimental|AVIGAN then FAVIRA|Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.
89300672|NCT03066778|Experimental|Pembrolizumab+EP|During each 21-day cycle, participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1). Participants who stop pembrolizumab as a result of obtaining a response of stable disease (SD), partial response (PR), complete response (CR) or those who stop after receiving pembrolizumab for 24 months for reasons other than disease progression or intolerability, are eligible for up to an additional 1 year of treatment after progressive disease if they meet the criteria for retreatment.
89300673|NCT03066778|Active Comparator|Placebo+EP|During each 21-day cycle, participants receive placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
89300674|NCT04348656|Experimental|Convalescent plasma|~500 mL ABO compatible convalescent apheresis plasma
89300675|NCT04348656|No Intervention|Standard of care|Treated as per institutional standard of care.
89300676|NCT04136548|Experimental|Fentanyl|Fentanyl will be administered intravenously during one visit.
89300677|NCT04136548|Placebo Comparator|Placebo|Placebo (saline) will be administered intravenously during one visit.
89300678|NCT04099264|Experimental|Intervention group: Personalized music|This arm will receive an intervention which will be personalized music. It will be provided by Music Care application (https://www.music-care.com/fr).
89300679|NCT04099264|Active Comparator|Control: Audio Books|Control will consist of audio books.
89300680|NCT04062058|Experimental|Total Neoadjuvant Chemoradiotherapy|Total neoadjuvant chemoradiotherapy arm receives intensity-modulated neoadjuvant chemoradiotherapy (45Gy in 25 fractions) concurrently with oral S-1(40-60mg/m2, orally twice daily every weekday) followed by six cycles of SOX neoadjuvant chemotherapy and surgery
89300681|NCT04347954|Experimental|Povidone-Iodine 2%|"Participants will administer PVP-I 2% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
89300682|NCT04347954|Experimental|Povidone-Iodine 0.5%|"Participants will administer PVP-I 0.5% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5"
89300683|NCT04347954|Placebo Comparator|Isotonic saline 0.9%|"Participants will administer two sprays of isotonic saline nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
89300684|NCT03065530|Placebo Comparator|control group|"The placebo group will pumped in the same volume of saline 0.9% as calculated by parturients' weight in 30 min and receive 1mg butorphanol after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
89300685|NCT03065530|Experimental|Dexmedetomidine 0.03ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.03ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
89300686|NCT03065530|Experimental|Dexmedetomidine 0.05ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.05ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
89300687|NCT03065530|Experimental|Dexmedetomidine 0.08ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.08ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
89300688|NCT03629158|Experimental|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks."
89300689|NCT03629158|No Intervention|Treatment as usual (TAU)|The TAU group will continue to receive their regular medical care.
89300690|NCT03797404||Mepolizumab|Patients receiving mepolizumab
89300691|NCT03797404||Patients w/o mepolizumab (retrospective)|Retrospective control group of patients not exposed to mepolizumab, included in the COBRA cohort and the ASMATHERM protocol, who had 2 sets of biopsies and BAL within a 6 to 12 month-interval, without change in their treatment. Clinical data for this patients are available at inclusion and after 12 months.
89300692|NCT03979820|Experimental|10 mg BI 1467335/10 mg BI 1467335 + Tyramine|
89300693|NCT03979820|Experimental|15 mg BI 1467335/15 mg BI 1467335 + Tyramine|
89300694|NCT03979820|Active Comparator|Phenelzine/Phenelzine + Tyramine|
89300695|NCT03979820|Placebo Comparator|Placebo/Placebo + Tyramine|
89300696|NCT03647488|Experimental|Run-in part: capmatinib + spartalizumab|Participants (enrolled in the run-in part) were treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
89300697|NCT03647488|Experimental|Randomized part: capmatinib+spartalizumab|Participants (enrolled in the randomized part) treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
89300698|NCT03647488|Active Comparator|Randomized part: docetaxel|Participants (enrolled in the randomized part) treated with docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
89300699|NCT03693950|Experimental|BCD-066 1 µg/kg|Healthy volunteers will receive BCD-066 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
89300700|NCT03693950|Active Comparator|Aranesp 1 µg/kg|Healthy volunteers will receive Aranesp 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
89300701|NCT04110314|Active Comparator|Gain-framed portal reminders + Pre-commitment Prompts|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
89300702|NCT04110314|Active Comparator|Gain-framed portal reminders + No pre-commitment prompt|Participants receive gain-framed reminder/recall messages regarding influenza vaccination via the patient portal and no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
89300703|NCT04110314|Active Comparator|Loss-framed portal reminders + Pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
89300704|NCT04110314|Active Comparator|Loss-framed portal reminders + No pre-commitment prompt|Participants receive loss-framed reminder/recall messages regarding influenza vaccination via the patient portal and a no pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
89300705|NCT04110314|Active Comparator|No portal reminder + Pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal but do receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
89300706|NCT04110314|No Intervention|No portal reminders + No pre-commitment prompt|Participants do not receive any reminder/recall messages regarding influenza vaccination via the patient portal and do not receive a pre-commitment prompt asking if they plan to receive the influenza vaccine in the upcoming season
89300707|NCT03579160|Experimental|0.25% Timolol gel applied to full-thickness skin graft|"During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks"
89300708|NCT03579160|Active Comparator|Standard of Care dressings|"FTSG surgery as per SOC~After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"
89300709|NCT03483220||cases|patients with cannabis use disorder
89300710|NCT03461458|Experimental|5×10^6 AD-MSCs|Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells
89300711|NCT03461458|Experimental|20×10^6 AD-MSCs|Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells
89300712|NCT04098458|Experimental|NDURE|NDURE is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT at the patient-, healthcare team-, and organization-levels.
89300713|NCT03745742|Other|control|standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.
89300714|NCT03745742|Experimental|study strategy|individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).
89300715|NCT03745664|Active Comparator|Treatment group|"Methylprednisolone Sodium Succinate (20mg/ml) will be given at the dose of 40 mg/day (20 mg x 2/day).~The treatment will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days)."
89300716|NCT03745664|Placebo Comparator|Placebo group|Saline Solution for Injection will be given ath the dose of 2 ml/day. The treatment placebo will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days).
89300717|NCT03447262|Experimental|VX-659/TEZ/IVA TC|Participants from parent studies VX17-659-102 (NCT03447249) or VX17-659-103 (NCT03460990) were administered VX-659 240 milligrams (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the TC treatment period for up to 96 weeks in the current study VX17-659-105.
89300718|NCT04094870|Active Comparator|Antidepressant medication|Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline 25 mg table
89300719|NCT04094870|Active Comparator|Interpersonal therapy|Up to 11 planned therapy sessions over a 24-week period beginning the day of randomization
89300720|NCT04399356|Active Comparator|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally on day 1 and daily for 6 more days (total 7 days of treatment)
89300721|NCT04399356|Placebo Comparator|Control|Participants in the control group will receive identical-appearing placebo by mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment)
89300722|NCT03692676||Subjects with Asthma|Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC
89300723|NCT03745872|Experimental|Testing|This is a preventative study model. All students who choose to participate will receive a pre and post test regarding their sun exposure behaviors and knowledge on sun exposure risk.
89300724|NCT04122534|Experimental|Treatment Group|Treatment groups receives the intervention training.
89300725|NCT04091360|Experimental|RPL554 100 mcg|"Part A: Patients receive 1 dose of either RPL554 100mcg via metered dose inhaler.~Part B: not applicable"
89300726|NCT04091360|Experimental|RPL554 300 mcg|Part A: Patients receive 1 dose of RPL554 300mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 300mcg via metered dose inhaler in crossover fashion.
89300727|NCT04091360|Experimental|RPL554 1000 mcg|Part A: Patients receive 1 dose of RPL554 1000mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
89300728|NCT04091360|Experimental|RPL554 3000 mcg|"Part A: Patients receive 1 dose of either RPL554 3000mcg via metered dose inhaler.~Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion."
89300729|NCT04091360|Experimental|RPL554 6000 mcg|"Part A: Patients receive 1 dose of either RPL554 6000mcg via metered dose inhaler.~Part B: not applicable"
89300730|NCT04091360|Placebo Comparator|RPL554 Placebo|Part A: Patients receive 1 dose of RPL554 placebo via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 placebo via metered dose inhaler in crossover fashion.
89300731|NCT04346628|Experimental|Favipiravir|In addition to SOC, participants will receive favipiravir for 10 days, and be evaluated for health outcomes through day 28.
89300732|NCT04346628|Active Comparator|Placebo|In addition to SOC, participants will receive placebo to match favipiravir for 10 days, and be evaluated for health outcomes through day 28.
89300733|NCT03681470|Experimental|Patients with Acne Vulgaris|Acne Vulgaris in Patients With Skin of Color
89300734|NCT02414750|Experimental|Treatment with BRAF/MEK inhibitor|"Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.~During the study biopsies and blood will be taken from the patients."
89300735|NCT04343976|Experimental|Lambda Treatment|Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda
89300736|NCT04343976|Placebo Comparator|Saline Placebo|Subcutaneous injection of saline placebo
89300737|NCT03322540|Experimental|Pembrolizumab + Epacadostat|Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.
89300738|NCT03322540|Active Comparator|Pembrolizumab + Placebo|Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.
89300739|NCT03619226|Experimental|test patch|two adhesive patches are applied to the abdominal area
89300740|NCT04339296|Experimental|Intervention group|Intervention group included medication management with Spencer.
89300741|NCT04339296|No Intervention|Control Group|The control group continued to use their current method of medication management, such as blister packs, strip packs, pill organizers and plastic prescription vials.
89300742|NCT02963740|Experimental|Weight Loss Intervention Group|Participants will take part in supervised exercise and home-based exercise sessions. Participants will be asked to follow a specific diet. Participants will be asked to take part in weekly behavioral group phone calls.
89300743|NCT02909452|Active Comparator|ENT 1mg daily with pembro every 3 weeks|Entinostat daily in combination with pembrolizumab every three weeks
89300744|NCT02909452|Active Comparator|ENT 5mg weekly with pembro every 3 weeks|Entinostat once weekly in combination with pembrolizumab every three weeks
89300745|NCT02909452|Active Comparator|ENT 10mg bi-weekly with pembro every 3 weeks|Entinostat once every other week in combination with pembrolizumab every three weeks
89300746|NCT02561182||Patients aged 5 years old and with a known diagnosis of a OGS|
89300747|NCT02517502|Experimental|DHA|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of DHA daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
89300748|NCT02517502|Placebo Comparator|Placebo|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of a matched placebo daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
89300749|NCT03629002||patients with systemic scleroderma|Use of the biological collection of the vascualire stromal fraction of the SCLERADEC 2 clinical trial.
89300750|NCT03629002||healthy volunteers|Recovery of a sample of adipose tissue during a liposuction operation in a context of routine cosmetic surgery.
89300751|NCT02025556|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
89300752|NCT02025556|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
89300753|NCT02025556|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
89300754|NCT04334460|Active Comparator|Active (BLD-2660) Group|
89300755|NCT04334460|Placebo Comparator|Placebo Group|
89300756|NCT01935466||Pioglitazone|Ever users of Pioglitazone
89300757|NCT01935466||Other drugs|Never users of pioglitazone
89300758|NCT01776034|Experimental|SystemCHANGE Group Lifestyle counseling|"The SystemCHANGE™ intervention will be delivered over a six-month period involving 12 face-to-face group sessions (1.5 to 2 hours each) held weekly for three months, followed by three monthly booster calls. Intervention groups include ~10 to 15 patients, and friends and family members are encouraged to attend. Intervention sessions consist of 30-min to 60-min of behavior change activities and 60-min focused on healthy behaviors."
89300759|NCT01776034|Active Comparator|Phone Lifestyle Counseling|Participants will receive pamphlets that contain information on healthy eating, physical activity, sleep, and symptom management, and will be followed-up with telephone calls.
89300760|NCT04334148|Active Comparator|Hydroxychloroquine|Hydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.
89300761|NCT04334148|Placebo Comparator|Placebo|Matching placebo tablets
89300762|NCT01423630|Experimental|Probiotics and fruit fibre|Probiotics and fruit fibre
89300763|NCT04399122|Active Comparator|Acetaminophen with codeine|codeine 30mg/acetaminophen 325mg Take one to two tablets every 4 to 6 hours as needed for pain for up to 4 days following surgery.
89300764|NCT04399122|Active Comparator|Acetaminophen with oxycodone|oxycodone 5mg/acetaminophen 325mg Take one tablet every 4 to 6 hours as needed for pain for up to 4 days following surgery.
89300765|NCT00826462|Experimental|1|"Corticosteroid injection in combination with physical therapy~Injection with triamcinolone 10 mg and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn Entero 500 mg bid for 14 days"
89300766|NCT00826462|Placebo Comparator|2|"Placebo injection in combination with physical therapy~Injection with sodium chloride and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn entero 500 mg bid for 14 days"
89300767|NCT00826462|Active Comparator|3|Control group: wait-and-see treatment Naprosyn entero 500 mg bid for 14 days
89300768|NCT04398732||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.
89300769|NCT04398030|Experimental|coil-reinforced soft polymer indwelling cannula|Participants in this arm are randomized into the coil-reinforced soft polymer indwelling cannula group and then switched to a soft Teflon indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
89300770|NCT04398030|Active Comparator|soft Teflon indwelling cannula|Participants in this arm are randomized into the soft Teflon indwelling cannula group and then switched to the coil-reinforced soft polymer indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
89300771|NCT03064438|Experimental|ACU-D1 Ointment|Twice-daily application of ACU-D1 ointment to the face for 12 weeks.
89300772|NCT03064438|Placebo Comparator|ACU-D1 Ointment Vehicle|Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.
89300773|NCT04327986|Experimental|Cohort 1 Phase 1A/Arm 1A|De-escalating doses of NHS-IL12 (M9241) in combination with bintrafusp alfa (M7824)
89300774|NCT04327986|Experimental|Cohort 2 Phase 1B/Arm 1B|De-escalating doses of NHS-IL12 (M9241) in combination with bintrafusp alfa (M7824) and stereotactic body radiotherapy (SBRT)
89300775|NCT04327986|Experimental|Phase II Cohort 3/Arm 2|Recommended phase 2 dose (RP2D) of bintrafusp alfa (M7824) and NHS-IL12 (M9241) in combination with stereotactic body radiotherapy (SBRT)
89300776|NCT05209516|Experimental|Parkinson's disease (PD) patients Group 1|PD patients treated by Dopamine replacement therapy, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
89300777|NCT05209516|Experimental|Parkinson's disease (PD) patients Group 2|PD patients treated by Deep Brain Stimulation, recruited through Movement Disorders consultations at the Saint-Luc University Hospital, mainly of Prof. Jeanjean, Prof. Ivanoiu, Dr. Wilhelm
89300778|NCT05209516|Active Comparator|Healthy individuals|Healthy participants, aged between 18 and 85, will be recruited as control subjects by means of ads posting.
89300779|NCT05209204||40 pateint glucoma suspect|ASOCT
89300780|NCT05209048||VTE of Derivation group|VTE of Derivation group includes patients who underwent orthotopic liver transplantation on 2018.8-2020.12 and developed VTE within 30 days after operation
89300781|NCT05209048||No-VTE of Derivation group|No-VTE of Derivation group includes patients who underwent orthotopic liver transplantation on 2018.8-2020.12 and did not develop VTE within 30 days after surgery or after 30 days
89300782|NCT05209048||VTE of Validation group|VTE of Validation group includes patients who underwent orthotopic liver transplantation on 2021.1-2021.12 and developed VTE within 30 days after operation
89300783|NCT05209048||No-VTE of Validation group|No-VTE of Validation group includes patients who underwent orthotopic liver transplantation on 2021.1-2021.12 and did not develop VTE within 30 days after surgery or after 30 days
89300784|NCT05208658|Experimental|Classical Vision Therapy Treatment: vision therapy exercises for fusional vergence abilities|"The Experimental Group (EG) it consist in a Classical Vision Therapy Treatment. This group will do weekly office-based therapy of 45 minutes of visual exercises during 12 weeks. The office-based done by the EG consists of a vergence therapy and its protocol will follow Scheiman's Protocol and Indications.~The exercises do not tough the eye or use drugs. They are just visual training exercises that improve fusional convergence and divergence response."
89300785|NCT05208658|Placebo Comparator|Eye Movement Therapy Treatment: vision therapy placebo exercises not improve fusional vergence|"The Control Group or Placebo Group consist in a Control: Eye Movement Therapy Treatment. This group will do weekly office-based placebo therapy of 15 minutes during 12 weeks of visual exercises. This placebo therapy will consist of smooth-pursuit and discrimination exercises that do not influence vergence response.~The exercises do not tough the eye nor use drugs. They are just visual training exercises that do not improve fusional vergence response as they improve smooth-pursuit eye movements."
89300786|NCT04322682|Active Comparator|Colchicine|Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
89300787|NCT04322682|Placebo Comparator|Placebo|Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
89300788|NCT05207878|Experimental|Movement task|"All participants perform the STEGA-MRI (standardized tracing evaluation & grapheme assessment - MRI) precision drawing task during fMRI scanning.~Motor assessments outside the MRI do not qualify as interventions."
89300789|NCT04322526|Experimental|Naltrexone, then placebo|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate neural responses during the Contextual Framing and the Antidepressant fMRI Task.
89300790|NCT04322526|Placebo Comparator|Placebo, then naltrexone|In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride.
89300791|NCT05207800||healthy pregnant woman|healthy pregnant woman
89300792|NCT05207800||pregnant women with TPROM|pregnant women with term premature rupture of membranes
89300793|NCT05207800||pregnant women with PPROM|pregnant women with preterm premature rupture of membranes
89300794|NCT04115358|Experimental|Hyaluronic acid|Gengigel teething (%0,54 hyaluronic acid), 0,1ml to the orifice of the root canals of the primary molar.
89300795|NCT04115358|Active Comparator|Formocresol|0,1 ml to the orifice of the root canals of the primary molar.
89300796|NCT04115358|Active Comparator|Ferric sulfate|0,1 ml to the orifice of the root canals of the primary molar.
89300797|NCT05207332|Experimental|Vegan product|
89300798|NCT05207332|Active Comparator|Control|
89300799|NCT05207176|Experimental|DWP16001|Total number of subjects: 24 (8 Korean, 8 Caucasian, and 8 Hispanic)
89300800|NCT03628690|Experimental|BandGrip|Topical skin closure device
89300801|NCT03628690|Active Comparator|Standard Suture|Standard sutures will be used for wound closure
89300802|NCT05668884|Experimental|experimental group|Combination of Gemox, Donafenib and Tislelizumab
89300803|NCT05187208|Experimental|Experimental|BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients (high-grade serous or high-grade endoemtrioid)
89300804|NCT04109118|Other|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|"This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) and psychoeducation about benzodiazepine use in OAT.~Of note, this is a pilot trial for feasibility and acceptability. There is no randomization and we are not comparing arms."
89300805|NCT03619954|Experimental|NK cells infusion|
89300806|NCT05081206|Experimental|Manually controlled|
89300807|NCT05081206|Experimental|Target controlled|
89300808|NCT04105998|Experimental|Oxytocin First, then Placebo|Subjects in this arm will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU) at the first visit. Then at the next visit, they will receive Intramuscular injection of (1 milliliter) saline.
89300809|NCT04105998|Experimental|Placebo, Then Oxytocin|Subjects in this arm will receive intramuscular injection of (1 milliliter) saline at the first visit. Then at the next visit, they will receive Intramuscular injection of Oxytocin (Pitocin®), 10 International Units (IU).
89300810|NCT05008822|Experimental|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
89300811|NCT05008822|Active Comparator|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
89300812|NCT03747510|Experimental|CarpX Device|Transverse carpal ligament release with CarpX Device
89300813|NCT04913116||SARS-Cov-2 positives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
89300814|NCT04913116||SARS-CoV-2 negatives|200 individuals will be tested by each antigen test. Testing is done with up to three swabs at a time from each anatomical test location
89300815|NCT04902898|Other|Circumcision|Adult patients treated with circumcision
89300816|NCT04902898|Active Comparator|Circumcision with device|Adult patients treated with sterile single-use circular stapling device CIRCCURERII (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
89300817|NCT04900714|Experimental|Decremental PEEP|Every participant will be exposed to a stepwise decremental PEEP.
89300818|NCT04397718|Placebo Comparator|Placebo + BSC|No active, only placebo (2 - prefilled syringes containing 3 ml of 0.9% saline) plus best supportive care.
89300819|NCT04397718|Experimental|Degarelix + BSC|Active Degarelix (2 - prefilled syringes containing 3 ml of reconstituted Degarelix concentrated to 40mg/ml) plus best supportive care.
89300820|NCT04679038|Experimental|combinational therapy part|SHR-1701 + famitinib
89300821|NCT04679038|Experimental|monotherapy part|famitinib
89300822|NCT04643860||General population|Subjects, at low and high risk of SARS-Cov-2, who undergo the nasopharyngeal swab procedure for the diagnosis of SARS-CoV-2 infection will be consecutively recruited at the Clinic Laboratory of IRCCS Neuromed in Pozzilli and Diagnostica Medica Spa in Avellino, Italy.
89523322|NCT03382613||Usual Care|Hospitals assigned to the Usual Care arm will not participate in the structured QI program but will continue with their standard hospital practice in treating patients with atrial fibrillation (AF) at risk for ischemic stroke. Hospitals will also complete a final survey and final retrospective chart reviews during the Measurement Period.
89300823|NCT04105218|Experimental|Evening Exercise|Participants will arrive in the Clinical and Translation Research Center (CTRC) and enter the whole room calorimeter approximately 1 hour after arrival. During the evening exercise condition, participants will perform 45-minutes of moderate intensity continuous exercise on a treadmill 12 hours after habitual wake time in the evening. Participants will begin with a warm-up for 5 minutes at 2.0-2.5 mph. Heart rate will be monitored continuously with a heart rate monitor. Participants will maintain heart rate at 65% of age-predicted maximum heart rate. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
89300824|NCT04105218|Placebo Comparator|Control|Participants will arrive in the Clinical and Translation Research Center (CTRC) in the morning within 2 hours of their habitual wake time. Participants will enter the whole room calorimeter approximately 1 hour after arriving at the CTRC. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
89300825|NCT03747354|Active Comparator|complete blood count|blood samples will be taken from patient and complete blood count is done early morning
89300826|NCT03747354|Active Comparator|erythrocyte sedimentation rate|blood samples will be taken from patient and erythrocyte sedimentation rate is done
89300827|NCT05730556|Experimental|Electrical Neuromodulation, Then Sham|Subjects will first have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.
89300828|NCT05730556|Experimental|Sham, Then Electrical Neuromodulation|Subjects will first have the sham device applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 12. Subjects will then have the Nerivio ® applied 20 minutes prior to clinical care onabotulinumtoxinA (Botox) injection, and continue to wear the device for a total of 40 to 45 minutes at week 24.
89300829|NCT04317690||High Cholesterol|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high cholesterol, who are either taking medication for high cholesterol for 2 years or less; or have discussed managing high cholesterol in the past 2 years. These people will see items only pertaining to high cholesterol.
89300830|NCT04317690||High Blood Pressure|People between the ages of 30-75 ,with no previous heart attack or stroke history, who have been diagnosed with high blood pressure, who are either taking medication for high blood pressure for 2 years or less; or have discussed managing high blood pressure in the past 2 years. These people will see items only pertaining to high blood pressure.
89300831|NCT04317690||Colorectal Cancer Screening|People between the ages of 50-75 with no previous diagnosis of colon cancer, who have been screened for colon cancer (or discussed screening for colon cancer) in the past 2 years, or who had first colon cancer screening in past 2 years. These people will see items only pertaining to colon cancer screening.
89300832|NCT04317690||Breast Cancer Screening|Females between the ages of 40-50 with no previous diagnosis of breast cancer who have had mammogram (or discussed having a mammogram) in the past 2 years, or had first mammogram in past 2 years. These people will see items only pertaining to breast cancer screening.
89300833|NCT04317690||Prostate Cancer Screening|Men between the ages of 45-69 with no previous diagnosis of prostate cancer who have been screened for prostate cancer (or discussed screening for prostate cancer) in the past 2 years or had first prostate cancer screening in the past 2 years. These people will see items only pertaining to prostate cancer screening.
89300834|NCT04543968|Experimental|hydroxytyrosol (HT) intake|"MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.~Doses of hydroxytyrosol (HT) intake: (1) 3-10 years old, 10 mg/day; (2) 11-18 years old 30mg/day"
89300835|NCT04543968|Experimental|hydroxytyrosol (HT) intake and withdraw|"MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.~Doses of hydroxytyrosol (HT) intake: (1) 3-10 years old, 10 mg/day; (2) 11-18 years old 30mg/day"
89300836|NCT04097106||Lean BMI (19-25)|
89300837|NCT04097106||Obese BMI (30-35)|
89300838|NCT04368910|Experimental|Pyronaridine - artesunate|"Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
89300839|NCT04368910|Active Comparator|Chloroquine|"Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.~For patients who complete the study up to Day 28 and who have normal G-6-PD activity, a 14-day course of primaquine (15 mg/day) shall be administered starting on Day 28, after all required assessments have been performed, to complete their radical cure. Patients who are deficient in G-6-PD and who complete the study up to Day 28 will be treated as per country policy."
89300840|NCT04249258|Experimental|Dobutamine|Measurements of various conduction parameters will be taken at baseline as is standard protocol for an EPS. Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min. At each of these dosages the same conduction parameters will be measured. A comparison will then be made between the conduction parameters at baseline and when the Dobutamine is administered.
89300841|NCT03938584|Experimental|Vitamin C|
89300842|NCT03938584|Placebo Comparator|Placebo|
89300843|NCT03781726|Experimental|Treatment with glecaprevir/pibrentasvir Fixed Dose Combination|8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir
89523323|NCT03125525||Active treatment patients|Patients using Cefaly device on routine daily basis
89300844|NCT03721276|Experimental|Therapy|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
89300845|NCT03721276|Other|Waitlist|Individuals assigned to waitlist will be put on a waitlist for 3 months after baseline assessment, after which they will also receive the same treatment as the therapy group.
89300846|NCT03311854|Experimental|Emapalumab|
89300847|NCT03269344|Placebo Comparator|Control Arm|Standard supportive care during definitive treatment plus placebo
89300848|NCT03269344|Experimental|Experimental Arm|Gabapentin plus standard supportive care
89300849|NCT04389840|Experimental|Cohort 1 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.25 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
89300850|NCT04389840|Placebo Comparator|Cohort 1 placebo|Placebo IV bolus on Day 1, followed by Placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours])
89300851|NCT04389840|Experimental|Cohort 2 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.325 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
89300852|NCT04389840|Placebo Comparator|Cohort 2 placebo|Subjects received placebo IV bolus on Day 1, followed by placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
89300853|NCT04389840|Experimental|Cohort 3 dociparstat|Subjects received 4 mg/kg of dociparstat administered as an intravenous (IV) bolus on Day 1, followed by 0.325 mg/kg/hr dociparstat by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
89300854|NCT04389840|Placebo Comparator|Cohort 3 placebo|Subjects received placebo IV bolus on Day 1, followed by placebo by continuous IV infusion for 24 hours daily for up to 7 days (starting on Day 1 and ending on Day 8 [168 hours]).
89300855|NCT03747198|Experimental|methylsulfonylmethane|Subjects will be given 2 g/day of methylsulfonylmethane (MSM). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points (ovulation, menstruation).
89300856|NCT03747198|Placebo Comparator|Placebo|Subjects will be given 2 g/day placebo (rice flour). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points as the intervention arm (ovulation, menstruation).
89300857|NCT02940106|Placebo Comparator|closed device|Standard cryopreservation system.
89300858|NCT02940106|Active Comparator|open device|New cryopreservation system.
89300859|NCT02933944|Experimental|TG02-treatment|"Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).~Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered."
89300860|NCT04307940|Experimental|Naproxen sodium|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
89300861|NCT04307940|Active Comparator|Hydrocodone/Acetaminophen|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
89300862|NCT04307940|Placebo Comparator|Placebo|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
89300863|NCT04495530||Patient|Patients will be considering commencing or discontinuing parenteral nutrition, or will be receiving home parenteral nutrition
89300864|NCT04495530||Carer|Carers will be those caring for a patient with advanced cancer who is considering commencing or discontinuing parenteral nutrition, or already receiving parenteral nutrition. Carers will also be recruited if they previously cared for a person with advanced cancer receiving parenteral nutrition in the last 12 months
89300865|NCT02717416|Experimental|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|The intervention group
89300866|NCT02717416|Active Comparator|Hemoclip (HX-610-135, Olympus, Japan) or electrical coagulation group|Patients in the control group will undergo endoscopic hemostasis with combination therapy, epinephrine injection therapy and hemoclip or electrical coagulation therapy.
89300867|NCT02547298||All participants|All participants will be filling out questionnaires and undergoing cystoscopy with hydrodistension for evaluative reasons
89300868|NCT02054104|Experimental|1/Vaccine Plus Chemotherapy|H1299 cell lysates with iscomatrix vaccine with metronomic chemotherapy
89300869|NCT02054104|Experimental|2/Vaccine Alone|H1299 cell lysates with iscomatrix adjuvant vaccine
89300870|NCT04377334|Experimental|MSC Treatment|
89300871|NCT04377334|No Intervention|control|
89300872|NCT04393974||Cancer patients with COVID-19|All cancer patients can be recruited onto this research following a positive test for Sars-Cov2. The research will follow what treatments they are given for the infection, but also look at their past medical history including prior and any current anti-cancer therapy.
89300873|NCT03749382|Experimental|Intervention Neutral instructions|Appearance based intervention group delivered with neutral instructions from the investigator alongside general stop smoking intervention leaflet.
89300874|NCT03749382|Experimental|Intervention Additional instructions|Appearance based intervention group delivered with neutral instructions with additional reassuring messages from the investigator alongside general stop smoking intervention leaflet.
89300875|NCT03749382|No Intervention|Control|Neutral task plus the general stop smoking intervention in the form of a leaflet, administered by the investigator.
89300876|NCT04323124|Experimental|Treatment|PF-07059013 assignment
89300877|NCT04323124|Placebo Comparator|Placebo|Placebo assignment
89300878|NCT04090242|Active Comparator|App plus Nano|Use of BD Diabetes Care Application for Mobile devices PLUS the use of BD Nano 2nd Gen Pen Needle for delivery of insulin
89300879|NCT04090242|No Intervention|Standard Care|Standard of Care/Subject is to continue on their current diabetes management regime
89300880|NCT04229290|Experimental|Dolutegravir|Participants in this arm will have a switch from a protease inhibitor based second line regimen to Dolutegravir maintaining the same NRTI backbone
89300881|NCT04229290|Active Comparator|Protease Inhibitor|Participants in this arm will be maintained on their protease inhibitor based second line regimen
89300882|NCT04181476|Other|Topical products and Untreated areas|The subject will serve as their own control. Four different products will be tested.
89300883|NCT04090164||Study group|The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.
89300884|NCT04090164||Control group|A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.
89300885|NCT04156438|Active Comparator|Low tidal volume ventilation|Conventional low tidal volume ventilation
89300886|NCT04156438|Experimental|Airway pressure release ventilation|Early use of airway pressure release ventilation
89300887|NCT04086654|Other|International Trauma Interview (ITI)|
89300888|NCT04099108|Experimental|Intervention|Combined cycle ergometry and bolus amino acid supplementation, along with standard of care
89300889|NCT04099108|No Intervention|Control|Standard of care only
89300890|NCT04068142|No Intervention|Clinical Personnel Safety Planning|Patients will complete a traditional written suicide safety plan with clinical personnel.
89300891|NCT04068142|Experimental|Peer Supporter Safety Planning|Patients will complete a traditional written suicide safety plan with peer supporters.
89300892|NCT03628222|Experimental|ENB-TBLB|Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion. After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
89300893|NCT03628222|Active Comparator|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
89300894|NCT03628144|Experimental|A: Intervention Group - Impact®|A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
89300895|NCT03628144|Active Comparator|B: Control Group - Boost®|B: Control Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Boost® High Protein: Identical schedule of a supplement with similar calorie and protein content, Boost® High Protein. Participants will undergo pre- and post-treatment assessments.
89300896|NCT03988192|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients treated by immunotherapy for lung cancer.
89300897|NCT03935698|Experimental|Physiotherapy|12 weekly 60-minute individual sessions of multimodal physiotherapy including education, stretching techniques, pelvic floor muscle biofeedback as well as home exercises.
89300898|NCT03855046|Experimental|Xeomin|Complex treatment of chronic anal fissure with drug-induced relaxation of the internal sphincter with Botulinum Toxin Type A. (IncobotulinumtoxinA 50 U Intramuscular Powder for Solution).
89300899|NCT03855046|Active Comparator|Xeomin control|Complex treatment of chronic anal fissure with lateral subcutaneous sphincterotomy.
89300900|NCT03483298||elevated sperm DNA fragmentation|Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure
89300901|NCT03255772||Acute Chest pain|All patients admitted to the Clinical Decision Unit presenting to the Emergency Department (ED) with chest pain with risk factors suggesting a possible cardiac etiology.
89300902|NCT03143842|Other|Vagus Nerve Stimulation|VNS paired with word pairs, VNS unpaired with word pairs, no VNS
89300903|NCT04292730|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
89300904|NCT04292730|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
89300905|NCT04292730|Active Comparator|Part A: SOC Therapy|Participants will receive continued standard of care therapy.
89300906|NCT04292730|Experimental|Part B: Extension Treatment, Remdesivir 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
89300907|NCT02861014|Experimental|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
89300908|NCT04382586|Experimental|Zanubrutinib + Supportive Care|Participants received zanubrutinib plus supportive care
89300909|NCT04382586|Active Comparator|Placebo + Supportive Care|Participants received placebo plus supportive care alone
89300910|NCT02728648|Other|Active|Open label IV Oxycodone 0.1 mg/kg Bolus Pharmacokinetic-Pharmacodynamic Study
89300911|NCT02717728|Active Comparator|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
89300912|NCT02717728|Sham Comparator|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
89300913|NCT03912454|Experimental|BMAC Injection|
89300914|NCT04480710|Experimental|CRV431 75mg|CRV431, softgel capsule, 75mg, QD, 28 days, fasted conditions
89300915|NCT04480710|Placebo Comparator|Placebo, 75mg|Placebo, softgel capsule, QD, 28 days, fasted conditions
89300916|NCT04480710|Experimental|CRV431 225mg|CRV431, softgel capsule, 225mg, QD, 28 days, fasted conditions
89300917|NCT04480710|Placebo Comparator|Placebo, 225mg|CRV431, 3 softgel capsules, 225mg, QD, 28 days, fasted conditions
89300918|NCT03749304|Experimental|ANI monitor|
89300919|NCT02358928|Other|Low calorie diet|Calorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
89300920|NCT02358928|Other|Low carbohydrate diet|Carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
89300921|NCT02324764|Experimental|Glidesheath Slender|The transradial procedure will be performed using the glidesheath slender (studied sheath)
89300922|NCT02324764|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)
89300923|NCT04268316|Experimental|Virtual Reality Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in virtual reality. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable activities to enjoy in virtual reality.
89300924|NCT04268316|Active Comparator|Behavioral Activation in real-life|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life.
89300925|NCT04268316|No Intervention|Waitlist Control|Participants randomized to this arm will not receive any type of intervention and will be asked to complete the PHQ-9 once a week for three weeks (4 sessions) to track symptoms. Participants will be offered to engage in behavioral activation in real life or with virtual reality when the four weeks are complete. Their data will only be used from the time they were on the waitlist.
89300926|NCT01971970||Pediatric IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
89300927|NCT01971970||Adult IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
89300928|NCT01161394|Experimental|Pioglitazone 15mg|8 patient will receive this drug
89300929|NCT01161394|Experimental|pioglitazone 30mg|8 patients will get this drug
89300930|NCT01161394|Placebo Comparator|Placebo|8 patient will get this drug
89300931|NCT05216458|Experimental|Control|Households in the control group did not receive any messages during the intervention period from June 2021 to August 2021
89300932|NCT05216458|Experimental|Generic Outreach|"Households in the generic outreach group were assigned to receive a letter and two email reminders in June 2021 and thereafter received the standard messages Covered California sends to prospective enrollees, which explain that nearly all Covered California members get subsidies to pay for health insurance and encourage them to explore their plan options using an online Shop & Compare tool.~For the generic arm, the outreach materials described new financial assistance under the American Rescue Plan and noted the availability of plans as low as $1/month."
89300933|NCT05216458|Experimental|Personalized Outreach|"Households in the personalized outreach group were assigned to receive a letter and two email reminders in June 2021 and thereafter received the standard messages Covered California sends to prospective enrollees.~For the personalized arm, the outreach explicitly informed the household that they were eligible for a $1/month CSR Silver 94 plan and described the benefits this plan confers. The outreach materials for the personalized group were not only designed to increase enrollment, but also to simplify the search process by providing households with a clear recommendation to pick a CSR Silver plan; this included highlighting the low out-of-pocket costs these plans provide when accessing care, a screenshot of what the plan would look like when they entered the shopping portal and peer comparison language that noted 9 out of 10 consumers like them choose CSR Silver plans"
89300934|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 1|Healthy adult subjects will receive a single oral dose of gepotidacin 1500 mg (2 X 750 mg, treatment A), tablets, on Day 1 of Period 1; two oral doses of gepotidacin 3000 mg (4 x 750 mg, Treatment C), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment E), tablets, at 0 and 6 hours on Day 9 of Period 3.
89300935|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 1|Healthy adult subjects will receive a single oral dose of matching placebo (treatment B), tablets, on Day 1 of Period 1; two oral doses of matching placebo (treatment D), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of matching placebo (treatment F), tablets, at 0 and 6 hours on Day 9 of Period 3.
89523324|NCT03125603||NSCLC's patients|"Patients with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy.~Consultation of the patient's medical files at the hospital."
88806277|NCT05412654|Experimental|High potassium water|All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The intervention group will receive high potassium water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.
88806278|NCT05412654|Placebo Comparator|Low potassium control water|All participants will be provided with bottled water for the duration of the 4 week intervention to consume 1L/day. The control group will receive regular bottled mineral water. Participants will be instructed to consume 1 bottle (500 mL) within 2 hours after waking up and 1 bottle (500 mL) within 2 hours before going to bed (total 1L/day). Participants will continue with the same diet and exercise patterns in their daily life similar to before participating in the study, for the whole length of the intervention.
88806279|NCT01160237|Experimental|Group A|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
88806280|NCT01160237|Experimental|Group B|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
88806281|NCT01160237|Active Comparator|Group C|Subjects not previously vaccinated with a vaccine against the pandemic H1N1 strain
88813889|NCT01045460|Experimental|ASCT + MILs|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.
89300936|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 2|Healthy adolescent subjects will receive a single oral dose of gepotidacin 1500 mg (2 x 750 mg, treatment A), tablets, on Day 1 of Period 1; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment G), tablets, at 0 and 6 hours on Day 1 of Period 2.
89300937|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 2|Healthy adolescent subjects will receive a single oral dose of matching placebo (treatment B), tablets on Day 1 of Period 1; and two oral doses of matching placebo (treatment H), tablets at 0 and 6 hours on Day 1 of Period 2.
89300938|NCT03749226|Active Comparator|AZLI group|Patients assigned to study group will receive nebulized Aztreonam lysine (AZLI 75 mg-dose) three times /day during 5 days by mean of the ultrasonic nebulizer (Aeroneb solo®) plus Combihaler® spacer adapted of the ventilator
89300939|NCT03749226|No Intervention|Control group|Patients assigned to control group will no receive any intervention for heavy Gram negative colonization
89300940|NCT03745482|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following application of the mobilisations outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
89300941|NCT03745482|No Intervention|Control|"The control condition will consist of the participant lying prone on a plinth for the same time if takes for intervention to be applied approximately 10 minutes.~Following the control condition outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
89300942|NCT04259346|Experimental|Ixekizumab (Reference)|Approved formulation of 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).
89300943|NCT04259346|Experimental|Ixekizumab (Test)|Test formulation of 80 mg ixekizumab administered as a SC injection via AI.
89300944|NCT03748914|Experimental|Intervention Group|Milking the cut umbilical cord once towards the Infant at a speed of 10cm/second.
89300945|NCT03748914|Active Comparator|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
89300946|NCT03748836|Active Comparator|Single Ascending Dose ALPN-101|
89300947|NCT03748836|Placebo Comparator|Single Dose Placebo|
89300948|NCT03748836|Active Comparator|Multiple Ascending Dose ALPN-101|
89300949|NCT03748836|Placebo Comparator|Multiple Dose Placebo|
89300950|NCT04228302|Experimental|EC5026|Single Ascending Doses of oral EC5026
89300951|NCT04228302|Placebo Comparator|Placebo|Single doses of matching oral placebo
89300952|NCT03746886||Breast-feeding women|A single breast-milk sample will be collected from 20 women who breast-feed their child (0-6 months old).
89300953|NCT01562262||CTR|Control group
89300954|NCT01562262||ASS|Apnea without complaints group
89300955|NCT01562262||ACS|SAOS Group
89300956|NCT01562340|Active Comparator|Pomegranate fruit extract|
89300957|NCT01562340|Active Comparator|Pomegranate juice|
89300958|NCT01562418|Experimental|Ergonomic consulting|Ergonomic consulting without biofeedback
89300959|NCT01562418|Experimental|Ergonomic consulting with biofeedback|Ergonomic intervention with biofeedback
89300960|NCT01562418|No Intervention|general instructions|general instructions with no intervention
89300961|NCT01348100|Experimental|Iloperidone 50 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
89300962|NCT01348100|Experimental|Iloperidone 125 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
89300963|NCT01348100|Experimental|Iloperidone 250 mg crystalline formulation - Phase B|Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
89300964|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase B|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
89300965|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
89300966|NCT01348100|Experimental|Iloperidone 500 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
89300967|NCT01348100|Experimental|Iloperidone 625 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
89300968|NCT03676634|Experimental|Vaccine|rBV A/B
89300969|NCT03675776|Experimental|Rapastinel 450mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
89300970|NCT03675776|Experimental|Rapastinel 225mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
89300971|NCT03675776|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration).
89300972|NCT03673670|Experimental|1.5 mg RPL554 and tiotropium/olodaterol|1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
89300973|NCT03673670|Experimental|6 mg RPL554 and tiotropium/olodaterol|6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
89300974|NCT03673670|Experimental|Placebo and tiotropium/olodaterol|Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
89300975|NCT04369742|Experimental|Hydroxychloroquine|
89300976|NCT04369742|Placebo Comparator|Placebo|
89300977|NCT04369430|Experimental|AKST4290|Subjects will receive AKST4290, 400 mg twice daily, for 12 weeks.
89300978|NCT04369430|Placebo Comparator|Placebo|Subjects will receive placebo, twice daily, for 12 weeks.
89300979|NCT04363736|Active Comparator|TCZ 8 mg/kg|Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
89300980|NCT04363736|Experimental|TCZ 4 mg/kg|Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.
89300981|NCT04362176|Experimental|pathogen reduced SARS-CoV-2 convalescent plasma|Transfusion of convalescent plasma will be administered by clinical or research personnel while the participant is hospitalized on Study Day 0. Plasma will be administered at a rate of 500 mL/hour and will be administered within 12 hours of randomization.
89300982|NCT04362176|Placebo Comparator|Placebo|Participants randomized to the control group will receive 250mL of Lactate Ringers containing multivitamins intravenously on Day 1 as a placebo.
89300983|NCT03748238|Experimental|Injury group|Endometrial injury with hysteroscopy
89300984|NCT03748238|No Intervention|Control group|No hysteroscopy
89300985|NCT03745586|Experimental|All study participants|
89300986|NCT05717920|Experimental|ADX-629|
89300987|NCT03745508|Active Comparator|Caffeinated Coffee (200 mg caffeine)|~200 mg of caffeine from instant coffee
89300988|NCT03745508|Active Comparator|Caffeinated Coffee (400 mg caffeine)|~400 mg of caffeine from instant coffee
89300989|NCT03745508|Placebo Comparator|Decaffeinated Coffee|Decaffeinated instant coffee
89300990|NCT03748160|No Intervention|Control|There is no intervention (letter) in the control arm. There is no control arm in the city of Espoo. 1/3 of subjects in all other municipalities are assigned to the control arm.
89300991|NCT03748160|Active Comparator|Mailing|This treatment arm consists of a standard letter reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
89300992|NCT03748160|Active Comparator|Herd|This treatment arm consists of a letter that highlights the herd immunity effects of vaccination and reminds elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
89300993|NCT04079816|Experimental|INVSENSOR00025|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor.
89300994|NCT03055936|Experimental|A1|levodopa 50 mg, carbidopa 12.5 mg
89300995|NCT03055936|Experimental|B1|levodopa 50 mg, carbidopa 65 mg
89300996|NCT03055936|Experimental|C1|levodopa 50 mg, carbidopa 65 mg, ODM-104 50 mg
89300997|NCT03055936|Experimental|D1|levodopa 50 mg, carbidopa 65 mg, ODM-104 100 mg A4 ; B4 l; C4 ; D4 levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
89300998|NCT03055936|Experimental|A2|levodopa 100 mg, carbidopa 25 mg
89300999|NCT03055936|Experimental|B2|levodopa 100 mg, carbidopa 65 mg
89301000|NCT03055936|Experimental|C2|levodopa 100 mg, carbidopa 65 mg, ODM-104 50 mg
89301001|NCT03055936|Experimental|D2|levodopa 100 mg, carbidopa 37,5 mg
89301002|NCT03055936|Experimental|A3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
89301003|NCT03055936|Experimental|B3|levodopa 150 mg, carbidopa 65 mg
89301004|NCT03055936|Experimental|C3|levodopa 150 mg, carbidopa 65 mg, ODM-104 50 mg
89301005|NCT03055936|Experimental|D3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
89301006|NCT03055936|Experimental|A4|levodopa IR 100 mg (Sinemet), carbidopa 25 mg
89301007|NCT03055936|Experimental|B4|levodopa 100 mg, carbidopa 65 mg
89301008|NCT03055936|Experimental|C4|levodopa 100 mg, carbidopa 25 mg, ODM-104 100 mg
89301009|NCT03055936|Experimental|D4|levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
89301010|NCT05215444||survivors|
89301011|NCT05215444||non survivors|
89301012|NCT05215366||children with febrile seizures|
89301013|NCT05215366||febrile children without seizures|
89301014|NCT05215366||healthy control children|
89301015|NCT05201170|Experimental|PL9643 Opthalmic Solution|PL9643 ophthalmic solution bilaterally three times a day.
89301016|NCT05201170|Active Comparator|Vehicle Opthalmic Solution|Vehicle opthalmic solution bilaterally three times a day.
89301017|NCT05194696||Caffeine questionnaire|A questionnaire concerning caffeine habits will be handed out to the patients
89301018|NCT03891524|Experimental|Group A: JNJ-70033093 25 mg + Placebo BID|Participants will receive JNJ-70033093 25 milligram (mg) (1*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
89301019|NCT03891524|Experimental|Group B: JNJ-70033093 50 mg BID|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules) BID orally for 10 to 14 postoperative days.
89301020|NCT03891524|Experimental|Group C: JNJ-70033093 100 mg + Placebo BID|Participants will receive JNJ-70033093 100 mg (1*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
89301021|NCT03891524|Experimental|Group D: JNJ-70033093 200 mg BID|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules) BID orally for 10 to 14 postoperative days.
89301022|NCT03891524|Experimental|Group E: JNJ-70033093 25 mg Once Daily + Placebo|Participants will receive JNJ-70033093 25 mg (1*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
89301023|NCT03891524|Experimental|Group F: JNJ-70033093 200 mg Once Daily + Placebo|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
89301024|NCT03891524|Experimental|Group G: JNJ-70033093 50 mg once daily + Placebo|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
89523325|NCT04923815||AVNRT|atrioventricular nodal reentrant tachycardia
89301025|NCT03891524|Active Comparator|Group I: Enoxaparin 40 mg Once Daily|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
89301026|NCT03055624|Experimental|Prostate artery embolization|Single arm study of patients undergoing the prostate artery embolization procedure with Embosphere particles.
89301027|NCT04695652|Experimental|MVC-COV1901(S protein with adjuvant)|S-2P protein with CpG and Aluminum Hydroxide/0.5mL
89301028|NCT04695652|Placebo Comparator|MVC-COV1901(Saline)|Saline/0.5 mL
89301029|NCT04636060|Experimental|Iron-treatment group|
89301030|NCT04489108|Experimental|Tranexamic Acid with Standard Medical Treatment|Arm A will Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours along with standard medical and interventional (Endoscopy) therapy.
89301031|NCT04489108|Active Comparator|Placebo + Standard Medical treatment|Arm B will receive similar volume of isotonic solution (saline) along with standard medical and interventional (Endoscopy) therapy.
89301032|NCT03931252|Experimental|High fat|Boost VHC (Very High Calorie), Nestle, 8 ounce can
89301033|NCT03931252|Experimental|High protein|Ensure High Protein 8 ounce can
89301034|NCT03771586|Experimental|SAGE-718|
89301035|NCT03771586|Placebo Comparator|Placebo|
89301036|NCT03263416|Experimental|Arm A|
89301037|NCT03263416|Other|Arm B|Standard
89301038|NCT03627910|Experimental|Treatment group|Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
89301039|NCT03627910|Active Comparator|Control group|Control group will be administered only an enteral nutrition formula rich in zinc and arginine
89301040|NCT02582164|Experimental|Adult|Duke Biomedical Engineering's long-working distance OCT system imaging of adult participants ages ≥18 year of age
89301041|NCT02582164|Experimental|Teenage minors|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥13-≤17 years of age
89301042|NCT02582164|Experimental|Children-pre teen|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥7-≤12 years of age
89301043|NCT02582164|Experimental|Target age group ≥6 months to ≤6 years|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥6 months to ≤6 years of age
89301044|NCT02541838|Experimental|Muscle, Balance, and aerobic exercise|This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.
89301045|NCT02335060|Experimental|Active N-acetylcysteine and Active Delta-9-THC|
89301046|NCT02335060|Placebo Comparator|Placebo and Active Delta-9-THC|
89301047|NCT02335060|Experimental|Active N-acetylcysteine and Placebo|
89301048|NCT02335060|Placebo Comparator|Placebo and Placebo|
89301049|NCT00284986|Experimental|Prochymal®|
89301050|NCT05219188||Heart failure with preserved ejection fraction and BMI <25|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
89301051|NCT05219188||Heart failure with preserved ejection fraction and BMI >30|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
89301052|NCT05219188||Healthy controls with BMI <25|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
89301053|NCT05219188||Healthy controls with BMI >30|Subjects will undergo DCE-CT. Radiation exposure has been calculated to be 3.7 mS, Iomeron dose admission during CT is 50 mL containing 714 mg/ml iomeprol
89301054|NCT05219032|Experimental|Interpreter|Professional Spanish interpreter
89301055|NCT05219032|No Intervention|Usual Care|Usual care provided to patients
89301056|NCT05218954||patients with heterotopic ossification|patients with heterotopic ossification following THR
89301057|NCT05218954||patients without heterotopic ossification|patients without heterotopic ossification following THR
89301058|NCT05218876|Experimental|Low- to moderate intensity strength and endurance training|Participants will perform a combination of strength and endurance training with low-to moderate-intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
89301059|NCT05218876|Experimental|High intensity strength and endurance training|Participants will perform a combination of strength and endurance training with high intensity during (neo-) adjuvant treatment with chemotherapy, approximately 6 months. All strength training will be supervised while the endurance training is home-based and followed up by a coach.
89301060|NCT05218564|Experimental|Group 1, consisting of participants with COPD and usually using O2|In this group, in addition to the standard care, the participant undergoes the 6 Minute Walking Test (6MWT) using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The same, then, in addition to the standard care, is subjected to the execution of the 6 Minute Walking Test (6MWT), thanks to the use of cylinders of Oxygen (O2), believing that inside the cylinder there is Oxygen (O2). The sequence of this group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen).
89301061|NCT05218564|Placebo Comparator|Group 2, consisting of participants with COPD and usually not using O2|In this group, in addition to standard care, the participant is given the 6 Minute Walking Test (6MWT) using oxygen (O2) cylinders, believing that there is oxygen (O2) inside the cylinder. Next, the participant undergoes the 6 Minute Walking Test (6MWT), using compressed medical air (RA) cylinders, believing that there is oxygen (O2) inside the cylinder. The sequence of this group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
89523326|NCT04923815||AVRT|atrioventricular reentrant tachycardia, including Wolff-Parkinson-White syndrome（WPW）
89523327|NCT03382535|Active Comparator|Voice therapy|An individually tailored voice therapy where the order and length of voice treatment methods will depend on the nature of each subject's voice problems. The intervention will take eight weeks and average of eight sessions (a' 45 min).
89301062|NCT05218174|Experimental|Exercise training program|"Participants in this arm will complete an 8-week exercise training program comprised of an initial functional assessment to create an exercise prescription, followed by 7 in-person weekly sessions. Each session consisting of approximately 50 minutes of individualized exercise training and approximately 10 minutes of cognitive training via the Sports Academy CogPT iPad app. All participants will receive exercise and cognitive training delivered weekly in a group-based setting at Sports Academy within the Star in Frisco, Texas during the intervention period. Additionally, they will have access to daily workouts pushed to their phone via the MOVE exercise app developed by our team."
89301063|NCT05218174|Sham Comparator|No training program|Participants in this arm will be wearing the WHOOP band for 8-weeks but will not be exposed to any active intervention.
89301064|NCT01346176|Experimental|Positive default|Patients in this arm will receive AD forms where specific life-extending interventions will be provided unless patients specifically opt-out from such selections
89301065|NCT01346176|Experimental|Negative default|Patients in this arm will receive AD forms where specific life-extending interventions will not be provided unless patients specifically opt-into such selections
89301066|NCT01346176|Experimental|Forced Choice|Patients in this arm will receive AD forms in which they must actively choose whether to receive each intervention.
89301067|NCT04075604|Experimental|Arm A: Nivolumab+Palbociclib+Anastrozole (ANZ)|
89301068|NCT04075604|Experimental|Arm B: Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ|
89301069|NCT04075604|Active Comparator|Arm C: Palbociclib+ANZ|
89301070|NCT05217550|Experimental|Intervention (Veggie Brek)|Nursery staff will present vegetables (raw carrot and cucumber batons) to children alongside their main breakfast food for five consecutive days every weekday morning for three weeks.
89301071|NCT05217550|No Intervention|Control|Children will be served their normal breakfast (with no vegetables) across the three-week intervention period.
89301072|NCT05217472|Experimental|Ravagalimab|Participants will receive a loading dose of intravenous (IV) ravagalimab dose A at Week 0 followed by subcutaneous (SC) ravagalimab dose A every other week (eow)
89301073|NCT05217472|Placebo Comparator|Placebo|Participants will receive a loading dose of intravenous (IV) placebo at Week 0 followed by subcutaneous (SC) placebo every other week (eow)
89301074|NCT05217394|Experimental|OTHIG|"Occupational Therapy Handwriting Intervention Guideline - this is the experimental guideline to be tested in this study.~Section C: Intervention for Handwriting Readiness Skills~Handwriting development~Pre-writing skills~Gross motor skills activities~Fine motor skills activities~Motor visual skills activities Section D: Intervention for Handwriting Skills~Handwriting tools~Pencil grasp~Posture and position~Hand dominance~Writing capitals, lowercase, and numbers~Handwriting speed Section E: Handwriting Intervention Module~Session 1: Development of Handwriting Skills Activities~Session 2: Pre-writing Skills Activities~Session 3: Gross and Fine Motor Skills Activities~Session 4: Writing Capital Letters~Session 5: Writing Lowercase Letters~Session 6: Writing Numbers"
89301075|NCT05217394|No Intervention|NOTi|"Natural Occupational Therapy Intervention - this means, the participants in this group are not exposed to the OTHIG. They receive natural OT intervention without exposure to the OTHIG.~The natural OT intervention includes:~Gross motor skills, fine motor skills, pre-writing skills, basic handwriting tasks such as copying, tracing, imitating and colouring.~It will follow the occupational therapist intervention set up by the respected therapist in charge. The OT in charge had qualifications from the local university in Malaysia.~The natural OT intervention includes:~Gross motor skills, fine motor skills, pre-writing skills, basic handwriting tasks such as copying, tracing, imitating and colouring.~It will follow the occupational therapist intervention set up by the respected therapist in charge. The OT in charge had qualifications from the local university in Malaysia."
89301076|NCT05217316|No Intervention|Control Group|Control group will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth.
89301077|NCT05217316|Experimental|Intervention Group|Both groups will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth. The intervention lies in which the intervention group will receive a supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child.
89301078|NCT05217238|Experimental|Age range of 18 to 44 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
89301079|NCT05217238|Experimental|Age range of 45 to 59 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
89301080|NCT05217238|Experimental|Age range of 60 to 80 years olds|The initial dose of lidocaine for pre-injection was set at 1ug/kg according to previous literature and preliminary test results. The dose of remifentanil was according to the patients' pain level. If there is no pain (negative reaction), the dose of remifentanil in the next patient will be reduced until the patient has pain. If there is pain (positive reaction), the dose of remifentanil will be increased in the next patient until the patient is painless.
89301081|NCT03796208|Experimental|Tobacco Intervention|Participants in this group will be randomized to the Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC) intervention.
89301082|NCT03796208|Active Comparator|Treatment As Usual|Participants in this group will be randomized to tobacco treatment as usual.
89523328|NCT03382535|Experimental|Voice therapy with carryover strategies|A voice therapy as described above and an enhanced carryover program. By carryover we mean the process of extending new vocal skills outside the clinic. It includes supplementary tasks and reminders that will be tailored individually out of those direct and indirect methods that the subjects have adopted during therapy sessions. Additionally, the teachers will be doing vocal warm-up and relaxation exercises together with their pupils int the beginning and in the middle of a school day. The intervention will take eight weeks.
89301083|NCT05217160|Experimental|KeraStat® Gel with Morphine|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes.~Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above."
89301084|NCT05217160|Active Comparator|KeraStat® Gel|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel 5mL tubes.~Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above."
89301085|NCT03739346|Experimental|Control|Tell, show, do technique
89301086|NCT03739346|Experimental|Intervention|Hypnosis.
89301087|NCT01318876||BC Children's and Women's Hospital, Vancouver.|
89301088|NCT01318876||University of British Columbia, Vancouver.|
89301089|NCT01318876||Health care workers in Halifax|
89301090|NCT01318876||Health care workers from CHUQ hospitals|
89301091|NCT01318876||Health care workers from Toronto|
89301092|NCT01318876||Centre hospitalier et universitaire de Sherbrooke|
89301093|NCT01318876||The Ottawa General Hospital, Ottawa|
89301094|NCT03668600|Experimental|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
89301095|NCT05103982|Experimental|Coping with Infertility Program|"The program consists of brief weekly videos, each addressing a particular psychological technique to be implemented that week. Participants receive the videos by email from the researcher and watch them on their own. Each video also assigns a homework exercise for the participant to complete that week."
89301096|NCT04073186|Experimental|ACUVUE® OASYS with Transitions™|Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.
89301097|NCT03737396|Active Comparator|Electronic health screening|Self-administered electronic health screening on tablet
89301098|NCT03737396|No Intervention|Paper-based health screening|Routine-care nurse-administered, paper-based health screening
89301099|NCT05052970|Experimental|12 mg/m ^ 2 dose group (ArmA)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 12 mg/m^2
89301100|NCT05052970|Experimental|16 mg/m ^ 2 dose group (ArmB)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 16 mg/m^2
89301101|NCT05052970|Experimental|20 mg/m ^ 2 dose group (ArmC)|Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 20 mg/m^2
89301102|NCT05025514||Patients treated for cancer, vaccinated or eligible for anti-COVID vaccination.|"Patients undergoing treatment with anti-PD immunotherapy, anti-PDL1 or anti-CTLA4 immunotherapy for any tumour (solid, liquid) treated in the medical oncology departments of the Occitanie area.~who have been vaccinated or who are eligible for inoculation with one of the available anti-COVID19 vaccines."
89301103|NCT04903210|Experimental|NMN group|NMN10000 WRIGHT LIFE® + lifestyle modification.
89301104|NCT04903210|Other|Control group|Lifestyle modification only.
89301105|NCT04879810|Active Comparator|Ginger exosomes|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
89301106|NCT04879810|Active Comparator|Curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
89301107|NCT04879810|Active Comparator|Ginger exosomes plus curcumin|Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire
89301108|NCT04719208|Experimental|Chlorhexidine gluconate (A)|Mouth rinse with 0.2% Chlorhexidine gluconate,
89301109|NCT04719208|Experimental|Hydrogen peroxide (B)|Mouth rinse with 1.5% hydrogen peroxide
89301110|NCT04719208|Experimental|Betadine (C)|Mouth rinse with betadine mouthwash,
89301111|NCT04719208|Experimental|Mouth wash (D)|Mouth rinse with alcohol-based mouthwash
89301112|NCT04719208|Placebo Comparator|Water (E)|Mouth rinse with water
89301113|NCT04701190|Active Comparator|Noradrenaline 0.05/10|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
89523329|NCT03382535|Other|Control group|No intervention during eight weeks since this group will act as a temporary control group. After eight weeks, half of the participants in this group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
89301114|NCT04701190|Active Comparator|Noradrenaline 0.075/5|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely. After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
89301115|NCT04701190|Active Comparator|Noradrenaline 0.1/0|"Study drug will be prepared as follows:4 milligram noradrenaline will be administered into 100 milliliter 5% dextrose solution.~The basal blood pressure of the parturient will be recorded as an arithmetic sum of the sequential three measurements of noninvasive blood pressure.~Maternal hypotension and severe hypotension will be described as a decrease of noninvasive systolic blood pressure according to basal systolic blood pressure by 20% and 40%, respectively.~If the heart rate of parturient will be under 60 beat/minute, this will be recorded as maternal bradycardia.~After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute without bolus dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
89301116|NCT04629664|Active Comparator|FX-322|FX-322, 1 dose (N=24)
89301117|NCT04629664|Placebo Comparator|Placebo|Placebo, 1 dose (n=6)
89301118|NCT04496362|Experimental|subcutaneous heparin anticoagulation|Experimental arm
89301119|NCT04496362|No Intervention|systemic intravenous anticoagulation|SOC arm
89301120|NCT04429126|Experimental|4-point acupressure group|"The 5-point acupressure group will be instructed on the following acupressure points: sanyinjiao (SP6), Zu San Li (ST36), shenmen (TF4), Yongquan (KI-1), and He Gu (LI4).~Bilateral 1.5 min for each point, three times daily for 4 weeks."
89301121|NCT04429126|Active Comparator|4 -point acupressure group|"The 2-point acupressure group will be instructed on the following acupressure points: He Gu (LI4) and Tai Chong (LV3).~Bilateral 1.5 min for each point, three times daily for 4 weeks."
89301122|NCT04429126|No Intervention|Usual care|The usual care group will be required to maintain their daily activities. Weekly telephone follow-up will be conducted by principle investigator.
89301123|NCT04423588|Other|Dexlansoprazole|The PPI Dexilant (active substance: dexlansoprazole) is administered to the study participants in a prophylactic Regimen for 6 months after the PRYGB-surgery. This drug is already approved by Swissmedic and on the markets in Switzerland. The dosage is 1 capsule 60 mg per os daily in the morning.
89301124|NCT03054064|Experimental|All Enrolled Subjects|All enrolled subjects will receive gait training with the Indego.
89301125|NCT04314778|Experimental|Intervention|Participants in the intervention arm will have a postoperative daily step goal that increases from baseline by 500 steps each day.
89301126|NCT04314778|No Intervention|Control|Participants in the control group will have data collected passively via Fitbit.
89301127|NCT04297852|Active Comparator|Vegan drink|Treatment group
89301128|NCT04297852|Placebo Comparator|Control|Placebo group
89301129|NCT03053518|Active Comparator|Life Style|
89301130|NCT03053518|Experimental|Life Style + Metformin|
89301131|NCT05659498|Experimental|Intervention|The standard cardiac rehabilitation program consists of the following: a (1) consultation with a kinesiologist to assess level of fitness and to prepare an individually customized exercise plan, (2) consultation with a dietitian to guide the participant with healthy nutrition choices, (3) on site supervised and/or virtual exercise sessions with gradual elaboration of a home program, (4) weekly educational capsules and monthly workshops related to cardiac health, and, (5) if deemed necessary by the treating team, consultation with a psychologist, an occupational therapist, a physiotherapist, or a social worker.
89301132|NCT05659498|No Intervention|Control|Participants in the control group will receive educational information on maintaining optimal cardiovascular health. Participants will be encouraged to undergo 30 minutes of moderate-intensity aerobic activity at least 5 days per week. Participants will be given educational materials on recommended diet and exercise.
89301133|NCT04090684|Experimental|Fixed dose Ciprofloxacin and Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
89301134|NCT04015336|Experimental|Arm 1-3x10^10 E7 T-Cell Receptor (TCR) T cells|Up to 3x10^10 E7 T-Cell Receptor (TCR) T cells (based on the number of cells that can be generated in the shortened manufacturing process) will be administered intravenously over 20 to 30 minutes on day 0.
89301135|NCT03970642|Experimental|Intervention group|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will receive the video directly observed therapy smartphone app. Research staff will be able to monitor these medication adherence video on a password protected server linked to the app. Upto 50 patients will be randomly assigned to this group.
89301136|NCT03970642|No Intervention|Control|The control group will receive current standard of care. Upto 50 patients will be randomly assigned to this group.
89301137|NCT05044078|Experimental|Group 1 (Autogenic Inhibition)|Autogenic Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the Conventional therapy including neck Isometric strengthening exercise (Neck Flexion, Extension, Both sides Rotation, and Neck Bending with each 5 rep, 10-sec hold, 1 set, in all sessions), Maitland Central posterio-anterior glide (Grade 1 and 2, 30 rep, 3 sets, in all sessions) and hot pack (10 minutes in all sessions on the back of the neck)
89301138|NCT05044078|Active Comparator|Group 2 (Reciprocal Inhibition)|Reciprocal Inhibition (5 reps, 10-sec hold, 5-sec rest in between each rep, 1 set, in all sessions) will be provided with the with same Conventional therapy as in group 1 .
89301139|NCT03627442|Active Comparator|Mastectomy with PhotonBlade|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with PhotonBlade
89301140|NCT03627442|Active Comparator|Mastectomy with Bovie|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with Bovie.
89301141|NCT04963816|Active Comparator|Group A Quadratus Lumborum Block with dexamethasone IV|QLB with (0.5 mL/kg of bupivacaine 0.25%) and IV dexamethasone (0.1-0.3 mg/kg with a maximum dose 10 mg) added to 5 mL normal saline
89301142|NCT04963816|Active Comparator|Group B Quadratus Lumborum Block with dexamethasone locally|QLB with (0.5 mL/kg of bupivacaine 0.25% plus dexamethasone 0.1 mg/kg), and IV 5 mL normal saline
89301143|NCT04963816|Placebo Comparator|Group C Quadratus Lumborum Block with bupivacaine alone|Patients will receive QLB (0.5 mL/kg of bupivacaine 0.25%) and IV 5 mL normal saline.
89301144|NCT04957732|Active Comparator|Standard of Care (SoC)|For subjects randomized to the control group, Standard of Care (SoC), which was normal saline, was used.
89301145|NCT04957732|Active Comparator|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
89301146|NCT04933240|Active Comparator|Tamoxifen|tamoxifen 10mg daily for 7 days
89301147|NCT04933240|Active Comparator|Estradiol|estradiol 1mg daily for 7 days
89301148|NCT04933240|Placebo Comparator|placebo|placebo daily for 7 days
89301149|NCT04071158|Experimental|Lower RSV vaccine dose and Tdap|Lower RSV vaccine dose and Tdap
89301150|NCT04071158|Experimental|Lower RSV vaccine dose and Placebo|Lower RSV vaccine dose and Placebo
89301151|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
89301152|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
89301153|NCT04071158|Placebo Comparator|Placebo and Tdap|Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
89301154|NCT01317940|Experimental|Group A (Newly Diagnosed Subjects)|
89301155|NCT01317940|No Intervention|Standard of Care Group A|
89301156|NCT01317940|Experimental|Group B (Early Survivors)|
89301157|NCT01317940|No Intervention|Observation Only - Group B|
89301158|NCT01317940|No Intervention|Group C (Siblings of Group A)|
89301159|NCT05707312||POLEmut (POLE mutant endometrial cancer patients)|POLE mutant endometrial cancer patients
89301160|NCT05707312||MMRd (mismatch repair deficient endometrial cancer patients)|mismatch repair deficient endometrial cancer patients
89301161|NCT05707312||NSMP (no specific molecular profile endometrial cancer patients to NSMP)|no specific molecular profile endometrial cancer patients to NSMP
89301162|NCT05707312||p53abn (p53 abnormal endometrial cancer patients)|p53 abnormal endometrial cancer patients
89301163|NCT05706688||Regional anesthesia|4,152 patients undergoing elective carotid endarterectomy under regional anesthesia
89301164|NCT05706688||General anesthesia|4,152 matched controls undergoing elective carotid endarterectomy under general anesthesia
89301165|NCT05706454|Experimental|Ramatroban 75 mg tablet|
89301166|NCT05706454|Placebo Comparator|Placebo|
89301167|NCT01345786|Experimental|Commercial NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
89301168|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch A), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
89301169|NCT01345786|Experimental|Commercial NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
89301170|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch B), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
89301171|NCT05706220||Control group|"Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~Visual processing speed~Microperimetry~Optical coherence tomography"
89301172|NCT05706220||Clinically Isolated Syndrome Patients|"Ophthalmologic examination~Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~Visual processing speed~Microperimetry~Optical coherence tomography~Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)"
89301173|NCT05706220||Relapsing-remitting Multiple Sclerosis Patients|"Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~Visual processing speed~Microperimetry~Optical coherence tomography~Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)"
89301174|NCT05706220||Primary Progressive Multiple Sclerosis Patients|"Ophthalmologic examination (best-corrected visual acuity, cover and uncover tests, slit-lamp biomicroscopy, funduscopy)~Eye movement recording with the Tobii™ Pro Nano hardware package eye-tracking system and Tobii™ Pro Lab - full edition software~Visual processing speed~Microperimetry~Patients with a history of optic neuritis will undergo additional tests at the discretion of the researcher (e.g. visual field, FarnsworthTest)~Optical coherence tomography"
89301175|NCT03627364||Post stroke patients|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals.
89301176|NCT03627364||Control group|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in post stroke patients.
89301177|NCT01317550|Experimental|Armodafinil + Placebo|Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks
89301178|NCT01317550|Experimental|Minocycline + Placebo|Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks
89301179|NCT01317550|Experimental|Armodafinil + Minocycline|Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks
89301180|NCT01317550|Placebo Comparator|Placebos|Placebo Capsules orally once/day for 10 weeks
89301181|NCT01317472|Experimental|Dexlansoprazole|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
89301182|NCT01317472|Placebo Comparator|Sugar pill|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
89301183|NCT05702086|Experimental|"Play now intervention group"|"The sequence of SPARX play differed for the youth depending on whether they were in Group A (play now intervention group) or Group B (play later waitlist group). Both groups completed the pre-intervention surveys at Time 1, the beginning of the study. Group A youth then began to play SPARX for seven weeks while Group B waited. During their wait time of seven weeks, Group B youth were not required to participate in any SPARX activities or meet with the community facilitator during their wait period, and they were provided with no additional SPARX-related information. After seven weeks (Time 2), Group A youth completed post-intervention surveys, while Group B youth began their engagement with SPARX by first completing an additional set of pre-intervention surveys, immediately followed by seven weeks of SPARX play. Once Group B youth completed their SPARX gameplay (Time 3), they completed post-intervention surveys."
89301184|NCT05702086|Active Comparator|"Play later waitlist group"|"The sequence of SPARX play differed for the youth depending on whether they were in Group A (play now intervention group) or Group B (play later waitlist group). Both groups completed the pre-intervention surveys at Time 1, the beginning of the study. Group A youth then began to play SPARX for seven weeks while Group B waited. During their wait time of seven weeks, Group B youth were not required to participate in any SPARX activities or meet with the community facilitator during their wait period, and they were provided with no additional SPARX-related information. After seven weeks (Time 2), Group A youth completed post-intervention surveys, while Group B youth began their engagement with SPARX by first completing an additional set of pre-intervention surveys, immediately followed by seven weeks of SPARX play. Once Group B youth completed their SPARX gameplay (Time 3), they completed post-intervention surveys."
89301185|NCT05701618|Experimental|Psychologically Informed Education|is arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with atraumatic lower extremity injuries.
89301186|NCT05701618|Placebo Comparator|Control Education|This arm will provide education of basic leg anatomy and will not address maladaptive psychological behaviors.
89301187|NCT01345630|Experimental|Maraviroc|Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
89301188|NCT01345630|Active Comparator|Emtricitabine/tenofovir|Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
89301189|NCT03693612|Experimental|Part 1: feladilimab +tremelimumab|In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
89301190|NCT03693612|Experimental|Part 2: feladilimab +tremelimumab|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered feladilimab in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.
89301191|NCT03693612|Active Comparator|Part 2: SOC|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.
89301192|NCT03746652|Experimental|DId|Daratumumab, Ixazomib, Dexamethasone
89301193|NCT03745248|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
89301194|NCT03745248|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
89301195|NCT04223232|Experimental|MD1003|radiolabeled 14C MD1003 (High Dose Biotin) 100mg
89301196|NCT03748524|Experimental|Single Influenza Vaccine|Single Influenza Vaccine,Quadrivalent
89301197|NCT03746574|Experimental|Intervention Clinics|Participants in the intervention clinics experienced a 12 session compassion curriculum intevention offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
89301198|NCT03746574|No Intervention|Control Clinics|Completed baseline, end of curriculum, and 6 month follow up survey. Otherwise no intervention
89301199|NCT04206384|Experimental|Treatment group|Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.
89301200|NCT04051944|Experimental|Rozanolixizumab|Subjects in this arm will receive predefined subcutaneous doses of rozanolixizumab at a specified frequency.
89301201|NCT04050618|Experimental|ocufilcon D control lens, then fanfilcon A test lens|Participants will wear the ocufilcon D control lens for 4 weeks, then crossover to fanfilcon A test lens for 4 weeks of daily wear.
89301202|NCT04050618|Experimental|etafilcon A controls, then fanfilcon A test lens|Participants will wear the etafilcon D control lens for 2 weeks, then crossover to fanfilcon A test lens for 2 weeks of daily wear.
89301203|NCT04067492|Experimental|RPH - 4 mg|Subjects randomized to receive RPH-104, 4 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 4 mg, 0.1 mL of RPH-104 solution is injected.
89301204|NCT04067492|Experimental|RPH - 20 mg|Subjects randomized to receive RPH-104, 20 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 20 mg, 0.5 mL of RPH-104 solution is injected.
89301205|NCT04067492|Experimental|RPH - 40 mg|Subjects randomized to receive RPH-104, 40 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 40 mg, 1 mL of RPH-104 solution is injected.
89301206|NCT04067492|Experimental|RPH - 80 mg|Subjects randomized to receive RPH-104, 80 mg, subcutaneous single-dose injection. In order to administer RPH-104 at the dose of 80 mg, 2 mL (whole vial) of RPH-104 solution is injected.
89301207|NCT04067492|Experimental|RPH - 160 mg|Subjects randomized to receive RPH-104, 160 mg, two subcutaneous injections of 80 mg administered at different injection sites. (1 vial of 2mL solution per each site)
89301208|NCT04067492|Active Comparator|Voltaren® (diclofenac)|Subjects randomized to receive Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)
89301209|NCT05280522||Repeated Measures Experiment|Participants are positioned in an isokinetic dynamometer (Biodex System 4 Isokinetic Dynamometer , Biodex Medical Systems, Inc., Shirley, NY) with the knee flexed to approximately 90 degrees. After 3-4 submaximal warm up contractions, participants generate maximum knee extension force while vigorous verbal encouragement is provided. Two trials are collected with 30 seconds between trials. The maximum forces from the 2 trials is used to determine the target force of 20% MVIC used for the volitional and NMES contractions and to normalize the force of the muscle contractions.
89301210|NCT04060446||Observational (smoke cigarettes)|Patients smoke 5 cigarettes separated by 30 minute washout periods. Between 48 hours and 1 week later, patients smoke another 5 cigarettes separated by 30 minute washout period with CReSSMicro topography measurement device and BioRadio device for recording inhalation patterns.
89301211|NCT03739190|Experimental|Test Condom: Thin NRL Condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
89301212|NCT03739190|Active Comparator|Reference condom A: Medium Thickness NRL Condom|
89301213|NCT03739190|Active Comparator|Reference condom B: Thick NRL Condom|
89301214|NCT04375878|Active Comparator|MS1819 2240 mg/day vs PERT arm,|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
89301215|NCT04375878|Active Comparator|MS1819 4480 mg/day vs PERT arm|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 for 3 weeks followed by PERT for another 3 weeks or the opposite sequence of treatments, PERT for 3 weeks followed by MS1819 for another 3 weeks.
89301216|NCT03746496||pre-hospital emergency patients|Patient in a need of an IO-access. Patient in a need of point-of-care laboratory analysis. Over 18 years. Alive (no Cardiac arrest.)
89301217|NCT04039776|Experimental|Bone patellofemoral joint indices|Evaluation of the bone index values in patients affected by patellofemoral joint disorders, obtained from CT scans performed in both orthostatism and clinostatism
89301218|NCT04189224|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Test/Control.
89301219|NCT04189224|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Control/Test.
89301220|NCT04186806|Experimental|3M Dry Mouth Moisturizing Spray|Dry mouth agent
89301221|NCT04186806|Active Comparator|Biotene Moisturizing Mouth Spray|Dry mouth agent
89301222|NCT04041414|Experimental|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
89301223|NCT04041414|Active Comparator|Control schools|Students in control schools will receive no intervention
89301224|NCT03748446|Active Comparator|X-TAU (xenon)|"Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug.~- xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)"
89301225|NCT03748446|Placebo Comparator|N-TAU (nitrogen-placebo)|Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)
89301226|NCT04370028||Divaza|Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.
89301227|NCT04037748|Experimental|First Puran T4®, then Eutirox®|Participants received single oral dose of Puran T4® 600 micrograms (mcg) (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
89301228|NCT04037748|Experimental|First Eutirox®, then Puran T4®|Participants received single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Puran T4® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
89301229|NCT04036110|Experimental|Intervention 1|Vitamin C 500 mg taken daily for 3 months
89301230|NCT04036110|Experimental|Intervention 2|Vitamin C 1000 mg taken daily for 3 months
89301231|NCT04036110|Placebo Comparator|Control|Placebo tablets taken daily for 3 months
89301232|NCT03053050|Experimental|SEL 18 mg|"Randomized Phase: Selonsertib (SEL) 18 mg tablet + placebo to match SEL 6 mg tablet for 240 weeks~Open-Label (OL) Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
89301233|NCT03053050|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
89301234|NCT03053050|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
89301235|NCT04369950|Active Comparator|2 percent Lidocaine with epinephrine and epidural morphine|
89301236|NCT04369950|Experimental|3 percent 2-Chloroprocaine and epidural morphine|
89301237|NCT04035564|Active Comparator|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life one
89301238|NCT04035564|Experimental|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life one
89301239|NCT03748368|Active Comparator|Cataract presentation|Cataract presentation prior to surgery
89301240|NCT03748368|Placebo Comparator|Placebo presentation|Placebo presentation prior to surgery
89301241|NCT02955602|Experimental|MBX-8025 (2 mg)|MBX-8025 2 mg capsule once daily
89301242|NCT02955602|Experimental|MBX-8025 (5 mg)|MBX-8025 5 mg capsule once daily
89301243|NCT02955602|Experimental|MBX-8025 (10 mg)|MBX-8025 10 mg capsule once daily
89301244|NCT04179786|Other|Sci-B-Vac™|Single arm study in healthy volunteers who had never been vaccinated with any hepatitis B vaccine and who were seronegative for antibodies to HBsAg, HBc and HBs at baseline.
89301245|NCT03748290|Experimental|People with a SCI who will receive Lyrica 75mg for 12 weeks|
89301246|NCT03748290|Placebo Comparator|People with a SCI who will receive Placebo for 12 weeks|
89301247|NCT03746418|Placebo Comparator|Group I|received 20 ml of 0. 25% bupivacaine plus one mL normal saline bilaterally.
89301248|NCT03746418|Active Comparator|Group II|received 20 ml of 0.25% bupivacaine with supplementation of 1 mL containing 100µg dexmedetomidine bilaterally
89301249|NCT05651074|Experimental|Vicagrel and omeprazole|D1 single dose of vicagrel was administered. Omeprazole administration was started on D4, once daily for 5 days, and a single dose of vicagrel and omeprazole coadministration on day 9.
89301250|NCT03738956|Experimental|Open label clinical trial|NSAID refractory axial spondyloarthritis patients who are eligible after considering inclusion and exclusion crietria will be put on 5 mg tofacitinib BD ,at the end of 1st and 3rd month they will be assessed for safety and efficacy.Those who will not respond will be put on 10 mg tofacitinib BD.All patients will be assessed at the end of 6th month.If any adverse event occur they will be treated accordingly.
89301251|NCT03639974|Active Comparator|PEP in a blow-bottle device|Blow-bottle device of 10cmH2O.
89301252|NCT03639974|Active Comparator|EPAP Positive airway expiratory pressure|EPAP with pressure of 10 cmH2O.
89301253|NCT03639974|Sham Comparator|conventional physiotherapy|Ventilatory exercises, bronchial hygiene techniques, exercises for upper and lower limbs (previous motor condition) stretching, orientation and walking.
89301254|NCT05609656|Experimental|IRE + CaEP + Pembrolizumab|Irreversible electroporation (IRE) and calcium electroporation (CaEP) on Day 1, followed by Pembrolizumab on Day 2 (+4 days) and then every 3 weeks (q3w) for up to 12 months in total.
89301255|NCT03737162|Experimental|Covered stent group|Covered stent
89301256|NCT03737162|Active Comparator|Bare-metal stent group|Bare-metal stent
89301257|NCT01064024|Active Comparator|Phenazopyridine Hydrochloride Tablets, USP 200 mg|
89301258|NCT01064024|Placebo Comparator|Placebo|Matching placebo to the phenazopyridine hydrochloride tablets
89301259|NCT03738722|Experimental|High-flow-nasal-cannula-therapy (HFNCT)|100% Oxygen at 80 l/min with flow reductions of 20 l/min, jaw thrust, with opened and closed mouth, using different flow rates (80l/min, 60l/min, 40l/min, 20l/min, 1l/min) within each subject.
89301260|NCT04175808|Experimental|Part A|After an overnight fast of at least 10 hours participants received a single oral dose of 25 mg omecamtiv mecarbil on Day 1.
89301261|NCT04175808|Experimental|Part B|"Participants with a maximum observed plasma OM concentration ≤ 350 ng/mL in Part A were randomly assigned to receive a single dose of each the following 3 treatments in one of six treatment sequences:~Placebo~50 mg omecamtiv mecarbil~400 mg moxifloxacin Each treatment was separated by a washout of at least 7 days."
89301262|NCT04057196|Experimental|Adults with Advanced Lung Cancer|Older adults with stage III or stage IV lung cancer will be enrolled in the Self-System Therapy intervention to treat illness-related distress, depression, and to enhance self-efficacy via delivery of behavioral coping skills across a period of 12 weeks.
89301263|NCT05598424|Experimental|Oral Glucocorticoids group|"Intervention Period I: nasal spray, Budesonide Nasal Spray, 64ug per Nostril, bid, for 4-week duration.~Intervention Period II: oral glucocorticoids methylprednisolone 24mg qd, and nasal spray, Budesonide Nasal Spray 64ug per Nostril, bid, for 2-week duration."
89301264|NCT03748212|Active Comparator|Group 1|D935 Cap. 1T
89301265|NCT03748212|Experimental|Group 2|CKD-385 Tab. 1T
89301266|NCT03745014|Active Comparator|Pheno|
89301267|NCT03745014|Active Comparator|Standard of Care|
89301268|NCT05552560||Experimental: Heterosexual couples, women or single women who have requested sperm donation|Heterosexual couples, female couples or single women who have requested a sperm donation in the center of the Toulouse University Hospital will be offered the study.
89301269|NCT04027686|Experimental|SRP + Adjunctive Laser Therapy|Laser therapy used as an adjunct to scaling and root planing
89301270|NCT04027686|Active Comparator|SRP alone|Scaling and root planing used as conventional non-surgical periodontal therapy
89301271|NCT05514418|Experimental|Intervention Arm|"This group will receive three monthly sessions of intensive adherence counselling (IAC) and psychosocial support, using the 5 A's principles for chronic care (which include; Assess, Advise, Agree, Assist and Arrange). Each monthly IAC session will be offered by the research assistants for about one hour, and adherence will also be assessed by pill counts. Colour-coded IAC forms will be developed and used to differentiate the study from routine IAC services for the non-suppressed patients; and the study will be conducted on different days, from those on which the routine clinic occurs.~Following the three months of the study, all the study participants both in the control and intervention groups will be reviewed at the health facility and a repeat viral load (VL) test done for each of the participants, to determine whether they have achieved a non-detectable VL or not."
89301272|NCT05514418|No Intervention|Control Arm|This group will comprise of participants who will receive the routine standard of care. These participants will receive the normal patient education and encouragement to continue with their antiretroviral therapy (ART) at the start of the study. They will not be reviewed monthly or offered any counselling for the entire three months. These participants will be given an appointment after three months for repeat viral load (VL) testing.
89301273|NCT05513482||Cryoballoon pulmonary vein isolation for atrial fibrillation ablation|Diaphragmatic kinetics of participants before and after pulmonary vein isolation will be evaluated with the Tissue Doppler and M Mode Imaging.
89301274|NCT05501860|Experimental|AG-920|Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%.
89301275|NCT05501860|Placebo Comparator|Placebo|Placebo Sterile Topical Ophthalmic Solution
89301276|NCT03052426|Active Comparator|30 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 30 minutes throughout their workday.
89301277|NCT03052426|Active Comparator|60 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 60 minutes throughout their workday.
89301278|NCT03052426|Active Comparator|90 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 90 minutes throughout their workday.
89301279|NCT05465668|Experimental|Intervention: DWP16001 Drug A|1 tablet, Oral, once daily single dose
89301280|NCT05465668|Experimental|Intervention: DWP16001 Drug C|1 tablet, Oral, once daily single dose
89301281|NCT05446948|Experimental|beveled 27G+ group|The group of patients underwent vitrectomy with a beveled 27G+ vitrectomy system.
89301282|NCT05446948|Active Comparator|25G+ group|The group of patients underwent vitrectomy with a standard 25G+ vitrectomy system.
89301283|NCT03688880|Active Comparator|Dermabond Advanced|Dermabond Advanced (a topical skin adhesive) was applied on Day 0. Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions; the wound was held for 60 seconds to allow for complete polymerization.
89301284|NCT03688880|Experimental|MAR-CUTIS|MAR-CUTIS (polyurethane-based skin adhesive) was applied on Day 0. MAR-CUTIS was applied in 1 to 2 millimeter (mm) thick layer ensuring that at least 1 cm of the glue is applied over the length of the wound on each side; the wound was held for approximately 30 seconds to allow for initial polymerization.
89301285|NCT03737084|Experimental|CBCT Intervention|The compassion intervention (CBCT) will be performed during the period of hospitalization, in the hospital room, and will be applied simultaneously to the patient his caregiver. The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
89301286|NCT03737084|No Intervention|Control group|Control group participants will receive standard hospital care. Patients and caregivers of the control group will receive the same CBCT intervention at the end of the study.
89301287|NCT05581966||Diabetic Foot Ulcer (DFU) Group|Patients with DFUs undergoing 30 day standard wound care (SWC) therapy as part of their standard of care
89301288|NCT05018390|Experimental|OMT|Osteopathic manipulative treatment : participants will receive low-amplitude tissue mobilizations on peripheral, vertebral, cranial and/or visceral articular systems.
89301289|NCT05018390|Sham Comparator|Sham|Participants will be applied gestures that look like actual osteopathic manipulations but are not therapeutic.
89301290|NCT05018390|No Intervention|Test-retest|Participants will undergo the two eye movement measurements, but will not receive any (actual or sham) treatment. 30 minutes will elapse between the two measurements.
89301291|NCT03738488|Experimental|3D printing + images|Surgery planification with the combination of all the images available and a 3D biomodel printed from that images.
89301292|NCT03738488|Active Comparator|Images|Surgery planification with all the images available
89301293|NCT03795142|Experimental|single intravenous dose; BGB149|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
89301294|NCT03795142|Placebo Comparator|single intravenous dose; placebo|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
89301295|NCT03051178|Experimental|Subjects with Essential Tremor|This cohort will receive deep brain stimulation (DBS) therapy responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
89301296|NCT03736850|Experimental|CS3006|
89301297|NCT03738254|Active Comparator|Paper PRO|Participants in the Paper PRO arm completed daily patient reported outcome diaries on paper
89301298|NCT03738254|Active Comparator|ePRO|Participants in the ePRO arm completed daily patient reported outcome diaries online via a smartphone app.
89301299|NCT03738254|Experimental|Game-Motivated ePRO|Participants in the Game-Motivated ePRO arm completed daily patient reported outcome diaries online via a smartphone app. These participants were also given access to a game that rewarded the participant with an in-game reward that helped the participant complete various in-game quests.
89301300|NCT03738176|Experimental|sesame oil in orabase|20 gm sesame oil-80 gm CMC 3 times per day for one month
89301301|NCT03738176|Active Comparator|triamcinolone in orabase|140 gm triamcinolone-50 gm Na CMC 3 times per day for one month
89301302|NCT03745274|Experimental|GHB04L1|GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
89301303|NCT03745274|Placebo Comparator|Placebo|Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.
89301304|NCT03736772|Experimental|LY3090106|LY3090106 administered subcutaneously (SC)
89301305|NCT03736772|Placebo Comparator|Placebo|Placebo administered SC
89301306|NCT03051100|Experimental|Triplet Therapy|Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
89301307|NCT03051100|Placebo Comparator|placebo|Matching placebos taken orally, daily.
89301308|NCT05280028||Tibolone|Tibolone 2.5 mg per day
89301309|NCT05280028||Indivina|Estradiol valerate (E2V) 1mg & medroxyprogesterone acetate 2.5 mg (MPA) per day
89301310|NCT05569876|Other|Controlled hypoglycemic state|
89301311|NCT05235724||Subset of study-OBS15333 patients|As a sub-study of the OBS15333 pediatric AD registry (PEDISTAD), all participants in this study will be receiving standard care of therapies for moderate to severe AD.
89301312|NCT05229328||Control group|Healthy volunteers
89301313|NCT05229328||Patients within the acute phase of disease|Patients within 24 hours after onset
89301314|NCT05229328||Recovery phase of disease|Inflammation was controlled, shock was corrected, and the patient remained fever free for 3 consecutive days.
89301315|NCT01343368|Experimental|Interventional - Received Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
89301316|NCT01343368|Active Comparator|Observational Arm|Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
89301317|NCT02955212|Placebo Comparator|Placebo / Upadacitinib 15 mg|Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.
89301318|NCT02955212|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.
89301319|NCT03050398|Experimental|ribociclib + letrozole|ribociclib with letrozole per the core study
89301320|NCT05175118|Other|Minimally invasive fixation|Minimally Invasive Surgical Fixation for Unstable Fractures of the distal end Radius in Adults
89301321|NCT03736694|Experimental|CBTI Workshop|The first intervention group (Group 1) will attend one half-day CBTI workshop in the community setting. The workshop is subdivided into 4 sessions, covering topics regarding regulation of stimuli, limit of sleeping duration, relaxation, sleep hygiene and alteration of cognitive beliefs (Arnedt, Cuddihy, & Swanson, et al, 2014; Morin, Savard, Ouellet, & Daley, 2003). One workshop has the capacity of 30 participants.
89301322|NCT03736694|Experimental|Self-Help CBTI|The second intervention group (Group 2) will receive self-help CBTI. A CBTI webpage will be set up and the subjects are asked to review all the materials in it. The content is the same as that in Group 1.
89301323|NCT03736694|Active Comparator|SHE Workshop|The control group (Group 3) will receive SHE. To ensure uniformity of the therapy model, the participants will also need to attend one half-day face-to-face session, covering topics related to sleep hygiene only. The capacity is also 30 participants.
89301324|NCT05173480|Experimental|Experimental group|VRRS rehabilitation exercise therapy through a virtual reality rehabilitation system in addition to conventional rehabilitation.
89301325|NCT05173480|Active Comparator|Control group|VRRS rehabilitation exercise therapy through a virtual reality rehabilitation system, with sensors not connected, in addition to conventional rehabilitation.
89301326|NCT03736460|Experimental|Mindfulness-based intervention|
89301327|NCT03736460|Active Comparator|Physical training|
89301328|NCT03736460|No Intervention|Wait-list|
89301329|NCT03737942||control group|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
89301330|NCT03737942||T2DM without neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
89301331|NCT03737942||T2DM with neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
89301332|NCT03627052|Experimental|Itacitinib|
89301333|NCT03627052|Placebo Comparator|Placebo|
89301334|NCT04246918|Placebo Comparator|Standard Treatment Group|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. This group would not receive any supplement other than the prescribed diet. Whey protein will be included in this group.
89523330|NCT03382379|Experimental|Active|Participants in the active arm will receive 2 milliamp anodal transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
89523331|NCT03382379|Placebo Comparator|Sham|Participants in the Sham arm will receive sham transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
89301335|NCT04246918|Active Comparator|Intervention Arm|The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. In addition to the normal diet this group would receive 16gm of branched chain amino acid (BCAA) supplement (Commercial oral BCAA granules) daily in 4 divided doses, keeping the protein levels within the same range of 1.5 gm/Kg/day.
89301336|NCT03662750|Experimental|Acute stroke cohort|Acute stroke cohort
89301337|NCT03626506|Experimental|spironolactone|Subjects will take spironolactone 20~40mg once daily on top of amlodipine 5~10mg once daily.
89301338|NCT03626506|Active Comparator|indapamide|Subjects will take indapamide 1.5~3.0mg once daily on top of amlodipine 5~10mg once daily.
89301339|NCT03737708|Experimental|tacrolimus + biologics|Participants will receive tacrolimus daily for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
89301340|NCT03737708|Active Comparator|methotrexate + biologics|Participants will receive methotrexate weekly for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
89301341|NCT05090072|Active Comparator|- Advance Directives Group|The group that will receive the principal physician intervention, using Advance Directives document as a communication tool between patients and caregivers, to find its efficacy on the promotion of better-prepared surrogates
89301342|NCT05090072|Placebo Comparator|Control Group|The group that will receive the Placebo Intervention, consisting of a clinical evaluation of patients' clinical status, by the physician
89301343|NCT04052204|Experimental|Combination A|Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck
89301344|NCT04052204|Experimental|Combination B|Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC). Phase 2 will focus on enrolling participants with DDR defect positive mCRPC.
89301345|NCT04052204|Experimental|Combination C|Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC
89301346|NCT03745196|Experimental|PC945|PC945 5mg once-daily, nebulized
89301347|NCT03745196|Placebo Comparator|Placebo|Placebo, nebulized
89301348|NCT04050722|Experimental|Test Product|Participants with no visible plaque will be instructed to apply full ribbon of the test product (containing 0.454 percent [%] of stannous fluoride] on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
89301349|NCT04050722|Other|Negative Control Dentifrice|Participants with no visible plaque will be instructed to apply full ribbon of the negative control dentifrice (containing sodium fluoride) on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
89301350|NCT03736382|Experimental|Experimental Group|The experimental group is comprised of participants with OSA and hypertension [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be treated with mild IH and CPAP. In the present proposal, the mild IH protocol will be administered during wakefulness each day for 15 days over a 3-week period to participants that will also be treated with CPAP during sleep. The mild IH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve - two minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2) = 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The PETCO2 will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol.
89301351|NCT03736382|Sham Comparator|Control Group|The control group is comprised of hypertensive OSA participants [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be exposed to a sham protocol in addition to being treated with CPAP during sleep. The sham protocol will be administered during wakefulness for 15 days over a 3-week period. During the sham protocol the participants will be exposed to atmospheric levels of oxygen and carbon dioxide for the duration of the protocol.
89301352|NCT04049552|Experimental|RAPA intervention|Rapamycin ointment will be applied to one keloid on the subject
89301353|NCT04049552|Placebo Comparator|Placebo|Placebo will be applied as a control on one keloid on the subject
89301354|NCT03737630|Experimental|GExp|This group will perform the inspiratory muscle training with moderate load
89301355|NCT03737630|Active Comparator|GCon|This group will initiate inspiratory muscle training with low load
89301356|NCT03737552||Children and adolescents with ADHD|Children and Adolescents with ADHD children or Adolescents, male or female, ages 6-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
89301357|NCT03737552||Healthy control children and adolescent|children or Adolescents, male or female, ages 6-17,medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
89301358|NCT03737474|Experimental|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
89301359|NCT03048058|Experimental|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
89301360|NCT03048058|Active Comparator|brimonidine topical gel 0.33% & SOC|Topical drug and standard of care follow-up, no weekly survey; only survey during 3 month and 6 month visits
89301361|NCT03047980|Experimental|Sirolimus|All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.
89301362|NCT03971188|Experimental|Internal Brace|Patients will undergo Internal Brace procedure for thumb CMC OA.
89301363|NCT03971188|Active Comparator|LRTI|Patients will undergo ligament reconstruction tendon interposition (most commonly performed surgery for thumb CMC OA) and serve as control group.
89301364|NCT03946774|Active Comparator|High protein|Subjects getting high protein shake
89301365|NCT03946774|Active Comparator|Low protein|Subjects getting low protein shake
89301366|NCT03876028|Experimental|Ibrutinib (before leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment before leukapheresis
89301367|NCT03876028|Experimental|Ibrutinib (after leukapheresis) + Tisagenlecleucel|Patients will start ibrutinib treatment after leukapheresis.
89301368|NCT03732482|Placebo Comparator|RT groups|participants was given radiotherapy only,50Gy in 10 fractions over 2 weeks to metastases synchronously with 25Gy WBRT
89301369|NCT03732482|Experimental|Drug plus RT groups|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
89301370|NCT04051762||Preterm neonates on HFNC|neonates extubated to HFNC (High flow nasal cannula)
89301371|NCT04051762||Preterm neonates on NCPAP|neonates extubated to NCPAP ( nasal continuous positive airway pressure)
89301372|NCT04048382|Experimental|Patient Navigation (PN)|This intervention consists of standardized health educational materials and manualized sessions that can be implemented based on a participant's stage in the PrEP continuum. The intervention will utilize bilingual peer lay navigators and also consist of barrier reduction strategies to assist individuals with implementing HIV prevention, including the use of PrEP.
89301373|NCT04048382|Other|Usual Care (UC)|Participants in this condition will receive the CDC's 2-page PrEP Information Sheet in the participant's preferred language (either English or Spanish).
89301374|NCT04051840|Experimental|ClinOleic group|Patients will be grouped to ClinOleic-based lipid parenteral nutrition regimen using ClinOleic or Structolipid-based lipid parenteral nutrition regimen using Structolipid. From day 0 to day 5, patients will not to receive any food or liquid oral or enteral nutrition. The goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid. The weight of patient calculated as ideal body weight. The patients will be allowed water based on the clinical judgment of the Investigator. From day 6 through the remainder of the study treatment period, liquid oral or enteral nutrition could be added to the study treatment. The intent is to supply the total calculated daily nutritional requirement with study treatment plus liquid oral or enteral nutrition. Liquid oral or enteral nutrition will be increased daily, as tolerated by the patient, with a concurrent reduction in study treatment, while still supplying the calculated daily nutritional requirement.
89301375|NCT04047446|Experimental|Liposomal bupivacaine & standard bupivacaine|
89301376|NCT04047446|Active Comparator|Standard bupivacaine & dexamethasone|
89301377|NCT03655106|Active Comparator|Standard Long IV 4.78 cm 20 g catheter|Placement of Standard Long IV 4.78 cm 20 g catheter
89301378|NCT03655106|Experimental|Ultra-Long IV 6.35 cm 20 g catheter|Placement of Ultra-Long length IV 6.35 cm 20 g catheter
89301379|NCT03736148|Experimental|Manual Manipulation|A single manual manipulation was applied to C3/C4 level, on the right side.
89301380|NCT03736148|Active Comparator|Instrument-assisted Manipulation|A single instrument-assisted manipulation was applied to C3/C4 level, on the right side.
89301381|NCT03736148|Placebo Comparator|Placebo|A placebo manipulation was applied on C3/C4 level, on the right side. The neck of th subject was placed in the pre manipulative position but no thrust was made. Then, the cervical was replaced in neutral position.
89301382|NCT03736148|No Intervention|Control|No contact was given to the subject.
89301383|NCT03732404|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
89301384|NCT03732404|Placebo Comparator|Placebo|The control group will receive plain water with the same volume and timing of treatment
89301385|NCT04041440|Experimental|Auditory Training|Pre- and post assessments of auditory training intervention
89301386|NCT03654560|Active Comparator|HemoStyp|Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.
89301387|NCT03654560|Active Comparator|Surgicel|Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.
89301388|NCT03629054|Experimental|Test treatment (T)|Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet
89301389|NCT03629054|Experimental|Reference treatment (R)|Single tablets of empagliflozin + linagliptin + metformin XR
89301390|NCT03628898|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor
89301391|NCT03628508|Experimental|Exercise|Six-week exercise including stretching, strengthening, endurance and gait modification
89301392|NCT03045328|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD beginning on week 1 day 1. Treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD beginning on week 9 day 1. Treatment with venetoclax continues up to week 61 day 7 in the absence of disease progression or unacceptable toxicity.
89301393|NCT02281864|Other|Control Group: Quitline|Quitline referral. If the family is randomized to the control group, the research team will give the parent a brochure for the QuitLine
89301394|NCT02281864|Experimental|Intervention Group|Smoking Cessation Intervention Bundle. The Investigator has developed an intervention that bundles the best evidence for tobacco dependence treatment, including the USPHS guidelines, and evidence from parent-specific interventions, to create a sustainable, transferrable intervention specific to using the inpatient stay to help parents quit smoking and reduce their children's exposure. The intervention bundle includes screening for exposure, assessing readiness to quit, providing at least one brief motivational interviewing session in the hospital, dispensing nicotine replacement therapy if appropriate, providing a smoking cessation/reduction starter kit and arranging for follow up after the child is discharged.
89301395|NCT03626272|Active Comparator|8-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 8 months.
89301396|NCT03626272|Active Comparator|4-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 4 months.
89301397|NCT03626272|Active Comparator|2-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 2 months.
89301398|NCT02154490||S1400A Arm I (MEDI4736) (CLOSED TO ACCRUAL 12/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
89301399|NCT02154490||S1400A Arm II (CLOSED TO ACCRUAL 4/2015)|Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
89301400|NCT02154490||S1400A Arm III (MEDI4736)|For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12- month periods will be allowed. Patients registered to Arm III receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
89301401|NCT02154490||S1400B Arm I (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Patients with tumors positive for PI3KCA randomized to Arm I receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89301402|NCT02154490||S1400B Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for PI3KCA randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
89301403|NCT02154490||S1400B Arm III (taselisib) (CLOSED TO ACCRUAL 12/12/2016)|Re-Registration Treatment with GDC-0032 (Taselisib). Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients will receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89301404|NCT02154490||S1400C Arm I (palbociclib)|Patients with tumors positive for CDK4/6, CCND1, CCND2, and CCND3 randomized to Arm I receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89301405|NCT02154490||S1400C Arm II (CLOSED TO ACCRUAL 12/18/2015)|Patients with tumors positive for CDK4, CCND1, CCND2, and CCND3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
89301406|NCT02154490||S1400C Arm III (palbociclib)|Re-Registration Treatment with palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients will receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89301407|NCT02154490||S1400D Arm I (AZD4547) (CLOSED TO ACCRUAL 04/12/2017)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm I receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89301408|NCT02154490||S1400D Arm II (CLOSED TO ACCRUAL 10/31/2016)|Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
89301409|NCT02154490||S1400D Arm III (AZD4547) (CLOSED TO ACCRUAL 10/31/2016)|Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients will receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89301410|NCT02154490||S1400E Arm I (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm I receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
89301411|NCT02154490||S1400E Arm II (CLOSED TO ACCRUAL 11/2014)|Patients with tumors positive for HGF/c-MET randomized to Arm II receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
89301412|NCT02154490||S1400F (durvalumab, tremelimumab)|Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
89301413|NCT02154490||S1400G (talazoparib)|Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89301414|NCT02154490||S1400I Arm I (nivolumab, ipilimumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm I receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third cycle. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89301415|NCT02154490||S1400I Arm II (nivolumab)|Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm II receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89301416|NCT01979770||Adolescents|Adolescents who participated in an intervention trial of iron and zinc supplementation and a follow-up study at 9 years of age in 3 rural districts in Khon Kaen province, northeast of Thailand.
88814090|NCT02461758|Other|Vedolizumab Group + standard dose influenza vaccine (SDIV)|A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV
89301417|NCT01682356|Placebo Comparator|BRJ crossover to placebo|Beetroot Juice without nitrate.s Patients will be studied before and after ingestion of beetroot juice
89301418|NCT01682356|Active Comparator|Beetroot Juice|Beetroot Juice with nitrates. Patients will be studied before and after ingestion of beetroot juice with nitrates
89301419|NCT01512316|Active Comparator|d-Cycloserine Acquisition|d-Cycloserine will be given on day1, before acquisition
89301420|NCT01512316|Active Comparator|d-Cycloserine Extinction|d-Cycloserine will be administered on day2, before extinction
89301421|NCT01512316|Placebo Comparator|Placebo|A placebo pill will be administered on day1 and 2
89301422|NCT03627494|Experimental|Part A: P1,PBO/GSK3439171A Dose 2/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 milligram (mg) up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence placebo (PBO) followed by Dose 2 of GSK3439171A followed by Dose 3 of GSK3439171A in period 1 (P1). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301423|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ PBO/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and PBO as per randomized sequence: Dose 1 of GSK3439171A followed by PBO followed by Dose 3 of GSK3439171A in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301424|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ GSK3439171A Dose 2/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 1 of GSK3439171A followed by Dose 2 of GSK3439171A followed by PBO in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301425|NCT03627494|Experimental|Part A: P2, PBO/GSK3439171A Dose 5/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 5 of GSK3439171A followed by Dose 6 of GSK3439171A in period 2 (P2). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301426|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ PBO/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by PBO followed by Dose 6 of GSK3439171A in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301427|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ GSK3439171A Dose 5/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by Dose 5 of GSK3439171A followed by PBO in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301428|NCT03627494|Experimental|Part A: P3, PBO/GSK3439171A Dose 8/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 8 of GSK3439171A followed by Dose 9 of GSK3439171A in Period 3 (P3). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301429|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ PBO/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by PBO followed by Dose 9 of GSK3439171A in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301430|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ GSK3439171A Dose 8/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by Dose 8 of GSK3439171A followed by PBO in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301431|NCT03627494|Experimental|Part B: GSK3439171A|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A in part B
89301432|NCT03627494|Placebo Comparator|Part B: Placebo|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of Placebo in part B
89301433|NCT03627494|Experimental|Part C: GSK3439171A fed followed by GSK3439171A fasted|Subjects will administer GSK3439171A in Fed condition in Part C P1 followed by GSK3439171A in fasted condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301434|NCT03627494|Experimental|Part C: GSK3439171A fasted followed by GSK3439171A fed|Subjects will administer GSK3439171A in fasted condition in Part C P1 followed by GSK3439171A in fed condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
89301435|NCT03735914|Experimental|neuralgic patients|MRI experimentation
89301436|NCT03627416|Experimental|active rTMS|10 hertz (Hz) rTMS will be administered over bilateral primary motor areas for the muscles of lower extremities. Therapy will include five daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
89301437|NCT03627416|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
89301438|NCT03735836|Experimental|MaxSimil 2 capsules daily|Subjects will receive two (2) capsules per day of MAG-EPA/MAG-DHA omega-3 oils for a total of 600mg of MAG-EPA and 260mg of MAG-DHA daily during 20 consecutive weeks of treatment.
89301439|NCT03735836|Experimental|MaxSimil 3 capsules daily|Subjects will receive two (3) capsules per day of of MAG-EPA/MAG-DHA omega-3 oils for a total of 900mg of MAG-EPA and 390mg of MAG-DHA daily during 20 consecutive weeks of treatment.
89301440|NCT03735758|Experimental|Pazopanib|Pazopanib; 800 mg; daily; oral
89301441|NCT03735758|Active Comparator|Chemotherapy|Guideline-conform chemotherapy
89301442|NCT05665946||AIN patients|Surgical verified AIN patients. A blood sample is drawn just after inclusion and stored for later analysis.
89301443|NCT05665946||Controls.|Non-AIN patients. A blood sample is drawn just after inclusion and stored for later analysis.
89301444|NCT03639818|Experimental|experimental group|HIV patients
89301445|NCT03639740|Other|Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor|Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor
89301446|NCT03735602|Experimental|perceptual training|Orientation discrimination task, which is a cognitive task. Patients were trained for 1 hour per day, 15 days in total.
89301447|NCT03639662|Experimental|experimental group|"Patients benefit from additional support consisting of at least 3 sessions of sophrology (sophrology sessions), one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for iratherapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
89301448|NCT03639662|No Intervention|control group|Between the announcement of their thyroid cancer and the post-therapeutic scintigraphy, the patients will follow the usual route: information on the management, receipt of an information booklet (containing the telephone contacts of the hospital units), and they wish it, meet with the staff and visit a room of hospitalization. The nurses of the hospitalization service are available to answer any questions they may have, either during this visit or during a telephone call
89301449|NCT01048138|Experimental|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
89301450|NCT01048138|Placebo Comparator|Placebo|5mg IV(in the vein)every 6 hours for 10 days
89301451|NCT05491174|Experimental|DBT-Informed Intervention|The DBT-informed group intervention, known as the 'Managing Emotions Group', will consist of 90-minute sessions, run weekly over 10 weeks.
89301452|NCT05491174|No Intervention|Wait-list control|Participants will be placed on a wait-list for up to 18 weeks.
89301453|NCT00823342|Placebo Comparator|Group A|CLEVUDINE 30 mg qd + TENOFOVIR Placebo
89301454|NCT00823342|Active Comparator|Group B|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
89301455|NCT00823342|Placebo Comparator|Group C|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
89301456|NCT00097539||Participants With Growth Disorders|Participants initiating therapy with Genentech GH products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) for the treatment of pediatric growth disorders as determined by their physician and who have consented to participate in the NCGS will be enrolled in the study and will be followed throughout their course of treatment, or until withdrawal from the NCGS.
89301457|NCT01082445|Experimental|N-acetylcysteine|50 patients that receive 600 mg of acetylcysteine for 3 times a day.
89301458|NCT01082445|Placebo Comparator|Placebo|50 subjects taking placebo pills 3 times a day
89301459|NCT03963219|Experimental|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
89301460|NCT03963219|Active Comparator|Standard Bolus Calculator|Standard bolus calculator
89301461|NCT01085877|Active Comparator|Trial part 1|
89301462|NCT01085877|Experimental|Trial part 2|
89301463|NCT01089855|Experimental|Carbamazepine|
89301464|NCT01589289|Experimental|Phase 3 RDTs|The different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. [To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated].
89301465|NCT01085955||Acute Peripartum|pregnant women who have recently given birth and diagnosed with peripartum cardiomyopathy
89301466|NCT01085955||Healthy Peripartum|Healthy pregnant women who have recently given birth, used as controls
89301467|NCT01085955||Healthy, non-pregnant women|Healthy non-pregnant women without cardiac disease, used as controls
89301468|NCT01085955||New Non-ischemic CMP|Women 18-60 years old who have been diagnosed with non-ishemic cardiomyopathy within the last 6 months and have an ejection fraction less than OR equal to 45% by echocardiogram.
89301469|NCT04676932|Experimental|Nursing Care Based on Kolcaba's Comfort Theory|"In this study, nursing care based on Kolcaba's Comfort Theory will be applied to the intervention groups.~Care will given when women after receiving the HSG attendance appointment. Care will terminated on the 15 minutes after the end of HSG undergoing.~The time of the study 1-3 days for each women. Intervention Nursing Care Based on Kolcaba's Comfort Theory"
89301470|NCT04676932|No Intervention|Routine hospital schedule|The researcher sincerely answered all questions asked by the control group during the HSG period.
89301471|NCT04600960|Experimental|50 subjects with chemotherapy-induced thrombocytopenia|50 enrolled subjects will be picked up to take eltrombopag at the indicated dose.
89301472|NCT04540042|Experimental|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
89301473|NCT04540042|Placebo Comparator|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
89301474|NCT04540042|Experimental|SelK2 (Part 2)|I.V., single-dose (Day 1)
89301475|NCT04540042|Placebo Comparator|Placebo (Part 2)|I.V., single-dose (Day 1)
89301476|NCT04481074|Experimental|Inspiratory muscle training group|Group intervention: home-based interval inspiratory muscle training during 8 weeks, two sessions with two sets of 30 breaths with one minute rest between them. Load set is determinated weekly, aiming 50% of actual PImax and according to Borg Score.
89301477|NCT04252144|Experimental|GERD|Patients with verified gastroesophageal reflux disease
89301478|NCT04252144|Other|Contol|Mostly healthy subjects who have no symptoms and other manifestations of gastroesophageal reflux disease by complex examination
89301479|NCT04051528|Experimental|combinatorial training group|Combinatorial training group will have the same procedure with the sequential training group in the first 8 sessions. After that the procedure for sessions from 9th to 16th will be 60 minutes of guiding training.
89301480|NCT04051528|Experimental|sequential training group.|Sequential training group will first undergo aerobic exercise training for 30 minutes followed by 30 minutes of computerized cognitive training. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
89301481|NCT04051372||BAL group|"Adult patients with hematology disease under allo-HSCT at any phase of treatment are enrolled according to the following criteria:~lung infiltration detection at computed tomography (CT) scan.~Patients with fever, cough, respiratory symptoms. According to the investigators, the patients fulfilling these criteria undergo BAL as soon as possible"
89301482|NCT05475574|No Intervention|Before discontinuation of contact precautions for ESBLE|Implementation of contact precaution in addition to standard precaution for any patient carrying (infected or colonized) ESBLE
89301483|NCT05475574|Experimental|After discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
89301484|NCT04092166|No Intervention|Controlled|Participants will have no intervention.
89301485|NCT04092166|Other|Cardiac Rehab Exercise: Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
89301486|NCT04037020||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa.
89301487|NCT03925324|Experimental|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.
89301488|NCT03925324|Placebo Comparator|Placebo|Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart.
89301489|NCT03841318|Experimental|Sjogren's Syndrome|
89301490|NCT03794986|Experimental|Motivational Interviewing|Sexual and gender minority males who are sexual abuse survivors.
89301491|NCT03794986|Active Comparator|MI with trauma-informed SGM affirmative care|MI w/trauma-informed SGM affirmative care
89301492|NCT03674320|Placebo Comparator|Placebo|Placebo (saline) injections will be given via intramuscular injection at study weeks 2,3, 6, 7, 10, and 11.
89301493|NCT03674320|Active Comparator|Testosterone Enanthate|Testosterone Enanthate (100mg men, 25mg women) will be given via intramuscular injection at study weeks 2, 3, 6, 7, 10 and 11.
89301494|NCT05457946|Experimental|Test group 1|Low dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib) for Stage 1/ selected dose of hexavalent vaccine Lot A for Stage 2
89301495|NCT05457946|Experimental|Test group 2|Middle dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib) for Stage 1/ selected dose of hexavalent vaccine Lot B for Stage 2
89301496|NCT05457946|Experimental|Test group 3|High dose of candidate hexavalent vaccine (DTwPHepB-Sabin IPV-Hib)for Stage 1/ selected dose of hexavalent vaccine Lot C for Stage 2
89301497|NCT05457946|Active Comparator|Control group|Co-administration of Pentavalent vaccine and Inactivated Polio vaccine for both stages
89301498|NCT03625960|Experimental|Cantharidine group|Application of cantharidine to perenial warts
89301499|NCT03625960|Active Comparator|trichloroacetic acid group|application of trichloroacetic acid to perenial warts
89301500|NCT03042910|Experimental|Patients with advanced solid tumors|Talazoparib 1 mg daily
89301501|NCT05450302||PURE EP|All patients from January 2022 till June 2022 in whom PURE EP was used at the Kansas City Heart Rhythm Institute, Overland Park, Kansas
89301502|NCT03243838|Experimental|Experimental Group|Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer
89301503|NCT03059446|Experimental|Cenicriviroc (CVC) 150 mg|Cenicriviroc 150 mg tablet once daily in the morning with food until the study was terminated (up to approximately 4 years).
89301504|NCT00090519|Experimental|Ruboxistaurin|32 milligrams (mg) once daily (QD) oral for up to 36 months
89301505|NCT00090519|Placebo Comparator|Placebo|QD oral for up to 36 months
89301506|NCT02980666|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
89301507|NCT02962102|Experimental|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
89301508|NCT02962102|Experimental|Calcitriol|Calcitriol 4mcg orally daily x 5 days
89301509|NCT02962102|Placebo Comparator|Placebo|Equal volume of medium chain triglyceride (MCT) oil orally daily x 5 days
89301510|NCT02853448|Experimental|Novel Device|Every Subject will be assigned to the same arm. This arm calls for blood to be drawn using an original blood drawing apparatus as well as using the novel blood drawing apparatus.
89301511|NCT02630368|Experimental|Experimental phase I dose escalating|"Prospective open-labeled phase I trial.~Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 14"
89301512|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 1.~Experimental phase II soft-tissue sarcoma :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 48"
89301513|NCT02630368|Experimental|Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 2.~Control-arm phase II soft-tissue sarcoma :~Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days.~Number of subjects : 24"
89523332|NCT03378401|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
89523333|NCT03378401|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
89301514|NCT02630368|Experimental|Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide|"Single-arm phase II clinical trial.~Experimental phase II Group breast cancer :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 32"
89301515|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP|"Experimental phase II soft-tissue sarcoma :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 47"
89301516|NCT02630368|Experimental|Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP|"Experimental phase II breast cancer :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 32"
89301517|NCT05693116||Nasal Vestibule Squamous Cell Carcinoma|Patients affected by primary squamous cell carcinoma of the nasal vestibule. Patients will be treated with upfront surgery according to the current practice and followed to identify any possible factor affecting prognosis.
89301518|NCT05364658|Experimental|Juvene IOL|Eyes that have been implanted with the LensGen Juvene IOL
89301519|NCT05244460|Experimental|Intervention|Patients who receive droperidol 2.5mg intravenous once and diphenhydramine 25mg intravenous once
89301520|NCT00096993|Placebo Comparator|Placebo + gemcitabine|Participants received placebo intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles).
89301521|NCT00096993|Active Comparator|Pertuzumab + gemcitabine|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Participants received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond. In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles
89301522|NCT03040336|Experimental|Prehabilitation|Standard of care + Prehabilitation
89301523|NCT03040336|No Intervention|Standard of Care|Standard of Care
89301524|NCT00072189|Experimental|Treatment (7-hydroxystaurosporine)|Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89301525|NCT03040024|Experimental|Ketamine 0.5 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 0.5 mg/kg.
89301526|NCT03040024|Experimental|Ketamine 1.0 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 1.0 mg/kg.
89301527|NCT03040024|Placebo Comparator|Placebo|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV saline/placebo.
89301528|NCT05128942|Experimental|Cohort 1: Age 11-17 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
89301529|NCT05128942|Experimental|Cohort 2: Age 11-17 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
89301530|NCT05128942|Experimental|Cohort 3: Age 2-10 Treatment with Tildacerfont|Oral Tildacerfont administered daily for 12 consecutive weeks.
89301531|NCT03625804|Experimental|PNS+AO+Training|"adopted PNS+AO+Training as the intervention"
89301532|NCT03625804|Experimental|PNS+AOsham+Training|"adopted PNS+AOsham+Training as the intervention"
89301533|NCT03625804|Placebo Comparator|PNSsham+AOsham+Training|"adopted PNSsham+AOsham+Training as the intervention"
89301534|NCT05332834|Experimental|Drug SM17|Peripheral intravenous injection
89301535|NCT05332834|Placebo Comparator|Drug Placebo|Peripheral intravenous injection
89301536|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 50 μg,1-Dose|Eligible participants who received Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminium hydroxide, IM on Day 28 in previous study NOR-107 were enrolled at 3rd year post-primary vaccination in this study.
89301537|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 50 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301538|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 50 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301539|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/15/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301540|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301541|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/50/500) μg- MPL 15 μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MPL and 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301542|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/15/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301543|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301544|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/50/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301545|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/150/500) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301546|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/167) μg,1-Dose|Eligible NOR-107 participants who had received Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, on Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301547|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/500) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301548|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (50/150/500) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301549|NCT03039790|Experimental|NOR-107: GI.1/GII.4 (15/50/167) μg,2-Dose|Eligible NOR-107 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminium hydroxide, IM, on Day 1 and Day 28 were enrolled at 3rd year post-primary vaccination in NOR-213 study.
89301550|NCT03039790|Experimental|NOR-210: GI.1/GII.4 (15/50/500) µg, 1-Dose|Eligible NOR-210 participants who had received Norovirus GI.1/GII.4 bivalent VLP vaccine NoV Vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminium hydroxide), IM injection, once on Day 1 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
89301551|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 1-Dose|Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) [15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide and 15 μg of monophosphoryl lipid A (MPL) (Composition B), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
89301552|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 60-94 yrs)|Eligible NOR-204 participants of age 60-94 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
89301553|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg, 1-Dose (Age: 18-49 yrs)|Eligible NOR-204 participants of age 18-49 years who had received Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus (NoV) [15 μg of GI.1 and 50 μg of GII.4 bivalent virus-like particle (VLP)] adjuvanted with 500 µg aluminium hydroxide (Composition A), on Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
89301554|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg - MPL 15 µg, 2-Dose|Eligible NOR-204 participants who had received Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide and 15 μg of MPL (Composition B), IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
89301555|NCT03039790|Experimental|NOR-204: GI.1/GII.4 (15/50/500) µg, 2-Dose|Eligible NOR-204 participants who had received Norovirus bivalent placebo-matching vaccine (15 μg of GI.1 50 μg of GII.4 bivalent VLP) adjuvanted with 500 µg aluminium hydroxide (Composition A) IM, on Day 1 and Day 29 were enrolled at 2nd year post-primary vaccination in NOR-213 study.
89301556|NCT05330806|Experimental|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
89523334|NCT03382067|Active Comparator|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves
89523335|NCT03382067|Placebo Comparator|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing < 0,0009 mg (-)-Epicatechin/100g
89301557|NCT05330806|Active Comparator|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
89301558|NCT04838236|Experimental|MASP app + NRT|MASP is an intervention designed to assist African American smokers with anxiety sensitivity quit smoking through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress and nicotine withdrawal.
89301559|NCT04838236|Other|QuitGuide app + NRT|The QuitGuide app is a standard of care app that allows users to track their nicotine cravings, and provides users with motivational messages.
89301560|NCT03619564||No protein restriction|No protein restriction
89301561|NCT03619564||Low protein diet (LPD)|LPD: < 0.8 g/kg bodyweight
89301562|NCT03619564||Ketoanalogue suppl. very LPD|sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues
89301563|NCT05278780|Experimental|Asynchronous screening|Participants will be screened for medication abortion eligibility using written or online materials and questionnaires, without a synchronous conversation between the prescribing clinician and the patient.
89301564|NCT04763278|Experimental|Prosthesis|Patient is temporarily fit with Point Digit partial hand prosthetic system
89301565|NCT05264116|Experimental|Healthy adult participants|All participants are enrolled in the test group and receive the noninvasive adhesive reprocessed pulse oximeter sensors.
89301566|NCT05233618|Experimental|Tagraxofusp (escalating doses)|IV tagraxofusp on days 1-3 of cycles 1-4 and days 1-2 of additional cycles for up to 9 cycles (some participants could receive more if considered in their best interest)
89301567|NCT04714216|Experimental|Hybrid closed-loop (HCL) automated insulin delivery (AID)|Hybrid closed-loop (HCL) automated insulin delivery (AID) using the Omnipod 5/Horizon HCL system with remote monitoring and device operation capabilities will be deployed to hospitalized patients admitted to the general medical/surgical floor with diabetes (type 1 or type 2) requiring insulin therapy.
89301568|NCT03038620|Experimental|Liraglutide 3.0 mg|"Drug: Liraglutide Active Drug~Other Names:~Saxenda~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
89301569|NCT03038620|Placebo Comparator|Placebo|"Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL~Other Names:~Placebo~Saline injection~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
89301570|NCT03689842|Experimental|Couple donor - recipient|
89301571|NCT02032810|Experimental|Dose Escalation|Dose Escalation of Panobinostat + Ipilimumab. Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg) along with a dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
89301572|NCT02024854|Experimental|skin-to-skin|immediately after birth the baby is laid on mother's chest for as long as justifiable medically to max 2 hours.
89301573|NCT02024854|Active Comparator|standard care|after birth the baby is transferred to the neonatal intensive care unit
89301574|NCT05034328||Healsea® Children: isotonic seawater based nasal spray supplemented with natural Symbiofilm® extract|Children will receive Healsea® Children nasal spray on top of conventional therapies for common cold, as needed.
89301575|NCT05034328||Conventional therapies|Children will receive conventional therapies for common cold as needed, nasal irrigation excluded
89301576|NCT01415674|Experimental|Arm A: Afatinib 40mg per os daily|Patients randomized to the arm A will take a single oral dose of Afatinib from Day 1, for 14 to 28 days, depending on the date of surgery. The number of dosing days will be chosen so that patients are off treatment for a maximum of 7 days before surgery.
89301577|NCT01415674|No Intervention|Arm B : No pre operative treatment|
89301578|NCT01350934|Experimental|Fosamax Plus|Participants received alendronate 70 mg plus vitamin D3 5600 IU in a combination tablet (FOSAMAX PLUS D) once weekly for 6 months (base study), and then once weekly for another 6 months (extension study).
89301579|NCT01350934|Active Comparator|Calcitriol|Participants received calcitriol 0.25 μg once daily orally for 6 months (base study), and then once daily orally for another 6 months (extension study).
89301580|NCT01330576|Placebo Comparator|Standard treatment of care at normothermia|Control group: Standard treatment of care at normothermia
89301581|NCT01330576|Experimental|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
89301582|NCT01146418|Experimental|Corifollitropin alfa 150 μg|Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
89301583|NCT01146418|Active Comparator|recFSH 300 IU|Participants in the reference group in Base Study P06029 received a single injection of placebo for corifollitropin alfa on Stimulation Day 1 and daily injections of 300 IU recFSH on Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
89301584|NCT05654896|No Intervention|No Antibiotic Prophylaxis Group|No antibiotic will be administered prophylactically for TACE.
89301585|NCT05654896|Experimental|Antibiotic Prophylaxis Group|Antibiotic will be administered prophylactically (i.e., Inj. Ceftriaxone 1g, intravenous × stat)
89301586|NCT00745108|Experimental|Tibolone 1.25 mg|
89301587|NCT00745108|Experimental|Tibolone 2.5 mg|
89301588|NCT00745108|Active Comparator|CE/MPA|
89301589|NCT00725374|Active Comparator|Arm 1|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with tibolone
89301590|NCT00725374|Placebo Comparator|Arm 2|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with placebo
89301591|NCT03622580|Experimental|A: Faricimab 6 mg Q8W|Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.
89301592|NCT03622580|Experimental|B: Faricimab 6 mg PTI|Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections once every 4 weeks (Q4W), 8 weeks (Q8W), 12 weeks (Q12W), or 16 weeks (Q16W) up to Week 96, followed by the final study visit at Week 100.
89301593|NCT03622580|Active Comparator|C: Aflibercept 2 mg Q8W|Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.
89301594|NCT00461032|Experimental|1|montelukast
89301595|NCT00461032|Placebo Comparator|2|Placebo
89301596|NCT00092092|Experimental|Montelukast→Placebo|Participants receive one montelukast 5 mg chewable tablet once daily (QD) for 3 weeks. After a 2-week washout period, participants receive one placebo chewable tablet QD for 3 weeks.
89301597|NCT00092092|Experimental|Placebo→Montelukast|Participants receive one placebo chewable tablet QD for 3 weeks. After a 2-week washout period, participants receive one montelukast 5 mg chewable tablet QD for 3 weeks.
89301598|NCT00092092|Active Comparator|Budesonide→Placebo|Participants receive budesonide 200 mcg inhalation powder twice daily (BID) for 3 weeks. After a 2-week washout period, participants receive placebo inhalation powder BID for 3 weeks.
89301599|NCT00092092|Active Comparator|Placebo→Budesonide|Participants receive placebo inhalation powder BID for 3 weeks. After a 2-week washout period, participants receive budesonide 200 mcg inhalation powder BID for 3 weeks.
89301600|NCT00092014|Experimental|Alendronate 70 mg|Alendronate sodium, 70 mg, orally once weekly for up to 24 months
89301601|NCT00092014|Active Comparator|Risendronate 35 mg|Risendronate, 35 mg, orally once weekly for up to 24 months
89301602|NCT00090142|Experimental|1|Montelukast - Placebo
89301603|NCT00090142|Experimental|2|Placebo - Montelukast
89301604|NCT00043108|Experimental|Treatment|Thoracic RT (50.4 Gy/1.8 Gy Fx) Paclitaxel (50mg/m2/weekly X 6) Carboplatin (AUC 2/weekly X 6)
89301605|NCT05225194||COVID-19 ARDS survivors|Survivors of hospitalization due to ARDS caused by SAS-CoV-2.
89301606|NCT05225194||Non-COVID-19 ARDS survivors|Survivors of hospitalization due to ARDS caused by other etiologies than SARS-CoV-2.
89301607|NCT05225194||Family controls|Family controls of participants with ARDS (either due to COVID-19 or other etiologies) without history of COVID-19 or hospitalization in the last 12 months.
89301608|NCT05224960|Experimental|Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)|UC-MSCs plus standard of care (SOC).
89301609|NCT05224960|Placebo Comparator|Placebo|Placebo plus SOC.
89301610|NCT05224570||Gunshot wounds admitted in ICU|patient with Gunshot wounds admitted to ICU
89301611|NCT05224024|Active Comparator|Retzius-repairing robot-assisted radical prostatectomy group|This group is randomized to operated with retzius-repairing technique as prostate cancer patients with robot assisted radical prostatectomy.
89301612|NCT05224024|Placebo Comparator|Retzius-sparing robot-assisted radical prostatectomy group|This group is randomized to operated with retzius-sparing technique as prostate cancer patients with robot assisted radical prostatectomy.
89301613|NCT05223946|Active Comparator|Passive Microwave Radiometry|Diagnostic Test: Passive Microwave Radiometry The MWR2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases.
89301614|NCT05223946|Experimental|SCENAR|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
89301615|NCT05223712||Development Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
89301616|NCT05223712||Development Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
89301617|NCT05223712||Validation Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
89301618|NCT05223712||Validation Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
89301619|NCT05223712||Test Dataset 01|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Department of Nephrology of the First Affiliated Hospital of Sun Yat-sen University
89301620|NCT05223712||Test Dataset 02|Slit-lamp, retinal fundus images, OCTA and kidney diseases examinations collected from Medical Centre of Aikang Health Care, Guangzhou, China
89301621|NCT05223634||oral and/or nasal specimen samples|After each patient has been tested according to conventional SOC and has enrolled in the study, up to ten oral and/or nasal specimen samples will be collected
89301622|NCT05199064||Chronic refractory migraine patients|25 patients who were diagnosed as having chronic refractory migraine and were refractory to conventional treatments, such as oral medications, GONB,and botulinum toxin injection were evaluated.All patients received pulsed RFtherapy to the GON from the proximal (C2) level in the pain clinic between September 2020 and September 2021.
89301623|NCT03619408||No/Mild Esophagitis|All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index <3% on pH-metry. Antacid therapy will be discontinued.
89523336|NCT03377933|Experimental|probiotics and quadruple therapy|Patients are given two-week compound Lactobacillus acidophilus probiotic (1 g t.i.d.), followed by a quadruple antibiotic regimen (esomeprazole [20 mg b.i.d.] + bismuth potassium citrate [220 mg b.i.d.] + tetracycline [750 mg b.i.d.] + furazolidone [100 mg b.i.d.]) for 10 days as rescue therapy.Meanwhile perform endoscopy and take gastric mucosa specimens for gene sequencing before and after the application of probiotic.
89301624|NCT03619408||Moderate/Severe Esophagitis|"All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have moderate or severe histologic esophagitis, and/or erosive esophagitis, and/or reflux index > 3% on pH-metry.~Antacid therapy with PPI (omeprazole 1mg/kg/dose BID) will be initiated. For patients already taking PPI at therapeutic dosing, an H2 blocker (ranitidine 3mg/kg/dose BID) will be added."
89301625|NCT03622112|Experimental|AZD7594 Dose 1|The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
89301626|NCT03622112|Experimental|AZD7594 Dose 2|The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
89301627|NCT03622112|Experimental|AZD7594 Dose 3|The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
89301628|NCT03622112|Experimental|AZD7594 Dose 4|The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
89301629|NCT03622112|Experimental|AZD7594 Dose 5|The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
89301630|NCT03622112|Placebo Comparator|Placebo|The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
89301631|NCT03622112|Active Comparator|Fluticasone Furoate|The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).
89301632|NCT04032158|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
89301633|NCT04032158|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
89301634|NCT03620708|Experimental|Motivational Interviewing|35 minute individual motivational interviewing intervention concluding with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line
89301635|NCT03620708|Active Comparator|Nicotine Replacement Therapy Sampling|Participants are provided with a 2-week supply of nicotine patches and a 2 week supply of nicotine lozenges with a recommendation to try them and are also given a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
89301636|NCT03620708|Other|Referral Only|Participants are provided with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
89301637|NCT03654326|Experimental|Gefapixant|Participants will receive a gefapixant 45 mg tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
89301638|NCT03654326|Placebo Comparator|Placebo|Participants will receive a placebo matching gefapixant tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
89301639|NCT03735524|Experimental|Exercise|Conventional rehabilitation
89301640|NCT04025684|Other|Test toothbrush 1|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 1 after applying a strip of standard fluoride (1450 parts per million [ppm] fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
89301641|NCT04025684|Other|Test toothbrush 2|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 2 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
89301642|NCT04025684|Other|Test toothbrush 3|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 3 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
89301643|NCT04025684|Other|Test toothbrush 4|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 4 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
89301644|NCT03735446|Experimental|Prexasertib+MEC|"Cytarabine is administered intravenously on days 1-5.~Etoposide is administered intravenously on days 1-5.~Mitoxantrone is administered intravenously on days 1-5.~Prexasertib is administered intravenously on days 1, 3, and 5."
89301645|NCT05665868|Experimental|Experimental group based on integrated care mode|① Obtain the health records of patients receiving targeted treatment of gastric stromal tumors in the big data platform; ② Patients upload health data, disease symptoms, complete questionnaires, health consultation and other functions; ③ The platform can regularly send audit reminders, automatically analyze the data uploaded and saved by patients, automatically and intelligently intervene when abnormal results occur, and remind medical staff to intervene manually; ④ Researchers can view the recent health status of patients through the terminal, and members of corresponding disciplines can give targeted health guidance according to the existing health problems of patients; Remind patients with complex conditions to have outpatient reexamination; ⑤ Push disease related knowledge every week for patients to learn independently.
89301646|NCT05665868|Active Comparator|Control group based on conventional care mode|① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
89301647|NCT03735368|Placebo Comparator|Control|placebo oral capsule+ dexmedetomidine+topical anesthesia
89301648|NCT03735368|Active Comparator|Dexmedetomidine- Pregabalin|Pregabalin Oral Capsule +Dexmedetomidine Injection+topical anesthesia
89301649|NCT03617588|Experimental|Gallium-68 THP-PSMA|Single intravenous administration of Gallium-68 THP-PSMA
89301650|NCT03732092||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
89301651|NCT03616106|Experimental|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.
89301652|NCT04019054|Experimental|Active iTBS, Ventromedial Prefrontal Cortex (vmPFC)|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vmPFC, as determined by position Fpz of the international 10-20 EEG electrode system."
89301653|NCT04019054|Placebo Comparator|Control iTBS, vertex|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vertex, as determined by position Cz of the international 10-20 EEG electrode system."
89301654|NCT00071799|Experimental|Azacitidine|Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
89301655|NCT00071799|Active Comparator|Conventional Care|Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted
89301656|NCT03615482|Experimental|Concomitant Vaccination|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
89301657|NCT03615482|Experimental|Non-concomitant Vaccination|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V114 on Day 30
89301658|NCT00090363|Placebo Comparator|Placebo|Matching placebo oral tablet once daily, with best supportive care
89301659|NCT00090363|Experimental|ZD4054 10 mg|ZD4054 10 mg oral tablet once daily, with best supportive care
89301660|NCT00090363|Experimental|ZD4054 15 mg|ZD4054 15 mg oral tablet once daily, with best supportive care
89301661|NCT03652610|Experimental|GSK3536820A ACWY_Liq Group|Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
89301662|NCT03652610|Active Comparator|ACWY Group|Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).
89301663|NCT03615404|Experimental|CMV-DCs with GM-CSF and Td (tetanus toxoid)|CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.
89301664|NCT03614156|Experimental|Rapastinel weekly|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
89301665|NCT03614156|Experimental|Rapastinel clinically driven schedule|Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
89301666|NCT03614156|Placebo Comparator|Placebo weekly|Placebo (prefilled syringe, weekly IV administration)
89301667|NCT03614078|Experimental|PRCL-02 Dose 1|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
89301668|NCT03614078|Experimental|PRCL-02 Dose 2|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
89301669|NCT03614078|Placebo Comparator|Placebo|Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
89301670|NCT03731936||Model establishment and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to establish the facial based diagnostic model of coronary artery diseases, and to prospectively validate the diagnostic effectiveness of the model.
89301671|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic coils|
89301672|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic plugs|
89301673|NCT03730064|Experimental|Bipolar depressed|
89301674|NCT03581786|Placebo Comparator|placebo combine with chemotherapy|Gemcitabine 1000 mg/m² IV are given on Days 1 & 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years
89301675|NCT03581786|Experimental|TORIPALIMAB INJECTION(JS001 )combine with chemotherapy|Gemcitabine 1000 mg/m² IV are given on Days 1 & 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years
89301676|NCT03580382|Experimental|NRAS mutant melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
89301677|NCT03580382|Experimental|WT melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
89301678|NCT03729986||Healthy adults|Healthy subjects without exercise habit that can cooperate with the measurements of this study, loaded inspiratory muscle test.
89301679|NCT05667350||Cancer arm|Baseline blood samples will be collected from participants newly diagnosed with biliary tract cancer.
89301680|NCT05667350||Benign disease arm|Baseline blood samples will be collected from participants newly diagnosed with benign biliary tract diseases.
89301681|NCT03611582|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
89301682|NCT03611582|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
89301683|NCT04015518|Other|Placebo & Spesolimab|Subcutaneous injections of placebo matching Spesolimab, with subcutaneous injections of Spesolimab starting at week 16, for a total treatment time of 52 weeks.
89301684|NCT04015518|Experimental|Spesolimab 'Speso Low'|Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
89301685|NCT04015518|Experimental|Spesolimab 'Speso Medium-low'|Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
89301686|NCT04015518|Experimental|Spesolimab 'Speso Medium-high'|Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
89301687|NCT04015518|Experimental|Spesolimab 'Speso High'|Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
89301688|NCT03577730|Experimental|Experimental|Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
89301689|NCT03577730|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
89301690|NCT03731780|Experimental|Personalized Treatment|Intervention by (standard preventive measures + targeting individual caries risk factors)
89301691|NCT03731780|Experimental|Chlorhexidine and Rremineralization|Intervention is (chlorhexidine + Remineralizing agent + standard preventive measures)
89301692|NCT03731780|Active Comparator|Control|standard preventative measures (tooth brushing, fluoride tooth paste, interdental cleaning)
89301693|NCT03729908|Experimental|Animal assisted mindfulness based intervention|"The intervention is the AAMI. Trained animals that live in the Therapie-Tiergarten of REHAB Basel will function as therapy animals. Trained psychologists will lead the AAMI."
89301694|NCT03729908|Active Comparator|Anti-stress program|The active control intervention consists of the same program, however without the inclusion of animals (Anti-Stress program, ASP).
89301695|NCT03735134|Active Comparator|Control Group|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment
89301696|NCT03735134|Active Comparator|Early colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI
89301697|NCT03735134|Active Comparator|Late colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI
89301698|NCT05665478|Active Comparator|model intervention group|The model was used for prediction to guide the later dosing regimen
89301699|NCT05665478|No Intervention|Non-intervention group|In the non-intervention group, the doctor chose the treatment plan.
89301700|NCT03608774|Experimental|Arm 1|1 gram of Azithromycin (4 capsules of 250 mg) administered orally as a single dose on Day 1, and Doxycycline placebo (1 capsule) administered orally twice daily for 7 days starting on Day 1. N=123
89301701|NCT03608774|Experimental|Arm 2|100 mg of Doxycycline (1 capsule) administered orally twice daily for 7 days starting on Day 1, and Azithromycin placebo (4 capsules) administered orally as a single dose on Day 1. N=123
89301702|NCT03744858||Group A - Participants with CVD|Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
89301703|NCT03744858||Group B - Healthy Participants|Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
89301704|NCT04021524|Active Comparator|Hibiclens Soap|
89301705|NCT04021524|Experimental|BPO Soap|
89301706|NCT03607682|Experimental|Prevention (TTF therapy, NovoTTF-200A device)|
89301707|NCT03606668|Experimental|People with Multiple Sclerosis (PwMS) and Chronic Pain|"Participants with MS will only be able to receive eight treatment sessions in this study group and will complete their treatment over four weeks. Two treatments sessions must be completed each week (of the four weeks) and separated by at least one day.~Participants will attend a baseline visit with assessment and training procedures and receive their first treatment immediately after all baseline assessments. Participants will then complete the remaining seven treatment sessions over four weeks. At the final treatment session, participants will repeat assessments. One week following the final treatment session, participants will be asked to return to clinic to complete assessments once more to test cumulative benefits one week following treatment end."
89301708|NCT05666492|Experimental|Less than 12 months PRP- Test|Patients randomized into the less than 12 months PRP arm will receive 3 doses of topical PRP each month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
89301709|NCT05666492|Placebo Comparator|Less than 12 months placebo- control|Patients randomized into the less than 12 months placebo arm will receive saline topically every month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
89301710|NCT05666492|Experimental|More than 12 months PRP- Test|Patients randomized into more than 12 months PRP arm will receive 3 doses of topical PRP each month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
89301711|NCT05666492|Placebo Comparator|More than 12 months Placebo- Control|Patients randomized into the less than 12 months placebo arm will receive saline topically every month apart and their sense of smell will be assessed during each visit followed by a monthly remote assessment of smell from home.
89301712|NCT03735056|No Intervention|Group 1 (Usual care)|Receives usual care only.
89301713|NCT03735056|Experimental|Group 2 (Usual care plus Support 1)|Receives usual care plus Support 1 (MS Nurse Support) which includes one one-to-one, face-to-face session with an MS Nurse Specialist in a hospital setting (or via Skype). The session will include answering newly diagnosed patients' questions about MS, providing psychoeducation and teaching Acceptance and Commitment strategies (Hayes, Strosahl & Wilson, 1999), and referring to other services (based on needs). Participants will also be given a self-help workbook ('Better living with a diagnosis of MS: Patient Workbook') by the nurses. This session will take place within 2 weeks of diagnosis and last up to 90 minutes. It will be supplemented by phone calls (depending on participant needs). MS Nurses will receive training and on-going supervision from experienced clinical psychologists.
89523337|NCT03377855|Experimental|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
89301714|NCT03735056|Experimental|Group 3 (Usual care plus Support 2)|Receives usual care plus Support 2 (i.e. MS Nurse Support plus Peer Support). In addition to receiving the MS Nurse Support (i.e. Support 1, as described in Group 2), this group will also receive peer support which will be provided by Peer Support Workers who are patients/carers with lived experience and who are recruited and trained to deliver peer support under supervision from experienced clinical psychologists. It will be delivered one-to-one, face-to-face (in a community setting or via Skype, based on participants' preferences). Patients in this group will be triaged to a Peer Support Worker by the MS Nurse during the 2-week MS Nurse Support session. The sessions will be scheduled to a convenient time between weeks 2-6 after diagnosis and each session will last up to 60 minutes.
89301715|NCT03731624||SLK|
89301716|NCT03731624||GVHD|
89301717|NCT03731624||Dry eye|
89301718|NCT03731624||Control|
89301719|NCT03734978||A blood group|prematurity with sepsis
89301720|NCT03734978||O blood group|prematurity with sepsis
89301721|NCT03734978||B blood group|prematurity with sepsis
89301722|NCT03734978||AB blood group|prematurity with sepsis
89301723|NCT03729674||Biosimilar|Exposed group
89301724|NCT03729674||Originator (legacy) drug|Reference group
89301725|NCT01310270|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation
89301726|NCT01310270|Placebo Comparator|Placebo|
89301727|NCT03731468|Active Comparator|dexmethasone group|8 mg dexamethasone will be added to local anaesthetics
89301728|NCT03731468|Sham Comparator|control group|isobaric bupivacaine will be given on each side
89301729|NCT03621098||Diet+Exercise|Diet with structured exercise (mostly walking) at a moderate-intensity level This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
89301730|NCT03621098||Diet+Daily Activity|"Diet with increased light-intensity physical activity and decreased sedentary behavior throughout the day.~This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)"
89301731|NCT03621098||Diet+Exercise+Daily Activity|Diet with structured exercise and increased daily activity. This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
89301732|NCT03734900|Placebo Comparator|Saline injection|Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections
89301733|NCT03734900|Experimental|PRP injection|PRP injection into the study knee joint every 4 weeks for a total of 3 injections
89301734|NCT03734900|Experimental|PL injection|PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.
89301735|NCT03734510|Active Comparator|hesperidin and flaxseed|
89301736|NCT03734510|Placebo Comparator|control|
89301737|NCT03734510|Active Comparator|flaxseed|
89301738|NCT03734510|Active Comparator|hesperidin|
89301739|NCT03731390|Experimental|GR1405 injection 3 mg/kg|According to the patient's weight, the dose of this group is 3mg/kg.
89301740|NCT03731390|Experimental|GR1405 injection 10 mg/kg|According to the patient's weight, the dose of this group is 10mg/kg.
89301741|NCT03731390|Experimental|GR1405 injection 20 mg/kg|According to the patient's weight, the dose of this group is 20mg/kg.
89301742|NCT03731390|Experimental|GR1405 injection 30 mg/kg|According to the patient's weight, the dose of this group is 30mg/kg.
89301743|NCT03601052|Experimental|Remlarsen - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
89301744|NCT03601052|Placebo Comparator|Placebo - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
89301745|NCT03600740|Experimental|GPi DBS|Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.
89301746|NCT03600428|Experimental|Live Attenuated Influenza Vaccine (LAIV)|Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
89301747|NCT03600428|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
89301748|NCT03729440||corrosive patients|
89301749|NCT03575702|Experimental|Uritos®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
89301750|NCT03575702|Active Comparator|Urotol®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
89301751|NCT05665400|Experimental|Bloomlife Lovelace FT|
89301752|NCT03639896|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
89301753|NCT03639896|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
89301754|NCT03573908|Experimental|Linaclotide 290 µg|Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
89523338|NCT01327885|Experimental|Arm A|
89523339|NCT01327885|Active Comparator|Arm B|
89301755|NCT03573908|Placebo Comparator|Placebo|Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.
89301756|NCT03734432|Experimental|Patients|IGAR-Breast TeleOp
89301757|NCT03573830|Active Comparator|Current material|Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
89301758|NCT03573830|Experimental|Enhanced material|Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.
89301759|NCT03729284|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
89301760|NCT03729284|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
89301761|NCT03729128|Experimental|dextromethorphan and memantine (DM+MM)|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on dextromethorphan 30mg/day and memantine 5mg/day combination (DM+MM) for 12 weeks.
89301762|NCT03729128|Placebo Comparator|Placebos|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on placebos for 12 weeks.
89301763|NCT03731312||Study group|We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.
89301764|NCT03595904|Experimental|E-Motivate group|Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
89301765|NCT03595904|Active Comparator|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
89301766|NCT03621020||Healthy controls|Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
89301767|NCT03621020||Aspirin monotherapy|Subjects taking 81+ mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
89301768|NCT03621020||von Willebrand Disease|Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
89301769|NCT03621020||Glanzmann's Thrombasthenia|Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
89301770|NCT03621020||Dual antiplatelet therapy (DAPT)|Subjects taking 81 mg daily aspirin and either 75 mg daily clopidogrel, 10 mg daily prasugrel, or 180 mg daily ticagrelor
89301771|NCT03731078||Motor Functional Neurological Disorder|The cohort will consist of patients with clinically-established motor functional neurological disorder, which includes individuals with functional movement disorders and functional limb weakness. Individuals with functional movement disorders and/or functional limb weakness who also have psychogenic nonepileptic seizures will be included. Patients will receive CBT informed PT intervention. The physical therapy intervention will be usual care in FND and based on consensus recommendations, clinical trials and good practices.
89301772|NCT03595280|No Intervention|Control|Participants in the control group receive no study messages
89301773|NCT03595280|Experimental|Untailored Messages|Participants in the untailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones.
89301774|NCT03595280|Experimental|Tailored Messages|Participants in the tailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones that are personalized to their hookah tobacco use behavior and beliefs.
89301775|NCT03729050|Experimental|Intervention with rehabilitation coordinator|
89301776|NCT03729050|No Intervention|Control|
88806282|NCT05379426||Screening tests and semi-structured interview|Battery of screening tests with semi-structured interview First, the Mini-Mental State Examination will be administered to participants to assess whether they meet the inclusion criteria and an identification code will be assigned to eligible participants. Posteriorly, a clinical psychologist will administer the Frontal Assessment Battery, Center for Epidemiologic Studies Depression Scale, Geriatric Anxiety Inventory, Loneliness Scale 3 Portuguese version, Quality of Life - Alzheimer's Disease, and will conduct a semi-structured interview about the difficulties experienced by the older adult during the pandemic period.
88806283|NCT03010787|Experimental|Part 1|Single ascending dose of oral V565
88806284|NCT03010787|Experimental|Part 2 - V565|Single dose level of oral V565 TID for 14 days
88806285|NCT03010787|Placebo Comparator|Part 1 and 2 - placebo|Oral placebo single dose (Part 1) or TID for 14 days (Part 2)
88806286|NCT03010787|Experimental|Part 3|Single dose of V565 in patient volunteers
88806287|NCT03010787|Experimental|Part 4|Single ascending dose of V565 in patients with Crohn's Disease
88806288|NCT01336140|Experimental|Aminophylline|75 mg of intravenous aminophylline.
88806289|NCT01336140|Placebo Comparator|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
88806290|NCT05398926|Experimental|Experimental group 1 (3-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (3-month interval）.
88806291|NCT05398926|Experimental|Experimental group 2 (4-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (4-month interval）.
88806292|NCT05398926|Experimental|Experimental group 3 (5-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (5-month interval）.
88806293|NCT05398926|Experimental|Experimental group 4 (6-month interval)|100 subjects who have received two doses of COVID-19 vaccine (Vero cell), Inactivated will receive a 3rd dose of the vaccine (6-month interval）.
88806294|NCT01184885|Experimental|Hyper-CVAD and Sirolimus|Hyper-CVAD and Sirolimus
88806295|NCT02187887|Experimental|Personalized normative feedback|Intervention participants receive feedback correcting their misperceptions of the drinking behavior and attitudes of fellow veterans
89301777|NCT03734276|Experimental|High intensity exercise|
89301778|NCT03734276|Active Comparator|Control|
89301779|NCT03593876|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
89301780|NCT03734120||men|men undergoing routine semen analysis for infertility
89301781|NCT03728894|Active Comparator|A: Midazolam-hydroxyzine with 100% O2|Midazolam-hydroxyzine with 100% O2 was administrated to 30 children. Drug: Oral Medication (midazolam 7.5 mg and hydroxyzine 10 mg) and Inhalation Gas 100% O2 Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
89301782|NCT03728894|Experimental|Midazolam-hydroxyzine with 50% N2O/ O2|children received Midazolam-hydroxyzine with 50% N2O/O2, one tablet of oral midazolam 7.5 mg and one tablet of hydroxyzine 10 mg with 50% N2O/O2. Drug: Oral Medication and Inhalation Gas Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
89301783|NCT01310426||anal sphincter damage|After assessing women after vaginal delivery, a comparison will be made between those with anal sphincter damage and those women without.
89301784|NCT03728816||SCAP groups|all the SCAP patients who meet the inclusion criteria
89301785|NCT03730766|Experimental|Bismuth Plus triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
89301786|NCT03733964|Experimental|Manual therapy|A group of 50 people using manual therapy as a treatment method.
89301787|NCT03733964|Experimental|PNF|A group of 50 people using PNF (Proprioceptive Neuromuscular Facilitation) as a treatment method.
89301788|NCT03733964|Experimental|Manual therapy + PNF|A group of 50 people using combination therapy - manual therapy and PNF.
89301789|NCT03733964|Experimental|Kinesiotherapy|A group of 50 people using traditional kinesiotherapy (exercises) as a treatment method.
89301790|NCT00071487|Placebo Comparator|Placebo plus SOC|
89301791|NCT00071487|Experimental|Belimumab 1 mg/kg plus SOC|
89301792|NCT00071487|Experimental|Belimumab 4 mg/kg plus SOC|
89301793|NCT00071487|Experimental|Belimumab 10 mg/kg plus SOC|
89301794|NCT03962283|Active Comparator|Rifaximin|ASA daily + misoprostol + Rifaximin (Rifaximin group)
89301795|NCT03962283|Placebo Comparator|Rifaximin Placebo|ASA daily + misoprostol + Placebo Rifaximin (Placebo group)
89301796|NCT03591146|Experimental|TLC590 190mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
89301797|NCT03591146|Experimental|TLC590 380mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
89301798|NCT03591146|Experimental|TLC590 570mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
89301799|NCT03591146|Experimental|TLC590 475mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
89301800|NCT03591146|Active Comparator|Naropin 150mg|Naropin injection contains ropivacaine hydrochloride (HCl). Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
89301801|NCT00096447|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89301802|NCT03590366|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
89301803|NCT03590366|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
89301804|NCT03728738|Experimental|Zero Degree HOB|Randomization to zero degree head of bed positioning until the time of initiation of thrombectomy
89301805|NCT03728738|Active Comparator|Thirty Degree HOB|Randomization to thirty degree head of bed positioning until the time of initiation of thrombectomy
89301806|NCT03728660|Experimental|LVES 2 first LEGACY second|Virtual bioptic magnification with large field of view (LVES 2) followed by 22-week washout period and then Full field magnification with small field of view (LEGACY)
89301807|NCT03728660|Active Comparator|LEGACY first LVES 2 second|Full field magnification with small field of view (LEGACY) followed by 22-week washout period and then Virtual bioptic magnification with large field of view (LVES 2)
89301808|NCT03733808|Active Comparator|Active rTMS treatment|Active High frequency rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. The stimulation protocol parameters will be set as follow: frequency of 15 Hz, of 100% of resting motor threshold (rMT), 40 trains, 60 pulses per train, 15 s intertrain-interval, 2400 pulses per session.
89301809|NCT03733808|Sham Comparator|Sham rTMS treatment|Sham rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same procedures of active High frequency rTMS will be used.
89301810|NCT03730532|Experimental|Randomised CBT|Cognitive Behavioural Therapy Guided Self Help
89301811|NCT03730532|Experimental|Randomised CAT|Cognitive Analytic Therapy Guided Self Help
89301812|NCT03730532|Experimental|Preference CAT|Cognitive Analytic Therapy Guided Self Help
89301813|NCT03730532|Experimental|Preference CBT|Cognitive Behavioural Therapy Guided Self Help
89301814|NCT03588572|Experimental|Venlafaxine Group|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.
89301815|NCT03588572|No Intervention|Controlled group|the patients in controlled group do not use the drug during the experiment, and the other treatments are same as the venlafaxine group.
89301816|NCT00090285|Experimental|qHPV Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
89301817|NCT00090285|Placebo Comparator|Placebo|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
89301818|NCT01086111||PMSF|type 2 diabetes patient receiving a protein sparing diet
89301819|NCT01086111||sleeve gastrectomy|type 2 diabetes patient receiving a gastric bypass
89301820|NCT01086111||RYGBP|type 2 diabetes patient receiving a gastric bypass
89301821|NCT00070941|Experimental|SAM-e|40 subjects receiving oral SAM-e, 1200mg or 1800mg daily in two divided doses, and placebo escitalopram.
89301822|NCT00070941|Active Comparator|Escitalopram|40 subjects receiving oral escitalopram 20mg or 40 mg daily, in two divided doses, and placebo SAM-e.
89301823|NCT00070941|Placebo Comparator|Placebo Comparator|20 subjects receiving oral placebo escitalopram and placebo SAM-3 daily in two divided doses.
89301824|NCT03960489|Experimental|Treatment Sequence 1 (ABCD)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 3 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
89301825|NCT03960489|Experimental|Treatment Sequence 2 (BDAC)|Participants will receive 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 1 followed by single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
89301826|NCT03960489|Experimental|Treatment Sequence 3 (CADB)|Participants will receive single dose of 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 2 followed by 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 3 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
89301827|NCT03960489|Experimental|Treatment Sequence 4 (DCBA)|Participants will receive single dose of 100 mg roxadustat azo dye-containing tablet (D), orally on day 1 in period 1 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet solid (C), orally on day 1 in period 2 followed by 100 mg roxadustat pediatric azo dye-free mini-tablet suspension (B), orally on day 1 in period 3 followed by 100 mg of roxadustat pediatric azo dye-free tablet (A), orally on day 1 in period 4. Each period will be of 6 days. A washout period of 7 days will be included between each period.
89301828|NCT00070707|Experimental|Mometasone|Mometasone nasal spray 200 mcg, administered once daily (QD) for 4 weeks
89301829|NCT00070707|Placebo Comparator|Placebo|Matching placebo nasal spray, administered QD for 4 weeks
89301830|NCT01082523|Active Comparator|Text message reminders|
89301831|NCT01082523|No Intervention|Control|
89301832|NCT01082601||Optimal Medical therapy|Subjects with Class I,IIor III congestive heart failure on optimal medical therapy. Planned catheter ablation for paroxysmal or persistent atrial fibrillation. Paroxysmal AF defined as recurrent AF(2 or more episodes in one month) that terminate within seven days. Persistent AF defined as sustained beyond seven days, or lasting less than seven days but requiring pharmacologic or electrical cardioversion.
89301833|NCT03036124|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
89301834|NCT03036124|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
89301835|NCT00070317|Experimental|Diagnostic|Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.
89301836|NCT01086345|Experimental|Arm I|Patients receive bevacizumab IV over 30 minutes on days 1 and 15. Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
89301837|NCT03960411|Experimental|Doxycycline|Doxycycline 100 mg capsule by mouth every 12 hours for 7 days, administered early after primary PCI
89301838|NCT03960411|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 7 days, administered early after primary PCI
89301839|NCT02531139|Experimental|MAP maintained at 80 mmHg|During anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
89301840|NCT02531139|Active Comparator|MAP maintained at 60 mmHg|During anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
89301841|NCT03649412|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2).
89301842|NCT03649412|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR.
89301843|NCT01326897|Active Comparator|Comparison Group|Comparison group participants will be given health education materials.
89301844|NCT01326897|Experimental|Intervention'|This group will receive the intervention (Healthy Homes/Healthy Families) as described below.
89301845|NCT03962049|Experimental|Normal Hepatic Function|Healthy participants with Normal Hepatic Function
89301846|NCT03962049|Experimental|Mild Hepatic Impairment|Presence of Mild Hepatic Impairment (score of 5 to 6, on the Child Pugh scale and with features of cirrhosis due to any etiology)
89301847|NCT03962049|Experimental|Moderate Hepatic Impairment|Presence of Moderate Hepatic Impairment (score of 7 to 9, on the Child Pugh scale and with features of cirrhosis due to any etiology)
89301848|NCT03962049|Experimental|Severe Hepatic Impairment|Presence of Severe Hepatic Impairment (score of 10 to 15 on the Child Pugh scale and with features of cirrhosis due to any etiology)
89301849|NCT01090167|Experimental|Clofarabine|
89301850|NCT05109130||laparoscopic surgery|Laparoscopic total mesorectal excision was performed on the enrolled patients.
89301851|NCT05109130||Transanal endoscopic surgery|Transanal total mesorectal excision was performed on the enrolled patients.
89301852|NCT03772444|Active Comparator|Beetroot juice|
89301853|NCT03772444|Placebo Comparator|Control group 1|
89301854|NCT03772444|Sham Comparator|Control group 2|
89301855|NCT03587636|Experimental|Liposome bupivacaine interscalene block|10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance
89301856|NCT03587636|Active Comparator|bupivacaine interscalene block|20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.
89301857|NCT03730376|No Intervention|Control|Participants in the control group will be given a hypothetical scenario about carpal tunnel syndrome and asked to make a treatment decision for that hypothetical patient.
89301858|NCT03730376|Experimental|Intervention|Participants in the intervetion group will be given a hypothetical scenario about carpal tunnel syndrome as well as information about the cost of treatment and asked to make a treatment decision for that hypothetical patient.
89301859|NCT03053362|Experimental|Major Depressive Disorder Population|"100 Individuals with DSM-5-defined MDD, aged 18-65~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D."
89301860|NCT03053362|Other|Healthy Control Population|50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education
89301861|NCT03733652|No Intervention|Tenofovir|Patents are treated with oral tenofovir 300mg once per day for 48 weeks. Then, tenofovir will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be continued if HBsAg is positive.
89301862|NCT03733652|Active Comparator|Interferon alfa|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
89301863|NCT03586544|Experimental|Albuterol first|Order albuterol and then interval warm up (IWU)
89301864|NCT03586544|Experimental|Interval warm-up first|Order is interval warm up (IWU) and then albuterol
89301865|NCT03730298|Experimental|American Ginseng|American Ginseng, cpr 700 mg (500 mg of Panax Quinquefolius 5%): 1 cpr twice a day orally for 3 months
89301866|NCT03730298|Placebo Comparator|Placebo|Placebo: 1 cpr twice a day orally for 3 months
89301867|NCT03737448|Experimental|Group 1|"AD with serum creatinine ≥ 1 and < 2 mg/dL, OR~ACLF 1 with~liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or~liver failure and West Haven grade 1-2 hepatic encephalopathy, or~coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or~coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR~ACLF 2 with~liver failure and coagulation failure, or~liver failure and West Haven grade 3-4 hepatic encephalopathy."
89301868|NCT03737448|Experimental|Group 2|"ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR~ACLF 2 with~liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or~coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL)."
89301869|NCT03585296|Experimental|ATI-502|ATI-502 topical solution applied daily for four weeks.
89301870|NCT03728270|Experimental|Patient Specific Titanium Eminoplasty|"The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~A multilayer closure of the incisions will be accomplished using Vicryl sutures."
89301871|NCT03728270|Active Comparator|Inlay Autogenous Bone Graft|"A safety distance of 5 mm will be maintained from the apex of the mandibular incisor and inferior mandibular border, the mental foramen, and permanent canine follicle.~One corticocancellous bone block with a maximum depth of 4 mm will be removed by mallet and chisel based on the recommendation that bone from the chin should be harvested at this maximum depth, compatible with the course of the mandibular incisive nerve canal on CT scans.~After removal of bone from the chin, the intervening bone struts will be removed using rongeur forceps and used as an additional bone graft.~The bone removed will be trimmed and contoured in a wedge form to be used as an inter-positional graft in the previously down fractured articular eminence to act as an obstacle in front of the mandibular condyle to prevent its hyper movement."
89301872|NCT03748056|Experimental|Targeted incentives arm|The interventions received by the experimental group include: 1) weekly emails with targeted coupons for healthier products, 2) weekly emails with targeted nutrition education, and 3) and a nominal discount on grocery purchases for using their loyalty card
89301873|NCT03748056|Active Comparator|Usual care arm|"The interventions included under usual care include 1) untargeted nutrition education, 2) occasional untargeted coupons for healthier products, and 3) a nominal discount on their grocery purchases for using their loyalty card. These interventions are only received by participants randomized to the usual care arm (rather than the entire population of shoppers), and will allow for testing whether targeting discounts and nutrition education improves the diet quality of purchases in comparison to untargeted approaches."
88806296|NCT02187887|No Intervention|Control|Control participants receive feedback correcting their misperceptions of the video game playing behavior and attitudes of fellow veterans
89301874|NCT03733574|Experimental|LY03005 cross-over to Pristiq® (Desvenlafaxine)|Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).
89301875|NCT03733574|Experimental|Pristiq® (Desvenlafaxine) cross-over to LY03005|Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005
89301876|NCT03728192|Experimental|Mangosteen treated group|"HeLa and H357 cell lines were procured and were further subdivided into 2 subdivisions and were assigned interventions:~Mangosteen group- cells treated with mangosteen extract and Camptothecin group - cells treated with standard anticancer drug camptothecin(25 micro mole)"
89301877|NCT03728192|No Intervention|Untreated group|H357 and HeLa cell line without any drug intervention.
89301878|NCT03639584||Group 1|Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days. Take blood sample on the day of enrollment.
89301879|NCT03639584||Group 2|Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days. Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th. Stop blood sample once exit.
89301880|NCT03639584||Group 3|Patients admitted to ICU 3~7 days. Take blood sample on the day of enrollment.
89301881|NCT03639584||Group 4|Patients admitted to ICU 8~14 days. Take blood sample on the day of enrollment.
89301882|NCT03639584||Group 5|Patients admitted to ICU 15~28 days. Take blood sample on the day of enrollment.
89301883|NCT03589768|Experimental|Group 1|"0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated Gestational Age (GA).~N=133"
89301884|NCT03589768|Active Comparator|Group 2|"0.5 ml single dose of Td (Tetanus, Diphtheria Toxoid) administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated GA.~N=67"
89301885|NCT03733340|Experimental|Imipenem prophylaxis group|Imipenem: 1g q8h i.v. daily for 5 consecutive days before the onset of conditioning of allo-HSCT
89301886|NCT03733340|No Intervention|Blank control group|Without antibacterial prophylaxis at the onset of condition of all-HSCT
89301887|NCT03730142|Experimental|WXFL10030390 tablet|"WXFL10030390 continuous oral dosing (0.1 mg once a day)~WXFL10030390 continuous oral dosing (0.2 mg once a day)~WXFL10030390 continuous oral dosing (0.4 mg once a day)~WXFL10030390 continuous oral dosing (0.7 mg once a day)~WXFL10030390 continuous oral dosing (1.1 mg once a day)~WXFL10030390 continuous oral dosing (1.4 mg once a day)~WXFL10030390 continuous oral dosing (1.7 mg once a day)"
89301888|NCT02892422|Experimental|Flexible-dose of Lu AF35700|
89301889|NCT03728114|Experimental|High Altitude RIC group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device (patent number ZL200820123637.X, China)
89301890|NCT03728114|Sham Comparator|High Altitude Sham group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
89301891|NCT03728114|Experimental|Low Altitude RIC group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device.
89301892|NCT03728114|Sham Comparator|Low Altitude Sham group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
89301893|NCT03571646|Other|Capnostream 20|Continuous monitoring of CO2
89301894|NCT03571646|Other|PM1000N-RR|Continuous monitoring of SpO2
89301895|NCT05183308||patients treated with Vitamin D|
89301896|NCT05183308||patients treated with Vitamin D and Clodronic Acid|
89301897|NCT05137600|Experimental|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
89301898|NCT05137600|Experimental|Midazolam|Midazolam is a sensitive CYP3A index substrate
89301899|NCT05137600|Experimental|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites
89301900|NCT03645434|Experimental|Treatment sequence A|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
89301901|NCT03645434|Experimental|Treatment sequence B|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
89301902|NCT03645434|Experimental|Treatment sequence C|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
89301903|NCT03645434|Experimental|Treatment sequence D|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
89301904|NCT03645434|Experimental|Treatment sequence E|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
89301905|NCT03645434|Experimental|Treatment sequence F|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
89301906|NCT00089505|Experimental|NVP/NVP|For participants who had SD NVP exposure prior to study entry. FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
89301907|NCT00089505|Experimental|NVP/LPV_r|For participants who had SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
89301908|NCT00089505|Experimental|NoNVP/NVP|For participants who did NOT have SD NVP exposure prior to study entry.FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
89301909|NCT00089505|Experimental|NoNVP/LPV_r|For participants who did NOT have SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
89301910|NCT05043376|Active Comparator|Standard of care|In this arm patients will receive the standard COVID-19 care as per the hospital guidelines.
89301911|NCT05043376|Experimental|BLIS K12|In this arm patients will receive the BLIS K12 as add-on to the standard COVID-19 care
89301912|NCT04009824|Placebo Comparator|Group 1: Saline Placebo|Participants received placebo on days 1 and 22 by subcutaneous injection
89301913|NCT04009824|Experimental|Group 2: AGS-v PLUS Non-Adjuvanted|Participants received 1012 µg of unadjuvanted AGS-v PLUS vaccine on days 1 and 22 by subcutaneous injection
89301914|NCT04009824|Experimental|Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo|Participants received 1012 µg of AGS-v PLUS and Montanide ISA-51 on day 1 and placebo on day 22 by subcutaneous injection
89301915|NCT04009824|Experimental|Group 4: AGS-v PLUS + Montanide ISA-51|Participants received 1012 µg of AGS-v PLUS + Montanide ISA-51 on days 1 and 22 by subcutaneous injection
89301916|NCT04009824|Experimental|Group 5: AGS-v PLUS + Alhydrogel® Adjuvant|Participants received 1012 µg of AGS-v PLUS and Alhydrogel® on days 1 and 22 by subcutaneous injection
89301917|NCT03727958|Active Comparator|Lung and coronary CT assessment|Subjects will undergo simultaneous CT assessment of both coronary arteries and thoracic area
89301918|NCT03727958|Active Comparator|Coronary CT assessment|Subjects will undergo CT assessment of coronary arteries only
89301919|NCT01090245|Active Comparator|Attendance Information Group|Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
89301920|NCT01090245|Experimental|Attendance Incentive Group|Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
89301921|NCT04928092||Active research group|Patients undergoing intravascular imaging guided, low contrast PCI procedure as part of standard care
89301922|NCT03555890|Experimental|Subjects of Group A: Part 1|Subjects in Group A will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 2.
89301923|NCT03555890|Experimental|Subjects of Group B: Part 1|Subjects in Group B will be randomized to receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
89301924|NCT03555890|Experimental|Subjects of Group C: Part 2|Subjects in Group C will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg without water in fasted state in Period 2.
89301925|NCT03555890|Experimental|Subjects of Group D: Part 2|Subjects in Group D will be randomized to receive levocetirizine ODT 5 mg without water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
89301926|NCT04905862||Hemodialyzed patients|Hemodialyzed patients vaccinated with BNT162b2 - mRNA vaccine against COVID-19
89301927|NCT04905862||Patients treated with peritoneal dialysis|Patients treated with peritoneal dialysis vaccinated with BNT162b2 - mRNA vaccine against COVID-19
89301928|NCT04905862||Patients without chronic kidney disease|Patients without chronic kidney disease vaccinated with mRNA BNT162b2 - vaccine against COVID-19
89301929|NCT04905862||Kidney transplant recipients|Kidney transplant recipients vaccinated with mRNA vaccine against COVID-19
89301930|NCT03688074|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
89301931|NCT03688074|Placebo Comparator|Placebo|Placebo subcutaneous injection
89301932|NCT03630120|Active Comparator|Standard of Care: DTC|Standard of Care (SOC) TKI Therapy for Differentiated Thyroid Cancer (DTC): Lenvatinib + Sorafenib.
89301933|NCT03630120|Experimental|Adaptive Care: DTC|SOC followed by Adaptive Care TKI Therapy for DTC Participants with >=50% drop: Lenvatinib + Sorafenib.
89301934|NCT03630120|Active Comparator|Standard of Care: MTC|Standard of Care (SOC) TKI Therapy for Medullary Thyroid Cancer: Cabozantinib + Vandetanib.
89301935|NCT03630120|Experimental|Adaptive Care: MTC|SOC followed by Adaptive Care TKI Therapy for MTC Participants with >=50% drop: Cabozantinib + Vandetanib.
89523340|NCT03381911|No Intervention|E-Consent|This arm is the standard of care, where the consent form is presented to the subject on a computer screen and he/she can scroll ahead and back as needed. There is also an option to have each screen read aloud.
89301936|NCT03733262||Hemodialysis Patients|There will be approximately 1,200 patients in the outpatient HD units from Toronto (300), Vancouver (200), Winnipeg (400) and Halifax (300). Based on a previous pilot study, it is assumed that 80% of patients have been prescribed at least one of the nine target drugs (i.e., n=960). Of those, it is assumed that 50% will be eligible for the study (i.e., n=480). Of eligible individuals, it is assumed 88% will initiate a De-prescribing Trial (Intervention Group), resulting in an anticipated cohort of n=420.
89301937|NCT03744702|Experimental|Treatment|All patients will receive ascorbic acid as this is a pilot study.
89301938|NCT03725774|Experimental|Quasi-experimental uncontrolled, before-and-after|The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action
89301939|NCT01060254|Experimental|JNJ-42160443|
89301940|NCT01060254|Placebo Comparator|Placebo|
89301941|NCT03725696||Observational group|Patients who are booked for RYGB gastric bypass surgery and enroll in the study will undergo semen analysis, sexual health questionnaire (IIEF survey), and a blood hormonal panel before and after surgery.
89301942|NCT03736980|Experimental|Psilocybin Group 1|Group 1: randomized, placebo-controlled, double-blind, cross-over design
89301943|NCT03736980|Experimental|Psilocybin Group 2|Group 2: randomized, placebo-controlled, double-blind, cross-over design
89301944|NCT03736980|Experimental|Psilocybin Group 3|Group 3: randomized, placebo-controlled, double-blind, cross-over design
89301945|NCT03736980|Experimental|Psilocybin Group 4|Group 4: randomized, placebo-controlled, double-blind, matched group design
89301946|NCT03555266|Experimental|NSS-2 Bridge and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
89301947|NCT03555266|Sham Comparator|Sham NSS-2 BRIDGE and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal. This arm will contain an inactive sham NSS-2 BRIDGE device plus standard of care for abdominal oncological surgeries. Rescue analgesia will be permitted as per the approved ERAS multi-modal anesthetic protocol
89301948|NCT03725618|Experimental|One-fifth fractional dose|One-fifth fractional dose (0.1 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
89301949|NCT03725618|Experimental|One-half fractional dose|One-half fractional dose (0.25 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
89301950|NCT03725618|Experimental|Full dose|Full dose (0.5 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
89301951|NCT01310504|Active Comparator|Non peritoneal dialysis patient|
89301952|NCT01310504|Active Comparator|Peritoneal dialysis patient|
89301953|NCT03727646|Experimental|Open-label nicotinamide riboside|"Participants scheduled to receive an LVAD will be prescribed nicotinamide riboside (NR) according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg)~Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily~Washout Day of LVAD Surgery and/or Day 15: None"
89301954|NCT03727646|No Intervention|Baseline controls|Patients previously receiving LVADs, in whom blood and myocardial tissue assays for NAD+ levels and mitochondrial function were performed.
89301955|NCT03656874|No Intervention|Usual Care|Usual care, practitioners review clinical guidelines for tobacco during consent process.
89301956|NCT03656874|Experimental|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care.
89301957|NCT03554486|Experimental|Fiasp then Novolog|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
89301958|NCT03554486|Experimental|Novolog then Fiasp|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Novolog insulin for 2 weeks, followed by Fiasp insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
89301959|NCT03733106|Experimental|digital breast tomosynthesis|Tomosynthesis and two dimension digital mammography
89301960|NCT03733106|Active Comparator|control|standard two dimension digital mammography
89301961|NCT04889794|Experimental|Exposed FMGs to GPS intervention|Patients who are followed by FMGs exposed to the GPS intervention. They will receive the GPS intervention.
89301962|NCT04889794|No Intervention|Non exposed FMGs to GPS intervention|Patients who are part of the FMGs not exposed to the GPS intervention. They will receive the usual care and services.
89301963|NCT03725540||I-gel group|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
89301964|NCT03725540||BASKA Group|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
89301965|NCT05462626|Experimental|the Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention will consist of six individualized sessions that will be conducted via a telehealth platform, each lasting about 45-60 minutes. Individual sessions allow for the participant's personal health factors to be discussed and reflected upon as the intervention is delivered weekly. Each week will comprise one or more lifestyle topics that are based on the twelve modules described in the Lifestyle Redesign® manual (Clark et al., 2015).
89301966|NCT03725462|Experimental|Cardioskin|Subjects performed a monitoring with Cardioskin. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Cardioskin, either by an opinion of an expert.
89301967|NCT03725462|Experimental|Neuronaute|Subjects performed a monitoring with Neuronaute. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Neuronaute, either by an opinion of an expert.
89301968|NCT04788238|Experimental|Intervention group|Participants in the intervention arm will participate in the dual-task Zumba Gold (DTZ) program. They will be grouped into 10 participants per class.
89301969|NCT04788238|No Intervention|Control group|Participants in the control group will receive health education about dementia risk reduction provided by community health nurses.
89301970|NCT04787692|Experimental|Opioid and Benzodiazepine Naive-patients|Opioid and Benzodiazepine Naive-patients, defined as no medications 30 days prior to surgery
89301971|NCT04787692|Experimental|Opioid and Benzodiazepine Tolerant-patients|Opioid and Benzodiazepine Tolerant-patients, defined as use of medications on most days for 1 or more months (>30 days) prior to surgery
89301972|NCT04775446||Patients with malignant pleural mesothelioma treated with Nivolumab.|Patients with malignant pleural mesothelioma treated with Nivolumab.
89301973|NCT03571256|Experimental|TEV-50717 High-Dose|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
89301974|NCT03571256|Experimental|TEV-50717 Low-Dose|TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
89301975|NCT03571256|Placebo Comparator|Placebo|Placebo matched to TEV-50717 for a total of 8 weeks
89301976|NCT05462548|Experimental|treatment group|accept Luspatercept treatment
89301977|NCT04625764|Experimental|patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB|
89301978|NCT03408340|Experimental|Paravertebral Nerve Block|Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
89301979|NCT03408340|Active Comparator|Standard of Care Anesthesia|Participants in the control arm will undergo an anesthetic consistent with the standard of care.
89301980|NCT03570554|Experimental|Treatment A-D-C-B|Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
89301981|NCT03570554|Experimental|Treatment B-C-D-A|Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
89301982|NCT03570554|Experimental|Treatment C-A-B-D|Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.
89301983|NCT03570554|Experimental|Treatment D-B-A-C|Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days
89301984|NCT03630172|Experimental|Dry Needling Group|"Dry needles will be sterile, and 0.30 x 60mm in gauge and length. Needles will be placed using an inferomedial approach with the subject positioned in prone. The needle is inserted perpendicular to the skin and then is guided inferiorly and medially until it reaches the lamina. Needles will be manipulated in a pistoning fashion for 15 seconds."
89301985|NCT03630172|Sham Comparator|Sham Needling Group|Non-penetrating needles were constructed by cutting 100mm needles where the handle meets the shaft, and sanding down any rough edges. Guide tubes from 40mm needles will be used. These needles will be place in the same location and manipulated in the same fashion as in the dry needling group, except the needles will not have penetrated the skin.
89301986|NCT04459624|Active Comparator|ESP block|Intervention: Erector Spina Plane Block will administer with 20 ml of % 0.25 bupivacaine
89301987|NCT04459624|Active Comparator|QLB 2 block|Intervention: Quadratus Lumborum Block 2 will administer with 20 ml of % 0.25 bupivacaine
89301988|NCT04004208|Experimental|Aflibercept arm|Subjects randomized to aflibercept will receive a intravitreal (IVT) injection of Dose A aflibercept per eligible eye at baseline and, if needed, up to a defined number of additional injections in each eye.
89301989|NCT04004208|Active Comparator|Laser photocoagulation arm|Subjects randomized to laser photocoagulation will receive treatment in each eligible eye at baseline. Retreatments may be administered if needed.
89301990|NCT03727412|Active Comparator|Naproxen Group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)
89301991|NCT03727412|Placebo Comparator|Control group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking placebo
89301992|NCT03643952|Experimental|Daptomycin|Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.
89301993|NCT03725306|Experimental|Librata|Librata Endometrial Ablation Device
89301994|NCT03035032|Experimental|Leuprolide Acetate 22.5 milligrams (mg)|Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.
89301995|NCT03629184|Experimental|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
89301996|NCT03629184|Active Comparator|Oseltamivir|Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
89301997|NCT03725228|Active Comparator|Magnesium Sulfate|Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery
89301998|NCT03725228|Experimental|Lidocaine|Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery
89301999|NCT03732872||Patient with habits and having OSMF|Patients who had history of arecanut chewing habit in any form and composition and who were not undergone any treatment for their current condition i.e, OSMF
89302000|NCT03732872||Patients with habits and had no clinical symptoms of OSMF|Patients who had history of arecanut chewing habit in any form and composition and had no symptoms of OSMF clinically
89302001|NCT03732872||Healthy human volunteers|patients who reported no history of areacnut chewing habits and had no clinical symptoms of OSMF
89302002|NCT04105738||Difficult airways|Documented history of difficult airways.
89302003|NCT04105738||Control (Not difficult airways)|Age matched with normal airways to be used as controls
89302004|NCT03725072|Experimental|Evobrutinib|
89302005|NCT04393948|Experimental|No irradiation|
89302006|NCT04393948|Experimental|100 cGy single lung irradiation|100 cGy single lung radiation
89302007|NCT04393948|Experimental|100 cGy bilateral lung irradiation|100 cGy bilateral lung radiation
89302008|NCT03549338|Experimental|Arm A (Sym004)|"Sym004 will be given as a loading dose of 9 mg/kg on Cycle 1 Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8.~For patients that crossover from Arm B and Arm C, Sym004 will be given at the dose level that contains the corresponding dose level of the respective individual antibody (futuximab or modotuximab) prior to crossover."
89302009|NCT03549338|Experimental|Arm B (Futuximab)|Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).
89302010|NCT03549338|Experimental|Arm C (Modotuximab)|Modotuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the EOC2, ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.
89302011|NCT03629028|Active Comparator|Single Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
89302012|NCT03629028|Active Comparator|Double Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
89302013|NCT03724838|Active Comparator|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of Sildenafil Citrate 40mg orally every 8 hours
89302014|NCT03724838|Active Comparator|Esomeprazole alone plus placebo to Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
89302015|NCT03724838|Placebo Comparator|placebo to Esomeprazole plus placebo to Sildenafil Citrate|Patients will take placebo identical in shape and consistency with esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
89302016|NCT03744234|Experimental|Platelet-Rich Plasma Injection|Autologous injection of platelet-rich plasma (PRP) in the sacroiliac joint
89302017|NCT03744234|Active Comparator|Steroid Injection|Steroid injection in the sacroiliac joint
89302018|NCT03549104|Experimental|Fear Reduction Efficacy Evaluation (FREE)|The FREE intervention group will participate in eight weekly individual one-hour sessions using CBT and exposure treatment for specific fears.
89302019|NCT03549104|Active Comparator|Attention Control|The attention control group will participate in eight weekly individual one-hour Diabetes Self-Management Education (DSME) sessions.
89302020|NCT03736434|Experimental|Mindfulness plus DASH group|Receives Mindfulness and DASH Diet education once a week for 8 weeks (2.5-hour sessions)
89302021|NCT03736434|Active Comparator|Education Group|The sham intervention includes general education on non-health related topics such as fire-safety and learning how to dispose of medication properly, once a week for 8 weeks (2.5-hour sessions)
89302022|NCT03736434|No Intervention|Control Group|Continue care as usual without intervention.
89302023|NCT02892344|Experimental|QMF149 150/80 μg|QMF149 150/80 microgram o.d. delivered via Concept1
89302024|NCT02892344|Active Comparator|MF 200 µg|MF 200 microgram o.d. delivered via Twisthaler®
89302025|NCT03724760|Experimental|Feedback|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve feedback regrding the number of steps taken by them at two time points.
89302026|NCT03724760|No Intervention|Control|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve no feedback regrding the number of steps taken by them.
89302027|NCT03724682|Experimental|Single arm|Single arm in which everyone enrolled in a trial receives treatment with Carry Life UF device,
89302028|NCT03724604||high NAR|Neuron-Specific Enolase to Albumin Ratio is higher than 3.2×10-7
89302029|NCT03724604||low NAR|Neuron-Specific Enolase to Albumin Ratio is lower than 3.2×10-7
89302030|NCT03727256|Active Comparator|Group 1 patients|Patients have grade 2 or 3 knee osteoarthritis ultrasound therapy
89302031|NCT03727256|Active Comparator|Group 2 patients|Patients have grade 2 or 3 knee osteoarthritis neuromuscular electrical stimulation application
89302032|NCT03567980|Experimental|topical crisaborole 2%|
89302033|NCT03726944|Other|Group 1 - Meditation1+Meditation2|8 weeks in total; 4 weeks of unnamed consumer-based meditation app + 4 weeks of Calm meditation app
89302034|NCT03726944|Other|Group 2 - Meditation2+Meditation1|8 weeks in total; 4 weeks of Calm meditation app + 4 weeks of unnamed consumer-based meditation app
89302035|NCT03726944|Other|Group 3 - Control+Meditation1|8 weeks in total; 4 weeks of educational control + 4 weeks of unnamed consumer-based meditation app
89302036|NCT03726944|Other|Group 4 - Control+Meditation2|8 weeks in total; 4 weeks of educational control + 4 weeks of Calm meditation app
89302037|NCT02894840|Active Comparator|an inactivated influenza vaccine|20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
89302038|NCT02894840|Placebo Comparator|Placebo|20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
89302039|NCT03358030|Placebo Comparator|Placebo|Participants received placebo, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
89302040|NCT03358030|Experimental|Cohort A: ISIS 416858, 200 mg|Participants received ISIS 416858, 200 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
89302041|NCT03358030|Experimental|Cohort B: ISIS 416858, 250 mg|Participants received ISIS 416858, 250 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
89302042|NCT03358030|Experimental|Cohort C: ISIS 416858, 300 mg|Participants received ISIS 416858, 300 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
89302043|NCT03566810|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
89302044|NCT03566810|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
89302045|NCT03566810|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
89302046|NCT03566810|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
89302047|NCT04013932|Experimental|KUPAA Intervention + Standard of Care|Patients will be assigned to a KUPAA group composed of approximately 6 patients (joined by their 6 matched caregivers). Patients will first participate in 1-2 joining sessions with a provider, followed by a 1-day group educational workshop. Participants will then attend weekly family psychoeducation group sessions (~1.5-2 hours) for 12 weeks.
89302048|NCT04013932|No Intervention|Control - Standard of Care|Patients will receive the standard of care.
89302049|NCT03628716|Experimental|CV301 + Atezolizumab|Subject receiving combination treatment with CV301 + Atezolizumab
89302050|NCT03844906|Experimental|SAGE-718|
89302051|NCT03844906|Placebo Comparator|Placebo|
89302052|NCT03736200|Active Comparator|Exergaming 1/day|Post stroke group that received 4 weeks of intensive therapy. (1/day)
89302053|NCT03736200|Active Comparator|physiotherapy|Post stroke group that received 4 weeks of traditional physiotherapy.
89302054|NCT03736200|Active Comparator|Exergaming 2/day|Post stroke group that received 4 weeks of intensive therapy. (2/day)
89302055|NCT04002960|Experimental|INVSENSOR00036|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00036 sensor
89302056|NCT04002648||MT-Right|
89302057|NCT04002648||Sternotomy|
89302058|NCT03732378|Experimental|Omega-3|one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given to treatment group along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time)
89302059|NCT03732378|Placebo Comparator|Placebo|one capsule of 500 mg corn oil, along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time) were given to placebo group
89302060|NCT03840616|Experimental|Oteseconazole (VT-1161) 150mg capsule|600mg oteseconazole administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14
89302061|NCT03840616|Active Comparator|Fluconazole 150mg capsule / Placebo|150mg fluconazole administered every 72 hours in 3 sequential doses starting on Day 1, followed by placebo administered once weekly starting on Day 14
89302062|NCT03744078|Active Comparator|PGE2 with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
89302063|NCT03744078|No Intervention|PGE2 vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
89302064|NCT00088413|Experimental|All Cohorts: Colorectal, Non-Colorectal, Breast, and Ovarian|All cohorts receive the same intervention (Cohort 1: Colorectal arm, non-colorectal cancers; Cohort 2: breast cancer; Cohort 3: ovarian cancers)
89302065|NCT04924348|Experimental|WALANT procedure|Local anesthesia of the WALANT type
89302066|NCT04924348|Active Comparator|Axial ALR|Axillary loco-regional anesthesia
89302067|NCT04924348|Active Comparator|Truncal ALR|Truncal loco-regional anesthesia
89302068|NCT03995784|Experimental|Intravenous Dose|Coagulation Factor IX variant, 50 IU/kg by intravenous route
89302069|NCT03995784|Experimental|Subcutaneous Dosing|Coagulation Factor IX variant, 100 IU/kg by subcutaneous route
89302070|NCT03787654|Experimental|electroacupuncture group|Acupoints of bilateral Zhongliao (BL33), Huiyang (BL35) and Sanyinjiao (SP6) are stimulated by Huatuo Brand disposable needles and SDZ-V electronic apparatus.
89302071|NCT03787654|Sham Comparator|sham electroacupuncture group|Sham acupoints 1 cun(≈15mm) horizontally outwardly lateral to BL33 and BL35, and 0.5 cun(≈10mm) horizontally behind SP6 are stimulated superficially with a small electricity current by needles of 0.30×40mm size and SDZ-V electronic apparatus.
89302072|NCT03787654|Active Comparator|Solifenacin group|subjects will orally take Solifenacin 5-10mg per day.
89302073|NCT03744000|Placebo Comparator|Immediate stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate stenting group.
89302074|NCT03744000|Active Comparator|Deferred stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred for 3-7 days in the deferred stenting group.
89302075|NCT00086385|Active Comparator|Brief Treatment|"Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT)~Brief Counseling - The counseling intervention consisted of five 90-minute group meetings.~There was no further treatment during Weeks 12-52."
89302076|NCT00086385|Experimental|Extended NRT|"Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT.~Counseling Treatment - This is identical to the Brief Counseling described above."
89302077|NCT00086385|Experimental|Tailored/No Extended NRT|This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.
89302078|NCT00086385|Experimental|Extended Tailored Counseling + NRT|Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).
89302079|NCT03993288|Experimental|Ferrum Lek|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
89302080|NCT03993288|Active Comparator|MALTOFER|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
89302081|NCT01093989|Placebo Comparator|Immediate iron|Iron-deficient children will be randomized to receive iron concurrently with anti-malarial treatment or one month later (delayed iron group).
89302082|NCT01093989|Active Comparator|Delayed iron|
89302083|NCT01090401|Experimental|Patients with Linox smart S DX lead|
89302084|NCT05093608|Experimental|Dose Level 1 - 60 mg Selinexor with Bevacizumab and Atezolizumab|60 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.
89302085|NCT05093608|Experimental|Dose Level 2 - 80 mg Selinexor with Bevacizumab and Atezolizumab|80 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.
89302086|NCT01090557||RSV positive subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are positive for RSV by Direct Fluorescent Antibody technique and/or viral culture
89302087|NCT01090557||RSV negative subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are negative for RSV by Direct Fluorescent Antibody technique and/or viral culture (usually positive for influenza A & B, parainfluenza, human metapneumovirus or adenovirus)
89302088|NCT01090557||Control group|Children with same age range, ethnic background, and gender distribution as the study group coming for evaluation in the outpatient setting without evidence of viral infection
89302089|NCT03625492|Experimental|Reduce Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
89302090|NCT03625492|Active Comparator|Adopt Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
89302091|NCT03991494|Experimental|Pamiparib|
89302092|NCT05080036|Experimental|Unbalanced healthy subjects|Subjects undergo an external perturbation of their balance
89302093|NCT03736122|Experimental|BSG-001|Inhalation route, daily
89302094|NCT03736044|Experimental|TNF-blockers withdrawal|Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.
89302095|NCT03736044|No Intervention|DMARDs control group|Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.
89302096|NCT05062798|Experimental|Control group (standart bottle)|After the surgery, standard bottle will be used for feeding
89302097|NCT05062798|Experimental|Experimental Group (squeezable bottle)|After the surgery, squeezable bottle will be used for feeding
89302098|NCT03735810|Experimental|SAD - Cohort 1|50 mg LBS-008 or placebo
89302099|NCT03735810|Experimental|SAD - Cohort 2|100 mg LBS-008 or placebo
89302100|NCT03735810|Experimental|SAD - Cohort 3|200 mg LBS-008 or placebo
89302101|NCT03735810|Experimental|SAD - Cohort 4|400 mg LBS-008 or placebo
89302102|NCT03735810|Experimental|SAD - Cohort 5|25 mg LBS-008 or placebo
89302103|NCT03735810|Experimental|MAD - Cohort 1|10 mg LBS-008 or placebo
89302104|NCT03735810|Experimental|MAD - Cohort 2|25 mg LBS-008 or placebo
89302105|NCT03735810|Experimental|MAD - Cohort 3|5 mg LBS-008 or placebo
89302106|NCT03735810|Experimental|MAD - Cohort 4|12 mg LBS-008 or placebo
89302107|NCT03383770|Active Comparator|Tuohy|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A tuohy needle is used."
89302108|NCT03383770|Active Comparator|Facet|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A facet needle is used."
89302109|NCT00086307|Active Comparator|Pramipexole|Patients receive pramipexole and placebo. The dosage of pramipexole is 0.125 milligrams (mg) three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
89302110|NCT00086307|Active Comparator|Escitalopram|Patients receive escitalopram and placebo. The dosage of escitalopram is 10 milligrams (mg) per day.
89302111|NCT00086307|Experimental|Escitalopram and Pramipexole|Patients receive escitalopram and pramipexole. The dosage of escitalopram is 10 milligrams (mg) per day. The dosage of pramipexole is 0.125 mg three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
89302112|NCT03624972|Active Comparator|Resources Only|Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.
89302113|NCT03624972|Experimental|Resources + Video|"Patients will receive a list of web resources on sexual and menopausal health in breast cancer. In addition to the resources, patients will be asked to view an online video called Starting the Conversation and to complete an accompanying workbook. Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit."
89302114|NCT03624972|No Intervention|Clinician Arm|Clinicians were consented in order to have their clinic visits audio recorded. No outcomes data were collected from clinician participants.
89302115|NCT04050904|Experimental|ExpHeart|The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment.
89302116|NCT05031364|Experimental|Consultation-Based Training on BIACA|Community mental health clinicians will be given online one-on-one training and consultation in the BIACA (Behavioral Interventions for Anxiety in Children with Autism; e.g., Wood et al., 2020) CBT program. Clinicians will be provided with weekly 30-minute video-conference-based consultation sessions with an expert in BIACA. These consultation sessions are manual-driven and utilize a Practice-Based Coaching format, in which a trained consultant meets weekly with clinicians to provide practice-based feedback (cf. McLeod et al., 2018). Consultation meetings include agenda setting, case material review, planning for the next treatment session, and a meeting summary. Relevant online training materials (e.g., demonstration videos of CBT sessions; corresponding written session materials) developed in the context of a NIMH R34 grant available on meya.ucla.edu (1R34MH110591) will also be provided to clinicians for each upcoming therapy session.
89302117|NCT05031364|Active Comparator|Usual Care Augmented by Self-Instruction Resources for CBT for Autism|Community mental health clinicians in this arm will provide any therapy, counseling, and/or behavioral treatment procedures they deem appropriate for each participating child. Clinicians randomized to this arm will be given immediate access to CBT-for-autism self-instruction materials that are already freely available to any clinician at meya.ucla.edu (see Consultation-Based Training on BIACA arm, above), to supplement their usual clinical care, if they so choose, until they complete their Usual Care/Self-Instruction participation and are offered direct training and weekly consultation in BIACA.
89302118|NCT01086579|Experimental|Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)|IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and provisional spot bare metal stenting (Bare Metal Stent).
89302119|NCT01086579|Active Comparator|Control Arm PES|Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.
89302120|NCT03743922|Experimental|Oral calciferol group|Subjects will receive oral calciferol 20,000 iu per week during pregnancy until delivered
89302121|NCT03743922|Placebo Comparator|oral placebo group|Subjects will receive oral placebo 1 tab per week during pregnancy until delivered
89302122|NCT02780206|Experimental|obese|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one approx 2 weeks of diet, one post-diet): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
89302123|NCT01326975||EAdi 1|babies in this group will first receive CPAP through IF-CPAP for 30 minutes. After another 45 minutes, they will be switched to HFNC for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
89302124|NCT01326975||EAdi 2|babies in this group will first receive CPAP through HFNC for 30 minutes. After another 45 minutes, they will be switched to IF-CPAP for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
89302125|NCT03988842|Experimental|Alteplase & Unfractionated Heparin & Apixaban|Alteplase 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
89302126|NCT03988842|Active Comparator|Placebo & Unfractionated Heparin & Apixaban|Alteplase placebo solution 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
89302127|NCT02668822|Experimental|ENG 125 μg + E2 300 μg (MK-8342B)|Participants received up to 4 cycles of etonogestrel-17β estradiol (ENG-E2) at a daily dose of 125 μg/300 μg via vaginal ring. Each cycle consisted of 21 days of MK-8342B vaginal ring use followed by 7 ring-free days.
89302128|NCT02668822|Placebo Comparator|Placebo|Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
89302129|NCT04112589|Experimental|Level dose 1 - 40mg, 14 days|Patients will receive an induction cycle (40mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
89302130|NCT04112589|Experimental|Level dose 2 - 60mg, 14 days|Patients will receive an induction cycle (60mg Quizartinib for 14 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
89302131|NCT04112589|Experimental|Level dose -1 - 60mg 7days|Patients will receive an induction cycle (60mg Quizartinib for 7 days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
89302132|NCT04112589|Experimental|Level dose -2 - 40mg 7 days|Patients will receive an induction cycle (40mg Quizartinib for 7days) followed by 1-3 consolidation cycles (Quizartinib at day 6) [with or without allogenic stem cell transplantation]- Responders will have 12 months maintenance starting at 30mg/day Quizartinib will be increased to 60 mg/day after 15 days if appropriate.
89302133|NCT02524288|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89302134|NCT03624504|Experimental|Micra Implant Group|Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)
89302135|NCT02954952|Other|Standard of care (baseline)|Subjects will receive the Sedline sensor. The anesthesiologist will be blinded to the PSI Rev 1.X score and the raw EEG data from the Masimo device. Anesthesia management will be in accordance with standard of care protocols and procedures.
89302136|NCT02954952|Experimental|PSI Rev 1.X|The anesthesiologist will be monitoring subjects using an old version of PSI (Rev 1.X).
89302137|NCT02954952|Experimental|PSI Rev 2.X|The anesthesiologist will be monitoring subjects using a new version of PSI (Rev 2.X).
89302138|NCT03547154|Experimental|Pegylated interferon alfa-2b|Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
89302139|NCT03547154|Active Comparator|Interferon alfa-2b|Participants received interferon alfa-2b (Intron^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
89302140|NCT02275546|Experimental|Applicator→No Applicator (manual)|Treatment period 1: Participants will use applicator to insert vaginal ring. Treatment period 2: Participants will manually insert vaginal ring using fingers only.
89302141|NCT02275546|Experimental|No applicator (manual)→Applicator|Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
89302142|NCT03624192|Experimental|RECELL® Autologous Cell Harvesting Device|RECELL + Telfa™ Clear and Xeroform™ dressings
89302143|NCT03624192|Active Comparator|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
89302144|NCT02157844||COPD and OSA|Subjects with diagnosis of COPD and OSA
89302145|NCT02157844||COPD|Subjects with diagnosis of COPD
89302146|NCT02157844||OSA|Subjects with diagnosis of OSA
89302147|NCT02157844||controls|Gender, age, BMI matched controls
89302148|NCT01310660||Nulliparous|
89302149|NCT03724292|Placebo Comparator|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
89302150|NCT03724292|Experimental|VTP-43742 Dose 1|VTP-43742 administered as oral capsule(s) once daily
89302151|NCT03724292|Experimental|VTP-43742 Dose 2|VTP-43742 administered as oral capsule(s) once daily
89302152|NCT03724292|Experimental|VTP-43742 Dose 3|VTP-43742 administered as oral capsule(s) once daily
89302153|NCT03724292|Experimental|VTP-43742 Dose 4|VTP-43742 administered as oral capsule(s) once daily
89302154|NCT03724292|Experimental|VTP-43742 Dose 5|VTP-43742 administered as oral capsule(s) once daily
89302155|NCT03034954|Active Comparator|Active HD-tDCS|"Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session."
89302156|NCT03034954|Sham Comparator|Sham HD-tDCS|Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.
89302157|NCT03546842|Experimental|9vHPV vaccine|Participants will receive a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6
89302158|NCT03724214|No Intervention|Pre-intervention|Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
89302159|NCT03724214|Active Comparator|Post-intervention|Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.
89302160|NCT01086657|Experimental|Group 1|Inactivated H5N1 Vaccine at Enrollment and inactivated H5N1 Vaccine at Week 24
89302161|NCT01086657|Experimental|Group 2|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 4
89302162|NCT01086657|Experimental|Group 3|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 8
89302163|NCT01086657|Experimental|Group 4|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 12
89302164|NCT01086657|Experimental|Group 5|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 16
89302165|NCT01086657|Experimental|Group 6|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 24
89302166|NCT01778764||retrospective cohort|retrospective follow-up of patients treated since 2006
89302167|NCT01778764||prospective cohort|patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter
89302168|NCT01090713|Active Comparator|Lisdexamfetamine|drug
89302169|NCT01090713|Placebo Comparator|Placebo|Placebo comparator
89302170|NCT03732716||Elderly with sarcopenia|50 patients aged 75 or older with sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
89302171|NCT03732716||Elderly without sarcopenia|50 patients aged 75 or older without sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
89302172|NCT01086735|Experimental|donor lymphocyte infusion|Donor T-cell transduction
89302173|NCT01086813|Experimental|1|
89302174|NCT03640052|Placebo Comparator|Placebo|Placebo capsule 1 time before bedtime
89302175|NCT03640052|Active Comparator|LTM1201L|LTM1201L capsule 1 time before bedtime
89302176|NCT03640052|Active Comparator|LTM1201LN|LTM1201LN capsule 1 time before bedtime
89302177|NCT03640052|Active Comparator|LTM1201LB|LTM1201LB capsule 1 time before bedtime
89302178|NCT03640052|Active Comparator|LTM1201LD|LTM1201LD capsule 1 time before bedtime
89302179|NCT01094145|Sham Comparator|Placebo|Stimulator setting is OFF
89302180|NCT01094145|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
89302181|NCT01096797|Experimental|Children undergoing adenotonsillectomy|Children between 2-6 years old undergoing elective adenoidectomy with or without tonsillectomy from the ENT Service of the San Gerardo Hospital.
89302182|NCT00068601|Active Comparator|Standard Chemotherapy|Patients receive cyclophosphamide-containing chemotherapy alone.
89302183|NCT00068601|Experimental|Chemotherapy Plus Goserelin|Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
89302184|NCT03638258|Experimental|Roflumilast Cream 0.3%|Roflumilast cream 0.3% topically applied QD for 12 weeks.
89302185|NCT03638258|Experimental|Roflumilast Cream 0.15%|Roflumilast cream 0.15% topically applied QD for 12 weeks.
89302186|NCT03638258|Placebo Comparator|Vehicle Cream|Vehicle cream matched to roflumilast cream (containing only excipients of active cream) applied QD for 12 weeks.
89302187|NCT01670656|Experimental|NOMAC-E2 700/300 mcg|NOMAC-E2 700/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89302188|NCT01670656|Experimental|NOMAC-E2 900/300 mcg|NOMAC-E2 900/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89302189|NCT01670656|Experimental|ENG-E2 100/300 mcg|ENG-E2 100/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89302190|NCT01670656|Experimental|ENG-E2 125/300 mcg|ENG-E2 125/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89302191|NCT01670656|Placebo Comparator|Placebo|Placebo will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
89302192|NCT00068445|Experimental|Arm I - lamotrigine|"Patients receive oral lamotrigine once daily for 2 weeks and then twice daily for 8 weeks. Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
89302193|NCT00068445|Other|Arm II - placebo|"Patients receive oral placebo once daily for 2 weeks and then twice daily for 8 weeks.~Treatment continues for 10 weeks in the absence of unacceptable toxicity.~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.~Patients are followed at 3-7 days."
89302194|NCT03653208|Experimental|Group 1 (hzVSF-v13 10mg)|Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.
89302195|NCT03653208|Experimental|Group 2 (hzVSF-v13 20mg)|Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.
89302196|NCT03653208|Experimental|Group 3 (hzVSF-v13 50mg)|Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.
89302197|NCT03653208|Experimental|Group 4 (hzVSF-v13 100mg)|Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.
89302198|NCT03653208|Experimental|Group 5 (hzVSF-v13 200mg)|Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.
89302199|NCT03653208|Experimental|Group 6 (hzVSF-v13 400mg)|Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.
89302200|NCT03653208|Experimental|Group 7 (hzVSF-v13 800mg)|Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.
89302201|NCT03653208|Experimental|Group 8 (hzVSF-v13 1200mg)|Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.
89302202|NCT03653208|Placebo Comparator|Placebo|Placebo group received a single placebo on Day 1.
89302203|NCT05053360|Experimental|Healing Touch|Subjects in this arm get a HT session post cesarean
89302204|NCT05053360|Active Comparator|Control|Subjects in this arm get a control activity of equal duration
89302205|NCT03957993|Experimental|Occupational Therapy via Telehealth|Participants in the telehealth-based model will undergo occupational therapy treatment via a telehealth-based video chat platform for the entire episode of care (generally 10-12 weeks in duration). The patient will use the video chat client to connect to his/her occupational therapist, and the therapist will conduct the session over this virtual connection.
89302206|NCT03957993|Active Comparator|Standard of Care Occupational Therapy|Participants in the standard of care model will undergo occupational therapy treatment via traditional in- person encounters in an outpatient clinic setting for the entire episode of care (generally 10-12 weeks). These children will receive routine occupational treatment via in-person sessions with an occupational therapist conducted in an outpatient clinic setting.
89302207|NCT03735342|Experimental|Audio Recording|Participants receive a verbal discharge discussion with a provider, written discharge instructions and a re-playable audio recording of the discharge discussion with the discharging provider.
89302208|NCT03735342|No Intervention|Usual care|Participants receive a verbal discharge discussion with a provider and written discharge instructions.
89302209|NCT03953469|No Intervention|Placebo Group|"(a) Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating, or caffeine consumption.~b) will be given 1/4 tsp of blackstrap molasses placebo. Subjects may not consume caffeine or eat food during this time.~(c) blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
89302210|NCT03953469|Active Comparator|Group II|"Baseline blood pressure readings and one heart rate reading taken after at least 5 minutes of rest time without talking, eating food, or caffeine consumption.~15 minutes after examination - will be given 1/8 tsp (900mg) of Passiflora incarnata solid extract by Wise Woman Herbals mixed with 1/8 tsp of blackstrap molasses to mask the taste.~blood pressure readings and one heart rate will be taken 15 minutes after the baseline reading."
89302211|NCT05665920|Active Comparator|Standard Whole breast Radiotherapy|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
89302212|NCT05665920|Experimental|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated radiation: Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
89302213|NCT03545984|Experimental|simulation-based training|The simulation-based training during the first week of rotation involves step-by-step instructions on insertion of the CSF drainage catheter including aseptic technique, position of patient (lateral vs. sitting), site of insertion. The simulation training is done on a mannequin to simulate actual conditions. We plan to use a simulation model, which is basically a torso with the ability to palpate the back and spinous processes and use the epidural needle with loss of resistance technique with haptic feedback. The trainees would be able to actually perform the procedure on the manikin.
89302214|NCT03545984|Active Comparator|problem based learning|The residents allocated to the non-simulation group (problem based learning) receives standard educational teaching in the form of a problem based learning discussion during the first week of rotation.
89302215|NCT03033784|Experimental|Autism Spectrum Disorder (ASD)|Male participants diagnosed with ASD will receive 12 puffs (6 in each nostril) of intranasal oxytocin (syntocinon) and placebo (assigned randomly) during 4 study visits.
89302216|NCT03033784|Placebo Comparator|Healthy Control|Age matched healthy controls will receive placebo intranasal spray (12 puffs, 6 per nostril) during one study visit.
89302217|NCT00038649|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
89302218|NCT03544268|Experimental|Acoustic Angiography|All clinical patients will be included in the experimental group.
89302219|NCT03544268|Experimental|Image Optimization|In addition to clinical patients, 30 participants will be recruited to aid in optimizing the imaging parameters.
89302220|NCT04893070||COVID+|Questionnaires on COVID-19 symptomatology and quality of life
89302221|NCT04893070||COVID-|Questionnaires on quality of life
89302222|NCT01094379|Active Comparator|Standard lap chole|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
89302223|NCT01094379|Active Comparator|Single incision lap chole|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
89302224|NCT02941900||Non-melanoma skin cancers (NMSCs)|
89302225|NCT02926690|Experimental|OTS167PO|
89302226|NCT03723902|Experimental|Strength training + protein supplement|Heavy-load strength training, Protein supplementation
89302227|NCT03723902|No Intervention|Control|No intervention
89302228|NCT03652818|Experimental|Group A|"Pre-op Placebo 1;~Post-op Placebo 1;~Post-op Placebo 2"
89302229|NCT03652818|Experimental|Group B|"Pre-op Placebo 1;~Post-op Placebo 2;~Post-op acetaminophen."
89302230|NCT03652818|Experimental|Group C|"Pre-op Placebo 1;~Post-op pregabalin;~Post-op Placebo 2."
89302231|NCT03652818|Experimental|Group D|"Pre-op Placebo 1;~Post-op pregabalin~Post-op acetaminophen."
89302232|NCT03652818|Experimental|Group E|"Pre-op pregabalin;~Post-op Placebo 1;~Post-op acetaminophen."
89302233|NCT03723824|Experimental|Zepatier therapy|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
89302234|NCT03723746|Experimental|Cohort 1: Dose 1 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (single day [SD] Dose 1) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
89302235|NCT03723746|Experimental|Cohort 2: Dose 2 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (Dose 2) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
89302236|NCT03723746|Experimental|Cohort 3: Dose 1 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Multiple Day [MD] Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days without antibiotic pretreatment after an overnight fast in Part 2.
89302237|NCT03723746|Experimental|Cohort 4:Antibiotic + Dose 1 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
89302238|NCT03723746|Experimental|Cohort 5: Dose 2 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily without antibiotic pretreatment for 14 days after an overnight fast in Part 2.
89302239|NCT03723746|Experimental|Cohort 6:Antibiotic + Dose 2 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
89302240|NCT03723746|Experimental|Cohort 7 (Optional): Laxative + Dose 2 or Placebo (Part 3)|Participants may receive pretreatment with an oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 7 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
89302241|NCT03723746|Experimental|Cohort 8 (Optional):Antibiotic+Laxative+Dose 2/Placebo(Part 3)|Participants may receive pretreatment with an oral antibiotic and oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 8 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
89302242|NCT03723746|Experimental|Cohort 9 (Optional): Dose 2 or Placebo (Part 3) + Biopsy|Participants may receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. After final dosing collection of sigmoid biopsies will be performed. Cohort 9 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
89302243|NCT05665010||premature ovarian insufficiency|Patients with premature ovarian insufficiency (female age <40 years, menopause or menstrual rarity for 4 months, basal FSH > 25 IU / L for two consecutive intervals of more than 4 weeks)
89302244|NCT05665010||declined ovarian function|Patients with diminished ovarian reserve(women before 40 years old; the number of antral follicles in both ovaries is less than 6, AMH < 1.1ng/ml, and basal FSH > 10 IU / L, which meets one of the three requirements)；Female with menopause between the age of 40 and 45.
89302245|NCT03619902|Experimental|Imsidolimab|Participants received imsidolimab 750 mg intravenously (IV) on Day 1 followed by administration of 3 doses of subcutaneous (SC) imsidolimab 100 mg on Days 29, 57, and 85.
89302246|NCT00620464|Active Comparator|Radiopaque Implanon (ro imp)|The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
89302247|NCT00620464|Active Comparator|Implanon (imp)|"Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year."
89302248|NCT03726866|Experimental|Sequence 1|Sequence 1
89302249|NCT03726866|Experimental|Sequence 2|Sequence 2
89302250|NCT03726866|Experimental|Sequence 3|Sequence 3
89302251|NCT03726866|Experimental|Sequence 4|Sequence 4
89302252|NCT03726866|Experimental|Sequence 5|Sequence 5
89302253|NCT03726866|Experimental|Sequence 6|Sequence 6
89302254|NCT03652662|Experimental|RESP-FIT Intervention|"Intervention:~IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS)"
89302255|NCT03652662|Active Comparator|RESP-FIT Comparator|"Active Comparator:~Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)"
89302256|NCT05666024||Parturients|Maternity about to give birth
89302257|NCT03732222|Experimental|Stretching the diaphragm muscle|The interventor places his hands on the last costal cartilages and the subject makes an inspiration and keeps his hands resisted in the expiration.
89302258|NCT03732222|Experimental|Impulse technique in rotation of cervical level 3 and 4|The thumbs position the head in a double chin and then place it with neutral flexion-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
89302259|NCT03732222|Experimental|Combined technique of diaphragm muscle stretch and cervical ro|combine both previous techniques.
89302260|NCT00413764|Experimental|1|tibolone
89302261|NCT00413764|Active Comparator|2|transdermal continuous combined E2-NETA (estradiol-norethisterone)
89302262|NCT03726788|Experimental|Botulinum Toxin Type A 100U|one intra-articular injection in the painful knee 30 days after the inclusion visit
89302263|NCT03726788|Experimental|Botulinum Toxin Type A 200U|one intra-articular injection in the painful knee 30 days after the inclusion visit
89302264|NCT03726788|Active Comparator|Triamcinolone Hexacetonide 20 MG/ML|one intra-articular injection in the painful knee 30 days after the inclusion visit
89302265|NCT03735264|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1)
89302266|NCT04789174|Active Comparator|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
89302267|NCT04789174|Placebo Comparator|Placebo|
89302268|NCT03743688||Influenza Vaccine Recipients (ccIIV-4)|All participants will receive one dose of FDA-approved inactivated influenza vaccine (Flucelvax Quadrivalent) via intramuscular injection (0.5 mL) as part of their standard of care.
89302269|NCT03726710|Experimental|Blood Pressure measurement and pharmacy|Blood Pressure measurement performed by barber and Blood pressure measurement and management visits with study pharmacist in person and through Telemedicine.
89302270|NCT03639506|Experimental|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
89302271|NCT03639506|Active Comparator|ICSI|only has intracytoplasmic sperm injection (ICSI)
89302272|NCT04949074||RNA extracted from Positive NSP samples|RNA extracted from NSP samples, found positive for the presence of SARS-CoV-2
89302273|NCT04949074||RNA extracted from Positive saliva samples|RNA extracted from saliva samples found positive for the presence of SARS-CoV-2
89302274|NCT04949074||RNA extracted from negative NSP samples|RNA extracted from NSP samples, found negative for the presence of SARS-CoV-2
89302275|NCT04949074||RNA extracted from negative saliva samples|RNA extracted from saliva samples found negative for the presence of SARS-CoV-2
89302276|NCT03560258|Experimental|Arm A: p24CE/full-length Gag DNA|Participants received p24CE1/2 pDNA vaccine at Weeks 0 and 4, followed by p24CE1/2 pDNA admixed with full-length p55^gag pDNA vaccine at Weeks 12 and 24.
89302277|NCT03560258|Experimental|Arm B: Full-length Gag DNA|Participants received full-length p55^gag pDNA vaccine at Weeks 0, 4, 12, and 24.
89302278|NCT03560258|Placebo Comparator|Arm C: Placebo|Participants received placebo at Weeks 0, 4, 12, and 24.
89302279|NCT02768662|Experimental|OTO-104|12 mg dexamethasone
89302280|NCT02759380|Experimental|Phytoestrogen-rich foods|"Introduced to the study by a dietitian.~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~Called one time during the study and perform a 24-hour recall.~The intervention continues until the day before the surgery (at least 6 weeks).~The patients in the experimental group will be given a package containing food with a high amount of phytoestrogens."
89302281|NCT02759380|No Intervention|Control group|"Introduced to the study by a dietitian.~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~Called one time during the study and perform a 24-hour recall.~The intervention continues until the day before the surgery (at least 6 weeks)."
89302282|NCT03539432|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily
89302283|NCT03539432|Placebo Comparator|Placebo|Microcrystalline cellulose powder packaged in capsules identical to the experimental condition
89302284|NCT04779970|Experimental|STOP: Caucasian patients|Cessation of treatment
89302285|NCT04779970|Experimental|STOP: non-Caucasian patients|Cessation of treatment
89302286|NCT04779970|No Intervention|Control group|Standard of care follow-up
89302287|NCT03723434|Active Comparator|Healthy Participants|Healthy participants without disorders or medications influencing brain function will be scanned with MRI and undergo single-pulse TMS and PAS during several visits, each with a different asynchrony, while EEG and MEPs are recorded.
89302288|NCT03723434|Experimental|Patients|Participants with stroke, traumatic brain injury (TBI), or multiple sclerosis (MS) will be scanned with MRI and undergo single-pulse TMS and paired associative stimulation during several visits while EEG is recorded.
89302289|NCT03615924|Experimental|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~>48 kg: Ticagrelor 45 mg, twice a day."
89302290|NCT03615924|Placebo Comparator|Placebo|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
89302291|NCT03625180||Treatment|NAMIC technique
89302292|NCT03535844|Experimental|Wolfberry with healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
89302293|NCT03535844|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
89302294|NCT05573932|Experimental|Leaderboard group|The group that has access to weekly leaderboards and on-demand videos.
89302295|NCT05573932|Active Comparator|Take-home packet group|The group that has access to paper take-home packets.
89302296|NCT03533114|Experimental|JZP-258|JZP-258 at the stable dose and regimen for 2 weeks.
89302297|NCT03533114|Placebo Comparator|Placebo|Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
89302298|NCT03033394||Beta-lactam antibiotic|Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.
89302299|NCT03723356||MS Patients|Definite diagnosis of RRMS
89302300|NCT03723356||Healthy Controls|gender aged match healthy
89302301|NCT03639428||6 - 23 months|8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
89302302|NCT03639428||2-11 years|17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
89302303|NCT03639428||12-17 years|12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
89302304|NCT04575688|Active Comparator|Periarticular Injection|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a periarticular injection by the surgeon using 10 milliliters of Exparel mixed with 10 milliliters of bupivicaine 0.5 percent at the end of the procedure.
89302305|NCT04575688|Active Comparator|Popliteal Block|Subjects undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair will recieve a popliteal block by the anesthesiologist using 30 milliliters of bupivicaine 0.5 percent in the pre-operative area, prior to surgery, using an ultrasound machine for guidance.
89302306|NCT04792060|Experimental|adult patients with distal ulna fractures|adult patients with distal ulna fractures
89302307|NCT03981822|Active Comparator|Part A: VP-102 2 hour-Active|For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments.
89302308|NCT03981822|Active Comparator|Part A: VP-102 6-hour Active|For part A, VP-102 will be applied for 6 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 6 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
89302309|NCT03981822|Active Comparator|Part A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
89302310|NCT03981822|Placebo Comparator|Part A: Placebo|For part A, VP-102 will be applied for 2-,6- or 24- hours and removed. Placebo is applied every 21 days for 4 treatments.
89302311|NCT03981822|Active Comparator|Part B & A: VP-102 6 hour-Active|Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
89302312|NCT03981822|Placebo Comparator|Part B & A: 6-hour-Placebo|Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
89302313|NCT03981822|Active Comparator|Part B & A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
89302314|NCT03981822|Placebo Comparator|Part B & A: 24-hour-Placebo|Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
89302315|NCT05506930|Active Comparator|Intrathecal Morphine|Intrathecal Morphine: spinal (neuraxial) dose of preservative free morphine (duramorph), usually about 4-5mcg/kg
89302316|NCT05506930|Active Comparator|quadratus lumborum block|Quadratus Lumborum Block: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per kg per side (total dose approximately 1mL/kg).
89302317|NCT03625414||Healthy individuals|Gingival biopsies of healthy individuals who had no systemic or oral disease or condition.
89302318|NCT03625414||Unaffected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were not affected by periodontal destruction.
89302319|NCT03625414||Affected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were affected by periodontal destruction.
89302320|NCT03625414||Unaffected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were not affected by the periodontal destruction.
89302321|NCT03625414||Affected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were affected by the periodontal destruction.
89302322|NCT04359706||Covid-19 group|Critically ill patients with SARS-CoV-2 infection
89302323|NCT04359706||control group|Historical critically ill patients with no SARS-CoV-2 infection
89302324|NCT03625336||Prostate Calcifications|Men with prostate calcifications
89302325|NCT04329754|Other|iPure|"A new single-piece hydrophobic acrylic IOL (IPure IOL). The study IOL is a one-piece aspheric acrylic hydrophobic glistening-free lens, with a 4.9% water content, a 360 square posterior edge design, and a 5 haptic angulation, providing UV and blue-light filtration.~Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
89302326|NCT04329754|Other|ZCB00|"A standard IOL (ZCB00).The control IOL, is a one-piece hydrophobic acrylic IOL with a biconvex aspheric optic and 360 continuous square posterior optic edge with a UV filter and an offset, stepped haptic design.~Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation."
89302327|NCT04322656|Active Comparator|Effect of Lipiflow treatment on biometrical outcomes|One eye of each patient will be treated with Lipiflow
89302328|NCT04322656|No Intervention|Control eye|The contralateral eye will serve as control eye
89302329|NCT04891978|Experimental|AIRQ, Asthma Checklist, and PRECISION Program|All participants in the trial will be given the behavioral interventions which include the AIRQ tool, the Asthma Checklist tool, and the PRECISION program educational resources.
89302330|NCT03735186|No Intervention|Control|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
89302331|NCT03735186|Experimental|Exercise|Participants will complete 60 min of treadmill exercise on day 1 (14:30-15:30). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
89302332|NCT03650556|Experimental|Ablation|Enrolled subjects who had the investigational catheter inserted into their vasculature for pulmonary vein isolation by radiofrequency ablation treatment TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE).
89302333|NCT03735108||pregnancy loss group|the times of pregnancy loss more than or equal to twice
89302334|NCT03735108||normal control group|no history of pregnancy loss
89302335|NCT03531632|Experimental|MGD007 + MGA012|MGD007 is a gpA33 x CD3 bi-specific DART antibody; MGA012 is an anti-PD-1 monoclonal antibody.
89302336|NCT05666466||case group|age between 12 to 50 disproportionate SRS to PTA level presence of OAE presence of CM Normal MRI and CT
89302337|NCT05666466||control group|age and sex matched to study group Normal hearing sensitivity and excellent speech discrimination no CAPD
89302338|NCT03732066|Experimental|Intervention Group|The intervention group will receive usual text messages, personalized reminders and interactive responses.
89302339|NCT03732066|Other|Control Group|The control group will receive usual text messages only.
89302340|NCT03722186|Experimental|SHR-1603|Multiple escalating doses of SHR-1603
89302341|NCT03735030|Experimental|human hCG|
89302342|NCT03735030|Active Comparator|recombinant hCG|
89302343|NCT01310738|Active Comparator|Meglumine antimoniate|Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
89302344|NCT01310738|Experimental|Liposomal Amphotericin B|Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
89302345|NCT01310738|Experimental|Amphotericin B|Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
89302346|NCT01310738|Experimental|Combination therapy|Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.
89302347|NCT03721978|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
89302348|NCT03721978|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
89302349|NCT03723122|Experimental|DCRI program|Patient-caregiver dyads will immediately attend the Dyadic communication reinforcement intervention. For both groups, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 2 weeks post-intervention. Pre-post assessments consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
89523341|NCT03381911|Experimental|ECA Consent|"In this arm an Embodied Conversational Agent (ECA) which is a computer generated character reads the consent form aloud to the subject, and also describes each section using a pre-loaded script. In addition, the character performs teach-back, where she asks the subject a question about the section that was just described, and then repeats the section if the question is answered incorrectly."
89302350|NCT03723122|No Intervention|Waiting List|Patient-caregiver dyads are in a waiting condition for 6 weeks. They will attend the Intervention after the second assessment time if they want to. For both group, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 6 weeks after first assessment time. First and second assessment consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
89302351|NCT03723044|Experimental|healthy volunteers|
89302352|NCT03979638|Experimental|BLU-5937 oral tablet BID|Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID
89302353|NCT03979638|Placebo Comparator|Placebo oral tablet BID|Randomized crossover design of matching placebo tablets to be administered orally BID
89302354|NCT03704506|Experimental|treatment group 1|Reyanning mixture+amoxil capsule simulator
89302355|NCT03704506|Experimental|treatment group 2|Reyanning mixture +amoxil capsule
89302356|NCT03704506|Active Comparator|control group|Reyanning mixture simulator +amoxil capsule
89302357|NCT03655054|Experimental|eCoin Tibial Nerve Stimulation|
89302358|NCT03615144|Active Comparator|Melphalan/Thiotepa/Clofarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
89302359|NCT03615144|Active Comparator|Melphalan/Thiotepa/ Fludarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
89302360|NCT03704428|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 dose 1
89302361|NCT03704428|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 dose 2
89302362|NCT03704428|Experimental|Cohort 3|Multiple subcutaneous injections of SHR-1314 dose 3
89302363|NCT03704428|Experimental|Cohort 4|Multiple subcutaneous injections of SHR-1314 dose 4
89302364|NCT03704428|Experimental|Cohort 5|Multiple subcutaneous injections of SHR-1314 dose 5
89302365|NCT03682302|Experimental|Group 1: 12 to less than 17 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
89302366|NCT03682302|Active Comparator|Group 1: 12 to less than 17 years, undergoing spine surgery, bupivacine|Single dose of bupivacaine hydrochloride (HCl) 2 mg/kg (not to exceed a maximum total dose of 175 mg) via local infiltration at the end of spine surgery.
89302367|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
89302368|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing cardiac surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of cardiac surgery.
89302369|NCT03734874|Active Comparator|hesperidin|
89302370|NCT03734874|Placebo Comparator|control|
89302371|NCT03522506|Experimental|TAK-925 Low Dose + Placebo + TAK-925 High Dose + Modafinil|TAK-925 low dose milligram (mg), intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
89302372|NCT03522506|Experimental|TAK-925 High Dose + TAK-925 Low Dose + Modafinil + Placebo|TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
89302373|NCT03522506|Experimental|Modafinil + TAK-925 High Dose + Placebo + TAK-925 Low Dose|Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
89302374|NCT03522506|Experimental|Placebo + Modafinil + TAK-925 Low Dose + TAK-925 High Dose|Placebo, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
89302375|NCT03320434|Experimental|PRT-2761 0.5%|
89302376|NCT03320434|Experimental|PRT-2761 1%|
89302377|NCT03320434|Active Comparator|Patanol|
89302378|NCT03320434|Active Comparator|Pred-forte|
89302379|NCT03320434|Placebo Comparator|PRT-2761 0%|
89302380|NCT03317080||patients with lung cancer|patients with stages I-III lung cancer eligible for surgery
89302381|NCT03722888|Experimental|adolescents who have previously smoked|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, behaviors around smoking, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
89302382|NCT05232214||short eyes|Axial length under 22.5 mm
89302383|NCT05232214||long eyes|Axial length under 25.5 mm
89302384|NCT02892734|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes Q2W and ipilimumab IV over 90 minutes Q6W in the absence of disease progression or unacceptable toxicity.
89302385|NCT05231590|Other|Children Aged 5 to <12 Years|
89302386|NCT05231590|Other|Children Aged 12 to <18 Years|
89302387|NCT05231590|Other|Adults Aged 18 to 40 Years|
89302388|NCT05198752|Experimental|Neoantigen mRNA Personalised Cancer|This study is a 3+3 dose escalation design. Participants will receive a total of 6 cycles of SW1115C3 every 21 days.
89302389|NCT00055497|Placebo Comparator|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
89302390|NCT00055497|Experimental|Double-blind adalimumab 40 mg every other week (eow)|Double-blind adalimumab 40 mg eow by subcutaneous injection
89302391|NCT00055497|Experimental|Double-blind adalimumab 40 mg every week (ew)|Double-blind adalimumab 40 mg every week by subcutaneous injection
89302392|NCT00055497|Experimental|Open-label adalimumab 40 mg|Open-label adalimumab 40 mg eow or ew by subcutaneous injection
89302393|NCT03615066|Experimental|Selgantolimod 3 mg + TAF|Participants with Hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
89302394|NCT03615066|Experimental|Selgantolimod 1.5 mg + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
89302395|NCT03615066|Placebo Comparator|Placebo + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
89302396|NCT03726398|Experimental|Opsumit|Opsumit 10 mg tablet by mouth once daily
89302397|NCT04050592|Other|Group A, Abrupt Discontinuation|Women in group A will discontinue HT (estradiol, 2 mg daily) abruptly after study week 9 and will continue with placebo for study weeks 10-20.
89302398|NCT04050592|Other|Group B, Tapered Discontinuation|"Women in group B will discontinue HT (estradiol, 2 mg daily) gradually during study weeks 7-9, as follows:~weeks 7-9: 1 mg estradiol daily for 10 days and then 1 mg estradiol every other day for 11 days.~weeks 10-20: placebo"
89302399|NCT04050592|Active Comparator|Group C, Control Group|Women in Group C, the control group, will continue with HT (estradiol, 2 mg daily) throughout the whole study period of 20 weeks.
89302400|NCT03726242|Active Comparator|Levcromakalim|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of 150 ug/ml levcromakalim after baseline time 0."
89302401|NCT03726242|Placebo Comparator|Saline|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of saline after baseline time 0."
89302402|NCT04050748|Placebo Comparator|Early Rehabiliation|6 weeks of non-weight bearing in addition to basic stretching exercises.
89302403|NCT04050748|Active Comparator|Accelerated Rehabilitation|Patients will be non-weight bearing for 2 weeks. After 2 weeks patients were transitioned to a boot with two heel wedges and were weight bearing as tolerated. At 4 weeks, patients were transitioned to one wedge, and at 6 weeks patients were weight bearing as tolerated in a flat shoe. Each heel wedge was ¾ inch tall. After 6 weeks, patient's in both groups underwent identical rehab regimens per protocol
89302404|NCT03726008|Experimental|Experimental group|The experimental group will receive the perinatal health promotion program and regular prenatal care
89302405|NCT03726008|No Intervention|Control group|The control group will receive the regular perinatal care
89302406|NCT01090869|Active Comparator|Physical training, unchanged diet|Daily endurance training equivalent to 600 kcal/day and unchanged habitual diet
89302407|NCT01090869|Active Comparator|Physical training, increased diet|Daily endurance training equivalent to 600 kcal/day, and increased diet by 600 kcal/day.
89302408|NCT01090869|Active Comparator|Diet, unchanged physical activity|Energy-reduced diet by 600 kcal/day, and unchanged sedentary lifestyle
89302409|NCT01090869|No Intervention|Control|Unchanged sedentary lifestyle and diet
89302410|NCT03704272|No Intervention|Control|Families in the control group will receive treatment as usual, which includes reporting to child welfare agencies when appropriate.
89302411|NCT03704272|Experimental|Treatment|SunBrite
89302412|NCT03722732|Active Comparator|Open pancreaticoduedenectomy|will include all the patients who will undergo open pancreaticoduodenectomy
89302413|NCT03722732|Active Comparator|Laparoscopic pancreaticoduodenectomy|will include all the patients undergoing laparoscopic pancreaticoduodenectomy
89302414|NCT04099095|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed
89302415|NCT04099095|Active Comparator|Delayed Appointment|Wait-list control group who receive Social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed
89302416|NCT03731988|Experimental|5.5% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 5.5%, 350 µm ablation depth, level 1 coagulation and a single pulse
89302417|NCT03731988|Experimental|11% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 11%, 350 µm ablation depth, level 1 coagulation and a single pulse
89302418|NCT03731988|Experimental|22% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 22%, 350 µm ablation depth, level 1 coagulation and a single pulse
89302419|NCT01094457|Active Comparator|standard group|patients in this group received standard dual antiplatelet therapy, i.e. aspirin 300mg/d and clopidogrel 75mg/d
89302420|NCT01094457|Experimental|intensive group|patients in this group received intensive antiplatelet therapy and the regimen can be adjusted according to results of platelet aggregation function test by LTA
89302421|NCT03734796||suspected NSTEMI|Patients aged 18-75 years old and highly suspected NSTEMI without Left bundle branch block (LBBB) will be included. Patients will be excluded if who is STEMI, underwent surgical operation within four weeks, medium and several kidney dysfunction (Ccr<30ml/min), anemia, acute myocarditis, chronic cardiac dysfunction (NYHA III-IV), serious cardiac arrhythmias, with history of intravenous drug, oncosis and recent thrombolysis treatment, or pregnant.
89302422|NCT03527966|Active Comparator|Intervention group - 5cc Vivigen and local autograft|
89302423|NCT03527966|Active Comparator|Control group - small kit rhBMP-2 with local autograft|
89302424|NCT03701854||Heart failure patients with pacemakers|Functional (6-Minute Walking test (6-MWT)) and maximal exercise capacity (Incremental Shuttle Walking test (ISWT)), respiratory (MIP, MEP; Mouth pressure device) and peripheral muscle strength (Dynamometer), pulmonary function (Spirometry) dyspnea (Modified Medical Research Council Dyspnea scale) (MMRC)), and fatigue (Fatigue Severity scale (FSS)) were evaluated in 50 patients.
89302425|NCT03701854||Healthy controls|Healthy individuals (n=40) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
89302426|NCT01096953|Active Comparator|Telepsychiatry|Psychiatry provided over telehealth network
89302427|NCT01096953|Active Comparator|Face-to-face care|Psychiatry provided in person
89302428|NCT03734718|Active Comparator|Glucose-Dependent Insulinotropic Polypeptide|6-day continuous infusion of Glucose-Dependent Insulinotropic Polypeptide
89302429|NCT03734718|Placebo Comparator|Placebo|Saline
89302430|NCT03957837||Steep Trendelenburg|Patients undergoing elective laparoscopic prostatectomy in steep Trendelenburg position (25 degrees head down position)
89302431|NCT03957837||Healthy controls|Healthy awake volunteers undergoing steep Trendelenburg position (25 degrees head down position)
89302432|NCT03701698|Experimental|combination therapy|"There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.~Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.~Ruxolitinib oral tablet, 5~10mg bid orally, for at least 28 days."
89302433|NCT03734562|Experimental|Ablation|Substrate-based radiofrequency catheter ablation
89302434|NCT03734562|Active Comparator|Antiarrhythmic drug therapy|Antiarrhythmic drug therapy; amiodarone or sotalol
89302435|NCT01090947||Patients referred to CAG.|Sequential design with ProtoCAD and CAG
89302436|NCT03012490|Active Comparator|Standard remote monitoring|Remote monitoring of CRT-P and CRT-D is activated. The physician will only receive the notifications related to technical events and ventricular arrhythmias. Therapy will be added or changed in response to these notifications and/or the symptoms and signs observed during ambulatory visits.
89302437|NCT03012490|Experimental|Comprehensive remote monitoring|Remote monitoring of CRT-P and CRT-D is activated, as well as remote assessment of symptoms and signs. In addition to notifications related to technical events and ventricular arrhythmias, the physician will receive notifications related to heart failure parameters, atrial arrhythmias, and patient's symptoms and signs. Therapy will be added or changed in response to these notifications, and/or to the symptoms and signs observed during ambulatory visits.
89302438|NCT03953391|Experimental|Tea-water|Tea before water
89302439|NCT03953391|Experimental|Water-tea|Water before tea
89302440|NCT03808545|Active Comparator|BIPAMS|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS group will continue receiving the established BIPAMS intervention for the remainder of the trial.
89302441|NCT03808545|Experimental|BIPAMS + Diet|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS+Diet arm will begin receiving dietary materials in week 9.
89302442|NCT03721874|Active Comparator|Dapagliflozin 10 mg|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 14 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 14 days."
89302443|NCT03721874|Placebo Comparator|Placebo matching to dapagliflozin 10 mg|"Patients will receive matching placebo in tablet for a maximum of 14 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 14 days"
89302444|NCT01310816|Active Comparator|IPI-926|IPI-926
88806297|NCT04346771|Experimental|Maintaining Positive Working memory|Maintaining positive working memory training is based on visual positive works n-back task.In this training, positive words are presented on the pictures of happy face.According to the rules, subjects are required to identify whether the word present currently is as the same type as the word presented n before then click the keys correspondingly.Each training session contains 15 blocks which are consisted with 20+n trails.
89302445|NCT01310816|Placebo Comparator|Sugar Pill|Placebo Arm, sugar pill
89302446|NCT03807843|Experimental|V184|Participants will receive 2 vaccinations with V184 administered via intramuscular (IM) injection at 5 × 10^5 Tissue Culture Infectious Dose (TCID50) per dose on Days 0 and 28.
89302447|NCT03807843|Placebo Comparator|Placebo|Participants will receive 2 injections of sterile physiological saline administered via IM injection on Days 0 and 28.
89302448|NCT03519932|Experimental|comfilcon A toric lens|Subjects who wear comfilcon A toric lens either as first or second pair during this cross-over study.
89302449|NCT03519932|Active Comparator|samfilcon A toric lens|Subjects who wear samfilcon A toric lens either as first or second pair during this cross-over study.
89302450|NCT01094535|Experimental|Secretin|One-arm (open label): Synthetic Human Secretin. Patients will undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations.
89302451|NCT01097031||Continuous Infusion|
89302452|NCT01097031||Intermittent Infusion|
89302453|NCT01097031||Infusion Continuous|
89302454|NCT03806127|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 12 weeks.
89302455|NCT03806127|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 12 weeks.
89302456|NCT02770300|No Intervention|Conventional therapy|"The control group of patients will perform a conventional therapy without the use of the exoskeleton. The conventional therapy will consist in a traditional treatment of occupational therapy or physiotherapy without the use of the robotic device. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals (i.e., 45 minutes per session, about 100, 150, 200 and 250 movements respectively for the first, second, third and fourth week). The level of difficulty of the exercises will be increased by the physiotherapist according to the degree of impairment of the patients.~The muscle and cerebral activity during the execution of the conventional therapy could be acquired."
89302457|NCT02770300|Experimental|Traditional robotic rehabilitation with ALEx RS|The rehabilitative task will be constituted of 3D reaching movements covering a sphere of fourteen centimeter of radius in front of the patient. The initial rehabilitative task will be the same for all the patients belonging to this group and the workspace will be extended accordingly to the therapist evaluation during the following training sessions. In order not to bias the comparisons of the effects of the different rehabilitative treatments, the therapist assisting this group during the rehabilitation will be the same for all the subjects belonging to this group and he/she will not take part in the rehabilitative treatment of the other groups. Initially, the patients will execute reaching movements in different directions in the horizontal plane. If the therapist will evaluate that the movements have been sufficiently recovered, reaching movements in the other planes will be proposed.
89302458|NCT02770300|Experimental|Automatic personalized robotic rehabilitation with ALEx RS|
89302459|NCT02667574|Other|open-label|Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance
89302460|NCT03704116|Active Comparator|Expedition: Strategic Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes escalating challenge levels.
89302461|NCT03704116|Placebo Comparator|Expedition: Informational Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes capped challenge levels.
89302462|NCT03734484|Experimental|Gram type infection-specific algorithm|The experimental arm will involve patients monitored by the Gram type infection-customized version of InSight.
89302463|NCT03734484|No Intervention|Standard treatment protocol|The control arm will involve patients treated with the regular diagnosis and treatment protocol for gram-type infection, where fluid cultures are run to determine infection type.
89302464|NCT03734328|Active Comparator|connective tissue graft|"Drug:local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~5/0 silk suture"
89302465|NCT03734328|Experimental|connective tissue graft&PRF|"Drug: local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~-5/0 silk suture"
89302466|NCT03650400|Experimental|Cohort A Fevipiprant 75 mg|QAW039 75 mg Chewable tablet
89302467|NCT03650400|Experimental|Cohort B Feviprant 375 mg|QAW039 375 mg Chewable tablet
89302468|NCT03734094|Experimental|Ceramic Barrier|The use of a ceramic barrier to induce bone formation during GBR
89302469|NCT03734094|Active Comparator|Titanium mesh|The use of a titanium mesh to induce bone formation during GBR
89302470|NCT00038103|Active Comparator|1.|
89302471|NCT00038103|Experimental|2.|
89302472|NCT03680742|Experimental|Treated|All eligible patients who underwent an attempt with the Contour device.
89302473|NCT03678870|Experimental|Education|Opioid Education
89302474|NCT03678870|No Intervention|Control|standard discharge instructions, which lists medications prescribed at discharge
89302475|NCT03805971||patient aged more than 18 years admitted for thoracoscopy|Probe based confocal laser endomicroscopy (Mauna kea technologies) will be used, after intravenous fluorescein injection, for every patients admitted for medical thoracoscopy, to study the pleural cavity. Images will be compared with biopsies
88806298|NCT04346771|Placebo Comparator|Positive Attention Bias Modification|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 10 sessions over 2 weeks. 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position.
89302476|NCT03032380|Experimental|Cefiderocol|Participants will receive 2 g cefiderocol administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
89302477|NCT03032380|Active Comparator|Meropenem|Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
89302478|NCT03519854|Placebo Comparator|Arm A. Placebo; given 3 minutes after Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302479|NCT03519854|Experimental|Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302480|NCT03519854|Experimental|Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302481|NCT03519854|Experimental|Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302482|NCT03519854|Experimental|Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302483|NCT03519854|Experimental|Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302484|NCT03519854|Placebo Comparator|Arm G. Placebo; given 5 minutes after Esmeron®|Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302485|NCT03519854|Experimental|Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302486|NCT03519854|Experimental|Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302487|NCT03519854|Experimental|Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302488|NCT03519854|Experimental|Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302489|NCT03519854|Experimental|Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302490|NCT03519854|Placebo Comparator|Arm M. Placebo; given 15 minutes after Esmeron®|Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302491|NCT03519854|Experimental|Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302492|NCT03519854|Experimental|Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302493|NCT03519854|Experimental|Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302494|NCT03519854|Experimental|Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302495|NCT03519854|Experimental|Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
89302496|NCT03704038|Active Comparator|PEEP 5|
89302497|NCT03704038|Active Comparator|PEEP 0|
89302498|NCT03704038|Experimental|PEEP 10|
89302499|NCT03479216|Experimental|Precedex|5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
89302500|NCT03479216|Experimental|Magnesium Sulfate|5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
89302501|NCT03701542||Group of 22 patients|Group of 22 patients who underwent vitrectomy due to macular hole
89302502|NCT03518840|Other|Sacroiliac Joint Belt|All patients will receive and be fitted by the PI with an SIJ belt.
89302503|NCT05660798|No Intervention|combustion tobacco|
88806299|NCT01187381||Participants with Breast Cancer|Participants with early or metastatic HER2-positive breast cancer who were receiving treatment with trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines, will be observed. Dosing and treatment duration of the trastuzumab will be at the discretion of the treating physician.
88806300|NCT01187771|Active Comparator|Laparoscopic Gastric Banding|
88806301|NCT01187771|Active Comparator|Continuous Positive Airway Pressure|
89302504|NCT05660798|Experimental|heated tobacco|
89302505|NCT03717116||control-normocalcemia group|
89302506|NCT03717116||hypocalcemia group|
89302507|NCT03703726|Active Comparator|Reference meal|50 g of Commercial Rice was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
89302508|NCT03703726|Experimental|Test meal A|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
89302509|NCT03703726|Active Comparator|Test meal B|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
89302510|NCT03703726|Experimental|Test meal C|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
89302511|NCT03703726|Experimental|Test meal D|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
89302512|NCT03703726|Active Comparator|Test meal E|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
89302513|NCT03703726|Active Comparator|Test meal F|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
89302514|NCT03717038|Experimental|Arm A (Sym004)|Sym004 will be administered as a loading dose of 9 mg/kg on Cycle 1 Day 1, followed by weekly doses of 6 mg/kg beginning Cycle 1 Day 8.
89302515|NCT03717038|Active Comparator|Arm B (TAS-102)|TAS-102 is commercially available and will be administered as per local prescribing instructions.
89302516|NCT03716960|Experimental|Pumpkin Seed Oil|This arm involved 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner). Likewise,
89302517|NCT03716960|Placebo Comparator|Placebo|This arm involved 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
89302518|NCT03716882||Infant at the birth|"Infant at the birth will be included. Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights.~At every cry, parent should answer the questionnaire of cry in infant."
89302519|NCT01310894|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
89302520|NCT01310894|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have low-risk prostate cancer
89302521|NCT03701464|Experimental|Endoscopic naso-gallbladder drainage|After selective bile duct cannulation, a 0.025- or 0.035-inch guidewire is advanced into the cystic duct and subsequently into the gallbladder. A 5F naso- Pancreas catheter was inserted into the gallbladder for ENGBD.
89302522|NCT03701464|Active Comparator|Percutaneous gallbladder drainage|Ultrasound guided，an 18-gauge needle is inserted into the gallbladder，0.035 inch guidewire is coiled into the gallbladder and 9Fr dilator expands the skin,then 8Fr-20cm catheter is placed.
89302523|NCT03436082||Data from a mHealth platform after bariatric surgery|Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
89302524|NCT03436082||Data from a mobile health platform after atrial fibrillation|Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.
89302525|NCT00143182|Experimental|1|Asenapine
89302526|NCT00143182|Active Comparator|2|Olanzapine
89302527|NCT03677934|Experimental|PDS Implant Arm|Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
89302528|NCT03677934|Active Comparator|Intravitreal Arm|Participants will receive ranibizumab 0.5 mg monthly intravitreal injections of 10 mg/mL formulation at Day 1 and every month thereafter.
89302529|NCT03701386|Active Comparator|cesarean hysterectomy|Elective Cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. The operation will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
89302530|NCT03701386|Experimental|N&H sandwich technique|In the N&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade was performed
89302531|NCT03435692|Experimental|Lumbar Plexus Catheter|"Children undergoing pediatric hip surgery will have a lumbar plexus catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
89302532|NCT03435692|Active Comparator|Lumbar Epidural Catheter|"Children undergoing pediatric hip surgery will have an epidural catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
89302533|NCT03435692|Active Comparator|Patient Controlled Analgesia|"Children undergoing pediatric hip surgery will have patient controlled analgesia (with morphine) started in the post anesthesia care unit for post operative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
89302534|NCT03705442|Placebo Comparator|Placebo|Placebo
89302535|NCT03705442|Experimental|Probiotics|Omni-Biotic 10
89302536|NCT03475316|Experimental|Social Dancing|The program includes Fox-trot, Waltz, and Latin dances.
89302537|NCT03475316|Active Comparator|Treadmill Walking|The treadmill walking training protocol is based on the recommendations of the American College of Sports Medicine (ACSM) and American Heart Association (AHA) for older adults.
89302538|NCT03705364|No Intervention|Wait List Control Group|Wait list control group
88806302|NCT01225289|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
89302539|NCT03705364|Experimental|Fall Management program|Intervention arm
89302540|NCT02355990|Experimental|MIMS|Minimally Invasive Micro Sclerostomy
89302541|NCT03731754|Active Comparator|Traditional Closure|Patients receive primary closure discontinuously for reconstruction of APR perineal wound
89302542|NCT03731754|Experimental|"Cross Closure"|"Patients receive cross closure for reconstruction of APR perineal wound"
89302543|NCT03673956|Experimental|Mupirocin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Mupirocin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
89302544|NCT03673956|Experimental|Tobramycin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Tobramycin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
89523342|NCT03377777||Infants|Outwardly healthy male and female infants at 6-7 months or 12-13 months. No intervention.
89523343|NCT03377621|Experimental|Whole Body Vibration|OSA subjects will be asked to use whole body vibration machine for 30 minutes, 3 times a week for 6 weeks in between visits.
89302545|NCT03673956|Experimental|Levofloxacin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Levofloxacin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
89302546|NCT03673956|Experimental|Vancomycin Topical Antibiotic Nasal Saline Rinse|Subjects with a history of chronic rhinosinusitis (CRS) who had previously undergone endonasal sinus surgery (minimum of maxillary antrostomy and anterior ethmoidectomy), will receive a trial of Vancomycin topical antibiotic rinses. Subjects will undergo a baseline assessment including an aerobic sinus bacterial culture with antibiotic sensitivity to determine baseline microbial antibiotic resistance and to direct selection of appropriate topical antibiotic therapy.
89302547|NCT03705208|Experimental|Youth First Curriculum|"The full Youth First curriculum provides holistic training of both emotional resilience and adolescent health concepts. The curriculum is comprised of a 15-session emotional resilience curriculum and a 10-session adolescent health program. The resilience curriculum aims to increase both internal assets (such as self-esteem, coping skills, health knowledge, and conflict-resolution skills) and external assets (such as positive bonds with peers and family).~The adolescent health curriculum provides in-depth training in physical health and wellness topics such as sexual and reproductive health, common diseases, nutrition, gender equality, and substance use.~The curriculum is imparted by school teachers are trained and certified by CorStone."
89302548|NCT03705208|No Intervention|School as usual|This arm is comprised of students attending school as usual and receiving the established government-designed curriculum.
89302549|NCT03673098|Experimental|Intervention Group: Adapted 3RP|The intervention condition will consist of the 10-week adapted 3RP intervention.
89302550|NCT03673098|No Intervention|Control Group: Supportive Psychotherapy|The control condition will be a 10-week supportive therapy program. Visits include supportive psychotherapy to address stressful or difficult topics related to aging as a woman living with HIV. The program was developed to approximate the most frequent mental health counseling provided to adults with HIV at the community level.
89302551|NCT03716804|Experimental|Intervention group|"Intervention:~To the prescribers- Educational intervention about guideline and present sensitivity trend.~To the Patients- Tablet Nitrofurantoin(100 mg), two times daily at 12 hours interval for 7 days."
89302552|NCT03716804|Active Comparator|Control Group|"Intervention:~To the Patients- Tablet Ciprofloxacin, 500 mg or,Tablet Cefixime 200 mg or,Tablet Cefuroxime 250 mg (According to physician's personal choice)."
89302553|NCT03701152|Experimental|Negative pressure therapy|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Continuous course
89302554|NCT03701152|Experimental|Investigator|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Splitted course
89302555|NCT03703570|Experimental|KW-6356 Low Dose|Oral administration
89302556|NCT03703570|Experimental|KW-6356 High Dose|Oral administration
89302557|NCT03703570|Placebo Comparator|placebo|Oral administration
89302558|NCT03435224|Experimental|INVSENSOR00012|All subjects consented are enrolled into the test group and will receive the INVSENSOR00012.
89302559|NCT01310166|Experimental|Fingolimod|
89302560|NCT03705130||Group 1|All subjects will wear the 3 contact lenses: Single Vision, Multifocal 1 and Multifocal 2.
89302561|NCT03716648|Active Comparator|Subjective titration|After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
89302562|NCT03716648|Experimental|DISE-assisted titration|Incremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated.
89302563|NCT03716648|Experimental|PSG-guided titration|An overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced.
89302564|NCT03705052|Other|Intervention|Patients and caregivers were asked to complete a questionnaire
89302565|NCT03672396|Experimental|Home-based Exercise|The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour.
89302566|NCT03698578|Experimental|group 1 combat fight|Consisting of professional, high-performance paratletas. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
89302567|NCT03698578|Experimental|group 2 combat fight|Constituted by amateur paratroopers. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
89302568|NCT03731676|Active Comparator|Rotating platform total knee arthroplasty|These patients were randomly assigned to receive a rotating platform total knee arthroplasty.
89302569|NCT03731676|Active Comparator|Fixed bearing total knee arthroplasty|These patients were randomly assigned to receive a fixed bearing total knee arthroplasty.
89302570|NCT03434834|Experimental|OCT of esophagus|optical coherence tomography of esophagus
89302571|NCT03733938||teeth with failed root canal treatement|endodontic microsurgery will be performed for teeth with failed root canal treatment
89302572|NCT03698500|Other|Patients with intestinal colitis and control patients|Device: qPCR diagnostic of specific microRNAs in peripheral blood (10 ml)
89302573|NCT03733860|Active Comparator|Cavernous sparing group|
88806303|NCT01225289|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo per day
88806304|NCT01161329|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
89302574|NCT03733860|Other|Conventional technique group|
89302575|NCT04390360|Other|Protective ventilation with HME|Protective ventilation + HME
89302576|NCT04390360|Other|Protective ventilation with Heated humidifier|Protective ventilation + HH
89302577|NCT04390360|Other|Implementation of protective ventilation|Protective ventilation implementation
89302578|NCT04390360|Other|Tidal Volume reduction|Tidal volume reduction
89302579|NCT03700840|Other|Clinical examination and sample|"Cross-sectional observational study~Measure of 6 indices:~Bleeding on Intergental Brush Index (BOIB)~Gingivitis Score (GI)~Plaque index score (PI)~ICDAS~Salivary test~Individual caries risk assessment~Determination of interdental brushes adapted to each interdental site~Recovery of the interdental brush passed through the 4 sites (between 15-16, 25-26, 35-36, 45-46) on which the interdental biofilm was fixed during the passage in the interdental space.~The interdental brush is immediately put in a sterile tube and then sent in dry ice to maintain the integrity of the genetic material.~Quantitative PCR experiments will be performed and a qualitative and quantitative analysis of the interdental flora will be made."
89302580|NCT03698422||Healthy controls|"Estimated glomerular filtration rate (eGFR) > 60 mL/min for > 3 months and no known current or chronic medical or surgical conditions.~Blood and urine samples are collected for every 3rd hour during 24 hours"
89302581|NCT03698422||Predialysis CKD subjects|"Estimated glomerular filtration rate (eGFR) between 30 and 15 mL/min for > 3 months (i.e. CKD stage 4).~Blood and urine samples are collected for every 3rd hour during 24 hours"
89302582|NCT03698422||ESKD subjects|"Maintenance haemodialysis treatment for > 3 months for ESKD and with anuria (urine excretion < 100 mL/day).~Blood and urine samples are collected for every 3rd hour during 24 hours"
89302583|NCT03605862|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 5 days
89302584|NCT03605862|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
89302585|NCT03700762||pathologically results|finally proved by pathologically results
89302586|NCT03700762||evaluate by ultrasound gray-scale ratio|the results confirmed by the cut-off value of ultrasound gray-scale ratio
89302587|NCT04709302||COVID-19 positive, HIV-positive with ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV who are on ART
89302588|NCT04709302||COVID-19 positive, HIV-positive without ART|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
89302589|NCT04709302||COVID-19 positive, HIV-negative|Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group
89302590|NCT03624868|Experimental|Tai Chi|A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
89302591|NCT03624868|Active Comparator|Wellness Education|The wellness education intervention will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives). The Whole Health program focuses on teaching mindful awareness to promote behavioral changes that are consistent with an individual's health goals. Components of the Whole Health model include working the body, surroundings, personal development, food and drink, recharge, family, friends and coworkers, spirit and soul, and power of the mind. Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. Goal-setting using the SMART goals model, with regards to health and wellness, and discussions about ways to address potential barriers will be included in this condition.
88806305|NCT01161329|Experimental|Intervention group|Exercising two times/week according to the High-Intensity Functional Exercise Program (HIFE) in groups of 5-7 patients in combination with motivational discussions.
89302592|NCT01310244|Experimental|Single arm, open label|"At the study entry each patient will receive a dose level assignment which will include a specific dose level and the dose of IV belinostat in mg/m2 to be administered during the study treatment.~Belinostat will be infused over 30 minutes once daily on Days 1-5 of each 21-day cycle. On Day 3, the infusion of belinostat must be completed at least 1 hour prior to the start of the paclitaxel infusion. Dose of belinostat will be assigned at study entry. The same dose and level will remain throughout the entire study for each patient and no dose adjustment will be allowed, except due to toxicity."
89302593|NCT03698344|Experimental|Biodiesel exhaust exposure|A single arm study in which first a filtered air baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute biodiesel exhaust will start.
89302594|NCT03672006|Experimental|alteplase|patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)
89302595|NCT03672006|Active Comparator|Heparin|patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)
89302596|NCT03698266|Other|All Enrolled Patients|Receive needle knife fistulotomy as a starting technique to gain access to the biliary system
89302597|NCT03698188|Experimental|Injectable platelet-rich fibrin|A platelet concentrate will be prepared from the patient's own blood in plain plastic tubes, without the use of anticoagulants, and applied immediately within the root canal before coagulation.
89302598|NCT03698188|Active Comparator|Platelet-rich plasma|A platelet concentrate will be prepared from the patient's own blood in tubes containing anticoagulants to maintain the fluid consistency and applied within the root canal.
89302599|NCT03731520|Experimental|Assessing exercise behavior|determining exercise behaviour in patients with JIA by using specific scales
89302600|NCT04514692|Experimental|Phase I -Dose finding, Cohort 1|Dosing will occur in cohorts of 4 patients with the start at dose of GCSF will be 780 mcg x 3 days
88806306|NCT01227005|Active Comparator|Whole Blood|Whole Blood plus pooled platelets
88806307|NCT01227005|Active Comparator|Component Therapy|Red blood cells, plasma, platelets
89302601|NCT04514692|Experimental|Phase I -Dose finding, Cohort 2|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 2 days
89302602|NCT04514692|Experimental|Phase I -Dose finding, Cohort 3|Dosing will occur in cohorts of 4 patients, If 4 out of 4 patients achieve the target SUVmean, the GCSF dose will be 780 mcg x 1 day
89302603|NCT04514692|Experimental|Phase II-G-CSF|Phase 2 participants will be treated with the optimal dose of GCSF found in the phase 1 portion of the study.
89302604|NCT03733782|Active Comparator|Modular enteral protein - Prosource|Subjects are patients admitted to the surgical intensive care unit and identified by one of the investigators as being appropriate for protein supplementation. Guidelines required that patients were: 1. Deemed ready to start enteral nutritional support by the attending physician within 72 hours of admission to the intensive care unit, 2. No contraindications to full enteral support, 3. No history of chronic liver disease, 4. Serum creatinine < 2.0 mg/dl.
89302605|NCT03733782|No Intervention|Control group|The investigators used the electronic medical record to identify control subjects. These were patients admitted to the surgical intensive care unit who were in the ICU long enough to undergo testing of 24 hour urine nitrogen excretion from January to December 2016.8 As part of standard clinical practice, measurement of urine nitrogen excretion is performed in patients who are in the ICU and receiving nutritional support for more than one week.
89302606|NCT03733704|Experimental|Healthy volunteers|Healthy volunteers
89302607|NCT03703414||Control|Healthy controls
89302608|NCT03703414||ECT|MDD patients receiving ECT treatment
89302609|NCT03703414||SSRI|MDD patients receiving SSRI treatment
89302610|NCT03621072|Other|Reference|Fluconazole 150mg Capsule Originator
89302611|NCT03621072|Experimental|Experimental|Fluconazole 150mg Capsule Localized Originator
89302612|NCT03698110|Experimental|Intervention Group|Participated in one introductory session, in the four sessions of PUEDES program during four weeks and in a closing session.
89302613|NCT03698110|No Intervention|Control Group|Participated in one introductory session and in a closing session.
89302614|NCT03733548|Experimental|Regulating Emotions Like An eXpert (RELAX)|Families at the Virginia Commonwealth University Center for Psychological Services and Development or Clark-Hill Institute for Positive Youth Development
89302615|NCT03697954||overactive bladder patients|Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation
89302616|NCT03700528|Experimental|Intervention|This is a single-cohort ACT based intervention.
89302617|NCT03512288|Experimental|Multivalent|Pneumococcal conjugate vaccines
89302618|NCT03512288|Active Comparator|Control|13vPnC
89302619|NCT03031678|Other|Study procedures|
89302620|NCT03669588|Experimental|ARGX-113|
89302621|NCT03669588|Placebo Comparator|Placebo|
89302622|NCT03697798|Active Comparator|Children aged between 7-10 years of age|Healthy children from 7 up to 10 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country. They will receive Boostrix®-IPV combination vaccine.
89302623|NCT03697798|Active Comparator|Children aged between 11-15 years of age|Healthy children from 11 up to 15 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country aiming for comparable numbers of participants with aP vs wP vaccination background. They will receive Boostrix®-IPV combination vaccine.
89302624|NCT03697798|Active Comparator|Adults aged between 20-34 years of age|Healthy young adults from 20 up to 34 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
89302625|NCT03697798|Active Comparator|Adults aged between 60-70 years of age|Older adults from 60 up to 70 years of age determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
89302626|NCT03716570|Experimental|Cohort 1: BIIB054 Dose A|Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
89302627|NCT03716570|Experimental|Cohort 2: BIIB054 Dose B|Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
89302628|NCT03716570|Experimental|Cohort 3: BIIB054 Dose C|Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
89302629|NCT03716570|Placebo Comparator|Cohorts 1-3: Placebo|Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
89302630|NCT05650502||ISC (ISAMIMA children group-Cobly)|"This group included children from 6 to 59 months living in Cobly and receiving the SMC treatment. The treatment is administered for three consecutives days for 4 months (from july to october).~For children under 12 months: one dose of SP 250/12.5mg on day 1 AQ 75mg once daily for 3 days For children from 12 to 59 months: one dose of SP 500/25mg on day 1 AQ 150 mg once daily for 3 days A monthly visit was planned for monitoring during the follow up. Sample was collected in jun, september, january and April."
89302631|NCT05650502||IST (ISAMIMA children group-Tchaourou)|"This group included children from 6 to 59 months living inTchaourou and who did not receiving the SMC treatment.~A monthly visit was planned for monitoring during the follow up. Sample was collected in jun, september, january and April."
89302632|NCT03719534|Active Comparator|Haplo-HCT|people enrolled in this arm will receive a typical haploidentical donor HCT
89302633|NCT03719534|Experimental|Haplo-cord HCT|people enrolled in this arm will receive a coinfusion of cord blood unit in addition to a typical haploidentical donor HCT
89302634|NCT03700450|Experimental|Cyclophosphamid post Tranplant|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
89302635|NCT03703180||MS|representative cohort of relapsing-remitting MS (n=50) and progressive MS patients (n=50) over the typical age range of 18-65. During two years of follow-up the integrity and function of the visual system will be observed annually with optical coherence tomography, high and low contrast visual acuity and a vision related quality of life questionnaire.
89302636|NCT03703180||Controls|Age and Gender matched healthy controls (n=100) will undergo the same assessments as the MS cohort to build up a representative normative dataset.
89302637|NCT03697642|Experimental|NG tube placement with nasopharyngeal tube|
89302638|NCT03697642|Active Comparator|NG tube placement without nasopharyngeal tube|
89302639|NCT03624556|Experimental|Experimental group DS and FXS|Cohort 1: a 35 DS children group taking EGCG FontUp. Cohort 2: a 6 FXS children group taking EGCG FontUp. (Experimental open-label)
89302640|NCT03624556|Placebo Comparator|Control group DS|Cohort 1: a 35 DS children group taking placebo FontUp.
89302641|NCT03700294|Experimental|ADCT-601|
89302642|NCT03700060||General Practice|Volunteering General Practices who registers contacts from nursing homes on residents with suspected UTI
89302643|NCT03703024|Placebo Comparator|Placebo|Maltodextrin
89302644|NCT03703024|Active Comparator|Low dose|200mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
89302645|NCT03703024|Active Comparator|High dose|400mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
89302646|NCT03702946|Experimental|study group|
89302647|NCT03702946|No Intervention|control group|
89302648|NCT04491526|Experimental|Tamsulosin Arm|p.o.
89302649|NCT04491526|Placebo Comparator|Placebo Arm|p.o.
89302650|NCT03699982|Experimental|Cystic fibrosis patients|Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.
89302651|NCT03699904|Experimental|Active arm|Valaciclovir 1 gram orally three times daily for 8 weeks.
89302652|NCT03699904|Placebo Comparator|Placebo arm|Matching placebo capsules (containing Avicel blend). Two capsules three times daily for 8 weeks.
89302653|NCT03697486|Experimental|High Protein|(40,6% protein)
89302654|NCT03697486|Experimental|Moderate Protein|(23.5% protein)
89302655|NCT03697486|Experimental|Low Protein|(12.4% protein)
89302656|NCT03697330|Active Comparator|Ringer's lactate 18-20 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group L:will receive 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
89302657|NCT03697330|Active Comparator|Ringer's lactate 4-6 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group R: will receive 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
89302658|NCT03702790||Back pain SPECT evaluation|Patients with poorly localized back pain being imaged for clinical decision making
89302659|NCT03697174|Experimental|Exposure group|Subjects in exposure group will be exposed to 200 ppb ozone for 2 hours in a chamber.
89302660|NCT03697174|Sham Comparator|Control group|Subjects in control group will be exposed to 0 ppb ozone (clean air) for 2 hours in a chamber.
89302661|NCT03702712|Active Comparator|Aerobic Exercise Only|Participants in the Aerobic Exercise Only arm will engage in three separate 20-minute sessions comprised of a 5-minute, resistance-free warm-up, and 15 minutes of moderate stationary aerobic cycling on a Cybex bike #525C (50-70% age-predicted heart rate max). Each session will be followed by 20 minutes of uninterrupted quiet rest. The bike will provide feedback including speed, rotations per minute, and time.
89302662|NCT03702712|Active Comparator|Relaxation Only|Participants in the Relaxation Only arm will complete three separate 20-minute sessions of relaxation using a commercial wearable neurofeedback (headband) device. The device's accompanying software (connected to the headband through Bluetooth) encourages breathing strategies in response to recorded brain wave activity. Real time auditory feedback includes sounds of calm (soft) or loud winds in response to detected brain activity. A visual report of affective states and the user's brain activity is given (alpha and beta waves). Participants will also be asked to take part in 20 minutes of uninterrupted quiet rest in order to match the time of the aerobic only condition.
89302663|NCT03702712|Experimental|Aerobic Exercise and Relaxation|Participants in the Aerobic Exercise and Relaxation arm will complete the three separate 20-minute aerobic exercise sessions (identical to the aerobic exercise only condition) followed by the same 20-minute neurofeedback-guided mindfulness training (identical to the relaxation only condition).
89302664|NCT03699592|No Intervention|Control|
89302665|NCT03699592|Experimental|Reach Home and Read|This arm will receive the Reach Home and Read early literacy intervention
89302666|NCT03697018|Experimental|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material, enriched with zirconia (10% by weight), the material offers natural esthetics with successful outcome.
89302667|NCT03697018|Active Comparator|monolithic zirconia|Zirconia or zirconium dioxide (ZrO2) is a highly attractive ceramic material in prosthodontics due to its excellent mechanical properties. It is widely used to build prosthetic devices.
89302668|NCT03699514||Subject who completed or will complete a BNA test|
89302669|NCT04483804||disease free survival|Time from randomization to relapse or death due to disease progression
89302670|NCT04483804||non-disease free survival|Time of metastasis or death
89302671|NCT04373122|Experimental|REBOA|Insertion of the ER-REBOA Catheter during ongoing CPR
89302672|NCT03696940|Experimental|Experimental Group|2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
89302673|NCT03696940|Active Comparator|Control Group|2 tablets of: Atorvastatin 10 mg
89302674|NCT03696862|Experimental|collagen plug|collagen plug used to seal the socket after atraumatic extraction of the badly deacayed teeth with immediate implant placement and bone graft
89302675|NCT03699436|Experimental|Electric Stimulation Therapy Group|The experimental group will receive an electrotherapy treatment with galvanic current in their hands. Electrotherapy with galvanic current has vasodilator action.
89302676|NCT03699436|Active Comparator|Control Group|The control group will be subjected to a conservative treatment. These patients will continue to take their usual medication and will not receive electrotherapy treatment
89302677|NCT03699358||Group 1: Myeloid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
89302678|NCT03699358||Group 2: Lymphoid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
89302679|NCT04694560||CLL/SLL|Diagnosis of CLL or SLL confirmed by the enrolling institution
89302680|NCT03696706|Active Comparator|LED group|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
89302681|NCT03696706|Placebo Comparator|Placebo group|For the placebo group, all measures described for the LED group will be adopted, however, the equipment will be switched off.
89302682|NCT03696706|No Intervention|Control group|In this group, the participants will only be evaluated. No intervention will take place.
89302683|NCT03731442|Experimental|Involved field irradiation|Patients after R0 surgery whose recurrence lesion larger than 5cm in diameter, or largest diameter was less than 5cm but with skip metastasis far from primary tumor or their time-to-recurrence longer than 16 months were assigned to involved field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 60Gy/2Gy/30f, and for lesions close to the thoracic stomach, the prescribed dose is 59.4-61.2Gy/1.8Gy/33-34f. Chest CT scan is planned at 50Gy. Radiation field should be modified according to the tumor response. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF (3-6mg) should be given after 48 hours of chemotherapy.If patients received postoperative chemotherapy of paclitaxel and platinum and went through local-regional recurrence within six months, it is allowed to deliver chemotherapy regimens in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
89302684|NCT03731442|Experimental|Elective field irradiation|Patients after R1/R2 surgery or R0 surgery with the recurrence lesion whose diameter was less than 5cm without skip metastasis far from primary tumor and time-to-recurrence shorter than 16 months were assigned to elective field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a simultaneously integrated boost up to 59.92-62.16Gy/2.14-2.22Gy/28f. For lesions close to the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a sequential boost of 10-12Gy/1.8-2Gy/5-7f. For patients whose planned thoracic stomach V50>50%, the dose should be lowered to 45Gy/1.8Gy/25f. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF should be given in need. If patients received postoperative chemotherapy of TP and went through local-regional recurrence within 6 months, chemotherapy regimens delivered in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
89302685|NCT03702478||No intervention, cross-sectional study|Questionnaire, cross-sectional study
89302686|NCT03702400|Active Comparator|Phenylephrine 100 mcg|Phenylephrine will be used at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug to be used whenever systolic blood pressure falls below 10% of baseline.
89302687|NCT03702400|Experimental|Norepinephrine 5 mcg|Norepinephrine will be used at a dose of 5 mcg at a dilution containing 1 mcg / mL to be used whenever systolic blood pressure falls below 10% of baseline.
89302688|NCT05666388|Experimental|Rescue stenting (RESFIT)|Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RESFIT)
89302689|NCT03699202|Experimental|100mg AK0529 Arm|Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.
89302690|NCT03699202|Experimental|200mg AK0529 Arm|Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.
89302691|NCT03699202|Experimental|300mg AK0529 Arm|Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.
89302692|NCT03699202|Placebo Comparator|Placebo Arm|Patients randomised into this arm will be orally administered with placebo q.d. for five days.
89302693|NCT03598140|Placebo Comparator|Placebo oral capsule|If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
89302694|NCT03598140|Active Comparator|Sildenafil Citrate|If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
89302695|NCT03733236|Experimental|Active Stimulation|The Implant will be implanted using a minimal invasive approach. Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure. ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.
89302696|NCT03733158|Experimental|Normal airway|intubation in normal aurway condition
89302697|NCT03733158|Experimental|Tongue edema|intubation in Tongue edema condition
89302698|NCT03733158|Experimental|Pharyngeal obstruction|intubation in Tongue edema condition
89302699|NCT03733158|Experimental|Manual cervical inline stabilization|intubation in Manual cervical inline stabilization condition
89302700|NCT03733158|Experimental|Cervical collar stabilization|intubation in Cervical collar stabilization condition
89302701|NCT03733158|Experimental|Cervical collar stabilization and pharyngeal obstruction|intubation in Cervical collar stabilization and pharyngeal obstruction condition
89302702|NCT03639870|Experimental|Implant Group|Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos® Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.
89302703|NCT03644550|Experimental|1/LMB- 100+pembrolizumab|"LMB-100 administered in cycles 1 and 2 + pembrolizumab administered in subsequent cycles.~LMB-100 140mcg/kg Intravenous infusion (IVI), Days 1, 3, 5 in cycles 1, 2. Pembrolizumab 200mg IVI, every (Q) subsequent cycle on Day 1."
89302704|NCT03738930|No Intervention|normal follow-up group|normal follow-up in ACS patients after PCI
89302705|NCT03738930|Experimental|AI based mHealth system follow-up group|AI based mHealth system follow-up in ACS patients after PCI. ACS patients in this group will receive message to take more notice to bleeding events.
89302706|NCT03716414||Experimental SLN arm|"Experimental SLN arm~Intra-operative sentinel lymph node (SLN) mapping with indocyanine green injected into the stroma of the cervix.~Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceed to a total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy including complete pelvic lymphadenectomy and aortic lymph node dissection.~If only unilateral SLN or non SLN are detected, surgeons will proceed to complete pelvic lymphadenectomy and aortic lymph node dissection."
89302707|NCT00054717|Other|Tipranavir(TPV)/low dose ritonavir(r)|
89302708|NCT00054717|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
89302709|NCT03721718|Experimental|GLS-5300 with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
89302710|NCT03721718|Experimental|GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
89302711|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (3 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
89302712|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (2 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
89302713|NCT03716336|Other|aerobic exercise|walking on treadmill
89302714|NCT03716336|Other|resistive exercise|Resistance exercise were performed for all participants in group (A) included 9 exercise for big muscles of upper limbs
89302715|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 45mg|Strength of each tablet is 15mg
89302716|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 30mg|Strength of each tablet is 15mg
89302717|NCT03430856|Active Comparator|Insulin Aspart|Pre-filled pen: 100 U/L
89302718|NCT01091025|Other|CF patients without known diagnose of CFRD|There is only one arm. All patients in the study had the same procedures (ie. an OGTT). Investigators used the screening criteria in parallel to this.
89302719|NCT03731364|Active Comparator|CA-008 5 mg (0.05 mg/mL) Cohort 1|Cohort 1 (5 mg), was prepared at 0.05 mg/mL CA-008 (vocacapsaicin)
89302720|NCT03731364|Placebo Comparator|Placebo - Cohort 1|"Placebo for Cohort 1~Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active"
89302721|NCT03731364|Active Comparator|CA-008 10 mg (0.1 mg/mL) Cohort 2|Cohort 2 (10 mg), was prepared at 0.1 mg/mL CA-008 (vocacapsaicin)
89302722|NCT03731364|Active Comparator|CA-008 15 mg (0.15 mg/mL) Cohort 3|Cohort 3 (15 mg), was prepared at 0.15 mg/mL CA-008 (vocacapsaicin)
89302723|NCT03731364|Placebo Comparator|Placebo - Cohorts 2 and 3|"Placebo - Cohorts 2 and 3~Placebo comparator identical in appearance to the investigational product, containing the same excipients as the active"
89302724|NCT03510182|Experimental|transcranial Direct Current Stimulation|tDCS will be given to all qualified patients with aphasia.
89302725|NCT01091181|Active Comparator|high incision group|hysterotomy at cesarean performed 2 cm above plica vesicouterina
89302726|NCT01091181|Active Comparator|low incision group|hysterotomy at cesarean performed 2 cm below plica vesicouterina
89302727|NCT03738540|Experimental|Experimental|This is the experimental arm of the study. This includes 25 weekly then biweekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
89302728|NCT03738540|Active Comparator|Control|This is the control arm of the study. This includes This includes 25 weekly then biweekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
89302729|NCT03731286|Active Comparator|Alpinia galanga|EnXtra: 2 capsules to be taken twice daily after breakfast and evening.
89302730|NCT03731286|Active Comparator|Composite (Alpinia galanga + Caffeine)|Composite: 2 capsules to be taken twice daily after breakfast and evening.
89302731|NCT03731286|Placebo Comparator|Placebo|Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.
89302732|NCT00066807|Experimental|OFS plus T or E|Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
89302733|NCT00066807|Experimental|Chemotherapy plus OFS plus T or E|Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
89302734|NCT03619330|Active Comparator|liraglutide|In the LIRA group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
89302735|NCT03619330|Active Comparator|testosterone|In the ANDRO group testosterone was initiated at a dose of 50 mg in a gel form once daily.
89302736|NCT03428750|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
89302737|NCT03428750|Placebo Comparator|Placebo|
89302738|NCT03666858||Neosaldina|Participants with episodic TTH and who have already been treated with Neosaldina will be included in the observation period of this study. During the observation period, participants will be administered with Neosaldina 2 tablets, orally in the beginning of the TTH episode, every 6 hours, and at maximum of 8 tablets per day, according to regular clinical practice of the physicians. The participants will be observed in this study from Day 1 until Day 45.
89302739|NCT03956199|Experimental|experimental pulpotomy|
89302740|NCT03956199|Active Comparator|Root canal treatment|
89302741|NCT00054639|Experimental|Treatment (oblimersen sodium and monoclonal antibody therapy)|Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.
89302742|NCT04686682|Experimental|JAB-8263 Part1|Monotherapy, dose escalation
89302743|NCT04686682|Experimental|JAB-8263 Part 2|Monotherapy, dose expansion
89302744|NCT03733002|Experimental|AngongNiuhuang|Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
89302745|NCT03733002|Placebo Comparator|Placebo of AngongNiuhuang|Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
89302746|NCT02530359|Active Comparator|Group 1|Pirfenidone extended release 600mg per mouth every 12 hours for 7 days.
89302747|NCT02530359|Active Comparator|Group 2|Pirfenidone extended release 600mg per mouth in the morning and placebo by night (each treatment every 12 hrs) for 7 days.
89302748|NCT02530359|Placebo Comparator|Group 3|Placebo equivalent per mouth every 12 hrs for 7 days.
89302749|NCT03731208|Experimental|Intervention group|The patient assign to this arm receive the telerehabilitation program for 8-week after a knee operation
89302750|NCT03696472|Experimental|robotic-assisted left colonic resection|Standard left colonic resection assisted by Davinci Robotic
89302751|NCT03696472|Active Comparator|laparoscopic left colonic resection|Standard laparoscopic left colonic resection
89302752|NCT03428360|Experimental|Subjects with Epilepsy|Male or female subjects between the ages of 2 and 65 years who had an established diagnosis of epilepsy exhibited by motor seizures with clear alteration of awareness, and while on a regimen of anti-epileptic medication(s), still experienced bouts of seizures (frequent breakthrough seizures, eg, seizure clusters) and who, in the opinion of the Investigator, could need benzodiazepine intervention for seizure control at least 1 time a month on average. Subjects must have been on at least 1 concomitant anti-epileptic drug at screening.
89302753|NCT03731130||neoadjuvant short term radiation|Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.
89302754|NCT03731130||neoadjuvant long-term chemoradiation|Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire
89302755|NCT03699046|Active Comparator|Subchondroplasty and Knee Arthroscopy|Patients randomized to the Subchondroplasty and Knee Arthroscopy group will receive the subchondroplasty procedure before or after knee arthroscopy that will be completed based on current standard of care guidelines.
89302756|NCT03699046|Sham Comparator|Knee Arthroscopy Alone|Patients randomized to the Knee Arthroscopy Alone group will receive the knee arthroscopy that will be completed based on current standard of care guidelines.
89302757|NCT03732924|Experimental|Five minute rest|
89302758|NCT03732924|Active Comparator|Zero minute rest|
89302759|NCT03696394|No Intervention|Group I|Group I consists of 5 patients receiving a microfracture as per standard of care.
89302760|NCT03696394|Active Comparator|Group II|Group II consists of 10 patients receiving a microfracture with BioCartilage®.
89302761|NCT03427892|Experimental|Brexpiprazole|Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.
89302762|NCT03738384|Experimental|TKR Patients|Any patient 3-6 weeks post-op from a TKR
89302763|NCT03698968|Other|Single prospective intervention|
89302764|NCT03738306|Experimental|Mezieres Method|The Mézières treatment has 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain. The time of tratment will be of 1 hour, two times a week, during 5 weeks.
89302765|NCT03738306|Active Comparator|Conventional Physiotherapy|The treatment with conventional physiotherapy will include stretching of hamstrings, gluteus, (and others) hot pack, transcutaneous electrical nerve stimulation, ultrasound and some exercises of core performance.The time of treatment will be of 1 hour, two times a week, during 5 weeks.
89302766|NCT03698890|No Intervention|Control|Usual care of 3 to 6-monthly clinic visit
89302767|NCT03698890|Experimental|Intervention|Network-based home blood pressure monitor (Fora P20b Blood Pressure Monitor) and telephone consult with care team
89302768|NCT03595332|Experimental|Immediate intervention|Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
89302769|NCT03595332|Experimental|Delayed intervention|Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.
89302770|NCT03702322|Other|Participants|All participants will undergo each treatment.
89302771|NCT03732846|Experimental|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression.
89302772|NCT03427268|Experimental|PM060184|PM060184
89302773|NCT03698812||CTL group|control group
89302774|NCT03698812||EXP group|Colonoscope
89302775|NCT03509948|Experimental|Schedule A: Fed Then Fasted|"Schedule A (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)"
89302776|NCT03509948|Experimental|Schedule B: Fasted Then Fed|"Schedule B (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)"
89302777|NCT03696238|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
89302778|NCT03696238|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
89302779|NCT03696004|Active Comparator|Retros FEC-100 +BRS|Contains record of already treated patients with six cycles of FEC-100 Fluorouracil ,Epirubicin and Cyclophosphamide and later had Breast conservative Surgery(BRS)
89302780|NCT03696004|Active Comparator|PROS 30 FEC-100 +BRS|These are new patients who will be treated with six cycles of FEC-100 (Flourouracil,Epirubicin and Cyclophosphamide) and will undergo Breast Conservative Surgery (BRS)after 6 weeks
89302781|NCT03695926|Experimental|[18F]MNI-1054|To measure blood metabolites, dynamic uptake, and washout of [18F]MNI-1054 in brain using positron emission tomography (PET) in healthy volunteers.
89302782|NCT03466658|Experimental|JumpStart group|This group will have the JumpStart dressing pre-operatively. Intervention: JumpStart dressing
89302783|NCT03466658|No Intervention|Control group|This group will have no intervention pre-operatively. Intervention: none
89302784|NCT04867928|Experimental|Venetoclax+azacitidine|subjects will receive treatment until alloSCT
89302785|NCT03425396|Experimental|Omadacycline 300/300 once every 24 hours|Participants received omadacycline 300 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
89302786|NCT03425396|Experimental|Omadacycline 450/300 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
89302787|NCT03425396|Experimental|Omadacycline 450/450 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
89302788|NCT03425396|Experimental|Omadacycline 450/450 once every 12 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
89302789|NCT03425396|Active Comparator|Nitrofurantoin 100/100 once every 12 hours|Participants received nitrofurantoin 100 milligrams orally, once every 12 hours, fed on Day 1 and nitrofurantoin 100 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
89302790|NCT03698734|Active Comparator|Evening primrose oil|
89302791|NCT03698734|Placebo Comparator|placebo|
89302792|NCT03695770|Experimental|target population|All the target population should be included in the experimental arm
89302793|NCT04394260||LGBT Caregivers Participating in a Focus Group|LGBT caregivers attending a focus group after watching the videos of the remote learning Savvy Caregiver Program. The focus group will guide modification of the Savvy Caregiver Program to meet the needs of LGBT caregivers of PLWD.
89302794|NCT03639350|Experimental|IER+MED group|The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
89302795|NCT03639350|Active Comparator|DASH group|The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
89302796|NCT03695692|Experimental|Connective tissue massage group|Pelvic floor exercises and connective tissue massage have been applied
89302797|NCT03695692|Experimental|Control group|Pelvic floor exercises alone have been applied
89302798|NCT03716102|Experimental|Svelte DES|Stent: A mounted Cobalt Chromium (Co-Cr) alloy based stent Polymer coating: Polyesteramide (PEA) Sirolimus drug
89302799|NCT03695614|Experimental|Cognitive Remediation|CR is a form of group therapy that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. CR is administered in groups consisting of 2-8 participants and one or two therapists. The CR groups meet twice per week for two hours per session over twelve weeks, for a total of 24 sessions.
89302800|NCT04070157|Experimental|Lofexidine|
89302801|NCT04070157|Placebo Comparator|Placebo|
88806308|NCT01161563|Active Comparator|Leuprolide acetate|Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area. Injection occurred either 6 months before or 6 months after injection of triptorelin pamoate suspension (Trelstar 22.5 mg) intramuscularly in the buttock.
88806309|NCT01161563|Active Comparator|Triptorelin pamoate|Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock. Injection occurred either 6 months before or 6 months after injection of polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) subcutaneously in upper or mid-abdominal area.
89302802|NCT04261738|No Intervention|Control|The first 2-hour session will be a control where participants will sit quietly (as they would in the hyperbaric chamber) and will not be allowed to consume carbohydrates unless directed to by the hyperbaric department hypoglycemia protocol.
89302803|NCT04261738|Experimental|Hyperbaric Oxygen|"The following day for the HBO2 session, subjects will be fitted for an oxygen hood and given a standard HBO2 treatment. In the chamber the pressure will increase to approximately 2-1/2 times normal atmospheric pressure (2.4 atmospheres absolute [ATA]). Once they reach the treatment pressure, subjects will breathe oxygen by placing the hood over their head and securing it in place. They will breathe oxygen for a 30-minute period, and then take the hood off for 5 minutes for an air break. They will have a total of three 30-minute oxygen periods and two 5-minute air breaks. A subject will be in the hyperbaric chamber for approximately 2 hours."
89302804|NCT01091337|Experimental|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
89302805|NCT01091337|Active Comparator|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
89302806|NCT04253314||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label. Decision to treat with Venetoclax was made prior to offering participation in this study.
89302807|NCT03955809|Active Comparator|Ketamine 0.5 mg/kg|ketamin 0.5 mg/kg intraarticular
89302808|NCT03955809|Active Comparator|Ketamine 1 mg/kg|ketamin 1 mg/kg intraarticular injection
89302809|NCT03955809|Sham Comparator|% 0.9 Saline|% 0.9 NaCL intraarticular injection
89302810|NCT03695536||ultrasound use during resuscitation|The group with ultrasound integrated into the resuscitation efforts.
89302811|NCT03695536||no ultrasound use during resuscitation|The group without ultrasound integrated into the resuscitation efforts.
89302812|NCT01094613|Experimental|Delayed Release 6MP|"6 Mercaptopurine delayed release oral tablet for targeted ileal delivery, to be administered once nightly before bedtime, for 12 weeks.~The dose is 2 x 40 mg DR-6MP (total dose, 80 mg DR-6MP)."
89302813|NCT01094613|Active Comparator|Purinethol|6 Mercaptopurine Tablet (50 mg) administered orally, at doses of 1-1.5 mg/kg body weight, daily for 12 weeks. Individual patient doses range from 50 mg to 150 mg, including 75, 100 and 125 mg daily, as per patient weight at baseline, and then are up-titrated to clinical efficacy at two week intervals, as needed. Doses may be down-titrated as well if occurrences of AE's warrant dose reduction.
89302814|NCT03953001|Experimental|Buzzy|Buzzy was used during Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel.
89302815|NCT03953001|Active Comparator|Control|Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel only.
89302816|NCT03695458|Placebo Comparator|Placebo-Control|Photobiomodulation Therapy with the placebo program will be applied in both legs.
89302817|NCT03695458|Active Comparator|irradiation effect Local|Photobiomodulation Therapy with the active irradiation will be applied on the exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the non-exercised leg.
89302818|NCT03695458|Active Comparator|irradiation effect Systemic|Photobiomodulation Therapy with the active program will be applied on non-exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the exercised leg.
89302819|NCT01583673|Experimental|Amino Acid Formula|Hypoallergenic baby formula
89302820|NCT01583673|Active Comparator|Amino Acid commercial formula|Hypoallergenic commercial amino acid formula
89302821|NCT04653922|Experimental|Bioengineered corneal substitute|A cell-free, sterilized bioengineered corneal substitute made from medical grade collagen
89302822|NCT03692806|Experimental|Stablor|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
89302823|NCT03692806|Placebo Comparator|placebo|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
89302824|NCT01583751|Experimental|control|excision and primer repair surgical technique will be perform
88806310|NCT03010085|Active Comparator|A (Open left-sided hepatectomy)|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
88806311|NCT03010085|Experimental|B (Laparoscopic left-sided hepatectomy)|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
89302825|NCT01097499|Active Comparator|LED application|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
89302826|NCT01097499|No Intervention|No LED application|These patients will receive conventional dental implant treatment without the application of the LED therapy.
89302827|NCT03695224||Group A|Subjects with normal topological perception
88806312|NCT01189409|Experimental|PEG then Senna|PEG in stepped bowel protocol
89302828|NCT03695224||Group B|Subjects with abnormal topological perception
89302829|NCT03692728||CC children|CC children were registered members of the Childhood Cataract Program of the Chinese Ministry of Health (CCPMOH). All of them were diagnosed with CC by two experienced pediatric ophthalmologists based on a comprehensive evaluation of the onset age (within one year after birth), morphological features of lens opacity, family history, and detailed medical records.
89302830|NCT03692728||NV children|NV children were recruited from the Optometry Department of the ZOC as the control group. NV was defined as BCVA ≥0.3 (log MAR) in children between 3-5 years old or BCVA ≥0.15 (log MAR) in children older than 5 years. Children with strabismus and high refractive error (myopia or hyperopia: >6.0 Diopters; astigmatism: >3.0 Diopters) were excluded from NV group.
89302831|NCT03694990||Short-term|Patients will be scheduled for PO follow-up visits 2 weeks, and 8 weeks after surgery.
89302832|NCT03694990||Intermediate|Patients will be scheduled for PO follow-up visits 4 weeks, and 8 weeks after surgery.
89302833|NCT03694990||Long-term|Patients will be scheduled for PO follow-up visits 8 weeks after surgery.
89302834|NCT01091415|Experimental|calcium phosphate bone cement|one arm; volar locking plate alone the other arm; calcium phosphate bone cement as well as volar locking plate
89302835|NCT03694912||Aggressive RCC Group|RCC with synchronous metastasis, recurrence, or cancer-specific death
89302836|NCT03694912||Non-aggressive RCC Group|RCC without synchronous metastasis, recurrence, or cancer-specific death
89302837|NCT00032487|Active Comparator|Standard glycemic control|Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs
89302838|NCT00032487|Experimental|Intensive glycemic control|Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1
89302839|NCT01091493|No Intervention|Non-Antibiotic|Patients will not receive antibiotics, although the study is double-blind.
89302840|NCT01091493|Active Comparator|Antibiotic|Patients will receive in a masked way, moxifloxacin.
89302841|NCT03692416|Active Comparator|Ibuprofen|"Patients in this group will receive:~Ibuprofen~Oral~At a dosage of 30 to 40 mg/kg/day, divided into 3 or 4 doses/day, max 2400 mg/day, given with food, in the form of suspension or tablets.~Duration of therapy: 4 - 6 weeks."
89302842|NCT03692416|Active Comparator|Prednisone Oral or Methylprednisolone IV|"Steroids:~Pednisone (for mild/moderate cases):~Oral~Single daily morning dosage of 0.05-2.0 mg/kg/day, or in 2 - 4 divided doses, max 80 mg/d.~Duration: 4 - 6 weeks, with gradual tapering to the lowest effective dose.~Methylprednisolone (for severe/acute cases):~IV~10-30 mg/kg/dose (max 1 g), over 1 hr daily for 1-5 days, followed by oral prednisone, with gradual tapering to the lowest effective dose.~The duration is variable according to the condition of the patient."
89302843|NCT03692416|Active Comparator|Methotrexate|"Patients in this group will receive:~Methotrexate~Oral~At a dosage of 10 to 20 mg/m2/wk (0.35 to 0.65 mg/kg/wk), max dose 25 mg/wk.~Duration of therapy: 6 - 12 weeks."
89302844|NCT03694678|Experimental|Recovering Together|Dyads who are randomly assigned to the Recovering Together program will receive any usual clinic care as determined by their clinicians. Additionally, dyads will be invited to participate in 6 30-minute skills sessions. All sessions will include both pt and cg. A clinical psychologist will deliver the majority of sessions while the PI will deliver at least 10% of the sessions. The main intervention goal is to provide dyads with resiliency and interpersonal communication skills necessary to optimize their recovery and reduce emotional distress and PTS.
89302845|NCT03694678|No Intervention|Health Education|Patients randomly assigned to the control condition will receive an educational program that mimics the dose and duration of the Recovering Together Program but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. The control will entail 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits after discharge.
89302846|NCT03594552|Experimental|Placebo, Arbaclofen_15, Arbaclofen_30|Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg
89302847|NCT03594552|Experimental|Placebo, Arbaclofen_30, Arbaclofen_15|Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg
89302848|NCT03594552|Experimental|Arbaclofen_30, Placebo, Arbaclofen_15|Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg
89302849|NCT03594552|Experimental|Arbaclofen_15, Placebo, Arbaclofen_30|Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg
89302850|NCT03594552|Experimental|Arbaclofen_15, Arbaclofen_30, Placebo|Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo
89302851|NCT03594552|Experimental|Arbaclofen_30, Arbaclofen_15, Placebo|Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo
89302852|NCT03692338|Experimental|12 week supervised exercise program|"Patients will be asked to complete 3 30-minute supervised exercise sessions/week under the guidance of the study exercise physiologist. The preferred mode will be treadmill walking, however, alternatives such as cycling or stair climbing machines will be used. For these sessions, patients will be asked to wear a heart rate monitor. Following a 5 minute warm-up, the exercise physiologist will increase speed to correspond with an intensity of approximately 80% VO2peak for 1-minute before returning to a lower speed for 1-minute (50% VO2peak). Patients will complete up to 20 of each 1-minute interval, then cool-down for 5 minutes. At the end of each higher intensity interval patients will be asked to rate their perceived exertion (RPE).~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
89302853|NCT03692338|Experimental|12 week semi-supervised exercise program|"This cohort will complete 12 weeks of a semi-supervised exercise program independently. Patients will be scheduled for an exercise session with a study exercise physiologist during clinical appointments to complete a sample intensity and time specific exercise session. The preferred mode will be walking, however cycling is also permitted. For each session the patient will wear a heart rate monitor. Following a 5 minute warm-up, patients will increase the intensity of exercise to reach a heart rate corresponding to approximately 60% VO2peak, and will continuously maintain this intensity for their individualized duration to elicit the desired energy expenditure. Each week, the exercise physiologist will call the patient and discuss how to approach the next set of exercise sessions.~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
89302854|NCT03692338|No Intervention|Control cohort|Participants will have routine care for 12 weeks. This will consist of nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks.
89302855|NCT03692260|Active Comparator|intervention group|3D stent in Herbert screw insertion vs titanium plate
89302856|NCT03692260|No Intervention|control group|titanium plate
89302857|NCT03692182||Study group|Participants enrolled in PACE who received an antipsychotic medication.
89302858|NCT03641508|Active Comparator|Triamcinolone|The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine
89302859|NCT03641508|Active Comparator|Dexamethasone|The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine
89302860|NCT03730896|No Intervention|standard care group|Normal manual therapy interventions Clinician will decide normal course of treatment
89302861|NCT03730896|Experimental|Dry needling|Dryneedling group Clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment
89302862|NCT03465878|Experimental|LY900014-Part A|Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
89302863|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part A|Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
89302864|NCT03465878|Experimental|LY900014-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
89302865|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.
89523344|NCT03381833|Active Comparator|Group A - Delayed therapy|standard chelation therapy alone for 26 weeks followed by standard chelation therapy plus LJPC-401 for 26 weeks
89302866|NCT03637374|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
89302867|NCT03637374|Other|Expanded Selection Arm|The Expanded Selection Arm will be treated the same as those in the Primary Study Arm. Your doctor will determine what arm you are in. TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
89302868|NCT01091571|Placebo Comparator|Endotoxemia placebo|Endotoxin combined with placebo
89302869|NCT01091571|Experimental|Endotoxemia Dipyridamole|Endotoxin combined with Dipyridamol treatment
89302870|NCT01091649|Active Comparator|A|Low dose ABT-450 capsule and ritonavir capsules (reference).
89302871|NCT01091649|Active Comparator|B|Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1)
89302872|NCT01091649|Active Comparator|C|Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2).
89302873|NCT01091649|Active Comparator|D|High dose ABT-450 capsule and ritonavir capsules (reference).
89302874|NCT01091649|Active Comparator|E|High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test)
89302875|NCT01091727|Experimental|Botulinum toxin A|Botulinum toxin A 300U diluted with sterile saline (1 ml per injection site) and injected into 30 sites of the bladder, sparing the trigone.
89302876|NCT01091727|Placebo Comparator|Placebo|Sterile saline 30 cc injected into 30 sites in the bladder, sparing the trigone.
89302877|NCT03421730|Experimental|AB - VR647 5 breaths, then VR647 10 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
89302878|NCT03421730|Experimental|AC - VR647 5 breaths, then VR647 20 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
89302879|NCT03421730|Experimental|AD - VR647 5 breaths, then Pulmicort|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
89302880|NCT03421730|Experimental|BA - VR647 10 breaths, then VR647 5 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
89302881|NCT03421730|Experimental|BC - VR647 10 breaths, then VR647 20 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
88806313|NCT01189409|Experimental|Senna then PEG|Stepped bowel protocol with Senna then PEG
88806314|NCT01227551|Experimental|Intratumoral injection|Each patient will receive 4 separate Coxsackievirus A21 (CVA21) administrations in the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day 22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a maximum of 10 sets of injections) until confirmed disease progression or development of excessive toxicity. Subjects with stable disease or better at Day 127 were eligible to receive up 9 more sets of CVA21 administrations under an extension protocol (VLA-008).
88806315|NCT03010475|Experimental|Furosemide/Rosuvastatin/SNAC/Semaglutide|
88806316|NCT03010553|Experimental|Oropharynx|Tumors of the oropharynx T1T2N0 treated with radiotherapy
88806317|NCT03010553|Experimental|Larynx|Tumors of the T1T2N0 larynx treated by surgery, laser or robot
88806318|NCT01227785||INCEPTA ICD and CRT-D|ICD and CRT-D indicated patients were included in the study. Overall patient population, CRT-D or ICD populations, and patients experiencing or not experiencing a protocol-defined heart failure event were included (dependent on outcomes measured).
88806319|NCT02191865|Experimental|Mild liver impairment|Patients with mild hepatic impaired function (Child-Pugh A)
88806320|NCT02191865|Experimental|Moderate liver impairment|Patients with moderate hepatic impaired function (Child-Pugh B)
88806321|NCT02191865|Experimental|Healthy volunteers|Healthy control subjects
88806322|NCT04352465|Experimental|A|Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
88806323|NCT04352465|Experimental|B|Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
88806324|NCT04352465|Experimental|C|Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
89302882|NCT03421730|Experimental|BD - VR647 10 breaths, then Pulmicort|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
89302883|NCT03421730|Experimental|CA - VR647 20 breaths, then VR647 5 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
89302884|NCT03421730|Experimental|CB - VR647 20 breaths, then VR647 10 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
89302885|NCT03421730|Experimental|CD - VR647 20 breaths, then Pulmicort|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
89302886|NCT03421730|Experimental|DA - Pulmicort, then VR647 5 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
89523345|NCT03381833|Active Comparator|Group B - Immediate therapy|standard chelation therapy plus LJPC-401 for 52 weeks
89523346|NCT03377465|Experimental|Experimental Group|Patients with stroke of undetermined cause age 18-65
89302887|NCT03421730|Experimental|DB - Pulmicort, then VR647 10 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
89302888|NCT03421730|Experimental|DC - Pulmicort, then VR647 20 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
89302889|NCT01094925|Placebo Comparator|Placebo|
89302890|NCT01094925|Active Comparator|Gabapentin 300mg|
89302891|NCT01094925|Active Comparator|Gabapentin 600mg|
89302892|NCT03694444|Active Comparator|AMY-101 treatment|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the AMY-101 treatment arm after clinical assessments and sample collection at baseline, test treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
89302893|NCT03694444|Placebo Comparator|Placebo|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the placebo arm, after clinical assessments and sample collection at baseline, placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
89302894|NCT03715868|Active Comparator|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
89302895|NCT03715868|No Intervention|Milked derived protein source formula diet|Formula diet based on a milked derived protein source
89302896|NCT03701932|Experimental|TMS and Lumosity® cognitive retraining|Group will receive TMS and will concurrently engage in cognitive retraining exercises comprised of the Lumosity® battery.
89302897|NCT03701932|Active Comparator|TMS and non cognitive computer games|Group will receive TMS while concurrently engaging in selected computer games from several gaming software that includes Play 101 Games and Hoyle Puzzle and Board Games®. They will also be allowed to spend time on gaming activities of their choice in order to keep them engaged
89302898|NCT04841876||Group-1|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-1, participants will be asked to play three consecutive rugby matches, with 40 min for each match. The total duration will be 2 hours. There is no additional intervention on this group.
89302899|NCT04841876||Group 2|Participants who are professional rugby-7s plays will be randomly assigned to one of the two groups. For Group-2, participants will be asked to only watch the rugby matches. They will not received any intervention.
89302900|NCT03694366||Five facilities in Bassar District|Estimated population of 34,676 served by five public sector facilities in Bassar District.
89302901|NCT03694366||Seven facilities in Binah District|Estimated population of 31,027 served by seven public sector facilities in Binah District.
89302902|NCT03694366||Four facilities in Dankpen District|Estimated total population of 40,165 served by four public sector facilities in Dankpen District.
89302903|NCT03694366||Five facilities in Kéran District|Estimated total population of 31,866 served by five public sector facilities in Kéran District.
89302904|NCT03718676|Other|Ferric sulphate|Group FS. Teeth in this goup will pulpotomized with ferris-sulphate.
89302905|NCT03718676|Experimental|Orto-mta|Group O-MTA.Teeth in this goup will pulpotomized with Ortho-mta.
89302906|NCT03718676|Experimental|Retro-mta|Group R-MTA. Teeth in this goup will pulpotomized with Retro-mta.
89302907|NCT00054327|Experimental|Regimen A|Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.
89302908|NCT00054327|Experimental|Regimen B-1|Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..
89302909|NCT00054327|Experimental|Regimen B-2|Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.
89302910|NCT00054327|Experimental|Regimen C|Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.
89302911|NCT00054327|Experimental|Regimen B-3|Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.
89302912|NCT00054327|Experimental|Regimen D|Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.
89302913|NCT03503162|Experimental|Colonoscopy with Pure-Vu System|Standard colonoscopy procedure with Pure-Vu System
89302914|NCT03952689|Experimental|Post cardiac surgery patients|For all patients, readings of the urine output from both the Serenno system and the collection bag (urinometer) (by camera) will be recorder every 10 minutes, for the duration of 24 hours.
89302915|NCT03029650|Active Comparator|Transderm Scop®|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
89302916|NCT03029650|Experimental|Intravenous scopolamine hydrobromide|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
89302917|NCT03462680|Active Comparator|niacin|Niacin 250 mg is compared to placebo tablet.
89302918|NCT03462680|Placebo Comparator|placebo|placebo
89302919|NCT03694132|Experimental|functional MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical and mechanical stimuli of ADM proprioceptors
89523347|NCT03377465|Active Comparator|Comparative group|Healthy patients age 18-65
89302920|NCT03694132|Experimental|structural MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have diffusion MRI acquisition to evaluate their brain structures
89302921|NCT03694132|Experimental|EEG/MEG|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical stimuli of ADM proprioceptors
89302922|NCT03952845|Experimental|Intranasal Capsaicin|Separate patients will be given escalating doses of intranasal capsaicinoid spray
89302923|NCT03692026|Experimental|Study group|Immediate implant placement in fresh extraction sockets with addition of Hyaluronic acid and Melatonin mixture to the implant surface, into the extraction socket and to the peri-implant area.
89302924|NCT03692026|Active Comparator|Control group|Immediate implant placement in fresh extraction sockets without adding any material.
89302925|NCT01095081||Group 1|
89302926|NCT03624322|Active Comparator|Period 1|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)
89302927|NCT03624322|Experimental|Period 2|Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)
89302928|NCT01097811|Active Comparator|Erythromycin|
89302929|NCT01097811|Active Comparator|Neomycin|
89302930|NCT03957291|Active Comparator|Povidine-Iodine|patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye before operation
89302931|NCT03957291|Active Comparator|chlorhexidine|patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye before operation
89302932|NCT01091883|Experimental|Exablate treatment|Exablate 2000
89302933|NCT01091883|Active Comparator|Radiation|External Beam Radiation
89302934|NCT04044976|Experimental|Treated infants|Infants who will receive caffeine in the delivery room.
89302935|NCT01097889|Active Comparator|Treatment Group 1|
89302936|NCT01097889|Experimental|Treatment Group 2|
89302937|NCT04300270||Validation cohort|Participants in validation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
89302938|NCT04300270||Clinical implementation cohort|Participants in a clinical implementation of the novel smartphone-based photoplethysmographic method for ambulatory heart rhythm diagnostics.
89302939|NCT03955653|Active Comparator|RAO projection|Patients will be randomized to right anterior oblique (RAO) projection by fluoroscopy for the access to the femoral artery
89302940|NCT03955653|Active Comparator|AP projection|Patients will be randomized to anterior-posterior projection by fluoroscopy for the access to the femoral artery
89302941|NCT03691636|Experimental|Eyelash Prostheses|Each subject in this arm will receive eyelash prostheses according to a specified algorithm by a certified eyelash extensions.
89302942|NCT03691636|Active Comparator|5.0% Lifitegrast Ophthalmic Solution|Each subject in this arm will receive 5.0% Lifitegrast eye drops BID
89302943|NCT01095159|Active Comparator|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
89302944|NCT01095159|Active Comparator|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
89302945|NCT04295902|Experimental|VL-group|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Germany) with blades Miller nr 0 and Miller nr 1.
89302946|NCT04295902|Active Comparator|DL-group|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
89302947|NCT01094847|Experimental|Treatment A|DWJ1252 given by oral administration under fasting conditions
89302948|NCT01094847|Active Comparator|Treatment B|DWJ1252 given by oral administration, 30 minutes after a meal
89302949|NCT01094847|No Intervention|Treatment C|mosapride by oral administration 30 minutes before meals
89302950|NCT01097967|Active Comparator|CPAP in sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
89302951|NCT01097967|No Intervention|no CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
89302952|NCT01097967|Active Comparator|CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
89302953|NCT03691558|Experimental|Ketogenic diet|Subjects followed 5 weeks of ketogenic diet
89302954|NCT03691558|Active Comparator|Western Diet|Subjects followed 5 weeks of a western diet
89302955|NCT01091961|Active Comparator|Continuing ACEi/ARB|Patients in this group will continue to take their chronic ACEi/ARB medications up to and including the day of surgery.
89302956|NCT01091961|Active Comparator|Holding ACEi/ARB|Patients in this arm will hold their chronic ACEi/ARB medication at least 24 hours prior to surgery.
89302957|NCT03955965||Emergency patients with medication reconciliation|All patients who beneficiated from medication reconciliation in the emergency department between November 2017 and April 2018
89302958|NCT01098045||HIV-infection with fat redistribution (lipoatrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-24 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~No evidence of fat redistribution rated by the investigator."
89302959|NCT01098045||Healthy controls|"No history of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-29.9 kg/m2"
89302960|NCT01098045||HIV-infected with fat redistribution (lipohypertrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 25-29.9 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck."
89302961|NCT01098045||Dicer Cohort|30 men [HV-infected with fat redistribution (n = 10), HIV-infected without fat redistribution (n=10), and healthy controls (n= 10)] will be recruited for this group.
89302962|NCT03956121||Exposed group|Exposed group( with magnesium sulfate): fetuses aged 24 + 0AW to 32 + 0AW and benefiting from MgSO4 for neuroprotective purposes, with decision of extraction or spontaneous or induced labour
89302963|NCT03956121||Control group|Control group (without magnesium sulfate) : fetuses aged 32 + 1SA to 35 + 0SA without MgSO4, with extraction decision or spontaneous or induced labour
89302964|NCT01098123||Diet counseling, nutritional index|Lightweight as athletes with weight limit
89302965|NCT01098123||nutritional index|Heavyweight athletes without weight limit
89302966|NCT03636906|Experimental|RSV1D Pooled Group|"Subjects received the interventions as follows:~Either 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31 and any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine or GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 61, 121 and at the end of RSV season 1).~Or 1 dose of experimental RSV (GSK3389245A) lower dose formulation at Day 1, followed by 1 dose of Placebo at Day 31."
89302967|NCT03636906|Experimental|RSV2D Pooled Group|"Subjects received the interventions as follows:~Either 2 doses of experimental RSV (GSK3389245A) higher dose formulation (administered at Day 1 and Day 31) and followed by any one the following active comparators: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 61 and at the end of RSV season 1) or 3 doses of GSK's multicomponent meningococcal B vaccine or Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine or GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 61, 121 and at the end of RSV season 1).~Or 2 doses of experimental RSV (GSK3389245A) higher dose formulation administered at Day 1 and Day 31."
89302968|NCT03636906|Active Comparator|Comparator_Placebo Pooled Group|"Subjects received either one of interventions schedules as follows:~3 doses of GSK's multicomponent meningococcal B vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121).~3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Days 1, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 31 and 121).~3 doses of GSK's pneumococcal polysaccharide conjugate vaccine (administered at Days 31, 61 and at the end of RSV season 1) and 2 doses of Placebo (administered at Day 1 and Day 121).~2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine (administered at Day 31 and at the end of RSV season 1) and 2 doses of Placebo (administered at Days 1 and 61) .~2 doses of Placebo alone (administered at Days 1 and 31)."
89302969|NCT03028870|Experimental|V120083 30 mg|V120083 30-mg capsules taken orally twice daily
89302970|NCT03028870|Experimental|V120083 60 mg|V120083 60-mg (2 x 30 mg) capsules taken orally twice daily
89302971|NCT03028870|Active Comparator|Naproxen|Naproxen 500-mg capsules taken orally twice daily
89302972|NCT03028870|Placebo Comparator|Placebo|Capsules to match V120083 and/or naproxen taken orally twice daily
89302973|NCT01092039|Experimental|XIGO pill|Oral Xigo tablet
89302974|NCT01092039|Placebo Comparator|Placebo|Oral placebo tablet
89302975|NCT03694054|Experimental|Care coordination patients, caregivers|Patients and caregivers enroll in using care coordination tool during oncology care and treatment.
89302976|NCT03694054|No Intervention|Standard of care patients, caregivers|Patients and caregivers receive oncology care and treatment.
89302977|NCT03694054|Experimental|Oncology Care Providers|Oncology care providers with patients enrolled in care coordination tool.
89302978|NCT01092273||Bimatoprost versus Travoprost|
89302979|NCT03663582|Experimental|Teduglutide 0.05 mg|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.
89302980|NCT01098357|Experimental|Biochaperone PDGF-BB low dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
89302981|NCT01098357|Experimental|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
89302982|NCT01098357|Active Comparator|Regranex|Becaplermin gel (Regranex® Gel 0.01%, Systagenix, formerly and Johnson & Johnson) is a topical gel of rhPDGF-BB conditioned in a gel tube.
89302983|NCT01098357|Experimental|Very Low Dose BioChaperone PDGF-BB|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
89302984|NCT03955731|Other|Single study arm|STEMI Patients treated with Magmaris resorbable magnesium scaffold
89302985|NCT03730740|Experimental|Lenalidomide|Administer the study drug in the following way with 28 days as one cycle. Lenalidomide 25mg Days 1-21 Dosing continues until disease progression is confirmed.
89302986|NCT01098513|Experimental|Part A|Subjects will be randomized in a three-way crossover design to receive a single dose of each of three different tablet formulations of GSK1349572 50 mg (2 tablets). Formulation AP, AW and AX.
89302987|NCT01098513|Experimental|Part B|A total of 18 subjects who complete Part A will return for Part B. Subjects from Part A will be asked to participate on a first come first served basis until there are 18 subjects, at which time enrolment to Part B will be closed. Part B will be a three way crossover design using either formulation AW or AX depending upon the results from Part A. Subjects will receive a single dose of 50 mg GSK1349572 with either a low fat, moderate fat or high fat meal in each period.
89302988|NCT05666154|Active Comparator|Real diet|Diet excluding the trigger nutrient identified by an acute mucosal reaction in CLE
89302989|NCT05666154|Sham Comparator|Sham diet|Diet excluding a sham nutrient without acute mucosal reaction in CLE
89302990|NCT05666154|Active Comparator|Wheat exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
89302991|NCT05666154|Active Comparator|Soy exclusion diet|In patients without identified trigger nutrient (i.e. no acute mucosal reaction to any nutrient), wheat will be excluded as an empirical diet in crossover fashion with soy.
89302992|NCT03732690|Other|Diet High Protein (HP)|Diet High Protein (HP) : 30% protein, 40% carbohydrate and 30% fat
89302993|NCT03732690|Other|Diet Low Protein (LP)|Diet Low Protein (LP) : 10% protein, 55% carbohydrate and 35% fat
89302994|NCT03688048|Experimental|Bright light treatment|Single-dose bright light treatment (1 hour, 10 000 lux)
89302995|NCT03688048|Placebo Comparator|Sham placebo|Deactivated negative ion generator in conjunction with a plausible cover story
89302996|NCT03732612||Control patients|"Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as healthy vessels in our study."
89302997|NCT03732612||Study patients|"Study patients (n=150): In individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue is sometimes excised to facilitate the surgery. Biopsies from these individuals will be categorized as vessels with vascular dysfunction."
89302998|NCT03693976||Ectoin Rhinosinusitis Nasal Spray|application of 1-2 sprays of SNS01 into each nostril several times a day
89302999|NCT03693976||Xylometazoline nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
89303000|NCT03693976||Xylometazoline + Ectoin Nasal Spray|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day
89303001|NCT03730584|Experimental|Patient with Hereditary Epidermolysis Bullosa|
89303002|NCT03502616|Experimental|Tofacitinib|
89303003|NCT03502616|Placebo Comparator|Placebo|
89303004|NCT04003012|Active Comparator|EMLA|The patient will receive 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure. The site of EMLA application will be covered with Tegaderm dressing.
89303005|NCT04003012|Active Comparator|Lidocaine|The patient will receive sham-EMLA cream (a fragrance-free hypoallergenic moisturizer cream) will be applied at least 60 minutes per standard protocol with Tegaderm dressing.- Following conscious sedation, the patient will receive lidocaine 1% injection (~1-2ml) at the appropriate site 30-60 seconds prior to LP needle insertion.
89303006|NCT03693898|Other|Persons with collagen VI defect|Observational
89303007|NCT03992560|No Intervention|Standard CRT implantation|
89303008|NCT03992560|Experimental|MRI guided CRT implantation|
89303009|NCT03691324|Experimental|Intervention|Patients receive an inhalation technique education based on standardized procedure developed by The Norwegian Pharmacy Association. In addition they are offered a discharge service day before or the day of discharge; a second inhalation training and dispensing of their prescribed COPD- medicines.
89303010|NCT03691324|No Intervention|Standard care|Patients receive standard care and follow up of their COPD-treatment
89303011|NCT05666076|Active Comparator|Group PENG|The investigators performed a pericapsular nerve block on that patient group for postoperative analgesia.
89303012|NCT05666076|Active Comparator|Group SSNB|The investigators performed a suprascapular nerve block on that patient group for postoperative analgesia.
89303013|NCT03028012|Experimental|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI.
89303014|NCT03028012|Experimental|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI.
89303015|NCT03028012|Experimental|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI.
89303016|NCT03635190|Experimental|Interventional|Orbital Circumferential Atherectomy
89303017|NCT03693820|Active Comparator|the infiltration group|a cocktail of 5 mg/Kg lidocaine normal saline in a volume of 3 ml/Kg 5 mcg/ml adrenaline. We will administrate 5 ml lidocaine at each port site before incision, then immediately after the creation of the pneumoperitoneum, the surgeon will spray 50-75 ml of the total solution on the upper surface of the liver under the right sub-diaphragmatic space and another 50-75ml over the parietal peritoneum. The Trendelenburg position will be maintained for 2 minutes. Then 50 ml will be infiltrated in the bladder bed and pedicle after clamping of the cystic duct and artery. Infiltration will be through a laparoscopic suction needle, diameter 0.9 /330 mm (Zhejiang, China).
89303018|NCT03693820|Placebo Comparator|the control group|the same technique but the 50 ml for gallbladder infiltration will be replaced by saline.
89303019|NCT03634800|Experimental|nivolumab/radiotherapy|"All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy (6 Gy x 5 fractions) to a targetable lesion.~Nivolumab 240 mg IV starts with the first radiotherapy fraction 240 mg IV every 2 weeks from first radiotherapy fraction until disease prograssion or dose limiting toxicity is reached~Radiotherapy Dose of 6 Gy x 5 days will be given (patients will receive 1 fraction over 5 days for a total of 5 fractions) during the first week of starting Nivolumab"
89303020|NCT03027466|Experimental|Baseline Affirmation and Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study and will receive affirmation text messages throughout the study"
89303021|NCT03027466|Active Comparator|Baseline Affirmation and No Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study but will not receive affirmation text messages throughout the study"
89303022|NCT03027466|Active Comparator|No Baseline Affirmation and Affirmation Texts|"Participants will not be given a Baseline Affirmation Quiz but will receive affirmation text messages throughout the study"
89303023|NCT03027466|Placebo Comparator|No Baseline Affirmation and No Affirmation Texts|Participants will experience the Smoke Free United Kingdom (UK) app without any affirmation content Smoke Free UK app (no baseline affirmation quiz and no affirmation text messages)
89303024|NCT03662334|Experimental|Hylenex recombinant|Comparing the preadministration of Hylenex recombinant in the setting of continuous subcutaneous insulin infusion (CSII).
89303025|NCT03662334|Sham Comparator|Sham Injection|Comparing the preadministration of a sham injection in the setting of CSII.
89303026|NCT03624088|Experimental|Single-Arm Intervention|Participants will complete a baseline questionnaire. They will then self-administer the web-based decision aid, RealRisks. Upon completion, they will complete two more surveys: one within 1 month of completing RealRisks and one six months after completing RealRisks.
88806325|NCT01191749|Experimental|Alemtuzumab|Alemtuzumab 10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
89303027|NCT04641052|Experimental|Music Intervention Group|The music intervention group will be listened to the music by the researchers for the duration of 15 minutes before the procedure as well as the standard care.
88806326|NCT01191827||risperidone|
89303028|NCT04641052|No Intervention|No Intervention Group|The control group patients will receive standard care only
89303029|NCT02955186|Experimental|125 mg saracatinib|Participants will take 125 mg of saracatinib daily for 8 days.
89303030|NCT02955186|Placebo Comparator|Placebo|Participants will take placebo daily for 8 days.
89303031|NCT03690934|Experimental|Fistula-tract laser closure (FiLAC™)|The treatment technique consists of laser coagulation of fistulous tract walls with a diode laser with a wavelength of 1470 nm, which leads to thermo-obliteration of the fistulous tract.
89303032|NCT03690934|Active Comparator|Fistula monopolar cogulation|The treatment technicque consists of monopolar coagulation of fistulous tract walls with suturing the internal fistulas opening.
89303033|NCT03737682||hemostasis achievement|in which hemostasis at the exposure site was achieved in five minutes were included in group A
89303034|NCT03737682||No hemostasis achievement|in which hemostasis at the exposure site couldn't be achieved in five minutes where included in group B
89303035|NCT03693508|Experimental|Arm 1|Naive HIV patients with severe immunosuppression.
89303036|NCT05089032||Physicians|
89303037|NCT05089032||Nurses|
89303038|NCT03693352||Patients undergoing surgeries|Patients ASA 1-3, undergoing different types of general anesthesia that need postural changes like Trendelenburg and anti-Trendelenburg positioning.
89303039|NCT03730506|Experimental|CBCT|
89303040|NCT03730506|Experimental|IOS|
89303041|NCT03730506|Active Comparator|desktop scanner|
89303042|NCT03690856|Experimental|depressiv people|
89303043|NCT03721250||thoracic epidural|patients receiving thoracic epidural
89303044|NCT03690778|Experimental|Group I|"Period I: administration of Metformin and Rosuvastatin seperately Period II: JLP-1310"
89303045|NCT03690778|Experimental|Group II|"Period I: JLP-1301 Period II: administration of Metformin' and Rosuvastatin seperately"
89303046|NCT03715634|Experimental|Depot buprenorphine (INDV-6200)|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive depot buprenorphine
89303047|NCT03715634|Placebo Comparator|Placebo|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive volume-matched placebo
89303048|NCT03693274|Experimental|Mindfulness Course|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center and will also be given access to BreatheAware for Pain Management, a 16- week web-based mindfulness course.
89303049|NCT03693274|No Intervention|Usual Care|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center.
89303050|NCT03502070|Other|Open-Label Placebo|One dose (4 capsules) of placebo
89303051|NCT03715556|Active Comparator|Amiodarone|Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated. Administration of the drug will be blinded within the first hour to the principal investigator.
89303052|NCT03715556|Placebo Comparator|No intervention|The Liberal group will receive only 0.9% physiological solution, also blinded to the principal investigator.
89303053|NCT03586830|Experimental|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
89303054|NCT03586830|Experimental|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
89303055|NCT03586830|Experimental|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
89303056|NCT03586830|Placebo Comparator|Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
89303057|NCT03026530|Experimental|Pulmonary recruitment maneuver|Ventilator-piloted pulmonary recruitment maneuver at the end of laparoscopic bariatric surgery.
89303058|NCT03026530|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic bariatric surgery.
89303059|NCT03418376|Experimental|MS beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
88806327|NCT01191827||clozapine|Patients with schizophrenia treated with clozapine
88806328|NCT04934696|Experimental|BMS-986166 + Oral contraceptive|
88806329|NCT01192139|Experimental|5 mg saxagliptin + a single 500 mg metformin XR tablet|
88806330|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)|under fed state
88806331|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)|under fasted state
89303060|NCT03418376|Placebo Comparator|MS placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
89303061|NCT03418376|Experimental|HC beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
89303062|NCT03418376|Placebo Comparator|HC placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
89303063|NCT03730038|Experimental|Pitavastatin treatment|Treatment of pitavastatin 4 mg qd for 12 weeks
89303064|NCT03730038|Active Comparator|Life-style modification|
89303065|NCT03693196|Other|Straumann®|Titanium implants the surfaces of which were roughened with SLA (sandblasted and acid-etched titanium surface) (Straumann®, Basel, Sweden). Immunological parameters (PICF, Perio-paper®) , microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
88806332|NCT04924400|Active Comparator|CHIP Program|GHP members randomized to the intervention arm will participate in the CHIP Program.
88806333|NCT04924400|Active Comparator|Usual Diabetes Care|GHP members assigned to the control arm will receive the routine standard of care for GHP members.
88806334|NCT01229423|Experimental|LATISSE®|bimatoprost 0.03% (LATISSE®)
88806335|NCT01283321|Experimental|Group A: RiaSTAP|Human fibrinogen concentrate
89303066|NCT03693196|Other|Astra Tech, OsseoSpeed™|Implants the surfaces of which were roughened by modifying with fluorine (Astra Tech, OsseoSpeed™, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
89303067|NCT03693196|Other|Nobel Biocare, Replace®|Implants the surfaces of which were roughened by anodization (TiUnite Nobel Biocare, Replace® Conical Connection, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis(subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
89303068|NCT03730350|Experimental|Hypnosis|Prior to surgery, a member of the pain psychology team will guide patients through a clinical hypnosis session aimed at preparing for surgery by reducing anxiety and introducing relaxation and self-soothing strategies that can be used after surgery for adaptive coping. They will also be provided with a recording of this hypnosis script to use at home, and it will be recommended that they listen to the recording on the two days prior to surgery. Following surgery, a clinician from the pain psychology team will visit the patient in hospital on post-operative day one or whenever they are able to be seen prior to hospital discharge, in order to guide them through a clinical hypnosis session targeted at increasing comfort and pain relief.
89303069|NCT03730350|No Intervention|Standard Care|This control group will receive standard care pre- and post-surgery. After the completion of their one-month trial, control participants will be offered access to the hypnosis recordings, as well as an in-person hypnosis session.
89303070|NCT03693118|Experimental|Grup1, Grup2|
89303071|NCT03693118|Experimental|Grup1,Grup2|
89303072|NCT03725904|Experimental|IVF/FET|
89303073|NCT03687424|Active Comparator|Normal weight 18<BMI<30 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89303074|NCT03687424|Active Comparator|Obese 30<BMI<40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89303075|NCT03687424|Active Comparator|Morbidly obese BMI ≥40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
89303076|NCT03687424|Experimental|Normal weight 18<BMI<30 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89303077|NCT03687424|Experimental|Obese 30<BMI<40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89303078|NCT03687424|Experimental|Morbidly obese BMI ≥40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
89303079|NCT03585504|Experimental|Intervention group|Patients will undergo etonogestrel contraceptive implant insertion prior to hospital discharge per package instructions.
89303080|NCT03585504|Active Comparator|Control Group|These patients will receive an appointment to undergo etonogestrel contraceptive implant insertion at the postpartum visit occuring approximately six weeks after delivery as is standard care in our institution.
89303081|NCT03417830|Experimental|Subjects with ATTR-CM in Part A|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part A will participate in two anti-SAP dosing sessions approximately 26 days in duration. The first two subjects in Part A will have up to three 89Zr PET scans, while the remaining subject will undergo up to two 89Zr PET scans.
89303082|NCT03417830|Experimental|Subjects with ATTR-CM in Part B|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
89303083|NCT03692962|Sham Comparator|Sleep restriction without acoustic stimulation|
89303084|NCT03692962|Experimental|Sleep restriction with acoustic stimulation|
89303085|NCT03729882|Other|EUS-guided gallbladder drainage|"In one arm, Endoscopic Ultrasound-Gallbladder Drainage (EUS-GBD) will be performed by using a 3,8 mm therapeutic echoendoscope and a lumen apposing metal stent ( Hot AXIOS™ Stent and Electrocautery Enhanced Delivered System; Boston Scientific Corporation, Natick, MA, USA) after conventional biliary drainage with self-expandable metallic stents during endoscopic retrograde cholangiopancreatography (ERCP).~All procedures will be performed under general anesthesia."
89303086|NCT03729882|Other|Non EUS-guided gallbladder drainage|"In the other arm, patients will undergo conventional biliary drainage with self-expandable metallic stent placement during ERCP evaluation without prophylactic EUS-GBD and will be considered as a Non EUS-guided gallbladder drainage.~All procedures will be performed under general anesthesia."
89303087|NCT03690622|Sham Comparator|BSS|Balanced salt solution
89303088|NCT03690622|Active Comparator|Dexmedetomidine|dexmedetomidine (0.0055%)
89303089|NCT03639636|Other|interventional prospective study|nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
89303090|NCT03683134|Experimental|Mediterranean diet group|Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.
89303091|NCT03683134|Active Comparator|American Heart Association group|Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.
89303092|NCT03683056|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
89303093|NCT03683056|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
89303094|NCT03576768|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
89523348|NCT02929849|Experimental|300mg SC|300 mg Salacia Chinensis (SC). This will be compared to placebo.
89303095|NCT03576768|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
89303096|NCT03576768|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
89303097|NCT03576768|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
89303098|NCT03682822|Experimental|Early artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
89303099|NCT03682822|Active Comparator|Delayed artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
89303100|NCT03715400|No Intervention|Control|The control group will not undergo the positive virtual reality training program. Instead, they will complete all self-report and behavioral measures and have the option to experience the positive virtual reality training program upon the conclusion of the study.
89303101|NCT03715400|Experimental|Positive Virtual Reality Training Intervention|The experimental group will undergo the positive virtual reality training program, which consists of 7 virtual reality (VR) sessions to be completed at home after orientation to the program, in addition to all self-report and behavioral measures.
89303102|NCT03690310|Experimental|Anti-CD19 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19 CAR NK cells will be administered at day0
89303103|NCT03715322|Active Comparator|tobramycin inhalation|300mg tobramycin dissolved in 5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
89303104|NCT03715322|Placebo Comparator|natural saline inhalation|5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
89303105|NCT03715322|Other|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
89303106|NCT03690232|Experimental|Glucose group|The glucose group underwent 3 sessions of 6cc 25% glucose injection with a 2-week interval between each treatment
89303107|NCT03690232|Active Comparator|hyaluronic acid group|The HA group was administered intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment.
89303108|NCT03687268|Placebo Comparator|Placebo|
89303109|NCT03687268|Experimental|Naloxone 24 mg|
89303110|NCT03687268|Experimental|Naloxone 48 mg|
89303111|NCT03682666|Active Comparator|KT group|the patients will perform Kinesiotaping for 5 days per week for 3 weeks
89303112|NCT03682666|Sham Comparator|mCIMT group|"the unaffected limb will be constraint for 2 hours a day, 5 days a week for three weeks.~And they will receive sham taping on the affected limb."
89303113|NCT03682666|Experimental|KT+mCIMT group|the patients will perform Kinesiology taping for 5 days per week for 3 weeks, and while being taped, the modified Constraint Induced Movement Training would be also executed.
89303114|NCT03576066|Experimental|ABI-H0731 + SOC NUC|Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
89303115|NCT03576066|Active Comparator|Placebo + SOC NUC|Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
89303116|NCT03557034|No Intervention|Standard of Care Monitoring|Standard of Care
89303117|NCT03557034|Experimental|Kardia Monitoring|Kardia Mobile/Kardia Pro
89303118|NCT03639480|Experimental|Test|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
89303119|NCT03639480|Active Comparator|Reference 1|Amlodipine 10mg+Valsartan 160mg
89303120|NCT03639480|Active Comparator|Reference 2|Valsartan 160mg+Atorvastatin 40mg
89303121|NCT03583554|Placebo Comparator|Placebo, then AV-101 720mg, then AV-101 1440mg|Participants first received oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules).
89303122|NCT03583554|Experimental|AV-101 720mg, then AV-101 1440mg, then placebo|Participants first received oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules). After at least 3 days wash-out participants get oral placebo.
89303123|NCT03583554|Experimental|AV-101 1440mg, then placebo, then AV-101 720mg|Participants first received oral AV-101 1440mg (matching placebo capsules). After at least 3 days wash-out participants get oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules).
89303124|NCT03690076||Control|patients with normal weight (23 < BMI < 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
89303125|NCT03690076||Endocarditis|patients with normal weight (23 < BMI < 27) carriers of endocarditis with surgery indication
89303126|NCT03690076||Obese|obese patients (BMI > 30 with waist to hip ratio > or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
89303127|NCT03682510|Active Comparator|stepwise devascularization|routine stepwise devascularization
89523349|NCT02929849|Active Comparator|500mg SC|500 mg Salacia Chinensis (SC). This will be compared to placebo.
89523350|NCT02929849|Placebo Comparator|Placebo|The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.
89523351|NCT03381755|Experimental|half-dose ticagrelor|
89303128|NCT03682510|Active Comparator|B-Lynch Transverse Compression Suture|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side."
89303129|NCT03682510|Experimental|N&H technique|"In the N&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade. As follow:~(i) 100-cm Vicryl no. 1 was thrown to form two nearly equal parts (each 50 cm) on a blunt semicircular 70-mm needle, the curve of the needle was straightened.~(ii) The needle transfixed the right side of the uterine wall from anterior to posterior, about 2 cm below the hysterotomy incises posterior, then the needle transfixed the left side of the uterine wall from posterior to anterior, about 2 cm below the hysterotomy incision."
89303130|NCT03729726|Experimental|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model will include: a mandatory school-year program that offers after-school programming 4 days a week, including 120 hours of education (direct instruction & homework support), 30 hours of health (social emotional learning & sexual health), and 15 hours of student advocacy; an optional, 4-week summer program that offers 120 hours of programming each summer, including 16 hours of health (social emotional learning - service learning), 104 hours of project-based learning and enrichment (project-based learning in STEM - 64 hours) and enrichment (i.e., field trips, career speakers, and arts and crafts opportunities- 40 hours); and an optional parent engagement program, which will offer monthly parent workshops and quarterly events.
89303131|NCT03729726|No Intervention|Control|
89303132|NCT03689998|Experimental|implant placement with melatonine|immediate implant placement with melatonine
89303133|NCT03689998|Active Comparator|immediate implant placement alone|immediate implant placement alone
89303134|NCT03722160|Other|Solo Tympanostomy Tube Device|The Solo Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
89303135|NCT03729492|Other|CTEPH/CTED work-up|
89303136|NCT03729414|Active Comparator|mucopexy with Doppler artery ligation|Doppler guided hemorrhoidal artery ligation and mucopexy: Group of patients with III degree hemorrhoids treated by THD or AMI device is introduced into the anal canal. The terminal branches of the rectal artery are detected by the Doppler 2-3 cm above the dentate line. The tip of the instrument is tilted and arteries ligated with a figure-of-eight suture inserted using a special needle-holder. After the haemorrhoid artery ligation, the suture is continued with 3/5 sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all artery ligations (6 ligations
89303137|NCT03729414|Experimental|mucopexy without Doppler artery ligation|Non Doppler guided hemorrhoidal artery ligation and mucopexy: A lubricating gel is applied to the tip of the THD or the AMI device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. the mucopexy will start at two o'clock and repeated at 4, 6 8, 10, 12, in clockwise direction
89303138|NCT03687112||Alzheimer desease and related disorders|Alzheimer desease and related disorders
89303139|NCT03725748|No Intervention|no irrigation group|nothing used for irrigation of cs scar
89303140|NCT03725748|Placebo Comparator|saline irrigation group|saline used for irrigation the cs scar before closure
89303141|NCT03725748|Experimental|betadine irrigation group|betadine used for irrigation of cs scar
89303142|NCT03725670|Experimental|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene
89303143|NCT03948178|Experimental|Levosimendan|Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.
89303144|NCT03940144|Experimental|goal-directed fluid therapy|Stroke Volume variation (SVV)-guided fluid therapy
89303145|NCT03940144|Active Comparator|Conventional fluid therapy|Conventional fluid therapy such as CVP and MAP guided fluid therapy
89303146|NCT03689764|Experimental|Group A|Group A underwent interactive video game-based exercise for the initial 6 weeks, with no treatment in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
89303147|NCT03689764|Experimental|Group B|Group B had no intervention in the first 6 weeks and then received interactive video game-based exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
89303148|NCT03689686|Experimental|Patients|Fifteeen children with Acute Respiratory Failure admitted to a PICU, needing noninvasive respiratory support
89303149|NCT03687034|Experimental|BRCX014|Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).
89303150|NCT03798574||IMD Case|No intervention
88806336|NCT01283321|Active Comparator|Group B: apheresis platelets|single apheresis unit
88806337|NCT01229891|Placebo Comparator|Plain yogurt drink|daily intake of two bottle (250 mL) plain yogurt drink
88806338|NCT01229891|Experimental|vitamin D-fortified yogurt drink|daily intake of two bottle yogurt drink fortified with 500 IU vitamin D/250 mL
89303151|NCT03798574||Control|No intervention
89303152|NCT03795610|Experimental|Arm A: IPI-549 40 mg PO qdaily|Patients enrolled in Arm A will receive IPI-549 40 mg by mouth daily for at least 14 days
89303153|NCT03682354|Active Comparator|Intercostal Nerve Block with PCIA|Intercostal Nerve Block with patient-controlled intravenous analgesia
89303154|NCT03682354|Experimental|Erector Spinae Plane Block (ESPB)|Continuous Erector Spinae Plane Block
89303155|NCT03686956|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
89303156|NCT03686956|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
89303157|NCT03520920|Experimental|R/R Non-GCB DLBCL|Participants with non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
89303158|NCT03520920|Experimental|R/R FL or MZL|Participants with R/R FL or MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
89303159|NCT03686878|Experimental|Intervention Group|Lifitegrast 5% ophthalmic solution group
89303160|NCT03682198|Other|One strategy for all enrolled patients:|All patients will participate in three substudies, in which they also act as controls, with exposure to the same three interventions: 1) NIRS-measurement on skin, skull and dura, 2) Phenylephrine 0.1 mg iv., and 3) inspired oxygen fraction of 0.3 vs. 0.8
89303161|NCT03686800|Experimental|Rivelin® plain patches|This is an open label study with the objectives to establish information on adhesion time, tolerability and usability of Rivelin® plain patches when applied to VLS lesions. Furthermore, the design of the Rivelin® plain patch will also be evaluated.
89303162|NCT02953340|Experimental|(Arm 1): SPI-2012 and TC|At each cycle for 4 cycles, participants received SPI-2012 at a fixed dose of 13.2 milligrams (mg)/0.6 milliliter (mL), [3.6 mg granulocyte colony-stimulating factor {G-CSF}] subcutaneously (SC) approximately 24-26 hours after receiving intravenous (IV) infusion of docetaxel 75 mg/m^2 and cyclophosphamide 600 mg/m^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
89303163|NCT02953340|Experimental|(Arm 2): Pegfilgrastim and TC|At each cycle for 4 cycles, participants received pegfilgrastim 6 mg (6 mg/0.6 mL GCSF) SC approximately 24-26 hours after receiving IV infusion of docetaxel 75 mg/m^2 and cyclophosphamide 600 mg/m^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
89303164|NCT03689218|No Intervention|Control|The control arm will receive routine public and private health services available in the area.
89303165|NCT03689218|Experimental|Intervention|Pregnant women in intervention arm will receive 30 sachets of Maamta (Nutritious Food Supplement) during pregnancy and first six months of lactation. Children 6-24 months of age will receive 30 sachets of Wawamum (Lipid-Based Nutrient Supplement) every month during the study.
89303166|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Single dose containing 62.5 mg of celecoxib in 10 ml solution
89303167|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 125 mg|Single dose containing 125 mg of celecoxib in 10 ml solution
89303168|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 250 mg|Single dose containing 250 mg of celecoxib in 10 ml solution
89303169|NCT03554772|Placebo Comparator|Placebo|Single dose containing 0 mg of celecoxib in 10 ml solution
89303170|NCT03689062|Active Comparator|conservative group|patient assigned to the observation group will be assessed in the labor and delivery suite for 2 to 4 hours with continuous external fetal heart rate monitoring and tocodynamometry. In the absence of non reassuring fetal status , initiation of labor , or infection , these women will be transferred to antepartum room where maternal vital signs. Patients will be restricted to bed rest with bathroom privileges and remained hospitalized until delivary .
89303171|NCT03689062|Experimental|active group|Patients assigned to active management will receive induction of labour with intravenous oxytocin with use of controlled infusion pump Oxytocin will be administered by continuous intravenous infusion beginning at 0.5 mU/min , doubling the dose every 30 minutes to 2mU/min , and then increasing by 2 mU/min every 30 minutes there after until a satisfactory labor pattern is achieved.
89303172|NCT03729336|Experimental|PEEZY specimen|All subjects will use PEEZY to give a urine specimen.
89303173|NCT03729336|Placebo Comparator|CATHETER specimen|All subjects will use CATHETER (performed by their clinician) to give a urine specimen, following PEEZY use.
88806339|NCT01229891|Experimental|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 mL
89303174|NCT03688984|Experimental|Cognitive Behavioural Therapy for Insomnia|Six sessions of in person Cognitive Behavioural Therapy for Insomnia (CBT-I)
89303175|NCT03688984|No Intervention|Treatment As Usual|Participants will receive regular care in the Treatment As Usual (TAU) condition. Participants will be offered CBT-I at the completion of the trial.
89303176|NCT01311206|Experimental|PBFR|Partial Blood Flow Restriction (PBFR) during Low-Intensity Exercise.
89303177|NCT01311206|Active Comparator|PBFR control|Low-Intensity Exercise without partial blood flow restriction.
89303178|NCT01310322|Experimental|1|AZD5423 iv
89303179|NCT01310322|Experimental|2|AZD5423 inhalation, Spira
89303180|NCT01310322|Experimental|3|AZD5423 inhalation I-neb
89303181|NCT01310322|Experimental|4|AZD5423 oral
89303182|NCT04050046|Active Comparator|Real tDCS + CBCT|20 minutes of 2.0mA of tDCS for 5 consecutive days
89303183|NCT04050046|Sham Comparator|Sham + CBCT|Sham stimulation closely imitates reals tDCS 30 second ramp-up / ramp-down
89303184|NCT04830020|Active Comparator|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt)
89303185|NCT04830020|Placebo Comparator|placebo|5 ml of saline via nebulizer b.i.d.
89303186|NCT05664672|No Intervention|Group 1|Subjects will be asked to continue smoking their UBCs ad libitum for 7 days.
89303187|NCT05664672|Experimental|Group 2|Subjects will exclusively use 2 mg NP, using at least 3 pouches per day for 7 days.
89303188|NCT05664672|Experimental|Group 3|Subjects will exclusively use 4 mg NP, using at least 3 pouches per day for 7 days.
89303189|NCT05664672|Experimental|Group 4|Subjects will exclusively use 8 mg NP, using at least 3 pouches per day for 7 days.
89303190|NCT05664672|Experimental|Group 5|Subjects will completely stop all tobacco product usage for 7 days.
89303191|NCT03624010|Experimental|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
89303192|NCT03686722|Active Comparator|Metformin|Subjects administered Metformin 500mg(Glucophage tablets) twice daily till day(4) then Metformin 1000mg twice daily till day(7)
89303193|NCT03686722|Experimental|Metformin and Daclatasvir|Subjects Coadministered Metformin 500mg(Glucophage tablets) twice daily and Daclatasvir 60mg tablets once daily till day (4) then Metformin 1000mg twice daily and Daclatasvir 60mg tablets once daily till Day(7)
89303194|NCT03573804|Experimental|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
89303195|NCT03681730|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
89303196|NCT03681730|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
89303197|NCT03417440|Other|PA App+ On Your Feet+ CoachMe+ Proof Pos|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 3 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (3) Proof Positive (explicit and implicit messaging to promote positive aging views)."
89303198|NCT03417440|Other|PA App + On Your Feet + Coach Me|"Participants in this arm will use a basic physical activity (PA) app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
89303199|NCT03417440|Other|PA App + On Your Feet + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
89303200|NCT03417440|Other|PA App + On Your Feet|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions)."
89303201|NCT03417440|Other|PA App + Coach Me + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
89303202|NCT03417440|Other|PA App + Coach Me|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
89303203|NCT03417440|Other|PA App + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Proof Positive (explicit and implicit messaging to promote positive aging views)."
89303204|NCT03417440|Other|PA App|Participants in this arm will use a basic physical activity (PA) tracker app without any additional features.
89303205|NCT04059874|Experimental|donafenib tablets 1|This is the dose group was given once a day. donafenib tablets 1 100mg qd dose group
89303206|NCT04059874|Experimental|donafenib tablets 2|This is the dose group was given twice a day. donafenib tablets 2 100mg bid dose group
89303207|NCT03722004|Active Comparator|mOPV1 + fIPV 6 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
89303208|NCT03722004|Active Comparator|mOPV1 + fIPV 10 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
89303209|NCT03722004|Active Comparator|mOPV1 only|mOPV1 administered at 6, 10, and 14 weeks.
89303210|NCT03722004|Active Comparator|bOPV only|bOPV administered at 6, 10, and 14 weeks.
89303211|NCT04629976|Experimental|NCO-48 Fumarate 4 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
89303212|NCT04629976|Experimental|NCO-48 Fumarate 20 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
89303213|NCT04629976|Active Comparator|Tenofovir alafenamide 25 mg|Eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg or 20 mg, or open-label TAF 25 mg for 28 days.
89303214|NCT03721848|Experimental|Healthy Community Clinic: NCD+MH|The arm of this study consists of a 28 session intervention, which are 45 minutes and meet 2-3 times a month providing health awareness on non-communicable diseases diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking; traumatic stress reactions, individual strategies for coping with stress and traumatic events and collective strategies for coping with stress and trauma.
89303215|NCT03721848|Active Comparator|Healthy Community Clinic: NCD|The arm of this study consists of a 24 session intervention, which are 45 minutes and meet 2 times a month providing health awareness on non-communicable disease diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking.
89303216|NCT03721848|No Intervention|Treatment as usual|This is treatment as usual where there is no intervention, but patients attend the clinic for treatment of non-communicable diseases.
88806340|NCT01283555|Experimental|User-Filled Applicator|
88806341|NCT01283555|Other|Prefilled applicator|
89303217|NCT04629430|Experimental|Prebiotic diet|2 servings a day of pre-biotics every day from start of conditioning regimen for HSCT through 100 days following HSCT
89303218|NCT03728946|Experimental|Liposomal Bupivacaine Interscalene Block|Liposomal bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
89303219|NCT03728946|No Intervention|Bupivacaine Interscalene Block|Bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
89303220|NCT03728868|Placebo Comparator|Placebo|One capsule containing placebo (identical to the capsule with active product (F. prausnitzii and D. piger) in taste and appearance but without the active component) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
89303221|NCT03728868|Active Comparator|High dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E9-5x1E9 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
89303222|NCT03728868|Active Comparator|Low dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E8-5x1E8 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
89303223|NCT03718598||Carpal tunnel syndrome|Patients with mild and moderate carpal tunnel syndrome
89303224|NCT03718598||normal|Patients without mild and moderate carpal tunnel syndrome
89303225|NCT03458702|Experimental|YogaFit then Quiet Rest|Participants participated in a 30 min YogaFit and then a session of 30 min of Quiet Rest on a separate day.
89303226|NCT03458702|Experimental|Quiet Rest then YogaFit|Participants participated in a 30 min Quiet Rest session and then a session of 30 min of YogaFit on a separate day.
89303227|NCT03452540|Experimental|1000mg DS102 (BID)|Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
89303228|NCT03573336|Experimental|Vilaprisan (BAY1002670) 2 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg
89303229|NCT03573336|Experimental|Vilaprisan (BAY1002670) 4 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg
89303230|NCT03573336|Placebo Comparator|Placebo group|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1
89303231|NCT03500198|Experimental|Investigational Device: Next Generation TECNIS IOL|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
89303232|NCT03500198|Active Comparator|Control Device: TECNIS Monofocal IOL|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
89303233|NCT03553758|Experimental|Ketamine|15 subjects undergoing ketamine general anesthesia.
89303234|NCT03552198|No Intervention|General public/usual health advice|Healthy participants with a self-reported existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
89303235|NCT03552198|Experimental|General public/alternative health advice|Generally healthy participants were randomised to receive targeted health advice about the adoption of protective behaviours in an alternative format.
89303236|NCT03552198|No Intervention|At risk group/usual health advice|Participants with a self-reported pre-existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
89303237|NCT03552198|Experimental|At risk group/alternative health advice|Participants with a self-reported existing health conditions were randomised to receive targeted health advice (based on their health condition) about the adoption of protective behaviours in an alternative format.
89303238|NCT01310556||coronary artery disease|patients with coronary artery disease
89303239|NCT03725514|Active Comparator|conventional|Conventional blood clot technique
89303240|NCT03725514|Experimental|PRF|Platelet Rich Fibrin Technique
89303241|NCT02954354|Experimental|Adults: Baloxavir Marboxil|Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
89303242|NCT02954354|Active Comparator|Adults: Oseltamivir|Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
89303243|NCT02954354|Placebo Comparator|Adults: Placebo|Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
89303244|NCT02954354|Experimental|Adolescents: Baloxavir Marboxil|Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
89303245|NCT02954354|Placebo Comparator|Adolescents: Placebo|Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
89303246|NCT03519516|Experimental|PRO-174|"Active ingredient: Levofloxacin 0.5%~o Dosage: 1 drop in both eyes, 8 times a day during the waking period"
89303247|NCT03519516|Active Comparator|Sophixín Ofteno®|o Dosage: 1 drop in both eyes, 8 times a day during the waking period
89303248|NCT03681574|Experimental|Placebo Group|The placebo group will receive placebo concentrate orally (0.3 mL/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
89303249|NCT03681574|Experimental|GABA 15mg/kg Group|The GABA 15mg/kg group will receive gabapentin syrup orally (15 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
89303250|NCT03681574|Experimental|GABA 30mg/kg Group|The GABA 30mg/kg group will receive gabapentin syrup orally (30 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
88806342|NCT00345176|Active Comparator|Lutein/Zeaxanthin|lutein (10mg)/zeaxanthin (2 mg)
89523352|NCT03381755|Active Comparator|standard-dose ticagrelor|
88806343|NCT00345176|Active Comparator|DHA/EPA|DHA (350 mg)/EPA (650 mg)
88806344|NCT00345176|Active Comparator|Lutein/Zeaxanthin + DHA/EPA|lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)
89523353|NCT03387163||Sacubitril/Valsartan|Chronic systolic heart failure patients newly prescribed in mg. twice daily.
89303251|NCT03519204|Experimental|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
89303252|NCT03519204|Experimental|No-treatment Control|No-treatment was administered during control period. After 3 months, participants were eligible to receive treatment with JUVÉDERM® VOLBELLA® XC with lidocaine if applicable followed by an optional touch-up retreatment one month following initial treatment.
89303253|NCT03681418|Other|Patients with operable breast cancer|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.
89303254|NCT03688594|Experimental|couple : man and pregnant women|
89303255|NCT03518658||Evaluation Group|Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
89303256|NCT03518658||Control Group|Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)
89303257|NCT03624166|Active Comparator|Ketamine|sub- anesthetic dose of ketamine 0.5 mg/kg will be given in 3 ml volume
89303258|NCT03624166|Placebo Comparator|isotonic saline|isotonic saline 3 ml volume will be given
89303259|NCT03688516|Experimental|Atypical development|30 children with Williams-Beuren syndrome will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
89303260|NCT03688516|Sham Comparator|Typical development|30 control children matched for mental age will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
89303261|NCT03688438|No Intervention|Standard of Care|Standard of care wound closure and dressing No active interventions
89303262|NCT03688438|Experimental|WoundVAC (CINPT)|Closed-Incision Negative-Pressure Therapy
89303263|NCT03518112|Experimental|Treatment (blinatumomab, combination chemotherapy)|See detailed description.
89303264|NCT03686254|Active Comparator|The control Arm|bevacizumab and second-line chemotherapy
89303265|NCT03686254|Experimental|The experimental Arm|RFA, bevacizumab and second-line chemotherapy
89303266|NCT03681340|Experimental|Hydroxyapatite toothpaste|4 weeks toothbrushing with a hydroxyapatite toothpaste
89303267|NCT03681340|Active Comparator|Fluoridated toothpaste|4 weeks toothbrushing with a fluoridated toothpaste
89303268|NCT03686098|Experimental|Dietary Soy Arm|Participants will be asked to increase soy in their diet by an equivalent of 50mg/day for 12 months
89303269|NCT03686098|Active Comparator|Soy Supplement Arm|Participants will consume 2 tablets of 50mg each per day for 12 months
89303270|NCT03686098|No Intervention|Control Arm|No diet or supplement changes
89303271|NCT03718442||Breast cancer patients - lumpectomy|Women who are 18 years or older, have Ductal carcinoma in situ (DCIS) or invasive breast-conserving surgery, have not had previous chest radiotherapy. 20 patients who meet above study population criteria will be enrolled in this study.Shaved margins for each lumpectomy site will be excised with either Bovie (3 sides) or PhotonBlade (3 sides) for each patient. The effect of PhotonBlade vs Bovie on pathology assessment of lumpectomy shaved surgical margins will be compared.
89303272|NCT03681106|Experimental|Kinesiotape|Kinesio Tex taping treatment for 10 days + usual care
89303273|NCT03681106|No Intervention|Control|usual care
89303274|NCT03688360|Experimental|Therapist-guided in-session|The participants will engage in 2 x 45 minutes of exposure exercises conducted together with the therapist in the mental health care centre. In addition, they will conduct 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
89303275|NCT03688360|Experimental|Self-guided out-session|The participants will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
89303276|NCT03688360|Experimental|Parent-guided out-session|The participants and one of their parents will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises together with their parent out of session as a homework assignment.
89303277|NCT03680950|Experimental|Upper Gastrointestinal Monitoring System|Participants who meet criteria of enrollment and is willing to join in this study will wear a real-time upper gastrointestinal monitoring system for checking whether upper gastrointestinal rebleeding occurs continuously for 3 days.
89303278|NCT03686020||Group I|participants suffering from oral potentially malignant lesions
89303279|NCT03686020||Group II|participants suffering from diagnosed oral malignant lesions
89303280|NCT03686020||Group III|healthy participants who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.
89303281|NCT03679780|Active Comparator|Control|This site will serve as the control site and will receive lactated Ringer's (saline solution) (2 µl/min) throughout the entire duration of the protocol. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
89303282|NCT03679780|Experimental|Inhibitor of Endothelin Type B Receptor|This site will receive 300 nM BQ-788, an inhibitor of the endothelin type B receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
89523354|NCT03387163||ACEi/ARB|Chronic systolic heart failure patients receiving ACEi/ARB and no s/v
89303283|NCT03679780|Experimental|Inhibition of Endothelin Type A Receptor|This site will receive 500 nM aBQ-123, an inhibitor of endothelin type A receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
89303284|NCT03679780|Experimental|L-Arginine|This site will receive 10 mM L-Arginine to supplement the substrate for endothelial nitric oxide synthase. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
89303285|NCT03517566|Placebo Comparator|placebo|Placebo
89303286|NCT03517566|Experimental|ZPL389 3mg|ZPL389 3 mg oral powder
89303287|NCT03517566|Experimental|ZPL389 10 mg|ZPL389 10 mg oral powder
89303288|NCT03517566|Experimental|ZPL389 30mg|ZPL389 30 mg oral powder
89303289|NCT03517566|Experimental|ZPL389 50mg|ZPL389 50 mg oral powder
89303290|NCT03725358|Experimental|Control: no training, low subsidies|No provider training and low (status quo) subsidies received: business as usual
89303291|NCT03725358|Experimental|No training, medium-level subsidies|No provider training, but receiving medium-level PBF payments for contraceptive methods provided
89303292|NCT03725358|Experimental|No training, high-level subsidies|No provider training, but receiving high-level PBF payments for contraceptive methods provided
89303293|NCT03725358|Experimental|Training, low-level subsidies|Providers being trained on modern contraception, but receiving low-level (status quo) PBF payments for contraceptive methods provided
89303294|NCT03725358|Experimental|Training, medium-level subsidies|Providers being trained on modern contraception, but receiving medium-level (status quo) PBF payments for contraceptive methods provided
89303295|NCT03725358|Experimental|Training, high-level subsidies|Providers being trained on modern contraception, but receiving high-level (status quo) PBF payments for contraceptive methods provided
89303296|NCT03725358|Experimental|Training+App, low-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving low-level (status quo) PBF payments for contraceptive methods provided
89303297|NCT03725358|Experimental|Training+App, medium-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving medium-level (status quo) PBF payments for contraceptive methods provided
89303298|NCT03725358|Experimental|Training+App, high-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving high-level (status quo) PBF payments for contraceptive methods provided
89303299|NCT03725280||Transgender men I|Transgender men after testosterone treatment
89303300|NCT03725280||Transgender men II|Transgender men before testosterone treatment
89303301|NCT03725280||IVF- PCOS|IVF- PCOS patients with high testosterone levels
89303302|NCT03725280||Egg donors|IVF- egg donors patients
89303303|NCT03721770||Relatives|Relative or adult companion (age <18 years) of a patient who died of cardiac arrest after organ removal request. A parent is defined as a close relative of the first degree: husband-wife, father-mother, son-daughter. Only one loved one is included per patient. Inclusion order of priority is husband-wife / father-mother / son-daughter.
89303304|NCT03677362|Experimental|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
89303305|NCT03464266|Active Comparator|DMPA and PrEP|
89303306|NCT03464266|Active Comparator|DMPA and no PrEP|
89303307|NCT03464266|Active Comparator|Condoms only and PrEP|
89303308|NCT03464266|Active Comparator|Condoms only and no PrEP|
89303309|NCT03685864|Experimental|Suture Embedding Acupuncture|Suture Embedding Acupuncture 1 time for two weeks, total 3 times.
89303310|NCT03685864|Sham Comparator|Sham acupuncture|Sham Acupuncture 1 time for two weeks, total 3 times.
89303311|NCT03623932|Active Comparator|immunosuppressor/TNFalpha|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment.
89303312|NCT03623932|Experimental|Hypnosis + Standard Treatment|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment.
89303313|NCT03680716|Experimental|IPACK block|Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.
89303314|NCT03680716|Active Comparator|Local infiltration analgesia|Periarticular infiltration by surgeon
89303315|NCT03680638|Sham Comparator|Control (Lactated Ringer's)|This site will only be infused with Lactated Ringer's during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
89303316|NCT03680638|Experimental|Tempol|This site will only be infused with tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
89303317|NCT03680638|Experimental|Apocynin|This site will only be infused with apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone; 100µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
89523355|NCT03381677|Experimental|Pedicle Lengthening Osteotomy|Lumbar decompressive surgery via Pedicle Lengthening Osteotomy Procedure with the Altum® Device
88806345|NCT00345176|Placebo Comparator|Placebo/Control|Considered control because all participants received the AREDS formulation
89303318|NCT03680638|Experimental|Allopurinol|This site will only be infused with tempol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
89303319|NCT03677206|Sham Comparator|Exposure to white LED light.|Subjects will exposed to white light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks
89303320|NCT03677206|Experimental|Exposure to green LED light|Subjects will exposed to green light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks.
89303321|NCT03677206|Other|Cross over|Subject will be exposed to white light (sham) for 10 weeks, then have a wash out period for 2 weeks, then exposed to green light (experimental) for 10 weeks.
89303322|NCT03680560|Experimental|ACTR T cell product in combination with trastuzumab|
89303323|NCT03677050|No Intervention|Control|patients receiving standard care (verbal and written instructions) before colonoscopy
89303324|NCT03677050|Experimental|Intervention|Patients instructed to use a smart phone patient education app in addition standard care
89303325|NCT03680482|Other|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose.
89303326|NCT03680482|No Intervention|Intervention ingest a water (control group)|Subjects with type 2 diabetes who ingest a water (control group)
89303327|NCT03680482|Other|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
89303328|NCT03685786|Experimental|Experimental: CART19 cell and auto-HSCT|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
89303329|NCT03916744|Experimental|Giredestrant 10 mg|
89303330|NCT03916744|Experimental|Giredestrant 30 mg|
89303331|NCT03916744|Experimental|Giredestrant 100 mg|
89303332|NCT03639610|Experimental|Cohort 1a|Patients with moderate renal impairment (eGFR ≥30 to <45 mL/min/1.73m²) and a starting dose of melflufen of 40 mg
89303333|NCT03639610|Experimental|Cohort 1b|Patients with moderate renal impairment (eGFR ≥30 to <45 mL/min/1.73m²) and a starting dose of melflufen of 30 mg
89303334|NCT03639610|Experimental|Cohort 2a|Patients with severe renal impairment (eGFR ≥15 to <30 mL/min/1.73m²) and a starting dose of melflufen of 20 mg
89303335|NCT03680404|Active Comparator|Control (Phenylephrine)|Subjects will be administered phenylephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
89303336|NCT03680404|Experimental|Phenylephrine + Apocynin|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and apocynin (10^-4 M) at the same rate and for the same time as the control arm.
89303337|NCT03680404|Experimental|Phenylephrine + Allopurinol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and allopurinol (10^-5 M) at the same rate and for the same time as the control arm.
89303338|NCT03680404|Experimental|Phenylephrine + Tempol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and Tempol (10^-5 M) at the same rate and for the same time as the control arm.
89303339|NCT03685630|Experimental|Brivaracetam|Subjects in this arm will receive open-label Brivaracetam.
89303340|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 60 mg + Bendamustine 90 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. Participants continued to receive TAK-659 monotherapy until they experienced progressive disease (PD) or unacceptable toxicities or up to 39 cycles.
89303341|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 80 mg + Bendamustine 90 mg/m^2|TAK-659 80 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 80 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 39 cycles.
89303342|NCT02954406|Experimental|Dose Escalation Phase Cohort A: TAK-659 100 mg + Bendamustine 90 mg/m^2|TAK-659 100 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 100 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 39 cycles.
89303343|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 60 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
89303344|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 80 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 80 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 80 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
88806346|NCT01194089|Active Comparator|Nasal Nicotine Spray|3 mg of nasal nicotine will be administered postoperatively.
89303345|NCT02954406|Experimental|Dose Escalation Phase Cohort B: TAK-659 100 mg + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 100 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 was escalated to 100 mg once daily after safety and tolerability of 60 mg dose was determined. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 12 cycles.
89303346|NCT02954406|Experimental|Dose Escalation Phase Cohort C: TAK-659 60 mg + Gemcitabine 1000 mg/m^2|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with gemcitabine 1000 mg/m^2, infusion, intravenously, over 30 minutes on Days 1 and 8 in a 21-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 2 cycles.
89303347|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 40 mg + Lenalidomide 25 mg|TAK-659 40 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 60 mg dose was de-escalated to 40 mg in case of dose limiting toxicity or if the starting dose was determined to be not tolerable. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
89303348|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 60 mg + Lenalidomide 25 mg|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 26 cycles.
89303349|NCT02954406|Experimental|Dose Escalation Phase Cohort E: TAK-659 60 mg + Ibrutinib 560 mg|TAK-659 60 mg, immediate-release tablet, orally, once daily along with ibrutinib 560 mg capsules, orally, once daily on Days 1 to 28 in a 28-day treatment cycle. Participants continued to receive TAK-659 monotherapy until they experienced PD or unacceptable toxicities or up to 3 cycles.
89303350|NCT02954406|Experimental|Safety Expansion Phase Cohort B: TAK-659 + Bendamustine 90 mg/m^2 + Rituximab 375 mg/m^2|TAK-659 immediate-release tablet, at the MTD/maximally administered dose (MAD)/RP2D determined from Dose Escalation Phase, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles in participants (who were to be entered in Phase 2) with advanced FL or MZL. Treatment could then be continued until they experienced PD or unacceptable toxicities or up to 12 cycles in participants who were to be enrolled in the Safety Expansion Phase Cohort.
89303351|NCT03514914|Experimental|CHARM2 Intervention|CHARM2 intervention will involve gender, culture & contextually-tailored family planning and gender equity counseling for married couples. Two sessions for men delivered by male health providers and two sessions for women delivered by female providers.
89303352|NCT03514914|No Intervention|Control|Control clusters will receive standard of care.
89303353|NCT03728322|Experimental|iHSCs treatment group|
89303354|NCT01310478|Experimental|Endostar combined with mFOLFOX6|
89303355|NCT03728244|Experimental|test group Hyaluronic acid|Patients scheduled for free gingival graft harvesting will receive Hyaluronic acid gel 0.2%
89303356|NCT03728244|Experimental|test group MEBO ointment|Patients scheduled for free gingival graft harvesting will receive MEBO ointment
89303357|NCT03728244|No Intervention|negative control group|Patients scheduled for free gingival graft harvesting
89303358|NCT03513588|Placebo Comparator|Placebo|
89303359|NCT03513588|Experimental|PF-06865571 100 mg|
89303360|NCT03513588|Experimental|PF-06865571 600 mg|
89303361|NCT03725124||Patients|Women with inflammatory bowel disease (IBD.
89303362|NCT03725124||Partners|Partners of women with IBD.
89303363|NCT03725124||Healthcare Professionals|Healthcare professionals working with women with IBD.
89303364|NCT03512028|Experimental|Remote Limb Ischemic Conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
89303365|NCT03512028|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.
89303366|NCT03511326|Experimental|Luxerm®|
89303367|NCT03727932|Other|VioOne HIV Profile|HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
89303368|NCT03721692|Experimental|RIC group|The patients will accept cardio-cerebrovascular disease secondary prevention treatment and use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
89303369|NCT03721692|No Intervention|non-RIC group|The patients will only accept cardio-cerebrovascular disease secondary prevention treatment.
89303370|NCT03727698|Experimental|Radiotherapy delivered on the MR Linac|MR Guided radiotherapy treatment
89303371|NCT03721614|Experimental|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|
89303372|NCT03721614|Active Comparator|Xience family Everolimus Coronary Stent Systems|
89303373|NCT03727620|Experimental|doxycycline group|Drug Longamycine 200 mg the first day , then 100 mg per day for 14 days
89303374|NCT03727620|Active Comparator|amoxicillin plus metronidazole group|Drug Dispamox 500 mg, 3 times a day for 7 days Flagyl 250 mg, 3 times a day for 7 days
89303375|NCT03727542|Experimental|Short AV-delay pacing|Participants will be their own control. Serum samples will be collected at baseline while the participants were in sinus rhythm and after 3 weeks of short AV-delay pacing serum samples will be recollected to measure matrix metalloproteinase levels .
89303376|NCT03724734|Experimental|Adaptive DBS|We will use our custom-built externalized research system (ERS) to deliver adaptive stimulation to the subthalamic nuclei.
89303377|NCT03724734|Active Comparator|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous stimulation to the subthalamic nuclei.
89303378|NCT03721536|Active Comparator|low-flow anesthesia|Patients in low-flow anesthesia receive a fresh gas flow of 4 L/min for the first 10 minutes and were then maintain with a fresh gas flow of 0.75 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
89303379|NCT03721536|Active Comparator|normal-flow anesthesia|Patients in normal-flow anesthesia received a fresh gas flow of 4 L/min for the first 10 minutes and were then maintained with a fresh gas flow of 1.5 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
89303380|NCT03727464|Experimental|Propofol Abstract Priming|Patients undergoing propofol general anesthesia and stimulation with a list of abstract words
89303381|NCT03727464|Experimental|Propofol Concrete Priming|Patients undergoing propofol general anesthesia and stimulation with a list of concrete words
89303382|NCT03727464|Active Comparator|Propofol Controls|Patients undergoing propofol anesthesia without any intraoperative priming
89303383|NCT03727464|Experimental|Sevoflurane Abstract Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of abstract words
89303384|NCT03727464|Experimental|Sevoflurane Concrete Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of concrete words
89303385|NCT03727464|Active Comparator|Sevoflurane Controls|Patients undergoing sevoflurane general anesthesia without any intraoperative priming
89303386|NCT03724656|Experimental|acupuncture treatment|"Patients in the TAES treatment group received Transcutaneous Acupoint Electrical Stimulation(TAES) 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
89303387|NCT03724656|Sham Comparator|Sham acupuncture treatment|"The control group was treated with non-acupoint shallow acupuncture method. The needle was inserted 5 cm beside the acupoint and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
89303388|NCT03508830|Experimental|Liposomal Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation: 266mg (20cc) Liposomal Bupivacaine admixed with 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) and varied 0.9% normal saline volume for total volume of 60cc."
89303389|NCT03508830|Active Comparator|Standard Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation - 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) admixed with varied 0.9% normal saline volume for total volume of 60cc."
89303390|NCT03508050|Experimental|Clamping double lumen tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
89303391|NCT03508050|No Intervention|Not Clamping double lumen tube|Not Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
89303392|NCT03727386|Experimental|Coconut oil|A dietary intervention that relies on the administration of 30 ml of extra virgin coconut oil per day for six months will be utilized in this study. Coconut oil administered will replace the cooking/vegetable oil usually used by the participants. .
89303393|NCT03727386|Placebo Comparator|Sunflower oil|A dietary intervention that relies on the administration of 30 ml of sunflower oil per day for 6 months will be utilized in this study. The oil administered will replace the cooking/vegetable oil usually used by the participants.
89303394|NCT03727308||Women recruited from pharmacies|"Investigators will enroll women seeking medical abortion pills without prescription from pharmacies.~- Medical abortion pills sourced from pharmacies"
89303395|NCT03727308||Women recruited from health clinics|"Investigators will enroll women seeking medical abortion pills from clinics.~- Medical abortion pills sourced from health clinics"
89303396|NCT03569202|Experimental|Emulsion Eye Drops|Daily treatment with Piiloset Trehalose Emulsion Eye Drops
89303397|NCT03569202|Active Comparator|Control Eye Drops|Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
89303398|NCT03680326||OCT|only optical coherence tomography and visual acuity testing at each visit, patients were recruited retrospectively, only data analysis
89303399|NCT03724578|Sham Comparator|standard preventive measures|the participants will only follow standard preventive measure twice a day brushing with fluoride toothpaste and flossing once a day
89303400|NCT03724578|Active Comparator|antimicrobial and fluoride mouth wash|participants will use mouth wash contains both chlorhexidine and fluoride in addition to standard preventive measures
89303401|NCT03724578|Experimental|grape seeds extract mouth wash|the intervention is grape seeds extract mouth wash
89303402|NCT03685552|Experimental|Prog: Purify-2|All subjects will be participating in a diet life style modification program (High Phytopro dietary program) ( a modified Mediterranean style low glycemic load food plan) and will be receiving a supportive nutritional supplements over a 4 week period.
89303403|NCT03721380|Experimental|BDRC|At the time of assignment to the counseling intervention arm of the study, there will be an initial meeting between the subject and the assigned counselor. As described in the counseling manual, this initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach.
89303404|NCT03721380|Other|TAU|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs.
89303405|NCT03685474|Experimental|Facing Your Fears-School Based (FYF-SB)|This group will receive the Facing Your Fears - School Based intervention during the fall semester
89303406|NCT03685474|Active Comparator|Usual Care (UC)|This group will receive usual care of anxiety treatment during the fall semester, but will be in the FYF-SB arm the following spring semester.
88806347|NCT01194089|Placebo Comparator|Nasal Normal Saline Spray|1 ml of nasal normal saline spray will be administered postoperatively.
89303407|NCT03680248|Experimental|Healthy subjects, Fat|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load intervention
89303408|NCT03680248|Experimental|Steatosis, Fat|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load intervention
89303409|NCT03680248|Other|Healthy subjects, Fasting|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fasting
89303410|NCT03680248|Other|Steatosis, Fasting|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fasting
89303411|NCT03680248|Experimental|Healthy subjects, Fat+Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + glucose administration
89303412|NCT03680248|Experimental|Steatosis, Fat+Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + glucose administration
89303413|NCT03680248|Experimental|Healthy subjects, Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - glucose administration
89303414|NCT03680248|Experimental|Steatosis, Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - glucose administration
89303415|NCT03680248|Experimental|Healthy subjects, Fat+Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + fructose administration
89303416|NCT03680248|Experimental|Steatosis, Fat+Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + fructose administration
89303417|NCT03680248|Experimental|Healthy subjects, Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fructose administration
89303418|NCT03680248|Experimental|Steatosis, Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fructose administration
89303419|NCT03680170|Experimental|Working memory updating training|"Training with web-based program on the internet for 30 sessions (4-5 times a week). The result of the training is registered.~Intervention Device: web-based cognitive training"
89303420|NCT03680170|Placebo Comparator|Placebo training|"Low dose, short term memory training. Intervention: Training with computer based program on the internet for 30 sessions (4-5 times a week).~Intervention Device: Web-based cognitive training"
89303421|NCT03568500|Experimental|Aripiprazole|Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
89303422|NCT03568500|Experimental|Olanzapine|Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
89303423|NCT03568500|Experimental|Quetiapine|Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
89303424|NCT03568500|Experimental|Risperidone|Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.
89303425|NCT03680014||1|Capable of independent of daily activities and able to mobilise unaided. No previous of falls.
89303426|NCT03680014||2|Capable of independent of daily activities and able to mobilise unaided. With a previous of atleast one fall.
89303427|NCT03680014||3|Requires help with most daily activities, mobilises with a single walking stick. No previous falls.
89303428|NCT03680014||4|Requires help with most daily activities, mobilises with a single walking stick. With a previous of atleast one fall.
89303429|NCT03680014||5|Requires help with most daily activities. Mobilise with frame or roller frame. No previous falls.
89303430|NCT03680014||6|Requires help with most daily activities. Mobilise with frame or roller frame. Previous history of at least one fall.
89303431|NCT03727230|Experimental|Asian-type DEL recipients|"First, to identify Asian-type DEL patients by phenotyping and genotyping methods in the Chinese recipients having a serologically apparent RhD-negative phenotype.~Then, blood transfusion of RhD+ blood rather than rare RhD-negative blood to the Asian-type DEL recipients which met the inclusion criteria."
89303432|NCT03676894|Sham Comparator|Sham Treatment|Sham Fotona SP Dynamis Treatment - minimum energy delivered through sham handpiece.
89303433|NCT03676894|Active Comparator|Intravaginal Treatment|Intravaginal Fotona SP Dynamis Treatment - energy delivered intravaginally.
89303434|NCT03676894|Experimental|Intravaginal and intraurethral Treatment|Intravaginal and intraurethral Fotona SP Dynamis Treatment Intravaginal Treatment - energy delivered intravaginally and intraurethrally.
89303435|NCT03721302||Main Study Clinical Sepsis|Clinical and Antimicrobial Assessments
89303436|NCT03721302||Microbiology Sub study|Clinical and Antimicrobial Assessments
89303437|NCT03679858||Platelet function test in patients|Platelet function test in patients on antiplatelet therapy
89303438|NCT03679858||Platelet function test in healthy|Platelet function test in healthy subjects
89303439|NCT03727074|Experimental|5-FU Cream|topical cream
89303440|NCT03727074|Active Comparator|Efudex®|topical cream
89303441|NCT03727074|Placebo Comparator|Vehicle|topical cream
89303442|NCT03676816|Experimental|Vaginal self-sampling and provider performed endocervical sampling|Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
89303443|NCT03685084|Placebo Comparator|0.9% saline infusion|Saline 0.9% infusion
89303444|NCT03685084|Experimental|AAI101 i.v.|"600 mg, 1g, 2g, 4g, 1g q6h, 2g q6h.~Drug-Drug Interaction:~Sequence 1 = piperacillin 4 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v. - cefepime 2 g i.v. - AAI101 2 g + cefepime 2 g i.v.~Sequence 2 = cefepime 2 g i.v. - piperacillin 4 g i.v. - AAI101 2 g + cefepime 2 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v."
89303445|NCT03685084|Experimental|Piperacillin i.v.|Piperacillin 3 g
89303446|NCT03685084|Experimental|Cefepime i.v.|Cefepime 1 g
89303447|NCT03724422|No Intervention|Control|This group will receive the standard of care treatment for their distal humerus fracture only.
89303448|NCT03724422|Experimental|Intervention|This group will receive the prophylactic radiation therapy in addition to the standard of care treatment of their distal humerus fracture.
89303449|NCT03679702|Other|Active treatment|
89303450|NCT03724344||Dimensions with Behavioral and psychological symptoms|
89303451|NCT03724266|Experimental|chitosan|chitosan as intracanal medication 0.2% in form of gel
89303452|NCT03724266|Active Comparator|calcium hydroxide|intracanal medication
89303453|NCT03679390|Experimental|10-20 y/o|We will include the teenagers who need intravenous general anesthesia(IVGA), and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
89303454|NCT03679390|Experimental|20-40y/o group|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
89303455|NCT03679390|Experimental|>70 y/o|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
89303456|NCT03684850|Active Comparator|Exercise therapy group|(n = 40)
89303457|NCT03684850|Experimental|Knee brace and exercise group|(n = 40)
89303458|NCT03684850|Experimental|Footwear device group|(n = 40)
89303459|NCT03679234|Experimental|Intervention|Routine infant formula
89303460|NCT03903796|Experimental|HS-10234 25mg|HS-10234 + TDF placebo for up to 96 weeks
89303461|NCT03903796|Active Comparator|TDF 300mg|TDF + HS-10234 placebo for up to 96 weeks
89303462|NCT03903796|Experimental|Open-label HS-10234|All participants who complete the double-blind period (96 weeks) will be eligible to receive open-label HS-10234 until week 144 of the study.
89303463|NCT03270748|Experimental|Experimental|Experimental: Experimental The experimental consists in the application of a therapeutic strategy: post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies Therapeutic intervention, namely conditioning regimen and GVHD prophylaxis, are based on standard current regimens: Busulfan 0,8 mg/kg 4 times per day during 2 h infusions for 4 consecutive days (from day -6 through day -3) Fludarabine 40 mg/m2 per day for 4 days (from day -6 through day -3); GvHD prophylaxis: Cyclosporine or Tacrolimus beginning day+5 up to at least 100 days. Micofenolate 15mg/kg twice a day from day +5 to +35.
89303464|NCT03676426|Experimental|Web-based AD|Patients will be encouraged to use the web platform for advance care planning/advance directive to document their care preferences..
89303465|NCT03676426|Active Comparator|Paper AD|Patients will be given the standard advance directive and encouraged to complete on their own.
89303466|NCT03684772|Experimental|ICVT|Digoxin and Furosemide (0.125%)
89303467|NCT03684772|Experimental|Furosemide|Furosemide (0.125%)
89303468|NCT03684772|Experimental|Digoxin|Digoxin (0.125%)
89303469|NCT03684772|Placebo Comparator|Placebo|Vehicle Gel
89303470|NCT03623542||Dementia or alzheimer dementia|All patients presenting with dementia syndrome and whose admission was unplanned between May 2010 and November 2011 were consecutively included in the study.
89303471|NCT03684616||Statin treatment prior to cardiac arrest|
89303472|NCT03684616||No Statin treatment prior to cardiac arrest|
89303473|NCT03676114|Experimental|ketamine group|
89303474|NCT03676114|Placebo Comparator|normal saline group|
89303475|NCT03504852|Experimental|Secukinumab 300 mg every 2 weeks (Q2W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.
89303476|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks (Q4W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.
89303477|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)|2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).
89303478|NCT03676036|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 28 days: DS107E taken topically twice a day
89303479|NCT03676036|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and Vehicle taken once a day Next 28 days: Vehicle taken topically twice a day
89303480|NCT03721224||Children with psychogenic cough|children who were examined by Pediatric Respiratory Disease specialist and diagnosed as having a psychogenic cough.
89303481|NCT03721224||control subjects|children who were referred to pediatrics clinics and do not have a chronical disease.
89303482|NCT03025828|Experimental|Acthar|Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly
89303483|NCT03546816|Experimental|5 mg Serlopitant Tablets|
89303484|NCT03546816|Placebo Comparator|Matching Placebo Tablets|
89303485|NCT03024970|Experimental|stenfilcon A lens with solution additive (test)|Participants were randomized to wear the stenfilcon A lens with solution additive (test) for 1 month during the cross over study.
89303486|NCT03024970|Active Comparator|stenfilcon A lens (control)|Participants were randomized to wear stenfilcon A (control) lens pair for 1 month during the cross over study.
89303487|NCT03500094|Experimental|migalastat HCl 150 mg|"One migalastat 123 milligrams (mg) capsule equivalent to 150 mg migalastat hydrochloride (HCl) (herein referred to as migalastat) was administered every other day for 12 months."
89303488|NCT03684382|Experimental|NeW-I group|Participants engage in a weekly structured writing task of 15-30 minutes which provides them an opportunity to reflect on the emotional, practical and financial demands of caregiving, and the means to cope with these challenges (week 1), explore avenues where they can seek information and resources for caregiving (week 2), explore the sources of support which they have within their network of family and friends (week 3) and examine how they (and their children) can rise above illness-related challenges and live their lives as fully as possible (week 4). After participants complete their weekly writing task, the written narrative will be reviewed and edited by the therapist within the next 3-4 days. The revised draft will be shared with the participant along with constructive feedback, empathic support and psychoeducation. In week 5, participants will receive a 'legacy' document and engage in a voice call with the therapist to receive psychosocial support and for closure of therapy.
89303489|NCT03684382|No Intervention|Control group|Participants engage in a weekly unstructured writing task of 15-30 minutes with a single open-ended question for each week which allows them to respond in any manner they find acceptable. Simple empathic weekly feedbacks are provided by the therapist to encourage continuous participation. In week 5, a consolidated document that includes all unedited journal writings together with a brief summary statement of appreciation by the therapist will be given to participants to indicate conclusion of participation.
89303490|NCT03726918||Osteoarthritis|Surgery for implantation of a prosthesis in case of Osteoarthritis
89303491|NCT03726918||Non Osteoarthritis|Surgery for implantation of a prosthesis fon non Osteoarthritis cases
89303492|NCT03566550||CF|people with cystic fibrosis
89303493|NCT03566550||Control|people without cystic fibrosis
89303494|NCT03679000||The reproductive health of couples|The study is a prospective cohort study, and its participants are childbearing couples who are seeking assisted reproductive technologies for having a baby in the reproductive center in Tongji Hospital.The study is a observational study.
89303495|NCT03675958|Experimental|GJPS + S|Experimental group: (GJPS + S) : Application Johnstone´s Pressure Splint plus Stretching in in 4 different treatment postures.
89303496|NCT03675958|Active Comparator|GS|Control group (GS): Just Stretching in 4 different treatment postures.
89303497|NCT03675880|Experimental|1.25mg(0.05ml) single-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) single-dose
89303498|NCT03675880|Experimental|2.00mg(0.08ml) single-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) single-dose
89303499|NCT03675880|Experimental|2.50mg(0.10ml) single-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) single-dose
89303500|NCT03675880|Experimental|1.25mg(0.05ml) multiple-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) multiple-dose after 1.25mg(0.05ml) single-dose
89303501|NCT03675880|Experimental|2.00mg(0.08ml) multiple-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) multiple-dose after 2.00mg(0.08ml) single-dose
89303502|NCT03675880|Experimental|2.50mg(0.10ml) multiple-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) multiple-dose after 2.50mg(0.10ml) single-dose
89303503|NCT03675802|Active Comparator|Arm number one ,misoprostol|
89303504|NCT03675802|Active Comparator|Arm number 2 dinoprostone|
89303505|NCT03678844|Experimental|Taekwondo practice|
89303506|NCT03678844|Placebo Comparator|CONTROL|
89303507|NCT03678610|Experimental|ICSI medium supplemented with Ionomycin and Latrunculin A|
89303508|NCT03678610|No Intervention|ICSI medium as it is|
89303509|NCT03684148|Experimental|Motor imagery practice|In addition to routine physical therapy patients that will be included in the motor imagery practice (MIp) group will receive an additional intervention based on motor imagery beginning immediately after the TKA procedure.
89303510|NCT03684148|No Intervention|Control group|Patients from the control group will underwent the same post-surgery rehabilitation program, but will not be engaged in MI practice.
89303511|NCT03675646|Experimental|Morphine group M|Experimental group M were administered preservative-free morphine 250 mcg in 2.5 ml NS intrathecal using 25 G needle in L1/2 - L5/S1 interspaces.
89303512|NCT03675646|No Intervention|Control group C|No intervention
89303513|NCT03675568|Experimental|study group|Non-Cultured autologous keratinocyte suspension
89303514|NCT03675568|Active Comparator|Control group|Split skin Graft
89303515|NCT03675490|Experimental|Exercise|Participants will engage in a physiotherapist-prescribed home exercise program with ABLE, the interactive technology. The exercises that will be prescribed are designed to improve functional mobility via challenging lower extremity strength and balance in a multicomponent exercise program. The difficulty of each exercise will be chosen at the discretion of the physiotherapist based on the participants' performance on the baseline assessments. The exercises will be prescribed at a moderate intensity (moderate balance challenge, 8-12 repetitions for strength exercises with the last few repetitions being challenging) and will be progressed over the study duration to ensure they remain a moderate challenge.
89303516|NCT03527914|Active Comparator|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
89303517|NCT03527914|Experimental|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
89303518|NCT03678532|Experimental|Daily interruption of sedation (control group)|Control group received daily interruption of sedation. After intubation, patients received IV infusion of midazolam. 1-2 mg / hour with increments 1-2 mg/hr gradually increasing dose till RASS reached -4 or -5. Infusion stopped at 7:00 AM. If the patient is awake no need for resuming infusion. If signs of discomfort occurred, infusion resumed at half of the prior dose, targeting conscious sedation (RASS 0: -3)
89303519|NCT03678532|Experimental|No sedation|Intervention group were managed by no-sedation strategy. Patients received bolus doses of midazolam (1-5 mg) only when needed, after atrial to control agitation by correcting the underlying cause. If the patient needed more than 3 bolus doses , IV infusion of midazolam was given by the daily interruption protocol as in the control group. No crossover was allowed between groups. Analysis was done by intension-to-treat principle.
89303520|NCT03675334|Active Comparator|Test Group|"Active comparator: gingival recession~the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions"
89303521|NCT03675334|Placebo Comparator|Control Group|the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions. The control group was treated with the same technique as the collagen matrix graft.
89303522|NCT03566238|Experimental|A4250 low dose|Capsules for oral administration (40 ug/kg) once daily for 24 weeks
89303523|NCT03566238|Experimental|A4250 high dose|Capsules for oral administration (120 ug/kg) once daily for 24 weeks
89303524|NCT03566238|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks
89303525|NCT02894502|Experimental|Motivational interviewing only for patients|In this arm the interventions will be delivered only to patients
89303526|NCT02894502|Experimental|Motivational interviewing to patients and caregivers|In this arm the interventions will be delivered both to patients and caregivers
89303527|NCT02894502|No Intervention|Control group|This Group will receive the usual care
89303528|NCT03206164|Experimental|Asynchronous, eLearning Intervention|Participants in the asynchronous, eLearning Intervention Group will participate in the on-demand HealthMatters Program Instructor Training Course that will be continuously and readily available.
89303529|NCT03206164|Active Comparator|Synchronous, Live Webinar Comparison|Participants in the synchronous, Live Webinar Comparison Group will receive HealthMatters Program Instructor Training Course via a live instructor taught 3-part live webinar.
89303530|NCT03678220|Experimental|Patients using LapAR system|
89303531|NCT03675178|Experimental|treatment group|Anerning particle +ceftriaxone sodium
89303532|NCT03675178|Placebo Comparator|control group|Anerning particle placebo+ceftriaxone sodium
89303533|NCT03675100|Sham Comparator|IBS group|Patients who were diagnosed with IBS according to the ROME III criteria. Colonoscopic mucosal biopsy was undertaken for every subject.
89303534|NCT03675100|Active Comparator|Control group|Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality. Colonoscopic mucosal biopsy was undertaken for every subject.
89303535|NCT03678064|Experimental|Lokomat|16 sessions total. Provided by study PT twice weekly for 8 weeks.
89303536|NCT03677908||13 high|High-Density ElectroEncephaloGraphy analysis of 13 healthy premature infants
89303537|NCT03677908||15 low|Low-Density ElectroEncephaloGraphy analysis of other 15 healthy premature infants
89303538|NCT03674866||Patients with diabetes|Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).
89303539|NCT03623776|Experimental|JS001 alone|Subjects receive JS001 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
89303540|NCT03623776|Experimental|JS001+chemotherapy|Subjects receive JS001 240 mg, pemetrexed of 500 mg/m^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
89303541|NCT03674788||TAVI|Transcatheter Aortic Valve Implantation
89303542|NCT03674788||TMVI|Transcatheter Mitral Valve Intervention
89303543|NCT03674788||TTVI|Transcatheter Tricuspid Valve Intervention
89303544|NCT03677674|Experimental|dehydrated|The participants will be dehydrated (at least 2% of their body weight) before performing the Sterkowicz test.
89303545|NCT03677674|No Intervention|euhydrated|The participants will be normally hydrated (= euhydration) before performing the Sterkowicz test (i.e. no specific intervention will be implemented).
89303546|NCT04059328||Physicians in Haiti|7 OBGYN physicians underwent a laparoscopic training and simulation course and then were proctored as they performed 3 in vivo cases using a check list to help the participants remember all the steps of laparoscopic set-up.
89303547|NCT03674710|Experimental|Group A|"Patients assigned to group A will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
89303548|NCT03674710|Experimental|Group B|"Patients assigned to group B will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
89303549|NCT03674710|Experimental|Group C|"Patients assigned to group C will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
89303550|NCT03674710|Experimental|Group D|"Patients assigned to group D will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
89303551|NCT03674710|Experimental|Group E|"Patients assigned to group E will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
89303552|NCT03674710|Experimental|Group F|"Patients assigned to group F will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
89303553|NCT03449030|Experimental|Part A Escalation Stage: TAK-164 Q3W|TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and/or RP2D.
89303554|NCT03449030|Experimental|Part B Expansion Stage: TAK-164 Q3W|TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 RP2D dose to be decided based on safety, PK, pharmacodynamics and antitumor response data observed in Part A escalation stage.
89303555|NCT03449030|Experimental|Part C Imaging Substudy: 89Zr-TAK-164 and TAK-164|89Zr-TAK-164, intravenous infusion, followed by unlabeled TAK-164, intravenous infusion in combination with 89Zr-TAK-164, intravenous infusion, and further followed by unlabeled TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 recommended imaging dose (RID) or RP2D dose to be decided based on safety, PK, PD and antitumor response data observed in Part A escalation stage.
89303556|NCT03674632|Experimental|relaxation meditation tape|Participants in this arm will be asked to use the relaxation therapy during the feed at least once a day. Participants will be given a diary to record when it is used. Participants will be encouraged to use the tape as often as they find it helpful.
89303557|NCT03674632|No Intervention|Normal care|Participants in this arm will receive normal care from the Beijing Children Hospital
89303558|NCT04058938|Active Comparator|Control|The control group received standard of care, including standard patient counseling from the surgical teams.
89303559|NCT04058938|Experimental|Intervention|In conjunction with oncologic psychology and plastic surgery, an instrument was developed to be provided as a single-paged paper handout to the intervention group. The instrument included information about expectations for pain control, information about the pain scale, and examples of opioid and adjunct medications which may be used as part of a multi-modal approach to pain control during the perioperative period.
89303560|NCT03683914|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
89303561|NCT03683914|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
89303562|NCT03721094|Other|Immersive virtual reality|Completing the procedures in immersive virtual reality
89303563|NCT03721094|No Intervention|Conventional virtual reality|Completing the procedures in conventional virtual reality
89303564|NCT03448406|Experimental|Empagliflozin|
89303565|NCT03448406|Active Comparator|Placebo|
89303566|NCT03672838|Active Comparator|Cohort 1|Patients with NF1
89303567|NCT03672838|Active Comparator|Cohort 2|Patients with NF2
89303568|NCT03674554|Experimental|titanium bases group|full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
89303569|NCT03674554|Experimental|transmucosal abutment group|a full-arch screw-retained implant prosthesis with transmucosal abutment
89303570|NCT03674476|Experimental|Mild Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
89303571|NCT03674476|Experimental|Moderate Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
89303572|NCT03674476|Experimental|Severe Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
89303573|NCT03674476|Other|Normal|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
89303574|NCT03623308|Experimental|Fiber Intervention I|Participants will be asked to consume two ½ cup servings of fiber cereal daily (equivalent to 28 g fiber) for 14 days, one in the morning and one in the evening.
89303575|NCT03623308|Experimental|Fiber Intervention II|Participants will be asked to consume two ¼ cup servings of fiber cereal daily (equivalent to 14 g fiber) for 14 days, one in the morning and one in the evening.
89303576|NCT03499028|No Intervention|Standard of Care Group|The Standard of Care Group will receive standard, routine medical care and will communicate with their surgeon and clinical care team through conventional methods such as phone.
89303577|NCT03499028|Experimental|Experimental (JointCOACH) Group|The Experimental Group will receive standard, routine medical care and utilize a web-based communication platform called JointCOACH to communicate with their care team via computer or smartphone throughout their episode of care. They will also receive information personalized to their treatment plan and will be asked to complete online questionnaires.
89303578|NCT03498560||MGH Surgery Patients|PSG data will be collected, and delirium assessments conducted, on patients undergoing surgery at MGH.
89303579|NCT00064701|Experimental|Tacrolimus|Participants received a first dose of tacrolimus between 0.075 and 0.10 mg/kg twice daily, orally prior to or within 48 hours of the completion of the transplant procedure, and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
89303580|NCT00064701|Active Comparator|Tacrolimus Modified Release|Participants received a first dose of tacrolimus modified release between 0.15 and 0.20 mg/kg/day, given as a single oral dose in the morning, prior to or within 48 hours following the completion of the transplant procedure, and subsequently as once daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
89303581|NCT00064701|Active Comparator|Cyclosporine|Participants received a first dose of cyclosporine between 4 to 5 mg/kg orally prior to or within 48 hours following the completion of the transplant procedure and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
89303582|NCT03957525|Experimental|Orthopaedic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
89303583|NCT03957525|No Intervention|Orthopaedic Control group|Gets written and oral preparation for surgery
89303584|NCT03957525|Experimental|Urologic Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
89303585|NCT03957525|No Intervention|Urologic Control group|Gets written and oral preparation for surgery
89303586|NCT03957525|Experimental|General Paediatric Surgery Intervention group|In addition to the written and oral preparation for surgery this arm receives an 'on-boarding' package containing a cardboard VR, a code to download the VR App and a plush penguin.
89303587|NCT03957525|No Intervention|General Paediatric Surgery Control group|Gets written and oral preparation for surgery
89303588|NCT03952455|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system in the Nucleus Accumbens. The DBS system will be active at two days after surgery.
89303589|NCT01098591||Myocardial infarction|Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial
89303590|NCT01098591||Ischemic cardiomyopathy|Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial
89303591|NCT03674398|Experimental|Exercise+CT|Aerobic exercise for 30 minutes and smart-phone delivered cognitive training application for 20 minutes, 3 times per week for 4 weeks
89303592|NCT03674398|Active Comparator|Exercise only|Aerobic exercise for 30 minutes and smart-phone delivered videos for 20 minutes, 3 times per week for 4 weeks
89303593|NCT03683602|Experimental|PNF group|PNF techniques, patterns, re-education of postural control, once a day 10 days,
89303594|NCT03683602|Active Comparator|Manual therapy group|traction, joints mobilization, pos-isometric relaxation, once a day 10 days
89303595|NCT03672682||DLBCL with chemoresistance|15 patients with DLBCL with chemoresistance or relapsed less than 2 years after completion of first-line therapy
89303596|NCT03672682||DLBCL with chemosensitivity|15 patients with DLBCL with chemosensitivity without relapse within 2 years following the end of first-line therapy.
89303597|NCT03672682||Healthy patients|15 healthy patients
89303598|NCT03672604|Placebo Comparator|Part A: Single Dose|"Cohort 1 = 0.25 mg NLY01 Cohort 2 = 0.8 mg NLY01 Cohort 3 = 2.5 mg NLY01 Cohort 4 = 5 mg NLY01 Cohort 5 = 10 mg NLY01~All cohorts include 8 subjects randomized to receive a single dose of NLY01 or placebo (6 active, 2 placebo)."
89303599|NCT03672604|Placebo Comparator|Part B: Multiple Dose|"In Part B, NLY01 or placebo will be administered once-weekly for 4 doses. There will be 3 sequentially-enrolled, ascending-dose cohorts of 8 subjects (6 active, 2 placebo). Doses in Part B will be a fraction of the maximum tolerated dose (MTD) established in Part A.~Cohort 6 = 15% of the single-dose MTD Cohort 7 = 35% of the single-dose MTD Cohort 8 = 70% of the single-dose MTD"
89303600|NCT03672604|Placebo Comparator|Part C:Multiple Dose|"In Part C, NLY01 or placebo will be administered once-weekly for 6 doses.~Cohort 10 = 2.5 mg NLY01 Cohort 11 = 5 mg NLY01"
89303601|NCT03674086||First-time hearing aid user|Using hearing aids less than or equal to three months.
89303602|NCT03674086||Existing hearing aid user|Using hearing aids for 6 months or more.
89303603|NCT00064077|Experimental|Arm I (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
89303604|NCT00064077|Experimental|Arm II (vinorelbine, cisplatin)|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
89303605|NCT00064077|Experimental|Arm III (gemcitabine, cisplatin)|Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
89303606|NCT00064077|Experimental|Arm IV (topotecan, cisplatin)|Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
89303607|NCT03672448||Neurocognitive disorder|Dementias
89303608|NCT03672448||Normal Aging|Normal Aging with normal cognitive function
89303609|NCT03674008|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
89303610|NCT03674008|Active Comparator|Propofol|1.5mg/kg/0.75mg/kg
89303611|NCT03673930|Active Comparator|Zanthozylum armatum|fruit extract
89303612|NCT03673930|Placebo Comparator|Placebo|placebo
89303613|NCT00063999|Active Comparator|Arm I (doxorubicin hydrochloride, cisplatin, paclitaxel)|Patients receive doxorubicin hydrochloride IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
89303614|NCT00063999|Experimental|Arm II (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
89303615|NCT01095315|No Intervention|standard|parturients were placed back to the supine position immediately after spinal injection following standard protocol of spinal anesthesia
89303616|NCT01095315|Experimental|lateral|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
89303617|NCT01092351|Experimental|Nitrofurantoin|Adult patients with a microbiologically confirmed uncomplicated urinary tract infection
89303618|NCT01098825||District VI AAP clinicians|
89303619|NCT03131440|Experimental|Experimental Condition #1|core, support calls
89303620|NCT03131440|Experimental|Experimental Condition #2|core, support calls, app+
89303621|NCT03131440|Experimental|Experimental Condition #3|core, support calls, buddy
89303622|NCT03131440|Experimental|Experimental Condition #4|core, support calls, online gym
89303623|NCT03131440|Experimental|Experimental Condition #5|core, support calls, app notifications
89303624|NCT03131440|Experimental|Experimental Condition #6|core, app+
89303625|NCT03131440|Experimental|Experimental Condition #7|core, app+, buddy
89303626|NCT03131440|Experimental|Experimental Condition #8|core, app+, online gym
89303627|NCT03131440|Experimental|Experimental Condition #9|core, app+, app notifications
89303628|NCT03131440|Experimental|Experimental Condition #10|core, buddy
89303629|NCT03131440|Experimental|Experimental Condition #11|core, buddy, online gym
89303630|NCT03131440|Experimental|Experimental Condition #12|core, buddy, app notifications
89303631|NCT03131440|Experimental|Experimental Condition #13|core, online gym
89303632|NCT03131440|Experimental|Experimental Condition #14|core, online gym, app notifications
89303633|NCT03131440|Experimental|Experimental Condition #15|core, app notifications
89303634|NCT03131440|Experimental|Experimental Condition #16|core, support calls, app+, buddy
89303635|NCT03131440|Experimental|Experimental Condition #17|core, support calls, app+, online gym
89303636|NCT03131440|Experimental|Experimental Condition #18|core, support calls, app+, app notifications
89303637|NCT03131440|Experimental|Experimental Condition #19|core, support calls, buddy, online gym
89303638|NCT03131440|Experimental|Experimental Condition #20|core, support calls, buddy, app notifications
89303639|NCT03131440|Experimental|Experimental Condition #21|core, support calls, online gym, app notifications
89303640|NCT03131440|Experimental|Experimental Condition #22|core, app+, buddy, online gym
89303641|NCT03131440|Experimental|Experimental Condition #23|core, app+, buddy, online gym, app notifications
89303642|NCT03131440|Experimental|Experimental Condition #24|core, support calls, buddy, online gym, app notifications
89303643|NCT03131440|Experimental|Experimental Condition #25|core, buddy, online gym, app notifications
89303644|NCT03131440|Experimental|Experimental Condition #26|core, app+, online gym, app notifications
89303645|NCT03131440|Experimental|Experimental Condition #27|core, support calls, app+, buddy, online gym
89303646|NCT03131440|Experimental|Experimental Condition #28|core, support calls, app+, buddy, app notifications
89303647|NCT03131440|Experimental|Experimental Condition #29|core, support calls, app+, online gym, app notifications
89303648|NCT03131440|Experimental|Experimental Condition #30|core
89303649|NCT03131440|Experimental|Experimental Condition #31|core, app+, buddy, app notifications
89303650|NCT03131440|Experimental|Experimental Condition #32|core, support calls, app+, buddy, online gym, app notifications
89303651|NCT03683446||Laparoscopic Rectal Surgery|A minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon. For abdominal entry, at the beginning of the procedure, the abdomen is inflated with carbon dioxide gas to provide a working and viewing space for the surgeon. For both, the laparoscope transmits images from the abdominal cavity or anus to high-resolution video monitors to allow the surgeon detailed images of the abdomen on the monitor.
89303652|NCT03683446||Open Rectal Surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
89303653|NCT02918734|Experimental|Endobutton CL BTB|Femoral fixation of the BPTB autograft with the Endobutton CL BTB Fixation System.
89303654|NCT02918734|Active Comparator|Metal interference screw|Femoral fixation of the BPTB autograft with a metal interference screw.
89303655|NCT03683368|Experimental|Soft cannula first|Subjects will be randomized (50%) to the soft cannula infusion set for two weeks and then will be switched to the steel needle infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the soft cannula infusion set.
89303656|NCT03683368|Experimental|Steel cannula first|Subjects will be randomized (50%) to the steel cannula infusion set for two weeks and then will be switched to the soft cannula infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the steel cannula infusion set.
89303657|NCT03673696|Experimental|50 mg single dose|It includes two group, one group is pilot study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=2) . Another group is formal study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
89303658|NCT03673696|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
89303659|NCT03673696|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg HEC74647PA capsule (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
89303660|NCT03673696|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
89303661|NCT03673696|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
89303662|NCT03673696|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
89303663|NCT03673696|Experimental|100 mg multiple doses|Healthy subjects, receiving 100 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
89303664|NCT03673696|Experimental|200 mg multiple doses|Healthy subjects, receiving 200 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
89303665|NCT03673696|Experimental|400 mg multiple doses|Healthy subjects, receiving 400 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
89303666|NCT03672214|Experimental|Without placement of a catheter|No placement of indwelling catheter prior to Caesarean section
89303667|NCT03672214|Active Comparator|With placement of a catheter|Placement of indwelling catheter prior to Caesarean section
89303668|NCT03683212|Experimental|Intervention period : early and comprehensive care bundle|
89303669|NCT03683212|No Intervention|acute heart failure standard therapy|
89303670|NCT03672136|Experimental|Concurrent Chemoradiotherapy+Anlotinib|"Radiotherapy: Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy. If radiotherapy and chemotherapy are conducted in the same day, chemotherapy should be priority to radiotherapy.~Chemotherapy: Platinum based dual drug regime determined by researcher.After finishing concurrent chemoradiotherapy, there is no need of maintenance chemotherapy.~Anlotinib: Combined with 12mg/d QD Anlotinib on the first, second weeks and fourth, fifth weeks of radiotherapy, that is on the day1~14, day22~36.~Maintenance therapy: One month after finishing concurrent chemoradiotherapy, 12mg/d QD Anlotinib can be administrated, each cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. The treatment can continue until disease progression or treatment intolerance, but should not exceed 24 months.~During the course of study, it's not allowed to receive other anti-tumor therapy."
89303671|NCT03673540|Experimental|CBT with smartphone application (EMI on)|CBT with CBT+ smartphone application (EMI on)
89303672|NCT03672058|Experimental|Fitbit plus personalised text messaging & Goal Setting|
89303673|NCT03672058|Active Comparator|Fitbit Only|
89303674|NCT03671980|Experimental|Web-intervention|30 participants using a self-management website and home faecal calprotectin smartphone monitoring instead of usual outpatient follow up as a means of managing their inflammatory bowel disease for 6 months after stopping an IBD medication.
89303675|NCT03671824||Lean|BMI ≤ 30 kg/m2
89303676|NCT03671824||Obese|BMI ≥30 kg/m2
89303677|NCT03671668|Active Comparator|Screw retained prosthesis on transmucosal abutments|
89303678|NCT03671668|Experimental|Screw retained prosthesis on titanium bases|
89303679|NCT03673384|Experimental|experimental group|"Received infrared-C ray irradiation by hot compress with a powered heating compress and an eye mask for 40 minutes/time/day Treated regions: eyes and nose region, back region of head, shoulder neck and low back.~Received medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate."
89303680|NCT03673384|Placebo Comparator|Control group|received only medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.
89303681|NCT03673306||Pregnant cohort|Women with one or more pregnancies any time after breast cancer diagnosis
89303682|NCT03673306||Non-pregnant cohort|Women with no subsequent pregnancies after breast cancer diagnosis
89303683|NCT03669796|Experimental|supplementary Marine protein hydrolysate|20 mg powder per kg body weight of Marine protein hydrolysate (MPH)
88806348|NCT00345254|Experimental|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
88806349|NCT00345254|No Intervention|Untouched cord|The cord was untouched after delivery of the anterior shoulder and prior to extraction of the body.
88806350|NCT00345332|Placebo Comparator|1|Placebo
88806351|NCT00345332|Experimental|2|Botox
88806352|NCT01650350|Experimental|Low Dose Naltrexone|LDN, 5 mg/day-(1 cycle = 28 days).
89303684|NCT03669796|Placebo Comparator|control|20 mg powder per kg body weight of casein/maltodextrin
89303685|NCT03673150||women with breast cancer|women who gave birth in 2002/2005 with cord blood collection and developed invasive or non-invasive breast cancer in the following years (2005- O6/2018) to the exclusion of another cancer.
89303686|NCT03673150||women without breast cancer|Controls will be obtained by matching by date of delivery, location, age (woman's date of birth), parity at the time of cord collection and not having had breast cancer
89303687|NCT03672994||Asthma|Patients with prior confirmed diagnosis of bronchial asthma
89303688|NCT03672994||Chronic Obstructive Pulmonary Disease|Patients with prior confirmed COPD
89303689|NCT03672994||Pneumonia|Patients with X-ray confirmed community acquired pneumonia
89303690|NCT03672994||Heart failure|Patients with confirmed heart failure
89303691|NCT03672994||Healthy volunteers|Healthy participants with no otherwise known cardiorespiratory condition
89303692|NCT02915302|Active Comparator|Fluzone Quadrivalent Vaccine, 0.25-mL|Participants received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.25-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
89303693|NCT02915302|Experimental|Fluzone Quadrivalent Vaccine, 0.5-mL|Participants received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.5-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
89303694|NCT03671512|Experimental|Periodontal Structure Repair (PSR)|Periodontal pockets treated with PSR
89303695|NCT03671512|Active Comparator|Standard Root Planing (SRP)|Periodontal pockets treated with SRP
89303696|NCT03023878|Experimental|Blinatumomab|"Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, 112 µg/day for 6 weeks, followed by a 4-week treatment free time.~An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress, with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, and 112 µg/day for 14 days.~There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death."
89303697|NCT03671278|Other|STarT Back Screening Tool Approach|After baseline consultation, all patients will receive usual care from their medical doctors as well as an educational booklet and weekly videos containing information on the prognosis of back pain and how patients could deal with their problems. Six weeks after baseline consultation all patients will be screened by the STarT Back Screening Tool (SBST) and will receive a stratified care according to their SBST classification.
89303698|NCT03670888|Experimental|JHL1101|Single dose IV infusion of 375 mg/m2 of JHL1101
89303699|NCT03670888|Active Comparator|Rituxan|Single dose IV infusion of 375 mg/m2 of Rituximab
89303700|NCT03022630|Other|Comprehensive Palliative Care services|Comprehensive Palliative Care services in addition to usual hepatic care
88806353|NCT00505466||Pre-Test Genetic Counseling + Genetic Sample|
88806354|NCT00349388|Experimental|Asacol once a day dosing|Asacol total dose in mg/kg given once a day
88806355|NCT00349388|Active Comparator|Asacol BID/TID dosing|Asacol total dose split BID or TID
88806356|NCT00349778|Experimental|High-Dose Sequential Therapy|Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim
88806357|NCT00305084|Experimental|A|
89303701|NCT03022630|Other|Usual hepatic care|Usual hepatic care
89303702|NCT03023722|Experimental|All Subjects|Patients with advanced metastatic pancreatic cancer who have measurable disease
89303703|NCT03670732|Active Comparator|CPAP first|The intervention is application of continuous positive airway pressure (CPAP). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
89303704|NCT03670732|Active Comparator|NIPPV first|The intervention is application of nasal intermittent positive pressure ventilation (NIPPV). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
89303705|NCT03623230|Sham Comparator|GCont|Only dressing will be applied to patients without actually nerve block performed
89303706|NCT03623230|Active Comparator|G125 Block|"Ultrasound Guided Femoral Nerve Block: 20ml Bupivacaine 0.125% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 15ml Saline solution."
89303707|NCT03623230|Active Comparator|G25 Block|"Ultrasound Guided Femoral Nerve Block: 10ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 5ml Saline solution."
89303708|NCT04058704|Experimental|Early intervention|Icotinib is administered orally three times per day. Radiation therapy (SRS/ WBRT/ HA-WBRT/SMART) start in 1 month since take icotinib orally.
89303709|NCT04058704|Experimental|Late intervention|Icotinib is administered orally three times per day. Until emerge the progression of the disease, then is given radiation therapy (SRS/WBRT/HA-WBRT/SMART)
89303710|NCT03670654|Active Comparator|Pilates Method|The intervention of active comparator will be Pilates Method exercises.
89303711|NCT03670654|Sham Comparator|Muscle stretching exercises|The intervention of sham comparator will be muscle stretching exercises.
89303712|NCT03022084|Experimental|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
89303713|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
89303714|NCT03670576||Case|A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.
89303715|NCT03670576||Control|Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.
89303716|NCT03670498|Experimental|4 channel Electrical Stimulation(revised sequential)|apply 4 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it sequentially Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
89303717|NCT03670498|Active Comparator|2 channel Electrical Stimulation(classical)|apply 2 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it simultaneously suprahyoid m (ch 1), thyrohyoid m (ch 2) with 2 channel electrical stimulation device.
89303718|NCT03021304|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe|Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subcutaneously as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (by caregiver only) at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
89303719|NCT03669562|Experimental|Alprostadil liposome|
89303720|NCT03669562|Placebo Comparator|Placebo|
89303721|NCT03670420|Experimental|Medical honey in addition to standard care|In addition to the usual care provided by the maternity unit, women allocated to this group apply honey on first and second degree perineal tears, episiotomies and anterior vulvar tears twice a day for four days from randomization.
89303722|NCT03670420|No Intervention|Standard care|This group benefits from the standard care offered by the maternity: hygiene advice, analgesics, ice packs, buoys and positioning.
89303723|NCT03670186|Experimental|V66V-HIIT|Val/Val carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
89303724|NCT03670186|Experimental|V66M-HIIT|Val/Met carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
89303725|NCT03670108||patients receiving an individualized SMS|
89303726|NCT03670108||patients receiving a standard SMS|
89303727|NCT03669484|Experimental|Remimazolam|"The induction of anesthesia: intravenous infusion of 6 mg/kg/h until registration of loss of consciousness.~Maintenance of anesthesia: Remimazolam intravenous infusion initiated at a dose of 1 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation to 2 mg/kg/h maximum; In case of loss of consciousness was not registered in 2.5 minutes of continuous intravenous infusion: drug administration was terminated. If loss of consciousness was not registered during 30 seconds, other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed: intravenous bolus infusion (maximum level of 12 mg/kg/h for 1 minute). If signs of awakening remained remimazolam administration was discontinued and other sedatives were used."
89303728|NCT03669484|Active Comparator|Propofol|"The induction of anesthesia: intravenous infusion of 1.5-2.5 mg/kg for about 1 minute.~Maintenance of anesthesia: intravenous infusion for a total dose of 4-12 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation.~In case of loss of consciousness was not registered other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed and propofol dose adjustment had not resulted in the desired effect and signs of awakening were saved: the use of propofol was discontinued and other sedatives were used."
89303729|NCT04058314|Experimental|Study Eye|Randomized eyes will receive a Gemini IV device in conjunction with an approved monofocal or toric IOL after cataract extraction
89303730|NCT04058314|Active Comparator|Control Eye|control eyes will received an approved monofocal or toric IOL after cataract extraction
89303731|NCT02264548|Experimental|Arm 1|Radiation: Radio-Ablation
89303732|NCT03669172|Experimental|NK cells infusion|NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor
89303733|NCT01814488|Experimental|allogenic transplant|The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias. Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.
89303734|NCT03669406|Experimental|Autograft fat|Paraplegic patients with healed pelvic eschar
89303735|NCT01330966|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
89303736|NCT03669952||Invasive ductal carcinoma|Patients with Invasive ductal carcinoma
89303737|NCT03496298|Placebo Comparator|Placebo|Participants received placebo (matched to Efpeglenatide) as subcutaneous (SC) injection once weekly up to end of treatment.
89303738|NCT03496298|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide as SC injection 2 milligrams (mg) per week for 4 weeks then 4 mg per week up to end of treatment.
89303739|NCT03496298|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide as SC injection 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 6 mg per week up to end of treatment.
89303740|NCT03718208|Experimental|Paediatric formula|"Each child will receive for a period of seven days. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube. One week intake diary, one week tolerance diary, product intake."
89303741|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 200 mg|Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.
89303742|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 100 mg|Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
89303743|NCT02914522|Placebo Comparator|Induction Study (Cohort A): Placebo|Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
89303744|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 200 mg|Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
89303745|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 100 mg|Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
89303746|NCT02914522|Placebo Comparator|Induction Study (Cohort B): Placebo|Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
89303747|NCT02914522|Experimental|Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).
89303748|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
89303749|NCT02914522|Experimental|Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).
89303750|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
89303751|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Placebo|Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).
89303752|NCT03669016|Experimental|Face-to-face group-based mindfulness|8 weeks training.
89303753|NCT03669016|Experimental|Internet-based mindfulness|8 weeks training.
89303754|NCT03669016|No Intervention|Waiting-list control group|No training during the study.
89303755|NCT02924428|Experimental|Diamondpolar applicator, AC Dual applicator|"Radio frequency (RF) and pulsed magnetic field (PEMF) treatment followed by intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The RF and PEMF applicator has 4 electrodes which emit RF and PEMF simultaneously.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
89303756|NCT02924428|Active Comparator|AC Dual applicator treatment|"Intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
88806358|NCT00305162|Experimental|Cangrelor|placebo capsules (to match) + cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + active clopidogrel (600mg) post infusion
88806359|NCT00305162|Active Comparator|Clopidogrel|clopidogrel capsules (600 mg) + placebo bolus & infusion (to match) + placebo capsules (to match) post infusion
88809731|NCT01279304||Group 1. Low risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. all nodes negative: ycN0~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~a. only micrometastases in the SN, and no risk factors (grade 3, LVI, tumour size > 3 cm)~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~no metastases in the post chemo SN"
89303757|NCT03668860|Active Comparator|Treatments A & B (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
89303758|NCT03668860|Active Comparator|Treatments B & A (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
89303759|NCT03668860|Active Comparator|Treatments C & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
89303760|NCT03668860|Active Comparator|Treatments D & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))"
88806360|NCT01791686|Experimental|Dense Deposit Disease|"► Induction Period~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri). There will be two doses of 5 mg/kg, with intrapatient dose-escalation in 5 mg/kg increments up to a maximum dose of 30 mg/kg. This period may last up to 8 weeks.~► Maintenance Period~The starting dose for CDX-1135 Maintenance will be the same dose level as the last dose during the Induction Period; however, the Maintenance Period allows for dose decrease to 2 mg/kg, which is lower than the starting dose in the Induction Period.~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri) for up to a total of 26 weeks."
89303761|NCT03668860|Active Comparator|Treatments E & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
89303762|NCT03668860|Active Comparator|Treatments D & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
89303763|NCT03668860|Active Comparator|Treatments C & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)"
89303764|NCT03668860|Active Comparator|Treatments E & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)"
89303765|NCT03668782||immediate cord clamping|Tthe umbilical cord of neonates was cut and clamped.
89303766|NCT03668782||umbilical cord milking.|Tthe umbilical cord of neonates was milked.
89303767|NCT04609618|Experimental|Obstructive Sleep Apnea patients|Appscent device will discharge odor during the in lab night sleep
89303768|NCT03668704||Medial Bicompartmental Knee Arthroplasty|Patient who have received a robotic-arm assisted medial and patellofemoral knee arthroplasty.
89303769|NCT00062751|Experimental|A|
89303770|NCT00062751|Experimental|B|
89303771|NCT00062751|Active Comparator|C|
89303772|NCT00945724|Experimental|R-CHOP, Depocyte, Methotrexate|
89303773|NCT00763828|Experimental|ThermoSuit-Induced Patient Cooling|The Life Recovery Systems ThermoSuit System will be used to cool STEMI patients under conditions of conscious sedation.
89303774|NCT01092429||one,two,and three vessels disease; mortality|
89303775|NCT00258310|Experimental|Capecitabine|Surgery, chemotherapy and/or radiotherapy, prior to administration of Capecitabine 1000mg/day for one year.
89303776|NCT00159406||cohort|Registry and Database
89303777|NCT00062439|Experimental|Etoposide, Cisplatin, Thoracic RT, Surgery, Docetaxel|
89303778|NCT01584141||Cases|Asian cases with lymphoid or myeloid neoplasma
89303779|NCT01584141||Controls|Controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan
89303780|NCT01327209||Patients with diabetes|
89303781|NCT00051363|Active Comparator|Active CPAP|Active Continuous Positive Airway Pressure (CPAP)
89303782|NCT00051363|Placebo Comparator|Sham CPAP|Sham Continuous Positive Airway Pressure (CPAP)
89303783|NCT01098903||Sunitinib|Patients with a malignancy treated with sunitinib
89303784|NCT01098981|Experimental|Target group|A combined treatment with transcranial US and systemic tPA
89303785|NCT01098981|Active Comparator|Control group|Systemic tPA alone
89303786|NCT01099059|Active Comparator|Ritalin|receive ritalin depending on weight
89303787|NCT01099059|Experimental|Amantadine|100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
89303788|NCT01583829|Experimental|Neurofeedback|
89303789|NCT01583829|Experimental|Cognitive Training|
89303790|NCT01583829|Active Comparator|Waitlist Control|
89303791|NCT01583907||different dietotherapy strategies|
89303792|NCT01092741|Experimental|Gleevec|Gleevec 400 mg by mouth (P.O.) twice daily = 800 mg total daily dose
89303793|NCT01095393||Certolizumab pegol (CZP)|Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)
89303794|NCT01095393||Non-biologic DMARD|Subjects with RA receiving treatment with non-biologic DMARD
89303795|NCT01095471|Experimental|PCV13|Initial vaccination with PCV13
89303796|NCT01095471|Experimental|PCV7|Initial intervention with PCV7
89303797|NCT03955341|No Intervention|conventional selective caries removal without disinfection|After collecting the first sample of dentin, the cavity will be restored
89303798|NCT03955341|Other|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
89303799|NCT03955341|Other|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
89303800|NCT00031551|Experimental|Main Study: Etanercept Mouthwash|Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
89303801|NCT00031551|Placebo Comparator|Main Study: Placebo Mouthwash|Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.
89303802|NCT00031551|No Intervention|Pilot Study|Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.
89303803|NCT01092819||acute ischemic stroke|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with an imaging-defined large cerebral vessel occlusion.
89303804|NCT01099137|Experimental|Vildagliptin|Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
89303805|NCT01099137|Active Comparator|Sulphonylurea dose-up|Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin
89303806|NCT01092897||Subjects with PAH treated with Imatinib|
89303807|NCT01584219||Women after cesarean section|Women after cesarean section
89303808|NCT01584219||pregnancy pathologies|pregnancy pathologies
89303809|NCT01584219||first/second trimester pregnancy|
89303810|NCT01584219||Women after vaginal delivery|Women after vaginal delivery
89303811|NCT01092975|Experimental|1.25 mg phenylephrine|
89303812|NCT01092975|Experimental|2.5 mg phenylephrine|
89303813|NCT01092975|Experimental|5.0 mg phenylephrine|
89303814|NCT01092975|Experimental|10.0 mg phenylephrine|
89303815|NCT01092975|Experimental|20.0 mg phenylephrine|
89303816|NCT01092975|Experimental|40.0 mg phenylephrine|
89303817|NCT01092975|Experimental|60.0 mg phenylephrine|
89303818|NCT01092975|Experimental|80.0 mg phenylephrine|
89303819|NCT01584297|Experimental|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
89303820|NCT01093053|Experimental|Mind-Body Skills Groups|
89303821|NCT01093053|Active Comparator|Standard Treatment|
89303822|NCT00049257|Experimental|Treatment|Please see intervention descriptions
89303823|NCT03951987|Experimental|Treatment A: 4 ml CG5503|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) was administered as a 2 minutes infusion.
89303824|NCT03951987|Experimental|Treatment B: 4 ml CG5503; 5 g charcoal powder|4 ml of the CG5503 i.v. infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride) with oral co-administration of charcoal (5 g charcoal were co-administered orally at 1, 0.5 hours and 10 minutes before the start of CG5503 infusion and 0.5, 1, 1.5, 2 and 4 hours thereafter)
89303825|NCT03955419|No Intervention|Control group|Participants in the control group will be fasted from midnight until surgery.
89303826|NCT03955419|Experimental|Study group|Participants will receive 800 mL of carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg). They will drink this beverage freely, starting from the evening before surgery until 2 hours before surgery.
89303827|NCT01093131|Active Comparator|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
89303828|NCT01093131|Active Comparator|Intravenous hydration and sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
89303829|NCT01093131|Active Comparator|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
89303830|NCT01093131|Active Comparator|Oral hydration and oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
89303831|NCT01099293||Cirrhosis, w/o hepatic encephalopathy|Patients with liver cirrhosis without hepatic encephalopathy by clinical (West-Haven), neurophysiological tests (PHES) nor Critical Flicker Frequency evidence.
89303832|NCT01099293||Cirrhosis-minimal hepatic encephalopathy|Patients with cirrhosis, without clinical evidence of hepatic encephalopathy (West Haven 0) and with positive tests for both, PHES and CFF.
89303833|NCT01099293||Cirrhosis, Hepatic encephalopathy I|Patients with cirrhosis and clinical evidence of hepatic encephalopathy with a West Haven score of I.
89303834|NCT01099293||Control|Healthy subjects willing to participate in the study
89303835|NCT01093209|Sham Comparator|Conventional Laser Therapy|
89303836|NCT01093209|Active Comparator|Interferential Laser Therapy|
89303837|NCT03668548|Experimental|Leucine group|To receive leucine on a daily basis for 10 weeks
89303838|NCT03668548|Placebo Comparator|Control group|To receive a placebo supplement on a daily basis for 10 weeks
89303839|NCT03668470|Experimental|Dulaglutide|Experimental group receiving 1.5 mg Dulaglutide subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
89303840|NCT03668470|Placebo Comparator|placebo|Control group receiving placebo subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
89303841|NCT03020992|Experimental|Certolizumab Pegol|Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks
89303842|NCT03020914|Experimental|Audiovisual Distraction|Patients get audiovisual distraction during surgery and in the recovery room using video goggles and headphones; patients can choose a movie from a preexisting library; with an initial dose of midazolam in preparation for the administration of the neuraxial anesthesia, additional sedation with midazolam in 1 mg increments if requested by the patient or deemed necessary by the anesthesia provider.
89303843|NCT03020914|No Intervention|Standard of care sedation|Standard of care sedation with with a initial dose of midazolam in preparation for the administration of the neuraxial anesthesia; propofol infusion titrated to effect.
89303844|NCT03668158||recurrent HCC|recurrent HCC after LT
89303845|NCT03668158||non-recurrent HCC|non- recurrent HCC after LT
89303846|NCT03668314|Experimental|Cohort 1:1 - 1:6 RDN-929|RDN-929 single dose capsule
89303847|NCT03668314|Placebo Comparator|Cohort 1:1 - 1:6 placebo|Placebo single dose capsule
89303848|NCT03668314|Experimental|Cohort 2:1|Fed/Fast RDN-929
89303849|NCT03668314|Experimental|Cohort 3:1- 3:4 RDN-929|RDN-929 multiple dose capsules once daily for 12 days
89303850|NCT03668314|Placebo Comparator|Cohort 3:1- 3:4 placebo|placebo multiple dose capsules once daily for 10 days
89303851|NCT03668080||surgical residents|Surgical specialties included general surgery, plastic surgery, urology, vascular surgery, obstetrics and gynecology, orthopedic surgery, pediatric surgery, cardiothoracic surgery and otolaryngology.
89303852|NCT03668080||non-surgical residents|Non-surgical specialties included cardiology, rheumatology, neurology, pulmonary disease, endocrinology, nuclear medicine, pediatrics, psychiatry, internal medicine, oncology, nephrology, hygiene and preventive medicine, anesthesiology, child and adolescent psychiatry, radiology, radiation oncology, infectious disease, dermatology, pathology, microbiology, hematology, gastroenterology, geriatric medicine, medical genetics, sports medicine, occupational and environmental medicine.
89303853|NCT03018340|Experimental|Pimavanserin 34 mg + SSRI/SNRI|Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
89303854|NCT03018340|Placebo Comparator|Placebo + SSRI/SNRI|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
89303855|NCT03667768|Experimental|Glass ionomer sealant|Two hand-mixed glass ionomer cements (GICs) available in the dental market were used, and they were mixed according to the manufacturer's instructions (powder/liquid ratio 1:1). The molars were cleaned with a toothbrush and wet cotton wool pellets. Isolation was performed with cotton wool rolls and the occlusal surface was conditioned with GIC liquid (20s), rinsed with wet cotton wool pellets and dried with dry cotton wool pellets. GIC was placed on the occlusal surface and pressed into the pits and fissures using the press-finger technique. The excess of material was removed and the occlusion checked and adjusted. Sealant was protected with a new layer of petroleum jelly and the children were instructed not to eat for at least one hour. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
89303856|NCT03667768|Other|Non-sealant (toothbrushing)|No sealant was performed. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
89303857|NCT03016078|Other|Mepilex Border Post-Op Ag Dressing|A soft silicone foam dressing that absorbs wound exudate maintains a moist wound healing environment and has antimicrobial properties
89303858|NCT00048165|Experimental|Daclizumab|Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram [mg/kg] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.
89303859|NCT00048165|Placebo Comparator|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.
89303860|NCT03952221|Active Comparator|Usual physiotherapy and continuous ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and continuous ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
89303861|NCT03952221|Active Comparator|Usual physiotherapy and pulsed ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and pulsed ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle) every working day for two weeks (10 occasions).
89303862|NCT03952221|Active Comparator|Usual physiotherapy and sonotens therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sonotens therapy (BTL-4825S Premium device, head size of 5 cm2, 3 MHz frequency, 0,5 W/cm2 SATA intensity, transcutanous electrical nerve stimulation) every working day for two weeks (10 occasions).
89303863|NCT03952221|Placebo Comparator|Usual physiotherapy and sham ultrasound therapy|Patients received usual physiotherapy (exercise, massage, balneotherapy) and sham ultrasound therapy (BTL-4825S Premium device, head size of 5 cm2, 0 MHz frequency, 0 W/cm2 SATA intensity) every working day for two weeks (10 occasions).
89303864|NCT01099371|Experimental|exercise|
89303865|NCT03955107|Other|Continuous Glucose Monitoring System|
89303866|NCT01099527|Experimental|Everolimus|"Everolimus (RAD001) dose escalation of capecitabine, everolimus~Capecitabine dose escalation of capecitabine, everolimus"
89303867|NCT01093365|Experimental|Schizophrenia|To measure the effects of varenicline on cognition of smokers with schizophrenia.
89303868|NCT01095549|Placebo Comparator|Control group|HD patients who will not receive far infrared therapy in this study.
89303869|NCT01095549|Experimental|Far infrared therapy|In this study, a WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on maintenance HD.
89303870|NCT03955497|Experimental|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
89303871|NCT03955497|Placebo Comparator|sodium hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
89303872|NCT01099605|Placebo Comparator|Pump device|One arm will have continuous subcutaneous infusion of normal saline.
89303873|NCT01099605|Active Comparator|Bupivacaine|will receive continuous infusion of bupivacaine
89303874|NCT00059787|Experimental|Paclitaxel, carboplatin, erlotinib|Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib
89303875|NCT01099683|Experimental|NRL001|All subjects will receive 10 mg NRL001 in a 2 g rectal suppository
89303876|NCT01099683|Placebo Comparator|Placebo|All subjects will receive placebo
89303877|NCT01093443|Placebo Comparator|A|Patients undergo a standard treatment with a classical GnRH antagonist protocol.
89303878|NCT01093443|Active Comparator|B|Before undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
89303879|NCT03954951|No Intervention|Control group|The clinicians in the control group will continue usual care without intervention. They will not receive the online course or performance feedback reports.
89303880|NCT03954951|Active Comparator|Intervention group|The primary care physicians will receive access to an online course on hypertension management based on the ACC/AHA and ESC guidelines. They will also receive feedback reports on their performance on hypertension management for 16 weeks.
89303881|NCT03955185|Experimental|Minimally invasive surgery|The patients will receive laparoscopic or robotic assisted radical hysterectomy with improved surgery details: 1) Uterine manipulator type Cup-shaped uterine manipulator is prohibited, uterus hanging wire is allowed. 2) Avoid tumor cells shedding into the pelvis: A. Cut the vagina with the transvaginal method, B. Cut the vagina after closed loop ligation of the vagina. After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
89303882|NCT03955185|Active Comparator|Open abdominal surgery|The patients will receive traditional radical hysterectomy.After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
89303883|NCT01099839|Experimental|one group|"Subjects will receive ASP1941 alone, Miglitol alone and ASP1941 + Miglitol in different order."
89303884|NCT03956823|Experimental|Telmisartan|generic name：telmisartan；dosage form：80 mg；dosage：80 mg；frequency：once a day；duration：June , 2019-June , 2021
89303885|NCT03956823|Active Comparator|Amlodipine|generic name： amlodipine；dosage form：5mg；dosage：5mg；frequency：once a day；duration：June , 2019-June , 2021
89303886|NCT01099995|Active Comparator|One HBO session|hyperbaric oxygen therapy one dive at 2 absolute atmosphere (1-hour plateau) - oxygen was delivered via a full face mask - followed by 4 hours of normobaric oxygen therapy
88806361|NCT00351416|Experimental|Aromatase inhibitor EFP|"Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
89303887|NCT01099995|Experimental|2 HBO sessions|Two sessions of hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) with oxygen delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
89303888|NCT03956667|Experimental|Experimental: Live Music|Live Music will be played during the required Emergency Department procedure.
89303889|NCT03956667|No Intervention|Control: No Live Music|There will be no music played during the required Emergency Department procedure.
89303890|NCT01095627|Other|Metacholine Challenge|Exhaled breath analysis following metacholine challenge
89303891|NCT03015532|Experimental|Cohort 1, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
89303892|NCT03015532|Experimental|Cohort 1, Group 2: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
89303893|NCT03015532|Placebo Comparator|Cohort 1, Group 3: Saline Placebo|Saline placebo via injection
89303894|NCT03015532|Active Comparator|Cohort 1, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
89303895|NCT03015532|Experimental|Cohort 2, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
89303896|NCT03015532|Experimental|Cohort 2, Group 2: HTX-011 + Ropivacaine|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
89303897|NCT03015532|Placebo Comparator|Cohort 2, Group 3: Saline Placebo|Saline placebo via injection
89303898|NCT03015532|Active Comparator|Cohort 2, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
89303899|NCT03954873|Experimental|Hyperglycaemia + GLP-2|Glucose + GLP-2
89303900|NCT03954873|Active Comparator|Hyperglycaemia + Placebo|Glucose + saline
89303901|NCT03954873|Experimental|Hypoglycaemia + GLP-2|Insulin + glucose + GLP-2
89303902|NCT03954873|Active Comparator|Hypoglycaemia + Saline|Insulin + glucose
89303903|NCT03954873|Experimental|Euglycaemia + GLP-2|GLP-2
89303904|NCT03954873|Active Comparator|Euglycaemia + Placebo|
89303905|NCT03954795|Active Comparator|Group 1: TAP Block|TAP Block performed from the petit triangle ( anterior axillary line and iliac crest.)
89303906|NCT03954795|Active Comparator|Group 2: OSTAP Block|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
89303907|NCT03954795|No Intervention|No Block|No interventions
89303908|NCT01093677|Experimental|A|750 mg of LIM-0705 BID for 14 days. Up to 20 subjects.
89303909|NCT01093677|Placebo Comparator|B|Placebo BID for 14 days. Up to 10 subjects.
89303910|NCT01584375|Other|Flat midline head position|
89303911|NCT01584375|Other|Right flat lateral head position|
89303912|NCT01095705|Active Comparator|Conventional procedure|Local anaesthesia (Lidocaïne)
89303913|NCT01095705|Experimental|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) and Hypnosis
89303914|NCT01100385|Placebo Comparator|Healthy (placebo)|
89303915|NCT01100385|Active Comparator|Healthy (Ateronon)|
89303916|NCT01100385|Placebo Comparator|Cardiovascular Group (placebo)|
89303917|NCT01100385|Active Comparator|Cardiovascular Group (Ateronon)|
88806362|NCT00351416|Experimental|Aromatase inhibitor LFP|"Letrozole administration (20 mg daily x 2) at follicle size of > 16 mm (LFP; late follicular phase) in cycle 2.~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
89303918|NCT01095783|Experimental|Physiotherapeutic intervention|
89303919|NCT01095783|Other|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
89303920|NCT00047463|Active Comparator|CPAP active comparator|continuous positive airway pressure (CPAP)
89303921|NCT00047463|Placebo Comparator|CPAP Placebo|Placebo-CPAP
89303922|NCT01095861|Experimental|FlexTip ETT|FlexTip ETT
89303923|NCT01095861|Placebo Comparator|Control|Standard Flexible ETT Mallinckrodt Hi-Lo cuffed tracheal tube Catalog # 86114 Mallinckrodt, ST. Louis, MO, 63134
89303924|NCT03954639|Experimental|Cohort 1, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.~EXPAREL will be mixed with Bupivacaine~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
89303925|NCT03954639|Active Comparator|Cohort 1, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.~Subjects enrolled in Cohort 1 will provide blood samples and measures for efficacy and safety."
89303926|NCT03954639|Experimental|Cohort 2, Group 1|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with EXPAREL.~EXPAREL will be mixed with Bupivacaine~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
89303927|NCT03954639|Active Comparator|Cohort 2, Group 2|"Subjects in this group will receive ultrasound guided combined sciatic (in popliteal fossa) and adductor canal nerve block with bupivacaine.~Subjects enrolled in Cohort 2 will provide measures for efficacy and safety."
89303928|NCT01095939|Placebo Comparator|Control Arm|
89303929|NCT01095939|Experimental|Benazepril|
89303930|NCT01093833|Experimental|Continuous Glucose Monitoring|Each subject will participate in one experimental intervention. Blood glucose will be measured with the BD continuous glucose monitor (BD CGM), with the Medtronic Guardian CGM and the YSI Glucose Analyzer as controls for 12-14 hours.
89303931|NCT01093911|Experimental|CDP7657|CDP7657 in dose escalating cohorts
89303932|NCT01093911|Placebo Comparator|Placebo|
89303933|NCT03956433|Experimental|Docosahexaenoic Acid enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) to be consumed daily for 4 weeks.
89303934|NCT03956433|Experimental|Beta-glucan enriched pancakes|One portion of pancakes enriched with 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
89303935|NCT03956433|Experimental|Anthocyanin enriched pancakes|One portion of pancakes enriched with 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
89303936|NCT03956433|Experimental|DHA+BG enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 3 g beta-glucan (BG) to be consumed daily for 4 weeks.
89303937|NCT03956433|Experimental|DHA+AC enriched pancakes|One portion of pancakes enriched with 250 mg docosahexaenoic acid (DHA) plus 320 mg anthocyanins (AC) to be consumed daily for 4 weeks.
89303938|NCT03956589|Experimental|Orkambi open-label arm|Open-label study: all subjects will receive Orkambi during 3 months.
89303939|NCT03956901|Experimental|Liberal Fluid Management|liberal fluid management: 500 ml bolus crystalloid after 4-8 ml/kg/h infusion during surgery total amount of crystalloid volume of fluid infused during gycnecologcy l surgery fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP <65 mmHg or <30%of basal value, infuse 250 ml cyristaloid/Gelofusine bolus and 5 mcg efedrin If MAP>65 mmHg no intervention
89303940|NCT03956901|Experimental|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \ kg crystalloid infusion to be started~If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.~PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13."
89303941|NCT03015220|Experimental|Oral semaglutide 3 mg|
89303942|NCT03015220|Experimental|Oral semaglutide 7 mg|
89303943|NCT03015220|Experimental|Oral semaglutide 14 mg|
89303944|NCT03015220|Active Comparator|Dulaglutide 0.75 mg|
89303945|NCT00022659|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89303946|NCT03667612||Patients with breast cancer|"Patients clinical data collection~Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres~Realization of tumor samples series of cuts and paraffin shavings for:~Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)~Characterization of lymphocyte populations~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
89303947|NCT03667612||Patients with colorectal cancer|"Patients clinical data collection~Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments~Realization of series of cuts and paraffin shavings of the tumor samples for:~Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)~Characterization of lymphocyte populations~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
89303948|NCT03667456|Experimental|Self-rehabilitation by digital support|"Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.~Monitoring and regulation of remote self-reeducation by tele-reeducation. Evaluation of the acceptance of the tool and the quality of life of the patients by questionnaire at day 0, and two and twelve months after."
89303949|NCT03014674|Experimental|Liquid mepolizumab in safety syringe|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled syringe within a safety syringe according to randomization.
89303950|NCT03014674|Experimental|Liquid mepolizumab in an autoinjector|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled autoinjector, according to randomization.
89303951|NCT03014674|Active Comparator|Lyophilised mepolizumab from vial|Subjects will receive a single dose of 100 mg reconstituted lyophilized mepolizumab manually administered subcutaneously according to randomization
89303952|NCT03018106|Experimental|Ospemifene|Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
89303953|NCT03018106|Active Comparator|Estrogen|Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
89303954|NCT03018028|Experimental|Oral semaglutide 3 mg|
89303955|NCT03018028|Experimental|Oral semaglutide 7 mg|
89303956|NCT03018028|Experimental|Oral semaglutide 14 mg|
89303957|NCT03018028|Placebo Comparator|Oral placebo|
89303958|NCT03018028|Active Comparator|Liraglutide 0.9 mg|
89303959|NCT03667222|Experimental|BPX-04 Active|BPX-04 1% minocycline topical gel
89303960|NCT03667222|Placebo Comparator|BPX-04 Vehicle|BPX-04 topical gel vehicle
89303961|NCT03667300|Active Comparator|Evogliptin Group|Intervention group will take daily evogliptin 5mg per oral, not linagliptin 5mg per oral
89303962|NCT03667300|Active Comparator|Linagliptin Group|Control group will take daily linagliptin 5mg per oral, not evogliptin 5mg per oral
88806363|NCT00305942|Experimental|1|"Topotecan 4mg/m2 IV on days 1, 8.~Carboplatin AUC=5 IV day 1 only .~- Cycles are repeated every 21 days for > 4 cycles of topotecan and carboplatin (maximum 6 courses). Restaging studies will be performed every 2 cycles (or 6 weeks.)"
88806364|NCT04737668|Other|Usual care|Pump refill will be performed as usual.
89303963|NCT03666520||Control Group|Clinician not prompted to change the drug from intravenous to oral equivalent.
89303964|NCT03666520||Cohort with clinician being prompted to convert drug|This arm would include the provider being prompted to change the intravenous drug to the oral equivalent.
89303965|NCT03010462|Active Comparator|Active|Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation
89303966|NCT03010462|Sham Comparator|Control|Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation
88806365|NCT04737668|Other|Virtual Reality|Children will play a commercially available VR game during pump refill
88806366|NCT04737668|Other|Distraction|Children will watch a commercial 360° music video on YouTube during pump refill
89303967|NCT03666910||children of rheumatic diseased mothers not on treatment|
89303968|NCT03666910||children of rheumatic diseased mothers on antimalarial drugs|
89303969|NCT03666910||children of normal mothers|
89303970|NCT00021255|Experimental|Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)|Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.
89303971|NCT00021255|Experimental|AC followed by Docetaxel + Herceptin (AC→TH)|Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
89303972|NCT00021255|Experimental|Docetaxel + Carboplatin + Herceptin (TCH)|Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
89303973|NCT03012334|Experimental|Lasmiditan 50mg (milligrams)|Participants received 50mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
89303974|NCT03012334|Experimental|Lasmiditan 100mg|Participants received 100mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
89303975|NCT03012334|Experimental|Lasmiditan 200mg|Participants received 200mg of Lasmiditan tablets given as single doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
89303976|NCT03012334|Active Comparator|Alprazolam 1mg|Participants received 1mg of Alprazolam tablets as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
89303977|NCT03012334|Placebo Comparator|Placebo|Participants received placebo tablets identical to Lasmiditan, administered as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
89303978|NCT03951285|Experimental|NR|"One intervention includes healthy BMI-discordant monozygotic twin pairs, which both are treated with NR. With this unique model, the investigators obtain the information on how beneficial NR is in two different BMI classes (obese and leaner) with an identical genomic background.~The final dose for NR will be 1 g/day. The daily NR dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full NR dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
89303979|NCT03951285|Placebo Comparator|Placebo|"The second intervention includes monozygotic twins concordant for body weight. It's randomized which member of the twin pair is treated with NR while the other co-twin gets placebo.~The final dose for placebo will be 1 g/day. The daily placebo dose is gradually escalated by 250 mg/week so that the full dose of 1 g/day is reached in one month. The intervention time with the full placebo dose is 4 months, total intervention time 5 months. At the end of the study, the daily dose will be decreased by 250 mg/week rate."
89303980|NCT02530203|Other|Conventional treatment|Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
89303981|NCT02530203|Experimental|Spinal Cord Stimulation System|This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.
89303982|NCT01327287||Trauma patients eligible to receive thoracic epidural|Patients admitted to the hospital suffering from blunt thoracic injury and who meet inclusion/exclusion criteria and receive thoracic epidural for pain
89303983|NCT01327287||Control Arm|Trauma patients eligible to receive thoracic epidural but did not receive thoracic epidural for pain
89303984|NCT04571944|Experimental|Suvorexant|Participants will receive 15 mg of suvorexant orally once daily (QD) for 5 to 7 days.
89303985|NCT04571944|Placebo Comparator|Placebo|Participants will receive suvorexant-matching placebo orally QD for 5 to 7 days.
89303986|NCT03951129||verbal group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal informing before hemodialysis catheter insertion
89303987|NCT03951129||verbal and video group|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) levels after verbal and video informing before hemodialysis catheter insertion
89303988|NCT03565068|Experimental|Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg|Healthy participants will receive MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
89303989|NCT03565068|Placebo Comparator|Panel A (Healthy Participants): Placebo Monotherapy|Healthy participants will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
89303990|NCT03565068|Experimental|Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
89303991|NCT03565068|Placebo Comparator|Panel B (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
89303992|NCT03565068|Experimental|Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg|In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia will receive MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
89303993|NCT03565068|Placebo Comparator|Panel C (Schizophrenia Participants): Placebo Add-on Therapy|In addition to background AAP treatment, participants with Schizophrenia will receive MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
89303994|NCT03565068|Experimental|Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg, depending on safety and tolerability.
89303995|NCT03565068|Placebo Comparator|Panel D (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-15.
89303996|NCT04052932|Placebo Comparator|Placebo|Placebo once a day, orally, for 12 weeks, followed by SHR4640 treatment to 36 weeks
89303997|NCT04052932|Experimental|SHR4640 dose1|SHR4640 dose1 once a day, orally, for 36 weeks
89303998|NCT04052932|Experimental|SHR4640 dose2|SHR4640 dose2 once a day, orally, for 36 weeks
89303999|NCT04052932|Active Comparator|Allopurinol|Allopurinol 300mg (milligram) once a day, Orally, for 36 week
89304000|NCT00010803|Placebo Comparator|Placebo|Placebo 1 pill twice a day
89304001|NCT00010803|Active Comparator|Ginkgo biloba|Ginkgo biloba EGb761 120 mg twice daily
89304002|NCT03666364|Experimental|Magnetic nanoparticle selection for teratozoospermia|
89304003|NCT03666364|No Intervention|Density gradient centrifugation for teratozoospermia|
89304004|NCT02914834|Experimental|Device Acupuncture|Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
89304005|NCT02914834|Active Comparator|Non-pain related video health education|The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
89304006|NCT03497130|Experimental|regimen group|After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log. These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
89304007|NCT03497130|No Intervention|control group|"After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks.~All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use."
89304008|NCT03726840|No Intervention|Driving performance no fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with no fragrance
89304009|NCT03726840|Experimental|Driving performance Fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with fragrance
89304010|NCT03006562|Experimental|Subcutaneous Heparin|Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
89304011|NCT03006562|No Intervention|Control|Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.
89304012|NCT03666208|Experimental|Thrombosed Arteriovenous Graft|Single arm pilot study to investigate effect of sirolimus coated balloon in thrombosed arteriovenous graft
89304013|NCT03007966|Active Comparator|Ilioinguinal / Iliohypogastric Block|Patient's randomized to receive an Ilioinguinal / Iliohypogastric nerve block (IINB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a supine position in a manner consistent with the technique described by Willschke, but modified to utilize an in-plane technique rather than an out-of-plane technique for needle to ultrasound probe orientation. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
89304014|NCT03007966|Experimental|Quadratus Lumborum Block|Patient's randomized to receive a Quadratus Lumborum block (QLB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a lateral position in a manner consistent with the technique described by Børglum. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
89304015|NCT03665974||Women with gestational diabetes mellitus|GDM screening at this hospital involves a two-step procedure. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
89304016|NCT03665974||Women non gestational diabetes mellitus|Women with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
89304017|NCT03723642|Active Comparator|OAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
89304018|NCT03723642|Active Comparator|LAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
89304019|NCT03665896|Active Comparator|VivaSight DLT group|Thoracic surgery patient is intubated with VivaSight double-lumen tube (intubation with VivaSight double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera, is recorded. The tube position is reconfirmed by fiberoptic bronchoscopy.
89304020|NCT03665896|Placebo Comparator|Standard DLT group|Thoracic surgery patient is intubated with standard double-lumen tube (intubation with standard double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by fiberoptic bronchoscopy, is recorded.
89304021|NCT03007888|Experimental|IPX203 then Sinemet|Participants first received IPX203 ER CD-LD Capsules for 15 days After a Washout Period of 7 days; participants then received Sinemet (IR CD-LD) Tablet for 15 days Study drug doses were determined based on the subject's prestudy IR CD-LD regimen The typical IPX203 dosing regimen was 3 times a day, dosed approximately every 7 to 8 hours.
89304022|NCT03007888|Experimental|Sinemet then IPX203|Participants first received Sinemet Capsules for 15 days After a Washout Period of 7 days; participants then received IPX203 ER CD-LD Capsules for 15 days Study drug doses were determined based on the subject's prestudy IR CD-LD regimen The typical IPX203 dosing regimen was 3 times a day, dosed approximately every 7 to 8 hours.
89304023|NCT03541044|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (2mg) by oral/buccal route of administration.
89304024|NCT03541044|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (2 mg) by oral/buccal route of administration.
89304025|NCT03666130|Active Comparator|endoscopic septoplasty|in this arm the participants will undergo endoscopic septoplasty for correction of the deviated nasal septum
89304026|NCT03666130|Active Comparator|conventional septoplasty|in this arm the participants will undergo conventional septoplasty operation for correction of the deviated nasal septum that will done by surgical traditional septoplasty technique using head lamb and anterior rhinoscopy
89304027|NCT00009945|Experimental|Arm 1: Clodronate|Patient receives 2 tablets once daily for 3 years.
89304028|NCT00009945|Placebo Comparator|Arm 2: Placebo|Patient receives 2 tablets once daily for 3 years.
89304029|NCT03540030|No Intervention|Observational|The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.
89304030|NCT03540030|Active Comparator|Non-Opioid Intervention|Oral dose of both gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without the aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but should include one dose of IV acetaminophen during the procedure. Anesthetic modalities will include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). As needed medications will include both oral and IV acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.
89304031|NCT04055662||Cannabis users|
89304032|NCT04055662||Cannabis naive|
89304033|NCT03720834||Patients|Questionnaire on risk perception
89304034|NCT03720834||Clinicians|Questionnaire on risk perception
89304035|NCT03003676|Experimental|Experimental: ONCOS-102+cyclophosphamide+pembrolizumab|"Part I: Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24).~Part II: Patients will receive 4 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, 8 and 15) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. ONCOS-102 will be given in combination with Pembrolizumab starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity or clinically relevant disease progression, whichever occurs first. Pembrolizumab will be given according to institutional practice (2mg/kg or 200mg flat dose)."
89304036|NCT00047385|Experimental|Low-Dose CT|
89304037|NCT00047385|Experimental|Chest X-ray|
89304038|NCT03665818|Experimental|Oral appliance intervention|
89304039|NCT03665818|No Intervention|Without oral appliance intervention|
89304040|NCT03665740|Experimental|Resveratrol|Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
89304041|NCT03665740|Placebo Comparator|Placebo|Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
89304042|NCT04059718|Experimental|Treatment|Treatment arm will be enrolled in the SCI Thrive Peer-Led Online Self-Management program and will take part in the next available group session.
89304043|NCT04059718|No Intervention|Wait-list Control|Wait-list control arm will only complete assessments during the 6 week group period. Subjects will be offered a place in the SCI Thrive Peer-Led Online Self-Management program after 6 weeks and completing the assessments.
89304044|NCT03665350|No Intervention|non insulin|standard care + antidiabetic therapy non insulin
89304045|NCT03665350|Experimental|Insulin|standard care including insulin
89304046|NCT03665272|Experimental|fixation by tissue adhesive|In this group, deepithelialized gingival grafts were fixed by tissue adhesive without any suture.
89304047|NCT03665272|Experimental|fixation by sutures|In this groups, deepithelialized gingival grafts were fixed by 4.0 round vicryl sutures.
89304048|NCT03665662|Experimental|Intervention|Patients in this arm will receive patient-selected music through headphones throughout their procedure.
89304049|NCT03665662|No Intervention|Control|Patients will be wearing headphones during their procedure (for the purpose of blinding the care team), but will not receive any music, sounds or sound-cancelling effects through the headphones.
89304050|NCT03002818||HCV Genotype 1 Participants|Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)
89304051|NCT03665584|Active Comparator|FxCO2 Laser|FxCO2 laser treatment will be performed by scanning across the entire affected anogenital region. The FxCO2 treatment will be performed at baseline and then repeated at 4 week intervals for a total of 5 treatments. The laser parameters change with each treatment: power (18, 20, 22, 24, 26W), dwell time (800, 900, 1000, 1000, 1000us) and spacing (1200, 1100, 1000, 1000, 1000um) in respective order.
89304052|NCT03665584|Sham Comparator|Sham Laser|Sham laser treatment will be performed by scanning across the entire affected anogenital region. The sham treatment will be performed using 4W (power), 400us (dwell time), and 1500um (spacing). The laser has no effect on the vulvar tissue using these parameters.
89304053|NCT03665194|Experimental|Cortexolone 17α-propionate 7.5% solution|
89304054|NCT03665194|Placebo Comparator|Vehicle solution|
89304055|NCT03002194|Experimental|RF and PEMF therapy|Each subject is to receive 8 weekly study treatments. The study treatment consists of Glide (medical grade glycerin) being applied thoroughly to the study treatment area (face). The energy will be delivered by the Diamondpolar applicator attached to the Venus Versa, a medical device approved by health regulatory authorities, to deliver combined radiofrequency (RF) and pulsed electromagnetic field (PEMF) energies. Change in skin elasticity will be measured by Cutometer. Change in appearance will be assessed by independent reviewer using photographs.
89304056|NCT03665428|Experimental|PAMB group|PAMB treatment (modified quadruple therapy) for 14 days
89304057|NCT03665428|Active Comparator|PMBT group|PBMT treatment (bismuth-containing quadruple therapy) for 14 days
89304058|NCT03669328||Group 1|patients of 2016, June with locoregional anesthesia
89304059|NCT03669328||Group 2|patients of 2018, June with locoregional anesthesia
89304060|NCT02912650|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
89304061|NCT02912650|Active Comparator|Ibuprofen 250 mg|2 caplets of IBU 125 mg
89304062|NCT02912650|Active Comparator|Acetaminophen 650 mg|2 tablets of APAP 325 mg
89304063|NCT02912650|Active Comparator|Placebo|2 caplets of Placebo
89304064|NCT03004924|Experimental|SHP640|Participants will instill 1 drop of SHP640 (povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
89304065|NCT03004924|Active Comparator|PVP-I 0.6%|Participants will instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID for 7 days
89304066|NCT03004924|Placebo Comparator|Placebo|Participants will instill 1 drop of placebo ophthalmic solution in each eye 4 times QID for 7 days.
89304067|NCT03002038|Experimental|Azathioprine|Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
89304068|NCT03002038|Experimental|Rituximab|Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.
89304069|NCT03664492|Other|Educational Whiteboard video|All the interested participants contacting us will be provided an info email and an internet link via email to access the study through REDCap. Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
89304070|NCT03664414|Placebo Comparator|Placebo group|Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.
89304071|NCT03664414|Active Comparator|Pentoxifylline group|Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.
89304072|NCT02911948|Experimental|Insulin degludec/liraglutide|
89304073|NCT02911948|Active Comparator|Insulin degludec|
89304074|NCT03622840|Other|Parkinson's disease patients with cognitive impairment|Online cognitive remediation program.
89304075|NCT03622918|Sham Comparator|colistin monotherapy|The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
89304076|NCT03622918|Experimental|colistin-rifampin combination|The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
89304077|NCT02996968|Experimental|Self-removal group|The patients randomized to the self-removal group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 7.
89304078|NCT02996968|No Intervention|Office-removal group|The patients randomized to the office-removal group will visit the office for a repeat voiding trial on postoperative day 6-8 (postoperative day 7 will be encouraged). At this visit, the patients will undergo a backfill voiding trial.
89304079|NCT03487666|Experimental|Arm A|Nivolumab 360 mg iv q3weeks for x 6 cycles
89304080|NCT03487666|Active Comparator|Arm B|Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
89304081|NCT03487666|Experimental|Arm C|Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
89304082|NCT03663634|Experimental|Handling Medium Supplemented with Cytochalasin B|
89304083|NCT03663634|No Intervention|Handling Medium as it is.|
89304084|NCT03663556||Very Preterm Infants|Newborn infants with less than 32 weeks admitted in the NICU.
89304085|NCT04058080|Experimental|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6 degrees Celsius, 40% humidity). The class opened with a deep breathing exercise and continued with 50 minutes of standing asanas and 40 minutes of floor-based asanas, including a quick, forceful breathing exercise to finish. All but the last asana (i.e., spine-twisting) were performed twice. Savasana, which is a restorative and relaxation posture, was performed between asanas throughout the floor series and at the end of class. The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
89304086|NCT04058080|Active Comparator|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Selecting these classes was done in consultation with the general manager of the YMCA, who was familiar with each class type. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration.
89304087|NCT04058080|No Intervention|Waitlist|Waitlisted individuals were not able to access yoga or exercise classes throughout the intervention period but participated in the rest of the study protocol. Following the post-treatment assessment, they received access to the class type of their choosing.
89304088|NCT04057690||MCA ischemia without malignant edema|MCA ischemia without malignant edema
89304089|NCT04057690||MCA ischemia with malignant edema|MCA ischemia without malignant edema w/o surgical treatment
89304090|NCT03472612|Experimental|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
89304091|NCT00046839|Experimental|Phase I: Celecoxib 200mg BID + RT|"COX-2 Inhibitor: Celecoxib 200 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
89304092|NCT00046839|Experimental|Phase I: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
89304093|NCT00046839|Experimental|Phase II: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
89304094|NCT00006903|Experimental|Treatment (fulvestrant)|Patients receive fulvestrant intramuscularly on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
89304095|NCT00026793||Kaposi's Sarcoma|Adult patients with biopsy-proven cutaneous Kaposi's sarcoma. Some participants received interleukin-12 and liposomal doxorubicin. However, the therapy was administered on a different protocol and was not part of this study.
89304096|NCT03951597|Experimental|Combined therapy using Gemox, Lenvatinib and PD1|"Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~Lenvatinib (8mg/d), continuous use for 1 year.~PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
89304097|NCT03954561|Experimental|endoscopist group|endoscopist-administered abdominal compression group
89304098|NCT03954561|Active Comparator|assistant group|assistant-administered abdominal compression group
89304099|NCT03539484|Experimental|Part I: Single Participant Cohorts IV/MAD-Escalation|Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).
89304100|NCT03539484|Experimental|Part II: Multiple Participant Cohorts IV/MAD-Escalation|Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation was determined by Part I and RO7172508 was initially given Q3W. Dose-escalation was undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity was reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
89304101|NCT03539484|Experimental|Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)|Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts. These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is equal to or above 2 mg. The starting-dose and regimen once a week or once every 3 weeks (QW or Q3W) for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration but will not exceed the highest safe dose tested in the IV Q3W dose escalation; a minimum dose of 2 mg is defined for a single SC administration. In addition, the QW SC starting-dose will not exceed one third of the IV MTD or of the highest safe IV dose tested. Dose escalation will continue based on safety until determination of the MTD or the planned maximum dose of 400 mg. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
89304102|NCT01327365|Experimental|Sheathless group|patient randomized to the sheathless guiding catheter group
89304103|NCT01327365|Active Comparator|Conventional group|patients randomized to the conventional guiding catheter group
89304104|NCT03951519|Experimental|Water|
89304105|NCT03951519|Active Comparator|Physiological serum|
89304106|NCT01100463|Placebo Comparator|Placebo Lotion|
89304107|NCT01100463|Experimental|0.1% Uracil|
89304108|NCT03726762|Experimental|Diet Beverages|'Diet beverages' after the main meal
89304109|NCT03726762|Experimental|Water|'Water' after the main meal
89304110|NCT01101009|Active Comparator|Perindopril+amlodipine|
89304111|NCT01101009|Active Comparator|Olmesartan/amlodipine|
89304112|NCT01101087|Experimental|Taurolock|
89304113|NCT01101087|Placebo Comparator|Placebo|
89304114|NCT03951363|No Intervention|Qualitative Interview|Interviews: The investigators will enroll at least 10 adults 18 years or older with CKD (self-report).
89304115|NCT03951363|Other|Pilot Testing|Pilot Study: The investigators will enroll 30 adults at least 18 years old with mild to moderate CKD (documented estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m2 plus albuminuria or eGFR 45-59 ml/min/1.73m2) who also have diabetes and/or hypertension.
89304116|NCT03561090|Experimental|1500 mg IW-3718 BID + PPI|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
89304117|NCT03561090|Placebo Comparator|Placebo + PPI|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
89304118|NCT02996500|Experimental|Arm 1: 20 mg QD|PF-06650833 , 20 mg QD
89304119|NCT02996500|Experimental|Arm 2: 60 mg QD|PF-06650833, 60 mg QD
89304120|NCT02996500|Experimental|Arm 3: 200 mg QD|Pf-06650833, 200 mg QD
89304121|NCT02996500|Experimental|Arm 4: 400 mg QD|PF-06650833, 400 mg QD
89304122|NCT02996500|Placebo Comparator|Placebo|Placebo, 0 mg BID
89304123|NCT02996500|Active Comparator|Arm 5: Tofacitinib|Tofacitinib 5 mg BID
89304124|NCT03726684|Experimental|Coding strategy for cochlear implants|Measure neural responses of cochlear implant recipient Use measured values of refractoriness, spread of excitation and facilitation as parameters for a bioinspired coding strategy perform listening tests to compare new coding strategy with standard clinical coding strategy
89304125|NCT00006489|Active Comparator|Naltrexone alone|Naltrexone alone
89304126|NCT00006489|Active Comparator|Naltrexone with CBT for PTSD|Naltrexone with CBT for PTSD
89304127|NCT00006489|Active Comparator|Placebo with CBT for PTSD|Placebo with CBT for PTSD
89304128|NCT00006489|Placebo Comparator|Placebo alone|Placebo alone
89304129|NCT03726606|Experimental|Extended depth of focus intraocular lens|Bilateral implantation of extended depth of focus intraocular lenses.
89304130|NCT03726606|Active Comparator|Trifocal intraocular lens|Bilateral implantation of trifocal intraocular lenses.
89304131|NCT03723408|Other|Single Arm post-approval study|Single Arm post-approval study.
89304132|NCT01096095|Placebo Comparator|Placebo|Placebo
89304133|NCT01096095|Experimental|Sodium phenylbutyrate|Active drug
89304134|NCT03720756|Experimental|Subjects WITH nickel-sensitivity|Subjects on nickel-free diet who have a positive patch-test result, indicating nickel-sensitivity.
89304135|NCT03720756|Active Comparator|Subjects WITHOUT nickel-sensitivity|Subjects on nickel-free diet who have a negative patch-test result, indicating they do NOT have nickel-sensitivity.
89304136|NCT03664102||Sutures with hand-tied knots|Minimally-invasive isolated aortic valve replacement with Sutures were secured with hand-tied knots
89304137|NCT03664102||Sutures with automated fastener device (Cor-Knot)|Minimally-invasive isolated aortic valve replacement with Sutures were secured with automated fastener device (Cor-Knot)
89304138|NCT03535974|Active Comparator|Preparation with Spirulina|6 weeks bid Preparation with Spirulina
89304139|NCT03535974|Placebo Comparator|Placebo|6 weeks bid Placebo
89304140|NCT00025233|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89304141|NCT00025155|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 2 additional courses after achieving CR.
89304142|NCT01100541|Experimental|Polymeric plate characteristics|Evaluation, in the volunteers viewpoint, of the polymeric plate characteristics.
89304143|NCT03720600|Experimental|MAB Intervention|Participants in this condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will watch a voice-guided PowerPoint on MAB strategies for coping with discrimination. For the following two weeks, they will be asked to complete multiple momentary assessments daily for two weeks. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires and complete a qualitative exit-interview.
89304144|NCT03720600|Other|Waitlist-Control|"Participants in the waitlist-control condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will complete an initial set of questionnaires. For the following two weeks, they will be asked to complete multiple daily momentary assessments daily. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires, watch a voice-guided PowerPoint on MAB strategies for coping with discrimination, and complete a qualitative exit-interview."
89304145|NCT03720600|No Intervention|No-EMA Control|"Participants in the No-EMA Control condition will only complete questionnaires at T1 and T2."
89304146|NCT02998996|Experimental|Immunose™ FLU 1%,|15 µg haemagglutinin(HA)/strain and 1% Endocine™
89304147|NCT02998996|Experimental|Immunose™ FLU 2%,|15 µg HA/strain and 2% Endocine™
89304148|NCT02998996|Experimental|Influenza antigen,|15 µg HA/strain
89304149|NCT02998996|Placebo Comparator|Saline (NaCl),|Placebo
89304150|NCT02998996|Active Comparator|i.m. comparator,|15 µg HA/strain
89304151|NCT02998996|Active Comparator|i.n. comparator|
89304152|NCT03663478|Active Comparator|Intervention|Ropivacaine
89304153|NCT03663478|Placebo Comparator|Control|Isotonic saline
89304154|NCT02994940|Experimental|Oral Acetaminophen|Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.
89304155|NCT02994940|Experimental|Intravenous Acetaminophen|Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.
89304156|NCT02994394|Experimental|OPC41061(15 mg) disintegrating tablet with water|OPC41061 (15 mg) orally disintegrating tablet is administered with water.
89304157|NCT02994394|Experimental|OPC-41061(15 mg) disintegrating tablet without water|OPC41061 (15 mg) orally disintegrating tablet is administered without water.
89304158|NCT02994394|Experimental|OPC-41061(15 mg) conventional tablet with water|OPC-41061 (15 mg) conventional tablet is administered with water.
89304159|NCT02994394|Experimental|OPC41061(30 mg) disintegrating tablet with water|OPC41061 (30 mg) orally disintegrating tablet is administered with water.
89304160|NCT02994394|Experimental|OPC-41061(30 mg) disintegrating tablet without water|OPC41061 (30 mg) orally disintegrating tablet is administered without water.
89304161|NCT02994394|Experimental|OPC-41061(30 mg) conventional tablet with water|OPC-41061 (30 mg) conventional tablet is administered with water.
89304162|NCT02998840|Active Comparator|B244 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
89304163|NCT02998840|Active Comparator|B 244 8 Pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
89304164|NCT02998840|Sham Comparator|Vehicle 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
89304165|NCT02998840|Sham Comparator|Vehicle 8 pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
89304166|NCT03663868|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
89304167|NCT03663868|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)
89304168|NCT03663868|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)
89304169|NCT03664570|Experimental|Condition A|"Infusion rate = 25 ml/h~Radiography: confirmation balloon position~VIPUN Balloon Catheter~13C-Octanoate Breath Test o"
89304170|NCT03664570|Experimental|Condition B|"Infusion rate = 75 ml/h~Magnetic resonance imaging~VIPUN Balloon Catheter~13C-Octanoate Breath Test"
89304171|NCT03664570|Experimental|Condition C|"Infusion rate = 250 ml/h~Magnetic resonance imaging~VIPUN Balloon Catheter~13C-Octanoate Breath Testt"
89304172|NCT04057222||Patients included|"Patient with multiple sclerosis and anorectal symptoms, with indication to realize a anorectal manometry, age > 18~A first record of rectal sensory function will be at strong desire to void. A second record will be after void. Rectal sensory function records consist on an anorectal manometry with 3 measures of external anal sphincter resting pressure, 5 measures of RAIR, 1 measure of perception, constant sensation to need to defecate and maximum tolerable threshold volumes."
89304173|NCT01063270|Active Comparator|Oral Antibiotics|
89304174|NCT01063270|Active Comparator|Topical Antibiotics and Laser treatment|
89304175|NCT00023673|Experimental|Phase I: 75.25 Gy/36 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 75.25 Gy given in 36 fractions (2.15 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
89304176|NCT00023673|Experimental|Phase I: 74 Gy/37 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
89304177|NCT00023673|Experimental|Phase I: 70 Gy/35 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 70 Gy given in 35 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
89304178|NCT00023673|Experimental|Phase II: 74 Gy/37 fx + chemotherapy|Phase II: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
89304179|NCT01069900|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride [NaCl solution]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.
89304180|NCT01069900|Active Comparator|Comparator Ertapenem|Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.
89304181|NCT01069120|Active Comparator|50 mg Proellex®|2, 25 mg capsules
89304182|NCT01069120|Active Comparator|25 mg Proellex®|1, 25 mg capsule
89304183|NCT00006237|Active Comparator|Arm I|Patients receive interferon alfa IV on days 1-5 of weeks 1-4 followed by interferon alfa subcutaneously (SC) on days 1, 3, and 5 of weeks 5-52 in the absence of disease progression or unacceptable toxicity.
89304184|NCT00006237|Experimental|Arm II|Patients receive cisplatin IV over 30 minutes followed by vinblastine IV on days 1-4. Patients also receive dacarbazine IV over 1 hour on day 1, interleukin-2 IV over 96 hours on days 1-4, and interferon alfa SC on days 1-5, 8, 10, and 12. In addition, patients receive filgrastim (G-CSF) SC on days 6-15. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
89304185|NCT03662932|Experimental|Early intensive mobilization|Progressed mobilization from postoperative day 0.
89304186|NCT04056988|Experimental|Acute spinal cord injury patients to undergo contrast-enhanced|"Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.~A hand-held intraoperative ultrasound probe will be used to collect sagittal images of the spinal cord centered above the spinal cord injury. A bolus IV injection of DEFINITY® contrast agent (1.5ml DEFINITY®/8.5ml saline) will be given. Continuous imaging will be obtained to record contrast inflow and washout."
89304187|NCT04057066|Experimental|Intervention|Participants receive physical activity counseling as well as an individualized exercise plan.
89304188|NCT03662854|Experimental|Hair Stimulating Complex|Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
89304189|NCT03662854|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline
89304190|NCT03662698|Experimental|Guided Imagery|The GI intervention will include direct, written, and audio delivery of one of three GI vignettes (depiction).The patient will be able to choose one of the three vignettes.
89304191|NCT03662698|Active Comparator|Treatment as Usual|The control, or treatment as usual condition, will include an orientation to RT from the clinic nurse coordinator.
89304192|NCT04056754|Experimental|Abiraterone acetate group|Subjects in this group administered 4 tablets abiraterone acetate once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
89304193|NCT04056754|Placebo Comparator|Placebo group|Subjects in this group administered 4 tablets abiraterone acetate blank analog tablet once daily and 5mg prednisone twice daily, in 28-day cycle on fasting conditions.
89304194|NCT04056442|Experimental|Cannabidiol|300 mg Cannabidiol (synthetic form) Olive Oil Solution, 5%
89304195|NCT04056442|Placebo Comparator|Placebo|Olive Oil Solution
89304196|NCT03663244|Experimental|MindfulnessBasedStressReduction(MBSR)|Standardised, curriculum-based MBSR-programme: 2.5-hour weekly group sessions over 8 weeks; one 6-hour silence retreat day; and 45 minutes daily homework 6 days a week.
89304197|NCT03663244|Experimental|Local Stress Reduction (LSR)|Local stress reduction programme ; developed and delivered by two local psychologists. This programme is delivered in groups of 12 participants, in 2.5-hour weekly sessions over 8 weeks and includes approximately 10 minutes daily homework between the sessions.
89304198|NCT03663244|No Intervention|Wait-list|Usual practice
89304199|NCT03622762|Experimental|Green tea extract|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
89304200|NCT03622762|Placebo Comparator|Placebo|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
89304201|NCT03661606|Experimental|Monitoring arm|Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.
89304202|NCT02993926||Treatment Phase: Enantone|Participants with CPP who were treated with Enantone (≥ 30 μg/kg up to 180 μg/kg) for at least 9 continuous months and who initiated and received the last dose of treatment during the index period from 01 September 1998 to 30 September 2018 (the mean duration of Enantone exposure was 22.3 months, ranging from 10.1 to 52.4 months).
89304203|NCT02993926||Follow Up: Participants No longer Treated for CPP|Participants who had completed their CPP during the treatment phase with Enantone and were no longer on treatment in the follow-up phase (the mean duration of follow up was 8.75 months with a range of 1.9 to 29.5 months).
89304204|NCT02993926||Follow Up: Treated with Non-Enantone GnRHa after Enantone|Participants who were continuing their CPP treatment with a non-Enantone gonadotropin releasing hormone agonist (GnRHa) after treatment with Enantone in the follow-up phase (the mean duration of follow up while on another GnRHa was 10.80 months with a range of 2.8 to 20.5 months, and the mean duration of follow up after stopping treatment was 4.26 months with a range of 0.0 [i.e. 1 day] to 12 months).
89304205|NCT04056676|Active Comparator|Intraoperative modified PEC block only|Intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
89304206|NCT04056676|Experimental|Adding preoperative thoracic paravertebral nerve block|Preoperative thoracic paravertebral nerve block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug and intraoperative modified PEC block with 0.5% bupivacaine 20 ml plus adrenaline 100 ug by surgeon
89304207|NCT04056598||Moderate to severe acne vulgaris|Determined by the acne severity grade of IGA 2 and above
89304208|NCT04056598||Mild acne vulgaris|Determined by the severity grade of IGA <2
89304209|NCT04055506|Experimental|Combination Therapy|
89304210|NCT02993224|Experimental|Deferasirox DT followed by deferasirox FCT|Participants were treated with deferasirox DT followed by deferasirox FCT (core phase). Those who entered the extension phase were treated with deferasirox FCT
89304211|NCT03203200|Experimental|health literacy and technology skill building|ZETRA cognitive behavioral and structural
89304212|NCT03203200|No Intervention|Standard Counselling|Standard of care prevention counselling
89304213|NCT03191812|Sham Comparator|Sham Stimulation|The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation. The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
89304214|NCT03191812|Experimental|M1 Stimulation|The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
89304215|NCT03191812|Experimental|DLPFC Stimulation|The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
89304216|NCT03191812|Experimental|M1+DLPFC Stimulation|The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
89304217|NCT03715088|Experimental|Older Adults (BMI ≥30 kg/m2)|Individuals aged 65-75 living with obesity will perform the Resistance Training Intervention.
89304218|NCT03715088|Experimental|Younger Adults (BMI ≥30 kg/m2)|Individuals aged 18-30 living with obesity will perform Resistance Training Intervention.
89304219|NCT03715010|Active Comparator|Brain Chain Amino Acid (BCAA)|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
89304220|NCT03715010|Placebo Comparator|Placebo|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
89304221|NCT05664620|No Intervention|Low risk|Standard of care to treat post-concussion symptoms in the community
89304222|NCT05664620|No Intervention|Medium risk|Patients who are assigned to the medium risk group will receive the same treatment as the low risk group for one month, after which they will be reassessed. If improving they will go into the low risk group, and if not improving they will go into the high risk group
89304223|NCT05664620|Other|High risk|"A multidisciplinary individualized treatment (personalized medicine) model of treating all post-concussion symptoms simultaneously including the following:~Headache therapy, balance therapy, vestibular therapy, exercise therapy* mental health support e.g. CBT and/or mindfulness meditation* (with more specialized diagnosis and care where required), cognitive assessment and therapy, vision therapy, sleep assessment and therapy, physiotherapy, education sessions*, occupational therapy These patients will be treated through the Altum Health Neurology Specialty Program~*Offered to all high risk patients"
89304224|NCT03714698|Active Comparator|Pilates Exercise Group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
89304225|NCT03714698|Placebo Comparator|Control Group|the control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
89304226|NCT03639038||Blood Assay Phase - 1|TB Positive / HIV Positive: 65 participants
89304227|NCT03639038||Blood Assay Phase - 2|TB positive / HIV Negative: 65 participants
89304228|NCT03639038||Blood Assay Phase - 3|TB positive and negative Paediatric: 30 participants
89304229|NCT03639038||Blood Assay Phase - 4|TB Negative/HIV positive: 50 participants
89304230|NCT03639038||Blood Assay Phase - 5|Healthy controls: 30 participants
89304231|NCT03639038||Sputum Collection Phase - 1|TB Positive: Xpert Rif sensitive: 100 participants
89304232|NCT03639038||Sputum Collection Phase - 2|TB Positive: Xpert Rif resistant: 20
89304233|NCT03639038||Sputum Collection Phase - 3|TB Negative: Other chest: unknown number
89304234|NCT03639038||Sputum Collection Phase - 4|TB Negative: Smear negative/Xpert negative: 20
89304235|NCT03495908|Experimental|VGo with Regular Human Insulin|U-100 short-acting insulin, Regular, human insulin rDNA origin, including Humulin® R, Novolin® R, and ReliOn (Novolin R) delivered by V-Go
89304236|NCT03495908|Active Comparator|VGo with Rapid Acting Insulin|U-100 fast-acting insulin including Humalog® (insulin lispro, rDNA origin) or NovoLog® (insulin aspart, rDNA origin), which have both been tested by Valeritas, Inc. and found to be safe for use in the V-Go or Apidra® (insulin glulisine, rDNA origin) delivered by V-Go
89304237|NCT03714542|Other|Pre- and postoperative MRI|All patients will undergo a preoperative MRI and will have a postoperative follow-up with CT and MRI.
89304238|NCT03714464|Experimental|Whole Apple|"Participants will be given 350g of whole apple and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
89304239|NCT03714464|Experimental|Apple Puree|"Participants will be given 384g of apple puree and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
89304240|NCT03714464|Experimental|Apple Juice|"Participants will be given 338g of apple juice and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes"
89304241|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with reduced ejection fraction
89304242|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with reduced ejection fraction
89304243|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with reduced ejection fraction
89304244|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with reduced ejection fraction
89304245|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with reduced ejection fraction
89304246|NCT02992288|Placebo Comparator|Placebo|Chronic heart failure with reduced ejection fraction
89304247|NCT03714386|Experimental|expanded hemodialysis (HDx)|HDx therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
89304248|NCT03714386|Active Comparator|online hemodiafiltration (HDF-OL)|OL-HDF therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
89304249|NCT03717818|Experimental|Good Psychiatric Management-Brief|
89304250|NCT03717818|Placebo Comparator|Treatment as Usual-Brief|
89304251|NCT02992132|Experimental|Pimavanserin 34 mg|Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
89304252|NCT02992132|Experimental|Pimavanserin 20 mg|Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
89304253|NCT02992132|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
89304254|NCT03660748|Experimental|Lower BMI|Use of MET-2 in subjects with BMI of 30.0 to 34.9
89304255|NCT03660748|Experimental|Higher BMI|Use of MET-2 in subjects with BMI of 35 to 39.9
89304256|NCT03444584|Experimental|MEDI0382|Participants will receive subcutaneous dose of MEDI0382 daily (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days) for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period.
89304257|NCT03444584|Placebo Comparator|Placebo|Participants will receive subcutaneous dose of placebo matched to MEDI0382 daily for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period
89304258|NCT02989168|Experimental|GBT440 900 mg Dose|"Part A, 900 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
89304259|NCT02989168|Experimental|GBT440 1500 mg Dose|"Part B , 1500 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
89304260|NCT02988622|Other|Scar treated with Fraxel and CO2 laser|One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
89304261|NCT03717740|Experimental|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
89304262|NCT03717740|Placebo Comparator|Placebo|Patients will take Placebo Oral Tablet once a daily oral tablet from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
89304263|NCT03720548|Experimental|LY3372993 (Part A)|LY3372993 administered intravenously (IV) to healthy participants.
89304264|NCT03720548|Placebo Comparator|Placebo (Part A)|Placebo administered IV to healthy participants.
89304265|NCT03720548|Experimental|LY3372993 (Part B)|LY3372993 administered IV to participants with AD. Part B was terminated before any participants received treatment.
89304266|NCT03720548|Placebo Comparator|Placebo (Part B)|Placebo administered IV to participants with AD. Part B was terminated before any participants received treatment.
89304267|NCT04055584||Sputum spot|
89304268|NCT03714152|Experimental|ABI-H2158|ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days
89304269|NCT03714152|Placebo Comparator|Matching Placebo for ABI-H2158|Matching Placebo in varying doses of tablets by mouth without and with food for 1 day or 10 days
89304270|NCT03622684|Experimental|Muscle relaxation according to Jacobson|. Does the use of the method of progressive relaxation according to Jacobson will be beneficial to reduce pain and improve the functioning of the stomatognathic system being evaluated in clinical trials?
89304271|NCT03412604|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.
89304272|NCT02991430|Active Comparator|active|active neuromodulation
89304273|NCT02991430|Placebo Comparator|placebo|placebo neuromodulation
89304274|NCT03411902|Active Comparator|Risedronate|Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.
89304275|NCT03411902|Placebo Comparator|Placebo|Active comparator: Identical 150 mg placebo capsules once every 4 weeks for 24 weeks.
89304276|NCT03714074|Experimental|PEEK abutment|PEEK abutment restored with PEEK superstructure
89304277|NCT03714074|Experimental|Zirconia abutment|zirconia abutment restored with PEEK superstructure
89304278|NCT03717662|Experimental|Brief counseling and NRT|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers (including all types of tobacco products such as shisha, electronic cigarettes and heat-not-burn (HNB) which are available in the market) who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
89304279|NCT03494816|Experimental|Axitinib|Axitinib - oral tablet twice daily for 8 weeks prior to surgery. Starting dose 5mg.
89304280|NCT03713996|Experimental|CBT-I intervention|The intervention includes several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components.
89304281|NCT03713996|Active Comparator|Diabetes Education|Sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity will be delivered for the Health Education group. During all sessions, subjects will be encouraged to engage in the discussion through open questions about their experience in diabetes, lifestyle, and understanding about provided materials.
89304282|NCT03492554|Other|Atrial fibrillation (AF)|Patient with a known history of AF who are in AF at the time of study screening.
89304283|NCT03492554|Other|Normal Sinus Rhythm (SR)|Patient with no known diagnosis of AF or other arrhythmia
89304284|NCT03713918|Experimental|Reinforced lithium silicate endocrown|Device: Endocrown restoration
89304285|NCT03713918|Active Comparator|Reinforced lithi silicate crn e post|Device: Post retained reinforced lithium silicate crowns
89304286|NCT03713840|Experimental|Healthy Beverages in Child Care|Child care centers in the experimental arm received 12-week intervention that promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
89304287|NCT03713840|No Intervention|Control|Child care centers in the control arm received access to intervention materials at a later date.
89304288|NCT03410420|Active Comparator|Non aneurysmal|Intervention: four non-aneurysmal patients undergoing coronary artery bypass graft or aortic valve replacement will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
89304289|NCT03410420|Experimental|Aneurysmal|Intervention: four patients who are candidates for aortic replacement due to aneurysm will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
89304290|NCT03713762|Experimental|Group 1 LB|Peribulbar block 1 was performed received 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml
89304291|NCT03713762|Experimental|Group 2 LBF|Peribulbar block 2 was performed received 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
89304292|NCT03713606||Overall eligible participants|Eligible participants will receive HVPG measurement by catheterization of a hepatic vein with a balloon catheter and run blood tests.
89304293|NCT05975437||Care as usual|Participants who are included during care as usual, before the hospital's transition to personalized follow-up. Care as usual is organized as 'one-size fits all' and does not take individual differences in prognoses and needs into account. For the majority of hospitals follow-up includes annual mammography and physical examination combined with discussing of the results of the mammogram and sometimes also the patient's needs.
89304294|NCT05975437||Personalized care|Participants who are included after the hospital's transition to personalized follow-up. After this transition, personalized follow-up becomes the standard form of care for all patients, regardless of their participation in this study. Participants of this group receive personalized follow-up, which is based on individual prognoses and needs. Personalized follow-up will be provided by the use of personalized surveillance (PSP) and personalized aftercare plans (PAP).
89304295|NCT05975424||Subjects treated with AST-OPC1 in the initial dosing study AST-OPC1-01|Subjects treated with AST-OPC1 in the initial dosing study AST-OPC1-01 will be followed for 15-year long-term safety monitoring
89304296|NCT05975411||telemedecine cabin|Anesthesia Consultation with telemedicine cabin installed in Dozulé
89304297|NCT05975411||telemedicine trolley|Anesthesia Consultation with telemedicine by way of the telemedicine trolley installed in a center close to their place of residence
89304298|NCT05975411||standard|Anesthesia Consultation at the CHU de Caen as usual.
89304299|NCT05975346||(K) Ketamine group|40 patients will receive ketamine 50mg (1.0 ml with 4.0 ml of the saline) nebulization
89304300|NCT05975346||(S) Saline group|40 patients will receive saline nebulization (5ml).
89304301|NCT05975294|Active Comparator|Group(E):|including 30 patients with multiple fracture ribs will undergo ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.
89304302|NCT05975294|Active Comparator|Group (C)|including 30 patients with multiple fracture ribs will be given intravenous PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
89304303|NCT05975242|Experimental|Interventional group|The interventional group will use the digital self-management smartphone application during the 12-week study period and will have access to 3 coaching sessions. The interventional group will be trained in the use of the app and receive education focused on self-monitoring blood glucose based on paired (before and 2 hours after a meal) blood glucose testing, which participants will conduct twice daily for 6 days once monthly for 3 months.
89304304|NCT05975242|No Intervention|Control group|The control group will not have use of the digital self-management smartphone application during the 12-week study period and will not have access to 3 coaching sessions. No structured self-monitoring blood glucose testing will be done.
89304305|NCT05975229|Experimental|experimental|Educational pamphlet and knitting program
89304306|NCT05975229|Other|control|Educational pamphlet and assigned to a waiting list
89304307|NCT05975190|Experimental|R&R arm (interventional arm)|The training program in the experimental arm includes relaxation techniques, breath hold training, music, and nature sounds that patients can listen to on an MP3 player. The training is offered one week before the planning CT scan and patients are encouraged to practice independently. Patients complete standardized questionnaires about their well-being and satisfaction at prospective time points before, during the radiation treatment course, as well as at 6 weeks follow-up.
89304308|NCT05975190|No Intervention|Standard arm|Patients in the standard arm receive current conventional DIBH instruction without an extended R&R training. Patients complete standardized questionnaires about their well-being and satisfaction at prospective time points before, during the radiation treatment course, as well as at 6 weeks follow-up.
89304309|NCT05975138||trans-gingival short implants|trans-gingival implant insertion in the posterior atrophic maxilla
89304310|NCT05975138||subcrestal short implants|subcrestal implant insertion in the posterior atrophic maxilla
88806367|NCT00352976|Experimental|Treatment with TBI|Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.
89304311|NCT05975125|Experimental|Iron supplement with Vitamin C|"Vitamin C with Iron supplement~Drug:~Vitamin C 500mg Triferdine(Component: Iodine 0.15 mg, Iron 60.81 mg, Folic acid 0.4 mg)"
89304312|NCT05975125|No Intervention|Iron supplementation alone|Iron supplement alone Drug: Triferdine Component: Iodine 0.15 mg, Iron 60.81 mg, Folic acid 0.4 mg
89304313|NCT05975112||cesarean section|"maternal blood is drawn immediately after the baby's cord is cut and analyzed using thrombelastography with the addition of tranexamic acid. In addition, the following parameters are examined:~Levels of Factor 1 (Fibrinogen) and Factor 2 (Thrombin)~Level of hs-D-Dimer~SpHb is measured before discharge from the delivery room in order to estimate blood loss and to be able to make a comparison with the level of Hb measured in the laboratory as part of clinical routine."
89304314|NCT05975112||vaginal delivery|"maternal blood is drawn immediately after the baby's cord is cut and analyzed using thrombelastography with the addition of tranexamic acid. In addition, the following parameters are examined:~Levels of Factor 1 (Fibrinogen) and Factor 2 (Thrombin)~Level of hs-D-Dimer~SpHb is measured before discharge from the delivery room in order to estimate blood loss and to be able to make a comparison with the level of Hb measured in the laboratory as part of clinical routine."
89304315|NCT05975034|Experimental|Probiotic|Participants assigned to the probiotic group.
89304316|NCT05975034|Placebo Comparator|Placebo|Participants assigned to the placebo group.
89304317|NCT05974995|Experimental|Robotic surgery|
89304318|NCT05974995|Active Comparator|Laparoscopic surgery|
88806368|NCT00306488|Experimental|OT-551 antioxidant eye drop|The fellow eye was treated with OT-551 antioxidant eye drops over the course of the study.
88806369|NCT04751006|Experimental|Gaze Group|Participants performed balance training with gaze stabilization exercises
89304319|NCT05974982|Experimental|Platelet-rich plasma|Under aseptic precautions 20 ml of venous blood was drawn and added to a test tube containing acid citrate dextrose in a ratio of 9:1 (blood: Acid citrate dextrose), centrifuged at 5000 rpm for 15 min to separate the red blood cells from the platelets and plasma. Then the supernatant and the buffy coat composed of platelets and plasma were collected and centrifuged again at 2000 rpm for 5-10 min. The bottom layer about 1.5 ml was taken and 10% calcium chloride was added (0.3 ml for 1 ml of PRP). Then the activated PRP was applied to the wound after proper surgical debridement and was dressed with a non-absorbent dressing (paraffin gauze). This process was repeated once weekly for 6 weeks.
89304320|NCT05974982|Active Comparator|Conventional therapy|These patients were treated conservatively by compression using graduated elastic stockings below the knee and dressing using saline and vaseline gauze weekly for 6 weeks.
89304321|NCT05974956|No Intervention|Control group|The control group exposed to routine care.
89304322|NCT05974956|Experimental|Study group|"The study group received the sessions of mastitis care teaching protocol."
89304323|NCT05974943|Experimental|the pre-post training and 3rd-month evaluations of problem-solving skills of the nurse managers in|The research was conducted with randomized control, pretest-posttest, experimental, and control group design. By using G*Power analysis, it was determined that the experimental group of the nurse managers was 30 people and included randomly in the sample calculation of the study. The experimental group was given 2 days of problem-solving and decision-making training. Before the training, the nurse administrators in the experimental group were administered the Participant Information Form-Nurse Manager, PSI, DMSS and two Case Evaluation Forms and Problem Solving and Decision Making Information Form-Pre-Test-Post-Test.
89304324|NCT05974943|No Intervention|the pre-post training and 3rd-month evaluations of the decision-making skills of the nurse managers|The research was carried out in randomized control, pretest-posttest, experimental and control group design. In the sample calculation of the study, 30 of the manager nurses were determined by using G*Power analysis as the control group and were included randomly. No intervention was made in the control group. At the same time as the experimental group, the nurse administrators in the control group were also administered the Participant Information Form-Nurse Manager, PSI and DMSS.
89304325|NCT05974943|No Intervention|pre-training and 3rd-month evaluations of regarding the problem-solving and decision-making skills|Three months after the initial assessment, the nurse managers in the experimental and control groups were administered PCI and CVSQ.
89304326|NCT05974930||Patients with STEMI undergoing IVUS-guided primary PCI|The ULTRA-STEMI trial will include consecutive patients with STEMI undergoing IVUS-guided primary PCI. All participants will undergo: IVUS intra-coronary imaging at baseline-, post-intervention and post-optimization. If manual thrombus aspiration is needed, the aspirated thrombotic material will be collected to be micro-CT scanned. Post-PCI iFR will be also performed in each participant. Clinical, angiographic and peri-procedural data will be collected. Each participant will be subject to telephone follow-up at 1, 6 and 12 months.
89304327|NCT05974917||Group 1|with 'Serious Game' to support the asthma treatment plan
89304328|NCT05974917||Group 2|without 'Serious Game' and will follow the standard treatment plan
89304329|NCT05974865|Experimental|Healthy Babies and Health Moms|Healthy Babies and Healthy Moms was designed as a 20-minute communication skills-based computer program based on key social learning principles designed to empower women to more actively and productively use targetted skills to improve the medical dialogue of their prenatal visits.
89304330|NCT05974865|Active Comparator|Baby Basics Prenatal Guide|The Baby Basics Prenatal Guide, published by the What to Expect Foundation, was used in a face-to-face educational session with a study research assistant during which pregnancy related information was personalized by reviewing relevant sections of the Baby Basics prenatal guide.
89304331|NCT05974813|Experimental|L-Citrulline|Participants will receive 6 g (3 g every 12 h) of L-citrulline (Now, L-citrulline Pure Powder) for six-days.
89304332|NCT05974813|Placebo Comparator|Placebo|Participants will receive 6 g (3 g every 12 h) of maltodextrin (Now, Maltodextrin) for six-days.
89304333|NCT05974761|Experimental|Side lying muscle massage|The patient was placed in a lateral decubitus position with the physician standing on the ventral side of the patient, with the crotch resting on the anterior edge of the superior iliac crest, and the elbow rising from the medial side of the highest point of the superior iliac crest, follow the palpation (avoiding the L3 transverse process) along the steep edge of the skeleton slowly toward the spine, and focus on the painful points or cords by repeatedly applying the elbow press method and the elbow flick method for 1-2 minutes, after that, the tendon was found to be induration with elbow tip probing, and the tendon was plucked 3-5 times vertically along the vertical direction.
89304334|NCT05974761|Other|Traditional Chinese massage|Through the point, massage, bone-setting treatment
89304335|NCT05974709||Office Workers|The study will document the sociodemographic attributes of the participants, encompassing variables such as age, gender, height, weight, educational attainment, marital status, occupation, daily working hours, and professional experience. The data pertaining to the variables in question were obtained through employment of a structured questionnaire.
89304336|NCT05974696||Patients RECAPitNETT|All adult subjects with pituitary tumours whose file is presented to the national HYPOcare RCP. There is only one group.
89304337|NCT05974683|Placebo Comparator|Basic Maintenance Treatment|Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
89304338|NCT05974683|Active Comparator|Enhancement Treatment|Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
89304339|NCT05974670||Wearing device|The subjects are required to fill in the COPD symptom diary every day, and conducted online or offline follow-up at the 4th, 8th, 12th, 16th, 20th, and 24th weeks after enrollment. The physiological parameters of wearable devices, including pulse rate, blood oxygen saturation, physical activity, electrocardiogram, and sleep, will be continuously collected during the study.
89304340|NCT05974657|Placebo Comparator|Placebo group|Composition: 400mg maltodextrin (excipient)； Capsule total weight: 400mg； Primary conditioning: HPMC Capsules (Hydroxypropyl Methylcellulose)； Secondary conditioning：Cardboard case Secondary packaging content：14 capsules / blister, 1 blisters per case Dosage regimen: Take one capsule daily before meals； Storage：Store in a cool, dry place without exposure to the sun.
89304341|NCT05974657|Active Comparator|Probiotic group|Composition: 20mg (2x109 UFC/ capsule) Lactobacillus acidophilus LA85 (active principle) and 380mg maltodextrin (excipient)； Capsule total weight: 400mg； Primary conditioning: HPMC Capsules (Hydroxypropyl Methylcellulose)； Secondary conditioning：Cardboard case Secondary packaging content：14 capsules / blister, 1 blisters per case Dosage regimen: Take one capsule daily before meals； Storage：Store in a cool, dry place without exposure to the sun.
89304342|NCT05974644||Asymptomatic carriers|
89304343|NCT05974644||Patients with cardiac hereditary transthyretin amyloidosis (hATTR)|
89304344|NCT05974618||First arm (primary objective):|"First arm (primary objective): Adnexal mass scanned at 11-14 weeks. If the decision is to manage the adnexal mass conservatively, the patient is to be re-scanned once more: 0 - 90 days postpartum. In addition, the patient will be asked to enter into the third arm of the study (see below) knowing that she can opt out from that arm at any point. If she consents to participate in the third arm, she will participate in a series of longitudinal examinations as described for the third arm.~All patients with a mass detected before 11 weeks will also be scanned at 11-14 weeks and can enter all three arms of the study. In this scenario, if more than one scan is performed during pregnancy before 11 weeks, only the first of several scans before 11 weeks will be included for the second and third arms of the study."
89304345|NCT05974618||Second arm (secondary objective):|"Second arm (secondary objective): Adnexal mass is seen for the first time during that pregnancy at any gestation. If the decision is to manage the adnexal mass conservatively, the patient is to be re-scanned once more: 0 - 90 days postpartum. For patients with a mass detected before 11 weeks, see also above (they will be re-scanned at both 11-14 weeks and at 0-90 days postpartum).~In addition, the patient will be asked to enter into the third arm of the study knowing that she can opt out from that arm at any point. If she consents to this, she will participate in a series of longitudinal examinations as described for the third arm."
89304346|NCT05974618||Third arm (secondary objective):|"Third arm (secondary objective): Patients from the first and second arms who agree to enrol into the third arm i.e. longitudinal examination of an adnexal mass during pregnancy. For the purposes of the longitudinal evaluation, the time points for the ultrasound examination are:~initial presenting scan if <11 weeks;~11-14 weeks;~16 week scan - endometriomas ONLY;~second trimester routine scan (18-22 weeks);~30-34 weeks;~any additional scans during pregnancy which resulted in either conservative management with extra scans or surgical intervention (with reason for the extra scan or for surgery documented);~0-90 days postpartum."
89304347|NCT05974566||HFrEF patients who accept finerenone therapy|Patients with HFrEF receive finerenone 10mg or 20mg daily treatment for 3 months in addition to other medications.
89304348|NCT05974566||HFrEF patients who accept Spironolactone or eplerenone therapy|Patients with HFrEF receive spironolactone or eplerenone treatment daily treatment for 3 months in addition to other medications.
89304349|NCT05974527|Experimental|Intervention - BXCL501|
89304350|NCT05974501|Active Comparator|Preoperative Adductor Canal Block Group|Participants in this group will receive the standard of care treatment for pain management for TKA including a preoperative adductor canal block. Participants will be in this group for up to 24 hours after surgery.
89304351|NCT05974501|Experimental|Postoperative Adductor Canal Block Group|Participants in this group will receive the standard of care treatment for pain management after TKA, however, the adductor canal block will be placed postoperatively. Participants will be in this group for up to 24 hours
89304352|NCT05974436|Experimental|Hemodiafiltration with high-flux dialyzer|Patients are dialysed at midweek using hemodiafiltration (autoflow) with an FX800 Cordiax high-flux dialyzer, with dialysate flow of 700mL/min
89304353|NCT05974436|Experimental|Hemodialysis with medium cut-off dialyzer and high dialysate flow|Patients are dialysed at midweek using hemodialysis with a Theranova 400 medium cut-off dialyzer with dialysate flow of 700mL/min
89304354|NCT05974436|Experimental|Hemodialysis with medium cut-off dialyzer and low dialysate flow|Patients are dialysed at midweek using hemodialysis with a Theranova 400 medium cut-off dialyzer with dialysate flow of 300mL/min
89304355|NCT05974423|Active Comparator|Control - Narcotic Prescription|"Oxycodone 5 mg 1 tablet every 6 hours PRN~Tylenol 1000 mg every 8 hours~Ibuprofen 600 mg every 6 hours as needed for pain"
89304356|NCT05974423|Experimental|Experimental - Non-narcotic only|"This group will not be sent home with an oxycodone prescription. They will be sent home with the following prescriptions. If this does not manage their pain, they will call the resident on call who will reach out to the PI. The PI will then electronically send in a prescription of oxycodone to their pharmacy if required. The PI or operating surgeon (co-investigators) will be available 24/7 to do this. They will be sent home with these two prescriptions:~Tylenol 1000 mg every 8 hours~Ibuprofen 600 mg every 6 hours as needed for pain"
89304357|NCT05974397||AMI|Patients with AMI
89304358|NCT05974397||STEMI|Patients with STEMI
89304359|NCT05974397||NSTEMI|Patients with NSTEMI
89304360|NCT05974371|Experimental|Emotional memory updating paradigm|All participants will encode AB/AC word pairs shown with images that have differing emotional valence (positive, negative, or neutral)
89304361|NCT05974332|Active Comparator|Ulcerative colitis Patients|45 Patients with UC. The diagnosis of UC will be based on endoscopic finding and histopathological finding
89304362|NCT05974332|Active Comparator|Control|45 apparently healthy subjects as controls who were not UC
89304363|NCT05974319|No Intervention|Control group|During the blood sample collection, the application was carried out in line with the routine care.
89304364|NCT05974319|Experimental|Dry heat application|The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
89304365|NCT05974319|Experimental|Dry cold application|The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
89304366|NCT05974306|Experimental|ILR group|patients implanted with an implantable loop recorder to be monitored remotely.
89304367|NCT05974306|No Intervention|in-hospital fup group|Patients that will be followed with in-hospital visits.
89304368|NCT05974215|Active Comparator|group 1|patients received mandibular implant supported removable overdenture
89304369|NCT05974215|Active Comparator|group 2|patients received mandibular implant supported fixed overdenture
89304370|NCT05974163||Model reconstruction cohort|8000 patients were recruited retrospectively from January 2023 to December 2025 as discovering group.
89304371|NCT05974163||External Validation cohort 1|1000 patients were recruited retrospectively from January 2023 to December 2025 as internal validation group.
89304372|NCT05974163||External validation cohort 2|1000 patients will be recruited prospectively during the period from January 2023 to December 2025 as external validation group
89304373|NCT05974085|Experimental|Selinexor+RCHOP|Selinexor: 60 mg QW Rituximab: 375 mg/m2, d0 Vincristine: 4 mg, d1 Epirubicin: 75 mg/m2, d1 or Liposomal doxorubicin: 35 mg/m2, d1 Cyclophosphamide: 750 mg/m2, d1 Prednisone: 100 mg, d1-5
89304374|NCT05974072|Active Comparator|Usual Care (Pharmacological Control)|The subjects in the control group will be treated following a pharmacological approach according to the latest clinical guidelines for patients with chronic low back pain. Thus, the pharmacological options to be considered in each patient will be those included in the first and second analgesic steps of the WHO (preferably without including minor opioids).
89304375|NCT05974072|Experimental|PAINDOC Program|"The PAINDOC Program is a multidisciplinary treatment that integrates four parts provided by different health professionals and consists of 8 sessions carried out in the pain unit of the Hospital Clinic of Barcelona over two months.~It consists of a therapeutic education (Empowered Relief) session given by a physician from the unit, a pain psychology session given by a psychologist, an introductory mindfulness meditation session given by an advanced practice nurse, and two pain neuroscience education sessions and three therapeutic exercise sessions given by a physiotherapist. This program is already part of the pain unit's routine care practice, so it is considered that the sessions of this program do not represent an additional and specific visit for the patients."
89304376|NCT05974059|Experimental|Cadonilimab|10 mg/kg, d1, Q3W;
89304377|NCT05974033|Experimental|Intervention group|Stenting plus medical therapy
89304378|NCT05974033|Active Comparator|Control group|Medical therapy alone
89304379|NCT05974007||Resectable stage I-III NSCLC|Patients with NSCLC patients receiving neoadjuvant therapy and undergoing surgeries. Resectability after neoadjuvant therapy is judged by the multidisciplinary team of thoracic surgeon, oncologist and radiation oncologist.
89304380|NCT05973994||Patients with significant calcific coronary artery stenosis candidate to PCI|Patients with coronary artery calcifications responsible for significant stenosis will undergo basal OCT acquistion. After intravascular lithotripsy (IVL) application, a second OCT acquisition will be made. The mean calcium density of the vessel's ROI before IVL and after IVL will be compared. Stent implantation will be performed after the second OCT acquisition.
89304381|NCT05973942|Experimental|Wingman-Connect|Wingman-Connect (Wyman et al., 2020) uses a network health theoretical framework to strengthen two suicide-protective functions of social networks: 1) Strengthening positive social bonds, and 2) Building healthy norms that incentivize adaptive coping. Training will be delivered in First Term Airmen classes among all Airmen arriving at base during the study period.
89304382|NCT05973916|Experimental|Comprehensive intervention|"Cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed."
89304383|NCT05973916|No Intervention|Common Practice|"Patients' rooms will be cleaned and disinfected according to the current common practice as detailed below."
89304384|NCT05973864|Experimental|Arm A : Pembrolizumab and capecitabine|"Pembrolizumab will be administered at a fixed dose of 200 mg every 3 weeks (Q3W), with a total of 9 cycles at adjuvant phase of the treatment;~Capecitabine will be administrated at a dose of 1250 mg/m² twice a day (BID) (14 days on / 7 days off) for a total of 8 cycles, with a dose reduction at 825 mg/m² BID during radiotherapy if indicated~Local radiotherapy will be performed as per standard practice if indicated."
89304385|NCT05973864|Active Comparator|Arm B : Pembrolizumab alone|"Pembrolizumab will be administered at a fixed dose of 200 mg Q3W, with a total of 9 cycles at adjuvant phase of the treatment;~Local radiotherapy will be performed as per standard practice if indicated."
89304386|NCT05973812|Experimental|Probiotic group|All infants (3-months-old) in the probiotic group consumed an infant formula supplemented with a freeze-dried probiotic (7 log10 colony-forming units [CFU] of B. breve PS1 per gram of formula) for 3 months.
89304387|NCT05973812|Sham Comparator|Control group|All infants (3-months-old) in the control group consumed the same infant formula but without probiotic supplementation.
89304388|NCT05973760||Hypertensive|Men or women previously diagnosed with hypertension
89304389|NCT05973760||Non-hypertensive|Men or women not previously diagnosed with hypertension
89304390|NCT05973721|Experimental|Phage treatment group|
89304391|NCT05973617||Glaucoma|Patients with diagnosis of glaucoma, that are receiving or had surgery to treat glaucoma
89304392|NCT05973617||Ocular hypertension|Patients with diagnosis of ocular hypertension, that are receiving or had surgery to treat ocular hypertension
89304393|NCT05973617||Keratoconus|Patients with diagnosis of keratoconus, that are receiving or had surgery to treat keratoconus
89304394|NCT05973617||Healthy controls|Healthy
89304395|NCT05973591||achieved HR ≥ 70 bpm without ivabradine|**Achieved HR : heart rate (HR) at 12 month follow up after the initiation of GDMT**
89304396|NCT05973591||achieved HR < 70 bpm without ivabradine|**Achieved HR : heart rate (HR) at 12 month follow up after the initiation of GDMT**
89304397|NCT05973591||achieved HR ≥ 70 bpm with ivabradine|**Achieved HR : heart rate (HR) at 12 month follow up after the initiation of GDMT**
89304398|NCT05973591||achieved HR < 70 bpm with ivabradine|**Achieved HR : heart rate (HR) at 12 month follow up after the initiation of GDMT**
89304399|NCT05973578|Other|Stereotactic body radiotherapy|Patients will be treated with a stereotactic body radiotherapy technique as a single fraction treatment up to a dose of 25 Gy delivered to the VT substrate
89304400|NCT05973552||All participants|Women (n=250), are followed throughout their pregnancy. Mother-infant pairs are followed throughout the first 6-months postpartum. Women receive daily oral iron supplementation during pregnancy in accordance with local standards of care. Using the stable iron isotopes dilution methodology, concentration of the stable iron isotope tracer (57Fe) in circulation will be measured throughout pregnancy and up to 6 months postpartum in both, mother and infant.
89304401|NCT05973552||Randomly selected sub-group|To directly assess dietary iron absorption, in a randomly selected subset of women (n=35), oral and intravenous stable iron isotope tracers (54Fe, 58Fe) will be administered. Oral iron absorption and erythrocyte iron incorporation will be measured 14 days after tracer administration.
89304402|NCT05973526|Experimental|Percutaneous|In one of the infraumbilical hemibody, for percutaneous electrolipolysis, 2 pairs of needles will be introduced (0 ,25mm x 40mm) paired at a distance of 5 cm at 45º reaching the dermis-hypodermis tissue. The needles will be positioned at a distance of 2 cm laterally to the umbilicus and 5 cm below this marking, covering an area of about 10 cm laterally. This technique will have their electrodes connected to the Neurodyn 10-channel device belonging to the brand Ibramed®, in the electrolipolysis program.
89304403|NCT05973526|Experimental|Transcutaneous|In one of the infraumbilical hemibody, for transcutaneous electrolipolysis, 1 pair of silicone electrodes with conductive gel will be fixed with adhesive tape. The surface electrodes will be positioned at a distance of 2 cm laterally to the umbilicus and 5 cm below this marking, This technique will have their electrodes connected to the Neurodyn 10-channel device belonging to the brand Ibramed®, in the electrolipolysis program.
89304404|NCT05973513||Immediate Enrollment|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
89304405|NCT05973266|Experimental|Experimental Group|Patients using mobile application as well as verbal and written information in bowel preparation training in patients who will undergo colonoscopy will constitute the experimental group.
89304406|NCT05973266|No Intervention|Control Group|Patients who will be given oral and written information in bowel preparation training in patients who will undergo colonoscopy will form the control group.
89304407|NCT05972148|Active Comparator|Intraoral Scanning|
89304408|NCT05972148|Experimental|Photogrammetry Scanning|
89304409|NCT05971927|Experimental|Experimental group|Simulation education
89304410|NCT05971927|No Intervention|Control groups|The control group did not receive any simulation training.
89304411|NCT05971797|Experimental|Comorbidities|Upon admission to the hospital for surgery to replace large joints (knee or hip joints) and diagnosis with osteoarthritis of the knee or hip joint (M15.0, M16, M17), patients with comorbidities underwent 20-minute psychological counseling (PC) session. During PC the levels of depression (F32.0, F32.1 or F32.9) and anxiety (F41.0, F41.1, F41.3, F41.8 or F41.9) were assessed using the STAI and HADS questionnaires. In the experimental group, patients with identified increased levels of depression or anxiety underwent a session of rational-emotional-behavioral therapy, which aimed to modify incorrect thinking patterns. The level of anxiety and depression was reassessed after the surgery.
89304412|NCT05971797|No Intervention|Comorbidities control|Upon admission to the hospital for surgery to replace large joints (knee or hip joints) and diagnosis with osteoarthritis of the knee or hip joint (M15.0, M16, M17), patients with comorbidities underwent 20-minute PC. During PC, their levels of depression (F32.0, F32.1 or F32.9) and anxiety (F41.0, F41.1, F41.3, F41.8 or F41.9) were assessed using the STAI and HADS questionnaires. In the first control group, patients with identified increased levels of depression or anxiety did not receive REBT therapy. The level of anxiety and depression was reassessed after the surgery.
89304413|NCT05971797|Active Comparator|No comorbidities|Upon admission to the hospital for surgery to replace large joints (knee or hip joints) and diagnosis with osteoarthritis of the knee or hip joint (M15.0, M16, M17), patients without comorbidities underwent 20-minute PC session. During PC the levels of depression (F32.0, F32.1 or F32.9) and anxiety (F41.0, F41.1, F41.3, F41.8 or F41.9) were assessed using the the STAI and HADS questionnaires. In the second control group, patients with identified increased levels of depression or anxiety underwent a session of rational-emotional-behavioral therapy, which aimed to modify incorrect thinking patterns. The level of anxiety and depression was reassessed after the surgery.
89304414|NCT05971667|Experimental|tadalafil|tadalafil 10 mg one tablet daily
89304415|NCT05971667|Experimental|pentoxifylline|pentoxyfilline 400 mg two tabs daily
89304416|NCT05971667|Experimental|sildenafil|sildenafil 20 mg two tablets
89304417|NCT05971667|No Intervention|control group.|no intervention is given
89304418|NCT05970939||Telerehabilitation Usability|Telerehabilitation Usability Group
89304419|NCT05970770|Experimental|Hypotension Prediction Index|Patients will be monitored with Hypotension Prediction Index which will guide vasopressor therapy with boluses of norepinephrine
89304420|NCT05970770|Active Comparator|Non Invasive Blood Pressure|Spinal-induced hypotension will be prevented by continuous preventive norepinephrine infusion and blood pressure will be monitored by non invasive arm cuff every minute
89304421|NCT05970159||Hypoalbuminemia group|Patients with hepatocellular carcinoma whose preoperative serum albumin concentration are < 36g/L.
89304422|NCT05970159||Normal group|Patients with hepatocellular carcinoma whose preoperative serum albumin concentration are ≥ 36g/L.
89304423|NCT05969964||Re_TUR|Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins will undergo second look as endorsed by the guidelines.
89304424|NCT05969964||No re_TUR|Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines and will receive directly intravesical BCG
89304425|NCT05969262||Head and neck cancer patients|Patients who meet the diagnostic criteria of the Guidelines for Diagnosis and Treatment of Head and Neck Cancer
89304426|NCT05969262||Healthy people|Healthy people without liver related medical history or other diseases known to affect blood lipid/protein metabolism.
89304427|NCT05968677|Experimental|FSMP|Nutritional counseling plus one sachet of the study product (6.5 g) per day, away from meals, starting the day after the first chemotherapy cycle until three weeks after the last chemotherapy cycle (for a total of 12 weeks)
89304428|NCT05968677|Other|Control|Nutritional counseling
89304429|NCT05968417||Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder|Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research.
89304430|NCT05965843||chronic liver disease|No additional interventions for this group.
89304431|NCT05965843||malignant tumor|No additional interventions for this group.
89304432|NCT05965843||autoimmune disease|No additional interventions for this group.
89304433|NCT05965843||medical staff|No additional interventions for this group.
89304434|NCT05965271||Fabulous Thoracic Aortic Stent System|
89304435|NCT05965063|Other|Dietary avoidance for allergy food|strict avoidance of the specific allergenic food
89304436|NCT05965063|Experimental|bifidobacterium intervention|Bifidobacterium M-16V for 12 weeks while strictly avoidance of the specific allergenic food
89304437|NCT05965063|No Intervention|Healthy control|without intervention
89304438|NCT05964205||PT-PENCIL cohort|patients discharged from the hospital while the PT-PENCIL was active
89304439|NCT05964205||Control cohort|patients discharged from the hospital while the PT-PENCIL was not active
89304440|NCT05957731|Experimental|Agonist Contract-relax group:|"In the agonist contract-relax group, participants were positioned in a supine position. A trained physiotherapist then passively dorsiflexed the ankle to its maximum available range and held it for 15 seconds, while ensuring that the knee remained straight by placing a hand on it. Following this, participants were instructed to perform a maximal voluntary isometric~35~contraction of the planter flexors for five seconds, while maintaining the stretched position.~After a 30-second rest period, the physiotherapist returned the ankle to the starting position of 0 degrees and repeat the procedure without any rest. This stretching protocol was repeated four times, with each repetition lasting 2 minutes. For the soleus muscles, the same procedure was performed, but with a slightly flexed initial position of the knee."
89304441|NCT05957731|Experimental|Antagonist contract-relax group:|"In the antagonist stretching groups, participants were positioned in a supine position. A trained physiotherapist stretched the antagonist&#39;s muscle, and then participants were instructed to perform a maximal voluntary isometric contraction of dorsiflexion for 5 seconds while maintaining a stretched position. The knee was kept straight during this contraction.~Following the contraction, the physiotherapist held the ankle at that angle for another 10 seconds by placing a hand on it. After a 30-second rest period, the physiotherapist returned the ankle to the starting position of 0 degrees and repeat the procedure without any rest intervals."
89304442|NCT05956496|Placebo Comparator|Control Group: Acellular Dermal Matrix - Superficial cut (ADM-S)|A commonly used allograft material is the Acellular Dermal Matrix (ADM) which is harvested from human donor dermal tissues. Most commercially available ADM products are superficial cuts.
89304443|NCT05956496|Active Comparator|Test Group:Acellular Dermal Matrix - Deep cut (ADM-D)|The use of a deep cut ADM for root coverage gingival plastic procedures.
89304444|NCT05955807||Patients hospitalized due to severe risk of suicide|This is an observational study that focus on patients wellbeing and life-experience in the discharge period after a stay in psychiatric care due to severe risk of suicide. Patients will be treated according to usual pratice in clinical care
89304445|NCT05953766|Experimental|Presacral Nerve Block|Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml instilled in the presacral space
89304446|NCT05953766|Sham Comparator|Sham Block|20mL of normal saline (sham block) instilled in the presacral space
89304447|NCT05951400|Experimental|Dydrogestrone|For pituitary suppression, the patients will receive either Dydrogestrone (Duphaston 20 mg/d; Abbott Healthcare, USA) orally starting at day 2-3
89304448|NCT05951400|Active Comparator|GnRH antagonist|For pituitary suppression, the patients will receive GnRH antagonist Cetrorelix (CETROTIDE 0.25Mg/d, Merck Serono, Germany) 0.25 mg/day subcutaneously from day 6 of induction until trigger day.
89304449|NCT05944939|Experimental|Case group|After third molar extraction concentrated growth factor is palced in socket and closure with silk3.0 compare bone density with control group
89304450|NCT05944939|Experimental|Control group|After extraction closure with silk 3.0 compare bone density with cases
89304451|NCT05939609|Active Comparator|Ballistic Stretching Exercise|Athletes will be asked to reach the floor by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes will be requested to make small rebounding motion at degrees between 3°-5° for half a minute.
89304452|NCT05939609|Active Comparator|Extender Exercise|Athletes will lie on his back. Then, athletes will be asked to do 90 degrees of knee and hip flexion at the same time. Finally, the athletes is expected to perform slow repetitive knee extension to the point of maximal possible extension. According to Askling et al. and Aspetar protocol, it will be applied 12 repetitions and 3 sets.
89304453|NCT05939609|Active Comparator|Kinesiotaping|Kinesio taping will be applied to the hamstring muscle in the direction of inhibition with a Y-shaped and 25% tension force.
89304454|NCT05886452||DT1fA contact lenses|Subjects fitted with DT1fA contact lenses
89304455|NCT05863481||Laparoscopic cerclage|Patients who underwent laparoscopic cerclage at Aarhus University Hospital, Denmark in the study period
89304456|NCT05863182|Experimental|Intervention Group|Students and parents attending the intervention school, will participate in the family-based intervention.
89304457|NCT05863182|No Intervention|Comparison Group|Students and parents attending the non-intervention school will not receive the intervention and serve as comparison group.
89304458|NCT05838586|Experimental|CON|Control group
89304459|NCT05838586|Experimental|Break|
89304460|NCT05838586|Experimental|BOUT|
89304461|NCT05837858|Experimental|whole grain-wheat flour food, then refined wheat flour food|Participants first received food made by 50 g whole grain wheat flour during breakfast in a fasting state. Standardized meals were provided to the volunteers from the dinner of the day before the intervention day, as well as up to 48 h after the administration of the test food. After a washout period of 5 days, volunteers followed a 2-day restricted diet before the intervention day. Participants then received food made by 50 g refined grain wheat flour in a fasting state.
89304462|NCT05837858|Experimental|refined wheat flour food, then whole grain-wheat flour food|Participants first received food made by 50 g refined grain wheat flour during breakfast in a fasting state. Standardized meals were provided to the volunteers from the dinner of the day before the intervention day, as well as up to 48 h after the administration of the test food. After a washout period of 5 days, volunteers followed a 2-day restricted diet before the intervention day. Participants then received food made by 50 g whole grain wheat flour in a fasting state.
89304463|NCT05837598|Experimental|Tumor Board Arm|"This intervention has three parts:~Part 1: Proactive identification and assessment of patient needs, values, psychiatric symptoms, and illness understanding~Part 2: Virtual tumor board discussion~o Bring together expertise in mental illness and cancer, the interdisciplinary team will co-design an integrated cancer and mental health treatment plan. Key strategies include: addressing resource-related barriers to care, framing next steps in terms of patient values, and identifying action steps to address barriers to psycho-oncology/specialty oncology expertise~Part 3: Closed Loop Communication~o Tumor board recommendations shared with treating oncologist, documented in medical record, and shared with patient. Team tracks steps taken to address barriers to care and follows up with patient at 12 weeks."
89304464|NCT05836155|Experimental|Intervention|The study product contains Lactobacillus acidophilus W53, Lactobacillus acidophilus W55, Lactobacillus casei W56, Lactobacillus plantarum W1, Lactobacillus plantarum W21, Lactobacillus rhamnosus W71, and Pediococcus acidilactici W143.
89304465|NCT05836038|Experimental|Visio-tactile stimulation (VTS) during Virtual Reality|Participants in this group will receive visio-tactile stimulation prior to engaging with the VR program. They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
89304466|NCT05836038|No Intervention|No Visio-Tactile Stimulation (NoVTS) during Virtual Reality|Participants in this group will not receive visio-tactile stimulation prior to engaging with the VR program. They will be asked to look at their virtual hands for approximately the same amount of time as the VST group receive their stimulation
89304467|NCT05822050|Experimental|Low risk group|10 patients. Selinexor 60mg QW Oral 21days/cycle
89304468|NCT05822050|Experimental|Medium/High risk group|10 patients. Selinexor 60mg QW Oral with Chemotherapy 21days/cycle
89304469|NCT05818956|Experimental|Sequence 1: (Treatment A + Treatment B + Treatment C)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing.
89304470|NCT05818956|Experimental|Sequence 2: (Treatment B + Treatment C + Treatment A)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A . There will be a washout period of at least 4 days between each dosing.
89304471|NCT05818956|Experimental|Sequence 3: (Treatment C + Treatment A + Treatment B)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing.
89304472|NCT05818956|Experimental|Sequence 4: (Treatment A + Treatment C + Treatment B)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing.
89304473|NCT05818956|Experimental|Sequence 5: (Treatment B + Treatment A + Treatment C)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing.
89304474|NCT05818956|Experimental|Sequence 6: (Treatment C + Treatment B + Treatment A)|TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A. There will be a washout period of at least 4 days between each dosing.
89304475|NCT05813080|Experimental|CARE interventional treatment|AI-computerassisted prognosis of high risk psychosis profile and adapted study-specific therapy taking place in early-recognition centers.
89304476|NCT05813080|Active Comparator|Standard of Care Control arm|Treatment as usual (TAU) patient will receive their usual treatment from their local physicians and therapeutic personnel.
89304477|NCT05808062|Active Comparator|Total dryness|matching paper points are used till they come out completely dry
89304478|NCT05808062|Active Comparator|Partial dryness|a single matching cone is inserted in the canal for 3 seconds only.
89304479|NCT05806788|Experimental|BESTOW behavioral intervention|The intervention will utilize behavioral-based strategies to reduce BE and improve health behaviors, with content including strategies to improve body image, regulation of eating behaviors, and integration of physical activity with an emphasis on body function, health, and longevity.
89304480|NCT05806164|Active Comparator|Beta-3 receptor agonist oral medication|Selective beta-3 receptor agonist oral medication approved for the treatment of urgency urinary incontinence including mirabegron or vibegron. Usual clinical care standards will be used for prescribing and dosing changes. For mirabegron, dosages are 25 mg and 50 mg as clinically indicated. For vibegron, dosage is 75 mg daily by mouth as clinically indicated.
89304481|NCT05806164|Active Comparator|Intradetrusor onabotulinumtoxinA|OnabotulinumtoxinA at a dose of 100 units will be injected into the bladder per usual care pathways.
89304482|NCT05805761|Experimental|Conventional Treatment Group|Participants in this group will receive the conventional treatment for the removal of dental biofilm (prophylaxis with bicarbonate jet).
89304483|NCT05805761|Experimental|aPDT + Conventional Treatment Group|Participants in this group will receive both the antimicrobial photodynamic therapy and the conventional treatment (prophylaxis with bicarbonate jet) for the removal of dental biofilm.
89304484|NCT05803317||Amputee patients|All patients with lower limb amputations, unilateral or bilateral, walking with or without technical aids hospitalized in the Rehabilitation Department of the CHU of Nîmes
89304485|NCT05795075|Experimental|Computerized Modified Paramedian Approach Technique|The L3-4 inter-laminar space will be selected as the target for puncture, and in the longitudinal direction, 1.0-1.5cm will be opened beside the upper edge of the spinous process (tip) of the lower vertebra as the entry point. The lumbar puncture needle will be inserted vertically along the axis of the anesthesia needle. The puncture path will be maintained completely perpendicular to the skin until the needle reached the PLTLF (posterior layer of the thoracolumbar fascia), where some resistance will be felt. The puncture direction is adjusted as needed. The tip of the needle will be tilted 20±10° in the sagittal direction and 15±5° inward such that the tip will point at the midpoint of the spinal canal. After the needle reaches the PLTLF, it will be further inserted 3-7 cm.
89304486|NCT05795075|Experimental|Conventional Midline Approach Technique|Puncture will be performed on the posterior median line near the midpoint of the L3-4 Space of spinous process. The lumbar puncture needle will be inserted vertically along the axis of the anesthesia needle, or the tip of the needle will be tilted 15° in the sagittal direction toward the head, so that the needle path is parallel to the space of spinous process.
89304487|NCT05785338||affected|patiente suspected for a cleft palate without cleft lip
89304488|NCT05785338||control|unaffected cases
89304489|NCT05782218|Experimental|Almond arm|Almonds will be provided to increase the gut content in mono and poly-unsaturated fatty acids.
89304490|NCT05782218|Experimental|Coconut arm|This snack is isocaloric and almost perfectly matches the macronutrient profile of the almonds. However, despite being in the same quantity, almost all provided fatty acids will be saturated fatty acids.
89304491|NCT05773313|Experimental|The Open Table Model|Subjects identified as having their health negatively impacted by Social Determinants of Health (SDOH) will meet with The Open Table members to determine their specific needs, decide on a plan for overcoming this need and following up to ensure resolution.
89304492|NCT05764759|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
89304493|NCT05764759|Active Comparator|Treatment as usual (TAU)|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
89304494|NCT05746533||Participants Undergoing Hip Preservation/Surgical Interventions|Data will be prospectively collected on participants undergoing hip preservation at Yale-New Haven Hospital.
89304495|NCT05726357|Active Comparator|standard root canal treatment|standard root canal treatment
89304496|NCT05726357|Active Comparator|Pulpotomy|vital pulp therapy
89304497|NCT05721716|Experimental|Mindfulness Booster Course|
89304498|NCT05721716|Other|Treatment as Usual Control|
89304499|NCT05714150|Experimental|Balance Intervention|Participants with TBI history and without TBI history will both complete the same intervention.
89304500|NCT05713136||People at risk of HCV acquisition|Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing
89304501|NCT05701540|Experimental|Tegoprazan 50mg|Tegoprazan 50mg, once daily, oral administration for two weeks
89304502|NCT05701540|Active Comparator|Esomeprazole 40mg or 20mg|"In case of ERD patients: Esomeprazole 40mg, qd, oral administration for two weeks~In case of NERD patients: Esomeprazole 20mg, qd, oral administration for two weeks"
89304503|NCT05691725||Patients with antisynthetase syndrome|
89304504|NCT05689593|Active Comparator|Low-intensity ESWT Group|low intensity extracorporeal shock wave therapy will be applied to patients shoulder, also patients will receive a conventional therapy program consisting of hotpack and exercises
89304505|NCT05689593|Active Comparator|Low-intensity laser Group|low intensity laser will be applied to patients shoulder, also patients will receive a conventional therapy program consisting of hotpack and exercises
89304506|NCT05689593|Other|Conventional Control Group|patients will receive a conventional therapy program consisting of hotpack and exercises
89304507|NCT05632614|Active Comparator|High-intensity IMST|Participants who will be trained with high-intensity IMST
89304508|NCT05632614|Sham Comparator|Low-intensity IMST|Participants who will be trained with low-intensity IMST
89304509|NCT05618353|Active Comparator|Colchicine|One day before surgery: Colchicine 1.2 mg with 0.6 mg PO one hour later. This load will be followed by colchicine 0.6 mg twice daily for a total of 14 days.
89304510|NCT05618353|Placebo Comparator|Placebo|Matching placebo at same time points as active comparator
89304511|NCT05597982|Experimental|KTFT|
89304512|NCT05597982|Experimental|PN|
89304513|NCT05595044|Experimental|Vitamin D therapy and habilitation|40 ASD children receiving Vitamin D therapy and habilitation
89304514|NCT05595044|Other|Habilitation|40 ASD children receiving habilitation
89304515|NCT05588401|Experimental|GenPHSat safety injection and GenPHSat efficacy injection|Initial intervention with six injections into the left biceps. A second intervention with 36 injections into the right biceps.
89304516|NCT05540132|Active Comparator|Fast Acting Carbohydrate|Prior to exercise performance test, subject will be randomized to consume 22 grams of fast-acting carbohydrate (maltodextrin) or slow-acting cornstarch based supplement
89304517|NCT05540132|Active Comparator|Slow-acting cornstarch supplement|Prior to exercise performance test, subject will be randomized to consume 22 grams of slow-acting cornstarch based supplement or fast-acting carbohydrate (maltodextrin)
89304518|NCT05520554||Telerehabilitation Satisfaction|Telerehabilitation Satisfaction Group
89304519|NCT05506839|Other|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
89304520|NCT05506696|Experimental|Vitamin D supplementation|3200IU cholecalciferol (Fultium) peri-operatively
89304521|NCT05506696|No Intervention|Control|No treatment. Control arm.
89304522|NCT05504447|Experimental|"Rong-Yang Zhengyifang tea bag"|"Inclusion criteria:~Aged over 20 years old, according to the guidelines of the Epidemic Command Center, during home isolation and self-epidemic prevention or home quarantine, use a household novel coronavirus antigen rapid screening reagent to test positive, and after the medical staff confirms the relevant symptoms or the PCR test is positive, it is determined to be mild. Those who were diagnosed with severe disease and who did not use antiviral drugs were given tea immediately.~Exclusion criteria:~(1)Patient characteristics: excluded under 20 years of age, incapacity, pregnancy or lactation women (2)Disease characteristics: Western medicine has clearly diagnosed mental diseases (3)Environmental characteristics: Other conditions that prevent the patient from cooperating. If you feel unwell after screening not to sign the subject's consent form, etc."
89304523|NCT05504447|Placebo Comparator|placebo tea bag|The appearance is exactly the same as the Zhengyifang tea bag, and the ingredient is oolong tea
89304524|NCT05502939|Experimental|Music|"57 Hispanic participants, aged 6-8~Participants will be enrolled in a music training program led by professional trained music instructor of the Colburn School of Music. The music curriculum follows the standard Suzuki training method. Students attend the program 3 days per week, 2 weekday afternoons and one weekend morning. Each session lasts approximately 1 hour long. Each student will be given a string instrument to take home (often a viola or a violin). Each learning day focuses on development of musical elements including rhythm and meter, form, pitch, and performance. Students will take part in annual performances intended to give them a motivational goal, sense of mastery and to share their accomplishments with their peers, family, and community."
89304525|NCT05502939|Active Comparator|After School Enrichment Group|"57 participants, aged 6-8~Participants will be enrolled in an after school program led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members. Duration and frequency of the after-school program will be matched to the music intervention."
89304526|NCT05486156|Experimental|Intervention A Time with e-Nature Group|After signing the Free and Informed Consent Term, participants will be directed to a multicomponent intervention based on the experience of aesthetic, emotional and multisensory appreciation, knowledge, environmental education/interpretation and active involvement. At the end of the activity, the participants will fill in the post-intervention questionnaires, which will be applied immediately and 30 days after the intervention.
89304527|NCT05486156|No Intervention|Control Group|The group will do an activity made up of contact with nature during a light walk with attention directed to the senses. The trail will be accompanied by a guide who will not make any type of intervention other than offering the questionnaires to be filled in at the end of the activity and driving in the section foreseen for the activity.
89304528|NCT05482607||SSc-ILD patients|
89304529|NCT05464225|Experimental|COSD|Participants assigned to the COSD, will use the investigational device.
89304530|NCT05464225|Active Comparator|SOC|"Tongue depressors are the standard-of-care so the control group will use these instead of the investigational Colorado Oral Strengthening Device."
89304531|NCT05463666||Population controls|Participants between 55 and 85 years of age without a diagnosis of RA, or other inflammatory RMD (osteoarthritis allowed). Controls > 80 years who are physically unable to complete the whole study procedure, are allowed to undergo only part of the study measurements.
89304532|NCT05463666||RA patients|Participants between 55 and 85 years of age with a diagnosis of RA by the treating rheumatologist. Patients > 80 years who are physically unable to complete the whole study procedure, are allowed to undergo only part of the study measurements.
89304533|NCT05462652|Experimental|Active Intervention|The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
89304534|NCT05462652|No Intervention|Usual Care|UC is based on a stepped care model for treatment for symptoms of depression. It can include any of the following: active monitoring of depressive symptoms and suicidality, supportive counseling by a healthcare provider, psychosocial support interventions, collaborative care (e.g. facilitation of parental and patient self-management, referral for peer support or other community or school-based behavioral health programs), psychoeducation, complementary and alternative medicine approaches, psychotherapy (e.g. behavioral treatment, interpersonal therapy, cognitive behavioral therapy), pharmacotherapy for mood problems, visit to a primary care provider, behavioral or mental health specialist or therapist, counselor or coach for mood disorder. For purposes of this study, UC will be enhanced by prompting participants to complete a weekly PHQ-8 assessment in a mobile app.
89304535|NCT05448313|Experimental|Dyadic intervention|Veterans and their support person will participate in MOVE!
89304536|NCT05448313|Active Comparator|Veteran-only intervention|Veterans will participate in MOVE! alone
89304537|NCT05428020|Experimental|Indwelling foley catheter|Short-term indwelling foley catheter
89304538|NCT05428020|Placebo Comparator|No Foley catheter|No foley catheter
89304539|NCT05423275|Active Comparator|Negative ion therapy|High density negative ions at 3.4 trillion ions per second with no detectable ozone, used for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am.
89304540|NCT05423275|Active Comparator|Light therapy|4000 Kelvin white fluorescent light rated at 10,000 lux at 14 inches from screen to cornea, with an ultraviolet filter, used for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am.
89304541|NCT05422326|Experimental|Group 1|Eligible subjects who received 2 doses of aH5N1c in the parent study V89_18 and have been randomized to receive two aH5N6c vaccinations, 3 weeks apart
89304542|NCT05422326|Experimental|Group 2|Eligible subjects who received 2 doses of aH5N1c in the parent study V89_18 and have been randomized to receive an aH5N6c vaccination on Day 1 and saline placebo on Day 22
89304543|NCT05422326|Experimental|Group 3|Eligible subjects who received placebo in the parent study V89_18 receive two aH5N6c vaccinations, 3 weeks apart.
89304544|NCT05408728||Obese patients scheduled for Bariatric surgery|Subjects scheduled for Bariatric Surgery (BS) and will receive pre-BS Esophagogastroduodenoscopy (EGD) as a part of your standard care will have biopsies from the small intestine taken during the EGD procedure for this study.
89304545|NCT05408728||Lean controls naive to Bariatric surgery|Subjects presenting for surveillance/screening EGD procedure as part of their standard medical care will have biopsies from the small intestine taken during the EGD procedure for this study.
89304546|NCT05398627|Experimental|Amygdala Neurofeedback|Participants will undergo real-time fMRI neurofeedback training to increase their amygdala response while recalling positive autobiographical memories. 2 sessions will occur within a one week period.
89304547|NCT05387499|Experimental|Single Ascending Dose Phase|Drug: NP-011 Dosage: 250μg, 500μg, 1000μg, 2000μg, 4000μg Dosage Form: Liquid for IV injection Route of Administration: Intravenous
89304548|NCT05387499|Experimental|Multiple Ascending Dose Phase|Drug: NP-011 Dosage: 1000μg, 2000μg, 4000μg Dosage Form: Liquid for IV injection Route of Administration: Intravenous
89304549|NCT05387499|Placebo Comparator|Placebo|Dosage Form: Liquid for IV injection Route of Administration: Intravenous
89304550|NCT05375344|Active Comparator|Exercise Group|Participants in this group will participate in the home-based exercise group intervention that consists of general balance and strength training, bladder training and urge suppression, and home hazard assessments.
89304551|NCT05375344|No Intervention|Control Group|Participants in this group will receive informational booklets on fall prevention and behavioral treatment for Urgency Incontinence.
89304552|NCT05372133|Experimental|Split Script|Participants will receive four doses initially, with opportunity to obtain four additional doses if required
89304553|NCT05356195|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.
89304554|NCT05347719|Experimental|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions led by a trained healthcare provider. Post-intervention, the experimental group will receive treatment as usual.
89304555|NCT05347719|No Intervention|Wait List Control|Participants will engage in treatment as usual during the baseline period. After the experimental group completes the MBCT intervention, the wait list control group will complete the MBCT intervention.
89304556|NCT05345795||SSc-ILD patients|
89304557|NCT05336344|Experimental|ENCODE Group|The intervention consists of three weekly video-conferencing sessions scheduled at the caregiver's convenience. Each session is scheduled to last approximately 40 minutes. The ENCODE intervention is manualized and has related curriculum designed specifically for caregivers of patients with ADRD. The agenda for the first session (week 1) includes an assessment of caregivers' pain management challenges and concerns. Once the barriers or challenges are identified, the interventionist works specific problem solving therapy steps covered over the three sessions.
89304558|NCT05336344|No Intervention|Attention Control Group|"Caregivers in the attention control group will receive standard hospice services and complete the same measures and receive the same number of contacts as participants in the intervention group. Three video-conferencing calls will be scheduled based on the caregiver's availability following, if possible, a timeline between days 5 and 30 of the hospice admission. During these calls, the interventionist will allow caregivers in the attention control group to discuss their feelings, thoughts, and relationships. This friendly call intervention controls for the nonspecific aspects of treatment, i.e., the passage of time, amount of contact with a researcher, and the general support of an empathic, concerned and skilled professional and is based on the principles of nondirective supportive therapy."
89304559|NCT05336318|Experimental|Intervention group|
89304560|NCT05336318|No Intervention|Control group|
89304561|NCT05318963|Experimental|LCAR-AIO cells product|Each subject will be given a single-dose LCAR-AIO cells infusion at each dose level.
89304562|NCT05318625|Experimental|Gynaecological laparoscopic surgery|Eligible women aged 18 - 70 years, regardless of parity, who need laparoscopic gynaecological surgery and who provide informed consent prior to surgery
89304563|NCT05316610|Experimental|Body Confident Athletes|Participants in the intervention condition will take part in an in-person program consisting of five sessions over five weeks.
89304564|NCT05316610|No Intervention|Waitlist control|Participants will not be explicitly told their study condition, although they will be made aware of the assessment time points and whether they receive the intervention between T1 and T2 (intervention) or after T2 (waitlist control). Following completion of post-intervention assessments (T2), the control condition will participate in the intervention; but, they will not be monitored or assessed.
89304565|NCT05300867|Active Comparator|Robotic|
89304566|NCT05300867|Active Comparator|Controll|
89304567|NCT05277714|Experimental|NF|
89304568|NCT05277714|Sham Comparator|Sham|
89304569|NCT05239494|Experimental|Dailies Total1|All participants will be asked to wear Dailies Total1 for the duration of this study.
88806370|NCT04751006|Other|Control Group|Participants performed balance training with saccade eye exercises
88820685|NCT05788601|Active Comparator|4 mg dapiglutide|Abdominal s.c. self-administration of 4 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks until the remaining nine weeks of treatment (12 weeks in total)
89304570|NCT05225584|Experimental|Phase 1a Dose Escalation Lymphomas|KT-333 dosed IV weekly in 28 day cycles
89304571|NCT05225584|Experimental|Phase 1a Dose Escalation Solid Tumors|KT-333 dosed IV weekly in 28 day cycles
89304572|NCT05225584|Experimental|Phase 1b Dose Expansion PTCL|KT-333 dosed IV weekly in 28 day cycles
89304573|NCT05225584|Experimental|Phase 1b Dose Expansion CTCL|KT-333 dosed IV weekly in 28 day cycles
89304574|NCT05225584|Experimental|Phase 1b Dose Expansion LGL-L|KT-333 dosed IV weekly in 28 day cycles
89304575|NCT05225584|Experimental|Phase 1b Dose Expansion Solid Tumor|KT-333 dosed IV weekly in 28 day cycles
89304576|NCT05225584|Experimental|Phase 1a Dose Escalation LGL-L|KT-333 dosed IV weekly in 28 day cycles
89304577|NCT05225584|Experimental|Phase 1a Dose Escalation T-PLL|KT-333 dosed IV weekly in 28 day cycles
89304578|NCT05197881|Experimental|Daily Adaptive External Beam Radiation Therapy|Daily adaptive radiation therapy delivered with Varian Ethos treatment system.
89304579|NCT05196230|Experimental|Experimental Condition (360° Video)|The 360° video (experimental) group will be mailed a study tablet with the 360° video prior to the dental visit.
89304580|NCT05196230|Active Comparator|Control Condition (Social Story)|The treatment-as-usual (control) group will be mailed a study tablet with a social story prior to the dental visit.
89304581|NCT05195203|Experimental|HS-10353|Capsules；Single dose: only one administration; Multiple doses: continuous administration for 7 days
89304582|NCT05195203|Placebo Comparator|Placebo|Capsules；Single dose: only one administration; Multiple doses: continuous administration for 7 days
89304583|NCT05186753|Experimental|(Part 1a) Bezuclastinib Dose 1 + BSC|
89304584|NCT05186753|Experimental|(Part 1a) Bezuclastinib Dose 2 + BSC|
89304585|NCT05186753|Placebo Comparator|(Part 1a) Placebo + BSC|
89304586|NCT05186753|Experimental|(Part 1b) Bezuclastinib Dose 1 + BSC|
89304587|NCT05186753|Experimental|(Part 1b) Bezuclastinib Dose 2 + BSC|
89304588|NCT05186753|Placebo Comparator|(Part 1b) Placebo + BSC|
89304589|NCT05186753|Experimental|(Part 2) Bezuclastinib Selected Dose + BSC|
89304590|NCT05186753|Placebo Comparator|(Part 2) Placebo + BSC|
89304591|NCT05186753|Experimental|(Part 3) Bezuclastinib + BSC|
89304592|NCT05177471||SSc-ILD patients with JAK inhibitors|
89304593|NCT05176561|Experimental|Treatment: Auditory-Cognitive Training|Behavioral: AR Group will complete sessions in their home or office via internet. Sessions will include independent work using computer software two hours per week and one hour meeting with the clinician each week. One half of the training is devoted to auditory training and one half to auditory cognitive activities. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
89304594|NCT05176561|Sham Comparator|Control: Non-auditory Cognitive Training|Behavioral: The CT Group will complete two hours of training in their home or office via internet. Sessions will include independent work using computer software two hours per week. Training exercises will be chosen from: Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Differences. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
89304595|NCT05167396|Experimental|Healthy Controls (HC)|n=90
89304596|NCT05167396|Experimental|Clinical High Risk of Psychosis (CHRP)|n=30
89304597|NCT05167396|Experimental|First Episode Psychosis (FEP)|n=30
89304598|NCT05161546|Experimental|patients with bipolar disorder (BD)|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit.~Between day 23 and day 28 (after the second visit), patients will be offered to assess the retinal structure and microvascularization using Spectral Domain Optical Coherence Tomography (SD-OCT) and OCT-Angiography (OCT-A)."
89304599|NCT05161546|Active Comparator|healthy volunteers|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit."
89304600|NCT05147181||Participants With HAE|Participants with type 1 or type 2 HAE when treated with lanadelumab in real life in accordance with Summary of Product Characteristics (SmPC) and NDP requirements will be observed in this prospective observational study for 36 months
89304601|NCT05130827|Experimental|Plinabulin|In this pilot study, 15 patients age 18-75 with multiple myeloma will be admitted to the hospital and treated with a single dose of high dose melphalan. Stem cell infusion will occur per institutional standard of care. Patients will then receive plinabulin 40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0. Pegfilgrastim 6mg will be administered as per standard of care on day +1.
89304602|NCT05129683|Experimental|Anodal tDCS cerebellar stimulation group:|Anodal tDCS cerebellar stimulation
89304603|NCT05129683|Experimental|Anodal tDCS cerebral (M1) stimulation group:|Anodal tDCS cerebral (M1) stimulation
89304604|NCT05129683|Sham Comparator|Sham Group|Sham: Single-session a-tDCS (2 mA, 20 min),
89304605|NCT05120544|Active Comparator|EXTEND|EXTEND participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS). Participants can review data and trends within the device apps and modify self-management practices accordingly. The EXTEND group continues chronic disease care with their existing providers during the study, and are instructed at baseline to address management questions via their primary clinics' established avenues (as would be the case for any patient using mobile monitoring in clinical practice).
89523356|NCT03381677|Active Comparator|Control group|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
89304606|NCT05120544|Experimental|EXTEND Plus|EXTEND Plus participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS) for use as part of nurse-delivered intervention combining mobile monitoring, self-management support, and medication management. The intervention is administered by clinical registered nurses (RNs) from Duke Primary Care (DPC) or Duke Endocrinology. For the medication management component, RNs work with a study PharmD affiliated with the participant's clinic. The PharmD determines if medication changes are needed, and prescribes accordingly. The RNs deliver EXTEND Plus via scheduled telephone encounters throughout the 12-month intervention. The initial encounter frequency is every two weeks, but may be extended to every four weeks for patients achieving treatment goals.
89304607|NCT05112003|Experimental|TLNS|Translingual neurostimulation will be paired with breathing and awareness training prior to CPT sessions
89304608|NCT05112003|No Intervention|Control|No TLNS
89304609|NCT05111886|Experimental|Primary Care Personnel Training|Primary care personnel within two Federally Qualified Health Center (FQHC) primary care clinics will be randomly assigned to receive communication skills training or a control condition.
89304610|NCT05111886|Active Comparator|Primary Care Personnel Training Control|Primary care personnel within two Federally Qualified Health Center (FQHC) primary care clinics will be randomly assigned to receive communication skills training or a control condition. Control group personnel will receive a written description of the referral process but no training.
89304611|NCT05111886|Experimental|Parents eHealth GenPMTO|Parents of 3- to 5-year-olds who receive services from primary care personnel at an Federally Qualified Health Center (FQHC) primary care clinic. Primary care personnel will refer parents of child with externalizing or internalizing behaviors to study therapists. Parents may be assigned to GenPMTO or control after referral.
89304612|NCT05111886|Active Comparator|Parents Control|Parents of 3- to 5-year-olds who receive services from primary care personnel at an Federally Qualified Health Center (FQHC) primary care clinic. Primary care personnel will refer parents of child with externalizing or internalizing behaviors to study therapists. Parents may be assigned to GenPMTO or control after referral.
89304613|NCT05111886|Other|Therapists|Community therapists trained to deliver GenPMTO.
89304614|NCT05094609|Experimental|Aerosol Ad5-triCoV/Mac dose level 10e5|Single dose by inhalation of 10e5 Ad5-tri-CoV/Mac
89304615|NCT05094609|Experimental|Aerosol ChAd-tri-CoV/Mac dose level 10e5|Single dose by inhalation of 10e5 ChAd-triCoV/Mac
89304616|NCT05094609|Experimental|Aerosol Ad5-triCoV/Mac dose level 10e6|Single dose by inhalation of 10e6 Ad5-triCoV/Mac
89304617|NCT05094609|Experimental|Aerosol ChAd-triCoV/Mac dose level 10e6|Single dose by inhalation of 10e6 ChAd-triCoV/Mac
89304618|NCT05094609|Experimental|Aerosol Ad5-triCoV/Mac dose level 10e7|Single dose by inhalation of 10e7 Ad5-triCoV/Mac
89304619|NCT05094609|Experimental|Aerosol ChAd-triCoV/Mac dose level 10e7|Single dose by inhalation of 10e7 ChAd-triCoV/Mac
89304620|NCT05094609|Experimental|Aerosol Ad5-triCoV/Mac dose level 3x10e7|Single dose by inhalation of 3x10e7 Ad5-triCoV/Mac
89304621|NCT05094609|Experimental|Aerosol ChAd-triCoV/Mac dose level 6x10e7|Single dose by inhalation of 6x10e7 ChAd-triCoV/Mac
89304622|NCT05094609|Experimental|Aerosol ChAd-triCoV/Mac dose level 1x10e8|Single dose by inhalation of 1x10e8 ChAd-triCoV/Mac
89304623|NCT05094362|Experimental|Validation of the new training system|The researchers will measure changes in H-reflex size achieved with the use of the new system and compare these measures with the existing results in 25 spastic individuals with chronic incomplete SCI. Each participant completes 6 baseline sessions and 30 conditioning sessions. In the 30 conditioning sessions, the soleus H-reflex will be down-conditioned to decrease the activity of the hyperactive spinal stretch reflex pathway in people with spasticity that is characterized by exaggerated reflex activity. It is anticipated that the magnitude of reflex change obtained with the use of the new system would be greater or at least the same as the bench-marked values from the previous studies that used the old prototype reflex conditioning system.
89304624|NCT05064631|Experimental|Active intervention|Oral Broncho-Vaxom (3.5mg) administered daily for 10 days per month for 24 months
89304625|NCT05064631|Placebo Comparator|Placebo control|Matched placebo administered daily for 10 days per month for 24 months
89304626|NCT05042440|Experimental|efanesoctocog alfa (BIVV001)|Each participant will be sequentially dosed with three single intravenous (IV) doses of first rFVIII (Advate®), second Polyethylene Glycol (PEG)-rFVIII (Adynovi® or Adynovate®), and lastly, BIVV001
89304627|NCT05039814||AKI|patients suffered postoperative acute kidney injury
89304628|NCT05039814||Non-AKI|patients did not suffer postoperative acute kidney injury
89304629|NCT05039099|Experimental|AP-101|AP-101 is administered by IV.
89304630|NCT05039099|Placebo Comparator|Placebo|Placebo is administered by IV.
89304631|NCT05022563||Parenteral anticoagulant only|LMWH, UFH
89304632|NCT05022563||Warfarin-based|Warfarin only + parenteral anticoagulant bridged warfarin
89304633|NCT05022563||NOAC-based|"NOAC only + parenteral anticoagulant bridged NOAC~NOAC: apixaban, rivaroxaban, dabigatran, edoxaban"
89304634|NCT04950426|Experimental|Treatment with reconsolidation therapy|Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet
89304635|NCT04936334|Experimental|Men diagnosed with clinically significant prostate cancer who are scheduled for prostatectomy|1. Men diagnosed with clinically significant prostate cancer who are scheduled or for prostatectomy will undergo injection of 68Ga-PSMA-11 at the time of their pre-treatment PSMA PET. Followed until 12 mo post surgery
89304636|NCT04927754|Experimental|Group 1 (cartoon movie, then tell-show-do technique)|Group 1: Dental treatment was carried out with showing cartoon movie as a visual/auditory distraction during the treatment in the second visit. The third visit did not consist any visual/auditory distractions, tell-show-do technique was used as a behavioural guidance technique.
89304637|NCT04927754|Experimental|Group 2 (tell-show-do technique, then cartoon movie)|Group 2: Dental treatment was carried out using tell-show-do technique without any visual/auditory distraction in the second visit. The third visit consisted cartoon movie as a visual/auditory distraction.
89304638|NCT04920097|Experimental|APA Group|A self-guided smartphone application to self-administered APA
89304639|NCT04920097|Experimental|Virtual APA group|A virtual APA (vAPA): APA app+ plus secure zoom sessions for APA coaching with questions and answers
89304640|NCT04920097|Active Comparator|Usual Care Control|Wait-List Usual Care Control (UC)
89304641|NCT04895085|Experimental|Caregiver of Children with medical complexity (CMC)|
89304642|NCT04884412|Experimental|PARKEO 2 targeting with asleep deep brain stimulation procedure|Participant with parkeo 2 targeting procedure
89304643|NCT04884412|Active Comparator|Usual DBS procedure|Participant with usual targeting and surgery
89304644|NCT04863950|Experimental|Imipramine Hydrochloride/Lomustine|
89304645|NCT04839822|Experimental|Intervention Arm: Psychoeducation with elements of CBT & mood chart.|Patients will receive full access to edupression.com® immediately after inclusion. This intervention includes all medical mechanisms of action of edupression.com®: Psychoeducation with elements of CBT (learning content and exercises) and a mood chart (depression symptom monitoring).
89304646|NCT04839822|Active Comparator|Active control arm: (occupational) interventions and progress monitoring.|These patients will also receive an edupression.com® account with different content. This content will be limited to medically useful tips, that have have not been shown to be effective in improving depressive symptoms in RCTs. Patients of both arms will be instructed to use chat functions to contact study personnel and to fill out questionnaires and tests to collect outcome and additional measures.
89304647|NCT04836377||Subjects with Gaucher 1 Disease|This is a long-term follow-up study of subjects who previously received AVR-RD-02 (single dose administration) in a preceding treatment study. No investigational product will be administered in this study.
89304648|NCT04826393|Experimental|ASP8374 and Cemiplimab-Cohort 1|"A 3+3 dose escalation design will be used to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when combined with cemiplimab.~Participants will receive ASP8374 and Cemiplimab every 3 weeks for up to 2 years. ASP8374 will be available until October 31, 2022. Subjects may continue treatment with cemiplimab alone after that date."
89304649|NCT04826393|Experimental|ASP8374 and Cemiplimab-Cohort 2|"Upon determination of the MTD/RP2D of ASP8374 plus cemiplimab in Cohort 1, a dose expansion will be performed in which eligible participants who are candidates for surgical resection will enroll to Cohort 2 and will be randomized into one of two treatment groups (2A-2B).~Group 2A: IV ASP8374 plus cemiplimab within 14± 5 days prior to surgery at the MTD/RP2D established in Cohort 1.~Group 2B: No immune checkpoint therapy prior to surgery.~Post-operatively, all Cohort 2 participants will receive ASP8374 plus cemiplimab every 3 weeks administered at the MTD/RP2D established by Cohort 1"
89304650|NCT04824391|Experimental|3 mcg/0.5 ml Vaccine|Low dose vaccine
89304651|NCT04824391|Experimental|6 mcg/0.5 ml Vaccine|Medium dose vaccine
89304652|NCT04824391|Placebo Comparator|Placebo|Placebo
89304653|NCT04823039|Other|Vaccination in patient with sepsis|
89304654|NCT04822597|Active Comparator|Ice Pack|Ice will be placed on the breast prior to radioactive tracer injection (usual treatment)
89304655|NCT04822597|Experimental|Lidocaine Patch|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection
89304656|NCT04822597|Experimental|Buzzy(R)|A vibrating distraction device (Buzzy(R)) and ice will be placed on the breast prior to radioactive tracer injection.
89304657|NCT04822597|Experimental|Lidocaine Patch and Buzzy(R)|A lidocaine patch (4% topical) will be placed on the breast for at least one hour prior to radioactive tracer injection. This will be removed and a vibrating distraction device (Buzzy(R)) and ice will be placed on the breast just prior to radioactive tracer injection.
89304658|NCT04821856|Experimental|Cannabidiol 100mg/ml|"The starting dose of cannabidiol (CBD) will be 5 mg/kg/day and will be administered orally twice daily in doses of 2.5 mg/kg (up titration phase from day 1 to 7). After one week, the dose of CBD will be increased to 10 mg/kg/day in two daily doses of 5mg/kg (8-week maintenance phase from day 8 to 63). On completion of the maintenance phase the dose of CBD will be decreased to 5mg/kg/day for one week (day 64 to 70), after which the CBD administration will cease.~A ceiling dose of 1000mg/day will be administered to all participants weighing 100kg or greater. These participants will receive a dose of 500mg/day during up- and down-titration.~Doses will be rounded to the nearest 10mg (0.1mL)."
89304659|NCT04821856|Placebo Comparator|Placebo|"The control group will receive placebo medium-chain triglyceride (MCT) oil which is indistinguishable from the active medication in appearance, smell and taste.~Dose will be matched for volume to the cannabidiol arm, and administered twice daily for 10 weeks (including up- and down-titration)."
89304660|NCT04807868||Biopsy Group|Adults undergoing a standard of care liver biopsy at AdventHealth Central Florida Division for any reason
89304661|NCT04807868||Non-Biopsy Group|Adults without any history of NAFLD
89304662|NCT04800562|Experimental|PCS499 900mg BID|PCS499 900mg twice a day with food
89304663|NCT04800562|Placebo Comparator|Placebo|similar in appearance to active study drug
89304664|NCT04797169|Experimental|Noom Health|
89304665|NCT04797169|Active Comparator|Noom Digital Health|
89304666|NCT04764227|Experimental|Concurrent chemoradiotherapy group|"Interventions:~Chemotherapy: Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5~Radiotherapy: A total dose of 50.4Gy will be delivered in 28 fractions at 1.8Gy/fraction, 5 fractions per week in 6 weeks. The CTV encompassed the bilateral supraclavicular, superior mediastinal, and subcarinal regions."
89304667|NCT04756583|Experimental|Intervention|
89304668|NCT04756583|No Intervention|Control|
89304669|NCT04733092|Experimental|Embolization|Embolization of the inflammatory hypervascularization with a lipiodol emulsion
89304670|NCT04730869|Experimental|Standard treatment in conjunction with MTP|"Standard:~Concurrent chemoradiation - Radiation (60-Gy in 30 fractions over 6 weeks) with daily oral temozolomide.~Adjuvant chemotherapy - Daily oral temozolomide (5 days per 4-week cycle, starting 4 weeks after completion of chemoradiation, with at least 6 cycles intended).~MTP:~- Two 5-day fasts (allowing water, salt, tea, coffee, and a magnesium supplement) during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet (one or two 1-hour eating windows per day, allowing oils, meats, vegetables, nuts, seeds, limited berries, and a multivitamin) between fasts."
89304671|NCT04729582|Experimental|Verum Group|Participants receive primary human muscle stem cells as one-time injection into the urethral sphincter region under visual control using cystoscopy.
89304672|NCT04729582|Placebo Comparator|Placebo group|Participants receive placebo solution as one-time injection into the external urethral sphincter region under visual control using cystoscopy.
89304673|NCT04727827|Experimental|Pharmacogenomic Testing|A pharmacogenomic (PGx) panel will be performed to test for genetic variations in genes related to drug response.
89304674|NCT04675255|Active Comparator|Immediate switch|Immediate switch
89304675|NCT04675255|Active Comparator|Delayed switch|Delayed switch
89304676|NCT04658550||Remote Weight Loss Behaviour Modification Program with Meal Replacements|This is the prospective study group who will receive 26-weeks of weight loss and maintenance counselling in a remote setting and a low-calorie meal replacement as part of their usual care.
89304677|NCT04658550||In Person Weight Bahaviour Modification Program with Meal Replacements|This is the retrospective study group who received 26-weeks of weight loss and maintenance counselling in person and a low-calorie meal replacement as part of their usual care.
89304678|NCT04639245|Experimental|Treatment (FH-MagIC TCR-T cells, atezolizumab)|"LYMPHODEPLETION: Patients receive cyclophosphamide IV and fludarabine IV on days -4, -3, and -2 before each T-cell infusion.~T-CELL INFUSION: Patients receive FH-MagIC TCR-T cells IV over 15-20 minutes. Six to twelve weeks after first T-cell infusion, patients with progressive disease and non-persisting transgenic TCR T cells may receive a second T-cell infusion.~In the Phase 2 portion of the study, atezolizumab will be administered as standard of care beginning 24-72 hours after T-cell infusion. Atezolizumab will be given IV every 3 weeks for at least 1 year in the absence of disease progression or unacceptable toxicity. An alternative PD1 inhibitor may be substituted if atezolizumab (preferred) is not available."
89304679|NCT04599465|Experimental|ELX/TEZ/IVA|Participants received ELX 200 mg /TEZ 100 mg /IVA 150 mg in the morning and IVA 150 mg in the evening.
89304680|NCT04589130|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets.
89304681|NCT04589130|Placebo Comparator|Placebo|Group given placebo
89304682|NCT04588298|Experimental|Stage 1: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 1 of the study.
89304683|NCT04588298|Experimental|Stage 1: AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 1 of the study.
89304684|NCT04588298|Experimental|Stage 2: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 2 of the study.
89304685|NCT04588298|Experimental|Stage 2: AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 2 of the study.
89304686|NCT04588298|Experimental|Stage 2: AZD9833 Dose C|Post-menopausal participants will receive once daily oral dose C of AZD9833 in stage 2 of the study.
89304687|NCT04588298|Experimental|Stage 3: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 3 of the study.
89304688|NCT04588298|Experimental|Stage 3: AZD9833: Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 3 of the study.
89304689|NCT04588207|Experimental|On Urea, Then Off Urea|Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
89304690|NCT04588207|Experimental|Off Urea, Then On Urea|Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)
89304691|NCT04587843|Experimental|Contrave 8mg/90mg Extended Release Tablet|Group treated with Contrave Extended Release Tablets
89304692|NCT04587843|Placebo Comparator|Placebo|Group given placebo
89304693|NCT04582903||Biological Relative|Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins
89304694|NCT04582903||Confirmed or Suspected SARS-CoV-2 infection|Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current), typically but not always supported by a positive PCR test for viral RNA
89304695|NCT04582903||Exposed but Uninfected|Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavy or extensive COVID-19 exposure in the workplace or home environment
89304696|NCT04577261||FNS Participants|Participants who will undergo surgery to treat a fractured femoral neck using the FNS (Femoral Neck System)
89304697|NCT04562441|Experimental|Axitinib and Avelumab|"Axitinib: 5 mg bd po Day 1 to Day 28~Avelumab: 10mg/kg Day 1 and Day 15 every 4 weeks"
89304698|NCT04547582|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.~Participants in this study receive spinal cord stimulation will be trans-tibial amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
89304699|NCT04516356|Experimental|Intervention Arm|Korean hand acupressure will be applied to the experimental group 30 minutes before the induction of anesthesia. After determining the pressure / therapy points associated with nausea and vomiting on the patient's hand, a massage will be made for 3-5 minutes with a diagnostic stick. The seeds will then be fixed at these points with a paper patch. Seeds will not be removed for 24 hours. It will be massaged for 3-5 minutes by pressing the seeds every 3-4 hours and making a curling motion at the same time. At the end of the 24th hour, the application will be terminated.
89304700|NCT04516356|No Intervention|Control Arm|In the control group, no application will be made during and after the surgical intervention, and routine treatment and care will be applied.
89304701|NCT04514133|Experimental|Action Civics program|Students in this arm will take part in an Action Civics (AC) program. AC delivers action civics programming to young people from diverse backgrounds nationwide. AC offers a school-based action civics curriculum in which classes collectively choose a local issue, learn strategies and skills for taking civic action, develop an action plan, and take action on their selected local issue. Students, as a class, tackle topics ranging from health-related (e.g., health of school lunches) to safety-related (e.g. lack of crosswalks) to community social issues (e.g., community-police relations).
89304702|NCT04514133|No Intervention|No Action Civics program|Students in this arm will receive no intervention.
89304703|NCT04510714|Experimental|Microwave ablation arm|Single arm patients with lung sarcoma metastasis that will be treated with microwave ablation
89304704|NCT04475198|Experimental|Single Ascending Dose: Cohort 1|5 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (ST-2427 n=1, placebo n=1) before remainder of cohort.
89304705|NCT04475198|Experimental|Single Ascending Dose: Cohort 2|10 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
89304706|NCT04475198|Experimental|Single Ascending Dose: Cohort 3|15 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
89304707|NCT04475198|Experimental|Single Ascending Dose: Cohort 4|22 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
89304708|NCT04475198|Experimental|Single Ascending Dose: Cohort 5|33 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.
89304709|NCT04467671|Experimental|Tissue Engineered Vascular Grafts|
89304710|NCT04454957|Experimental|Mastering Diabetes|Adults (hospital employees, their spouses, and community members) who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
89304711|NCT04454957|No Intervention|Usual care|Employees and spouses of the hospital system who are participating in the employee wellness program, who have been identified as having diabetes or prediabetes based on a health risk assessment, who have chosen not to participate in Mastering Diabetes. They may or may not be receiving additional usual care.
89304712|NCT04433780|Experimental|Delstrigo|Once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF).
89304713|NCT04426214|Experimental|Active tDCS|
89304714|NCT04426214|Placebo Comparator|Sham tDCS|
89304715|NCT04408664|Experimental|Sodium Cromoglycate|Patients will take Sodium Cromoglycate (SCG) (Lomudal®) 4 times daily during 6 months: SCG 4X1 ampulla of 2 mL daily (by Omron pocket aerosol).
89304716|NCT04408664|Placebo Comparator|Sodium Chloride 0.9%|Patients will take Sodium Chloride 0.9% 4 times daily during 6 months: Sodium Chloride 4X1 ampulla of 2 mL daily (by Omron pocket aerosol).
89304717|NCT04362293|Experimental|Matched Sibling Donor (MSD)|Patients with a suitable HLA matched sibling donor (MSD) will be enrolled on the MSD arm.
89304718|NCT04362293|Experimental|Haploidentical (HAPLO)|Patients without an eligible MSD who have a suitable haploidentical (HAPLO) donor available will be enrolled on the HAPLO arm of the study.
89304719|NCT04332367|Experimental|Carboplatin, Taxane And Ramucirumab|Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg/m2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg/kg IV every 3 weeks
89304720|NCT04309370|Experimental|20 Hz rTMS targeting the LDLPFC first, then 20 Hz rTMS targeting the LSPC|
89304721|NCT04309370|Experimental|20 Hz rTMS Targeting the LSPC first, then 20 Hz rTMS Targeting the LDLPFC|
89304722|NCT04258033|Experimental|PLB1001|Subjects will receive 200mg of PLB1001 twice daily in cycles of 28-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
89304723|NCT04222309|Experimental|Laparoscopically harvested omental free flap|"Standard neurosurgical removal of recurrent GBM,~Removal of fat from the abdomen called omentum using a camera (laparoscopically),~Lining the brain tumor cavity with the piece of omentum,~Joining the blood vessels of the omentum to blood vessels in the scalp or neck to ensure that it maintains good blood flow."
89304724|NCT04202159||Perampanel|Participants with PGTC or SGTC seizures may receive perampanel tablets or oral suspension as only add-on therapy based on physicians decision in accordance with summary of product characteristics (SmPC) and will be observed at baseline, 6 months (intermediate visit), and 12 months (final visit).
89304725|NCT04186559|Experimental|Topical pentoxifylline (PTX) gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical PTX gel in their initial course of treatment will receive topical placebo gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
89304726|NCT04186559|Placebo Comparator|Topical placebo gel|As part of a randomized, placebo-controlled trial with a crossover component, patients who receive topical placebo gel in their initial course of treatment will receive topical PTX gel once they are re-enrolled for their second course of treatment upon recurrence of another crop of genital ulcers.
89304727|NCT04184362|Experimental|Experimental group tested at the active treatment site|The theranova empower device will be tested at the active treatment site.
89304728|NCT04184362|Sham Comparator|Control sham group tested at the sham control treatment site|The theranova empower device will be tested the sham control treatment site.
89304729|NCT04183452||17-Hydroxyprogesterone Caproate 250 mg IM Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 250 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
89304730|NCT04183452||17-Hydroxyprogesterone Caproate 275 mg SC Group|This will be an open label study and participants will not be randomized to a treatment group. The women will be prescribed 17-OHPC by their physicians because of their obstetric history. The investigators will approach pregnant women who are going to be treated with 17-OHPC and ask them to participate. The participants will select the route of administration they prefer, IM or SC. 36 participants will receive the weekly 275 mg IM dose from 16-20 weeks of pregnancy until 36 weeks or delivery.
89304731|NCT04171479||Manual|Subjects who underwent epicardial mapping and/or ablation using a manual technique will comprise this group.
89304732|NCT04171479||Remote Magnetic Navigation|Subjects who underwent epicardial mapping and/or ablation using a remote magnetic technique (using Stereotaxis Niobe system) will comprise this group.
89304733|NCT04156373|Experimental|Fuerte|This group will receive the Fuerte prevention program over the span of six to eight weeks.
89304734|NCT04156373|No Intervention|Delayed waitlist control|This group will be the delayed waitlist control group. They will not receive the Fuerte prevention program until the following semester.
89304735|NCT04134585||People aged 60|People aged 60 and over who had refused to participate in fall prevention workshops will be included. They will have semi-structured interviews.
89304736|NCT04133298|Active Comparator|Tunneling with laser de-epithelized gingival graft.|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
89304737|NCT04133298|Active Comparator|Tunnelingwith subepithelial connective tissue graft.|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid.
89304738|NCT04123938|Experimental|Pea Protein|Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
89304739|NCT04123938|Active Comparator|Whey Protein|Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
89304740|NCT04123938|Placebo Comparator|Maltodextrin|Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
89304741|NCT04106245|Experimental|Supportive care (PACK health coach, survey)|Patients are contacted once weekly by a health coach by text message, phone call, email, or a mobile application, for 3 months. The total time interacting with the health coach is about 3.5-4.5 hours across the study. Patients also complete surveys over 30 minutes each time at baseline and every 30 days for 3 months.
89304742|NCT04104646|Experimental|CHF6563|Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo
89304743|NCT04104646|Active Comparator|Morphine|Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.
89304744|NCT04075487|Experimental|User experiences with MEPS-Pain|This is a pilot study to assess user experience with MEPS-Pain App, there is only one arm.
89304745|NCT04048421|Experimental|hvNOTES group|Participants will undergo hvNOTES radical colectomy.
89304746|NCT04047589||Subjects|Cancer patients with curable or previously treated malignancies
89304747|NCT04047589||Providers|Physicians seeing patients in the outpatient clinics at the IU Simon Cancer Center
89304748|NCT04000763|Experimental|Transcutaneous Nerve Stimulator(TENS)|Adult females who have difficulty emptying their bladder due to non-obstructive urinary retention or because of an under-active bladder will be given transcutaneous nerve stimulation (TENS) therapy.
89304749|NCT03997643|Active Comparator|Standard Radiotherapy|Radiotherapy to all dissected areas
89304750|NCT03997643|Experimental|Radiotherapy to smaller treatment area|Omit radiation to pN0 neck
89304751|NCT03978897|Experimental|Blood flow restriction with physical/occupational therapy|physical/occupational therapy including use of blood flow restriction tourniquet over 6 visits (within a twelve week period).
89304752|NCT03978897|Active Comparator|Evidence based physical/occupational therapy|evidence based physical/occupational therapy program over 6 visits (within a twelve week period) without use of blood flow restriction tourniquet
89304753|NCT03954171|Other|Patients treated with platinum based-chemotherapy|
89304754|NCT03926533|Experimental|Telehealth ICU Recovery Program|Components of the ICU RC telehealth visit will be structured parallel to what is done during a typical in-person clinic visit. The telehealth intervention consists of 5 chronological components conducted during two 1.5 hour telehealth clinic visits (the same time required for an in-person visit). Upon completion of the pre-intervention baseline assessment, the study coordinator will contact patients randomized to the intervention arm to schedule the first telehealth visit. Study visits will occur at 3 weeks and 3 months following hospital discharge.
89304755|NCT03926533|No Intervention|Standard Recovery Conditions|participants assigned to the standard of care control group will be contacted by the study coordinator to ensure the patient has a primary care and/or specialist appointment scheduled. At this time, patients will also receive an electronic PICS guide for ICU survivors created by the Society of Critical Care Medicine. Patients will be directed to use the information provided in the PICS guide for ICU survivors to connect with resources.
89304756|NCT03919669|Experimental|All Subjects|"All subjects will complete PET imaging sessions evaluating the tau PET radioligand [18F]MK-6240 at baseline, as well as at 6, 12 and 24 months post-baseline.~If unable to complete the 6 month, 12 month, or 24 month visit, an 18 month and/or 30 month visit may instead be scheduled, totaling a maximum of four time points."
89304757|NCT03900767|Experimental|Clinic-Level|"Clinics will receive the AAC intervention consisting of an EHR-based point of care alert that prompts clinic staff to Ask every patient about tobacco use, Advise tobacco using patients to quit, and Connect interested tobacco users to the Utah Tobacco Quit Line~Assigned Interventions = Electronic Health Record intervention AAC"
89304758|NCT03900767|Experimental|Phase I Group I (Continued EHR and text messages)|Patients receive a weekly text message for one month followed by a monthly text message over the next 5 months (i.e., 6 months of text messages following each tobacco users' clinic visit). All messages will include a motivational message, the Quit Line website, the Quit Line phone number, and simple two-touch response that directly connects interested tobacco users to the Quit Line.
89304759|NCT03900767|Experimental|Phase I Group II (Continued clinic-level EHR intervention only)|Patients receive continued clinic level EHR intervention only (CO).
89304760|NCT03900767|Experimental|Phase II Group I (Text messages, Counseling call)|Patients receive a monthly text message plus 2 brief telephone calls from patient navigators/health educators for 6-12 months following each tobacco user's clinic visit.
89304761|NCT03900767|Experimental|Phase II Group II (Text messages continued)|Patients receive a monthly text message for 6-12 months following each tobacco user's clinic visit that includes a simple one-touch response to directly connect to the Quitline.
89304762|NCT03896867|Experimental|Anapod™ Humi-Therm Heated Humidification System|Patient warming will be provided via the Anapod™ Humi-Therm Heated Humidification System Breathing Circuit.
89304763|NCT03896867|Active Comparator|Bair Hugger™ Warming Blanket|Patient warming will be provided via the Bair Hugger™ Warming Blanket.
89304764|NCT03860558|Experimental|Lifestyle Intervention|20 overweight men with T1D or T2D will undergo an intensive 3 month lifestyle intervention program aimed at improving metabolic health, glycemic control, and body weight.
89304765|NCT03860558|Active Comparator|No-Intervention Controls|10 overweight men with T1D or T2D will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
89304766|NCT03860558|Active Comparator|Healthy Controls|10 healthy men will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
89304767|NCT03832634|Other|Fetal Genome Profiling|Trophoblast cells will be collected from the cervix approximately 5-6 weeks once pregnancy is achieved.
89304768|NCT03819309|Experimental|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
89304769|NCT03819309|Active Comparator|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
89304770|NCT03818360|Experimental|Smokers attending A&E|Receive an evidence-based smoking cessation intervention comprising brief advice plus active referrals for smokers attending emergency departments in Hong Kong.
89304771|NCT03790553|Active Comparator|50.4Gy|Total radiotherapy dose of 50.4Gy.
89304772|NCT03790553|Experimental|61.2Gy|Total radiotherapy dose of 61.2Gy.
89304773|NCT03772665|Experimental|Emixustat|10 mg
89304774|NCT03772665|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
89304775|NCT03729115|Other|Screening Arm|Enrolled patients will undergo Magnetic Resonance Imaging (MRI) every 6 months (2x/year) in addition to an annual screening mammogram.
89304776|NCT03683342|Active Comparator|Ankle Block|Ankle block will be performed under ultrasound guidance.
89304777|NCT03683342|Active Comparator|Popliteal sciatic nerve block (PSNB)|PSNB will be performed under ultrasound guidance, along with a saphenous nerve block at the ankle
89304778|NCT03677947|Active Comparator|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning and overvalued ideas. IBCT does not include exposure, but aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
89304779|NCT03677947|Active Comparator|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, patients will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention).
89304780|NCT03626701|Experimental|RECELL® Autologous Cell Harvesting Device|"RECELL + Telfa™ Clear and Xeroform™ dressings~Conventional autografting (only when indicated)"
89304781|NCT03626701|Active Comparator|Mepilex® Ag Wound Dressing|"Mepilex® Ag Wound Dressing~Conventional autografting (only when indicated)"
89304782|NCT03604692|Experimental|Cohorts of escalating dose levels of SNDX-6352|"Escalating dose levels of SNDX-6352 to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D).~Intravenous (IV) infusion; SNDX-6352 at a dose of 0.15 milligrams (mg)/kilogram (kg) to 3 mg/kg."
89304783|NCT03604692|Experimental|Phase 2 Dose Expansion|"Phase 2, dose expansion, is an open-label design, evaluating the 1 mg/kg dose in a larger sample size.~IV infusion; SNDX-6352 at a dose of 1 mg/kg."
89304784|NCT03602079|Experimental|Phase I: Dose Escalation|Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
89304785|NCT03602079|Experimental|Phase II: • Cohort 1|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
89304786|NCT03602079|Experimental|Phase II: • Cohort 2|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
89304787|NCT03602079|Experimental|Phase II: • Cohort 3|HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
89304788|NCT03602079|Experimental|Phase II: • Cohort 4|All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
89304789|NCT03598218|Experimental|Hypofractionated dose IMRT|Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.
89304790|NCT03598218|Experimental|Standard-dose IMRT|Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..
89304791|NCT03580824|Experimental|Group 1|Group 1 adults (n=20) will be administered 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the non-dominant arm). A booster dose will be administered at 9-25 months post 3rd dose.
89304792|NCT03580824|Experimental|Group 2|"Group 2A children 1-5 years (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 2B children 1-5 years (n=17) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid). A booster dose will be administered at 9-25 months post 3rd dose."
89523357|NCT03394651||Oral medication group|Patients in this group will receive oral medications to treat lower urinary tract symptoms
89523358|NCT03394651||Surgical treatment group|Patients in this group receive minimal invasive transurethral prostate procedures.
89523359|NCT03377309|Experimental|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
89304793|NCT03580824|Experimental|Group 3|"Group 3A infants 5-<12 months (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3B infants 5-<12 months (n=3) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3C infants 5-<12 months (n=15) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3D infants 5-<12 months (n=15) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3E infants 5-<12 months (n=15) will be receiving 5mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~A booster dose will be administered at 9-25 months post 3rd dose."
89304794|NCT03569215||IVF/ICSI failure|These patients had prolonged infertility with one or more failure of IVF/ICSI cycles
89304795|NCT03569215||Prolonged infertility only|These patients had prolonged infertility without any trials of IVF/ICSI cycles
89304796|NCT03566797||SC-CIP|Patients developing SC-CIP
89304797|NCT03566797||noSC-CIP|Patients with similar severity of critical illness not developing SC-CIP
89304798|NCT03543735|Experimental|Wisepill+SMS|
89304799|NCT03543735|Active Comparator|Wisepill-only|
89304800|NCT03543735|No Intervention|Disulfiram-only|
89304801|NCT03536546|Experimental|Alcohol Peer-Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
89304802|NCT03536546|Active Comparator|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
89304803|NCT03497676|Experimental|Cohort 1C: CAB|"Step 1: CAB administered orally as one 30 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2: CAB LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (600 mg/3 mL), and at Week 8 (600 mg/3 mL)."
89304804|NCT03497676|Experimental|Cohort 1R: RPV|"Step 1: RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit, for 4-6 weeks.~Step 2: RPV LA administered as one IM injection at Week 4b (Step 2 Entry) study visit (900 mg/3 mL), and at Week 8 (900 mg/3 mL)."
89304805|NCT03497676|Experimental|Cohort 2: CAB + RPV|"Step 3: CAB administered orally as one 30 mg tablet once daily AND RPV administered orally as one 25 mg tablet once daily, beginning at the Entry visit for 4-6 weeks.~Step 4: First injection: CAB LA administered as one 600 mg (3 mL) IM injection AND RPV LA administered as one 900 mg (3 mL) IM injection, at Week 4b (Step 4 Entry) and at Week 8. Subsequent injections: starting at Week 16, CAB LA administered as a 600 mg (3 mL) IM injection AND RPV LA administered as a 900 mg (3 mL) IM injection, every eight weeks through Week 96."
89304806|NCT03494933|Experimental|CRT-P group|Intervention: CRT-P implantation
89304807|NCT03494933|Active Comparator|CRT-D group|Intervention: CRT-D implantation
89304808|NCT03427424||AUD-E|Early-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP within 2 months of starting treatment (AUD-E)
89304809|NCT03427424||AUD-L|Long-term-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (AUD-L)
89304810|NCT03427424||Characterization|substance use disorder participants currently enrolled in PHP, not eligible for main imaging study
89304811|NCT03427424||CON|healthy, non-drug using control participants (CON)
89304812|NCT03427424||POAUD-E|Early-in-treatment, healthy dual prescription opioid and alcohol and use disorder participants currently enrolled in PHP within 2 months of starting treatment (POAUD-E)
89304813|NCT03427424||POAUD-L|Long-term-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POAUD-L)
89304814|NCT03427424||POUD-E|Early-in-treatment, healthy prescription opioid use disorder participants currently enrolled in physician health program (PHP) within 2 months of starting treatment (POUD-E)
89304815|NCT03427424||POUD-L|Long-term-in-treatment, healthy prescription opioid use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POUD-L)
89304816|NCT03387137|Experimental|Group 1: RSV 6120/∆NS2/1030s Vaccine|RSV-seropositive children will receive a single dose of 10^5.7 plaque-forming units (PFUs) of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
89304817|NCT03387137|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (Day 0).
89304818|NCT03387137|Experimental|Group 2: RSV 6120/∆NS2/1030s Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
89304819|NCT03387137|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (Day 0).
89304820|NCT03386513|Experimental|Escalation and Expansion|"Escalation: IMGN632 was administered by IV on 2 different schedules for participants with relapsed/refractory AML, ALL, or BPDCN.~Expansion: IMGN632 was administered by IV:~Cohort 1: Relapsed or refractory BPDCN participants who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN)~Cohort 2: Relapsed AML~Cohort 3: Relapsed or refractory ALL~Cohort 4: Other relapsed or refractory hematologic malignancies~Cohort 5: Relapsed or refractory AML at alternate dose or schedule~Cohort 6: Pivotal cohort for frontline BPDCN participants who have not received prior systemic therapy and participants with frontline BPDCN who have prior or concomitant hematologic malignancy (PCHM) and have not received prior systemic therapy."
89304821|NCT03366142|Experimental|Single Arm|treatment with ustekinumab based on weight
89304822|NCT03330795|Experimental|CD3/CD19 neg allogeneic BMT|All participants will receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
89304823|NCT03300947|Experimental|High-dose Psilocybin|Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
89304824|NCT03300947|Experimental|High- or Low-dose Psilocybin|Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
89304825|NCT03300947|Placebo Comparator|High-dose Psilocybin or Lorazepam|Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
89304826|NCT03287154|Experimental|Active tDCS stimulations|Patients in this arm will receive 10 tDCS active stimulations of 2 mA (1 stimulation per day from Monday to Friday during 2 weeks).
89304827|NCT03287154|Sham Comparator|Sham tDCS|"Patients in this arm will receive 10 sham stimulations (1 stimulation per day from Monday to Friday during 2 weeks).~As soon as the power will have reached the maximal intensity as in the active arm, the stimulation will be stopped."
89304828|NCT03255746|Experimental|Sleep Enhancement|
89304829|NCT03255746|Placebo Comparator|Health Education|
89304830|NCT03209531|Experimental|Operant Conditioning|Participants will receive operant conditioning training and single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks.
89304831|NCT03209531|Experimental|Control|Participants will receive single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks without operant conditioning training.
89304832|NCT03190200||MRI|Subjects with healthy knees
89304833|NCT03129893||Patients intubated with uncuffed tracheal tubes|Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
89304834|NCT03129893||Patients intubated with cuffed tracheal tubes|Cuffed TT sizes selected as follows: ID 3.0 mm for birth (>3 kg body weight) to < 8 months; ID 3.5 mm for 8 to < 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
89304835|NCT03107884|Experimental|Metformin (Bed Rest)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). During bed rest, participants will be given 1 gram of metformin two times a day (morning and evening). This dosage and frequency will occur during four consecutive days of bed rest.
89304836|NCT03107884|Placebo Comparator|Placebo (Bed Rest)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. During bed rest, participants will be given the same amount of pills and given at the same time of day (morning and evening) as the experimental group. This strategy will occur during four consecutive days of bed rest.
89304837|NCT03107884|Experimental|Metformin (2 week run-in only)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). These participants will not participate in the bed rest portion of the protocol.
89304838|NCT03107884|Placebo Comparator|Placebo (2 week run-in only)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. These participants will not participate in the bed rest portion of the protocol.
89304839|NCT03106415|Experimental|Treatment (binimetinib, pembrolizumab)|Patients receive binimetinib PO BID on days 1-14 of cycle 1 and on days 1-21 of cycle 2 and subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycle 1 equals 14 days. Cycles 2 and beyond repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89304840|NCT03082963|Other|EMR Feasibility|In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.
89304841|NCT03080129|Experimental|Cirrhosis + sarcopenia|Patients with cirrhosis will receive 200ml of an oral nutritional supplement daily for 7 days.
89304842|NCT03080129|No Intervention|Control|Patients with sarcopenia and no evidence of cirrhosis and healthy controls
89304843|NCT03024996|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
89304844|NCT03024996|Placebo Comparator|Placebo|Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
89304845|NCT03003325|Active Comparator|Phlebotomies + ASA|Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)
89304846|NCT03003325|Experimental|Phlebotomies + ASA + AOP2014|Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).
89304847|NCT02969798|No Intervention|Healthy normal glucose tolerance (NGT) subjects|Subjects (Fasting Plasma Glucose or FPG < 100 mg/dl and 2-h PG < 140 mg/dl) without FH (family history) of diabetes in a first degree relative
89304848|NCT02969798|Active Comparator|Isolated IGT with Dapagliflozin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive dapagliflozin, 10 mg/day
89304849|NCT02969798|Active Comparator|Isolated IGT with Saxagliptin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive saxagliptin, 5 mg/day
89304850|NCT02969798|Active Comparator|Isolated IGT with Pioglitazone|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
89304851|NCT02969798|Active Comparator|Isolated IGT with Metformin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
89304852|NCT02969798|Active Comparator|Isolated IFG with Dapagliflozin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive dapagloflozin, 10mg/day
89304853|NCT02969798|Active Comparator|Isolated IFG with Saxagliptin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive saxagliptin, 10mg/day
89304854|NCT02969798|Active Comparator|Isolated IFG with Pioglitazone|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
89523360|NCT04446403|Experimental|circumflex|patients will undergo ultrasound guided SSN+circumflex
89304855|NCT02969798|Active Comparator|Isolated IFG with Metformin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
89304856|NCT02969798|Active Comparator|IGT plus IFG with Dapagliflozin|Healthy subjects with IGT plus IFG will receive dapagliflozin, 10mg/day
89304857|NCT02969798|Active Comparator|IGT plus IFG with Saxagliptin|Healthy subjects with IGT plus IFG will receive saxagliptin, 10mg/day
89304858|NCT02969798|Active Comparator|IGT plus IFG with Pioglitazone|Healthy subjects with IGT plus IFG will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
89304859|NCT02969798|Active Comparator|IGT plus IFG with Metformin|Healthy subjects with IGT plus IFG will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
89304860|NCT02855203|Experimental|SABR + Pembrolizumab|SABR treatment (18Gy-20Gy/1#) followed by 200mg pembrolizumab IV once every 3 weeks for a total of 8 cycles
89304861|NCT02854215|Other|Ovarian cancer|Patient undergoing primary surgery for a newly diagnosed ovarian, tubal or peritoneal malignancies; Stage IIIc or IVa with extrapelvic carcinomatosis according to the International Federation of Gynecology and Obstetrics classification 2014
89304862|NCT02824822||High SUDEP risk cohort|Patients with epilepsy who have a high SUDEP-7 risk score and/or a blood-relative with epilepsy, seizure, cardiac arrest, sudden death, drowning/near-drowning, syncope or arrhythmia.
89304863|NCT02824822||Low SUDEP risk cohort|Patients with epilepsy and a low SUDEP-7 score.
89304864|NCT02748564|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks and aldesleukin IV every 8 hours for up to 14 doses at weeks 4, 7, 16, 19, 28, and 31 in the absence of disease progression or unacceptable toxicity.
89304865|NCT02723734||African-American Men (AAM)|AAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
89304866|NCT02723734||Non-African American Men (NAAM)|NAAM with low risk or intermediate risk prostate cancer (PCa). Decipher® testing and standard treatment.
89304867|NCT02642965|Experimental|Treatment (CPX-351 and FLAG)|"COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.~COURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5."
89304868|NCT02376127||pts with known spinal metastases|(20 patients from any solid cancer) who are to undergo radiation treatment (RT) will be recruited. The patients will undergo DCE-MRI before and after RT. RT will be classified as success based on evidence of tumor contraction on conventional MRIs, negative PET, or stability for more than 11 months and blinded from DCE MRI sequencing. For each patient, a scanning profile for the first scan will be saved and used for the follow-up scans to acquire the same locations over time. Each patient will be scanned 4 times (one pre-treatment and 3 follow up post treatment) during their consecutive clinical visits. The DCE MRI sequence is a part of MR sequences for standard care. No additional scans will be added in the standard clinical sequences.
89304869|NCT02311959|Experimental|Invasive or in situ breast carcinoma.|
89304870|NCT02266420|Other|TNBC pT1a/b with size < or = 10 mm|Patients with pN0 triple negative breast tumor with size < or = 10 mm (pT1a/b) Study intervention = blood samples collected at initial visit
89304871|NCT02266420|Other|TNBC pT1c T2 with size <or = 30 mm|Patients with pN0 triple negative breast tumor with size < or = 30 mm (pT1c T2) Study intervention = blood samples collected at initial visit
89304872|NCT02197013||Introcan Safety 3|Closed IV Catheter
89304873|NCT02197013||Introcan Safety|IV catheter
89304874|NCT01936532|Experimental|assessment of treatment lenalidomide, dexamethasone,MLN9708|
89304875|NCT01815619|Experimental|on-site evaluation of specimens by cytopathologist|The specimen will be evaluated onsite by a cytopathologist during the procedure to render a diagnosis
89304876|NCT01815619|Active Comparator|off-site specimen evaluation|The specimen will be evaluated offsite by a cytopathologist during the procedure and render a diagnosis
89304877|NCT01325506||Prostatectomy subjects|
89304878|NCT01054625|Experimental|zalutumumab 4 mg/kg|zalutumumab 4 mg/kg iv single infusion week 1,3, 4 and 5
89304879|NCT01054625|Experimental|zalutumumab 8 mg/kg|zalutumumab 8 mg/kg iv single infusion week 1, 3, 4 and 5
89304880|NCT01054625|Experimental|zalutumumab 16 mg/kg|zalutumumab 16 mg/kg iv single infusion week 1, 3, 4 and 5
89304881|NCT00909909|Active Comparator|A|3DCRT/IMRT lumpectomy bed boost followed by accelerated whole breast irradiation (AWBI)
89304882|NCT00909909|Active Comparator|B|Accelerated whole breast irradiation (AWBI) followed by 3DCRT/IMRT lumpectomy bed boost
89304883|NCT00747396|Experimental|Foster Care Placement Group|Children randomized to this group were placed in high quality foster care developed for the study.
89304884|NCT00747396|No Intervention|Care As Usual Group|Children randomized to this group remained in institutional care.
89304885|NCT00707655|Experimental|Zalutumumab 4 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
89304886|NCT00707655|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
89304887|NCT00542308|Experimental|Zalutumumab 4-16 mg/kg|Zalutumumab iv infusion once weekly. The dose was titrated until grade 2 rash occurred.
89304888|NCT00488605|Active Comparator|Treatment Arm A|
89304889|NCT00488605|Experimental|Treatment Arm B|
89523361|NCT04446403|Experimental|posterior cord|patients will undergo ultrasound guided SSN+circumflex
89523362|NCT03377231|Experimental|Prevention|
89523363|NCT03377231|Experimental|Treatment|
89304890|NCT00482352||Ancillary-Correlative (marker identification, molecular test)|Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia).
89304891|NCT00327860||Cohort 1|"Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2"
89304892|NCT00327860||Cohort 2|"Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease."
89304893|NCT00327860||Cohort 3|Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
89304894|NCT00074373||human beings|human beings of all sexes, ages, and health statuses
89304895|NCT00006734|Experimental|Regimen A|Test the hypothesis that chemotherapy given every two weeks (Regimen B) will produce higher event-free survival. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks (four cycles on Regimen A. The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide, etoposide, MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (Surgery, Radiation Therapy, or a combination) will begin on Week 13 which will be after four cycles of chemotherapy.
89304896|NCT00006734|Experimental|Regimen B|Conventional every-three-week chemotherapy for patients with Ewing sarcoma and related tumors. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks six cycles on Regimen B). The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide etoposide MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (surgery, Radiation Therapy, or a combination) will begin on Week 13, which will be after six cycles of chemotherapy.
89304897|NCT01311128||Heart rate and blood pressure determination|All subjects have the same conditions (T-line, blood pressure cuff, and radial artery catheter), in order to compare them within-subjects.
89304898|NCT03443414|Experimental|0.75 mg RPL554|
89304899|NCT03443414|Experimental|1.5 mg RPL554|
89304900|NCT03443414|Experimental|3 mg RPL554|
89304901|NCT03443414|Experimental|6 mg RPL554|
89304902|NCT03443414|Placebo Comparator|Placebo|
89304903|NCT02991118|Experimental|bempedoic acid|bempedoic acid 180 mg/day
89304904|NCT02991118|Placebo Comparator|Placebo|Placebo control
89304905|NCT03720314||IBS|Irritable bowel syndrome patients
89304906|NCT03720314||control|healthy controls
89304907|NCT03662152|Experimental|Foam roller|Non-Vibration Foam Rolling (NVFR) Group: subjects performed the FR protocol using a custom-made foam roller composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long).
89304908|NCT03662152|Experimental|vibration foam roller|Vibration Foam Rolling (VFR) Group: subjects performed the same protocol using a foam roller with vibration (frequency: 18 Hz) composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long) (Hyperice ®).
89304909|NCT03491150|Placebo Comparator|Parent Placebo|Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
89304910|NCT03491150|Experimental|Parent Crenezumab|Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
89304911|NCT03661450||PICU-Patients|Pediatric patients admitted after 01.08.2018
89304912|NCT03660514|No Intervention|Standard Family Planning|Counseling Clients receive standard FP counseling services.
89304913|NCT03660514|Experimental|Jovenes Sanos Intervention in FP Counseling|Clients receive the Jovenes Sanos intervention in addition to standard FP counseling services.
89304914|NCT04056130|Experimental|Cohort SAD1|9 Subjects for SAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
89304915|NCT04056130|Experimental|Cohort SAD2|9 Subjects for SAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.
89304916|NCT04056130|Experimental|Cohort MAD1|9 Subjects for MAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
89304917|NCT04056130|Experimental|Cohort MAD2|9 Subjects for MAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo
89304918|NCT02991040|Experimental|Revanesse Ultra+|Revanesse Ultra+ (with lidocaine) vs Revanesse Ultra without lidocaine
89304919|NCT03661216|Placebo Comparator|Placebo|3g of non-GMO maltodextrin
89304920|NCT03661216|Active Comparator|Nephure|3g of Nephure
89304921|NCT04056286|Experimental|Healthy + Whey|Healthy (overnight fast)
89304922|NCT04056286|Experimental|Catabolic + Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
89304923|NCT04056286|Experimental|Catabolic + 3-OHB / Whey|Catabolic (Inflammation (LPS) + 36 hour fast and bed rest)
89304924|NCT03660436|Experimental|BMS-986165 + MMF|Oral administration
89304925|NCT03660358|Experimental|Kinesiotape|Kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
89304926|NCT03660358|No Intervention|Control|No kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
89304927|NCT02910466|Experimental|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on albumin-corrected serum calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
89304928|NCT03662620|Experimental|ARM1|"In ARM1, 32 subjects will be assigned and the subjects will be administered comparator drug at Day1/Day43 and study drug at Day22/64."
89304929|NCT03662620|Experimental|ARM2|"In ARM2, 32 subjects will be assigned and the subjects will be administered study drug at Day1/Day43 and comparator drug at Day22/64."
89523364|NCT05237791|Experimental|magnesium group|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
89304930|NCT03415178|Experimental|Auto-Injector Device (AI)|Alirocumab 300 milligram (mg) subcutaneous (SC) injection on Week 0 (Day 1), self-administered using AI device, on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, participants switched to other arm of SYDNEY device to receive Alirocumab 300 mg, self- administered (unsupervised) using new auto-injector device (SYDNEY) every 4 weeks (Q4W) from Week 4 until Week 16 in the single arm treatment period added to lipid modifying therapy (LMT).
89304931|NCT03415178|Experimental|New Auto-injector Device (SYDNEY)|Alirocumab 300 mg SC injection on Week 0 (Day 1), self-administered using new auto-injector device (SYDNEY), on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, same treatment (Alirocumab 300 mg) with the same device (SYDNEY) was self-administered, (unsupervised) Q4W until Week 16 in the single arm treatment period added to LMT. Duration of single arm treatment period was 12 weeks, i.e. from Week 4 to 16.
89304932|NCT03660202|Experimental|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of Firesorb BVS
89304933|NCT04056052|Sham Comparator|Home Activity Only|Over the 8-week project, families were asked to try eight different vegetable recipes from a choice of 12. All family members could participate in the home activities as the families wished. Families were also asked to complete a weekly recipe cooking tracking sheet.
89304934|NCT04056052|Active Comparator|Home Activity + cooking Workshop|The 8-week cooking workshop condition incorporated all of the home activities previously described, however, this cohort also participated in two, two-hour cooking workshops held at a local cooking school.
89304935|NCT03659968|Experimental|EXPERIMENTAL GROUP|patients in advanced phase of pediatric cancer Physical activity training will be performed in drug development
89304936|NCT04055974|Experimental|BeAMom|Low-risk (LR) women will receive a web-based intervention for the promotion of maternal mental health (the Be a Mom program). In addition, women will receive postpartum treatment as usually performed in primary care settings (TAU).
89304937|NCT04055974|No Intervention|Control|Low-risk (LR) women will receive postpartum treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
89304938|NCT04055896|No Intervention|Control Group|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
89304939|NCT04055896|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making) Pause of medication and clinical monitoring"
89304940|NCT03659890|Placebo Comparator|Low nucleotide|2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose
89304941|NCT03659890|Experimental|High nucleotide|2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose
89304942|NCT03659890|Experimental|High nucletide + Ribose|2 week supplementation with a high nucleotide mycoprotein drink, with added ribose
89304943|NCT03659812|Experimental|MACS is applied to the sperm sample|Previous to the AID technique, the sperm sample undergoes capacitation through Percoll density gradient and MACS
89304944|NCT03659812|No Intervention|MACS is not applied to the sperm sample|Previous to the AID technique, MACS only undergoes capacitation through Percoll density gradient, but not MACS technique
89304945|NCT03660982||FDRs of RBD cases|FDRs of RBD cases. The diagnosis of RBD is based on ICSD-II criteria, as confirmed by v-PSG and with the aid of REM sleep behaviour disorder questionnaire (RBDQ-HK). RBD cases which are secondary to narcolepsy, neurodegenerative diseases or other neurological diseases are excluded.
89304946|NCT03660982||FDRs of non-RBD controls|FDRs of non-RBD controls. Non-RBD control probands are free of narcolepsy, significant clinical RBD symptoms and other neurological diseases.
89304947|NCT03660904|Experimental|Home made media|home made vitrification & thawing kit
89304948|NCT03660904|Active Comparator|Commercial media|commercially available vitrification & thawing kit
89304949|NCT03659656|Other|Fitbit (FB)|The Fitbit only (FB) group will receive the Fitbit monitor to use for 3 months.
89304950|NCT03659656|Experimental|Fitbit + Health coaching (FB+)|The Fitbit + Health coaching (FB+) group will receive a Fitbit, weekly personalized physical activity report and health coaching by phone. The 3-month intervention will be delivered through health coaching (1-time per week for month 1, 1-time every other week for month 2 and 1 time for month 3) and use of a Fitbit activity monitor.
89304951|NCT03661918|Other|Group 1|In-person first session, no second caregiver, no wifi-enabled scale
89304952|NCT03661918|Other|Group 2|In-person first session, no second caregiver, wifi-enabled scale
89304953|NCT03661918|Other|Group 3|In-person first session, second caregiver, no wifi-enabled scale
89304954|NCT03661918|Other|Group 4|In-person first session, second caregiver, wifi-enabled scale
89304955|NCT03661918|Other|Group 5|No in-person first session, no second caregiver, no wifi-enabled scale. 10 core coaching calls only
89304956|NCT03661918|Other|Group 6|No in-person first session, no second caregiver, wifi-enabled scale
89304957|NCT03661918|Other|Group 7|No in-person first session, second caregiver, no wifi-enabled scale
89304958|NCT03661918|Other|Group 8|No in-person first session, second caregiver, wifi-enabled scale
89304959|NCT03659500||Four-week routine bloodwork|Routine bloodwork every 4-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from June 1, 2012 to March 23, 2014
89304960|NCT03659500||Six-week routine bloodwork|Routine bloodwork every 6-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from March 25, 2014 to December 31, 2015
89304961|NCT03659422|Other|Intervention Arm|Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
89304962|NCT01068730|Other|Treatment A|500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
89304963|NCT01068730|Other|Treatment B|500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
89304964|NCT01068730|Other|Treatment C|1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
89304965|NCT01068730|Other|Treatment D|1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
89304966|NCT01068652|Active Comparator|Detemir + Met|Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.
89304967|NCT01068652|Active Comparator|BIAsp 30 + Met|Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
89304968|NCT03659344|Active Comparator|Vicryl plus|In this group, vicryl plus(Triclosan coated) sutures were used to close flaps
89304969|NCT03659344|No Intervention|vicryl|In this group, vicryl sutures were used to close flaps
89304970|NCT02921776|Experimental|Aim 1- VidaTalk post-extubation|"Aim 1 is a two group iterative design preliminary to clinical trial. Group 1 and Group 2 will each consist of five previously mechanically ventilated patients who will be recruited from the ICUs at the OSUWMC (Ohio State University Wexner Medical Center), including discharged patients.~Group 1 will use an initial android prototype of VidaTalk tablet application to be assessed for functionality (ergonomics, ease of use, ease of learning, simplicity, effectiveness and user interface) and usability on customizable communication, picture symbols, and integration with mobile communication devices.~Group 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Group 1 sessions."
89304971|NCT02921776|Experimental|Aim 2 - VidaTalk intubated|"Usability testing preliminary to Clinical Trial (Aim 3). Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.~Intervention is usability tasks with the VidaTalk app"
89304972|NCT02921776|Experimental|Aim 3 - VidaTalk tablet app|"Test the clinical efficacy of VidaTalk with MV patients by examining qualitative and quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.~Intervention will be receipt of VidaTalk tablet application."
89304973|NCT02921776|Other|Aim 3 - attention-control|"35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.~Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.~Interventions will be Aim 3 - attention-control with non-VidaTalk tablet."
89304974|NCT02921776|No Intervention|Aim 5-VidaTalk Efficacy in Family caregivers|"Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively.~Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured .Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured."
89304975|NCT03658720|Experimental|Single tablet|Ibuprofen acid ODT: 1x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
89304976|NCT03658720|Experimental|Two tablets|Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
89304977|NCT02922634||older surgical patients|Older surgical patients presenting for elective spine surgery
89304978|NCT00023595|Active Comparator|H01: Medication|Medical therapy alone to treat Coronary Artery Disease
89304979|NCT00023595|Active Comparator|H01: Medication + CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
89304980|NCT00023595|Active Comparator|H02: Medication+CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
89304981|NCT00023595|Active Comparator|H02: Medication+CABG+SVR|CABG plus Medication and Surgical ventricular reconstruction (SVR)
89304982|NCT03658564|Experimental|Oral carbohydrate|fast from midnight the night before surgery, and patients consume 400 ml Preoperative oral carbohydrate preOp®(12.5% carbohydrates, 0.5%kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
89304983|NCT03658564|No Intervention|Fasting|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
89304984|NCT03657784|Experimental|Cohort 1|P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.
89304985|NCT03657784|Experimental|Cohort 2|P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.
89304986|NCT03657784|Experimental|Cohort 3|P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.
89304987|NCT03657784|Experimental|Cohort 4|P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.
89304988|NCT03657784|Experimental|Cohort 5|P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.
89304989|NCT06324357|Experimental|Phase Ib - Cohort A: zongertinib + Trastuzumab emtansine|Dose escalation (Phase Ib)
89304990|NCT06324357|Experimental|Phase Ib - Cohort B: zongertinib + Trastuzumab deruxtecan|Dose escalation (Phase Ib)
89304991|NCT06324357|Experimental|Phase Ib - Cohort C: zongertinib + Trastuzumab deruxtecan|Dose escalation (Phase Ib)
89304992|NCT06324357|Experimental|Phase II - Cohort D: zongertinib + Trastuzumab emtansine|Dose optimization (Phase II).
89304993|NCT06324357|Experimental|Phase II - Cohort E: zongertinib + Trastuzumab deruxtecan|Dose optimization (Phase II).
89304994|NCT06324357|Experimental|Phase II - Cohort F: zongertinib + Trastuzumab deruxtecan|Dose optimization (Phase II).
89304995|NCT06324331|Experimental|Non decidual sparing|uterine incision repair including suturing of the endometrium
89304996|NCT06324331|Experimental|Decidual sparing|uterine incision repair without including the endometrium.
89304997|NCT06324318|Experimental|Parenting in 2 Worlds (treatment)|A 10-week parenting intervention focused on improving overall family functioning and strengthen parenting skills to communicate with adolescents to avoid risk behaviors.
89304998|NCT06324318|Active Comparator|Healthy Families in 2 Worlds|A 10-week parenting intervention curriculum focused on improving parental knowledge of family health topics.
89304999|NCT06324305|Active Comparator|Group 1|drainage of sub-retinal fluid from the original (primary) break
89305000|NCT06324305|Active Comparator|Group 2|drainage of sub-retinal fluid using perfluorocarbon (PFC) and removing sub-retinal fluid through the original break or peripheral retinotomy
89305001|NCT06324305|Active Comparator|Group 3|drainage of sub-retinal fluid through formation of a posterior drainage retinotomy only.
89305002|NCT06324279||term pregnant women with Singleton living fetus attending for induction of labor|
89305003|NCT06324266|Experimental|arm CTX|Cyclophosphamide monotherapy: CTX, 0.1g×7days，1/every other week, 28 days per course of treatment,total two years
89305004|NCT06324266|Placebo Comparator|arm Len|Lenalidomide monotherapy:Len,10mg/day×21days， 28 days per course of treatment,total two years
89305005|NCT06324253|Active Comparator|Erector Spinae Block|after induction of anesthesia bilateral US ESP block will be performed in the left lateral decubitus position under strict aseptic precautions. linear ultrasound transducer will be placed in a sterile cover, and positioned on the midline to identify the T10 spinous process. From this position, the ultrasound transducer will be moved 2-3 cm laterally to visualise the hyperechoic line of the T10 transverse process with its associated acoustic shadow inferiorly, and the overlying erector spinae muscle superiorly. Using in-plane approach a needle will be inserted in caudal-cephalad direction, until the tip is contact with the T10 transverse process and will be in the interfacial plane deep to the erector spinae muscle group and A dose of 30 ml 0.125% Bupivacaine will be injected bilateral in this plane . All patients will receive 1g intravenous paracetamol and 4 grams ondansetron 8mg dexamethasone
89305006|NCT06324253|Active Comparator|Thoracic Epidural Block|"before induction of anesthesia under strict aseptic precautions, 18Gauge Tuohy's needle with Huber's tip will be inserted via median approach after local infiltration with 5 ml of 2% lignocaine at the level of T9-T10 or T10-T11 intervertebral space in the sitting position. After identifying epidural space using loss of resistance technique, 5 ml of saline will be administered after negative aspiration for blood or cerebrospinal fluid and 20Gauge epidural catheter will be threaded 5 cm cranially.~the patients in group B will be administered with a bolus dose of 10 ml of 0.125% bupivacaine through epidural catheter followed by continuous infusion of 0.125% bupivacaine at the rate of 0.1 ml/kg/hour All patients will receive 1g intravenous paracetamol and 4 grams ondansetron 8mg dexamethasone"
89305007|NCT06324240|Experimental|Phase Ia (TMV vaccine)|Patients receive TMV vaccine ID at weeks 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.
89305008|NCT06324240|Experimental|Phase Ib Arm A ( TMV vaccine, pembrolizumab)|Patients receive TMV vaccine ID at weeks 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV on day 1. Treatment with pembrolizumab repeats every 21 days for 6-9 cycles in the absence of disease progression or unacceptable toxicity.
89305009|NCT06324240|Experimental|Phase Ib Arm B ( TMV vaccine, ipilimumab)|Patients receive TMV vaccine ID at weeks 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV on day 1. Treatment with ipilimumab repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
89305010|NCT06324227|Experimental|multimodal music therapy group|using twice a week, 12 weeks music intervention with singing and physical movement with rhythm
89305011|NCT06324227|Experimental|no intervention group|no intervention
89305012|NCT06324214|Placebo Comparator|Placebo Group|Participants will participate in a standard PR program and will receive placebo.
89305013|NCT06324214|Active Comparator|Intervention (Urolithin A) Group|Participants will participate in a standard PR program and will receive the oral supplement.
89305014|NCT06324188|Other|Early atrial fibrillation ablation|
89305015|NCT06324188|Other|Usual Care|
89305016|NCT06324175||Observational Prospective Cohort|
89305017|NCT06324162|Experimental|2-slot brackets|50 patients treated with 2-slot brackets.
89305018|NCT06324162|Experimental|Twin brackets|50 patients treated with traditional twin brackets.
89305019|NCT06324149||older volunteers|"1250 individuals of the FRASNET study (original promoter of the study Ospedale San Raffaele, Principal Investigator Professor Paolo Manunta): older volunteers who were either robust or frail at the evaluations performed in 2016-2017)~completion of scales and questionnaires~venous blood sampling~muscle ultrasound~cardiac ultrasound~electrocardiogram~bioelectrical impedance analysis"
89523365|NCT05237791|Placebo Comparator|control group|normal saline 100ml (loading for 10 minutes), 15mg/kg/hr (continuous infusion)
89305020|NCT06324149||neurology patients|"720 patients suffering from cognitive impairment and clinically followed at the Neurology Department of the San Raffaele Hospital (UniSR Prof Agosta)~completion of scales and questionnaires~venous blood sampling~muscle ultrasound~cardiac ultrasound~electrocardiogram~bioelectrical impedance analysis"
89305021|NCT06324136|Experimental|Rare kidney diseases|Patients with rare kidney diseases
89305022|NCT06324110|Experimental|Screening (LCS coordination)|Patients receive lung cancer screening follow-up care coordination services, delivered by a lung cancer screening care coordinator at their care site.
89305023|NCT06324058|Experimental|Cryoablation group|Transurethral resection of bladder tumor, instant cryoablation of the bladder tumor resection site.
89305024|NCT06324058|Active Comparator|Control group|Transurethral resection of bladder tumor, conventional BCG instillation after surgery
89305025|NCT06324045|No Intervention|Control arm|Includes patients who will receive usual ambulatory, and at discharge care
89305026|NCT06324045|Experimental|Intervention arm|Includes patients who will receive a structured deprescribing intervention by the multidisciplinary team during patients' time at the center, and discharge (as applicable)
89305027|NCT06324032||Patients with subepithelial gastrointestinal tumors|Patients with subepithelial gastrointestinal tumors
89305028|NCT06324019|Experimental|Developing Gynecological Examination Dress|Gown will be put on the patient before gynaecological examination and their satisfaction will be evaluated
89305029|NCT06323993||Piezoelectric osteotomy|This group used piezoelectric osteotomy (exposure) to prepare the lateral window acceding maxillary sinus
89305030|NCT06323993||Round Bur|This group used round bur (control) to prepare the lateral window acceding maxillary sinus
89305031|NCT06323980|Experimental|INHANCE Stemless Reverse|INHANCE(TM) Stemless Reverse Total Shoulder
89305032|NCT06323980|Active Comparator|INHANCE Stemmed Reverse|INHANCE(TM) Stemmed Reverse Total Shoulder
89305033|NCT06323967|Experimental|Large unconditional cash transfers plus voluntary peer support|These participants will receive monthly cash transfers of $1,500 via debit card for 24 months and can elect to participate in peer support services plus usual care from shelter staff.
89305034|NCT06323967|Active Comparator|Nominal cash transfers|These participants will receive monthly cash transfers of $50 via debit card for 24 months plus usual care from shelter staff.
89305035|NCT06323967|Other|Passive comparison|These propensity-matched families will reside in other New York City shelters and will be followed anonymously in administrative records only. The will receive usual care from shelter staff.
89305036|NCT06323928|Placebo Comparator|Group A: Placebo|Participants will receive 2 injections of placebo.
89305037|NCT06323928|Experimental|Group B: Lu AG09222|Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
89305038|NCT06323928|Experimental|Group C: Lu AG09222|Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
89305039|NCT06323928|Experimental|Group D: Lu AG09222|Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
89305040|NCT06323928|Experimental|Group E: Lu AG09222|Participants will receive 2 injections, each containing Lu AG09222.
89305041|NCT06323915|Active Comparator|FineVision|"28 patients will be implanted bilaterally with Intensity FineVision (PhysIOL, Belgium) trifocal IOLs.~The device is CE-marked and used according to the intended purpose."
89305042|NCT06323915|Active Comparator|Artis Symbiose|"28 patients will be implanted bilaterally with Artis Symbiose (Cristalens Industrie, France) IOLs.~The device is CE-marked and used according to the intended purpose."
89305043|NCT06323915|Active Comparator|Synergy|"28 patients will be implanted bilaterally with Tecnis Synergy model ZFR00V (Johnson & Johnson, USA) IOLs.~The device is CE-marked and used according to the intended purpose."
89305044|NCT06323902||Patients with giant full thickness macular hole|13 patients with a diagnosis of macular hole with a total thickness greater than 400 microns were chosen. Without prior vitreoretinal surgery
89305045|NCT06323889|Active Comparator|Modified Alternate Day Fasting (mADF)|"Participants in the mADF group will be instructed to eat every second-day ad libitum (feast days), and to consume a very low carbohydrate snack, restricted to the evening, provided by the study team and to otherwise abstain from calorie intake on the rest of the fast day."
89305046|NCT06323889|Active Comparator|Time-Restricted Eating (TRE)|TRE participants are instructed to eat two main meals and limit snacking from 12:00 to 20:00 daily, and to fast from 20:00 until 12:00 daily
89305047|NCT06323889|Other|Control group|The control group will receive guidance on a quantitative reduction in total caloric intake by following a balanced diet, but no timing window for food intake will be prescribed to the participants in the control group.
89305048|NCT06323876||University of Chicago|This cohort will have prior consent to the Natural History of Interstitial Lung Disease, which is an ongoing, longitudinal cohort of patients with clinically diagnosed ILD, including IPF. Patients are recruited from University of Chicago Interstitial Lung Disease Program during their clinic visit. Blood, plasma, and serum samples are collected upon enrollment and stored in a biorepository at University of Chicago. Subsets of patients have repeat blood draw at return clinic visits for specific research studies. The investigators propose collection of 1-year HRCTs, FVC, and DLCO.
89305049|NCT06323876||University of Virginia|This cohort will have prior consent to the Natural History of Interstitial Lung Disease, which is an ongoing, longitudinal cohort of patients with clinically diagnosed ILD, including IPF. Patients are recruited from the UVA Interstitial Lung Disease Program during their clinic visit. Blood, plasma, and serum samples are collected upon enrollment and stored in a biorepository at UVA (Pinn Hall RM#2232B, IRB#20937). Subsets of patients have repeat blood draw at return clinic visits for specific research studies. The investigators propose collection of 1-year HRCTs, FVC, and DLCO.
89305050|NCT06323863||patients who underwent stapes surgery at our instution|patients with otosclerosis who underwent stapedectomy in our institution
89305051|NCT06323850|Experimental|Experimental Group|The experimental group will receive the intervention first then a 2-month follow-up
89305052|NCT06323850|Experimental|Waitlist Group|The waitlist group receives no intervention (Phase 1) at first. After the 2-month intervention period, the waitlist group will receive the intervention, while the experimental group participates in a 2-month follow-up
89305053|NCT06323837|Experimental|MZP+TAU|Mirtazapine + Treatment as Usual
89305054|NCT06323837|Placebo Comparator|PLO+TAU|Placebo + Treatment as Usual
89305055|NCT06323824|Experimental|Office-based methadone|Under special Drug Enforcement Administration (DEA) exception, Clinician prescribes methadone and oral methadone is administered and/or dispensed at a pharmacy which also has an exception to do so. All randomized controlled trial (RCT) participants are offered additional behavioral treatments (e.g., individual, group, telehealth, phone-based).
89305056|NCT06323824|Active Comparator|Office-based buprenorphine (BUP)|Clinician prescribes BUP formulations that are dispensed at a pharmacy or administered in the office (e.g., extended-release formulations). All RCT participants are offered additional behavioral treatments (e.g., individual, group, telehealth, phone-based).
89305057|NCT06323811|Experimental|MINOCA|Patients with myocardial infarction with non-obstructive coronary artery disease (MINOCA) prospectively investigated with advanced CMR
89305058|NCT06323811|Experimental|Myocarditis|Patients with suspected myocarditis prospectively investigated with advanced CMR
89305059|NCT06323811|Experimental|Takotsubo cardiomyopathy|Patients with suspected Takotsubo cardiomyopathy prospectively investigated with advanced CMR
89305060|NCT06323811|Experimental|Spontaneous coronary artery dissection (SCAD)|Patients with suspected/diagnosed spontaneous coronary artery dissection prospectively investigated with advanced CMR
89305061|NCT06323811|Active Comparator|NSTEMI|Patients with confirmed non-ST elevation myocardial infarction on coronary angiography prospectively investigated with advanced CMR
89305062|NCT06323798||cases|patients with a paranasal sinus mri and a confirmed pyocele at bacteriologic sample reviewed in the medical file
89305063|NCT06323798||controls|patients with a paranasal sinus mri and a confirmed simple retention mucus at bacteriologic sample reviewed in the medical file
89305064|NCT06323785|Active Comparator|Active whole-body hyperthermia|
89305065|NCT06323785|Sham Comparator|Sham whole-body hyperthermia|
89305066|NCT06323772||PDE6A patients|15 patients with mutation in PDE6A
89305067|NCT06323772||PDE6B patients|15 patients with mutation in PDE6B
89305068|NCT06323772||RHO patients|10 patients with mutation in RHO
89305069|NCT06323759|No Intervention|CONTROL GROUP|Pregnant women have taken a routine parenthood preparation courses and follow-up by independent midwives in antenatally
89305070|NCT06323759|Other|INTERVENTION GROUP|Pregnant women have taken a new parenthood preparation courses and follow-up by independent midwives in antenatality, postnatality short term, and postnatality long term)
89305071|NCT06323746|Experimental|Denneroll Group|"The participants will be instructed to lie flat on their back on the ground with their legs extended and arms by their sides and gently folded across their stomach. The subject will place the Denneroll on the ground and the examiner positions the apex of the Denneroll.~The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements."
89305072|NCT06323746|Other|Wait List|This group will receive the same posture correction program after all data will be collected.
89305073|NCT06323733|Experimental|Exercise intervention|"The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. Heart rate will be monitored using a pulse oximeter. Participants will report their rate of perceived exertion during endurance training using a 5-point scale (very easy, easy, moderate, difficult, very difficult)."
89305074|NCT06323720||Episodic tension-type headache|Patients with 1 - 14 days of TTH/month.
89305075|NCT06323720||Chronic tension-type headache|Patients with more than 14 days TTH/month
89305076|NCT06323720||Healthy controls|Participants without tension-type headache
89305077|NCT06323707|Experimental|Exercise & Self-Management|
89305078|NCT06323707|Experimental|Self-Management Only|
89305079|NCT06323707|No Intervention|Usual Care|
89305080|NCT06323694||Patients with vertebroplasty|measuring the quality of life in patients on the waiting list for spinal surgery
89305081|NCT06323694||Patients with spinal fusion|measuring the quality of life in patients on the waiting list for spinal surgery
89305082|NCT06323681|Experimental|Peginterferon α-2b based treatment group|
89305083|NCT06323681|Active Comparator|NAs monotherapy group|
89305084|NCT06323668|Active Comparator|Cardiac implantable electronic device removal + empirical antibiotic therapy|"CIED removal + guideline antibiotic therapy (at least 10 days iv antibiotic therapy and then per oral treatment to 6 weeks total by POET criteria).~The antibiotic therapy is targeted according to microbiological analyses per microorganism.~The CIED removal will be done as soon as possible within 7 days."
89305085|NCT06323668|Experimental|Empirical antibiotic therapy|Guideline antibiotic therapy (at least 10 days iv antibiotic therapy and then per oral treatment to 6 weeks total by POET criteria). The antibiotic therapy is targeted according to microbiological analyses per microorganism.
89305086|NCT06323655|Experimental|Tasimelteon|single dose
89305087|NCT06323655|Placebo Comparator|Placebo|single dose
89305088|NCT06323655|Active Comparator|Active Control|single dose
89305089|NCT06323642|Experimental|A|probiotic mixture will be given daily to patients probiotic mixture containing: Lactobacillus rhamnosus GG
89305090|NCT06323642|Placebo Comparator|B|placebo mixture will be given to patients with pneumonia
89305091|NCT06323629|Experimental|Adaptive recursive self-feedback procedure|Using a tablet, participants listen to speech playback of their response to a prompt and self-correct/minimize their speech errors in a subsequent attempt. This process is looped multiple times per prompt. It adapts across narrative prompts with low and high complexities.
89305092|NCT06323629|Experimental|Non-adaptive recursive self-feedback procedure|Using a tablet, participants listen to speech playback of their response to a prompt and self-correct/minimize their speech errors in a subsequent attempt. This process is looped multiple times per prompt. However, it only uses narrative prompts with high complexity.
89305093|NCT06323616|No Intervention|Control Group|Sevoflurane anesthesia will be applied with an endtidal agent consumption of 0.8 MACage, with 2 standard deviations for MACage:1 to the control group, as we apply in routine anesthesia practice. (During the surgery, the parameters showing the depth of anesthesia will be placed away from the anesthesiologist and covered to ensure blindness. At the end of the surgery, the data will be received via USB.)
89305094|NCT06323616|Experimental|Study Group|Sevoflurane anesthesia will be applied to the study group by adjusting the MAC to keep the PSI median value between 25-50 (if PSI<25, MAC will be reduced by 0.1, if PSI>50, MAC will be increased by 0.1).
89305095|NCT06323590||Cohort A|Patients with AML, receiving standard induction chemotherapy
89305096|NCT06323577|Experimental|Restricted kinematic alignment|
89305097|NCT06323577|Active Comparator|Mechanical alignment|
89305098|NCT06323564||Parkinson Disease (PD)|"The trial will be divided into two periods T0 (first evaluation at the time of admission to hospital) and T1 (15 days after T0, during rehabilitation period in hospital for patients with Parkinson's disease).~First, as soon as patients are admitted to acute care,neuropsychological tests and self-report questionnaires will be administered.~Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1)."
89305099|NCT06323564||Anorexia Nervosa (AN)|"The trial will be divided into two periods T0 (first evaluation at the time of admission to hospital) and T1 (4 weeks after T0, during rehabilitation period in hospital.~First, as soon as patients are admitted to acute care, neuropsychological tests and self-report questionnaires will be administered.~Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1). Furthermore, the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1."
89305100|NCT06323525|Experimental|Patients with refractory or relapsed B-cell lymphoma|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, Power3 gene knock-out allogeneic CD19-targeting CAR-T.
89305101|NCT06323486|Other|absTBS-sham treatment sequence arm|Those assigned to the accelerated bilateral sequential theta burst stimulation (absTBS)-sham arm shall receive the blinded active absTBS treatment at Week 1. At Week 3, they shall receive the blinded sham treatment.
89305102|NCT06323486|Other|Sham-absTBS treatment sequence arm|In the sham-absTBS arm, the blinded sham treatment shall be administered at Week 1. The blinded active absTBS treatment shall be given at Week 3.
89305103|NCT06323473|Experimental|Treatment|Maitake given alongside systemic chemotherapy and/or CD4/6 inhibitors
89305104|NCT06323460|Experimental|Arm I (reduced > 95% of TTMV, external beam radiotherapy)|"Patients undergo external beam radiotherapy daily for 5 days a week for 4 weeks. Patients also receive cisplatin IV weekly or every 3 weeks or carboplatin/paclitaxel IV weekly at the discretion of treating physician for 4 weeks. Patients undergo blood sample collection for circulating tumor DNA testing at week 4.~Patients with reduced > 95% of TTMV undergo external beam radiotherapy QD 5 days a week for 5 weeks. Patients also receive cisplatin IV weekly or every 3 weeks or carboplatin/paclitaxel IV weekly at the discretion of treating physician for 5 weeks. Patients also undergo blood sample collection during screening and throughout the trial."
89305105|NCT06323460|Active Comparator|Arm II (not reduced > 95% of TTMV, external beam radiotherapy)|"Patients undergo external beam radiotherapy daily for 5 days a week for 4 weeks. Patients also receive cisplatin IV weekly or every 3 weeks or carboplatin/paclitaxel IV weekly at the discretion of treating physician for 4 weeks. Patients undergo blood sample collection for circulating tumor DNA testing at week 4.~Patients without reduced > 95% of TTMV undergo external beam radiotherapy daily for 5 days a week for 7 weeks. Patients also receive cisplatin IV weekly or every 3 weeks or carboplatin/paclitaxel IV weekly at the discretion of treating physician for 7 weeks. . Patients also undergo blood sample collection during screening and throughout the trial."
89305106|NCT06323434||cSDH|"Chronic subdural hematoma on imaging (CT/MRI)~Age: 18 years or older~Informed consent"
89305107|NCT06323421|Experimental|Mindfulness|8-week group and individual mindfulness training and practice
89305108|NCT06323408||Embryonal|Embryonal tumors, including medulloblastoma and ATRT
89305109|NCT06323408||Glioma, IDH-mutated|IDH-mutated gliomas, including WHO grades 2, 3 and 4
89305110|NCT06323395|Experimental|Vizol S LIPID BALANCE|topical administration of 1 drop of Vizol S LIPID BALANCE in each eye 4 times a day for 30 days
89305111|NCT06323395|Placebo Comparator|ophthalmic saline eyedrops|topical administration of 1 drop of ophthalmic saline eye drops matching Vizol S LIPID BALANCE in each eye 4 times a day for 30 days
89305112|NCT06323369|Experimental|Neoadjuvant Tislelizumab + Chemotherapy (Arm A)|"Neoadjuvant therapy ( 3 cycles ) ： Cycle1、2、3（Cycle length: 21 days）：Tislelizumab(IV) , dose= 200mg, day=1; Cisplatin(IV) , dose=75 mg/m2, or Carboplatin(IV) , AUC=5, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.~Following surgical resection, lymph node positive participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Lymph node negative participants receive 200 mg Tislelizumab Q3W as adjuvant therapy."
89305113|NCT06323369|Active Comparator|Up-front Surgery (Arm B)|Following surgical resection, lymph node positive participants receive chemoradiotherapy as adjuvant therapy. Lymph node negative participants receive follow-up.
89305114|NCT06323356|Experimental|TAK-279 for Generalized Pustular Psoriasis|Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.
89305115|NCT06323356|Experimental|TAK-279 for Erythrodermic Psoriasis|Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.
89305116|NCT06323343|Experimental|Video Intervention|Participants assigned to the video intervention group receive a text message prior to their prenatal fetal anomaly appointment. Embedded in that text message is a link to an animated video which provides education on best practices of communicating with providers.
89305117|NCT06323343|Active Comparator|Webpage links|Participants assigned to the webpage links group receive links to the clinic's publicly available webpages prior to their prenatal fetal anomaly appointment. The webpages provide background about the providers and services available as well as a tour of the clinic.
89305118|NCT06323330|Experimental|Intervention|The intervention arm will be given the Music Therapy, the Indian language adapted module
89305119|NCT06323330|Active Comparator|Active comparator|The active comparator arm will be given the standard speech rehabilitation.
89305120|NCT06323317|Experimental|Frailty-Specific Prehabilitation Program|Participants in the frailty-specific prehabilitation program (intervention group) will participate in a comprehensive prehabilitation programme comprising the following components: 1) structured preoperative education; 2) nutritional optimization; 3) stress management; and 4) exercise training. These four components are recommended by the international association as core elements of prehabilitation to optimize cardiac patients' physical and psychological capacity to withstand the challenges of cardiac surgical procedures. The prehabilitation will last for at least 4 weeks, and it will continue throughout the preoperative period.
89305121|NCT06323317|Placebo Comparator|Routine Preoperative Care|Participants in the control group will receive routine preoperative care provided by the clinical team, which includes unstructured patient education on the surgeries/procedures, and a brief session on the use of an incentive spirometer, breathing, and coughing exercise. Other perioperative care procedures will be implemented according to the existing clinical protocols.
89305122|NCT06323304|Experimental|Auricular acupressure + fluticasone propionate nasal spray|Auricular acupressure therapy (AAT) once a week on the left ear for a total of four weeks (4 sessions). Fluticasone propionate nasal spray will be used whenever symptoms occur.
89305123|NCT06323304|Sham Comparator|Sham acupressure + fluticasone propionate nasal spray|Sham acupressure therapy (SAT) once a week on the left ear for a total of four weeks (4 sessions). Fluticasone propionate nasal spray will be used whenever symptoms occur.
89305124|NCT06323291|Other|Digital Health Coaching for Pancreatic Cancer Patients|Initial in-person and/or virtual supportive care, social work, and dietitian consultation within 4 weeks of diagnosis and/or 3 weeks of study enrollment.
89305125|NCT06323291|Other|Digital Health Coaching for Caregivers|Initial in-person and/or virtual supportive care, social work, and dietitian consultation within 4 weeks of diagnosis and/or 3 weeks of study enrollment.
89305126|NCT06323278||PD with GBA gene mutation|Patients with Parkinson's disease and GBA gene mutation treated with cognitive training
89305127|NCT06323278||PD without genetic mutation|Patients with Parkinson's disease without genetic mutation treated with cognitive training
89305128|NCT06323252|Active Comparator|Intervention group|Participants with hypetriglyceridemia will be subjected to nutritional counsel and the intake of 1 soft gel capsule daily for a total of 3 months.
89305129|NCT06323252|Active Comparator|Control group|Participants with hypetriglyceridemia will be subjected to nutritional counsel for a total of 3 months.
89305130|NCT06323239|Experimental|SBRT+LDRT+PD-1+Chemotherapy|Patients will receive SBRT and LDRT one day before the GP chemotherapy and PD-1 antibody (six cycles), then followed by PD-1 antibody until progressive disease, intolerable toxicity, withdrawal of consent or a maximum of 2 year treatment.
89305131|NCT06323213|Experimental|610 group|Subjects will receive 610 for 52 weeks.
89305132|NCT06323213|Placebo Comparator|placebo group|Subjects will receive placebo for 52 weeks.
89305133|NCT06323200||Lymphedema duration > 3.6 years|
89305134|NCT06323200||Lymphedema duration ≤ 3.6 years|
89305135|NCT06323187||Pregnant Participants|Pregnant participants will be randomly assigned to provide a cervical sample using one of the devices/procedures for cervical fluid collection.
89305136|NCT06323187||Non-Pregnant Participants|Non-pregnant participants will be randomly assigned to provide a cervical sample using one of the devices/procedures for cervical fluid collection.
89305137|NCT06323174|Active Comparator|CagriSema Dose 2|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.
89305138|NCT06323174|Placebo Comparator|Placebo Dose 2|Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.
89305139|NCT06323174|Active Comparator|Cagrisema Dose 1|Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.
89305140|NCT06323174|Placebo Comparator|Placebo Dose 1|Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.
89305145|NCT06323148|Placebo Comparator|ct-DNA-positive patients receiving no adjuvant osimertinib|ct-DNA-positive patients receiving no adjuvant osimertinib
89305146|NCT06323148|Experimental|ct-DNA-positive patients receiving adjuvant osimertinib|ct-DNA-positive patients receiving adjuvant osimertinib
89305147|NCT06323122||group (I)|ORIF was done using two 2.0 miniplates
89305148|NCT06323122||Group II|ORIF was done using 2.3 high profile miniplates
89305149|NCT06323122||Group III|ORIF was done using 3D miniplates.
89305150|NCT06323109||Healthy Controls|Age-matched healthy men with no lower urinary tract symptoms
89305151|NCT06323109||Known BPH/LUTS|Adult men diagnosed with BPH/LUTS
89305152|NCT06323096||Polytrauma with SIRS|No intervention(s) to be administered.
89305153|NCT06323096||Polytrauma with Bloodloss|No intervention(s) to be administered.
89305154|NCT06323096||Polytrauma with ATC|No intervention(s) to be administered.
89305155|NCT06323096||Polytrauma with Pneumonia|No intervention(s) to be administered.
89305156|NCT06323083|Experimental|Intervention group|"Emotional Freedom Technique (EFT) application was applied to those in the intervention group.~The study was carried out in three stages with three EFT applications, applied for approximately 20-30 minutes, at 7-day intervals. In the first stage, students who met the inclusion criteria were identified by interviewing students who thought they had a fear of childbirth."
89305157|NCT06323083|No Intervention|Control group|The control group was also tested at the first interview and again 3 weeks later.
89305158|NCT06323044|Experimental|Arm A (MedSupport)|Participants receive the MedSupport intervention consisting of three components: universal screening for adherence barriers, tailored virtual education enhancement, and communication of barriers to activate multidisciplinary healthcare teams for 12 months. Participants also use the MEMS device to track oral chemotherapy adherence at baseline and follow-up. Patients also undergo blood sample collection throughout the study.
89305159|NCT06323044|Active Comparator|Arm B (usual care)|Participants receive usual care consisting of medical consultations and supportive care for 12 months. Participants also use the MEMS device to track oral chemotherapy adherence at baseline and follow-up. Patients also undergo blood sample collection throughout the study.
89305160|NCT06323031||Patients with DoC consecutively admitted to participating units and met the inclusion criteria|Patients in VS or MCS due to severe acquired brain injury with different etiology (traumatic, anoxic, vascular) consecutively admitted at participating neurorehabilitation units. The total sample will be composed of 70 patients (n=9 pts per participating unit).
89305161|NCT06323018|Sham Comparator|Control group|SHAM procedure is done one hour before cemented hip arthroplasty and comprises of 4 cycles of 5min sham procedure. Everything apart from the pressure in the cuff is similar to the RIPC procedure.
89305162|NCT06323018|Active Comparator|Remote Ischemic preconditioning group|RIPC procedure is done one hour before cemented hip arthroplasty and comprises of 4 ischemia (using brachial cuff with suprasystolic blood pressure for 5 min) and reperfusion (5 min) cycles.
89305163|NCT06322979|Active Comparator|MTA group|After the endodontic procedure, MTA will be placed into the apical 4 mm of the root canals. then a moist cotton pellet will be placed and the access cavity will be restored with GIC. Next day, GIC and the cotton pellet will be removed the coronal and middle third of the root canal will be filled with gutta-percha. The coronal restoration will be completed with GIC, composite.
89305164|NCT06322979|Experimental|Premixed Bioceramic Putty group|After the endodontic procedure, Premixed Bioceramic Putty (Well-Root™ PT) will be placed into the apical 4mm of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha. The coronal restoration will be completed with GIC, composite.
89305165|NCT06322940|Experimental|2-3 servings of regular-fat milk|Milk
89305166|NCT06322940|Experimental|2-3 servings of regular-fat yogurt|Yogurt
89305167|NCT06322940|Experimental|2-3 servings of regular-fat cheese|Cheese
89305168|NCT06322927||Patient Interviews|Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference.
89305169|NCT06322914||Technical successful group|Technical success of CTO PCI was defined as successful CTO revascularization with achievement of <30% residual diameter stenosis within the treated segment and restoration of antegrade TIMI flow grade 3.
89305170|NCT06322914||Technical unsuccessful group|Technical unsuccess of CTO PCI was defined as unsuccessful CTO revascularization（guide wire or stent cannot cross through the lesion）
89305171|NCT06322901|Experimental|test side|A mid-crestal incision was made on the test side with a no. 12 scalpel and a sulcular incision was made around the first natural tooth and a 5-mm vertical incision was made disto-obliquely to the distal crestal incision
89305172|NCT06322901|Active Comparator|control side|Only a mid-crestal incision was made on the control side with a no. 12 scalpel and a sulcular incision was made around the first natural tooth
89305173|NCT06322888|Experimental|Arm A: Exercise Intervention|"Participants will be randomized and will complete:~Baseline study visit with assessments, breast biopsy, and blood draw.~Exercise program for 12 weeks 3x weekly and exercise logs. Additional blood draw after first exercise session.~End of study visit with assessments, breast biopsy, and blood draw."
89305174|NCT06322888|No Intervention|Arm B: Waitlist Control|"Participants will be randomized and will complete:~Baseline study visit with assessments, breast biopsy, and blood draw.~End of study visit with assessments, breast biopsy, and blood draw.~Participants will be offered a complimentary 12-week exercise program after completing the study."
89305175|NCT06322875|Experimental|Test Side|Each subject will randomly formulate the face on one side as the test side
89305176|NCT06322875|Placebo Comparator|Control Side|Each subject will randomly formulate the face on one side as the control side
89305177|NCT06322862|Other|single arm|
89305178|NCT06322849|Experimental|Arm 1|"Experimental: Breathing exercise + active elements 1, 2, 3~In this arm, all three factors are set to active (i.e. yes):~Psychoeducation~Testimonials and Saying is believing exercises~Action planning"
89305179|NCT06322849|Experimental|Arm 2|"Experimental: Breathing exercise + active elements 1, 2~In this arm, two factors are set to active (i.e. yes):~Psychoeducation~Testimonials and Saying is believing exercises"
89305180|NCT06322849|Experimental|Arm 3|"Experimental: Breathing exercise + active elements 1, 3~In this arm, two factors are set to active (i.e. yes):~Psychoeducation~Action planning"
89305181|NCT06322849|Experimental|Arm 4|"Experimental: Breathing exercise + active elements 2, 3~In this arm, two factors are set to active (i.e. yes):~Testimonials and Saying is believing exercises~Action planning"
89305182|NCT06322849|Experimental|Arm 5|"Experimental: Breathing exercise + active element 1~In this arm, one factor is set to active (i.e. yes):~• Psychoeducation"
89305183|NCT06322849|Experimental|Arm 6|"Experimental: Breathing exercise + active element 2~In this arm, one factor is set to active (i.e. yes):~• Testimonials and Saying is believing exercises"
89305184|NCT06322849|Experimental|Arm 7|"Experimental: Breathing exercise + active element 3~In this arm, one factor is set to active (i.e. yes):~• Action planning"
89305185|NCT06322849|Experimental|Arm 8|"Experimental: Breathing exercise only~In this arm, none of the three factors are set to active (i.e. yes)"
89305186|NCT06322836|Other|intervention arm|there is only one intervention arm
89305187|NCT06322823|Experimental|direct thawing|
89305188|NCT06322823|Active Comparator|commercially available vitrification thawing|
89305189|NCT06322810|Experimental|Group E|Patients who receive erector spinae plane block(ESPB) before cardiac surgery
89305190|NCT06322810|Active Comparator|Group P|Patients who receive Pecto-intercostal plane block(PIFB) before cardiac surgery
89305191|NCT06322797|Experimental|rTMS over the M1 cortex of the injured hemisphere localized by motor action potential|Experimental A group : rTMS was administered by trained physicians over the M1 cortex of the injured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb.
89305192|NCT06322797|Experimental|rTMS over the specific site of the injured hemisphere localized by fMRI|Experimental B group : rTMS was administered by trained physicians over the specific site which is after checking the brain site activated during finger tapping during fMRI imaging, target coordinates are set based on the 10-20 EEG system coordinate system in the taken MRI image.
89305193|NCT06322797|Sham Comparator|Sham group|Sham group: shame rTMS( sound mode) is applied over the M1 cortex of the injured hemisphere which is the site that caused the largest visible twitch in the participant's thumb when stimulation is applied
89305194|NCT06322784|Experimental|Experimental group|12 week Mediterranean diet+dietary fiber intervention
89305195|NCT06322784|No Intervention|Control group|12 week Mediterranean diet
89305196|NCT06322771||Refusal|A questionnaire will be given to patients who have refused to participate in the RANSPRE trial
89305197|NCT06322771||Acceptance|A questionnaire will be given to patients who have agreed to participate in the RANSPRE trial
89305198|NCT06322745|Active Comparator|suture renorrhaphy group|involves cases of laparoscopic partial nephrectomy done with suture renorrhaphy only for hemostasis of the tumor bed.
89305199|NCT06322745|Active Comparator|thulium beam coagulation group|involves cases of laparoscopic partial nephrectomy with thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed
89305200|NCT06322719|Experimental|Hyperangulated videolaryngoscope|Tracheal intubation facilitated by a hyperangulated videolaryngoscope
89305201|NCT06322719|Active Comparator|Macintosh videolaryngoscope|Tracheal intubation facilitated by a videolaryngoscope with a Macintosh type blade
89305202|NCT06322706|Experimental|ABSK021|
89305203|NCT06322706|Experimental|ABSK021and Omeprazole|
89305204|NCT06322693|Experimental|Part 1a: TSR-022 monotherapy|
89305205|NCT06322693|Experimental|Part 1b: TSR-022 in combination with nivolumab|
89305206|NCT06322693|Experimental|Part 1c: TSR-022 in combination with TSR-042|
89305207|NCT06322693|Experimental|Part 1d: TSR-022 in combination with TSR-042 and TSR-033|
89305208|NCT06322693|Experimental|Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)|
89305209|NCT06322693|Experimental|Part 1f: TSR-022 in combination with TSR-042 and Docetaxel|
89305210|NCT06322693|Experimental|Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin|
89305211|NCT06322693|Experimental|Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin|
89305212|NCT06322693|Experimental|Part 2: Cohort A Melanoma-TSR-022 as monotherapy|
89305213|NCT06322693|Experimental|Part 2: Cohort A Melanoma-TSR-022 with TSR-042|
88806371|NCT05378334|Experimental|Combination Group|"Standard treatment: 4-6 cycles (3 weeks per cycle) of ICI + chemotherapy followed by ICI maintenance therapy, until tumor progression or at least 1 year.~HGXJT decoction: 1 dose daily, until tumor progression or accumulation for 1 year."
89305214|NCT06322693|Experimental|Part 2:Cohort B Non-small cell lung cancer-TSR-022-monotherapy|
88806372|NCT05378334|Placebo Comparator|Control group|"Standard treatment: 4-6 cycles (3 weeks per cycle) of ICI + chemotherapy followed by ICI maintenance therapy, until tumor progression or at least 1 year.~Placebo: 1 dose daily, until tumor progression or accumulation for 1 year."
89305215|NCT06322693|Experimental|Part 2:Cohort B Non-small cell lung cancer-TSR-022 with TSR-042|
89305216|NCT06322693|Experimental|Part 2:Cohort C Colorectal cancer-TSR-022 as monotherapy|
89305217|NCT06322693|Experimental|Part 2:Cohort C Colorectal cancer-TSR-022 with TSR-042|
89305218|NCT06322693|Experimental|Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)-TSR-022 with TSR-042|
89305219|NCT06322693|Experimental|Part 2: Cohort E-Non-small cell lung cancer-TSR-022 with docetaxel|
89305220|NCT06322693|Experimental|Part 2: Cohort F- Hepatocellular carcinoma (HCC)-TSR-022 with TSR-042|
89305221|NCT06322680|Experimental|Main pancreatic duct and biliary duct external drainage|"Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve."
89305222|NCT06322680|Experimental|Main pancreatic duct and biliary duct internal drainage|"Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures."
89305223|NCT06322667||All Participants|Participants prescribed lecanemab by a physician in routine clinical practice (post-marketing surveillance) will be observed prospectively for up to a maximum of 156 weeks or to the time of discontinuation, whichever occurs first.
89305224|NCT06322654|Experimental|Robotically Assisted Locomotion|
89305225|NCT06322654|Active Comparator|Robotically Assisted Verticalization|
89305226|NCT06322641||Nephrologist|Nephrologist with ASCVD and CKD patients
89305227|NCT06322628|Experimental|VSA006 low dose|
89305228|NCT06322628|Placebo Comparator|VSA006 low dose comparator|
89305229|NCT06322628|Experimental|VSA006 high dose|
89305230|NCT06322628|Placebo Comparator|VSA006 high dose comparator|
89305231|NCT06322615|Experimental|Supportive Care (acupressure)|Patients undergo acupressure over 15-120 seconds at a time for up to 15 minutes. After completion of the session, patients may optionally receive an education session on using acupressure at home.
89305232|NCT06322589|Placebo Comparator|placebo drink|
89305233|NCT06322589|Experimental|SOD like Super Drink|
89305234|NCT06322563|Experimental|Safety introduction trial：LTC004+regorafenib|LTC004 in combination with regorafenib safety introduction trial and completing a 28-day safety assessment
89305235|NCT06322563|Experimental|Formal trial phase：LTC004+regorafenib|After Safety introduction trial, safety will be confirmed before entering the formal trial phase.Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC
89305236|NCT06322550|Experimental|Migraine Patient|"122 migraine patients assigned the role of patient"
89305237|NCT06322550|Experimental|Migraine Healthy|"122 migraine patients assigned the role of healthy participant"
89305238|NCT06322550|No Intervention|headache-free controls|122 headache-free controls with no cover story
89305239|NCT06322537||Cardiac Surgery Patients|Adult (≥18 years old) patients who have undergone cardiac surgery.
89305240|NCT06322524||insomnia group|"insomnia participants participants underwent polysomnography (PSG), the Insomnia Severity Index (ISI), the Pittsburgh Sleep Quality Index (PSQI), the Self-Rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS). prior to the commencement of the study.~8 weeks of the intervention of Gamma sensory flicker, 30 min per day. After 8 weeks study, participants underwent polysomnography again. In the first week of study, participants were required to keep a daily sleep diary everyday.~In the eighth week of study ,participants were required to keep a daily sleep diary everyday."
89305241|NCT06322511|Experimental|Intervention group|These families receive Dialogical family guidance, including six meetings (during 3 months) within the intervention manual proceedings. Parents fill the questionnaires before and after the intervention.
89305242|NCT06322511|No Intervention|comparative group|"These families (parents in the family) give responses how they manage in ordinary life with their child with neurodevelopmental disorders.~These families do not receive the intervention."
89305243|NCT06322498|Experimental|Intact uterus|Patients with intact uterus
89305244|NCT06322498|Experimental|Scarred uterus|Patients with scarred uterus
89305245|NCT06322485|Experimental|Internet-based self-management intervention|At the beginning of the treatment, a face-to-face introductory meeting is scheduled between the participant and a psychologist, where treatment goals will be set. Afterwards, a tailored self-management intervention, based on cognitive-behavioral methods, will be offered via an internet-based program. The psychologists offering the treatment have been trained in the tailored cognitive-behavioral protocol. One month and 2,5 months after finishing the online program, patients will be contacted by their treating psychologist for two booster sessions via telephone. Patients' goals will be evaluated and strategies to strengthen the achieved results will be discussed.
89305246|NCT06322485|No Intervention|Waitlist|Patients in the control condition will be assigned to a waiting list and will receive the internet-based self-management intervention after the active treatment group (after 6 months).
89305247|NCT06322472|Experimental|23 children with cochlear implants|The children with cochlear implants was applied The Early Childhood Phonological Sensitivity Scale and The Turkish Early Language Development Test.
89305248|NCT06322472|Other|23 parents|Demographic Questionaries, Family Literacy Scale and ELHES were applied to the families of the participants
89305249|NCT06322459|Experimental|Sport Eucation Curriculum|The Teaching experiment period of the Sport Education Model was 12 weeks, 40 minutes per lesson which included warm-up (10 minutes), basic content (20 minutes), rest of basic content (5 minutes), and cool-down (5 minutes).
89305250|NCT06322459|Active Comparator|Normal Teaching|The Teaching experiment period of Normal Teaching was 12 weeks, 40 minutes per lesson which included warm-up (10-min), basic content (20min), rest of basic content (5min), and cool-down (5min). Normal Teaching includes Teacher-directed learning (10 minutes) and Individual practice (10 minutes).
89305251|NCT06322446|Experimental|Intervention|"Telematic Exercise:~A remotely supervised resistance exercise program will be carried out for 16 weeks, with two weekly sessions lasting approximately 60 minutes each. Training will be performed in groups of four patients, according to their lung function/physical fitness.~The first training session will be on site (University) for familiarization, planning and adjustment of the exercises, and the following sessions will be performed online. Each session is divided into: (i) Warm-up and joint mobility; (ii) main part: strength exercises for different muscle groups; and (iii) cool down: stretching and breathing exercises."
89305252|NCT06322446|No Intervention|Control|Control group will follow routine recommendations from the multidisciplinary CF team based on WHO´s guidelines
89305253|NCT06322420|Experimental|Treatment|Active treatment provided to all participants in the study.
89305254|NCT06322407|Experimental|Stellate Ganglion Block plus standardized drug treatment group|Besides orally topiramate plus ibuprofen as standardized drug treatment, patients will also receive SGBs plus standardized drug therapy; SGB will be performed once a week for 4 consecutive times in an individual series. The interval of each separate SGB procedure is 1 week. Every time patients with bilateral headache will be administered SGB alternately on each side at an interval of 40 min, and patients with unilateral headache will be administered SGB on the ipsilateral side;
89305255|NCT06322407|Active Comparator|standardized drug treatment group|The patients will only receive Topiramate plus ibuprofen as standardized drug treatment according to the guidelines for the treatment of CM.
89305256|NCT06322394|Experimental|BXOS110 high-dose group|Name:BXOS110 Dosage form:injection Dosage:3.0 mg/kg, maximum dose not exceeding 300 mg Frequency:Frequency of injection is once Duration:10±1 min
89305257|NCT06322394|Experimental|BXOS110 low-dose group|Name:BXOS110 Dosage form:injection Dosage:2.0 mg/kg, maximum dose not exceeding 300 mg Frequency:Frequency of injection is once Duration:10±1 min
89305258|NCT06322394|Placebo Comparator|Placebo control group|Dosage:0 mg/kg Frequency:Frequency of injection is once Duration:10±1 min
89305259|NCT06322381|Active Comparator|Reinsertion achilles tendon|Reinsertion Achilles tendon by 2-4 anchors.
89305260|NCT06322381|Active Comparator|Zadek osteotomy|A calcaneal osteotomy was then performed, two Kirschner wires, were then inserted from the posterior aspect of the calcaneus, over which cannulated screws were used for fixation of the osteotomy.
89305261|NCT06322368|Experimental|Myofunctional and respiratory training|Patients with chronic stroke receiving an exercise training program for the muscles around the face, mouth, and tongue and a respiratory training focused on inspiratory and expiratory muscle strengthening.
88806373|NCT01793636|Experimental|AZD2014|AZD2014- tablets, starting dose 50mg BD everyday, until disease progression or untolerable toxicity
88806374|NCT01793636|Active Comparator|Everolimus|Everolimus- tablets, starting dose 10mg OD everyday until disease progression or untolerable toxicity
88806375|NCT05345418|Experimental|Umbilical Cord-Derived Mesenchymal Stem Cell, then Placebo (group A)|"Cohort 1 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 0, and Study Month 3.~- Each treatment period was separated by a 4 - week washout to allow the effective systemic elimination of the UC MSCs before subsequent treatment initiation"
88806376|NCT05345418|Active Comparator|Placebo, then Umbilical Cord-Derived Mesenchymal Stem Cell (group B)|Cohort 2 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 7, and Study Month 10
88806377|NCT00308282|Experimental|A|
88806378|NCT00308282|Placebo Comparator|B|
88806379|NCT00343460|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
88806380|NCT00343460|Experimental|Arm II|Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
88806381|NCT00343460|Experimental|Arm III|Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
88806382|NCT01659996|Experimental|Menactra Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® at 15 to 18 months of age.
88806383|NCT01659996|Experimental|Menactra and Pentacel Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed (Pentacel®) concomitantly at 15 to 18 months of age.
88806384|NCT01659996|Active Comparator|Pentacel Vaccine Group|Participants will receive only Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Pentacel®) at 15 to 18 months of age.
88806385|NCT00309140|Experimental|Enzastaurin|
88806386|NCT05395806|Experimental|Health App|"This group will have access to a gamified App to help them to control their cardiovascular risk factors and to improve their adherence to medication therapy.~Half of the participants will be allocated to the App group. They will be stratified by age and cardiovascular risk level according to national standards based on the Framingham risk factors level."
88806387|NCT05395806|Active Comparator|Usual Care|This group will not have access to the gamified App and will receive their usual care at the primary care clinic. In addition, they will receive extra information on cardiovascular risk factors control. Both groups will have the same access to clinical checks and medications at the clinic.
88806388|NCT00353522|Experimental|Dalcetrapib|Dalcetrapib 900mg po daily for 24 weeks
88806389|NCT00353522|Placebo Comparator|Placebo|Placebo po daily for 24 weeks
88806390|NCT05597046||Healthcare Professionals|Planning Phase Interviews
88806391|NCT05376774||Critically ill patients|Patients admitted to intensive care units
88806392|NCT00310076|Experimental|Chemo therapy followed by thalidomide|After cytoreductive surgery with intraperitoneal hyperthermic chemotherapy, patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
88806393|NCT00353834|Active Comparator|Glargine insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve fasting blood glucose of 100 mg/dl and avoid hypoglycemia.
89305262|NCT06322368|Active Comparator|Range of motion and stimulation exercises|Standard treatment focused mainly on range of motion, such as opening and closing the mouth and stimulation exercises
89305263|NCT06322342|Experimental|2 mg/Mn/kg|6 subjects each will receive RVP-001 at a doses of 2 mg Mn/kg
89305264|NCT06322342|Experimental|7 mg/Mn/kg|6 subjects each will receive RVP-001 at a doses of 7 mg Mn/kg
89305265|NCT06322342|Experimental|12 mg/Mn/kg|6 subjects each will receive RVP-001 at a doses of 12 mg Mn/kg
89305266|NCT06322329|Experimental|Full cohort|All subjects are included in the same arm.
89305267|NCT06322316|Active Comparator|The Ultrasound-guided Retrolaminar Block (RLB) Group|Received a preoperative ultrasound-guided retrolaminar block using 20 ml levobupivacaine 0.25% Ultrasound probe was placed on the back in a transverse orientation on the lateral side of the posterior median line to identify the lamina of the 5th vertebra, ESM, and transversospinalis muscles of the target segment.
89305268|NCT06322316|Active Comparator|The Ultrasound-guided Erector Spinae Plane Block (ESPB) Group|"Received a preoperative ultrasound-guided erector spinae plane block using 20 ml levobupivacaine 0.25%.~ultrasound probe was placed on the back in a transverse orientation to identify the tip of the T5 transverse process as flat, squared-off acoustic shadows with a faint image of the pleura visible. When the tip of the transverse process was centered on the ultrasound screen, the probe was rotated to a longitudinal orientation. In the parasagittal view The block needle was inserted in-plane in a cranial-to-caudal direction until contact was made with the T5 transverse process."
89305269|NCT06322290||pneumococcal, meningococcal, and hemophilus Invasive Bacterial Diseases|Pediatric and adult patients diagnosed with pneumococcal, meningococcal, and hemophilus Invasive Bacterial Diseases, as defined in the Italian Superior Institute of Health (ISS) protocol.
89305270|NCT06322277|Other|Patients with viral/bacterial infection|
89305271|NCT06322238|Experimental|PGx testing arm|
89305272|NCT06322238|Placebo Comparator|Delayed PGx testing arm|
89305273|NCT06321809||Intervention group|They were given a calorie-restricted diet and exercise plan by a dietician or physiotherapist at their first visit, and were followed up by telephone calls at weeks 2, 4, 6, 8 and 10 over 12 weeks.
89305274|NCT06321809||Control-1 group|During the initial medical interview, the participants were given a calorie-restricted diet programme by a dietician and an exercise programme by a physiotherapist; they were followed up over 12 weeks with telephone calls at week 4.
89305275|NCT06321809||Control-2 group|During the initial medical interview, the participants were given a calorie-restricted diet programme by a dietician and an exercise programme by a physiotherapist; they were followed up over 12 weeks with telephone calls at week 4.
89305276|NCT06321757||Patients with small native vessel coronary artery disease|- Patients with small native vessel coronary artery disease y/or patients with High Bleeding Risk
89305277|NCT06321367||elderly COVID-19 patients with coinfection|
89305278|NCT06321367||elderly COVID-19 without coinfection|
89305279|NCT06320743|Active Comparator|Group LFA|NIRS probe will be attached to the inner surface of the forearm and cerebral right-left frontotemporal region and the values will be noted. Standard ASA monitoring and induction will be performed. Fresh gas flow will be 4 lt/min, 50% oxygen/air mixture, sevoflurane vaporizer will be turned on at 4%, continue for 10 minutes and then fresh gas flow will be reduced to 0.8 lt/min, sevoflurane the MAK value will be adjusted to be between 0.9-1.1. Alarm limits appropriate to the patient's weight will be determined for all patients, the lower limit of inspired O2 will be set as 30%, the upper limit of inspired CO2 will be set as 5mmHg. If the inspired O2 value drops below 30%, the pulse oximeter peripheral SpO2 drops below 97, and the NIRS values drop by 20%, the oxygen concentration will be increased by 10%. The sevoflurane vaporizer will be turned off 10 minutes before the end of the operation. When the extubation criteria are met, the patient will be extubated.
89305280|NCT06320743|Active Comparator|Group HFA|NIRS probe will be attached to the inner surface of the forearm and cerebral right-left frontotemporal region and the values will be noted. Standard ASA monitoring and induction will be performed.Fresh gas flow will be 3lt/min, 50% oxygen/air mixture, and the sevoflurane vaporizer will be turned on at 3%, sevoflurane the MAK value will be adjusted to be between 0.9-1.1. The sevoflurane vaporizer will be turned off the end of the operation. When the extubation criteria are met, the patient will be extubated.
89305281|NCT06320366|Placebo Comparator|Sham TMS|Participants have baseline assessments/evaluation, are admitted to the inpatient research unit, randomized via permuted block design to 5 days of sham TMS, and then have weekly study visits for the next 12 weeks.
89305282|NCT06320366|Experimental|Active TMS|Participants have baseline assessments/evaluation, are admitted to the inpatient research unit, randomized via permuted block design to 5 days of active TMS, and then have weekly study visits for the next 12 weeks.
89305283|NCT06319729|Experimental|Treatment group|During the 4-week intervention, participants are required to consume 4.7g of CDD-2105 granule (a Chinese herbal medicine formula containing four granular herbs) twice per day.
89305284|NCT06319729|Placebo Comparator|Placebo group|During the 4-week intervention, participants are required to consume 4.7g of placebo twice per day.
89305285|NCT06319378|Experimental|psilocybin 25 mg (active)|
89305286|NCT06319378|Active Comparator|psilocybin 1 mg|
89305287|NCT06319131|Experimental|TIPS group|The cirrhotic patients with persistent PVT despite 6 months of anticoagulation therapy will receive transjugular-intrahepatic-portosystemic shunt.
88806394|NCT00353834|Experimental|Exenatide|Exenatide 5ug twice daily for 4 weeks followed by 10 ug twice daily for 8 weeks.
88806395|NCT05344404|Experimental|Nicotinamide Riboside|Nicotinamide riboside 3000mg daily for the duration of the trial (4 weeks). Administered in tablet form in doses of 1500mg twice daily.
88806396|NCT05344404|Placebo Comparator|Placebo|Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (4 weeks).
88806397|NCT00354224|Experimental|Oxaliplatin + Capecitabine|Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.
88806398|NCT05395260|Experimental|FL-101-IV|Open Label Infusion of FL-101 on Day 1 and Day 15
89305288|NCT06319131|Active Comparator|Nadroparin group|The cirrhotic patients with persistent PVT despite 6 months of anticoagulation therapy will continue with the nadroparin therapy
89305289|NCT06318416|Experimental|Early|Urine spectrophotometry for rifampin absorbance and rifampin dose adjustment at Day 14
89305290|NCT06318416|Experimental|Delayed|Urine spectrophotometry for rifampin absorbance and rifampin dose adjustment at Day 21
89305291|NCT06318299|Active Comparator|Ketone 1 hour|Ketone ester drink administered one hour before elective lumbar puncture
89305292|NCT06318299|Active Comparator|Ketone 2 hours|Ketone ester drink administered two hours before elective lumbar puncture
89305293|NCT06318299|Placebo Comparator|Placebo 1 hour|Placebo drink administered one hour before elective lumbar puncture
89305294|NCT06317584|Experimental|Empowerment Application for CAM Health Education.|Using empowerment software applications for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of the assistive tool of the empowerment software application
89305295|NCT06317584|Placebo Comparator|Written Paper for CAM Health Education.|Using written paper for complementary and alternative therapy education, explaining the risk factors that need to be considered
89305298|NCT06316505|No Intervention|Control group (CG)|Conventional oral hygiene education (COHE)
89305299|NCT06316505|Experimental|Intervention group (IG)|In addition to COHE, oral hygiene motivation with individual oral photographs
89305300|NCT06316102|No Intervention|Control|This group will not receive an intervention; however, provider training in gender affirmation will be conducted at the clinic level, so control participants may be exposed to changes in provider attitudes and practices.
89305301|NCT06316102|Experimental|Gender Affirming Abriendo Puertas (Opening Doors) (GAP)|"This group will be exposed to all four components of the multilevel intervention.~1) individual counseling and education; 2) peer navigation; 3) provider capacity building; and 4) community support building."
89305302|NCT06315426|Experimental|Interleukin-4 receptor responder 1|
89305303|NCT06315426|Experimental|Interleukin-4 receptor responder 2|
89305304|NCT06315426|Placebo Comparator|Placebo|
89305305|NCT06315348|Experimental|Collagen matrix|a cross-linked volume stable collagen matrix (VCMX; Geistlich Fibro-Gide, Geistlich Pharma AG)
89305306|NCT06315348|Active Comparator|Xenograft|a graft consisting of bovine hydroxyapatite xenograft (Geistlich Bio-Oss; Geistlich Pharma AG), covered by a native collagen membrane (Geistlich Bio-Gide; Geistlich Pharma AG), tagged with pins at the ends.
89305307|NCT06315335|Experimental|Cohort 1 (Caucasian)|Study participants enrolled in this arm will receive either injections (sc) of the lowest dose level of UCB9741 or Placebo
89305308|NCT06315335|Experimental|Cohort 2 (Japanese)|Study participants enrolled in this arm will receive either subcutaneous (sc) injections of the lowest dose level of UCB9741 or Placebo
89305309|NCT06315335|Experimental|Cohort 3 (Caucasian)|Study participants enrolled in this arm will receive either subcutaneous (sc) injections of the highest dose level of UCB9741 or Placebo
89305310|NCT06315335|Experimental|Cohort 4 (Japanese)|Study participants enrolled in this arm will receive either subcutaneous (sc) injections of the highest dose level of UCB9741 or Placebo
89305311|NCT06315335|Experimental|Cohort 5 (Caucasian)|Study participants enrolled in this arm will receive either subcutaneous (sc) injections of the highest dose level of UCB9741 (using a different volume per injection than cohort 3) or Placebo
89305312|NCT06315218|Experimental|Intervention Arm|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) with mHealth interventions, iTHRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. iTHRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. iTHRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of Black SGLM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
89305313|NCT06315218|No Intervention|Control Arm|The 6-month waitlist control group will only have access to THRIVE SS services not encompassed by iTHRIVE 365, such as in-person events. The investigators will ensure the control group does not access the iTHRIVE 365 mHealth app portion by screening all new app users, giving the intervention group unique private log-ins, and explaining the importance of securing those log-ins to ensure the accuracy of study results.
89305314|NCT06314906|Experimental|True Acupuncture Combined with Antiemetic Therapy|Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz.
89305315|NCT06314906|Placebo Comparator|Antiemetic therapy|Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group. They will also receive the same antiemetic medications as the experimental group.
88806399|NCT00310310|Placebo Comparator|Usual Care|Usual sleep apnea and cpap care
89305316|NCT06314815||1|Patients that received the ilioinguinal-iliohypogastric nerve block [IINB] were chosen by the anesthetists prior to surgery based on patient suitability, consultation with patients, and availability of time and resources. The Ilioinguinal-iliohypogastric nerve block contained one of 0.5% Bupivacaine and 2% Lidocaine, 0.5% Marcaine and 2% Lidocaine, 0.25% Marcaine with Epinephrine, 0.25% or 0.1% Bupivacaine 2ith 2% Lidocaine (mixtures such as: 0.5% Bupivacaine (also called Marcaine) and 2% Lidocaine, with or without Epinephrine mix).
89305317|NCT06314815||2|Matched patients in terms of biometric and peroperative data, who did not receive an Ilioinguinal-iliohypogastric nerve block.
89305318|NCT06314633|Other|study procedures|Hair cut for DNA damage and chemical exposome variation analysis and Socio-economic characteristics
88806400|NCT00310310|Experimental|Self-Management|sleep apnea self-management program - 4 sessions, group-based
88806401|NCT01792388|Placebo Comparator|Soya Bean oil|
89305319|NCT06310070|Experimental|Receiving 3D Personalized Ostomy Appliance|The personalized ostomy appliances are designed based off of a 3D scan. We will scan your ostomy to create a 3D picture in the computer system that is an exact copy of your ostomy using plastic. We then apply computer aided design (CAD) tools to modify your normal ostomy baseplates.
89305320|NCT06308029|Experimental|eHealth self-management support program|This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle.
89305321|NCT06308029|Active Comparator|Face-to-face rehabilitation program|The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist (recruited and trained by the research team) to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally (explanation by the therapist) and written (information leaflet, summaries, pictures, metaphors and diagrams on computer and paper). After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions.
89305322|NCT06308029|No Intervention|Usual care group|Usual care for breast cancer survivors with persistent pain consists of primarily a pharmacological approach and general advice to stay or become active. This information is given to the participant by means of a brochure.
89305323|NCT06307548|Experimental|Treatment (aminolevulinic, fluorescence-guided surgery, PDT)|Patients receive aminolevulinic acid PO 2 to 4 hours prior to SOC surgery. Patients then undergo image-guided fluorescence 5-10 minutes post surgery, and intraoperative PDT 15-45 minutes post surgery. Patients also undergo CT or MRI during screening and on follow up. Patients also undergo blood sample collection throughout the trial.
89305324|NCT06305247|Experimental|Phase I (Dose Escalation with Backfilling)|Nine dose levels are planned to be tested.
89305325|NCT06305247|Experimental|Phase IIa (Cohort Expansion)|Study intervention will be administered at one of two doses of interest determined at the end of Phase I.
89305326|NCT06304857|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablet orally once daily for 12 months
89305327|NCT06304857|Placebo Comparator|Placebo|Placebo tablet matching dapagliflozin orally once daily for 12 months
89305328|NCT06301867||Extubated Patients|All patients receiving mechanical ventilation who are extubated in the intensive care units during the study period.
89305329|NCT06301178|Active Comparator|vitamin D deficiency|patients with vitamin D deficiency or insufficiency (<12 ng/ml and 12-19 ng/ml, respectively) received systemic and intralesional vitamin D injections
89305330|NCT06301178|Active Comparator|vitamin D sufficiency|Patients with vitamin D sufficiency (20 and greater ng/mL) of vitamin D received only intralesional injections of vitamin D on hypertrophic scars and keloids.
89305331|NCT06300996|Experimental|Spinal Cord Stimulation|All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the cervical epidural (C4-T1 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.
89305332|NCT06299956|Other|The intervention group|Supervised exercise therapy. Walking on a treadmill 3 times a week, for 12 weeks. Supervised by a physiotherapist.
89305333|NCT06299813|Experimental|Bentelan|The experimental treatment will consist of the active ingredient betamethasone, specifically using the medication Bentelan 0.5mg® effervescent tablets. A single dose of betamethasone will be administered according to the weight categories (0.5 mg if the patient's weight is greater than 5 and less than or equal to 7; 1 mg if the patient's weight is greater than 7 and less than or equal to 12; 1.5mg if the patient's weight is greater than 12 and less than or equal to 17; 2.0 mg if the patient's weight is greater than 17 and less than or equal to 22; 2.5 mg if the patient's weight is greater than 22 and less than or equal to 27.)
89305334|NCT06299813|Placebo Comparator|Placebo|The placebo used in the study will consist of 100 ml of purified water (PPI BBU). The water will be administered in an identical manner to the medication and, like the medication, will be odorless, tasteless, and visually indistinguishable, making it unrecognizable to parents. Regarding the patient population, the study population will primarily consist of infants and preschool-aged children, an age group where the palatability of the medication is perceived to be similar to that of water.
88806402|NCT01792388|Active Comparator|Vitamin D|
88806403|NCT01793870|Experimental|Treatment A (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 milligram [mg]) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
88806404|NCT01793870|Experimental|Treatment B (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
89305335|NCT06299098|Placebo Comparator|Placebo|Part A Randomized 1:1
89305336|NCT06299098|Experimental|Trevogrumab|Part A Randomized 1:1
89305337|NCT06299098|Experimental|Arm A0|Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
89305338|NCT06299098|Experimental|Arm A1|Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1
89305339|NCT06299098|Experimental|Arm B0|Part B Sema, low dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
89305340|NCT06299098|Experimental|Arm B1|Part B Sema, low dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
89305341|NCT06299098|Experimental|Arm C0|Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
89305342|NCT06299098|Experimental|Arm C1|Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
89305343|NCT06299098|Experimental|Arm D0|Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1
89305344|NCT06299098|Experimental|Arm D1|Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
89305345|NCT06297148|Experimental|Self-management|"The intervention will consist of 3-5 individual sessions over 12 weeks with a physiotherapist.~There will be 3 physiotherapists delivering the self-management intervention."
89305346|NCT06297148|Active Comparator|Usual care|Given standardized information at baseline and free to choose further treatment in primary care.
89305347|NCT06297096|Experimental|combined therapy Nintedanib + Tocilizumab with or without standard treatment + extended diagnostics|tocilizumab pre-filled syringe 162 mg subcutaneously once a week nintedanib tablets 150 mg twice a day or 2 x 100 mg a day
89305348|NCT06297096|Active Comparator|standard treatment (reference group) + extended diagnostics|mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
89305349|NCT06287970|Experimental|taVNS Group|"Bilateral auricular points of Xin (CO15) and Shen (CO10) will be stimulated by electrical stimulation. A disperse-dense wave will be used with a frequency of 4Hz/20Hz, a pulse width of 0.2ms will be set, and the current intensity will be modulated by the tolerance of the patient.~note: taVNS, transcutaneous auricular vagus nerve stimulation"
89305350|NCT06287970|Sham Comparator|Sham-taVNS Group|"Bilateral ear lobes will be stimulated by electrical stimulation. A disperse-dense wave will be used with a frequency of 4Hz/20Hz, a pulse width of 0.2ms and a current intensity of 0.1mA will be set.~note: taVNS, transcutaneous auricular vagus nerve stimulation"
89305351|NCT06284902|Experimental|Treatment Sequence Group 1|
89305352|NCT06284902|Experimental|Treatment Sequence Group 2|
89305353|NCT06284902|Experimental|Treatment Sequence Group 3|
89305354|NCT06284902|Experimental|Treatment Sequence Group 4|
89305355|NCT06284902|Experimental|Treatment Sequence Group 5|
89305356|NCT06284902|Experimental|Treatment Sequence Group 6|
89305357|NCT06284681|Experimental|Weight-Focused Health Coaching with Intensified Lifestyle Approach for Nonresponders|Participants will start with weight-focused health coaching for 7 weeks and individuals achieving <3% weight loss will be given a 4-month membership to the YMCA and enrolled in group fitness classes.
89305358|NCT06284681|Experimental|Weight-Neutral Health Coaching with Intensified Lifestyle Approach for Nonresponders|Participants will start with weight-neutral health coaching for 7 weeks and individuals achieving <150 minutes of moderate physical activity will be given a 4-month membership to the YMCA and enrolled in group fitness classes.
89305359|NCT06284681|Experimental|Weight-Focused Health Coaching with Enhanced Medical Management|Participants will start with weight-focused health coaching for 7 weeks and individuals achieving <3% weight loss will meet with their primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
89305360|NCT06284681|Experimental|Weight-Neutral Health Coaching with Enhanced Medical Management|Participants will start with weight-neutral health coaching for 7 weeks and individuals achieving <150 minutes of moderate physical activity will meet with their primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
89305361|NCT06284239|No Intervention|Control group|For six weeks, theoretical training on the history of Nursing will be given by the researchers. Then, all the topics learned in the course will be repeated using question-answer and discussion methods, using questions prepared by the researchers, with the control group for four weeks. After this process, carried out by one of the researchers, is completed, the students will be given a nursing history knowledge test (posttest) and a nursing history teaching evaluation form and asked to fill it out.
89305362|NCT06284239|Experimental|Interversion group|For six weeks, theoretical training on the history of Nursing will be given by the researchers. Then, the intervention group will be played the tell-all game with game cards prepared by the researchers for four weeks. After this process, carried out by one of the researchers, is completed, the students will be given a nursing history knowledge test (posttest) and a nursing history teaching evaluation form and asked to fill it out.
88806405|NCT01793870|Experimental|Treatment C (33.75 mg total maximum dose)|Single oral dose of carvedilol (31.25 mg) as a 1 x 25 mg immediate release tablet, a 1 x 6.25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
89305363|NCT06283394|No Intervention|Usual Care|Participants in the usual care arm will not receive weekly subsidies on Instacart, and they will not receive any modifications to the virtual storefront on Instacart. They will have access to the standard Instacart platform and Instacart + memberships with a waiver of service and delivery fees and coverage of delivery tips for 3 months.
89305364|NCT06283394|Experimental|Arm A|Arm A will receive a $160 subsidy per month for 3 months to be used on healthy foods (fruits and vegetables, whole grains, etc.). They will see the usual Instacart storefront and will see the discount applied at checkout. They will have Instacart + memberships with a waiver of service and delivery fees and coverage of delivery tips for 3 months.
89305365|NCT06283394|Experimental|Arm B|Arm B will receive a $160 subsidy per month for 3 months to be used on healthy foods (fruits and vegetables, whole grains, etc.). They will see a storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible) and will see the discount applied at checkout. They will have Instacart + memberships with a waiver of service and delivery fees and coverage of delivery tips for 3 months.
89305366|NCT06283394|Experimental|Arm C|Arm C will receive a $160 subsidy per month for 3 months to be used on produce.They will see the usual Instacart storefront and will see the discount applied at checkout. They will also receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following the end of the month). They will have Instacart + memberships.
89305367|NCT06283394|Experimental|Arm D|Arm D will receive a $160 subsidy per month for 3 months to be used on produce. They will see a storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible) and will see the discount applied at checkout. They will also receive text messages detailing how much of their $160 subsidy is left (as in arm C). They will have Instacart + memberships.
89305368|NCT06279494|Experimental|Sirolimus+Abatacept+Mycophenolate mofetil (MMF)+anti-thymocyte globulin (ATG)|Patients receiving haplo-HSCT who are intolerant to calcineurin inhibitors would receive Sirolimus+Abatacept+MMF+ATG (SAMA) for prophylaxis of aGVHD
89305369|NCT06275620|Experimental|Group 1 (High Dose, Standard Corticosteroid)|"Following a pars plana vitrectomy, the previously untreated eye of participants (n=6) will receive a central subretinal injection at the high dose in the study eye at the Baseline visit; no treatment will be administered in the previously treated fellow eye.~The corticosteroid taper for all treated participants in Groups 1 and 2 (high and low doses with standard corticosteroid regimen) will be a standard taper over the course of several weeks."
89305370|NCT06275620|Experimental|Group 2 (Low Dose, Standard Corticosteroid)|"Following a pars plana vitrectomy, the previously untreated eye of participants (n=6) will receive a central subretinal injection at the low dose in the study eye at the Baseline visit; no treatment will be administered in the previously treated fellow eye.~The corticosteroid taper for all treated participants in Groups 1 and 2 (high and low doses with standard corticosteroid regimen) will be a standard taper over the course of several weeks."
89305371|NCT06275620|Experimental|Group 3 (High Dose, Modified Corticosteroid)|"Following a pars plana vitrectomy, the previously untreated eye of participants (n=approximately 3-6) will receive a central subretinal injection at the high dose in the study eye at the Baseline visit; no treatment will be administered in the previously treated fellow eye.~Participants in Group 3 (high dose, modified corticosteroid) will have a more rapid corticosteroid taper."
89305372|NCT06275126|No Intervention|Usual care|"Prior to institutional crossover, participants receive care as per usual for 6 months (run-in period) and are not sent CONSYDER."
89305373|NCT06275126|Other|CONSYDER decision aid|Web-based breast cancer surgery decision aid
89305374|NCT06272942||Post intensive care unit (ICU) morbidity|All adult patients in Optum Claims data from January 1, 2016 until October 1, 2022.
89305375|NCT06271343||Donor patients|
89305376|NCT06271343||Recipient patients|
89305377|NCT06268613|Experimental|SB27|SB27 will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
89305378|NCT06268613|Active Comparator|EU sourced Keytruda|EU sourced Keytruda will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
89305379|NCT06268613|Active Comparator|US sourced Keytruda|EU sourced Keytruda will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
89305380|NCT06261944|Other|All participants|All individuals will be screened for their diabetes risk / status (if previously undiagnosed)
89305381|NCT06256653|Experimental|Freeze-dried Blueberries|Participants will be provided with an 8-week supply of study product (freeze-dried blueberry) to be consumed daily.
89305382|NCT06256653|Placebo Comparator|Maltodextrin, Glucose, Fructose and Sucrose Placebo|Participants will be provided with an 8-week supply of placebo product (maltodextrin, glucose 31%, fructose 30%, sucrose 0%; produced as a purple powder, with blueberry aromatics generated from natural (non-anthocyanin) and artificial colour and flavourings) to be consumed daily.
89305383|NCT06256380|Experimental|Enhanced cognitive-behavior therapy for adolescents with an eating disorder (CBT-E)|CBT-E posits the eating problem as belonging to the individual, and is designed to encourage the adolescent, rather than their parent, to take control of the problem. Parents are not excluded from participating in treatment, but their involvement is limited to helping to create a family environment that allows for recovery. Patients are actively involved in all phases of treatment, including the decision to address weight regain and/or binge eating and purging, with the goal of promoting self-management. A primary goal of CBT-E is to address the patient's eating disorder psychopathology, i.e. patients' concerns about shape, weight, dietary restraint and restriction, and other extreme weight control behaviors. Following manualized CBT-E guidelines, for patients in the lower weight cohort, treatment involves 40 sessions over 9-12 months. For those in the higher weight cohort, treatment involves 20 sessions over the course of 6 months.
89523366|NCT03381599|Experimental|Bone marrow aspirate|This study will utilize one group of participants. This group of participants will have bone marrow aspirate and a blood sample collected from the iliac crest and subsequently analyzed with the Arthrex Angel system. Thirty days following bone marrow aspiration, participants will receive a subcutaneous Filgrastim injection on four serial days. On the fifth day, a peripheral blood sample sample will be obtained.
89305384|NCT06256380|Active Comparator|Family-based treatment for adolescents with an eating disorder (FBT)|FBT for adolescent eating disorders usually includes all members of the adolescent's immediate family. Treatment progresses through three phases, with the first (∼10 sessions) focusing mainly on guiding the parents to support their adolescent toward weight restoration (when appropriate), and disrupting eating disorder behaviors (e.g. binge eating and purging). The second phase (∼5-7 sessions) focuses on assisting the parents to restore food choices to the adolescent, with an emphasis on the developmental stage of the adolescent. Phase 3 is brief (2-3 sessions), focusing on adolescent developmental matters and helping the parents and their offspring navigate these tasks largely in the absence of acute eating disorder symptoms. Twenty treatment sessions are provided over a span of approximately 6 months.
89305385|NCT06253312||Open surgery|Patients with complex TASC C and D aortoiliac occlusive disease undergoing open surgery: aortobifemoral bypass, crossover bypass, axillobifemoral bypass, aortoiliac endarterectomy, iliofemoral bypass
89305386|NCT06253312||Hybrid repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing simultaneous open surgical femoral artery reconstruction (endarterectomy, bypass, profundoplasty) and stenting of the iliac axis
89305387|NCT06253312||Endovascular repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing total endovascular repair using different material: bare metal stents (self and balloon expandable), stent-grafts (self and balloon expandable), covered endovascular reconstruction of aortic bifurcation (CERAB), simple plain old balloon angioplasty (POBA)
89305388|NCT06252311|Experimental|Mindfulness-Based Breastfeeding Programme group|"Participants in the experimental group will receive the Mindfulness-Based Breastfeeding Programme, which consists of six 30-minute sessions within 0-72 hours. They will also be asked to complete a personal information form. In addition to the hospital sessions, educational materials, including home applications and audio recordings, will be sent via WhatsApp after discharge. During the first week after discharge, counselling will be provided by phone or WhatsApp on the continuation of mindfulness-based practices, continuation of breastfeeding and problems related to breastfeeding, and referral to the health facility in case of problems, Iowa Infant Feeding Attitude Scale and Mindful Breastfeeding Scale will be administered by phone call in the 2nd month and finally the Infant Feeding Follow-up Form prepared by the researcher based on the literature will be used to assess the continuity of breastfeeding in the 1st week, 2nd month, 4th month and 6th month."
89305389|NCT06252311|No Intervention|Control group|After the women in the control group have been informed about the study and have given their consent, they will complete a personal information form and then receive general information about correct breastfeeding technique, duration and breast care. They will also receive routine breastfeeding support and standard hospital care. The control group will be administered the Iowa Infant Feeding Attitude Scale and the Mindful Breastfeeding Scale by telephone interview at month 2 and the Infant Feeding Follow-up Form at week 1, month 2, month 4 and month 6.
89305390|NCT06252012|Experimental|Mobile Application Group|Within the scope of the mobile application, information modules on cervical cancer screening tests, cervical cancer risk factors, ways to prevent cervical cancer, types of HPV, and HPV vaccine will be provided. A parallel-group pretest-posttest randomized controlled trial design will be used in the second stage of the study.
89305391|NCT06252012|No Intervention|Control Group|The relevant brochures of the Ministry of Health on the prevention of cervical cancer will be given to the experimental and control groups.
89305392|NCT06249282|Experimental|Treatment (carfilzomib, sotorasib)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of each cycle and sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO at screening and undergo CT or MRI and collection of blood samples at screening and on study. Patients may undergo optional biopsies on study.
89305393|NCT06248086|Experimental|Group A: ASP2802 Low Dose followed by MA-20|Participants will receive a low dose of ASP2802 on Day 0 of cycle 1. Each participant will then receive up to 2 doses of MA-20 booster in each 28-day cycle.
89305394|NCT06248086|Experimental|Group B: ASP2802 Intermediate Dose followed by MA-20|Participants will receive an intermediate dose of ASP2802 on Day 0 of cycle 1. Each participant will then receive up to 2 doses of MA-20 booster in each 28-day cycle, with dose level(s) selected from Group A.
89305395|NCT06248086|Experimental|Group C: ASP2802 High Dose followed by MA-20|Participants will receive a higher dose of ASP2802 on Day 0 of cycle 1. Each participant will then receive up to 2 doses of MA-20 booster in each 28-day cycle, with dose level(s) selected from Group B.
89305396|NCT06247943|Experimental|Lung Protective Ventilation Strategy Group|Use of lung-protective ventilation strategies
89305397|NCT06247943|Other|Control Group|Use of general ventilation strategies
89305398|NCT06247917|Experimental|FBM group|undergoing FBM regiment
89305399|NCT06245421|Experimental|Investigational product|
89305400|NCT06245421|Active Comparator|Comparator|
89305401|NCT06244316|Experimental|IMP 1: rhNGF concentration 1|Investigational Medicinal Product (IMP) 1
89305402|NCT06244316|Experimental|IMP 2: rhNGF concentration 2|Investigational Medicinal Product (IMP) 2
89305403|NCT06244316|Placebo Comparator|Vehicle IMP|
89305404|NCT06243744|Other|Procedure with the Renuvion APR System in lower facelift area|Subjects will receive a lower facelift surgery per the Investigator's standard clinical practice and treatment with the Renuvion APR System.
89305405|NCT06243575|Experimental|Multimodal Intraosseous Femoral Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
89305406|NCT06243575|Experimental|Multimodal Intraosseous Tibial Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
89305407|NCT06239272|Experimental|Low-Risk Subset A|Participants with low grade tumors of any size, or high-grade tumors < 5 cm that have been (or are expected to be) completely removed by surgery. When the pathologist reviews the tumor specimen, the tissue around the tumor (margins) must be negative for cancer cells, meaning all of the cancer has been removed. These participants will have surgery to remove the tumor, followed by close observation. There will no further therapy after surgery, just monitoring for tumor recurrence and any side effects from surgery.
89305408|NCT06239272|Experimental|Low-Risk Subset B|Participants with high-grade tumors that are < 5 cm with positive margins. This means that the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed. These participants will have surgery followed by radiation therapy for about 5-6 weeks.
89305409|NCT06239272|Experimental|Intermediate-Risk Subset A (participants with low grade tumors):|"If your tumor is completely removed at surgery [meaning the tissue around the tumor (margins) is negative for tumor cells], you will receive no further therapy and you will be closely observed for any signs of tumor recurrence.~If your tumor cannot be completely removed at surgery [meaning the tissue around the tumor (margins) is positive for tumor cells] and the tumor is low-grade, you will get consolidation therapy with additional chemotherapy and radiation therapy, followed by 6 months of maintenance therapy with pazopanib."
89305410|NCT06239272|Experimental|Intermediate-Risk Subset B (participants with high-grade tumors between 5 and 10 cm in size|"If your tumor is completely removed at surgery [meaning the tissue around the tumor (margins) is negative for tumor cells] you will continue with consolidation chemotherapy with additional chemotherapy without radiation therapy, followed by 6 months of maintenance therapy with pazopanib.~If your tumor cannot be completely removed at surgery [meaning the tissue around the tumor (margins) is positive for tumor cells], you will get consolidation therapy with additional chemotherapy and radiation therapy, followed by 6 months of maintenance therapy with pazopanib."
89305411|NCT06239272|Experimental|Intermediate-Risk Subset C (participants with high-grade tumors > 10 cm):|"After 3 cycles of induction chemotherapy, your doctor may decide to give an additional 4th cycle if he/she thinks it would be beneficial before surgery.~You will get consolidation therapy with additional chemotherapy and radiation therapy, followed by 6 months of maintenance therapy with pazopanib. The dose of radiation that you receive will be higher if your tumor cannot be completely removed at surgery (positive margins)."
89305412|NCT06239272|Experimental|High-Risk - 2 groups|"If you have a low-grade tumor that has spread to other parts of the body AND the surgeon was able to completely remove all tumors from all parts of your body, you will have no further therapy after surgery. You will be closely followed to monitor you for any signs of tumor recurrence.~If you have a high-grade tumor OR a tumor that cannot be completely removed by surgery OR you have the CIC-DUX4 mutation, you will get consolidation chemotherapy and radiation therapy, followed by 6 months of maintenance therapy with pazopanib."
89305413|NCT06236438|Experimental|Stage 1 (Cohort 1): Livmoniplimab Dose A|Participants will receive livmoniplimab (dose A)+ budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
89305414|NCT06236438|Experimental|Stage 1 (Cohort 2): Livmoniplimab Dose B|Participants will receive livmoniplimab (dose B) + budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
89305415|NCT06236438|Experimental|Stage 1 (Cohort 3): Budigalimab|Participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed.
89305416|NCT06236438|Experimental|Stage 1 (Cohort 4): Pembrolizumab|Participants will receive pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed.
89305417|NCT06236438|Experimental|Stage 2 (Arm 1): Livmoniplimab (Dose Optimized)|Participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
89305418|NCT06236438|Experimental|Stage 2 (Arm 2): Placebo|Participants will receive placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed.
89305419|NCT06234423|Experimental|Monotherapy Dose Finding - Phase 1a|
89305420|NCT06234423|Experimental|Expansion as Monotherapy - Phase 1b|
89305421|NCT06230224|Experimental|Odronextamab|Participants will receive odronextamab monotherapy.
89305422|NCT06230224|Active Comparator|Standard Of Care|Participants will receive salvage therapy (ifosfamide, carboplatin, etoposide ± rituximab [ICE ± R], or dexamethasone, cisplatin, cytarabine ± rituximab [DHAP ± R], or gemcitabine, dexamethasone, cisplatin ± rituximab [GDP ± R]) and continue with autologous stem cell transplant (ASCT) following a complete response (CR)/partial response (PR).
89305423|NCT06229470|Experimental|ECAP-Controlled, Closed-Loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude.
89305424|NCT06224764|Other|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
89305425|NCT06222502|Experimental|Planning, Reminders, and Micro-Incentives|
89305426|NCT06222502|Active Comparator|Health Education|
89305427|NCT06220201|Experimental|Administration of CC-97540 (RMS arm)|
89305428|NCT06220201|Experimental|Administration of CC-97540 (PMS arm)|
89305429|NCT06219902|Experimental|Treatment sequences A-C-D-B|Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
89305430|NCT06219902|Experimental|Treatment sequences B-D-C-A|Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
89305431|NCT06219902|Experimental|Treatment sequences C-B-A-D|Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
89305432|NCT06219902|Experimental|Treatment sequences D-A-B-C|Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).).
89305433|NCT06216574|Experimental|SHINE 1|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - 45 minutes, 4) Intimacy - 45 minutes Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
89523367|NCT03385447|Experimental|Physical Activity|Participants were subjected to a 12-week exercise program targeting the federal physical activity guidelines.
89523368|NCT03377153|Active Comparator|Hesperidin and Flaxseed|
89523369|NCT03377153|Placebo Comparator|control|
89523370|NCT03394573||OCT guided treatment arm|OCT guided aflibercept injection
89523371|NCT03394573||VA guided treatment arm|VA guided aflibercept injection
89305434|NCT06216574|Experimental|SHINE 2|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - 45 minutes, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner."
89305435|NCT06216574|Experimental|SHINE 3|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - NONE, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
89305436|NCT06216574|Experimental|SHINE 4|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - NONE, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician."
89305437|NCT06216574|Experimental|SHINE 5|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - 45 minutes, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
89305438|NCT06216574|Experimental|SHINE 6|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - 45 minutes, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner."
89305439|NCT06216574|Experimental|SHINE 7|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - NONE, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
89305440|NCT06216574|Experimental|SHINE 8|"SHINE components assigned: 1) Psycho-education (Enhanced) - 45 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - NONE, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy. Enhanced version is tailored, interactive instruction and recommendations for over-the-counter products and aids."
89305441|NCT06216574|Experimental|SHINE 9|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - 45 minutes, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
89305442|NCT06216574|Experimental|SHINE 10|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - 45 minutes, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner."
89523372|NCT03381443||ERC|all students assessed by the methods used by the European Resuscitation Council
89523373|NCT03381443||AHA|all students assessed by the methods used by the American Heart Association
89305443|NCT06216574|Experimental|SHINE 11|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - NONE, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
89305444|NCT06216574|Experimental|SHINE 12|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - 45 minutes, 3) Communication with Partner - NONE, 4) Intimacy -NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with the clinician reviews clinical terminology to describe physical symptoms of sexual concern and potential scripts for discussion with an appropriate clinician."
89305445|NCT06216574|Experimental|SHINE 13|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - 45 minutes, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
89305446|NCT06216574|Experimental|SHINE 14|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - 45 minutes, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Communication with partner provides effective models and exercises to practice clear communication regarding sexual concerns with partner."
89305447|NCT06216574|Experimental|SHINE 15|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - NONE, 4) Intimacy - 45 minutes.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy.~Intimacy module provides strategies for increasing non-sexual intimacy, reconsidering sexual scripts, and focus exercises."
89305448|NCT06216574|Experimental|SHINE 16|"SHINE components assigned: 1) Psycho-education (Standard) - 20 minutes, 2) Communication with Clinician - NONE, 3) Communication with Partner - NONE, 4) Intimacy - NONE.~Each component is a single lesson accessed at participant's convenience and may be repeated.~Standard psycho-education has content on effects of cancer on sexual function, self-image, and relationships, managing sexual concerns, and basic sexual anatomy."
89305449|NCT06215911|Experimental|Tovinontrine (CRD-750) - low dose|
89305450|NCT06215911|Experimental|Tovinontrine (CRD-750) - medium dose|
89305451|NCT06215911|Experimental|Tovinontrine (CRD-750) - high dose|
89305452|NCT06215911|Placebo Comparator|Placebo|
89305453|NCT06215586|Experimental|Tovinontrine (CRD-750)|
89305454|NCT06215586|Placebo Comparator|Placebo|
89305455|NCT06214819|Experimental|VIVO ISAR DES in the first lesion|
89305456|NCT06214819|Active Comparator|XIENCE Skypoint DES in the first lesion|
89305457|NCT06214806|Experimental|Instacart|Voucher for grocery purchase and delivery via Instacart
89305458|NCT06214806|Active Comparator|Rouses Market|Voucher for grocery purchase in-person at Rouses Market in New Orleans
89305459|NCT06214741|Experimental|survodutide 3.6 mg|
89305460|NCT06214741|Experimental|survodutide 4.8 mg|
89305461|NCT06214741|Placebo Comparator|Placebo|
89305462|NCT06213818|Experimental|Cohort 1: Dose|INCB160058 will be administered at protocol defined dose.
89305463|NCT06213818|Experimental|Cohort 2: Dose|INCB160058 will be administered at protocol defined dose.
89305464|NCT06213818|Experimental|Cohort 3: Dose|INCB160058 will be administered at protocol defined dose.
89305465|NCT06213818|Experimental|Cohort 4: Dose|INCB160058 will be administered at protocol defined dose.
89305466|NCT06213818|Experimental|Cohort 5: Dose|INCB160058 will be administered at protocol defined dose.
89305467|NCT06213818|Experimental|Cohort 6: Dose Treatment A|INCB160058 will be administered at protocol defined dose after an overnight fast.
89305468|NCT06213818|Experimental|Cohort 6: Dose Treatment B|INCB160058 will be administered at protocol defined dose after a high-fat-calorie meal.
89305469|NCT06213818|Experimental|Cohort 7: Dose|INCB160058 and Esomeprazole will be administered at protocol defined schedule and dose.
89305470|NCT06212999|Experimental|Cohort A|Povorcitinib at the protocol-defined dose strength based on cohort assignment.
89305471|NCT06212999|Experimental|Cohort B|Povorcitinib at the protocol-defined dose strength based on cohort assignment.
89305472|NCT06212999|Experimental|Cohort C|Povorcitinib at the protocol-defined dose strength based on cohort assignment.
89305473|NCT06212752|Experimental|Arm 1 (MK-3475A + Platinum Doublet Chemotherapy)|Participants with treatment-naïve metastatic NSCLC will receive MK 3475A SC in combination with platinum doublet chemotherapy.
89305474|NCT06212752|Active Comparator|Arm 2 (Pembrolizumab + Platinum Doublet Chemotherapy)|Participants with treatment-naïve metastatic NSCLC will receive Pembrolizumab IV in combination with platinum doublet chemotherapy.
89305477|NCT06212622||STANDARD CARE WITH ORAL OXYCODONE|"These patients will receive oral oxycodone prior to their post operative day 1 and 2 physiotherapy sessions~The dose is age dependent (and also on frailty status):~< 65 years old: Oxycodone 5mg immediate release~65 - 85 years old: Oxycodone 4mg immediate release~> 85 years old: Oxycodone 3mg immediate release~<50kg or particularly frail: Oxycodone 2mg immediate release"
89305478|NCT06212622||INTERVENTION GROUP WITH SUBCUTANEOUS ALFENTANIL|"These patients will receive subcutaneous alfentanil prior to their post operative day 1 and 2 physiotherapy sessions~This is 100 micrograms as a subcutaneous injection"
89305479|NCT06205134|Experimental|6 Healthy volunteers, sequence ABC|"Three drug administrations to each subject, each administration on a separate day.~treatment order: A B C"
89305480|NCT06205134|Experimental|6 Healthy volunteers, sequence BAC|"Three drug administrations to each subject, each administration on a separate day.~treatment order: B A C"
89305481|NCT06202833|Experimental|Tongyuan acupuncture|Point selection of Tongyuan acupuncture group: baihui, zhongwan, guanyuan, qihai, tianshu (double).The method of lifting, inserting and twisting was used once a day, 5 days a week for 4 consecutive weeks. Twenty days in total. Consciousness levels were assessed before intervention, at 1, 2, 3, and 4 weeks of treatment, and 4 weeks after discharge.
89305482|NCT06202833|Sham Comparator|Sham acupoint acupuncture|In the sham-acupoint group, acupuncture treatment was carried out 1cm beside the selected points of the experimental group, once a day, 5 days a week, for 4 consecutive weeks. Twenty days in total. Consciousness levels were assessed before intervention, at 1, 2, 3, and 4 weeks of treatment, and 4 weeks after discharge.
89305485|NCT06198699|Experimental|Jing Si Herbal Tea Group|Frequency: Two times of herbal tea (one in the morning; one in the afternoon) per day Duration: Consumption for three months Dosage: One pack (14g) with 600 ml water for each time of herbal tea consumption
89305486|NCT06198699|Placebo Comparator|Barley Tea Group|Frequency: Two times of barley tea (one in the morning; one in the afternoon) per day Duration: Consumption for three months Dosage: 600 ml each time of barley tea consumption
89305487|NCT06197243|Experimental|Feasibility, Adherence and Acceptability Measure|Assay of feasibility of study enrollment and feasibility of study treatments, the latter of which is measured via fidelity, adherence, and acceptability of/to treatments and interventions. Interventions administered for 12 weeks. Fidelity, adherence, and acceptability will be measured via patient survey and engagement.
89305488|NCT06196788|Experimental|gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1 (venous injection), 8 (venous injection), and 15 (transcatheter arterial infusion) every 4 weeks.
89305489|NCT06195982|Experimental|ketone ester|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate, a ketone ester
89305490|NCT06195982|Placebo Comparator|placebo|KE-free solution
89305491|NCT06190275|Experimental|GT201 in combination with PD-1 inhibitors treatment group|
89305492|NCT06187415|Experimental|The harm reduction mobile app|Participants in the intervention arm will receive access to all the app functions. The primary features of the app include PrEP taking diary, setting harm reduction goals, providing location of needle and syringe services program, providing accurate information on chemsex urban legends, and sending alerts to emergency contact in case of intoxication.
89305493|NCT06185764|Experimental|Part A: Single Ascending Dose|Participants will be randomized to receive a single dose of different dose levels of VX-670.
89305494|NCT06185764|Placebo Comparator|Part A: Placebo|Participants will be randomized to receive single dose of placebo matched to VX-670.
89305495|NCT06185764|Experimental|Part B: Single and Multiple Ascending Dose|Participants will be randomized to receive single and multiple doses of different dose levels of VX-670. The dose levels will be determined based on the data from Part A.
89305496|NCT06185764|Placebo Comparator|Part B: Placebo|Participants will be randomized to receive single or multiple doses of placebo matched to VX-670.
89305497|NCT06179407|Experimental|MK-6552|In Part 1, participants will receive single oral doses of MK-6552 in ascending fashion approximately 6 hours apart for a single day, based on safety and tolerability of the previous dose. In Part 2, participants will receive multiple days of MK-6552 dosing (7 consecutive days) at the highest safe and well tolerated MK-6552 dose determined on an individual basis from Part 1.
89305498|NCT06179407|Placebo Comparator|Placebo|In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
89305499|NCT06179160|Experimental|Part 1a: Dose Escalation monotherapy|INCB161734 at the protocol-defined dose strength based on cohort assignment.
89305500|NCT06179160|Experimental|Part 1b: Dose Expansion monotherapy|INCB161734 at the protocol-defined dose strength based on cohort assignment.
89305501|NCT06179160|Experimental|Part 1c: Pharmacodynamic cohort|INCB161734 at the protocol-defined dose strength based on cohort assignment.
89305502|NCT06179160|Experimental|Part 2a: Dose Escalation combination|INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.
88806406|NCT01793870|Experimental|Treatment D (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg x immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fed conditions.
88806407|NCT01793948|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
89305503|NCT06179160|Experimental|Part 2b: Dose Expansion combination|INCB161734 in combination at the protocol-defined dose strength based on cohort assignment.
89305504|NCT06174298|Experimental|GCSF-Supplemented Embryo Transfer Media|"Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
89305505|NCT06174298|Placebo Comparator|Standard Embryo Transfer Media|"Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of standard embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of standard embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
89305506|NCT06174116|Placebo Comparator|Placebo|
89305507|NCT06174116|Experimental|Lumateperone|
89305508|NCT06169579|Experimental|ND-003 tablets_Dose 1|Adult patients with solid tumors receiving 40 mg of ND-003 tablets once daily (dose escalation cohort).
89305509|NCT06169579|Experimental|ND-003 tablets_Dose 2|Adult patients with solid tumors receiving 80 mg of ND-003 tablets once daily (dose escalation cohort).
89305510|NCT06169579|Experimental|ND-003 tablets_Dose 3|Adult patients with solid tumors receiving 160 mg of ND-003 tablets once daily (dose escalation cohort).
89305511|NCT06169579|Experimental|ND-003 tablets_Dose 4|Adult patients with solid tumors receiving 300 mg of ND-003 tablets once daily (dose escalation cohort).
89305512|NCT06169579|Experimental|ND-003 tablets_Dose 5|Adult patients with solid tumors receiving 500 mg of ND-003 tablets once daily (dose escalation cohort).
89305513|NCT06169579|Experimental|ND-003 tablets_Dose 6|Adult patients with solid tumors receiving 800 mg of ND-003 tablets once daily (dose escalation cohort).
89305514|NCT06169579|Experimental|ND-003 tablets_Expansion 1|"Adults patients with solid tumors harboring NTRK or RET Fusion or Mutation (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of ND-003 tablets as determined in the dose escalation part, one to two dose cohorts are set."
89305515|NCT06169579|Experimental|ND-003 tablets_Expansion 2|"Adults patients with solid tumors harboring NTRK or RET Fusion or Mutation (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of ND-003 tablets as determined in the dose escalation part, one to two dose cohorts are set."
89305516|NCT06162767|Active Comparator|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach: Ivor-Lewis Procedure.
89305517|NCT06162767|Active Comparator|Optimized Sweet Procedure|Arm B: Esophagectomy was conducted by single-incision thoracoscope combined with laparoscopy with the patient in a right oblique side position at 45 degrees: Optimized Sweet Procedure.
89305518|NCT06160921||2|
89305519|NCT06156020|Other|Endoscopic endonasal surgery|Patients who received endoscopic endonasal resection of pituitary adenomas
89305520|NCT06155344||Pregnant women included in the VEGALIM project|Pregnant women consulting CEMAFOER (Center for Maternal and Fetal Pathology Screening and Risk Assessment) of Nantes University Hospital for pregnancy monitoring
89305521|NCT06152601|Experimental|Group experimental|Patient between 12 and 18 years old with a spinal surgery for idiopathic scoliosis programmed. Immediately postoperatively, during his stay in a PACU or ICU, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position.
89305522|NCT06151626|Experimental|virtual-reality based rhythmic skill training|Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.
89305523|NCT06151626|Active Comparator|rhythmic skill training with visual feedback|The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface
89305524|NCT06151626|Active Comparator|strengthening group|The patients receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.
89305525|NCT06150664|Experimental|Dose Escalation Cohort 1|Escalating doses of CTX-8371
89305526|NCT06150664|Experimental|Dose Expansion Cohort 2|Dose of CTX-8371 depending on Cohort 1 data
89305527|NCT06147830||Cohort A - Historical Cohort|Cohort A will comprise of approximately 2000 patients admitted for major bleedings in the presence of Factor Xa inhibitor treatment during a defined period (up to 2 years prior to commencing enrolment of patients in Cohort B). Patients who developed major bleeding in the presence of Factor Xa inhibitor treatment while already admitted in hospitals will also be included. Patients may or may not have received a reversal/replacement therapy. Patients are followed in medical charts from admission to discharge.
89305528|NCT06147830||Cohort B - Prospective Cohort|Cohort B will enrol approximately 2000 patients who were administered any reversal or replacement agent during the acute care phase for a major bleeding in the presence of Factor Xa inhibitor treatment at the participating sites. Patients will be followed up to three months after administration of reversal or replacement therapy.
89305529|NCT06145308|Experimental|HER2 expression group|Vedicetumab monotherapy or combination therapy
89305530|NCT06145308|Experimental|NTRK gene fusion or mutant group|NTRK inhibitor therapy
89305531|NCT06145308|Experimental|AR positive group|Antiandrogen therapy
89305532|NCT06145308|Experimental|TROP-2 positive group|Anti-trop-2 therapy
89305533|NCT06145308|Experimental|Adenoid cystadenocarcinoma group（ACCgroup）|Small molecule tyrosine hormone inhibitor therapy
89305534|NCT06145308|Experimental|Other group|Albumin-paclitaxel combined with platinum-based chemotherapy drugs
89305535|NCT06143306|Experimental|Bupivacaine group|Patients undergoing total shoulder arthroplasty or reverse total shoulderarthroplasty aged 18- 85, randomized to the experimental group.
89305536|NCT06143306|Placebo Comparator|control group|Patients undergoing total shoulder arthroplasty or reverse total shoulderarthroplasty aged 18- 85, randomized to the control group.
89305537|NCT06139510|Other|Individuals living with sickle cell disease|Participants living with sickle cell disease will undergo standardized testing called quantitative sensory testing. Quantitative sensory testing measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
89305538|NCT06139146|Experimental|Group A Control|A moist heat pack for 15-20 minutes MET of the upper trapezius, levator scapula and pectoral Major muscles Strengthening exercise of deep neck flexors
89305539|NCT06139146|Experimental|Group B Experimental|A moist heat pack for 15-20 minutes Core stability exercises MET of the upper trapezius, levator scapula and pectoral Major muscles Strengthening exercise of deep neck flexors
89305540|NCT06136260|Experimental|CommunityRx-Bereavement (CRx-B)|
89305541|NCT06136260|Active Comparator|General Bereavement Support Information (GBSI)|
89305542|NCT06132958|Experimental|MK-2870|Participants will receive 4 mg/kg of MK-2870 via intravenous (IV) infusion on Day 1 of each 14-day cycle. Additionally, participants receive diphenhydramine (or equivalent), a Histamine (H2 antagonist) of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of MK-2870. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
89305543|NCT06132958|Active Comparator|Chemotherapy|Participants will receive 60 mg/m^2 of doxorubicin by IV infusion on Day 1 of each 21-day cycle; or 80 mg/m^2 of paclitaxel by IV infusion on Days 1, 8, and 15 of each 28-day cycle.
89305544|NCT06132763|Experimental|Hydration Intervention|Students and staff at the intervention school will receive a school-based hydration intervention that includes a student-developed marketing campaign and incentivizes water bottles in school.
89305545|NCT06132763|Placebo Comparator|Control|Students and staff at the control school will participate in assessments only.
89305546|NCT06131567|Experimental|Implantoplasty|Implantoplasty to all the implant surface
89305547|NCT06131567|Active Comparator|Implantoplasty on the supracrestal component|Implantoplasty only in the supra-crestal component and the infra bony hydrogen peroxide
89305548|NCT06128005|Experimental|knowledge translation in nursing for pressure injury care|Using guideline and evidence based practice for pressure injury. The experimental group has received knowledge translation in nursing for pressure injury care with precaution teaching plan by using self-designed teaching materials, manuals, videoes, multimedia tools (power point, LINE official account, LINE one-on-one lesson, virtual lesson), in-person assistance and assessment in 12weeks.
89305549|NCT06128005|Placebo Comparator|Regular care|The controlled group maintained the regular nursing intervention.
89305550|NCT06126744|Experimental|MVR-C5252|Open label single arm infusion of MVR-C5252, genetically engineered type 1 oHSV (oncolytic herpes simplex viruses) into the tumor via Convection-enhanced delivery (CED) a modality that can bypass the BBB (Blood Brain Barrier), allowing the intracranial delivery through the BBB and avoiding systemic toxicities.
89305551|NCT06121843|Experimental|Arm A: BMS-986393 + Alnuctamab|
89305552|NCT06121843|Experimental|Arm B: BMS-986393 + Mezigdomide|
89305553|NCT06121843|Experimental|Arm C: BMS-986393 + Iberdomide|
89305554|NCT06121453|Experimental|Single Arm: Adherence Intervention|Multicomponent Adherence Intervention
89305555|NCT06116422|Active Comparator|Cash Benefit Group|Provides financial support weekly, in the form of an unrestricted cash benefit. The investigators will partner with Held to provide the card to participants, load the card with $50/week for the 12 months of enrollment, and view the purchases at the vendor level using an existing dashboard Held maintains. Participants will also receive a monthly nutrition guidance brochure tailored to the infant's developmental stage.
89305556|NCT06116422|Active Comparator|Grocery Benefit Group|Provides financial support weekly in the form of a grocery benefit. The investigators will enroll participants in the Food Lion MVP program, linking the account to a Duke email address. The study team will work with the participants to order $50 worth of groceries from Food Lion, for the participants to pick up from the store. Groceries will be ordered weekly for the 12 months of enrollment and coordinators will have access to view items purchased at Food Lion by each participant.
89305557|NCT06115018|Active Comparator|Palatal surgery group|In the palatal surgery group, the participants will receive palatal surgery.To evaluate the effect of treatments on the severity of OSA, tongue muscle strength and the space of the upper airway, the participants will receive polysomonogrphy test, tongue muscle strength test and computed tomography. The time of evaluation will include baseline, 3 and 6 months after treatment.
89305558|NCT06115018|Active Comparator|Oropharyngeal rehabilitation group|In the oropharyngeal rehabilitation (OPR) group, the participants will receive 12-week OPR. The OPR for the OPR group included three 30-minute sessions of OPR per day, and the exercise would be performed 3-5 days per week for 3 months. The performance of the home exercise will also be recorded by the force-sensing resistor. In addition to home exercise sessions, there will also be twice-weekly clinical visits to adjust the contents of OPR program and monitor training progress. To evaluate the effect of treatments on the severity of OSA, tongue muscle strength and the space of the upper airway, the participants will receive polysomonogrphy test, tongue muscle strength test and computed tomography. The time of evaluation will include baseline, 3 and 6 months after treatment.
89305559|NCT06115018|Experimental|Palatal surgery combined OPR group|In the palatal surgery combined OPR group, the participants will receive palatal surgery, then 12-week OPR. The program of OPR for this group is as the same of OPR group.
89305560|NCT06112184|Experimental|All participants|All participants will use the SK-M11/3A1 digital health program for 12 weeks.
89305561|NCT06111586|Experimental|Frexalimab Dose 1|
89305562|NCT06111586|Experimental|Frexalimab Dose 2|
89305563|NCT06111586|Experimental|Frexalimab Dose 3|
89305564|NCT06111586|Placebo Comparator|Placebo|Matching Placebo
89305565|NCT06110247||Group R|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded. NIRS monitoring will be performed in addition to routine ASA monitoring. After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value. NIRS, pulse oximetry, and hemodynamic data will be recorded every 5 minutes until recovery from anesthesia just prior to induction. When comparing the NIRS values measured during follow-up with the baseline NIRS value, a decrease of 20% or more than 20% will be considered significant. Anesthesia and surgery times will also be recorded. Postoperative fever and the amount of irrigation fluid used during the surgical procedure will be recorded .
89305566|NCT06110247||Group U|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded. NIRS monitoring will be performed in addition to routine ASA monitoring. After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value. NIRS, pulse oximetry, and hemodynamic data will be recorded every 5 minutes until recovery from anesthesia just prior to induction. When comparing the NIRS values measured during follow-up with the baseline NIRS value, a decrease of 20% or more than 20% will be considered significant. Anesthesia and surgery times will also be recorded. Postoperative fever and the amount of irrigation fluid used during the surgical procedure will be recorded .
89305567|NCT06110247||Group H|The study involves continuous NIRS monitoring in addition to routine ASA monitoring. To establish the initial value of regional oxygen saturation (rSO2), renal NIRS probes will be positioned using ultrasonography, and an average of three measurements will be taken. Throughout the procedure, NIRS data, along with pulse oximetry and hemodynamic data, will be recorded at 5-minute intervals until the patient recovers from anesthesia just prior to induction. Significant changes in NIRS values will be determined if a decrease of 20% or more compared to the baseline measurement is observed. Anesthesia and surgery times will also be recorded.
89305568|NCT06109441|Other|ALTB-268|ALTB-268 IP will be administered via subcutaneous injection. One loading dose will be followed by 10 weekly doses of ALTB-268 in the 12 weeks induction study phase. Additional 20 biweekly doses of ALTB-268 will be administered in the 40 week maintenance study period.
89305569|NCT06108739|Experimental|ATG-PTCy cohort|The conditioning regimen is ATG/G-CSF based protocol (the so-called Beijing protocol). The rabbit ATG (Sangstat-Genzyme) 2.5mg/kg/day i.v., on days from - 5 to - 2 were administered.Two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
89305570|NCT06108739|Active Comparator|ATG cohort|The conditioning regimen is ATG/G-CSF based protocol (the so-called Beijing protocol). The rabbit ATG (Sangstat-Genzyme) 2.5mg/kg/day i.v., on days from - 5 to - 2 were administered.
89305571|NCT06107686|Experimental|Corhort A|YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic NSCLC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
89305572|NCT06107686|Experimental|Corhort B|YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic BC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
89305573|NCT06107686|Experimental|Corhort C|YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic HNSCC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
89305574|NCT06107686|Experimental|Corhort D|YL202 is provided as the lyophilized powder, 200 mg/vial. Other locally advanced cancer patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.
89305575|NCT06105983|Experimental|Treatment A|Sisunatovir without rabeprazole
89305576|NCT06105983|Active Comparator|Treatment B|Sisunatovir with rabeprazole
89305577|NCT06105359|Experimental|experimental group|Patients in this group will be treated with dignity therapy by the researcher.
89305578|NCT06105359|Active Comparator|control group|Patients in this group will receive standard care and no treatment will be performed by the researcher.
89305579|NCT06104228|Other|Idiopathic Pulmonary Arterial Hypertension|Arm 1... patients with IPAH
89305580|NCT06104228|Other|Pulmonary Arterial Hypertension Associated with Connective Tissue Disease|Arm 2... patients with CTD-PAH
89305581|NCT06103630|Sham Comparator|Control group|Mandibular advancement device
89305582|NCT06103630|Experimental|Intervention group|Participants will received 1-2 times a week, 12-week-intervention of Oropharyngeal Exercises and Mandibular advancement device.
89305583|NCT06102174|Placebo Comparator|Placebo|Oral or Nasogastric tube (NG)
89305584|NCT06102174|Active Comparator|Sisunatovir|Oral or NG tube
89305585|NCT06090357|Experimental|Post-surgical foot and ankle patients|
89305586|NCT06087029|Experimental|Upfront TEVAR plus Medical Therapy|Participants randomized to upfront TEVAR will receive a commercially available device customized to their individual anatomical requirements. Stent-graft implantation will be performed either in the operating room with appropriate digital imaging equipment to allow fluoroscopic and trans-esophageal echo (TEE) guidance or the catheterization laboratory, angiographic suite (with digital angiographic equipment).
89305587|NCT06087029|Active Comparator|Medical Therapy with surveillance for deterioration|Participants randomized to upfront Medical Therapy with Surveillance for Deterioration will be treated per routine clinical care with suggested antihypertensive therapy and cardiovascular risk factor reduction as per appropriate cardiovascular guidelines.
89305595|NCT06083220|Experimental|School Readiness Intervention Program|The School Readiness Program is a 64 hour intensive therapy program focused on school readiness skills for young children with unilateral cerebral palsy (UCP). The program will include 64 hours of intervention supporting the development and goal attainment across 5 school readiness domains: (1) health and physical development, (2) emotional well-being and social competence, (3) approaches to learning, (4) communication skills, and (5) cognitive skills and general knowledge.
89305596|NCT06082895|Experimental|intervention group|This group will consist of 45 pregnant women. The training program based on the motivational interviewing method will continue once a week for a total of 4 weeks.
89305597|NCT06082895|No Intervention|control group|This group will consist of 45 pregnant women. This group will not be given any training program and routine pregnancy follow-ups will continue.
89305601|NCT06079398|Experimental|Navepegritide|Once weekly double-blinded treatment with SC injection of 100 µg/kg of Navepegritide for 52 weeks
89305602|NCT06079398|Placebo Comparator|Placebo for Navepegritide|Once weekly double-blinded treatment with SC injection of 100 µg/kg of Placebo for Navepegritide for 52 weeks
89305603|NCT06079320|Experimental|Sisunatovir|
89305604|NCT06079320|Placebo Comparator|Placebo|
89305605|NCT06078774|Experimental|Virtual Health Coach - Parent/Child Dyad|Focuses on providing personalized care conveyed in an integrated and visually demonstrated way for parent-child pairs. Healthy lifestyle changes and behaviors covered in sessions are designed to initiate and maintain behavior change in nutrition and physical activity with BMI improvement.
89305606|NCT06077435|Active Comparator|CAD-EYE|AI system 1. Sealed envelopes in blocks of four were used for randomisation.
89305607|NCT06077435|Active Comparator|GI-GENIUS|AI system 2. Sealed envelopes in blocks of four were used for randomisation
89305608|NCT06077435|Active Comparator|Endo-AID|AI system 3. Sealed envelopes in blocks of four were used for randomisation
89305609|NCT06077435|No Intervention|No AI|No AI. conventional examination. Sealed envelopes in blocks of four were used for randomisation
89305610|NCT06074588|Experimental|MK-2870|Participants will receive 4 mg/kg of MK-2870 via intravenous (IV) infusion on Days 1, 15 and 29 of each 6-week cycle. Additionally, participants receive diphenhydramine (or equivalent), an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to the first 4 infusions of MK-2870. At subsequent infusions, the H2 antagonist and dexamethasone are optional, at the discretion of the investigator.
89305611|NCT06074588|Active Comparator|Chemotherapy|Participants will receive 75 mg/m^2 of docetaxel or 500 mg/m^2 of pemetrexed by IV infusion on Days 1 and 22 of every 6-week cycle.
89305612|NCT06070012|Experimental|Tebentafusp (IMCgp100)|"Dose: 20mcg W1D; 30mcg W2D1; 68mcg W3D1and subsequent doses~Frequency: Weekly on D1 of 12-week cycles"
89305613|NCT06068855|Experimental|Double-Blind Period: Botox|Participants will receive 6 intramuscular injections of BOTOX to the masseter on Day 1.
89305614|NCT06068855|Placebo Comparator|Double Blind Period: Placebo|Participants will receive 6 intramuscular injections of Placebo to the masseter on Day 1.
89305615|NCT06068855|Experimental|Open-Label Period: Botox|Participants who are eligible for retreatment will be given open-label BOTOX on Day 180 and will be followed for up to 6 months
89305616|NCT06067425|Experimental|Cohort 1|
89305617|NCT06067425|Experimental|Cohort 2|
89305618|NCT06067425|Experimental|Cohort 3|
89305619|NCT06066801|Experimental|Bedside blind bone biopsy procedure|Bedside blind bone biopsy procedure performed by a physician of the participating center through healthy skin with bone trocar following local and light systemic anesthesia. Samples will be analyzed for microbiology and histopathology
89305620|NCT06066801|Active Comparator|Standard bone biopsy procedure|Standard BB procedure (surgical or radiological) performed according to the local standard of care of each participating center and done through healthy skin and under locoregional anesthesia. Samples will be analyzed for microbiology and histopathology
89305621|NCT06065202|Experimental|SeND Home Pathway|Total parenteral nutrition (TPN) will begin within 72 hours of abdominal surgery. Calorie needs will be determined by indirect calorimetry. Nutritional shakes will begin when a liquid diet is started. These will be taken 3 times a day while in the hospital and for 4 weeks after discharge.
89305622|NCT06065202|No Intervention|Standard Nutrition|Standard nutrition as determined by clinical providers.
89305623|NCT06064422|Experimental|BeatIt-MV Treatment Group|Participants, along with support persons, will complete 12 weekly sessions of the BeatIt-MV intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.
89305624|NCT06052267|Experimental|TEV-56248 Low Dose|Inhalation powder via multidose dry powder inhaler with integrated electronic module (eMDPI) with a dosing frequency of 2 inhalations as needed to control asthma symptoms.
89305625|NCT06052267|Experimental|TEV-56248 High Dose|Inhalation powder via multidose dry powder inhaler with integrated electronic module (eMDPI) with a dosing frequency of 2 inhalations as needed to control asthma symptoms.
89305626|NCT06052267|Active Comparator|Albuterol sulfate|Inhalation powder via multidose dry powder inhaler with integrated electronic module (eMDPI) with a dosing frequency of 2 inhalations as needed to control asthma symptoms.
89305627|NCT06049212|Experimental|Arm 1: MK-2870 Monotherapy|Participants receive single doses of MK-2870 monotherapy once every 2 weeks (Q2W).
89305628|NCT06049212|Experimental|Arm 2: MK-2870 + Pembrolizumab Combination Therapy|Participants receive MK-2870 Q2W in combination with pembrolizumab once every 6 weeks (Q6W).
88806408|NCT01793948|Placebo Comparator|Arm II (placebo)|Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
88806409|NCT04623320||NAFLD+T1DM+|Subjects with type 1 diabetes and ultrasound-defined NAFLD
89305629|NCT06049212|Experimental|Arm 3: MK-2870 + Pembrolizumab/Carboplatin Combination Therapy|Participants receive MK-2870 once every 3 weeks (Q3W) during induction and Q2W during maintenance in combination with pembrolizumab Q6W and carboplatin Q3W.
89305630|NCT06044714|Experimental|Manual Standardized Stress Acupuncture (MSSA) and Mindfulness-Based Stress Reduction (MBSR)|
89305631|NCT06044714|Active Comparator|Mindfulness-Based Stress Reduction (MBSR)|
89305632|NCT06042205|Experimental|Hernia repair|There is no comparator for this study. All patients are in the treatment allocated group for hernia repair with TISSIUM™ Adhesive Hernia Repair System (TAHRS)
89305633|NCT06034561|Experimental|Bortezomib|"Patients with refractory or relapsed acute lymphoblastic leukemia will receive one-two courses of salvage regimen composed by:~Bortezomib 1.3 mg/m2 I.V. D1,D4,D8,D11;~Vincristine 1.5 mg/m2 I.V. (maximum at 2 mg) - D1, D8,D15,D22;~Doxorubicin 60 mg/m2 I.V. - D1;~Peg-asparaginase 2000 IU/m2 I.V. - D4 and D18;~Dexamethasone 20 mg/m2 P.O. or I.V. (divided BID) - D1-D5 and D15-D19~Intrathecal chemotherapy: methotrexate 12 mg + dexamethasone 2 mg."
89305634|NCT06034028|Experimental|J-Valve TF System|
89305635|NCT06034002|Experimental|Part 1a Dose Escalation Cohort Disease Group A - with MF|INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE[s]). Participants with myelofibrosis (MF) will enroll in this group.
89305636|NCT06034002|Experimental|Part 1a Dose Escalation Cohort Disease Group A - with ET|INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE[s]). Participants with essential thrombocythemia (ET) will enroll in this group.
89305637|NCT06034002|Experimental|Part 1b: Dose Expansion - with MF|INCA033989 will be administered at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) myelofibrosis MF will enroll in this group.
89305638|NCT06034002|Experimental|Part 1b: Dose Expansion - with ET|INCA033989 will be administered at the RDE(s) identified during Part 1a. Participants with treatment group A (TGA) essential thrombocythemia (ET) will enroll in this group.
89305639|NCT06033833|Experimental|Treatment group 1|Subcutaneous Injection as per protocol
89305640|NCT06033833|Experimental|Treatment group 2|Subcutaneous injection as per protocol
89305641|NCT06027411||Pre-implementation of qER|"Baseline data:~During the pre-implementation phase, we will be gathering data around the technical requirements for integrating qER into the radiology workflow. A random sample of 500 scans per site will be sent for the ground-truthing process for the purpose of technical evaluation.~We will also be collecting data on the baseline status of all the endpoints including TAT. The reporting of NCCT scans will follow the same workflow as the current standard of care (i.e., the images/cases will appear in the RIS chronologically and the radiologist either follows this order or prioritises some cases based on communication from ED)."
89305642|NCT06027411||Post-implementation of qER|"Post-implementation (Trial Intervention)~In the post-implementation phase, there will be a notification (prioritised flag) in RIS. The order of the cases in RIS will not be altered. When the radiologist clicks a case in RIS, a secondary capture of qER along with the original images will be available in PACS. This secondary capture will have a contour showing the algorithm's attention point for a specific abnormality. The radiologist can then choose to agree with qER findings as it is or modify or ignore it according to their clinical judgement, writing and finally signing off the report. For scans which were not processed by qER the radiologist can prioritise and report as per the standard of care."
89305643|NCT06024135|Experimental|NeoKidney therapy|"Every patient will receive NeoKidney therapy which will be referenced to SDHD sessions with the usual device as their own baseline.~The study is designed in a way that allows an incremental increase of the ratio of NeoKidney versus SDHD sessions with the usual device. In order to minimize the study burden to the patient, most SDHD sessions with the usual device will be done in the patient's home. The NeoKidney therapy sessions, and 2 SDHD sessions with the usual device will be performed in the study center, thus ensuring the necessary patient care and observation as well as sample collection."
89305644|NCT06016985|Experimental|caffeine gum|Chewed caffeine gum containing 3 mg/kg for 10 minutes
89305645|NCT06016985|Placebo Comparator|placebo|Chewed placobo gum for 10 minutes
89305646|NCT06015880|Experimental|Treatment (mosunetuzumab, polatuzumab vedotin, lenalidomide)|Patients receive mosunetuzumab IV over 2-4 hours on days 1, 8, and 15 of cycle 1 and then day 1 of each subsequent cycle. Treatment repeats every 28 days for 8 cycles in patients who achieve a CR or up to 17 cycles for patients with a PR or SD in the absence of disease progression or unacceptable toxicity. Patients also receive polatuzumab vedotin IV over 30-90 minutes on day 1 for 6 cycles and lenalidomide PO on days 1-21 for 8 cycles in patients who achieve CR or up to 17 cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT and blood sample collection throughout the study.
89305647|NCT06004661|Experimental|AAA617|Participants will receive a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for 3 to 6 cycles according to eGFR calculation at screening and radiation absorbed dose results from Cycle1 Day1.
89305648|NCT06001255|Experimental|HS-20093|Participants will receive HS-20093 at 8 mg/kg.
89305649|NCT05998967|Experimental|Self-directed MRP|Self-directed instruction in MRP via Internet
89305650|NCT05998967|Active Comparator|Supported MRP|Supported instruction in MRP via Internet
89305651|NCT05998447|Experimental|GEN-001 with pembrolizumab or GEN-001 with pembrolizumab and mFOLFOX|"Drug: GEN-001~Drug: pembrolizumab~Drug: mFOLFOX"
89305652|NCT05997979|Active Comparator|QUTENZA|"The experimental product is QUTENZA®, a cutaneous patch which contains 179 mg of capsaicin (capsaicin 8%).The patch measures 14 cm x 20 cm.~The second application takes place three months after the first application."
89305653|NCT05997979|Placebo Comparator|Placebo|"The placebo comparator is a hydrocolloid dressing: COMFEEL PLUS TRANSPARENT, a medical device class IIb commercialized by Coloplast. The patch measures 15 cm x 15 cm.~The second application takes place three months after the first application."
88806410|NCT04623320||NAFLD-T1DM+|Subjects with type 1 diabetes without ultrasound-defined NAFLD
89305654|NCT05996107|Experimental|RT + Ribociclib|All patients will be treated with Ribociclib and standard of care radiation therapy
89305655|NCT05992142|Other|UC patients|UC patients, treated by 5-ASA for at least 6 months, free of concomitant UC medications for at least 3 months and presenting for a routine follow-up visit
89305656|NCT05990465|Experimental|Pirtobrutinib and CAR T Cells|Pirtobrutinib is an oral agent. LV20.19 CAR T cells will be administered either fresh or thawed after cryopreservation by IV injection.
89305657|NCT05984277|Experimental|Arm 1|Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion
89305658|NCT05984277|Active Comparator|Arm 2|Pembrolizumab plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion
89305659|NCT05981027|Experimental|Mulligan bent leg raise technique|A single session of 3 repetitions of Mulligan bent leg raise was applied to the participants.
89305660|NCT05981027|Experimental|Static stretching exercise|A single session of 5 repetitive stretching exercises was performed on the participants.
89305661|NCT05977036|Experimental|TKa suppressed at Cycle 1 Day 15|"Study visits will occur at Baseline, Week 2 (C1D15), C2D1, C4D1, and clinical progression. Blood serum samples will be collected and analyzed using DiviTum® TKa at each of these dictated time points.~Patients with suppressed TKa levels at C1D15 will continue on CDK4/6i + endocrine therapy until clinical progression. There will be an option to elongate the time between restaging scans from Q3M to Q6M if TKa remains suppressed in this group. Physicians may repeat TKa in 2 weeks if TKa rise is noted and if TKa again becomes suppressed, may delay imaging. These patients will undergo TKa level monitoring at C2D1, C4D1, every 3 months thereafter, and at the time of clinical progression. The feasibility endpoint relates specifically to the Week 24 imaging time point."
89305662|NCT05977036|Experimental|TKa unsuppressed at Cycle 1 Day 15|"Study visits will occur at Baseline, Week 2 (C1D15), C2D1, C4D1, and clinical progression. Blood serum samples will be collected and analyzed using DiviTum® TKa at each of these dictated time points.~Patients with lack of TKa suppression at C1D15 (defined as >145 DuA) will be recommended to switch to an alternative therapy after compliance with the medication is ensured (by pill count) and potential drug-drug interactions are reviewed. These patients will have TKa samples drawn at initiation of second-line therapy and on the first day of subsequent cycles until progression."
89305663|NCT05977036|No Intervention|Physicians|"-Physicians will be asked to complete surveys as follows:~Physician Survey 1 for patients in the TKa C1D15 Suppressed group who have the option to delay the Week 24 scan at Week 24~Physician Survey 2 for patients in the TKa C1D15 Unsuppressed group at C1D15 (after TKa results have returned but before switching therapy)"
89305664|NCT05972850|Experimental|Vivo Heart|This virtual intervention will include weekly group exercise sessions with a Vivo trainer (2 times/week), weekly health education classes with a registered dietitian (RD) (1 time/week), and two individual meetings with the RD over the course of 12 weeks. Participants will also be asked to complete a weekly aerobic exercise session on their own (1 time/week).
89305665|NCT05972720|Experimental|Experimental Drug|Single infusion of CRG-022 following conditioning chemotherapy
89305666|NCT05970731|Active Comparator|Beclomethasone|84 mcg of Beclomethasone administered twice in each nostril via a microsponge (Day 1 and Day 14)
89305667|NCT05970731|Placebo Comparator|Placebo|Placebo (0.9% sodium chloride) administered twice in each nostril via a microsponge (Day 1 and Day 14)
89305668|NCT05970289|Experimental|Cohort 1|Participants will receive multiple doses of PEG-IFNα for 48 weeks.
89305669|NCT05970289|Experimental|Cohort 2|Participants will receive multiple doses of higher dose level of BRII-835 + PEG-IFNα for 48 weeks.
89305670|NCT05970289|Experimental|Cohort 3|Participants will receive multiple doses of lower dose level of BRII-835 + PEG-IFNα for 48 weeks.
89305671|NCT05970289|Experimental|Cohort 4|Participants will receive multiple doses of lower dose level of BRII-835 + PEG-IFNα for 48 weeks (participants who received BRII-179 in a previous study will roll over into this cohort).
88806411|NCT05394402|Experimental|SHR0410 Injection High dose|
88806412|NCT05394402|Experimental|SHR0410 Injection Low dose|
88806413|NCT05394402|Placebo Comparator|Placebo for SHR0410 Injection|
88806414|NCT05374434|Active Comparator|Conventional irrigation|Root canal cleaning will be performed by manual irrigation with sodium hypochlorite NaOCl solution.
88806415|NCT05374434|Experimental|Inertial cavitation|Root canal cleaning will be performed by inertial cavitation-generating device.
88806416|NCT05374200|Experimental|Intervention group|Participants will receive the standard of care for PBC and access to the online intervention. During the intervention period, participants will also receive weekly brief (~10-minute) motivational interview style telephone check-ins.
88806417|NCT05374200|No Intervention|Wait list control group|During the 12-week wait list period, participants will receive the standard of care for PBC in addition to weekly emails with motivational messages.
88806418|NCT05393310|Experimental|post-isometric relaxation|effects of post-isometric relaxation on pain, disability and dynamic balance in athletes with chronic ankle sprain
88806419|NCT05393310|Experimental|mulligan mobilization with movement|effects of mulligan mobilization with movement on pain, disability and dynamic balance in athletes with chronic ankle sprain
88806420|NCT00310466|Active Comparator|Sublingual immunotherapy|sublingual immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
89305672|NCT05969860|Experimental|Arm A (at-home treatment)|Patients continue receiving their SOC chemotherapy regimen at home for approximately 24 weeks in the absence of disease progression or unacceptable toxicity. This includes drug administrations, injections/infusions and routine clinical laboratory tests in the home from the HHNP, overseen by Mayo Clinic's home health program CCBW Command Center. Patients are also provided biometric devices for health monitoring vital signs, as well as a computer tablet for video visits with the Mayo Clinic care team.
89305673|NCT05969860|Experimental|Arm B (clinic & at-home treatment)|Patients continue receiving their SOC chemotherapy regimen in the clinic for approximately 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then begin receiving their SOC chemotherapy regimen at home as in Arm I for an approximate additional 16 weeks in the absence of disease progression or unacceptable toxicity.
89305674|NCT05969223|Experimental|Study G Risankizumab|Participants with moderate to severe genital psoriasis will receive risankizumab during the 52 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
89305675|NCT05969223|Experimental|Study G Placebo for Risankizumab|Participants with moderate to severe genital psoriasis will receive placebo for risankizumab during the 16 week treatment period followed by risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
89305676|NCT05969223|Experimental|Study S Risankizumab|Participants with moderate to severe scalp psoriasis will receive risankizumab during the 52 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
89305677|NCT05969223|Experimental|Study S Placebo for Risankizumab|Participants with moderate to severe scalp psoriasis will receive placebo for risankizumab during the16 week treatment period followed by risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
89305678|NCT05967182|Experimental|Pembrolizumab with Gemcitabine and Cisplatin|Participants will receive 4 cycles (21 days each) of the combined chemotherapy before and after your scheduled surgery. During the 9 months of chemotherapy treatment, participants will have clinic visits every 3 weeks or so. During the 2-4 year follow-up period, participants will come to the clinic every 3 months or so
89305679|NCT05965752|Active Comparator|BrainHQ Active Comparator|5 sessions/week at 30 min/session
89305680|NCT05965752|Experimental|BrainHQ|5 sessions/week at 30 min/session
89305681|NCT05965752|Experimental|BrainHQ + PASC CoRE|BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions at 1 hr/session
89305682|NCT05965752|Experimental|Brain HQ + tDCS-active|2.0 mA stimulation delivered for 30 min during each BrainHQ session
89305683|NCT05965752|Placebo Comparator|Brain HQ + tDCS-sham|Inactive stimulation delivered for 30 min during each BrainHQ session
89305684|NCT05961189|Experimental|Antibiotics and exercise|Participants will be tested before and after 5 days of azithromycin, per manufacturer's instructions, to determine if that impacts exercise performance and the gut microbiome and gut/serum metabolome.
89305685|NCT05959356|Experimental|Arm A|cetuximab+envafolimab+mFOLFOXIRI up to 8 cycles followed by maintenance with cetuximab+envafolimab+5-FU/LV
89305686|NCT05959356|Active Comparator|Arm B|cetuximab+mFOLFOX6/FOLFIRI up to 8 cycles followed by maintenance with cetuximab+5-FU/LV
89305687|NCT05957445|Active Comparator|active cTBS group|active cTBS combined with speech language therapy
89305688|NCT05957445|Sham Comparator|sham cTBS group|sham cTBS combined with speech language therapy
89305689|NCT05956509|Experimental|Part 1: ABBV-950 Dose A|Participants will receive ABBV-Dose A on Day 1.
89305690|NCT05956509|Placebo Comparator|Part 1: Placebo for ABBV-950 Dose A|Participants will receive placebo for ABBV-950 on Day 1.
89305691|NCT05956509|Experimental|Part 1: ABBV-950 Dose B|Participants will receive ABBV-950 Dose B on Day 1.
89305692|NCT05956509|Placebo Comparator|Part 1: Placebo for ABBV-950 Dose B|Participants will receive placebo for ABBV-950 on Day 1.
89305693|NCT05956509|Experimental|Part 1: ABBV-950 Dose C|Participants will receive ABBV-950 Dose C on Day 1.
89305694|NCT05956509|Placebo Comparator|Part 1: Placebo for ABBV-950 Dose C|Participants will receive placebo for ABBV-950 on Day 1.
89305695|NCT05956509|Active Comparator|Part 2: BOTOX Dose A|Participants will receive BOTOX Dose A on Day 1.
89305696|NCT05956509|Experimental|Part 2: ABBV-950 Dose A|Participants will receive ABBV-950 Dose A on Day 1.
89305697|NCT05956509|Experimental|Part 2: ABBV-950 Dose B|Participants will receive ABBV-950 Dose B on Day 1.
89305698|NCT05956509|Experimental|Part 2: ABBV-950 Dose C|Participants will receive ABBV-950 Dose C on Day 1.
89305699|NCT05956509|Placebo Comparator|Part 2: Placebo for ABBV-950|Participants will receive placebo for ABBV-950 on Day 1.
89305700|NCT05949632|Experimental|Part 1: Dose Escalation|Up to 6 doses of INCB099280 administered twice daily (BID) in combination with axitinib BID will be evaluated to identify dose(s) for further evaluation in the dose expansion phase of the study.
89305701|NCT05949632|Experimental|Part 2: Dose Expansion|On completion of Part 1, participants will be enrolled in 1 of 2 disease-specific cohorts: Cohort 1: Adults with clear-cell gynecological cancers with at least 50% clear-cell histology whose disease progressed on or following at least 1 prior line of systemic chemotherapy and are not candidates for curative surgery or (chemo)radiation. Cohort 2: Adults with rare histological subtype epithelial cancers of the gynecological tract whose disease progressed on or following at least 1 prior line of systemic chemotherapy and are not candidates for curative surgery or (chemo)radiation. One or two doses may be selected from Part 1 for each cohort in the Part 2 Expansion.
89305702|NCT05947357|Experimental|Nutrition Assistance Program|A total of 30 Latinx cancer patients on active cancer treatment who have screened positive for food insecurity will receive a $40.00 voucher for use each month for 6 months for nutrition assistance in the produce section of local grocery stores after enrollment in the program.
89305703|NCT05947357|No Intervention|Usual Care|A total of 30 patients who have screened positive for food insecurity will receive usual care consisting of referral to the local food bank as part of the nutrition assistance program.
89305704|NCT05947279|Experimental|Posterior parietal cortex group|Posterior parietal cortex group, which will receive the stimulation to their left posterior parietal cortex
89305705|NCT05947279|Experimental|Cerebellum group|Cerebellum group, which will receive stimulation to their right cerebellum,
89305706|NCT05947279|Sham Comparator|Sham group|Sham group, which will have the electrode cap placed on their head but receive no stimulation
89305707|NCT05946759|Active Comparator|Prospective|50 prospective subjects
89305708|NCT05946759|No Intervention|Historical|40 historical subjects
89305709|NCT05946746|Experimental|PeptiStrong - fava bean hydrolysate preparation|PeptiStrong 2.4g/day will be supplemented as 5 capsules (480mg each) taken with approx. 150mL water at breakfast once per day for 56 days
89305710|NCT05946746|Placebo Comparator|Silicated micro-crystalline cellulose (SMCC)|The placebo 2.4g/day will be supplemented as 5 capsules taken with approx. 150mL water at breakfast once per day for 56 days
89305711|NCT05944432|Active Comparator|FreeStyle Libre system|FreeStyle Libre 3 continuous glucose monitoring system
89305712|NCT05944432|Other|Standard of care (control)|Self monitoring of blood glucose
89305713|NCT05938816|Experimental|Mindfulness-Based Stress Reduction|
89305714|NCT05938816|Placebo Comparator|Health and Wellness Education|
89305715|NCT05935748|Experimental|Lead-in Doublet combination|Lead-in Doublet assesses safety of oral dosing NKT2152 at increasing dosage levels in combination with palbociclib to determine a recommended dose for expansion (RDE).
89305716|NCT05935748|Experimental|Lead-in Triplet combination|Lead-in Triplet assesses the safety of two doses of NKT2152 identified in the Doublet arm (RDE and RDE-1) by orally dosing ccRCC patients with NKT2152 in combination with palbociclib and sasanlimab
89305717|NCT05935748|Experimental|Expansion Doublet combination|Subjects randomized to Arm 1 will receive the Doublet combination (NKT2152 in combination with palbociclib) to provide an assessment of anti-tumor activity and to determine the RP2D.
89305718|NCT05935748|Experimental|Expansion Triplet combination|Subjects randomized to Arm 2 will receive the Triplet therapy (NKT2152 in combination with palbociclib and sasanlimab) to provide an assessment of anti-tumor activity and to determine the RP2D.
89305719|NCT05934474||IBIS-PSY patients|
89305720|NCT05933083|Active Comparator|In-person cardiac rehabilitation|Participants will participate in 12-week in-person cardiac rehabilitation as delivered at the site where they are enrolled. The typical course is 36 sessions of group exercise, health education, and counseling over 12 weeks.
89305721|NCT05933083|Active Comparator|Telehealth cardiac rehabilitation|Participants will participate in 12-week telehealth cardiac rehabilitation. The program will follow the same core components as in-person cardiac rehabilitation, but in-person supervised exercise will not be required. The core element of telehealth cardiac rehabilitation is 12 weekly individual telehealth sessions between the patient and cardiac rehabilitation provider.
89305722|NCT05929235|Experimental|Dose Escalation|3+3 design, 5 dose levels,
89305723|NCT05929235|Experimental|Expansion Expansion|When a preliminary RP2D has been identified (this dose may be equal to or below the MTD) evaluate the antitumor activity in locally advanced (unresectable) and metastatic urothelial carcinoma.
89305724|NCT05919316|Experimental|Rhinophototherapy|Intranasal Rhinophototherapy is an electronic allergic rhinitis treatment device (brand Bionette) also a medical device that producing low level narrow band red light at a wavelength of 630nm. It is a Class B medical device (registration of Malaysia number GB67793908818). It is powered by two alkaline button batteries with a dimension of 52mm x 40mm and weighing less than 20g . Light is produced via nasal prongs which are to be inserted into both nostrils. Plastic nasal cannula are available and can be replaced to ensure sterility and prevent transmission of infection.
89305725|NCT05919316|Active Comparator|Intranasal Corticosteroids|Mometasone furoate will be available in the form of Nasonex Nasal Spray. It has a dose of 50 mcg/dose mometasone furoate per spray, registration no: MAL20001010AZ, distributed by: Merck Sharp & Dohme (Malaysia) Sdn. Bhd.
89305726|NCT05916378||Patients and Caregivers|We will survey 100 patients and 50 caregivers.
89305727|NCT05916183|Experimental|Dehydration and Rehydration Arm|Participants will complete exercise until 5% body mass loss, followed by ad libitum rehydration throughout 2 hours of recovery.
89305728|NCT05912387|Experimental|Rosuvastatin therapy|Participants will receive rosuvastatin for 12 weeks followed by a 2 week washout period prior to the final follow-up visit. All patients will receive the study drug, and will serve as their own control. No participants will receive placebo. Rosuvastatin is FDA approved for treatment of high cholesterol, but its use in this trial is off label.
89305729|NCT05903924|Experimental|Tradipitant High Dose|
89305730|NCT05903924|Placebo Comparator|Placebo|
89305731|NCT05903924|Experimental|Tradipitant Low Dose|
89305732|NCT05902234||Pediatric pain patients and their parents|patients and their parents
88806421|NCT00310466|Placebo Comparator|Placebo|placebo sublingual drops
88806422|NCT00355394|Placebo Comparator|Placebo|Standard care including intravenous fluid, but no metoclopramide.
88806423|NCT00355394|Active Comparator|Metoclopramide|Standard care including intravenous fluid PLUS metoclopramide.
88806424|NCT00355706|Active Comparator|Group I - without Steroids|Thoracic Facet Joint Nerve Blocks with Local Anesthetic(0.25% Bupivacaine)
88806425|NCT00355706|Active Comparator|Group II - with steroid|Thoracic Facet Joint Nerve Blocks with Local Anesthetic (0.25% Bupivacaine) and Sterioids(0.15 mg of non-particulate betamethasone)
88806426|NCT00311246|Experimental|An open-label|Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52
88806427|NCT02105246|Experimental|Home-based|Referral to a home-based cardiac rehabilitation program (intervention).
88806428|NCT02105246|Active Comparator|Center-based|Referral to a center-based cardiac rehabilitation program (standard of care).
88806429|NCT01792466|Experimental|Transpacnreatic sphincterotomy|In patients randomized to TPS, a transpancreatic sphincterotomy will be performed with the sphincterotome superficially in the pancreatic duct over a wire.
89305733|NCT05882253|Other|MRI imaging using Siemens MRI|Participants enrolled will undergo routine Magnetic Resonance Imaging (MRI) to obtain Restricted Spectrum Mapping (RSM). These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
89305734|NCT05882253|Other|MRI imaging using Phillips MRI|Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
89305735|NCT05882253|Other|MRI imaging using General Electric (GE) MRI|Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
89305736|NCT05881005|Other|open-label study|hepatic MRI, Fibroscan
89305737|NCT05878041||Peripartum cardiomyopathy|Diagnosis of Peripartum cardiomyopathy (PPCM) will be defined according to the ESC guidelines as: (i) the development of the disease in the last month of pregnancy or within 5 months of delivery; (i) absence of an identifiable cause of heart failure; (iii) absence of recognizable heart disease before the last month of pregnancy; (iv) left ventricle systolic dysfunction demonstrated by classical echocardiographic criteria.
89305738|NCT05878041||Healthy pregnant volunteers|Healthy pregnant women
89305739|NCT05874297|Active Comparator|Arm I (standard of care)|Patients receive standard of care consisting of symptom monitoring, scheduled nurse visits, and access to current Cook for Your Life website.
89305740|NCT05874297|Experimental|Arm II (enhanced Cook for Your Life)|Patients receive standard of care as in Arm I and access to enhanced Cook for Your Life information on symptom management.
89305741|NCT05870540|Experimental|Low dose|Active placebo comparator
89305742|NCT05870540|Experimental|Medium dose|
89305743|NCT05870540|Experimental|High dose|
89305744|NCT05855174|Active Comparator|Low Protein|Protein intake at 0.15g/kg body weight
89305745|NCT05855174|Experimental|High Protein|Protein intake at 0.4 g/kg body weight
89305746|NCT05844891|Experimental|Telehealth-Enhanced Asthma Care for Home After the Emergency Room|New model of patient-centered asthma management.
89305747|NCT05844891|Active Comparator|Enhanced Care (EC) Comparison Group|Standard emergency department care for asthma exacerbations, enhanced through a report of recent symptoms sent to PCPs, and systematic feedback on asthma management/care at intervals that parallel the TEACH-ER group's telemedicine assessments.
89305748|NCT05844020|Experimental|TVIC Intervention|
89305749|NCT05844020|No Intervention|Usual Care|
89305750|NCT05836571|Active Comparator|Arm A (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity for 4 cycles. Patients then receive nivolumab IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans, tumor biopsies, and collection of blood throughout the trial.
89305751|NCT05836571|Experimental|Arm B (cabozantinib, nivolumab, ipilimumab)|Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity. Patients receive nivolumab IV and ipilimumab IV on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity for 4 cycles. Patients then receive nivolumab IV on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans, tumor biopsies, and collection of blood throughout the trial.
89305752|NCT05834829|Experimental|Repeat measure LIFU and Sham|LIFU or Sham applied in repeat sessions to varying brain regions (dAI and dACC).
89305753|NCT05830188|Experimental|CERIA|Participants in the experimental group will receive six-weekly 45-60 minutes CERIA sessions in a classroom setting.
89305754|NCT05830188|Active Comparator|Control|Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group. There will be no face-to-face meeting between the participants in the control group and the interventionist.
89305755|NCT05823727|Experimental|Collagen Peptides|10 grams per day for 24 weeks
89305756|NCT05823727|Placebo Comparator|Placebo|10 grams per day maltodextrin for 24 weeks
89305757|NCT05817266|Experimental|Proctosigmoiditis|Participants with confirmed proctosigmoiditis will undergo one FCI scan.
89305758|NCT05815810|Experimental|Transgender and gender diverse (TGGD) individuals using the pilot app|The investigators will develop Attuned, an open access voice and communication modification training (VCMT) app based on standard of care. Participants will undergo VCMT via the mobile application, Attuned. Participants will include healthy transgender and gender diverse (TGGD) individuals seeking voice modification to better reflect their identity.
89305759|NCT05815810|Active Comparator|Transgender and gender diverse (TGGD) individuals receiving standard voice modification|VCMT via speech pathology will be compared to the efficacy of an app-based VCMT program. Participants will undergo VCMT in-person. Participants will include healthy transgender and gender diverse (TGGD) individuals seeking voice modification to better reflect their identity.
89305760|NCT05813275|Experimental|AD109|AD109
89305761|NCT05813275|Placebo Comparator|Placebo|Placebo
89305762|NCT05807529|Experimental|2ccPA|IP name: 2-carba-cyclic phosphatidic acid (2ccPA)
89305763|NCT05807529|Placebo Comparator|placebo|Placebo
89305764|NCT05806931|Experimental|Tolerability of TAS-102, oxaliplatin, irinotecan with bevacizumab|Each treatment cycle will be fourteen days long. TAS-102 25 mg/m2 will be taken orally twice daily on days 1-5 of each cycle. Oxaliplatin 85 mg/m2 infusion will be given on day one for one cycle alternating with Irinotecan 150 mg/m2 infusion, which will be given on day one the next cycle.
89305765|NCT05803850|Experimental|HNC1058 Capsules|HNC1058 Capsules, single ascending doses
89305766|NCT05803850|Placebo Comparator|HNC1058 Placebos|HNC1058 Placebos, single ascending doses
89305767|NCT05803850|Experimental|HNC1058 Capsules FED|HNC1058 Capsules, food effect, Single dose
89305768|NCT05803850|Placebo Comparator|HNC1058 Placebos FED|HNC1058 Placebos, food effect, Single dose
89305769|NCT05801965|Experimental|Digital intervention group|"Participants will be instructed to download Sidekick Health app and receive a code to access the 14-week digital intervention in addition to standard of care, as is defined for the control arm.~Beyond this, all participants in the interventional arm will also receive standard of care as defined for the control arm."
89305770|NCT05801965|Active Comparator|Standard of care - control group|Participants in the control arm will receive standard of care treatment. Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
89305771|NCT05799651|Experimental|Step 1 (Low Dose)|A total of 12 participants will receive three injections, spaced by two weeks, of Glycovax-002 Low Dose or placebo (ratio 3:1).
89305772|NCT05799651|Experimental|Step 2 (Medium Dose)|A total of 12 participants will receive three injections, spaced by two weeks, of Glycovax-002 Medium Dose or placebo (ratio 3:1).
89305773|NCT05799651|Experimental|Step 3 (High Dose)|A total of 12 participants will receive three injections, spaced by two weeks, of Glycovax-002 High Dose or placebo (ratio 3:1).
89305774|NCT05786742|Experimental|ultra hypo fractionation radiation therapy|comparative PRO's of 25 Gy in 5 daily fractions (Ultra hypo fractionation) administered to prostate and 1st centimeter of proximal seminal vesicle, starting mid week and ending mid following week.
89305775|NCT05786742|Active Comparator|moderate hypo fractionation radiation therapy|PRO's of moderate hypo fractionation, 37,5 Gy in 15 or 36 Gy in 12 daily fractions administered 5 days per week.
89305776|NCT05786547|Experimental|Varenicline + Positively Smoke Free - Mobile|"Offer of varenicline per package dosing with dose escalation over week 1: 0.5 mg once daily on days 1 - 3, 0.5 mg twice daily on days 4 -7, followed by 1.0 mg twice daily on days 8 to 84.~Offer of Positively Smoke Free Mobile delivered by mobile phone including 42 days of content, tailored to individual quit date."
89305777|NCT05786547|Active Comparator|Standard Care|Brief advice to quit tobacco Offer of referral to the national tobacco quitline
89305778|NCT05785624|Experimental|DBT: Cohort 1: Vixarelimab|Participants with IPF will receive vixarelimab, subcutaneously (SC), once every two weeks (Q2W) for 52 weeks in the DBT period.
89305779|NCT05785624|Placebo Comparator|DBT: Cohort 1: Placebo|Participants with IPF will receive vixarelimab matching placebo, SC, Q2W for 52 weeks in the DBT period.
89305780|NCT05785624|Experimental|DBT: Cohort 2: Vixarelimab|Participants with SSC-ILD will receive vixarelimab, SC, Q2W for 52 weeks in the DBT period.
89305781|NCT05785624|Placebo Comparator|DBT: Cohort 2: Placebo|Participants with SSC-ILD will receive vixarelimab matching placebo, SC, Q2W for 52 weeks in the DBT period.
89305782|NCT05785624|Experimental|OLE Period: Cohort 1: Vixarelimab|Participants with IPF who complete 52 weeks of treatment in the DBT period can choose to enroll in the OLE period to receive vixarelimab, SC, Q2W for 52 weeks.
89305783|NCT05785624|Experimental|OLE Period: Cohort 2: Vixarelimab|Participants with SSC-ILD who complete 52 weeks of treatment in the DBT period can choose to enroll in the OLE period to receive vixarelimab, SC, Q2W for 52 weeks.
89305784|NCT05779787||TAVR performed with commissural alignment technique (Aligned Group)|Patients with severe aortic stenosis undergoing TAVR procedure performed with commissural alignment technique. We consider in this groups only the Accurate and Accurate Neo 2 Valve which are the first choice due to the best stent frames position predictability with this technique
89305785|NCT05779787||TAVR performed with random implantation of Navitor valve (Random Group)|Patients with severe aortic stenosis undergoing TAVR procedure performed with random implantation of Navitor Valve
89305786|NCT05775900|Experimental|Cetuximab in Combination With Capecitabine|"Patients were given cetuximab (a '3+3' design was adopted in the experimental arm, with four dose levels of 400mg/m2, 500mg/m2, 600mg/m2 and 700mg/m2 for dose exploration) every 3 weeks (Q3W).~Capecitabine, 1000mg/m2, twice a day (BID, once in the morning and once in the evening), 14 days of continuous oral administration followed by 7 days of rest.~The two-drug combination therapy was continued every 3 weeks in a cycle until patients developed disease progression or met other criteria for termination of study treatment specified in the protocol."
89305787|NCT05773274|Experimental|Arm I (177Lu-DOTATATE)|Patients receive 177Lu-DOTATATE IV Q8W. Treatment repeats for two cycles in the absence of disease progression or unacceptable toxicities. Patients also undergo CT scan and collection of blood samples while on study.
89305788|NCT05773274|Active Comparator|Arm II (everolimus)|Patients receive everolimus PO QD. Treatment continues in the absence of disease progression or unacceptable toxicities. Patients whose cancer worsens may cross over to ARM I. Patients also undergo CT scan and collection of blood samples while on study.
89305789|NCT05766397|Other|Health volunteer|Health volunteers will follow a standard protocol for inhalation of methoxyflurane while the off-gassing will be captured.
89305790|NCT05764239|Experimental|RWP (Part 2)|
89305791|NCT05764239|Placebo Comparator|RWP/Part 2|
89305792|NCT05761964|Experimental|Health and Harmony|Participants will take part in a program combining yoga practices and Christian spirituality.
89305793|NCT05761964|Other|Health Education (Control)|Participants will take part in a series of health education sessions.
89305794|NCT05760313|Experimental|Part 1, Linaclotide Dose A|Linaclotide Dose A capsules, mixed with water and administered orally, once daily for 4 weeks
89305795|NCT05760313|Experimental|Part 1, Linaclotide Dose B|Linaclotide Dose B capsules, mixed with water and administered orally, once daily for 4 weeks
89305796|NCT05760313|Experimental|Part 1, Linaclotide Dose C|Linaclotide Dose C capsules, mixed with water and administered orally, once daily for 4 weeks
89305797|NCT05760313|Experimental|Part 2, Linaclotide|Participants will receive Linaclotide capsules mixed with water and administered orally in Part 2 for 4 weeks.
89305798|NCT05760313|Experimental|Part 2, Placebo|Participants will receive placebo capsules mixed with water and administered orally in Part 2 for 4 weeks.
89305799|NCT05759936|Placebo Comparator|Placebo|Placebo capsule consumed for 28 days
89305800|NCT05759936|Experimental|500mg seaweed|Seaweed capsule consumed for 28 days
89305801|NCT05755191|Experimental|NEU-411|Part A: Single-ascending dose cohorts; food effect; Part B: Multiple-ascending dose cohorts (7 days)
89305802|NCT05755191|Placebo Comparator|Placebo|Part A: Single-ascending dose cohorts; food effect; Part B: Multiple-ascending dose cohorts (7 days)
89305803|NCT05750927||ASCoP (severe Aortic Stenosis with Complex PCI features)|Subjects with severe aortic stenosis undergoing transcatheter aortic valve intervention and with concomitant, complex coronary artery disease with a clinical indication for percutaneous coronary intervention
89305804|NCT05746767|Experimental|Treatment|Participants randomly assigned to this condition will be provided all features of the SilverCloud platform as well as be assigned a peer-supporter who will provide regular support.
89305805|NCT05746767|Active Comparator|Control|Participants randomly assigned to this condition will be provided all features of the SilverCloud platform with the exception of the peer supporter.
89305806|NCT05744869|Experimental|SBAT Implementation|"For schools randomized to implementing SBAT, the program will include the components already available in comparison (usual care) schools (asthma symptom screening forms, access to telemedicine visits, and protocol for initiating DOT), as well as the following elements that will be facilitated with the support of an implementation team:~telemedicine asthma visits through school with primary care and/or specialist providers to prescribe needed initial medication as well as medication step-ups for DOT~school-based DOT of preventive asthma medications~follow-up telemedicine asthma control assessments~centralized case management support and care coordination"
89305807|NCT05744869|Active Comparator|Usual Care|During student health services orientation, the SBAT team will recommend school-based DOT for all children with persistent or poorly controlled asthma, and will provide a simple asthma screening survey to assess symptoms and a written protocol for initiating DOT. Telemedicine visits and DOT are available for all children in the school district, but the implementation team will not help to facilitate these components within the usual care schools.
89305808|NCT05741411|Experimental|Concussed youth at risk for prolonged symptoms|
89305809|NCT05739617|Sham Comparator|Sleep Hygiene Education|Participants will received once per month of sleep hygiene education for three months.
89305810|NCT05739617|Experimental|Comprehensive Respiratory Training Exercise Program|Participants will received Comprehensive Respiratory Training Exercise Program twice per weeks for three months.
89305811|NCT05732532|Active Comparator|Anesthetic without steroid group|Subjects scheduled for bilateral greater/lesser occipital nerve blocks as part of clinical care will receive standard of care medication, including lidocaine and bupivacaine and normal saline.
89305812|NCT05732532|Experimental|Anesthetic with dexamethasone group|Subjects scheduled for bilateral greater/lesser occipital nerve blocks as part of clinical care will receive standard of care medication, including lidocaine and bupivacaine and dexamethasone.
89305813|NCT05726864|Experimental|Phase 1A: ELI-002 7P (Low Peptide dose)|ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (1.4mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
89305814|NCT05726864|Experimental|Phase 1A: ELI-002 7P (High Peptide dose)|ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (4.9mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
89305815|NCT05726864|Experimental|Phase 1B: ELI-002 7P|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
89305816|NCT05726864|Experimental|Phase 2 randomized: ELI-002 7P|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
89305817|NCT05725304||kidney cancer|RCC arms: Retrospective studies for ccRCC (N=100) and nccRCC (N=100). The studies aim to obtain clinical information to correlate with genetic characterization of RCCs of all types.
89305818|NCT05725304||urothelial cancer|UC arm: This is a prospective study for UC originated from the translational epithelium in the urinary tract (N=300). The study aims to obtain cancer tissues that originated from bladder (N=100), ureter (N=100), and renal pelvis (N=100).
89305819|NCT05718700||Bulevirtide (previously participated in Study MYR-Reg-2)|Participants who are currently receiving bulevirtide (BLV) according to the approved label and have participated in Study MYR-Reg-02.
89305820|NCT05718700||Bulevirtide|Participants who are scheduled to receive BLV according to the approved label.
89305821|NCT05717959|Experimental|intervention group|We conducted a once a week, 12-week-intervention of Oropharyngeal Exercises and Mandibular advancement device
89305822|NCT05717959|Sham Comparator|control group|Mandibular advancement device
89305823|NCT05711940|Experimental|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
89305824|NCT05711940|Experimental|10 mg COMP360 Psilocybin|10 mg COMP360 Psilocybin
89305825|NCT05711940|Active Comparator|1 mg COMP360 Psilocybin|1 mg COMP360 Psilocybin, active comparator
89305827|NCT05705349|Experimental|DOR/ISL|Participants take DOR/ISL and placebo to BIC/FTC/TAF once daily (qd) for 96 weeks.
89305828|NCT05705349|Active Comparator|BIC/FTC/TAF|Participants take BIC/FTC/TAF and placebo to DOR/ISL qd for 96 weeks.
89305829|NCT05704933|Experimental|Pre-Surgery Nivolumab + Ipilimumab|Patients will be given one dose of Nivolumab (1mg/kg IV) and Ipilimumab (3mg/kg IV) prior to standard of care surgery for tumor resection.
89305830|NCT05704933|Experimental|Pre-Surgery Nivolumab + Relatlimab(Opdualag)|Patients will be given one dose of Opdualag (Nivolumab 480 mg IV + Relatlimab160 mg IV), prior to standard of care surgery for tumor resection.
89305831|NCT05704933|Active Comparator|No Pre-Surgery treatment (Standard of Care)|Patients will be on standard of care treatment, therefore no infusion will be given prior to standard of care surgery for tumor resection.
89305832|NCT05703230|No Intervention|Preoperative care as usual|Patients undergoing preoperative care as usual, which does not include a structured preoperative multidisciplinary team meeting (no sMDT meeting)
89305833|NCT05703230|Active Comparator|Structured preoperative multidisciplinary team meeting|Patients are discussed preoperatively in a structured preoperative multidisciplinary team meeting
89305834|NCT05698914|Experimental|Telehealth mindfulness-based intervention (MBI)|Eight, weekly telehealth mindfulness sessions delivered one-on-one with mindfulness instructor
89305835|NCT05698914|Active Comparator|Telehealth Education (EDU)|Eight, weekly post-surgical educational sessions delivered one-on-one with physical therapist
89305836|NCT05696691|Experimental|Ketamine and Crisis Response Plan (CRP)|Individuals randomized to the experimental arm will receive 100mg intramuscular ketamine injection before completing the Crisis Response Plan. The average timeframe for the experimental arm is anticipated to be approximately 60 minutes of active treatment. Following ketamine administration, the subject will be monitored for 45 minutes with pulse oximetry and recurrent vital signs. The study team will record when the CRP is completed in relation to the ketamine injection.
89305837|NCT05696691|No Intervention|Treatment as Usual|Individuals randomized to the no intervention arm will receive routine care from emergency providers and psychiatry staff.
89305838|NCT05696548|Experimental|Lenvatinib plus Nivolumab|Step 1: 3 patients, Step 2: 48 patients
89305839|NCT05688670|Active Comparator|Regional Anesthesia|Ultrasound guided blocks
89305840|NCT05688670|Active Comparator|Wound Infiltration|Surgeon-delivered wound infiltration
89305841|NCT05685628|Experimental|Cinnamon dressing group|Use of the cinnamon dressing for 14 days
89305842|NCT05685628|Active Comparator|Charcoal dressing Group|Use of the charcoal dressing for 14 days
89305843|NCT05681442|Experimental|continuous infusion dosing of a pivotal AND AG infusion for 5 days|continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT group)
89305844|NCT05681442|Experimental|intermittent infusion dosing of a pivotal βL-AB ND AG infusion for 5 days|intermittent infusion dosing of a pivotal βL-AB (IID = control group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT = group)
89305845|NCT05681442|Experimental|continuous infusion dosing of a pivotal βL-AB AND AG infusion at most 1 dose|continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion at most 1 dose (AMT group )
89305846|NCT05681442|Experimental|intermittent infusion dosing of a pivotal βL-AB AND AG infusion at most 1 dose|intermittent infusion dosing of a pivotal βL-AB (IID = group) AND AG infusion at most 1 dose (AMT group)
89305847|NCT05667246|Active Comparator|Caffeinated Group|Caffeinated coffee, 1 cup, 8 oz water setting, 95 mg caffeine
89305848|NCT05667246|Placebo Comparator|Decaffeinated Group|Decaffeinated coffee, 1 cup, 8 oz water setting
89305849|NCT05665062|Experimental|SYNCAR-001 + STK-009 Cohort A|"Dose escalation: A single fixed dose of autologous SYNCAR-001 CAR-T intravenously (IV) will be administered in combination with repeated sequential ascending doses of STK-009 subcutaneously (SC)~Dose expansion: A single fixed dose of autologous SYNCAR-001 CAR-T IV will be administered in combination with repeated doses of STK-009 SC at the RP2D"
89305850|NCT05665062|Experimental|SYNCAR-001 + STK-009 Cohort B|"Dose escalation: A single fixed dose of autologous SYNCAR-001 CAR-T intravenously (IV) will be administered in combination with repeated sequential ascending doses of STK-009 subcutaneously (SC)~Dose expansion: A single fixed dose of autologous SYNCAR-001 CAR-T IV will be administered in combination with repeated doses of STK-009 SC at the RP2D"
89305851|NCT05664711|Experimental|Stellate Ganglion Block|The stellate ganglion and nearby cervical sympathetic ganglia will be blocked with 10 mL 0.5 percent bupivacaine under ultrasound guidance.
89305852|NCT05664308||Electrocardiogram|
89305853|NCT05664308||Electrocardiogram + Connect Watch|
89305854|NCT05664113|Experimental|Stratum A|Diagnosed with GvHD
89305855|NCT05664113|Experimental|Stratum B|GI Dysfunction
89305856|NCT05663957||EVUSHELD arm|Individuals given EVUSHELD for prophylaxis
89305857|NCT05663957||Concurrent Control arm|Individuals eligible for Evusheld prophylaxis but did not receive EVUSHELD
89305858|NCT05662228|Experimental|Lorazepam|Participants will receive lorazepam as an oral pill three times daily for 12 weeks as well as titration doses for an additional 4 weeks (approximately).
89305859|NCT05662228|Experimental|Intravenous immunoglobulin (IVIG)|Participants will receive 4 doses of IVIG treatment over 12 weeks.
89305860|NCT05662228|Experimental|Tofacitinib|Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
89305861|NCT05660031|No Intervention|Leaving LHB Intact|The long head of the biceps (LHB) will be left intact.
89305862|NCT05660031|Experimental|LHB tenotomy|The long head of the biceps (LHB) will be cut at its origin.
89305863|NCT05660031|Experimental|LHB Tenodesis|The long head of the biceps (LHB) will be cut at its origin and reattached.
89305864|NCT05659667||Stroke|Case group: 50 adults (between 18 and 70 years old) in chronic phase of stroke (> 6 months from stroke), in possession of driving license and having to have driven in the three months before stroke.
89305865|NCT05659667||Healthy adults|50 healthy adults with the same age as case group, match up in driving experience, age, sex and educational level with the group of people with stroke, and driver´s license in validity.
89305866|NCT05658341|Experimental|ADA intervention|The ADA intervention arm
89305867|NCT05658341|Active Comparator|Usual Care|The usual care arm
89305868|NCT05657275|Experimental|Intervention period|Patient management will be guided by a multimodal algorithm integrating the performance of biological and iconographic examinations
89305869|NCT05657275|No Intervention|Control period|Patient management will be done according to the usual practices of centers and emergency physicians
89305870|NCT05650411|Experimental|P2Y12 inhibitor-based single antiplatelet therapy after a short DAPT strategy arm|"Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland).~P2Y12 inhibitor SAPT with any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, or prasugrel 10 mg) after a short DAPT course during 2 years after the index LMCA procedure.~In patients with intended clopidogrel use, a platelet function or genetic test is mandatory before hospital discharge for patients with intended treatment with clopidogrel. In case of high on-treatment platelet reactivity or an ABCD-GENE score =/>10, patients treated with clopidogrel should be switched to either ticagrelor or prasugrel with corresponding on-label loading dose regimens, at the investigator's discretion.~At the discretion of the investigator, aspirin will be discontinued after LMCA PCI, or continued during the hospital stay. In all cases, aspirin will be discontinued at latest at hospital discharge."
89523374|NCT03387007|Experimental|Intervention|Two teachers from each of the schools included in this arm received training on providing psycho-social support to their students to be implemented in their regular routine school activities
89523375|NCT03387007|No Intervention|Control|The teachers from the schools in this arm did not receive training on psycho-social support
89305871|NCT05650411|Active Comparator|Conventional DAPT strategy arm|"Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland) DAPT combining aspirin and any of the commercially available oral P2Y12 receptor inhibitors (clopidogrel, ticagrelor, or prasugrel) during 6 or 12 months followed by aspirin-based SAPT.~In patients with index ACS presentation and who have tolerated DAPT for 12 months without bleeding complications, a prolonged DAPT course with aspirin and ticagrelor 60 mg bd (clopidogrel or prasugrel allowed, if patient not eligible for treatment with ticagrelor) beyond 12 months may be considered in those patients with high thrombotic risk and without an increased risk for major or life-threatening bleeding, and those with moderately elevated thrombotic risk."
89305872|NCT05649228|Experimental|Capsaicin Palmitate|Cream containing 0.25% capsaicin palmitate will be applied to an 8 cm2 area of skin on the subject's forearm
89305873|NCT05649228|Active Comparator|Capsaicin|Cream containing 0.1% capsaicin will be applied to an 8 cm2 area of skin on the subject's forearm
89305874|NCT05649228|Placebo Comparator|Placebo Cream|Placebo cream will be applied to an 8 cm2 area of skin on the subject's forearm
89305875|NCT05643885||apixaban|patients treated with apixaban
89305876|NCT05643885||Low molecular weight heparin (LMWH)|patients treated with low molecular weight heparin
89305877|NCT05642377|Experimental|HGR4113 300 mg Single Dose|Single oral dosing of HGR4113 300 mg
89305878|NCT05642377|Placebo Comparator|Placebo 300 mg Single Dose|Single oral dosing of placebo 300 mg
89305879|NCT05642377|Experimental|HGR4113 600 mg Single Dose|Single oral dosing of HGR4113600 mg
89305880|NCT05642377|Placebo Comparator|Placebo 600 mg Single Dose|Single oral dosing of placebo 600 mg
89305881|NCT05642377|Experimental|HGR4113 1200 mg Single Dose|Single oral dosing of HGR41131200 mg
89305882|NCT05642377|Placebo Comparator|Placebo 1200 mg Single Dose|Single oral dosing of placebo 1200 mg
89305883|NCT05642377|Experimental|HGR4113 200 mg Multiple Dose|Multiple oral dosing of HGR4113 200 mg, twice daily
89305884|NCT05642377|Placebo Comparator|Placebo 200 mg Multiple Dose|Multiple oral dosing of placebo 200 mg, twice daily
89305885|NCT05642377|Experimental|HGR4113 400 mg Multiple Dose|Multiple oral dosing of HGR4113 400 mg, twice daily
89305886|NCT05642377|Placebo Comparator|Placebo 400 mg Multiple Dose|Multiple oral dosing of placebo 400 mg, twice daily
89305887|NCT05637749|Experimental|Control|Serious game intervention to be played as is, without facilitation.
89305888|NCT05637749|Active Comparator|Intervention|Serious game intervention to be played with facilitator present in game environment.
89305889|NCT05635838|Experimental|Ruxolitinib Cream|Ruxolitinib 1.5% cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
89305890|NCT05635838|Experimental|Vehicle Cream|Vehicle cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
89305891|NCT05632133|Experimental|lacosamide group|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
89305892|NCT05632133|Experimental|control group|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
89305893|NCT05630703|Experimental|Mindfulness Training|Behavioral: Mindfulness-based Eating Awareness Training in IBS - The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
89305894|NCT05630703|Active Comparator|fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet|Dietary: Low FODMAP Diet - Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format.
89305895|NCT05628363|Experimental|Adaptive stereotactic body radiotherapy (SBRT)|"Treatment consists of adaptive dose-escalated stereotactic body radiotherapy (SBRT) to the pelvic nodes to 25 Gy in 5 weekly fractions with simultaneous integrated boosts (SIB) to the prostate and proximal seminal vesicles to 36.25 Gy in 5 fractions (full seminal vesicles if involved), to the prostate to 40 Gy in 5 fractions, and to the involved MR-detected nodule(s) to up to 50 Gy in 5 fractions.~Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Unfavorable Intermediate-risk Disease: Patients should receive a minimum of 4 months of ADT. Patients can receive longer duration of ADT at the discretion of the treating physician. High-risk disease: Patients should receive a minimum of 1 year of ADT. Patients can receive up to 2 years of ADT at the discretion of the treating physician."
89305896|NCT05627908||abdominal trauma|CEUS in detecting post-traumatic splenic, hepatic, and renal PAs
89305897|NCT05626114|Experimental|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
89305898|NCT05624268|Experimental|25 mg COMP360 Psilocybin|25 mg COMP360 Psilocybin
89305899|NCT05624268|Placebo Comparator|Placebo|Matched placebo
89305900|NCT05620823|Experimental|Povorcitinib Dose A|Participants will receive Povorcitinib Dose A for 54 weeks.
89305901|NCT05620823|Experimental|Povorcitinib Dose B|Participants will receive Povorcitinib Dose B for 54 weeks.
89305902|NCT05620823|Placebo Comparator|Placebo|Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
89305903|NCT05611710|Placebo Comparator|Placebo|The control group will be formed of 80 dengue patients with warning signs or severe dengue receiving placebo.
89305904|NCT05611710|Experimental|Anakinra|The intervention group will include 80 dengue patients with warning signs or severe dengue receiving anakinra.
89305905|NCT05610605|No Intervention|Control Group|Participants who do not receive attention from the Fragsalud program. The control group follows the usual care and preventive measures in Primary Care, according to different protocols implemented and the criteria of nurses and family doctors responsible for their care.
89523376|NCT03898817||Taking of cutaneous cells by biopsy|Taking of cutaneous cells by biopsy and a sample of blood
89523377|NCT03385369|Placebo Comparator|Placebo Japanese Descent|Participants of Japanese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
88806430|NCT01792466|No Intervention|Double wire without sphincterotomy|In patients randomized to the DWT group, the PD wire will be left in place, the catheter removed and then reinserted next to the PD wire with a second wire to attempt CBD cannluation
89305906|NCT05610605|Experimental|Intervention Group|The FRAGSALUD Programme is a multidomain intervention programme, which covers the prevention and treatment of frailty from different aspects, fundamentally from a physical and cognitive aspect and to maintain social integration, although other modifiable factors that are related to the presence of fragility such as hearing impairment, visual deficit or depression.
89305907|NCT05610111|Active Comparator|CLC, then CLC+BAM, then CLC+ABC|Participants will be using closed loop control (CLC) for 2 weeks. Participants will then use closed loop control (CLC) with behavioral adaption module (BAM) for 4 weeks, followed by closed loop control (CLC) adaptive biobehavioral control (ABC) for 16 weeks.
89305908|NCT05610111|Active Comparator|CLC+ABC, then CLC+BAM, then CLC|Participants will be using closed loop control (CLC) with adaptive biobehavioral control (ABC) for 16 weeks. Participants will then use closed loop control (CLC) with behavioral adaptation module (BAM) for 4 weeks, followed by closed loop control (CLC) for 2 weeks.
89305909|NCT05609994|Experimental|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
89305910|NCT05606250|No Intervention|Physical therapy protocol|The physiotherapy protocol is based on manual therapy (passive joint mobilization), myofascial work, active exercise, high intensity neuromuscular electrical stimulation and cryotherapy.
89305911|NCT05606250|Experimental|Ultrasound-Guided Percutaneous Neuromodulation|"Ultrasound-guided percutaneous neuromodulation (e-NMP) is the electrical stimulation by means of a needle with ultrasound guidance of a peripheral nerve at some point in its course or of a muscle at a motor point, with a therapeutic purpose.~The application of the stimulation is carried out with a puncture needle accompanied by a low or medium frequency electrical current.~In e-MPN, a sensory and/or motor response is sought when the peripheral nerve is stimulated, and a motor response is achieved by stimulating the motor point (uncontrolled exaggerated response that normalizes after the application of the technique)."
89305912|NCT05598177|Experimental|Group D|The participant will be infused with dexmedetomidine during anesthesia to protect the myocardium.
89305913|NCT05598177|Placebo Comparator|Group R|The participant will use saline of the same volume as dexmedetomidine as a placebo during anesthesia.
89305914|NCT05592483||HER2+ Cohort|Patients with HER2+ unresectable and/or mBC who are prescribed T-DXd and have received a prior anti-HER2 based regimen.
89305915|NCT05592483||HER2-low cohort|Patients with HER2-low unresectable and/or mBC who are prescribed T-DXd and have received a prior chemotherapy.
89305916|NCT05592145|Other|ViOptix T.Ox|ViOptix T.Ox machine is used to measure the oxygenation of composite tissue.
89305917|NCT05590507|Experimental|Group A/Intervention|Subjects will use mindfulness audio recordings along with their physical activity, and will receive a weekly health coaching phone call along with supplemental educational materials.
89305918|NCT05590507|No Intervention|Group B/Control|Subjects will receive education materials on healthy habits for increasing physical activity based on the National Institutes of Health, and bi-weekly check-in phone call.
89305919|NCT05589363|Active Comparator|ABC block with bupivacaine and liposomal bupivacaine|The study solution used in the active arm will comprise 20 mL of liposomal bupivacaine (266 mg) admixed with 40 mL of 0.25% bupivacaine HCl. The solution will be administered as bilateral parasternal blocks (40 mL) and bilateral epigastric rectus sheath blocks (20 mL).
89305920|NCT05589363|Sham Comparator|ABC block with saline|The study solution used in the active arm will comprise 60 mL of 0.9% saline. The solution will be administered as bilateral parasternal blocks (40 mL) and bilateral epigastric rectus sheath blocks (20 mL).
89305921|NCT05580744|Active Comparator|Traditional occupational therapy|Traditional occupational therapy delivered skill training related to daily living tasks.
89305922|NCT05580744|Active Comparator|Mirror therapy using a mirror box|Exercise of mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise using a mirror box .
89305923|NCT05580744|Experimental|Augmented reality-based mirror therapy|"Exercise of augmented reality-based mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise using an augmented reality mirror therapy system~."
89305924|NCT05576350|Experimental|SAM-Only Comparison Group|Participants in this group will engage only in smartphone-based alcohol monitoring.
89305925|NCT05576350|Experimental|TRAC plus SAM|Participants in this group will receive the Tracking and Reducing Alcohol Consumption (TRAC) intervention and smartphone-based alcohol monitoring.
89305926|NCT05576350|Experimental|TRAC-ER plus SAM|Participants in this group will receive the Tracking and Reducing Alcohol Consumption (TRAC) intervention combined with GPS-based ecological momentary interventions (EMI) and smartphone-based alcohol monitoring.
89305927|NCT05575219|Active Comparator|Usual care (without protocolized clonidine initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
89305928|NCT05575219|Experimental|Intervention (protocolized clonidine initiation)|A protocol for clonidine initiation will be implemented based on the time on dexmedetomidine and the average hourly dose of dexmedetomidine.
89523378|NCT03385369|Experimental|MEDI0382 50 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 50 mcg MEDI0382.
89523379|NCT03385369|Experimental|MEDI0382 100 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
89523380|NCT03385369|Experimental|MEDI0382 150 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 150 mcg MEDI0382.
88806431|NCT02105324|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
89305929|NCT05574699|Active Comparator|Social Risk Score and Closed Loop Referral|Patients in intervention arm will have a social risk score available through the CDS tool, which the provider can review and decide whether the patient needs more assessment. If the patient is identified as with high social needs based on the risk score in the CDS tool, the providers will refer the patient to social workers/ care managers for further in-depth assessment of the participants social needs at HCC. HCC will reach out to the patients over the phone and will perform an in-depth assessment of the patients social needs. If any social needs are identified and patient agrees to address those needs HCC staff will refer the patient to CBOs.
89305930|NCT05574699|Active Comparator|Control|Patients randomized into the control arm will be provided with the standard-of-care screening, assessment, and addressing social needs in the clinic setting. This would not include any automated mechanism of pre-collected data in the EHR. Currently providers on an ad-hoc basis apply a series of needs-assessment tools including one available within JHHS-EHR. Patients in the control arm that are identified as someone with social needs will then be referred to appropriate services through current standard-of-care mechanisms, this may include a sheet of various educational resources, or a list of organizations that can address the identified social need.
89305931|NCT05574075||group of preterm and term children|group 1: preterm children group 2: term children
89305932|NCT05574075||group of different ages of preschool children|group 1: children with age of 25 months-36 months group 2: children with age of 37 months-48 months group 3: children with age of 49 months-60 months
89305933|NCT05573126|Experimental|Module A - EP0062 Dose Finding|Patients are assigned to dose level cohorts to identify MTD and assess safety, tolerability and PK profile.
89305934|NCT05573126|Experimental|Module B - EP0062 Dose level 1|Patients randomised to one of the 2 expansion doses selected from Module A, with up to 30 patients included per dose level, to further characterise the safety and efficacy of EP0062.
89305935|NCT05573126|Experimental|Module B - EP0062 Dose level 2|Patients randomised to one of the 2 expansion doses selected from Module A, with up to 30 patients included per dose level, to further characterise the safety and efficacy of EP0062.
89305936|NCT05572281|Experimental|Sequence A|tasimelteon liquid suspension formulation then tasimelteon capsule formulation
89305937|NCT05572281|Experimental|Sequence B|tasimelteon capsule formulation then tasimelteon liquid suspension formulation
89305938|NCT05568719|Other|Hemophilia A / giroctocogene fitelparvovec|Participants have received treatment with giroctocogene fitelparvovec in a previous study and are not receiving any investigational product in this study
89305939|NCT05568719|Other|Hemophilia B / fidanacogene elaparvovec|Participants have received treatment with fidanacogene elaparvovec in a previous study and are not receiving any investigational product in this study
89305940|NCT05567224||Pilot Group|This group of TennCare recipients will be referred to VUMC primary care services and will be allowed to utilize these services for at least two years. Those referred to VUMC primary care services will be those who belong to the two of state's three Medicaid Managed Care plans who have agreed to participate in this pilot.
89305941|NCT05567224||Control Group|This group of TennCare recipients will not be referred to VUMC primary care services and will receive care as usual. Those not referred to VUMC primary care services will be those who belong to one of the state's three Medicaid Managed Care plans who has not agreed to participate in this pilot.
89305942|NCT05567120|Other|PATH-Care|Problem Adaptation THerapy (PATH) adapted for caregivers along with tablet based exercises to enhance and reinforce the therapy sessions.
89305943|NCT05563506|Experimental|Healthy Kids +|Three times a week for 30 weeks with each session lasting 1 hour.
89305945|NCT05554380|Experimental|Treatment (paclitaxel, ipatasertib)|Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up.
89305946|NCT05554354|Experimental|Cohort I (Arm I) (fulvestrant, binimetinib)|Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
89305947|NCT05554354|Active Comparator|Cohort I (Arm II)|Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone are asked to reaffirm their willingness to enroll in cohort II. Patients not willing to transition to cohort II continue further therapy as clinically indicated. Patients undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
89305948|NCT05554354|Experimental|Cohort II (fulvestrant, binimetinib)|Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan and tumor biopsy during screening and on study.
89305949|NCT05547451||Trial population|Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes.
89305950|NCT05544396|Experimental|probiotic group|Routine eradicate treatment H. pylori, and probiotics (2 packs per day) for 6 months.
89305951|NCT05544396|Placebo Comparator|control group|Only routine eradicate treatment H. pylori.
89305952|NCT05539794|Experimental|Intervention|The intervention group will follow a physical exercise and lifestyle counselling program.
89305953|NCT05539794|No Intervention|Control|Standard care
89305954|NCT05538624|Experimental|Part 1 escalating AVB-001 between 0.6 and 3.6 ug hIL-2/kg/day; and Part 2 AVB-001 at the MTD/RP2D|"Part 1: one of four ascending doses of AVB-001 planned for IP, single dose administration at each dose level cohort of the Dose Escalation Phase.~Part 2: a single dose of AVB-001 at the MTD/RP2D level (determined in Part 1) to be further evaluated in the Dose Expansion Phase."
89305955|NCT05537233|Experimental|Semaglutide|Participants in this group will receive semaglutide once weekly injection in addition to their standard closed-loop therapy
89305956|NCT05537233|Placebo Comparator|Control|Participants in this group will receive placebo once weekly injection in addition to their standard closed-loop therapy
89305957|NCT05537103||1|15-17 year olds from US general population
89305958|NCT05530486|Placebo Comparator|Comparador de placebo: CC + curativo|The group will receive placebo LASER application associated with Helianthus annuus oil dressing.
89305959|NCT05530486|Active Comparator|Comparador ativo: LG1 + curativo|The group will receive application of LASER Gallium Arsenide (GasAs) 660 nm 4 J/cm² associated with Helianthus annuus oil dressing.
89305960|NCT05530486|Active Comparator|Comparador ativo: LG2 + curativo|The group will receive application of LASER Gallium Arsenide (GaAs) 660 nm 8 J/cm² associated with Helianthus annuus oil dressing.
89305961|NCT05530486|Active Comparator|Comparador ativo: LG3 + curativo|The group will receive application of LASER Gallium Arsenide (GaAs) 660 nm 12 J/cm² associated with Helianthus annuus oil dressing.
89305962|NCT05530460|Experimental|OCT Imaging|
89305963|NCT05523570|Experimental|20 mg HNC364|"pre-study will recruit 2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension.~Then 8 subjects will be admitted to the clinical study center on Day -1 and receive a single intramuscular dose of 20 mg HNC364 on Day 1, and undergo timed safety, PK, and PD assessments for 80 days post dose."
89305964|NCT05523570|Experimental|40 mg HNC364|8 subjects will be admitted to the clinical study center on Day -1 and receive a single intramuscular dose of 40 mg HNC364 on Day 1, and undergo timed safety, PK, and PD assessments for 29 days post dose.
89305965|NCT05523570|Experimental|60 mg HNC364|8 subjects will be admitted to the clinical study center on Day -1 and receive a single intramuscular dose of 60 mg HNC364 on Day 1, and undergo timed safety, PK, and PD assessments for 60 days post dose.
89305966|NCT05523570|Experimental|80 mg HNC364|8 subjects will be admitted to the clinical study center on Day -1 and receive a single intramuscular dose of 80 mg HNC364 on Day 1, and undergo timed safety, PK, and PD assessments for 60days post dose.
89305967|NCT05519982|Experimental|Sleep Treatment Education Program (STEP-1)|"Prior to being randomized, all participants will complete health questionnaires.~Participants assigned to the Sleep Treatment Education Program (STEP-1) group will receive online instruction on making changes to sleep habits and health behaviors.~Participants will be contacted at 1 month and 2 months after the education session to complete follow up online questionnaires."
89305968|NCT05519982|Active Comparator|Enhanced Usual Care: Relaxation Education|"Prior to being randomized, all participants will complete health questionnaires.~Participants assigned to the Enhanced Usual Care group will receive information on relaxation techniques to improve sleep~Participants will be contacted at 1 month and 2 months after the education session to complete follow up online questionnaires."
89305969|NCT05517109|No Intervention|Control group. Standart care|Standart hemodynamic goals: systolic blood pressure 160-185 mmHg in first 24 hours after intravenous thrombolysis
89305970|NCT05517109|Experimental|Systolic blood pressure ≤ 160 mmHg|Lower hemodynamic goals: systolic blood pressure ≤ 160 mmHg in first 24 hours after intravenous thrombolysis
89305971|NCT05512819|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (20vPnC)
89305972|NCT05512819|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine (13vPnC)
89305973|NCT05496738|Experimental|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously
89305974|NCT05496738|Experimental|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously
89305975|NCT05496738|Placebo Comparator|Intravenous placebo|Placebo will be administered intravenously
89305976|NCT05496738|Placebo Comparator|Subcutaneous Placebo|Placebo will be administered subcutaneously
89305977|NCT05493709|Experimental|FP-001 42 mg|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
89305978|NCT05490550|Active Comparator|COAST-enhanced CBTI|Patients randomized to COAST will receive CBTI via the COAST platform, with the assistance of a licensed clinician via NOCTEM's digital sleep hub. Participants will utilize the COAST patient app on their smartphone for engagement in insomnia treatment and receipt of clinician's recommendations. COAST clinicians will utilize the COAST web-based portal for adherence monitoring, progress review, and for providing personalized insomnia treatment recommendations.
89305979|NCT05490550|Active Comparator|Military Treatment Facility Insomnia Care As Usual|Patients randomized to the ICAU arm will receive insomnia care as usual by a certified clinician at their respective site, according to current referral and treatment practices.
89305980|NCT05471791|Experimental|App group|Participants will use the Back2Play App to support them in following the guidelines for recovery from concussion
89305981|NCT05471791|No Intervention|Usual Care|Participants will receive usual care which often means they are provided concussion recovery guidelines in handout format and receive whatever follow up is deemed necessary by treating physician
89305982|NCT05458297|Experimental|Cohort A|Participants will receive zilovertamab vedotin 2.5 mg/kg every 3 weeks (Q3W) until disease progression or discontinuation.
89305983|NCT05458297|Experimental|Cohort B|Participants will receive zilovertamab vedotin 2.5 mg/kg every 3 weeks (Q3W) until disease progression or discontinuation.
89305984|NCT05458297|Experimental|Cohort C|Participants will receive zilovertamab vedotin every 3 weeks (Q3W) combined with nemtabrutinib daily until disease progression or discontinuation.
89305985|NCT05458297|Experimental|Cohort D|Participants will receive either zilovertamab vedotin 2.5 mg/kg every 3 weeks (Q3W) or 2.0 mg/kg with infusions on Days 1 and 8 of each 3 week cycle (Q2/3W) until disease progression or discontinuation.
89305986|NCT05458297|Experimental|Cohort E|Participants will receive either zilovertamab vedotin 2.5 mg/kg every 3 weeks (Q3W) or 2.0 mg/kg with infusions on Days 1 and 8 of each 3 week cycle (Q2/3W) until disease progression or discontinuation.
89305987|NCT05458297|Experimental|Cohort F|Participants will receive either zilovertamab vedotin 2.5 mg/kg every 3 weeks (Q3W) or 2.0 mg/kg with infusions on Days 1 and 8 of each 3 week cycle (Q2/3W) until disease progression or discontinuation.
89305988|NCT05452941||Case|Cases will be defined as participants hospitalized for RAD+CAP in whom the 7 additional serotypes in 20vPnC beyond 13vPnC plus 15C are identified.
89305989|NCT05452941||Control|All other participants who meet study inclusion criteria but for whom 20vPnC serotypes are not identified from any source and all other RAD+CAP of non-pneumococcal etiologies will serve as test-negative controls.
89305990|NCT05447286|Placebo Comparator|Placebo + Oxycodone|Participants will receive placebo with + 15 mg oxycodone then placebo + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
89305991|NCT05447286|Active Comparator|NYX-783: 50 mg dose + Oxycodone|Participants will receive NYX-783 50 mg dose with + 15 mg oxycodone then NYX-783 50 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
89305992|NCT05447286|Active Comparator|NYX-783: 150 mg dose + Oxycodone|Participants will receive NYX-783 150 mg dose with + 15 mg oxycodone then NYX-783 150 mg + 30 mg oxycodone in separate inpatient randomized sessions in this, cross-over study over 6 experimental sessions.
89305993|NCT05436691|Experimental|Information and Coping with Anxiety Training Intervention|The intervention group received information and coping with anxiety training by an instructor.
89305994|NCT05436691|No Intervention|Control|No intervention was applied to the control group.Data were collected from the control group simultaneously with the study group.
89305995|NCT05433844|Other|Group 1|Test Drug for Period I Reference Drug for Period II
89305996|NCT05433844|Other|Group 2|Reference Drug for Period I Test Drug for Period II
89305997|NCT05432232|Experimental|HistoSonics Investigational System|
89305998|NCT05426200|Experimental|Health Coaching|Patient will work with a health coach to improve self-management skills, and receive usual pre-transplant education.
89305999|NCT05426200|No Intervention|Control|Patients will receive usual pre-transplant education.
89306000|NCT05425030|Experimental|Free LSSS Arm|Participants will receive 6 months of free low-sodium salt by delivery from a community health worker. In addition, the same educational information as provided in Arm 2 (Information Only Arm, below) will be provided.
89306001|NCT05425030|Active Comparator|Information Only Arm|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
89306002|NCT05425030|No Intervention|No Intervention|Participants will not receive any intervention of any sort.
89306003|NCT05423028|Active Comparator|Dextrose|
89306004|NCT05423028|Experimental|Vitamin B12|
89306005|NCT05423028|Experimental|Dextrose + Vitamin B12|
89306006|NCT05419024|Experimental|ATI|Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
89306007|NCT05419024|No Intervention|Continue ART|Participants will continue on their pre-study ART throughout the trial.
89306008|NCT05408624||prospective group - ultrasound transvaginal drainage|Patients with TOA with ultrasound-guided transvaginal drainage with outpatient management
89306009|NCT05408624||retrospective group - ultrasound transvaginal drainage|Patients with TOA in 2016, 2017 and 2018 with ultrasound-guided transvaginal drainage in conventional hospitalization
89306010|NCT05408624||retrospective group - laparoscopy|Patients with TOA in 2016, 2017 and 2018 with laparoscopy in conventional hospitalization
89306011|NCT05406401|Experimental|Zilovertamab Vedotin + R-CHP: Dose Escalation/Confirmation|Participants in the dose escalation/confirmation phase receive a dose level of zilovertamab vedotin (from 1.5 mg/Kg up to 2.5 mg/Kg) plus 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar (truxima) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 8 cycles (up to approximately 5.5 months). Participants also receive 100 mg prednisone or prednisolone per day during Days 1-5 of each 21-day cycle for up to 8 cycles (up to approximately 5.5 months).
89306012|NCT05406401|Experimental|Zilovertamab Vedotin + R-CHP: Efficacy Expansion|Participants in the efficacy expansion phase receive the RP2D of zilovertamab vedotin plus 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar (truxima) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 8 cycles (up to approximately 5.5 months). Participants also receive 100 mg prednisone or prednisolone per day during Days 1-5 of each 21-day cycle for up to 8 cycles (up to approximately 5.5 months).
89306013|NCT05403476|Experimental|FE 999049 (Follitropin Delta)|
89306014|NCT05403476|Placebo Comparator|Placebo|
89306015|NCT05400239||Cohort 1|Surgically resectable disease, followed by adjuvant radiotherapy +/- chemotherapy
89306016|NCT05400239||Cohort 2|Primary radiotherapy +/- concurrent chemotherapy
89306017|NCT05400239||Cohort 3|Recurrent or metastatic HNSCC undergoing platinum based chemotherapy +/- cetuximab
89306018|NCT05400005|No Intervention|Normal protein diet (control)|"Subjects are to consume normal-protein diet based on the My Healthy Plate diet (launched by Health Promotion Board of Singapore) for the duration of the 16-week study."
89306019|NCT05400005|Experimental|High protein diet (soy)|"Subjects are to consume higher-protein diet by following the My Healthy Plate diet (launched by Health Promotion Board of Singapore) and 20g of soy protein isolate for the duration of the 16-week study."
89306020|NCT05400005|Experimental|High protein diet (Micellar Casein)|"Subjects are to consume higher-protein diet by following the My Healthy Plate diet (launched by Health Promotion Board of Singapore) and 20g of micellar casein isolate for the duration of the 16-week study."
89306021|NCT05398991|Experimental|Experimental Arm|Subjects in experimental group will be implanted with the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.
89523381|NCT03385369|Experimental|Placebo Chinese Descent|Participants of Chinese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
89523382|NCT03385369|Experimental|MEDI0382 100 mcg Chinese Descent|Participants of Chinese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
89523383|NCT03381365|Experimental|investigational arm|
89306022|NCT05389800|Experimental|Aerobic Exercise (Moderate-Intensity Interval Training)|"Preoperative program: 120 seconds of moderate intensity exercise (64-76% HRmax, 12-13 in rate of perceived exertion (RPE), based on ACSM) and 120 seconds of passive rest in a total of 4 cycles. The basic program will last about 14 minutes, plus 6 minutes for warm-up and recovery. The program will be performed twice a day.~Postoperative program: 120 seconds of moderate intensity exercise (64-76% HRmax, 12-13 in RPE, based on ACSM) and 120 seconds of passive rest in a total of 8 cycles. The basic program will last about 30 minutes, plus 6 minutes for warm-up and recovery. The program will be performed 3 times a week for a total of 8 weeks."
89306023|NCT05389800|No Intervention|Control|"Preoperatively: mild intensity activities focusing on memory and attention performing with upper limb movements using the interactive platform Kinems. The program will last about 20 minutes. To ensure that the intensity of activities is mild, there will be a simultaneous recording of heart rate, while at the end of each session the RPE scale will be evaluated.~Postoperatively: none"
89306024|NCT05388916||Cosentyx|Pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx
89306025|NCT05383183|Experimental|Choline Alfoscerate 1,200mg + Donepezil 5mg or 10mg|Oral administration of choline alfoscerate 400mg TID, donepezil QD (evening) for 48 weeks, no dosage change during trial period
89306026|NCT05383183|Placebo Comparator|Placebo + Donepezil 5mg or 10mg|Oral administration of placebo TID, donepezil QD (evening) for 48 weeks, no dosage change during trial period
89306027|NCT05382299|Experimental|Sacituzumab Govitecan-hziy (SG)|Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle.
89306028|NCT05382299|Active Comparator|Treatment of Physician's Choice (TPC)|"Participants will receive TPC determined prior to randomization from 1 of the 3 allowed regimens:~Paclitaxel 90 mg/m^2 on Days 1, 8, and 15 of a 28-day cycle~Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of a 28-day cycle~Gemcitabine 1000 mg/m^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of a 21-day cycle"
89306029|NCT05374512|Experimental|Dato-DXd|Arm 1: Dato-DXd
89306030|NCT05374512|Active Comparator|Investigator's Choice of Chemotherapy (ICC)|"Arm 2:~If no prior taxane, or prior taxane in the (neo)adjuvant setting and DFI > 12 months, paclitaxel or nab-paclitaxel~If prior taxane and DFI ≤ 12 months: capecitabine, carboplatin, or eribulin."
89306031|NCT05368129|Experimental|POT group|A total of 24 patients are assigned to POT group after randomization schedule.
89306032|NCT05368129|Active Comparator|NCB group|A total of 24 patients are assigned to NCB group after randomization schedule.
89306033|NCT05366712|Experimental|Trident® II HA coated shells|Patients will receive a Trident® II acetabular component as part of primary total hip arthroplasty at the study centre. This component is CE marked and widely available for use by UK surgeons. The Trident® II shells are HA coated, cementless, press-fit acetabular shells composed of a Titanium (Ti-6Al-4V) substrate featuring a CpTi roughened surface with PureFix™ HA.
89306034|NCT05365711||Pregnant women|Microbiological samples are collected from the pregnant women in the mid-pregnancy and during the delivery. Patient records of these women and newborns are investigated for any infections or complications during and after the delivery.
89306035|NCT05365711||Partners|Partners of the pregnant women will be studied to understand the household transmission of studied bacteria and possible risk factors for carriage.
89306036|NCT05365282||Group A|Access pathway a. radialis (right or left) and neurophysiological measurements of the same hand (ipsilateral intervention group).
89306037|NCT05365282||Group B|Access pathway a.radialis (right or left) and neurophysiological measurements of opposite hand (contralateral intervention group).
89306038|NCT05361707|Experimental|Tasimelteon|Drug: Tasimelteon
89306039|NCT05358951|Active Comparator|NON-COACHING CONDITION STEP-YA|"Participants will receive a single online education session and complete online questionnaires then be randomized to not receive additional coaching support sessions.~Participates will also complete follow up questionaires at 4 and 8 weeks post baseline."
89306040|NCT05358951|Experimental|COACHING CONDITION STEP-YA|"Participants will receive a single online education session and complete online questionnaire then be randomized to receive 2 individualized remote coaching sessions.~Participates will also complete follow up questionaires at 4 and 8 weeks post baseline."
89306041|NCT05344469||Ofatumumab|Patients treated with ofatumumab
89306042|NCT05344469||Standard of Care (SoC)|Patients treated with either interferon β1 (IFN-β1) or glatiramer acetate (GA)
89306043|NCT05344365|Experimental|Iloperidone (Cohort 1)|
89306044|NCT05344365|Experimental|Iloperidone (Cohort 2)|
89306045|NCT05342636|Experimental|Pembrolizumab plus chemotherapy|Participants will receive pembrolizumab intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
89306046|NCT05342636|Experimental|Coformulation Favezelimab/Pembrolizumab plus Chemotherapy|Participants will receive coformulation of favezelimab/pembrolizumab administered intravenously plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
89306047|NCT05342636|Experimental|Pembrolizumab plus MK-4830 plus Chemotherapy|Participants will receive pembrolizumab intravenously plus MK-4830 plus chemotherapy (investigator's choice of irinotecan or paclitaxel) at specified doses on specified days for a total treatment duration of up to approximately 2 years.
89306048|NCT05342636|Experimental|Pembrolizumab plus MK-4830 plus lenvatinib|Participants will receive pembrolizumab intravenously plus MK-4830 plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.
89306049|NCT05336903|Experimental|APP-led model of care for chronic pain management|The APP-led model of care involves integrating an APP as the first point of contact within an interprofessional chronic pain clinic setting. This is in contrast to the usual physician- or nurse practitioner-led model of care.
89306050|NCT05330338|Other|Congenital heart disease|
89306051|NCT05328713||Prospective group with perinatally acquired HIV infection from Duke University Health System clinics|
89306052|NCT05328713||Control retrospective group|A retrospective age- and sex-matched HIV-uninfected comparator group from Duke University Health System (DUHS) electronic health record (EHR) and imaging database systems
89523384|NCT03381209|Experimental|Group A|Sugammadex given in a dose of 2mg/kg based on ideal body weight
89523385|NCT03381209|Experimental|Group B|Sugammadex given in a dose of 2mg/kg based on adjusted body weight
89306053|NCT05327010|Experimental|Treatment (ZEN-3694, talazoparib)|Patients receive ZEN-3694 PO QD and talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo diagnostic imaging throughout the study and undergo blood sample collection and tumor biopsy while on study.
89306054|NCT05324358|Experimental|NTM-001 Treatment Arm|"NTM-001 loading dose of 12.5 mg administered over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mg/h for 24h, by a pre-programmed infusion pump.~Subjects will also receive placebo to IV Morphine (injections)."
89306055|NCT05324358|Active Comparator|Morphine Treatment Arm|"A single IV morphine bolus (4 mg) every 4h for up to 24h.~Subjects will also receive placebo to NTM-001."
89306056|NCT05324358|Placebo Comparator|Placebo Treatment Arm|"Subjects randomized will receive placebos of both active treatments concomitantly.~Placebo to NTM-001: Placebo loading dose applied over approximately 60 seconds, followed by a continuous IV infusion at a rate of 3.5 mL/h for 24h by a pre-programmed infusion pump.~Placebo to IV morphine injections: A single IV placebo bolus every 4h for up to 24h."
89306057|NCT05320614|Experimental|case 1|Case Group:Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
89306058|NCT05320614|Experimental|control 1|Control Group: Explaining the routine care given in the service by the pediatric surgery nurse to the child and parent in the control group.
89306059|NCT05313529|Experimental|Liraglutide|"Liraglutide will be titrated from 0.6mg/day to a final dose 1.8mg/day during the first 2 weeks, if well tolerated.~Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but liraglutide could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
89306060|NCT05313529|Experimental|Empagliflozin|"Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study.~Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but Empagliflozin could not be adjusted. If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
89306061|NCT05313529|Experimental|linagliptin|"linagliptin will be initiated at 5mg/ day every morning. Meanwhile, All patients will also continue on their existing dose and regimen of metformin throughout the study. Visits at 8-week intervals will be performed to evaluate the safety of drugs. Metformin dose can be reduced in response to hypoglycaemia, but linagliptin could not be adjusted.~If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study."
89306062|NCT05297279|Active Comparator|Active/Intervention Treatment Arm|Participants will receive weekly food voucher (with a specified amount) for home delivery of omega-3 rich food (with a minimum of 4 grams of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in the weekly food order) and personalized dietary coaching. Participant will also receive a single 1-hour one-on-one session (dietary motivational coaching) by a dietary coach to guide participants to consume at least 500 mg of EPA+DHA daily at the beginning of the study, followed by weekly 30-minute calls during the 12-week intervention study period.
89306063|NCT05297279|Placebo Comparator|Control Treatment Arm|Participants will receive a voucher of weekly food voucher (with a specified amount) for home delivery. Participants in the control arm will also receive a single one-on-one session by a trained research staff member at the beginning of the study, which will be followed by weekly 30-minute calls with the participant during the 12-week intervention study period. The trained research staff member will assist with the online ordering of foods and will provide calls centered on general publicly available, guideline-based dietary recommendations without tailoring or personalization (no dietary coaching). This group will not receive guidance specifically about omega-3 fatty acids.
89306064|NCT05296681|Experimental|NM108 Drinks|"NBT-NM108 Drinks four times daily before meals and 2 hours after dinner for 56 days.~Beginning 5 days before starting chemotherapy, patients receive NBT-NM108 PO QID for 56 days. Patients receive irinotecan-based chemotherapy per standard of care."
89306065|NCT05296681|No Intervention|No Microbiome Support|"No microbiome~Patients receive irinotecan-based chemotherapy per standard of care."
89306066|NCT05279001|Experimental|Jaktinib|
89306067|NCT05270213|Experimental|Treatment Group A-1|For Treatment Group A-1, a cohort of three (3) subjects will be dosed at the starting dose of 100 mg twice a day (BID) of RBS2418. Subsequent subjects will then be enrolled in serial, three (3) subject cohorts, with 100% dose increments (doubling the dose) until 800 mg BID
89306068|NCT05270213|Experimental|Treatment Group A-2|For Treatment Group A-2, a cohort of three (3) subjects will be dosed at the starting dose of 100 mg twice a day (BID) of RBS2418 in combination with pembrolizumab 200 mg IV (administered on Day 1 and every 3 weeks). Subsequent subjects will then be enrolled in serial, three (3) subject cohorts, with 100% dose increments (doubling the dose) until 800 mg BID
89306069|NCT05270213|Experimental|Treatment Group B|After dose escalation phase is completed in both monotherapy and combination therapy setting (A-1 and A-2), an expansion treatment group will be enrolled, and subjects (n=20- 40) will be treated with a fixed dose of RBS2418 to be selected by the Sponsor in consultation with the SRC and after reviewing the totality of the dose escalation data both as monotherapy and combination therapy.
89306070|NCT05264714|Experimental|Cluster Headache Subjects|Subjects with cluster headaches will track their headaches for a one-week baseline headache diary. After establishing the baseline headache frequency, severity, and abortive medicine use, subjects will be asked to start their first dose of rimegepant with their next moderate to severe cluster headache.
89306071|NCT05252364|Experimental|Part 1 - Dose Escalation, 25mg/d (Cohort 1)|Oral tablet(s), once daily in 28-day cycles
89306072|NCT05252364|Experimental|Part 1 - Dose Escalation 100mg/d (Cohort 2)|Oral tablet(s), once daily in 28-day cycles
89306073|NCT05252364|Experimental|Part 1 - Dose Escalation 200mg/d (Cohort 3)|Oral tablet(s), once daily in 28-day cycles
89306074|NCT05252364|Experimental|Part 1 - Dose Escalation 300mg/d (Cohort 4)|Oral tablet(s), once daily in 28-day cycles
89306075|NCT05252364|Experimental|Part 1 - Dose Escalation 400mg/d (Cohort 5)|Oral tablet(s), once daily in 28-day cycles
89306076|NCT05252364|Experimental|Part 1 - Dose Escalation 500mg/d (Cohort 6)|Oral tablet(s), once daily in 28-day cycles
89306077|NCT05252364|Experimental|Part 2 - Dose Expansion|Oral tablet(s), once daily in 28-day cycles
89306078|NCT05247567|Other|First year students|Students in their first year of Hairdressing School
89306079|NCT05247567|Other|Third year students|Students in their third year of Hairdressing School
89306080|NCT05246397|Experimental|Cardiac surgery patients|Patients undergoing cardiac surgery
89306081|NCT05239741|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years).
89306082|NCT05239741|Active Comparator|Standard of Care Chemotherapy|Participants receive 1 of 6 possible standard chemotherapy regimens at the discretion of the investigator: (1) mFOLFOX6; (2) mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 14-day cycle (Q2W); (3) mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly Q2W; (4) FOLFIRI; (5) FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 Q2W; OR (6) FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly Q2W. Participants with documented disease progression following chemotherapy can receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years).
89306083|NCT05237388|Experimental|Baricitinib|Participants will take one pill of Baricitinib daily with their regular medications.
89306084|NCT05237388|Placebo Comparator|Placebo|Participants will take a Baricitinib placebo pill matching Baricitinib daily with their regular medications.
89306085|NCT05228457|Active Comparator|Active Transcranial Magnetic Stimulation|Active Intensive iTBS involves intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over the left dorsal lateral prefrontal cortex (L-DLPFC).
89306086|NCT05228457|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham Intensive iTBS involves using the coil's electric stimulation functionality that allows for the delivery of a brief electric pulse to the scalp simultaneous to the TMS pulse, which mimics the scalp sensation from active stimulation.
89306087|NCT05217446|Experimental|Arm A: encorafenib, cetuximab and pembrolizumab|Participants receive encorafenib orally + cetuximab IV + pembrolizumab IV.
89306088|NCT05217446|Active Comparator|Arm B: pembrolizumab|Participants receive pembrolizumab IV.
89306089|NCT05217108|Other|Fit Bit (Study Groups)|Participants wear a Fitbit every day for 8 weeks to record the number of steps you take
89306090|NCT05216250|Experimental|BOTOX/BOTOX Unilateral|Participants will receive BOTOX in Cycle 1 and Cycle 2 and unilateral BOTOX in Cycle 3
89306091|NCT05216250|Experimental|BOTOX/BOTOX Bilateral|Participants will receive BOTOX in Cycle 1 and Cycle 2 and bilateral BOTOX in Cycle 3
89306092|NCT05216250|Experimental|Placebo/BOTOX Unilateral|Participants will receive placebo in Cycle 1 and Cycle 2 followed by unilateral BOTOX in Cycle 3.
89306093|NCT05216250|Experimental|Placebo/BOTOX Bilateral|Participants will receive placebo in Cycle 1 and Cycle 2 followed by bilateral BOTOX in Cycle 3.
89306094|NCT05211323|Experimental|Arm A (atezolizumab, bevacizumab, gemcitabine, cisplatin)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV on days 1 and 8. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI throughout the trial. Patients undergo blood specimen collection on study.
89306095|NCT05211323|Active Comparator|Arm B (atezolizumab, gemcitabine, cisplatin)|Patients receive atezolizumab IV over 30-60 minutes on day 1, and gemcitabine IV over 30 minutes and cisplatin IV on days 1 and 8. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or magnetic resonance imaging MRI throughout the trial. Patients undergo blood specimen collection on study.
89306096|NCT05196269|Experimental|Artificial Intelligence and Digital Health Arm|Using an Artificial Intelligence approach integrated in a cloud-based healthcare platform CANKADO to give the patient complete information about the proposed type of locoregional treatment and access to photographs and data of patients with similar characteristics previously treated with the same technique. All interaction will be through the CANKADO Platform.
89306097|NCT05196269|Other|Control Comparator|The standard approach of proposing patients for locoregional treatment with or without printed or digital materials and hypothetic visualization of results.
89306098|NCT05195814||Effectiveness of tofacitinib|Participants receiving tofacitinib will be included to assess the effectiveness of tofacitinib overall and stratified by key variables of interest
89306099|NCT05190094|Experimental|Palbociclib + Aromatase Inhibitors (AI) (Letrozole or Anatrozole)|The participants will receive a combination of: Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os). This combination will continue until progression for an average duration of 2 years.
89306100|NCT05183243|Experimental|Monotherapy Dose Escalation.|Treatment with GH21 alone, conducted until disease progression, intolerance or end of study.
89306101|NCT05172570|No Intervention|No Gabapentin|Patients will not receive any gabapentin postoperatively after open thoracotomy
89306102|NCT05172570|Active Comparator|300 mg Gabapentin 3X per day|Patients will receive 300mg gabapentin 3x a day after open thoracotomy
89306103|NCT05172570|Active Comparator|300 mg Gabapentin once per day at night|Patients will receive 300mg gabapentin once a day at night after open thoracotomy
89306104|NCT05171816|Experimental|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
89523386|NCT03381209|Experimental|Group C|Sugammadex given in a dose of 2mg/kg based on actual body weight
89306105|NCT05171816|Placebo Comparator|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
89306106|NCT05170438|Experimental|Lenvatinib 12 or 16 mg/day orally,D28; Paclitaxel 80 mg/m2 in 250-500 mL of NS, IV D 1, 8, 15;|one arm Lenvatinib 16 or 12 mg/day orally day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15;
89306107|NCT05156073|Experimental|Intervention|"The intervention consists of providing educational materials on deprescribing to:~Patient and care partner cohort~Primary care physician cohort"
89306108|NCT05147805|Experimental|Treprostinil Palmitil Inhalation Powder|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be up-titrated to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
89306109|NCT05147805|Placebo Comparator|Placebo|Participants will be administered a placebo matching TPIP once per day for 16 weeks.
89306110|NCT05139459||Participants with sepsis|
89306111|NCT05139017|Experimental|ZV + R-GemOx (Part 1)|Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m^2, Gemcitabine 1000 mg/m^2 and Oxaliplatin 100 mg/m^2 (R-GemOx) given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles.
89306112|NCT05139017|Experimental|ZV + R-GemOx (Part 2)|Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
89306113|NCT05139017|Active Comparator|R-GemOx (active control for Part 2)|Participants will receive R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
89306114|NCT05139017|Experimental|ZV + BR (Part 2)|Using RP2D from Part 1, participants will receive ZV plus Rituximab 375 mg/m^2, given intravenously on Day 1 and Bendamustine 90 mg/m^2 given intravenously on Day 1 and 2, of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
89306115|NCT05139017|Active Comparator|Bendamustine Rituximab (BR)|Participants will receive Rituximab 375 mg/m^2, given intravenously on Day 1 Bendamustine 90 mg/m^2 given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
89306116|NCT05139017|Experimental|ZV + BR (Part 1)|Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m^2, Bendamustine 90 mg/m^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles.
89306117|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 1|Participants will receive single intramuscular (IM) injection of mRNA-1283 at Dose Level 1 on Day 1.
89306118|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 2|Participants will receive single IM injection of mRNA-1283 at Dose Level 2 on Day 1.
89306119|NCT05137236|Experimental|Part A: mRNA-1283 Dose Level 3|Participants will receive single IM injection of mRNA-1283 at Dose Level 3 on Day 1.
89306120|NCT05137236|Experimental|Part A: mRNA-1283.211 Dose Level 1|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 1 on Day 1.
89306121|NCT05137236|Experimental|Part A: mRNA-1283.211 Dose Level 2|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 2 on Day 1.
89306122|NCT05137236|Active Comparator|Part A: mRNA-1273|Participants will receive single IM injection of mRNA-1273 on Day 1.
89306123|NCT05137236|Experimental|Part B: mRNA-1283.529 Dose Level 1|Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 1 on Day 1.
89306124|NCT05137236|Experimental|Part B: mRNA-1283.529 Dose Level 2|Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 2 on Day 1.
89306125|NCT05136196|Experimental|Treatment (nivolumab and cabozantinib)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cabozantinib PO daily. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans and collection of blood samples throughout the trial. Patients undergo a tumor biopsy during screening and optionally during follow-up.
89306126|NCT05134233|Experimental|Parameter Trials|Approximately 36 parameter combinations will be tested per study session, expected 6 sessions of trials. Response recorded using TMS and EMG.
89306127|NCT05129761||• Patient with a clinical history of cough|Syrup Hydryllin ( Syrup Hydryllin & Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan & Diphenhydramine) in the symptomatic management of cough in routine practice by physicians. Subjects will be observed for overall safety and effectiveness of study drug from visit 1 (baseline visit, screening, and start of treatment), to visit 2 (Week 1-2, end of treatment) in the routine practice.
89306128|NCT05128006||In-person new VA dermatology patients|In-person dermatology patients that are new patients at three facilities
89306129|NCT05128006||New patient consultative Teledermatology users|New patient consultative Teledermatology users at three facilities
89306130|NCT05128006||New patient Mobile teledermatology users|New patient Mobile teledermatology users at three facilities
89306131|NCT05128006||In-person new patient in Community Care|In-person new patient in Community Care
89306132|NCT05125328|Experimental|neurosurgery with fixation|
89306133|NCT05114746|Experimental|177Lu-PSMA-617|PSMA positivity will be confirmed by PET/CT scan after administration of 68Ga-PSMA-11. All eligible participants will receive recommended dose of 177Lu-PSMA-617 via intravenous injection every 6 weeks (+/- 1 week) for a maximum of 6 cycles.
89523387|NCT03461887|Experimental|Exercise intervention|Home-based, minimal equipment exercise training program.
89306134|NCT05111574|Experimental|Arm 1 (nivolumab, cabozantinib)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo stool sample collection at baseline, and blood and tissue sample collection at baseline and on the trial.
89306135|NCT05111574|Active Comparator|Arm 2 (nivolumab, placebo)|Patients receive nivolumab IV over 30 minutes on day 1 and placebo PO QD of each cycle. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo stool sample collection at baseline, and blood and tissue sample collection at baseline and on the trial.
89306136|NCT05111574|Experimental|Arm 3 (nivolumab, cabozantinib)|Patients receive nivolumab IV over 30 minutes and cabozantinib PO QD of each cycle. Treatment repeats every 28 days for up to 26 cycle in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated throughout the trial. Patients may undergo CT, MRI, or PET/CT at baseline, CT and MRI may be repeated every 6 months on study. Additionally, patients may undergo stool sample collection at baseline, and blood and tissue sample collection at baseline and on the trial.
89306137|NCT05107492|Experimental|Cohort 1|12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 450mg and placebo arms.
89306138|NCT05107492|Experimental|Cohort 2|12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 150mg and placebo arms.
89306139|NCT05103215|Experimental|lidocaine group|Patients in the lidocaine group receive an intravenous injection of 1.5 mg/kg Lidocaine HCl 2% at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
89306140|NCT05103215|Placebo Comparator|control group|Patients in control group receive the same volume of saline injection.
89306141|NCT05098613|Experimental|CD19x22 CAR T Cell Infusion|Lymphodepleting chemotherapy following by infusion of CD19x22 CAR T Cells
89306142|NCT05093881|Experimental|Cellgram-LC|Patients with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.
89306143|NCT05086731|Experimental|Group I (SMRxT smart pill bottle)|Patients receive a SMRxT smart pill bottle, report symptoms weekly, and receive reminders for missing or incorrect dose for standard of care 3-week capecitabine/Xeloda treatment cycles.
89306144|NCT05086731|Active Comparator|Group II (standard of care)|Patients receive a SMRxT smart pill bottle and standard of care.
89306145|NCT05083975|Experimental|Buzzy System|Maxillary anesthetic infiltration injection using a conventional 2-ml syringe and a short needle after activating the buzzy device extra orally proximal to the site of injection for 30-60 seconds.
89306146|NCT05083975|Active Comparator|Control|Maxillary anesthetic infiltration injection using a conventional 2-ml syringe and a short needle after application of 20% Benzocaine topical anesthestic gel.
89306147|NCT05081921|Experimental|MesoCellA-Ortho - treated Patients with type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
89306148|NCT05081921|Active Comparator|Control Patients with type 2 diabetes and obesity|The patients with osteoarthritis of knee, suffering also with type 2 diabetes and obesity (BMI > 30) will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
89306149|NCT05081921|Experimental|MesoCellA-Ortho - treated Patients without type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
89306150|NCT05081921|Active Comparator|Control Patients without type 2 diabetes and with obesity|The patients with osteoarthritis of knee, suffering also with obesity (BMI > 30), but with no type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
89306151|NCT05081921|Experimental|MesoCellA-Ortho - treated Patients without type 2 diabetes and without obesity|The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be treated with MesoCellA-Ortho (single intraarticular application of 20 mln of AT-MSCs resuspended in carrier solution mixed with hyaluronic acid)
89306152|NCT05081921|Active Comparator|Control Patients without type 2 diabetes and without obesity|The patients with osteoarthritis of knee, with no obesity (BMI < 30) nor type 2 diabetes will be enrolled into this group and will be injected with hyaluronic acid (single intraarticular application of HA)
89306153|NCT05081479|Experimental|Participants with Lymphoma, Cohort 1|The first dose escalation cohort in the study will be treated at 25% of that target dose level
89306154|NCT05081479|Experimental|Participants with Lymphoma, Cohort 2|The second cohort in the study will be treated at 50% of that target dose level
89306155|NCT05081479|Experimental|Participants with Lymphoma, Cohort 3|The third cohort in the study will be treated at 100% of that target dose level only if no DLTs are seen at lower doses.
89306156|NCT05077735|Experimental|Treatment (hypofractionated RT)|Patients undergo hypofractionated RT over 10 fractions. Patients who achieve progression undergo up to 2 retreatment courses. Patients undergo MRI and PET-CT scan throughout the study.
89306157|NCT05067283|Experimental|Arm 1|Participants will receive daily oral escalating doses of up to 800 mg of MK-1084 until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety.
89306158|NCT05067283|Experimental|Arm 2|Participants will receive MK-1084 daily oral escalating dose of up to 800 mg plus pembrolizumab given as a 200 mg intravenous infusion once every 21-day cycle up to a total of 35 cycles (up to ~24 months). Treatment with MK-1084 will continue until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety.
89306159|NCT05067283|Experimental|Arm 3|Participants will receive alternate formulation of MK-1084 until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety.
89306160|NCT05067283|Experimental|Arm 4|Participants will receive MK-1084 daily oral dose plus an intravenous infusion of pembrolizumab (200 mg) once every 21-day cycle for up to 35 cycles (up to ~24 months). Participants will also receive carboplatin (per label) and pemetrexed (per label) once every 21-day cycle for the first 4 cycles.
89306161|NCT05067283|Experimental|Arm 5|Participants will receive MK-1084 daily oral dose plus an intravenous infusion of cetuximab (per label) every 2 weeks of each 28-day cycle.
89306162|NCT05067283|Experimental|Arm 6|Participants will receive MK-1084 daily oral dose. Additionally, participants receive an intravenous infusion of cetuximab (per label) every 2 weeks of each 28-day cycle, oxaliplatin (per label) for first 6 cycles, and leucovorin (per label) and 5-fluorouracil (per label) once every 14-days.
89306163|NCT05057546|Experimental|Premenopausal Group: GnRH antagonist|Gonadotropin releasing hormone (GnRH) antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection.
89306164|NCT05049382|Experimental|Low Difficulty|Classified as low difficulty according to Escoda's classification
89306165|NCT05049382|Experimental|Modarate Difficulty|Classified as modarate difficulty according to Escoda's classification
89306166|NCT05049382|Experimental|High Difficulty|Classified as high difficulty according to Escoda's classification
89306167|NCT05047172|Experimental|Experimental Arm: Ticagrelor and Aspirin|Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
89306168|NCT05047172|Active Comparator|Standard of Care Arm: Clopidogrel and Aspirin|Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily)
89306169|NCT05047172|Experimental|Experimental Arm: Rivaroxaban and Aspirin|Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
89306170|NCT05044130|Active Comparator|Type 2 Diabetes with NAFLD|"Patients with Type 2 Diabetes with NAFLD~MR spectroscopy verified steatosis"
89306171|NCT05044130|Active Comparator|Type 2 Diabetes without NAFLD|"Patients with Type 2 Diabetes without NAFLD~MR spectroscopy verified no steatosis"
89306172|NCT05027945|Experimental|Arm A|Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis
89306173|NCT05027945|Experimental|Arm B|Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis
89306174|NCT05027932|Experimental|Group A|15 participants receiving IM BPL1357 &amp; IN Placebo
89306175|NCT05027932|Experimental|Group B|15 participants receiving IN BPL1357 &amp; IM Placebo
89306176|NCT05027932|Sham Comparator|Group C|15 participants receiving IM and IN placebo
89306177|NCT05024747|Experimental|Test Product|Participants will receive a single NicoDerm CQ patch (GSK Dungarvan) placed topically under fasted conditions to the upper part of the back for a total duration of 24 hours.
89306178|NCT05024747|Active Comparator|Reference Product|Participants will receive a single NicoDerm CQ patch (Alza) placed topically under fasted conditions to the upper part of the back for a total duration of 24 hours.
89306179|NCT05020678|Experimental|NKX019 - CAR NK cell therapy|All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 weekly doses of NKX019 on Day 0, 7, and 14 of a 28-day cycle. Combination cohorts (if opened) will additionally receive rituximab with each cycle.
89306180|NCT05011565||Fontan Group|"Fontan Group Inclusion Criteria~be between the ages of 8-50~Having undergone Fontan operation in our hospital or another center~Clinical stability of the patients (preserved ventricular function),~No change in ongoing drug therapy that adversely affects clinical stability,~At least 1 year after the operation and to be followed in the Pediatric Cardiology Polyclinic of our hospital~Fontan Group Exclusion Criteria:~Inability to access the patient's medical data~Neurological and/or genetic musculoskeletal disease~Having orthopedic and cognitive problems that prevent testing~The patient's and/or family's unwillingness to participate in the study"
89306181|NCT05011565||Control Group|"Control Group Inclusion Criteria:~Not have cardiovascular, neurological and/or genetic musculoskeletal disease~Not having orthopedic and cognitive problems that prevent testing~The patient's and/or family's willingness to participate in the study"
89306182|NCT05011019|Experimental|AL2846 Capsules|"During the dose escalation phase, patients enrolled in the group will first receive a single fasting administration（AL2846 capsules 120-150mg，oral）. The observation period is 3 days. If dose-limited toxity (DLT) does not occur, they will continue to receive multiple consecutive fasting administrations (120mg-150mg，once a day，oral ),every 28 days as a treatment cycle.~During the dose expansion phase, patients will receive multiple consecutive fasting administrations (AL2846 capsules，120mg-150mg, oral ), every 28 days as a treatment cycle."
89306183|NCT04996316||Clinical staff (interview, training, survey)|Before implementation, some participants will complete usability testing of the interface in the electronic health record and MammoScreen. Participants undergo training sessions over 20 minutes and participate in interviews over 30 minutes at baseline, prior to MammoScreen launch. Clinical staff also participate in interviews over 30 minutes after MammoScreen launch during years 2-4. Participants complete surveys during the maintenance phase, about six months after the last reminders are sent.
89306184|NCT04996316||Patients (interview, MammoScreen)|Patients participate in interviews up to 1 hour. Patients medical records are reviewed. Patients use the MammoScreen at enrollment. Some Patients will also participate in interviews up to 1 hour, each during years 3-5.
89306185|NCT04992975||Alzheimer's disease|"Patients with Early Onset Alzheimer's disease (with known cerebrospinal fluid Amyloid/tau status) during prodromal or mild phase will have MRI of the brain at 7T, neurocognitive assessments, and blood test to check APOe status.~Repeat neuroimaging and neurocognitive tests after one year."
89306186|NCT04992975||Control group|"Age and gender matched individuals with normal cognition will have MRI of the brain at 7T, neurocognitive assessments and blood test to check APOe status.~Repeat neuroimaging, neurocognitive tests after one year."
89306187|NCT04988724|Experimental|Intervention|Intervention group that receive 30 min exercise training twice weekly in 20 weeks
89523388|NCT03461887|No Intervention|Control|Usual care (study participation does not have any impact on regular treatment or treatment decisions, including participation in other exercise training programs or rehabilitation programs)
88806432|NCT02105324|Experimental|Usual Care|Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
89306188|NCT04977310|No Intervention|Control|After LVAD implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using echocardiographic imaging and other standard-of-care practices. During the Unloading phase, patients are serially evaluated with echocardiograms to assess for cardiac recovery, and LVAD explantation performed when predefined criteria are met. After explantation, patients undergo cardiac rehab and regular follow up.
89306189|NCT04977310|Experimental|Intervention|After LVAD and wireless monitoring system (CardioMEMS) implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using CardioMEMS. During the Unloading phase, invasive hemodynamic guidance (via CardioMEMS) will be utilized to optimize pressure and volume unloading along with serial echocardiographic evaluations to assess for cardiac recovery, and LVAD explantation will be considered. After explantation, patients will undergo cardiac rehab and regular follow up with adjustments of HF medications based on the CardioMEMS-guided hemodynamic assessment.
89306190|NCT04966559|Placebo Comparator|Placebo treatment|"Film-coated matched placebo-tablets consisting of:~Core:~Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP~Coating:~Opadry Yellow Purified Water, USP/EP"
89306191|NCT04966559|Active Comparator|Naldemedine treatment|"Film-coated matched active-tablets consisting of:~Core:~Naldemedine Tosylate (0,2 mg) Mannitol, USP/Ph. Eur./JP Croscarmellose Sodium, NF/Ph. Eur./JP Magnesium Stearate, NF/Ph. Eur./JP~Coating:~Opadry Yellow Purified Water, USP/EP"
89306192|NCT04962152|Experimental|Group Naldebain|ultrasound-guided intramuscular injection of Naldebain 150mg after the induction anesthesia immediately
89306193|NCT04962152|Placebo Comparator|Group Placebo|ultrasound-guided intramuscular injection of sesame oil (placebo) 2mL after the induction anesthesia immediately
89306194|NCT04955730|Experimental|NPWT - Negative Pressure Wound Therapy|Participants will receive Negative Pressure Wound Therapy (NPWT) after surgery and wear the NPWT until postop day 3. NPWT dressing will be removed and a new NPWT will be replaced until Postop day 7, where NPWT dressing will be removed.
89306195|NCT04955730|No Intervention|Standard of Care Wound Therapy|Participants will receive standard of care wound therapy after surgery. Postop day 3, dressings will be removed and new sterile dressings will be applied if needed.
89306196|NCT04953689|Experimental|Intervention|
89306197|NCT04953689|No Intervention|Waitlist Control|
89306198|NCT04938830|Experimental|Clesrovimab|Participants will receive intramuscular (IM) injections of clesrovimab and placebo
89306199|NCT04938830|Active Comparator|Palivizumab|Participants will receive IM injections.
89306200|NCT04936048|Active Comparator|Music therapy/Play therapy|"This sequence of interventions begins with 12 weeks of music therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of play therapy intervention.~Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, and interaction. In both interventions, children can choose 4 activities per session using a visual schedule."
89306201|NCT04936048|Active Comparator|Play therapy/Music therapy|"This sequence of interventions begins with 12 weeks of play therapy intervention, followed by a 3 month washout period and concluding with 12 weeks of music therapy intervention.~Both interventions will consist of 12 weekly one-on-one sessions, 45 minutes each, conducted in the same setting by a licensed music therapist, in accordance with an intervention manual. Using a theoretically motivated approach, both interventions will target similar domains: creating a shared experience, building meaningful relationships, fostering self-expression. A varied set of activities combining therapist- and child-led interactions will target common goals: multisensory integration, verbal and social communication, emotion regulation, turn-taking, social appropriateness, interaction. In both interventions, children can choose 4 activities per session using a visual schedule."
89306202|NCT04929015|Experimental|Diagnostic (biospecimen collection)|"Patients will receive standard treatment with surgery, HIPEC, and chemotherapy as appropriate to the patient situation, extent of disease and multi-disciplinary evaluation.~Patients undergo blood sample collection for ctDNA analysis at baseline, pre-surgery, post-surgery and every 3 months up to 2 years.~Patients undergo tissue collection before or during surgery and their medical records are reviewed."
89306203|NCT04927351|Experimental|Intervention|New electronic medical record based discharge medication order set.
89306204|NCT04927351|No Intervention|Control|Usual Care
89306205|NCT04912388|Experimental|The stabilization group|The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.
89306206|NCT04912388|Experimental|The general exercise group|The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
89306207|NCT04912388|No Intervention|The control group|Individuals in the control group will not be treated.
89306208|NCT04907383||Diverticular disease|"All consecutive patients admitted to a Surgical Unit with a diagnosis of left-side colinic diverticulitis will be enrolled in the registry. Patients will be identified through their medical record numbers. One investigator in each center will obtain written informed consent from each patient and keep the patients updated on data collection.~Inclusion criteria: 1) imaging-proven colonic diverticular disease 2) patient aged > 18 years old; 3) Written informed consent obtained. 4) A colonoscopy showing diverticular disease will be required during the follow-up or before surgical treatment if possible"
89306209|NCT04899661||Molidustat|Participants diagnosed with renal anemia treated with Molidustat at the discretion of investigators
89306210|NCT04895722|Active Comparator|Pembrolizumab|Participants receive pembrolizumab 400 mg intravenously (IV) every 6 weeks (Q6W) for up to approximately 2 years.
89306211|NCT04895722|Experimental|Pembrolizumab/Quavonlimab|Participants receive co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) Q6W for up to approximately 2 years.
89306212|NCT04895722|Experimental|Pembrolizumab/Favezelimab|Participants receive co-formulated pembrolizumab/favezelimab (200 mg/800 mg) every 3 weeks (Q3W) for up to approximately 2 years.
89306213|NCT04895722|Experimental|Pembrolizumab/Vibostolimab|Participants receive co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) Q3W for up to approximately 2 years.
89306214|NCT04895722|Experimental|Pembrolizumab Plus MK-4830|Participants receive pembrolizumab 200 mg plus MK-4830 800 mg Q3W for up to approximately 2 years.
89306215|NCT04892641|Experimental|Epetraborole for Dose Ranging|Epetraborole hydrochloride 250 mg, 500 mg, 750 mg, or 1000 mg PO q24h or 500 mg or 1000 mg PO q48h
89306216|NCT04892641|Placebo Comparator|Placebo for Dose Ranging|Matching placebo for dose ranging
89306217|NCT04892641|Experimental|Epetraborole for Food Effect|Food effect cohort, single dose in fed and fasted conditions, dosage to be determined based on pharmacokinetics data obtained from previous cohorts
89306218|NCT04892641|Placebo Comparator|Placebo for Food Effect|Food effect cohort, single dose in fed and fasted conditions, dosage to be determined based on pharmacokinetics data obtained from previous cohorts
89306219|NCT04890054|Active Comparator|SMARTER CRC Intervention Year 1|In year 1, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
89306220|NCT04890054|Active Comparator|SMARTER CRC Intervention Year 2|In year 2, patients receive mailed FITs from CCO, screening reminders from clinics, and patient navigation as appropriate; Health record data collected.
89306221|NCT04876248|Experimental|Treatment (belantamab mafodotin, lenalidomide)|Patients receive belantamab mafodotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-28. Treatment repeats every 8 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.
89306222|NCT04869137|Experimental|Lenvatinib plus Pembrolizumab|Participants with Merkel cell carcinoma amenable to complete resection will receive two cycles (6 weeks) of therapy with the combination of lenvatinib plus pembrolizumab and then proceed to planned resection within 2-4 weeks following completion of cycle 2. Following surgical recovery and completion of adjuvant radiation therapy (if indicated), treatment will resume with pembrolizumab monotherapy with intent to complete 17 cycles total of pembrolizumab.
89306223|NCT04866758||Cancer Survivors|Ambulatory cancer population already seeking psychosocial support.
89306224|NCT04864145|Active Comparator|Medical therapy|Patients in medical therapy will receive conservative care, mainly including angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
89306225|NCT04864145|Experimental|Transcatheter Aortic Valve Implantation|Patients in TAVR group will receive transcatheter aortic valve replacement.
89306226|NCT04858334|Experimental|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans or CT/MRI and collection of blood throughout the study.
89306227|NCT04858334|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-28 of each cycle. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans or CT/MRI and collection of blood throughout the study.
89306228|NCT04853992|Experimental|Active - Placebo|Patients will receive active treatment for 7 days, followed by a washout period of 7 days and then placebo for 7 days
89306229|NCT04853992|Experimental|Placebo - Active|Patients will receive placebo for 7 days, followed by a washout period of 7 days and then active treatment for 7 days
89306230|NCT04843332|No Intervention|Usual Oncology Care|This arm is the control group. They will receive usual oncology care from their regular oncologist and care team with no change in their care plan or treatment as a result of the intervention. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
89306231|NCT04843332|Experimental|Community Health Worker Intervention|This arm is the treatment group. Patients randomized into the intervention will be assigned a community health worker who will contact the patient to begin the intervention. They will receive usual oncology care from their regular oncologist and care team but will also receive supplemental support and health education from a community health worker. The lay health worker will assist patients in ensuring that patients discuss the following with their cancer care teams: 1) precision medicine 2) cancer diagnosis and treatment plan 3) adherence to treatments and 3) goals of care and 4) symptom burden. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
89306232|NCT04832100||Patients with primary fibromyalgia|Adults with complaints of chronic widespread pain at the outpatient department of KMUH were consecutively enrolled over a 5-year period from July 2017 to June 2022. Participants were interviewed by experienced neurologists , and those who fulfilled the 2011 American College of Rheumatology (ACR) criteria for FM were recruited .
89306233|NCT04832100||Healthy controls|Age- and sex-matched subjects without pain and soreness were also prospectively recruited as healthy controls.
89306234|NCT04829604|Experimental|ARX788|The investigational medicinal product (IMP), ARX788, will be administered every 3 weeks (Q3W) by intravenous (IV) infusion.
89306235|NCT04827576|Experimental|Safety Run-in Cohort 1, mNSCLC, mUC, mSCLC (Magrolimab + Docetaxel)|Participants with solid tumors (metastatic non-small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), metastatic small cell lung cancer (mSCLC)) will receive an escalating dose of magrolimab and docetaxel.
89306236|NCT04827576|Experimental|Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)|Participants with mNSCLC will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety Run-in Cohort 1 and docetaxel.
89306237|NCT04827576|Experimental|Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)|Participants with mUC will receive magrolimab at the RP2D determined in the Safety Run-in Cohort 1 and docetaxel.
89306238|NCT04827576|Experimental|Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)|Participants with mSCLC will receive magrolimab at the RP2D determined in the Safety Run-in Cohort 1 and docetaxel.
89306239|NCT04805021||Patients in the Acquired Hemophilia A group.|
89306240|NCT04805021||patients in the constitutional hemophilia A group.|
89306241|NCT04805021||patients in the control subjects group.|
89306242|NCT04805021||patients in the group of patients with inflammatory pathology.|
89306243|NCT04804033|Active Comparator|BHV-3500 200mg|Zavegepant 200mg oral soft gel capsule.
89306244|NCT04804033|Placebo Comparator|Placebo 200mg|Matching placebo 200mg oral soft gel capsule.
89306245|NCT04804033|Active Comparator|BHV-3500 100mg|Zavegepant 100mg oral soft gel capsule.
89306246|NCT04804033|Placebo Comparator|Placebo 100mg|Matching placebo 100mg oral soft gel capsule.
89306247|NCT04802564|Experimental|Multisensory-based music treatment|Using a multisensory-based music treatment synchronizing with vibrotactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
89306248|NCT04802564|Active Comparator|Traditional sensory reeducation intervention|Using constant and moving tactile stimulation on the finger pulps during the protection phase (week 0-4) for hand injury patients.
89306249|NCT04792086||Inhabitants in Nord-Trøndelag 70 years of age and older|All inhabitants in Nord-Trøndelag 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
89306250|NCT04792086||Inhabitants in one area in Trondheim, 70 years of age and older|All inhabitants one area in Trondheim, 70 years of age and older, who participated in the HUNT4 70+-study, between 2017 and 2019.
89306251|NCT04784065|Active Comparator|Treatment arm with control orthosis|
89306252|NCT04784065|Experimental|Treatment arm with experimental orthosis|
89306253|NCT04770896|Experimental|Atezolizumab + Lenvatinib or Sorafenib|Participants will receive atezolizumab plus lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89306254|NCT04770896|Active Comparator|Lenvatinib or Sorafenib|Participants will receive lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
89306255|NCT04758624|Experimental|Deep Brain Stimulation(DBS)|
89306256|NCT04743934|Experimental|Flibanserin + ADT|Flibanserin at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
89306257|NCT04743934|Placebo Comparator|Placebo + ADT|Placebo at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
89306258|NCT04743284||tele-assessment|The balance evaluations will be applied by the tele-assessment method.
89306259|NCT04743284||face-to-face assessment|The balance evaluations will be applied by the face-to-face assessment method in a clinical setting
89306260|NCT04740697|Other|Patient with localized breast cancer.|
89306261|NCT04740580|Experimental|Glycine plus N-acetylcysteine|Glycine and cysteine are amino-acid (protein) precursors of glutathione. Cysteine is provided as N-acetylcysteine
89306262|NCT04740580|Placebo Comparator|Alanine|Alanine is an amino-acid (protein), and not a precursor of glutathione synthesis
89306263|NCT04729959|Experimental|Group I (tocilizumab, atezolizumab, FSRT)|Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days in the absence of disease progression or unacceptable toxicity. Starting 4 weeks from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial.
89306264|NCT04729959|Experimental|Group II, Arm I (tocilizumab, atezolizumab, FSRT, surgery)|Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days. Within 7-14 days after FSRT, patients undergo surgery. Within 21-24 days from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial, as well as blood sample and tumor tissue collection on study.
89306265|NCT04729959|Experimental|Group II, Arm II (tocilizumab, atezolizumab, FSRT, surgery)|Patients receive systemic treatment with atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3-5 fractions over 3-5 days. Within 7-14 days after FSRT, patients undergo surgery. Within 21-24 days from the first dose of systemic treatment, patients resume treatment with tocilizumab IV over 60 minutes with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and tumor tissue collection on study. Patients undergo MRI throughout the trial, as well as blood sample and tumor tissue collection on study.
89306268|NCT04701918|Experimental|Pembrolizumab/Avelumab + Cryoablation|"If patient is receiving pembrolizumab: Participants will be given 200 mg pembrolizumab intravenously once every 3 weeks. This will continue for up to 2 years as per standard of care. Participants will receive cryoablation between the 1st and 2nd doses of pembrolizumab. Cryoablation consists of using a CT scan to guide one or more thin needles to the tumor through your skin, where extreme cold is applied.~If patient is receiving avelumab: Participants will be given 800 mg avelumab intravenously once every 2 weeks. This will continue for up to 2 years as per standard of care. Participants will receive cryoablation between the 1st and 2nd doses of avelumab. Cryoablation consists of using a CT scan to guide one or more thin needles to the tumor through your skin, where extreme cold is applied."
89306269|NCT04689152|No Intervention|Control group|Best Supportive care
89306270|NCT04689152|Experimental|Injection group: Cellgram-LC|Within 1 month after extracting bone marrow, directly inject 7X10^7 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
89306271|NCT04686981||mesenteric artery thromboembolism patients|If all the radiography, physical signs, and laboratory markers hint at intestinal necrosis, exploratory laparotomy followed by enterectomy and thrombectomy is the first choice. If none of them hint at intestinal necrosis, endovascular therapy is superior. Laparoscopic exploration followed by endovascular therapy was performed for other patients, after that the intestinal blood supply was evaluated again by laparoscopy.
89306272|NCT04682769||Patients with medically stable coronary heart disease and Depressive Disorder|
89306273|NCT04675710|Experimental|Treatment (dabrafenib, trametinib, pembrolizumab)|Patients receive 21-day cycles of dabrafenib 150 mg orally (PO) twice daily from Days 1-21, trametinib 2mg PO once daily from Days 1-21, and pembrolizumab 200mg intravenously (IV) on Day 1 of each cycle.
89523389|NCT03124433|Experimental|Neoadjuvant apalutamide|Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection
89306274|NCT04665739|Experimental|Arm I (lutetium Lu 177 dotatate)|Patients receive lutetium Lu 177 dotatate IV over 30-40 minutes on day 1 of each cycle. Treatment repeats every 56 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET during screening. Patients also undergo CT or MRI during screening and on the trial as well as FDG PET and SPECT on the trial. Additionally, patients undergo blood and tissue sample collection during screening and on the trial.
89306275|NCT04665739|Active Comparator|Arm II (everolimus)|Patients receive everolimus PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may be able to cross-over to Arm I. Patients undergo PET during screening. Patients also undergo CT or MRI during screening and on the trial as well as FDG PET and SPECT on the trial. Additionally, patients undergo blood and tissue sample collection during screening and on the trial.
89306276|NCT04661839|Experimental|COVID-HIGIV Dose Level 1 (100 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 1 (100 mg/kg).
89306277|NCT04661839|Experimental|COVID-HIGIV Dose Level 2 (200 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 2 (200 mg/kg).
89306278|NCT04661839|Experimental|COVID-HIGIV Dose Level 3 (400 mg/kg)|Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 3 (400 mg/kg).
89306279|NCT04661839|Placebo Comparator|Dose Placebo (saline)|Eligible subjects randomized to receive a single IV infusion of saline placebo.
89306280|NCT04661410|Experimental|Reward Re-Training|10 weekly sessions of Reward Re-Training Group Therapy.
89306281|NCT04661410|Active Comparator|Supportive Therapy|10 weekly sessions of Supportive Group Therapy.
89306282|NCT04639297|Experimental|NeuroVision® IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of NeuroVision® IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
89306283|NCT04639297|Active Comparator|Conventional hospital based IONM|Patients scheduled to undergo a primary single or multilevel lateral spinal surgery procedures for non-trauma condition. Use of hospital based IONM in lateral spine surgery to provide real-time visible and auditory tcMEP and CMAP waveforms.
89306284|NCT04626479|Experimental|Coformulation Pembrolizumab/Quavonlimab + Lenvatinib|Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to ~2 years). Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
89306285|NCT04626479|Experimental|Coformulation Favezelimab/Pembrolizumab+ Lenvatinib|Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) PLUS lenvatinib 20 mg. Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
89306286|NCT04626479|Experimental|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~2 years). Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
89306287|NCT04626479|Experimental|Pembrolizumab + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to ~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
89306288|NCT04626479|Experimental|Coformulation Vibostolimab/Pembrolizumab+Belzutifan|Participants will receive vibostolimab/pembrolizumab (coformulation of 200 mg vibostolimab and pembrolizumab 200 mg). Vibostolimab/pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Belzutifan will be administered orally QD until progressive disease or discontinuation.
89306289|NCT04622384||ICU patients|Patients who are treated with dialysis as CRRT and planned to undergo dialysis weaning.
89306290|NCT04610866|Experimental|1|Subjects will be treated with a maintenance dose of mitapivat previously assessed for safety and tolerability in the Phase I study for an initial 48 weeks and undergo safety monitoring, evaluation of pharmacokinetics and pharmacodynamics, and assessment of secondary laboratory and clinical endpoints at pre-specified intervals during the study period.
89306291|NCT04604561||Participants receiving SmartClip|Participants will undergo a preoperative physical exam and at least one preoperative ultrasound demonstrating the mass for resection. The SmartClip will be placed under ultrasound guidance. Post-placement mammogram will be obtained after placement of the clip. The SmartClip can be placed up to 30 days prior to the planned surgical resection. At the time of definitive surgery, the Envisio system will be used to identify the clip and the targeted lesion for resection. Intraoperatively, a specimen radiograph will be performed to confirm the presence of the SmartClip and the targeted lesion in the surgical specimen. The breast surgical specimen will be sent for gross examination, including measurements of the tumor in 3 axes. Immediately post-procedure, the performing surgeon will fill out a questionnaire to determine the ability of localizing in-breast lesions using the Envisio Navigation and SmartClip system in surgery.
89306292|NCT04604561||Radiologist Placing SmartClip|Radiologist will place SmartClip under ultrasound guidance. A Post-placement mammogram will be obtained after placement of the SmartClip. Immediately post-procedure, the performing radiologist will fill out a questionnaire.
89306293|NCT04604561||Surgeon|The surgeon will use the EnVisio™ Navigation System to identify the SmartClip and the targeted lesion for resection. Immediately post-procedure, the performing surgeon will fill out a questionnaire
89306294|NCT04604496|Experimental|PF-06882961 participants without Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
89306295|NCT04604496|Experimental|PF-06882961 participants with mild Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
89306296|NCT04604496|Experimental|PF-06882961 participants with moderate Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
89306297|NCT04604496|Experimental|PF-06882961 participants with severe Hepatic Impairment|This arm includes participants who will receive an oral dose of PF-06882961 20 mg on Day 1
89523390|NCT03124589|No Intervention|No Intervention|A questionnaire that asks individuals what components of an online intervention they might find useful.
89306298|NCT04602858|Experimental|Reactive Balance Training|"Participants randomised to the intervention group will initially undertake 3 x 40 min training sessions of reactive balance training over 3 weeks followed by 3-monthly retraining sessions at 3, 6 and 9 months, and final assessment at month 12.~During the training, participants will be exposed to unpredictable slips and trips whilst they are walking on the Trip and Slip Walkway (Okubo et al. 2019). They will be required to consistently walk at their normal walking pace using our gait regulation protocol (i.e. individually adjusted stepping tiles and metronome). Each training session will involve up to 30 trips and slips which progress in unpredictability.~Participants will also receive a Staying active and on your feet fall prevention booklet containing guidance regarding fall risk factors including exercise, diet, vision, footwear, medications and home safety."
89306299|NCT04602858|Active Comparator|Control|"After exposing the control group to one trip and one slip at baseline, participants will then be provided with the Staying active and on your feet fall prevention booklet, an educational booklet providing guidance on fall risk factors including exercise, diet, vision, footwear, medications and home safety. The control group will then return for a reassessment after 12 months."
89306300|NCT04602078|Experimental|AUREA single-arm|"Atezolizumab (1200 mg) intravenously administered every 21 days (one cycle) up to disease progression, unacceptable toxicity or absence of clinical benefit.~Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle plus Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles."
89306301|NCT04595968|Experimental|Vestal DM active device|150 subjects randomised to receive active device plus lifestyle intervention for 24 weeks
89306302|NCT04595968|Sham Comparator|Vestal DM sham device|150 subjects randomised to receive sham device plus lifestyle intervention for 24 weeks.
89306303|NCT04594902|Experimental|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
89306304|NCT04594902|Active Comparator|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
89306305|NCT04593277|Experimental|Arm I (INSPIRE, telehealth care)|Patients receive a personalized SCP and use the INSPIRE mobile application. Patients may receive telehealth stepped care after 1 month.
89306306|NCT04593277|Active Comparator|Arm II (control website)|Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.
89306307|NCT04586335|Experimental|CYH33 in Combination with Olaparib|CYH33 in Combination with Olaparib; 20 mg CYH33 QD in combination with olaparib 300 mg BID. Additional dose levels of CYH33 at20 and 30 mg QD and CYH33 at 40 mg QD in combination with olaparib 200 mg BID will be evaluated.
89306308|NCT04579224|Active Comparator|Arm I (standard of care chemotherapy)|Patients receive 1 of the 4 standard of care chemotherapy regimens based on treating investigator's choice: Choice A: Patients receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Choice B: Patients receive gemcitabine IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Choice C: Patients receive paclitaxel IV on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Choice D: Patients receive sacituzumab govitecan IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI and bone scan throughout the trial. Patients also undergo blood and urine sample collection on the trial.
89306309|NCT04579224|Experimental|Arm II (eribulin)|Patients receive eribulin IV over 2-5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI and bone scan throughout the trial. Patients also undergo blood and urine sample collection on the trial. (CLOSED TO ACCRUAL)
89306310|NCT04579224|Experimental|Arm III (eribulin, gemcitabine)|Patients receive eribulin IV over 2-5 minutes and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI and bone scan throughout the trial. Patients also undergo blood and urine sample collection on the trial.
89306311|NCT04577755|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with complete response, partial response, or stable disease may continue pomalidomide for an additional 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray imaging throughout the trial. Patients may CT as clinically indicated. Patients also undergo blood sample collection and may optionally undergo tissue biopsy during screening and on the trial.
89306312|NCT04574947|Active Comparator|Intravenous lidocaine|
89306313|NCT04574947|Experimental|Topical lidocaine|
89306314|NCT04574947|Placebo Comparator|Placebo|
89306315|NCT04572815|Experimental|Arm I (ustekinumab)|Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive ustekinumab IV. Beginning 8 weeks after receiving IV ustekinumab, patients receive ustekinumab SC on days 50 (+/- 5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.
89306316|NCT04572815|Placebo Comparator|Arm II (placebo)|Between 4 and 72 hours prior to start of HCT conditioning therapy, patients receive a placebo IV. Beginning 8 weeks after IV placebo, patients receive a placebo SC on days 50 (+/- 5 days), 100 (+/- 7 days), and 160 (+/- 7 days) post-HCT in the absence of grade III-IV acute GVHD, disease relapse, or unacceptable toxicity. NOTE: HCT infusion takes place on day 0.
89306317|NCT04567680|Experimental|Acceptance and Commitment Therapy to Improve Social Support|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
89306318|NCT04567680|Active Comparator|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
89306319|NCT04550481|Experimental|Prevention (lisinopril)|Patients receive lisinopril PO QD for 24 weeks in absence of unacceptable toxicity. Patients undergo transient elastography during screening and on study. Patients also undergo blood sample collection on study and may undergo a PDFF MRI and MRE on study.
89306320|NCT04542837|Experimental|KN046 plus Lenvatinib|
89306321|NCT04540497|Experimental|VIB0551|Inebilizumab administered as an IV infusion.
89306322|NCT04540497|Placebo Comparator|Placebo|Placebo administered as an IV infusion.
89306323|NCT04524273|Experimental|Inebilizumab, (AChR-Ab+) MG|"Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the RCP.~Participants who elect to enter the open label phase (OLP) will receive inebilizumab administered IV on OLP Days 1, IV placebo on OLP Day 15 (to avoid potential unblinding), and inebilizumab IV on OLP Days 183, 365, 547, 729, and 911."
89306324|NCT04524273|Placebo Comparator|Placebo, (AChR-Ab+) MG|"Participants will receive placebo administered IV on Days 1, 15, and 183 of the RCP.~Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911."
89306325|NCT04524273|Experimental|Inebilizumab, (MuSK-Ab+) MG|"Participants will receive inebilizumab administered IV on Days 1 and 15 of the RCP.~Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Day 1, IV placebo on OLP Day 15 (to avoid potential unblinding), and inebilizumab IV on OLP Days 183, 365, 547, 729, and 911."
89306326|NCT04524273|Placebo Comparator|Placebo, (MuSK-Ab+) MG|Participants will receive placebo administered IV on Days 1 and 15 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911.
89306327|NCT04524208|Experimental|Treatment-Arm|
89306328|NCT04515472|Active Comparator|Healthy Volunteer Male|Healthy male currently on no testosterone treatment
89306329|NCT04515472|Active Comparator|Healthy Volunteer Female|Healthy female currently on no estrogen treatment
89306330|NCT04515472|Active Comparator|MTF group|MTF transgender currently on estrogen treatment
89306331|NCT04515472|Active Comparator|FTM group|FTM transgender group currently on testosterone treatment
89306332|NCT04509700|Experimental|parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
89306333|NCT04509700|Experimental|parsaclicib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
89306334|NCT04509700|Experimental|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
89306335|NCT04509700|Experimental|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
89306336|NCT04508647|Experimental|Ublituximab Only|Treatment-Naive Stage II (non-contiguous), Stage III, Stage IV FL + MZL will receive Ublituximab 900mg IV weekly x 4 doses. End of treatment assessment 8 weeks post last dose of single agent ublituximab will be performed.
89306337|NCT04508647|Experimental|Ublituximab first, then Ublituximab and Umbralisib|Patients who achieve less than a complete response will receive a combination of ublituximab AND umbralisib for a total of 12 cycles. (In the combination arm ublituximab will be administered on day 1,8 and 15 on cycle 1 and on day 1 on each cycle thereafter. Umbralisib will be administered at 800 mg daily for 12 cycles)
89306338|NCT04502446|Experimental|CTX130|Administered by IV infusion following lymphodepleting chemotherapy.
89306339|NCT04500275|Experimental|Vancomycin group|"i. Timing of application: the Vancomycin (China Chemical & Pharmaceutical Co., Ltd., CCPC, Taiwan R.O.C.) paste will be spread on sternal edge immediately after sternotomy and before sternal closure.~ii. Regimen: The Vancomycin paste will be prepared using 2.5 g of Vancomycin powder mixed with 2 ml normal saline for each time. A total of 5 g of Vancomycin powder will be applied during the cardiac surgery."
89306340|NCT04500275|Placebo Comparator|Placebo group|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure.
89306341|NCT04489823|Experimental|Paravalvular Leak Closure|Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.
89306342|NCT04489069|Other|Clinical, neuropsychological and MRI evaluations|
89306343|NCT04479397|Active Comparator|Sling Arm|This arm of the study will receive a sling for 3 weeks in postoperative care.
89306344|NCT04479397|Experimental|No Sling Arm|This arm of the study will not receive a sling during the postoperative care,
89306345|NCT04470427|Experimental|mRNA-1273|"Part A (Blinded): Participants will receive 1 intramuscular (IM) injection of 100 microgram (μg) mRNA-1273 on Day 1 and on Day 29.~Part B (Open-label): Participants who receive mRNA-1273-matching placebo during Part A and choose to be unblinded by participating in Part B, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1 and Day 29. Participants who are only able to receive 1 dose of mRNA-1273 due to administrative reasons, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1, if the participant chooses.~Part C: Eligible participants in Part B who choose to receive booster dose of mRNA-1273, will receive 1 IM injection of 50 μg mRNA-1273 on Day 1."
89306346|NCT04470427|Placebo Comparator|Placebo|Part A only: Participants will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29, if the participant chooses.
88806433|NCT02105558|Experimental|Epidural anesthesia|Trial of labor after cesarean with an epidural for anesthesia: Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
89306347|NCT04461678|Experimental|Screening population and ASCUS referral population|"The screening population: Two cervical cytology samples will be collected from each subject. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks. In case of visible lesions under colposcopy, a biopsy of tissues at the site of the lesion will be performed; in case of no visible lesions, randombiopsy and/or ECC will be performed. Patients with histopathological results ≥ CIN2 will completed the study.~ASCUS referral population: Female subjects with an ASCUS cytology result will be recalled undergo colposcopy, the remaining samples for cytology test collected prior to enrollment will be used for BD Onclarity Assay HPV test."
89306348|NCT04457674|Other|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi is a non-medication therapy that includes cognitive and behavioral treatment components.
89306349|NCT04457674|Other|Sleep Hygiene Education (SHE)|SHE is a non-medication therapy that focuses on identifying and changing several behavioral and environmental factors that can interfere with sleep.
89306350|NCT04455841|Experimental|Treatment Group A (TGA)|INCB000928 will be administered once daily( QD).
89306351|NCT04455841|Experimental|Treatment Group B (TGB)|INCB000928 will be administered in combination with ruxolitinib.
89306352|NCT04451408|Experimental|LY3372993 (Part A)|LY3372993 administered as multiple doses either intravenously (IV) or subcutaneously (SC).
89306353|NCT04451408|Experimental|LY3372993 (Part B)|LY3372993 administered as single dose IV or SC.
89306354|NCT04451408|Placebo Comparator|Placebo (Part A)|Placebo administered as multiple doses IV or SC.
89306355|NCT04451408|Placebo Comparator|Placebo (Part B)|Placebo administered as single dose IV or SC.
89306356|NCT04442022|Experimental|Phase 2: Selinexor 40 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
89306357|NCT04442022|Experimental|Phase 2: Selinexor 60 mg + R-GDP|Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
89306358|NCT04442022|Active Comparator|Phase 2: R-GDP|Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
89306359|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mg|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
89306360|NCT04442022|Experimental|Phase 3: Selinexor (Selected Dose) + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
89306361|NCT04442022|Placebo Comparator|Phase 3: Placebo + R-GDP followed by Placebo|Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
89306362|NCT04433273|No Intervention|Group A: Healthy control group|Neither placebo nor vestibular stimulation is administered
89306363|NCT04433273|Placebo Comparator|Group B: Placebo control group|Placebo stimulation along with regular treatment
89306364|NCT04433273|Active Comparator|Group C: Intervention group|Electrical vestibular nerve stimulation along with regular treatment
89306365|NCT04433117|Other|Control Group|Control group in this study will comprise of 10 subjects and will receive Bio-Oss xenograft bone material.
89306366|NCT04433117|Experimental|Test Group|The test group in this study will comprise of 10 subjects and will receive Shefabone synthetic bone substitute.
89306367|NCT04416191|Other|Limb immobilization|Participants will undergo a 2-week leg immobilization period
89306368|NCT04411654|Experimental|Low Dose|
89306369|NCT04411654|Experimental|High Dose|
89306370|NCT04363112|Other|study with just one arm|"All of participants are in this arm. Mini Kid II and CBCL score are administered between day 3 and 7. Moreover, salivary test will be remove to evaluate cortisol secretion, 4 time per day during 2 consecutive days.~Psychologic aftercare will be propose if children have psychologic troubles (results of Mini Kid II)"
89306371|NCT04358757||Cesarean patients|participants undergoing elective cesarean will have measures of recovery assessed (patient-reported outcome measures and activity data from watch)
89306372|NCT04344873|Experimental|Older Adult participants|Older adult participants (ages 55-75) will be assessed for arterial function using FMD analysis, PWV calculations, T Cell phenotyping, and proportion of inflammatory biomarkers after injections of placebo and abatacept.
89306375|NCT04327661|Experimental|Tradipitant High Dose|
89306376|NCT04327661|Experimental|Tradipitant Low Dose|
89306377|NCT04327661|Placebo Comparator|Placebo|
89306378|NCT04313881|Experimental|Magrolimab + Azacitidine|"Participants will receive the following magrolimab and azacitidine dosing regimens:~Magrolimab:~Magrolimab Priming Dose:~1 mg/kg on Days 1 and 4~15 mg/kg on Day 8~30 mg/kg on Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50)~Magrolimab Maintenance Dose:~30 mg/kg on Day 57 and 30 mg/kg every 2 weeks thereafter.~Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each 28-day cycle."
88820689|NCT05786456|Experimental|Supportive Care (DBD)|Patients receive DBD intervention consisting of group and web-based self-study sessions and check-in calls on study. Patients also watch videos and receive handouts to reinforce the group sessions.
89306379|NCT04313881|Placebo Comparator|Control Arm (Placebo + Azacitidine)|"Participants will receive the following placebo dosing regimens to mirror magrolimab dosing regimen in addition to azacitidine:~Placebo: On Days 1 and 4; Day 8; Days 11, 15, followed by weekly administration for 5 doses (on Days 22, 29, 36, 43, and 50). Additionally, placebo was administered on Day 57 and every 2 weeks thereafter.~Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle."
89306380|NCT04309396|Experimental|Breath analyzer|Candidates who, after the screening period are eligible to receive the AIRE device.
89306381|NCT04308759|Experimental|Group I (QuitBot Experimental)|Participants participate in the Quitbot program for 42 days to support quitting smoking. Therapy description withheld to protect the integrity of the study.
89306382|NCT04308759|Active Comparator|Group II (QuitBot Control)|Participants participate in the Quitbot program for 42 days to support quitting smoking. Therapy description withheld to protect the integrity of the study.
89306383|NCT04300127|Experimental|Pioglitazone|Candidates who after the screening period are eligible to receive Pioglitazone
89306384|NCT04294264|Experimental|Treatment (TAS-102, oxaliplatin)|Patients receive TAS-102 PO BID on days 1-5 and oxaliplatin IV over 2 hours on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
89306385|NCT04284787|Active Comparator|Arm I (AZA, VEN)|"INDUCTION THERAPY PHASE: Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2. Patients also receive venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY PHASE: Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2. Patients also receive venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Cycles repeat every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment per physician discretion.~Patients also undergo bone marrow biopsy and/or aspiration and collection of blood samples throughout the trial and undergo a skin biopsy at baseline."
89306386|NCT04284787|Experimental|Arm II (AZA, VEN, pembrolizumab)|"INDUCTION THERAPY PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitidine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and every 3 weeks in cycle 2-6, azacitidine IV over 10-40 minutes or SC on days 1-7 or days 1-5 in week 1 and 1-2 in week 2, and venetoclax PO on days 1-28 of cycle 1 and days 1-21 or 1-28 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. After completion of 24 cycles, patients who respond to treatment or have SD may continue treatment with azacitidine and venetoclax per physician discretion."
89306387|NCT04265586|No Intervention|No insomnia|This group contains participants who report only mild symptoms of insomnia (Insomnia Severity Index, ISI<15).
89306388|NCT04265586|Experimental|Digital Cognitive Behavioural Therapy (iCBT)|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Intervention is iCBT for participants with insomnia (7-16 weeks).
89306389|NCT04265586|Experimental|Sleep hygiene education|This group contains participants with moderate to severe symptoms of insomnia symptoms (Insomnia Severity Index, ISI >14). Sleep hygiene education (approximately 1 hour)
89306390|NCT04260919|No Intervention|Control|The participants just received standard medical treatment
89306391|NCT04260919|Experimental|Intervention|The participants received medical treatment and chest physiotherapy sessions
89306392|NCT04248855|Experimental|SAD Cohort 1|All enrolled patients will receive one dose of KAN-101 Dose A
89306393|NCT04248855|Experimental|SAD Cohort 2|All enrolled patients will receive one dose of KAN-101 Dose B
89306394|NCT04248855|Experimental|SAD Cohort 3|All enrolled patients will receive one dose of KAN-101 Dose C
89306395|NCT04248855|Experimental|SAD Cohort 4|All enrolled patients will receive one dose of KAN-101 Dose D
89306396|NCT04248855|Experimental|MAD Cohort 5|All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo
89306397|NCT04248855|Experimental|MAD Cohort 6|All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo
89306398|NCT04248855|Experimental|MAD Cohort 7|All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo
89306399|NCT04245228|No Intervention|Usual Care Group|Routine caregiver transplant education
89306400|NCT04245228|Experimental|Wellness Coaching Intervention|Caregivers will be assigned a wellness coach
89306401|NCT04245215|Placebo Comparator|1. Subcutaneous ustekinumab every 8 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 8 weeks (Q8W) for 48 weeks - receiving Q8W placebo to mimic Q4W injections
89306402|NCT04245215|Active Comparator|2. Subcutaneous ustekinumab every 4 weeks|re-induction (≈6mg/kg) intravenous ustekinumab followed by 90 mg Subcutaneous ustekinumab every 4 weeks (Q4W) for 48 weeks
89306403|NCT04243941|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
89306404|NCT04215003|Active Comparator|A|6 cycles of Paclitaxel,Carboplatin, Herceptin and Pertuzumab treatment with a good clinical benefit response depending on HR/HER-2 status.
89306405|NCT04215003|Experimental|B|2 cycles of Paclitaxel,Carboplatin, Herceptin treatment with a good clinical benefit response depending on HR/HER-2 status following surgery
89306406|NCT04215003|Experimental|CL1|If patients were HR+ and HER2- without PI3K-AKT pathway mutation
89306407|NCT04215003|Experimental|CL2|If patients were HR+ and HER2- with PI3K-AKT pathway mutation
89306408|NCT04215003|Experimental|CLH1|If patients were HR+ and HER2+ without PI3K-AKT pathway mutation
89306409|NCT04215003|Experimental|CLH2|If patients were HR+ and HER2+ with PI3K-AKT pathway mutation
89306410|NCT04215003|Experimental|CH1|If patients were HR- and HER2+ without PI3K-AKT pathway mutation
89306411|NCT04215003|Experimental|CH2|If patients were HR- and HER2+ with PI3K-AKT pathway mutation
88820690|NCT05780749|Experimental|Active arm - DDI-IBS-001|
88820691|NCT05780749|Placebo Comparator|Placebo arm|
89306412|NCT04215003|Experimental|CT1|If patients were HR- and HER2- with LAR subtype
89306413|NCT04215003|Experimental|CL4|HR+ and HER2-; No correlated pathway variation
89306414|NCT04215003|Experimental|CL3|HR+ and HER2-; No correlated pathway variation
89306415|NCT04215003|Experimental|CT2|TNBC
89306416|NCT04215003|Experimental|CT3|TNBC with Homologous Recombination Repair Defect (HRD)
89306417|NCT04215003|Experimental|CT4|TNBC CD8≥10%
89306418|NCT04157985|Active Comparator|Continue Treatment with PD-1/PD-L1 inhibitor|Continued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
89306419|NCT04157985|Experimental|Discontinue Treatment with PD-1/PD-L1-1 inhibitor|Discontinued standard of care treatment with PD-1/PD-L1 -1 checkpoint inhibitor after 12 months of checkpoint inhibitor treatment.
89306420|NCT04153916|Other|Single use and continuous use|"Patients with a continuous unilateral facial paralysis that underwent an operation for facial reanimation will be enrolled at least one year after the operation according to review of medical records of the Department of plastic surgery.~Patients with temporary unilateral facial paralysis secondary to Bell's palsy as was identified in the admission to the Hospital Department of Plastic Surgery or to the Department of Ear, Nose and Throat."
89306421|NCT04143724|Experimental|Cohort 1: 12 to < 18 years - Luspatercept 0.75 mg/kg|
89306422|NCT04143724|Experimental|Cohort 2: 12 to < 18 years: Luspatercept 1.0 mg/kg,|
89306423|NCT04143724|Experimental|Cohort 3 (Expansion Cohort): 12 to <18 years Luspatercept 1.0 mg/kg|
89306424|NCT04143724|Experimental|Cohort 4: 6 to < 12 years: Luspatercept 1.0 mg/kg|
89306425|NCT04143724|Experimental|Cohort 5: 6 to <12 years: Luspatercept 1.2 mg/kg|
89306426|NCT04143724|Experimental|Cohort 6 (Dose Confirmation Phase): NTD 12 to < 18 years - Luspatercept 1.0 mg/kg|
89306427|NCT04143724|Experimental|Cohort 7 (Expansion Phase): NTD 12 to < 18 years|
89306428|NCT04143724|Experimental|Cohort 8: NTD 6 to < 12 years - Luspatercept 1.0 mg/kg|
89306429|NCT04143724|Experimental|Cohort 9: NTD 6 to < 12 years - Luspatercept 1.2 mg/kg|
89306430|NCT04116671|Experimental|Neuromechanical Gait Assist|All participants will participate in developing controllers to coordinate device assistance with walking ability. Walking will be compared before gait training and after gait training. Walking will be evaluated both with and without device assistance.
89306431|NCT04115059|Experimental|Dasatinib|"-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.~Dasatinib: Oral Study Drug(s):~Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.~This will continue for up to 24 cycles."
89306432|NCT04106349||1st line|
89306433|NCT04106349||2nd line|
89306434|NCT04106349||later lines|
89306435|NCT04102371|Experimental|Balanced fluids (BF)|Balanced fluids (BF), including Lactated Ringer's and Plasma-Lyte (PL), will be administered to patients randomized to the experimental arm. BF will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
89306436|NCT04102371|Active Comparator|"0.9% Normal Saline Fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calendar day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
89306439|NCT04064060|Experimental|ACE-536|Luspatercept will be administered as a subcutaneous (SC) injection to participants by the study staff at the clinical site and administration will be documented in the subject's source record.
89306440|NCT04042935|Experimental|Alpha Lipoic Acid (ALA) during chemoradiation|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation as standard of care will receive ALA before, during, and after treatment. The drug will have dose escalation in a 3+3 design. The first group of 3 patients will receive 600 mg twice a day. If there are no DLTs, the next 3 patients will receive the highest dose of 600 mg three times a day. If one or more patients develop a DLT at any of the dosing levels, the group will either be expanded or dropped to a lower dose level.
89306441|NCT04040205|Experimental|Abemaciclib|Subjects will be treated with abemaciclib 200 mg twice daily by mouth.
89306442|NCT04035434|Experimental|CTX110|Administered by IV infusion following lymphodepleting chemotherapy.
89306443|NCT04019197|Experimental|Participants with HIV and lipohypertrophy: semaglutide arm|Participants with HIV/lipohypertrophy will receive semaglutide 0.25 mg x4 weeks, then semaglutide 0.5 mg x4 weeks, then semaglutide 1.0 mg x24 weeks, then no drug x24 weeks.
89306444|NCT04019197|Placebo Comparator|Participants with HIV and lipohypertrophy: placebo arm|Participants with HIV/Lipohypertrophy will receive placebo x32 weeks, then no placebo for 24 weeks.
89306445|NCT03975647|Experimental|Tucatinib + T-DM1|Tucatinib + T-DM1
89306446|NCT03975647|Active Comparator|Placebo + T-DM1|Placebo + T-DM1
88820692|NCT05780138|Experimental|Intervention group|Participants will receive 10 remote sessions with the curriculum
88820693|NCT05779631|Experimental|mpMRI plus a same-day cystoscopic bladder biopsy|multiparametric MRI plus same-day cystoscopic bladder biopsy
89306447|NCT03968393|Experimental|Non-vitamin K oral anticoagulant (NOAC)|Participants randomized to the intervention arm will be prescribed one of the following NOACs for 24 months, unless they are undergoing a procedure with an increased risk of bleeding, have an adverse event or low calculated creatinine clearance, or decide to discontinue their use.
89306448|NCT03968393|No Intervention|No anticoagulation|Participants randomized to the control arm will not be prescribed an oral anticoagulant unless they develop a clear indication for one during follow-up (e.g., recurrent nonoperative AF). They can be newly prescribed or continue taking low dose aspirin or another single antiplatelet agent as per the protocol. This will be decided by the participant's physician.
89306449|NCT03952598|Experimental|1/Arm 1|Monitoring of quantitative levels of 2-hydroxyglutarate (2-HG) via proton magnetic resonance spectroscopy (1H-MRS)
89306450|NCT03936465|Experimental|Arm 1 Cohort A|"Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.~Patients with unselected relapsed or refractory solid tumors or lymphoma"
89306451|NCT03936465|Experimental|Arm 1 Cohort B|"Patients will receive BMS-986158 monotherapy orally for 5 days on / 2 days off per week in 28-day cycles.~Patients with relapsed or refractory solid tumors or lymphoma that have defined molecular features predicted to increase sensitivity to BET inhibition"
89306452|NCT03936465|Experimental|Arm 2 Cohort A|"Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.~Patients with relapsed or refractory CNS tumors or CNS metastatic tumors"
89306453|NCT03936465|Experimental|Arm 2 Cohort B|"Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.~Patients with relapsed or refractory CNS tumors or CNS metastatic tumors that have defined molecular features predicted to increase sensitivity to BET inhibition"
89306454|NCT03907046|Active Comparator|Apixaban|Apixaban dosing will be 5 mg tablet in morning and 5 mg tablet in evening. A reduced dose of 2.5 mg tablet in morning and 2.5 mg tablet in evening will be used if: (1) ≥2 of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine 1.5-2.4 mg/dL, or (2) Patient is taking a strong CYP3A4/pGP inhibitor (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin).
89306455|NCT03907046|Placebo Comparator|Aspirin|Aspirin dose will be 81 mg tablet once daily.
89306456|NCT03885037||Infliximab [infliximab biosimilar 3]|Patients with Rheumatoid Arthritis treated by Infliximab BS
89306457|NCT03872427|Experimental|Treatment (telaglenastat hydrochloride)|Patients receive telaglenastat hydrochloride PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, or PET/CT during screening and on study, and collection of blood samples during screening and on study.
89306458|NCT03872180|Experimental|Venetoclax, bendamustine, obinutuzumab|Patients receive venetoclax PO on days 1-28 of course 1 and days 1-10 of subsequent courses, bendamustine IV on days 1 and 2, and obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unaccepted toxicity.
89306459|NCT03867747|Experimental|Cardiac Radiosurgery|25 Gy in a single fraction
89306460|NCT03854474|Experimental|Treatment (tazemetostat, pembrolizumab)|Patients receive tazemetostat PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI throughout the trial and undergo collection of blood samples on study.
89306461|NCT03845140|Experimental|Cohort 1a: 4 to 6 years L-PZQ ODT 50 mg/kg|Participants aged 4 to 6 years infected with Schistosoma (S.) mansoni received Levorotatory enantiomer of praziquantel (L-PZQ) orodispersible tablets (ODT) (150 milligrams [mg]) orally at a dose of 50 milligram per kilogram (mg/Kg) as a single oral dose after food-intake on Day 1.
89306462|NCT03845140|Active Comparator|Cohort 1b: 4 to 6 years Biltricide® 40 mg/kg|Participants aged 4 to 6 years infected with S. mansoni received Racemate Praziquantel tablets (Biltricide®) (600 mg) orally at a dose of 40 mg/kg as a single oral dose after food-intake on Day 1.
89306463|NCT03845140|Experimental|Cohort 2: 2 to 3 years L-PZQ ODT 50 mg/kg|Participants aged 2 to 3 years infected with S. mansoni received L-PZQ ODT (150 mg) tablet orally at a dose of 50 mg/kg as a single oral dose after food-intake on Day 1.
89306464|NCT03845140|Experimental|Cohort 3: 3 to 24 months L-PZQ ODT 50 mg/kg|Participants aged 3 to 24 months infected with S. mansoni received L-PZQ ODT (150 mg) tablet orally at a dose of 50 mg/kg as a single oral dose after food-intake on Day 1.
89306465|NCT03845140|Experimental|Cohort 4a: 3 months to 6 years L-PZQ ODT 50 mg/kg|Participants aged 3 months to 6 years infected with S. haematobium received L-PZQ ODT (150 mg) tablet orally at a dose of 50 mg/kg as a single oral dose after food-intake on Day 1.
89306466|NCT03845140|Experimental|Cohort 4b: 3 months to 6 years L-PZQ ODT 60 mg/kg|Participants aged 3 months to 6 years infected with S. haematobium received L-PZQ ODT (150 mg) tablet orally at a dose of 60 mg/kg as a single oral dose after food-intake on Day 1.
89306467|NCT03842696|Experimental|Vorinostat|
89306468|NCT03834818|Experimental|COMPAS Participants|Patents between the ages of 18 and 90 who are undergoing orthopedic surgery at Duke Health will be eligible for enrollment.
89306469|NCT03825835|Active Comparator|30% group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
89306470|NCT03825835|Experimental|60% group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
89306471|NCT03822871|Experimental|Dose Escalation|Escalating doses of 0.75 GBq - 2.0 GBq of CTT1403
89306472|NCT03822871|Experimental|Dose Escalation/Expansion|Escalating doses of 3.0 GBq - 9.0 GBq of CTT1403
89306473|NCT03820817|Experimental|Treatment (rifaximin)|Patients receive rifaximin PO TID on days 1-14 in the absence of disease progression or unacceptable toxicity.
89306474|NCT03816176|Experimental|Isavuconazonium sulfate|Participants received 10 milligrams/killograms (mg/kg) dose of isavuconazonium sulfate every 8 hours (± 2 hours) on days 1 and 2 for a total of 6 doses (via intravenous or oral administration at the investigator's discretion) followed by once-daily maintenance dose of 10 mg/kg for up to 84 days IA or 180 days IM or until the participant had a successful outcome as judged by the investigator, whichever occured first. The route of administration could have been changed per the investigator's discretion.
89306475|NCT03814564||Circulatory failure / NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
89306476|NCT03814564||Circulatory Failure / no NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
89306477|NCT03814564||Gut dysbiosis, delirium and long term cognition|"ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing.~Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission."
89306478|NCT03772925|Experimental|Treatment (belinostat, pevonedistat)|Patients receive belinostat IV QD over 30 minutes on days 1-5 and pevonedistat IV QD over 60 minutes on days 1, 3, and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89306483|NCT03745287|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
89306484|NCT03738228|Experimental|Arm A (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days -21, 0, and 21 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy IV over 90 minutes on days 0, 7, 14, 21, 28, and 35. Beginning on day 0, patients also receive standard of care radiation therapy once daily (Monday-Friday) for a total of 25 fractions with image guided brachytherapy beginning in week 4, 5, or at the end of radiation therapy.
89306485|NCT03738228|Experimental|Arm B (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy, radiation therapy, and image guided brachytherapy as in Arm A.
89306486|NCT03724747|Experimental|BAY2315497 dose escalation|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. The total antibody dose of 50 mg will be evaluated first; on the basis of emerging clinical data, doses within the range of 20-100 mg may be investigated.
89306487|NCT03724747|Experimental|BAY2315497 dose escalation in combination with darolutamide|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. In addition, Darolutamide oral dosing at the approved dose of twice daily 600 mg will be initiated 14 days prior to the first BAY2315497 Injection dose on Day 1 of the first cycle. Daily darolutamide dosing will continue throughout the entire BAY2315497 Injection treatment period until withdrawal criteria from study treatment period are met.
88806434|NCT02105558|Experimental|Combined spinal and epidural anesthesia|Trial of labor after cesarean with a combined spinal and epidural (CSE) for anesthesia: the epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
88806435|NCT00312884|Active Comparator|Usual Care|Recieved usual hospital and community care
88806436|NCT00312884|Experimental|Intervention Arm|Recieved telemonitoring
88806437|NCT02106728|Experimental|Multi-Family Therapy|Multi-family group therapy involving eight to ten families who meet as a group with two therapists for a duration of 8, 1.5h sessions.
88806438|NCT02106728|Active Comparator|Supportive Family Therapy|Family supportive counseling consists of people with eating disorders and their family members meeting with a family therapist. This is treatment as usual in the Eating Disorders Program at University Health Network.
89306488|NCT03724747|Experimental|BAY2315497 dose expansion:Dose regimen 1|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
89306489|NCT03724747|Experimental|BAY2315497 dose expansion:Dose regimen 2|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
89306490|NCT03713476|Experimental|Robot-assisted training|The participants will receive 20 minutes of robot assisted tenodesis-grip therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
89306491|NCT03713476|Active Comparator|Traditional occupational therapy|The participants will receive 20 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
89306492|NCT03711032|Experimental|BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1)|Participants receive BCG (Induction and Maintenance) in combination with 200 mg pembrolizumab administered intravenously (IV) every 3 weeks (Q3W) for 35 doses (~2 years).
89306493|NCT03711032|Experimental|BCG Monotherapy: Post-induction Cohort A (Arm A-2)|Participants receive BCG monotherapy (Induction and Maintenance).
89306494|NCT03711032|Experimental|BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1)|Participants receive BCG (Induction and reduced Maintenance) in combination with 400 mg pembrolizumab administered IV every 6 weeks (Q6W) for 9 doses (~1 year).
89306495|NCT03711032|Experimental|BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2)|Participants receive BCG (Induction and full Maintenance) in combination with 400 mg pembrolizumab administered IV Q6W for 9 doses (~1 year).
89306496|NCT03711032|Experimental|BCG Monotherapy: BCG Naïve Cohort B (Arm B-3)|Participants receive BCG monotherapy (Induction and Maintenance).
89306497|NCT03696953|Experimental|Probiotic|"Florajen3 Combination Probiotic Product 15 billion CFU per capsule~1 capsule daily from 28 weeks until the time of birth."
89306498|NCT03696953|No Intervention|Placebo|Microcrystalline Cellulose
89306499|NCT03685721||HbAS|HbAS genotype, of African American descent;Between 18 and 80 years of age
89306500|NCT03685721||Healthy control|African American descent;Between 18 and 80 years of age
89306501|NCT03685721||SCD|HbSS, HbSC, HbSbeta-thal has sickle cell disease and is of African American descent;Between 18 and 80 years of age
89306502|NCT03614949|Experimental|Combination Therapy|Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.
89306503|NCT03610724|Experimental|Tisagenlecleucel|Participants were infused once with CAR-positive viable T cells
89306504|NCT03587116|Other|Standard of Care FIX replacement therapy|
89306505|NCT03587116|Other|Standard of Care FVIII replacement therapy|
89306506|NCT03580057|Experimental|Breastfeeding promotion intervention (BPI)|
89306507|NCT03580057|Experimental|Diet- and weight loss intervention (D)|
89306508|NCT03580057|Experimental|BPI and D|Both interventions.
89306509|NCT03580057|No Intervention|Control|
89306510|NCT03574363|Experimental|KBP-5074 0.25 mg tablet|KBP-5074 0.25 mg tablet QD orally, 84 days
89306511|NCT03574363|Experimental|KBP-5074 0.5 mg tablet|KBP-5074 0.5 mg tablet QD orally, 84 days
89306512|NCT03574363|Placebo Comparator|Placebo tablet|Placebo tablet QD orally, 84 days
89306513|NCT03560882|Experimental|Atorvastatin|Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)
89306514|NCT03538652|Placebo Comparator|EMA only|randomized control group undergoing mobile assessment without JITAI
89306515|NCT03538652|No Intervention|Formative Interviews|First stage, before content of mobile intervention is finalized
89306516|NCT03538652|Active Comparator|JITAI|group receiving microrandomized active intervention: JITAI with both CBT and ACT
89306517|NCT03520647|Experimental|Treatment Arm|G-CSF mobilized peripheral stem cells and post haplo-identical transplantation cyclophosphamide
89306518|NCT03519009|Experimental|IPS Plus Abstinence-Contingent Wage Supplement|Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
89306519|NCT03519009|No Intervention|Usual Care Control|Counseling and referrals to employment and treatment programs.
89306520|NCT03499236|Experimental|Treatment|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
89306521|NCT03499236|Other|Control|Control arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility, but will not have transseptal catheterization or shunt implantation.
89306522|NCT03499236|Experimental|Roll in|Roll in arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
89306523|NCT03495440|Experimental|Center Sessions|Treatment condition in which participants receive psychoeducation and communication coaching.
89306524|NCT03495440|Active Comparator|At-home|Active, self-study control condition in which participants receive regular communication with study personnel and self-study materials to review on their own.
89306525|NCT03486873|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants.
89523391|NCT03124589|Experimental|Online Gambling Internet Intervention|An online gambling Internet intervention (housed at CAMH and developed based on the self-help materials created by Professor David Hodgins)
88820694|NCT05779631|Active Comparator|TURBT|Transurethral resection of the bladder tumor
88820695|NCT05775328||Patients with hypertrichosis|Patients suffering from hypertrichosis or hirsutism according to Ferriman-Galway scale criteria and treated with intense pulse light for a total of 5 sessions.
88820696|NCT05773820|Experimental|WJB001 capsules|Once a day (QD).
88820697|NCT05766501|Experimental|DOR/ISL|Participants will receive fixed dose combination (FDC) tablet of DOR/ISL (100 mg/0.25 mg) taken once daily (QD) orally from Day 1 to Week 96.
89306526|NCT03486873|Experimental|Pembrolizumab 400 mg|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants.
89306527|NCT03486873|Experimental|Pembrolizumab 200 mg + SOC: Per Parent Study)|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle PLUS standard of care (SOC) treatment (or per parent study if there is no SOC) for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
89306528|NCT03486873|Experimental|Pembrolizumab 400 mg + SOC (Per Parent Study)|Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle PLUS SOC treatment (or per parent study if there is no SOC) for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
89306529|NCT03486873|Active Comparator|SOC (Per Parent Study)|Participants receive the dose matched non-pembrolizumab SOC treatment (e.g. chemotherapy) they were receiving as per parent study protocol.
89306530|NCT03486873|Experimental|Lenvatinib 20 mg|Participants with body weight (BW)>60kg receive Lenvatinib 20mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
89306531|NCT03486873|Experimental|Lenvatinib 24 mg|Participants with body weight (BW)>60 kg receive Lenvatinib 24 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
89306532|NCT03486873|Experimental|Lenvatinib 12 mg|Participants with body weight (BW)>60 kg receive Lenvatinib 12 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
89306533|NCT03486873|Experimental|Lenvatinib 8 mg|Participants with body weight (BW)<60 kg receive Lenvatinib 8 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
89306534|NCT03469505|Active Comparator|data from veterans using COPES|Data from veterans using COPES for chronic pain
89306535|NCT03469505|Active Comparator|data from veterans using CBT-CP|Data from veterans using CBT-CP for chronic pain
89306536|NCT03456336|Active Comparator|Active Treatment Group|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other.
89306537|NCT03456336|Active Comparator|Expectant Management Group|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
89306538|NCT03456128|Experimental|Intervention|The experimental group will receive CAPABLE services. These include ≤10 sessions: ≤ 6 with an Occupational Therapist (OT) and ≤ 4 sessions with a Registered Nurse (RN) and up to ≤ $1,500 of home safety and home modifications from a licensed handyman who is guided by the OT. The OT and RN sessions will target participants' self-identified functional goals (e.g., getting safely into the tub, getting upstairs to sleep in own bed).
89306539|NCT03456128|No Intervention|Usual Care|Participants in the usual care group will not receive visit from study clinicians and will continue to receive their usual VNSNY CHOICE benefits and healthcare.
89306540|NCT03434262|Experimental|A: ribociclib + gemcitabine|"Stratum A participants with a diagnosis of refractory or recurrent medulloblastoma (Group 3/4) or refractory or recurrent ependymoma. (including: ependymoma, not otherwise specified (NOS), WHO Grade III; ependymoma, RELA fusion positive; anaplastic ependymoma; ependymoma, NOS, WHO grade II). They receive combination treatment with ribociclib and gemcitabine. They may also receive growth therapy support with filgrastim.~Stratum A has completed all the necessary accrual"
89306541|NCT03434262|Experimental|B: ribociclib + trametinib|"Stratum B participants with a diagnosis of one of the following refractory or recurrent CNS diseases: medulloblastoma, [sonic hedgehog (SHH)- or WNT-activated];; high grade glioma (including: high grade glioma, (NOS), WHO Grade III or IV; anaplastic astrocytoma, IDH mutant; glioblastoma, IDH-wildtype; glioblastoma, IDH-mutant; diffuse midline glioma, H3K27-mutant; anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted; anaplastic pleomorphic xanthoastrocytoma); select CNS embryonal tumors (including: embryonal tumors with multilayered rosettes, C19MC-altered; embryonal tumors with multilayered rosettes, NOS; medulloepithelioma; CNS neuroblastoma; CNS ganglioneuroblastoma; CNS embryonal tumor, NOS; atypical teratoid/rhabdoid tumor; CNS embryonal tumor with rhabdoid features). They receive combination treatment with ribociclib and trametinib.~Stratum B has completed all the necessary accrual"
89306542|NCT03434262|Experimental|C: ribociclib + sonidegib|"Stratum C participants with refractory or recurrent medulloblastoma (SHH-activated) >6 months off smoothened inhibitor, presence of 9q loss or PTCH1 mutant, skeletally mature. They received combination treatment with ribociclib and sonidegib.~Stratum C is being closed due to low accrual"
89306543|NCT03426306|Experimental|4DCT-ventilation|The patient will undergo 4DCT imaging. The 4DCT imaging data along with image processing techniques will be used to generate a 4DCT-ventilation map. All surgical decisions will be based on the current standard of care imaging (VQ scans) and not on the 4DCT imaging results.
89306544|NCT03424109||Beneficiaries with a one-year mortality of at least 30%|The patient cohort will be extracted via the Centers for Medicare and Medicaid Services (CMS) Research Data Assistance Center (ResDAC) using a two-step process to maximize diversity, and minimize intentional or unintentional exclusions based on risk, age, health literacy, demographics, or expected adherence.
89306545|NCT03391869|Experimental|Arm A (ipilimumab, nivolumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 90 minutes on days 1, 15, and 29, and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients receive nivolumab IV over 60 minutes on days 1, 15, and 29 and ipilimumab IV over 90 minutes on day 1. Courses repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
89306546|NCT03391869|Experimental|Arm B (ipilimumab, nivolumab, LCT)|"INDUCTION PHASE: Patients receive nivolumab IV over 90 minutes on days 1, 15, and 29, and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients receive LCT consisting of surgery and/or radiation 14 days after completion of Induction Phase. Patients then receive nivolumab and ipilimumab as in arm A beginning within 4 weeks after LCT. Courses repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
89306548|NCT03353272|No Intervention|Impairment Based Treatment|an impairment-based conservative intervention that has been created by compiling the evidence associated with established, effective treatment interventions for rotator cuff related shoulder pain.
89306549|NCT03353272|Experimental|Impairment Based Treatment PLUS PEERC|Participants assigned to the impairment-based care plus PEERC condition will also receive the PEERC protocol. This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
89306550|NCT03347838|Experimental|Nivolumab Injection [Opdivo]|240 mg IV every 2 weeks for 4 doses
89306551|NCT03329417|Active Comparator|Traditional occupational therapy|The program includes 30 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
89306552|NCT03329417|Active Comparator|Mirror therapy using a mirror box|The program includes 30 minutes of mirror therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
89306553|NCT03329417|Experimental|Virtual reality based mirror therapy|The program includes 30 minutes treatment session of virtual reality mirror therapy, followed by 20 minutes of motor task specific training in each treatment session.
89306554|NCT03326921|Experimental|Treatment (CD4+ and CD8+ HA-1 TCR T cells)|Patients receive fludarabine for 1-3 doses 3-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV over 1 hour.
89306555|NCT03324646||controls|healthy subjects
89306556|NCT03319368|Experimental|Intervention: Targeted gown and glove use|Additional gowns and gloves used for high risk care activities
89306557|NCT03311997|No Intervention|Non-operative treatment|Active rehabilitation program
89306558|NCT03311997|Active Comparator|Operative treatment|Surgical reattachment of hamstring tendons using suture anchors followed by active rehabilitation program
89306559|NCT03307980|Experimental|PF-06838435 Dose-Escalation|Single intravaneous infusion of PF-06838435. After 2 participants receive initial dose, data will be evaluated and a decision will be made to escalate or reduce the dose being evaluated, increase the number of participants receiving the dose, or stop dosing. Multiple iterations may be undertaken.
89306560|NCT03304704||DSF Cohort|Accrual/Screening up to 1800 will include volunteers between the ages of 5 and 17 years and will be enrolled for genotyping and monthly blood sampling
89306561|NCT03304704||Genotype Cohort|Accrual/Screening up to 1500 will complete a single visit with blood draw for genotyping for future fidelity assessments with blood-fed, spray wild-caught mosquitoes.
89306562|NCT03304704||Parasite Surveillance Cohort|Accrual/Screening up to 1500 will be enrolled for genotyping and a minimum of six monthly blood sampling and mosquito wild catches wild-caught mosquitoes within their compound
89306563|NCT03272906|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
89306564|NCT03272906|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 mA) plus speech-language therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 mA.
89306565|NCT03269110||Mother and child(ren)|FACT 4 Child is the post-delivery follow-up of the offspring born to FACT mothers once these children are between the age of 4 - 6 years.
89306566|NCT03226704||1|Patients 3-39 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to one or more standard regimens and/or deemed incurable by standard therapy.
89306567|NCT03216109|Experimental|Weekly telephone symptom assessment|"Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Symptom assessments will be documented into an encrypted, HIPAA compliant digital platform which provides longitudinal symptom data management and also provides symptom assessment tools for the clinical team in their intervention strategies.~In addition, patients will complete symptom and quality of life surveys at 0, 3, 6 and 9 months."
89306568|NCT03216109|No Intervention|Control Arm|Patients randomized to usual clinical care will receive standard of care for thoracic malignancies as provided by the VA Palo Alto Health Care System. Patients will complete outcome surveys at 0, 3, 6, and 9 months.
89306569|NCT03204786|Experimental|Vasopressin-Vasopressin|8 weeks of vasopressin nasal spray (16 international units twice daily)
89306570|NCT03204786|Experimental|Placebo-Vasopressin|4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
89306571|NCT03204786|Placebo Comparator|Placebo-Placebo|8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
89306572|NCT03204357|Experimental|Fresh Autologous whole blood transfusion|The experimental group will have 15% of the estimated blood volume of autologous blood collected. This transfusion will be given at the end of the procedure.
89306573|NCT03204357|Active Comparator|Standard of Care Expectant Management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
89306574|NCT03157804|Experimental|Autologous CD34+ cells transducted with PGK-FANCA-Wpre *|CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.
89306575|NCT03149029|Experimental|BRAFV600 mutant|"Pembrolizumab administered intravenously every three weeks~Dabrafenib taken every twelve hours orally~Trametinib taken every twelve hours orally"
89306576|NCT03149029|Experimental|BRAFV600 wild type|"Pembrolizumab administered intravenously every three weeks~Trametinib taken every twelve hours orally"
89306577|NCT03094806|Experimental|Acapella Vibratory PEP Therapy Device|Subject will use the device 3 times a day throughout hospital stay
89306578|NCT03094806|Placebo Comparator|Sham Acapella Vibratory PEP Device|Subject will use the sham device 3 times a day throughout hospital stay
89306579|NCT03074812|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation where current will be reduced to zero after standardized ramp up to 2 mA
89306580|NCT03074812|Experimental|Active tDCS|Transcranial direct current stimulation according to protocol maintained for 30 minutes after ramping up to 2 mA
89306581|NCT03072927||MILD|All Medicare patients treated with MILD as reported via CPT® Code 0275T (or successor code(s)).
89306582|NCT03072927||Interspinous Process Decompression|All Medicare patients treated with interspinous process decompression (CPT Code 22869 or 22870, or successor code(s)) for the treatment of LSS with NC.
89306583|NCT03062657|Experimental|PRESTIGE LP|Patients receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
89306586|NCT03025087|Experimental|Phase 1|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery.
89306587|NCT03025087|Experimental|Phase 2|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg daily until the day of MRI imaging on postoperative day 1-5
89306588|NCT03025087|Experimental|Phase 3|6 evaluable cardiac subjects 1000 mg HCQ on the day prior to surgery followed by 400 mg twice daily (800 mg total) until the day of MRI imaging on postoperative day 1-5.
89306589|NCT03025087|Experimental|Phase 4|6 evaluable cardiac subjects: 1000 mg HCQ on the day prior to surgery followed by 500 mg twice daily (1000 mg total) until the day of MRI imaging on postoperative day 1-5.
89306590|NCT03025087|Experimental|Phase 5|6 evaluable cardiac subjects: 1000 mg HCQ 1-2 hours after separation from CPB followed by the highest tolerated dose from the previous 4 phases divided into 2 equal daily doses until the day of MRI imaging on postoperative day 1-5.
89306591|NCT02978625|Experimental|Treatment (talimogene laherparepvec, nivolumab)|Patients receive talimogene laherparepvec IT and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo, CT scan or PET/CT on study. Patients also undergo blood sample collection and biopsies on study.
89306592|NCT02965027|Experimental|Prazosin|Prazosin capsules beginning at 1 mg orally at bedtime. Titrate over 5 weeks to maximum dose of 5 mg in the morning and 20 mg at bedtime.
89306593|NCT02965027|Placebo Comparator|Placebo|Placebo capsules
89306594|NCT02926196|Experimental|Arm Avelumab|Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)
89306595|NCT02926196|No Intervention|Arm Observation|Observation as per guidelines
88806439|NCT02106962|Experimental|Clotting time Using Tranexamic Acid 5%|Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
89306596|NCT02912559|Experimental|Arm I (combination chemotherapy, atezolizumab)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, beginning in cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.
89306597|NCT02912559|Active Comparator|Arm II (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3 of each cycle. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI every 6 months for the first 2 years, then for years 3-5 or until evidence of relapse, whichever comes first. Patients may also undergo blood sample collection throughout the trial.
89306598|NCT02901457|Experimental|Healthy Body Image|Students receive the Healthy Body Image intervention containing 3x90 minutes of interactive workshops with the addition of related homework after each workshop.
89306599|NCT02901457|No Intervention|Control group|Students do not receive the intervention program.
89306600|NCT02890329|Experimental|Arm A (decitabine, ipilimumab)|"PRIMING PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.~INDUCTION PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Post allo-HCT patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
89306601|NCT02890329|Experimental|Arm B (decitabine, ipilimumab)|"PRIMING PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 out of 28 days.~INDUCTION PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Transplant naive patients receive decitabine IV over 60 minutes on days 1-5 and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 4 or 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity."
89306602|NCT02875314|Experimental|Induction|"The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.~Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate."
89306603|NCT02875314|Experimental|Single Cycle Intensive Chemotherapy|"The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:~Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells"
89306604|NCT02875314|Experimental|Tandem 3 Cycle Intensive Chemotherapy|"The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.~Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks."
89306605|NCT02842463||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
89306606|NCT02776215|Experimental|Pharmacokinetic Dosing|Single-dose pharmacokinetics of tasimelteon
89306607|NCT02767986||Spanish-speaking Latinas|Women who speak Spanish as their primary language
89306608|NCT02689440|Experimental|Treatment (dasatinib, venetoclax)|Patients receive dasatinib PO QD for 15 years in the absence of disease progression or unacceptable toxicity. After 3 months of dasatinib treatment, patients also receive venetoclax PO QD on days 1-14 of each month for 3 years in the absence of disease progression or unacceptable toxicity (patients enrolled prior to 4/1/2018 receive only dasatinib).
89306609|NCT02656680|Experimental|Continuous Enrollment (Randomized)|The Continuous Enrollment is a Facebook-delivered weight loss intervention. Participants in this arm were randomized to this Facebook group and started the intervention together. For this group, the study team continued to enroll participants through week 8.
89306610|NCT02656680|Active Comparator|Closed Enrollment (Randomized)|Closed Enrollment is a Facebook-delivered weight loss intervention. Participants in this arm were randomized to this Facebook group and started the intervention together. No additional participants were added to this group during the study.
89306611|NCT02656680|Other|Continuous Enrollment (Non-Randomized)|The Continuous Enrollment is a Facebook-delivered weight loss intervention. For this group, the study team continued to enroll participants through week 8. This arm captures only those participants that were added to the group during these 8 weeks. They were enrolled in the study after the original 80 participants were randomized.
89306613|NCT02635256|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
89306614|NCT02631733|Experimental|Treatment (liposomal irinotecan, veliparib)|Patients receive liposomal irinotecan IV over 90 minutes on days 1 and 15 and veliparib PO BID on days 5-12 and 19-25 or 3-12 and 17-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Within 2-6 days prior to beginning liposomal irinotecan treatment, patients may optionally receive FMX IV and undergo MRI at baseline and 24 hours after FMX infusion.
89306615|NCT02625961|Experimental|Pembrolizumab|Participants with carcinoma-in-situ (CIS) with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) will receive pembrolizumab, 200 mg, intravenously, every 3 weeks (Q3W) for up to 24 months.
89306616|NCT02625961|Experimental|Pembrolizumab coformulation|Participants with CIS with or without papillary tumors (Cohort C) will receive either pembrolizumab/vibostolimab or favezelimab/pembrolizumab coformulation intravenously Q3W for up to 24 months
89306617|NCT02582489|Experimental|Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)|Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.
89306618|NCT02582489|Placebo Comparator|Meniscectomy with Placebo|Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee.
89306619|NCT02576223|Active Comparator|Ropivacaine hydrochloride|Ropivacain 7.5mg/ml, 5 ml injected perineural at the suprascapular nerve.
89306620|NCT02576223|Placebo Comparator|Isotonic Saline|0.9% Saline solution, 5 ml injected perineural at the suprascapular nerve.
89306621|NCT02567435|Experimental|Regimen A (VAC/VI)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37. Patients also undergo primary site RT beginning at week 13 or metastatic site RT beginning at week 43 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
89306622|NCT02567435|Experimental|Regimen B (VAC/VI/temsirolimus)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 7, 13, 22, 28, 34, and 40, irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 4, 10, 16, 19, 25, 31, and 37 and temsirolimus IV over 30-60 minutes on day 1 of weeks 1-12 and 21-42. Patients also undergo RT as in Regimen A. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then receive vinorelbine IV over 6-10 minutes on days 1, 8, and 15 and cyclophosphamide PO QD on days 1-28. Cycles repeats every 28 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
89306623|NCT02567435|Experimental|Regimen C (FOXO1 fusion negative, VAC/VA)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-10 and 13-22, dactinomycin IV over 1-5 or 10-15 minutes on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, and 22, cyclophosphamide IV over 60 minutes on day 1 of weeks 1, 4, 7, and 10. Patients undergo RT beginning at week 13 for up to 6.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89306624|NCT02496663|Experimental|Treatment (osimertinib, necitumumab)|Patients receive osimertinib PO QD on days 1-21 and necitumumab IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI and blood sample collection throughout the study.
89306625|NCT02474641|Active Comparator|Standard radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
89306626|NCT02474641|Experimental|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
89306627|NCT02407509|Experimental|Part I - Twice weekly (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours.
89306628|NCT02407509|Experimental|Part I - Three times weekly (COMPLETED)|VS-6766 will be administered three times weekly in 4 week cycles in patients with solid tumours.
89306629|NCT02407509|Experimental|Part IIA (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway.
89306630|NCT02407509|Experimental|Part IIB (CLOSED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with multiple myeloma with a mutation in KRAS, NRAS or BRAF. In order to accommodate steroid use for patients with multiple myeloma, patients will be administered for 3 weeks followed by a week interruption.
89306631|NCT02407509|Experimental|Part IIC (COMPLETED)|VS-6766 will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. Upon occurrence of specified G2 toxicity, dosing intensity will be reduced to 3 weeks followed by a week interruption in a 4 week cycle.
89306632|NCT02407509|Experimental|Part IID - Once weekly dose confirmation (COMPLETED)|VS-6766 and everolimus will be administered once weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
89306633|NCT02407509|Experimental|Part IID - Twice weekly dose confirmation (COMPLETED)|VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with solid tumours with a mutation in the RAS-RAF-MEK pathway. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
89306634|NCT02407509|Experimental|Part IID - Dose expansion|VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with KRAS-mutant lung cancer. All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
89306635|NCT02407509|Experimental|Part IIE- Biopsy Cohort|VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with documented RAS or RAF mutant solid tumours All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle.
89306636|NCT02407509|Experimental|Part IIF- LGSOC Cohort|"VS-6766 and everolimus will be administered twice weekly in 4 week cycles in patients with LGSOC who have previously been treated with the combination of VS-6766 and defactinib within 24 months of trial entry. Additionally, all patients must have displayed anti-tumour activity on the VS-6766 and defactinib combination, defined as follows:~• Experienced a response - confirmed partial response (PR) or complete response (CR) - according to RECIST 1.1.~Or~• Experienced stable disease (SD) according to RECIST 1.1 (Appendix 3) AND patient received VS-6766 and defactinib treatment for a minimum of 12 months.~All patients will dose for 3 weeks followed by a week interruption in a 4 week cycle."
89306637|NCT02403843||Evaluation|A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
89306638|NCT02400216||Group A|Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)
89306639|NCT02400216||Group B|Patients with minimal fibrosis (Ishak score 0-1).
89306640|NCT02394769|Placebo Comparator|Placebo (For Aspirin)|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose, once daily, until the final visit. Duration not to exceed 12 weeks.
89306641|NCT02394769|Active Comparator|Low Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (81 mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
89306642|NCT02394769|Active Comparator|Standard Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (325mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
89306643|NCT02341326||Healthy nonsmokers|"n=20 for Aim 1 n=20 for Aim 2~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 2.To test the hypothesis that FGFR2 signaling is necessary for normal SAE BC stem cell function and suppression of FGFR2 caused by inhibitors and smoking associated factors (EGF and TGF- beta)leads an altered stem cell functional phenotype similar to SAE BC from COPD smokers with reduced capacity as characterized by Aim 1."
89306644|NCT02341326||Healthy smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
89306645|NCT02341326||COPD smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
89306646|NCT02337530|Active Comparator|Arm A|"Selumetinib: 75mg/ bid PO given on days 2-19 Pemetrexed: 500mg/m^2 & Cisplatin or Carboplatin*: AUC6: 75mg/m^2 given on day 1 Schedule = q 21 days~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
89306647|NCT02337530|Active Comparator|Arm B|"Selumetinib: 75mg/ bid PO given on days 1-21 (continuous) Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC 6 given on day 1 Schedule = q 21 days~**Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
89306648|NCT02337530|Active Comparator|Arm C|"Selumetinib: NOT GIVEN Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC6 given on day 1 Schedule = q 21 days~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
89306649|NCT02275780|Experimental|Doravirine 100 mg|Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
89306650|NCT02275780|Active Comparator|Darunavir 800 mg and Ritonavir 100 mg|Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o. q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o. q.d. for an additional 96 weeks. Eligible participants may continue to receive the Doravirine regimen in Study Extension 2 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first. Eligible participants may continue to receive the Doravirine regimen in Study Extension 3 until Doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
89306651|NCT02188264|Experimental|Treatment (selumetinib and cyclosporine)|Patients receive selumetinib PO BID on day -7 of course 1 and then on days 1-28 (one dose on day 1 only). Patients also receive cyclosporine PO BID on day -3 of course 1 and then on days 1-28 (one dose on day 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89306653|NCT02051218|Active Comparator|Arm A (standard arm)|Denosumab 120mg (XGEVA®) sc. q4w
89306654|NCT02051218|Experimental|Arm B (reduced arm)|Denosumab 120mg (XGEVA®) sc. q4w [weeks 1, 5, 9] followed by Denosumab 120mg (XGEVA®) sc. q12w [weeks 13, 25, …]
89306655|NCT01923662|Experimental|Neuroprosthesis|Eligible subjects will receive an implanted device (IRS-8 or IST-16) and surgically implanted electrodes to excite muscles that move paralyzed muscles. These electrodes are connected to the implanted stimulator that delivers electrical pulses to the nerves. These pulses cause the muscles to contract to perform functional movements or to exercise.
89306656|NCT01921686||Gastroesophageal Reflux Disease (GERD)|"History of troublesome symptoms (e.g. heartburn, chest pain, acid regurgitation) secondary to reflux of gastric contents at least three times per week~AND, At least one of the following:~Mucosal breaks on endoscopy (at least Grade-A esophagitis based on Los Angeles classification)~Abnormal pH index (pH less than 4 for greater than 6% of study)~Abnormal MII-pH (greater than 73 episodes of total reflux per 24 hours)"
89306657|NCT01921686||Eosinophilic Esophagitis (EoE)|"History of troublesome esophageal symptoms (e.g. dysphagia, food impaction, vomiting, upper abdominal or chest pain)~Greater than or equal to 15 eosinophils in at least one high powered field (HPF) from distal OR proximal esophageal biopsy~Lack of histological response to 6-8 weeks of high dose Proton Pump Inhibitor (PPI) OR negative pH probe (pH less than 4 for less than 6% of study). Subjects with greater than 15 eosinophils/HPF and abnormal pH results may have an overlap syndrome and will be excluded from the primary analysis."
89306658|NCT01921686||Control|Patients with no history of troublesome esophageal symptoms or esophageal disease AND normal esophagoscopy (for example, patients undergoing evaluation for chronic abdominal pain, inflammatory bowel disease, celiac disease).
89306659|NCT01851018|Experimental|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
89306660|NCT01851018|Active Comparator|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.
89306661|NCT01751776|Placebo Comparator|Part 1, Placebo BI 655064 80/120mg (HV)|Part 1, Healthy volunteers (HV): Placebo matching BI 655064 80 or 120 milligram (mg) injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks follow-up period.
89306662|NCT01751776|Placebo Comparator|Part 1, Placebo BI 655064 180/240mg (HV)|Part 1, Healthy volunteers (HV): Placebo matching BI 655064 180 or 240 mg injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks (180mg dosing group) or 8 weeks (240mg dosing group) follow-up period.
89306663|NCT01751776|Experimental|Part 1, BI 655064 80mg (HV)|Part 1, Healthy volunteers (HV): 80 mg of BI 655064 injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks follow-up period.
89306664|NCT01751776|Experimental|Part 1, BI 655064 120mg (HV)|Part 1, Healthy volunteers (HV): 120 mg of BI 655064 injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks follow-up period.
89306665|NCT01751776|Experimental|Part 1, BI 655064 180mg (HV)|Part 1, Healthy volunteers (HV): 180 mg of BI 655064 injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 6 weeks follow-up period.
89306666|NCT01751776|Experimental|Part 1, BI 655064 240mg (HV)|Part 1, Healthy volunteers (HV): 240mg of BI 655064 injected subcutaneous on days 1, 8, 15, and 22 (once weekly, for 4 weeks) followed by 8 weeks follow-up period.
89306667|NCT01751776|Placebo Comparator|Part 2, Placebo BI 655064 120mg (RA)|Part 2, patients with Rheumatoid arthritis (RA) who had prior inadequate response to Methotrexat (MTX) therapy: Placebo matching BI 655064 120 milligram (mg) injected subcutaneous on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (once weekly for 12 weeks) followed by 8 weeks follow-up period.
89306668|NCT01751776|Experimental|Part 2, BI 655064 120mg (RA)|Part 2, patients with RA who had prior inadequate response to MTX therapy: 120 milligram (mg) of BI 655064 injected subcutaneous on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (once weekly for 12 weeks) followed by 8 weeks follow-up period.
89306669|NCT01738139|Experimental|Treatment (ipilimumab, imatinib mesylate)|Patients receive ipilimumab IV over 90 minutes on day 1 and imatinib mesylate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89306670|NCT01712620|Experimental|Group A|Spironolactone
89306671|NCT01712620|Placebo Comparator|Group B|Placebo
89306679|NCT01594723|Experimental|120 mg LY2784544|120 milligram (mg) administered orally once daily for 6 cycles (168 days)
89306680|NCT01496599||Healthy Volunteers|Subjects without PD diagnosis
89306681|NCT01496599||Parkinsons Disease subjects|Subjects fitting the MSD Clinical Diagnostic Criteria for PD
89306682|NCT01496599||Prodromal Parkinson disease|Subjects fitting the MDS prodromal criteria for PD
89306683|NCT01493570|Experimental|BI 409306 25mg|
89306684|NCT01493570|Experimental|BI 409306 50 mg|
89306685|NCT01493570|Experimental|BI 409306 100 mg|
89306686|NCT01493570|Experimental|BI 409306 200 mg|
89306687|NCT01493570|Placebo Comparator|Placebo|
89306688|NCT01441583|Active Comparator|Pacemaker - RYTHMIQ Off at Pre-discharge, On at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ Off at Pre-Discharge will have RYTHMIQ programmed Off until their 1-month follow up, when they will be crossed over to RYTHMIQ On until their 3-month follow up.
89306689|NCT01441583|Active Comparator|Pacemaker - RYTHMIQ On at Pre-Discharge, Off at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ On at Pre-Discharge will have RYTHMIQ programmed On until their 1-month follow up, when they will be crossed over to RYTHMIQ Off until their 3-month follow up.
89306690|NCT01441583|Experimental|CRT-P|CRT-P devices were not involved in RYTHMIQ endpoint evaluation, only RAAT.
89306691|NCT01303341|Experimental|Treatment (riluzole and sorafenib tosylate)|Patients receive riluzole PO BID and sorafenib tosylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89306692|NCT01168271||Children Ages 0-3 years|Children aged 0-3 years in Ouelessebougou,
89306693|NCT01168271||Febrile Hospitalized Children|Febrile hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Tour(SqrRoot)(Copyright) Hospital in Bamako
89306694|NCT01168271||Later Childhood and Adolescence|Re-enrollees who were originally enrolled at birth and completed the Pregnant Women and Newborn Cohort
89306695|NCT01168271||Non-Hospitalized Children|Febrile non-hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Tour(SqrRoot)(Copyright) Hospital in Bamako
89306696|NCT01168271||Pregnant Women + Newborns|Pregnant women presenting for antenatal consultations and delivery and their newborns
89306697|NCT01087294|Experimental|1A/T cell Arm (closed)|Dose escalation of CAR+ T cells based on the patients actual body-weight
89306698|NCT01087294|Experimental|1B/T memory stem cell arm|Dose Escalation with 5 dose levels of CAR+ T memory cells based on the patients actual body-weight
89306699|NCT01087294|Other|2/Donor arm|Leukapheresis
89306700|NCT01051635|Experimental|Cohort A|LMP400 administered IV daily for 5 days per dose escalation table.
89306701|NCT01051635|Experimental|Cohort B|LMP776 administered IV daily for 5 days per dose escalation table.
89306704|NCT00936325||Healthy volunteers|healthy volunteers to act as controls.
89306705|NCT00936325||Patients with SCLS|patients who have been diagnosed, or are suspected of having systemic capillary leak syndrome.
89306706|NCT00936325||Relatives|relatives of patients who have systemic capillary leak syndrome.
89306707|NCT00753545|Experimental|1|AZD2281
89306708|NCT00753545|Placebo Comparator|2|matching placebo
89306709|NCT00713492|Experimental|1|Alcohol
89306710|NCT00694850|Experimental|Arm 1|
89306711|NCT00605085|Experimental|1|IC51
89306712|NCT00605085|Placebo Comparator|2|Placebo
89306713|NCT00604708|Experimental|IC51|6 mcg (microgram) i.m. (intramuscular) on Day0, 14 and 28
89306714|NCT00604708|Active Comparator|JE-VAX|given s.c. on Day 0, 7 and 28
89306715|NCT00600496|Experimental|1|AZD6244 + docetaxel
89306716|NCT00600496|Experimental|2|AZD6244 + Dacarbazine
89306717|NCT00600496|Experimental|3|AZD6244 + Erlotinib
89306718|NCT00600496|Experimental|4|AZD6244 + Temsirolimus
89306719|NCT00594958|Active Comparator|IC51 Group A|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
89306720|NCT00594958|Active Comparator|IC51 Group B|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
89306721|NCT00594958|Active Comparator|IC51 Group C|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
89306722|NCT00588185|Experimental|1|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
89306723|NCT00342927||Volunteers|Volunteers for a genetic study of diabetes and nephropathy
88806440|NCT02106962|Experimental|Clotting Time Using Tranexamic Acid 25%|Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
88806441|NCT00315146|Placebo Comparator|Hypocaloric diet (and placebo)|
89306725|NCT00092222|Active Comparator|Active Treament 3|Patients not responding to high- dose zidovudine and valganciclovir alone may be treated with botezomib plus high- dose zidovudine and valganciclovir
89306726|NCT00092222|Active Comparator|Active Treatment 1|Single agent sirolimus for patients where targeted oncolytic virotherapy seems suboptimal
89306727|NCT00092222|Active Comparator|Active Treatment 2|EPOCH chemotherapy with rituximab may be utilized to rescue such patients, with the intent of stabilizing suchpatients
89306728|NCT00092222|Active Comparator|Active Treatment 4|Rituximab with liposomal doxorubicin (R-Dox) followed by consolidation or lmaintenancel therapy with dose escalating interferon-alpha
89306729|NCT00092222|Active Comparator|Active Treatment 5|High dose zidovudin and valganciclovir
89306730|NCT00092222|Active Comparator|Natural History|Observation Only
89306731|NCT00013559||Family|Parents and/or siblings of patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
89306732|NCT00013559||Patients|Patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
89306733|NCT00011648||non-SCD|200 Men and Women without a diagnosis of sickle cell disease 18 years of age or older
89306734|NCT00011648||SCD|1000 Men and Women with a diagnosis of sickle cell disease
89306737|NCT00001367||family members|Family Members who are 2 years old or older of people with a neurological disorder
89306738|NCT00001367||healthy volunteers|healthy volunteers age 18 and older
89306739|NCT00001367||patients|subjects with neurological disorders who are 2 years old or older
89306740|NCT00001360||1|Normal volunteer participants aged 18-65 who are in good general health.
88806442|NCT00315146|Active Comparator|Hypocaloric diet, resist. training to maximize power, placebo|
88806443|NCT00315146|Active Comparator|Hypocaloric diet and a PPAR- γ agonist (pioglitazone/Actos™)|
88806444|NCT00315146|Active Comparator|Hypocaloric diet,resistance training, pioglitazone/Actos™|
89306741|NCT03659110||1000 subjects receive the HPV 4 vaccine|
89306742|NCT03658408|Experimental|4-aminopyridine|Participants with recent prostatectomies receiving 4-aminopyridine
89306743|NCT03658408|Placebo Comparator|Placebo|Participants with recent prostatectomies receiving placebo
89306744|NCT03659032|Experimental|Pediatric Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
89306745|NCT03659032|Active Comparator|Control Group|"Only Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
89306746|NCT03034330|Experimental|Two-Tier Stroke Family Empowerment|The intervention is individualized, tailor-made according to caregivers' needs. The intervention will last for 2 to 3 months with 6 to 10 weekly sessions at the home of caregivers or stroke survivors. Each session will last for 60 to 90 minutes. The care managers will determine the intensity of the intervention after the initial family assessment.
89306747|NCT03034330|Active Comparator|Volunteer Support Psychoeducation|The intervention will last for 2 months with 4 weekly sessions at the home of caregivers or stroke survivors in the first month and 2 telephone contacts in the second month (6 contact points in total). Each session will last for 60 to 90 minutes. Care managers will not provide any direct intervention for participants in the control group.
89306748|NCT03657706|Active Comparator|group A|tunnel procedure with subepithelial connective tissue graft (sCTG)
89306749|NCT03657706|Active Comparator|group B|tunnel procedure with modified free gingival graft (mFGG)
89306750|NCT03658330|Experimental|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
89306751|NCT03658252|Experimental|Intervention|"Participants in the intervention arm will be shown a 2 minute educational video, and given an information leaflet on topical steroids. At 1 month of follow up, a link encouraging participants to sign up for a pre-selected, disease specific, moderated online support group would be sent to their emails.~Participants will continue to receive standard medical care and counselling by their dermatologists as clinically indicated."
89306752|NCT03658252|No Intervention|Control|Patients in the control arm will receive only standard medical care and counseling by their dermatologist as clinically indicated.
89306753|NCT04486222|Experimental|Experimental Group|The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.
89306754|NCT04486222|Active Comparator|Standard Treatment Group|The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.
89306755|NCT03658174|Active Comparator|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice to be taken twice a day. This contains 5-6 mmol of inorganic nitrate.
89306756|NCT03658174|Placebo Comparator|Nitrate-free beetroot juice|70mls of concentrated nitrate-free beetroot juice to be taken twice a day. This is an identical juice from which the nitrate has been removed using a standard anion exchange resin.
89306757|NCT02920528|Placebo Comparator|Placebo|placebo controlled arm
89306758|NCT02920528|Experimental|very low dose ketamine|0.25 mg/kg of sub-dissociative ketamine as an experimental arm
89306759|NCT02920528|Experimental|low dose ketamine|0.50 mg/kg of sub-dissociative ketamine as an experimental arm
89306760|NCT01068418|Experimental|Vitamin D3|15000IU of vitamin D3 daily: open-label, single-arm
89306761|NCT01100619|Experimental|All subjects|All subjects will receive daily XL184, and two single doses of rosiglitazone, 3 weeks apart
89306762|NCT01101243|Active Comparator|Group 1|Body surface area: 88 %
89306763|NCT01101243|Active Comparator|Group 2|Body surface area: 22 %
89306764|NCT01101243|Active Comparator|Group 3|Body surface area: 88 %
89306765|NCT01101243|Active Comparator|Group 4|Body surface area: 88 %
89306766|NCT01101243|No Intervention|Group 5|Body surface area: 0 %
89306767|NCT03954093|Sham Comparator|Sham stimulation|
89306768|NCT03954093|Active Comparator|Motor cortex stimulation|
89306769|NCT03954093|Experimental|MEG-localized stimulation|
89306770|NCT01100697||thoracal lesion|spinal lesion at thoracal level detected at prenatal ultrasound exam
89306771|NCT01100697||lumbar lesion|spinal lesion at lumbar level detected at prenatal ultrasound exam
89306772|NCT01100697||sacral lesion|spinal lesion at sacral level detected at prenatal ultrasound exam
89306773|NCT05626023|Experimental|Human TH-SC01 cell injection|Single injection of 0.6×10^7, 1.2×10^8, 1.8×10^8 cells/kg
89306774|NCT01068262|Experimental|Panel A - Odanacatib|Panel A - Healthy male subjects receiving Odanacatib
89306775|NCT01068262|Placebo Comparator|Panel A - Placebo|Panel A - Healthy male subjects receiving placebo
89306776|NCT01068262|Experimental|Panel B - Odanacatib|Panel B - Healthy female subjects receiving Odanacatib
89306777|NCT01068262|Placebo Comparator|Panel B - Placebo|Panel B - Healthy female subjects receiving placebo
89306778|NCT03658018|Experimental|Intracept System Ablation|
89306779|NCT03657940|Experimental|Exercise intervention|multicomponent exercise training program [VIVIFRAIL],
89306780|NCT03657940|No Intervention|Usual Care|Participants randomly assigned to the usual care group will receive normal outpatient care, which includes physical rehabilitation when needed.
89306781|NCT03657550|Other|Test Drug - Reference Product - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
89306782|NCT03657550|Other|Reference Product - Test Drug - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
89306783|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 1[110 mg])|
89306784|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 2[150 mg])|
89306785|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 3[180 mg])|
89306786|NCT02920450|Experimental|Treatment Arm (Phase 2; MTD of Gedatolisib from Phase Ib)|
89306787|NCT03622450|Experimental|Medication arm|Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
89306788|NCT03622450|Active Comparator|Control arm|Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
89306789|NCT03657862|Experimental|SDF treated|application of 38% silver diamine fluoride solution
89306790|NCT03657862|Placebo Comparator|Placebo|application of a placebo (tonic water)
89306791|NCT02730130|Experimental|Pembrolizumab Plus Radiotherapy|Subjects will receive pembrolizumab 200 mg as an IV infusion. RT begins D1 prior to dose 1 of Pembrolizumab. Pembrolizumab will be administered as a 30 minute IV infusion. Radiotherapy will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. The dose of radiation will be a standard regimen/fractionation used in palliation: 3000 cGy, delivered in five 600 cGy fractions within 5-7 days.
89306792|NCT02919436|Experimental|Tamsulosin|Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.
89306793|NCT02919436|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.
89306794|NCT04456972|Experimental|One arm only|
89306795|NCT03657472|Experimental|Sequence 1(RTR)|
89306796|NCT03657472|Experimental|Sequence 2(RRT)|
89306797|NCT03657472|Experimental|Sequence 3(TRR)|
89306798|NCT03657082|Experimental|Arm A|In this arm, patients will receive the experimental condition first, then the sham condition
89306799|NCT03657082|Experimental|Arm B|In this arm, patients will receive the sham condition first, then the experimental condition
89306800|NCT03622372|Experimental|CoNextions TR Implant|Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System
89306801|NCT03622372|Active Comparator|Suture Repair|Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture
89306802|NCT03804879|Experimental|LMB763|50 mg LMB763 (two LMB763 25 mg capsules) were orally administered once daily for 24 weeks in addition to SoC.
89306803|NCT03804879|Placebo Comparator|Placebo|Placebo was orally administered once daily for 24 weeks in addition to SoC.
89306804|NCT04438330|Experimental|Nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
89306805|NCT04438330|Active Comparator|non-nickel allergic individuals|Nickel sulfate hexahydrate in petrolatum. Exposed in a patch test dose-range with a max concentration of 5% nickel sulfate hexahydrate
89306806|NCT02746510|Experimental|Array comparative genomic hybridization|The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV) or a pathogenic sequence variation (exome trio sequencing).
89306807|NCT03803475|Experimental|Ga-68 labeled PSMA-11 PET PSMA|The imaging agent (Ga-68 PSMA-11 or PSMA-HBED-CC) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET imaging. The injected dose will be 3 to 7 millicurie (mCi) +/- 10% of 68Ga-PSMA-11.
89306808|NCT02682004||Women with postpartum depression|
89306809|NCT02682004||Women without postpartum depression|
89306810|NCT01101399|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 4 (week 2).
89306811|NCT01101399|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
89306812|NCT03657316|Experimental|experimental school 1|"The experimental school 1 will receive the following:~Nutritional and physical activity educational workshop~Enhanced physical education~Involvement of the morning broadcast~Educational brochure will be sent to the parents~A monthly telephone call or a text message will be sent to the parents~Message to school administration to prevent selling of soft drinks and to sell healthy food~A monthly session (3 months)"
89306813|NCT03657316|Experimental|experimental school 2|The experimental school 2 school will receive a nutritional and physical activity educational workshop; that will be held on three days through one week; one hour session each day
89306814|NCT03657316|No Intervention|control|The control school will receive no intervention
89306815|NCT00005937|Experimental|Antithymocyte globulin & cyclosporine|Myelodysplastic syndromes (MDS) subjects will be treated with Anti-thymocyte Globulin (ATG) and cyclosporine (CsA). The subjects will receive ATG at a dose of 40mg/kg orally on days 1-4 in combination with oral prednisone at a dose of 1mg/kg/day on day one. The prednisone will be tapered on day 10. The taper schedule will be every two days over a total of eight days (days 10-17). Drug the ATG administration the subjects will receive at least 4 units of platelets daily for platelet counts less than 20,000/ microliters. Cyclosporine (CsA) will be started on day 14 at a dose of 5mg/kg twice daily with dose adjustments based on drug levels (target 200-400 ng/ml). Cyclosporine therapy will be continued for six months.
89306816|NCT02644798||ARDS patients|Adult ARDS (according to Berlin definition) patients were enrolled in the trial. The diagnostic criteria included (a) within one week of a known clinical insult or new or worsening respiratory symptoms; (b) chest imaging showing that bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules; (c) respiratory failure not fully explained by cardiac failure or fluid overload; and (d) arterial partial pressure of oxygen / fraction of inspiration oxygen (PaO2/FiO2 ratio, P/F ratio) less than or equal to 300 mmHg.
89306817|NCT01102881|Placebo Comparator|No fiber|No fiber added to muffins or cereal
89306818|NCT01102881|Experimental|Fiber made from corn starch|Muffins and cereal made with novel corn fiber
89306819|NCT01102881|Experimental|Glucose polymer fiber|Muffins and cereal made from glucose polymer fiber
89306820|NCT03657238|Experimental|Experimental|Doses were escalated from 0.2μg/kg up to 4.8μg/kg
89306821|NCT03657238|Placebo Comparator|Placebo|
89306822|NCT03443024|Experimental|125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W)|"125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.~Baseline: Loading dose 250 mg Lebrikizumab SC (two injections SC 1-milliliter (mL) of 125 mg/mL Lebrikizumab and 1-mL placebo).~Week 2: Four 1-mL SC injections placebo.~Weeks 4, 8, 12: 125 mg SC Lebrikizumab and 1-mL SC placebo.~Weeks 6, 10, 14: Two 1-mL SC placebo."
89306823|NCT03443024|Experimental|250 mg Lebrikizumab - Q4W|"250 mg Lebrikizumab administered SC once Q4W.~Baseline: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 2: Four 1-mL SC injections of placebo.~Weeks 4, 8, 12: 250 mg (two 1-mL injections of 125 mg/mL Lebrikizumab).~Weeks 6, 10, 14: Two 1-mL injections of placebo."
89306824|NCT03443024|Experimental|250 mg Lebrikizumab - Every 2 Weeks (Q2W)|"250 mg Lebrikizumab administered SC once Q2W.~Baseline and Week 2: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 4, 6, 8, 10, 12, 14: 250 mg (two 1-mL SC injections of 125 mg/mL Lebrikizumab)."
89306825|NCT03443024|Placebo Comparator|Group 4 - Placebo|"Placebo administered SC once Q2W.~Baseline and Week 2: Four 1-mL SC injections of placebo.~Week 4, 6, 8, 10, 12, 14: Two 1-mL SC injections of placebo."
89306826|NCT01096251|Experimental|CBT|CBT group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of CBT) plus 8 outpatient telephone-based sessions of CBT-oriented psychological support and monitoring with the same CBT inpatient psychotherapists.
89306827|NCT01096251|Experimental|BST|BST group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of BST) plus 8 outpatient telephone-based sessions of BST-oriented psychological support and monitoring with the same BST inpatient psychotherapists.
89306828|NCT03656458|Active Comparator|Control Group A|Warm Up followed by Conventional Balance Training (Internal and External Perturbations)
89306829|NCT03656458|No Intervention|Control Group B|Control group. No intervention given to participants.
89306830|NCT03656458|Experimental|Experimental Group|Warm Up followed by Biodex Balance Training
89306831|NCT01102959|Experimental|Photographic Material|Photographic Educational Material on Carbohydrate Counting
89306832|NCT01096329|Active Comparator|Cohort 2|Testosterone Spray (5%) vs Intrinsa® Patch
89306833|NCT01096329|Active Comparator|Cohort 3|Testosterone Spray (1%) vs Intrinsa® Patch
89306834|NCT01096329|Active Comparator|Cohort 1|Testosterone Spray (5%) vs Testosterone Spray (1%)
89306835|NCT03656770|No Intervention|V1: Control|This version of the survey questionnaire depicts a young woman with no symptoms of mental illness.
89306836|NCT03656770|Experimental|V2: Schizophrenia|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic schizophrenia."
89306837|NCT03656770|Experimental|V3: Schizophrenia + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with complete response."
89306838|NCT03656770|Experimental|V4: Schizophrenia + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with partial relapse."
89306839|NCT03656770|Experimental|Version 5: Bipolar|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic bipolar disorder."
89306840|NCT03656770|Experimental|V6: Bipolar + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with complete response."
89306841|NCT03656770|Experimental|V7: Bipolar + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with partial relapse."
89306842|NCT03656770|Experimental|V8: Depression|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic major depressive disorder."
89306843|NCT03656770|Experimental|V9: Depression + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with complete response."
89306844|NCT03656770|Experimental|V10: Depression + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with partial relapse."
89306845|NCT02908516|Experimental|Tranexamic acid|Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
89306846|NCT02908516|Placebo Comparator|Placebo|Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.
89306847|NCT03622294|Experimental|Right Breast Mammogram Measurements and Survey|"A right breast screening mammogram will be performed with Bella Blankets protective coverlets on the imaging receptor plate, then removed from the equipment.~The screening mammogram continues with a left breast and second right breast screening mammogram on a bare imaging receptor plate.~Clinical image quality measurements for the right breast mammograms will automatically be captured by VolparaEnterprise for a comparative analysis.~A patient satisfaction survey will be completed by each participant and the results will be analyzed."
89306848|NCT03717350|Placebo Comparator|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously
89306849|NCT03717350|Active Comparator|Antibiotic|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously
89306850|NCT03656302||Case offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having at least one biological parent with a lifetime or current diagnosis of bipolar disorder; 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder; 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
89306851|NCT03656302||Control offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having no biological parent(s) with lifetime or current diagnosis of mood disorders. 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form.~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder. 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
89306852|NCT03656224||Observational (survey)|Participants complete surveys over 15 minutes at 1-2 days before discharge and at 1 month after discharge.
89306853|NCT03713372|Experimental|Anti-EGFR monoclonal antibody|6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
89306854|NCT02907892|No Intervention|Control|Standard cesarean section surgical technique per surgeon preference
89306855|NCT02907892|Experimental|Glove Change|Cesarean section including changing of sterile surgical gloves immediately prior to abdominal closure
89306856|NCT03656614||sugammadex 0.125|Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
89306857|NCT03656614||Sugammadex 0.25|Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
89306858|NCT03656614||Sugammadex 0.5|Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
89306859|NCT03656614||Sugammadex 1.0|Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
89306860|NCT03656614||Sugammadex 2.0|Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
89306861|NCT03656614||Neostigmine 10|Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
89306862|NCT03656614||Neostigmine 25|Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
89306863|NCT03656614||Neostigmine 40|Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
89306864|NCT03656614||Neostigmine 55|Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
89306865|NCT03656614||Neostigmine 70|Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
89306866|NCT03656614||Placebo|Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3
89306867|NCT02906644|Experimental|Lorcaserin + Patch|Participants will receive lorcaserin (10mg twice a day) and nicotine patches (21mg/24hr) for 14 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
89306868|NCT02906644|Experimental|Patch|Participants will receive nicotine patches (21mg/24hr) and placebo lorcaserin for 2 weeks; after 2 weeks participants will begin to receive active lorcaserin (10mg twice a day) along with the nicotine patches for 12 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
89306869|NCT03622216|Experimental|Bradanicline QD|Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
89306870|NCT03622216|Placebo Comparator|Placebo|Randomized crossover design of matching placebo tablets to be administered orally QD
89306871|NCT03410108|Experimental|Brigatinib 90 mg + Brigatinib 180 mg|Brigatinib 90 milligram (mg), tablets, orally, once daily (QD) for first 7 days followed by brigatinib, 180 mg, tablets, orally, QD in Cycle 1 of 28 days followed by brigatinib 180 mg, tablets, orally, QD in Cycle 2 and onward cycles of 28 days until investigator-assessed progressive disease (PD) or intolerable toxicity, withdrawal of consent, or discontinuation for any other reason, whichever comes first up to Cycle 34 of 28-day cycle, until data cut-off date 29 September 2020.
89306872|NCT02982772|Experimental|Tailored Combination Therapy|"Combination of Brief behavioral intervention Plus Nicotine replacement. The test product is a transdermal nicotine patch and Nicotine replacement gums for 12 weeks. The dosage of the test product depends on the amount of cigarettes used.~Doses will be tailored and adjust as need it"
89306873|NCT02982772|Active Comparator|Standard Care Intervention|"Brief behavioral intervention The test product is a transdermal nicotine patch plus regular flavored gums for 10 weeks. The dosage of the test product depends on the amount of cigarettes used.~Standard Flavored gums will be used as needed for 10 weeks."
89306874|NCT03713216|Experimental|Naldebain|Subjects will receive one dose of Naldebain before surgery.
89306875|NCT03713216|Active Comparator|Morphine|Subjects will receive morphine after surgery.
89306876|NCT03720236|Experimental|Full preparation|Group A: the complete milling protocol indicated by the manufacturer for the 3.75x10 mm BLX implant will be performed.
89306877|NCT03720236|Experimental|Partial preparation|Group B: the partial / under milling protocol for the 3.75x10 mm implant, indicated by the manufacturer, will be carried out.
89306878|NCT03720236|Experimental|Deferred loading|Code 2: for implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. Impressions will be taken at 6 weeks to place the provisional prosthesis at 8 weeks. At 6 months the final impressions will be taken for the definitive load.
89306879|NCT03720236|Experimental|Immediate load|The code 1: to the implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. The impression will be made in the same surgery and the placement of the provisional prosthesis before 7 days. At 6 months the final impressions will be taken for the definitive load.
89306880|NCT03655834|Experimental|Microdosing|Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment
89306881|NCT03713138|Experimental|Intervention Flaxseed powder|"Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Intervention/ Dietary Supplement:~Flax seed powder~Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Other Name: intervention"
89306882|NCT03713138|No Intervention|Control group; Comparison group|"The controlled group was given no intervention. No intervention was done to this group.~Three different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day."
89306883|NCT03488108|Experimental|Platelet Rich Plasma first, then Minoxidil Foam|Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
89306884|NCT03488108|Experimental|Minoxidil Foam first, then Platelet Rich Plasma|Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.
89306885|NCT03712748|Experimental|Imaginal Exposure Session|
89306886|NCT03712670|Active Comparator|AM group|Intravitreal aflibercept monotherapy
89306887|NCT03712670|Experimental|AP group|Intravitreal aflibercept along with 0.1% pranoprofen
89306888|NCT03712670|Experimental|AN group|Intravitreal aflibercept plus daily supplementation of nutraceutical tablets
89306889|NCT03712592|Experimental|160km|
89306890|NCT03712592|Experimental|40km|
89306891|NCT03712592|Experimental|100km|
89306892|NCT03712592|Experimental|4x40km|
89306893|NCT03712436|Experimental|patients receiving palliative care|Patients receiving standard oncologic care plus palliative care.
89306894|NCT03712436|Active Comparator|patients receiving standard oncological care|Patients receiving standard oncologic care.
89306895|NCT03440918|Active Comparator|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
89306896|NCT03440918|Experimental|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
89306897|NCT03717272|Experimental|AEF0117|AEF0117 capsules ; dose range 0.02 to 1.2mg by mouth, once a day for 5 consecutive days.
89306898|NCT03717272|Placebo Comparator|Placebo oral capsule|corn oil capsules once a day for 5 consecutive days.
89306899|NCT05657834|Experimental|Treatment Arm 1|Single dose of TVB-2640, 50 mg, oral administration
89306900|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 1|Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
89306901|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 2|Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
89306902|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 3|Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
89306903|NCT03486392|Placebo Comparator|Double-Blind: Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
89306904|NCT03486392|Active Comparator|Open-Label: 3.0 milligram (mg) Liraglutide|Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
89306905|NCT01311440|Experimental|Modified Atkins diet treatment|12 weeks of Modified Atkins diet treatment, recording seizures
89306906|NCT01311440|No Intervention|No intervention|12 weeks seizure record
89306907|NCT02981602|Experimental|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
89306908|NCT02981602|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
89306909|NCT01838824|Experimental|Speed of Processing Training - Group 1|Group 1 will receive speed of processing training immediately following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
89306910|NCT01838824|Experimental|Speed of Processing Training - Group 2|Group 2 will receive speed of processing training 6 weeks following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
89306911|NCT02981524|Experimental|CY/GVAX with Pembrolizumab|During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells for the first 4 cycles of treatment. After cycle 4, cyclophosphamide and GVAX will be administered with every 4th cycle.
89306912|NCT04297150||Patients that satisfy inclusion criteria|Patients who satisfy the inclusion criteria and sign the informed consent.
89306913|NCT03653962|Active Comparator|only informed consent|The first group was given verbal-written informed consent and a 15 question quiz about the informed consent content afterwards.
89306914|NCT03653962|Experimental|video assisted group|The second group got an additional information video presentation and then the same quiz.
89306915|NCT03655600|Active Comparator|Self-administered acupressure|Acupressure administered by participant self-taught from computer application
89306916|NCT03655600|No Intervention|Usual care|Usual care
89306917|NCT03486314|Experimental|Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg|Pevonedistat 50 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants had opportunity to continue into optional Part B.
89306918|NCT03486314|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 intravenously in combination with docetaxel 75 mg/m^2 or at 20 mg/m^2 in combination with carboplatin +paclitaxel 175 mg/m^2; pevonedistat was given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants were treated for up to 12 cycles or symptomatic deterioration or PD, treatment was discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) was based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
89306919|NCT02905006|Placebo Comparator|Placebo|
89306920|NCT02905006|Experimental|Bimekizumab dosing regimen 1|
89306921|NCT02905006|Experimental|Bimekizumab dosing regimen 2|
89306922|NCT02905006|Experimental|Bimekizumab dosing regimen 3|
89306923|NCT02905006|Experimental|Bimekizumab dosing regimen 4|
89306924|NCT02905006|Experimental|Bimekizumab dosing regimen 5|
89306925|NCT03655522|Active Comparator|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
89306926|NCT03655522|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state.
89306927|NCT03655366||Dog owners with epilepsy|Epilepsy patients that own one or more dogs.
89306928|NCT03655366||Training organisations|Trainers of seizure response and seizure alerting dogs.
89306929|NCT03655210|Experimental|Experimental|HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment
89306930|NCT03655210|Placebo Comparator|Placebo Comparator|HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment
89306931|NCT01066780|Experimental|Group A: ClearVoice Medium|Chronic use of ClearVoice MEDIUM for two weeks followed by chronic use of ClearVoice HIGH for two weeks.
89306932|NCT01066780|Experimental|Group B: ClearVoice High|Chronic use of ClearVoice HIGH for two weeks followed by chronic use of ClearVoice MEDIUM for two weeks.
89306933|NCT02975206|Experimental|Serlopitant High Dose|serlopitant tablets - high dose
89306934|NCT02975206|Experimental|Serlopitant Low Dose|serlopitant tablets - low dose
89306935|NCT02975206|Placebo Comparator|Placebo Oral Tablet|matching placebo tablets
89306936|NCT03654820|Experimental|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
89306937|NCT03654820|Active Comparator|SDF treated|Annual application of 38% SDF solution
89306938|NCT01066156|Experimental|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
89306939|NCT03654352||High Risk for ARDS/ALI|Mechanically ventilated patients with risk factors for the development of ARDS/ALI. These factors are classified into two categories: pulmonary insults, such as pneumonia and extrapulmonary insults such as sepsis.
89306940|NCT03654352||Low Risk for ARDS/ALI|Mechanically ventilated patients with low risk factors for the development of ARDS/ALI. These factors include mechanical ventilation for airway protection, pain management, or procedure.
89306941|NCT03654196|Experimental|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
89306942|NCT03654196|Active Comparator|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
89306943|NCT03654586|Active Comparator|Calorie label|"Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels."
89306944|NCT03654586|Experimental|Text warning label|Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay
89306945|NCT03654586|Experimental|Sugar graphic warning label|"Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage"
89306946|NCT03654586|Experimental|Health graphic warning label|"Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."
89306947|NCT03654430|Other|Healthy Newborns|
89306948|NCT02980042|Experimental|Switching Group|600 mg of ocrelizumab will be administered as one 600-mg IV infusions at a scheduled interval of every 24 weeks. The first dose of ocrelizumab will be a split dose of 300 mg on day 1 and day 15 followed by 600 mg, six months later. Each ocrelizumab infusion should be given as a slow IV infusion over approximately 150 minutes (2.5 hours) for the 300-mg dose. Ocrelizumab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and ocrelizumab should be infused through a dedicated line.
89306949|NCT02980042|Active Comparator|Comparator Group|Standard of care rituximab doses are 1000 mg infusion given as first dose followed by 500mg (or 1000 mg if evidence of early B cell recovery) infusion every 6 months thereafter. Rituximab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and rituximab should be infused through a dedicated line
89306950|NCT03653728||Traumatic brain injury with cerebral contusions|
89306951|NCT01066000|Experimental|Mircera|
89306952|NCT01065844|Experimental|Nelfinavir|1250 mg Nelfinavir twice daily Monday-Sunday
89306953|NCT00004635|Experimental|Thalidomide|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received thalidomide orally 200 mg a day. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received the placebo for thalidomide once a day.
89306954|NCT00004635|Experimental|Placebo|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received placebo for thalidomide. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received thalidomide 200 mg once a day.
89306955|NCT00004563|Experimental|Cylophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
89306956|NCT00004563|Placebo Comparator|Placebo|Matching gel caps at a dose of 25 mg
89306957|NCT03951051|Other|Sequence AB|16 subjects assigned to the sequence AB will receive a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89306958|NCT03951051|Other|Sequence BA|16 subjects assigned to the sequence BA will receive a single 40 mg dose of the reference product Olmetec® (1 x 40 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 40 mg dose of the test product Olmesartan Medoxomil (1 x 40 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89306959|NCT03948945|No Intervention|before treatment|The patient with facial and neck photoaging did not receive laser treatment.
89306960|NCT03948945|Experimental|after treatment|The patient with facial and neck photoaging received Profile HaloTM mixed fractional laser treatment
89306961|NCT01096407||Paclitaxel-Induced Myalgias/Arthralgias|
89306962|NCT01103115|Placebo Comparator|Placebo|Subjects in this group will take the placebo tablets
89306963|NCT01103115|Active Comparator|Ca600mg+VitD400IU|subjects receive a daily dose of 600 mg elemental calcium and 400 IU vitamin D3
89306964|NCT01103115|Active Comparator|Ca600mg+VitD800IU|subjects receive a daily dose of 600 mg elemental calcium and 800 IU vitamin D3
89306965|NCT01103193|Active Comparator|remifentanil injected|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
89306966|NCT01103193|Active Comparator|sevoflurane in step up concentration|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
89306967|NCT03949023||Standard of Care Cerebral Angiogram Group|Participants undergoing a standard of care cerebral angiogram.
89306968|NCT03949101|Experimental|combined use of 1% atropine and 0.01% atropine|first week, use atropine sulfate 1% ophthalmic ointment every night before sleep; then use atropine sulfate 1% ophthalmic ointment once every week(Friday night before sleep is recommended) for half a year; then use atropine sulfate 0.01% eye drop every night before sleep for one year and a half.
89306969|NCT03949101|Active Comparator|0.01% atropine|use atropine sulfate 0.01% eye drop every night before sleep for two years.
89306970|NCT01096485|Experimental|Arm 1|
89306971|NCT01096485|Active Comparator|Arm 2|
89306972|NCT01096563|Experimental|1|AZD9164
89306973|NCT01096563|Placebo Comparator|2|
89306974|NCT00003645|Experimental|Arm I - Leuprolide + Flutamide|Arm I: Patients receive leuprolide intramuscularly once every 3 months and oral flutamide three times daily for 1 year.
89306975|NCT00003645|No Intervention|Arm II - No Treatment|Arm II: Patients receive no initial treatment.
89306976|NCT00003537|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89306977|NCT00003531|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89306978|NCT03949179||Pain and Disability Drivers Management model|Participating clinicians will use the PDDM model to guide assessment and treatment of their patients for a 6-weeks period.
89306979|NCT05625711|Experimental|Robot assisted surgery|The robot will assist doctors to complete lower limb artery surgery, including but not limited to the transfer and withdrawal of guide wire, catheter and stent
89306980|NCT01327443|Other|Weight loss|10% weight loss in 24 weeks time period through nutritional counseling.
89306981|NCT01327443|Active Comparator|Exercise without weight loss|24 weeks under direct supervision.
89306982|NCT01327443|No Intervention|Control|No change in usual exercise levels or food intake.
89523392|NCT03381053||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
89306983|NCT02918968|Experimental|Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT|Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
89306984|NCT02918968|Experimental|Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT|Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
89306985|NCT03653572|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
89306986|NCT01065766||All participants|Korean participants with type 2 diabetes mellitus treated with sitagliptin/metformin
89306987|NCT03653494|Experimental|phrenic block group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block
89306988|NCT03653494|Active Comparator|Control group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block
89306989|NCT03653260|Experimental|Lidocaine (Zingo)|0.5mg lidocaine at 20 bar pressure
89306990|NCT03653260|Placebo Comparator|Placebo|no emitted particle at 20 bar pressure, identical in external appearance to Zingo
89306991|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fasting|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
89306992|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fasting|Subjects will take a single Azilva 20mg Tablet under fasting condition
89306993|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fed|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
89306994|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fed|Subjects will take a single Azilva 20mg Tablet under fed condition
89306995|NCT01063972|Experimental|Experimental 1|Experimental: 1 Centralized disease management
89306996|NCT01063972|Experimental|Experimental 2|Experimental: 2 Counseling alone
89306997|NCT04054960|Experimental|Real tPCS|Patients will be randomized to any of the 3 arms. In Real tPCS arm, we will give active tPCS for 20 mins.
89306998|NCT04054960|Sham Comparator|Sham tPCS|Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.
89306999|NCT04054960|Active Comparator|Levodopa|Patients will be randomized to any of the 3 arms. In Levodopa arm, we will give 3 tablets of Levodopa-Carbidopa (100/25).
89307000|NCT03653182||normal|A normal constitution condition in TCM.
89307001|NCT03653182||Qi deficiency|One of an abnormal constitution condition in TCM.
89307002|NCT03653182||Damp heat|One of an abnormal constitution condition in TCM.
89307003|NCT03653182||Yang deficiency|One of an abnormal constitution condition in TCM.
89307004|NCT03653182||Yin deficiency|One of an abnormal constitution condition in TCM.
89307005|NCT03653182||Phlagm|One of an abnormal constitution condition in TCM.
89307006|NCT03653182||Blood stasis|One of an abnormal constitution condition in TCM.
89307007|NCT03653182||Qi stagnation|One of an abnormal constitution condition in TCM.
89307008|NCT03653182||Special|One of an abnormal constitution condition in TCM.
89307009|NCT04055194|Active Comparator|Tranexamic acid group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
89307010|NCT04055194|Placebo Comparator|Placebo group|100 pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
89307011|NCT01103427|Active Comparator|Internet-based coaching .|"Arm 1. Those in the active comparator arm will benefit from automated internet-based coaching. The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
89307012|NCT01103427|Experimental|SMS based coaching|"Arm 2. The subjects will receive automated coachingby SMS.The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
89307013|NCT01103427|Experimental|SMS coaching UNN recruited|Arm 3.The subjects will be recruited from those reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4.
89307014|NCT01103427|Experimental|Craving/Panic function. UNN recruited|"Arm 4. The subjects will in addition to the automated coachingby SMS get a SMS panic/craving function. The subjects will be recruited from subjects reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4."
89307015|NCT03653104|Experimental|Melodica Intervention|An 8-week group intervention including twice-weekly sessions. Each session will last one hour in duration with approximately 20 minutes for instruction, 30 minutes in group music-making, and 10 minutes allocated for educational information about COPD, tobacco cessation, and pulmonary rehabilitation.
89307016|NCT03653104|Active Comparator|Education Control|A single 90-120 minute education session including the same educational information about COPD, tobacco cessation, and pulmonary rehabilitation provided to the melodica intervention group.
89307017|NCT03653104|No Intervention|Usual Care Control|Usual care at Richard L. Roudebush VA Medical Center.
89307018|NCT03653104|No Intervention|Interview Only|Semi-structured interviews will be conducted with Veterans who meet eligibility criteria, but who do not agree to participate in the intervention, to identify potential barriers to participation
89307019|NCT01101633|Active Comparator|1|500 ml beverage containing alginate (3%)
89307020|NCT01101633|Active Comparator|2|330 ml beverage containing alginate (3%)
89307021|NCT01101633|Placebo Comparator|3|500 ml beverage without alginate (placebo)
89307022|NCT01101633|Placebo Comparator|4|330 ml beverage without alginate (placebo)
89307023|NCT00003483|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89307024|NCT04186000|Experimental|group 1|Booster vaccine with AD26.ZEBOV after 1 year
89307025|NCT04186000|Experimental|group 2|Booster vaccine with AD26.ZEBOV after 2 years
89307026|NCT01103583|Experimental|Hydroxyurea|
89307027|NCT01103583|Placebo Comparator|Placebo|
89307028|NCT03654118||ISIS cohort|"Patients operated between December 2007 and December 2008 for recurrent shoulder instability using the arthroscopic procedure (Arthroscopic Bankart) in the investigative centers and presenting at the time of indication for surgery an ISIS score ≤ 4 points~Phone follow-up"
89307029|NCT01101711||Patients with subarachnoid hemorrhage|
89307030|NCT02530047|Experimental|Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ)|MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INFβ tested. Symptom questionnaire completed once a week for 4 weeks.
89307031|NCT02529969|Active Comparator|intervention|500 mg curcumin capsule
89307032|NCT02529969|Placebo Comparator|placebo|500 mg placebo
89307033|NCT01103661|Other|Numeris-AF Guided Coagulation System|
89307034|NCT01584687|Experimental|Omalizumab|All patients will receive omalizumab.
89307035|NCT00003477|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89307036|NCT01101789|Active Comparator|triclosan|triclosan-coated sutures
89307037|NCT01101789|Placebo Comparator|control|sutures without triclosan-coating
89307038|NCT00003471|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89307039|NCT04185220|Experimental|1- Experimental Treatment: Dose Escalation|Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with mogamulizumab by intravenous (IV) infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle to determine MTD.
89307040|NCT04185220|Experimental|2- Experimental Treatment: Dose Expansion|Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion at the maximum tolerated dose (MTD) on days 1- 5 of each 28-day cycle (max 6 cycles) with mogamulizumab by intravenous (IV) infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle.
89307041|NCT01103739|Experimental|cohort 1|
89307042|NCT01103739|Experimental|cohort 2|
89307043|NCT03652948|Experimental|Meru Health Ascend Program|"The Meru Health Ascend Program is an 8-week mobile application (app) based intervention that teaches cognitive-behavioral and mindfulness skills. The intervention also includes a group discussion board with the other participants in the intervention group and therapist support via chat within the app.~Study 2 is examining a revised version of the Meru Health Ascend Program that is 12 weeks long and incorporates sleep and nutrition information in addition to the 8-week program."
89307044|NCT04054024|Active Comparator|Active drug|
89307045|NCT04054024|Placebo Comparator|Placebo|
89307046|NCT00002931|Experimental|HD Chemo and Auto Stem Cells|
89307047|NCT02918266|Experimental|Part 1: TAK-071 80 mg + Scopolamine 0.5 mg|TAK-071 80 milligram (mg), drug in capsule (DIC), orally, Day 1, followed by scopolamine 0.5 mg, injection, subcutaneously, Day 2. TAK-071 will be taken 24 hours before scopolamine injection.
89307048|NCT02918266|Experimental|Part 2: Treatment Sequence ABDEC|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307049|NCT02918266|Experimental|Part 2: Treatment Sequence BCEAD|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307050|NCT02918266|Experimental|Part 2: Treatment Sequence CDABE|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307051|NCT02918266|Experimental|Part 2: Treatment Sequence DEBCA|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307052|NCT02918266|Experimental|Part 2: Treatment Sequence EACDB|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307053|NCT02918266|Experimental|Part 2: Treatment Sequence ACBED|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307054|NCT02918266|Experimental|Part 2: Treatment Sequence BDCAE|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307055|NCT02918266|Experimental|Part 2: Treatment Sequence CEDBA|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307056|NCT02918266|Experimental|Part 2: Treatment Sequence DAECB|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307057|NCT02918266|Experimental|Part 2: Treatment Sequence EBADC|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
89307058|NCT00041067|Experimental|Trastuzumab, docetaxel, vinorelbine and filgrastim|Trastuzumab, docetaxel, vinorelbine and filgrastim
89307059|NCT01063036|Experimental|Entecavir + Tenofovir|
89307060|NCT04054102|Experimental|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot
89307061|NCT04054102|Sham Comparator|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot
89307062|NCT03622060|Active Comparator|Nitroglycerin|500 microgram intraarterial Nitroglycerin
89307063|NCT03622060|Placebo Comparator|Nicardipine|200 microgram intraraterial Nicardipine
89307064|NCT00040365|Experimental|Amifostine|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
89307065|NCT02974114|Experimental|Paracetamol and caffeine|Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
89307066|NCT02974114|Experimental|Paracetamol|Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
89307067|NCT02974114|Placebo Comparator|Placebo|Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
89307068|NCT01584999|Active Comparator|Fresh not-leukocyte-reduced RBCs|
89307069|NCT01584999|Active Comparator|Fresh RBCs leukocyte-reduced|
89307070|NCT01584999|Active Comparator|RBCs with storage longer than 15 days|
89307071|NCT01585077|Experimental|Naive volunteers|Volunteers without previous exposure to malaria, and negative antibody titers (<1:20) against native protein of P. vivax.
89307072|NCT01585077|Experimental|Pre-immune volunteers|Volunteers with previous exposure to malaria, and positive antibody titers against native protein of P. vivax
89307073|NCT03948633|Experimental|CARD (multi-faceted knowledge translation intervention)|CARD will be integrated into the school vaccination program. This includes pre-vaccination day preparation (e.g., planning of clinic spaces, student and school staff education about CARD) and vaccination day activities (e.g., clinic set-up, processes for triaging students, implementing pain/fear/fainting mitigation interventions from CARD during vaccination).
89307074|NCT03948633|No Intervention|Control|There are no specific procedures being undertaken to plan or execute clinics. Usual practices will be instituted (i.e., no education specific to CARD, nor clinic set-up or execution to incorporate interventions for pain, fear or fainting).
89307075|NCT03950505|Experimental|1|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
89307076|NCT00001941|Experimental|Phase I - 2 mg/kg cohort|2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2
89307077|NCT00001941|Experimental|Phase I - 4 mg/kg cohort|4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
89307078|NCT00001941|Experimental|Phase I - 6 mg/kg cohort|6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
89307079|NCT00001941|Experimental|Phase I - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
89307080|NCT00001941|Experimental|Phase II - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
89307081|NCT01061866|Experimental|Thalidomide|Open-labeled preliminary trial
89307082|NCT03652714|Experimental|Local anesthetic|
89307083|NCT03652714|Placebo Comparator|Isotonic NaCl|
89307084|NCT01061008|Experimental|Handgrip exercise|Handgrip exercise - patients allocated to this intervention will carry out an eight week post operative progressive handgrip exercise training program
89307085|NCT01061008|Active Comparator|Treatment as usual|
89307086|NCT00039741|Experimental|PI/1K|Two NRTIs plus a PI with a regimen change recommended at when viral load reaches 1000 copies/ml or higher
89307087|NCT00039741|Experimental|NNRTI/1K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 1,000 copies/ml or higher
89307088|NCT00039741|Experimental|PI/30K|2 NRTIs plus 1 PI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
89307089|NCT00039741|Experimental|NNRTI/30K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
89307090|NCT02973802|Experimental|ATX-GD-59 treatment|An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.
89307091|NCT01096641|Other|Fatigued patients: Immediate start CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients. At the end of the therapy, after 6 months, a second assessment will take place.This assessment will include the same measurements as at baseline.
89307092|NCT01096641|Other|fatigues patients: delayed CBT (after 6 months)|The fatigued patients on the waiting list will start with CBT after 6 months
89307093|NCT01096641|No Intervention|non-fatiqued controls|Non-fatigued control group. This group is not included in the randomization.
89307094|NCT03652558|Experimental|ozone group|topical gaseous ozone was applied into periodontal pockets during active periodontal therapy
89307095|NCT03652558|No Intervention|non-ozone group|Only active periodontal therapy was performed
89307096|NCT03948477|Other|Pantoprazole/Placebo|Participants will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 1 then they will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 2
89307097|NCT03948477|Other|Placebo/Pantoprazole|Participants will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 1 then they will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 2
89307098|NCT03652324|Other|randomized|
89307099|NCT03953781||group 1|25 participants, were treated by valproate (VPA) as a monotherapy till became seizure free at the last 8-weeks before post treatment check-point, with ages ranged from 18-43 years
89307100|NCT03953781||group 2|25 participants were treated by levetiracetam (LEV) with the same regimens of valproate as a monotherapy, with ages ranged from 20-45 years.
89307101|NCT01102023|Experimental|solar salt based-diet|
89307102|NCT01103817|No Intervention|Vitamin D Sufficient|"Sufficient is defined as a 25 OH vitamin D level >50 nmol/l measured at baseline. No clinical intervention will be assigned to this group.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
89307103|NCT01103817|Experimental|Vitamin D Deficient|"Deficient is defined as a 25 OH vitamin D level ≤ 37.5 nmol/l. This group will receive Vitamin D.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
89307104|NCT01096719|Experimental|Energy Density|
89307105|NCT01096719|Active Comparator|Lifestyle Treatment|
89307106|NCT01096719|Experimental|Energy Density + Lifestyle Treatment|
89307107|NCT05524389|Experimental|Molecular classification based treatment|"Establishment of molecular-clinicopathological classification to make adjuvant treatment decisions: observation for favourable group; vaginal brachytherapy(VBT) for intermediate group; external beam radiotherapy(EBRT) for unfavourable group.~Molecular-clinicopathological classification strategy：Favourable group：POLE-mutated. CTNNB1(wide-type)with IA (G1-3) or IB(G1-2)and LVSI(lymph-vascular space invasion) focal/-.~Intermediate group：MMRD and LVSI focal/-. CTNNB1(wide-type) and IB(G3) or II with LVSI focal/-. CTNNB1-mutated and IA(G1-3) or IB (G1-2) with LVSI focal/-.~Unfavourable group: TP53 mutation. CTNNB1-mutated and IB (G3) or II. Substantial LVSI."
89307108|NCT05524389|Active Comparator|Conventional risk stratification based treatment|"Adjuvant vaginal brachytherapy alone for intermediate risk patients (IA G1-2 with LVSI present or age>60, IA G3 or IB G1-2 regardless of LVSI status).~EBRT for high-intermediate risk (stage I B with G3, or stage II)"
89307109|NCT01105455|Placebo Comparator|High fiber|High fiber carbohydrate foods with a high / medium glycemic index. Whole wheat bread and/or brown rice are provided to subjects if they wish. Subjects are provided with a list of other recommended carbohydrate foods.
89307110|NCT01105455|Active Comparator|Low GI|Carbohydrate foods with a low glycemic index. Low GI rice and whole grain bread provided to subjects if they wish. Subjects are provided with a list of recommended foods.
89307111|NCT01102179||Chronic kidney disease|"All patients with stage 2-5 (pre-dialysis) chronic kidney disease~One-time blood draw (10 ml)"
89307112|NCT01102335|Experimental|Telbivudine|
89307113|NCT01102335|Active Comparator|TACE only|
89307114|NCT05522517|Experimental|Candin + Cosentyx|Participants will receive a single dose of candin injection intradermally on Day 6 along with a single dose of saline solution injection of 0.9 percent (%) sodium chloride (NaCl) and a single dose of Cosentyx injection subcutaneously on Day 1.
89307115|NCT05522517|No Intervention|Candin Challenge|All participants will receive single dose of candin injection intradermally on Day 6 along with a single dose of saline solution injection of 0.9 percent (%) sodium chloride (NaCl) administered intradermally and no Cosentyx.
89307116|NCT01104051||Radiofrequency Ablation|The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
89307117|NCT01104051||Sham|subjects to be blinded,to receive sham procedure; The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
89307118|NCT03950349||"Anterior cervical discectomy group"|
89307119|NCT03949803|Experimental|Morning Chocolate|Test the if Chocolate Timing in the morning changes the metabolism
89307120|NCT03949803|Experimental|Evening Chocolate|Test the if Chocolate Timing before bedtime changes the metabolism
89307121|NCT03949803|Experimental|No Chocolate (Control)|Test the if no Chocolate Timing may affect the metabolism
89307122|NCT02973100|Experimental|Dulaglutide 4.5mg|4.5mg of Dulaglutide administered subcutaneously (SC)
89307123|NCT02973100|Experimental|Dulaglutide 3.0mg|3.0mg of Dulaglutide administered SC
89307124|NCT02973100|Active Comparator|Dulaglutide 1.5mg|1.5mg of Dulaglutide administered SC
89307125|NCT02973100|Placebo Comparator|Placebo|Placebo administered SC
89307126|NCT05627583||Anorexia Nervosa (AN)|Anorexia Nervosa patients hospitalized for rehabilitation
89307127|NCT01104129||Control Group|Individual who has not had pancreatic cancer/IPMN; surgical resection for lesion of pancreas; history of colorectal, gastric cancer, esophageal, or head-and-neck cancer; administration of chemotherapy less than 1 week prior to enrollment; or an endoscopic procedure conducted less than 1 week prior to enrollment.
89307128|NCT01104129||Diagnosis of Pancreatic Cancer/IPMN|Patients diagnosed with Pancreatic Cancer/Intraductal Papillary Mucinous Neoplasm who are scheduled for surgical resection.
89307129|NCT01104363|Experimental|Snow white Plaster 2|Test
89307130|NCT01104363|Active Comparator|Primopattern LC gel + PVS|Control
89307131|NCT01105611|Experimental|Raltegravir|Raltegravir in combination with Tenofovir/Emtricitabine
89307132|NCT01105611|Active Comparator|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine
89307133|NCT03652168|Experimental|Meditation Group|Headspace application: Participants in the intervention group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks.
89307134|NCT03652168|No Intervention|No intervention, control group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
89307135|NCT01060540|Experimental|CR+G|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus genetic testing for type 2 diabetes
89307136|NCT01060540|Active Comparator|CR+EYE|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus eye disease counseling
89307137|NCT01584765||Rechallenge|positive, negative, indeterminate and intermediate rechallenge subtypes
89307138|NCT01584765||Severe positive rechallenge|Subtype of positive rechallenge is defined as: ALT≥5 xULN or AP ≥2 xULN and bilirubin ≥2 xULN with one of the following: INR ≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy is less than 26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; liver-related hospitalization
89307139|NCT01792882||Cancer Subjects|
89307140|NCT03652090||cystic fibrosis patients|Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling
89307141|NCT03652090||healthy heterozygotes|healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling
89307142|NCT03652090||healthy control|subject with no evidence of any symptoms compatible with Cystic Fibrosis undergoing cell sampling
89307143|NCT03948399||STROKE GROUP|150 patients admitted to Stroke Unit with a diagnosis of acute ischemic stroke (IS) or transient ischemic attack (TIA)
89307144|NCT03948399||CONTROL GROUP|50 individuals admitted to hospital without diagnosis of acute cerebrovascular disease; with diagnosis of dizziness, epilepsy, sclerosis multiplex.
89307145|NCT03651544|Experimental|Group 1 (GamFluVac dose1)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 1010 VP/dose.
89307146|NCT03651544|Experimental|Group 2 (GamFluVac dose2)|Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose
89307147|NCT03651544|Experimental|Group 3 (GamFluVac dose3)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
89307148|NCT03948555||Acute aortic dissection|stable patients with confirmed diagnosis of acute AD.
89307149|NCT03948555||Chronic aortic dissection|patients with diagnosis of chronic AD, being followed up in outpatient aortic clinic.
89307150|NCT03948321|Experimental|Painless Photodynamic Therapy（P-PDT）|The painless photodynamic therapy（P-PDT）group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 400 J/cm2) after applying 20% 5-aminolevulinic acid（ALA）cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
89307151|NCT03948321|Active Comparator|Conventional Photodynamic Therapy（C-PDT）|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 100 J/cm2) after applying 20% 5-aminolevulinic acid cream for 3h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
89307152|NCT03949569|Experimental|Arm 1|In this condition, children will interact with the therapy dog prior to the psychosocial stress task and with the stuffed toy dog prior to the prosocial behavior tests.
89307153|NCT03949569|Experimental|Arm 2|In this condition, children will interact with the stuffed toy prior to the psychosocial stress task collection and with the therapy dog prior to the prosocial behavior tests.
89307154|NCT03948165||Distal Radial Approach|Distal transradial access will be performed on patients above 18 years of age, undergoing diagnostic and/or therapeutic coronary angiography, with palpable pulse at the level of the radial fossa, and these patients will be also subjected to the following tests: Allen maneuver and Barbeau maneuver; a positive Allen test was indication to perform the transradial access, while a type D Barbeau test will be a contraindication for it.
89307155|NCT03949413||Control group (A)|30 normal children
89307156|NCT03949413||study Group (B)|30 children from both sexes (22 boys and 8 girls) with attention deficit hyperactivity disorder (ADHD)
89307157|NCT01102647|Experimental|Phytosterol ester|Plant sterol compared with placebo
89307158|NCT03946917|Experimental|JS001/regorafenib|recombinant humanized anti-PD-1 monoclonal antibody for injection (JS001) in combination with regorafenib tablet
89307159|NCT01482286|Experimental|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
89307160|NCT01482286|Experimental|Dietary Restriction|Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
89307161|NCT01482286|Experimental|Exercise|Subjects randomized to the exercise training group will complete a structured program of aerobic training 3 to 4 times per week and resistance exercises 2 times per week.
89307162|NCT01482286|No Intervention|Control|Subjects randomized to the no treatment control group will be asked to continue, as normal their usual dietary and exercise regimen. Subjects will be asked to not begin diet or exercise regimens through the 24-week study or to begin medical treatment for PCOS.
89307163|NCT03651934|Experimental|Normal iron|
89307164|NCT03651934|Experimental|Weak iron|
89307165|NCT03651934|Experimental|Normal selenium|
89307166|NCT03651934|Experimental|Weak selenium|
89307167|NCT01105923|Experimental|Receive CDS intervention|Providers in clinics that will receive the CDS alert, as their clinic was randomized into our study.
89307168|NCT01105923|No Intervention|No CDS intervention|
89307169|NCT03948087|Experimental|Vacuum Removable Rigid Dressing (VRRD)|Application of a Vacuum Removable Rigid Dressing (VRRD)
89307170|NCT03948087|No Intervention|Soft Dressing Control Group|Application of standard of care soft dressing (SD) intra-operatively.
89307171|NCT02972632|Experimental|Vortioxetine 10-20 mg|Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
89307172|NCT01106001|Active Comparator|Levobupivacaine|Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children
89307173|NCT01106001|Placebo Comparator|Saline|Saline (also saline solution) is a general term referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water but is only sterile when it is placed intravenously, otherwise, a saline solution is a salt water solution.
89307174|NCT03946995|Experimental|Dry needling|Dry needling will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
89307175|NCT03946995|Active Comparator|Graston|Graston Technique will be applied on active myofascial trigger points in upper trapezius along with conservative physical therapy management.
89307176|NCT01102725||Colorectal Surgery|Subject who are undergoing a colon or rectal resection
89307177|NCT05626335||Study group|From all the patients meeting the inclusion criteria every third patients was randomly chosen and invited to participate in the study. Written informed consent was obtained from every participant. Thus 100 patients have agreed to participate. All fixed retainers (stainless steel braided rectangular wire) were bonded in both arches by the same experienced clinician, who subsequently made impression for thermally formed splints and delivered them on the day of debonding. The effect of each of the procedures was verified by two independent experienced clinicians. On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0). The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3). The displacements were assessed by superimposition of the scans. The patients were recommended to wear removable retainers 22h/day. They were instructed to immediately report a failure and to apply immediately to the office in case of failure.
89307178|NCT04892121|Experimental|Intervention group|The teams in the intervention group will have to follow a warm-up prevention program twice a week
89307179|NCT04892121|No Intervention|Control group|The teams in the control group will have to reply each month to a questionnaire about the potential injuries they experienced during the previous month.
89307180|NCT03949257|Experimental|colonic TET and FMT|gut microbiota will be collected through the colonic TET after FMT
89307181|NCT01104519|Experimental|1|Niaspan - Placebo
89307182|NCT01104519|Experimental|2|Placebo - Niaspan
89307183|NCT03944733|Active Comparator|Iron Intervention|IDA mothers will receive a 65 mg of iron (ferrous sulfate) daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
89307184|NCT03944733|Placebo Comparator|Placebo|IS mothers will receive 600 mg of gelatin daily for 4.5 months in the postpartum period (6 weeks to 6 months post delivery).
89307185|NCT01108653|Other|Group 1: Usual care sick-leave management|
89307186|NCT01108653|Other|Group 2: Structuralised sick-leave program|
89307187|NCT01060150|Experimental|OROS Methylphenidate HCl|
89307188|NCT03950193||premature child|Premature children evaluated during their 24 months follow up consultation
89307189|NCT03863223|Experimental|A|Pyrotinib Plus trastuzumab and docetaxel
89307190|NCT03863223|Placebo Comparator|B|Placebo plus trastuzumab and docetaxel
89307191|NCT02972242|Active Comparator|Modified Field of View|In patients randomized to undergo the modified non-contrast CT scan to assess coronary calcification burden, this study will be performed by a radiologist and cardiologist as follows: axial acquisition obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage 80kV and tube current 250mA. The scan length will be from 1 cm below the carina to the level beneath the proximal coronary vessels defined as the greatest diameter of the apex of the right atrium.
89307192|NCT02972242|Placebo Comparator|Standard Field of View|In patients randomized to standard coronary artery calcium scoring, this scan will be performed in usual axial fashion obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage, 120 kV and tube current 250mA. The scan length, in accordance with current protocol, will be from 1 cm below the carina through the diaphragms.
89307193|NCT01106079|Experimental|Intensive management|
88806445|NCT04462562|Experimental|quantitative ultrasound imaging parameters|"quantitative ultrasound imaging parameters~tissue attenuation imaging (TAI) parameter~tissue scatter-distribution imaging (TSI) parameter~Hepatorenal index (semi-auto, EzHRI)"
89307194|NCT01106079|Active Comparator|Standard management|
89307195|NCT03652012|Experimental|Mild Cognitive Impairment|"The following revised Mayo Clinic criteria for MCI (Petersen, et al. 2014) will be used: (1) cognitive concern expressed by a physician, informant, participant, or nurse; (2) impairment in 1 or more cognitive domains (memory, language, visuospatial skills, or executive functions); (3) essentially normal functional activities; and (4) absence of dementia. Individuals with MCI will have Mini-Mental State Exam (MMSE, Appendix 19) scores between 18 and 23 (inclusive) and have a Clinical Dementia Rating Scale score of 0.5.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
89307196|NCT03652012|Active Comparator|Healthy Controls|"Participants who are matched for age and gender.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
89307197|NCT01327911|Experimental|Ciliary Neurotrophic Factor (CNTF)/NT-501|Biological/Vaccine:NT-501 implant
89307198|NCT03651466|Experimental|Cohort 1: GX-G6 + placebo|Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)
89307199|NCT03651466|Experimental|Cohort 2: GX-G6 + placebo|Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)
89307200|NCT03651466|Experimental|Cohort 3: GX-G6 + placebo|Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)
89307201|NCT03651466|Experimental|Cohort 4: GX-G6 + placebo|Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)
89307202|NCT03651466|Experimental|(Optional) Cohort 5: GX-G6 + placebo|Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)
89307203|NCT03651466|Experimental|(Optional) Cohort 6: GX-G6 + placebo|Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)
89307204|NCT03651310|No Intervention|Control Group|waiting in preoperative area without music listening.
89307205|NCT03651310|Active Comparator|Music Listening Group|The music listening group will be given a set of noise canceling headphones and an MP3 player with multiple tracks representing different music genres to use while in preoperative area.
89307206|NCT02970292|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
89307207|NCT02970292|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
89307208|NCT01104675|Experimental|ENMD-2076 treatment|
89307209|NCT03944655|Active Comparator|Strepsils|
89307210|NCT03944655|Placebo Comparator|Placebo|
89307211|NCT03944421|Experimental|Red and Processed Meat|240 grams (raw weight) of red and processed meat every day for 2 weeks
89307212|NCT03944421|Experimental|Quorn|240 grams (uncooked weight) of Quorn every day for 2 weeks
89307213|NCT05276895|Active Comparator|(Quercetin +Fisetin)|"20 participants with symptomatic knee osteoarthritis and ultrasonography defined effusion-synovitis will take natural Senolytic agents.~The senolytic agents act by Hit-and-run strategy therefore, intermittent dosing regimens will be applied. 1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks.over 12 weeks"
89307214|NCT05276895|Active Comparator|Quercetin +Fisetin +Glycyrrhizin)|20 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis will take Quercetin 1250 mg + Fisetin 1000 mg for 3 consecutive days followed by 100mg/day Glycyrrhizin for one week every 3 weeks over 12 weeks .
89307215|NCT05276895|Placebo Comparator|Placebo|Placebo controlled group
89307216|NCT02971228|Experimental|Part 1, Lilly glucagon then ZP4207|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
89307217|NCT02971228|Experimental|Part 1, ZP4207 then Lilly Glucagon|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
89307218|NCT02971228|Experimental|Part 2, Lilly glucagon then ZP4207|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
89307219|NCT02971228|Experimental|Part 2, ZP4207 then Lilly Glucagon|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
89307220|NCT01104753||Non-interventional post-authorisation safety study|
89307221|NCT01104831|Placebo Comparator|21 degree Cooling|Room temperature water circulated through cryotherapy sleeve.
89307222|NCT01104831|Active Comparator|10 degree cooling|Cooled water circulated through a cryotherapy sleeve.
89307223|NCT01060072|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5% ophthalmic suspension
89307224|NCT01060072|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ophthalmic suspension
89307225|NCT03741075|Active Comparator|BUAL plus placebo|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus 200 ml saline topical application to placental bed
89307226|NCT03741075|Experimental|BUAL plus topical tranexamic acid|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus topical application of 20ml saline contains 2 gm tranexamic acid
89307227|NCT01104909|Active Comparator|Clinical dry weight|Group which the dry weight will be assessed based on clinical examination.
89307228|NCT01104909|Active Comparator|Bioimpedance|Group which the dry weight will be assessed by bioimpedance data.
89307229|NCT01328223||radiotherapy efficacy|"Concurrent stage with RT: sorafenib 400mg twice daily~Maintenance stage after RT: sorafenib 400mg twice daily Treatment can be continued until the occurrence of clinical or radiologic progression, the occurrence of either unacceptable adverse events, death, or any criteria met for removal from the protocol treatment. Basically, minimum maintenance duration of 6 months is recommended, not mandatory."
89307230|NCT01108965||Extraventricular Drainage|Includes hydrocephalus patients that are in recovery from shunt explanation.
89307231|NCT01104987||alendronate|A cross sectional study assessing the prevalence of osteoporosis and vertebral fractures in AS has been conducted during the spring in 2009. Patients with osteoporosis that fulfilled the inclusion criteria and did not have any exclusion criteria for the present trial were asked to join this study.
89307232|NCT03651232|Experimental|yoga|weekly prenatal yoga group class
89307233|NCT03651232|Active Comparator|support|weekly group support class
89307234|NCT03741153||study group|includes patients who will be diagnosed with Pseudoexfoliation syndrome
89307235|NCT03741153||control group|age matched controls who do not have Pseudoexfoliation syndrome
89307236|NCT01106235|Experimental|Treatment (immunostimulant, autologous lymphocytes, and chemo)|Patients receive cyclophosphamide IV on days -3 and -2 followed by an infusion of IL-21 modulated, MART-1 specific CD8+ cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T cell infusion, patients receive low-dose aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity.
89307237|NCT02969590|No Intervention|No Intervention: Spontaneous Cycle (1 month)|In order to qualify for the intervention phase, subjects needed to demonstrate favorable mucus at ovulation (Insler score of greater than or equal to 10 within 24h of an LH surge) and progesterone level in the luteal phase consistent with ovulation (a single P4 of greater than or equal to 3ng/ ml between days 18-35 of menstrual cycle).
89307238|NCT02969590|Active Comparator|NET Arm - Norethindrone (4 months)|"This arm will receive Norethindrone (NET) first then experience estradiol withdrawal (E2WD).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
89307239|NCT02969590|Active Comparator|E2WD Arm - Estradiol (4 months)|"This arm will experience estradiol withdrawal (E2WD) first and then receive Norethindrone (NET).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches ; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
89307240|NCT02529891||COPD Patients|Patients with COPD, within 48h after hospital admission for exacerbation.
89307241|NCT02529891||non-COPD patients|Healthy person of the entourage of COPD patients.
89307242|NCT03651388||Patient|Patient with a new phenotype combining premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia
89307243|NCT03651388||Related parties of the 1st degree|1st degree related family of Group A patient
89307244|NCT03650998|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
89307245|NCT03650998|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
89307246|NCT01106469|Experimental|001|JNJ-41443532 25mg tablet once daily
89307247|NCT01106469|Experimental|002|JNJ-41443532 100mg tablet once daily
89307248|NCT01106469|Experimental|003|JNJ-41443532 250mg tablet once daily
89307249|NCT01106469|Experimental|004|JNJ-41443532 500mg once daily (with 250mg tablets)
89307250|NCT01106469|Experimental|005|JNJ-41443532 1000mg once daily (with 250mg tablets)
89307251|NCT01106469|Experimental|006|JNJ-41443532 1500mg once daily (with 250mg tablets)
89307252|NCT01106469|Placebo Comparator|007|Placebo Matching placebo
89307253|NCT03649594||TAVI and no therapeutic anticoagulation|Subjects in this group do not have an indication for therapeutic anticoagulation.
89307254|NCT03649594||TAVI and therapeutic anticoagulation|Subjects in this group have an indication for therapeutic anticoagulation such as atrial fibrillation.
89307255|NCT04053400||Ketamine Group|Active duty military service member injured in theater, AEROVAC-ED out, and received ketamine.
89307256|NCT04053400||Non-Ketamine Comparison Group|Active duty military service member injured in theater, AEROVAC-ED out, and did NOT receive ketamine treatment for pain.
89307257|NCT04091542|Experimental|FiO2 group 1|FiO2 changes over the four days in 60 with ventilator, 80 with ventilator, 60 with optiflow and 80 with optiflow.
89307258|NCT04091542|Experimental|FiO2 group 2|FiO2 changes over the four days in 80 with ventilator, 60 with ventilator, 80 with optiflow and 60 with optiflow.
89307259|NCT04091542|Experimental|Duration 1|In duration goup changes the preparation over the four days in 2 min. with ventilator, 6 min. with ventilator, 2 min. with optiflow and 8 min. with optiflow.
89307260|NCT04091542|Experimental|Duration 2|In duration goup changes the preparation over the four days in 6 min. with ventilator, 2 min. with ventilator, 6 min. with optiflow and 2 min. with optiflow.
89307261|NCT04091542|Experimental|respiratory rate 1|In the RR group changes the respiratory rate in the four days: 16 times with ventilator, 20 times with ventilator, 16 times with optiflow and 20 times with optiflow.
89307262|NCT04091542|Experimental|respiratory rate 2|In the RR group changes the respiratory rate in the four days: 20 times with ventilator, 16 times with ventilator, 20 times with optiflow and 16 times with optiflow.
89307263|NCT04091542|Experimental|Position 1|The position changes over the four days in supine with ventilator, prone with ventilator, supine with optiflow and prone with optiflow.
89307264|NCT04091542|Experimental|Position 2|The position changes over the four days in prone with ventilator, supine with ventilator, prone with optiflow and supine with optiflow.
88806446|NCT04428164||Hospitalized patients|Any patient admitted to the study units (MDMC: 10ST; MCMC: A6; MMMC: A3; MRMC: 3Medical ) that do not have any of the exclusion criteria
89307265|NCT03345849|Placebo Comparator|Placebo|Participants will receive placebo once daily for 12 weeks in Part 1. Clinical non-responders will receive 45 mg upadacitinib once daily for 12 weeks in Part 2.
89307266|NCT03345849|Experimental|Upadacitinib|Participants will receive 45 mg upadacitinib once daily for 12 weeks in Part 1. Clinical non-responders will receive 30 mg upadacitinib once daily for 12 weeks in Part 2.
89307267|NCT01105143|Active Comparator|lifestyle intervention|Multimodal lifestyle intervention to reduce body weight
89307268|NCT01105143|Placebo Comparator|placebo|placebo
89307269|NCT01105221|Experimental|Acupuncture|
89307270|NCT01105221|Active Comparator|Artificial tear drop|
89307271|NCT03944343|Sham Comparator|Reference product|Commercial cereals and a commercial yogurt
89307272|NCT03944343|Experimental|Test product A|Specific designed cereals A and yogurt
89307273|NCT03944343|Experimental|Test product B|Specific designed cereals B and yogurt
89307274|NCT03944343|Experimental|Test product C|Specific designed cereals C and yogurt
89307275|NCT03944343|Experimental|Test product D|Specific designed cereals D and yogurt
89307276|NCT01109121|Active Comparator|Allopurinol|Allopurinol
89307277|NCT01109121|Experimental|Combination 400|Tranilast and Allopurinol
89307278|NCT01109121|Experimental|Combination 600|Tranilast and Allopurinol
89307279|NCT01109199|Experimental|PolyGlycopleX (PGX)|
89307280|NCT01109199|Placebo Comparator|Rice Flour|
89307281|NCT01106547|Experimental|Methylprednisolone|
89307282|NCT01106547|Placebo Comparator|placebo/sodium chloride|
89307283|NCT03944109|Experimental|SHR-1209|Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.
89307284|NCT03944109|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
89307285|NCT05196399|Experimental|Aprocitentan (reference product)|25 mg film-coated tablet
89307286|NCT05196399|Experimental|Aprocitentan (test product)|25 mg film-coated tablet
89307287|NCT03944031|Experimental|LY3372689 + [18F]LSN3316612|LY3372689 administered orally followed by [18F]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later.
89307288|NCT04617639|Experimental|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion [RPE] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
89307289|NCT04617639|Active Comparator|Control group I|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
89307290|NCT04617639|Other|Control group II (observation group)|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel.
89307291|NCT04617405||Type A|Healthy normal-weight pregnant women
88820777|NCT05662254|Experimental|Personalized Behavioral Intervention|Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns.
89307292|NCT04617405||Type B|Pregnant women with gestational diabetes diagnosed at early screening (before gestational week 20)
89307293|NCT04617405||Type C|Pregnant women with type 2 diabetes
89307294|NCT04617405||Type D|Healthy overweight pregnant women
89307295|NCT03947229|Active Comparator|Clopidogrel mono-therapy|After randomization, patients will receive clopidogrel monotherapy after DES implantation for 24 months.
89307296|NCT03947229|Active Comparator|Dual-antiplatelet therapy|Patients will receive dual antiplatelet consisting of aspirin and clopidogrel.
89307297|NCT01109277||Healthy term and late-preterm neonates|
89307298|NCT03011307|Experimental|Oxytocin|Oxytocin 100 micrograms administered intrathecally
89307299|NCT03011307|Placebo Comparator|Placebos|Placebo injection administered intrathecally
89307300|NCT02985177|Experimental|INF2.0 + IBU|The participant will receive a dose of intranasal fentanyl (2.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
89307301|NCT02985177|Active Comparator|INF1.0 + IBU|The participant will receive a dose of intranasal (1.0 mcg/kg) AND a dose of oral ibuprofen (10 mg/kg).
89307302|NCT03946683|Experimental|Cyberknife for Early Stage Breast Cancer|Cyberknife Robotic Radiosurgery will be utilized as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer.
89307303|NCT03947463|Experimental|PECS block group|20ml of 0.25% bupivacaine was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualised on the ultrasound screen. similarly, in Serratus plane block, ultrasound probe was placed over the mid-axillary region of the thoracic cage in a sagittal plane. Ribs were identified inferiorly and laterally, until the identification of the 3rd rib in the mid axillary line. 10 ml of 0.25% bupivacaine was infiltrated in between Serratus anterior muscle and Latissimus Dorsi muscle
89307304|NCT03947463|No Intervention|Control group|Patient were given multimodal analgesia without the regional block
89307305|NCT02936271|Active Comparator|Active Vasculera (diosmiplex)|Active Vasculera will be prescribed as one (1) tablet (630 mg) twice a day.
89307306|NCT02936271|Placebo Comparator|Vasculera Placebo|Vasculera Placebo will be prescribed as one (1) tablet twice a day.
89307307|NCT03943797|Experimental|Cultivated oral mucosal epithelial cell transplantation|Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.
89307308|NCT01106703|Experimental|PG102 group|
89307309|NCT01106703|Placebo Comparator|placebo group|
89307310|NCT02814591||Cohort 1: Controls|40 volunteers free from bone disease. No family histroy of osteogenesis imperfecta (OI). No history of non-accidental fracture. No history of osteoarthritis (OA) or clinical manifestations of disease. No clinical features of OI, OA or osteoporosis (OP). Normal haemoatology and biochemical blood screen. Controls will be gender and age matched (within five years) to the disease cohort patients. Children and adults both required.
89307311|NCT02814591||Cohort 2: Patients with ostegenesis imperfecta (OI).|40 patients with OI. Patients must have been clinically diagnosed with OI. Participants will be identified form the Royal National Orthopaedic Hospital, Metabolic Unit database. Bone mineral density (BMD) confirmed with DXA.
89307312|NCT02814591||Cohort 3: Patients with osteoarthritis (OA)|40 patients with OA. Patients must have been clinically diagnosed with OA. Participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database.
89307313|NCT02814591||Cohort 4: Patients with osteoporosis (OI)|40 patients with OI receiving treatment with bisphosphonates. Patients must have been clinically diagnosed with OI and bisphosphonates prescribed as a course of treatment. 20 Adults and 20 Children. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed.
89307314|NCT02814591||Cohort 5: Patients with osteoporosis (OP) (2 treatment groups)|Patients must have been clinically diagnosed with OP. The first group will have been prescribed with bisphosphonate anti-resorptive treatment; the second with anabolic agents. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed. Bone mineral density (BMD) will be confirmed with DXA. Where possible measurements will be acquired prior to the start of treatment and then up to 4 follow up visits at flexible time points to allow scheduling to coincide with hospital appointments. Minimum time between vistis should be 2 months.
89307315|NCT02814591||Cohort 6: Patients with rickets and osteomalacia|10-15 participants with rickets and 10-15 participants with osteomalacia. Patients must have been clinically diagnosed with rickets/osteomalacia. Blood tests for 25-hydroxyvitamin D should be less than or equal to 25 nmol/L. Once participants are on treatment further measurements will be made 6 months afterwards. Participants for rickets and osteomalacia groups will be recruited to give a total of 10 complete sets of data per group.
89307316|NCT02814591||Cohort 7: 5 patients with suspected bone infection.|Participants will have been diagnosed at RNOH with a suspected bone infection. Participants will be scanned around the localised area of suspected infection. Participants may have 1 or 2 vists; the latter to take place after all infection has cleared up. This is not subject to a fixed time frame.
89307317|NCT01327755|Experimental|Selenium|
89307318|NCT01327755|Placebo Comparator|Placebo|
89307319|NCT03947073|No Intervention|Standard of Care|Subjects with newly diagnosed gestational diabetes are randomized to standard of care diabetes education.
89307320|NCT03947073|Experimental|Interactive Educational Application|Subjects with newly diagnosed gestational diabetes are randomized to standard of care plus an interactive educational application.
89307321|NCT01327833||Cardiac Arrest|
89307322|NCT01208727|No Intervention|Control|22 controls patients without post conditionment
89307323|NCT01208727|Experimental|Intervention|22 posconditioned patients
89307324|NCT03943485|Active Comparator|Uterien Manipulator Arm|Patients in this group will receive a uterine manipulator during abdominal hysterectomy.
89307325|NCT03943485|No Intervention|Control|Patients in this group will receive standard abdominal hysterectomy without adoption of a uterine manipulator.
89307326|NCT02044887|Experimental|INTERVENTION|Participants will receive instructions to do physical activity with an adapted physical activity program. This program will be designed and applied by Primary Health Care professionals in patients with dementia and caregivers.
89307327|NCT02044887|No Intervention|Control|The control group will receive regular care.
89307328|NCT01106781||1|Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.
89307329|NCT01208805||Candidates for dorsal column stimulation|
89307330|NCT01106937||Patients with low Factor XIII|Postoperative occurence of pulmonary embolism in patients scheduled to undergo a neurosurgical procedure with laboratory-confirmed low levels of Factor XIII
89307331|NCT01208883|Experimental|repetitive per-treatment [18F]FDG-PET for treatment adaptation|
89307332|NCT01111695|Experimental|Honey and ionic silver dressing|
89307333|NCT03946137|Experimental|Sample|"30 patients of both sexes aged between 0 and 6 years with chronic neurological involvement with respiratory complications.~Individual sessions of chest therapy every fifteen days for three months, in total 6 respiratory physiotherapy sessions of 30 minutes each were performed. And the postural hygiene workshops were given to the parents, this educational intervention was carried out at the beginning of the study, at 3 months and at 6 months from the beginning. Each intervention lasted 4 hours with theoretical and practical part."
89307334|NCT01107093|Placebo Comparator|Placebo|
89307335|NCT01107093|Active Comparator|CDB-2914|
89307336|NCT01118793||double dosing of Clopidogrel|This is a Scripps pilot study on the effect of high clopidogrel maintenance dosing and its relationship to cytochrome P450 2C19 polymorphism status [STSI/CTSA].
89307337|NCT03943563|Other|single cohort|"There is only one cohort where each patient experiment the classic sequences as the standard of care and the DIXON sequences for the study."
89307338|NCT00127335|Placebo Comparator|1|
89307339|NCT00127335|Active Comparator|2|statin administration
89307340|NCT01109511|Active Comparator|oxycodone+naloxone|
89307341|NCT01109511|Active Comparator|Control|Oxycodone alone without naloxone
89307342|NCT03942939|Experimental|A - TKA with short tourniquet time|50 arms: subjects will receive a tourniquet with a short tourniquet time during TKA surgery. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
89307343|NCT03942939|Active Comparator|B - TKA with tourniquet|50 arms: subjects will receive a tourniquet during TKA surgery.
89307344|NCT01109589||Children aged 0-2 yrs|
89307345|NCT01109589||Women aged 15-60 yrs|
89307346|NCT03946293|Active Comparator|White bread|White bread 3 x 30 g, single serving
89307347|NCT03946293|Active Comparator|Wholegrain|Standard wholegrain, 3 x 30 g, single serving
89307348|NCT03946293|Experimental|Wholegrain Enzyme|Enzyme-treated wholegrain, 3 x 30 g, single serving
88820778|NCT05656404|Experimental|Donor lungs assessed using TorEx Lung Perfusion System|
89307349|NCT01111929|Active Comparator|Counseling for LAM|"Will receive proper postpartum counseling for LAM by trained research nurse. This is in addition to, adequate contraceptive counseling including information about LAM and its prerequisites.~Women that choose to use LAM will be advised to return to our contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires."
89307350|NCT01111929|Experimental|Counseling for LAM+ LNG-EC|LAM counseling and contraceptive counseling +two 0.75 mg Levonorgestrel EC pills
89307351|NCT03946371||Extubation Success|Patients who do not require re-intubation, upto 48 hours after a planned extubation in the adult intensive care unit.
89307352|NCT03946371||Extubation failure|Patients who required re-intubation within 48 hours after a planned extubation in adult intensive care unit.
89307353|NCT01207557|Active Comparator|Standard education only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
89307354|NCT01207557|Active Comparator|Standard Education plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials plus the Ottawa Influenza Decision Aid and tested on their confidence with their immunization decision
89307355|NCT01109667||oral anticoagulant|Patients receiving and not receiving oral anticoagulant therapy.
89307356|NCT01109667||INR Level|Group I: Patients not receiving OAT, Group II: Patients under OAT and INR values in good therapeutic range and Group III: Patients under OAT and INR values over the therapeutic range.
89307357|NCT01112007||prehypertension|Subjects with prehypertension, that is, individuals with systolic blood pressure in the range of 120-139 mmHg or diastolic BP between 80-89 mmHg.
89307358|NCT01109745|No Intervention|usual primary care|Number of participating children: 85
89307359|NCT01109745|Experimental|PELICAN Primary care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 85 children
89307360|NCT01109745|No Intervention|usual secondary care|number of participating children: 50
89307361|NCT01109745|Experimental|PELICAN Secondary Care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 50 children
89307362|NCT01112085|Experimental|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
89307363|NCT01112085|Experimental|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
89307364|NCT01207635||Breast Cancer Patients|
89307365|NCT01107171|Placebo Comparator|placebo|Tang-min Lin pills analogue
89307366|NCT01107171|Experimental|Tang-min-ling pills high dosage|Tang-min-ling pills, high dosage, 12g, tid po
89307367|NCT01107171|Experimental|Tang-min-ling pills low dosage|low dosage group:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
89307368|NCT01107249|Other|BS Ultraflex or Wallstent stents|All subjects receive a stent of surgeons choice from selected stents.
89307369|NCT01112163|Experimental|Enhanced external counter pulsation|One session of enhanced external counter pulsation (60 minutes)
89307370|NCT03943251|Experimental|HEC113995PA•H2O tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
89307371|NCT03943251|Placebo Comparator|placebo tablet|Including 7 dose groups(2.5-、5、10-、20-、40-、60-、80mg).Each dose group was given only once.After an overnight stay of at least 10h on an empty stomach, 240mL of water was administered in the morning under the condition of an empty stomach. Water was forbidden for 1h before and 1h after administration, and fasting for 4h after administration.
89307372|NCT01328301|Experimental|Speed-dependent treadmill training (SDT)|Subjects underwent short interval of walking trials with stepwise increases in the treadmill speed
89307373|NCT01328301|Active Comparator|speed-stable treadmill training|Control subjects received gait training on the treadmill with a steady speed.
89307374|NCT01209039|Experimental|Part A, cohort 1 and 2|Part A, Cohorts 1 and 2, will investigate escalating multiple daily doses of GSK1144814 in 19 subjects
89307375|NCT01209039|Experimental|Part A, cohort 3|Cohort 3 will investigate safety, tolerability and PK of a dose of GSK1144814 over a repeat treatment period of 28 days in 18 subjects and a potential drug drug interaction between GSK1144814 and the CYP3A4 sensitive substrate midazolam (in 15 subjects).
89307376|NCT01209039|Experimental|Part B|Part B will assess NK1 receptor occupancy following repeated administration of GSK1144814 given once daily until steady state is obtained
89307377|NCT01109823|Active Comparator|patients with normal renal function|Patients with normal renal function hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
88820779|NCT05651711|Experimental|Rocatinlimab|Rocatinlimab Dose 1 every 4 weeks (Q4W) for 24 weeks with a loading dose at Week 2.
89307378|NCT01109823|Active Comparator|patients with hyperfiltration|Patients with hyperfiltration hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
89307379|NCT03943407|Experimental|Zyclara/vehicle|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle.
89307380|NCT03943407|Experimental|Zyclara/Doxepin|All subjects will be treated with the topical antihistamine cream (Prudoxin, containing 5% doxepin hydrochloride, Healthpoint, San Antonio, TX) or a placebo cream. After removal, subjects will be treated with Zyclara cream
89307381|NCT03943407|Experimental|Zyclara/Histamine/Cowage|All subjects will be treated with Zyclara cream, vehicle cream, histamine and cowhage
89307382|NCT03943407|Experimental|Zyclara/L-menthol/trans-cinnamaldehyde|All subjects will be treated with Zyclara cream (Imiquimod 3.75%) and vehicle. After removal, subjects will be treated with L/menthol and trans-cinnamaldehyde
89307383|NCT04451109||Cases in which Dilapan-S was used for cervical ripening.|Every participating site will select 50 cases of pregnant women who underwent cervical ripening by Dilapan-S prior to induction of labor. These cases has to fulfill inclusion/exclusion criteria defined in the protocol.
89307384|NCT04383951|Active Comparator|Ketogenic diet|For participants randomized to the ketogenic diet arm, a consultation with the providers of medically supervised weight loss clinic of Indiana University Health will be arranged. Subjects will be educated on the concepts of ketosis, symptoms associated with it, and dietary manipulation to achieve ketosis. Participants in this arm will use the suggested recipes in combination with strict carbohydrate monitoring though checking for urine ketone bodies. These recipes were gathered and vetted by the dietitian at the medically supervised weight loss clinic. We anticipate that this approach will allow for more calorie intake and easier carbohydrate restriction. The follow up visits will be determined by the providers of the medically supervised weight loss clinic based on the symptoms reported and subject's compliance with carbohydrate restriction.
89307385|NCT04383951|Sham Comparator|Standard of Care|For participants randomized to this arm, a consultation with the providers of medically supervised weight loss clinic will be arranged. The discussion will focus on portion control using a balanced diet. A follow up visit will be at 16 weeks. This is the extent of interventions received for participants in this arm.
89307386|NCT01209117|Experimental|Periods 1 - 4|Subjects will be randomized in a cross over fashion to receive the GSK2248761 WBM capsule formulation or one of three WBM tablet formulations in one of four sequences.
89307387|NCT01209117|Experimental|Period 5|Subjects in Part B will receive a formulation of GSK2248761 200mg WBM Tablet chosen from Periods 1 - 4 in part A in the fed state (moderate fat meal).
89307388|NCT01209273||APD group|which can be 3 to 5 exchanges daily, and up to 20 liters daily( including up to two daytime exchanges)
89307389|NCT01209273||CAPD group|which can be 1 to 4 exchanges daily and up to 16 liters daily(including up to two daytime exchanges)
89307390|NCT01207791|Other|Minimal screening only (MSO)|Minimal screening
89307391|NCT01207791|Active Comparator|Screening, assessment, and referral (SAR)|
89307392|NCT01207791|Experimental|Brief intervention plus telephone boosters (BI-B)|
89307393|NCT01207869|Experimental|Mesenchymal stem cells|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
89307394|NCT01207869|Placebo Comparator|Control|Normal saline
89307395|NCT01209351|Placebo Comparator|Placebo|Placebo
89307396|NCT01209351|Experimental|teduglutide|
89307397|NCT03942471|Other|Intervention Mindfulness Based Stress Reduction|Six Modules each delivering an important principle of Mindfulness Based Stress Reduction
89307398|NCT03942471|No Intervention|Control Group|Wait Group - received no mindfulness teaching
89307399|NCT01107483||AC group|asymptomatic carriers
89307400|NCT01107483||CH group|patients with chronic hepatitis
89307401|NCT01107483||HC group|patients with hepatic cirrhosis
89307402|NCT01107483||ACLF group|patients with acute on chronic liver failure
89307403|NCT01107483||healthy control|healthy volunteers
89307404|NCT03798717|No Intervention|Control|Participants will lie in a semi recumbent position in minimal clothing for the entirety of the visit. Initially, participants will be cannulated and blood samples drawn.every 30 min of each experimental visit. Following cannulation an 180 min OGTT (75g) will commence in a thermoneutral room (~ 23C). During the OGTT, HR will be measured continuously, whilst blood pressure, deep body temperature (rectal probe) and resting metabolic rate will be assessed every 30 min.
89307405|NCT03798717|Experimental|Pre OGTT|Condition 2 will employ identical procedures to condition 1, except thirty minutes into the OGTT, the participant will be immersed into an immersion tank (~39oC) for 60 min. Water temperature will be manipulated as required to achieve and maintain a target Trec at 38.5 oC using water between 37.5 and 39oC, and then participants will be removed horizontally back into the thermoneutral room for the reminder of the OGTT. Participants will be towel dried and given a towelled robe to wear.
89307406|NCT03798717|Experimental|Post OGTT|Condition 3 will employ identical procedures to condition 2, with the exception that the heating via immersion will start as soon as the participant is instrumented (and following a 15 min rest period) and the OGTT will commence 30 min after the 60 min immersion time for a further 180 min.
89307407|NCT01109901|Other|anterior submuscular transposition|it is kind of surgical method
89307408|NCT01109901|Other|Anterior subcutaneous transposition|it is kind of surgical method
89307409|NCT01110057|Experimental|Active|GW856553
89307410|NCT01110057|Placebo Comparator|Placebo|Placebo
89307411|NCT01112319|Experimental|Elf_care|The trial group will receive with Elf_Care unit (Hot-Cold & Electrotherapy) during physiotherapy treatment ( 28 minutes twice a week)
89307412|NCT01112319|Active Comparator|control group|The control group will receive before physiotherapy COLD HOT or Electrotherapy treatment depends on the patient and physiotherapy prefer.
89307413|NCT01112397|Experimental|1|AZD1480 until Maximum Tolerated Dose (MTD) is reached
89307414|NCT01112397|Experimental|2|AZD1480 dose expansion of MTD
89307415|NCT01107561|Experimental|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire.
89307416|NCT01107561|Active Comparator|Surgical airway approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
89307417|NCT02529579|Active Comparator|Gemcitabine|Standard Gemcitabine Therapy
89307418|NCT02529579|Experimental|cellular immunotherapy & Gemcitabine|iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
89307419|NCT01209429|Experimental|42 hour fast/GH infusion|
89307420|NCT01209429|Experimental|42 hour fast/Placebo infusion|
89307421|NCT01209429|Experimental|12 hour fast/GH infusion|
89307422|NCT01209429|Placebo Comparator|12 hour fast/Placebo infusion|
89307423|NCT01110213|Experimental|Physical activity|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging leisure time physical activity. Content was based on goal setting theory and decisional balance.
89307424|NCT01110213|Experimental|Fruit and vegetable|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging fruit and vegetable intake. Content was based on goal setting theory and decisional balance.
89307425|NCT01110291||Breast cancer|Twenty patients with verified high risk breast cancer will be included in the study.
89307426|NCT01207947||Group 1|
89307427|NCT01208025||symptomatic carotid stenosis 30-69%|Patients with neurological symptoms due to ischemia in the carotid artery territory and with a carotid stenosis between 30% and 69% according to the European Carotid Surgery Trial (ECST) criteria.
89307428|NCT01107639|Experimental|Additional immunotherapy (cetuximab)|All patients in the experimental arm will be given additional immunotherapy (cetuximab) during cycles 1 and 2, during RT and after surgery.
89307429|NCT01107639|Active Comparator|Without additional immunotherapy|Standard therapy without immunotherapy (cetuximab).
89307430|NCT03946215|Experimental|well-trained athletes|A cardiorespiratory stress test
89307431|NCT03942861||Severe Ulcerative Colitis|Consecutive patients admitted as in-patients to the Department of Gastroenterology at four University Hospitals in Denmark, with acute severe UC defined as an affirmed diagnosis of UC according to well established criteria, combined with a Mayo score of 8 or more (i.e. severe disease activity) and the need for intravenous corticosteroid treatment will be screened for participation in the study after informed consent.
89307432|NCT01209507||Chemotherapy every 3 weeks|One treatment of chemotherapy every 3 weeks. Chemotherapy will either be 2 doses of 20 mg orally (PO) (12 hrs prior and immediately before treatment) or 1 dose via IV. The total dose per cycle is 20-40 mg every 3 weeks for 18 weeks.
89307433|NCT01209507||Weekly chemotherapy|Chemotherapy will be given three times in a three week cycle. Chemotherapy will be given either Day 1, 8, and day 15 or Day 1,2 and day 8). Chemotherapy will either be 2 doses of 20 mg PO (12 hrs priors and immediately before treatment) or 1 dose via IV. The total dose per cycle will be 20-40 mg approximately for 18 weeks.
89307434|NCT01209585||Rheumatoid Arthritis|Subject must have RA with inflamed joint
89307435|NCT01209585||Osteoarthritis|Subjects must have OA of the knee
89307436|NCT01209585||Pseudo gout|Subjects must have peusdo-gout of knee
89307437|NCT03942705||Kenyan Women|Women living in western Kenya will be asked to complete a self collected vaginal sample for HPV DNA screening and asked to undergo a second screening by VIA. As per Kenyan standard of care, vaccination against HPV will be offered to children/grandchildren (boys and girls) of women, and to the women themselves if age 26 or younger. The second vaccine dose (for children ages 9 through 14) and third doses (for children and adult women ages 15 through 26) will be administered at subsequent visits. There will be no requirement for HPV vaccination (of children or mothers up to 26 years of age) for participation in the study. Results of the screening will be returned to participants and they will be referred to receive standard care as applicable.
89307438|NCT01110369|Experimental|Resistance exercise training and protein drink|
89307439|NCT01110369|Placebo Comparator|Resistance exercise training and placebo drink|
89307440|NCT01110447|Experimental|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus.
89307441|NCT01110447|Placebo Comparator|Placebo|Placebo sachets contain corn starch
89307442|NCT01107873||duplex ultrasonography|conduct duplex ultrasonography after caudal block with sevoflurane anaesthesia in children
89307443|NCT03942549||MUS Cohort|This cohort will undergo midurethral sling placement.
89307444|NCT01208259|Experimental|Binge Eating Disorder/Therapy|
89307445|NCT03942237|Experimental|single-injection QLB (quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
89307446|NCT03942237|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
89307447|NCT01107951|Other|Rituximab -dexamethasone|only one arm receive four doses weekly rituximab and four dosis daily dexamethasona
89307448|NCT01112553||Treximet|All migraine subjects will receive Treximet during a migraine episode at Visit 2.
89307449|NCT01328067|Active Comparator|Treatment|MR guided Focused Ultrasound
89307450|NCT01328067|Active Comparator|Surgery|Myomectomy
89307451|NCT01112631||Stage II patients post surgery|Stage II patients treated with surgery alone
89307452|NCT01112631||Stage III patients post surgery|Stage III patients treated with surgery and PORT
89307453|NCT01108029|Active Comparator|memantine|memantine 20 mg/day (2 tablets 1 time a day in the morning)
89307454|NCT01108029|Placebo Comparator|placebo|2 tablets (1 time a day in the morning) during 3 months
89307455|NCT01112709|Experimental|SCT|This arm is a long-term, Social Cognitive Theory (SCT)-based intervention, emphasizing self-regulation and other SCT strategies to optimize training, with faded contact.
89307456|NCT01112709|Active Comparator|Control|"This arm will be the control condition; a Standard intervention with minimal contact."
89307457|NCT01208493|Experimental|high protein preterm infant formula|preterm infant formula with high protein levels
89307458|NCT01208493|Active Comparator|control preterm formula|
89307459|NCT01208571|Experimental|Lifestyle counseling|
89307460|NCT01208571|No Intervention|Treatment as usual|
89307461|NCT01209663|Active Comparator|Ward Care|Protocol based discharge to the surgery ward. Observation and treatment is conducted by ward nurses and general surgeons (current treatment).
89307462|NCT01209663|Experimental|Intermediate Care|Observation and treatment in an intermediate care bed in a minimum of 48 hours after randomization. Daily rounds will be carried out by both general surgeons and intensive care physicians.
89307463|NCT04308291||MiniMed™ 780G System|Subject will use the MiniMed™ 780G System as per standard of care.
89307464|NCT03941925|Experimental|Prebiotic fructans|Prebiotic fructans. Prebiotic will be mixed into foods or drinks and consumed twice daily.
89307465|NCT03941925|Placebo Comparator|Maltodextrin|Maltodextrin. Maltodextrin will be mixed into foods or drinks and consumed twice daily.
89307466|NCT01209741|Active Comparator|1|MK-0974 12MoRT
89307467|NCT01209741|Active Comparator|2|MK-0974 5Mo5C
89307468|NCT01209741|Active Comparator|3|MK-0974 12Mo5C
89307469|NCT01110525|Experimental|1|AZD1981 + Oral contraceptive
89307470|NCT01110525|Placebo Comparator|2|Placebo + Oral contraceptive
89307471|NCT01110603|Experimental|MK-4827 + carboplatin|
89307472|NCT01110603|Experimental|MK-4827 + carboplatin/paclitaxel|
89307473|NCT01110603|Experimental|MK-4827 + carboplatin/liposomal doxorubicin|
89307474|NCT03942003|Experimental|Rhomboid|When applying the Rhomboid nerve block, the patient is tilted to the side position so that the corresponding breast is at the top. After T7 up to T10 sterile preparation of the C7 spinous projection, the convex probe shows a rhomboid muscle at the level of T5 and block is applied with 0.25% bupivacaine (20 cc), 2% lidocaine (10 cc) and 10 cc SF mixture.
89307475|NCT03942003|Experimental|Pectoral|The PEC I field block is performed by administering 10 cc of local anesthetic between the pectoralis minor and the major at the 2nd costal position. PEC II field block is performed using linear USG probe visibly in 3rd and 4th ribs while the patient is in supine position. In this block, a total of 20 cc 0.25% bupivacaine (10 cc), 2% lidocaine (5 cc) and 5 cc SF mixture were used to block the area between the pectoralis minor muscle and the serratus muscle
89307476|NCT03942003|Sham Comparator|Control|Infiltration analgesia was performed.
89307477|NCT04258683|Experimental|Pembrolizumab with CyBorD|This will be a single arm study of pembrolizumab with cyclophosphamide, bortezomib and dexamethasone (CyBorD).
89307478|NCT01112787|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene Foam 0.1%,
89307479|NCT01112787|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam.
89307480|NCT01112787|Active Comparator|Sodium Laural Sulfate|Subjects will be exposed to patches containing Sodium Laural Sulfate.
89307481|NCT01112787|Placebo Comparator|Distilled Water|Subjects will be exposed to patches containing Distilled Water.
89307482|NCT01110759||Under Local Infiltration|
89307483|NCT01110759||Under Peripheral Nerve Block|
89307484|NCT01110837|Active Comparator|Allergen|
89307485|NCT01110837|Placebo Comparator|Placebo|
89307486|NCT01209897|Active Comparator|Stage of Change|
89307487|NCT01209897|Experimental|Common Sense Model|
89307488|NCT01209897|Active Comparator|Action Model|
89307489|NCT01209975||untreated glaucoma patients|We will evaluate the blood flow before and after Selective Laser Trabeculoplasty in patients with primary open angel glaucoma.
89307490|NCT01111071||STEMI|patients with discharge diagnosis of ST elevation myocardial infarction
89307491|NCT01111071||nSTEMI|patients with discharge diagnosis of non ST elevation myocardial infarction
89307492|NCT01111071||unstable angina|patients with discharge diagnosis of unstable angina
89307493|NCT01108107|Other|Chemotherapy only|Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
89307494|NCT01108107|Other|Chemotherapy + biological treatment|Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.
89307495|NCT01210053|Experimental|Single arm|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
89307496|NCT01210131|Experimental|[18F]HX4|
89307497|NCT01112943|Experimental|Acupuncture|Acupuncture on predefined points once a week for 20 minutes over the seven week pulmonary rehabilitation course
89307498|NCT01112943|Active Comparator|Pulmonary Rehabilitation|A seven week exercise and educational class run twice a week using international guidelines.
88806447|NCT01792544|Experimental|Statement|A statement is added to the echocardiography report describing if and when a follow-up echocardiogram is recommended. The statement may be positive (e.g. follow-up recommended in 6 months) or negative (e.g. no follow-up recommended).
88806448|NCT01792544|Experimental|No Statement|No statement is added to the echocardiography report
88806449|NCT01792700|Active Comparator|MEA|MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.)
88806450|NCT01792700|Active Comparator|EBMT|EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d)
89307499|NCT01112943|No Intervention|Control|Three assessments over the same time frame of three months but without intervention
88806451|NCT00315302|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye
88806452|NCT00315302|Active Comparator|Atropine plus plano|Atropine 1% once each weekend day in the sound eye plus a plano lens for the sound eye
89307500|NCT01208649|Active Comparator|Exenatide|Drug (including placebo)
89307501|NCT01208649|Placebo Comparator|Placebo|
89307502|NCT03798483|Experimental|Individualized exercise|Participants after a lateral kneecap dislocation will be enrolled into an individualized exercise intervention supervised by a physiotherapist
89307503|NCT03942159||Donors|HLA-matched or haploidentical nursing relative donors
89307504|NCT03942159||Patients|recipients of allogeneic HSCT
89307505|NCT03942315||Liver transplant in Hereditary Hemorrhagic Telangiectasia|Hereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.
89307506|NCT01114347|Experimental|Cranberry|Patients randomized to this arm will recieve one gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water.
89307507|NCT01114347|Placebo Comparator|Placebo|The patients randomized to this arm will recieve one placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
89307508|NCT03945201|Active Comparator|Standard of care|"Participants receive normal cardiac rehabilitation according to approved standard of care. They use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session."
89307509|NCT03945201|Experimental|Virtual walking trails|"Participants use multiple pieces of exercise equipment at each session for increasing amounts of time and at incrementally increasing levels of difficulty. After establishing a baseline, participants are allowed to use the treadmill for up to 15 minutes at each session. The treadmill is positioned in front of a vertically oriented high definition television screen showing Bionautica Trails, virtual walking trails created by Plas.md."
89307510|NCT01113021|Experimental|LLLT and Physical Strength training in Humans|
89307511|NCT03945123|Experimental|Ginseng trial|compare experimental group to controlled group
89307512|NCT03972033|Experimental|Eye Movement Desensitization and Reprocessing|"The DeprEND manualized protocol (Hofmann, Ostacoli, et al., 2015) is based on the eight-phase protocol by Shapiro (2001) that was adapted for the treatment of depression by the European Depression EMDR Network and used in previous studies (Hase et al., 2015; Hofmann et al., 2014; Ostacoli et al., 2018). EMDR targets will be selected using the Adaptive Information Processing model that looks for stressful events linked with depression. The DeprEnd Fidelity Rating Scale will be used to assess treatment fidelity. The scale will be completed by trained EMDR therapists who will listen to the audio recordings of the sessions.~In each centre, EMDR is provided by psychotherapists specialized in Level II EMDR and with a minimum of three years of experience in treating patients with depression. They receive extensive training and supervision in the manualized protocol established for the study, from a certified senior EMDR instructor."
89307513|NCT03972033|Active Comparator|Cognitive Behavioral Therapy|Treatment protocol is based on the principles described by Beck (Beck et al., 1979) will be utilized. The treatment includes behavioral activation and cognitive restructuring with homework assignments. In each centre, CBT treatment is performed by psychotherapists with certified training in CBT techniques and a minimum of three years of experience in treating patients with depression. They receive regular CBT supervision to ensure that the quality of their CBT treatment was maintained.
89307514|NCT01211847|Experimental|DCCR|DCCR Treatment with 290 mg Diazoxide Choline
89307515|NCT01211847|Placebo Comparator|Placebo|Placebo matching DCCR
89307516|NCT01210287|No Intervention|Observation|Observation of the HBV reactivation in HBsAg negative/HBcAg positive patients receiving RCHOP without prophylactic anti-HBV treatment.
89307517|NCT02529657|Placebo Comparator|Placebo|23 patients were induced to think they will be getting the same treatment, although the LLLT is not operating.
89307518|NCT02529657|Experimental|Low level Laser Therapy|25 patients were submitted to spine surgery and have received low level laser therapy during surgery, 24 hours after surgery and 48 hours after surgery.
89307519|NCT01211925|Experimental|critical ischemia|
89307520|NCT01211925|No Intervention|Control|Best medical treatment
89307521|NCT03940599|Experimental|Fitbit with visible screen|The first group will receive a FitBit with the screen visible, displaying their daily step count (the Step-Counter group).
89307522|NCT03940599|Experimental|Scale group|The second will receive a BodyTrace scale that will display and record their weight in kilograms and a FitBit with the screen covered as it was for the run-in period so their physical activity can be measured, but the only feedback they will receive is from the scale (the Scale group).
89307523|NCT03940599|Experimental|Step counter and scale|The third group will receive a BodyTrace scale and a FitBit with the screen visible (the Step-Counter and Scale group).
89307524|NCT03940599|Sham Comparator|Fitbit with screen covered|The remaining 5 participants will serve as normal controls and continue wearing the FitBit with the screen covered as it was during the run in period for the duration of follow up.
89307525|NCT01108419|Active Comparator|1 = Test Product normal dose|Fermented dairy product containing probiotics - normal dose
89307526|NCT01108419|Active Comparator|2 = Test Product high dose|Fermented dairy product containing probiotics - high dose
89307527|NCT01108419|Sham Comparator|3 = Control Product normal dose|Non-fermented dairy product - normal dose
89307528|NCT01108419|Sham Comparator|4 = Control Product high dose|Non-fermented dairy product - high dose
89307529|NCT01113099|Experimental|Academic detailing of physicians|
89307530|NCT01113099|No Intervention|Usual care|
89307531|NCT03940755||Critical Illness Survivors|Those intensive care unit(ICU) patients who survive from critical illness.
89307532|NCT01113177||Distraction splint therapy|All JIA patients with asymmetric mandibular growth due to unilateral TMJ arthritis are offered non-surgical functional orthodontic splint therapy with a distraction splint. Mandibular growth is thereafter evaluated in the affected side compared with the mandibular growth in the healthy side of the same individual.
89307533|NCT01113255|Active Comparator|CHRONIC REPIRATORY FAILURE|
89307534|NCT01113255|Active Comparator|ACUTE RESPIRATORY FAILURE|
89307535|NCT03940833|Experimental|anti-tumor response of BCMA CAR-NK-92|Patients with relapsed and refractory MM of BCMA expression will be treated with BCMA CAR-NK 92 cells.
89307536|NCT03940911|Other|anti-TNFα treatment and severe fatigue (FSS)|"See bellow (section Interventions) the full description for~Measurement of aerobic exercise on cycloergometer~Measurement of muscle mass by two-photon absorptiometry: specific study~Measurement of Isometric Muscle Strength~Blood sampling for measurement of cytokine levels in the blood~Measurement of sedentarity~Psychological impact~Fatigue mesurement~Needle muscle of the vastus lateralis (This act will be limited to patients in care at Strasbourg University Hospital n=30)"
89307537|NCT03940911|Other|anti-TNFα treatment and with mild fatigue (FSS <4)|"See bellow (section Interventions) the full description for~Measurement of aerobic exercise on cycloergometer~Measurement of muscle mass by two-photon absorptiometry: specific study~Measurement of Isometric Muscle Strength~Blood sampling for measurement of cytokine levels in the blood~Measurement of sedentarity~Psychological impact~Fatigue measurement~Needle muscle of the vastus lateralis (This act will be limited to patients in care at Strasbourg University Hospital n=30)"
89307538|NCT01108575|Experimental|Inspiratory muscle strength training|
89307539|NCT01108575|Sham Comparator|Sham Inspiratory muscle strength training|
89307540|NCT03941691|Experimental|Treatment Group|Experimental group is allocated to use novel fully degradable ventricular septal defect closure system manufactured by Shanghai shape memory alloy materials co. LTD.
89307541|NCT03941691|Active Comparator|Control Group|Control Group is allocated to use Interposition conveying device for ventricular septal defect closure produced by Shanghai shape memory alloy material co. LTD.
89307542|NCT01328145|Active Comparator|ASA|
89307543|NCT01328145|Placebo Comparator|Placebo|
89307544|NCT01210521|No Intervention|Prior to intervention with Vitamin D|Patients will be analyzed for clinical, serological and immunological parameters before starting the interventional drug, Vitamin D.
89307545|NCT01210521|Active Comparator|Vitamin D Intervention|Patients will be analyzed for clinical, serological and immunological parameters after one month taking Vitamin D.
89307546|NCT01114659||Women with PCOS|
89307547|NCT01114659||Normal Control|
89307548|NCT01210599|Experimental|IV infusion of pamidronate vs placebo|
89307549|NCT03944889|Placebo Comparator|Placebo Topical|Placebo Cream, applied topically to trapezius muscle
89307550|NCT03944889|Active Comparator|Low Dose, Topical|Capsaicin Cream- low dosage, applied topically to trapezius
89307551|NCT03944889|Active Comparator|High Dose, Topical|Capsaicin Cream- higher dosage, applied topically to trapezius
89307552|NCT03944889|Placebo Comparator|Placebo, Intrafascial|Injection placebo(saline)- injected intrafascially into trapezius
89307553|NCT03944889|Active Comparator|Low Dose, Intrafacial|Injection Capsaicin formulation low dose- injected intrafascially into trapezius
89307554|NCT03944889|Active Comparator|High Dose, Intrafascial|Injection Capsaicin formulation higher dose- injected intrafascially into trapezius
89307555|NCT03944889|Placebo Comparator|Placebo, Intramuscular|Injection placebo (saline) - injected intramuscularly into trapezius
89307556|NCT03944889|Active Comparator|Low Dose, Intramuscular|Injection Capsaicin formulation low dose - injected intramuscularly into trapezius
89307557|NCT03944889|Active Comparator|High Dose, Intramuscular|Injection Capsaicin formulation higher dose - injected intramuscularly into trapezius
89307558|NCT01210677|Active Comparator|Prednisone|Prednisone 0.5 mg/Kg per day orally for 3 months
89307559|NCT01210677|Placebo Comparator|Placebo|Matching placebo tablets(s) taken orally per day
89307560|NCT01210755|Experimental|Rivaroxaban then Dabigatran|Cross-over study with 15 days between administration of Rivaroxaban and Dabigatran
89307561|NCT01210755|Experimental|Dabigatran then Rivaroxaban|Cross-over study with 15 days between administration of Dabigatran and Rivaroxaban
89307562|NCT03940287|Experimental|Muscle Energy Technique and Conventional Physiotherapy|Muscle Energy Technique will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks, where each session of Muscle Energy Technique will be repeated for 3-5 repetitions.
89307563|NCT03940287|Experimental|Kinesiotaping and Conventional Physiotherapy|Kinesiotape application will be given with conventional physiotherapy for 3 days per week and will be continue for 4 weeks
89307564|NCT01210833|Active Comparator|Healthy participants|Healthy participants aged from 18 to 60 with no history of hand injuries recruited by convenience sampling.
89307565|NCT01210833|Experimental|Hand Injured participants|Participants with hand injuries aged from 18 to 60 recruited from the outpatients attending the occupational therapy clinic.
89307566|NCT01210911|Experimental|Gemcitabine, erlotinib and metformin|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. Metformin will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
89307567|NCT01210911|Placebo Comparator|Gemcitabine, erlotinib and placebo|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. PLacebo will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
89307568|NCT01113333|Experimental|SAR113945|SAR113945, single dose according to dose escalation design
89307569|NCT01113333|Placebo Comparator|Placebo|0.9% saline solution, single dose
89307570|NCT01210989|Active Comparator|Hepaguard|
89307571|NCT01210989|Placebo Comparator|Placebo|
89307572|NCT01115049|Experimental|Experimental mouthwash|The experimental mouthwash (Buccagel®, Curaden Healthcare, Saronno, Italy) was made up of: purified water, dicaprylyl-ether, coco-caprylate caprate, xylitol, glyceryl-stearate, ceteareth-20, ceteareth-12, cetyl-palmitate, cetearyl-alcohol, chlorobutanol, aroma, hexetidine, methylparaben, propylparaben, sodium saccharin, citric acid and colorant C.I. 16255.
89307573|NCT01115049|Active Comparator|Chlorexidine-based mouthwash|A conventional commercial mouthwash (Curasept® ADS 0.20%, Curaden Healthcare, Saronno, Italy) made up of: water, xylitol, propylenglycol, Peg-40 of hydrogenated ricin oil, ascorbic acid, chlorhexidine digluconate, aroma, poloxamer 407, sodium metabisulfite, sodium citrate and colorant C.I. 42090.
89307574|NCT03941535|Experimental|Decreasing Daily Dose of Vitamin K|"This group of patients will receive a decreasing dose of Vitamin K IV:~Days 1-2 = 10mg/day (standard of care) Days 3-4 = 5mg/day Days 5-90 (or date of discharge, death, etc) = 2mg/day"
89307575|NCT03941535|Active Comparator|Standard of Care Dose of Vitamin K|This group of patients will be reviewed retrospectively and would have received Vitamin K IV at 10mg/day during their entire hospital course
89307576|NCT01211067||Patients age: 15 - 40 years-old|Patients within the 15 to 40 years-old age-group
89307577|NCT01211067||Patients age: 41 to 60 years-old|Patients within the group-age from 41 to 60 years-old
89307578|NCT01211067||Patients age: older than 61 years-old|Patients within the group-age from 61 years-old and older
88806453|NCT00315614|Experimental|Islet Transplantation and Bone Marrow|Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.
89307579|NCT03941457|Experimental|anti-tumor response of BiCAR-NK cells (ROBO1 CAR-NK cells)|Patients with relapsed and refractory pancreatic cancer of ROBO1 expression will be treated with BiCAR-NK cells (ROBO1 CAR-NK cells).
89307580|NCT01115127|Active Comparator|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
89307581|NCT01115127|Active Comparator|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
89307582|NCT01115127|Active Comparator|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
89307583|NCT01115205|Experimental|Supervised walking groups|Patients included in walking groups, under the supervision of a qualified personal trainer.
89307584|NCT01115205|Active Comparator|Controls|Patients receiving the standard counselling procedures of the Verona Diabetic Clinic.
89307585|NCT01117545|Experimental|EFT|Six sessions of EFT (Emotional Freedom Techniques)
89307586|NCT01117545|No Intervention|Wait List|One month wait period
89307587|NCT01113411|Active Comparator|Intensive Rehabilitation|
89307588|NCT01113411|Active Comparator|Standard Rehabilitation|
89307589|NCT03940443||Ground Emergency Medical Services|Patients suffering TBI or acute MI and has been treated by GEMS dispatched by an emergency dispatch centre.
89307590|NCT01211223|Experimental|Scaling and root planning + placebo + antibiotics|"Scaling and root planning + placebo~Scaling and root planning + metronidazole plus amoxicillin~Metronidazole plus amoxicillin + scaling and root planning"
89307591|NCT01212237||fMRI Evaluation|"All patients will undergo the following standard imaging and radiotherapy procedures will be performed for each patient:~Standard MRI for radiotherapy treatment planning which takes about 60 minutes.~Radiotherapy treatment simulation with CT.~Radiotherapy treatment planning~Radiotherapy treatment~Routine follow-up every 3 months after the radiotherapy.~Special Procedures.~The following special imaging and radiotherapy procedures will be performed for each patient:~fMRI (30 minutes)~The 3MS examination, administered every 3 months during routine follow-up for one year after the completion of the radiotherapy."
89307592|NCT01113489|Experimental|beclomethasone dipropionate suspension for nebulization|
89307593|NCT01113489|Placebo Comparator|placebo|
89307594|NCT01211301|Active Comparator|Food-based, Reduced Energy Diet Plan|
89307595|NCT01211301|Experimental|Medifast 5 & 1 Plan|
89307596|NCT01115361|Experimental|PPFP in child immunization|Women attending immunization services for their infant will receive educational brochures, group education and individual counseling on the benefits of the health timing and spacing of births,, pregnancy risk and return to fertility during the extended postpartum period (12 months), and referral to family planning services for those who are interested.
89307597|NCT01115361|No Intervention|Control - Standard of care|The control arm will receive standard of care infant immunization services.
89307598|NCT01115439||falciparum malaria|Febrile children (above six months of age) and non-pregnant adults with confirmed uncomplicated P. falciparum infection
89307599|NCT01117701|Experimental|A - with SGW|Measurement of the forces needed to passage the ureteroscope in the ureter with a SGW in place.
89307600|NCT01117701|Experimental|B - without SGW|Measurement of the forces needed to passage the ureteroscope in the ureter without a SGW in place.
89307601|NCT02529423|Placebo Comparator|Placebo|Placebo
89307602|NCT02529423|Experimental|Multi-nutrient supplement|Multi-nutrient supplement
89307603|NCT02529423|Experimental|Placebo + Behavioral Activation|Placebo + Behavioral Activation
89307604|NCT02529423|Experimental|Multi-nutrient + Behavioral Activation|Multi-nutrient + Behavioral Activation
89307605|NCT03940053|No Intervention|Observation|Subjects only accept the routine treatment for underlying diseases.
89307606|NCT03940053|Experimental|Intervention|Based on the routine treatment for underlying diseases, subjects were administrated by arginine.
89307607|NCT01113645||Cerebral perfusion evaluation|All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores. Hemodynamic monitoring by CT perfusion scan, as well as by trans-cranial Doppler.
89307608|NCT01212315|No Intervention|Control group|Ordinary sutures (Vicryl / Monocryl) is used for wound closure
89307609|NCT01212315|Active Comparator|Group A|Triclosan coated sutures (Vicryl Plus / Monocryl Plus) is used for wound closure
88820780|NCT05651711|Placebo Comparator|Placebo|Placebo Q4W for 24 weeks with a loading dose at Week 2.
89307610|NCT01115595|Active Comparator|Intervention|injection by Mite extract with standard allergic medication (oral antihistamine and/or topical nasal steroid)
89307611|NCT01115595|Other|Control Group|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid
89307612|NCT03938259||Control group; patients without obstructive sleep apnea|Children without OSA having procedures requiring endotracheal intubation and an who will receive opioids for evaluation of respiratory changes
89307613|NCT03938259||Patients with known obstructive sleep apnea|Children with OSA having adenotonsillectomy for obstructive apnea will receive opioids with evaluation of respiratory changes
89307614|NCT01211379|No Intervention|FLU-Only Arm|In this arm, primary care patients who got flu shots were only provided with FOBT if the doctor decided to order it.
89307615|NCT01211379|Experimental|FLU-FOBT Arm|In this arm, patients who came in for primary care got a flu shot and were assessed by nurses for eligibility for colorectal cancer screening. Eligible patients were provided with home FOBT.
89307616|NCT01117935|Experimental|Arm I|Patients undergo hypofractionated intensity modulated radiotherapy once daily, 5 days a week, for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with intermediate- and high-risk disease may also receive concurrent and adjuvant or long-term androgen deprivation therapy for up to 36 months.
89307617|NCT01212393||Intervention group|reminders
89307618|NCT01212393||current practice group|no intervention
89307619|NCT03939663|Placebo Comparator|placebo group|2 tablets vaginally
89307620|NCT03939663|Experimental|misoprostol group|400 mcg vaginally
89307621|NCT03941067|Experimental|Pre-event massage|
89307622|NCT03941067|No Intervention|Control|
89307623|NCT01213407|Experimental|Standard therapy plus Trivax|Standard therapy with Surgery, Temozolomide, and Radiotherapy; plus Trivax, 5x10e6 autologous interleukine-12 secreting dendritic cells charged with autologous tumour lysate.
89307624|NCT01213407|Active Comparator|Standard therapy|Surgery, Temozolomide, Radiotherapy
89307625|NCT03941145|Experimental|Exercise|Participants allocated to the intervention group will be asked to perform 2 exercise sessions per week for 6 weeks. Each session will involve 10 min of low-intensity cycling (25 W) interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 5% of body mass. The exercise intervention will be delivered on a commercially available cycle ergometer with software developed by CAR.O.L.
89307626|NCT03941145|No Intervention|Control|The effects of the intervention will be compared to a no-intervention control group recruited from the same workplace settings.
89307627|NCT01211457|Experimental|Sapacitabine/decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
89307628|NCT01211457|Experimental|sapacitabine/venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
89307629|NCT01114035|Experimental|Patients|intestinal epithelial dysplasia
89307630|NCT01114035|Other|Control|Children without intestinal epithelial dysplasia
89307631|NCT01212549|Active Comparator|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 weeks imiquimod
89307632|NCT01212549|Active Comparator|Cryoimmunotherapy|Cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 5 weeks imiquimod
89307633|NCT01115751|Experimental|LY2780301|"Part A: daily dosing~Part B (if determined as needed by pharmacokinetic, pharmacodynamic, and safety data): twice daily dosing~Part C: Dose and frequency as determined by Parts A and B of the study."
89307634|NCT01213485||Cohort|
89307635|NCT01114113|Active Comparator|non-trigger meal|"Measurement of intestinal transport eating a non-trigger meal."
89307636|NCT01114113|Active Comparator|"trigger meal baseline"|"Measurement of intestinal transport after eating a trigger meal."
89307637|NCT01114113|Placebo Comparator|"trigger meal with placebo"|Measurement of intestinal transport with blinded placebo
89307638|NCT01114113|Active Comparator|"trigger meal with enzymes (blinded)"|Measurement of intestinal transport with blinded active enzyme capsule
89307639|NCT01213563|Experimental|Actrapid insulin|Intensive glycaemic control Intervention: Actrapid insulin
89307640|NCT01213563|Active Comparator|Actrapid insulin+Gloucose|conventional glycaemic control Intervention: Actrapid insulin+Glucose
89307641|NCT01118169||Veterans|
89307642|NCT01115907|Experimental|Freedom SOLO stentless valve implant|Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.
89307643|NCT01115985|Experimental|single-add first group|single administration first, then concomitant administration
89307644|NCT01115985|Experimental|combi-add first group|concomitant administration first, then single administration
89307645|NCT01116063|Experimental|Single arm open label|All patients will receive the study drugs and will be evaluated
89307646|NCT03941223|Experimental|pectoral PECS II block|Ultrasound-guided PECS II block with ropivacaine 0.75% 20 ml (patients N = 75) + Parasternal ultrasound-guided block at T2, T4 levels with ropivacaine 0.375% 10 ml
89307647|NCT03941223|Active Comparator|Paravertebral nerve block|Ultrasound-guided paravertebral block with ropivacaine 0.75% 20 ml at T1-T2 and T3-T4 levels (10 ml each) (patients N = 75)
89307648|NCT01116219|Active Comparator|Stratum mut EGFR|"Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~Erlotinib 150 mg p.o. daily until progression."
89307649|NCT01116219|Active Comparator|Stratum wtEGFR|"Cohort 1:~Induction chemotherapy with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.~Cohort 2:~Induction chemotherapy with~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~o Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
89307650|NCT01213719|Experimental|creatine|will receive creatine monohydrate (20g/d) throughout 10 days
89307651|NCT01213719|Experimental|betaine|will receive betaine (2g/d) throughout 10 days
89307652|NCT01213719|Placebo Comparator|placebo (dextrose)|will receive dextrose(20g/d)throughout 10 days.
89307653|NCT01213719|Active Comparator|creatine plus betaine|will receive creatine (20g/d) plus betaine (2g/d) throughout 10 days
89307654|NCT01213797||Suicide attempter and its entourage|"Suicide attempter and its close relatives (who are living under the same roof)~Comparison of the population of the close relations of committing suicide with the data of the Research Institute and Documentation in Economy of Health (IRDES) on the French population (sample of 20.000 people, representative of 95% of the French households)."
89307655|NCT01114191|Experimental|Arm 1|
89307656|NCT01211691|Experimental|Phase 1 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects with heme malignancies will be assigned to one of 11 planned KB004 (dose levels (20mg, 40mg, 70mg, 100mg, 140mg, 190mg, 250mg, 330mg)"
89307657|NCT01211691|Experimental|Phase 2 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects will be assigned to the recommended Phase 2 dose of 250 mg"
89307658|NCT01121523|Experimental|Cue-directed tactile stimulation|
89307659|NCT01121523|Active Comparator|Control group|
89307660|NCT03937869|Other|Single dose Solosec (secnidazole) 2g oral|Solosec 2 grams, oral
89307661|NCT02529501||SA|Patients undergoing spinal anesthesia
89307662|NCT02529501||GA|Patients undergoing short general anesthesia
89307663|NCT01116297|Experimental|Imaging with S-FLARE imaging system|3 patients to be imaged by S-FLARE imaging system.
89307664|NCT01121601|Experimental|Group COSEAL|
89307665|NCT01121601|Active Comparator|Reference group|
89307666|NCT03936075|Experimental|intervention|treatment with the provision of 6 individual sessions of the Guided Imagery and Music method as a psychological supportive intervention, and psychometric questionnaires collection
89307667|NCT03936075|Placebo Comparator|control|standard care treatment with psychometric questionnaires collection and two individual counselling sessions, at baseline (week 1) and at the end (week 6)
89307668|NCT01121679||Patients aged 80 years and older|Patients aged 80 years and older and hospitalized in a cardiology department
89307669|NCT01116375||Obese children with OSA|To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR
89307670|NCT01116453|Experimental|Acupuncture|
89307671|NCT01116453|Active Comparator|Usual Care|usual care followed by delayed acupuncture
89307672|NCT01118247|Experimental|pure Ti|Cup and stem partly coated with pure titanium
89307673|NCT01118247|Active Comparator|pure Ti and HA|Cup and stem partly coated with pure titanium, and fully coated with HA.
89307674|NCT01215825||HD, LD, NIL|HD: the highest daily dose of steroids receiving more than 60 mg/day LD: the highest daily dose of steroids receiving less or equal to 60 mg/day NIL: no steroid use
89307675|NCT01116531|Active Comparator|Duloxetine and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
89307676|NCT01116531|Active Comparator|Pregabalin and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
89307677|NCT03939975|Experimental|Study arm|"Patients with stable diseases or atypical progression to ICIs monotherapy would be additionally treated with incomplete thermal ablation along with ICIs therapy; and for those who with no lesions eligible for Incomplete ablation, ICIs would be given solely.~Others with complete or partial responses would keep on going with mono-ICIs therapy."
89307678|NCT01215903|Experimental|Fish gelatin and omega-3|
89307679|NCT01215903|Experimental|Omega-3|
89307680|NCT03937557|Active Comparator|men's hair count|
89307681|NCT03937557|Placebo Comparator|women's hair count|
89307682|NCT01118403|Experimental|Sultamicillin, Antibiotic Prophylaxis|Sultamicillin, Antibiotic Prophylaxis
89307683|NCT01118403|Placebo Comparator|Placebo|Physiologic Sodium Chloride Solution
89307684|NCT01121835|Experimental|Insulin glargine|"Administered once a day in the evening, at the same time every day. The starting daily dose is 0.2 U/Kg of body weight or 12 U, at the investigator's decision.~Insulin glulisine is administered for patients of the insulin glargine group requiring insulin glulisine at week 12 (visit 11).~Insulin glulisine is administered prior (10-15 min) to the main meal of the day, which is the meal with highest Post-Prandial Plasma Glucose (PPPG) on the 3 profiles performed before week 12.~Starting dose is of 4 units per day."
89307685|NCT01121835|Experimental|Premixed insulin|administered once a day (in the evening at dinner) or twice a day (in the morning before breakfast and in the evening at dinner). Starting daily dose will be 6 U at breakfast and 6 U at dinner, if administered twice a day or 12 U at dinner if administered once a day
89307686|NCT01216059|Experimental|Intervention group|Subjects will receive daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study.
89307687|NCT01216059|No Intervention|Control Group|Subjects will receive a weekly text message reminder about pop-culture, sports or weather.
89307688|NCT01116843|Experimental|PF-00299804|Patient will receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days depending on surgery schedule.
89307689|NCT01116843|Placebo Comparator|Placebo arm|Patient will receive matching Placebo for 7-11 days depending on surgery schedule.
89307690|NCT03792477|Experimental|Part 1: Treatment A|Single 200mg IM testosterone cypionate solution (Test formulation)
89307691|NCT03792477|Active Comparator|Part 1: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
89307692|NCT03792477|Experimental|Part 2: Treatment A|Single 200 mg IM testosterone cypionate solution (Test formulation)
89307693|NCT03792477|Active Comparator|Part 2: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
89307694|NCT03788967|Experimental|TBPM-PI-HBr 600 mg|TBPM-PI-HBr 600 mg (300 mg×2 ) film-coated tablets, administered orally three times per day (every 8 hours [q8h] ± 0.5 h) plus a single dummy IV infusion over 30 minutes (min) once daily (every 24 hours [q24h] ± 0.5 h) up to Day 15; participants with moderate renal insufficiency (creatinine clearance [CrCl] >30 to ≤50 mL/min) required TBPM-PI-HBr dosage adjustment to 300 mg (one tablet) q8h ± 0.5 h.
89307695|NCT03788967|Active Comparator|Ertapenem 1 g|Ertapenem for IV injection, administered as a 1-gram IV infusion over 30 min once daily (q24h ± 0.5 h) plus dummy placebo tablets administered orally q8h (±0.5 h) up to Day 14; no dose adjustment of ertapenem was required for participants with renal insufficiency.
89307696|NCT01118481||Pressure and flow velocity|
89307697|NCT01118481||Pressure only|
89307698|NCT01118559|Experimental|fast-fed sequence group|drug is administered in a fasted condition first, and fed-condition study follows
89307699|NCT01118559|Experimental|fed-fast sequence group|drug is administered in a fed condition first, and fasted-condition study follows
89307700|NCT01216137|Experimental|Exercise: Vestibular Rehabilitation|Balance and eye movement training
89307701|NCT01216137|Active Comparator|Exercise Control|Bicycle ergometry and stretching
88806454|NCT01792778|Active Comparator|ViaValve Safety IV Catheter|Catheter insertion using the ViaValve Safety IV Catheter.
88806455|NCT01792778|Active Comparator|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|Catheter insertion using the Insyte Autoguard BC Shielded IV Catheter
88806456|NCT01794026|Experimental|diffusion MRI|histopathology of lymph nodes diagnosed by diffusion weighted magnetic resonance imaging
88820781|NCT05651022|Experimental|Cohort -3|A single dose of Decoy20 at a dose of 0.75 x 10^7 Killed Bacteria (KB)
88820782|NCT05651022|Experimental|Cohort -2|A single dose of Decoy20 at a dose of 1.5 x 10^7 KB
89307702|NCT01216137|No Intervention|Wait-listed Control|Wait-listed Control
89307703|NCT01216215||Asthmatic sporadic and familial|
89307704|NCT01216215||Control subjects spradic and familial|
89307705|NCT03939507|Experimental|Intervention group|AEP score results were made available to the treating physician at each assessment visit.
89307706|NCT03939507|No Intervention|Control group|AEP scores were only made available at the end of follow-up.
89307707|NCT01585311||Subarachnoid Hemorrhage patients|SAH patients with hourly eMR values of Heart Rate
89307708|NCT01118637|Experimental|Immediate|Assigned immediately after baseline assessment to receive step 1 treatment (web-based self-help)
89307709|NCT01118637|No Intervention|Wait list|Assigned to wait list for 10 weeks before receiving step 1 treatment.
89307710|NCT01212705|Experimental|ASV|
89307711|NCT01216371|Active Comparator|Sunitinib|one year adjuvant treatment with sunitinib
89307712|NCT01216371|Placebo Comparator|Placebo|one year treatment with placebo
89307713|NCT01212783|Active Comparator|Present-Centered Therapy|Mothers will receive 15 weekly sessions of PCT plus two monthly booster sessions following the 15th session.
89307714|NCT01212783|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus two booster sessions scheduled monthly following the 15th session.
89307715|NCT01118871|Active Comparator|Standard of care|
89307716|NCT01118871|Experimental|NRTI sparing arm|
89307717|NCT01122069||Contrast echocardiography|110 patients with acute non-ST elevation myocardial infarct were examined with contrast echocardiography prior to coronary angiography.
89307718|NCT01216449|Experimental|Intravenous Citalopram|
89307719|NCT01216449|Placebo Comparator|Normal Saline|250mL of 0.9% Sodium Chloride Solution
89307720|NCT01122147|Active Comparator|chamomilla tincture mouthwash|Chamomile comprises bisaboloids, matricine and chamazulene, flavonoids, and cumarins having therapeutical anti-inflammatory, analgesic, musculotropic, and spasmolytic action
89307721|NCT01122147|Placebo Comparator|placebo mouth wash|placebo mouthwash is produced with the same taste and smell for using in placebo/ control group.
89307722|NCT01212861|Experimental|Suprachoroidal Dissection Instrument|
89307723|NCT01122225||Septic shock|
89307724|NCT03937401|Experimental|Patients treated with oxytocin during MRI-HIFU|
89307725|NCT01119027||Surgeons|Surgeons and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience. .
89307726|NCT01119027||Trainee Surgeons|Surgeon and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience.
89307727|NCT01122303||SJS|Stevens-Johnson syndrome patients with dry eye
89307728|NCT01122303||Control|Non-autoimmune dry eye patients
89307729|NCT01213875|Experimental|Experimental: Intervention and control|"I: Experimental Routine monitoring by health team in the reference institution, four home visits and four telephone contacts with trained nurses.~II: Control Routine monitoring by health team in the reference institution."
89307730|NCT01213875|No Intervention|Control|
89307731|NCT03935841|Experimental|3-OHB orally|36 gram 3-OHB salt consumed orally
89307732|NCT03935841|Active Comparator|3-OHB intravenously|Variable amounts of 3-OHB salt given i order to replicate the same individual plasma concentrations measured during the experimental arm.
89307733|NCT01116999|Experimental|Tracheal intubation|
89307734|NCT03935529|Experimental|Behavioural Acitivation|Behavioural Activation. Originally a component of cognitive behavioural therapy, Behavioural Activation is a structured psychotherapeutic approach which aims to (a) increase engagement in activities associated with pleasure or mastery, (b) decrease engagement in activities that maintain depression, and (c) problem solve barriers limiting access to reward or maintain aversive control. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
89307735|NCT01119261|Active Comparator|Non-genotype-guided dosing algorithm|
89307736|NCT01119261|Experimental|Genotype-guided dosing algorithm|
89307737|NCT01216527|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Surgery
89307738|NCT01216527|Active Comparator|control group|only Surgery
89307739|NCT01119339|Experimental|LAS 41004 dosage 1|
89307740|NCT01119339|Experimental|LAS 41004 dosage 2|
89307741|NCT01119339|Experimental|LAS 41004 dosage 3|
89307742|NCT01119339|Experimental|LAS 41004 dosage 4|
89307743|NCT01119339|Experimental|LAS 41004 dosage 5|
89307744|NCT01119339|Experimental|LAS 41004 dosage 6|
89307745|NCT01119339|Placebo Comparator|Placebo|
89307746|NCT01119339|Active Comparator|Reference|
89307747|NCT03939039||Dyslipidemia|Genotype/phenotype correlation in patients with dyslipidemia
89307748|NCT03939273|Active Comparator|Active group|A preoperative seven day course of oral ciprofloxacin 500 mg twice a day, oral vancomycin 500 mg thrice per day, oral metronidazole 500 mg thrice per day and a six day course of oral fluconazole 200 mg once per day.
89307749|NCT03939273|Placebo Comparator|Control group|A preoperative seven day course of placebo, consisting of pills and capsules identical in appearance and number to the active group
89307750|NCT01213017|Experimental|Certolizumab pegol|
89307751|NCT02529111|Experimental|intervention|"The Echonavigator software will be used on all patients. It will be used after the introduction of the percutaneous closure of ASD prosthesis. The image fusion on fluoroscopy will then be applied."
89307752|NCT03938805|Experimental|I-CBT|Internet-based cognitive behavioral therapy program including 1-week introduction, 2 weeks psycho education on Cardiovascular disease/insomnia, 6 weeks of sleep hygiene, stimulus control and sleep restriction
89307753|NCT03938805|Active Comparator|Control group|3 weeks internet-based sleep hygiene education
89307754|NCT01119417|Experimental|BQ123|endothelin blocker
89307755|NCT01119417|Placebo Comparator|Saline|IV saline
89307756|NCT01216605|Active Comparator|Oxytocin|
89307757|NCT01216605|Placebo Comparator|Placebo|
89307758|NCT01213095|Experimental|Rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
89307759|NCT01122459|Active Comparator|Hartmanns|These patients will receive Hartmanns during anaesthesia
89307760|NCT01122459|Active Comparator|Voluven 6%|
89307761|NCT03938883|Experimental|Ocular Bandage Gel (OBG)|Cross-linked Hyaluronic Acid 0.75%, regulated through CDRH (device). EyeGate Ocular Bandage Gel will be applied topically to both eyes (OU) four times a day. Ocular Bandage Gel use is discontinued once complete re-epithelialization has occurred in that eye.
89307762|NCT03938883|Other|Bandage Contact Lens (BCL)|standard-of-care post-operative intervention following PRK. BCL (Acuvue® Oasys plano lens) applied OU. Bandage contact lens use is discontinued once complete re-epithelialization has occurred in that eye.
89307763|NCT01216839|Experimental|Everolimus|
89307764|NCT01119651|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
89307765|NCT01119651|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
89307766|NCT01119651|Experimental|Tazarotene Foam & UVA/UVB/visible light|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB and visible light irradiation
89307767|NCT01119651|Placebo Comparator|Vehicle Foam without irradiation,|Subjects will be exposed to Vehicle Foam Patch without irradiation
89307768|NCT01119651|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
89307769|NCT01119651|Placebo Comparator|Vehicle Foam with UVA & UVB visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
89307770|NCT01119651|Sham Comparator|Blank patch without irradiation|Subjects will be exposed to blank patch without irradiation,
89307771|NCT01119651|Sham Comparator|Blank patch with UVA and UVB irradiation|Subjects will be exposed to blank patch with UVA and UVB irradiation
89307772|NCT01119651|Sham Comparator|Blank Patch with UVA & UVB visible light irradiation|Subjects will be exposed to Blank Patch with UVA and UVB and visible light irradiation
89307773|NCT01117233|Experimental|Single IV Dose 1|
89307774|NCT01117233|Experimental|Single IV Dose 2|
89307775|NCT01117233|Experimental|Single IV Dose 3|
89307776|NCT01117233|Experimental|Single IV Dose 4|
89307777|NCT01117233|Experimental|Single IV Dose 5|
89307778|NCT03971877||Patients admitted in ICU or oncohaematology ward|
89307779|NCT01119729||HIV-infected Outpatients|
89307780|NCT01328925|Experimental|Nitazoxanide Oral Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml
89307781|NCT01328925|Placebo Comparator|Placebo Oral Suspension|Placebo Oral Suspension
89307782|NCT01117389||Mothers of Childhood cancer survivors|Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the After Completion of Therapy (ACT) clinic at SJCRH. Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the ACT clinic surviving childhood cancer will be asked to complete a questionnaire which queries sociodemographic, medical, and psychological variables which may relate to HPV vaccination.
89307783|NCT01117389||Acquaintance control Group|"Mothers or female primary caregivers ( with daughters aged 9-17) and young adult females aged 18-26 referred for study participation by participants from the ACT clinic. Participants have daughters aged 9-17 years or young adult females aged 18-26 at the time of study enrollment For those acquaintance controls electing to complete the paper-and-pencil questionnaire, the study team will send it to them in the mail along with a pre-addressed, stamped, return envelope. For those electing to complete the on-line questionnaire, the participant's email address will be collected and a secured link to our on-line questionnaire will be sent to them in an email.~A supplemental community control sample (meeting the inclusion and exclusion criteria outlined above) will also be utilized via the subject pool in the Department of Psychology at The University of Memphis."
89307784|NCT01119885||001|fentanyl matrix Knee osteoarthritis starting with 12mcg/h (flexible dose)
89307785|NCT01119885||002|fentanyl matrix Hip osteoarthritis starting with 12mcg/h (flexible dose)
89307786|NCT01216917||Fitness|
89307787|NCT01216917||Whole-body vibration|
89307788|NCT01216917||Control|
89307789|NCT01120041|Experimental|Prenatal MI - Postpartum MI|Motivational interviewing counseling given during the prenatal and postpartum phases
89307790|NCT01120041|Experimental|Prenatal MI - Postpartum Health Ed|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
89307791|NCT01120041|Experimental|Prenatal Health Ed - Postpartum MI|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
89307792|NCT01120041|Placebo Comparator|Prenatal Health Ed/Postpartum Health Ed|Traditional health education given during the prenatal phase and the postpartum phase
89307793|NCT03938493||endotracheal intubation under general anesthesia|Adults who require endotracheal intubation for head and neck surgery under general anesthesia
89307794|NCT01117467|Experimental|Solo|Students will perform their simulation scenario solo and receive feedback within the group
89307795|NCT01117467|Experimental|Paired|Students will be paired with one of their peers for this simulation scenario
89307796|NCT01216995|Active Comparator|Dose A|Dose A
89307797|NCT01216995|Placebo Comparator|Placebo|Placebo
89307798|NCT01218945||Fat Removal|Patients undergoing surgical fat removal
89307799|NCT03933891||Decompensated liver cirrhosis with TIPS|
89307800|NCT01124487|Experimental|palm olein|
89307801|NCT01124487|Experimental|olive oil|
89307802|NCT01124487|Experimental|lard|
89307803|NCT01120119|Experimental|Calcitriol|
89307804|NCT01120119|Placebo Comparator|placebo|
89307805|NCT01214031|Other|Confocal Laser Endomicroscopy Arm|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy.
89307806|NCT01217151|Sham Comparator|Usual treatment|The hemodynamic management will be performed according to the institution's standard of care, using fluids at the discretion of the anesthesiologist and the ICU specialist.
89307807|NCT01217151|Active Comparator|NICOM|"For volume replacement, crystalloids will be used following the standard procedure according to the anesthesiologist or ICU specialist. Mean arterial pressure and cardiac index will be assessed every 5 minutes, and a volume bolus (250 mL colloid in 10 minutes) will be used to achieve a:~Mean arterial pressure ≥ 65 mmHg (intra and postoperatively), AND~Cardiac index ≥ 2.5 L/min/m2 (intra and postoperatively).~If these cardiovascular parameters are not met after the first colloid infusion, a supplementary bolus will be added. In case of not achieving the target, additional colloid boluses and/or pharmacologic support (norepinephrine in case of persistent hypotension, dobutamine in case of low cardiac output) will be provided according to the protocol"
89307808|NCT01217541|Other|Education and supervision|Personnel in nursing home units get intervention in form of education and supervision
89307809|NCT01217541|No Intervention|Control|Only registering of patient and personnel data in the beginning and the end of the study without any form of intervention.
89307810|NCT03936855|Active Comparator|Incremental filling technique|Glass ionomer in the pulp chamber and incremental filling technique using composite resin
89307811|NCT03936855|Experimental|Bulk Fill|Bulk fill composite resin filling all the cavity
89307812|NCT01219101|Experimental|clomiphene citrate and ethinyl estradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
89307813|NCT01219101|Active Comparator|clomiphene citrate and placebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
89307814|NCT01219179|Experimental|sterile water|Intervention group received sterile water if their sodium value was greater or equal to 150 mEq/liter
89307815|NCT03782571|Experimental|Test1/Test2/Control/Test3|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
89307816|NCT03782571|Experimental|Test2/Test3/Test1/Control|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
89307817|NCT03782571|Experimental|Test3/Control/Test2/Test1|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
89307818|NCT03782571|Experimental|Control/Test1/Test3/Test2|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
89307819|NCT01217619|Experimental|Erlotinib|Single-arm
89307820|NCT01122615|Experimental|Sunitinib + Temsirolimus|Sunitinib 12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle. Temsirolimus 6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
89307821|NCT01214343|Experimental|Sorafenib with Low-dose FP|
89307822|NCT01214343|Active Comparator|Sorafenib|
89307823|NCT01120431|Active Comparator|Oral rehydration therapy|
89307824|NCT01120431|Experimental|hylenex-facilitated SC hydration|
89307825|NCT03937089||Patients|Patients with persistent AF, who underwent a CA procedure in the Nancy hospital between January 2011 and April 2017, will be included in this retrospective study.
89307826|NCT01214499|Active Comparator|Treatment Control|Transmyocardial revascularization (TMR) with Holmium YAG (yttrium aluminium garnet) laser, according to habitual clinical practice in the Department of Cardiovascular Surgery.
89307827|NCT01214499|Experimental|Experimental Treatment|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.
89307828|NCT01124721|Experimental|Cogmed cognitive training|Computerized working memory, attention and cognitive tasks
89307829|NCT01124721|Active Comparator|Active placebo|Cognitive training, however the training does not increase in difficulty, or does so to a minimal degree.
89307830|NCT01124799|Experimental|001|TMC435 one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening for 9 days
89307831|NCT01124799|Placebo Comparator|002|Placebo placebo dose in the morning at noon and in the evening for 9 days
89307832|NCT01124799|Active Comparator|003|Ciprofloxacin one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg for 9 days
89307833|NCT01124877|Other|Open|
89307834|NCT03935061|Experimental|Mulberry juice|Two bottles (600 ml/bottle) of sanitized mulberry juice are delivered to the patients of the experimental group 20 days before the next clinic visit, with instruction to consume 50 ml of juice diluted with drinking water at room temperature. A reminder of the next clinic visit for continuous treatment is attached.
89307835|NCT03935061|No Intervention|Controlled|Patients of the controlled group are informed of their allocation results along with a reminder of the next clinic visit. On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
89307836|NCT03935373||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) primary or secondary SS; (2) aged between 20 and 75 years; (3) fulfilled the 2002 American-European Consensus Criteria for SS (AECG); (4) had no abnormal findings of immune, liver, kidney, or blood function evaluations. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; or (3) steroid pulse therapy within three months prior to the commencement of our study.
89307837|NCT03935373||Health subjects|Health subjects were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 41 and 63 years (which the age could match the SS patients enrolling in the SS-1 trial); (2) had no chronic inflammatory illness. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; (3) abnormal findings of immune, liver, kidney, or blood function evaluations; (4) total sleeping time insufficiency less than 6 hours before one day of enrollment; (5) ever took the conventional medicine or hormone within one month; (6) ever encountered the acute illness, allergy reaction, immune, or rheumatic disease within one month.
89307838|NCT01217775|Experimental|PH80 intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
89307839|NCT01217775|Placebo Comparator|Placebo intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
89307840|NCT01217853||SENSIMED Triggerfish|
89307841|NCT01122693|Active Comparator|standard 2D ultrasound images|
89307842|NCT01122693|Experimental|high-quality 2D ultrasound images|
89307843|NCT01122693|Active Comparator|nerve stimulation techniques|
89307844|NCT01219413|Experimental|aliskiren, placebo, perindopril|
89307845|NCT01219413|Experimental|perindopril, placebo, aliskiren|
89307846|NCT01219491||Egg donor recipients|
89307847|NCT01214577|Experimental|1|Up to three days of treatment
89307848|NCT03783039|Experimental|SURGICEL Powder|SURGICEL Powder is an absorbable hemostat that is oxidized regenerated cellulose in a powder form
89307849|NCT03783039|Active Comparator|SURGICEL Original|SURGICEL Original is an bsorbable hemostat that is oxidized regenerated cellulose in a fabric form
89307850|NCT01214733|Experimental|1|
89307851|NCT03933501|Experimental|FMUD + AM|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
89307852|NCT03933501|Placebo Comparator|FMUD|One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
89307853|NCT03933501|Experimental|SRP + AM|Four sessions (1/week) of scaling and root planning, plus 375 mg amoxicillin and 250 mg metronidazole (AM) prescribed on the last session of treatment and taken every 8 hours for 7 days.
89307854|NCT03933501|Placebo Comparator|SRP|Four sessions (1/week) of scaling and root planning, plus two distinct placebo pills prescribed on the last session of treatment and taken every 8 hours for 7 days.
89307855|NCT01122771|Active Comparator|Ambisome|15mg Ambisome on days 1,3 and 5
89307856|NCT01122771|Experimental|Ambisome + Miltefosine|Ambisome 5mg + miltefosine 10 days
89307857|NCT01122771|Experimental|Ambisome +paromomycin|AmBisome IV infusion (single dose, day 1) + Paromomycin base 11mg/kg/day IM (Gland Pharma, India) for 10 days (days 2-11)
89307858|NCT01122771|Experimental|Miltefosine + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
88814630|NCT01614509|Experimental|Monotherapy group|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
89307859|NCT01120509|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
89307860|NCT03934983||Trauma patients|Subject experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
89307861|NCT01125033|Experimental|Vitamin C & Vitamin E.|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
89307862|NCT01125033|Experimental|Vitamin C & Placebo|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
89307863|NCT01125033|Experimental|Vitamin E & Placebo|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
89307864|NCT01125033|Placebo Comparator|Double Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
89307865|NCT01125111||robotic surgery group|
89307866|NCT01125111||laparoscopic surgery group|
89307867|NCT01125267|Experimental|multifamily group-adherence|multifamily group treatment with a focus on improving adherence to antipsychotic medication
89307868|NCT01125267|Active Comparator|multifamily group-standard|multifamily group focused on problems identified by group participants
89307869|NCT01125267|No Intervention|treatment as usual|
89307870|NCT01123005|Experimental|Carbogen arm|
89307871|NCT01123005|Experimental|DCA arm|
89307872|NCT01120665|Experimental|PLACEBO-CONTROL|PLACEBO + CONTROL TO EXERCISE
89307873|NCT01120665|Experimental|ESTROGEN THERAPY + CONTROL|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + CONTROL TO EXERCISE
89307874|NCT01120665|Experimental|PLACEBO+AEROBIC TRAINING|PLACEBO + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
89307875|NCT01120665|Experimental|ESTROGEN THERAPY + AEROBIC TRAINING|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
89307876|NCT03740763|Active Comparator|Spinal Cord Stimulation (SCS)|"Spinal Cord Stimulation (SCS)~Pharmacological analgetic treatment and treatment with SCS for 3 months~Add-on physiotherapy for 6 months to SCS and pharmacological analgetic treatment~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
89307877|NCT03740763|Active Comparator|Physiotherapy|"Physiotherapy~Pharmacological analgetic treatment for 3 months~Physiotherapy for 3 months and pharmacological analgetic treatment~Add-on SCS in combination with physiotherapy and pharmacological analgetic treatment for 3 months~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
89307878|NCT01120821|Experimental|Study drug|Gleevec treatment
89307879|NCT03936543|Experimental|Extended axillary midline|Operator stands at the bedside on extended midline of the patient's lt. axilla during lt. internal jugular vein catheterization
89307880|NCT03936543|Active Comparator|Extended head midline|Operator stands at the bedside on extended midline of the patient's head during lt. internal jugular vein catheterization.
89307881|NCT01125345|Experimental|Hydrophobic IOL|The single piece Acrysof hydrophobic IOL model- SN60WF
89307882|NCT01125345|Active Comparator|Hydrophilic IOL|Rayner Intraocular Lenses Ltd., England, Model C-flex 570C
89307883|NCT01125345|Active Comparator|Hydrophillic IOL|Bausch and Lomb ltd, model Akreos Adapt
89307884|NCT03740685||Patients with acute pancreatitis|All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
89307885|NCT03936621|Active Comparator|Group 1: Omega 3 Fatty Acid|Omega 3 fatty acids for 6 months and then off omega 3 fatty acids for the next 6 months. In the first 6 months, you will be asked to take one capsule of Omega 3 fatty acids with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks. In the next 6 months (Months 7 to 12), you will have a blood test for markers of inflammation at the end of Month 7 and at Month 9 and 12 to determine if the anti-inflammatory effects of Omega 3 acids are still there after you have stopped taking it.
89307886|NCT03936621|Placebo Comparator|Group 2: Control Arm|No Omega 3 fatty acids for the first 6 months followed by Omega 3 fatty acids for the next 6 months. You will be asked to have a blood test for markers of inflammation at Month 1, 3 and 6 for markers of inflammation to determine the natural variation of the levels of these markers without Omega 3 fatty acid supplements. In Month 7, you will be asked to take one capsule of Omega 3 with breakfast and 1 with dinner/day for the first week, 2 capsules in the morning and one capsule in the evening for the second week and then 2 capsules with breakfast and 2 with dinner/day for the remaining 24 weeks.
89307887|NCT01123239|Experimental|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches who have been trained to promote patient participation in the medical visit. The coaches, who themselves have diabetes, meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making."
89307888|NCT01123239|Active Comparator|Standard Diabetes Education|Patients receive one-on-one diabetes education sessions before each medical visit. These sessions are purely informational, and do not include the specific patient activation components of the coached care intervention.
88806457|NCT00316862|Experimental|Treatment (chemotherapy, chemoradiotherapy, surgery)|"INDUCTION CHEMOTHERAPY (COURSES 1-2): Patients receive cisplatin intravenously (IV) over 30 minutes and irinotecan hydrochloride IV over 30-90 minutes on days 1 and 8 of courses 1 and 2. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY (COURSES 3-4): Beginning 2 weeks after completion of induction chemotherapy, patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 1 and 8 of courses 3 and 4 and undergo radiotherapy daily 5 days a week in course 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo surgery to remove the tumor."
88806458|NCT00357032|Experimental|Treatment (belinostat)|Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity.
88806459|NCT00357734|Experimental|Gefitinib (ZD1839)|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
88806460|NCT01791842|Experimental|Tocilizumab first, then placebo|one IV infusion per month of Tocilizumab for 6 months followed by 1 infusion per month of placebo, for 6 months.
89307889|NCT01125423|Active Comparator|Subjects with Fibromyalgia|Subjects with Fibromyalgia have skin biopsies taken from the dominant trapezius and palm. Subjects will receive an eight week supply of milnacipran to be titrated 12.5 mg x one day, 12.5 mg twice a day x 2 days, 25mg twice daily for 4 days, then 50mg twice a day x 7 weeks.
89307890|NCT01125423|Other|Control subjects without Fibromyalgia|Subjects without Fibromyalgia have skin biopsies taken from the dominant trapezius and palm.
89307891|NCT01219569||2. Sevoflurane|Subjects will receive sevoflurane at 1.5% and 2.5% end tidal after steady state maintenance has been achieved and have pupillometry readings taken and every 10 minutes for 30 minute at each drug dose.
89307892|NCT01219569||1.Propofol|1.Subjects will receive propofol infusion and have pupillometry readings taken in both eyes after induction, after steady state maintenance has been achieved and at 30 minutes
89307893|NCT03933345||People who use illicit opioids|The study will recruit an adult-age (18+) sample of 600 people who use illicit opioids (either heroin or prescription opioid analgesics without a doctor's prescription) in New York City using Respondent Driven Sampling.
89307894|NCT02529345|Experimental|RoadSaver stent|patient treated with the RoadSaver stent of Terumo
89307895|NCT01219647|Experimental|aerobic exercise|Subjects will train on a recumbent cross trainer 20-30 minutes/session for three times/week for six months under supervision of a fitness specialist
89307896|NCT01219647|Active Comparator|stretching|Subjects will particiate in supervised stretching at same frauency, duration and intensity of aerobic exericse arm
89307897|NCT01120977||Male|
89307898|NCT01120977||Female|
89307899|NCT01218165|No Intervention|Control Group|without intervention
89307900|NCT01218165|Experimental|Intervention Group|This group receives a probiotic drink daily for 6 week.
89523393|NCT03381053||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
89523394|NCT03394417|No Intervention|standard clinical practice (control)|aqueous cream
89523395|NCT03394417|Active Comparator|StrataXRT (intervention)|silicon-based gel
88806461|NCT01791842|Experimental|Placebo first, then Tocilizumab|one IV infusion per month of Placebo for 6 months followed by 1 infusion per month of Tocilizumab, for 6 months.
88806462|NCT01791998|Experimental|Treatment (MR-thermal image guided LITT)|Patients undergo MR-thermal image guided LITT over 1 hour.
88806463|NCT00318812|Experimental|Heme Iron|Heme Iron Polypeptide 11mg PO tid for 6 months
89307901|NCT03934515||Group A - etCO2|"At the end of the anaesthesia , as usual, the secretions are aspirated with a suction tube of 18 Fr of caliber (diameter 6 mm). When the tube is inserted into the endotracheal tube, before proceeding with the aspiration of the secretions, a capnometer is attached to its outer end, measuring the etCO2 value for 10-15 seconds. At the end of the measurement, authors proceed with the aspiration of the secretions as usual.~Authors then proceed with the laying of a NGT according to local protocols. Also in this case, once the NGT has been inserted, the etCO2 is measured at the end of the probe for 10-15 seconds. At the end of the measurement, the capnometer can be detached, as a standard procedure, and the NGT can be used as usual.~At the end of the procedure, therefore, for each patient, two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values recorded at the endotracheal level and the one recorded at the oesophageal level."
89307902|NCT03934515||Group B - pH|"At the end of the anaesthesia , once the NGT is inserted, the pH is measured by aspirating the gastric contents and measuring on specific litmus paper the pH values, both at a distance of 25 cm from the mouth (oesophageal site) and at a distance of 40 cm (gastric site).~At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at oesophageal level and a value at the gastric level."
89307903|NCT01121055|Placebo Comparator|Control|Placebo 1T by mouth (po) at night one day before FB and placebo 1T po 30min before the FB
89307904|NCT01121055|Experimental|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
89307905|NCT01121133|Experimental|Arm A (navitoclax and rifampin)|
89307906|NCT03933111|Experimental|patients with pancreatic solid neoplasms|Patients with pancreatic solid neoplasms are enrolled in this study and accept the test.
89307907|NCT01219803|Experimental|High dose GGQL Decoction|
89307908|NCT01219803|Experimental|Mild dose GGQL Decoction|
89307909|NCT01219803|Experimental|Low dose GGQL Decoction|
89307910|NCT01219803|Placebo Comparator|Placebo|
89307911|NCT03934593|Experimental|Faith-Based (FB, BHT DSMS)|The BHT DSMD intervention strategies adapted Stanford DSMP in a spiritual context is used in this group. Participants in the FB group will participate in BHT DSMS, which includes a Health Sermon, a 6-session Health Bible Study with cooking demonstrations, the Stanford DSMP and a Diabetes Resource Seminar delivered by two trained church lay leaders.
89307912|NCT03934593|Active Comparator|Faith-Placed (FP, Stanford DSMP)|The traditional Stanford DSMP is conducted in this control group. Participants in the FP group will first attend a 7-session community health and safety curriculum as a partial attention control intervention, followed by the Stanford DSMP and Diabetes Resource Seminar facilitated by the local public health department.
89307913|NCT01218321||Antiepileptic treatment group|Group of patients treated by antiepileptic medications
89307914|NCT01214889|Experimental|Study Group A|Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.
89307915|NCT01214889|Active Comparator|Study Group B|Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.
88806464|NCT00318812|Active Comparator|Venofer|Venofer q month IV x 6 months
88814737|NCT04354142|No Intervention|Control|The control group participants will continue to use their usual method of carbohydrate counting for a 3-month period.
89307916|NCT01123317|Experimental|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
89307917|NCT01121289|Experimental|NN1218, formulation A|
89307918|NCT01121289|Experimental|NN1218, formulation B|
89307919|NCT01121289|Experimental|NN1218, formulation B (high)|
89307920|NCT01121289|Experimental|NN1218, formulation C|
89307921|NCT01121289|Experimental|NN1218, formulation D|
89307922|NCT01121289|Active Comparator|insulin aspart|
89307923|NCT03933267|Experimental|Group I|This group of participant will receive Cervical sensorimotor control training exercises. In addition to it conventional physical therapy protocol will be given.
89307924|NCT03933267|Active Comparator|Group II Control|this group of participant will receive Conventional physical therapy protocol.
89307925|NCT01125501|Active Comparator|Protandim|one capsule a day for 30 days of protandim given, followed by a wash out period.
89307926|NCT01125501|Placebo Comparator|Placebo|one capsule a day for 30 days will be given followed by a washout period.
89307927|NCT03934749||standard mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV using Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
89307928|NCT03934749||Lowenstein mode|after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV without Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
89307929|NCT01123473|Experimental|Lapatinib|Chemotherapy + lapatinib
89307930|NCT01123473|Placebo Comparator|Placebo|Chemotherapy + placebo
89307931|NCT01125579||Children aged 6-12|"Children suffering from nervous restlessness, e.g. in agitated depression (ICD 10, F3 and DSM IV affective disorders), aged 6-12 years"
89307932|NCT01123551|Experimental|Nebulized Morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
89307933|NCT01123551|Active Comparator|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
89307934|NCT01125657|Experimental|formualation-A to -B sequence group|
89307935|NCT01125657|Experimental|formulation-B to -A sequence group|
89307936|NCT01214967|Experimental|1|Problem Solving Education, a psycho-educational intervention
89307937|NCT01214967|No Intervention|2|Usual care
89307938|NCT01121367||Emphysema-alone|
89307939|NCT01121367||CPFE group|
89307940|NCT01121367||IPF-alone|
89307941|NCT01121367||smokers|
89307942|NCT01121367||nonsmokers|
89307943|NCT01215045||ReSTOR +4|AcrySof ReSTOR Aspheric +4
89307944|NCT03932955|Experimental|MC-19PD1 CAR-T Cells|
89307945|NCT01125735|Experimental|MIST Therapy|MIST Therapy is a low energy, low intensity ultrasound delivered through a saline mist to the wound bed.
89307946|NCT01125735|Other|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
89307947|NCT03932877||late-onset preeclampsia, group1|30 late-onset preeclampsia patients as group1 (gestational age≥34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg will consider mild, and higher values will consider to being severe.
89307948|NCT03932877||Control, group 2|33 patients with normal pregnancies as group2 (gestational age≥34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
89307949|NCT03932877||early-onset preeclampsia, group 3|31 early-onset preeclampsia patients as group3 (gestational age<34 weeks). The diagnosis of preeclampsia, as defined by the Committee on Terminology of the American College of Obstetricians and Gynecologists (ACOG), will establish based on the presence of proteinuria (urinary excretion of 300 mg protein or higher, or at least 1+in dipstick in a 24-h urine specimen) and a blood pressure level of ≥140/90mmHg (two blood pressure measurements 6 h apart) that occurs after 20 weeks of gestation in a previously normotensive woman. Diastolic and/or systolic blood pressure up to 110/160 mm Hg considered mild, and higher values considered to being severe.
89307950|NCT03932877||Control, group 4|31 patients with normal pregnancies as group 4 (gestational age<34 weeks). The control groups' samples obtained during the routine obstetrical care examination in the third trimester of pregnancy. Then these pregnant women followed-up until the delivery.
89307951|NCT01123863||Patient Group|"This study will administer Brigance Preschool Screen -II to 3 year old children with SCD followed at St. Jude Children's Research Hospital~Intervention: Brigance Preschool Screen -II"
89307952|NCT01123863||control group|"The control group will consist of 3-year-old children attending day care in the Memphis area and serve as a population that come from a similar socioeconomic background as the SCD patient population.~Intervention: Brigance Preschool Screen -II"
89307953|NCT01121445|No Intervention|CPAP with heated humidification|Standard of care
89307954|NCT01124019||Random Sample|A random sample of 600 women undergoing screening mammography
89307955|NCT01124019||BIRADS score of 4|An additional 600 women determined to have a Breast Imaging Reporting and Data System (BIRADS) score of 4 as determined by final mammogram results.
89307956|NCT01220037|Experimental|Young regular diet|During the time of the study this group will adhere to a standardized regular diet.
89307957|NCT01220037|Experimental|Young low protein diet|During the time of the study this group will adhere to a standardized low protein diet.
89307958|NCT01220037|Experimental|Young high protein|During the time of the study this group will adhere to a standardized high protein diet.
89307959|NCT01220037|Experimental|Elderly|During the time of the study this group will adhere to a standardized high protein diet
89307960|NCT03934047|Experimental|Group A|Group A: Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
89307961|NCT03934047|No Intervention|Group B|Group B: No Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
89307962|NCT01218633|Placebo Comparator|Saline|
89307963|NCT01218633|Active Comparator|GLP-1-(9,36)-amide|
89307964|NCT01218633|Active Comparator|Exendin-9,39 @30pmol/kg/min|
89307965|NCT01218633|Active Comparator|Exendin-9,39 @300pmol/kg/min|
89307966|NCT03933033|Active Comparator|Group A|treated with platelet rich plasma
89307967|NCT03933033|Active Comparator|Group B|treated with Erbium Yag Laser
89307968|NCT03933033|Active Comparator|Group C|treated with both line of treatments
89307969|NCT01220115||No treatment|Patients aged 2 to less than 12
89307970|NCT01220115||No treatment patients aged 12 to less than 18|Patients aged 12 to less than 18
89307971|NCT01220115||No treatment Patients greater than 18 years|patients greater than 18 years
89307972|NCT01220193||Normal cornea|
89307973|NCT01220193||Post laser refractive surgery|
89307974|NCT01220193||Cornea pathology|
89307975|NCT01220193||Cataract surgery|
89307976|NCT01329003||exposed workers|At least six months of occupational exposure to Caesar stone
89307977|NCT01125891|Experimental|gemcitabine and ON 01910.Na|
89307978|NCT01215591|Active Comparator|Gradual wean from Nasal CPAP|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
89307979|NCT01215591|No Intervention|Sudden wean from Nasal CPAP|Usual practice to wean the preterm neonates from nasal CPAP
89307980|NCT01124253|Experimental|NP plus recombinant human endostatin|
89307981|NCT01124253|No Intervention|vinorelbine plus cisplatin|
89307982|NCT01215669|Experimental|Group 1: Adult Intradermal (ID) Vaccine|Participants aged 18 to 59 years will be vaccinated with IDflu™ influenza vaccine
89307983|NCT01215669|Active Comparator|Group 2: Adult Intramuscular (IM) Vaccine|Participants aged 18 to 59 years will be vaccinated with Vaxigrip® Influenza vaccine
89307984|NCT01215669|Experimental|Group 3: Elderly Intradermal (ID) Vaccine|Participants aged 60 years or older will be vaccinated with IDflu™ Influenza vaccine
89307985|NCT01215669|Active Comparator|Group 4: Elderly Intramuscular (IM) Vaccine|Participants aged 60 years or older will be vaccinated with Vaxigrip® Influenza vaccine
89307986|NCT01215747|Experimental|Kiacta (eprodisate disodium)|
89307987|NCT01215747|Placebo Comparator|Placebo|
89307988|NCT01222065||Glaucoma/Normal|Two groups will be studies: patients with glaucomatous visual field loss and age and gender matched normal patients without visual field loss
89307989|NCT01220349|Experimental|Echocardiographic 2D strain analysis|
89307990|NCT01125969|Active Comparator|Control|
89307991|NCT01125969|Experimental|Incentive|
89307992|NCT01125969|Experimental|Peer Mentoring|
89307993|NCT01125969|Experimental|Incentives and Peer Mentoring|
89307994|NCT01124331|Experimental|High Oxygen saturation|Higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
89307995|NCT01124331|Active Comparator|Lower oxygen saturation|Lower (SpO2 85-89%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
89307996|NCT01220427||Clinical high-risk prostate cancer, radical prostatectomy|
89307997|NCT01222143|Experimental|NOVE-HiDAC and Nilotinib|All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.
89307998|NCT01218789|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
89307999|NCT01126047|Other|PFT's, eCO, and pulse oximetry|All subjects in the study will undergo complete pulmonary function testing (spirometry, blood collection for carboxyhemoglobin, diffusing capacity); exhaled carbon-monoxide testing, and pulse oximetry.
89308000|NCT03932175|Experimental|Intervention group|The multicomponent intervention will comprise three aspects on-top of usual care: i) Motivational interview to assess patient's adherence profile and to raise the compromise with the behaviour change towards NIV, physical activity and nutritional habits; ii) Bi-directional interaction between the study participants and clinical staff delivered by the MyPathway app, where specific clinical problems regarding NIV will be addressed as they arise; and iii) Motivational messages and educational material delivered via the MyPathway app regarding changes in physical activity and/or nutritional habits. As part of the behavioural intervention, goal setting for NIV adherence and life-style changes will be introduced to the MyPathway app in order for the participants to follow the advice.
89308001|NCT03932175|No Intervention|Control group|Patients will receive usual care according to guidelines on management of chronically ventilated patients, without any mHealth tool or behavioural intervention
89308002|NCT01124409|Active Comparator|3DCRT with EPID|this patients randomised to this arm will be planned by 3DCRT and during treatment setup error will be identified and corrected by weekly EPID if error >3mm.Weekly CBCT will be done for this arm to note the setup error but will not be corrected.
89308003|NCT01124409|Active Comparator|IGRT with CBCT|The patients randomised to this arm will be planned by 3DCRT and set up error during RT will be verified by CBCT and error corrected if >3mm.Weekly EPID will be done for setup error documentation but no correction based on EPID in this arm.
89308004|NCT03933189|Active Comparator|Biomedical (BIOM) physical therapy|Six 60 minute PT sessions consisting of 15 minutes of education on topics such as ideal postural alignment (sitting, sleeping), maintenance of normal spinal curves, body mechanics, proper lifting techniques, home pain control via anti-inflammatory modalities such as ice; 15 minutes of manual therapy to region of pain (soft tissue and/or joint mobilization); 30 minutes of region specific exercises to address identified muscle imbalances -stretching and strengthening of the muscles local to the area of pain.
89308005|NCT03933189|Active Comparator|Biopsychosocial (BPS) physical therapy|"Six 60 minute PT sessions consisting of 15 minutes of pain neuro-science education, 15 minutes of Graded Motor Imagery (GMI) techniques, (a progressive program of visual and mental exercises consisting of laterality exercises, motor imagery and mirror therapy); 30 minutes of a general conditioning exercise program individualized for each participant based on initial examination findings and participant presentation consisting of:~A cardiovascular component which may include walking on a treadmill, stationary cycling, or a seated stepping machine.~A muscle strengthening component for extremities and trunk. A flexibility component for upper and lower extremity musculature."
89308006|NCT01126125|Experimental|Iodized oil to mother|400 mg iodine as iodized oil to breastfeeding mother
89308007|NCT01126125|Active Comparator|Iodized oil to infant|100 mg of iodine as iodized oil to infant
89308008|NCT01225809||AD01with or without adjuvant|Patients who have received at least one immunization of AD01 with or without adjuvant during AFF001
89308009|NCT01126203|Experimental|selective laser trabeculoplasty (SLT)|
89308010|NCT01126203|Experimental|Argon laser trabeculoplasty (ALT)|
89308011|NCT01220661|Experimental|One dose|One dose prophylactic antibiotic
89308012|NCT01225965|Experimental|EIL05, Inhalation|
89308013|NCT01225965|Placebo Comparator|Placebo, 0,9% NaCl|
89308014|NCT01222377|Experimental|Arm I|Patients undergo endoscopic breast surgery.
89308015|NCT01329393|Experimental|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
89308016|NCT01329393|Active Comparator|Illness Management and Recovery|
89308017|NCT03931629|Active Comparator|CONVENTIONAL PHACO|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
89308018|NCT03931629|Active Comparator|FEMTOSECONDLASER (FLACS)|In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery
89308019|NCT01222455|Experimental|1|Mild hepatic impairment
89308020|NCT01222455|Experimental|2|Moderate hepatic impairment
89308021|NCT01222455|Experimental|3|Severe hepatic impairment
89308022|NCT01222455|Experimental|4|Matched healthy volunteers with normal hepatic function
89308023|NCT01126281|Experimental|Floseal use|
89308024|NCT01220817|Active Comparator|1 POMx capsule|1 POMx capsule daily
89308025|NCT01220817|Experimental|3 POMx capsules daily|
89308026|NCT03776175|Placebo Comparator|Placebo|Placebo (PF 05221304) BID Placebo (PF 06865571) BID
89308027|NCT03776175|Experimental|PF-05221304 Monotherapy|15 mg PF-05221304 BID Placebo (PF-06865571) BID
89308028|NCT03776175|Experimental|PF-06865571 Monotherapy|Placebo (PF-05221304) BID 300 mg PF-06865571 BID
89308029|NCT03776175|Experimental|PF-05221304 and PF-06865571 Combination|15 mg PF-05221304 BID 300 mg PF-06865571 BID
89308030|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 50mg twice daily|Monotherapy Part 1a: INCB001158 administered orally in patients with advanced/metastatic solid tumors. Escalating doses will be explored to determine the recommended phase 2 dose (RP2D).
89308031|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 75mg twice daily|Monotherapy Part 2a: INCB001158 administered orally at the RP2D in patients with advanced/metastatic NSCLC (EGFR and Anaplastic Lymphoma Kinase (ALK) negative) previously treated with Standard of Care (SOC).
89308032|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 100mg twice daily|Monotherapy Part 2b: INCB001158 administered orally at the RP2D in patients with advanced/metastatic CRC previously treated with SOC.
89308033|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 150mg twice daily|Monotherapy Part 2c: INCB001158 administered orally at the RP2D in patients with Bladder Cancer, Gastric or Gastroesophageal Junction (GEJ) Cancer, Renal Cell Cancer (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Urothelial Cell Cancer (UCC), or Melanoma, previously treated with SOC.
89308034|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 50mg twice daily|Monotherapy Part 2d: INCB001158 administered orally at the RP2D in patients with any tumor types in Parts 2a, 2b, or 2c.
89308035|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 75mg twice daily|Combination Part 1b: INCB001158 and Pembrolizumab administered in patients with advanced/metastatic NSCLC, Melanoma, Urothelial Cell Cancer, MSI CRC, MSS CRC, Gastric or Gastroesophageal Junction (GEJ) Cancer, SCCHN and Mesothelioma. Multiple dose levels will be explored to determine the recommended phase 2 dose (RP2D).
89308036|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 100mg twice daily|Part 3a: INCB001158 and Pembrolizumab the combination RP2D in patients with advanced/metastatic NSCLC (EGFR and ALK negative) with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
89308037|NCT02903914|Experimental|INCB001158 50 mg BID in combination with pembrolizumab|Part C: evaluated a reduced dose of INCB001158 50 mg BID in combination with pembrolizumab with patients with moderately impaired renal function.
89308038|NCT03932565|Experimental|The fourth-generation CAR-T therapy|Clinical trial study of Interventional therapy sequential with the fourth-generation CAR-T cells (IL7 and CCL19 or / and IL12) targeting Nectin4/FAP in the treatment of advanced malignant solid tumors with Nectin4-positive .
89308039|NCT01329471||Umbilical cord blood|
89308040|NCT01126515||Hyperbaric oxygen|In this open-label feasibility study, all subjects will receive 60 hyperbaric oxygen sessions (100% oxygen, 1.5 atmospheres absolute (atm abs), for 60 minutes), delivered daily, five days per week.
89308041|NCT01222611|No Intervention|Standard HAART|ART with 3 drugs including 2 NRTIs plus a ritonavir boosted PI (different to FPV) or a NNRTI
89308042|NCT01222611|Experimental|HAART inlcuding Fos APV/r|ART with 3 drugs including 2 NRTIs plus ritonavir boosted fosamprenavir
89308043|NCT03649516|Experimental|iCKD APP Group|Use iCKD APP
89308044|NCT03649516|No Intervention|Traditional Care Group|Accept traditional care
89308045|NCT03740451|Experimental|Experimental group 1|Active mobilization of soft tissues
89308046|NCT03740451|Experimental|Experimental group 2|Passive mobilization
89308047|NCT03740451|No Intervention|Control group|No intervention
89308048|NCT03928353|Experimental|1: 18 g PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
89308049|NCT03928353|Experimental|2: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
89308050|NCT03928353|Experimental|3: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
89308051|NCT03928353|Experimental|4: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
89308052|NCT03928353|Experimental|5: 18 g or greater PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg BID for a total of 5 doses
89308053|NCT03650530|Experimental|The Family Talk Intervention|These families will participate in a psychosocial support program.
89308054|NCT01226277|Experimental|A|
89308055|NCT03649282|Experimental|HFNC/NCPAP|HFNC will be provided for 45 minutes followed by NCPAP for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
89308056|NCT03649282|Experimental|NCPAP/HFNC|NCPAP will be provided for 45 minutes followed by HFNC for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
89308057|NCT03931863|Active Comparator|Group A|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
89308058|NCT03931863|Active Comparator|Group B|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
89308059|NCT03931863|Placebo Comparator|Group C|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
89308060|NCT03650608|Experimental|Cohort 1: HL217 Ophathalmic Solution QD|HL217 3mg/mL, Ophthalmic solution, two drop once a day
89308061|NCT03650608|Experimental|Cohort 2: HL217 Ophathalmic Solution BID|HL217 3mg/mL, Ophthalmic solution, two drop twice a day
89308062|NCT03650608|Experimental|Cohort 3: HL217 Ophthalmic Solution QID|HL217 3mg/mL, Ophthalmic solution, two drop four times a day
89308063|NCT03650608|Placebo Comparator|Placebo Ophthalmic solution|Placebo Ophthalmic solution, two drop once or twice or four times a day
89308064|NCT01226355|Experimental|NOYA|implant NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stents Intervention: Device: stent
89308065|NCT01226355|Active Comparator|Firebird2|implant Firebird2 drug-eluting stents Intervention: Device: stent
89308066|NCT01220895|Experimental|ACT (mutlimer selection) plus standard therapy|Adoptive Cellular Therapy prepared using Multimer Selection in combination with standard best available antiviral drug therapy
89308067|NCT01220895|Active Comparator|Best available antiviral drug therapy|
89308068|NCT03932487||AITD group|Thyroid antibody positive and hypothyroidism
89308069|NCT03932487||normal group|Thyroid antibody negative and hypothyroidism
89308070|NCT01129089|Experimental|LNS-PLW|There will be 48 pregnant or lactating women (PLW) in this arm. They will be randomized to receive cumin flavored LNS-PLW or LNS-PLW with no added flavor on day 2. On day 3, the PLW getting a test-dose of cumin flavored LNS-PLW on day 2 will receive LNS-PLW with no added flavor and the PLW getting a test-dose of LNS-PLW with no added flavor on day 2 will receive cumin flavored LNS-PLW.
89308071|NCT01129089|Experimental|LNS-Child|There will be 48 infant and young children(IYC) in this arm. They will be randomized to receive cardamom flavored LNS-Child or LNS-Child with no added flavor on day 2. On day 3, the IYC getting a test-dose of LNS-Child with no added flavor on day 2 will receive cardamom flavored LNS-Child and the IYC getting a test-dose of cardamom flavored LNS-Child on day 2 will receive LNS-Child with no added flavor.
89308072|NCT01129089|Experimental|MNP-Child|There will be 48 infant and young children(IYC) in this arm. They will receive MNP on day 2 and day 3.
89308073|NCT01129323|Experimental|Reduced-Intensity Preparative Regimen for Allogeneic SCT|Patient in this arm will receive maximally tolerated (reduced) doses of cytotoxic therapy with the goals of suppressing the immune system, and ablate host hematopoiesis to ensure engraftment of the donor's hematopoietic system.
89308074|NCT01221051|Active Comparator|oxytocin|early cord clamping, administration of oxytocin 10 IU i.v, controlled cord traction, uterine massage after placenta expulsion
89308075|NCT01221051|Placebo Comparator|saline solution|early cord clamping, wait for signs of placenta detachment, encourage the woman to push out placenta by her own effort, uterine massage after placenta expulsion
89308076|NCT01221129||Dietary Restriction|
89308077|NCT02969044|Experimental|PF-06651600|Study Drug
89308078|NCT02969044|Placebo Comparator|Placebo|Placebo
89308079|NCT01222845|Experimental|Pinhead oat porridge|
89308080|NCT01222845|Experimental|Rolled oat porridge|
89308081|NCT01129401|Other|Stonewall Project Participants|
89308082|NCT03931395|Experimental|Honey Plus Standard of Care|The Honey standard of care group will receive treatment as usual, alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic, plus 1 tsp of honey with every dose of acetaminophen. The Honey standard of care group will receive the first dose of honey in the recovery room with the administration of acetaminophen and will be provided with honey upon discharge.
89308083|NCT03931395|Active Comparator|Standard of Care|The standard of care group will receive treatment as usual (alternating acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
89308084|NCT02967562|Active Comparator|Inflation Breaths|Five 'inflation breaths' lasting two - three seconds
89308085|NCT02967562|Experimental|Sustained inflation|One fifteen second 'sustained inflation'
89308086|NCT01126827|Active Comparator|Supportive Psychotherapy|
89308087|NCT01126827|Active Comparator|Mindfulness-Based Cognitive Behavioral Therapy|
89308088|NCT03928197|Other|Healthy Volunteers|
89308089|NCT03928197|Other|Volunteers with Venous Insuficiency|
89308090|NCT04053244|Experimental|treatment|all participants will be assigned to the treatment, consisting of therapist-assisted iCBT.
89308091|NCT01222923|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
89308092|NCT01222923|Experimental|1|Risperidone 1 mg ODT tablets of Ranbaxy Laboratories, Ltd
89308093|NCT03648580|Experimental|Intervention group|Give the verbal nutrition education and supply Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
89308094|NCT03648580|Other|Control group|just give the verbal nutrition education.
89308095|NCT03649126||Dutch pathologists hospital I|"Pathologists in hospital I using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
89308096|NCT03649126||Dutch pathologists hospital II|"Pathologists in hospital II using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
89308097|NCT03649126||Dutch pathologists hospital III|"Pathologists in hospital III using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
89308098|NCT03649126||Dutch pathologists hospital IV|"Pathologists in hospital IV using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
89308099|NCT03649126||Dutch pathologists hospital V|"Pathologists in hospital V using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
89308100|NCT03649126||Dutch pathologists hospital VI|"Pathologists in hospital VI using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
89308101|NCT03648502|Experimental|dementia (D-HI)|hearing impaired dementia
89308102|NCT03648502|Other|Mild cognitive impairment (MCI-HI)|MCI with hearing loss
89308103|NCT03648502|Active Comparator|normal (N-HI)|normal cognition with hearing loss
89308104|NCT01223079|Other|r-hFSH (Gonal F)|Patients will be treated with r-hFSH throughout the stimulation phase of their first cycle until r-hCG administration.
89308105|NCT01223079|Other|r-hFSH (Gonal F) and r-hLH (Luveris)|Patients will be treated with r-hFSH only until they have 2 follicles greater than or equal to 14mm. Patients will then bring 300IU/day of r-hLH until r-hCG administration.
89308106|NCT03648424||Linagliptin|Patients who initiate Linagliptin with no use in the prior 180 days
89308107|NCT03648424||Glimepiride|Patients who initiate Glimepiride with no use in the prior 180 days
89308108|NCT01221519|Experimental|1|AZD1656
89308109|NCT01221519|Experimental|2|AZD1656
89308110|NCT01221519|Experimental|3|AZD1656
89308111|NCT03648970|Experimental|Pravastatin Treatment Group|In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
89308112|NCT03648970|No Intervention|Control Group|"In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.~In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group"
89308113|NCT03927963|Placebo Comparator|propofol|
89308114|NCT03927963|Active Comparator|dexmedetomidine|
89308115|NCT03648346|Experimental|Cohort 1: HL217 Ophathalmic Solution BID|Low dose: two drops of 3 mg/mL of the treatment in one eye twice a day
89308116|NCT03648346|Experimental|Cohort 2: HL217 Ophathalmic Solution QID|High dose: two drops of 3 mg/mL of the treatment in one eye 4 times a day
89308117|NCT03648346|Placebo Comparator|Placebo Ophathalmic Solution|Placebo: two drops of placebo in one eye twice a day or 4 times a day
89308118|NCT01126983|Experimental|Non-Suture|No suture will be used to secure the leads. Benzoin and Steri-Strips will be used like in the other two arms.
89308119|NCT04053010|Experimental|group 1|234 subjects; simultaneously administration of Sabin-IPV and DTaP at the age of 3/4/5 months old, 0.5 ml each dose, respectively
89308120|NCT04053010|Active Comparator|group 2|234 subjects; Sabin-IPV only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
89308121|NCT04053010|Active Comparator|group 3|234 subjects; DTaP only at the age of 3/4/5 months old, 0.5 ml each dose, respectively
89308122|NCT01127529||Subjects with severe congenital protein C deficiency|Registry subjects will be identified by working with Hemophilia Treatment Centers and Thrombosis Centers known to have subjects with severe congenital protein C deficiency, as well as by working with centers that use Ceprotin in emergency care situations.
89308123|NCT05285020|Experimental|Alter G group|"This group will perform the hospital's standard protocol for these injuries once a day during two weeks.~They carried out the re-education of the gait (at the parallel bars) with a progressive load in scale controlled by the patient.~Also, they carried out a re-education of the gait and progressive loading in the system Alter G (anti-gravity treadmill)."
89308124|NCT05285020|Other|Control group|"This group will perform the hospital's standard protocol for these injuries once a day during two weeks.~They just carried out the re-education of the gait (at the parallel bars) with a progressive load in scale controlled by the patient."
89308125|NCT01226667|Active Comparator|Flexible Dose|flexibly dosed pregabalin given BID (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4 weeks
89308126|NCT01226667|Active Comparator|Fixed Dosing|75 mg BID for one week and increased to 150 mg BID for 7 weeks
89308127|NCT03648736||HOCM patients|selected for routine TASH procedure
89308128|NCT03927807|Experimental|repetitive hourly dose of oral misoprostol|The dose will be 10 microgram oral misoprostol that will be administered hourly up to 12 doses or till onset of regular uterine activity.
89308129|NCT03927807|Experimental|two hourly dose of oral misoprostol|The dose will be 20 microgram oral misoprostol solution that will be administered every 2 hours up to 6 doses or till onset of regular uterine activity.
89308130|NCT03648190||Inherited qualitative platelets defect|"Clinical manifestations in the form of mucocutaneous bleeding or hemorrhage.~Bleeding patients with acquired bleeding disorders, coagulation defects, and those on antiplatelet drugs will be excluded from the study."
89308131|NCT03648190||Control|Normal healthy participants, with no manifestations of bleeding disorders.
89308132|NCT03740607|Experimental|Virtual reality during PIV placement|Randomized consented adult subjects will participate in a six-minute healthcare virtual reality software program via Samsung Gear virtual reality headsets while receiving 18 or 20-gauge peripheral intravenous catheter placement in peri-operative suite in preparation for surgery. They will be asked to rate their pain and discomfort afterwards using a graphic rating scale. They will be asked several questions about satisfaction, in order to elicit clinical significance of this intervention. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
89308133|NCT03740607|Placebo Comparator|Standard PIV placement|Adult control arm subjects will receive 18 or 20-gauge peripheral intravenous catheter placement according to current standard protocol, without virtual reality distraction .They will be asked to rate pain and discomfort afterwards using a graphic rating scale. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
89308134|NCT05284942|Experimental|Mycophenolate mofetil|Mycophenolate mofetil oral 500mg twice a day from baseline to week 108
89308135|NCT03648034|Experimental|ropivacaine|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.5% ropivacaine
89308136|NCT03648034|Placebo Comparator|saline|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.9% saline
89308137|NCT01129479|Active Comparator|Galantamine|
89308138|NCT01129479|Placebo Comparator|Placebo|
89308139|NCT03647956|Experimental|Arm 1|Using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
89308140|NCT03927729|Experimental|Penthrox|Patients with moderate to severe post-traumatic acute pain will be included in the emergency room.
89308141|NCT05285254|Experimental|Immunization Administration with Certified Child Life Specialist Support (CCLS)|Nursing will administer immunizations to children with the support of a CCLS
89308142|NCT05285254|No Intervention|Current Standard of Care for Immunization Administration|Nursing will administer immunizations to children per their current standard of care.
89308143|NCT01223157|Experimental|Obese patients|
89308144|NCT01223157|Experimental|Normal weight subjects|
89308145|NCT03650296||Resusci Baby|Resusci Baby used for the simulated emergency scenario
89308146|NCT03650296||MegaCode-Kid|MegaCode-Kid used for the simulated emergency scenario
89308147|NCT03650296||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
89308148|NCT01226823|Placebo Comparator|Placebo|obstetrical monitoring plus placebo
89308149|NCT01226823|Experimental|Ursodeoxycholic acid|obstetrical monitoring plus active drug
89308150|NCT02968576|Active Comparator|Truvada|Naked form Truvada (drug)
89308151|NCT02968576|Experimental|PSS-Truvada|Proteus Sensor System (PSS) (device) encapsulated Truvada (drug)
89308152|NCT01127217|Experimental|amlodipine/losartan|
89308153|NCT01127217|Active Comparator|amlodipine|
89308154|NCT03647722||Lemtrada treated - 6 month|Patients that received their first course of treatment with Lemtrada approximately 6 months prior.
89308155|NCT03647722||Lemtrada treated - 12 month|Patients that received their first course of treatment with Lemtrada approximately 12 months prior but who have not received the second course of treatment.
89308156|NCT03647722||Lemtrada treated - 18 month|Patients that received their first course of treatment with Lemtrada approximately 18 months prior and their second course of treatment with Lemtrada approximately 6 months prior.
89308157|NCT03647722||Lemtrada treated - 24 month|Patients that received their first course of treatment with Lemtrada approximately 24 months prior and their second course of treatment with Lemtrada approximately 18 months prior and who have not received any further treatment.
89308158|NCT03647722||Lemtrada qualified - untreated|Patients that are qualified to start treatment with Lemtrada but have not yet being untreated.
89308159|NCT01226901|Experimental|MK-4827 once daily|MK-4827
89308160|NCT05284864|Experimental|Early stoma closure|Stoma closure 2-3 weeks after rectal surgery.
89308161|NCT05284864|Active Comparator|Late stoma closure|Stoma closure 16-24 weeks after rectal surgery.
89308162|NCT03648658|Experimental|Paracetamol 15mg/kg|
89308163|NCT03931239|Experimental|Vaccination|DTPw-HB-Hib vaccine
89308164|NCT01129635|Experimental|CRT Candidate|"Patients with NYHA Class III or IV heart failure; EF ≤ 30% and QRS duration ≥ 120 ms, who are scheduled for CRT surgery.~Intervention: Cardiac Resynchronization Therapy (CRT) implantation"
89308165|NCT03927495|Experimental|Concurrent chemoradiotherapy and KN046|Participants in the Arm I will receive chemoradiotherapy and concurrent KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
89308166|NCT03927495|Experimental|chemoradiotherapy and sequential KN046|Participants in the Arm II will receive chemoradiotherapy and sequential KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.
89308167|NCT02966002|Experimental|Intervention: aspirin|650 mg. Twice a day for 8 weeks
89308168|NCT01223313|Experimental|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
89308169|NCT01127295|Other|Tamoxifen, Anastrozole, letrozole, Exemestane|Current hormonotherapy treatment in hormono dependent breast cancer
89308170|NCT02965846|Experimental|AGN-195263|
89308171|NCT02965846|Placebo Comparator|Vehicle|
89308172|NCT01129713|Active Comparator|Nexium|Comparing 40 mg.once daily in healing erosive esophagitis.
88820783|NCT05651022|Experimental|Cohort -1|A single dose of Decoy20 at a dose of 3 x 10^7 KB
89308173|NCT01129713|Active Comparator|Secretol|Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.
89308174|NCT03647644||Acute Normovolemic Hemodilution Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. If clinically indicated and appropriate per the discretion of the anesthesiologist, Acute Normovolemic Hemodilution (ANH) blood, about 2 units, will be withdrawn from the patients and stored carefully at room temperature per standard protocol. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients prior to re-infusing the ANH blood and after the blood has been infused per standard institutional protocol.
89308175|NCT03647644||Control Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. In this arm, ANH would be clinically appropriate, however, the anesthesiologist determined they would not have ANH preformed. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients and again 30 minutes later to mirror the time lapse in the ANH group.
89308176|NCT01221831|Experimental|estetrol dose 1 / P1|
89308177|NCT01221831|Experimental|estetrol dose 1 / P2|
89308178|NCT01221831|Active Comparator|estradiol valerate/dienogest pill|
89308179|NCT01221831|Experimental|estetrol dose 2 / P1|
89308180|NCT01221831|Experimental|estetrol dose 2 / P2|
89308181|NCT05284708|Other|Clinical Operators|Experimental: 15 healthcare professionals will be recruited for the study. The group includes physiotherapists (PTs), physiotherapist assistants (PTAs), clinical exercise physiologists (EPs), and rehabilitation technicians (RTs), all resident in US and representing the final users of the device. Operators are representative of the final users of the exoskeleton.
89308182|NCT01223391|Experimental|Abdominal binder|Standing with abdominal compression using elastic vs. non-elastic abdominal binders.
89308183|NCT01223391|Placebo Comparator|No abdominal binder|Standing without abdominal compression
89308184|NCT03646942|Active Comparator|Lingual orthodontics|Patients will be treated with lingual braces without being irradiation with low level laser therapy. Treatment will go forward in the normal manner. Archwires will be changed in the traditional way.
89308185|NCT03646942|Experimental|Low level laser therapy|Patients will be subjected to low level laser therapy during their orthodontic treatment using lingual braces.
89308186|NCT03931317|Other|Latanoprostene bunod 0.024% QD|4 weeks of Latanoprostene bunod 0.024% QD, then a 2 Week washout, followed by 4 weeks of Timolol maleate 0.5% BID
89308187|NCT03931317|Other|Timolol maleate 0.5% BID|4 weeks of Timolol maleate 0.5% BID, then a 2 Week washout, followed by 4 weeks of Latanoprostene bunod 0.024% QD
89308188|NCT01221909|Experimental|Tranexamic acid single dose of 500mg|
89308189|NCT01221909|Placebo Comparator|Saline|
89308190|NCT01221987||Cohort A|Females > 21 years of age, diagnosed with invasive cervical cancer
89308191|NCT01221987||Cohort B|Females > 21 years of age, diagnosed with moderate or severe cervical intraepithelial neoplasia
89308192|NCT01129947|Experimental|DHEA|
89308193|NCT02900092|Experimental|Ganaxolone|Participants received ganaxolone
89308194|NCT01130025|Experimental|Innohep®|Long-term treatment with Innohep® only.
89308195|NCT01130025|Active Comparator|Warfarin|Oral treatment with warfarin in combination with overlapping initial (5 to 10 days) treatment with Innohep®.
89308196|NCT03646864|Experimental|Treatment A|ACT-541468 50 mg from Day 1 to Day 5 of Period A
89308197|NCT03646864|Placebo Comparator|Treatment B|Placebo from Day 1 to Day 5 of Period B
89308198|NCT03925155|Experimental|Chlorhexidine gluconate vaginal scrub|Use of chlorhexidine 4% vaginal scrub instead of current standard of care 10% povidone iodine vaginal scrub for cesarean sections
89308199|NCT03925155|Active Comparator|Povidone-iodine vaginal scrub|Current standard of care 10% povidone iodine vaginal scrub for cesarean sections
89308200|NCT03924999|Experimental|Combined decongestive treatment & Combined exercise|"Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 5 days a week, for 6 weeks (totally, 30 sessions).~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
89308201|NCT03924999|Experimental|Intermittent pneumatic compression & Combined exercise|"Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).~All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises."
89308202|NCT03924999|Active Comparator|Combined exercise|All participants received 30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
89308203|NCT03647410||lumbopelvic fixation|sacral fractures fixed with lumbopelvic fixation
89308204|NCT03647410||novel adjustable plate|sacral fractures fixed with novel adjustable plate
89308205|NCT03647332|Active Comparator|Cooled RFA treatment|
89308206|NCT03647332|Active Comparator|Steroid injection|
89308207|NCT03924921|Experimental|autogenic training|Autogenic training
89308208|NCT03924921|Experimental|wait list|usual care for 6 months Autogenic training after 6 months
89308209|NCT04052464||endometrium biopsy only|In these cases, only endometrium biopsy is investigated for the selected biomarkers gene expression profile.
89308210|NCT04052464||endometrium lavage followed by endometrium tissue biopsy|In these cases before the endometrium tissue biopsy, an endometrial lavage is performed and from both samples, the selected biomarkers gene expression profile are investigated.
89308211|NCT04052464||serial endometrium lavage followed by endometrium biopsy|In these cases before the endometrium tissue biopsy, at different days endometrial lavage samples are taken. From all samples, the selected biomarkers gene expression profile are investigated.
89308212|NCT01131195|Active Comparator|Arm A: bevacizumab and paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle. Both medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug is given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion.
89308213|NCT01131195|Active Comparator|Arm B: bevacizumab, cyclophosphamide and capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily. All three medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug(s) is (are) given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion
89308214|NCT04076644|Active Comparator|TMS Treatment Arm|Subjects will receive either a 20min 10hz TMS treatment, or a 3min theta-burst TMS treatment at certain monthly intervals. The TMS treatment protocol they receive depends on what they received in their acute clinical treatment. Subjects in the arm will be tapered off antidepressant medication before TMS treatment begins. Subjects will be assessed monthly for depression using QIDS and PHQ9.
89308215|NCT04076644|No Intervention|No TMS Arm|Subjects will be followed and assessed for depressive symptoms at monthly time intervals similar to the active treatment arm using QIDS and PHQ9. This group does not receive TMS treatment.
89308216|NCT01223547|No Intervention|Control group|Participants in this arm continues their usual insulin therapy
89308217|NCT01223547|Active Comparator|Carb counting|Participants in this arm are taught carb counting
89308218|NCT01223547|Active Comparator|Carb counting and bolus calculator|Participants in this arm are taught carb counting and are provided with an integrated glucose meter and bolus calculator.
89308219|NCT03647254|Experimental|Patient Education Group|A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls
89308220|NCT03647254|No Intervention|Control group|Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate.
89308221|NCT01223625|Active Comparator|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
89308222|NCT01223625|Active Comparator|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
89308223|NCT03650218|Experimental|THIODERM STRONG|"THIODERM STRONG injected into the upper arm (cohort 1)~THIODERM STRONG injected into nasolabial folds (cohort 2)"
89308224|NCT01228227|Active Comparator|ROSUVASTATIN|
89308225|NCT01228227|Experimental|ATORVASTATIN|
89308226|NCT03740373|Experimental|Treatment Sequence 1|Subjects will receive BGF MDI with 10 s breath hold during Treatment Period 1 and BGF MDI with 3 s breath hold during Treatment Period 2
89308227|NCT03740373|Experimental|Treatment Sequence 2|Subjects will receive BGF MDI with 3 s breath hold during Treatment Period 1 and BGF MDI with 10 s breath hold during Treatment Period 2
89308228|NCT03621826||Children with Sickle Cell Anemia|Data from patients with sickle cell anemia will be entered into a retrospective database for evaluation of implementation rates of TCD (stroke) screening). A small number of these children/parents/stakeholders will be selected by convenience sampling to participate in a survey and/or interview to assess barriers and enablers to stroke prevention therapy.
89308229|NCT01228305|Experimental|Acetaminophen|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
89308230|NCT01228305|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
89308231|NCT02902120|Experimental|Post-transplant|This arm will evaluate the treatment of patients with HCV and chronic kidney disease (GFR <50) who have had a kidney transplant using grazoprevir and elbasvir.
89308232|NCT01227291|Experimental|SYL040012|SYL040012 Ophthalmic drop administration
89308233|NCT03650140|Active Comparator|Tart cherry concentrate 60 mL|Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
89308234|NCT03650140|Active Comparator|Tart cherry concentrate 120 mL|Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
89308235|NCT01227369||Bisphosphonates|Korean postmenopausal osteoporosis patients with bisphosphonate treatment
89308236|NCT03646552|Experimental|THX-110|All participants will be titrated up on THX-110 (Dronabinol) dose during the first week of the trial (2.5mg Dronabinol for 3 days, 5mg Dronabinol for 3 days to 7.5mg Dronabinol for 3 days and finally increasing to 10mg for the remainder of the trial). Dronabinol will only be increased if the subject is tolerating the previous dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. Participants will be receiving 800mg PEA concomitantly.
89308237|NCT03924609||Bone metastasis screening|The information about bone metastasis screening is retrospectively collected.
89308238|NCT04052386|Experimental|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
89308239|NCT04052386|No Intervention|Control|Participants randomized to the control group did not receive any intervention. They were an assessment-only control group.
89308240|NCT03924687|Experimental|ACT group|ACT group: participants receiving the 8-week bibliotherapy intervention based on Acceptance and Commitment Therapy
89308241|NCT03924687|No Intervention|control group|Wait-list control condition: participants placed on a wait-list (and receiving the intervention following the 9 week duration of the intervention)
89308242|NCT03646396|Experimental|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
89308243|NCT01131273|Active Comparator|Methadone maintenance for 12 weeks|Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
89308244|NCT01131273|Active Comparator|buprenorphine-naloxone (Suboxone)|12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling
88820784|NCT05651022|Experimental|Cohort 1|A single dose of Decoy20 at a dose of 7 x 10^7 KB
89308245|NCT03943576|Experimental|GXCPC1|GXCPC1 contains 6.7×10^6 or 4×10^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL
89308246|NCT03943576|Active Comparator|hyaluronic acid|Hya Joint Plus synovial fluid supplement 3mL
89308247|NCT01223781|Experimental|Feedforward stimulation|Prior to any gait condition likely to invoke freez, auditory stimulation is presented
89308248|NCT01223781|Experimental|Feedback stimulation|Once a device identifies freezing, a auditory stimulation is triggered
89308249|NCT02965456|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
89308250|NCT02965456|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
89308251|NCT03927339||pre and post excercise group|
89308252|NCT03927183|Other|Person-centred practice|Person-centred care
89308253|NCT03646318|Experimental|Ketanserin|Ketanserin is a serotonin type 2-receptor blocker (5-HT2). In normal endothelium, the 5-HT1 effects (vasodilation) are the most prominent [Dabire 1990]. In endothelium that is damaged, which is the case in sepsis, the 5HT2 effects (vasoconstriction) surpass the 5-HT1 effects. Blocking the 5-HT2 receptor with ketanserin can attenuate this pathological vasoconstriction. In addition, ketanserin has favourable α1-adrenergic blocking properties in the endothelium (vasodilation) that may further reverse the pathological vasoconstriction. In these ways ketanserin can reduce vasoconstriction and can improve the microcirculation.
89308254|NCT03646318|Placebo Comparator|Placebo|The placebo is a standard glucose 5% solution.
89308255|NCT01130181|Experimental|Cholecalciferol|
89308256|NCT01130181|Placebo Comparator|Placebo|
89308257|NCT03621514|Other|painless indwelling catheter|This group of patients underwent catheterization after anesthesia. At the end of the operation, the patient was removed from the catheter before anesthesia was awakened.
89308258|NCT03621514|Other|indwelling catheter|This group of patients underwent catheterization after anesthesia,and the catheter was indwelled. The patient was routinely removed for 24 to 72 hours after surgery.
89308259|NCT03930927|Experimental|Self Assembling peptide|intervention
89308260|NCT03930927|Experimental|Fluoride|Comparator
89308261|NCT01228461||AYA with Fatigue and Hodgkin Lymphoma|
89308262|NCT03647176|Active Comparator|small polyps|Cold snare polypectomy ; Polyp size will be measured using the tip of the snare catheter (2.5mm).Small (5-9 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, biopsies were performed from two marginal sites located symmetrically on the left and right of the mucosal defects to confirm residual polyp tissue.
89308263|NCT03647176|Experimental|large polyps|Cold snare polypectomy; Polyp size will be measured using the tip of the snare catheter (2.5mm). Large (10-15 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, 4 biopsies will be performed from all four quadrants of resection margins.
89308264|NCT01228539|Experimental|TARGET|Affect regulation psychotherapy for PTSD
89308265|NCT01228539|Active Comparator|Prolonged Exposure|Cognitive behavioral therapy for PTSD with trauma memory exposure
89308266|NCT01127841|Experimental|Rituximab and Bendamustine|
89308267|NCT01223859|Experimental|intervention|Interstitial soft palate RF surgery
89308268|NCT03924531|Experimental|Mindful Awareness Program|The group that received mindfulness training.
89308269|NCT03924531|Active Comparator|Health Promotion Program|The group that received the health information.
89308270|NCT01227603|Experimental|Nifedipine-candesartan FDC|Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
89308271|NCT01227603|Active Comparator|Nifedipine and candesartan|Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
89308272|NCT01227603|Active Comparator|Nifedipine|Each subject received one dose of nifedipine GITS 60 mg orally.
89308273|NCT01227603|Active Comparator|Candesartan|Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.
89308274|NCT03926871|Experimental|Novices|They received ergonomic training after 1-2 days of hiring to do the work in the cutting room, and packaging sectors. They did not have experience in the refrigerator or butchers, so they had the minimum of information about tasks and risks.
89308275|NCT03926871|Experimental|Experienced|They received the same ergonomic training as the newbies, and should have been hired for more than 6 months in the company. In this period they had already acquired patterns of movement and self-protection to accomplish the tasks.
89308276|NCT03924297|Experimental|Chilipad Arm|Subjects will use chilipad nightly for 5 weeks
89308277|NCT03924453||Pearl Powered by Proov|Participants are given hormone tests strips and a digital app and all instructions for use, collectively called the Pearl Power by Proov kit. The app will analyze hormonal test strip information to predict and confirm ovulation
89308278|NCT03923985|Active Comparator|Active Arm|1 tablet / day of probiotic containing 10 Mld L. crispatus during two months
89308279|NCT03923985|No Intervention|Control Arm|No treatment
89308280|NCT01585623|Experimental|Segment 1|two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days
89308281|NCT01585623|Experimental|Segment 2|SAR302503 500 mg once daily without food in 28-day per cycle
89308282|NCT03924141|Experimental|Third year nursing students - intervention|Third year nursing students will receive the intervention in de-escalation training
89308283|NCT03924141|No Intervention|Third year nursing students - control|Third year nursing students will receive no training in de-escalation
89308284|NCT03926793|Experimental|Cohort 1|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
89308285|NCT03926793|Experimental|Cohort 2|Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days
89308286|NCT03926793|Experimental|Open Label Extension|Eligible subjects may participate in the Open Label Extension (OLE) study for a period of 24 weeks.
89308287|NCT01127919||Low Commitment|Group 1 participants will take a 1-credit hour course that involves exercise training only.
89308288|NCT01127919||High Commitment|Group 2 participants will take a 3-credit hour course that involves exercise training plus an online cognitive component that provides information on fitness and health topics and includes quizzes and other written course work
89308289|NCT01127919||Non-Exercise|Group 3 participants will take the cognitive component of the formal course but will not partake in the formalized exercise program for a period of 35 weeks.
89308290|NCT01127997||study A|post-breakfast meal tolerance test + post-lunch meal tolerance test
89308291|NCT01127997||study B|fasting + post-lunch meal tolerance test
89308292|NCT03926559|Experimental|Duramorph (Morphine)|2mg of Neuraxial Morphine given through epidural once after the patient has delivered.
89308293|NCT03926559|No Intervention|No intervention|Patient does not get any intervention.
89308294|NCT01228617|Experimental|A1 Short, no buffer|Nicotine / not yet marketed
89308295|NCT01228617|Experimental|A2 Short, low buffer|Nicotine / not yet marketed
89308296|NCT01228617|Experimental|A3 Short, high buffer|Nicotine / not yet marketed
89308297|NCT01228617|Experimental|B1 Long, no buffer|Nicotine / not yet marketed
89308298|NCT01228617|Experimental|B2 Long, low buffer|Nicotine / not yet marketed
89308299|NCT01228617|Experimental|B3 Long, high buffer|Nicotine / not yet marketed
89308300|NCT01228617|Active Comparator|R = Nicotine Gum|Nicorette® Gum
89308301|NCT01227759|Experimental|Verum|
89308302|NCT01227759|No Intervention|Untreated|
89308303|NCT01227759|Placebo Comparator|Vehicle|
89308304|NCT03923829|Experimental|Zinc administration with scaling and root planing|systemic administration of Zinc cap of 50 mg elemental zinc as zinc sulphate, once a day for 12 weeks in addition to scaling and root planing
89308305|NCT03923829|Active Comparator|scaling and root planing|scaling and root planing
89308306|NCT01128075||naïve subjects|Cohort of RMS patients who initiate disease modifying treatment with Rebif®
89308307|NCT01128075||non-naïve subjects|Cohort of RMS patients who initiate treatment with Rebif® after having failed therapy with other disease modifying drugs on the basis of lack of efficacy, compliance, safety, tolerability or convenience, as per clinical judgment of study investigator
89308308|NCT03930693|Experimental|Normotensive pregnant women|Normotensive pregnant women
89308309|NCT03930693|Experimental|Hypertensive pregnant women|Hypertensive pregnant women
89308310|NCT03930693|Experimental|Normotensive non-pregnant women|Normotensive non-pregnant women
89308311|NCT03930693|Experimental|Hypertensive non-pregnant women|Hypertensive non-pregnant women
89308312|NCT03923517|Experimental|YOD caregiver|The participants will be encouraged to use RHAPSODY for four weeks. After that they will have two individual MEET sessions with experts (social worker and psychologist).
89308313|NCT01228695||steroid treatment|
89308314|NCT03923751||Polish Hospitals|Hospitals with anesthesia or intensive care practices
89308315|NCT03923205|Active Comparator|Control meal|The control meal will be a standard OGT test containing 75 g glucose dissolved in 300 mL of water followed by 100 mL water.
89308316|NCT03923205|Active Comparator|The test meal|The test meal contains 100 g of the buckwheat beverage and 75 g glucose dissolved in 300 mL water followed by 100 mL water.
89308317|NCT03923361|Experimental|Propofol|
89308318|NCT01130415||Patients treated with sacral neuromodulation|
89308319|NCT01228773|Experimental|A|"Providing tailored web-based care program(Health Navigation®), which provides various information related to the CRF.~Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue etc."
89308320|NCT01228773|Other|B|Attention control arm: Providing usual care for CRF. Three months later, as attention control, they will be provided tailored web-based care program(Health Navigation®), which provides various information related to the CRF.
89308321|NCT03740295|Placebo Comparator|Control Multiple Sclerosis|
89308322|NCT03740295|Experimental|Intervention Multiple Sclerosis|
89308323|NCT02965378|Experimental|Arm I - AZD4547|Participants receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89308324|NCT02965378|Experimental|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.~-closed to accrual 12/18/2015"
89308325|NCT02965378|Experimental|Arm III - AZD4547 re-registration|Participants in Arm II eligible for re-registration receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89308326|NCT01224093||First line|
89308327|NCT01224093||Relapsed/refractory|
89308328|NCT03772041|Experimental|OPC-61815 injection 16 mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
89308329|NCT03772041|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
89308330|NCT01227837|Sham Comparator|placebo|use of placebo in control group
89308331|NCT01227837|Experimental|omega 3|use of omega 3 2 gr/day for 6 months
89308332|NCT01224249|Active Comparator|Fish and shellfish|
89308333|NCT01224249|No Intervention|Control|Assessment only
89308334|NCT01329237|Other|dynamic physical exercise OCT|dynamic physical exercise and optical coherence tomography imaging
89308335|NCT03923127|Experimental|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
89308336|NCT01130571||Non-Small Cell Lung Cancer|
89308337|NCT03922815|Experimental|haemodynamic parametres-guided deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to disappearance of cilliary reflex; in the case of heart rate and/or arterial blood pressure increase by 20% a rescue dose of fentanyl 0,5 mcg per kilogram of body weight will be administered
89308338|NCT03922815|Experimental|SE-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE < 80 alongside with a rescue dose 0,5 mcg per kilogram of body weight of fentanyl in the case of heart rate and/or arterial blood pressure increase by 20%
89308339|NCT03922815|Experimental|AoA-guided propofol-fentanyl deep sedation|propofol will be tirtrated in a single dose of 0,5 mg/kg of body weight to a target SE < 80 alongside with a rescue dose 0,5 mcg per kilogram of body weightof fentanyl in the case of increase of SPI value > delta 15
89308340|NCT03922659|Placebo Comparator|Regular treatment (symptomatic treatment) with blank TMS|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation
89308341|NCT03922659|Active Comparator|Regular treatment (RT) with blank TMS and CBT|Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy
89308342|NCT03922659|Active Comparator|RT with right DLPFC hf-rTMS|Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
89308343|NCT03922659|Active Comparator|RT with right DLPFC hf-rTMS and CBT|Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
89308344|NCT03922659|Active Comparator|RT with left DLPFC hf-rTMS|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)
89308345|NCT03922659|Active Comparator|RT with left DLPFC hf-rTMS and CBT|Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)
89308346|NCT02529267||Experienced abuse|Experienced IPV in the past 12 months
89308347|NCT02529267||Did not experience abuse|Did not experience IPV in the past 12 months.
89308348|NCT01224327|Experimental|umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
89308349|NCT01224327|Active Comparator|Conserved therapy|Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
89308350|NCT01130649||Epilepsy patients, electronic diary|Cohort of epilepsy patient using an electronic diary system to record all seizures, side effects, and medication compliance
89308351|NCT01130649||Epilpesy patient, no electronic diary|Group of epilepsy patients who are followed using the standard of care, which is a paper diary and routine outpatient follow up visits
89308352|NCT01227915|Experimental|Test|tobramycin 0.3% + dexamethasone 1% - União Química Lab
89308353|NCT01227915|Active Comparator|Comparator|tobramycin 0.3% + dexamethasone 1% - Alcon Lab
89308354|NCT01224405|Active Comparator|Treatment arm|ten docetaxel cycles + maintenance androgen deprivation.
89308355|NCT01224405|Experimental|suspension arm|Ten Docetaxel cycles + stop androgen deprivation therapy
89308356|NCT01224405|Experimental|intermittent arm|Intermittent Docetaxel
89308357|NCT01224405|Active Comparator|Continuous arm|Continuous Docetaxel
89308358|NCT01228851|Experimental|Balance Training|Balance training using Wii Fit Balance Board
89308359|NCT03925857|Experimental|Allocetra-OTS|Standard of Care (SOC) Drug: One dose Allocetra-OTS 140 140x106 /kg
89308360|NCT03925857|Experimental|Allocetra-OTS Two doses|Standard of Care (SOC) Drug: Two doses Allocetra-OTS 140 140x106 /kg
89308361|NCT03922425|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
89308362|NCT03922425|No Intervention|Standard care|
89308363|NCT02899156|Active Comparator|Flumazenil Infusion|The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
89308364|NCT02899156|Placebo Comparator|Placebo Infusion|The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
89308365|NCT01131429|Experimental|first-line erlotinib|erlotinib in first-line treatment and docetaxel/cisplatin in second-line treatment
89308366|NCT01131429|Active Comparator|second-line erlotinib|docetaxel/cisplatin in first-line treatment and erlotinib in second-line treatment
89308367|NCT03922503|Experimental|Advanced- platelets rich fibrin with DFDBA|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
89308368|NCT03922503|Active Comparator|Collagen membrane and DFDBA|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
89308369|NCT03645304|Experimental|Ropivacaine group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .
89308370|NCT03645304|Placebo Comparator|0.9% Saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
89308371|NCT03649984|Experimental|Symptom Navi© Program|Nurses provide two semi-structured consultation to facilitate basic symptom self-management of patients based in the Symptom Navi© Flyers
89308372|NCT03649984|No Intervention|Standard care|Standard care including information about treatment, potential side effects and expected symptoms under treatment with or without additional written material following the established procedure at the centre.
89308373|NCT03649906|Experimental|Optimized Localization Group|Subjects have small pulmonary nodules. In order to facilitate the search for nodules during surgery, it is necessary to indwelling markers pre-operative.
89308374|NCT03773133|Experimental|Treatment|i.v. administrations of up to three radioactivity levels of Satoreotide tetraxetan.
89308375|NCT03646084|Experimental|Sleep Intervention Program (SCIP)|Based on the results of the studies, patients will be treated according to current guidelines: 1) Improve rest/activity rhythms. 2) To treat and control Sleep Disorder Breathing. 3) To improve anxiety, depression and insomnia. 4) To treat RLS if needed. 5) To try opioid dose reduction. 6) To trial of non-opioid in lieu of opioids. 7) Avoiding use of benzodiazepines, sedatives, hypnotics. 8) Caution against alcohol use.
89308376|NCT03646084|Active Comparator|Control|Rehabilitation according to current clinical practice.
89308377|NCT03922737|Active Comparator|In-person office visit|
89308378|NCT03922737|Active Comparator|Telehealth visit with provider|
89308379|NCT02969356|Experimental|Dysport|Each subject will undergo two intramuscular injection (treatment) cycles, receiving AbobotulinumtoxinA (Dysport®) 1500 U on Day 1 of each cycle; the two dosing occasions will be separated by at least 12 weeks (maximum 20 weeks). Subjects will also receive daily GSC therapy. The main focus of GSC will be on the primary treatment target (TT) limb (as determined at the Baseline Visit) and then the other limb. All muscle groups requiring active training and/or stretching should be trained. Subjects will be be given a diary to record each day whether they have performed the GSC therapy.
89308380|NCT03649828|Experimental|kefir group|The kefir group (KG) received orally probiotic milk fermented with kefir grains and was compared with the control group (CG) that received only curd
89308381|NCT03649828|Experimental|control group|control group (CG) that received only curd
89308382|NCT03646006|Experimental|Pre-sacral nerve block|10 mL bupivacaine (5mg/mL)
89308383|NCT03646006|Sham Comparator|Sham block|10 mL normal saline
89308384|NCT03621436|Experimental|TRVD Therapy|
89308385|NCT03915262||Crohn's Disease|
89308386|NCT03854344|Experimental|Group 1|Liposomal Bupivicaine (266mg/20ml) will be diluted into Lactated Ringer solution (280 ml) and injected once intra-operatively subcutaneously before donor site harvesting
89308387|NCT03854344|Active Comparator|Group 2|Lidocaine (50 mg/50 ml) will be diluted into Lactated Ringer (1000ml) and injected once subcutaneously before donor site harvesting
89308388|NCT03854344|Experimental|Group 3|Subjects will receive regional anesthesia with a bupivacaine nerve block; either a fascia iliaca, lateral femoral cutaneous, or femoral nerve block based on the proposed donor site location
89308389|NCT03609424|Experimental|PDR001 plus Imatinib|
88806465|NCT02109458|Experimental|Assessing peripheral pulmonary nodules|To evaluate the feasibility and safety of a procedure path including convex Endobronchial Ultrasound (EBUS) lymph node sampling, navigation guided bronchoscopy (NB) and navigation guided transthoracic needle aspiration (N-TTNA).
89308390|NCT03645850|Experimental|Investig. device:Vismed Gel Multi 0.3%|Vismed gel Multi 0.3% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
89308391|NCT03645850|Active Comparator|Comparative device: Vismed Multi 0.18%|Vismed Multi 0.18% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
89308392|NCT03644446||Bisoprolol 5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
89308393|NCT03644446||Bisoprolol 7.5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 7.5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
88806466|NCT00319748|Experimental|Intent-To-Treat|Patients treated with at least one dose - 852A subcutaneous injection.
88806467|NCT00319748|Experimental|Evaluable Cohort|Patients who received all 24 doses of 852A per protocol.
88806468|NCT01794260|Placebo Comparator|Placebo cream|Placebo cream
88806469|NCT01794260|Experimental|Plai cream|Cream from Zingiber cassumunar Roxb. extract
89308394|NCT03644446||Bisoprolol 10mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 10mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
89308395|NCT04052152|Experimental|Group A|"Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12mg/day(D1-D14 ) and Sintilimab injection 200mg Q3W (D1). Sintilimab injection will be administered until disease progressioncor un-tolerable toxicity. Anlotinib will be administered until disease progression. If anlotinib is not tolerated, the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again"
89308396|NCT03783364|Experimental|preoperative|preoperative radiotherapy
89308397|NCT03783364|Active Comparator|postoperative|postoperative radiotherapy
89308398|NCT03645616|Experimental|Functional Tests|Participants undertook 6-minute walk test, 10 meters walk test and 30 second sit to stand test.
89308399|NCT03644992||Thromboembolic Disease|the patients who undergo gynecological operations but develop thromboembolic disease
89308400|NCT03644914|Experimental|Intervention Group (Reading Program)|First graders who will receive the 10-week reading program (a total of 20 hours), twice weekly in 1-hour sessions, and will continue to receive typical classroom reading instruction.
89308401|NCT03644914|No Intervention|Control Group|First graders who will not take part in the reading program but will continue to receive typical classroom reading instruction.
89308402|NCT02898454|Experimental|Dupilumab 300 mg q2w|Dupilumab 300 mg subcutaneous (SC) injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
89308403|NCT02898454|Experimental|Dupilumab 300 mg q2w then q4w|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50.
89308404|NCT02898454|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
89308405|NCT03645538||Parkinson's disease patients|"PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).~The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
89308406|NCT03645538||No drug - Control group|PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
89308407|NCT05284162|Experimental|Health coaching|Health coaching
89308408|NCT05284162|No Intervention|Usual care|Usual care
89308409|NCT05283850|Active Comparator|High-Calcium, High- Sodium (HCHS) group|Patients will receive a drip of blinded, intravenous, normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.
89308410|NCT05283850|Experimental|High-Calcium, Low- Sodium (HCLS) group|Patients will receive a drip of blinded, intravenous, half-normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.
89308411|NCT03772587|Placebo Comparator|Group 1|
89308412|NCT03772587|Experimental|Group 2|
89308413|NCT03772587|Experimental|Group 3|
89308414|NCT03772587|Experimental|Group 4|
89308415|NCT03772587|Experimental|Group 5|
89308416|NCT03645460|Experimental|TYF-ADA-modified autologous stem cells|Autologous hematopoietic and/or mesenchymal stem cells transduced with lentiviral vector carrying the ADA gene
89308417|NCT03644836|Experimental|Retraining with respiratory effort+ amino acids|
89308418|NCT03644836|Placebo Comparator|Retraining with respiratory effort+ placebo|
89308419|NCT03645382|Placebo Comparator|baked barley powder consumption|Subjects randomized to the placebo group received one tablet containing baked barley powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
89308420|NCT03645382|Experimental|jeju steam onion powder consumption|Subjects randomized to the test group received one tablet containing jeju steam onion powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
89308421|NCT03925779|Active Comparator|(Dexmedetomidine)Dex group|The patients will be administered a loading dose of i.v. dexmedetomidine 1 μg/kg over 10 min, followed by a continuous infusion of 0.2-1 μg/kg/h, titrated according to the sedation score, till the end of the procedure
89308422|NCT03925779|Active Comparator|Propofol-Remifentanil (P-R) group|Propofol will be started by a loading dose of 0.5 mg/kg over 3-5 minutes then a maintenance infusion of 25-75 μg kg/min. Remifentanil infusion will be started at 1 μg kg over one minute then and 0.01-0.1 μg kg/min.
89308423|NCT03644758||professional and voluntary firefighter|Professional and voluntary firefighter in Service Departmental Fire and Rescue of Loire will be included. They will have to answer at the self-administrated questionnaires. It is composed of 5 parts: socio-demographic data and personal medical history, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Insomnia Severity Index (ISI) and stop-BANG questionnaire.
89308424|NCT03644290|Experimental|Cognitive training|Semantic categorization training sessions
88806470|NCT00361712|Experimental|Preemptive epidural analgesia|Parturients will receive epidural analgesia immediately upon arrival in the labor ward before onset of painful contractions (VAS<3).
88806471|NCT00361712|Active Comparator|Standard of care|Parturients with cervical dilatation and painful labor (VAS >5) will receive epidural analgesia as soon as possible
88806472|NCT04008056||Patients undergoing chemotherapy|
89308425|NCT03644290|Active Comparator|Control condition|Five sessions of behavioral control condition with information and education
89308426|NCT05283694|Experimental|Risankizumab Dose A|Participants will receive 3 Subcutaneous (SC) injections of risankizumab Dose A administered via prepared syringe at Day 1 and followed for 140 days.
89308427|NCT05283694|Experimental|Risankizumab Dose B|Participants will receive 1 SC injection of risankizumab Dose B administered via syringe pump at Day 1 and followed for 140 days.
88806473|NCT03710096|Experimental|Mac grath group|
88806474|NCT03710096|Active Comparator|Macintosh Group|
88806475|NCT03993002|Active Comparator|Normoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 < 100 (FiO2 >= 21%) PaCO2 of 30-40"
89308428|NCT05283694|Experimental|Risankizumab Dose C|Participants will receive 1 SC injection of risankizumab Dose C administered via syringe pump at Day 1 and followed for 140 days.
89308429|NCT05283694|Experimental|Risankizumab Dose D|Participants will receive 1 SC injection of risankizumab Dose D administered via prepared syringe at Day 1 and followed for 140 days.
89308430|NCT03925701|Experimental|vildagliptin|vildagliptin 50 mg twice daily
89308431|NCT03925701|Active Comparator|vildagliptin\metformin|vildagliptin\metformin twice daily
89308432|NCT03645772|Experimental|Plyometric exercise|12-week progressive exercise program, consisting of plyometric exercises such as countermovement jump, forward and sideways step-up.
89308433|NCT03645772|Active Comparator|Resistance exercise|12-week resistance exercise program for the leg muscles (2-4 sets of 8-15 repetitions at 8-15RM, leg press, leg extension, calve extension).
89308434|NCT03645772|Active Comparator|Walking|12-week progressive walking program.
89308435|NCT03925623||Commercial closure system|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with a standard two piece push and turn cap and asked to open this during 2 five minute trials.
89308436|NCT03925623||Physically based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped a novel closure that was designed using anthropometric data such that it disallows children from engaging the system and enables adults. Children will be asked to open this during 2 five minute trials.
89308437|NCT03925623||Cognitively based design strategy|Participants (42-54 months of age) will be assigned to try to open one of three treatments. One cohort will receive a 38/400 bottle equipped with the design feature that was introduced as part of the physical intervention (above); however, this treatment is sized such that children should be able to engage it (if they understand how). In having these three treatments, we began to evaluate the paradigm which enables the design to work. (Do they fail to understand how?- Cognitive treatment fail- and or Can they not effectively manipulate the closure? --- Physical failure).
89308438|NCT03922347|No Intervention|routine care|
89308439|NCT03922347|Active Comparator|Screening program including 2 consecutive tests|
89308440|NCT03922347|Active Comparator|Screening program with mobile health|
89308441|NCT03922113||Critically ill patients|Patients who spent a minimum of 48h in ICU
89308442|NCT03922113||Surgical patients|Patients who were scheduled for elective colorectal surgery
89308443|NCT03922113||Healthy subjects|Healthy volunteers
89308444|NCT03931083||Portable magnification device (Gynocular™)|The Gynocular™ examination will be performed following the steps involved in colposcopy as described in the IARC colposcopy manual. These steps include: visualization of the vagina, vulva and cervix following insertion of a speculum, magnified assessment after application of normal saline, examination of cervical vessel patterns using the red-free mode (or green filter), application of 5% acetic acid for 1 minute and finally assessment following application with Lugol's iodine. The findings of the live examination will be documented using the parameters of the Swede score. Each parameter is scored between zero and two. Treatment will be based on the results found at histopathology, unless the woman is also VIA positive in which case, after biopsy she will undergo routine treatment as per local guidelines. The results will be used to determine the optimal threshold for treatment in WLHIV.
89308445|NCT03931083||Testing for high risk HPV (HRHPV)|To reduce the number of examinations undergone by the study participant during the same day, HRHPV testing will be carried out at the time of the first gynecological examination by the VIA nurse (see next arm). Using specific single-use cervical cytobrush provided by GeneXpert, a specimen will be collected immediately prior to VIA examination. Cervical cytobrush specimens will be placed into ThinPrep PreservCyt (Cepheid, Sunnyvale, CA) immediately after collection. The HR-HPV testing of cervical specimens will be conducted by a GeneXpert™ machine (Cepheid, Sunnyvale, CA), which will be placed at the health facility and will be operated by a trained nurse in accordance with the manufacturer's instructions. Additionally, as part of the baseline clinical characteristics of the study participant, the study participant will undergo an STI test at the same time. The sample will be collected and tested using the same GeneXpertTM platform.
89308446|NCT03931083||Visual inspection with acetic acid (VIA)|VIA, which is standard of care for cervical cancer screening in Zambia, will be carried out using the methodology described by IARC. This is summarized as follows: visualization of the vagina, vulva and cervix following insertion of a speculum; assessment with the naked eye after application of normal saline; and further assessment after application of 5% acetic acid for 1 minute. This will be recorded as normal or abnormal by the assessor.
89308447|NCT03931083||Histopathological examination of tissue biopsies|All acetowhite lesions will be biopsied. When no lesion is seen, one biopsy is taken from each quadrant at the squamocolumnar junction. Biopsies will be sent and examined in a South African based lab. All histological slides will also be verified independently by an IARC trained pathologist at the end of the study. Histological endpoints are defined by the CIN classification system: CIN 1 affects only the lower third of the epithelium (mild dysplasia), CIN 2 involves two thirds of the epithelium and CIN 3 involves the full thickness (severe dysplasia and carcinoma in situ). These findings can be dichotomized by the Lower Anogenital Squamous Terminology into low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). All patients with CIN grade 2 that stained diffusely positive for p16 are considered as HSIL, all patients with CIN 3 are considered as HSIL. Expression of p16 will be visually assessed by immunohistochemistry.
89308448|NCT01224561||Constitutional thinness|Women with a a body mass index of less than 16.5 kg/m2
89308449|NCT01224561||Healthy Volonteer|Women with a body mass index between 20 and 25 kg/m2
89308450|NCT03930303|Active Comparator|Multimedia Arm|
89308451|NCT03930303|No Intervention|Control|
89308452|NCT01130727|Active Comparator|green tea extract|
89308453|NCT01130727|Active Comparator|Cocoa extract rich in polyphenols|
89308454|NCT01130727|Placebo Comparator|placebo|
89308455|NCT01130727|Placebo Comparator|cocoa extract with low polyphenol|
89308456|NCT03925545|Experimental|Unilateral|Implantation with the FluidVision AIOL in one eye during cataract surgery. Only one eye was treated.
89308457|NCT03925545|Experimental|Contralateral|Implantation with the FluidVision AIOL in the first eye during cataract surgery, followed by implantation with the AcrySof IQ monofocal IOL in the fellow eye during a subsequent cataract surgery
89308458|NCT01224717|Experimental|PTH134|
89308459|NCT01224717|Placebo Comparator|Placebo|
89308460|NCT01224717|Active Comparator|Forsteo|
89308461|NCT01229007|Experimental|Biostate|
89308462|NCT03925467|Experimental|proximal acupoints|Acupuncture needles will be administered at proximal acupoints
89308463|NCT03925467|Experimental|distal acupoints|Acupuncture needles will be administered at distal acupoints
89308464|NCT03925467|Placebo Comparator|sham acupoints|Sham acupuncture needles will be administered in the abdominal sham acupoints.
89308465|NCT03925233||HER2+ Breast Cancer|
89308466|NCT03925233||ER+ Breast Cancer|
89308467|NCT03925233||Triple Negative Breast Cancer|
89308468|NCT02963506|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
89308469|NCT02963506|Experimental|Bimekizumab Dose 1|Subjects will receive for 12 Weeks Bimekizumab Dose 1 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
89308470|NCT02963506|Experimental|Bimekizumab Dose 2|Subjects will receive for 12 Weeks Bimekizumab Dose 2 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
89308471|NCT02963506|Experimental|Bimekizumab Dose 3|Subjects will receive for 48 Weeks Bimekizumab Dose 3.
89308472|NCT02963506|Experimental|Bimekizumab Dose 4|Subjects will receive for 48 Weeks Bimekizumab Dose 4.
89308473|NCT01130805|Experimental|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
89308474|NCT03922191||Pediatric population|Infants diagnosed with cardiac post-surgery mediastinitis within the HUDERF Hospital within the last 20 years.
89308475|NCT03922191||Adult population|Adults diagnosed with cardiac post-surgery mediastinitis within the CHU Brugmann Hospital within the last 20 years.
89308476|NCT03921957|Experimental|stereotactic|
89308477|NCT03644680|Experimental|Nasal Provocation with Birch Extract|Birch allergic patient receiving 3 consecutive nasal challenges with birch extract (Allergopharma). Total dose of 1.5ug of Bet v 1 per challenge
89308478|NCT03644680|Placebo Comparator|Nasal Provocation with NaCl 0.9%|Birch allergic patient receiving 3 consecutive nasal challenges with sterile NaCl 0.9%. Total dose of 100ul per nostril per challenge
89308479|NCT03921879|Experimental|Stage 1 Dose Escalation|The dose escalation arm will use a modified 3+3 design to determine the maximum tolerated dose. or maximum tested dose.
89308480|NCT03921879|Experimental|Stage 2 Dose Expansion|The dose expansion arm will use the maximum tolerated dose to determine preliminary efficacy.
89308481|NCT01345162|Other|ketorolac|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then Ketorolac postoperative 10mg 1cp x 3/die, from the day of surgery for 4 days after surgery.
89308482|NCT01345162|Other|acetaminophene+tramadol|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then postoperative Patrol (acetaminophene 325mg+tramadol 37,5mg) 1cp x 3/die for 4 days after surgery.
89308483|NCT01131039|Experimental|Single|
89308484|NCT01229085|Experimental|Test|mometasone 0,1% + salicylic acid 5%
89308485|NCT03644602|Active Comparator|IBD patients|"All subjects with Crohn's disease in clinical remission (defined in the presence of a Crohn's Disease Activity Index, CDAI <150), and with Ulcerative colitis in clinical remission (defined in the presence of <3 evacuations / day without blood, in the absence of endoscopic alterations) received a low FODMAPs diet.~The low FODMAPs diet was administered for 3 months."
88815940|NCT03013010|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
89308486|NCT03644602|Active Comparator|Coeliac patients|Celiac patients on a gluten free diet for at least one year received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
89308487|NCT03644602|Active Comparator|IBS patients|Patients with Irritable Bowel Syndrome received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
89308488|NCT03921645|Experimental|aerosol combined group|aerosol combined intravenous antibiotics group，amikacin 15mg/kg, qd
89308489|NCT03921645|No Intervention|No intervention group|this group follow the usual treatment without any intervention
89308490|NCT03643666|Placebo Comparator|control group|this group will include 25 patients receiving intraperitoneal 40 ml of normal saline only at the end of laparoscopic cholecystectomy
89308491|NCT03643666|Active Comparator|dexamethasone group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone in 40 ml saline at the end of laparoscopic cholecystectomy
89308492|NCT03643666|Active Comparator|dexamethasone plus magnesium sulphate group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone plus 2 gm magnesium sulphate at the end of laparoscopic cholecystectomy
89308493|NCT03740061||Antwerp|
89308494|NCT03740061||Barcelona|
89308495|NCT03740061||Istanbul|
89308496|NCT03740061||Oldenburg|
89308497|NCT03740061||Krakow|
89308498|NCT03740061||Bialystok|
89308499|NCT03740061||Rome|
89308500|NCT03740061||Madrid|
89308501|NCT03740061||Leuven|
89308502|NCT03644524|Experimental|Heat Therapy|Subjects assigned to heat therapy underwent 30 1-hour hot tub sessions over 8-10 weeks (3-4 per week). The hot tub was set to 40.5 Celsius, and core temperature and heart rate were monitored throughout each session.Subjects were instructed to not make any other dietary or lifestyle changes.Cardiovascular and metabolic health assessments were made Pre (0 heat sessions), mid (after 14-16 heat sessions, ~4-5 weeks), and post (after all 30 heat sessions; ~8-10 weeks).
89308503|NCT03644524|No Intervention|Time Control|Subjects were monitored at matched timepoints (start of study, 4-5 weeks, and 8-10 weeks) but not exposed to any intervention. Subjects were instructed to not make any dietary or lifestyle changes.
89308504|NCT03930537|Active Comparator|Hip replacement with cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of cemented femoral component of hip prothesis.
89308505|NCT03930537|Active Comparator|Hip replacement with non-cemented femoral component|A special device that measure the pressure will be used to measure the change of pressure before, during and after implantation of non-cemented femoral component of hip prothesis.
89308506|NCT03643588|Experimental|HYAJOINT Plus group|The HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
89308507|NCT03643588|Active Comparator|Hyalgan group|The Hyalgan group received intraarticular injection of 2 ml Hyalgan for three continuously weeks and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
89308508|NCT03920085|Experimental|LifeScan BGMSs|OneTouch Verio, OneTouch Select Plus and OneTouch Ultra Blood Glucose Monitoring Systems (BGMSs) tested using subject capillary blood and compared to a reference instrument (YSI 2900).
89308509|NCT03641482|Active Comparator|NBF|Propolis Extract, Ascorbic Acid, Tocopherol Acetate, Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
89308510|NCT03641482|Placebo Comparator|Placebo|Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
89308511|NCT01224951|Active Comparator|Qvar 100|"Patients will be randomized to receive either the active arm (3/4) or a SABA as rescue medication (1/4). The patient will be asked to take Qvar 100 (2puffs) in the morning and in the evening.~Daily dose (400 microgram)."
89308512|NCT01224951|No Intervention|Control|Patients are allowed to use their SABA as rescue medication only. During the last 4 weeks, the patients will receive 400 microgram of Qvar.
89308513|NCT03641404|Experimental|Ergothioneine|Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
89308514|NCT03641404|Placebo Comparator|Placebo|Subjects will be given placebo (99% microcrystalline cellulose, 1% magnesium stearate; capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
89308515|NCT01131741|Experimental|Epinephrine|
89308516|NCT01131741|Placebo Comparator|Control|
89308517|NCT03644134|Experimental|Intervention Group|Assessment of physiological stress and sleep pattern intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns
89308518|NCT03644134|No Intervention|Control Group|The control protocol only includes (i) information session (ii) pre-assessment (initial assessment and (iii) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
89308519|NCT03555448|Active Comparator|Once daily regimen|Once daily medication regimen (Envarsus and azathioprine)
89308520|NCT03555448|Active Comparator|Twice daily regimen|Twice daily medication regimen (Tacrolimus and mycophenolic acid)
89308521|NCT01128309|Experimental|Stress Reduction Intervention|Stress Reduction Intervention
89308522|NCT01128309|Active Comparator|Active Control Condition|
89308523|NCT05257486||NMSC Treatment|Patients who completed Xoft eBx treatment at least five years from the last treatment.
89308524|NCT03919695|Experimental|structural and behavioral intervention|The KISOBOKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component changes the mode of work payment from cash to mobile money.
89308525|NCT03919695|Active Comparator|Screening and Referral|Brief feedback on AUDIT-C score, referral for alcohol counseling, and briefly discussion of the importance of HIV care engagement and adherence.
89308526|NCT03930225|Experimental|study group|"In the study group, both patients and their family members will be required to attend a weekly 1 hour long psycho-educational sessions. Moreover assessment sessions will be attended also.~The stigma directed intervention program"
89308527|NCT03930225|Other|control group|"In the control group, only Patients will attend the psycho-educational sessions.~Family members and patients will be required to attend the assessment sessions."
89308528|NCT03921567|Experimental|Group I|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
89308529|NCT03921567|Active Comparator|Group II|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
89308530|NCT03921567|Placebo Comparator|The control group|will be given opioids during surgery, opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
89308531|NCT01345318|Experimental|Open-label Treatment|
89308532|NCT01329315|Active Comparator|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
89308533|NCT01329315|Active Comparator|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
89308534|NCT01329315|No Intervention|DPB|Drug Prevention Booklet (DPB)- National Institute on Drug Abuse (NIDA)-developed drug prevention booklet to address preventing marijuana initiation, and marijuana use.
89308535|NCT01229865|Experimental|VB-111|antiangiogenic and vascular disruptive agent
89308536|NCT01132131|Active Comparator|Delegation form|
89308537|NCT01132131|Active Comparator|Regular doctor's consultation|
89308538|NCT02961244|No Intervention|Control Group|Perioperative management and warming was not performed according to a standard normothermia protocol, with our clinic's traditional methods except prewarming.
89308539|NCT02961244|Active Comparator|Intervention Group|Perioperative management and warming was performed according to a standard normothermia protocol with active prewarming.
89308540|NCT03771963|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously (SC), once on Day 1 (first dose) and Day 90 (second dose).
89308541|NCT03641170|Experimental|Experimental intervention|Fixed diet and physical activity.
89308542|NCT03641170|Other|Control intervention|Fixed diet and inactivity.
89308543|NCT01229241|Other|levobupivacaine|
89308544|NCT01229241|Other|ropivacaine|
89308545|NCT01132209|Active Comparator|Large tissue bites|As control the conventional large bites technique (mass closure) will be applied in with bites widths of 1 cm and inter-suture spacing of 1 cm with the use of PDS plus ll 1-0 double loop suture material with a 48 mm needle.
89308546|NCT01132209|Experimental|small tissue bites|In the other group of 288 patients the small bites technique will be applied with bite widths of 0,5 cm and inter suture spacing of 0,5 cm with the use of PDS plus ll 2-0 single suture material with a 31 mm needle placed in the linea alba. In the small bites technique, twice as many stitches will be placed per sutured cm, with a smaller needle and thinner suture material.
89308547|NCT05252884|Experimental|calcium correction according to PTH levels|A PTH blood test will be performed 4 hours post-thyroidectomy.
89308548|NCT05252884|Active Comparator|routine postoperative calcium and calcitriol|The patient will receive Calcium carbonate + calcitriol
89308549|NCT03921177|Experimental|Multiple micronutrient supplement|Daily micronutrient supplement
89308550|NCT03921177|Placebo Comparator|Placebo|Daily identifcal placebo tablet
89308551|NCT01229319|Experimental|cryo + imiquimod to Left|Cryotherapy alone to Right arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Left arm
89308552|NCT01229319|Experimental|Cryo + imiquimod to Right|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
89308553|NCT03643120|Other|Development of diagnostic typology|One main goal is to Development a typology of sub-types of gender dysphoria.
89308554|NCT03642886|No Intervention|Continued Strenuous Exercise|Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period
89308555|NCT03642886|Experimental|Prescribed Detraining|"Detraining period of 8-weeks which is defined as:~a 75% decrease in the amount of exercise (from baseline)~a 50% decrease in the intensity of exercise as measured in METS (from baseline)~Mitchell Classification classes 1A, 2A, 2B of activity are permitted"
89308556|NCT01225107|Placebo Comparator|Inert Placebo Capsule|
89308557|NCT01225107|Experimental|Cranberry Extract|
89308558|NCT01225185||Patients undergoing shoulder surgery|"This observational study will compare cerebral blood flow autoregulation in patients undergoing surgery in either the supine lateral position or the semi-recumbent or beach chair position. The choice of patient positioning is not randomized but based on usual surgical considerations."
89308559|NCT03644056|Experimental|IMC-001|Multiple Dose Level (IMC-001 2 mg/kg etc. every 2 weeks)
89308560|NCT01132287|Experimental|1 FID 112903|FID 112903
89308561|NCT01132287|No Intervention|No Intervention|
89308562|NCT03641014|Experimental|Sequential pH culture (7.23 then 7.35)|A split embryo at day 3 to continue culture at a pHe of 7.23±0.02 or to be cultured at a pH of 7.35±0.02 and monitor the effect on blastocyst development.
89308563|NCT03641014|No Intervention|Continuously pH culture at 7.23|Embryo culture from day 0 to 5 or 6 at 7.23
89308564|NCT03921099|No Intervention|Vancomycin only|Vancomycin 15-20mg/kg intravenous every 8-12 hours.
89308565|NCT03921099|Experimental|Vancomycin +Ascorbic acid|Vancomycin 15-20mg/kg intravenous every 8-12 hours. Ascorbic acid 1gm every 12 hours orally just before vancomycin by half an hour for seven days.
89308566|NCT03920943|Other|Core and TAT measurements|As part of the standard of care, flight paramedics will insert an esophageal or rectal temperature probe in patients meeting including criteria to enable continuous temperature monitoring. Paramedics will measure core temperature on at least two occasions, the first measurements made at least 5 minutes after insertion of the temperature probe, and also prior to departure from the sending facility.
89308567|NCT01132365||knee arthroplasty|
89308568|NCT02962648|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
89308569|NCT01229475|Active Comparator|Stepwise approach|Stepwise approach for repeat AF ablation
89308570|NCT01229475|Active Comparator|Linear ablation|Linear ablation for repeat procedure in patients with recurrent atrial fibrillation
89308571|NCT03920631|Experimental|Cohort 1: Microtransplantation (MST)|MST:Infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
89308572|NCT03920631|Experimental|Cohort 2/2b: MST + Nivolumab|"2: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day+14)~2b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day+14)."
89308573|NCT03920631|Experimental|Cohort 3/3b: MST + Nivolumab|"3: Microtransplantation (Day 0) + nivolumab (3 mg/kg) every 2 weeks (beginning on Day-1).~3b: Microtransplantation (Day 0) + nivolumab (1 mg/kg) every 2 weeks (beginning on Day-1)."
89308574|NCT03920631|Experimental|Cohort 4: Expansion|Microtransplantation (Day 0) + nivolumab (at RP2D)
89308575|NCT03642730|Experimental|Scanned patients|Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
89308576|NCT03642730|Experimental|Non-expert scanning volunteers|Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
89308577|NCT02528955|Active Comparator|A:De-Intensification Radiotherapy (RT) primary tumor region|"A:De-Intensification Radiotherapy (RT) primary tumor region~≤ pT2, R ≥ 5 mm, L0, Pn0~> 3 lymph node metastasis or patients with < 3 ipsilateral lymph node metastasis and a bilateral primary tumor without adequate contralateral neck dissection"
89308578|NCT02528955|Active Comparator|B:De-Intensification Radiotherapy contralateral lymph nodes|"> pT2 and/or R < 5mm and/or L1 and/or Pn1~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
89308579|NCT02528955|Active Comparator|C:De-Intensification RT primary tumor region /contralateral LN|"≤ pT2, R ≥ 5 mm, L0, Pn0~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
89308580|NCT02962882|Experimental|A. Mepilex Border Sacrum (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the sacrum area at pressure points in patients in the ICU, prone to get pressure injuries (PI).
89308581|NCT02962882|Experimental|B. Mepilex Border Heel (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the heels (on both left and right heels), in patients in the ICU, prone to get pressure injuries (PI).
89308582|NCT03930069|Active Comparator|misoprostol group|20 cases received 400 microgram prostaglandin E1 analogue, misoprostol, (Misotac®, 200 microgram, by SIGMA pharmaceutical industries, Alexandria, Egypt), intra-vaginally, 2 hr before operation.
89308583|NCT03930069|Active Comparator|vasopressin group|20 patients who had hysteroscopic guided intralesional vasopressin injection before hysteroscopic myomectomy
89308584|NCT03642652|Experimental|SMS|"Each patient in the intervention group also received an automated text message up to a week after the positive FOBT result. The text read: Hello. There is a lab test result ready for you. Contact your physician for an explanation of the findings. Two additional automated text message reminders were sent to the patient at 2 weeks and 1 month reading, Hello, This is a reminder. It is essential that you contact your physician if you have not already done so."
89308585|NCT03642652|No Intervention|Control|Routine care
89308586|NCT01132443|Experimental|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily; clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)
89308587|NCT01132443|Active Comparator|Duac/ formulation 1|Apply topically once daily, Topical Gel (CLN 1%-BPO 5%), methylparaben-preserved
89308588|NCT01132443|Active Comparator|Duac/ formulation 2|Apply topically once daily, Duac Once Daily Gel (CLN 1%-BPO 5%), MPF
89308589|NCT01132521|Experimental|ulinastatin group|Regular treatments plus ulinastatin. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
89308590|NCT01132521|Placebo Comparator|placebo group|Regular treatment plus placebo. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
89308591|NCT03643978|Experimental|Decision Aid Group|These patients review a decision aid.
89308592|NCT03643978|No Intervention|Control Group|These patients do not review a decision aid.
89308593|NCT01131819|Other|1|The novel intervention we propose to use, the Wii Fit, will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects in the study.
89308594|NCT03929835|Experimental|Avidekel Oil|The cannabis oil, sort T1/C20 CBD as categorized by the MOH guidelines will be made from Avidekel strain and olive oil extract. Avidekel oil contains Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
89308595|NCT03929835|Placebo Comparator|Placebo|Patients in the control group will receive placebo oil containing olive oil and Chlorophyll.
89308596|NCT01132677|Active Comparator|Hyaluronic Acid (HA) Injection|Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's). All injections will be administered as outlined on the company label. Aspiration of the knee will not be performed.
89308597|NCT01132677|Active Comparator|Corticosteroid Injection|Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.
89308598|NCT02961790|Experimental|Group I (low-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.
89308599|NCT02961790|Placebo Comparator|Group II (low-dose placebo)|Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.
89308600|NCT02961790|Experimental|Group III (high-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.
89308601|NCT02961790|Placebo Comparator|Group IV (high-dose placebo)|Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.
89308602|NCT01225341|Experimental|onabotulinumtoxinA/placebo|Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.
88820785|NCT05651022|Experimental|Cohort 2|A single dose of Decoy20 at a dose of 20 x 10^7 KB
89308603|NCT01225341|Placebo Comparator|Bacteriostatic normal saline/ onabotulnimtoxinA|Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.
89308604|NCT03929991||Case|"All women admitted or already hospitalized with suspected or confirmed infection after C/S will be screened for inclusion in the study as a case. Case confirmation will be clinically established by an infectious disease expert.SSI post C/S will be classified as:~Superficial incisional surgical site infection,~Deep incisional surgical site infection,~Organ/space surgical site infection."
89308605|NCT03929991||Control|For each case, 3 patients undergoing the C/S on the same day and admitted to the same ward but not presenting Surgical Site Infection
89308606|NCT03920787|Experimental|Inositol|Administration of Inofolic Combi (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg - Lo.Li Pharma S.r.l.) 2 capsules every day for 1 month
89308607|NCT03920787|Placebo Comparator|Placebo|Administration of placebo. 2 capsules every day for 1 month
89308608|NCT03642496|Experimental|The low dose group|
89308609|NCT03642496|Experimental|The middle dose group|
89308610|NCT03642496|Experimental|The high dose group|
89523396|NCT03380975|Experimental|Montelukast 10 mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis.
89523397|NCT01913587|Experimental|Acupuncture & Nerve block|Acupuncture will be performed 3 times per week, total 9 sessions, during 3 weeks. Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
89308611|NCT03920553|Experimental|Test Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it. No bleeding was observed after the frenectomy performed with laser. Then, commercially available Hiyaluronic acid was topically applied to the relevant area to completely cover the surgical field to the test group. Following the frenectomy performed with laser, no application was made to the control group patients.
89308612|NCT03920553|No Intervention|Control Group|Preoperatively all patients gargled for 1 min with 0.2% chlorhexidine mouthwash. Local anaesthesia was applied to the area where the surgical procedure was to be applied. Then the frenectomy operation was performed with a continuous 970nm wavelength of the diode laser at power setting of 1,5W for approximately 60 seconds from the base to the apex of the frenum, thereby excising it.
89308613|NCT03643900|Experimental|indomethacin with stenting group|Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients
89308614|NCT03643900|Active Comparator|indomethacin group|Rectal indomethacin 100mg at preoperative 30min in 100 patients
89308615|NCT01229553|Experimental|Decolonization group|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
89308616|NCT03919383|Experimental|Lenvatinib Plus Toripalimab|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 21-day treatment cycles, and received 240mg toripalimab intravenously every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89308617|NCT01131897|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
89308618|NCT01131897|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
89308619|NCT01229631|Placebo Comparator|Supplementation with non-active|Subjects will be supplemented with placebo capsules (3 capsules am & 3 capsules pm)
89308620|NCT01229631|Active Comparator|Dietary supplementation with Juice plus+|Subjects will be supplemented with Juice plus+ capsules (3 capsules am & 3 capsules pm)
89308621|NCT03929445|Active Comparator|AIR-Q group|the group which selected randomly to try AIR-Q device
89308622|NCT03929445|Active Comparator|I-LMA group|the group which selected randomly to try I-LMA device
89308623|NCT03919461|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows. Etodolac:400mg PO bid for the entire intervention period, Propranolol (slow release): 20 mg PO b.i.d. for 5 preoperative days; 80 mg PO b.i.d. on the day of surgery; 40 mg PO b.i.d. for the first post-operative week and 20 mg PO b.i.d. for the second post-operative week.
89308624|NCT03919461|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
89308625|NCT03919227|Experimental|Group 1: empty bladder|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS.
89308626|NCT03919227|Active Comparator|Group 2: natural state of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS.
89308627|NCT02528877|Experimental|Supportive care (ruxolitinib phosphate, tacrolimus, sirolimus)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV over 20 minutes on day -4. Beginning greater than 48 hours after completion of melphalan, patients undergo peripheral blood stem cell or bone marrow transplant according to standard guidelines on day 0.~GVHD PROPHYLAXIS: Patients receive ruxolitinib phosphate PO BID on days -3 to 30 tapered to day 60, tacrolimus IV continuously or PO BID on days -3 to 100 , and sirolimus PO QD on day -3 to 100. Treatment continues in the absence of disease progression or unacceptable toxicity."
89308628|NCT03918993||Group T|31 Patients with ED who receiving 5 mg/day of Tadalafil for 8 weeks.
89308629|NCT03918993||Group C|Thirty-one healthy men who were admitted to the internal medicine outpatient clinic for their annual follow-up
89308630|NCT03929055|Active Comparator|venturi mask|oxygen is delivered by venturi mask to achieve peripheral oxygen saturation of al least 92%
89308631|NCT03929055|Active Comparator|HFNC|HFNC is set to obtain the same oxygen fraction of venturi mask and flow of 40l/min
89308632|NCT03929055|Active Comparator|CPAP|Helmet CPAP is set to obtain the same esophageal pressure variation during HFNC step
89308633|NCT01225497|Active Comparator|Standard eccentric exercise|Participants randomised to this group shall complete 180 repetitions a day of Alfredsons heel drop protocol. This has been accepted as standard management for mid-portion Achilles pain in the first instance.
89308634|NCT01225497|Experimental|Eccentric exercise as able|Participants randomised to this group shall carry out exactly the same eccentric exercises as per Alfredsons heel drop protocol. However, these individuals will be instructed to do what they can.
89308635|NCT03920475||TAU (treatment as usual) group|Patients with depression, meeting inclusion criteria, who needed antidepressant treatment and received either sertraline or venlafaxine.
89308636|NCT01229709|Experimental|Mindfulness Based Tinnitus Reduction|
89308637|NCT01229709|No Intervention|Tinnitus Counseling Only Control|Control group subjects will have had treatment as usual (TAU) care from the UCSF Audiology Clinic which includes Tinnitus Counseling (TC) at least three-months prior to enty into the study.
88815941|NCT01100762|Experimental|Single Group|10 subjects with Parkinson's Disease receiving tPCS during the first session, treadmill walk, 7-10 days later (second session, and combined tPCS and treadmill 7-10 days week later (third session)
89308638|NCT03920319|Experimental|Bupropion|Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
89308639|NCT03920319|Placebo Comparator|Placebo|Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.
89308640|NCT03920397|Experimental|Adipose tissue-derived stem/stromal cells|Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.
89308641|NCT03920397|Experimental|Daily 2000 UI of daily oral cholecalciferol|To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes.
89308642|NCT01131975|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
89308643|NCT01131975|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
89308644|NCT03918681|Experimental|Intervention Group|The experimental group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups experimental group participants will receive gait retraining cues to transition to a NRFS running pattern.
89308645|NCT03918681|No Intervention|Control Group|The control group participants (approximately 20 participants) will receive, a standard graduated return-to-run program, a 4-week lower-extremity exercise program, and an activity log to track exercise progress. Participants will be instructed to follow-up with their research physical therapist once a week for the first 4 weeks and then every other week until the run progression is completed. During follow-ups control group participants will not receive any gait retraining cues and will only be instructed on standard of care return to run metrics to include volume, load, and duration of running.
89308646|NCT01231737|Active Comparator|Prulifloxacin|
89308647|NCT01134237|Active Comparator|Urokinase|arm of interest
89308648|NCT01134237|Placebo Comparator|Control|Normal saline as a placebo for control arm
89308649|NCT02528565||Patients with failed RYGB (EWL <50%)|
89308650|NCT01128699|Experimental|ISA+AVI|injection of intraoperative subconjunctival Avastin as an adjunct to Ahmed valve implant
89308651|NCT01128699|Active Comparator|AVI|Ahmed valve implant
89308652|NCT01230099|Experimental|Supportive Information Team Group|Protocolized information and support meetings led by palliative care clinicians
89308653|NCT01230099|No Intervention|Usual Care Group|
89308654|NCT01231815|Experimental|PET|15O-H2O PET
89308655|NCT01231815|Experimental|MRI|MRI
89308656|NCT03918291|Experimental|Addition of whole-body vibration to squat training|The addition of whole-body vibration to squat training (for 12 weeks, 3x/week). The mechanical stimulation parameters of the vibration consisted of the following: frequency of 35 to 40 Hz, amplitude of 4 mm and acceleration that ranged from 2.78 to 3.26 G
89308657|NCT03918291|Other|Squat training|Squatting exercises for 12 weeks, 3x/week
89308658|NCT01329627|Experimental|Paclitaxel/doxorubicin/cyclophosphamide|
89308659|NCT03929211|Experimental|CPI-613 and hydroxychloroquine|The initial phase of the study will be a dose escalation of hydroxychloroquine from 600 mg to 1,200 mg orally flat dose given 2 hours before the CPI-613 infusion on days 1-5 of every 28 days. CPI-dose will be 2,000 mg/m² and will not be escalated.
89308660|NCT01128777|Experimental|Cognitive behavioral group therapy|Cognitive behavioral group therapy for adolescents and a parallel group for parents
89308661|NCT01128777|Active Comparator|Nondirective supportive group therapy|Nondirective supportive group therapy for adolescents and a parallel group for parents
89308662|NCT01128855|Experimental|Cohort 1|3 mg/kg GSK2402968 / placebo
89308663|NCT01128855|Experimental|Cohort 2|6 mg/kg GSK2402968 / placebo
89308664|NCT01128855|Experimental|Cohort 3|9 mg/kg GSK2402968 / placebo
89308665|NCT01128855|Experimental|Cohort 4|12 mg/kg GSK2402968 / placebo
89308666|NCT03928899|No Intervention|old guideline group|"Women randomized to the old guideline group will be followed up once-weekly by electronic fetal heart rate monitoring and biophysical profile until 40 weeks 0 days (unless a medical indication arises), when induction of labor was then offered."
89308667|NCT03928899|Experimental|new procedure group|"Women randomized to new procedure group will first undergo fetal weight ultrasound estimation at 38 weeks 0 days to 38 weeks 6 days of gestation, if the fetus is estimated to be LGA/macrosomia by ultrasound, women should have an elective induction of labor immediately (at 38 weeks 0 days to 38 weeks 6 days of gestation). On the contrary, if the fetus is estimated to be normal size, the pregnant women were then given a cervical assessment. If the Bishop score ≥6, women will have at least weekly follow-up visits with their doctors and unless a medical indication is present, continue pregnancy and have selective induction at 40 weeks 0 days of gestation. Whereas, if the Bishop score <6, women will be followed up until 41 weeks 0 days of gestation with a close assessment of fetal wellbeing through the cardiotocographic trace. And women who will not deliver by this gestational age will be admitted for labor induction. Certainly, medical indication should warrant delivery without delay."
89308668|NCT01231893|Experimental|olfactory ensheathing cell recipient|
89308669|NCT01231893|Active Comparator|control|
89308670|NCT01230255|Experimental|Percutaneous catheter decompression|Ultrasound guided percutaneous catheter drainage of free intra-peritoneal fluid or blood
89308671|NCT01230255|Active Comparator|Open abdominal decompression|Surgical treatment of elevated intra-abdominal pressure through traditional open abdominal decompression
89308672|NCT01232049|Experimental|A|Pitavastatin 4mg
89308673|NCT01232049|Experimental|B|Valsartan 320mg
89308674|NCT01232049|Experimental|C|Pitavastatin 4mg + Valsartan 320mg
89308675|NCT05402085|Experimental|High Protein Diet|Diet consisting of 40% carbohydrate, 40% protein, 20% fat, with Glycemic Index ~55-65.
89308676|NCT05402085|Experimental|High Fat Diet|Diet consisting of 40% carbohydrate, 40% fat (25% monounsaturated fatty acids), 20% protein, with Glycemic Index ~55-65.
89308677|NCT05402085|Experimental|High Carbohydrate-Low Glycemic Index Diet|Diet consisting of 60% carbohydrate, 20% fat, 20% protein, with Glycemic Index ~45-50.
89308678|NCT05402085|Placebo Comparator|High Carbohydrate-High Glycemic Index Diet|Diet consisting of 60% carbohydrate, 20% fat, 20% protein.
89308679|NCT01225575|Active Comparator|co.don chondrosphere®, 3-7 spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect"
89308680|NCT01225575|Active Comparator|co.don chondrosphere®,10-30spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group B is 10-30 spheroids/cm2 defect"
88820786|NCT05651022|Experimental|Cohort 3|A single dose of Decoy20 at a dose of 70 x 10^7 KB
89308681|NCT01225575|Active Comparator|co.don chondrosphere®,40-70spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group C is 40-70 Spheroids/cm2 defect"
89308682|NCT03928977|Other|Confirmed TIA|Confirmed TIA at 3 months with standardized neurological expertise
89308683|NCT03928977|Other|Confirmed non-TIA|Not-confirmed TIA at 3 months with standardized neurological expertise
89308684|NCT03917979|Experimental|Individual GIM|Participants are provided with a series of individual GIM sessions.
89308685|NCT03917979|Other|Waitlist Control|Participants complete an initial wait list period, then are provided with a series of Group GIM sessions.
89308686|NCT01225653|Experimental|Latanoprost|Topical treatment with latanoprost
89308687|NCT01225653|Placebo Comparator|Placebo|Placebo arm
89308688|NCT01134471|No Intervention|Control|
89308689|NCT01134471|Active Comparator|Bonewax|Patients treated with the hemostatic bonewax
89308690|NCT01134471|Active Comparator|Ostene|Patients treated with the hemostatic Ostene
89308691|NCT01133145|Experimental|vascularized transplantation|allogeneic vascularized knee transplantation
89308692|NCT05401773|Experimental|COVID-19 patients with olfactory dysfunction|
89308693|NCT05401773|Experimental|COVID-19 patients without olfactory dysfunction|
89308694|NCT05401773|Experimental|Healthy controls|
89308695|NCT05401773|Experimental|Patients with Parkinson's disease|
89308696|NCT01134861|Active Comparator|Arm 1: Sequential ChemoRT|Vinblastine 6 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 50
89308697|NCT01134861|Experimental|Arm 2: Concurrent STD RT|Vinblastine 5 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 GY/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1
89308698|NCT01134861|Experimental|Arm 3: Concurrent HFX RT|Oral VP-16 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40 (76 mg/day if BSA < 1.7m2) Cisplatin 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36 RT: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1
89308699|NCT01128933|Experimental|Hypertensive patients|Hypertensive patients with at least moderate renal artery stenosis
89308700|NCT01133223|Active Comparator|Thrombectomy|
89308701|NCT01133223|Active Comparator|Usual Care|
89308702|NCT01137513||Chest Pain|Acute Myocardial ischemia
89308703|NCT05401695|No Intervention|The historical control group|The historical control group was composed of patients treated septic shock between May 2019 and May 2021. They was received routine treatment for septic shock including intravenous fluid resuscitation, antibiotics, removal of source of infection and inotropic drugs within 6 hours after the diagnosis of sepsis.
89308704|NCT05401695|Active Comparator|The HA-treated group|The HA-treated group will be enrolled between July 2021 and May 2022. This group included children with sepsis, who were admitted to our PICU during the study period. All children initially received routine treatment for septic shock as the historical control group. An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in this intervention group.
89308705|NCT05401617|No Intervention|control group|patient benefiting from a traditional anesthesia consultation as performed daily in the department (control group). The information will be delivered according to local customs and the MAR: oral, which can be supplemented by the delivery of the SPARADRAP booklet and the written documents usually delivered
89308706|NCT05401617|Experimental|experimental group|patient benefiting, in addition to this traditional anesthesia consultation, from additional information via the computerized tool. The operation of this tool will be explained by paramedical staff and its access will be free as soon as you leave the consultation.
89308707|NCT01233219||Group A|Homozygous patients for the more frequent allele of the polymorphism A118G of OPRM1 gene
89308708|NCT01233219||Group B|Both homozygous and heterozygous patients for the less frequent allele of the polymorphism A118G of OPRM1 gene
89308709|NCT02960854|Experimental|Nivolumab 1|Dose 1
89308710|NCT02960854|Experimental|Nivolumab 2|Dose 2
89308711|NCT01133301|Active Comparator|Naltrexone-Placebo|In the first three weeks of the study, 50 mg Naltrexone will be administrated, the following three three weeks placebo will be administrated.
89308712|NCT01133301|Placebo Comparator|Placebo-Naltrexone|The first three weeks, placebo will be administrated, the following three weeks 50 mg Naltrexone will be administrated.
89308713|NCT05401539|Experimental|Group 1: VR- Operating Theater Tour Group|The 7-minute operating theatre tour, which describes the preparation process for the surgery, covers the following process: 6-12-year-old children's leaving their room, entering the operating theatre, and meeting the surgery team after they are taken to the operating theatre. The tour ends in the postoperative recovery unit. The actual operating theatre tour also will include information about how and when the child would wear the surgical gown, and how he or she would go to the operating theatre. In order to shoot the operating theatre tour scenes in the most appropriate way, all the procedures to be applied to the children to be operated will observe by the researcher in the pre-, intra- and post-operative periods. The scenario created for the scene shots will reviewe by experts in the field of filming and the final version will decide. The children who will have surgery will watch the real operating theatre tour with the cardboard VR headset.
89308714|NCT05401539|Experimental|Group 2: VR- Documentary Film Group|The children in this group will watch the 5-minute musical documentary film featuring farm animals suitable for their age group with a cardboard VR headset. This group will form as a parallel group to determine whether the VR-Operating theatre Tour or the VR- Documentary Film is more effective.
89308715|NCT03918135|Experimental|Paracetamol|Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 100 patients
89308716|NCT03918135|Experimental|İbuprofen|İbuprofen 400mg of ibuprofen (intrafen 400mg/4ml solution Gen ilaç sanayi,Turkey ) intravenous (IV) was given 100 patients
89308717|NCT05226988|Experimental|Hybrid-RT|hybrid robot-assisted training
89308718|NCT05226988|Experimental|Exo-RT|exoskeleton robot-assisted training
88815942|NCT02462967|Active Comparator|2 mg/kg GR MD 02|GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
89308719|NCT05226988|Experimental|EE-RT|end-effector robot-assisted training
89308720|NCT05226988|Active Comparator|conventional training groups|
89308721|NCT01135173|Active Comparator|Arm A|Motivational and educational intervention, delivered by a trained physician from the SCTS plus written self-help materials.
89308722|NCT01135173|Experimental|Arm B|"Behavioral counseling intervention conducted by a trained physician at the SCTS cessation clinic. Subjects complete homework before the session to facilitate this process. Subjects are asked to identify high-risk situations and difficulties in previous cessation attempts and are walked through a series of suggestions in the event of a slip. Three brief (approximately 10 minute) phone calls are provided to subjects during the 90 day follow-up period. These calls are used to identify early relapse, encourage participants, and provide support. In addition, they are used to review materials and information provided during the sessions."
89308723|NCT01135251|Experimental|dimiracetam|Capsules containing 400 mg of dimiracetam will be administered orally, twice a day for 8 weeks in ascending schedule, contingent on tolerability of the previous dose, as follows: 1 capsule for two weeks (800mg/day), two capsules for the next two weeks (1600mg/day)and 4 capsules for the final 4 weeks (3200mg/day).
89308724|NCT01135251|Placebo Comparator|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day with the same modalities used for the dimiracetam arm: one capsule for 2 weeks, 2 capsules for another 2 weeks and 4 capsules for 4 weeks
89308725|NCT05480475|Experimental|Study treatment (Period 1, 2, and 3)|Period 1: Treatment A1 - dabigatran etexilate; Treatment A2 - rosuvastatin Period 2: Treatment B - daridorexant Period 3: Treatment C1 - dabigatran etexilate and daridorexant; Treatment C2 - rosuvastatin and daridorexant
89308726|NCT03642184|Active Comparator|Empagliflozin|Jardiance 10mg/25mg Film-coated tablets， once daily
89308727|NCT03642184|Active Comparator|Linagliptin|Trajenta 5mg Film-coated tablets， once daily
89308728|NCT01137591|Experimental|APAP and NAC combination|N-acetyl-p-aminophenol and placebo (APAP-NAC) combination pill
89308729|NCT01137591|Placebo Comparator|APAP and Placebo combination|N-acetyl-p-aminophenol and placebo (APAP-placebo) combination pill
89308730|NCT03640936||Healthy|Healthy controls, without asthma or allergy (negative prick test)
89308731|NCT03640936||Allergic asthma|Patients with allergic asthma sensitized to Dermatophagoides pteronyssinus, tested by prick test or specific IgE
89308732|NCT03640936||Non-allergic asthma|Patients with asthma not sensitized to Dermatophagoides pteronyssinus, with negative prick test or specific IgE
89308733|NCT01133457|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
89308734|NCT01133457|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
89308735|NCT01137669|Placebo Comparator|Placebo|10 subjects to receive placebo subcutaneously.
89308736|NCT01137669|Experimental|ZOSTAVAX®|30 subjects to receive 0.65 mL ZOSTAVAX® subcutaneously.
89308737|NCT01344538|Experimental|Ginger Root Extract|
89308738|NCT01344538|Placebo Comparator|Lactose Capsule|
89308739|NCT01135407||group #1|Parkinson's disease patients at a disease's stage characterized by motor complications
89308740|NCT01135407||group #2|Parkinson's disease patients treated by subthalamic nucleus deep brain stimulation.
89308741|NCT01135407||group #3|healthy controls
89308742|NCT01135485||Study group I|Study group I will include children who have undergone stage I palliation employing allograft material for left ventricular outflow tract reconstruction at CHOP during infancy (<1 year of age). Stage I palliation is defined as an operation in which augmentation of the native ascending aorta and aortic arch is performed to bypass atresia or critical obstruction of the left heart structures.
89308743|NCT01135485||Study Group II|Study group II who have undergone stage II palliation in which allograft material is used, but have not undergone antecedent stage I palliation. Stage II palliation is defined as a superior cavopulmonary anastomosis in which the superior vena cava is anastomosed to the ipsilateral pulmonary artery via either the bidirectional Glenn or hemi-Fontan procedures.
89308744|NCT01135485||Control Group|The control group who have undergone palliative or corrective surgery for congenital heart disease during infancy (<1 year of age) not requiring allograft material.
89308745|NCT01344460|Experimental|Arm 1|
89308746|NCT01230645|Experimental|RV568 treatment group|
89308747|NCT01230645|Placebo Comparator|Placebo treatment group|
89308748|NCT01135563|Experimental|Vinblastine and Sirolimus|The standard 3+3 Phase 1 trial design will be used for the conduct of this study. Three to six patients can be concurrently enrolled onto a dose level. Accrual is suspended when a cohort of three has been enrolled until toxicity data for that cohort have been reported, or when the study endpoints have been met.
89308749|NCT05401383||Group A|fasting from solids (6 hours before) and clear fluids (2 hours before the exam)
89308750|NCT05401383||Group B|Lumevis intake (50 ml), 30 minutes before the exam plus fasting as group A
89308751|NCT05401305|Experimental|Hib vaccine|"Volunteers will be vaccinated with Vaccine for the prevention of infections caused by Haemophilus influenza type b once intramuscularly at a dose of 0.5 mL.~Stage I: 5 volunteers Stage II: 25 volunteers"
89308752|NCT05401305|Placebo Comparator|Placebo|Volunteers will receive a placebo once intramuscularly at a dose of 0.5 mL. Stage I: 5 volunteers Stage II: 25 volunteers
89308753|NCT03641950|Experimental|Botulinum Toxin Type A (Botulax)|Botulinum Toxin Type A (Botulax)
89308754|NCT03764631||subjects with Type 2 Diabetes mellitus|
89308755|NCT03641872||Acute-on-Chronic Liver Disease|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients and non-alcoholic fatty liver disease patients.~ALI(acute liver injury): including [ALT > 3 ULN(upper limited of normal),AST > 3 ULN or TB > 2 ULN within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding and/or jaundice(TB > 5 ULN) within 1 month before enrollment)].~Standary therapy for chronic liver disease with ATI and/or AD"
89308756|NCT03641794|Experimental|DN1406131|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
89308757|NCT03641794|Placebo Comparator|Placebo|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
88815943|NCT02462967|Active Comparator|8 mg/kg GR MD 02|GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
89308758|NCT01133535||Pancreatitis, acute, recurrent|Patients with acute recurrent pancreatitis where the cause is unknown
89308759|NCT03641638||Low level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 34-102 IU/ml.
89308760|NCT03641638||Medium level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 103-204 IU/ml.
89308761|NCT03641638||High level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb >205IU/ml.
89308762|NCT03641638||Control group|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of negative Thyroid antibody, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L.
89308763|NCT01137747|Experimental|Dose Level 0 (starting dose)|"Carfilzomib - 20 mg/m2 days 1 and 2, 27 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 36 mg/m2 for all subsequent doses. If DLT occurs while receiving 36 mg/m2, the dose may be reduced to 27 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
89308764|NCT01137747|Experimental|Dose Level +1|"Carfilzomib - 20 mg/m2 days 1 and 2, 36 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 45 mg/m2 for all subsequent doses. If DLT occurs while receiving 45 mg/m2, the dose may be reduced to 36 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
89308765|NCT01137747|Experimental|Dose Level +2|"Carfilzomib - 20 mg/m2 days 1 and 2, 45 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 56 mg/m2 for all subsequent doses. If DLT occurs while receiving 56 mg/m2, the dose may be reduced to 45 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
89308766|NCT03640780||cataract extraction (CE)|Patients received CE without IOL implantation in the first surgical stage, and received IOL implantation at secondary surgical stage.
89308767|NCT03640780||cataract extraction and IOL implantation|Patients received CE and IOL implantation in the first surgical stage.
89308768|NCT01135641|Experimental|Rituximab, ciclosporine and corticosteroids|As soon as the diagnosis of chronic GVHD requiring systemic immunosuppressive therapy is confirmed, patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.Rituximab should be administered within 14 days of starting prednisone. Follow-up dates for response assessment and laboratory tests relate to the date of Rituximab infusion.Patients having a partial response after the 1st cycle of Rituximab will be eligible to receive a second cycle of 4 infusions during 4 weeks. A delay of 8 weeks (from the first infusion of Rituximab) will be observed between the two cycles of Rituximab therapy.Patients who relapse after an initial treatment with one cycle of 4 infusions of Rituximab will be eligible to receive a second cycle of Rituximab therapy.
89308769|NCT03640156|Experimental|Oxytocin (OXT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).
89308770|NCT03640156|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
89308771|NCT01230723|Active Comparator|Arm 1|Everolimus-Eluting Stent
89308772|NCT01230723|Active Comparator|Arm 2|Zotarolimus-Eluting-Stent
89308773|NCT03640702||Prolonged second stage of labor|Women with prolonged second stage of labor as specified before.
89308774|NCT03917901|Experimental|Anxiety Sensitivity Training|The Anxiety Sensitivity training (AST) will provide: (1) psychoeducation on anxiety sensitivity and its consequences, (2) psychoeducation on the relationship between anxiety sensitivity and obesity-related health behavior correlates, and (3) concrete, evidenced-based strategies to reduce anxiety sensitivity.
89308775|NCT03917901|Placebo Comparator|Health Control|The Health Control (HC) will cover general health care, such as information on wearing sunscreen and regular attendance to doctor appointments. The HC will not provide any recommendations or education on mood, dietary, or physical habits.
89308776|NCT03640078|Experimental|experimental group|Vasculitis patients The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis of serum. (acquisition imaging)
89308777|NCT03917277|Experimental|Musculoskeletal ultrasound of the ankle|"see Intervention description"
89308778|NCT05116072|Experimental|Experimental group|Patients benefited from total pancreatectomy for resectable adenocarcinoma of the cephalic region at high risk of postoperative pancreatic fistula, with intaportal/intramuscular islet autotransplantation
89308779|NCT01135797||Patients from phase I-II studies|
89308780|NCT01135875||GBM Patients|GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.
89308781|NCT01135875||Normal Controls|Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.
89308782|NCT01135953|Experimental|ARM 1 - CONTROL|Subject given tDCS every day of the week (5 sessions) at 2 mA.
89308783|NCT01135953|Experimental|Arm 2 - INCREASING|Subjects given increasing intensity during tDCS across the week (Monday 1mA, Tuesday 1.5mA, Wednesday 1.5 mA, Thursday 2 mA, Friday 2mA).
88815944|NCT02462967|Placebo Comparator|Placebo|Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions
88815945|NCT03013166||Cohort 1|IR hydrocortisone
88815946|NCT03013166||Cohort 2|IR prednisolone
89308784|NCT01135953|Experimental|ARM 3 - CYCLOSERINE|D-cycloserine (100 mg) given on the Monday and Thursday sessions, administering tDCS at 2 mA.
89308785|NCT01136031|Experimental|Paclitaxel and irinotecan|
89308786|NCT01137903|Other|Patients undergoing medical treatment|"Antibiotic treatment within 90 days with:~Ciprofloxacin Amoxicillin /Clavulanic acid. Trimethoprim /Sulfamethoxazole."
89308787|NCT01137903|Other|Patients undergoing surgical treatment|Conservative surgical Minor amputation 7 days antibiotic after surgical
89308788|NCT03739671|Placebo Comparator|Non-vitamin D supplementation|Group not receiving vitamin D supplementation
89308789|NCT03739671|Experimental|Vitamin D supplementation|Group receiving vitamin D supplementation
89308790|NCT01233453|Active Comparator|the everolimus eluting ® stent|the everolimus eluting XIENCE-V®, XIENCE-Prime® or PROMUS® stent
89308791|NCT01233453|Active Comparator|Biolimus A9 stent|the Biolimus A9 eluting NOBORI® stent
89308792|NCT01133613|Experimental|Cohort 1|0.03 mg/ml BMP-7 or placebo via intraarticular knee injection
89308793|NCT01133613|Experimental|Cohort 2|0.1 mg/ml BMP-7 or placebo via intraarticular knee injection
89308794|NCT01133613|Experimental|Cohort 3|0.3 mg/ml BMP-7 or placebo via intraarticular knee injection
89308795|NCT01133691||healthy children aged 6 - 12 years|
89308796|NCT03917121|Experimental|Jet anesthesia|Local infiltration anesthesia delivered using Madajet XL® (MADA Medical Products, Inc., Carlstadt, NJ, USA) needle-free jet injector
89308797|NCT03917121|Active Comparator|Conventional infiltration anesthesia|Local infiltration anesthesia delivered using 25 gauged short needle attached, 1.8 ml carpule loaded standard metal dental syringe
89308798|NCT01232361||Methylphenidate|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
89308799|NCT01232361||Amphetamine / dextroamphetamine|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
89308800|NCT01133769||Surgical vs Non surgical|This is an open, prospective, randomized, dual arm, parallel group clinical study of open reduction and internal fixation (ORIF) or intramedullary nail (IMN) versus non operative treatment for clavicle fracture in polytrauma patients with associated chest injury, with or without additional injuries to the head, abdomen, pelvis and extremities.
89308801|NCT01133925|Active Comparator|ODESSA|ODESSA trial (NCT 00693030)Patients were randomized (2:2:2:1) to receive multiple TAXUS Libertè™ vs Cypher Select™ vs Endeavor™ vs Libertè BM stents, in overlap. At 6-months follow-up coronary angiography (QCA), IVUS and Optical Coherence Tomography assessments were made. Data reported in J. Am. Coll. Cardiol. Intv. 2010;3;531-539. DOI 10.1016/j.jcin.2010.02.008.
89308802|NCT01133925|Experimental|Resolute Sprint arm|Zotarolimus Eluting stents (Resolute Sprint) implanted in overlap to treat long coronary lesions
89308803|NCT01232439|Experimental|opioid receptor kappa antagonist|
89308804|NCT01138059||Acute ischemic stroke patients with unclear onset|
89308805|NCT01138137|Experimental|All subjects|
89308806|NCT01138215|Experimental|1|Receive 1 course of VZV vaccine : 2 doses of vaccines with 3 months apart.
89308807|NCT01136187|Experimental|Radial approach|Primary percutaneous coronary intervention from the radial approach
89308808|NCT01136187|Active Comparator|Femoral approach|Primary percutaneous coronary intervention from the femoral approach
89308809|NCT01231113|Active Comparator|artesunate-amodiaquine arm|A co-blistered pack of amodiaquine and artesunate.The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
89308810|NCT01231113|Experimental|Dihydroartemisinin-piperaquine arm|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
89308811|NCT01138293|Experimental|motion sensor integrated in a mobile phone|A motion sensor integrated in a mobile phone. The system analyses kind, intensity and duration of physical activity and eating habits.
89308812|NCT05402709|Active Comparator|Posterior mobilization group|Posterior mobilization, classical stretching, strengthening exercises were applied and home exercise program were given
89308813|NCT05402709|Active Comparator|Posterior capsule stretching|Posterior capsule stretching, classical stretching, strengthening exercises were applied and home exercise program were given
89308814|NCT05402709|No Intervention|Control group|No treatment was given, only assessment of posterior capsule tightness was applied.
89308815|NCT05402163|Other|Continuous DBS|
89308816|NCT05402163|Active Comparator|Adaptive DBS|
89308817|NCT01136421|Active Comparator|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
89308818|NCT01136421|Experimental|Magnesium sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
89308819|NCT03916887|Experimental|golf training|10-week golf training program
89308820|NCT01136499|Experimental|LBH PANOBINOSTAT|40 mg 3 days per week
89308821|NCT01231191|Active Comparator|IV Acetaminophen|Intraoperative IV acetaminophen administered
89308822|NCT01231191|Placebo Comparator|IV Placebo|Intraoperative IV normal saline administered
89523398|NCT01913587|Active Comparator|Nerve block|Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
89523399|NCT03377075||Healthy subjects|
89308823|NCT01138371||Familial hypercholesterolemia|"Heterozygous FH with documented CAD and LDL-C ≥ 200 mg/dL (Documented CAD may be represented as: Lesion(s) on coronary angiography, history of myocardial infarction, CABG, PTCA, progressive angina demonstrated by stress testing, history of other revascularization procedure)~Homozygous FH and LDL-C > 500 mg/dL~Heterozygous FH and LDL-C ≥ 300 mg/dL~On stable LDL apheresis therapy for at least 6 months"
89308824|NCT01231269|Experimental|MRI|diffusion-weighted MRI
89308825|NCT01136577|Experimental|LEDDYBLOO®|LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs
89308826|NCT01136577|Experimental|Double BILITRON®|Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS
89308827|NCT01136577|Experimental|Futura®|Future phototherapy device equipped with 8 fluorescent tubes
89308828|NCT01231425||With usual concomitant treatment|Two observational cohorts of patients will be evaluated: with and without concomitant analgesic/ antiinflammatory drugs. The objective is evaluate that both therapies (drugs and acupuncture) could be used as adjunctive therapy in order to maximize the analgesia that could be reached
89308829|NCT01231425||Without usual concomitant treatment|This group include patients that are not been treated with analgesic drugs at the beginning of the study. As an observational and naturalistic study any indicated treatment is allowed in any time
89308830|NCT01232673|Experimental|BMAC treatment active group|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC. This ammount is applied by one ml per injection into the critical limb ischemia along the calf vessels.
89308831|NCT01232673|No Intervention|Control Study Group|Standard treatment group of patients with CLI after surgical or interventional revascularisation will serve as control.
89308832|NCT05336487|Experimental|Physical Activity group (PA-group)|The intervention group. Participants with intellectual disabilities is recruited from a local daily activity center, where the participants participate in teacher-organized physical activity ~2 hours/day, 5 days/week.
89308833|NCT05336487|No Intervention|Control Group (CON-group)|The control group. The participants with intellectual disabilities is recruited from daily activity centers, which does not use physical activity in their daily work with the participants.
89308834|NCT01134159||Xience V|Those who have only received a Xience V stent
89308835|NCT01134159||Taxus Liberte|Those who have received only a Taxus Liberte stent
89308836|NCT05403021|Experimental|GETCare Intervention|
89308837|NCT01138449|Experimental|Vitamin A|Vitamin A capsules have retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil
89308838|NCT01138449|Placebo Comparator|Placebo|Placebo capsules contain minute amounts of vitamin E in soybean oil
89308839|NCT01136889|Active Comparator|PFMT plus routine pessary management|"Women allocated to the intervention group will be invited to attend 5 out-patient appointments over a 16 week period with a trained specialist women's health physiotherapist at the study centre. Women will be taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Tailored advice will be given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise. A prolapse specific Lifestyle Advice sheet will also be given to the women by the physiotherapist."
89308840|NCT01136889|Active Comparator|Lifestyle|Women allocated to the control group will be sent a Lifestyle Advice Leaflet only. They will have no planned intervention after their pessary is fitted, other than routine pessary management according to local protocols. The Lifestyle Advice Leaflet gives instructions on seeking advice, where appropriate, about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause the prolapse to worsen.
89308841|NCT05402865||Denosumab group|patients who had received denosumab
89308842|NCT05402865||Non-denosumab group|patients who had received anti-GCTB drug therapy other than denosumab, or who did not receive any anti-GCTB medication
89308843|NCT05402787|Experimental|Experimental|The virtual visit will be started within the first 24 hours after birth. Mothers in this group will be informed about how the virtual visit will be. The virtual visit will be made online through the Whatshup video call program. The virtual visit will be twice a day, starting 24 hours after birth until the baby's first meeting with the mother. The first virtual visit to be made during the day will be aimed at understanding the mother's feelings, increasing her motivation and informing about the clinical condition of the baby. In the second interview, it will be supported to provide approximately 10 minutes of visual and audio communication that will help the mother to establish a connection with her baby. During the virtual visiting hour, the videos of the baby will be sent to the mother so that the mother can watch it. In each visit, it will be ensured that the mother sees her baby in every situation by paying attention to the fact that the baby is in a different situation.
89308844|NCT05402787|No Intervention|Control Groups|The mothers in the control group will be followed in line with the hospital's routine health monitoring and information.
89308845|NCT05550987|Experimental|Vibramoov Device|Rehabilitation program with the use of mechanical vibration using the Vibramoov device and conventional physiotherapy
89308846|NCT05550987|Experimental|Ekso GT exoskeleton Device|Rehabilitation program with gait training using the Ekso GT exoskeleton and conventional physiotherapy
89308847|NCT05550987|Experimental|RoboGait Device|Rehabilitation program with the use of gait training with the use of a RoboGait stationary robot and conventional physiotherapy.
89308848|NCT05550987|Experimental|ZEBRIS Device|Rehabilitation program with the use of gait training with the use of the ZEBRIS treadmill and conventional physiotherapy
89308849|NCT05550987|Experimental|PABLO Device|Rehabilitation program with the use of upper limb function training with the use of the PABLO device and conventional physiotherapy
89308850|NCT05550987|Experimental|Control Group|Rehabilitation program with conventional physiotherapy
89308851|NCT01138527||Biopsy-proven prostate cancer|Patients with biopsy-proven prostate cancer, planned for radical prostatectomy
89308852|NCT01138605|Experimental|005|Darunavir 400 mg tablet intake of 2 tablets once daily in combination with ritonavir
89308853|NCT01138605|Experimental|006|Ritonavir Liquid formulation 80 mg/ml taken in combination with Darunavir
89308854|NCT01138605|Experimental|007|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
89308855|NCT01138605|Experimental|008|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
89308856|NCT01138605|Experimental|001|Darunavir Oral suspension 100 mg/ml 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
89308857|NCT01138605|Experimental|002|Darunavir 375 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 20 and 30 kg
89308858|NCT01138605|Experimental|003|Darunavir 450 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 30 and 40 kg
89308859|NCT01138605|Experimental|004|Darunavir 600mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight as of 40 kg
89308860|NCT01138605|Experimental|009|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
89308861|NCT01234545||A|
89308862|NCT01138683|Active Comparator|ultrafiltration group|
89308863|NCT01138683|Active Comparator|diuretics group|
89308864|NCT01138761|No Intervention|Physician/resident instruction|This arm is standard of care instruction given to parents/caregivers of children with atopic dermatitis by the dermatologist and/or dermatology resident during a patient visit.
89308865|NCT01138761|Active Comparator|Nurse instruction|Following the usual standard of care instruction by physician/resident (which both the treatment group and the non-treatment group will receive); the dermatology nurse will give enhanced instruction about skin care and medications to the caregivers/parents who were randomized to the treatment group.
89308866|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen|35 healthy volunteers
89308867|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen|35 healthy volunteers
89308868|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
89308869|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen plus ERIG|35 WHO category III patients
89308870|NCT01137045|Active Comparator|SPEEDA with ESSEN IM regimen plus ERIG|35 healthy volunteers
89308871|NCT01137045|Active Comparator|TRCS SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
89308872|NCT04800939|Experimental|Acupressure Group|The experimental group will be given acupressure on their own, three times a week for four weeks, one hour before going to bed at night.
89308873|NCT04800939|Other|Placebo Acupressure Group|The control group will be given plasebo acupressure on their own, three times a week for four weeks, one hour before going to bed at night.
89308874|NCT04767243|Sham Comparator|open flap debridement and filled with A-PRF|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
89308875|NCT04767243|Active Comparator|open flap debridement and filled with Bioactive glass (Perioglas®)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of Bioactive glass (Perioglas®) in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
89308876|NCT04767243|Active Comparator|with open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF.|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of Bioactive glass (Perioglas®) along with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
89308877|NCT01232907|Experimental|L-Carnitine|This study has a single subject design. Each subject acts as its own control. All subjects will go through intervention phase (treatment with L-Carnitine).
89308878|NCT01138839|Placebo Comparator|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery.
89308879|NCT01138839|Experimental|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
89308880|NCT01140555|Experimental|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
89308881|NCT01234623||UCB eyedrops, single arm|One-centre pilot study, open, non randomized.
89308882|NCT01232985|Experimental|RD047-26|Study Device
89308883|NCT01140711|Experimental|Gastric bypass|Patients submitted to gastric bypass for treatment of morbid obesity
89308884|NCT01140711|Experimental|Sleeve gastrectomy|Patients submitted to sleeve gastrectomy for treatment of morbid obesity
89308885|NCT01233063|Experimental|Alive2|Lifestyle Intervention delivered via email and web
89308886|NCT01233063|Experimental|Alive2 plus automated phone/print|All of Arm 1 components, plus biweekly tailored automated phone coaching plus monthly tailored automated print materials.
89308887|NCT01233063|Placebo Comparator|Control|Monthly emailed newsletter on other aspects of wellness, excluding diet and physical activity
89308888|NCT05283915|Experimental|Mild hepatic impairment group|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
89308889|NCT05283915|Experimental|Normal hepatic function group|Single dose of tolebrutinib (SAR442168) will be administered on Day 1 under fed condition
89308890|NCT04727697|Active Comparator|Standard of Care, preoperative teaching group|The participants in this group will receive the preoperative teaching and handouts as is the current standard of care.
89308891|NCT04727697|Experimental|Augmented Reality perioperative experiences group|The participants in this group will receive the preoperative teaching and handouts as is the current standard of care in addition to receiving the augmented reality (AR) perioperative experience.
89308892|NCT05282667|Experimental|Resorbable cross-linked barrier membrane|Bone graft will be covered with a resorbable barrier membrane to exclude undesired cells from the area aimed at being regenerated (peri-implantitis bone defect)
89308893|NCT05282667|Experimental|No barrier membrane|Bone graft will be solely packed in the peri-implantitis bone defect with no membrane to cover
89308894|NCT01234701||Primary liver tumors, non-cirrhotic|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonance Imaging (MRI) and underwent resection for primary liver tumors.
89308895|NCT05280717|Experimental|Part A Cohort 1: Concentration 1 of sotrovimab|administered at injection site 1
89308896|NCT05280717|Experimental|Part A Cohort 2: Concentration 2 of sotrovimab|administered at injection site 1
89308897|NCT05280717|Experimental|Part A Cohort 3: Concentration 2 of sotrovimab|administered at injection site 2
89308898|NCT05280717|Experimental|Part A Cohort 4: Concentration 2 of sotrovimab|administered at injection site 3
89308899|NCT05280717|Experimental|Part B Cohort 5: Concentration 1 of sotrovimab|administered at potential injection site 1,2,3 or other
89308900|NCT05280717|Experimental|Part B Cohort 6: Concentration 2 of sotrovimab|administered at potential injection site 1,2,3 or other
89308901|NCT05280717|Experimental|Part C Cohort 7: Concentration 2 of sotrovimab|administered by intravenous (IV) infusion
89308902|NCT05280717|Experimental|Part C Cohort 8: Concentration 2 of sotrovimab|administered by IV infusion
89308903|NCT05275179||Posaconazole Therapeutic Drug Monitoring|Therapeutic Drug Monitoring of posaconzole is performed by measuring posaconazole concentrations in serum
89308904|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum WCFS1)|
89308905|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum NIZO3400)|
89308906|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L. plantarum NIZO2877)|
89308907|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum CBS125632)|
89308908|NCT01137357|Active Comparator|Yoghurt with Lactobacillus casei Shirota|
89308909|NCT01137357|Placebo Comparator|Placebo Yoghurt|
89308910|NCT04712019|Experimental|Closed Incision Negative Pressure Therapy (ciNPT) Dressing|Prevena Restor Arthro-Form Dressing with Prevena Plus Therapy Unit
89308911|NCT04712019|Active Comparator|Standard Silver-containing Dressing|
89308912|NCT01233141||one group only|all participants
89308913|NCT01139151|Experimental|Group 1 - 3 Day Thiarabine|Thiarabine 3 days in a row in each cycle.
89308914|NCT01139151|Experimental|Group 2 - 5 Day Thiarabine|Thiarabine 5 days a row in each cycle.
89308915|NCT01139229|Other|HE group|
89308916|NCT01139229|Other|HS group|
89308917|NCT01139229|Other|SA group|
89308918|NCT01233765||Control volunteers with periodontal health|Control volunteers with periodontal health
89308919|NCT01233765||Patient volunteers with chronic periodontitis|Patient volunteers with chronic periodontitis
89308920|NCT05264649|Experimental|acupuncture group|Stainless steel, disposable, sterile needles choosing based on the needs of different body parts (0.22 gauge x 25mm, 0.22 gauge x 40mm, or 0.25 gauge x 100mm) were inserted to acupoints at traditional depths and angles.
89308921|NCT05264649|Experimental|Chinese medicine group|The Chinese medicine group used Guizhi-Shaoyao-Zhimu decoction (GZSD) as their medical intervention. The GZSD samples were made and packed by Sun Ten Pharmaceutical Co. Ltd., a firm that meets the requirements of the good manufacturing practice (GMP) certification in Taiwan. Every 4g of concentrated GZSD was sealed in an isolated paper drug bag.
89308922|NCT05264649|Experimental|combined group|The combined group would have both acupuncture and Chinese medicine interventions.
89308923|NCT01142817||HIV Postive Women|Women living with HIV who meet study eligibility criteria
89308924|NCT01142817||Healthy Control Subjects|Women without HIV who meet study eligibility criteria
89308925|NCT01234857|Experimental|Part A: ridaforolimus + dalotuzumab|Approximately 15 patients will be enrolled to the ridaforolimus-dalotuzumab combination treatment arm. Subsequent Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to exemestane single-therapy treatment.
89308926|NCT01234857|Active Comparator|Part A: exemestane|Exemestane 25 mg daily; single-agent therapy.
89308927|NCT01234857|Experimental|Part B: ridaforolimus + dalotuzumab|Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to one of two single-therapy treatments (ridaforolimus alone or dalotuzumab alone). With the implementation of Amendment 3, this study arm will not be opened.
89308928|NCT01234857|Experimental|Part B: ridaforolimus|Ridaforolimus; 40 mg daily five days a week, single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
89308929|NCT01234857|Experimental|Part B: dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg weekly; single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
89308930|NCT01236261||Fungemia|Patients with a fungal isolate from a blood culture
89308931|NCT01233843|Other|Drug and radiation|Radiotherapy : 70 grays , fractionization : 2Gy/day, 5 days / week, for 7 weeks . Concurrent administration of Carboplatin: 70 mg/m2/day (day 1 until day 4)and 5FU 600 mg/m2/day (day 1 until day 4). Weeks 1; 4; 7.
89308932|NCT01233843|Experimental|drug and radiation|"Induction chemotherapy by Docetaxel 100mg/m2, day 1; cisplatin 100mg/m2, day 1; 5-Fluorouracil 1000mg/m2 (from day 1 to day 5), for a total of three cycles .Those cycles are administrated at day 1; day 22, day43.~This induction chemotherapy is followed ( for responders or stable disease patients)by radiotherapy (70 grays for 7 weeks) and concurrent Erbitux( weekly administration)."
89308933|NCT01234935|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88815947|NCT03013166||Cohort 3|MR hydrocortisone
89308934|NCT01234935|Experimental|Arm II|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity. NOTE: *Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
89308935|NCT01140945||Males attending in vitro fertilization clinic|
89308936|NCT01137201|Experimental|Mesenteric defects sutured|Closure of the mesenteric defects using running, non-absorbable suture
89308937|NCT01137201|No Intervention|Mesenteric defects not sutured|Non-closure of the mesenteric defects
89308938|NCT03674541|Active Comparator|Study Drug - Pyridostigmine|Pyridostigmine 60 mg by mouth as a one time dose
89308939|NCT03674541|Placebo Comparator|Placebo|Placebo by mouth as a one time dose
89308940|NCT02528799|Experimental|Nexvax2 DQ2.5 Homozygotes (Cohort 1)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
89308941|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Homozygotes (Cohort 1)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
89308942|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
89308943|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
89308944|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
89308945|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 Placebo by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
89308946|NCT01236417|Experimental|Exercise|Subjects will be participating in a home-based flexibility and exercise program
89308947|NCT01235013|Experimental|Maraviroc|
89308948|NCT01235013|No Intervention|Control|Patients continue with their usual treatment
89308949|NCT03668847|Experimental|DM-CHOC-PEN|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 75 or 98.7 mg/m2 emulsion will be administered IV once every 21-days until relapse
89308950|NCT01236495|Experimental|spinal morphine 0.2 mg|spinal morphine 0.2 mg
89308951|NCT01236495|Active Comparator|spinal morphine 0.3 mg|spinal morphine 0.3 mg
89308952|NCT04599153|Experimental|High initial|At the one month follow-up, the shunt is adjusted into a high opening pressure (2.5), which is crossed over to 1.0 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
89308953|NCT04599153|Experimental|Low initial|At the one month follow-up, the shunt is adjusted into a low opening pressure (1.0), which is crossed over to 2.5 at the two months follow-up. At the three months follow-up the opening pressure is set at 0.5 until the next day.
89308954|NCT03739359|Active Comparator|Gas flow 50 L/min|In this group, nasal cannula gas flow will be set at 50 L/min.
89308955|NCT03739359|Experimental|GF:IF=1|In this group, nasal cannula gas flow will be set at each individual patient's own inspiratory flow (GF:IF=1)
89308956|NCT03739359|Experimental|GF:IF=0.5|In this group, nasal cannula gas flow will be set at 50% of each individual patient's own inspiratory flow (GF:IF=0.5)
89308957|NCT01143129|Experimental|dexamethasone|Single dose of dexamethasone (1 mg/kg) at the start of the cardiac surgical procedure
89308958|NCT01143129|Placebo Comparator|Placebo|
89308959|NCT03621501|Placebo Comparator|Staged complete revascularization|• Culprit only + staged (within six weeks after index procedure) complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Control arm)
89308960|NCT03621501|Active Comparator|Immediate complete revascularization|• Immediate complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Experimental arm)
89308961|NCT01139385||clipless|laparoscopic cholecystectomy performed by harmonic scalpel with closure and division of the cystic duct only by the device
89308962|NCT01139385||traditional|laparoscopic cholecystectomy performed by harmonic scalpel with closure of the cystic duct only by titanium clip
89308963|NCT01141101||MRSA-exposed|The MRSA-exposed group will include 100 MRSA-colonized mothers and their babies
89308964|NCT01141101||MRSA-unexposed|The MRSA-unexposed group will include 100 MRSA-negative mothers and their babies.
89308965|NCT01139463||Antipsychotic treatment|Patients were not taking any medications - apart from the prescribed antipsychotic - for a period of 1 month prior to the study with psychotic relapse or newly diagnosed psychotic disorder were recruited from psychiatric inpatient and outpatient clinics of the Split Clinical Hospital.
89308966|NCT03528447|Experimental|Pulmonary Rehabilitation|Lung transplantation candidates who refered from Lung Transplantation surgery team will undergo the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Patient will evaluate at the beginning and end of the program.Cognitive functions and exercise capacities of the patients before and after the program will be evaluated.
89308967|NCT01235091|Other|Standard|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
89308968|NCT01235091|Experimental|SI/WWE|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam
89308969|NCT01235091|Experimental|SI/WWE/PD|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam and Peer-delivered Enhanced Intervention
89308970|NCT02956486|Experimental|Core Study: Elenbecestat 50 mg|Participants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded.
89308971|NCT02956486|Placebo Comparator|Core Study: Placebo|Participants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded.
89308972|NCT02956486|Experimental|Open-label Extension Phase: Elenbecestat 50 mg|Participants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning.
89308973|NCT03619096|Active Comparator|Test Group (tunnel technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a tunnel Technique
89308974|NCT03619096|Placebo Comparator|Control Group (extended flap technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a extended flap technique
89308975|NCT03640468|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
89308976|NCT03640468|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
89308977|NCT03640390|Experimental|Dexmedetomidine group|This group will receive dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour
89308978|NCT03640390|Active Comparator|Magnesium Sulphate group|This group will receive Magnesium Sulphate infusion at a rate of 15 mg/Kg/hour
89308979|NCT03640390|Placebo Comparator|Saline group|This group will receive normal saline infusion
89308980|NCT02236624|Experimental|Aerobic Exercise|
89308981|NCT03618472|Experimental|metformin|The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy
89308982|NCT03618472|Placebo Comparator|placebo|The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy
89308983|NCT03618940|Experimental|School-based educational intervention|"assessed for knowledge and attitude on burn injury prevention~underwent the School-based educational intervention~impact evaluation~Output evaluation 3 months after School-based educational intervention"
89308984|NCT02031718|No Intervention|Online Education|
89308985|NCT02031718|Experimental|Online Education & Virtual Counseling|Online virtual counseling
89308986|NCT03618394||Smoflipid|premature neonates receiving MCT/ω-3-PUFA-containing lipid emulsion
89308987|NCT03618394||Intralipid|premature neonates receiving Soybean Based lipid emulsion
89308988|NCT00001984|Experimental|Alemtuzumab and DSG|The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.
89308989|NCT03462550|Active Comparator|LMA Supreme|
89308990|NCT03462550|Experimental|LMA Protector|
89308991|NCT02031796|Experimental|CAVAREC images|CAVAREC images from x-ray angiography
89308992|NCT03618316|Experimental|Open-label imeglimin + cimetidine|Day 1: single oral dose of 1,500 mg imeglimin Day 5 to Day 10 inclusive: repeated doses of 400 mg cimetidine twice daily Day 8: second 1,500 mg dose of imeglimin together with the morning dose of cimetidine
89308993|NCT02236702||Asymptomatic control|Asymptomatic control
89308994|NCT02236702||Mildly symptomatic with depressive symptoms|Mildly symptomatic with depressive symptoms
89308995|NCT02236702||Moderately symptomatic with depressive symptoms|Moderately symptomatic with depressive symptoms
89308996|NCT02236702||Severely symptomatic with depressive symptoms|Severely symptomatic with depressive symptoms
89308997|NCT03618706|Experimental|involved-field RT + standard salvage treatment|Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer
89308998|NCT03618238|Experimental|Anlotinib|patients will be given anlotinib 12 mg daily for continus 14 days every 21 days until disease progression.
89308999|NCT03445533|Experimental|Arm A: ipilimumab|ipilimumab 3 mg/kg intravenous
89309000|NCT03445533|Experimental|Arm B: IMO-2125 plus ipilimumab|IMO-2125 by intratumoral injection plus ipilimumab 3 mg/kg intravenous
89309001|NCT01143285|Experimental|I - Early and active nutritional support.|During the initial consultation, the dietician will answer the questions of the patient and their family. Patients will be seen regularly in follow-up for weight measurement, serum albumin assay, a 1 or 3 day food record and an evaluation of appetite level. Nutritional counselling is then adjusted accordingly and:Balanced meals are continued if weight is stable and appetite is undiminished.Protein and energy fortification is recommended if weight loss is observed or if food intake decreases between 2 consultations leading to total food intake of less than 50% of required food intake. When a patient presents with signs of malnutrition according to the criteria set out by the Authority for Health, oral nutritional support (ONS) is set up, in agreement with the department head. Two 200ml bottles of Fortimel Extra are to be taken every day. If this ONS strategy is insufficient to improve the patient's nutritional status, artificial nutrition should be discussed.
89309002|NCT01143285|No Intervention|II - No nutritional support|Should malnutrition develop in a group II patient, ONS will be ordered. It will consist of two 200ml Fortimel Extra* bottles per day in addition to regular meals. Ideally, the ONS should be taken as a snack outside of meal times so as to not spoil the appetite. If this ONS is insufficient to improve the nutritional status of the patient, artificial nutrition (either enteral or parenteral) will be discussed.
89309003|NCT01337050|Experimental|A|PF-03446962
89309004|NCT01336972|Experimental|Group A - eGFR > 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
89309005|NCT01336972|Experimental|Group B - eGFR 30 to 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
89309006|NCT01336972|Experimental|Group C - eGFR < 30 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
89309007|NCT03618160|Experimental|Part 1: SAD (Cohort 1 to 3)|Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
89309008|NCT03618160|Experimental|Part 2: MAD (Cohort 4 to 6)|Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
89309009|NCT03618160|Experimental|Part 3: Single Dose (Cohort 7)|Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
89309010|NCT03762681|Experimental|Part 1: Single Ascending Dose, HV|Healthy volunteers will be administered a single dose of RO7239958 or placebo subcutaneously (SC).
89309011|NCT03762681|Experimental|Part 2a: Multi-dose, CHB|Participants with chronic hepatitis B will be administered different dose levels of RO7239958 or placebo SC. Dosages will be determined from data collected from Part 1.
89309012|NCT03762681|Experimental|Part 2b: Multi-dose, CHB (Optional)|Additional study arm to open based on data collected from Part 2a. Participants with chronic hepatitis B will be administered different doses and frequencies of RO7239958 or placebo SC.
89309013|NCT01139541|No Intervention|Control|Participants in the control condition will be asked to refrain from using the WalkStations during the study period.
89309014|NCT01139541|Experimental|Individual|In the individual condition, participants will not be part of a team. They will receive weekly email feedback on their Walkstation performance (e.g. number of time slots they signed up for, and number of times they showed up for the time slot.)
89309015|NCT01139541|Experimental|Pairs|In the pair condition, participants will be randomly assigned to a partner. They will receive the same feedback as those in the individual condition, for both themselves AND their partner.
89309016|NCT01139541|Experimental|Groups|In the group condition, participants will be randomly assigned to a group of 5 people. They will receive the same feedback as those in the individual condition, for both themselves AND each member of their group.
89309017|NCT03618082|Active Comparator|usual practice|control group (usual practice): patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance. The dosage of the anesthetic agent, as well as the prophylactic administration of morphine at the end of the intervention, will be decided by the anesthesiologist.
89309018|NCT03618082|Experimental|targeted analgesia to ANI|"experimental group: patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance, as well as the prophylactic administration of morphine at the end of the intervention, will be administered according to the ANI.~- In addition, desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC)."
89309019|NCT03617068|Active Comparator|Coconut Oil Cream|This group consist of batik traditional workers who use coconut oil cream for 2 weeks.
89309020|NCT03617068|Placebo Comparator|Placebo Cream|This group consist of batik traditional workers who use placebo cream which contained the vehiculum of the cream; using for 2 weeks.
89309021|NCT03764475|Other|Long-term Safety of Roflumilast|Participants applied roflumilast (ARQ-151) cream 0.3% once daily for 52 weeks
89309022|NCT01139619||1|Inoperable non small cell lung cancer patients. Diagnosed between 2010-05-31 and 2009-06-01.
89309023|NCT01236651|Experimental|meperidine and duration of 1st stage of labor|meperidine 100mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
89309024|NCT01236651|Experimental|drotaverine and duration of 1st stage of labor|drotaverine 40mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
89309025|NCT01141179|Experimental|LEO 27847|
89309026|NCT03739515|Experimental|HSCP team|Patients in this arm will receive comprehensive assessment and/or pre-discharge services by an ED-based HSCP team
89309027|NCT03739515|Active Comparator|Routine care|Patients in this arm will receive routine ED care
89309028|NCT01235169|Experimental|Proximal Femoral Nail Antirotation|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation
89309029|NCT04484025|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 7 days, with 30-day follow-up
89309030|NCT04484025|Experimental|SPI-1005 800 mg BID|Oral administration of SPI-1005 800 mg BID for 7 days, with 30-day follow-up
89309031|NCT04484025|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 7 days, with 30-day follow-up
89309032|NCT01143363|Placebo Comparator|Resting - control|No exercise
89309033|NCT01143363|Experimental|Moderate intensity exercise|Moderate intensity exercise (continuous) 1h after breakfast
89309034|NCT01143363|Experimental|High intensity intermittent training|High intensity intermittent training 1h after breakfast
89309035|NCT01143363|Experimental|Short sprint|Short sprint 1h after breakfast
89309036|NCT01141257|Experimental|Angiocal®|Angiocal®
89309037|NCT01141335|Experimental|PTFE mesh|A Lichtenstein tension-free hernioplasty is performed using PTFE mesh
89309038|NCT01141335|Active Comparator|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using polypropylene mesh
89309039|NCT01143441|Experimental|Cohort A|Long-Term daclizumab cohort
89309040|NCT01143441|Experimental|Cohort B|New Treatment Cohort
89309041|NCT01143441|No Intervention|Cohort C|MS Controls
89309042|NCT01141413||RA patients using Remicade®|
89309043|NCT01141413||RA patients using Orencia®|
89309044|NCT05009134||Control|18-55 years, healthy
89309045|NCT05009134||Allergic rhinitis|patients with AR without AIT
89309046|NCT05009134||Allergen immunotherapy|patients with AR with AIT for more than 1 year
89309047|NCT03618004|Experimental|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
89309048|NCT03618004|Active Comparator|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
89309049|NCT03616756|Experimental|Intervention group|
89309050|NCT03616756|Active Comparator|Control group|
89309051|NCT03616678|Experimental|VenTouch System Implant|"The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have moderately severe or severe mitral regurgitation (grade 3 or 4 MR)."
89309052|NCT01064518|Active Comparator|Dose A|RT001 Topical Gel
89309053|NCT01064518|Placebo Comparator|Dose B|Placebo Comparator
89309054|NCT04976296||Stage I-IIIA NSCLC patients after complete resection|For stage I-IIIA NSCLC patients who underwent complete resection.
89309055|NCT03616444|Experimental|TCM-Shenbai Granules|"Shenbai Granules: Hedyotis diffusa 10g, Sophorae flavescentis radix 4.5g, Codonopsis radix 7.5g, Atractylodis macrocephalae rhizoma 6g, Mume fructus 4.5g, Coptidis rhizoma 1.5g, Zingiberis rhizome praeparatum 3g, Coicis semen 10g.~Orally, 1 sachet once, diluted in 150-200 ml of boiling water, 2 times a day."
89309056|NCT03616444|Placebo Comparator|TCM-Placebo|"It contains 5% SBG content, and the remaining ingredients are flavoring agents, starch and coloring agents. It is the same with SBG in appearance, smell and dosage form.~Orally, 1 sachet once, diluted in 150-200 ml of boiling water, 2 times a day."
89309057|NCT02031952|Experimental|hepatectomy combined lymphadenectomy|hepatectomy combined lymphadenectomy
89309058|NCT02031952|Active Comparator|hepatectomy|hepatectomy alone
89309059|NCT03616288|Placebo Comparator|Negative Control|placebo; 0 mg thiamine
89309060|NCT03616288|Experimental|EAR Group|1.2 mg thiamine as thiamine hydrochloride
89309061|NCT03616288|Experimental|Double EAR Group|2.4 mg thiamine as thiamine hydrochloride
89309062|NCT03616288|Experimental|Positive Control|10 mg thiamine as thiamine hydrochloride
89309063|NCT01064440|Experimental|Low Dose VM202|Patients in this group will receive 8mg total of VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
89309064|NCT01064440|Experimental|High Dose VM202|Patients in this treatment group will receive a total of 16mg VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day42: 4mg of VM202 (16 injections of 0.5ml of VM202)
89309065|NCT01064440|Sham Comparator|Placebo|Patients in this group will receive a total of 8ml normal saline. Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
89309066|NCT03616210|Experimental|Protective ventilation|Protective ventilation strategy (tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O)
89309067|NCT03616210|No Intervention|Conventional ventilation|Conventional mechanical ventilation (tidal volume between 9 to 10 ml.kg-1 of predicted body weight and PEEP between 3 and 5 cmH2O)
89309068|NCT03617614||Collaborative Care Model|Participants who received care from the Medical Psychiatry Alliance Seniors Outpatient Collaborative Care Program at Trillium Health Partners.
89309069|NCT03617614||Mood Consult|Participants who received a one time mood consultation at the Centre for Addiction and Mental Health.
89309070|NCT03616132|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions.
89309071|NCT02031874||Miami Cohort|Measured vaccine response to H1N1 in HIV perinatally infected children
89309072|NCT05037760|Experimental|Arm 1a|Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) monotherapy
89309073|NCT05037760|Experimental|Arm 1b|Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
89309074|NCT05037760|Experimental|Arm 2a|Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) monotherapy
89309075|NCT05037760|Experimental|Arm 2b|Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)
89309076|NCT03617380|Experimental|PHARMD-TOC i|PharmD Follow-Up Post Discharge
89309077|NCT03617380|Active Comparator|USUAL CARE|Usual Post Discharge Procedures
89309078|NCT03615820|Experimental|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which PPE entrapped in niosomes then incorporated in oromucoadhesive films
89309079|NCT03615820|Placebo Comparator|Oromucoadhesive film|Oromucoadhesive film that has no niosomal PPE in its content
89309080|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
89309081|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
89309082|NCT02872012|Experimental|Cryoanesthesia Device -7 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
89309083|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
89309084|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
89309085|NCT02872012|Active Comparator|Lidocaine|"Participants randomized to this arm will have their other eye receive anesthesia via the current standard of care treatment method (lidocaine) prior to receiving an intravitreal injection.~Lidocaine: Lidocaine will be applied to the non-cryoanesthesia eye."
89309086|NCT03617224|Experimental|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
89309087|NCT03617224|Experimental|Radiation: TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
89309088|NCT03617146|Experimental|Intervention Arm|"Participants in the intervention arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education.~Months 1 to 3: Six 30 to 45-minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.~Month 3: Follow up distress-specific education.~Months 4 and 5: Two 30 to 45 minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement."
89309089|NCT03617146|Active Comparator|Control Arm|"Participants in the control arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education (same as for the intervention arm).~Month 3: Follow up distress-specific education (same as for the intervention arm)."
89309090|NCT04942678||Pediatric patients ages 4-7 years old in the Pediatric Emergency Department|Patients will receive a 10-minute visit with therapy dog and child life handler
89309091|NCT04942678||Pediatric patients ages 8-12 years old in the Pediatric Emergency Department|Patients will receive a 10-minute visit with therapy dog and child life handler
89309092|NCT03615586|Active Comparator|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone. The intervention consists of the presence of a female chaperone.
89309093|NCT03615586|Active Comparator|Without Chaperone|Female patients examined by male physicians without a chaperone. The intervention is the absence of a female chaperone.
89309094|NCT04870528|Experimental|Experimental group|- This group will be composed of 30 patients with lower limb burn of second-degree. Subjects will receive pulsed magnetic field over thigh areas for 24 sessions over a period of 8 weeks (3sessions/week) with receiving strengthening exercises for quadriceps muscle and traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living.
89309095|NCT04870528|Active Comparator|control group|Subjects will receive strengthening exercises for quadriceps muscle and traditional physical therapy program in the form of range of motion exercise, stretching, splinting, massage, functional training for ambulation and activities of daily living for 24 sessions over a period of 8 weeks (3sessions/week)
89309096|NCT02959138|Experimental|Moderate Renal Impairment (Cohort 1)|Participants with moderate renal impairment and matched healthy controls will receive a single dose of lanraplenib
89309097|NCT02959138|Experimental|Severe Renal Impairment (Adaptive Cohort 2)|Participants with severe renal impairment and matched healthy controls will receive a single dose of lanraplenib
89309098|NCT02959138|Experimental|Mild Renal Impairment (Adaptive Cohort 3)|Participants with mild renal impairment and matched healthy controls will receive a single dose of lanraplenib
89309099|NCT03615430|Placebo Comparator|Control group|saline control group, 15 mL of the saline was administered to superficial and deep surface of serratus anterior in Control group via ultrasound before the surgery
89309100|NCT03615430|Experimental|SPB group|Serratus plane block group, 15ml of 0.25% ropivacaine, a widely used local anesthetic for peripheral nerve block, was administered to superficial and deep surface of serratus anterior in SPB group via ultrasound before the surgery
89309101|NCT03615352|Experimental|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
89309102|NCT03615352|Experimental|ovarian cyst aspiration and coagulation|laparoscopic ovarian endometrioma aspiration and coagulation
89309103|NCT03615274|Experimental|Experimental|Children in the training group must complete home-based executive function training by iPad. At the same time, they are asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
89309104|NCT03615274|Active Comparator|Placebo non-adaptive training|Children in the control group must complete cognitive control tasks. They are also asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
89309105|NCT03615196|Experimental|USB005 0.03%|USB005 (aclerastide) Ophthalmic Solution 0.03%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
89309106|NCT03615196|Experimental|USB005 0.1%|USB005 (aclerastide) Ophthalmic Solution 0.1%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
89309107|NCT03615196|Experimental|USB005 0.3%|USB005 (aclerastide) Ophthalmic Solution 0.3%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
89309108|NCT03615196|Experimental|USB005 0.45%|USB005 (aclerastide) Ophthalmic Solution 0.45%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
89309109|NCT03615196|Placebo Comparator|USB005 Placebo|USB005 Ophthalmic Solution Placebo; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
89309110|NCT04905784|Active Comparator|Control group: Usual brushing.|Usual motivation to brush teeth in the clinic (KAI brushing technique) in addition to brushing teeth by the parents.
89309111|NCT04905784|Experimental|Test group: Differential learning group.|Use of differential learning of tooth brushing at home, including children and parents.
88815948|NCT03013166||Cohort 4|IR to MR hydrocortisone
89309112|NCT03615118|Experimental|Intervention|Patients randomized to the intervention group will receive the AniMóvil intervention, including: the Sentirse Mejor manual that patients can refer to for information about CBT and skill practice, weekly IVR depression symptom assessments and psychoeducational messages, daily SMS mood monitoring and CBT reinforcement messages, and CHW telephone CBT sessions in the event of elevated PHQ-9 scores during the study. CHWs will use information from patients' IVR/SMS monitoring to support intervention-group patients' depression self-management under close supervision from their mental health specialist supervisor. Intervention patients will be part of a 'stepped' intervention based on the severity of their depression upon entry into the program and assessment throughout the intervention.
89309113|NCT03615118|Active Comparator|Enhanced Usual Care|Enhanced usual care patients will receive usual care, including the Sentirse Mejor manual developed by the research team in conjunction with local Ministries of Mental Health and tailored by the study team, emphasizing CBT principles, and daily SMS messages asking participants to report their mood on a 1 to 9 scale. Enhanced usual care group patients who report mood scores of 1 or 2 (worst scores) for at least 3 days per week and 3 consecutive weeks will be called by the Community health worker and referred to the national program office for depression services support - a free service available to all citizens diagnosed with depression. Enhanced usual care patients will be part of a 'stepped' program based on the severity of their depression upon entry into the program and assessment throughout the intervention.
89309114|NCT04841512|Placebo Comparator|Placebo|Sterile phosphate-buffered saline for injection Single 1mL injection into the facet joint
89309115|NCT04841512|Experimental|XT-150 Dose #1|Lower dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint
89309116|NCT04841512|Experimental|XT-150 Dose #2|Higher dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint
89309117|NCT03614104|Active Comparator|mobile health technology|Health education with mobile health technology
89309118|NCT03614104|Sham Comparator|Without mobile health technology|Health education without mobile health technology
89309119|NCT03613714|Active Comparator|Intervention Group|At-home blood pressure monitoring at 2-5 days post-discharge from the hospital using a digital blood pressure cuff. Participants will receive text message reminders to check blood pressure. Contacted by clinic staff to review blood pressure log.
89309120|NCT03613714|No Intervention|Usual Care|Blood pressure monitoring assessment will be done at 2-5 days post-discharge in the office. Participants will be given high blood pressure information hand-outs and instructed to follow-up in obstetric clinic for blood pressure check within 5 days after discharge from the hospital.
89309121|NCT04837768|Active Comparator|Serum Progesterone Levels >9.2 ng/ml|These patients will receive only twice-daily vaginal progesterone supplementation following embryo transfer
89309122|NCT04837768|Active Comparator|Serum Progesterone Levels <9.2 ng/ml|These patients will receive twice-weekly intramuscular progesterone supplementation in addition to the twice-daily vaginal supplementation following embryo transfer
89309123|NCT02869438|Experimental|Benralizumab arm|Benralizumab administered subcutaneously
89309124|NCT02869438|Placebo Comparator|Placebo arm|Placebo administered subcutaneously
89309125|NCT03614884|Experimental|Gambling and Smoking Treatment|Participants in this arm will be given access to the online integrated treatment for gambling and smoking.
89309126|NCT03614884|Active Comparator|Gambling Only Treatment|Participants in this arm will be given access to the online gambling only treatment.
89309127|NCT03614806|Experimental|Patients tested for hyperventilation|Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.
89309128|NCT02236858|Sham Comparator|Sham HEPA Air Cleaner|Sham HEPA Air Cleaner and Delayed Intervention. Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
89309129|NCT02236858|Active Comparator|HEPA Air Cleaner|HEPA Air Cleaner also containing carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time. These air cleaners are suitably sized to provide clean air delivery rates for the rooms in which they will be placed. Participants will be instructed to run the air cleaners continually during the course of the study and the units will be modified to prevent them from being turned off by the participants.
89309130|NCT03613636||CAP cohort|"Children of age 3 to 16 years;~In- and outpatients;~Clinically diagnosed community-acquired pneumonia (CAP)."
89309131|NCT03613636||Healthy control cohort|"Healthy asymptomatic children of age 3 to 16 years;~undergoing an elective surgical procedure."
89309132|NCT03613636||Family control cohort|- Family members of index CAP patients.
89309133|NCT03614650|Experimental|EIE cells to treat cancer|EIE cells to treat cancer
89309134|NCT02868892|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.
89309135|NCT03442426|Experimental|Intervention Cohort|Integrated model of primary care
89309136|NCT03614338|Experimental|Core Participants Weight Loss Program|Small changes weight loss program
89309137|NCT03613558|Experimental|Dexmedetomidine Sedation|This group will receive 1mcg/kg bolus of dexmedetomidine over 15 minutes after intubation followed by an infusion of dexmedetomidine at 0.5mcg/kg/hr until approximately 30 minutes before the end of surgery.
89309138|NCT03613558|Placebo Comparator|Placebo|This group will receive a colorless, odorless liquid (i.e. normal saline) in order to resemble Dexmedetomidine.
89309139|NCT03352557|Experimental|Low-dose BIIB092|Intravenous (IV) infusion once every 4 weeks OR once every 12 weeks and placebo at the other 4-week dosing visits to maintain the treatment blind.
89309140|NCT03352557|Experimental|Medium-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
89309141|NCT03352557|Experimental|High-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
89309142|NCT03352557|Placebo Comparator|Placebo|Intravenous (IV) infusion once every 4 weeks.
89309143|NCT05384314||COPD|Patients admitted with COPD as the primary admission.
89309144|NCT05384314||Respiratory Compromised General|Patients admitted with Pneumonia, COPD, COVID, to be included
89309145|NCT02866942|Experimental|Asthma|LAIV administration in children with asthma receiving treatment according to British Thoracic Society step 2+
89309146|NCT03614182|Experimental|physical training concurrent with cognitive training|The physical training concurrent with cognitive training group (the P+C group) will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
89309147|NCT03614182|Active Comparator|physical training followed by cognitive training|The physical training followed by cognitive training will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
89309148|NCT03614182|Active Comparator|physical training without cognitive training|The physical training without cognitive training group will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
89309149|NCT01139697||Patients with systolic heart failure|Patients with systolic heart failure defined as ejection fraction <45%
89309150|NCT02032108|Experimental|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
89309151|NCT01235247|Experimental|reminders, no reminder|
89309152|NCT03440866|Experimental|Intervention|Administration of drugs concomitantly.
89309153|NCT03440866|No Intervention|Control|Administration of oral Mifepristone 600 mg and after interval of 48 hours administration of oral Misoprostol 400 mcg.
89309154|NCT01141803|No Intervention|control|
89309155|NCT01141803|Active Comparator|Apples|
89309156|NCT01141803|Active Comparator|Apple pomace|
89309157|NCT01234077|No Intervention|ECG recording|In-laboratory vs. in-home recordings
89309158|NCT03384706|Active Comparator|Cognitive Processing Therapy (CPT)|PTSD Psychotherapy CPT will be implemented using the Cognitive-Only version, excluding the trauma account.
89309159|NCT03384706|Experimental|Accelerated Resolution Therapy (ART)|PTSD Psychotherapy
89309160|NCT03384706|No Intervention|Wait List Control|Wait List control will include a 7 week minimal attention control period with weekly check-in calls to ensure that the participant has not experienced any significant worsening in their symptoms that might require interventions, (e.g. suicidal intent).
89309161|NCT02032264|Experimental|Comprehensive Chromosome Screening|Trophectoderm biopsy will be performed on all blastocysts and CCS via next generation sequencing screening performed on biopsy samples. Patients will proceed with a single or double embryo transfer of the one or two morphologically best euploid embryos
89309162|NCT02032264|Placebo Comparator|No Comprehensive Chromosome Screening|The patients in this group will proceed with a single or double embryo transfer of the one or two morphologically best embryos.
89309163|NCT03613168|Experimental|Trastuzumab plus Gem/Cis|Gemcitabine 1,000 mg/m2 Day 1 and Day 8, every 3 weeks Cisplatin 25 mg/m2 Day 1 and Day 8, every 3 weeks Trastuzumab, every 3 weeks, 8 mg/kg at first cycle then, 6 mg/kg
89309164|NCT01141881|Experimental|TPA,IVB,F/U|
89309165|NCT04742062|Active Comparator|ApTOLL single dose|ApTOLL is administered intravenously in a single ascending dose pattern in seven dose levels (0.7mg - 70mg). Levels 1 - 3 include one subject per level and levels 4 - 7 include six subjects per level (1 sentinel + 5 subjects).
89309166|NCT04742062|Placebo Comparator|Placebo single dose|Placebo is administered intravenously during seven dose levels. Levels 1 - 3 include one subject per level and levels 4 - 7 include two subjects per level (1 sentinel + 1 subject).
89309167|NCT04742062|Active Comparator|ApTOLL multiple dose|ApTOLL is administered intravenously every eight hours during 24h (21mg). This arm includes six subjects (1 sentinel + 5 subjects).
89309168|NCT04742062|Placebo Comparator|Placebo multiple dose|Placebo is administered intravenously every eight hours during 24h. This arm includes twosubjects (1 sentinel + 1 subject).
89309169|NCT03613090|Experimental|Collagen-hydroxyapatite Scaffold (Syn-Oss)|Placement of a collagen-hydroxyapatite scaffold (Syn-Oss), placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material).
89309170|NCT03613090|Active Comparator|Collagen Scaffold (Colla-Plug)|Placement of a collagen scaffold (Colla-Plug) over a blood clot, placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material). The Colla-Plug material is placed adjacent to the blood clot that has formed inside the root canal space. It act as a matrix for the subsequent placement of the mineral trioxide aggregate material. It has been used as the standard of care in regenerative endodontics since 2004.
89309171|NCT03613324||Bladder outlet obstruction (BOO)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was <12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
89309172|NCT03613324||Detrusor underactivity (DU)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having DU when Qmax was <12 mL/s and PdetQmax was <10 cmH2O during voiding cystometry.
89309173|NCT03613324||ND BOO/DU|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. This group revealed no demonstrated bladder outlet obstruction nor detrusor underactivity.
88806476|NCT03993002|Active Comparator|Normoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 < 100 (FiO2 >= 21%) PaCO2 of 50-60"
88815949|NCT01119716||All Enrolled Participants|Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options
89309174|NCT03613012||Pain index|Pain index will be extracted from the EEG of chronic pain patients before and after pain treatments
89309175|NCT03097497|Experimental|Physiotherapy re-education program|Physiotherapy re-education program based on the pre-activation of the transverse abdominal muscle, performed with progressive difficulty and supervised at all times by an expert physiotherapist. The intervention will last 4 weeks, with two weekly sessions of 30-35 minutes each. Sessions will be held individually.
89309176|NCT03097497|Active Comparator|Conventional treatment by GP|"Will follow conventional treatment prescribed by the general practitioner in a primary care consultation. This conventional treatment is based on the clinical guidlines of the Institut Català de la Salut~http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf"
89309177|NCT01143597|Active Comparator|Somatosensory stimulation (SS)|Participants in the SS group receive median nerve electrical stimulation applied to the skin of the wrists.
89309178|NCT01143597|Active Comparator|Massed practice + somatosensory stimulation (MP+SS)|Participants in the MP+SS group receive a combined intervention consisting of SS and a skill-based exercise protocol
89309179|NCT01143597|Active Comparator|Conventional resistance training (CRT)|Participants in the CRT group will participate in a weight-based exercise program
89309180|NCT03612934||patients under the age of 65 years|patients under the age of 65 years
89309181|NCT03612934||patients at the age of 65 years and over|patients at the age of 65 years and over
89309182|NCT01139853|Active Comparator|Nasogastric Tube|10 French Nasogastric Tube inserted before surgery
89309183|NCT01139853|No Intervention|No Nasogastric Tube|
89309184|NCT02032342|Active Comparator|Fuji Uni-blocker|Fuji Uni-blocker for selective lobar deflation
89309185|NCT02032342|Active Comparator|Cohen blocker|Cohen blocker for selective lobar deflation
89309186|NCT02032342|Active Comparator|Arndt® blocker|Arndt® blocker for selective lobar deflation
89309187|NCT02032342|Placebo Comparator|Endobronchial double lumen tube|Endobronchial double lumen tube for one lung ventilation
89309188|NCT05384002||Retrospective (training model)|
89309189|NCT05384002||Prospective (validation model)|
89309190|NCT01142037|Experimental|Furanocoumarin|Includes participants first refraining from eating foods with furanocoumarins for one week, followed by 2 weeks of increasing furanocoumarin consumption. Participants will be asked to consume cooked parsnips and parsley.
89309191|NCT03612778|Experimental|Plant-based diet|Participants will receive a meal plan based on unrefined plant-based foods with the following macronutrient composition: approximately 15% of calories from vegetable protein, <15% from fat, and 70-75% from carbohydrates. Additionally, to ensure adequate intake of n-3 polyunsaturated fatty acids, they will receive a supplement in the form of one 840 mg n-3 acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
89309192|NCT03612778|Active Comparator|Mediterranean diet|Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
89309193|NCT03612388||cardioplegia with MPS® (Myocardial protection system)|cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
89309194|NCT03612388||cardioplegia with Cardioplexol ®|cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)
89309195|NCT03611842||Healthy eardrum|OME (otitis media with effusion)with normal tympanic membrane
89309196|NCT03611842||Atrophic eardrum|OME (otitis media with effusion) with atrophic membrane : thinning of the membrane, retraction pocket
89309197|NCT04631380|No Intervention|CONTROL|THIS GROUP WILL RECEIVE THE PROTCOLL TREATMENT GIVEN TO PATIENTS COVID -POSITIVE TESTED.
89309198|NCT04631380|Experimental|PRAYER|THIS GROUP WILL RECEIVE THE SAME TREATMENT GIVEN TO THE CONTROL GROUP, PLUS PRAYERS BY THEOLOGIANS WHOSE PRAYERS INTERCEDE IN FAVOR OF THEIR PROMPT RECOVERY
89309199|NCT03611764|Experimental|Arm 1: Body Scan|"The mindfulness-based intervention (MBI) of the Body Scan is expected to take 20 minutes~Participants will then be guided through the Body Scan. Beginning with awareness of sensations of the left toe, patients will be asked to observe these sensations without judgment, simply noticing and allowing them. Awareness of sensations will continue up through the left leg, then from the right toe up the right leg, then abdomen and chest, then fingertips to arms, then neck, and finally the head. After completing the Body Scan, participants will be given several minutes of quiet to reflect upon how they feel. After opening their eyes, participants will be given the opportunity to discuss and ask questions.~Caregivers will be encouraged to practice with the patient or on their own, in an additional space on the floor called the Zen Den"
89309200|NCT05383768|Placebo Comparator|Restoration with conventional no heated bulk-fill resin composite|Restoration with conventional no heated bulk-fill resin composite, X-tra fill (VOCO, GERMANY)
89309201|NCT05383768|Active Comparator|restoration with one-time preheated conventional bulk-fill resin composite|restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
89309202|NCT05383768|Active Comparator|restoration with five-time preheated conventional bulk-fill resin composite|restoration with five-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
89309203|NCT05383768|Active Comparator|restoration with ten-time preheated conventional bulk-fill resin composite|restoration with ten-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
88815950|NCT02518191|Experimental|GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
88820787|NCT05651022|Experimental|Cohort 4|A single dose of Decoy20 at a dose of 200 x 10^7 KB
89309204|NCT03612700|Experimental|CPFA-rich diet|Free living diet controlled in CPFA intake
89309205|NCT03611686||patient followed for metastatic prostate adenocarcinoma|patient wil be followed for metastatic prostate adenocarcinoma during 3 years
89309206|NCT03612622|Active Comparator|Transcranial Magnetic Stimulation-Real|Participants will receive active TMS once daily for two weeks
89309207|NCT03612622|Placebo Comparator|Transcranial Magnetic Stimulation-Sham|Participants will receive sham TMS once daily for two weeks
89309208|NCT03612076||Global cost of management of PJI|
89309209|NCT03611608|Experimental|LY3316531 Dose 1|LY3316531 administered IV
89309210|NCT03611608|Experimental|LY3316531 Dose 2|LY3316531 administered IV
89309211|NCT03611608|Placebo Comparator|Placebo|Placebo administered IV
89309212|NCT03611998|Experimental|Survivors of Sex Trafficking|Survivors of sex trafficking (SST) who were living in a residential facility participated in this project by receiving occupation-based programming to address limitations in executive function skills over the course of the 8-month project. Sessions were held twice-monthly for an hour duration at each session.
89309213|NCT03611920||Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
89309214|NCT03611920||Dexamethasone|Teeth were soaked in dexamethasone (60μ ml-1) for 20 minutes before replantation
89309215|NCT05383690|Experimental|Bright Light Arm|This is a one-arm study. Subjects will be provided with the LiteBook Edge™ (LiteBook Company LTD), which is a patented smart phone sized BLT device that provides 10,000 lux illumination at a recommended distance of 61 cm from an LED panel with peak spectral radiance in the blue color spectrum that closely corresponds to the peak spectral frequency (480 nm) of melanopsin photoreceptors that project to the suprachiasmatic nucleus and entrain the circadian clock (Hatori & Panda, 2010).
89309216|NCT03611218|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and on follow-up week per patient. Each treatment week includes three hemodiafiltration HDFsessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Nipro: Sureflux-17UX and comparator Baxter/Gambro: Polyflux 170 H.
89309217|NCT03611140|Experimental|Dietary portfolio (DP)|The dietary portfolio was given daily at the breakfast and dinner for 2 months. The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein, oat, and inulin) that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
89309218|NCT03611140|Placebo Comparator|placebo (P)|The placebo (P) was given daily at the breakfast and dinner for 2 months. The placebo intervention consisted of a mixture of calcium caseinate, maltodextrins, sweetener and of artificial flavoring that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
89309219|NCT03611452|Experimental|Simple continuous|the sutures will be taken continuously by simple method
89309220|NCT03611452|Active Comparator|subcuticular|the sutures will be taken subcuticular
89309221|NCT03611452|Active Comparator|interrupted|the sutures will be taken interrupted method
89309222|NCT02032498|Experimental|Indocyanine Green|superficial injections of Indocyanine Green in the breast
89309223|NCT03059355|Experimental|Pilot Phase: Group 1 (UCMSCs - 20 million)|Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.
89309224|NCT03059355|Experimental|Pilot Phase: Group 3 (UCMSCs - 100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
89309225|NCT03059355|Experimental|Pilot Phase: Group 2 (BMMSCs - 20 million)|Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.
89309226|NCT03059355|Experimental|Pilot Phase: Group 4 (BMMSCs -100 million)|Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.
89309227|NCT03059355|Experimental|Group A (UCMSCs - 100 million)|Participants randomized to receive a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.
89309228|NCT03059355|Experimental|Group B (BMMSCs - 100 million)|Participants randomized to receive a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.
89309229|NCT03059355|Placebo Comparator|Group C (Placebo)|Participants randomized to receive a single administration of placebo via peripheral intravenous infusion.
89309230|NCT01235325|Placebo Comparator|Placebo oil capsule|Banner Pharmacaps Europe
89309231|NCT01235325|Experimental|phylloquinone (1000 mcg)|Banner Pharmacaps Europe
89309232|NCT01143753|Experimental|RO5212054: Continuous Dosing Cohort|Participants will receive RO5212054 in escalating dose levels.
89309233|NCT01143753|Experimental|RO5212054: New Formulation (F05) Bridging Cohort|Participants will receive RO5212054 as a single dose of new formulation (F05-150 mg film-coated tablet with different ratios of ingredients than F03 to increase bioavailability) and a single dose of current clinical Formulation (F03-150 mg film-coated tablet) in a cross-over manner. Participants will be alternately assigned to receive either F05 or F03 as their first dose, followed by the opposite Formulation as their second dose. Dose of RO5212054 will be decided based on the results of continuous dosing cohort.
89309234|NCT01140009|Placebo Comparator|Group 1|FLuviral 2010/11Tri-valent Seasonal Influenza Vaccine (TIV)1st; saline placebo 10 days later
89309235|NCT01140009|Placebo Comparator|Group 2|Saline placebo 1st; Fluviral 2010/11 Tri-valent Seasonal Influenza Vaccine (TIV)10 days later
89309236|NCT01235481|Experimental|Exercise DVD|Exercise DVD to be used by participants 30-60 minutes, once daily to facilitate maintenance exercise training
89309237|NCT01235481|Other|Usual Care|Participants advised to perform maintenance exercise training 30-60 minutes, once daily without benefit of exercise DVD
89309238|NCT01140087|Experimental|Interventional|Face Transplantation
89309239|NCT01235637|Active Comparator|Alfentanil|
89309240|NCT01235637|Sham Comparator|Sufentanil|
89309241|NCT04042311|Experimental|High-Intensity interval training|High-intensity interval training performed for 20 minutes, 3 times weekly for a period of 6 weeks at 85-100% of maximal heart rate.
89309242|NCT04974489|Experimental|Emotion-based messages about the harm of VLNC|
89309243|NCT04974489|Experimental|Continued-harm-framed messages about the harm of VLNC|
89309244|NCT04974489|Experimental|Myth-refuting messages about the harm of VLNC|
89309245|NCT04974489|Active Comparator|Control messages about littering|
89309246|NCT01143831|Experimental|All study participants|Three blood collections, one at baseline, one two weeks later, and the final blood collection 4 weeks from baseline, after taking Vitamin K orally for 14 days.
89309247|NCT01143909|Experimental|No FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to omitting transfusion of fresh frozen plasma before they undergo an intervention.
89309248|NCT01143909|No Intervention|FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to transfusion of fresh frozen plasma before they undergo an intervention. This is considered standard care.
89309249|NCT01142271|Experimental|Billroth-I|Patients in this group should be underwent gastroduodenostomy as reconstruction procedure after standard distal subtotal gastrectomy with lymph node dissection.
89309250|NCT01142271|Experimental|Roux en Y|Patients in this group should be underwent jejunojejunostomy and gastrojejunostomy as reconstruction procedure after standard distal gastrectomy.
89309251|NCT01142349|Experimental|Lifestyles A|Cognitive Behavioral Therapy for Pain and Insomnia
89309252|NCT01142349|Experimental|Lifestyle B|Cognitive Behavioral Therapy for Pain
89309253|NCT01142349|Active Comparator|Lifestyles C|Osteoarthritis Education
89309254|NCT01234155|No Intervention|Control|
89309255|NCT01234155|Experimental|Exercise - Continuous Walking|
89309256|NCT01234155|Experimental|Exercise - Interval Walking|
89309257|NCT01236885|Experimental|Supportive care (Glucommander)|Patients receive blood glucose management with IV insulin using Glucommander.
89309258|NCT03913689||StimRouter Neuromodulation System|Implant of the Bioness StimRouter Neuromodulation System in subjects with chronic pain of peripheral nerve origin
89309259|NCT01140165|Active Comparator|butter|Danish butter
89309260|NCT01140165|Experimental|cheese|
89309261|NCT01235871|Experimental|SB1578|
89309262|NCT01235871|Placebo Comparator|Placebo|
89309263|NCT01234233|No Intervention|Group 1|Control group - no intervention: no preoperative warming
89309264|NCT01234233|Active Comparator|Group 2 - 10 min prewarming|10 min prewarming preoperatively
89309265|NCT01234233|Active Comparator|Group 3 - 20 min prewarming|20 min prewarming preoperatively
89309266|NCT01234233|Active Comparator|Group 4 - 30 min prewarming|30 min prewarming preoperatively
89309267|NCT01143987|Experimental|Cinacalcet|Oral cinacalcet
89309268|NCT01144065||Patient with acute MI|Patients with acute MI ( elevated cardiac enzymes + chest pain or typical ECG changes)admitted to the cardiology department at Meir Medical Center
89309269|NCT01144065||Patient with prior cardiovascular disease and/or diabetes|These patients do not have acute coronary syndrome or stroke. Prior cardiovascular disease (CVD) is defined as a history of hospital admission due to acute coronary artery occlusion, percutaneous coronary interventions (PCI), coronary artery bypass grafting, any aortic or peripheral vascular disease that was either symptomatic or required intervention, ischemic or hemorrhagic stroke or transient ischemic attack.
89309270|NCT01144065||Patients without prior cardiovascular disease or diabetes|These patients do not have acute coronary syndrome or stroke Prior cardiovascular disease (CVD) or diabetes
89309271|NCT01329705|Active Comparator|Control|All patients will be treated with the current standard of care including onabotulinum toxin
89309272|NCT01329705|Experimental|Dynasplint|Patients in the experimental Dynasplint group will be treated with the current standard of care, including onabotulinum toxin, and use the Ankle Dorsiflexion Dynasplint
89309273|NCT01142505|Placebo Comparator|Placebo|Patients in the placebo arm will be given an inactive version of the investigational medical product formed of the excipient mannitol (which is coated with the active drug montelukast in the active comparator arm)
89309274|NCT01142505|Active Comparator|Montelukast|Patients in the active arm will be given an active version of the investigational medical product formed of the inactive excipient mannitol with a coating of active drug montelukast.
89309275|NCT01236963|Experimental|Essential oils mouthrinse|Subjects use the essential oils mouthrinse
89309276|NCT01236963|Active Comparator|Dental floss|Subjects use dental floss
89309277|NCT03305926|Active Comparator|Conventional CVR|
89309278|NCT03305926|Experimental|eCVR|
89309279|NCT03610672|Active Comparator|OD prevention/response training|Immediately following the baseline assessment, trained research staff will conduct a brief (20 min.) OD training with each participant. Participants will be asked to view the NYC Department of Health and Mental Hygiene's 13-minute OD prevention and response training video (available online free-of-charge). Following the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to execute this assembly procedure. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
89309280|NCT03610672|Experimental|OD training + mobile PI intervention|Participants will complete the same baseline assessment and OD training (plus naloxone) as those in the first condition. Participants also will receive mobile phones pre-loaded with the PI App and will be sent daily prompts. As part of the PI App, participants will be asked to share information about avoiding problems associated with opioid use with peers in their social network, and to encourage their peers to download the PI App for their own use.
89309281|NCT02032732||suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for suspected infection
89309282|NCT02032732||no suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for reason other than suspected infection
89309283|NCT02032966|Experimental|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
89309284|NCT02032966|Active Comparator|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
89309285|NCT02032966|Other|syndesmotic injury|"Non-randomized / syndesmotic injury: patients who have a positive ligament stress test (signifying a syndesmotic injury) during surgery will require surgical treatment of both the tibia and the fibula and cannot be randomized to either arm (nonsurgical versus surgical). Patients in this arm will still be included in the study for the collection of clinical and functional outcomes."
89309286|NCT02033278|Experimental|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
89309287|NCT02033278|Placebo Comparator|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
89309288|NCT01336894|Active Comparator|Arm I (SR+Brachytherapy)|Patients undergo sublobar resection comprising either a wedge resection or anatomical segmentectomy with or without intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
89309289|NCT01336894|Experimental|Arm II (SBRT)|Patients undergo 3 fractions of stereotactic body radiation therapy at 2-8 days apart.
89309290|NCT02572167|Experimental|Brentuximab Vedotin + Nivolumab|Brentuximab vedotin plus nivolumab
89309291|NCT01140243|Experimental|test product|Dietary supplement
89309292|NCT01140243|Active Comparator|standart|Dietary supplement
89309293|NCT01140321|Experimental|Neridronato|Thalassemia Major or Severe Thalassemia Intermedia
89309294|NCT01140321|No Intervention|Placebo|Thalassemia Major or Severe Thalassemia Intermedia
89309295|NCT01336738|Placebo Comparator|Placebo|Matching placebo for PF-04991532 and Sitagliptin
89309296|NCT01336738|Experimental|150 mg PF-04991532|
89309297|NCT01336738|Experimental|450 mg PF-04991532|
89309298|NCT01336738|Experimental|750 mg PF-04991532|
89309299|NCT01336738|Active Comparator|Sitagliptin 100 mg|
89309300|NCT01236027||HIV-negative women|HIV-negative women who agree to have specimens collected for validation of laboratory procedures
89309301|NCT01140399|Active Comparator|Infusional drug treatment|Diuretics or diuretics plus fixed low dose dopamine infusion
89309302|NCT01140399|Experimental|Ultrafiltration|Device: Ultrafiltration appliance Sessions of 8 h UF are conducted on 2 subsequent days in the first 48 hours after randomization; a third session is performed on day 3 in case of persistent congestion
89309303|NCT02410317|Experimental|Continuous wound infusion group|Patients receive analgesia through a multiorifice wound catheter connected to ropivacaine infusion. Saline solution is given in the epidural bolus.
89309304|NCT02410317|Active Comparator|Epidural morphine group|Patients receive epidural analgesia through an epidural bolus of morphine. Saline solution is perfused through the wound catheter.
89309305|NCT01237119|Experimental|Liraglutide|A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
89309306|NCT01237119|Placebo Comparator|Placebo|Liraglutide-Placebo manufactured by Novo Nordisk.
89309307|NCT04888455||Painful neuropathy|Patients with presence of probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of NC or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy AND with probable or definite neuropathic pain according to the NeuPSIG algorithm.
89309308|NCT04888455||Painless neuropathy|Patients with presence of probable (presence of a combination of symptoms and signs of neuropathy include any two or more of the following: neuropathic symptoms, decreased distal sensation, or unequivocally decreased or absent ankle reflexes) or confirmed (presence of an abnormality of NC or validated measure of small fiber neuropathy with class 1 evidence with corresponding symptoms) neuropathy AND with unlikely neuropathic pain according to the NeuPSIG algorithm.
89309309|NCT01144221|Experimental|Stem cell treatment|Patients treated via stem cell injection
89309310|NCT01142739||Parkinson's Disease patient|levodopa-treated parkinson's disease (PD) patients
89309311|NCT01142739||Non Parkinson's disease controls|Non Parkinson's disease controls
89309312|NCT01237275|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline
89309313|NCT01237977|Experimental|Botulinum toxin type A(Meditoxin®)|
89309314|NCT01237977|Active Comparator|Botulinum toxin type A(Botox®)|
89309315|NCT01234389|Other|H. pylori positive patients|
89309316|NCT01234389|Other|H. pylori negative patients|
89309317|NCT02865538|Placebo Comparator|BAY3427080 Placebo|
89309318|NCT02865538|Experimental|50mg BAY3427080|
89309319|NCT02865538|Experimental|100mg BAY3427080|
89309320|NCT02865538|Experimental|150mg BAY3427080|
88815951|NCT02518191|No Intervention|None GnRHa group|Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.
89309321|NCT02865538|Experimental|300mg BAY3427080|
89309322|NCT02033434|Experimental|Intranasal Ketamine|All patients
89309323|NCT03610594|Experimental|kalaripayattu|The experimental groups will treated with kalaripayattu exercises for the period of 12 weeks
89309324|NCT03610594|No Intervention|Wait list control|Control group will not be given any intervention. After the treatment period is over, all the subjects will be given Kalaripayattu training.
89309325|NCT03610204|Experimental|Deep massage (DM) group|"The therapist performs the deep massage with buffalo horn technique. A small rod with a cone-like end was used in the technique. By pressuring the rod end with a higher force against the body surface of the participant, it produces higher pressure that may release the deep-layer fascia of muscles. Thus this technique features a deep massage."
89309326|NCT03610204|Active Comparator|Superficial massage (SM) group|"The therapist performs the superficial massage with buffalo horn technique. By pressuring the rod end with a lower force against the body surface of the participant, it produces lower pressure. Thus this intervention features a superficial massage."
89309327|NCT02712112|Experimental|Intermittent dosing arm|one-week on and one-week off schedule(Imatinib Mesylate, 400 mg once daily, oral)
89309328|NCT02712112|Sham Comparator|Continuous dosing arm|continuous dosing without off-treatment schedule(Imatinib Mesylate, 400 mg once daily, oral)
89309329|NCT02860546|Experimental|TAS-102 + Nivolumab|Participants received a dose of 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice per day (BID) within 1 hour after completion of morning and evening meals, in 4-week cycle. In each 4-week cycle, TAS-102 was administered for 2 weeks, as 5 days a week with 2 days rest, followed by a 14-day rest. Also participants received 3 milligrams per kilogram per dose (mg/kg/dose) Nivolumab intravenous (I.V) infusion over 60 minutes every 14 days (on Day 1 and Day 15 of each 4-week cycle).
89309330|NCT01982955|Experimental|Phase 1b: Tepotinib 300 mg + Gefitinib 250 mg|Participants received Tepotinib 300 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
89309331|NCT01982955|Experimental|Phase 1b: Tepotinib 500 mg + Gefitinib 250 mg|Participants received Tepotinib 500 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
89309332|NCT01982955|Experimental|Phase 2: Tepotinib 500 mg + Gefitinib 250 mg (MET + T790 negative)|Participants randomized to receive Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
89309333|NCT01982955|Experimental|Phase 2: Pemetrexed and Cisplatin/Carboplatin (MET + T790 negative)|Participants randomized to receive 500 milligram per square meter (mg/m^2) of Pemetrexed as intravenous infusion over 10 minutes in combination with Cisplatin (75 mg/m2 as an intravenous infusion over 2 hours) or Carboplatin (intravenously at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator) on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment or up to 6 cycles if or 4 cycles followed by Pemetrexed maintenance monotherapy.
89309334|NCT01982955|Experimental|Phase 2: Single-arm Cohort (MET+ T790M positive)|Participants with MET+ T790M positive Non-small Cell Lung Cancer (NSCLC) received a Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
89309335|NCT01144533|Placebo Comparator|Isotonic saline|
89309336|NCT01144533|Experimental|Steroid|
89309337|NCT01144533|Experimental|Hyaluronate|
89309338|NCT01144533|Experimental|Steroid + Hyaluronate|
89309339|NCT01238055|Experimental|Docetaxel + Sunitinib|Docetaxel and Sunitinib
89309340|NCT01238055|Active Comparator|Docetaxel|Docetaxel only
89309341|NCT01144611|Active Comparator|bIAP|intravenous as a bolus of bIAP (alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
89309342|NCT01144611|Placebo Comparator|placebo|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
89309343|NCT01144923|Active Comparator|Conservative treatment|Pharmacotherapy with nortriptyline and/ or gabapentin, physical therapy (e.g. range of motion, therapeutic massage, strengthening exercises), and possibly others (e.g. acupuncture)
89309344|NCT01144923|Experimental|Epidural Steroids|A series of up to 3 epidural steroid injections (ESI)with depo-methylprednisolone
89309345|NCT01144923|Experimental|Combination Treatment|These patients will receive both treatments. They can have up to 3 epidural steroid injections (ESI) with depo-methylprednisolone, and conservative treatment (i.e. pharmacotherapy with nortriptyline and/ or gabapentin, and physical therapy)
89309346|NCT01329783||EuroSIDA sub-cohort|HIV infected patients in the EuroSIDA cohort who meet the entry criteria for maraviroc pivotal clinical trials (MOTIVATE 1 and MOTIVATE 2)
89309347|NCT05667675|Experimental|Community Support Worker|Participants in the intervention group will have a structured review of their financially related needs and resources with a trained CSW, who will have a thorough understanding of potential income supports and community support agencies. The CSW will use a structured approach to identify financial needs and benefits for which the family is eligible The CSW will work intensively with families in the intervention arm to identify and meet their goals. They will conduct weekly meetings to complete forms, and provide advocacy (in person and by telephone) as needed up to six meetings as needed for system navigation.
89309348|NCT05667675|Active Comparator|Control|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. For this proposal, participants in the comparator group will receive Usual care, defined as: Participants in both groups will receive a written summary of available resources.
89309349|NCT01238133|Experimental|Treatment (RO4929097, paclitaxel, carboplatin, surgery)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17, paclitaxel IV over 60 minutes on days 1, 8, and 15 (day -1 of course one), and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after completion of neoadjuvant therapy, patients undergo definitive breast surgery.
89309350|NCT01237431|Experimental|liver transplanted patients|Target group to confirm the hypothesis. Transplantation has to be between 6 an 24 Month before participation.
89309351|NCT01237431|Active Comparator|kidney transplanted patients|Control group, age, gender and medication matched. Transplantation has to be between 6 an 24 Month before participation.
89309352|NCT01144689|Experimental|Mindfulness Training|
89309353|NCT01144689|Active Comparator|Smoking Cessation Therapy|
89309354|NCT05306145|Experimental|High Freqnence Irreversible Electroporation|Using high freqnence irreversible electroporation to treat patients with benign prostatic hyperplasia
89309355|NCT05306145|Active Comparator|Trans Urethral Resection Prostate|Using trans urethral resection prostate to treat patients with benign prostatic hyperplasia
89309356|NCT01237509||group1|Patients with T1D
89309357|NCT01200147|No Intervention|Study withdrawn no details|
89309358|NCT01144767|Experimental|Computer-generated advisor|Participants receive sessions with a computer-generated adviser who will provide tailored advice and encouragement to engage in physical activity.
89309359|NCT01144767|Active Comparator|Comparison control condition|Participants will receive live, group sessions on health topics unrelated to physical activity.
89309360|NCT04378179||HFpEF|HF patients with preserved ejection fraction (HFpEF)
89309361|NCT04378179||HFrEF|HF patients with reduced ejection fraction (HFrEF)
89309362|NCT04378179||PH|Patients with Pulmonary hypertension (PH)
89309363|NCT04378179||Control|Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF or PH but meet other inclusion criteria and none of the exclusion criteria.
89309364|NCT04378179||Controls with suspected CAD|Elective patients visiting hospital cardiology who are not diagnosed with either HFpEF or HFrHF or PH but meet other inclusion criteria and none of the exclusion criteria, and may have a diagnosis of Coronary Artery Disease (CAD) or may be suspected to have CAD.
89309365|NCT01145079|Experimental|Endeavor arm|
89309366|NCT01145079|Active Comparator|Endeavor resolute arm|
89309367|NCT01145079|Active Comparator|Xience arm|
89309368|NCT01145079|Active Comparator|Cypher arm|
89309369|NCT01145157|Experimental|Signature Knee Guide|Total Knee Arthroplasty using the Signature Knee Guide with the Vanguard Knee System
89309370|NCT01145157|Active Comparator|Conventional Instrumentation|Total Knee Arthroplasty will be performed using Conventional Instrumentation with the Vanguard Knee System
89309371|NCT01145157|Active Comparator|Computer Assisted Navigation|Total Knee Arthroplasty will be performed using Computer Assisted Navigation with the Vanguard Knee System
89309372|NCT01146483|Active Comparator|Pantoprazole|two-arm study: 2-period, 2-sequence, cross-over study.Volunteers will be administered either sequence 1 or sequence 2 randomly.
89309373|NCT01146483|Placebo Comparator|Placebo|
89309374|NCT01244373||Patients with senile cataract|Patients with senile cataract
89309375|NCT01144845||Thoracic surgical patients|Patients with pulmonary malignancies
89309376|NCT01145313||Patients diagnosed with Major Depressive Disorder|Patients diagnosed with MDD who are treated with antidepressants and subsequently augment with atypical antipsychotic therapy.
89309377|NCT01237665|Experimental|IXO regimen|single-group
89309378|NCT01244997|Experimental|Immediate implant placement|This arm is an immediate placement of a dental implant following tooth extraction.
89309379|NCT01244997|Active Comparator|Delayed Implant|This is the traditional method for implants. This arm will be done following a healing of the area.
89309380|NCT01245153|Experimental|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught Foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water. Subjects will contract pelvic floor muscle in standing position by contracting the pelvic floor muscle, hold and count 1 to 5, then relax and count 1 to 5. Subjects are instructed to do the exercise 15 times/set, 3 sets/day, every day for 6 weeks.
89309381|NCT01245153|Active Comparator|Control group|Patients receive Pelvic floor muscle training without inserting any kinds of equipment.
89309382|NCT00396279|Experimental|Denosumab|Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.
89309383|NCT01238367|Experimental|recombinant factor VIII (N8)|
89309384|NCT01347866|Experimental|Arm D: PF-05212384 + PD-0325901|
89309385|NCT01347866|Experimental|Arm C: PF-05212384 + irinotecan|
89309386|NCT01347710|Experimental|Flurpiridaz F18|Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to a single dose of 99mTc sestamibi or tetrofosmin for SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization
89309387|NCT03485222|Experimental|Empagliflozin|10mg once a day
89309388|NCT03485222|Placebo Comparator|Placebos|placebo once a day
89309389|NCT01347554|Active Comparator|Xience V stent group|Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction
89309390|NCT01347554|Active Comparator|Endeavor resolute group|Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction
89309391|NCT05567354|Experimental|PF614 100 mg capsule|Eligible subjects will be admitted to the clinical site on Day-1. Subjects will receive PF614 100mg capsules in a randomized, double-blind, crossover manner.
89309392|NCT05567354|Active Comparator|Oxycodone HCl tablets|Eligible subjects will be admitted to the clinical site on Day -1. Subjects will receive crushed oxycodone HCl IR 40mg in a randomized, double-blind, crossover manner.
89309393|NCT05567354|Placebo Comparator|Placebo powder in capsules|Eligible subjects will be admitted to the clinical site on Day-1. Subjects will receive Placebo powder in a randomized, double-blind, crossover manner.
89309394|NCT03482882|Experimental|Drug - pimavanserin|
89309395|NCT01311518|Placebo Comparator|Placebo|
89309396|NCT01311518|Active Comparator|Drug: Thymosin Beta 4 injectable|
89309397|NCT03480932|Active Comparator|SOF+DAC+PEG|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach
89309398|NCT03480932|Active Comparator|SOF+DAC, DOT|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach
89309399|NCT03480932|Active Comparator|SOF+DAC, standard|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)
89309400|NCT03387020|Experimental|Treatment (ribociclib, everolimus)|Patients receive ribociclib PO QD on days 1-21 of course 1 and subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1 and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for up to 13 additional courses in the absence of disease progression or unacceptable toxicity.
89309401|NCT03386474|Experimental|Brolucizumab|Brolucizumab 6 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8, and Week 16 or Week 20
89309402|NCT03386474|Other|Aflibercept|Aflibercept 2 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8 and Week 16 to maintain the masking of the extension trial only.
89309403|NCT03405818|Experimental|Tavaborole 5% Topical Solution|All study participants apply study drug
89309404|NCT03403634|Experimental|Treatment (celecoxib, interferon alfa-2b, rintatolimod)|Patients receive celecoxib orally PO BID, recombinant interferon alfa-2b IV QD over 20 minutes, and rintatolimod IV QD on days 1, 2, 3, 8, 9, 10, 15, 16 and 17 in the absence of disease progression or unacceptable toxicity.
89309405|NCT03403400|Experimental|VRWP Group|Vestibular Rehabilitation plus Walking with Pedometer Groupd
89309406|NCT03403400|Active Comparator|VRW Group|Vestibular Rehabilitation plus Walking without Pedometer Group
89309407|NCT03403400|No Intervention|VR Group|Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
89309408|NCT02863354|Experimental|Q4WKS|"Aflibercept 2 mg every 4 weeks (defined as every 28 days (+ 7 days) and at least 21 days between injections) through week 48. Following week 48, aflibercept 2 mg every 12 weeks through week 96.~If NV or PDR are worse per pre-specified criteria at week 60, or at any study visit thereafter, the subject will be treated every 4 weeks through the end of the study."
89309409|NCT02863354|Experimental|Q12WKS|"Aflibercept 2 mg every 12-weeks. Subjects will be followed every 4 weeks through week 12, and can be treated if the pre-specified criteria are met. Starting at week 12 if NV or PDR are stable or improved (as assessed by investigator) the subject will be monitored and treated at a 12-week interval through week 48. If NV or PDR are worse per the pre-specified criteria at week 12, or at any study visit thereafter, the subject will be treated monthly through the end of the study.~At week 52, aflibercept 2 mg every 4 weeks (defined as 28 days (+ 7 days) and at least 21 days between injections) for subjects with visible retinal non-perfusion. If retinal non-perfusion has completely resolved at week 72, aflibercept every 12 weeks through end of study. For subjects without retinal non-perfusion at week 52, aflibercept 2 mg every 12 weeks through the end of study."
89309410|NCT03480152|Experimental|1/Phase - Escalating doses of mRNA vaccine|Escalating doses of messenger ribonucleic acid (mRNA) vaccine
89309411|NCT03480152|Experimental|2/Phase II -MTD of mRNA vaccine established in Phase I|Maximum tolerated dose (MTD) of messenger ribonucleic acid (mRNA) vaccine established in Phase I
89309412|NCT05554172|Experimental|Vagal Nerve Stimulation (taVNS)|taVNS stimulation administered during intervention
89309413|NCT05554172|Sham Comparator|Sham Stimulation (Sham)|Sham stimulation administered during intervention
89309414|NCT02859454|Experimental|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
89309415|NCT02862730|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient. The predictive low glucose suspend system will run through the artificial pancreas controller in predictive low glucose suspend mode and utilize the patient's optimized basal rates, correction factor, and carb ratio, but it will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
89309416|NCT02862730|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in dual hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
89309417|NCT02862730|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
89309418|NCT02862730|Active Comparator|Sensor Augmented Pump Therapy arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient with subject's insulin pump and glucose sensor, if he/she typically uses one. Subjects will still wear a heart rate monitor uploading to a smart phone.
89309419|NCT02033668|Active Comparator|Arm A|Participants in this arm will receive single 200 milligram (mg) dose of GSK933776 administered by IV infusion
89309420|NCT02033668|Experimental|Arm B|Participants in this arm will receive single 200 mg dose of GSK933776 administered SQ
89309421|NCT02033668|Experimental|Arm C|Participants in this arm will receive 50 mg dose of GSK933776 administered SQ once weekly for 4 weeks (total dose = 200 mg).
89309422|NCT02033668|Experimental|Arm D|Participants in this arm will receive single 200 mg dose of GSK933776 administered IM
89309423|NCT02033590|Experimental|SERI® Surgical Scaffold|
89309424|NCT03609970|No Intervention|Control|No intervention
89309425|NCT03609970|Experimental|UVR (Solar simulated radiation)|Twice weekly 1.25 SED (sub-erythemal) (4 weeks)
89309426|NCT03609970|Experimental|Vitamin D3 supplementation|4X 1000IU cholecalciferol tablets daily (28 days)
89309427|NCT03610282|Experimental|EEG Dynamics|EEG data will be collected on patients receiving propofol and IV methylphenidate together.
89309428|NCT03610282|Placebo Comparator|Propofol EEG Dynamics|EEG data will be collected on patients receiving propofol and a saline placebo.
89309429|NCT05544500|Placebo Comparator|Placebo|Sugar-free tablet
89309430|NCT05544500|Active Comparator|Basic sugar-free gum|Sugar-free chewing gum
89309431|NCT05544500|Experimental|Functional gum|Sugar-free chewing gum with functional ingredients
89309432|NCT05459558|Experimental|Experimental Dentifrice 1|Randomized participants will brush their teeth with the experimental dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks.
89309433|NCT05459558|Experimental|Experimental Dentifrice 2|Randomized participants will brush their teeth with the experimental dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks.
89309434|NCT05459558|Active Comparator|Reference Dentifrice|Randomized participants will brush their teeth with the Reference dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks.
89309435|NCT03353792|Active Comparator|CL/AP system|To improved glycemic control and strict avoidance of hypoglycemia via 8-week use of a CL/AP system (closed-loop/artificial pancreas) reverses brain metabolic adaptations in older adult T1DM patients.
89309436|NCT03353792|Placebo Comparator|usual care|Subjects in this control group will continue their usual diabetic care (insulin pump therapy) along with CGM recording.
89309437|NCT02862574|Experimental|Andecaliximab 300 mg|Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
89309438|NCT02862574|Experimental|Andecaliximab 150 mg|Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
89309439|NCT02862574|Placebo Comparator|Placebo|Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
89309440|NCT02862574|Experimental|Open-Label Extension|On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
89309441|NCT04581538|No Intervention|Control group|This arm is being provided with continued home care as it was before
89309442|NCT04581538|Experimental|E-learning platform & networking platform|This arm is being provided with the e-learning platform and networking platform as components of the 24-h-quAALity package
89309443|NCT04581538|Experimental|Entire intervention|This arm is being provided with the entire intervention (e-learning platform, networking platform and digital care documentation)
89309444|NCT05383300|Other|Violent offenders with psychopathy|Violent offenders with psychopathy
89309445|NCT05383300|Other|Violent offenders without psychopathy|Violent offenders without psychopathy
89309446|NCT05383300|Other|Healthy non-offenders|Healthy non-offenders
89309447|NCT04576702|Experimental|Investigational aIIV4c group|aIIV4c will be administered as a single dose intramuscularly on Day 1
89309448|NCT04576702|Active Comparator|licensed IIV4c type 1 group|IIV4c will be administered as a single dose intramuscularly on Day 1
89309449|NCT04576702|Active Comparator|licensed aIIV4 group|aIIV4 will be administered as a single dose intramuscularly on Day 1
89309450|NCT04576702|Active Comparator|licensed RIV4 type 2 group|RIV4 will be administered as a single dose intramuscularly on Day 1
89309451|NCT05530928|No Intervention|Control Group|This group will receive the standard care (standard family planning counseling)
89309452|NCT05530928|Other|Intervention Group|This group will receive the standard family planning counseling + reproductive life plan counseling.
89309453|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm A|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator while receiving concurrent buprenorphine-naloxone as prescribed
89309454|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm B|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator treatment while receiving concurrent buprenorphine-naloxone as prescribed
89309455|NCT02033824|Other|Group 1 Control|Will receive only traditional craniectomy
89309456|NCT02033824|Experimental|Group 2 Treatment dHACM|Will receive craniectomy, but with the addition of a piece of dHACM placed over any dural defect or dural closure.
89309457|NCT03712046|Experimental|Main arm|PET-CT imaging of the ankles and feet following injection of 18F-FDG
89309458|NCT02862106|Experimental|εPA-44 900μg group-placebo|These subjects from the placebo group of protocol 71006.01 InjectεPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
89309459|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
89309460|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
89309461|NCT02862106|No Intervention|Follow-up group-placebo|These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only
89309462|NCT02862106|No Intervention|Follow-up group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
89309463|NCT02862106|No Intervention|Follow-up group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
89309464|NCT03609892|Experimental|berberine plus amoxicillin quadruple therapy|Berberine 500mg three time daily for 14days, amoxicillin 1000 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
89309465|NCT03609892|Active Comparator|tetracycline plus furazolidone quadruple therapy|Tetracycline 500mg three time daily for 14days，furazolidone 100 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
89309466|NCT03609814||Pediatric Bone Marrow Transplantation Recipients|Children undergoing alloHCT at UCSF Benioff Children's Hospital.
89309467|NCT03610126||volume controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway mechanical ventilation of patients will be maintained with volume controlled ventilation mode
89309468|NCT03610126||pressure controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway and mechanical ventilation of patients will be maintained with pressure controlled ventilation mode
89309469|NCT04157296|Experimental|CBT and computerized cognitive training (CCT)|Participants will play CCT games at home 5 times per week for two weeks before beginning CBT and for two weeks after the first CBT session. Then participants will have CCT games immediately prior to CBT for nine more weeks (one time a week).
89309470|NCT04157296|Active Comparator|Cognitive behavioral therapy|Participants will receive CBT sessions once a week for 12 weeks.
89309471|NCT02859142|Experimental|Augmented Treatment|"Participants receive 12 weeks of Chantix along with standard smoking cessation treatment of nicotine patches and behavioral counseling visits.~Chantix (Varenicline) and NicodermCQ (Nicotine Patches): Administered according to package insert directions~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
89523400|NCT03376997|Experimental|Perampanel: 30-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 milligram (mg) dose of perampanel intravenous (IV) infusion (30-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
89309472|NCT02859142|Active Comparator|Standard Treatment w/ placebo|"Participants receive 12 weeks of standard smoking cessation treatment of nicotine patches and behavioral counseling visits in addition to placebo pills identical in appearance to varenicline~Placebo pills (identical to varenicline)~NicodermCQ (Nicotine Patches): Administered according to package insert directions~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
89309473|NCT02033902||Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
89309474|NCT04530760||intraabdominal hypertension group|patients with intraabdominal hypertension defined as intravesical pressure more than 12 mmHg
89309475|NCT04530760||control group|patients with no intraabdominal hypertension
89309476|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part A)|Single intravenous (i.v.) bolus of sugammadex at 2 mg/kg.
89309477|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part A)|Single i.v. bolus of sugammadex at 4 mg/kg.
89309478|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part B)|Single i.v. bolus of sugammadex at 2 mg/kg.
89309479|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part B)|Single i.v. bolus of sugammadex at 4 mg/kg.
89309480|NCT03351608|Active Comparator|Neostigmine (Part B)|Single i.v. bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
89309481|NCT03711968|Active Comparator|Treatment group|"Rehabilitative treatment protocol:~Therapeutic exercise 8 mono-weekly sessions, 5 patients per group, duration 60 minutes and two sessions of single treatment, duration 60 minutes (duration of treatment about two months, considering also any recovery sessions)"
89309482|NCT03711968|No Intervention|Waiting list|Intervention: The WL patients will be taken into the same treatment at the end of the experimental protocol, after T2 evaluation. In this period they act like a control group.
89309483|NCT03711344|Experimental|Culturally adapted Cognitive Behavioral therapy|The experimental group will receive the culturally adapted version of cognitive behavioral therapy.
89309484|NCT03711344|Active Comparator|Non-adapted Cognitive Behavioral therapy|The control group will receive the original (non-adapted) version of cognitive behavioral therapy.
89309485|NCT03711734|Experimental|Acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.~Patients will have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally with electrostimulation at Shen men and Hypothalamus at 30 hz."
89309486|NCT03711734|No Intervention|No acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.~Patients will not have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally."
89309487|NCT02857816|Other|NURO System PTNM Therapy|Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.
89309488|NCT04433728||Adults Phenylketonuric|Adults patients screened in neonatal period for PKU and treated
89309489|NCT02858440|Experimental|DTPa-IPV/Hib Group|All subjects receive three doses of primary vaccination of the study vaccine, Infanrix-IPV/Hib (DTPa-IPV/Hib), at 3, 4.5 and 6 months of age and a single dose of booster vaccination at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
89309490|NCT03609268|Active Comparator|MWA|Patients receive microwave ablation (MWA)
89309491|NCT03609268|Experimental|SBRT|Patients receive stereotactic body radiotherapy (SBRT)
89309492|NCT03382418|Experimental|Group 1: gp145 C.6980 (high dose)|Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
89309493|NCT03382418|Experimental|Group 2: gp145 C.6980 (low dose)|Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
89309494|NCT03382418|Placebo Comparator|Group 3: Placebo|Participants will receive placebo at Day 0 and Months 2 and 6.
89309495|NCT02858362|Experimental|Cohort 1: SMT C1100 Formulation 1|Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
89309496|NCT02858362|Experimental|Cohort 2: SMT C1100 Formulation 2|Participants received 1 g SMT C1100 formulation 2 orally twice-daily for at least 48 weeks.
89309497|NCT02858362|Experimental|Cohort 3: SMT C1100 Formulation 1|Participants in this cohort had previously received SMT C1100, but were not eligible for Cohorts 1 or 2. Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
89309498|NCT03609502|Experimental|behavioral|Adults with and without language impairment will be given three different types of behavioral training, and assessments of learning through those trainings, at two time points.
89309499|NCT03609502|Experimental|neuroimaging|Following speech sound behavioral training, adults with and without language impairment will undergo post-training perceptual assessments in an MRI scanner before and after post-training sleep.
89309500|NCT02236936|Active Comparator|Arm A - Standard of care|"Standard care of parenteral nutrition (with or without parenteral nutrition during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
89309501|NCT02236936|Experimental|Arm B - Parenteral over night nutrition|"Parenteral over night nutrition with ZentroOLIMEL 5.7% parenteral over night with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) 15 ml/kg body weight/day (weight loss >5% from baseline; parenteral nutrition increased up to 25 ml/kg body weight per day) during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
89309502|NCT03638960|Active Comparator|Bupivacaine|Patients in group A will receive a bolus injection with 20 mL of 0.5% bupivacaine.
89309503|NCT03638960|Experimental|Liposomal bupivacaine|Group B will receive 10 mL of 133 mg of liposomal bupivacaine mixed with 10 mL 0.5% bupivacaine.
89309504|NCT02259790|Experimental|Telmisartan/amlodipine fixed-dose combination|
89309505|NCT02259790|Active Comparator|Telmisartan tablet and amlodipine tablet|
89309506|NCT02857270|Experimental|LY3214996 Dose Escalation|LY3214996 given orally once a day (or twice a day) for 21 days.
89309507|NCT02857270|Experimental|LY3214996 + Midazolam|"(Preliminary Drug-Drug Interactions [DDI])~LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days)."
89309508|NCT02857270|Experimental|LY3214996 Dose Expansion|LY3214996 given orally (once a day) during each 21 day cycle.
89309509|NCT02857270|Experimental|LY3214996 + Abemaciclib|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.
89309510|NCT02857270|Experimental|LY3214996 + Nab-Paclitaxel + Gemcitabine|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.
89309511|NCT02857270|Experimental|LY3214996 + Encorafenib + Cetuximab|Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV.
89309512|NCT02857270|Experimental|Japan Part 1|LY3214996 given orally.
89309513|NCT02857270|Experimental|Japan Part 2|LY3214996 given orally and abemaciclib given orally.
89309514|NCT03350750|Active Comparator|Open Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to active (open shunt group)(setting 4)(110 mm H2O) at time of shunt implantation
89309515|NCT03350750|Sham Comparator|Closed Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to placebo (closed shunt group)(setting 8)(>400 mm H2O) at time of shunt implantation followed by setting to active (setting 4) (110 mm H2O) four months after the procedure.
89309516|NCT04095676|Experimental|VATS / surgical group|The VATS procedure must be completed as soon as possible and no later than 48 hours after randomisation. The surgery is performed with the patient in a 90 degree sideways position, using general anesthesia. Access is obtained through one to three ports, followed by purification and possibly decortication, and insertion of one pleural drain (sizes 24 - 32F) at the end of surgery. 20 ml Marcain is used as local analgetic and applied at the incision sites or as a nerve block. In the VATS group, suction on drain (- 15 cm H20) is applied in the first day after the procedure. Operator must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be registered and approved by the steering committee.
89309517|NCT04095676|Active Comparator|Drain and intrapleural therapy group|"Pigtail is applied as soon as possible and within 48 hours after randomisation. Drain placement is carried out using ULS. Operators (conductors of the procedure) must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be approved by the steering committee to conduct the procedure. A pigtail catheter (minimum 10F) is inserted. Operator determines the size of drain and whether drain placement is done with one-step or Seldinger technic.~The intrapleural therapy consists of treatment with the following two drugs:~intrapleural Actilyse® (alteplase) 10 mg twice daily for three days~intrapleural Pulmozyme® (DNase) 5 mg twice daily for three days"
89309518|NCT03609190|Experimental|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
89309519|NCT03609190|Placebo Comparator|Placebo|i.v. infusion of NaCl over 40 min
89309520|NCT03394508|Placebo Comparator|Placebo|ALK diluent 0,3% human albumin'
89309521|NCT03394508|Experimental|Active treatment|Intervention: Drug ALK Alutard birch or 5-grasses. Grass pollen suspension or birch pollen suspension
89309522|NCT02856880|Experimental|Test zinc-IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 milliliter (mL) water for 60 seconds(s) followed by rinse with 10mL water
89309523|NCT02856880|Experimental|Test zinc non- IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
89309524|NCT02856880|Active Comparator|Positive control Toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
89309525|NCT02856880|Active Comparator|SLS Negative Control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
89309526|NCT02856880|Active Comparator|non-SLS negative control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
89309527|NCT03393806|Experimental|Participants receiving GSK3772847|Participants will be randomized to receive GSK3772847 as IV infusion. Participants will receive three doses ( Day 1, Day 29 and Day 57) of GSK3772847 every 4 weeks
89309528|NCT03393806|Placebo Comparator|Participants receiving placebo|Participants will be randomized to receive matching placebo as IV infusion
89309529|NCT02856802|Experimental|DFN-02|Participants self-administered a single-dose of DFN-02 (sumatriptan 10-mg/100 μL nasal spray) intranasally within one hour of an acute migraine pain episode.
89309530|NCT02856802|Other|Placebo|Participants self-administered a single-dose of DFN-02 placebo nasal spray matching DFN-02 intranasally within one hour of an acute migraine pain episode.
89309531|NCT02237170||Castration Resistant Metastatic Prostate Cancer|Castration Resistant Metastatic Prostate Cancer with no history of prior systemic chemotherapy
89309532|NCT02024230|Active Comparator|Rivaroxaban|Patients were treated over a median of 4.75 years with either rivaroxaban (10 mg once daily for patients with a creatinine clearance of 15-49 mL/min or 15 mg once daily for patients with a creatinine clearance ≥50 mL/min)
89309533|NCT02024230|Active Comparator|Warfarin|The dose of warfarin can be controlled with dose adjustment to achieve a target international normalized ratio [INR] of 2.0-3.0 or in patients aged >70 years and having a high bleeding risk, a target INR of 1.6-2.6) according to the guideline of Japanese Circulation Society based on the following paper (Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J 2013;77(9):2264-70.)
89309534|NCT03380390|Experimental|Oxymetazoline + Energy-Based Therapy|Participants will receive energy-based therapy (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL]) plus once daily application of oxymetazoline hydrochloride (HCl) cream 1.0%.
89309535|NCT03350672|Experimental|Cohort 1a|"Age 18 or older at the time of signed informed consent~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~Willing and able to independently provide written informed consent~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
89309536|NCT03350672|Experimental|Cohort 1b|"Age 18 or older at the time of signed informed consent~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~Willing and able to independently provide written informed consent~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
89309537|NCT03350672|Active Comparator|Cohort 2|"Age 18 or older at the time of signed informed consent~Willing and able to independently provide written informed consent~Last viral load < 20 copies/mL within the last four weeks of screening~Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months~Undetectable viral load, as defined by < 50 copies/ml, for at least 6 months"
89309538|NCT02034292|Experimental|10mg MD|APD791 10mg Multiple dose and
89309539|NCT02034292|Experimental|20mg MD|APD791 20mg Multiple dose
89309540|NCT02034292|Experimental|40mg MD|APD791 40mg Multiple dose
89309541|NCT02034292|Experimental|60mg MD|APD791 60mg Multiple dose
89309542|NCT02034292|Placebo Comparator|Placebo MD|Placebo for Multiple dose group
89309543|NCT02034292|Experimental|120mg SD|APD791 120mg Single dose
89309544|NCT02034292|Experimental|240mg SD|APD791 240mg Single dose
89309545|NCT02034292|Experimental|320mg SD|APD791 320mg Single dose
89309546|NCT02034292|Placebo Comparator|Placebo SD|Placebo for Single dose
89309547|NCT03709628|Experimental|Patients with active Crohn's disease|EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.
89309548|NCT03609112||Patients treated for a brain tumor|As part of their usual follow-up, these patients have neuropsychological evaluations following their treatment. A complete neuropsychological evaluation will therefore be performed as part of their usual follow-up during the inclusion period of this study and only the data from this evaluation will be taken into account for the statistical analysis of this study.
89309549|NCT03609112||Patients treated for a non-cerebral tumor|A single neuropsychological assessment will be proposed to these patients after the end of treatment and during the inclusion period of this study. This evaluation will be carried out during a visit to Gustave Roussy as part of their usual follow-up. If on the occasion of this evaluation, cognitive disorders or psychological disorders were highlighted, a neuropsychological and / or psychological follow-up would be proposed.
89309550|NCT03609112||Patients who received Methotrexate|"Methotrexate is used in the treatment of certain brain tumors as in that of non-cerebral tumors. Some of these patients, particularly those who have had neurological complications with methotrexate, will already have longitudinal neuropsychological follow-up as part of their usual follow-up. For these patients, only one complete neuropsychological assessment will be performed during the inclusion period and will be considered for statistical analysis.~For patients in the course of treatment with methotrexate, during the period of inclusion of this study, a longitudinal follow-up will be carried out with neuropsychological evaluations close and successive at the time of their coming to Gustave Roussy within the usual framework of their care."
89309551|NCT01311830|Active Comparator|Telephone Counseling|
89309552|NCT01311830|Placebo Comparator|Written Materials|
89309553|NCT01311908||Surgery, Roux-en-Y , reflux esophagitis|Patients with roux-en-Y reconstruction (study group)
89309554|NCT01311908||surgery, traditional gastrojejunostomy|Traditional gastrojejunostomy reconstruction (control group).
89309555|NCT02034448||Acute Kidney Injury|CRRT intervention with adult patients with Acute Kidney Injury
89309556|NCT03608332|No Intervention|Group S|"weaning readiness will be evaluated with the standard criteria :- A) Clinical assessment:-~Resolution of acute phase of disease for which patient was intubated~Adequate cough~Absence of excessive tracheobronchial secretions~B) Objective criteria:-~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200~Respiratory rate <30~PH and PaCO2 appropriate for patients' baseline respiratory status~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~HR<140 beats/minute~Patient is arousable or Glasgow coma scale (GCS)>13"
89309557|NCT03608332|Experimental|Group SD|"weaning readiness will be evaluated with the following criteria:- A) Clinical assessment:-~Resolution of acute phase of disease for which patient was intubated~Adequate cough~Absence of excessive tracheobronchial secretions~B) Objective criteria:-~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200~Respiratory rate <30~PH and PaCO2 appropriate for patients' baseline respiratory status~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~HR<140 beats/minute~Patient is arousable or Glasgow coma scale (GCS)>13~C) Ultrasound criteria:-~• Diaphragmatic excursion >11 mm"
89309558|NCT03392168|Experimental|Cohort 1 - ARQ-151 cream 0.5%|Single-dose application of ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s)
89309559|NCT03392168|Experimental|Cohort 2 - ARQ-151 cream 0.5%|ARQ-151 cream 0.5% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
89309560|NCT03392168|Experimental|Cohort 2 - ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
89309561|NCT03392168|Placebo Comparator|Cohort 2 - ARQ-151 vehicle cream|Vehicle cream applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
89309562|NCT03608722|Experimental|BrainCheck vs Pen and paper tests|Compare patient performance on BrainCheck neurocognitive test vs pen and paper dementia tests (SLUMS, MMSE, MoCA), as well as an exploratory analysis comparing BrainCheck performance to aid in identifying patients with MCI and dementia vs physician diagnosis
89309563|NCT03608722|Experimental|BrainCheck performance in ESRD patients|Assess BrainCheck test performance in patients with ESRD and how undergoing hemodialysis treatment can impact cognitive performance.
89309564|NCT03711656|Experimental|isCGM and Physical exercise tracker|"Participants will perform CGM during 12 weeks using an isCGM (intermittently scanned Continuous Glucose Monitoring), Freestyle Libre, (Abbott Diabetes Care, Witney, Oxon, UK). Insulin dose (rapid-acting and long acting), carbohydrates and Self-monitoring blood glucose (SMBG) per day will be recorded by the patient in the reader or in the App (LibreLink, Abbott Diabetes Care, Witney, Oxon, UK). Moreover, participants will be instructed to collect data about moderate or high intensity exercise, illness and other disturbances occurring during the study period at home.~Patients will wear a physical exercise tracker (Fitbit Alta HR® wristband (Fitbit, Inc., San Francisco, California, USA)) to track physiological variables such as heart rate, steps, activity level and sleep quality."
89309565|NCT03608176|Experimental|PASO diet group|
89309566|NCT03608176|Active Comparator|Low-fat diet group|
89309567|NCT03608176|Other|Waiting list group|
89309568|NCT03391232|Experimental|PolyPEPI1018 CRC Vaccine|The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses.
89309569|NCT04125550|Experimental|Group P|In Group P, 2-3 mg/kg propofol, 5 µg/kg iv fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 10 mg/kg/h propofol infusion and 5 µg/kg/h fentanyl infusion will be administered.
89309570|NCT04125550|Active Comparator|Group S|In Group S, sevoflurane inhalation (2-8%), 5 microgr/kg intravenous (iv) fentanyl will be administered for anesthesia induction and 0.6 mg/kg rocuronium will be used as muscle relaxants. 2% sevoflurane inhalation and 5 µg/kg/h fentanyl infusion will be administered for the maintenance of anesthesia.
89309571|NCT03710954|Experimental|Experimental Group|All the volunteers were evaluated through numerical evaluation of pain that assumes a subjective condition, the researcher showed the numerical scale of pain, being 0 without pain, 1 to 4 mild pain, 5 moderate pain, 6 to 9 severe pain and 10 worse pain possible pain, which was interpreted by the volunteer. In the Fuzzy Pain Scale, the evaluation of the range of motion was done where the evaluator used the goniometer (plastic instrument that verifies the angulation of the joint movement) and supplied the Fuzzy system with these data.
89309572|NCT03608878|Active Comparator|TACE alone arm|TACE (Transarterial Chemoembolization)
89309573|NCT03608878|Experimental|adagloxad simolenin arm|TACE plus adagloxad simolenin/OBI-821 adjuvant therapy
89309574|NCT03379376|Experimental|Supportive Care (eMMB)|Participants receive a self-directed 20-minute eMMB video and are instructed to practice eMMB at least once before surgery and daily for 2 weeks after surgery. Participants may also request additional guidance from a yoga instructor via telephone and video conference before surgery and again 1 day after surgery or as soon as feasible.
89309575|NCT05383222|Experimental|ICU clinicians- technical first|Staff working on the Great Ormond Street ICUs Completing technical task first
89309576|NCT05383222|Experimental|ICU clinicians- administrative first|Staff working on the Great Ormond Street ICUs Completing administrative task first
89309577|NCT03608800|Experimental|Intermittent fasting|two nonconsecutive days of 75% diet energy restriction per week for 8 weeks
89309578|NCT03608800|No Intervention|Control diet|maintain the energy intake as usual
89309579|NCT03349034|Experimental|Test Group|Local Ropivicaine Infusion
89309580|NCT03349034|Placebo Comparator|Control Group|Local Saline Infusion
89309581|NCT02237326|Active Comparator|Visual Inspection with Lugol's Iodine|Participants underwent colposcopic exam, followed by Visual Inspection with Lugol's Iodine (VILI) by a second, blinded clinician (the order of exams was reversed to eliminate potential interference with exam results due to iodine staining). Biopsy was done after the VILI.
89309582|NCT02237326|Active Comparator|Visual Inspection with Acetic Acid|Participants underwent Visual Inspection with Acetic Acid followed by colposcopy by a second clinician who was blinded to the screening test result.
89309583|NCT03607864|Experimental|coral bone graft and xenograft|Extraction of upper anterior badly broken teeth with immediate implant placement with the use of coral bone and xenograft as grafting material between the implant and the labial socket bone
89309584|NCT02034604|Experimental|Naftopidil Group|Naftopidil medication patients
89309585|NCT02034604|Active Comparator|Tamsulosin Goup|Tamsulosin medication patients
89309586|NCT03608098|Active Comparator|Short Pulse Duration Group|A short pulse duration (300 μs or 350 μs) will be used in this group.
89309587|NCT03608098|Active Comparator|Long Pulse Duration Group|A long laser pulse duration (700 μs or 1500 μs) will be used in this group.
89309588|NCT02034994|Experimental|Intervention group|Reduction of sugar sweetened beverages. cookies, sedentary activities and increasing physical activity
89309589|NCT02034994|No Intervention|Control group|No intervention
89309590|NCT02035072|Experimental|Hypofractionated RT + Gem + Oxali|Hypofractionated radiotherapy + Gemcitabine + Oxaliplatin
89309591|NCT03953560|Experimental|Screening|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~Pulsioximetry.~Electrocardiogram.~Blood sample with determination of NT-ProBNP.~Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis"
89309592|NCT03606148||SurePathTM|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In SurePathTM group, subjects who underwent SurePathTM liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
89309593|NCT03606148||Conventional|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePathTM liquid cell test with the second obtained sample."
89309594|NCT03606070|Other|Patients with NSCLC|"Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI.~Patients will realize:~a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
89309595|NCT03605992|Experimental|Home-based Rehabilitation|Home-based cardiac rehabilitation that includes the components of education and physical exercises mainly unsupervised and oriented by telephone.
89309596|NCT03605992|Active Comparator|CentreRehabilitation|Traditional cardiac rehabilitation offered at the outpatient centre including components of education and physical exercises mainly supervised.
89309597|NCT03607786|Active Comparator|RIVP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(28-30℃). The combination of selective antegrade cerebral perfusion and retrograde inferior vena caval perfusion is performed. The antegrade perfusion flow rate was is maintained at 6-12 mL/min/kg.Pump pressure of retrograde perfusion was is maintained at 20-30 mmHg, and blood flow was is maintained at 8-12 mL/min/kg.
89309598|NCT03607786|Active Comparator|ACP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(26-28℃). Only select antegrade cerebral perfusion is performed by maintaining the flow rate at 6-12 mL/min/kg.
89309599|NCT00358215|Experimental|Darbepoetin alfa|Starting dose of 0.75 µg/kg subcutaneously every 2 weeks until hemoglobin concentrations reach 13.0 g/dL on 2 consecutive visits, then monthly dosing, titrated to achieve hemoglobin target of 13.0 g/dL, not to exceed 14.5 g/dL.
89309600|NCT00358215|Placebo Comparator|Placebo|Participants received dose and administration schedule (every 2 weeks or once a month) changes that simulated the changes for participants receiving darbepoetin alfa.
89309601|NCT02855164|Experimental|LJN452 10 μg|Tropifexor (LJN452) Part A
89309602|NCT02855164|Experimental|LJN452 30 μg|Tropifexor (LJN452) Part A
89309603|NCT02855164|Experimental|LJN452 60 μg|Tropifezor (LJN452) Parts A + B
89309604|NCT02855164|Experimental|LJN452 90 μg|Tropifexor (LJN452) Parts A + B
89309605|NCT02855164|Placebo Comparator|Placebo A+ B|Placebo Parts A + B
89309606|NCT02855164|Experimental|LJN452 140 μg|Tropifexor (LJN452) Part C
89309607|NCT02855164|Experimental|LJN452 200 μg|Tropifexor (LJN452) Part B
89309608|NCT02855164|Placebo Comparator|Placebo C|Placebo Part C
89309609|NCT02035306|Experimental|non-invasive Haemaglobin|Measuring haemaglobin using non-invasive co-oximetry device
89309610|NCT02237404|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
89309611|NCT02237404|Experimental|Remote monitoring of pacemakers|"Telemedicine System:~Patients have not to go to the hospital to be monitorized"
89309612|NCT03605446|Experimental|Animal 12%|Animal based protein biscuit containing 12% of total energy as protein
89309613|NCT03605446|Experimental|Animal 20%|Animal based protein biscuit containing 20% of total energy as protein
89309614|NCT03605446|Experimental|Plant 12%|Plant based protein biscuit containing 12% of total energy as protein
89309615|NCT03605446|Experimental|Plant 20%|Plant based protein biscuit containing 20% of total energy as protein
89309616|NCT03605446|Placebo Comparator|Wheat biscuit|
89309617|NCT02035150|Experimental|Oatmeal Breakfast|Participants will consume oatmeal breakfast daily for 4 weeks
89309618|NCT02035150|Experimental|Frosted Flakes|Participants will consume a frosted flakes breakfast daily for 4-weeks
89309619|NCT02035150|Placebo Comparator|No Breakfast|Participants will consume no breakfast for a 4-week period
89309620|NCT03605290|Active Comparator|Mechanically aligned TKR|patients were operated using the standard mechanically aligned technique
89309621|NCT03605290|Experimental|Kinematically aligned TKR|patients were operated using the newer mechanically aligned technique
89309622|NCT03605134||study group|level of cardiac troponin and diastolic function assessment by means of transthoracic echocardiography
89309623|NCT03605056|Experimental|CRD regimen|CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
89309624|NCT01002742|Experimental|Placebo|Corticosteroids with placebo
89309625|NCT01002742|Experimental|Mycophenolate Mofetil|Corticosteroids with Mycophenolate Mofetil
89309626|NCT03604822|Experimental|Music therapy protocol|Each participant received 12 home-based music therapy treatment sessions over 6-week time period.
89309627|NCT02035384||All patients|
89309628|NCT02034682|Experimental|Volulyte 6%|"- Volulyte 6% (HES 130/0.4 in an isotonic composition). In 1000 ml:~Maize starch 60 gr. Molar substitution 0.38-0.45. 130000 Da~Na acetate trihydrate 4.63 gr~Sodium Chloride 6.02 gr~Potassium Chloride 0.3 gr~MgCl 0.3 gr~Sodium hydroxide-hydrochloric acid & H2O"
88806477|NCT03993002|Active Comparator|Hyperoxia with Normocarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 > 250 (FiO2 >= 70%) PaCO2 of 30-40"
88806478|NCT03993002|Active Comparator|Hyperoxia with Hypercarbia|"Mechanical ventilation will be adjusted based on arterial blood gas results. Patient will remain on study settings for 48 hours from achieving target setting. Blood and BAL will be collected at the time of enrollment, at 24 hours, at 48 hours and at 72 hours.~PaO2 > 250 (FiO2 >= 70%) PaCO2 of 50-60"
88806479|NCT00362882|Experimental|Arm 1|Patients receive docetaxel IV over 60 minutes on day 1 and bortezomib IV over 3-5 seconds on days 1 and 8.
89309629|NCT02034682|Active Comparator|Geloplasma|"In 1000 ml:~Modified fluid gelatin 30 gr~Sodium Chloride 5.4 gr~Potassium Chloride 0.37 gr~MgCl 0.14 gr~Sodium lactate 3.36 gr"
89309630|NCT03607708|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
89309631|NCT03607708|Active Comparator|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
89309632|NCT03604744|Experimental|LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89309633|NCT03604744|Placebo Comparator|LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89309634|NCT03604744|Placebo Comparator|Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89309635|NCT03604744|Placebo Comparator|Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89309636|NCT03604744|Placebo Comparator|Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
89309637|NCT03604666||Health care process with Nurse Navigator|"A Nurse Navigator will:~Be present at the announcement consultation~Give information on the outpatient circuit~Offer assistance for patients over 75 years~Complete onco-geriatric orientation questionnaires~Take care of patients on the ambulatory circuit"
89309638|NCT03604666||Health care process|Health care process
89309639|NCT03604588|Other|Patients with oropharyngeal cancer|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
89309640|NCT03604510|Experimental|Electroencephalographic recordings|Electroencephalographic recordings
89309641|NCT02237482|Experimental|Small periacetabular bone defects|Patients with cup loosening and small periacetabular bone defects
89309642|NCT02237482|Experimental|Large periacetabular bone defects|Patients with cup loosening and large periacetabular bone defects
89309643|NCT03604354|Active Comparator|Pregabalin|Pregabalin 150mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
89309644|NCT03604354|Experimental|Tapentadol|tapentadol 100mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
89309645|NCT03604120|Experimental|Preoxygenation with high flow therapy by nasal cannula|High flow oxygen therapy by nasal cannula.
89309646|NCT03604120|Active Comparator|Preoxygenation by standard Facial mask|"Patients randomized in STANDARD FACIAL MASK group will receive a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction or Fiber-optic intubation under spontaneous ventilation."
89309647|NCT03604042|Active Comparator|Weight-driven protein fortification|Individualized protein fortification based on weight gain
89309648|NCT03604042|Experimental|BUN-driven protein fortification|Individualized protein fortification based on BUN concentrations
89309649|NCT03603886|Experimental|Telemedicine Pain Management|
89309650|NCT03603886|Other|Waitlist Control|Treatment as usual comparator
89309651|NCT02034760|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
89309652|NCT02034760|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
89309653|NCT02034760|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
89309654|NCT02034760|Active Comparator|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
89309655|NCT02034760|Placebo Comparator|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
89309656|NCT04045990|Experimental|Active stimulation|Active rTMS will be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). Active rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. rTMS will be administered in an excitatory pattern as 20Hz. Stimulation parameters will remain well within established safety guidelines (Rossi et al. 2009).
89309657|NCT04045990|Sham Comparator|SHAM stimulation|SHAM stimulation will also be administered with a MagPro X100 stimulator (MagVenture, Denmark), using a 70 mm figure-of-eight liquid cooled coil capable of doing active or sham stimulation (e.g. the Cool B70 coil or the Cool B65 A/P coil). SHAM rTMS will be delivered at 80-120% of a patient's resting or active motor threshold. SHAM stimulation will be delivered to the exact same cortical targets as active rTMS. While no electromagnetic stimulation will be delivered during SHAM, the sounds will approximate active stimulation and skin electrodes will approximate the sensation of active rTMS. Inclusion of a sham condition in this protocol is critical to measure whether or not the stimulation is improving memory or language performance, or whether practice effects or other non-specific effects are responsible for any changes in memory or language performance which may be observed.
89309658|NCT04044898|Experimental|Low dose|
89309659|NCT04044898|Experimental|High dose|
89523401|NCT03376997|Experimental|Perampanel: 60-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (60-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
89309660|NCT04014868|Experimental|Nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with active nasal high-flow :~Flow : 30 L/min; Temperature : 34°C;~The device will be out of sight of the patient. The device allow for oxygen supplementation (fitting on the back of the device). Usual oxygen prescription (if any) will be adjusted to reach a transcutaneous oxygen saturation superior to 90%. A second fitting will be placed just before the nasal canula to allow for oxygen supplementation during the sham nasal high-flow (device turned OFF) test.~Due to the cross-over design of the study, all patients will perform both interventions."
89309661|NCT04014868|Sham Comparator|Sham nasal high-flow|"Patients will perform a constant workload exercise testing (75% of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing) with a sham nasal high-flow :~The procedure will be exactly the same but the device (out of sight of the patient) will be turned OFF. Oxygen supplementation will be possible through the fitting placed just before the nasal canula.~Due to the cross-over design of the study, all patients will perform both interventions."
89309662|NCT03607630|No Intervention|Waiting Pre-Intervention Control|Participant completes measures for 1-3 weeks (randomly chosen) before they complete the intervention. Participants act as their own controls
89309663|NCT03607630|Experimental|Imagery Rescripting|3 Sessions of Imagery Rescripting
89309664|NCT03603574|Experimental|EWA through the needle|EWA through the needle group, 5 mL of normal saline are injected through the epidural needle after the occurrence of LOR. The needle is subsequently connected to the pressure transducer (leveled with the heart) via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
89309665|NCT03603574|Experimental|EWA through the catheter|EWA through the catheter group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
89309666|NCT03603418|Experimental|Group D (Study group-Dexamethasone group)|Forty patients undergoing induction of labor will receive 8 mg (2ml) of the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product from Epico-Egypt, and labor induction will be performed according to the American College of Obstetricians and Gynecologists protocol, i.e, starting by 25 mcg of PGE1 vaginally, in the form of Vagiprost, every 3-6 hours according to patient response, Dexamethasone will be given one hour before the first dose of Vagiprost, when bishop score reaches 6 to 8, oxytocin will be added by 5 drops/minute of 500 cc saline + 5 units of oxytocin with the dose increasing by 5-10 drops / minute every 30 minute till optimal contractions are reached which are three uterine contractions in 10 minutes and each lasting for 40-50 seconds
89309667|NCT03603418|Placebo Comparator|Group C (Control group)|Forty patients undergoing induction of labor will receive 2ml of distilled water intramuscular one hour before the initiation of labor induction, and labor induction will be performed by the same protocol as above.
89309668|NCT02034838|Experimental|atazanavir 300mg boosted with ritonavir 100mg|"Two period drug interaction. Period one: atazanavir 300mg boosted with ritonavir 100 mg once daily as part of current treatment standard of care.~Period two: atazanavir 300 mg boosted with ritonavir 50 mg once daily for study days 2-8 inclusive"
89309669|NCT03603262|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
89309670|NCT02697136|Experimental|CER-001|CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
89309671|NCT02697136|Placebo Comparator|Placebo|Saline infusion; 9 weekly infusions followed by 20 biweekly infusions
89309672|NCT02853760|Experimental|Outdoor mountain hiking (M)|"First part of the intervention: an uphill walking phase on single trails and forest roads in a sparse forest with view on the mountainous region around Innsbruck for 6 km in around 1.5 hours together with the test leader. Regarding the walking intensity, the participants were instructed to choose a brisk without overspending pace (average speed: 4 km/h).~In the second part of the intervention, the participants were walking downhill on the same track for around 70 minutes back to the starting point to respond to the post-test (average speed: 5.2 km/h)."
89309673|NCT02853760|Active Comparator|Indoor treadmill walking (T)|"To ensure that all physical parameters were simultaneous to the outdoor mountain hiking condition, the distance, the difference in height, the average inclination of the track, and the time needed for the outdoor mountain hiking situation were measured in a pilot study.~First part: uphill walking, inclination: 10%, time: 1.5 hours, and speed: 4 km/h (resulting in 600 m difference in height). In accordance to possible differences in outdoor speed, the participants were allowed to change the treadmill's speed in a small range (3.8 to 4.2 km/h) to adapt to the wording brisk without overspending. Second part of the intervention contained 70 minutes of level walking on the same treadmills (5.2 km/h, 6km)."
89309674|NCT02853760|No Intervention|Sedentary control condition (C)|The sedentary control situation was located in a quiet room at the university with access to computers. The participants were allowed to use the computers, to read, and to talk, but had to remain in a sedentary position. To control for possible differences in affective response due to the daytime, the sedentary control condition contained the same timing of the measurements than the intervention condition. Sociodemographic data were collected for 5 to 10 minutes in this condition using a web-based questionnaire.
89309675|NCT02852434|Experimental|Self-administered Gel|Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure
89309676|NCT02852434|Active Comparator|Paracervical Block|Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement
89309677|NCT03607240|Experimental|LUS-guided alveolar recruitment|Lung ultrasound-guided alveolar recruitment maneuver will be performed
89309678|NCT03607240|Active Comparator|conventional alveolar recruitment|Alveolar recruitment maneuver will be provided with positive pressure of 30 cmH2O for 10 seconds.
89309679|NCT03607084|Experimental|Intervention|The intervention group receives a school health program that has two components: the training of selected teachers to become school Health Workers and bi-annual health screenings of all students.
89309680|NCT03607084|No Intervention|Control|The control group receives regular school programming.
89309681|NCT03602950|No Intervention|Control group|50 diabetic ladies at full term will undergo elective CS and will receive the usual surgical care routinely done at our hospital
89309682|NCT03602950|Active Comparator|study group|50 diabetic ladies will undergo elective CS at full term and autologous PRP will be injected subcutaneously before skin closure.
89309683|NCT03607006|Experimental|Patient specific PEEK sheets|Patient specific PEEK sheets will be fixed with titanium screws and act as containment system for the mixed autogenous/xenogenic bone graft that will fill the gap between the sheets and the ridge .
89309684|NCT03607006|Active Comparator|Autogenous bone shell technique|Bone shells will be fixed with titanium screws to the ridge and mixed autogenous/xenogenic bone graft will fill the gap between the shells and the ridge .
89309685|NCT03602872|Experimental|Group 1|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
89309686|NCT03602872|Experimental|Group 2|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
89309687|NCT03602872|Experimental|Group 3|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
89309688|NCT03606928|Experimental|modified FLOT|modified FLOT Docetaxel 40mg/m2 ivgtt day 1 over 1 hour Oxaliplatin 65mg/m2 ivgtt day 1 over 2hours Dose escalation will be performed. Leucovorin 200mg/m2 ivgtt day 1 over 2 hours 5-FU 2200mg/m2 civ over 24 hours
89309689|NCT03602794|Active Comparator|PECs Block|"Total local anaesthetic dose: 30ml ropivacaine 0.5%~•Pecs block will be performed by anaesthetist using ultrasound guidance in plane approach: 10ml ropivacaine 0.5% will be delivered at the plane between pectoralis major and pectoralis minor, another 20ml ropivacaine 0.5% will be delivered in the plane between the pectoralis minor and serratus anterior muscles at the level of the third and fourth ribs"
89309690|NCT03602794|Placebo Comparator|Local Infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
89309691|NCT03602326|Experimental|Neurodevelopmental Therapy-Bobath group|Bobath Approach Principles and exercises will be performed 5 days a week with physical therapists and everyday with caregivers. Physiotherapy will be initiated as early as possible according to the principles of the method by experienced NDT-B therapists. Exercises will be implemented according to the patients' status and will be used to maintain and improve muscle strength and endurance. Both the unaffected and affected side will be included in rehabilitation. The exercises given are designed to be simple, understandable, task-oriented and repetitive, in accordance with the Bobath approach and the functional state of the patient at that time. In order to prevent motor amnesia and neglect of the affected side, correct positioning and sensory input will be provided since the first session.
89309692|NCT03602326|Active Comparator|Standart Rehabilitation Group (SR group)|Patients will be included in standard rehabilitation sessions, 5 days per week. The rehabilitation sessions will be performed by standard clinical physiotherapists according to the hospital routine. The rehabilitation program will consist of in-bed joint range of motion exercises and bedside mobilization applications. The patients will be included in the rehabilitation program as early as possible and the program will continue until the patients are discharged
89309693|NCT03606850|Experimental|Treatment by citalopram|The patients will receive a treatment by citalopram at 20mg/day. If patients respond by at least 20% on the HAMD-21 scale at day 14 : continuation at 20 mg/day. If patients do not respond by at least 20% at day 14 : increase the dose at 40 mg/day. The patients who will not respond by at least 50% on the HAMD-21 scale at day 28 will be excluded of the study and will undergo a new treatment plan. The patients who will respond by at least 50% on HAMD-21 at day 28 will continue citalopram at the same dose and will be reappraised at day 60. The patients will be assessed for the markers of neuroexcitability at day 1, day 3, day 7, day 14, day 28 and day 60.
89309694|NCT03606772||supracervical hysterectomy|Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix
89309695|NCT03602248|Experimental|Speed endurance training protocol A|"Performance of two different speed endurance training protocols:~Speed endurance training protocol A will consist of 1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)."
89309696|NCT03602248|Experimental|Speed endurance training protocol B|Speed endurance training protocol B will consist of 1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
89309697|NCT03602248|No Intervention|Control condition|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
89309698|NCT03602716|Experimental|HD-tDCS group|This HD-tDCS group will be stimulated by active HD-tDCS.
89309699|NCT03602716|Sham Comparator|Sham HD-tDCS group|This sham HD-tDCS group will have a sham stimulation with HD-tDCS.
89309700|NCT03602638|Experimental|Sitagliptin|
89309701|NCT03602638|Active Comparator|CONTROL|Acarbose
89309702|NCT02237560|Experimental|Cybercycle-Game|Combined aerobic & cognitive exercise for 6 months, 3-5x/week.
89309703|NCT02237560|Active Comparator|Cybercyle-Tour|Aerobic exercise only for 6 months, 3-5x/week.
89309704|NCT02237560|Active Comparator|Game Only|Cognitive exercise only 6 months, 3-5x/week.
89309705|NCT02237638|Experimental|hVEGF26-104/RFASE vaccination|hVEGF26-104/RFASE is investigated in dose escalation in which hVEGF26-104 is escalated from 62.5 ug to 500 ug and RFASE is given in a fixed dose of 20 mg. Three patients are treated at each dose level. If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort. If 1 of the 3 patients shows DLT, 3 additional patients are treated at that dose level. If none of these show DLT, the dose level is escalated for the next cohort; otherwise, the prior dose level is defined as the MTD. At the highest dose level 6 patients will be treated. The recommended dose for a phase II trial will be the lowest dose that results in the most effective VEGF neutralization, together with acceptable safety and toxicity.
89309706|NCT03602170|Experimental|High-Intensity Interval Training|8 weeks of high-intensity interval training. Three sessions per week will be performed (24 total sessions).
89309707|NCT03602170|Active Comparator|Moderate-Intensity Continuous Training|8 weeks of moderate-intensity continuous training. Three sessions per week will be performed (24 total sessions).
89309708|NCT03954886|Experimental|Induced myopic defocus|Subjects will view a television through a lens that induces blur to the retina for one hour. Images of the eye will be captured every 10 minutes
89309709|NCT03954886|No Intervention|No defocus|Subjects will view a television through a lens that induces no blur to the retina for one hour. Images of the eye will be captured every 10 minutes
89309710|NCT03601936|Other|Infants less than 6 months of age|The Evivo Infant Gut Bifidobacterium Screening Test study is a single-group interventional study of 600 female and male infants who are less than 6 months of age and generally healthy.
89309711|NCT03601780|Active Comparator|Local wound infiltration|local wound infiltration plus usual care
89309712|NCT03601780|Placebo Comparator|Control|usual care only
89309713|NCT03606304|Experimental|Problem-solving therapy|The intervention is based on an established PST protocol for medical patients, with an additional focus on HF to link depressed mood to impaired HF self-care. Seven steps are included: 1) select and define the problem; 2) establish realistic and achievable goals for problem resolutions; 3) generate multiple solution alternatives (brainstorming); 4) implement decision-making guidelines (pros and cons); 5) evaluate and choose the solutions; 6) implement the preferred solution(s); and 7) evaluate the outcome.
89309714|NCT02035228|Experimental|Seated|"Patients breathing will be compared across a series of 9 trials in which unassisted breathing is compared to abdominal stimulation (SecondBreath) assisted breathing at various intensities. Each breathing trial will last for 2 minutes and will be conducted while the patient is seated. The following abdominal stimulation trials were included:~Abdominal Stimulation - low / early Abdominal stimulation - low/late Abdominal Stimulation - low/full Abdominal stimulation - med/early Abdominal stimulation - med/late Abdominal Stimulation - med/full Abdominal Stimulation - high/early Abdominal Stimulation - high/late Abdominal Stimulation - high/full"
89309715|NCT02035228|Experimental|6 minute step test|"Patients will complete a 6 minute step test with and without abdominal stimulation (SecondBreath).~Abdominal Stimulation - high/full"
89309716|NCT03587896|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
89309717|NCT03587896|No Intervention|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
89309718|NCT02237794||Patients Without Acute Heart Conditions|Patients without acute heart conditions who were hospitalized for other medical indications.
89309719|NCT03601624|Experimental|Experimental|"Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
89309720|NCT03601546||Patients with HCV infection|
89309721|NCT03597646|Experimental|Kinesio Taping|Kinesio Taping group consisted of 19 patients. Kinesio Tape was applied 2 times a week for a period of 4 weeks. Kinesio Taping was applied for musculus diaphragmaticus, musculus externus obliquus abdominis and internus obliquus abdominis.
89309722|NCT03597646|Active Comparator|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT) group consisted of 19 patients. IMT sessions were applied 2 sessions/everyday for a period of 4 weeks and 15 minutes for each session. Every session patients performed 5 breathing circles, then rested and continued again. By this way they used the device for 15 minutes each session. The patients visited the clinic every week and the therapist adjusted the IMT device in terms of their maximal inspiratory pressures.
89309723|NCT03597646|No Intervention|Control|Control group also consisted of 19 CHF patients. No interventions were applied for them. Pharmacological treatment of control group continued and they were advised for using their medication properly.
89309724|NCT02238418|Experimental|Usual vitamin D supplementation|
89309725|NCT03601390||PET/CT and EBV DNA|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT protocol 12 weeks after the end of IMRT (primary endpoint).Plasma EBV DNA test will be performed 4, 12, 24 weeks after the end of IMRT. In patients with negative PET/CT results, 2 follow-up visits are required to complement nasopharyngoscope examination and plasma EBV DNA test in the frist year. All patients will undergo annual PET/CT or traditional follow-up examination and plasma EBV DNA test 1 year after completing chemoradiation unless recurrent/residual disease is histopathologically-confirmed.
89309726|NCT03587818|No Intervention|Control group|"Conventional care. Patients were receiving several written patient education materials (PEMs), mostly related to specific parts or procedures related to the surgery and the recovery.~Communication between patients and professionals during consultations occurred according to conventional care practice."
89309727|NCT03587818|Experimental|Intervention group|"I. Written interactive PEM structured into chapters/phases of the care process. Designed to serve three purposes:~generic information of the surgery and recovery process on a group level to promote high readability, suitability and comprehensibility~arena of dialogues between patient and professionals; voicing concerns, share perspectives~for the patient to personally reflect on generic information.~II. Person-centred communication in dialogues using the PEM as a supportive tool, facilitated by four communication strategies:~professionals guiding the patient through the care process~communicating an introduction, agenda and closing~being sensitive to the patient's questions, beliefs, experiences and resources~dialogue based on story, posing open-ended questions, and following up."
89309728|NCT03601312|Active Comparator|Treatment-As-Usual|Individuals receiving treatment as usual will be receiving exposure and response prevention (ERP), the standard of care for pediatric OCD.
89309729|NCT03601312|Experimental|OC-Go|Individuals in the OC-Go group will be receiving exposure and response prevention (ERP) augmented by the OC-Go application.
89309730|NCT03601234|Experimental|laparoscopic surgery|This is a kind of traditional surgical method.only use laparoscopy to resect the GIST.
89309731|NCT03601234|Experimental|laparoscopic and endoscopic combined surgery|LECS resects the GIST completely by laparoscopy with the help of the precise positioning and guidance of endoscopy.
89309732|NCT03601156|Experimental|NATACE-RT|Patients receive Oxaliplatin 130mg/m2 intraarterial chemoembolization on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
89309733|NCT03601156|Active Comparator|NACT-RT|Patients receive Oxaliplatin 130mg/m2 intravenous chemotherapy on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
89309734|NCT03587506||Patients: group|Group I (n=10) included patients who did not develop any major or minor seizure during the follow-up period and their follow up EEG was free of any epileptiform discharge
89309735|NCT03587506||Patients: group II|Group II (n=11) included patients who developed only minor seizures and their follow up EEG showed epileptiform discharge
89309736|NCT03587506||Patients: group III|Group III (n=9) were patients who developed one or more major seizures during the follow-up period whatever their EEG findings.
89309737|NCT03587506||Controls|healthy volunteers (n=30) who were not related to the patients and had no family history of epilepsy.
89309738|NCT03601000|Experimental|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.
89309739|NCT03601000|Placebo Comparator|Placebo|Placebo given three times every day for 16 weeks.
89309740|NCT02850016|Experimental|Group A|Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .
89309741|NCT02850016|Experimental|Group B|Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .
89309742|NCT03600922|Experimental|Intervention group|
89309743|NCT02849704|Experimental|Chronic Pancreatitis (CP) Subjects|"CP subjects will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary.~Subjects will take Creon36™ for 9 days.~Subjects will have two study visits, one before and one after treatment initiation with Creon36™. Both visits will be identical with the exception of completion of questionnaires and fecal elastase assessment (only Visit 1)."
89309744|NCT02849704|No Intervention|Healthy Controls|Healthy controls will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary. Controls will only have 1 study visit and receive no intervention.
89309745|NCT03586882|Experimental|Spinal Cord Stimulation Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
89309746|NCT03586882|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
89309747|NCT03600766|Active Comparator|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks
89309748|NCT03600766|Active Comparator|Placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
89309749|NCT03600610|Experimental|patient group|malnourished patients with anorexia nervosa gadolinium-enhanced cardiac MRI will be performed
89309750|NCT03600610|Active Comparator|control group|age- and sex- matched, normal weight, healthy volunteers gadolinium-enhanced cardiac MRI will be performed
89309751|NCT03600532|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
89309752|NCT03600532|No Intervention|Treatment as Usual (TAU)|Usual care at Laureate Psychiatric Clinic and Hospital Adult Stabilization Unit who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization. Patients will engage in usual care or a rest period before completing the post-assessment.
89309753|NCT03600532|No Intervention|Community Control Group (CCG)|Patients will engage in a rest period before completing the post-assessment.
89309754|NCT03600454|Experimental|Hip surgery: spinal anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive spinal anesthesia in combination with monitored anesthesia care (MAC).
89309755|NCT03600454|Experimental|Hip surgery: general anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive general anesthesia
89309756|NCT03600454|Experimental|Colectomy: general anesthesia and epidural analgesia|Patients scheduled to undergo elective laparoscopic hemicolectomy will receive general anesthesia combined with epidural analgesia (EA).
89309757|NCT03600454|Experimental|Colectomy: general anesthesia|Patients will receive general anesthesia.
89309758|NCT03594604|Experimental|Norethindrone|Delaying menstruation using Norethindrone 5mg three times daily in women who desire postponement of their period for social or personal reasons.
89309759|NCT03594604|Active Comparator|Oral Contraceptive Pills|Women who desire postponing their periods are typically treated with oral contraceptive pills, the current standard of care.
89309760|NCT03594526|Experimental|Maternal support to become mother|"Maternal support to become mother: is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of:~Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~Four Educational sessions and support sessions for maternal empowerment in each home visit.~Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
89309761|NCT03594526|Active Comparator|Control group: usual Care|The participants will receive the usual education about the care of the mother during the puerperium, the care of the newborn, including breastfeeding.
89309762|NCT03593824|Experimental|dense cataract group|
89309763|NCT03593824|Experimental|non-dense nuclear cataract group|
89309764|NCT03593746|Experimental|HIIT and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with high intensity interval training (HIIT)
89309765|NCT03593746|Sham Comparator|High intensity interval training (HIIT)|Light-Emitting Diode (LED) therapy simulation followed by physical training with high intensity interval training (HIIT)
89309766|NCT03593746|Experimental|Combined training and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with combined training
89309767|NCT03593746|Sham Comparator|Combined training|Light-Emitting Diode (LED) therapy simulation followed by physical training with combined training.
89309768|NCT02855008|Experimental|STEPS|Experimental: Individuals with ID and residential staff in group homes receive 6 one-hour STEPS sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games to build group cohesiveness, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice social problem-solving skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
89309769|NCT02855008|Active Comparator|Food for Life|Active Comparator: Individuals with ID and residential staff in group homes receive 6 one-hour Food for Life sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games regarding food and nutrition followed, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice Food for Life skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
89309770|NCT03586492|Other|Patient with myocardial ischemia|
89309771|NCT03585400||Observational Study|Observational Study: Not Applicable for Observational Studies
89309772|NCT02238184||Chronic Obstructive Pulmonary Disease|patients receiving Atrovent®
89309773|NCT02238184||Cronic Obstructive Pulmonary Disease|patients receiving Ventilat®
89309774|NCT03592498|Active Comparator|Sulfadiazine, Silver|Intervention: Treatment with silver sulfadiazine ointment. Procedures: wound washing, application of silver sulfadiazine ointment, bandage covered with gauze and bandage. These patients undergone the change of dressings on alternate days.
89309775|NCT03592498|Experimental|Skin of Nile tilapia|"Intervention: treatment with skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.~Procedures: wound washing, application of tilapia skin and dressing with gauze and bandage. These dressings were changed if the skin of the tilapia was loose (not adhered)."
89309776|NCT03600298|Other|Pediatric intensive care unit-nurses|"Phase I: During the month leading up to the simulation two trained observers / raters will observe the rate of Closed-Loop Communication in the pediatric intensive care unit (PICU) among study participants.~Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.~Phase II + III: During the follow up phase, trained raters will again observe the study-participating PICU staff relative to their communication behaviour in the month following simulation training (Phase II) and again three months later (Phase III)."
89309777|NCT03600220|No Intervention|drug use|routine drug use, each patient was using 1-3 antihypertensive drug of a heterogeneous pharmacological group ranging from ACE inhibitors, diuretics, and beta blockers
89309778|NCT03600220|Experimental|drug combine acupuncture|routine drug use combine acupuncture twice a week for 3 months
89309779|NCT03584776|Experimental|Virtual Reality Post Spinal Fusion|Patients randomized to the VR group will have the opportunity to utilize VR during the post operative period, and will also experience VR during research visits each day following surgery.
89309780|NCT03584776|No Intervention|Standard of Care|Patients randomized to the non-VR condition will experience the usual standard of care following spinal fusion surgery. This will include 15-30 minutes of movie viewing during research visits.
89309781|NCT03600064|Other|Misoprostol group|
89309782|NCT03600064|No Intervention|NO intervention|
89309783|NCT02721082|Experimental|Opt Out|"Participants in this arm will be first enrolled to receive cessation treatment and will only not receive it by opting out. Participant will receive a Opt Out treatment program. Participants will receive counseling and nicotine replacement therapy."
89309784|NCT02721082|Active Comparator|Opt In|"Traditional approach to tobacco treatment program. Participants must first indicate they are ready to quit smoking by opting in to receive Opt In treatment program."
89309785|NCT03912844||Liver resection/liver transplantation after SIRT|The cohort consist of patients that, after decision of a multidisciplinary tumor board have received a SIRT/TARE or will receive a SIRT/TARE to make them later eligible for following liver resection or liver transplantation.
88806480|NCT00362882|Experimental|Arm 2|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 2 and 8.
89309786|NCT03592108|Experimental|CSR remote monitoring|The remote monitoring of CPAP treatment will be modified in order to detect the presence of CSR as soon as any significant increase of the apnea-hypopnea index occurs.
89309787|NCT02238574|Experimental|follow up & surgery|CIN positive with surgery and intensified follow up
89309788|NCT02238574|Active Comparator|follow up|CIN positive, only intensified outpatient follow up
89309789|NCT03583840|No Intervention|Control group|Participants who will not be directed to the ScreenMen website
89309790|NCT03583840|Experimental|Intervention group|Participants who will be directed to the ScreenMen website
89309791|NCT02238106|Experimental|Salmeterol inhalation powder, medium dose|administered via HandiHaler®
89309792|NCT02238106|Active Comparator|Salmeterol inhalation powder, low dose|administered via HandiHaler®
89309793|NCT02238106|Active Comparator|Salmeterol inhalation powder, high dose|administered via HandiHaler®
89309794|NCT02238106|Active Comparator|Serevent® Diskus®|administered via Diskus®
89309795|NCT02238106|Placebo Comparator|Placebo|administered via Diskus® or HandiHaler®
89309796|NCT03583216||Diabetic pregnancy|Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
89309797|NCT03583216||Non-diabetic pregnancy|Healthy non-diabetic pregnant patients will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
89309798|NCT03598660||Breast cancer patients|"The present study will be carried on 50 breast cancer patients before surgery.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA)."
89309799|NCT03598660||Healthy controls|"The present study will be carried on 15 age and sex matched controls.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
89309800|NCT03598660||Benign breast diseases|"The present study will be carried on 15 patients with benign breast diseases.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
89309801|NCT02238652|No Intervention|Control|
89309802|NCT02238652|Active Comparator|Intervention|Communication Systematic Pain Assessment and Treatment Medication Review Occupational therapy Safety
89309803|NCT02035618|Experimental|Exercises and manual therapy|
89309804|NCT02035618|Active Comparator|Exercises|
89309805|NCT03577912|Active Comparator|TAP block administered by Surgery|transversus abdominis (TAP) plane block is performed by the surgeon at the conclusion of the surgery, still under general anesthesia, prior to removing the trocars a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under direct surgeon observed laparoscopic visualization. (Split dose 30cc/side)
89309806|NCT03577912|Active Comparator|TAP block administered by Anesthesia|transversus abdominis (TAP) plane block is performed by the anesthesiologist at the conclusion of the surgery after incisions are closed and dressing are on, prior to emergence from general anesthesia, a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under by the anesthesiologist using ultrasound visualization. (Split dose 30cc/side)
89309807|NCT02238262||essential hypertension patients|
89309808|NCT03581812|Active Comparator|Intervention snack 1|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
89309809|NCT03581812|Active Comparator|Intervention snack 2|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
89309810|NCT03581812|Placebo Comparator|Control snack|Control snack food reflecting the macro-nutrient profile of a typical UK snack.
89309811|NCT03581032||A-Active reprogram follwed by sham|This arm will be randomized to have PACING device reprogramming followed by sham reprogramming
89309812|NCT03581032||B-Sham followed by active reprogram|This arm will be randomized to have sham reprogramming followed by active pacing reprogramming
89309813|NCT03580954|Experimental|Repetitive TMS (estimulation)|
89309814|NCT03580954|Active Comparator|Repetitive TMS (inhibition)|
89309815|NCT03577834|Experimental|Liquid vinegar|Participants in this arm were instructed to drink 2 tablespoons of red wine vinegar (provided) mixed with water twice each day for weeks 1 to 8 of the trial.
89309816|NCT03577834|Placebo Comparator|Vinegar pill|Participants in the control group were instructed to take one vinegar pill (provided) each day for weeks 1-8 of the trial.
89309817|NCT03580720|Experimental|Intervention|Intervention group, receiving Inspiratory threshold loading protocol.
89309818|NCT03347396|Experimental|BIVV009|Participants with primary CAD who had a recent history of transfusion (defined as at least 1 transfusion during the last 6 months prior to screening) received an intravenous (IV) infusion of BIVV009 6.5 grams (g) (if body weight was less than [<] 75 kilograms [kg]) or BIVV009 7.5 g (if body weight was greater than or equal to [>=] 75 kg) on Day 0 and Day 7 and every 14 days thereafter in Part A up to Week 25. Participants who completed Part A per protocol through the end of treatment visit (Week 26) could continue to receive BIVV009 in Part B, every 2 weeks starting at Week 27 for up to an additional 149 weeks. All participants who completed Part A elected to continue in Part B.
89309819|NCT03707678|Experimental|Subjects receiving GSK2245035|Eligible subjects will be administered 20 nanograms (ng) of GSK2245035 nasal spray solution using a metered Valois VP7 pump (1 spray=10 ng per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol metered dose inhaler (MDI) will be given for symptom relief from screening to the end of the study.
88820788|NCT05647473|Experimental|add-on low dose Astragalus|
88820789|NCT05647473|Experimental|Routine treatment|
89309820|NCT03707678|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be administered placebo nasal spray solution using a metered Valois VP7 pump (1 spray per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol MDI will be given for symptom relief from screening to the end of the study.
89309821|NCT03709394|Active Comparator|Group A: Full utrasound guidance|Full utrasound guidance of cathether insertion. Intervention: Ultrasound portable device used for the identification of the target vein and for the ultrasound control of proper catheter placement during the procedure of peripheral venous cannula insertion.
89309822|NCT03709394|Active Comparator|Group B: Partial ultrasound guidance|Catheter insertion under partial ultrasound guidance. Intervention: Ultrasound portable device used only for the identification of the target vein, the catheter placement will be done by conventional approach.
89309823|NCT03709394|Active Comparator|Group C: No ultrasound guidance|Catheter insertion by conventional approach, without ultrasound guidance
89309824|NCT03335150|Active Comparator|Supportive Care|Support Group for PD-MCI
89309825|NCT03335150|Experimental|CogSMART-PD|Cognitive Rehabilitation for PD-MCI
89309826|NCT03334448|Experimental|LY900014-U200|Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods
89309827|NCT03334448|Experimental|LY900014-U100|Single SC dose of 15 U LY900014 U-100 in two of four study periods
89309828|NCT04773002||Group P|Total intravenous anesthesia (TIVA)
89309829|NCT04773002||Group S|Volatile anestesia
89309830|NCT03707600|Sham Comparator|Sham|The sham coil setting is designed to mimic the auditory artifact and scalp sensations evoked by the real coil without stimulating the brain.
89309831|NCT03707600|Active Comparator|TMS|Active TMS
89309832|NCT03710798|Experimental|Low carbohydrate high fat diet|Low carbohydrate high fat (LCHF) diet
89309833|NCT03709316|Experimental|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
89309834|NCT03709316|Placebo Comparator|Placebo|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
89309835|NCT02849080|Experimental|Semaglutide flexible dosing (3, 7 or 14 mg)|
89309836|NCT02849080|Active Comparator|Sitagliptin 100 mg|
89309837|NCT03346070|Experimental|Sugammadex 2 mg/kg ABW|Following administration of NMBA, participants received a single intravenous (i.v.) bolus of Sugammadex at 2 mg/kg as determined utilizing participant ABW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
89309838|NCT03346070|Experimental|Sugammadex 2 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 2 mg/kg as determined utilizing participant IBW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
89309839|NCT03346070|Experimental|Sugammadex 4 mg/kg ABW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant ABW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
89309840|NCT03346070|Experimental|Sugammadex 4 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant IBW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
89309841|NCT03346070|Active Comparator|Neostigmine/Glycopyrrolate|Following administration of NMBA, participants received a single i.v. bolus containing both Neostigmine (50 µg/kg; up to 5 mg maximum dose) and Glycopyrrolate (10 µg/kg; up to 1 mg maximum dose) as determined utilizing participant ABW. Neostigmine/Glycopyrrolate was used for reversal of moderate NMB. Active comparator treatment for reversal for deep NMB was not available.
89309842|NCT03590704|Experimental|Intervention Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region. The bandage will not be applied on the scar. If there are any complications such as itching, redness, discomfort and / or others, the patients will remove the material at home and communicate on return to the institution. They will remain four days approximately for revaluation and intervention suspension.
89309843|NCT03577756||Infants with cystic fibrosis|Twelve months infants with cystic fibrosis will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
89309844|NCT03577756||Healthy infants|Twelve months healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
89309845|NCT03590626|Experimental|Dulaglutide group|receive dulaglutide 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks plus standard treatment for type 2 diabetes
89309846|NCT03590626|No Intervention|Control group|receive standard treatment for type 2 diabetes and up titration of treatment will be done by anti-diabetic medicines other than the GLP-1 receptor agonist
89309847|NCT03580486||Patients with Parkinson's Disease|Parkinson's Disease (Hoehn and Yahr stage 1-4)
89309848|NCT03580486||Healthy controls|Healthy people
89309849|NCT03580330|Experimental|Intervention Group|
89309850|NCT03580330|No Intervention|Control Group|
89309851|NCT03580174|Active Comparator|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed physiotherapy
89309852|NCT03580174|Active Comparator|Routine physiotherapy group|Ten children with CP will receive conventional, traditional physiotherapy
89309853|NCT03577678|Experimental|observational|orthopaedic Surgery to fix lateral half prosthesis for clavicle
89309854|NCT03590470|Experimental|Experimental_INTERCARE intervention|Implementation of a nurse-led model of care adapted to the Swiss context, comprising a geriatric nurse expert with specific training in multidimensional clinical assessment and quality improvement tools.
89309855|NCT03590470|No Intervention|Control|The design used for the INTERCARE intervention is a non-randomized stepped wedge design, therefore all nursing homes will receive the intervention but at different time points. All nursing homes will be in a control phase before receiving the intervention, and switch to the intervention phase, once the intervention is implemented.
89309856|NCT03590314|Experimental|Experimental group|The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland).
89309857|NCT03590314|Active Comparator|Control group|The control group was treated using a conventional training, without end effector robot.
89309858|NCT03577600|Experimental|QMRT using the Cytotron®|Experimental: QMRT using the Cytotron® Intervention: 28 days of treatment with QMRT with the Cytotron®. Patients diagnosed with terminal brain tumors between 3 and 16 years of age whose parents agree to participate in the study and have signed informed consent and informed consent in patients with age or mental age over 8 years.
89309859|NCT03577444||Dysphagia patients|Patients who had been diagnosed with neurogenic dysphagia related to either stroke or traumatic brain injury at two university affiliated hospitals
89309860|NCT03745690|Experimental|Treatment (near-infrared image guided surgical resection)|Patients receive indocyanine green IV on day 0 and undergo near-infrared image guided surgical resection on day 1.
89309861|NCT03589378|Experimental|PEAF|Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.
89309862|NCT03589378|No Intervention|Control group|HVHF for septic shock with MODS is permitted in Control group routinely（Blood pump: 200ml/min, replacement fluid pump 45ml/kg/min, dialysate pump 45ml/kg/min, waste pump 90ml/kg/min, and high-volume hemofiltration for 16 hours with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) in the first 3 days after randomization.If hemodynamically unstable or AKI stage 2or 3,continue HVHF.
89309863|NCT02238730|Active Comparator|Ultrabrief Right Unilateral|Ultrabrief (0.25 ms) Right Unilateral Electroconvulsive Therapy
89309864|NCT02238730|Active Comparator|Brief Pulse Bitemporal|Brief Pulse (0.5 ms) Bitemporal Electroconvulsive Therapy
89309865|NCT03577210|Other|computer-guided augmentation genioplasty|patient-specific PEEK implant
89309866|NCT03556462|Experimental|Sleep Health Interventions|"Sleep Health Interventions:~Parents- a) invited to 1 hour workshop about healthy sleep, b) invited to attend a brief (app. 20 minute) Sleep Health Flipchart education either 1-on-1 or in a small group.~Children: exposed to 2 week 40min/day healthy sleep curriculum in the classroom.Agency: Video and print material"
89309867|NCT03556462|No Intervention|Control Period|No Intervention, but data collection
89309868|NCT03579706|Experimental|Intervention|The intervention condition will involve participants completing baseline measures, the Cognitive Anxiety Sensitivity Treatment, post measures, and a 4 month follow up assessment.
89309869|NCT03579706|Placebo Comparator|Control|The control condition will involve participants completing baseline measures, the Physical Health Education Training, post measures, and a 4 month follow up assessment.
89309870|NCT03579550|Active Comparator|Intervention arm: Hysterocopy group|Office hyteroscopic metroplasty will be performed. After oparetion 9 months spontaneous conception Intervention arm for hysteroscopy group
89309871|NCT03579550|No Intervention|Spontaneous cycles plus COH/IUI|Six months spontaneous coitus cycles plus 3 cycles of Clomiphene citrate and intrauterine insemination (COH/IUI)
89309872|NCT02951780|Experimental|LY3185643|LY3185643 administered subcutaneous (SC)
89309873|NCT02951780|Experimental|rGlucagon|rGlucagon administered subcutaneous (SC)
89309874|NCT02238340|Experimental|Extended-release oxycodone 10mgr|Extended-release oxycodone 10 mgrs , started 12 hours before orthopaedic surgery
89309875|NCT02238340|Experimental|Extended-release oxycodone 20 mgr|Extended-release oxycodone 20 mgr , started 12 hours before orthopaedic surgery
89309876|NCT02239198|Experimental|C|Nutrition bar without omega-3 fatty acids
89309877|NCT02239198|Experimental|B|Nutrition bar without added minerals and vitamins
89309878|NCT02239198|Active Comparator|A|Complete nutrition bar
89309879|NCT03574948|Experimental|5-HTP|8 weeks active substance 5-HTP (2 x 100 mg per day)
89309880|NCT03574948|Placebo Comparator|placebo oral capsule|8 weeks placebo (2 x 1 capsule per day)
89309881|NCT03574870|Experimental|Chemoraditherapy|"Patients with head and neck cancer require chemo and radiation therapy (Cohort A):~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from the time of their radiation simulation through one week following the end of radiation treatment"
89309882|NCT03574870|Experimental|Primary surgery w/o radiotherapy|"Patients with head and neck cancer require primary surgery alone (Cohort B-SA)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery through 1 month following surgery~Patients with head and neck cancer require primary surgery and postoperative radiotherapy (Cohort B-RT)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery to one week following the end of radiation treatment ."
89309883|NCT03577132|Experimental|Luminal type|Luminal type in previous transurethral resection of bladder tumor pathology. Luminal type in Immunohistochemistry (KRT5/6-KRT14-FOXA1+GATA3+)
89309884|NCT03577132|Experimental|Basal typr|Basal type in previous transurethral resection of bladder tumor pathology. Basal type in Immunohistochemistry (KRT5/6+KRT14+FOXA1-GATA3-)
89309885|NCT03334214|Experimental|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
89309886|NCT03334214|Placebo Comparator|Placebo (sterile saline 0.9)|Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks
89309887|NCT02250664|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
89309888|NCT02250664|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
89309889|NCT02250664|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
89309890|NCT03707444||Scrambler Therapy|All participants get the same device treatment with the Scrambler Therapy device, up to 10 treatments.
89309891|NCT02239432||Suspected Adenocarcinoma of the Lung|Patients with suspected adenocarcinoma of the lung referred for surgical lung biopsy after multi-disciplinary team recommendation.
89309892|NCT02239432||Healthy Control|Age and sex-matched patients with no known lung disease or other chronic inflammatory disease or malignancy
89309893|NCT02239432||Age-matched controls with proven solid lung malignancy|Patients with biopsy-proven advanced solid malignancy of the lung
89309894|NCT03577054|Experimental|HBB Prompt|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~Providers at this hospital will have access to the most updated version of HBB Prompt (beta) after HBB training.~Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training). The recommended frequency to use the app will be once per shift."
89309895|NCT03577054|Placebo Comparator|Control|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~The control group will not have exposure to the HBB Prompt app post training. Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training)."
89309896|NCT03660592||operator 1|ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
89309897|NCT03660592||operator 2|a different ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
89309898|NCT03579238|No Intervention|Distant|The clinician sits quietly 3 feet away from participant who is lying on a soft table at rest.This position is held for 5 minutes without moving.
89309899|NCT03579238|No Intervention|close|The clinician sits at the head of the table with his arms on the table alongside the participant's head but not touching the resting patient who is lying at rest on the table. This position is held for 5 minutes without moving.
89309900|NCT03579238|Sham Comparator|touching|"The clinician lifts the patient's head passively off the table in order to place his hands underneath the participant's head, palms facing upwards and in contact with the back of the head of the participant. The participant's head is gently lowered to rest upon the clinician's hands. No external force is provided by the clinician upon the participant's head as the head rests in the clinician's palms on the table. This position is held for 5 minutes without moving. This is called a touching intervention and is meant to be a sham. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
89309901|NCT03579238|Experimental|Occipital motion inhibition|"The clinician gently inhibits motion of the participant's occiput into flexion phase of the primary respiratory mechanism, and allows extension phase only. Upon sensing a still point, where no further flexion motion is palpated, the clinician will state to the research assistant now to indicate he feels a still point. This position is held for 5 minutes without moving. This is called a CV4 or modified CV4 intervention. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
89309902|NCT03576820|Experimental|Lidocaine|Subjects will receive a one time dose of 20mg of 2% lidocaine (1 mL) via nasal mucosal atomizer
89309903|NCT03576820|Placebo Comparator|Placebo|Subjects will receive a one time dose of 1 mL of 0.9% sodium chloride solution via nasal mucosal atomizer.
89309904|NCT03579082|Experimental|Arm A|"R±DHAP + decitabine:~decitabine:10mg/d,ivgtt,d(-5)-(-1);R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle."
89309905|NCT03579082|No Intervention|Arm B|R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle.
89309906|NCT03579004|Experimental|Trimodality approach|"2 cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750 mg/m2/day continuous infusion, day 1-4 every 3 weeks). 3-4 weeks later - preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20 mg/m2 weekly + radiotherapy 44 Gray (Gy) for 4 weeks).~4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy."
89309907|NCT03576508|Experimental|CNTX-4975-05 Intra-Articular (IA) Injection|Receives IA injection into the most painful OA knee.
89309908|NCT03576508|Active Comparator|Topical 8% Capsaicin Patch|Receives Capsaicin Patch on posterior rib cage.
89309909|NCT03574636|Active Comparator|OCT guidance|"Firehawk stent implantation will be performed with Optical Coherence Tomography guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
88815952|NCT03012464||Pathologic and functional assessment|Patients of both genders, aging below 45 years with internal or external rectal prolapse
88820790|NCT05647473|Experimental|add-on high dose Astragalus|
88820791|NCT05646069|Experimental|Storz Flex-XC1 disposable flexible ureteroscope|A patient is randomized to the experimental arm using the Storz Flex-XC1 disposable flexible ureteroscope.
88820792|NCT05646069|No Intervention|Analogue scope|A patient is not randomized to the experimental arm using the Storz Flex-XC1 disposable flexible ureteroscope.
89309910|NCT03574636|Active Comparator|IVUS guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
89309911|NCT03574636|Active Comparator|QCA guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
89309912|NCT03574558|Experimental|MD-Logic Switch Advisor|MD-Logic Switch Advisor Algorithm for personalized automated determination of insulin pump settings for subjects with type 1 diabetes switching from MDI to pump therapy and vice versa
89309913|NCT02238886|Experimental|Parenteral nutrition|Patients receives a goal-directed nutritional intervention combining oral intake and parenteral nutrition
89309914|NCT02238886|No Intervention|Standard treatment|patients receives a standard nutritional strategy of resting the bowel till clear signs of bowel recovery and feeding orally after bowel recovery
89309915|NCT02238964|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice(TM) Reconstructive Tissue Matrix will be placed intra-peritoneally fashion. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl).
89309916|NCT02238964|Active Comparator|Standard closure|"Fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The technique recommended is the fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. This technique can include either interrupted or continuous sutures.~Closure of the muscle, soft tissues and skin is up to the discretion of the operating surgeon."
89309917|NCT02646982|Experimental|Candesartan|Candesartan will be given orally once a day in a stepwise manner as follows: All participants will be initiated on 8 mg candesartan. The dose will be increased in 2 week increments to 16 mg and 32 mg as long as the systolic blood pressure (SBP) >100 mm Hg, diastolic blood pressure (DBP) >40 mm Hg and participant reports no symptoms of hypotension (dizziness or weakness). The highest achievable dose will be the Maximal Tolerated Dose (MTD) and the participant will receive this dose for the remaining duration of the study (participants will be treated for 1 year).
89309918|NCT02646982|Placebo Comparator|Placebo|Participants will receive a matched placebo once a day orally for 12 months.
89309919|NCT03576430|Active Comparator|active|active stress handling
89309920|NCT03576430|No Intervention|control|no stress handling
89309921|NCT03578848|Active Comparator|uAOBP & Home BP|On the scheduled visits, the uAOBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
89309922|NCT03578848|Experimental|CBP & Home BP|On the scheduled visits, the CBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
89309923|NCT02239666||Moderate to Severe Plaque Psoriasis|Prospective cohort study of usual care for subjects initiating therapy for plaque psoriasis on approved biologic agents. A non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
89309924|NCT03576352|Experimental|Pediatric anesthesiologist|10 rapid sequence tracheostomy (RST) on rabbit cadaver
89309925|NCT03576352|Experimental|Pediatric intensivists|10 rapid sequence tracheostomy (RST) on rabbit cadaver
89309926|NCT03576352|Experimental|Pediatric surgeons|10 rapid sequence tracheostomy (RST) on rabbit cadaver
89309927|NCT03576352|Experimental|Pediatric emergency physicians|10 rapid sequence tracheostomy (RST) on rabbit cadaver
89309928|NCT03576196|Experimental|Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
89309929|NCT03576196|Other|Usual Care|"Patients in the control group received usual care, which consists of an educational session prior to surgery, based on medical, anatomical and pathological aspects of the syndrome.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
89309930|NCT03574324|Experimental|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
89309931|NCT03574324|Other|CCRE+PF|Cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy followed by PF adjuvant chemotherapy
89309932|NCT03578692||Surgery group|The protocol for patients assigned to surgery group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed bad response to medicine (glucocorticoid for 5 days and rescue therapy for 3 days) were recommended and classified in the surgery group. Their baseline manifestations were collected and compared with the medical group, to exploit the baseline indicators with great sensitive and specificity predicting the high risk for surgery.
89309933|NCT03578692||Medical group|The protocol for patients assigned to medical group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed response to medicine (glucocorticoid for 5 days or rescue therapy for 3 days) were classified in the medical group. Their baseline manifestations were collected and compared with the surgery group.
89309934|NCT03578614|No Intervention|Control Group|There is no intervention for Control Group
89309935|NCT03578614|Experimental|Intervention Group|Intervention Group will be submitted to three physical activity sessions (two supervised and one nonsupervised) conducted over 6 months
89309936|NCT03578458|Other|US Healthy diet|Subjects will install a mobile app for use and will be randomly assigned to a healthy diet.
89309937|NCT03578458|Other|Vegetarian diet|Subjects will install a mobile app for use and will be randomly assigned to a vegetarian diet.
89309938|NCT03578458|Other|Mediterranean diet|Subjects will install a mobile app for use and will be randomly assigned to a Mediterranean diet.
89309939|NCT03574246|Experimental|CHXBNZ|Pharyngeal pack moisturized with chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15 and placed to oropharynx
89309940|NCT03574246|Active Comparator|SF|Pharyngeal pack moisturized with %0,9 NaCl and placed to oropharynx
89309941|NCT03574168|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
89309942|NCT03575728|Other|Mood disorder|Participants who screen positive for a history of mood disorders
89309943|NCT03575728|Other|Other|Participants who do not screen positive for a history of mood disorders
89309944|NCT02239042|Sham Comparator|Low-level laser therapy (LLLT) Sham|LLLT Sham on the palatal donor site of connective tissue graft
89309945|NCT02239042|Experimental|Low-level laser therapy (LLLT)|LLLT on the palatal donor site of connective tissue graft
89309946|NCT02239822|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
89309947|NCT02239822|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
89309948|NCT02239900|Experimental|Group 1 Liver: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 1: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.
89309949|NCT02239900|Experimental|Group 2 Liver: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 2: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.
89309950|NCT02239900|Experimental|Group 3 Lung: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 1 - 4 of Cycle 1.
89309951|NCT02239900|Experimental|Group 4 Lung: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 29 - 33 of each 21 day cycle.
89309952|NCT02239900|Experimental|Group 5 Liver/Lung Metastasis: (late) Ipilimumab and SBRT|Participants with 1 liver or lung metastasis - Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2 - 4. Each cycle is 21 days. SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
89309953|NCT02239900|Experimental|Thyroid Expansion Cohort|"Participants enrolled in this arm treated to a total dose of 50 Gy in 4 fractions, 60 Gy in 10 fractions, or 20 Gy in 5 fractions with stereotactic radiotherapy to a liver or lung lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.~Participants receive Ipilimumab every 21 days for a total of 4 doses."
89309954|NCT03575494||female infertility|Women who had regular menses and can't conceive despite a long-term regular sexual intercourse for more than 12 months
89309955|NCT03575494||healthy|healthy patients who had minimum two normal pregnancies
89309956|NCT03575338|Active Comparator|Open Scarf Osteotomy|This group of patients will undergo surgery performing an open scarf osteotomy
89309957|NCT03575338|Experimental|Minimally invasive scarf Osteotomy|This group of patients will undergo surgery performing a Minimally invasive scarf osteotomy
89309958|NCT03575260||Fulvestrant|Fulvestrant 500 mg on days 0, 14, and 28, and every 28 days thereafter
89309959|NCT03575260||Exemestane|Exemestane 25mg per day
89309960|NCT02239588|Experimental|Pure Canterbury milk powder|Oral consumption of infant formula (0-6 months) milk powder
89309961|NCT02239588|Active Comparator|Other infant formula milk powder|"Oral consumption of milk powder (other than the experimental product) selected by subjects' parents. The products including:~Yashili Ambery Infant Formula Milk Powder (Stage 1: 0-6 months)~Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
89309962|NCT02239588|Placebo Comparator|Breast milk|Oral consumption of breast milk
89309963|NCT03575182|Experimental|Gait retraining program|
89309964|NCT03575182|No Intervention|Physical therapy standard care|
89309965|NCT03572296|Placebo Comparator|Placebo|No polyphenols or fibre will be delivered in a low sugar drink.
89309966|NCT03572296|Experimental|Polyphenol and fibre|Blackcurrant extract (800 mg total polyphenols) and pulp (source of fibre) will be delivered in a low sugar drink.
89309967|NCT03572296|Experimental|Fibre|Pulp (source of fibre) will be delivered in a low sugar drink.
89309968|NCT03572140||group A|RAVS IN resistent cases after daclatasvir plus sofosbuvir treatment
89309969|NCT03572140||group B|RAVS IN relapsed cases after daclatasvir plus sofosbuvir treatment
89309970|NCT03573934|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2) injection
89309971|NCT03573934|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP) injection
89309972|NCT03573934|Experimental|GLP-2+GIP|GLP-2+GIP injection
89309973|NCT03573934|Placebo Comparator|Placebo|Placebo injection
89309974|NCT03573778|Experimental|iHEAL|10-18 visits (over 6 months) with a Registered Nurse
89309975|NCT03573778|Active Comparator|Usual Care|Information about Community Services
89309976|NCT02240836|Experimental|Intervention. Exercise|The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
89309977|NCT02240836|No Intervention|Control group|Control group, standard treatment regimen
89309978|NCT02229136|Experimental|Miracle Mouthwash plus Hydrocortisone|Miracle Mouthwash plus Hydrocortisone, swish and expectorate 10cc (10 mLs) 4 times per day, every day for 12 weeks.
89309979|NCT02229136|Active Comparator|Prednisolone|Prednisolone oral solution 15 mg/5 ml; swish and expectorate 10cc (10 mL) 4 times per day, every day for 12 weeks.
89309980|NCT03570580||Main Group - OSA Scoring|All patients include in this study for whom the four OSA scoring will be evaluated
89309981|NCT02523898|Experimental|metformine and clomiphene citrate|. metformin will be given at a dose of 500 mg three times a day for 8weeks. .In case of failure of ovulation after the end of this period, metformin was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene. When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose.
89309982|NCT02523898|Active Comparator|placebo and clomiphene citrate|"The patients in group two will be receiving placebo. In case of failure of ovulation after the end of this period, placebo was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration .In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene.When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose. .~10 days). ."
89309983|NCT02845336|Experimental|Celecoxib|Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
89309984|NCT02845336|Active Comparator|Control|Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)
89309985|NCT02844946|Experimental|ACT on Life|One day workshop aimed at providing Veterans with new tools and skills needed to pursue valued goals and directions in the face of life's challenges. Mindfulness, acceptance, values clarification, and goal-setting will be taught.
89309986|NCT02844946|No Intervention|Treatment as Usual|Veterans will continue receiving care as usual.
89309987|NCT02244502|Experimental|TTFields in combination with weekly paclitaxel|Patients will be treated continuously with the NovoTTF-100L(O) device, in addition to weekly paclitaxel.
89309988|NCT03571906|Experimental|Pre-rehab intervention|"Subjects in the prehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.~Periodic encouragements and consultations will be provided by exercise trainer, physiologist and nurse from the cardiac rehabilitation center. A physician will be available for consultations.~In addition to monitored physical activity, patients will receive nutritional and psychological counseling. This is part of a multi-professional rehabilitation program accepted by the rehabilitation center."
89309989|NCT03571906|No Intervention|pre-operative usual care arm|"The control group will receive recommendations for a healthy and active lifestyle and physician follow-up~All subjects will undergo a stress test at baseline (post enrollment), and again prior to cardiac surgery."
89309990|NCT02241538|Experimental|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
89309991|NCT02241538|Experimental|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
89309992|NCT02241538|Experimental|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
89309993|NCT02241538|Active Comparator|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group will not receive additional exercise.
89309994|NCT03573622|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
89309995|NCT03573622|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
89309996|NCT03573388||Optical coherence tomography (OCT)|
89309997|NCT03570424|Placebo Comparator|Placebo|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass of artificially flavoured and textured placebo 45 minutes prior to HIIT exercise
89309998|NCT03570424|Experimental|Whey Protein|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass intact whey protein 45 minutes prior to HIIT exercise
89309999|NCT03570424|Experimental|Whey Protein Hydrolysate|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to HIIT exercise
89310000|NCT02951156|Experimental|Phase 1b Arm A|avelumab/utomilumab/rituximab
89310001|NCT02951156|Experimental|Phase 1b Arm B|avelumab/utomilumab/azacitidine
89310002|NCT02951156|Experimental|Phase 1b Arm C|avelumab/rituximab/bendamustine
89310003|NCT02951156|Experimental|Phase 3 Arm D (selected from Phase 1b)|Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine
89310004|NCT02951156|Active Comparator|Phase 3 Arm E|Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin
89310005|NCT02245984|Experimental|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
89310006|NCT02245984|Experimental|electronic nursing process|for two weeks students in this group will be implemented electronic nursing process for patients.
89310007|NCT03573076|Experimental|Thulium laser + photodynamic therapy|Non-ablative Thulium laser (NAFL) + Photodynamic therapy combination treatment
89310008|NCT03573076|Experimental|RF microneedles + photodynamic therapy|Radio-frequency microneedles (RF-MN) + Photodynamic therapy combination treatment
89310009|NCT03573076|Active Comparator|Non-ablative Thulium laser|Non-ablative Thulium laser (NAFL) single treatment
89310010|NCT03573076|Active Comparator|RF microneedles|Radio-frequency microneedles (RF-MN) single treatment
89310011|NCT03573076|No Intervention|Control|Control receiving no intervention
89310012|NCT03572998|Other|Breast cancer patients|study subject
89310013|NCT05340608||Observation Group One|Twenty subjects with high functioning autism spectrum disorder, aged between 20 and 40 years, residing at home.
89310014|NCT05340608||Control Group|Twenty typically-developed subjects matched for sex and age distribution with participants in the Observation Group One.
89310015|NCT05340608||Observation Group Two|This group will include ten people with autism spectrum disorders, aged between 20 and 40 years, residing at home and presenting aggressive or disruptive challenging behaviors, and their caregivers.
89310016|NCT05340608||Proof of Concept|One participant with autism spectrum disorder, aged between 20 and 40 years attending a special school and living at home and exhibiting aggressive or disruptive challenging behavior, and healthcare professionals and teachers who care for him in the school setting, will participate in the proof-of-concept phase of the present study.
89310017|NCT03571594|Experimental|ONO-5788 Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
89310018|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
89310019|NCT03571594|Experimental|ONO-5788 Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
89310020|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
89310021|NCT03571594|Experimental|ONO-5788 Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
89310022|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
89310023|NCT03571594|Experimental|ONO-5788 Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
89310024|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
89310025|NCT03571594|Experimental|ONO-5788 Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
89310026|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
89310027|NCT03571594|Active Comparator|Octreotide Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
88820793|NCT05646069|Experimental|Digital ureteroscope|A patient is randomized to the experimental arm using a Digital ureteroscope.
88820794|NCT05644665|Experimental|Arm A: Ozanimod|
89310028|NCT03571438|Experimental|CK2(CX4945) and ATM(Ku 60019)|Treatment of cell culture with a combination of CK2 and ATM inhibitors serine/ threonin Kinase combination
89310029|NCT03571438|Active Comparator|Sunitinib|Treatment of cell culture with Sunitinib
89310030|NCT03571438|Active Comparator|Pazopanib|Treatment of cell culture with Pazopanib
89310031|NCT03571438|Active Comparator|Temsirolimus|Treatment of cell culture with Temsirolimus
89310032|NCT03571360|Other|Pembrolizumab|Pembrolizumab 200 mg i.v., every 3 weeks, maximum of 2 years
89310033|NCT03572920||Patients with hip/knee arthroplasty.|RAR description by actgraphy Objective sleep evaluation by actigraphy. Subjective sleep quality with sleep diary Pittsburgh Sleep Quality Index (PSQI).
89310034|NCT02246296|Active Comparator|Standard F75 Milk|F75 with 63% of total energy from carbohydrates, including 10% of energy from lactose (standard F75).
89310035|NCT02246296|Experimental|Modified F75 Milk|F75 milk with 43% of total energy from carbohydrates, without any lactose, and providing the same amount of energy as standard F75 by increased lipid in the form of medium chain triglycerides.
89310036|NCT05368324|Experimental|CogFun-RV|It consists of 12 sessions, each lasting 75 minutes for each children. Parallel parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child.
89310037|NCT05368324|Other|Control group on waiting list|After 6 months, the participants of the control group on the waiting list will be invited to participate if the results of the analysis show positive effects of the intervention.
89310038|NCT03572842|Other|quantiferon monitor|Test measuring interferon gamma production after T cells and Natural Killers (NK) in vitro stimulation : QuantiFERON Monitor® (QFM)
89310039|NCT03571282|Experimental|treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
89310040|NCT01874860|Experimental|Extensive treatment group|"Doxycycline capsule, 100 mg, taken twice daily; sunscreen SPF 30 or higher applied to exposed skin areas at least 30 minutes before going outdoors each morning; moisturizer applied to the face, hands, feet, neck, back, and chest each morning after sunscreen; Hydrocortisone 1% topical cream applied to the face, hands, feet, neck, back, and chest each evening.~For patients with grade 1 rash, hydrocortisone 1% cream and clindamycin 1% gel (tetracycline antibiotic) are recommended for daily use.~For patients with grade 2 rash, hydrocortisone cream and doxycycline 100mg twice daily or minocycline (tetracycline antibiotic) 100mg once daily is recommended.~For patients with grade 3 rash, systemic steroid therapy (a Medrol dose-pack) will be added to the grade 2 treatment."
89310041|NCT01874860|Experimental|Standard care group|Patient will not receive preventive treatment but will be allowed to use sunscreen and moisturizer if desired.
89310042|NCT03570346|Experimental|Hemay005|6 subjects in each cohort(15mg, 30mg, 60mg) will receive Hemay005
89310043|NCT03570346|Placebo Comparator|Placebo|2 subjects in each cohort(15mg, 30mg, 60mg) will receive placebo
89310044|NCT03345914|Experimental|Group 1|Participants will receive dupilumab, dosing regimen 1
89310045|NCT03345914|Experimental|Group 2|Participants will receive dupilumab, dosing regimen 2
89310046|NCT03345914|Experimental|Group 3|Participants will receive matching placebo
89310047|NCT03571126|Placebo Comparator|Placebos group|"Patients will be administered with dexamethasone plus tropisetron from D1 to D3.~Patients will also be administrated with placebos from D1-D4"
89310048|NCT03571126|Experimental|Experimental group|Patients will receive a regimen with dexamethasone plus tropisetron from D1-D3. Patients will also be administrated with olanzapine from D1-D4.
89310049|NCT03570268|Experimental|Experimental group: Education group|Participants in the experimental intervention group (education group) received an educational program and tailored home exercises. This intervention consist of multiple, interacting components supported by a handbook and audio-video material designed to teach people the skills, techniques, and strategies for preventing falls, and increase social participation and engagement in inactivity of daily living. . After the educational session, two one hour sessions were spent to teach safe balance exercises that were developed in preceding studies, the patient was invited to perform at home for 2 months.
89310050|NCT03570268|Active Comparator|Control Group: Usual care|Participants allocated to the control group received ongoing usual treatments. In addition, two one hour lessons were spent to teach stretching exercises that the patient was invited to perform at home for 2 months.
89310051|NCT03572686|Sham Comparator|Group Ropivacaine High (RH)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml + N/S 1.6mL.
89310052|NCT03572686|Placebo Comparator|Group Ropivacaine Low (RL)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + N/S 1.6mL.
89310053|NCT03572686|Experimental|Group Ropivacaine Low + Dexamethasone (RLD)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + Dexamethasone 8mg (1.6mL).
89310054|NCT02524132|Experimental|Physical Activity|5 minute movement breaks
89310055|NCT02523820|Experimental|fluticasone propionate|Fluticasone 1 mg + Normal saline (NSS) upto 4 ml nebulized after extubation
89310056|NCT02523820|Placebo Comparator|placebo|Normal saline (NSS) 4 ml nebulized after extubation
89310057|NCT03707288|Other|Spine exercise program|"The preclinical second year medical students will be prospectively randomized into two (2) groups, a control group (Group A) and an intervention group (Group B) that will be given a standardized spine exercise program. They will be asked to complete a Questionnaire B to evaluate changes in knowledge, attitude and practice towards musculoskeletal problem of the back and neck pain after intervention; the numeric rating scale (NRS), and the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) at eight (8) weeks.~The standardized spine exercise program will be provided in a handout and given only to the intervention Group B subjects, these are basic low back exercises to be done three (3) times per week for 20mins, as well as a few very brief stretching exercises to be done during periods of sitting for greater than sixty (60) minutes."
89310058|NCT03570034||Obalon Balloon System|Obalon Balloon System with moderate intensity Weight Loss Behavioral Modification Program
89310059|NCT03570970|Experimental|Banapenem C1 group|250mg Once daily for 7
89310060|NCT03570970|Experimental|Banapenem C2group|500mg Once daily for 7
89310061|NCT03570970|Experimental|Banapenem C3group|1000mg Once daily for 7
89310062|NCT03707210|Experimental|Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
89310063|NCT03707210|No Intervention|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
89310064|NCT02247076|Placebo Comparator|Grazing|"Participants will eat meals spread over the course of the day (grazing)."
89310065|NCT02247076|Experimental|Time-restricted feeding (early eating)|Participants will eat meals only in the early part of the day (early lunch and very early dinner).
89310066|NCT03572608|Experimental|Acupuncture Treatment|Acupuncture group will receive 3 acupuncture sessions. The first session will be one week before embryo transfer. The second session will be 30 minute before embryo transfer. And the last session will be 30 minute after embryo transfer.
89310067|NCT03572608|No Intervention|Control Group|Control Group will not receive any acupuncture session before or after embryo transfer.
89310068|NCT03369704|Experimental|Omalizumab|Eligible patients randomized to this arm received omalizumab subcutaneously for 12 weeks
89310069|NCT03369704|Placebo Comparator|Placebo|Eligible patients randomized to this arm received placebo subcutaneously for 12 weeks
89310070|NCT03572452|Experimental|McKenzie - method group|Participants will be sent to an experienced MDT therapist for therapy. They are 1) assessed clinically, 2) treated according the MDT-approach which includes home exercise program, consisting i) an educational component, and ii) an active therapy component with directional preference exercises, several times a day with sustained end range positions according to symptom response, and with avoiding aggravating positions. Participants have a maximum of 7 treatment visits. They will also have physiotherapy counselling at study entry about the good prognosis of sciatica.
89310071|NCT03572452|Active Comparator|Advice to stay active group|"Participants enrolled into this group will receive physiotherapist's counselling at study entry for at least 60 minutes time about the good prognosis of sciatica, the spontaneous regression of the intervertebral disc herniation and pain tolerance (natural healing). In addition, they will get ergonomic advice and advice to stay normally active. The participants are also told to avoid bed rest and advised to continue their normal routines as actively as possible including exercise activities with limits permitted by their signs and symptoms. A two-page summary booklet related to these items will be given to them."
89310072|NCT03569254|Experimental|Neomedlight Phototherapy Blanket|Phototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period.
89310073|NCT03569254|Active Comparator|Ohmeda-Fiber Optic Phototherapy Blanket|Phototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket
89310074|NCT03569722||Older adults|Older adults, ages 65+
89310075|NCT05708872|Experimental|Study group|
89310076|NCT05708872|Active Comparator|Control group|
89310077|NCT05424848||patient group|"Inclusion Criteria~Having Parkinson's~50-75 years old~Exclusion criteria~Limited cooperation~The patient has moderate to severe dementia or mental retardation, which may cause limitations in examination, testing and treatment~The patient's refusal to participate in the study~Application of total joint prosthesis for the knee area~Secondary osteoarthritis"
89310078|NCT05424848||Control group|Healthy control group
89310079|NCT03570736|Experimental|Minimal Invasive Surgical Technique|
89310080|NCT03570736|Active Comparator|Open Flap Debridement|
89310081|NCT03707132||Tourniquet Group|'Tourniquet: Folley catheter in the low segment of the uterus
89310082|NCT03707132||Control Group|Standard hysterectomy is performed
89310083|NCT03569644|Other|qualitative study|heterogeneous group of patients
89310084|NCT03569176|Experimental|Autism Glass Intervention|Participants in the experimental group will receive the autism glass for 6 weeks once they are assigned to the experimental condition. Participants will be asked to use the glasses at least 3 times a week for 20 minutes sessions in addition to continuing Applied Behavior Analysis (ABA) therapy.
89310085|NCT03569176|Other|Crossover Control for Autism Glass|Participants randomized to the control arm, will continue treatment as usual (receiving ABA twice a week) while the intervention participants will receive the Autism Glass intervention (while continuing to receive ABA therapy). After 6 weeks, control participants will receive the Autism Glass intervention after which, they will be asked to come in for a second round of follow-up testing following 6 weeks of use (at week 18).
89310086|NCT03709160|Experimental|BUMETANIDE|we will administrated bumetanide at dosis: oral, 2mg each 8hours for seven day.
89310087|NCT03709160|Active Comparator|INDAPAMIDE|we will administrated indapamide at dosis:oral,1.5MG each 8hours for seven day.
89310088|NCT05354050|Experimental|DARE-BV1|
89310089|NCT05332496||Study group: TACE+PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|TACE was performed up to 3 months after the first PD-1/PD-L1 inhibitor/anti-angiogenic drug treatment or within 1 month before treatment. The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
89310090|NCT05332496||Control group: TACE|TACE monotherapy
89310091|NCT03567304|No Intervention|EFV-based|"HIV-infected patients, who has been taking efavirenz (EFV)-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to continue EFV-based regimen.~EFV based regimen defines as efavirenz 600 mg per oral once daily (OD) + 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)."
89310092|NCT03567304|Experimental|RPV-based|"HIV-infected patients, who has been taking efavirenz-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to switch antiretroviral therapy to rilpivirine (RPV)-based regimen.~RPV based regimen defines as rilpivirine 25 mg PO OD + 2 NRTIs."
89310093|NCT03567226|Experimental|Intervention Group|The intervention group will be enrolled into a WeChat Group to receive reminders to exercise and health education materials.
89310094|NCT03567226|Active Comparator|Control Group|Controls will receive a handout telling them to increase walking and that walking may be helpful for the eye at the return visit.
89310095|NCT03569410|Active Comparator|Supplement Group|The protein supplement group was instructed by their dietician in how many protein supplements to consume in addition to their natural food intake in order to reach their goal protein intake.
89310096|NCT03569410|Experimental|Natural Food Group|The Natural food group was instructed by their dietician in how much additional protein rich foods to eat in order to reach their goal protein intake.
89310097|NCT03569332|Experimental|Test Group|Participants will receive the mobile self-input tool providing alarm on tablet, and their practicing rate will be sent to Nurse's Dashboard.
89310098|NCT03569332|No Intervention|Control Group|Participants will receive the mobile self-input tool on tablet (to compare the rate with Test group). But it won't contain alarm function and their practicing rate won't be sent to Nurse's Dashboard, either.
89310099|NCT02247778|Active Comparator|conventional plate osteosynthesis|Standard procedure
89310100|NCT02247778|Active Comparator|mini-incision-type osteosynthesis|mini-incision
89310101|NCT03567148|Active Comparator|PRF group|Four layers of PRF membranes were placed in the palatal wound and sutured with 5/0 resorbable sutures
89310102|NCT03567148|Active Comparator|Essix retainer group|An impression of palatal region was taken and the Essix retainer was prepared before the patients underwent surgery.
89310103|NCT03567148|Active Comparator|Ozone therapy group|Ozone was applied to the donor sites at five different points (four corner-points and a center point) at a fixed concentration of 2100 p.p.m. through a connected hand-piece, using a sterile, specially-formed perio-tip with 80% oxygen for 30 seconds. The applications were performed immediately after surgery and on the 1st, 3rd, and 7th days following the operation.
89310104|NCT03567148|Active Comparator|LLLT group|Irradiation was performed at the same points described above using a diode laser (λ=970±15 nm, 14-W source power) (SIROLaser Xtend; Sirona Dental Systems GmbH, Bensheim, Germany) that continuously emitted a wavelength with 320µm fiberoptic; the power was 2W and the tissue dose was 35 J/cm2. Total irradiation time was 30 seconds. The applications were performed immediately after surgery, and on the 1st, 3rd and 7th, days following the operation.
89310105|NCT03567148|Active Comparator|Collagen fleece group|Collagen fleece (BEGO Collagen Fleece, Bremen, Germany) was sutured with 5/0 resorbable sutures (Pegesorb, Istanbul, Turkey) on the open wound with the aid of vertical mattress sutures.
89310106|NCT03567148|No Intervention|Control group|Palatal wounds were left for spontaneous healing
89310107|NCT03567070|Other|qualitative study based on an individual clinical interview|
89310108|NCT03566992|Active Comparator|Gastric Tube Placement|Nasoenteric tube placed in the stomach.
89310109|NCT03566992|Experimental|Small bowel|Nasoenteric tube placed in the small bowel.
89310110|NCT05356858|Experimental|zanubrutinib|zanubrutinib orally, 80mg bid for 1 year
89310111|NCT03566914|Experimental|Tadalafil|Tadalafil 10 mg once daily per oral for 3 months
89310112|NCT03566914|Placebo Comparator|Placebo|Tablet placebo once daily per oral for 3 months
89310113|NCT03566836||AF Detection|Participants will be asked to wear the Garmin smart watch and Garmin chest band. Both are commercially available. The devices will collect information about heart rates before and after a cardioversion procedure.
89310114|NCT03565042||MoA ustekinumab|Patients with a diagnosis of psoriatic arthritis according to the CASPAR criteria with at least one swollen knee or ankle joint who are planning to receive treatment with ustekinumab at the outpatient clinic. An arthroscopy will be done in the swollen knee/ankle at week 0, 12 and 24.
89310115|NCT03366428|Experimental|All Participants|All participants will receive DS-8201a by intravenous infusion
89310116|NCT05682794||taTME|patients who underwent transanal total mesorectal excision
89310117|NCT05682794||laTME|patients who underwent laparoscopic total mesorectal excision
89310118|NCT02839876|Experimental|Intravenous acetaminophen|Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.
89310119|NCT02839876|Active Comparator|Oral acetaminophen|Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.
89310120|NCT03706820||normal rest and exercise hemodynamics|
89310121|NCT03706820||normal rest and abnormal exercise hemodynamics|
89310122|NCT03706820||resting pulmonary hypertension|
89310123|NCT03706820||abnormal wedge pressure at exercise|
89310124|NCT01312064|Active Comparator|rituximab and everolimus|Patients of the study arm will receive rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus will be given with an initial dose of 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
89310125|NCT01312064|Active Comparator|thymoglobulin and tacrolimus|The control arm will receive thymoglobulin induction and tacrolimus-based immunosuppressive therapy. The dose of thymoglobulin would be 1.0mg/kg/d for 3 days25. The first dose of thymoglobulin will be administered before graft kidney reperfusion, and so is rituximab. All patients will receive corticosteroid therapy as usual. The initial daily dose of tacrolimus will be 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation. The doses of tacrolimus will be adjusted to target the whole blood trough levels between 8 to 12 ng/ml during the first 30 days after transplantation, and tapered to 6 to 10 ng/ml at 6 months.
89310126|NCT03566602|Other|Dura Sealant Patch|Application of Dura Sealant Patch after closure of the dura mater
89310127|NCT01312142||patients with difficult weaning|
89310128|NCT05682716|Experimental|Intervention group|Controlled low central venous pressure (CLCVP) technology
89310129|NCT05682716|No Intervention|control group|
89310130|NCT03566368||Study Group|Isolated Traumatic Brain Injury Patients requiring emergency surgical intervention.
89310131|NCT03366194|Experimental|Experimental|Each subject shall have a relatively homogenous section of the total scar divided into two relatively equal sides. One side shall be treated with SkinStylus Sterilock System and the other not treated. The side that is chosen for treatment remains constant. The side that is chosen is done so randomly and prior to meeting the subject via a coin flip randomization.
89310132|NCT03566212|Experimental|conventional syringe|Individuals requiring local anesthesia for dental treatment were treated in first group by using conventional syringe.
89310133|NCT03566212|Experimental|camouflaged syringe|Individuals requiring local anesthesia for dental treatment were treated in second group by using camouflage syringe.
88814091|NCT02461758|Other|High dose influenza vaccine (HDIV)|"This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
89310134|NCT03566134|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
89310135|NCT03566134|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
89310136|NCT03566134|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
89310137|NCT03566134|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
89310138|NCT05708560||Non-MAFLD, antiviral therapy|
89310139|NCT05708560||Non-MAFLD, no antiviral therapy|
89310140|NCT05708560||MAFLD, antiviral therapy|
89310141|NCT05708560||MAFLD, no antiviral therapy|
89310142|NCT03568864|Placebo Comparator|Low nucleotide meal|Mixed meal containing mycoprotein with a reduced nucleotide content (~ 2% nucleotides)
89310143|NCT03568864|Experimental|High nucleotide meal|Mixed meal containing mycoprotein with a high nucleotide content (~ 10% nucleotides)
89310144|NCT03568786|Experimental|End-inspiratory pause (EIP) 10%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a of 10% of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 10% of total inspiratory time.
89310145|NCT03568786|Experimental|End-inspiratory pause (EIP) 30%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a 30 % of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 30 % of total inspiratory time.
89310146|NCT03101722|Experimental|Huperzine A intervention|Huperzine A intervention: Huperzine A with a dose 0.1~0.2 mg/time, 2 times/day. BTHE：basic treatment and health education
89310147|NCT03101722|Sham Comparator|control|Participants in the BTHE group will receive advice regarding lifestyle modification, avoiding alcohol and cigarette consumption.
89310148|NCT05354518|Experimental|gestational diabetes management simulation|
89310149|NCT05354518|No Intervention|no intervention will be made|
89310150|NCT03568474|Experimental|Silver Diamine Fluoride|Silver Diamine fluoride will be applied after after minimal caries removal then glass ionomer over it followed by composite resin restoration.
89310151|NCT03568474|Active Comparator|Glass Ionomer|Glass ionomer will be applied after minimal caries removal followed by composite resin restoration.
89310152|NCT05353504|Active Comparator|prebiotic dietary supplement|high-dose daily inulin
89310153|NCT05353504|Experimental|behavioural lifestyle intervention|new educational program to change eating behaviour, provided through weekly sessions.
89310154|NCT05353504|Placebo Comparator|placebo dietary supplement|equicaloric daily maltodextrin
89310155|NCT03568396||Pupillometry|The relationship between the target effect site concentration of remifentanil and the pupil diameter and reactivity in response to a standard noxious stimulus.
89310156|NCT03565978|Experimental|BAMA solution|This group will use BAMA solution. This is an digital solution used for cardiac post-discharge management. It is an application installed on a tablet. This arm will use this application and also have usual outpatient follow up.
89310157|NCT03565978|No Intervention|Usual care|Not using the application installed on the tablet. Usual outpatient follow up.
89310158|NCT03565822|Other|interview|There are two data collection phases (individual interviews +/- focus groups) with parents of children with esophageal atresia, congenital diaphragmatic hernia or short bowel syndrome.
89310159|NCT05353894|Experimental|Part 1 Cohort 1|Three (3) Healthy volunteers, each receiving a single oral dose (50mg) of GNS561 tablets and capsules, after a high fat meal and with a wash-out period of seven days.
89310160|NCT05353894|Experimental|Part 1 Cohort 2|Six (6) healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets and capsules, after a high fat meal and with a wash-out period of fourteen days.
89310161|NCT05353894|Experimental|Part 2|"Nine (9) healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets or capsules (according results of Part 1), in fed condition then in fasting condition, after a wash-out period of fourteen days.~Nine (9) other healthy volunteers, each receiving a single oral dose (200mg) of GNS561 tablets or capsules (according results of Part 1), in fasting condition then in fed condition, after a wash-out period of fourteen days."
89310162|NCT02839798|Experimental|sTMS active|Treatment with the NEST Device
89310163|NCT03565510|No Intervention|Control|Those assigned to the Control group will receive a diet composed of 55% of carbohydrate, 15% of protein, and 30% of lipid (similar to the North American dietary pattern).
89310164|NCT03565510|Experimental|High-Protein Diet|Those assigned to the High-Protein Diet group will receive a diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based total diet replacement.
89310165|NCT05354284||Sexual gender minority people|People self defining Lesbian, Bi-sexual, Transgender, Quer or other are recruited and asked to fill in a questionnaire during pregnancy, three months postpartum and one year later.
89310166|NCT03345836|Placebo Comparator|Part 1 (Double-blind): Placebo|Participants received upadacitinib matching placebo tablets, orally, once daily (QD) for 12 weeks during the Double-blind (DB) Induction Period.
89310167|NCT03345836|Experimental|Part 1 (Double-blind): Upadacitinib 45 mg|Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.
89310168|NCT03345836|Experimental|Part 2 (Open-label): Upadacitinib 45 mg|Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.
89310169|NCT03345836|Experimental|Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo|Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.
89310170|NCT03345836|Experimental|Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg|Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.
89310171|NCT03345836|Experimental|Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg|Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
89310172|NCT03709004|Experimental|Pacifier|Mother given a pacifier during birth hospitalization, along with other baby items
88820795|NCT05644665|Placebo Comparator|Arm B: Placebo|
88820796|NCT05640180||External control arm (ECA)|ECA built from patients from Optum® Electronic Health Records (EHR) real world data (RWD) that closely match Sodium/glucose cotransporter-2 inhibitors (SGLT2i) subgroups from the randomized clinical trials (RCTs).
88820797|NCT05640180||Internal control arm (ICA)|ICA built from participants from two RCTs called FIDELIO-DKD and FIGARO-DKD pooled for the FIDELITY analyses. FIDELIO-DKD/FIGARO-DKD placebo controls treated with SGLT2is at baseline.
88820833|NCT05600556|Experimental|Cohort II (virtual reality)|Patients receive image review using virtual reality stimulation on study. Patients also view MRI treatment room using virtual reality stimulation. Patients undergo MRI and CT imaging at screening and on study
89310173|NCT03709004|No Intervention|Control|Mother not given a pacifier, just the other baby items
89310174|NCT05420012|Experimental|Vericiguat|Study drug
89310175|NCT05420012|Placebo Comparator|Placebo|Placebo
89310176|NCT05414864|Other|Control Group|Sleep hygiene alone (control group)
89310177|NCT05414864|Other|Intervention Group|Sleep Hygiene and Ramelteone (RozeremTM) 8 mg at night
89310178|NCT03706742|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
89310179|NCT03706742|Active Comparator|Mailed outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening among baby-boomers in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in baby boomers and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody blood test. Written materials will be developed and validated in Spanish using the Spanish Language Translation Resource. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will place a follow-up call to this potential subject. These follow-up calls will occur in the 2nd - 4th week after mailing invitations; up to three attempts in total will be made to reach the patient to facilitate HCC screening completion.
89310180|NCT03708926|Experimental|abaloparatide|abaloparatide 80 mcg subcutaneously once daily for 90 days
89310181|NCT03708926|Placebo Comparator|placebo|placebo formulated similarly but without active abaloparatide injected subcutaneously once daily for 90 days
89310182|NCT03568240||30 men suffering from apnea|
89310183|NCT03568240||15 men defined as snorers|
89310184|NCT03568240||15 men without complaints|
89310185|NCT03706586|Active Comparator|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
89310186|NCT03706586|Experimental|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
89310187|NCT02839330|Experimental|Group A|aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)
89310188|NCT02839330|Experimental|Group B|aH5N1c lot #2; receive 2 doses (on Day 1 and Day 22)
89310189|NCT02839330|Experimental|Group C|aH5N1c lot #3; receive 2 doses (on Day 1 and Day 22)
89310190|NCT02839330|Placebo Comparator|Group D|Placebo; receive 2 doses (on Day 1 and Day 22)
89310191|NCT03568006|Experimental|Intervention|"Intervention will consist of passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint.~Besides, participants will receive a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene."
89310192|NCT03568006|Active Comparator|Control|Control treatment will consist of a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene.
89310193|NCT03567928|Active Comparator|Standard Treatment|Standard Treatment Sedation with propofol target controlled infusion (TCI) and no airway devices (mandatory spontaneous breathe)
89310194|NCT03567928|Experimental|Interventional Treatment|Interventional Treatment Sedation with propofol target controlled infusion (TCI) and Gastro Cuff Pilot Laryngeal Mask (possibility to use a pressure-support ventilation)
89310195|NCT03565432||IBD in KHUH|Registered patients with Inflammatory bowel disease at Kyung Hee University Hospital
89310196|NCT03565354|Active Comparator|Treatment arm|intravenous iron isomaltose 3-10 weeks before operation date. The dose will be determined by the patient's body weight: > 50kg: 1000mg; <50kg: 20mg/kg body weight, to be infused over 30 minutes. 2 weeks after intravenous iron isomaltoside administration, blood test for hemoglobin level and iron profile would be repeated. Subjects with hemoglobin level less than 10g/dL will receive a second dose of intravenous iron isomaltoside. The second dose would be identical to the first dose
89310197|NCT03565354|No Intervention|Control arm|Patient randomized to the control arm will follow the standard perioperative care and the perioperative management they received will be identical to the treatment arm except no intravenous iron isomaltoside will be given.
89310198|NCT03363776|Experimental|Monotherapy|BMS-986277 administered alone
89310199|NCT03363776|Experimental|Combination Dose Escalation Therapy|BMS-986277 administered in combination with Nivolumab
89310200|NCT03363776|Experimental|Combination Expansion Therapy|BMS-986277 monotherapy with option for subsequent Nivolumab therapy
89310201|NCT03565276|Experimental|Experimental: TXA|Intravenous Tranexamic Acid beginning at 5mg/kg administered as part of a dose-escalation design.
89310202|NCT03565120|Experimental|Arm-R|patients in this arm will receive aggressive thoracic radiotherapy.
89310203|NCT05409794||Suicide attempters/ideations|Patients currently suffering from a major depressive disorder and reporting at least one suicidal event (suicide attempt or hospitalization for suicidal ideation) over the last 12 months.
89310204|NCT05409794||Affective controls|Patients currently suffering from a major depressive disorder and reporting no suicidal event (suicide attempt or hospitalization for suicidal ideation) over the last 12 months.
89310205|NCT03564730|Active Comparator|Total Knee Arthroplasty (TKA)|Patient will have complete replacement - Simultaneous vs Staged
89310206|NCT03564730|Active Comparator|Unicompartmental Knee Arthroplasty (UKA)|Patient will have half-knee replacement (partial) - Simultaneous vs Staged
89310207|NCT03708848|Experimental|Tailored Therapy|Medications will be adjusted according to clarithromycin，metronidazole and levofloxacin sensitivity. All drugs will be prescribed for 14 days.(1) When three of them or clarithromycin and metronidazole are sensitive, esomeprazole 20mg bid, clarithromycin 0.5g bid and metronidazole 0.4g bid will be prescribed. (2) When two of them (levofloxacin and clarithromycin or metronidazole) are sensitive, esomeprazole 20mg bid, levofloxacin 0.5g qd plus clarithromycin 0.5g bid or metronidazole 0.4g bid will be prescribed. (3) When one of them (clarithromycin or levofloxacin) is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus clarithromycin 0.5g bid or levofloxacin 0.5g qd will be prescribed.(4) When only metronidazole or none of them is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus tetracycline 0.4g qid will be prescribed.
89310208|NCT03710408|Experimental|Subcutaneous hydration|
89310209|NCT03710408|Active Comparator|Intravenous hydration|
89310210|NCT05353582|Experimental|Chemotherapy group|6 cycles of mFOLFOXIRI±Bev is followed by cytoreductive surgery. Postoperative 6 cycles of mFOLFOX is scheduled.
89310211|NCT05353582|Active Comparator|Upfront surgery group|Upfront surgery group is followed by 12 cycles of mFOLFOX+Bev
89310212|NCT05353426|Experimental|PG-ANB Block|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four of the areas are next to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries
89310213|NCT05353426|No Intervention|Control|No paragastric neural block is performed in the control group. The same standard analgesic protocol consisting of acetaminophen (1 g) and morphine (3-5 mg) is used in all patients before extubation and TAP block is performed in both groups (control and experimental)
89310214|NCT05353270|Experimental|Yoga|Yoga sessions (35 minutes each) will be performed 5 times weekly for 4 weeks.
89310215|NCT05353270|Other|Waitlist control|Waitlisted participants will maintain their normal diet and exercise patterns for 4 weeks prior to rerandomization to the yoga group.
89310216|NCT03564652|No Intervention|Arm A|Control arm: Lactating women (LW) randomized in this arm will only receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
89310217|NCT03564652|Experimental|Arm B|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
89310218|NCT03564652|Experimental|Arm C|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, the same infant of LW will receive a single dose of Azithromycin (20mg/kilogram) at day 42 of age. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
89310219|NCT03564574|Experimental|Study group|"Inclusion criteria~History of consumption of OP compound.~Symptom complex consistent with OP poisoning~Age > 18 years~Informed consent from the patient or next kin.~Exclusion criteria~History of combined poisoning with a non OP compound.~All other patients not fitting in the organophosphate symptom complex.~Patients with underlying liver and kidney disease.~History suggestive of acute pancreatitis in the past.~All patients with history and clinical features of OP compound poisoning admitted to the emergency department in PGIMER during the study period, meeting the inclusion, exclusion criteria and who gave consent were enrolled in the study.~Intervention : Administration of 100mL of 20% Lipid emulsion to all patients in the study group"
89310220|NCT03564574|No Intervention|Historic controls|The control arm The study group was compared with data of patients admitted for OP poisoning between the years 2013 and 2014 ( 2 calendar years), fulfilling the inclusion and exclusion criteria as stated above.
89310221|NCT05352802|Experimental|Prehabilitation group|The prehabilitation group received multimodal prehabilitation combined with ERAS before the gastrectomy.
89310222|NCT05352802|Active Comparator|ERAS group|The ERAS group patients were treated according to the ERAS pathway.
89310223|NCT03564418|Active Comparator|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points. Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.
89310224|NCT03564418|Active Comparator|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.
89310225|NCT03564808|Experimental|Fat graft enriched with MSCs|Adipose tisse derrived MSCs
89310226|NCT03564808|Experimental|Fat graft only|Fat graft withiut enrichment with MSCs
89310227|NCT03706352|Experimental|tunneling group|Epidural Catheter Insertion and fixation by subcutaneous tunneling procedure.
89310228|NCT03706352|Active Comparator|taping group|Epidural Catheter Insertion and fixation by use of adhesive tape without tunneling.
89310229|NCT05273606|Experimental|Experimental Group|one group for contact lens
89310230|NCT03706274|Experimental|CX-188 Escalation|
89310231|NCT03706274|Experimental|CX-188 Alternative Dosing Schedule|
89310232|NCT03710330|Placebo Comparator|normal saline|the patients receives 110 ml normal saline IV just before skin incision
89310233|NCT03710330|Active Comparator|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
89310234|NCT03710330|Active Comparator|0.5 gm tranexamic acid|0.5 gm tranexamic acid (1 ampoule of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
89310235|NCT03360344|Experimental|Kinesio Tape|"Dorsal application of Kinesio Tape to the affected extremity: Approximately 12 inches of Kinesio tape will be applied from the musculotendinous junction of the participant's forearm over digits 1 and 5. Two - 2 inch strips of Kinesio Tape will be applied to the participant's wrists over the volar and dorsal aspects. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application by the researchers four times during the course of the study.~A tape removal form will be provided should the participants want to remove it prior to the next visit."
89310236|NCT03360344|Sham Comparator|Control group|Approximately 4 inch strip of Kinesio Tape will be applied to the scapular spine of the same side as the affected extremity. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application four times during the course of the study by the researcher. A tape removal form will be provided should the participants want to remove it prior to the next visit.
89310237|NCT03360344|Active Comparator|Standard of Care|Currently, the standard of care is a general cock-up splint and lumbrical exercises. A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
89310238|NCT03710252|Experimental|Single|Ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) + databuvir (DSV) +/- ribavirin (RBV)
89310239|NCT02838628|Experimental|KX2-391 50 mg (Days 1 to 5)|Participants were applied 50 milligrams (mg) of KX2-391 Ointment 1% topically on face or scalp in 25 centimeter square (cm^2) treatment area, once daily for 5 consecutive days.
89310240|NCT02838628|Experimental|KX2-391 50 mg (Days 1 to 3)|Participants were applied 50 mg of KX2-391 Ointment 1% topically on face or scalp in 25 cm^2 treatment area, once daily for 3 consecutive days.
89310241|NCT03708692||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
89310242|NCT03708692||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
89310243|NCT03706196||high incidence crohn's disease area|subjects living in high incidence crohn's disease area coming in dentist for dental extraction linked to medical indication
89310244|NCT03706196||low incidence crohn's disease area|subjects living in low incidence crohn's disease area coming in dentist for dental extractionlinked to medical indication
89310245|NCT03706118|Experimental|MRI and Neuropsychologic testing|"102 healthy controls will be examined by magnetic resonance imaging (MRI) of brain, spinal and thoracic cord at month 0, 12, 24 and 36.~102 healthy controls will be examined by neuropsychological and walking testing designed for patients with multiple sclerosis at month 0, 12, 24 and 36."
89310246|NCT03708614|Other|Controlled energy intake with elevated protein intake|Dietary intervention - Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks.
89310247|NCT02835820|Experimental|Ketogenic Diet Group|Ketogenic meals (3 meals/day, 7 days/week x 12 weeks) prepared and delivered to participants.
89310248|NCT02835820|No Intervention|Patient Choice Diet|Control.
89310249|NCT03705884|Other|Cardiac Sarcoidosis|Patients with an established diagnosis of cardiac sarcoidosis.
89310250|NCT03705884|Other|Healthy volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
89310251|NCT02569450||Intervention arm|Hospitals randomly assigned to the intervention arm with surgical outcomes monitoring
89310252|NCT02569450||Hospitals in control arm|Hospitals randomly assigned to the control arm without surgical outcome monitoring
88806481|NCT05532384|Experimental|Early resumption of oral intake|Drink 30-50ML of normal temperature water after meeting the PACU transfer out standard. If the patient swallows successfully and does not cough, after returning to the ward, the medical staff of the ward will guide him or her to resume drinking and eating early: patient will resume drinking water within one hour after returning to the ward, a small amount of water for many times until the amount of drinking water reaches 300ml. If the patient does not have discomfort symptoms, he or she will resume eating according to normal drinking and eating habits.
88806482|NCT05532384|Other|Late resumption of oral intake|Drink 30-50ML of normal temperature water after 6h after the operation. A small amount of water can be used several times, and the amount of water can reach 300ml. If the patient does not have any discomfort symptoms, it can guide the patient to recover diet according to his/her normal eating habits.
88806483|NCT05339568||Platform follow-up cohort|This cohort will be managed and follow-up by patients' whole process follow-up platform. The patients can report the symptoms, get the reminder of the hospital visit, get the reminder of medicine taking, get the information of patients education.
88806484|NCT05339568||Routine follow-up cohort|This cohort will be managed and follow-up by the investigators or nurses. This cohort will take the routine follow-up and management way by the hospital.
88806485|NCT00365144|Experimental|Bevacizumab Plus Erlotinib Hydrochloride|"A treatment cycle is 21 days:~bevacizumab 15 mg/kg as a 60-90 min infusion once every 21 days, with erlotinib hydrochloride 150 mg by mouth daily"
88806486|NCT01793012||critically ill intensive care patients|Treatment with one or more of the following antibiotics: piperacillin/tazobactam, cefepime, meropenem, ciprofloxacin, linezolid, colistin
88806487|NCT00365768|Experimental|Arm I: Glutamine|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
89310253|NCT03359174|Experimental|All-trans retinoic acid (ATRA) therapy|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
89310254|NCT03564106|Experimental|group A|receive intraarticular radiofrequency + methylprednisolone (30 mg)
89310255|NCT03564106|Experimental|group C|receive intraarticular methylprednisolone (30 mg)
89310256|NCT03710174|No Intervention|Control group|Without bruxism and no intervention. They will be submitted to electromyographic assessment and evaluation of salivary cortisol and dopamine.
89310257|NCT03710174|Experimental|LED group|The volunteers in Group 2 will be submitted to the initial evaluation of the morphological and psychosocial variables. During the same appointment, red LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of 650 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later. They will be submitted before and after LED to electromyographic assessment and evaluation of salivary cortisol and dopamine.
89310258|NCT03710174|Experimental|Occlusal splint group|They will be treated using the standard protocol of a rigid occlusal splint. After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
89310259|NCT03710174|Placebo Comparator|Placebo group|Subjects with bruxism. The same procedures as LED group, but the device will be turn off.
89310260|NCT05345704||Lay rescuers|Volunteer participants in a role lay rescuers
89310261|NCT05345704||Health care professionals (HCPs)|Health care professionals (HCPs) trained in advanced life support
89310262|NCT03564262|Experimental|Cerebrovascular Reactivity|"Cerebrovascular reactivity (CVR) will be assessed using transcranial Doppler ultrasound with carbon dioxide as the vasoactive stimuli.~The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. The CVR test will be performed prior to soup consumption as well as after soup consumption."
89310263|NCT03564262|Experimental|Blood Pressure Reactivity|Blood pressure responses during dynamic exercise will be assessed. The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. Blood pressure reactivity during dynamic exercise will be assessed after soup consumption.
89310264|NCT02832622||MPP Programming|This post-market study was designed to characterize the real-world use of MPP technology in patients indicated for CRT device implant. Therefore in order to adequately characterize MPP, data from subjects with MPP programmed continuously or for at least 3 months prior to the final follow-up are reported as the MPP programming group.
89310265|NCT00093015|Active Comparator|Active|
89310266|NCT00093015|Placebo Comparator|Placebo|
89310267|NCT01145703|Active Comparator|RDA Vitamin D|
89310268|NCT01145703|Experimental|Vit D repletion + 6M Supplementation|
89310269|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +AEX|
89310270|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +RT|
89310271|NCT05137587|Active Comparator|Group P|Patients sedated with propofol
89310272|NCT05137587|Active Comparator|Group K|Patients sedated with ketamine
89310273|NCT01245621|Active Comparator|Early entry group|Early entry group will begin the intervention at time of diagnosis of advanced cancer
89310274|NCT01245621|Active Comparator|Later entry group|Later entry group will begin the intervention 12 weeks after enrollment in the study.
89310275|NCT01145781|Active Comparator|Single-freeze cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw.
89310276|NCT01145781|Active Comparator|Double-freeze cryotherapy|Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
89310277|NCT01145859|Experimental|Arm 1|
89310278|NCT01250847|Experimental|Seroquel-XR|The subjects At-Risk Mental States will be treated with Quetiapine(Seroquel-XR) from baseline to end of trial.
89310279|NCT01250847|Experimental|Schizophrenia Comparator|The subject with schizophrenia will be treated with standard treatment
88806488|NCT00365768|Placebo Comparator|Arm II: Placebo|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
89310280|NCT01250847|No Intervention|Healthy Control Comparator|The subjects will not be required to treat
89310281|NCT01238523|Experimental|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
89310282|NCT01238523|Experimental|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
89310283|NCT01238679|Experimental|Cohort 1|Participants received an oral solution of 0.03 milligrams (mg) of PF-04958242, every 12 hours for 14 days.
89310284|NCT01238679|Experimental|Cohort 2|Participants received an oral solution of 0.05 mg of PF-04958242, every 24 hours for 14 days.
89310285|NCT01238679|Experimental|Cohort 3|Participants received an oral solution of 0.10 mg of PF-04958242, every 24 hours for 14 days.
89310286|NCT01238679|Experimental|Cohort 4|Participants received an oral solution of 0.15 mg of PF-04958242, every 24 hours for 14 days.
89310287|NCT01238679|Experimental|Cohort 5|Participants received an oral solution of 0.20 mg of PF-04958242, every 24 hours for 14 days.
89310288|NCT01238679|Experimental|Cohort 6|Participants received an oral solution of 0.25 mg of PF-04958242, every 24 hours for 14 days.
89310289|NCT01238679|Placebo Comparator|Matching Placebo|Participants received an oral solution of matching placebo, every 12 or 24 hours for 14 days.
89310290|NCT03913533|Active Comparator|Control group|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
89310291|NCT03913533|Experimental|Intervention group|Heart rate assessment using Tap-based smartphone application At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
89310292|NCT05368688||Cancer-free|Have confirmed colorectal cancer-free and Polyp-free colon using colonoscopy
89310293|NCT05368688||Pre-cancerous|Have benign or precancerous polyps, including tubulovillous or villous adenomas, using colonoscopy
89310294|NCT05368688||Colorectal cancer stage I|"Have confirmed TNM staging of colorectal cancer~The T refers to the size and extent of the main tumor. The main tumor is usually called the primary tumor.~The N refers to the number of nearby lymph nodes that have cancer. The M refers to whether the cancer has metastasized. This means that the cancer has spread from the primary tumor to other parts of the body."
89310295|NCT05368688||Colorectal cancer stage II|"Have confirmed TNM staging of colorectal cancer~The T refers to the size and extent of the main tumor. The main tumor is usually called the primary tumor.~The N refers to the number of nearby lymph nodes that have cancer. The M refers to whether the cancer has metastasized. This means that the cancer has spread from the primary tumor to other parts of the body."
89310296|NCT05368688||Colorectal cancer stage III|Have confirmed TNM staging of colorectal cancer
89310297|NCT01146639|Experimental|MDCT and additional DynaCT|
89310298|NCT03708536|Experimental|bevacizumab plus s-1|
89310299|NCT03708536|Active Comparator|bevacizumab plus capecitabin|
89310300|NCT01146717|Experimental|Exercise|
89310301|NCT01146717|Placebo Comparator|Control group|
89310302|NCT03705728|Experimental|Intravenous group|"Propofol & remifentanil administration using the closed-loop controller with the Easy-TIVA platfrom."
89310303|NCT03705728|Active Comparator|volatile anesthesia group|Sevoflurane will be administered manually according to the BIS values. Remifentanil will be administered manually using a Target Controlled Infusion pump using the Minto model.
89310304|NCT01147419|Experimental|bypass|Patients presenting with long occlusion of the superficial femoral artery enrolled in bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery. And the graft will be artificial blood vessel.
89310305|NCT01147419|Experimental|stent|
89310306|NCT03705650|Experimental|Medicare Primary Care Provider (PCP) Patients|This is a non-randomized study of non-significant risk (NSR) that will be conducted at Northwestern's Central Dupage Hospital. Medicare patients > 65 years who are scheduled for a routine physical exam with their PCP that meet inclusion and exclusion criteria will be asked to participate in this study. Consenting patients will be scheduled for 2 back to back ultrasound scans including 5 standard 2D echocardiogram views each. The first scan will be performed by a non-ultrasound specialist using EchoGPS experimental guidance technology and the second control exam will be performed by a trained sonographer using a cleared conventional ultrasound platform.
89310307|NCT03705572|Active Comparator|Dietary Supplement: Phospholipid drink.|Participant in an intervention parallel group consumed a drink with added phospholipids (Lacprodan PL20).
89310308|NCT03705572|Placebo Comparator|Dietary Supplement: Placebo milk drink.|Participant in an intervention parallel group consumed a drink without added phospholipids.
89310309|NCT01238757|Active Comparator|Non-Invasive Pressure support|"in this arm, non-invasive pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS) with ETS +15% with ETS -15%"
89310310|NCT01238757|Active Comparator|NAVA|"Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm. Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.~The proportion named gain is chosen to obtain under NAVA the same peak pressure than during Presure Support"
89310311|NCT01251081|Experimental|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
89310312|NCT01251081|Sham Comparator|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
89310313|NCT01145937|Experimental|PET|"Partial endothelial trepanation in addition to anterior lamellar keratoplasty.~The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature."
89310314|NCT01145937|Active Comparator|DALK|Conventional DALK grafting procedure where the Big Bubble technique is used according to Anwar et al.
89310315|NCT03358238|Placebo Comparator|No weekly review|Individuals will not review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
89310316|NCT03358238|Experimental|Weekly review|Individuals will review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
89310317|NCT01238913||benign esophageal lesions|All patients who have a benign esophageal lesion where it is medically indicated that they receive a stent.
89310318|NCT03710018||A Patient who underwent open cavity BCS|Patients undergoing Open cavity Breast Conservative Surgery
89310319|NCT03710018||B Patient who underwent close cavity BCS|Patients undergoing Close cavity Breast Conservative Surgery
89310320|NCT03710018||C Patient who underwent oncoplasty|Patients undergoing oncoplasty for breast cancer
89310321|NCT01147575|Active Comparator|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH respectively the groups were switched for another 6 months (period 2).
89310322|NCT01147575|Placebo Comparator|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day in identically prepared capsules. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without Placebo respectively the groups were switched for another 6 months (period 2).
89310323|NCT01239069|Experimental|DE-110 ophthalmic suspension high dose|
89310324|NCT01239069|Experimental|DE-110 ophthalmic suspension low dose|
89310325|NCT01239069|Placebo Comparator|Placebo|
89310326|NCT03342638|Experimental|Control Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.
89310327|NCT03342638|Experimental|IVIg Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.
89310328|NCT01246167|Active Comparator|Conservative|Active physiotherapy and self-training
89310329|NCT01246167|Active Comparator|Philos locking plate|After operative treatment active physiotherapy and self-training
89310330|NCT01246167|Active Comparator|Epoca prosthesis|After operative treatment active physiotherapy and self-training
89310331|NCT01246323|Active Comparator|combined anesthesia|Patients will receive spinal and general anesthesia for benign laparoscopy gynecological surgery
89310332|NCT01246323|No Intervention|Control|
89310333|NCT03342560|Experimental|30 Patients with known liver biopsy results|Patients with chronic liver disease with known biopsy results
89310334|NCT05160363|Experimental|PYR and PQP Combination|Single dose in the morning on Days 1, 2 and 3 of the study Pyronaridine tetraphosphate 540 mg (three tablets) if body weight 50kg - <65kg; OR, 720 mg (4 tablets) if body weight is ≥65 kg Piperaquine tetraphosphate 960 mg (three tablets) if body weight 50kg - <75kg; OR, 1280 mg (4 tablets) if body weight ≥75kg
89310335|NCT05160363|Placebo Comparator|PYR and Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Pyronaridine tetraphosphate 540 mg (three tablets) if body weight 50kg - <65kg; OR, 720 mg (4 tablets) if body weight is ≥65 kg Matched placebo for piperaquine (3 or 4 tablets based on body weight)
89310336|NCT05160363|Placebo Comparator|PQP and Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Piperaquine tetraphosphate 960 mg (three tablets) if body weight 50kg - <75kg; OR, 1280 mg (4 tablets) if body weight ≥75kg Matched placebo for pyronaridine (3 or 4 tablets based on body weight)
89310337|NCT05160363|Sham Comparator|Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Matched placebo for pyronaridine (3 or 4 tablets dependent on body weight) and matched placebo piperaquine (3 or 4 tablets dependent on body weight)
89310338|NCT05177276|Experimental|Dose Level -1|Selinexor 12mg po twice weekly (Monday & Wednesday or Tuesday & Thursday); Irinotecan 50mg/m2 IV once daily on days 1, 8 & 15
89310339|NCT05177276|Experimental|Dose Level 1|Selinexor 15mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 & 15.
89310340|NCT05177276|Experimental|Dose Level 2|Selinexor 20mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 100mg/m2 IV once daily on days 1, 8 & 15.
89310341|NCT05177276|Experimental|Dose Level 3|Selinexor 30mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 & 15.
89310342|NCT05177276|Experimental|Dose Level 4|Selinexor 30mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 125mg/m2 IV once daily on days 1, 8 & 15.
89310343|NCT01311986||Patients with atopic dermatitis|
89310344|NCT01311986||Patients with nummular eczema|
89310345|NCT01311986||Normal control|
89310346|NCT01239147|Other|Whole grain diet|
89310347|NCT01239147|Other|Refined grain diet|
89310348|NCT03708458|Active Comparator|Control group|Control group - patients receiving 100 mg indomethacin suppository immediately post ERCP
89310349|NCT03708458|Active Comparator|Group A|Group A - patients receiving N-acetylcysteine (NAC) 600 mg before performing ERCP and indomethacin suppository 50 mg before and after performing ERCP
89310350|NCT03708458|Active Comparator|Group B|Group B - patients receiving indomethacin suppository 50 mg before and 50 mg after ERCP
89310351|NCT01251237|Experimental|Moviprep Orange|All patients receive 2 litres of NRL0706 solution.
89310352|NCT05105529|Experimental|Ozone (O3) group|Participants of the experimental group will perform sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone delivered continuously during each exercise session.
89310353|NCT05105529|Sham Comparator|Filtered Air|Participants of the sham group will also perform sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer similar to intervention. However, only in this group, the ozone generator will not be activated so that just filtered air will be delivered to the participant while performing each exercise session.
89310354|NCT01239225|Experimental|Abdominal ultrasound|Abdominal ultrasound
89310355|NCT01239303|Active Comparator|citrulline|
89310356|NCT01239303|Placebo Comparator|alanine|
89310357|NCT05153265||Residents|We plan to distribute a survey to the Stanford anesthesiology residents to determine their assessment of the bleeding risk of nerve blocks. The survey will list the most common nerve blocks and ask the resident anesthesiologists at Stanford whether the block is low/intermediate/high risk based on a scoring system of location relative to critical structures, compressibility, and whether bleeding or hematoma would be readily apparent.
89310358|NCT05153265||Attending physicians|We plan to distribute a survey to the Stanford anesthesiology attending physicians to determine their assessment of the bleeding risk of several different nerve blocks. The survey will list the most common nerve blocks and ask Stanford anesthesiologists whether the block is low/intermediate/high risk based on their experience with nerve blocks.
89310359|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 1|
89310360|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 2|
89310361|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 3|
89310362|NCT03912441|Experimental|BCD-147 Monotherapy Dose Level 4|
89310363|NCT03912675|Experimental|RigeneraTM protocol|Teatment with Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol.
89310364|NCT03912675|Experimental|Control|Treatment with Integra® dermal substitute only.
89310365|NCT03912597|Experimental|Virtual Reality [A]|Participants watch a 4-minute virtual reality video, on top of reading a brochure, then answer post-intervention questionnaires.
89310366|NCT03912597|Active Comparator|Brochure Waitlist Control [A]|Participants read an informational brochure about depression, then answer post-intervention questionnaires. After that, they will be given a chance to watch the VR video at the end of their participation session.
89310367|NCT03912597|Active Comparator|Standard Video Control [B]|Participants watch a 4-minute standard video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
89310368|NCT03912597|Experimental|Virtual Reality [B]|Participants answer pre-questionnaires, then watch a 4-minute virtual reality video. After which, using a video, a discussion of the video will be facilitated for participants to contextualise and understand the video better. Then, participants answer post-intervention questionnaires.
89310369|NCT01251471|Experimental|Escitalopram|Escitalopram, p.o., 10 mg/d; optional 20 mg/d after 2 weeks for 8 weeks
89310370|NCT03680469|Active Comparator|standard early rehabilitation|The standard early rehabilitation program after acute stroke is an intervention regularly utilized in the stroke center of National Taiwan University Hospital.
89310371|NCT03680469|Experimental|adding early out-of-bed mobilization|The adding early out-of-bed mobilization treatment will be defined as the patients with acute ischemic stroke who receive out-of-bed mobilization treatment in addition to standard early rehabilitation care.
89310372|NCT01247805|Experimental|Treatment A|Revatio: 1 x 20 mg IR oral tablet.
89310373|NCT01247805|Experimental|Treatment B|2 x 10 mg sildenafil citrate IR oral tablet.
89310374|NCT01247805|Experimental|Treatment C|2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
89310375|NCT01247883|Active Comparator|single dose PF-04634817 tablet|subjects receive a single dose of PF-04634817 as a tablet
89310376|NCT01247883|Active Comparator|single dose PF-04634817 solution|subjects receive a single dose of PF-04634817 as a solution
89310377|NCT01146015|Experimental|1|
89310378|NCT05631717|Experimental|MSCs group|In this group, patients will receive intravenous injection of human umbilical cord mesenchymal stem cells (2 × 10^6 cells / kg body weight, suspended in 30ml saline)
89310379|NCT05631717|Experimental|IL-2 group|In this group, patients will receive subcutaneous injection of IL-2 (1×10^6IU) every other day for 2 weeks (7 times), with an interval of 2 weeks.
89310380|NCT03065517|Experimental|VillageWhere App|Parent-youth dyads assigned to the VillageWhere condition will be asked to use the VillageWhere App that has been developed for this study. Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 12 week trial. The app is designed to be used several times throughout each day.
89310381|NCT03065517|Placebo Comparator|Attention-Control Placebo App|Parent-youth dyads assigned to the control condition will be asked to use a free placebo control app that is well-liked by parents and youth but void of content already part of an existing evidence-based treatment for youth with conduct problems (e.g., geolocation tracking). Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 12 week trial.
89310382|NCT01147731|Experimental|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
89310383|NCT01239537||Baxter H1N1 vaccine|Previously received 2 dose schedule of Baxter H1N1 vaccine
89310384|NCT01239537||GSK H1N1 vaccine|Previously received 2 dose schedule of GSK H1N1 vaccine
89310385|NCT03912285|Experimental|Amlodipine, losartan, and amlodipine plus losartan|"Period 1:~amlodipine 10mg will be administered orally once a day for 9 days.~Period 2:~losartan 100mg will be administered orally once a day for 9 days after 13 days of the washout period.~Period 3:~amlodipine 10mg once a day plus losartan 100mg once a day will be administered orally for 9 days after 6 days of the washout period."
89310386|NCT01239615||healthy volunteers|
89310387|NCT01251549|Experimental|Experimental: A|A group of paraplegics.
89310388|NCT01251627|Experimental|Decitabine|Eligible patients will recieve Dacogen 20mg/m2 in 1 hour iv infusion for 5 days every 28 days (1 cycle)plus Best Supportive Care.A total of 6 courses is planned.
89310389|NCT03912129|Other|pediatric Evans Syndrome|Collection of biological samples of children with pSE included in the the OBS'CEREVANCE cohort and their parents, for genetic and functional immunological analyzes.
89310390|NCT05667519|Experimental|Transesophageal echocardiography + fluoroscopy guided lead implantation|TEE will be done in addition to fluoroscopy to guide lead implantation.
89310391|NCT05667519|No Intervention|Fluoroscopy guided lead implantation|Fluoroscopy only will be used to guide lead implantation.
89310392|NCT01146093|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
89310393|NCT01146093|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
89310394|NCT03912051|Experimental|asymmetric balloon|Asymmetric air filled (max 25 cc, Leur lock syringe) epistaxis balloon
89310395|NCT04938999|Experimental|MVgPA group|"The MVgPA group consists of 24 sessions conducted over 12 weeks for the study participants by the staff of residential care facilities.~The structured MVgPA group session (10 - 12 participants) will be conducted twice per week. The 75-min music-paced physical activities will be presented in the PowerPoint slideshow. The instructions for an upper limb exercise will be presented in a large number pad in the slideshow, and the participants will then be asked to follow the actions and directions presented on the slide."
89310396|NCT04938999|Other|Control group|residential care facilities will conduct their usual activities during the study period. A trained RA2 will record the activities conducted by the residential care facilities during the study period.
89310397|NCT01239771|Experimental|1|TC-5214
89310398|NCT01239771|Placebo Comparator|2|Placebo matched to TC-5214
89310399|NCT02452983|Experimental|Sertraline|Sertraline tablets 100mg daily for 4 (28-day) cycles
89310400|NCT01147887|Experimental|001|Drug combination/ 26489112 On Day 1 and on Day 19 a single oral dose of a drug combination consisting of midazolam (2 mg/mL liquid) tolbutamide (a 500 mg tablet) and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21 a single oral dose of two 26489112 tablets will be taken.
89310401|NCT01251783|Active Comparator|Infant Formula|Infant Formula without lactobaillus or Metlin or Metlos
89310402|NCT01251783|Active Comparator|Fully breast milk|Group non randomized with fully breast milk
89310403|NCT01251783|Experimental|Metlin+Metlos+Lactobacillus GG|Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC
89310404|NCT01251783|Active Comparator|Metlin+Lactobacillus GG|Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC
89310405|NCT01251783|Active Comparator|Metlos+Lactobacillus GG|Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC
89310406|NCT01251783|Active Comparator|Lactobacillus GG|Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos
89310407|NCT03911817|No Intervention|IV vasopressor|Will receive IV vasopressor infusion only
89310408|NCT03911817|Active Comparator|Midodrine|Will receive midodrine in addition to IV vasopressor infusion
89310409|NCT01147965|Experimental|Ad5 CEA Vaccine|Single arm dose escalation study
89310410|NCT01251939||Treatment with ibuprofen|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and echocardiographic evidence of hemodynamically significant PDA
89310411|NCT01251939||Controls|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and without significant PDA
89310412|NCT01252017|Experimental|Nilotinib|Single arm, open label study
89310413|NCT01248039||Total arthroplasty|Patients with osteoarthrosis going for hip or knee arthroplasty
89310414|NCT01146171|Experimental|BMS-844203 (CT-322)|
89310415|NCT01299987|Experimental|Intraoperative radiotherapy|single arm with intraoperative radiotherapy
89310416|NCT03911895||patients with coronary artery diseas undergoing PCI|Effect of stent length on patients with coronary artery undergoing PCI
89310417|NCT04896489|Experimental|hydrocortisone|Participants receive hydrocortisone (20mg)
89310418|NCT04896489|Placebo Comparator|placebo|Participants receive placebo.
89310419|NCT01148043|Placebo Comparator|Placebo|
89310420|NCT01148043|Experimental|Hydroxychloroquine|
89310421|NCT03911427|Experimental|Powder Mix 1|Oat powder product, mixed with water
89310422|NCT03911427|Placebo Comparator|Powder Mix 2|Brown rice milk powder product, mixed with water
89310423|NCT03911583|Active Comparator|Control Group (CG)|Education, modifying diet and light physical activity (LPA)
89310424|NCT03911583|Active Comparator|Moderate physical activity group (MPA)|Education, modifying diet and moderate physical activity (MPA)
89310425|NCT03911583|Active Comparator|Intense physical activity group (IPA)|Education, modifying diet and intense physical activity (IPA)
89310426|NCT04865835|Placebo Comparator|placebo and metformin|single dose of placebo + single dose of metformin-HCl 850 mg (approximately 663 mg metformin) (placebo will be dosed 1 hour prior to metformin administration)
89310427|NCT04865835|Experimental|SEP-363856 and metformin|single dose of SEP 363856 100 mg + single dose of metformin-HCl 850 mg (SEP 363856 will be dosed 1 hour prior to metformin administration)
89310428|NCT01248195|Other|Phase I: 1 arm 'amisulpride open label'|For 4 weeks, all patients will be treated with amisulpride open label.
89310429|NCT01248195|Active Comparator|Phase II: 'amisulpride double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'
89310430|NCT01248195|Active Comparator|Phase II 'olanzapine double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'
89310431|NCT01248195|Other|Phase III: 1 arm 'clozapine open label'|Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'
89310432|NCT01248195|Experimental|Psychosocial intervention|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.
89310433|NCT01248195|No Intervention|Psychosocial Intervention phase: 'TAU'|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.
89310434|NCT03916653|Experimental|Test group|Osseous resection using piezoelectric device
89310435|NCT03916653|Active Comparator|Control group|Osseous resection using conventional rotary instruments
89310436|NCT03911193|Experimental|Cabozantinib|Elegible NSCLC patients with MET exon 14 skipping mutations or MET amplification will be treated with open label orally cabozantinib 60 mg/daily, cycles each 28 days.
89310437|NCT01241253|No Intervention|Cross-over study|beans and rice in a 50 gram carbohydrate dose
89310438|NCT03911037|Active Comparator|Standard Medical Therapy + G CSF Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required). G-CSF ( prefilled syringe) at the dosage of 5 μg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
89310439|NCT03911037|Placebo Comparator|Standard Medical Therapy + Placebo|"Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required).~Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered."
89310440|NCT04802733|Experimental|MSK-DA01|
89310441|NCT01252329|Active Comparator|Elective lymph node treatment arm|Patients entering this arm will undergo selective nodal dissection of the draining lymph nodes with subsequent radiation and/or chemotherapy if indicated.
89310442|NCT01252329|No Intervention|Clinical observation arm|Patients who enter into this arm will undergo regular, periodic clinical nodal observation with subsequent evaluation and treatment if indicated upon discovery of a palpable lymph node.
89310443|NCT01146327|Experimental|PF-04620110|
89310444|NCT01146327|Placebo Comparator|Placebo Comparator|
89310445|NCT01252407|Experimental|tens|
89310446|NCT03910803|Other|Brodalumab - Open Label|"Randomized subjects will be receiving Brodalumab (210 mg) administered by subcutaneous injection at the following visits: Baseline, week 1, week 2 and every two weeks thereafter, until Week 24.~Investigational Product not to be administer into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by Hidradenitis Suppurativa."
89310447|NCT03916497||Group 1 : kidney transplant recipients (KTR)|
89310448|NCT03916497||Group 2 : hemodialysis patients|
89310449|NCT03916497||Group 3 : Control patients|
89310450|NCT01241643|Experimental|CYT107|repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
89310451|NCT01241643|No Intervention|Control|Control arm with possible CYT107 injection after 12 months of study participation
89310452|NCT03910647|Experimental|pantoprazole with normal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
89310453|NCT03910647|Experimental|pantoprazole with abnormal kidney function|use pantoprazole for one month and after one month i will do for them kidney functions test
89310454|NCT01242657|No Intervention|Brief Advice|Standard of care arm with no intervention; includes standard communication regarding youth tobacco cessation such as a brief discussion and printed materials
89310455|NCT01242657|Active Comparator|Not On Tobacco (N-O-T) Program|Teens randomized to this arm participated in the N-O-T program, a proven teen cessation program.
89310456|NCT01242657|Experimental|Quit & Fit|Teens randomized to this arm participated in the Not On Tobacco (N-O-T) program with an added physical activity module.
89310457|NCT03355742|Experimental|XIENCE|XIENCE + Short duration (1 month) of DAPT
89310458|NCT03911115||Bariatric surgery|Individuals that have undergone a gastric bypass (RYGB) or a sleeve gastrectomy (SG)
89310459|NCT03910881|Experimental|open-platform patient support system|Proof of concept testing of app
89310460|NCT03916107|Experimental|Levator muscle and tarsus resection|
89310461|NCT03916107|Active Comparator|Frontal muscle flap|
89310462|NCT03709940|Experimental|Placebo, MPH|"Dose order: placebo, methylphenidate (MPH)~Participants receive a placebo tablet (ascorbic acid 50 mgs) on DAY 1 and a clinically effective dose of short-acting MPH (20 mgs) on DAY 2."
89310463|NCT03709940|Experimental|MPH, Placebo|"Dose order: methylphenidate (MPH), placebo~Participants receive a clinically effective dose of short-acting MPH (20 mgs) on DAY 1 and a placebo tablet (ascorbic acid 50 mgs) on DAY 2."
89310464|NCT03910725||Obesity|Patients with BMI >40 awaiting stapled bariatric surgery, without a history of or concomitant ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication, will be recruited prospectively from the bariatric surgery preoperative assessment clinics.
89310465|NCT03910725||Rheumatoid arthritis|Patients with RA without diagnosed or known ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication will be recruited prospectively from rheumatology clinics, prior to initiation of biologic or diseased modifying anti-rheumatic drugs.
89310466|NCT03910725||Dilated cardiomyopathy|TTNtv-positive and -negative DCM patients from the Royal Brompton Hospital biobank have provided informed consent to be contacted for research
89310467|NCT03910335||LSS patients|"Case/control study: Patients from surgical departments awaiting surgery for LSS will will out the questionnaire.~Cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)"
89310468|NCT03910335||Non-LSS patients|Case/control study and cohort study: Patients from a medical department will fill out the questionnaire, and a clinician will determine if LSS is present (reference standard)
89310469|NCT05681234|Experimental|18F-RD2|
89310470|NCT03910257|Experimental|nutrition education module|12 activities of the nutrition education module pre and post test
89310471|NCT03910257|No Intervention|control group|no intervention pre and post test
89310472|NCT03910023|Active Comparator|Control group|The control group will perform home exercises alone
89310473|NCT03910023|Experimental|Spa group|The spa group will be proposed an additional spa treatment
89310474|NCT03341312|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
89310475|NCT03341312|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
88806489|NCT05336994|Experimental|Multivitamin/mineral supplement A to B|Participants will be randomly assigned to receive Supplement A and after 5-7 days of follow-up, they will receive Supplement B.
89310476|NCT03341312|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
89310477|NCT03341312|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
89310478|NCT05176730|Experimental|Patients with hemodialysis receiving mindfulness meditation|The ABC standardized version of mindfulness meditation was used. The experimental group received 30-minute mindfulness meditation sessions 3 times a week for 5 weeks (450 minutes). An additional two-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. To ensure the consistent delivery of the intervention, the researcher recorded the intervention instructions in Arabic based on the intervention protocol and sent the audio-recorded instructions to the participants via WhatsApp or email. The audio-recorded intervention contents were validated by two psychologists and experts in meditation. The recorded intervention instructions were accessed by the participants during the sessions using their cell phones and headsets, as recommended. This method allowed for up to 3-5 participants to listen to the instructions and perform the intervention simultaneously.
89310479|NCT05176730|No Intervention|Control group|The participants in the control group were instructed to sit with their eyes closed and relaxed for 30 minutes 3 times a week for 5 weeks during hemodialysis sessions to control for the nonspecific effects of social interaction and environment. The timings of the control group sessions were similar to those of the experimental group, whereby if a given experimental group intervention lasted for 30 minutes, the control group participants would be asked to sit with their eyes closed and relax for 30 minutes also.
89310480|NCT03915873||vWB patients|
89310481|NCT03915873||control|
89310482|NCT01249911|Experimental|Lreuteri|Group of 130 infants allocated to receive L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
89310483|NCT01249911|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
89310484|NCT03708380|Experimental|Dietary intervention|Community-based dietary intervention to Black and African American barbers identified as having previously undiagnosed diabetes and prediabetes
89310485|NCT03915483|Experimental|tDCS group|one session of computerized change detection attentional filter exercise (selective attention) combined with real tDCS
89310486|NCT03915483|Sham Comparator|sham group|one session of computerized change detection attentional filter exercise (selective attention) combined with sham tDCS
89310487|NCT05176340|Experimental|Intervention group|Participants in the experimental group were provided an education program through the Care Action Module during their hospitalization period, and follow-up was conducted one and two months after discharge.
89310488|NCT05176340|No Intervention|Control group|The control group received no intervention, except for the regular care followed by the nurses in general in the rehabilitation ward.
89310489|NCT03908229|Experimental|Trainee colonoscopy|"In the investigation arm colonoscopy will be performed by gastroenterology fellows. The fellows will always start the case and proceed generally until they are unable to make further progress despite coaching from the staff attending.~During the procedures with fellows, the staff attending will always actively participate in the entire procedure and assess for the presence of any lesions."
89310490|NCT03908229|Active Comparator|Experienced physician colonoscopy|In the control arm all colonoscopy will be performed by full-time board-certified gastroenterologists who have each done more than 5000 colonoscopy examinations.
89310491|NCT01239459|Experimental|Severe impaired renal function|Subjects with severe renal impairment as defined by Cockroft-Gault formula
89310492|NCT01239459|Experimental|Normal renal function|Subjects with normal renal function as defined by Cockroft-Gault formula
89310493|NCT03915561|Active Comparator|Study group|This group will be received intravenous injection with 10ml transparent mixture solution with 40mg Dynastat and 0.9% saline twice
89310494|NCT03915561|Placebo Comparator|Placebo|This group will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice
89310495|NCT03915639|Experimental|Cocktail|Participants in Group Cocktail are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with the multimodal cocktail.
89310496|NCT03915639|Active Comparator|Ropivacaine|Participants in Group Ropivacaine are planned to infiltrate the head fixation sites after intubation and peri-incisionally prior to skin incision. The infiltration will be performed by the attending neurosurgeon. The muscle and the subcutaneous tissue beneath the fixation sites and incision site will be fully irrigated with ropivacaine.
89310497|NCT02949908||Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS)|
89310498|NCT03909945|Experimental|Interventional arm|The intervention consisted in the daily administration, during 60 days, of a 796 mg tablet of aqueous extracts of leaves of Annona muricata between 08:00 AM and 09:00 AM.
89310499|NCT01253499|Experimental|TRx0037|Double blind placebo controlled study of TRx0037 in healthy elderly volunteers to assess safety, tolerability, bioavailability and pharmacokinetics
89310500|NCT01252797|Active Comparator|Stereotactic Radiosurgery (15 Gy)|Group A: If the tumor which will be surgically removed is at least 2 cm and up to 4 cm in maximum diameter, then this group will receive Dose Level II (15 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
89310501|NCT01252797|Experimental|Stereotactic Radiosurgery (12Gy)|Group B: If the tumor which will be surgically removed is larger than 4 cm and up to 6 cm in diameter, then this group will receive Dose Level I (12 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
89310502|NCT03909633||A: anesthesia group|Patients accepting endoscopy check under anesthesia will be included in this group as group A,will doing a series of tests
89310503|NCT03909633||B:Non-anesthesia group|patients undergoing endoscopy check without anesthesia will be included in this group as controls voluntarily,namely group B,will doing a series of tests
89310504|NCT01148199|Active Comparator|Multiple plastic stents|Multiple plastic stents placement after sphincterotomy and stricutre dilation. ERCP repeated every 3 - 4 months during 1-year
89310505|NCT01148199|Experimental|Self-expandable metalic stent|Self-expandable metalic stent after sphincterotomy. Stent removal scheduled for 6 months
89310506|NCT03909789|Active Comparator|plant based bioequivalent dietary nitrate supplement|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
89310507|NCT03909789|Placebo Comparator|placebo|The Placebo does not contain any nitric oxide supplement.
89310508|NCT01252875|Other|LDL-C to100 mg/dL (+/-10 mg/dL)|"Target : 100 mg/dL (+/-10 mg/dL):~Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of 100 mg/dL(+/-10 mg/dL)."
89310509|NCT01252875|Other|LDL-C < 70 mg/dL|70 mg/dL: Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of less than 70 mg/dL.
89310510|NCT01148277|Active Comparator|Propofol and Remifentanyl|Propofol, colonoscopies, liver diseases, cirrhosis
89310511|NCT01148277|Active Comparator|midazolam and fentanyl|midazolam and fentanyl, colonoscopies, liver diseases
89310512|NCT01148277|Experimental|control midazolam anf fentanyl|midazolam anf fentanyl
89310513|NCT01253031||Group 1|young normal hearing
89310514|NCT01253031||Group 2|older normal hearing
89310515|NCT01253031||Group 3|older hearing impaired
89310516|NCT03909555||Short-term intensive insulin therapy|Patients who used to participated in short-term intensive insulin therapy for 14 days when diabetes was newly diagnosed
89310517|NCT03909555||Routine diabetic therapy|Received routine diabetic therapy
89310518|NCT03907839|Active Comparator|Endurance Training (ET)|endurance training for control group
89310519|NCT03907839|Experimental|ET+cognitive training(CT)|endurance training added to cognitive training for exprimental COPD group
89310520|NCT01253109||SENSIMED Triggerfish|
89310521|NCT01250301|Experimental|De-nicotinised cigarettes + standard treatment|
89310522|NCT01250301|Active Comparator|Standard treatment|
89310523|NCT01253655|Experimental|PF-05212365|
89310524|NCT03907995|Experimental|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
89310525|NCT03907293||Phase-III Cardiac Rehabilitation|Eight weeks of supervised exercise sessions (one session per week).
89310526|NCT03907293||Phase-III and Phase IV Cardiac Rehabilitation|Twenty weeks of supervised exercise sessions (one session per week for first eight weeks [phase-III], session frequency determined by participant for remaining twelve weeks [phase-IV].
89310527|NCT03907293||No Cardiac Rehabilitation|Participants who declined to take part in a cardiac rehabilitation programme.
89310528|NCT03907449||Symptoms of Strep Throat|"Any patient presenting with symptoms of pharyngitis~Fever~Sore throat~Swollen lymph nodes in neck~Redness of throat/tonsils~White/yellow patches on tonsils~Not currently on antibiotics"
89310529|NCT03907527|Experimental|Treatment (PRGN-3005 UltraCAR-T cells) IP Administration|Patients receive autologous PRGN-3005 UltraCAR-T cells via IP administration with or without lymphodepleting chemotherapy.
89310530|NCT03907527|Experimental|Treatment (PRGN-3005 UltraCAR-T cells) IV Administration|Patients receive autologous PRGN-3005 UltraCAR-T cells via IV administration with or without lymphodepleting chemotherapy.
89310531|NCT03908931|Experimental|MRI|
89310532|NCT03915093|Experimental|study group|receive educational nursing protocol
89310533|NCT03915093|Active Comparator|control group|receive routine hospital care
89310534|NCT03915015|Other|the study|Patients with a PPM or ICD getting a clinically indicated MRI
89310535|NCT03908775|Active Comparator|Group VL|C-MAC Videolaryngoscope Patients intubated with C-MAC Videolaryngoscope
89310536|NCT03908775|Active Comparator|Group DL|Direct Laryngoscope Patients intubated with Direct laryngoscope
89310537|NCT03907371|Experimental|Donepezil|Patients receive donepezil with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
89310538|NCT03907371|Placebo Comparator|Control|Patients receive placebo with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24), in the absence of unacceptable toxicity or severe deterioration.
89310539|NCT03908619|Active Comparator|TTP (Group A)|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
89310540|NCT03908619|Active Comparator|TTP (Group B)|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
89310541|NCT03908619|Active Comparator|TTP (Group C)|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
89310542|NCT03908619|Experimental|TTP (Group D)|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
89310543|NCT03908853||Patients|Subjects with painful bone metastases caused by primary breast cancer.
89310544|NCT03908853||Controls|Gender and age matched healthy volunteers.
89310545|NCT03906981||Caries free|6-9 year old caries free children
89310546|NCT03906981||Caries active|6-9 year-old caries active (>5 dmft/DMFT) children
89310547|NCT03906903|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, three per weekday, with a final result of 30 sessions in this modality with a 30 minutes Cognitive Stimulation after session.
89310548|NCT03906903|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 30 sessions, three per weekday with a 30 minutes Cognitive Stimulation afterwards.
89310549|NCT03908697|Experimental|Single cohort|All 20 participants will use ClearBlue and Mira monitors on first morning urine
89310550|NCT03907059|Active Comparator|Omnivorous|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (whey) + 12 weeks of resistance training
89310551|NCT03907059|Experimental|Vegan|Interventions: Daily protein intake was adjusted to 1.6g/kg/day via supplementation (soy) + 12 weeks of resistance training
89310552|NCT03903393||preeclamptic women|systolic blood pressure(BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg; hypertension diagnosed after 20 weeks gestation; new-onset hypertension with new-onset proteinuria or other signs/symptoms of preeclampsia after 20 weeks or chronic proteinuria with newonset hypertension.
89310553|NCT03903393||controls|Normal pregnant women
89310554|NCT01358734|Experimental|Lenalidomide in combination with azacitidine|Repeated cycles of azacitidine 75 mg/m^2/day subcutaneous (SC) on Days 1-7 and lenalidomide 50 mg/day by mouth (PO) on Days 8-28 followed by a 14-day break plus best supportive care
89310555|NCT01358734|Experimental|Lenalidomide - single agent|Lenalidomide 50 mg PO daily for 28 days for the first 2 cycles and lenalidomide 25 mg daily for 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg daily PO plus best supportive care
89310556|NCT01358734|Experimental|Azacitidine-single agent|Repeated cycles of azacitidine 75mg/m^2/day subcutaneous on Days 1-7 followed by a 21-day break plus best supportive care
89310557|NCT03907215|Other|Treatment A and B|"On Day 1 and Day 2, subjects will EITHER receive:~a single dose of 50 mg ACT-541468 (Treatment A) on Day 1 and a single dose of ACT- 541468 placebo (Treatment B) on Day 2 OR~a single dose of ACT-541468 placebo (Treatment B) on Day 1 and a single dose of 50 mg ACT-541468 (Treatment A) on Day 2."
89310558|NCT03907215|Other|Treatment C, D, E, and F|"From Day 3 to Day 10, subjects will on each day receive:~• a single dose of 20 mg citalopram and EITHER a single dose of ACT-541468 placebo OR a single dose of 50 mg ACT-541468."
89310559|NCT03914937||Intervention Group: Virtual Reality|Patients will wear a virtual reality device in addition to standard lidocaine/novocaine numbing agent
89310560|NCT03914937||Control Group: Music|Patients will listen to music in addition to standard lidocaine/novocaine numbing agent
89310561|NCT03914781|Experimental|SPIN-SELF program|Offered access to the online SPIN-SELF program in addition to usual care
89310562|NCT03914781|No Intervention|Not Offered the SPIN-SELF program|Usual care
89310563|NCT01253733|Experimental|SMS and Internet|The SMS and Internet group will receive information, tips, strategies, and questions related to the self management of chronic disease (cystic fibrosis, inflammatory bowel disease, or type 1 diabetes) on a web-based program and via SMS messages.
89310564|NCT01253733|No Intervention|Control|The Control group will receive monthly tip sheets on various health topics for adolescents and young adults.
89310565|NCT03915171|Experimental|MSI-H|IHC/PCR tested as dMMR/ MSI-H
89310566|NCT03915171|Experimental|MSS|IHC/PCR tested as pMMR/ MSS
89310567|NCT03564028|Experimental|energy conservation technique|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
89310568|NCT03564028|Other|Control session|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
89310569|NCT01250457|Experimental|Topical timolol|topical Timolol 0.5% solution applied twice daily
89310570|NCT05559723|Experimental|study group|electromagnetic field therapy
89310571|NCT05559723|Experimental|control group|the selected exercise program
89310572|NCT03906825|Active Comparator|dietary supplement CEAG|The dietary supplements consists of Curcuminoids, EPA (Omega-3), Astaxanthin and GLA (CEAG).
89310573|NCT03906825|Placebo Comparator|Placebo|The Placebo does not contain any CEAG.
89310574|NCT01148433||TESTIM® - drug given by prescription|Male patients with Hypogonadism
89310575|NCT03906591|Experimental|allogenic bone ring|
89310576|NCT03906591|Active Comparator|autogenous bone ring|
89310577|NCT03902925|Experimental|Group 1- Sub-tenon plus lidocaine jelly|Patients are going to be submitted to lidocaine 2% jelly topical anesthesia for 5 minutes then to sub-tenon injection of 2-4 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
89310578|NCT03902925|Active Comparator|Group 2- peribulbar|Patients are going to be submitted to peribulbar injection of 4-6 ml of ropivacaine 10% previous to 23 G pars plana vitrectomy.
89310579|NCT03903081|Experimental|100 mg single dose|It includes two groups, one group is pilot study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=2) . Another group is formal study, healthy subjects receive a single dose of 100 mg HEC110114 tablet (N=8) or matching placebo (N=2)
89310580|NCT03903081|Experimental|300 mg single dose|Healthy subjects, receiving a single dose of 300 mg HEC110114 tablet (N=8) or matching placebo (N=2)
89310581|NCT03903081|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
89310582|NCT03903081|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC110114 tablet (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study
89310583|NCT03903081|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg HEC110114 tablet (N=8) or matching placebo (N=2)
89310584|NCT03903081|Experimental|1200 mg single dose|Healthy subjects, receiving a single dose of 1200 mg HEC110114 tablet (N=8) or matching placebo (N=2)
89310585|NCT03903081|Experimental|1600 mg single dose|Healthy subjects, receiving a single dose of 1600 mg HEC110114 tablet (N=8) or matching placebo (N=2)
89310586|NCT03903081|Experimental|600 mg multiple doses|Healthy subjects, receiving 600 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
89310587|NCT03903081|Experimental|800 mg multiple doses|Healthy subjects, receiving 800 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
88806490|NCT05336994|Experimental|Multivitamin/mineral supplement B to A|Participants will be randomly assigned to receive Supplement B and after 5-7 days of follow-up, they will receive Supplement A.
89310588|NCT03903081|Experimental|1000 mg multiple doses|Healthy subjects, receiving 1000 mg HEC110114 tablet (N=10) or placebo(N=2) once daily (q.d.) for 7 days
89310589|NCT01250535|Experimental|Warfarin plus lovastatin|Warfarin plus lovastatin
89310590|NCT01250535|Placebo Comparator|Warfarin plus placebo|Warfarin plus placebo
89310591|NCT02527941|Experimental|metronidazole|50 women who test negative for HIV and classical sexually transmitted infections but test positive for Bacterial Vaginosis will be treated with metronidazole at a dosage of 400mg/dose, 3 doses per day, for 7 days (as per Kenyan National Guidelines).
89310592|NCT03906513|Active Comparator|Active treatment|20 patients will be treated with active treatment (OMK2)
89310593|NCT03906513|Placebo Comparator|Placebo|10 patients will be treated with placebo (lubricant eye drops)
89310594|NCT01254825|Experimental|Adductor-Canal-Block, Ropivacain|Adductor-Canal-Block, 30 mL Ropivacain 7,5 mg/mL. Single dose. Ultrasound-guided application. 36 patients
89310595|NCT01254825|Placebo Comparator|Adductor-Canal-Block (ACB) - Saline|Adductor-Canal-Block, Placebo (30 mL Saline). Ultrasound-guided application. 36 patients.
89310596|NCT03906201|Experimental|Control Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 with placebo treatment
89310597|NCT03906201|Experimental|Ecdysterone Group|Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 whit ecdysterone treatment
89310598|NCT01250691||hospital acquired pneumonia|
89310599|NCT01250691||isolated rooms|
89310600|NCT01250691||ward-type ICU|
89310601|NCT03903003|Active Comparator|preoxygenation mask applied to the cesarean|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
89310602|NCT03903003|Active Comparator|high flow nasal oxygenation applied to the ceserian|In order to protect the mother from hypoxia, preoxygenation is performed with high flow nasal oxygenation mask before induction of anesthesia.
89310603|NCT01253889|Active Comparator|Oral Glucose with soother|Oral Glucose 25% first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
89310604|NCT01253889|Placebo Comparator|Oral water with soother|Oral water first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
89310605|NCT01253889|Active Comparator|Oral glucose with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
89310606|NCT01253889|Placebo Comparator|Oral water with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
89310607|NCT03902847|Experimental|Motor imagery|All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but previously, a mental practice based on kinesthetic mental motor imagery was performed. To reinforce the process of motor imagery, a video with the exercises was shown to the subjects before performing the mental practice. All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
89310608|NCT03902847|Experimental|Action observation|"All the subjects in this group were informed of the procedure at the beginning of the intervention, which consisted of the following: in the first phase (the first week), all participants had to perform the same motor control exercises program than the control group, but prior to the real execution, a video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.~All the participants also received a booklet with written information about the indications and exercises to be practiced at home to ensure that the training program was performed properly. Each week, participants received messages to remind and motivate them to undertake the exercise program daily."
89310609|NCT03902847|Active Comparator|Control group|The subjects in this group received an intensive training program based on stabilization exercises of lumbo-pelvic region, which are common exercises used in rehabilitation of patients with chronic non-specific low back pain.
89310610|NCT03902769|Experimental|No allogeneic SCT|For standard or intermediate risk AML patients who achieved good rapid response, allogenic SCT will be excluded from treatment plan
89310611|NCT03902769|Active Comparator|Standard post induction therapy|For slow responding AML patients, post induction therapy will be provided according to treating physician discretion
89310612|NCT03914859|Other|Exposed|Urinary level of 1-hydroxypyrene, the most sensitive biomarker of PAH exposure greater than 0.1 μmol / mol creatinine
89310613|NCT03914859|Other|Not exposed|Urinary level of 1-hydroxypyrene, the most sensitive marker of PAH exposure below 0.1 μmol / mol creatinine
89310614|NCT03906045|Experimental|All patients|10 patients with moderate COPD and 10 patients with severe/very severe COPD inhale BGF followed by a breath hold of up to 10 seconds.
89310615|NCT01149213|Experimental|Transcranial Direct Current Stimulation|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~The patient will receive tDCS every other week during the first three months, then once a month during the next three months."
89310616|NCT03902457|Experimental|test site|The sinus mucosa will be elevated and, at the test sites, a collagen membrane will be placed subjacent the sinus mucosa
89310617|NCT03902457|Experimental|control site|The sinus mucosa will be elevated and, at the control sites, a collagen membrane will not be placed subjacent the sinus mucosa
89310618|NCT03906123|Experimental|NBP|DL-3-n-butylphthalide (NBP), soft capsule, 200mg Tid, po, for 48 weeks.
89310619|NCT03906123|Placebo Comparator|Placebos|Placebo, soft capsule, 200mg Tid, po, for 48 weeks.
89310620|NCT03902379|Experimental|Supportive Care (CCI intervention)|Patients complete 3 modules of online CCI intervention.
89310621|NCT01341652|Experimental|pTVG-HP vaccine with GM-CSF|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
89310622|NCT01341652|Active Comparator|GM-CSF alone|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
89310623|NCT01147185|Other|Intensive training|Locomotor training using a robotic device of at least 50 minutes
89310624|NCT01147185|Active Comparator|Standard training|Locomotor training using a robotic device of maximally 25 minutes
89310625|NCT01253967||Group A|Subjects who are hospitalised for acute gastroenteritis
89310626|NCT01253967||Group B|Subjects who visit an emergency room for acute gastroenteritis
89310627|NCT01253967||Group C|Subjects who have rotavirus positive laboratory results and developed acute gastroenteritis at least 48 hours after hospitalisation.
89310628|NCT03567772|Experimental|Wiifit Nintendo video game|Pulmonary rehabilitation program using video games exercise from Nintendo
89310629|NCT03567772|Active Comparator|Pulmonary rehabilitation program|Pulmonary rehabilitation program with ergometer cycle
88806491|NCT00366626|Experimental|1.|Naltrexone one capsule a day
88806492|NCT00366626|Placebo Comparator|2|One capsule a day match to naltrexone
88806493|NCT00367016|Experimental|Omalizumab|Subjects will receive subcutaneous Omalizumab for 6 months. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
88806494|NCT00367016|Experimental|Placebo|Subjects will receive subcutaneous placebo for 6 months. Prior to placebo administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
88806495|NCT05372250|Experimental|Order of body positions for ultrasound measurements : supine position, 45°, sitting, standing|
89310630|NCT03567694|Experimental|Single Ascending Dose and Food effect|This is the SAD / Food effect arm. For SAD, a total of 80 subjects will be enrolled into 8 groups of 10 subjects each; within each group, 8 will receive HA115 at a single ascending dose 10, 25, 50, 100, 200, 400, 800, 1200 mg, and 2 subjects will be placebo control. For food effect study,10 participants will be administered HA115 at a single dose to be selected based on SAD results.
89310631|NCT03567694|Experimental|Multiple Ascending Dose|For the MAD portion, 3 dose levels will be selected based on SAD results.
89310632|NCT01149291||End stage renal disease patients|
89310633|NCT03567460|Experimental|10,000 Steps/day for Pediatric Marfan Patients|Participants will be given a Garmin VivoFit and asked to take at least 10,000 steps per day. A study coordinator will reach out at least once per week to check in on progress made and help make weekly goals.
89310634|NCT01254981|Experimental|Nobori|Percutaneous coronary intervention with implantation of coronary stent (Nobori)
89310635|NCT01254981|Experimental|Cypher|Percutaneous coronary intervention with implantation of coronary stent (Cypher)
89310636|NCT03563794|Experimental|CSII(insulin Lispro)+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
89310637|NCT03563794|Active Comparator|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
89310638|NCT03905967|Experimental|Lenvatinib + TACE|Patients in Lenvatinib + TACE group will take oral lenvatinib within 3 days of randomization and receive TACE 1 day after oral administration of lenvatinib.
89310639|NCT03905967|Active Comparator|Lenvatinib|Lenvatinib alone
88806496|NCT05372250|Experimental|Order of body positions for ultrasound measurements : 45°, sitting, standing, supine position.|
89310640|NCT02828644|Active Comparator|EVO Multitasking|EVO Multitasking is a digital intervention that requires subjects to navigate a character through a game-like space, while collecting objects, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
89310641|NCT02828644|Active Comparator|EVO Words|EVO Words is a digital intervention that requires subjects to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
89310642|NCT03914313|Experimental|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat Pro, in which the exoskeleton device is equipped with a VR screen. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Lokomat will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
89310643|NCT03914313|Active Comparator|Robotic treatment without VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Nanos, in which the exoskeleton device is equipped with a screen with a visual feedback (but not virtual reality). The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Nanos will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
89310644|NCT03914313|Active Comparator|Conventional treatment|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a conventional gait rehabilitation. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). Beside conventional overground training for gait, motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatement.
89310645|NCT03905577|Experimental|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
89310646|NCT03905577|Experimental|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
89310647|NCT03905577|Placebo Comparator|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
89310648|NCT03563950|Experimental|Rifampin + BMS-986224|Oral administration
89310649|NCT03902145||Intervention Group|Children previously in the intervention group received one egg per day for 6 months beginning when the child was between 6-9 months of age.
89310650|NCT03902145||Control Group|
89310651|NCT03905733||general anesthesia with rigid bronchoscopy|Patients 7 years or younger who undergo general anesthesia with rigid bronchoscopy
89310652|NCT03914001|Other|NMIBC patients|eligible patients will undergo initial mpMRI before initial TURBT, then followed by second mpMRI and second resection TURBT after 4 weeks
89310653|NCT03905499|Experimental|Robotic mediated therapy|Robotic mediated therapy with MJS (multi joint system) Tecnobody
89310654|NCT05667363|Experimental|Digital Intervention|Accept metered-dose inhaler medication treatment equipped with digital therapeutics consist of smartphone app and intelligent medication recorder. The intelligent medication recorder can automatically record medication using data and reminds patients through the app. Patients can also record their symptom on the app for doctors to monitor.
89310655|NCT05667363|No Intervention|Usual use|Accept regular metered-dose inhaler medication treatment.
89523402|NCT03376997|Experimental|Perampanel: 90-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (90-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
89523403|NCT03460015|Experimental|Sevoflurane group|
89523404|NCT03460015|Active Comparator|Propofol group|
89523405|NCT03376919|Experimental|CLs++|CLs ++ gait training
89310656|NCT03914235|Experimental|Tumescent anesthesia|A tumescent solution was prepared; consisting of 40 cc of 0.9% Saline Solution, 10 cc of 2% Lidocaine, 0.4 cc of Epinephrine (1: 1000) and 4 cc of 7.5% Sodium Bicarbonate. This solution was applied in the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc of tumescent solution was injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc of tumescent solution was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Subsequently, 20 minutes were waited for the epinephrine to cause vasoconstriction, and the asepsis of the limb was continued , sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.
89310657|NCT03914235|Active Comparator|Local anesthesia with tourniquet.|"Lidocaine 1% was applied to the incision sites according to the diagnosis and the proposed procedure. In case of trigger finger, 3 cc was applied subcutaneously in the proximal palmar crease of the affected finger; for Quervain syndrome, 5 to 6 cc were injected along the first extensor compartment at the radial styloid level; and in the case of Carpal Tunnel Syndrome, 10 cc was infiltrated on the flexor retinaculum in the subcutaneous tissue and from 7 to 10 cc below it. Afterwards, a pneumatic tourniquet was placed at the level of the forearm at 250 mmHg after exsanguination with a bandage from Esmarch. The asepsis of the limb was continued, sterile fields were placed, the incision site was corroborated and the surgical procedure proposed for each pathology was started.~At the end of the surgical procedure, it was closed by planes, a soft bandage was placed, the tourniquet was removed and the patient was taken to recovery."
89310658|NCT03901677|Experimental|Tai-chi training|Tai-chi training performe as a group exercise. Duration for tai chi exercise will be 60 minutes for 2 days per week for 12 weeks. Each session includes 10 min warm-up and cool-down and 40 min Tai Chi exercises. During exercises, attention paid to correct positioning of the upper and lower extremity joints, and mentally concentration achieve. Slow and controlled movements will carry out by a specialized physiotherapist.
89310659|NCT01255059||Female lung cancer group|Female, non-smoker, non-small cell lung cancer
89310660|NCT01255059||Health control|Female, non-smokers, no lung cancer or other types of cancers' healthy population
89310661|NCT03905343|Experimental|A: endocrine therapy + ribociclib|
89310662|NCT03905343|Active Comparator|B: mono-chemotherapy|
89310663|NCT03901989|Active Comparator|zeolite|50 subjects receive the substance 3 times per day as powder
89310664|NCT03901989|Placebo Comparator|cellulose|50 subjects receive the substance 3 times per day as powder
89310665|NCT03901599||Children between 5-10Kg|Children with a body weight between 5-10Kg
89310666|NCT03901599||Children between 10-20Kg|Children with a body weight between 10-20Kg
89310667|NCT03901599||Children between 20-40Kg|Children with a body weight between 20-40Kg
89310668|NCT01147263||Patients diagnosed with Fibromyalgia|
89310669|NCT03905109|Experimental|ABX464|50 mg
89310670|NCT03905109|Placebo Comparator|Placebo|50 mg matching placebo
89310671|NCT01148667|Active Comparator|Infants drink formula added with LGG|Infants have been randomized (1:1) to get casein hydrolysate with or without LGG
89310672|NCT01148667|Placebo Comparator|Infants drink casein hydrolysate without LGG|Infants get extensively hydrolysed casein formula
89310673|NCT01256307|Experimental|training group|training and educational program
89310674|NCT01256307|Other|control group|
89310675|NCT01254123|Active Comparator|Exenatide|
89310676|NCT01254123|Placebo Comparator|Placebo|
89310677|NCT03898635||Background group|The treatment regimen does not include linezolid throughout the treatment course.
89310678|NCT03898635||Background-linezolid group|Linezolid was added in the middle of the treatment course but not in the initial treatment regimen.
89310679|NCT03898635||Linezolid initial group|Linezolid was in initial treatment regimen.
89310680|NCT03901365|Experimental|Group 1|Patient received manual therapy in addition neuroscience pain education sessions
89310681|NCT03901365|Active Comparator|Group 2|Patient received manual therapy in addition tradition education sessions
89310682|NCT03905187|Other|Control Group|Group received education only
89310683|NCT03905187|Other|Traditional CR Group|Group received cardiac rehabilitation including education and exercise
89310684|NCT03905187|Experimental|Stress-Modified CR Group|Group received cardiac rehabilitation including education, exercise and stress management
89310685|NCT01254201||Dry Eye|Female patients over the age of 18 years with ocular complaints of dryness, grittiness, irritation, or related symptoms, without any identifiable cause.
89310686|NCT01254201||Fibromyalgia|Female patients over the age of 18 years diagnosed with Fibromyalgia.
89310687|NCT01254201||Healthy Control|Female patients over the age of 18 years with no symptoms of dry eyes and with no known diagnosis of Fibromyalgia.
89310688|NCT03901287|Experimental|dual energy CT|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
89310689|NCT03904953|Experimental|Study group|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
89310690|NCT03904953|Active Comparator|Control group|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
89310691|NCT03901209|Experimental|Laser osteotomy|The planned mid-face osteotomy (e.g. LeFort I) is performed using the CARLO osteotomy device, where a patient-specific intervention plan based on preoperative imaging is loaded on the system to allow the device to show and suggest a location for the osteotomy.
89310692|NCT01256463|No Intervention|Comparison|
89310693|NCT01256463|Experimental|HIV prevention intervention|The HIV prevention intervention will be delivered to HIV-seropositive patients in HIV care and treatment clinics during all routine visits. Health care providers (including physicians, clinical officers, and nurses) will deliver HIV prevention messages on correct and consistent condom use, disclosure of serostatus, partner HIV testing, adherence and alcohol reduction during clinic visits. Health care providers will also assess and treat sexually transmitted infections (STIs), and provide basic contraceptives and brief safer pregnancy counseling.
89310694|NCT01150305||1|Patient presenting familial dominant non syndromic hearing loss starting between 4 and 40 years old, over 2 generations
89310695|NCT01150305||2|Healthy volunteer from the same families
89310696|NCT01149525|Experimental|1|oral solution of L-Carnitine, 4g per day
89310697|NCT01149525|Placebo Comparator|2|Similar oral solution without L-Carnitine
89310698|NCT02528019|Active Comparator|DPP-4 inhibitors|sitagliptin (25-100mg daily), vildagliptin (50-100mg daily), alogliptin (12.5-25mg daily), linagliptin (2.5-5mg daily), teneligliptin (20-40mg), anagliptin (100-200mg daily), saxagliptin (2.5-5mg daily) or trelagliptin (50-100mg weekly)
89310699|NCT02528019|Active Comparator|SGLT2 inhibitors|ipragliflozin (50-100mg daily), dapagliflozin (5-10mg daily), luseogliflozin (2.5-5mg), tofogliflozin (20mg daily), canagliflozin (100mg daily) or empagliflozin (10-25mg daily)
89310700|NCT02528019|Active Comparator|Glimepiride|glimepiride (0.5-8mg daily)
89310701|NCT03900585|Experimental|Interval walking|Interval walking for 10 weeks, 150 minutes per week administered by an app on the patient's telephone.
89310702|NCT03900585|No Intervention|Control|Patients live as normal, though aerobe training restricted to a maximum of 30 minutes a week.
89310703|NCT03900663||Breast fed infants|
89310704|NCT03900663||Formula fed infants|
89310705|NCT03900663||vaginally delivered infants|
89310706|NCT03900663||Infants delivered by caesarean section|
89310707|NCT03904797|Experimental|e-PRO|EI service coordinators participated in a 90-minute training on the study protocol, to gain clearance to recruit families when they were being contacted to schedule their annual reviews of progress. The recruitment protocol was later modified in response to low enrollment, such that a designated EI staff member was paired with research staff to recruit participants. Eligible and interested caregivers visited the project website to create an account, confirmed study eligibility, provided informed consent and HIPAA authorization for abstracting select EI service use data, and completed a demographic questionnaire and the Young Children's Participation and Environment Measure (YC-PEM) e-PRO. Caregivers received immediate access to an online report summarizing their e-PRO responses to share with their child's EI team
89310708|NCT03900741|Experimental|Submerged healing|Bone regeneration of peri-implantitis defects following a submerged healing
89310709|NCT03900741|Active Comparator|Non-submerged healing|Bone regeneration of peri-implantitis defects following a non-submerged healing
89310710|NCT01150383|Active Comparator|group RO (Room air / Oxygen)|RO (Room air / Oxygen): First 6 weeks of exercise training under normoxic conditions (Room air), followed by 6 weeks of exercise training with oxygen supplementation.
89310711|NCT01150383|Active Comparator|group OR (Oxygen / Room air)|OR (Oxygen / Room air): First 6 weeks of exercise training with oxygen supplementation, followed by 6 weeks of exercise training under normoxic conditions (room air).
89310712|NCT01148823|Experimental|Postoperative day 1|Dressing was removed on the first postoperative day
89310713|NCT01148823|Experimental|Postoperative day 6|Dressing was removed on the 6th postoperative day
89310714|NCT03898401|Experimental|1 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310715|NCT03898401|Experimental|2 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
88806497|NCT05372250|Experimental|Order of body positions for ultrasound measurements : sitting, standing, supine, 45°.|
88806498|NCT05372250|Experimental|Order of body positions for ultrasound measurements : standing, supine, 45°, seated.|
88806499|NCT04422678|Experimental|Imatinib Standard Dose|"Imatinib 400 mg oral tablet once daily for 21 days~In addition for the treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
88806500|NCT04422678|Experimental|Imatinib Low Dose|"Imatinib 200 mg oral tablet once daily for 21 days.~In addition to the treatment for COVID-19 Pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH)."
88806501|NCT04422678|Active Comparator|Control|Treatment for COVID-19 pneumonia according to the Egyptian National Protocol by the Ministry of Health (MOH).
89310716|NCT03898401|Experimental|3 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310717|NCT03898401|Experimental|4 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310718|NCT03898401|Experimental|5 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310719|NCT03898401|Experimental|6 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310720|NCT03898401|Experimental|7 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310721|NCT03898401|Experimental|8 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310722|NCT03898401|Experimental|9 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310723|NCT03898401|Experimental|10 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310724|NCT03898401|Experimental|11 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310725|NCT03898401|Experimental|12 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310726|NCT03898401|Experimental|13 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310727|NCT03898401|Experimental|14 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310728|NCT03898401|Experimental|15 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310729|NCT03898401|Experimental|16 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310730|NCT03898401|Experimental|17 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310731|NCT03898401|Experimental|18 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310732|NCT03898401|Experimental|19 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310733|NCT03898401|Experimental|20 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310734|NCT03898401|Experimental|21 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310735|NCT03898401|Experimental|22 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310736|NCT03898401|Experimental|23 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310737|NCT03898401|Experimental|24 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310738|NCT03898401|Experimental|25 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310739|NCT03898401|Experimental|26 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310740|NCT03898401|Experimental|27PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310741|NCT03898401|Experimental|28 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310742|NCT03898401|Experimental|29 PRP|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310743|NCT03898401|Experimental|30 PRp|"Inclusion criteria:~I. Postmenopausal for at least 3 years. II. Vaginal health index <15. III. Any parity.~Exclusion criteria:~I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy."
89310744|NCT01255215|Experimental|Inhaled Nitric Oxide|iNO, a gaseous molecule, will be administered by inhalational route over a maximum period of 72 hours.
89310745|NCT01255215|Placebo Comparator|Room air|Room air will be delivered by air compressor through an indistinguishable mask system.
89310746|NCT03900351|Active Comparator|Group A: Study group|They will receive the Wii fit protocol of virtual reality games for 40 minutes, 3 times per week, for 8 weeks, in addition to the regular exercise rehabilitation protocol according to the criterion of Adams et al. (2012).
89310747|NCT03900351|Experimental|Group B: Control group|They will receive the regular exercise rehabilitation protocol only for 40 minutes, for 3 days per week, for 8 weeks.
89310748|NCT02527785|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"triple combination with oxaliplatin, irinotecan, and S-1.~Treatment will be delivered as a 2-week cycle.~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day 1-7"
89310749|NCT01254279|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
89310750|NCT01254357||YA Burned Subjects|Any person between the years of 19-30 years old treated for a burn injury, having incurred within past 12 months.
88809732|NCT01279304||Group 2: Intermediate risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. 1-3 nodes positive: ypN1~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~micrometastases in the SN and at least 1 risk factor; or~≤ 2 macrometastases and no risk factor~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~micrometastases in the post chemo SN and no risk factors (grade 3, LVI, tumour size > 3 cm)"
89310751|NCT01149603|Experimental|Implantation of the HeartMate II VAD|Consenting patients who meet the study inclusion and exclusion criteria will be implanted with a HeartMate II ventricular assist device.
89310752|NCT01254435|Active Comparator|'Free' positioning withdrawal|Withdrawal of the colonoscope with the patient positioned at the discretion of the endoscopist
89310753|NCT01254435|Experimental|'Fixed' position withdrawal|Patient positioned in the left lateral position to visualise the caecum, ascending colon and hepatic flexure; supine to visualise the transverse colon; and in the right lateral position to visualise the splenic flexure, descending colon and the sigmoid colon
89310754|NCT02527863|Active Comparator|60 mg Tolvaptan|Oral administration of 60 mg tolvaptan on each examination day.
89310755|NCT02527863|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet.
89310756|NCT03904485||SPKT|patients with end-stage diabetic nephropathy got simultaneous pancreas-kidney transplantation
89310757|NCT03904485||RT|patients with end-stage diabetic nephropathy got single kidney transplantation
89310758|NCT01150539|Experimental|Overweight/obese women with PCOS|10 overweight/obese women with polycystic ovary syndrome
89310759|NCT01256541|Experimental|Kristalose|Kristalose as Bowel Evacuant
89310760|NCT03900195|Experimental|Bottle PEP|Bottle PEP is a positive expiratory system that is applied via a tube of more than 5 mm of thickness and a bottle filled with water about 10 cms.
89310761|NCT03900195|No Intervention|Control|No interventions will be applied.
89310762|NCT01255293|Active Comparator|1000 centistoke silicone oil|
89310763|NCT01255293|Active Comparator|5000 centistoke silicone oil|
89310764|NCT03904719|Experimental|CM082 plus JS001|CM082 tablets 150mg is orally given once daily in a 28-day cycle, combinational JS001 240mg was given intravenously on day 1 once every 21 days.
89310765|NCT03900039|Active Comparator|Conventional Polyethylene versus metal head|This is the more conventional group bearing surfaces
89310766|NCT03900039|Experimental|Conventional Polyethylene versus oxidized zirconium head|This group uses the more conventional polyethylene against the newer head
89310767|NCT03900039|Experimental|Newer Cross linked Polyethylene metal head|In this group we continued with the conventional polyethylene, but added in the new type of head (oxidized zirconium)
89310768|NCT03900039|Experimental|Newer Cross linked Polyethylene versus oxidized zirconium head|In this group, we added both the new head and the new polyethylene
89310769|NCT01148901|Experimental|Remicade|Infliximab 5 mg/kg was administered as specified in the Summary of Product Characteristics for patients with ankylosing spondylitis
89310770|NCT01150617|Active Comparator|long-acting insulin plus analogues|three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening.
89310771|NCT01150617|Active Comparator|long-acting insulin and oral agents|treatment will be once-daily long-acting insulin and oral antidiabetic agents
89310772|NCT03904407|Experimental|Probiotic|Lactobacillus probiotic capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
89310773|NCT03904407|Placebo Comparator|Placebo|Matching Lactobacillus probiotic placebo capsules in addition to a routine-care prescribed anticholinergic or beta-3 agonist medication for 4 weeks.
89310774|NCT01256619|Active Comparator|marvelon|
89310775|NCT03898011|Other|Sequence Test-Reference (TR)|14 participants (total number of enrolled volunteers - 28) assigned to sequence TR will receive a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 1 and a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89310776|NCT03898011|Other|Sequence Reference-Test (RT)|14 participants (total number of enrolled volunteers - 28) assigned to sequence RT will receive a single 100 mg dose of the reference product Lamictal (1 x 100 mg tablet) marked as R in period 1 and a single 100 mg dose of the test product Lamotrigine (1 x 100 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89310777|NCT01586247|Experimental|Synbiotic|8g/day gluco-oligosaccharide + 109 CFU/day B. lactis BI07
89310778|NCT01586247|Experimental|Placebo|8g/day maltodextrin
89310779|NCT01586247|Experimental|Prebiotic|8g/day galacto-oligosaccharides (GOS)
89310780|NCT01586247|Experimental|Probiotic|109 CFU/day B. lactis BI07
89310781|NCT01254513|Experimental|Arm A - Docetaxel every 3 weeks + Prednisone|"Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks~Prednisone 10 mg/day continuously"
89310782|NCT01254513|Experimental|Arm B - Docetaxel weekly + Prednisone|"Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)~Prednisone 10 mg/day continuously"
89310783|NCT03898557|Experimental|Usual Care|"Participants randomized to this arm will receive a card with information to report results via WhatsApp, similar to the existing card used in the STAR program. This card will have a dedicated Usual Care WhatsApp number (different from the existing STAR program numbers).~Potential self-test recipients will be shown the WhatsApp card and instructed on how to anonymously report use of self-test to the WhatsApp number. Recipients will be instructed to message the WhatsApp number for the following reasons:~1. So study staff know the self-test recipients used the test and it went ok. 2. So study staff can help the self-test recipients understand the results of the test. 3. If the self-test recipients need support from study staff to access care and services."
89523406|NCT03380897|Active Comparator|Outpatient group|"After insertion of induction catheter for labor, women of the outpatient group can go home and assess their pain with visual analogy scale at home. The intervention is to go home.~Intervention for outpatient group was to go home."
89523407|NCT03380897|Placebo Comparator|Inpatient group|"After insertion of induction catheter for labor, women of the inpatient group assess their pain with visual analogy scale in the ward. The intervention is to stay at ward.~Intervention for inpatient group was to stay at ward."
89523408|NCT03376841|Experimental|Severe hepatic impairment|Cenicriviroc tablet; single-dose oral administration
89310784|NCT03898557|Experimental|Plan and Pledge|"Participants randomized to this arm will revive the Usual Care WhatsApp card and and a brief template to make a plan and make a pledge for test completion and results reporting, to take the HIV self-test. The card will include a dedicated Plan and Pledge WhatsApp number.~Potential self-tester recipients will be shown the WhatsApp card, including Plan and Pledge statements, and will be encouraged by STAR field staff to use the card in their own time to make a plan and sign the pledge as part of receiving the test kit and instructions for how to complete the card. Importantly, testers will be able to keep the card for themselves. There is no expectation to share the plan or the pledge signature with the STAR field staff who distribute self-tests. Field staff will clarify for self-tests recipients that the Plan and Pledge process and card do not change the confidentiality of testing in any way."
89310785|NCT03904641|Experimental|aPDT + ART group|In this group, both aPDT and ART will be performed.
89310786|NCT03904641|Experimental|ART group|In this group, only ART will be performed.
89310787|NCT01256697|Experimental|Alga Dunaliella Bardawil|
89310788|NCT01256697|Placebo Comparator|Sugar pill|
89310789|NCT01149837||residual blood donor samples|Protocol describes testing an HTLV-I/II antibody reactive population from this cohort using the InnoLIA HTLV I/II Score line immunoassay
89310790|NCT03898245|Active Comparator|active tDCS|intervention : Intensity 2mA, 30minues, 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS
89310791|NCT03898245|Sham Comparator|sham tDCS|Intensity 2mA, 8 seconds (but looks same as an intervention 30mins), 7 times (post operation in 30min, in 4hrs, and 1 time a day from POD#1 to POD #7) apply tDCS (sham mode)
89310792|NCT03904095|Active Comparator|Psoas compartment block group (PCB)|Single- shot ultrasound (Esaote Mylab30) guided PCB with 15 ml 0.25% bupivacain ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the PCB group (Group I).
89310793|NCT03904095|Active Comparator|Erector spinae plane block group (ESP)|Single- shot ultrasound (Esaote Mylab30) guided ESP block with 15 ml 0.25% ( Marcain 0.5%, Astra zeneca, Turkey) at the L4 vertebral level will performed preoperatively to patients in the ESP group (Group II).
89310794|NCT03904095|Placebo Comparator|The Control group|The Control group receive no intervention ( Group III).
89310795|NCT03897855|Other|Patient (TSPT-R)|Post Traumatic Stress Disorder
89310796|NCT03897855|Experimental|control|No Post Traumatic Stress Disorder
89310797|NCT03899727||Pregnant group|pregnant women in the third trimester of pregnancy
89310798|NCT03899727||Non-pregnant group|middle aged women
89310799|NCT01149993|Experimental|pre-transplant immunosuppression|subjects in this arm will receive Myfortic 720mg twice daily for 7 days prior to transplantation. Intra-operatively, the donor kidney will receive an infusion of Thymoglobulin, prior to the transplantation.
89310800|NCT01149993|Experimental|pre-transplant induction|subjects in this arm will not receive any pre-transplant immunosuppression. However, the donor kidney will receive an infusion of Thymoglobulin prior to transplantation.
89310801|NCT01149993|Active Comparator|standard of care|subjects in this arm will not receive any pre-transplant immunosuppression, and the donor kidney will not receive an additional dose of Thymoglobulin prior to transplantation. This is the standard of care protocol for Georgetown University Hospital
89310802|NCT01255371|Active Comparator|Arm A : Lopinavir|"Emtricitabine/tenofovir :~TDF300mg.FTC200mg (Fixed Dose Combination)~1 tablet per day~Lopinavir/ritonavir :~LPV200mg/RTV50mg~2 tablets twice a day"
89310803|NCT01255371|Experimental|Arm B : Atazanavir|"Lamivudine/tenofovir :~3TC300mg/TDF300mg (Fixed Dose Combination)~1 tablet per day~Atazanavir/ritonavir :~ATV300mg/RTV100mg~2 tablets once a day"
89310804|NCT03898089|Other|Core Exercise Group|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks.
89310805|NCT03898089|Experimental|Core Exercise plus Myofascial Relaxation Group|In addition to the core stabilization exercises myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks.
89310806|NCT03903783|Active Comparator|Cefotaxime|
89310807|NCT03903783|Active Comparator|Ceftriaxone|
89310808|NCT01150851|Active Comparator|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
89310809|NCT01150851|Active Comparator|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
89310810|NCT01150851|Active Comparator|caloric restriction and aerobic exercise|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration, and supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
89310811|NCT01150851|No Intervention|usual diet and usual activity|usual diet and usual activity
89310812|NCT03899493||Primiparous & Multiparous|Women having borne at least one child > 20 weeks gestational age
89310813|NCT03899493||Nulliparous|Women in whom this is their first pregnancy > 20 weeks who are anticipated to deliver
89310814|NCT03899337|Active Comparator|Standard of Care Arm (CHOP-R)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5"
89310815|NCT03899337|Experimental|Experimental Arm (CHOP-R + Acalabrutinib)|"Arm in the randomised trial. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
89523409|NCT03376841|Experimental|Normal Hepatic function|Cenicriviroc tablet; single-dose oral administration
89310816|NCT03899337|Experimental|Cohort 1 - Acalabrutinib Monotherapy - Platform Trial|Registration arm in platform study. Patients registered to Cohort 1 will receive 100 mg acalabrutinib monotherapy, twice daily, continuously from day 1 until disease progression, toxicity, patient choice or death.
89310817|NCT03899337|Experimental|Cohort 2 - CHOP-R + Acalabrutinib - Platform Trial|"Registration arm in platform study. CHOP-R chemoimmunotherapy will continue for up to 6 cycles (each cycle is 21 days), and will be given according to the following schedule:~Rituximab, 375 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Cyclophosphamide, 750 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Doxorubicin, 50 mg/m2, IV bolus, OD, 6 cycles, days of cycle: 1 Vincristine, 1.4 mg/m2, IV infusion, OD, 6 cycles, days of cycle: 1 Prednisolone, 40 mg/m2, PO, OD, 6 cycles, days of cycle: 1-5~Acalabrutinib 100 mg, PO, BD will be taken on days 6-21, of each cycle - up to cycle 6. Acalabrutinib treatment will be continuous thereafter until disease progression toxicity, patient choice or death."
89310818|NCT01149135|Active Comparator|Standard light treatment|standard light treatment 5000K; 10 000 lux
89310819|NCT01149135|Experimental|blue enriched light|Blue enriched light with a low intensity (750 lux)
89310820|NCT03903627|Experimental|Verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~(1) contract your pelvic floor - all sphincters; (2) contract your anus; (3) contract your pelvic floor as if you're trying to stop urinating.~Those who will not be able to contract will be taught by the ultrasound as a biofeedback."
89310821|NCT01150071||Children born extremely preterm|national cohort of children born before 28 weeks' gestational age or with a birthweight less than 1000 g. 365 eligible survivors
89310822|NCT01256775|Placebo Comparator|NCX4016 placebo|NCX4016 placebo b.i.d for 6 months
89310823|NCT01256775|Active Comparator|NCX4016|ncx4016,800 mg b.i.d., on top of aspirin 100 mg o.d.
89310824|NCT01256853|Experimental|MVA Vaccine|
89310825|NCT03899571|Active Comparator|5 days|oral oseltamivir 75 mg once daily for 5 days post-exposure
89310826|NCT03899571|Active Comparator|10 days|oral oseltamivir 75 mg once daily for 10 days post-exposure
89310827|NCT01150149|No Intervention|1|
89310828|NCT01150149|Experimental|2|No face touch
89310829|NCT01150149|Experimental|3|Surgical face mask
89310830|NCT01150149|Experimental|4|Surgical face mask + no face touch
89310831|NCT03894267|Experimental|Experimental Arm|"Self-adhesive silicone bordered foam dressing will be secured to the heels and sacrum.~Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.~Follow up 20 days"
89310832|NCT03894267|No Intervention|Control Arm|"Daily SEM reading, visual skin assessment. Early Sense placed under study subject's mattress.~Follow up for 20 days."
89310833|NCT03899415|Experimental|TCR-Redirected T Cells|HBV antigen specific TCR redirected T cells
89310834|NCT03893877|Experimental|nasal cannula|device:nasal cannula will be applied to patients for oxygenation under deep sedation
89310835|NCT03893877|Active Comparator|nasal mask|device:nasal mask will be applied to patients for oxygenation under deep sedation
89310836|NCT01258257|Active Comparator|Lumbar drain (LD) / Tuohy drain|Intervention: Insertion of a lumbar drain All patients in the LD group receives a lumbar drain during anesthesia required for aneurysm treatment. Drainage of CSF is started after the post-procedural CT scan on day one after aneurysm securement.
89310837|NCT01258257|No Intervention|No Lumbar drain (NoLD)|Patients randomized to the control group should not receive a lumbar drain before the planned control angiography to be performed on day 7 to 10 after SAH. If the patient develops hydrocephalus, and no EVD was placed initially for CSF drainage, a lumbar drain may be installed at the discretion of the local investigator. These patients are analyzed in the intention-to-treat analysis, but are not suitable for per-protocol analysis.
89310838|NCT01256931||organ transplant patients|
89310839|NCT01256931||healthy controls|
89310840|NCT01258335|Active Comparator|Omega 3 Fatty acids|"II. Study arms:~a. Participants in the dry AMD study group will be randomized into two arms with a 4:1 ratio: i. Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)"
89310841|NCT01258335|Placebo Comparator|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
89310842|NCT01257009|Other|1|Arm 1: cessation of any statin therapy for at least 6 weeks, then the first sympathetic activity measurement will be done.Subsequently, atorvastatin 20mg is added for 6 weeks. Then the second sympathetic measurement will be performed.
89310843|NCT01257009|Other|2|Patients will receive atorvastatin for 6 weeks, then the first sympathetic measurement will be done. Then atorvastatin will be stopped and 6 weeks the second measurement will be done
89310844|NCT01255527|Active Comparator|Busulfan|
89310845|NCT01255527|Active Comparator|Melphalan|
89310846|NCT01151787|Active Comparator|cyclobenzaprine hydrochloride|
89310847|NCT01151787|Placebo Comparator|placebo|
89310848|NCT03899025|Other|Suspected scaphoid fracture|Patients with a suspected scaphoid fracture
89310849|NCT01151865|Active Comparator|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
89310850|NCT01151865|Placebo Comparator|Saline placebo|An identical syringe to that in the intervention arm, but which does not contain dexmedetomidine, will be provided. The initial rate of infusion and subsequent adjustments will be the same as in the dexmedetomidine group.
89310851|NCT03898947||Tamoxifen users|Women undergoing therapy with Tamoxifen after surgery for breast cancer.
89310852|NCT03898947||Aromatase inhibitors|Women undergoing therapy with Aromatase Inhibitors after surgery for breast cancer.
89310853|NCT03898947||No treatment|Women who did not undergo any hormonal therapy after surgery for breast cancer.
89310854|NCT03898791|Experimental|LY3295668 Erbumine Cohort A|LY3295668 erbumine administered orally.
89310855|NCT03898791|Experimental|LY3295668 Erbumine Cohort B|LY3295668 erbumine administered orally.
89310856|NCT03898791|Experimental|LY3295668 Part JP|LY3295668 erbumine administered orally.
89310857|NCT03893721||malnourished under five children|children from 2 to 5 years with malnutrition
89310858|NCT03893721||well nourished under five children|children from 2 to 5 years without malnutrition
89310859|NCT03897543|Experimental|ABX196|IM injection of 0.1, 0.2, and 0.4 µg of ABX196
89310860|NCT03893409||pulmonary function|
89310861|NCT03893409||biological sample detection outcome|
89310862|NCT01255683||Chronic rhinosinusitis|
89310863|NCT01258413|Experimental|Laparoscopic Radical Hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
89310864|NCT01258413|Active Comparator|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
89310865|NCT01255839|Active Comparator|Double-balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
89310866|NCT01255839|Active Comparator|Prostglandin E2|The prostaglandin 2 minprostin (3mg) was applied vaginally
89310867|NCT01255917||Chronic pancreatitis|
89310868|NCT01151007||Patients with colorectal carcinoma|Patient with colorectal carcinoma operated in Martinique between January 1st, 2007 and December 31st, 2009
88813149|NCT01836926|Active Comparator|Open intersphincteric resection|surgical Instruments for open approach intervention: Open laparotomy through abdominal incision and mobilization of the colon and rectum up to the splenic flexure with high ligation of the inferior mesenteric vessels and mesorectal excision till the levator ani then the peranal approach to resect the distal margin of the rectum through high or low intersphincteric resection in the plane between internal and external anal sphincters.
89310869|NCT03893643||pediatric population|Pediatric population aged 0 to 15 years with neurofibromatosis type 2
89310870|NCT03893097|Active Comparator|Praziquantel|Participants in this arm will receive one dose of PZQ at baseline at 40 mg/kg.
89310871|NCT03893097|Experimental|Artesunate-Mefloquine|Participants in this arm will receive the Artesunate-Mefloquine (fixed-drug)combination at 4 mg/kg artesunate and 8 mg/kg mefloquine at 3 consecutive days. This will be repeated twice; at week 6 and week 12.
89310872|NCT01255995||Control Patients|Controls without PXF who require cataract surgery
89310873|NCT01255995||Pseudo Exfoliation patients|PXF subjects with or without glaucoma who require cataract surgery
89310874|NCT01256073|Experimental|IPH2101|
89310875|NCT03897153|Experimental|Experimental:Diagnostic|Diagnostic Test: SONAS® Ultrasound Device
89310876|NCT01257165|Experimental|Zopiclone 5 mg|Zopiclone 5 mg pill + placebo pill + placebo drink
89310877|NCT01257165|Experimental|Zopiclone 10 mg|2 x zopiclone 5 mg pills + placebo drink
89310878|NCT01257165|Active Comparator|Ethanol 0.8 g/L|2 x placebo pills + ethanol 50 g/70 kg
89310879|NCT01257165|Placebo Comparator|Placebo|2 x placebo pills + placebo drink
89310880|NCT01151943|Experimental|Transversus Abdominis Plane (TAP) Block|Patients will receive a bilateral transversus abdominis plane block
89310881|NCT01151943|Active Comparator|Incisional Infiltration of Local Anesthetic|Patients will receive an incisional infiltration with local anesthetic (continuous administration of levobupivacaïne during 48 hours)
89310882|NCT01256151|Active Comparator|Alprazolam conventional tablet|Alprazolam conventional tablet
89310883|NCT01256151|Experimental|Alprazolam sublingual tablet|Alprazolam sublingual tablet
89310884|NCT01256229|Experimental|Developmentally delayed - Hearing aids|This arm contains deaf children that have developmental delays and are randomized to be treated with the conventional therapy, hearing aids.
89310885|NCT01256229|Experimental|Developmentally Delayed - Cochlear implant|This arm contains deaf children that have developmental delays and are randomized to be treated with cochlear implantation.
89310886|NCT01256229|Active Comparator|Not developmentally delayed|This control arm contains deaf children that do not have developmental delays and will be treated with cochlear implantation.
89310887|NCT03889431|Experimental|Capsule group|Group one received iodine capsule
89310888|NCT03889431|Experimental|Iodized salt group|Group two received iodized salt
89310889|NCT01259895||Obesity|BMI > 30kg/m2
89310890|NCT01259895||Normal weight|BMI between 19 and 24,9kg/m2
89310891|NCT03889587|Experimental|Innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibula bone flaps. In simultaneous innervated group, neurorrhaphy between the ilioinguinal nerve or fibula flap nerve with inferior alveolar nerve or great auricular nerve will be performed.~Intervention: Procedure: Innervation"
89310892|NCT03889587|Active Comparator|Non-innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibular bone flaps. In traditional noninnervated group, neurorrhaphy will not be performed.~Intervention: Procedure: Non-innervation"
89310893|NCT03893019|Experimental|Dose Level 1: 1x10e5 MB-CART20.1 cells|3+3 patients will be treated with 1x10e5 MB-CART20.1 cells per kg body weight administered intravenously
89310894|NCT03893019|Experimental|Dose Level 2: 1x10e6 MB-CART20.1 cells|3+3 patients will be treated with 1x10e6 MB-CART20.1 cells per kg body weight administered intravenously
89310895|NCT03893019|Experimental|Dose Level 3: 1x10e7 MB-CART20.1 cells|3+3 patients will be treated with 1x10e7 MB-CART20.1 cells per kg body weight administered intravenously
89310896|NCT01259973|Experimental|Risperidone|
89310897|NCT01259973|Placebo Comparator|Placebo|
89310898|NCT01259973|Experimental|Haloperidol|
89310899|NCT01257243|Experimental|DRUG 1|Syrup of oxomemazine, guaifenesin and potassium iodate
89310900|NCT01257243|Active Comparator|DRUG 2|Syrup of guaifenesin
89310901|NCT01258569|Active Comparator|Entereg|
89310902|NCT01258569|Placebo Comparator|Placebo|
89310903|NCT03892941|Experimental|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
89310904|NCT03892941|No Intervention|Clinical routine|Mapping of the electrical input of the cochlear implant will be based on a one-size-fits-all, as is part of clinical routine.
89310905|NCT03889041||Caregivers of children with EA-TEF|Caregivers of children with esophageal atresia and tracheoesophageal fistula will be included in the study.
89310906|NCT01258647|Experimental|Feeding group|The feeding group will include 20 mother/infant dyads. The infants will be between 8 and 10 months of age.
89310907|NCT03896841||PCOS|premenopausal patients with PCOS
89310908|NCT03896841||control subjects|non-pregnant healthy control subjects
89310909|NCT03892629|Experimental|Baduanjin exercise group|Participants in this group received Baduanjin exercise
89310910|NCT03892629|Active Comparator|Instrument rehabilitation group|Participants in this group received rehabilitation by using tri-ball respiratory trainer
89310911|NCT03892629|Active Comparator|Baduanjin Exercise and Instrument Rehabilitation|Participants in this group received both instrument rehabilitation and Baduanjin exercise
89310912|NCT03892629|No Intervention|No Intervention|Participants in this group only received routine drug-treatment
89310913|NCT01258725|Experimental|amnioinfusion|The investigators propose an open trial comparing baseline Doppler waveforms in the uteroplacental and fetal pulmonary circulation in patients presenting with severe, idiopathic olighydramnios (AFI<5, no apparent ethiopathology), managed either with single or with serial amnioinfusions. The patients will be followed up weekly in the fetomaternal unit, Dept. of ObGyn for measuring AFI repeatedly to assess the need for further infusions. These will be carried out when the AFI falls below 5cm again
89310914|NCT03888963|Experimental|PRF|
89310915|NCT03888963|Sham Comparator|SHAM|
89310916|NCT01257321||post tonsillectomy|children
89310917|NCT03892863|Active Comparator|active repetitive transcranial magnetic stimulation|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
89310918|NCT03892863|Sham Comparator|sham repetitive transcranial magnetic stimulation|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
89310919|NCT01257399|Experimental|Asacol®|Import Mesalazine
89310920|NCT01257399|Active Comparator|Mesalazine|Marketed Mesalazine
89310921|NCT01258959||Ophthalmic surgery patients|Patients (men and women) of at least 18 years of age undergoing an ophthalmic procedure on the posterior section of the eye under local anaesthesia, i.e. with a peribulbar block. Inclusion and exclusion criteria for the study are the same as for the peribulbar anaesthesia.
89310922|NCT03888807|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees.
89310923|NCT03888807|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees
89310924|NCT01153659|Experimental|1|
89310925|NCT01153659|Active Comparator|2|
89310926|NCT01153659|Active Comparator|3|
89310927|NCT01153737|Experimental|manual therapy|
89310928|NCT01153737|Active Comparator|TENS|Electric Nerve Stimulation (TENS)
89310929|NCT01257555||Treatment Group|
89310930|NCT01260129|Experimental|Silodosin 8 mg|
89310931|NCT01260129|Experimental|Silodosin 4 mg|
89310932|NCT03892551||patients admitted to emergency ward|all patients admitted to the emergency ward and awaiting triage are observed
89310933|NCT01260207|Experimental|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
89310934|NCT01260207|No Intervention|Usual care|Patients in this arm will not receive IVR follow-up. One year after discharge, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
89310935|NCT03896919||cases|HLA-DQ mismatched recipient-donor pairs
89310936|NCT03896919||control|HLA-DQ matched recipient- donor pairs
89310937|NCT01152099|Active Comparator|GroupA|"Ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. Multilayer bandage is applied daily during the first four weeks.~The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
89523410|NCT03125135|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the MightySat RX Pulse Oximeter Sensor.
89523411|NCT03376685|Experimental|Endurance Exercise Training (END)|This group is performing END training for 6 weeks in duration. Intervention: Behavioral: Endurance Exercise Training (END)
89310938|NCT01152099|Experimental|GroupB|"Ambulatory treatment is carried out during one month. Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
89310939|NCT01260285|Experimental|Vardenafil|
89310940|NCT03888573|Active Comparator|Stretch|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms.
89310941|NCT03888573|Active Comparator|Traction|Patients within Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
89310942|NCT03888729|Experimental|HCV treatment-naïve participants|HCV-infected individuals naïve to DAA therapy regimen; in this group we consider also HCV-infected individuals who have failed interferon-based therapy. Sofosbubir/velpatasvir (SOF/VEL) will be administered once daily for 12 weeks to eligible HCV treatment-naïve participants.
89310943|NCT03888729|Experimental|HCV treatment-experienced participants|HCV treatment-experienced participants, i.e.HCV-infected individuals with a history of virologic failure to SOF/LDV or other DAA-containing regimen. Sofosbubir/velpatasvir /voxilaprevir (SOF/VEL/VOX) will be administered once daily for 12 weeks to eligible HCV treatment-experienced participants
89310944|NCT01257633||The study population|Laryngeal cancer patients requiring surgical tumor resection.
89310945|NCT01152177|Active Comparator|Electronic reminders|Electronic reminders
89310946|NCT01152177|No Intervention|Usual care|usual care
89310947|NCT01260363|Active Comparator|Naropin, Adrenalin, applicationsite|
89310948|NCT01260363|Active Comparator|Femoral nerve block|
89310949|NCT03892473|Experimental|Flexible Assertive Community Treatment (FACT)|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
89310950|NCT03892473|Active Comparator|Care as usual (CAU)|Active Comparator: CAU (Care as usual) Patients with SMI receiving usual care, meaning mostly medical treatment
89310951|NCT01260441|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected over various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
89310952|NCT01260441|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
89310953|NCT01152255|Experimental|Panel A - MK6186 40 mg|MK6186 40 mg
89310954|NCT01152255|Placebo Comparator|Panel A - Placebo|placebo
89310955|NCT01152255|Experimental|Panel B - MK6186 150 mg|MK6186 150 mg
89310956|NCT01152255|Placebo Comparator|Panel B - Placebo|placebo
89310957|NCT01152255|Experimental|Panel C - MK6186 <=150 mg|MK6186 <=150 mg
89310958|NCT01152255|Placebo Comparator|Panel C - Placebo|placebo
89310959|NCT01152255|Experimental|Panel D - MK6186 <=150 mg|MK6186 <=150 mg
89310960|NCT01152255|Placebo Comparator|Panel D - Placebo|placebo
89310961|NCT03896451|Other|GMK Sphere|"Patients receiving total knee replacement surgery with the device Medacta GMK Sphere"
89310962|NCT03896451|Other|GMK PS|"Patients receiving total knee replacement surgery with the device Medacta GMK PS"
89310963|NCT01152333|Active Comparator|Exendin (9-39) Acetate|Exendin (9-39) is a synthetic peptide that acts as an antagonist to the GLP-1 receptor. Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length at 600-750 pM/kg/min.
89310964|NCT01152333|Placebo Comparator|Saline|Saline 0.9% will be used as the control infusion.
89310965|NCT03896373||Lupus erythematosus|Patients with inactive lupus erythematosus, active lupus erythematosus or newly diagnosed
89310966|NCT01151241|Experimental|Early discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
89310967|NCT01151241|Active Comparator|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
89310968|NCT01154049|Experimental|single arm|3 doses of the vaccine, on days 0, 30 and 60.
89310969|NCT03892083|Active Comparator|Anodal tDCS (M1)|tDCS applied over primary motor cortex. Dose: 1mA, 20 minutes
89310970|NCT03892083|Experimental|Anodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
89310971|NCT03892083|Experimental|Cathodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
89310972|NCT03892083|Sham Comparator|Sham tDCS|tDCS applied over the cerebellum Dose: 1mA, 20 minutes (30s ON)
89310973|NCT01154205||Patients post implantation of ICD or CRTD|
89310974|NCT01152411|Experimental|Autologous bone marrow stem cells|
89310975|NCT03888495|Experimental|Gender socialization (GS)|Gender socialization workshops raised awareness on gender, its social construction and inequality, notions of masculinity and femininity, division of labor, access and control over resources. The workshop also included skill-building sessions on effective communication and negotiation and relationship building.
89310976|NCT03888495|Experimental|GS + Financial literacy (FL)|Financial literacy workshops promoted knowledge and skills in budgeting, financial planning and accessing and using financial services and income generating activities.
89523412|NCT03376685|Experimental|Sprint Exercise Training (SIT)|This group is performing SIT training for 6 weeks in duration. Intervention: Behavioral: Sprint Exercise Training (SIT)
89310977|NCT03888495|Experimental|GS + FL + Family planning|Family planning counseling was provided to couples by family planning providers from nearby facilities. Couples were encouraged to seek services in facilities of their choice. A voucher system provided financial support for the poorest couples.
89310978|NCT03888495|No Intervention|Control|Couples were interviewed at baseline, and will be interviewed at endline.
89310979|NCT02949362|Experimental|Standard of Care (SOC) Treatment +/- Teduglutide|TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment
89310980|NCT03892317|Other|Medication adherence interventions|Pharmacist led medication adherence interventions which will be tailored to individual patient need
89310981|NCT03895905||Genotype of HR-HPV 16/18|Patients with genotype of HR-HPV 16/18 who underwent cervical biopsy with colposcopy
89310982|NCT03895905||Genotype of HR-HPV Non-16/18|Patients with genotype of HR-HPV non-16/18 who underwent cervical biopsy with colposcopy
89310983|NCT01152489|No Intervention|Standard Care|Immunizations are given with standard care of no pain control
89310984|NCT01152489|Active Comparator|Experimental|Vibrating device with cold pack held to arm proximal to injections within the same dermatome; caretakers offered and instructed in use of distraction cards.
89310985|NCT01152489|Sham Comparator|Sham Device|The device without batteries or cold pack held to arm proximal to injections. No formal distraction.
89310986|NCT01586403|Experimental|Dose 1|Subjects in cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight
89310987|NCT01586403|Experimental|Dose 2|cohort 2 will receive 7.5 x 106 TIL 1383I TCR transduced T cells per kg body weight.
89310988|NCT01586403|Experimental|Dose 3|Subjects in cohort 3 will receive 2.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
89310989|NCT01586403|Experimental|Dose 4|Subjects will then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
89310990|NCT05176028|Experimental|Control group|conventional physiotherapy
89310991|NCT05176028|Experimental|Intervention group|conventional physiotherapy and fascial release
89310992|NCT03892161|Experimental|Standard dose DRV/r|Standard dose DRV/r 800/100mg without Rifampicin
89310993|NCT03892161|Experimental|Standard DRV/r with Rifampicin|Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.
89310994|NCT03892161|Experimental|Boosed ritonavir 200mg|Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
89310995|NCT03892161|Experimental|Double dose DRV/r 1600/200mg QD|Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
89310996|NCT03892161|Experimental|Double dose DRV/r 800/100mg BD|Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
89310997|NCT05175950|Experimental|Test group 1: primary vaccination completed with ChAdOx1 nCOV-19|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
89310998|NCT05175950|Placebo Comparator|Placebo group 1: primary vaccination completed with ChAdOx1 nCOV-19|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
89310999|NCT05175950|Experimental|Test group 2: primary vaccination completed with BNT162b2(Pfizer)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
89311000|NCT05175950|Placebo Comparator|Placebo group 2: primary vaccination completed with BNT162b2(Pfizer)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
89311001|NCT05175950|Experimental|Test group 3: primary vaccination completed with mRNA-1273(Moderna)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
89311002|NCT05175950|Placebo Comparator|Placebo group 3: primary vaccination completed with mRNA-1273(Moderna)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
89311003|NCT05175950|Experimental|Test group 4: primary vaccination completed with Ad26.COV2.S(Janssen)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
89311004|NCT05175950|Placebo Comparator|Placebo group 4: primary vaccination completed with Ad26.COV2.S(Janssen)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
89311005|NCT05175950|Experimental|Test group 5: primary vaccination completed with ChAdOx1 nCOV-19(AZ)-BNT162b2(Pfizer)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
89311006|NCT05175950|Placebo Comparator|Placebo group 5: primary vaccination completed with ChAdOx1 nCOV-19-BNT162b2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
89311007|NCT05175950|Experimental|Test group 6: primary and 1st booster vaccination completed with mRNA vaccine|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
89311008|NCT05175950|Placebo Comparator|Placebo group 6: primary and 1st booster vaccination completed with mRNA vaccine|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
89311009|NCT05175950|Experimental|Test group 7: primary and 1st booster vaccination completed with ≥1 dose of non-mRNA vaccine|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
89311010|NCT05175950|Placebo Comparator|Placebo group 7: primary and 1st booster vaccination completed with ≥1 dose of non-mRNA vaccine|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
89311011|NCT01154361|Experimental|Arm A|
89311012|NCT01154361|Active Comparator|Arm B|
89311013|NCT04743830|Experimental|Treatment Group|Neurodevelopmental Treatment (Bobath) + Scapular Training Group
89311014|NCT04743830|Active Comparator|Control Group|Neurodevelopmental Treatment (Bobath) Group
89311015|NCT01260519|Experimental|active arm: heparin|
89311016|NCT02527629||Decellularized human valves|Aortic heart valve replacement
89311017|NCT01257711|Other|Billroth II reconstruction|Following Radical Distal Subtotal Gastrectomy, patient will be randomised to restore the continuity of the intestine with the stomach using Billroth II reconstruction.
89311018|NCT01257711|Other|Roux-en-Y reconstruction|Following Radical Distal Subtotal Gastrectomy, patient will be randomised to restore the continuity of the intestine with the stomach using Roux-en-Y reconstruction.
89311019|NCT05175638||Control|A total of 20 term newborn infants with a median gestational age of 40 weeks (range: 37-42 weeks) will be selected from the Gynecology and Obstetrics Hospital (Assiut University). All control infants should have an Apgar score of > 9 at 1, 5, and 10 minutes.
89311020|NCT05175638||Study group|"Thirty newborn infants born for Covid-19 positive mothers will be prospectively included in this study. The diagnosis of hypoxia will made based on Apgar score, clinical signs present during the first hours of life and acid-base status.~The following inclusion criteria will be used (all necessary): Covid-19 positive mothers, term newborn (>37 completed gestational weeks), free from severe malformations. All infants will be examined generally, systemically and neurologically at birth for clinical assessment of HIE if present and for detection of outcome of these neonates."
89311021|NCT03888183|Placebo Comparator|salt solution without 0.15% HA|
89311022|NCT03888183|Active Comparator|preservative-free 0.15% HA|
89311023|NCT05003336|Experimental|Xiangshao Granules|dissolve 1 sachet (4 g) of Xiangshao Granules in water to be drank 3 times a day after meal for 8 weeks
89311024|NCT05003336|Placebo Comparator|Xiangshao Granules Placebo|dissolve 1 sachet (4 g) of Xiangshao Granules placebo in water to be drank 3 times a day after meal for 8 weeks
89311025|NCT03891693|Experimental|Passeo-18 Lux and SUPERA® stent|Target lesion will be treated with Passeo-18 Lux Drug Eluting Balloon and SUPERA® stent during angioplasty
89311026|NCT03896139||VUMC EHR cohort|De-identified version of the electronic health record (EHR) at Vanderbilt University Medical Center (VUMC).
89311027|NCT03896139||Toxicity induced by kinase inhibitors in Vigibase database|Case reported in the World Health Organization (WHO) of toxicity or complication of patient treated by KIs, with a chronology compatible with the drug toxicity
89311028|NCT05207150|Active Comparator|LINQ II/Apple Watch Series 6|
89311029|NCT05207150|Active Comparator|LINQII/SkyLabs CART-I ring|
89311030|NCT03891927|Experimental|olive group|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO ( high polypheol Extra virgin olive oil)
89311031|NCT03891927|No Intervention|non olive group|No intervention
89311032|NCT03888261|Active Comparator|Active Intervention:|Mind-body intervention (incl. Relaxation Response Resiliency Program & the Open and Calm Program)
89311033|NCT03888261|No Intervention|No Intervention|No intervention (Study participants will receive routine clinical practice)
89311034|NCT04438538||Patients with Dizziness|All trial participants are within this group. All trial participants will either have a diagnosis or a suspected diagnosis of Ménière's Disease in order to take part.
89311035|NCT03891615|Experimental|Niraparib + Osimertinib|"Niraparib will be administered orally once daily~Osimertinib will be administered by mouth once daily"
89311036|NCT01152567||ACE|Patients treated for hypertension with ACEs without CVD
89311037|NCT01152567||Candesartan|Patients treated for hypertension with candesartan without CVD
89311038|NCT03887793|Experimental|VACs intervention|Integrated healthcare delivery systems randomly assigned to this arm will participate in the Vaccinate Adolescents against Cancers (VACs) model for HPV vaccine QI. Specific QI activities will be chosen by healthcare system leadership and healthcare providers on the systems' QI teams.
89311039|NCT03887793|No Intervention|Wait list control|Integrated healthcare delivery systems randomly assigned to this arm will be placed on a waiting list to receive the intervention after the conclusion of the study period.
89311040|NCT02947022|Experimental|Calcium DTPA followed by Zinc DTPA|Subjects will receive IV administration of Ca-DTPA on Day 1 and Zn-DTPA on Day 2 at each of treatment time-points. Three identical treatment time-points are scheduled on Month 1, Month 2 and Month 3.
89311041|NCT01259193|Experimental|Sorafenib and Zoledronic Acid|
89311042|NCT03887949|Active Comparator|VCV|Volume controlled ventilation
89311043|NCT03887949|Active Comparator|PCV|Pressure controlled ventilation
89311044|NCT03887949|Experimental|PCV-VG|Pressure controlled ventilation with volume guarantee
89311045|NCT05182892|Experimental|Part 1: All participants|All participants who will participate in part 1.
89311046|NCT05182892|No Intervention|Part 2: All participants|All participants who participated in part 1
89311047|NCT05182892|No Intervention|Part 3: All participants|All participants who will participate in part 3
89311048|NCT03895983||Thrombus aspiration group|Will include 135 patients who will have PPCI with thrombus aspiration
89311049|NCT03895983||Standard PPCI group|Will include 135 patients who will have PPCI without thrombus aspiration
89311050|NCT05178134|Active Comparator|The wet formulation of ETVAX.|The wet formulation consists of a liquid suspension of inactivated bacteria (ETEX 21-24) and LCTBA in one vial, freeze-dried dmLT adjuvant in a second vial, and effervescent buffer granules in a separate sachet. Prior to administration, the buffer is dissolved in 150 ml tap water, followed by the addition of the content of the vaccine vial (inactivated bacteria mixed with LCTBA) and reconstituted and diluted adjuvant dmLT from the second vial.
89311051|NCT05178134|Active Comparator|The partially dried formulation of selected components of ETVAX.|The partially dried formulation, dmLT and LCTBA are spray-dried and mixed with the buffer granules and stabilizing excipients in a sachet. Prior to administration, the content of the buffer sachet (buffer, dmLT, and LCTBA) is dissolved in 150 ml tap water, followed by the addition of a liquid suspension of inactivated bacteria (ETEX 21-24).
89311052|NCT03891459|Experimental|spray+ group|"In spray+ condition, participants learned oxytocin materials on a self-paced basis and then intranasally administered with saline (but it was told as oxytocin). Participants were instructed to refrain from smoking or drinking (except water) for 2 h before the experiment. The spray was administered to each participant three times, and each administration consisted of one inhalation into each nostril. Participants took a rest (they were told it was a time period waiting for treatment to produce effects) for 10min and then performed the experimental tasks."
89311053|NCT03891459|Placebo Comparator|control group|"In control condition, the materials and procedure were same with the spray+ condition except the nasal spray was told as saline instead. Oxytocin materials used in current experiments were adopted from previous study"
89311054|NCT01257789||gastric bypass patients|Consecutive series of 300 patients undergoing laparoscopic gastric bypass
89311055|NCT01260597|Experimental|Life Style Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report not being quit and are randomized to the intervention condition, tailored messages are delivered via the IVR system. The automated calls would include an assessment of the individual's interest in another quit attempt and deliver brief, tailored messages to perceived barriers for re-engaging into treatment. The system is programmed to transfer the caller to a live quit line counselor if the individual is willing to re-engage in cessation treatment.
89311056|NCT01260597|Active Comparator|Life Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report still smoking the IVR will thank them for their time and the call will end.
89311057|NCT05219708|Experimental|Calorie and protein nutritional supplementation|Study participants randomized to the intervention will receive 30 days worth of the nutritional supplement (i.e. Ensure Original) to be consumed twice per day in between meals in addition to standard of care for heart failure.
89311058|NCT05219708|Active Comparator|Control|The control group will receive standard of care for heart failure.
89311059|NCT02527551|Other|Haptic massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
89311060|NCT01260675||NanoBUP Capsules|Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8 mg/2 mg oral capsules
89311061|NCT01260675||Suboxone Sublingual Tablets|Buprenorphine HCl/Naloxone HCl 8 mg/2 mg sublingual tablets
89311062|NCT01152645|Experimental|ARQ 197|
89311063|NCT01259271|Experimental|Supra-threshold|Supra-threshold is defined as the nerve stimulation amplitude at which a subject can tolerate sensory responses (like tingling, tapping in the thumb, index or middle fingers) but will not cause pain or duress to the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers and they feel the paresthesia or tingling sensation.
89311064|NCT01259271|Experimental|Sub-threshold|Sub-threshold is defined as the nerve stimulation amplitude just below the sensory perception of the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers. Subjects do not feel the paresthesia or tingling sensation despite there being a signal transmitted..
89311065|NCT01259271|Sham Comparator|Sham Control|All subjects in the sham arm will go through the same process / experimental setup as in each of the active stimulation arms; however there will be no stimulation signal during the sham stimulation (output set and SNS box locked at 0 V). As this is the Sham control, there is no intervention but rather the intevention (TAMS device) setup (Tyco electrodes, wires and stimulator) are sent with the subject as if it were on (and just like Subthreshold arm the subjects cannot feel the stimulation). Audible alerts (to signify that the box is unplugged) will be disabled throughout the duration of the study. This sham arm will be used to assess the placebo effect caused by the stimulation and hence isolate the true effect of stimulation.
89311066|NCT05122910|Experimental|SMART-MR Program|Participants will participate in the Stress Management and Resilience Training - Moral Resilience (SMART-MR) program.
89311067|NCT03887871|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
89311068|NCT03887871|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~Period 2: Harnal-D Tab. 1T"
89311069|NCT03708146|Experimental|Cohort 1 (BIA 5-1058 /50 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311070|NCT03708146|Experimental|Cohort 2 (BIA 5-1058 /25 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 25 mg (as 1 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311071|NCT03708146|Experimental|Cohort 3 (BIA 5-1058 /100 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311072|NCT03708146|Experimental|Cohort 4 (BIA 5-1058 /50 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo 12 active and 3 placebo)
89311073|NCT03708146|Experimental|Cohort 5 (BIA 5-1058 /150 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 150 mg (as 1 x 100 mg and 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311074|NCT03708146|Experimental|Cohort 6 (BIA 5-1058 /75 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 75 mg (as 3 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311075|NCT03708146|Experimental|Cohort 7 (BIA 5-1058 /200 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311076|NCT03708146|Experimental|Cohort 8 (BIA 5-1058 /100 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311077|NCT03708146|Experimental|Cohort 9 (BIA 5-1058 /400 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311078|NCT03708146|Experimental|Cohort 10 (BIA 5-1058 /200 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311079|NCT03708146|Experimental|Cohort 11 (BIA 5-1058 /400 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
89311080|NCT03895749|Active Comparator|Neo40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
89311081|NCT03895749|Placebo Comparator|Placebo|Per Capsule: Beet Juice concentrate, Carmine, Croscarmellose Sodium, D-Mannitol, Magnesium Stearate, Orange flavour, Silicon dioxide, Stevia rebaudiana leaf, Xylitol.
89311082|NCT05309798|Experimental|Evening Fasting|Participants will undertake acute evening fasting (feeding between 8am-4pm)
89311083|NCT05309798|Experimental|Control|Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm).
89311084|NCT05309798|Experimental|Morning Fasting|Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm).
89311085|NCT03891303||Transfused group (TR)|Group received allogenic blood transfusion (ABT) alongside with autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
89311086|NCT03891303||Non-transfused (non-TR)|Group received only autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
89311087|NCT05671796|Experimental|Mesenchymal stem cell transplantation|Two intrathecal autologous bone marrow stem cell transplantation of 1 ml solution containing 5x10,000,000 MSCs each with a 90-day interval between applications.
89311088|NCT05671796|Placebo Comparator|Placebo|Two subcutaneous injections of 1 ml each, containing glycophysiological solution.with a 90-day interval between applications.
89311089|NCT03887637||Danoprevir Sodium triple therapy|"DNV(Danoprevir Sodium)/PegIFNα(Peginterferon α-2a)/RBV(Ribavirin) : (1) DNV : 100mg (one tablet) orally twice daily for 12 weeks. (2) PegIFNα: 180ug subcutaneous infection on abdomen or thigh once a week for 12 weeks. (3) RBV: 500mg (5 tablets) orally twice daily for 12 weeks in patients weighing less than 75kg; 600mg (6 tablets) orally twice daily for 12 weeks in patients weighing ≥75kg.~Dosing time: In the morning, participants will be instructed to take DNV and RBV with food or one hour after food. The drugs are not allowed to be cut or divided. The interval between DNV and RBV dosing time should be 12±2 hours."
89311090|NCT03887637||Sofosbuvir/ Velpatasvir therapy|Sofosbuvir/ Velpatasvir :500mg (two drugs in one tablet) orally once daily for 12 weeks.
89311091|NCT03887637||Ombitasvir/Paritaprevir therapy|Ombitasvir/Paritaprevir: Ombitasvir two tablets orally once daily for 12 weeks; Paritaprevir one tablet orally twice daily for 12 weeks.
89311092|NCT03887637||Grazoprevir/elbasvir therapy|Grazoprevir/elbasvir: 150mg (two drugs in one tablet) orally once daily for 12 weeks.
89311093|NCT03887637||Daclatasvir/Asunaprevir therapy|Daclatasvir (60mg)one tablet once daily and Asunaprevir (100mg)one tablet twice daily for 24weeks
89311094|NCT03887637||Danoprevir Sodium/Sofosbuvir therapy|Danoprevir Sodium: 100mg (one tablet) orally twice daily for 12 weeks;Sofosbuvir:400mg (one tablet) orally once daily for 12 weeks.
89311095|NCT01260753|Experimental|UR-63325|
89311096|NCT01260753|Active Comparator|Fluticasone propionate nasal spray|
89311097|NCT01260753|Placebo Comparator|Placebo|
89311098|NCT01259349|Experimental|one percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
89311099|NCT01259349|Active Comparator|40 percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
89311100|NCT03891147|Experimental|Electro-acupunture (EA) group|"Patients will receive the treatment of electro-acupuncture with acupoints (i) Riyue (GB-24) ; (2) Danshu (B19) ; (3) Ganshu (B18) ; (4) Qimen (LR14) ; (5) Yanglingquan (GB34)~The EA will be conducted by using disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length). The needles are inserted at a depth of 10-30 mm vertically or obliquely into acupoints, on which electrical stimulation with continuous waves with 2 Hz and 100 Hz are delivered for 15 min for each frequency through an electrical acupuncture treatment instrument (Hwarto, SDZ-II). The intensities of stimulation are adjusted to a level at which patients feel most comfortable. Each session lasts for 30 minutes."
89311101|NCT03891147|No Intervention|Usual care group|Participants randomized to usual care will continue regular follow up arranged by their visiting physicians in public or private sectors. Current usual care of these patients is limited to symptomatic treatment and dietary advice only during the follow-up session in out-patient clinic until the end of observation period (week 10).
89311102|NCT03891225|Experimental|Amniotic Membrane implantation Arm|All consecutive patients undergone pancreaticoduodenectomy with high FRS will be treated with implantation of AM, by overlapping it over the pancreo-jejunal anastomosis.
89311103|NCT01260831|Experimental|Intervention Hospitals|hospitals randomized to implement bedsidePEWS documentation system (vital sign assessment record)
89311104|NCT01260831|Active Comparator|Control Hospitals|hospitals randomized to continue with their pre existing documentation system (vital sign assessment record)
89311105|NCT03887403|Experimental|Multimodal Intervention|Multimodal Intervention Based on Person-centered Communication
89311106|NCT03887403|Active Comparator|Usual Care|Patients receive usual advices in primary health care centers
89311107|NCT03895671|Experimental|AP-CML|Patient with Philadelphia chromosome positive CML in accelerated phase is defined by the presence of 15-29% blasts in peripheral blood (PB) or bone marrow (BM), ≥ 20% basophils in PB or BM, ≥ 30% blasts plus promyelocytes (with blasts <30%) in PB or BM, <100 x109/L platelets unrelated to therapy, or by clonal cytogenetics evolution (i.e., the presence of cytogenetic abnormalities other than the Philadelphia chromosome);
89311108|NCT03895671|Experimental|MBC-CML|Patient with Philadelphia chromosome positive CML in myeloid blast crisis is defined by the presence of ≥ 30% blasts in the bone marrow and/or peripheral blood or the presence of extramedullary disease.
89311109|NCT01151319|Experimental|Stage 1.|The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).
89311110|NCT01151319|Experimental|Stage 2|The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.
89311111|NCT01151319|Experimental|Stage 3|Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.
89311112|NCT01151319|Experimental|Stage 4|Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).
89311113|NCT01151319|Placebo Comparator|Stage 2 Placebo|Time-course matched to vaccinations (n=2)
89311114|NCT01151319|Placebo Comparator|Stage 3 placebo|Time-course matched to vaccinations (n=2)
89311115|NCT01151319|Placebo Comparator|Stage 4 placebo|Time-course matched to vaccinations (n=2)
89311116|NCT03891069|Experimental|Interventional arm|Participants will be invited to play the five different Exergames, for a total of 5 minutes.
89311117|NCT03895437|Experimental|TOL-3021|TOL-3021 2 mg/mL
89311118|NCT03895437|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
89311119|NCT03895125|Experimental|[year1] PD group|
89311120|NCT03895125|Active Comparator|[year1] healthy control group|
89311121|NCT03895125|Experimental|[year2-3] freezer|
89311122|NCT03895125|Experimental|[year2-3] non-freezer|
89311123|NCT01154595|Active Comparator|Food-for-Training component|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
89311124|NCT01154595|Experimental|Food-for-Training + RUF (Plumpy Doz(r))|"Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.~In addition, a blanket supplementation with 47g RUF (Plumpy Doz(r)) per day per child is provided."
89311125|NCT01152723|Experimental|UNG-GA|New NRT product
89311126|NCT01152723|Experimental|UNG-GB|New NRT product
89311127|NCT01152723|Active Comparator|Nicorette® Gum|Nicorette® Gum
89311128|NCT01260909||Real-time kV/MV Prostate Imaging|
89311129|NCT01259505|Experimental|Safety|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
89311130|NCT01260987|Active Comparator|AK split-face treatment|Split-face treatment of two symmetrical areas with moderate to severe actinic keratoses. One area is treated with conventional PDT the other with fractional laser assisted PDT.
89311131|NCT01260987|Active Comparator|Fractional laser assisted PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is pretreated with fractional CO2 laser followed by methyl-aminolevulinate PDT.
89311132|NCT01260987|Active Comparator|Konventional PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is treated with methyl-aminolevulinate PDT.
89311133|NCT01257867|Experimental|Lithia spring water|Lithia water (active) for 4 weeks then placebo water for 4 weeks
89311134|NCT01257867|Placebo Comparator|Natural spring water|Placebo water for 4 weeks then lithia water (active) for 4 weeks
89311135|NCT03338972|Experimental|Treatment (chemotherapy, BCMA CAR-T cells) at dose level 1|"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).~Arm 1 contains patients treated as dose level 1 (50 x 10^6 EGFRt cells)"
89311136|NCT03338972|Experimental|Treatment (chemotherapy, BCMA CAR-T cells) at dose level 2|"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).~Arm 2 contains patients treated as dose level 2 (150 x 10^6 EGFRt cells)"
89311137|NCT03338972|Experimental|Treatment (chemotherapy, BCMA CAR-T cells) at dose level 3|"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).~Arm 3 contains patients treated as dose level 3 (300 x 10^6 EGFRt cells)"
89311138|NCT03338972|Experimental|Treatment (chemotherapy, BCMA CAR-T cells) at dose level 4|"Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).~Arm 4 contains patients treated as dose level 4 (450 x 10^6 EGFRt cells)"
89311139|NCT01151397|Active Comparator|Peg + Vitamin D + Ribavirin|Peg + Vitamin D + Ribavirin for 3 months
89311140|NCT01151397|Active Comparator|Peg + Ribavirin|Peg + Ribavirin for 6 months
89311141|NCT03890757||serratus anteriorblock|Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe
89311142|NCT03890835|Active Comparator|Mineral Trioxide Aggregate (MTA)|
89311143|NCT03890835|Experimental|Biodentine|
89311144|NCT03887325|Active Comparator|Maxipost|
89311145|NCT03887325|Placebo Comparator|Saline|
89311146|NCT01152801|Experimental|RAD001|
89311147|NCT05211518|Other|Tasty&Healthy|Tasty&Healthy intervention: subjects will receive dietary advice to exclude pro-inflammatory dietary components
89311148|NCT05211518|Other|Habitual diet|Habitual diet: subjects will continue their habitual diet.
89311149|NCT03887247|Active Comparator|E-Mail Alert|Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.
89311150|NCT03887247|No Intervention|As-Usual|As-usual (no email) approach.
89311151|NCT05100524|Experimental|Motivational interview|8 motivational interviews were conducted with the intervention group.
89311152|NCT05100524|Active Comparator|Control Group|No application was made to increase physical compliance and improve quality of life.
89311153|NCT03887169|Experimental|Methionine|
89311154|NCT01257945|Experimental|Flexibility & Function|Subjects take part in an exercise program based on flexibility and function.
89311155|NCT01257945|Experimental|Aerobic Exercise|Subjects will take part in an aerobic exercise program
89311156|NCT01257945|Other|Home exercise|Standard of care home exercise program
89311157|NCT03638882|Experimental|Duolingo Spanish Course|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
89311158|NCT03638882|Active Comparator|BrainHQ|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
89311159|NCT03638882|Placebo Comparator|Passive Control|No intervention.
89311160|NCT01258023|Experimental|transplant recipients|Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation
89311161|NCT01586325|Experimental|Panel 1|Study participants will receive double-blind treatment with JNJ-47910382 30 mg or matching placebo. Participants in each of Panel will be treated sequentially (ie, participants in Panel 1 will be treated before participants in Panel 2, participants in Panel 2 will be treated before participants in Panel 3).
89311162|NCT01586325|Experimental|Panel 2|Study participants will receive double-blind treatment with JNJ-47910382 90 mg or matching placebo. Participants in each of Panel will be treated sequentially.
89311163|NCT01586325|Experimental|Panel 3|Study participants will receive double-blind treatment with JNJ-47910382 200 mg (maxiumum dose) or matching placebo. Participants in each of Panel will be treated sequentially.
89311164|NCT03890523|Experimental|Segmented Airway Stent for Gastro-Respiratory fistula|Segmented covered metallic airway stent modified with 3D printing was used for gastro-respiratory fistula.
89311165|NCT01586481|Active Comparator|barouk|
89311166|NCT01586481|Experimental|sanidiab|
89311167|NCT03886779|Active Comparator|Prolensa (Bromfenac Ophthalmic Solution) 0.07%|Bausch and Lomb, Rochester, NJ Dose: Subjects will instill one drop into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one days prior to surgery (Day 1), continue on the day of surgery plus 1 hour before surgery and for 14 days after surgery.
89311168|NCT03886779|Active Comparator|Ilevro® (nepafenac ophthalmic suspension ) 0.3%|Alcon Laboratories, Inc., Fort Worth, TX Dose: Subjects will instill one drop of test article into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one day prior to surgery (Day 1), continue on the day of surgery plus1 hour before surgery and for 14 days after surgery.
89311169|NCT01152879||Home Parenteral Nutrition|Patients receiving home parenteral nutrition
89311170|NCT03887013|No Intervention|CHD routine therapy|Patients with CHD will be treated with evidence-based therapy including antiplatelet drugs,beta-blockers,statins,angiotensin-converting enzyme inhibitor (ACEI),nitrates,etc. Percutaneous coronary intervention (PCI) could be performed if needed.
89311171|NCT03887013|Experimental|CHD routine therapy+Trimetazidine|Apart from the drug and PCI therapy mentioned above,patients will be given treatment of trimetazidine.
89311172|NCT01259583|Experimental|CO2|CO2 insufflation instead air insufflation in unsedated colonoscopy
89311173|NCT01259583|Experimental|Warm Water irrigation|warm water irrigation during the insertion phase of colonoscopy
89311174|NCT01152957|Experimental|Community Health Worker Model|Care, Attention, Resources, Information, Nutrition and Optimism Project (CARIÑO Project) will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
89311175|NCT01152957|Active Comparator|Enhanced Usual Care|Usual Care and mailing of 4 health education brochures over the year.
89311176|NCT03886935||Fontan patients|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
89311177|NCT03886935||Healthy biventricular controls|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
89311178|NCT03890055|Experimental|Clinical trial group|（Carboplatin/cisplatin + etoposide）+ （Anlotinib Hydrochloride 12 mg/day ，Each cycle was defined as 2 weeks on-treatment fol- lowed by 1 week off-treatment）, after 4-6 cycles of treatment, the treatment was continued with anlotinib until disease progression.
88813689|NCT03001193|Experimental|DF01 medium dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in medium dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
89311179|NCT01589679|Other|control/ standard of care|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Control subjects will be treated with the Standard of Care during the first 12 weeks, but after the 12 weeks patients will be fit with MTP, which delivers a low-load, prolonged-duration stretch after completion of this study.
89311180|NCT01589679|Experimental|Dynasplint|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Experimental subjects will be immediated treated with the Metatarsal Dynasplint, which delivers a low-load, prolonged-duration stretch for 60 minutes, three times per day.
89311181|NCT01259661|Experimental|Experimental Group|
89311182|NCT01259661|Active Comparator|Control Group|
89311183|NCT03894579|Experimental|SNK01|SNK01 infused weekly for 4 consecutive weeks
89311184|NCT01261299|Experimental|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
89311185|NCT01261377|Active Comparator|Bi-level positive airway pressure (BPAP)|bi-level will be titrated to optimize oxygenation and ventilation.
89311186|NCT01261377|Active Comparator|Nocturnal oxygen|oxygen will be provided as per standard of care.
89311187|NCT01261377|Active Comparator|Continuous positive airway pressure|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
89523413|NCT03376607|Experimental|Intervention group 1|Intervention group 1 will receive access to the newly-established HBCP programme.
89523414|NCT03376607|Experimental|Intervention group 2|Intervention group 2 will receive access to the newly-established HBCP programme, and facilitated access to a mobile health application.
89311188|NCT03890211|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, the mother will be encouraged to provide KMC whenever possible. For hypothermic infants, if the temperature is not rising by ½°C per hour with KMC alone, the Infant Warmer will be offered as an addition. In these cases, the heat will be provided by placing the Infant Warmer over the infant's back while the mother provides KMC. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the Infant Warmer by being placed directly on the warmer as it lies flat. Use of hat and socks will be encouraged by additional clothes will only be added in addition to the warmer per caregiver request, as it reduces heat transfer.
89311189|NCT03890211|No Intervention|Control|Data such as infant temperature, date of birth, etc. will be collected from those who enroll in the control group. No experimental intervention will be administered.
89311190|NCT03889821|Active Comparator|Child-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM).
89311191|NCT03889821|Experimental|Child- and Parent-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM). Parents also participate in 6 separate, individual sessions of Mindfulness Based Stress Reduction (MBSR).
89311192|NCT03889977|Experimental|Exercise|Resistance exercise 45 min following breakfast
89311193|NCT03889977|No Intervention|Control|No exercise (resting) following breakfast
89311194|NCT01261455|Active Comparator|Superior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from superior conjunctival tissue.
89311195|NCT01261455|Experimental|Inferior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from inferior conjunctival tissue.
89311196|NCT01153113|Experimental|Treatment Arm A|• 5x106 cells per infusion administered ID
89311197|NCT01153113|Experimental|Treatment Arm B|• 1x107 cells per infusion administered ID (Treatment arm B).
89311198|NCT03887091|Experimental|Postwire© Virtual Education Cohort|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility.~In randomized into the Virtual Education Cohort:A video based, personalized web page will be created that has information related to the participants therapeutic clinical trial.~This web page will have videos of a research nurse explaining how to take study medication(s), how to fill out the study drug diary, and a description of the main side effects associated with the study drugs.~Clinic Visit Video Recording Cycle 1-4/Day 1~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7"
89311199|NCT03887091|No Intervention|No Video Intervention|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility~Participants randomized to the control cohort will follow standard of care procedures involving clinic visits that do not include the use of video or access to a personalized web page.~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7."
89311200|NCT01154829|Active Comparator|first choice treatment|Treatment with amisulpride
89311201|NCT01154829|Active Comparator|second choice treatment|treatment with aripiprazole
89311202|NCT01151631|Active Comparator|100% occipital nerve stimulation|Stimulation frequency and pulse width will be uniformly held constant at 60 Hz and pulse width at 450 ms. The perception and discomfort amplitude will be defined by increasing the stimulation amplitude in steps of 0.1 V. The amplitude at which the patient starts feeling paraesthesis is called the perception threshold. The threshold at which the patient does not want the voltage to be increased any further because of painful sensations is designated the discomfort threshold. 100% stimulation is defined as stimulation at 90% of the range between perception and discomfort thresholds.
89311203|NCT01151631|Sham Comparator|30% occipital nerve stimulation|30% stimulation means a stimulation level at 30% of the range between perception threshold and 100% stimulation level
89311204|NCT01153191|Experimental|Pressurized irrigation|first group-After closure of patients abdominal wall fascia, Hydrostatic irrigation with 3 liters of normal saline with Simpulse Solo irrigation system (Davol) at less than 15PSI will be applied to subcutaneous tissues prior to closure
89311205|NCT01153191|Experimental|Sub Q Antibiotic|second group of patients will receive 2mg/lg of gentamicin in 20 ml of sterile saline injected into the superficial tissues above the ABD wall fascia prior to initial incision
89311206|NCT01258179||Sepsis Group|Patients suffering from sepsis in the postoperative course after major abdominal surgery
89311207|NCT01258179||Control Group|Patients without suffering sepsis during postoperative follow up after major abdominal surgery
89311208|NCT01261533|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
89311209|NCT01259739|Experimental|Flavanol rich cocoa|(596 mg), dissolved in water, twice daily intervention
89311210|NCT01259739|Experimental|flavanol poor cocoa drink|( 13mg) dissolved in water, twice daily intervention
89311211|NCT01259817|Experimental|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
89311212|NCT01259817|Active Comparator|Aspirin|81 or 100 mg daily.
89311213|NCT01261689|Active Comparator|Epidural analgesia|Women will be allocated to the EA group. In the EA group, women are given an EA as soon as they are in labour.
89311214|NCT01261689|Other|Care as-usual pain treatment|Women will be allocated to the care-as-usual group. In this care-as-usual(restrictive) group, women receive pain relief only on their explicit request. If necessary epidural analgesia.
89523415|NCT03376607|No Intervention|Control group|The control group will receive routine practice.
88813690|NCT03001193|Experimental|DF01 high dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in high dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
89523416|NCT03125291|No Intervention|Bridges Workshop|Participants will receive a one-time, 90-minute workshop.
89311215|NCT03886623|Experimental|4-day systematic oral hygiene|The intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
89311216|NCT03886623|Other|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
89311217|NCT01261767|Experimental|Anti-IL-20|
89311218|NCT01261767|Placebo Comparator|Placebo|
89311219|NCT03886389|Experimental|Carbohydrate/intervention group|Breast cancer patients receive 2 x preoperative carbohydrate loading [PreOP(TM)] before surgery; the 1st dose 18 hours before and 2nd dose 2-4 hours before surgery.
89311220|NCT03886389|No Intervention|Control group|Breast cancer patients receive standard prep fasting procedure with nil food per os 8-10 hours before surgery, drinking tap water until 2 hours before surgery.
89311221|NCT01154907||Girls ages 10-12|"In 18 rural schools in Ugu District, South Africa. Undergoing mass-treatment provided by the Department of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
89311222|NCT01154907||Young adult women|"In rural schools in three districts, South Africa. Undergoing mass-treatment provided by the Departments of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
89311223|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency|metabolism of 30 mg alitretinoin single dose in 8 patients with Hepatic Insufficiency
89311224|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency Controls|metabolism of 30 mg alitretinoin single dose in 8 healthy controls.
89311225|NCT03886545||caregivers with shoulder pain|
89311226|NCT03886545||Healthy subjects|
89311227|NCT01261143|Experimental|BK-C-0701, diabetic neuropathy|
89311228|NCT01261143|Active Comparator|alpha lipoic acid, diabetic neuropathy, capsule|
89311229|NCT01157247|Other|Group SNI|Insertion of spinal needle with introducer
89311230|NCT01157247|Other|Group SNI+LA|Local infiltration of lidocaine was applied three minutes after insertion of spinal needle with introducer
89311231|NCT01157247|Other|Group SNI+F|Intravenous fentanyl was applied 3 min before insertion of spinal needle with introducer
89311232|NCT01157247|Other|Group SN|Spinal puncture was performed only with spinal needle without introducer, local anesthetic infiltration or intravenous fentanyl before spinal puncture.
89311233|NCT01157325|Active Comparator|Non-neuraxial analgesia|Parturients will not receive neuraxial analgesia
89311234|NCT01157325|Active Comparator|Neuraxial analgesia|Parturients will receive neuraxial analgesia
89311235|NCT01157403|Experimental|mesenchymal stem cells|To study the safety and efficacy of autologous transplantation of bone marrow mesenchymal stem cells in treatment of newly diagnosed patients with T1DM.
89311236|NCT03881787|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
89311237|NCT03881787|Active Comparator|Cetuximab|Cetuximab,Erbitux 250mg/m2 single administration
89311238|NCT03881709|Experimental|The intervention group|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
89311239|NCT03881709|No Intervention|The control group|The control group will receive a health education about prostate biopsy.
89311240|NCT01157481|Experimental|Conventional therapy plus nifedipine|
89311241|NCT01157481|Active Comparator|Conventional therapy|
89311242|NCT03894189|Active Comparator|doxapram group (GROUP D)|The patients in this group will receive loading dose of (1 mg/kg) followed by an infusion of (1mg/kg/h)
89311243|NCT03894189|Active Comparator|theophylline group (GROUP T)|the therapeutic loading dose (5mg/kg) followed by an infusion of (0.5 mg/kg/h)
89311244|NCT03894111||living patients|living patients in intersivecare unit about 28 days
89311245|NCT03894111||deceased patients|deceased patients in intersivecare unit about 28 days
89311246|NCT01151709||physicians|primary care practitioners, both family practice and internal medicine physicians from a random sample of providers nationwide
89311247|NCT01155297|Sham Comparator|Control Group|At the control group, with 34 subjects, will be performed stretching and metabolic exercises. This group will make the assessments before and the reassessments after the end of the program.
89311248|NCT01155297|Active Comparator|Training group|At the training group, with 34 subjects, will be performed stretching, physical training and resistance. This group will make the assessments before and the reassessments after the end of the program.
89523417|NCT03125291|Experimental|Bridges 4-week Program|Parents and adolescents will attend separate 1.25-hour groups simultaneously and then meet together for 45 minutes. Group meetings will be conducted at the school once per week for four weeks. Each week will cover a different topic. The parent program will focus on positive parenting and goal setting, parent-adolescent relationship strengthening, behavior management, and monitoring. The adolescent program will focus on personal goals and motivation, emotion regulation, cognitive control, and adaptive coping.
89311249|NCT03886311|Experimental|Talimogene laherparepvec, Nivolumab and Trabectedin|"This is an open label phase 2 study using known doses of TALIMOGENE LAHERPAREPVEC injected intratumorally, and NIVOLUMAB AND TRABECTEDIN given intravenously.~A total of 40 previously untreated and treated patients will receive TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks, NIVOLUMAB 240 mg IV over 30 min q 2 weeks and TALIMOGENE LAHERPAREPVEC intratumorally q 2 weeks according to tumor size (see Schematic of Study Design and Imlygic product information; www.accessdata.fda.gov). Patients in this study may continue treatment until significant disease progression (see below for criteria for discontinuation of therapy) or unacceptable toxicity occurs up to one year of therapy."
89311250|NCT01155453|Experimental|BKM120 + GSK1120212 DE|Dose Escalation
89311251|NCT01155453|Experimental|BKM120 + GSK1120212 NSCLC patients|Advanced RAS or BRAF mutant NSCLC patients
89311252|NCT01155453|Experimental|BKM120 + GSK1120212 ovarian cancer patients|Advanced RAS or BRAF mutant ovarian cancer patients
89311253|NCT01155453|Experimental|BKM120 + GSK1120212 pancreatic cancer patients|Advanced RAS or BRAF mutant pancreatic cancer patients
89311254|NCT01262079||Group 1: 6-15 years old|
89311255|NCT01262079||Group 2: 16-25 years old|
89311256|NCT01262079||Group 3: 26-35 years old|
89311257|NCT01262079||Group 4: 36-45 years old|
89311258|NCT01262079||Group 5: 46-55 years old|
89311259|NCT01262079||Group 6: 56-65 years old|
89311260|NCT01262079||Group 7: 66-75 years old|
89311261|NCT01262079||Group 8: 76-85 years old|
89311262|NCT01262079||Group 9: > 85 years old|
89311263|NCT01262157|Sham Comparator|placebo|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
89311264|NCT01262157|Active Comparator|Shock wave therapy|12 treatment sessions twice a week during 9 weeks with an interim of 3 weeks no treatment
89311265|NCT03886233||Traditional Treatment for Autoimmune uveitis|Corticosteroids are considered the gold standard in management of acute AU. They can only be administered after excluding infectious origin. Their use for prolonged time and/ or in high doses may be associated with serious adverse events . Therefore, it is necessary to combine them with other immunosuppressive drugs.Based on their mechanism of action, immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus).Dosage form, dosage, frequency and duration differ according to age and case severity.
89311266|NCT03886233||Biological Treatment for Autoimmune uveitis|Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. In many cases, these agents will be seen listed as first choice in some autoimmune diseases, depending on the patient's history, age, sex, type and severity of the inflammatory disease.
89311267|NCT03885843|Experimental|RDN Group|renal nerve stimulation, mapping and denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator after renal angiography.
89311268|NCT03885843|Sham Comparator|Sham Group|renal artery angiography group, without any renal nerve stimulation, mapping or denervation
89311269|NCT03885687|Experimental|Exercise with Music Intervention|The Exercise with Music intervention is a recorded exercise playlist, which is tailored to a patient's individual physical abilities and music choices.
89311270|NCT03885687|Active Comparator|Active Control Group|The active control group will receive exercise brochure and will be advised to exercise at least twice daily.
89311271|NCT03885609|Experimental|Treatment - toothwave brush|Subjects using the Silk'n ToothWave RF utilizing toothbrush
89311272|NCT03885609|Sham Comparator|Control - powered toothbrush|Subject using a regular powered toothbrush with no RF.
89311273|NCT01265355|Experimental|Anti-rotavirus protein|
89311274|NCT01265355|Placebo Comparator|Maltodextrin|
89311275|NCT03885453||Panic Disorder / Agoraphobia|Patients with Panic Disorder / Agoraphobia as major diagnosis
89311276|NCT03885453||Depression|Patients with Depression as major diagnosis
89311277|NCT03885219|Experimental|nab-paclitaxel and S-1|chemotherapy of Nab-Paclitaxel and S-1, repeat 21 days for up to 8 cycles. The following treatment including pancreatectomy, continuing same chemotherapy, S-1 maintenance therapy, or radiotherapy will be decided after discussion between physicians and patients.
89311278|NCT01263951|Experimental|Everolimus and sorafenib|All patients will receive everolimus and sorafenib daily.
89311279|NCT01265433|Experimental|WT-1-vaccine Montanide + GM-CSF|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
89311280|NCT01265433|Active Comparator|Montanide adjuvant + GM-CSF (This arm is closed)|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
89311281|NCT01159509||Infants ages -13 years that had HPS in infancy|
89311282|NCT02527473|No Intervention|Standard Education Group|Control group will receive standard basic life support training for one hour.
89311283|NCT02527473|Experimental|HEROS Group|HEROS group will receive the dispatcher-assisted basic life support training that includes standardized video-based CPR education, interactive role-playing with the dispatcher as well as group discussion for one hour.
89311284|NCT01264029|Experimental|Group A|Movement meditation for 2 hours
89311285|NCT01264029|Active Comparator|Group B|Non-moving sitting meditation for 2 hours
89311286|NCT01264029|Active Comparator|Group C|Mall Walking for 2 hours
89311287|NCT01264029|Active Comparator|Group D|Weekly Discussion
89311288|NCT03881475||healthcare workers|Participants will participate in several sessions where they will complete the questionnaires. The questionnaires will be spaced: 0, 1 week, 6 months, 1 year and then at each occupational visit within 5 years.
89311289|NCT03885063|Experimental|Benjamin Rose Institute Care Consultation (BRI-CC)|
89311290|NCT03885063|No Intervention|No intervention|
89311291|NCT01265589|Placebo Comparator|I=surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
89311292|NCT01265589|Experimental|II=surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
89311293|NCT01159587||Group 1|
89311294|NCT01159587||Group 2|
89311295|NCT05667051||Controlled type 2 diabetes mellitus|
89311296|NCT05667051||Diabetes mellitus free patients|
89311297|NCT03885297||Overweight/obese participants|Patients will be recruited prospectively from the weight management and Polycystic Ovary Syndrome (PCOS) clinics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust following discussion with their treating physician, who will also be a member of the research team and joint agreement on initiation of treatment with 3mg Liraglutide once daily as per clinical management plan. Patients will additionally receive standard NHS Tier 3 lifestyle advice and support for the duration of the study. Lifestyle modification aimed at weight loss will be delivered by a dietician or other trained health care professional within individual sessions for a period of 6 months. Finally, all patients will be able to withdraw from treatment and/or the study at any point without giving any explanation. This will have no impact in their clinical management.
89311298|NCT01265745|Active Comparator|Valortim|Valortim 1mg,5mg,10mg
89311299|NCT01265745|Placebo Comparator|Placebo|Saline solution will be used as the placebo
89311300|NCT03881397|No Intervention|Control (Track B assessed at Time 2)|A survey regarding tech use, health behaviors and well-being including physical activity, anxiety, and sleep
89311301|NCT03881397|Experimental|Online Family Media Use Plan (Track A)|The Online Family Media Use Plan group will receive a link to American Academy of Pediatrics Family Media Use plan at the end of the survey, which describes internet safety ideas for teens and parents to review and create together.
89311302|NCT03881397|Experimental|Media Use Resources Awareness (Track B assessed at Time 3)|Resources offered to parents and teens that include tools and data for safe technology use among teens
89311303|NCT01155609|Experimental|Supportive care (oral complications management)|Patients receive L-Lysine PO QD until completion of radiotherapy and resolution of mucositis in the absence of disease progression or unacceptable toxicity.
89311304|NCT03879213|Experimental|Active|freeze-dried red raspberry powder (25 g) in active breakfast meal
89311305|NCT03879213|Placebo Comparator|Placebo|Placebo breakfast
89311306|NCT01159821|Experimental|001|31001074/paroxetine 1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
89311307|NCT03881319|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
89311308|NCT03881319|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
89311309|NCT03881319|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
89311310|NCT01265979||GIST treated with regorafenib/placebo|patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo
89311311|NCT03884751|Experimental|CAR-GPC3 T Cells|The subjects are enrolled into 2 dose levels cohorts in sequence
89311312|NCT03885141|Placebo Comparator|Men - Placebo|Men - Placebo, 1 tablet if a wake up occurs
89311313|NCT03885141|Experimental|Men - Zolpidem 1.75 mg|Men - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
89311314|NCT03885141|Experimental|Men - Zolpidem 3.5 mg|Men - Zolpidem 3.5 mg, 1 tablet if a wake up occurs
89311315|NCT03885141|Placebo Comparator|Women - Placebo|Women - Placebo, 1 tablet if a wake up occurs
89311316|NCT03885141|Experimental|Women - Zolpidem 1.0 mg|Women - Zolpidem 1.0 mg, 1 tablet if a wake up occurs
89311317|NCT03885141|Experimental|Women - Zolpidem 1.75 mg|Women - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
89311318|NCT03879057|Experimental|Surufatinib 200mg/JS001 240mg|Surufatinib at a dose of 200mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
89311319|NCT03879057|Experimental|Surufatinib 300mg/JS001 240mg|Surufatinib at a dose of 300mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
89311320|NCT01155687||Psychosocial counseling|the group received annualized treatment of psychosocial counseling
89311321|NCT01155687||Medication|this group received medical treatment by the local medical doctor
89311322|NCT03880773|Experimental|Stapler|
89311323|NCT03880773|Active Comparator|ultrasonic shears|
89311324|NCT03878901|Sham Comparator|control group|Cotton Blanket Warming (CBW) starts 30 min preoperatively and then continues throughout the entire operation.
89311325|NCT03878901|Experimental|warm group|"Warm according to different hypothermia risk for low risk ---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) continues throughout the entire operation.~moderate risk---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) and fluid warming continues throughout the entire operation.~high risk ----Forced-air warming(FAW) starts at least 30 min preoperatively, FAW and fluid warming continues throughout the entire operation."
89523418|NCT03125369|Experimental|Duodenojejunal bypass|patients receive sleeve gastrectomy plus duodeno-jejunal bypass
89523419|NCT03125369|Active Comparator|Roux-en-Y gastric bypass|patients receive roux-Y gastric bypass
88820834|NCT05592678|Active Comparator|Predicted Responders|Group assignment determined by a response predictor algorithm derived from remotely acquired caregiver reports of cognitive performance.
88820835|NCT05592678|Active Comparator|Predicted Non-Responders|Group assignment determined by a response predictor algorithm derived from remotely acquired caregiver reports of cognitive performance.
88820836|NCT05590221|Experimental|Relmacabtagene Autoleucel|Participants will receive cyclophosphamide250 mg/m^2/day intravenously (IV) and fludarabine 25 mg/m^2/day IV conditioning chemotherapy for 3 days followed by Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day 1.
88820837|NCT05586802|No Intervention|Group 1 (Fertility) - positive micro-dissection testicular sperm extraction (mTESE) biopsy 1|Men with Klinefelter syndrome seeking fertility or interested in fertility preservation that undergo mTESE biopsy after wash-out of testosterone replacement therapy and have positive sperm retrieval (detectable spermatozoids)
88821241|NCT04805333|Experimental|Dose Expansion - Recommended Phase II Dose|This cohort will be an expansion of 6 patients for further tolerability and secondary endpoints analysis. They will consume the recommended phase II dose (dependent on prior analysis).
89311326|NCT01157715|Experimental|0.5 mg cohort|patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
89311327|NCT01157715|Experimental|2.0 mg cohort|patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
89311328|NCT01266057|Experimental|Hydroxychloroquine + Sirolimus|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Sirolimus starting dose of 2 mg by mouth every day for a 21 day cycle.
89311329|NCT01266057|Experimental|Hydroxychloroquine + Vorinostat|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Vorinostat starting dose of 200 mg by mouth per day for a 21 day cycle.
89311330|NCT01262313|Sham Comparator|Control Group|"The Control group will have an hour-long meeting of instruction by a registered dietitian on using the provided A Healthier You: Everyday Healthy Eating and Physical Activity for Life book, based on the Dietary Guidelines for Americans 2005."
89311331|NCT01262313|Experimental|lifestyle counseling intervention|"This group will participate in the weekly Healthy Creations classes for 8 weeks presented by a Registered Dietitian and a certified fitness trainer. This is a community based lifestyle intervention program."
89311332|NCT01266213|Experimental|Fulvestrant plus Goserelin|
89311333|NCT01266213|Experimental|Anastrozole plus Goserelin|
89311334|NCT01266213|Active Comparator|Goserelin alone|
89311335|NCT01262391|Experimental|AD-PED 2.5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 2.5 mg of solifenacin succinate.
89311336|NCT01262391|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 5 mg of solifenacin succinate.
89311337|NCT01262391|Experimental|AD-PED 10 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 10 mg of solifenacin succinate.
89311338|NCT01262391|Experimental|CH-PED 2.5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 2.5 mg of solifenacin succinate.
89311339|NCT01262391|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
89311340|NCT01262391|Experimental|CH-PED 10 mg|Male and female children aged 5 to less than 12 years old who receive PED of 10 mg of solifenacin succinate.
89311341|NCT03884595||No SIRS|Children without clinical signs of SIRS, according to Goldstein criteria.
89311342|NCT03884595||SIRS|Children with clinical signs of SIRS, according to Goldstein criteria.
89311343|NCT03884595||Sepsis|Children with clinical signs of sepsis, according to Goldstein criteria.
89311344|NCT03884595||Severe sepsis|Children with clinical signs of severe sepsis, according to Goldstein criteria.
89311345|NCT03884595||Septic Shock|Children with clinical signs of septic shock, according to Goldstein criteria.
89311346|NCT03880851|Other|Hypofractionated image-guided radiotherapy|"Hypofractionated image-guided radiotherapy IGRT to a total dose of 60 Gy (20 fractions) is performed.~Weekly MRI are used to estimate volume/deformation changes of OAR and target volume.~Intervention: In case of a significant change of target volume or OARs (threshold based) the radiation treatment plan is adapted on individual MR-anatomy."
89311347|NCT03880695|Experimental|Anlotinib+ Liposomal Doxorubicin|Anlotinib Hydrochloride Combined With Liposomal Doxorubicin Liposomal Doxorubicin 50mg/m2 Day 1 every-3-weeks (Q3W) and Anlotinib 12mg QD po at Day 8-21 Q3W and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
89311348|NCT01159977|Experimental|Facilitated small group|Facilitated small groups.
89311349|NCT01159977|Active Comparator|Unstructured protected time|Same time provided as for facilitated small groups, but without structure.
89311350|NCT01159977|Placebo Comparator|Usual practice|No protected time.
89311351|NCT01155765|Experimental|Prasugrel|Prasugrel per os 10 mg/day
89311352|NCT01155765|Active Comparator|Clopidogrel|Clopidogrel per os 150 mg/day
89311353|NCT01155843||Asthmatic, chronic stress|
89311354|NCT01155843||Asthmatic, non-stress|
89311355|NCT01266369|Experimental|masitinib 3 mg/kg/day|masitinib 3 mg/kg/day
89311356|NCT01266369|Experimental|masitinib 6 mg/kg/day|masitinib 6 mg/kg/day
89311357|NCT01264263||1|
89311358|NCT01160055||Cohort A|Subjects with a new episode of Acute Otitis Media (<3 days of onset) who have not yet received antibiotic therapy for the episode.
89311359|NCT01160055||Cohort B|Subjects who have had a diagnosis of Acute Otitis Media within 2-3 days prior to study enrolment and received antibiotic therapy, but remain symptomatic.
89311360|NCT01157793|Experimental|Group 1|
89311361|NCT01157793|Experimental|Group 2|
89311362|NCT03880149|Experimental|Omega-3 supplementation|Omega-3 fatty supplementation and vitamin E. Each 1 g omega-3 capsule contain 600 mg omega-3 including 400 mg EPA + 200 mg DHA. Individual omega-3 dose will be determined according to the athlete's body mass, 1 g omega-3 / 15 kg body mass per day and vitamin E: 1 capsule of vitamin E (400 IU) for every five omega-3 capsules
89311363|NCT03880149|Placebo Comparator|Placebo|Medium-chain triglyceride (MCT) and vitamin E. Each MCT capsule contain 1 g, the dose will be 115 mg per kg body mass per day, and vitamin E: 1 capsule of vitamin E (400 IU) for every five MCT capsules
89311364|NCT01157871|Experimental|placebo|4 administrations at 2-week interval of placebo solution
89311365|NCT01157871|Experimental|NV1FGF 16 mg|4 administrations at 2-week interval of 4mg at each administration
89311366|NCT01157871|Experimental|NV1FGF 32 mg|4 administrations at 2-week interval of 8mg at each administration
89311367|NCT01264341|Experimental|Bevacizumab combined with temsirolimus|Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly
89311368|NCT01157949|Active Comparator|Study withdrawn|Study withdrawn
89311369|NCT01157949|Placebo Comparator|Withdrawn|Study withdrawn
89311370|NCT03884361|Experimental|Vaginal Microbiome as result of aminocentesis|aginal Microbiome as result of aminocentesis by a blood and a vaginal samples that will taken before and after the aminocentesis
89311371|NCT01589835|Experimental|Lifestyle counseling|Green prescription with facilitator support
89311372|NCT01589835|Other|Usual care|
89311373|NCT01262469|Experimental|Lapatinib + Capecitabine|lapatinib 1250 mg/day (once daily) Capecitabine 2x850 mg/m2/day, days 1-14 during the first cycle and 2x1000 mg/m2/day, days 1-14, every 21 days for following cycles ( if no unacceptable toxicity is observed).
89311374|NCT01155921|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
89311375|NCT01155921|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
89311376|NCT01160133|Experimental|Systane|Systane Lubricant Eye Drops
89311377|NCT01160133|Experimental|Refresh Tears|Refresh Tears Lubricant Eye Drops
89311378|NCT03653169|Experimental|Open-Label Active TMS|All subjects will receive open-label treatment with active Transcranial Magnetic Stimulation (TMS)
89311379|NCT03884127||hyperlipidaemia|On the basis of the intervention of therapeutic sexual life style, a case control study was conducted on the intervention of oral ezetimibe tablet and orlistat capsule for 12 weeks and hyperlipidemia patients who persisted in the use of basic treatment.
89311380|NCT03883815||Assesment treatment intensity|Assesment treatment intensity during neurodevelopmental therapy session and active video games therapy session
89311381|NCT03338816|Experimental|Givosiran/Givosiran|Givosiran 2.5 mg/kg administered subcutaneously (SC), monthly (QM), for 6 months during the 6-Month Double-blind (DB) Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the Open-label Extension (OLE) Period.
89311382|NCT03338816|Placebo Comparator|Placebo/Givosiran|Matching placebo (normal saline [0.9% NaCl]) was administered SC, QM, for 6 months during the 6-Month DB Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the OLE period.
89311383|NCT02527395|Other|Clinical pain models|Brief thermal sensitization. Heat pain detection threshold. Pain during 1 min. thermal stimulation
89311384|NCT03883971|Experimental|3D model|patient is given 3D printed model of her fetus's face
89311385|NCT03883971|Placebo Comparator|picture|patient is given a fetal picture only.
89311386|NCT01158027||children|
89311387|NCT03880071|Experimental|DBT + ACT group|- The experimental group (DBT+ ACT) led in Montpellier during 6 months.
89311388|NCT03880071|Other|DBT group|The control group (DBT) led in Geneva during 12 months.
89311389|NCT01158105|Experimental|Bortezomib|1.6 mg/m2 intravenous infusion will be administered on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles. Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles. This maintenance dose will be administered on days 1 and 15.
89311390|NCT03337490|Experimental|Ivermectin 0.5% Lotion|Ivermectin 0.5% lotion, topical, 117g, single dose
89311391|NCT03337490|Active Comparator|Ivermectin 0.5% Lotion [SKLICE]|Sklice 0.5% Lotion, topical, 117g, single dose
89311392|NCT03337490|Placebo Comparator|Placebo 0% Lotion|0% lotion, 117g, single dose
89311393|NCT01158183||Group 1|No intervention
89311394|NCT01264575|Experimental|BPV6E1|
89311395|NCT01264575|Experimental|BPV7E1|
89311396|NCT01264575|Experimental|BPV8E1|
89311397|NCT01264575|Experimental|BPV9E1|
89311398|NCT01264575|Experimental|BPV10E1|
89311399|NCT01264575|Experimental|BPV11E1|
89311400|NCT01264575|Experimental|BPV6E2|
89311401|NCT01264575|Experimental|BPV7E2|
89311402|NCT01264575|Experimental|BPV8E2|
89311403|NCT01264575|Experimental|BPV9E2|
89311404|NCT01264575|Experimental|BPV10E2|
89311405|NCT01264575|Experimental|BPV11E2|
89311406|NCT05000528|Experimental|Therapeutic education|
89311407|NCT05000528|Active Comparator|Individualized consultation|
89311408|NCT04999280|Experimental|Fiber Croissant (FIBCRO) Group|Daily consumption at breakfast for 2 weeks of a fiber-enriched croissant
89311409|NCT04999280|Active Comparator|Control Croissant (CONCRO) Group|Daily consumption at breakfast for 2 weeks of a control croissant
89311410|NCT03879993|Experimental|Exercise group|Exercise group was resistance training three times per week, during 45 to 60 minutes per day. Training program was composed by bench press, leg press 45°, lat pulldown, knee extension, dumbbell lateral raise, horizontal leg curl, triceps pulldown, seated calf raise, biceps curls and abdominal. Participants should complete 3 series with 8-12 repetitions of each exercise, which was supervised by trained research personnel. There were 60 seconds of interval between series and exercises were separated by a 120 seconds recovery period.
89311411|NCT03879993|No Intervention|Control group|Control group was not do any exercise during intervention period. Participants was asked to keep their habitual routine until finish the final evaluations.
89311412|NCT05309174|No Intervention|General anesthesia group|Patients received general anesthesia.
89311413|NCT05309174|Experimental|General anesthesia combined laryngeal nerve block|Group L received ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine, along with general anesthesia.
89311414|NCT01312532|Other|fixed-bearing|fixed-bearing device is a kind of prosthesis
89311415|NCT01312532|Other|mobile-bearing|mobile-bearing device is a kind of prosthesis
89311416|NCT01266681|Active Comparator|Amiodarone|this group will be given Amiodarone to maintain sinus rhythm powst cardioversion.
89311417|NCT01266681|Active Comparator|Dronedarone|this group will be given dronedarone to maintain sinus rhythm post DC cardioversion
89311418|NCT03638648|Active Comparator|Low risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk receiving capecitabine.
89311419|NCT03638648|No Intervention|Low risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk NOT receiving any additional chemotherapy.
89311420|NCT03638648|Experimental|High risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk receiving capecitabine.
89311421|NCT03638648|No Intervention|High risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk NOT receiving any additional chemotherapy.
89311422|NCT01266759|Experimental|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
89311423|NCT01266759|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
89311424|NCT05174936|Experimental|PLWH intervention sessions|The PLWH in this arm will receive five 2-hour intervention sessions delivered over five weeks (one session per week) in the clinics. Two trained facilitators will deliver the materials through interactive trainings that include multimedia presentations, group discussions, role-play, personal testimonies, and/or games. The same two facilitators will deliver all five sessions within a clinic to increase group cohesion and rapport with PLWH. The goal of this intervention is to assist PLWH in identifying and developing internal and external resilience resources to aid in coping HIV stigma.
89311425|NCT05174936|Experimental|Family member intervention|The intervention sessions for family members will be similar to PLWH sessions in terms of format and content and will be led by trained facilitators. Family member intervention sessions will emphasize supporting PLWH to cope with HIV-related stigma and to improve their clinical outcomes. The goal of this intervention is to provide social support for PLWH's resilience building as well as foster resilience at the family level.
89311426|NCT05174936|Experimental|Health care provider intervention|The HCP intervention curriculum consists of four 1.5-hour sessions (e.g., one per week) that will be delivered in small groups in the clinic setting by trained facilitators (e.g., health educators from Guangxi CDC). The delivery schedule and format will be flexible and individually tailored (e.g., four sessions can be given one per week or consolidated into two longer sessions). The goal of this intervention is to reduce the institutional stigmatizing attitudes and practices toward PLWH and other social identities, such as MSM, sex workers, and drug users, and improving the provider-patient relationships.
89311427|NCT03884205||test group|patients with PTCL who receive GDPE/CEOPE as the first-line therapy strategy
89311428|NCT03884205||control group|patients with PTCL who receive CEOPE as the first-line therapy strategy
89311429|NCT03707990|Experimental|NNC0165-1875|Participants will receive NNC0165-1875 alone in cohorts 1-5 (part 1) and NNC0165-1875 along with semaglutide in cohorts 6-11 (part 2).
89311430|NCT03707990|Placebo Comparator|Placebo|Participants will receive placebo alone in cohorts 1-5 (part 1) and placebo along with semaglutide in cohorts 6-11 (part 2).
89311431|NCT03883737|Experimental|Group 1: PNM in pain knee|participants in whom PNM will be applied to the femoral nerve of the pain knee
89311432|NCT03883737|Experimental|Group 2: PNM in non-pain knee|participants in whom PNM will be applied to the femoral nerve of the non-pain knee
89311433|NCT01158339|Active Comparator|Arm 1: CBGT|Cognitive Behavioural Group Therapy (CBGT)
89311434|NCT01158339|Experimental|Arm 2: CBGT-ISE|Cognitive Behavioural Group Therapy, with in-Session Exposure (CBGT-ISE).
89311435|NCT01262703|Experimental|REVA Medical ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
89311436|NCT03878667|Placebo Comparator|No Diet|No diet or exercise or calcium intervention
89311437|NCT03878667|Experimental|High Calorie Diet|High calorie (2,600 calorie) diet and exercise and calcium
89311438|NCT03878667|Experimental|Low Carbohydrate/High Protein Diet|Low carbohydrate (63% protein, 7% carbohydrate, 30% fat) diet and exercise and calcium
89311439|NCT03878667|Experimental|High Carbohydrate/Low Protein|High carbohydrate (15% protein, 55% carbohydrate, 30% fat) diet and exercise and calcium
89311440|NCT03883425||Case 1: formal home service recipients|Adults aged 65 or older living at home who receive formal home service (household, meal delivery, transportation, shopping) at least one a week
89311441|NCT03883425||Case 2: formal home care recipients|Adults aged 65 or older living at home who receive formal home care (shower/bath nursing assistance, nursing care) at least once a week
89311442|NCT03883425||Control: free of formal home care or home service|Adults aged 65 or older living at home who do not receive formal home care or home service.
89311443|NCT04958954||Cohort 1a: Pre-COVID|All participants meeting eligibility criteria in the Pre-COVID-19 period (immediately preceding the emergence of COVID-19) (Time Period 1) from 01 December 2018 to 30 November 2019
89311444|NCT04958954||Cohort 1b: Pre-COVID|All participants with evidence of an influenza vaccination and meeting eligibility criteria in the Pre-COVID-19 period (immediately preceding the emergence of COVID-19) (Time Period 1) from 01 December 2018 to 30 November 2019
89311445|NCT04958954||Cohort 2: Active-COVID|All participants meeting eligibility criteria in the Active-COVID-19 period, Pre-Emergency Use Authorization (EUA) period (following the emergence of COVID-19 but before the first COVID-19 vaccine EUA) (Time Period 2) from 01 December 2019 to 10 December 2020 (1 day prior to first United States SARS-CoV-2 vaccine EUA)
89311446|NCT04958954||Cohort 3: Post-EUA|All mRNA-1273 vaccinated participants meeting eligibility criteria in the Post-EUA period (Time Period 3) from date of first United States SARS-CoV-2 vaccine EUA to 31 December 2022
89311447|NCT01264653|Experimental|experimental group,control group|Intraocular adrenalin,topical mydriatics, experimental group: Intervention: Procedure:refractive cataract surgery with Intraocular adrenalin, control group:refractive cataract surgery with topical mydriatics
89311448|NCT01266837|Other|single arm|Treatment with Everolimus
89311449|NCT01264731|Active Comparator|peptide vaccine plus imiquimod|Peptide Vaccine: Days 1, 8, 15, 36, 57, 78 Imiquimod: Applied daily on days 1-85.
89311450|NCT01264731|Active Comparator|Imiquimod|Imiquimod: Applied daily on days 1-85.
89311451|NCT01586559||Control group|Nulliparous women
89311452|NCT01586559||Diastasis|Patients after rectus sheath plication due to diastasis
89311453|NCT01264809|Experimental|A : immediate physical activity counseling|Participants randomized in the experimental group (group A) will receive physical activity counseling during a one-to-one consultation at both baseline and 3 months.
89311454|NCT01264809|Active Comparator|B : later physical activity counseling|Exercise consultation will be realised only at 3 months in the control group(group B). Furthermore, patients of group B will not received any physical activity counseling at baseline.
89311455|NCT05308706|Experimental|Commercial Apollo System Device|The active experimental group received the commercial Apollo System device.
89311456|NCT05308706|Sham Comparator|Sham Apollo System Device|The control experimental group received a sham/placebo device that is identical to the commercial Apollo System device but uses an ultra-low (i.e., effectively zero) frequency pattern of vibrations.
89311457|NCT03878511|Experimental|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
89311458|NCT03878511|Placebo Comparator|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
89311459|NCT03879837|Experimental|Investigational Test Product|Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation
89311460|NCT03879837|Active Comparator|Reference Listed Drug|Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation
89311461|NCT03879837|Placebo Comparator|Placebo|Placebo pressurized metered dose inhaler, no active content
89311462|NCT05308628|Active Comparator|Post-Transplant-Liver Allograft Fibrosis|
89311463|NCT05308628|Sham Comparator|Post-Transplant-Liver Allograft regular recovery|
89311464|NCT05308550|Other|Phase 1|"Version 1 of the rapid test:~The clinician taking the nasopharyngeal / oropharyngeal swab for standard PCR testing for Covid-19 collected a second swab directly afterwards for the rapid RNA test. The swab was placed in a dry tube, labelled with the patient's ID, date and time of taking the sample, and was taken to the microbiology laboratory for processing.~In the laboratory, 2ml of RNase-free water was added to the tube and shaken with the swab. Twenty-five microlitres of the swab solution was transferred into a PCR tube containing the dried reagents for the rapid RNA test. This tube was then incubated for 45 minutes at 65'C, then taken out to cool down. The colour of the tube was recorded by the laboratory technician."
89311465|NCT05308550|Other|Phase 2|"Version 2 of the rapid test:~The clinician taking the nasopharyngeal / oropharyngeal swab for standard PCR testing for Covid-19 collected a second swab directly afterwards for the rapid RNA test. The swab was placed in a tube containing 1ml of normal saline (instead of a dry tube). If the patient was eligible but the standard swab had already been taken >12 hours before, we asked them for their consent to take a second standard swab alongside the swab for the rapid RNA test, to ensure that the samples were comparable.~In the laboratory, the swab was heated to 95'C for 5 minutes to inactivate the virus. Nine ml of RNase-free water was added to the tube and shaken with the swab, before transferring 25ul of the swab solution into the PCR tube containing the dried reagents. This tube was then incubated for 30 minutes at 65'C, then the colour of the tube was recorded and photographed by the laboratory technician at 30 minutes (primary reading) and 45 minutes (secondary reading)."
89311466|NCT01156077|Experimental|oral TR-701 FA|Single oral dose of 200 mg TR-701
89311467|NCT01156077|Experimental|IV TR-701 FA|Single IV infusion of 200 mg TR-701 FA
89311468|NCT03878433|Active Comparator|Drug|Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast
89311469|NCT03878433|Placebo Comparator|No Drug|2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo
89311470|NCT03883503|Experimental|Beer alone|Consumption of beer (correlated for weight to reach a blood alcohol concentration of 0.8) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
89311471|NCT03883503|Active Comparator|Beer and water|Consumption of beer and additional water (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of water, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
89311472|NCT03883503|Active Comparator|Beer and stock|Consumption of beer and additional stock(correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
89311473|NCT03883503|Placebo Comparator|Water alone|Consumption of water alone (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
89311474|NCT02944448|Active Comparator|CR845 tablet 1 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
89311475|NCT02944448|Active Comparator|CR845 tablet 2.5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
89311476|NCT02944448|Active Comparator|CR845 tablet 5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
89311477|NCT02944448|Placebo Comparator|Placebo tablet|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
89311478|NCT03878355|Experimental|radical endoscopic sinus surgery plus Draf 3 surgery|
89311479|NCT03878355|Experimental|radical endoscopic sinus surgery|
89311480|NCT03878355|Experimental|functional endoscopic sinus surgery|
89311481|NCT01158729|Experimental|ATIII experimental group|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive Antithrombin (Recombinant) prior to initiation of bypass
89311482|NCT01158729|Placebo Comparator|Placebo Controls|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive placebo prior to initiation of bypass
89311483|NCT03883659|Active Comparator|traditional paper hangouts group|patients use the traditional paper hangouts to conduct the home exercise program at home
89311484|NCT03883659|Experimental|smartphone group|patients use the smartphone to conduct the home exercise program at home
89311485|NCT01160367|Active Comparator|standard of care health decision making|Patient-family dyads will receive the standard of care for support of patient and family members health care decision making during a clinic appointment.
89311486|NCT01160367|Experimental|TAILORED intervention|Patients and family members who receive the TAILORED Decision Making Intervention
89311487|NCT03647943|Experimental|Active tDCS|Participants will receive 10 sessions of active tDCS + cognitive training.
89311488|NCT03647943|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of sham tDCS + cognitive training.
89311489|NCT05295914||Patient with chronic hepatitis B infection|Patient with chronic hepatitis B infection visited at liver and internal medicine clinic, Siriraj hospital between January 2015-2020
89311490|NCT01262859|Experimental|Study Intervention|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
89311491|NCT05294354|Experimental|aerobic exercise group (AE)|35-min cycling at moderate intensity (50-60% heart rate reserve).
89311492|NCT05294354|Experimental|aerobic exercise with virtual reality group (AE-VR)|35-min cycling at moderate intensity (50-60% heart rate reserve) with 3D virtual reality.
89311493|NCT05294354|Experimental|combined exercise group (CE)|This 35-min exercise combines aerobic, bodyweight exercise, and meditation.
89311494|NCT05294354|Active Comparator|control group|It has a 35-minute video about exercise science.
89311495|NCT03879759|Experimental|Arm 1|NAC - Relapse Prevention (4 wks)
89311496|NCT03879759|Placebo Comparator|Arm 2|NAC - Relapse Prevention (4 wks)
89311497|NCT01265043|Experimental|OHI|Patients provided with oral hygiene instruction and electric toothbrush
89311498|NCT01265043|Experimental|OHI + CHX mouthrinse|Patients provided with oral hygiene instruction and Corsodyl mouthrinse
89311499|NCT01265043|Experimental|OHI + CHX mouthrinse + assisted brushing|Oral hygiene instruction, Corsodyl mouthrinse, and assisted brushing
89311500|NCT05077670||Study group|"LAA + LA Map in AF~Identify LAA connections and detect rotors with CartoFinder~Electrical cardioversion. Sinus rhythm restoration~Pacing from the coronary sinus at 300 and 600ms periods~Analyze COHERENT activation maps in sinus rhythm~Ablation as suggested by current clinical guidelines and the characteristics of the patient"
89311501|NCT02527083|Active Comparator|BIA|Balanced Inhalational Anesthesia (consisting of a sevoflurane inhaled anesthestic only)
89311502|NCT02527083|Active Comparator|TIVA-K|Total intravenous anesthetic with ketamine
89311503|NCT02527083|Active Comparator|TIVA-R|Total intravenous anesthetic with remifentanil
89311504|NCT05156684|Experimental|placebo group|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
89311505|NCT05156684|Experimental|pentoxifylline group|Intervention group 1: received pentoxifylline (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily)
89311506|NCT05156684|Experimental|Zinc group|Intervention group 2: received zinc ( Zinc Sulfate 220mg Capsules,One time daily)
89311507|NCT05156684|Experimental|pentoxifylline+ zinc group|Intervention group 3: received pentoxifylline+ zinc (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily + Zinc Sulfate 220mg Capsules,One time daily )
89311508|NCT01265121|Experimental|CPAP treatment|This acromegalic patients is going to have sleep apnea treated for 3 months with a with a continuous positive air pressure device (CPAP)
89311509|NCT01265121|Placebo Comparator|Nasal adhesive|This acromegalic patients will be treated will an external nasal dilator adhesive intended to serve as a placebo treatment
89311510|NCT01159041|Experimental|Family Focused Treatment (FFT)|15 session family-based treatment emphasizing improving relationship skills to combat depression symptoms and support recovery.
89311511|NCT01159041|Active Comparator|Individual Treatment (IP)|15 session individually-based treatment to assist children in understanding the causes of their symptoms.
89311512|NCT05153642|Experimental|Microsurgical intervention|Microsurgical intervention will be used for treatment of acute symptomatic occlusion of middle cerebral artery (in M1 or M2 segment) with or without intracranial ICA occlusion in patients who failed to reach recanalization using standard treatment
89311513|NCT05153642|No Intervention|Standard treatment|Acute symptomatic occlusion of middle cerebral artery (in M1 or M2 segment) with or without intracranial ICA occlusion in patients who failed to reach recanalization using standard treatment - intravenous thrombolysis and/or mechanical thrombectomy
89311514|NCT01262937||Biliary Confocal Imaging|
89311515|NCT01262937||Esophageal Confocal Imaging|
89311516|NCT05153096|Experimental|Experimental: solid tumors|"Dose-escalation stage: Patients will receive NBL-015 once every two or three weeks, starting at a dose of 1 mg/kg.~Cohort-expansion stage: Patients will receive NBL-015 at selected dose as per the results of dose-escalation stage."
89311517|NCT03883347|Active Comparator|Group DEX|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.6 mcg / kg / h.
89311518|NCT03883347|Active Comparator|Group REMI|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.025 mcg / kg / min.
89311519|NCT05145530|Active Comparator|Group C|selective anterior cervical discectomy and fusion (ACDF)
89311520|NCT05145530|Experimental|Group SNRB|US-guided selective nerve root block (SNRB) then selective anterior cervical discectomy and fusion (ACDF)
89311521|NCT03878043||Patients without Readmissions|Patients with TSDH who were not readmitted within a 6-month time period following their initial visit.
89311522|NCT03878043||Patients with Readmissions|Patients with TSDH who were readmitted within a 6-month time period following their initial visit.
89311523|NCT01159119|Experimental|EUR-1066-A|Treatment with Eur-1006-A.
89311524|NCT01159119|Experimental|EUR-1066-B|Treatment with Eur-1066-B
89311525|NCT01159119|Active Comparator|Zenpep|Control Group: Consist of treatment with Zenpep
89311526|NCT05206994|Experimental|Close to Home Intervention|Sites receiving the intervention arm were determined prior to the initiation of the research. The rape crisis center in each community applied for funding from the California Department of Public Health to implement the Close to Home model in their community and they were accepted via a competitive application process. Close to Home (C2H) is a community mobilization model developed in Boston and adapted for California and is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms.
89311527|NCT05206994|No Intervention|Control Program|"The control program is the 4-H Youth Development Program, which is implemented across every county in California via the University of California Cooperative Extension. In 4-H programs, kids and teens complete hands-on projects in areas like health, science, agriculture and civic engagement in a positive environment where they receive guidance from adult mentors and are encouraged to take on proactive leadership roles. The model does not use community mobilization and does not address sexual violence.~Control communities were selected based on propensity score matching using sociodemographic and community-level variables related to risk for sexual violence. The closest match was recruited first, and a next-best match was used if the first match declined participation."
89311528|NCT01159197|Experimental|cognitive behaviorial therapy|
89311529|NCT01159275|Other|1|First Generic LPV/r 200/50 mg BID, then cross over to Pediatric Aluvia 200/50 mg BID
89311530|NCT01159275|Other|2|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
89311531|NCT01267071|Experimental|A|GSK962040 (50 mg, SD, oral)
89311532|NCT01267071|Experimental|B|14C GSK962040 (100 μg, SD, iv)
89311533|NCT01159353|Experimental|insulin glulisine + insulin aspart|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
89311534|NCT01159353|Experimental|insulin aspart + insulin glulisine|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
89311535|NCT02943668|Experimental|Treatment (deferasirox)|Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
89311536|NCT03879681|No Intervention|No Intervention|
89311537|NCT03879681|Experimental|Jelly Snakes|
89311538|NCT01312610|Experimental|High flavonone orange juice drink|
89311539|NCT01312610|Placebo Comparator|Control orange juice drink|Juice drink matched for sugar content
89311540|NCT01263171|Other|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy prior to short course pre-operative radiotherapy followed by adjuvant chemotherapy.
89311541|NCT05098340||AIS group|This group includes patients with acute ischemic stroke (AIS).
89311542|NCT05098340||HC group|This group includes healthy controls (HC).
89311543|NCT01156233|Experimental|Cuff palpation technique|Cuff palpation by the investigator's finger.
89311544|NCT01156233|Experimental|Withdrawing tube technique|Identification of the tube by withdrawing until good quality breath sounds
89311545|NCT03491397|Experimental|GAE OA|Subjects will be treated with a genicular artery embolization (GAE) procedure performed with Embozene Microspheres. The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the subject's pain.
89311546|NCT05166824|Experimental|Surgical- abdominoplasty|Subjects enrolled in the surgical arm were treated with the device being placed in contact with the skin on the abdomen. The hand piece, number of passes and parameters used for the treatment were determined by the Investigator.
89311547|NCT05166824|Experimental|Women's Health|Subjects enrolled in the women's health were treated with the device in the vaginal and perineal area.
89311548|NCT05166824|Experimental|Skin Rejuvenation|The hand piece, applicator or tip was placed in contact with the skin. The entire defined treatment area was treated by delivering energy to the skin. The hand piece, number of passes and parameters used for the treatment was determined by the Investigator.
89311549|NCT05166824|Experimental|Surgical- blepharoplasty|Subjects enrolled in the surgical arm were treated with the device being placed in contact with the skin on the eyelids. The hand piece, number of passes and parameters used for the treatment were determined by the Investigator.
89311550|NCT01263249|Active Comparator|Catheter Anterior to Femoral Nerve|Each subject will have one lower extremity (Right or Left) randomized to receive a perinural catheter, placed anterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
89311551|NCT01263249|Active Comparator|Catheter Posterior to Femoral Nerve|Each subject will have the opposite lower extremity (Right or Left) randomized to receive a perinural catheter, placed posterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
89311552|NCT03877731|Active Comparator|hypertrophic cariomyopathy, isolated septal myectomy|Patients with hypertrophic obstructive cardiomyopathy who will undergo isolated septal myectomy
89311553|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + edge-to-edge|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and edge-to-edge mitral valve repair (O. Alfieri technique)
89311554|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + sliding plasty|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and posterior leaflet sliding plasty ( A. Carpentier technique)
89311555|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + chordae|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and secondary chordae transection
89311556|NCT03877731|No Intervention|Arterial hypertension + left ventricular hypertrophy|Patients with arterial hypertension with left ventricular hypertrophy whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
89311557|NCT03877731|No Intervention|Control|Patients without structural heart disease whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
89311558|NCT01265277||at home|Infants 0-3 months who will stay at home with a parent
89311559|NCT01265277||child care|Infant 0-3 months who will attend a licensed child care center
89311560|NCT03883269|Experimental|Erythromycin 4%|Erythromycin 4% topical gel formulation, BID, 4 weeks
89311561|NCT03883269|Experimental|Clindamycin 1%|Clindamycin 1% topical lotion formulation, BID, 4 weeks
89311562|NCT03883269|Placebo Comparator|ethanol solution|70% topical ethanol solution, BID, 4 weeks
89311563|NCT01267305|Active Comparator|lung lmwh1|use LMWH once daily after lung resection
89311564|NCT01267305|Experimental|lung lmwh2|use LMWH twice daily after lung resection
89311565|NCT01267305|Experimental|lung Fondaparinux|use Fondaparinux once daily after lung resection
89311566|NCT01267305|Active Comparator|eso lmwh1|use LMWH once daily after esophagectomy
89311567|NCT01267305|Experimental|eso lmwh2|use LMWH twice daily after esophagectomy
89311568|NCT01267305|Experimental|eso Fondaparinux|use Fondaparinux once daily after esophagectomy
89311569|NCT01263327|Experimental|HPV 16/18|Participants in this arm would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
89311570|NCT02891408|Experimental|Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg|Participants with mild hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
89311571|NCT02891408|Experimental|Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
89311572|NCT02891408|Experimental|Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg|Participants with moderate hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
89311573|NCT02891408|Experimental|Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
89311574|NCT02891408|Experimental|Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg|Participants with severe hepatic impairment will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
89311575|NCT02891408|Experimental|Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
89311576|NCT02891408|Experimental|Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg|Participants with mild hepatic impairment will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
89311577|NCT02891408|Experimental|Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg|Matched normal hepatic function participants to mild hepatic impairment participants, will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
89311578|NCT03877107|Other|single cohort|Participants presenting at least 2/3 of symptom triad : gait disturbance, urinary symptoms and cognitive disturbance Ventricular enlargement non explained by cortical atrophy Cognitive capacity to understand the study and give informed consent (mini mental state > 13), speaking and reading french.
89311579|NCT01160757|Other|ultrasound|
89311580|NCT05121194|Active Comparator|ZOOM Video Conference Participants|Participants will be offered the opportunity to join one of two weekly meeting times. Participants will be sent a link to join a Zoom videoconference session at the outset of each week, allowing them to log in at their chosen timeslot. These meeting times will be arranged based on discussions with the PAC around optimal timeslots for their shift workers. Sessions will be 90 minutes in length and will be facilitated by a minimum of 2 trained clinician facilitators and 1 research assistant. The session will include a PowerPoint presentation of the CBTm material in a lecture format. Participants will be invited and encouraged to discuss, comment and ask questions of the facilitators about the material throughout the presentation. Homework will be assigned each session relating to the material that was covered. Participants will have 1 week to work through and practice the skills learned, and this homework will be discussed at the next session.
89311581|NCT05121194|Active Comparator|WEB Online CBTm Course Participants|Participants will receive access to the online self-guided CBTm course. The material is identical to the material taught in the facilitator-led group. Participants will receive access to the Class 1 upon joining the study at which point they can move through the material. The material is presented in a slide show format with pre-recorded audio to accompany each slide, in accordance with the material covered for in person classes. Material may be completed in a single sitting or they can choose to pause and return to it at a later time. Homework will be assigned as in Arm 1, through online forms at the end of each class. If a participant has questions, they can use a 'contact us' button, allowing questions to be sent to our research team. One week after completion of Class 1, participants will receive access to Class 2. The one-week timeframe prior to accessing the next class is used to mirror the timeline in the facilitator-led groups (Arm 1)
89311582|NCT05121194|No Intervention|WAIT participants|(WAIT) participants will be assigned to a waitlist control. These individuals will not receive any type of active intervention but will continue to receive mental health questionnaires to complete in line with the ZOOM and WEB participants at weekly intervals. These individuals will be offered a choice of videoconference CBTm or online CBTm at completion of their waitlist period (6 months).
89311583|NCT01161693|No Intervention|Standard pillow under head|Control (C) - Standard pillow under head (figure 1) as is the usual practice at BC Women's Hospital
89311584|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP|TROOP® elevation pillow (designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table)
89311585|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP-H|Operating table tilted in Trendelenberg position so angle of Troop pillow is parallel to floor (figure 3) until establishment of adequate block and then the bed levelled to horizontal i.e. to the same position as group (HERP) (figure 2)
89311586|NCT03883035|Experimental|EAS-aided group|esophagogastroduodenoscopy examination with the assistance of automatic quality-control system
89311587|NCT03883035|No Intervention|control group|conventional standard esophagogastroduodenoscopy examination without the assistance of automatic quality-control system
89311588|NCT03882879|Experimental|Arm 1|Participants in Arm 1 will begin participation in 6 months of karate classes immediately after the pre-intervention study visits.
89311589|NCT03882879|Experimental|Arm 2|Participants in Arm 2 will continue their usual exercise routine for six months followed by karate classes for six months
88821242|NCT04797611|Other|Investigational Treatment 1|Investigational treatment mode (stimulation pattern) 1
89311590|NCT01160835|Experimental|Quadriceps-sparing total knee arthroplasty|Quadriceps-sparing arthrotomy with side-cutting instruments
89311591|NCT01160835|Active Comparator|Medial parapatellar total knee arthroplasty|Medial parapatellar arthrotomy with front-cutting instruments
89311592|NCT01160913|Active Comparator|Continuous wound infusion above the fascia|
89311593|NCT01160913|Active Comparator|Continuous wound infusion below the fascia|
89311594|NCT03189212|Active Comparator|Usual Care Visit|
89311595|NCT03189212|Experimental|Telemedicine Visit|
89311596|NCT01268007||Normal ECG measurements|Observational, un-blinded, non-interventional study designed to collect ECG data on at least one (1) male patient in an outpatient setting.
89311597|NCT01160991|Active Comparator|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
89311598|NCT01160991|Experimental|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
89311599|NCT01160991|Placebo Comparator|Placebo|Placebo capsules are given at 8:00 a.m. Procedures are performed as described above.
89311600|NCT01161069|Active Comparator|PF-03049423|Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers
89311601|NCT01161069|Placebo Comparator|Drug|Placebo in oral solution, given once daily for 14 days
89311602|NCT01263405||Normal|normal volunteers without sarcoma
89311603|NCT01263405||Sarcoma|Sarcoma
89311604|NCT05064254|Active Comparator|Treatment as usual|All participants allocated to the control group will have access to standard care.
89311605|NCT05064254|Experimental|Mindful Adaptive Practice in Pregnancy Therapy|"Participants allocated to the intervention group will have access to treatment as usual in addition to synchronous virtual MAPP.~MAPP draws upon existing integrative principles of structured psychotherapies (mindfulness-based, cognitive, behavioural and relational psychotherapy)"
89311606|NCT01161147|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
89311607|NCT01161147|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
89311608|NCT03882567|Experimental|Electro Neuro adaptative Regulator|8 SCENAR sessions (twice a week) (30 min of duration) following the protocols for treatment several points in the body
89311609|NCT03882567|Sham Comparator|Sham Electro Neuro adaptative Regulator|8 Sham SCENAR sessions (twice a week) (30 min of duration), following the same protocol tan experimental group but the machine will be turn off 30 seconds after starting on the treatment.
89311610|NCT05057000|Experimental|Group A|DIET PROGRAM IN ADDITION TO AEROBIC EXRCISES
89311611|NCT05057000|Other|Group B|DIET PROGRAM
89311612|NCT01268085|Experimental|Radiation Safety Alert|A provider placing an electronic order for a CAT scan will receive a radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part.
89311613|NCT01268085|Active Comparator|Control|Parallel control with no intervention
89311614|NCT05053490|Experimental|Static Stretching|Participants will perform static stretching on day 1 and dynamic stretching after the switching.
89311615|NCT05053490|Experimental|dynamic stretching|Participants will perform dynamic stretching on day 1 and static stretching after the switching.
89311616|NCT01161927|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
89311617|NCT01161927|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
89311618|NCT01267383|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
89311619|NCT01267383|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
89311620|NCT01156467|Active Comparator|Control|Infants randomised to this arm will receive a regular nasogastric tube, and the ventilatory care is given as routinely is done.
89311621|NCT01156467|Active Comparator|NAVA|Infants randomised to this arm will receive and Edi-catheter as an oro-/nasogastric tube and the Edi-signal will be monitored and when possible NAVA-ventilation used.
89311622|NCT03283670|Experimental|1. 25% nitrous oxide, 25% nitrogen, 25% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
89311623|NCT03283670|Experimental|2. 50% nitrous oxide, 50% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
89311624|NCT03283670|Placebo Comparator|3. Placebo gas: 50% nitrogen(inert), 50% oxygen|Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
89311625|NCT02526927|Experimental|Patients 20 - 30 years-old|HR-pQCT and DEXA for measure bone quality and quantity
89311626|NCT02526927|Experimental|Patients 10 - 20 years-old|Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
89311627|NCT01162083||Mitral Valve disease|Patients with mitral valve disease, deemed suitable and ready for elective valve repair or replacement. No significant arrhythmias, other valvular disease or LV dysfunction present. We shall also be recruiting patients undergoing a Mitraclip procedure.
89311628|NCT01162083||COPD|Patients with isolated chronic obstructive pulmonary disease and no cardiac disease.
89311629|NCT01162083||Mixed Lesions|Patients with proven limitation from both cardiac and respiratory disease.
89311630|NCT01162083||CRT|Patients with symptomatic heart failure who have responded to cardiac resynchronisation therapy (biventricular pacemaker).
89311631|NCT01162083||Cardiomyopathy|Heart Failure of primarily myopathic origin, without rhythm disturbance, ongoing ischaemia or significant valvular disease.
89311632|NCT01162161||hydrostatic pulmonary edema|patients with a pulmonary edema caused by chronic heart failure
89311633|NCT01162161||toxic pulmonary edema|patients with a pulmonary edema preceded by pneumonia
89311634|NCT01162161||control group|not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure)
89311635|NCT02526849|Experimental|Fecal microbiota transplantation (FMT)|On day 1-6, patients received 100ml fresh FMT by nasointestinal tube, once per day. The nasointestinal tube was placed in the patient's proximal jejunum through endoscopy. Then, donor fecal microbiota was infused within 5 minutes through nasointestinal tube.
89311636|NCT02526849|Experimental|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
89311637|NCT01162395|Experimental|A|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
89311638|NCT03620864|Active Comparator|Motor control exercise|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
89311639|NCT03620864|Experimental|Motor control exercise plus neurodynamic intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
89311640|NCT03876405|Experimental|sensory feedback|"A non-invasive air-mediated sensory feedback system embedded in the prosthesis socket.~Group description: Individuals with acquired forearm amputation."
89311641|NCT01267617||chronic hemodialysis outpatients|
89311642|NCT01156623|Experimental|With EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, further EBUS-TBNA will be arranged if patients agreed it.
89311643|NCT01156623|No Intervention|Without EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, no EBUS-TBNA will be arranged if patients refused it despite we advised it.
89311644|NCT01161381||Normal|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) < 5.
89311645|NCT01161381||OSAHS patients|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) > 5.
89311646|NCT03205358|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine.
89311647|NCT03205358|Active Comparator|Group 2: NIMENRIX®|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of NIMENRIX® vaccine.
89311648|NCT01162629||Osteon|Patients requiring dental implants with deficient alveolar bone height
89311649|NCT01358578|Experimental|AIN457 150mg|AIN457 150mg
89311650|NCT01358578|Experimental|AIN457 300mg|AIN457 300mg
89311651|NCT01358578|Placebo Comparator|Placebo|Placebo
89311652|NCT01358578|Active Comparator|Etanercept|Etanercept
89311653|NCT01358578|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
89311654|NCT01358578|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase
89311655|NCT01162707|Experimental|Pressure Measurement System|CardioMEMS HF Pressure Measurement System
89311656|NCT05050994|Experimental|Microwave ablation|Patients receiving microwave ablation of splenomegaly
89311657|NCT01161459|Experimental|Tripterygium wilfordii|120mg/d for 6 months,then decrease to 60mg/d by 30mg/d every month for 12 months
89311658|NCT01161459|Active Comparator|FK506|
89311659|NCT05046236|Experimental|Interactive POWER rehabilitation|Participants in this group would be treated with POWER for twice a week, total 12 weeks.
89311660|NCT05046236|Active Comparator|Conventical physical training Group|Participants in this group would be treated with traditional exercise rehabilitation for twice a week, total 12 weeks.
89311661|NCT05046236|No Intervention|Control group|Usual care
89311662|NCT03882489||Cohort 1 : Height 150-165 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 1 includes patients whose the height is between 150 and 165 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 40 mg in the cohort 1 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 25 to 50 mg for cohort 1.
89311663|NCT03882489||Cohort 2 : Height 166-180 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 2 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 45 mg in the cohort 2 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 30 to 55 mg for cohort 2.
88813691|NCT03001193|Placebo Comparator|PL1|The subjects will receive intravenous infusion of placebo as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
89311664|NCT03882489||Cohort 3 : Height 181-195 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 3 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 50 mg in the cohort 3 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 35 to 60 mg for cohort 3.
89311665|NCT05003024|Active Comparator|TOF scan train of four ratio monitoring|Recovery of train of four ratio after sugammadex administration
89311666|NCT05003024|Experimental|ITF device tetanus stimulation monitoring|Recovery of tetanus 100 Hz ratio after sugamamdex administration
89311667|NCT03877263|Other|OB/GYN physician-collected vaginal swab|"Patients assigned to the physician-collected vaginal swab group will have their Vaginal swab for detection of STI collected by their obstetrics and gynecology (OB/GYN) physician.~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
89311668|NCT03877263|Other|Patient-collected vaginal swab|"Patients assigned to the patient-collected vaginal swab group will self-collect the Vaginal swab for detection of sexually transmitted infection (STI). Patients who self-collect will receive instructions from their OB/GYN physician and in paper form.~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
89311669|NCT04993664|Experimental|Pelacarsen group (TQJ230)|The first group will receive 80 mg of pelacarsen every month subcutaneously for 6 months.
89311670|NCT04993664|Placebo Comparator|Placebo group|The first group will receive 80 mg of placebo every month subcutaneously for 6 months.
89311671|NCT03882099||Pregnant women with pre-eclampsia|
89311672|NCT03882099||Pregnant women with eclampsia|
89311673|NCT03882099||Normotensive pregnant women|
89311674|NCT01268163|Active Comparator|1|European Taxotere® (Taxotere EU) 60-100 mg/m^2
89311675|NCT01268163|Experimental|3|Hospira Docetaxel Injection 60-100 mg/m^2
89311676|NCT01268163|Active Comparator|2|American Taxotere® (Taxotere US) 60-100 mg/m^2
89311677|NCT01268241||Observation|Hemizygous male or heterozygous female patients of any age with genetically confirmed diagnosis of Anderson-Fabry disease.
89311678|NCT04745780|Experimental|Study Arm|Treated with a formulation containing Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months.
89311679|NCT04745780|Placebo Comparator|Placebo Arm|Treated with Placebo - Two-times daily on an empty stomach, for 6 months.
89311680|NCT02833948|Active Comparator|ASA + Clopidogrel|ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
89311681|NCT02833948|Experimental|Rivaroxaban + ASA|Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
89311682|NCT01268319|Experimental|(+)HR-LCP and EPD|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation with an embolic protection device (EPD)in place prior to any angioplasty.
89311683|NCT01268319|Placebo Comparator|(+)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
89311684|NCT01268319|Placebo Comparator|(-)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will NOT contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 54 Subjects who meet this criteria will be assigned (not randomized) to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
89311685|NCT02678702|Experimental|CBT-I|Behavioral intervention: CBT-I
89311686|NCT02678702|Active Comparator|Treatment as usual|Intervention: Control group receiving treatment as usual
89311687|NCT02527005|Active Comparator|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
89311688|NCT02527005|Active Comparator|Sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets every 4 weeks for 3 doses
89311689|NCT03563872|Active Comparator|Active Comparator|Team-based care
89311690|NCT03563872|Experimental|Intervention|Enhanced team-based care
89311691|NCT05708170|Experimental|Intravenous iron therapy group|This group will receive intravenous iron calculated based on body weight and level of anaemia (hemoglobin concentration), as per the iron therapy's SPC.
89311692|NCT05708170|Active Comparator|Active Control Group|This group will receive oral ferrous sulphate prescribed by their GP Randmisation: Simple randomisation/parallel assignment/single-blinded
89311693|NCT02454842|Experimental|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity
89311694|NCT02828020|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
89311695|NCT02828020|Experimental|Ubrogepant 100 mg|2 Ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
89311696|NCT02828020|Placebo Comparator|Placebo|2 placebo-matching ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take 2-placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
89311697|NCT01162785|Experimental|First Dose SCH 721015|Part1: 2 Instillations of intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume
89311698|NCT01162785|Experimental|Second Dose SCH 721015|Part 2: Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration of SCH 721015 with Syn3 on same Day 1 and Day 4 regimen at same dose level.
89311699|NCT01267773|Active Comparator|Sequential Treatment|
89311700|NCT01267773|Experimental|Integrated Treatment|
89311701|NCT01268397|Active Comparator|ORIF|Open reduction and internal fixation with a volar plate
89311702|NCT01268397|Active Comparator|plaster treatment|Closed reduction and plaster treatment
89311703|NCT02624102|Experimental|Cognitive therapy|Major depressive disorder treated with cognitive therapy (Trial Based Cognitive Therapy plus Drug).
89311704|NCT02624102|Experimental|Behavioral Therapy|Major depressive disorder treated with behavioral therapy (Behavioral Activation plus drug).
89311705|NCT02624102|Other|Antidepressants|Major depressive disorder treated only with antidepressants (Drug alone).
89311706|NCT03877185||3-Injection-Protocol Group|Women in group A (3-Injection-Protocol Group) receive a bolus late luteal dose of Degarelix, a new long acting GnRH antagonist, a sole Elonva injection in the early follicular phase followed by the administration of a single dose of triggering agent (GnRH agonist or hCG a, according to the individual response).
89311707|NCT03877185||Multiple-Injection- Protocol Group|Women assigned to group B (Multiple- Injection- Protocol Group) are administered a single dose of Elonva (corifollitropin alfa) in the early follicular phase followed by daily GnRH antagonist doses, either fixed on day 6 of the stimulation cycle, or when 2 or 3 follicles over 12-14 mm are present. Ovulation triggering is the same as in group A, with either GnRH agonist or hCG a, accordingly.
89311708|NCT03874533|Experimental|self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
89311709|NCT03563638||GDM group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study,and excluded if they had multiple pregnancy, pre-gestational diabetes mellitus, hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness,and fetal abnormalities occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
89311710|NCT03563638||NGT group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study. Women were excluded if they had multiple pregnancy, pre-gestational diabetes mellitus (PGDM), hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness. if there were fetal abnormalities including chromosomally abnormal fetuses and/or structural defects and fetal growth restriction occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.those who not met the criteria were the NCT group.
89311711|NCT03876561|Experimental|Prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 sessions per week before stoma closure and 1 sessions per week during 6 weeks following stoma closure. Complementary sessions are allowed if necessary.
89311712|NCT03876561|No Intervention|No intervention|No pelvic floor prehabilitation will be proposed before stoma closure. The pelvic floor prehabilitation will be proposed to patients suffering from LARS
89311713|NCT02563574|Experimental|Motivational Interviewing Group|This group of participants will receive the motivational interviewing. In addition to blood specimen collection, a questionnaire assessment and neurocognitive assessments will also be performed.
89311714|NCT02563574|Active Comparator|Control Group|This group of participants will not receive motivational interviewing. They will have blood specimen collection, questionnaire assessment, and neurocognitive assessments performed.
89311715|NCT05321290|Experimental|Robotic Therapy Program|The intervention will consist of identification of 3-5 therapy goals using GAS (Turner-Stoke, 2009), joint planning with a therapist to achieve these goals during the program, and a robotic therapy plan. The robotic therapy plan will be negotiated with participants and consist of 3 sessions (about 1 h) per week for 8 weeks. The plan will detail the types of robotic activities (e.g. selection of interactive activities and games) to be completed by the participant. Homework relevant to participants' therapy goals will also be developed after each session. The intervention for each participant will be 24 robotic therapy sessions and 10 progress review sessions. The robotic system includes a tabletop 2-degree of freedom haptic robot that provides assisted and resisted shoulder and elbow movement therapy (Lu et. al, 2012). Interactive games are used with the system to engage and motivate participants to continue therapy.
89311716|NCT01162941|Experimental|Steroid dependant ITP|more than 10 mg of prednisolone per day is required to maintain a platelet count above 20X109/L (minimum follow up duration: 3 months after diagnosis)
89311717|NCT01156779|Experimental|DA-3091|SR-exenatide
89311718|NCT01156779|Placebo Comparator|Placebo of DA-3091|Placebo
89311719|NCT02233088|Experimental|ELM Group|A 6-month group lifestyle intervention, consisting of 12 weekly and 6 bi-weekly 2-hour sessions. The sessions consist of 30-min physical activity, 30-min meal demonstration, and 60-min group behavioral intervention, with a focus on experiential learning in naturalistic setting. Sessions are facilitated by dietitian/personal trainer and behavioral specialist.
89311720|NCT02233088|Other|ELM Classes|A 6-month health education, consisting of 12 weekly and 6 bi-weekly 30-45 min sessions. The sessions consist of didactic classes, with a focus on health education curriculum. Sessions are facilitated by a health educator and medical providers.
89311721|NCT02233088|Active Comparator|ELM Individual|A 6-month intervention, that consists of educational manuals on physical activity, diet and stress reduction and recommended 3 medical visits every 3 months for medical counseling and feedback using 5A (Ask, Advise, Assess, Assist, and Arrange) framework . These Metabolic syndrome care materials and provider documentation will be embedded in electronic medical record system, and will be accessible to medical providers by usual means. This enhanced usual care by participant's usual health care provider focuses on metabolic syndrome and lifestyle modifications to reduce the risk of chronic disease.
89311722|NCT01156857|Experimental|A|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
89311723|NCT01156857|Experimental|B|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).
89311724|NCT02558504|Active Comparator|Oesophagectomy|While surgical reference technique for invasive cancer of the lower esophagus is the technique according to Lewis Santy, there is no consensus on the technique and surgical approaches lack of specific work in the particular case of superficial lesions . The centers will have the choice of using the technique according to Lewis Santy with gastric plasty or technique of esophagectomy without thoracotomy with lower mediastinal dissection. In the absence of consensus to date available, abdominal surgery time will be by laparotomy or laparoscopy (laparoscopic assisted technique called). In both cases, an exploratory laparoscopy for diagnostic purposes is realized to remove an extension of the disease that would indicate against-resection with curative intent. For surgery, patients will be put under antisecretory therapy proton-pump inhibitor; this at least throughout the duration of the study.
89311725|NCT02558504|Experimental|Radiofrequency ablation|"The equipment processing is:~The radiofrequency generator,~The radiofrequency balloon 360,~the radiofrequency probe 90.~The radiofrequency treatment should be carried out according to the following protocol:~The radiofrequency treatment is done within 2 months following the last endoscopic assessment.~The maximum number of sessions is 4, including 2 maximum with 360 Halo probe.~Endoscopy is performed under general anesthesia.~The removal must begin at the top 1cm above the upper pole of the lesion and must end 1cm below the lower pole of the lesion.~The patient is left fasting until morning. In case of chest pain, the patient may receive analgesics.~During the time of treatment, the patient must follow an antisecretory therapy pump inhibitor with dual proton dose orally. The patient should avoid taking aspirin or nonsteroidal anti-inflammatory drugs during the 10 days following each session."
89311726|NCT01269333|Active Comparator|fluvoxamine|
89311727|NCT01269333|Experimental|omeprazole|
89311728|NCT01269333|Placebo Comparator|placebo|
89311729|NCT01269411|Experimental|Treatment (RO4929097 and surgery)|"PART A: Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive oral RO4929097 once daily on days 1-7 and undergo surgery on day 8. Beginning 28 days later, patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
89311730|NCT03882255|Experimental|Treatment Period 1: Ponesimod (2 mg)|Participants will receive a single dose ponesimod 2 milligram (mg) oral tablet under fed conditions on Day 1. Participants not fulfilling discontinuation criteria can continue to Treatment Period 2 after a washout period of at least 7 days and a maximum of 14 days.
89311731|NCT03882255|Experimental|Treatment Period 2:Ponesimod, Propranolol, Placebo Propranolol|Participants who do not fulfill any of discontinuation criteria will be randomized to 1 of 2 Treatments (Treatment A or B) on Day 1. Treatment A: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus placebo propranolol once daily from Day 1 to Day 19; Treatment B: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus 80 mg propranolol once daily from Day 1 to Day 19.
89311732|NCT04895072|Active Comparator|Standard group|standard injection rate will be applied
89311733|NCT04895072|Active Comparator|Long group|long injection rate will be applied
89311734|NCT03882333|Experimental|Acute exercise|Acute exercise (bicycle at stationary cycle).
89311735|NCT03882333|No Intervention|Rest|Rest (lying down or sitting in a chair) for 30 minutes, i.e. same time duration as in experimental arm.
89311736|NCT05433272|Experimental|Trial group of participants have received two doses of CoronaVac®|400 participants have received two doses of CoronaVac® at least 3 months prior to this study ,including 150 participants aged 3-17 years old,125 participants aged 18-59 years old and 125 participants aged 60 years and above,will receive one booster dose of trivalent COVID-19 vaccine.
89311737|NCT05433272|Active Comparator|Control group of participants have received two doses of CoronaVac®|400 participants have received two doses of CoronaVac® at least 3 months prior to this study ,including 150 participants aged 3-17 years old,125 participants aged 18-59 years old and 125 participants aged 60 years and above,will receive one booster dose of CoronaVac®.
89311738|NCT05433272|Experimental|Trial group of participants have received three doses of CoronaVac®|300 participants have received three doses of CoronaVac® at least 3 months prior to this study ,including 150 participants aged 18-59 years old and 150 participants aged 60 years and above,will receive one booster dose of trivalent COVID-19 vaccine.
89311739|NCT05433272|Active Comparator|Control group of participants have received three doses of CoronaVac®|300 participants have received three doses of CoronaVac® at least 3 months prior to this study ,including 150 participants aged 18-59 years old and 150 participants aged 60 years and above,will receive one booster dose of CoronaVac®.
89311740|NCT01269489||general population|a representative sample from general Slovenian population
89311741|NCT01163019||Chest pain|Patients who present to the emergency department with a chief complaint of chest pain and have a moderate pre-test probability for an acute coronary syndrome
88813692|NCT01049360|Experimental|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
88821243|NCT04797611|Other|Investigational Treatment 2|Investigational treatment mode (stimulation pattern) 2
89311742|NCT01268631|Active Comparator|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
89311743|NCT01268631|Active Comparator|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
89311744|NCT04862390||Normal Pregnancy|Pregnant women with no diabetes
89311745|NCT04862390||Gestational diabetes on diet alone|
89311746|NCT04862390||Gestational diabetes on diet + Metformin therapy|
89311747|NCT01269567|Active Comparator|Drainage|Rectal excision with aspiration pelvic drainage
89311748|NCT01269567|Experimental|No drainage|Rectal excision without aspiration pelvic drainage
89311749|NCT03876639|Active Comparator|IPM_2/18|Application of formulation IPM_2/18
89311750|NCT03876639|Active Comparator|PAR_2/18|Application of formulation PAR_2/18
89311751|NCT03876327|Experimental|PD patients that will receive FMT|fecal microbial transplantation once at the beginning of the study-15 patients.
89311752|NCT03876327|No Intervention|PD patients that will not receive FMT|do not receive treatment-35 patients.
89311753|NCT03876327|No Intervention|healthy people live with PD patients|do not receive treatment-50 participants.
89311754|NCT01268709|Active Comparator|doxepin|
89311755|NCT01268709|Active Comparator|nortriptyline|
89311756|NCT01268709|Placebo Comparator|placebo|
89311757|NCT05034848|Other|PAD group|PAD patients, diagnosis after undergoing an echo-doppler in the Vascular Medicine Department of Orleans regional Hospital
89311758|NCT04804358|Other|Anorexic women|Anorexic women with or without history of psychological trauma will perform study procedure : sociodemographic and clinical assessments, measurement of cardiac variability and salivary cortisol changes, before, during and after the exposition test.
89311759|NCT01156935|Experimental|Laugh yoga|experimental laugh yoga
89311760|NCT02827708|Experimental|Semaglutide|
89311761|NCT02827708|Placebo Comparator|Placebo|
89311762|NCT03881943|Active Comparator|Ticagrelor|Ticagrelor 60mg BD for 3 months
89311763|NCT03881943|Active Comparator|Aspirin|Aspirin 100mg daily for 3 months
89311764|NCT04742270|Experimental|SIMEOX+ respiratory physiotherapy telecare|Use the device for 3 months in addition to usual care
89311765|NCT05370950|Experimental|Treatment group A|
89311766|NCT05370950|Experimental|Treatment group B|
89311767|NCT05370950|Experimental|Treatment group C|
89311768|NCT03760185|Experimental|Brimonidine Tartrate 0.2%|One eye was treated with Brimonidine Tartrate 0.2% after a 20-day washout period. Patients will treat right eye 3 times per day for 7 days of treatment.
89311769|NCT03760185|No Intervention|Control - untreated|The left eye will serve as the control for the study and will not receive the Brimonidine Tartrate 0.2% treatment
89311770|NCT01164969||H. pylori eradication failure|People who are not able to eradicate H. pylori although the appropriate antibiotic therapy taken.
89311771|NCT01269645|Active Comparator|Usual care|"Usual care and provision of National Cancer Institute brochure Taking Part in Cancer Treatment Research Studies. Participants will be asked to read this brochure after completion of the baseline surveys and will be given a copy to take home with them."
89311772|NCT01269645|Experimental|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
89311773|NCT04884776|Active Comparator|Active arm|Subject will be instructed to take microbiome immunity formula 2 sachets daily for a total of 12 weeks.
89311774|NCT04884776|Placebo Comparator|Placebo arm|Subject will be instructed to take active placebo daily for a total of 12 weeks.
89311775|NCT03875937|Experimental|Tranexamic acid 1 gram intramuscularly|Patients will receive a 1 gram dose of TXA by IM injection at least 1 hour and 30 minutes after their initial IV injection received at the scene or on arrival to hospital. The IM dose will be given as two 5mL (0.5 gram each) injections into the thigh (rectus femoris or vastus lateralis), gluteal or deltoid muscles, depending on the clinical scenario (e.g. taking into account the type of injury). Injections should be given in a non-injured muscle.
89311776|NCT01157013|Experimental|Advanced Hepatocellular Carcinoma|Hepatocellular carcinoma patients not candidates to local and/or curative treatment and an expected overall survival of at least three months and who are susceptible of receiving sorafenib therapy.
89311777|NCT01584466|Experimental|Paliperidone|
89311778|NCT05364164|Experimental|CT-L01 12.5/1,000 mg FDC Tablet, dosing under fasting condition|Alogliptin Benzoate 12.5 mg/Metformin HCl XR 1,000 mg, FDC Tablet, dosing under fasting condition
89311779|NCT05364164|Experimental|CT-L01 12.5/1,000 mg FDC Tablet, dosing under fed condition|Alogliptin Benzoate 12.5 mg/Metformin HCl XR 1,000 mg, FDC Tablet, dosing after high-fat meal
89311780|NCT03874611|Experimental|electrophysiological data from DBS|
89311781|NCT01163331|Experimental|Singing Therapy Group|Singing Therapy Group
89311782|NCT05363384|Experimental|CT-L01 25/1,000 mg FDC Tablet|Alogliptin Benzoate 25 mg/Metformin HCl XR 1,000 mg, FDC Tablet
89311783|NCT05363384|Active Comparator|Alogliptin Benzoate 25 mg, Metformin HCl XR 1,000 mg|"Alogliptin Benzoate 25 mg~Metformin HCl XR 1,000 mg"
89311784|NCT01165125|Other|FF/GW642444 and keto|Ketoconazole (400mcg) administered on Days 1-11, with co-administration of fFF / GW642444 (200mcg/25mcg) on Days 5-11
89311785|NCT01165125|Other|Ketoconazole Placebo to match & FF/GW642444|ketoconazole placebo to match administered on days 1-11. FF/GW642444 (200mcg/25mcg) co-administered on Days 5-11
89311786|NCT04905524|Other|Intervention arm|All participants received the intervention in this trial (VPNP diet and supplement recommendations).
89311787|NCT01163409|Experimental|acupuncture|will be made with classic acupuncture needling in traditional points, surpassing the skin
89311788|NCT01163409|Experimental|sham acupuncture|sham acupuncture will be done through a needle and a plastic device attached to skin in traditional acupuncture points.
89311789|NCT01163409|Experimental|exercise training resistance and aerobic|Aerobic exercise for 1 hour and resistance exercises for major muscle groups.
89311790|NCT01163409|No Intervention|healthy lifestyle|Group 4 - will be the control group who receive follow-up and recommendation for physical activity, but without any intervention supervised.
89311791|NCT01166919|Experimental|Medical Tool|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
89311792|NCT01165359|Experimental|Part A: ITX 5061|Participants will receive ITX 5061 once a day for 3 days.
89311793|NCT01165359|Placebo Comparator|Part A: Placebo|Participants will receive placebo once a day for 3 days.
89311794|NCT01165359|Experimental|Part B: ITX 5061|Participants will receive ITX 5061 once a day for 14 days.
89311795|NCT01165359|Placebo Comparator|Part B: Placebo|Participants will receive placebo once a day for 14 days.
89311796|NCT01165359|Experimental|Part C: ITX 5061|Participants will receive ITX 5061 once a day for 28 days.
89311797|NCT01165359|Placebo Comparator|Part C: Placebo|Participants will receive placebo once a day for 28 days.
89311798|NCT00782444|Active Comparator|Computer navigated knee replacement|Computer navigation system from Brainlab, vector vision, kolibri.
89311799|NCT00782444|Placebo Comparator|Conventional knee replacement|Conventional total knee replacement is performed with intramedullary guides in the traditional way.
89311800|NCT01163565|Active Comparator|Ligasure device|
89311801|NCT01163565|No Intervention|Hand ties|
89311802|NCT01269723|Active Comparator|Broccoli sprout homogenate|"The broccoli sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
89311803|NCT01269723|Placebo Comparator|alfalfa sprout homogenate|"Alfalfa sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
89311804|NCT02384018|No Intervention|Control|Patients will receive standard islet transplantation.
89311805|NCT02384018|Experimental|autologous mesenchymal stromal cell|Patients will receive MSCs together with standard islet transplantation.
89311806|NCT01163799|Experimental|Alefacept (ASP0485)|Safety and efficacy of alefacept in combination with alemtuzumab induction and calcineurin inhibitor (CNI) and corticosteroid withdrawal.
89311807|NCT03876249||RSV positive group|Children who had RSV infection within the first 60 days of life
89311808|NCT03876249||RSV negative group|Children without known RSV infection within the first 60 days of life
89311809|NCT02891174|Active Comparator|Ibuprofen followed by acetaminophen|Ibuprofen administered immediately post-partum, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours followed by acetaminophen, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours.
89311810|NCT02891174|Active Comparator|Acetaminophen followed by ibuprofen|Acetaminophen administered immediately post-partum, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours followed by ibuprofen, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours.
89311811|NCT03876015||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
89311812|NCT01167075|Active Comparator|Fresubin Original|
89311813|NCT01167075|Experimental|Intestamin plus Fresubin Original|
89311814|NCT04808180|Experimental|Trial Group|Teeth from this group suffer from MIH. They will be evaluated after home oral care with BioRepair toothpaste containing microRepair®.
89311815|NCT04808180|Active Comparator|Control Group|Teeth from this group suffer from MIH. They are in the contralateral quadrants in respect to teeth from trial group. They will not be treated with the hydroxyapatite toothpaste.
89311816|NCT01280175|Experimental|pMDI + charcoal block|BDP/formoterol 100/6 µg pMDI with charcoal ingestion
89311817|NCT01280175|Experimental|pMDI + Aerochamber Plus|BDP/formoterol 100/6 µg with Aerochamber Plus
89311818|NCT01280175|Active Comparator|pMDI|BDP/formoterol 100/g µg pMDI
89311819|NCT05019404|Experimental|Functional anterior temporal lobectomy (FATL)|FATL via minicraniotomy is a new surgical approach, consisting of amygdalohippocampectomy and the lateral temporal lobotomy.
89311820|NCT05019404|Active Comparator|Anterior temporal lobectomy (ATL)|ATL via large frontotemporal craniotomy is a conventional surgical approach, consisting of amygdalohippocampectomy and en bloc resection of the lateral temporal lobe.
89311821|NCT03871881||Atrial septal defect|Patients with an open atrial septal defect, diagnosed in childhood
89311822|NCT03871881||Ventricular septal defect|Patients who had surgical closure of a ventricular septal defect in childhood
89311823|NCT03871881||Healthy control|Healthy, young adults matched on age, gender and education
88813693|NCT01049360|Experimental|Aclidinium 400 μg / formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
89311824|NCT01165437||Suspected Arterial Disease|Patients with known or suspected arterial disease and patients screened using AHA/ACC criteria for P.A.D.
89311825|NCT01583283|Experimental|ACY-1215, Lenalidomide and Dexamethasone|Open label dosing cohorts will evaluate oral ACY-1215 (doses ranging from 40 - 480 mg days 1-5, 8-12, 15-19) in combination with oral Lenalidomide (doses ranging from 15 - 25 mg days 1-21) and oral Dexamethasone (40 mg once weekly).
89311826|NCT02076620|Experimental|L19TNFα + doxorubicin|"Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNFα in combination with 60 mg/m2 of doxorubicin, according to the following study design:~cohort 1 --> 10.4 μg/kg L19TNFα + doxorubicin; cohort 2 --> 13 μg/kg L19TNFα + doxorubicin; cohort 3 --> 17 μg/kg L19TNFα + doxorubicin."
89311827|NCT01269879|Active Comparator|Active control (Flexi-Bar only)|Flexi-Bar vibration training only over 12 weeks with three distinct exercises and 10min training twice daily
89311828|NCT01269879|Experimental|Intervention Flexi-Bar + XCO-Trainer|Combination intervention using vibration device Flexi-Bar and XCO-Trainer (oscillating mass witin a tube moved during running 40-60min/week suggested)
89311829|NCT02046512|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
89311830|NCT02046512|Placebo Comparator|Sugar Pill|Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis
89311831|NCT01163877|Other|Symptomatic malaria infection|
89311832|NCT01163877|Other|Asymptomatic malaria infection|
89311833|NCT01163877|Other|Hookworm infection|
89311834|NCT01163877|Other|Schistosoma haematobium infection|
89311835|NCT03638804|Experimental|89Zr-KN035 injection|
89311836|NCT03872037|Active Comparator|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
89311837|NCT03872037|Experimental|Selective removal of caries and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
89311838|NCT01269957||Mouth breathing|
89311839|NCT01269957||Nasal breathing|
89311840|NCT01164033|Active Comparator|A|
89311841|NCT01164033|Experimental|B|
89311842|NCT01164033|Experimental|C|
89311843|NCT01164033|Experimental|D|
89311844|NCT01313000||Autologous fat transfer|
89311845|NCT01270737|Active Comparator|Whole soy|
89311846|NCT01270737|Active Comparator|daidzein|
89311847|NCT01270737|Placebo Comparator|milk powder|
89311848|NCT01268787|Active Comparator|EV 71 vaccine 5ug|EV71 Vaccine 5ug
89311849|NCT01268787|Experimental|EV 71 vaccine 10ug|EV71 vaccine 10ug
89311850|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 400 to 500 calories|
89311851|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 600 to 750 calories|
89311852|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 800 to 1000 calories|
89311853|NCT01270815|Other|Pregabalin immediate release, 300 mg|Reference
89311854|NCT01164111|Experimental|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise. Frequency: 2 times/week
89311855|NCT01164111|No Intervention|Control|Standard preoperative track.: No training intervention. Standard preoperative information.
89311856|NCT01751984|Experimental|ETC-1002|ETC-1002 treatment, once daily oral
89311857|NCT01751984|Placebo Comparator|Placebo|Placebo treatment, once daily oral
89311858|NCT03873909|Active Comparator|Fruit Smoothie|Post-prandial study feeding 155-200 g mamey sapote mesocarp, 6 g of soybean oil , crushed ice and 150-200 g of water to reach a total volume of 450 mL. (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin).
89311859|NCT03873909|Active Comparator|Matrix-Free Shake|Post-prandial study feeding 2 g of carotenoid powder formula (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin), 37.5 g of sugar, 75 µg of citric acid, 6 g of soybean oil emulsified into 300 g of water using 3 g of soy lecithin as well as ca. 100 g of crushed ice, yielding a shake volume of 450 mL.
89311860|NCT03874143|Experimental|RCom equipped with a smartphone|
89311861|NCT03874143|No Intervention|RCom with paper-based system|
89311862|NCT01280487|Experimental|Oral ZSTK474|Daily oral dosing for 21 days per cycle
89311863|NCT01268865||HBV-infected|
89311864|NCT01268865||HCV-infected|
89311865|NCT03330236|Experimental|Study arm|"All patients in the study arm will receive the anesthetic care guided by the SedLine EEG Brain Function Monitor in addition to the conventional monitors. In addition to the conventional/standard interventions of anesthetic care, an additional intervention related to this trial is the anesthetic depth management via the titration of the propofol and remifentanil infusion rates to maintain SEF and PSI in the targeted ranges based on the SedLine EEG monitoring."
89311866|NCT03330236|No Intervention|Control arm|All patients in the control arm will receive the anesthetic care guided by the conventional monitors only. Patients in the control arm will be monitored using the SedLine EEG Brain Function Monitor; however, the screen of this monitor will be covered by an opaque cloth and blinded to the anesthesia team.
89311867|NCT05666817|Experimental|experiment group|Breastfeeding training will be given to each mother in the room she stays in the form of lectures and after the training, the question and answer method will be used. In addition, the practices explained by the researcher (the way of holding the baby, grasping the breast and positioning the baby appropriately for the baby, determining the position suitable for breastfeeding and the process of expressing and storing breast milk) will be demonstrated using the mother demonstration method in order to evaluate whether the mother understands the breastfeeding education after the breastfeeding training. Breastfeeding training will take approximately 40-45 minutes.
89311868|NCT05666817|No Intervention|Control group|No attempt will be made to the mothers in the control group following the pre-test application, within the scope of the post-test application before discharge; Breastfeeding Knowledge Level Diagnostic Form, LATCH Scale and Postnatal Self-Efficacy Scale will be applied. In addition to the breastfeeding education given to the intervention group following the post-test application to the mothers in the control group, a guide on the importance of breast milk and breastfeeding will also be given.
89311869|NCT03872115|Experimental|Setting 1|PDVibe2 set to high frequency and low amplitude
89311870|NCT03872115|Experimental|Setting 2|PDVibe2 set to high frequency and medium amplitude
89311871|NCT03872115|Experimental|Setting 3|PDVibe2 set to high frequency and high amplitude
89311872|NCT03872115|Experimental|Setting 4|PDVibe2 set to medium frequency and low amplitude
89311873|NCT03872115|Experimental|Setting 5|PDVibe2 set to medium frequency and medium amplitude
89311874|NCT03872115|Experimental|Setting 6|PDVibe2 set to medium frequency and high amplitude
89311875|NCT03872115|Experimental|Setting 7|PDVibe2 set to low frequency and low amplitude
89311876|NCT03872115|Experimental|Setting 8|PDVibe2 set to low frequency and medium amplitude
89311877|NCT03872115|Experimental|Setting 9|PDVibe2 set to low frequency and high amplitude
89311878|NCT03871725|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
89311879|NCT03330002||CE-marked MANTA vascular closure devices per IFU|Transcatheter Aortic Valve Replacement (TAVR), Endovascular aneurysm repair (EVAR), TEVAR, etc.
89311880|NCT01271361|Experimental|primary PCI with thrombectomy|thrombectomy before implantation of drug eluting stent
89311881|NCT01271361|Active Comparator|primary PCI without thrombectomy|implantation of a drug eluting stent without thrombectomy
89311882|NCT03638726|Experimental|Atropine sulfate and Epinephrine|Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).
89311883|NCT03638726|Other|Topical cyclopentolate and phenylephrine|Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.
89311884|NCT01164189|Other|Temozolomide|Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles
89311885|NCT01164189|Experimental|Temozolomide + Bevacizumab|"TMZ: Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles~Beva: 10 mg/kg bw IV in 90 minutes on day 1 and 14, 4 week cycles."
89311886|NCT01165515||Healthy young females|20 healthy females, aged between 18 and 35 years
89311887|NCT01165515||Healthy young males|20 healthy males, aged between 18 and 35 years
89311888|NCT01165515||Healthy elderly smokers|20 healthy smokers, aged between 45 and 75 years
89311889|NCT01165515||Healthy elderly non-smokers|20 healthy non-smokers, aged between 45 and 75 years
89311890|NCT01165515||Healthy young female smokers|20 healthy female smokers, aged between 18 and 35 years
89311891|NCT01165515||Healthy young male smokers|20 healthy male smokers, aged between 18 and 35 years
89311892|NCT01165515||Healthy postmenopausal women|20 healthy postmenopausal women
89311893|NCT01165515||Female CMP Patients|20 female patients suffering from cardiomyopathy (ischemic or dilating)
89311894|NCT01165515||Male CMP Patients|20 male patients suffering from cardiomyopathy (ischemic or dilating)
89311895|NCT01165515||Female CHD patients|30 female patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
89311896|NCT01165515||Male CHD Patients|30 male patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
89311897|NCT01165515||male athlets|20 male athlets
89311898|NCT01165515||female athlets|20 female athlets
89311899|NCT01164345|Experimental|MOZOBIL|treatment with mozobil for autologous stem cell collection
89311900|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
89311901|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
89311902|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
89311903|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
89311904|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
89311905|NCT02948582|Placebo Comparator|Placebo 0.5mL|Placebo 0.5mL via e-flow nebulizer, once daily
89311906|NCT02259868|Experimental|Group A|randomized sequence of current low dose formulation (3 tablets) and high dose (1 tablet) BILR 355 BS 1B formulation, separated by 14-day washout
89311907|NCT02259868|Experimental|Group B|randomized sequence of BILR 355 BS (JM) + SDS formulation low dose (2 tablets) ,BILR 355 BS (HM) + SDS formulation low dose (2 tablets), BILR 355 BS high dose 1B formulation (4 low dose tablets), separated by 14-day washout
89311908|NCT02259868|Experimental|Group C|randomized sequence of BILR 355 BS (JM) + SDS formulation high dose (4 tablets) , BILR 355 BS (JM) + SDS formulation mid dose (3 tablets), BILR 355 BS (HM) + SDS formulation high dose (4 tablets), separated by 14-day washout
89311909|NCT02259868|Experimental|Group D|randomized sequence of BILR 355 BS Suspension high dose, BILR 355 BS Suspension low dose, current low dose BILR 355 BS 1B formulation (3 tablets) separated by 14-day washout
89311910|NCT03756285|Experimental|AZD4831|AZD4831 tablets taken orally for for 90 days.
89311911|NCT03756285|Placebo Comparator|Placebo|Placebo tablets taken orally for 90 days.
89311912|NCT04105244|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post-enrollment plus the current standard of care, whereby caregivers phone their healthcare providers when they have questions or concerns
89311913|NCT04105244|Experimental|Resourcefulness Training Intervention©|The Resourcefulness Training© arm will receive (a) individually tailored instruction on personal and social resourcefulness skills via the Resourcefulness Video and intervention nurse, (b) journal-writing instruction to describe resourcefulness application, (c) access to the study website with videotape vignettes and Resourcefulness Video, and (d) boosters at 2 and 4 months post-enrollment that will include reinforcement of skills learned and additional journal writing.
89311914|NCT01167231||Group 1|
89311915|NCT03871803|Active Comparator|Arm A|"Controlled Withdrawal of Beta-blockers and Cardiopulmonary Exercise Testing (CPET) Patient will be assessed for chronotr0pic incompetence by CPET. If the patient exhibits chronotropic incompetence, we will reduce half dose of previous beta-blocker.~A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day.~After second CPET, the patient will introduce the half-dose of beta-blocker and will be evaluated in 3 days. If clinical stability, the patient will introduce the previous dose of beta-blocker A third CPET will be performed at 15-day"
88813694|NCT01049360|Experimental|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID)
88813695|NCT01049360|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily
89311916|NCT03871803|Active Comparator|Arm B|"Cardiopulmonary Exercise Testing (CPET) and Controlled Withdrawal of Beta-blockers Patient will be assessed for chronotropic incompetence by CPET.If the patient exhibits chronotropic incompetence, a cardiologist will evaluate clinically the patient and the heart rate in 3 days and will be assessed by CPET at 15-day.~After second CPET, the patient will reduce half dose of previous beta-blocker. A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day."
89311917|NCT01164423|Experimental|1|Space TGC system with incorporated eMPC advised insulin infusion to establish glycaemic control
89311918|NCT01167309|Active Comparator|Part 1 SAD|four diffferent doses
89311919|NCT01167309|Placebo Comparator|Part 2a MAD|three doses
89311920|NCT01167309|Active Comparator|Part 2b|0.24 mg LEO 27847
89311921|NCT01167309|Active Comparator|Part 2c|0.24 mg LEO 27847
89311922|NCT01167309|Placebo Comparator|Parat 2a MAD|one dose
89311923|NCT01165593||Patients with atrial fibrillation|Patients with atrial fibrillation who have received a cardiac CT scan as part of normal care prior to catheter-based treatment of atrial fibrillation.
89311924|NCT01586637|Experimental|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
89311925|NCT01586637|Experimental|Walking|The group walked twice a week during one hour.
89311926|NCT03873753|Experimental|Oral cleaning|The oral cavity will be clean with gauze and mineral water three times a day.
89311927|NCT03873753|Active Comparator|No oral cleaning|The oral cavity will not be cleaned.
89311928|NCT01280799|Experimental|Active Treatment|
89311929|NCT03875469|Experimental|CT patients_Centargo_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
89311930|NCT03875469|Experimental|CT-patients_Stellant_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
89311931|NCT03875469|Experimental|CT-patients_Centargo_2|Adult patients referred for contrast-enhanced computed tomography in study part 2 (includes all patients of Arm 1)
89311932|NCT03873831|Active Comparator|Social Skills Control (A-A)|"The children in the A-A condition, a true control, will remain without a dog for the full 10 weeks."
89311933|NCT03873831|Experimental|Social Skills Dog (A-B)|"The A-B condition will involve standard instruction for 5 weeks (A), followed by 5 weeks of group instruction while a therapy dog is present in the room (B)."
89311934|NCT03873831|Experimental|Social Skills Dog (B-A)|"The B-A condition will be identical, except the first 5 weeks of instruction will include the dog, followed by 5 weeks of standard instruction with no dog."
89311935|NCT01587183|Other|Educational materials control|Enhanced usual care
89311936|NCT01587183|Active Comparator|Group running style B|Basic running instruction using group based training.
89311937|NCT01587183|Experimental|Group running style A|Form focused running instruction using group based training.
89311938|NCT01587261|Placebo Comparator|Placebo|Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours
89311939|NCT01587261|Experimental|Vitamin C|Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours
89311940|NCT02526771|Experimental|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
89311941|NCT02526771|Active Comparator|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
89311942|NCT05072548|Experimental|Intervention|The intervention arm will receive access to the ABCs of SLEEPING Intervention.
89311943|NCT05072548|No Intervention|Control group|The control group arm does not receive the ABCs of SLEEPING intervention. This arm is free to access other resources while enrolled in the study. After the post-test follow up time point, the control group arm will be able to access the intervention.
89311944|NCT01280877|Experimental|Verum stimulation|Complete treatment with transorbital alternating current stimulation (tACS)
89311945|NCT01280877|Sham Comparator|Sham stimulation|Same electrode montage set-up is used during tACS- and placebo-stimulation. Sham stimulation condition consists of minimal treatment with low intensity/few impulses tACS.
89311946|NCT01165671|Experimental|Experimental Arm|Carbon Ion Radiotherapy to the Macroscopic Tumor 6 x 3 Gy E up to 18 Gy E
89311947|NCT01165671|Active Comparator|Standard Arm|Proton Radiotherapy to the Macroscopic Tumor 5 x 2 Gy E up to 10 Gy E (Standard dose) applied after 48-52 Gy photon radiotherapy
89311948|NCT03831646||dermatological patients|atopic dermatitis and psoriasis patients with mild and moderate severity of dermatoses in the stage of exacerbation
89311949|NCT01164657|Experimental|study group|Randomized to give birth on a birthing seat
89311950|NCT01164657|No Intervention|control group|Randomized to birth in any other position except the birthing seat
89311951|NCT03563404||Portal Blood Flush|participants that receive the portal blood flush
89311952|NCT03563404||No Portal Blood Flush|participants that don't receive the portal blood flush
89311953|NCT01272375|Experimental|Treatment A PF-04764793|PF-04764793 using inhaler A
89311954|NCT01272375|Experimental|Treatment B PF-04764793|PF-04764793 using inhaler A
89311955|NCT01272375|Experimental|Treatment C PF-04764793|PF-04764793 using inhaler A
89311956|NCT01272375|Experimental|Treatment D PF-04764793|PF-04764793 using inhaler A
89311957|NCT01272375|Experimental|Treatment E PF-04764793|PF-04764793 using inhaler B
89311958|NCT01272375|Experimental|Treatment F PF-04764793|PF-04764793 using inhaler B
89311959|NCT01272375|Experimental|Treatment G PF-04764793|PF-04764793 using inhaler B
89311960|NCT01281033|Active Comparator|thrombus-aspiration group|In patients in the thrombus-aspiration group, the thrombus-aspiration is manually performed.
89311961|NCT01281033|Experimental|AngioJet Rheolytic Thrombectomy|AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter.
88813696|NCT01049360|Placebo Comparator|Placebo|Placebo twice-daily
89311962|NCT01164735||Correlative studies|Archived tumor tissue samples are analyzed for topoisomerase 2-alpha gene alteration and expression and chromosome 17 polysomy by FISH and IHC. Clinical information associated with each endometrial carcinoma sample (e.g., age, race/ethnicity, cell type, histologic grade, disease stage, and regimen type) is also collected.
89311963|NCT01272687||Observation|Adults (>18 years) with a confirmed diagnosis of Parkinson's disease
89311964|NCT01269021|Experimental|mycophenolate mofetil|
89311965|NCT01269021|Active Comparator|Prednisone|
89311966|NCT03871569|Active Comparator|telemedecine nursing home|One buccodental teleexpertise at the completion day and a second buccodental teleexpertise at the end of study
89311967|NCT03871569|No Intervention|control nursing home|Only one buccodental teleexpertise at the end of study
89311968|NCT02825992|Other|AcQMap System|All patients who underwent catheter ablation using the AcQMap System
89311969|NCT01272843||Carotid endarterectomy patients|
89311970|NCT01272843||Lumbar stenosis laminectomy patients|
89311971|NCT05026684|Experimental|Experimental group|Personalized cost information group.
89311972|NCT01269099|Active Comparator|Control|Control-group
89311973|NCT01269099|Experimental|IV-PCA|IV-PCA group
89311974|NCT03831568||Children with given device for mechanical cough|
89311975|NCT01269177||Patients with acute cardiogenic pulmonary edema|
89311976|NCT01165827||Patients with aortic valve procedures|"All consecutive patients from participating hospitals with aortic valve defects who have received one of the following therapies:~surgical aortic valve replacement,~percutaneous transvascular (retrograde) aortic valve implantation~percutaneous transapical aortic valve implantation as principal indication. If the aortic valve insufficiency is concurrent with combination procedures (e.g. coronary artery bypass graft, mitral valve surgery) the aortic valve stenosis must fulfil only the criteria for indication according to the German National guidelines (see: detailed study description)."
89311977|NCT03830710||Group A|30 patients diagnosed with oral leukoplakia
89311978|NCT03830710||Group B|30 patients diagnosed with oral lichen planus
89311979|NCT03830710||Group C|30 patients having oral squamous cell carcinoma with the tongue being the most commonly affected site
89311980|NCT03830710||Group D|30 age and gender matched individuals having no oral mucosal lesions acting as a control group
89311981|NCT01164813|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
89311982|NCT01164813|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
89311983|NCT03563326|Experimental|CAR-T cell and chemotherapy|Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist
89311984|NCT03563326|Active Comparator|chemotherapy|Chemotherapy: determined by medical Oncologist
89311985|NCT05176600|Experimental|Bimanual group|In this group, patients will perform a robotic rehabilitation based on bimanual serious games
89311986|NCT05176600|Active Comparator|Unimanual group|In this group, patients will perform a robotic rehabilitation based on unimanual serious games
89311987|NCT01339000|Experimental|Arm A -Sequence 1 Immunizations|Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)
89311988|NCT01339000|Experimental|Arm B - Sequence 2 Immunizations|Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7
89311989|NCT01269255|Experimental|Combination group|
89311990|NCT03871413|Active Comparator|Manual repositioning maneuver|Diagnostics and treatment of BPPV with manual repositioning maneuvers. In case of posterior canal involvement, Epley's maneuver will be used. In case of horizontal canal involvement, the log roll maneuver will be used.
89311991|NCT03871413|Experimental|Treatment in mechanical rotational chair (TRV-chair)|"Diagnostics and treatment of BPPV with the use of a TRV chair. In case of posterior canal involvement, Epley's maneuver will be used with the addition of 10 kinetic impulses in each position.~In case of horizontal canal involvement, the log roll maneuver will be used with the addition of 10 kinetic impulses in each position."
89311992|NCT03563170|Experimental|NANT Hepatocellular Carcinoma Vaccine|Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, N-803, haNK™, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib tosylate, SBRT.
89311993|NCT03563170|Active Comparator|Sorafenib Monotherapy|Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SOC treatment.
89311994|NCT01274013||Study Group|Individuals with chronic Hepatitis C
89311995|NCT01274013||Control Group|Healthy individuals
89311996|NCT01281111|Experimental|BG00012 plus ASA|
89311997|NCT01281111|Experimental|BG00012 plus ASA matching placebo|
89311998|NCT01281111|Placebo Comparator|BG00012 Placebo plus ASA|
89311999|NCT01281111|Experimental|BG00012 Placebo plus ASA matching placebo|
89312000|NCT01281111|Experimental|BG00012|modified dose regimen
89312001|NCT04945798|No Intervention|No OMT|The STAI (Y2), DASS and Scale of Body Connection administered to this cohort at baseline (T1), after two treatments (T3), and after four treatments (T4).
89312002|NCT04945798|Active Comparator|OMT|"OMT: direct myofascial release for the triplanar diagnonosis to the OA, thoracic outlet, respiratory diaphragm and pelvic diaphragm concluding with a pedal pump for 120 seconds.~The STAI (Y2), DASS and Scale of Body Connection administered to this cohort at baseline (T1), after two treatments (T3), and after four treatments (T4)."
89312003|NCT03869931|Experimental|Fenofibrate|(Refer to intervention)
89312004|NCT05173168|Experimental|Probiotic Dietary Supplement|resB® Lung Support - 1 capsule 2x daily for 4 weeks
89312005|NCT04876066|Experimental|Ketamine dose|The recommended ketamine dose of 0.5 mg/kg will be administered using a transmucosal route of administration wherein the subject will be instructed to place the liquid solution beneath their tongue and hold it in their mouth for 5 minutes. The pharmacy will prepare two 0.5 mg/kg solutions of ketamine in two syringes for each subject based on subject weight. For example, a 70 kg adult subject will receive a 0.35 mL solution of ketamine. The patient will receive a dose every 7 days for two weeks, for a total of two doses.
89312006|NCT01169805|Experimental|ONSERAN|
89312007|NCT01169805|Experimental|NASEA|
89312008|NCT01169805|Experimental|ALOXI|
89312009|NCT01169805|Placebo Comparator|normal saline|
89312010|NCT04865926|Experimental|Scapular and Neck Proprioceptive Neuromuscular Facilitation Group|Participants in the intervention group will be applied neck and scapular Proprioceptive Neuromuscular Facilitation exercises lasting 40 minutes for 3 sessions a week for 4 weeks.
89312011|NCT04865926|Experimental|Control Group|McKenzie and Kendall exercises will be given to the participants in the control group. Exercises will be done 3 sessions a week over a 4-week period.
89312012|NCT01169883|Active Comparator|Attention Control Group|1) Doctor Asthma Messages delivered over a 10 week time period; 2) Asthma Supervision; and 3) Music Tracks.
89312013|NCT01169883|Experimental|Intervention Group|1) Coping Peer Support delivered over a 10 week time period; 2) Coping Peer Asthma Messages delivered over a 10 week time period; 3) Asthma Supervision; and 4) Music Tracks.
89312014|NCT03563092|Experimental|Lap Inguinal Hernia repair with Drain|A (14 French sizes) closed suction drain will be placed in preperitoneal space after laparoscopic inguinal hernia (TEP/TAPP) surgery.
89312015|NCT03563092|Active Comparator|Lap Inguinal Hernia repair without Drain|No drain will be placed after laparoscopic inguinal hernia (TEP/TAPP) surgery.
89312016|NCT01166061|Experimental|Cohort 1|Subjects to receive either active or placebo
89312017|NCT01166061|Experimental|Cohort 2|Subjects to receive either active or placebo comparator
89312018|NCT01166061|Experimental|Cohort 3|Subjects to receive either active or placebo comparator
89312019|NCT01166061|Experimental|Cohort 4|Subjects to receive either active or placebo comparator
89312020|NCT01166061|Experimental|Cohort 5|Subjects to receive either active or placebo comparator
89312021|NCT05319886||Anlotinib and Penpulimab|
89312022|NCT01283061|Experimental|zafirlukast|Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited
89312023|NCT01283061|Active Comparator|Accolate|ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals
89312024|NCT01167387|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
89312025|NCT01167387|Placebo Comparator|water|The control group will receive plain water with the same volume and timing of treatment.
89312026|NCT01281267|Experimental|Face transplantation|
89312027|NCT03563014||Radium-223 (Xofigo, Bay88-8223)|Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
89312028|NCT01275495|Experimental|Telephone Assessment and Skill-Building Kit (TASK II)|The TASK II group will fill out a checklist about their needs and concerns, and will receive written tip sheets by mail that address the needs and concerns that they feel are most important. A nurse will call by telephone (lasting about 30 minutes or less) once a week for a total of 8 weeks, with another call at 12 weeks, to provide more information, answer questions, and to discuss more written tip sheets based on the caregiver's needs and concerns.
89312029|NCT01275495|Active Comparator|Information, Support, and Referral (ISR)|The ISR group will receive existing educational materials about stroke and caregiving developed by the American Stroke Association and weekly telephone calls by a nurse (lasting about 30 minutes or less) for a total of 8 weeks, with another call at 12 weeks.
89312030|NCT02526459|Experimental|birth plan|Use of birth plan
89312031|NCT02526459|No Intervention|no birth plan|No use of birth plan
89312032|NCT01283217|Experimental|DS(Docetaxel with S-1)|Docetaxel with S-1
89312033|NCT01283217|Active Comparator|SP(S-1 with cisplatin)|S-1 with cisplatin
89312034|NCT01275807|Experimental|acupuncture|10 acupuncture sessions
89312035|NCT01275807|Active Comparator|self care|psychological support, phisical exercice, diet, self care groups
89312036|NCT03873597|Experimental|Tele-coaching + Usual Care|This group will undergo a 12 week physical activity tele-coaching intervention consisting of a step-counter and smartphone application, in addition to usual care. Usual care will also include sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
89312037|NCT03873597|No Intervention|Usual Care|This group will receive sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
89312038|NCT01276431|Other|Buprenorphine transdermal patch|For two age groups: 50-60 years and >= 75 years of age
89312039|NCT03869619||All enrolled patients|All patient who signed the consent form for participation to the study
89312040|NCT01166217|Experimental|ABCE, ACBD, BACD, BCAE, CABE and CBAD|
89312041|NCT03869385|Experimental|Albumin group|Patients assigned to the Albumin group will receive a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.
89312042|NCT03869385|No Intervention|Control group without albumin:|The control group will be treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.
89312043|NCT01283373|Experimental|A|Dose escalation cohorts
89312044|NCT01283373|Experimental|B|Dose expansion cohorts
89312045|NCT01281579|Experimental|001|Canagliflozin 50 mg Tablets oral 50-mg once daily on Day 1 and on Days 4 through 9.
89312046|NCT01281579|Experimental|002|Canagliflozin 100 mg Tablets oral 100-mg once daily on Day 1 and on Days 4 through 9.
89312047|NCT01281579|Experimental|003|Canagliflozin 300 mg Tablets oral 300-mg once daily on Day 1 and on Days 4 through 9.
89312048|NCT03873285|Experimental|Genodermatosis patients|Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression
89312049|NCT03869229|Active Comparator|osteoarthritis of the knee|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
89312050|NCT03869229|Active Comparator|osteoarthritis of the hip|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
89312051|NCT03869229|Active Comparator|osteoarthritis of the glenohumeral joint|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
89312052|NCT03873519|Experimental|Cold North|Group A: Cold color scheme, room facing North
89312053|NCT03873519|Experimental|Cold South|Group B:Cold color scheme, room facing South
89312054|NCT03873519|Experimental|Warm North|Group C: Warm color scheme, room facing North
89312055|NCT03873519|Experimental|Warm South|Group D: Warm color scheme, room facing South
89312056|NCT01283451||Exercise|NIRS values of all participants will be measured at baseline and following each 30-60 second exercise.
89312057|NCT01283529||Children 0 - 15 years|Children undergoing neurosurgery in general anesthesia
89312058|NCT01283607|Active Comparator|Digicoach|Women randomized in the Digicoach group will be treated by the Digicoach therapy. Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for in vitro fertilization (IVF) women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
89312059|NCT01283607|No Intervention|Control|Women in the control group will get the usual treatment, there will be no additional intervention.
89312060|NCT03871101|Active Comparator|Scalpel|Soft tissue incision with scalpel in second- stage implant surgery.
89312061|NCT03871101|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz H mode, 10% water and 10% air) in second-stage implant surgery.
89312062|NCT01281657||Prescribed fingolimod 0.5 mg/day|
89312063|NCT01166451|Experimental|Low-iron|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age.
89312064|NCT01166451|Experimental|High-iron|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age.
89312065|NCT03873441|Experimental|Computer Games-Aided Balance Training Group|The participants in CGR group will be asked to sit or stand (as per the screening result) on fixed & compliant surfaces; to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects using bi-manual grip gradually progressing to head rotations (mouse mounted on a cap worn by participant); finally using trunk movements as a part of experimental therapy protocol. While performing CGR; children will be standing on a thin pressure mat (placed over fixed or compliant surface). This will allow us to record the information of COP displacement [body sway] while CGR intervention implementation. This information will be used to quantify therapy dosage. The CGR Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
89312066|NCT03873441|Active Comparator|Conventional Balance Training Group|The control group will be receiving the conventional balance training for static and dynamic balance function improvement. The therapy will be provided in sitting or standing (as per the screening result) in a graded manner progressing from fixed surfaces to movable compliant surfaces. The Conventional Balance Training Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
89312067|NCT01277991|Experimental|Sequence 1|
89312068|NCT01277991|Experimental|Sequence 2|
89312069|NCT01166529|Experimental|EUS-CPN|
89312070|NCT03755661|Experimental|Intervention|This intervention arm is a combined in-person text messaging intervention
89312071|NCT03755661|No Intervention|Assessment Only Control|The is the assessment only comparison condition
89312072|NCT03873129|Experimental|A-CHESS|participant will be using the A-CHESS mobile app for 12 months
89312073|NCT02526615|Placebo Comparator|Placebo|placebo, 2 tablets per day
89312074|NCT02526615|Active Comparator|Metformin|500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day
89312075|NCT02526615|Active Comparator|Rosiglitazone|2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day
89312076|NCT03872817|Experimental|Intervention ProLiSMentAl|"Experimental Group receive mental health literacy psychoeducational intervention called ProLiSMentAl that consist of 4 sessions of 90 minutes."
89312077|NCT03872817|No Intervention|Control Group|Control Group receive usual approach.
89312078|NCT01283763|Experimental|Topical Imiquimod|16 weeks topical Imiquimod
89312079|NCT01283763|Active Comparator|Conization|Large loop excision of the transformation zone
89312080|NCT01283841|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
89312081|NCT01283841|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
89312082|NCT01278537|Experimental|Empowerment, shared-decision making,|Patients receive a booklet with informations. Assessment of health-related risk factors. Assessment of psychological and physical social support Delirium protection. Early mobilization.
89312083|NCT01278537|No Intervention|control group|
89312084|NCT03868917|No Intervention|ultrasound group|The participants have continuous thoracic paravertebral block performed using only the ultrasound approach.
89312085|NCT03868917|Experimental|pressure measurement group|The participants have continuous thoracic paravertebral block performed using the ultrasound-guided approach combined with pressure measurement techniqueduring needle advancement.
89312086|NCT03872661|Experimental|Drug and surgery|Neoadjuvant therapy followed by surgery. Neoadjuvant therapy included four drugs. IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles; bevacizumab was administered at a dose of 15 mg/kg; pemetrexed was given 500 mg/m^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles; carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles. Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
89312087|NCT01167543||Pediatric patients with symptoms or diagnosis of GER|
89312088|NCT01167543||Control group of pediatric subjects with no symptoms of GER.|
89312089|NCT02526303|Experimental|Anticoagulation|Drug: Nadroparin Calcium and Warfarin Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,along with Nadroparin Calcium 85IU／kg，subcutaneous, q12h,for the first 5 days at least.
89312090|NCT02526303|No Intervention|Non-anticoaglated|No anticoagulatoin or other treatment for PVT will be used in this group of patients.
89312091|NCT03869073|Experimental|Low Dose|This treatment arm will receive the highest dose of evolocumab currently marketed and approved: 420mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
89312092|NCT03869073|Experimental|High Dose|This treatment arm will receive double the highest dose of evolocumab currently marketed and approved: 840mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
89312093|NCT03869073|Placebo Comparator|Placebo|This treatment arm will receive saline solution. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
89312094|NCT03872739|Experimental|distilled water|Oral distilled water at the rate of 3 mL/kg/h rate during undergoing enhanced computed tomography examination before 1-2 and after 4-6 hours
89312095|NCT03872739|Placebo Comparator|Saline|intravenous saline hydration at the rate of 1 mL/kg/h rate during undergoing enhanced computed tomography examination before and after 12 hours
89312096|NCT01587495|Experimental|Ertapenem|Women diagnosed with postpartum endometritis
89312097|NCT03872973|Experimental|Training Group|Neuromuscular training will be performed in this group for 6 weeks.
89312098|NCT03872973|Experimental|Strobe Group|This group will perform neuromuscular training for 6 weeks with a strobe glasses.
89312099|NCT03872973|No Intervention|Control Group|This group will not perform any neuromuscular training program.
89312100|NCT03870867||Seniors who have fallen|Emergency department patients over the age of 65 who present to the emergency department after a fall.
89312101|NCT01170351|Active Comparator|Group-A|Treatment-naive AIH patients consenting to participate
89312102|NCT01170351|Experimental|Group-B|Treatment-naive AIH patients consenting to participate. This group will receive Cyclosporine-A according to a set protocol.
89312103|NCT01170429|Experimental|I. Procaterol Hydrochloride|Meptin (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
89312104|NCT01170429|Placebo Comparator|II. Procaterol hydrochloride placebo|Meptin placebo (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
89312105|NCT03868995|Sham Comparator|Sham injection|Dextrose water injection to subcutaneous layer at tender point
89312106|NCT03868995|Experimental|Tendon injection|Dextrose water injection to injured tendon
89312107|NCT01170507|Active Comparator|vitamin D3 1000 IU|
89312108|NCT01170507|Active Comparator|Vitamin D3 3000 IU|
89312109|NCT01170507|Active Comparator|Vitamin D3 5000 IU|
89312110|NCT01170507|Placebo Comparator|Placebo|
89312111|NCT01170585|Placebo Comparator|Placebo|randomised to placebo.
89312112|NCT01170585|Active Comparator|Active|randomised to rosuvastatin.
89312113|NCT01170741|No Intervention|Delayed Control Condition|Participants assigned to the delayed treatment control condition will be offered biological testing and the tailored cue-card intervention upon completion of their 3- month follow-up interview. Use of a delayed treatment control group design will permit us to separate intervention effects on HIV risk behaviors from the general effects of participating in the study and completing a detailed HIV risk assessment.
89312114|NCT03868527||Hematological diseases|Cohort of patients followed for lymphoid malignant hemopathy in Lyon Sud Hospital
89312115|NCT01170819|Active Comparator|Dinoprostone Vaginal Insert|
89312116|NCT01170819|Experimental|Double Balloon Catheter|
89312117|NCT03868683|Other|Glucose Reference 1|Glucose solution containing 30 g of glucose
89312118|NCT03868683|Other|Glucose Reference 2|Glucose solution 2 containing 30 g of glucose
89312119|NCT03868683|Other|Glucose Reference 3|Glucose solution 3 containing 30 g of glucose
89312120|NCT03868683|Experimental|Sucrose|Sucrose solution containing 30 g of sucrose
89312121|NCT03868683|Experimental|Regular Bake beans in tomato sauce|Bake bean in tomato sauce with high levels of sucrose (37%)
89312122|NCT03868683|Experimental|Bake beans in tomato sauce, reduced sugar|Bake bean in tomato sauce with medium levels of sucrose (29.9%)
89312123|NCT03868683|Experimental|Bake beans in tomato sauce, low GI|Bake bean in tomato sauce with low levels of sucrose (18.5%)
89312124|NCT01170897|Other|Maximally Tolerated Dose|To identify the maximally tolerated dose (MTD) of PEGPH20.
89312125|NCT01170975|Other|Treatment sequence 1|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
89312126|NCT01170975|Other|Treatment sequence 2|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
89312127|NCT03868449|Experimental|Question Prompt List|Participants will be given a Question Prompt list that has been developed by the research team
89312128|NCT03868449|Active Comparator|3 questions list|Participants will be given 3 questions from the AskShareKnow method
89312129|NCT03868761|Other|Single Arm|21 male and female teenage participants will be randomized to one of three varying baseline assessment periods of two, four, or six weeks. Multiple baseline is a type of single-case experimental design (SCED) that is a time- and cost-effective method for evaluating efficacy of a new treatment, Sonoma Rises. The randomization of participants to baseline periods of varying lengths enables assessment of whether symptom changes occur when, and only when, the intervention is applied.
89312130|NCT01171053|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
89312131|NCT01171053|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support
89312132|NCT03868293|Experimental|Drug-Resistant Epilepsy (temporal lobe)|Pulsed low intensity focused ultrasound
89312133|NCT03752151|Experimental|MARVEL 2 Algorithm Monitor Mode, Then MARVEL 2 Adaptive Mode|Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.
89312134|NCT03868371|Active Comparator|1. high - 2. low|These are the patients receiving a high phosphorous containing meal in the first trial day, and a low phosphorous containing meal in the second trial day.
89312135|NCT03868371|Active Comparator|1. low - 2. high|These are the patients receiving a low phosphorous containing meal in the first trial day, and a high phosphorous containing meal in the second trial day.
89312136|NCT03868137|Placebo Comparator|Placebo|3 doses of placebo identical to study drug will be given to patients starting 1 day before IUD insertion
89312137|NCT03868137|Experimental|Ibuprofen|3 doses of Ibuprofen 800 mg will be given to patients starting 1 day before IUD insertion. Patient will take 800 mg Ibuprofen at noon and 8 PM day before IUD insertion and at 8 AM on the day of IUD insertion.
89312138|NCT01283919|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
89312139|NCT01283919|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
89312140|NCT01167777||male/female|Symtomatic and asymptomatic males and females attending STD, family planning, public health and women's health clinics, or other applicable centers, who are being screened for CT or GC.
89312141|NCT01167855|Experimental|Intervention|"Telemedicine asthma education sessions~Asthma health assessment via telemonitoring~Provider treatment prompts~School absenteeism~Prescription filling profile"
89312142|NCT01167933|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
89312143|NCT01167933|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
89312144|NCT01168011|Experimental|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day every day of 21-day cycles.
89312145|NCT03871023|Active Comparator|Simple dressing|Standard, waterproof dressing applied to wound
89312146|NCT03871023|Active Comparator|PICO Dressing|Negative Wound pressure applied second cohort
89312147|NCT03871023|Active Comparator|PREVENA Dressing|Negative wound presure applied to third cohort
89312148|NCT01168167||raltegravir-based cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus raltegravir (n=10 patients) will be offered to participate in this observation arm, but only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
89312149|NCT01168167||standard of care-cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus either a boosted protease inhibitor or efavirenz (n=10 patients) at standard doses will be offered to participate in this observation arm. They will be offered to participate in this trial only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
89312150|NCT01168245|Experimental|NICE-System NeuroAD|Treatment Group
89312151|NCT01168245|Sham Comparator|Sham-TMS|Control Group
89312152|NCT01168323|Experimental|Spaced education clinicians - cohort 1|Spaced education clinicians receive four isomorphic cycles of 9 spaced education emails over 36-weeks (0-2 emails per week). Each email contained one question-explanation.
89312153|NCT01168323|No Intervention|Control clinicians - cohort 2|Control clinicians received no intervention
89312154|NCT01171209|Experimental|IFN-alfa|One single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c.
89312155|NCT01171209|Experimental|Interferon-beta|One single injection of IFN-beta followed by blood test for MxA9.12 hours after injection
89312156|NCT01166685|Active Comparator|Everolimus-eluting stent|A Xience Prime stent (Everolimus-eluting stent) is implanted in significant coronary lesions.
89312157|NCT01166685|Active Comparator|Bare-metal stent|Implantation of a bare-metal stent
89312158|NCT01166685|Experimental|Biodegradable Polymer-DES|Implantation of a Biodegradable Polymer-DES
89312159|NCT02526537||Gefitinib|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Gefitinib for postoperative therapy (Gefitinib 250 mg daily for 2 years).
89312160|NCT02526537||Non-specific treatment|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Non-specific treatment.(Chinese herbal medicine and nonspecific immunomodulators as adjuvant anti-cancer treatment for 2 years).
89312161|NCT01171287|Experimental|Aircast Walker|Automobile driving with an Aircast Walker applied to each participant's right lower extremity
89312162|NCT01171287|Experimental|Walking cast|Automobile driving with a walking cast applied to each participant's right lower extremity
89312163|NCT01171287|Active Comparator|Running shoe|Automobile driving with a running shoe applied to each participant's right lower extremity
89312164|NCT03870789||Retrospective|The Investigators will examine data from 1-year prior to paramedic implementation of the Hamilton Early Warning Score tool.
89312165|NCT03870789||Prospective|The Investigators will examine data from 1-year after paramedic implementation of the Hamilton Early Warning Score tool.
89312166|NCT03870711|Experimental|group A|10% lidocaine spray
89312167|NCT03870711|Placebo Comparator|group B|sterile water
89312168|NCT03868215||Patients with endoscopically removed malignant polyps|Patients with endoscopically removed malignant polyps
89312169|NCT03872505|Active Comparator|Chemotherapy + Durvalumab|Arm A: Carboplatin, Paclitaxel and Durvalumab
89312170|NCT03872505|Experimental|Chemo + Durvalumab + Radiation Therapy|Arm B: Carboplatin, Paclitaxel and Durvalumab + Radiation Therapy
89312171|NCT03872193|Experimental|Physio Therapy|We intervention this group some routine exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees.
89312172|NCT03872193|Experimental|Virtual Reality|This group had physical therapy program plus virtual reality exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees. And virtual reality exercises were done for this group. Skiing,kayak, football,rafting and jumping activities were done in this exerciese.
89312173|NCT02526381|Experimental|Danlou Tablets|Danlou prescription is a tablet, each piece weighs 0.3 g, taken orally, three times a day, five at a time, from jilin Cornell's pharmaceutical corporation, Limited Liability Company .
89312174|NCT02526381|Experimental|Tongmai Yangxin Pills|Tongmai Yangxin prescription is a pill,each pill weighs 0.1 g,taken orally, 2 times a day,40 pills at a time,produced by tianjin new pharmaceutical group corporation, Limited Liability Company . LeRenTang pharmaceutical.
89312175|NCT02526381|No Intervention|no drugs|
89312176|NCT01171365|Active Comparator|Ciclesonide|Ciclesonide 320 microgrammes twice daily
89312177|NCT01171365|Placebo Comparator|Placebo|Placebo 2 inhalations twice daily
89312178|NCT01281891|Experimental|Local Infiltration Analgesia|Combination of ropivacaine, ketorolac and adrenaline
89312179|NCT01281891|Active Comparator|Intrathecal morphine|Morphine special (preservative-free) injected intrathecally
89312180|NCT01168479|Active Comparator|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
89312181|NCT01168479|Experimental|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
89312182|NCT01279395||naproxen|Patients age 40-70 who fulfill the American College of Rheumatology (ACR) criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed naproxen (1000 mg/day) for a minimum of two weeks.
89312183|NCT01279395||diclofenac|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis. The group consists of patients who have been prescribed diclofenac (150 mg/day)for a minimum of two weeks.
89312184|NCT01279395||celecoxib|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed celecoxib (200 mg/day) for a minimum of two weeks.
89312185|NCT01166841|Experimental|PSVC line clamped|Clamping of the percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
89312186|NCT01166841|No Intervention|Unclamped PSVC|Unclamped percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
89312187|NCT01280019|Experimental|FRC guided|Patients receive an alveolar recruitment manoeuvre if FRC falls below 94% of baseline FRC
89312188|NCT01280019|Active Comparator|Saturation guided|Patients receive an alveolar recruitment manoeuvre if peripheral oxygen saturation falls below 90%
89312189|NCT01282047|Experimental|Lenalidomide|
89312190|NCT01280097||Prospective cohort study|Observational only
89312191|NCT02525991|Experimental|Staccato® Delivery System Loxapine|Staccato® Delivery System Loxapine, 9.1 mg one dose
89312192|NCT01282125||sleep apnea|100 patients suffering from obstructive sleep apnea syndrome
89312193|NCT01282125||controls|100 subjects matching cases to age, sex, and body weight
89312194|NCT01172613||healthy subjects no symptoms|
89312195|NCT01172613||allergic rhinitis patient|
89312196|NCT01171755|Experimental|Gemcitabine, Ts-1|Gemcitabine : 1000/m2 will be administered on days 1 and 8 at every 3 weeks . TS-1 will be administered orally according to body surface area (BSA) as follows : BSA<1.25 M2, 80 mg/day; 1.25 M2≤BSA<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
89312197|NCT01172691|Experimental|Placebo and Study|
89312198|NCT01171833|Experimental|Group A(Sevoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
89312199|NCT01171833|Experimental|Group B(Desflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
89312200|NCT01171833|Experimental|Group C(Isoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
89312201|NCT01172769|Experimental|Temsirolimus|
89312202|NCT01284075|Experimental|Guided Imagery and Music therapy group (GIMT)|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
89312203|NCT01284075|Active Comparator|White Noise Group (WN)|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
89312204|NCT01284075|Active Comparator|No Interventions Group (CP)|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
89312205|NCT02526147|No Intervention|Control|Receives no intervention
89312206|NCT02526147|Experimental|Cash|Household receives cash transfer monthly for 6 months
89312207|NCT02526147|Experimental|Voucher|Household receives food voucher to use at local supermarket monthly for 6 months
89312208|NCT02526147|Experimental|Food|Household receives food transfer composed of rice, lentils, canned sardines, and vegetable oil, monthly for 6 months
89312209|NCT01282281||Individuals aged 14-18 and 19-65 with a diagnosis of BD|
89312210|NCT02525835|Experimental|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
89312211|NCT02525835|Experimental|High Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
89312212|NCT01584531|Experimental|21-Day Regimen|560 mg oral rigosertib in the morning and 280 mg rigosertib in the afternoon on days 1 to 21 of 21-day cycle
89312213|NCT02526069|Other|SweetSpot users|Participants will interact with the smartphone application for as long or as little as they wish. They will be asked to complete questionnaires at baseline (pre), 4 weeks (post), and to attend an interview.
89312214|NCT03870321|Experimental|Core training|The subjects who are in the experimental group will carry out the Core training routine
89312215|NCT03870321|No Intervention|Control|The subjects who are in the control group will not receive intervention and will continue with their daily routine and training
89312216|NCT03870165|Active Comparator|Salmon|After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide.
89312217|NCT03870165|Experimental|Isolated mixture|After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet.
89312218|NCT01168557|Experimental|Stress-Echo and EIT|Patients who routinely undergo stress-echocardiography will additionally be measured by EIT using a rubber belt, which will be placed around their chest
89312219|NCT01582503|Experimental|MEMP1972A 150 mg|
89312220|NCT01582503|Experimental|MEMP1972A 300 mg|
89312221|NCT01582503|Experimental|MEMP1972A 450 mg|
89312222|NCT01582503|Placebo Comparator|Placebo|
89312223|NCT01168635|Experimental|Intervention|Virtually-delivered spirometry quality improvement program
89312224|NCT01168635|No Intervention|Standard of Care|
89312225|NCT01172925|Experimental|Tiotropium|Inhaler
89312226|NCT01172925|Placebo Comparator|Placebo|Inhaler
89312227|NCT03867669|Experimental|Single Patient Room|Patients randomized to this arm will be admitted to a NICU single patient room.
89312228|NCT03867669|Placebo Comparator|Open Bay|Patients randomized to this arm will be admitted to the open bay NICU Unit.
89312229|NCT01284465|Experimental|Intervention group|Education and patient liaison combination
89312230|NCT01284465|Experimental|Control group|Education only
89312231|NCT01284231|Experimental|MEDI-565 - Dose Escalation|Up to 15 dose-escalation cohorts will be enrolled
89312232|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 1|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
89312233|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 2|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
89312234|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 3|Subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biological dose
89312235|NCT03870087||Robotic PCI|All subjects treated with CorPath GRX during the PCI procedure.
89312236|NCT01282359|Other|Clinical Practice Group|Patients collected in centres randomized as usual clinical practice, who will not receive the limited educational asthma program.
89312237|NCT01282359|Other|"Gold Standard educational group"|Patients will receive a formal program of structured and individualized education, enrolled in centres recognized by using high standard procedures in asthma education.
89312238|NCT01282359|Other|Intervention group|This group will receive a limited educational asthma program (minimal educational intervention)
89312239|NCT03867591|Experimental|Gastro-AD® Group|The participants randomized to this group 1 g of Gastro-AD® powder per sachet + flavoring agents.
89312240|NCT03867591|Placebo Comparator|Placebo Group|Participants in this arm will take a sachet containing maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
89312241|NCT01172223|Experimental|LAPADO|Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m2 i.v. day 1 q3 weeks), Paclitaxel (175 mg/m2 i.v. day 1 q3 weeks), and Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery)
89312242|NCT01284543|Active Comparator|Busin glide delivery of donor graft|Use of the Busin glide to insert the donor graft
89312243|NCT01284543|Experimental|Tan EndoGlide for insertion of the donor graft|Use of the Tan EndoGlide for insertion of the donor graft
89312244|NCT01173081|Experimental|Teriparatide|Patients randomized into this group will inject 20mcg of teriparatide once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
89312245|NCT01173081|Placebo Comparator|Placebo Control|Patients randomized into this group will inject a matching dose of placebo once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
88821244|NCT04794803|Experimental|Reparixin|Reparixin oral tablets 1200 mg TID for 7 days
89312246|NCT03867513||mTBI cases|Those diagnosed with mild traumatic brain injury (mTBI) without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
89312247|NCT03867513||Acute trauma controls|Non-head trauma controls matched for age and sex with the mTBI group
89312248|NCT03866733|Active Comparator|Narcotics group (group N)|intervention: injection of boluses of intra venous Narcotics (fentanyl) in the dose of (3-5 mcg/kg) during the surgery after induction of anesthesia. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till 48 hours after surgery. NSAID every 12 hrs if there is no contraindication and iv acetaminophine igm/6hrs.
88821245|NCT04794803|Active Comparator|Standard of care|Standard of care
89312249|NCT03866733|Experimental|Erector spinea block group (group B)|intervention: after induction our intervention will be the performance of ultrasound guided bilateral continous Erector spinea block with insertion of catheters then 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 8 ml/h. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till extubation and iv acetaminophine igm/6hrs.
89312250|NCT03869775||control group|no additional disease
89312251|NCT03869775||working group-1|additional disease only DM and no cardıovascular autonomous neuropathıa
89312252|NCT03869775||working group-2|additional disease only DM and pozitif cardıovascular autonomous neuropathıa
89312253|NCT03866811|Experimental|Intervention arm|The intervention consists of a brief contraception educational video and then the 10-week texting intervention which consists of 30 automated, personalized and interactive texting algorithms (3 texts per week).
89312254|NCT03866811|No Intervention|Control arm|Patients randomized to the control arm will receive the current standard discharge instructions provided in the investigator's ED.
89312255|NCT05379933|Experimental|C-PRIME|Participants will wear an activity tracker for 8 weeks. During the 8 weeks of the study, participants will complete weekly survey questions about health and well-being and engage in weekly, 15-20 minute telephone/videoconference coaching sessions with a health coach.
89312256|NCT01168791|Experimental|doxorubicin plus palifosfamide-tris|
89312257|NCT01168791|Active Comparator|doxorubicin plus placebo|
89312258|NCT01172301|Experimental|Oral EAA vs total AA supplement|
89312259|NCT03867279|Experimental|Flossing|The subjects included in this group will perform a protocol of reeducation exercises plus the application of the Flossing technique. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
89312260|NCT03867279|Active Comparator|Reeducation exercises|The subjects included in this group will carry out a protocol of reeducation exercises. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
89312261|NCT01284309|Experimental|Mirabegron|
89312262|NCT01284309|Placebo Comparator|Placebo|
89312263|NCT03866889|Experimental|Strength|Maximum strength protocol based on a Maximum Repetition (1RM). The aim of the application of the training is to produce an increase in strength based on training with high loads (80% 1RM), individually and covering the muscles of the lower extremity (quadriceps, hamstrings, gluteus maximus).
89312264|NCT03866889|Active Comparator|Normal activity|The subjects included in the control group will perform the same physical activity to improve the strenght until the beginning of the study. The exercises will be done in the same conditions and with the same period (4 days / week)
89312265|NCT01284777||patients|
89312266|NCT02525913|Other|Bi-lateral mastectomy|
89312267|NCT01168869||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
89312268|NCT01282437|Experimental|Prophylactic Cranial Irradiation|
89312269|NCT01282437|No Intervention|Observation|Patients will not receive PCI, but will be observed and the same items will be measured as in the PCI-arm.
89312270|NCT01168947|Experimental|5% dextrose|5% dextrose rinsing fluid
89312271|NCT03867045|Experimental|mRCC treated with cabozantinib|Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria.
89312272|NCT01173237|Active Comparator|Tracheal intubation|Endotracheal tube is a airway device used for ventilation or surfactant administration, in preterm babies with SDR surfactant deficiency.
89312273|NCT01173237|Experimental|Proseal laryngeal mask airway|Laryngeal mask airway is a airway device used for ventilation with self-inflating bag or flow-inflating bag. In this study it will be used for surfactant administration, in preterm babies with SDR surfactant deficiency.
89312274|NCT01172379|Experimental|Experimental 1|
89312275|NCT01172379|Experimental|Experimental 2|
89312276|NCT01172379|Experimental|Experimental 3|
89312277|NCT01172379|Placebo Comparator|Placebo Comparator|
89312278|NCT01172457|Active Comparator|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
89312279|NCT01172457|Placebo Comparator|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
89312280|NCT01169025|Experimental|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
89312281|NCT01169025|Active Comparator|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
89312282|NCT01582347|Experimental|RBP-6300|During the Double-Blind Transfer Period (Days 1-7), participants take RBP-6300 at a level (either 10, 20 or 30 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for Subutex®/Suboxone®. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
89312283|NCT01582347|Active Comparator|Subutex®/Suboxone®|During the Double-Blind Transfer Period (Days 1-7), participants take Subutex®/Suboxone® at a level (either 8, 16 or 240 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for RBP-6000. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
89312284|NCT01336634|Experimental|Cohort A (Dabrafenib Monotherapy)|"Participants received Dabrafenib 150mg BID and continued treatment until disease progression, death, or unacceptable adverse event.~Participants receiving and adequately tolerating dabrafenib as a single agent and who continue to meet the inclusion and exclusion criteria had the option to switch to Dabrafenib (150 mg BID) and Trametinib (2 mg once daily) combination treatment within 4 weeks of radiologic disease progression with prior approval from a medical monitor."
89312285|NCT01336634|Experimental|Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E|Participants received Dabrafenib 150 mg BID in combination with Trametinib 2 mg once daily and continued treatment until disease progression, death, or unacceptable adverse event.
89312286|NCT01336634|Experimental|Cohort C - Double Combination (Dabrafenib+Trametinib) naive mBRAF V600E|Participants received Dabrafenib 150 mg BID in combination with Trametinib 2 mg once daily and continued treatment until disease progression, death, or unacceptable adverse event.
89312287|NCT01284855|Active Comparator|Low initial dose|This arms corresponds to Nepal national protocol and involves the initial administration of 2 vials of antivenom over one hour followed by the slow infusion of 4 vials over 4 hours
89312288|NCT01284855|Experimental|High initial dose|This arms corresponds to Indian national protocol and involves the initial administration of 10 vials of antivenom over one hour followed by the slow infusion of saline over 4 hours
89312289|NCT01169181|Active Comparator|AMES therapy with rTMS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+rTMS, followed by an EMG test. During the hand-opening phase of the AMES therapy, the subjects assigned to the AMES+rTMS treatment group will be subjected to trains of TMS pulses.
89312290|NCT01169181|Active Comparator|AMES therapy with tDCS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+tDCS, followed by an EMG test. A constant current will be applied throughout the entire 20-minute therapy session with the AMES device.
89312291|NCT03863847|Active Comparator|Online Neurofeedback|This intervention entails online feedback of pain-related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
89312292|NCT03863847|Sham Comparator|Online Sham Neurofeedback|This intervention entails online sham feedback of non-pain related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
89312293|NCT01284933||Acute Ischemic Stroke, TIA|Patients admitted to a specialized stroke service because of an acute ischemic stroke or a transient ischemic attack (TIA).
89312294|NCT00785798|Experimental|vorinostat doxil|Escalating doses of vorinostat 200mg to 400mg twice daily on days 1-7, and fixed-dose IV PLD 30mg/m2 on day 3 of a 21-day cycle
89312295|NCT01175109|Experimental|Escalating doses of imatinib and LBH589|"Study will incorporate a 3+3 dose escalation design."
89312296|NCT01282515|Experimental|ELP active|one PDT treatment with 2 ml hexaminolevulinate 6 mg/ml gel
89312297|NCT01282515|Active Comparator|topical steroids|treatment with clobetasol propionate 0.05% ointment used daily for 6 weeks
89312298|NCT03866343|Active Comparator|Low AGE diet|Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.
89312299|NCT03866343|Other|High AGE diet|Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.
89312300|NCT05348265|Active Comparator|Low Intensity steady state training|Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
89312301|NCT05348265|Experimental|High intensity interval training|"Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches."
89312302|NCT03638492|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
89312303|NCT03638492|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
89312304|NCT02947100|Experimental|SCD-Omegatex™|single arm
89312305|NCT03329846|Active Comparator|Nivolumab + Placebo|"Specified dose on specified day~Participants will no longer receive BMS-986205 Placebo"
89312306|NCT03329846|Experimental|Nivolumab + BMS-986205|"Specified dose on specified day.~Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion"
89312307|NCT04247516|No Intervention|Standard Control Group|The standard control group (CG) will not have access to the self-regulatory (SR) intervention program.
89312308|NCT04247516|Experimental|Online-intervention group I (IGI)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration."
89312309|NCT04247516|Experimental|Online-intervention group II (IGII)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration; iii) the program includes gamification strategies with the purpose of promoting engagement in participants."
89312310|NCT03325010|Placebo Comparator|Placebo|Participants received placebo (matching valbenazine) once daily for 12 weeks.
89312311|NCT03325010|Experimental|Valbenazine|Participants received valbenazine once daily for 12 weeks. The starting dose was 20 mg for participants <50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects <50 kg and 80 mg for subjects ≥50 kg to achieve an optimal dose of valbenazine for each participant.
89312312|NCT03638102|Experimental|Sleep intervention|Sleep extension
89312313|NCT03638102|Active Comparator|Healthy living|Health education
89312314|NCT04020848||Patients with Alternating Hemiplegia of Childhood (AHC)|"Patients who fit the Aicardi Alternating Hemiplegia of Childhood clinical criteria of any age. The Aicardi Criteria are six (Heinzen et al 2015). (1) Paroxysmal hemiplegia episodes. (2) Bilateral hemiplegia or quadriplegia episodes. (3) Other paroxysmal manifestations, such as abnormal eye movements, nystagmus, strabismus, ataxia, dystonia, choreoathetosis, tonic spells, or autonomic disturbances. (4) Evidence of permanent neurological dysfunction, which can manifest as cognitive impairment, developmental delay, and/or persistent motor deficits such as spastic diplegia/quadriplegia, hypotonia, ataxia, choreoathetosis, or dystonia. (5) Sleep relieves symptoms, although attacks may resume soon after awakening. (6) First signs of dysfunction occur prior to the age of 18 months.~Patients having some but not all the above criteria and have the mutation in ATP1A3 gene can be included."
89312315|NCT05295706|Experimental|Intervention Group|Participants in this group will complete the same measures as the control group, but will additionally be involved in a counterfactual intervention conducted by an advanced graduate student.
89312316|NCT05295706|No Intervention|Control Group|Participants in this group will complete the same measures as the experimental group. Instead of being involved in a counterfactual intervention, participants will be asked about their intentions to complete future study components.
89312317|NCT02824432|Experimental|TAK-085 2g|A dose of 2 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered once a day immediately after meal.
89312318|NCT02824432|Experimental|TAK-085 4g|A dose of 4 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered twice a day immediately after meal.
89312319|NCT02823964|Experimental|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
89312320|NCT03824470||Group E(rocuronium)|E, after the administration of 1 mg / kg lidocaine, 2 mg / kg propofol, 1 mcg / kg remifentanil and 0.6 mg / kg rocuronium intravenously, patients will be intubated and general anesthesia will be performed when the Tof value is 0.
89312321|NCT03824470||Group R (remifentanil)|1 mg / kg lidocaine, 4 mcg / kg remifentanil and 2 mg / kg propofol intravenously.patients will be intubated and general anesthesia will be performed when the Tof value is 0
89312322|NCT05279794|Experimental|Jones Group (Strain Counterstrain)|Jones Group consist in 90 seconds in a ralease positioning of no pain in muscle acortation
89312323|NCT05279794|Active Comparator|Myofascial Induction Group|Myofascial Induction Group consist in 15 minutes of superficial and deep lumbar fascia maneuvers
89312324|NCT05279794|Placebo Comparator|Placebo Group|Placebo Group only have to mantain no pain positioning for 3 minutes
89312325|NCT01338610|Experimental|ESBA105|ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day for 4 weeks
89312326|NCT01338610|Placebo Comparator|Vehicle|ESBA105 vehicle, 1 drop in each eye 3 times per day for 4 weeks
89312327|NCT01355302|Experimental|Phase Ib: Cohort 1 and 2 and 3|"Phase Ib: Cohort 1; 200 mg E7050 + 80 mg/m2 cisplatin + 1000 mg/m2 capecitabine~Cohort 2; 300 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine Cohort 3; 400 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine"
89312328|NCT01355302|Active Comparator|Phase II: Arm 1; E7050 + cisplatin+ capecitabine|Phase II: Arm 1; MTD E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine
89312329|NCT03562858|Active Comparator|Delayed dentine sealing|
89312330|NCT03562858|Experimental|Immediate dentin sealing|
89312331|NCT05250076|Active Comparator|Intervention Group|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination (Posturarte® Olympic). To clean the participant's skin, cotton (MASMI®) will be passed with ethyl alcohol (Fergus®). Scissor (Maped®) will be used to cut the Kinesio Tape."
89312332|NCT05250076|No Intervention|Control Group|The participants will remain at rest in a supine position on a treatment table (Posturarte® Olympic) without inclination for 5 minutes.
89312333|NCT01355068|Active Comparator|Treatment A|Epanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)
89312334|NCT01355068|Experimental|Treatment B|Dilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)
89312335|NCT04592848||Population study|"Female patients who undergone a cystectomy and/or urinary diversion for a non-malignant disease at Lyon Sud Hospital between January 2007 and December 2019."
89312336|NCT03562702|Active Comparator|Standard IV Rehydration Therapy|Patients randomized into the IV rehydration group will receive a Normal Saline bolus of IVF (usually 20 mL/kg) which is the standard therapy up to 24 hrs or as needed depending on patient's weight
89312337|NCT03562702|Experimental|Oral Rehydration Therapy (ORT)|Patients randomized into the oral rehydration group will receive the oral Speedlyte product instead of the IV rehydration therapy.
89312338|NCT03562780|Experimental|Fortolin Tab 500mg|During the study session, healthy subjects will be administered a single oral dose of Fortolin Tab 500mg after an overnight fast of approximately 10 hours.
89312339|NCT03562780|Active Comparator|Panadol Caplet 500mg|During the study session, healthy subjects will be administered a single oral dose of Panadol Caplet 500mg after an overnight fast of approximately 10 hours.
89312340|NCT02259946|Experimental|BI 1744 CL - single rising dose + Tiotropium|Single rising dose of BI 1744 CL (conjointly with Tiotropium bromide)
89312341|NCT02259946|Placebo Comparator|Placebo|
89312342|NCT03756129|Experimental|MIJ821 low dose weekly|Infusion. MIJ821 low dose weekly - 0.16 mg/kg
89312343|NCT03756129|Experimental|MIJ821 low dose bi-weekly|Infusion. MIJ821 low dose bi-weekly - 0.16 mg/kg
89312344|NCT03756129|Experimental|MIJ821 high dose weekly|Infusion. MIJ821 high dose weekly - 0.32 mg/kg
89312345|NCT03756129|Experimental|MIJ821 high dose bi-weekly|Infusion. MIJ821 high dose bi-weekly - 0.32 mg/kg
89312346|NCT03756129|Placebo Comparator|Placebo weekly|Infusion. Placebo weekly
89312347|NCT03756129|Active Comparator|Ketamine 0.5 mg/kg weekly|Infusion. Ketamine 0.5 mg/kg weekly
89312348|NCT03820102||Vit D deficiency|Chronic HCV patients with vitamin D deficiency Sustained virological response after treatment
89312349|NCT03820102||Normal Vit D|Chronic HCV patients with normal vitamin D level Sustained virological response after treatment
89312350|NCT03863691|Active Comparator|amisulpride group|300 mg of the atypical antipsychotic drug amisulpride
89312351|NCT03863691|Placebo Comparator|placebo group|Similar looking capsules for placebo control
89312352|NCT02822794|Experimental|SOF/VEL FDC + RBV 12 weeks|SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
89312353|NCT02822794|Experimental|SOF/VEL FDC + RBV 24 weeks|SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection
89312354|NCT01173315|Experimental|Group MV|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg
89312355|NCT01173315|Experimental|Group MVB|Group MVB: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg)plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg)
89312356|NCT01173315|Placebo Comparator|Group P|Group P: starch (placebo
89312357|NCT01173393|No Intervention|Standard Treatment|"For patients randomised to hospital cooling:~LMA/ Intubation and ventilation with 100% oxygen~Measure temperature using tympanic probe and record~Insert IV line and administer drugs as per protocol~Fluid challenge with standard temperature saline only as per current guideline (suspected hypovolemia)~Post resuscitation: midazolam 1-5 mg only to maintain LMA/ intubation as needed.~Pancuronium 8 mg only if intubation unable to be maintained with midazolam.~After arrival at the Emergency Department, all patients receive standard care."
89312358|NCT01173549|Experimental|001|no intervention Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
89312359|NCT01173549|Experimental|002|Canagliflozin/Placebo Placebo/Canagliflozin Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
89312360|NCT01175187||EPIDURAL FEVER|
89312361|NCT01175187||EPIDURAL WITHOUT FEVER|
89312362|NCT01175187||GROUP 1: EPIDURAL FEVER . GROUP 2 EPIDURAL WITHOUT FEVER|
89312363|NCT01175265|No Intervention|pulmonary rehabilitation, no breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
89312364|NCT01175265|No Intervention|breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
89312365|NCT01286337|Experimental|vessel sealing|axilla dissection using this device
89312366|NCT01286337|Active Comparator|control|standard surgical technique
89312367|NCT01338298|Active Comparator|Aripiprazole|
89312368|NCT01338298|Placebo Comparator|Placebo|
89312369|NCT03863535|Experimental|Intravitreal conbercept+Panretinal coagulation|
89312370|NCT03863535|Active Comparator|Panretinal coagulation|
89312371|NCT01169415|Experimental|Protracted (30 days), Dexamethasone|Participants will receive a protracted course (30 days) of dexamethasone after surgery.
89312372|NCT01169415|Experimental|Abbreviated (14 days), dexamethasone|Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
89312373|NCT04487704|Other|Camrelizumab in the treatment of liver cancer|Camrelizumab intravenous infusion (no need for prophylactic administration), no less than 30 min
89312374|NCT04215406||The level of maternal air pollution exposure during pregnancy|The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.
89312375|NCT01173627|Experimental|A - Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche
89312376|NCT01173627|Active Comparator|B - Actiq 400 mcg|Actiq 400 mcg
89312377|NCT01169571||Group I - No loading dose|No loading dose to be administered during the loading-dose paradigms
89312378|NCT01169571||Group II - Loading dose over 10 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 10 minutes during the loading-dose paradigms
89312379|NCT01169571||Group III - Loading dose over 20 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 20 minutes during the loading-dose paradigms
89312380|NCT01286415|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
89312381|NCT01286415|Active Comparator|Group Present Centered Therapy|
89312382|NCT01354132|Active Comparator|n-acetyl-cysteine|N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks
89312383|NCT01354132|Placebo Comparator|Placebo|matching effervescent tablets in water 2 in am and 1 in pm
89312384|NCT01285011||Ipp-On|Patient implanted with the Ipp-On
89312385|NCT01175421||Patients undergoing sleep study|
89312386|NCT03866265|Active Comparator|Supplement Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a food supplement capsule (containing 0.125 g of FGE-Salmon-PLs) per day for a period of 28 days.~After the period of 28 days, each participant will provide blood samples at the 29th day.~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the food supplement will now be administered the placebo capsules for 28 days (a placebo capsule per day)"
88821246|NCT04794764|Experimental|McGrath MAC|First pass success rate using the McGrath Mac
89312387|NCT03866265|Placebo Comparator|Placebo Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a placebo capsule (containing 0.125 g of glycerin) per day for a period of 28 days.~After the period of 28 days, each participant will provide blood samples at the 29th day.~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the placebo capsules will now be administered the food supplement capsules for 28 days (a food supplement capsule per day)"
89312388|NCT05707936|Experimental|Normal saline 20 ml|
89312389|NCT05707936|Experimental|Normal saline 10 ml|
89312390|NCT05707936|Active Comparator|usual care (heparin)|
89312391|NCT01285089||A|
89312392|NCT01282671|Experimental|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months.
89312393|NCT01282671|No Intervention|Control group|No breathing exercises.
89312394|NCT01285167||DACOTA|
89312395|NCT01353898|Experimental|MK-1972 50 mg once daily (Part I)|Ten capsules containing a total daily dose of 50 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
89312396|NCT01353898|Experimental|MK-1972 200 mg once daily (Part I)|Ten capsules containing a total daily dose of 200 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
89312397|NCT01353898|Experimental|MK-1972 800 mg once daily (Part I)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
89312398|NCT01353898|Experimental|MK-1972 25 mg twice daily (Part I)|Ten capsules containing a total daily dose of 25 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
89312399|NCT01353898|Experimental|MK-1972 100 mg twice daily (Part I)|Ten capsules containing a total daily dose of 100 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
89312400|NCT01353898|Placebo Comparator|Placebo twice daily (Part I)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part I)
89312401|NCT01353898|Experimental|MK-1972 800 mg twice daily (Part II)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part II)
89312402|NCT01353898|Placebo Comparator|Placebo twice daily (Part II)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part II)
89312403|NCT03562624|Experimental|BAY98-7443 (low IND dose)|Combi IUS Treatment, LNG (Levonorgestrel) with lowest dose of IND (indomethacin)
89312404|NCT03562624|Experimental|BAY98-7443 (middle IND dose)|Combi IUS Treatment, LNG with medium dose of IND
89312405|NCT03562624|Experimental|BAY98-7443 (high IND dose)|Combi IUS Treatment, LNG with highest dose of IND
89312406|NCT03562624|Active Comparator|Marketed comparator|Marketed comparator IUS
89312407|NCT02035852||Adult Gilomas|
89312408|NCT01372150|Experimental|DVS SR|
89312409|NCT01372150|Other|Fluoxetine|Active control for assay sensitivity
89312410|NCT01372150|Experimental|Placebo|
89312411|NCT01282749|Experimental|SisterTalk Hartford First|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
89312412|NCT01282749|Other|SisterTalk Hartford Second|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
88810962|NCT04930198|Other|Social Plus Financial Incentive|"For the financial incentive, the top 5 scorers in the PEER+ arm will be eligible win a lottery prize each month of the 24 week pilot of 1000 Nigerian Naira (NGN) of data that can be directly loaded onto the winner's phone. Behavioral economics theory tells us that individuals are more averse to losses than rewarded by gains, so that even incentives/prizes should be framed in terms of losses. Accordingly, participants in the financial incentive arm will receive weekly motivating messages such as take your dose today or you lose the chance of winning the lottery."
89312413|NCT01285245|Experimental|kineret|
89312414|NCT01286571|Experimental|BI 135585 (T)|single dose per subject as tablet formulation after high fat, high caloric meal
89312415|NCT01286571|Experimental|BI 135585 (R)|single dose per subject as tablet formulation after an overnight fast
89312416|NCT01173705||Normal weight: abdominal surgery|Lean individuals undergoing elective abdominal surgery
89312417|NCT01173705||Obese: abdominal or bariatic surgery|Obese subjects undergoing elective abdominal or bariatric surgery
89312418|NCT01282827|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
89312419|NCT01282827|Placebo Comparator|Placebo stimulation|no intervention (Sham stimulation)
89312420|NCT04260334|Experimental|Intervention Group|RFNP was created by researchers. RFNP comprises positive language, a positive environment, relaxation exercise and methods of coping with stress (Mete et al., 2017; Mete et al., 2015; Lazarus, 1984). This programme has a content which reducing women's anxiety and pain. Such programmes are expected to enhanced level of the knowledge about ovarian cancer and its surgery. Women are usually admitted to the clinic two days before surgery. The program duration was for 2 days each day with two sessions, of 6 hr each. There are four relaxation exercises in the program because repetition is recommended for the relaxation exercises to be effective. Deep breathing exercise, progressive muscle relaxation, and guided imagery were used in program. In addition, RFNP is divided into four sections so that the information is not intensely transferred to women.
89312421|NCT04260334|No Intervention|Control Group|In the control group, women received routine nursing care in the hospital, and data collection tools were applied at the parallel hours as the experimental group. Usual nursing care included information about visitor and meal times, nurse call button, diet, drug administration and not to leave the hospital. Relaxation exercises were not practiced to patients in usual nursing care to reduce stress and anxiety.
89312422|NCT01282905||Healthy controls|
89312423|NCT01282905||Ulcerative colitis|
89312424|NCT04242628|Experimental|Facebook course|T1 study members attended a three week course (two classes per week) on smartphones and SNS use. Specifically, the course covers the following topics: smartphone use; Facebook use; WhatsApp use, privacy rules and fraud risk prevention using Facebook. Throughout the duration of the intervention, a tutor was available every Tuesday and Thursday to assist T1 participants in using SNSs.
89312425|NCT04242628|Experimental|Lifestyle course|T2 study members attended 5 interactive 90-min meetings on lifestyle education and brain functioning in older people. These meetings covered the following topics regarding good habits for wellbeing at older age: nutrition, brain ageing, physical activity, leisure activities, resources of the city for older people. A goodbye tea was offered after the meetings.
89312426|NCT04242628|No Intervention|Waiting list|Throughout the duration of the intervention, we put C study members on a waiting list; at the end of the intervention, in June 2019, interested group C study members attended the SNSs course (held on June 2019).
89312427|NCT01175577|Active Comparator|Supplement 1|
89312428|NCT01175577|Active Comparator|Supplement 2|
89312429|NCT01175577|Active Comparator|Food-based Intervention|
89312430|NCT01175577|Placebo Comparator|Placebo|
89312431|NCT03863301|Experimental|MR-guided single dose preoperative PBI|
89312432|NCT01173861|Experimental|Physical activity counseling|Group receives face-to-face physical activity counseling.
89312433|NCT01173861|Active Comparator|Manual|Group receives physical activity manual.
89312434|NCT01370980||Study population|Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
89312435|NCT01175733|Experimental|Panitumumab|
89312436|NCT02035930|Other|menstrual cycle,dexmedetomidine|
89312437|NCT01175889|Experimental|one side ACE blade|
89312438|NCT01175889|Active Comparator|one side scalpel|
89312439|NCT03562546|Experimental|Structured Resistance Exercise|12 week at home structured resistance exercise programme ('Strength From Within') using resistance bands. Under the supervision of an experienced exercise specialist.
89312440|NCT01282983|Active Comparator|fiber|
89312441|NCT01282983|Placebo Comparator|Placebo|
89312442|NCT05707624|Experimental|experimental|"During the process; Phone numbers were obtained and recorded at the first meeting with the parents. The link of the first two training videos was sent to the smartphones of the participants at the same time. Parents are explained how to access the videos from the link. Afterwards, other training videos, prepared once a week and as 2 videos, were sent to the parents' smartphones on a regular basis.~After the procedure; Participants were contacted by phone 2 weeks after the last videos were watched. They were asked to fill out and send the questionnaire and scale online sent to their phones."
89312443|NCT05707624|Placebo Comparator|Control group|"During the process; The phone number obtained from the parents was recorded and no other application was made other than the routine procedure of the clinic. Parents were not contacted in the following weeks.~After the procedure; The control group was also reached via telephone 2 weeks after the video submission to the intervention group was completed. They were asked to fill out and send the questionnaire and scale online sent to their phones."
89312444|NCT03865875|Experimental|Multimodal Prehabilitation Program|"Pretreatment exercise program and nutrition program~-The prehabilitation intervention will include the following components: (1) a standardized fitness program and (2) nutritional counseling and optimization. Patients are enrolled in the program within 8 weeks of being diagnosed and continued until operation"
89312445|NCT03866109|Experimental|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
89312446|NCT01177839||Intussusception cohort|Subjects with Intussusception
89312447|NCT03865797|Experimental|Experimental|Before carrying out each session of the intervention, each subject included in the experimental group will have a sports bandage on both ankles. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
89312448|NCT03865797|Active Comparator|Control|The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
89312449|NCT01173939|Active Comparator|Active comparator: Standard Pravastatin Group|
89312450|NCT01173939|Active Comparator|Intensive Rosuvastatin Group|
89312451|NCT01174017|Active Comparator|Standard loose Iodine 125 seeds|Prostate brachytherapy implant to be performed with standard format loose Iodine 125 seeds
89312452|NCT01174017|Experimental|AnchorSeed Iodine 125 implant|Prostate brachytherapy implant to be performed with a new design of Iodine 125 seed that has a coating to increase adherence to tissue
89312453|NCT01288131|Active Comparator|CSA+MMF|Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks
89312454|NCT01288131|Active Comparator|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day
89312455|NCT01177917|Experimental|Cow milk-based infant formula with prebiotic blend|
89312456|NCT01177917|Placebo Comparator|Marketed Cow milk-based infant formula|
89312457|NCT01286649|Other|Injection of verum and control|Patients will receive randomized, blinded, injections of BOTH autologous hair follicle cells in medium (verum) and of medium alone (control) into two separate pre-defined treatment areas on their scalp.
89312458|NCT02525211|Experimental|Ropivacaine|Ropivacaine
89312459|NCT02525211|Placebo Comparator|placebo|physiological saline
89312460|NCT01176045||Pre-surgical treatment|Patients who are pre & post-surgical treated with ocular lubricants.
89312461|NCT01176045||Non-presurgical treatment|Patients who are only post-surgical treated with ocular lubricants
89312462|NCT01174095||Follow-up Group|"Subjects who received AdGVVEGF121cDNA in either IRB protocol #0794-894 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease or IRB protocol #0297-693 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease Via Minimally Invasive Surgery."
89312463|NCT01177995|Experimental|Social Network|Leaders of labor migrant social networks will be trained to disseminate HIV prevention messages to the members of their social networks. The training will sequentially target ways to increase network members' HIV-related knowledge and norms, attitudes, intentions, and confidence in how to avoid risk. Leaders will be encouraged to have these discussions with network members between and after training sessions.
89312464|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
89312465|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
89312466|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
89312467|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters;~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
89312468|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster:high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
89312469|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
89312470|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
89312471|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
88810963|NCT04924114|Experimental|MK-6194|Participants will be enrolled in sequential cohorts treated with successively higher doses of MK-6194 via subcutaneous injection.
88810964|NCT04924114|Placebo Comparator|Placebo|Participants will receive MK-6194-matching placebo via subcutaneous injection.
89312472|NCT03862443|Experimental|Fixed Incentive|Eligible to earn a weekly payment during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will win $5; high adherence threshold (brushing twice per day for 14 days in a week) will win $10.
89312473|NCT03862443|Experimental|Drawing Incentive|Eligible to earn a weekly drawing entry with different winning probabilities during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
89312474|NCT03862443|No Intervention|Control - Delayed Incentive|No rewards during the first 2-months, but information on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app. After the Month 2 follow-up visit, may opt to participate in a delayed 2-month open label extension to earn the same monetary rewards the fixed incentive intervention group could earn Baseline through Month 2. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
89312475|NCT03862677||Patients with (suspicion of) primary EOC|
89312476|NCT03862677||Patients with recurrent EOC|
89312477|NCT03865563|Experimental|Pancreatic adenocarcinoma|Participants with resectable, borderline-resectable or locally-advanced pancreatic adenocarcinoma will receive pancreatic retrograde venous infusion of gemcitabine/lipiodol
89312478|NCT01174329|Experimental|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"Patient regulated (by a remote control) neuro-electrostimulation by Saliwell Crown"
89312479|NCT01174329|Active Comparator|"Automatic neuro-electrostimulation by Saliwell Crown"|No remote control used
89312480|NCT01286727|Placebo Comparator|Normal Saline|Placebo
89312481|NCT01286727|Active Comparator|BB3|
89312482|NCT01286883||Blood draws|Laboratory studies will be performed at baseline; Cycle 1, Day 1; Cycle 1, Day 7; Cycle 2, Day 1; Cycle 3, Day 1; Cycle 4, Day 1; Cycle 6, Day 1; Cycle 12, Day 1.
89312483|NCT02525445|Active Comparator|acupuncture positive communication|Genuine acupuncture needles combined with positive communication regarding the expected treatment effects
89312484|NCT02525445|Sham Comparator|sham acupuncture positive communication|Sham acupuncture needles combined with positive communication regarding the expected treatment effects
89312485|NCT02525445|Active Comparator|acupuncture neutral communication|Genuine acupuncture needles combined with neutral communication regarding the expected treatment effects
89312486|NCT02525445|Sham Comparator|sham acupuncture neutral communication|Sham acupuncture needles combined with neutral communication regarding the expected treatment effects
89312487|NCT01286961||outpatient colonoscopy, bowel preparation, split dose PEG|adult outpatients who undergo colonoscopy
89312488|NCT03862521|Experimental|Low carbohydrate diet group|Low carb diet, carbohydrates make up 30-40% of total daily calories.
89312489|NCT03862521|Experimental|Very low carbohydrate diet|Very low carb diet, carbohydrates make up 20-29% of total daily calories.
89312490|NCT01176123|Active Comparator|CBT-I in person|Cognitive behavioral therapy for insomnia delivered in person
89312491|NCT01176123|Experimental|CBT-I via telephone therapy|Cognitive behavioral therapy for insomnia delivered by telephone
89312492|NCT03860493||Study group|Only patients who might benefit from intraoperative fluorescent tissue perfusion assessment according to the primary surgeon will be enrolled in the study. The patients will be screened and consent during their office visit with their surgeon at the Cleveland Clinic Foundation. Each surgeon will follow the standard Open surgical protocol of his/her subspecialty, and will comply with the following additional steps according to the type of surgery:
89312493|NCT03860649|Experimental|Nordic Walking|The patient walk program consists of 3 moments: warm up, walk and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.
89312494|NCT03860649|Experimental|Jogging|This group will undergo 24 Dance sessions. Aquatic therapy patients will receive deep water running intervention with the use of flotation vests. The exercises will consist of: immersion, balance, strength, agility, and movement within the water. The intensity of the classes will be measured in each moment and by the Borg Scale of Perceived Exertion.
89312495|NCT03860649|Experimental|Dance|This group will undergo 24 Dance sessions inspired by Forró dance rhythm and Samba dance rhythm. Classes will be divided into four stages: Joint warm up and stretching on the chairs; strengthening, balance and rhythm exercises with the support of the barre; exercises inspired by the Samba and Forró dance (Brazilian ballroom dance) basic steps; and Final cool down. The intensity of the classes will be measured according to the beats per minute (BPMs) of the songs used in each moment and by the Borg Scale of Perceived Exertion.
89312496|NCT03860649|Experimental|Pilates Training|"Classes composed of three phases: Warming up, main part and back to calm. Warming up will begin with pre-Pilates training exercises for 5 minutes (eg. breathing exercises, hip joint mobilization, shoulder girdle, etc.), the main part of the lesson will be the Pilates training drill sequence for the beginner level that will be conducted for 50 minutes in which all exercises will be performed on the floor.~The sequence of the eighteen exercises of the main part of the lesson is described in the table below. Back to Calm: will be carried out for 5 final minutes with standing exercises with the subject reclining on the wall to reconnect the subject with orthostatic posture.~In the each of the phases of the lesson will be shown to the subject the table of BORG with the objective of measuring the intensity of perceived exertion, using the Borg Scale of Perceived Exertion."
89312497|NCT01178151|Experimental|afinitor|10mg afinitor daily orally
89312498|NCT01174407||cd35|
89312499|NCT01174485|Experimental|exercise|exercise plus liposuction
89312500|NCT01174485|No Intervention|sedentary|physical inactivity plus liposuction
89312501|NCT03865641|Experimental|Virtual reality intervention|Experimental group : virtual reality intervention
89312502|NCT03865641|No Intervention|Control group|conventional rehabilitation without virtual reality intervention
89312503|NCT03860415|Experimental|Probiotic|Vivomixx
89312504|NCT03860415|Placebo Comparator|Placebo|
89312505|NCT03865251|Experimental|experimental group|Kinesiology tape application to dominant leg during lying and standing positions
89312506|NCT01178229|Experimental|Physiotherapy|group of bruxist children that received physiotherapy to change the head posture
89312507|NCT01178229|No Intervention|Control|Group of bruxist children that did not receive treatment
89312508|NCT01176201|Experimental|A|400 mg suspension
89312509|NCT01176201|Active Comparator|B|5 x 200 mg immediate release capsule
89312510|NCT01176279|Active Comparator|Manual and automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of TM BD DTXPlus ™), put the needless connector included in the kit to make the extractions of blood. Connect an arterial blood sampling syringe on the proximal 3-way stopcock key. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
89312511|NCT01176279|Experimental|Automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of BD DTXPlus™), put the needless connector included in the kit to make the extractions of blood. On the proximal 3-way stopcock key put a second identical needless connector: in the intervention group the two 3-way stopcock keys have, each one, a needless connector. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
89312512|NCT03864939|Experimental|dHAM|dHAM wrap is placed during RRP.
89312513|NCT03864939|Placebo Comparator|Standard|A standard RRP is performed.
89312514|NCT01176357||1|CABG
89312515|NCT01176357||2|Valve surgery
89312516|NCT03862287|Active Comparator|Intrathecal Lidocaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median or paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 60 mg of isobaric preservative-free Lidocaine 2% will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
89312517|NCT03862287|Active Comparator|Intrathecal Bupivacaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median/paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 6 mg of 0.5% isobaric bupivacaine will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
89312518|NCT03862053|Active Comparator|Manuka honey eyedrops|optimel manuka eyedrops 10 ml used as directed in a CAC (Conjunctival allergen challenge) study
89312519|NCT03862053|Placebo Comparator|Normal saline 0.9% eyedrops|sterile normal saline eyedrops used as directed in a CAC (conjunctival allergen challenge) study
89312520|NCT03860337|Experimental|Alginate then Control|This group will be given the alginate then the control sausages
89312521|NCT03860337|Experimental|Control then Alginate|This group will be given the control then alginate sausages
89312522|NCT01288365|Experimental|Exercise training|Protocol of 3 month exercise training program.
89312523|NCT01288365|No Intervention|Control|Control group
89312524|NCT01174641|Experimental|TMS intervention|Trans-cranial magnetic stimulation will be applied at a 1Hz rate for 20min over the ipsilesional posterior parietal cortex of patients showing left neglect after a right hemisphere stroke
89312525|NCT01174641|Placebo Comparator|Placebo TMS|1 Hz trans-cranial magnetic stimulation will be applied over the vertex
89312526|NCT03859947||Patients with acute bronchiolitis|
89312527|NCT01287273||Group A|Transfer at the day of embryo thawing
89312528|NCT01287273||Group B|Transfer of thawed embryos 24-72 hours post thawing
89312529|NCT01285869|Experimental|Multidisciplinar intervention|Patients that will receive the multidimensional intervention during the ambulatory follow-up.
89312530|NCT01285869|No Intervention|Conventional follow up|This is an observation only group and outpatient follow up will be indicated in accordance with usual and customary practices.
89312531|NCT01178307||Part 1|Patient interview and developmental questionnaires
89312532|NCT01178307||Part 2|Content Expert Panel (doctors, nurses) + Patients and Caregivers Questionnaire Development
89312533|NCT01178307||Part 3|Patient MDASI-GIST Questionnaire
89312534|NCT03860025||Single dislocation.|Patients with a single postoperative hip dislocation without subsequent revision surgery.
89312535|NCT03860025||Recurrent dislocation.|Patients with two or more postoperative hip dislocations without subsequent revision surgery.
89312536|NCT03860025||Revision due to dislocation.|Patients with one or more postoperative hip dislocations with subsequent revision surgery due to recurrent instability.
89312537|NCT03860025||Controls.|Matched patients without postoperative hip dislocation or revision of any reason.
88810965|NCT04910204|Experimental|Early FEST + TST|Participants will receive FEST+TST at 3 to 6 months from SCI onset.
89312538|NCT01287351||IPDI: Qvar|ICS initiation as Qvar
89312539|NCT01287351||IPDI FP|ICS initiation as fluticasone
89312540|NCT01287351||IPDA Qvar|ICS step-up as Qvar
89312541|NCT01287351||IPDA FP|ICS step-up as fluticasone
88810966|NCT04910204|Experimental|Delayed FEST + TST|Participants will receive FEST+TST at 6 to 9 months from SCI onset.
88810967|NCT04907136|Experimental|Preferred ENDS|All participants will complete a lab visit where they will use their preferred ENDS ad libitum for up to 60 minutes
89312542|NCT03862209|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
89312543|NCT03862209|No Intervention|Standard care|Health care settings and their providers randomised to the control condition receive usual care: participant will gain standard care; ambulatory care, day hospitals or hospital admission.
89312544|NCT01287429||acute dyspnea|
89312545|NCT01174719|Active Comparator|Hydroxyethylstarch|
89312546|NCT01174719|Active Comparator|Humanalbumin|
89312547|NCT01174719|Active Comparator|Ringer lactate|
89312548|NCT01178463||I. Obstructive Azoospermia|
89312549|NCT01178463||II. Non-Obstructive Azoospermia Patients|
89312550|NCT03864783|Experimental|Curcumin (Meriva®)|Meriva® 500 mg tablet (contains 100 mg curcumin) Dosage: 2 tablets twice daily for 42 days (+/- 3 days)
89312551|NCT03864783|Placebo Comparator|Placebo|Placebo. Dosage: 2 tablets twice daily to mimic Meriva® tablets.
89312552|NCT01287507|Placebo Comparator|Placebo|In born VLBW infants with parental consent form signed will be given oral saline daily as placebo until discharge
89312553|NCT01287507|Experimental|Lactoferrin|In born VLBW infants with parental consent form signed will be given oral bovine lactoferrin daily until discharge
89312554|NCT03865017|Experimental|Regulatory T cells|Biologicals: Autologous Regulatory T cells (1.7*10^5 cells/kg, i.v) other name: GB301
89312555|NCT03865017|Placebo Comparator|Placebo|Saline+cell suspension solution infusion
89312556|NCT01174797||Patients being evaluated for active ischemia|Subjects with known or suspected CAD who are scheduled to undergo routine exercise MPI or stress echocardiography for the detection of active ischemia are eligible for enrollment.
89312557|NCT01287663|Placebo Comparator|no permethrin|
89312558|NCT01287663|Experimental|permethrin|
89312559|NCT01286025|Active Comparator|Video modality|
89312560|NCT01286025|Active Comparator|Text modality|
89312561|NCT03864549|Experimental|probiotic femina II|research group will receive the probiotic formula Femina II (2 capsules/day) until delivery.
89312562|NCT03864549|Placebo Comparator|Placebo|control group will receive a placebo (2 capsules/day) until delivery.
89312563|NCT01176669|Experimental|Apatinib|
89312564|NCT03861741|Experimental|Participants|All participants will be screened through complete clinical evaluations, genetic tests and imaging modalities (TTE and MRI) for the presence of newly Non Syndromic-Thoracic Aortic Diseases. Demographic and clinical data from all participants will be collected using case report forms, and by accessing their medical records. Data on imaging investigations will be obtained from TTE and MRI. Blood samples will be used for the purpose of isolation of genetic material and subsequent whole exome sequencing along with the analysis of selected loci. Additional citrated blood samples and plasma will be collected and stored for the potential analysis of circulating microvesicles and miRNA.
89312565|NCT03864471|Experimental|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
89312566|NCT03864471|Active Comparator|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
89312567|NCT03864393|Experimental|Multimodal overground locomotor training|Individuals with Parkinson's Disease that meet the inclusion/exclusion criteria and enrolled in the study will participate in a 12-week multimodal exercise training intervention performed twice per week.
89312568|NCT03861819|Experimental|VIIT Intervention|This is a single-arm trial. The intervention itself proceeds as follows: After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total.
89312569|NCT01288599|Experimental|Single port access laparoscopy|Single port access laparoscopy for benign adnexal disease.
89312570|NCT01288599|Active Comparator|Conventional laparoscopy|Conventional laparoscopy for benign adnexal disease.
89312571|NCT03861585|Experimental|semantic group|"Half of the participants (named the semantic group) perform a semantic categorisation task."
89312572|NCT03861585|Experimental|emotional group|"Half of the participants (named the emotional group) perform an emotional evaluation task."
89312573|NCT01174875||Pregnant mothers, infants and children|Women in their early pregnancy who are attending the first trimester antenatal ultrasound scan at the public maternity units at KK Women's and Children's Hospital (KKH) and National University Hospital (NUH). Only women age 18 years and above who are Singapore Citizens or Singapore Permanent Residents. Participants have to intend to eventually deliver in NUH or KKH and to reside in Singapore for the next 5 years. Willingness to donate cord, cord blood and placenta. The fetus should be racially homogenous with both sets of grandparents of the same ethnicity. Babies born from these mothers will be followed up until the child is at least 14 years of age.
89312574|NCT01176747|Experimental|BDP/formoterol NEXT DPI|Radiolabelled BDP/formoterol 100/6 µg dry powder administered via the NEXT inhaler
89312575|NCT03861663|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
89312576|NCT03859479|Experimental|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
89312577|NCT03859479|Active Comparator|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
89312578|NCT01174953|Other|Finasteride plus soy|Finasteride and soy
89312579|NCT02525367|Experimental|PD-Experimental|PD patients using the online cognitive training for 8 weeks, 3 times a week
89312580|NCT02525367|Active Comparator|PD-Control|PD patients using the active control condition for 8 weeks, 3 times a week
89312581|NCT02525367|Experimental|MS-Experimental|MS patients using the online cognitive training for 8 weeks, 3 times a week
89312582|NCT02525367|Active Comparator|MS-Control|MS patients using the active control condition for 8 weeks, 3 times a week
89312583|NCT02525367|Experimental|postECT-Experimental|Depressed elderly treated with ECT patients using the online cognitive training for 8 weeks, 3 times a week
89312584|NCT02525367|Active Comparator|postECT-Control|Depressed elderly treated with ECT patients using the active control condition for 8 weeks, 3 times a week
89312585|NCT03861429|Experimental|Me & My Wishes Intervention/Group 1|In Group 1 (early intervention group) NHs, video recording, editing, and viewing will occur within three months of baseline.
89312586|NCT03861429|Other|Me & My Wishes Wait-list control/Group 2|In Group 2 (delayed sharing) NHs, residents will be on a wait-list; after the delayed start, their video will be produced and viewed within three months.
89312587|NCT03864315|Experimental|Vitiligo|30 Patients with Vitiligo
89312588|NCT01286103|Experimental|001|Canagliflozin 300 mg once daily and 150 mg twice daily Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
89312589|NCT01286103|Experimental|002|Canagliflozin 100 mg once daily and 50 mg twice daily Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
89312590|NCT01176825|Experimental|CBT|14-week individual cognitive-behavior therapy
89312591|NCT01176825|No Intervention|Treatment As Usual|14-week waitlist control
89312592|NCT03864237|Experimental|Alcohol texts|Participants assigned to this arm will receive a text message each day for 10 weeks, containing factual information about campus drinking norms.
89312593|NCT03864237|Placebo Comparator|Attention control|"Participants assigned to this arm will receive a text message each day for 10 weeks, containing this day in history facts."
89312594|NCT01176903|Experimental|Glyco SD1|Single administration of Glyco pMDI dose level 1
89312595|NCT01176903|Experimental|Glyco SD2|Single administration of Glyco pMDI dose level 2
89312596|NCT01176903|Experimental|Glyco SD3|Single administration of Glyco pMDI dose level 3
89312597|NCT01176903|Experimental|Glyco SD4|Single administration of Glyco pMDI dose level 4
89312598|NCT01176903|Experimental|Glyco SD5|Single administration of Glyco pMDI dose level 5
89312599|NCT01176903|Placebo Comparator|Placebo SP|Single administration of Placebo pMDI
89312600|NCT01176903|Experimental|Glyco MD1|Multiple administration of Glyco pMDI dose level 1
89312601|NCT01176903|Experimental|Glyco MD2|Multiple administration of Glyco pMDI dose level 2
89312602|NCT01176903|Experimental|Glyco MD3|Multiple administration of Glyco pMDI dose level 3
89312603|NCT01176903|Placebo Comparator|Placebo MP|Multiple administration of placebo pMDI
89312604|NCT01176903|Active Comparator|Tiotropium|Multiple administration of tiotropium
89312605|NCT01288677|Experimental|001|TMC649128 Escalated doses
89312606|NCT03864159|Experimental|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time.The intervention through the suction cups will consist of its application and produce increased flexibility of the hamstring musculature. The technique will be performed with the subject in prone position, on the stretcher, while the physiotherapist will be placed next to the member to be treated. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
89312607|NCT03864159|Active Comparator|Foam roller|The intervention will be carried out before starting the training session. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
89312608|NCT01286181|Experimental|Device-guided slow breathing|
89312609|NCT01178619||AGA|
89312610|NCT01178619||symmetrical IUGR|
89312611|NCT01178619||asymmetrical IUGR|
89312612|NCT03863925|Experimental|Propofol Target Controlled Infusion Group (Group T)|Patients in group T underwent anesthesia with Propofol (dosage form: 10mg/mL) target controlled infusion by Schnider model, starting at concentration of effect site (Ce) of 1.5 mcg/mL and titrating to achieve Observer's Assessment of Alertness/Sedation (OAA/S) Scale level 3 (responds only after name called loudly or repeatedly). Patients were paralyzed with suxamethonium (dosage form: 20mg/mL; dosage: 1mg/kg) once adequate sedation level achieved. TCI was stopped once the psychiatrist applied electroconvulsive stimulation to patients' bilateral frontal regions. Assisted ventilation with bag-valve-mask device by experienced anesthesiologists was began since patients were sedated until adequate spontaneous respiration was regained after each single electroconvulsive therapy (ECT) session. Every patient receive total six to twelve ECT sessions, and each ECT session was conducted one day apart.
89312613|NCT03863925|Active Comparator|Propofol Bolus Group (Group B)|Patients in group B underwent anesthesia with bolus of propofol for sedation, and the dosage raged between 0.75 to 1.5 mg/kg to achieve at least OAA/S scale level 3. Dosage of suxamethonium, application of electroconvulsive stimulation, ventilation maneuver, frequency of ECT session, and number of total ECT sessions were same as patients in group T.
89312614|NCT01178697|Active Comparator|Intravitreal triamcinolone|
89312615|NCT01178697|Active Comparator|Intravitreal bevasizumab|
89312616|NCT03858075|Experimental|Single ascending doses with BLU-782|
89312617|NCT03858075|Placebo Comparator|Single ascending doses with placebo|
89312618|NCT03858075|Experimental|Multiple ascending doses with BLU-782|
89312619|NCT03858075|Placebo Comparator|Multiple ascending doses with placebo|
89312620|NCT03858075|Experimental|Food effect of BLU-782 taken with food|
89312621|NCT03858075|Experimental|Food effect of BLU-782 taken without food|
89312622|NCT01178775|No Intervention|1|control design
89312623|NCT01178775|No Intervention|2|education only group
89312624|NCT01178775|Experimental|3|education and education and walking program design
89312625|NCT01177215||Digital chest tube|All patients will be treated with the digital chest tube device
89312626|NCT03329690|Experimental|Parallel: DS-8201a|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
89312627|NCT03329690|Active Comparator|Parallel: Physician's Choice|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
89312628|NCT03329690|Other|Exploratory: Naïve HER2 IHC 2+/ISH-|A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
89312629|NCT03329690|Other|Exploratory: Naïve HER2 IHC 1+|A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.
89312630|NCT03328832|Active Comparator|Combined topical TXA and Floseal|Floseal® was applied on potential bleeding sites before prosthesis implantation, and intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
89312631|NCT03328832|Active Comparator|Topical TXA alone|Intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
89312632|NCT02820844|Experimental|GSK1358820 Injection 100 U|"Initially, subjects will receive a single (double-blind) treatment with GSK1358820 (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment with GSK1358820 (open-label). A third treatment with GSK1358820 (open-label) may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
89312633|NCT02820844|Placebo Comparator|Placebo Injection|"Initially, subjects will receive a single (double-blind) treatment with Placebo (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment, this time with open-label GSK1358820. A third treatment with open-label GSK1358820 may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
89312634|NCT02942576|Experimental|Edoxaban-based regimen|Edoxaban-based regimen for 21 days pre- and 90 days post-ablation period.
89312635|NCT02942576|Active Comparator|VKA-based regimen|VKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)
89312636|NCT04683224|Placebo Comparator|Placebo Stratum 1: 18 to 59 age group without comorbidities|Placebo by intramuscular injection at Day 1 and 29
89312637|NCT04683224|Experimental|UB-612 Stratum 1: 18 to 59 age group without comorbidities|UB-612 by intramuscular injection at Day 1 and 29
89312638|NCT04683224|Placebo Comparator|Placebo Stratum 2: ≥60 age group without comorbidities|Placebo by intramuscular injection at Day 1 and 29
89312639|NCT04683224|Experimental|UB-612 Stratum 2: ≥60 age group without comorbidities|UB-612 by intramuscular injection at Day 1 and 29
89312640|NCT04683224|Placebo Comparator|Placebo Stratum 3: 18 to 59 age group with comorbidities|Placebo by intramuscular injection at Day 1 and 29
89312641|NCT04683224|Experimental|UB-612 Stratum 3: 18 to 59 age group with comorbidities|UB-612 by intramuscular injection at Day 1 and 29
89312642|NCT04683224|Placebo Comparator|Placebo Stratum 4: ≥60 age group with comorbidities|Placebo by intramuscular injection at Day 1 and 29
89312643|NCT04683224|Experimental|UB-612 Stratum 4: ≥60 age group with comorbidities|UB-612 by intramuscular injection at Day 1 and 29
88810968|NCT04907136|Experimental|Preferred ENDS with HWL|All participants will complete a lab visit where they will use their preferred ENDS with a HWL on the device ad libitum for up to 60 minutes
88821247|NCT04794764|Experimental|Macintosh Laryngoscope|First pass success rate using the Macintosh laryngoscope
89312644|NCT02820298|Experimental|Group 1 - Bexagliflozin dosed in fed state, then in fasted state|Group 1 subjects will take one dose of 20 mg of bexagliflozin with food on day 1 after an overnight fast and will take a second dose of bexagliflozin without food on day 8 after an overnight fast.
89312645|NCT02820298|Experimental|Group 2 - Bexagliflozin in fasted state, then in fed state|Group 2 subjects will take one dose of 20 mg bexagliflozin without food on day 1 after an overnight fast and will take a second dose of bexagliflozin with food on day 8 after an overnight fast.
89312646|NCT02036008|Other|Liver MRI with EcGd and with Gdfos|All participants will receive two contrast-enhanced MRI studies of the liver: one with gadofosveset trisodium (Gdfos) and one with gadobutrol (EcGd) at a dose of 0.1 mL/kg body mass up to 10 mL.
89312647|NCT05707780|Experimental|Resin-matrix ceramic|To assess the survival and clinical performance of resin-matrix posterior crows in a complete digital flow
89312648|NCT05707780|Active Comparator|Monolithic zirconia|To assess the survival and clinical performance of monolithic zirconia posterior crows in a complete digital flow
89312649|NCT05707780|Active Comparator|Metal-ceramic|To assess the survival and clinical performance of metal-ceramic posterior crows in a complete digital flow
89312650|NCT02819440|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
89312651|NCT02819440|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
89312652|NCT03562468|Placebo Comparator|Placebo|Each subject will be randomly assigned to receive placebo for an 8-week treatment period. Subjects will be instructed to take two capsules (placebo) in the morning with breakfast and two capsules (placebo) in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
89312653|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 300 mg/day|Each subject will be randomly assigned to receive 300 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
89312654|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 1000 mg/day|Each subject will be randomly assigned to receive 1000 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
89312655|NCT02036164|Active Comparator|Concurrent chemoradiation|"Radiation: Radiation Therapy~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine~Vaginal brachytherapy for 4-5 fractions~Chemotherapy: Cisplatin~- Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy"
89312656|NCT02036164|Experimental|Concurretn chemoradiation plus adjuvant chemotherapy|"Radiation: Radiation Therapy~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine~Vaginal brachytherapy for 4-5 fractions~Chemotherapy: Cisplatin, paclitaxel, carboplatin~Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy~Paclitaxel 175 mg/m2 i.v. q 4 wks, 3 cycles starting 4 week after completion of CCRT~Carboplatin AUC 5 i.v. q 4 wks, 3 cycles given together with paclitaxel"
89312657|NCT03875794|Experimental|Osteopathic Manipulation|"This research will be carried out as a prospective, non-randomized pilot study in women aged 18-40 who are 2 weeks to 28 weeks postpartum.~The intervention investigated in this study is osteopathic manipulation."
89312658|NCT03814720|Experimental|Group 1: H1ssF_3928 (20 mcg), ages 18-40 years|H1ssF_3928 (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0)
89312659|NCT03814720|Experimental|Group 2A: H1ssF_3928 (60 mcg), ages 18-40 years|H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
89312660|NCT03814720|Experimental|Group 2B: H1ssF_3928 (60 mcg), ages 41-49 years|H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
89312661|NCT03814720|Experimental|Group 2C: H1ssF_3928 (60 mcg), ages 50-59 years|H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
89312662|NCT03814720|Experimental|Group 2D: H1ssF_3928 (60 mcg), ages 60-70 years|H1ssF_3928 (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16)
89312663|NCT02818036|Experimental|naltrexone|single 50mg dose of naltrexone
89312664|NCT02818036|Placebo Comparator|sugar pill|single sugar pill
89312665|NCT01287741|Active Comparator|Rituximab+Chemotherapy|Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
89312666|NCT01287741|Experimental|Obinutuzumab+Chemotherapy|Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
89312667|NCT01180959|Experimental|Erlotinib + Bevacizumab|Erlotinib 150 mg by mouth once a day. Bevacizumab 10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes.
89312668|NCT01177371|Experimental|Arm I|"HIGH-DOSE CHEMOTHERAPY: Patients receive oral busulfan every 6 hours on days -8 to -5 and cyclophosphamide IV over 2 hours on days -4 and -3, or -4 to -2.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine IV over 6 hours on day -1, over 10 hours twice daily on days 0-20, and then orally every 12 hours beginning on day 21 and continuing for 12 months with taper at 9 months. Patients also receive methylprednisolone IV or orally beginning on day 8 and continuing for 7 months with taper at 4 months. Some patients may also receive methotrexate IV on days 1, 3 and 6."
89312669|NCT01287819||APOE4 (+) and APE4 (-)|APOE4 (+) 10 people APOE4 (-) 20 people from 200 participants
89312670|NCT01178931|Active Comparator|Oral dydrogesterone|Study group receiving 2x10mg of oral dydrogesterone until a pregnancy test or in the case of pregnancy until 10 week.
89312671|NCT01178931|Active Comparator|Crinone 8% vaginal gel|Control group is receiving vaginal gel, 1x90mg, until a pregnancy test or in the case of pregnancy until 10 week.
89312672|NCT01289379|Experimental|HFJV|
89312673|NCT03857997||Patients|
89312674|NCT03857997||Parents|
89312675|NCT01181037||100 patients, displaced subcapital fracture, T.A.N nail.|100 patients sustained a displaced femoral subcapital fracture, that were operated on with closed reduction and internal fixation with TAN nail.
89312676|NCT01181037||100 patients, displaced subcapital fracture, Bipolar H.A..|
89312677|NCT01181115|Experimental|Active treatment|Interferon treatment for MS
89312678|NCT03857685||Proliferation in an in-vitro model|An in-vitro model is used to study lens epithelial cell proliferation
89312679|NCT01179165||Type 2 diabetes age 40-75|Only one diagnostic/observational group
89312680|NCT02525289|No Intervention|Control Group|six hours after extubation receiving breathing exercises. After 48 hour postoperative time, sitting on armchair and keeping the erect position and walking in the same place.
89312681|NCT02525289|Active Comparator|Bed Rotation Group|six hours after extubation receiving breathing exercises and submitted the continuous rotational bed therapy in the first postoperative day until 48 hours.
89312682|NCT02525289|Active Comparator|Orthostatic Group|six hours after extubation receiving breathing exercises and changing the body position following the sequence: sitting on the bed, sitting on the bed with the feet on the floor , standing and walking in the same place, in the first postoperative day until 48 hours.
88810969|NCT04904094|Experimental|Intervention group|This group will receive casting of the lower limb for approximately 2 weeks combined with a passive stretching program of the knee flexors, followed by a homebased stretching exercise program for the plantar flexors and hamstrings for 4 weeks after casting.
89312683|NCT01179243||intensive care patients|no interventions
89312684|NCT05666661|Experimental|Sound and light therapy group (BBT and FL group)|30 minutes of intervention every day for 14 consecutive days.
89312685|NCT05666661|Experimental|Sound therapy group (BBT)|30 minutes of intervention every day for 14 consecutive days.
89312686|NCT05666661|Sham Comparator|Relaxing music group|30 minutes of intervention every day for 14 consecutive days.
89312687|NCT01177605|Placebo Comparator|Vanilla flavored milk-based beverage containing no prebiotics|Vanilla flavored milk-based beverage containing no prebiotics
89312688|NCT01177605|Experimental|Vanilla flavored milk-based beverage containing prebiotics|Vanilla flavored milk-based beverage containing prebiotics
89312689|NCT01287975|Active Comparator|Standard Occupational Therapy|Standard Occupational Therapy for Wrist and Hand Training
89312690|NCT01287975|Experimental|BCI Haptic Knob|BCI controlled robotic-assisted training for wrist and hand
89312691|NCT01287975|Experimental|Haptic Knob|Robotic-assisted training for wrist and hand
89312692|NCT01289535|Experimental|antibody rates|
89312693|NCT03857919|Experimental|TearCare|Subjects will have heat applied to the eyelids for 15 minutes followed by manual expression of the meibomian glands.
89312694|NCT03857919|Active Comparator|LipiFlow|Subjects will have heat and pressure applied to the eyelids for 12 minutes.
89312695|NCT01289613||Children|Children
89312696|NCT01289613||Adults|Adults
89312697|NCT03859245|Experimental|Experimental group|Subjects in the experimental group will receive clinically prescribed meal plans designed to facilitate prolonged benign dietary ketosis (BDK) purposed at glucose regulation, improved insulin sensitivity and restored metabolic flexibility. Photobiomodulation therapy, via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
89312698|NCT03859245|Active Comparator|Control group|Subjects in the control group will follow current dietary protocol (Standard American Diet- SAD). Photobiomodulation therapy,via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
89312699|NCT01179321|No Intervention|Control|
89312700|NCT01179321|Experimental|Early nutrition intervention|
88810970|NCT04904094|No Intervention|Control group|This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic devices.
88810971|NCT04899765|Experimental|Measles vaccine|Measles vaccine in standard dose of 0.5 ml.
89312701|NCT01181427|Placebo Comparator|Single Ascending Dose (SAD)|Healthy volunteers, receiving single ascending doses of ABT-267 or placebo.
89312702|NCT01181427|Placebo Comparator|Multiple Ascending Dose (MAD)|Healthy volunteers, receiving multiple ascending doses of ABT-267 or placebo, OR, multiple doses of ABT-267 + single dose of a Cytochrome P450 inhibitor or placebo + single dose of a Cytochrome P450 inhibitor.
89312703|NCT01181427|Active Comparator|Food Effect (FE)|Healthy volunteers, receiving ABT-267, multi-dose, food effect.
89312704|NCT01181427|Placebo Comparator|Antiviral Activity|HCV genotype 1-infected treatment naïve subjects receiving multiple ascending doses of ABT-267 or placebo monotherapy for 3 days.
89312705|NCT01181427|No Intervention|Resistance Monitoring|"HCV genotype 1-infected treatment naïve subjects, receiving at least one dose of ABT-267 or placebo in the Antiviral Activity arm, follow-up to monitor resistance developed to ABT-267, no treatment and only blood samples will be collected"
89312706|NCT03855579|Experimental|Levosimendan|Intraoperative infusion of Levosimendan
89312707|NCT03855579|Active Comparator|Milrinone|Intraoperative infusion of Milrinone
89312708|NCT03855423|Experimental|Tocotrienol-rich Fraction (TRF)|Pre-operative patients will be receiving TRF at different doses assigned to them in a cohort of 3 patients at each level.
89312709|NCT01181505|Experimental|Tolterodine|
89312710|NCT01290705|Experimental|high exercise|High dose, high repetition exercise therapy, 3 times weekly in 12 weeks
89312711|NCT01290705|Experimental|low exercise|low dose, low repetition exercise therapy, 3 times weekly in 12 weeks
89312712|NCT01181583|Experimental|Tailored Internet-delivered CBT|
89312713|NCT01181583|Experimental|Non-tailored Internet-delivered CBT|
89312714|NCT01181583|Active Comparator|Online discussion group|
89312715|NCT01290783|Active Comparator|FOLFIRI|
89312716|NCT01290783|Experimental|FOLF(HA)iri|
89312717|NCT01184469||Fresh embryo transfers|Patients who received fresh blastocyst transfer
89312718|NCT01184469||Thawed embryo transfers|Patients who received transfers of frozen/thawed embryos
89312719|NCT01290861||pre-manifest HD|
89312720|NCT01290861||early manifest HD|
89312721|NCT01290861||healthy controls|
89312722|NCT01184547|Experimental|COMBEX|Community Based Exercise Program or exercise group and quality of life Intervention- The community-based exercise program consisted of 12 weeks of exercise with a community-based trainer after hospital discharge.
89312723|NCT01184547|Active Comparator|Standard Of Care|Standard of Care group, group with no exercise and quality of life. Intervention- No exercise training received.
89312724|NCT03859401|Experimental|Control - Experimental Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Control-Experimental Arm will undergo the Control Admission first, utilizing an artificial pancreas (AP) controller that does not anticipate exercise (rMPC - naïve model predictive control), followed by the Experimental Admission, which will utilize an AP controller that has the ability to anticipate exercise (EnMPC - ensemble model predictive control). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
89312725|NCT03859401|Experimental|Experimental - Control Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Experimental-Control Arm will undergo the Experimental Admission first, utilizing an artificial pancreas (AP) controller that has the ability to anticipate exercise (EnMPC), followed by the Control Admission, which will utilize an AP controller that does not have the ability to anticipate exercise (rMPC). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
89312726|NCT03857763|Experimental|Apatinib+Paclitaxel+Cisplatin+RT|Apatinib：250mg,po,qd, d1-35; Paclitaxel：50mg/m2 iv, d1，8，15，22，29; Cisplatin: 30mg/m2 iv, d1，8，15，22，29; Radiotherapy：41.4Gy/23f , 1.8Gy/f，5 f/w
89312727|NCT01181661|Experimental|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
89312728|NCT01181661|Experimental|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
89312729|NCT06008691||B-cell NHL patients treated with novel MAB in Italian real life (approved by EMA and AIFA).|"B-cell NHL patients treated with novel MAB in Italian real life (approved by EMA since 2020 and prescribed according to the indications for use authorized for marketing in Italy).~Patients first-line and relapsed or refractory who had received at least 1 dose of MAB.~Different cohorts will be analyzed according to approved treatment indications, type of antibody employed and NHL hystotypes."
89312730|NCT06008678|Other|Treatment|RXiBreeze PAP System, Model RXiBreeze 20A
89312731|NCT06008665|Experimental|Action observation therapy with Otago exercise|"Participants' Instructions:~Watch a video on a 22-inch screen.~Screen positioned 1 meter away from them.~Comfortably seated in a chair with armrests.~No following along or movement allowed.~Video Features: Model in the video is 70 years old or older. Model similar to the participants.~Video Viewing: Duration: 17 minutes (1 minute per video). Supervised by the same investigator. Quiet environment during observation.~Physical Training Session: Supervised by a therapist.~Duration: 35 minutes (2 minutes max per session).~Based on content from the video.~Action Observation Training: Activities during the physical education workshops featured in the videos."
89312732|NCT06008665|Active Comparator|Otago exercise|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.~Training Frequency and Guidance: Exercises conducted three times a week,Guidance provided by a therapist.~Training Session Duration: Each session lasts for 35-40 minutes.~Warm-up and Cool-down:5-minute warm-up before each session and 5-minute cool-down after each session."
89312733|NCT06008587|Experimental|Nasal High Flow therapy in association with the standard therapy|
89312734|NCT06008587|Active Comparator|Standard therapy alone|
89312735|NCT06008548||TACE group|Incorporated HCC patients underwent TACE therapy.
89312736|NCT06008548||Liver resection group|Incorporated HCC patients underwent liver resection therapy.
89312737|NCT06008509|Experimental|Gastric Echography|All the patients that entry to the study are going to recieve gastric echography to determine the level of gastric emptying before the induction of anesthesia.
89312738|NCT06008483|Other|Dose Level 1|Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 0.5 mCi/kg
89312739|NCT06008483|Other|Dose Level 2|Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 1.0 mCi/kg
89312740|NCT06008483|Other|Dose Level 3|Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 2.0 mCi/kg
89312741|NCT06008483|Other|Dose Level 4|Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 3.0 mCi/kg
89312742|NCT06008457||Self-collection first|Subjects will self-collect an anterior nasal swab first
89312743|NCT06008457||HCP-collection first|Subjects will have their healthcare provider collect an anterior nasal swab first
89312744|NCT06008431|Experimental|tDCS intervention|Ten, once-daily, 20-min sessions of tDCS will be provided over two consecutive weeks.
89312745|NCT06008431|Sham Comparator|Sham and then tDCS|Five, once-daily, 20-min sessions of sham in week one followed by five, once-daily, 20-min sessions of tDCS in week two.
89312746|NCT06008418|Experimental|The LINE Chatbot|"Participants of the experimental group are required to use the Chatbot before discussing with their physicians.~Outcome variables are mainly measured at three points: baseline (immediately before the outpatient visit), 24 hours within the outpatient visit, and a week after. At baseline, participants provide their demographic information and complete questionnaires to evaluate their communication self-efficacy and quality of life. After 24 hours, participants are invited to evaluate their satisfaction, communication self-efficacy, shared-decision making process, and the experience of illness invalidation. After a week, the research assistant will remind the participant to evaluate their quality of life. Finally, a retrospective chart review will be conducted one month after the visit to confirm any emergency department visits. Except for the demographic variables (i.e., age, sex, educational level, and diagnosis) and emergency visits."
89312747|NCT06008418|No Intervention|Routine|"The comparison group participants will receive routine care (i.e., oral instruction regarding the overall process of outpatient department visits).~Outcome variables are mainly measured at three points: baseline (immediately before the outpatient visit), 24 hours within the outpatient visit, and a week after. At baseline, participants provide their demographic information and complete questionnaires to evaluate their communication self-efficacy and quality of life. After 24 hours, participants are invited to evaluate their satisfaction, communication self-efficacy, shared-decision making process, and the experience of illness invalidation. After a week, the research assistant will remind the participant to evaluate their quality of life. Finally, a retrospective chart review will be conducted one month after the visit to confirm any emergency department visits. Except for the demographic variables (i.e., age, sex, educational level, and diagnosis) and emergency visits."
89312748|NCT06008392||Participants with a confirmed cancer diagnosis|Potential participants may be identified through the following sources: patients who will undergo or are currently undergoing clinical evaluation in practices such as, but not limited to, hematology-oncology, gastroenterology-hepatology, radiation-oncology and surgery. Participants will be enrolled in the study indefinitely unless a request to withdraw is made.
89312749|NCT06008327|Experimental|Group A Topical 15% Trichloroacetic acid|15 % Trichloroacetic acid (TCA) and 0.05%Tretinoin for 02 months Trichloroacetic acid, a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. 9-10 Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
89312750|NCT06008327|Experimental|Group B Topical 0.05% Tretinoin|Topical tretinoin is the first choice of drug in the treatment of acanthosis nigricans. Despite several therapeutic modalities, acanthosis nigricans (AN) remains a difficult dermatosis to treat.
89312751|NCT06008262|Experimental|Cold Application Group|An ice pack will be applied to the posterior upper neck regions of patients with nausea in Group-I, with an interval of 5 minutes. The vital signs of the patients will be recorded. The severity of nausea and pain of the patients will be evaluated with a numerical rating scale. The effectiveness of its application as perceived by the patient will be evaluated.
89312752|NCT06008262|No Intervention|Control Group|In the control group, the severity of nausea and pain will be determined by using a numerical evaluation scale in patients with postoperative nausea. Vital signs will be recorded at this stage. Normal procedures will be applied to these patients within the scope of nursing practices.
89312753|NCT06008249|Experimental|Lithium carbonate|Lithium carbonate 400 mg capsules will be taken once daily, starting with one capsule (400 mg daily) initially titrated up to two or three capsules daily, depending on blood lithium levels. The target range for the lithium plasma level will be between ≥0.4 mmol/l and ≤ 0.8 mmol/l. Maximum duration is 24 months.
89312754|NCT06008249|Placebo Comparator|Placebo|Patients start with 1 capsule to be taken once daily, with subsequent sham dose adjustments made to patients on placebo to maintain blinding in clinical sites.
89312755|NCT06008223|Experimental|experimental group (vitamin B6)|
89312756|NCT06008223|Placebo Comparator|control group (0.9% sodium chloride solution)|
89312757|NCT06008171|Active Comparator|Patient Decision Aid|Consult about treatment options for field-directed therapies for actinic keratosis by the dermatologist, with the use of a Patient Decision Aid.
89312758|NCT06008171|No Intervention|Without Patient Decision Aid (conventional)|Conventional consult about treatment options for field-directed therapies for actinic keratosis by the dermatologist, without the use of a Patient Decision Aid.
89312759|NCT06008119|Experimental|Experimental|Tunlamatinib plus Vemurafenib
89312760|NCT06008119|Active Comparator|Control|Investigators' choice
89312761|NCT06008106|Experimental|tunlametinib|Drug tunlametinib will be administered as 12mg BID
89312762|NCT06008106|Active Comparator|Assigned Interventions|combination chemotherapy
89312763|NCT06008067||Survivors|Patients who survived after day 28.
89312764|NCT06008067||Non-survivors|Patients who died at or before day 28.
89312765|NCT06007989||Basic science study, no intervention.|Basic science study, no intervention.
89312766|NCT06007950|No Intervention|Ad-libitum eating duration|24 patients will be randomly assigned to the control group. Participants will be asked to continue usual eating duration. Participants will receive the standard care and heart-healthy nutrition education.
89312767|NCT06007950|Experimental|Time-restricted eating (TRE) duration|24 patients will be randomly assigned to the intervention group. Participants in this arm will be asked to limit the number of hours they eat in a day to 10 hours in addition to receiving the standard of care health and heart-healthy nutrition education.
89523420|NCT03375515|Experimental|PCA IV Hydromorphone titration|PCA titration using programmable pump: bolus hydromorphone at 0.5mg (for opioid intolerance) or hydromorphone dose equivalent to 10% to 20% of the total opioid taken in the previous 24 hours with a lockout time 15 min (for opioid tolerance) was administered by the patients educated. No basal infusion was set in the pump.Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient himelf/herself) in 24hrs.
89312768|NCT06007937|Experimental|Lorlatinib and ramucirumab|The phase 1 safety portion of the study will assess whether a dose of lorlatinib 100 mg orally daily and ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose. Six patients will be enrolled at this dose level and assessed for dose limiting toxicities (DLTs) for one full cycle (21 days). Once the phase 1 portion of the study is complete, patients will be enrolled in the phase 2 portion of the study, cohort expansion at the MTD. Patients will be enrolled in two patient cohorts: cohort 1, treatment-naïve and cohort 2, patients who have progressed on prior second-generation ALK TKI. A cycle will be 21 days in length. Response to therapy will initially be assessed by interval imaging every 2 cycles.
89312769|NCT06007898|Experimental|Parent self-help psychological resource|A self-help psychological resource will be provided for parents to use with their CYP in the home.
89312770|NCT06007898|No Intervention|Wait list control|Parents randomised to the control arm will be put on the waiting list (wait-list controls) to receive the group intervention after they have completed their final follow-up at 2 months.
89312771|NCT06007859||section orientation of ultrasound shear wave elastography|
89312772|NCT06007833|Experimental|physical therapy and rehabilitation program in addition to conservative treatment|Orthoses and positioning will be applied to the experimental group as a conservative treatment, following post-surgical plastering. In addition, they will receive a physical therapy and rehabilitation program
89312773|NCT06007833|Active Comparator|Conventional Group|As a conservative treatment in the control group, post-surgical plastering followed by orthoses and positioning will be applied
89312774|NCT06007820|Experimental|Large Volume Thoracocentesis|Group 1 - on-demand therapeutic thoracocentensis
89312775|NCT06007820|Active Comparator|Pigtail Catheter|Group 2 - small volume frequent thoracocentesis using PCD
89312776|NCT06007768||Fabry Disease|Patients with Fabry disease, older than 18 years, and without autoimmune or autoinflammatory diseases.
89312777|NCT06007768||Control|Subjects without Fabry disease or autoimmune/autoinflammatory diseases, matched for age (± 5 years) and sex.
89312778|NCT06007716|Active Comparator|Experimental group|it was planned to apply reflexology massage once a day for each patient for 2 consecutive days, in total 2 sessions.
89312779|NCT06007716|Placebo Comparator|placebo group|placebo massage was applied once a day for each patient for 2 consecutive days, for a total of 2 sessions.
89312780|NCT06007599|Active Comparator|Group A: suture with skin adhesive|After surgery the closure technique utilized by the surgeons will be subcuticular running 3-0 monocryl sutures without skin adhesive
89312781|NCT06007599|Active Comparator|Group B: suture without skin adhesive|After surgery the closure technique utilized by the surgeons will be subcuticular running 3-0 monocryl sutures with skin adhesive.
89312782|NCT06007573|Experimental|treatment group|On the basis of the control group treatment, the treatment group also adopted the acupuncture treatment
89312783|NCT06007573|Other|control group|The control group received oral nimodipine tablets
89312784|NCT06007560|Other|<80% eNK|Women with low eNK bright cell numbers, defined as <80% of the total endometrial NK cell population
89312785|NCT06007534|Other|Adult male patient|Men having Sex with Men on PrEP (pre-Exposition Prophylaxy) regularly taking doxycycline for Sexually Transmitted Infection (STI) prevention
89312786|NCT06007495|Experimental|Single-limb non-invasive ventilation with expiratory washout|In a random order, 30 minute period of non-invasive ventilation using the investigational mask, a vented full-face mask with expiratory washout
89312787|NCT06007495|Active Comparator|Single-limb non-invasive ventilation|In a random order, 30 minute period of non-invasive ventilation with a conventional vented full-face mask (RT077 or equivalent)
89312788|NCT06007495|Active Comparator|Dual-limb non-invasive ventilation|In a random order, 30 minute period of non-invasive ventilation with a conventional vented full-face mask (RT076 or equivalent)
89312789|NCT06007469||Critical Limb Threatening Ischaemia|Patients presenting with Critical Limb Threatening Ischaemia
89312790|NCT06007469||Non-limb threatening peripheral vascular disease|Patients presenting with non-limb threatening peripheral vascular disease
89312791|NCT06007339|Experimental|Investigational Device Arm (PerQseal Elite- Venous)|Large hole percutaneous venous closure device - PerQseal Elite
89312792|NCT06007300||Normal Group|Patients with normal endometrium
89312793|NCT06007300||Precancerous Group|Patients with atypical hyperplasia of endometrium
89312794|NCT06007300||Carcinoma Group|Patients with endometrial cancer
89312795|NCT06007274||Active surveillance by means of troponin measurements|
89312796|NCT06007274||No active surveillance by means of troponin measurements|
89312797|NCT06007248||Case Group|IR-CAD patients (from the IR-CAD cohort study)
89312798|NCT06007248||Control Group|AS-CAD patients
89312799|NCT06007222|Active Comparator|Aspirin group|Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
89312800|NCT06007222|Experimental|Non-antithrombotic group|No antithrombotic agents will be administered after randomization until the end of the study period.
89312801|NCT06007170|Experimental|Treatment Group|SPIRION Laryngeal Pacemaker System Implantation and follow-up
89312802|NCT06007144|Experimental|Treatment Group|SPIRION Laryngeal Pacemaker System Implantation and follow-up
89312803|NCT06007118|Experimental|APBI, accelerated partial breast irradiation|The APBI group will be irradiated with a dose of 30Gy in 5 fractions in 5 working days.
89312804|NCT06007118|Active Comparator|WBI, whole breast irradiation|The control group of patients will be irradiated with a standard accelerated mode within 20 working days.
89312805|NCT06007105|Experimental|SUCCEED Community-Based Intervention|The SUCCEED community-based intervention (offering a combination of peer support, case management and livelihoods activities) will be delivered to 10 participants with lived experience of psychosis at each of the 4 pilot sites.
89312806|NCT06007092|Experimental|level dose 1 HPVDC injection|10 patients with experimental injection at 1.0 mg
89312807|NCT06007092|Placebo Comparator|level dose 1 placebo injection|2 patients with experimental injection at 1.0 mg
89312808|NCT06007092|Experimental|level dose 2 HPVDC injection|10 patients with experimental injection at 3.0 mg
89312809|NCT06007092|Placebo Comparator|level dose 2 placebo injection|2 patients with experimental injection at 3.0 mg
89312810|NCT06007066|Experimental|Preoperative administration of HSK16149 40mg|HSK16149 40mg will be administered the night before and 2h before surgery
89312811|NCT06007066|Experimental|Preoperative administration of HSK16149 60mg|HSK16149 60mg will be administered the night before and 2h before surgery
89312812|NCT06007066|Experimental|Preoperative and postoperative administration of HSK16149 40mg|HSK16149 40mg will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery
89312813|NCT06007066|Experimental|Preoperative and postoperative administration of HSK16149 60mg|HSK16149 60mg will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery
89312814|NCT06007066|Placebo Comparator|placebo|The placebo will be administered orally the night before surgery, 2h before surgery, 4h and 16h after surgery
89312815|NCT06007027|Experimental|Active laser group|In the active laser group, participants are treated intravaginally with the fractional microablative CO2 laser system (SmartXIDE2V2LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting; dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μs and the smart stack parameter from 2 to 3. At the level of the vaginal introitus, the dot power decreases to 20 Watt.
89312816|NCT06007027|Sham Comparator|Sham laser group|In the sham laser group, participants are treated intravaginally with the fractional microablative CO2 laser system (SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy), using the following setting; dot power 0,5 watt, dwell time 100 μs, dot spacing 2000 μs and the smart stack parameter from 1 to 1
89312817|NCT06007001|Experimental|Telemedicine|Patients in the intervention group will receive weekly teleconsultation of 30 minutes during 8 weeks through the secure Edumeet platform. In pilot 1, tele-rehabilitation training will be performed by a remote physiotherapist and will consist of a series of rehabilitation exercises. In pilot 2, tele-psychological support will be performed by a remote psychologist and will consist of techniques for managing emotions and stress. In the intervention group, patients will also have the possibility to wear a smartwatch to automatically collect physical parameters.
89312818|NCT06007001|No Intervention|Usual care|Patients in the control group will receive usual care.
89312819|NCT06006988|Experimental|trunk disorder scale|It is a 17-parameter scale developed for the evaluation of trunk control. Existing sections in the scale; static sitting balance (GBÖ Static), dynamic sitting balance (GBÖ Dynamic) and coordination (GBÖ Coordination). The total score is a minimum of 0 and a maximum of 23 points and it is accepted that the higher score shows better performance.
89312820|NCT06006949|Experimental|roxadustat and luspatercept|"Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg.~Roxadustat (150mgqod) was administered for at least 6 months to evaluate efficacy.~Hemoglobin ≥120g/L can be discontinued, and hemoglobin <120g/L can continue to use. Those who are effective will continue to be given the combination therapy until ineffective or intolerant."
89312821|NCT06006949|Experimental|luspatercept|"Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg.~Luspatercept was given for at least 6 months to evaluate the efficacy. Hemoglobin ≥120g/L can be discontinued, and hemoglobin <120g/L can continue to use. Those who are effective will continue to be given the therapy until it is ineffective or intolerant"
89312822|NCT06006936|Experimental|Intervention Condition|This arm will receive the Coping with Infertility intervention.
89312823|NCT06006936|No Intervention|Waitlist/Treatment as Usual Control Condition|This arm will continue with everyday life-including their attempts to conceive.
89312824|NCT06006923|Experimental|Pembrolizumab + Regorafenib|"Pembrolizumab: 200mg, Q3 weeks~Regorafenib: 60mg Cycle 1 Day 1 90 mg Cycle 2 Day 1"
89312825|NCT06006923|Active Comparator|Pembrolizumab|Pembrolizumab: 200mg, Q3 weeks
89312826|NCT06006845||A|Tumor patients infected with COVID-19
89312827|NCT06006832||maintenance steroid therapy group|Maintaining low-dose oral steroids
89312828|NCT06006832||immunosuppresants withdrawal group|Withdraw all immunosuppresants
89312829|NCT06006780|Active Comparator|Coronally advanced flap (CAF)|
89312830|NCT06006780|Experimental|Coronally advanced flap associated with the porcine acellular dermal matrix (CAF+ PADM)|
89312831|NCT06006728||naliri|Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy
89312832|NCT06006715||DanFunD baseline|The baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590).
89312833|NCT06006715||DanFunD 5-years follow-up investigation|The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).
89312834|NCT06006663|Active Comparator|group 1|ibuprofen as intracanal medicament
89312835|NCT06006663|Active Comparator|group 2|modified triple antibiotic paste as intracanal medicament
89312836|NCT06006663|Active Comparator|group 3|curcumin as intracanal medicament
89312837|NCT06006663|Active Comparator|group 4|olive leaves as intracanal medicament
89312838|NCT06006650|Experimental|Pembrolizumab Plus Albumin Paclitaxel and Cisplatin|Preoperative neoadjuvant (pembrolizumab 200mg, d1 intravenously, q3w+ albumin paclitaxel 100mg/m2, d1/d8/d15 intravenously, q3w+ cisplatin 75mg/m2, d1 intravenously, q3w) 3 cycles + surgery + 16 cycles of postoperative pembrolizumab adjuvant therapy
89312839|NCT06006650|Active Comparator|Pembrolizumab Plus 5-fluorouracil and Cisplatin|Preoperative neoadjuvant (pembrolizumab 200mg, d1 intravenously, q3w+ 5-fluorouracil 800mg/m2, d1-5 intravenously, q3w+ cisplatin 75mg/m2, d1 intravenously, q3w) 3 cycles + surgery + 16 cycles of postoperative pembrolizumab adjuvant therapy
89312840|NCT06006650|Active Comparator|5-fluorouracil and Cisplatin|Preoperative neoadjuvant (5-fluorouracil 800mg/m2, d1-5 intravenously, q3w+ cisplatin 75mg/m2, d1 intravenously, q3w) 3 cycles + surgery + 16 cycles of postoperative pembrolizumab adjuvant therapy
89312841|NCT06006637|Experimental|CognilumTM|During the study participants will be wear the transcranial photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
88810972|NCT04899765|Experimental|BCG vaccine|BCG vaccine in standard dose of 0.1 ml.
88810973|NCT04899765|Placebo Comparator|Placebo|Saline injection
89312842|NCT06006637|Sham Comparator|Sham control|During the study participants will wear the transcranial photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
89312843|NCT06006624|Active Comparator|Group 1: ACL repair + Exparel + nerve block|30 mL Liposomal bupivacaine (Exparel) + 5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal and iPACK block (35 mL total)
89312844|NCT06006624|Active Comparator|Group 2: ACL repair + Exparel + Dexamethasone + nerve block|30 mL Liposomal bupivacaine (Exparel) + 10 mg preservative free Dexamethasone + 5 cc's of 0.5% bupivacaine evenly distributed for both adductor canal and iPACK block (35 mL total)
89312845|NCT06006572|Active Comparator|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive|After surgery, the closure technique utilized by the surgeons will be wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive
89312846|NCT06006572|Active Comparator|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive|After surgery, the closure technique utilized by the surgeons will be wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
89312847|NCT06006468||Genetic risk of Type 1 diabetes|750 individuals with the highest type 1 diabetes genetic risk
89312848|NCT06006468||Genetic risk of coeliac disease|750 individuals with the highest coeliac disease genetic risk
89312849|NCT06006468||Controls|750 individuals with Neutral type 1 diabetes and coeliac disease genetic risk
89312850|NCT06006455|Experimental|Erchonia LunulaLaser|The Erchonia LunulaLaser emits red light (635 nm) and violet light (405 nm) to the affected toenail for 12 minutes per treatment. The treatment phase involves an initial weekly treatment administration phase, 1 treatment a week for 4 weeks, followed by an every two-month maintenance treatment administration phase, months 3, 5, 7, 9, and 11.
89312851|NCT06006429|Experimental|Patients|
89312852|NCT06006299|Experimental|taVNS|Participants will use the transauricular Vagus Nerve Stimulator provided to them by the lab for 14 days, 15 minutes prior to sleeping. Data will be collected via surveys, interviews, and Fitbit wear over the course of 2 months. A sleep diary will be kept to record sleep quality.
89312853|NCT06006234||residents of elderly care institutions|residents of elderly care institutions
89312854|NCT06006195||patients with dysphagia symptoms|
89312855|NCT06006195||patients without dysphagia symptoms|
89312856|NCT06006182|Experimental|Group A-Grape Powder then Placebo|Group A block will be the Grape Powder for the first 8 weeks, and then after the washout period, they will begin the Placebo. The experimental Grape Powder is a food-it is simply freeze-dried grape powder
89312857|NCT06006182|Placebo Comparator|Group B-Placebo-then Grape Powder|Group B block will be the Placebo for the first 8 weeks, and then after the washout period, they will begin the Grape Powder
89312858|NCT06006143|Experimental|Varenicline|Participants will receive a prescription for generic varenicline
89312859|NCT06006104|Experimental|HRS-4357 injection|
89312860|NCT06006091|Experimental|Letrozole-induced endometrial preparation protocol|Starting at D3 of the menstrual cycle, letrozole 2.5 mg po qd was administered for 5 days. After 1 week, ultrasound was performed to dynamically monitor follicular development, and 75-150 IU im qd of human menopausal gonadotrophin (hMG) given to continue ovulation stimulation as needed, and oestradiol valerate 2 mg po qd was given to regulate endometrial thickness until the follicle developed to 16 mm in diameter and 7 mm in endometrial thickness. The follicles developed to ≥16 mm in diameter and ≥7 mm in lining thickness and were dynamically monitored by ultrasound and serum sex hormone levels to determine the day of ovulation. From the day of ovulation, dexamethasone 10 mg po tid was administered, and cleavage-stage embryos were transferred 2 or 3 days later, or blastocysts were transferred 5 days later. Deferiprone 10 mg po tid was continued for 14 days after transfer.
89312861|NCT06006091|No Intervention|Natural cycles endometrial preparation protocol|Follicular development was monitored dynamically by ultrasound from D8-D11of the menstrual cycle until the follicles developed to ≥16 mm in diameter and ≥7 mm in endothelial thickness, and the day of ovulation was determined by dynamic ultrasound monitoring and detection of serum sex hormone levels. Deferiprone 10 mg po tid was administered from the day of ovulation, and D2 or D3 cleavage stage embryos were transferred 2 or 3 days later, or blastocysts were transferred 5 days later. Deferiprone 10 mg po tid was continued for a total of 14 days after transfer. Cycles were canceled if endothelial thickness was <7 mm on the day of ovulation or if serum progesterone levels were 5 nmol/L before ovulation.
89312862|NCT06006091|No Intervention|Hormone replacement cycles endometrial preparation protocol|Starting from D1-D5 of the menstrual cycle, estradiol valerate 2 mg po bid was administered for 7 days, followed by ultrasound for dynamic monitoring of endothelial and follicular development, and if the endothelial thickness was <7 mm, the dosage of estradiol valerate was increased to 3-4 mg po bid as appropriate. The number of days of hormone replacement ranged from 11-20 days, and when the endothelial thickness was 7 mm, luteinizing hormone vaginal slow-release gel 90 mg pv qd was added, as well as dexedrine and progesterone 10 mg po bid to transform the endothelium 2 or 3 days later or 5 days later. Progesterone 10 mg po bid was added to transform the endothelium, and cleavage stage embryos were transferred 2 or 3 days later, or blastocysts were transferred 5 days later. Luteal support as described above was continued for a total of 14 days after transfer.
89312863|NCT06006078|Active Comparator|Endoscopic Facemask|Patients undergoing endoscopy with the use of an endoscopic facemask
89312864|NCT06006078|No Intervention|No Endoscopic Facemask|Patients undergoing endoscopy without an endoscopic facemask
89312865|NCT06006052|Experimental|study group DDM|Group I: 10 teeth will be treated with demineralized dentin matrix attached to collagen membrane as a scaffold in the regenerative endodontic procedure.
89312866|NCT06006052|Active Comparator|Control group|Group II: 10 teeth will be treated with the conventional regenerative endodontic procedure (blood clot scaffold).
89312867|NCT06006052|Active Comparator|positive control|Group III: 10 teeth will be treated with collage membrane as a scaffold in the regenerative endodontic procedure
89312868|NCT06005987|Experimental|Mobile App arm|Patient will input their daily blood glucose levels (fasting and 2 hours after breakfast, lunch and dinner) into the OneTouch Reveal app
89312869|NCT06005987|No Intervention|Paper Log Arm|Patients will input their daily blood glucose levels onto paper logs which is the current process in the prenatal clinic.
89312870|NCT06005909|Experimental|Cawthorne-Cooksey|These exercises, which are designed to reduce vertigo, stabilize the gaze and improve balance by stimulating or operating the vestibular system during daily activities, consist of a series of eye, head, trunk and balance movements that provoke vestibular symptoms and whose difficulty increases. The degree of difficulty of the exercises was increased with the improvement of the patient. Head and trunk movements while sitting, standing and walking were added to the exercises that initially started with simple eye-head movements in bed.
89312871|NCT06005909|Experimental|Mechanical Hippotherapy|Before being taken to the device, the patients were informed about the working principle of the device, the exercises to be performed on the device, and that the exercise would be terminated in case of a possible health problem. After being placed on the device, the patient was given time until the initial balance was achieved. When the patient felt ready, a 15-minute hippotherapy session was applied at the 5th level of the 20-stage speed level by the physiotherapist.
89312872|NCT06005896||Success|Patients who were alive and free from RRT 7 days after interrupting RRT.
89312873|NCT06005896||Failure|Patients who were not alive or who needed to dialyse again after interrupting RRT for at least 48h.
89312874|NCT06005870|Experimental|Z-RCHOP|Patients with newly diagnosed DLBCL with p53 expression were treated with a combination of Zanubrutinib and RCHOP.
89312875|NCT06005831|Other|Sandbag|Sandbag
89312876|NCT06004869|Experimental|EMA/I CBT-I group|The participants allocated to the EMI/A CBT-I group will receive 6 weeks of smartphone-based CBT-I for approximately 1 hour per week. The EMA feature will capture the participant's momentary ratings of experiences to support therapeutic decision making. The trained therapist will prescribe EMI, provide personalised sleep advice, and adjust the treatment by dynamically adapting real-time rest-activity assessments collected using EMA and wearable devices. The participants will receive tailored moment-specific feedback from therapists when daytime symptoms are indicated. Therapists will also monitor the relationship between daytime symptoms (EMA app) and the sleep-wake pattern (wearables).
89312877|NCT06004869|Active Comparator|Pure self-help CBT-I group|The participants in the pure self-help CBT-I group will receive 6 weeks of self-help CBT-I without EMA/I and therapist support. The CBT-I content will be identical to the content used in the EMI/A CBT-I group.
89312878|NCT06004869|No Intervention|Care as usual|
89312879|NCT06004310|Experimental|Post-COVID-19 Patients|"Post-COVID-19 patients are individuals who have recovered from the acute phase of COVID-19 but continue to experience lingering symptoms and health challenges for weeks or even months after their initial infection. These individuals are often referred to as long haulers or post-acute sequelae of SARS-CoV-2 infection (PASC) patients. The symptoms experienced by post-COVID-19 patients can vary widely and may include fatigue, shortness of breath, chest pain, joint pain, cognitive difficulties, and more. Medical professionals and researchers are working to better understand and address these conditions, providing supportive care and rehabilitation to help these patients regain their health and well-being."
89312880|NCT06003738|Active Comparator|The fascia iliaca compartment block group|The first group 34 patients
89312881|NCT06003738|Active Comparator|The pericapsular nerve block group|The second group 34 patients
89312882|NCT06003452|Active Comparator|Giomer Based Sealant Without Pre-Treatment With Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied without surface treatment
89312883|NCT06003452|Experimental|Giomer Based Sealant With Pre-Treatment With Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion
89312884|NCT06003413||Osteoarthritic Knee|"Knees with Kellgren-Lawrence Stage 2-4 will admitted to this group~Vastus Lateralis, Tibialis Anterior, Lateral Gastrocnemius and Medial Gastrocnemius ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.~Outcome Measures in Rheumatology (OMERACT) Ultrasound scores for knee will be evaluated~Isometric knee extension, isometric ankle dorsiflexion and isometric ankle plantar flexion strength will be evaluated with hand held dynamometer"
89312885|NCT06003413||Healthy Knee|"Healthy knees will be admitted to this group~Vastus Lateralis, Tibialis Anterior, Lateral Gastrocnemius and Medial Gastrocnemius ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.~Isometric knee extension, isometric ankle dorsiflexion and isometric ankle plantar flexion strength will be evaluated with hand held dynamometer"
89312886|NCT06003140|Experimental|Hypothermic Neonates (90)|A trained study clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual (such that the temperature sensor is positioned using a vertical line from the mid-clavicular line and just below the ribs). The time of sensor placement will be recorded.
89312887|NCT06002451|Experimental|WEB-BASED PRECONCEPTİONAL CARE AND COUNSELİNG|At the beginning of the study, Pre-test Forms were applied and data were obtained.A total of 9 Module Trainings for PC and maintenance were given over the Web Base for 2 weeks. While the trainings were continuing, the modules were monitored from the Admin Panel and reminder messages were sent to the people who did not watch the modules regularly. During the training, PD and care services were provided via the communication. At the end of the 10th week, the post-test forms were applied and the data were obtained. that they can reach 24/7 for a total of 10 weeks, 2 weeks and the following 8 weeks.
89312888|NCT06002451|No Intervention|CONTROL|Pre-test Forms were applied and data were obtained.No attempt has been made. This group received routine training and follow-ups at the family health center and premarital counseling unit.At the end of the 10th week, the post-test forms were applied and the data were obtained.
89312889|NCT06002295|Experimental|Umbilical Cord Care with Chlorhexidine (Group A)|
89312890|NCT06002295|Experimental|Umbilical Cord Care with Methylated Spirit (Group B)|
89312891|NCT06001736|Experimental|Contralateral C7 root transfer for the treatment of spastic hemiparesis.|The C7 nerve root transfer will occur to the patients on this arm.
89312892|NCT06001723|Experimental|Forest Therapy|This is a pretest-posttest designed experiment. A two-hour guided forest healing activity was used as an intervention method. For the purpose of comparison, an urban area adjacent to the Taipei Botanical Garden, specifically the Wanhua district, was selected. This choice ensures the exclusion of extensive green spaces commonly used for walking.
89312893|NCT06001554|Experimental|ICC-T|5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
89312894|NCT06001554|No Intervention|monitoring condition|No intervention
89312895|NCT06001307|Experimental|Program STARS (Supporting Trans Affirmation, relationships, and Sex)|"STARS is an HIV prevention intervention for trans women/femmes with recent intimate partner violence (IPV). Delivered by peer counselors, STARS consists of two one-hour sessions held one week apart and two brief 20-30 minute booster sessions held two- and four-weeks after the 2nd hour long session. Requirements for peer counselors include identifying as trans women or trans feminine and having leadership roles in the trans community.~STARS is an empowerment-based intervention that integrates trauma-informed and gender affirmation approaches. The first session emphasizes education and discussion around HIV and IPV, as well as the interaction between IPV and HIV risk. The second session focuses on identifying partners where HIV/IPV risk exists and developing an empowerment plan to address those risks. Participants create an empowerment plan in session 2 and this plan is reviewed and updated in the booster sessions."
89312896|NCT06001307|Active Comparator|Relaxation and Stress Reduction|"The Relaxation and Stress Reduction Program is structured to mirror STARS (time matched, attention-controlled). Delivered by peer counselors, the Relaxation and Stress Reduction Program consists of two one-hour sessions held one week apart and two brief 20-30 minute booster sessions held two- and four-weeks after the 2nd hour long session. Requirements for peer counselors include identifying as trans women or trans feminine and having leadership roles in the trans community.~The relaxation and stress reduction protocol is an attention and time-matched control condition. The intervention focuses on providing both education and opportunities to practice various relaxation strategies. In addition, education is provided on healthy eating as an additional tool for reducing stress. Booster sessions focus on providing participants with additional practice of relaxation strategies."
89312897|NCT06000293|Experimental|Treatment Group|"At baseline, the eligible infant aged 6 months old will undergo clinical oral examination and their primary caregivers will be given the pre-evaluation questionnaires for 6-9 months old. The primary caregivers will then be given the strengthened MOH AG intervention for 6-9 months old infants.~Following three months, at evaluation 1, the 9-month-old infant will undergo a clinical oral examination, and their primary caregivers will be given the post-evaluation questionnaires for 6-9 months old and pre-evaluation questionnaires for 9-12 months old. The primary caregivers will then be given the strengthened MOH AG intervention for 9-12 months old infants.~After three months, at evaluation 2, the 12-month-old infant will undergo a clinical oral examination, and their primary caregivers will be given the post-evaluation questionnaires for 9-12 months old."
89312898|NCT06000293|No Intervention|Control Group|"At baseline, the eligible infant aged 6 months old will undergo clinical oral examination and their primary caregivers will be given the pre-evaluation questionnaires for 6-9 months old. The primary caregivers will be allowed to receive the conventional MOH AG given by oral healthcare providers from the nearest dental clinic.~Following three months, at evaluation 1, the 9-month-old infant will undergo a clinical oral examination, and their primary caregivers will be given the post-evaluation questionnaires for 6-9 months old and pre-evaluation questionnaires for 9-12 months old.~After three months, at evaluation 2, the 12-month-old infant will undergo a clinical oral examination, and their primary caregivers will be given the post-evaluation questionnaires for 9-12 months old."
89312899|NCT05999721|Active Comparator|Treatment Arm|In addition to standard care, the treatment arm will receive an ultrasound-guided bilateral single-shot superficial parasternal intercostal plane block at two levels.
89312900|NCT05999721|Active Comparator|Control Arm|The control arm will receive standard care alone.
89312901|NCT05995457|Experimental|"Intramuscular injection of Haloperidol decanoate using the Z-track and Airlock techniques"|"Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the Z-track and Airlock techniques."
89312902|NCT05995457|Other|Control arm, Intramuscular injection as usual|Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique
89312903|NCT05991362|Experimental|SAD:100mg|Participants received single PO dose of GFH312 100 mg.
89312904|NCT05991362|Experimental|SAD:200mg|Participants received single PO dose of GFH312 200 mg.
89312905|NCT05991362|Experimental|MAD:120mg|Participants received multiple PO doses of GFH312 120 mg for 14 days.
89312906|NCT05991362|Placebo Comparator|Placebo|Participants receiving placebo matching with the GFH312 dose groups
89312907|NCT05990855|Experimental|eCBTi-obj|In the experimental condition, participants will complete a 5-week eCBTi program delivered via a mobile application while wearing an EEG headband (Muse S) during sleep. As part of the sleep restriction therapy component of CBTi, participants will be asked to follow an individualized sleep window (i.e., bed and wake schedule) which will be adjusted each week based on objective sleep data derived from their EEG recordings from the previous week. Participants will also receive a weekly sleep report based on this data.
89312908|NCT05990855|Active Comparator|eCBTi-subj|In the active comparator condition, participants will complete the same 5-week eCBTi program, but will not be wearing an EEG headband during the intervention. As part of the sleep restriction therapy component of CBTi, participants will be asked to follow an individualized sleep window (i.e., bed and wake schedule) which will be adjusted each week based on the subjective sleep data derived from their sleep diary of the previous week, as is typically done during classical CBTi. Participants will not receive any EEG-based sleep report during the intervention.
89312909|NCT05988528|Active Comparator|control group|Control group (Mesalamine group, n =30 ) who will receive 1 g mesalamine three times daily for 6 months
89312910|NCT05988528|Active Comparator|Nifuroxazide group|Patients will receive 1 g mesalamine three times daily plus Nifuroxazide 200 mg two times daily for 6 months
89312911|NCT05988099|Experimental|Complex product (chokeberry extract, L-arginine, vitamin E, vitamin A, folic acid, chromium)|Single oral dose - 2 capsules
89312912|NCT05988099|Active Comparator|Chokeberry extract in liposomal formulation|Single oral dose - 2 capsules
89312913|NCT05988099|Active Comparator|Chokeberry extract in traditional formulation|Single oral dose - 2 capsules
89312914|NCT05988099|Placebo Comparator|Placebo|Single oral dose - 2 capsules
89312915|NCT05980494|Experimental|Scanning group|Lung ultrasound (LUS), Inferior vena cava ultrasound (IVC US) and pulse pressure variation (PPV) will be done to every patient in the study.
89312916|NCT05979376||Group I (Control group)|group I: quadratus lumborum block with 0,25% bupivacaine 0,5 ml/kg
89312917|NCT05979376||Group II|groupII: quadratus lumborum block with 0,25%bupivacaine 0,5 ml/kg and dexmedetomidine 0,5 mcg/kg as an adjuvant
89312918|NCT05979376||Group III|groupIII: quadratus lumborum block with 0,25% bupivacaine 0,5 ml/kg and dexmedetomidine 1 mcg/kg as an adjuvant
89312919|NCT05978375||Irreducible Atlantoaxial Dislocation|Atlantoaxial dislocation which could not be reducted under anesthesia traction with 1/6 weight.
89312920|NCT05970965|Experimental|Child patient consulting the service|"Trisomy 21 patient with gingival inflammation (subgroup 1)~Trisomy 21 patient with healthy gingiva on intact periodontium with no history of periodontitis (subgroup 2)~Patient with psychomotor retardation with no known repercussions on the orofacial sphere or immunity, presenting gingival inflammation (subgroup 1)~Patients with psychomotor retardation and no known repercussions on orofacial health or immunity, presenting gingival health on intact periodontium with no history of gingival inflammation (subgroup 2).~Patients with no known general pathology and gingival inflammation (subgroup 3)~Patients with no known general pathology and healthy gingiva on intact periodontium with no history of gingival inflammation (subgroup 4)"
89312921|NCT05970445||Patients with enlarged vestibular aqueduct|This study will analyze the SLC26A4 mutation, and audiological and imaging characteristics of PS/NSEVA to summarize the clinical manifestations of PS/NSEVA patients. The study also will analyze the effects of SLC26A4 mutation and inner ear imaging on the degree of hearing loss in PS/NSEVA patients to provide predictive measures for the genetic diagnosis and clinical phenotype of PS/NSEVA. Finally, the effects of sex and age on the degree of hearing loss in patients with PS/NSEVA will be analyzed to provide insight on PS/NSEVA pathogenesis.
89312922|NCT05969821||Dysimmune manifestations with or without clonal hematopoiesis|Dysimmune manifestations with or without clonal hematopoiesis
89312923|NCT05969704|Active Comparator|fusion biopsy|This biopsy procedure that combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal area of prostate in order to guide the biopsy needle into the abnormal area. A sample of tissue can then be taken and checked under a microscope for cancer. A fusion biopsy may help find prostate cancer cells that may be missed with other types of biopsies. It may help find cancer at an early stage and plan cancer treatment.
89312924|NCT05969704|Active Comparator|cognitive biopsy|the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from it
89312925|NCT05964283||Anesthesia Specialists|
89312926|NCT05964283||Anesthesiologist residencies|
89312927|NCT05962957|Active Comparator|control group|control group ( levo-dopa group, n =25 ) who will receive levo-dopa/carbidopa (125/12.5) mg three times daily for 6 months.
89312928|NCT05962957|Active Comparator|PTX group|(Pentoxyifylline group, n= 25) will receive levo-dopa/carbidopa (125/12.5) mg three times daily plus pentoxifylline 400 mg two times daily for 6 months.
89312929|NCT05957848|Experimental|Guanfacine extended-release|Guanfacine extended-release (target dose 4 mg), once daily for approximately 12 weeks plus treatment as usual
89312930|NCT05957848|Placebo Comparator|Placebo|Placebo once daily for approximately 12 weeks plus treatment as usual
89312931|NCT05957016|Experimental|local advanced rectal cancer|local advanced rectal cancer are defined as T3/4NanyM0 or T1-2N+M0
89312932|NCT05938556|Experimental|Group Coaching Program|The study intervention is a hybrid asynchronous-synchronous group coaching treatment that will occur over four months. Participants will be given access to a members-only, web-based platform to access the intervention.
89312933|NCT05938556|Placebo Comparator|Usual Treatment|This group will participate in the study intervention following a 4-month waitlist/control group.
89312934|NCT05928871|Active Comparator|preop|60 women: will receive preoperative 600 microgram of misoprostol ( 3 tablets ) rectally after spinal anaesthesia and urinary catheterization and postoperative placebo (3 tablets). (as per WHO dose recommendation)
89312935|NCT05928871|Active Comparator|postop|"60 women: will receive preoperative placebo 3 tablets and postoperative 600 microgram of misoprostol  3 tablets at operating theatre (as per WHO dose recommendation)."
89312936|NCT05928234||Biventricular circulation|Research subjects with PA-IVS who have biventricular circulation
89312937|NCT05928234||Univentricular circulation|Research subjects with PA-IVS who have univentricular circulation
89312938|NCT05920850|Other|Single Arm|"A culturally tailored video that provides education about the process of low-dose helical computed tomography (LDCT) lung cancer screening~A culturally tailored shared decision-making tool that educates participants about the shared decision-making process~The use of a flip chart that reinforces the information provided in the video and shared decision-making tool~Navigation support for participants who express interest in LDCT and quitting smoking"
89312939|NCT05914532||group 1|healthy controls
89312940|NCT05914532||group 2|axial spondyloarthropathy
89312941|NCT05913882|Experimental|Lung Volume Recruitment +Expiratory Muscle Strength Training|All enrolled participants will commence a combined lung volume recruitment and expiratory muscle strength training exercise regimen following a 5-week no-intervention lead-in period.
89312942|NCT05903976|Experimental|CLOPIDOGREL 75 mg qd|50 patients treated with clopidogrel 75mg
89312943|NCT05903976|Experimental|PRASUGREL 5mg qd|50 patients treated with prasugrel 5mg
89312944|NCT05903976|Experimental|TICAGRELOR 60mg bid|50 patients treated with ticagrelor 60mg bid
89312945|NCT05903976|Active Comparator|Continue Potent P2Y12i Full-Dose|50 patients in the full-dose potent P2Y12 inhibitor (prasugrel 10 mg or ticagrelor 90 mg bid according to prior prescription)
89312946|NCT05902689|No Intervention|blank group|After non-traumatic tooth extraction, the control group will undergo natural healing.
89312947|NCT05902689|Active Comparator|control group|After non-traumatic tooth extraction, the control group will use alveolar ridge preservation with bio-oss collagen
89312948|NCT05902689|Experimental|experimental group|After non-traumatic tooth extraction, the experimental group will use Sticky Bone for alveolar ridge preservation
89312949|NCT05892237|Experimental|central-type squamous NSCLC|"1. Phase I:~Chemo-Immulo-embolization via Tumor Arterial, CIETAI:~DSA guided tumor artery infusion of nano-paclitaxel 200 mg+PD-1 inhibitor (Tirelizumab) 200mg, followed by gelatin sponge particles (350-560um) embolization~two cycles of chemotherapy combined with immune checkpoint inhibitors (q3w): Nano-paclitaxel 260 mg/m2, d1, ivgtt; Cisplatin 75mg/m2, d1, ivgtt; PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min 2. phase II: Chest radiotherapy: 60Gy/2Gy/30f 3. phase III: PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min Maintenance for 1 year"
89312950|NCT05883462|Experimental|Single arm treated by Airiver Nasal DCB|Subjects with recurrent symptomatic nasal obstruction will be treated by Airiver Nasal Drug Coated Balloon (DCB) Catheter at the index procedure. The balloon is coated with a paclitaxel drug (3.5ug/mm2).
89312951|NCT05875337|Experimental|Acupressure Group (experimental)|In the acupressure groups the points are LI4, LI11 and HT7.
89312952|NCT05875337|Placebo Comparator|Placebo Acupressure Group (control)|In the placebo acupressure group the points are 1.5 cm away from LI4, LI11 and HT7 points.
89312953|NCT05874323|Experimental|Type I Diabetes Mellitus|177 patients with Type I Diabetes Mellitus
89312954|NCT05874323|Other|Control|include 177 Healthy Control Cases.
89312955|NCT05840016|Experimental|Experimental: AK112 in Combination With Paclitaxel Plus Carboplatin|AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Carboplatin will be administered at AUC5, Q3W, intravenously (IV) for 4 cycles. Paclitaxel will be administered at 175 mg/m2, Q3W, intravenously (IV) for 4 cycles.
89312956|NCT05840016|Active Comparator|Active Comparator: Tislelizumab in Combination With Paclitaxel Plus Carboplatin|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) every three weeks (Q3W). Carboplatin will be administered at AUC5, Q3W, intravenously (IV) for 4 cycles. Paclitaxel will be administered at 175 mg/m2, Q3W, intravenously (IV) for 4 cycles.
89312957|NCT05798247||Patients with cutaneous diphteria|The study group consists of all the patients suffering from cutaneous diphtheria in metropolitan France and for which microbiological data were registered by the National Reference Center fo corynebacteria of the diphteriae complex between 2018 and 2022.
89312958|NCT05797870|Experimental|188Re-SSS lipiodol SIRT|Patients in the experimental arm will be treated with 188Re-SSS lipiodol Selective Internal Radiotherapy (SIRT).
89312959|NCT05790213|Experimental|Focal Prostate Ablation + Androgen Deprivation + Novel Hormonal Therapy|"A. Apalutamide 240 mg by mouth daily for a total of 6-months B. ADT therapy will consist of any generic luteinizing hormone-releasing hormone agonist which will provide either 6-months of treatment or two injections every 3-months. (e.g., one injection with a treatment period of 6 months or two injections, one at drug start and one 3-months later).~C. Focal therapy to be completed within 8- to 12-weeks of the initiation of apalutamide but after the completion of the 8-week mpMRI to allow for it to be used in FT planning"
89312960|NCT05777733|Experimental|N_acetylcystein as antioxidant on iron and frequency of blood transfusion in thalassemia major|N_acetylcystein administration on single oral dose 10mg /kg for 6 months and it's effect on iron and frequency of blood transfusion before and after its use.
89312961|NCT05777109|Experimental|HS-20090|Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day
89312962|NCT05777109|Active Comparator|Xgeva®|Subcutaneously injection of Xgeva® (120mg/1.7mL) once on the first day
89312963|NCT05773365|Experimental|Pericapsular Nerve Group Block plus local infiltration|"Group A (study group) will receive both PENG block and local infiltration at the end of the surgery.~Spinal anaesthesia will be administered to the patient using 7.5-12.5 mg heavy 0.5% bupivacaine at L3-L5 lumbar spine using 25 G spinal needle.~If spinal anaesthesia is contraindicated or failed, patients will have general anaesthetics.~General anaesthesia will be induced with 2-3 mcg/kg fentanyl, Propofol 1-2 mg/kg titrated to effect, and muscle relaxant if required.~PENG block will be administered according to the description by injecting 20 ml of 0.25% bupivacaine below the psoas tendon.~A 20 ml of 0.25% bupivacaine will be infiltrated by the surgeons to the tissues at the end of the surgery."
89312964|NCT05773365|Active Comparator|Pericapsular Nerve Group Block|In Group B, only PENG block will be administered in this arm
89312965|NCT05772481||Adult population with rectal cancer|
89312966|NCT05754086||Parkinsons (PD) Group|This cohort includes individuals who have been diagnosed with Parkinson's disease.
89312967|NCT05754086||Neurotypical (NT) Group|This group consists of age-matched control participants. They are neurologically healthy and do not have any neurological diagnoses.
89312968|NCT05726162|Active Comparator|Control|Patients sleep as usual with noise-canceling earplugs
89312969|NCT05726162|Experimental|Biofeedback-based music|Patient is provided with a biofeedback-based music program using a smart device application for sleep.
89312970|NCT05721599|Experimental|Intervention group|Structured integrated care model
89312971|NCT05721599|No Intervention|Control group|General outpatient care
89312972|NCT05707481|No Intervention|Control group (Usual Standard Care)|"Control group patient will undergo routine care by their physician and nurses. However, the investigator will only provide basic counseling regarding drug prescribed during discharge to the patients. In another term Usual care will be provided to the patients"
89312973|NCT05707481|Other|Intervention Group (Clinical Pharmacist-led educational Intervention)|In addition to routine care by physician and nurses, Patients in interventional group will receive two consecutive face to face interview and counseling of 20-40 minutes during the baseline period and the first follow-up period at 3-month by clinical pharmacist. Teaching and counseling session involves information on various non-pharmacological and pharmacological disease management strategies.
89312974|NCT05702567|Experimental|RF + PFMT|The participants recieve 18 sessions of radiofrequency (RF) and pelvic floor muscle training (PFMT), divided into three sessions per week for a total of six weeks, with a net treatment time of 40 minutes, each one.
89312975|NCT05702567|Placebo Comparator|PFMT|The participants recieve 18 sessions of no radiofrequency (RF) and pelvic floor muscle training (PFMT), divided into three sessions per week for a total of six weeks, with a net treatment time of 40 minutes, each one. The RF device is started, but in this case, the program does not work or apply radiofrequency to the patients.
89312976|NCT05683223|Experimental|Responders|The experimental arm involves EEG + MRI before and after exposure therapy for social anxiety disorder.
89312977|NCT05683223|Experimental|Non-Responders|The experimental arm involves EEG + MRI before and after exposure therapy for social anxiety disorder. Non-responders to initial exposure therapy will receive sertraline and additional exposure therapy prior to final EEG and MRI.
89312978|NCT05683223|No Intervention|Controls|Controls will receive baseline EEG and MRI, screening questionnaires and intake interview. They will not participate in therapy but complete weekly symptom measures and a second EEG/MRI session 12 weeks after baseline. Control participants will be compared with social anxiety participants to determine differences in neuro-markers at baseline and over follow-up.
89312979|NCT05668273|Experimental|education with simulated patient|Participants will be given training on auscultation skills with a simulated patient.
89312980|NCT05668273|Experimental|education with simulator|Participants will be given training on auscultation skills with a simulation.
89312981|NCT05668273|Active Comparator|control group|Participants will be given training on auscultation skills with their peer students.
89312982|NCT05665387|Experimental|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID
89312983|NCT05665387|Experimental|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID
89312984|NCT05665387|Placebo Comparator|Placebo (Vehicle) ophthalmic solution|Placebo (Vehicle) ophthalmic solution BID
89312985|NCT05655845||Dysfunction group|Bowel function score(BFS,total 20 points) was approved by Rintala in 1995 and patients with a score < 17 were considered to have bowel dysfunction.
89312986|NCT05655845||near-normal group|Bowel function score(BFS,total 20 points) was approved by Rintala in 1995 and patients with a score > 17 were considered to have normal bowel habits.
89312987|NCT05653856|Experimental|Diagnostic Imaging with 64Cu-PSMA-I&T|64Cu-PSMA I&T
89312988|NCT05611528|Experimental|Evinacumab-treated patients|
89312989|NCT05609864||Injectable drugs|Patient's data and data relating to prepared/administrated/discarded injectable drugs will be collected during 24 hours in the operating rooms by anesthesia department
89312990|NCT05602935|Experimental|Camrelizumab+SOX|The patients in the experimental arm will receive camrelizumab concurrently with SOX(S-1 and oxaliplatin).
89312991|NCT05573659|Experimental|video-assisted capillary refill time.|
89312992|NCT05573659|Active Comparator|visual capillary refill time.|
89312993|NCT05565599|Experimental|Treatment|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system.
89312994|NCT05525455|Experimental|Single agent TT-816|Escalating doses followed by expansion targeting advanced cancers
89312995|NCT05525455|Experimental|Combination TT-816 plus a PD-1 inhibitor|Escalating doses followed by expansion targeting advanced cancers
89312996|NCT05507073|Active Comparator|Manual Total Hip Replacement|Manual Total Hip Replacement
89312997|NCT05507073|Experimental|Robot-Assisted Total Hip Replacement|Robot-Assisted Total Hip Replacement
89312998|NCT05492916|Experimental|INCLUDE|Participants will receive one Diabetes Prevention Program (DPP) video per week for 24 weeks. Additionally, community health workers (CHWs) will help participants to join the community-supported agriculture (CSA) program and assess and address other social determinants of health (SDOH) barriers.
89312999|NCT05492916|No Intervention|CONTROL|Participants will receive the standard of usual care.
89313000|NCT05431335|Experimental|Structured exercise program|The structured exercise program will be applied for 12 weeks, 2 days a week, for 45 minutes by a physiotherapist.
89313001|NCT05431335|Other|Aerobic exercise program|The aerobic exercise program will be applied for 12 weeks, 2 days a week, for 45 minutes by a physiotherapist.
89313002|NCT05421208|Experimental|Compare inflammatory markers (IL-6) in post- COVID 19 POTS patients with Controls|"Biochemical endpoints: Measurement of Inflammatory markers (especially IL-6) in both Post- COVID-19 POTS patients and compare it with controls.~Controls are the participants who recovered from COVID 19 infection with no sequelae"
88810974|NCT04891991|Active Comparator|Infliximab group|This group will receive 1 mg/0.05 mL of intravitreal infliximab at the end of standard pars plana vitrectomy.
88810975|NCT04891991|Sham Comparator|Standard of care group|This group will undergo standard pars plana vitrectomy.
89313003|NCT05421208|Experimental|Effect of OI symptoms & inflmmation after Restoring PNS functions in post-COVID POTS patients.|Effects of restoring PNS function in post-COVID-19 POTS patients with chronic transcutaneous vagus nerve stimulation (tVNS) on inflammation, orthostatic tachycardia and OI symptoms.The subjects with POTS will be randomized, where TENS 7000 device will be placed to active and sham location.Autonomic symptoms assessment questionnaire (COMPASS-31),32 quality of life EQ-5D and neuropsychological tests
89313004|NCT05410782|Experimental|Power Prenatal for Sperm|This is a single arm study. Participants will take supplements for 3 months. The supplements is Power Prenatal for Sperm (active ingredients - https://birdandbe.com/the-power-prenatal-for-sperm)
89313005|NCT05383482|Experimental|Afuresertib in combination with Sintilimab and Nab-paclitaxel|Afuresertib in combination with Sintilimab and Nab-paclitaxel in patients with Endometrial Cancer and Cervical Cancer
89313006|NCT05383482|Experimental|Afuresertib in combination with Sintilimab and Docetaxel|Afuresertib in combination with Sintilimab and Docetaxel in patients with Gastric and Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer and Esophageal Cancer
89313007|NCT05375253|Experimental|Donor Enriched Activated NK Infusion (DEA-NK)|Infusion of DEA-NK on day +7 post-transplant
89313008|NCT05372315|Other|Lower Punctum Insertion (Group 1)|"DEXTENZA (dexamethasone ophthalmic insert, 0.4mg) for intracanalicular use~Group 1 (up to 40 eyes) will receive the insert in the lower punctum on the day of surgery in the OR."
89313009|NCT05372315|Other|Upper Punctum Insertion (Group 2)|"DEXTENZA (dexamethasone ophthalmic insert, 0.4mg) for intracanalicular use~Group 2 (up to 40 eyes) will receive the insert in the upper punctum on the of surgery in the OR."
89313010|NCT05354804|Placebo Comparator|Standard|Patients randomized to standard care will be sampled at admission and after 1 hour (and furthermore as clinically indicated). High sensitive Troponin T (cTnT) and standard laboratory tests will be measured in the central hospital laboratory using Cobas e801 from Roche Diagnostics and eligibility for rule-out will be judged in accordance with the ESC 0/1 hour rule-out algorithm for cTnT. ECG and HEART-score will be obtained in all patients, other clinical investigations will be ordered by the attending physician. If NSTE-ACS is low risk based on the cTnT algorithm, HEART< 4 and non-ischemic ECG, patients will be investigated according to the ED flow chart for non-coronary acute chest pain, in order to identify differential diagnoses. Patients will be admitted or discharged based on the clinical judgement of the attending physician.
89313011|NCT05354804|Active Comparator|POC|Blood samples will be obtained at admission, standard blood tests will be measured at the central laboratory whilst high sensitive troponin I at 0 and 1 hour will be analyzed using a POC instrument from Siemens Healthineers in the ED. ECG and HEART-score will be obtained in all patients, other clinical investigations will be ordered by the attending physician. If the cTnI concentration at admission and the 1-hour delta is below a pre-specified concentration, the HEART- score < 4, and the ECG is non-ischemic the patients will be allocated to the rule-out of NSTEMI group and investigated according to the ED flow chart for non-coronary acute chest pain, in order to identify differential diagnosis. Finally, patients will be admitted or discharged based on the clinical judgement of the attending physician.
89313012|NCT05332002|Other|4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),|"A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:~Odd Cycles (e.g. 1, 3, 5, etc…) - mFOLFOX6 initiated on days 1 & 15: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)~Even Cycles (e.g. 2,4,6, etc…) - FOLFIRI initiated on days 1 & 15: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)~Nivolumab (optional, in-line with labelled approval) - 240 mg every 2 weeks"
89313013|NCT05321381|Active Comparator|RISE Early|RISE peer support program available early, launched study year 1
89313014|NCT05321381|Active Comparator|RISE Late|RISE peer support program available later, launched study year 2
89313015|NCT05305196|Experimental|Eccentric-focused exercise group|Three eccentric-focused exercises addition to the general treatment group
89313016|NCT05305196|Active Comparator|General treatment group|hot pack application on shoulder region upper trapezius massage two stretching exercises (modified sleeper stretch and modified cross-body stretch)
89313017|NCT05284526|Experimental|parkinsonian patients with and without dopaminergic drug treatment|Electroencephalogram (EEG) of 10 parkinsonian subjects with and without dopaminergic drug treatment during the preparation and execution of movements
89313018|NCT05284526|Experimental|parkinsonian patients with and without High-frequency stimulation of the subthalamic nucleus|Electroencephalogram (EEG) of 10 parkinsonian subjects with and without High-frequency stimulation (HFS) of the subthalamic nucleus (STN) during the preparation and execution of movements
89313019|NCT05284526|Active Comparator|control subjects|Electroencephalogram (EEG) of control subjects during the preparation and execution of movements
89313020|NCT05253326|Experimental|Exercises Group|Patients will be taught Progressive Muscle Relaxation Exercises before the surgery and will be applied twice a week for 2 months after the surgery.
89313021|NCT05253326|No Intervention|Control Group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital.
89313022|NCT05243433|Experimental|Procedure using the Maestro Platform|Study participants will be adults aged ≥ 18 to ≤ 75 years scheduled for a non-emergent laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic bariatric surgery (gastric sleeve or gastric bypass), or laparoscopic colectomy.
89313023|NCT05212207||PBH|
89313024|NCT05184790||Brain cancer|Patients having radiation therapy for treatment of brain cancer.
89313025|NCT05184790||Breast cancer|Patients having radiation therapy for treatment of breast cancer.
89313026|NCT05184790||Head and neck cancer|Patients having radiation therapy for treatment of head and neck cancer.
89313027|NCT05184790||Kidney cancer|Patients having radiation therapy for treatment of kidney cancer.
89313028|NCT05184790||Liver cancer|Patients having radiation therapy for treatment of liver cancer.
89313029|NCT05184790||Pancreatic cancer|Patients having radiation therapy for treatment of pancreatic cancer.
89313030|NCT05184790||Prostatic cancer|Patients having radiation therapy for treatment of prostate cancer.
89313031|NCT05184790||Spinal neoplasm|Patients having radiation therapy for treatment of spinal cancer.
89313032|NCT05184790||Cardiac arrhythmia|Patients having radiation therapy for treatment of cardiac arrhythmia
88810976|NCT04887480|Active Comparator|Negative Wound Pressure Therapy|Negative Pressure Would Therapy
89313033|NCT05182060|Experimental|Transition Intervention|"We will implement a bundle of care transition safety resources with the assistance of home health coordinators at the study site.~These resources include a link to a video about home health services, a caregiver assessment, a care task role assignment sheet, and a shopping list."
89313034|NCT05182060|No Intervention|Control|"We will select other home health provider teams that provide care to similar populations to serve as concurrent controls.~No interventions will be administered."
89313035|NCT05177458|Experimental|Moderate Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete eight trials of imaginal exposure (blocks of four neutral and four trauma narrative trials presented as text and sound) with heart rate monitoring and skin conductance. Anxiety will be measured at baseline and after each imagery trial. Participants will then complete 30 minutes of moderate intensity (70-75% maximum heart rate) exercise on a treadmill.~Visit 3: Participants will complete eight more imaginal trials with heart rate and anxiety ratings as per visit 2."
89313036|NCT05177458|Active Comparator|Control - Low Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete eight trials of imaginal exposure (blocks of four neutral and four trauma narrative trials presented as text and sound) with heart rate monitoring and skin conductance. Anxiety will be measured at baseline and after each imagery trial. Participants will then complete 30 minutes of light intensity (40-50% maximum heart rate) exercise on a treadmill.~Visit 3: Participants will complete eight more imaginal trials with heart rate and anxiety ratings as per visit 2."
88810977|NCT04887480|Active Comparator|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation|Negative Wound Pressure Therapy with Direct Peritoneal Resuscitation
88820831|NCT05608629|Experimental|Transcutaneous Non-Invasive Vagus Nerve Stimulation|Application of electrode to left tragus with stimulus intensity at that which is just below pain threshold for 35 min a day
89313037|NCT05159401|Experimental|"the first group: the method of vibroacoustic lung massage using the BARK VibroLUNG device"|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
89313038|NCT05159401|Experimental|the second group:the method of oscillating REР therapy using Acapella DH Green|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
89313039|NCT05159401|Experimental|the third group:the method of hardware stimulation of cough (Comfortable cough Plus)|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
89313040|NCT05159401|Experimental|the fourth group:classical manual chest massage with percussion|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
89313041|NCT05154578|Experimental|Group 1: 4 week dose interval; 2 doses|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
89313042|NCT05154578|Experimental|Group 2: early intervention; 4 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of placebo at 30 (±1) weeks GA
89313043|NCT05154578|Experimental|Group 3: early intervention; 8 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of placebo at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
89313044|NCT05154578|Experimental|Group 4: single dose|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA, and one injection of placebo at 30 (±1) weeks GA.
89313045|NCT05154578|Placebo Comparator|Group 5: placebo|Participants will receive one injection of placebo at 22, 26 and 30 weeks (±1) GA
89313046|NCT05148494|Active Comparator|Fleet Enema|Patient is to administer one sodium bisphosphate (Fleet) enema at home 2 hours prior to arrival for surgery and a second enema one hour prior to arrival for surgery. Each 120 mL application of rectally administered enema contains 19g of monobasic sodium phosphate and 9 g of dibasic sodium phosphate. Patient is to follow standard packaging instructions from the manufacturer.
89313047|NCT05148494|Active Comparator|Pico Salax|Patient is to take Pico Salax oral bowel preparation which is a combination product consisting of 10 mg picosulfate sodium, 3.5 g magnesium oxide, and 12 g citric acid per sachet the day prior to surgery. Patient is to take 2 doses of this product, as per standard packaging instructions from the manufacturer. Specifically patient is to take the first packet contents dissolved in 150 mL water at 3pm the day before surgery. Patient is to take the second packet dissolved in 150 mL water at 8pm the day before surgery. Patient should drink 2-3L of clear liquids after each dose, for a total of 4-6L.
89313048|NCT05139199|Experimental|Auricular Point Acupressure|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
89313049|NCT05139199|No Intervention|usual-care group|These participants follows the standard Chemotherapy follow-up consisting of counseling by nurses and doctors.
89313050|NCT05130125||fresh embryo|fresh embryo transfer after ovarian hyperstimulation
89313051|NCT05130125||frozen embryo|frozen embryo transfer after ovarian hyperstimulation
89313052|NCT05127486|Experimental|Galcanezumab|"Galcanezumab administered subcutaneously (SC).~Placebo for rimegepant will be used for blinding."
89313053|NCT05127486|Active Comparator|Rimegepant|"Rimegepant administered oral disintegrating tablets (ODT).~Placebo for galcanezumab will be used for blinding."
89313054|NCT05121883||Edaravone dexborneol group|Patients with edaravone dexborneol initiating within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days will be classified into this group.
89313055|NCT05121883||Standard medication group|Patients who do not recieve edaravone dexborneol will be classified into this group.
89313056|NCT05104983|Experimental|Sirolimus|Sirolimus
89313057|NCT05104983|Placebo Comparator|Placebo|Placebo
89313058|NCT05103631|Experimental|CATCH T cells|GPC3-CAR and the IL15 (CATCH T cells) will be administered to patients with GPC3-positive solid tumors.
89313059|NCT05094206|Experimental|Indolent B-cell NHL Dose Level -2: 0.75x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
89313060|NCT05094206|Experimental|Indolent B-cell NHL Dose Level -1: 1x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
89313061|NCT05094206|Experimental|Indolent B-cell NHL Dose Level 0: 2.5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
89313062|NCT05094206|Experimental|Indolent B-cell NHL Dose Level 1: 5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 2.5x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
89313063|NCT05094206|Experimental|Indolent B-cell NHL Dose Expansion: CAR20.19.22|The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.
89313064|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level -1: .75x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
89313065|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level 0: 1x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
89313066|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level 1: 2.5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
89313067|NCT05094206|Experimental|Aggressive B-cell NHL Dose Level 2: 5x10^6 cells/kg: CAR20.19.22|The investigators will start at a dose of 1.0x10^6 cells/kg and either escalate or de-escalate based on the presence of toxicities.
89313068|NCT05094206|Experimental|Aggressive B-cell NHL Dose Expansion: CAR20.19.22|The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10^6 cells/kg, 1x10^6 cells/kg, 2.5x10^6 cells/kg or 5x10^6 cells/kg.
89313069|NCT05092009||All patiens|There is only one arm in this trial
89313070|NCT05085210|Experimental|Visual Training with Noninvasive Brain Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of tRNS with visual training on the computer
89313071|NCT05085210|Experimental|Visual Training with Sham Stimulation|10 daily (Monday-Friday) 20-30 minute sessions of sham stimulation with visual training on the computer
89313072|NCT05085210|Experimental|Noninvasive Brain Stimulation without visual training|10 daily (Monday-Friday) 20-30 minute sessions of tRNS alone
89313073|NCT05085210|Sham Comparator|Sham Stimulation without visual training|Placebo control. Simulation of tRNS without receiving any actual stimulation
89313074|NCT05056350|Other|Assessment of the feasibility and impact of a back-to-work support program|questionnaires, back to work coaching
89313075|NCT05051787|Experimental|Breastfeeding women|Mothers over 18, treated with amoxicillin alone or associated with clavulanic acid for at least 2 days, breastfeeding their child.
89313076|NCT04997018|Experimental|Prostate cancer patients|"Intermediate-risk prostate cancer patients will be eligible for this study. Risk groups will be assigned as per NCCN guidelines. Intermediate-risk patients will be defined as:~PSA 10-20 ng/ml or~Gleason score = 7~Clinical stage T2b/T2c"
89313077|NCT04993859||Male Cancer Survivors with DVSS Score ≥ 9|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
89313078|NCT04993859||Female Cancer Survivors with DVSS Score ≥ 6|Childhood cancer survivors treated with DOX and/or VCR with evidence of BD on DVSS
89313079|NCT04993859||Male Cancer Survivors with DVSS Score < 9|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
89313080|NCT04993859||Female Cancer Survivors with DVSS Score < 6|Childhood cancer survivors treated with DOX and/or VCR without evidence of BD on DVSS
89313081|NCT04963023||frequent exacerbation patients|
89313082|NCT04963023||non frequent exacerbation patients|
89313083|NCT04963023||Asthma-and-COPD overlap syndrome|
89313084|NCT04963023||Asthmatic patients (without COPD)|
89313085|NCT04955951||polarized light group|group A (20 patients) will receive Polarized light therapy
89313086|NCT04955951||topical corticosteroid group|group B (20 patients) will receive topical corticosteroid therapy
89313087|NCT04940117|Experimental|blood test data before and after taking|Checking eGRF value before and after taking Eefooton oral solution
89313088|NCT04929678|Experimental|Braive™ Growth Modulation System (Braive™ GMS)|
89313089|NCT04929262|Active Comparator|Researcher-Only|The researcher-facilitated presentation, led by two clinical psychology graduate students, will be the same for all schools.
89313090|NCT04929262|Experimental|Key Opinion Leader|The key opinion leader (KOL) co-facilitated presentations will include the same core principles as the researcher-facilitated presentation but may vary by school in terms of specific examples and content emphasized based on KOL feedback. A caregiver KOL from the local community (selected by the parent teacher association or a similar group) will co-facilitate the presentation with a clinical psychology graduate researcher.
89313091|NCT04920630|Experimental|CBT-I|5-weekly Cognitive Behavioral Therapy for Insomnia group therapy sessions conducted virtually.
89313092|NCT04920019|Experimental|Thoracic continuous epidural analgesia|"Thoracic continuous epidural analgesia at T7-8 or T8-9 combined with IV PCA fentanyl (bolus mode only 15 ug/bolus, 5 minutes lockout, 4 hours limit 200 ug).~Multimodal analgesia Intraoperative : thoracic epidural infusion with 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h, morphine 2 mg epidurally are given.~Postoperative: 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h is given combined with IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug, multimodal analgesia: paracetamol 1000 mg iv every 6 hours until patient can take orally, change to 1000 mg orally every 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (etoricoxib 90 mg orally x2 days)"
89313093|NCT04920019|Active Comparator|No CEA|IV PCA fentanyl, IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug multimodal analgesia: paracetamol 1000 mg IV every 6 hours until patient can take orally, change to 1000 mg orally q 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (Etoricoxib 90 mg orally x2 days)
89313094|NCT04918875||Patients 12 years of age or older with suspected or confirmed COVID-19, deemed to require oxygen.|
89313095|NCT04914741|Experimental|Glofitamab plus R-CHOP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by R-CHOP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
89313096|NCT04914741|Experimental|Glofitamab plus polatuzumab vedotin-RCHP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by polatuzumab vedotin-RCHP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
89313097|NCT04872478|Experimental|Dose Escalation - Level 1|MRX-2843 capsules, QD - 28 day cycles
89313098|NCT04872478|Experimental|Dose Escalation - Level 2|MRX-2843 capsules, QD - 28 day cycles
89313099|NCT04872478|Experimental|Dose Escalation - Level 3|MRX-2843 capsules, QD - 28 day cycles
89313100|NCT04872478|Experimental|Dose Escalation - Level 4|MRX-2843 capsules, QD - 28 day cycles
89313101|NCT04872478|Experimental|Dose Escalation - Level 5|MRX-2843 capsules, QD - 28 day cycles
89313102|NCT04872478|Experimental|Expansion Arm at RP2D|MRX-2843 capsules, QD - 28 day cycles
89313103|NCT04868396||Glioblastoma patients|Glioblastoma patients selected to undergo surgical removal of a glioblastoma (based on MRI image).
89313104|NCT04859595|Experimental|telephone follow-up arm|"The experimental arm corresponds to the patient benefiting from a monthly telephone follow-up during the first 6 months of their discharge from the reeducation center : CRIL (from M1 to M6). They will be contacted each month by CRIL's speech therapist for a telephone interview (20 to 30 minutes)."
89313105|NCT04859595|No Intervention|control arm|The comparison group will follow the standard follow-up protocol. A technician will contact the patients in the control arm to obtain the TIMES score each month. No further telephone follow-up will be carried out.
89313106|NCT04838678|Experimental|Healthy Control|Healthy age matched controls with no history of cardiovascular disease and normal bodyweight
89313107|NCT04838678|Experimental|Hypertensive|Hypertensive adults who are not obese
89313108|NCT04838678|Experimental|Obese|Obese adults who are not hypertensive
89313109|NCT04838678|Experimental|Obese-hypertensive|Obese adults who are being treated for hypertension
89313110|NCT04836546|Experimental|Self monitoring of blood glucose, then CGM System|All participants will first manage their diabetes with SMBG for 6 months followed by managing their diabetes with Eversense CGM system for the next 6 months
89313111|NCT04827732|Experimental|Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 1.~The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
89313112|NCT04827732|Experimental|Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 2.~The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
89313113|NCT04827732|Experimental|Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)|"Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 3.~The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime)."
89313114|NCT04797845|Experimental|telemonitoring of non invasive ventilation at home|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months. Ventilation machines make it possible to carry out remote monitoring, with the help of healthcare providers.
89313115|NCT04760314|Experimental|Lebrikizumab 250 mg Every 4 weeks (Q4W)|Participants received 500 mg of Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections as a loading dose at Baseline followed by 250 mg of Lebrikizumab administered SC Q4W from Week 4 until Week 12, in combination with topical corticosteroid. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
89313116|NCT04760314|Experimental|Lebrikizumab 250 mg Every 2 weeks (Q2W)|Participants received 500 mg of Lebrikizumab (2 x 250 mg) SC injections as a loading dose at Baseline and Week 2 followed by 250 mg of Lebrikizumab administered SC Q2W from Week 4 until Week 14, in combination with topical corticosteroid. Week 16 responders entered maintenance period and were randomly allocated to receive 250 mg lebrikizumab Q2W or 250 mg lebrikizumab Q4W, in a 1:1 ratio. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
89313117|NCT04760314|Placebo Comparator|Placebo|Participants received two SC injections of Placebo as a loading dose at Baseline in combination with topical corticosteroid and Week 2 followed by a single injection Q2W from Week 4 until Week 14. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
89313118|NCT04752371|Experimental|Cohort 1: Camoteskimab 7 mg/kg|6 participants will be administered camoteskimab at a dose of 7 mg/kg (500 mg maximum) at Baseline, Week 4, and Week 8.
89313119|NCT04752371|Experimental|Cohort 2: Camoteskimab Dose escalation/reduction|Cohort 2 dose will be determined based on a review of Cohort 1 data. 6 participants will be administered camoteskimab at the determined dose at Baseline, Week 4, and Week 8.
89313120|NCT04684654|Experimental|Part A (SAD)|Single Ascending Dose (SAD)
89313121|NCT04684654|Placebo Comparator|Part A (SAD) Placebo|
89313122|NCT04684654|Experimental|Part B (MAD)|Multiple Ascending Dose (MAD)
89313123|NCT04684654|Placebo Comparator|Part B (MAD) Placebo|
89313124|NCT04684654|Experimental|Part C (pSS)|Primary Sjögren's Syndrome (pSS)
89313125|NCT04684654|Placebo Comparator|Part C (pSS) Placebo|
89313126|NCT04678895|Experimental|Group A, Low-Dose Naltrexone, Then Placebo|Group A will receive active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the first 8 weeks. Capsules of different dosages will be indistinguishable. Then followed by 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily).
89313127|NCT04678895|Experimental|Group B, Placebo, Then Low-Dose Naltrexone|Group B will receive 4 weeks of placebo (placebo capsule will be matched with LDN capsule, microcrystalline cellulose filler, 1 capsule daily). Then followed by active drug (Naltrexone 1 capsule by mouth daily, 1.5mg x1 week, 3mg x1 week, and 4.5 mg x6 weeks) for the last 8 weeks. Capsules of different dosages will be indistinguishable.
89313128|NCT04677569|Experimental|ALIS + Background Regimen|Participants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered azithromycin 250 mg and ethambutol 15 mg/kg, once daily.
89313129|NCT04677569|Placebo Comparator|ELC + Background Regimen|Participants will be administered ELC (empty liposome control), a visually matching placebo to ALIS (amikacin liposome inhalation suspension), once daily. Participants will also be administered azithromycin 250 mg and ETH (ethambutol) 15 mg/kg, once daily.
89313130|NCT04648930||Xolair|S.C. Injection
89313131|NCT04633148|Experimental|UniCAR02-T-pPSMA|Preconditioning (lymphodepletion) with cyclophosphamide and fludarabine, followed by combination treatment of genetically modified T-cells carrying universal chimeric antigen receptors (UniCAR02-T) with the peptide TMpPSMA.
89313132|NCT04622683|Experimental|Control Group- Healthy, Lean Individuals|Determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels in lean, healthy control subjects.
89313133|NCT04622683|Active Comparator|Overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance|Determine whether three episodes of porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
89313134|NCT04615923|Experimental|Pridopidine|Pridopidine is administered orally twice daily for 24 weeks.
89313135|NCT04615923|Placebo Comparator|Matching Placebo|Matching placebo is administered orally twice daily for 24 weeks.
88820832|NCT05600556|Active Comparator|Cohort I (standard imaging)|Patients receive 2D image review using standard computer screen on study. Patients undergo MRI and CT imaging at screening and on study
89313136|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women living with HIV
89313137|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women living with HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women living with HIV
89313138|NCT04596878|Experimental|GBS-NN/NN2 in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection GBS-NN/NN2 containing 50 µg GBS-NN and 50 µg NN2 administered 28 days apart in pregnant women who do not have HIV
89313139|NCT04596878|Placebo Comparator|Placebo Comparator in pregnant women who do not have HIV|2 doses of 0.5mL intramuscular injection 0.9% normal saline administered 28 days apart in pregnant women who do not have HIV
89313140|NCT04569097|Experimental|Patient group|lingual strengthening
89313141|NCT04569097|No Intervention|Controls|No history of dysphagia (swallowing disorder) or minimal to mild dysphagia not requiring a strengthening program
89313142|NCT04530916|Experimental|Blueberry|22 g blueberry powder per day
89313143|NCT04530916|Placebo Comparator|Control|22 g placebo control powder per day
89313144|NCT04526379|Experimental|children with PWS|Evaluation of cognitive abilities of children with PWS by several cognitive tasks and neuropsychological tests.
89313145|NCT04526379|Other|non affected children|Evaluation of cognitive abilities of children with PWS compared to a non-pathologic population of children by several cognitive tasks and neuropsychological tests
89313146|NCT04518371|Experimental|Indirect Restoration|Milled Resin Composite Block, Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments (inorganic pigments such as ferrous oxide or titanium dioxide).
89313147|NCT04518371|Active Comparator|Direct Restoration|"3M™ Filtek™ One Bulk Fill Restorative is a visible light activated, restorative composite optimized to create fast and easy restorations.~It is composed of fillers which are a combination of a non-agglomerated/non-aggregated 20 nm silica filler, 4 to 11 nm zirconia filler, zirconia/silica cluster filler and ytterbium trifluoride filler consisting of 100nm particles. The inorganic filler loading is about 76.5% by weight (58.5% by volume)."
89313148|NCT04512820|Experimental|TRUCLEAR TREATMENT|patients up to 10 weeks of gestation with missed miscarriage undergoing evacuation of products of conception using the TRUCLEAR tissue removal system under direct hysteroscopic visualization
89313149|NCT04494529|Placebo Comparator|Single-Dose (12 mg betamethasone + placebo)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.~Participants randomized to the experimental Single-Dose arm will receive a similar appearing placebo injection instead of the standard 2nd dose of 12 mg of betamethasone (i.e. they will receive the experimental single-dose regimen, total 12 mg of betamethasone only from the first injection)."
89313150|NCT04494529|Active Comparator|Double-Dose (12 mg betamethasone + 12 mg betamethasone)|"The standard course of betamethasone consists of 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg. Before enrolment and randomization in the SNACS trial, all women will have received a first 12 mg injection of betamethasone according to local hospital protocols. After this first injection, randomization is performed.~Participants randomized to the Double-Dose arm will receive the standard 2nd dose of 12 mg of betamethasone injected intramuscularly (i.e. they will receive the standard double-dose regimen, total 24 mg of betamethasone)."
89313151|NCT04493684|Experimental|Part 1: Cohort 1: Participants receiving GSK3739937|Part 1 cohort 1 may contain up to 4 escalating doses (Period 1- 10 milligram [mg], Period 2- 80 mg, and Period 3- 320 mg, Period 4- 800 mg) of GSK3739937.
89313152|NCT04493684|Placebo Comparator|Part 1: Cohort 1: Participants receiving Placebo|In this cohort, participants will be randomized to receive placebo.
89313153|NCT04493684|Experimental|Part 1: Cohort 2: Participants receiving GSK3739937|Part 1 cohort 2 may contain up to 3 escalating doses ( Period 1- 30 mg, Period 2- 160 mg, and Period 3- 640 mg) of GSK3739937.
89313154|NCT04493684|Placebo Comparator|Part 1: Cohort 2: Participants receiving Placebo|In this cohort, participants will be randomized to receive placebo.
89313155|NCT04493684|Experimental|Part 2: Cohort 3: Participants receiving GSK3739937|Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 25 mg GSK3739937 for 14 days.
89313156|NCT04493684|Placebo Comparator|Part 2: Cohort 3: Participants receiving Placebo|Eligible participants in part 2 cohort 3, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
89313157|NCT04493684|Experimental|Part 2: Cohort 4: Participants receiving GSK3739937|Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 50 mg GSK3739937 for 14 days.
89313158|NCT04493684|Placebo Comparator|Part 2: Cohort 4: Participants receiving Placebo|Eligible participants in part 2 cohort 4, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 14 days.
89313159|NCT04493684|Experimental|Part 2: Cohort 5: Participants receiving GSK3739937|Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 7 participants will be randomized to receive a once-daily dose of 100 mg GSK3739937 for 18 days.
89313160|NCT04493684|Placebo Comparator|Part 2: Cohort 5: Participants receiving placebo|Eligible participants in part 2 cohort 5, will consist of approximately 10 participants out of 3 participants will be randomized to receive a once-daily dose of placebo for 18 days.
89313161|NCT04493684|Experimental|Part 2: Cohort 6: Participants receiving GSK3739937|Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 7 participants will be randomized to receive three 500 mg doses of GSK3739937 administered at once weekly intervals over two weeks.
89313162|NCT04493684|Placebo Comparator|Part 2: Cohort 6: Participants receiving placebo|Eligible participants in part 2 cohort 6, will consist of approximately 10 participants out of 3 participants will be randomized to receive three doses of placebo administered at once weekly intervals over two weeks.
89313163|NCT04493684|Experimental|Part 3: Cohort 7: Participants receiving treatment sequence ABC|Participants will receive Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 1; Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 2; and Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 3.
89313164|NCT04493684|Experimental|Part 3: Cohort 7: Participants receiving treatment sequence BCA|Participants will receive Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 1; Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 2; and Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 3.
89313165|NCT04493684|Experimental|Part 3: Cohort 7: Participants receiving treatment sequence CAB|Participants will receive Treatment C: GSK3739937 Tablet, 100 mg administered under fasted conditions in Period 1; Treatment A: GSK3739937 PiB, 100 mg administered under moderate fat conditions in Period 2; and Treatment B: GSK3739937 Tablet, 100 mg administered under moderate fat conditions in Period 3.
89313166|NCT04474522|Active Comparator|intervention group using morphology and NIPGT-A|Both morphology and NIPGT-A result will be used to prioritize the sequence of embryo transfer in the intervention group.
89313167|NCT04474522|No Intervention|control group based on morphology alone|Morphology only will be used to prioritize the sequence of embryo transfer in the intervention arm.
89313168|NCT04464200|Experimental|19(T2)28z1xx CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of 19(T2)28z1XX CAR T cells to establish the RP2D. There are 4 planned flat-dose levels: 25x10^6, 50 x 10^6, 100 x 10^6 and 200 x 10^6 CAR T cells and one de-escalation dose: 12.5 x 10^6 CAR T cells. A standard 3+3 dose escalation design will be implemented starting from dose 1.
89313169|NCT04440462|Experimental|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
89313170|NCT04440462|Active Comparator|Sterile water|2 ml of sterile water
89313171|NCT04432142||Proton|Patients receiving proton therapy
89313172|NCT04432142||Photon|Patients receiving photon therapy in 4 fractions or less
89313173|NCT04356209|Experimental|EXPERIMENTAL GROUP|ePRO intervention + PRAVASTATINE treatment
89313174|NCT04356209|Other|CONTROL GROUP|PRAVASTATINE treatment ( without ePRO)
89313175|NCT04346394|Experimental|Yohimbine|The first visit in the study has no interventional drug. Yohimbine (5mg) is administered orally during visit two, during a head up tilt test, to manipulate the noradrenergic system to determine the association between OH and NP symptoms in those with PD. Yohimbine is not administered as a treatment in this study, but as a pharmacologic tool to study the adrenergic system.
89313176|NCT04299438|Active Comparator|Propranolol|IV Propranolol - 2mg; one possible repeat dose ≥2 hours later
89313177|NCT04299438|Placebo Comparator|Placebo|Normal saline placebo- 2 mL; one possible repeat dose ≥2 hours later
89313178|NCT04289298|Experimental|Engage-A|Participants receive 9 individual in-person or remote therapy sessions. Each session will last approximately 60 minutes. During the sessions, the therapist will encourage the participant to engage in physical and social activities that are pleasurable or rewarding.
89313179|NCT04289298|Experimental|Clinician|Clinicians will be trained in Engage-A and supervised while utilizing the therapy.
89313180|NCT04282395|Experimental|Resilience-Based Diabetes Self-Management Education|The RB-DSME structure involves 8 weekly classes, 8 bimonthly support group sessions, and 2 booster sessions. The RB-DSME builds on foundational resilience resources (e.g., self-efficacy, social support), infusing novel resilience resources (e.g., adaptation to stress, finding positive meaning, spiritual coping) into the RB-DSME curriculum.
89313181|NCT04282395|Active Comparator|Standard Diabetes Self-Management Education|The scope and sequence of the standard diabetes self-management education (DSME) curriculum are aligned with national standards of the American Diabetes Association. DSME groups receive a 10-month intervention: 8 weekly educational sessions, followed by 8 bimonthly support group sessions, followed by 2 booster sessions.
89313182|NCT04269265|Experimental|All Participants|In this single-arm study, all participants will receive the intervention
89313183|NCT04267328||Patients having surgery|Older adults undergoing elective orthopedic surgery.
89313184|NCT04259450|Experimental|AFM24|"Phase 1: Treatment of escalating doses of AFM24.~Phase 2a: Treatment of AFM24 at maximum tolerated dose/recommended phase 2 dose, stratified into cohorts by tumor type."
89313185|NCT04244006|Experimental|Dupilumab|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of Dupilumab 300 mg (syringe of 2 mL for subcutaneous administration).
89313186|NCT04244006|Placebo Comparator|Placebo|The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of placebo (syringe of 2 mL for subcutaneous administration)..
89313187|NCT04240821|Experimental|Open-label theophylline|Oral theophylline - either once daily capsule or q6h elixir.
89313188|NCT04214678|Experimental|Underwater clip closure|The post-resection defect is closed using endoscopic clips with underwater technique
89313189|NCT04214678|Active Comparator|Conventional clip closure|The post-resection defect is closed using endoscopic clips with conventional gas insufflation (CO2)
89313190|NCT04207619|Experimental|Arm 1|Participants will have their glial acetate metabolism measured by carbon-13 magnetic resonance spectroscopy as well as their neuroendocrine response to hypoglycemia 3 days later.
89313191|NCT04196491|Experimental|Dose Escalation|"bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 800 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy with a planned starting dose of 450 x 10^6 CAR+ T cells.~Lenalidomide maintenance therapy is recommended for all patients and should be initiated upon adequate bone marrow recovery or from 90-day post-bb2121 infusion, whichever is later"
89313192|NCT04165967|Experimental|Tumor-infiltrating lymphocyte product (TIL) transfer|The TIL product will be produced from excised tumor lesions from the patient. Expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to Patient at Day 0.
89313193|NCT04120155|Other|Dissecting the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary dessection during the upper lobe thoractomy.
89313194|NCT04120155|Other|Preserving the inferior pulmonary ligament|This group of patients will undergo the inferior pulmonary preservation during the upper lobe thoractomy.
89313195|NCT04116710|Experimental|Phase 1: HS-130 + HS-110 (viagenpumatucel-L)|Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
89313196|NCT04062305|Experimental|Diagnostic (nTMS, sensory testing)|Patients undergo nTMS over 1 hour. Patients also perform 4 tasks that test grip and pinch strength, and the ability to use and feel with their hands for 1 hour.
89313197|NCT04044872|Experimental|Single Arm:Diagnosing Cardiotoxicity when on Radiation therapy|
89313198|NCT04044859|Experimental|Autologous genetically modified ADP-A2M4CD8 cells|
89313199|NCT04007224|Active Comparator|Oxytocin|Intranasal Oxytocin
89313200|NCT04007224|Experimental|Autologous umbilical cord blood|Intravenous administration of autologous umbilical cord blood
89313201|NCT03995628|Experimental|Steroid Group|Participants will receive a one-time dose of oral dexamethasone at 0.5 mg/kg on the third post-operative day
89313202|NCT03995628|Placebo Comparator|No Steroid Group|Participants will receive placebo on third post-operative day
89313203|NCT03923556|Experimental|Sugammadex|Sugammadex
89313204|NCT03923556|Active Comparator|Neostigmine|Neostigmine
89313205|NCT03913247||Group with different size measures|Each patient included in the study will have different measure of size.
89313206|NCT03908125|Other|Continuous Glucose Monitoring Device|
89313207|NCT03891797|Experimental|Cognitive Processing Therapy|12 sessions of group-based Cognitive Processing Therapy administered 1x/week for 90 minutes each session.
89313208|NCT03891797|No Intervention|Control|No treatment/treatment as usual. Participants will complete questionnaires at three time points with no intervention.
89313209|NCT03861455|Experimental|dupilumab group|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
89313210|NCT03861455|Placebo Comparator|placebo group|patient receive placebo
89313211|NCT03845127|Experimental|Revivent TC Ventricular Enhancement System plus GDMT|Patients will receive treatment with the Revivent TC Ventricular Enhancement System while being maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
89313212|NCT03845127|Active Comparator|GDMT Only|Patients will be maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
89313213|NCT03816982|Active Comparator|Bupivacaine HCl/Bupivacaine CISB|23 patients will be enrolled to receive a single-injection bupivacaine HCL interscalene block with bupivacaine CISB added.
89313214|NCT03816982|Experimental|Liposomal Bupivacaine Added to Interscalene Block|23 patients will be enrolled to receive a single-injection bupivacaine HCl interscalene block with liposomal bupivacaine added to same injection.
89313215|NCT03815214|Experimental|Diet Intervention|The diet intervention is a partial meal replacement program using the commercially available OPTAVIA® Optimal Weight 4&2&1 Plan™. In the OPTAVIA program, subjects are asked to eat 6 times each day, once every 2 to 3 hours.
89313216|NCT03815214|Placebo Comparator|Enhanced Standard Care|The control group will receive instruction on a healthy diet as defined by the United States Department of Agriculture.
89313217|NCT03794635|Experimental|Patients|Latino/a advanced cancer patients
89313218|NCT03794635|Experimental|Caregivers|Caregivers of Latino/a advanced cancer patients
89313219|NCT03736629|Placebo Comparator|Placebo|8 weeks of placebo capsule once daily by mouth
89313220|NCT03736629|Active Comparator|Azithromycin|8 weeks of Azithromycin (250 mg) capsule once daily by mouth
89313221|NCT03736629|No Intervention|Non-asthmatic controls|Non-asthmatic controls to assess variability of microbiome composition and diversity over time in a normal population. No intervention given.
89313222|NCT03681639|Experimental|Patients who received Metasul Monoblock in hip resurfacing|Patients who received the Zimmer Hip Resurfacing System utilising the Metasul Monoblock Component™ Cup in a Hip Resurfacing Application with the Durom® Hip Resurfacing Femoral Component and whose Serum metal ion levels is being measured.
88810978|NCT04878562|Experimental|I-COPE Intervention|5 out of the 25 participating primary care sites are randomly assigned to any of the 5 steps. The ICOPE intervention is implemented after a pre interventional period of 3-15 months. The intervention is implemented during 8 weeks. The length of the post interventional period is 11-23 months.
88810979|NCT04878562|No Intervention|No intervention|Standard of care offered to all patients.
89313223|NCT03680729|Experimental|aBSB|aBSB is the adaptation of BSB. BSB a two part intervention to improve rates of community-based HIV testing and prevention education in black young MSM (YMSM). BSB was developed on Information Motivation Behavioral Skills (IMB) theory. The first part of BSB uses Motivational Interviewing in a culturally appropriate way to encourage participants to accept testing and return for test results. The second part is conducted after the participant has received his result, assuming it was not reactive and offers prevention education.
89313224|NCT03680729|Active Comparator|Street Outreach|Standard street outreach was used as the control in the original BSB trial.
89313225|NCT03656380|Experimental|Mepolizumab 300 mg|Subjects will receive Mepolizumab 300 mg subcutaneously (SQ) monthly for 6 months
89313226|NCT03656380|Other|Placebo, followed by Mepolizumab 100 mg|This arm will receive placebo, followed by Mepolizumab 100 mg. Subjects will receive placebo subcutaneously (SQ) monthly for 3 months, followed by Mepolizumab 100 mg subcutaneously (SQ) monthly for 3 months. Mepolizumab will be administered with 2 SQ injections of placebo and 1 SQ injection of Mepolizumab 100 mg to maintain blinding.
89313227|NCT03632551|Active Comparator|Symmetrical hearing|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
89313228|NCT03632551|Experimental|Single-sided deafness|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
89313229|NCT03632551|Experimental|Bilateral profound hearing loss treated|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
89313230|NCT03622905|Experimental|DBS On|DBS system On
88810980|NCT04875351||Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Testing|Female patients diagnosed with hormone receptor-positive (HR+), lymph node-negative (LN-) or lymph node-positive (LN+, with 1-3 positive nodes) early-stage invasive breast cancer, who are distant recurrence-free.
89313231|NCT03622905|Sham Comparator|DBS Off|DBS System Off
89313232|NCT03513666|Experimental|treatment arm|Toripalimab 240 mg or 360 mg Q3W in combination with chemotherapy
89313233|NCT03482115|Experimental|Comatose patient|Subject with coma of traumatic or anoxic aetiology : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
89313234|NCT03482115|Other|control volunteers|subject control : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
89313235|NCT03453632|Experimental|Botulinic toxin|Injections of botulinic toxin (Dysport®, Allergan) 200 UI
89313236|NCT03453632|Placebo Comparator|Placebo|Injections of physiological serum
89313237|NCT03424304|Other|Excel V™ Laser With Green Genesis|Treatment with Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment for skin quality in desired area
89313238|NCT03409016||Immune Checkpoint Inhibitor Therapy|Patients starting treatment with ipilimumab, nivolumab, pembrolizumab, or atezolizumab, alone or in combination, for treatment of a metastatic solid tumor cancer will be enrolled. Patients will receive checkpoint inhibitor therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
89313239|NCT03409016||Control|An additional 18 patients starting standard chemotherapy will be enrolled as a control population. Patients will receive chemotherapy per standard protocol
89313240|NCT03314987|Active Comparator|intervention group|Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks
89313241|NCT03314987|Placebo Comparator|placebo group|Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks
89313242|NCT03260855|Other|Lymphoma survivorship|This present study is based on an interventional (with an analysis of human blood sample) and on the use of different Questionnaires/Scales.
89313243|NCT03260361|Experimental|Hypnosis Kinesitherapy and MEOPA|combined therapy of Hypnosis Kinesitherapy and MEOPA (HKM)
89313244|NCT03260361|Other|usual practice|physiopathology and treatments
89313245|NCT03235271||Group A: Large-Vessel Ischemic Stroked|Group A will include subjects that present with focal neurological deficits and clinical features consistent with ischemic stroke with a large vessel occlusion (see Key Terms for definition). Subjects in this group will have a clinical presentation consistent with ischemic stroke and a large vessel occlusion confirmed through angiography. It is common practice to have the CTA completed immediately after CT imaging. Clinical presentation will include classic features of stroke syndromes that occur based on the localization of the infarct, which includes cortical symptoms that can be lateralized to the left side or right side of the brain.
89313246|NCT03235271||Group B: Hemorrhagic Stroke|Subjects in this group will present with symptoms similar to Group A. In addition, they will present with clinical symptoms consistent of increased intracranial pressure such as nausea, vomiting, loss of consciousness and severe headache. In order for a subject to be eligible, the hemorrhage will be limited to primarily intracerebral hemorrhage with a minimum volume of 10mL. Subarachnoid hemorrhage and intraventricular hemorrhage may also be present as incidental findings. Since it is unlikely that these subjects proceed for neuro-intervention, they will not have a follow-up BrainPulse recording and they will be exited after completing study procedures.
89313247|NCT03235271||Group C: Transient Ischemic Attack|Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
89313248|NCT03235271||Group D: Non-Stroke Subjects|Subjects in this group will present with stroke-like symptoms but do not have a diagnosis of stroke nor TIA. In order to qualify for this group, subjects will also need to show evidence of no stroke on radiological imaging (CT and/or MRI). Diagnoses in this group may include seizure, systemic infection, brain tumor, metabolic disorder, positional vertigo, hemiplegic migraine, encephalopathy, cranial nerve injury, spinal cord injury, brachial/sacral plexus injury, peripheral nerve injury, etc.
89313249|NCT03217201|Experimental|Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
89313250|NCT03217201|Active Comparator|Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
89313251|NCT03217201|Experimental|Neo-Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
89313252|NCT03217201|Active Comparator|Neo-Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
89313253|NCT03206814|Active Comparator|Group 1 - Usual care|Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
89313254|NCT03206814|Experimental|Group 2 - POST-strategy|Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
89313255|NCT03173729||Phase 1 Cohort 1|CRC (n = 150)
89313256|NCT03173729||Phase 1 Cohort 2|Precancerous polyps (n = 150)
89313257|NCT03173729||Phase 1 Cohort 3|Normal controls (n = 150)
89313258|NCT03173729||Phase 2 Field Test|75 patients who are high risk for CRC as described in the eligibility
89313259|NCT03173729||Phase 2 Validation Study Cohort 1|Family history of CRC (n = 330)
89313260|NCT03173729||Phase 2 Validation Study Cohort 2|LGI bleeding (n = 240)
89313261|NCT03173729||Phase 2 Validation Study Cohort 3|Patients with history of CRC (n = 75)
89523421|NCT03375515|Active Comparator|non-PCA IV Hydromorphone titration|Non-PCA titration administered by a nurse or clinician: Initial hydromorphone doses were same with PCA titration. Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The dose of hydromorphone increased by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.
89313262|NCT03161535|Experimental|exercise group|The rehabilitation program was composed of two parts: an exercise program and a diet-teaching program. The exercise program was a 12-week home-based program that comprised moderate-intensity brisk walking for 40 min per session, with 3 sessions per week; in addition, weekly exercise counseling was provided through telephone. The diet teaching program was provided to the patients by using a diet booklet at baseline (same timing as the exercise program), and its contents were used to instruct the patients regarding dietary principles to be followed.
89313263|NCT03161535|No Intervention|usual-care group|The control group (CG) received usual care, whereas a nurse, the manager for esophageal cancer treatment, provided routine care, conducted follow-ups, and offered information on esophageal cancer to the experimental group (EG).
89313264|NCT03156010|Other|TBI Group|Subjects with history of TBI will undergo testing with all three devices.
89313265|NCT03156010|Other|Control Group|Subjects with no history of TBI will undergo testing with all three devices.
89313266|NCT03128164|Experimental|Six arm including in dose expansion stage by following:|"Arm A: patients with MZL (subtype including nodal, extra-nodal and splenic) who received ≥ 1 previous line of systematic treatment and at least one line included CD20-directed regimen~Arm B: patients with CLL/SLL who received ≥ 1 previous line of systematic treatment and at least one of which included purine-based regimen or CD20-directed regimen~Arm C: patients with FL (grade 1, 2, and 3a) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~Arm D: patients with MCL who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~Arm E: patients with DLBCL (including GCB and non-GCB, Richter' transformation) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen~Arm F: patients with PTCL who received ≥ 2 previous line of systematic treatment"
89313267|NCT03099070|No Intervention|Control, Not-Fasting|Participants will experience the control intervention and will not fast prior to the lab visit.
89313268|NCT03099070|Experimental|Control, Fasting|Participants will experience the control intervention and will fast prior to the lab visit.
89313269|NCT03099070|Experimental|Stress, Not-Fasting|Participants will experience the stress intervention and will not fast prior to the lab visit.
89313270|NCT03099070|Experimental|Stress, Fasting|Participants will experience the stress intervention and will fast prior to the lab visit.
89313271|NCT03040505||Patients with schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
89313272|NCT03040505||Control participants|- Control participants without psychiatric nor neurological history
89313273|NCT03029429|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
89313274|NCT03029429|Placebo Comparator|Placebos|Theophylline capsule by mouth once daily or Theophylline elixir by mouth q6h
89313275|NCT02955979||CT scan with iodinated contrast agents|Patients under 16 years old and must pass a CT scan with iodinated contrast agents. The following data will be collected in the medical record (creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern).
89313276|NCT02946515|Experimental|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
89313277|NCT02946515|Experimental|Waitlist Control Group|The control group will participate in pre- and post-test assessments of their conversational skills with a trained actor. At the end of the study, the waitlist control group will be allowed to access to the simulation and the study team will provide training to participants upon request.
89313278|NCT02834481|Other|: ventilated children|ventilated children admitted in PICU postoperative of cardiac surgery with extracorporeal circulation with ANI/NIPE
89313279|NCT02792582|Active Comparator|Tumor-Surgery|"Participants who are eligible to undergo surgery to remove the tumor will proceed to surgery. If all tumor is removed, they will be followed over 5 years for outcome comparison to the other participant groups.~If the entire tumor is not removed by surgery, participants will receive 6 weeks of proton therapy. They will then be followed for 5 years to collect outcome data for comparison to the other participant groups."
89313280|NCT02792582|Active Comparator|Tumor-No Surgery|Participants whose tumor cannot be resected through surgery will receive 6 weeks of proton therapy. They will then be followed over 5 years for outcome comparison to the other participant groups.
89313281|NCT02754765|Experimental|endTB regimen 1 (BeLiMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
89313282|NCT02754765|Experimental|endTB regimen 2 (BeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
89313283|NCT02754765|Experimental|endTB regimen 3 (BeDeLiLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
89313284|NCT02754765|Experimental|endTB regimen 4 (DeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
89313285|NCT02754765|Experimental|endTB regimen 5 (DeCMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
89313286|NCT02754765|Active Comparator|endTB regimen 6 (Control)|endTB regimen 6 is the control regimen.
89313287|NCT02726360||Oncology physician|Physicians (MD or DO) in the oncology departments of participating hospitals will complete a survey. Non-English language proficiency will be assessed by self-assessment using Interagency Language Roundtable (ILR) scale, which the PI has previously used. The physician survey is collected among treating physicians of patients enrolled to MSK IRB approved protocols 12-099 and 12-223 at some of the participating hospitals. For physicians who already completed this survey as part of participation in protocol 12-099 or 12-223, data will be extracted from the respective study's REDCap database.
89313288|NCT02726360||patients|Audio record the initial visits between patients and their treating physician. Analyze 48 patient-physician dyad recordings using the Roter Interaction Analysis System (RIAS).
89313289|NCT02637505|Active Comparator|Arthroscopic microfracture (MF)|"The AM group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The cartilage is cut sharp forming a rim of 90 degrees. The calcified layer is removed using a curette before an arthroscopic awl is then used to perform multiple holes (microfractures) from the periphery towards the center. The microfractures are 3 - 4 mm apart and 2 - 4 mm deep into the subchondral bone. The correct and successful technique is confirmed by direct visualization: while reducing the fluid pump pressure, the release of marrow fat droplets and blood will be observed."
89313290|NCT02637505|Sham Comparator|Arthroscopic debridement (AD)|The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The lesion is stabilized, debriding all loose or marginally attached cartilage from the surrounding rim to form a stable edge of healthy cartilage around the defect using a ring curette, where cartilage slops down to the defect.
89313291|NCT02620007|Experimental|Experimental arm|oral Ciprofloxacin 500 mg bid and oral Rifaximin 800 mg bid for 12 weeks
89313292|NCT02620007|Placebo Comparator|Control arm|a placebo of Ciprofloxacin bid and a placebo of Rifaximin bid for 12 weeks
89313293|NCT02586623|Experimental|Open Label Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally. During the Open Label Titration Period, patients will first receive 100 mg TID and their dose will be raised (in 100 mg increments) at subsequent visits until optimal dose is determined. During the Open Label Treatment Period, patients will receive active droxidopa100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to the patient's individual dose at the end of the Open-Label Titration Period).
89313294|NCT02586623|Placebo Comparator|Randomized Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to patients individual dose at the end of the Open-Label Period) or matching placebo.
89313295|NCT02246634|Experimental|Diffusion Weighted MRI scan|Patients who are enrolled in the study will undergo an additional diffusion weighted MRI (T2W, DWI and ADC sequences) of the liver.
89313296|NCT02236377|Active Comparator|ERRT - Enhanced Exposure|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced exposure techniques
89313297|NCT02236377|Active Comparator|ERRT - Sleep and Relaxation|Exposure, Relaxation, and Rescripting Therapy protocol, 5 sessions, focused on sleep and relaxation
89313298|NCT02236377|Active Comparator|ERRT-Rescription|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with rescription but no exposure
89313299|NCT02236377|Active Comparator|ERRT-Sleep|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced sleep techniques
89313300|NCT02236377|Active Comparator|ERRT - Consensus Manual|Consensus Protocol, 6 sessions, includes components of ERRT and other nightmare protocols.
89313301|NCT02193295|Experimental|Lifestyle Intervention|Caloric Restriction to reverse lipid-induced insulin resistance.
89313302|NCT02193295|Experimental|Baseline Assessment of Hepatic Mitochondrial Fat Oxidation|Tracer study to assess hepatic mitochondrial fat oxidation (PINTA).
89313303|NCT02170181||OLIGOMETASTATIC ARM|SBRT to Oligometastases
89313304|NCT02170181||CONSOLIDATION ARM|SBRT as Consolidation to Residual Disease
89313305|NCT02170181||NORTON-SIMON ARM|SBRT to Debulk Gross Disease
89313306|NCT02170181||RE-IRRADIATION ARM|
89313307|NCT02057653||Before GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record prior to the start of the training curriculum.
89313308|NCT02057653||After GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record after the training program took place
89313309|NCT02043418||children VIH+|children infected with HIV
89313310|NCT02043418||Chlidren VIH-|uninfected children born from HIV-positive or HIV-negative mothers
89313311|NCT01819831|Experimental|Preoperative proton radiation|Patients will receive 50 Gray equivalents (GyE) in 25 fractions with proton therapy, followed by surgery 4-8 weeks after completion of radiation.
89313312|NCT01622543|Active Comparator|Folfox plus Bevacizumab and Reolysin|
89313313|NCT01622543|Active Comparator|Folfox plus Bevacizumab|
89313314|NCT01618357|Experimental|Intervention|All subjects will receive pre-operative Neo-Adjuvant Chemotherapy (NAC) but only those with an incomplete response to NAC will be treated with the PARPi experimental portion of the trial explained below. Those with a complete response will be treated per standard of care.
89313315|NCT01584882|No Intervention|Control (Usual care)|Return patients seen within the data collection window in HealthPartners Dental Clinics (new patient exams were excluded) who were documented as using tobacco, specifically cigarettes, at their last dental encounter. Randomization was at the clinic level.
89523422|NCT03375281|Experimental|No touch group|RFA for small HCC would be done by using no touch technique
89313316|NCT01584882|Experimental|Tobacco Cessation Tool (CATI Tool)|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a 'CATI'[Computer Assisted Tobacco Intervention] tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
89313317|NCT01214473|Experimental|Probiotic group|Once daily oral administration of a probiotic preparation (1 billion cells of Lactobacillus plantarum and 150 mg of fructooligosaccharides) for one week to newborn infants
89313318|NCT01214473|Placebo Comparator|Placebo|Once daily oral administration of maltodextrin for one week to newborn infants
89313319|NCT01147835|Placebo Comparator|Placebo Lollipop|The placebo group will ingest the same herbal lollipop formula without the active ingredient.
89313320|NCT01147835|Experimental|Chinese Licorice Root|The experimental group will ingest the herbal lollipop formula with the active ingredient.
89313321|NCT00988988|Active Comparator|Steroid Cream|1% steroid cream
89313322|NCT00988988|Active Comparator|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled
89313323|NCT00988988|Active Comparator|placebo|inactive cream
89313324|NCT00700414||Participants|Any participant who meets eligibility criteria and consents to participate in the trial.
89313325|NCT00684580||Observational Group|Data Collection
89313326|NCT00662740|Experimental|Tiotropium/Salmeterol quaque die (QD, once daily)|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
89313327|NCT00662740|Active Comparator|Tiotropium quaque die (QD, once daily)|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
89313328|NCT00662740|Active Comparator|Salmeterol bis in die (BID, twice daily)|Salmeterol Inhalation Powder, hard PE capsule
89313329|NCT00662740|Active Comparator|Tiotropium/Salmeterol quaque die (QD, once daily)+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
89313330|NCT00662740|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
89313331|NCT00588562||Primary Hyperoxaluria patients|Registry will include data on patients with confirmed diagnosis of Primary Hyperoxaluria.
89313332|NCT00588562||Dent Disease Patients|Registry will include data on patients with confirmed diagnosis of Dent Disease.
89313333|NCT00588562||Cystinuria Patients|Registry will include data on patients with confirmed diagnosis of Cystinuria.
89313334|NCT00588562||APRT deficiency Patients|Registry will include data on patients with confirmed diagnosis of APRT deficiency.
89313335|NCT00581334||Robotic Sacrocolpopexy Group|laparoscopic mesh augmented prolapse repair for post-hysterectomy prolapse repair using the Da Vinci robot
89313336|NCT00581334||Open Sacrocolpopexy Group|matched cohort that underwent mesh augmented prolapse repair for post-hysterectomy prolapse performed via open laparotomy
89313337|NCT00078949|Experimental|Salvage arm I|Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
89313338|NCT00078949|Experimental|Salvage arm II|Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
89313339|NCT00078949|Experimental|Maintenance arm I|Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
89313340|NCT00078949|No Intervention|Maintenance arm II|Patients undergo observation only.
89313341|NCT01184625|Experimental|Exercise|
88810981|NCT04873050|Experimental|Semaglutide Pen Injector (Ozempic)|Weekly injections of semaglutide for 8 months total (2 months of titration; 6 months of full dose- 1mg/week)
88810982|NCT04873050|Sham Comparator|Placebo|Weekly injections of placebo for 8 months total
89313342|NCT01184625|No Intervention|No intervention|12 weeks of stable physical exercise level.
89313343|NCT01181817|Other|SCS|patients with Failed back Surgery syndrome treated with SCS
89313344|NCT01289691|Experimental|Air/Oxygen Mixture|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
89313345|NCT01289691|Active Comparator|Oxygen|Patients in this group will be ventilated with only oxygen during one lung ventilation.
89313346|NCT01289769|Active Comparator|dexmedetomidine|
89313347|NCT01289769|Placebo Comparator|control|
89313348|NCT01184781|Other|A|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
89313349|NCT01184937|Experimental|Patient education program|
89313350|NCT01184937|No Intervention|Standard care|
89313351|NCT03855345|Experimental|Control group|In this group, the participants will be submitted to the conventional treatment. The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
89523423|NCT03449771|Experimental|Single Arm|To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire.
89523424|NCT03371615|Active Comparator|Fermented IF + LBG + Gos Fos|Fermented infant formula with Locust bean gum and Gos Fos
89523425|NCT03371615|Placebo Comparator|Fermented IF +LBG|Fermented infant formula with Locust bean gum
89313352|NCT03855345|Experimental|aPDT group|In this group, besides the conventional treatments, patients will also receive aPDT. aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F & A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
89313353|NCT01179555|Experimental|Pt. 1 Behavioral Activation|"Behavioral Activation (BA) is a behavioral technique to help people overcome avoidant tendencies through goal setting, activity scheduling, and graded task assignment. The key component of BA involves developing an Action Plan, and having the subject document each step of the plan as he or she implements it, reinforcing the steps towards goal attainment. Action Plans are easily applied to diabetes self-care tasks because the latter lend themselves to documentation of simple, step-by-step plans. In this study, a Community Health Educator (CHE) - interventionist will schedule and deliver four 45-60 minute in-home BA sessions within 3 months of randomization (i.e., one session every 2-3 weeks)."
89313354|NCT01179555|Placebo Comparator|Pt. 1 Supportive Therapy|The purpose of Supportive Therapy (ST) is to explore the impact of aging and diabetes on the subject's life. In contrast to the BA intervention, the interventionist does not discuss the importance of dilated eye exams. In subsequent sessions, ST facilitates and deepens knowledge about the subject's life situation in relation to his or her health and other life difficulties. The ST therapist encourages this process and creates an accepting, nondirective, and supportive opportunity for discussion.
89313355|NCT01181973|Active Comparator|Treatment sequence #1|One 1-mL subcutaneous injection at 30 mg/mL in Period 1 and two 1-mL subcutaneous injections at 15 mg/mL each in Period 2
89313356|NCT01181973|Active Comparator|Treatment sequence #2|Two 1-mL subcutaneous injections at 15 mg/mL each in Period 1 and one 1-mL SC injection at 30 mg/mL in Period 2
89313357|NCT01185093||Fourth grade students|Each participant will attend two presentations and six hands-on activities led by St. Jude faculty and research staff on topics within their expertise, such as cells and cancer, and healthy living. The pre-test will take place within 7±1 days before the program presentations and before students receive copies of the printed material. Two post-tests will take place. The first post-test will be administered within 7±1 days after the final scheduled program presentation and will be a measure of knowledge acquisition. The second post-test will take place 90±7 days post-intervention and will be a measure of knowledge retention.
89313358|NCT01289925|Experimental|Selenium|
89313359|NCT01289925|Placebo Comparator|Sugar Pill|
89313360|NCT01290939|Experimental|Arm 1|Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment will be according to investigators discretion). In the absence of hematological toxicity > grade 1 during the first cycle the dose of lomustine can be escalated to 110 mg/m² (cap 200 mg) in their second cycle.
89313361|NCT01290939|Active Comparator|Arm 2|Lomustine single agent 110 mg/m² every 6 weeks (cap. 200 mg) (at further progression treatment will be according to investigators discretion).
89313362|NCT01179633|Active Comparator|Oplon Active Patch|
89313363|NCT01179633|Placebo Comparator|Placebo patch|
89313364|NCT01288755|Experimental|001|TMC278 One 25 mg tablet once daily for 11 days (TrtA and C)
89313365|NCT01288755|Experimental|002|Raltegravir One 400 mg tablet twice daily for 4 days (Trt B) and for 11 days (TrtC)
89313366|NCT01182051|Experimental|Cognitive behavioral therapy|Key treatment ingredients in CBT include psychoeducation, trigger identification, progressive muscle relaxation training, cognitive restructuring, problem solving, in vivo exposure, and relapse prevention (see Appendix I for an outline of the treatment manual).
89313367|NCT01182051|Active Comparator|Relaxation Training|RT will consist of progressive muscle relaxation training, diaphragmatic breathing, and thermal biofeedback.
89313368|NCT01290003|Experimental|Antibiotic Group|Neonates randomized to intervention Group(Antibiotic group)will receive the first line antibiotics (Piperacillin-Tazobactam and Amikacin) as per the unit policy for 72 hours. These neonates will also be monitored by performing sepsis screens and blood culture for development of sepsis.
89313369|NCT01290003|No Intervention|No Antibiotic Group|Neonates randomized to 'No antibiotic group' will receive supportive treatment as per standard unit protocol. These neonates will be monitored by performing sepsis screens and blood culture for development of sepsis.
89313370|NCT03858933|Experimental|Limbic Modulation Index Neurofeedback|"This arm of the study will undergo a novel neurofeedback treatment, targeting downregulation of deep limbic structures, specifically the amygdalae.~Participants in this arm will complete 15 neurofeedback sessions."
89313371|NCT03858933|Active Comparator|Alpha/Theta Neurofeedback|"This arm of the study will undergo a proven PTSD neurofeedback treatment, alpha/theta regulation, during which participants will try various mental strategies to increase the presence of theta waves.~Participants in this arm will complete 15 neurofeedback sessions."
89313372|NCT02524509||CHONDRON|Patients who already received autologous chondrocyte implantation using CHONDRON (Autologous Cultured Chondrocyte) for knee cartilage defects
89313373|NCT02524509||Microfracture|patients already underwent microfracture
89313374|NCT01290081|Active Comparator|Active referral|Case management intervention group - study personnel scheduled the TB doctor appointment for the participant, reminded to keep it, and transportation to the clinic was organized when needed.
89313375|NCT01290081|No Intervention|Passive referral|Participants were instructed to schedule an appointment with TB services themselves.
89313376|NCT01291095|Active Comparator|CONCURRENT CHEMO-RADIOTHERAPY ARM|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy).
88810983|NCT04865965|Experimental|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
88810984|NCT04865965|No Intervention|No Exercise|No Exercise Session
89313377|NCT01291095|Experimental|ACCELERATED FRACTIONATION RADIOTHERAPY ARM|Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
89313378|NCT03739203|Placebo Comparator|Placebo + ADT|Cariprazine matching placebo capsules, orally, once daily in addition to their ongoing antidepressant therapy (ADT) [same antidepressant and dose of ADT they were on at the Baseline] during the Double-blind Treatment Period, up to Week 6.
89313379|NCT03739203|Experimental|Cariprazine 1.5 mg/day + ADT|Cariprazine 1.5 mg capsules, orally, once daily in addition to their ongoing ADT (same antidepressant and dose of ADT they were on at the Baseline) during the Double-blind Treatment Period, up to Week 6.
89313380|NCT03739203|Experimental|Cariprazine 3 mg/day + ADT|Cariprazine 1.5 mg capsules, orally, once daily for 2 weeks starting at the Baseline, titrated to 3.0 mg capsules, orally, once daily from Week 2 through Week 6 in addition to their ongoing ADT (same antidepressant and dose of ADT) during the Double-blind Treatment Period, up to Week 6.
89313381|NCT01185327||Study|Infants to Israeli Ethiopian-origin Mothers
89313382|NCT01185327||Control|Infants to Israeli non-Ethiopian-origin mothers
89313383|NCT01185405|Experimental|EA group|Voriconazole dosage adjustment according to the each measurements of voriconazole levels from day 1, using NONMEM program
89313384|NCT01185405|Active Comparator|CA group|Voriconazole dosage adjustment according to the levels from day 5, using predefined protocol
89313385|NCT01182129|Active Comparator|Swedish Snus Type 1|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
89313386|NCT01182129|Active Comparator|Swedish Snus Type 2|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
89313387|NCT01182129|Active Comparator|4 mg Nicorette chewing gum|Nicorette is chewed according to instructions in package insert over 30 minutes.
89313388|NCT01179711|Other|glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
89313389|NCT01587729||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
89313390|NCT01587729||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
89313391|NCT01182363|No Intervention|Control|Usual early intervention services
89313392|NCT01182363|Experimental|Problem Solving Education|
89313393|NCT01179789|Active Comparator|Optimal Diet|Diet advices will receive the Optimal Diet for Elderly
89313394|NCT01179789|Experimental|VSL#3|Diet advices + VSL-3: will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
89313395|NCT01179789|Experimental|AISA-5203-L|Diet advices + 5203-L: will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
89313396|NCT01179789|Experimental|Argan oil|Diet advices + Argan oil: will receive the Optimal Diet for Elderly + Argan
89313397|NCT03855267|Placebo Comparator|Group A|Propofol 20 mg/ml, recommended anesthesia induction dose of 0.1~0.125 ml/kg, anesthesia maintenance pump speed of 0.2~0.5ml/kg/h. keep bispectral index within 40 # 60
89313398|NCT03855267|Active Comparator|GroupB|EP1:3, that is, 10ml etomidate was mixed with 30ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
89313399|NCT03855267|Active Comparator|Group C|EP1:1, that is, 20ml etomidate was mixed with 20ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
89313400|NCT03855267|Active Comparator|Group D|EP3:1, that is, 30ml etomidate was mixed with 10ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
89313401|NCT01185795|Experimental|Cardioviva™ yogurt|
89313402|NCT01185795|Placebo Comparator|Placebo yogurt|
88810985|NCT04858009|Experimental|Treatment (HIPEC)|Patients undergo HIPEC with nab-paclitaxel and cisplatin over 90 minutes in the absence of disease progression or unacceptable toxicity. Patients may undergo additional HIPEC with paclitaxel and cisplatin up to 5 times. Patients undergo CT scan, MRI or PET during screening.
89313403|NCT01182519||Diagnosed with metastatic breast cancer|"The primary objective of this study is to examine the association between urinary PGE-M and the presence or absence of lung metastases in patients with breast cancer. These patients will be subdivided into a set with lung metastases (group 1A; clinically assessed as per guidelines below) versus those with no evidence of lung metastases (group 1B; no known lung metastases). Group #2 (control) will have been treated for early stage breast cancer and will have no known metastases."
89313404|NCT01182519||History of early breast cancer|History of early breast cancer and currently no evidence of disease
89313405|NCT01291329|Experimental|WJ-MSC|Wharton's jelly- Derived Mesenchymal Stem Cells Transfer
89313406|NCT01179867|Experimental|Electronic Medication Reconciliation|"Electronic medication reconciliation includes:~Electronic retrieval of the community drug list at admission~Generation of discharge prescription using the discharge reconciliation module at discharge~Transfer of information on discontinued and changed medication to respective dispensing pharmacies and prescribing physicians"
89313407|NCT01179867|No Intervention|Usual practice medication reconciliation|Usual practice in dealing with medication reconciliation. This includes viewing the hospital medications through the hospital electronic pharmacy system, and viewing the community drugs in the patient's chart, if it was collected at admission (not always the case). However not all physicians view the community drugs before writing the discharge prescription. The physician will write a paper discharge prescription to be given to the patient, but communications are generally not made directly to the community pharmacist or previous prescribing physicians.
89313408|NCT01290159||post heat stroke heat tolerant|
89313409|NCT01290159||post heat stroke heat intolerant|
89313410|NCT01290159||healthy controls|
89313411|NCT01179945|Experimental|sodium benzoate containing|
89313412|NCT01179945|Active Comparator|non sodium benzoate containing|
89313413|NCT03858855|Experimental|Group I (bergamot essential oil)|Patients inhale 7 drops of bergamot essential oil using an essential oil administration bottle TID (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
89313414|NCT03858855|Experimental|Group II (chamomile essential oil)|Patients inhale 7 drops of chamomile essential oil and complete journal as in group I.
89313415|NCT03858855|Experimental|Group III (ginger essential oil)|Patients inhale 7 drops of ginger essential oil and complete journal as in group I.
89313416|NCT03858855|Active Comparator|Group IV (almond essential oil)|Patients inhale 7 drops of almond essential oil and complete journal as in group I.
89313417|NCT03854955|Experimental|iScribes|Device-based scribing service used for dictation and documentation.
89313418|NCT03854955|No Intervention|Traditional Dictation|Standard dictation and documentation methods used.
89313419|NCT03855033|Experimental|Media Aware Sexual Health - High School|Students received the web-based Media Aware Sexual Health - High School program.
89313420|NCT03855033|No Intervention|Typical Health Education Programming|Students received their regular health education programming not related to sexual health education.
89313421|NCT01185873|Experimental|1|
89313422|NCT01182597|Active Comparator|IV PPI|Pantoprazole 3.3mg/hr for 72hrs
89313423|NCT01182597|Experimental|Oral PPI|Lansoprazole (Takepron OD) 30mg PO q12h
89313424|NCT01185951|Active Comparator|Achilles tendinopathy|Patients suffering both, insertional and midportion Achilles tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
89313425|NCT01185951|Active Comparator|Patella tendinopathy|Patients suffering patella tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
89313426|NCT01185951|Active Comparator|Epikondylitis|Patients suffering both, lateral (tennis elbow) or medial (golfers' elbow) elbow tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
89313427|NCT01180023|Experimental|Sweeping|
89313428|NCT01180023|No Intervention|No sweeping|
89313429|NCT03856983|No Intervention|Control group|Control group who will do usual rehabilitation.
89313430|NCT03856983|Experimental|Experimental group|Experimental group who will do usual rehabilitation and visualization of point-light human actions
89313431|NCT03856905|Active Comparator|Physical therapy group|The children in this group will receive the conventional physical therapy program (CPTP). It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neuro-developmental techniques, and gait training. The total program will be conducted for 1 h, three sessions/week for 12 weeks.
89313432|NCT03856905|Experimental|Extra-corporeal shock wave therapy group|The children in this group only will receive the extra-corporeal shock wave therapy (ESWT). An electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG) will be used. The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode, one session/week for 12 weeks. The treatment is painless and does not require any kind of anesthesia or the use of analgesic drugs
89313433|NCT03856905|Experimental|Functional electrical stimulation group|"The children in this group will receive the functional electrical stimulation (FES). The FES will be applied by using the WalkAide system (Innovative Neurotronics, Austin, TX, USA).~The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait."
89313434|NCT03857217||Post-cardiotomy patients|Patients submitted to cardiac surgery
89313435|NCT01587807|Experimental|Cohort 1|single inhaled dose of GSK1995057 (dose 1) or placebo
89313436|NCT01587807|Experimental|Cohort 2|single inhaled dose of GSK1995057 (dose 2) or placebo
89313437|NCT01587807|Experimental|Cohort 3|single inhaled dose of GSK1995057 (dose 3) or placebo
89313438|NCT01587807|Experimental|Cohort 4|single inhaled dose of GSK1995057 (dose 4) or placebo
89313439|NCT01587807|Experimental|Cohort 5|single inhaled dose GSK1995057 (dose 4) with bronchoalveolar lavage (BAL)sampling procedure conducted approximately 30 minutes post GSK1995057 dose
89313440|NCT01587807|Experimental|Cohort 6|high dose of GSK1995057 or placebo followed by an inhaled LPS challenge and BAL sampling procedure.
89313441|NCT01289145|Experimental|Intervention|"Participants will be allocated to a motivational intervention, a volitional intervention or the active control group.~The motivational intervention promotes positive outcome expectancies on physical activity. The volitional intervention promotes the formulation of action plans for physical activity. Participants in the active control group, receive a quiz on physical activity and sports."
89313442|NCT03858543|Experimental|Fractional laser treatment & Poly-L Lactic Acid (Sculptra)|One Fractional laser treatment on half of the body with Sciton Laser and Scluptra
89313443|NCT03858543|Active Comparator|Fractional laser treatment|One Fractional laser treatment on half of the body with Sciton Laser
89313444|NCT01180101|Active Comparator|Lifestyle modification group|This group will undergo supervised exercise training 5 days per week and follow hypocaloric diet for 12 weeks. All exercise training sessions will be supervised by an Exercise Physiologist or Research Nurse, and will be conducted in the Exercise Physiology Laboratory at the CCF CRU. Exercise training will consist of walking, running on a treadmill, and stationary cycling on a cycle ergometer. Each exercise session will include a brief standardized warm-up and cool-down that include a series of stretching exercises.
89313445|NCT01180101|Active Comparator|Bariatric Surgery Group|This group will include CKD patients who undergo bariatric surgery.
89313446|NCT01180101|No Intervention|CKD Group (control)|This group will not undergo any form of weight loss intervention
89313447|NCT03854877|Experimental|Health behaviour intervention|Personalised health behaviour e-health intervention. The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to promote health habits. Based on personal needs participants can choose tasks for physical activity, relaxation, healthy eating, sleep etc. They get regular feedback, tasks and support from their personal trainer via phone and computer.
89313448|NCT03854877|No Intervention|Control group|Only before and after measurements
89313449|NCT03854643|Experimental|Pilates group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
89313450|NCT03854643|Experimental|Control group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
89313451|NCT03854565||Mild ARDS|patients have mild ARDS according to Berlin definition
89313452|NCT03854565||Moderate ARDS|patients have moderate ARDS according to Berlin definition
89313453|NCT03854565||Severe ARDS|patients have severe ARDS according to Berlin definition
89313454|NCT01182753|Experimental|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
89313455|NCT01182753|Active Comparator|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
89313456|NCT01186107|Experimental|Endeavor Resolute stent|zotarolimus-eluting stent
89313457|NCT01186107|Active Comparator|Cypher stent|sirolimus-eluting stent
89313458|NCT01186185|Experimental|Fludrocortisone|
89313459|NCT01186263|Experimental|99mTc- labeled albumin macroaggregates (MAA)|Diagnostic MAA- SPECT- imaging.
89313460|NCT01186263|Experimental|99mTc- labeled albumin microspheres (B20)|Diagnostic B20- SPECT- imaging.
89313461|NCT01180179|Active Comparator|Lansoprazole 30mg once daily|Lansoprazole 30mg once daily
89313462|NCT01180179|Active Comparator|Famotidine 40mg once daily|Famotidine 40mg once daily
89313463|NCT01182831|Active Comparator|percutaneous fluoro guided celiac plexus neurolysis|
89313464|NCT01182831|Active Comparator|EUS guided neurolysis|
89313465|NCT01588275|Active Comparator|MRA therapy|During 12 months patients will be treated with a bibloc MRA (SomnoDent® MAS, SomnoMed Australia/Europe AG). The MRA will be customized by certified dentists or dental-specialists experienced in the field of dental sleep medicine.
89313466|NCT01588275|Active Comparator|CPAP therapy|"During 12 months patients will be treated with Continuous positive airway pressure (CPAP).Treatment with CPAP prevents upper airway collapse by pneumatically splinting the upper airway during sleep."
89313467|NCT01587573||oral lesions|oral lesions suspicious for squamous cell carcinoma with saliva collection prior to clinically driven oral biopsy
89313468|NCT01182987|Active Comparator|Dementia care management|Patients and family caregivers will be offered dementia care management, which includes detailed comprehensive assessment, education, counseling, referrals to community agencies, collaboration with medical providers and frequent telephone follow-up
89313469|NCT01182987|No Intervention|Usual care|Patients and care family care givers will receive usual support and medical care offered by the health plan.
89313470|NCT01289223|Active Comparator|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
89313471|NCT01289223|Experimental|Bendamustine IV|Up to 8 cycles of Bendamustine (120mg/m2 Days 1 and 2, every 21 days (+ 3 days).
89313472|NCT01186497|Experimental|Treatment sequence AEBDC|
89313473|NCT01186497|Experimental|Treatment sequence BACED|
89313474|NCT01186497|Experimental|Treatment sequence CBDAE|
89313475|NCT01186497|Experimental|Treatment sequence DCEBA|
89313476|NCT01186497|Experimental|Treatment sequence EDACB|
89313477|NCT01183299|Active Comparator|High salt intake|
89313478|NCT01183299|Placebo Comparator|Low salt intake|
89313479|NCT03854409|Experimental|Part A - Deltoid Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
89313480|NCT03854409|Experimental|Part A - Gluteal Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
89313481|NCT03854409|Experimental|Part A - Deltoid Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
89313482|NCT03854409|Experimental|Part A - Gluteal Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
89313483|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (X)|Participants will receive a single dose of aripiprazole LAI.
89313484|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (Y)|Participants will receive a single dose of aripiprazole LAI.
89313485|NCT03854409|Experimental|Part B - Gluteal Site: Group 2|Participants will receive a single dose of aripiprazole LAI.
89313486|NCT03854487|Experimental|Mirror therapy|
89313487|NCT03854487|Sham Comparator|Sham mirror|
89313488|NCT03854487|Active Comparator|Covered mirror|
89313489|NCT01186575|Experimental|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
89313490|NCT01186575|No Intervention|Usual Care|Usual care after adult male circumcision (no text messages)
89313491|NCT01291407|Experimental|S-1,peroral BID,capsule|
89313492|NCT01186653|Experimental|Symbicort|Symbicort® (budesonide / formoterol, 400 micrograms/9 micrograms one puff bd, dose as per NICE guidelines
89313493|NCT01186653|Active Comparator|Seretide|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
89313494|NCT01186731|Experimental|Liposome Entrapped Docetaxel (LE-DT)|
89313495|NCT01186887|Placebo Comparator|Celecoxib|
89313496|NCT01186887|Placebo Comparator|Placebo|
89313497|NCT03858309|Experimental|Breathing Group 1|Arm 1 will receive an 8-week intervention that consists of a set of breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
89313498|NCT03858309|Active Comparator|Breathing Group 2|Arm 2 will receive an 8-week intervention that consists of slow breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
89313499|NCT03858699||Individuals with stroke|Participants in sub-acute and chronic phases post-stroke (>1 month post-stroke) will be recruited for participation in this study.
89313500|NCT03858699||Adult control participants|Even age distributions will be recruited in the adult control group, stratified under 40 years old and over 40 years old.
89313501|NCT01180335|Active Comparator|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
89313502|NCT01180335|Experimental|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
89313503|NCT01180413|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment
89313504|NCT03858387||Meropenem|Critically ill patients who require meropenem therapy
89313505|NCT03858387||Imipenem|Critically ill patients who require imipenem therapy
89313506|NCT01289301|Experimental|mTOR-receiving arm|switching from calcineurin-inhibitor-based immunosuppression to mTOR-based immunosuppression
89313507|NCT01289301|Active Comparator|calcineurin-inhibitor keeping arm|continuing calcineurin-inhibitor based immunosuppression
89313508|NCT02524899|Active Comparator|Cognitive Remediation Therapy and placebo|7.5 weeks of twice weekly cognitive remediation sessions
89313509|NCT02524899|Experimental|Guanfacine and CRT|7.5 weeks of twice weekly cognitive remediation sessions with 8 weeks of guanfacine
89313510|NCT02524821|Active Comparator|drugs only, fasted|1 x 850 mg metformin tablet, under fasting conditions.
89313511|NCT02524821|Experimental|Gelesis100 plus drugs, fasted|3 x 0.75 g Gelesis100 capsules, followed 30 minutes later by the administration of 1 x 850 mg metformin tablet, under fasting conditions.
89313512|NCT02524821|Active Comparator|drugs only, fed|1 x 850 mg metformin tablet, followed by the ingestion of a high-fat, high-caloric meal.
89313513|NCT02524821|Active Comparator|Gelesis100 plus drugs, fed|3 x 0.75 g Gelesis100 capsules, followed by the ingestion of a high-fat, high-caloric meal, followed by the administration of 1 x 850 mg metformin tablet (fed conditions).
89313514|NCT01183377||1|Female athlete Triad syndrom was based on menstrual disorder,Eating Disorder and bone loss
89313515|NCT01291485|Experimental|Lifestyle counseling|Intervention includes education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve HIV medication adherence and clinical outcomes.
89313516|NCT01291485|No Intervention|Treatment as Usual|
89313517|NCT01183455|Experimental|Aralast NP|Participants will receive Aralast NP (90mg/kg) intravenously once a week for 12 weeks.
89313518|NCT01183455|Placebo Comparator|Placebo|Participants will receive placebo intravenously once a week for 12 weeks.
89313519|NCT03854175|Active Comparator|Sildenafil group|40 women are give sildenafil citrate 25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle, in addition to oral 2mg of estradiol valerat 6-8 hourly from the day 2-14 of the menstrual cycle
89313520|NCT03854175|Active Comparator|estradiol group|40 women are given oral estradiol valerate tablets 2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium in addition to placebo in the same way as sildenafil
89313521|NCT01183611|Experimental|A1|health neonates born to mother with positive for both HBsAg and e antigen
89313522|NCT01183611|Active Comparator|A2|health neonates born to mother with positive for both HBsAg and e antigen
89313523|NCT01183611|Experimental|B1|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
89313524|NCT01183611|Active Comparator|B2|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
89313525|NCT01183611|Experimental|C1|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
89313526|NCT01183611|Active Comparator|C2|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
89313527|NCT01183611|Placebo Comparator|C3|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
89313528|NCT01187121||Experimental|Those persons randomized to the Decide Your Time program.
89313529|NCT01187121||Standard Pracitice|Those persons randomized to the standard probationary practice condition.
89313530|NCT01180569|Experimental|lenalidomide|Eligible patients for this clinical trial will be treated for 6 cycles with lenalidomide at 15 mg daily by mouth on Days1-21 of 28 day cycle, preceded by an escalating schema for safety (5mg daily for 2 weeks; 10 mg daily for 2 weeks; and 15 mg daily for 2 weeks) and then a one week rest).
89313531|NCT03856281|Experimental|Intervention Group A|LymphAssist IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
89313532|NCT03856281|Experimental|Intervention Group B|Sequential IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
89313533|NCT03856125|Experimental|PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
89313534|NCT03856125|Sham Comparator|Sham PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of sham percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
89313535|NCT02942264|Experimental|Phase I Arm 1 Dose Dense Temozolomide plus Zotiraciclib (TG02)|dose dense (dd) Temozolomide (TMZ) 125 mg/m^2 x 7 days on / 7 days off plus Zotiraciclib (TG02) dose escalation
89313536|NCT02942264|Experimental|Phase I Arm 2 Metronomic Temozolomide Plus Zotiraciclib (TG02)|metronomic Temozolomide (TMZ) 50 mg/ m^2 daily plus Zotiraciclib (TG02) dose escalation
89313537|NCT02942264|Experimental|Phase II Arm 1 Maximum Tolerated Dose (MTD) of Zotiraciclib (TG02) Plus Temozolomide (TMZ)|"Maximum tolerated dose (MTD) of Zotiraciclib (TG02) from phase I plus and winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I"
89313538|NCT02942264|Active Comparator|Phase II Arm 2 Metronomic Temozolomide (TMZ)|"winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I alone"
89313539|NCT03854097|Experimental|Active PAD group|-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
89313540|NCT03854097|Experimental|Placebo PAD group|-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
89313541|NCT03854097|Experimental|Healthy Volunteers|-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
89313542|NCT01313234|Experimental|Education|Educational theory based intervention and systematic daily pain assessment
89313543|NCT01313234|No Intervention|Control|Control group with care as usual
89313544|NCT03855891|Experimental|Study group|A group of patients with blood tests
89313545|NCT03853863|Experimental|minimalist shoes walking group (MSW)|Subjects in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., in-school walking training with minimalist shoes).
89313546|NCT03853863|Active Comparator|traditional shoes walking group (TSW)|Subjects in the TSW group will be given a pair of protective shoes with arch support while following the same wearing pattern as the MSW group (i.e., in-school walking training with protective shoes).
89313547|NCT04203134|Experimental|Treatment Group|Patients in the randomly assigned treatment group will receive a mouthguard at first visit along with standard treatment of BMS.
89313548|NCT04203134|No Intervention|Control Group|Control group will proceed through treatment for BMS in an otherwise standard treatment protocol and will not receive a mouthguard.
89313549|NCT01187277|Experimental|Group A|Group A = conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
89313550|NCT01187277|Active Comparator|Group B|Group B = conventional therapy plus robot-assisted means: 30 min individual physiotherapy plus 20 min robot-assisted gait training and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
89313551|NCT03638414|Experimental|Group 1 - Interventional Treatment|This group will be given the ePainQ questionnaire and an interview.
89313552|NCT03638414|No Intervention|Group 2 - Usual care|This group will be receiving normal routine care without the study intervention
89313553|NCT01183767|Active Comparator|EGCG|Epigallocatechin-Gallate (EGCG)
89313554|NCT01183767|Placebo Comparator|Placebo|
89313555|NCT01290393||Exposed vaccinated cohort|Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.
89313556|NCT01290393||Non-exposed vaccinated cohort|Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.
89313557|NCT03853785|Active Comparator|Intralesional MMR vaccine|Intralesional Mumps, measles and rubella (MMR) vaccine in genital warts
89313558|NCT03853785|Active Comparator|intralesional candida antigen|intralesional candida antigen in genital warts
89313559|NCT03853785|Active Comparator|Topical Podophyllin|Topical Podophyllin in genital warts
89313560|NCT01180803|Experimental|oxygen-saving valves|
89313561|NCT01180803|Active Comparator|continuous oxygen supplementation|
89313562|NCT04094792|Experimental|Intervention|For the intervention group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later). Intervention group subjects will use the Breather app twice daily, five minutes each time, for a period of 21 days.
89313563|NCT04094792|No Intervention|Control|For the control group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later).
89313564|NCT01183845|Experimental|Exam with colon capsule|Colon Capsule Endoscopy
89313565|NCT02524431|Active Comparator|Glaucoma subjects|During glaucoma surgery, collection of trabecular meshwork tissue during surgery that is not needed is cut away from the surgical site. The physician will keep this tissue for analysis by the researchers at Wills Eye Hospital and Thomas Jefferson University Center for Translational Medicine.
89313566|NCT02524431|Active Comparator|Control cadaver eyes|control cadaver eye are ordered and the collection of trabecular meshwork tissue during surgery and is processed at Thomas Jefferson University
89313567|NCT03322514|Experimental|experimental group|10 g of Inulin-Propionate Esters will be administered per day
89313568|NCT03322514|Active Comparator|Inulin|10 g of Inulin will be administered per day
89313569|NCT01184001|Experimental|Sequence 1|
89313570|NCT01184001|Experimental|Sequence 2|
89313571|NCT01290471|Experimental|Part 1 Dose Escalation|Dose escalation of U3 1565 will follow a modified 3+3 study design with a starting intravenous (IV) dose of 2 mg/kg. A maximum of 2 new subjects will receive their first dose of U3-1565 per 24-hour period during the dose-escalation phase. Subsequent escalating doses of 8, 16, and 24 mg/kg are planned. Three to 6 subjects will be enrolled in 4 sequential dose level cohorts.
89313572|NCT01290471|Experimental|Part 2a Dose Expansion|For Part 2a, 6 or 12 subjects with advanced solid malignant tumors will be enrolled and treated at the MTD or MAD to further define the safety and tolerability of U3-1565. These additional subjects are expected to permit the detection of relatively rare toxicities that would not likely be observed during the dose escalation part of the study, whose 3+3 design implies a maximum of 6 subjects only will be treated at the MTD or MAD. Six subjects will be treated; however, if toxicities meeting the definition of DLT are observed during the first cycle of treatment, 6 more subjects will be treated for a total of 12 subjects.
89313573|NCT01290471|Experimental|Part 2b Dose Expansion and Anti-tumor Impact|For Part 2b, up to 30 subjects with advanced solid malignant tumors, with a preference for those with advanced ovarian cancer, will be enrolled and treated at the MTD or MAD. This number of subjects should allow demonstrating U3-1565 has anti-tumor impact by showing treatment-induced changes in pharmacodynamic biomarkers and clinical activity. Ovarian cancer may be more likely to be impacted by U3 1565 than other tumors, considering that in this cancer, high levels of HB-EGF have been associated with an unfavorable clinical outcome. Six subjects will be initially treated; at which point, a safety analysis will be conducted after these initial subjects have completed the first cycle of treatment, to allow the reevaluation of the appropriateness of the dosing level.
89313574|NCT02524587|Active Comparator|acetabular polyethylene vitamys®|acetabular polyethylene vitamys®
89313575|NCT02524587|Active Comparator|standard polyethylene acetabular irradiated at 3 Mrad|standard polyethylene acetabular irradiated at 3 Mrad
89313576|NCT01291563|Experimental|001|TMC207 8 tablets of TMC207 (100 mg/tablet) on Day 1
89313577|NCT01291563|Placebo Comparator|002|TMC207 placebo 8 tablets of TMC207 placebo on Day 1
89313578|NCT01291563|Active Comparator|003|Moxifloxacin 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
89313579|NCT01291563|Placebo Comparator|004|Moxifloxacin placebo 1 capsule of moxifloxacin placebo on Day 2
89313580|NCT01187589|Experimental|Pulsehaler|Fully operational Pulsehaler, with protocol enabled
89313581|NCT01187589|Active Comparator|Nebulizer|Deactivated Pulsehaler (protocol disabled), so only the nebulizer is active
89313582|NCT03853161|Experimental|Vapotherm arm|Preterm infants in this arm will be given respiratory support of heated humidified high flow via Precision Flow Vapotherm, Exeter, USA
89313583|NCT03853161|Experimental|NIPPV arm|Preterm infants in this arm will be given respiratory support of Nasal Intermittent Positive Pressure Ventilation via the Leoni Plus neonatal ventilator
89313584|NCT01187979|Active Comparator|Control|All eligibly enrolled learners in the intervention schools will receive a prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education. No cash incentives will be paid for meeting milestones
89313585|NCT01187979|Experimental|Cash incentive|All eligibly enrolled learners in the intervention schools will receive a cash incentivised prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education
89313586|NCT01184157|Experimental|Home|Home-based STI screening using self-obtained vaginal swabs and postal return of samples.
89313587|NCT01184157|Active Comparator|Clinic|Receive STI screening in a clinical setting such as a private physician or clinic.
89313588|NCT02524353|Experimental|cardiac surgery|cardiac surgery
89313589|NCT01290549|Experimental|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by an IV infusion of escalating doses (starting dose of 0.1 mg/kg, potentially to be followed by 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, and 4.0 mg/kg doses) every 3 weeks (q3w) (Day 1 of each 21 day cycle).
89313590|NCT01290549|Experimental|Polatuzumab Vedotin + Rituximab|Polatuzumab vedotin will be administered by an IV infusion q3w (Day 1 of each 21 day cycle). Rituximab was administered by an IV infusion at 375 milligrams per square meter (mg/m^2) body surface area dose q3w.
89313591|NCT04966377|Experimental|Intervention Group|Intervention Group First, pre-tests were applied to the women in the experimental group. A 4-week training program created by taking into account the cultural characteristics of Syrian women; Explaining breast health, Explaining breast structure, Cancer, Breast cancer, Early diagnosis and its importance, BSE application, CBE and mammography, Barriers on breast cancer, Cancer Early Diagnosis, Screening and Education Center. A 'Nurse-directed screening counseling telephone support line' will be established for the women in the experimental group. Then, motivational interviews will be applied to the women in the experimental group by the researcher, who emphasizes the importance of early diagnosis in line with the health belief model. Reminders will be made by phone every week in the 3rd month. The final tests will be held 4 months after the end of the training.
89313592|NCT04966377|No Intervention|Control Group|Pre-tests will be applied to the women in the control group. No intervention will be applied to the women in this group and post-tests will be performed 4 months after the pre-test.
89313593|NCT01184235||Autism Spectrum Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Autism Spectrum Disorder
89313594|NCT01184235||Attention Deficit Hyperactivity Disorder|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Attention Deficit Hyperactivity Disorder.
89313595|NCT01184235||Unaffected 1st Degree Relatives|This group will include unaffected, non treated first degree relatives of this study's subjects receiving or anticipating receiving pharmacological intervention.
89313596|NCT01184235||Mood Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is mood disorder.
89313597|NCT03853239|Active Comparator|face mask crossover nasal ventilation|
89313598|NCT03853239|Active Comparator|nasal ventilation crossover face mask|
89313599|NCT03852849|No Intervention|routine care group|Medical institutions will provide patients routine care according to the national program standard.
89313600|NCT03852849|Experimental|medicine intervention group|The dosage of 400 mg EFV will be used in the antiviral therapy.
89313601|NCT03852849|Experimental|consolidated intervention group|Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.
89313602|NCT03853005|Placebo Comparator|Group A (controlled group)|They will not receive HVHDF treatment
89313603|NCT03853005|Active Comparator|Group B (HVHDF group)|They will receive HVHDF treatment for at least 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 35-50 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours. The survival status of all of the subjects were followed up at 28 days after being diagnosed as severe sepsis.
89313604|NCT01184313||aortic valve surgery|
89313605|NCT04927221|Experimental|DC371739 20mg Dose MAD|Orally administered DC371739 tablets QD afer meal
89313606|NCT04927221|Placebo Comparator|DC371739 Placebo MAD|Placebo orally administered
89313607|NCT01187667||Haloperidol prevention group|ICU patients with a high risk for delirium who are treated with haloperidol for preventive reason.
89313608|NCT01187667||Control group|Historical cohort group of patients (2008-2009)with a determined risk of 50% or more for delirium who were not treated with haloperidol for preventive reason.
89313609|NCT01184391|Experimental|Test: Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
89313610|NCT01184391|Active Comparator|Reference: Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
89313611|NCT03853083|Experimental|Hypoxi Equipment|
88806502|NCT01794416|Active Comparator|Thoracoscopic epicardial ablation|"Patients were treated with video-assisted thoracoscopy under general anesthesia. PVI was performed from the epicardial side with a bipolar RF ablation clamp (AtriCure). At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. An additional application was made in the interatrial Waterston groove in the right side to isolate the ganglionic plexi from the atria. On the left side, the ligament of Marshal was cut, but no additional ablation of ganglionic plexi was pursued.~The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
88810986|NCT04825132|Experimental|Bacteremia and/or acute respiratory infection|Hospitalized in a study center (emergency department, infectious disease, internal medicine or geriatric hospital wards…) for with bacteraemia and/or acute respiratory infection
89313612|NCT03853083|Active Comparator|Recumbent Bicycle|
89313613|NCT02524743|Placebo Comparator|Placebo (Group I)|"For pretreatment the patients were administered IV 5ml normal saline.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
89313614|NCT02524743|Active Comparator|Group II|"For pretreatment the patients were administered IV acetaminophen 50 mg~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
89313615|NCT02524743|Active Comparator|Group III|"For pretreatment the patients were administered IV acetaminophen 25 mg.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
89313616|NCT02524743|Active Comparator|Group IV|"For pretreatment the patients were administered IV lidocaine 20 mg~The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
89313617|NCT02524743|Active Comparator|Group V|"For pretreatment the patients were administered IV lidocaine 40 mg.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
89313618|NCT01188057|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
89313619|NCT01188057|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
89313620|NCT01291641|Placebo Comparator|Group A|HMGCoA reductase inhibitor continued
89313621|NCT01291641|Active Comparator|Group B|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID
89313622|NCT01291641|Active Comparator|Group C|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID + Cilostazol 100 mg PO, BID
89313623|NCT03855501|Active Comparator|Mineral trioxide aggregate|The root canals were gently instrumented with K-files and copious irrigation was done with 2.5% sodium hypochlorite(NaOCI) by means of a 30 gauge endodontic irrigating needle . After drying with large sterile paper points, calcium hydroxide(CH) paste was mixed with saline and applied to the root canal with a lentulo spiral filler at low speed. A cotton pellet was used to gently compress CH into the root canal and its placement was examined radiographically before placing ZOE as temporary restoration into the access cavity. After one week, CH was removed from the canal by using both the files and the irrigation with 2.5% NaOCI and 17% ethylenediaminetetraacetic acid (EDTA). A final irrigation was made with 2% chlorhexidine (CHX) before obturation. Following drying the root canal with sterile paper points, MTA was placed with a MTA Endo Gun into the apical portion of canals with a minimum 4-mm thickness and adapted to the canal walls with an endodontic hand plugger.
89313624|NCT03855501|Active Comparator|Calcium hydroxide|After using the same biomechanical root canal preparation protocol, the root canal was filled to working length with CH paste. Both clinical and radiographical examinations were performed to evaluate the barrier formation and periapical healing. When a continuous hard tissue barrier was observed apically on radiographs that was verified by clinical probing and complete or significant periapical healing was noticed, the root canal was obturated and coronary restorations were completed as done in MTA group
89313625|NCT03853629||CF|"Age 1-17~Diagnosis of Cystic Fibrosis~Living in or around London"
89313626|NCT03853629||Controls|"Age 1-17~Healthy~Living in or around London"
89313627|NCT01188135|Experimental|Interactive Voice messaging|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed"
89313628|NCT01188135|No Intervention|Usual care arm|usual care treatment with no interactive phone reminder calls phone
89313629|NCT01188135|Experimental|IVR messaging w/ Psycho-ed. materials|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed. In addition, participants will receive educational material about antidepressant medication."
89313630|NCT03852771|Experimental|Treatment|All participants will receive the intervention
89313631|NCT02334345|Experimental|EVOSKIN|Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
89313632|NCT02334345|Active Comparator|TRIXIERA|Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
89313633|NCT01588587||DPP-IV inhibitors|
89313634|NCT01187745||suspect kidney stones|Patients presenting with flank abdominal pain
89313635|NCT04930029||OAGB150|One anastomosis gastric bypass with 150cm biliary limb
89313636|NCT04930029||OAGB200|One anastomosis gastric bypass with 200cm biliary limb
89313637|NCT01187823|Active Comparator|Nocturnal oxygen therapy|
89313638|NCT01187823|Active Comparator|Adaptive servo ventilation|Bipap® auto SV Advanced
89313639|NCT03325712|Experimental|Dose group 1: BI 705564 10 mg|
89313640|NCT03325712|Experimental|Dose group 2: BI 705564 20 mg|
89313641|NCT03325712|Experimental|Dose group 3: BI 705564 40 mg|
89313642|NCT03325712|Experimental|Dose group 5: BI 705564 60 mg|
89313643|NCT03325712|Experimental|Dose group 4: BI 705564 80 mg|
89313644|NCT03325712|Placebo Comparator|Placebo matching BI 705564|
89313645|NCT03325712|Experimental|Dose group 8: BI 705564 40 mg - SPT|SPT stands for skin prick test.
89313646|NCT03325712|Placebo Comparator|Placebo matching BI 705564 - SPT|SPT stands for skin prick test.
89313647|NCT03847779|Experimental|Non-neuropathy|"Type 2 diabetic without neuropathy:~Negative findings on Semmes-Weinstein monofilament~Neuropathy symptom score (NSS) <3~Negative findings on Nerve Check and Diabetic Peripheral Neuropathy check.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~pedometer during 4 days~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
89313648|NCT03847779|Experimental|Neuropathy|"Type 2 diabetic with neuropathy~Positive findings on Semmes-Weinstein monofilament~Neuropathy symptom score (NSS) >3~Positive findings on Nerve Check and Diabetic Peripheral Neuropathy check.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~pedometer during 4 days~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
89313649|NCT03847779|Experimental|Controls|"matched for age, sexe and BMI with diabetic patients.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
89313650|NCT03848013|Active Comparator|Treatment|Treatment of cases of melasma using Q switched Nd YAG laser and Fractional CO2 laser separately and in combination
89313651|NCT03848013|No Intervention|Follow -up period|follow up of the treated cases for 2 months
89313652|NCT01293747|Experimental|Estradiol 0.5 mg/Progesterone 15 mg microspheres|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension
89313653|NCT01293747|Experimental|Estradiol 1 mg/Progesterone 20 mg microspheres|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension
89313654|NCT01193829||NSCLC patients|
89313655|NCT04615442|Experimental|All subjects|Subjects that undergo a clinical video EEG are asked to additionally wear a wearable EEG headband for up to 2 periods of 4h during the video EEG.
89313656|NCT03849729|Active Comparator|Phentermine|Low-calorie diet + Phentermine Capsules 15 mg po by 6 weeks, one time a day before bariatric surgery.
89313657|NCT03849729|Placebo Comparator|Placebo|Low-calorie diet + Placebo Capsules po by 6 weeks, one time a day before bariatric surgery.
89313658|NCT01193985|Experimental|Intervention|
89313659|NCT01194063|Experimental|Omegaven|Administration of intravenous Omega-3 fish oil lipid emulsion 1 g/kg continuous infusion over 12-24 hrs
89313660|NCT05282979|Experimental|Tixel 2|Tixel 2 Treatment, 4 treatment sessions, followed by 2 Follow up sessions, 1 and 3 months after last treatment visit. Subject would be questioned about pain level, subjective downtime assessment and subjective response assessment. Images would be taken at the baseline and in Follow up visits.
89313661|NCT03325556|Placebo Comparator|Placebo|
89313662|NCT03325556|Experimental|Drug - Pimavanserin|
89313663|NCT01191177|Experimental|Lovaza group|Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day
89313664|NCT01191177|Placebo Comparator|Placebo group|Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day
89313665|NCT03847935||Surgery|Patients who underwent surgical release of A1 pulley
89313666|NCT03847935||corticosteroid injections only|Patients who underwent local corticosteroid injections only, and no other treatment
89313667|NCT03847935||hand therapy only occupational/physical|1 visit: orthosis fabrication, range of motion, nodule and ice massage.
89313668|NCT03847935||Injection and Hand therapy|This group of participants received a combination of corticosteroid injection in the affected finger and one visit of hand therapy.
89313669|NCT03847935||Modality Hand Therapy|Ongoing hand therapy treatment, which included the above plus modalities such as ultrasound or iontophoresis.
89313670|NCT03847935||Injection and Modality Hand Therapy|Ccombination of local cortiscosteroid injection to the affected digit and ongoing hand therapy with modalities.
89313671|NCT01194141|Experimental|Exercise training|Aerobic exercise training 45-60 min/3x/week/12 weeks
89313672|NCT01188213|Experimental|Purified MSM|
89313673|NCT01293903|Experimental|Qiliqiangxin capsule|
89313674|NCT01293903|Placebo Comparator|Placebo|
89313675|NCT03320564|Experimental|Infiltration|Repeat F-18 FDG PET
89313676|NCT03852303|Active Comparator|ivermectin once a year|Ivermectin one dose per year and anti-epileptic treatment
89313677|NCT03852303|Experimental|ivermectin 2 times a year|Ivermectin one dose 2 times a year and anti-epileptic treatment
89313678|NCT03852303|Experimental|ivermectin 3 times a year|vermectin one dose 3 times a year and anti-epileptic treatment
89313679|NCT01293981||Lumbar Degenerative Disc Disease|
89313680|NCT03638180|Experimental|Single Ascending Doses|Single ascending doses, 6 dose levels
89313681|NCT03638180|Experimental|Multiple Ascending Doses|Multiple ascending doses, 3 dose levels
89313682|NCT01296321|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
89313683|NCT01296321|Active Comparator|Waitlist|Waitlist.
89313684|NCT03325166|Experimental|Treatment (pembrolizumab, ferumoxytol MRI)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (or up to 32 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI at baseline, 12 weeks after radiation, at suspected radiographic progression, and 6 weeks after suspected radiographic progression.
89313685|NCT03847623|Experimental|Curcumin|Capsules, taken orally, 8g per day (Bi-daily dosing)
89313686|NCT03847623|Placebo Comparator|Placebo|Capsules, taken orally, bi-daily dosing
89313687|NCT01294059|Placebo Comparator|Sugar pill|One sugar pill twice daily over 6 weeks
89313688|NCT01294059|Active Comparator|Milnacipran|Milnacipran 50 mg bid over 6 weeks
89313689|NCT01291797||Neonates with congenital heart disease|The case group will consist of newborns born between 32 and 41 weeks gestation diagnosed with a congenital cardiac anomaly requiring surgical repair during their hospitalization and managed in the Mount Sinai Neonatal Intensive Care Unit. The control arm will include newborns born between 32 and 41 weeks without congenital cardiac anomalies. Both groups will undergo a neurological screening assessment and receive an AEEG to look at sleep wake cycles.
89313690|NCT01188291||Sleep Apnea / Hypopnea syndrome|Study group composed of patients with Obstructive Sleep Apnea / Hypopnea syndrome
89313691|NCT01294137|Active Comparator|ventilatory polygraphy|
89313692|NCT01291875|Experimental|Intensive periodontal treatment|
89313693|NCT01291875|Active Comparator|Supragingival biofilm control|
89313694|NCT01296399||Bare metal stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary bare metal stent, for de-novo stenosis
89313695|NCT01296399||Drug eluting stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary drug eluting stent, for de-novo stenosis
89313696|NCT03847155|Experimental|Nicotine|The patients randomized into this study arm will receive a medical intervention - nicotine patch for the period of a maximum of 7 days.
89313697|NCT03847155|Placebo Comparator|Placebo|The patients randomized into this study arm will receive a placebo patch for the period of a maximum of 7 days.
89313698|NCT01296477||Asthma IQ Primary Care Tool|
89313699|NCT01296477||Usual Asthma Care in Primary Care|
89313700|NCT01294215|Experimental|Arm 1|
89313701|NCT03849495|Experimental|Group A|"Period 1: D745~Period 2: CKD-370"
89313702|NCT03849495|Experimental|Group B|"Period 1: CKD-370~Period 2: D745"
89313703|NCT01296555|Experimental|Phase I, Stage 1: GDC-0032 as Single Agent|Participants with locally advanced or metastatic solid tumors will receive increasing doses of GDC-0032 administered orally daily in 28-day cycles. Dose escalation decisions will be based upon the observed incidence of DLTs.
89313704|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Fulvestrant|Participants (Cohorts F, J, K, L, and M) will receive GDC-0032 in combination with fulvestrant until disease progression.
89313705|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Letrozole|Participants (Cohorts E, N, P, Q, R, and S) will receive GDC-0032 in combination with letrozole until disease progression.
89313706|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 as Single Agent|Participants (Cohorts A, B, C, D, G, H, T, T2, and X) will receive GDC-0032 until disease progression.
89313707|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Midazolam|Participants (Cohort C) will receive GDC-0032 in combination with midazolam.
89313708|NCT01296555|Experimental|Phase II: GDC-0032 + Fulvestrant|Post-menopausal females with locally advanced or metastatic HER2-negative, hormone receptor-positive breast cancer will receive GDC-0032 in combination with fulvestrant until disease progression.
89313709|NCT01296633|Experimental|Medtable|The Medtable is a patient education tool used for collaborative planning. The Medtable focuses patients on how to take their medication and prompts them to anchor this task to familiar routines. The tool serves as an external workspace that helps provider and patient jointly visualize how to integrate constraints from medications (e.g., which can be taken together; dose spacing) and patients' routine (e.g., typical meal times) in order to create an optimal daily schedule. The completed Medtable shows providers how patients are thinking about taking their medications, allowing them to clear up any confusion. It encourages teach-back and teach-to-goal strategies recommended for patients with low health literacy. Completing the Medtable helps patients implement as well as create plans by encouraging them to think about when and where they will actually take their medication. It also provides a template developed with their providers that could help patients load pill organizers at home.
89313710|NCT01296633|Active Comparator|Usual care|Patients in the usual care condition at both research sites will receive the medication counseling and communication that is standard of care at these sites. This includes a medication reconciliation process, where patients are given a card with list of medications that is periodically checked. This provides an opportunity for providers to correct patient knowledge of their medications, and is similar to the process of creating a list for the Medtable. However, the Medtable also encourages patients and providers to collaborate in order to organize this list in terms of the patient's routine to create a patient-specific, concrete plan for taking the medications.
89313711|NCT01294293|Experimental|Treatment (TLR8 agonist VTX-2337, PLD, and Paclitaxel)|Patients receive TLR8 agonist VTX-2337 SC on days 3, 10, and 17 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 or TLR8 agonist VTX-2337 SC on days 1, 8, and 15 and paclitaxel IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89313712|NCT01294527|Experimental|Implant|Implant of the WiCS-LV system
89313713|NCT01194609|Experimental|Low dose radiation, Immune cell therapy|Combination treatment of low-dose radiation 20cGy every 3 weeks three times and autologous immune cell therapy 2 consecutive weeks 3 times every 3 weeks
89313714|NCT01296789|Active Comparator|Tissue perfusion guided protocol|Active comparator group, where parameters of tissue perfusion are used to guide hemodynamic therapy
89313715|NCT01296789|Other|Usual Care|Usual Care
89313716|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in high risk patients|
89313717|NCT01191489|Active Comparator|Non-invasive mechanical ventilation in High Risk Patients|
89313718|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in Low Risk Patients|
89313719|NCT01191489|Active Comparator|Conventional Oxygen Therapy in Low Risk Patients|
89313720|NCT03847077|Experimental|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application
89313721|NCT03847077|Active Comparator|Standard counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
89313722|NCT01294605|Experimental|Group A|
89313723|NCT01294605|Experimental|Group B|
89313724|NCT01294605|Active Comparator|Group C|
89313725|NCT01296945|Active Comparator|Kiosk|
89313726|NCT01296945|Active Comparator|Paper|
89313727|NCT01296945|Active Comparator|Kiosk PLUS paper|
89313728|NCT01296945|Active Comparator|kiosk PLUS web|
89313729|NCT03849339|Experimental|Group 1|"Period 1: D635~Period 2: CKD-387"
89313730|NCT03849339|Experimental|Group 2|"Period 1: CKD-387~Period 2: D635"
89313731|NCT03852225||OHCA patients|Patients resuscitated for out-of-hospital cardiac arrest of non-traumatic origin and investigated by intra-arrest echocardiography.
89313732|NCT02888756|Experimental|iHIVARNA-01|Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
89313733|NCT02888756|Active Comparator|TriMix|Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
89313734|NCT02888756|Placebo Comparator|Placebo|Water for injection 3 vaccinations, two weeks interval
89313735|NCT01294761|Experimental|Raltegravir, Darunavir/r|"An arm to change the regimen from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD~to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID"
89313736|NCT01294761|No Intervention|Tenofovir, Emtricitabine, Lopinavir/r|An arm continuing on the same regimen before the randomization as Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
89313737|NCT03849183|Experimental|Nitroglycerin|Nitroglycerin 5mcg/kg (0.5cc) is subcutaneously injected before radial artery cannulation.
89313738|NCT03849183|Active Comparator|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation.
89313739|NCT01294839|Experimental|RVOTs|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVOTs arm, the RV lead of this group patients will be implanted in right ventricular outflow tract septum,the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
89313740|NCT01294839|Experimental|AAI|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in AAI arm, the RV lead of this group patients will be implanted in right ventricular apex.
89313741|NCT01294839|Active Comparator|RVA|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVA arm, the RV lead of this group patients will be implanted in right ventricular apex, the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
89313742|NCT01194765|Experimental|Cognitive Behavioural Therapy|
89313743|NCT01194765|No Intervention|Waiting List|
89313744|NCT03305666|Active Comparator|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
89313745|NCT03305666|Active Comparator|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).
89313746|NCT01194843|Experimental|Ropivacaine|Ropivacaine administration by local per and post surgery infiltration
89313747|NCT01194843|Active Comparator|Physiological serum|Administration of physiological serum by local per and post surgery infiltration
89313748|NCT01294995|Experimental|Tea-flavor Liquor, taken with meal|including 12 males and 11 females
89313749|NCT01294995|Placebo Comparator|Guizhou Meijiao Liquor, taken with meal|including 11 males and 11 females
89313750|NCT04837976||Individuals with Parkinson's Disease|
89313751|NCT04837976||Supportive individuals|For example carers, family members or any other individual providing regular support or care to the person with Parkinson's.
89313752|NCT04837976||Healthcare Professionals|
89313753|NCT01297023|Experimental|calcium phosphate|
89313754|NCT01297023|Experimental|vitamin d|
89313755|NCT01297023|Experimental|calcium phosphate and vitamin d|
89313756|NCT01297023|Placebo Comparator|placebo|
89313757|NCT03846843|Experimental|OCR-002 - Treatment A|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions
88806503|NCT01794416|Active Comparator|Endocardial catheter ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster). The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
89313758|NCT03846843|Experimental|OCR-002 - Treatment B|A single 5 g oral dose of OCR-002 oral solution administered under fed conditions
89313759|NCT03846843|Experimental|OCR-002 - Treatment C|A single 5 g intravenous dose of OCR-002 solution infused over 1 hour under fasting conditions
89313760|NCT03846843|Experimental|OCR-002 - Treatment D|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions following discontinuation of lactulose
89313761|NCT03846843|Experimental|OCR-002 - Treatment E|6 g OCR-002 per day (2 tablets TID for 6 g total daily dose)
88806504|NCT05370768|Experimental|Parenting Mindfully (PM) Intervention|PM is an group based 8 week mindfulness intervention for parents.
88806505|NCT05370768|Active Comparator|Parent Education (PE) Intervention|PE is a group based 8 week educational intervention for parents that teaches parents about adolescent development.
88806506|NCT00573378|Experimental|PEG-IFN-a2b|
88806507|NCT05334654|Active Comparator|Enoxaparin sodium|Enoxaparin sodium twice daily, according to the renal function and clinical indication
89313762|NCT03846843|Experimental|OCR-002 - Treatment F|12 g OCR-002 per day (4 tablets TID for 12 g total daily dose)
89313763|NCT03846843|Experimental|OCR-002 - Treatment G|21 g OCR-002 per day (7 tablets TID for 21 g total daily dose)
89313764|NCT04781426||HIV-negative MSM/TG|Oral pre-exposure prophylaxis (PrEP) will be offered to HIV negative MSM, TG identified to be at substantial risk for HIV infection and those motivated to take daily PrEP.
89313765|NCT03620630|No Intervention|Usual Care|Patients allocated to usual care will continue with their current NHS management in line with national and local guidelines.
89313766|NCT03620630|Active Comparator|myCOPD|Patients allocated to the myCOPD arm will receive access to a web based application called myCOPD
89313767|NCT03846921||Viral infection|Patients with proven viral infections will have laboratory blood test taken
89313768|NCT03846921||Bacterial Infection|Patients with proven bacterial infections will have laboratory blood test taken
89313769|NCT01292031|Experimental|Colistin|Colistin 4.5 MU/iv.plus Colistin 3 MU/iv./8 h. 30 minutes infusion
88806508|NCT05334654|Experimental|Bivalirudin|Bivalirudin will be administered by continuous infusion, until day 7. Bivalirudin will be administered at dosage of 0,25 mg/kg in first 30 minutes, followed by continuous infusion of 0,2 mg/kg/h until 7 days. The infusion rate will be adjusted targeting a prothrombin time ratio of about 1.5.
88806509|NCT03561584|Active Comparator|Active Drug (Sulfasalazine)|
88806510|NCT03561584|Placebo Comparator|Placebo|
88806511|NCT00369512|Experimental|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
89313770|NCT01292031|Active Comparator|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
89313771|NCT04633226|Experimental|V114|Participants receive 4 total doses of V114, administered at ~2, 4, 6, and 12-15 months of age.
89313772|NCT03849027|Experimental|Methoxyflurane|"Inhaled methoxyflurane once-off dose of 3 ml will be administered via the inhaler at each dosing visit .~Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®)."
89313773|NCT03849027|Sham Comparator|Sham Methoxyflurane|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test
89313774|NCT03849261|Experimental|Group 1|"Period 1: D635~Period 2: CKD-387"
89313775|NCT03849261|Experimental|Group 2|"Period 1: CKD-387~Period 2: D635"
89313776|NCT01191567|Active Comparator|Conventional treatment|
89313777|NCT01191567|Experimental|VAC treatment|
89313778|NCT01188759|Experimental|Voriconazole and Anidulafungin Combination|Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.
89313779|NCT01188759|Active Comparator|Voriconazole Monotherapy|Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.
89313780|NCT01295073|Active Comparator|A|Oral Trientine 1500mg x 1 week before cataract surgery and 3 days post surgery
89313781|NCT01295073|Placebo Comparator|B|Oral Placebo x 1 week before cataract surgery and 3 days post surgery
89313782|NCT05671185|Experimental|conventional rTMS|"target: left DLPFC~protocol: 10Hz for 4 seconds, 120% motor threshold, 75 trains with 26-second interval, 3000 pulses per session, one session per day, five sessions per week, two weeks in total"
89313783|NCT05671185|Experimental|iTBS|"target: left DLPFC~protocol: 3 pulses at 50Hz, 90% motor threshold, repeated at 5Hz, 60 trains of 10 bursts with 8-second intervals, 1800 pulses per session, one session per day, five sessions per week, two weeks in total"
89313784|NCT05671185|Sham Comparator|sham rTMS|"target: left DLPFC~sham probe, the same protocol as active conventional rTMS"
89313785|NCT05671185|Sham Comparator|sham iTBS|"target: left DLPFC~sham probe, the same protocol as active iTBS"
89313786|NCT03304184|Placebo Comparator|Photac-fil|Participants will have a restoration placed with photac-fil in the lesion near the gum line.
89313787|NCT03304184|Experimental|Biodentine|Participants will have a restoration placed with Biodentine in the lesion near the gum line.
89313788|NCT01195077|Experimental|Seaweed, Spirulina, Seaweed + Spirulina|"Randomized to:~Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day."
89313789|NCT01195155|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
89313790|NCT01195155|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
89313791|NCT01195155|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
89313792|NCT01292109||PICOPREP®|
89313793|NCT03848637|Experimental|Group 1|"Period 1: D387 (reference drug)~Period 2: CKD-387 (test drug)"
89313794|NCT03848637|Experimental|Group 2|"Period 1: CKD-387 (test drug)~Period 2: D387 (reference drug)"
89313795|NCT03851913|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
89313796|NCT03851913|No Intervention|control group|no neo-adjuvant treatment before operation
89313797|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy|
89313798|NCT01188837|Active Comparator|Full Kinetic Chain Rehabilitation|
89313799|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy with Rehabilitation|
89313800|NCT05601921|Experimental|Active stimulation group|Patients in the real stimulation group will receive rTMS treatment to the motor cortex (M1) of the affected hemisphere at a frequency of 5 Hz, once a day for 3 weeks and a total of 15 sessions. The application will be performed with Neurosoft-Neuro MS / D device. Before each session, the patient's resting motor threshold (RMT) value will be determined. RMT will be detected by obtaining a motor evoked potential of >50 μV amplitude on electromyography recording of the contralateral first dorsal interosseous muscle in at least five out of 10 stimulations to the primary motor cortex.The stimulus intensity to be used in the treatment will be set as 90% of the motor threshold for the affected motor cortex and 100% of the motor threshold for the unaffected motor cortex.One session of stimulation will last for a total of 20 minutes and a total of 1000 pulses in the form of 5 Hz stimulation.
89313801|NCT05601921|Sham Comparator|Sham stimulation group|Fifteen sessions of sham repetitive transcranial magnetic stimulation (rTMS) treatment will be applied to the lesional primary motor cortex. The application will be performed with Neurosoft-Neuro MS / D device. The probe of the device will be held perpendicular to the motor cortex and operated from the lowest operating power of 1, so that the device makes the same sounds as the active application.
89313802|NCT01191645|Experimental|Primperan|
89313803|NCT01191645|Active Comparator|Naloxon|
89313804|NCT01191645|Placebo Comparator|Natriumklorid|
89313805|NCT01191645|Experimental|Ultiva|
89313806|NCT01195233|Other|bioxtra spray and mouth rinse|Drug: BioXtra spray or mouth rinse Patients had been xerostomia due to radiation of head and neck were selected for the study. Gender, age, medical history, VAS, dichotomous questionnaire of xerostomia , and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received BioXtra spray and second group used BioXtra mouth rinse for 2 weeks and then 1 weeks wash -out period and for other 2 weeks drugs is switched . Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and 35 days after first visit.
89313807|NCT01188915|Experimental|intensive screening|annual breast cancer detection based on mammography, echography and RMI.
89313808|NCT03736785|Experimental|LY3209590 Algorithm 1|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous (SC) injection. Dose titration was done to maintain fasting blood glucose of <140 milligram per deciliter (mg/dL).
89313809|NCT03736785|Experimental|LY3209590 Algorithm 2|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous injection. Dose titration was done to maintain fasting blood glucose of <120 mg/dL.
89313810|NCT03736785|Active Comparator|Insulin Degludec|Participants received same dose of Degludec as the total basal insulin dose already administered prior to randomization. Dose was titrated to maintain fasting blood glucose of ≤100 mg/dL to achieve glycemic goal of HbA1C <7%.
89313811|NCT03734991|Experimental|Ibrexafungerp (SCY-078)|300 mg orally every 12 hrs for 1 day (2 doses in 1 day)
89313812|NCT03734991|Placebo Comparator|Placebo|Matching Placebo
89313813|NCT01295151|Experimental|TNF-blocking drug|
89313814|NCT01295151|Experimental|Abatacept|
89313815|NCT01295151|Active Comparator|Rituximab|
89313816|NCT01295229|Active Comparator|Lifestyle Intervention|
89313817|NCT01295229|Active Comparator|Surgery|
89313818|NCT01295307|Experimental|Single Arm|Induction therapy with clofarabine/cytarabine. Post-remission therapy with either allogeneic HCT after conditioning with clofarabine/melphalan if a donor is available, or clofarabine/cytarabine if no donor is available
89313819|NCT01188993|Active Comparator|septic shock TPT then TEE|Group 1: Each patient will be assessed by both the transpulmonary thermodilution technique and transesophageal echocardiography (TEE)..
89313820|NCT01188993|Active Comparator|septic shock TEE then TPT|Goup 2: Each patient will be assessed by both transesophageal echocardiography (TEE) and the transpulmonary thermodilution technique.
89313821|NCT01195311|Experimental|INCB024360|
89313822|NCT01191879||acute MI group|Patients presenting with acute ST elevation myocardial infarction, admitted to the intensive cardiac care unit and that are planned for emergency primary PCI
89313823|NCT01191879||Controls|Patients undergoing a non-invasive evaluation of possible myocardial ischemia.
89313824|NCT03852069|Placebo Comparator|Placebo|16 g maltodextrin/day + recipes based on vegetables poor in inulin-type fructans
89313825|NCT03852069|Experimental|Inulin|16 g inulin/day + recipes based on vegetables rich in inulin-type fructans
89313826|NCT01192113|Experimental|Group A: Diabetic Peripheral Neuropathy (IV)|
89313827|NCT01192113|Experimental|Group B: Diabetic Peripheral Neuropathy (IM)|
89313828|NCT01192113|Experimental|Group C: Idiopathic Peripheral Neuropathy|
89313829|NCT01192113|Experimental|Group D: Nutritional & Metabolic Peripheral Neuropathy|
89313830|NCT01192113|Experimental|Group E: Compression Peripheral Neuropathy|
89313831|NCT01195389|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
89313832|NCT01195389|Placebo Comparator|Placebo treatment|
89313833|NCT01292499|No Intervention|Pharmacological treatment|Pharmacological treatment consists of the administration of a single antidepressant drug. The treatment will be administered as currently done by the mental health center, taking into due account patient's age, general health, previous response to antidepressant drugs, comorbidity, and potential side effects of drugs.
89313834|NCT01292499|Experimental|Psychotherapy|Will receive psychotherapy as well (10 sessions). Psychoterapy will consist of 10 weekly sessions, lasting about 50 minutes each. Psychotherapy will begin after 4-6 weeks from the beginning of the pharmacological treatment, to allow drugs to be effective. The overall list of visits scheduled for the patients is defined during the second psychiatric visit, to allow a reasonable planning of all of the appointments required for that particular patient. Psychotherapists will be free to follow the approach they were trained.
89313835|NCT01292499|Experimental|Psychoeducation|Will receive psychoeducation as well, with phone monitoring and regular follow-ups. Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect. In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive. Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months. In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.
89313836|NCT01292499|Experimental|Psychoeducation and psychotherapy|Will receive both psychoeducation and psychotherapy sessions.
89313837|NCT01192269|Experimental|Docosahexaenoic Acid Supplement|"DHA supplement: Experimental~1 x 950 mg capsules per day orally, each capsule providing ~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric)."
89313838|NCT03303092|Experimental|TEV-48125 (225/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).
89313839|NCT03303092|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
89313840|NCT03303092|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
89313841|NCT05283291|Experimental|İmaginary group|"Expert opinion for the scenario will be taken from a psychologist and a psychiatric nurse.~The flow of the script; It will start with breathing exercises and continue with the safe place application, after affirming the functionality that is said while in a safe place in the mind, it will be in the form of waking up by turning to the body and returning to the present.~Headphones will be provided for each patient by the researcher. In the first meeting, the voice recordings will be transferred to the phones of the individuals via the phone in the Neurosurgery Service. Communication with the patient will be provided in accordance with the pandemic rules.~The audio recording will be played twice, in the evening before the operation and on the evening of the operation day."
89313842|NCT05283291|No Intervention|Control group|In the routine care applied to the patients, the vitals of the patients are followed, drug treatments are administered and the motor functions of the patients are monitored. In addition, analgesics are routinely administered in the ward for pain and no attempt is made for sleep.
89313843|NCT03846609|Experimental|double balloon platform|Device: double balloon interventional platform (DiLumen)
89313844|NCT03846609|Active Comparator|no double balloon platform|Device: no double balloon interventional platform (DiLumen)
89313845|NCT04898439|Experimental|Green school|The children from schools that are being greened will be investigated and compared to the control school. We will measure cognitive function, BMI, black carbon levels and emotional wellbeing.
89313846|NCT04898439|No Intervention|control school|The children from schools that are not being greened will be investigated and used as a control group. We will measure cognitive function, BMI, black carbon levels and emotional wellbeing
89313847|NCT03851757|Active Comparator|waist-shaped interdental brush|waist-shaped interdental brush, use four times per interdental space
89313848|NCT03851757|Active Comparator|cylindric interdental brush|cylindric interdental brush, use four times per interdental space
89313849|NCT03851679||pregnancy woman|woman who are submitted to elective Cesarean Section in spinal anesthesia
89313850|NCT01292577|Experimental|CET/PT|Behavioral Intervention: Participants will receive adapted Cognitive Enhancement Therapy/Personal Therapy.
89313851|NCT01292577|Active Comparator|Treatment as Usual|Behavioral Intervention: Participants will receive treatment as usual.
89313852|NCT01295385|Experimental|healthy volunteers|
89313853|NCT01295385|Active Comparator|patients with a diabetic cardiomyopathy|
89313854|NCT01292655|Experimental|Arm A1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
89313855|NCT01292655|Experimental|Arm A2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
89313856|NCT01292655|Experimental|Arm B1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
89313857|NCT01292655|Experimental|Arm B2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
89313858|NCT03846375|Experimental|Participants in DBT|Psychotherapy: The participants will be given standard DBT treatment.
89313859|NCT03846375|Other|Control Group|Control Group at preintervention.
89313860|NCT01295541||4 months of observation|CVICU
89313861|NCT03328988|Experimental|Quadratus lumborum block|Single shot bilateral QLB, ropivacaine 75 mg (20 mL) per side, placed under ultrasound control, at the end of surgery. 22 patients will be allocated in this group.
89313862|NCT03328988|No Intervention|Epidural|"Epidural catheter (placed before anesthesia induction), ropivacaine 75 mg in 50 mL isotonic saline (1,5 mg/mL), induction bolus after surgery 1 mL/10 kg ideal weight and there on continuous infusion 2-8 mL/h according to analgesic need. 22 patients will be allocated in this group.~This is the current standard for postoperative pain relief in cystectomy patients in our hospital"
89313863|NCT05518305||All|Blood sampling and an MRI will be conducted alongside standard stroke cognitive tests upon enrollment. A follow-up three-month visit will check for adverse events and a follow-up cognitive stroke test. At 12 months, an MRI will be conducted alongside a cognitive test.
89313864|NCT04155788|Experimental|Food Exposure|
89313865|NCT01189149|Experimental|IV fluids|Infants will get IV fluids whem indicated until able to tolerate full oral feedings
89313866|NCT01189149|Experimental|Oro/naso gastric tube feeding|Infants will get oro/naso gastric tube feeding whem indicated until able to tolerate full oral feedings
89313867|NCT04711928||Trained athletes|Active individuals with at least 4 training hours per week.
89313868|NCT01192503|Active Comparator|rasagiline|
89313869|NCT01192503|Placebo Comparator|placebo (sugar pill)|
89313870|NCT03302936|Experimental|Pyridium arm|Phenazopyridine 200mg tablet, once prior to surgery
89313871|NCT03302936|No Intervention|Control arm|No intervention in this group. Routine perioperative care.
89313872|NCT01192581|No Intervention|control|routine treatment for brain hypoperfusion
89313873|NCT01192581|Experimental|Vuloven1|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
89313874|NCT01192581|Experimental|Vuloven2|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
89313875|NCT01192581|Experimental|Vuloven3|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
89313876|NCT01292733|Experimental|Ovarian Cancer Screening|CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires
89313877|NCT03851289|Experimental|test (PRF-CS)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and calcium sulfate was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
89313878|NCT03851289|Active Comparator|control (PRF-X)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and xenograft (MinerOss® X) was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
89313879|NCT03733899|Experimental|Upper lid margin/Lower lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences of an ocular surface region. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
89313880|NCT03733899|Experimental|Lower lid margin/Cornea/ Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
89313881|NCT03733899|Experimental|Cornea/Upper lid margin/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
89313882|NCT03733899|Experimental|Cornea/Lower lid margin/Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
89313883|NCT03733899|Experimental|Upper lid margin/Cornea/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
89313884|NCT03733899|Experimental|Lower lid margin/Upper lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
89313885|NCT03848559|Experimental|Airway device placement|airway device is placed during the dive
89313886|NCT01192659||Patients treated with saxagliptin or placebo|Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.
89313887|NCT01192659||Patients currently or previously on treatment|Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.
89313888|NCT01196013|Experimental|Clofarabine|
89313889|NCT03851367|Experimental|Sling suspension therapy|3-week duration of exercises using red cord and consisting of 15 sessions for 30 minutes each.
89313890|NCT03851367|Active Comparator|Swiss ball therapy|3-week duration exercise for trunk muscles strengthening and posture improvement consisting of 15 sessions for 30 minutes each.
89313891|NCT01196169|Experimental|Daptomycin|Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
89313892|NCT01196169|Active Comparator|Vancomycin|Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
89313893|NCT01192893||OPUS|OPUS is a prospective study of postmenopausal women recruited in the general population between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin (Germany), Kiel (Germany), Paris (Hospital Cochin, France), and Sheffield (UK)). Investigations were approved at each institution according to the Declaration of Helsinki. Written consent was obtained from all subjects. Each center recruited approximately 500 postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79. Ninety-nine percent of subjects were of white ethnicity.
89313894|NCT01193205|Experimental|20 weeks skills group|Participants receive 20 weeks of Dialectical Behaviour Therapy Skills training, covering 5 modules: mindfulness, interpersonal effectiveness, emotional regulation, distress tolerance, dialectics.
89313895|NCT01193205|No Intervention|Waitlist|Participants on the waitlist condition will be assessed at baseline and symptoms monitored at 10 weeks, 20 weeks and 8 months following baseline assessment. They will then be offered the active treatment.
89313896|NCT01189305|Experimental|Behavioral Couples Therapy|
89313897|NCT01189305|Experimental|Individual Drug Counseling|
89313898|NCT03851055|Active Comparator|intervention group|will receive zinc supplementation
89313899|NCT03851055|No Intervention|Control group|Patients will receive placebo only
89313900|NCT01196325||Laser Group|Patients who are clinically indicated for the laser treatment
89313901|NCT01196325||Anti-VEGF Group (Bevacizumab)|Patients who are clinically indicated for the intravitreal injection of Bevacizumab
89313902|NCT01196325||Anti-VEGF Group (Ranibizumab)|Patients who are clinically indicated for intravitreal injection of Ranibizumab
89313903|NCT01196325||Age-matched controls|Group of non-diabetic participants who will be age and gender matched
89313904|NCT01196481|Experimental|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD + VSL#3
89313905|NCT01196481|Active Comparator|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3-4 weeks till variceal ligation
89313906|NCT01193439||Patients with high risk|
89313907|NCT01193439||Patients in normal conditions|
89313908|NCT01189383|Experimental|IL15-DC Vaccine|Approximately 9 x 10^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12.At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
89313909|NCT05283057|Active Comparator|Group 1: Empagliflozin|25 patients with glomerulonephritis and proteinuria who were treated with Empagliflozin
89313910|NCT05283057|Placebo Comparator|Group 2:|25 patients with glomerulonephritis and proteinuria who were treated with standard treatment and placebo
89313911|NCT01193595|Experimental|AVE8062/ bevacizumab|The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.
89313912|NCT01292811|Experimental|Functional electrical Stimulation|The functional electrical stimulation for the treatment group will begin by designing a stimulation protocol that can generate the palmar and/or the lateral grasp on demand. In other words, the stimulation sequence (protocol) will be developed for each patient individually using either Compex Motion or HEWHS stimulator; this will allow the patient, who otherwise cannot grasp, to do so with the system. Both stimulators will be used to deliver the same FES therapy. Stimulation parameters are: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from 250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
89313913|NCT01292811|Other|Control Group|"The Control group will receive conventional occupational therapy pertaining to hand function [15].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
89313914|NCT01196559|Experimental|Vinorelbine and Gemcitabine|Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks
89313915|NCT01196637||Thoracic outlet syndrome|These patients have documented thoracic outlet syndrome
89313916|NCT01196637||Normal Subjects|These patients have no thoracic outlet syndrome
89313917|NCT01292889||Seasonal Affective Disorder|Consists of Individuals with Seasonal Affective Disorder
89313918|NCT01292889||Subsyndromal Seasonal Affective Disorder|Consists of individuals who do not meet SAD criteria,but present more symptoms for the disorder than do controls.
89313919|NCT01292889||Major Depressive Disorder|Consists of individuals who have MDD.
89313920|NCT01292889||Controls|Consists of individuals who do not present symptoms of SAD or MDD.
89313921|NCT01295619|Experimental|I-020805|This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery. If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura. If necessary, autologous grafts were to be used to augment dural closure.
89313922|NCT01295775|Active Comparator|Sulodexide group|50 mg of sulodexide a day will be administered by oral route (1+1 capsule/day) for 360 days
89313923|NCT01295775|Placebo Comparator|Placebo group|Sulodexide placebo will be administered at the same schedule (1+1 capsule/day) and for the same lengths of time (for 360 days) as Sulodexide group
89313924|NCT01295853|Active Comparator|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
89313925|NCT01295853|Active Comparator|t4 sypathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
89313926|NCT01581177|Experimental|T1|Two inhalations, one of Albuterol DPI 25 mcg/inh and one of Placebo DPI; Total Albuterol dose of 25 mcg
89313927|NCT01581177|Experimental|T2|Two inhalations of Albuterol DPI 25 mcg/inh; Total Albuterol dose of 50 mcg
89313928|NCT01581177|Experimental|T3|Two inhalations, one of Albuterol DPI 90 mcg/inh and one of Placebo DPI; Total Albuterol dose of 90 mcg
89313929|NCT01581177|Experimental|T4|Two inhalations of Albuterol DPI 90 mcg/inh; Total Albuterol dose of 180 mcg
89313930|NCT01581177|Placebo Comparator|P|Two inhalations Placebo DPI; Total Albuterol dose of 0 mcg
89313931|NCT01581177|Active Comparator|R1|One inhalation of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 90 mcg
89313932|NCT01581177|Active Comparator|R2|Two inhalations of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 180 mcg
89313933|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and active cholecalciferol|500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months
89313934|NCT01580007|Active Comparator|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate
89313935|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and placebo cholecalciferol|Drug: Sodium Phenylbutyrate Placebo: cholecalciferol
89313936|NCT01580007|Placebo Comparator|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate Placebo cholecalciferol
89313937|NCT01295931|Experimental|IC-Green + Imaging|Indocyanine Green (IC-Green) Injections + Imaging
89313938|NCT05434143|Experimental|Chorus Sleep|"During the 6-week intervention, participants will receive daily reminders to complete their daily sleep log and a link to a chorus sleep class for them to listen to that night.~The daily sleep class involve listening to 15 minute audio sessions, which include guided mediation and breathing exercises. Participants will be encouraged to complete classes every day but will be asked to complete classes at least 3 times per week in order to be considered as adhering to the intervention. Participation will be tracked based on participants self-reports in the daily sleep logs. Participants who did not adhere to the intervention will be excluded from per-protocol analyses.~Participants will complete surveys online at baseline, after 3 weeks, and after 6 weeks. The baseline questionnaires will include demographic information."
89313939|NCT05434143|No Intervention|Waitlist|"Participants will be placed on a 6 week waitlist to access the chorus sleep app. There will be no daily activities for them to complete during those 6 weeks.~Participants will complete surveys online at baseline, after 3 weeks, and after 6 weeks. The baseline questionnaires will include demographic information."
89313940|NCT01296009|Experimental|traditional Chinese medicine|The pregnancy rate in traditional Chinese medicine group is higher than the control group
89313941|NCT01189695|Experimental|Boosted lopinavir monotherapy|
89313942|NCT01189695|Active Comparator|boosted lopinavir + optimized background regimens (OBRs)|
89313943|NCT03848169|Experimental|Experimental group|Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.
89313944|NCT03848169|Sham Comparator|Control Group|Ultrasound guidance will be used with a high- frequency linear transducer. After the joint has been identified, the researcher will ask the patient to hold his or her mouth in a neutral position. Masseter, temporalis and lateral pterigoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection (mainly over the most common sites of trigger points for the masticatory muscles). Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, an electrode will not be inserted, but a simulation for PRF will be done during 4 minutes for each muscle (sham). At the end of each muscle puncture, 1 ml of local anesthetic (lidocaine 1%) will be injected through the needle, and the needle will be removed.
89313945|NCT03848247|Experimental|Control group|Participants will be injected with 0.5ml Isotonic saline into a neck muscle
89313946|NCT03848247|Experimental|Neck pain|Participants will be injected with 0.5ml NGF into the a neck muscle
89313947|NCT01196715|Active Comparator|Darbepoetin Alfa|
89313948|NCT01196715|Active Comparator|G-CSF|
89313949|NCT01196715|Active Comparator|Best Supportive Care|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl
89313950|NCT03846141|Placebo Comparator|Placebo|Room air for inhalation
89313951|NCT03846141|Experimental|Hydrogen|Hydrogen (4%) for inhalation
89313952|NCT01292967|Placebo Comparator|Low flavanol|Low-flavanol chocolate contained 48 mg of cocoa flavanols. macro- and micro-nutrient matched with active comparator
89313953|NCT01292967|Active Comparator|High-flavanol with sugar|High-flavanol chocolate made with added sugar containing 251 mg of cocoa flavanols
89313954|NCT01292967|Active Comparator|High flavanol Maltitol|High-flavanol chocolate made with the sugar substitute maltitol containing 266 mg cocoa flavanols
89313955|NCT01189773|Experimental|1|Ibuprofen given orally (10 mg/kg, max = 600 mg) and codeine given orally (1 mg/kg, max = 60 mg).
89313956|NCT01189773|Placebo Comparator|2|Ibuprofen given orally (10 mg/kg, max = 600 mg) and placebo given orally ( identical in taste color to codeine preparation).
89313957|NCT03845907|Active Comparator|Imagio Gen 1B|Gen 1B duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System and the Gen1B duplex probe
89313958|NCT03845907|Active Comparator|Imagio Gen 1|Gen 1 duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System
89313959|NCT01193751||asphyxiated newborns > 37 weeks of gestation|
89313960|NCT01296165||Travellers visiting India|People that are older than 18 years and planning to visit India for a period of at least 5 days will be approached by the personal at the travel clinics to participate in the study. Informed consent will be obtained prior to enrolling subjects.
89313961|NCT03850821|Experimental|Connect Social Mechanisms Intervention|"The primary components of the intervention included: Get-to-know-you sessions aimed specifically at providing youth guided social opportunities to foster friendships, group belonging, and social skills, and novel socially-oriented 'PA sessions' infused within the daily time slot that ASPs' allocated towards recreation. Drawing from theoretical models of motivation, and the investigators' previous ASP studies, key essential elements were identified for facilitating improvements in targeted PA social mechanisms (i.e., friendships, group belonging, and staff connection) and included: 1) social-emotional goal-oriented support, 2) collaborative/cooperative play centered on friendship and informal fun; 3) equal treatment/access, and; 4) inclusive and engaging."
89313962|NCT03850821|No Intervention|Typical ASP curriculum wait-list control|No intervention was implemented within the active wait-list control condition, which served as the typical ASP curriculum control/comparison. After completion of the 8-week intervention (12 weeks including baseline and post-intervention data collection), the control condition received the social mechanisms curriculum as a token of appreciation for participating in measurement.
89313963|NCT01296243|Experimental|Tesetaxel once every 3 weeks|
89313964|NCT03846063|Experimental|Intervention: Home-based rehabilitation program|"A twelve-week home-based exercise strategy will be offered to patients after their discharge from the hospital. This home-based exercise strategy will be delivered by means of videos on a tablet-pc and consist of specified exercise instructions for improving muscle strength, balance and functional movements.~The intervention group will be compared with existing patientdata who received usual care in the Netherlands"
89313965|NCT04910529|Experimental|Yoga group|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students. This application includes the most basic yoga exercises and does not pose any health risks for practitioners. During the yoga practice in the online environment, the cameras of the students in the yoga group will be turned on and the researcher who has the application will be able to see each student. Yoga will be applied to this group twice a week for 60 minutes each for three menstrual cycles (12 weeks).
89313966|NCT04910529|No Intervention|Control group|No intervention will be made to the control group, only the data will be collected at the same time as the study group.
89313967|NCT01196949|Active Comparator|Manipulative and Rehabilitative Therapy|
89313968|NCT01196949|Active Comparator|Rehabilitative Therapy|
89313969|NCT05670873|Experimental|rTMS treatment|20 days of repetitive transcranial magnetic stimulation: stimulation site is the left dorsolateral prefrontal cortex, stimulation intensity at 90% RMT, stimulation frequency is 10Hz. A total of 1000 pulses, 10s 10Hz train stimulation, repeated 10 times, each interval 60s, a total of 11 minutes and 40 seconds, 1 treatment per day, a total of 20 days.
89313970|NCT05670873|Experimental|iTBS treatment|20 days of intermittent theta-burst stimulation: stimulation site is the left dorsolateral prefrontal cortex, stimulation intensity at 90% RMT, stimulation frequency is 50Hz. A total of 600 pulses, 3 pulses each time, with an interval of 200 ms, for a total of 2 seconds (10 groups), and then repeat the above process after an interval of 10 seconds, a total of 190 seconds, 1 treatment per day, a total of 20 days.
89313971|NCT01197105|Experimental|Aroeira|
89313972|NCT01189929|Experimental|Gemcitabine and demcizumab With or Without Abraxane®|Gemcitabine and demcizumab With or Without Abraxane®
89313973|NCT03844425|Active Comparator|Conventional Vacuum-Formed Retainers|Vacuum-formed retainers constructed on conventional stone models.
89313974|NCT03844425|Experimental|Vacuum-Formed Retainers From SLA|Vacuum-formed retainers constructed on 3D reconstructed models using stereolitography (SLA) technique.
89313975|NCT03844425|Experimental|Vacuum-Formed Retainers From FDM|Vacuum-formed retainers constructed on 3D reconstructed models using fused deposition modeling technique (FDM).
89313976|NCT03844191|Experimental|Part 1 Cohort 1|Cohort 1: 0.05 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
89313977|NCT03844191|Experimental|Part 1 Cohort 2|Cohort 2: 0.075 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
89313978|NCT03844191|Experimental|Part 2 Cohort 1|Cohort 1: initial dose to be selected by the Safety Review Committee (SRC) after completion of Part 1 (the same initial dose used in Part 1 or one of the previously studied higher doses that is lower than the overall RUC-4 BED) 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
89313979|NCT03844191|Experimental|Part 2 Cohorts 2-3|7 subjects (6 receiving RUC-4, 1 receiving placebo) will be enrolled in each dose cohort, with a safety evaluation performed after 2 subjects in a dose cohort receive RUC 4 and at the completion of dosing for all subjects in the dose cohort. Dose escalation to be determined by the SRC charter and will continue until identification of the overall RUC-4 BED or MTD
89313980|NCT03844191|Experimental|Part 2 Dose Expansion Cohort 1|"14 subjects will receive a selected dose of RUC-4 based on SRC review of dose escalation data.~In the expansion cohort, 7 subjects weighing 55 to 65 kg and 7 subjects weighing 100 to 120 kg will be enrolled; 12 subjects will receive a single subcutaneous dose of RUC-4 and 2 will receive matched placebo"
89313981|NCT03845673|Experimental|Psyllium|This group of patients was given psyllium for 6 weeks
89313982|NCT03845673|Experimental|Bowel recipe|This group was administered a specialized bowel recipe for 6 weeks
89313983|NCT01190163|Experimental|A|
89313984|NCT01190163|Active Comparator|B|
89313985|NCT01199445|Experimental|triple fortified extruded rice|
89313986|NCT01199445|Other|regular meal|regular vitamin A meal
89313987|NCT01199523|Placebo Comparator|Placebo|
89313988|NCT01199523|Experimental|mirabegron high dose|
89313989|NCT01199523|Experimental|mirabegron medium dose|
89313990|NCT01199523|Experimental|mirabegron low dose|
89313991|NCT01199523|Active Comparator|moxifloxacin|
89313992|NCT01190241|Experimental|Targeted treatment|Targeted treatment with desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
89313993|NCT03844113|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
89313994|NCT03844113|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo for 6 months
89313995|NCT03845595|Experimental|(LF-rTMS) group|Patients in the study group were treated with the contralesional (LF-rTMS) once per day for 20 minutes, Daily, 5 sessions per week (Sunday to Thursday), for 2 consecutive weeks in addition to the conventional upper limb physical therapy interventions.
89313996|NCT03845595|Active Comparator|Control group|Patients in the control group were treated with the conventional upper limb physical therapy interventions (40 minutes to 1 hour, daily, 5 times per week for two consecutive weeks )
89313997|NCT01197261|Active Comparator|OXN PR|Oxycodone Naloxone tablets
89313998|NCT01197261|Placebo Comparator|PLA|
89313999|NCT01197339|Experimental|treatment|
89314000|NCT01197339|Sham Comparator|Controls|
89314001|NCT01293045|Experimental|HC Group|Group of volunteers fed with Hydrolyzed Collagen
89314002|NCT01293045|Active Comparator|CT Group|Group of volunteers fed with wheat proteins
89314003|NCT04817319|Experimental|Major patients diagnosed with Covid + requiring oral care.|
89314004|NCT01190319|Placebo Comparator|Placebo Beverage|The placebo beverage is matched in energy, macronutrient composition and sensory properties to the active beverage, but is devoid of strawberry polyphenols.
89314005|NCT01190319|Experimental|Strawberry Beverage|The strawberry beverage is matched in energy, macronutrient composition and sensory properties to the placebo beverage, but contains strawberry polyphenols.
89314006|NCT01190397|Experimental|Blephasteam Arm|
89314007|NCT01190397|Active Comparator|warm and moist compresses arm|
89314008|NCT05362461||Bitewing first, CariVu second|Bitewing images will be taken first. CariVu images will be taken second.
89314009|NCT05362461||CariVu first, Bitewing second|CariVu images will be taken first. CariVu images will be taken second.
89314010|NCT01199679|Experimental|Endoscopic Mucosal Resection (EMR) Group|
89314011|NCT01199679|Experimental|Banding Group|
88806512|NCT03459482|Experimental|Group 1 - True Food Elimination Diet|Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
88814738|NCT04354532||209 patients were submitted to primary LBSG|All patients submitted to primary Laparoscopic Banded Sleeve Gastrectomy were examined. Collected data included demographic factors, pre-operative weight, pre-operative BMI, operative time, surgical complications, and clinical outcomes in terms of short and mid-term weight loss.
89314012|NCT03727347|Experimental|InSeca Stylus Treatment Group|Subjects treated with low power radiofrequency energy applied to the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus)
89314013|NCT01197729||STEMI|(ST-Elevation myocardial infarction)
89314014|NCT01197729||NSTEMI|Non-ST-Elevation myocardial infarction
89314015|NCT05670327||Bilateral lung recipients|Adult patients undergoing bilateral LT, not requiring invasive mechanical ventilation before surgery, were eligible for inclusion in the study only when they met the predefined 'readiness-to-wean' criteria on daily screening and were therefore deemed ready to undergone a first 30-min weaning trial.
89314016|NCT01293201|Experimental|STAHIST Investigational Medical Product|STAHIST Tablet, dosed one tablet BID
89314017|NCT01293201|Placebo Comparator|Placebo|Placebo tablet, identical appearance to IMP, dosed one tablet BID
89314018|NCT04778163|Experimental|Humor group 1|"Group 1 - experimental - will participate in a humor group with a one-hour group session per week for 6 weeks."
89314019|NCT04778163|No Intervention|Control group 2|"Group 2 - the control group - will follow an usual treatment regimen for 6 weeks. At the end of the Humor Group of group 1, the 2 groups of patients will undergo a second series of tests identical to those of the pregroup. The paired patients should be randomly assigned. The control group will do the Humor Group after 6 weeks."
89314020|NCT01190553|Experimental|Treatment|IV amantadine treatment
89314021|NCT01197807|Active Comparator|Bulb suctioning|Bulb suctioning of mouth and nose immediately after delivery
89314022|NCT01197807|Active Comparator|Wiping|Gentle wiping of mouth then nose with soft cloth
89314023|NCT04753983|Experimental|Anterior Nucleus of the Thalamus (ANT) Deep Brain Stimulation (DBS)|"Subjects that have undergone DBS placement for treatment of refractory epilepsy will undergo a fMRI scan. During the fMRI, the subject will undergo alternating short periods of their DBS in the on and off state with high- and low frequency settings to measure the brain activation changes induced by the DBS."
89314024|NCT03844035|Experimental|Oral irrigator group|Fifteen patients using toothbrush and oral irrigator(oxytet oral irrigatör).All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual).PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites.Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
89314025|NCT03844035|Experimental|Interdental brush group|Fifteen patients using toothbrush and interdental brush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
89314026|NCT03844035|Active Comparator|Control group|Fifteen patients using only toothbrush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
89314027|NCT01199757||FF|Cohort of patients receiving fluticasome furoate
89314028|NCT01199757||MF|cohort of patients on mometasone furoate
89314029|NCT01199757||FP|cohort of patients receiving fluticasone propionate
89314030|NCT01197885|Experimental|IMAB362|Two different doses (antibody / body surface area) of IMAB362 will be administered sequentially.
89314031|NCT01197963|Other|Surgical treatment|Surgical treatment of one arm of the patient population.
89314032|NCT01197963|Other|Medically controlled group|Managed by endocrinologists using current medical therapy such as pills, injections and life style medication.
89314033|NCT05668299|Experimental|TrachFlush group|Patients in this arm received the intervention.
89314034|NCT01293279||HCV Patients who are treatment naive|Han ethnic Chinese male or female ≥ 18 years old with recent a confirmation of anti-HCV-antibody positive and HCV RNA positive but antiviral or interferon treatment naive at the time this study starts from 28 university affiliated hospital throughout China.
89314035|NCT01293357|Experimental|Patches|
89314036|NCT03843801|Active Comparator|Volume reduction|Intragastric sutures are done to reduce the volume of the stomach
89314037|NCT03843801|Active Comparator|Gastric emptying reduction|Intragastric sutures are done to slower the gastric emptying
89314038|NCT03843801|Active Comparator|Increasing distension|Intragastric sutures are done to maximalize the gastric distension
89314039|NCT01190631|Experimental|Acrysof IQ (SN60WF) IOL|AcrySof IQ SN60WF intraocular lens (IOL) implanted in one eye only during cataract surgery.
89314040|NCT03843879|Active Comparator|TAP Block|Single-injection transversus abdominis plane block
89314041|NCT03843879|Active Comparator|IV Lidocaine|Continuous intravenous lidocaine infusion
89314042|NCT03850587|Experimental|YYC301-1 & Celocoxib placebo|"YYC301-1 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-1 is a capsule. It is composed of Celocoxib 200mg and Tramadol 37.5mg complex)."
89314043|NCT03850587|Experimental|YYC301-2 & Celocoxib placebo|"YYC301-2 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-2 is a capsule. It is composed of Celocoxib 200mg and Tramadol 75mg complex)"
89314044|NCT03850587|Experimental|YYC301-3 & Celocoxib placebo|"YYC301-3 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-3 is a capsule. It is composed of Celocoxib 200mg and Tramadol 150mg complex)"
89314045|NCT03850587|Active Comparator|YYC301 placebo & Celecoxib|Concomitant Drugs with Celecoxib 200mg and YYC301 one capsule.
89314046|NCT01199835|Experimental|high calcium|Dietary intake of calcium ~ 1500 mg/ d, including ~1200 mg/d from dairy products
89314047|NCT01199835|Active Comparator|Low calcium|Low dietary intake of calcium, i.e. ~ <600 mg/d, including 0-1 portion of dairy products
89314048|NCT04751630|Experimental|Therapeutic Exercise group|The study participants corresponding to the Therapeutic Exercise (ET) intervention group will follow the prescriptions given to them by their primary care physician. In addition, and as the main part of the intervention, they will undergo a six-week ET program with two sessions per week, for a total of 12 sessions. Full participation in 10 sessions will be necessary to be included in the ET group during the statistical analysis. Each session will be one hour long. The sessions will be given and supervised by a physiotherapist expert in therapeutic exercise prescription through the online modality.
89314049|NCT04751630|No Intervention|Control group|Study participants in the control group will follow the prescriptions given to them by their primary care physician and will receive a weekly call to assess their recovery. At the end of the study follow-up, when their participation in the study as a control group ends, participants in this group will be offered to participate in the structured ET program to be carried out by the ET group. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of the research.
89314050|NCT03850665|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
89314051|NCT03850665|Active Comparator|Anterolateral approach|Anterolateral Approach surgery to replace the hip.
89314052|NCT03850665|Active Comparator|Posterolateral approach|Posterolateral Approach surgery to replace the hip.
89314053|NCT04745702|Other|Low-Calorie Control Group|The control group will receive for 2 calorie-restricted balanced meals per day, consisting of a portion of meat, a portion of vegetables, a portion of medium to high GI carbohydrates and prepared with refined corn oil. The control meals will be devoid of any whole legumes and will contain minimal amounts of spices. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by ~5%.
89314054|NCT04745702|Active Comparator|Low-Calorie Treatment Group|The treatment group will receive for 2 calorie-restricted (isocaloric with control group) meals per day containing 100 g cooked whole legumes (amounting to a total of 200 g cooked legumes, approximately 1 cup of cooked legumes)and/or certain meat analogues (textured vegetable [soy] proteins), and/or a portion of vegetables, low GI, wholegrain carbohydrates for their starch sources (rice/noodles/pasta), added spices (dried spice powder) at dietary and culinary acceptable doses and blended vegetable oil. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by ~5%.
89314055|NCT05671497|Experimental|Cilostazol arm|35 patients receiving conventional synthetic disease modifying antirheumatic drugs in addition to Cilostazol 100 mg twice daily for 6 months.
89314056|NCT05671497|Active Comparator|Control|35 patients receiving conventional synthetic disease modifying antirheumatic drugs for 6 months.
89314057|NCT03915626|Experimental|RLD patch|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
89314058|NCT03915626|Experimental|generic patch|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours
89314059|NCT03915626|Experimental|RLD patch with heat|RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
89314060|NCT03915626|Experimental|generic patch with heat|generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application
89314061|NCT04491968|Experimental|Mindfulness Oriented Recovery Enhancement|The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
89314062|NCT04491968|Other|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
89314063|NCT03301844|Experimental|Study treatment|Blephapad Combo twice daily for one month. Blephapad is a disposable wet wipe containing Hy-Ter® solution (sodium hyaluronate acid and 4-terpineol), aloe, natural anti-inflammatories and antiseptics.
89314064|NCT03301844|Other|Standard treatment|Wet, warm gauze twice daily for one month.
89314065|NCT01199913||desflurane and sevoflurane|Subjects will be randomized to either desflurane or sevoflurane. They will be given the Mini Mental State exam at 1, 6 and 24 hours after the end of anesthesia.
89314066|NCT01199991||Normative database|
89314067|NCT03313310|Experimental|Employment Intervention|An employment intervention (iFOUR) that has been adapted from previous piloting work of focus groups, key informant interviews and a community advisory board.
89314068|NCT03850119|Experimental|Intradermal Nanofat|This side of the scar received intradermal injection of nanofat during the closure of the donor site.
89314069|NCT03850119|No Intervention|Control|This side of the scar received no injection.
89314070|NCT04677309||Lung resection less than lobectomy|participants scheduled for lung resection that is less than lobectomy
89314071|NCT04677309||Lung resection equal to or greater than lobectomy|participants scheduled for lung resection that is equal to or greater than lobectomy
89314072|NCT05670249|Active Comparator|surgical plus medical treatment|Decompressive surgery protocol was kept constant throughout the study period and defined the following surgical interventions: (1) extensive bilateral suboccipital decompresive craniectomy with duraplasty, optional resection of the posterior arch of atlas, (2) preceding insertion of an external ventricular drainage (EVD) in all cases, and (3) evacuation of necrotic tissue.
89314073|NCT05670249|No Intervention|conservative medical treatment|Control group (conservative medical) was treated equally aggressive with regard to intensive care measures. Medical management generally followed the Turkish and European guidelines on acute stroke care valid at the time of patient admission.
89314074|NCT01190709|Other|unreamed Intramedullary Nailing|tibial fracture fixed with unreamed Intramedullary Nailing
89314075|NCT01190709|Other|Dynamic Compression Plate|tibial fracture fixed with Dynamic Compression Plate
89314076|NCT01198119|Experimental|Patient with oral cavity cancer|Patient treated by surgery for the oral cavity cancer
89314077|NCT01200225||Cohort|
89314078|NCT03313076|Experimental|n-3 PUFA (O3FA) + Vitamin D3|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule
89314079|NCT03313076|Experimental|n-3 PUFA (O3FA) Placebo + Vitamin D3|4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule
89314080|NCT03313076|Experimental|n-3 PUFAs (O3FA) + Vitamin D3 Placebo|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule
89314081|NCT03313076|Placebo Comparator|n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo|4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule
89314082|NCT01293435||1|
89314083|NCT03850197||TMM followed by EarPopper + Tympanometry|"Participants will be asked to complete the tubomanometry (TMM) then EarPopper plus tympanometry tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize Eustachian tube (ET) pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
89314084|NCT03850197||EarPopper + Tympanometry followed by TMM|"Participants will be asked to complete the EarPopper plus tympanometry then TMM tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize ET pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
89314085|NCT01200303|Active Comparator|non-cathartic CTC and OC|This is a single arm, open label, prospective test comparison of non-cathartic, CAD-assisted CTC to segmentally unblinded optical colonoscopy (OC). All study subjects receive both tests, starting with CTC, followed by OC within 5 weeks. CTC results are recorded and revealed to endoscopist on a segment-by-segment basis after initial (blinded) OC evaluation; endoscopist can double check / confirm lesion presence after unblinding and this second read serves as reference standard.
89314086|NCT03262610|Experimental|Setmelanotide daily subcutaneous injection|Up to 18 weeks setmelanotide treatment.
89314087|NCT03180554|Other|tVNS version 1|Transcutaneous vagus nerve stimulation (tVNS) version 1 will be delivered non-invasively via a portable take-home stimulation device which attaches to the concha of the outer ear. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
89314088|NCT03180554|Other|tVNS version 2|Transcutaneous vagus nerve stimulation (tVNS) version 2 will be delivered non-invasively via a portable take-home stimulation device which attaches to the center of the left ear lobe. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
89314089|NCT03180554|Other|MNRB version 1|Motivational nondirective resonance breathing (MNRB) version 1 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a deep breathing session. Participants will practice MNRB version 1 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
89314090|NCT03180554|Other|MNRB version 2|Motivational nondirective resonance breathing (MNRB) version 2 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a paced breathing session. Participants will practice MNRB version 2 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
89314091|NCT01191021|Other|Propofol|Volunteers will receive propofol anesthesia on the study day.
89314092|NCT05224479|Active Comparator|Traditional workflow triage|Radiologists follow standard triage of chest radiographs.
89314093|NCT05224479|Active Comparator|Machine learning workflow triage|Radiologists follow machine learning triage of chest radiographs.
89314094|NCT05224479|Sham Comparator|Random workflow triage|Radiologists follow randomly ordered triage of chest radiographs.
89314095|NCT01200381|Active Comparator|Group A|Automatic anonymous ICD/CRTD follow up (quarterly remote follow ups)
89314096|NCT01200381|Active Comparator|Group B1|Personal ICD/CRTD follow up (phone calls + quarterly remote follow ups)
89314097|NCT01200381|Active Comparator|Group B2|Personal ICD/CRTD follow up (Quarterly visits)
89314098|NCT01293591|Other|Control|270 kcal White bread with 15 g margarine
89314099|NCT01293591|Other|Garlic Treatment|270 kcal white bread with 15 g margarine and 5 g crushed garlic
89314100|NCT01200459|Experimental|Social/Mobile Intervention|Theory-based intervention to promote weight loss utilizing web, mobile phone and social media.
89314101|NCT01200459|No Intervention|Control|"Participants randomized to this group will have access to usual care health information via the SMART study website. This arm will be compared to our intervention group."
89314102|NCT01200537|Active Comparator|Estradiol Patch|This group of patients will receive estradiol patches prior to the IVF cycle.
89314103|NCT01200537|Active Comparator|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
89314104|NCT01200615|Other|Explanation about common side effects|50 patients started on SSRI's will be updated about its common side effects
89314105|NCT01200615|Other|Explaning side effects and the nocebo effect|subjects started on SSRI's will be updated about its common side effects and the nocebo effect
89314106|NCT01200615|Other|explanation about the nocebo effect|3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will not be updated about common side-effects. Nonetheless, they will be informed of severe side-effects.
89314107|NCT05670483|Active Comparator|APRV group|"Group A: APRV group (30 Patients) Post operatively, Patients will be ventilated with APRV mode using GE Carescape R860 ventilator Initial Settings15~P high at the P plateau (or desired P mean + 3cm H2O). keep P high below 30-35 cm H2O~T high at 4-6 seconds~P low at 0~T low at 0.5 to 0.8 seconds.~ATC (automatic tube compensation) on.~FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 > 60 mmhg on FIO2 < 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of APRV will start as following, P-High will be lowered 2 or 3 cm of H2O pressure at a time, and T Low will be lengthened in 0.5-2.0 s increments, depending on patient tolerance. When the P-high reaches 10 cmH2O and the Thigh reaches 12-15 seconds, change the mode to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
89314108|NCT05670483|Active Comparator|Standard group|"Group B: Standard (control) group (30 Patients) Post-operatively, Patients will be ventilated with conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode using GE Carescape R860 ventilator Initial Settings: 16~Tidal Volume 6-8 ml/kg predicted body weight~Respiratory rate (RR) 14 /min~Positive end expiratory pressure (PEEP)= 5 cmH2o~Pressure Support (PS) = 10 cmH2o~Inspiratory time 1.4 Sec~FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 > 60 mmhg on FIO2 < 50 %"
89314109|NCT01198353|Experimental|Ziprasidone|During the 12-week study period, patients were prescribed ziprasidone at 20 to 160 mg/day flexibly based on their effectiveness and tolerability. Fifty to one hundred percent of the past antipsychotic dose was maintained in the first week; during next 3 weeks, flexible dosing of 0-100% was used; then, ziprasidone was discontinued. This study included four visits: baseline, week 4, week 8, and week 12. Concomitant benzodiazepines (oral formula or injection) were allowed up to a dose of 4 mg of lorazepam-equivalents per day for anxiety and agitation.
89314110|NCT03843333|Experimental|CHW Intervention|CHWs will deliver three intervention components (Tai Ji Quan: Moving for Better Balance, Behavioral Activation, and Resource Navigation) to all participants at intervention sites over a 6-month period.
89314111|NCT03843333|Active Comparator|Enhanced Usual Care|Comparison participants will receive a guide on community resources for older adults, and assistance from the research team in making initial connections to resources if desired.
89314112|NCT02940626|Placebo Comparator|Placebo|Placebo administered as 2 separate intravenous (IV) infusions
89314113|NCT02940626|Experimental|ASN100|ASN100 administered as 2 separate intravenous (IV) infusions
89314114|NCT03622424|Active Comparator|Gelesis200|Subjects on this ARM will receive Gelesis200
89314115|NCT03622424|Placebo Comparator|Placebo|Subjects on this ARM will receive a placebo device
89314116|NCT03622424|Active Comparator|Gelesis200 and Placebo|Subejcts on this ARM will receive both Gelesis200 and placebo.
89314117|NCT03844971|Experimental|Computer assisted surgery|Intervention will be fabrication of patient specific surgical guide for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction using patient computed tomography with the aid of computer aided surgical simulation software
89314118|NCT04154085|Experimental|Study Group|This study only has one arm; all patients receive the treatment intervention.
89314119|NCT05078619|Experimental|TAVI only|Patients randomly allocated to this study arm will undergo transcatheter aortic valve implantation without preceding PCI of significant coronary artery disease
89314120|NCT05078619|No Intervention|TAVI with preceding PCI|Patients randomly allocated to this study arm will undergo transcatheter aortic valve implantation with preceding PCI of significant coronary artery disease which is currently the standard of care.
89314121|NCT01200693|Active Comparator|ZES|Patients with coronary bifurcation lesions treated by Zotarolimus eluting stent
89314122|NCT01200693|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
89314123|NCT01200693|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
89314124|NCT03844581|Active Comparator|interferential current|interferential current with a constant frequency of 100Hz for pain relief, then using rhythmic frequency of 1-100 Hz that help to disperse infiltration and adhesions for 8 successive weeks
89314125|NCT03844581|Active Comparator|anticholinergics|anticholinergics (propiverine hydrochloride 20 mg/once per day in the morning) for 8 successive weeks
89314126|NCT03844503|Placebo Comparator|Cereal Bar no fiber|Cereal bar without fiber
89314127|NCT03844503|Active Comparator|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
89314128|NCT03844503|Active Comparator|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
89314129|NCT05670093|Experimental|Neural Pressure Support|Patients will be ventilated in Pressure Support and Neural Pressure Support at 3 different levels of support in randomized order
89314130|NCT04135365||Pediatric T1D|A sample of 20 children with Type 1 Diabetes and their caregivers will be asked to stay after their diabetes clinic appointment to complete enrollment, or they may choose to come back for a study visit. Trained study staff will describe the study in detail to interested families. They will be encouraged to ask questions before giving consent. After obtaining informed consent/assent, children and caregivers will schedule time for a neurocognitive assessment and neuroimaging assessment. Children and caregivers will complete assessments again approximately 12 months later.
89314131|NCT04135365||Comparison|Children with no known chronic medical conditions or intellectual disability will undergo the same procedure listed for the Pediatric T1D group
89314132|NCT01198431|Experimental|Sleep restriction|Each participant will be engaged in three consecutive nights of 4 hours of sleep per night (from 3.00 a.m. to 7.00 a.m.)
89314133|NCT01198431|Placebo Comparator|Normal sleep duration|Each participant will be engaged in three consecutive nights of 9 hours of sleep per night (from 10.00 p.m. to 7.00 a.m.)
89314134|NCT01200849|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
89314135|NCT01200849|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
89314136|NCT01202097|Experimental|Salmeterol/Fluticasone|
89314137|NCT01202097|Active Comparator|Seretide|
89314138|NCT05670015|Active Comparator|Glaucoma suspect group|Cases diagnosed as glaucoma suspect
89314139|NCT05670015|Active Comparator|Post-refractive surgery group|Cases had undergone refractive surgery
89314140|NCT01201005|Active Comparator|Hydroxycobalamin|"Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma) is given as a singel intramuscular injection.~The syringe is covered so it is impossible to see whether it contains any substance"
89314141|NCT01201005|Sham Comparator|needle injection|"The controls receive an intramuscular injection: which is merely an introduction of the needle into the muscle whithout any injection. The syringe is covered so it is not possible to see whether the syringe contains any substance"
89314142|NCT04533087||Candida blood stream infection|
89314143|NCT04533087||Aspergillosis|
89314144|NCT04533087||Rare mold infections|
89314145|NCT01198665|Experimental|RAD001-CHOP|Prospective multicenter open-label phase I/II study Phase I: RAD001 2.5 - 10 mg PO daily D1-14 + CHOP every 3 weeks Phase II: Determined dosage of RAD001 + CHOP every 3 weeks Treatment will be continued until planned 6 cycles or disease progression
89314146|NCT03843567|Placebo Comparator|Didactic Training|Training will be conducted in a classroom for those participants randomised to receive didactic training, with training provided via a PowerPoint (Microsoft Inc., Redmond, Washington, USA) presentation by an expert endoscopist. An endoscopist with extensive experience in optical characterisation using virtual chromoendoscopy reviewed all teaching material.
89314147|NCT03843567|Active Comparator|Computer-based self-training|Participants randomised to the computer-based self-learning group will be given the same PowerPoint presentation as the didactic group and completed the training in a separate room. Participants completed training without feedback interaction.
89314148|NCT04111809||intravenous biphosphonate|Patients treated with intravenous bisphosphonate until 12 months in routine care
89314149|NCT03843099|Active Comparator|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
89314150|NCT03843099|Experimental|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
89314151|NCT03843177||Ingrown toenails|
89314152|NCT03843177||Control|
89314153|NCT05282589|Experimental|Lumbopelvic manipulation and conventiontional therapy|Group A an experimental group was given conventional therapy and lumbopelvic manipulation. conventional therapy include TENS and Hot pack for 20 minutes , hamstrings stretching, calf stretching,transversus abdominis strengthening and lumber multipedes muscle strengthening. while lumbopelvic manipulation include high velocity thrust given in posterior direction to ASIS.
89314154|NCT05282589|Active Comparator|conventional therapy|Group B, control group was given only conventional therapy which include TENS and Hot pack for 20 minutes , hamstrings stretching, calf stretching,transversus abdominis strengthening and lumber multipedes muscle strengthening . 1 set of 10 repetitions, 3 sessions per week with a total of 12 sessions.
89314155|NCT01198821|Experimental|Oral sodium bicarbonate and Gemcitabine|
89314156|NCT05015751||Hydrocephalus Patients|Hydrocephalus patients with an existing ventriculoperitoneal shunt and symptoms of a shunt malfunction.
89314157|NCT05013801|Experimental|Cosmetic Facial Serum Q69|Cosmetic facial serum. To be used twice daily on lesional areas of the face for 12 weeks.
89314158|NCT05013801|Other|2% Hydroquinone|2% hydroquinone cream to be used twice daily on lesional areas of the face as directed by the dermatologist for no longer than 8 weeks.
89314159|NCT01198899||left ventricular hypertrophy|Patients with left ventricular hypertrophy will be used.
89314160|NCT04088565|Experimental|PAS+VNS|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with VNS in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
89314161|NCT04088565|Sham Comparator|PAS+Sham|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with sham stimulation in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
89314162|NCT04477395|Experimental|SRP plus fish oil|Patients will receive scaling and root planing (SRP) supplemented with the dietary fish oil rich in omega-3 PUFAs: 2.6 g of EPA and 1.8 g DHA daily for 6 months.
89314163|NCT04477395|Active Comparator|SRP alone|Patients will receive scaling and root planing (SRP) only.
89314164|NCT03842553||Police officers|Police officers from the cantonal police forces in Bern, Switzerland
89314165|NCT03842553||Firefighters|Firefighters from the professional fire service of the Canton Bern, Switzerland
89314166|NCT03842553||Ambulance personnel|Ambulance personnel of the Canton Bern, Switzerland
89314167|NCT03842553||Emergency nurses|Emergency nurses of the Emergency Unit of the University Hospital of Bern, Switzerland
89314168|NCT03842553||Psychiatric nurses|Psychiatric nurses of the University Hospital of Psychiatry, University of Bern, Switzerland
89314169|NCT01566591|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
88814739|NCT04354298|Experimental|Fall 2019 ID Class|The ID group participated in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2019-December 2019.
89314170|NCT01566591|Active Comparator|Deep TMS Treatment|Deep TMS treatment is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions.
89314171|NCT01566669|Placebo Comparator|Normal Saline|Before incision, patients in controlled Group received NS
89314172|NCT01566669|Experimental|parecoxib sodium|Before incision, parecoxib patients received 40mg of parecoxib IV
89314173|NCT04472559|Experimental|Self-acupressure|
89314174|NCT04472559|No Intervention|Control|
89314175|NCT03841773|Experimental|TNX-102 SL Tablet 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
89314176|NCT03841773|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.
89314177|NCT01201083||HIV-|This study measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 105 HIV- recently tested men who have sex with men (MSM) and followed them for a year.
89314178|NCT01201083||HIV+ Acutely Infected|This study enrolled and followed 125 acutely infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
89314179|NCT01201083||HIV+ Chronically Infected|This study enrolled and followed 91chronicially infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
89314180|NCT03841851|No Intervention|temporization without soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.~Atraumatic extraction of badley decayed teeth in the aesthetic area~traditional drilling for immediate implant placement .~immediate temporization ."
89314181|NCT03841851|Active Comparator|temporization with soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.~Atraumatic extraction of badley decayed teeth in the aesthetic area~traditional drilling for immediate implant placement .~immediate temporization .~subepithelial connective tissue graft from the palate ."
89314182|NCT05282511||Patients with acute myocardial infarction|Patients with acute myocardial infarction
89314183|NCT05282511||Healthy controls|Healthy controls
89314184|NCT05282511||Patients with vasospastic angina|Patients with vasospastic angina
89314185|NCT05670171|Active Comparator|Debulking Atherectomy|Excimer laser atherectomy combined with drug-coated balloon angioplasty
89314186|NCT05670171|Active Comparator|Stent Angioplasty|Nickel-titanium self-expanding bare stent
89314187|NCT01201161|Experimental|RANI/PPV|Preoperative intravitreal ranibizumab and pars plana vitrectomy
89314188|NCT01201161|Placebo Comparator|PPV|Sham injection and pars plana vitrectomy
89314189|NCT05282355|Experimental|Astaxanthin|The astaxanthin group received 12 mg/day of astaxanthin. Each capsule contained 6 mg of astaxanthin and sunflower oil, and each subject ingested one capsule in the morning and one in the evening.
89314190|NCT05282355|Placebo Comparator|Placebo|The placebo group ingested two capsules per day, one in the morning and one in the evening. Each capsule contained sunflower oil and mimicked the size and appearance of the astaxanthin supplement.
89314191|NCT05667831|Experimental|Alginate silver dressing|The experimental group received alginate calcium and silver ion dressing
89314192|NCT05667831|No Intervention|traditional dressing|Study subjects received traditional dressing changes such as wet dressing or SSD
89314193|NCT03841383||Healthy controls|
89314194|NCT03841383||Hypertensive patients|
89314195|NCT01199133|Active Comparator|Dpte and Dfar Allergen Extract|
89314196|NCT01199133|Placebo Comparator|Placebo tablets|
89314197|NCT04968639||Axial pain positive group|Postoperative VAS score ≥ 3 points at 3-month follow-up
89314198|NCT04968639||Axial pain negative group|Postoperative VAS score ≤ 2 points at 3-month follow-up
89314199|NCT01199211||Exercise training, women, marathon.|Other: prospective study with no intervention
89314200|NCT05667987|No Intervention|General anesthesia without intravenous lidocaine administration|
89314201|NCT05667987|Experimental|General anesthesia with intravenous lidocaine administration|
89314202|NCT03844737|Experimental|VisuXL® Treatment|
89314203|NCT01201239|Experimental|raltegravir|HIV-infected patients aged over 18 who have failed previous antiretroviral treatment with multi-drug resistant or with multi-drug intolerance are to accept Ral plus OBT.
88806513|NCT03459482|Sham Comparator|Group 2 - Sham Food Elimination Diet|"Group 2 (control group): Subjects will be given a Sham elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates."
88806514|NCT05528484|Experimental|ERAS group|the patients accepting eras nursing protocol ;
89314204|NCT01199367|Experimental|Dose escallation|
89314205|NCT03840213||Patients undergoing chemotherapy treatment|Patients over 18 years of age, followed at the ICLN day hospital or hospitalized and undergoing chemotherapy treatment
89314206|NCT01203735|Other|Valproic acid, Chemoradiotherapy|
89314207|NCT04029753|Experimental|Walk out from operating room|Patients will return to the ward after surgery by walking.
89314208|NCT04029753|No Intervention|Leave operating room by transporting bed|Patients will return to the ward after surgery by lying on the transporting bed.
89314209|NCT01201395||Dental caries assessment|
89314210|NCT03966417|Active Comparator|Exercise training group|"Patient to be randomized to exercise training group will have exercise training sessions 2 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 75% of Vo2max."
89314211|NCT03966417|No Intervention|Usual care group|"Patient to be randomized to usual care group will undergo standard care fo 12 weeks."
89314212|NCT01203813|Experimental|Physician Intervention|"Physicians randomized to the intervention will receive:~Electronic alerts during office visits for patients with chronic kidney disease~Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
89314213|NCT01203813|No Intervention|Physician Control|Physicians randomized to the control arm will continue to manage their patients with chronic kidney disease according to routine primary care standards.
89314214|NCT01203891||Healthy brain subjects|The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging.
89314215|NCT01203969|Experimental|Single port laparoscopic surgery|
89314216|NCT01203969|Active Comparator|Conventional laparoscopic surgery|
89314217|NCT03842631||Superficial Group|Hemangioma depth evaluated by B-ultrasonoscope is lower than or equal to 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
89314218|NCT03842631||Deep Group|Hemangioma depth evaluated by B-ultrasonoscope is more than 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
89314219|NCT03841227|Active Comparator|Active-tDCS|10 patients will receive Active-tDCS intervention (2mA, 20 min) at home.
89314220|NCT03841227|Sham Comparator|Sham-tDCS|10 patients will receive Sham-tDCS intervention (2mA, 20 min) at home.
89314221|NCT03300050|Experimental|Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
89314222|NCT03300050|Experimental|Group 2: cH8/1N1 LAIV and cH5/1N1 IIV|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85.
89314223|NCT03300050|Placebo Comparator|Group 3: Placebo|Participants received 0.5 mL of normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85.
89314224|NCT03300050|Experimental|Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
89314225|NCT03300050|Placebo Comparator|Group 5: Placebo|Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85.
89314226|NCT03842787||SLE patients with lupus Nephritis|"14 SLE patients with lupus Nephritis~Biological analysis and biopsy were (routinely) performed~Ethics The protocol will be submitted to a randomly chosen Institutional Review Board (Comité de Protection des Personnes), in compliance to French regulation.~Investigators will include patients followed for routine care. Patients will be informed that samples (serum and kidney biopsy) that are performed for routine patient care will subsequently be used for research purposes, with no additional blood draw/biopsy. They will sign informed consent."
89314227|NCT03841071||ROM/CFS intervention|The ROM/CFS group (N>100), consists of patients who have undergone urostomy, colostomy, or ileostomy operations, and who are included in the routine follow-up program of the outpatient ostomy clinic at the Department of Surgery, Førde Central Hospital from April 2018 to June 2021.
89314228|NCT05669781|Active Comparator|Gum-Metoclopramide|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and to chew one a stick of sugar free gum (to be chewed over 15minutes) 8 hourly till either first flatus or feces was passed
89314229|NCT05669781|Active Comparator|Gum-only|Chew one stick of sugar free gum (to be chewed over 15minutes) 8 hourly till either first flatus or feces was passed
89314230|NCT05669781|Active Comparator|Metoclopramide-only|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively
89314231|NCT05669781|Placebo Comparator|Control|10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
89314232|NCT05118867|Experimental|IPREPARED Hospital Recovery Club|Participants and their recovery partners (informal caregivers) will use the iPREPARED mobile health technology. They will watch a short video to prepare them for their hospital stay and asked to use the provided resources and tools to maintain their brain health during their hospital stay.
89314233|NCT05118867|No Intervention|Standard Hospital Care Group|Participants will receive standard protocolized care procedures.
89314234|NCT01202331|No Intervention|J|Stop Annual Treatment
89314235|NCT01202331|No Intervention|K|Stop Biannual Treatment
89314236|NCT01202331|Other|L|Continue Annual Treatment
89314237|NCT01202331|Other|M|Continue Biannual Treatment
89314238|NCT01202331|Experimental|N|Targeted Treatment by Age
89314239|NCT01202331|Experimental|O|Targeted Treatment by Clinical Exam
89314240|NCT01201473||Measure impact of research participation|
89314241|NCT01201551|Active Comparator|healthy subjects without PVD|healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
89314242|NCT01201551|Active Comparator|healthy subjects with PVD|healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
89314243|NCT03838809|Experimental|INTERVENTION|A group that underwent a neurological physiotherapy program with electromyography-biofeedback on the hand and the foot
89314244|NCT03838809|Active Comparator|CONTROL|A group that underwent a conventional physiotheraphy intervention
89314245|NCT01204125|Experimental|SAR240550 twice weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 5.6mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions twice weekly (day 1 and day 4; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
89314246|NCT01204125|Experimental|SAR240550 weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 11.2 mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions once weekly (day 1; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
89314247|NCT01204125|Active Comparator|Paclitaxel alone|Paclitaxel will be administered at the dose of 80mg/m2 as a 60-min IV infusion. Patients will receive weekly (day 1) paclitaxel infusions.
89314248|NCT03074240|Active Comparator|TAPB Group|Compare the instance in the TAPB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing TAPB to anesthetize the abdominal wall.
89314249|NCT03074240|Active Comparator|RSB Group|Compare the instance in the RSB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing RSB to anesthetize the abdominal wall.
89314250|NCT05276882|Experimental|hypnosis|
89314251|NCT05276882|Active Comparator|pre-surgery consultation|
89314252|NCT03725085|Experimental|Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)|"2 tablets of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID dose) every 12 hours (twice daily, in the morning and the evening) orally with a full glass of water for 7 days.~GGE = Guaifenesin~BID = Twice in a day"
89314253|NCT03638024||Study group|Maternal plasma cell free fetal DNA levels will be measured in 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
89314254|NCT03638024||Control group|Maternal plasma cell free fetal DNA levels will be measured in 25 matched control with normally situated placenta without ultrasound finding suggestive of placental adhesion or invasion.
89314255|NCT03838185|Experimental|Study Drug|Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.
89314256|NCT03838185|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours.
89314257|NCT05282199|Experimental|IMT group|In the group of post-COVID patients in which reduced endurance and inspiratory muscle power are identified, inspiratory muscle training (IMT) will be performed with a load equivalent to 50% of MIP (assessed weekly) for eight weeks.
89314258|NCT01566825|Active Comparator|Amitriptyline|
89314259|NCT01566825|Placebo Comparator|white 8 mm Lichtenstein®|
89314260|NCT02940392|Experimental|Rezum Treatment|Patients will receive the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia.
89314261|NCT04306809|Experimental|Treatment|Internet delivered Acceptance and Commitment Therapy for PTSD and Chronic Pain, supported by a psychologist
89314262|NCT03559010|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time everyday for up to 16 weeks
89314263|NCT03298412|Experimental|Blinatumomab|"After a run-in period of up to 24 months to evaluate MRD status and assess eligibility for treatment assignment, participants received blinatumomab intravenous (IV) infusion at an initial dose of 9 μg/day for the first 7 days of treatment, escalated (dose-step) to 28 μg/day starting on Day 8 (Week 2), followed by a dose-step to 112 μg/day starting on Day 15 (Week 3) and continuing until completion of therapy (Day 57 of Cycle 1).~Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval."
89314264|NCT03297398|Placebo Comparator|Other|Placebo Group
89314265|NCT03297398|Experimental|Drug Group 1|15mg, OPK-88004
89314266|NCT03297398|Experimental|Drug Group 2|25,mg OPK-88004
89314267|NCT01202019|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
89314268|NCT01202019|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
89314269|NCT03293654|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
89314270|NCT03293654|Active Comparator|US licenced Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
89314271|NCT03293654|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
89314272|NCT03312218|Experimental|Intervention|Intervention site residents will receive alerts through an app to adaptively reinforce the learning of clinical content based on cases and test questions (spaced education).
89314273|NCT03312218|No Intervention|Control|Residents in the control group will receive the same app providing identical clinical cases and test questions-on-demand, but with alerts inactivated (no spaced education).
89314274|NCT03930615|Experimental|Letermovir|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of LET (480 mg once daily alone or 240 mg once daily for participants on cyclosporin A) treatment.
88806515|NCT05528484|Active Comparator|non-eras group|the patients not accepting eras nursing protocol ;
88806516|NCT05386134||Study Subjects|Approximately 175 Study Subjects
88806517|NCT05386134||Control Group|Approximately 25 Control group
88806518|NCT00324272|Experimental|Groin dissection: sealant used.|
88806519|NCT00324272|Active Comparator|Groin dissection: no sealant used.|
88806520|NCT00324272|Experimental|Axillary dissection: sealant used.|
88806521|NCT00324272|Active Comparator|Axillary dissection: no sealant used.|
88806522|NCT05332158|Experimental|Intervention arm|A single arm to administer questionnaires for patients barriers to adherence.
88806523|NCT00369590|Experimental|All Study Patients|"Patients receive VEGF Trap (ziv-aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis."
88806524|NCT03367910|Experimental|FMT for MDRO UTI|Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.
88806525|NCT00324350|Active Comparator|1|intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%)
89314275|NCT03930615|Placebo Comparator|Placebo|Participants who received HSCT transplant and 100 days of LET prophylaxis were randomized to an additional 100 days of placebo treatment.
89314276|NCT05276648|Experimental|ESP BLOCK|erector spina plane block applied
89314277|NCT05276648|Active Comparator|no ESP BLOCK|those who did not apply erector spina plan block
89314278|NCT03838029|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 35 days as follows. Etodolac:400mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery and the following morning, 40 mg PO bid for following 6.5 days, and 20 mg PO bid for next 22 days.
89314279|NCT03838029|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
89314280|NCT03842397|Experimental|Implanted Patients|Implantation of Kephalios Device 1
89314281|NCT04708340|Active Comparator|Arm A: RJX|"RJX 20 mL (10 mL of Vial A plus 10 mL of Vial B) mixed in normal saline, total volume 120 mL, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily.~Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment).~Patients in Part 1 are allowed to receive only one 7-day cycle of RJX while patients in Part 2 may be treated daily for up to 14 days."
89314282|NCT04708340|Placebo Comparator|Arm B: Placebo|"Placebo (total of 20 mL normal saline) mixed in normal saline IV, total volume 120 mL of normal saline IV, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily.~Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment).~Patients in Part 1 will not receive placebo.~Patients in Part 2 may be treated daily for up to 14 days."
89314283|NCT05282433|Experimental|Research Group|Patients with advanced hepatocellular carcinoma who had failed previous standard 1/2-line therapy and could not tolerate or reject existing therapies.
89314284|NCT01204281|Experimental|High assistance PAV+|Ventilatory support performed by PAV at 80% assistance (PB 840-plus) FiO2 and PEEP according to routine practice
89314285|NCT01204281|Active Comparator|Assist-control ventilation|Tidal volume, FiO2 and PEEP set according to routine practice
89314286|NCT04204629|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
89314287|NCT04204629|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
89314288|NCT03292640|Experimental|DFD-03 Lotion (0.1% tazarotene)|DFD-03 Lotion (0.1% tazarotene)
89314289|NCT03292640|Placebo Comparator|DFD-03 Vehicle (0% tazarotene)|DFD-03 Vehicle Lotion (0% tazarotene)
89314290|NCT01204359|No Intervention|follow-up|
89314291|NCT01567215|Experimental|Granuloma|
89314292|NCT02871141||ECT group|Patients with a major depressive episode treated with ECT. Patients will be investigated (i) prior to the 1st ECT session, (ii) after the 4th ECT session, (iii) after the 12th ECT session, and (iv) 6 months after the 1st ECT session.
89314293|NCT02871141||Antidepressant group|Patients with a major depressive episode treated with antidepressants. Patients will be investigated (i) prior to treatment, (ii) after 10 days of treatment, (iii) after 4 weeks of treatment, and (iv) after 6 months.
89314294|NCT01202487|Experimental|Pre-treatment with LET|Pre-treatment with Lidocaine Epinephrine Tetracaine solution at least 45 minutes prior to laceration repair with tissue adhesive
89314295|NCT01202487|Placebo Comparator|Pre-treatment with Placebo|Pre-treatment with Placebo solution at least 45 minutes prior to laceration repair with tissue adhesive
89314296|NCT03882411|Experimental|Electronic shared decision making (eSDM) Tool|"In the pre-intervention period, patients in clinic clusters will receive usual care.~When a clinic cluster's randomly allotted intervention period arrives, coronary heart disease patients in that given clinic cluster will complete a web application, which delivers screening, behavioral activation and shared decision making (eSDM), and providers will receive education and a patient preference report generated from the application.~During both the pre and post intervention periods, patients will be assessed at baseline and 6 month follow up."
89314297|NCT03841461||Academicians|The academicians working in any program of any higher education institution
89314298|NCT03852381|Experimental|Spinal Cord Stimulation|"At baseline, the following data will be recorded: standard-of-care questionnaire scores, neuroimaging (fMRI, MEG), psychophysical testing (QST), accelerometer sleep and activity data.~The trial will proceed as follows:~Day 1-4: Paresthesia-based SCS (PB-SCS)~Day 5-8: No SCS (placebo)~Day 9-12: PF-SCS~Neuroimaging and psychophysical testing will be conducted at the end of the trial, and will be assessed 6-months post-implantation of the SCS device along with adverse effects. A decision to implant the SCS system will be made based on reduction of patient pain intensity by 50% in PB-SCS and/or PF-SCS modes, but not with placebo SCS.~Based on the response in the trial, the patient will either not be a candidate for an SCS implant, or they will receive one of the four modes upon implantation (PB-SCS, or one of the three PF-SCS: Burst, High Frequency, High Density)."
89314299|NCT02696109|Experimental|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
89314300|NCT02696109|Active Comparator|Treatment as Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
89314301|NCT03292406|Experimental|CD11301 Gel 0.06%|Participants applied 0.06% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
89314302|NCT03292406|Experimental|CD11301 Gel 0.03%|Participants applied 0.03% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
89314303|NCT03292406|Experimental|Placebo|Participants applied placebo gel during cycle one followed by 0.03% CD11301 gel topically during cycle two once daily, 3 to 5 times per week, for 24 weeks.
89314304|NCT01201707|Experimental|Treatment of CCSVI with Angioplasty|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will be treated with angioplasty.
89314305|NCT01201707|Sham Comparator|Observation of CCSVI|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will not be treated with angioplasty. These patients will be observed after treatment and compared to those patients who received treatment.
89314306|NCT01204437|Active Comparator|EC standard chemotherapy 4 cycles|
89314307|NCT01204437|Active Comparator|CMF standard chemotherapy 6 cycles|
89314308|NCT01204437|Experimental|Nab-Paclitaxel + Capecitabine 6 cycles|6 cycles of weekly nab-Paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
89314309|NCT01201941||Intervention group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will have access to the e-Chasqui system."
89314310|NCT01201941||Simultaneous/historical control group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will not have access to the e-Chasqui system."
89314311|NCT02633241|Other|Dexmedetomidine (bolus and high infusion)-Propofol arm|Patients in this cohort will receive a combination of Dexmedetomidine 1mcg/kg bolus, Dexmedetomidine 1 mcg/kg/hour infusion, and Propofol 100mcg/kg/minute to accomplish an MRI examination.
89314312|NCT02633241|Other|Dexmedetomidine (bolus and low infusion)-Propofol arm|Patients in this cohort will receive a combination of Dexmedetomidine 1mcg/kg bolus, Dexmedetomidine 0.5 mcg/kg/hour infusion, and Propofol 100mcg/kg/minute to accomplish an MRI examination.
89314313|NCT02633241|Other|Dexmedetomidine (bolus only)-Propofol arm|Patients in this cohort will receive dexmedetomidine 1mcg/kg over 5 minutes and then propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion to accomplish MRI
89314314|NCT03292016|Experimental|APL-130277, sublingual thin film|APL-130277, sublingual thin film, once daily
89314315|NCT03292016|Active Comparator|Subcutaneous APO-go|Subcutaneous APO-go, once daily
89314316|NCT03292016|Active Comparator|Subcutaneous APOKYN|Subcutaneous APOKYN, once daily
89314317|NCT03836313|Experimental|cryoneurolysis treatment|TKA patients randomized to receive preoperative rehabilitation and cryoneurolysis treatment with the iovera° device (n=70)
89314318|NCT03836313|No Intervention|no cryoneurolysis treatment (standard of care)|TKA patients randomized to receive preoperative rehabilitation only (no cryoneurolysis treatment) (n=70)
89314319|NCT05669391|Experimental|Pharmacogenomics Group|
89314320|NCT05669391|No Intervention|Non Pharmacogenomics Group|
89314321|NCT01206075|Other|Mozobil + G-CSF - 001|Up to four patients (splenectomized and non-splenectomized) previously mobilized with G-CSF (previous study), who failed to yield by 2 leukaphereses sufficient CD34+ cells for a future gene therapy procedure, will receive the combination of G-CSF+Mozobil
89314322|NCT01206075|Other|Mozobil|Sixteen or more patients (non-splenectomized and splenectomized) who were not previously mobilized will receive Mozobil alone.
89314323|NCT01206075|Other|Mozobil + G-CSF - 002|Patients who, in this study, fail to mobilize sufficient yields of blood stem cells with Mozobil alone will be invited to be re-mobilized with the combination of Mozobil plus G-CSF.
89314324|NCT03637946|Experimental|SHOFU Beautifil II LS|Experimental: SHOFU Beautifil II LS Restorative system FL-Bond II (self-etching adhesive system)/ Beautifil II (composite restorative)
89314325|NCT03829527|Experimental|Psychotherapy|
89314326|NCT03835377|Experimental|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
89314327|NCT03835377|Active Comparator|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety)
89314328|NCT03289676|Experimental|Quitting Smoking Video|This arm will receive a storytelling narrative intervention by watching a video of women living with HIV taking about their success in quitting smoking.
89314329|NCT03289676|Active Comparator|HIV Infection Video|This arm will watch an attention-control storytelling narrative intervention by watching a video of women living with HIV taking about their life after the diagnosis of HIV.
88806526|NCT00324350|Active Comparator|2|standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)
89314330|NCT03834831|Active Comparator|Coenzyme Q10|Coenzyme Q10 200mg/day for 3 months
89314331|NCT03834831|Active Comparator|Selenium|Selenium mcg/day for 3 months
89314332|NCT01206153|Experimental|metformin|
89314333|NCT01206231||1|Patients with hypercholesterolemia
89314334|NCT01298115||Stage 5 chronic kidney disease|Incident patients commencing renal replacement therapy or conservative care
89314335|NCT01298271|No Intervention|Cyanoacrylate|Endoscopic Cyanoacrylate Injection treatment of primary prevention GVB
89314336|NCT01298271|Active Comparator|Propranolol|Propranolol is used for primary prevention of GVB
89314337|NCT03840681|Experimental|Ridge augmentation by collagen membrane|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at defected area then covered at the defected area by a collagen membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
89314338|NCT03840681|Active Comparator|augmentation by titanium reinforced PTFE|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
89314339|NCT03536858|Active Comparator|Centrality|The patients at clinic one who receive hemodialysis on Tuesday, Thursday, Saturday and the patients on the Monday, Wednesday, Friday schedule at clinic two, will be assigned to the Centrality arm. Two patients per hemodialysis shift with the highest centrality will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patients selected by centrality will have a centrality greater than 1 standard deviation (SD) from the mean of the other patients on their hemodialysis clinic shift and a clustering less than 1 SD from the mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
89314340|NCT03536858|Active Comparator|Clustering|The patients at clinic one who receive hemodialysis on Monday, Wednesday, Friday and the patients on the Tuesday, Thursday, Saturday schedule at clinic two, will be assigned to the Clustering arm.Two patients per hemodialysis shift with the highest clustering coefficient will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patient selected by clustering coefficient, will have a clustering coefficient greater than 1 SD from the mean of the other patients on their hemodialysis clinic shift and centrality 1 SD less than a mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
89314341|NCT03840759|Experimental|usual care|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant and inpatient geriatric consultation team after a complete geriatric assessment (CGA). The CGA includes the assessment of depression, dementia, physical performance of Activity of Daily Living (ADL) and nutrition using Geriatric Depression Scale (GDC-15), Mini-Mental State Examination (MMSE), Barthel Index (BI), and Mini Nutritional Assessment-Short Form (MNA®-SF) respectively. Besides the geriatric physician, our multidisciplinary team included a social worker, nutritionist and physical therapist. In the control group, the participants only received routine hospital care and no geriatric physician was consulted.
89314342|NCT05281965|Experimental|Experimental group|
89314343|NCT05281965|Placebo Comparator|Placebo group|
89314344|NCT04251884|Experimental|Receiving the pudendal nerve block|
89314345|NCT04251884|Active Comparator|Not receiving the pudendal nerve block|
89314346|NCT01202799|Experimental|Treatment A|2% w/w diclofenac sodium topical gel
89314347|NCT01202799|Active Comparator|Treatment B|
89314348|NCT01202799|Active Comparator|Treatment C|
89314349|NCT01204515||Girls with IBS|Girls ages 7-12 years who meet Rome III criteria for IBS
89314350|NCT01204515||Healthy Girls (controls)|Girls ages 7-12 years who are otherwise healthy and have no complaints of stomach pain
89314351|NCT03637868|Experimental|Eribulin|eribulin 1.4 mg/m² administered intravenously between 6 and 7 cycles.
89314352|NCT03829605||Group I:|Fifty AMI patients on admission
89314353|NCT03829605||Group II:|The previous AMI patients after 12 hours
89314354|NCT01206309||Controls|Never develop an immune mediated disorder
89314355|NCT01206309||Immune Mediated Disorder|Develop an immune mediated disorder
89314356|NCT03287804|Experimental|AUTO2|Relapsed or refractory Myeloma patients
89314357|NCT01298349||schizophrenic patients|
89314358|NCT01298349||normal population|
89314359|NCT03834207|Experimental|Intervention Group|Use of the C3-Cloud IT system
89314360|NCT01298505|Experimental|PF-03654764 2.5mg plus fexofenadine 60mg|
89314361|NCT01298505|Experimental|PF-03654764 5mg plus fexofenadine 60mg|
89314362|NCT01298505|Placebo Comparator|placebo|
89314363|NCT01204593|Experimental|Insulin glargine + insulin glulisine|"Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L).~Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) < 180 mg/dL (<10.0 mmol/L) and ideally around 140 mg/dL."
89314364|NCT03286400||CTAG Device with ACTIVE CONTROL|All consecutive patients meeting protocol selection criteria, consented, with an intention to be treated with CTAG Device with ACTIVE CONTROL.
89314365|NCT01298583|Experimental|ankle tracking|subjects track a target with ankle movement
89314366|NCT01298583|No Intervention|ankle movement|
89314367|NCT02019303|Other|Abnormal lymph nodes|There is only one arm to this study and includes all eligible and consented patients with abnormal axillary lymph node on ultrasound.
89314368|NCT03310970|Active Comparator|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
89314369|NCT03310970|Active Comparator|Lidoderm® 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
89314370|NCT03310970|Active Comparator|Intravenous lidocaine|A single intravenous dose of 0.5 mg/kg lidocaine hydrochloride will be administered to each subject.
89314371|NCT03833505||Group 1,|E. vermicularis-positive
89314372|NCT03833505||Group 2|E. vermicularis-negative
89314373|NCT01298817|Experimental|Soy, Prepared Meals|Soy-based meal replacement weight loss group with additional meals provided
89314374|NCT01298817|Active Comparator|Non soy prepared meals|Non-soy based meal replacement weight loss group with additional meals provided
89314375|NCT03828981|Active Comparator|fast-track recovery program|"Pre-operative Verbal and video information Tobacco cessation Daily physical activity Light meal 6 hours and clear liquids up to 2 hours before surgery No bowel preparation A warm blanket Premedication paracetamol 1g and tematsepam 20mg~Intraoperatively For nausea and voimiting dexamethasone 10mg, dehydrobensperidol 1mg and ondancetron 4mg before emergence Analgesia: ropivacain at port sites before incision and at vaginal vault Opioids intravenously at discretion of anesthesiologist supplemented with Dexketoprofen 50mg Urinary catheter early removal Postoperative Pain: tramadol 50mg and ketoprofen100mg i.v., oral opioid if needed; patients with normal pain control receive oral pregabalin 25mg every 8 hours, paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours until discharge Out of bed after 2 hours from the end of surgery A liquid diet, if tolerated regular normal diet. For emesis ondansetron 4mg"
89314376|NCT03828981|No Intervention|conventional recovery program|"Preoperative preparation Verbal and written information Cessation of oral intake after previous midnight. Premedication paracetamol 1g+ diatsepam 5mg.~Intraoperative A warm blanket at the start of procedure. Prophylaxis for nausea and vomiting: Dexamethasone 5mg at induction, and Dehydrobenzperidol 1mg, ondancetron 4mg before emergence. Analgesia: injection of ropivacain 5% 20ml at port sites at the end of surgery, Opioids i.v. (oxycodone)~Postoperative Pain medication:Opioids i.v. (oxycodone), paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours Urinary catheter removal on next morning. Prolonged bowel and bed rest and gradual reintroduction of feeding."
89314377|NCT01312688|Other|Standard hemodynamic therapy|Standard hemodynamic therapy currently accepted in our ICU
89314378|NCT01312688|Experimental|Early Goal Directed Hemodynamic Therapy|Early Goal Directed Hemodynamic Therapy according to the Surviving Sepsis Campaign Guidelines
89314379|NCT05275322|Experimental|Treatment group|
89314380|NCT05275322|No Intervention|Waiting list group|
89314381|NCT01204827|Experimental|CHBV Sebivo|
89314382|NCT01775709|Experimental|PE tube with Duckbill Valve|PE tube with Duckbill Valve
89314383|NCT01770717||Pressure Ulcer Formation|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
89314384|NCT01680237|Active Comparator|Cognitive behavior therapy|"Identification of bodily sensations, cognitions and safety behaviors characteristic of the individual patient~Modification of dysfunctional beliefs and assumptions using socratic questioning and behavioral experiments~Exposure in-vivo~Relapse prevention"
89314385|NCT01680237|Active Comparator|Exposure in-vivo|"Preparation of a brief behavior analysis of the individual case and construction of a hierarchy of relevant (internal and external) phobic situations~Exposure with internal stimuli~Exposure with external stimuli~Relapse prevention~Remark: In this condition there is no active work with the patient's catastrophic cognitions"
89314386|NCT03840603|No Intervention|Control|Usual care of patients with suspected Low RespiratoryTract Infection at the discretion of the attending physician. Care may entail a CRP and/or a PCT measurement, but no nasopharyngeal swab sampling.
89314387|NCT03840603|Experimental|Film Array RP2 Assay guided|In the emergency room a nasopharyngeal swab sample will be collected from subjects with a suspected Low RespiratoryTract Infection for the Film Array RP2 Assay guided plus a blood sample for the PCT assay if the PCT measurement has not been already prescribed.
89314388|NCT03832959|No Intervention|Non esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation to study esophageal lesions. The esophageal protection probe will not be used.
89314389|NCT03832959|Experimental|Esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation, using the esophageal protection probe EnsoETM
89314390|NCT01206543|Experimental|Intraoperative imaging|
89314391|NCT05281419|Experimental|Intralesional triamcinolone injection with whole breast detection radical surgery|
89314392|NCT05281419|Active Comparator|Whole breast detection radical surgery|
89314393|NCT01566903||arteriovenous malformations|
89314394|NCT01566903||Arterial stenosis|
89314395|NCT01566903||Post-treatment follow-up|Patient with an arteriovenous malformation for which treatment by embolization or radiosurgery is indicated
88806527|NCT00390182|Experimental|Single Arm|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy."
89314396|NCT01206621||ED patients presenting with dyspnea|
89314397|NCT01485471||Medical Tool|Diffuse optical spectroscopy imaging ear exam
89314398|NCT03285308|Placebo Comparator|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
89314399|NCT03285308|Experimental|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 μg injected subcutaneously twice daily for up to 12 weeks.
89314400|NCT01298895||PEX group|The first group consisted of 47 eyes with cataract complicated with pseudoexfoliation syndrome (PEX).
89314401|NCT01298895||control group|The control group included 177 eyes with uncomplicated cataract in eyes without other ocular pathology
89314402|NCT01298973|Experimental|Saline|One group will receive Saline to irrigate the wound
89314403|NCT01298973|Experimental|Viscoat|One group will receive Viscoat to close the surgical wound
88806528|NCT05366868|Experimental|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
88806529|NCT05366868|Active Comparator|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
88806530|NCT05366868|Active Comparator|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
88806531|NCT01793246||pCLE for Discrete lung lesions|Patients undergoing bronchoscopy for the diagnosis of a lesion with probe based laser endomicroscopy (pCLE) imaging before biopsy
88806532|NCT01793246||pCLE for acute lung transplant rejection|Patients undergoing bronchoscopy for the detection of acute rejection of lung transplant with probe based laser endomicroscopy (pCLE) imaging before biopsy
88806533|NCT05610774|Experimental|Group (D)|Patients will receive a loading dose of iv dexmedetomidine followed by a maintenance infusion.
89314404|NCT03831867|Experimental|Pilates|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
89314405|NCT03831867|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
89314406|NCT03831399|Placebo Comparator|Control Group|"Subjects in control group will receive placebo (lactose) 6g/day in two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
89314407|NCT03831399|Active Comparator|Intervention Group|"Subjects in intervention group will receive leucine 6g/day, in tin two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
89314408|NCT01206699|Experimental|corticoid|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
89314409|NCT01206699|Placebo Comparator|physiological solution|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
89314410|NCT03525327||Line Dance Class participants|The group will be participating in line dance classes as intervention.
89314411|NCT03523923|No Intervention|Usual Care|If assigned to the Usual Care (UC) arm, participants receive the same care as they would normally received from the HMC or UWMC outpatient TBI clinics, which could include similar types of treatment (medication changes, referral to specialists, etc.).
89314412|NCT03523923|Active Comparator|Collaborative Care|If assigned to the Collaborative Care (CC) arm, participants receive up to 12 sessions (45-60 minutes) of scheduled contacts with a Collaborative Care Manager (CCM) over 16 weeks of treatment. The CCM meets weekly for supervision with a team of experts to determine appropriate care.
89314413|NCT01299051|Active Comparator|Steps to Health|Steps to Health worksite weight management program at Duke.
89314414|NCT01299051|Experimental|Steps to Health Plus!|Steps to Health Plus! worksite weight management program at Duke. Also known as Pathways to Change.
89314415|NCT01299051|No Intervention|Observational Comparison|Observational comparison group consisting of employees who are eligible for the study but do not take part will also be used in analyses (approximately 1500 subjects).
89314416|NCT01203033||AML patients|newly diagnosed or relapsed AML patients
89314417|NCT01206855|Active Comparator|SOC Treated Side of Incision|One side of the incision will be treated with surgeon's standard postoperative care including cleansing, creams, dressings
89314418|NCT01206855|Active Comparator|MIST Treated Side of Incision|One half of the incision will receive MIST Therapy treatments 3 times per week for 2 weeks
89314419|NCT01203111|Experimental|Intensive insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)
89314420|NCT01203111|Experimental|insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c <7% at week 12 (end of treatment period 1)
89314421|NCT01299207||CAD treated with Xience stents|Patients with CAD who undergo successful stenting with the Xience drug-eluting stent will represent the patient population.
89314422|NCT02722941|Active Comparator|Cohort A: Maintenance Therapy|Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.
89314423|NCT02722941|Active Comparator|Cohort B: Maintenance Therapy|Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.
89314424|NCT03420339|Experimental|Subjects on stimulant medication|All participants: Children and adolescents diagnosed with AD/HD, displaying disruptive behavior, and taking stimulant medication.
89314425|NCT03830775|Experimental|Experimental - PRP injection|2cc of PRP is injected into the ulnocarpal joint
89314426|NCT03830775|Placebo Comparator|control - Saline injection|2cc of 0.9% sterile saline is injected into the ulnocarpal joint
89314427|NCT01206933||Detectable HIV RNA and HCV RNA|HIV and HCV co-infected with detectable HIV RNA and HCV RNA
89314428|NCT01206933||Undetectable HIV and Detectable HCV|HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.
89314429|NCT01206933||Undetectable HIV and HCV|HIV and HCV infected, Undetectable HIV RNA and HCV RNA
89314430|NCT01206933||Undetectable HCV|HCV(mono-infected,) HCV RNA undetectable
89314431|NCT01206933||Detectable HCV RNA|Monoinfected HCV, detectable RNA
89314432|NCT01206933||Detectable HIV RNA|Monoinfected HIV, Detectable RNA
89314433|NCT01207089|Placebo Comparator|1|
89314434|NCT01207089|Experimental|2|AZD8329
89314435|NCT01205139|Experimental|001|TMC435 150 mg capsule once daily for 11 days
89314436|NCT01205139|Experimental|002|TMC278 25 mg tablet once daily for 11 days
89314437|NCT01205139|Experimental|003|TMC435 + TMC278 150 mg TMC435 capsule + 25 mg TMC278 tablet once daily for 11 days
89314438|NCT01205139|Experimental|004|TMC435 150 mg capsule once daily for 7 days
89314439|NCT01205139|Experimental|005|TDF 300 mg tablet once daily for 7 days
89314440|NCT01205139|Experimental|006|TMC435 + TDF 150 mg TMC435 capsule + 300 mg TDF tablet once daily for 7 days
89314441|NCT01205217|Experimental|Arm A|"Lapatinib in combination with epirubicin and cyclophosphamide followed by paclitaxel and lapatinib.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea"
89314442|NCT01205217|Active Comparator|Arm B|"Epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week"
89314443|NCT01203267|Experimental|paclitaxel plus carboplatin (PCb) Arm|4 cycles of neoadjuvant paclitaxel plus carboplatin
89314444|NCT01299363|No Intervention|No dilator use|
89314445|NCT01299363|Active Comparator|Dilator use|Women randomized to vaginal dilators will be given instructions to perform softening exercises from postoperative weeks 4 to 8
89314446|NCT01205295||Mental disorders|Preoperative and postoperative screening of mental disorders and efficacy of treatment in hip and shoulder patient.
89314447|NCT03826953|Other|Nurse led allergy clinic|nurse led allergy clinic
89314448|NCT05666427|No Intervention|Control Group|No application will be made until the end of this group work. After the end of the study, the effective protocol will be applied.
89314449|NCT05666427|Active Comparator|Classic Application Group|In this group, classical pelvic floor muscle training will be applied.
89314450|NCT05666427|Active Comparator|Study Group|The protocol determined for the study will be applied in this group. This protocol is planned as follows: It will perform stabilization exercises with the activation of the pelvic floor muscles.
89314451|NCT01299441||OLT patients intubated with ECOM ETT|Patients undergoing liver transplantation and intubated with ECOM endotracheal tube (ETT).
89314452|NCT01299519|Experimental|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
89314453|NCT01299519|Active Comparator|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
89314454|NCT01207245|Active Comparator|Morning dose of tobramycin|Administration of tobramycin once daily dose in the morning
89314455|NCT01207245|Active Comparator|Evening tobramycin|Evening dose of tobramycin once daily
89314456|NCT01297413|Experimental|Stem cells|All subjects will receive allogeneic adult mesenchymal bone marrow stem cells
89314457|NCT01297569|Experimental|Ranibizumab|
89314458|NCT01203345|Active Comparator|Immune globulin|Lyophilized human immune globulin product
89314459|NCT01203345|Placebo Comparator|Albumin solution|
89314460|NCT01299597|Experimental|Cohort 1: Atorvastatin|single dose session with Atorvastatin with PK samples collected up to 72h post dose, then 14 days repeat dose session with SB649868 with Atorvastatin single dose co-administered on day 8 (same time as SB649868) and on day 12 (2 hours before SB649868).
89314461|NCT01299597|Experimental|Cohort 2: Simvastatin|single dose session with Simvastatin with PK samples collected up to 24h post dose, then 14 days repeat dose session with SB649868 with Simvastatin single dose co-administered on day 12 (same time as SB649868) and on day 14 (2 hours before SB649868).
89314462|NCT03723915|Experimental|Treatment (pembrolizumab, wild-type reovirus)|See Detailed Description
89314463|NCT01205373|Experimental|BI 671800 high dose|Oral drinking solution
89314464|NCT03826407||DOC patients|Patients in coma (GCS score of 3-8) or with other disorder of consciousness, primarily Minimally Conscious State (MCS) or Unresponsive Wakefulness Syndrome (UWS; also known as vegetative state)
89314465|NCT03826407||Healthy Control|Matched healthy controls without current neurological diagnoses
89314466|NCT01207323|Experimental|Dose Escalation (MEHD7945A)|Participants will receive intravenous (IV) infusion of MEHD7945A in escalating doses Q2W until MTD is reached or up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first. Approximately 5 dose levels between 1 and 30 mg/kg will be evaluated.
89314467|NCT01207323|Experimental|Dose Expansion (MEHD7945A)|Participants will receive IV infusion of MEHD7945A Q2W at or below the MTD (decided from dose escalation part) up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
89314468|NCT01205607|Experimental|ITPR -9 & then -5 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
89314469|NCT01205607|Experimental|ITPR -5 & then _9 mm HG|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
89314470|NCT01297647|Experimental|Spinal cord injured|Patients with neurogenic lower urinary tract infection (Spinal Cord Injury,MS,M. Parkinson)
89314471|NCT03840057|Experimental|Azithromycin|Participants randomized to the azithromycin arm would receive 250mL of reconstituted solution containing 500mg of generic azithromycin to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic or renal impairment. No dose adjustment is made for geriatric population.
89314472|NCT03840057|Experimental|Metoclopramide|Participants randomized to the metoclopramide arm would receive 2mL of solution containing 10mg of generic metoclopramide to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic impairment. A 50% dose reduction is made for those with creatinine clearance of less than 40mL/minute. No dose adjustment is made for geriatric population.
89314473|NCT03840057|Placebo Comparator|Placebo|Participants randomized to the placebo arm during Part 1 (azithromycin) of the study would receive 250mL of 0.9% sodium chloride solution to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. Participants randomized to the placebo arm during Part 2 (metoclopramide) of the current study would receive 2mL of 0.9% sodium chloride solution to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy.
89314474|NCT05623917|Experimental|Exercised group|the group will contain 20 females. the females will receive tele-supervised Diaphragmatic Respiratory Exercise ( applied at the homes of the females two times per the day, at the morning and at the evening, twenty minutes for every time, the sessions will be applied daily for 3 months in all females).
89314475|NCT05623917|No Intervention|control group|he females in the this group will be waiting-list control females who will receive no training.
89314476|NCT01299675||Chronic Performance|Subjects enrolled prior to or within 30 days post implant of SureScan pacing system. In office follow-up visits required every 6 months.
89314477|NCT01299675||Multiple MRI Scan Characterization|Subject enrolled into study at the time of MRI Scan indication. Subject followed per clinic standard of care.
89314478|NCT01297725|Experimental|Right sharp, left blunt|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
89314479|NCT01297725|Experimental|Right blunt, left sharp|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
89314480|NCT01205841|Experimental|Adults|Patients from 16 years of age onwards
89314481|NCT01205841|Experimental|Children|Patients aged 5 to 15 years
89531748|NCT05563805|Experimental|Intervention|intervention participants will engage in a 30-minutes VR adventure games on a non-mobilized treadmill (5-min warm-up, 20-minutes treadmill, and 5-min cool-down) for a total of 24 sessions over 8 weeks. Participants in the V-RATE group will be instructed to self-pace walking/running on the treadmill while they are fully immersed in the VR games for two 10-minute bouts with a complete rest interval (heart rate reduces to normal range). Participants will complete measures at baseline, post-8-week training, and one-month follow-up.
89314482|NCT03825627|Active Comparator|Antisaccade Task (active tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
89314483|NCT03825627|Sham Comparator|Antisaccade Task (sham tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm sham Transcranial Direct Current Stimulation will be used during the task.
89314484|NCT03825627|Active Comparator|Approach Avoidance Task (active tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
89314485|NCT03825627|Sham Comparator|Approach Avoidance Task (sham tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm sham Transcranial Direct Current Stimulation will be used during the task.
89314486|NCT01205919|Experimental|Internet-based self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
89314487|NCT01205919|Active Comparator|Discussion forum group|To the participants of the control group the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
89314488|NCT01297803|Active Comparator|Mitomycin_c application before sclera flap dissection|
89314489|NCT01297803|Active Comparator|Mitomycin_c application after sclera flapdissection|
89314490|NCT03178383|Experimental|Integrated Approach|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
89314491|NCT03178383|Active Comparator|Standard Comparison|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
89314492|NCT03824691|Experimental|Cabozantinib + Durvalumab|Subjects will receive 1500 mg durvalumab (MEDI4736) IV infusion every 28 days + Cabozantinib 40 mg orally once daily
89314493|NCT01297881||Caucasian outpatients with respiratory symptoms|all consecutive new Caucasian outpatients with respiratory symptoms like dyspnoea, cough, sputum but without diagnosis who are being examined for the first time.
89314494|NCT01299831|Experimental|72 hour fast|
89314495|NCT01299831|Experimental|12 hours fast|
89314496|NCT01299831|Experimental|12 hour fast, growth hormone bolus|
89314497|NCT01299831|Experimental|72 hour fast, inhibition of lipolysis|
89314498|NCT01205997|Active Comparator|fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
89314499|NCT01205997|Placebo Comparator|placebo|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
89314500|NCT01205997|Active Comparator|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
89314501|NCT05622825|Experimental|cryoablation combined DC-CIK|To explore the therapeutic effect and safety of cryoablation combined with autologous DC-CIK (through hepatic artery infusion, HIA) for patients with advanced liver cancers
89314502|NCT05281575|Active Comparator|Treatment as Usual BFS (TAU BFS)|Continuation of existing Baby Friendly Spaces program activities in integrated nutrition centers, which are not manualized and without re-training have naturally drifted in fidelity to the intervention and supervision approach due to time since initial training.
89314503|NCT05281575|Experimental|Enhanced BFS|The implementation-enhanced BFS intervention includes re-training using newly developed training materials that focus on building core therapeutic engagement skills. Ongoing supports include brief guidance sheets for each of the most commonly delivered BFS activities, as well as newly established group supervision focused on BFS, discussion facilitation, activities and self-care.
89314504|NCT03818997|Experimental|BTC Cohort|Patient in BTC cohort will receive immune therapy and DKN-01 IV until PD
89314505|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab + paclitaxel (Arm 1)|Patient randomized in the EGC Arm 1 will receive immune therapy, DKN-01 and chemotherapy intravenously (IV) until PD.
89314506|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab without paclitaxel (Arm 2)|Patient randomized in the EGC Arm 2 will receive immune therapy and DKN-01 IV until PD
89314507|NCT03818841|Experimental|High-flow nasal cannula group|Patients randomised in this group will receive oxygen therapy via a high-flow nasal cannula device with a 60 L/min flow and a 100% fraction of inspired oxygen
89314508|NCT03818841|Other|Non-rebreathing oxygen mask group|In this group patients will be treated with standard oxygen therapy delivered through a non-rebreathing face mask with a 15 L/min flow
89314509|NCT01203657|Experimental|Tai Chi|Tai Chi instruction, 2x week in a community senior center setting
89314510|NCT01203657|No Intervention|Wait List Control|This is a wait list control group. There is no active or placebo intervention.
89314511|NCT03818919|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
89314512|NCT03818919|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-Acetaminophen Cap 5-500
89314513|NCT03822195||asymptomatic|asymptomatic patients undergoing carotid endoarterectomy for stenosis >70% (velocimetric criteria at echodoppler)
89314514|NCT03822195||symptomatic|symptomatic (TIA, crescendo TIA, minor stroke) patients undergoing carotid endoarterectomy, independently from stenosis evaluated by echodoppler
89314515|NCT03821493|Experimental|PF-06651600 treatment arm|This arm includes two treatment periods. Period 1-Single oral dose of PF-06651600 30 mg as tablets on Day 1 followed by Period 2 in which itraconazole 200 mg (oral solution) is given for 5 days. On Day 4 of Period 2, a single oral dose of PF-06651600 30 mg is given with itraconazole
89314516|NCT01300221||Group 1|Subjects who are healthy normal children.
89314517|NCT01300221||Group 2|Subjects who have congenital heart disease.
89314518|NCT01300221||Group 3|Subjects who have sickle cell disease
89314519|NCT01300221||Group 4|Subjects who have Duchenne muscular dystrophy
89314520|NCT01300221||Group 5|Patients who have Marfan syndrome and other aortic disease
89314521|NCT05621265|Experimental|Intervention|Automated Text messaging for sleep behavior change
89314522|NCT05621265|No Intervention|Control|Control, Traditional physical therapy only
89314523|NCT05346237||Adult laryngectomised patients|Patients who have undergone total laryngectomy and completed minimal their 12-month period without disease after surgery and post-operative treatments such as radiotherapy or chemotherapy
89314524|NCT01301937|Active Comparator|High continuous dose|Meglumine antimoniate 20 mg/kg/day for 30 continuous days
89314525|NCT01301937|Active Comparator|Low continuous dose|Meglumine antimoniate 5 mg/kg/day for up to 120 continuous days according to clinical cure
89314526|NCT03814551||Comparison|Cohort of participants who regularly eat in cafeteria without health signage.
89314527|NCT03814551||Signage|Cohort of participants who regularly eat in cafeteria in which health signage is placed.
89314528|NCT01300299|Experimental|All subjects|Subjects will receive chemotherapy after stereotactic body radiation therapy.
89314529|NCT03818451|No Intervention|Control Group|"All patients are treated by standard treatments according to patterns of severity and in the light of different variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows:~Surgical evacuation of hemorrhagic masses and brain contusion~Medical management aimed to maintenance of euvolemia and adequate brain perfusion. Prevention of secondary complications of critical illness included: preventive treatment of venous thromboembolism (VTE) and seizures~Patient who undergo surgical treatment, will recieve also postoperative intensive care treatments including: position of the head high, lower values of end-tidal CO2, sedation with reduced metabolic consumption of O2, increase in plasma osmolarity by administration of mannitol in controlled doses or hypernatremia, therapeutic CSF drainage"
89314530|NCT03818451|Experimental|Study Group|Standard treatment plus specific treatment. The investigational agent, the co-ultraPEALut, is administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e. diabetes, arterial hypertension).
88806534|NCT05610774|Placebo Comparator|Group (C)|patients will receive saline loading and infusion
89314531|NCT05623371|Experimental|Treatment group|Leadership training comprising 5 modules and group exercises
89314532|NCT05623371|Other|Control group|Active control group receiving the offer of a webinar and written material
89314533|NCT01300845|Active Comparator|Humidification|
89314534|NCT01300845|Experimental|No Humidification|
89314535|NCT05618223|Experimental|Dapagliflozin group|Dapagliflozin 10 mg once a day and standard treatment
89314536|NCT05618223|No Intervention|Control group|Standard treatment only.
89314537|NCT03814473|Experimental|Dietary intervention|All participants will follow an ad libitum self-administered Paleo diet for 8-weeks
89531749|NCT05563805|No Intervention|Control|Control participants will not receive the intervention. Participants will complete measures at baseline, 8 weeks, and one-month follow-up.
89531750|NCT05558566|Experimental|Neurofeedback from the SMA|
89314538|NCT05623293||Carotid endarterectomy|he population corresponds to patients submitted to elective CEA. Consecutive patients from a tertiary referral center who undergo CEA for carotid artery stenosis (CS) under regional anesthesia will be prospectively recruited from September 2021 - December 2022. The expected patient follow-up will be of 2years.
89314539|NCT03814629|Other|precancerous lesions of gastric cancer|120 cases of chronic atrophic gastritis with intestinal metaplasia or dysplasia,It was randomly divided into 60 cases of treatment group and 60 cases of control group,treatment group was given Weifuchun tablets,The control group was given vitamin tablets.
89314540|NCT01585935|Experimental|Smoflipid|SMOFLIPID will be used for parenteral lipid supply
89314541|NCT01585935|Active Comparator|Intralipid|INTRALIPID will be used for parenteral lipid supply
89314542|NCT05623215||Cementless ATTUNE|Cementless ATTUNE Rotating Platform Cruciate Sacrificing Knee System
89314543|NCT05623215||Cementless LCS|Cementless LCS rotating platform Cruciate Sacrificing Knee System
89314544|NCT01300377|Active Comparator|Bupivacaine / Lidocaine|Lidocaine/Bupivacaine mixture - 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
89314545|NCT01300377|Active Comparator|Lidocaine|Lidocaine - 10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
89314546|NCT05334303||epigenetic MMR deficiency|Tumors with MMR abnormalities by IHC and MLH1 methylation
89314547|NCT05334303||probable MMR mutations|Tumors with MMR abnormalities by IHC and without MLH1 methylation
89314548|NCT05334303||MMR proficient|without MMR abnormalities by IHC
89314549|NCT03814707|Active Comparator|Topical application 0.2%Hyaluronic Acid|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting and covered by periodontal pack
89314550|NCT03814707|Experimental|Platelet Rich Fibrin|Palatal donor site will receive a platelet rich fibrin and then will be sutured by criss cross suture then covered by periodontal pack.
89314551|NCT03819777||Idiopathic PAH|
89314552|NCT03819777||CTD-PAH|
89314553|NCT03819777||CTD without PAH|
89314554|NCT03818295|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-praliciguat
89314555|NCT03819699|Experimental|Cohort 1 - dose regimen 1|Cohort 1: encompasses patients enrolled prior to the PA1
89314556|NCT03819699|Experimental|Cohort 2 - dose regimen 2|Cohort 2: 10 patients who will receive one administration of booster vaccine prior to the first IMP administration
89314557|NCT03819699|Experimental|Cohort 2 - dose regimen 3|Cohort 2: 10 patients who will not receive a booster vaccine
89314558|NCT03817827|Experimental|Acupuncture|this group will receive Acupuncture therapy for 30 minutes three times per week
89314559|NCT03817827|Experimental|diet modification|this group will receive diet using soy products a
89314560|NCT03817827|Experimental|combined group|will receive both acupuncture therapy and soy products
89314561|NCT03814239||no protocol|liberal fluid therapy
89314562|NCT03814239||protocol|fluid therapy according to stroke volume variation (SVV) monitor, tranexamic acid administration, use of cell saver
89314563|NCT03819621|Experimental|OCULAR PROSTHESIS MOTILITY|All participants ocular prosthesis motility will be measured using the mediGrid app, Image J software in comparison to the ruler as a gold standard.
89314564|NCT01300611|Experimental|TXA127 300 mcg/kg/day|Treatment group 1 (300 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
89314565|NCT01300611|Experimental|TXA127 1000 mcg/kg/day|Treatment group 2 (1000 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
89314566|NCT05323851||Surgeon|Any Resident, Fellow, PhD candidate, consultant or attending surgeon in any surgical specialty in Italy
89314567|NCT03817749|Experimental|Experimental|"Participants will consume 20 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.~All meals will be provided throughout the supplementation period~Participants will wear a continuous glucose monitor for 6 consecutive days during the supplementation period."
89314568|NCT03817749|Placebo Comparator|Placebo|Participants will consume a flavor matched placebo drink and undergo the same procedures described in the Experimental Arm
89314569|NCT03817671|Other|Control arm (5% O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 5% O2, and 89.3% N2 till embryo transfer
89314570|NCT03817671|Experimental|Experimental arm (2%O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 2% O2, and 92.3% N2 till embryo transfer
89314571|NCT01301235||Subjects with mitochondrial disease|
89314572|NCT01301313|Experimental|Levosimendan|
89314573|NCT01301313|Active Comparator|Conventional intensified inotropic treatment|
89314574|NCT03817359|Experimental|Mix infusion using single TCI pump|participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump infusion
89314575|NCT03817359|No Intervention|Separate infusion using two TCI pumps|participants receive total intravenous anesthesia with remifentanil and propofol separately by two TCI pumps infusion
89314576|NCT03281876|Experimental|GSK3277511A Group|Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2) at Day 1 and Day 61.
89314577|NCT03281876|Placebo Comparator|CONTROL Group|Healthy males and females, 40 to 80 years of age, who received two doses of placebo vaccine at Day 1 and Day 61.
89314578|NCT03813927|Experimental|Vitamin D|supplementation with tablet 170 μg Vitamin D each day.
89314579|NCT03813927|Placebo Comparator|Placebo|Placebo, tablet with 20 μg Vitamin D each day.
89531751|NCT05558566|Active Comparator|Neurofeedback from control region|
89314580|NCT03809091||Bronchiectasis|The patient with bronchiectasis who has no apparent bronchiectasis-causing etiology will be enrolled. The patient's family who has no bronchiectasis will be also enrolled to identify the patient-specific variants.
89314581|NCT01302015|Experimental|RNL-Vascostem®|drug name and ingredients : RNL-Vascostem[Autologous adipose tissue derived mesenchymal stem cells] dosage : Intramuscular infusion, 5 x 10e6 cells/kg
89314582|NCT03817047|Experimental|Physical active learning (PAL)|"Three components:~Physical education (60 minutes)~Physical active learning (30 minutes)~Physical activity (30 minutes)"
89314583|NCT03817047|Experimental|Don't worry - be happy|"Two components:~Physical education (60 minutes) - don't worry class~Physical activity (60 minutes) - be happy class"
89314584|NCT03817047|No Intervention|Control group|Current practice
89314585|NCT01313546|Active Comparator|quadriceps|quadriceps muscular contraction
89314586|NCT01313546|Active Comparator|sartorius|stimulation of sartorius muscle through femoral nerve
89314587|NCT03817281||Accuryn Monitoring System|Observational only (no intervention). Study Cohort is patients using the Accuryn Monitoring System as a standard-of-care digital urimeter, during their standard course of treatment.
89314588|NCT01560351|Experimental|rTMS|Session of repeated low-frequency Transcranial Magnetic Stimulation
89314589|NCT01560351|Sham Comparator|Placebo|Sessions of sham rTMS
89314590|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
89314591|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
89314592|NCT03310580|Placebo Comparator|Placebo Comparator|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
89314593|NCT04514991|Experimental|Treatment|Surgical sites (osteotomy) assigned to this group received endodontic microsurgery procedure+ Foundation (J. Morita USA).
89314594|NCT04514991|No Intervention|Control|Surgical sites (osteotomy) assigned to this group receives endodontic microsurgery procedure only.
89314595|NCT03816969|Active Comparator|Self-pressurized air-Q with blocker|Self-pressurized air-Q with blocker has a greater seal pressure compared to Air-Q blocker, easier and faster in insertion and has less morbidity and complications while and after insertion
89314596|NCT03816969|Active Comparator|Air-Q ILA blocker|It has a drain tube through which a suction tube is passed
89314597|NCT03817203|Experimental|Kinesio tape group|Kinesio tape application and pelvic floor exercise have been applied
89314598|NCT03817203|Sham Comparator|Control group|Sham kinesio tape application and pelvic floor exercise have been applied
89314599|NCT03816579|Experimental|PRO-A|Beef protein
89314600|NCT03816579|Experimental|PRO-B|Complementary proteins at each meal
89314601|NCT03816579|Experimental|PRO-C|Complementary proteins over 24 hours
89314602|NCT03816579|No Intervention|CON|Low protein (<5 g) meal
89314603|NCT03638336|Experimental|flexible ureteroscopy|
89314604|NCT03813771|Experimental|Abnormal T-cells: Benepali + T2T Care|"Treatment Arm C will receive Benepali and methotrexate combination therapy and followed as per T2T care over a total duration of 24 weeks. Sulfasalazine or Hydroxychloroquine may be added to therapy at follow up visits in-line with T2T care.~Benepali will be administered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).~Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks."
89314605|NCT03813771|Active Comparator|Abnormal T-cells: Methotrexate + T2T Care|"Treatment Arm B will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination synthetic DMARD (Including sulfasalazine and/or hydroxychloroquine).~therapy if not achieving low disease activity (LDA) at, or after, 8 weeks)."
89314606|NCT03813771|Other|Normal T-cells: Methotrexate + T2T Care|Treatment Arm A will receive standard T2T care as per Arm B.
89314607|NCT03813693|Experimental|towels with chlorhexidine gluconate 2%|Composed of 25 patients, who received 2 towels with chlorhexidine gluconate 2% packages each containing six towels and detailed instructions on the form and sequence of application of the towels; the time of application, that is, the night before surgery, between 20 and 22h, and, on the morning of surgery, between 5 and 6h; besides other general orientations.
89314608|NCT03813693|Active Comparator|chlorhexidine gluconate 2% liquid|Composed of 23 patients, two 100 ml flasks of chlorhexidine gluconate 2% liquid were supplied, and detailed instruction manual for the product, containing form and application sequence; time of application (the night before surgery, between 20 and 22h, and on the morning of surgery, between 5 and 6h); and general guidelines.
89314609|NCT02036242|Experimental|Sole local anesthetic|Epidural analgesia will be given with sole local anesthetic (0.125% ropivacaine) intermittently
89314610|NCT02036242|Active Comparator|Opioid plus local anesthetic|Epidural analgesia will be given with opioid (sufentanil) combined with local anesthetic (0.125% ropivacaine) intermittently
89314611|NCT05281107|Placebo Comparator|Placebo, 500 mg calcium|Participants received 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
89314612|NCT05281107|Active Comparator|600 IU vitamin D + 500 mg calcium|Participants received 600 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
89314613|NCT05281107|Active Comparator|1200 IU vitamin D + 500 mg calcium|Participants received 1200 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
89314614|NCT05281107|Active Comparator|4000 IU vitamin D + 500 mg calcium|Participants received 4000 IU vitamin D with 500 mg calcium in berry flavoured sachet powder daily for 16 weeks
89314615|NCT03415022|Experimental|4-week computer-based treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
89314616|NCT03415022|Experimental|8-week computer-based treatment|An 8-week (12-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks, and then once a week for the subsequent four weeks.
89314617|NCT02816398|Experimental|Treatment|Interventional use of experimental Ellipsys catheter system for percutaneous creation of an arteriovenous fistula
89314618|NCT03816501|Other|music|The preference of the patients will be listened to preoperatively through the headphones.
89314619|NCT03816501|Other|no music|preoperative music will not be listened
89314620|NCT02036398|Active Comparator|Nephrostomy tube + double J stent|Standard therapy group with nephrostomy tube and double J stent left at the end of the PCNL
89314621|NCT02036398|Experimental|Double J stent without nephrostomy|Double J stent only left at the end of the procedure
89314622|NCT04384809|Experimental|Leukocyte rich platelet rich plasma injection|Patients will be injected with leukocyte rich platelet rich plasma in their common extensor tendon
89314623|NCT04384809|Experimental|Percutaneous tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
89314624|NCT02812186|Other|Deep to Moderate NMB|This group will undergo deep neuromuscular blockade, defined as post tetanic count (PTC) of 1 to 2, in the beginning portion of the surgery followed by a period of moderate blockade.
89314625|NCT02812186|Other|Moderate to Deep NMB|This group will undergo moderate neuromuscular blockade, defined as 1-2 twitches, in the beginning portion of the surgery followed by a period of deep blockade.
89314626|NCT01303185||Experimental Group|
89314627|NCT01303185||Control Group|
89314628|NCT02811640||Study Participants|Adults with chronic kidney disease who will have a PD catheter inserted at the Ottawa Hospital
89314629|NCT03310268|Experimental|Test Product|Participants will be instructed to self administer experimental dentifrice containing 0.454% SnF2 and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total).
89314630|NCT03310268|Active Comparator|Negative Control|Participants will be instructed to self administer negative control dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (SMFP).
89314631|NCT03310268|Active Comparator|Positive Control|Participants will be instructed to self administer positive control dentifrice containing SnCl2 and 0.15% NaF (1450 ppm fluoride in total).
89314632|NCT01301469|Experimental|1|6% HES 130/0.42 in plasma adapted Ringer's solution (balanced solution)
89314633|NCT01301469|Active Comparator|2|HES 130/0.4 in a saline solution
89314634|NCT03805113|Experimental|Intervention group|Treatment with magnetotherapy device 15 20-minute-sesions every consecutive working day.
89314635|NCT03805113|Placebo Comparator|Control group placebo|Treatment with misconnected magnetotherapy device 15 20-minute-sesions every consecutive working day.
89314636|NCT01303263|Other|Intervention Group|Residents Randomized to Receive Educational Intervention
89314637|NCT01303263|No Intervention|Control Group|Residents randomized not to receive a teaching intervention.
89314638|NCT02810392|Active Comparator|Intranasal Insulin|Intranasal Insulin (20 IU BID): Humulin insulin packaged is in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
89314639|NCT02810392|Placebo Comparator|Intranasal Saline|Intranasal saline: Saline is packaged in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
89314640|NCT03816423|No Intervention|Traditional counseling|Patients will undergo routine prenatal care visit with clinical practicioner only
89314641|NCT03816423|Experimental|video group|"Participants randomized to the intervention group (video education) will view the prenatal screening video How to Decide About Prenatal Genetic Testing, followed by a routine prenatal appointment."
89314642|NCT03805035|Sham Comparator|sham EA group|Minimal needling at ST36 and GB34 (n=10)
89314643|NCT03805035|Experimental|true EA group|EA at ST36 and GB34 (n=10)
89314644|NCT03805035|Active Comparator|EA+antihistamine(low dose) group|EA at ST36 and GB34 plus low-dose chlorpheniramine( Dexchlorpheniramine maleate 2mg/tab, 1 tab; n=10)
89314645|NCT03805035|Active Comparator|EA+antihistamine(high dose) group|EA at ST36 and GB34 plus high-dose chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 2 tabs; n=10)
89314646|NCT02815540|Other|Heart Function and Dysautonomia|This study looks at participants already receiving CBD from the state of MN. We are not providing the CBD. We are looking at heart function with ECGs and Holter monitoring before and after CBD is taken by the participant. We are also looking at dysautonomia signs and symptoms and seizure frequency before and after CBD is taken by the participant.
89314647|NCT03816267|Active Comparator|Nebulizer|Containing salbutamol
89314648|NCT03816267|Experimental|Metered Dose Inhaler and spacer|Containing Salbutamol
89314649|NCT03280550|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
89314650|NCT03280550|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
89314651|NCT02036554|Experimental|Tacrolimus plus Everolimus|Low dose Tacrolimus + Everolimus
89314652|NCT02036554|Active Comparator|Tacrolimus plus Mycophenolic acid|standard dose Tacrolimus + Mycophenolic acid
89314653|NCT05577117|Active Comparator|opioid free (OFA) group|1000 mg paracetamol + dexmedetomidine 1 µg/kg over 10 min as loading dose and dexamethasone 0.1 mg/kg and lidocaine 1 mg/kg IV bolus Then continuous infusion of dexmedetomidine at a rate of 0.5 µg/kg/h with lidocaine 2 mg/kg/hr and magnesium sulfate 1.5 g/hr during surgery .
89314654|NCT05577117|No Intervention|fentanyl (F) group|fentanyl 2 µg/kg as loading dose followed by continuous infusion at a rate of 1 µg/kg/h during surgery.
89531752|NCT05556642||Group 1|Patients with relapsed/ refractory Hepatoblastoma
89314655|NCT03813303|Active Comparator|Midazolam group|Midazolam and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist . Complications and procedure and recovery times were recorded for comparison with the Fentanyl group.
89314656|NCT03813303|Active Comparator|Fentanyl group|Fentanyl and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist .Complications and procedure and recovery times have were recorded for comparison with the Midazolam group.
89314657|NCT03804801|Experimental|Intervention Arm (or Group)|This arm will receive the intervention (Hibiscus Sabdariffa extract supplement)
89314658|NCT03804801|No Intervention|Control Arm (or Group)|This arm will receive no intervention whatsoever, not even placebo
89314659|NCT03637790|Other|PF 04965842|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
89314660|NCT03637790|Other|Rifampin and PF 04965842|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
89314661|NCT03816033|Active Comparator|Cryotherapy|Cryotherapy ablation energy will be utilised in the catheter ablation procedure
89314662|NCT03816033|Active Comparator|Radiofrequency|Radiofrequency ablation energy will be utilised in the catheter ablation procedure
89314663|NCT03356132||Textured Group|Women undergoing primary and secondary breast augmentation with Silimed® Textured Silicone Gel-Filled Breast Implant.
89314664|NCT03356132||Polyurethane Group|Women undergoing primary and secondary breast augmentation with Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
89314665|NCT04576598|Experimental|Self-management group to increase physical activity levels|This group will perform a self-management program along 6 months. This program will aim to increase the level of physical activity and adherence to healthier lifestyle habits and will be carried out through several sessions that will incorporate: education, goal setting, identification of barriers, self-control and feedback.
89314666|NCT04576598|Active Comparator|Control group|This group will participate in the initial educational session and will be given a leaflet with recommendations for physical activity to follow throughout the six months.
89314667|NCT03813069|Other|Laboratory study|
89314668|NCT03813069|Other|Field study: IR3535|
89314669|NCT03813069|Other|Field study: Permethrin lower dose|
89314670|NCT03813069|Other|Field study: Permethrin higher dose|
89314671|NCT03813069|No Intervention|Field study: control arm|
89314672|NCT03276026|Active Comparator|Control Group/Neostigmine|The control group will be the 63 patients who receive Neostigmine in a dose of 5mg, along with the anti-cholinergic glycopyrrolate 0.6mg.
89314673|NCT03276026|Active Comparator|Study Group/Sugammadex|63 patients will be given Sugammadex in a dose of 2mg/kg if the train of four twitch count is 2 and 4mg/kg if the twitch response has reached 1-2 post-tetanic counts with no twitch response to train of four.
89314674|NCT03813225|No Intervention|Conventional Analgesia|"These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation for handling an analgesic in cardiovascular surgery, this start in surgery with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.~and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus."
89314675|NCT03813225|Experimental|Serrato intercostal plane Block|These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.In this Arm the patient will give a bilateral serratus intercostal plane block, will be performed echo-guided puncture in the line anterior axillar with fifth costal arch, whit 21 ml of anesthetic mass, 20 ml of Levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone. and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus
89314676|NCT01303497|Other|Arm A : Paclitaxel|administration of paclitaxel drug during cycle of 28 days (6 cycles Max) + blood sample on day 1, 8, 15, 29 and 57
89314677|NCT01303497|Other|Arm B : Paclitaxel + Bevacizumab|"administration of paclitaxel drug during per cycle of 28 days (6 cycles Max) + Bevacizumab every two weeks during paclitaxel cycles then every 3 weeks during P cycles until disease progression or inacceptable toxicity~+ blood sample on day 1, 8, 15, 29 and 57"
89314678|NCT05221424|Experimental|Active Comparator|"MARS, PAIS-SR and Patient Information Form, containing data about the patient and the disease were applied to each patient in the experimental group during pretest. Then, the individual training was given to each patient by giving the Hypertension Training Booklet prepared in line with the Roy Adaptation Model. The training period lasted for averagely 45-50 minutes for each patient. After the training, the patients were called by phone at least once a week, every week for four weeks and reminder information was obtained and their follow-ups were made. One month after the training, post-test data were applied to the patients. In the posttest phase; MARS, PAIS-SR and the questions containing lifestyle changes were repeated and their follow-ups were then terminated."
89314679|NCT05221424|No Intervention|No Intervention|• MARS, PAIS-SR and Patient Information Form containing data about the patient and the disease were applied to each patient in the control group in the pretest. Without giving any training to the patients in the control group, only the patients were called at least once a week, every week for four weeks and their health status was examined. One month after the collection of initial data, posttest data were applied to the patients. In the posttest phase; MARS, PAIS-SR and the questions containing lifestyle changes were repeated and then their follow-ups were terminated. After the follow-up, the training prepared in line with Roy Adaptation Model was applied to the voluntary patients and the training booklet was given to them.
89314680|NCT03816189||Diffuse SSc|Recruitment of 20 patients with diffuse SSc
89314681|NCT03816189||Limited SSc|Recruitment of 20 patients with limited SSc
89314682|NCT03816189||Healthy subjects|Recruitment of 20 healthy subjects (control)
89314683|NCT01589523|Experimental|GlycoCholic Acid, Study Drug|An open label, single arm, non-randomized, non-comparative, treatment study of Glycocholic Acid in the treatment of defects of bile acid metabolism.
89314684|NCT03804177|Experimental|implant with hyaluronic melatonin vit c|implant placement with topical application of hyaluronic and melatonin and systemic administration of vitamin C
89314685|NCT03804177|Active Comparator|immediate implant|immediate implant placement alone without melatonin or hyauronic acid nor vitamin c
89314686|NCT03815877|Active Comparator|The intervention group (C group receiving caffeinated coffee)|100cc coffee at 3, 6 and 9 hours after the Cesarean section
89314687|NCT03815877|Placebo Comparator|The control group (N group receiving decaffeinated coffee)|100cc decaf coffee at 3, 6, 9 hours after the Cesarean section
89314688|NCT03277352|Experimental|INCAGN01876 + Pembrolizumab + Epacadostat|INCAGN01876 in combination with pembrolizumab and epacadostat
89314689|NCT01302093|Experimental|Experimental Tablet|A single 100 mg dose of an experimental Racecadotril Film-Coated Tablet (FCT)
89314690|NCT01302093|Active Comparator|Marketed Capsule|A single 100 mg dose of a marketed Racecadotril capsule
89314691|NCT03803865|Active Comparator|Headspace|30-day smartphone based mindfulness training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
89314692|NCT03803865|Active Comparator|Recharge|30-day smartphone based reflection and problem solving training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
89314693|NCT03803709|Placebo Comparator|placebo|"maltodextrin received at 4g/day on day 3 and 4~maltodextrin received at 8g/day from day 5 to 14~maltodextrin received at 16g/day from day 15 to 20"
89314694|NCT03803709|Experimental|inulin|"inulin received at 4g/day on day 3 and 4~inulin received at 8g/day from day 5 to 14~inulin received at 16g/day from day 15 to 20"
89314695|NCT01303575|Experimental|HIV, STI, and Pregnancy Prevention Curriculum|
89314696|NCT01303575|Active Comparator|Control curricula: Science Education|No sexual health elements
89314697|NCT04975737|Experimental|Vaccine Group|3590 volunteers who will receive 1 dose (0.5 ml) of the vaccine GamTBvac administered twice with an 8-week interval between administrations.
89314698|NCT04975737|Placebo Comparator|Placebo group|3590 volunteers who will receive 1 dose (0.5 ml) of the placebo administered subcutaneously twice with an 8-week interval between administrations.
89314699|NCT03812913||Turner Syndrome|"35 girls with Turner syndrome (except patients with part of a Y chromosome in their karyotype and r(X) cases).~age : 7 years -16 years and 11 months.~Psychological evaluation of cognition, social cognition and affective cognition"
89314700|NCT03812913||isolated GHD|"35 girls with isolated Growth Hormone Deficiency (GHD).~age : 7 years -16 years and 11 months.~Psychological evaluation of cognition, social cognition and affective cognition"
89314701|NCT03815955|Experimental|Non-Sedentary Behaviour Group|Participants in this arm will model the primary care team as they engage in minimal sedentary behaviour and replace sitting with standing and light, incidental movements.
89314702|NCT03815955|No Intervention|Standard Care Control Group|Participants that are limited to standing, due to amputations, diabetic foot pain and ulcers, or sensory diabetic neuropathy, will follow standard care and attend the DIGMA in a seated position.
89314703|NCT01301703|Active Comparator|Tdap vaccination|Patients and controls will be vaccinated with BOOSTRIX (Tdap vaccine)
88806535|NCT00369746||Alcohol and major depression, citalopram|Patients with alcohol use disorder and major depression, treated with citalopram tablets, 20-60 mg, once daily, for 12 weeks
88806536|NCT00369746||Major Depression, citalopram|Patients with major depression, treated with citalopram tablets 20-60 mg daily, for 12 weeks
89314704|NCT03803007|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
89314705|NCT03803007|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
89314706|NCT03812757||Supraclavicular fossa US scanning|Following insertion of at least 20 cm of the guidewire into the right subclavian vein, the probe is shifted to the right supraclavicular fossa to scan the right internal jugular vein in order to exclude malposition of the guidewire. The probe is then tilted in a caudal direction to obtain a view of the guidewire within the superior vena cava. Misplaced guidewires will be corrected under real-time ultrasound guidance.
89314707|NCT03802149|Experimental|Ulipristal Acetate|Participants will be administered a one time dose of 90mg ulipristal acetate 18-24-hours prior to dilation and evacuation (surgical abortion) for cervical preparation.
89314708|NCT02036632|Other|Eye Patching|Intervention
89314709|NCT03815565|Experimental|levobupivacaine 0.125%|continuous femoral block with levobupivacaine 0.125%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
89314710|NCT03815565|Active Comparator|ropivacaine 0.2%|continuous femoral block with ropivacaine 0.2%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
89314711|NCT02047552|Active Comparator|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
89314712|NCT02047552|Active Comparator|Oxandrolone|Oxandrolone 10 mg PO q12 hours will be dosed for seven days.
89314713|NCT02047552|Experimental|Iron sucrose + oxandrolone|Combination goal-directed iron sucrose (as described in the iron sucrose only arm) and oxandrolone (as described in the oxandrolone only arm) for seven days.
89314714|NCT02047552|Placebo Comparator|IV iron placebo and Oxandrolone placebo|100 mL normal saline in place of iron and similar color and size sugar pill for Oxandrolone placebo
89314715|NCT01303731|Active Comparator|Standard dose Marcaine Spinal 0.5% Heavy|Standard group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml).
89314716|NCT01303731|Experimental|Minidose of Marcaine Spinal 0.5% Heavy|Minidose group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
89314717|NCT03815487|Experimental|Therapy with Hybrid Closed Loop (HCL)|"The Intervention is the specific function of the Insulin Pump from Medtronic® with the name MiniMed® 670G (MMT-1780) to deliver Insulin as medication.~This Medtronic MiniMed 670G Insulin Pump in Auto Mode is an Hybrid closed loop (HCL) system including an Auto Mode function. It provides as intervention several additional effects concerning automatically insulin delivery by pump: e.g. in case of high values (or predicted) - more insulin will be administered automatically, in case of low values (or predicted) - the insulin infusion will be decreased a suspended and resumed again. The patients will wear the pump continuously."
89314718|NCT03815487|Active Comparator|Sensor Augmented Pump (SAP) therapy|"The Intervention is the specific therapy of the Sensor Augmented Insulin Pump MiniMed® 670G (MMT-1780) without Auto Mode.~This Medtronic MiniMed 670G Insulin Pump without Auto Mode' is a Sensor Augmented Pump (SAP) therapy and means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. The patients will wear the pump also continuously, but have to respond manually after the alarm. There are no automatically steps from the pump."
89314719|NCT02036710||Cecum|Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
89314720|NCT02036710||Ileum|Food hydrolysate instilled into terminal ileum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
89314721|NCT03815799|Experimental|Erector Spinae Plane Block Group|"Procedure:~In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve erector spinae block under ultrasound guidence after the strict aseptic precautions."
89314722|NCT03815799|Sham Comparator|Control|Routine standard perioperative and postoperative analgesic protocol will be given.
89314723|NCT03276728|Placebo Comparator|Part A: Placebo|Healthy participants were administered placebo either intravenously (IV) or by mouth (PO) to match the 5 IV cohorts and 6 PO cohorts of AMG 986.
89314724|NCT03276728|Experimental|Part A: AMG 986|Healthy participants were administered a single dose of AMG 986 either IV or PO. The 5 IV cohorts started at a 0.5 mg loading dose over one hour up to to the Cohort 5 IV dosage consisting of a 60 mg loading dose over 1 hour and a 360 mg maintenance dose lasting 23 hours. The 6 PO cohorts started at a single 5 mg dose up to the Cohort 6 PO dose of 650 mg.
89314725|NCT03276728|Placebo Comparator|Part B: Placebo|Healthy participants were administered placebo either IV for 4 consecutive days or PO for 7 days to match the 2 IV cohorts and 6 PO cohorts of AMG 986.
89314726|NCT03276728|Experimental|Part B: AMG 986|Healthy participants were administered AMG 986 either IV or PO. IV cohort 1 was administered a loading dose of 6 mg over one hour followed by maintenance doses of 36 mg lasting 23 hours on Day 1 and 38 mg lasting 24 hours on Days 2-4. IV cohort 2 was administered a loading dose of 60 mg over one hour followed by maintenance doses of 360 mg lasting 23 hours on Day 1 and 376 mg lasting 24 hours on Days 2-4. The 6 PO cohorts started at 5 mg for 7 days up to Cohort 6 PO dose of 650 mg for 7 days.
89314727|NCT03276728|Placebo Comparator|Part C: HFrEF Placebo|Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO placebo tablet daily from Days 1-21.
89314728|NCT03276728|Placebo Comparator|Part C: HFpEF Placebo|Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO placebo tablet daily from Days 1-21.
89314729|NCT03276728|Experimental|Part C: HFrEF AMG 986|Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO AMG 986 tablet daily from Days 1-21 in ascending doses of 10 mg for Days 1-7, 30 mg for Days 8-14 and 100 mg for days 15-21.
89314730|NCT03276728|Experimental|Part C: HFpEF AMG 986|Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO AMG 986 tablet daily from Days 1-21 in ascending doses of 10 mg for Days 1-7, 30 mg for Days 8-14 and 100 mg for days 15-21.
89314731|NCT03815188||Heart Valve Surgery|Pre-operative patients undergoing heart valve surgery will be selected and data recorded from each patient on the day of their surgery. This patient cohort is required in order to be able to accurately measure their JVP upon physical examination. Patients must have a central line inserted as part of their ongoing clinical management.
89314732|NCT01301859|Active Comparator|TIP Adherence Intervention|The TIP program is a brief, individualized intervention designed as an adjunct to pharmacotherapy for depression prescribed by a primary care physician. The key to the intervention is the involvement of the older adult in creating an adherence strategy tailored to his/her barriers and needs.
89314733|NCT01301859|Placebo Comparator|Usual Care|Treatment as usual in a primary care setting
89314734|NCT02260024|Active Comparator|Pramipexole IR|
89314735|NCT02260024|Experimental|Pramipexole SR C2 in the fasted state|
89314736|NCT02260024|Experimental|Pramipexole SR C2A in the fasted state|
89314737|NCT02260024|Experimental|Pramipexole SR C2B in the fasted state|
89314738|NCT02260024|Experimental|Pramipexole SR C in the fasted state|
89314739|NCT02260024|Experimental|Pramipexole SR C2 in the fed state|
89314740|NCT02037100||T2DM|Children 6-20 years old diagnosed with T2DM
89314741|NCT02037100||Obesity|
89314742|NCT03800667|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1000 mg of vitamin C for one month,
89314743|NCT03800667|No Intervention|Women not taking vitamin C|Women who are undergoing elective gynecological surgeries and who are randomized not to take any vitamin C for one month.
89314744|NCT02037178||The study population|"See inclusion/exclusion criteria.~Intervention: First ultrasound reading~Intervention: Second ultrasound interpretation"
89314745|NCT01302171|Experimental|Peripheral|Half the patients will be randomised to the non-interventional part of the trial. In this subgroup of patients will be randomised 1:1 to 5 day course of subcutaneous placebo injections or a 5 day course of G-CSF(Granocyte™) subcutaneous injections
89314746|NCT01302171|Experimental|Interventional arm|In the subgroup of the interventional arm patients will be randomised 1:1 to receive a 5 day course of subcutaneous G-CSF (Granocyte™) injections and bone marrow aspiration at day 5, they will then receive either stem cells or placebo via intracoronary injection
89314747|NCT03275246|Experimental|Total knee arthroplasty|Patients undergoing total knee arthroplasty
89314748|NCT02047630|Experimental|Generic latanoprost|1 eye drop hs
89314749|NCT02047630|Active Comparator|Brand-name latanoprost|1 eye drop hs
89314750|NCT03815331|Experimental|PD treatment with Xiaflex® plus Aveed|Peyronie's Disease treatment with Xiaflex® and Aveed®. All 20 subjects will be treated with Xiaflex® and Aveed®. The data collected from this pilot project will be analyzed and compared to historical data regarding treatment for PD with Xiaflex® alone.
89314751|NCT04305470|Experimental|Single Arm|Open-label, single-arm
89314752|NCT02036788||Postsurgical patients sedated and paralized|Patients admitted to ICU after surgery, treated with mechanical ventilation, sedated and paralized
89314753|NCT02036788||Postsurgical patients intubated and breathing spontaneously|
89314754|NCT01560039|Active Comparator|Real EEG-NF|10 EEG based neurofeedback sessions modulating the activity of the primary motor cortex
89314755|NCT01560039|Sham Comparator|Sham EEG-NF|10 sessions of Sham EEG_NF of the motor cortex area
89314756|NCT01560039|Active Comparator|Transcrainal Magnetic Stimulation|10 dailt TMS stimulation sessions of M1
89314757|NCT03799809|Active Comparator|Voriconazole|Will receive 400 mg of Intrabronchial Voriconazole every week for 4 weeks along with standard medical therapy.
89314758|NCT03799809|No Intervention|Control|Will receive standard medical therapy alone (hemostatics, anti-tussive and others as deemed appropriate by treating physician)
89314759|NCT02036866|Experimental|Physical Therapy Positive Expectation|The physical therapist will read a script indicating that the intervention is an effective treatment for knee osteoarthritis and is expected to reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS (transcutaneous electrical nerve stimulation) unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
89314760|NCT02036866|Experimental|Physical Therapy Neutral Expectation|The physical therapist will read a script indicating that the intervention may or may not be an effective treatment for knee osteoarthritis and may nor may not reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
89314761|NCT02036866|Experimental|Control- No Intervention|The patients in the control group will be reminded of their appointment in 1 week and instructed to maintain their usual activity level during that time.
89314762|NCT03812523|Active Comparator|Control|Duloxetine 60 mg qd
89314763|NCT03812523|Experimental|Intervention|Lorcaserin 10 mg bid
89314764|NCT03799575||A|Two samples of ILM per patient are harvested, group A will be immediately fixed and submitted to Optic Microscopy (OM) and Transmission Electron Microscopy (TEM) analysis, and another sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
89314765|NCT03799575||B|Group B sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
89314766|NCT03562312|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
89314767|NCT03562312|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
89314768|NCT05503251|Experimental|Arm I (neuropsychological evaluation)|Patients undergo neuropsychological evaluations with a certified neuropsychologist at baseline, 3 months, and 6 months.
89314769|NCT05503251|Active Comparator|Arm II (usual care)|Patients receive usual care.
89314770|NCT02047786||General Hospital Patients|Those patients undergoing appendicectomy in a general (non-specialised) surgical centre.
89314771|NCT02047786||Paediatric Hospital Patients|Those patients undergoing appendicectomy in specialised paediatric centres.
89314772|NCT03799029|Active Comparator|active control group low-intensity|Low intensity version of the same cognitive training program Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
89314773|NCT03799029|Experimental|experimental training group cognitive training|a multifactorial cognitive program that tackles working memory, attention, inhibition, planification and reasoning Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
89314774|NCT03799029|No Intervention|control healthy participants|Just a control group including healthy participants No intervention
89314775|NCT02047864|Experimental|Creatine monohydrate|Creatine monohydrate to be given during a resistance training program
89314776|NCT02047864|Placebo Comparator|Sugar pill|Placebo to be given during a resistance training program
89314777|NCT03798873|Experimental|FeelWell™ Compression garment use with increase mobility|"Subjects are randomized to wear custom-fitted FeelWell™ Compression garment daily during regular and exercise activities.~Subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity."
89314778|NCT03798873|Other|Increase mobility|For the control group, subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity. The control group will not be assigned a compression garment during the trial.
89314779|NCT02047942|Active Comparator|Center-based cardiac rehabilitation|Patients randomized to the center-based training group will continue their training sessions at the outpatient clinics of UZ Leuven under direct supervision of physical therapists
89314780|NCT02047942|Experimental|Home-based training with telemonitoring guidance|Patients will receive an patient-tailored exercise prescription and will be asked to perform the exercise sessions in their home environment wearing heart rate monitors. Training data will be accessed by the research group on weekly basis in order to keep a record of frequency; duration and intensity of the sessions. Feedback will be given weekly to every patient.
89314781|NCT02047942|No Intervention|Control|
89314782|NCT03812445|No Intervention|No Intervention|the patients in this arm will not receive probiotics.
89314783|NCT03812445|Experimental|Experimental|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus for 3 months.
89314784|NCT02049970|Experimental|dexmedetomidine and bupivacaine|Bupivacaine 50 mg and dexmedetomidine 1 microgram/kg
89314785|NCT02049970|Experimental|Bupivacaine and placebo|Bupivacaine 100 mg and SF 10 ml
89314786|NCT02048020|Experimental|Treatment (paclitaxel, carboplatin, IMRT)|"INDUCTION: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY: At least 2 weeks after completion of induction chemotherapy, patients receive paclitaxel IV over 1 hour weekly and undergo IMRT daily 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity."
89314787|NCT03562390|Experimental|Experimental group|124 women with locally recurrent or metastatic breast cancer who will receive treatment at 17 research centers in Liaoning Province and Heilongjiang Province of China. Irinotecan is administered intravenously on days 1 and 8 of each 3-week cycle.
89314788|NCT01302405|Experimental|PRI-724|
89314789|NCT05690932|Experimental|Capsule|Study drug will be administered with water after an overnight fast.
89314790|NCT05690932|Experimental|Tablet|Study drug will be administered with water after an overnight fast.
89314791|NCT05690932|Experimental|Suspension|Study drug will be administered with water after an overnight fast.
89314792|NCT05690932|Experimental|Fasted|Study drug will be administered with water after an overnight fast.
89314793|NCT05690932|Experimental|Low-fat Meal|Study drug will be administered with water after an overnight fast, after which time a standard low-fat breakfast will be given.
89314794|NCT05690932|Experimental|High-fat Meal|Study drug will be administered with water after an overnight fast, after which time a standard high-fat breakfast will be given.
89314795|NCT03798249|Active Comparator|Gluten|Patients will receive acutely 16 g of gluten and 2 muffins glutenfree with 8 g of gluten, twice a day, during 5 days
89314796|NCT03798249|Placebo Comparator|Placebo|Patients will receive acutely 16 g of whey protein and 2 glutenfree muffins, twice a day, during 5 days
89314797|NCT02048098|Active Comparator|Buccal misoprostol|400 µg buccal misoprostol per 3 hours
89314798|NCT02048098|Active Comparator|vaginal misoprostol|400 µg vaginal misoprostol per 3 hours
89314799|NCT01302561|Placebo Comparator|Sugar Pill|
89314800|NCT01302561|Experimental|Galactooligosaccharide 5 g|
89314801|NCT02048176||Posterior Fossa Mutism|Patients with Posterior Fossa Mutism
89314802|NCT02048176||Non Posterior Fossa Mutism|Patients that did not develop Mutism
89314803|NCT01303809|Active Comparator|ERAS|The perioperative management of the patients in this arm will be according to a fast-track protocol designed by the investigators. The preoperative component of this program is the same as routine practice. Intraoperative and postoperative components which are different to routine practice are as described in the intervention section. This protocol is based on current literature regarding Enhanced Recovery After Surgery (ERAS).
89314804|NCT01303809|No Intervention|non ERAS|The perioperative management of patients in this arm will be according to routine practice currently implemented at our institution.
89314805|NCT03666442|Experimental|chemotherapy group|patients receive 4 cycles of Xelox
89314806|NCT03812055||LSD|Subjects diagnosed or suspected to have any of the following lysosomal storage diseases: Gaucher disease, Fabry disease, Pompe disease, Mucopolysaccharidoses.
89314807|NCT03812055||Control|Subjects with no known lysosomal storage disorder
89314808|NCT05081271|Active Comparator|Homologous booster vaccine group|A single dose booster of the same type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
89314809|NCT05081271|Active Comparator|Heterologous booster vaccine group|A single dose booster of the opposite type of COVID-19 vaccine (i.e., mRNA or DNA) that the study participant received as part of an initial vaccine series prior to enrolling in this study.
89314810|NCT02050126|Experimental|Scar Revision|Caesarean Scar Revision using Lumenis UltraPulse Encore.
89314811|NCT02050204|Experimental|LEEF Industry only: Intervention|"Customized to the Leef (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
89314812|NCT02050204|No Intervention|LEEF Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
89314813|NCT02050204|Experimental|TOMO Industry only: Intervention|"Customized to the Tomo (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
89314814|NCT02050204|No Intervention|TOMO Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
89314815|NCT03812211|Active Comparator|Active Supplement|Participants will be allocated in a randomized, double-masked manner to receive a multi-faceted supplement for the 12-week duration of the study
89314816|NCT03812211|Placebo Comparator|Placebo|Participants will be allocated in a randomized, double-masked manner to receive a placebo supplement (the placebo will be made of microcrystalline cellulose, and will be matched in size, appearance, taste and caloric value) for the 12-week duration of the study
89314817|NCT02050282|No Intervention|Business as usual|Triage and treatment based on routine clinical assessment as usual
89314818|NCT02050282|Experimental|Supplementary NT-proBNP measurement|Triage and treatment based on routine clinical assessment supplemented with measurement of NT-proBNP
89314819|NCT03811977|Experimental|Test group|Test group will receive investigational product - lutein syrup (2 mg/mL; daily dose 20 mg). Participants in this group will test continuous administration of investigational product for 12 weeks.
89314820|NCT03811977|Placebo Comparator|Placebo group|Placebo group will receive placebo product - placebo syrup (lutein 0 mg/mL; daily dose 0 mg). Continuous administration of placebo product for 12 weeks.
89314821|NCT02050360|Experimental|Sildenafil 80 mg|Sildenafil 80 mg
89314822|NCT02050360|Experimental|Sildenafil 40 mg|Sildenafil 40 mg
89314823|NCT02050360|Placebo Comparator|Placebo|placebo
89314824|NCT02940860|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
89314825|NCT02940860|Active Comparator|Iron sucrose|Administered IV
89314826|NCT04142541|Experimental|Carotid artery stenting with Neuroguard IEP System|To evaluate the safety and feasibility of the Neuroguard IEP System when used in patients with clinically significant carotid artery stenosis requiring revascularization.
89314827|NCT02037646|Other|Qualitative fecal immunochemical test|"Stool samples will be tested with the qualitative fecal immunochemical test (qFIT), and will be stratified for colonoscopy as follows:~>200 ng/dL - colonoscopy with one month 100-200 ng/dL - colonoscopy as per waiting list <100 ng/dL - no colonoscopy~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
89314828|NCT02037646|Other|Quantitative fecal immunochemical test|"Stool samples will be tested with the quantitative fecal immunochemical test (FIT), and will be scheduled for colonoscopy as follows:~Positive - colonoscopy as per waiting list Negative - no colonoscopy~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
89314829|NCT03799965|Active Comparator|ERAS protocol are evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital~It is to compare the incidences of complications of the groups"
89314830|NCT03799965|Active Comparator|ERAS protocol are not evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital~It is to compare the incidences of complications of the groups"
89314831|NCT02048254|Experimental|brachytherapy|Iodine-125 radioactive seeds permanent interstitial implantation brachytherapy
89314832|NCT02048254|Active Comparator|IMRT|IMRT (intensity-modulated radiation therapy), 6 Millivolt (MV)-x fractionated irradiation, 1 time/day, 5 times a week, till the end. Add up to 33 times.
89314833|NCT01303887|Active Comparator|R-CVP|Repeated every 21 days for up to 8 cycles with response assessment after 4 cycles. Responders (PR/CR) after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
89314834|NCT01303887|Experimental|R-FC|Repeated every 21 days for 4 cycles. Responders (PR/CR) after 4 cycles will receive 4 further cycles of Rituximab only. Responders after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
89314835|NCT02048410|Active Comparator|diet plus Lactobacillus paracasei B21060|low saturated fats diet plus the symbiotic (2.5×109cfu, bid)
89314836|NCT02048410|Placebo Comparator|low saturated fats diet|low saturated fats diet
89314837|NCT02050438||Knee Osteoarthritis patients with prostesis treatment|Patients operated previously of Knee Osteoarthritis with different prostesis designs according the Hospital guide
89314838|NCT02050516|Active Comparator|single embryo culture|single embryo culture in single drops inside micro-well group culture dish
89314839|NCT02050516|Experimental|group embryo culture|group embryo culture in a single drop inside micro-well group culture dish
89314840|NCT02050594||Melanoma patients on Ipilimumab|All unresectable, recurrent or metastatic melanoma patients
89314841|NCT02994758|Other|Personalised medicine arm|"This is a prospective n-of-1 type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care."
89314842|NCT03309020|Active Comparator|Control|Control with clinical need for cataract surgery
89314843|NCT03309020|Experimental|EVD Survivors|EVD survivors with need for cataract surgery
89314844|NCT02806960|Experimental|Treatment 1|Treatment 1, single nasal glucagon (NG) dose of 3 milligram (mg).
89314845|NCT02806960|Experimental|Treatment 2|Treatment 2, NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later.
89314846|NCT02806960|Experimental|Treatment 3|Treatment 3, NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later.
89314847|NCT02806960|Experimental|Treatment 4|Treatment 4, NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.
89314848|NCT03718143|Experimental|Arm A: Elderly Newly diagnosed AML|"Combination AZD1775 with AraC~Elderly, newly diagnosed AML"
89314849|NCT03718143|Experimental|Arm B:Relapsed AML and MDS|"Combination AZD1775 with AraC~Relapsed/Refractory AML & HMA failure AML/ MDS"
89314850|NCT03718143|Active Comparator|Arm C: Relapsed AML, MDS and MF|"AZD1775 only~Relapsed/Refractory AML & HMA failure AML/ MDS and Relapsed/Refractory Primary & Secondary MF"
89314851|NCT02955134|Experimental|Chinese medicine prescription|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in experimental group use the traditional Chinese medicine application prescription.
89314852|NCT02955134|Placebo Comparator|placebo|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
89314853|NCT02048488|Experimental|Experimental Drug TSR-011|Experimental Drug TSR-011
89314854|NCT03799887|Active Comparator|0% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
89314855|NCT03799887|Experimental|10% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
89314856|NCT03799887|Experimental|20% unweighed BWSTT|20% unweighed Body Weight Supported Treadmill Training
89314857|NCT03562234||Pre-op Chemotherapy for CLM: MR & LiMAx|"Patients undergoing pre-operative chemotherapy for colorectal liver metastases being treated at the Christie NHS (National Health Service) Foundation Trust.~No intervention - participants will continue with standard care. Observation of changes in liver fat and liver function measured by MR (Magnetic Resonance) scan and LiMAx test (Maximum liver capacity)."
89314858|NCT02048566|Experimental|hTEEPM|Group hTEE protocolled monitoring (hTEEPM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration (see below) and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
89314859|NCT02048566|Experimental|hTEESM|Group hTEE standard monitoring (hTEESM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management in which case an hTEE assessment has to be performed. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
89314860|NCT02048566|Active Comparator|ControlPM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
89314861|NCT02048566|Active Comparator|ControlSM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
89314862|NCT01304121|Experimental|Bioactive glass|Resorbable bioactive glass granules
89314863|NCT02050672|Active Comparator|untreated|Semen was prepared with routinely used media
89314864|NCT02050672|Experimental|myo-inositol|"routinely used semen preparation media have been enriched with myo-inositol 2mg/ml.~in particular the stock solution was prepared in order to add 15microliters per ml of medium"
89314865|NCT01302639|Experimental|EGCG and resveratrol|
89314866|NCT01302639|Experimental|EGCG, resveratrol and genistein|
89314867|NCT01302639|Placebo Comparator|placebo|
89314868|NCT03561922|Experimental|RETINA IMPLANT Alpha AMS|All participants receive the subretinal device RETINA IMPLANT Alpha AMS
89314869|NCT03274466|Experimental|Closed Incision Negative Pressure Therapy (ciNPT)|Prevena Peel & Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit
89314870|NCT03274466|Active Comparator|Standard of Care Dressing|Silver impregnated dressing
89314871|NCT03811431|Experimental|CEUS guidance|SonoVue 2, 4 ml
89314872|NCT03811431|Experimental|Conventional US guidance|No drugs
89314873|NCT02806726|Experimental|iDesign 1.3-PRESBY|iDesign 1.3-PRESBY in one eye of subject (experimental) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
89314874|NCT02806726|Active Comparator|iDesign 1.3|iDesign 1.3 in one eye of subject (control) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
89314875|NCT01304199||Adult Cancer Survivors|"Intervention:~Behavioural:~Questionnaires for patient/family caregiver interview"
89314876|NCT02037802|Active Comparator|caudal epidural catheterization group|30 patients received continuous intra and post-operative caudal epidural infusion of bupivacaine 0.125% with fentanyl (2 microgram/ml) over 24 hours
89314877|NCT02037802|Sham Comparator|control group|30 patients didn't receive caudal epidural analgesia
89314878|NCT01302717|Active Comparator|Right ventricular pacing|
89314879|NCT01302717|Experimental|Left ventricular pacing|
89314880|NCT02051530|Experimental|tryptophan depletion first day|tryptophan depletion on the first day. on the other day participants receive placebo.
89314881|NCT02051530|Experimental|tryptophan depletion on day 2|tryptophan depletion on the second day. on the first day participants receive placebo.
89314882|NCT03797703|Experimental|Treatment|Patients will be randomly allocated into the treatment group. The treatment group will receive a 15 mL lidocaine gel enema rectally immediately following completion of the procedure.
89314883|NCT03797703|No Intervention|Control|Patients will be randomly allocated into the control group. The control group will not receive a rectal enema.
89314884|NCT02048644|Placebo Comparator|placebo inhaler|matched placebo inhaler, to be taken 2 puffs, twice a day for 28 days
89314885|NCT02048644|Experimental|fostair|fostair 100mcg/6mcg 2pufss, twice a day.
89314886|NCT03797781|Experimental|High protein|
89314887|NCT03797781|Experimental|Low protein|
89314888|NCT03797781|Experimental|Minimum protein|
89314889|NCT03562078|Experimental|Tai Chi Quan for Type 2 Diabetes|diabetic patients care education and Tai Chi Quan training, including 10-minute warm-up, 40-minute Tai Chi lesson, and 10-minute cool-down exercise in the training, twice a week for 12 weeks.
89314890|NCT03562078|No Intervention|Control Group for Type 2 Diabetes|diabetic patients care education
89314891|NCT01302795|Experimental|Canakinumab|Canakinumab s.c. 150-300mg Week 0, (2), 8
89314892|NCT02048800||Treosulfan PK|Children with indication to HSCT receiving Treosulfan
89314893|NCT03811353||Children with cerebral palsy|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
89314894|NCT03811353||Healthy children|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
89314895|NCT02048956|Experimental|Hydrotherapy intervention|30 people will be recruited in order to the inclusion criteria for the study and they will receive an hydrotherapy intervention.
89314896|NCT02048956|Active Comparator|Control group|30 people will be recruited and included in this control group. The are not going to receive hydrotherapy treatment, only the treatment they receive as usual.
89314897|NCT03797625|Experimental|Endostar Combined With IP|Endostar15mg/m2 Irinotecan 60mg/m2，D1，8 DDP 60mg/m2，D1
89314898|NCT02051842|Experimental|Metadoxine|Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
89314899|NCT02051842|Placebo Comparator|Placebo tablet|Placebo tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
89314900|NCT02806414|Experimental|Ivermectin|All subjects will be treated with topical ivermectin daily for up to 12 weeks.
89314901|NCT02049034|Placebo Comparator|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
89314902|NCT02049034|Experimental|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
89314903|NCT03561844|Active Comparator|aromatherapy-scent|
89314904|NCT03561844|Active Comparator|aromatherapy-touch|
89314905|NCT03561844|No Intervention|waiting-list control|
89314906|NCT02049112|Experimental|Salivary equivalent|Single dose stick without any active substance
89314907|NCT02049112|Sham Comparator|Aequasyal|Multidose moisturizing oral spray without any active substance
89314908|NCT02049112|Sham Comparator|Biotene|Multidose moisturizing oral spray without any active substance
89314909|NCT01304355||Controls|Healthy Control Subjects
89314910|NCT01304355||IBS Group|Subjects diagnosed with IBS
89314911|NCT01302873|Experimental|BGG492|
89314912|NCT01302873|Placebo Comparator|Placebo|
89314913|NCT02049190|Experimental|onapristone 10 mg BID|onapristone 10 mg BID extended-release tablets
89314914|NCT02049190|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
89314915|NCT02049190|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
89314916|NCT02049190|Experimental|onapristone 40 mg BID|onapristone 40 mg BID extended-release tablets
89314917|NCT02049190|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release
89314918|NCT02049190|Experimental|onapristone 30 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 30 mg BID + abiraterone 1000 mg
89314919|NCT02049190|Experimental|onapristone 50 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 50 mg BID + abiraterone 1000 mg
89314920|NCT02049190|Experimental|Expansion cohort: onapristone 50 mg BID|Expansion cohort: onapristone 50 mg BID
89314921|NCT03811509|Active Comparator|AI with osteoporosis|Patients with osteoporosis receive intervention with antiresorptive treatment, bisphosphonates or denosumab . All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
89314922|NCT03811509|No Intervention|AI without osteoporosis|All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
89314923|NCT02037412|Experimental|Ticagrelor Arm|Ticagrelor Arm
89314924|NCT02037412|Active Comparator|Clopidogrel Arm|Clopidogrel Arm
89314925|NCT03811119|Active Comparator|MANTA vascular closure device|Arteriotomy closure with a collagen-based vascular closure device (MANTA™)
88806537|NCT05366478|Experimental|Autologous tumor infiltrating lymphocytes (TILs)|In vitro expanded autologous TILs will be infused i.v. to patients with advanced solid tumors
89314926|NCT03811119|Active Comparator|Suture based vascular closure device|Arteriotomy closure with 2 or more suture-based vascular closure devices (ProGlide)
89314927|NCT03810885|Experimental|Salt reduced bread|Bread with reduced salt content
89314928|NCT03810885|Experimental|Dietary advice and Salt reduced bread|bread with reduced salt content, dietary advice
89314929|NCT03810885|Placebo Comparator|Normal bread|Bread with standard salt content
89314930|NCT03932019|Experimental|Jitongning tablet High dose group|Jitongning tablet,3tablets,bid,po
89314931|NCT03932019|Experimental|Jitongning tablet Low dose group|Jitongning tablet,2tablets,bid,po Jitongning tablet placebo,1tablet,bid,po
89314932|NCT03932019|Placebo Comparator|Placebo Comparator controlled group|Placebo Comparator: Jitongning tablet placebo,3tablets,bid,po
89314933|NCT02052076|Experimental|Irregular meal pattern|Participants will be asked to consume a standard diet, spread over a different number of meals/snacks per day, for a 2week intervention period. Number of meals will range from 3 to 9 per day.
89314934|NCT02052076|Placebo Comparator|Regular Meal Pattern|Participants will be asked to consume a standard diet, spread over 6 of meals/snacks every day, for a 2week intervention period.
89314935|NCT03810963|Experimental|FES Cycling and Nutrition Counseling|"Device:~HIIT-FES cycling will be performed 30 minutes per session, 3 times per week for 3 weeks combined with~Behavior:~Nutrition counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
89314936|NCT03810963|Other|Nutritional Counseling Only|"Behavior:~Nutritional counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
89314937|NCT02052154|Experimental|Prime-boost pneumococcal immunization|
89314938|NCT03797079|Active Comparator|Group A (ESP block)|Ultrasound-guided ESP block will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
89314939|NCT03797079|Active Comparator|Group B (TEA)|TEA will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
89314940|NCT02049268|Experimental|Nicotine + Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
89314941|NCT02049268|Experimental|Placebo Nicotine + Alcohol|A placebo nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (placebo nicotine) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
89314942|NCT02049268|Experimental|Nicotine + Placebo Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink a placebo alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
89314943|NCT02049346|Active Comparator|Epoetin alpha or beta (Epoetin group)|Patients in that arm were continued on the previous same dose and route of administration of Epoetin alpha/ beta (Epoetin group).
89314944|NCT02049346|Active Comparator|Darbepoetin alpha|subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol.
89314945|NCT02049346|Experimental|Methoxy polyethylene glycol-epoetin beta|Patients in that arm received Intravenous Methoxy polyethylene glycol-epoetin beta monthly.
89314946|NCT03561532|Active Comparator|FMT|50% of the participants will receive fecal suspension of a healthy donor administered in colonoscopy into the cecum
89314947|NCT03561532|Placebo Comparator|Placebo|50% of the participants will receive fecal suspension made of their own feces administered in colonoscopy into the cecum.
89314948|NCT03796845|Experimental|No-limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
89314949|NCT03796845|Active Comparator|Limited movement after surgery|Participants should move their arms with restricted movements on the first postoperative day, with maximum amplitude of 90º for flexion and abduction of the shoulder, until withdrawal surgical points. Actual hospital's routine.
89314950|NCT04898283|Experimental|10,000 MG01 + 10,000 T521|10,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy
89314951|NCT04898283|Experimental|30,000 MG01 + 10,000 T521|30,000 TU/mL of MG01 + 10,000 TU/mL of T521 of subcutaneous immunotherapy
89314952|NCT04898283|Placebo Comparator|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
89314953|NCT03561688|Sham Comparator|Standard insole|a flat insole
89314954|NCT03561688|Experimental|Foot orthotics|Custom-made foot orthoses
89314955|NCT02049424||transplanted patients|T-repleted haploidentical transplanted patients in Italy
89314956|NCT01304433||1|hydroxyethyl starch (HES) 130/0.42
89314957|NCT02806024|Experimental|Treatment Arm (Tranexamic Acid, or TXA)|Patients will be randomized to treatment or placebo arms preoperatively. In our treatment arm of pregnant patients with suspected placenta accreta or at high risk for placenta accreta, patients will receive 1 gram intravenous TXA administered over 10 minutes immediately after delivery of the infant. The drug will be prepared and ready to hang at the beginning of the case. The study drug will be administered only once.
89314958|NCT02806024|Placebo Comparator|Placebo Arm|Patients will be randomized to treatment or placebo arms preoperatively. In our placebo arm of pregnant patients with suspected placenta accreta, patients will receive plain normal saline in a 50 cc bag identical to the preparation of study drug immediately after delivery of the infant.
89314959|NCT02037490|Experimental|Grow2Gether Intervention|"Participants in the intervention group will:~Participate in the Grow2Gether intervention~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
89314960|NCT02037490|No Intervention|Control|"Participants in the control group will:~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
89314961|NCT02052232|Active Comparator|Control|Control protein powder sachet
89314962|NCT02052232|Experimental|Experimental|Experimental protein powder sachet
89314963|NCT03811197|Experimental|individual MNT|Dietary counseling via face to face meeting
89314964|NCT03811197|Experimental|Individual MNT and T|Dietary counseling via face to face meeting and Telemedicine
89314965|NCT03811197|Experimental|Individual MNT and HS|Dietary counseling via face to face meeting and Hypnotic Suggestions
89314966|NCT02049580|Experimental|RIC regimen|Thiotepa, Fludarabine, Cyclophosphamide pre- and post- transplantation.
89314967|NCT03797235|Experimental|Dominant Arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the dominant forearm
89314968|NCT03797235|Active Comparator|Non-dominant arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the non-dominant forearm.
89314969|NCT03796923|Active Comparator|Intervention I|Intervention (I): early follow-up visit from the community nurse within 24 hours after discharge
89314970|NCT03796923|Experimental|Intervention II|Intervention (II): early follow-up by the geriatric team within 24 hours after discharge
89314971|NCT03796923|Other|Control|Usual care: individualized follow-up performed by the GP and municipality services
89314972|NCT02805790|Experimental|Elamipretide, Then Placebo|Participants first received 40 mg of elamipretide once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received placebo administered once daily subcutaneously for 4 weeks.
89314973|NCT02805790|Placebo Comparator|Placebo, Then Elamipretide|Participants first received placebo once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received 40 mg of elamipretide once daily subcutaneously for 4 weeks.
89314974|NCT01302951|Experimental|Moxifloxacin|Moxifloxacin 400 mg i.v.
89314975|NCT01302951|No Intervention|No drug|2 Patients were included as controls- no MXF given
89314976|NCT03796533|Other|Posaconazole pharmacokinetics|Patients with AML over the age of 18 years treated with intensive chemotherapy in induction and consolidation whose was under antifungal prophylaxis by PCZ formulation tablets.
89314977|NCT03796377|Other|Rivaroxaban|Single oral dose of 20 mg rivaroxaban
89314978|NCT03796377|Other|Rivaroxaban after CYP- and P-gp induction|Single oral dose of 20 mg rivaroxaban after pretreatment with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
89314979|NCT03796299||1|Patients with bladder cancer
89314980|NCT03796299||2|Patients with upper urinary tract cancer
89314981|NCT03796299||3 (control)|Controls
89314982|NCT03796143|Experimental|ACT self-help book condition|Participants in this condition will be asked to read The Mindfulness and Acceptance Workbook for Depression by Strosahl and Robinson (2008), a self-help book based on acceptance and commitment therapy.
89314983|NCT03796143|Active Comparator|CBT self-help book condition|Participants in this condition will be asked to read Cognitive Behavioral Workbook for Depression by Knaus (2006), a self-help book based on acceptance and commitment therapy.
89314984|NCT03796143|Other|Choice of two self-help books|Participants in this condition will have the option of receiving either the self-help book by Strosahl and Robinson (2008) or the book by Knaus (2006).
89314985|NCT02049736|Experimental|Telbivudine|
89314986|NCT01303029|Active Comparator|Control|Gemcitabine+erlotinib
89314987|NCT01303029|Experimental|Experimental|Gemcitabine+erlotinib+capecitabine
89314988|NCT02052388|Experimental|Low Single Dose Brilacidin|0.6mg/kg Brilacidin IV (single dose)
89314989|NCT02052388|Experimental|High Single Dose Brilacidin|0.8mg/kg Brilacidin IV (single dose)
89314990|NCT02052388|Experimental|3-Day Regimen Brilacidin|0.6mg/kg Brilacidin IV on Day 1, followed by 0.3mg/kg Brilacidin IV on Days 2 & 3
89314991|NCT02052388|Active Comparator|Standard dosing regimen Daptomycin|4mg/kg Daptomycin IV daily for 7 Days
89314992|NCT03795987|Experimental|Open Label Treatment Arm|Intervention with NightWare Therapeutic System
89314993|NCT02051140|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry.
89314994|NCT02051140|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo.
89314995|NCT01303107|Active Comparator|bupivacaine S50:R50|3 ml subarachnoid block
89314996|NCT01303107|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
89314997|NCT03562000|Experimental|Intervention group on cough and ventilation assistance|Mechanical cough assistance during physiotherapy post-extubation in ICU and systematic indication of NIV.
89314998|NCT03562000|Other|Control group on cough and ventilation assistance|Control group of extubated patients receiving the current gold standard strategy during physiotherapy after extubation in ICU and with selected indications of NIV.
89314999|NCT03795909|Experimental|Ruxolitinib and Placebo|Ruxolitinib 2.5 mg twice daily by oral
89315000|NCT03795909|Placebo Comparator|Placebo and Ruxolitinib|Sugar pill 2.5 mg twice daily by oral
89315001|NCT02049892||Metal Ion|
89315002|NCT03795597|Experimental|Carfilzomib IV at dose: 20 mg/m2|The participants will receive Carfilzomib IV at dose: 20 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and Granulocyte-Colony stimulating factor (G-CSF) given daily until engraftment occurs.
89315003|NCT03795597|Experimental|Carfilzomib IV at dose: 27 mg/m2|The participants will receive Carfilzomib IV at dose: 27 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
89315004|NCT03795597|Experimental|Carfilzomib IV at dose: 36 mg/m2|The participants will receive Carfilzomib IV at dose: 36 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
89315005|NCT03795597|Experimental|Carfilzomib IV at dose: 45 mg/m2|The participants will receive Carfilzomib IV at dose: 45 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
89315006|NCT03795597|Experimental|Carfilzomib IV at dose: 56 mg/m2|The participants will receive Carfilzomib IV at dose: 56 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
89315007|NCT02802592|Active Comparator|Epogen|1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
89315008|NCT02802592|Placebo Comparator|Normal Saline|250 ml normal saline infused over 1 hr
89315009|NCT03637972|Experimental|Ventilated cigarettes only|Filters with approximately 30-36% filter ventilation
89315010|NCT03637972|Experimental|Unventilated cigarettes only|Filters with approximately 3.0-4.6% filter ventilation
89315011|NCT03637972|Experimental|Ventilated cigarettes + alternative nicotine delivery systems|Filters with approximately 30-36% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
89315012|NCT03637972|Experimental|Unventilated cigarettes + ANDS|Filters with approximately 3.0-4.6% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
89315013|NCT02053324|Experimental|AvidinOX/ST2210|AvidinOX/ST2210 - vial containing 22.5 mg AvidinOX + vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to 15 % of the lesion volume followed by intravenous infusion of 177Lu-ST2210 Diagnostic dose : 10 ml, 250 MBq±10%177Lu, approximately 1 mg ST2210, 100 mg/mL ascorbic acid, followed by intravenous infusion of a therapeutic dose: 25 ml, escalating 177Lu dose starting at 5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210, 100 mg/ml ascorbic acid
89315014|NCT03383679|Experimental|Arm 1 Darolutamide|Darolutamib: 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally, continuously until disease progression
89315015|NCT03383679|Other|Arm 2 Capecitabine|"according to the 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC3) capecitabine monotherapy is one of the recommended options even in first line (Cardoso et al, 2017).~According to each center policy (minimum 1000 mg/m²) twice daily for 2 weeks followed by 1-week rest period, until progression or unacceptable toxicity"
89315016|NCT02037880||MPS IIIA/B Subjects|Cohort will be followed for one year to assess natural history of the disease.
89315017|NCT04743219|Active Comparator|Biodentine Group|Biodentine group: patients with mature permanent posterior teeth with deep caries lesions treated with the selective removal technique to soft dentin with Biodentine as indirect pulp capping material before placement of a definitive direct composite resin restoration.
89315018|NCT04743219|Experimental|No base Group|The experimental group or No Base group: patients with mature permanent posterior teeth with deep caries lesions treated with the selective removal technique to soft dentin without the placement of a bioactive material as a base and restored directly with a definitive direct composite resin restoration.
89315019|NCT03561610|Active Comparator|Study group 1|normal Nutrition + sip feed (covers individual energy and nutrient demands)
89315020|NCT03561610|Experimental|Study group 2|normal Nutrition + gumdrops (covers individual energy and nutrient demands)
89315021|NCT03795519|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-olinciguat
89315022|NCT02037958|Experimental|Laryngeal Mask Airway-Supreme|Patients who are randomly assigned to receive the LMA-Supreme
89315023|NCT02037958|Active Comparator|Endotracheal Tube|Patients who are randomly assigned to receive endotracheal intubation
89315024|NCT02053402|Placebo Comparator|Placebo|Placebo to be given daily for six months
89315025|NCT02053402|Active Comparator|Vitamin D|1200 IU of vitamin D, daily for six months
89315026|NCT02052856||ACL Surgery|All English speaking patients 16 years and older having anterior cruciate ligament (ACL) surgery without any other surgery to knee or contralateral knee.
89315027|NCT02053480||Pyruvate Kinase Deficiency|Patients of all ages with Pyruvate Kinase Deficiency
89315028|NCT04650945|Active Comparator|isCGM-arm|isCGM (intermittently scanned continuous glucose monitor) data obtained from a FreeStyle Libre Flash continuous glucose monitoring system will be viewed real-time and used to adjust diabetes treatment
89315029|NCT04650945|No Intervention|POC-arm|POC glucose readings are used to adjust diabetes treatment. CGM data from the Freestyle Libre monitor are blinded to all and only gathered for comparison purposes to intervention group.
89315030|NCT04639011|Active Comparator|Group A Placebo|Participants randomized to Group A will receive placebo (sugar pill) and Boston Medical Center (BMC) standard of care.
89315031|NCT04639011|Experimental|Groups B Intervention|Participants randomized to Group B will receive duloxetine and Boston Medical Center (BMC) standard of care.
89315032|NCT02053558|Placebo Comparator|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
89315033|NCT02053558|Active Comparator|TAP BLOCK with ropivacaine|TAP block will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
89315034|NCT03809949|Active Comparator|Fentanyl Opioid Anesthesia|Fentanyl (1mg/kg i.v.) will be administered before general anaesthesia (GA). GA will be maintained with inhalation anaesthetics (isoflurane) at a minimum alveolar concentration of 0.7-1.3.
89315035|NCT03809949|Placebo Comparator|Saline Nonopioid Anesthesia|Opioid free anesthesia (syringe of saline is given instead of fentanyl) and the same general anesthesia is given as group A(muscle relaxant ,propofol, inhalation for maintance).
89315036|NCT03810027||OAB with nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Precence of nocturnal polyuria will be classified in this group.
89315037|NCT03810027||OAB without nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Absence of nocturnal polyuria will be classified in this group.
89315038|NCT02053636|Experimental|lucitanib|"Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg.~5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent"
89315039|NCT04577079||IPMF Screened|Patient screened and assessed by intelligent patient flow management system.
89315040|NCT03807232||pbARDS|Burn patients who developed post-burn ARDS
89315041|NCT03807232||No pbARDS|Burn patients without development of post-burn ARDS
89315042|NCT02053714|Other|Self-management and education group|Self-management and education group - 8 weeks of group-based information and activities designed to improve diabetes self-management
89315043|NCT01560273||Aspen Spinous Process Fixation Device|The Aspen device provides supplemental posterior fixation for fusion
89315044|NCT02052934|Experimental|Cohort 1|Three sublingual (SL) doses of dMLT, 1 microgram (mcg), on Days 1, 15 and 29, 8 subjects
89315045|NCT02052934|Experimental|Cohort 2|Three SL doses of dMLT, 5 mcg, on Days 1, 15 and 29, 8 subjects
89315046|NCT02052934|Experimental|Cohort 3|Three SL doses of dMLT, 25 mcg, on Days 1, 15 and 29, 11 subjects
89315047|NCT02052934|Experimental|Cohort 4|Three SL doses of dMLT, 50 mcg, on Days 1, 15 and 29, 11 subjects
89315048|NCT02052934|Experimental|Cohort 5a|Three SL doses of dMLT,25 mcg on Days 1, 15 and 29, 13 subjects.
89315049|NCT02052934|Experimental|Cohort 5b|Three oral doses of dMLT, 25 mcg on Days 1, 15and 29, 13 subjects
89315050|NCT03810261|Experimental|Oil-based vitamin D group|Oil-based vitamin D, 1000 IU/day for 8 weeks
89315051|NCT03810261|Experimental|Water-based vitamin D group|Water-based vitamin D, 1000 IU/day for 8 weeks
89315052|NCT03810261|Experimental|Vitamin D capsules group|Vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks
89315053|NCT03810261|No Intervention|Control group|This group will receive no intervention.
89315054|NCT05659342|Experimental|ELDOA Technique|ELDOA positions (hold for 1 minute, 3 alternative days for 4 weeks). Hot pack (10-15 minutes) McKenzie extension Exercises
89315055|NCT05659342|Experimental|Mechanical Lumbar Traction|"Mechanical Lumbar Traction (50% of body weight was applied, in supine position, the hip and knee at 90- degree flexion, and the legs were supported.~Hot pack (10-15 minutes) McKenzie extension Exercises"
89315056|NCT01614483|Experimental|Yellow cassava + placebo capsule|
89315057|NCT01614483|Placebo Comparator|White cassava + placebo capsule|
89315058|NCT01614483|Active Comparator|White cassava + B-carotene capsule|
89315059|NCT02037724|Other|supplement containing 60 mg iron sulfate|nutrient supplement containing 60 mg of iron as ferous sulfate
89315060|NCT02037724|Experimental|iron rich food supplement (60 mg iron)|contains 60 mg Iron
89315061|NCT02037724|Experimental|iron rich food supplement (10 mg iron)|contains 10 mg of iron
89315062|NCT02037724|Other|supplement containing 10 mg iron sulfate|nutrient supplement containing 10 mg of iron as ferous sulfate
89315063|NCT02053870|Experimental|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
89315064|NCT02053870|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
89315065|NCT03327675|Experimental|68Ga-PSMA PET/MR|Hybrid 68Ga-PSMA PET/MR scan
89315066|NCT02053012||PVT-192|
89315067|NCT03795441|Experimental|Ad26.RSV.preF|Participants will receive one intramuscular injection of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on Day 1.
89315068|NCT02053948|Experimental|Pursestring Wound Closure group|use Pursestring Wound Closure technique to close the stoma
89315069|NCT02053948|Experimental|Gunsight Skin Incision and Closure group|use Gunsight Skin Incision and Closure Technique to close the stoma
89315070|NCT01569633|Placebo Comparator|Placebo|This group of infant will not receive any medication but sugar water or placebo
89315071|NCT01569633|Active Comparator|Metclopramide|This group of infants will receive Metoclopramide at 0.1mg/kg q8 hrs.
89315072|NCT01569633|Active Comparator|Erythromycin|mediaction used to treat feeding disorder
89315073|NCT02053090|Active Comparator|Group Education with Stretching|"Group Education with Stretching will receive 10 small group educational classes at the Oregon Health & Science University (OHSU), based on the book Fibromyalgia (Biographies of Disease). Each chapter of Fibromyalgia covers different aspects of the disease and its treatment including global, economic, and risk statistics; a timeline of key events in the study of fibromyalgia; common symptoms and diagnostic indicators; natural history of fibromyalgia; pharmacologic and non-pharmacologic treatments; associated disorders and syndromes; and impact of fibromyalgia at home, in the workplace and in society at large. Participants will be informed that they should not start additional treatments until the end of the study and complementary and alternative treatments won't be covered until the last session. Participants will also receive a digital video disk (DVD) covering stretching appropriate for fibromyalgia patients and will be asked to incorporate the DVD over the next 10 weeks."
89315074|NCT02053090|Experimental|Group Acupuncture|20 treatments in 10 weeks will include individualized acupuncture in a group setting, dietary and lifestyle recommendations each based on the Traditional Chinese Medicine diagnosis (zhang fu) at the time of the visit.
89315075|NCT03795051|Experimental|Navigated TMS|Each participant will receive 30 sessions of 10 Hz or 20 Hz navigated transcranial magnetic stimulation over the left DLPFC.
89315076|NCT02054026|Experimental|Reducing the Risk|An eight-lesson (approximately eight-hour) version of Reducing the Risk
89315077|NCT02054026|No Intervention|Control|
89315078|NCT03795285||Septic neonates:|fifty neonates with sepsis.
89315079|NCT03795285||Controls:|twenty healthy neonates.
89315080|NCT02054182|Active Comparator|Vitamin D|Vitamin D 2 500 IU daily from enrolment until hospital discharge
89315081|NCT02054182|Placebo Comparator|Placebo|Placebo
89315082|NCT03795129|Experimental|SleepLife Application w/FitBit|"Subject receives a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subject physicians will receive subject sleep data. Subject and physicians have the option of messaging each other through the SleepLife application."
89315083|NCT03795129|Active Comparator|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
89315084|NCT02803138||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablets; 1000 or 1200 mg divided twice a day) up to 24 weeks
89315085|NCT01305525||Spinal Cord Stimulation|
89315086|NCT02054260|Experimental|Surgicel add therapy|
89315087|NCT03795207|Experimental|Arm SBRT + DURVALUMAB|"Radiation (SBRT) + Immunotherapy treatment (Durvalumab)~64 patients will be enrolled in this arm~Durvalumab, will be started one month prior to SBRT and then given for a total of 12 months.~Patient will receive one injection per months (1500 mg/cycle)~SBRT will be started one month after Durvalumab and patients will receive 3 fractions of radiation"
89315088|NCT03795207|Active Comparator|Arm SBRT|"Radiation (SBRT)~32 patients will be enrolled in this arm~Patients will receive only 3 fractions of radiation"
89315089|NCT02056210|Experimental|Stem cell mobilization in diabetic patients|Injection of Mozobil (Plerixafor / AMD3100) in diabetic patients
89315090|NCT02056210|Experimental|Stem cell mobilization in non diabetic subjects|Injection of Mozobil (Plerixafor / AMD3100) in non diabetic subjects
89315091|NCT03794973|Experimental|TOL-3021|TOL-3021 2 mg/mL
89315092|NCT03794973|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
89315093|NCT02038114|Experimental|Instructed to read pamphlets|This group will be instructed to read patient education pamphlets.
89315094|NCT03792789|Experimental|mCIMT with real rTMS|Modified Constraint Induced Movement Therapy (mCIMT) with real Repetitive Transcranial Magnetic Stimulation (rTMS). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with real rTMS over contralateral primary motor cortex.
89315095|NCT03792789|Sham Comparator|mCIMT with sham rTMS|Modified Constraint Induced Movement Therapy with sham Repetitive Transcranial Magnetic Stimulation (using sham coil). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with sham rTMS over contralateral primary motor cortex using sham coil which simulated sound and touch of real coil but has no electro-magnetic waves.
89315096|NCT03795831||Cohort|Adult patients, undergoing surgery requiring general anesthesia, planned to be monitored with a system that accurately measures and stores the intra-arterial waveform.
89315097|NCT02801578|Experimental|Ibrutinib|"Participants take Ibrutinib capsules by mouth every day for 3, 28 day cycles.~During Cycle 1, participants receive the highest dose of Ibrutinib by taking 3 capsules each day. During Cycle 2, participants receive the second-highest dose and will take 2 capsules each day. During Cycle 3, participant takes the lowest dose of Ibrutinib and takes 1 capsule each day."
89315098|NCT03794895|Experimental|Single arm clinical trial|
89315099|NCT03794505|Active Comparator|Shoulder infiltration|Shoulder infiltration using 2 ml of Lidocaine 2% Injectable Solution and methylprednisolone acetate 40 mg
89315100|NCT03794505|Experimental|Suprascapular nerve block|Suprascapular nerve block ultrasound guided using 25 mg of Ropivacaine HCl Inj 7.5 MG/ML and methylprednisolone acetate 40 mg
89315101|NCT05625243|Experimental|Bulk-fill ormocer with Precontoured circumferential matrix system|A suitable size precontoured circumferential matrix band will be selected and placed. Teeth separation will be acquired with a suitable size wedge and a separation ring . Then the bulk-fill ormocer will be applied and light cured according to the manufacturer instructions.
89315102|NCT05625243|Experimental|Bulk-fill ormocer with Precontoured Saddle matrix system|Teeth separation will be acquired with a suitable size wedge (fixing wooden wedges and a separation ring Then the bulk-fill ormocer will be applied and light cured according to the manufacturer instructions.
89315103|NCT05625243|Experimental|X-tra fill, Voco) with Precontoured circumferential matrix (Palodent 360, Dentsply )|.Bulk-fill resin composite (X-tra fill, Voco) with Precontoured circumferential matrix system (Palodent 360) will be applied
89315104|NCT05625243|Active Comparator|Bulk-fill resin composite with Precontoured sectional matrix systym|Teeth separation will be acquired with a wooden wedge and a separation ring (Delta ring, TORVM, Moscow, Russia). Then the bulk fill resin composite will be applied and light cured according to the manufacturer instructions.
89315105|NCT03023007|Experimental|Loco-regional anaesthesia|Loco-regional anaesthesia Anesthesia technique used : loco-regional PECS for patients requiring Mastectomy; And/or Axillary node dissection ; And/or Reconstruction of breast by prosthesis
89315106|NCT01304745|Experimental|Physical traning in group|
89315107|NCT01304745|Experimental|Educational and counselling group|
89315108|NCT01304745|No Intervention|Control group|
89315109|NCT03792945|Active Comparator|extracorporeal shock wave therapy|ESWT will be applied to Group 1 once a week for a total of 3 weeks. Modus ESWT device will be used. The patient's wrist will be applied at a pressure of 4 bar and 2000 Hz at a frequency of 5 Hz. Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
89315110|NCT03792945|Active Comparator|local injection|40 mg of local Depomedrol (methylprednisolone) injection will be applied to group 2 once. Injection will be made from wrist with carpal tunnel syndrome.Patients will be given a splint at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
89315111|NCT03792945|No Intervention|carpal tunnel wrist brace|"Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day.~Participants will use the carpal tunnel wrist brace 3 months."
89315112|NCT05579925|Experimental|CM310|600 mg + 300 mg, subcutaneous injection, once every two weeks
89315113|NCT01304823|Active Comparator|glucose|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
89315114|NCT01304823|Active Comparator|glucose + lactisole|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
89315115|NCT01304823|Active Comparator|mixed liquid meal|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
88806538|NCT00392054|Experimental|Catheter Ablation|Pulmonary vein isolation performed by catheter ablation for the prevention of recurrence of symptomatic atrial fibrillation
88806539|NCT00392054|Active Comparator|Antiarrhythmic Drug Therapy|Conventional antiarrythmic drug therapy for the prevention of recurrence of symptomatic atrial fibrillation
88806540|NCT02525874|Experimental|dimethyl fumarate|120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
89315116|NCT01304823|Active Comparator|mixed liquid meal + lactisole|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
89315117|NCT01304823|Placebo Comparator|saline + lactisole|saline (0.9 %; rate: 2.5 mL/min for 180 min) + 450 ppm lactisole
89315118|NCT01304901|Active Comparator|1-Montelukast|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
89315119|NCT01304901|Placebo Comparator|2- Placebo|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
89315120|NCT01304979|No Intervention|Usual care alone|Subjects receive usual care alone before and after spine fusion surgery
88814740|NCT04354298|Experimental|Fall 2020 ID Class|The ID group will participate in a 12-week IMPROVment® intervention, which consists of weekly ID classes that progress according to a standardized method, from September 2020-December 2020.
89315121|NCT01304979|Experimental|Active Intervention|Acupuncture therapies, ear seeds, acupuncture treatment and gua sha, designed to reduce pain and facilitate recovery for low back spine fusion patients.
89315122|NCT01304979|Sham Comparator|Control Arm|Indirect therapies with same encounter time and timing as direct care group.
89315123|NCT02799472|Experimental|GSK3196165 + MTX arm|Subjects will receive GSK3196165 (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
89315124|NCT02799472|Placebo Comparator|Placebo + MTX arm|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
89315125|NCT03794271|Experimental|Pupilometer group|In this group, intraoperative analgesia is performed using pupilometer guided anesthesia.
89315126|NCT03794271|Active Comparator|SPI group|In this group, intraoperative analgesia is performed using SPI guided anesthesia
89315127|NCT03792321|Active Comparator|Testosterone|Testosterone arm patients were receiving testosterone undecanoate 1000 mg intramuscular injections two years; according to the protocol every 10 weeks
89315128|NCT03792321|Placebo Comparator|Placebo|Placebo arm patients were receiving placebo throughout the first year of this study and testosterone undecanoate 1000 mg intramuscular injections during second year.
89315129|NCT01305057|Experimental|Evaluation of P-IP on hydration and barrier function|Effects of P-IP on improvement of skin hydration and TEWL were examined.
89315130|NCT03792399|Experimental|Immediate feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to immediate feedback after data downloaded into computer.
89315131|NCT03792399|Other|Delayed feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to delayed feedback (standard care, i.e., CGM graphs interpretation at scheduled 3 months outpatient visit).
89315132|NCT05624697|Other|Augmented group|Patient Specific Sticky Bone /Implant Housing PEEK Shell in Anterior Atrophic Maxilla with simultaneous implant placement
89315133|NCT03792009|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
89315134|NCT03792009|Placebo Comparator|Paracervical block with normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
89315135|NCT01305135|Experimental|azacitidine 75mg/m²/d + idarubicin 5mg/m²/d|"phase I : palier 1 have 10 patients and palier 2 have to 10 patients.~palier 1: Ida 5mg/m²/d (D8) + AZACITIDINE 75mg/m²/d (D1-D7)"
89315136|NCT01305135|Experimental|Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d|palier 2: Ida 10mg/m²/d (D8)+ Azacitidine 75mg/m²/d (D1-D7)
89315137|NCT03793959|Experimental|Synbiotic Supplement|Daily synbiotic supplement (5g prebiotic fiber + 8 billion CFU probiotic B. lactis, identical to Placebo-- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
89315138|NCT03793959|Placebo Comparator|Placebo Supplement|Daily placebo supplement (5g maltodextrin, identical to Experimental -- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
89315139|NCT03793647|Active Comparator|Low Intensity EMS|Conventional Stimulation
89315140|NCT03793647|Experimental|High Intensity EMS|Russian Stimulation
89315141|NCT03793647|Placebo Comparator|Placebo|no Stimulation, supported by phone contact
89315142|NCT03792087|Experimental|SmofKabiven Peripheral|Continuous intravenous Infusion for SmofKabiven Peripheral via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
89315143|NCT03792087|Active Comparator|Hospital compounded emulsion|Continuous intravenous Infusion for Hospital compounded emulsion via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
89315144|NCT01305603|Active Comparator|Dual TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness.
89315145|NCT01305603|Active Comparator|Classical (or single) TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness
89315146|NCT01305291|Placebo Comparator|tea only without fibersol-2|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects (11).~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~The beverage will be consumed at 10 am.~Blood samples will be taken at specified time points prior to after the treatments."
89315147|NCT01305291|Active Comparator|tea only with fibersol-2 (10 g)|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~The beverage will be consumed at 10 am.~Blood samples will be taken at specified time points prior to and after the treatments.~Ingredient only test will be done without the meal to determine independent effects of Fibersol-2."
89315148|NCT01305291|Placebo Comparator|tea without fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
89531753|NCT05547048|Experimental|Athena Strategy|Virtual care model that includes direct synchronous videoconferencing with a provider, telephone/ texting communication, electronic health records, e-prescribing for the purposes of delivering PrEP and medications for opioid use disorder. This is combined with a decision aid for PrEP
89531754|NCT05547048|Active Comparator|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
88814741|NCT04354298|No Intervention|Control Group|Participants are pre- and post-tested 12-14 weeks apart after not having changed anything drastic in their daily life.
89315149|NCT01305291|Experimental|tea with 5 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
89315150|NCT01305291|Experimental|tea with 10 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
89315151|NCT03791931|Other|Patients|Oxidative stress measurement in cleavage state embryos
89315152|NCT02058784|Experimental|Single-dose food effect in nonsmokers|Randomized, two-treatment design in nonsmoking healthy subjects. Single-dose pracinostat to be given under fasted and fed conditions followed by PK sampling for up to 48 hour post dose.
89315153|NCT02058784|Experimental|Single-dose food effect in smokers|Single-dose parallel treatment design in moderate to heavy smoking healthy subjects. Single-dose pracinostat will be given under fasted conditions followed by PK blood sampling up to 48 hours.
89315154|NCT03793725|Experimental|SHR-1210 + Apatinib|Drug: SHR-1210 SHR-1210 was administered 200mg iv every 2 weeks Drug: Apatinib Apatinib was administered 500mg oral daily during the first 2 weeks and then 250 mg qd
89315155|NCT02054416|Active Comparator|Art Assist Device|The ArtAssist© (model AA1000) device is made by ACI Medical located in San Marcos, CA (http://acimedical.com/) and is cleared per FDA under K942530.The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
89315156|NCT02054416|Sham Comparator|Sham Device|"Sham devices look identical to the actual ArtAssist© devices, but provide low-pressure and differ only in number-coded tubing. The study sham intervention will consist of one hour of IPC with the sham ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the sham device has an internal device that stores the usage data) to evaluate subject compliance."
89315157|NCT02056366|Active Comparator|α-lipoic acid|α-lipoic acid PO medication, 600mg per day, for 6weeks α-lipoic acid PO medication, 1200mg per day, for 6weeks
89315158|NCT02056366|No Intervention|No treatment group|No Intervention
89315159|NCT03793569|No Intervention|Control group|Participants will be recruited and asked to complete Edinburgh Postnatal Depression Scale (EPDS) at specific timepoints postpartum.
89315160|NCT03793569|Experimental|Intervention group|Participants will be recruited, asked to complete Edinburgh Postnatal Depression Scale at specific timepoints postpartum, and attend a peer discussion group.
89315161|NCT03793491||Patients having Parkinson's disease|Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease. Patients will have TCI scale and PDQ-39 scale.
89315162|NCT02056444|Experimental|Topical tranexamic acid (TXA)|Single dose 1.5 grams topical TXA infiltrated into the surgical field at time of arthrotomy closure.
89315163|NCT02056444|Active Comparator|Intravenous TXA|Single 20 mg/kg dose of intravenous TXA administered prior to skin incision.
89315164|NCT01305447|Experimental|Exercise Maintenance|"Randomization and Group-Mediated Cognitive Behavioural therapy (GMCB) sessions will begin on week 8 of the program. Topics of self-regulation related to exercise (Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the GMCB principles on how to maintain exercise behavior."
89315165|NCT01305447|Experimental|Ex. Maintenance + relapse prevention|"The same topics of self-regulation related to exercise maintenance(Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the Group-Mediated Cognitive Behavioural therapy (GMCB) principles on how to maintain exercise behavior.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
89315166|NCT01305447|Active Comparator|relapse prevention|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
89315167|NCT01305447|Active Comparator|Contact Control|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time."
88814742|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 7|
89315168|NCT02665234|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
89315169|NCT02665234|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
89315170|NCT05624229|Placebo Comparator|Standard group|"Early treatment is mainly aimed at correcting hypovolemic shock, preventing gastrointestinal bleeding-related complications, effective control of bleeding, monitoring vital signs and urine output.~Medical treatment included initiation and maintenance of vasoactive agents as soon as possible for 2 to 5 days, and prophylactic antibiotics (preferably ceftriaxone sodium or quinolones) by intravenous infusion for 5 days.~Endoscopic intervention was performed within 12 hours after presentation and generally no longer than 24 hours. PPI was stopped immediately after endoscopic treatment.~Early TIPS is determined according to the technology and concept of each unit."
89315171|NCT05624229|Experimental|Standard group+PPI|PPI continued after endoscopic treatment for 5 days.
89315172|NCT02038192|Experimental|Living with Hope Program|"All participants in this group will receive the Living with Hope Program. It consists of viewing a 15 minute film on hope. Then for 5 minutes at the end of each day to write Stories of the Presentto work on over one month. Stories of the present is a directed journaling activity which includes writing challenges of the day, what was their hope that day and what would be their hope tomorrow."
89315173|NCT02038192|Experimental|Stories of the Present|Participants in this group will write Stories of the Present and not see the film.
89315174|NCT02038192|No Intervention|Usual Care|Participants in this group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
89315175|NCT03793413|Experimental|Surgical group|
89315176|NCT03793413|No Intervention|Observation group|
89315177|NCT02038270||surgical patients|120 Adult patients, that are having a routine surgical procedure.
89315178|NCT02056522||Suspicious skin lesions.|No intervention is administered.
89315179|NCT03793101||BiMICS 1.4|Group 1.4 - Patients operated with 1.4 mm BiMICS technique
89315180|NCT03793101||BiMICS 1.8|Group 1.8 - Patients operated with 1.8 mm BiMICS technique
89315181|NCT05622370|Experimental|Brivaracetam sustained-release tablets 100mg|"Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
89315182|NCT05622370|Experimental|Brivaracetam sustained-release tablets 50mg|"Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
89315183|NCT05622370|Active Comparator|Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)|"Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd."
89315184|NCT04895787|Experimental|Aerobic exercise group (AEX)|Gait training followed by 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle.
89315185|NCT04895787|Experimental|Resistance exercise group (REX)|Gait training followed by 20 minutes of resistance training targeting major muscle groups.
89315186|NCT04895787|Active Comparator|Conventional physical therapy group (CPT)|Gait training followed by 20 minutes of conventional PT programs that do not involve aerobic or resistance exercise.
89315187|NCT04895787|Active Comparator|Control group (CON)|Gait training followed by 20 minutes of rest (sitting on a chair and read magazines).
89315188|NCT03791775|Experimental|Polidocanol 3% Foam|Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden, Germany).
89315189|NCT03791697|Active Comparator|Telephone Group|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes."
89315190|NCT03791697|No Intervention|In Person Clinic Visit Group|For the patient randomized into the clinic group, the clinic visit will entail questions about common postoperative complications (including fever, nausea/vomiting, pain, urinary symptoms, constipation, etc.). As per usual, vital signs and a focused physical examination will be completed at the clinic visit. All clinic visits will be performed by an FPRMS fellow and/or attending physician
89315191|NCT03789123|Experimental|Study Group (patients with OMA)|"I) Untreated patients (n=142)~II) Dienogest (n=142)~III) Dienogest/Estradiol valerate+Dienogest (n=142)"
89315192|NCT03789123|Sham Comparator|Control Group(patients without OMA)|"I) Untreated patients (n=142)~II) Dienogest/Estradiol valerate+Dienogest (n=142)"
89315193|NCT05471817|Experimental|EZN - DBG|Participants will receive a single oral dose of dabigatran (DBG) etexilate in fasted state in Period 1; followed by a single oral dose of elinzanetant (EZN) and DBG etexilate (30 min after EZN) in fasted state in Period 2.
89315194|NCT03788889|Active Comparator|Lorazepam + Ketamine + Placebo A|"Ketamine - infusion (0.15 - 0.4 mg/kg/hr) and placebo injections titrated by increases of 0.075 mg/kg/hr every 30 minutes for Clinical Institute Withdrawal Assessment for Alcohol (revised version) (CIWA-Ar) greater than or equal to 10 in addition to lorazepam symptom-triggered therapy~Ketamine dosing will be based on ideal body weight~Ketamine infusion will be discontinued once CIWA-Ar less than 10 for 4 hours"
89315195|NCT03788889|Active Comparator|Lorazepam + Phenobarbital + Placebo B|"Phenobarbital - IV push (260 mg loading followed by 130 mg q1 hour) with placebo infusion until CIWA-Ar less than 10 with a maximum daily dose of 10mg/kg in addition to lorazepam symptom-triggered dosing for recurrent symptoms (Gold 2007)~Maximum daily dose will be used in order to prevent over sedation as well as provide adequate storage in pharmacy monitored refrigerators for study drugs"
89315196|NCT03788889|Placebo Comparator|Lorazepam + Placebo A + Placebo B|Lorazepam will be administered every 30 minutes as indicated based on CIWA-Ar protocol for Cottage Health in addition to placebo injections and placebo infusion
89315197|NCT01306227|Placebo Comparator|water|Oral treatment with water for 6 weeks
89315198|NCT01306227|Experimental|L-Thyroxine|Oral treatment with L-Thyroxine for 6 weeks
89315199|NCT01305681|Active Comparator|LoFric® catheters|LoFric® catheters during clean intermittent catheterization will be compared to non-LoFric® catheters during clean intermittent catheterization
89315200|NCT03788733|Experimental|Melatonin|Melatonin ORAL FILM 3mg will be taken by the subject once a day for 8 weeks
89315201|NCT03788733|Placebo Comparator|placebo|ORAL FILM 3mg placebo will be taken by the subject once a day for 8 weeks
89315202|NCT03791385|Experimental|Study subjects|Children with ASD and their parents/caregivers were trained on tooth-brushing twice, two weeks apart using Picture Exchange Communication System (PECS) PECS as a pictures/cards series showing a structured tooth-brushing method.
89315203|NCT05403801|Experimental|STAMP+CBT PILOT|"Patients in this Pilot Cohort will be in the research study for 6 weeks total including:~a 4-week intervention period and 2-week post intervention period.~Patients will use the app for a total of 4 weeks (4-week intervention period), and will complete surveys at baseline, 4 weeks (end of intervention period), and at 6 weeks (end of 2-week post intervention period)."
89315204|NCT03791541|No Intervention|No Intervention|Only surveys will be done and re admissions tracked. No additional interventions based on survey results will be done.
89315205|NCT03791541|Experimental|Intervention|"Pharmacist Services~Surveys plus increased outpatient pharmacist/pharmacy student services including but not limited to pre and post clinic visit phone calls, prescription counseling, and helping with adherence and compliance with medications. Increased services will be given based on survey results."
89315206|NCT03791463|Experimental|After meal|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
89315207|NCT03791463|Experimental|Fasting|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered at the end of a 10-hour fast.
89315208|NCT01305759||YoungTKA|Adults under 60 years who are having primary TKA
89315209|NCT01305759||YOUNGTHA|Adults under 60 years who are having primary THA
89315210|NCT01305759||PAOAarhus|Adults under 60 years who are having primary PAO
89315211|NCT01306383|Active Comparator|SODIS Bottles given|Caregivers in the intervention group were given two 2-litre plastic bottles. Bottle was filled with available water and placed in direct sunlight for a minimum of 6 hours. Water was consumed the next day while second bottle was being consumed.
89315212|NCT01306383|Active Comparator|Usual practices|Caregivers in this group were asked to maintain their usual practices regarding drinking water so that disease rates could be compared with the SODIS arm
89315213|NCT04753515|Active Comparator|Group DMR|dexmedetomidine combined with midazolam and remifentanil.
89315214|NCT04753515|Active Comparator|Group PMR|propofol combined with midazolam and remifentanil.
89315215|NCT01306461|Active Comparator|Timolol and Tafluprost|Concomitant administration of preservative-free timolol and tafluprost eye drops
89315216|NCT01306461|Experimental|Fixed Dose Combination of tafluprost and timolol|Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops
89315217|NCT01306539|Experimental|Deep Brain Stimulation|Parkinson's patients with deep brain stimulation in the subthalamic nucleus.
89315218|NCT03791307|Experimental|Traditional Pilates group|This group will perform only exercises based on the traditional Pilates method
89315219|NCT03791307|Experimental|Modified Pilates group|This group will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer
89315220|NCT03791307|No Intervention|Control group|This group will not perform any physical exercise during the trial period.
89315221|NCT01306695|Experimental|NYUCI|New York University Caregiver Intervention (NYUCI) in addition to community-based case management using community health workers: The first component consists of two individual and four family counseling sessions that include relatives suggested by the caregiver.
89315222|NCT01306695|Other|CHW Intervention|Community-based case management using community health workers (CHWs): The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6.
89315223|NCT01305837|Experimental|methylprednisolone|all patients will be treated with the active drug methylprednisolone 500 mg in 3 days every month for 60 weeks.
89315224|NCT03790995||High risk prostate cancer|"Patients with initial cT2c-3-4, cN +, Gleason score (GS) more than 7 or PSA > 20ng/mL were labelled as high-risk prostate cancer.~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
89531755|NCT05536609|Experimental|Epineural suture|The injured digital nerve is exposed during a surgical intervention and sutured with 2 or three epineural sutures 8.0 or 9.0 synthetic monofilament non-resorbable suture. Postoperative treatment includes 3 weeks in a plaster cast followed by rehabilitation.
89315225|NCT03790995||Low - intermediate risk prostate cancer|"Initial PSA levels less or equal than 20 ng/mL with GS of 7 or less and cT1-2a-2b, 2 were labelled as low and intermediate risk prostate cancer and served as a control group.~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
89315226|NCT01306773|Active Comparator|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma
89315227|NCT01306773|Active Comparator|Oral Oseltamivir alone|Oseltamivir 75mg bid during ICU hospitalization
89315228|NCT05557305|Experimental|Videogame therapy|The participants of the experimental group will only undergo video game therapy and will be called twice a week to perform supervised video game rehabilitation therapy, for a period of 45-50 minutes per session, for 10 weeks
89315229|NCT05557305|Active Comparator|Conventional therapy|The participants in the control group will undergo the conventional therapy prescribed by their treating physician, at the INP they are prescribed occupational therapy, which is usually focused on game activities with balls, dice, cubes, tying ropes, etc., twice a week for 10 weeks.
89315230|NCT03790761|Experimental|PREP 8.0 Curriculum|All participants enrolled in the program will be given the PREP 8.0 curriculum - there will be no comparison group.
89315231|NCT03788265|Experimental|injection|
89315232|NCT03788031|Experimental|Perceptual learning group - Amblyopia|Visual training
89315233|NCT03788031|Active Comparator|Perceptual learning group - Control|Visual training
89315234|NCT03788031|Placebo Comparator|Occlusion therapy - Amblyopia|Patching
89315235|NCT03790605|Experimental|1% curcumin chip|Following routine full mouth scaling and root planing within 48 hours, a single chip of 1% curcumin will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)
89315236|NCT03790605|Placebo Comparator|Placebo chip|Following routine full mouth scaling and root planing within 48 hours, a single placebo chip will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)
89315237|NCT03788109|Other|device: combined solid state HRiM|combined solid state high resolution esophageal impedance and manometry (HRiM)
89315238|NCT03787953||Anti-PD-1/PD-L1 antibodies|Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy
89315239|NCT01306851|Active Comparator|Fibrin glue|
89315240|NCT03790449|Experimental|PreLiFe-programme|A Mobile Preconception Lifestyle programme
89315241|NCT03790449|Other|Attention Control|Attention Control Programme
89315242|NCT03790527|Experimental|CBM training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.~Half of the participants will be random-assigned into the CBM training group; Each participant will do these task twice( e.g. Before training and after training)"
89315243|NCT03790527|Sham Comparator|Sham training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.~Half of the participants will be random-assigned into the sham training group; Each participant will do these task twice( e.g. Before training and after training)"
89315244|NCT05544123||Cohort 1 HER2+ EBC|newly diagnosed or completed definitive breast surgery
89315245|NCT05544123||Cohort 2 HR+ HER2- EBC|newly diagnosed or completed definitive breast surgery
89315246|NCT05544123||Cohort 3 HER2+ ABC|De novo or relapsed from adjuvant therapy
89315247|NCT05544123||Cohort 4 HR+ HER2- ABC|De novo or relapsed from adjuvant therapy
89315248|NCT03790215|Experimental|cohort for treatment|Participants enrolled are given dydrogesterone tablet of 10mg twice a day, from day 15 to day 24 of the menstrual cycle over a period of 3 months.
89315249|NCT01307085|Experimental|preconditioning|Adult patients undergoing elective pulmonary lobectomy were received a remote ischemic preconditioning group after induction of anaesthesia.
89315250|NCT01307085|No Intervention|conventional|Adult patients undergoing pulmonary lobectomy were received no treatment after induction of anaesthesia.
89315251|NCT01307241||one cohort|Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
89315252|NCT05694975|Experimental|Vitamin C|12 g Vitamin C will be infused within 6 hours by an infusion pump. This treatment will be repeated every 12 hours for 4 days.
89315253|NCT05694975|Placebo Comparator|Placebo|The control group is assigned a placebo (5% glucose).
89315254|NCT01305915|No Intervention|Control|participant will receive standard print material
89315255|NCT01305915|Experimental|Intervention|patient will receive standard print material and a single session group psychoeducational intervention (GBOT)
89315256|NCT03787875||Control|The control group included 10 periodontally healthy subjects without signs or symptoms of periodontal disease.
89315257|NCT03787875||Study|"The study group included 15 subjects diagnosed with mild or advanced chronic periodontitis. Each periodontal patient had one non-affected single-rooted tooth (healthy site) and another single-rooted tooth with periodontitis (periodontitis site) with the following features:~Healthy site: a single-rooted tooth with probing depths below or equal to 3 mm without recession and without bleeding on probing.~Periodontitis site: another single-rooted tooth from the same patient with clinical attachment loss equal to or greater than 6 mm and bleeding upon probing."
89315258|NCT03790371|Active Comparator|misoprostol group|misoprostol (misotac® sigma pharmaceutical industries) 200 mcg vaginally applied ten and four hours prior to the second attempt of IUD insertion
88814743|NCT03032042|Experimental|azithromycin at day 0, albendazole at day 7|
89315259|NCT03790371|Placebo Comparator|placebo|while the control group received a placebo tablet in the same regimen as the study group.
89315260|NCT03787563|Active Comparator|Active Herbal tea|One tea bag infusion three times a day each before breakfast, lunch and dinner.
89315261|NCT03787563|Placebo Comparator|Placebo Tea|Similar looking tea bag infusion three times a day each before breakfast, lunch and dinner.
89315262|NCT01307475||Proband Group|Patients identified with FSS or a related condition
89315263|NCT01307475||Family Group|Persons who are genetically or legally related to a person with FSS or related condition
89315264|NCT01307475||Other Affected Individuals Group|Persons who have had significant and meaningful contact with a person with FSS or related condition but do not qualify for family group enrolment
89315265|NCT03787641|Other|Protamine doze|Protamine Sulfate will be administered through an infusion pump in aliquots at a predefined rate (25 mg/min). Blood samples will be withdrawn after each aliquot and quantified for anti-Xa, IIa and ACT.
89315266|NCT03790293|Experimental|Rituximab|Rituximab in combination with reduced corticosteroids is administrated
89315267|NCT03790293|Active Comparator|Standard corticosteroid|Standard corticosteroid is administrated
89315268|NCT05694663||Patients Undergoing Vagal Nerve Stimulation for Stroke Recovery|"Individuals undergoing vagal nerve stimulation (VNS) paired rehabilitation will be included in this cohort.~This is a registry study with no active intervention outside standard of care. Patients with chronic ischemic stroke will be implanted with the Vivistim vagal nerve stimulation device per standard of care."
89315269|NCT03790059|Experimental|RFA combined with H101 group|The experimental group was RFA combined H101.H101 has oncolysis in HCC after RFA and reduce tumor recurrence.
89315270|NCT03790059|Other|Conventional RFA group|The standard control group was the conventional RFA.Using RFA for the treatment of small HCC.The efficacy was compared with that of the experimental group combined with H101.
89315271|NCT01307553||PCS Group|
89315272|NCT03245450|Experimental|Eribulin mesilate plus irinotecan hydrochloride|In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m^2 or 40 mg/m^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m^2 or 125 mg/m^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
89315273|NCT05694585|Experimental|esmolol group|esmolol group: esmolol 50 μg/kg /min were intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg /min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
89315274|NCT05694585|Placebo Comparator|Saline solution|Saline group: saline 50 μg/kg /min were intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg /min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
89315275|NCT03787329||Bone marrow concentration group|The patients receive core decompression surgery with bone marrow concentration.
89315276|NCT03787329||Historical control group|The previous age-, gender-, and stage-matched patients who received core decompression surgery only.
89315277|NCT03787407|Experimental|Mindfulness training with neurofeedback|mindfulness training with neurofeedback using mobile application instruction and review of the application will be provided
89315278|NCT03787407|Active Comparator|Mindfulness training|mindfulness training using mobile application instruction and review of the application will be provided
89315279|NCT03787407|No Intervention|Self-care|
89315280|NCT03637478|Experimental|Enhanced Systems of Care Team|The four intervention sites have been selected based on their size: taken together, their pediatric populations comprise over 80% of the total number of children receiving care at Cambridge Health Alliance. At the four intervention sites, the study will involve: 1) an integrated child mental health assessment done by the E-SOC team within primary care, 2) active follow-up, collaboration with specialty providers and support to families, 3) School, child welfare and other community linkages as appropriate.
89315281|NCT03712917|Active Comparator|Greater Occipital Nerve Block|"The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼ (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood."
89315282|NCT03712917|Active Comparator|Topiramate|Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
89315283|NCT03712917|Active Comparator|Flunarizine|Flunarizine is introduced with a single dose of 10 mg/day.
89315284|NCT03789981||At diagnosis|Immunogenic profile in patients affected by primary or secondary AML at diagnosis
89315285|NCT03789981||At relapse|Immunogenic profile in patients affected by primary or secondary AML at relapse
89315286|NCT03787485||LINKS Participants|Study participants who took part in the LINKS intervention.
89315287|NCT03787485||Electronic Medical Record Controls|The principal analytical strategy is propensity score matching, which will lead to the generation of a natural control group from the health centers existing electronic medical records. Propensity matching is highly effective in addressing selection bias of known confounders and enables causal inferences when randomization is not possible, feasible or appropriate, by creating matched groups with similar covariate distributions. Matched controls will be extracted from the electronic medical record from the participating clinics.
88814744|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 0|
88814745|NCT03032042|Other|Delayed treatment|albendazole at day 7, azithromycin at day 7
89315288|NCT03786861|Active Comparator|42 eyes in aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free in aberration free group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
89315289|NCT03786861|Active Comparator|24 eyes in corneal WFG group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing corneal WFG patterns in corneal WFG group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
89315290|NCT03789435||Amputees|Patients underwent trans-tibial and trans-femoral amputation of any etiology at the Rizzoli Orthopedic Institute from 2015 to 2017 with the presence of analgesia data for surgery in a computerized record (SIR, Rizzoli information system). A questionnaire for the detection of residual limb pain will be administrate to all the survivors.
89315291|NCT03787017|Experimental|Sequence Group A|"1st period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted~2nd period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted"
89315292|NCT03787017|Experimental|Sequence Group B|"1st period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted~2nd period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted"
89315293|NCT03786705||Trauma patients' SBP ≥ 90 mm Hg with EMS|Only patients who were transferred by emergency medical service from the accident site with a systolic blood pressure ≥ 90 mm Hg at the ER were included in this study. The enrolled trauma patients divided into 2 groups, those who had received blood transfusion ≥ 10 U (massive transfusion) and those who had not (non-massive transfusion).
89315294|NCT03786315||Usual care|Older patients with multimorbidity and the GPs with whom they consult, from across five GP practices in Devon
89315295|NCT01307865|Experimental|Sculptra Aesthetic|Patients receiving Sculptra Aesthetic
89315296|NCT04730427|Experimental|GX-I7|GX-I7
89315297|NCT04730427|Placebo Comparator|GX-I7 vehicle|GX-I7 vehicle
89315298|NCT01307943|Experimental|Mindfulness Based Stress Reduction|"Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat at the completion of the eight sessions to review and consolidate experience with the various mindfulness practices. The MBSR concepts and techniques will emphasize portability. Participants will be encouraged to find moments throughout their day in which to practice the techniques. The language used to describe mindfulness practices will be accessible to youth. Mindfulness concepts will be linked with tag phrases like breathing break, autopilot, and choice points. Homework will emphasize experiential, concrete tasks (notice five new things today; eat one meal mindfully this week)."
89315299|NCT01307943|Active Comparator|Usual Care|The control group will be youth receiving therapies and programs already used at the site. The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
89315300|NCT01308021|Experimental|gpASIT400|gpASIT+TM 400 µg
89315301|NCT01308021|Experimental|gpASIT800|gpASIT+TM 800 µg
89315302|NCT01308021|Placebo Comparator|Placebo|
89315303|NCT05693883|Experimental|Pilates training|The participant completed receiving pilates training program three time a week for ten week-long (60 minutes/time)
89315304|NCT05693883|No Intervention|Control group|
89315305|NCT01308177|Placebo Comparator|PPI+placebo|
89315306|NCT01308177|Active Comparator|PPI+ES|
89315307|NCT01308099||POTS & Controls|"Participants will have a physical prior to the study day and collect urine for 24 hours.~On the study day the following procedures take place:~After blood samples taken (about 2 tbsp), the subject will lie down. A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The arm blood pressure cuff will be inflated 60 points above the highest number on your normal blood pressure for five minutes. The blood pressure and forearm blood flow will be recorded. At the end of 5 minutes, the cuff will be released and the measurements of blood pressure and calf blood flow will be repeated. The brachial artery diameter and flow will be measured at baseline, during cuff inflation and for 3 minutes after deflation.~The study lasts about 2 hours."
89315308|NCT01308255|Experimental|Infliximab Arm|For those randomised to the infliximab arm, infliximab will be administered at a dose of 3mg/kg according to the standard treatment protocol.
89315309|NCT01308255|Placebo Comparator|Steroid/Placebo Arm|Patients randomised to this arm will receive an IV infusion of 250mg methylprednisolone at week 0 & those without an adequate clinical response after 26 wks will receive additional steroid as IM methylprednisolone 120mg. Patients on this arm will receive an IV placebo infusion of 250ml of 9mg/l NaCl.
89315310|NCT05694039|No Intervention|Control Group|Procedure: no intervention
89315311|NCT05694039|Active Comparator|Intervention Group|Procedure: a intervention via hearing aids for 5 years
89315312|NCT03786393||Fibromyalgia|100 participants diagnosed with fibromyalgia according to ACR 1990 criteria.
89315313|NCT03786393||Control|
89315314|NCT01308333||XLHED children|
89315315|NCT01308333||XLHED adults|
89315316|NCT01308333||Control children|
89315317|NCT01308333||Control adults|
89315318|NCT05693961|Experimental|CART-I plus|CART-I pulse oximeter with a ring-type wearable PPG sensor was placed on each volunteer to evaluate the SpO2 accuracy during steady-state, non-motion conditions.
89315319|NCT01310907||sinus node dysfunction|
89315320|NCT01310907||Atrioventricular block|
89315321|NCT01310907||control|
89315322|NCT03782025||Patients with increased PK-INR|Critically ill patients with spontaneously increased prothrombin complex (PK-INR) who are given phytomenadione intravenously at the discretion of the treating physician
89315323|NCT03781947|Experimental|90 mg s.c.|A single s.c. injection of 90 mg teverelix TFA administered on Day 1
89315324|NCT03781947|Experimental|60 mg s.c.|A single s.c. injection of 60 mg teverelix TFA administered on Day 1
89315325|NCT03781947|Experimental|90 mg i.m.|A single i.m. injection of 90 mg teverelix TFA administered on Day 1
89315326|NCT03781947|Experimental|120 mg s.c.|A single s.c. injection of 120 mg teverelix TFA administered on Day 1
89315327|NCT01311219|Active Comparator|No surgery|Non-operative Treatment
89315328|NCT01311219|Active Comparator|Plate fixation|Operative Treatment-Plate fixation
89315329|NCT01311219|Active Comparator|Intramedullary pinning|Operative Treatment-Intramedullary Pinning
89315330|NCT03781869|Experimental|Anlotinib + Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, and Anlotinib 12mg/d on day 1 to day 14 , repeated every 21 days, a total of 4-6 cycles, and then continue to take Anlotinib 12mg/d on day 1 to day 14, repeated every 21 days until progressive Disease(PD).
89315331|NCT03781869|Placebo Comparator|Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, repeated every 21 days, a total of 4-6 cycles, and then follow up observation until PD.
89315332|NCT01311765|Active Comparator|8 day-antibiotherapy|Duration of antibiotic therapy limited to 8 days: Antibiotics received for up to 8 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit
89315333|NCT01311765|No Intervention|15 day-antibiotherapy|Antibiotics received for up to15 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit corresponding to usual practice and recommendations
89315334|NCT01308411|Experimental|50% reduction in ICS dose|All patients will reduce their inhaled corticosteroid dose by 50%
89315335|NCT01308489|Experimental|Arm I (posterior spinal tumor resection)|Patients undergo posterior spinal tumor resection on day 0.
89315336|NCT01308489|Experimental|Arm II (anterior and posterior spinal tumor resection)|Patients undergo anterior and posterior tumor resection on day 0.
89315337|NCT03781635|Active Comparator|bolus of intravenous ketamine|A bolus of 0.25mg.kg-1 of ketamine will be first administered at the time of incision (T0) then every single hour for the rest of the surgery. Study starts at incision (T0) for ketamine administration and ends when the surgical team starts closing the deep layers of the abdominal incision.
89315338|NCT03781635|Experimental|continuous infusion of intravenous ketamine|An infusion of 0.25 mg.kg-1.h-1 is started at T0 (incision) with an infusion pump and is kept at the same rate until the surgical team starts closing the deep layers of the abdominal incision. Consumption of the infusion pump is noted at T0 (incision) and at each hour during the surgery until the infusion is discontinued.
89315339|NCT01560897|Experimental|C13|The dose of sodium [1-13C] acetate is calculated according to patient weight (27mg/kg) or (0.33 mmol / kg).
89315340|NCT03781557|Experimental|High-concentrated DHA|High-concentrated DHA fish oil softgels
89315341|NCT03781557|Experimental|High-concentrated EPA|High-concentrated EPA fish oil softgels
89315342|NCT03781557|Placebo Comparator|Olive Oil|Olive Oil softgels
89315343|NCT03781713|Active Comparator|STUDY GROUP|patients who triggered triggers and had interventions. Kdigo: interventions to prevent renal replacement therapy Delta SOFA: interventions to improve SOFA score Hypoglycemia: Interventions to prevent new episodes of hypoglycemia in the next 24 hours Drug interaction risk D or X - Intervention in the therapeutic plan in order to avoid adverse drug reactions. Antimicrobial stewardship: optimization of antimicrobial therapy based on Gram stain, MALDI TOF, MIC, antimicrobial susceptibility
89315344|NCT03781713|No Intervention|CONTROL GROUP|patients who did not triggered triggers
89315345|NCT03785535|Experimental|Actual treatment|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (2-90 Hz), low intensity and long daily duration (3h).
89315346|NCT03785535|Sham Comparator|Sham|Sham treatment will be applied using identical instruments and with power and duration programmed identically. However, in this case, the output will not be the signal activating the vibration motors, but rather an electrical signal turning on an incorporated pilot light indicating that the (simulated) treatment was operating
89315347|NCT05693415||Control Group|No treatment
89315348|NCT05693415||Trial Group|"Non drug and none surgical treatment of contracted Lumber Spine~Other Names:~Contracture Correction Therapy"
89315349|NCT01312701||cancer patients|as described patietns with solid cancer about to be treated with anticancer therapies
89315350|NCT01312701||control group|normal populations who domated blood for further use
89315351|NCT05399823|Experimental|Self Stretching and Kinesio Taping Group|Kinesio taping in addition to self stretching exercises will be given for 15-20 minutes at home or in the office every day for four weeks.
89315352|NCT05399823|Sham Comparator|Self Stretching and Sham Taping Group|Sham kinesio taping in addition to self stretching exercises will be given for 15-20 minutes at home or in the office every day for four weeks.
89315353|NCT05399823|Active Comparator|Self Stretching Group|A program consisting of stretching exercises for pectoral, erector spinae, latismus dorsi, multifidus, rhomboid and trapezius muscles will be given for 15-20 minutes at home or in the office every day for four weeks.
89315354|NCT03785613|Experimental|Test Product T1: Buprenorphine patch (9 mg)|"Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to T1: simultaneous application for 96 hours on the upper back."
89315355|NCT03785613|Experimental|Test Product T2: Buprenorphine patch (3.8 mg)|"Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters. Single application of patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to T2: simultaneous application for 96 hours on the upper back."
89315356|NCT03785613|Active Comparator|Reference Product R: Transtec patch (20 mg)|"Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to R: simultaneous application for 96 hours on the upper back."
89315357|NCT03785379|Active Comparator|Caloric restriction and early SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a caloric restriction and early exercise training (SSET) during the first 12-week, followed by no exercise at health centers for 3 months. Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
89315358|NCT03785379|Active Comparator|Caloric restriction and late SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a one-year caloric restriction with no exercise at health centers for 3 months, and then a 12-week exercise training (SSET). Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
89315359|NCT05691777||Healthy participants|right handed healthy participants aged between 18 and 40.
89315360|NCT01308723|Experimental|Part I|
89315361|NCT01308723|Experimental|Part II (A)|
89315362|NCT01308723|Active Comparator|Part II (B)|
89315363|NCT01561131|Active Comparator|Whey protein supplement|Whey protein
89315364|NCT01561131|Active Comparator|Whey protein enriched with calcium supplement|Whey protein enriched with calcium
89315365|NCT01561131|Active Comparator|Soy protein supplement|Soy protein
89315366|NCT01561131|Placebo Comparator|Control supplement|Maltodextrin
89315367|NCT03780933|No Intervention|control group|conventional treatment (corticosteroids, mechanical ventilation)
89315368|NCT03780933|Experimental|test group (vitamin C)|high dose vitamin c iv infusion
89315369|NCT03785301|Experimental|FGM group|Diabetic patients will use FreeStyle Libre Flash Glucose Monitoring (FGM) system(unmasked) to monitor glucose level once a month for 3 months.
89315370|NCT03785301|No Intervention|SMBG group|Diabetic patients will use Standard Blood Glucose Monitoring (SMBG) to monitor glucose level for 3 months. A 14-day masked wear of FreeStyle Libre H Flash Glucose Monitoring system is included for these subjects once a month, to collect glycaemic variability data for comparison to the intervention group of the study.
89315371|NCT03780855|Experimental|nerve scaffold group|the experimental group of cases with peripheral sensory nerve injuries will be treated with nerve scaffold.
89315372|NCT03780855|No Intervention|non-nerve scaffold group|the control group of cases will be treated without nerve scaffold.
89315373|NCT03780621|Experimental|Andrographis and Withania|Active ingredient: 550 mg of Andrographis paniculata (standardized to 40 mg andrographolides) and Withania somnifera (standardized to 10 mg withanolides) taken twice daily, once in the morning and once in the evening
89315374|NCT03780621|Placebo Comparator|Placebo|550 mg capsule visually identical to the active dietary supplement, containing brown sugar, microcrystalline cellulose, corn starch, and magnesium stearate
89315375|NCT05688891|Experimental|Virtual reality|"Before the procedure, Visual Analogue Scale-VAS, Spielberger State and Trait Anxiety Inventory, Burn-Specific Pain Anxiety Scale were filled in.5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Video monitoring with Virtual Reality continued throughout the entire dressing.This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings.After the procedure, the scales were filled again."
89315376|NCT05688891|Experimental|Music|"5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings.After the procedure, the scales were filled again."
89315377|NCT05688891|No Intervention|Control|"During the burn dressing procedure, no intervention method was used, and routine treatment and care interventions were continued.This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings."
89315378|NCT03780777|Experimental|Home Hazard Removal Group|A tailored home-modification (home-hazard removal) intervention for residents with a high fall risk, delivered in the home by occupational therapists over one to two visits and with a booster session at three months.
89315379|NCT02748694|Placebo Comparator|Part 1 (SRD): Placebo Cohorts 1-5|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
89315380|NCT02748694|Experimental|Part 1 (SRD): Cohort 1: TAK-041 5/20 mg|TAK-041 5 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 20 mg, suspension, orally, once on Day 8 in the SRD period.
89315381|NCT02748694|Experimental|Part 1 (SRD): Cohort 2: TAK-041 10/40 mg|TAK-041 10 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 40 mg, suspension, orally, once on Day 8 in the SRD period.
89315382|NCT02748694|Experimental|Part 1 (SRD): Cohort 3: TAK-041 80 mg|TAK-041 80 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
89315383|NCT02748694|Experimental|Part 1 (SRD): Cohort 4: TAK-041 120 mg|TAK-041 120 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
89315384|NCT02748694|Experimental|Part 1 (SRD): Cohort 5: TAK-041 160 mg|TAK-041 160 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
89315385|NCT02748694|Placebo Comparator|Part 2 (MRD): Placebo Cohorts 1-4|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the multiple-rising dose (MRD) period.
89315386|NCT02748694|Experimental|Part 2 (MRD): Cohort 1: TAK-041 40/20 mg|TAK-041 40 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 20 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
89315387|NCT02748694|Experimental|Part 2 (MRD): Cohort 2: TAK-041 80/40 mg|TAK-041 80 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 40 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
89315388|NCT02748694|Experimental|Part 2 (MRD): Cohort 3: TAK-041 120/60 mg|TAK-041 120 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 60 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
89315389|NCT02748694|Experimental|Part 2 (MRD): Cohort 4: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
89315390|NCT02748694|Experimental|Part 3: Relative Bioavailability (RBA)/Food Effect: Regimen A|TAK-041 40 mg, tablet, orally, once on Day 1 in fasted state (Regimen A) in Cohort 1.
89315391|NCT02748694|Experimental|Part 3: RBA/Food Effect: Regimen B|TAK-041 40 mg, tablet, orally, once on Day 1 in fed state (Regimen B) in Cohort 2.
89315392|NCT02748694|Placebo Comparator|Part 4: MRD: Placebo|TAK-041 placebo-matching, suspension, orally, on Days 1, 8, 15 and 22 in participants with schizophrenia
89315393|NCT02748694|Experimental|Part 4: MRD: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in participants with schizophrenia.
89315394|NCT03785067|Experimental|Triple Pill (Active Treatment)|"Main Study: Fixed low-dose combination BP-lowering pill (Triple Pill) telmisartan 20mg + amlodipine 2.5mg + indapamide 1.25mg~Sub-Study: single-arm"
89315395|NCT03785067|Placebo Comparator|Placebo|"Main Study: Matched placebo, received via blinded study capsules~Sub-Study: single-arm"
89315396|NCT02059018|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions over two examination days
89315397|NCT02059018|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions over two examination days
89315398|NCT03780465|Active Comparator|Oral idronoxil|10 male and female subjects randomised to 400 mg active Oral idronoxil suspension or oral placebo suspension (n=8 active; n= 2 placebo).
89315399|NCT03780465|Experimental|NOX66 400 mg|10 male and female subjects randomised to 400 mg active NOX66 (A) suppository or 400 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
89315400|NCT03780465|Experimental|NOX66 600 mg|10 male and female subjects randomised to 600 mg active NOX66 (A) suppository or 600 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
89315401|NCT02059096|Experimental|Repetitive transcranial magnetic stimulation (rTMS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation
89315402|NCT02059096|Other|Theta-Burst Stimulation (pcTBS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
89315403|NCT02059096|Other|repetitive Transcranial Magnetic Stimulation (rTMS)placebo|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
89315404|NCT01308801|Experimental|active rTMS + rehabilitation exercise|14 weeks of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
89315405|NCT01308801|Placebo Comparator|placebo rTMS + rehabilitation exercise|14 weeks of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
89315406|NCT01561209|Active Comparator|Amitryptiline|Amitryptiline 5 mg before bedtime
89315407|NCT01561209|Placebo Comparator|Placebo|Placebo pill
89315408|NCT01308879|Experimental|Weekly feedback|After clinical questionnaires are entered into the system (CFStm), an automated online report is available weekly to clinicians in the experimental group that shows current mental health status of youths, alerts, and trends over time based on youth, caregiver, and clinician responses. Reports also show some clinical data on caregivers.
89315409|NCT01308879|Other|No feedback|Clinicians in the control group do not have access to weekly feedback. Instead, they receive reports every 90 days after the youth is enrolled in CFStm. Because the average duration of CFS enrollment was 3.8 months, many youths would have been discharged before the first 90-day report became available three months after treatment start. Thus, we considered the 90-day feedback group to be essentially a no-feedback group.
89315410|NCT02800642|Experimental|Intravitreal (IVT) aflibercept|Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept
89315411|NCT01308957|Experimental|Long chain omega-3 fatty acids|
89315412|NCT01308957|Placebo Comparator|Corn oil|
89315413|NCT01308957|No Intervention|Young healthy controls|Young subjects' muscle mass and physical function will be evaluated once (i.e., during baseline testing only). The data in young subjects will be used to determine the magnitude of the aging-induced decline in muscle mass and physical function in the older subjects prior to starting the interventions.
89315414|NCT02056600|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
89315415|NCT02056600|Experimental|C|Combination of gemigliptin50mg/metformin HCl sustained release 1000mg
89315416|NCT02054494||HIV patients with high CD4+ cell counts|HIV Infection, Chronic high CD4+ cell counts (>500 /μl), No known cardiac disease
89315417|NCT02054494||HIV patients with low CD4+ cell counts|HIV Infection, Chronic low CD4+ cell counts (<200 /μl), No known cardiac disease
89315418|NCT02054494||Control Group|No known cardiac disease.
89315419|NCT01313793|Experimental|Sequence 1|Subjects will receive clinical formulation (treatment A) followed by commercializable formulation (treatment B).
89315420|NCT01313793|Experimental|Sequence 2|Subjects will receive commercializable formulation (treatment B) followed by clinical formulation (treatment A).
89315421|NCT02054650|Experimental|Osteopathic Manual Treatment (OMT)|The OMT protocol will be delivered following an examination for somatic dysfunction at each treatment session. The protocol will target the thoracic, lumbosacral, iliac, and pubic regions using the following techniques: high-velocity, low-amplitude thrusts; moderate-velocity, moderate-amplitude thrusts; soft tissue including stretching, kneading, and pressure; myofascial stretching and release; counterstrain; muscle energy; and other optional techniques as time permits and indicated. The intervention will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
89315422|NCT02054650|Sham Comparator|Sham OMT|Sham OMT will involve hand contact, active and passive range of motion, and sham techniques that simulate OMT (including optional OMT techniques), but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force. Sham OMT will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
89315423|NCT03779919|Experimental|High Energy|Extracorporeal shock wave therapy with 0.3 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
89315424|NCT03779919|Experimental|Low Energy|Extracorporeal shock wave therapy with 0.05 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
89315425|NCT03779919|Placebo Comparator|Sham|Extracorporeal shock wave therapy with 0 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
89315426|NCT02056678|Active Comparator|IV acetaminophen, OSA, laparoscopic cholecystectomy|IV acetaminophen 1000mg to be administered to obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy
89315427|NCT02056678|No Intervention|OSA, laparoscopic cholecystectomy, narcotics|No IV acetaminophen in obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy; patients will receive other modalities for pain control primarily including IV narcotics
89315428|NCT04662567|Active Comparator|Oral acetaminophen group|the subjects in this group will receive 1000 mg oral acetaminophen 30-45min prior to oocyte retrieval
89315429|NCT04662567|Active Comparator|IV acetaminophen group|the subjects in this group will receive 1000 mg IV acetaminophen formulation intraoperatively
89315430|NCT04616625||Methamphetamine exposed|Infants born to mothers with prenatal history of MA use during current pregnancy and/or positive meconium toxicology positive for MA in infant.
89315431|NCT04616625||Methamphetamine non-exposed|Infants born to mothers without prenatal history of MA use during this pregnancy and negative meconium toxicology for MA in infant.
89315432|NCT02799784|Experimental|Sequence 1: UMEC/VI 62.5/ 25 mcg|Subjects will receive UMEC/VI 62.5/25 mcg (as one inhalation) administered QD via the ELLIPTA Inhaler for 8 weeks followed by a washout period of 3 weeks
89315433|NCT02799784|Experimental|Sequence 2: TIO/OLO 5/5 mcg|Subjects will receive TIO/OLO 5/5 mcg (as 2 inhalations of 2.5/2.5 mcg per inhalation) administered QD via the RESPIMAT inhaler for 8 weeks followed by a washout period of 3 weeks
89315434|NCT03779685|Active Comparator|General anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
89315435|NCT03779685|Experimental|Regional anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
89315436|NCT03779607|Active Comparator|IPS e.max Press(lithium di silicate)|Lithium disilicate reinforced glass ceramics are available in the market in two forms according to the technique of manufacturing, either heat pressed ingots or CAD/CAM blocks for milling. The heat pressed lithium disilicate glass ceramic consists of approximately 70% lithium disilicatecrystals(the main crystal phase) having a needle like shape that are embedded in a glassy matrix. The crystals length is about 3 to 6 μm. The heat pressed ingots are fully crystallized and the restoration is fabricated by the lost wax technique where the lithium disilicate ingots are pressed into the investment mold at high temperature. The pressed lithium disilicate has strong flexural strength values(range 400 ± 40 MPa)
89315437|NCT03779607|Experimental|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
89315438|NCT02059252|Experimental|SmartMatrix scaffold|SmartMatrix dermal replacement scaffold
89315439|NCT03779451|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery
89315440|NCT03779451|Active Comparator|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily at bedtime starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
89315441|NCT03779451|No Intervention|control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
89315442|NCT02059330|Experimental|Healthy Subjects of Japanese Descent|Enrolled Japanese subjects will receive four palbociclib single doses of differing dose amounts in fixed sequence over four treatment periods.
89315443|NCT02059330|Experimental|Healthy Non-Asian Subjects|Enrolled healthy non-Asian subjects will receive a single 125mg oral dose of palbociclib in a single treatment period.
89315444|NCT03561142|Experimental|Radiochemotherapy -> chemotherapy.|Radiochemotherapy followed by consolidation chemotherapy. Deep regional hyperthermia can additionally be performed at the centers in Tübingen and Erlangen.
89315445|NCT03561064|Experimental|Receiving CBT-I|This is a single arm study. All participants will receive CBT-I (cognitive behavioral therapy for insomnia).
89315446|NCT05652075|Experimental|PENG and LFCN|
89315447|NCT05652075|Experimental|lumbar plexus|
89315448|NCT03802474||Group A|girls with primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
89315449|NCT03802474||Group B|girls with normal painless menstruation without primary dysmenorrhea subject to three-dimensional analysis of the back will conducted with the 4D formetric device and inclinometer to measure range of motion of spine
89315450|NCT01309035|Active Comparator|With Tourniquet|Total Knee Arthroplasty. Surgery performed during use of a tourniquet.
89315451|NCT01309035|Experimental|Without Tourniquet|Total Knee Arthroplasty. Surgery performed without use of a tourniquet.
89315452|NCT02056912|Other|Lipodystrophie Héréditaire|
89315453|NCT01314885|Experimental|PF-03715455|
89315454|NCT01314885|Experimental|PH-797804|
89315455|NCT01314885|Placebo Comparator|Placebo for PF-03715455|
89315456|NCT01314885|Placebo Comparator|Placebo for PH-797804|
89315457|NCT02054728|Experimental|RHC and IMT|
89315458|NCT02054806|Experimental|Pembrolizumab|Participants receive pembrolizumab 10 mg/kg, intravenously (IV), once every 2 weeks (Q2W) for up to ~2 years
89315459|NCT03779529|Active Comparator|Arm label extra-vergin olive oil (EVOO)|Participants will ingest two tablespoons of extra-vergin olive oil (EVOO) Coratina during the day: one spoon containing 10g of olive oil (>5mg of total biophenols/kg of olive oil) at lunch and one at dinner. The total biophenols ingested per day will be >10mg.
89315460|NCT03779529|Active Comparator|Arm label refined olive oil (ROO)|Participants will ingest two tablespoons of refined olive oil during the day: one spoon containing 10 g of refined olive oil at lunch and one at dinner.
89315461|NCT02054884|Experimental|Arm A: F16IL2 in combination with paclitaxel|
89315462|NCT02054884|Experimental|Arm B: Paclitaxel|
89315463|NCT01309113|Placebo Comparator|Placebo of VAC BNO 1095|1 tablet of placebo in the morning, 1 tablet of placebo in the evening
89315464|NCT01309113|Active Comparator|10 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of placebo in the evening
89315465|NCT01309113|Active Comparator|20 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of VAC BNO 1095 10 mg in the evening
89315466|NCT01315197|Experimental|massage|The massage Anma has Japanese origin and a protocol was used with smoothing, kneading and pressure points on the bladder meridian.
89315467|NCT02056990||training advise|
89315468|NCT02057146|Experimental|Mother-baby endoscopy|Spyglass mother-baby endoscopy in conjunction with ERCP
89315469|NCT03779373|Active Comparator|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
89315470|NCT03779373|Experimental|EV1000 monioring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
89315471|NCT02057224|Experimental|Single arm|15 clinical patients undergoing renal denervation
89315472|NCT05212701|Experimental|Reparixin|Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) three times daily (total dose of 3600 mg/day) with no interruptions during each cycle.
89315473|NCT05212701|Placebo Comparator|Placebo|Masked placebo will be administered orally (2 tablets) three times daily with no interruptions during each cycle.
89315474|NCT01333072|Active Comparator|Risperidone|Atypical antipsychotic
89315475|NCT01333072|Active Comparator|Aripiprazole|Atypical antipsychotic
89315476|NCT03784365|Active Comparator|First group|This group will receive an intravenous antibiotic for three days. The first dose will be given within half hour before the POEM procedure.
89315477|NCT03784365|Experimental|Second group|This group will receive only one dose of intravenous antibiotic within half hour before the POEM procedure
89315478|NCT02059486|Experimental|Teen Choice|The curriculum provides comprehensive sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress. The curriculum can be delivered in different formats that range in length from 6 to 12 weeks.
89315479|NCT02059486|No Intervention|Control|Business as usual school health curriuclum
89315480|NCT02059564|Experimental|Cohort A|The weekly treatment of the 6 mg HM11260C or placebo will be maintained
89315481|NCT02059564|Experimental|Cohort B|The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg
89315482|NCT02059564|Experimental|Cohort C|The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg
89315483|NCT03778749|Experimental|electromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
89315484|NCT03778749|Experimental|acceleromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
89315485|NCT03778749|Experimental|acceleromyographic NMT monitoring at the eyebrow|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
89315486|NCT05622058|Experimental|ALRN-6924 Dose plus TAC|ALRN-6924 plus Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
89315487|NCT02054962||Elderly|The investigators intend to asses the effect of fear of movement, PTSD symptoms, and physical activity on persistent pain and functional decline.
89315488|NCT02057302|Placebo Comparator|Group B|There are 538 patients recruited in this group. Patients in this group will take 2 capsules of placebo every time, twice every day, respectively after breakfast and supper.
89315489|NCT02057302|Experimental|Group A|There are 1614 patients recruited in this group. Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper.
89315490|NCT02055196|Experimental|Treatment (neuronal stem cells, irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells via intracerebral catheter on day 1 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Patients also receive irinotecan hydrochloride IV over 90 minutes on day 3 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
89315491|NCT02057536|Experimental|Arm A|8 week directed exercise program
89315492|NCT02057536|Active Comparator|Arm B|No directed exercise other than patients normal level of activity
89315493|NCT02059720|Active Comparator|auto|patients receive autologous SCT
89315494|NCT02059720|Active Comparator|haplo|patients receive haplo-SCT
89315495|NCT01315353|Experimental|Arm A: Immediate cryotherapy (HPV test-and-treat)|Participants in Arm A (HPV test-and-treat) had cervical cryotherapy at entry. Post entry, participants in Arm A were seen at regular intervals for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP.
89315496|NCT01315353|Experimental|Arm B: cytology-based strategy|Participants in Arm B followed a cytology-based management plan involving three steps- cytology, colposcopy with directed biopsies, and LEEP (as needed).
89315497|NCT01315353|Experimental|Arm C : Ineligible for randomization to Arm A or B|Participants were eligible for Arm C under the conditions noted in the inclusion criteria. Participants in Arm C had colposcopy and directed biopsies at entry. If CIN2+ was found by biopsy, then LEEP was performed and a follow-up visit 26 weeks after these procedures was scheduled for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP. After the week 26 visit, Arm C participants went off study.
89315498|NCT02055274|Experimental|LY03003|4 Stable doses of LY03003 14, 28, 42 and 56 mg
89315499|NCT02055274|Active Comparator|Neupro|Neupro patch 2 mg/24 hours in the first week, and then be titrated to 4, 6 and 8 mg/24 hours at weekly intervals
89315500|NCT02055274|Active Comparator|Neupro PK|Neupro patch 2 mg/24hr in the first week then titrated to 4 and 6mg/24hr
89315501|NCT02055508|Experimental|Exercise Intervention Program (EIP)|"Inpatient periods: The combined resistance and endurance program consist of free weight and rubber band training for major upper and lower body muscle groups respectively of cycling/walking on an ergometer/treadmill 3x/week.~Outpatient periods (3x/week at least two/one supervised training sessions): Supervised training sessions in the local outpatient training center will comprise of resistance exercise on machines and endurance training on an ergometer/treadmill. For non-supervised training session during the outpatient period participants will receive an exercise manual for individualized home-based exercising.~In weekly phone calls, the advanced practice nurse will review adherence to the intervention and identify problems. Furthermore, the patients will also be asked the same questions as in the CMPC group."
89315502|NCT02055508|Active Comparator|Care-Management-Phone-Calls (CMPC)|"Patients in this arm will receive a weekly care-management-phone-call (CMPC), performed by an advanced practice nurse (APN). The CMPCs are based on a structured questionnaire, reflecting pain, shortness of breath, disturbed sleep, exhaustion and distress and potentially treatment related side effects (e.g. infections, polyneuropathy, etc.). In case of demanding management of symptoms or complaints (e.g. uncontrolled pain or breathlessness) the treating physician is contacted by the APN to facilitate improvement."
89315503|NCT02059798||Decompression of cervical myelopathy|JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy Compliance Rigidity activity unit
89315504|NCT03778905||stroke patient with complete post-acute care hospitalization|This study aims on stroke patients with complete rehabilitative program in post acute care institution and we try to assess their functional improvements after rehabilitative training.
89315505|NCT03783897|Experimental|EDP-305 and Oral Contraceptive|
89315506|NCT01315821|Experimental|Saccharomyces boulardii|Saccharomyces boulardii 5 million unit/day for 3 months
89315507|NCT01315821|Placebo Comparator|control|Placebo- for 3 months
89315508|NCT03779061|Experimental|Remimazolam Tosilate|
89315509|NCT03779061|Active Comparator|Propofol|
89315510|NCT03784053||Immersive virtual reality|Participants will receive eight 30-minute sessions of immersive virtual reality.
89315511|NCT01316445|Experimental|nasal Midazolam|3 mg of the standard IV solution of midazolam (5 mg/mL) was given via a metered-dose nasal sprayer (6 sprays × 0.1 ml/spray, or 6 × 0.5 mg/spray) divided between the two nostrils within 1-2 min. During the EEG, vital signs (blood oxygen saturation, blood pressure, pulse and respiratory rate) were monitored and a nurse and a physician were available at all times. Subjects were monitored for 2 hours after administration of midazolam to ensure adequate recovery from sedation.
89315512|NCT03517540|Experimental|Arm A: Tropifexor (LJN452) - Dose 1|tropifexor 140 mcg, once daily; given orally
89315513|NCT03517540|Experimental|Arm B: Cenicriviroc (CVC)|CVC 150 mg, once daily; given orally
89315514|NCT03517540|Experimental|Arm C: Tropifexor (LJN452) Dose 1 + CVC|tropifexor 140 mcg + CVC 150 mg, once daily; given orally
89315515|NCT03517540|Experimental|Arm D: Tropifexor Dose 2 + CVC|tropifexor 90 mcg + CVC 150 mg, once daily; given orally
89315516|NCT03778359||Gonadotropin-releasing hormone agonist treatment|Endometriosis post-operative Gonadotropin-releasing hormone agonist treatment
89315517|NCT03778359||Intrauterine device treatment|Endometriosis post-operative intrauterine device treatment
89315518|NCT03778359||Hormone therapy|Endometriosis post-operative hormone therapy
89315519|NCT03778359||Oral contraceptive|Endometriosis post-operative oral contraceptive
89315520|NCT03560908|Experimental|Dasatinib plus chemotherapy|Dasatinib combined with chemotherapy for relapsed t(8;21) AML with D816 mutation
89315521|NCT02038426|Experimental|the patients with SpA|
89315522|NCT02038426|Experimental|sports subjects|
89315523|NCT02038426|Other|control subjects|
89315524|NCT02057770|Experimental|Treatment (preparative regimen, transplant, cyclophosphamide)|"BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2.~OR~FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0.~AND~DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0.~AND~POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4."
89315525|NCT02057770|Experimental|CRS preventive regimen|The final ~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.
89315526|NCT02038504||gastrointestinal fistula|
89315527|NCT02057848|Active Comparator|low amount of carbohydrates|2 x 10 g carbohydrates (muesli bars)
89315528|NCT02057848|Active Comparator|high amount of carbohydrates|2 x 20 g carbohydrates (muesli bars)
89315529|NCT02057848|Other|Rapid-acting carbohydrates|30 g rapidly absorbable carboh. + 20 g muesli bar
89315530|NCT03778281|Experimental|Baclofen group|Treatment of Chemotherapy-related Hiccups With Baclofen
89315531|NCT03778281|Other|Methoxyclopramide group|Treatment of Chemotherapy-related Hiccups With Methoxyclopramide
89315532|NCT03778281|Experimental|Baclofen group 2|After 3 days, if the metoclopramide treatment is ineffective, it will cross into the baclofen group 2.
89315533|NCT03778281|Other|Methoxyclopramide group 2|After 3 days, if the baclofen treatment is ineffective, it will cross into the metoclopramide group 2.
89315534|NCT02055586||Diagnostic (FLT-PET/MRI)|Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of treatment.
89315535|NCT03778593|Experimental|mFOLFIRINOX|D1 Oxaliplatin 65 mg/m2 + 5% dextrose water (5DW) 200 mL mix IV over 2 hours followed by, D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1 liter (1L) continuous IV over 23 hours repeat every 2 weeks
89315536|NCT02055664|Experimental|treatment|
89315537|NCT02055664|Placebo Comparator|control|
89315538|NCT02055742||Specimen Collection|
89315539|NCT03778437|Active Comparator|landmark techniques|Subclavian vein catheterization is performed without the guidance of ultrasound. The needle was inserted 1 cm inferior and 1 cm lateral to the junction of the middle and medial thirds of the clavicle (infraclavicular approach)
89315540|NCT03778437|Experimental|ultrasound-guided with aiming method|Subclavian vein catheterization is performed with our newly proposed aiming method with the guidance of ultrasound.
89315541|NCT03778437|Experimental|ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique.
89315542|NCT03778047|Experimental|enzalutamide|160mg
89315543|NCT03778047|Experimental|HC-1119|To be determined
89315544|NCT03560830||Control|Sedentary control subjects with no medical or psychiatric disorder
89315545|NCT03560830||POTS GWI|GWI with Postural Orthostatic Tachycardia Syndrome (POTS) GWI veterans who had postural orthostatic tachycardia before exercise and after 2 submaximal exercise stress tests. Postural orthostatic tachycardia was defined by 2015 Consensus as an increase in heart rate of greater than or equal to 30 beats per minute between recumbent (after 5 minutes of rest) and standing up. Standing heart rates were measured every minute for 5 minutes. Postural orthostatic tachycardia was defined if the change in heart rate was more than 30 beats per minute at at least 2 of the 5 standing time points. The average change in heart rate did not have to be above 30. There were 11 GWI POTS subjects.
89315546|NCT03560830||START|"START = Stress Test Activated Reversible Tachycardia One third of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) BEFORE EXERCISE, but AFTER EXERCISE (submaximal exercise stress tests) they developed postural orthostatic tachycardia with changes in heart rate of 30 or more between recumbent and standing. The effect was transient as it lasted about 36 to 48 hr.~The START group had brainstem atrophy and reduced brain activation during a cognitive task compared to sedentary control and other GWI subjects."
89315547|NCT03560830||STOPP|"STOPP = Stress Test Originated Phantom Perception Two thirds of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) both before and after 2 submaximal exercise stress tests. STOPP did not develop postural orthostatic tachycardia. their changes were equivalent to the sedentary control group.~The STOPP group increased brain activation of the basal ganglia and anterior insula during a cognitive task compared to sedentary control subjects."
89315548|NCT03777891|Experimental|group A|received Silicone gel phonophoresis: Silicone gel (strataderm) was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes. The Ultrasound Device is Sonopulse 590: Nonius, sonopuls 590, S.NO.03-202 type 14663.900 was a therapeutic ultrasound device manufactured by Enraf Holland.
89315549|NCT03777891|Experimental|group B|received Contractubex phonophoresis: Contractubex (Merz Pharma, Frankfurt, Germany was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes.
89315550|NCT03777891|Experimental|group C|received Corticosteroid phonophoresis: A thin film of coupling medium (gel) was put on the hypertrophic scar and sufficient quantity of Triamcinolone was put by a syringe over the whole scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes
89315551|NCT01309425|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 25mg TRF single oral dose
89315552|NCT01309425|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50mg TRF single oral dose
89315553|NCT01309425|Experimental|003|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
89315554|NCT01309425|Experimental|004|tapentadol (CG5503) ER two 100-mg TRF 200mg TRF single oral dose
89315555|NCT03561298|Experimental|Single Arm: BGB-3111 + Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
89315556|NCT05648422|No Intervention|FG (FOLLOW GROUP)|FG receive: Conventional diet (WHO).
89315557|NCT05648422|Experimental|CG (CONTROL GROUP)|CG receive: Conventional diet (WHO), deworming (nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days), and probiotics (Saccharomyces Boulardii, 200 mg every 12 hours for 6 days at week 1, 5 and 9).
89315558|NCT05648422|Experimental|IG (INTERVENTION GROUP)|IG receive: Deworming (nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days), probiotics (Saccharomyces Boulardii, 200 mg every 12 hours for 6 days at week 1, 5 and 9), specific diet, and NSS envelope (glutamine, arginine, folic acid, PUFA-n3, vegetal protein, nicotinic acid, cobalamin, thiamine, pyridoxine, magnesium, zinc, selenium, cholecalciferol, resveratrol, ascorbic acid, Spirulina Máxima, and inuline) every 12 hours for 12 weeks.
89315559|NCT01309503||Normal hearing|Children and adults
89315560|NCT01309503||Unilateral hearing loss|
89315561|NCT01309503||Severe hearing loss high frequencies|
89315562|NCT01309503||Adult CI users|Unilateral and bilateral CI
89315563|NCT01309503||Bilateral CI users|"Children and adults~Sequential CIs~Simultaneous CIs"
89315564|NCT03783663|Experimental|Sleep education plus Misfit Shine 2|This arm receives sleep education from the study nurse and also receives a Misfit Shine 2 to wear for 12 weeks to self-monitor sleep.
89315565|NCT03783663|No Intervention|sleep education only|This arm receives only sleep education from the study nurse.
89315566|NCT02057926|Experimental|Tetracycline, Without Tetracycline|The study consist in two groups: test group (membrane treated with tetracycline) and control group (membrane no treated with tetracycline).
89315567|NCT01561287|Experimental|Dermal Autograft|
89315568|NCT01561287|Experimental|AlloDerm|
89315569|NCT02058004|Experimental|Cricoid pressure|Patients randomized to receive cricoid pressure during endotracheal intubation.
89315570|NCT02058004|No Intervention|No cricoid pressure|Patients randomized to receive no cricoid pressure during endotracheal intubation.
89315571|NCT02058082|Active Comparator|ejaculated sperm|Intracytoplasmic sperm injection (ICSI) cycles using ejaculated sperm
89315572|NCT02058082|Active Comparator|testicular extracted sperm|Intracytoplasmic sperm injection (ICSI) cycles using testicular extracted sperm
89315573|NCT03777579|Experimental|JS001 Plus Nab-Paclitaxel|Participants assigned to JS001 plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
89315574|NCT03777579|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
89315575|NCT02059876|Experimental|carboplatin and paclitaxel ± trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer.
89315576|NCT03777423|Experimental|PEEK framework partial dentures|High performance ketone polymers introduced lately.These polymer-based frameworks provide better esthetics, higher elasticity, lighter in weight, have low water sorption and solubility, and are easily repaired and reproduced.
89315577|NCT03777423|Active Comparator|Cobalt-chromium framework partial dentures|it is considered the gold standard framework. These frameworks are less bulky with high strength, conduct heat and electricity well, and have good durability. some disadvantages include hypersensitivity, adverse tissue reactions and bad aesthetics.
89315578|NCT05617924||Conventional Physiotherapy|Treatment method using physical agents such as analgesic currents and superficial-deep heaters
89315579|NCT05617924||Mechanical Traction|It is a stretching process for the spine with a weight and pulling system for the spine.
89315580|NCT05617924||Nonsurgical Spinal Decompression|Non-surgical spinal decompression is a technique that uses a precision computerized mechanism and opens spinal nerve roots through segmental distraction.
89315581|NCT03777501|Experimental|non-random whole body vibration group|Each participant will receive the non-random type whole body vibration treatment about one hour after the administration of medicine.
89315582|NCT03777501|Active Comparator|conventional therapy group|For the conventional therapy group, participants will receive the occupational therapy including dynamic balance training and functional ambulatory training. Each session is 10 minutes.
89315583|NCT03783819|Active Comparator|Active treatment|One forearm will be treated with ointment containing Hypericum perforatum oil. Forearm (left or right) will be chosen according to randomization protocol.
89315584|NCT03783819|Placebo Comparator|Placebo treatment|Other forearm will be treated with placebo ointment. Forearm (left or right) will be chosen according to randomization protocol.
89315585|NCT02059954|Active Comparator|Vaginal hysterectomy|Vaginal hysterectomy
89315586|NCT02059954|Active Comparator|Total laparoscopic hysterectomy|Laparoscopic hysterectomy
89315587|NCT02058238||Arm 1: Robotic-guided, Open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
89315588|NCT02058238||Arm 2: control-arm - non-robotic, open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
89315589|NCT02058238||Arm 3: robotic-guided, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
89315590|NCT02058238||Arm 4: control-arm - freehand, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
89315591|NCT03777111|Active Comparator|Single Task Training Group|"Gait and balance exercises will be applied in single task training group.~Semi-tandem, tandem stand with eyes open and close~One leg stance with eyes open and close~Gait exercises; walking forwards, backwards, sidewards, semi-tandem and tandem walking~Reaching forward and sidewards with eyes open and close"
89315592|NCT03777111|Experimental|Dual Task Training Group|"The exercises given in the single task training group will be combined with the cognitive tasks.~Semi-tandem, tandem stand with recall a sequence of numbers~One leg stance with writing pre-defined letters or words with other foot~Semi-tandem or tandem walking with saying previous number (one or two previous) from number that researcher has given before~Walking sidewards with collecting numbers that researcher has given~Walking backwards with counting forward by one (then two or three)~Reaching forward with counting backward one (then two or three)~Reaching sidewards with saying next number (one or two next) from number that researcher has given before"
89315593|NCT02058316||Patients at risk for IPA|
89315594|NCT03783585|Experimental|cognitive behavioral therapy for insomnia (CBT-I)|Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
89315595|NCT03783585|Experimental|CBT-I + biweekly support|Participants randomized to this arm will participate in a 6-week web-based CBT-I program. In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
89315596|NCT02058394||Cataract Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
89315597|NCT03777189|Experimental|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
89315598|NCT01561365|Experimental|Emergency|
89315599|NCT01561365|Experimental|Orthopedic residents|
89315600|NCT02038582|Active Comparator|POC CD4 & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and follow up with clinic accompaniment
89315601|NCT02038582|Active Comparator|POC CD4 & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and lay counselor follow up
89315602|NCT02038582|Active Comparator|POC CD4 & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and referral to clinic
89315603|NCT02038582|Active Comparator|CD4 Referral & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and follow up with clinic accompaniment
89315604|NCT02038582|Active Comparator|CD4 Referral & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and lay counselor follow up
89315605|NCT02038582|Active Comparator|CD4 Referral & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and referral to clinic
89315606|NCT02038582|Active Comparator|Circumcision - SMS Reminder|HIV negative uncircumcised males, randomized to SMS reminder for male circumcision
89315607|NCT02038582|Active Comparator|Circumcision - Lay Counselor|HIV negative uncircumcised males, randomized to lay counselor follow-up for male circumcision
89315608|NCT02038582|Active Comparator|Circumcision - Promotion|HIV negative uncircumcised males, randomized to promotion of male circumcision at the time of HIV testing
89315609|NCT02038582|Active Comparator|POC VL|HIV positive persons on ART, randomized to POC viral load testing
89315610|NCT02038582|Active Comparator|Laboratory based VL assay|HIV positive persons on ART, randomized to laboratory based viral load testing
89315611|NCT03777033|No Intervention|Control Group|Patients after thyroidectomy will be managed as usual. Oral or IV supplements of Calcium will be giver on demand and recorded according to the clinical picture or the biochemical hypocalcaemia.
89315612|NCT03777033|Experimental|Study group|Intervention: the patients will be given prophylactically ca and vit D. Patients after thyroidectomy will be given systematically from the day of operation a scheme with oral calcium in the form of 1000ca++mg/tab and oral alfacalcidol in the form of 0.5 micrograms/tb Intervention: The patients will receive one tablet three times a day oral calcium (3g/d) and 2 tablets , two times a day alfacalcidiol (2 micrograms/d) for the first 5 days. Afterwards they will be taking 2 tablets a day of oral calcium ( 2g) and 2 tablets a day alfacalcidiol (1micrograms/d) for another 10 days ( total 15 days)
89315613|NCT05654584||agression before surgery|The group that the aggression assessment when morbidly obese before surgery
89315614|NCT05654584||agression after surgery|group reassessed for aggression following postoperative weight loss
89315615|NCT02058472|Experimental|G3041|Amlodipine orotate 10mg/Olmesartan medoxomil 40mg
89315616|NCT02058472|Active Comparator|SEVIKAR®|Amlodipine besylate 10mg/Olmesartan medoxomil 40mg
89315617|NCT02058550|No Intervention|Arm I (no intervention)|Patients receive no additional reminders.
89315618|NCT02058550|Experimental|Arm II (email survey)|Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
89315619|NCT02058550|Experimental|Arm III (email surveys and phone calls)|Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
89315620|NCT01315899|Experimental|ORM-12471 30mg|
89315621|NCT01315899|Placebo Comparator|placebo|
89315622|NCT01315899|Experimental|ORM-12471 100mg|
89315623|NCT01317147||Gastric bypass patients|
89315624|NCT02060968||IRIS PREMIER Cohort|Promus PREMIER
89315625|NCT02060032|Active Comparator|Atorvastatin|1.2% atorvastatin local drug delivery
89315626|NCT02060032|Sham Comparator|Simvastatin|1.2% simvastatin local drug delivery
89315627|NCT02060032|Placebo Comparator|Placebo|Placebo local drug delivery
89315628|NCT03783273|Experimental|Whey protein complex-bound D3 + juice|200 microgram vitamin D3 in a whey protein-complex added to 500 mL of juice.
89315629|NCT03783273|Active Comparator|D3 + juice|200 microgram vitamin D3 added to 500 mL of juice.
89315630|NCT03783273|Active Comparator|D3 + milk|200 microgram vitamin D3 added to 500 mL of skimmed-milk.
89315631|NCT03783273|Active Comparator|D3 droplets|200 microgram vitamin D3 as droplets + 500 mL of water.
89315632|NCT03783273|Placebo Comparator|No vitamin D|500 mL of Water.
89315633|NCT02060110||MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study
89315634|NCT02060110||MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study
89315635|NCT02060266|Experimental|Semaglutide|
89315636|NCT03777345|Active Comparator|cobalt-chromium framework partial dentures|It's the gold standard biocompatible metal alloy used in thin sections, provide high strength and stiffness ,conduct heat and cold for a more natural experience, and is resistant to corrosion but their disadvantages include esthetic issues with metal display, oral galvanism, adverse tissue reactions,and osteolysis of abutment teeth.
89315637|NCT03777345|Experimental|PEEK framework partial dentures|It's a promising polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
89315638|NCT03776721|Experimental|Active treatment|
89315639|NCT03776721|Placebo Comparator|Placebo treatment|
89315640|NCT01318005|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
89315641|NCT01318005|Active Comparator|Ovcon® 35|Ovcon® 35 is an oral contraceptive that contains less progestin.
89315642|NCT01318005|Active Comparator|Microgestin Fe® 1/20|is an oral contraceptive that contains less estrogen.
89315643|NCT02799082|Placebo Comparator|Vehicle|Topical application of matched placebo gel (without containing active ingredient). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
89315644|NCT02799082|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
89315645|NCT03783117|Experimental|Magnetic field treatment|Each subject will place his/her right arm into a bore of the Magnetic Blood Pressure Lowering (MBPL) Device for magnetic treatment of 15 minutes, while the blood pressure is monitored with the left arm. The MBPL device produces a magnetic field around 1T parallel to the blood flow inside the arm. The subject's blood pressure will be lowered. The subject needs to come back to check the blood pressure 24 hours after the treatment.
89315646|NCT02062138|Active Comparator|continuous passive motion (CPM)|
89315647|NCT02062138|Experimental|controlled active motion (CAM I)|
89315648|NCT02062138|Experimental|controlled active motion (CAM II)|
89315649|NCT03710889|Experimental|Abaloparatide|Participants self-administered a single daily dose of 80 micrograms (µg) of abaloparatide subcutaneously (SC) during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.
89315650|NCT02061046||On CPAP therapy|OSA patients assessed before and after 8 weeks of CPAP therapy
89315651|NCT01318473|Other|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
89315652|NCT03782961|Experimental|Stand up|After application of the product (sodium lactate and combination of polymers) will remain standing for 30 minutes
89315653|NCT03782961|Experimental|Lying down|After application of the product (sodium lactate and combination of polymers) remained lying down with the legs stretched for 30 minutes;
89315654|NCT02061124|Active Comparator|T2DM, sevelamer|Patients with type 2 diabetes treated with sevelamer
89315655|NCT02061124|Placebo Comparator|T2DM, placebo|Patients with type 2 diabetes treated with placebo
89315656|NCT02061124|Active Comparator|Healthy subjects, sevelamer|Healthy subjects treated with sevelamer
89315657|NCT02061124|Placebo Comparator|Healthy subjects, placebo|Healthy subjects treated with placebo
89315658|NCT01318941||Ranibizumab|
89315659|NCT02060422|Placebo Comparator|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
89315660|NCT02060422|Experimental|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
89315661|NCT02062216||STEMI|Patients with ST-elevation myocardial infarction (STEMI) with angiographic evidence of massive thrombosis in the culprit artery undergoing primary percutaneous coronary intervention (PCI)
89315662|NCT02062216||STABLE ANGINA|Patients with coronary artery disease in stable conditions scheduled to undergo elective percutaneous coronary intervention and patients with Class I indication to elective percutaneous coronary intervention
89315663|NCT02060500|Experimental|Cardiaplication|
89315664|NCT02060578|Other|Intervention|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
89315665|NCT03560440||Plasma exposure vancomycin|Pediatric patients treated with vancomycin
89315666|NCT02797678|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week. Participants will then be crossed over and will wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week
89315667|NCT02797678|Sham Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week. Participants will then wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week.
89315668|NCT03776955|Experimental|Oral Carvedilol|6.25 mg or 12.5 mg if tolerated
89315669|NCT03776955|Placebo Comparator|Oral Placebo|
89315670|NCT01319019|Experimental|GSK961081 100 mcg QD|
89315671|NCT01319019|Experimental|GSK961081 100mcg BD|
89315672|NCT01319019|Experimental|GSK961081 200mcg QD|
89315673|NCT01319019|Experimental|GSK961081 400mcg QD|
89315674|NCT01319019|Experimental|GSK961081 400mcg BD|
89315675|NCT01319019|Experimental|GSK961081 800mcg QD|
89315676|NCT01319019|Active Comparator|Salmeterol 50mcg BD|
89315677|NCT01319019|Placebo Comparator|Placebo|
89315678|NCT05079945|Experimental|Spinal cord Tractography|Healthy volunteer having the tractography exam
89315679|NCT01309815||Cancer in elderly people|other
89315680|NCT05076903|Experimental|OFA group|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
89315681|NCT05076903|Active Comparator|Control group|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
89315682|NCT03308786|Experimental|IL2 treatment|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles, in addition to combination antiretroviral therapy.
89315683|NCT03776565||Operative hysteroscopy|women with an operative hysteroscopy planned
89315684|NCT03776565||Planned caesarean section|Pregnant women with a planned caesarean section
89315685|NCT05061303||Group Omperazole|Patients will receive p.o. the standard, most commonly used triple immunosuppression regimen: tacrolimus, mycophenolate mofetil, prednisone and p.o. omeprazole 20 mg (group Omeprazole).
89315686|NCT05061303||Group Famotidine|Patients will receive p.o. the standard, most commonly used triple immunosuppression regimen: tacrolimus, mycophenolate mofetil, prednisone and p.o. famotidine 20 mg (group Famotidine).
89315687|NCT03776409||vancomycin plus piperacillin/tazobactam|Critically ill patients who received the combination of VAN (vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and PTZ were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
89315688|NCT03776409||vancomycin plus other beta-lactams|Critically ill patients who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
89315689|NCT05534607|Experimental|Intervention group|The intervention group will immediately receive the Ola Mau i ka Hula intervention after randomization for 12 months. The intervention program is 8 months with a 4 month self-monitoring period.
89315690|NCT05534607|No Intervention|Wait-list control group|"After baseline data collection, participants randomized to the wait-list control arm will not receive the Ola Mau i ka Hula Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not be offered the intervention until after the intervention arm is completed and their 12-month follow-up data collection is completed. They will only receive the educational component of the intervention from us during this 12-month period but they will be instructed to continue with their routine medical care as usual.~Wait-list control group will be offered the opportunity to receive intervention at the conclusion of 12 month assessment period, regardless of whether they were retained for the full 12 months of data collection."
89315691|NCT03776331||Myeloma Patients|
89315692|NCT03776331||Controll group|
89315693|NCT01560741|Active Comparator|Telemedicine Group|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be provided with a ventilator outfitted with a wireless transmitter to allow the remote data collection of compliance and efficacy information. While patient sleeps, data is collected. If abnormalities criteria will be detected, remote titration of ventilator settings will be done to optimise therapy. Patient will be monitored again and data analyzed. This procedure will be repeated until we obtained the optimal ventilator parameters for each patient in this group. Nocturnal oximetry under home mechanical non-invasive ventilation will be carried out after one week and one month of treatment. Subjects also receive pre-arranged telephone calls to assist with progress.
89315694|NCT01560741|Other|Usual care|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be assessed by a hospital visit scheduled at the end of third month after their initial adaptation. In this hospital visit data provided by the ventilator will be transferred to research team computer so they could evaluate patient compliance and efficacy of ventilation criteria under the parameters used at home present at the time of assessment. If abnormality criteria will be detected, re-titration of ventilator settings will be made. Patients will be encouraged to call their respiratory consultant any time they had a problem or concern.
89315695|NCT03782805|Experimental|treatment group|Group receiving a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) to be taken 3 times a week for a period of six months.
89315696|NCT03782805|Placebo Comparator|Placebo group|Group receiving a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months
89315697|NCT01309971||Questionable occlusal lesions|
89315698|NCT03776097||Defect Fill.|Observational study of the patients that were treated with biomaterials at the surgery in the previous study
89315699|NCT03776097||No defect Fill.observational|Observational study of the patients that were not treated with biomaterials at the surgery of te previous study
89315700|NCT05533203|Experimental|Prodencel Treated for mCRPC|"Cohort 1: Each subject would receive Prodencel treatment at a dose of 5×10^6 cells every two weeks for a total of 3 doses.~Cohort 2: Each subject would receive Prodencel treatment at a dose of 10×10^6 cells every two weeks for a total of 3 doses.~Cohort 3: Each subject would receive Prodencel treatment at a dose of 15×10^6 cells every two weeks for a total of 3 doses.~Cohort 4: The safe and effective dose from cohort 1-3 is recommended for booster immunization of cohort 4. Subjects will receive additional Prodencel treatment every 4 weeks, until disease progression or intolerance after the 3 doses of immune induction, to evaluate the safety and tolerability of the booster immunization."
89315701|NCT03776019|Experimental|Modulated|modulated music
89315702|NCT03776019|Sham Comparator|Typical|typical music
89315703|NCT03782649|Experimental|RSP-08|All subjects undergo the same procedures. Subjects will be subjected to measurements on the IMD (Working Model 3.4NR), FreeStyle Libre, Dexcom, microdialysis, venous and capillary blood collection.
89315704|NCT05518227||The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
89315705|NCT03775863||Latin American multicenter Cohort|Transplanted patients with HCC in LATAM from 2005-2011
89315706|NCT03775863||French mutlicenter Cohort|Transplanted patients with HCC in France from 2003-2005
89315707|NCT03775863||Italian multicenter Cohort|Transplanted patients with HCC in Italy from 2005-2011
89315708|NCT03274076|Active Comparator|Tofacitinib|5mg Tofacitinib twice a day
89315709|NCT03274076|Placebo Comparator|Placebo|5mg Placebo twice a day
89531756|NCT05536609|Active Comparator|Non-operative treatment|The injured digital nerve is not surgically exposed. The skin is closed over the injury site and the finger is protected in a plaster cast for three weeks followed by rehabilitation.
89315710|NCT03775707|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89315711|NCT03775551|No Intervention|Control|The participants belonging to the hospitals assigned to the control group the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC following usual practice.
89315712|NCT03775551|Experimental|Improvement cycle|In participants belonging to the hospitals assigned to the intervention group,the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC using innovative intervention to assure continuity of care and assistant level approach. This innovations will be crafted from the rapid improvement cycles considering the environment and key aspects of the every day care at the participating centers.
89315713|NCT02780414||Study Cohort|A group of at least 1,541 pregnant women with NO Pre-E diagnosis
89315714|NCT02780414||Positive Pre-E Control|A group of at least 250 pregnant women diagnosed with Pre-E
89315715|NCT01320501|Experimental|Erlotinib|150 mg PO daily
89315716|NCT04442607|Experimental|AI arm|Only one arm in this study. Every patient who is eligible for this study and is included, after informed consent, will receive a standard colonoscopy combined with real-time AI video analysis
89315717|NCT02764268|Experimental|Apatinib|
89315718|NCT01320111|Active Comparator|Arm 1: PA|patient is treated with paclitaxel only
89315719|NCT01320111|Experimental|Arm 2: PASO|patient is treated with paclitaxel AND sorafenib
89315720|NCT03773601|Experimental|Athletes|Athletes will undergo a 4-days sleep monitoring with the use of the Sleep Profler. At the same time, they will fill the Total Quality of Recovery (TQR) scale and the Pittsburgh Sleep Quality Index (PSQI).
89315721|NCT01320579|Experimental|Group 2 Cis-UCA 5% emulsion cream|
89315722|NCT01320579|Placebo Comparator|Group 3 Placebo cis-UCA emulsion cream|
89315723|NCT01320579|Active Comparator|Group 4 Protopic® 0.1% ointment|
89315724|NCT01320579|Experimental|Group 1 Cis-UCA 2.5% emulsion cream|
89315725|NCT01320189|Experimental|Protein intake of 5 energy percent|
89315726|NCT01320189|Experimental|Protein intake of 15 energy percent|
89315727|NCT01320189|Experimental|Protein intake of 30 energy percent|
89315728|NCT03775317|Experimental|Video Laryngoscopy|
89315729|NCT03775317|Active Comparator|Direct Laryngoscopy|
89315730|NCT01320267|Experimental|SILS right hemicolectomy|Single arm with intervention only.
89315731|NCT03775395|Experimental|HAIC plus Lenvatinib|
89315732|NCT03775395|Active Comparator|HAIC plus Sorafenib|
89315733|NCT03775005|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
89315734|NCT03775005|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
89315735|NCT02797522|Experimental|NHV Participants: Cohort 1|NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.
89315736|NCT02797522|Experimental|NHV Participants: Cohort 2|NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.
89315737|NCT02797522|Experimental|NHV Participants: Cohort 3|NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.
89315738|NCT02797522|Experimental|NHV Participants: Cohort 4|NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.
89315739|NCT02797522|Experimental|NHV Participants: Cohort 5|NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.
89315740|NCT02797522|Experimental|NHV Participants: Cohort 6|NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.
89315741|NCT02797522|Placebo Comparator|NHV Participants: Placebo|NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.
89315742|NCT02797522|Experimental|CHB Participants: Cohort 3b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual nucleoside analog (NUC) therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
89315743|NCT02797522|Experimental|CHB Participants: Cohort 4b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
89315744|NCT02797522|Experimental|CHB Participants: Cohort 3c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.
89315745|NCT02797522|Experimental|CHB Participants: Cohort 4c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.
89315746|NCT01320813|Experimental|Robot arm|Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.
89315747|NCT01320813|Active Comparator|Open surgery|Patients in this arm will have a thyroidectomy using an open surgical technique.
89315748|NCT02060656|Active Comparator|Control: R-GEM-P|Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
89315749|NCT02060656|Experimental|Experimental: LR-GEM|Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
89315750|NCT03773211|Experimental|Renaparin|Solution administered once to kidney ex-vivo
89315751|NCT03773211|Placebo Comparator|Placebo|Placebo administered once to kidney ex-vivo
89315752|NCT02062372|Experimental|Biopsy|Subjects will receive a 7 T MRI and one additional biopsy to their standard diagnostic biopsies
89315753|NCT03774537|Experimental|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs.
89315754|NCT03774537|Other|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
89531927|NCT04775069|Active Comparator|Adenovirus-vector Group|The subjects will be vaccinated with adenovirus-vector COVID-19 vaccine (Astrazeneca-Oxford).
89315755|NCT03774771|Placebo Comparator|Placebo|In Part 1 participants received placebo capsules orally once a day for 6 weeks. In Part 2 participants received placebo capsules twice a day for 15 days.
89315756|NCT03774771|Experimental|Cinacalcet 50 mg QD|In Part 1 participants received 50 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 30 mg cinacalcet capsules twice a day for 15 days.
89315757|NCT03774771|Experimental|Cinacalcet 75 mg QD|In Part 1 participants received 75 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 40 mg cinacalcet capsules twice a day for 15 days.
89315758|NCT03774771|Experimental|Cinacelcet 100 mg QD|In Part 1 participants received 100 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 50 mg cinacalcet capsules twice a day for 15 days.
89315759|NCT01320891|Experimental|balanced|arm in which the subjects received only balanced solutions
89315760|NCT01320891|Experimental|not balanced|arm in which the subjects received only not balanced solutions that means only normal saline and colloid dissolved in normal saline
89315761|NCT03774927|Experimental|10 Hz treatment group|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
89315762|NCT03774927|Experimental|20 Hz treatment group|In active rTMS, 20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
89315763|NCT03774927|Sham Comparator|Control Group|In sham rTMS, all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
89315764|NCT01320969|Experimental|Mindfulness-Based Stress Reduction course|an eight week mindfulness-based stress reduction course
89315765|NCT01320969|No Intervention|Waitlist group|waitlist group
89315766|NCT03774693|Active Comparator|GS [General anesthesia]|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.
89315767|NCT03774693|Active Comparator|GR [General anesthesia + regional block]|"Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.~Also patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block. Fentanyl boluses of 0.5 mcg.Kg-1 will be given when needed to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1."
89315768|NCT03774615|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
89315769|NCT01321047|Active Comparator|Propofol group|the conventional propofol group (P group), sedation was induced by an intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV).
89315770|NCT01321047|Active Comparator|BPS group|the balanced propofol sedation group (BPS group), both midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, an initial bolus of propofol (0.5 mg/kg body weight) was given intravenously. Sedation was maintained with repeated doses of 10 to 20 mg propofol.
89315771|NCT01320423|Other|surgery|
89315772|NCT01321125|Experimental|Whole group of 30 volunteers|The arm is composed of 30 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and two controls.
89315773|NCT01321125|Experimental|test group of substantivity|The arm is composed of 10 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City)
89315774|NCT03773055|Active Comparator|NPC-06 (High dosage)|18 mg (iv) in Day 1 as an induction dosage and 9 mg (iv) in Day 2 - 7 as a maintenance dosage
89315775|NCT03773055|Active Comparator|NPC-06 (Low dosage)|15 mg (iv) in Day 1 as an induction dosage and 6 mg (iv) in Day 2 - 7 as a maintenance dosage
89315776|NCT03773055|Placebo Comparator|Placebo|Saline will be administered intravenously
89315777|NCT03815253|Experimental|Acupuncture group|"Body electro-acupuncture will be conducted for 2 sessions per week over 8 consecutive weeks.~Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
89315778|NCT03815253|Placebo Comparator|sham-acupuncture group|"As to the participants allocated to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to act as sham control at the same acupoints with same stimulation modality. However, the needles will be only adhered to the skin instead of insertion. The validity and credibility of this model has been well demonstrated."
89315779|NCT03774303|Experimental|mobile intervention|families to be prepared for day surgery with a mobile application
89315780|NCT03774303|Active Comparator|control group|families to be prepared for day surgery with current practice
89315781|NCT03774459|Experimental|High dose ANAVEX2-73|High dose ANAVEX2-73
89315782|NCT03774459|Experimental|Mid dose ANAVEX2-73|Mid dose ANAVEX2-73
89315783|NCT03774459|Placebo Comparator|Placebo oral capsule|Placebo oral capsule
89315784|NCT03815409|Experimental|BWSTT group|The sessions were conducted on a treadmill with partial weight unload.
89315785|NCT03815409|Other|Control group|The traditional PT rehabilitation treatment included passive, active and active-assisted exercises, according to the methods commonly used (Kabat, Bobath).
89315786|NCT01560195|Experimental|Pegylated rhG-CSF: 100µg/kg|Staged III or IV NSCLC patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
89315787|NCT01560195|Experimental|Pegylated rhG-CSF: 6mg|Staged III or IV NSCLC patients receiving chemotherapy and pegylated rhG-CSF 6mg
89315788|NCT01560195|Placebo Comparator|Placebo|Staged III or IV NSCLC patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF in cycle 2 to 4
89315789|NCT03774225|Experimental|Manual and verbal guidance (MVG)|The MVG Group will be done by experimental group with the manual and verbal guidance of a physiotherapist using four games of X-Box Kinect system®
89315790|NCT03774225|Experimental|No manual and verbal guidance (NMVG)|The NMVG Group will be done by experimental group using four games of X-Box Kinect system® in the presence of a physiotherapist that will care about the safety of the participants without interfere in their moviment pattern.
89315791|NCT03774225|Active Comparator|Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
89315792|NCT05435313|Experimental|combination therapy|"Combination: Fruquintinib plus Tislelizumab and HAIC (TOMOX/TOMIRI)~Maintenance: Fruquintinib plus Tislelizumab"
89315793|NCT05419791|Experimental|Lokomat Group I (Endurance)|"Faster application used with Lokomat gait training~Conventional Physiotherapy"
89315794|NCT05419791|Experimental|Lokomat Group II (Attention and Motivation)|"Smile and Gabarello applications used with Lokomat gait training~Conventional Physiotherapy"
89315795|NCT05419791|Experimental|Lokomat Group III (Activity Timing)|"High Flyer, Curve Pursuit and Treasures applications used with Lokomat gait training~Conventional Physiotherapy"
89315796|NCT05419791|Other|Control|-Only Conventional Physiotherapy
89315797|NCT03773913||Four facilities in Kozah District|Baseline estimated population of 33,412 served by four public sector facilities in Kozah District.
89315798|NCT03774381|Experimental|Bifidobacterium breve B-3 group|160 mg mg of Bifidobacterium breve B-3 was orally administered per day for 12 weeks.
89315799|NCT03774381|Placebo Comparator|Control group|160 mg of placebo was orally administered per day for 12 weeks.
89315800|NCT05472675|Experimental|local anesthetic and botulinum toxin group|patients who have vestibular migraine and who accepted for study gruoup as local anesthetic and botulinum toxin group
89315801|NCT05472675|No Intervention|beta-blocker control group|patients who have vestibular migraine and who have standard migraine treatment as beta-blocker
89315802|NCT03773835|Experimental|HSK3486|0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,
89315803|NCT04673721|Active Comparator|Fortified eggs + Intermittent fasting|Consume at least 12 fortified eggs per week with 16-hour fast and then an 8-hour nutritional window.
89315804|NCT04673721|Active Comparator|Non-egg supplemented diet + Intermittent fasting|Maintain consumption of 2 or less eggs per week with 16-hour fast and then an 8-hour nutritional window.
89315805|NCT04673721|Active Comparator|Fortified eggs + Usual care diet|Consume at least 12 fortified eggs per week with consistency with current diet.
89315806|NCT04673721|Placebo Comparator|Non-egg supplemented diet + Usual care diet|Maintain consumption of 2 or less eggs per week with consistency with current diet.
89315807|NCT03773679|Experimental|Exercise Group|"Daily exercise program involved Range of Motion (ROM) exercises against extremity resistances and extension and flexion in upper and lower extremities. Exercises were implemented on wrists, elbows, shoulders, ankles, knees, and hip joints of the infants by the same researcher (YSE). The daily exercise program was repeated 5-8 times, 1 session/day (a similar time of the day), for 30 days. Each session continued for 7-10 minutes."
89315808|NCT03773679|No Intervention|Control Group|The preterm infants in the control group did not receive the daily exercise program, only the standard clinical routine.
89315809|NCT01321203||Group-A, use of air;|
89315810|NCT01321203||Group-B use of CO2|
89315811|NCT03815097|Experimental|Intervention|Monitored anesthesia care with a mapleson circuit and nasal trumpet
89315812|NCT03815097|No Intervention|Standard of care|Standard monitored anesthesia care
89315813|NCT03763461|Experimental|HFNC|HFNC will be started at flow of 40 L/min and FiO2 of 40%.
88814746|NCT01622699|Experimental|Transcutaneous bilirubin measurements|In this intervention group, the initial visual assessment of jaundice wille be followed by measurement by transcutaneous bilirubinometer
89315814|NCT03763461|Other|Oxygen Mask|Standard non-humidified oxygen therapy via an oxygen mask at 6 l/min will be performed.
89315815|NCT03769779|Experimental|Treatment|Lutein (FloraGLO™) in safflower oil
89315816|NCT03769779|Placebo Comparator|Placebo|safflower oil
89315817|NCT01321905|Experimental|Ergocalciferol|"Patients younger than 16 years of age are administered 35,000 IU ergocalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU ergocalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
89315818|NCT01321905|Experimental|Cholecalciferol|"Patients younger than 16 years of age are administered 35,000 IU cholecalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU cholecalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
89315819|NCT01321905|No Intervention|Control|Patients continue their ordinary vitamin supplementation without getting extra vitamin D supplements.
89315820|NCT02659514|Experimental|Cohort 1: Poziotinib 24 mg|Participants received poziotinib 24 milligrams (mg), administered as three 8 mg tablets, orally, once daily (QD) on an intermittent dosing schedule of 14 days on treatment followed by 7 days off treatment, in a 21-day cycle until disease progression, death, intolerable adverse events (AEs) or for up to a maximum of 24 months, whichever occurs first.
89315821|NCT02659514|Experimental|Cohort 2: Poziotinib 16 mg|Participants received poziotinib 16 mg, administered as two 8 mg tablets, orally, QD, on a continuous dosing schedule in a 21-day cycle until disease progression, death, intolerable AEs or for up to a maximum of 24 months, whichever occurs first.
89315822|NCT03769623|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter
89315823|NCT03769623|Active Comparator|Powerline|Balloon dilated catheter
89315824|NCT03763383||Free lateral arm flap|included patients who had free lateral Arm flap
89315825|NCT03763383||pedicled lateral arm flap|included patients who had pedicled lateral arm flap
89315826|NCT01561599|Placebo Comparator|Normal saline|Placebo
89315827|NCT01561599|Active Comparator|BB3|Small molecule mimetic of hepatocyte growth factor/scatter factor
89315828|NCT04570670|Experimental|Test (BLS-11)|A single oral dose administration of BLS-11 190 mg (2 × 95 mg monomethyl fumarate delayed-release capsules) at Hour 0 on Day 1
89315829|NCT04570670|Active Comparator|Reference (Tecfidera)|A single oral dose administration of Tecfidera 240 mg (1 × 240 mg dimethyl fumarate delayed-release capsule) at Hour 0 on Day 1
89315830|NCT03763227|Active Comparator|Carbonic Anhydrase Inhibitor (CAI) Arm|Patients who have received carbonic anhydrase inhibitor (CAI) therapy namely oral acetazolamide or topical brinzolamide
89315831|NCT03763227|Experimental|Intravitreal ranibizumab (IVR) arm|"Intravitreal ranibizumab (IVR) injection administered to patients who have not shown adequate response or who have not tolerated CAI therapy~IVR therapy = Three 0.5mg IVR injection at monthly intervals"
89315832|NCT03769389|Experimental|assessing the GI + GL of Birhi + YEO 0% fat yoghurt|47g of total carbohydrate in which contains 43.6g of Freeze-dried of Birhi powder+ 150g of 0% fat yoghurt
89315833|NCT03769389|Experimental|assessing the GI + GL of Khassab + YEO 0% fat yoghurt|47g of total carbohydrate in which contains34.6g of freeze-dried Khassab powder+ 150g of 0% fat yoghurt
89315834|NCT03769389|Experimental|assessing the GI + GL of 50g of Glucose in 100 ml of water|50g of pure glucose dissolved in 100ml of water
89315835|NCT04570124|Experimental|Remote Surveillance|Women will use the home blood pressure monitoring device to record their blood pressure everyday for the first postpartum week, and then weekly until postpartum week 6.
89315836|NCT04929548|Experimental|ECPy-THP Programs|Epirubicin 100 mg/m2, iv cyclophosphamide 600 mg/m2, iv + Pyrotinib 400 mg/d, po 4-week treatment, sequential docetaxel 80 mg/m2, iv + trastuzumab 6 mg/kg (first dose 8 mg/kg), iv + patuximab 420 mg (first dose 840 mg), iv ,po 4 weeks of treatment
89315837|NCT04205474|Active Comparator|VSRR with tricuspid aortic valve|Patients with a tricuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
89315838|NCT04205474|Active Comparator|VSRR with bicuspid aortic valve|Patients with a bicuspid valve that previously underwent a valve sparing root procedure for aortic root aneurysm
89315839|NCT03769233|Experimental|Mindfulness-based Intervention|5 week, manual-based group MBI treatment for depressive and anxious symptoms
89315840|NCT03769077|Experimental|Exergaming (Case) Group|"Participants assigned to the exergame condition will play the exergames for 30 minutes, 5 days a week for 3 weeks (15 exergame sessions). Outcomes will be acquired at baseline (before intervention), and at the end of every week during the 3 week intervention phase. Participants will also receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital.~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
89315841|NCT03769077|No Intervention|Comparison Group|"Participants will receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital and will complete questionnaires and assessments at the same time points during study participation.~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
89315842|NCT03768921|Experimental|PEEP Titriation|patients with respiratory distress syndrome will undergo alveolar recruitment in the mechanical ventilator and will have their final positive mechanical ventilator pressure determined by ventilator evaluation by the electrical impedance tomograph. The increase of the peep in the mechanical ventilator to perform the alveolar recruitment will be of 2 in 2 cmH2O every 2 minutes until the pressure reaches 25 cmH20, after the pressure was reduced in the same way being evaluated in the tomograph what will be the point with greater alveolar recruitment, having greater ventilation, without alveolar hyperdistension or alveolar collapse.
89315843|NCT02797132|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A (<14 kg): Participants weighing less than (<) 14 kilograms (kg) at screening received LUM 100 milligram (mg)/IVA 125 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part A (>=14 kg): Participants weighing greater than or equal to (>=) 14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part B (<14 kg): Participants weighing <14 kg at screening received LUM 100 mg/IVA 125 mg fixed-dose combination every 12 hours for 24 weeks in Part B.~Part B (>=14 kg): Participants weighing >=14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 24 weeks in Part B."
89315844|NCT02519270|Experimental|Dose Escalation Stage/ Expansion Stage|"The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.~In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles."
89315845|NCT03768843|Other|traumatic odontoid fracture|C1 C2 fusion screws
89315846|NCT03768765||Long Term Medication Usage|Patients who have been on medication for over a year for benign prostatic hyperplasia (BPH)
89315847|NCT03768765||Short Term Medication Usage|Patients who have been on medication for under a year for benign prostatic hyperplasia (BPH)
89315848|NCT02060734|Experimental|lidocaine|The treatment group will receive a 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point. Three to five points injection.
89315849|NCT02060734|Active Comparator|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
89315850|NCT03270644|Experimental|Lasmiditan Reference|Single oral dose of lasmiditan 200 mg on Day 1 as reference treatment.
89315851|NCT03270644|Active Comparator|Propranolol Reference|Twice-daily oral doses of propranolol 80 mg on Days 4-10 as reference treatment.
89315852|NCT03270644|Experimental|Lasmiditan + Propranolol Test|Single oral dose of lasmiditan 200 mg + two oral doses of propranolol 80 mg on Day 9 as test treatment.
89315853|NCT02062528|Experimental|omega-3 fatty acids|3 capsules each day during 8 weeks
89315854|NCT02062528|Placebo Comparator|placebo|3 capsules each day during 8 weeks
89315855|NCT03772275|Active Comparator|New york Heart Association Class II-IV|New york Heart Association Class II-IV heart failure
89315856|NCT03772275|Active Comparator|New york Heart Association Class I|New york Heart Association Class I with no heart failure
89315857|NCT02062684|Experimental|Blisibimod|Blisibimod administered subcutaneously
89315858|NCT02062684|Placebo Comparator|Placebo|Placebo administered subcutaneously
89315859|NCT04535102|Experimental|Polatuzumab + BR (minimum 3 cycles)|Patients will be treated with a minimum of 3 cycles up to a maximum six cycles to optimize response prior to ASCT (stem cell transplant) per investigator discretion
89315860|NCT02062762|Experimental|Online-MBSR|8 week mindfulness based stress reduction online
89315861|NCT02062762|Active Comparator|Expressive Writing Online|Online distributed expressive writing intervention as active control
89315862|NCT04529720||acellular pertussis vaccine|Antibody persistence at 5 years after a single dose vaccination of acellular pertussis vaccines (Pertagen;Boostagen;Adacel)
89315863|NCT02060812|Experimental|Group I, SSNB & ANB|21 patients were randomly allocated into group I, and received suprascapular nerve block (SSNB) and axillary nerve block (ANB) both with 10mL ropivacaine.
89315864|NCT02060812|Placebo Comparator|Group II, SSNB alone|The other 21 patients were allocated into group II, and received suprascapular nerve block (SSNB) with 10mL ropivacaine and axillary nerve block (ANB) with placebo (10mL normal saline).
89315865|NCT04445558|Experimental|Membrane PEPA®|Patient will use the membrane PEPA® for the dialysis
89315866|NCT04445558|Active Comparator|Standard membrane of dialysis|Patient will use a standard membrane for the dialysis
89315867|NCT03763071||Participants|Pregnant women in the 2nd or 3th trimester Patient-reported scales to measure sleep disorders
89315868|NCT03768609|Experimental|Group 1: Sequence AB|Participants will receive Treatment A (pimodivir 600 milligram [mg] orally as two tablets of 300 mg each) on Day 1 in Period 1 followed by Treatment B (pimodivir 600 mg as two tablets of 300 mg each plus cyclosporine 400 mg orally as four capsules of 100 mg each) on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
89315869|NCT03768609|Experimental|Group 2: Sequence BA|Participants will receive Treatment B on Day 1 in Period 1 followed by Treatment A on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
89315870|NCT03269552|Experimental|Treatment (carfilzomib, rituximab)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib, receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.
89315871|NCT03771729|Experimental|LCZ696 treatment|LCZ696 200mg twice daily
89315872|NCT02796664|Experimental|Ginseng|
89315873|NCT02796664|Placebo Comparator|Placebo|
89315874|NCT04163198|Experimental|Insufflation optimisation|Patient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.
89315875|NCT04163198|Experimental|Exsufflation optimisation|Patient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF
89315876|NCT01561677|No Intervention|apnea/hypopnea index (AHI<5 : no OSAS)|
89315877|NCT01561677|No Intervention|apnea/hypopnea index (5≥AHI<15 : mild OSAS)|
89315878|NCT01561677|No Intervention|apnea/hypopnea index (15≤AHI<30 :moderate OSAS)|
89315879|NCT01561677|Active Comparator|apnea/hypopnea index ( AHI≥30 : severe OSAS treated).|Treated with CPAP
89315880|NCT01561677|Sham Comparator|apnea/hypopnea index ( AHI≥30:severe OSAS untreated).|Treated with sham CPAP (placebo)
89315881|NCT03560362|Active Comparator|Bupivacaine with epinephrine|Patients will receive intraoperative intercostal nerve block with bupivacaine
89315882|NCT03560362|Experimental|Lipossomal extended release bupivacaine|Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine
89315883|NCT03771807|Placebo Comparator|Placebo & facial cleansing|"Maltodextrin and food coloring~Subjects will clean the right side of their face with a cosmetic instrument daily"
89315884|NCT03771807|Active Comparator|Beauty From Within & facial cleansing|"Study Product contains collagen hydrolysate, ceramide wheat extract oil and lutein~Subjects will clean the right side of their face with a cosmetic instrument daily"
89315885|NCT02061670|Experimental|Ragweed-SPIRE 1|Ragweed-SPIRE regimen 1 given 2 weeks apart
89315886|NCT02061670|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
89315887|NCT02061670|Placebo Comparator|Placebo|Placebo given 2 weeks apart
89315888|NCT03762837||Exposure group：Benign gallbladder disease|Patients with benign gallbladder diseases, such as gallbladder polyps, gallstones, etc.
89315889|NCT03762837||Non-exposed group: healthy people|Patients without benign gallbladder diseases
89315890|NCT03560596|Experimental|High Risk Latino Patients Adherence Intervention|74 high risk Latinos with uncontrolled hypertension
89315891|NCT03560596|Active Comparator|High Risk Latinos Usual Care|74 high risk Latinos with uncontrolled hypertension
89315892|NCT03768531|Experimental|Arm A: Nivolumab|
89315893|NCT03768531|Experimental|Arm B: Nivolumab and Cabrilizumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes, a 30 minute rest, followed by cabiralizumab every 2 weeks. (Cycle length 2 weeks).
89315894|NCT02061904|Other|Bone Mineral Density|"Bone mineral density measurement with intervention DEXA at the bone impaction graft site:~DEXA: dual energy X-ray absorptiometry"
89315895|NCT02061904|Other|Hip function|"Hip Function/mobility development:~Harris Hip Score"
89315896|NCT02061904|Other|pain experience|Pain experiences after surgery in the hip joint VAS-pain
89315897|NCT02061904|Other|General Patients Health condition|"Patients health condition monitoring: intervention SF12:~Short Form Health Survey 12"
89315898|NCT02061904|Other|Intervention Satisfaction|Patients satisfaction development after the intervention VAS-satisfaction
89315899|NCT01322061|Active Comparator|Vitamin C|
89315900|NCT01322061|Placebo Comparator|mirinda|
89315901|NCT02062918|No Intervention|Control group|Patients in the control group did not use an abdominal belt.
89315902|NCT02062918|Experimental|Experimental group|Patients were instructed in how to use the abdominal belt for activities of physical effort that exacerbated lumbar pain as well as during moments of pain, and not to use it during rest. They should record the number of hours of belt use per day on spreadsheets distributed for this purpose.
89315903|NCT03768375|Experimental|target therap|The patients wil receive conventional chemotherapy(FORFIRINOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
89315904|NCT03768375|Experimental|FORFIRINOX|The patients wil receive conventional chemotherapy(FORFIRINOX)
89315905|NCT03768297|Experimental|immediate implant with dual zone therapeutic concept|
89315906|NCT03768297|Active Comparator|immediate implant with buccal bone fill|
89315907|NCT03762525|Other|ECG gated CTA pre and post operative at Gore IBE|To prospectively enroll 15 patients that are scheduled for endovascular aneurysm repair using the Gore IBE device in conjunction with its dedicated self expanding Internal Iliac component. Each patient will have an ECG gated CTA scan before the operation and 6-8 weeks after operation, in stead of a regular CT scan.
89315908|NCT03762525|Other|ECG gated CTA post operative at Gore IBE and Cook IBD|To compare 15 patients that have been treated in the period October 2006- July 2016 with the Cook IBD with a non-dedicated IIA component (Advanta-V12 or Fluency) and 15 matched patients treated with Gore IBE device. Each patient will have an ECG gated CTA after the operation, at the first doctor's appointment, in stead of a regular CT scan.
89315909|NCT02063308|Experimental|Oxaloacetate (OAA)|100 mg OAA to be taken twice daily over the course of a month
89315910|NCT03768219|Experimental|Stage 1 (SAD) Cohort 1|6 subjects will receive 2 mcg/kg of APVO210 2 subjects will receive placebo
89315911|NCT03768219|Experimental|Stage 1 (SAD) Cohort 2|6 subjects will receive 5 mcg/kg of APVO210 2 subjects will receive placebo
89315912|NCT03768219|Experimental|Stage 1 (SAD) Cohort 3|6 subjects will receive 10 mcg/kg of APVO210 2 subjects will receive placebo
89315913|NCT03768219|Experimental|Stage 1 (SAD) Cohort 4|6 subjects will receive 20 mcg/kg of APVO210 2 subjects will receive placebo
89315914|NCT03768219|Experimental|Stage 1 (SAD) Cohort 5|6 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
89315915|NCT03768219|Experimental|Stage 1 (SAD) Cohort 6|6 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
89315916|NCT03768219|Experimental|Stage 1 (SAD) Cohort 7|6 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
89315917|NCT03768219|Experimental|Stage 1 (SAD) Cohort 8|6 subjects will receive 320 mcg/kg of APVO210 2 subjects will receive placebo
89315918|NCT03768219|Experimental|Stage 2 (MAD) Cohort 9|8 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
89315919|NCT03768219|Experimental|Stage 2 (MAD) Cohort 10|8 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
89315920|NCT03768219|Experimental|Stage 2 (MAD) Cohort 11|8 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
89315921|NCT03768219|Experimental|Stage 2 (MAD) Cohort 12|8 subjects will receive 360 mcg/kg of APVO210 2 subjects will receive placebo
89315922|NCT03768219|Experimental|Expansion Cohort (Psoriasis)|"12 subjects will receive the starting dose for the Psoriasis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.~8 subjects will receive placebo"
89315923|NCT03768219|Experimental|Expansion Cohort (Ulcerative Colitis)|"12 Subjects will receive the starting dose for the Ulcerative Colitis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.~8 subjects will receive placebo"
89315924|NCT02063386|Experimental|AZD1722|Single oral dose 15 mg of [14C]AZD1722
89315925|NCT02062996|Experimental|ENT - full strength|Full strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
89315926|NCT02062996|Experimental|ENT - 1/2 strength|½ strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
89315927|NCT02062996|Experimental|DENTAL - Full strength 1.0 mL|Full strength oxymetazoline 1.0 mL to each naris (total =1000 mcg).
89315928|NCT02062996|Experimental|DENTAL - Full strength 0.5 mL|Full strength oxymetazoline 0.5 mL to each naris (total = 500 mcg).
89315929|NCT02062996|Experimental|DENTAL - ½ strength 0.5 mL|½ strength oxymetazoline 0.5 mL to each naris (total = 250 mcg).
89315930|NCT03762369|Experimental|CKD-351|Latanoprost+D930
89315931|NCT03762369|Active Comparator|Latanoprost|
89315932|NCT03762369|Active Comparator|D930|
89315933|NCT03762057||Surgical patients|All postoperative patients admitted to surgical ICU with foley catheter in place
89315934|NCT03768141||Liver surgery|Any type of liver surgery
89315935|NCT02061982|Experimental|Caffeine|Instant coffee with or without caffeine will be provided
89315936|NCT02061982|Placebo Comparator|Coffee without caffeine|Coffee without caffeine
89315937|NCT03771573|Experimental|Home based intervention|will be submitted to a total of 24 sessions of an unsupervised Cardiovascular Physical Therapy protocol, composed of the following steps: warm up, proper training (aerobic training + muscle training for upper and lower limbs with theraband in 5 series with 10 repetitions) often three times a week for eight weeks.
89315938|NCT03771573|Placebo Comparator|Control group|Will not be submitted to the Cardiovascular Physiotherapy Rehabilitation protocol for unsupervised domiciliary, only monitorization of cardiovascular variables.
89315939|NCT03771573|Active Comparator|Professional seupervision based|eight weeks of supervised activities by professional. Each day and for 20 days (20 sessions), volunteers will undergo exercises on cycle ergometer during 30 minutes for upper and lower limbs
89315940|NCT02063152||Entire Taiwan women|
89315941|NCT03761979|Active Comparator|Strontium dose of 170 mg|The Sponsor provided each 170 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
89315942|NCT03761979|Active Comparator|strontium dose of 340 mg|The Sponsor provided each 340 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
89315943|NCT03761979|Active Comparator|Strontium dose of 680 mg|The Sponsor provided each 680 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
89315944|NCT02065414|Placebo Comparator|Neg Control Mouth Rinse W002194-0221-P|"Mouth rinse containing 5% Hydroalcohol~Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse W002194-0221-P for 30 seconds and spit it out."
89315945|NCT02065414|Experimental|Experimental: Mouth Rinse 19668-012|Listerine Advance Gum Defense Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
89315946|NCT02065414|Active Comparator|Active Comparator Mouth Rinse 5000347078873|"Mouth rinse containing Chlorhexidine Corsodyl ®Mouthwash~Twice each day, brush in usual manner with a fluoride-containing dentifrice, in the usual manner, rinse mouth with water, wait 5 minutes after brushing and then rinse with 10 ml of mouth rinse 5000347078873for 60 seconds and spit it out - do not swallow."
89315947|NCT03771339|Active Comparator|Continuous Epidural Analgesia|Continuous epidural analgesia using ropivacaine 0.375% 3 mL boluses followed by ropivacaine 0.2% with rate 6 mL per hour for 24 hours
89315948|NCT03771339|Experimental|Bilateral Quadratus Lumborum Block|Bilateral Quadratus lumborum block using ropivacaine 0.2% 20 mL each injection after surgery
89315949|NCT03767985|Active Comparator|Occlusion therapy|Participants are prescribed 2 hours of occlusion therapy per day, 7 days a week.
89315950|NCT03767985|Experimental|Dichoptic video game therapy|Participants receive dichoptic video game therapy: 1 hour per week at the out-patient clinic under direct supervision.
89315951|NCT03761901||Patients with EGFR mutation positive NSCLC|
89315952|NCT03767829|Experimental|Part A: SAD: ALN-AAT02|Participants will be administered a single dose of ALN-AAT02.
89315953|NCT03767829|Placebo Comparator|Part A: SAD: Placebo|Participants will be administered a single dose of matching placebo.
89315954|NCT03767829|Experimental|Part B: MAD: ALN-AAT02|Participants will be administered multiple doses of ALN-AAT02.
89315955|NCT03767829|Placebo Comparator|Part B: MAD: Placebo|Participants will be administered multiple doses of matching placebo.
89315956|NCT04233879|Experimental|Group 1: DOR/ISL|Treatment-naïve participants with HIV-1 receive blinded DOR/ISL and placebo to BIC/FTC/TAF once daily (QD) from Day 1 to Week 96, and open-label DOR/ISL up to Week 144. Participants who are benefitting from treatment are then eligible to continue on open-label DOR/ISL up to Week 168.
89315957|NCT04233879|Active Comparator|Group 2: BIC/FTC/TAF|Treatment-naïve participants with HIV-1 receive blinded BIC/FTC/TAF and placebo to DOR/ISL QD from Day 1 to Week 96, and open-label BIC/FTC/TAF up to Week 144. Participants who are benefitting from treatment are then eligible to continue on open-label BIC/FTC/TAF up to Week 168.
89315958|NCT01370356|Active Comparator|Varenicline Tartrate|
89315959|NCT01370356|Placebo Comparator|Placebo|
89315960|NCT04545411|Active Comparator|Treatment A|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 35mg in 1mL solution REMD-477
89315961|NCT04545411|Placebo Comparator|Treatment B|Daily, Oral,10mg dapagliflozin in combination with Weekly, Subcutaneous, 1mL solution Placebo
89315962|NCT02065492|Experimental|Standard Chelation & Amlodipine|"This arm will receive both chelation and amlodipine.~Amlodipine will be administered as a single daily dose. It will be administered at a dose of 0.1 mg/kg/day or maximum of 2.5 mg/day.~Standard Chelation therapy will be administered either by subcutaneous infusion of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.~The dosage will depend on individual requirement, as determined by the treating hematologist."
89315963|NCT02065492|Active Comparator|Standard Chelation|"Deferasirox or Deferoxamine or Deferiprone. Patients in this arm will be administered only standard chelation therapy,either by subcutaneous infusion of Chelation therapy of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.~The dosage will depend on individual requirement, as determined by the treating hematologist.~This will serve as the control arm of the study without any additional intervention."
89315964|NCT02062840|Experimental|High intensity whole-body infrared heating and Neuroimaging|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
88814747|NCT01622699|Active Comparator|Visual assessment of neonatal jaundice|In this control group (standard of care) the visual assessment will be followed by measurement of blood bilirubin as indicated by the physician
89315965|NCT02062840|Sham Comparator|Low intensity whole-body infrared heating and|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH-control intervention where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
89315966|NCT03767673|Experimental|Patients after esophageal atresia|Patients older than 12 years following surgical repair of congenital esophageal atresia will be included after written informed consent. Patients will be subjected to spirometry to determine their age, weight (determined by Kilogram (kg) on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
89315967|NCT03767673|Active Comparator|Control group|Age and sex matched adolescents will be recruited as control group and will be included after written informed consent. Adolescents will be subjected to spirometry to determine their age, weight (determined by Kilogram on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
89315968|NCT02063620|Active Comparator|ketamine HCL|%0.5 Lidocaine+Ketamine HCL 0.8 mg/kg, total 40ml, single dose administration, 30 minute duration, total 200mg lidocaine
89315969|NCT02063620|No Intervention|lidocaine+ serum physiologic|% 0.5 lidocaine+ serum physiologic, total 40ml, total 200 mg lidocaine, 30 minute duration, single dose administration,
89315970|NCT02063776||Children on HDF|
89315971|NCT02063776||Children on conventional HD|
89315972|NCT03761667|Experimental|NBI|The group of NBI inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
89315973|NCT03761667|No Intervention|White light endoscopy (WLE)|The group of WLE inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
89315974|NCT02065648||Syngo NATIVE MRA|All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.
89315975|NCT03761589|Experimental|AFL Intervention Group|The AFL intervention consisted of twice a week physical activity and nutrition sessions for children and twice a week educational and physical activity sessions for parents. Each session lasted 90 minutes and all sessions were conducted in a municipal recreation center. The child program was delivered in English while the parent program was delivered in separate English-only or Spanish-only classes.
89315976|NCT03761589|Other|Wait-List Control Group|The wait-list control group received the 12-week AFL intervention after all follow-up data had been completed.
89315977|NCT02065726|Experimental|Whey protein|Nutritional counseling + 20 g (2 x 10 g) of whey proteins (Prother® - Spepharm Italy)
89315978|NCT02065726|Active Comparator|Nutritional counseling|Nutritional counseling
89315979|NCT03767439|Experimental|Nivolumab, Vismodegib, Ipilimumab|"Patients will receive a two week run-in of Vismodegib 150 mg PO daily followed by concurrent Nivolumab 480 mg IV every 4 weeks and Vismodegib 150 mg PO daily.~In an exploratory fashion, patients will have the option to receive combination Ipilimumab 1 mg/kg IV every 6 weeks and Nivolumab 360 mg IV every 3 weeks at the time of disease progression."
89315980|NCT02063932||endomicroscopy|
89315981|NCT03771495|Experimental|Hip Joint Mobilization|passive accessory movement on femur in anterior/posterior direction, grade III for four minutes and passive physiological movement of the most restricted hip joint movement, grade III for one minute (without pain), and a verbal education of hypothesized underlying effect mechanisms.
89315982|NCT03771495|Sham Comparator|Laying on of Hands|grade I, very small amplitude without encountering any tissue resistance for five minutes, thus effectively a Laying on of Hands, with a verbal education of hypothesized underlying effect mechanisms.
89315983|NCT04539405||Memsorb|M for memsorbTM group with the minimal gas flow possible (sevoflurane administration at 0.2L.min-1) with the ventilator Draeger A-500 Perseus,
89315984|NCT04539405||Dräegersorb|D for DraegersorbTM group with gas flow at 2L.min-1 (classical sevoflurane administration) with the same ventilator Draeger A-500 Perseus.
89315985|NCT03767361|Active Comparator|Fresh PRBCs|Neonates will receive fresh packed red blood cells transfusion within 7 days of donation
89315986|NCT03767361|Active Comparator|Old PRBCs|Neonates will receive fresh packed red blood cells transfusion older than 7 days yet within the standard range accepted universally will be transfused to this group.
89315987|NCT03761433||SPI group|All patients who received the liver resection surgery will receive surgical pleth index
89315988|NCT01321281|Experimental|AquaCal|Osteoarthritis and healthy volunteers
89315989|NCT01321281|Active Comparator|AquaPT|Osteoarthritis
89315990|NCT03761199|Experimental|a group of patients with AD|15 people with clinically diagnosed atopic dermatitis (AD), established on the basis of criteria Hanifin and Rajka
89315991|NCT03761199|Other|control group|15 healthy persons which will form the control group
89315992|NCT02794870|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants received a single dose of the RSV LID ΔM2-2 1030s vaccine at study entry (Day 0).
89315993|NCT02794870|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
89315994|NCT03767205|Experimental|stroke patients|All participants perform overground walking and treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot).
89315995|NCT01321593||hemoglobin determination|emergency unit patients
89315996|NCT02065804|Experimental|Active drug|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
89315997|NCT02065804|Placebo Comparator|Placebo|10 ml of normal saline deposited by ultra-sound guidance around the spermatic cord
89315998|NCT02064712|Active Comparator|Low CPAP Wean|NCPAP weaned to 5cm H2O for minimum of 24h, and if the neonate remains clinically stable as defined, wean in 1cm increments to 3cm H2O for minimum of 24h, at which time move to room air or 1L/min nasal cannula if supplemental O2 is required.
89315999|NCT02064712|Active Comparator|High CPAP Wean|NCPAP weaned to 5cm H2O for a minimum of 24h, and if the neonate remains clinically stable, move to room air or 1L/min nasal cannula if supplemental O2 is required.
89316000|NCT02064790||Group G - receiving gabapentin|Receiving gabapentin as standard of care. No intervention
89316001|NCT02064790||Group P - receiving pregabalin|Receiving pregabalin as standard of care No intervention
89316002|NCT02064790||Group Z - no neuropathic agent|Receiving only conservative treatment No drug treatment No intervention
89316003|NCT03767049||Lung transplant patients readmitted in ICU|
89316004|NCT02064010|Experimental|SNC-102, low dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
89316005|NCT02064010|Experimental|SNC-102, high dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
89316006|NCT02064010|Placebo Comparator|Placebo|Placebo tablet 4 week duration dosing
89316007|NCT02065960|Experimental|Stereotactic body radiotherapy (SBRT)|Radiotherapy with SBRT to a dose of 40 Gy in 5 fractions delivered every other day over a period of 10-12 days, followed by breast conserving surgery.
89316008|NCT03761043|No Intervention|Pre-Intervention Arm|The nurses will have not been exposed to the behavior change intervention.
89316009|NCT03761043|Experimental|Post-Intervention Arm|The nurses will have been exposed to the behavior change intervention.
89316010|NCT02064088|Experimental|Small volume|Local analgesia by one injection of 0,2 ml/kg of 0,2% lévobupivacaine
89316011|NCT02064088|Experimental|High volume|Local analgesia by one injection of 0,4 ml/kg of 0,1% lévobupivacaine
89316012|NCT03760887|Sham Comparator|No Home Sensory training|Patients who perform a home exercise program only
89316013|NCT03760887|Experimental|Home sensory training|Patients who perform home exercise and home sensory training
89316014|NCT03560050|Experimental|Behavioral: Nutrition assistance|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
89316015|NCT03560050|Experimental|Behavioral: Children's environmental health|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
89316016|NCT02066038|Experimental|A|Pemetrexed 500mg/m2+Carboplatin area under curve(AUC)=5, every 3 weeks, maximum 4 cycles, Erlotinib 150mg/d every cycle d2-15, and Erlotinib 150mg/d from the last cycle until disease progression
89316017|NCT03766893|Experimental|Pharmacy based opioid use disorder care|A single-arm pilot study to test the collaborative pharmacy practice agreement for MAT (using the medications buprenorphine or injectable naltrexone) care model with up to 12 patients with opioid use disorder, assessing feasibility of medication dispensing, administration, and monitoring in the pharmacy, and determining patient acceptability of this model.
89316018|NCT02066116|Experimental|Kinect-based Rehabilitation|
89316019|NCT02066116|Active Comparator|Self-exercises education|
89316020|NCT03766815|Placebo Comparator|Placebo|Fiber supplement mixed with jelly will be ingested for 18 days with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
89316021|NCT03766815|Experimental|BCAA 200mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (200mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
89316022|NCT03766815|Experimental|BCAA 400mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (400mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
89316023|NCT02066194|Active Comparator|Electroacupuncture|Patients randomized to the experimental group will receive EA at acupoints relevant to the treatment of abdominal pain and anxiety. Selection of these acupoints is based on a consensus between the acupuncturist of the study (Leung WW) and several professors of the Diploma Course of Clinical Acupuncture of the School of Professional and Continuing Education, University of Hong Kong.
89316024|NCT02066194|Placebo Comparator|Sham Acupuncture|Patients randomized to the control group will receive Sham acupuncture with sterile blunt-tip needles
89316025|NCT02064244||Acute renal failure in ICU|Ultrasound for measurement of Inferior Vena Cava size
89316026|NCT03766737|Other|Eligible patients for AI test.|Device: An intelligent visual acuity diagnostic system for children. An artificial intelligence to evaluate children's vision.
89316027|NCT02066272||IBD patients|IBD patients who start or re-start anti-TNF therapy
89316028|NCT03760809|Experimental|group A|Dexmedetomidine(0.5 μg／kg)/hydromophine-based general anesthesia
89316029|NCT03760809|Experimental|group B|Dexmedetomidine(1μg／kg)/hydromophine-based general anesthesia
89316030|NCT03760497|Experimental|CIV Group|Temporary Restoration with Glass Ionomer (Equia Forte® - GC Corporation, Tokyo, Japan) for 30 days + Restoration in Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA).
89316031|NCT03760497|Experimental|Composite Resin Group|Restoration with Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, United States).
89316032|NCT03760497|Experimental|Composite Resin Group + Laser|Composite Resin Restoration (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA) + Application of Diode Laser.
89316033|NCT01370590|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 20 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
89316034|NCT01370590|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/20 mg, placebo to ezetimibe, and placebo to atorvastatin.
89316035|NCT03770871|Active Comparator|IPT using Dycal (TM )|Indirect pulp treatment; IPT using Dycal (TM ); (2 paste system) by partial caries removal
89316036|NCT03770871|Experimental|IPT using Vitrebond (TM )|Indirect pulp treatment; IPT using Vitrebond (TM );(powder and liquid) by partial caries removal
89316037|NCT03771027|Experimental|Low FODMAP diet group|four weeks of the low FODMAP diet based on Monash University low FODMAP diet App.
89316038|NCT03771027|Active Comparator|Control group|four weeks of the diet based on NICE guidelines and contained products with different FODMAP content
89316039|NCT02064322||SImmetry Implant|Subjects who are indicated for the SImmetry Device according to the approved product labeling and inclusion/exclusion criteria will receive a SImmetry implant.
89316040|NCT03770793|Experimental|Lung-sono guided|Before starting one-lung ventilation, alveolar recruitment is performed under the examination with ultrasound. Find the minimal airway pressure that actually starts to resolve the observed atelectasis. Repeat alveolar recruitment with the minimal pressure untill the atlelectasis is not visible.
89316041|NCT03770793|No Intervention|Conventional|Before starting one-lung ventilation, alveolar recruitment is performed with the pressure of 30mmHg for 10 seconds which is a conventional method.
89316042|NCT02064400||Observational study group|Musculoskeletal ultrasound (all patients) and semi-structured patient interview (anticipated maximum 15 patients)
89316043|NCT03766503|Other|Intervention|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
89316044|NCT01567683|Experimental|Limtop solution (imiquimod), Vehicle solution for topical use|
89316045|NCT01322217||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at sites newly participating in ATN III and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
89316046|NCT03760341|Active Comparator|cold adenoidectomy group|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - cold method
89316047|NCT03760341|Active Comparator|hot method adenoidectomy|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - hot method
89316048|NCT03770637|Experimental|Glucagon RTU (glucagon injection)|Glucagon Ready-to-Use (RTU); 60 μL injection (0.3 mg glucagon)
89316049|NCT03770637|Placebo Comparator|Placebo|Non-active vehicle for Glucagon RTU; 60 μL injection
89316050|NCT03766269|Other|Baseline Opioid|One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.
89316051|NCT03760107|Experimental|Incentive Level High, Call|
89316052|NCT03760107|Experimental|Incentive Level High, No Call|
89316053|NCT03760107|Experimental|Incentive Level Medium, Call|
89316054|NCT03760107|Experimental|Incentive Level Medium, No Call|
89316055|NCT03760107|Experimental|No Incentive, Call|
89316056|NCT03760107|Experimental|No Incentive, No Call|
89316057|NCT03765957|Experimental|Mesenchymal Stem Cells|The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment.
89316058|NCT03770247|Experimental|intraoperative group (IOCPN group)|Intraoperative celiac plexus neurolysis Before closure of the abdomen the surgeon will expose the aorta at the level of the celiac trunk.With the stomach retracted inferiorly, the index and second finger of the surgeon's left hand straddle the aorta with the index finger placed on the splenic artery and the second finger on the common hepatic artery. we will use of a 20- gauge spinal needle (in contrast to the usual short intravenous needle) allows better visualization and access to this area, especially in deep patients, while a 10 ml syringe permits the surgeon to control the injection with the right hand alone.(10) Twenty ml of 90 % alcohol, five ml lidocaine 2%, five mg dexamethasone will be injected in each side of the aorta after aspiration to exclude intravascular or subarachnoid injection.
89316059|NCT03770247|Active Comparator|CT group (CTCPN group)|CT guided celiac plexus neurolysis After one week of the operation and the patient completely awake, the patient will be transferred to CT lab. The procedure will be done after attachment of basic monitors and transfusion of 500 ml saline in 20 G cannula before starting the procedure and the patient will be given 5 mg midazolam as a sedation. The procedure will be done by anesthetist and radiologist who had a good experience in celiac plexus neurolysis. In our study we will use the classic posterior bilateral approach. The patient will be in the prone position. After sterilization of the back by chlorohixidine 10 % , subcutaneous injection of 5 ml lidocaine as a local anaesthesia until a wheel will be formed then the procedure will be done. We will use 20 G Chiba needle under guidance of CT. Twenty ml of 95% alcohol , five ml lidocaine 2 % and five mg dexamethasone in each side of the aorta after aspiaration to exclude intravascular injection and subarachnoid injection
89316060|NCT03770325|Experimental|Berberine|berberine (500 mg orally twice a day)
89316061|NCT03770325|Placebo Comparator|Placebo|placebo (500 mg orally twice a day)
89316062|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fed)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fed conditions after consumption of a high-fat and high-calorie test meal.
89316063|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fasting)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
89316064|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fed)|Participants will receive two 60 mg GRTA9906 IR capsules under fed conditions after consumption of a high-fat and high-calorie test meal.
89316065|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fasting)|Participants will receive two 60 mg GRTA9906 IR capsules under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
89316066|NCT03765645|Active Comparator|3 doses on intra venous antibiotics|Patients will receive 3 doses of intra venous antibiotics. (1 dose preoperative, 1 intra operative and 1 post-operative)
89316067|NCT03765645|Active Comparator|9 doses of intra venous antibiotics|Patients will receive 9 doses of intra venous antibiotics. (1 dose preoperative, rest 8 doses at equal intervals)
89316068|NCT03223935|Active Comparator|Roasted snacks|Corn nuts
89316069|NCT03223935|Experimental|Roasted chickpeas|Chickpeas
89316070|NCT03223935|Experimental|Roasted yellow peas|Yellow peas
89316071|NCT03223935|Experimental|Roasted pinto beans|Pinto beans
89316072|NCT03223935|Experimental|Roasted soybeans|Soybeans
89316073|NCT03223935|Experimental|Roasted almonds|Almonds
89316074|NCT03765489|Experimental|electrical muscle stimulation|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al. plus electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction"
89316075|NCT03765489|Active Comparator|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
89316076|NCT03765411||Open Proctectomy Patients|Patients who underwent Proctectomy through an open approach
89316077|NCT03765411||Laparoscopic Proctectomy Patients|Patients who underwent Proctectomy through a Laparoscopic approach
89316078|NCT03765411||Robotic Proctectomy Patients|Patients who underwent Proctectomy through a Robotic approach
89316079|NCT03759483||AI group|The visual field reports in this group will be evaluated by the convolutional neural network.
89316080|NCT03759483||Human group|The visual field reports in this group will be evaluated by 3 ophthalmologists independently.
89316081|NCT03765255|Experimental|In the Know (ITK): sexual health education|Cohorts/participants in the experimental (treatment) arm receive an intervention that combines 6 hours of in-person sexual health and adolescent development education with an app that includes a resource locator, text message reminders (for one month), goal setting, and other resources.
89316082|NCT03765255|No Intervention|Control: do not receive ITK intervention|Cohorts/participants in the no intervention arm do not receive either the in-person education or the app. However, after completing the 10 month survey, they will have access to the app and will be invited to participate in the in-person program after the study implementation phase is completed (years 4 and 5).
89316083|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
89316084|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, fasted|
89316085|NCT01321671|Other|Pregabalin immediate release, 300 mg|
89316086|NCT03770013|Active Comparator|bupivacaine 0.25% and Dexmedetomidine|bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml each side) was used for the TAP block.)
89316087|NCT03770013|Active Comparator|bupivacaine and clonidine|20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml each side) was used for the TAP
89316088|NCT03770013|Placebo Comparator|bupivacaine and placebo|bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used for the TAP
89316089|NCT03759249|Experimental|Treatment group|Standard Treatment of Sleep disorder according to applicable guideline
89316090|NCT03759249|No Intervention|Waiting list|Continuation of former treatment, after completing the study standard treatment of Sleep disorder according to applicable guidelines
89316091|NCT03769935|Experimental|experimental arm|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
89316092|NCT03769935|Active Comparator|active comparator|cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.
89316093|NCT03769857|Experimental|NEM® + BIOCURC®|"NEM® + BIOCURC®~NEM, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS BIOCURC, 350 mg, #10 oval softgel, once daily orally for 2 weeks"
89316094|NCT03769857|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS Placebo, 350 mg, #10 oval softgel, once daily orally for 2 weeks
88806541|NCT05288036|Experimental|Proprioceptive Neuromuscular Rehabilitation group|PNF techniques; It is based on facilitating the responses of neuromuscular mechanisms by stimulating proprioceptors. It is a method used to improve active movement ability by increasing muscle strength, to increase muscle endurance, to improve stabilization at the point where the technique is applied within the movement pattern.
89316095|NCT03765021|Experimental|Tranexamic acid injection (Kapron)|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will be prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
89316096|NCT03765021|Active Comparator|Fractional CO2 laser resurfacing|The other side of the face will be randomly assigned to do low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
89316097|NCT03764787|Experimental|Radiation+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
89316098|NCT03759171|Experimental|Immediate Entry Group|Following the baseline interview, veterans randomized to the immediate entry group directly engaged in the Guitars for Vets Intervention and were interviewed at the end of the intervention period, roughly 6 weeks later. The intervention content and duration (6 weeks) was the same across both groups.
89316099|NCT03759171|Experimental|Delayed Entry Group|Those randomized to the delayed entry group had their baseline interview repeated at the end of the delayed entry period (4 weeks) prior to receiving the 6-week Guitars for Vets Intervention as well as after intervention completion. The intervention content and duration (6 weeks) was the same across both groups.
89316100|NCT05418699||Type I diabetic patient|
89316101|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.~The experimental arm will wear wireless monitoring for 5 days after transfer in subacute care unit"
89316102|NCT03764709|Active Comparator|Control arm GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.~The active comparator arm will be monitored by nursing staff."
89316103|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.~The experimental arm will wear wireless monitoring for 5 days after discharge at home"
89316104|NCT03764709|Active Comparator|Control Arm GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.~The active comparator arm will perform usual checks by caregivers at home."
89316105|NCT01322373||Healthy control subjects (HC)|Subjects who met criteria as healthy control subjects and completed Orasi Protocol ADG-08-01.
89316106|NCT01322373||Alzheimer's disease subjects (AD)|Subjects with a diagnosis of DAT according to DSM-IV-TR criteria who completed Orasi Protocol ADG-08-01.
89316107|NCT03764397|Experimental|Prehabilitation group|A 4-week prehabilitation educational programme (i.e., a behavioral change intervention) and to pilot that prehabilitation in combination with a 6-week gentle self-paced walking programme (with weekly telephone support) in people with FM.
89316108|NCT03758859|Experimental|sodium hyaluronate eye drops|the randomly allocated eye will receive sodium hyaluronate drops, followed by a repeat OCT scan; images are then evaluated for clarity by the masked assessor.
89316109|NCT03764319|Active Comparator|Intervention group|Ultra-protective ventilator settings in patients with ARDS and ECMO.
89316110|NCT03764319|Active Comparator|Control group|Standard ventilator settings in patients with ARDS and ECMO.
89316111|NCT02646969|Active Comparator|Formula regimen 1|"Product Control from enrollment to transition phase 1 (blinded administration), followed by open label administration for 2 months.~Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old"
89316112|NCT02646969|Active Comparator|Formula regimen 2|Product Test 1 from enrollment to transition phase 1 (blinded administration) Product Control for 2 months(open label) Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old
89316113|NCT02646969|No Intervention|Reference group|Infants fed HM exclusively through at least 4 months of age. Once breastfeeding is over and if wished Infant will receive Product test 2 until 1 year old followed by the commercial follow-up formula
89316114|NCT03764241|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy
89316115|NCT03764241|Active Comparator|Vitamin K Antagonist|warfarin will be added in addition to dual antiplatelet therapy
89316116|NCT03764163|Experimental|Study Participants|Pulmonary Function Test, Questionnaires, CT scans, perfusion scan, ventilation scan, Xenon gas ventilation CT scan with hyperpolarized 3-Helium MRI Scan.
89316117|NCT03764085|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
89316118|NCT03764085|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
89316119|NCT01322451|Experimental|Single oral dose, single capsule|
89316120|NCT01322451|Experimental|Single oral dose, two capsules|
89316121|NCT01321827|Experimental|Itraconazole group|Itraconazole 200 mg BD for 4 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
89316122|NCT01321827|Active Comparator|Glucocorticoid group|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
89316123|NCT03758937|Active Comparator|volume-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
89316124|NCT03758937|Active Comparator|pressure-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
89316125|NCT04294251|Experimental|DWP450|
89316126|NCT04294251|Placebo Comparator|Placebo|
89316127|NCT01756365|Experimental|ACCE (Autologous Cultured Corneal Epithlium) graft for the treatment of corneal lesions|Surgical transplantation of Autologous Cultured Corneal Epithelium
89316128|NCT02402517|Placebo Comparator|Extruded snack control|100% corn flour
89316129|NCT02402517|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
89316130|NCT02402517|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
89316131|NCT02402517|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
89316132|NCT02402517|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
89316133|NCT02402517|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
89316134|NCT03756675||haplotype PBSCT group|"Subjects in this group will receive haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system in the treatment of acute leukemia."
89316135|NCT03765099|Experimental|Animal-Assisted Interactions|Children and their caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
89316136|NCT03765099|Active Comparator|Usual Care|Children and their caregivers randomly assigned to the usual care group will receive usual care which may include play therapy, music therapy or visits with a social worker during their visits to the hospital.
89316137|NCT03763851|Experimental|Cannabis group|"Delta-9 Tetrahydrocannabidiol (THC) /Cannabidiol (CBD) ratio 1:1 capsule~These capsules contain different cannabis formulations with low-dose and high-dose preparations according to the treatment group:~Cannabis group low-dose capsule contains THC 1mg CBD 1mg~Cannabis group high-dose capsule contains THC 2.5mg CBD 2.5mg"
89316138|NCT03763851|Placebo Comparator|Placebo group|"The placebo capsule will have no cannabis, it will look identical to the active treatment capsule, and it will also be prepared in low-dose and high-dose presentations."
89316139|NCT03756519|Experimental|Exercise|Participants in the exercise intervention arm will receive the usual care protocol plus a standardized, evidence informed exercise intervention provided by trained physiotherapy students. The exercise intervention will begin with a brief assessment to rule out contraindications to exercise and to identify any directional preferences (e.g. pain with lumbar flexion and relief with extension). The PT will then be taught four standardized exercises: the pelvic tilt exercise, a rotational exercise, a tailored graded walking program taking into account the current abilities of the patient, and an exercise based on the directional preference of the individual. These will be re-enforced with a handout including the rationale, instructions and dosage recommendations for the exercises.
89316140|NCT03756519|Active Comparator|Usual care|Our usual care protocol was developed based on 30 responses to an 18 item survey of Queen's Department of Emergency Medicine physicians. Three themes emerged as interventions most commonly used. Each of these strategies has evidence for small, but positive treatment effects and low risk of harms: 1) advice to stay active and engaged in usual activities, 2) use of ice or heat to manage pain, and 3) recommendation for analgesia using NSAIDs if needed and appropriate.
89316141|NCT03763695||Retrospective control group|Patients admitted in our PICU before the implementation of the protocol for VAP prevention (from 01/01/2016 to 12/31/2017)
89316142|NCT03763695||Prospective group|Patients admitted to our PICU since the VAP bundle has been introduced in the clinical practice (from 01/01/2018)
89316143|NCT03763617|Active Comparator|Test group|A d-ptfe membrane will be placed between the buccal bone and periosteum of an extraction socket during a 4 months healing time before it is surgically removed.
89316144|NCT03763617|No Intervention|Control group|The extraction socket will be left to heal naturally without a socket preservation intervention.
89316145|NCT03763539|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.~The rest of the session at 22kv (full power)."
89316146|NCT03763539|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
89316147|NCT03758703|Experimental|Pre-recorded music intervention group|The experimental group will be receiving the pre-recorded music care intervention. The intervention is to be delivered once a day for 30 minutes, over one week, on a portable Bluetooth speaker system. Participants will select their own music from the list of pre-recorded songs playlist and are free to switch to another playlist within their treatment arm should they desire. This music was specifically designed for use in palliative care. Specifically, all songs are played at 60 beats per minute to mimic resting heart rate. Instrumentation was specifically chosen to be soothing and calming
89316148|NCT03758703|Active Comparator|Pre-recorded soothing poetry group|The control group will be provided pre-recorded soothing poetry which they will self-select. Participants are allowed to switch playlists within their treatment arm each day should they desire. This control group is designed to control time, attention, and placebo effect. Thus, the soothing poetry will be offered the identical time duration of listening to recorded soothing poetry readings and played at the same time the intervention group receives the pre-recorded music.
89316149|NCT03756441|Experimental|Experimental: Mindfulness group|This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion protocol. They will group with have eight meetings, one per week, during a half hour and will learn the techiques to practice everyday during the week.
89316150|NCT03756441|Active Comparator|Psychotherapy group|This group will learn group problem solving techniques during eight weeks
89316151|NCT03756363|Experimental|Non-solvent|Non-solvent use of a rotary retreatment system
89316152|NCT03756363|Experimental|Solvent|Solvent use in combination with a rotary retreatment system
89316153|NCT04660383|Experimental|IMT 50|"IMT intervention: IMT50 - 50% of the maximum inspiratory pressure (MIP), using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
89316154|NCT04660383|Experimental|IMT 30|"IMT intervention: IMT30 - 30% of the maximum inspiratory pressure, using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
89316155|NCT04660383|Sham Comparator|IMT 10|"IMT intervention: IMT10 - 10% of the maximum inspiratory pressure, using equipment Threshold IMT® or Power Breathe®, which are respiratory incentives of linear pressure load, where the patient uses a nose clip and breathes through a mouthpiece with a resistance in the inspiratory branch, using the respective MIPs."
89316156|NCT03758547|Experimental|in-exufflator and percussion technique|"assess the physiological effects, of a common daily practice of secretion removal in intubated patients, that are: in-exufflator technique and percussion technique"
89316157|NCT03753633|Experimental|Speech therapy Group|25 patients will be treated with speech therapy, once a week, during 40 minutes for 12 weeks. Oropharyngeal exercises will be performed under the supervision of a speech therapist. Patients will perform the oropharyngeal exercises at home every day.
89316158|NCT03753633|Sham Comparator|Control Group|25 patients will perform inspiratory and expiratory exercises recruiting diaphragmatic muscle.
89316159|NCT03753477|Experimental|Test Drug|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)
89316160|NCT03753477|Active Comparator|Reference Drug|Sevikar and Crestor
89316161|NCT03756207|Experimental|Multidisciplinary Therapy|Multidisciplinary bladder-preservation therapy: Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
89316162|NCT03758469|Experimental|HSK3486|0.4 mg/kg
89316163|NCT03758469|Experimental|rifampin , HSK3486|600 mg;0.4 mg/kg
89316164|NCT03753399|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
89316165|NCT03753399|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
89316166|NCT03753399|No Intervention|Usual care|Chemotherapy without acupuncture
89316167|NCT05460897|Experimental|Experimental|12-week intervention consisting of educational sessions and health behaviour change techniques
89316168|NCT05460897|No Intervention|Waitlist control group|After the first 12 weeks, this group will receive the same intervention as the experimental group
89316169|NCT03753321|Experimental|Whey protein|Whey protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
89316170|NCT03753321|Experimental|Soy protein|Soy protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
89316171|NCT03753321|Placebo Comparator|Placebo (maltodextrin)|Isoenergetic, maltodextrin (7 day pre-loading phase and 3 day training phase)
89316172|NCT05200455|Experimental|Microelectrodes|Patients who qualify for this study will be implanted with standard electrodes as well as microelectrodes for their intracranial seizure monitoring.
89316173|NCT04646109|No Intervention|Control Group|"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with PCR positivity in respiratory tract samples were included into the study. They were randomized to the control and study group, respectively. Hydroxychloroquine, favipiravir and azithromycin (HFA) standard treatment protocol were given to the control group as recommended in the COVID-19 (SARS-CoV-2 Infection) Guide prepared by the Republic of Turkey Ministry of Health."
89316174|NCT04646109|Experimental|Study Group|In addition to HFA treatment, ivermectin 200 micrograms/kg/day (9mg between 36-50 kg, 12mg between 51-65 kg, 15mg between 66-79 kg and 200 micrograms/kg in > 80 kg) in the form of a solution prepared for enteral use was added (HFA+I) to the treatment protocol of the study group's for five days. Blood sample was taken with the first dose of ivermectin and haplotype analysis was performed in ABCB1 and CYP3A4 genes in the whole study group.
89316175|NCT03753165|Experimental|High Intensity Interval Exercise group|Patients suffering from chronic low back pain perform 12 sessions of high intensity interval exercise (HIIE) over a period of 6 weeks at an intensity of 80% of their maximal Heart rate. In addition they also receive conventional physiotherapy in the form of hot pack or TENS
89316176|NCT03753165|No Intervention|Conventional physiotherapy|Patients suffering from chronic low back pain will receive conventional physiotherapy such as TENS and hot packs applied over appropriate areas over a period of 6 weeks
89316177|NCT05320107|Experimental|Ketamine first, then placebo|0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study, then placebo
89316178|NCT05320107|Experimental|Placebo frist, then ketamine|0.9% NaCl, then ketamine
89316179|NCT03753009||iontophoretic transepithelial corneal cross-linking (I-ON CXL)|Twenty eyes of 15 patients with keratoconus (mean age 13±3.5 [SD] years, range 9 to 18) underwent Iontophoresis epi-on CXL
89316180|NCT03753009||epithelium-off collagen cross-linking (epi-off CXL)|Twenty eyes of 13 patients with keratoconus (14±4 [SD] years, range 10 to 18) underwent standard epi-off CXL
89316181|NCT03752931|Active Comparator|Celiprolol|receiving 1 tablet per day of celiprolol (Celiprol®) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
89316182|NCT03752931|Active Comparator|Diltiazem|receiving 1 capsule per day of diltiazem (Monotildiem® LP) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobectomy for 2 weeks.
89316183|NCT04502979|Experimental|Responsive Feeding|Intervention families will receive approximately 4 hours of ASL and development specific content related to language and feeding during home visits and phone calls. The initial in-home session with families will focus on teaching ASL signs indicative of hunger, thirst, and satiety. A video and placemat of mealtime signs will be left with families at the completion of the first visit. The remaining sessions, in-home over the next 3 months and by phone monthly thereafter for 6 months total, will focus on reinforcing ASL signing in addition to focused education on particular aspects of language development (receptive language preceding expressive language and increasing intentional communication), feeding development (such as hunger and fullness cues, fear of new foods, the importance of repeated food exposures, variations in intake from meal-to-meal, and the propensity to reject bitter tastes [many vegetables]55], and appropriate portion sizes and variety for healthy growth.
89316184|NCT04502979|No Intervention|Routine Care|No intervention is provided to the families in this group; however, portions of the intervention lessons will be made available after completion of data collection.
89316185|NCT03752853|Experimental|iCBT for depression - behavioral activation first (BAF)|internet-based intervention for mild to moderate depression: patients receive behavioral activation first, followed by cognitive restructuring
89316186|NCT03752853|Experimental|iCBT for depression - cognitive restructuring first (CRF)|internet-based intervention for mild to moderate depression: patients receive cognitive restructuring first, followed by behavioral activation
89316187|NCT03758391|No Intervention|Traditional Didactic Education|Education will be provided to fellows using the traditional didactic approach (lecture-based).
89316188|NCT03758391|Experimental|Flipped Classroom Education|Education will be provided to fellows using the flipped classroom approach.
89316189|NCT03758235|Experimental|Incobot/A 100 U|Incobot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
89316190|NCT03758235|Experimental|Incobot/A 200 U|Incobot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered in patients performin intermittent catheterization.
89316191|NCT03758235|Active Comparator|Onabot/A 100 U|Onabot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
89316192|NCT03758235|Active Comparator|Onabot/A 200 U|Onabot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered to patients performing intermittent catheterization
89316193|NCT04587453|Experimental|Tralokinumab+TCS|Week 0 to Week 16: Tralokinumab will be given as subcutaneous injections. Participants will receive tralokinumab loading dose on Day 0 followed by multiple tralokinumab injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
89316194|NCT04587453|Placebo Comparator|Placebo+TCS|Week 0 to Week 16: Placebo will be given as subcutaneous injections. Participants will receive placebo loading dose on Day 0 followed by multiple placebo injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
89316195|NCT02793232|Experimental|Single Ascending Dose Crossover|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
89316196|NCT02793232|Experimental|Multiple Ascending Dose|Multiple dose administration to Healthy Subjects in parallel cohorts (PF-06751979).
89316197|NCT02793232|Experimental|Multiple Dose Elderly|Multiple dose administration to Healthy Elderly Subjects (PF-06751979). This cohort is optional.
89316198|NCT04584645|Experimental|cardiovascular disorders digital intervention arm (CVD-I)|Individuals with cardiovascular disease who receive a targeted digital intervention aimed at increasing influenza vaccination
89316199|NCT04584645|No Intervention|cardiovascular disorders without digital intervention arm|Individuals with cardiovascular disease who receive no intervention
89316200|NCT03755817|Experimental|Scenar application|Application of SCENAR device on
89316201|NCT03755817|Placebo Comparator|Scenar application with the device off|Application of SCENAR device off
89316202|NCT02066350|Experimental|Single pancreas transplantation|This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation. Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft. A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.
89316203|NCT02066428|Experimental|AERAS-404(50mcg H4/0nmol IC31) or Placebo|1 dose
89316204|NCT02066428|Experimental|AERAS404 (50mcgH4/100nmol IC31) or Placebo|1 dose
89316205|NCT02066428|Experimental|AERAS404 (50mcgH4/0nmol IC31) or Placebo|2 dose
89316206|NCT02066428|Experimental|AERAS404 (150mcgH4/0nmol IC31) or Placebo|1 dose
89316207|NCT02066428|Experimental|AERAS404 (50mcgH4/5000nmol IC31) or Placebo|1 dose
89316208|NCT02066428|Experimental|AERAS404 (50mcgH4/500nmol IC31) or Placebo|2 dose
88806542|NCT05288036|Experimental|Progressive Resistance Exercise Group|Progressive resistance training (PRT) is a method for increasing muscle strength and endurance based on the determination of the amount of resistance appropriate for the individual. Free weights and resistance machines are used in the practice of this technique.To facilitate continued adaptation, training intensity (i.e. load) and training volume (i.e. number of sets) are progressively increased, and exercises are adjusted as indicated throughout the training regimen, to attenuate the onset of a plateau in physiological adaptation.
89316209|NCT02066428|Experimental|AERAS404|2 dose placebo
89316210|NCT02066428|Experimental|AERAS404 (50mcg H4/100nmol IC31) or Placebo|2 dose
89316211|NCT02064478||Tissue preservation|Ponto implant installed using a tissue preservation surgical technique
89316212|NCT02064478||Tissue reduction|Ponto implant installed using a classical technique with skin thinning
89316213|NCT02066506|Sham Comparator|asymptomatic group|patients with systemic right ventricle who are asymptomatic,
89316214|NCT02066506|Sham Comparator|symptomatic group|symptomatic group : patients with systemic right ventricle and heart failure signs and/or decrease exercise performance
89316215|NCT02066506|Sham Comparator|control|healthy subject matched with patients of asymptomatic group
89316216|NCT03752463|Experimental|DAOI-A group|
89316217|NCT03752463|Experimental|DAOI-B group|
89316218|NCT03752463|Experimental|DAOI-C group|
89316219|NCT03752463|Placebo Comparator|Placebo group|
89316220|NCT02064946|Active Comparator|Vitamin D3|Vitamin D3 50,000 IU: Patients will be assigned to receive weekly high-dose vitamin D (50,000 IU/week) along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium) and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
89316221|NCT02064946|Placebo Comparator|Control|Control: Patients will be assigned to receive a weekly vitamin D placebo along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium)and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
89316222|NCT05359809|Experimental|Grasping Palmar Reflex|
89316223|NCT05359809|No Intervention|Control|
89316224|NCT02064556|Experimental|A(Amlodipine 10mg)|Amlodipine 10mg 1T, PO, QD for 9days
89316225|NCT02064556|Experimental|B(Amlodipine 10mg/Candesartan 32mg)|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
89316226|NCT03752385|No Intervention|Control Group|No intervention
89316227|NCT03752385|Experimental|Intervention Group|"Will cut their smartphone screen time in half, sleep without phone in bedroom, and have a bedtime for their phone use."
89316228|NCT02064634||Shinbaro (only)|
89316229|NCT02064634||Celecoxib (only)|
89316230|NCT02064634||Shinbaro + NSAIDs|
89316231|NCT02064634||Shinbaro + Celecoxib|
89316232|NCT03755583|Other|EEN group|Received exclusive enteral nutrition after enrollment.
89316233|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 610|
89316234|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
89316235|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 430|
89316236|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 420|
89316237|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 520|
89316238|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 450|
89316239|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 545-549|
89316240|NCT03752229|Experimental|Owem Mumford lancet|
89316241|NCT03752229|Experimental|Medicore lancet|
89316242|NCT03752229|Experimental|Arkray lancet|
89316243|NCT03752229|Experimental|Medipurpose lancet|
89316244|NCT03752229|Experimental|Sterilance lancet|
89316245|NCT03752229|Experimental|Dynarex lancet|
89316246|NCT03752229|Experimental|Ypsomed lancet|
89316247|NCT03752229|Experimental|Promismed lancet|
89316248|NCT03752229|Experimental|Cambridge Sensors lancet|
89316249|NCT03755505||Healthy Smoker|Healthy smoker with normal spirometry value
89316250|NCT03755505||COPD|Patients with smoking history at least 10 pack-year Patients with persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
89316251|NCT03695367|Experimental|Cohort 1: HTX-011 + MMA Regimen|HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen.
89316252|NCT03695367|Experimental|Cohort 2: HTX-011 + MMA Regimen + Ketorolac|HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen and IV ketorolac.
89316253|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo AZ MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily (QD) for 28 days and Placebo AZ MDI taken as two inhalations twice daily (BD) for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
89316254|NCT02794480|Experimental|Placebo AZ MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive AZ MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
89316255|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo GSK MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily for 28 days and Placebo GSK MDI taken as two inhalations twice daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period.
89316256|NCT02794480|Experimental|Placebo GSK MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive GSK MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
89316257|NCT02065024|Active Comparator|b-cryptoxanthin plus phytosterols|Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols
89316258|NCT02065024|Placebo Comparator|control|Fruit and milk based beverage not enriched
89316259|NCT03755427|Experimental|15μg H7N9 Vaccine|Participants will be inoculated with 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
89316260|NCT03755427|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will be first inoculated with one dose of seasonal influenza vaccine and followed with one dose of aluminum hydroxide adjuvant at 21-day intervals.
89316261|NCT02066584||Universal IVF Medium|An oocyte culture medium containing 5.55 Mm glucose (Origio, Medi-Cult)
89316262|NCT02066584||ISM1 Medium|An oocyte culture medium containing 1mM glucose ((Origio, MediCult)
89316263|NCT02066584||P1 Medium|An oocyte culture medium containing no glucose (Irvine)
89316264|NCT02066584||ECM Medium|An oocyte culture medium containing 0.5mM glucose (Irvine)
89316265|NCT03758079|Active Comparator|Doxepin|10 mg Doxepin daily for 4 weeks
89316266|NCT03758079|Active Comparator|Gabapentin|Gabapentin 100mg after each dialysis session
89316267|NCT02067910|Active Comparator|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept during 48 weeks
89316268|NCT02067910|Placebo Comparator|Placebo|First phase: Weekly subcutaneous administration of placebo during 24 weeks. Second phase: Weekly subcutaneous administration of 125 mg Abatacept during 24 weeks.
89316269|NCT05460351|Experimental|BRJ+Nitrate|This arm underwent a 3 days a week, 10 weeks of resistance exercise training program and consumed for a 70 mL bottle of beetroot juice containing 380 mg of nitrate plus a 15 dose of whey protein after each exercise session.
89316270|NCT05460351|Placebo Comparator|Control|This arm underwent a 3 days a week, 10 weeks of resistance exercise training program and consumed for a 70 mL bottle of beetroot juice containing 0 mg of nitrate plus a 15 dose of whey protein after each exercise session.
89316271|NCT02066662|Experimental|Rivaroxaban|Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing
89316272|NCT02066662|Active Comparator|Marcumar|Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
89316273|NCT05280873|Experimental|Experimental group|Grade 3-4 checkpoint inhibitor-related pneumonitis
89316274|NCT05280873|Experimental|Control group|Grade 3-4 checkpoint inhibitor-related pneumonitis
89316275|NCT02066818|Active Comparator|Lidocaine Injection|Incision and drainage performed after patient received placebo patch with injection of 1% lidocaine into the site of the abscess.
89316276|NCT02066818|Experimental|Lidocaine/tetracaine patch|Incision and drainage performed after patient received active lidocaine/tetracaine patch and injection of 10cc of saline into site of abscess
89316277|NCT04558125|Experimental|Low-dose TNKase and Standard of Care Anticoagulation|"TNKase (0.25 mg/kg) bolus Other names: Tenecteplase, TNK~Standard of care anticoagulation (heparin or enoxaparin)"
89316278|NCT04558125|Active Comparator|Placebo and and Standard of Care Anticoagulation|"Placebo bolus (intravenous syringe identical to that of TNK )~Standard of care anticoagulation (heparin or enoxaparin)"
89316279|NCT02067988|Experimental|Treatment arm|Holmium-166 microspheres hepatic radioembolization, adjuvant to systemic 177Lu-dotatate.
89316280|NCT05460195|Experimental|Combination therapy group|Sintilimab combined with anlotinib
89316281|NCT05460195|Experimental|Single-agent therapy group|Sintilimab monotherapy
89316282|NCT02065180|Experimental|commercially available nutrition supplement|this group receives a commercially available nutritional supplement for a period of 2 months
89316283|NCT02065180|Placebo Comparator|control group|this group receives a placebo for a period of 2 months
89316284|NCT02065258|Active Comparator|Breathing Exercise|It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions and will be part of the routine of breathing exercises the following exercises: I) Kapalabhati ; II) Uddhiyana ;III) Surya Bedhana
89316285|NCT02065258|Active Comparator|Aerobic Exercise|Exercise will be performed on a treadmill, with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957).Aerobic training sessions that will consist in 40 minutes divided in 5 minutes of warm-up, 35 minutes of aerobic training and 5 minutes of cool down. Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. The program will be performed twice a week, for 3 months.
89316286|NCT02793622|Active Comparator|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Women will be given SP (3 full strength tabs, 500 mg/25 mg) every four weeks times during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
89316287|NCT02793622|Active Comparator|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
89316288|NCT02066974||Hepatoma, Circulating tumor genome|Hepatoma requiring radiotherapy
89316289|NCT02067130|Other|Fibroscan|Subjects enrolled will undergo Fibroscan. It is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Fibroscan reading will be collected at the Gastroenterologist's (Dr. Ko) outpatient clinic (Pacific Gastroenterology Associates) where a qualified research nurse/assistant will perform the scan under supervision of the physician. Anticipated timing of this procedure will be October to December 2013
89316290|NCT02067208|No Intervention|Waitlist Control|A waitlist control condition, where the participant receives no insole for 3 months. During this 3 month period, the participant will continue to be monitored for outcome variables.
89316291|NCT02067208|Experimental|Experimental wedged insole|Either a medially wedged or laterally wedged footwear insole (whichever reduces knee joint mechanical loading more, as determined from subject-specific biomechanical tests), constructed using a 3D printer will be inserted into each participant's shoe. The participant will be asked to utilize this insole as much as possible throughout the day over the course of 3 months.
89316292|NCT02068144|Experimental|Cranberry Extract|Cranberry Extract in a 15.2oz beverage daily for 8 weeks
89316293|NCT02068144|Placebo Comparator|Placebo|Placebo 15.2oz beverage daily for 8 weeks
89316294|NCT04493931|Experimental|Cohort 1: Gepotidacin 1500 mg + Cimetidine 400 mg|This is a fixed sequence (Sequence AB) cohort. Participants will receive gepotidacin 1500 milligrams (mg) single dose (SD) on Day 1 of Period 1 (Treatment A); and Cimetidine 400 mg 4 times daily on Days 1 through 4 of Period 2 and gepotidacin 1500 mg single dose (Treatment B). Gepotidacin will be administered 1 hour after the first dose of cimetidine on Day 2 of Period 2. There will be a washout of at least 3 days between Treatment A and Treatment B, and a follow-up visit 5 to 7 days after the last dose of cimetidine.
89316295|NCT04493931|Experimental|Cohort 2: Gepotidacin 1500 mg + Rifampicin 600 mg|This is a fixed sequence (Sequence CDE) cohort. Participants will receive gepotidacin 1500 mg single dose on Day 1 of Period 1 (Treatment C), rifampicin 600 mg (administered in the evenings) once daily for 7 days (Days 1 through 7 of Period 2, to elicit maximal enzyme induction) (Treatment D); and gepotidacin 1500 mg single dose administered in the morning on Day 8 and rifampicin 600 mg administered in the evening on Days 8 and 9 of Period 2 (Treatment E). There will be a washout of at least 3 days between Treatment C and Treatment D, and a follow-up visit 7 to 10 days after the last dose of rifampicin.
89316296|NCT04493931|Experimental|Cohort 3: Digoxin 0.5mg+Midazolam 2mg then Gepotidacin 3000mg|Participants will receive digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 1 on Day 1 then gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 2 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G). There will be a washout of at least 10 days between treatments. In Sequence 2, these regimens are reversed. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
89316297|NCT04493931|Experimental|Cohort 3: Gepotidacin 3000mg then Digoxin 0.5mg+Midazolam 2mg|Participants will receive gepotidacin two 3000 mg doses (given 12 hours apart) co-administered with digoxin 0.5 mg and midazolam 2 mg in Period 1 on Day 1, with the 2 probe drugs administered with the second daily dose of gepotidacin only (Treatment G) followed by digoxin 0.5 mg and midazolam 2 mg (Treatment F) in Period 2 on Day 1. A follow-up visit will occur 7 to 10 days after the last dose of study intervention in Period 2.
89316298|NCT04493931|Experimental|Cohort 4: Gepotidacin 1500 mg fed then fasted then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fed conditions in Period 1 (Treatment H), then a single dose of gepotidacin 1500 mg under fasted conditions in Period 2 (Treatment I), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
89316299|NCT04493931|Experimental|Cohort 4: Gepotidacin 1500 mg fasted then fed then 3000 mg fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of gepotidacin 1500 mg under fasted conditions in Period 1 (Treatment I), then a single dose of gepotidacin 1500 mg under fed conditions in Period 2 (Treatment H), followed by two doses of gepotidacin up to 3000 mg (given 12 hours apart) under fed conditions in Period 3 (Treatment J). There will be a washout of at least 3 days between each treatment, and a follow-up visit 5 to 7 days after the last dose of gepotidacin.
89316300|NCT04493931|Placebo Comparator|Cohort 4: Placebo fed then fasted then fed|Cohort 4 will include Japanese participants. Participants will receive a single dose of placebo under fed conditions in Period 1, then a single dose of placebo under fasted conditions in Period 2, followed by two doses of placebo (given 12 hours apart) under fed conditions in Period 3. There will be a washout of at least 3 days between each period, and a follow-up visit 5 to 7 days after the last dose of placebo.
89316301|NCT03437278|Experimental|Ligelizumab 120 mg|Participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).
89316302|NCT03437278|Experimental|Ligelizumab 24 mg|Participants received a dose of ligelizumab 24 mg (low dose) which consisted of one injection of 0.2 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).
89316303|NCT03437278|Placebo Comparator|Placebo + Ligelizumab 120 mg|Participants received Placebo which consisted of one injection of 1 ml placebo every 4 weeks from Day 1 to Week 8 (inclusive). From week 12 to week 20 (inclusive), participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial.
89316304|NCT02068378|Experimental|CMPE Optical Sensor Device|Single arm study
89316305|NCT06264349|Experimental|Group A: frontal lessons|50 women will receive a Lifestyle Educational Intervention (LEI) from research staff regarding a correct lifestyle during pregnancy and lactation through 6 interactive online lectures lasting approximately 30 minutes each.
89316306|NCT06264349|Experimental|Group B: web-mobile app|50 women will receive Lifestyle Educational Intervention (LEI) from research staff regarding a correct lifestyle during pregnancy and lactation through a digital tool (web-mobile app), previously developed.
89316307|NCT06264349|No Intervention|Control Group|50 women of the same age as the intervention group will be selected within the LIfestyle and Microbiome InTeraction) Early Adiposity Rebound in Children (LIMIT) project cohort. The LIMIT protocol is registered on clinicaltrials.gov (NCT04960670)
89316308|NCT06264297|Active Comparator|GROUP I|RFP on the affected level or levels will be carried out during three cycles of 120 s, limited to a temperature of 42° and a voltage of 45V
89316309|NCT06264297|Experimental|GROUP II|RFP on the affected level or levels will be carried out during three cycles of 120 s, limited to a temperature of 42° and a voltage of 65V
89316310|NCT06264284||epidural anesthesia|
89316311|NCT06264284||general anesthesia|
89316312|NCT06264219|Active Comparator|FMT (Fecal microbiota transplantation)|Mother-to-infant fecal microbiota transplantation
89316313|NCT06264219|Active Comparator|FVT (Fecal virome transplantation)|Mother-to-infant fecal virome transplantation
89316314|NCT06264219|Placebo Comparator|Placebo|Inactive solution buffer placebo
89316315|NCT06264219|Other|Vaginal control group|Non-randomized control group used for secondary outcomes comparisons.
89316316|NCT06264206|Experimental|KIR AA|Patients from arm KIR AA received immunomodulatory treatment, and the pregnancy rate was calculated after this treatment, and compared to the one before the treatment
89316317|NCT06264206|No Intervention|KIR BX|Patients from arm KIR BX did not receive immunomodulatory treatment, and the pregnancy rate was calculated and compared with the ones from arm KIRR AA- before and after immunomodulatory treatment
89316318|NCT06264193|Experimental|Hypoxia|live high-train low method was used
89316319|NCT06264180|Experimental|VO + nivolumab|
89316320|NCT06264180|Active Comparator|Physicians Choice|"Choosing from 1 of the following (to be consistent with approved label and/or applicable local clinical guidelines):~Nivolumab + relatlimab (as Opdualag)~Anti-PD-1 monotherapy (nivolumab or pembrolizumab)~Single-agent chemotherapy (dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel)"
89316321|NCT06264167|Experimental|Participants with normal/negative baseline groin ultrasounds|Interventional Treatment: serial high-resolution bilateral groin ultrasound surveillance in conjunction with clinical examinations every 2 months (n=13).
89316322|NCT06264167|No Intervention|Participants with normal/negative baseline groin ultrasounds - Standard Care|Standard Treatment: receive upfront full groin LND or sentinel node biopsy (SNB) based on clinician choice (according to local clinical practice management guidelines).
89316323|NCT06264167|No Intervention|Participants with suspicious/indeterminate baseline groin ultrasound|Participants with suspicious/indeterminate baseline groin ultrasound (third group) will receive an upfront full groin LND or SNB, consistent with the current standard treatment, according to local clinical practice management guidelines.
88814868|NCT03033524|Experimental|Cohort 3|Patients will be treated with 12mg/kg of TTAC-0001 weekly in every 4 weeks of cycle.
89316324|NCT06264154|Experimental|Fruit-flavored E-cigarettes|Participants randomized to fruit-flavored e-cigarettes will be provided with an e-cigarette device and be instructed to switch from smoking combustible cigarettes to using only the study provided e-cigarette device and fruit-flavored nicotine pods. Participants will be able to choose between blueberry or watermelon-flavored pods. They will receive their supply of nicotine pods in 7-day increments, based on baseline smoking behavior.
89316325|NCT06264154|Active Comparator|Tobacco-flavored E-cigarettes|Participants randomized to tobacco-flavored e-cigarettes will be provided with an e-cigarette device and be instructed to switch from smoking combustible cigarettes to using only the study provided e-cigarette device and tobacco nicotine pods. Participants will receive their supply of nicotine pods in 7-day increments, based on baseline smoking behavior.
89316326|NCT06264154|Active Comparator|Menthol-flavored E-cigarettes|Participants randomized to menthol-flavored e-cigarettes will be provided with an e-cigarette device and be instructed to switch from smoking combustible cigarettes to using only the study provided e-cigarette device and menthol nicotine pods. Participants will receive their supply of nicotine pods in 7-day increments, based on baseline smoking behavior.
89316327|NCT06264141|Active Comparator|Nitric Oxide Releasing Solution|"Nasal spray with nitric oxide releasing solution (NORS) delivered five times per day spaced 1 to 4 hours between each dose while awake.~Maximum volume delivered: 0.56 mL NORS @ 0.11ppm*hrs"
89316328|NCT06264141|Placebo Comparator|Placebo|"Nasal spray with isotonic saline delivered five times per day spaced 1 to 4 hours between each dose while awake.~Maximum volume delivered: 0.56 mL Saline @ 0.9%"
89316329|NCT06264102|Experimental|Intervention group|Physical exercises program
89316330|NCT06264102|No Intervention|Control group|Were advised not to change anything about their current lifestyle, and in particular not to undertake any new structured physical activity.
89316331|NCT06264089|Other|No Arms have been specified for this study|No Arms have been specified for this study
89316332|NCT06264076|Experimental|Single interventional group|Patients that need ligament balancing will receive the procedure using a novel instrument
89316333|NCT06264063|Experimental|experimental group|patients with dystonia were submitted to a neuropsychological evaluation
89316334|NCT06264063|Experimental|control group|healthy patients were submitted to a neuropsychological evaluation
89316335|NCT06264050|Other|Patients in the psychological support group|Patients in neurorehabilitation attending a psychological support group
89316336|NCT06264037||Patients with stroke|Patients with stroke during the hospital neurorehabilitation
89316337|NCT06264037||People with Parkinson's disease|patients with Parkinson's disease the hospital neurorehabilitation
89316338|NCT06264037||Patients with multiple sclerosis|Patients with multiple sclerosis during the hospital neurorehabilitation
89316339|NCT06264037||Patients post operative oncological neuro surgery|Patients after oncological neurosurgical operation during the hospital neurorehabilitation
89316340|NCT06264024|Active Comparator|CXL|Treatment with CXL alone
89316341|NCT06264024|Experimental|CXL and t-PTK|Treatment with t-PTK combined with CXL
89316342|NCT06264011|Experimental|Salaat|The salaat consists of praying the Duha prayer, an optional superogatory prayer that typically occurs in the early morning, to control for differences in timing and duration of prayer. The Duha is completed between the dawn and noon prayers and consists of four cycles of prayer as well as Qur'an recitation and supplication throughout the four positions. The salaat condition includes four cycles with four different positions during each cycle (standing with bowing at a 90-degree angle with both hands covering the knees, standing again briefly with arms at the sides, prostrating with forehead, hands, knees, and feet touching the ground, followed by sitting with knees bent under the torso, prostrating, and sitting again).
89316343|NCT06264011|Sham Comparator|Counting|"The counting condition will include the same physical component as the salaat condition. This will include 4 cycles of movement through the four different positions (i.e., standing, bowing at a 90-degree angle with both hands covering the knees, standing again briefly with arms at the sides, prostrating with forehead, hands, knees, and feet touching the ground, followed by sitting with knees bent under the torso, prostrating, and a final sitting position in cycles two and four. The counting condition will include replacing Qur'anic recitation and subsequent supplications throughout the prayer by counting one one-thousand, two one-thousand, three one-thousand, etc. throughout the duration of time typically required to perform the full salaat."
89316344|NCT06263998|Experimental|Single Ascending dose NCP112 Dose A(0.01%)|NCP112 is administered once at a specified time in 1d.
89316345|NCT06263998|Placebo Comparator|Single Ascending dose NCP112 Dose A(0.01%) Placebo|NCP112 Placebo is administered once at a specified time in 1d.
89316346|NCT06263998|Experimental|Single Ascending dose NCP112 Dose B(0.02%)|NCP112 is administered once at a specified time in 1d.
89316347|NCT06263998|Placebo Comparator|Single Ascending dose NCP112 Dose B(0.02%) Placebo|NCP112 Placebo is administered once at a specified time in 1d.
89316348|NCT06263998|Experimental|Single Ascending dose NCP112 Dose C(0.05%)|NCP112 is administered once at a specified time in 1d.
89316349|NCT06263998|Placebo Comparator|Single Ascending dose NCP112 Dose C(0.05%) Placebo|NCP112 Placebo is administered once at a specified time in 1d.
89316350|NCT06263998|Experimental|Multiple Ascending dose NCP112 Dose A(0.01%)|NCP112 is administered once at a specified time in 1d.
89316351|NCT06263998|Placebo Comparator|Multiple Ascending dose NCP112 Dose A(0.01%) Placebo|NCP112 Placebo is administered once at a specified time in 1d.
89316352|NCT06263998|Experimental|Multiple Ascending dose NCP112 Dose B(0.02%)|NCP112 is administered once at a specified time in 1d.
89316353|NCT06263998|Placebo Comparator|Multiple Ascending dose NCP112 Dose B(0.02%) Placebo|NCP112 Placebo is administered once at a specified time in 1d.
89316354|NCT06263998|Experimental|Multiple Ascending dose NCP112 Dose C(0.05%)|NCP112 is administered once at a specified time in 1d.
89316355|NCT06263998|Placebo Comparator|Multiple Ascending dose NCP112 Dose C(0.05%) Placebo|NCP112 Placebo is administered once at a specified time in 1d.
88814869|NCT02249741|Experimental|Patients with osteoporosis|Treated with Ibandronic acid as per protocol
89316356|NCT06263985|Other|Subjects undergoing a pelvic organ prolapse repair procedure using Axis Dermis biologic mesh|This is a single are which will be composed of subjects with Stage II or greater pelvic organ prolapse who have agreed to undergoing a pelvic organ prolapse repair procedure using Axis Dermis biologic mesh. They will undergo the procedure and be followed for a period of 3 years.
89316357|NCT06263972|Active Comparator|Direct Stimulation of the Primary Motor Cortex (M1) Combined With Aerobic Activity.|low current electrical stimulation to Motor cortex for 3 weeks.
89316358|NCT06263972|Active Comparator|Direct Stimulation the Prefrontal Cortex Combined With Aerobic Activity|with low current electrical stimulation to Prefrontal cortex for 3 weeks.
89316359|NCT06263972|Sham Comparator|Shame Stimulation Combined With Aerobic Activity|Shame low current electrical stimulation to cortex for 3 weeks.
89316360|NCT06263959|Experimental|Cohort 1|Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 1) or placebo for 28 days.
89316361|NCT06263959|Experimental|Cohort 2|Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 2) or placebo for 28 days.
89316362|NCT06263959|Experimental|Cohort 3|Patiants on stable nucleos(t)ide analog (NA) therapy will be randomized 4:1 to receive repeat dose of either GST-HG131 (Dose 1 or 2) or placebo for 12 weeks.
89316363|NCT06263933|Sham Comparator|Control group|Patients are followed in routine care.
89316364|NCT06263933|Experimental|DIPEM group|Patients have 5 session of mutual assistance with a mediator psychologist, during five days, with 1 session per day. Each session lasts 1h30, with 45 min for atelier, 15 min for pause and 30 min about collective discussion.
89316365|NCT06263920||Case (Late-onset epilepsy)|"Observational study - no intervention. Participants with first seizure or new diagnosis of epilepsy, in adulthood.~Inclusion criteria for cases includes:~diagnosis of LOE or first seizure after the age of 18.~diagnosis confirmed or established at a tertiary neurology centre.~sequential cases will be used; in the unlikely event that eligible cases outstrip capacity, an annual cap of the first 150 patients per year per cohort will be used.~Exclusion criteria for cases includes:~another 'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma, vascular or congenital abnormality of likely aetiological significance.~people with migraine or headache syndrome can be included in case group - the presence or absence of a seizure syndrome is mutually exclusive between case and control groups, not the presence or absence of migraine."
89316366|NCT06263920||Control (migraine)|"Inclusion criteria for controls includes:~established diagnosis of migraine.~with or without therapeutic medications with antiepileptic properties.~Exclusion criteria for controls includes:~diagnosis of epilepsy or confirmed seizure.~'lesional' attributable cause for seizures including malignancy, stroke (excluding transient ischaemic attack), hypoxic brain injury, trauma.~However, in both cases and controls, people with dementia, alcohol excess, recreational drug use or pre-existing small vessel disease will be included, as excluding these conditions would bias against the inclusion of the population who may benefit from this research and against the inclusion of patients with high risk of small vessel disease."
89316367|NCT06263829|Experimental|Tappt App|Participants will download and utilize the Tappt app to record adherence to oral medication. For the purposes of this study, adherence for participants in the intervention arm will be measured using a modified medication possession ratio (MPR) measure called medication tag scan ratio (MTSR). MTSR is defined as a percentage of the number of times participants scanned their passive tags versus the total of expected tag scans based on that participant's medication regimen and treatment period.
89316368|NCT06263829|No Intervention|Historical Control|Upon study completion, a retrospective matched control will be established for the intervention group. Historic data for the matched control's adherence, treatment completion, SVR assessment, and SVR rates will be compared to the intervention arm.
89316369|NCT06263803|Other|control group|Participants in the control group will receive classical physiotherapy 5 days a week for 4 weeks (Tens 20 min, ultrasound 5 min, hotpack 20 min).
89316370|NCT06263803|Experimental|Music group|Participants in the music group will be played Pachabel Canon D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes) during the classical physical therapy session, free from external sounds (max 70 dB through headphones).
89316371|NCT06263790|Experimental|Intubation via laryngeal mask|Participants will be required to position the endotracheal tube in the manikin via a laryngeal mask
89316372|NCT06263790|Active Comparator|Intubation via direct laryngoscope|Participants will be required to position the endotracheal tube in the manikin via direct laryngoscopy
89316373|NCT06263777|Experimental|Nurses group|Nurse training program on early detection of disability. It included four main elements, which are: a booklet defining different disabilities; a list of the guidelines for early detection; a guide for family guidance for families of children with disabilities; and a monitoring and follow-up form for cases of children with disabilities.
89316374|NCT06263764|Experimental|Qur'an Arm|"Participants in the intervention group will be asked to listen to a Qur'an recital by Surah Ar-Rahman using an MP3 player twice a day for a minimum of 15 minutes each for 40 days.~The participants will listen to the same Qur'an recital (recited by Freed Ghalib) using the same MP3 player."
89316375|NCT06263764|No Intervention|Control Arm|The control group will not receive any specific intervention and will continue with their usual routine
89316376|NCT06263725|Experimental|Restricted dietary protein|5 week intake of a isocaloric diet restricted in protein
89316377|NCT06263725|Experimental|Habitul diet|5 week intake of habitual, high protein diet
89316378|NCT06263686|Experimental|Pasteurised yoghurt|
89316379|NCT06263686|Experimental|Fresh natural yoghurt|
89316380|NCT06263686|Experimental|Sterilised yoghurt|
89316381|NCT06263673|Experimental|Sitagliptin Group|Subjects will receive sitagliptin for the approximately 4-week treatment period.
89316382|NCT06263673|Experimental|Dapagliflozin Group|Subjects will receive dapagliflozin for the approximately 4-week treatment period.
89316383|NCT06263673|Placebo Comparator|Placebo Group|Subjects will receive placebo for the approximately 4-week treatment period.
89316384|NCT06263647|Experimental|Houston-HVIP treatment group|
89316385|NCT06263647|Active Comparator|Case Manager group|
89316386|NCT06263595||GLP-1 Agonist Group|Intervention: elective surgical patients taking GLP-1 receptor agonists
89316387|NCT06263595||Non GLP-1 Agonist Group|Intervention: elective surgical patients not taking GLP-1 receptor agonists
89316388|NCT06263569||Total hip arthroplasty (THA)|Total hip arthroplasty surgery
89316389|NCT06263569||Non-Total hip arthroplasty (THA)|No total hip arthroplasty surgery performed / control group.
89316390|NCT06263556|Experimental|Pelvic floor exercises and Transcutaneous tibial nerve stimulation|"Patients in this group will receive pelvic floor exercise program as described before and transcutaneous tibial nerve stimulation (TTNS).~The intervention will comprise 12 session of transcutaneous tibial nerve stimulation (Twice a week, for 6 continuous weeks). Each session will last 30 minutes. Two self adhesive surface electrodes will be positioned according to the protocol used by Booth et al and Sonmez et al, with the negative electrode 2 cm behind the medial malleolus, and positive electrode 10 cm proximal to it. Correct positioning will be determined by noting a hallux reaction (plantar flexion of great toe). Stimulation will be delivered at fixed frequency of 20 Hz and pulse width of 200 ms. The intensity level of the stimulation current (range 0-50 mA) will be determined once hallux reaction is observed, according to patient's tolerance."
89316391|NCT06263556|Sham Comparator|Pelvic floor exercises and Sham Stimulation|"Patients in this group will receive pelvic floor exercise program as described before and Sham stimulation.~The intervention will comprise 12 session of sham stimulation. (Twice a week, for 6 continuous weeks) Each session will last 30 minutes. Two self adhesive surface electrodes will be positioned According to the protocol used by Booth et al, with the negative electrode 2 cm behind the lateral malleolus, and positive electrode 10 cm proximal to it, therefore avoiding the posterior tibial nerve. The stimulation current will be reduced to 2 mA once the tingling sensation is obtained and patients will be informed that they may not feel electrical sensation during the session. Stimulation will be delivered at fixed frequency of 20 Hz and pulse width of 200 ms.~If willing, patients in this group will receive TTNS treatment after the study is completed."
89316392|NCT06263543|Experimental|Sacituzumab Govitecan (SG) Infusion|SG will be administered on Days 1 and 8 of continuous 21-day cycles at 10 mg/kg via intravenous (IV) infusion until disease progression or unacceptable toxicity.
89316393|NCT06263530||Standard first line treatment, stages I or II without risk factors|Standard first-line treatment that includes 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and involved site radiotherapy of 20 Gy in early clinical stages I or II without risk factors.
89316394|NCT06263530||Patients < 60 years, stages I or II and 1 risk factor|Patients below 60 years in intermediate clinical stages I or II with at least one risk factor are treated with 2 cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) escalated and 2 cycles of ABVD in PET-4 negative cases. Involved site radiotherapy of 30 Gy is indicated in PET-4 positive patients with intermediate stages after chemotherapy.
89316395|NCT06263530||Patients < 60 years, stages III or IV with MMT and/or EN disease|Patients in advanced stages III or IV and patients in stage IIB with massive mediastinal tumor and/or extranodal disease are treated with 4 or 6 cycles of BEACOPP escalated based on PET-2 negativity or positivity.
89316396|NCT06263530||Elderly patients ≥ 60 years and 1 risk factor|Elderly patients in intermediate stages are treated with 2 cycles of ABVD and 2 cycles of AVD without bleomycin and involved site radiotherapy of 30 Gy.
89316397|NCT06263530||Elderly patients ≥ 60 years, stages III or IV|Elderly patients in advanced stages are treated with 2 cycles of ABVD and 4 cycles of AVD without bleomycin
89316398|NCT06263530||Relapsed patients up to 65 years|The treatment for patients in relapse up to the age of 65 years is two cycles of platinum based salvage chemotherapy: cisplatin, cytarabine and dexamethasone (DHAP) or ifosfamide, carboplatin, etoposide (ICE) followed by high- dose chemotherapy and autologous stem cell transplantation (ASCT).
89316399|NCT06263517|Experimental|Arm 1|Intra articular clodronate 2 mg/2 ml once a week for 4 weeks (total clodronate dose = 8 mg)
89316400|NCT06263517|Experimental|Arm 2|Intra articular clodronate 5 mg/2 ml once a week for 4 weeks (total clodronate dose = 20 mg).
89316401|NCT06263517|Experimental|Arm 3|Intra articular clodronate 10 mg/2 ml once a week for 4 weeks (total clodronate dose = 40 mg)
89316402|NCT06263517|Placebo Comparator|Arm 4|Placebo 2 ml once a week for 4 weeks (total clodronate dose = 0 mg).
89316403|NCT06263478|Experimental|Axatilimab Dose|Axatilimab at the protocol-defined dose.
89316404|NCT06263439||Children with hand, foot and mouth disease or herpangina|Children with hand, foot and mouth disease or herpangina will be proposed to have a throat or buccal swab collected to do the diagnosis of an enterovirus infection.
89316405|NCT06263426|Experimental|HIV D+/R+|People living with HIV who receive kidneys from deceased donors with HIV
89316406|NCT06263426|Experimental|HIV D-/R+|People living with HIV who receive kidneys from deceased donors without HIV
89316407|NCT06263400|Experimental|Psychoeducation|Experimental:Experimental group ın the first meeting with the patients and their caregivers in the experimental group, information about the training was given, information about the patient was obtained, and training days were determined.Structured education and follow-up In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.Structured education and follow-up In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.
89316408|NCT06263400|No Intervention|Control group|The control group continued to receive the routine care
89316409|NCT06263374|Experimental|Physiotherapy with self-rehabilitation including motor imagery|Patients will undergo maxillofacial rehabilitation, comprising a single 30-minute session per week during the first month post-surgery, followed by one session every two weeks for up to three months. In between these sessions, patients will participate in a self-rehabilitation program at home, involving jaw and tongue movements as well as massages, each lasting 5 minutes, three times a day. Compliance with the program will be monitored by the physiotherapist. The program has been standardized across all centers, ensuring consistency in this multicentric study.
89316410|NCT06263374|Sham Comparator|Physiotherapy with self-rehabilitation including control task|Patients allocated to the control group will receive physiotherapy along with self-rehabilitation, incorporating a control task. The delivery of physiotherapy and self-rehabilitation will mirror that of the experimental group. The control task, substituting motor imagery, will involve completing Sudoku or crossword puzzles based on patient preference. (i.e., an equivalent duration to the motor imagery practice of the experimental group). The physiotherapist will ensure adherence to the rehabilitation and intervention protocols.
89316411|NCT06263361||Included patients|Adult patients (>18 years) candidates to stereotactic biopsy for histopathological diagnosis of intra-axial lesions suspected for primary central nervous system lymphoma (PCNSLs).
89316412|NCT06263348|Experimental|Dorzagliatin group|Dorzagliatin tablet (75 mg, BID) treatment for 52 weeks
89316413|NCT06263335|Experimental|Interventional Group (Receiving Mindfulness Based Intervention)|after the young adults have been randomized into interventional and control groups based on high levels of psychological distress, SI and NSSI, n=30 participants from this group would receive the mindfulness based intervention.
89316414|NCT06263335|No Intervention|Control Group (No Intervention)|A wait list control group of n=30 randomized participants from the initial cohort would be in this group and receive no intervention, until the trial is completed.
89316415|NCT06263322|Experimental|ROAMM-EHR|Patients will wear a smartwatch equipped with a smartwatch app before their surgery and for approximately a month after the surgery. Patients will be asked to wear the watch every day when awake. When wearing the smartwatch, patients will be asked questions about their symptoms following surgery and data will be sent to providers electronically and displayed in their EHR portal. Healthcare Providers will use this information along with patient medical history to decide on the next course of action. The study does not provide specific instructions about how to care for the patient. Those decisions are made by the provider team and their clinical judgement.
89316416|NCT06263322|Active Comparator|Active Comparison|The active comparison patients will wear and respond to questions on the smartwatch. However, the information will not be viewable by their doctor and medical team. All standard of care procedures will remain.
89316417|NCT06263309||Good Functional Score|Harris hip score > 80
89316418|NCT06263309||Bad Functional Score|Harris Hip score < 80
89316419|NCT06263283|No Intervention|Control Group|Standard care according to the modalities of each center (concomitant treatment prescription, psychological support, physiotherapy or dietetic are supports that can be proposed if needed)
89316420|NCT06263283|Experimental|Experimental Group|"Standard support with Daily realization of a session of Kine-Yoga supervised by a physiotherapist at J2, J3 and J4 of uterovaginal brachytherapy.~Possibility for the patient to practice this session in autonomy (using PEP tools given to the Shared Educational Check-up) according to her wish during the duration of the treatment and up to 15 days post treatment."
89316421|NCT06263270|Active Comparator|Active Treatment Arm (CYT-108)|One intra articular (IA) injection of 5mL at 5mg/mL into one target knee with mild to moderate OA for total of 25mg CYT-108 on Days 1 and 85 (2 injections [50 mg] in total).
89316422|NCT06263270|Placebo Comparator|Placebo Control Arm (Phosphate Buffered Saline)|Equivalent volume 5mL of phosphate buffer saline, PBS (equal volume to the active treatment arm injection) at the same time intervals as the treatment arm.
89316423|NCT06263257|Experimental|Intervention Group|For the intervention group, the first measurement (afternoon of the day before surgery) will include State-Trait Anxiety Inventory and General Comfort Questionaire, the second measurement (Postoperative Day 5 - discharge day) will include State Anxiety Inventory and General Comfort Questionaire. The sessions of the Mandala Art Therapy training program for the intervention group will be conducted as follows: Session 1 on Postoperative Day 5 - discharge day (after the scales), Session 2 on 1st Control (1 week after surgery), Session 3 on 2nd Control (2 weeks after surgery), and the third measurement at 3rd Control (1 month after surgery).
89316424|NCT06263257|No Intervention|Control Group|"After obtaining consent from eligible participants within the scope of the study, the first measurement (STAI and GCQ) will be conducted on the afternoon of the preoperative day. Participants in this group will not be aware of their group assignment. The second measurement will be taken on postoperative day 5, the day of discharge (SAI and GCQ).~The third measurement will be carried out during the participant's 3rd check-up after discharge (one month after surgery) for both STAI and GCQ. The intervention group's program will be shared with the control group participants on a voluntary basis after their discharge."
89316425|NCT06263231|Experimental|INT230-6 Monotherapy|INT230-6 administered intratumorally. Participants will be dosed every 2 weeks (± 2 days) for up to a total of 5-cycles (e.g., Days 1, 15, 29, 43 and 57). Once the participant has completed the treatment phase, they will continue into a 22-month maintenance phase, where investigators may inject new lesions or previously injected lesions with up to 175 mL every 12 weeks (Q12W) ± 14 days. Dose volume in a session is dependent on the participants presenting tumor burden.
89316426|NCT06263231|Active Comparator|US Standard of Care|"Participants in this arm may receive any of the following depending on Soft tissue sarcoma (STS) subtype and PI preference:~Pazopanib: 800 mg PO every day until clinical deterioration~Trabectedin: 1.5 mg/m2 body surface area as 24-hour IV infusion every 3 weeks until clinical deterioration~Eribulin: Non- European Union (EU) sites: 1.4 mg/m2 eribulin mesylate body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration EU sites: 1.23 mg/m2 (free base) body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration"
88814870|NCT03033836|Experimental|single arm|ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
89316427|NCT06263205|Experimental|Non-Dressing Group|Participants in this group will receive standard wound disinfection and initial postoperative care with dressings applied immediately after their gastrointestinal tumor surgery. However, 48 hours post-surgery, these dressings will be removed and the wounds will be left exposed without any further dressing. This arm aims to evaluate the outcomes of wound healing, pain levels, and healthcare costs when the surgical wound is kept open postoperatively, in contrast to traditional dressing methods.
89316428|NCT06263205|Active Comparator|Dressing Group|Participants in this group will receive standard postoperative care, which includes regular wound dressings. Their surgical wounds will be covered with dressings, which will be changed every 48-72 hours following the surgery. This group serves as a comparator to assess the effectiveness and safety of the non-dressing approach in terms of wound healing, pain management, and associated healthcare costs.
89316429|NCT06263192||AMH < 1.1 ng/ml|
89316430|NCT06263192||AMH > 1.1 ng/ml|
89316431|NCT06263179|Experimental|Target Heartrate Aerobic Exercise (THRAE)|Participants will be asked to complete the Buffalo Concussion Treadmill Test (BCTT), a safe graded exercise test that is used to identify concussion-related exertion intolerance. Participants will wear a heart rate (HR) monitor for the collection of continuous HR data. The test is stopped when a participant's symptoms increase subjectively by an intensity of 3 points or more from the pre-exercise value on a scale from 0-10, or they report being physically exhausted. Their HR at the time of test termination constitutes the HR threshold (HRt). An individualized THRAE program will be prescribed based on 80% of the HRt on the BCTT. Participants will be given a Polar HR monitor to wear while performing their THRAE prescription, which will be performed at home for 20 minutes, 4-5 days per week, for 6 weeks or until medically cleared from their concussion.
89316432|NCT06263166|No Intervention|Control group|No intervention other than usual care
89316433|NCT06263166|Experimental|Intervention group|Received stress ball intervention and usual care
89316434|NCT06263140||1. Patients diagnosed with drug-induced severe non-immediate cutaneous reactions|Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptom (DRESS), acute generalized exanthematous pustulosis (AGEP)
89316435|NCT06263140||2. Patients diagnosed with drug-induced non-severe non-immediate cutaneous reactions|Maculopapular exanthem (MPE), fixed drug eruption (FDE)
89316436|NCT06263140||3. Subjects who tolerated drugs potentially causing severe non-immediate cutaneous reactions|Studied drug groups matched patients in group 1
89316437|NCT06263140||4. Subjects who tolerated drugs potentially causing non-severe non-immediate cutaneous reactions|Studied drug groups matched patients in group 2
89316438|NCT06263127|Experimental|OS group|The participants receive the prefeeding oral stimulation intervention twice a day,10 days.
89316439|NCT06263127|Experimental|OS+ IM group|The participants receive both prefeeding oral stimulation and infant massage once a day, in random order, 10 days.
89316440|NCT06263075||Infants undergoing craniosynostosis corrective surgery|Infants aged 3 to 8 months with craniosynostosis admitted to the operating room of Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria (AOU) of Bologna Polyclinic Sant'Orsola to undergo corrective surgery.
89316441|NCT06263062|Experimental|Experimental group|"routine care after a colopscopy procedure Mindfulness-Based Coping Programme in addition to routine care Prepared in accordance with the MBSR programme. Applied online with Zoom programme Teams in groups of 6 people 6 sessions in 2 weeks"
89316442|NCT06263062|No Intervention|Control group|routine care after a colopscopy procedure Routine care will be provided by the nurse training handbook created by the researcher
89316443|NCT06263049|Active Comparator|control group|(TURP group underwent traditional TURP
89316444|NCT06263049|Active Comparator|observation|TURP with preserved urethral mucosa at the prostatic apex
89316445|NCT06263036||Men|Cadavra
89316446|NCT06263036||Women|Cadavra
89316447|NCT06263023||Hard-to-Place (HTP) Donor Kidneys|The study will be open to all eligible HTP kidneys from male and female donors at all participating Organ Procurement Organization (OPO) study sites. Consent for both organ donation for transplant and medical research will be obtained from the legally authorized party (LAP) by the OPO Coordinator using industry standard consent procedures and documents.
89316448|NCT06262958|Active Comparator|Treatment as usual|Clients are receiving normal adolescent psychiatric care, mostly psychotherapy, medications, or both.
89316449|NCT06262958|Experimental|e-form of ASSIST alcohol and substance use mini-intervention|Clients are receiving normal adolescent psychiatric care, mostly psychotherapy, medications, or both. In addition to that, they will receive a mini-intervention for substance and alcohol use.
89316450|NCT06262945||Group 1|platelet rich fibrin placed into the socket of the extraciton tooth + Augmentin 1gr tablet prescribed 2 times a day
89316451|NCT06262945||Group 2|platelet rich fibrin placed in to the socket of the extractraciton tooth combined with low laser treatment extraorally to the extraction area for three days within surgery day + Augmentin 1gr tablet prescribed 2 times a day
89316452|NCT06262945||Group 3|Low Laser Treatment was applied to the extraorally to the extraction area for three days within surgery day + Augmentin 1gr tablet prescribed 2 times a day
89316453|NCT06262945||Control group.|Tradional osteomy was made. + Augmentin 1gr tablet prescribed 2 times a day
89316454|NCT06262893|Active Comparator|Interscalene block in shoulder arthroscopy|
89316455|NCT06262893|Active Comparator|Combined Supraclavicular block and suprascapular block in shoulder arthroscopy|
89316456|NCT06262854|Experimental|Calcium-sulphate granules with tobramicina+vancomicina|
89316457|NCT06262854|Sham Comparator|Calcium-sulphate granules without antibioitcs|
89316458|NCT06262841|Experimental|Piezosurgery group|"In the experimental group, a piezosurgery device was used to remove the bone surrounding the impacted third molar.~Intervention: Device: Piezosurgery"
89316459|NCT06262841|Active Comparator|Conventional group|"In the control group, conventional burs were used to remove the bone surrounding the impacted third molar.~Intervention: Device: Conventional burs"
89316460|NCT06262815||Patients with nasogastric tube treatment|Adult patients with diagnosed small bowel obstruction in the Emergency Department for a nasogastric tube was placed
88806543|NCT05288036|Active Comparator|Control Group|This group was created to determine the amount of self-healing of the disease in the process. The approach was taken in a way that did not affect the outcome measures.
89316461|NCT06262815||Patients without nasogastric tube treatment|Adult patients with diagnosed small bowel obstruction in the Emergency Department for no nasogastric tube was placed
89316462|NCT06262815||Patients living with frailty|Subgroup of patients, with small bowel obstruction in the Emergency Department over 65 years of age with a clinical frailty score of &gt;4.
89316463|NCT06262815||Patients not living with frailty|Subgroup of patients, with small bowel obstruction in the Emergency Department over 65 years of age with a clinical frailty score of &lt;5.
89316464|NCT06262802|Experimental|Intervention|
89316465|NCT06262802|Active Comparator|Control|
89316466|NCT06262789|Experimental|"Experimental arm with return-to-work after cancer consultation"|
89316467|NCT06262789|No Intervention|"Standard arm without with return-to-work after cancer consultation"|Patient are treated according to usual care, according to local practice.
89316468|NCT06262776|Experimental|Vaccination group|All participants will receive the assigned intervention, a 2-dose course of Zoster recombinant adjuvanted vaccine. Study participants will include kidney transplant recipients receiving specific immunosuppressive medications, and non-immunosuppressed household cohabitants, with comparisons made in magnitude of vaccine response.
89316469|NCT06262763|Experimental|Group (A)|Laser with traditional exercises
89316470|NCT06262763|Placebo Comparator|Group (B)|Placebo LASER with traditional exercises
89316471|NCT06262711|Experimental|Vitamin C, then Placebo|Participants will first consume one 500mg vitamin C capsule daily for 6 weeks. After a 4-week washout period, participants will crossover and consume one placebo capsule daily for 6 weeks.
89316472|NCT06262711|Experimental|Placebo, then Vitamin C|Participants will first consume one placebo capsule daily for 6 weeks. After a 4-week washout period, participants will crossover and consume one 500mg vitamin C capsule daily for 6 weeks.
89316473|NCT06262698|Experimental|experimental|"Based on the SIM model, the intervention group will receive 6 sessions of training (each session lasting 40 minutes). The training sessions will be as follows:~st Session: Traditional/Alternative medical systems~nd Session: Mental-physical interventions~rd Session: Biologically based treatments~th Session: Manipulative and physical-based therapies~th Session: Energy therapies~th Session: Training on proper prescription drug use"
89316474|NCT06262698|Other|Control|Nursing students will receive their regular semester courses; no additional intervention will be implemented.
89316475|NCT06262685|Experimental|Experimental Group|Patients in this Experimental Group will receive any of the statins authorized in Spain for lipid-lowering, both for primary and secondary prevention. Subjects in the Experimental Group will be administered the specific type and dosage of statins recommended by the Clinical Pharmacogenetics Consortium's genotype guidelines, utilizing the patient's pharmacogenetic information and characteristics
89316476|NCT06262685|Active Comparator|Control Group|Patients in this Control Group will receive any of the authorized statins in Spain for lipid-lowering, whether for primary or secondary prevention. They will be administered statins according to clinical practice and the drug's product labeling, without exceeding the already authorized dosages
89316477|NCT06262646|Experimental|FACT Group|Parents will receive 4-6 FACT consultation sessions, one weekly session, 45-60 mins per session. These sessions will be one-on-one, conducted face-to-face or via video conferencing.
89316478|NCT06262646|Active Comparator|Control Group|Parents will receive standard parenting advice about positive parenting tips recommended by the Child Assessment Services under the Department of Health.
89316479|NCT06262620|Experimental|EBUS-TBNA|Participants would undertake EBUS-TBNA.
89316480|NCT06262620|Experimental|EBUS-TBCB|Participants would undertake EBUS-TBCB.
89316481|NCT06262620|Experimental|EBUS-TBFB|Participants would undertake EBUS-TBFB.
89316482|NCT06262594|Placebo Comparator|Placebo First|0mg
89316483|NCT06262594|Active Comparator|Investigational Product First|10mg qhs
89316484|NCT06262581|Experimental|dMMR/MSI-H stage I-III CRC patients|Patients will accept 4 dose of Tisleizumab(BGB-A317) treatment after enrollment and the assessment of the therapeutic effect by clinicians would be finished after that. Once the patients has been qualified as cCR , they could be exempted for surgery and continued the watch and wait management. If the patient has been assessed as able to R0 surgery , then they would received surgery. Otherwise ,they would be excluded from the trial.
89316485|NCT06262555|Experimental|Arm 1|Photophrin 2mg/kg 48 hours before treatment. Navigational bronchoscope guide the catheter into the tumor and adjacent to the tumor and give lipiodol for light diffusion and give light 200J/cm from different angle
89316486|NCT06262542|Experimental|Experimental group (moxibustion and Chinese herbal medicine group)|
89316487|NCT06262542|Placebo Comparator|Control group (sham moxibustion and placebo herbal medicine group)|
89316488|NCT06262529|Experimental|Acute ischemic stroke|
89316489|NCT06262516|Experimental|Nephroureterectomy With Lymph Node Dissection|Participants will undergo nephroureterectomy for UTUC and will receive LND.
89316490|NCT06262516|Active Comparator|Nephroureterectomy Without Lymph Node Dissection|Participants will undergo nephroureterectomy for UTUC and will not receive LND.
89316491|NCT06262490|Active Comparator|Control group A|They will receive traditional ultrasound therapy for six weeks
89316492|NCT06262490|Experimental|Study group B|They will receive the same traditional ultrasound therapy in addition to pelvic floor rehabilitation for six weeks
89316493|NCT06262477|Experimental|BIIB800|Participants will receive a single dose of BIIB800 via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.
89316494|NCT06262477|Experimental|Actemra|Participants will receive a single dose of Actemra via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.
89316495|NCT06262438|Experimental|Quizartinib|Quizartinib will be administered for 14 days following the completion of standard of care chemotherapy for up to 3-5 cycles of induction and consolidation. After high dose chemotherapy or allo-Stem Cell Transplantation (allo-SCT), patients will receive continuation treatment with quizartinib for six 28-day courses
88806544|NCT05287880||Non-N0 stage|Patients with malignant lymph nodes.
88806545|NCT05287880||N0 stage|Patients without malignant lymph nodes.
89316496|NCT06262386|Experimental|Patient at risk for disease relapse after surgery|"we utilized a relapse prediction model that combined perioperative variation trends of circulating tumor cells and pathologic characteristics that were collated with relapse~circulating tumor cell variation trend: difference between the CTC count on post-operation day 3 and day 1; difference between the CTC count on post-operation day 3 and post-operation~pathologic staging 0-1a/ 1b-4~patient with high relapse for relapse~Adjuvant was recommended as NCCN guidelines recommended"
89316497|NCT06262321|Experimental|Prophylactic Palliative Radiotherapy|Prophylactic Palliative Radiotherapy
89316498|NCT06262308|Experimental|Psychological intervention|Women will be given psychological intervention
89316499|NCT06262295||Implantation of the pacemaker without lead AVEIR VR LP|
89316500|NCT06262282||People with cystic fibrosis who are receiving phage treatment for NTM.|People with cystic fibrosis who have identified at least one phage effective against their NTM infection and are receiving treatment with the phage. These subjects will remain on guideline based NTM antibiotic treatment and their standard CF care. They will receive therapeutic phage twice daily for 1 year.
89316501|NCT06262282||People with cystic fibrosis who are not receiving phage treatment for NTM.|People with cystic fibrosis who have not identified any phage effective against their NTM infection and are not receiving phage treatment. These subjects will continue with guideline based NTM antibiotic treatment for their NTM disease and standard CF care.
89316502|NCT06261710|Experimental|Sonography Only|The use of ultrasound parameters to asses the progress of labour from admission to delivery. Namely, Angle of Progression, Head Perineum Distance, Midline Angle and Cervix Dilatation at 3-4 hour intervals until delivery.
89316503|NCT06261710|No Intervention|Traditional|The traditional use of internal vaginal examination to assess cervix dilatation, fetal head position, station and orientation within the pelvis during the course of labour as routinely performed every 3-4 hours in labour and until delivery.
89316504|NCT06261541|Experimental|Gait training with exoskeleton|Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.
89316505|NCT06261242|Experimental|Intervention|Tripod-Fix will be used to treat osteoporotic vertebral compression fractures.
89316506|NCT06261008|No Intervention|Standard Care|An automated noninteractive short message service (SMS) text reminder, used by the Program as standard care (SC), is delivered to participants who are due for repeat FIT.
89316507|NCT06261008|Experimental|Telehealth Intervention group|Subjects randomized to the Telehealth Intervention (TI) group will receive the SC as well as an interactive TI with interactive health education messages via a WhatsApp-based chatbot on the repeat FIT due date. All subjects will be followed up on WhatsApp at 3 months after their repeat FIT due date and asked about their repeat FIT status.
89316508|NCT06260072|Active Comparator|Active study product|400 mg of Magnesium Oxide and 400 mg Riboflavin in capsule formation
89316509|NCT06260072|Placebo Comparator|Placebo study product|Inert placebo in capsule formation
89316510|NCT06259851|Experimental|rTMS-DBT group|Patients receiving combined DBT and active prefrontal rTMS treatment
89316511|NCT06259851|Active Comparator|Sham-DBT group|Patients receiving combined DBT and sham rTMS treatment
89316512|NCT06259851|Active Comparator|rTMS-only group|Patients receiving only active prefrontal rTMS treatment
89316513|NCT06259851|Sham Comparator|sham-only group|Patients receiving only sham rTMS treatment
89316514|NCT06259747|Experimental|acutaping and traditional medical treatment|received acutaping in addition to traditional medical treatment (Doxylamine and Pyridoxine)
89316515|NCT06259747|Experimental|traditional medical treatment only|received traditional medical treatment only (Doxylamine and Pyridoxine
89316516|NCT06259500||anorexia nervosa|
89316517|NCT06259500||healthy controls|
89316518|NCT06259084|Experimental|Measurement|Intrauterine biomarker will be measured twice in all enrolled patients during the frozen embryo transfer cycle: on the day before embryo transfer and on the day of embryo transfer.
89316519|NCT06258525|Experimental|Single Arm|
89316520|NCT06258356|Experimental|patients receiving Remimazolam|
89316521|NCT06258356|Placebo Comparator|patients without Remimazolam|
89316522|NCT06258005||PocDoc testing of primary care patients|There are significant numbers of patients in primary care who should be given annual lipid checks who are not receiving them. PocDoc is a digital rapid 5-marker lipid panel that uses a smartphone as a diagnostic reader. PocDoc tests will be offered to patients overdue their annual lipid check either in surgery, in the community or in their own home.
89316523|NCT06258005||Pocdoc testing in the community|Providing lipid testing in community settings such as in pharmacy may offer a more attractive solution to consumers. This hypothesis will be tested by offering PocDoc lipid tests in a community setting.
89316524|NCT06258005||PocDoc testing in workplaces|Providing lipid testing as part of a health wellness screen in employees workplaces in may offer an attractive solution to consumers needing their lipid levels check. This hypothesis will be tested by offering PocDoc lipid tests as part of corporate wellness screens.
89316525|NCT06257875|Experimental|Induction Group 1|Participants will receive Dose 1 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction. Adalimumab placebo will be utilized to maintain the blind.
89316526|NCT06257875|Experimental|Induction Group 2|Participants will receive Dose 2 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind.
89316527|NCT06257875|Experimental|Induction Group 3|Participants will receive adalimumab per label throughout induction. Lutikizumab placebo will be utilized to maintain the blind.
89316528|NCT06257875|Experimental|Maintenance Group 1|Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Adalimumab placebo will be utilized to maintain the blind.
89316529|NCT06257875|Experimental|Maintenance Group 2|Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind.
89316530|NCT06257875|Experimental|Maintenance Adalimumab|Participants who respond to adalimumab induction group 3 will continue to receive adalimumab per label in the maintenance period. Lutikizumab placebo will be utilized to maintain the blind.
89316531|NCT06257875|Experimental|Maintenance Non-Responders|Participants who do not respond to study drug at the end of induction period will receive open label SC lutikizumab in the maintenance period.
89316532|NCT06257251||Breast implant capsulectomy|Patients admitted and operated at CHU-Brugmann hospital for surgical revision of their breast implants.
89316533|NCT06256601|Experimental|Theracal (calcium silicate)|"TheraCal LC is a light-cured resin-modified calcium silicate pulp protectant/liner designed to perform as a barrier and to protect the dental pulpal complex. It contains; resin bis-phenyl glycidyl methacrylate (BisGMA) & polyethylene glycol dimethacrylate (PEGD), modified calcium silicated with CaO, calcium silicate particles (type III Portland cement), Sr glass, fumed silica, barium sulphate, barium zirconate.~After caries removal, TheraCal is applied directly to the cavity floor in incremental layers. The layer is not to exceed 1 mm in depth. Each layer polymerized for 20 seconds."
89316534|NCT06256601|Active Comparator|Dycal (calcium hydroxide)|"Dycal,Calcium Hydroxide Liner is a two-component, rigid-setting, self-curing material designed for use in direct and indirect pulp capping and as a protective liner under dental adhesives, varnishes, filling materials, cements, and other base materials. It will not inhibit the polymerization of acrylic and composite restorations. Dycal, a two-paste system made of a base paste (1,3-butylene glycol disalicylate, zinc oxide, calcium phosphate, calcium tungstate, iron oxide pigments) and a catalyst paste (calcium hydroxide, N-ethyl-o/p-toluene sulphonamide, zinc oxide, titanium oxide, zinc stearate, iron oxide pigments) is prepared following the manufacturer's instructions by mixing equal amounts of catalyst paste and base paste.~After caries removal, Dycal is applied directly to the cavity floor, material thickness should be approximately 0.8mm-1mm. The mixed material will set in approximately 2-3 minutes."
89316535|NCT06255626|Experimental|1-CD40.RBDv non adjuvanted or mRNA vaccine (5:1 ratio)|Low dose (LD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio). If randomized to receive LD CD40.RBDv vaccine non adjuvanted in part 1, the subject will be randomised a second time to receive LD CD40.RBDv vaccine non adjuvanted (1:1) in part 2.
89316536|NCT06255626|Experimental|2-CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio)|LD CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive LD CD40.RBDv vaccine adjuvanted in part 1, the subject will be randomised a second time to receive LD CD40.RBDv vaccine adjuvanted (1:1) in part 2.
89316537|NCT06255626|Experimental|3-High dose (HD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio)|High dose (HD) CD40.RBDv vaccine non adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive HD CD40.RBDv vaccine non adjuvanted in part 1, the subject will be randomised a second time to receive HD CD40.RBDv vaccine non adjuvanted (1:1) in part 2.
89316538|NCT06255626|Experimental|4-High dose (HD) CD40.RBDv vaccine adjuvanted or mRNA vaccine|HD CD40.RBDv vaccine adjuvanted or mRNA vaccine (5:1 ratio) If randomized to receive HD CD40.RBDv vaccine adjuvanted in part 1, the subject will be randomised a second time to receive HD CD40.RBDv vaccine adjuvanted (1:1) in part 2.
89316539|NCT06255197||Patients with surgically resected lung cancer|Patients who were diagnosed with lung cancer and received surgical resection in participating medical centers during the designed study period.
89316540|NCT06254885|Experimental|Sub-crestal|Implants will be placed 1mm under the bone crest level
89316541|NCT06254885|Active Comparator|Equi-crestal|Implants will be placed at the bone crest level
89316542|NCT06250790||Assigned to Best Medical Therapy (BMT) alone|Patients who have undergone successful lower extremity revascularization and are assigned to BMT alone within 14 days following revascularization.
89316543|NCT06250790||Assigned to Best Medical Therapy (BMT) + coronary CT angiography + CT-FFRct analysis|Patients who have undergone successful lower extremity revascularization and are assigned to BMT plus coronary CT angiography (which must be completed within 14 days of randomization) and FFRct analysis to determine the functional significance of coronary lesions identified on the CT scan.
89316544|NCT06249880||Normative|40 neurotypical pediatric subjects
89316545|NCT06249113|Placebo Comparator|NaCl 0.9% continous intravenous on tumor craniotomy surgery|NaCl 0.9% continous intravenous on general anesthesia during tumor craniotomy surgery
89316546|NCT06249113|Active Comparator|Adjuvant lidocaine continous intravenous on tumor craniotomy surgery|Adjuvant lidocaine continous intravenous on general anesthesia during tumor craniotomy surgery
89316547|NCT06247475||Medical professionals|Attending physicians of National Taiwan University Hospital
89316548|NCT06247475||Healthcare-related professionals|Medical Radiation Technologist of National Taiwan University Hospital
89316549|NCT06247475||Medical students|Medical students of National Taiwan University College of Medicine who have passed the first stage of Taiwan Medical Licencing Exam.
89316550|NCT06247475||General public|Volunteers from Taiwan Emergency Medical Technician Association
89316551|NCT06244745|Experimental|Study group: Oral administration of letrozole|Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture. day for 5 days starting the night of the follicular puncture.
89316552|NCT06244745|No Intervention|Control group: No specific treatment of letrozole|No specific treatment with letrozol
89316553|NCT06232707|Experimental|Arm A: Alnuctamab|
89316554|NCT06232707|Active Comparator|Arm B: Standard of Care Regimens|
89316555|NCT06228469||Women diagnosed with cytolytic vaginosis|Women presenting to an outpatient clinic with vaginitis symptoms and diagnosed with cytolytic vaginosis.
89316556|NCT06225479|Active Comparator|Control Arm|"Participants in this study arm will receive a remote health education program which consists of twice-monthly Successful Aging newsletters and phone calls to reinforce and discuss topics in each newsletter."
89316557|NCT06225479|Experimental|Exercise Arm|Participants in this study arm will receive an individualized 12-week exercise intervention plus a remote health education program.
89316558|NCT06224712|Experimental|Arogya Sangama Intervention|"The villages in the service area of both the intervention and control PHC-HWCs will be selected randomly, weighted by population size (PPS). There are two different population groups that are being examined to get a comprehensive picture of primary health services.~Group 1: To assess the impact of the intervention in improving the coverage and utilisation of antenatal and post-natal services, a cross-sectional sample of 1680 women, 840 in each arm, in the age group of 18-49 years who delivered in the last 12 months will be interviewed in the baseline and similarly in the endline.~Group 2: To estimate the effect of the intervention on improving the access to screening and management of NCDs among diabetic and hypertensives, a cross-sectional sample of 200 persons in the age group of 30 years and above from each arm will be interviewed in the baseline and similarly in the endline. Hence in each round the total sample will be 400."
89316559|NCT06224712|No Intervention|Control|Same inclusion criteria as above, without Arogya Sangama intervention.
89316560|NCT06216288|Active Comparator|repeated back extension exercise (McKenzie)|Repeated back extension exercise as described by McKenzie in prone position was performed of three sets of ten repetitions with one minute rest between the sets. The patient was asked to reach the maximum extension possible in all attempts and maintain this position for one second. The intervention was done 3 times per week for 6 weeks.
89316561|NCT06216288|Experimental|Combined mechanical lumbar traction and repeated back extension exercise (McKenzie)|Participants allocated to mechanical lumbar traction received the McKenzie approach described above in combination with mechanical lumbar traction. The traction was applied using a 3D ActiveTrac table which is a motorized split table. Participants were placed in prone position and static traction was applied for 15 minutes at an intensity of 40% to 60% of the participant's body weight. At the end of traction intervention, participants continued with the McKenzie repeated back extension exercise intervention. The intervention was done 3 times per week for 6 weeks.
89316562|NCT06215274||People in the stage of preclinical Alzheimer's disease|Observe the cognitive leisure activity levels, cognitive function, and MRI characteristics in patients in the preclinical stage of Alzheimer's Disease
89316563|NCT06208423|Active Comparator|GPT-4|Group will be given access to GPT-4
89316564|NCT06208423|No Intervention|Usual Resources|Group will not be given access to GPT-4 but will be encouraged to use any resources they wish besides large language models (UpToDate, Dynamed, google, etc).
89316565|NCT06206629||ALS patients|Patients with ALS (Awaji criteria)
89316566|NCT06206629||Non-ALS patients|Patients referred to the neurophysiology unit for a suspicion of ALS du to motor weakness, but in whom the diagnosis is ruled out.
89316567|NCT06206629||Healthy volunteers|Healthy volunteers who will undergo a blink reflex evaluation on ENMG.
89316568|NCT06203613|Experimental|patients with gastric cancer|Subjects were recruited from the Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
89316569|NCT06203613|Experimental|patients with pancreatic cancer|Subjects were recruited from the Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
89316570|NCT06197659|Active Comparator|Liberal Fluid Group|Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.
89316571|NCT06197659|Sham Comparator|Restrictive Fluid Group|Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
89316572|NCT06189183|Experimental|Adjuvant Hypofractionation Radiotherapy|Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
89316573|NCT06188793|Experimental|Virtual reality-directed BGBT|
89316574|NCT06186778|Active Comparator|conventional colonoscopy group|It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
89316575|NCT06186778|Experimental|secondary colonoscopy group|After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
89316576|NCT06182423|Experimental|STEPS-CI Intervention Group|Participants will engage in a behavioral intervention for chronic pain self-management that includes watching brief educational videos on a website and weekly sessions with a community health worker.
89316577|NCT06182423|No Intervention|STEPS-CI Control Group|Members of the control group will not receive the STEPS-CI intervention. After completing the 8-week follow-up telephone survey, control group members will be invited to take part in a virtual workshop covering key STEPS-CI content and will receive program materials.
89316578|NCT06177483|Active Comparator|95% curcumin extract powder|1,265 mg of 95% curcumin extract (minimum 1,200 mg of curcuminoids) in three #0 vegetarian capsules as a single oral dose
89316579|NCT06177483|Experimental|curQ+ curcumin formulation|2,860 mg of curQ+® containing a total of 400 mg of curcuminoids in six #0 vegetarian capsules as a single oral dose
89316580|NCT06154629|Experimental|Botanical ingredient|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
89316581|NCT06154629|Placebo Comparator|Control Group|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
89316582|NCT06154616|Placebo Comparator|Control|Subjects will consume 250 ml of milk half an hour before bedtime.
89316583|NCT06154616|Experimental|Ashw 250|Subjects will consume 250 ml of milk half an hour before bedtime.
89316584|NCT06154616|Experimental|Ashw 250 + TRP|Subjects will consume 250 ml of milk half an hour before bedtime.
89316585|NCT06154616|Experimental|Ashw 600|Subjects will consume 250 ml of milk half an hour before bedtime.
89316586|NCT06148220|Experimental|patients with renal cancer|Intravenous injection of 3.7 MBq [0.1 mCi]/kg of [18F]RCCB6 or [68Ga]Ga-NOTA-RCCB6 in a single dose
89316587|NCT06148220|Experimental|patients with lymphoma|Intravenous injection of 3.7 MBq [0.1 mCi]/kg of [18F]RCCB6 or [68Ga]Ga-NOTA-RCCB6 in a single dose
89316588|NCT06148155|Experimental|patients with primary and/or metastatic hepatocellular carcinoma (HCC)|The diagnosis of HCC is established by surgery or biopsy pathology.
89316589|NCT06138509||Patients|"Patients with albinism aged 2 to 17 years old and followed in the MAGEC-Necker reference center (reference center for rare diseases of the skin and mucous membranes of genetic origin), during the inclusion period.~During an initial or a follow-up consultation for patients with albinism, an additional volume of blood will be drawn during a blood sample drawn as part of routine care."
89316590|NCT06138509||Control patients|"Control patients are patients who were seen at Necker-Enfants Malades Hospital during the inclusion period, in the emergency and surgical departments, and whose care required a blood test analyzed in the Necker-Enfants Malades Hospital hematology laboratory.~These patients will be selected on their age (2 to 17 years old), and must have a normal complete blood count and CRP. Leftover blood not used by the hospital hematology laboratory will be used for study analyses."
89316591|NCT06137690||Group A|the elderly group , the age ≥ 60 years
89316592|NCT06137690||Group B|the non-elderly group , the age < 60 years
89316593|NCT06133439|No Intervention|Phase 1|Usual care and planning period.
89316594|NCT06133439|Other|Phase 2|"Implementation period.~Clinics are randomized into clusters"
89316595|NCT06133439|Other|Phase 3|Maintenance period.
89316596|NCT06130826|Experimental|Treatment (SBRT, M5A-IL2 ICK)|Patients undergo SOC SBRT over 3 fractions on days 1, 3, and 5, followed by M5A-ICK SC on days 8, 9, and 10 once daily for a single cycle on study. Patients undergo CT or PET/CT as well as blood sample collection throughout the trial. Patients may undergo magnetic resonance imaging or bone scan as clinically indicated on the trial. Additionally, patients may optionally undergo tissue biopsy during screening and on study.
89316597|NCT06129773|Experimental|anti biotic coated group|
89316598|NCT06129773|No Intervention|non coated group|
89316599|NCT06128070|Experimental|Prevention (Ruxolitinib, tacrolimus, methotrexate)|Patients receive ruxolitinib PO BID from day -1 to day +100, tacrolimus IV on day -1, and methotrexate IV on days +1, +3, +6, and +11, and undergo HCT on day 0. Patients also undergo chest CT and ECHO/MUGA at screening and undergo collection of blood samples throughout the trial.
89316600|NCT06125691|Experimental|Cohort 1 of ARCT-2138, younger adults|"Dose Level 1 of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
89316601|NCT06125691|Experimental|Cohort 2 of ARCT-2138, younger adults|"Dose Level 2 of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
89316602|NCT06125691|Experimental|Cohort 3 of ARCT-2138, younger adults|"Dose Level 3 of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
89316603|NCT06125691|Experimental|Cohort 4 of ARCT-2138, younger adults|"Dose Level 4 of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
89316604|NCT06125691|Experimental|Low Dose, younger and older adults|"Low dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
89316605|NCT06125691|Experimental|Medium Dose, younger and older adults|"Medium dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
89316606|NCT06125691|Experimental|High Dose, younger and older adults|"High dose level of ARCT-2138 administered through intramuscular injection in the deltoid muscle.~Interventions:~Investigational Vaccine: ARCT-2138"
89316607|NCT06125691|Active Comparator|Control Dose, younger adults|"Licensed Quadrivalent Vaccine administered through intramuscular injection in the deltoid muscle.~Interventions:~Control Vaccine: Licensed Quadrivalent Vaccine for younger adults"
89316608|NCT06125691|Active Comparator|Control Dose, older adults|"Licensed Quadrivalent Vaccine administered through intramuscular injection in the deltoid muscle.~Interventions:~Control Vaccine: Licensed Quadrivalent Vaccine for older adults"
89316609|NCT06124586|Experimental|immediate PTA|study participant in this group will receive a PTA in ''readiness'', that means 48h after the initial study examination.
89316610|NCT06124586|Active Comparator|elective PTA|A study participant in this group will receive a PTA according to the hospital's standard of care, that means 3 weeks after the initial study examination
89316611|NCT06114992||Servo-n HFOV treatment|As this study is single-armed (non-controlled), all patients in this study receive the same treatment, i.e. Servo-n HFOV treatment. There are however two subgroups, elective HFOV and rescue HFOV treatment
89316612|NCT06110832|Experimental|Mindfulness-based Meditation and Yoga Intervention Group|"After randomization, participants in the experimental group underwent mindfulness-based meditation and yoga practices with 90-minute sessions on Thursdays for 8 weeks. In these practices, a different theme was determined each week.~The 8-week theme headings are as follows:~Week 1 exploring mindfulness Week 2: How do we perceive the world? week 3 being in the body Week 4 meeting stress with mindful awareness Week 5 our relationship with stress-inducing thoughts Week 6 Communication with mindfulness Week 7 taking care of yourself Week 8 farewell and a new beginning"
89316613|NCT06110832|No Intervention|Control Group|No intervention was applied to the control group
89316614|NCT06106672|Experimental|CNP-106|200 mL intravenous infusion on Day 1 and Day 8: CNP-106
89316615|NCT06106672|Placebo Comparator|Placebo|CNP-106 Placebo
89316616|NCT06103591|Experimental|EmStop Embolic Protection System|Transcatheter aortic valve replacement (TAVR) procedures with the EmStop Embolic Protection System (EmStop System).
89316617|NCT06090864|Experimental|ATLCAR.CD30|Subjects will be enrolled on 1 of 3 dose levels as determined by a 3+3 design. Up to 25 evaluable subjects may then be enrolled in the phase II portion of the study. Subjects may have cells procured to manufacture the ATLCAR.CD30.CCR4 cells if they meet eligibility for procurement. During the time period necessary to manufacture the ATLCAR.CD30.CCR4 cells, Subjects will be allowed to receive standard-of-care bridging therapy at the discretion of their local oncologist. Prior to cell infusion, subjects will undergo additional eligibility evaluations, and then if eligible, will undergo lymphodepletion followed by cell infusion 2-14 days later. Subjects will then be followed for 15 years as is required for studies involving gene transfer experiments
89316618|NCT06088862|Experimental|Group I - NRT Responder|Participants that were successful in quitting smoking using NRT in the first four weeks of the study will have the option of remaining on their current NRT or switching to one of the other two options for the next five weeks.
89316619|NCT06088862|Experimental|Group IIa NRT Non-Responder - Pouch Preferrers|Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try a nicotine pouch. Randomized to be switched to nicotine pouch for the next five weeks.
89316620|NCT06088862|Experimental|Group IIb NRT Non-Responder - Pouch Preferrers Control|Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try a nicotine pouch. Randomized to be remain on NRT for the next five weeks.
89316621|NCT06088862|Experimental|Group IIIa NRT Non-Responder - ENDS Preferrers|Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try ENDS. Randomized to be switched to ENDS for the next five weeks.
89316622|NCT06088862|Experimental|Group IIIb NRT Non-Responder - ENDS Preferrers Control|Participants that were unsuccessful in quitting smoking using NRT in the first four weeks and reported a preference to try ENDS. Randomized to be remain on NRT for the next five weeks.
89316623|NCT06087822|Experimental|IMD SiPore21®|IMD Class IIb Total daily dose: 3 stick packs (1 x 3 main meals) uration 12 weeks
89316624|NCT06087822|Placebo Comparator|Placebo Comparator|Placebo Total daily dose: 3 stick packs (1 x 3 main meals) duration 12 weeks
89316625|NCT06078644|Experimental|Intervention group|Patients in this group will be asked to perform breathing exercises in the form of using a spirometer 10 times every hour during the preoperative period while they are awake for three days, starting from the first day after the surgery. Patients in this group will be given a breathing exercise diary.
89316626|NCT06078644|No Intervention|Control group|Patients in this group will not undergo any treatment and will continue to receive care according to their clinical routine. In the clinic, when patients are admitted to the hospital, nurses give them a spirometer during the pre-operative period and it is stated that they should use it before and after the surgery. After the data collection tools are applied to the patients in this group, they will be asked how many times a day they use a spirometry.
89316627|NCT06075797|Experimental|PQ-ResPOND (Intervention)|"Participants in the intervention arm will (i) answer weekly PQ-ResPOND Surveys over 12 weeks, (ii) receive feedback reports (generated by the PediQUEST system to summarize parents answers), and (iii) engage with the pediatric palliative care (PPC) team.~The interprofessional PPC team will focus on child's recurrent pain and related symptoms using a standardized approach and work on family activation strategies."
89316628|NCT06075797|No Intervention|Usual care (Control)|"Participants randomized to the control arm will be assigned weekly PQ-ResPOND Surveys up to week 12. Participants in this arm will not have access to the full PediQUEST system, i.e. no reports will be generated. They will not meet the PPC team but can receive regular palliative care consultations following the site's usual referral procedures.~Children in the usual care arm will receive standard care, which at Boston Children's Hospital usually involves several primary clinicians (primarily neurologists or Complex Care Service attending physicians) and access to psychosocial clinician care throughout the illness course. PPC referrals are typically made at the discretion of the primary clinician, often for decision making reasons and/or closer to end-of-life. If a child presents persistent distress, they will be cared through the usual mechanisms. The rationale for collecting weekly surveys is to minimize reporting bias and may increase adherence and retention."
89316629|NCT06074861|Active Comparator|Test group|Patients will receive the non-surgical periodontal therapy plus three cycles of fasting-mimicking diet.
89316630|NCT06074861|No Intervention|Control group|Patients will receive the non-surgical periodontal therapy and will continue with their normal (and ad libitum) diet.
89316631|NCT06058871|Experimental|EMI intervention group|Participants in the intervention group will receive instant messaging (i.e., an EMI delivery platform). Our multidisciplinary team, including an obstetrician, midwife, lactation consultant, biostatistician, and social psychologist, will develop a message library and protocol for EMI delivery.
89316632|NCT06058871|No Intervention|Control group|Participants in the control group will receive text messages containing general information on breastfeeding from the Hospital Authority, which is open to the public and includes reminder text messages of important follow-up surveys. Messages will not be personalised, and nurse-led real-time support messages will not be available.
89316633|NCT06057844|Other|Non applicable|
89316634|NCT06057350|Active Comparator|Surgery|Patients randomized to surgery are treated according to current guidelines with either open, laparoscopic or robotic surgical segmental bowel resection corresponding to lymphovascular drainage of the cancer.
89316635|NCT06057350|Experimental|EFTR (Endoscopic Full-Thickness Resection)|Patients randomised to EFTR are treated using devices approved for eFTR in the European Union and affiliated countries for the indication as applied in the trial. Before EFTR, the scar is identified and documented. The colonoscope is then removed, the EFTR device mounted, the colonoscope re-introduced, and eFTR performed.
89316636|NCT06055309|Experimental|Cannabis (up to three doses)|Brownies containing a dose of cannabis
89316637|NCT06024889|Experimental|Furosemide|80 mg of furosemide is administered IV
89316638|NCT06024629||Patients with equivocal BCC lesions|Patients with equivocal BCC lesions (18+ years) who will undergo biopsy conform regular care will undergo a cOCT and LC-OCT scan.
89316639|NCT06016712|Experimental|Participant|SENSIMED Triggerfish lenses will be applied on this Arm and Intraocular pressure during active phase of delivery will be measured
89316640|NCT06016270|Experimental|hSTC810 400 mg + Paclitaxel|hSTC810 400 mg will be administered with a standard dose of paclitaxel
89316641|NCT06016270|Experimental|hSTC810 800 mg + Paclitaxel|hSTC810 800 mg will be administered with a standard dose of paclitaxel
89316642|NCT06011577|Experimental|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
89316643|NCT06011577|Placebo Comparator|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT)
89316644|NCT06002737|Experimental|Arm 1|Using Experimental harmonic scalpel to dissect the vessel
89316645|NCT06002737|Active Comparator|Arm 2|Using Harmonic Ace+7(Ethicon Endo-Surgery, LL), 5mm Diameter Shears with Advanced Hemostasis to dissect the vessel
89531588|NCT06011863||Group TEA (Thoracic Epidural Analgesia)|Group TEA (Thoracic Epidural Analgesia): Thoracic Epidural Application: The epidural area will be accessed from the 7th (T7)-8th (T8) level of the thoracic vertebral midline with an 18 gauge (G) epidural needle using the hanging drip technique. After 2 ml of 2% lidocaine is administered and no spinal effect is observed, a mixture of morphine and local anaesthetic 3-4 mg morphine hydrochloride + 5 ml 0.5% bupivacaine + 2 ml 0.9% saline will be administered through the epidural needle at once and the epidural needle will be withdrawn and sterile dressing will be applied.
89316646|NCT05993611|Experimental|Treatment (CD6-CAR Treg, tafasitamab)|Donors undergo leukapheresis over 2-4 hours for collection of PBMSc and the manufacturing of CD6-CAR Treg cells over 2 weeks. Patients then receive CD6-CAR Treg intravenously on day 0. Patients may also receive ablation tafasitamab IV post Treg cell infusion on days 1, 4, 8, 15, 22 for 1 cycle. If ablation is not complete by day 28, patients may receive an additional 1-2 cycles per investigator's discretion. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO, CT, and x-ray imaging during screening and as clinically indicated. Patients undergo blood specimen collection on study and during follow-up. Patients may undergo a biopsy on study as well as a lumbar puncture and MRI/CT as clinically indicated on study.
89316647|NCT05992857|Experimental|Retromesenteric omental flap covering all exposed peripancreatic arteries|A J-shaped omental flap is created by extensive mobilization of the greater omentum, and if needed, lengthening by division of vertical collaterals of gastroepiploic vessels section or thinning it out in patients with visceral obesity. This omental flap is ascended through the retromesentric route to cover all the peri-pancreatic vessels at risk of bleeding after pancreatic resection (hepatic artery, proximal part of the splenic artery, superior mesenteric artery, and right hepatic artery originating from superior mesenteric artery when present)
89316648|NCT05992857|Active Comparator|Control|No omental flap or an omental flap not using the retromesenteric route and only interposed between the pancreatic anastomosis and the hepatic artery, or a single round ligament flap wrapping the hepatic artery only.
89316649|NCT05990413||Hemiplegic Participants|Participants will be evaluated in terms of inclusion criteria, and fugl-meyer upper extremity performance assessment will be applied to eligible patients and it will be clarified whether they can be included. Participants who may be included in the study will fill in the patient demographic information form prepared by the researchers as a face-to-face interview. This form will take approximately 5 minutes, during which time the muscles will be rested. Then, the viscoelastic properties of the determined muscles of the participants will be evaluated. Finally, the participants will be evaluated in terms of the activation timing and percentages of the muscles determined during an open and closed kinetic chain activity. Half of the participants will do the open kinetic chain activity before the closed kinetic chain activity with a five-minute resting period between activities. The others will start with the closed kinetic chain activity first and then the open kinetic chain activity.
89316650|NCT05990413||Healthy Participants|Participants will be evaluated in terms of inclusion criteria. Eligable participants will fill in the patient demographic information form prepared by the researchers as a face-to-face interview. This form will take approximately 5 minutes, during which time the muscles will be rested. Then, the viscoelastic properties of the determined muscles of the participants will be evaluated. Finally, the participants will be evaluated in terms of the activation timing and percentages of the muscles determined during an open and closed kinetic chain activity. Half of the participants will do the open kinetic chain activity before the closed kinetic chain activity with a five-minute resting period between activities. The others will start with the closed kinetic chain activity first and then the open kinetic chain activity.
89316651|NCT05988866|Experimental|Intervention group|"Participants allocated to the intervention group will receive access to lipodia in addition to treatment as usual (TAU).~lipodia is a digital health application designed for individuals with hypercholesterinemia, accessible through a web browser. The application focuses on treatment methods derived health behavior change and cognitive behavioral therapy (CBT). Topics addressed by lipodia are activity planning and impulse control, dietary habits, physical activity, stress management, mood management, sleep management, weight management, as well as quitting smoking and drinking.~The program operates through interactive dialogues, which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 365 days."
89316652|NCT05988866|No Intervention|Control group|Participants allocated to the control group will receive access to treatment as usual (TAU).
89316653|NCT05984329||Tonic then Burst DR(TM)|Tonic Motor Cortex Stimulation (MCS) for 3 months then Burst DR(TM) MCS for 3 months
89316654|NCT05984329||Burst DR(TM) then tonic|Burst DR(TM) MCS for 3 months then tonic MCS for 3 months
89316655|NCT05976750||AONDA contact lenses|Lotrafilcon A contact lenses worn daily and removed at night for cleaning and disinfection as instructed by the eye care professional
89316656|NCT05976750||PV2 contact lenses|Balafilcon A contact lenses worn daily and removed at night for cleaning and disinfection as instructed by the eye care professional
89316657|NCT05976334|Experimental|[14C] Subasumstat 90 mg|Participants will receive a single dose of [14C] Subasumstat 90 mg, IV infusion on Day 1 in Part A of the study. Following Part A, participants will have an option to receive subasumstat 90 mg, IV infusion on Days 1, 4, 8, and 11 of a 21 day cycle for 3 cycles followed by weekly maintenance dosing in Part B of the study up to maximum treatment duration of 1 year.
89316658|NCT05959629|Experimental|Waterlase Express™, BIOLASE®|Root canals will be instrumented up to size 30/0.04 taper using Er,Cr:YSGG laser (Waterlase Express™, BIOLASE®), followed by standard of care (NaOCl).
89316659|NCT05959629|Active Comparator|Sodium Hypochlorite|Root canals will be instrumented up to size 30/0.04 taper using standard of care (NaOCl).
89316660|NCT05935878|Experimental|Cementless Oxford Unicompartmental Knee Arthroplasty|Phase III Cementless Oxford Unicompartmental Knee Replacement (Biomet)
89316661|NCT05935878|Active Comparator|Cemented Oxford Unicompartmental Knee Arthroplasty|Phase III Cemented Oxford Unicompartmental Knee Replacement (Biomet)
89316662|NCT05929833|Experimental|BETTER TBI (Traumatic Brain Injury) Transitional Care Intervention|Skilled clinical interventionists follow a manualized intervention protocol to address patient/family needs; establish goals; coordinate post-hospital care, services, and resources; and provide patient/family education and training on self- and family-management and coping skills <16 weeks post-discharge.
89316663|NCT05929833|Placebo Comparator|Usual Care|In alignment with U.S. usual care for patients with TBI (Traumatic Brain Injury), usual care arm activities for younger adults with TBI and their family caregivers will includes usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments).
89316664|NCT05928390|Experimental|Pasireotide s.c. 50 mcg|Pasireotide 50 mcg s.c. tid
89316665|NCT05928390|Experimental|Pasireotide 100 mcg|Pasireotide 100 mcg s.c. tid
89316666|NCT05928390|Experimental|Pasireotide 200 mcg|Pasireotide 200 mcg s.c. tid
89316667|NCT05928390|Placebo Comparator|Placebo|Placebo s.c. tid
89316668|NCT05904054|Experimental|Adult-CoronaVac® group|Aged 18-59 AND received 2 to 4 homologous doses of CoronaVac® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history.
89316669|NCT05904054|Experimental|Adult-Comirnaty® group|Aged 18-59 AND received 2 to 4 homologous doses of Comirnaty® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history.
89316670|NCT05904054|Experimental|Adult-mixed group|Aged 18-59 AND received 2 to 4 heterologous doses of CoronaVac® and Comirnaty® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history; OR Aged 18-59 AND received 2 to 4 heterologous doses of CoronaVac® and Comirnaty® at least 3 months prior to enrollment AND recovered from SARS-CoV-2 infection at least 3 months prior to enrollment; OR Aged 18-59 AND received 2 to 4 homologous doses of CoronaVac® or Comirnaty® at least 3 months prior to enrollment AND recovered from SARS-CoV-2 infection at least 3 months prior to enrollment.
89316671|NCT05904054|Experimental|Elderly-mixed group|Aged 60-75 AND received 2 to 4 heterologous doses of CoronaVac® and Comirnaty® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history; OR Aged 60-75 AND received 2 to 4 heterologous doses of CoronaVac® and Comirnaty® at least 3 months prior to enrollment AND recovered from SARS-CoV-2 infection at least 3 months prior to enrollment; OR Aged 60-75 AND received 2 to 4 homologous doses of CoronaVac® or Comirnaty® at least 3 months prior to enrollment AND without SARS-CoV-2 infection history; OR Aged 60-75 AND received 2 to 4 homologous doses of CoronaVac® or Comirnaty® at least 3 months prior to enrollment AND recovered from SARS-CoV-2 infection at least 3 months prior to enrollment.
89316672|NCT05898399|Experimental|Part A1 (ART6043 as monotherapy)|Patients with advanced or metastatic cancer will receive ART6043 administered in 21-day cycles.
89316673|NCT05898399|Experimental|Part A2 (ART6043 in combination with Olaparib)|Patients with advanced or metastatic cancer and with PARPi as an appropriate treatment option will receive ART6043 in combination with Olaparib twice daily (BID) in 21-day cycles.
89316674|NCT05898399|Experimental|Part A3 (ART6043 in combination with Talazoparib)|Patients with advanced or metastatic cancer and with PARPi as an appropriate treatment option will be given ART6043 in combination with Talazoparib once daily (QD) in 21-day cycles.
89316675|NCT05898399|Experimental|Part B (ART6043 in combination with a PARPi or a PARPi alone)|Patients with g/sBRCA-m, HER2-ve locally advanced or metastatic breast cancer will be randomly assigned to receive ART6043 in combination with a PARPi or a PARPi alone (Olaparib and Talazoparib).
89316676|NCT05897814|Experimental|Parturients|Adult patients admitted to the delivery room of Necker-Enfants Malades hospital maternity with an epidural catheter.
89316677|NCT05890664|Experimental|Experimental Group|Study participants in the active study arm will receive a daily oral dose of 0.5 mg Colchicine for 3 months without a loading dose. The dose is recommended to be taken in the morning. There is no deviation from the usual treatment intake.
89316678|NCT05890664|Placebo Comparator|Control Group|Study participants in the placebo group will receive a matched placebo.
89316679|NCT05885490||Group 1|Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck - clinical data only
89316680|NCT05885490||Group 2|Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck - clinical data and optional biobank sampling
89316681|NCT05885490||Group 3|Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck - clinical data and optional quality of life data
89316682|NCT05885490||Group 4|Patients undergoing treatment for histologically proven or suspected recurrent cancer of the head and neck - clinical data and optional quality of life data and optional biobank sampling
89316683|NCT05869682|Experimental|Group I (Immediate BWL therapy)|Patients wear AYOpro BWL therapy glasses starting on day 1 of SOC ADT combination therapy for 12 months on trial.
89316684|NCT05869682|Experimental|Group II (Delayed BWL therapy)|Patients wear AYOpro BWL therapy glasses starting 6 months after the start of SOC ADT combination therapy for 6 months on trial.
89316685|NCT05865990|Experimental|Patritumab deruxtecan (HER3-DXd)|"HER3-DXd will be dosed at 5.6 mg/kg body weight as an intravenous (IV) infusion administered on day 1 (D1) of each 21-day cycle for patients from all cohorts until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.~Cohort 1: MBC with untreated or progressing BM after local treatment.~Cohort 2: aNSCLC with untreated or progressing BM after local treatment.~Cohort 3: advanced solid tumor with treatment-naive LMD or LMD progressing after radiotherapy."
89316686|NCT05865171|Experimental|Cohort 1: Severe Renal Impairment|Participants will receive a single dose of IXP on Day 1.
89316687|NCT05865171|Experimental|Cohort 1: Healthy Participants|Participants will receive a single dose of IXP on Day 1.
89316688|NCT05856305|Experimental|Chlorophyllin|Drug name: Sodium Copper Chlorophyllin Dosage form: Tablet Dosage: 750 mg Route of administration: Oral Frequency: Once daily in the morning before food. Duration: From 10-14 days before radiotherapy up to 3 months after the last dose of cytotoxic therapy
89316689|NCT05856305|Placebo Comparator|Placebo|Drug Name: Placebo Dosage form: 1 Tablet Route of administration: Oral Frequency: Once daily in the morning before food. Duration: From 10-14 days before radiotherapy up to 3 months after the last dose of cytotoxic therapy
89316690|NCT05853887|Other|Penn Medicine New Jersey|All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.
89316691|NCT05853887|Other|Penn Medicine Lancaster General Health|All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.
89316692|NCT05853887|Other|Penn Presbyterian Medical Center|All sites with be randomized to implement the nudge at different points in time. Prospective data with be compared with each site's respective baseline numbers over a two-year period.
89316693|NCT05849389|Experimental|Vosoritide treatment arm|Vosoritide will be administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
89316694|NCT05843877|Experimental|Experimental Therapy|Total pancreatectomy with autologous islet cell transplantation
89316695|NCT05843877|Other|Standard Therapy|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)
89316696|NCT05839028||Patients with hypertension of stages 1 and 2|Individuals with stage 1 and 2 hypertension living in a temperate climate zone and doing rotational shiftwork in the Arctic.
89316697|NCT05839028||Healthy volunteers|Virtually healthy individuals living in a temperate climate zone and and doing rotational shiftwork in the Arctic.
89316698|NCT05833347||2-8 Years Paediatric Patients|"During the preoperative evaluation, demographic data and airway physical examination results (Mallampati score) of the patients will be recorded. Patients who have received preoperative sedation will be positioned supine on the operating table, and ultrasound-guided measurements of soft tissue distances will be taken using a linear probe with a frequency range of 6-13 Hz. The distance between the hyoid bone and skin (DSHB), distance between the vocal cord anterior commissure and skin (DSAC), and distance between the epiglottis and skin (DSE) will be measured. The A/E (Anterior Commissura/Epiglottis) ratio will be calculated after measurements.~After standard monitoring and anesthesia induction, difficult laryngoscopy will be evaluated using the Modified Cormack Lehane Score, which grades the visibility of vocal cords and glottic structures. A grade of 3 or 4 on this scale will be considered as difficult laryngoscopy and recorded as such."
89316699|NCT05832502|Placebo Comparator|Placebo (saline) in HIV-uninfected pregnant woman|Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
89316700|NCT05832502|Active Comparator|GBS6 in HIV-uninfected pregnant woman|GBS6 administered intramuscularly by injecting 0.5 mL into the deltoid muscle
89316701|NCT05832502|Placebo Comparator|Placebo (saline) in HIV-infected pregnant woman|Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
89316702|NCT05832502|Active Comparator|GBS6 in HIV-infected pregnant woman|GBS6 administered intramuscularly by injecting 0.5 mL into the deltoid muscle
89316703|NCT05826119|Active Comparator|Magnesium sulfate|Before induction, a bolus of 20 mg/kg magnesium sulfate in 100 mL saline was administered for 15 minutes, followed by a continuous infusion of 20 mg/kg/hour until the skin was closed.
89316704|NCT05826119|Active Comparator|Placebo|The control group received only 100 ml of saline 15 minutes before induction.
89316705|NCT05825950||HR NMIBC group|"High Risk (HR) NMIBC group of participants studied include ones with American Urological Association (AUA) / Society of Urologic Oncology (SUO) criteria such as : high grade T1, recurrent high grade Ta, high grade Ta >3 cm, multifocal high grade Ta, any Carcinoma in-situ (CIS), any BCG failure in high grade disease, any variant histology, any lymphovascular invasion.~Note: Ta means the cancer is just in the innermost layer of the bladder lining. T1 means the cancer has started to grow into the connective tissue beneath the bladder lining."
89316706|NCT05825950||IR NMIBC group|Intermediate Risk (IR) NMIBC group of participants studied include ones with AUA/SUO criteria such as : recurrence within 1 year low grade Ta, solitary low grade Ta >3 cm, multifocal low grade Ta, high grade Ta ≤3 cm, low grade T1 Note: Ta means the cancer is just in the innermost layer of the bladder lining. T1 means the cancer has started to grow into the connective tissue beneath the bladder lining.
89316707|NCT05824065|Experimental|OMA102 1 mg|Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
89316708|NCT05824065|Experimental|OMA102 2 mg|Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
89316709|NCT05824065|Placebo Comparator|Placebo|Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep
89316710|NCT05817383|Experimental|Freeze-dried Blueberry Powder|Randomized participants will be asked to consume 48 grams of freeze-dried blueberry powder each day for 12 weeks.
89316711|NCT05817383|Placebo Comparator|Placebo Powder|Randomized participants will be asked to consume 48 grams of a nutritionally matched placebo powder devoid of fiber and anthocyanins each day for 12 weeks.
89316712|NCT05817279||AI-OCT|Group of 124 patients with equivocal BCC lesions. Of these lesions, OCT scans have been obtained in the past. These scans will be evaluated with AI-assistance.
89316713|NCT05817279||Unaided OCT|Group of 124 patients with equivocal BCC lesions (same patients as in AI-OCT group). Of these lesions, OCT scans have been obtained in the past. These scans will be evaluated without AI-assistance.
89316714|NCT05816382|Experimental|TAK-861 Dose 1|Participants will receive TAK-861 dose 1 for up to 104 weeks.
89316715|NCT05816382|Experimental|TAK-861 Dose 2|Participants will receive TAK-861 dose 2 for up to 104 weeks.
89316716|NCT05816382|Experimental|TAK-861 Dose 3|Participants will receive TAK-861 dose 3 for up to 104 weeks.
89316717|NCT05816382|Experimental|TAK-861 Dose 4|Participants will receive TAK-861 dose 4 for up to 104 weeks.
89316718|NCT05812768|Experimental|Suture-Tight|Subjects meeting all inclusion and exclusion criteria will receive graft anchoring utilizing the Suture-Tight Suture Delivery System.
89316719|NCT05809739|Experimental|Treatment Group|"Device: STYLAGE® Hydro~1 mL up to 2.0 mL per area will be injected in the face, neckline and neck (optionally) at each injection session."
89316720|NCT05797740||Single cohort|This is a single cohort study enrolling Participants with relapsing multiple sclerosis (RMS), who are prescribed treatment with cladribine tablets in routine clinical practice following the summary of product characteristics (SmPC).
89316721|NCT05786196|Active Comparator|iTrack Advance|Ab-interno canaloplasty utilizing the iTrack Advance microcatheter device (Nova Eye, Inc.)
89316722|NCT05786196|Active Comparator|OMNI Surgical System|Ab-interno canaloplasty utilizing the OMNI Surgical System
89316723|NCT05784961|Experimental|Active transcranial direct current stimulation (active tDCS)|The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the L DLPFG and the cathode over the left temporo-parietal junction (L TPJ)
89316724|NCT05784961|Placebo Comparator|Sham tDCS|"Sham Comparator: sham transcranial direct current stimulation tDCS device allows sham stimulation. tDCS device sham technology allows optimum placebo stimulation via the same stimulation impresssion than active stimulation.~Electrode placement is the same than the active arm"
89316725|NCT05783323|Experimental|Larotrectinib monotherapy with 131I therapy|"Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.~Patients will receive 131I therapy after 6 months of larotrectinib. Larotrectinib will be continued for 5 days after RAI therapy and then patients will enter a wait and see period off treatment.~Patients who experience disease progression at any point while on larotrectinib will proceed to 131I therapy and discontinue larotrectinib."
89316726|NCT05763771|Experimental|Part 1|Participants will use the app for 4 weeks, during which participants will follow a smoking schedule on the app to help you reduce your cigarette consumption
89316727|NCT05763771|Experimental|Part 2|"Participants will also use the app for the duration of the study (about 3 months).~Participants will be asked to record your smoking using the app and complete online surveys"
89316728|NCT05760989|Experimental|Treatment with the Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System|
89316729|NCT05757895||Hemiparetic SP|The Level of Gross Motor Function Classification System (GMFCS), Trunk Affect Level ( Trunk Impairment Scale- TIS), Activity Level ( Gross Motor Function Criterion- GMFM-88), Participation Level ( Pediatric Data Collection Tool- PODCI) and Quality of Life Level (Cerebral Palsy Questionnaire for Children Cerebral Palsy Module- PedsQL) will be evaluated.
89316730|NCT05757895||Diparetic SP|The Level of Gross Motor Function Classification System (GMFCS), Trunk Affect Level ( Trunk Impairment Scale- TIS), Activity Level ( Gross Motor Function Criterion- GMFM-88), Participation Level ( Pediatric Data Collection Tool- PODCI) and Quality of Life Level (Cerebral Palsy Questionnaire for Children Cerebral Palsy Module- PedsQL) will be evaluated.
89316731|NCT05757570|Experimental|Part 1: povetacicept 240mg|
89316732|NCT05757570|Experimental|Part 2: povetacicept Dose A|
89316733|NCT05757570|Experimental|Part 2: povetacicept Dose B|
89316734|NCT05754424|Experimental|AT278|Single subcutaneous injection of 0.5 U/kg
89316735|NCT05754424|Active Comparator|NovoRapid|Single subcutaneous injection of 0.5 U/kg
89316736|NCT05751980|Experimental|Med Wise Rx|An evidence-informed two-session interactive behavioral workshop. Participants will begin intervention within 3 weeks of enrollment.
89316737|NCT05751980|Active Comparator|Waitlist Control|Participants will be crossed over to Med Wise Rx intervention up to 2 months after enrollment.
89316738|NCT05743907|Experimental|DA-2811|DA-2811 + Forxiga placebo
89316739|NCT05743907|Active Comparator|Forxiga|Forxiga + DA-2811 placebo
89316740|NCT05743543|Experimental|Active SPG block|The block will be performed using a topical aerosolized nasal spray followed by the administration of a local anesthetic.
89316741|NCT05741307|Experimental|Patients 2|"Patient aged 7 to 12 with a diagnosis of ADHD made by a child psychiatrist or neuropediatrician and followed by the child psychiatry department - Reference Center for Language and Learning Disorders of the Necker Enfants Malades Hospital.~These patients will use of the self-hypnosis application 6 weeks after inclusion : from T2 to T3."
89316742|NCT05741307|Experimental|Patients 1|"Patient aged 7 to 12 with a diagnosis of ADHD made by a child psychiatrist or neuropediatrician and followed by the child psychiatry department - Reference Center for Language and Learning Disorders of the Necker Enfants Malades Hospital.~These patients will use of the self-hypnosis application at inclusion : from T0 (inclusion) to T1."
89316743|NCT05736224|Experimental|Sunscreen|Portion of skin covered by sunscreen.
89316744|NCT05736224|Other|No treatment control|Portion of skin not covered by sunscreen.
89316745|NCT05735587|Experimental|Freeze-dried Blueberry Powder|Randomized participants will be asked to consume 48 grams of freeze-dried blueberry powder each day for 12 weeks.
89316746|NCT05735587|Placebo Comparator|Placebo Powder|Randomized participants will be asked to consume 48 grams of a nutritionally matched placebo powder devoid of fiber and anthocyanins each day for 12 weeks.
89316747|NCT05734989||Hispanic/Latinx patients at risk for CKD|Adult patients in the Hispanic/Latinx Durham community screened for CKD
89316748|NCT05734989||PCPs caring for Hispanic Latinx patients screened for CKD in the Durham Community|Primary Care Providers (PCPs) caring for Hispanic Latinx patients who agree to use the study guidelines and interventions for screening and monitoring their patients for CKD.
89316749|NCT05733312|Experimental|Focused Ultrasound|Subjects with known or suspected glioma (≥3cm) undergoing routine planned neurosurgical resection will undergo a focused ultrasound prior to the surgery with the InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system
89316750|NCT05731349|Experimental|NEWS-1 care|During the interventional period, the 2018 Sepsis Hour-1 Bundle will be initiated in the ED if NEWS2 score ≥ 5.
89316751|NCT05731349|No Intervention|Standard care|During the standard care period, emergency physicians will assess the patients based on history, physical examination, laboratory tests, chest radiography or other imaging studies, and will offer treatment based on clinical expertise, intuition, and local or international guidelines
89316752|NCT05725109||Before Period (1/16/2022 to 10/17/2022)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the before phase of this study. In the before phase, alerts identifying patients with active hepatitis C infection will NOT be disseminated to healthcare providers and clinic staff. Routine clinical care will be administered without knowledge of the intervention.
89316753|NCT05725109||After Period (1/16/2023 to 10/17/2023)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the after phase of this study. In the after phase, alerts identifying patients with active hepatitis C infection will be disseminated to healthcare providers and clinic staff.
89316754|NCT05724576|Experimental|Low dose allogeneic mesenchymal stromal cells|Intracoronary administration 1.5 x 10^7 OmniMSC-AMI in first AMI patients who just underwent primary PCI
89316755|NCT05724576|Experimental|High dose allogeneic mesenchymal stromal cells|Intracoronary administration 3.0 x 10^7 OmniMSC-AMI in first AMI who just underwent primary PCI
89316756|NCT05722067|Experimental|oocytes treated with calcium ionophore|Oocytes treated with a ready-to-use ionophore compound (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF). After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes subjected to AOA will transfer to the same time-lapse culture dish with the controlled sibling group.
89316757|NCT05722067|No Intervention|oocytes undergo routine IVF/ICSI protocol|Untreated control oocytes will immediately place into the time-lapse imaging system, and the culture protocol was routine.
89316758|NCT05720624|Active Comparator|Cohort I, Arm A (standard of care therapy)|Patients in Cohort I, Arm A receive standard of care therapy. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
89316759|NCT05720624|Experimental|Cohort I, Arm B ( standard of care therapy, AEO)|Patients in Cohort I, Arm B receive standard of care therapy and receive AEO PO BID for 1 month on study. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
89316760|NCT05720624|Active Comparator|Cohort II, Arm A (standard of care therapy)|Patients in Cohort II, Arm A receive standard of care therapy. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
89316761|NCT05720624|Experimental|Cohort II, Arm B (standard of care therapy, AEO)|Patients in Cohort II, Arm B receive standard of care therapy and receive AEO PO BID for 3 months on study. Patients also undergo MRS imaging, collection of CSF, and collection of blood on study.
89316762|NCT05710120||Before Period (January 2022 to October 2022)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the before phase of this study. In the before phase, alerts identifying patients who are eligible to be screened for hepatitis C infection will NOT be disseminated to healthcare providers and clinic staff. Routine clinical care will be administered without knowledge of the intervention.
89316763|NCT05710120||After Period (January 2023 to October 2023)|All AIDS Healthcare Foundation Healthcare Centers will be contributing to the after phase of this study. In the after phase, alerts identifying patients who are are eligible to be screened for hepatitis C infection will be disseminated to healthcare providers and clinic staff.
89316764|NCT05707260|Active Comparator|CKD SMS intervention|CKD SMS (Chronic Kidney Disease Self-Management Support) intervention (6,27), guided by the Social Cognitive Theory, through the manipulation of self-efficacy, is educational for the adult with CKD in early stages where a primer will be used which contains a primer that explains the functions of the kidneys, the first signs and symptoms of CKD and the strategies to control or delay the progression of CKD, such as the benefits of maintaining a healthy lifestyle and adherence to treatment. Also, a diary for participants to record side effects of medications, monitor their clinical data, treatment plan and questions for medical appointments.
89316765|NCT05707260|No Intervention|Conventional intervention|The conventional intervention corresponds to the protocol established in the program of the renal unit for the management of people with CKD in early stages.
89316766|NCT05701878|Experimental|Intervention (App) Group|Participants in this group will be given access to a COVID-19 self-testing app (SMARTest). Access to the app, given exclusively to this group, will be in addition to the 12 COVID-19 self-test kits participants receive.
89316767|NCT05701878|No Intervention|Control (No App) Group|Participants in this group will not be given access to the COVID-19 self-testing app (SMARTest). Participants will only receive the 12 COVID-19 self-test kits.
89316768|NCT05701137|Experimental|EMDR-RTE|Eye movement desensitization and reprocessing in its recent traumatic episode version.
89316769|NCT05701137|Active Comparator|TAU|Usual treatment by a psychologist.
89316770|NCT05684380|Experimental|MAZ-101|One applications in each nostril, twice a day.
89316771|NCT05684380|Active Comparator|DYMISTA®|One applications in each nostril, twice a day.
89316772|NCT05673785|Experimental|Brentuximab Vedotin + CHP|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m^2 and doxorubicin 50 mg/m^2 IV, on Day 1 of each 21-day cycle, and prednisone 100 mg tablets, orally, on Days 1 through Day 5, for up to 8 cycles (6 months) or until progressive disease (PD), unacceptable toxicity, whichever occurs first.
89316773|NCT05664191|Experimental|LEVOSIMENDAN|Experimental : Levosimendan group
89316774|NCT05664191|Placebo Comparator|PLACEBO|Placebo : Comparator group
89316775|NCT05655949|Experimental|Gemcitabine + Cisplatin + Durvalumab + Yttrium-90 Selective Internal Radiation Therapy|"Participants will receive:~Cycle 1:~Day 1 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy) plus Durvalumab (immunotherapy).~Day 8 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy)~Week 2 or 3 of 21 Day Cycle: One time treatment of Y-90 radiation.~Cycles 2-8:~Day 1 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy) plus Durvalumab (immunotherapy).~Day 8 of 21 Day cycle: Pre-determined dose(s) of Gemcitabine and Cisplatin (Chemotherapy)~Cycles 9+:~Day 1 of 21 Day Cycle: Durvalumab (immunotherapy) maintenance"
89316776|NCT05652361|Experimental|Additional visualisation of surgical assistance during surgery|
89316777|NCT05644873|Active Comparator|Magnesium sulfate|Before induction, a bolus of 20 mg/kg magnesium sulfate in 100 mL saline was administered for 15 minutes, followed by a continuous infusion of 20 mg/kg/hour until the skin was closed.
89316778|NCT05644873|Active Comparator|Placebo|The control group received only 100 ml of saline 15 minutes before induction.
89316779|NCT05642182|Experimental|Drug (SFA002) Vitamin D, Magnesium|Drug (SFA002) 1000 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 IU once daily
89316780|NCT05642182|Experimental|Drug (SFA002) Vitamin D, Magnesium and Propionate|Drug (SFA002) 1000 mg, Propionate 150 mg, 80 mg Calcium, 40 mg Magnesium 3 times daily after meals and Vitamin D 1000 mg once daily
89316781|NCT05640232|Experimental|Experimental|CDE100 The patient must take 1 pill of CDE100 association and placebo of Buscopan® Composto association, if pain, until three times a day.
89316782|NCT05640232|Active Comparator|Control|"Buscopan® Composto association.~The patient must take 1 pill of Buscopan® Composto association and placebo of CDE100 association, if pain, until three times a day."
89316783|NCT05637840|Experimental|Sleep limited|Participants will be asked to limit their sleep
89316784|NCT05637840|Experimental|No sleep limitation|Participants will be asked to get their normal amount of sleep.
89316785|NCT05634421||Dermatologists|Dermatologists who have no experience with OCT.
89316786|NCT05634421||Residents|Residents who have no experience with OCT
89316787|NCT05634421||Medical students|Medical students who have no experience with OCT
89316788|NCT05634421||Nurses|Nurses who have no experience with OCT
89316789|NCT05634421||Research physicians|
89316790|NCT05628779|Experimental|Transcatheter Edge-to-Edge Repair (TEER) on top of the Standard Of Care (SOC)|Transcatheter Edge-to-Edge Repair (TEER) on top of the Standard Of Care (SOC)
89316791|NCT05628779|No Intervention|Standard Of Care (SOC)|Patients will continue the SOC with heart failure medication following the European Society of Cardiology guideline 2021 recommendations (e.g. diuretics)
89316792|NCT05628688||Test group|Up to 50 subjects will be enrolled with unilateral or bilateral edema in the upper or lower extremity.
89316793|NCT05628688||Control group|Up to 50 patients will be enrolled from a healthy volunteer group as a control, with no edema.
89316794|NCT05617560|Experimental|Telemedical care|
89316795|NCT05613218|Active Comparator|Liberal oxygenation group|SpO2 target of 96%
89316796|NCT05613218|Active Comparator|Restrictive oxygenation group|SpO2 target of 90%.
89316797|NCT05602766||NGENLA (Somatrogon)|Patients with GHD without epiphyseal closure who received NGENLA (Somatrogon)
89316798|NCT05579691|Experimental|CTI-160l|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
89316799|NCT05579691|Placebo Comparator|Placebo|Placebo Comparator
89316800|NCT05568069|Experimental|Intervention|ICD or CRTD fitted
89316801|NCT05568069|No Intervention|Control|No ICD fitted (with Implantable Loop Recorder) or Cardiac Resynchronisation Therapy Pacemaker (CRTP)
89316802|NCT05568069|No Intervention|Registry|Usual medical care
89316803|NCT05566964||ME&MGopen|Use of ME&MGopen mobile app, at home for 12 months
89316804|NCT05564091|Active Comparator|Cataract surgery combined with ab-interno canaloplasty|Ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.)
89316805|NCT05564091|Other|Control: Cataract surgery|Cataract surgery alone
89316806|NCT05562089|Experimental|Prevail|
89316807|NCT05561374|Experimental|Low-dose OKN-007, two times a day (BID)|Dose Escalation Cohort 1
89316808|NCT05561374|Experimental|Low-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 2
89316809|NCT05561374|Experimental|Mid-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 3
88806546|NCT05329662|Active Comparator|AD-MSCs infusions, then Placebo|Patients in group A will receive two autologous AD-MSC administrations on day 0 and day 90 ± 7
89316810|NCT05561374|Experimental|High-dose OKN-007, three times a day (TID)|Dose Escalation Cohort 4
89316811|NCT05559411||Wire-guided Localization|
89316812|NCT05559411||Intraoperative Ultrasound|
89316813|NCT05559411||Magnetic Localization|
89316814|NCT05559411||Radar Reflector Localization|
89316815|NCT05559411||Radiofrequency Localization|
89316816|NCT05559411||Radioactive Localization|
89316817|NCT05559411||Ink Localization|
89316818|NCT05556044|Other|Empagliflozin 10 MG|
89316819|NCT05556018|Experimental|Tailor-made CRT delivery|Cardiac resynchronization therapy given according to Electrical Activation Mapping result
89316820|NCT05548023|Other|unprotected left main coronary artery disease treated with PCI|
89316821|NCT05542173|Experimental|BALI 25 + 25 + 15|Three applications per day or more in case of pain, not exceeding six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops.
89316822|NCT05542173|Placebo Comparator|PLACEBO|Three applications per day or more in case of pain, not exceeding six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops.
89316823|NCT05531565|Experimental|Part A (Phase 2): BIIB059|Participants will receive BIIB059 subcutaneously (SC) once every 4 weeks (Q4W) from Week 0 to Week 20, with an additional dose of BIIB059 at Week 2 during the double-blind placebo-controlled (DBPC) treatment period. Following the DBPC treatment period, participants will receive BIIB059 during the extended treatment period (ETP) from Week 24 to Week 48, with an additional dose of BIIB059-matching placebo at Week 26.
89316824|NCT05531565|Placebo Comparator|Part A (Phase 2): Placebo|Participants will receive BIIB059-matching placebo SC Q4W from Week 0 to Week 20, with an additional dose of BIIB59-matching placebo at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive BIIB059 during the ETP from Week 24 to Week 48, with an additional dose of BIIB059 at Week 26.
89316825|NCT05531565|Experimental|Part B (Phase 3): BIIB059|Participants will receive BIIB059 SC Q4W from Week 0 to Week 20, with an additional dose of BIIB059 at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive BIIB059 during the ETP from Week 24 to Week 48, with an additional dose of BIIB059-matching placebo at Week 26.
89316826|NCT05531565|Placebo Comparator|Part B (Phase 3): Placebo|Participants will receive BIIB059-matching placebo SC Q4W from Week 0 to Week 20, with an additional dose of BIIB59-matching placebo at Week 2 during the DBPC treatment period. Following the DBPC treatment period, participants will receive BIIB059 during the ETP from Week 24 to Week 48, with an additional dose of BIIB059 at Week 26.
89316827|NCT05526833|Experimental|Non-responders undergo rTMS of the right superior temporal sulcus (STS)|Non-responders to protocol #8116 will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will be administered 10 days (10 sessions) of MRI-guided 1 Hz rTMS delivered to the right superior temporal sulcus (STS). The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
89531613|NCT05929469|Experimental|Human-Enhanced Kick-Off + App|"This arm includes participants who respond to the Human-Enhanced Kick-Off + App in stage 1.~In stage 1, the participant's kick-off will include a session with a study interventionist. They will also receive an mHealth program.~In stage 2, responders to the Human-Enhanced Kick-Off + App will continue with the mHealth program, alone, for the remainder of the study."
89316828|NCT05526833|Experimental|Partial responders undergo rTMS of the left temporo-parietal junction (TPJ)|Partial responders to protocol #8116 will receive a type of TMS called repetitive TMS (rTMS) wherein the magnetic pulses delivered will be close together in a rapid sequence. They will be administered 10 days (10 sessions) of MRI-guided 1 Hz rTMS delivered to the original left temporo-parietal junction (TPJ) target. The rTMS parameters that will be used are a frequency of 1 Hz (1 pulse per second) at an intensity of 90% of the motor threshold (MT). Therefore, the investigators will deliver 1200 continuous pulses per session/day which adds up to 12,000 pulses in total for the whole treatment.
89316829|NCT05526833|No Intervention|Complete responders undergo four follow-up clinical assessments|Complete responders to protocol #8116 will be offered followup clinical assessments at 1, 2, 4, and 8 weeks to assess sustainability of their response.
89316830|NCT05525117|Experimental|online intervention in addition to treatment-as-usual|online intervention: covivio in addition to treatment as usual
89316831|NCT05525117|Other|treatment-as-usual|Other: treatment as usual
89316832|NCT05525104|No Intervention|Control|In patients randomised to the control group, sevoflurane will be titrated according to a Minimal Alveolar Concentration (MAC) of 0.9 respectively an end tidal sevoflurane concentration of 2.3% based on standard practice in our paediatric anaesthesia department.
89316833|NCT05525104|Experimental|Treatment|In patients randomised to the intervention group of the trial, the anaesthetic agent sevoflurane will be titrated according to the typical DSA pattern for general anaesthesia with sevoflurane, provided by the Narcotrend
89316834|NCT05521178||Ibrutinib|Patients receiving ibrutinib for the treatment of CLL.
89316835|NCT05521178||Acalabrutinib|Patients receiving acalabrutinib for the treatment of CLL.
89316836|NCT05520723|Experimental|Sacituzumab Govitecan + Loperamide + G-CSF|"Upon meeting all selection criteria, patients enrolled in the study will receive the combination of:~Sacituzumab govitecan :10 mg/kg, intravenously (IV) on Days 1 and 8 every 21-day cycle .~This treatment will continue until disease progression, unacceptable toxicity, or physician's/patient's decision.~Loperamide : 2 mg orally (PO), twice a day (BID), or 4 mg once a day (QD) during three consecutive days after administration of sacituzumab govitecan, (D2, D3, D4 and D9, D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).~G-CSF : 30 MU subcutaneously (SC) QD during two consecutive days, 48 hours after administration of sacituzumab govitecan (D3, D4 and D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician)."
89316837|NCT05516992|Experimental|SB-01 For Injection|Subjects receive a SB-01 For Injection intradiscal injection per treated disc.
89316838|NCT05516992|Placebo Comparator|Sham Needle|Subjects receive a sham needle placement for each treated disc.
89316839|NCT05508503||CRC group|patients with colorectal cancer
89316840|NCT05508503||Control group|patients without colorectal cancer
89316841|NCT05464277|Active Comparator|Intermediate normal oxygen|"For the intermediate normal oxygen group, an oxygen saturation by pulse oximetry (SpO2) of 95-97% will be recommended in the light of the Improving Oxygen Therapy in Acute-illness (IOTA) meta-analysis. The acceptable lower limit of PaO2 will be set to 80 mmHg according to a recent consensus of experts endorsed by the European Society of Intensive Care Medicine. The lower-limit and higher-limit monitor alarm for SpO2 will be set at 94% and 98%, respectively.~In case that the emergency department of a study site uses ventilators, which allow for only two options of FiO2 titration (namely, air mix and FiO2 of 1.0), then the intermediate normal oxygen group should receive air mix."
89316842|NCT05464277|Active Comparator|High normal oxygen|"For the high normal oxygen group, an oxygen saturation by pulse oximetry (SpO2) of 99-100% will be recommended. The lower-limit monitor alarm for SpO2 will be set at 98%. No upper alarm limit for SpO2 will be set.~In case that the emergency department of a study site uses ventilators, which allow for only two options of FiO2 titration (namely, air mix and FiO2 of 1.0), then the high normal oxygen group should receive FiO2 of 1.0."
89316843|NCT05462834|Experimental|Compressed Air then Supplemental Oxygen|
89316844|NCT05462834|Experimental|Supplemental Oxygen then Compressed Air|
89316845|NCT05448443|Experimental|AD981|AD981
89316846|NCT05448443|Placebo Comparator|Placebo|Placebo
89316847|NCT05443646|Experimental|HLX10 (Serplulimab) Consolidation After Chemotherapy Concurrent Hypofractionated Radiotherapy|Participants will receive at least 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) concurrently with Hypofractionated Radiotherapy, followed by HLX10 300 mg every 3 weeks (Q3W) with maximum 1 years or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
89316848|NCT05443100|Experimental|Rehabilitation|Multidisciplinary rehabilitation program consisting of diet and physical exercise for 4 weeks.
89316849|NCT05443100|Experimental|Whole-Body Cryotherapy|Rehabilitation program consisting of 10 WBC sessions over two weeks.
89316850|NCT05437809|Other|Adults with obesity|All participants (n=50 adults with obesity) will complete each of the four food consumption appointments (order of the four appointments will be randomized/counterbalanced).
89316851|NCT05437003|Experimental|PD patients visiting clinic|All patients will undergo a NeuraLight session for oculometric evaluation along with eye-tracking recordings. All assessments will be performed during a clinic visit unless authorized to be conducted remotely.
89316852|NCT05437003|Experimental|Healthy subjects|All patients will undergo a NeuraLight session for oculometric evaluation along with eye-tracking recordings. All assessments will be performed during a visit unless authorized to be conducted remotely.
89316853|NCT05435092||Patients scheduled for primary TKA|Adult Patients diagnosed with osteoarthritis of the knee and who are scheduled for a primary total knee arthroplasty
89316854|NCT05411198|Experimental|XEN45 (Glaucoma Gel Stent)|Participants will receive XEN45 implanted using an ab externo approach on Day 1.
89316855|NCT05409118|Experimental|Alto Abdominal Stent Graft System|Subjects randomized to receive the Endologix Alto Abdominal Stent Graft System for implantation to repair Abdominal Aortic Aneurysm.
89316856|NCT05409118|Active Comparator|Comparators|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm.
89316857|NCT05403229|Experimental|Topiramate arm|"The experimental group receives a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.~The experimental group receives additional oral topiramate for 6 weeks. The dosage of topiramate is 25 mg orally before bedtime with the weekly escalation of 25 mg up to 100 mg. The total duration of oral topiramate is 6 weeks."
89316858|NCT05403229|Active Comparator|Control arm|The control arm receives a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
89316859|NCT05396872|Experimental|CLOSED TO ENROLLMENT: Stage 1 & 2: Patients, Caregivers, Providers|Patient participants will be instructed to install a mobile app to record their medical appointment, which research staff will use to analyze patient-provider communication. All participants will undergo semi-structured interviews and/or focus groups. Post appointment follow-up with surveys and assessments regarding knowledge of disease information, quality of life, and other measures will be administered after the provider-patient appointment.
89316860|NCT05396872|Experimental|Stage 3: Patients, Caregivers using developed GA platform|About 14 days prior to scheduled germline testing appointment, patients and caregivers call or meet with a coach to select decision aid GA platform preference delivery (online, print, or both online and print), review the GA online platform, and possibly undergo consultation and training for audio recording of the scheduled appointment. Patients and caregivers attend the scheduled germline testing appointment on day 1. Patients complete surveys and patients and caregivers may complete an interview on study. Providers participate in focus groups and complete surveys on study.
89316861|NCT05395039|No Intervention|Usual Care: Control Group|No interventions administered. Participant will receive usual care in the hospital.
89316862|NCT05395039|Experimental|VCHIPS: Intervention Group|Individuals in this group will work with a study nurse to schedule the intervention.
89316863|NCT05390918|Experimental|TAILOR|Half of the participants will be randomized into the experimental arm of this study. A study clinician will call each family approximately 4 times over 2 months. The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary. The TAILOR intervention will then be administered. TAILOR includes the assessment of existing sleep problems and sleep practices and education on Cognitive Behavioral Therapy (CBT) strategies for insomnia, with Motivational Interviewing (MI) as the communication style.
89316864|NCT05390918|Other|Enhanced Usual Care (EUC)|Half of the participants will be randomized into Enhanced Usual Care (EUC). A study clinician will call each family approximately 4 times over 2 months. The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
89316865|NCT05382975|Other|Wedge 1 includes Schools 1 and 2.|
89316866|NCT05382975|Other|Wedge 2 includes Schools 3, 4, and 5.|
89316867|NCT05382975|Other|Wedge 3 includes Schools 6, 7, and 8.|
89316868|NCT05382104|Experimental|Sequence 1: Treatment A + Treatment B + Treatment C|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 under fasting condition (Treatment A), followed by maribavir single 400 mg tablet, on Day 1 of Period 2. administered with a low fat/low calorie meal (Treatment B), and further followed by maribavir single 400 mg tablet, on Day 1 of Period 3 administered with a high fat/high calorie meal (Treatment C). There will be a washout period of minimum of 72 hours between each ID dosing.
89316869|NCT05382104|Experimental|Sequence 2: Treatment A + Treatment C + Treatment B|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 under fasting condition (Treatment A), followed by maribavir single 400 mg tablet on Day 1 of Period 2 administered with a high fat/high calorie meal (Treatment C), and followed by maribavir single 400 mg tablet, on Day 1 of Period 3 administered with a low fat/low calorie meal (Treatment B). There will be a washout period of minimum of 72 hours between each ID dosing.
89316870|NCT05382104|Experimental|Sequence 3: Treatment B + Treatment A + Treatment C|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 administered with a low fat/low calorie meal (Treatment B), followed by maribavir single 400 mg tablet, on Day 1 of Period 2 under fasting condition (Treatment A), and followed by maribavir single 400 mg tablet, on Day 1 of Period 3 administered with a high fat/high calorie meal (Treatment C). There will be a washout period of minimum of 72 hours between each ID dosing.
89316871|NCT05382104|Experimental|Sequence 4: Treatment B + Treatment C + Treatment A|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 administered with a low fat/low calorie meal (Treatment B), followed by maribavir single 400 mg tablet, on Day 1 of Period 2 administered with a high fat/high calorie meal (Treatment C), and followed by maribavir single 400 mg tablet, on Day 1 of Period 3 under fasting condition (Treatment A). There will be a washout period of minimum of 72 hours between each ID dosing.
89316872|NCT05382104|Experimental|Sequence 5: Treatment C + Treatment A + Treatment B|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir single 400 mg tablet, on Day 1 of Period 2 under fasting condition (Treatment A), and followed by maribavir single 400 mg tablet, on Day 1 of Period 3 administered with a low fat/low calorie meal (Treatment B). There will be a washout period of minimum of 72 hours between each ID dosing.
89316873|NCT05382104|Experimental|Sequence 6: Treatment C + Treatment B + Treatment A|Participants will receive maribavir single 400 mg tablet, on Day 1 of Period 1 administered with a high fat/high calorie meal (Treatment C), followed by maribavir single 400 mg tablet, on Day 1 of Period 2 administered with a low fat/low calorie meal (Treatment B), and followed by maribavir single 400 mg tablet on Day 1 of Period 3 under fasting condition (Treatment A). There will be a washout period of minimum of 72 hours between each ID dosing.
89316874|NCT05376878|Experimental|Treatment ( 64Cu-DOTA-trastuzumab PET/MRI)|Patients receive trastuzumab IV over 15 minutes on day 0. Patients then receive 64Cu-DOTA-trastuzumab IV and then undergo PET/MRI scan on day 1. Patients undergo repeat brain MRI every 6 weeks for 24 weeks and then every 9 weeks until disease progression. Patients then receive trastuzumab deruxtecan IV every 21 days in the absence of disease progression or unacceptable toxicity.
89316875|NCT05375084|Experimental|Dose Escalation Level 1|Level 1 oral capsules administered in combination with nivolumab
89316876|NCT05375084|Experimental|Dose Escalation Level 2|Level 2 oral capsules administered in combination with nivolumab
89316877|NCT05375084|Experimental|Dose Escalation Level 3|Level 3 oral capsules administered in combination with nivolumab
89316878|NCT05375084|Experimental|Dose Expansion|RP2D defined dose. Oral capsules administered in combination with nivolumab
89316879|NCT05368883|Experimental|One-legged cycling ergometer training|One-legged cycling ergometer training; 10 minutes for each leg in the first 2 weeks, 15 minutes of cycling training in the following weeks.
89316880|NCT05368883|Active Comparator|Two-legged cycling ergometer training|Two-legged cycling ergometer training; 20 minutes for the first 2 weeks, 30 minutes of cycling training in the following weeks.
89316881|NCT05368571|Experimental|CHOICES-TEEN|This is a four session session utilizing Motivational Interviewing (MI) and cognitive-behavioral approaches to enhance motivation for change in one or more primary behaviors: alcohol, marijuana, and condom/contraceptive use. The intervention is delivered by a trained master's level counselor and an Adolescent Medicine Specialist using one in-person session, and three Telehealth sessions.
89316882|NCT05368571|Active Comparator|Health and Life Skills Education|This four session life skills education program provides detailed information on time management, sleep, nutrition and exercise, and financial management. This program is delivered in person for the first session and then by Telehealth platform.
89316883|NCT05361200|Experimental|Adaptive dynamic cycling|For the patient-specific adaptive dynamic cycling group, the optimization process will be done after the 3rd, 6th, and 9th sessions. The optimization procedure is based on sample entropy of cadence calculation from the previous session's cycling performance. After optimization, participants will receive specific settings for the next session.
89316884|NCT05361200|Active Comparator|Non-adaptive dynamic cycling|For the non-adaptive group, individuals will cycle on the dynamic bike with pre-determined settings that will stay constant throughout the exercise protocol.
89316885|NCT05360888|Active Comparator|Tools for Life|All youth will receive the Tools for Life (Qungasvik) intervention. Tools for Life is an evidence-based, community-developed intervention focused on providing protective cultural experiences for Alaska Native youth to address suicide risk and alcohol use.
89316886|NCT05360888|Active Comparator|Tools for Life + Motivational Interviewing Social Network intervention (MISN)|Half of the youth will will also receive MISN in addition to the Tools for Life intervention. MISN is an evidence-based treatment that augments motivational interviewing with personal social network composition and structure visualization as a means to cultivating healthy social networks and cultural worlds.
89316887|NCT05360446|Placebo Comparator|Placebo|Subcutaneous injection
89316888|NCT05360446|Experimental|Inclisiran sodium|Subcutaneous injection
89316889|NCT05356884|Experimental|Diabetes Intervention|12-session behavioral intervention covering diabetes pathology, self-monitoring, medication adherence, identifying and responding to emergency situations, diet, physical activity, health care utilization and maintaining healthy habits.
89316890|NCT05356884|Active Comparator|Leadership & Life Skills|12-session leadership and life skills intervention focusing on adolescent self-esteem, self-efficacy, communication skills, mindfulnesss, healthy habits.
89316891|NCT05328401|Experimental|Intervention group (verum laser acupuncture group )|After blind random allocation, investigators applied verum laser acupuncture on patient with shoulder pain after stroke.
89316892|NCT05328401|Sham Comparator|Control group (sham laser acupuncture group)|After blind random allocation, investigators applied sham laser acupuncture on patient with shoulder pain after stroke.
89316893|NCT05327972|Experimental|1- Botulinum toxin|"The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).~The dosage is:~Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance."
89316894|NCT05327972|Placebo Comparator|2- PLACEBO|"The placebo comparator represents a saline solution containing an inactive lyophilisate.~The dosage is:~Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance."
89316895|NCT05325788|Other|Single daily message followed by location-based messaging|Participants in this condition receive a single daily message through the intervention app for two weeks (14 days) followed by location-based messaging for two weeks (14 days).
89316896|NCT05325788|Other|Location-based messaging followed by single daily message|Participants in this condition receive location-based messaging through the intervention app for two weeks (14 days) followed by a single daily message for two weeks (14 days) .
89316897|NCT05298748|Other|Ambient noise followed by Womb sound|At 34 weeks corrected age, preterm infants (29-33 weeks gestational age at birth), who are off respiratory support >1.5 lpm, will be exposed to alternating 6-hour periods of a recording of ambient noise followed by commercially available womb sounds over a 24-hour period for a combined total of 12 hours of womb sounds and 12 hours of ambient noise.
89316898|NCT05298748|Other|Womb sound recordings followed by ambient noise|At 34 weeks corrected age, preterm infants (29-33 weeks gestational age at birth), who are off respiratory support >1.5 lpm, will be exposed to alternating 6-hour periods of a recording of commercially available womb sounds followed by ambient noise over a 24-hour period for a combined total of 12 hours of womb sounds and 12 hours of ambient noise.
89316899|NCT05277337|Experimental|Group 1 (Alluzience)|Single treatment at the baseline visit with Alluzience. Glabellar lines will be treated with 10 U/0.05 mL per injection point. In total 50 s.U in 0.25 mL for 5 injection points.
89316900|NCT05277337|Active Comparator|Group 2 (powder BoNT-A: BOTOX/Vistabel)|Single treatment at the baseline visit with powder BoNT-A (BOTOX/Vistabel). Glabellar lines will be treated with 4 U/0.1 mL per injection point. In total 20 U in 0.5 mL for 5 injection points.
89316901|NCT05257876|Experimental|Intervention group|Participants in the intervention group will receive breathing exercise training, pain information booklet, and usual care.
89316902|NCT05257876|No Intervention|Control group|Participants in the control group will receive pain information booklet and usual care.
88806547|NCT05329662|Placebo Comparator|Placebo, then AD-MSCs infusions|Patients in group B will receive two autologous AD-MSC administrations on day 180 ± 14 and day 270 ± 14
88810987|NCT04825132|Active Comparator|Without suspicion of infection|The control patient will undergo the exact same procedures as the case patient described before except for the blood and respiratory sample part. • The typical control patient will be of the same age (+/- 3 years, but aged above 65 years), same sex, without suspicion of infection and hospitalized during the past or upcoming month in the same centre. There will be 2 controls for one case.
89316903|NCT05257109|Experimental|"Experimental E-Liquid Order A"|All participants will be given all e-liquids (i.e. all 16 flavor*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water will be presented in the same order from hypothesized least irritating to most irritating.
89316904|NCT05257109|Experimental|"Experimental E-Liquid Order B"|All participants will be given all e-liquids (i.e. all 16 flavor*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water will be presented in the same order from hypothesized least irritating to most irritating.
89316905|NCT05257109|Experimental|"Experimental E-Liquid Order C"|All participants will be given all e-liquids (i.e. all 16 flavor*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water will be presented in the same order from hypothesized least irritating to most irritating.
89316906|NCT05257109|Experimental|"Experimental E-Liquid Order D"|All participants will be given all e-liquids (i.e. all 16 flavor*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water will be presented in the same order from hypothesized least irritating to most irritating.
89316907|NCT05249985|Experimental|NMES plus protein supplementation|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps in addition to a daily protein supplement.
89316908|NCT05249985|Active Comparator|NMES|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.
89316909|NCT05248100|Experimental|Conditional Cash Transfer|Eligible and consenting participants living in an intervention health facility catchment area will receive the same standard of care HIV tracing and clinical services as control participants, plus the opportunity to receive a one-time incentive of 22,500 Tanzanian Shillings (TSH) (~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
89316910|NCT05248100|No Intervention|Control|Eligible and consenting participants living in a control health facility catchment area will receive the standard of care HIV tracing and clinical services.
89316911|NCT05246709|Active Comparator|Control Group|This group will be received the current standard of care (SOC) dressing method for PICC lines.
89316912|NCT05246709|Experimental|Cyanoacrylate Glue Group|This group will receive a few drops of cyanoacrylate glue on PICC line site prior to application of usual standard film dressing over the PICC line site.
89316913|NCT05240625|Experimental|Computer-aided colonoscopy|The subject will receive the standard colonoscopy procedure simultaneously with a computer-aided detection (CADe) analysis software designed to automatically detect and highlight potential polyps on colonoscopy images in a real-time manner during colonoscopy procedures.
89316914|NCT05240625|Active Comparator|Standard colonoscopy|The subject will receive the standard colonoscopy procedure.
89316915|NCT05239793|Other|NJOY e-cigarette|NJOY e-cigarette containing 5% nicotine strength pods
89316916|NCT05231460|Active Comparator|narcotic regimen with TAP block|Patient will receive Tap Block and will be administered the Narcotic Pain Regimen post-operatively
89316917|NCT05231460|Active Comparator|narcotic regimen with no TAP block|Patient will not receive TAP block and will be administered the Narcotic Pain Regimen post-operatively
89316918|NCT05231460|Active Comparator|non-narcotic regimen with TAP block|Patient will receive Tap Block and will be administered Non-narcotic Pain Regimen post-operatively
89316919|NCT05231460|Active Comparator|non-narcotic regimen with no TAP block|Patient will not receive TAP block and will be administered Non-narcotic Pain Regimen post-operatively
89316920|NCT05229341|Experimental|Diagnostic (needle biopsy, DDMS-2)|Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.
89316921|NCT05220332|Experimental|Heart to Heart|
89316922|NCT05220332|Active Comparator|Money Smart|
89316923|NCT05219292||Adult patients followed for a recent lung transplant.|Patients will be recruited during the pre-transplant assessment by the physiotherapist, the pneumologist and/or the transplant nurse coordinator. The patient has the hospital stay of the pre-transplantation to give his answer. The protocol starts on arrival in the rehabilitation department.
89316924|NCT05217537|Experimental|Cohort 1 (adolescents)|12 to < 18 years of age
89316925|NCT05217537|Experimental|Cohort 2 (children)|8 to < 12 years of age
88810988|NCT04806620||People with ME/CFS|No intervention will be administered.
88810989|NCT04806620||People with Long-COVID|No intervention will be administered.
88810990|NCT04806620||Healthy Controls|No intervention will be administered.
89316926|NCT05216068|Other|donated abandonment embryos|Embryos biopsies for PGT-A (by use of NGS platforms from our institute) will be used for the validation of our Lab QC.
89316927|NCT05211869|Experimental|T1D-CATCH|The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, peer support, and social needs management. Over the 9-month study period, session frequency will involve weekly individual sessions based on participant technology milestones and an optional monthly CHW-led peer group support session. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institutional COVID-19 rules.
89531614|NCT05929469|Experimental|Fully Automated Kick-Off + App + Check-In|"This arm includes participants who do not respond to the Fully Automated Kick-Off + App in stage 1.~In stage 1, participants will receive a Fully Automated Kick-Off and an mHealth program.~In stage 2, they will continue with the mHealth program, but will also receive a check-in with a study interventionist."
88810992|NCT04805177|Experimental|hematoma evacuation|Early minimally invasive image guided hematoma evacuation
89316928|NCT05211869|No Intervention|Usual Care Control Condition|Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.
89316929|NCT05208450|No Intervention|Usual care (UC) Group|"The study design is a randomized stepped wedge cluster trial whereby all clusters (practice sites) begin as part of the Usual Care (UC) control condition.~Clusters are then randomly assigned to cross over at different times with all clusters eventually receiving PACE. The study will involve each site starting with the UC, followed by a period of 3 months during which practice facilitators will train NCMs and CHWs, and finally followed by the PACE intervention for 12 months with a 6-month follow-up for outcome assessment. During the UC Period, patients at the sites will receive standard HTN care and standard printed HTN treatment guidelines. Immediately following this period, prior to implementation of PACE, we will conduct a practice capacity assessment at each site for 3 months. This period is then followed by the implementation of PACE."
89316930|NCT05208450|Experimental|Intervention Group|Thus, each cluster will belong successively to the control group and the intervention group. During the control period (UC) patients at the sites will receive standard HTN care delivered by their primary care providers and standard printed HTN treatment guidelines. This period is then followed by the implementation of PACE. Clusters are randomly assigned to cross over at different times with all clusters eventually receiving PACE. During the PACE implementation period, which will last 12 months, practice facilitators will work with each site to implement the components of PACE.
89316931|NCT05202925|Experimental|Musical Training|All subjects in the intervention group will receive a weekly 45-minute lesson, one-to-one musical training for 52 weeks.
89316932|NCT05197270|Experimental|4D-150 Dose Escalation up to 4 dose levels|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89316933|NCT05197270|Experimental|4D-150 Dose Expansion Dose 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89316934|NCT05197270|Experimental|4D-150 Dose Expansion Dose 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89316935|NCT05197270|Active Comparator|4D-150 Dose Expansion Control|Aflibercept at a fixed regimen will be administered.
89316936|NCT05197270|Experimental|4D-150 Steroid Optimization|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89316937|NCT05197270|Experimental|4D-150 Population Extension Dose 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89316938|NCT05197270|Experimental|4D-150 Population Extension Dose 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89316939|NCT05192941|Experimental|Inclisiran sodium 300 mg s.c. + open label rosuvastatin|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~Inclisiran sodium 300 mg s.c.~Corresponding placebo~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."
89316940|NCT05192941|Placebo Comparator|Corresponding placebo + open label rosuvastatin|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~Inclisiran sodium 300 mg s.c.~Corresponding placebo~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."
89316941|NCT05180435|Experimental|Family Meals|Have at least 5 dinners per week.
89316942|NCT05180435|Active Comparator|Standard|Consume the recommended amounts of fruits and vegetables.
89316943|NCT05178992|Experimental|Socially Assistive Robot Activity|Participants will attend two sessions per week and interact with the robot. Four weeks with a humanoid robot and four weeks with a dog robot. Participants can continue to join other activities held within the facility.
89316944|NCT05178992|Active Comparator|Usual Activity Program|Participants will attend at least two sessions per week at activities held within the facility. They will not be exposed to the robot activities.
89316945|NCT05175352|Experimental|Administration of Cendakimab and Cytochrome P450 (CYP) substrates|
89316946|NCT05173974|No Intervention|Negative Control|Denture adhesive will not be used.
89316947|NCT05173974|Active Comparator|Positive Control|A single application of 1 gram of Super Poligrip Free denture adhesive will be applied topically to oral tissues via the upper denture.
89316948|NCT05173974|Experimental|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
89316949|NCT05173974|Experimental|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
89316950|NCT05169073|Experimental|Virtual Reality MRCP|The MRCP images will be transferred into a 3D VR rendering software (Specto VR TM) for each patient. Residents will have the opportunity to use the virtual reality environment the day before surgery until a sufficient understanding of the anatomy is achieved.
89316951|NCT05169073|Active Comparator|Conventional MRCP|Controls will have regular access to the conventional MRCP images.
89316952|NCT05168839|Experimental|FLUO+|"Experimental arm = surgery with IOFA.~In the experimental arm, cancer resection and anastomosis will be performed after assessment of descending colon perfusion using intravenous injection of indocyanine green 0.1ml/kg."
89316953|NCT05168839|No Intervention|FLUO-|"Control arm = Surgery without IOFA.~In the control arm, cancer resection and anastomosis will be performed without intraoperative fluorescence angiography."
89316954|NCT05153915|Experimental|Tacrolimus granules (Modigraf)|"The first dose of Modigraf should be administered within 24 hours after reperfusion. Participants will be treated with a Modigraf-based immunosuppressive regimen.~The initial daily dose of Modigraf is given in two divided doses (recommended interval 12 hours) postoperatively. Subsequent oral Modigraf doses will be adjusted by the investigator based on clinical evidence of efficacy, occurrence of AEs, and tacrolimus whole blood trough level."
89316955|NCT05152628|Experimental|Tacrolimus granules (Modigraf)|Participants will receive the first dose of Modigraf in the morning within 24 hours after reperfusion. Total initial dose will be received in two divided doses post operatively. Subsequent oral Modigraf doses will be adjusted by the investigator and will be received in two doses (recommended interval 12 hours)
89316956|NCT05141708||Talazoparib-treated adults with HER2- gBRCAm mBC|Adult patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib treatment in first-line or later line of therapy between January 1, 2018 and September 30, 2020.
89316957|NCT05132868|Experimental|pre-educated with educational video|"Participants will receive a message to view educational videos prior to their genetic counseling appointment if they are assigned to a pre-educated arm. The video will be shared with patients via MyHealth in the education tab in advance of the genetic counseling session"
89316958|NCT05132868|Experimental|pre-educated with pamphlet|Participants will receive a message to view a pamphlet prior to their genetic counseling appointment if they are assigned to a pre-educated arm. The pamphlet will be sent to patients who cannot access the video via regular mail in advance of the genetic counseling session
89316959|NCT05132868|Other|educated during the session|Participants will receive traditional genetic counseling. . After the genetic counseling session, they will fill out a validated survey called the Multi-dimensional Measure of Informed Choice (MMIC) that assesses attitudes, knowledge, and uptake of genetic testing
89316960|NCT05117151||Observation|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
89316961|NCT05115630|Experimental|Cyclophosphamide|On Days 3 and 4, you will receive cyclophosphamide by vein over about 3 hours to help lower the risk of graft-versus-host disease
89316962|NCT05115630|Experimental|Mesna|On Days 3 and 4, You will also receive mesna by vein over 30 minutes every 4 hours for a total of 10 mesna doses.
89316963|NCT05115630|Experimental|Filgrastim|Starting on Day 7, you will begin to receive filgrastim as an injection under the skin 1 time a day.
89316964|NCT05115630|Experimental|Melphalan|On Day -7, you will receive melphalan by vein over about 30 minutes.
89316965|NCT05115630|Experimental|Fludarabine phosphate|On Days -7, -6, -5, and -4, you will receive fludarabine by vein about 1 hour.
89316966|NCT05115630|Experimental|Tacrolimus|Starting on Day 5, you will begin receiving tacrolimus to help lower the risk of GVHD. You will begin by receiving it nonstop by vein until you are able to take it by mouth. You will then take tacrolimus by mouth 2 times a day for about 3 months.
89316967|NCT05115630|Experimental|Mycophenolate mofetil|by mouth 3 times a day for 90 days or longer.
89316968|NCT05115630|Experimental|Total Body Irradiation One Dose|on Day -2, you may receive 1 dose of total body irradiation (TBI).
89316969|NCT05112731||First Ischemic Cardiac Event|Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up
89316970|NCT05106231|Experimental|PICC arm|Participants assigned to the intervention group will attend the PICC program, which will take four-month and each session 2.5 hours.
89316971|NCT05106231|Active Comparator|Control arm|Participants assigned to the DMTAC group will receive a standard intervention of pharmacist-led education.
89316972|NCT05105035|Active Comparator|Placebo|Patients are administered either IV ceftazidime or IV meropenem per standard of care and placebo. Placebo will be administered every 12 hours for Days 1-14.
89316973|NCT05105035|Experimental|ARV-1801 (ACG-701)|Patients are administered either IV ceftazidime or IV meropenem per standard of care and active ARV-1801. Day 1 dosing will be two doses of 1500mg of ARV-1801 administered 12 hours apart. Days 2-14 dosing will be 600mg of ARV-1801 administered every 12 hours.
89316974|NCT05098002|Experimental|Mindful based stress classes|6 week mindfulness program
89316975|NCT05096988|Experimental|PKU sphere liquid|PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.
89316976|NCT05090891|Experimental|Group A: INCB000928|Participants will receive INCB000928 for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 52 weeks.
89316977|NCT05090891|Placebo Comparator|Group B: Placebo followed by INCB000928|Participants will receive placebo for 24 weeks (double-blind period). Participants who completed the double-blind period will receive INCB000928 in the 52 week open-label extension period.
89316978|NCT05077657||Single-Arm|This is a multi-center, single arm, open-label study to evaluate the safety of complex high-risk PCI using Impella and surveillance with the Saranas Early Bird Bleed Monitoring System (EBBMS).
89316979|NCT05065541|Experimental|Part 1|
89316980|NCT05065541|Experimental|Part 2|
89316981|NCT05065541|Experimental|Part 3|
89316982|NCT05051657|Experimental|express pus range (PKU, MSUD, HCU, TYR and GA)|express plus to be transitioned onto over a maximum of 6 weeks and then incorporated into each participants usual diet for 28 days. Amount taken and frequency to be determined by dietitian.
89316983|NCT05046613||Pregnant women with migraine exposed to Rimegepant|Pregnant women with a diagnosis of migraine who are exposed to rimegepant at any time during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
89316984|NCT05046613||Pregnant women with migraine not exposed to Rimegepant|Pregnant women with a diagnosis of migraine who are not exposed to rimegepant (up to 5 product half-lives prior to conception) but who may be exposed to other products for the treatment/prevention of migraine at any time during pregnancy or just prior to pregnancy
89316985|NCT05044065|Experimental|Exercise group|The experimental group will in addition to standard care receive supervised and home-based exercise training program with a specific focus to induce metabolic stress (blood flow restriction exercise), and protein supplementation to ensure adequate protein intake.
89316986|NCT05044065|No Intervention|Usual care|The control group will in addition to standard care receive protein supplementation to ensure adequate protein intake.
89316987|NCT05028452|Other|Internet based support|Internet based support for informal caregivers to individuals who are undergoing treatment for head and neck cancer.
89316988|NCT05028140|Experimental|Piemonte association|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 tablet Piemonte, oral;~1 placebo tablet of empagliflozin, oral;~1 placebo tablet of piglitazone, oral."
89316989|NCT05028140|Active Comparator|Empagliflozin|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 placebo tablet of Piemonte, oral;~1 tablet of empagliflozin, oral;~1 placebo tablet of piglitazone, oral."
89316990|NCT05028140|Active Comparator|Pioglitazone|"The study is triple-dummy, thus the patient must take 3 tablets once a day, as follows:~1 placebo tablet of Piemonte, oral;~1 placebo tablet of empagliflozin, oral;~1 tablet of piglitazone, oral."
89316991|NCT05027581|Experimental|Chondrochymal® group|Subjects will be IA injected at the target knee with 3 mL of Chondrochymal® containing 5.0 x 107 BM-MSCs in lactated Ringer's solution at Day 1.
89316992|NCT05027581|Active Comparator|Hya-Joint Plus Synovial Fluid Supplement|Hya-Joint Plus Synovial Fluid Supplement containing 60 mg/3 mL of hyaluronic acid will be IA administrated into the subject's target knee at Day 1.
89316993|NCT05001737|Experimental|Cohort 1 (sJIA and AOSD) and Cohort 2 (SLE)|MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE
89316994|NCT04999761|Experimental|Cohort A-1|AB122 will be given in participants with advanced or metastatic solid tumor.
89316995|NCT04999761|Experimental|Cohort A-2|AB122 will be given in participants with advanced or metastatic solid tumor.
89316996|NCT04999761|Experimental|Cohort B-1|AB122 will be given in combination with TAS-116 in participants with pancreatic ductal adenocarcinoma.
89316997|NCT04999761|Experimental|Cohort B-2|AB122 will be given in combination with TAS-116 in participants with unresectable metastatic MSS/pMMR CRC without liver metastases.
89316998|NCT04999761|Experimental|Cohort B-3|AB122 will be given in combination with TAS-116 in participants with unresectable metastatic non-squamous NSCLC without actionable gene alterations.
89316999|NCT04999761|Experimental|Cohort D-1|AB122 will be given in combination with TAS-120 in participants with unresectable metastatic NSCLC with PD-L1 high expression and without actionable gene alterations.
89317000|NCT04999761|Experimental|Cohort E-1|AB122 will be given in combination with TAS-115 in participants with unresectable metastatic NSCLC without actionable gene alterations.
89317001|NCT04999761|Experimental|Cohort E-2|AB122 will be given in combination with TAS-115 in participants with unresectable metastatic ASPS, in those who received or no prior regimen for advanced disease.
89317002|NCT04999761|Experimental|Cohort C-1|AB122 will be given in combination with TAS-102 and Ramucirumab in participants with unresectable or recurrent gastric cancer or gastroesophageal junction cancer.
89317003|NCT04999761|Experimental|Cohort C-2|AB122 will be given in combination with TAS-102 and Bevacizumab in participants with unresectable metastatic CRC.
89317004|NCT04993807|Experimental|Shared decision-making tool|Participants in this arm will view a shared decision-making tool while they are undergoing consultation to have an atrial fibrillation ablation.
89317005|NCT04993261|Experimental|Diagnostic (dual energy CT scan)|Patients undergo one dual energy CT scan during scheduled CT scan.
89317006|NCT04986202|Experimental|Part A 2.5 mg|AZD4831 2.5 mg
89317007|NCT04986202|Experimental|Part A 5 mg|AZD4831 5 mg
89317008|NCT04986202|Placebo Comparator|Part A Placebo|Placebo
89317009|NCT04986202|Experimental|Part B Dose based on Part A|AZD4831 Dose based on Part A
89317010|NCT04986202|Placebo Comparator|Part B Placebo|Placebo
89317011|NCT04985643||Participants With MM|Participants diagnosed with MM (complete response [CR], very good partial response [VGPR] and partial response [PR]) and who have received one prior first line treatment within 3 months preceding the enrollment, will be observed retrospectively and medical data will be monitored and collected prospectively every 3 months until the second biochemical and symptomatic relapse is identified.
89317012|NCT04971564||Case|Patients with cerebral hypoxia victims of ischaemic stroke, acute parenchymal haemorrhage or subarachnoid haemorrhage
89317013|NCT04971564||Control|Patients without cerebral hypoxia
89317014|NCT04946552|Active Comparator|Individuals with normal BMI|(BMI 18-25 kg/m2)
89317015|NCT04946552|Active Comparator|Individuals with obesity|(BMI 30-40 kg/m2)
89317016|NCT04941599|Active Comparator|2-Hydroxybenzylamine (2-HOBA)|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
89317017|NCT04941599|Placebo Comparator|Placebo|Placebo- three tabs TID (po) for 6 weeks.
89317018|NCT04922554|Experimental|Omadacycline 300 mg PO|omadacycline 150 mg tablets (x 2) administered orally, once daily, q24h
89317019|NCT04922554|Placebo Comparator|Placebo PO|Placebo tablets resembling omadacycline (x 2) administered once daily, q24h
89317022|NCT04907357|Active Comparator|rTMS|Participants will receive up to 30 rTMS sessions within the 8-week treatment period.
89317023|NCT04907357|Sham Comparator|Sham (Placebo)|Participants will receive up to 30 sham rTMS sessions within the 8-week treatment period.
89317024|NCT04903132||Longhauler's Syndrome Cohort|Subject's with longhaulers
89317025|NCT04903132||Control Cohort|Control cohort will not have had a known case of COVID-19 or Longhauler's syndrome
89317026|NCT04903132||COVID Control Cohort|Subjects who have had COVID-19 but no known Longhauler's syndrome
89317027|NCT04901195|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period.
89317028|NCT04901195|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period.
89317029|NCT04886934|Experimental|Safety and clinical performance of the CS1 system|Placement of the CS1 device on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery.
89317030|NCT04872998|Experimental|Reduced Activity|Reduction of daily step count by 70% for two weeks, followed by two week recovery to normal activity level
89317031|NCT04856982|No Intervention|Part A: Natural History Run-in|Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess neurofilament light chain (NfL) levels.
89317032|NCT04856982|Experimental|Part B: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive tofersen 100 milligram (mg) or placebo via intrathecal (IT) injection on Days 1, 15, 29, and every 28 days thereafter for up to approximately 5.6 years.
89317033|NCT04856982|Experimental|Part C: Open-Label Extension|Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter up to the final maintenance dost visit. Participants who received tofersen during Part B will receive tofersen 100 mg on Days 1, 29, and every 28 days thereafter up to the final maintenance dost visit, with a dose of placebo on Day 15 to maintain the study blind. The combined duration of Part B and Part C is up to approximately 5.6 years.
89317034|NCT04856982|Experimental|Part D: Open-Label Treatment|Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will receive tofersen100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
89317035|NCT04855747|Experimental|REL-1017 25 mg|During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
89317036|NCT04855747|Placebo Comparator|Placebo|During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT).
89317037|NCT04854135|Experimental|CGM Intervention|All eligible patients will receive a Continuous Glucose Monitor (CGM) prior to hospital discharge after signing an informed consent.
89317038|NCT04849130|Active Comparator|Static reconstruction technique according to Schöttle|Static reconstruction technique according to Schöttle
89317039|NCT04849130|Active Comparator|Dynamic reconstruction technique according to Becher|Dynamic reconstruction technique according to Becher
89317040|NCT04831372|Active Comparator|On Table Group|"The Direct Anterior Approach (DAA) is a common way to perform total hip arthroplasty. There are two main techniques to perform total hip replacement through the anterior approach.~The control group will be using the first method, which is the on-table method, which uses a specialized surgical table, called a traction table. This table involves placing both feet in specialized boots that are then hooked up to the table, and allows for positioning of the operative leg with aid of the table.~Both the on-table and off-table techniques are routinely used both worldwide and by our joint replacement specialists at Carilion Clinic. This study will aim to compare the efficiency and efficacy of performing the DAA for total hip arthroplasty utilizing either the on-table or off- table technique. Patients will be randomized to receive their total hip arthroplasty with either the on- table or off-table method."
89317041|NCT04831372|Experimental|Off Table Group|"The Direct Anterior Approach (DAA) is a common way to perform total hip arthroplasty. There are two main techniques to perform total hip replacement through the anterior approach.~The experimental group will be using the second method, which is the off-table method. In this method the patient is placed on a standard operating room table and the operative leg is manually positioned by the surgeon during the procedure . This obviates the need for the additional staff members or purchase of a specialized table.~Both the on-table and off-table techniques are routinely used both worldwide and by our joint replacement specialists at Carilion Clinic. This study will aim to compare the efficiency and efficacy of performing the DAA for total hip arthroplasty utilizing either the on-table or off- table technique. Patients will be randomized to receive their total hip arthroplasty with either the on- table or off-table method."
89317042|NCT04823286|Experimental|Virtual reality health platform during hemodialysis|During 12 weeks subjects will use a VR platform during hemodialysis. The intervention will be virtual reality exercise, nutritional advice and psychological wellbeing support plus cognitive training.
89317043|NCT04823286|No Intervention|Control group-usual care|During 12 weeks subjects will carry on with the usual care in the hemodialysis unit
89317044|NCT04810546|Experimental|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.
89317045|NCT04810546|No Intervention|Usual care|Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
89317046|NCT04802161|Experimental|Arm A (daunorubicin and cytarabine liposome, pomalidomide)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 and then pomalidomide PO QD beginning between days 21-30 for 14 days in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial."
89531615|NCT05929469|Experimental|Fully Automated Kick-Off + App + Counseling|"This arm includes participants who do not respond to the Fully Automated Kick-Off + App in stage 1.~In stage 1, participants will receive a Fully Automated Kick-Off and an mHealth program.~In stage 2, they will continue with the standard mHealth program, but will also receive counseling from a study interventionist."
88814871|NCT05710835||irritant medications group|Patients who used midline catheter to infuse irritant medications.
88814872|NCT05710835||nonirritant medications group|Patients who used midline catheter to infuse nonirritant medications.
89317047|NCT04802161|Active Comparator|Arm B (daunorubicin and cytarabine liposome)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. Patients who do not respond, may receive a second cycle of liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression and unacceptable toxicity. Patients also undergo bone marrow aspirate and biopsy and collection of blood samples throughout all phases of the trial."
89317048|NCT04772638|Experimental|PLAY intervention|The PLAY intervention with educators, parents and children
89317049|NCT04772638|Placebo Comparator|Wait list control|
89317050|NCT04769752||No beta-blocker|Patient do no treat with beta-blocker before the surgery
89317051|NCT04769752||Beta blocker|Patient treat with beta-blocker in accordance to international guidelines
89317052|NCT04769752||Beta blocker2|Patient treat with beta-blocker without respect of international guidelines
89317053|NCT04763161||Experimental group|"Patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy.~Intervention is decompressive hemicraniectomy in the context of a malignant sylvian ischaemic cerebral"
89317054|NCT04763161||Control group|"Patients not suffering from AIC, hospitalised in neurosurgery for another reason,~Patients to be opered on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach."
89317055|NCT04733027|Experimental|Part 2 cohort 1 : PEP010 in combination with paclitaxel|Fort part 2 the Cohort 1 will include patients with PDAC treated with the combination of PEP-010 at the dose of 2.5 mg/kg and weekly paclitaxel 80 mg/m².
89317056|NCT04733027|Experimental|Part 2 cohort 2 : PEP010 in combination with gemcitabine|"In arm B, the dose escalation phase will begin with DL4 (1.2 mg/kg) and will follow a 3+3 design For part 2 Cohort 2 will include patients with PDAC or OC treated with the combination of PEP-010 in ascending doses, and gemcitabine at 1000 mg/m2.~Four doses of PEP-010 will be tested: 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg and 10 mg/kg, according to a 3+3 dose escalation design."
89317057|NCT04718194|Experimental|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
89317058|NCT04718194|Placebo Comparator|Self-monitoring|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
89317059|NCT04701619|Other|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
89317060|NCT04691778|Active Comparator|CTO PCI using antegrade wiring strategy starting with the Gladius guidewire|Study subjects will undergo CTO PCI with primary antegrade wiring strategy starting with the Gladius guidewire. In case of failed CTO crossing with the Gladius wire, the decision on continuing antegrade wire escalation with a different wire or switching to a different CTO PCI strategy will be left to the discretion of the operator.
89317061|NCT04691778|Other|CTO PCI using standard antegrade wire escalation strategy|Control subjects will undergo CTO PCI using standard antegrade wiring strategy starting with the lower/intermediate penetration force guidewires and, if necessary, escalating up to high gram-force guidewires, but without the use of first-choice Gladius guidewire.
89317062|NCT04690322|Active Comparator|Extended half-life factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
89317063|NCT04690322|Active Comparator|Non-Factor VIII-based replacement therapy|"Subjects who are either already on prophylactic standard half-life FVIII products or have not started prophylactic treatment will be randomized to start prophylactic extended half-life FVIII products or non-factor product (emicizumab). Both therapies are considered the current standard of care.~The study has 4 planned visits at baseline, 1 month, 6 months, and 12 months. They will coincide with the standard of care visits."
89317064|NCT04679467|Experimental|Experimental - single arm|All patients to recieve PKU sphere as part of their dietary management for phenylketonuria (PKU)
89317065|NCT04672226|Experimental|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
89317066|NCT04670666|Experimental|MADALENA|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Madalena association, oral;~1 tablet empagliflozin + linagliptin association placebo, oral;~1 tablet metformin placebo, oral."
89317067|NCT04670666|Active Comparator|Metformin + empagliflozin + linagliptin|"The patient must take 3 tablets once a day, as follows:~1 tablet Madalena association placebo, oral;~1 tablet empagliflozin + linagliptin association, oral;~1 tablet metformin, oral."
89317068|NCT04667078|Experimental|Cangrelor group|treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM. The dose of cangrelor will be started with a 30 micrograms/kg IV bolus over 1 minute right after randomization and before MT. The bolus will be immediately followed with 4 micrograms/kg/min IV infusion for the duration of MT up to 4 hours. Cangrelor infusion will be stopped at the end of the MT procedure and will not go further 4 hours. Transition to oral antiplatelet therapy will be possible 1 hour after cangrelor infusion discontinuation. No other anti-thrombotic drug is authorized during cangrelor infusion. MT technique choice is left to the investigator decision.
89317069|NCT04667078|Active Comparator|Best medical management group|treated by BMM associated to MT. Anti-thrombotic including alteplase are authorized if they follow the recommendations of the international guidelines. If alteplase infusion is given, no other anti-thrombotic drug is allowed for the following 24 hours. MT technique choice is left to the choice of the investigator.
88814873|NCT03030872||Predicate software|Olea Sphere PACS with Perfusion and DWI Modules
88814874|NCT03030872||Investigational software|Vue PACS v12.2 Magnetic Resonance (MR) Perfusion and Diffusion Weighted Imaging
89317070|NCT04666714|Experimental|Praga formulation|"The study is double-dummy. The participant must take pills twice a day, as follows:~Morning:Placebo pregabalin tablet, oral Night: Placebo pregabalin tablet, oral plus Praga formulation,oral"
89317071|NCT04666714|Active Comparator|Pregabalin|"The study is double-dummy. The participant must take pills twice a day, as follows:~Morning:Pregabalin tablet, oral Night: Pregabalin tablet plus, oral placebo Praga formulation, oral"
89317072|NCT04662541|Experimental|Mobile Integrated Health (MIH)|Patients with urgent medical needs are seen and treated in the home by trained community paramedics. The community paramedics perform a standardized assessment, including a physical examination, vital signs, home safety evaluation, and medication reconciliation. During the MIH encounter, the emergency medicine physician at each site is contacted via telemedicine. Physicians can access clinical notes, discharge summaries, and medication lists via the institutional EHR. Adjustments to outpatient medications can be e-prescribed and follow-up appointments can be scheduled with primary care clinicians.
89317073|NCT04662541|Active Comparator|Transitions of care coordinator (TOCC)|Patients receive a follow-up phone calls for a nurse coordinator within 48-72 hours of hospital discharge. Phone calls include clinical/social needs assessment with escalation to primary care team, emergency care, or social work as needed; patient education; and reminder about follow-up appointments.
89317074|NCT04661982||Observational (long term follow-up)|Patients undergo long term follow-up and complete questionnaires.
89317075|NCT04652570|Experimental|VB119 dose escalation|Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.
89317076|NCT04652453|Experimental|Post-Intervention Group (Geriatrics Bundle)|Enrolled participants in the intervention arm will receive all 3 components of the geriatrics bundle: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
89317077|NCT04652453|No Intervention|Pre-Intervention Group (Control)|Participants in the control arm will be enrolled prior to implementation of the geriatrics bundle to gather preliminary data about the secondary outcomes.
89317078|NCT04642885||dyad|parent with dementia and an adult child who is a caregiver
89317079|NCT04620915|Experimental|High-level construal|"Participants will be sent messages asking them to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014)."
89317080|NCT04620915|Experimental|Effortful down-regulation of craving for cigarettes|"Participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences)."
89317081|NCT04620915|Experimental|Up-regulation of goal energization|Participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking.
89317082|NCT04614233|Experimental|RiduZone (90% Oleoylethanolamide (OEA))|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA) daily for 16 months.
89317083|NCT04614233|Placebo Comparator|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months.
89317084|NCT04611737|Experimental|Experimental group|The researcher interviews with participants for 3 times.
89317085|NCT04611737|No Intervention|Control group|The participants receive usual care.
89317086|NCT04604873|No Intervention|No hospital one day care|No hospital one day care
89317087|NCT04604873|Other|Hospital one day care|Hospital one day care
89317088|NCT04602754|Experimental|BERLIM 25/20|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/20 association, oral;~1 tablet empagliflozin placebo, oral;~1 tablet rosuvastatin calcium placebo, oral."
89317089|NCT04602754|Active Comparator|Empagliflozin + rosuvastatin calcium|"The patient must take 3 tablets once a day, as follows:~1 tablet Berlim 25/20 association placebo, oral;~1 tablet empagliflozin, oral;~1 tablet rosuvastatin calcium, oral."
89317090|NCT04594018|Experimental|FINLÂNDIA|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:~1 tablet finasteride placebo, oral, once a day.~1 mL Finlândia hair lotion, topical, twice a day."
89317091|NCT04594018|Active Comparator|Minoxidil + finasteride|"The study is double-dummy. The patient must take 1 pill and apply hair lotion as follow:~1 tablet finasteride, oral, once a day.~1 mL minoxidil hair lotion, topical, twice a day."
89317092|NCT04566237|Experimental|24 months follow up after vitrectomy|Objective Scatter Index (OSI) and Average Lens Density (ALD) at inclusion, then 3 months, 12 months and 24 months after vitrectomy
89317093|NCT04562116|Experimental|CYP 450 Substrates plus Nemolizumab|Participants will receive 1 single oral dose of selected, commercially available, cytochrome P450 substrates (CYP450-S) on Day 1 and after a 1-week washout period, participants will receive a 60 milligram (mg) loading dose of nemolizumab via 2 consecutive subcutaneous (SC) 30-mg injections at the Week 1 visit, followed by a single 30-mg injection once in every 4 weeks (Q4W) at Week 5 and Week 9. Participants will receive a second oral dosing of CYP450-S at Week 10.
89317094|NCT04530136|Experimental|Ruconest|Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.
89317095|NCT04530136|Other|Standard of Care|SOC
89317096|NCT04528459|Active Comparator|Traditional fluoroscopy|Cohort 1 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using traditional fluoroscopy for insertion of the lag screw (current standard of care).
89317097|NCT04528459|Experimental|Stryker© ADAPT™ platform|Cohort 2 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using the Stryker© ADAPT™platform to assist with insertion of the lag screw.
89317098|NCT04522336|Experimental|Treatment (pembrolizumab, chemoradiotherapy)|See Detailed Description
88810993|NCT04804046|Experimental|Synbiotic|Bifidobacterium longum spp. longum R0175, Bifidobacterium animalis spp. Lafti B94, Bifidobacterium bifidum R0071 at 3x10^9 CFU/d plus resistant starch type 2, arabinoxylan, and galactooligosaccharide at 24 g/d will serve as the treatment.
88810994|NCT04804046|Placebo Comparator|Digestible Maltodextrin|Digestible maltodextrin will serve as the placebo.
89317099|NCT04504643|Experimental|Technology-assisted circuit training|Multicomponent circuit training using FItLight Trainer™ as an embodied tool to perform motor task. The circuit training is composed by aerobic, muscular, coordination and balance exercises.
89317100|NCT04504643|Experimental|Conventional circuit training|Multicomponent circuit training composed by aerobic, muscular, balance and coordination exercises. Coordination exercises wll be charged of simple dual task cognitive exercises (counting backwards, or making some easy math calculations, repeating words backward, finding words of the same family).
89317101|NCT04504643|Experimental|Nordic Walking|The training sessions are performed in a natural parc, which offers pathways of different lengths and levels of difficulty that will increase over the weeks.
89317102|NCT04503278|Experimental|Part 1 - CLDN6 CAR-T|Dose escalation in lymphodepleted patients until the MTD and/or RP2D.
89317103|NCT04503278|Experimental|Part 2 Vaccine-modulated - CLDN6 uRNA-LPX/CLDN6 modRNA-LPX|Dose escalation until the MTD and/or RP2D.
89317104|NCT04498767|Active Comparator|Arm 1: Standard of Care + palliative RT|"Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).~Systemic therapy will be pre-specified based on the standard of care approach for that patient, and it may include cytotoxic, targeted, hormonal, or immunotherapy."
89317105|NCT04498767|Experimental|Arm 2: Standard of Care + SBRT|"The experimental arm consists of SBRT (and standard of care systemic therapy). Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size & location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.~Patients treated with prior or concomitant systemic therapy are eligible for this study. Use of chemotherapy regimens, targeted therapy or immunotherapy containing potent enhancers of radiation damage (e.g. gemcitabine, doxorubicin) can be postponed or interrupted for a duration of one month after radiation."
89317106|NCT04487639|Experimental|Cohort : patients needing oncofertility preservation|
89317107|NCT04476953|Experimental|Treatment Group|Subjects will receive treatment drug Fisetin
89317108|NCT04476953|Placebo Comparator|Placebo Group|Subjects will receive placebo
89317109|NCT04448808|Experimental|BX-1 (dronabinol)|BX-1
89317110|NCT04448808|Placebo Comparator|Placebo|Placebo of BX-1
89317111|NCT04435197|Experimental|Arm A|"Arm 1:~A: Pembrolizumab 200mg(100mg if weight less than 50kg) IV on days 1 and 22 B: Carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~D: Ivor-Lewis or McKeown esophagectomy~The participants will receive preoperative A+B+C. 4-6 weeks after completion of preoperative therapy ，D will be performed if there is no contraindication."
89317112|NCT04428541|Experimental|Questionnaire|Description : 18 items questionnaire, filled by the parents of the child
89317113|NCT04407767|Experimental|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
89317114|NCT04407767|Active Comparator|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
89317115|NCT04365387|Experimental|Nemolizumab|Participants will receive a loading dose of nemolizumab (60 milligram [mg]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) will then be administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12.
89317116|NCT04365387|Placebo Comparator|Placebo|Participants will receive a placebo via 2 SC injections at baseline. Placebo will then be administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.
89317117|NCT04352569|Active Comparator|transcranial direct current stimulation|The transcranial direct current stimulation (tDCS) with two elecrodes placed over the scalp: the anode over the LTP, le cathode over L DLPFG.
89317118|NCT04352569|Sham Comparator|transcranial direct current stimulation sham|tDCS device allows sham stimulation. This technic give the same impression that active stimulation and allows optimum placebo stimulation.
89317119|NCT04334109|Experimental|Family-DSME|"Approach~Family motivational interviewing techniques~Family goal setting~Understanding supportive and nonsupportive family behaviors~Family behavioral changes Mode of Delivery~Group sessions delivered by a certified diabetes educator (CDE) to patients and their family members Dosage~10 hours delivered in one-hour sessions over 10 weeks Participants~300 patients with T2D and 300 family members (family members will take part in educational sessions and data collection)"
89317120|NCT04334109|Active Comparator|Standard-DSME|"Approach~Individual motivational interviewing techniques~Individual goal setting~Individual behavioral changes Mode of Delivery~Group sessions delivered by a CDE to patients Dosage~10 hours delivered in one-hour sessions over 10 weeks Participants~300 patients with T2D (family members will take part in data collection but not educational sessions)"
89317121|NCT04310345|Experimental|Animal-Assisted Interaction|Children and their caregivers will spend approximately 10-15 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
89317122|NCT04305067|Experimental|Supervised aerobic and resistance exercise|16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
89317123|NCT04283617|Experimental|Diabetic with short duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes < 5 years
89317124|NCT04283617|Experimental|Diabetic with long duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes > 5 years
89317125|NCT04272034|Experimental|Cohort 1|Participants with select solid tumors who are immunotherapy treatment-naive
89317126|NCT04272034|Experimental|Cohort 2|Participants with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors who are immunotherapy treatment-naïve.
89317127|NCT04272034|Experimental|Cohort 3|Participants with progression of any solid tumor treated with an approved anti-PD-1 monoclonal antibody therapy
89317128|NCT04263792|Other|Biodistribution cohort|The Biodistribution cohort will include up to 5 patients who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [18F]fluoropropyl-trimethoprim PET/CT scans over a period of approximately 4 hours.
89317129|NCT04263792|Other|The Dynamic cohort|The Dynamic cohort will include up to 15 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans post injection of [18F]fluoropropyl-trimethoprim.
89317130|NCT04258852|Experimental|Low Strength, High Strength|
89317131|NCT04258852|Experimental|High Strength, Low Strength|
89317132|NCT04257201|Active Comparator|Control -- no mushrooms|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
89317133|NCT04257201|Experimental|Yellow Oyster -- 84 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
89317134|NCT04257201|Experimental|Yellow Oyster -- 168 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
89317135|NCT04257201|Experimental|White button -- 84 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
89317136|NCT04257201|Experimental|White button 168 g|Subjects will be randomized to consume a test day salad with 0 g, 84 g (yellow oyster or white button) or 168 g (yellow or white button) mushrooms. Mushrooms will be cooked prior to serving.
89317137|NCT04240106|Experimental|Niraparib in combination with Aromatase Inhibitors|Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib orally, once daily, flat- fixed, continuously in 28-day cycles plus aromatase Inhibitors.
89317138|NCT04226365|Experimental|Experimental|10mg capsule once daily for 4 weeks of nortriptyline
89317139|NCT04226365|Placebo Comparator|Control|10mg capsule once daily for 4 weeks of Thick-It filler
89317140|NCT04211675|Other|Treatment|"The planned therapy will involve 6 cycles of 21 days each consisting of irinotecan, temozolomide, dinutuximab, sargramostim, and natural killer (NK) cells.~Treatment cycles will be repeated every 21 days based upon disease response and toxicity criteria. Tumor response will be assessed after Cycles 2, 4 and 6. Patients who do not experience dose-limiting toxicities and achieve complete response, partial response or stable disease may continue to receive the assigned therapy."
89317141|NCT04201353|Experimental|Conditional Cash Transfer|Participants attending intervention clinics will have the opportunity to receive up to 6 consecutive monthly cash transfers of 22,500 TSH (~$10) each, conditional on visit attendance with the HIV care provider. Cash transfers will be given once monthly for up to 6 months, spaced ≥25 days apart (consistent with National Guidelines for monthly or bimonthly visits) and are conditional on visit attendance. This means that the cash transfer is only given when the patient visits the clinic for their routine appointment, regardless of whether the visit is earlier or later than the scheduled appointment.
89317142|NCT04201353|No Intervention|Control|Participants attending control clinics will receive the standard of care.
89317143|NCT04196959|Experimental|Single Arm|All patients will receive TYR sphere, a Food for Special Medical Purposes, as part of thier restricted diet for 28 consecutive days.
89317144|NCT04193436|Experimental|PF-06835919 with severe hepatic impairement|This arm includes participants with severe hepatic impairment who will receive a 25mg oral dose of PF-06835919
89317145|NCT04193436|Experimental|PF-06835919 with moderate hepatic impairement|This arm includes participants with moderate hepatic impairment who will receive a 25mg oral dose of PF-06835919
89317146|NCT04193436|Experimental|PF-06835919 with mild hepatic impairement|This arm includes participants with mild hepatic impairment who will receive a 25mg oral dose of PF-06835919
89317147|NCT04193436|Experimental|PF-06835919 without hepatic impairment|This arm includes participants without hepatic impairment who will receive a 25mg oral dose of PF-06835919
89317148|NCT04188405|Experimental|Treatment (ponatinib, venetoclax, decitabine)|See Detailed Description.
89317149|NCT04168528|Experimental|Part I: safety, tolerability, biodistribution and dosimetry|Phase I
89317150|NCT04168528|Experimental|Part II: tumor targeting potential and correlation to IHC|Phase II
89317151|NCT04154631|Experimental|Standard TranS-C|Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.
89317152|NCT04154631|Experimental|Adapted TranS-C|The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions.
89317153|NCT04154631|Active Comparator|UC-DT|Usual Care Delayed Treatment. Usual care in the partner CMHCs starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
89317154|NCT04128488||Transgender women and non-binary individuals without HIV|
89317155|NCT04128488||Transgender women and non-binary individuals with HIV|
89317156|NCT04127110|Experimental|Lorlatinib|"Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).~Lorlatinib will be taken continuously on a daily basis until disease progression, unacceptable toxicity, occurrence of any withdrawal criterion, whichever comes first."
89317157|NCT04104776|Experimental|Phase 2 Cohort M1|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M1: patients with urothelial carcinoma or other advanced/metastatic solid tumors (with known ARID1A mutation)"
89317158|NCT04104776|Experimental|Phase 2 Cohort M2|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M2 patients with ovarian clear cell carcinoma (with known ARID1A mutation)"
89317159|NCT04104776|Experimental|Phase 2 Cohort M3|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M3 patients with endometrial carcinoma (with known ARID1A mutation)"
89317160|NCT04104776|Experimental|Phase 2 Cohort M4|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M4 patients with peripheral T-cell lymphoma (PTCL) and patients with diffuse large B-cell lymphoma (DLBCL), including patients with documented germinal center B cell like diffuse large B-cell lymphoma (GCB-DLBCL) with at least 1 EZH2 hotspot mutation"
89317161|NCT04104776|Experimental|Phase 2 Cohort M5|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M5 patients with relapsed or refractory malignant pleural or peritoneal mesothelioma with known BAP1 loss"
89317162|NCT04104776|Experimental|Phase 2 Cohort M6|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M6 patients with castration-resistant prostate cancer(mCRPC) with measurable soft tissue disease"
89317163|NCT04102150|Experimental|DS-3201b|
89317164|NCT04089930||Vaccine|Those SLE patients who had been given herpes zoster vaccine in our original RCT
89317165|NCT04089930||Placebo|Those SLE patients who had been given placebo vaccination in our original RCT
89317166|NCT04089059|Other|Treatment Arm|Pulmonary Artery Pressure Guided Heart Failure Management (PAPGHFM) and Guideline Directed Medical Therapy (GDMT) considering daily Pulmonary Artery Pressure (PAP) measurements and vital signs collected by Cordella Heart Failure System (CHFS).
89317167|NCT04088097|Experimental|Cognitive-Behavioral Therapy|Adapted Cognitive-Behavioral Therapy (CBT) for adolescents with binge eating or loss-of-control eating.
89317168|NCT04088097|Other|Control Condition|Educational materials related to adolescent health and nutrition.
89317169|NCT04085237|Experimental|Ultrasound-guided continuous ESP block with opioid PCA|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T7/T8 spinous process. The patient's skin will be anesthetized with 2% lidocaine. A Contiplex Echo ultra 360 18G needle with 20G × 55 cm Contiplex Echo catheter will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg) followed by insertion of the echo catheter system under direct vision 2-3 cm beyond the needle tip.
89317170|NCT04085237|Sham Comparator|Ultrasound-guided sham block and catheter with opioid PCA|The exact same procedure as the experimental group will be followed, substituting saline for local anesthetic at the same amounts and rate. As with the ESP group, the patients will have PCA initiated postoperatively in the PACU at the same doses.
89317171|NCT04076176|Active Comparator|L-amino Acids|"The specific amount and timing of L-amino acid consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.~Consumption period: 12 weeks."
89317172|NCT04076176|Experimental|PKU Sphere|"The specific amount and timing of PKU sphere consumption will be at the instruction of a dietitian following a review of the individual patient's dietary needs.~Consumption period: 12 weeks."
89317173|NCT04040439||Dexmedetomidine Hydrochloride|"Pediatric patients (45 weeks corrected gestational age to <18 years old) administered Precedex (Dexmedetomidine Hydrochloride) for sedation during and after mechanical ventilation in the intensive care setting"
89317174|NCT04017962|Experimental|Hematopoietic cell transplantation/HCT|"Participants will be hematopoietic cell transplantation (HCT) recipients with a history of CMV infection. INTERVENTIONAL COHORT: Patients receive letermovir PO QD (or IV over 1 hour for patients unable to receive PO) for 14 weeks in the absence of disease progression or unacceptable toxicity.~OBSERVATIONAL COHORT: Patients undergo collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180."
89317175|NCT03997786|Active Comparator|Part A|Part A is a DOSE FINDING COMPONENT: OPEN LABEL PK lead-in and safety component
89317176|NCT03997786|Experimental|Part B Part 1: Placebo and active comparator controlled study|
89317177|NCT03997786|Experimental|Part B-1 and B-2: Randomized withdrawal and retreatment after relapse|
89317178|NCT03997786|No Intervention|Part B 3: Efficacy and Safety Follow-up|
89317179|NCT03997786|Experimental|Part C: LTE|
89317180|NCT03981575||Study Visits|Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months
89317181|NCT03967288|Experimental|Chloroprocaine|50 mg of 1% spinal chloroprocaine (5 mL) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
89317182|NCT03967288|Active Comparator|Bupivacaine|10.5 mg of spinal hyperbaric bupivacaine (1.4 mL of 0.75% bupivacaine hydrochloride in 8.25% dextrose) injected into the intrathecal space over approximately 5 seconds once prior to the start of surgery
89317183|NCT03954483|Experimental|Buspirone|Participants will receive buspirone 10 mg prior to experiments.
89317184|NCT03954483|Experimental|Triazolam|Participants will receive triazolam 0.25 mg prior to experiments.
89317185|NCT03954483|Placebo Comparator|Placebo|Participants will receive a placebo prior to experiments.
89317186|NCT03954327|Experimental|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir|one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
89317187|NCT03954327|Placebo Comparator|Placebo|Identical tablets resembling one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets
89317188|NCT03940690|Experimental|Anti-VEGF injections (bevacizumab)|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9
89317189|NCT03940690|Active Comparator|Arm : laser only|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
89317190|NCT03934372|Experimental|Ponatinib|Phase 1: Ponatinib administered according to age-based cohort doses and formulations to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2: Ponatinib administered at the recommended Phase 2 dose.
89317191|NCT03933670|Experimental|Diagnostic (HP C-13 MRI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over less than one minute, then undergo MRSI after 1-2 minutes. Within 15-60 minutes, patients may receive optional hyperpolarized carbon C 13 pyruvate and undergo MRSI. Patients also undergo MR/US fusion-guided prostate biopsy within 12 weeks following HP C-13 MRSI.
89317192|NCT03924466|Experimental|Cancer patients|"Cohort 1: locally advanced or metastatic breast cancer patients~Cohort 2: Patients with locally advanced, unresectable, or metastatic cancer disease of breast with low, intermediate or high HER2-expression, salivary gland; gastric body or gastro-esophageal junction; endometrium; uterus; lung; biliary tract; gallbladder; pacreas; colorectum; urothelium; prostate; other solid with intermediate or high HER2-expression~Cohort 3: Patients with local or locally advanced HER2-+ breast carcinoma, who are planned for neo-adjuvant treatment prior to surgery, and who are suspected for axillary lymph node invasion."
89317193|NCT03866668|Experimental|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
89317194|NCT03861702|Experimental|FOLFOX + Irinotecan|"Oxaliplatin 60 mg/m2 Intravenously (IV) over 2 hours~Liposomal Irinotecan (free base) 50 mg/m2 IV over 90 minutes after completion of oxaliplatin~Leucovorin 400 mg/m2 IV over 30 minutes after completion of liposomal irinotecan~5-Fluorouracil 2,400 mg/m2 IV over 46 hours via infusion pump at home~All drugs administered on day 1 of each 14 day cycle."
89317195|NCT03846167||FTT PET/CT|"The imaging procedure may include one or both of the following imaging sessions; 1) a 45- 60 minute dynamic scan, starting at approximately the same time as the injection and/or 2) a skull base to mid-thigh scan starting approximately 60 minutes post injection of [18F]FTT.~Participants will be asked to complete the following research procedures: [18F]FTT PET/CT scan before surgery or treatment [18F]FTT PET/CT scan after you start treatment (optional)"
89317196|NCT03815643|Experimental|Avelumab|
89317197|NCT03794856||Asthma patients|Asthma patients will undergo behavioral testing and imaging at a single timepoint.
89317198|NCT03794856||Healthy Volunteers|Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.
89317199|NCT03791437|Experimental|Experiment groups|Post chest operative use Digital chest drainage system until Patient's discharge day
89317200|NCT03791437|Active Comparator|Control groups|Post chest operative use traditional drainage system until Patient's discharge day Not use Digital chest drainage system
89317201|NCT03773653|Experimental|BMT to be combined with BAT|Participants in this group will receive bilateral robotic priming and bilateral arm training or mirror therapy within the 90-minute training sessions.
89317202|NCT03773653|Experimental|BMT to be combined with MT|Participants in this group will receive bilateral robotic priming and mirror therapy within the 90-minute training sessions.
89317203|NCT03773653|Active Comparator|BMT to be combined with IOT|Participants in this group will receive bilateral robotic priming and impairment-oriented training within one 90-minute training session.
89317204|NCT03771391|Experimental|4 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 4 weeks.
89317205|NCT03771391|Experimental|8 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 8 weeks.
89317206|NCT03771391|Experimental|12 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 12 weeks.
89317207|NCT03752970|No Intervention|Screening Cohort|Patients enrolled in the Screening Cohort did not receive study treatment. This was a feasibility phase for fistula preparation and seton placement to determine the tissue samples that were suitable for analysis of the primary endpoint in the Study Cohort.
89317208|NCT03752970|Placebo Comparator|Study Cohort - Placebo|Patients with perianal fistulising Crohn's disease received Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
89317209|NCT03752970|Experimental|Study Cohort - Spesolimab|Patients with perianal fistulising Crohn's disease received Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).
89317210|NCT03746769|Experimental|Single Arm Study|
89317211|NCT03720704||GORE VIABAHN VBX Balloon Expandable Endoprosthesis|The GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted according to the institution standard of practice in patients needing preservation of peripheral vessels due to multiple pathologies and conditions.
89317212|NCT03681184|Placebo Comparator|Placebo|Lumasiran-matching placebo (normal saline [0.9% NaCl]) was administered subcutaneously (SC) at Day 1 and Months 1, 2 and 3 during the 6-Month Double-blind (DB) Period, followed by lumasiran SC, 3.0 mg/kg, at Months 6, 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month Open-label Extension (OLE) period.
89317213|NCT03681184|Experimental|Lumasiran|Lumasiran was administered SC, 3.0 mg/kg, at Day 1 and Months 1, 2 and 3 during the 6-Month DB Period, followed by lumasiran SC, 3.0 mg/kg at Month 6, and lumasiran-matching placebo SC at Months 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month OLE period.
89317214|NCT03661645|Active Comparator|Methylprednisolone Treated Group|Subjects in this group will receive single intraoperative course of 10 mg IV dexamethasone & 6 day oral methylprednisolone taper that is 10 mg Intravenous IV dexamethasone and 6 day oral methylprednisolone taper course
89317215|NCT03661645|Other|Control Group|Subjects in this group will receive single intraoperative dose of 10 mg IV dexamethasone; that is 10 mg Intravenous (IV) dexamethasone
89317216|NCT03658980|Experimental|Health Education Intervention|Face-to-face health education session on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminders at Day 7, 30 and 90.
89317217|NCT03658980|No Intervention|Control Group|No Intervention will be conducted in this control group
89317218|NCT03658486|Other|Exercise|12 weeks of progressive, home-based, moderate intensity, aerobic and strengthening exercise. Aerobic exercise will be completed 5 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous brisk walking at week 12. Strengthening exercises will involve whole body activities and commence with 1 set of each exercise (8-15 repetitions) and progress to 3 sets. The strengthening exercises will gradually progress in difficulty throughout the program.
89317219|NCT03602937|Experimental|Renastep|All participants to incorporate Renastep into their usual dietary regime.
89317220|NCT03583957|Experimental|Entire Study|Each patient is eligible for all interventions in the study.
89317221|NCT03575793|Experimental|Phase I (Dose Escalation): nivolumab, ipilimumab and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (escalating cohorts, IV).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur.~Plinabulin escalation is as follows:~Level -1 : 13.5mg/m^2~Level 1 (start) : 20mg/m^2~Level 2 : 30mg/m^2"
89317222|NCT03575793|Experimental|Phase II: nivolumab, ipilimumab, and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (MTD from Phase I).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur ."
89317223|NCT03573401|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Photodynamic therapy (PDT)"
89317224|NCT03573401|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)
89317225|NCT03559868|Active Comparator|Digoxin 3 mcg/Kg/day|Patients receiving oral digoxin 3 mcg/Kg/day
89317226|NCT03559868|Active Comparator|Digoxin 0.15 mcg|Patients receiving oral digoxin 0.15 mcg/Kg/day
89317227|NCT03559868|Placebo Comparator|Placebo|oral placebo
89317228|NCT03542708|Experimental|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma.
89317229|NCT03542708|No Intervention|Control|The contralateral ovary will not be injected.
89317230|NCT03539731|Active Comparator|Group I ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.
89317231|NCT03539731|Experimental|Group II ([18F]DASA-23, PET)|Intracranial tumor participants receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.
89317232|NCT03539731|Experimental|Group III ([18F]DASA-23, PET)|Patients with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan. These patients will undergo one [18F]DASA 23 PET/MRI scan before the initiation of therapy, and a second/final [18F]DASA 23 PET/MRI scan within 2-6 weeks after initiation of therapy for their GBM.
89317233|NCT03539731|Active Comparator|Group IV ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET/MRI brain scan for 60 mins
89317234|NCT03527069|Experimental|CIPROS 10|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Cipros 10 association; and~1 tablet crestor placebo Oral, once a day."
89317235|NCT03527069|Active Comparator|Crestor|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Crestor 10mg; and~1 tablet Cipros association placebo Oral, once a day."
89317236|NCT03524469||Normal weight|"Normal Weight will be defined as pre-pregnant BMI between 18.5-23.9 kg/m2 and passing the 28 week oral glucose tolerance test."
89317237|NCT03524469||Insulin resistant|"Insulin Resistance will be defined as meeting any of the following:~pre-pregnant BMI ≥ 28 and failed the 28 week oral glucose screening test~pre-pregnant BMI ≥ 28 and diagnosis of either A1 (diet controlled) or A2 (insulin-requiring) gestational diabetes during pregnancy, but insulin therapy discontinued after birth.~pre-pregnant BMI ≥ 28 and diagnosed with type 2 diabetes during pregnancy~pre-pregnant BMI ≥ 30, and unmediated."
89317238|NCT03467386|Experimental|Treatment (TMLI, cyclophosphamide)|Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.
89317239|NCT03430037|Experimental|Treatment|Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
89317240|NCT03430037|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days, for 2 consecutive months.
88810995|NCT04798651|Experimental|patients with multiple sclerosis or clinically isolated syndrome|subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome
89317241|NCT03419819|Experimental|PKU Sphere|"Phase 1: 1 week To evaluate the acceptability of PKU Sphere during a short-term (1 week) period. Individuals with PKU will aim to consume a minimum of 30% of the medical food component of the diet as PKU Sphere. The amount will be assessed and advised on an individual basis.~Phase 2: 4 weeks To evaluate longer-term acceptability and metabolic control in individuals with PKU consuming an agreed target of 50 - 100% of their medical food component of the diet as PKU Sphere for 4 weeks. Some individuals, particularly young children between the ages of 3 - 6 years, may require a 1 - 3 week build up period to reach target volume which will be assessed on an individual basis."
89317242|NCT03329677|Experimental|Transference-focused Psychotherapy (TFP)|Transference-focused psychotherapy is a psychodynamic talk therapy utilized in treating borderline personality disorder in men and women.
89317243|NCT03326102|Experimental|DHP107|"The 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of cycle 1.~Total 48 subjects (including PK subjects) will receive DHP107 200 mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days."
89317244|NCT03326102|Experimental|IV paclitaxel|Total 24 subject will receive IV paclitaxel 80 mg/m2 weekly.(3 weeks on/1 week off)
89317245|NCT03324308|Experimental|Interventional Group|"Participants undergoing dynamic computed tomography myocardial perfusion imaging.~Intervention: Diagnostic Test: Dynamic Computed Tomography Angiography Imaging"
89317246|NCT03321019||Healthy controls|Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
89317247|NCT03321019||Parkinson's disease|Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
89317248|NCT03318978|Experimental|25 ng dose|Capsule containing 25 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
89317249|NCT03318978|Experimental|50 ng dose|Capsule containing 50 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
89317250|NCT03318978|Experimental|100 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
89317251|NCT03318978|Experimental|250 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
89317252|NCT03317405|Experimental|Cohort I (endoxifen hydrochloride)|Participants apply endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
89317253|NCT03317405|Placebo Comparator|Cohort II (placebo)|Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
89317254|NCT03316573|Experimental|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks for 35 cycles
89317255|NCT03285321|Experimental|Arm 1|Nivolumab 480mg IV every 4 weeks for up to 6 cycles
89317256|NCT03285321|Experimental|Arm 2|Nivolumab 240mg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)
89317257|NCT03273907|Experimental|CyPass System|CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery
89317258|NCT03247972||Patients with peripheral artery disease receiving evolocumab + high dose statins|"Adult patients with a history of Peripheral Artery Disease (PAD) defined as one or more of the following:~Documented history of PAD~Previous limb or foot amputation for arterial vascular disease (i.e., excludes trauma),~Carotid artery disease (defined as >50% stenosis or prior revascularization )"
89317259|NCT03202108|Experimental|Consumption of Krio|Incorporation of Krio into the daily diet.
89317260|NCT03168399|Experimental|Consumption of PKU Explore|Daily feed, substituting the participant's normal phe-free protein substitute for PKU Explore.
89317261|NCT03161353|Experimental|Cohort A|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel (during 4 cycles):~PET responders or not responders after surgery: Continue with Perjeta+Herceptin+ Endocrine therapy (tamoxifen or letrozole) during 12 cycles~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
89317262|NCT03161353|Experimental|Cohort B|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) during 2 cycles.~PET responders: Perjeta+Herceptin+Endocrine therapy during 6 cycles. -Complete response: continue with Perjeta+Herceptin+ Endocrine therapy during 10 cycles -Non-complete response: Perjeta+Herceptin+ Carboplatin+ Docetaxel during 6 cycles and Perjeta+Herceptin+Endocrine therapy during 4 cycles.~PET non-responders: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients with or without complete response will continue with Perjeta+Herceptin+Endocrine therapy during 10 cycles.~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
89317263|NCT03161353|Experimental|Cohort C|cohorts C if there is evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients will continue with Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) after surgery or no surgery.
89317264|NCT03103321|Experimental|"Arm A (Knowing your Options, Prostate Choice)"|"Patients receive decision aids Knowing your Options before and Prostate Choice during their consultation visit."
89317265|NCT03103321|Experimental|"Arm B (Knowing your Options)"|"Patients receive Knowing your Options decision aid before their consultation visit."
89317266|NCT03103321|Experimental|"Arm C (Prostate Choice)"|"Patients receive Prostate Choice decision aid during their consultation visit."
89317267|NCT03103321|Active Comparator|Arm D (usual care)|Patients undergo usual care.
89317268|NCT03084757|Experimental|research of druggable molecular alterations on tumor biopsy|
89317269|NCT03058848|Experimental|Consumption of PKU Start|Daily feed, substituting the participant's normal phe-free formula for PKU Start.
89317270|NCT03033251|Active Comparator|Non invasive ventilation|Patients will receive non invasive ventilation with setting decided by the attending physician.
89317271|NCT03033251|Active Comparator|High Flow 50 L/min|High Flow Oxygen Cannula with a flow set at 50 L/min.
89317272|NCT03033251|Active Comparator|High Flow 30 L/min|High Flow Oxygen Cannula with a flow set at 30 L/min.
89317273|NCT02915211|Experimental|Consumption of Keyo|Participants will consume their normal KD and take Keyo as advised by the lead dietitian.
89317274|NCT02901184|Active Comparator|Spironolactone treatment|Spironolactone will be prescribed by the Investigator and filled by patient at conventional pharmacies as 25 mg tablets. The treatment will be on top of standard care. Initial dose is 25 mg/day, which will be increased to target dose 50 mg/day if tolerated. Eplerenone can be prescribed if spironolactone is not tolerated.
89317275|NCT02901184|Placebo Comparator|Standard care alone|Patients in the control arm will get the standard care alone
89317276|NCT02879136|Active Comparator|Physical Therapy|Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
89317277|NCT02879136|Active Comparator|Physical Therapy plus Methylphenidate|Methylphenidate 20 mg daily in combination with PT
89317278|NCT02879136|Active Comparator|Physical Therapy plus Atomoxetine|Atomoxetine 10 mg daily in combination with PT or PT alone.
89317279|NCT02869243|Experimental|hrBMP4|Intra-tumour and interstitial convection enhanced delivery (CED) as a continuous infusion via intracranial catheters of hrBMP4 solution and gadolinium
89317280|NCT02862119|Experimental|FFR Treatment Arm|"Following PCI of the infarct related artery it is up to the PCI operator to perform FFR-guided PCI of non-infarct related lesion(s) during the index procedure or later during the index hospital admission. For stenosis grade 90-99% FFR is not mandatory (but recommended). An FFR value of ≤0.80 is to be considered significant for ischemia with a recommendation that non-culprit PCI is performed. It is up to the operator to decide whether to use intra-venous or intracoronary adenosine during FFR. An FFR of >0.80 is to be considered non-significant for ischemia with a recommendation that medical management is pursued.~Pressure wires: Only Fractional Flow Reserve pressure wires from St Jude Medical or Boston Scientific can be used in this study."
89317281|NCT02862119|Active Comparator|Conservative Treatment Arm|Only the infarct-related artery will be treated with PCI in this treatment arm during the index hospital admission. Medical therapy for angina pectoris is at the investigators discretion. Clinical follow-up of symptoms is recommended, but it is also acceptable to make a plan at hospital discharge for a later outpatient non-invasive stress-test. It is not acceptable to plan for an elective PCI in this treatment arm without signs of ischemia or symptoms.
89317282|NCT02825784|Experimental|Renastart|"Compared to cows' milk and/or standard pediatric enteral feeds, Renastart has the following additional nutritional features that are beneficial in children with CKD: lower phosphorus, calcium and vitamin A. The powder presentation allows flexibility with dilutions to facilitate the provision of adequate energy and protein to support growth in children with CKD.~For each subject, the recommended daily intake of Renastart is determined by the dietitian in collaboration with the local PI and primary nephrologist based on individual nutritional requirements, specifically dietary intake of potassium and serum potassium levels.~Renastart is to be given by the clinician and based on clinical and nutritional needs. Standard preparation guidelines can be found on the Renastart label."
89317283|NCT02825758|Experimental|ZestiVits|"Supplement for use in ketogenic and restricted therapeutic diets, from the age of 11.~Daily use for 7 days. Daily intake level for each subject will be determined and prescribed by a dietitian."
89317284|NCT02825745|Other|Betashot|"Children:will take Betashot as a proportion of their daily energy requirements calculated from the dietary information obtained during Visit A for up to 12 weeks.~Adults:will introduce Betashot and increase the amount taken in ml incrementally for up to 12 weeks."
89317285|NCT02802969|Experimental|[18F]FAZA PET/CT|In residual chordoma tumors after surgery, Investigators propose a protontherapy guided by conventional imaging (CT/MRI) and a boost guided by FAZA PET/CT, in order to target the hypoxic zones and to increase the dose in an adequate manner, which could result in improving long-term local control and reducing complications.
89317286|NCT02788981|Experimental|Nab-Paclitaxel+Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
89317287|NCT02788981|Placebo Comparator|Nab-Paclitaxel+Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
89317288|NCT02767661|Experimental|Capecitabine+Aromatase inhibitor|Capecitabine, 500mg, orally three times daily in combination with an aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
89317289|NCT02767661|Active Comparator|Aromatase inhibitor|Aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
89317290|NCT02744612|Experimental|Arm I: Ibrutinib 420 mg PO QD + BV 1.8 mg/kg IV Q21 days|Patients receive ibrutinib 420 mg PO QD on days 1-21 and brentuximab vedotin 1.8 mg/kg IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89317291|NCT02744612|Experimental|Arm II: Ibrutinib 560 mg PO QD + BV 1.8 mg/kg IV Q21 days|Patients receive ibrutinib 560 mg PO QD on days 1-21 and brentuximab vedotin 1.8 mg/kg IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89317292|NCT02711826|Active Comparator|Maintenance CNI based immunosuppression therapy group|"Standard of care~(N=7 participants in this group)"
89317293|NCT02711826|Experimental|Polyclonal Regulatory T Cells group|"Subjects to receive polyTregs (550 ± 450 x 10^6). After receiving at least 300X10^6 polyTregs infusion, eligible subjects will start mammalian Target of Rapamycin (mTOR) inhibitor.~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued.~(N=7 participants in this group)"
89317294|NCT02681549|Experimental|pembrolizumab plus bevacizumab|
88810996|NCT04788004||Cohort 1|Participants in this group started their recovery process < 1 year ago
89317295|NCT02665195||Prospective Registry of Multiplex Testing|This is a prospective ascertainment study that will obtain medical information and biospecimens from two different types of families: 1) Families transmitting sequence variants in non-BRCA predisposition genes that are either functionally deleterious or likely to be functionally deleterious based upon the interpretation of the laboratory that performed the testing on the Index Participant (Initial PROMPT enrollee), and 2) Families transmitting variants of uncertain significance (usually rare missense variants) in non- BRCA predisposition genes. Attempts will be made to collect a biospecimen and a completed risk factor questionnaire from each participant.
89317296|NCT02493322|Experimental|Test 1: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 12,5 mg) a day, in the morning.
89317297|NCT02493322|Experimental|Test 2: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 25 mg) a day, in the morning.
89317298|NCT02493322|Experimental|Comparator: Benicar HCT®|The patients will take 1 tablet (Olmesartan 20 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
89317299|NCT02483936|Experimental|Test 1: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 12,5 mg) a day, in the morning.
89317300|NCT02483936|Experimental|Test 2: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 25 mg) a day, in the morning.
89317301|NCT02483936|Active Comparator|Comparator 1: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
89317302|NCT02483936|Active Comparator|Comparator 2: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 25 mg) a day, in the morning.
89317303|NCT02362035|Experimental|Acalabrutinib plus Pembrolizumab|"A nonrandomized study that will be conducted in 2 stages. In the first stage, (Safety), subjects will receive Acalabrutinib Dose A orally administered (PO) twice daily (BID) in combination with Pembrolizumab Dose B administered every 3 weeks (Q3W).~The second stage was an expansion of Cohorts with the same dose regimen as the first stage. An additional expansion in subjects with Myelofibrosis was planned but not conducted."
89317304|NCT02318966|Active Comparator|Glycosade|Participants will be randomised to receive the medical food Glycosade as a starch load with a maximum dose of 100g. Glycosade to be taken as one dose.
89317305|NCT02318966|Placebo Comparator|Uncooked corn starch|Participants will be randomised to receive uncooked corn starch as a starch load with a maximum dose of 100g. Uncooked corn starch to be taken as one dose.
89317306|NCT02315157|Experimental|Bendamustine 200 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 400 mg/m2).
89317307|NCT02315157|Experimental|Bendamustine 250 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 500 mg/m2).
89317308|NCT02293954|Experimental|Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)|Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.
89317309|NCT02245100||Predictive value of circulating DNA|Patients undergo blood sample collection within 1 month before surgery, radiation therapy, or chemotherapy; within 1 week after surgical resection (for patients having upfront surgery); within 1 month before beginning of post-operative radiation therapy (for patients having upfront surgery); during the second week of radiation therapy, during the last week of radiation therapy; and at 1 and 3 months after radiation therapy and then every 3 months for up to 18 months. Patients also undergo saliva sample collection within 1 month before surgery, radiation therapy, chemoradiation therapy, or system chemotherapy and tissue collection at the time of surgery (if upfront surgery is indicated). Blood, saliva, and tissue samples are analyzed for tumor mutations via next generation sequencing.
89317310|NCT02041936|Experimental|NanoKnife IRE System|
89317311|NCT02034617|No Intervention|Standard care|The family receive standard care when enrolled in the Neonatal intensive care unit
89317312|NCT02034617|Experimental|Observation|The family receive standard care when enrolled in the Neonatal intensive care unit and are also included in an observational program called LiMoNid.
89317313|NCT01939275|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)|Patients receive copper Cu 64-DOTA-trastuzumab IV on day 1 and then undergo PET/CT scan on days 2 or 3.
89317314|NCT01600755|Experimental|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intrasphincteric injection of 250 x 10^6 cells.
89317315|NCT01437215|Experimental|Fenestrated Endografting|
89317316|NCT01318317|Experimental|Treatment (cellular adoptive immunotherapy following PBSCT)|Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with G-CSF and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplant. Patients receive standard myeloablative conditioning followed by autologous PBSCT. Patients then undergo infusion of ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR on day 2 or 3 after transplant.
89317317|NCT00647387|Experimental|1|Implantation with the device
89317318|NCT00580437|Experimental|Arm 1|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
89317319|NCT00577278|Experimental|Treatment (chemo, monoclonal antibody therapy, transplant)|REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.
89317320|NCT00544466|Experimental|Treatment (enzyme inhibitor, radiation therapy, transplant)|PREPARATIVE REGIMEN*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: *Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
89317321|NCT00493298||Tysabri|According to the local prescribing information
89317322|NCT02067364|Other|Fit & function test|CRT ShuntCheck sensors will be applied over the shunts of asymptomatic hydrocephalus patients. The device will be activated, cooling the skin under the sensor. Patients will change positions during the one hour procedure and data will be recorded. Data will be analyzed offline to identify product performance issues due to motion.
89317323|NCT04949373|Experimental|HILT+nerve/tendon gliding exercise+rest splint|Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for three weeks (one session per day for a total of 15 sessions). A 3-phase treatment program will be performed in each session, and a physiotherapist will then apply nerve/tendon gliding exercises program to the patients once daily. The patients will use rest splint at night.
89317324|NCT04949373|Sham Comparator|Sham HILT+nerve/tendon gliding exercise+rest splint|Patients will receive sham laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for three weeks (one session per day for a total of 15 sessions). A 3-phase treatment program will be performed in each session, and a physiotherapist will then apply nerve/tendon gliding exercises program to the patients once daily . The patients will use rest splint at night.
89317325|NCT02260336|Experimental|Panax Notoginseng Powder 1g|Panax Notoginseng Powder 1g, daily
89317326|NCT02260336|Experimental|Panax Notoginseng Powder 5g|Panax Notoginseng Powder 5g,daily
89317327|NCT02260336|Experimental|Panax Notoginseng Powder 10g|Panax Notoginseng Powder 10g,daily
89317328|NCT02260336|Experimental|Panax Notoginseng Powder 15g|Panax Notoginseng Powder 15g,daily
89317329|NCT02260336|Active Comparator|Celecoxib Capsule 400 mg daily|Celecoxib Capsule 400 mg daily
89317330|NCT02068456||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved Korean label.
89317331|NCT03755193|Active Comparator|SERM plus ELD|To examine the effects of SERM plus ELD in osteoporosis patients
89317332|NCT03755193|Active Comparator|BP plus ELD|To examine the effects of BP plus ELD in osteoporosis patients
89317333|NCT03755193|Active Comparator|ELD alone|To examine the effects of ELD alone in osteoporosis patients
89317334|NCT02068534||survivors from charcoal-burning suicide|survivors from charcoal-burning suicide and at least above 20 years old.
89317335|NCT03755115|Experimental|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, D1,30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
89317336|NCT03751995|No Intervention|Control|Participants from medical centers assigned to the control arm will receive usual care.
89317337|NCT03751995|Experimental|Intervention|Participants from medical centers assigned to the intervention arm will receive access to their choice of a mindfulness app or a webinar-based mindfulness course for 6 weeks.
89317338|NCT03755037|Active Comparator|Estradiol and cc|"Group 1 received estradiol, cc and placebo simillar to sildenafil for induction of ovulation.~CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient then ethinyl estradiol 0.05mg orally twice daily on the 8th day of same cycle till 11th day."
89317339|NCT03755037|Active Comparator|Sildenafil and cc|Group 2 received CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient, sildenafil citrate (Respatio) 20 mg tab orally 3 times daily from8th day of same cycle till 11th day and placebo simillar to estradiol.
89317340|NCT03755037|Placebo Comparator|Placebo and cc|Group 3 received cc and placebo similar to sildenafil and placebo similar to estradiol with the same doses.
89317341|NCT04553913|Experimental|cooling device placed|A basic medical grade cooling pad will be secured to the non operative leg. Intermittent coolness will be assessed and subject will inform recovery room staff when sensation returns.
89317342|NCT04553913|No Intervention|standard of care no intervention|Subjects in intervention arm will serve as their own control; standard nursing pinprick testing on the same (non-operative) thigh
89317343|NCT03751917||APL patients|The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.
89317344|NCT05460117|Experimental|Radiofrequency stimulus on the dominant PLANTAR FASCIOPATHY|448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus on the dominant Plantar fasciopathy
89317345|NCT03751839|Experimental|Diagnostic|The investigators will examine all participants in the same way by performing biochemical tests, clinical tests, osteodensitometry, HRQCT and HRpQCT measurements.
89317346|NCT04490499|Experimental|HBVAXPRO™|Healthy children vaccinated approximately 8-9 years previously with a 2- or 3-dose infant series and toddler dose of Vaxelis® who will receive a single dose of Hepatitis B vaccine challenge (HBVAXPRO™).
89317347|NCT04909983|Experimental|Intervention|Medical Device, an occlusive patch for 3 days.
89317348|NCT04909983|Active Comparator|Control|Standard of Care
89317349|NCT01332994|Experimental|1|
89317350|NCT01332994|Experimental|2|
89317351|NCT03698331|Experimental|Valbenazine|Valbenazine or placebo oral capsules administered once daily for 7 weeks.
89317352|NCT03698331|Placebo Comparator|Placebo|Placebo oral capsules administered once daily for 7 weeks.
89317353|NCT03754959|Experimental|Dose Group 1|
89317354|NCT03754959|Experimental|Dose Group 2|
89317355|NCT03754959|Experimental|Dose Group 3|
89317356|NCT03754959|Experimental|Dose Group 4|
89317357|NCT03754959|Experimental|Dose Group 5|
89317358|NCT05391165|Experimental|Experimental group|ntervention based on the Back School was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min.
89317359|NCT05391165|No Intervention|Control group|I declare that I will not change my lifestyle during the study process.
89317360|NCT04889625|Experimental|Test/Control/Control|Eligible subjects will be randomized to one of two possible lens wear sequences, Test/Control/Control.
89317361|NCT04889625|Experimental|Control/Test/Test|Eligible subjects will be randomized to one of two possible lens wear sequences, Control/Test/Test.
89317362|NCT04883541|Experimental|The Study Group|Pregnant women participated in the applications, which lasted two days a week, for ten weeks, and for 60 minutes a day.
88810997|NCT04788004||Cohort 2|Participants in this group started their recovery process 1 to <2 years ago
89317363|NCT04883541|Placebo Comparator|Control Group|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
89317364|NCT02068612|Experimental|MICT + IT|Moderate Intensity Continuous Training+Interval Training
89317365|NCT02068612|Active Comparator|LICT|Low Intensity Continuous Training
89317366|NCT02068690|Experimental|BI 425809 single rising dose|BI 425809 powder for oral solution (PfOS) in single rising doses
89317367|NCT02068690|Experimental|BI 425809 Crossover|Bioavailability of BI 425809 PfOS
89317368|NCT04882995|Experimental|Intervention - Received fiber|Participants received 14 doses of psyllium fiber packet (Metamucil, 3.4g). They were instructed to take 1 packet twice a day beginning 7 days before surgery.
89317369|NCT04882995|No Intervention|Control - Did not receive fiber|Participants did not take any preoperative fiber.
89317370|NCT02068924|Experimental|slow freezing|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
89317371|NCT02068924|Other|vitrification|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
89317372|NCT02067442|Active Comparator|oral acetaminophen|Patients in this arm of the study will receive oral acetaminophen and an IV placebo
89317373|NCT02067442|Active Comparator|intravenous acetaminophen|Patients in this arm of the study will receive IV acetaminophen and an oral placebo
89317374|NCT04483011|Experimental|RiaGev|RiaGev, 2000mg, BID
89317375|NCT04483011|Active Comparator|Comparator|Comparator matched to RiaGev, BID
89317376|NCT02067520|Other|IT hydromorphone dose|dose response study
89317377|NCT02067598|Experimental|Scapular exercise|The participants will receive thirty minutes session of scapular exercise for 12 sessions
89317378|NCT02067598|No Intervention|Control|
89317379|NCT02069002|Experimental|Cognitive-Behavioral Therapy (CBT)|"There will be ten (10) manualized session, fist 90 minutes and nine (9) 45-minute individual sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after the treatment. Sessions include psychoeducation about indoor air related symptoms and personal health behavior factors integrated on patients individual symptomatology, cognitive restructuring, behavioral experiments of patients health promoting behavior, imagery rescripting and relapse prevention.~Intervention: Behavioral: Psychotherapy (CBT)"
89317380|NCT02069002|Experimental|Applied relaxation group therapy|"There will be seven (7) manualized session, first 120 minutes and six (6) 90-minute group sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after treatment. Sessions include information about indoor air related symptoms, behavioral training and experiments focusing on applied relaxation technique and relapse prevention.~Intervention: Behavioral: group therapy (ART)~NB: The Applied Relaxation group Therapy won´t be carried out due to slow and prolonged recruiting process (A steering group agreement 4/2015 and the Ethics Committee approval 5/2015 for the change of the study plan)."
89317381|NCT02069002|Experimental|Information session (psychoeducation)|"There will be one (1) manualized 90-minute individual session. The session includes information about indoor air related symptoms and factors affecting individual health behavior.~Intervention: Information session (psychoeducation)"
89317382|NCT05255757|No Intervention|No intervention|This group will only complete study survey and refer members of their family and social network for participation in a web survey.
89317383|NCT05255757|Experimental|Script Intervention|This group will complete the survey, refer members of their family and social network for participation in a web survey, and review a set of suggested talking points and an example script to guide discussion of potential living donation with members of their network.
89317384|NCT05255757|Experimental|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
89317385|NCT05255757|Experimental|Both Search and Script Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation, and review a set of suggested talking points and an example script to guide discussion of potential living donation with members of their network.
89317386|NCT02067754||metastatic Cancer|metastatic gastrointestinal cancer, genitourinary cancer , rare cancer with treated any anti-cancer therapy
89317387|NCT03559972|Experimental|Treatment Group #1|"Subject in Treatment group 1 will apply the following products in the morning and evening.~SkinMedica Facial Cleanser~Hulk (cosmetic investigational)~Marvel AM (cosmetic investigational)~Marvel PM (cosmetic investigational)~SkinMedica HA5 Rejuvenating Hydrator~SkinMedica Rejuvenative Moisturizer~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
89317388|NCT03559972|Experimental|Treatment group #2|"Subject in Treatment group 2 will apply the following products in the morning and evening.~SkinMedica Facial Cleanser~SkinMedica TNS Essential Serum~Marvel AM (cosmetic investigational)~Marvel PM (cosmetic investigational)~SkinMedica HA5 Rejuvenating Hydrator~SkinMedica Rejuvenative Moisturizer~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
89317389|NCT02076490|Experimental|Software Supported Mirror Therapy|First experimental condition Physical/Occupational Therapy
89317390|NCT02076490|Experimental|Traditional mirror therapy|Second experimental condition Physical/Occupational Therapy
89317391|NCT02076490|Active Comparator|Sensomotor exercises without mirror|Control condition Physical/Occupational Therapy
89317392|NCT04545567|Experimental|RocketAP|Adolescents will be assessed for a 48-70 hour period on the Rocket AP. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the USS Virginia system under the same conditions.
88810998|NCT04788004||Cohort 3|Participants in this group started their recovery process 2 to <3 years ago
89317393|NCT04545567|Active Comparator|USS Virginia|Adolescents will be assessed for a 48-70 hour period on the USS Virginia system. This time will include two dinner times, one with and one without announcement of carbohydrate content. This is a cross-over study, so all participants will also be tested on the Rocket AP system under the same conditions.
89317394|NCT02076568|Experimental|Education - Diabetes and Partnership|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Partnership"
89317395|NCT02076568|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
89317396|NCT02076724|Experimental|Biological mesh (Strattice Firm)|Strattice Firm is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
89317397|NCT02076724|Experimental|Synthetic mesh (Prolene)|Prolene mesh is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
89317398|NCT02076802||lifestyle counseling|physical exercises
89317399|NCT03754647|No Intervention|Patients receiving SSRIs|This group will be receive SSRIs only
89317400|NCT03754647|Active Comparator|Patients receiving Vitamin C with SSRIs|This group will be receive vitamin C (500mg) twice daily with SSRIs for 8 weeks
89317401|NCT02076880|Experimental|Arm with caloric restriction|"Patients in this arm will have, during 7 days before surgery, a caloric restriction of 1000 kcal per day compared to the usual food intake. They will be hospitalized during this period.~Intervention: caloric restriction"
89317402|NCT02076880|Experimental|Arm without caloric restriction|"Patients in this arm will not have a caloric restriction before surgery.~Intervention: No caloric restriction"
89317403|NCT03757923|Experimental|metformin|TAB METFORMIN 500mg TDS
89317404|NCT03757923|Experimental|pioglitazone|TAB PIOGLITAZONE 30 mg OD
89317405|NCT02077036|Experimental|Active medical device|
89317406|NCT02077036|Placebo Comparator|Inactive medical device|
89317407|NCT02077114|Experimental|Ipilimumab|Patient who according to standard criteria are candidates to treatment with Ipilimumab
89317408|NCT02077114|Experimental|Vemurafenib|Patients who according to standard criteria are candidates to treatment with Vemurafenib
89317409|NCT03757767|Experimental|Intervention arm|Fasting for 26-hours.
89317410|NCT02077270|Experimental|electroacupuncture|patients in whom precolonoscopic electroacupuncture is preformed
89317411|NCT02077270|Placebo Comparator|Sham electroacupuncture|sham electroacupuncture
89317412|NCT02077270|Sham Comparator|No intervantion|no intervantion
89317413|NCT02071888|Experimental|CB-839|CB-839 is administered as oral capsules three times daily (TID) or twice daily with food (BIDf) in 21-day cycles until disease progression or unacceptable toxicity
89317414|NCT02071888|Experimental|CB-839 and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with dexamethasone until disease progression or unacceptable toxicity
89317415|NCT02071888|Experimental|CB-839, pomalidomide, and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with pomalidomide and dexamethasone until disease progression or unacceptable toxicity
89317416|NCT02071966|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
89317417|NCT02071966|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day
89317418|NCT02072044|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89317419|NCT02072122||women during fertility treatment|
89317420|NCT02072278|Experimental|Vortioxetine 10 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
89317421|NCT02072278|Experimental|Vortioxetine 20 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
89317422|NCT02072278|Active Comparator|Escitalopram 15 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
89317423|NCT02072278|Placebo Comparator|Placebo|capsules; 3 daily doses in each treatment period; orally
89317424|NCT02072512|Active Comparator|Fulvestrant|Goserelin plus High Dose Fulvestrant
89317425|NCT02072512|Active Comparator|Anastrozole|Goserelin plus Anastrozole
89317426|NCT04534491|Experimental|Oxytrol|Subjects decided to purchase Oxytrol.
89317427|NCT02069080|Experimental|1|All subjects are administered the study drug
88810999|NCT04788004||Cohort 4|Participants in this group started their recovery process 3 to <4 years ago
89317428|NCT03751527|Experimental|ZENFLEX stent Group|subjects applying ZENFLEX peripheral stent system
89317429|NCT02077348|No Intervention|Insulin|"good glycemic control: 50 % of the subject's basal insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) and on the study-day. Basal period from 7.00 am to 12.00pm. The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
89317430|NCT02077348|Experimental|Insulin withdrawal|"10 % of the individual subject's regular insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) Basal period from 7.00 am to 12.00 pm (without insulin). The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
89317431|NCT02077348|Experimental|Norditropin (Growth Hormone)|"Same amount of insulin administered on the control day (good glycemic control) overnight and on the study day (hospitalized and fasting from 10 p.m.). On the study day, a bolus injection of 0,4 mg of growth hormone (Norditropin) will be administered at 7.05 am. Basal period from 7.00 am to 12.00 pm (good glycemic control).The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
89317432|NCT03694821|Experimental|Ketorolac|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
89317433|NCT03694821|Active Comparator|Corticosteroid|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
89317434|NCT03694821|Active Comparator|Hyaluronic Acid|One knee injection of Hylan G-F 20 (Synvisc-One)
89317435|NCT02077426|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises
89317436|NCT02077504|Experimental|CONDUCTOME|MEG and MRI
89317437|NCT05342259|Active Comparator|dorsal penile block patients|
89317438|NCT05342259|Active Comparator|caudal block patients|
89317439|NCT05342259|Active Comparator|combined block patients|
89317440|NCT02077660|Placebo Comparator|4 daily placebo tea bags for 12 weeks|"All subjects will undergo a 12 weeks supplemented with four daily placebo maltodextrin tea-bags. The subjects will be instructed than to brew the placebo sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Placebo period)."
89317441|NCT02077660|Experimental|Four green tea bags per day for 12 weeks|After the placebo period, all subjects will undergo a 12 weeks supplemented with four daily green tea bags. The subjects will be instructed than to brew the green tea sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Green tea period).
89317442|NCT02069158|Experimental|PF-05212384, Carboplatin, Paclitaxel|starting dose of PF-05212384: 95 mg iv weekly Dose of Carboplatin: 5 AUC every 28 days Dose of Paclitaxel: 80 mg/m2 on days 1, 8 and 15
89317443|NCT04531527|Experimental|Phototoxicity reaction test|Participants received approximately 60 μl of Butenafine HCl 1% on the treated irradiated test site followed by Ultraviolet Radiation (UV) irradiation and to the treated non-irradiated test site without UV irradiation. Participants also had two more test sites, the untreated irradiated control site without Butenafine HCl 1% followed by UV irradiation and the untreated non-irradiated control site without Butenafine HCl 1% or UV irradiation. All test sites were evaluated for erythema on the following day. Afterwards, participants received same procedure on all 4 test sites, and evaluation of the test sites occurred at 24 hours and 48 hours post-irradiation.
89317444|NCT02077738|Experimental|HFCWO|HFCWO for 15 min twice a day
89317445|NCT02077738|Placebo Comparator|placebo|not to receive high-frequency chest wall oscillation (HFCWO)
89317446|NCT02069236|No Intervention|G6PD Testing|All subjects receive G6PD test
89317447|NCT02077816||Central venous catheter|Inpatients with CVC for medical care.
89317448|NCT02069314|Experimental|Whey protein supplementation|50 grams of whey blended into frozen drink
89317449|NCT02069314|Experimental|Carbohydrate supplementation|50 grams of polycose blended into frozen drink
89317450|NCT02069470|Experimental|Continuing Medical Education|Continuing Medical Education
89317451|NCT02069470|No Intervention|Usual care|Usual care
89317452|NCT02069548||Cervical dystonia|
89317453|NCT02069548||matched controlled subjects|matched in age (+/- 5 years) and gender
89317454|NCT02069626|Active Comparator|No wait|Usage of linear stapler without waiting of compression time
89317455|NCT02069626|Active Comparator|20 second wait|Usage of linear stapler with 20 second compression time
89317456|NCT02069626|Active Comparator|60 second wait|Usage of linear stapler with 60 second compression time
89317457|NCT02069938||Healthy Subjects|Noninvasive Brain Computer Interface Control
89317458|NCT02077972|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
89317459|NCT02078050|Other|Phrenic nerves magnetic stimulations|
89317460|NCT02070016|Experimental|TMS Parameter Condition 1 first|Application of Transcranial Magnetic Stimulation
89317461|NCT02070016|Experimental|TMS Parameter Condition 2 First|Application of Transcranial Magnetic Stimulation
89317462|NCT02078128|Experimental|oral beta-glucans|Daily give kg per day to 30 mg of β-glucan (30mg/kg/day), taking to the wound healed.
89317463|NCT02078128|Placebo Comparator|oral sugar powder|control group, daily give and the glucose powder 30 mg per kilogram of body weight (30mg/kg/day) a day, taking to the wound healed.
89317464|NCT02070172||Cervicogenic Headache Group|This group of subjects is considered the symptomatic group. No intervention was provided in this study so there are no intervention groups.
89317465|NCT02070172||Healthy, Asymptomatic Group|Subjects in this group had no headache symptoms. Their neck motion was compared to subjects in the headache group. No intervention was provided to subjects in either group for this study.
89317466|NCT02078440|Other|Bromocriptine mesylate (Cycloset)|Bromocriptine mesylate (Cycloset)
89317467|NCT02070250|Experimental|From Cancer to Health (C2H-D)|Individuals participating in the From Cancer to Health (C2H-D) Stress Management Psychological Intervention
89317468|NCT04474197|Placebo Comparator|Placebo|Participants received placebo matched to VX-864 in the treatment period for 28 days.
89317469|NCT04474197|Experimental|VX-864 100 mg|Participants received VX-864 100 milligrams (mg) every 12 hours (q12h) in the treatment period for 28 days.
89317470|NCT04474197|Experimental|VX-864 300 mg|Participants received VX-864 300 mg q12h in the treatment period for 28 days.
89317471|NCT04474197|Experimental|VX-864 500 mg|Participants received VX-864 500 mg q12h in the treatment period for 28 days.
89317472|NCT02070406|Experimental|Treatment (gene-modified T-cells, vaccine therapy, ipilimumab)|"CONDITIONING CHEMOTHERAPY REGIMEN: Patients receive cyclophosphamide IV on days -5 and -4 and fludarabine phosphate IV over 30 minutes daily on days -4 to -1.~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV on day 0.~IPILIMUMAB ADMINISTRATION: Patients receive ipilimumab IV over 90 minutes before the NY-ESO-1 TCR PBMC infusion on day 0 or after the infusion on day 1. Treatment repeats every 3 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity.~NY-ESO-1(157-165) PEPTIDE PULSED DC ADMINISTRATION: Patients receive NY-ESO-1(157-165) peptide pulsed DC vaccine ID on days 1, 14, and 30.~LOW DOSE IL-2 ADMINISTRATION: Patients receive aldesleukin (IL-2) SC BID on days 1-14."
89317473|NCT02070562||Community Group|Chinese lactating mothers from community maternal & child healthcare centre
89317474|NCT02070562||VIP Group|Chinese lactating mothers from VIP clinics (maternal care center)
89317475|NCT03757611|Experimental|tabetri|Tabetri capsule will be administered orally twice daily for 12 weeks
89317476|NCT03757611|Placebo Comparator|Placebo|Placebo capsule will be administered orally twice daily for 12 weeks
89317477|NCT02078518||Multiple Myeloma|Questionnaires will be given to patients for completion.
89317478|NCT02078596|Experimental|Divalproex|Divalproex at 10 mgs/lb
89317479|NCT02078596|Placebo Comparator|Sugar Pill|Equivalent 250 mg pills titrated to 10 mgs / lb over six weeks
89317480|NCT02070718|Placebo Comparator|Placebo|Cornstarch, National Formulary
89317481|NCT02070718|Experimental|Standard Dose Kappa Agonist|Pentazocine/Naloxone 50/0.5 mg
89317482|NCT02070718|Experimental|Half Dose Kappa Agonist|Pentazocine/Naloxone 25/0.25 mg
89317483|NCT02078830|Placebo Comparator|3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
89317484|NCT02078830|Experimental|3M™ Tegaderm™ CHG Securement Dressing|- CHG activity at EVD entry site
89317485|NCT02070796|Experimental|Treatment A - B|Single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours.
89317486|NCT02070796|Active Comparator|Treatment B - A|Single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours.
89317487|NCT02070874|Experimental|telehealth enhanced pain management|video-case conferences for providers PainTracker for patients
89317488|NCT02070874|No Intervention|usual care|usual care
89317489|NCT02078908|Active Comparator|40 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
89317490|NCT02078908|Active Comparator|120 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
89317491|NCT02078908|Active Comparator|240 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
89317492|NCT02078908|Placebo Comparator|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
89317493|NCT02078986|Experimental|Whole Body Electromyostimulation|
89317494|NCT02078986|Experimental|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise 2-3 session/week/14 weeks
89317495|NCT03559738||Patients With Upper Ureteric Stones|Patients with upper ureteral stones more than 1cm and 1000 HU
89317496|NCT02079064|Experimental|Desflurane|Desflurane at 1 MAC and
89317497|NCT02079064|Experimental|propofol|propofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1
89317498|NCT02070952|Experimental|CyberKnife|CyberKnife Stereotactic Ablative Body Radiation Therapy
89317499|NCT02079142|Experimental|High Intensity Strategy: Train-the-trainer|One therapist from each counseling center randomized to this arm will be selected to become the trainer and will be trained to train their colleagues.
89317500|NCT02079142|Active Comparator|Low Intensity Strategy: Expert Consultation|The IPT expert from Washington University will travel to all counseling centers randomized to this condition and train all participating therapists on site and be available for monthly phone consultation for up to one year following training on site.
89317501|NCT02071030|Other|CBCT|Cone Beam CT
89317502|NCT02071030|Other|Panoramic radiograph|
89317503|NCT02079220|Experimental|Arm A|"Arm A (every 2 week schedule) Dosage and dosage regimen for all study periods~Capecitabine: will be administered 1,000 mg/m2 orally twice a day on Days 1 - 7 of each cycle, repeating every 14 days.~Oxaliplatin: will be administered 85 mg/m2 IV on Day 1 of each cycle, repeating every 14 days.~Ziv-aflibercept: will be administered 4 mg/kg IV on Day 1 of each cycle, repeating every 14 days."
89317504|NCT02079220|Experimental|Arm B|"Arm B (every 3 week schedule):~Dosage and dosage regimen for all study periods~Capecitabine: will be administered 850 mg/m2 orally twice a day on Days 1 - 14 of each cycle, repeating every 21 days.~Oxaliplatin: will be administered 130 mg/m2 IV on Day 1 of each cycle, repeating every 21 days.~Ziv-aflibercept: will be administered 6 mg/kg IV on Day 1 of each cycle, repeating every 21 days."
89317505|NCT02071186|Experimental|Virtual Reality training|Subjects will be asked to walk on a treadmill while negotiating virtual obstacles. The VR system includes a camera based motion capture and a computer generated simulation. The camera is used to capture the movement of the participant's feet. These images are then transferred to the computer simulation and projected to the patient on a screen. The speed, orientation, size, frequency of appearance and shape of the targets are manipulated to increase task difficulty. The Virtual environment imposes a cognitive load requiring attention and response selection as well as processing of rich visual stimuli involving several perceptual processes. The system provides visual and auditory feedback of task performance to enhance motor learning.
89317506|NCT02071186|Experimental|Computerized Cognitive Remediation|"The AttenGo program will be used for neuro-cognitive remediation aimed at enhancing attention, concentration, working memory, and executive function. The program has shown to be effective in improving attention and executive function in children with ADHD. The training is composed of cognitive exercises that challenge subjects with problem solving, information processing, response inhibition and dividing attention. The users receive immediate feedback from the system when losing focus. The program is adaptive and progresses according to the subjects abilities."
89317507|NCT02071186|Active Comparator|Control group|Subjects in this group will be assessed based on the study protocol but will receive no treatment other than their standard of care which could include pharmacological or/ and non-pharmacological treatment.
89317508|NCT02079298|Active Comparator|1|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated only with fluconazole.
89317509|NCT02079298|Active Comparator|2|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated with both fluconazole and Ibuprofen.
89317510|NCT02079298|Active Comparator|3|Premature newborn infants with Gestational Age 27+0 to 36+6 who are treated only with ibuprofen.
88811000|NCT04788004||Cohort 5|Participants in this group started their recovery process 4 to <5 years ago
89317511|NCT02079298|Placebo Comparator|4|Premature newborn infants with Gestational Age 27+0 to 36+6 and fullterm infants who are not treated either with fluconazole or ibuprofen.
89317512|NCT02079376|Experimental|Low blood TG patients|subjects with baseline blood triglyceride level ≤ 1.7 mmol/l will have intervention device (DIAMOND Implantable Pulse Generator (IPG)) programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period.
89317513|NCT02079376|Experimental|High blood TG patients treated with blood TG lowering therapy|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive fenofibrate at the dose of 160mg per day
89317514|NCT02079376|Placebo Comparator|High blood TG patients|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive placebo of fenofibrate administered in the same schedule as the drug.
89317515|NCT02071264|Other|HIV/STI intervention|This study implements a socio-behavioral intervention in Metro Manila, the Philippines, using a community-based participatory approach with 1-2 psychosocial and health education training workshops for the establishment managers and their workers, including street sex workers, focusing on HIV/AIDS risk reduction information, condom use, and condom negotiation skill-building. Participants participate in dream-building activities to explore personal goals and goals for their organization of peers. The interventions are directed at organizational behavior change and social influence modeling through training peers and managers. The participants receive information on STIs along with standard care, held on a day convenient to the participants and at a neutral location.
89317516|NCT02071342||acute coronary syndrome|patients with acute myocardial infarction who are undergoing coronary angioplasty. MACE at 30 days and 1 year will be assessed . The acute recoil after implantation of bioabsorbable stents will also be assessed
89317517|NCT02071498|Experimental|Pillbox app named ALICE|pillbox app for elderly patients taking multiple medications. App was used during three months
89317518|NCT02071498|Active Comparator|oral and written information|oral and written information regarding the main risks related to their medications and the most common errors of patients
89317519|NCT02079688|Experimental|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.~Comparison and random assignment of treatments to two distinct treatment areas (area 1, area 2).~IMP SB011: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments) daily dosage: Approximately 10 mg hgd40 total dosage: Approximately 145 mg hgd40"
89317520|NCT02079688|Placebo Comparator|Multiple W/O/W formulation, active ingredient-free vehicle|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.~Comparison and random assignment of treatments to two distinct treatment areas (Area 1, Area 2).~Vehicle: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments)"
89317521|NCT02079766|Experimental|High Risk of CTE|Flortaucipir PET scans in subjects at high risk of developing CTE (former National Football League players)
89317522|NCT02079766|Experimental|Control|Flortaucipir PET scans in former non-contact athletes
89317523|NCT02071576|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes
89317524|NCT02079922|Experimental|Cohort 1|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89317525|NCT02079922|Experimental|Cohort 2|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89317526|NCT02079922|Experimental|Cohort 3|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89317527|NCT02079922|Experimental|Cohort 4|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89317528|NCT02079922|Experimental|Cohort 5|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89317529|NCT02079922|Experimental|Cohort 6|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
89317530|NCT02080000|Experimental|Optimised V-V timing delay|V-V timing delay setting on biventricular pacemaker will be optimised guided by size of R-wave on surface ECG
89317531|NCT02080000|Active Comparator|Standard V-V timing delay|Standard settings
89317532|NCT02071654|Experimental|Venus P-valve transcatheter implantation|Single arm of percutaneous implantation of Venus-P valve for treating RVOT stenosis
89317533|NCT02080078|Experimental|Increasing dose of Theophylline|Patients will be put on the standard dose of 150 mg/day of erlotinib. Patients will be entered into the study on different dose levels of theophylline (100 mg/bid, 150 mg/bid, 200 mg/bid, or 200 mg/tid) for 28 days to find what is the lowest dose that effectively controls the diarrhea caused by erlotinib.
89317534|NCT02080078|Experimental|Increasing dose of erlotinib|Patients will be kept on a specified dose of theophylline while the dose of erlotinib increases in each group of patients enrolled (200 mg/qd, 225 mg/qd, or 250 mg/qd) for 28 days to determine what the maximum dose of erlotinib that can be given with theophylline and maintain a safety profile.
89317535|NCT02080156|No Intervention|no-CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
89317536|NCT02080156|Experimental|CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
89317537|NCT02071732|Active Comparator|Real rTMS|Real rTMS is real continuous theta burst stimulation.
89317538|NCT02071732|Sham Comparator|Sham rTMS|Sham rTMS is sham continuous theta burst stimulation.
88811001|NCT04788004||Cohort 6|Participants in this group started their recovery process 5 to <6 years ago
88811002|NCT04788004||Cohort 7|Participants in this group started their recovery process 6 to <7 years ago
89317539|NCT02083276|Experimental|Pivmecillinamhydrochlorid|Selexid 400 mg x 3 , 7 days
89317540|NCT03559504||Group 1|Infant period: 1 month-1 year old
89317541|NCT03559504||Group 2|Toddler period:1-3 years old
89317542|NCT03559504||Group 3|Preschool age period:3-6 years old
89317543|NCT03559504||Group 4|School age period:7-18 years old
89317544|NCT03559504||Group 5|Adults:18-65 years old
89317545|NCT03559504||Group 6|Elderly:65-80 years old
89317546|NCT02080234|Experimental|concurrent chemoradiotherapy with GELOX|"GELOX:~gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days~IFRT~IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.~the first cycle of chemotherapy was initiated on the same day of radiotherapy."
89317547|NCT02083432|Active Comparator|5-weeks waiting list control|Half of the participants were randomly assigned to 5-weeks waiting list/Control group.The participants in the waiting list/Control Group are enrolled to the treatment Group (INtervention: 5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
89317548|NCT02083432|Experimental|5 session of CBT|Half of the participants were direct enrolled to 5 weeks(5 sessions) of cognitive behaviour therapy (CBT) performed by specially trained dentists. (Intervention: CBT)
89317549|NCT02080390||Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
89317550|NCT04841577|Experimental|Co-Ad Group|Participants received 1 dose of RSV_PreF3 Older Adult (OA) investigational vaccine and 1 dose of FLU-QIV at Day 1 and were followed up until the study end.
89317551|NCT04841577|Active Comparator|Control Group|Participants received 1 dose of FLU-QIV at Day 1 and 1 dose of RSV_PreF3 OA investigational vaccine at Day 31 and were followed up until the study end.
89317552|NCT04529109|Experimental|Test/Control|Eligible subjects that are habitual soft contact lens wearers and current wearers of circle/cosmetic contact lenses will be randomized into lens wear sequence (Test/Control).
89317553|NCT04529109|Experimental|Control/Test|Eligible subjects that are habitual soft contact lens wearers and current wearers of circle/cosmetic contact lenses will be randomized into lens wear sequence (Control/Test).
89317554|NCT04528641|Experimental|Arm 1 - Low dose|Arm-1 Healthy adult volunteers aged 18-55y will receive IM single dose of 5e10vp. N=15
89317555|NCT04528641|Experimental|Arm 2 - Intermediate dose|Arm-2 Healthy adult volunteers aged 18-55y will receive IM single dose of 1e11vp. N=15
89317556|NCT04528641|Experimental|Arm 3 - High dose|Arm-3 Healthy adult volunteers aged 18-55y will receive IM single dose of 2e11vp. N=15
89317557|NCT04528641|Experimental|Arm 4 - Low dose|Arm-4 Healthy elderly volunteers aged 65-85y will receive IM single dose of 5e10vp. N=16
89317558|NCT04528641|Experimental|Arm 5 - Intermediate dose|Arm-5 Healthy elderly volunteers aged 65-85y will receive IM single dose of 1e11vp. N=15
89317559|NCT04528641|Experimental|Arm 6 - High dose|Arm-6 Healthy elderly volunteers aged 65-85y will receive IM single dose of 2e11vp. N=15
89317560|NCT05459727|Experimental|Intervention arm|"Basic oral hygiene instructions.~Full-mouth subgingival scaling and root planing under local anesthesia.~Additional full-mouth subgingival scaling and root planing under local anesthesia every 3 months during the follow-up period if necessary."
89317561|NCT05459727|Placebo Comparator|Control arm|"Basic oral hygiene instructions.~Full-mouth supragingival ultrasonic scaling."
89317562|NCT05337189||Bladder cancer group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting urine specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) test, eligible subjects also need to undergo the examination of standard method.
89317563|NCT05337189||The normal group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting urine specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) test, eligible subjects also need to undergo the examination of standard method.
89317564|NCT04527471|Active Comparator|Ensifentrine + Standard of Care|30 subjects randomized to receive blinded, inhaled ensifentrine in addition to standard of care treatment for COVID-19 infection
89317565|NCT04527471|Placebo Comparator|Placebo + Standard of Care|15 subjects randomized to receive blinded, inhaled placebo in addition to standard of care treatment for COVID-19 infection
89317566|NCT05070039|Other|patients with invasive and non invasive urothelial carcinoma|patients with urothelial carcinoma will be subjected to radical cystectomy or trans uretheral resection of the tumor, specimens will be sent to the pathology lab. to be examined.
89317567|NCT03754569|Experimental|Peritoneal biopsies|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
89317568|NCT05459649|Experimental|Cyclosporin plus Steroid|"Cyclosporin: started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count.~Standard regimen of steroid for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week."
88811003|NCT04788004||Cohort 8|Participants in this group started their recovery process 7 to <8 years ago
88811004|NCT04788004||Cohort 9|Participants in this group started their recovery process 8 to <9 years ago
89317569|NCT05459649|Active Comparator|Standard steroid|Standard regimen for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
89317570|NCT04471935|Other|At home Speech Hero therapy|
89317571|NCT04468347|Experimental|Alzheimer's disease (AD)|Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
89317572|NCT04468347|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
89317573|NCT04468347|Experimental|Subjective memory complainers (SMC)|Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
89317574|NCT04468347|Experimental|Cognitively normal (CN)|Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months
89317575|NCT03754491|Experimental|One stage stone removal in mild cholangitis|one-stage stone removal at the first session of ERCP in mild cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
89317576|NCT03754491|Experimental|One stage stone removal in moderate cholangitis|one-stage stone removal at the first session of ERCP in moderate cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
89317577|NCT04822701|Placebo Comparator|Phase II, Arm 1: Placebo intravenous (i.v.) + placebo inhaled|Single dose of sterile normal saline (NaCl 0.9%) used as placebo for intravenous (i.v.) was administered as intravenous infusion over a period of 60 minutes plus a single inhaled of solvent for dilution of BI 767551 used as placebo for inhalation administered via inhalation through a mouthpiece (Aerogen® Ultra) using a mesh nebulizer (Aerogen® Solo) on Day 1, followed by a 90-day follow-up period. The inhalation procedure was to start approximately 25 min after the start of infusion.
89317578|NCT04822701|Experimental|Phase II, Arm 2: BI 767551 10 milligrams (mg)/kilogram (kg) intravenous (i.v.) + placebo inhaled|
89317579|NCT04822701|Experimental|Phase II, Arm 3: BI 767551 40 mg/kg intravenous (i.v.) + placebo inhaled|
89317580|NCT04822701|Experimental|Phase II, Arm 4: Placebo intravenous (i.v.) + BI 767551 250 mg inhaled|Single dose of sterile normal saline (NaCl 0.9%) used as placebo for intravenous (i.v.) was administered as intravenous infusion over a period of 60 minutes plus a single inhaled of 250 milligrams (mg) of BI 767551 administered via inhalation through a mouthpiece (Aerogen® Ultra) using a mesh nebulizer (Aerogen® Solo) on Day 1, followed by a 90-day follow-up period. The inhalation procedure was to start approximately 25 min after the start of infusion.
89317581|NCT04822701|Experimental|Phase III, Arm 1: BI 767551 (medium or high dose infusion) or low dose inhalation|
89317582|NCT04822701|Placebo Comparator|Phase III, Arm 2: Placebo|
89317583|NCT03754413|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
89317584|NCT03754413|Other|Comparator device|No-treatment
89317585|NCT04461795|Experimental|AJOVY (fremanezumab-vfrm)|Participants received 225 mg/1.5 mL solution via single-dose prefilled syringe administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for 12 weeks.
89317586|NCT04461015|Other|0.4mU Insulin|During the euglycemic clamp insulin will be infused at 0.4mU/Kg/Min
89317587|NCT04461015|Other|0.8mU Insulin|During the euglycemic clamp insulin will be infused at 0.8mU/Kg/Min
89317588|NCT04810221|Experimental|Experimental|Measure of SpO2 and HR obtained in enrolled subjects using BrOxy M and a reference pulse oximeter in paired observations
89317589|NCT03754179|Experimental|Arm A phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
89317590|NCT03754179|Active Comparator|Arm B phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily until disease progression. At disease progression, add-on of hydroxychloroquine 200 mg twice daily. Treatment until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment"
89317591|NCT03754179|Experimental|Phase 1|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
89317592|NCT03694353|Experimental|Pegvaliase|Beginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in 165-302 or PAL-003 (pegvaliase dosing should continue without interruption from the previous study). Subsequent revisions to dosing regimens are allowed following consultation with the medical monitor.
89317593|NCT04521777|Experimental|Supportive care (exercise intervention)|Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week.
89317594|NCT03751293|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
89317595|NCT03700671|Experimental|High intensity interval training|HIIT was set at > 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
89317596|NCT03700671|Active Comparator|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80%. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated. Each station was occupied for three to six minutes depending on session duration with minimal rest in-between.
89317597|NCT05377125|Experimental|Response Inhibition Training (RIT)|Response Inhibition Training (RIT) is a about 40-level computer game designed to offer systematic practice of RI. Participants use the computer keyboard and mouse to respond to the demands of trials that are designed to offer training on response inhibition abilities, including suppressing pre-potent but irrelevant stimuli and responses. Each training session will last approximately 45 minutes. All participants will be offered a minimum of 8 sessions. Throughout training, we will continually monitor their behavioral RI index (= stop signal reaction time; SSRT) using a stop-signal task. If a participant's Index SSRT fails to reach a criterion-level reduction (i.e., approximately 1 SD) after the standard 8 session intervention, the RIT intervention will be extended up to 16 sessions until the criterion-level improvement in behavioral RI is attained.
89317598|NCT05377125|Placebo Comparator|Placebo Training (PLT)|This training condition is designed to serve as an appropriate control condition for RIT, by providing no active ingredient of RI training components, while maintaining the overall training materials and structure similar. Similar to RIT, PLT uses the same task materials and a similar 40-level game structure. However, PLT will present simple RI-irrelevant visual judgment tasks to avoid changing RI-relate processes. The number of 45-min training sessions will be determined by their counterpart RIT participants through a yoked-control design.
89317599|NCT04764669|Experimental|DLB Without Amyloid Copathology|Participants with DLB (without amyloid copathology) will receive E2027 50 milligram (mg) capsules, orally, once daily up to 12 weeks.
89317600|NCT04764669|Experimental|DLB With Amyloid Copathology|Participants with DLB (with amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
89317601|NCT04764669|Experimental|PDD Without Amyloid Copathology|Participants with PDD (without amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
89317602|NCT04764669|Experimental|PDD With Amyloid Copathology|Participants with PDD (with amyloid copathology) will receive E2027 50 mg capsules, orally, once daily up to 12 weeks.
89317603|NCT03753867|Experimental|Acitretin treatment|
89317604|NCT05459415|Experimental|Reducing Excision Margins|In resectable HPV-negative locally advanced head and neck squamous cell carcinoma, 3 cycles of preoperative neoadjuvant chemotherapy combined with immunotherapy are proposed, in patients with significant tumor shrinkage (≥50%) as assessed by imaging, to conduct research on narrowing the scope of surgery, preserve the patient's organ function, improve or improve the quality of life, and achieve a curative effect that is not inferior to traditional radical surgery
89317605|NCT03751215|Experimental|Monofocal IOL|Patients will be implanted with two different monofocal lenses (Clareon and AcrySof) during cataract surgery
89317606|NCT04438785|Experimental|INTERVENTION (AirwayGym) GROUP|Patients newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the AirwayGym app for 20 min a day for 90 days.
89317607|NCT04438785|No Intervention|CONTROL GROUP|Patients newly diagnosed with severe OSAHS do no therapy for 90 days.
89317608|NCT05280951|Experimental|Focused-PPC Group|Focused-PPC will be implemented in 12 groups (3 groups per health center), with each group having 8 postpartum women. Each group will meet at 1-2 weeks, 6 weeks, and monthly thereafter for up to 1 year postpartum following the Ghana Health Service (GHS) postnatal care schedule.
89317609|NCT05280951|Active Comparator|Standard PNC Group|The control group will contain parallel number of participants as the intervention group in each health center
89317610|NCT01322685||Health Group|
89317611|NCT01322685||Tuberculosis Group|Tuberculosis or lung cancer group
89317612|NCT04741503|Experimental|Breast Cancer Screening Decision Support Tool|-After randomization, participants will complete pre-questionnaires, review the Breast Cancer Screening Decision support tool, and then complete the post-questionnaire.
89317613|NCT04741503|Active Comparator|Standard Breast Cancer Screening Education|-After randomization, participants will complete pre-questionnaires, review the standard breast cancer screening education from the NCI, and then complete the post-questionnaire.
89317614|NCT04734873|Experimental|CPI-006 (2 mg/kg) Plus Standard of Care|Participants will receive a single dose of CPI-006 at 2 mg/kg up to a maximum dose of 200 mg intravenously on Day 1 plus standard of care.
89317615|NCT04734873|Experimental|CPI-006 (1 mg/kg) Plus Standard of Care|Participants will receive a single dose of CPI-006 at 1 mg/kg up to a maximum dose of 100 mg intravenously on Day 1 plus standard of care.
89317616|NCT04734873|Placebo Comparator|Placebo Plus Standard of Care|Participants will receive a single dose of placebo intravenously on Day 1 plus standard of care.
89317617|NCT03750669|Experimental|Neoadjuvant Chemotherapy|Patients receive the sequential neoadjuvant chemotherapy of AG regimen (nab-paclitaxel plus gemcitabine) and mFOLFIRINOX before resection.
89317618|NCT03750669|No Intervention|control|Patients receive surgical treatment without any neoadjuvant treatments.
89317619|NCT03757221|Experimental|Combination ixazomib + daratumumab without dexamethasone|Elderly Relapse Refractory Multiple Myeloma Patients treated by Combination ixazomib + daratumumab without dexamethasone
89317620|NCT03757143|Active Comparator|PVI et Insyte|Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD
89317621|NCT03757143|Experimental|CHG et Insyte|Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD
89317622|NCT03757143|Experimental|PVI et Nexiva|Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
89317623|NCT03757143|Experimental|CHG et Nexiva|Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
89317624|NCT04435665|Experimental|NFX-179 Gel Low|NFX-179 Gel for topical administration, once daily for 28 days
89317625|NCT04435665|Experimental|NFX-179 Gel Mid|NFX-179 Gel for topical administration, once daily for 28 days
89317626|NCT04435665|Experimental|NFX-179 Gel High|NFX-179 Gel for topical administration, once daily for 28 days
89317627|NCT04435665|Placebo Comparator|Vehicle Arm|Vehicle Gel, for topical administration, once daily for 28 days
89317628|NCT04428411||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease
89317629|NCT03751059|Active Comparator|NSAID|Bromfenac 0.07% Oph Susp: used from one week post-op to three months post-op
89317630|NCT03751059|Active Comparator|Steroid|Dexamethasone: used from one week post-op to three months post-op
89317631|NCT04422561|Experimental|Ivermectin group|Contacts who will receive prophylactic ivermectin
89317632|NCT04422561|No Intervention|Control group|Contacts who will be only observed without prophylaxis
89317633|NCT03750591||Integrative Korean medicine treatment group|"Observation of pain, function, quality of life, satisfaction, and adverse events in inpatients with lumbar intervertebral disc herniation hospitalized at 4 Korean medicine hospitals~Interventions:~Drug: Herbal medicine Procedure/Surgery: Chuna manual therapy Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s)"
89317634|NCT03747861|Other|Arm for HRV monitoring|For monitoring HRV each subject will put Wristband for registration of ECG RR intervals for one hand, SenceBand in the left wrist and Holter monitor electrodes will be placed in standard configurations places.
89317635|NCT01369498|Experimental|Simtuzumab 200 mg|Participants in Stage 1 of study will receive simtuzumab 200 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
89317636|NCT01369498|Experimental|Simtuzumab 700 mg|Participants in Stage 1 of study will receive simtuzumab 700 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
89317637|NCT01369498|Experimental|Simtuzumab 200 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 200 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
89317638|NCT01369498|Experimental|Simtuzumab 700 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 700 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
89317639|NCT03756987|Experimental|ESPB group|Patient will receive a single shot of Ropivacaine injection 0.5% 25 mL injected at the erector spinae plane.
89317640|NCT03756987|Placebo Comparator|Control Group|Patient will receive a single shot of normal saline 25 mL injected at the erector spinae plane.
89317641|NCT02072746|Active Comparator|Zinc|zinc sulfate 220 mg daily
89317642|NCT02072746|Placebo Comparator|Placebo|Placebo study for comparison
89317643|NCT04940338|Experimental|Bromfenac|Group 1 will receive topical bromfenac (0.9 mg/mL) 2x daily, 7 days before the surgery
89317644|NCT04940338|Experimental|Dexamethasone|Group 2 will receive topical dexamethasone (1mg/mL) 2x daily before the surgery
89317645|NCT04940338|Placebo Comparator|Placebo|Group 3 will receive topical placebo (artificial tears substitute) 2x daily before the surgery
89317646|NCT04709835|Placebo Comparator|Placebo|Participants will receive AT-527-matched placebo twice a day (BID) on Days 1-5.
89317647|NCT04709835|Experimental|AT-527 550 mg (1x550 mg)|Participants will receive 550 mg AT-527 (1x550 mg) twice a day (BID) on Days 1-5.
89317648|NCT04709835|Experimental|AT-527 1100 mg (4x275 mg)|Participants will receive 1100 mg AT-527 (4x275 mg) twice a day (BID) on Days 1-5.
89317649|NCT02083510|Experimental|Colchicine|Patients will be enrolled with either gout/pericarditis or hypertriglyceridemia, have VAP and Apolipoprotein CIII levels at baseline, administer Colchicine for 6 weeks with reassessment of Apolipoprotein CIII and VAP.
89317650|NCT02083588|Experimental|open - single arm|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
89317651|NCT02072902||diabetes free|No intervention
89317652|NCT02072902||Diabetes prevalent|The exposure is diabetes morbidity present at study entery
89317653|NCT02072902||Diabetes incidence|The exposure is diabetes incidence during study follow up
89317654|NCT02083666|Experimental|SOBI002|Single and repeated administration of different doses of test product
89317655|NCT02083666|Placebo Comparator|placebo|Single and repeated administration of placebo comparator
89317656|NCT02083744|Active Comparator|Control Group|Usual care group - patients will receive scales to take home and heart failure literature for self-monitoring of heart failure. Patients will complete final questionnaires
89317657|NCT02083744|Experimental|Psychoeducational Counseling|"1-on-1 psychoeducation session conducted by a bilingual research nurse at the clinic site or in the patient's home. Patients will receive a scale to measure weight, a diary to record weight and symptoms of heart failure, and telephone follow-up from the research nurse to reinforce the content of the education program every other week.~Focus-groups - Perception of the intervention will be assessed with two focus groups."
89317658|NCT04407507|Experimental|Ivermectin|Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
89317659|NCT04407507|Placebo Comparator|Placebo|Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
89317660|NCT02073136|Experimental|Phosphate modified diet|
89317661|NCT02073214|Experimental|Probiotic|"Single dose of probiotic, was administered enterally twice daily with food (in the morning and in the evening). The first dose of probiotic was administered within the first 48 hours after birth. The probiotic administration was continued for 6 weeks or until hospital discharge (whichever was earlier).~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the probiotic. If the probiotic was discontinued for more than 7 days, the patient was withdrawn from the study."
89317662|NCT02073214|Placebo Comparator|Placebo|"Single dose of placebo was administered enterally twice daily with food (in the morning and in the evening). The first dose of placebo was administered within the first 48 hours after birth. The placebo administration was continued for 6 weeks or until hospital discharge (whichever was earlier).~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the placebo. If the placebo was discontinued for more than 7 days, the patient was withdrawn from the study."
89317663|NCT04698993|Other|Symptomatic|Collection of specimens from symptomatic COVID-19 positive participants
89317664|NCT04698993|Other|Asymptomatic|Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2
89317665|NCT02080624|Experimental|Rapamycin|Topical rapamycin applied once a day
89317666|NCT02080702||Monosyn|Construction of a gastrointestinal anastomoses
89317667|NCT01562457|Experimental|Low dose|
89317668|NCT01562457|Experimental|Medium dose|
89317669|NCT01562457|Experimental|High dose|
89317670|NCT03747783||Survival Group|status from radical operation to follow-up
89317671|NCT03747783||Non-Survival Group|status from radical operation to follow-up
89317672|NCT02083822|Experimental|MRI assessment|
89317673|NCT02083900|Experimental|Banana Leaf Dressing Group|The Banana Leaf Dressing site will receive a single layer of banana leaf dressing
89317674|NCT02083900|Active Comparator|Hydrocolloid Dressing Arm|The donor under Hydrocolloid dressing was covered with hydrocolloid (DuoDERM CGF).
89317675|NCT02080858|Experimental|Ticagrelor + Apixaban + ASA|180 mg Ticagrelor loading dose + apixaban 2.5 mg bid + 300 mg ASA loading dose (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg + 100 mg ASA od to reach steady state conditions within 4.5 days
89317676|NCT02080858|Active Comparator|Ticagrelor + Apixaban|180mg ticagrelor loading dose + apixaban 2.5 mg bid (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg to reach steady state conditions within 4.5 days
89317677|NCT02073370||health subjects; outpatients aged over 65|The research subjects will be culled from outpatients aged over 65 at NTUH; 1000 Taiwanese subjects aged 20-40 equally divided in both genders will be recruited in order to establish the norm of Taiwanese's skeletal muscle index.
89317678|NCT02083978||Bipolar Diagnosis|Individuals identified as having a Bipolar Diagnosis with a manic episode
89317679|NCT02083978||Control|Individuals identified as not having a major psychiatric diagnosis
89317680|NCT03750435|Experimental|Ablation for AF or left-sided AT|The patient will be admitted in hospital as for a standard ablation procedure and discharged the next day. The procedure will be carried out without using fluoroscopy and relying on the visualization of the electroanatomical mapping system.
89317681|NCT02073526||Anti-TNF|Inflammatory bowel patients age 18 and over treated with anti-TNF agents
89317682|NCT03558568|Active Comparator|DBS off|
89317683|NCT03558568|Active Comparator|DBS on 60 Hz.|
89317684|NCT03558568|Active Comparator|DBS on 99 Hz.|
89317685|NCT03558568|Active Comparator|DBS on 130 Hz.|
89317686|NCT03558568|Active Comparator|DBS on 230 Hz.|
89317687|NCT02073604|Other|Healthy volunteers|Healthy volunteers
89317688|NCT02073604|Other|Congenital mirror movements|Patients presenting with congenital mirror movements
89317689|NCT04359771|Active Comparator|Yellow MPL|
89317690|NCT04359771|Active Comparator|Diode MPL|
89317691|NCT02081092||Pulmonary Alveolar Proteinosis (PAP)|Patients diagnosis with Pulmonary Alveolar Proteinosis.
89317692|NCT02084212|Other|Patients about to undergo epiretinal membrane surgery|
89317693|NCT03756831|Active Comparator|Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
89317694|NCT03756831|Active Comparator|Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
89317695|NCT03756831|Active Comparator|Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
89317696|NCT02081170|Experimental|autologous platelet concentrate|
89317697|NCT03750357|Experimental|Primary Relief v 2.0 with Paracetamol|Group A will be treated with Primary Relief v 2.0(1 - 100Hz) sweep stimulation with increase in power of the stimulation for fixed interval of time.
89317698|NCT03750357|No Intervention|Only Paracetamol|Group B will be treated with paracetamol drug.
89317699|NCT02073760||Infection Prevention Experts|Adult caregivers of cardiac surgery patients (e.g. surgeons, nurses, infection preventionists) and administrators
89317700|NCT02084290|Experimental|Shared Decision Making Program|Patients will have access to an educational decision making program and a risk prediction model, this web based program will be sent subjects in the intervention arm upon enrollment, they can access the program as many times as they wish.
88811005|NCT04788004||Cohort 10|Participants in this group started their recovery process 9 to <10 years ago
89317701|NCT02084290|No Intervention|Control|Subjects enrolled at sites participating as control arms will access the same web-based surveys as the intervention group, and receive the same contacts from the study coordinator as the subjects enrolled at intervention sites.
89317702|NCT04356573|Placebo Comparator|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects first ate 2 gold kiwifruit with midday meal for 2 weeks before crossing over to the green Hayward kiwifruit intervention
89317703|NCT04356573|Active Comparator|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects first ate 2 green Hayward kiwifruit with midday meal for 2 weeks before crossing over to the gold kiwifruit intervention
89317704|NCT02073916|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 with Laptinib followed by Abraxane
89317705|NCT02084368|Experimental|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block guided by PNS.
89317706|NCT02084368|Placebo Comparator|combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group.
89317707|NCT02084446|Active Comparator|Mycophenolate + Low Tacrolimus|"Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.~Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
89317708|NCT02084446|Experimental|Everolimus + Very Low Tacrolimus|"Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.~Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.~Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
89317709|NCT02801656|Experimental|Fecal Microbiota Transplantation|Oral, encapsulated fecal microbiota transplantation
89317710|NCT02801656|Active Comparator|Vancomycin|125 mg po qid x 10 days
89317711|NCT02074072|Experimental|Direct laryngoscope|Macintosh laryngoscope
89317712|NCT02074072|Experimental|Videolaryngoscope-1|Glidescope
89317713|NCT02074072|Experimental|Videolaryngoscope-2|Airwayscope
89317714|NCT02084524|No Intervention|Nutritional evaluation|
89317715|NCT02081482|Experimental|subjects with refractory chronic cluster headache|Adult subjects with refractory chronic cluster headache and ONS indication
89317716|NCT02084602|Experimental|Artesunate/mefloquine|Orally administration of artesunate 4mg/Kg by three days Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
89317717|NCT03542877|Experimental|Oral Cabozantinib|Patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks. If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.
89317718|NCT02081560|Other|colistin pharmacokinetics|Intravenous colistin 9 million units loading dose and 3 million units q8h maintenance dose as long as treatment of infection is required
89317719|NCT02074150|Experimental|Biceps Brachii|"Biceps Brachii (elbow flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89317720|NCT02074150|Experimental|Flexor Carpi Radialis|"Flexor Carpi Radialis (wrist flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89317721|NCT02074150|Experimental|Flexor carpi ulnaris|"Flexor carpi ulnaris (wrist flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89317722|NCT02074150|Experimental|Flexor digitorum profundus|"Flexor digitorum profundus (finger flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89317723|NCT02074150|Experimental|Flexor digitorum sublimis|"Flexor digitorum sublimis (finger flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89317724|NCT02074150|Experimental|Adductor pollicis|"Adductor pollicis (thumb flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89317725|NCT02074150|Experimental|Flexor pollicis longus|"Flexor pollicis longus (thumb flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
89317726|NCT02074150|Experimental|Change from Baseline in Elbow Ashworth|"Change from Baseline in Elbow Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
89317727|NCT02074150|Experimental|Change from Baseline in Wrist Ashworth|"Change from Baseline in Wrist Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
89317728|NCT02074150|Experimental|Change from Baseline in Finger Ashworth|"Change from Baseline in Finger Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
89531616|NCT05929469|Experimental|Human-Enhanced Kick-Off + App + Check-In|"This arm includes participants who do not respond to the Human-Enhanced Kick-Off + App in stage 1.~In stage 1, the participant's kick-off will include a session with a study interventionist. They will also receive an mHealth program.~In stage 2, they will continue with the mHealth program, but will also receive a check-in with a study interventionist."
88811006|NCT04772170||Current Challenge Study Participant|Current participation in a respiratory virus challenge study at the NIH CC
89317729|NCT02074150|Experimental|Change from Baseline in Thumb Ashworth|"Change from Baseline in Thumb Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
89317730|NCT02074150|Experimental|Change from Baseline in PGAS|Change from Baseline in PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
89317731|NCT02074150|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30
89317732|NCT02074150|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317733|NCT02074150|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317734|NCT02074150|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317735|NCT02074150|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317736|NCT02074150|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317737|NCT02074150|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317738|NCT02074150|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317739|NCT02074150|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317740|NCT02074150|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317741|NCT02074150|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
89317742|NCT03747549|Experimental|Acupuncture and Home Exercise|Acupuncture and home exercise.
89317743|NCT03747549|Active Comparator|Home Exercise Alone|The prescribed home exercise program alone.
89317744|NCT03750123||Kawasaki Disease (KD)|Children 5 years after Kawasaki Disease
89317745|NCT03750123||Healthy controls (HC)|Age- and sexmatched healthy siblings of children after Kawasaki Disease
89317746|NCT04797741|Experimental|IDEA3 Intervention|
89317747|NCT04352127|Experimental|Dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and routine clinical monitor on non-dominant hand
89317748|NCT04352127|Experimental|Non-dominant hand|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and routine clinical monitor on dominant hand
89317749|NCT02074228|Experimental|Methylphenidate|Methylphenidate (Concerta) 18mg or 36mg 1# qd, 12 weeks
89317750|NCT02084680|No Intervention|Control|Control group standard care
89317751|NCT02084680|Experimental|Community Health Workers|individual prenatal education
89317752|NCT03750045|Experimental|Experimental group|For the tests, the volunteers used the access device (Leap Motion) and a computer that were previously installed. The intervention was composed by 8 sessions of 15 minutes each, where the volunteers used a virtual environment attached it to a Leap Motion, which is a sensor that allows to capture the movements that are produced by the hands and reproduce them in a computer through a 3D virtual environment in order to stimulate the execution of their finer movements. The strength (Jamar) and motor coordination (wooden box) evaluations were made in the first, fourth and eighth sessions with the objective of checking the gain progression or not of motion coordination and grip strength.
89317753|NCT02084758|Active Comparator|Nitrate supplementation|Sodium nitrate solution
89317754|NCT02084758|Placebo Comparator|Placebo supplementation|Sodium chloride solution
89317755|NCT02074306|Experimental|UROSHIELD®|Randomly selected patients,(ratio 1:1) with newly begun mechanical ventilation, will be connected to a low energy acustic wave generator UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation.
89317756|NCT02074306|Sham Comparator|SHAM UROSHIELD®|same as abouve but with Sham device.
89317757|NCT04351269||CanGaroo Envelope|Patients who received a CanGaroo Envelope with their Cardiac Implantable Electronic Device (CIED) implantation.
89317758|NCT04351269||TYRX Envelope|Patients who received a TYRX Envelope with their Cardiac Implantable Electronic Device (CIED) implantation.
89317759|NCT04351269||No Envelope|Patients who had their Cardiac Implantable Electronic Device (CIED) implanted with no envelope.
89317760|NCT02081716||high CMV ELISPOT results|high spot counts in ELISPOT
89317761|NCT02081716||low CMV ELISPOT results|low spot counts in ELISPOT
89317762|NCT02084836||Lean adolescents|
88811007|NCT04770909|Experimental|Combined|Weekly incentives for dietary self-monitoring and weight loss
88811008|NCT04770909|Experimental|Dietary self-monitoring|Weekly incentives for dietary self-monitoring
89317763|NCT02081794|Experimental|Arm I (Tailored education intervention)|Participants receive a tailored educational intervention on the risk of falls comprising one of four two-minute videos determined by which educational group the participant is placed in: high risk/high perception, high risk/low perception, low risk/high perception, or low risk/low perception. Participants also receive tailored printed educational information concerning hospital falls based on the participants' answers given on the Perceived Risk Survey and are tailored to the participants' perception of falls risk. Participants also complete an investigator-constructed satisfaction survey at 24 and 72 hours post-intervention.
89317764|NCT02081794|Active Comparator|Arm II (standard fall care)|Participants receive standard care by nurses comprising a falls risk assessment and verbal education and receive an educational instruction sheet on falls prevention.
89317765|NCT04348851|Experimental|4-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
89317766|NCT04348851|Experimental|8-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
89317767|NCT04348851|Active Comparator|8-Week Attention Control|The Registered Nurses (RNs) will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare provider.
89317768|NCT04348851|No Intervention|Standard Care|Caregivers receiving standard of care
89317769|NCT02084914|Experimental|Group A|Endometrial scraching of uterine cavity by pipelle .
89317770|NCT02084914|Active Comparator|Group B|Uterine sound intoduced into uterine cavity without scratch .
89317771|NCT05508568||Non-muscle invasive bladder cancer patients in follow-up|Patients with a previous diagnosis of non-muscle invasive bladder cancer, attending a urology clinic for the purposes of bladder cancer recurrence monitoring.
89317772|NCT02074540||Diabetes Type II Patients|
89317773|NCT02074618|Experimental|Physical Exercise|The program of physical exercise was a resistance and aerobic training, initiated at low intensity and with a slow progressing according to the patient's tolerance. In aerobic exercise, for greater effectiveness of the training, the literature recommends moderate intensity, which corresponds with 50 to 70% of the maximum heart rate. Patients were instructed to keep the most constant as possible the speed during exercise on treadmill or cycle ergometer. For muscle strengthening exercises, the number of repetitions varied from 1 to 4 sets of 10 to 15 repetitions.
89317774|NCT04346199|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
89317775|NCT04346199|No Intervention|Arm 2|Best Supportive Care
89317776|NCT02084992|Experimental|Expanded technology disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, patients randomized to this arm will be given tablet computers with a web-based heart failure disease management application. Patients will be asked to interact with the system daily with transmission of weight, heart rate, blood pressure and symptom reports to the nurse manager. A nurse manager will check the data daily and contact patients if any parameters exceed pre-specified parameters. Nurse managers will also touch base with the participants at regular intervals as in the control arm. In addition, educational modules will be placed onto individual tablet computers and given to each patient.
89317777|NCT02084992|Active Comparator|telephonic disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, the nurse manager will telephone participants weekly for the first month followed by either every two weeks or monthly calls depending on clinical status with the goal of transitioning all participants to monthly calls. During these phone calls the nurse manager will focus on identifying changes in clinical condition and education reinforcement. Participants will be instructed to check and record their weight, heart rate and blood pressure daily and will be encouraged to call if there are any changes in their clinical status.
89317778|NCT03558490|Experimental|ZEMY software|
89317779|NCT04345653|Experimental|Study arm - Hydroxychloroquine Sulfate (HCQ)|HCQ sulfate HCQ 400mg (2x 200mg tablets) by mouth 6-12 hours apart on day 1, followed by 3 weeks of weekly 400mg (2x 200mg tablets) by mouth
89317780|NCT02074774|Experimental|IntellO2|Automated control of FiO2
89317781|NCT02074774|Active Comparator|Manual|Manual control of FiO2
89317782|NCT02074852||Immediate catheter removal|The catheter was removed immediately after the CS
89317783|NCT02074852||Delayed catheter removal|The catheter was removed 12 hours postoperatively
89317784|NCT04342689|Experimental|Intervention|Subjects will receive a dietary supplement containing resistant starch and be instructed to take 2 tablespoons (~20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days prior to increasing to 2 tablespoons twice daily.
89317785|NCT04342689|Placebo Comparator|Control|Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.
89317786|NCT03779152||non asthmatic subjects|
89317787|NCT03779152||intermittent asthmatics|
89317788|NCT03779152||severe asthmatics sensitive to corticosteroids|
88811009|NCT04770909|Experimental|Weight loss|Weekly incentives for weight loss
88811010|NCT04770909|No Intervention|Control|
88811011|NCT04758819|No Intervention|Control group|Embryo selection according to Day 5/6 usual morphological criteria (Istanbul consensus)
88814875|NCT03033290|Experimental|Bu-Zhong-Yi-Qi-Tang (BZYQT)|capsule of BZYQT, 4gm tid, 12gm a day for 2 months
89317789|NCT03779152||severe asthmatics resistant to corticosteroids|
89317790|NCT03779152||moderate asthmatics|
89317791|NCT02082028|Experimental|A (BGStar)|Patients will be educated within the context of the SINERGIA educational program to understand how to manage their own diabetes on the basis of their Self Monitoring of Blood Glucose values obtained with BGStar. Patients will be requested two 6-points profiles monthly.
89317792|NCT02082028|Active Comparator|B (traditional approach)|Usual approach for the disease management. Patients in Group B will receive usual education and, at any time during the study duration, if needed, will be instructed on Self Monitoring of Blood Glucose, performed with any glucose meter.
89317793|NCT02082106||males/females|Participants should be capable of alpine skiing and cross country skiing.
89317794|NCT02085226|Experimental|Creative Engagement Intervention|Creative Engagement Intervention participants will receive 4-8 art sessions over 3-5 weeks, depending on length of inpatient stay. Sessions will be delivered as 1:1 sessions with the artist lasting up to one hour (depending on patient fatigue levels) and group sessions, with up to 5 participants, lasting up to two hours (depending on patient fatigue levels). Participant with receive one group and one individual session per week of inpatient stay. The sessions will cover 5 activity stages of the intervention, taking the participant through a progressive artwork development process. Participants will explore basic visual art materials and processes and progress to creating artworks with a personal context that they have directed and controlled.
89317795|NCT02085226|Placebo Comparator|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
89317796|NCT02085304|Experimental|GammaKnife(R) stereotactic radiosurgery|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive a one-day GammaKnife(R) stereotactic radiosurgery procedure and will also take temozolomide (Temodar(R)) chemotherapy daily for six weeks with a one month break before taking temodar for additional 12 monthly cycles.
89317797|NCT02085304|Active Comparator|Standard fractionated radiation therapy|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive six weeks of standard fractionated radiation therapy plus daily temozolomide (Temodar(R)) chemotherapy for six weeks. This is followed by a one month break before taking temodar for additional 12 monthly cycles.
89317798|NCT02085382|Other|Kangaroo Mother Care Group|"Mothers in the KMC group were oriented in detail about KMC procedure. The mothers provided skin to skin contact using a specially tailored kangaroo tube made of soft flannel cloth. The mothers were encouraged to keep the baby in KMC as long as possible during the day and night for an accumulated time of at least 6 hours per day. The duration of the kangaroo care by each of the mother were recorded and tallied accordingly."
89317799|NCT02085382|Other|Conventional Mother Care|Conventional method of care was the routine care offered in the neonatal unit to low birth weight infants.
89317800|NCT02260414|Experimental|Patients with multiple myeloma|Patient with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
89317801|NCT02260414|Active Comparator|Patients with agressive lymphoma|Patient hospitalized for aggressive lymphoma treated with chemotherapy treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
89317802|NCT02260414|Active Comparator|Patients with acute medical condition|Patient older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
89317803|NCT02085538|Experimental|Normal Renal Function|
89317804|NCT02085538|Experimental|Mild Renal Impairment|
89317805|NCT02085538|Experimental|Moderate Renal Impairment|
89317806|NCT02085538|Experimental|Severe Renal Impairment|
89317807|NCT02074930|Other|Single Arm|
89317808|NCT02085616|Experimental|Proactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the proactive service the callers to the quitline are offered a number of callbacks.
89317809|NCT02085616|Active Comparator|Reactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
89317810|NCT04169061|Experimental|All participants|"Participants receive:~a shot of Acthar (80 units) under the skin twice a week for 12 weeks~a shot of Acthar (40 units) twice a week for 2 weeks~a shot of Acthar (40 units) once a week for 2 more weeks~At each visit they will have medical tests and answer questions about their symptoms."
89317811|NCT01562691|Experimental|Nasopore only|Packing using nasopore without airway integrated
89317812|NCT01562691|Active Comparator|nasopore with airway integrated|packing using airway integrated nasopore
89317813|NCT01562691|Active Comparator|airway-integrated Vaseline gauze|Nasal packing using airway-integrated Vaseline gauze
89317814|NCT03749889|Experimental|100 g carbs|100 grams of carbohydrate allowance for the day
89317815|NCT03749889|Active Comparator|MyPlate|Carbohydrate suggestions based on standard MyPlate. 45-65% kcal intake from carbs.
89317816|NCT03749811|Experimental|Pupillometry group|A group of participants who receive remifentanil infusion under pupillometry monitoring.
88814876|NCT03033290|Placebo Comparator|placebo control|similar placebo capsule 4gm tid, 12gm a day for 2 months
88814877|NCT03030560|Active Comparator|Lidocaine group|Patients will receive lidocaine infusion.
88814878|NCT03030560|Placebo Comparator|Control group|Patients will receive 0.9% Sodium-chloride infusion infusion
89317817|NCT03749811|No Intervention|Conventional group|A group of participants who receive remifentanil infusion without pupillometry monitoring; their analgesic dose is mainly determined via hemodyamic change.
89317818|NCT02792218|Experimental|OMB 20 mg|Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily
89317819|NCT02792218|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
89317820|NCT02075086|Experimental|Chemotherapy treatment|Chemotherapy treatment with Xelox or Xeliri and bevacizumab
89317821|NCT02075164|Experimental|Fructose|Volunteers will be challenged with oral 150g Fructose per day for 56 days.
89317822|NCT02075164|Experimental|Glucose|Volunteers will be challenged with oral 167g Fructose per day for 56 days.
89317823|NCT02075164|No Intervention|NAFLD|Patients with confirmed simple fatty liver will be compared at baseline with other arms.
89317824|NCT02075164|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.
89317825|NCT02082418|Experimental|Healthy|healthy control subjects
89317826|NCT02082418|Experimental|MCI|mild cognitive impariments
89317827|NCT02082418|Experimental|Dementia|established diagnosis of dementia
89317828|NCT02082496|Experimental|Control Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
89317829|NCT02082496|Experimental|Case Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
89317830|NCT02085694|Experimental|Lactobacillus brevis CD2 lozenges|
89317831|NCT02082574||patients|HIV infected for more than 5 years, aged over 50, treated with ARV
89317832|NCT02082574||control|non HIV (matched for age and gender)
89317833|NCT02075242|Active Comparator|tacrolimus|Control group: Tacrolimus + Corticosteroid (dual oral therapy)
89317834|NCT02075242|Experimental|Mycophenolate Mofetil|Tacrolimus + Mycophenolate Mofetil+Corticosteroid (triple oral therapy)
89317835|NCT02085850||Subjects identified in the Tema Eye Survey|Subjects identified in the Tema Eye Survey
89317836|NCT02082652|Active Comparator|Control group (No ART)|Etonogestrel implant in participants not yet receiving ART (control group)
89317837|NCT02082652|Active Comparator|Nevirapine-based ART group|Etonogestrel implant in participants receiving nevirapine (NVP)-based ART
89317838|NCT02082652|Active Comparator|Efavirenz-based ART group|Etonogestrel implant in participants receiving efavirenz (EFV)-based ART
89317839|NCT02082730|Active Comparator|Mid treatment Group|Patients who have completed 6 sessions at the Manchester CFS/ME Service for Children & Young People will be recruited. They would have had previous experience of using paper diaries.They will collect activity data using the ASARM system.
89317840|NCT02082730|Experimental|Start of Treatment Group|Newly presented patients, will collect activity data using the ASARM system.
89317841|NCT02082730|No Intervention|Audit group|"To provide comparative baseline data for general treatment response, we will audit pre-treatment and post-treatment clinical data on the regular gold standard clinical measures package, as these are the outcome measures routinely used in the clinic."
89317842|NCT02082808|Experimental|Sequence 1|Participants will receive the study Treatment A for 5 days (DTG 50mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment B for 5 days (DCV 60mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
89317843|NCT02082808|Experimental|Sequence 2|Participants will receive the study Treatment B for 5 days (DCV 60mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment A for 5 days (DTG 50mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
88811012|NCT04758819|Experimental|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts: CTTEB group|Trophectoderm cells will be analyzed by NGS. Culture media will also be stored for further non-invasive chromosomal testing. Embryo selection will be done according to international guidelines (www.pgdis.org; Newsletter May 27, 2019).
89317844|NCT02085928||Lateral epicondylitis|Patients with lateral epicondylitis with persistent pain for at least 3 months
89317845|NCT02075788|Placebo Comparator|Commercial white bread|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
89317846|NCT02075788|Experimental|Millet based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
89317847|NCT02075788|Active Comparator|Corn based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
89317848|NCT03558412|Experimental|Arm A|Decitabine+CODOX-M/IVAC for patients with relapsed or refractory T-lymphoblastic lymphoma who used Hyper-CVAD or BFM-90 as first-line therapy:regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.Regimen B :IVAC:ifosfamide,etoposide，cytarabine.Decitabine,10mg,ivgtt,used for 5 days before A+B.
89317849|NCT04401579|Experimental|Remdesivir plus Baricitinib|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
89317850|NCT04401579|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
89317851|NCT02082964|Experimental|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
89317852|NCT02082964|Experimental|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course.
89317853|NCT03558880|Active Comparator|Erector Spinae Plane Block|Before the general anesthesia Erector Spinae Plane Block was performed.
89317854|NCT03558880|Active Comparator|Tumescent Anesthesia|After the general anesthesia was given, 1 mL of 0.1% adrenaline (1/1000) and as 20 mL of 0.5% bupivacaine solution of tumescent in a total of 1000 mL Ringer's lactate applied by the surgeon applied equally to both breasts
89317855|NCT02083120|Experimental|nasal High Flow and Oxygen|overnight nasal High Flow (NHF) therapy+ individually titrated supplemental oxygen (2-6 L/min),total 35 L/min, 4 weeks at home
89317856|NCT02083120|Active Comparator|Long term Oxygen Therapy (LOT)|individually titrated supplemental oxygen (2-6 L/min), 4 weeks at home
89317857|NCT02075944|Experimental|High intensity aerobic exercise|30 minutes of high intensity aerobic exercise 3 times a weeks for 9 weeks - incorporation interval training
89317858|NCT02075944|Experimental|Low intensity aerobic exercise|30 minutes of low intensity aerobic exercise 3 times a weeks for 9 weeks
89317859|NCT02075944|No Intervention|Control|No intervention. Participants are told not to make any changes in their everyday life
89317860|NCT02086084|Active Comparator|NIV|Standard application of NIV in hypercapnic respiratory failure as per usual standard of care
89317861|NCT02086084|Experimental|ECCO2R|Addition of ECCO2R to NIV in AECOPD
89317862|NCT04161807|Experimental|Nerivio device treatment|participant will receive the Nerivio device for treating their migraine attacks. Treatment will be perform as soon as the participant feel that the migraine attack started
89317863|NCT02083198||High Chloride|Patients receiving .9% sodium choride for resuscitation
89317864|NCT02083198||Low chloride|Patients receiving Plasmalyte for resuscitation
89317865|NCT02086240|Experimental|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity. In a previous study (approved by NRES Committee London-West London, REC ref No. 12/LO/0735), we administered an oral dose of XBD173 (up to 90mg) in 12 subjects. No adverse events due to XBD173 occurred and it was well tolerated.
89317866|NCT04401423|Experimental|TXA127|Participants will receive one 3-hour dosage (0.5 mg/kg per day), intravenously, for 10 days consecutively (or until discharge if less than 10 days).
89317867|NCT04401423|Placebo Comparator|Placebo|Participants will receive one 3-hour dosage (0.5 mg/kg per day), intravenously, for 10 days consecutively (or until discharge if less than 10 days).
89317868|NCT03749733|Experimental|Test Product|"Participants will receive a single film-coated tablet of the test formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.~The tablet will be taken with water and in a fasting condition."
89317869|NCT03749733|Active Comparator|Reference Product|"Participants will receive a single film-coated tablet of the marketed reference formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.~The tablet will be taken with water and in a fasting condition."
89317870|NCT04399161|Experimental|Child Participants|Residential school children aged 5-12 yrs at high risk for caries. A total of 36 children will be recruited for the study and randomly divided into 3 groups with 12 participants per group.The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
89317871|NCT04399161|Experimental|Elderly Participants|Elderly citizens (above 60 yrs) at high risk for caries. A total of 36 elderly will be chosen based on eligibility criteria and randomly divided into 3 groups with 12 participants per group. The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
89317872|NCT02076178|Experimental|Arm 1|Participants will receive daily oral 744 (30 mg tablets) for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of 800 mg of 744 LA at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
89317873|NCT02076178|Experimental|Arm 2|Participants will receive daily oral matching placebo for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of saline at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
89317874|NCT02076256|No Intervention|Control Group|
89317875|NCT02076256|Experimental|The helping relationships intervention program|The helping relationships intervention program will be implemented on the experimental group. And the control group will be provided with routine nursing care. Data will be collected at baseline, the sixth and the ninth month of the third year of study. Data will be analyzed using generalized estimating equation measures to evaluate the effect of the intervention program.
89317876|NCT02087878||Group 1|To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and genetic mutations in patients who develop HSTCL.
89317877|NCT03969251|Experimental|Transcranial Magnetic Stimulation (rTMS)|repetitive transcranial magnetic stimulation
89317878|NCT03969251|Sham Comparator|Sham (SS)|repetitive sham rTMS
89317879|NCT03558334|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to preterm infants with BPD.
89317880|NCT03558334|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to preterm infants with BPD.
89317881|NCT01582607|Active Comparator|Group B|subarachnoid administration of 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5%
89317882|NCT01582607|Active Comparator|Group R|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75%
89317883|NCT01582607|Active Comparator|Group LB|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5%
88811013|NCT04755699|Active Comparator|Healthy Volunteers|This arm consists of healthy volunteers receiving transcutaneous electrical stimulation to the arms, legs, and/or spinal column to evoke various arm/hand and leg/foot movements.
89317884|NCT01582607|Active Comparator|Group RF|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl
89317885|NCT01582607|Active Comparator|Group BF|subarachnoid administration of 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
89317886|NCT01582607|Active Comparator|Group LBF|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
89317887|NCT02086318||OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle
89317888|NCT00149825|Experimental|MED+CBTI|Escitalopram plus Cognitive Behavioral Therapy for Insomnia
89317889|NCT00149825|Active Comparator|MED+CTRL|Escitalopram plus Pseudo-desensitization Therapy for Insomnia
89317890|NCT04397757|Experimental|COVID-19 Convalescent plasma|COVID-19 Convalescent plasma on Study Day 1 in addition to standard care
89317891|NCT04397757|No Intervention|Standard care|Standard care alone
89317892|NCT02792062|Experimental|TAK-385 40 mg (Group A)|A single oral dose of TAK-385 40 milligram (mg) (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
89317893|NCT02792062|Experimental|TAK-385 40 mg (Group B)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
89317894|NCT02792062|Experimental|TAK-385 40 mg (Group C)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
89317895|NCT02792062|Experimental|TAK-385 40 mg (Group D)|A single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
89317896|NCT02792062|Experimental|TAK-385 40 mg (Group E)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
89317897|NCT02792062|Experimental|TAK-385 40 mg (Group F)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
89317898|NCT02090842|Experimental|Whey protein isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks.
89317899|NCT02090842|Experimental|Ca-caseinate|Subjects are asked to supplement their habitual diet with 56 g of Ca-caseinate a day for 8 weeks.
89317900|NCT02090842|Other|Maltodextrin|Subjects are asked to supplement their habitual diet with 54 g of maltodextrin a day for 8 weeks.
89317901|NCT05027295|Active Comparator|Continuous UVA|Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of continuous UVA light for 7.5 minute exposure time
89317902|NCT05027295|Active Comparator|Pulsed UVA|Riboflavin administration one drop every two minutes with administration of 12mW/cm2 of pulsed UVA light for 15 minute exposure time
89317903|NCT02090920||Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
89317904|NCT01562535|Experimental|Pronation group|In this group, participants will receive the pronation procedure. The technique is described below
89317905|NCT01562535|Active Comparator|Supination group|Participants in this group will be performed the supination technique. Description below.
89317906|NCT02091076|Experimental|Silk with bioactive coated dressing|Silk fibroin coated with bioactive layer, apply once only
89317907|NCT02091076|Active Comparator|Control|Bactigras wound dressing, apply once only
89317908|NCT03747471|Experimental|Experimental Arm|Intervention: Diabetic Conversation Map x 4 Sessions
89317909|NCT03747471|No Intervention|Control Arm|No intervention
89317910|NCT02086396|Experimental|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
89317911|NCT02086396|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
89317912|NCT03558100|Experimental|Reducing Fall Risks in Obesity|Adults with obesity will be asked to perform the obstacle crossing intervention for adults with obesity for reducing falls risk. This will involve crossing obstacles of different heights under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters will be collected using a gait carpet and body-worn sensors.
89317913|NCT02086474|Experimental|Hyaluronan|Hyaluronan acid Neovisc : one 6cc (viscosupplement) intra-articular injection
89317914|NCT02086474|Placebo Comparator|Bupivacaine|one Marcain extra-capsular injection
89317915|NCT05280483|Experimental|Fed states in healthy subjects|A single 25mg dose of ABSK021 administered in a fed state.
89317916|NCT05280483|Experimental|Fasted states in healthy subjects|A single 25mg dose of ABSK021 administered in a fasted state.
89317917|NCT03749577|Experimental|L-citrulline|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
89317918|NCT03749577|Experimental|Beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
89317919|NCT03749577|Placebo Comparator|L-citrulline placebo|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
89317920|NCT03749577|Placebo Comparator|Denitrated beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
89317921|NCT02088268|Experimental|platelet-rich plasma|wound healing
89317922|NCT02091310|Placebo Comparator|Placebo (Study Part I)|Hard gelatin capsules, oral administration, 5 or 6 capsules per day before breakfast with a glass of water
89317923|NCT02091310|Experimental|GFT505 300 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 5 capsules per day before breakfast with a glass of water
89317924|NCT02091310|Experimental|GFT505 360 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 6 capsules per day before breakfast with a glass of water
89317925|NCT02091310|Placebo Comparator|Placebo (Study Part II)|Hard gelatin capsules, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
89317926|NCT02091310|Experimental|GFT505 120 mg (Study Part II)|Hard gelatin capsules dosed at 60mg, oral administration, 2 capsules per day plus 2 to 4 capsules of placebo per day before breakfast with a glass of water
89317927|NCT02091310|Experimental|GFT505 xx mg (Study Part II)|Supra-therapeutic dose: hard gelatin capsules dosed at 60mg, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
89317928|NCT02091310|Active Comparator|Moxifloxacin 400 mg (Study Part II)|On days 1 to 13, 4 to 6 placebo capsules per day, then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14
89317929|NCT00196937|Experimental|Cervarix (15-25 Years) Group|Women aged 15 to 25 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
89317930|NCT00196937|Experimental|Cervarix (26-45 Years) Group|Women aged 26 to 45 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
89317931|NCT00196937|Experimental|Cervarix (46-55 Years) Group|Women aged 46 to 55 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
89317932|NCT04397445|Experimental|Ranitidine and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of ranitidine (300 mg) plus low nitrite/NDMA meals (noncured-meats diet)
89317933|NCT04397445|Placebo Comparator|Placebo and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of placebo plus low nitrite/NDMA meals (noncured-meats diet)
89317934|NCT04397445|Experimental|Ranitidine and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of ranitidine (300 mg) plus high nitrite/NDMA meals (cured-meats diet)
89317935|NCT04397445|Placebo Comparator|Placebo and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of placebo plus high nitrite/NDMA meals (cured-meats diet)
89317936|NCT02091388|Experimental|LY03004 25 mg|5 intramuscular injections 25 mg over 113 days
89317937|NCT02091388|Active Comparator|Risperdal® Consta® 25 mg|5 intramuscular injections 25 mg over 113 days
89317938|NCT02088346||Teleconsultation|Intravenous thrombolysis guided by telemedicine consultation system based on portable hardwares
89317939|NCT02088346||Historical control|Usual stroke care without the guidance from hub hospital
89317940|NCT02086942|Experimental|modified VCD regimen1|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen1 for 5 cycles.~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.~Interventions:~Drug: Bortezomib 1.6mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
89317941|NCT02086942|Experimental|modified VCD regimen2|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen 2 for 5 cycles.~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.~Interventions:~Drug: Bortezomib 1.3mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
89317942|NCT02088424||group A|cases with recurrent abortion with insulin resisance
89317943|NCT02088424||GROUP B|cases that are pregnant with no history of recurrent abortion with no insulin resistance
89317944|NCT02091544||Lifestyle intervention|lifestyle intervention
89317945|NCT00191945|Experimental|Atomoxetine|atomoxetine: 0.5 mg/kg/day every day (QD),by mouth (PO) for 2 weeks, 1.2 - 1.4 mg/kg/day QD, PO for 10 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year
89317946|NCT00191945|Placebo Comparator|Placebo|placebo every day (QD), by mouth (PO) for 12 weeks,then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year (open-label extension)
89317947|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
89317948|NCT02091622|No Intervention|No intervention|No intervention.
89317949|NCT02091700||Normals|Subjects with normal visual and retinal function will be enrolled
89317950|NCT02087020||Periprosthetic joint infection|Patient treated with 'Debridement, antibiotics and implant retention' for early postoperative periprosthetic joint infection at Danderyd Hospital between 2007-01-01 and 2012-12-01
89317951|NCT02088502|Active Comparator|N-acetylcysteine|Patients in the N-acetylcysteine group receive 600 mg non-effervescent N-acetylcysteine tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
89317952|NCT02088502|Active Comparator|Theophylline|Patients in the Theophylline group receive 200 mg Theophylline slow-release tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
89317953|NCT02088502|Active Comparator|Theophylline plus N-acetylcysteine|Patients in the Theophylline plus N-acetylcysteine group receive Theophylline slow-release 200 mg tablet plus non-effervescent N-acetylcysteine 600 mg tablet twice daily from 24 hours before to 48 hours after administration of contrast material.
89317954|NCT02087098||Patients with residual OAB symptoms|Urge urinary incontinence, urgency, and frequency after treatment with other antimuscarinics
89317955|NCT01369342|Placebo Comparator|Placebo IV|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
89317956|NCT01369342|Experimental|Ustekinumab 130 milligram (mg)|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
89317957|NCT01369342|Experimental|Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
89317958|NCT00191477|Experimental|A|
89317959|NCT00191477|Placebo Comparator|B|
89317960|NCT03741413|Experimental|Gain-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to save their lives. Thank you for your support. were send to donors in this group."
89317961|NCT03741413|Experimental|Loss-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to prevent them from death. Thank you for your support. were send to donors in this group."
89317962|NCT03741413|Experimental|Control SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can donate blood again. Thank you for your support. were send to donors in this group."
89317963|NCT03741413|No Intervention|Control group|Donors in this group were not received SMS reminders.
89317964|NCT03969173|Active Comparator|PEEP3|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
89317965|NCT03969173|Active Comparator|PEEP6|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
89317966|NCT03969173|Active Comparator|PEEP9|The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP. Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation.
89317967|NCT04320615|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
89317968|NCT04320615|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
89317969|NCT02087332|Experimental|Prolonged release Torasemide (Britomar)|"Prolonged release Torasemide (Britomar) - round, biconvex, white to off-white tablets debossed SN with one side. 1 tablet contains active substance - torasemide 5 or 10 mg and excipients - guar gum, maize starch, anhydrous colloidal silica, magnesium stearate, lactose.~Dosage scheme: per os, once a day, regardless of meals. The common starting dose in CHF - 10-20 mg once a day. If adequate diuretic effect is absent, the dose is increased approximately twofold up to adequate diuretic effect."
89317970|NCT02087332|Active Comparator|Torasemide (Diuver)|Torasemide (Diuver) - white to off-white, round, biconvex tablets. 1 tablet contain active substance - torasemide 5 or 10 mg and excipients - lactose monohydrate, maize starch, sodium glycolate starch, anhydrous colloidal silica, magnesium stearate. Dosage scheme: per os, once a day, after meals. Therapeutic dose - 5 mg a day. If necessary, a dose may be increased up to 20 mg a day, in some cases - up to 40 mg.
89317971|NCT02092012|Active Comparator|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anesthesia induction
89317972|NCT02092012|Active Comparator|dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
89317973|NCT00149747|Experimental|Exercise training|Group based exercise training. Two weekly classes including aerobic endurance physical activity and strength and flexibility training, and up to three home-based sessions of similar composition of aerobic endurance, strength and flexibility training.
89317974|NCT00149747|Placebo Comparator|2|Attention-control of exposure to study staff. Weekly general health education classes conducted in group sessions.
89317975|NCT02092090|No Intervention|Control|Dietary advice at baseline only
89317976|NCT02092090|Experimental|Dietary sodium reduction|Dietary advice and reduced-sodium added-potassium salt substitute
89317977|NCT02087410||study|patients with polycystic ovary syndrome
89317978|NCT02087410||control|healthy patients serves as control group
89317979|NCT00187889|Active Comparator|Eplerenone|Eplerenone 25 mg (1 pill)daily for 1 week then uptitrated to 50 mg (2 pills)daily for 15 weeks.
89317980|NCT00187889|Placebo Comparator|Placebo or sugar pill|Placebo blinded as 25 mg tablet once daily for 1 week then uptitrated to 2 pills daily for 15 weeks.
89317981|NCT03747315||Familial Mediterranean Fever (patients)|Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)
89317982|NCT03747315||Control group (patients)|Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.
89317983|NCT03747315||Healthy donors|Patients without symptoms (anonymous blood donors)
89317984|NCT02087488|Experimental|auricular acupuncture(AA) & Eszopiclone|The disposable Seirin Pyonex Needle will be chosen as AA material to attach every 3 days for 4 weeks, meanwhile, oral Eszopiclone 1 piece (3mg) will be applied 15 minutes before going to sleep everyday for 4 weeks. The manufacturer of disposable Seirin Pyonex Needles is Seirin Corporation, a Japanese company.
89317985|NCT02087488|Placebo Comparator|placebo AA & Eszopiclone|The disposable Pyonex Zero Needle, a non-invasive material will be chosen as placebo AA, with auricular acupoints have no certain effect on PI. Additionally, 1 piece (3mg) Eszopiclone will be administrated to participants 15 minutes before going to sleep everyday for 4 weeks.
89317986|NCT02092246|Active Comparator|Ultrasound Machine Guided Injection|Use of ultrasound machine guidance in needle placement into the knee joint
89317987|NCT02092246|Active Comparator|Unguided Injection|Needle placement performed without ultrasound machine guidance
89317988|NCT00148343|Experimental|ODFS|Odstock Dropped-Foot Stimulator (ODFS)
89317989|NCT00148343|Active Comparator|Standard of Care (inc. AFO)|Conventional Standard of Care (which may include a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) [Traditional Physical Therapy Treatment]
89317990|NCT02087566|Other|Administration of linezolid to 6 healthy volunteers|Administration of linezolid to 6 healthy volunteers {six healthy subjects with normal renal function (CLcr ˃80 ml/min)}
89317991|NCT02087566|Other|Administration of linezolid to 6 acute renal failure patients|Administration of linezolid to 6 acute renal failure patients {(six patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)}
89317992|NCT02087566|Other|Administration of linezolid to 6 ESRD patients|Administration of linezolid to 6 end-stage renal disease (ESRD) patients during an intra-dialytic period (on-dialysis): 6 patients on long term HD (minimum period of dialysis was 40 month while maximum period were 130 month) with an ideal body weight of >60 kg (calculated as {height (cm) -100}×0.9) and a body mass index between 20 and 26 kg/m2 (calculated as {weight (kg)/height (m2)}).
89317993|NCT02092402|Placebo Comparator|Fecal transplantation of own stool|Autologous fecal transplantation (own stool)
89317994|NCT02092402|Experimental|Fecal transplantation (stool from donor)|Allogeneic fecal transplantation (from donor)
89317995|NCT03557866|Experimental|pronated group|individuals with pronated foot
89317996|NCT03557866|Active Comparator|control group|individuals with normal foot posture
89317997|NCT04150341|Experimental|TD-8236 Dose A (low dose)|TD-8236 Dose A (QD x 14 days)
89317998|NCT04150341|Experimental|TD-8236 Dose B (high dose)|TD-8236 Dose B (QD x 14 days)
89317999|NCT04150341|Placebo Comparator|Placebo|Placebo (QD x 14 days)
89318000|NCT00148109|Active Comparator|EGFR positive|The EGFR positive group will be conducted in a 2-stage minimax trial design to determine the rate of four-month progression free survival in this patient population treated with cetuximab
89318001|NCT00148109|Active Comparator|EGFR Negative|The EGFR negative group will help us explore the possibility of benefit of cetuximab in a patient whose tumor does not express or minimally expresses EGFR. If benefit in progression-free survival or in another surrogate such as tumor response or a molecular event is seen in this group it would provide rationale to study this group further in subsequent trials
89318002|NCT03558256|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness- based cognitive therapy added to the usual medication treatment, and guided by two therapists for 8 sessions. Every group of 6 people can form a closed structural group. Each session lasts 2 hours once a week, and has daily homework assignments.
89318003|NCT03558256|Active Comparator|Medication|Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of depression (fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram and escitalopram).
89318004|NCT02088580|Experimental|Triple Chronotherapy|Total sleep deprivation, Sleep phase advance, and Bright light therapy.
89318005|NCT00186485|Experimental|Right Sided Low Frequency Unilateral TMS|1Hz unilateral TMS delivered to the right DLPFC using the MagStim device
89318006|NCT02092480|Experimental|Intervention|After baseline data collection, four schools will be randomly assigned to the intervention arm, those receiving the If I Were Jack programme. RSE teachers will deliver the intervention to all participating Year 11 pupils during four weekly lessons of the 'Learning for Life and Work' strand of the Key Stage 4 curriculum.
89318007|NCT02092480|No Intervention|Control|After baseline data collection, three schools will be randomly assigned to the control arm. Participating pupils will not receive the If I Were Jack intervention and will continue with normal RSE practice.
89318008|NCT03746223|Experimental|R2-R/IV-MTX（methotrexate）|experimental arm will be treated rituximab plus lenalidomide (R2) regimen for 6 cycles and followed by lenalidomide maintenance for 2 years, meanwhile intravitreal methotrexate will be given as protocol
89318009|NCT03969017|Experimental|NAs+Peg IFN Group|NAs+Peg IFN Group will receive the treatment of NAs (patients previously treated with telbivudine will be changed to entecavir) plus pegylated interferon (Peg IFN)α-2b.
89318010|NCT03969017|Other|NAs Group|NAs Group will be treated with NAs as before enrollment.
89318011|NCT04596033|Experimental|Multiple Low Dose (MLD)|GEN-011 is administered by IV infusion at 4-week intervals, up to 5 doses maximum. Each dose is followed by IL-2 administration. MLD patients will not undergo lymphodepletion.
89318012|NCT04596033|Experimental|Single High Dose (SHD)|GEN-011 is administered as a single IV infusion at the maximum available cell yield, after the patient completes a fludarabine/cyclophosphamide lymphodepletion regimen. The single GEN-011 dose is followed by IL-2 administration.
89318013|NCT02087644|Experimental|CYT003|Injections of CYT003
88811014|NCT04755699|Experimental|Individuals with a Spinal Cord Injury|This arm consists of individuals with a spinal cord injury receiving transcutaneous electrical stimulation to the arms/hand and/or spinal column to evoke various arm/hand movements.
89318014|NCT02087644|Placebo Comparator|Placebo|Injections of placebo
89318015|NCT03968783|Experimental|Monofilament suture|continuous double-layer unlocked suturing with 1.0 monofilament synthetic absorbable suture
89318016|NCT03968783|Active Comparator|Multifilament suture|continuous double-layer unlocked suturing with 1.0 multifilament synthetic absorbable suture
88811015|NCT04755699|Experimental|Individuals with a Stroke|This arm consists of individuals with a stroke receiving transcutaneous electrical stimulation to the arms/hand and/or spinal column to evoke various arm/hand movements.
89318017|NCT02092558||Female 1|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
89318018|NCT02092558||Male 2|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
89318019|NCT03747237|Experimental|1. method, Edema measurement methods|"The surgeon will measure from three different places on the patient's face with the help of a paper ruler to measure the edema.~Tragus-Pogonion Tragus-Labial Comissura Angulus Mandible-Latheral Cantus Measurements will be made preoperative, postoperative 2. and 7. days and saved as milimetre."
89318020|NCT03747237|No Intervention|2. method, Edema measurement methods|Patients will be given edema scale.With the help of the edema scale, the patients will be evaluated the edema by themselves. When the patient stand in front of the mirror, they will be assessed the edema on their face. And a value between 0 and 5 will be pointed on the scale postoperative 2. and 7. days.
89318021|NCT02092636|Experimental|NIR/US Diagnostic Group|These patients will include women who have breast lumps/lesions visible by ultrasound and are prescribed follow up with an ultrasound-guided biopsy at the UCHC Cancer Center for evaluation and diagnosis of actual/suspected breast abnormalities.
89318022|NCT02092636|Experimental|NIR/US Neoadjuvant Chemotherapy Group|These patients will include women who have breast lumps/lesions visible by ultrasound and have been diagnosed with breast cancers and will undergo neoadjuvant chemotherapy. These patients may be identified from the diagnostic group or after initial diagnosis. Patients will only be enrolled to one of the two groups.
89318023|NCT02092636|Other|NIR/US Process Validation Group|This group will contain data from about five women who did not have ultrasound visible lumps on the day of the planned biopsy. Data from the NIR/US scan will be used to validate instrument measurements.
89318024|NCT00147251|No Intervention|SANDS Control Group|Standard Treatment for blood pressure and cholesterol
89318025|NCT00147251|Active Comparator|SANDS Intervention Group|FDA approved drugs to treat blood pressure and cholesterol
89318026|NCT04390191|Experimental|Continuous Positive Airway Pressure (CPAP)|Patients will be given CPAP at fixed pressure of 8-10 cm water pressure for 72 hours continuously
89318027|NCT04390191|No Intervention|Control|Patients in this arm will be not be given any intervention and will be monitored for 72 hours continuously, and then daily for a total of 14 days.
89318028|NCT02092714||Ancillary-correlative (molecular analysis)|Previously collected tissue samples are analyzed via mutational sequencing and immunohistochemistry.
89318029|NCT03967691|Placebo Comparator|Saline infusion|Subjects will be infused with saline (placebo) on study day 1
89318030|NCT03967691|Active Comparator|Tocilizumab infusion|Subjects will be infused with tocilizumab on study day 2
89318031|NCT03967691|Other|Saline infusion under tocilizumab influence|Subjects will be infused withsaline (but still under the influence of tocilizumab) on study day 3
89318032|NCT02088736|Active Comparator|Intravenous and Intraosseous|'IV + IO' Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If IV is unsuccessful, IO will attempt at the Primary site (proximal tibia). If IO is unsuccessful at scene, 2nd attempt can be done in the ambulance. Adrenaline will be delivered as according to protocol.
89318033|NCT02088736|Experimental|Intravenous|Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If 1st IV is unsuccessful at scene, 2nd IV attempt can be done in the ambulance. Adrenaline will be delivered according to protocol.
89318034|NCT02092792|Experimental|Dose-Escalation Phase|
89318035|NCT02092792|Experimental|Dose-expansion cohort|
89318036|NCT03968549|Placebo Comparator|Placebo|These patients will receive capsules containing vegetable oil and corn starch
89318037|NCT03968549|Active Comparator|Probiotic|These patients will receive capsules containing Lactobacillus acidophilus
89318038|NCT03558178|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated.
89318039|NCT03558178|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
89318040|NCT04333563|Active Comparator|CPAP|respiratory stressed infants getting Continuous positive airway pressure (CPAP)
89318041|NCT04333563|Experimental|respiratory stressed infants getting NIV NAVA|respiratory stressed infants getting Non-invasive neurally adjusted ventilatory assist (NIV NAVA)
89318042|NCT04405076|Experimental|mRNA-1273: Dose 50 microgram (ug) - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 intramuscular (IM) injection of 50 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 18-54 years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
89318043|NCT04405076|Experimental|mRNA-1273: Dose 50 ug - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
89318044|NCT04405076|Experimental|mRNA-1273: Dose 100 ug - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 18-54 years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
89318045|NCT04405076|Experimental|mRNA-1273: Dose 100 ug - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1."
89318046|NCT04405076|Placebo Comparator|Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 18-54 years|"Part A: Participants aged 18-54 years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.~Part B: Participants aged 18-54 who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29."
89318047|NCT04405076|Placebo Comparator|Placebo (Part A) and mRNA-1273 100 ug (Part B) - Participants Aged 55+ years|"Part A: Participants aged 55+ years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29.~Part B: Participants aged 55+ years who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29."
89318048|NCT04405076|Experimental|mRNA 1273.351 20 ug (Part C)|Part C: Participants will receive 1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1.
89318049|NCT04405076|Experimental|mRNA 1273.351 50 ug (Part C)|Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA 1273.351 on Day 1.
89318050|NCT04405076|Experimental|mRNA-1273/mRNA-1273.351 mixture (Part C)|Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA-1273/mRNA-1273.351 mixture on Day 1.
89318051|NCT01074359|Experimental|A0001|A0001 (0.75 g BID)
89318052|NCT01074359|Placebo Comparator|Placebo|Placebo
89318053|NCT02088814|Experimental|'EPICAP'|Secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
89318054|NCT02088814|No Intervention|Medical treatment as usual|Medical treatment of burn injuries as usual
89318055|NCT02087722|Experimental|KI1001|
89318056|NCT02087722|Placebo Comparator|Placebo|
89318057|NCT01326221||1|Single dose of Truvada
89318058|NCT04311177|Experimental|Losartan|Participants in this arm will receive the study drug, Losartan.
89318059|NCT04311177|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
89318060|NCT01582685|Experimental|Exercise Group|The intervention is a structured walking program which will be performed partly in the Pavilion Physical Therapy clinic and partly at home. The participant will be instructed in how hard to exercise, how long to exercise, and how many times in a week to exercise. You will also be instructed in how to exercise safely.
89318061|NCT01582685|No Intervention|No Exercise|These participants will receive standard of care follow up.
89318062|NCT02088892|Experimental|Group A|10 BCG-naïve subjects receiving intradermal BCG SSI at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
89318063|NCT02088892|Experimental|Group B|10 BCG-naïve subjects receiving BCG Tice at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
89318064|NCT02088892|Experimental|Group C|10 BCG-naïve subjects receiving intradermal BCG SSI at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
89318065|NCT02088892|Experimental|Group D|10 BCG-naïve subjects receiving intradermal BCG Tice at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
89318066|NCT02088892|Experimental|Group E|8-12 BCG-naïve subjects receiving the optimal strain and dose of intradermal BCG identified from preliminary results obtained from Group A, B, C and D, followed by a punch biopsy at the challenge site 14 days later.
89318067|NCT03968627||Protocol application|The study describes the method and the criteria used in the development of the protocol, the steps followed in its implementation in two Don Gnocchi Foundation Pilot Hospitals
89318068|NCT02092870|Experimental|Treatment of Chronic Wound|Patients will receive a single treatment with ASCs in the form of multiple injections of cells within and immediately surrounding the wound. Cells will be delivered using a 1 cc syringe with an appropriate gauge and length needle. Each injection will have a volume less than 250 micro-liters. The number of injections will be determined by the surgeon as a function of total wound volume.
89318069|NCT04304781|Experimental|Dimer Application with SFE imaging|Subjects having a standard-of-care ERCP will have the dimer sprayed on an area of interest in the bile duct and images taken with the SFE.
89318070|NCT02092948|Experimental|All patients|Patients will receive one intravenous dose of 4 mg, 20mg or 40 mg of A11 minibody labeled with 5 mCi (185 MBq) of 124I, followed by [124I] PSCA-Minibody PET/CT imaging of the whole body.
89318071|NCT03267212|Active Comparator|Non-invasive Ventilation(NIV)|Subjects will perform FES-row testing while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
89318072|NCT03267212|Sham Comparator|Sham Non-invasive ventilation(NIV)|Subjects will perform FES-row testing while receiving sham ventilation applied through a full face-mask.
89318073|NCT01074593|Experimental|Test|Bergamo - Interferon beta-1a
89318074|NCT01074593|Active Comparator|Comparator - Merck Serono|Merck Serono - Interferon beta-1a
89318075|NCT02088970|Active Comparator|antibiotic treatment alone|
89318076|NCT02088970|Experimental|Crosslinking + Antibiotic|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
89318077|NCT01326299|Active Comparator|Nutritional ingredient|Dissolve in water and consume with meal
89318078|NCT01326299|Placebo Comparator|Carbohydrate|dissolve in water and consume with meal
89318079|NCT01326299|Experimental|#1 Nutrtitional ingredient + Fiber|Dissolve in water and consume with meal
89318080|NCT01326299|Experimental|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
89318081|NCT01326299|Experimental|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
89318082|NCT02087800||F Phase Lab session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the F phase lab session will be first. Followed by the L phase lab session.
89318083|NCT02087800||L Phase Lab Session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the L phase lab session will be first. Followed by the F phase lab session.
89318084|NCT03968861||Standard care with moderate hypothermia|Surviving children allocated to standard care with moderate hypothermia in the TOBY-Xe trial
89318085|NCT03968861||30% Xenon for 24 hours combined with moderate hypothermia|Surviving children allocated to inhaled xenon combined with moderate hypothermia in the TOBY-Xe trial
89318086|NCT04292535|Active Comparator|Passive Control|20 minute sedentary control period during which participants watched an emotionally neutral video.
89318087|NCT04292535|Experimental|Acute Exercise|20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video.
89318088|NCT04301180|Experimental|Experimental|"The experimental group conducted 10 weekly sessions, with an approximate duration of 45 minutes per session, which consisted of the presentation of food education content while conducting an orchard with seasonal vegetables. Simple recipes were also described in which these vegetables were included to be made at home, along with information on children's books that dealt with the topic of food and were available in the public library.~All children in the experimental groups were given written instructions so that they could perform at their home, together with their parents, the manipulative activities suggested each week. All these contents were common for all the participants in the study. Session material was renewed weekly."
89318089|NCT04301180|No Intervention|Control|"The control group received the usual training corresponding to the contents of the human body module that is currently taught in each center."
89318090|NCT03967535||Control|Individuals between 45-85 years old with no diagnosis of dementia. No intervention used
89318091|NCT03967535||Dementia|Individuals between 45-85 years old with a diagnosis of dementia. No intervention used
89318092|NCT03967301|Experimental|Probiotic isolated intestinal bacteria (active)|Patients randomized to active arm, will consume 5ml every 12 hours per day of a suspension of probiotics (Bioflora ® Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis y Bifidobacterium brevis) for 14 days.The content of each bottle is reconstituted up to 50 ml (10 doses) with drinking water The prescription of the intervention will be carried out and monitored through the electronic medical record. In the hospital setting, the probiotic is reconstituted by the nursing staff. If the patient is discharged before this period the patient and family will be instructed to perform the reconstitution at home.
89318093|NCT03967301|Placebo Comparator|Placebo|Patients randomized to the placebo arm, will consume 5ml every 12 hours per day of a suspension of placebo for 14 days. The prescription of the intervention will be carried out and monitored through the electronic medical record.
89318094|NCT04158986|No Intervention|Standard treatment|Receives standard post-discharge care with planned follow-up in the clinic for liver failure or ambulatory.
89318095|NCT04158986|Experimental|Nurse-driven post-discharge intervention|Participates in a nurse-driven post-discharge intervention program.
89318096|NCT03747081|Experimental|Rivoroxaban|Patients would be administered Enoxaparine (60 mg/SC/BID)in first day, after dicontinuing Enoxaparin in second day, Rivoroxaban 20 mg per day will use. .it would be given once a day.The total duration of Rivoroxaban would be 3 months.
89318097|NCT03747081|Active Comparator|warfarin|Patients would be administered Warfarin with overlap of Enoxaparine utill INR adjust to 2-3 then enoxaparine will disconstinue.it would be given once a day.The total duration of Warfarin would be 3 months
89318098|NCT04677140||experiment group|By a specialist physician with existing anteroposterior and lateral radiographs have been diagnosed with adolescent idiopathic scoliosis
89318099|NCT03967613|Experimental|FES|Functional Eletrical Stimulation
89318100|NCT05031819|Experimental|Practice Facilitation to support TASSH integration (group A).|Components of the PF strategy include: (a) establishment of a steering committee of key stakeholders (ministry of health, state primary care agency, AIDS control agency, patient advocates) to provide leadership and guide integration of TASSH into HIV care platform; (b) training of the HIV nurses on TASSH protocol; and (c) training of practice facilitators, who will serve as coaches, provide support, and performance feedback to the PHC nurses on TASSH implementation.
89318101|NCT05031819|Sham Comparator|TASSH only (group B)|HIV nurses based at Group B facilities will be trained on the 5As counseling approach strategy (Ask, Assess, Advise, Assist, and Arrange) and referral for the participants to the health center. However, they will not receive practice facilitation from the POFs. Participants attending PHC randomized to Group B will receive standard care offered by the facility.
89318102|NCT04385199|Experimental|Convalescent Plasma Intervention|Convalescent plasma 200mL transfusion
89318103|NCT04385199|No Intervention|Standard Therapy Control|Standard therapy for COVID-19 disease as defined by institutional protocols
89531617|NCT05929469|Experimental|Human-Enhanced Kick-Off + App + Counseling|"This arm includes participants who do not respond to the Human-Enhanced Kick-Off + App in stage 1.~In stage 1, the participant's kick-off will include a session with a study interventionist. They will also receive an mHealth program.~In stage 2, they will continue with the standard mHealth program, but will also receive counseling from a study interventionist."
88811016|NCT04755699|Experimental|Individuals with other Brain or Nerve Injuries|This arm consists of individuals with a other brain and nerve injuries receiving transcutaneous electrical stimulation to the arms/hand, legs/foot, and/or spinal column to evoke various arm/hand or leg/foot movements.
88811017|NCT04753086||Gynecologic Cancer Pts|Gynecologic cancer patients being treated with radiation at UNC.
89318104|NCT01341626|Experimental|Treatment Foster Care Oregon (TFCO)|Youth are placed individually in well-trained and supervised foster homes. Basic components include: (a) daily telephone contact with TFCO parents using the Parent Daily Report; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation.
89318105|NCT01341626|Active Comparator|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%).
89318106|NCT04286217||No prior hypertension (HTN); no HDP in pregnancy|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
89318107|NCT04286217||No prior HTN; de novo HDP, GH type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
89318108|NCT04286217||No prior HTN; de novo HDP, GH type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
89318109|NCT04286217||No prior HTN; de novo HDP, PE type; no macular injury|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
89318110|NCT04286217||No prior HTN; de novo HDP, PE type; macular injury found|No pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
89318111|NCT04286217||No prior HTN; no HDP in pregnancy; postpartum HDP|No pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
89318112|NCT04286217||Pre-existing HTN; no HDP in pregnancy|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event
89318113|NCT04286217||Pre-existing HTN; de novo HDP, GH type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, but no abnormal SD-OCT findings in the eye
89318114|NCT04286217||Pre-existing HTN; de novo HDP, GH type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset gestational hypertension, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
89318115|NCT04286217||Pre-existing HTN; de novo HDP, PE type; no macular injury|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, but no abnormal SD-OCT findings in the eye
89318116|NCT04286217||Pre-existing HTN; de novo HDP, PE type; macular injury found|Pre-existing hypertension, incident pregnancy complicated by new onset preeclampsia, with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
89318117|NCT04286217||Pre-existing HTN; no HDP in pregnancy; postpartum HDP|Pre-existing hypertension, incident pregnancy not complicated by a hypertensive event, patient developed postpartum HDP, either gestational hypertension or preeclampsia,with abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury
89318118|NCT04286217||Other causes of macular injury leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury leading to HDP, either gestational hypertension or preeclampsia
89318119|NCT04286217||Other causes of macular injury not leading to HDP|Other causes of abnormal SD-OCT findings in the eye consistent with possible hyperperfusion injury not leading to HDP
89318120|NCT04131062|No Intervention|Control (no intervention)|Consented using the traditional, human-mediated consent process already in use for MyCode consenting.
89318121|NCT04131062|Experimental|Electronic Consent (iPad)|Consented using the Sage eConsent framework, which presents participants with an iPad that describes MyCode and allows participants to choose to learn more information at various steps along the process.
89318122|NCT04284813|Experimental|Telemedicine|Community Reinforcement and Family Training for first episode psychosis delivered via telemedicine (CRAFT-FT) with 6-8 weekly sessions of 60-minute therapy.
89318123|NCT04151966||Cardioversion Group|Subjects scheduled to undergo direct current cardioversion (DCCV) as part of the clinical plan of care
89318124|NCT05571332|Experimental|Avatrombopag+CsA+ p-ATG|Patients received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. CSA is started at 3 mg/kg orally in two doses. Concentrations maintained at 200-250 ng/ml to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: 40 mg orally once daily for a total of 12 weeks. A total of 39 patients were expected to be included.
89318125|NCT03263780|Experimental|18F-Fluciclovine|10mCi +/-20% 18F-fluciclovine injection
89318126|NCT02791438|Experimental|Azilsartan 2.5 - 20 mg (Weight < 50 kg)|Following a 2-week placebo run-in period, azilsartan 2.5 mg (titrated as needed to the highest dose of 20 mg) was administered orally once daily before or after breakfast, for the participants weighing < 50 kg.
89318127|NCT02791438|Experimental|Azilsartan 5 - 40 mg (Weight ≥ 50 kg)|Following a 2-week placebo run-in period, azilsartan 5 mg (titrated as needed to the highest dose of 40 mg) was administered orally once daily before or after breakfast, for the participants weighing ≥ 50 kg.
89318128|NCT04653584||1|Parkinson Disease patients treated by domperidone according the recommendation
89318129|NCT04653584||2|Parkinson Disease patients treated by domperidone in misuse conditions regarding the recommendation
89318130|NCT04653584||3|Parkinson Disease patients without treathment by domperidone
89318131|NCT02089048|Experimental|Cohort 1|15 subjects receive 6mg of auranofin once every 24 hours for 7 days
89318132|NCT02089126|Experimental|Gemigliptin/Glimepiride combination|Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination & Placebo for Glimepiride.
89318133|NCT02089126|Placebo Comparator|Placebo|The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination & Glimepiride.
89318134|NCT05571176|Experimental|S-ketamine infusion|12 healthy volunteers, S-ketamine infusion 0.29 mg/kg/h for 4 hours
89318135|NCT05571176|Placebo Comparator|Placebo (NaCl 0.9%) infusion|12 healthy volunteers, placebo (NaCl 0.9%) infusion for 4 hours
89318136|NCT03920462|Other|Programme of intelligent electric bike for health (single arm)|All volunteers will realise the programme of intelligent electric bike for health with connected vests.
89318137|NCT03556930|Experimental|Movie Induced Sedation Effect|Pediatric Radiation Oncology with Movie Induced Sedation Effect monitored by an AlignRT system (VisionRT LTD, UK).
89318138|NCT03772652||Peri-implantitis|Subjects who were diagnosed with peri-implantitis and received treatment at least five years ago at the Graduate Periodontics Clinic at University of Michigan with sufficient baseline data. Soft tissue measurements (observation) of the implant will be completed.
89318139|NCT02095756|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of melasma
89318140|NCT02250430|Experimental|Topical SB204|Topical application of SB204 2% and 4% twice daily for 2 days and once on Day 3
89318141|NCT03712124|Experimental|CNSA-001|Participants will receive CNSA-001 20 mg/kg/day (10 mg/kg twice daily [BID]) as an oral suspension for 14 days.
89318142|NCT03712124|Placebo Comparator|Placebo|Participants will receive placebo matching to CNSA-001 BID for 14 days.
89318143|NCT02093260|Experimental|Vaccine|"Vaccine~Flubio (Influenza HA) vaccine~2 doses for infants and children (6 months - 8 years old)~1 doses for children (9-11 years old)~The vaccine will be given intramuscularly"
89318144|NCT03556540|Placebo Comparator|Control|The volunteers without performing exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
89318145|NCT03556540|Experimental|Experimental|The volunteers will perform physical exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
89318146|NCT03689582|Experimental|68Ga-PSMA|PET/CT imaging with 68Ga-PSMA
89318147|NCT02093338|Experimental|fermentum 3x|Lactobacillus fermentum CECT5716 at 3x10e9 cfu/day
89318148|NCT02093338|Experimental|fermentum 6x|Lactobacillus fermentum CECT5716 at 6x10e9cfu/day
89318149|NCT02093338|Experimental|fermentum 9x|Lactobacillus fermentum CECT5716 at 9x10e9cfu/day
89318150|NCT02093338|Placebo Comparator|maltodextrin|maltodextrin
89318151|NCT04089956||Extubation Success|extubation Success which defined as no need of reintubation or tracheostomy after extubation.
89318152|NCT04089956||Extubation Failure|Extubation Failure was defined as need for any invasive ventilatory support after fist extubation during ICU stay or tracheostomy befor any extubation attempt.
89318153|NCT02093416||Group 1: Control Group|BMI <30 There are 20 controls in this group
89318154|NCT02093416||Group 2|BMI 30-35 There were 12 controls in this class
89318155|NCT02093416||Group 3|BMI 35-40 There were 9 controls in this clas
89318156|NCT02093416||Group 4|BMI >40 There were 9 controls in this class
89318157|NCT02095834|Experimental|Treatment (dexamethasone, bendamustine, carfilzomib)|Patients receive dexamethasone PO or IV over 20 minutes on days 1, 2, 8, 9, 15, 16, 22, and 23 of courses 1-3; on days 1, 2, 15, and 16 of courses 4-12; and on days 1 and 2 of all subsequent courses. Patients also receive bendamustine hydrochloride IV over 10 minutes on days 1 and 2 of courses 1-3 and on day 1 of all subsequent courses and carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of courses 1-12 and on days 1, 2, 15, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89318158|NCT02791516|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a month for 6 months.
89318159|NCT02791516|Experimental|Romosozumab|Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.
89318160|NCT02093494|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used to collect the blood culture.
89318161|NCT02093494|Active Comparator|Lab standard practice (LSP)|The ISDD will not be used to collect the blood culture. Standard blood culture specimen collection kits will be utilized.
89318162|NCT03263702|Experimental|Computational Mapping Algorithm|AF mapping (utilizing CMA) will be performed and used to point the operator to regions within a heart chamber that should be interrogated further for suspicious electrogram activity, as measured by the St. Jude Ensite System, and ablated if the suspicious electrogram activity persists.
89318163|NCT03556852|Active Comparator|CARBETOCIN|received 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby.
89318164|NCT03556852|Active Comparator|MISOPROSTOL|received 4 rectal misoprostol tablets (800 μg) after the delivery of the baby.
89318165|NCT05571098|Experimental|Experimental|Individualized colorectal cancer education, psycho-oncological counseling, and a nurse-managed telephone support hotline were provided to the individuals in the experimental group within the NNP. Data were collected before NNP (once in the first week after chemotherapy), during NNP (once in the second week after chemotherapy, once in the first week after the next chemotherapy), after NNP (once in the second week after the next chemotherapy). The duration of the interventions performed via the WhatsApp application varied between 45-60 minutes between individuals.
89318166|NCT05571098|No Intervention|No intervention|No intervention was applied to this group.
88811639|NCT00856232|Placebo Comparator|Medical Air|Air inhalation at 15L / min x 15 minutes followed by standard emergency department evaluation and treatment for headache
89318167|NCT02093572|Experimental|Control|Subjects randomized to this group will consume 3 standard meals/day during the 2 week intervention period of the study.
89318168|NCT02093572|Experimental|Breakfast skipping|Subjects randomized to this group will consume 2 meals/day (omit breakfast - with caloric intake equal to consuming 3 meals/day) during the 2 week intervention period of the study.
89318169|NCT02093650|Active Comparator|Black cohosh extract|black cohosh extract 80 mg daily
89318170|NCT02093650|Placebo Comparator|Placebo|Matching placebo
89318171|NCT02808572|Experimental|Cardiovascular risk evaluation|Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
89318172|NCT02093728|Experimental|selumetinib; itraconazole; selumetinib + itraconazole|Volunteers will receive selumetinib 25mg alone; itraconazole 200mg pre-dosing; selumetinib 25mg and itraconazole 200mg; all adminstered by mouth as a capsule
89318173|NCT02093728|Experimental|selumetinib; fluconazole; selumetinib + fluconazole|Volunteers will receive selumetinib 25mg alone administered by mouth as a capsule; fluconazole 400mg and fluconazole 200mg pre-dosing, administered by mouth as a tablet; selumetinib 25mg and fluconazole 200mg.
89318174|NCT03986684||Non-NAFLD|
89318175|NCT03986684||NAFLD|
89318176|NCT02089204||FMISO-PET/CT|18F-MISO PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
89318177|NCT02089204||FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
89318178|NCT02089204||contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy . GTVs were delineated based on fusing diagnostic CT images with simulation CT images.All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
89318179|NCT02089282||Clavicle fractures|
89318180|NCT02095990|Experimental|Hydroquinone|"Hydroquinone 4% Cream will be applied in one side of the face while the other side of the face receives placebo.~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.~It will be applied daily, at night, during 8 weeks."
89318181|NCT02095990|Placebo Comparator|Placebo|"Placebo cream (vehicle of Hydroquinone 4% cream), will be applied in one side of the face, while the other side receives the active treatment.~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.~It will be applied daily, at night, during 8 weeks."
89318182|NCT03557632|Experimental|TREATMENT:Virtual Reality Cue Exposure Therapy (VRCET)|Virtual Reality Cue Exposure Therapy (VRCET) - Active Intervention - comprised of exposure to VR based heroin cues, such as heroin use paraphernalia and scenes of people using injection heroin or snorting heroin. Exposure will be supplemented by the use of a standardized CBT based skills coping protocol teaching relapse prevention skills such as urge surfing, thought stopping and reframing. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
89318183|NCT03557632|Active Comparator|Control: Relapse Prevention Drug Education|Relapse Prevention Drug Education (RPDE) is our Active Comparator. Comprised of watching a series of videos on the health risks of heroin use as well as information about relapse prevention. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
89318184|NCT02096068|Experimental|Study group|"Application of Dexmedetomidine (Dexdor®) perioperatively for a maximum of 48 hours~Dosing Scheme:~during operation and mechanical ventilation: 0,7μg/kgABW/h; recovery time until extubation: 0,4μg/kgABW/h; after extubation: 0,2-1,4μg/kgABW/h"
89318185|NCT02096068|Placebo Comparator|Control group|Application of placebo for a maximum of 48 hours
89318186|NCT02096068|No Intervention|POCD control group|A non-surgical control group of 15 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. The participants are matched on age, education, and gender to the study patients.
89318187|NCT02093806||CT of the temporal bone|
89318188|NCT02089438|Experimental|Saxagliptin|Ssaxagliptin is given before breakfast
89318189|NCT02089438|Experimental|´Sitagliptin|Sitagliptin is given before breakfast
89318190|NCT02089438|Experimental|Vildagliptin|Vildagliptin is given before breakfast
89318191|NCT02096146|Other|TMT Fusion Plate|Patients are treated with TMT Fusion Plate to encourage bony fusion of the 1st TMT joint.
89318192|NCT02096146|Other|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion .
89318193|NCT05471674|Experimental|Treatment|
89318194|NCT02093884|Experimental|Text Messaging Intervention|Patients in the text messaging group will receive educational and motivational text messages.
89318195|NCT02093884|Active Comparator|Standard Referral|Patients in the standard referral arm will receive paper based information about the Family Planning Clinic.
89318196|NCT02250040|Active Comparator|Control group|Conventional physiotherapy for stroke.
89318197|NCT02250040|Experimental|Target group|Techniques based on patients' functional level were added.
89318198|NCT02096224|Experimental|Sevoflurane|Sevoflurane will be administered as the maintenance agent of general anesthesia.
89318199|NCT02096224|Active Comparator|Desflurane|Desflurane will be administered as the maintenance agent of general anesthesia.
89318200|NCT02089516||Frail elderly|Measuring movement activity in frail elderly (GFI score ≥ 4) of 75 years and older using DynaPort.
89318201|NCT02096302|Experimental|Experimental Formula|Infant formula with a novel probiotic CECT7210
89318202|NCT02096302|Active Comparator|Standard Formula|Standard infant formula without probiotics
89318203|NCT02096380||one cycle induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~Other Names:~docetaxel, cisplatin and fluorouracil"
89318204|NCT02096380||three cycles induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~Other Names:~docetaxel, cisplatin and fluorouracil"
89318205|NCT03557554|Experimental|Massage Therapy|Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.
89318206|NCT03557398|Experimental|Hydeal-D vaginal pessaries|Vaginal application of Hydeal-D vaginal pessaries
89318207|NCT02089594|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Hyperbaric Oxygen Therapy at 1.5 ATA (atmospheres absolute). The subjects will receive 40 low pressure HBOT's on a once/day, 5d/week eight week schedule.
89318208|NCT02089594|Experimental|No Hyperbaric Oxygen Treatment (HBOT)|Subjects will receive eight weeks of no hyperbaric treatment while they continue any pre-study maintenance medication and/or pre-study counseling. Subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
89318209|NCT02094040|Experimental|Follow-up visit|Receive municipality-based follow-up visit including primary physician.
89318210|NCT02094040|No Intervention|Usual care|Does not receive follow-up visit
89318211|NCT02250118|Experimental|Bevacizumab|Intrapleural use: range 0.5 - 5 mg/kg
89318212|NCT02250196|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
89318213|NCT02250196|Active Comparator|SPMC 2|group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
89318214|NCT02089672||Atrial flutter patients|Atrial flutter patients undergoing catheter ablation
89318215|NCT03060772|Experimental|Alcohol use disorder - Pioglitazone Treatment|Participants with alcohol use disorder randomized to this group will receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy after taking the study medication for 2 to 4 weeks.
89318216|NCT03060772|No Intervention|Alcohol use disorder - No Pioglitazone|Participants with alcohol use disorder randomized to this group will receive their usual care but will not receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy 2 to 4 weeks later.
89318217|NCT03060772|No Intervention|Healthy controls without alcohol use disorder|Healthy individuals who do not have alcohol use disorder will be enrolled will serve as a control group. Healthy controls will be a matched to participants receiving the treatment based on age, gender, and smoking status. This group will have a single bronchoscopy.
89318218|NCT02096536|Other|Vancomycin|All included patients receive vancomycin for medical reasons. Decision for start of therapy is made by the treating physician.
89318219|NCT02089750|Active Comparator|Orthotics|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
89318220|NCT02089750|Active Comparator|Orthotics Plus Chiropractic Care|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period in addition to receiving Chiropractic Care 1-4 times per week during the first 6 weeks of the 12 week study period.
89318221|NCT02089750|Other|Wait List|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last six weeks they are fitted for the custom-made shoe orthotics.
89318222|NCT02096614|Experimental|Low dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
89318223|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
89318224|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 2|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
89318225|NCT02096614|Experimental|TBI-1201 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
89318226|NCT02089828|Experimental|autologous purified CD34+ cell|transplantation of autologous purified CD34+ cell
89318227|NCT02089828|Active Comparator|autologous PB-MNC|transplantation of autologous peripheral blood mononuclear cells
89318228|NCT02089906||Chinese Elderly|multi-center cross-sectional study
89318229|NCT02094196||Controls, highrisk for AD|Community-based ad-hoc participants, high risk for alcohol dependence, matched to inpatients by sociodemographics
89318230|NCT02094196||Controls, low risk for AD|Community-based ad-hoc participants, low risk for alcohol dependence, matched to inpatients by sociodemographics
89318231|NCT02094196||Alcohol detoxification|Inpatients with alcohol dependence from local psychiatric hospital wards (18-65 years old)
88811640|NCT00856232|Experimental|Oxygen|Oxygen inhalation at 15 L/min for 15 minutes followed by standard emergency department evaluation and treatment for headache
89318232|NCT03556774|Experimental|With smoking cessation training|Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
89318233|NCT03556774|No Intervention|Without smoking cessation training|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.
89318234|NCT02094274|Experimental|LAS40468|Single dose, administered via Genuair® dry powder inhaler (DPI)
89318235|NCT02094274|Active Comparator|Salmeterol/fluticasone propionate|Single dose, Seretide® (salmeterol fluticasone propionate) administered via Accuhaler™
89318236|NCT02094274|Placebo Comparator|Placebo|Single dose administered via Genuair® or Accuhaler™ dry powder inhaler (DPI)
89318237|NCT02094430|Experimental|FGTW|
89318238|NCT03556150|Experimental|Manual Therapy protocol|Massages, mobilisation and stretching techniques in the most painful joint
89318239|NCT03556150|Active Comparator|Effleurage|Superficial massage in the most painful joint.
89318240|NCT03556072||Intradiverticular papilla (IDP) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
89318241|NCT03556072||Juxtapapillary diverticulum (JPD) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
89318242|NCT02094742|Other|all-commers|All patients will undergo a biopsy of their metastatic lesion and have a blood sample taken for molecular screening purposes. No drugs are administered or other interventions are performed.
89318243|NCT02089984|Experimental|Internet-Based Training|On-line tutorial followed by live remote training via videoconferencing
89318244|NCT03038074|Experimental|Test Group|The subjects will be enrolled in the test group and will receive Pulse Oximeter with respiration rate sensor to examine the respiration rate.
89318245|NCT04130919|Experimental|Tilpisertib 300 mg|Participants will receive blinded tilpisertib 300 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
89318246|NCT04130919|Experimental|Tilpisertib 100 mg|Participants will receive blinded tilpisertib 100 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
89318247|NCT04130919|Placebo Comparator|Placebo|Participants will receive blinded tilpisertib matching placebo for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
89318248|NCT04130919|Experimental|Open-label Tilpisertib 300 mg|Based on the efficacy assessment results at Week 10, participants who do not achieve MCS response will have the option to receive open-label tilpisertib 300 mg for up to 50 weeks.
89318249|NCT02094820||Single Group Study|Questionnaires
89318250|NCT03774862||Medullary carcinoma of colorectal cancers|
89318251|NCT03774862||non-medullary carcinomas of the colorectal cancers|
89318252|NCT03749031|Placebo Comparator|Orange juice only|16 oz. orange juice per day for 4 weeks
89318253|NCT03749031|Experimental|orange juice + orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
89318254|NCT03749031|Placebo Comparator|Apple juice only|16 oz. apple juice per day for 4 weeks
89318255|NCT03749031|Experimental|Apple Juice + Apple Pomace|16 oz. apple juice + apple Pomace per day for 4 weeks
89318256|NCT02096926|Placebo Comparator|Placebo|placebo
89318257|NCT02096926|Active Comparator|Ibuprofen|400 mg PO
89318258|NCT04128267|Experimental|Response to Pain|Brain's response to pain using magnetic resonance imaging (MRI)
89318259|NCT02097004|Experimental|Concomitant:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
89318260|NCT02097004|Experimental|Sequential:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
89318261|NCT02097004|Active Comparator|Control Group|"Continue Entecavir(0.5mg) for 100 weeks(once daily)~After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks"
89318262|NCT02090296|Placebo Comparator|Sugar water|Placebo arm
89318263|NCT02090296|Active Comparator|Hydroxyurea|Treatment Arm
89318264|NCT02094976|Active Comparator|Group C|Group C means active comparator group which use chest rolls intraoperatively for prone position.
89318265|NCT02094976|Active Comparator|Group W|Group W means experimental group which use Wilson frame intraoperatively for prone position.
89318266|NCT02094976|Experimental|Group J|Group J means experimental group which use Jackson surgical table intraoperatively for prone position.
89318267|NCT03691779|Experimental|Part A: ELX/TEZ/IVA|Participants in Part A received ELX 100 milligrams (mg) once daily (qd)/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) in the treatment period for 15 days.
89318268|NCT03691779|Experimental|Part B: ELX/TEZ/IVA|Participants in Part B weighing less than (<) 30 kilograms (kg) at Day 1 received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h and participants weighing greater than equals to (>=) 30 kg at Day 1 received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
88811641|NCT01474109|Active Comparator|macitentan 3mg|macitentan 3mg tablet once daily
88811642|NCT01474109|Active Comparator|macitentan 10mg|macitentan 10mg tablet once daily
89318269|NCT02095054|Experimental|Regorafenib + Cetuximab|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle. Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.~Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle. Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.~Symptom questionnaire completed at each study visit."
89318270|NCT02095210|Experimental|[68Ga]ABY-025 PET imaging|Radiolabeled [68Ga]ABY-025
89318271|NCT03774784||ALECT2 Disease|
89318272|NCT03555994|Experimental|MEDI0382 (Part A)|MEDI0382 administered subcutaneously (Part A)
89318273|NCT03555994|Placebo Comparator|Placebo (Part A)|Placebo comparator administered subcutaneously (Part A)
89318274|NCT03555994|Active Comparator|Liraglutide (Part B)|Active comparator administered subcutaneously (Part B)
89318275|NCT03555994|Experimental|MEDI0382 (Part B)|MEDI0382 administered subcutaneously (Part B)
89318276|NCT03555994|Placebo Comparator|Placebo (Part B)|Placebo comparator administered subcutaneously (Part B)
89318277|NCT02095366|Experimental|IN Sufentanil AND IV Placebo|Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration
89318278|NCT02095366|Active Comparator|IV Morphine AND IN Placebo|Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray
89318279|NCT04258995|Experimental|GBS6 no aluminum phosphate (GBS6 no AlPO4)|
89318280|NCT04258995|Experimental|GBS6 with aluminum phosphate (GBS6 with AlPO4)|
89318281|NCT02097082|Experimental|STANZA Drug-eluting Resorbable Scaffold|Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold
89318282|NCT02097160|Active Comparator|Control Group 1|regular fortified milk + regular cheese/yogurt
89318283|NCT02097160|Experimental|Intervention Group 2|Vitamin D fortified yogurt and cheese; vitamin D dose increment of 252 IU vs grp 1
89318284|NCT02097160|Experimental|Intervention Group 3|Vitamin D fortified yogurt and cheese, vitamin D dose increment of 420 IU vs grp 1
89318285|NCT04247061|Experimental|Smoking Cessation intervention|At a dental cleaning visit, participants will watch a brief educational video that provides guidance and advice on smoking cessation. Participants will then interact with a text program for a month to motivate them to use smoking cessation resources. Participants will also be required to make contact with the resources in order to demonstrate feasibility of study flow.
89318286|NCT02095444|Experimental|Menstrual blood stem cells|1x10*7 cells/kg, IV(in the vein) twice a week. Number of course for two weeks.
89318287|NCT01562223|Experimental|Repeatability Assessment|Gadolinium motexafin gadolinium All participants will undergo two consecutive DCE-MRI and DWI scans per same imaging parameters and subsequent comparison for repeatability.
89318288|NCT02090452|Experimental|Transmission of vital signs, ecg, chat|Data from patients transported in ambulances with equipment which enables real time transmission of vital signs, ecg and chat from ambulances to the emergency department.
89318289|NCT02090452|No Intervention|No transmission of data|Patient transported with conventional ambulances without the possibility to transmit real time patient related data.
89318290|NCT02097316|Experimental|JewelPump|JewelPump for the first treatment period followed by the usual pump for the second treatment period
89318291|NCT02097316|Active Comparator|Usual insulin pump|Patients in the arm 2, will have the usual insulin pump for the first treatment period, followed with the second period which they will have the JewelPump.
89318292|NCT04241133|Experimental|Experimental Group|A 12 week pilot trial will be conducted at two rural food pantries in Montana with 40 low-income adults to measure within-participant changes over time. The study will provide the initial investigation of the extent to which UP3 will improve overall dietary quality as measured by the Healthy Eating Index-2015 (HEI) compared to baseline. Psychosocial factors will be measured to understand changes in knowledge, attitudes, and perceptions about processed foods. Data on biomarkers of health (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to assess the feasibility of measuring potential short-term health effects of UP3.
89318293|NCT04241133|No Intervention|Control Group|20 separate participants from a different food pantry will be enrolled into a control group. The control group will be assessed at baseline and 12 weeks for dietary intake, height, weight, waist circumference, food security, demographics, and psychosocial factors.
89318294|NCT02095522|Experimental|Colchicine|Colchicine 1mg per day for one month
89318295|NCT02095522|Placebo Comparator|Placebo|Placebo 1mg per day
89318296|NCT03748875|Experimental|Intervention group|an 8-session mindfulness-based relapse prevention program
89318297|NCT03748875|No Intervention|Control group|treatment as usual
89318298|NCT02097394|Active Comparator|Combizym-treated group|The patients who received polypectomy of colon polyps take the digestion enzyme (Combizym) regularly.
89318299|NCT02097394|Active Comparator|Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take Bifidobacteri regularly
89318300|NCT02097394|Active Comparator|Combizym + Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take drugs (Combizym + Bifidobacteri) regularly
89318301|NCT02097394|No Intervention|control|The patients who received polypectomy of colon polyps take no drugs
89318302|NCT03747003||HIV-infected male patients|Male patients (age 18-50 years) with HIV-infection and ongoing HAART therapy No intervention is provided
89318303|NCT02095600|Experimental|Radiosurgical thalamotomy|
89318304|NCT03555682|Placebo Comparator|Placebo|Placebo
89318305|NCT03555682|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
89318306|NCT03555682|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
89318307|NCT04123665|Experimental|Experimental Test Dentifrice|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
89318308|NCT04123665|Placebo Comparator|Control Dentifrice|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as sodium monofluorophosphate [SMFP] to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
89318309|NCT02090608|Experimental|Paricalcitol|In patients identified by the inclusion criteria, data will be collected at baseline , during administration of oral Paricalcitol (PCT) (after 1, 3 and 6 months), and three months after PCT withdrawal. PCT will administered at dosage of 1 mcg/day; this dosage was chosen as it is not associated with excessive decline of parathyroid hormone (PTH) levels in most patients
89318310|NCT02090686|Active Comparator|Pulsatile Cupping|
89318311|NCT02090686|Active Comparator|Minimal Cupping|
89318312|NCT02090686|No Intervention|No Intervention|Waiting list
89318313|NCT02102386||CerOx|Patients will be monitored using the CerOx monitor. Probes will be attached bi-laterally in the OR to the forehead.
89318314|NCT03746145|Experimental|Bifidobacterium longum 1714|Participants consume one 2g sachet containing 10e11 colony-forming units Bifidobacterium longum 1714 strain with maltodextrin and magnesium stearate on a daily basis over 1 year.
89318315|NCT03746145|Experimental|Placebo|Participants consume one 2g placebo sachet containing maltodextrin and magnesium stearate.
89318316|NCT02097628|Active Comparator|pressure-controlled ventilation|pressure-controlled ventilation: a peak airway pressure that provided a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column, respiratory rate 12-16 times per minute.
89318317|NCT02097628|Experimental|volume-controlled ventilation|volume-controlled ventilation: tidal volume 8-12ml/kg, respiratory rate 12-16 times per minute.
89318318|NCT02097784|Other|cirrhosis with portal hypertension,ascite and acute kidney|
89318319|NCT02098720|Experimental|Conbercept|Subjects will receive Conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 3 months, the investigator will decide whether repeat injections are needed based on the monthly assessment results.
89318320|NCT02250508|Experimental|Optivate®|
89318321|NCT02250508|Active Comparator|Haemate P®|
89318322|NCT03555604||Scheduled cesarean section|Gastric ultrasound in term pregnant patients to correlate with NPO time in relation to body mass index
89318323|NCT03555526|Experimental|Genotypic resistance guided therapy|The regimen will be chosen according to the genotyping of 23S rRNA and gyrase A of H. pylori. In the absence of gyrase A mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of gyrase A mutation but in the absence of 23S rRNA mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both gyrase A and 23S rRNA mutation, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
89318324|NCT03555526|Active Comparator|Phenotypic resistance guided therapy|The regimen will be chosen according to the susceptibility testing result. In the absence of levofloxacin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of levofloxacin resistance but in the absence of clarithromycin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both levofloxacin and clarithromycin resistance, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
89318325|NCT02098798||HD|High Definition Colonoscopy alone
89318326|NCT02098798||HD + iSCAN|HD colonoscopy + iSCAN
89318327|NCT02098798||HD + Dye|High definition colonoscopy + dye spraying chromoendoscopy
89318328|NCT03555760||Surgery patient|Observation of informed consent form readings of all patients who are scheduled for surgery
89318329|NCT02102542||Antisialagouge|A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
89318330|NCT02102542||Bradycardia|A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
89318331|NCT02102542||For reversal of neuromuscular blocking agents|Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
89318332|NCT02102620|Experimental|IAI triamcinolone hexacetonide|"Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).~Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day)."
89318333|NCT02102620|Placebo Comparator|IAI lidocaine|Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.
88806548|NCT05287802|Active Comparator|Biodex Training (BT) group|Biodex Balance System features a platform that can move simultaneously in the anteroposterior (AP) or medio-lateral (ML) direction in 12 different levels of stability within a 20-degree range of inclination, as well as a locked position for static environments. For this platform, 1 represents the least stable level and 12 represents the most stable level. Interactive, game-like training modes are provided with the on-screen grid and score-keeping functions. Patients in the BT group performed exercises with the Balance SystemTM SD once a day, three days a week for 10 weeks under the physicians' supervision. Furthermore this group received closed kinetic chain exercises (CKCE) in addition to their own exercise program, which was applied in exactly the same way. The CKCE were performed in three sets of 10 repetitions with five seconds rest between each exercise. The exercises consisted of mini-squats, wall sits, and lunges.
88806549|NCT05287802|Active Comparator|Classical balance training group (CT group)|Patients in the CT group completed the exercise program once a day and three days a week during the 10-week period under the physicians' supervision. The exercises consisted of standing on one leg, tandem walking (heel-to-toe), balance board exercises, Romberg exercise, backward walking, and side-to-side stepping exercises. The total duration of these exercises was 20-30 minutes. Furthermore this group also received CKCE in addition to their own exercise program, which was applied in exactly the same way. The CKCE were performed in three sets of 10 repetitions with five seconds rest between each exercise. The exercises consisted of mini-squats, wall sits, and lunges.
88806550|NCT05287802|Active Comparator|Control group|Isometric home exercises, which can be considered the most basic and feasible strengthening program, were selected to compare the effects they had when added to the intervention groups and administered alone. All patients in the study performed isometric exercises for the quadriceps and hamstrings at home once a day, three days a week for 10 weeks. The exercises were performed as 10 repetitive cycles of six-second contractions and two-second rest periods. All patients were given a daily exercise chart to mark the home program, and adherence to the exercises was monitored weekly by telephone call.
88811643|NCT01474109|Placebo Comparator|placebo|matching placebo once daily
88811644|NCT01405469|Experimental|Peroral Endoscopic Myotomy|Patients with achalasia who are designed to either get balloon dilatation or have botulinum toxin injection, or to have surgical intervention (Heller myotomy)for treatment
88811645|NCT01405937|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
89318334|NCT02099032|Experimental|3g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
89318335|NCT02099032|Experimental|5 g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
89318336|NCT02099032|Placebo Comparator|Unfortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks
89318337|NCT02097940|Active Comparator|treatment|The treatment group performed of proprioceptive exercises with shifts and one-leg jumps.
89318338|NCT02097940|No Intervention|control|The control group remained in soccer training
89318339|NCT03555214|Experimental|Manual Therapy based on soft tissue|
89318340|NCT03555214|Placebo Comparator|Control Group|
89318341|NCT03555214|Experimental|Manual Therapy based on structural techniques|
89318342|NCT03555214|Experimental|Manual Therapy based on soft tissue and structural techniques|
89318343|NCT02098018|Active Comparator|Program 1|Program 1
89318344|NCT02098018|Active Comparator|Program 2|Program 2
89318345|NCT02102698|Experimental|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1/D5 receptor family that is being studied as a treatment for Tourette's Syndrome
89318346|NCT02102698|Placebo Comparator|Placebo|Placebo is the inactive comparator
89318347|NCT02098096|Experimental|Negative Work|Negative work exercise via isokinetic knee extension/flexion will be performed twice per week for 12 weeks.
89318348|NCT02098096|Placebo Comparator|Stretching|A home exercise program consisting of stretches for the major lower extremity muscles groups will be performed twice per week for 12 weeks.
89318349|NCT02102776|Active Comparator|MMC after pterygium excision|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision. The conjunctival defect will be left bare without graft.
89318350|NCT02102776|Active Comparator|AMT after Pterygium Excision|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
89318351|NCT02102776|Active Comparator|CAG after Pterygium Excision|A conjunctival autograft will be harvested from the superior side of the operating eye's bulbar conjunctiva. Then the graft will be sutured to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
89318352|NCT05570942|Active Comparator|Probiotic group|The patients with staged III colorectal cancer receiving adjuvant chemotherapy who will be given probiotics.
89318353|NCT05570942|Placebo Comparator|Control group|The patients with staged III colorectal cancer receiving adjuvant chemotherapy who will be given placebo.
89318354|NCT02102854|Active Comparator|Standard dose rATG|Standard dose rATG given as daily infusions of 1.5 mg/kg x 4-5 days
89318355|NCT02102854|Experimental|Single dose rATG|Single dose rATG give as 2 consecutive 3 mg/kg IV infusions to be completed over a 24-36 hour duration
89318356|NCT05570864||Study group (with CS)|A population of patients acquired from multiple national registries aged > 18 years, admitted for ACS without CS and proceeding to coronary angiography who developed cardiogenic shock (CS).
89318357|NCT05570864||Control group (without CS)|A population of patients acquired from multiple national registries aged > 18 years, admitted for ACS without CS and proceeding to coronary angiography who did not develop cardiogenic shock (CS).
89318358|NCT02103010||HNC patients|head and neck cancer patients
89318359|NCT03637244|Experimental|Experimental Condition|Patients assigned to the experimental condition (LDQ + DS and HDQ + DS) will be asked to use the bookmarked link to the decision-aid within the first 7-14 days (and thereafter as needed) during the study period. The routine care group will be asked to use a bookmarked link to frequently asked questions on tenofovir + emtricitabine for PrEP. All groups will be compared on decision-quality at 14-days, self-reported PrEP initiation at 30-days, and PrEP adherence at 60-days post enrollment.
89318360|NCT02099500|Experimental|Stem Cell Injection|Non-Randomized
89318361|NCT02590328||Screened patients|SCID screening: some drops of blood are placed on a second Guthrie card when current screening is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
89318362|NCT02098174|Experimental|Healthy participants|MP-3180 (1 µmol/kg or 0.372 mg/kg) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. The iohexol comparator (Omnipaque 300, 5 mL) was then administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
89318363|NCT02099578|Placebo Comparator|Control Group|Freeze-dried placebo powder - two doses of 25 g/day for 8 weeks
89318364|NCT02099578|Active Comparator|25 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry and placebo powder - one dose of 25 g/day of each for 8 weeks
89318365|NCT02099578|Experimental|50 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry powder - two doses of 25 g/day for 8 weeks
89318366|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 400mg + Cobi 40mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
89318367|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 600mg + Cobi 40mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
88811646|NCT01405937|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
88811647|NCT01368653|Active Comparator|Standard treatment|In this arm, smokers receive a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help them quit smoking
88814879|NCT03033212|Experimental|Early Structured Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 7 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
89318368|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 800mg + Cobi 40mg)|Participants received Venetoclax 800mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
89318369|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 400mg + Cobi 60mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 60mg daily on Days 1-21 of each 28-day treatment cycle.
89318370|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 400mg + Ida 200mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
89318371|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 600mg + Ida 150mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 150mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
89318372|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 600mg + Ida 200mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
89318373|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 400mg + Ida 400mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 400mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
89318374|NCT02670044|Experimental|Dose Optimisation: Arm B (Ven 600mg (Day 1 to 21) + Ida 150mg)|Participants received Venetoclax 600mg daily on Days 1-21 of each 28 day treatment cycle and Idasanutlin 150mg daily on Days 1-5 of each 28 day treatment cycle.
89318375|NCT02103088|Experimental|Sexual and urological intervention|Standard care and the PROCAN intervention consisting of i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
89318376|NCT02103088|No Intervention|Control|Standard care consists of:systematic offer of medical treatment for erectile dysfunction, if not contra indicated. The medical treatment will consist of either daily treatment with Cialis 5 mg or phosphodiesterase type 5 inhibitor on demand before sexual activity. Alternatively use of alprostadil as either urethral pin or penile injection. Furthermore standard treatments include preoperative instruction in pelvic floor muscle training, regular outpatient visits and possible referral to rehabilitation in accordance with the rules that apply to the Danish Health legislations. In case of prolonged incontinence the patients may on request be referred to a private practicing physiotherapist.
89318377|NCT02307656|Other|Atazanavir and Cobicistat|"Stage 1:Taste evaluation using Active Pharmaceutical Ingredient (API)~Stage 2:Taste Optimization using API (flavours and sweeteners)~Stage 3:Prototypes of the API - containing clinical trial materials"
89318378|NCT04232943|Active Comparator|Inactivated Poliomyelitis Vaccine (IPV)|Participants will receive a single intramuscular injection of 0.5 mL inactivated poliomyelitis vaccine (IPV) on Day 1 followed by a single dose (2 drops) of bivalent oral polio vaccine (bOPV) 28 days later.
89318379|NCT04232943|Experimental|Inactivated Poliomyelitis Vaccine + dmLT|Participants will receive a single intramuscular injection of 0.5 mL IPV co-administered with 0.5 μg of dmLT on Day 1 followed by a single dose (2 drops) of bOPV 28 days later.
89318380|NCT04232943|Active Comparator|Bivalent Oral Polio Vaccine|Participants will receive one dose (2 drops) of bOPV on Day 1 followed by a second dose of bOPV 28 days later.
89318381|NCT02098330|Active Comparator|: Ginkgo biloba & methylprednisolone|Patients receive Ginkgo biloba & methylprednisolone per oral.
89318382|NCT02098330|Placebo Comparator|Ginkgo biloba|Patients receive Ginkgo biloba per oral.
89318383|NCT02103166|Experimental|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
89318384|NCT02103166|Placebo Comparator|Physiological serum|100 ml of physiological serum (0.9% NaCl).
89318385|NCT02103244|Experimental|carboplatin|An adjusted dosing algorithm will be applied to calculate the dose of carboplatin. in 24 patients blood will be obtained in order to determine the pharmacokinetics of carboplatin after adjusted dosing
89318386|NCT02099656|Experimental|Lebrikizumab|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8.
89318387|NCT02099656|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8.
89318388|NCT02098408|Experimental|Standard treatment + cognitive remediation|The cognitive remediation therapy targets neurocognition as well as social cognition.
89318389|NCT02098408|Active Comparator|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling
89318390|NCT02098486|Active Comparator|Ceftraxone|ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min)
89318391|NCT02098486|Active Comparator|Moxifloxacin|Intravenous moxifloxacin (400 mg/day, infused more than 60 min)
89318392|NCT02099812||Obese|Obese individuals
89318393|NCT02099812||Non-obese|Non-obese individuals
89318394|NCT02250820|Experimental|Nasal Dexmedetomidine and oral placebo|If the patient is assigned to the dexmedetomidine arm, they will receive dexmedetomidine through the nose. In order to keep the assignment blinded, the patient will also receive an oral placebo.
89318395|NCT02250820|Experimental|Nasal placebo and oral pentobarbital|If the patient is assigned to the pentobarbital arm, they will receive pentobarbital through the mouth. In order to keep the assignment blinded, the patient will also receive an nasal placebo.
89318396|NCT02103400|Experimental|Experimental group|Patients hospitalized for community-acquired pneumonia
89318397|NCT02103400|Active Comparator|Control group|Patients hospitalized for community-acquired pneumonia
89318398|NCT03694275|Experimental|Soticlestat Dup 15q|Soticlestat tablets twice daily (BID) orally or via gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, BID. Participants with Dup 15q weighing <60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
88814880|NCT03033212|Experimental|Delayed Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 13 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
88806551|NCT01794572|Experimental|Total BM irradiation dose|"Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.~For Every patients:~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication."
88806552|NCT05385666|Experimental|group experimental|
88806553|NCT01794650|Other|Meal composition|Changing the glycaemic index of the meals consumed after exercise and before sleep. (High GI - High GI, Low GI - Low GI, High GI - Low GI, Low GI - High GI).
89318399|NCT03694275|Experimental|Soticlestat CDD|Soticlestat tablets BID orally or via G-tube/ PEG tube, BID. Participants with CDD weighing <60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
89318400|NCT02098564|Active Comparator|strong sense of coherence control group|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
89318401|NCT02098564|Experimental|strong sense of coherence intervention|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
89318402|NCT02098564|Active Comparator|weak sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
89318403|NCT02098564|Experimental|weak sense of coherence intervention|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
89318404|NCT02098564|Experimental|medium sense of coherence intervention|Patients with a medium sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
89318405|NCT02098564|Active Comparator|medium sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
89318406|NCT02099968|Experimental|Comprehensive Lifestyle Modification|
89318407|NCT02099968|Active Comparator|Standard Lifestyle Modification / modified DASH|
89318408|NCT02100046|Experimental|ethosuximide|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
89318409|NCT02100046|Other|control group|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
89318410|NCT02250586|Experimental|CBT-CSO|"The CBT-CSO program will be based on concepts from cognitive-behavioral therapy and motivational interviewing, and is specifically developed for use with CSOs of treatment refusing problem gamblers. The program resembles the community reinforcement and family training approach that has been successfully used with CSOs of substance abusers.~The program will be given as guided self-help with guidance given via email and telephone. There are 8 modules, which all contain homework exercises and about 5-10 pages of text."
89318411|NCT02250586|No Intervention|Wait-list|The participants allocated to the control condition will be put on a waiting list and offered the CBT-CSO program after 10 weeks. The CSOs will receive information about available treatment options-in their area and web-based-for the problem gambler.
89318412|NCT02100202|Placebo Comparator|Placebo|Capsules containing 250 mg of placebo, two times a day
89318413|NCT02100202|Experimental|BioTurmin|Capsules containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
89318414|NCT02100202|Experimental|BioTurmin-WD|Capsules containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
89318415|NCT02100202|Experimental|MaQxan|Capsules containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
89318416|NCT05423392|Experimental|The first tasted group using 4% Articaine|"The group was divided into three subgroups depending on the age of the participials: 1st group from 5-9 years, 2nd from 10-13 years and 3th from 14-18 years.~Following placement of 5% lidocaine topical anaesthetic for 3 minutes prior to and at the site of needle penetration, patients were randomly given one of the following local anesthetic regimes administered by the principle investigator. For indicated dental treatment patients would receive 2.0 ml 4% articaine with 1:100,000 epinephrine as a local infiltration in the mucobuccal region,the lateral region of the lower jaw.Criteria for measuring efficacy would be to measure pain during anesthetic injection, 10 minutes after injection,during and after the intervention. The child's behavior would be monitored through all phases of clinical work by direct observation of the dentist( examiner) using the above methodology. After that, the examiner would fill in the questionnaire based on the answer of the child / parent (guardian)."
89318417|NCT05423392|Active Comparator|The second tasted group using 2% Lidocaine-chloride|The group was divided into three subgroups depending on the age of the participials: 1st group from 5-9 years, 2nd from 10-13 years and 3th from 14-18 years. Following placement of 5% lidocaine topical anesthetic for 3 minutes prior to and at the site of needle penetration, patients were randomly given one of the following local anesthetic regimes administered by the principle investigator. For the indicated dental treatment will be used 2.0 ml 2% lidocaine with 1:80,000 epinephrine as an IANB anesthesia for n.alveolaris inferior. Criteria for measuring efficacy would be to measure pain during anesthetic injection, 10 minutes after injection,during and after the intervention. The child's behavior would be monitored through all phases of clinical work by direct observation of the dentist( examiner) using the above methodology. After that, the examiner would fill in the questionnaire based on the answer of the child / parent (guardian).
89318418|NCT02103556|Active Comparator|Mineral oil|4ml daily (adjusted as needed), for 4 weeks
89318419|NCT02103556|Active Comparator|Olive oil|4ml daily (adjusted as needed), for 4 weeks
89318420|NCT02103556|Active Comparator|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
89318421|NCT02099890|Experimental|Anti-inflammatory Supplementation|Omega-3 pill (500 EPA / 250 DHA) taken orally 3 times daily, Vegetation Protein Powder (45g) taken orally once daily, InflanNox capsule (400mg curcumin) taken 3 times daily, Anti-oxidant Network capsule (615mg) taken twice daily, Chlorella tablet (1000mg) taken 6 times daily
89318422|NCT02103634||Lesion Imaging|Image patients with the standard of care of a FDG PET/CT and the experimental method of the NaF PET/MRI and compare the number of images found within and between patients to determine the most effective way of looking at breast cancers metastasized to bone
89318423|NCT03555136||Patients initiating vortioxetine treatment|Patients with major depressive disorder initiating treatment with vortioxetine
89318424|NCT02103712||Hypospadias|
89318425|NCT03554980|Experimental|Group 1|"38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up at 0,1,3,6, 9 and 12.~SDF is a brush-on liquid."
89318426|NCT03554980|Active Comparator|Group 2|5% sodium fluoride varnish will be applied four times annually and patients will be followed up at 0,1,3,6,9 and 12.
89318427|NCT02103790|Experimental|Home NIV installation|
89318428|NCT02103868|No Intervention|Control|No active intervention will be given for tobacco cessation.
89318429|NCT02103868|Experimental|Medium Intervention|Tobacco Cessation Counseling : Medium intervention in the form of 3 contact sessions will be given for tobacco cessation.
89318430|NCT02103868|Experimental|Low intensity intervention|Tobacco Cessation Counseling: Only a single contact session will be done for tobacco cessation.
89318431|NCT04230213|Experimental|Treatment Arm 1|Subcutaneous (SC) injection given every other week
89318432|NCT04230213|Active Comparator|Treatment Arm 2|SC injection given every other week
89318433|NCT02103946|Active Comparator|Serratus anterior muscle plane block|Serratus anterior muscle plane block with general anesthesia MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
89318434|NCT02103946|Active Comparator|Paravertebral block|Paravertebral block with general anesthesia. MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
89318435|NCT03770884||Rheumatoid arthritis|EULAR-ACR criteria Whatever the treatment and the disease activity
89318436|NCT03770884||Axial spondyloarthritis|ASAS criteria for axial disease Whatever the treatment and the disease activity
89318437|NCT03770884||digital osteoarthritis|According to ACR criteria Whatever the treatment and the disease activity
89318438|NCT02100358||acute cholecystitis|acute cholecystitis
89318439|NCT02250742|Experimental|low back pain group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utielized. The needles will be left in situ for 10 minutes.
89318440|NCT02250742|Active Comparator|healthy group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utilized. The needles will be left in situ for 10 minutes.
89318441|NCT02098642||Patients with passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT), including the mobilization of the metatarsophalangeal joint of the hallux
89318442|NCT02098642||No passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT)
89318443|NCT03746691|Experimental|Citalopram, 20 mg, IV|After placement of a high resolution impedance manometry catheter (transnasally), citalopram will be administered IV over 30 minutes (20 mg in 100ml saline). Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
89318444|NCT03746691|Placebo Comparator|Placebo, IV|After placement of a high resolution impedance manometry catheter (transnasally), placebo (saline 100ml) will be administered IV over 30 minutes. Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
89318445|NCT02100592|Experimental|Erigo treated|Early rehabilitation treatment on Erigo Hocoma, a tilt table with integrated stepping device within 3 - 30 days from injury
89318446|NCT04222725|Experimental|TRS01 low dose|
89318447|NCT04222725|Experimental|TRS01 medium dose|
89318448|NCT04222725|Experimental|TRS01 high dose|
89318449|NCT04222725|Placebo Comparator|Placebo|
89318450|NCT03554668||1|Post total knee replacement patients
89318451|NCT03746613|Experimental|Minimally invasive robotic cochlear implantation with HEARO|
89318452|NCT02104024||Kidney transplant recipients|CEUS in Kidney Transplant recipients
89318453|NCT02104024||Pancreas transplant recipients|CEUS in pancreas transplant recipients
89318454|NCT04213989|Active Comparator|Conservative Care|Conservative care (may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT)
89318455|NCT04213989|Experimental|Flexitouch Plus and Conservative Care|Flexitouch Plus with conservative care
89318456|NCT05414734|Experimental|SAD HHT120|Subjects will receive a single dose of HHT120 from 7 doses.
89318457|NCT05414734|Placebo Comparator|SAD Placebo|Subjects will receive a single dose of matched Placebo.
89318458|NCT05414734|Experimental|MAD HHT120|Subjects will receive a mutiple-dose of HHT120 twice daily for 7 days from 3 doses.
89318459|NCT05414734|Placebo Comparator|MAD Placebo|Subjects will receive a mutiple-dose of matched placebo twice daily for 7 days.
89318460|NCT05414734|Experimental|FE K-C|Subjects will receive a single dose of HHT120 in the morning in fasted condition in Period 1; followed by a single dose of HHT120 administered in the morning in fed condition in Period 2. A washout period of 7 days will be maintained between 2 periods.
89318461|NCT05414734|Experimental|FE C-K|Subjects will receive a single dose of HHT120 in the morning in fed condition in Period 1; followed by a single dose of HHT120 administered in the morning in fasted condition in Period 2. A washout period of 7 days will be maintained between 2 periods.
89318462|NCT02100982|Other|Care As Usual|Before the office visit with the PCP, patient participants in the Care As Usual arm will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
89318463|NCT02100982|Experimental|Customized Care|Before the office visit with the PCP, patient participants in the intervention group will interact with the computer based components of the customized care intervention while in the waiting room. The research staff will help the participant use an iPad in the waiting room and direct them to the Discussion Prioritization tool (DPT). After participants use the DPT, the program automatically generates a customized questions prompt list (QPL) which will be printed out in the office. Study staff will hand the QPL to intervention patients to bring to their office visit with the PCP. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
89318464|NCT03746067|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
89318465|NCT03746067|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, the 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
89318466|NCT03555370|Experimental|Standard of Care Group|"Standard of Care:~The standard of care protocol consists of standardized in office and at home behavioral management to include sleep, hydration, nutrition, and stress management interventions. Participants will also be assigned physical activity that they will complete during their visits and at home. Physical activity for the standard of care group will include 15 minutes of flexibility/range of motion exercises, and 10 minutes of aerobic-based daily physical activity (e.g.,walking, stationary cycle)."
89318467|NCT03555370|Experimental|Vestibular Exercise Intervention Group|The vestibular group will complete the behavioral management activities described above, as well as prescribed in-office and at home vestibular exercises from each of four groups: 1) gaze stability training (i.e., integrated eye and head movements on fixed target), 2) visual motion training (i.e., integrated eye and head movements with busy visual background), 3) standing balance (i.e., standing in different stances), and 4) dynamic gait (i.e., walking with head turns). Participants will be prescribed to one of four levels of these four exercise groups based on presentation of symptoms/impairment as indicated on the VOMS. Progression through the four levels will be based on symptom tolerance and successful completion of all exercises at the current level.
89318468|NCT03745911|Experimental|Paclitaxel plus TAK-228|"Paclitaxel will be given on days 1, 8, and 15 of each 28 day cycle intravenously (every Monday or first day of business week if holiday), the day before the first TAK-228 dose. It should be given over approximately one hour.~TAK-228 will be given orally on Days 2-4, 9-11, 16-18 and 23-25 of each 28-day cycle."
89318469|NCT03242252|Placebo Comparator|Placebo|Following a 2-week run-in period, participants received two placebo tablets (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 54 weeks.
89318470|NCT03242252|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, participants received two tablets, 1 sotagliflozin 200 mg tablet and 1 placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 58 weeks.
89318471|NCT03242252|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, participants received sotagliflozin 400 mg, administered as two 200 mg sotagliflozin tablets, orally once daily, before the first meal of the day for up to 60 weeks.
89318472|NCT02106208|Experimental|Cheese diet|A 4-week experimental diet with all meals and foods be provided to participants, including 90g of regular cheddar cheese daily per 2500 kcal. The diet will contain 13% of saturated fat (SFA), 14% of mono-unsaturated fat (MUFA), 5% of polyunsaturated fat (PUFA) and 53% of carbohydrate (CHO).
89318473|NCT02106208|Experimental|Butter diet|A 4-week experimental diet with all meals and foods be provided to participants, the diet will contain 13% of SFA mostly from butter. The diet will contain 14% of MUFA, 5% of PUFA and 53% of CHO.
89318474|NCT02106208|Experimental|CHO diet|A 4-week experimental diet with all meals and foods will provided to participants. The diet will contain 60% of CHO, 6% of SFA, 14% of MUFA and 5% of PUFA.
89318475|NCT02106208|Experimental|MUFA diet|A 4-week experimental diet with all meals and foods be provided to participants. The diet will contain 21% of MUFA, 6% of SFA, 5% of PUFA and 53% of CHO.
89318476|NCT02106208|Experimental|PUFA diet|A 4-week experimental diet with all meals and foods will be provided to participants. The diet will contain 12% of PUFA, 14% of MUFA, 6% of SFA and 53% of CHO.
89318477|NCT03554590|Experimental|carbo-counters|carbohydrate counting: patients attending a structured carbohydrate-counting training and practicing this tecnique to manage insulin therapy
88806554|NCT01794728||Elderly inpatients with heart failure|A single cohort group of elderly patients hospitalized for heart failure.
89318478|NCT03554590|Active Comparator|control group|insulin therapy according to standard care. patients who don't practice carbohydrate-counting to manage insulin therapy
89318479|NCT05362864||ZNN Bactiguard CMN|Subjects that have received or will receive the ZNN Bacitugard Cephalomedullaryl Nail to treat trochanteric, sub-trochanteric, and shaft fractures and osteotomies according to the cleared/approved indications.
89318480|NCT02106286|Active Comparator|Bisoprolol|Patients not betablocked at baseline receive an acute 72hr dose of beta blocker therapy before CPET
89318481|NCT02106286|No Intervention|No Bisoprolol|No beta blocker given
89318482|NCT04109391|Experimental|Test Product (TX05)|"IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles TX05 (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment.~These subjects received TX05 on the TX05-03 study and continued to receive TX05 in this extension study."
89318483|NCT04109391|Active Comparator|Reference Therapy (Herceptin)|"IV trastuzumab (Herceptin) TX05 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles Herceptin (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment.~These subjects received Herceptin on the TX05-03 study and were randomized to receive Herceptin in this extension study."
89318484|NCT04109391|Experimental|Test Product (Herceptin/TX05 Transition)|"IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles TX05 (trastuzumab): Subjects will receive up to 13 cycles of adjuvant treatment.~These subjects received Herceptin on the TX05-03 study and were randomized to receive TX05 in this extension study."
89318485|NCT02104102|Experimental|Mirror group|Composed of 30 volunteers who carry out the mirror therapy, whose name shall Mirror Group (MG).
89318486|NCT02104102|Experimental|Control Group - kinesiotherapy|Called by Control Group (CG), composed of 30 volunteers who will carry out the kinesiotherapy with the same sequence of movements for the Mirror Therapy that the MG, but without the view in the mirror, since it will be blocked.
89318487|NCT03554512|No Intervention|Standard of Care|No Intervention
89318488|NCT03554512|Experimental|Telehealth|Telehealth virtual appointment
89318489|NCT02106364|Experimental|LY2605541|LY2605541 administered by subcutaneous (SQ) injection once daily for 52 weeks. Initial dose is 10 units (10 U) and is titrated by investigator. Participants may continue oral antihyperglycemic medication (OAM) as prescribed by their personal physician.
89318490|NCT02106364|Active Comparator|Insulin Glargine|Insulin glargine administered by SQ injection once daily for 52 weeks. Initial dose is 10 U and is titrated by investigator. Participants may continue OAM as prescribed by their personal physician.
89318491|NCT04077866|Active Comparator|Temozolomide alone|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
89318492|NCT04077866|Experimental|Temozolomide + B7-H3 CAR-T|"Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.~The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide treatment in the cycles of B7-H3 CAR-T treatment will be stopped."
89318493|NCT04106817|Experimental|Cohort 1|1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 10^6TCID50/dose)
89318494|NCT04106817|Experimental|Cohort 2|1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
89318495|NCT04106817|Experimental|Cohort 3|1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
89318496|NCT02101138|Experimental|Dexpramipexole|Dexpramipexole treatment
89318497|NCT04104477|Active Comparator|CMC OA Group|During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported.
89318498|NCT04104477|Active Comparator|Age-Matched Control Group|During testing, participants will be asked to perform range of motion tasks, as well as strength tasks at varying effort levels (maximal and sub-maximal). Through a combination of quantitative testing and self-reported assessments, data on experimental pain, clinical pain, hand function, and disease severity will be reported.
89318499|NCT02106520|Experimental|Bevacizumab 25mg|Three administrations of 25 mg of Bevacizumab spaced of 14 days
89318500|NCT02106520|Experimental|Bevacizumab 50mg|Three administrations of 50 mg of Bevacizumab spaced of 14 days
89318501|NCT02106520|Experimental|Bevacizumab 75mg|Three administrations of 75 mg of Bevacizumab spaced of 14 days
89318502|NCT02106520|Placebo Comparator|Placebo|Three administrations of placebo spaced of 14 days
89318503|NCT05572268|Experimental|ANSA Sachet|Ansa sachet having three APIs (Vaccinium macrocarpon, Saraca indica, Cimicifuga racemosa)
89318504|NCT05572268|Active Comparator|Cran Max Sachet|Cran Max is only having Vaccinium macrocarpon
89318505|NCT03745833|Experimental|Intervention|Participants will be shown a brief VR-based mindfulness intervention after meals.
89318506|NCT02106676||Pregnant women with PCOS and offspring|Exposures of interest: Polycystic ovary Syndrome (PCOS) according to Rotterdam
89318507|NCT02106676||Pregnant women without PCOS and offspring|Exposures of interest: Pregnant women without polycystic ovary Syndrome (PCOS) according to Rotterdam
89318508|NCT03748797|Experimental|Exercise group|8-week moderate intensity exercise training under supervision
89318509|NCT03748797|No Intervention|Control group|No supervised exercise training given. Participants were advised to continue their routine daily activities and self exercises if they have
89318510|NCT02101216|Experimental|Pharmacokinetics of low dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 50 mg (1 tablets) to 6 subjects
89318511|NCT02101216|Experimental|Pharmacokinetics medium dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 100 mg (2 tablets) to 6 subjects
89318512|NCT02101216|Experimental|Pharmacokinetics of high dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 200 mg (4 tablets) to 6 subjects
89318513|NCT02101216|Experimental|Bioequivalence of Prurisol (350 mg)|Single dose of Prurisol™ 350 mg (7 x 50 mg tablets)
89318514|NCT02101216|Active Comparator|Bioequivalence of Ziagen (300 mg)|Single dose of Ziagen 300 mg (1 x 300mg tablet)
89318515|NCT05412862|Experimental|Positive Psychology + Motivational Interviewing|Each week, participants in the PP-MI intervention group will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. Each phone session will include PP and goal setting portions. In the PP portion, the study trainer will (a) review the week's PP exercise, (b) discuss the rationale of the next week's PP exercise through a guided review of the PP-MI manual, and (c) assign the next week's PP exercise. In the goal-setting portion, the trainer will (a) review the participant's physical activity goal from the prior week, (b) discuss techniques for improving physical activity (e.g. tracking activity), and (c) help the participant to set a physical activity goal for the next week. Participants also will receive supplemental text messages throughout the 12 weeks of the intervention and during the initial follow-up period (Week 13-24).
89318516|NCT05412862|No Intervention|Treatment as Usual|Participants in the treatment as usual (TAU) arm will not receive any specific intervention, though they will be free to receive any post-ACS treatment.
89318517|NCT04097925|Experimental|Doravirine + Descovy® TAF/FTC|Doravirine (MK-1439) 100 mg administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC 25/200 mg) and administered orally once daily during 16 weeks
89318518|NCT04645784|Experimental|Intervention|Receives the supporting student-athlete mental wellness module
89318519|NCT04645784|No Intervention|Waitlist|Receives no intervention
89318520|NCT02104492|Experimental|Intervention group|a 12-week respiratory muscles training program (RMTP) with ORYGEN Dual® device and peripheric resistive muscle training program
89318521|NCT02104492|Active Comparator|Control Group|Peripheric resistive muscle training program and Health Education Program.
89318522|NCT03637166|Experimental|Order A|"The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)"
89318523|NCT03637166|Experimental|Order B|"The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level)."
89318524|NCT02104570|Other|Control|In this session, participants will be evaluated before and after a muscle fatigue protocol, with no intervention.
89318525|NCT02104570|Experimental|Kinesio taping with tension|A kinesio taping technique for the deltoid muscle will be applied before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
89318526|NCT02104570|Sham Comparator|Kinesio taping without tension|A kinesio taping technique will be applied on the deltoid muscle without tension (tension is considered to be the therapeutic effect) before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
89318527|NCT04195893|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to etafilcon A daily disposable lenses for one week.
89318528|NCT04195893|Active Comparator|etafilcon A|Subjects will be randomized to wear etafilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
89318529|NCT02106754|Experimental|Brief Intervention|Youth may receive brief intervention from their provider based on randomization.
89318530|NCT02106754|Active Comparator|Treatment As Usual|Youth may receive treatment as usual from their provider based on randomization.
89318531|NCT02106754|Experimental|Brief Intervention with Coaching|Youth may receive brief intervention with coaching from their provider based on randomization.
89318532|NCT04640012|Experimental|DC371739 100mg|Single dose of 100 mg tablet orally administered
89318533|NCT04640012|Placebo Comparator|Placebo|Placebo orally administered
89318534|NCT02104648|Placebo Comparator|Part A: Placebo|
89318535|NCT02104648|Experimental|Part A: RO4602522|
89318536|NCT02104648|Experimental|Part B: RO4602522 Multiple Doses|
89318537|NCT02104648|Experimental|Part B: RO4602522 Single Dose|
89318538|NCT02104648|Experimental|Part B: moxifloxacin Single Dose|
89318539|NCT01562301|Experimental|Anvirzel + Carboplatin + Docetaxel|Anvirzel administered sublingually. A total of five dose cohorts evaluated (6, 12, 24, 36, 48 mg/m2/day; SL divided into 3 doses given every 8 hrs) with 3 patients per cohort. Patients receive the assigned dose (2, 4, 8, 12, or 16 mg/m2) of Anvirzel three times a day throughout each cycle for a total of 4 cycles of chemotherapy. Cycles occur every 21 days. Patients start with an AUC of 6 for Carboplatin and 75mg/m2 for docetaxel, and on subsequent cycles, modifications at the discretion of the treating team. Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
89318540|NCT04639778|Active Comparator|Control Group|In the control group, patients will follow a care pathway respecting the current recommendations : a systematic clinical visit scheduled each year with the multidisciplinary team.
89318541|NCT04639778|Experimental|Experimental Group|In the intervention group, patients will follow a new care pathway with visits triggered by weight evolution
89318542|NCT02104726|Active Comparator|Blind Steroid Injection|Blind Steroid Injection for patients with OA deemed qualified for it clinically
89318543|NCT02104726|Active Comparator|Fluoroscopy guided steroid injection|Fluoroscopy guided Steroid Injection for patients with OA deemed qualified for it clinically. We want to see which one is better.
89318544|NCT02104882|Experimental|Intraoperative Radiotherapy|Following conventional frameless neuronavigation-guided microsurgical tumor resection, patients will receive IORT with 20-40 Gy (prescribed to the applicator surface). Not later than 4 weeks, radiochemotherapy (RCT) will be initiated, consisting of a total EBRT dose of 60 Gy (delivered in fractions of 2 Gy) and concomitant chemotherapy with temozolomide (50 mg/m2/d). Four weeks after RCT, cycling chemotherapy with temozolomide (150-200mg/m2/d/cycle) will be applied.
89318545|NCT04195581|Experimental|comfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
89318546|NCT04195581|Experimental|comfilcon A with All in One Light Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
89318547|NCT04195581|Experimental|comfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
89318548|NCT04195581|Active Comparator|fanfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
89318549|NCT04195581|Active Comparator|fanfilcon A with All in One Light multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
89318550|NCT04195581|Active Comparator|fanfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
89318551|NCT02104960||PROOF|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date. (NCT00759304)
89318552|NCT02105038|Experimental|Knob|Steering in a driving simulator using a steering wheel spinner knob.
89318553|NCT02105038|Active Comparator|No Knob|Steering in a driving simulator immediately following surgical treatment of hip fractures.
89318554|NCT02101372|Active Comparator|treatment as usual|
89318555|NCT02101372|Experimental|Psychoeducation Group|
89318556|NCT02250976|Experimental|Livasupril Cap.160/2mg|"Fenofibrate pellet ( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~once a day"
89318557|NCT02250976|Active Comparator|Lipilfen cap.160mg, Livaro tab. 2mg|"Lipilfen cap.160mg : Micronized fenofibrate 160mg , Livaro tab. 2mg : Pitavastatin ca 2mg~Coadministariton of Lipilfen cap.160mg and Livaro tab. 2mg, once a day"
89318558|NCT04096365|Experimental|Subcostal temporary extracardiac pacing lead|All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.
89318559|NCT02101450|No Intervention|Intra-abdominal removal of the placenta|The uterus will be left in the abdominal cavity and the placenta will be manually removed with uterine massage as soon as possible. After removal of the placenta, the uterus will be dragged out of the abdominal cavity. The cesarean incision will be sutured with no. 1 Vicryl ®. Uterus will be replaced in the abdominal cavity. Intra-abdominal cavity will be cleaned by aspirator and mounted-gauze tampon. The weight of the placenta will be measured. The weight of the gauze tampons will be measured with gravimetric method before and after use.
89318560|NCT02101450|Experimental|Extra-abdominal removal of the placenta|"No drug or device is used. The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.~The placenta will be manually removed with uterine massage as soon as possible. The cesarean section will be completed as described in No intervention group."
89318561|NCT02101528||PD Patients|"PD patients with a diagnosis of clinically probable idiopathic PD in Hoehn-Yahr stage 2-3, with the ability to walk without any assistance, with mini-mental state examination score ≥26, without any relevant comorbidity or vestibular/visual dysfunctions limiting locomotion or balance."
89318562|NCT02101528||Controls|age and sex matched healthy volunteers
89318563|NCT02250898|Experimental|Experimental/Myofascial|The intervention group will receive Myofascial Massage Therapy specific to breast/chest/shoulder of the affected side(s). These massages will include a variety of techniques specifically aimed at reducing pain, inflammation, and tissue sensitivity while also increasing mobility by breaking up scar tissue and thick fibrosis. The intervention massages will include the following specific techniques: skin glide, j stroking, vertical stroking, strumming, fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage. These massages will be twice a week at 30 minutes per massage for a period of 2 months after study enrollment.
89318564|NCT02250898|Active Comparator|Control/Global Relaxation|The control group will receive a general full body massage referred to as a Global Relaxation massage. The massage technique used here will be relaxation massage, avoiding the breast/chest/arm area. This includes light kneading and stroking in order to restore a sense of well- being. The relaxation massage will also be twice a week at 30 minutes per massage for a period of 2 months, avoiding the area of the affected shoulder/shoulders. In this way they are still being seen and touched by a massage therapist, without receiving the intervention treatment.
89318565|NCT03748719|Experimental|Stereotactic Body Radiation Therapy, followed by Prostatectomy|Patients will receive 6 Gy per day of Stereotactic Body Radiation Therapy (SBRT) per day for 5 days, followed by prostatectomy in 3 weeks.
89318566|NCT03746457|No Intervention|Control ART Center|Control arm with no intervention throughout the course of the study
89318567|NCT03746457|Active Comparator|Control and Cycle 3 integrated package|Control arm in Cycles 1 and 2 and in Cycle three converts to experimental
89318568|NCT03746457|Experimental|GI + CA + IC|Receives one alternative sequence of three interventions
89318569|NCT03746457|Experimental|IC + GI + CA|Receives a second alternative sequence of three interventions
89318570|NCT03746457|Experimental|CA + IC + GI|Receives a third alternative sequence of three interventions
89318571|NCT02251054|Experimental|Avatar group|"Intervention group viewed two avatar coaches: a generic avatar coach (GAC) and a self-avatar, peer mentor (SAP)."
89318572|NCT02251054|Active Comparator|No Avatar group|The control group version (voice only) observed the identical program, including introductions, question asking, narration of animations, delivery of key points, and summary of each section with identical pre-recorded voices without the avatars.
89318573|NCT02107066|Active Comparator|attention control|Women randomized to attention control will receive the same attention as women randomized to exercise intervention, i.e., weekly phone calls for 6 months. Each call is about 15 min. Women in the attention control will receive information on ovarian cancer health education topics.
89318574|NCT02107066|Experimental|exercise|Women randomized to exercise will receive telephone-counseling weekly for 6 months to increase their exercise
89318575|NCT04094883|Experimental|4CMenB Vaccine|Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.
89531618|NCT05923294|Experimental|De-epithelialized gingival unit graft|In this split-mouth randomized controlled trial, the coin toss method will determine test and control groups. In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area. To obtain the connective tissue graft, the gingival unit graft will be de-epithelialized in the test group.
88806555|NCT00392444|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
89318576|NCT02104258|Active Comparator|Physiotherapy ASPETAR|"The patients will follow the ASPETAR Hamstring Rehabilitation Protocol, which is a standardised physiotherapy protocol, including range of motion exercises, progressive strengthening exercises, core stability training and agility exercises [10].~The ASPETAR protocol consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
89318577|NCT02104258|Active Comparator|Physiotherapy ASPETAR+|"The patients will follow the ASPETAR+ Hamstring Rehabilitation Protocol. ASPETAR+ is similar to ASPETAR, but consists of additional lengthening exercises which will be initiated early in the rehabilitation phase.~ASPETAR+ consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
89318578|NCT02101606|Experimental|Tenecteplase|
89318579|NCT02101684|Experimental|Orteronel 300mg b.i.d.|Orteronel 300mg BID (600mg per day) will be administered to all included patients in a 28 days cycle schedule.
89318580|NCT03555292|Experimental|PD without dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
89318581|NCT03555292|Experimental|PD with MCI|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
89318582|NCT03555292|Experimental|PD with dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
89318583|NCT03555292|Experimental|dementia with Lewy bodies|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
89318584|NCT03555292|Experimental|healthy control|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
89318585|NCT02101762||Silver Coated Catheters|Subjects that had previously received silver coated Foley catheters.
89318586|NCT02101762||ERASE CAUTI Non-Silver Coated Catheters|Subjects that received non-silver catheters from an ERASE CAUTI tray.
89318587|NCT02101840|Active Comparator|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
89318588|NCT02101840|Active Comparator|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
89318589|NCT02101840|Placebo Comparator|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
89318590|NCT02107222|No Intervention|mechanical ventilation (MV)|mechanical ventilation according to guidelines
89318591|NCT02107222|Experimental|MV + ECCO2-R(PALP-Device/MaquetCP)|MV according to the guidelines plus CO2-Removal with PALP
89318592|NCT02101996||Healthy|Not insulin resistant
89318593|NCT02101996||Insulin resistant|Insulin resistant by an insulin clamp
89318594|NCT02105194|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
89318595|NCT02107378|Experimental|DCVAC/OvCa in parallel with chemo (SoC)|Combination therapy with DCVAC/OvCa and Standard of Care (SoC)
89318596|NCT02107378|Active Comparator|Standard of Care (Chemotherapy)|Standard of Care as an Active Comparator (Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy)
89318597|NCT02105350|Experimental|MEK 162, gemcitabine, and oxaliplatin|MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.
89318598|NCT02105428|No Intervention|Sedentary Control|Participants will be randomized to an exercise training program or sedentary control group. The sedentary will not perform any structured physical activity or exercise. Participants will be encouraged to maintain their sedentary lifestyle and will be monitored by an accelerometer to track physical activity.
89318599|NCT02105428|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of aerobic exercise training
89318600|NCT02102152|Active Comparator|TOBI / Placebo|TOBI / Placebo.
89318601|NCT02102152|Active Comparator|Placebo / TOBI|Placebo / TOBI
89318602|NCT02107456|Experimental|Dry Needling|The taut band of trigger point in upper trapezius muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
89318603|NCT02102308|Experimental|Exercise|Multicomponent exercise
89318604|NCT02102308|Placebo Comparator|Education classes|Education classes
89318605|NCT01368562|Experimental|Methylnaltrexone|Participants will receive single dose of MNTX 0.15 milligrams per kilogram (mg/kg) subcutaneously (SC). Subsequent dosing could be adjusted upward (to a maximum of 0.3 mg/kg) to achieve a desired clinical response or decreased to improve tolerability.
89318606|NCT03554824||Pre-Transfer Adolescents aged 10-16 years|
89318607|NCT03554824||Post-Transfer Young Adults aged 16-25 years|
88806556|NCT02528214|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
89318608|NCT03554824||Parents/Guardians of Pre-Transfer Patients|
89318609|NCT02105506|Experimental|Tachosil patch|Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.
89318610|NCT02105584|Experimental|LAA closure device|Implantation of LAA closure device
89318611|NCT02107534|Experimental|parent training (dyslexia)|Participants take part in parent training, five two-hour sessions held biweekly.
89318612|NCT02107534|No Intervention|wait list control group|Participants of the waiting list control group had the possibility to take part in the parent training after the follow-up was completed.
89318613|NCT03242018|Placebo Comparator|Placebo|Following a 2-week run-in phase, participants received two placebo tablets (identical to sotagliflozin 200 milligrams [mg] in appearance) orally once daily for up to 56 weeks.
89318614|NCT03242018|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in phase, participants received two tablets, one sotagliflozin 200 mg tablet and one placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily for up to 56 weeks.
89318615|NCT03242018|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received sotagliflozin 400 mg, administered as 2 sotagliflozin 200 mg tablets, orally once daily for up to 56 weeks.
89318616|NCT02107612|Experimental|Integrated system to insert two splinted (bar) miniimplants|Participants were randomly assigned to experimental group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
89318617|NCT02107612|Active Comparator|Denture|Participants were randomly assigned to comparator group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
89318618|NCT02107690|Experimental|low temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
89318619|NCT02107690|Experimental|room temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
89318620|NCT02107690|Experimental|body temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
89318621|NCT02105818||Systemic sclerosis|Patients with diagnosed systemic sclerosis treated in the Reha Rheinfelden, Switzerland (European Centre for the Rehabilitation of Scleroderma).
89318622|NCT02107768|Experimental|Exercise recommendation|Patients randomized to the control group receive general advice for physical training and activity but no specific training or other rehabilitation efforts
89318623|NCT02107768|Experimental|Aerobic exercise|"The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added. The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20, Rate of Perceived Exertion (Borg 's RPE scale)~Two fitness goals was to be achieved during the training session:~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) .Which corresponds to 85% of maximum heart rate."
89318624|NCT02639780||healthy young female|
89318625|NCT02639780||healthy young male|
89318626|NCT02639780||healthy older female|
89318627|NCT02639780||healthy older male|
89318628|NCT02639780||obese older female|
89318629|NCT02639780||obese older male|
89318630|NCT02110030|Experimental|Transcutaneous nerve stimulation|"The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 15 sessions at a frequency of 80 Hz and with a pulse width of 150 ns.~The group with TENS received electrical stimulation by using an approved electrotherapy device (Endomed 182, Enraf-nonius, Germany). The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2)."
89318631|NCT02110030|Active Comparator|Interferential Currents|The group with Interferential Currents (IC) received a base frequency of 4000 Hz by using the same approved electrotherapy device than the TENS group (Endomed 182, Enraf-nonius, Germany).
89318632|NCT04688684|Experimental|Family-based intervention|These participants will undergo the health coach based intervention with fitness tracker and diet changes, which will be delivered to all family members who meet the inclusion criteria and are enrolled in the study.
89318633|NCT02789176||Outpatient Enrollees|This is a cohort of 150 subjects who were previously enrolled in the Neonatal Seizure Registry, a multi-center association of institutions across the United States, They were contacted to participate in the study after discharge from the Neonatal Intensive Care Unit (NICU) but prior to the prospective follow up. They were asked to take part in all prospective follow up surveys at 12, 18, & 24 months of age.
89318634|NCT02789176||NICU Enrollees|This is a cohort of 150 subjects who were enrolled in the study prior to discharge from the NICU. They were asked to complete surveys prior to discharge from the NICU, returned to the hospital for a 1 hour EEG to monitor brain activity between 2-4 months of age, & completed the follow surveys at 12, 18, & 24 months of age.
89318635|NCT04049942|Experimental|Prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
89318636|NCT04049942|Experimental|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
89318637|NCT05568836|Active Comparator|Intervention|single dose of 300000 IU vitamin D injection (IM)
89318638|NCT05568836|Other|Control|No intervention
89318639|NCT03554122|Active Comparator|Shotblocker Group|Patients spinal injections were performed with Shotblocker placed onto injection site
89318640|NCT03554122|Placebo Comparator|Placebo Group|Patients spinal injections were performed without Shotblocker
89318641|NCT02106052|Active Comparator|Aerobic exercise|
89318642|NCT02106052|Other|Stretching and toning exercise|
89318643|NCT03259490|Experimental|Test Treatment|High dose empagliflozin/linagliptin/metformin XR fixed dose combination tablet
89318644|NCT03259490|Experimental|Reference Treatment|Single tablets of empagliflozin + linagliptin + metformin XR
89318645|NCT02107846|Experimental|50 Units|PRX-112 50 Units daily for 5 days
89318646|NCT02107846|Experimental|100 Units|PRX-112 100 Units daily for 5 days
89318647|NCT02107846|Experimental|200 Units|PRX-112 200 Units daily for 5 days
89318648|NCT02107846|Experimental|400 Units|PRX-112 400 Units daily for 5 days
89318649|NCT02106130|Experimental|R - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
89318650|NCT02106130|Experimental|R+M - R|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
89318651|NCT02106130|Experimental|M - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
89318652|NCT02106130|Experimental|R+M - M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
89318653|NCT01314092|Experimental|Group 1|Low dose group
89318654|NCT01314092|Experimental|Group 2|high dose group
89318655|NCT02110186|Experimental|Discectomy and dynamic stabilization|Discectomy with posterior dynamic stabilization
89318656|NCT02110186|Active Comparator|Discectomy alone|Discectomy
89318657|NCT02110186|Active Comparator|Discectomy and fusion|Discectomy with internal fixation and fusion
89318658|NCT02251132|Experimental|TPV/RTV Low 1|
89318659|NCT02251132|Experimental|TPV/RTV Low 2|
89318660|NCT02251132|Experimental|TPV/RTV Low 3|
89318661|NCT02251132|Experimental|TPV/RTV Medium 1|
89318662|NCT02251132|Experimental|TPV/RTV Medium 2|
89318663|NCT02251132|Experimental|TPV/RTV High 1|
89318664|NCT02251132|Experimental|TPV/RTV High 2|
89318665|NCT02251132|Experimental|TPV/RTV High 3|
89318666|NCT02110342|Experimental|Treatment|
89318667|NCT02110420|Experimental|CC-90001 10mg (Single Dose)|
89318668|NCT02110420|Experimental|CC-90001 30mg (Single Dose)|
89318669|NCT02110420|Experimental|CC-90001 60mg (Single Dose)|
89318670|NCT02110420|Experimental|CC-90001 120mg (Single Dose)|
89318671|NCT02110420|Experimental|CC-90001 240mg (Single Dose)|
89318672|NCT02110420|Experimental|CC-90001 10mg (Multiple Doses)|
89318673|NCT02110420|Experimental|CC-90001 30mg (Multiple Doses)|
89318674|NCT02110420|Experimental|CC-90001 60mg (Multiple Doses)|
89318675|NCT02110420|Experimental|CC-90001 120mg (Multiple Doses)|
89318676|NCT02110420|Experimental|CC-90001 240mg (Multiple Doses)|
89318677|NCT02110420|Experimental|Placebo|
89318678|NCT02110420|Experimental|CC-90001 480mg (single dose)|CC-90001 480mg will be administered as a single oral dose
89318679|NCT02110420|Experimental|CC-90001 720mg (single dose)|CC-90001 720mg will be administered as a single oral dose
89318680|NCT02110420|Experimental|CC-90001 480mg (multiple doses)|CC-90001 480mg will be administered daily for 14 days
89318681|NCT03259334|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligrams (mg) of ontamalimab (SHP647) subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
89318682|NCT03259334|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
89318683|NCT03259334|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
89318684|NCT02113696|Experimental|Placebo group|Placebo Capsules
89318685|NCT02113696|Experimental|Omega 3 intake|Omega 3 intake, morbid obesity
89318686|NCT03553966|Experimental|Tooth Brushing HAP+Restorative dentistry|"Arm Intervention: HA-Toothpaste Tooth Brushing HA Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite 3x daily over the duration of the study (336 days).~Procedure: Tooth Brushing HA"
89318687|NCT03553966|Active Comparator|Tooth Brushing F+Restorative dentistry|"Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (500 ppm F-), (three times daily over the duration of the study (336 days).~Intervention:~Procedure: Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated toothpaste."
89318688|NCT01331824|Experimental|Amrubicin|35 mg/m2/day intravenously
89318689|NCT02113774|No Intervention|no therapy|
89318690|NCT02113774|Active Comparator|antimicrobial treatment according to in-vitro susceptibility|
89318691|NCT05571800|Experimental|Mango Supplement|Participants will consume 120g of fresh mango per day for 24 weeks
89318692|NCT05571800|Placebo Comparator|Placebo Matched Supplement|Participants will consume 200g isocaloric granola bar per day for 24 weeks
89318693|NCT02113930||Idiopathic CD4 lymphocytopenia|Constitution of a biobank of frozen cells, plasma and serum samples
89318694|NCT02113930||Genetic Study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
89318695|NCT05571722|Active Comparator|Control group: Vancomycin|Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
89318696|NCT05571722|Experimental|Experimental group: linezolid|Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
89318697|NCT02114008|Active Comparator|Abbreviated fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin).
89318698|NCT02114008|Active Comparator|Traditional fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test).
89318699|NCT02110576||Healthy Controls|Healthy controls in general good health, without chronic disease/illness, including but not limited to: cancer, diabetes mellitus, renal disease, cardiac disease, hypertension, lung disease, liver disease, complications of morbid obesity, autoimmune/inflammatory disease, or any condition of sufficient severity that it requires daily medication to manage
89318700|NCT02110654|Active Comparator|mometasone furoate nasal spray|mometasone furoate nasal spray,200ug qd, 6 months
89318701|NCT02110654|Experimental|mometasone furoate nasal spray combined with montelukast|montelukast tablet,10mg,qd + mometasone furoate nasal spray, 200ug qd,6 months
89318702|NCT03258710|Experimental|All subjects treated with Tenofovir Disoproxil Fumarate|Subjects with on-going ETV treatment will be switched to Tenofovir Disoproxil Fumarate treatment. Subjects will start TDF on the day ETV is discontinued, without having overlapping treatment periods. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
89318703|NCT02110810|Experimental|Indomethacin|100 mg of Indomethacin suppository immediately afterwards while still under sedation
89318704|NCT02110810|Placebo Comparator|2.6-g suppository of glycerin|suppository of 2.4 g of glycerin immediately afterwards while still under sedation
89318705|NCT02107924||APPI of TKR-Stimulan|Surgery Stimulan beads 2.4 G Tobramycin 2.0 G Vancomycin
89318706|NCT02107924||APPI of TKR-historical|Surgery 2.4 G Tobramycin 2.0 G Vancomycin
89318707|NCT02110888|Experimental|SCS + PNS|Mutlticolumn SCS lead + Monocolumn SCS lead
89318708|NCT02110888|Active Comparator|SCS|Mutlticolumn SCS lead
89318709|NCT02108236|No Intervention|Blank control group|A control group of patients is put on a waiting list for no intervention and remaining unchanged lifestyle.
89318710|NCT02108236|Active Comparator|intervention group|An intervention group of patients is put on a waiting list for acupuncture treatment.
89318711|NCT03240692|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
89318712|NCT02114320|Experimental|EUS-BD-1|EUS-BD-1 inserts a partially covered self-expanding metallic (hybrid) stent with a dedicated introducer for EUS-BD
89318713|NCT02114320|Experimental|EUS-BD-2|EUS-BD-2 inserts a fully covered self-expanding metallic stent
89318714|NCT02108314|No Intervention|Control Group|Participants in the control arm were blinded as to the hypothesis of the study, undergoing a series of questions in about general health behaviours before their consultation, allowing the investigators to determine eligibility for the study. The associated participant information sheets for the control arm did not specifically mention breast cancer screening, maintaining blinding throughout. There was no reminder to the physician to promote mammography to participants. The physician continued with his or her usual counseling on health screening and mammography, if any. A 3-minute health promotion video by the Singapore Heart Foundation on healthy eating habits was administered to each participant, followed by a post-consultation questionnaire. The entire process took approximately 10 minutes.
89318715|NCT02108314|Active Comparator|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
89318716|NCT02114398|Experimental|usual treatment|usual treatment
89318717|NCT02114398|Experimental|usual treatment + sophrology|usual treatment + sophrology
89318718|NCT02114476|Placebo Comparator|nonhormonal contraception|nonhormonal intrauterine device tubal sterilization
89318719|NCT02114476|Experimental|progestin implant|Jadelle
89318720|NCT03233048|Experimental|ORBERA™ Intragastric Balloon|Participants will have the ORBERA™ Intragastric Balloon inserted for 6 months. In addition, participants will have ongoing visits with a physician, dietitian, and psychologist before the balloon is inserted, while its in place, and for 6 months after the balloon is removed, for a total of approximately 1 year.
89318721|NCT02110966|Experimental|Mepivacaine plus Tramadol|1.3 ml of Mepivacaine 2% epinephrine 1:100000 mixed with 0.5 ml of Tramadol (50mg/ml) will be used for the anesthetic blockade in the experimental group
89318722|NCT02110966|Active Comparator|Mepivacaine|The control group will receive the inferior alveolar nerve block using 1.8 ml of Mepivacaine 2% epinephrine 1: 100000.
89318723|NCT02937740|Other|Naive patients - ARM 1|"NATESTO Testosterone Nasal Gel administered intranasally to patients with no prior TRT experience. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
89318724|NCT02937740|Other|Non-naive patients - ARM 2|"NATESTO Testosterone Nasal Gel administered intranasally to patients who had prior TRT. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
89318725|NCT02111044|Active Comparator|Octreotide|Octreotide 100 mcg sc three times daily (t.i.d) for 4 weeks
89318726|NCT02111044|Experimental|ITF2984 500 mcg|ITF2984 500 mcg sc twice a day (b.i.d) for 4 weeks
89318727|NCT02111044|Experimental|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
89318728|NCT02111044|Experimental|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
89318729|NCT02320994||stroke patients|post-rehabilitation stroke patients
89318730|NCT02108470|No Intervention|Dental consultation without OHQoL assessment|Dentist performs consultation in the traditional method
89318731|NCT02108470|Experimental|Dental consultation using OHIP|Dental consultation using OHIP incorporating OHRQoL issues.
89318732|NCT05444426|Experimental|Treatment Group|"A 24-session physiotherapy program will be applied to the patients in the treatment group.~The conventional physiotherapy program of the patients in the treatment group; will consist of 20 minutes of the hot pack, 20 minutes of conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound) on the shoulder joint for 5 minutes. In the exercise program; A combined exercise program including active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied. As the severity of pain decreases, strengthening exercises for the rotator cuff and scapulary muscles will be given."
88814881|NCT03033212|Active Comparator|Self Rehabilitation|Patients will begin Self-Guided Rehabilitation at 7 weeks postoperatively in a self-guided fashion. They will be provided with instructions for recommended exercises. They will undergo rehabilitation for a total of 10 weeks.
89318733|NCT05444426|No Intervention|Control Group|Pain, Active range of motion, balance, and postural stability will be assessed in the first week .
89318734|NCT02114632|Active Comparator|Polyunsaturated fatty acids|"6 capsules of food supplement Eye q per day divided in two daily doses (558 mg EPA, 174 mg DHA, 60 mg GLA per day)"
89318735|NCT02114632|Placebo Comparator|placebo|6 capsules of olive oil per day divided in two daily doses.
89318736|NCT02114710|Experimental|Hydrocortisone|little doses of hydrocortisone
89318737|NCT02114710|No Intervention|Placebo|Placebo
89318738|NCT03927716|Experimental|SB206 12%|SB206 12% topically once daily
89318739|NCT03927716|Placebo Comparator|Placebo|Placebo topically once daily
89318740|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose|
89318741|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose - Food Effect|
89318742|NCT02108548|Placebo Comparator|Part 1: Placebo|
89318743|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose|
89318744|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose Elderly|
89318745|NCT02108548|Placebo Comparator|Part 2: Placebo|
89318746|NCT02108548|Active Comparator|Part 2: Naproxen|
89318747|NCT02111122|Experimental|Sodium Oxybate|"Treatment (500mg Natrii oxybas/ml) will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. The dosage starts at 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
89318748|NCT02111122|Placebo Comparator|Placebo|"Treatment will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. As with the active compound, placebo will be given with a starting dose of 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
89318749|NCT03924050|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
89318750|NCT03924050|Placebo Comparator|Group Placebo combined with standard chemotherapy|
89318751|NCT02108626|Active Comparator|E-Cigarette with nicotine|Electronic cigarette with cartridge fluid containing nicotine
89318752|NCT02108626|Placebo Comparator|E-Cigarette without nicotine|Electronic cigarette with cartridge fluid containing no nicotine (placebo)
89318753|NCT04173741||Leg Rise Position - 3 Minutes|Patients who stayed in passive leg rise position for 3 minutes
89318754|NCT04173741||Leg Rise Position - 1 Minute|Patients who stayed in passive leg rise position for 1 minute
89318755|NCT02108704|Active Comparator|Helicobacter pylori eradication therapy|Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD
89318756|NCT02108704|Placebo Comparator|Placebo|Maltodextrin
89318757|NCT03745599|Experimental|Diclofenac|Diclofenac group, which received diclofenac 50 mg capsules (Cataflam) and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
89318758|NCT03745599|Experimental|Flurbiprofen|Flurbiprofen group, which received flurbiprofen 100 mg capsules and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
89318759|NCT03745599|Experimental|Benzydamine|Benzydamine group, which received benzydamine 0.045 g, 30 mL oral sprays (Tantum Verde) and placebo capsules. Placebo capsules contained starch.
89318760|NCT02111278|Experimental|lumbar Manipulation|Patients randomized to this treatment group will receive lumbar manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
89318761|NCT02111278|Placebo Comparator|Sham Manipulation|Patients randomized to this treatment group will receive a sham manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
89318762|NCT02108782|Experimental|Treatment (dovitinib lactate)|Patients receive dovitinib lactate PO on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89318763|NCT03231800|Experimental|Dasotraline|Dasotraline capsule 2mg/day
89318764|NCT03231800|Placebo Comparator|Placebo|Placebo capsule
89318765|NCT02111356|Experimental|Pinhole glasses|All subjects perform ophthalmic examinations before and after the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
89318766|NCT03553654|Experimental|CT monitoring arm|18-75 year old patients with newly-diagnosed cancer, scheduled to undergo anthracycline-based chemotherapy.
89318767|NCT01314248||children weighing 10 to 15 kg|
89318768|NCT02114788||group 1|No intervention
89318769|NCT02114788||Group 2|Intervention with interactive website
89318770|NCT04577144||Individuals who participated in the RECOVER study|Individuals who enrolled in the Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery (RECOVER) study. Individuals who received at least one injection in a SUBLOCADE Phase III program were eligible to participate in the original study.
89318771|NCT02108938||Case|Subject's with Crohn's disease at least 18 years of age
89318772|NCT02108938||Control|"Findings from this study will be compared to controls. These controls will come from the well documented CNS changes which have been found in patients with IBS and chronic pancreatitis (HS-IRB# 2013-1561 and HS-IRB 2009-0171)."
89318773|NCT03553342|Experimental|Corticoids|
89318774|NCT03553342|Placebo Comparator|Placebo|
89318775|NCT04085601|No Intervention|Standard of Care (SOC) excluding complement inhibitors|
89318776|NCT04085601|Experimental|1,080mg APL-2 administered subcutaneously twice weekly|
89318777|NCT02111434|Experimental|testosterone|testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months
89318778|NCT03230864|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
89318779|NCT03230864|Experimental|Double-blind treatment (DBT) period, Lu AF35700 10 mg|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks
89318780|NCT03230864|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks. Patients in this arm will continue with the same treatment and dose as at the last visit of the PC Period
89318781|NCT02109094||Pregnant|
89318782|NCT02109094||Not Pregnant|
89318783|NCT02111512|Other|Egg allergic children|Children with a physician diagnosis of egg allergy will be recruited to receive the intranasal LAIV as part of a safety surveillance study
89318784|NCT03636854|Experimental|Concentric Exercises|2 different concentric exercises will be done 3 times a week for 8 weeks.
89318785|NCT03636854|Experimental|Eccentric Exercises|2 different eccentric exercises will be done 3 times a week for 8 weeks.
89318786|NCT02111590||IVIG to SCIG|Patients with CIDP or MMN in maintenance therapy with IVIG every 3rd to 6th week are shifted to weekly SCIG treatment in unaltered dose.
89318787|NCT02111590||SCIG to SCIG|Patients with CIDP or MMN in maintenance therapy with SCIG (Subcuvia(R) or Hizentra(R)) are shifted to treatment with Gammanorm(R) in unaltered weekly dose.
89318788|NCT04085367|Experimental|MAL 16.8% Cream|Participants received two treatment session at least 2 weeks apart. Investigator applied a thin layer of methyl aminolevulinate (MAL) hydrochloride 16.8% cream to each lesion during treatment. At 30 minutes after cream application, participants went outside in daylight for 2 hours (Daylight photodynamic therapy [DL-PDT]). After this time, the cream was removed by investigative site personnel by washing the skin with gentle skin cleanser.
89318789|NCT04085367|Placebo Comparator|MAL Vehicle Cream|Participants received two treatment session at least 2 weeks apart. Investigator applied a thin layer of vehicle cream to each lesion during treatment. At 30 minutes after cream application, participants went outside in daylight for 2 hours (DL-PDT). After this time, the cream was removed by investigative site personnel by washing the skin with gentle skin cleanser.
89318790|NCT03553888||HS patient|patients with HS
89318791|NCT03553888||no HS patients|patients without HS
88814882|NCT03033368|Experimental|opened label|Open-label, single-arm study, rilpivirine is the study drug
89318792|NCT03228836|Experimental|Sintilimab (IBI308)|
89318793|NCT02109250||all Belgian patients treated with Caprelsa® (vandetanib)|It is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).
89318794|NCT02111824|Experimental|Group 2|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
89318795|NCT02111824|Experimental|Group 3|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
89318796|NCT02111824|No Intervention|Group 1|Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.
89318797|NCT02937350|Experimental|Study Population|D6-25-hydroxyvitamin D3
89318798|NCT02115022||Potentially resectable pancreatic cancer|Patients with a confirmed pancreatic mass (suspected neoplastic) deemed resectable or borderline resectable on multislice (at least 16 simultaneously acquired slices) pancreatic protocol computed tomography (CT), fit and willing to undergo surgery with a curative (R0) intent.
89318799|NCT02167022|Experimental|Intense Physiotherapy (Group 1)|30 minutes each of physical and occupational therapy each weekday for 12 weeks (intense physiotherapy) followed by the same therapies administered once a week for 36 weeks (the current standard of care).
89318800|NCT02167022|Experimental|Delayed Intense Physiotherapy (Group 2)|30 minutes each of physical and occupational therapy once a week for 36 weeks (the current standard of care) followed by the same therapies administered each weekday for 12 weeks (intense physiotherapy).
89318801|NCT02109328|Experimental|Alisertib + Paclitaxel|After the first single arm phase with Alisertib monotherapy (20 patients, primary endpoint: response-rate), 110 patients will be randomized 1:1 in the second part of the trial.
89318802|NCT02109328|Placebo Comparator|Paclitaxel + Placebo|Weekly paclitaxel + oral Placebo
89318803|NCT02134574||hematologic malignancy|hematologic malignancy with a sampling of blood
89318804|NCT02115178||Lithotomy or Prone position|
89318805|NCT02115334|Experimental|professional-based group|professional therapists delivering the PHPA
89318806|NCT02115334|Experimental|parents-based group|parents executing the PHPA
89318807|NCT02115334|Active Comparator|control group|health education only
89318808|NCT02115412||medication non-adherence|
89318809|NCT04085289|Experimental|Galcanezumab|Participants received single subcutaneous (SC) doses of 120 milligram (mg) or 240 mg Galcanezumab.
89318810|NCT04085289|Placebo Comparator|Placebo|Participants received a single SC dose of Placebo.
89318811|NCT02112058|Experimental|Program|A series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program. Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula. The third component was family support services.
89318812|NCT02112058|No Intervention|Control|Business as usual
89318813|NCT02251210|Experimental|BIIL 284 BS low dose|
89318814|NCT02251210|Experimental|BIIL 284 BS medium dose|
89318815|NCT02251210|Experimental|BIIL 284 BS high dose|
89318816|NCT02251210|Placebo Comparator|Placebo|
89318817|NCT02115490||Osteoporosis_with_Bisphosphonates|This group of patients are taking Bisphosphonates orally in their treatment
89318818|NCT02115490||Osteoporosis-without-Bisphosphonates|This group of patients has not taken Bisphosphonates in the course of treatment
89318819|NCT03553264|Experimental|Head Mounted Device|"In addition to the Vestibular Rehabilitation protocol, each HMD group patient will perform Virtual Reality Rehabilitation by means of the game protocol Track Speed Racing 3D uninterruptedly for 20min/day, while sitting on a chair or sofa, after the smartphone accommodation into the HMD 'Revelation' 3D VR Headset. The game consists of a point-of-view race in which the car is steered from the cockpit by tilting the head to the left and to the right to avoid swerving off the road and to achieve all the goals before finishing the lap. During this real car experience, the visual background and the scenario change perspective according to the patients' left or right tilted head movements, possibly emulating eye-head exercises that induce visual-vestibular conflicts."
89318820|NCT03553264|Active Comparator|Vestibular Rehabilitation|Patients will be actively involved in adapting the exercise program to suit their symptoms, capabilities, and lifestyle. Following previous protocols, the home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises, and all chronic unilateral vestibular hypofunction patients will be seen twice a week for 4 weeks for 30-45 min and monitored for adherence. Between supervised sessions, patients will perform a twice-daily home exercise program for a total of 30-40min/day.
89318821|NCT02251288|Experimental|Group 1|12 patients receive Intramuscular (IM) A/H7N9 15 mcg on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of Intranasal (IN) sprayer 10^7 FFU H7 N9 pLAIV on Day 29
89318822|NCT02251288|Experimental|Group 2|12 patients receive A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer10^7 FFU H7 N9 pLAIV on Day 85
89318823|NCT02251288|Experimental|Group 3|12 patients receive S A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer 10^7 FFU H7 N9 pLAIV on Day 169
89318824|NCT02251288|Experimental|Group 4|8 patients receive A/H7N9 15 mcg IM on Day 1, 8 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1
89318825|NCT02251288|Experimental|Group 5|12 patients receive A/H7N9 15 mcg plus MF59 adjuvant on Day 1 and Day 29
89318826|NCT04080297|Experimental|100 mg Q-122|10 patients treated with Q-122, 100 mg. Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.
89318827|NCT04080297|Experimental|200 mg Q-122|11 patients treated with Q-122, 200 mg. Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.
89318828|NCT02115568||Long-term safety follow-up|To be eligible, subjects must have actively participated in a Juventas (JVS-100) sponsored trial under IND 14203.
89318829|NCT04371549|Active Comparator|Glue|Skin closure after cesarean section using glue
89318830|NCT04371549|Active Comparator|Monocryl|Skin closure after cesarean section using running subcuticular sutures using synthetic monofilament
89318831|NCT02109718|Experimental|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with Open Dressing with Petrolatum Jelly
89318832|NCT02109718|Active Comparator|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed with Silver Sulfadiazine Gauze Dressing.
89318833|NCT03744897|Experimental|Hypnotic analgesia|"Intervention:~- Subjects will receive hypnotic analgesia"
89318834|NCT03744897|Experimental|a-tDCS|"Intervention: transcranial direct current stimulation - tDCS~active tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current:2 milliamps~time: 20 minutes"
89318835|NCT03744897|Sham Comparator|s-tDCS|"Sham comparator: transcranial direct current stimulation - tDCS~sham tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current: 0 milliamps~time: 20 minutes"
89318836|NCT03744897|Experimental|Hypnotic analgesia + a-tDCS|"Intervention:~hypnotic analgesia~active tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current:2 milliamps~time: 20 minutes"
89318837|NCT02115802|Experimental|Activa PC+S|Specific features of LFP recorded from the deep brain nuclei will be examined for possible correlation with different natural behaviors, such as movement, walking, or speech.
89318838|NCT02112136|Other|GeneQuest|"No drug will be administrated in this study~Blood collection"
89318839|NCT02112292|Experimental|T-C-P|Order of administrations: tetrahydrocannabinol - cannabidiol - placebo
89318840|NCT02112292|Experimental|T-P-C|Order of administrations: tetrahydrocannabinol - placebo - cannabidiol
89318841|NCT02112292|Experimental|C - T - P|Order of administrations: cannabidiol - tetrahydrocannabinol - placebo
89318842|NCT02112292|Experimental|C - P - T|Order of administrations: cannabidiol - placebo - tetrahydrocannabinol
89318843|NCT02112292|Experimental|P - T - C|Order of administrations: placebo - tetrahydrocannabinol - cannabidiol
89318844|NCT02112292|Experimental|P - C - T|Order of administrations: placebo - cannabidiol - tetrahydrocannabinol
89318845|NCT02109796|Experimental|hemiplegic patient|anodal transcranial direct current stimulation
89318846|NCT02109796|Sham Comparator|patient control|Sham transcranial direct current stimulation
89318847|NCT03748407|Other|dosages in Healthy volunteers|"Only one arm : healthy volunteer blood donors. Performing a blood test for the determination of parameters that explore thyroid status : only once.~Absence of other healthy volunteers group all healthy volunteers have a blood test performed in the same way."
89318848|NCT02115958|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89318849|NCT02115958|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89318850|NCT02115958|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89318851|NCT02115958|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89318852|NCT04013529|Placebo Comparator|Control|Participate in technology-enabled care without regret lottery
89318853|NCT04013529|Experimental|Experimental|Participate in technology-enabled care with regret lottery
89318854|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 5/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
89318855|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 15/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
89318856|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 50/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
89318857|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 150/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
89318858|NCT02109874|Placebo Comparator|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|Placebo: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl. This is the identical buffer solution in which IC31 is formulated.
89318859|NCT02116036|Experimental|Rivaroxaban|Rivaroxaban 20mg po daily
89318860|NCT04011735||Respimat SMI-experienced: Switching to re-usable Respimat|patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry.
89318861|NCT04011735||Respimat SMI-naïve|patients who have not previously used a Respimat SMI product and receive their first prescription at study entry
89318862|NCT04011735||Respimat SMI-experienced: Maintenance treatment|patients who have been on maintenance treatment with a Respimat SMI product and receive a refill prescription at study entry.
89318863|NCT02251366|No Intervention|SOC Examination Based Cohort|Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
89318864|NCT02251366|Active Comparator|Physician-Guided Diagnostic|Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant. At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
89318865|NCT04009629|Experimental|Exercise - apolipoprotein e4 carrier|A single 15 minute bout of moderate intensity aerobic exercise for individuals with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.
89318866|NCT04009629|Experimental|Exercise - apolipoprotein e4 non-carrier|A single 15 minute bout of moderate intensity aerobic exercise for individuals with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.
89318867|NCT02116114|Experimental|Aquatic exercises|"3 times a week~heating~aerobic training~slowdown"
89318868|NCT02116114|No Intervention|control group|The control group participated in the study only to usual care , conventional medical treatment orientation about the disease , methods of energy conservation and evaluation.
89318869|NCT02116192|Active Comparator|General Healthy Diet|Control: General Healthy Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat)
89318870|NCT02116192|Experimental|Low-fructose, reduced carbohydrate diet|"Intervention: Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
89318871|NCT02118844|Active Comparator|Moderate rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain moderate neuromuscular blockade (TOF-count 2-4) during gastrojejunal anastomosis
89318872|NCT02118844|Experimental|deep rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain deep neuromuscular blockade (here defined as a Posttetanic Count 1 - 5) during gastrojejunal anastomosis
89318873|NCT02116270|Other|Control group|Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.
88814883|NCT03031262|Active Comparator|High Dose of Cytarabine|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine.
88814884|NCT03031262|Experimental|HDAC + Chidamide|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine plus chidamide.
89318874|NCT02116270|Experimental|Severe renal failure|Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.
89318875|NCT02116270|Experimental|Peritoneal dialysis|Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.
89318876|NCT02116270|Experimental|Hemodialysis|Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.
89318877|NCT02116348|Experimental|Cerebrolysin|Nerve growth factor Cerebrolysin will be given to the intervention group
89318878|NCT02116348|No Intervention|Conventional|These children will receive conventional treatment for cerebral palsy
89318879|NCT02116426||The study population|"The study population includes all adult patients taken in charge by the emergency ambulance services of the participating centers for non-traumatic chest pain for suspected Acute Coronary Syndrome (ACS) without ST segment elevation.~Intervention: Blood work in the ambulance Intervention: Blood work upon arrival in the emergency room Intervention: Blood work at 3 hours post-arrival in the emergency room"
89318880|NCT02119000|Experimental|PEG electrolytes 2L/2L split dose|
89318881|NCT02119000|Active Comparator|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|
89318882|NCT02119078|Active Comparator|ACE Service|Admission to the Acute Care for Elders (General Medicine Team 1) service. (See Intervention, below)
89318883|NCT02119078|No Intervention|Standard care (other General Medicine teams)|Admission to one of the 4 non-ACE general medicine teaching teams at OHSU.
89318884|NCT02116504|Other|Global population|"All included patients :~Sampling of blood"
89318885|NCT02119234|Experimental|CHF5993 pMDI + Spacer|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using Aerochamber Plus Flow-vu VHC spacer
89318886|NCT02119234|Active Comparator|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using standard actuator only
89318887|NCT02119234|Placebo Comparator|Placebo pMDI|Placebo pMDI x 4 inhalations
89318888|NCT02112604||Ventilated patients|Patients who have been extubated within 24 hours and have been mechanically ventilated for at least 24 hours. Alice PDx, pulmonary function tests, muscle strength tests, grip strength measurements, ventilator, Sedatives and muscle relaxants given in the ICU
89318889|NCT02112682|Active Comparator|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
89318890|NCT02112682|No Intervention|No completion axillary treatment|
89318891|NCT02119390|Other|Standard Care|Participants in the Standard Care group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care.
89318892|NCT02119390|Experimental|Pill Trial+|Participants in the Pill Trial+ group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care plus three 25-minute individualized, behavioral, staff-delivered intervention sessions at HAART initiation, and 1-, and 3-month follow-up visits. Two brief booster sessions will also be provided following sessions 1 (in clinic) and 2 (by phone).
89318893|NCT03694197|Experimental|Open label|
89318894|NCT02112760|Experimental|Patient|To evaluate the effect of specific stabilization intervention in recurrent low back pain participants
89318895|NCT02119546|Experimental|Exercise intervention|Aerobic exercise and dual-task training
89318896|NCT02119546|Active Comparator|Stretch exercise|Stretch exercise & sitting balance
89318897|NCT02251444|Experimental|outpatient rehabilitation program|whole-body resistance training, psychological interventions, sessions for information related to ergonomics and healthy alimentation
89318898|NCT02251444|Active Comparator|physical therapy|prescribed physical therapy
89318899|NCT04365699|Experimental|Interventional Patients: AT-001|AT-001 1500 mg (3 capsules) were administered by mouth twice daily for up to 14 days
89318900|NCT04365699|No Intervention|Control Match Group 1|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The first matching approach selected all subjects with diabetes mellitus and hypertension, and available data to match participants who received AT-001 for gender, age group (in bins of 5 years), weight, and C-reactive protein (CRP) value at the time of hospital admission.
89318901|NCT04365699|No Intervention|Control Match Group 2|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The second matching approach selected all subjects in the registry with diabetes mellitus and available data to match participants who received AT-001 for gender, age group (in bings of 5 years), and weight (+/- 0.5 kgs).
89318902|NCT04005885|Experimental|somofilcon A then stenfilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear somofilcon A daily disposable test lens for 1 week of daily wear and stenfilcon A daily disposable test lens for 1 week of daily wear.
89318903|NCT04005885|Experimental|stenfilcon A then somofilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear stenfilcon A daily disposable test lens for 1 week of daily wear and somofilcon A daily disposable test lens for 1 week of daily wear.
89318904|NCT04003623|Experimental|Pemigatinib|
89318905|NCT01562847||Nilotinib|
89318906|NCT03744195|Experimental|Group I Experimental Kinesotaping|Application of kinesotaping along with conventional treatment
89318907|NCT03744195|Active Comparator|Group II conventional training group|Application of conventional treatment
89318908|NCT04480424|Experimental|GAMUNEX-C + Standard Medical Treatment|Participants received 2 grams per kilogram (g/kg) of GAMUNEX-C, which was capped to a maximum of 160 g infusion intravenously (IV) for participants weighing more than 80 kg on Day 1. The 2 g/kg net total dose was divided either into infusions of 500 mg/kg body weight over 4 days or 400 mg/kg body weight over 5 days as per investigator's decision. Participants received standard of care interventions as per Principal Investigator's discretion from Day 1 up to Day 29.
89318909|NCT04480424|Active Comparator|Standard Medical Treatment|Participants received all standard of care interventions required as per Principal Investigator's discretion throughout the participant's hospitalization, from Day 1 to Day 29.
89318910|NCT03745443|Experimental|Intervention group|Intervention: increase and decrease positive end-expiratory pressure. PEEP titration: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11 ventilation was maintained on PEEP 11 for 2 minutes.Then, PEEP was reduced by 2 for every 5 breaths to 5.Total time to titrate was 5 minutes.
89318911|NCT03745443|No Intervention|Control|Ventilation with PEEP 3 during anesthesia and surgery
89318912|NCT01562769||Standard precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
89318913|NCT01562769||contact precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
89318914|NCT04474886|Experimental|Fresubin® powder fibre|2 servings of Fresubin® powder fibre per day as supplement to normal diet
89318915|NCT04474886|No Intervention|Usual diet|Maintain usual diet
89318916|NCT03891680|Experimental|Botox injection|
89318917|NCT03891680|Active Comparator|Genicular Radio frequency|
89318918|NCT03887234|Active Comparator|Through the coracoid|The semitendinosus tendon graft goes through the 4.5 mm coracoid drill hole.
89318919|NCT03887234|Experimental|Around the coracoid|The semitendinosus tendon graft goes around the coracoid.
89318920|NCT03256526|Placebo Comparator|Placebo|
89318921|NCT03256526|Experimental|PF-06835919 Low Dose|75 mg once daily
89318922|NCT03256526|Experimental|PF-06835919 High Dose|300 mg once daily
89318923|NCT03255980|Experimental|Xonrid®|Xonrid® is a medical device for radiation dermatitis
89318924|NCT03255980|Active Comparator|Standard of Care|Standard of care suggested by MASCC guidelines
89318925|NCT03228212|Experimental|TEST/CONTROL/CONTROL|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)
89318926|NCT03228212|Experimental|CONTROL/TEST/TEST|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)
89318927|NCT04000815|Active Comparator|Reproductive age women|The healthy women between 18-40 years old.
89318928|NCT04000815|Active Comparator|Perimenopausal women|The healthy women between 40-49 years old.
89318929|NCT04000815|Active Comparator|Postmenopausal women|The healthy women that has been in to menopause more than a year
89318930|NCT04000581|Active Comparator|Arm I (usual care)|Patients walk one to two laps around the ward twice per day, and have mobility tracked with Xsens over 5-10 minutes, until discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
89318931|NCT04000581|Experimental|Arm II (additional mobility)|Patients walk for minimum 30 minutes per day and mobility is tracked with Xsens over 5-10 minutes up to discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
89318932|NCT03919617|Experimental|Open-Label REMD-477|
89318933|NCT03748251|Experimental|Short fermented pizza|the patients ate a pizza that fermented for 8 hours
89318934|NCT03748251|Experimental|Long fermented pizza|the patients ate a pizza that fermented for 24 hours
89318935|NCT03748173|Experimental|Treatment|Subjects randomized to the aerosol surfactant evaluation will occur at the end of 60 minutes, with the aerosol continued if the bronchiolitis score is > 4 or there has been less than a 2-point improvement in the bronchiolitis score. Similar evaluation will be performed, if necessary, at 30-minute intervals (maximum 2 hours) with stoppage of the aerosol for an improved bronchiolitis score (≤ 4 or 2-point improvement) at any of the time points. The aerosol would be stopped at any time for significant sustained deterioration in clinical status or any serious adverse event felt related to the treatment. Retreatment can be given at > 4 but < 24 hours if the initial response was positive and there has been subsequent deterioration.
89318936|NCT03748173|No Intervention|Usual Care|The only difference in care between treatment and usual care will be treatment with up to two doses of aerosolized Infasurf®.
89318937|NCT03848403|Experimental|Ixekizumab (Reference)|Reference formulation 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection in a prefilled syringe in one of three study periods.
89318938|NCT03848403|Experimental|Ixekizumab (Test 1)|Test 1 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
89318939|NCT03848403|Experimental|Ixekizumab (Test 2)|Test 2 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
89318940|NCT03745365|Experimental|sleeve gastrectomy|"The greater omentum is divided 5 cm from the pylorus with an energy device. The antral pouch is measured 2-6cm from the pylorus along greater curve as risk benefit ratio is best within these limits.~Devascularization is continued up the greater curve of the stomach to the short gastric vessels with the help of the assistant who maintains traction and exposure during this process. Eventually, one reaches the left crus which is an important landmark of dissection. We selectively explore the hiatus of the symptomatic and endoscopically proven hiatus hernia , and the hernia should be reduced and repaired."
89318941|NCT03745365|Experimental|sleeve gastrectomy with loop bipartition|Sleeve gastrectomy is performed first, then a loop gastro-ileostomy 200-250 cm from doudeno-jejunal junction was created at the dependent part of the antrum with 2 layers of with stapler but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastro-ileostomy. The staple line and anastomosis was tested with methylene blue. A drain is inserted.
89318942|NCT03737409|Experimental|Oxygen therapy with POC (AOT group)|Patients will receive ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
89318943|NCT03737409|Sham Comparator|Sham oxygen therapy with POC (air group)|Patients will receive sham ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
89318944|NCT04054011|Experimental|deoxycholic acid|Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)
89318945|NCT04053465|Experimental|Exercise in heat group|Exercise in a hot environment
89318946|NCT04053465|Placebo Comparator|Exercise in cool group|Exercise in a cool environment
89318947|NCT03743961||Group A : control group|"Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients with 14 Questions) and QoL EORTC Q30 (Quality Qf Life with 30 Questions)~for patients with G8 score > 14/17"
88814885|NCT03030326|Experimental|Heart rate variability biofeedback|This group will receive treatment in the first three months of the study and will be observed during the second three months
89318948|NCT03743961||Group B : geriatric intervention group|Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients) and QoL (Quality Qf Life) EORTC Q30 for patients with G8 score ≤14/17 ( in this arm there is two groups : patient who received geriatric intervention before treatment initiation (group A) and group of patient did not received geriatric intervention before treatment initiation( group B))
89318949|NCT03743883||Low-dose ASA cohort|A person is identified as newly exposed to low-dose ASA, he/she will become member of new user low-dose ASA cohort and that date will be the start date for outcome follow-up.
89318950|NCT03743883||Comparison unexposed cohort|When a member of new user low-dose ASA cohort is confirmed, one comparison member will be confirmed also from the source population not yet censored on that day (start date) and with the same distribution of matching factors (age, sex, time interval since entry date and number of PCP visits in the year prior to start date) of its low-dose ASA pair with the only difference of being free of ASA on start date.
89318951|NCT01562925|Active Comparator|Red Wine|Patients assigned to red wine group will receive standard care plus two doses of red wine: the evening before contrast-medium use and the morning of contrast-medium exposure
89318952|NCT01562925|Active Comparator|White wine|
89318953|NCT01562925|Active Comparator|Beer|
89318954|NCT01562925|No Intervention|Control|Patients assigned to control group will receive standard care. Patients receive ordinary still water without alcohol the evening before(7.8 ml per kg bodyweight) and 60-120 minutes before contrast exposure (at least 3.9 ml per kg bodyweight)
89318955|NCT03737175|Experimental|Carotid Artery Stenting group|Carotid Artery Stenting
89318956|NCT03737175|Active Comparator|Carotid Endarterectomy group|Carotid Endarterectomy
89318957|NCT00143507|Experimental|Ivabradine|
89318958|NCT00143507|Placebo Comparator|Placebo|
89318959|NCT03988803|Experimental|All subjects|
89318960|NCT00181883|Experimental|Quetiapine|"2.5 - 5.0mg/kg PO BID quetiapine~Other Names:~Seroquel"
89318961|NCT00180713|Placebo Comparator|Arm 1: Control|Placebo tablet once daily
89318962|NCT00180713|Experimental|Arm 2: Experimental|Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
89318963|NCT02531477|Experimental|experimental group|Intracarotid injection of propofol to detect efficacy and safety as a novel route for drug delivery
89318964|NCT03988023|Experimental|AMPION™ 4 mL dose|4 mL injection of Ampion
89318965|NCT03988023|Placebo Comparator|Saline|4 mL injection of placebo
89318966|NCT04052139|Active Comparator|Low-dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
89318967|NCT04052139|Active Comparator|Gabapentin|Participants randomized to the gabapentin arm begin on a dose of 300 mg daily (300 mg qd). In week 2, participants will take 300 mg of gabapentin three times daily. In week 3 the dose will be titrated up to 1800 mg daily (300 mg+300 mg tid) will remain on the dose until week 8, when they will be tapered back down to 900 mg daily (300 mg tid). In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
89318968|NCT04052139|Placebo Comparator|Placebo|Participants will receive a placebo to be taken three times daily for 8 weeks.
89318969|NCT03745209|Experimental|Ultrasound-guided peripheral IV.|Ultrasound-guided peripheral IV cannulation
89318970|NCT03745209|No Intervention|Traditional landmark technique|Traditional landmark technique
89318971|NCT03737097|Experimental|Online Spaced Education|The intervention cohort will participate in an online spaced education on fall prevention education developed for patients with multiple sclerosis.
89318972|NCT03737097|Active Comparator|Brochure Education|The control cohort will receive the fall prevention education in bolus through a Brochure developed by the National Multiple Sclerosis Society. The brochure was translated to portuguese and will be used in the study with authorization of the Society.
89318973|NCT03737019|Experimental|ACT in County Council of Kalmar|Group education with ACT in six primary health care centers in County Council of Kalmar
89318974|NCT03737019|Placebo Comparator|Control health care centers of County Council of Jönköping|Five primary health care centers of County Council of Jönköping that do not get education.
89318975|NCT03743805|Experimental|Reversal drugs|Flumazenil and naloxone
89318976|NCT05668533|Active Comparator|1. Interscalene group|Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).
89318977|NCT05668533|Active Comparator|2. PENG Block|Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).
89318978|NCT03984825|Experimental|Portia followed by Portia co-administered with GSK3640254|Subjects will be administered Portia (0.03 mg EE/0.15 mg LNG) once daily on Days -3 to -1 during run-in period and on Days 1 to 10 in treatment period A. Subjects will then receive Portia (0.03 mg EE/0.15 mg LNG) co-administered with GSK3640254 200 mg once daily on Days 11 to 21 in treatment period B.
89318979|NCT03743727|Experimental|Combined Therapy LDV and SOF|
89318980|NCT03745131||Pre-exposure prophylaxis recipients|40 healthcare workers who provide specialist medical care to patients with monkeypox and who received vaccine as pre-exposure prophylaxis.
89318981|NCT03745131||Post-exposure prophylaxis recipients|40 healthcare workers who received vaccine as post-exposure prophylaxis following monkeypox-exposure risk assessments.
89318982|NCT03745131||Control Group 1|20 healthcare workers who provided specialist medical care to patients with monkeypox but declined the offer of vaccine as pre-exposure prophylaxis.
89318983|NCT03745131||Control Group 2|Healthcare workers not involved in the care of, and have not had known exposure to, patients with monkeypox and, therefore, were not offered vaccine.
89318984|NCT03736551|Experimental|Intervention|The intervention arm will involve standard care plus an intermittent modified fasting regimen consisting of a very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet). All dietary intake on modified fasting days will be from LighterLife foodpacks, (4 x 150 kcal portions/day presented as milkshakes, cereal bars, soups and modified meals such as spaghetti bolognese, or macaroni cheese) providing ~600 kcal/day and 100% of the RNI for vitamins and minerals.
89318985|NCT03736551|Active Comparator|Standard Care|Renal Weight management Programme - Patients will attend individual appointments with the specialist dietitian and physiotherapist once a month, for 6 months. Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure (9). In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
89318986|NCT03981861|Experimental|Overall Study|Treatment with Metformin and Spironolactone
89318987|NCT03736473|Other|MEDI9447 monotherapy|Dose escalation of MEDI9447 monotherapy for patients with advanced solid malignancies
89318988|NCT01332266|Active Comparator|Active Comparator; Phase 1b: Cohort 1,2,and 3|"Phase 1b:~Cohort 1; 200 mg E7050 + 250 mg/m2 cetuximab Cohort 2; 300 mg E7050 + 250 mg/m2 cetuximab Cohort 3; 400mg E7050 + 250mg/m2 cetuximab~Phase 2: Arm 1; MTD E7050 + 250 mg cetuximab Arm 2; 250 mg cetuximab~Interventions: Drug cetuximab"
89318989|NCT01332266|Active Comparator|Phase 2|"Phase 2:~Arm 1; MTD E7050 + 250 mg/m2 cetuximab Arm 2; 250 mg/m2 cetuximab"
89318990|NCT03736317|Sham Comparator|control group|Sham TBS delivered on left dlPFC or medial prefrontal cortex of amphetamine-dependent patients. Stimulation pulses are the same as the real group.
89318991|NCT03736317|Experimental|real mPFC cTBS group|The real cTBS stimulation pattern will be delivered on the medial prefrontal cortex.
89318992|NCT03736317|Experimental|real dlPFC iTBS group|The real iTBS stimulation pattern will be delivered on the left dorsal prefrontal cortex.
89318993|NCT03736317|Experimental|real dlPFC iTBS + real mPFC cTBS group|Combination therapy of real iTBS stimulation delivered on the left dorsal prefrontal cortex and real cTBS stimulation delivered on the medial prefrontal cortex.
89318994|NCT03127839|Active Comparator|Eccentric Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing eccentric strengthening exercises of the rotator cuff to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the eccentric strengthening exercises daily at home.
89318995|NCT03127839|Active Comparator|Traditional Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing traditional rotator cuff strengthening exercises to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the traditional rotator cuff strengthening exercises daily at home.
89318996|NCT03127839|Active Comparator|Eccentric Exercise + pain education|"In addition to the treatment provided in the Eccentric Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
89318997|NCT03127839|Active Comparator|Traditional Exercise + pain education|"In addition to the treatment provided in the Traditional Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
89318998|NCT03637712|Experimental|Screening Colonoscopy|Patients undergoing standard screening or surveillance colonoscopy will be included
89318999|NCT03255824|Active Comparator|Propofol Group|Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination.
89319000|NCT03255824|Experimental|Dexmedetomidine Group|Group of patients to be administered the Dexmedetomidine and Midazolam anesthesia combination.
89319001|NCT03238352|Experimental|Test Product|Participants will rinse twice daily (morning and evening) with 10 milliliters (mL) of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
89319002|NCT03238352|Other|Negative Control|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
89319003|NCT03238352|Placebo Comparator|Placebo|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
89319004|NCT04284254|Experimental|Phase 1: Dose Escalation|
89319005|NCT04284254|Experimental|Phase 2 - Expansion at MTD|
89319006|NCT01222754|Experimental|1|Radiation with Lenalidomide
89319007|NCT05179694|Experimental|Local Anaesthetic Transperineal Prostate Biopsy (LATP)|"LATP prostate biopsy performed with an average of 12 biopsy cores in 6 sectors depending on prostate size, plus typically 4 target cores per MRI lesion, using an ultrasound probe-mounted LATP needle guidance device (e.g. the Precision-Point access system, or BK UA1232, or any other which is used in a virtually identical fashion)."
89319008|NCT05179694|Active Comparator|Transrrectal Ultrasound-guided Prostate Biopsy (TRUS)|TRUS prostate biopsy performed according to each hospital's standard practice, with an average of 12 biopsy cores, in two sectors with additional target pots (typically 4 target cores per MRI lesion).
89319009|NCT05280782|Experimental|Dosimetry Group|Normal Volunteers will receive a single intravenous injection of 8 mCi ± 20% (6.4-9.6 mCi) of the PET radiotracer 68Ga-Galmydar. They will undergo whole-body PET/CT imaging at three-time points, immediately post [68Ga]Galmydar injection, and at 2 hours and 4 hours after injection. Serum chemistries, complete blood count, EKG, vital signs, and physical examination will performed before injection and at the completion of the examinations.
89319010|NCT05274308||Patient blood sample collection|30 mL of whole blood collected from eligible patients in one sampling
89319011|NCT05256914|Experimental|Peri-implant mucositis sites|Peri-implant mucositis sites will be randomly assigned to ozone treatment.
89319012|NCT05256914|Experimental|Contralateral peri-implant mucositis sites|Contralateral peri-implant mucositis sites with respect to those treated with ozone will be assigned to chlorhexidine treatment.
89319013|NCT03842150||derivation cohort|
89319014|NCT03842150||validation cohort|
89319015|NCT05175482|Experimental|Education received group|Health belief model based education on HPV infection and vaccination
89319016|NCT05175482|No Intervention|Control Group|No virtual education
89319017|NCT00180479|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
89319018|NCT00180479|Active Comparator|2|TAXUS® EXPRESS2™Paclitaxel Eluting Coronary Stent System
89319019|NCT05173064|Experimental|Machine learning-based exercise training system|Participants will join 6 individual exercise sessions (i.e., 20 minutes each session, once every two weeks) in our lab. During the exercise sessions, they will use the machine learning-based exercise training system to perform lower limb exercises. In addition, participants will receive an educational booklet on knee pain management. They will be encouraged to perform exercises at home at least 3 times per week over a 12-week period.
89319020|NCT05173064|Experimental|Video-based exercise training system|Participants will join 6 individual exercise sessions (i.e., 20 minutes each session, once every two weeks) in our lab. During the exercise sessions, they will use the video-based exercise training system to perform lower limb exercises. In addition, participants will receive an educational booklet on knee pain management. They will be encouraged to perform exercises at home at least 3 times per week over a 12-week period.
89319021|NCT05173064|No Intervention|Usual care|Participants will receive the same educational booklet as the other groups. They will be encouraged to perform exercises at home at least 3 times per week over a 12-week period. No other intervention will be provided.
89319022|NCT03224234|Experimental|Insulclock with feedback (Group A)|Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
89319023|NCT03224234|Active Comparator|Insulclock without feedback (Group B)|Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
89319024|NCT03636776|Experimental|quality of life in metastatic BC|"Patients benefit from a longitudinal follow-up determined according to the treatments.~Each type of treatment has its own schedule based on medical consultation times. At each change of treatment, from chemotherapy to hormone therapy or vice versa, the assessment times are determined according to the nature of the treatment.~The rhythm of the evaluation visits will therefore be defined by the doctor, according to the habits of the centre.~The evaluation times used to collect the questionnaires (QLQ-C30, BR23, PDS, STAI, BDI II)."
89319025|NCT05169944|Experimental|Treatment (Magrolimab)|Each participant will receive magrolimab intravenously (IV) at a priming dose of 1 mg/kg during Cycle 0, followed by either 30 mg/kg or 45mg mg/kg dose weekly for eight weeks (Cycles 1 and 2), followed by either 30 mg/kg or 45 mg/kg dose every two weeks for the remainder of the study.
89319026|NCT02955069|Experimental|PDR001|Subjects with advanced or metastatic, well-differentiated, NET of pancreatic, GI, or thoracic origin or poorly-differentiated GEP-NEC, that have progressed on prior treatment were treated with 400mg PDR001 administered via intravenous infusion once every 4 weeks.
89319027|NCT03254108|Experimental|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
89319028|NCT03254108|Experimental|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
89319029|NCT03254108|Experimental|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
89319030|NCT03254108|Experimental|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
89319031|NCT03254108|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
89319032|NCT02585895|Experimental|Evolocumab|Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
89319033|NCT02585895|Active Comparator|Low Density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
89319034|NCT03736161|Experimental|Group A- Tofacitinib|Tofacitinib 5mg twice daily orally. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD.
89319035|NCT03736161|Placebo Comparator|Group B- Methotrexate|Methotrexate in increasing dose starting from 15 mg weekly to a maximum dose of 25 mg weekly from the end of 1st month. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD.
89319036|NCT03773978|Experimental|Baricitinib|Baricitinib was administered QD (once daily) as a 4-mg oral tablet for adolescent participants (12 to <18 years of age) and children ≥9 years of age; and 2 mg for children <9 years of age. Participants <6 years of age received an oral suspension. Participants ≥6 to <12 years old had the option of receiving an oral suspension. Participants >12 years old were supplied tablets. The oral suspension dose was administered as 4-mg, 2-mg, 1-mg, and 0.5-mg as needed.
89319037|NCT03773978|Placebo Comparator|Placebo|Placebo matched to baricitinib was administered to participants during the DBW period.
88806557|NCT02528214|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
89319038|NCT03682107|Experimental|Arm 1 (2 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.~11 subjects assigned to the 3-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
89319039|NCT03682107|Experimental|Arm 2 (2 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.~11 subjects assigned to the 4-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
89319040|NCT03682107|Experimental|Arm 3 (4 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.~11 subjects assigned to the 3-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
89319041|NCT03682107|Experimental|Arm 4 (4 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.~11 subjects assigned to the 4-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
89319042|NCT03673046|Experimental|Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)|12-week Smartphone-delivered CBT for BDD.
89319043|NCT03673046|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
89319044|NCT02956005|Other|Envarsus|Open Label; Envarsus XR started at the time of transplant. Initial dosing of 0.17mg/kg. Target trough level of 8-10 ng/mL
89319045|NCT02579499|Active Comparator|Fixed high-potent statin group|According to 2013 ACC/AHA guideline, patients will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels.
89319046|NCT02579499|Experimental|Targeted LDL-C goal statin group|Patients will be tiltrated statin intensity guided by follow-up LDL-C level
89319047|NCT03253094|Active Comparator|Fluconazole|150 mg/day for 1 day
89319048|NCT03253094|Experimental|Ibrexafungerp 750mg|750mg QD for 1 day only
89319049|NCT03253094|Experimental|Ibrexafungerp 300mg|300mg BID for 1 day only
89319050|NCT03253094|Experimental|Ibrexafungerp 450mg|450mg BID for 1 day only
89319051|NCT03253094|Experimental|Ibrexafungerp 150mg|150mg BID for 3 days
89319052|NCT03253094|Experimental|Ibrexafungerp 300mg D1-D3|300mg BID for 3 days
89319053|NCT03654885|Active Comparator|XEN-45 Gel Stent|Participants underwent at least one preoperative visit and had XEN-45 gel stent implantation on Day 0 (The day of surgery).
89319054|NCT03654885|Active Comparator|Trabeculectomy|Participants underwent at least one preoperative visit and had trabeculectomy as per standard of care in each investigative center on Day 0 (The day of surgery).
89319055|NCT03736083|Active Comparator|Freestyle Libre Group|Freestyle Libre Group: Participants will use the Freestyle Libre flash glucose monitoring system throughout the study for 2-3 months.
89319056|NCT03736083|No Intervention|Control Group (standard diabetes care)|This group will receive standard care. At the around 1 week and 2 month visits, control group subjects will use a blinded Freestyle Libre Pro to provide data that can be used to compare glucose variability between groups. The Libre sensor will allow the study team to measure glucose values but the subjects will not have access to this information for management/treatment decisions and usual diabetes care will be unaffected. The Freestyle Libre Pro last 14 days, can be activated in clinic, and the sensor can be returned in person or via mail where the investigators will download the data.
89319057|NCT03236246|Experimental|Group 1|KRX-0502 1 tablet thrice daily (TID) with meals
89319058|NCT03236246|Experimental|Group 2|KRX-0502 2 tablets twice daily (BID) with the largest 2 daily meals
89319059|NCT05179070|Experimental|UpTitration|the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively
89319060|NCT05179070|Active Comparator|Control|And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
89319061|NCT05178836|Experimental|F520+F007|"Treatment period：~F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 14-day cycle for 8 cycles.~F520 (200mg) administered intravenously (IV) on Day 2 of each 14-day cycle for cycle 1.~F520 (200mg) administered intravenously (IV) on Day 1 of each 14-day cycle for cycle 2 to 8.~Maintenance period：~F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 56-day cycle for 10 cycles.~F520 (200mg) administered intravenously (IV) on Day 1/15/29/43 of each 56-day cycle for 10 cycles."
89319062|NCT01314170|No Intervention|Susanna Implant|Patients with refractory glaucoma neovascular type or that failed in trabeculectomy will undergo surgery to place implants Susana.
88806558|NCT00392678|Placebo Comparator|Placebo|Placebo, appearance matched to active drug
88806559|NCT00392678|Active Comparator|3 gram|Salsalate 3.0 grams daily, divided
88806560|NCT00392678|Active Comparator|3.5 gram|Salsalate 3.5 g daily, divided
89319063|NCT03637088|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
89319064|NCT03637088|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
89319065|NCT02937584|Experimental|GP MDI (PT001) 14.4 μg|Glycopyrronium
89319066|NCT02937584|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
89319067|NCT00179621|Placebo Comparator|Placebo|Placebo matching to active study arms.
89319068|NCT00179621|Experimental|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
89319069|NCT00179621|Experimental|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
89319070|NCT02531399|Experimental|Healthy Subjects|20 healthy female and male volunteers, age 18-45 years, non-smokers. Measurements with FDOCT, DVA, LDV and LSFG will be done in all healthy subjects.
89319071|NCT00179309|Experimental|Arm I - PANVAC + docetaxel|Patients receive vaccinia-carcinoembryonic antigen (CEA)- mucin-1 (MUC-1)- triad of costimulatory molecules (TRICOM) vaccine subcutaneously (SC) once and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) SC once daily for 4 days in week -2. Patients also receive fowlpox-CEA-MUC-1-TRICOM vaccine SC once and GM-CSF SC once daily for 4 days in weeks 1, 5, and 9. Patients also receive docetaxel intravenous (IV) over 30 minutes once weekly in weeks 1-3, 5-7, and 9-11. After week 12, patients with no disease progression continue with docetaxel once weekly for 3 weeks followed by 1 week of rest and fowlpox-CEA-MUC-1-TRICOM vaccine plus GM-CSF every 4 weeks until disease progression.
89319072|NCT00179309|Experimental|Arm II - Docetaxel alone|Patients receive docetaxel as in arm I. After week 12, patients with disease progression discontinue docetaxel and receive vaccinia-carcinoembryonic antigen (CEA)- mucin 1(MUC-1)-triad of costimulatory molecules (TRICOM) vaccine, fowlpox-CEA-MUC-1-TRICOM vaccine, and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) as in arm I until further disease progression. Patients with no disease progression after week 12 continue with docetaxel as in arm I until disease progression.
89319073|NCT03594500|Experimental|Intervention: PockeTalker|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
89319074|NCT03594500|Other|Control: No PockeTalker|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
89319075|NCT02933528|Experimental|Dsxs topical product|treatment with DSXS once daily for 28 days
89319076|NCT01075919|Active Comparator|DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA
89319077|NCT01075919|Active Comparator|EPA-rich fish oil|1 g EPA-rich fish oil containing 300 mg EPA + 200 mg DHA
89319078|NCT01075919|Placebo Comparator|Placebo|1 g Olive oil
89319079|NCT00177671|Experimental|1|"escitalopram plus donepezil (DNP)in the experimental maintenance phase of the study.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation donepezil.~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
89319080|NCT00177671|Placebo Comparator|2|"escitalopram plus placebo (PBO) in the experimental maintenance phase of the study.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo.~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of venlafaxine or duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
89319081|NCT02933060|Experimental|IV fluid bolus|Patients will receive a 1000 ml bolus of normal saline, administered over 60 minutes.
89319082|NCT02933060|Sham Comparator|Control|Patients will have an IV catheter and will be connected to an IV bag, but will receive only 10 ml of normal saline over 60 minutes.
89319083|NCT05178602|Experimental|The experimental group|Routine treatment, and tai Chi exercise,5 times a week
89319084|NCT05178602|No Intervention|The control group|Routine treatment, and cardiac rehabilitation is not mandatory
89319085|NCT05178368||Early aortic valve replacement|Asymptomatic severe aortic stenosis patients randomised to early aortic valve replacement
89319086|NCT05178368||Standard care|Asymptomatic severe aortic stenosis patients randomised to 'watchful waiting' until symptom onset.
89319087|NCT03235154|Other|Treatment Arm|In this open label, single arm study, all subjects will receive the intervention as prescribed by psychiatrists in the office based opiate addition treatment program.
89319088|NCT05178290|Experimental|CHILD testing|One child and parent dyad will be tested for COVID-19 using the ASU saliva test as part of back-to-ECE safely programming. All sites will receive this condition.
89319089|NCT05178290|Experimental|CHILD+ personnel testing|This arm receives the CHILD condition plus ECE site personnel are screened biweekly for COVID-19 using the ASU saliva test.
89319090|NCT05178290|Experimental|SAGE garden|The SAGE arm is a garden-based curriculum that emphasizes outdoor learning opportunities such as active games, songs, and garden-activities. About half of the original 40 sites (roughly evenly divided by CHILD and CHILD+) will receive this in year one, and the remaining sites will receive this condition in year two.
89319091|NCT05178290|Sham Comparator|Wait list|Those in the wait list condition will receive SAGE in year two.
89319092|NCT03234608|Experimental|AASPIRE Healthcare Toolkit|Patients will use the AASPIRE Healthcare Toolkit and will share a copy of their Autism Healthcare Accommodations Report with their primary care provider.
89319093|NCT03234608|No Intervention|Usual Care|Patients will receive usual care.
89319094|NCT03248882|Placebo Comparator|Placebo|Double-Blind, PF-05221304-matching Placebo
89319095|NCT03248882|Active Comparator|PF-05221304 - 2 mg|PF-05221304 - 2 mg, once-daily
89319096|NCT03248882|Active Comparator|PF-05221304 - 10 mg|PF-05221304 - 10 mg, once-daily
89319097|NCT03248882|Active Comparator|PF-05221304 - 25 mg|PF-05221304 - 25 mg, once-daily
89319098|NCT03248882|Active Comparator|PF-05221304 - 50 mg|PF-05221304 - 50 mg, once-daily
89319099|NCT02116738|Experimental|Flap Transposition Technique|Flap Transposition Technique
89319100|NCT03233438|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
89319101|NCT03233438|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
89319102|NCT02116816|Experimental|Polyphenol|Polyphenol preparations
89319103|NCT02251600|Experimental|Deflazacort|This is an open label and single period study , dosed with 0.9mg/kg Deflazacort.
89319104|NCT02119624||1|Healthy non-treatment-seeking heavy drinkers
89319105|NCT02119624||2|Healthy light drinkers
89319106|NCT02888288|Experimental|Mental Health Intervention|This arm was designed based on mental health needs of HIV-infected youth in Tanzania. It incorporates principles of cognitive behavioral therapy, interpersonal psychotherapy, and motivational interviewing built into 10 group sessions, approximately 90 minutes each (2 sessions with caregiver participation) and 2 individual sessions. Groups are age and gender matched and facilitated by lay counselors with a mix of lived experience and prior mental health research experience.
89319107|NCT02888288|Active Comparator|Standard of Care|This arm includes standard medical care and adherence counseling with routine education prior to the start of the HIV youth clinic from which participants are recruited.
89319108|NCT02116894|Experimental|PF-03446962 plus regorafenib|
89319109|NCT02856620||Moderate AS with HF|
89319110|NCT02856620||Severe AS with HF|
89319111|NCT02856620||Moderate AS without HF|
89319112|NCT02856620||Severe AS without HF|
89319113|NCT02856620||HFpEF without AS|
89319114|NCT02856620||Normal age-matched controls|
89319115|NCT02113072|Experimental|Probiotics & Beclomethasone|"It will be supplied in lyophilized form, in each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.~Beclomethasone HFA 50mcg spray - 100 mcg/day as initial treatment for primary and wheezing in this age group, at doses considered minimal, for 4 months."
89319116|NCT02113072|Active Comparator|Beclomethasone & Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics. It will be supplied in lyophilized form in each sachet containing 1 g of placebo, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
89319117|NCT02113150|Active Comparator|remifentanil|remifentanil, short acting opioid
89319118|NCT02113150|Active Comparator|ketamine|ketamine, intravenous anesthetic
89319119|NCT04647500|Other|22q11DS naive|22q11DS participants naive to methylphenidate
89319120|NCT04647500|Other|22q11DS consumer|22q11DS participants with a prolonged treatment of methylphenidate
89319121|NCT02113228||Short Bowel Syndrome|Verify the total energy expenditure in patients with short bowel syndrome using the doubly labeled water method.
89319122|NCT02113228||Control Group|Verify the total energy expenditure in patients without short bowel syndrome using the doubly labeled water method.
89319123|NCT01368406|Experimental|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
89319124|NCT01368406|No Intervention|treatment as usual|patients were on regular visits on psychiatrist
89319125|NCT02119780|Experimental|YVOIRE® contour|
89319126|NCT02119780|Active Comparator|Restylane SubQ™|
89319127|NCT02113306|Experimental|t-VNS|"electrical stimulation of the concha of the ear~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
89319128|NCT02113306|Sham Comparator|sham t-VNS|"Sham stimulation of the earlobe will be conducted by positioning the electrode upside down~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
89319129|NCT02113384||Observational study|Patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
89319130|NCT03553108|Experimental|Olaparib Treatment Sequence ABCD|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg"
89319131|NCT03553108|Experimental|Olaparib Treatment Sequence BDAC|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg"
89319132|NCT03553108|Experimental|Olaparib Treatment Sequence CADB|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg"
89319133|NCT03553108|Experimental|Olaparib Treatment Sequence DCBA|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg"
89319134|NCT02119858|Experimental|Diagnostic (ICG, diffuse optical imaging, surgery)|Patients receive indocyanine green transperineally and undergo diffuse optical imaging during robot-assisted laparoscopic radical prostatectomy with bilateral lymph node dissection using the da Vinci Robotic Surgical System.
89319135|NCT02117128|Experimental|Tranexamic acid, IA group|Tranexamic acid 1g, intra-articular injection, post-operationally
89319136|NCT02117128|Active Comparator|Tranexamic acid, IV group|Tranexamic acid, 1g, intravenous injection, post-operationally
89319137|NCT02117128|Experimental|Tranexamic acid, IV+IA group|Tranexamic acid, 1g, intravenous injection, post-operationally; Tranexamic acid, 1g, intra-articular injection, post-operationally
89319138|NCT02117206|Active Comparator|L-Arginine|Femoral arterial infusion of 2 g L-Arginine for 30 min
89319139|NCT02117206|Placebo Comparator|Nacl|Femoral arterial infusion of Nacl for 30 min
89319140|NCT00175877|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
89319141|NCT02120014|Experimental|Heart Failure Reduced EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.~Measurements form the right heart catheterization will be recorded for analysis."
89319142|NCT02120014|Experimental|Heart Failure Preserved EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.~Measurements form the right heart catheterization will be recorded for analysis."
89319143|NCT02117284||Coronary artery disease|All patients present to participating nuclear imaging facilities for diagnosis of CAD and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the clinical indications listed in the approved Ruby-Fill product monograph.
89319144|NCT02117362|Experimental|Cohort 1|1 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
89319145|NCT02117362|Experimental|Cohort 2|2 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
89319146|NCT02117362|Experimental|Cohort 3|4 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
89319147|NCT02117362|Experimental|Cohort 4|8 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
89319148|NCT02113540|Placebo Comparator|placebo group|taking atorvastatin like placebo 12 hours before the procedure
89319149|NCT02113540|No Intervention|long term statin group|taking atorvastatin for a long time before entering the study (their routine treatment)
89319150|NCT02113540|Experimental|preoperation statin group|taking atorvastatin 12 hours before the procedure
89319151|NCT02113618|Active Comparator|Cogmed Training|Cogmed® working memory training is a computer program that will be administered online. The program consists of 7 verbal and non-verbal working memory tasks and gives immediate performance feedback to the subject undergoing training.
89319152|NCT02113618|Placebo Comparator|Standard training|Individuals randomised to the placebo arm will receive a standard training online program from Cogmed also consisting of 90 trials to be performed 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level.
89319153|NCT03552484|Active Comparator|Home Visit Arm|"Participants and their caregivers, when available, will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~[Completion of Home Visit Program]"
89319154|NCT03552484|Active Comparator|Usual Care Arm|"Participants and their caregivers, when available, will be asked to complete an initial online survey. Twelve months later, patients (and caregivers, if available) will be asked to complete an online follow-up survey.~[Completion of Usual Care/Online Survey]"
89319155|NCT02122978|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
89319156|NCT02122978|Experimental|MBSCT 8 week course|Mindfulness Based Self Compassion Therapy
89319157|NCT02122978|Active Comparator|Mindfulness Based Self-Compassion - Audio guided|MBSC - minimal contact
89319158|NCT02117518||no treatment|T1D patients at ages 0-25
89319159|NCT02123056|Active Comparator|Metoprolol|Metoprolol 50 mg po tablets will be provided for final dosing range (25 mg po BID to 100 mg po BID) for study duration (1 year). Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
89319160|NCT02123056|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill. Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
89319161|NCT02120092|Active Comparator|Clopidogrel + ASA|
89319162|NCT02120092|Placebo Comparator|Clopidogrel + Placebo|
89319163|NCT02120092|Active Comparator|Ticagrelor + ASA|
89319164|NCT02120092|Placebo Comparator|Ticagrelor + Placebo|
89319165|NCT02117596|Other|Sirolimus|Single arm
89319166|NCT02120170|Active Comparator|Hemoclipping during colon polypectomy for all lesion|The enrolled patients of group 1 will be performed hemoclipping for all polypectomy lesion irrespective of the presence of immediate bleeding.
89319167|NCT02120170|No Intervention|No hemoclipping if there were no bleeding during polypectomy|The patients of group 2 will be performed hemoclipping only for the immediate bleeding during colon polypectomy
89319168|NCT02117674|Active Comparator|standard forward-viewing colonoscopy|polyp detection with standard forward-viewing colonoscopy polyp detection in the right colon with scope retroflexion
89319169|NCT02117674|Active Comparator|full-spectrum colonoscopy|polyp detection with full-spectrum colonoscopy polyp detection in the right colon with scope retroflexion
89319170|NCT02117752|Experimental|Dapsone Gel Subset 1|Dapsone gel, dapsone gel vehicle and controls applied to the skin by separate occlusive patches every 24 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
89319171|NCT02117752|Experimental|Dapsone Gel Subset 2|Dapsone gel, dapsone gel vehicle and negative control applied to the skin by separate occlusive patches every 48 to 72 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
89319172|NCT03553030||prediabetics|patients with diagnosed of prediabetes.
89319173|NCT03553030||normo glycemics (controls)|patients without diagnosed of prediabetes.
89319174|NCT02123212|Experimental|Mt. Sinai|Cluster randomization with EHR Alert intervention
89319175|NCT02123212|Experimental|Henry Ford Health System|Simple randomization with mailer intervention
89319176|NCT02123212|Experimental|University of Alabama, Birmingham|Crossover randomization with in-person recruitment intervention
89319177|NCT02120248|No Intervention|Control|Participants receive standard WIC breastfeeding support but do not have contact with a breastfeeding peer counselor
89319178|NCT02120248|Other|Low Intensity|Participants will receive four scheduled phone calls from a peer counselor. Two prenatal calls and 2 postpartum.
89319179|NCT02120248|Active Comparator|High Intensity|Participants will receive eight scheduled phone contacts from a peer counselor. Two are prenatal and 6 are postpartum.
89319180|NCT02120326|Experimental|active tDCS|
89319181|NCT02120326|Placebo Comparator|simulated tDCS|
89319182|NCT02120560|Active Comparator|Interrupted Anticoagulation|Patients randomized to undergo atrial fibrillation ablation with interrupted anticoagulation with apixaban (5mg twice daily; 2.5mg twice daily >80 years old, Cr > 1.5, wt < 60kg), rivaroxaban (20mg daily; 15mg daily CrCl < 50 mL/minute), dabigatran (150mg twice daily; 75mg twice daily CrCl < 30mL/minute), or warfarin (dosed case-by-case).
89319183|NCT02120560|Active Comparator|Uninterrupted anticoagulation with warfarin|Patients randomized to undergo atrial fibrillation ablation with uninterrupted anticoagulation with warfarin (dosed case-by-case).
89319184|NCT02117830|Experimental|Androxal 25 mg|
89319185|NCT02117830|Experimental|Androxal 250 mg|supratherapeutic dose
89319186|NCT02117830|Placebo Comparator|Placebo|
89319187|NCT02117830|Other|Moxifloxacin 400 mg|positive control
89319188|NCT02120638|Active Comparator|Pyrazinamide Sensitive Comparator|"Pyrazinamide containing regimen: Regimen B1 - 6ZAmkLfxClrPto\6ZlfxClrPto~Six months of chemotherapy with Pyrazinamide,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by~Six months of Pyrazinamide,Levofloxacin,Clarithromycin,plus Prothionamide"
89319189|NCT02120638|Experimental|Pyrazinamide Resistant Comparator|"Regimen without Pyrazinamide: Regimen B2 - 6HAmkLfxClrPto\18HlfxClrPto~Six months of chemotherapy with Isoniazid,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by~Eighteen months of Isoniazid,Levofloxacin,Clarithromycin,plus Prothionamide"
89319190|NCT02117908|Experimental|CPAP +4 cm H2O|CPAP +4 cm H2O pressure using ResMedTM face mask
89319191|NCT02117908|Sham Comparator|ShamCPAP|shamCPAP using ResMedTM CPAP face mask modified for technical sham
89319192|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 1)|1 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
89319193|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 2)|3 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
89319194|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 3)|5 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
89319195|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 4)|10 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
89319196|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 5)|20 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
89319197|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 1: Monotherapy)|ISU104 20 mg/kg to be administered every three weeks (Q3W) as monotherapy
89319198|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 2: Combination therapy)|ISU104 20 mg/kg (or decreased dose) Q3W in combination with cetuximab* 250 mg/m2 QW (*Initial dose: 400 mg/m2)
89319199|NCT02123290|Experimental|Plasmodium falciparum|Patients with Plasmodium falciparum malaria
89319200|NCT02123290|Experimental|Plasmodium vivax|Patients with Plasmodium vivax malaria
89319201|NCT02123368|Active Comparator|Hialuronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
89319202|NCT02123368|Active Comparator|Hyaluronic acid and MSC 10|Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
89319203|NCT02123368|Active Comparator|Hyaluronic acid AND MSC 100|Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells
89319204|NCT02123524|Experimental|Rivaroxaban|Rivaroxaban 10mg tablet daily for 45 days
89319205|NCT02123524|Placebo Comparator|Control|Placebo tablet daily for 45 days
89319206|NCT02117986|Experimental|loading dose of colistin|Patients will receive a loading dose of colistin (6 million international units) followed by a maintenance dose of 3 million international units of colistin every 8 hours intravenous
89319207|NCT02117986|Active Comparator|without loading dose of colistin|Patients will receive 3 million international units of colistin every 8 hours intravenous
89319208|NCT02118064|Experimental|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
89319209|NCT03552328|Experimental|Intervention|Seniors receiving daily meals from Meals on Wheels. Intervention: Lunch with Medical Student.
89319210|NCT03552328|Placebo Comparator|Control|Seniors receiving daily meals from Meals on Wheels
89319211|NCT03552952||Preterm infants|100 preterm infants
89319212|NCT03552952||Term infants|100 term healthy infants
89319213|NCT02123602|Experimental|Core stabilization|This arm will receive 3 weeks of core stabilization training followed by 3 weeks of lower extremity stretching and strengthening as appropriate to address impairments noted in the examination and to progress function.
89319214|NCT02123602|Active Comparator|Lower extremity training only|This arm with receive 6 weeks of impairment based stretching and strengthening to restore function.
89319215|NCT02120872|Active Comparator|PRF and SMV Group|sites treated with Open Flap Debridement with Platelet Rich Fibrin along with Simvastatin
89319216|NCT02120872|Sham Comparator|PRF Group|sites treated with Open Flap Debridement with autologous Platelet Rich Fibrin
89319217|NCT02120872|Other|OFD Group|sites treated with Open Flap Debridement i.e. conventional flap surgery
89319218|NCT03552016|Experimental|200 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 200 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
89319219|NCT03552016|Experimental|400 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 400 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
89319220|NCT03552016|Placebo Comparator|0 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 0 mg oral riboflavin (placebo) each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
89319221|NCT02123836|Experimental|NK cells|Peripheral blood cell will be collected by apheresis from donors. Peripheral blood mononucleated cells will be cultured with irradiated K562-mb15-41BBL cells and low dose (10 IU/mL) IL-2 for 10 days. After T-cell depletion, expanded activated NK cells will be infused. Before infusion, patients will receive immunosuppressive therapy to promote temporary engraftment of NK cells. After infusion, they will receive IL-2 to support NK cell viability and expansion in vivo. The effects of NK cell infusion will be determine by comparing MRD levels before and after treatment.
89319222|NCT02118142|Active Comparator|Betaine|6 gram dose of betaine delivered in encapsulated form
89319223|NCT02118142|Placebo Comparator|Dextrose|6 gram dose of dextrose delivered in encapsulated form
89319224|NCT02118220|Other|Concussion Questionnaire|"The questionnaire is specifically designed to elicit occurrence and symptoms of a concussion. If the patient answers yes to question 2a, which asks At the time of the injury do you recall a blow to the head, neck, face or body that resulted in sustained symptoms of concussion (e.g., headache, dizziness, confusion, nausea, vomiting, etc.)?, the research team will administer the 22 item self-reporting symptom scale in the above mentioned SCAT3. The responses obtained from the questionnaire will be used to determine the incidence of symptomatic concussions, either known or unrecognized, in pediatric patients sustaining an orthopedic injury requiring surgical repair."
89319225|NCT03552874||Patient Group|Children whose ages between 5-10 years with Duchenne Muscular Dystrophy.
89319226|NCT03552874||Healthy Group|Healthy peers
89319227|NCT02121028||Intracranial Atherosclerotic Disease, Stroke/TIA|Stroke/TIA due to high grade IAD ≤21 days from symptom onset.
89319228|NCT02118298||Multiple Sclerosis|Ages 18 - 66, 10 years or less of MS,
89319229|NCT02118298||Demographically matched controls|Ages 18 - 66, No known neurological disorder, no learning disorder, and no psychiatric disturbance that is actually interfering with life.
89319230|NCT02118376|Experimental|exenatide|exenatide, 5ug, bid, 3months
89319231|NCT02118454|Experimental|Daily IVR calls|"The Daily IVR Calls Intervention: consisting of two (2) automated voice calls (intervention messages) each day for six months, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months"
89319232|NCT02118454|Active Comparator|Weekly IVR Survey Only|The Weekly IVR Survey Only control condition: consisting of standard care, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months.
89319233|NCT02123914|Experimental|Aerobic exercise with Vit. C & Aerobic exercise|
89319234|NCT02123914|Active Comparator|exercise without vit. c supplement & no exercise|
89319235|NCT02123992|Active Comparator|Elevate Apical and Posterior|The experimental arm of the study will include the implantation of the Elevate Posterior surgical mesh for the treatment of posterior vaginal prolapse
89319236|NCT02123992|Active Comparator|Native Tissue Repair|The control arm of the study will include the treatment of posterior vaginal prolapse using standard surgical sutures
89319237|NCT02121106|Experimental|Cognitive Remediation|Participants in this group will receive active cognitive remediation.
89319238|NCT02121106|Sham Comparator|Sham Cognitive Remediation|Participants in this group will receive a sham comparison, which is a computerized exposure to the same exercises as the active intervention, but with cognitively complex elements removed and no titration of the difficulty of tasks.
89531619|NCT05923294|Experimental|De-epithelialized free gingival graft|In this split-mouth randomized controlled trial, the coin toss method will determine test and control groups. In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area. To obtain the connective tissue graft, the traditional free gingival graft will be de-epithelialized in the control group.
89531620|NCT05916963|Experimental|Furosemide|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
89531621|NCT05916963|No Intervention|Usual care|Usual care, without injection of Furosemide.
89319239|NCT02121340|Experimental|Behavioral Activation|CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.
89319240|NCT02121340|No Intervention|Usual Care|Usual Care
89319241|NCT03551860|Experimental|TQL Group|Administration of a single shot transmuscular quadratus lumborum (TQL) peripheral nerve block following spinal neuraxial blockade.
89319242|NCT03551860|Active Comparator|FIB Group|Administration of a single shot fascia iliac (FIB) peripheral nerve block following spinal neuraxial blockade.
89319243|NCT05287048||Patients with postmenopausal bleeding|Patients attending a gynaecology clinic for investigation of postmenopausal bleeding and undergoing a transvaginal ultrasound (TVUS).
89319244|NCT02118532|Experimental|IN.PACT Admiral|
89319245|NCT02118688|Placebo Comparator|Placebo|"Drug: Placebo~Placebo suspension administered PO/NG/FT q12h to mimic risperidone~Placebo suspension administered PO/NG/FT q8h to mimic trazodone"
89319246|NCT02118688|Active Comparator|Risperidone alone|"Drug: Risperidone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
89319247|NCT02118688|Active Comparator|Trazodone alone|"Drug: Trazodone~Initiate trazodone dosing at 50 mg PO/NG/FT q8h~Trazodone dose can be titrated upwards every 24 hours by 25 mg per dose~Maximum trazodone daily dose 600 mg per day (200 mg every 8 hours)"
89319248|NCT02118688|Active Comparator|Risperidone and Trazodone combination|"Drug: Risperidone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)~Drug: Trazodone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
89319249|NCT02126722||Patients with dyspepsia on PPI|One hundred patients on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
89319250|NCT02126722||Patients with dyspepsia not on PPI|Fifty patients not on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
89319251|NCT02121496|Experimental|Resources for Postpartum Parenting|Behavioral intervention will include techniques to help mothers get their infants to cry/fuss less and sleep more to determine if this has an effect on prevalence of postpartum depression in low SES women and if it improves the quality of mother-infant interaction and subsequent child development.
89319252|NCT02121496|No Intervention|Control Group|This group will not receive the coaching tips to help babies cry less and sleep more.
89319253|NCT02126956|Experimental|ACT-128800|Subjects received a single oral dose of 40 mg 14C-labeled ACT-128800 (one capsule)
89319254|NCT02124148|Experimental|Prexasertib + Cisplatin (Part A)|"Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days.~Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days.~Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days.~Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose.~Participants may remain on treatment until discontinuation criteria are met."
89319255|NCT02124148|Experimental|Prexasertib + Cetuximab (Part B)|"Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days.~Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days.~Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days.~Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose.~Participants may remain on treatment until discontinuation criteria are met."
89319256|NCT02124148|Experimental|Prexasertib + Pemetrexed (Part C)|"Part C: Pemetrexed administered IV on day one and prexasertib administered IV on day one and two every 21 days.~Participants may remain on treatment until discontinuation criteria are met."
89319257|NCT02124148|Experimental|Prexasertib + 5-FU (Part D)|"Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days.~Participants may remain on treatment until discontinuation criteria are met."
89319258|NCT02124148|Experimental|Prexasertib + LY3023414 (Part E)|"Part E: Prexasertib administered IV on day one and LY3023414 administered orally twice daily every 14 days.~Part E will be expanded at the recommended dose in participants with advanced or metastatic cancer, participants with PIK3CA mutations (E2 expansion), or with advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer (E3 expansion).~Participants may remain on treatment until discontinuation criteria are met."
89319259|NCT03753854|Active Comparator|SS patients|"Homozygous sickle cell patients~Each patient will undergo the following:~polysomnography and oxygen saturation exam~calculation of VOC rate within the two previous years~Blood samples~Physiological measurements"
89319260|NCT03753854|Experimental|SS patients apneic|"Homozygous sickle cell patients after one year of continuous positive airway pressure treatment~Each patient will undergo the following:~polysomnography and oxygen saturation exam~calculation of VOC rate within the two previous years~Blood samples~Physiological measurements"
89319261|NCT02124226|Experimental|Methotrexate|Starting dose of 7.5 mg/week + folic acid the day after for 3 weeks as add-on therapy to their existing medication. Study treatment dosage will be increased, the maintenance dose will be 10 mg/week + folic acid the day after for 27 weeks
89319262|NCT02124226|Placebo Comparator|Matched placebo|Placebo pills
89319263|NCT02127034|Experimental|Digoxin / digoxin + solifenacin and mirabegron|Digoxin alone then followed by digoxin with solifenacin and mirabegron
89319264|NCT02127034|Experimental|Digoxin + solifenacin and mirabegron / digoxin|Digoxin with solifenacin and mirabegron then followed by digoxin alone
89319265|NCT02251678|Experimental|Elimune capsules|Elimune capsules 2 capsules BID (four total capsules per day)
89319266|NCT01389050|No Intervention|Follow-up|Data from these patients will be added to retrospectively gathered data from the PMH radiotherapy data bank (approximately 50 patients). The data collected will be analyzed using descriptive statistics.
89319267|NCT01389050|Experimental|Prospective|
89319268|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 1application|Actinica, 0.8 mg/cm2, 1application over one day of sun exposure
89319269|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 2 applications|Actinica, 0.8 mg/cm2, 2 applications over one day of sun exposure
89319270|NCT02251756|Experimental|Actinica, 2 mg/cm2, 1 application|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
89319271|NCT02251756|Experimental|Actinica, 2 mg/cm2, 2 applications|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
89319272|NCT01072370|Active Comparator|Treatment Group 1|
89319273|NCT01072370|Sham Comparator|Treatment Group 2|
89319274|NCT03247556|Placebo Comparator|Placebo|Placebo, qd, oral capsule
89319275|NCT03247556|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
89319276|NCT03247556|Experimental|600mg SPN-812|600mg SPN-812, qd, oral capsule
89319277|NCT03216746|Experimental|Oral orientation and App for smartphone|The oral health educational method of this group comprised a total of 66 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
89319278|NCT03216746|Experimental|Oral orientation|The oral health educational method of this group comprised a total of 71 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases.
89319279|NCT03216746|Experimental|Video orientation and App for smartphone|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
89319280|NCT03216746|Experimental|Video orientation|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience.
89319281|NCT02787304|Experimental|SHP626 5 Milligram (mg)|Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
89319282|NCT02787304|Experimental|SHP626 10 Milligram (mg)|Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
89319283|NCT02787304|Experimental|SHP626 20 Milligram (mg)|Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
89319284|NCT02787304|Placebo Comparator|Placebo (PBO)|Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
89319285|NCT02251834|Experimental|Community Health Worker|Community Health Worker (CHW) home visits, coaching phone calls, group sessions .
89319286|NCT02251834|Other|Usual Care|usual care and health education brochures every 4 months.
89319287|NCT02127112|Active Comparator|Block Allograft plus Matrix Allograft|The positive control treatment will include a block allograft plus a demineralized bone matrix moldable allograft.
89319288|NCT02127112|Experimental|Moldable Matrix Allograft|In the test arm of the study the treatment will include a demineralized bone matrix moldable allograft.
89319289|NCT02121574||Zero-flux and ingestible thermometer|Ingestion of a capsule thermometer pre-operatively Attachment of a zero flux temperature electrode intraoperatively Standard oesophageal thermometer
89319290|NCT02127190|Placebo Comparator|CXA-10 placebo emulsion|single intravenous dose of CXA 10 placebo emulsion
89319291|NCT02127190|Experimental|CXA-10 Emulsion|single ascending intravenous doses of CXA-10 emulsion
89319292|NCT02121730||Kidney Transplantation|Patients who had undergone renal transplantation for 10 years in the interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).
88806561|NCT00392678|Active Comparator|4 gram|Salsalate 4.0 g daily, divided
89319293|NCT02127268|Active Comparator|Arm T|Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy
89319294|NCT02127268|No Intervention|Arm B|With best support according to NCCN Guideline
89319295|NCT03551704|Active Comparator|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
89319296|NCT03551704|Experimental|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
89319297|NCT03552250|Other|Parenting for Lifelong Health|"Parenting Programme Parenting for Lifelong Health for Young Children (PLH) for parents of children aged 2-9, 12 sessions"
89319298|NCT02121886|Experimental|Parietal peritoneum|
89319299|NCT02124616||Neuromuscular diseases|Prospective cohort of children with inherited or acquired neuromuscular diseases.
89319300|NCT02124694|Experimental|HTUG and IPT|This arm includes the Historical Trauma and Unresolved Grief intervention (HUTG) combined with group Interpersonal Psychotherapy (IPT).The HTUG/IPT arm is 12 two-hour sessions delivered weekly on average, except for weather delays, over 16 weeks. HTUG/IPT includes sessions on identifying relationship issues which may trigger depressive symptoms, using group support, and connecting the impact of collective tribal trauma and losses with personal lifespan and current losses. HTUG/IPT is aimed at reducing depressive symptoms related to interpersonal conflicts and grief. HTUG is a Tribal Best Practice which may serve to engage AI in IPT, an empirically supported treatment for depression.
89319301|NCT02124694|No Intervention|IPT Only|IPT is a standard empirically supported treatment. This IPT Only group is not receiving the experimental HTUG component and is being compared to the combined HTUG with IPT.
89319302|NCT02127346||Chronic Periodontitis|"Male patients~Patients are suffering from chronic periodontitis~Patients do not have any systemic diseases~Subjects should have 20 teeth at least~Age: 30 years or greater"
89319303|NCT02127346||Healthy Volunteers|"Males~Healthy with no systemic diseases or periodontitis~30 years old at least~20 teeth are present at least"
89319304|NCT02127424|Experimental|Combination of the nurse-driven HIV targeted screening and the|Nurses will offer screening to all patients at EDs, aged 18-64 years old, identified as high-risk by a self-administered questionnaire, not know to be HIV positive, accepting to participate by providing an informed consent and not being seen at ED for post-exposure prophylaxis or unstable medical illness. The questionnaire was previously tested in one ED. In case of reactive rapid test result, blood specimen will be collected for standard enzyme-linked immunosorbent assay and Western blot confirmation. A follow-up visit with an on-site infectious disease specialist will be arranged within the following 48 hours.
89319305|NCT02127424|Active Comparator|Current practice (no intervention)|Physician-directed HIV diagnostic testing
89319306|NCT02127502||Critically ill patients sepsis suspected|
89319307|NCT03551158|Other|Atrial fibrillation patients|Patients with atrial fibrillation who underwent cryoballoon ablation
89319308|NCT02121964|Other|Capsulectomy|Capsulectomy in Direct Anterior Total Hip Arthroplasty
89319309|NCT02121964|Other|Capsulotomy|Capsulotomy in Direct Anterior Total Hip Arthroplasty
89319310|NCT02127580||with BAV|Patients undergoing TA-TAVI WITH predilation of the AV (Group A)
89319311|NCT02127580||without BAV|Patients undergoing TA-TAVI WITHOUT predilation of the AV
89319312|NCT02127658|Active Comparator|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
89319313|NCT02127658|Active Comparator|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
89319314|NCT02932904|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
89319315|NCT02932904|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
89319316|NCT02932904|Active Comparator|Paroxetine 20 mg|Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
89319317|NCT02932904|Placebo Comparator|Placebo|Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
89319318|NCT02127736|Experimental|Experimental group|
89319319|NCT02127736|Placebo Comparator|Control group|
89319320|NCT03552172||Prescription physical activity|
89319321|NCT03552172||No prescription for physical activity or suspension|
89319322|NCT02122042|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
89319323|NCT02122042|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
89319324|NCT02124850|Experimental|Motolimod plus cetuximab|Cohort 1: motolimod plus cetuximab
89319325|NCT02124850|Experimental|Motolimod, cetuximab, and nivolumab|Cohort 2: motolimod, cetuximab, and nivolumab
89319326|NCT02124928||carotid artery stenosis|Patients with symptomatic or asymptomatic carotid artery stenosis indicated for carotid endarterectomy, who provide written informed consent, will be included in this study. The investigators will compare patients ultrasonographic data, serum laboratory analyses and histomorphological preferances to look for biomarkers for the plaque instability.
89319327|NCT02122120||Before HEN|Patients with tube feeding with kitchen diet for at least twelve months
89319328|NCT02125006|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
89319329|NCT02125006|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
89319330|NCT02127814|Experimental|L. reuteri|
89319331|NCT02127814|Placebo Comparator|Identical Placebo|
89319332|NCT02122276|Experimental|SCI|SCI participated in a 4-month robot-assisted passive ankle exercise regimen.
89319333|NCT02125084|Experimental|Everolimus and Enzalutamide|"Dose Escalation Phase (18 patients): 3-6 patients will be treated at each dose level until the Maximum Tolerated Dose (MTD) is determined.~Everolimus: Orally (PO) once daily (dose to be determined;~Enzalutamide: 160mg (four 40mg capsules) PO continuous daily dosing.~Dose Expansion Phase (23 patients): Everolimus and Enzalutamide to be administered using the MTD determined in the dose escalation phase."
88814886|NCT03030326|No Intervention|Observation first|This group will be observed during the first three months and given biofeedback during the second three months
89531622|NCT05916040||TNTRect MRI-guided radiotherapy group with simultaneous integrated boost|Interventions include having received MRI-guided therapy with simultaneous integrated boost on the gross tumor volume in patients with rectum cancer.
89319334|NCT02122432|Experimental|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association and sends them to the dermatologist using a secured email server.~Dermatologist answer is standardized."
89319335|NCT02122432|No Intervention|Usual care|Usual care for dermatologic conditions requiring an expertise from a dermatologist involves the general practitioner 1) giving the patient a paper letter containing at least the following information: date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes) and 2) telling him to see the dermatologist of his choice (patient manages his appointments alone).
89319336|NCT03551080|Active Comparator|Endotoxin|0.8 ng lipopolysaccharide/kg body weight injection
89319337|NCT03551080|Placebo Comparator|Placebo|Saline injection
89319338|NCT02125162|Experimental|Treatment A|BCX4161 400 mg formulated as hard gelatin capsules given orally under fasting conditions x1
89319339|NCT02125162|Experimental|Treatment B|BCX4161 400 mg formulated as soft gelatin capsules given orally under fasting conditions x1
89319340|NCT02125162|Experimental|Treatment C|BCX4161 400 mg formulated as soft gelatin capsules given orally after a high-fat breakfast x1
89319341|NCT02122510|Active Comparator|dexmetomedine group|dexmetomedine group will receive pre-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe labeled G 2.
89319342|NCT02122510|Active Comparator|Bupivacaine group|Bupivacaine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline in 20 ml syringe labeled G 2.
89319343|NCT02125240|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
89319344|NCT02125240|Active Comparator|Placebo|1 tablet three times daily by mouth
89319345|NCT02125318|Experimental|Anagrelide CR (GALE-401)|
89319346|NCT02128048||Heavy smokers|Assessment of body composition and muscle function
89319347|NCT02128126|Experimental|ISA101/ISA101b|The maximum total treatment duration for a patient is six cycles (1 cycle is 21 days) for a total of 18 weeks. On day 15 of cycles 2, 3 and 4 patients are to receive the vaccination scheme of ISA101/ISA101b. Patients will be vaccinated with a fixed dose of ISA101/ISA101b every three weeks for a total of three rounds of vaccination. Four dose levels of ISA101 have been tested. ISA101b will be tested in bridging cohorts.
89319348|NCT02122588||OVATAR study patients|Females with serous and endometrioid ovarian, peritoneal and fallopian tube cancer 18 years and older, diagnosed 3 months before enrolment into the study or later, consented to participate in this non-interventional study, who are being treated for OC, FTC (Fallopian Tube Cancer) and PC (Peritoneal Cancer) in the oncology hospitals/departments in the Russian Federation.
89319349|NCT02128204|Experimental|HYADERMIS LA Facial Dermal Implant|Subjects will be randomly assigned to receive experiment treatment, lidocaine contained hyaluronate facial dermal filler, in one side of the face.
89319350|NCT02128204|Active Comparator|Hya-Dermis Facial Dermal Implant|Subjects will be randomly assigned to receive control treatment, hyaluronate facial dermal filler, in one side of the face.
89319351|NCT02125474|Experimental|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
89319352|NCT02125552|Experimental|Ultrasound guided intravenous access|This group will have their IV placed by ultrasound guidance.
89319353|NCT02125552|Placebo Comparator|Traditional intravenous access|The patients randomized to traditional IV access will have their IVs placed by standard technique.
89319354|NCT02128282|Experimental|Escalation CX-4945 plus Cis/Gem|"CX-4945 capsules at the combination MTD on Days 0, 1 and 2, and Days 7, 8 and 9.~PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle."
89319355|NCT02128282|Active Comparator|Cisplatin plus Gemcitabine|Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
89319356|NCT02128282|Experimental|10-day CX-4945 plus Cis/Gem|CX-4945 capsules at 1000mg/BID, 10-day continuous dosing (Day 0 through Day 9). PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
89319357|NCT02128282|Experimental|21-day CX-4945 plus Cis/Gem|CX-4945 capsules at 1000mg/BID, 21-day continuous dosing PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
89319358|NCT02122744|Active Comparator|Super Rapid Magstim Stimulator rTMS QP|rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients
88814887|NCT05089058|Experimental|Brief cognitive task (delivered digitally)|
88814888|NCT05089058|Placebo Comparator|Brief relaxation exercise task (delivered digitally)|
88814889|NCT03032978|Experimental|Calcium silicate|intervention
88814890|NCT03032978|Active Comparator|Calcium Hydroxide|Comparator
89319359|NCT02122744|Placebo Comparator|Placebo|rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients.
89319360|NCT03551002||Retrospective|
89319361|NCT03551002||Prospective|
89319362|NCT02125630||Systemic therapy|Standart chemotherapy
89319363|NCT02125630||Primary surgery|Standart surgery
89319364|NCT02125630||Neoadjuvant chemotherapy|Standart chemotherapy followed by surgery
89319365|NCT02122822|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
89319366|NCT03551548|Placebo Comparator|Reference treatment|
89319367|NCT03551548|Experimental|experimental treatment|Spironolactone 25 mg
89319368|NCT03551470||Synchronous colorectal cancer and liver metastases|Robotic (Da Vinci) one-stage colorectal and liver resection
89319369|NCT02125708|Other|OvulaRing®|Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
89531623|NCT05913739|Active Comparator|Oxygen Therapy|Participants received nocturnal oxygen therapy (minimum 6 hours) for 6 months.
89319370|NCT02128360|Active Comparator|Minimal stimulation protocol|Low dose Letrozole 2.5 mg over 5 days, starting from cycle day 2, overlapping with low dose gonadotropins, starting from day 3 of the Letrozole at 150 units per day. GnRH antagonist to avoid premature LH surge will be introduced when one or more of the growing follicles reached approximately 14 mm in size
89319371|NCT02128360|Active Comparator|High dose protocol|High dose of gonadotropins (≥300 IU/day) starting from cycle day 3. GnRH antagonist will be introduced to avoid premature LH surge when one or more of the growing follicles will reach approximately 14 mm in size
89319372|NCT02128516|Active Comparator|whey protein|whey protein
89319373|NCT02128516|Placebo Comparator|placebo|placebo
89319374|NCT02128516|Experimental|pea protein|pea protein
89319375|NCT02125942|Experimental|meditation|Central Meditation and Imagery Therapy
89319376|NCT02125942|No Intervention|wait list|waiting list
89319377|NCT02126020|Experimental|topical infliximab|topical infliximab 10 mg/mL QID x 3 months followed by BID x 9 months
89319378|NCT02126098||Adults who diagosed ANCA-vasculitis|"Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had~Positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA~manifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)"
89319379|NCT00688376|Experimental|1|
89319380|NCT00688376|Placebo Comparator|2|
89319381|NCT02131090|Experimental|Tegaderm TM|Participants in this arm of the study will receive the Tegaderm dressing to secure the epidural catheter
89319382|NCT02131090|Experimental|Lock-it Plus|Participants in this arm of the study will receive the Lock-it Plus dressing to secure the epidural catheter
89319383|NCT02131090|Experimental|Epifix|Participants in this arm of the study will receive the Epifix dressing to secure the epidural catheter
89319384|NCT02126332|Other|Conventional group|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
89319385|NCT02126332|Experimental|EA group (Epidural anesthesia )|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
89319386|NCT02128594|Experimental|Standard of Care|Standard of care
89319387|NCT02128672|Active Comparator|Conventional SCS lead|Conventional Thoracic-lumbar SCS lead placement
89319388|NCT02128672|Experimental|SCS Experimental Lead Placement|Experimental SCS lead placement in a novel position
89319389|NCT02133248||kidney recipient waitlist|Subjects on waitlist for Kidney transplant who are sensitized
89319390|NCT02133248||chronic antibody mediated rejection|Kidney transplant recipient who are diagnosed with chronic antibody mediated rejection
89319391|NCT02133248||control|Normal subjects-no kidney transplant or chronic rejection
89319392|NCT03550612||Neonates with hypoxic ischemic encephalopathy|Cranial ultrasound,Magnetic resonant imaging and amplitude integrated encephalogram performed to All neonates with hypoxic ischemic encephalopathy in period between January 2010 to December 2015.
89319393|NCT03214952||Vonoprazan 20 mg|The usual adult dosage for oral use is 20 mg of vonoprazan administered orally once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use was administered for a total of 4 weeks of treatment, and if that dosing proved insufficient, the administration may have been extended, but for no longer than 8 weeks of treatment. Participants received vonoprazan as part of a routine medical care.
89319394|NCT02126488|Experimental|treadmill perturbation|treadmill slip perturbation
89319395|NCT02126488|Placebo Comparator|treadmill placebo|treadmill training placebo
89319396|NCT02126488|Sham Comparator|observation|observation training
89319397|NCT02126566|Experimental|Single Arm|Administration of light therapy - measurement of results before and after therapy
89319398|NCT01314404||KAP/WTP study population|"The participants will range in age from 12 to 50 and will be selected randomly. The study population will be representative of the following categories: men, women, adolescent boys, and adolescent girls.~As our study seeks to take a broad-based view of knowledge related to cervical cancer and HPV, our study population is necessarily wide-ranging. Adolescent boys and girls will be between the ages of 12 and 18; men and women will be older than 18, with at least one child that falls within the adolescent age range."
89319399|NCT01314404||Prevalence study population|"We plan to identify and recruit women diagnosed with cervical cancer who are being treated by a doctor from the department of gynecology of the Hospital Gabriel Touré in Bamako, Mali. These patients will have been previously identified and diagnosed by clinical exam by an obstetrician-gynecologist at Gabriel Touré, and will have been identified as surgical candidates by a doctor.~The subject has expressed a willingness to have a biopsy or other gynecological operation and have a doctor collect tissue samples during a standard medical appointment, has agreed to have blood drawn, was older than 18, and has the capacity to give informed consent."
89319400|NCT02128750|Experimental|revascularization group|Subjects in this arms have an contrast echographie with sonovue(r) then a revascularization and finnaly an other contrast echographie with sonovue.
89319401|NCT02131246|Experimental|Faster-acting insulin aspart|Each subject will be allocated to two treatments (in random sequence).
89319402|NCT02131246|Active Comparator|NovoRapid®|Each subject will be allocated to two treatments (in random sequence).
89319403|NCT01367704|Active Comparator|Control School|Control schools (where the coaches do not receive the Coaching Boys into Men (CBIM) training until following academic year 'wait list control')
89319404|NCT01367704|Experimental|Intervention School|Intervention schools (where coaches receive the CBIM training at start of sports season)
89319405|NCT03214094||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
89319406|NCT02126644|Other|Single Arm|Single arm of 10 patients - efficacy and safety assessed pre and post peel
89319407|NCT03550534|Experimental|Calcium Carbonate|Calcium carbonate 3 x 500 mg was given to 23 study participants for 12 weeks
89319408|NCT03550534|Placebo Comparator|Placebo oral capsule|Placebo oral capsule 3 x 1 was given to 23 study participants for 12 weeks
88814891|NCT03030092|No Intervention|Control group|Today's standard care
89319409|NCT03551314|Active Comparator|Nasal Intermittent Positive Pressure|"In this group, soon after extubation, the newborns will be studied initially in NIPPV for one hour. Infants will be studied in supine while in their incubator.~NIPPV: Nasal Intermittent Positive Pressure Ventilation"
89319410|NCT03551314|Active Comparator|Continuous Positive Airway Pressure|"In this group, soon after extubation, the newborns will be studied initially in CPAP for one hour. Infants will be studied in supine while in their incubator.~CPAP: Continuous Positive Airway Pressure"
89319411|NCT03550924|Active Comparator|Low flow Oxygen Group|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
89319412|NCT03550924|Experimental|THRIVE Group|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
89319413|NCT02131480|Experimental|Soft tissue|
89319414|NCT02131480|Experimental|Uterus|
89319415|NCT02131558|Experimental|ICG Dye|Patients received injections of Indocyanine green (ICG) for sentinel lymph node (SLN) visualization using near-infrared (NIR) imaging.
89319416|NCT02128984|Experimental|Vitafos Junior|Symbiotic Formula with DHA and antioxidants
89319417|NCT02128984|Active Comparator|Standard Formula|Standard isocaloric and isonitrogenous formula.
89319418|NCT02252224||T2DM patients treated with Forxiga|Korean patients who are at least 18 years old, diagnosed with type2 diabetes and treated with Forxiga according to the approved lable
89319419|NCT06149273|Experimental|Sleep School|Participants attend the Sleep School once a week for six weeks.
89319420|NCT06149273|Active Comparator|Treatment as usual|Participants receive short counselling about insomnia at the enrollment visit.
89319421|NCT06149221|Experimental|NTAP treatment|Treatment arm subjects receive the trial intervention
89319422|NCT06149143||Cardiac Function Monitoring|Subjects scheduled for cardiac catheterization will undergo measurement with the Cardiac Performance System non-invasive device for a brief period before the catheterization procedure.
89319423|NCT06149130|Experimental|treatment group|"Adebrelimab: 1200mg intravenously ,Q3W~dalpiciclib : 150mg once a day for 3 weeks, stop for 1 week, Q4W~Endocrine recommended drugs untreated: aromatase inhibitors (letrozole/anastrozole/exemestane), given orally once daily at a specific dose (letrozole 2.5mg/ day; Anastrozole 1mg/ day, exemestane 25mg/ day); first-line endocrine therapy failed: fluvestrant was given once every 28 days, 500mg intramuscular injection, and then 500mg intramuscular injection 2 weeks after the first administration;"
89319424|NCT06149117|Experimental|"test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®"|TR
89319425|NCT06149117|Experimental|"reference product (R) azithromycin capsule Sumamed®and test product (T) azithromycin capsule"|RT
89319426|NCT06149091|Active Comparator|Tranexamic Acid Group|Patients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with tranexamic acid for hemostasis.
89319427|NCT06149091|Active Comparator|Adrenalin Group|Patients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with Adrenalin for hemostasis.
89319428|NCT06149091|Experimental|Hemagglutinase Group|Patients with iatrogenic airway bleeding who were randomly assigned to the group and failed to achieve hemostasis after three applications of cold saline within a given week were treated with Hemagglutinase for hemostasis.
89319429|NCT06149078||cases group|hyperurecemic
89319430|NCT06149078||control group|normal
89319431|NCT06149052|Active Comparator|Group A: warm up exercises with SMART training|For sensory stimulation planter massage will be given, and it will be applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization will be given. For balance, single and double leg stance will be performed. For functional training, lateral hops and SEBT will be performed. And at the end, for resistance training, theraband will be used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions will be held per week each lasting approximately 45 - 60 min, including 10 min warm up.
89319432|NCT06149052|Active Comparator|Group B: Warm up exercises with foot intensive rehabilitation(FIRE)|The FIRE intervention will include the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage will consist of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises will target the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension.
89319433|NCT06149039||Nonmyopathic dermatomyositis with interstitial lung disease|
89319434|NCT06149039||Classical dermatomyositis with interstitial lung disease|
89319435|NCT06149039||Rheumatic disease with interstitial lung disease in non-inflammatory myopathy|
88814892|NCT03030092|Experimental|Intervention group|Maximal Strength Training
88815127|NCT00966446|Experimental|Supervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Study staff is in contact with household members during this intervention to ensure compliance.
89319436|NCT06149039||Healthy adult|
89319437|NCT06149026|No Intervention|Control group|The control group will receive written, detailed, and standardized instructions on nutritional recommendations and physical activity at visit 1. Patients will have follow-up evaluations by a physician to reinforce adherence and make necessary adjustments for compliance with nutritional requirements. Nutritional intake reminder surveys will be conducted during the last 24 hours (E24H) at weeks 0, 4, 8 and 12.
89319438|NCT06149026|Experimental|Intervention group|Intervention group consisting of physical therapy guided by a kinesiologist for 10 sessions during which the patient will be trained to maintain physical activity three times a week. In addition, patients will be evaluated by a nutritionist who will give specific indications regarding the quality, quantity, and timing of food intake, as well as the daily frequency of food consumption. Patients will have two follow-ups by a nutritionist (week 4 and 8) to check adherence and make the necessary adjustments to meet nutritional requirements. Nutritional intake reminder surveys will be conducted during the last 24 hours (E24H) at weeks 0, 4, 8 and 12.)
89319439|NCT06149000|Experimental|Avulux Lenses|This group will be receiving migraine treatment using Avulux lenses
89319440|NCT06149000|Placebo Comparator|Placebo Lenses|This group will be using identical placebo lenses as treatment
89319441|NCT06148922|Experimental|Intervention|Intervention group parents will receive a 2-hour workshop delivered by a registered nurse with a MHFA training certificate, in groups of up to 10 parents. Parents will receive a leaflet summarizing the training contents after the workshop. At 1 week and 1-, 3-, and 6-month follow-ups, the trained registered nurse will send a 5-minute reminder video via WhatsApp/WeChat to parents describing the key MHFA techniques. A set of online questionnaires will also be delivered to the parent-child dyads at these follow-ups.
89319442|NCT06148922|No Intervention|Control|The control group will receive no intervention. Only completing the sets of questionnaire.
89319443|NCT06148922|Other|Intervention (Interview)|Parents in the intervention group with the highest and lowest mental health literacy scores will be purposively invited to participate in one-to-one semi-structured interviews to explore their experience of the intervention.
89319444|NCT06148909|Experimental|Small Talk Motivational Interviewing (STMI)|during the 8 session of smoking cessation, the first three sessions will be used to do small talks with the participant. And then from the fourth session onwards, the RA will add 30 minutes of MI about smoking cessation after engaging in small talk.
89319445|NCT06148909|No Intervention|Control (only MI)|Another two RA with at least one-year experience on counselling will be delivering the control group. Participant will receive MI for 30 minutes in each of the first three sessions and 1 hour in each of the remaining sessions. The control group will also receive the same duration and content of boosters as in the intervention group.
89319446|NCT06148883|Active Comparator|Electrocardiogram Ambulatory Monitoring for 1 month and immediate discharge|In this group, Pacemaker implantation will be decided, after discharge, on documented Electrocardiogram abnormalities obtained from the 1 month Electrocardiogram Ambulatory Monitoring.
89319447|NCT06148883|Experimental|Electrocardiogram Ambulatory Monitoring for infra-hisian conduction evaluation|In this group, Pacemaker implantation will be decided, before discharge, in case of prolonged His-Ventricular interval ≥ 70 ms.
89319448|NCT06148844|No Intervention|Control Group|The routine preparation procedure in this group in the hospital will be applied by the nurses responsible for preoperative preparation. After pre-operative preparation, the child, parent and nurse will be asked to fill out the anxiety and fear scales to evaluate the child's anxiety and fear levels.
89319449|NCT06148844|Experimental|Interactive robot group|In addition to the routine preparation procedure interactive robot will be used to preparation as a therapeutic approach. The interactive robot will accompany to the child the preparation for the surgery. Then, the features of the interactive robot will be explained to the children and parents and it will be introduced to the children. The interactive robot will meet the child with its speech feature and the robot will accompany to child to the operating room entrance. The child will be informed that he/she can request the interactive robot to follow him/her if he/she wishes. The child will be transferred to the operating room accompanied by the nurse, researcher and robot. After pre-operative preparation, the child, parent and nurse will be asked to fill out the anxiety and fear scales to evaluate the child's anxiety and fear levels.
89319450|NCT06148805|Experimental|Pilates Group|"fifteen patients diagnosed with shoulder rotator cuff tendinopathy for at least 3 months randomly selected from ministry of health units will receive Pilates exercises program additional to traditional (RCT) physical therapy program containing Hot-Pack (HP), Therapeutic Ultrasound (US) and upper extremity strengthening and stretching exercise program)~The assessment of pain intensity was carried out by visual analog scale~The assessment of pain threshold was carried out by pressure algometer.~The assessment of lateral rotation strength and abduction strength were carried out by hand heled dynamometer.~The assessment of shoulder function was carried out by Arabic version of the Disability of the Arm, Shoulder and Hand (DASH-Arabic)~The assessment of the functional exercise performance was carried out by Six-min walk test"
89319451|NCT06148805|Experimental|diaphragmatic Group|"fifteen patients diagnosed with shoulder rotator cuff tendinopathy for at least 3 months randomly selected from ministry of health units will receive diaphragm manual therapy techniques and traditional rotator cuff tendinopathy physical therapy program containing Hot-Pack (HP), Therapeutic Ultrasound (US) and upper extremity strengthening and stretching exercise program)~The assessment of pain intensity was carried out by visual analog scale~The assessment of pain threshold was carried out by pressure algometer.~The assessment of lateral rotation strength and abduction strength were carried out by hand heled dynamometer.~The assessment of shoulder function was carried out by Arabic version of the Disability of the Arm, Shoulder and Hand (DASH-Arabic)~The assessment of the functional exercise performance was carried out by Six-min walk test"
89319452|NCT06148805|Active Comparator|traditional Group|"fifteen patients diagnosed with shoulder rotator cuff tendinopathy for at least 3 months randomly selected from ministry of health units will receive 15 received traditional rotator cuff tendinopathy physical therapy program containing Hot-Pack (HP), Therapeutic Ultrasound (US) and upper extremity strengthening and stretching exercise program)~The assessment of pain intensity was carried out by visual analog scale~The assessment of pain threshold was carried out by pressure algometer.~The assessment of lateral rotation strength and abduction strength were carried out by hand heled dynamometer.~The assessment of shoulder function was carried out by Arabic version of the Disability of the Arm, Shoulder and Hand (DASH-Arabic)~The assessment of the functional exercise performance was carried out by Six-min walk test"
89530145|NCT03434041|Experimental|Intranasal Esketamine plus Oral Antidepressant|Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.
88806562|NCT01793324||GER|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012
88815128|NCT00966446|No Intervention|No Intervention|Households do not undergo active MRSA decolonization protocol
89319453|NCT06148805|Experimental|pilates and diaphragmatic Group|"fifteen patients diagnosed with shoulder rotator cuff tendinopathy for at least 3 months randomly selected from ministry of health units will receive diaphragm manual therapy, Pilates exercises program and traditional rotator cuff tendinopathy physical therapy program containing Hot-Pack (HP), Therapeutic Ultrasound (US) and upper extremity strengthening and stretching exercise program)~The assessment of pain intensity was carried out by visual analog scale~The assessment of pain threshold was carried out by pressure algometer.~The assessment of lateral rotation strength and abduction strength were carried out by hand heled dynamometer.~The assessment of shoulder function was carried out by Arabic version of the Disability of the Arm, Shoulder and Hand (DASH-Arabic)~The assessment of the functional exercise performance was carried out by Six-min walk test"
89319454|NCT06148740|Experimental|Pro Vitality Daily Restorative Face Serum|"Participants will be required to apply the test product in the morning and before sleeping at night.~After thoroughly cleansing and toning the face, the participants will apply 2-3 drops onto clean dry fingers and massage over the entire face until fully absorbed.~The product should be followed with the participants' preferred moisturizer."
89319455|NCT06148727|Active Comparator|Conventional heat cured overdenture group|patients received 4 interforamenal implants connected by 3 bar assembly and conventional heat cured overdenture (Control Group)
89319456|NCT06148727|Active Comparator|3d- printed overdenture group|patients received 4 interforamenal implants connected by 3 bar assembly and 3d printed overdenture (Study Group)
89319457|NCT06148649|Experimental|HEC88473 dose1|T2DM subjects, receiving a weekly dose of HEC88473 dose1
89319458|NCT06148649|Experimental|HEC88473 dose2|T2DM subjects, receiving a weekly dose of HEC88473 dose2
89319459|NCT06148649|Experimental|HEC88473 dose3|T2DM subjects, receiving a weekly dose of HEC88473 dose3
89319460|NCT06148649|Placebo Comparator|Placebo|T2DM subjects, receiving a weekly dose of placebo
89319461|NCT06148649|Active Comparator|Dulaglutide|T2DM subjects, receiving a weekly dose of dulaglutide
89319462|NCT06148623|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection have the Philips FAST SpO2 with Masimo Pulse Oximetry Sensors
89319463|NCT06148610||NewSpringForMe cohort|Patients with hematological diseases intended to be allotransplanted (bone marrow or Hematopoietic Stem Cells)
89319464|NCT06148584|Experimental|Intervention Barbershops Group|Participants recruited from intervention barbershops will receive the barbershop-based HIV prevention initiative. The trained barber will provide the following services during regular haircut services: general, status-neutral HIV education, HIV self-test kits, and information about where to receive HIV prevention services. The barber will also lead peer support group education every two months for clients enrolled in the study.
89319465|NCT06148584|Active Comparator|Control Barbershops Group|Participants recruited from control barbershops will receive standard-of-care HIV prevention services which include facility-based HIV risk reduction counseling and testing and providing information about facility distributed HIV self-test kits.
89319466|NCT06148571||Prospective LBBAP-HF cohort|Patient who underwent attempted left bundle branch area pacing using Biotronik Selectra 3D sheath and stylet driven lead (Solia S60, Biotronik).
89319467|NCT06148571||Retrospective LBBAP-HF cohort|Patients who underwent attempted left bundle branch area pacing using Biotronik Selectra 3D and Solia S60 lead prior to prospective enrollment.
89319468|NCT06148558|Other|Single-Cell|
89319469|NCT06148545|Experimental|Iron supplementation|Children with a diagnosis of iron deficiency anemia. Patients who received standard therapy (Fe preparations) 3 mg/kg BW/day for 4 weeks, were then checked again for complete blood count, serum fe, and serum ferritin.
89319470|NCT06148545|Experimental|Iron and Vitamin D supplementation|Children with a diagnosis of iron deficiency anemia. Patients who received standard therapy (Fe preparations) 3 mg/kgBW/day and received standard therapy combination vitamin D, 400 IU for 4 weeks, were then checked again for complete blood count, serum fe, and serum ferritin.
89319471|NCT06148532||PRC Database|EHR records for hospital delivery admissions and postpartum readmissions obtained from Perinatal Research Consortium (PRC) sites to be harmonized with SDoH data and analyze to optimize sepsis risk prediction.
89319472|NCT06148519|Experimental|Using 2WIN-S portable refractor for amblyopia screening|
89319473|NCT06148480||Mother-Infant Dyads|Women and their neonates admitted to the postpartum floor will be enrolled after being screened for the exclusion criteria
89319474|NCT06148454|Experimental|Positive Psychology A & B|Module A and B
89319475|NCT06148454|Experimental|Positive Psychology C & D|Module C and D
89319476|NCT06148454|No Intervention|Control Group with no intervention|
89319477|NCT06148415|Experimental|Fetal Heartbeat Monitoring Group|"The prospective fathers will be trained by the investigators on how to perform the 1st and 2nd leopold maneuvers using visual materials. Each couple will be provided with a stethoscope to listen to the fetal heartbeat and will be given a schedule to listen to the fetal heartbeat together for 5-10 minutes at least once a day for 15 days.~Leopold maneuver (Posture): The first maneuver is performed to determine the height of the fundus and the part that is located on the fundus.~Leopold's maneuver (Position: back right, back left): This maneuver is used to determine which side the fetal back is on. On palpation, the side with the baby's back is flat and firmer, and the other side feels bumpy."
89319478|NCT06148415|No Intervention|Control|Standard care group without fetal heart rate monitoring
89319479|NCT06148402|Experimental|Fruquintinib plus camrelizumab and capecitabine|fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
89319480|NCT06148376||MDI T2DM|Patients wit type 2 diabetes (T2DM) treated with multiple dose insulin therapy (MDI)
89319481|NCT06148363|Active Comparator|real stimulation|The central electrode was placed over F3, with return electrodes at Fp1, Fz, F7 and C3. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 15 and 15 seconds, respectively) were applied for 20 minutes per session, twice daily over 7 consecutive days.
89531624|NCT05913739|No Intervention|No Oxygen Therapy|Participants will not received oxygen therapy
89319482|NCT06148363|Sham Comparator|sham stimulation|In the sham condition, tDCS was delivered only during the ramp-up and ramp-down periods (15 and 15 s); no current was delivered during the 20-minute intervention. Participants will receive sham tDCS twice daily for two weeks.
89319483|NCT06148350|Experimental|Group A: Frenkel's Exercise|"Frenkel's exercises spanned four weeks with distinct positions:~Week 1: Recumbent position, focusing on heel sliding, knee, and hip movements. Week 2: Seated exercises, emphasizing leg elevation and standing from a chair. Week 3: Erect posture activities, including forward, sideways, and backward walking with diverse steps and turns.~Week 4: Comprehensive exercises across all positions, emphasizing varied movements.~Each exercise set included 8-10 repetitions with 1-2 minutes of rest."
89319484|NCT06148350|Active Comparator|Group B: Conventional Balance Exercises|"Structured program with 8-10 reps and 1-2 min rest:~I. Strengthening: Targets hips, knees, and ankles-squats, lunges, leg presses. II. Weight-Shifting: Enhances balance with side-to-side, forward-backward steps.~III. Trunk Stabilization: Improves core control-planks, crunches, twists. IV. Proprioception: Balance board exercises challenge spatial awareness, performed under physiotherapist supervision."
89319485|NCT06148298||Pancreatic Ductal Adenocarcinoma|
89319486|NCT06148285|Experimental|100% oxygen under 2.0ATA|The first intervention arm consists of ischemic stroke patients who would undergo HBOT at 2.0 ATA with 100% oxygenation for 60 minutes x10 treatments (Monday-Friday of two sequential weeks).
89319487|NCT06148285|Active Comparator|21% oxygen under 2.0ATA|The second intervention arm would consist of ischemic stroke patients undergoing HBOT at 2.0 ATA with 21% oxygen (room air) for 60 minutes x10 treatments (Monday-Friday of two sequential weeks).
89319488|NCT06148285|Sham Comparator|21% oxygen under 1.14ATA|For sham-control; ischemic stroke patients will undergo placement in the hyperbaric oxygen chamber for the same duration of time (60 minutes x10 treatments, Monday-Friday of two sequential weeks) and pressure maintained at 1.14 ATA with 21% oxygen (room air), a non-therapeutic dose of HBOT that sufficiently increases pressure to simulate ear popping, hence maintaining participants blinded to the intervention / sham.
89319489|NCT06148259|Active Comparator|Sodium glucose cotransporter 2 inhibitors|patients with diabetes treated with sodium glucose cotransporter 2- Dapagliflozin
89319490|NCT06148259|Active Comparator|Dipeptidyl peptidase 4 inhibitors|patients with diabetes treated with Dipeptidyl peptidase 4 inhibitor-sitagliptin
89319491|NCT06148233|Experimental|patients with Alzheimer's Disease|AD subjects recruited from geriatric wards or memory clinics.
89319492|NCT06148233|Experimental|Cognitively normal control group|Cognitively normal subjects recruited from the community
89319493|NCT06148207|Experimental|Low-dose group|Subjects in this group were injected intravenously with 5 ± 1 mCi [18F]BF3-BPA
89319494|NCT06148207|Experimental|High-dose group|Subjects in this group were injected intravenously with 9 ± 1 mCi [18F]BF3-BPA
89319495|NCT06148168|Active Comparator|Group A|24 patients will receive OSCTAP block with 25 ml volume on each side (5 ml normal saline plus 20 ml of 0.25 % bupivacaine)
89319496|NCT06148168|Active Comparator|Group B|24 patients will receive OSCTAP block with 25 ml volume on each side (5 ml normal saline containing 500 mg MgSO4 plus 20 ml of 0.25% bupivacaine)
89319497|NCT06148168|Active Comparator|Group C|24 patients will receive OSCTAP block with 25 ml volume on each side (5 ml normal saline containing 250 mg MgSO4 plus 20 ml of 0.25% bupivacain)
89319498|NCT06148142|Experimental|Assigned Interventions|The intervention to experimental/intervention group will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; and third, end-line survey at 12 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance. Patients will be able to view the educational material in the pharmacy via a tablet, since audio-visual presentations make learning easier. The intervention group will receive phone call intervention at 3 months and 6 months.
89319499|NCT06148142|Active Comparator|Control group|In the control group, routine pharmacy services and counselling will be provided without interference during all-pharmacy visits, as per each country's pharmacy practice guidelines, and they will serve as a comparator group to determine the impact of the intervention implementation. Assessments will be completed at the same time points as those in the intervention group.
89319500|NCT06148129|Active Comparator|Study group|
89319501|NCT06148129|No Intervention|Excluded Patients|
89319502|NCT06148103|Other|D group|Patients who received Dexmedetomidine. The starting dose of dexmedetomidine was 1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
89319503|NCT06148103|Other|PF group|Patients who received Propofol-Fentanyl infusions. Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
89319504|NCT06148077|Experimental|Manual Therapy|Manual Therapy-based intervention: the session will be performed with the patient in a supine position. If they cannot reach this position, it can be done with the patient sitting in a chair to receive the treatment. The selected maneuvers will focus on the intraoral, cervical, mandibular, and shoulder regions. Afterward, motor control exercises will be conducted.
89319505|NCT06148077|Active Comparator|Control Motor|Control motor (exercise): the session will focus on strengthening and stretching exercises for the intraoral, cervical, mandibular, and shoulder musculature.
89319506|NCT06148077|No Intervention|Waiting List|Patients waiting list
89319507|NCT06148064|Experimental|Collaplug application with low level laser application.|
89319508|NCT06148064|Active Comparator|Collaplug application|
89319509|NCT06148051||CADASIL cohort|
89319510|NCT06148051||Control Cohort|
89319511|NCT06148025|Experimental|Substudy 1 - BCG vaccine, antibiotics and 2nd BCG vaccine|Randomised to receive antibiotics and a BCG vaccine at visit 1 and a second BCG vaccine 6 months later
89319512|NCT06148025|Experimental|Substudy 1 - BCG vaccine, no antibiotics and 2nd BCG vaccine|Randomised to receive no antibiotics and a BCG vaccine at visit 1 and a second BCG vaccine 6 months later
89319513|NCT06148025|Experimental|Substudy 1 - BCG vaccine, antibiotics and placebo vaccine|Randomised to receive antibiotics, a placebo vaccine at visit 1 and a BCG vaccine 6 months later
89319514|NCT06148025|Experimental|Substudy 1 - BCG vaccine, no antibiotics and placebo vaccine|Randomised to receive no antibiotics, a placebo vaccine at visit 1 and a BCG vaccine 6 months later
89319515|NCT06148025|Experimental|Substudy 2 - Yellow Fever vaccine, antibiotics and BCG vaccine|Randomised to receive antibiotics, a BCG vaccine at visit 1 and a Yellow Fever vaccine 3 months later
89319516|NCT06148025|Experimental|Substudy 2 - Yellow Fever vaccine, no antibiotics and BCG vaccine|Randomised to receive no antibiotics, a BCG vaccine at visit 1 and a Yellow Fever vaccine 3 months later
89319517|NCT06148025|Experimental|Substudy 2 - Yellow Fever vaccine, antibiotics and placebo vaccine|Randomised to receive antibiotics, a placebo vaccine at visit 1 and a Yellow Fever vaccine 3 months later
89319518|NCT06148025|Experimental|Substudy 2 - Yellow Fever vaccine, no antibiotics and placebo vaccine|Randomised to receive no antibiotics, a placebo vaccine at visit 1 and a Yellow Fever vaccine 3 months later
89319519|NCT06148012|Experimental|RTEU Oral and Maxillofacial Surgery|
89319520|NCT06147973|Experimental|Acceptance-based Treatment (ABT)|ABT will consist of 18, 90-minute group sessions over 6 months.
89319521|NCT06147973|Sham Comparator|Health Education (HE) Comparison|HE will include nine, 75-minute group health education sessions handouts over 6 months.
89319522|NCT06147947||study group|All participants included will be in one study group.
89319523|NCT06147934||study group|All participants included will be in one study group.
89319524|NCT06147921|Experimental|SAD Dose Level 1|Sinonasal irrigation of lowest dose Verasone vs placebo
89319525|NCT06147921|Experimental|SAD Dose Level 2|Sinonasal irrigation of second lowest dose Verasone vs placebo
89319526|NCT06147921|Experimental|SAD Dose Level 3|Sinonasal irrigation of third lowest dose Verasone vs placebo
89319527|NCT06147921|Experimental|SAD Dose Level 4|Sinonasal irrigation of highest dose Verasone vs placebo
89319528|NCT06147921|Active Comparator|Crossover Component|Each active component from the highest well tolerated dose of Verasone will be administered via sinonasal irrigation alone in a within subject crossover to compare plasma drug levels to that seen when dosed with Verasone.
89319529|NCT06147921|Experimental|MAD Dose Level 1|The next to highest well tolerated dose of Verasone in the SAD study will be compared to one of the active components in Verasone and to placebo in a 5 day b.i.d. dosing regimen
89319530|NCT06147921|Experimental|MAD Dose Level 2|The highest well tolerated of Verasone in the SAD study will be compared to one of the active components in Verasone and to placebo in a 5 day b.i.d. dosing regimen.
89319531|NCT06147908|Experimental|Sequence A|cross-over
89319532|NCT06147908|Experimental|Sequence B|cross-over
89319533|NCT06147882|Active Comparator|Psychoeducation Group|The group of patients who are given psychoeducation program
89319534|NCT06147882|No Intervention|Control Group|The group of patients who are not given psychoeducation program
89319535|NCT06147869|Active Comparator|photopheresis|
89319536|NCT06147869|Active Comparator|Low level laser|
89319537|NCT06147843|Other|ALL participants|"ALS patients will be stratified in 4 groups according to the weight loss percentage: a) no weight loss; b) <5% of weight loss; c) 5-10% of weight loss; d) >10% of weight loss.~In order to identify the genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss."
89319538|NCT06147804|Experimental|Females after gynaecological and obstetric operations|Comaprison of the outcome
89319539|NCT06147791|Experimental|Group with drainage|
89319540|NCT06147791|No Intervention|Group without drainage|
89319541|NCT06147778|Experimental|MuCopilot comparison to clinical standards|Performance of digital tests and questionnaire at Day 0, D1, D3, D5, D7, M1, M2, M3-1 and M3, against clinical standards performed at Day 0 and 3 months.
89319542|NCT06147752|Experimental|"Mobile internet healthcare treatment and three disciplines co-management"|"100 patients who met the enrollment conditions were randomly divided into control group and intervention group by 1:1. The intervention group adopted the intervention of mobile Internet healthcare and co-management of three disciplines (endocrinologists, dietitians and weight managers). The three disciplines team tracked and assessed the patients' daily diet and weight changes. The duration of intervention was 6 months."
89319543|NCT06147752|Experimental|Traditional diagnosis and treatment mode|100 patients who met the enrollment conditions were randomly divided into control group and intervention group by 1:1. The control group was treated according to the traditional mode: the diagnosis and treatment plan was formulated by the endocrinologist, and the diet education was conducted by the dietitian, and the individualized diet plan was formulated. Given a calorie-restricted diet, it is recommended to reduce daily energy intake by 500kcal on the basis of requirement. At least 150 minutes of moderate-intensity exercise per week is recommended. After the visit, the patient underwent follow-up self-weight monitoring and diet management outside the hospital.
89319544|NCT06147726|Active Comparator|VR group|group to receive virtual reality supported upper extremity rehabilitation in addition to conventional physiotherapy
89319545|NCT06147726|Active Comparator|Control group|The group that will receive conventional physiotherapy for the total treatment time of the VR group
89319546|NCT06147700||Healthy fertile male|No intervention for this study.
89319547|NCT06147700||Healthy infertile male|No intervention for this study.
89319548|NCT06147687||Patients with endometriosis and Healthy controls|5 000 people with endometriosis will be enrolled and followed up for 1one year. To participate in the study, the women must meet the inclusion criteria.
89319549|NCT06147687||Control|5 000 people in a control group will be enrolled and followed up for 1one year. To participate in the study, the women must meet the inclusion criteria.
89319550|NCT06146985|Experimental|Differentiated Thyroid Cancer refractory to standard treatment（DTC）|Participants will receive 1200mg Adebrelimab i.v. once every 3 weeks and 20 mg Famitinib orally before or after the meal every day for 3 weeks until PD and/or endurable toxicity appears.
89319551|NCT06146985|Experimental|Medullary Thyroid Cancer(MTC)|Participants will receive 1200mg Adebrelimab i.v. once every 3 weeks and 20 mg Famitinib orally before or after the meal every day for 3 weeks until PD and/or endurable toxicity appears.
89531625|NCT05910814|Experimental|PP (physical practice)|Acquired the motor sequence physically
89319552|NCT06146985|Experimental|Anaplastic Thyroid Carcinoma（ATC）|Participants will receive 1200mg Adebrelimab i.v. once every 3 weeks and 20 mg Famitinib orally before or after the meal every day for 3 weeks until PD and/or endurable toxicity appears.
89319553|NCT06145945|Experimental|Ropivacaine|20ml 0.5% ropivacaine is sprayed intraperitoneally
89319554|NCT06145945|Placebo Comparator|Saline|20ml saline is sprayed intraperitoneally
89319555|NCT06145867|Experimental|PBM therapy|All participants will use the 670 nm lamp for 2 minutes each morning for 14 days.
89319556|NCT06144554||Omnipod User|All new users for the Omnipod 5 System will be required to register with Insulet's Podder Central. Users already in Podder Central will be required to log into their account before logging into the Omnipod 5 Controller if transitioning to the Omnipod 5 System. As part of the onboarding process, users will be invited to participate in this registry.
89319557|NCT06144541||General public|This survey and ITA measurements will be performed among the general public
89319558|NCT06144463|No Intervention|Control group|No intervention will be given
89319559|NCT06144463|Sham Comparator|traditional group|Non-invasive cardiac output monitoring ( NICOM ) assisted fluid resuscitation.
89319560|NCT06144463|Experimental|LUGFR group|lung ultrasound-guided fluid resuscitation
89319561|NCT06142786|Experimental|Individual upper alpha neurofeedback|
89319562|NCT06142786|Sham Comparator|Sham neurofeedback|
89319563|NCT06142149|Experimental|Ultrasound group|Use ultrasound to check the position of the endotracheal tube cuff, check its movement according to the surgical position, and position the cuff according to the size of the endotracheal tube.
89319564|NCT06142149|No Intervention|Conventional group|Adjust the position of the endotracheal tube to account for movement in the surgical position and confirm that the endotracheal tube air sac is palpable at the suprasternal notch in the final position for surgery.
89319565|NCT06141902|Other|NORMAL|daily diet
89319566|NCT06141902|No Intervention|Take Jing Si Herbal Drink|Take Jing Si Herbal Drink daily
89319567|NCT06141798|Active Comparator|Twice-weekly hemodialysis with incremental approach|
89319568|NCT06141798|No Intervention|Thrice-weekly hemodialysis|
89319569|NCT06140459|Experimental|Disabled children|Special education school students
89319570|NCT06140459|Active Comparator|Healthy children|Systemically healthy school children
89319571|NCT06139497|Experimental|PLHIV|"The following information is gathered during the visit:~HIV infection history~Medical evaluation of disabilities and comorbidities: a complete clinical assessment and cognitive evaluation are conducted.~Evaluation of functional and activity limitations~Assessment of social aspects of disability~Evaluation of associated factors~A qualitative interview will be conducted with a subgroup of the study population (20 participants)"
89319572|NCT06139497|Active Comparator|Control|"The following information is gathered during the visit:~Medical evaluation of disabilities and comorbidities: a complete clinical assessment and cognitive evaluation are conducted.~Evaluation of functional and activity limitations~Assessment of social aspects of disability~Evaluation of associated factors"
89319573|NCT06139315|Experimental|BI 765845 treatment group (Part A)|Part A
89319574|NCT06139315|Experimental|BI 765845 treatment group (Part B)|Part B
89319575|NCT06139315|Placebo Comparator|Placebo group|Part A and B
89319576|NCT06139185||Patients with nasal septum deviation|
89319577|NCT06139185||Patients without nasal septum deviation|
89319578|NCT06138782|Experimental|TMS (Aim 2)|Our protocol consists of five treatments of inhibitory continuous TBS (cTBS) to the R OFC lasting three minutes delivered every hour over the course of 10 days (2 weeks) for a total of 50 treatments.
89319579|NCT06137976|Experimental|Gastric decompression|Placement of the nasogastric or orogastric tube will occur after intubation while surgeons are scrubbing and out of the room to maintain blinding. At the end of surgery, the nasogastric or orogastric tube will be removed prior to removal of the surgical drapes to ensure the surgeon remains blinded. Patients will then be returned to routine post-operative care as otherwise planned or necessitated by surgery.
89319580|NCT06137976|No Intervention|No gastric decompression|No placement of gastric decompression tube.
89319581|NCT06136728|Active Comparator|Dalfampridine only|10 mg tablet twice per day
89319582|NCT06136728|Active Comparator|Physical therapy|One-on-one outpatient physical therapy twice per week
89319583|NCT06136728|Active Comparator|Dalfampridine plus physical therapy|10 mg tablet twice per day while receiving one-on-one outpatient physical therapy twice per week
89319584|NCT06134986|Experimental|Time restricted eating (TRE)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
89319585|NCT06134986|Experimental|Daily calorie restriction (CR)|25% energy restriction every day Diet counseling provided
89319586|NCT06134986|No Intervention|Control|Ad libitum food intake, eating over more than 10 hours per day
89319587|NCT06131385||Acute ischemic stroke treated with intravenous thrombolysis|All of acute ischemic stroke patients who treated with intravenous thrombolysis.
89319588|NCT06130527|Active Comparator|Nicardipine|Nicardipine is a dihydropyridine derivative vasoselective drug. Rapid onset of action i.v. nicardipine is used when rapid control of blood pressure is needed. The potential role of i.v. nicardipine was shown in many cardiovascular and neurovascular surgical procedures and surgical procedures in which CH was performed with hemostasis (6).
89319589|NCT06130527|Active Comparator|Remifentanil|"Although remifentanil has unique pharmacokinetic properties, its pharmacodynamic effects are similar to those of other opioids. Remifentanil has dose-dependent analgesic, sedation and respiratory suppression side effects. All of these effects are antagonized by the mu receptor-specific opioid antagonist naloxone. Remifentanil has vagotonic and sympatholytic effects, and common side effects are bradycardia (heart rate <50 beats/min) and hypotension (SBP <80 mm Hg). Other common side effects are itching, nausea and vomiting, and chest wall stiffness after bolus administration (35).~The elderly population is more sensitive to opioid effects. It has been shown that it suppresses the delta wave in EEG due to the effects of opioids in the cerebral cortex. This feature is twice as common in the elderly as in the younger population."
89319590|NCT06129084||Metastatic Bladder Cancer|Patients with metastatic bladder cancer who will have archival tissue sent for FGFR testing.
89319591|NCT06128772|Other|Waitlist control|Eight weeks of waitlist control and then 8 weeks of weekly treatment
89319592|NCT06128772|Other|Immediate treatment|Eight weeks of weekly treatment and then eight weeks of follow up
89319593|NCT06125379|Experimental|MindCARE|Group A is an experimental group that will receive mindfulness intervention for 4 consecutive weeks. Group A consists of 2-3 cohorts with 10-15 subjects per cohort.
89319594|NCT06125379|No Intervention|Wait-list control group|Group B is the wait-list control group which did not receive any intervention for 4 weeks.
89319595|NCT06119490|Other|Arocitinib-arm|Evaluation of the efficacy and safety of methylprednisolone combined with abrocitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with Arocitinib 200 mg daily.
89319596|NCT06119490|Other|Tofacitinib-arm|Evaluation of the efficacy and safety of methylprednisolone combined with tofacitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with tofacitinib 10 mg daily.
89319597|NCT06116201|Experimental|Transgender women with orchiectomy|Transgender women who took medication for sex transition form male to female via estradiol hormone therapy and orchiectomy surgery. They were recruited for measurement of all variables in the study to compare with another group.
89319598|NCT06116201|Experimental|Transgender women without orchiectomy|Transgender women who took medication for sex transition form male to female via estradiol hormone and anti-androgen hormone therapy. They were recruited for measurement of all variables in the study to compare with another group.
89319599|NCT06116201|Sham Comparator|Cisgender men|Cisgender men who lived in normal life were not used medication process for sex transition. They were recruited for measurement of all variables in the study to compare with another group.
89319600|NCT06116201|Sham Comparator|Cisgender women|Cisgender women who lived in normal life were not used medication process for sex transition. They were recruited for measurement of all variables in the study to compare with another group.
89319601|NCT06116175|Experimental|lateral epicondylitis|chronic patients of tennis elbow
89319602|NCT06115538|Active Comparator|levodopa benserazide group|levodopa benserazide (100+25 mg)
89319603|NCT06115538|Active Comparator|levodopa carbidopa entakapon grubu|levodopa carbidopa entacapone (100+25+200 mg)
89319604|NCT06106217|Experimental|bapne|
89319605|NCT06106217|Experimental|qi gong|
89319606|NCT06105125|Experimental|Autologous micrograft from the palate|Modified papilla preservation technique with a combined approach using a bone substitute soaked with autologous micrografts from the palate.
89319607|NCT06105125|Active Comparator|Control group|Modified papilla preservation technique with a combined approach using a bone substitute.
89319608|NCT06104735|Experimental|All participants|Each participant will undergo varying conditions in separate phases to determine optimal: Pairing interval; Frequency; Number of bouts, Inter-bout spacing, and the order of SCAP when given in conjunction with task-oriented hand exercise.
89319609|NCT06102915||Rocuronium|Rocuronium 1mg/kg to be given at induction of anaesthesia and another 1mg/kg would be given when the patient is on hypothermic cardiopulmonary bypass
89319610|NCT06102915||Cis-atracurium|Cis-atracurium 0.2mg/kg to be given at induction of anaesthesia and another 0.2mg/kg would be given when the patient is on hypothermic cardiopulmonary bypass
89319611|NCT06102616|Experimental|periodontal compromised orthodontic pateints|periodontal compromised adults female patients with sever dental crowding and seeking for orthodontic treatment
89319612|NCT06100042||Asthma patients|Adult patients with a diagnosis of moderate to severe asthma treated with BDP/FF/G medium strength or high strength as per clinical practice.
89319613|NCT06096506|Experimental|Intervention clinics|Participants will be recruited from those receiving care at University of Texas (UT) Physician Clinics serving the Acres Homes neighborhood in Houston
89319614|NCT06096506|No Intervention|Control Clinics|Participants will be recruited from UT Physicians clinics outside of the Acres Homes service area
88821694|NCT02696993|Experimental|Group A (nivolumab, SRS)|Patients receive nivolumab IV over 90 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
88821695|NCT02696993|Experimental|Group B (nivolumab, WBRT)|Patients then receive nivolumab as in Group A. Patients undergo WBRT once daily for 10 days.
88821696|NCT02696993|Experimental|Group C (nivolumab, ipilimumab, SRS)|Patients receive nivolumab as in Group A and ipilimumab IV over 90 minutes every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
88821697|NCT02696993|Experimental|Group D (nivolumab, ipilimumab, WBRT)|GROUP D: Patients receive nivolumab as in Group A and ipilimumab as in Group C. Patients undergo WBRT once daily for 10 days.
88821698|NCT02695667||OSAS subjects|CPAP Referral OSAS
88821699|NCT02695667||Risk-Free subjects|paired normal control subjects
88821700|NCT02658565|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
88821701|NCT02658565|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
88821702|NCT02635061|Experimental|ACY-241 in combination with nivolumab|
88821703|NCT02632409|Experimental|Nivolumab|Nivolumab dose as specified
88821704|NCT02632409|Placebo Comparator|Placebo|Placebo dose as specified
88821705|NCT02625480|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg or 1 x 10^6 anti-CD19 CAR+ T cells/kg
88821706|NCT02620046|Experimental|Group A: Vedolizumab SC 108 mg Q2W|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who:~Completed the Maintenance Period (Week 52), or~Were not randomized into Maintenance Period and achieved response at Week 14 after having received a third vedolizumab IV infusion at Week 6."
88821707|NCT02620046|Experimental|Group B: Vedolizumab SC 108 mg QW|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who withdrew early from the Maintenance Period due to treatment failure.~•Participants from current study who experience treatment failure while on study."
88821708|NCT02590822|No Intervention|Standard Care|The Standard Care group will be contacted weekly (where possible) to reinforce cognitive behavioural adaptations and encourage compliance to diet and exercise. They will be provided with standard lifestyle advice according to NICE guidance.
89319615|NCT06093932|Experimental|Lifestyle intervention + Songling Xuemaikang Capsules|"Therapeutic Hypertensive Lifestyle Modifications, everyday, duration: 12 weeks~Songling Xuemaikang Capsules, 3 capsules at a time, three times a day, duration: 12 weeks"
89319616|NCT06093932|Placebo Comparator|Lifestyle intervention + placebo|"Therapeutic Hypertensive Lifestyle Modifications, everyday, duration: 12 weeks~placebo, 3 capsules at a time, three times a day, duration: 12 weeks"
89319617|NCT06087731|Experimental|tocilizumab|administrated with tocilizumab (8mg/kg) every four weeks
89319618|NCT06086145||Adults in Davis and the greater Sacramento area of California|Adults in Davis and the greater Sacramento area of California
89319619|NCT06084754|Experimental|Group A (Study group)|pulsed electromagnetic field and medical treatment ( vancomycin IV injection 1gm divided 250mg every 6hours )
89319620|NCT06084754|Active Comparator|Group B(control group)|medical treatment only (vancomycin IV injection 1gm divided 250mg every 6hours )
89319621|NCT06080139|Experimental|parenting sessions group|This arm will receive a culturally adapted parenting curriculum twice a week for 4 weeks during month 3 of the study
89319622|NCT06080139|Active Comparator|waitlist control group|This arm will receive a handout about parenting techniques in Spanish during month 3. They then receive the same parenting curriculum during month 4.
89319623|NCT06078514||Loop electrosurgical excision procedure (LEEP)|Women directed to colposcopy examination due to cytological abnormality or repeated HPV-positivity and undergone a LEEP procedure due to HPV-related cervical lesion
89319624|NCT06078514||Colposcopy only|Women directed to colposcopy examination due to cytological abnormality or repeated HPV-positivity with no indication to LEEP
89319625|NCT06077786|Experimental|Part A: Lu AG06474 + Placebo|Participants will receive a single dose of Lu AG06474 (oral solution) and a single dose of placebo (3 placebo capsules).
89319626|NCT06077786|Experimental|Part B: Ibuprofen + Placebo to Lu AG06474|Participants will receive a single dose of ibuprofen (3 ibuprofen capsules) and a single dose of placebo to Lu AG06474 (oral solution).
89319627|NCT06077786|Experimental|Part C: Pregabalin + Placebo to Lu AG06474|Participants will receive a single dose of pregabalin (1 capsule + 2 placebo capsules) and a single dose of placebo to Lu AG06474 (oral solution).
89319628|NCT06077786|Experimental|Part D: Placebo to Lu AG06474 + Placebo|Participants will receive a single dose of placebo to Lu AG06474 (oral solution) and a single dose of placebo (3 placebo capsules).
89319629|NCT06072586|Experimental|Recurrent high-grade glioma participants with EGFR alterations|
89319630|NCT06072586|Experimental|Recurrent high-grade glioma participants with EGFR fusion|
89319631|NCT06069336|Active Comparator|Hypertonic saline|3% hypertonic saline (NEBU-dose hypertonic). The treatment will be delivered through nebulisation using oxygen with 5 litres of O2 flow, or through a compressed air-driven jet nebuliser, every 6 hours for three times daily with a night break, until discharge.
89319632|NCT06069336|Placebo Comparator|Normal saline|0,9% normal saline (NEBU-dose isotonic).The treatment will be delivered through nebulisation using oxygen with 5 litres of O2 flow, or through a compressed air-driven jet nebuliser, every 6 hours for three times daily with a night break, until discharge.
89319633|NCT06065176|Active Comparator|Novavax COVID-19 booster|Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2023-2024 formula (XBB containing) in the deltoid muscle of the arm.
89319634|NCT06065176|Active Comparator|Pfizer COVID-19 booster|Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2023-2024 formula (XBB containing) in the deltoid muscle of the arm.
89319635|NCT06065176|No Intervention|Non-boosted comparison group|Participants will not receive a dose of the study vaccine.
89319636|NCT06065033|Experimental|Exercise|"Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance."
89319637|NCT06065033|No Intervention|Control|The control protocol will include a combination of light stretching and controlled breathing.
89319638|NCT06063343|Experimental|KAND145 for SAD (Part 1)|In Part 1, SAD of KAND145 will be administered to up to 6 cohorts. Six participants in each cohort will receive KAND145. The first cohort will receive a starting dose of 60 mg KAND145 which is expected to lead to an average drug plasma concentration (Cave) of 0.2 µM. The maximum dose will be chosen to achieve a Cave of 10 µM.
89319639|NCT06063343|Placebo Comparator|Placebo for SAD (Part 1)|In Part 1, 2 participants per cohort in up to 6 cohorts will receive placebo at the same dosing frequency as detailed for the experimental arm.
89319640|NCT06063343|Experimental|KAND145 for MAD (Part 2)|In Part 2, MAD of KAND145 will be administered to up to 5 cohorts. Six participants in each cohort will receive doses of KAND145 BID for 8 days. The first cohort will receive a dose of KAND145 which is expected to lead to a Cave of 2 µM. The maximum daily dose will be 3000 mg KAND145.
89319641|NCT06063343|Placebo Comparator|Placebo for MAD (Part 2)|In Part 2, 2 participants per cohort in up to 5 cohorts will receive placebo at the same dosing frequency as detailed for the experimental arm.
89319642|NCT06061705|Experimental|procedure/surgery: Tumor biopsy|Following the start of immunotherapy, an ENT surgeon will perform a cervico-facial tumor biopsy between D30 and D180.
89319643|NCT06058416|Other|immunogenicity group with vaccination interval of 6 month|
89319644|NCT06058416|Other|immunogenicity group with vaccination interval of 18 month|
89319645|NCT06058416|Other|immunogenicity group with vaccination interval of 36 month|
89319646|NCT06058416|Other|immunogenicity group with vaccination interval of 60 month|
89319647|NCT06058416|Other|safety observation group|
89319648|NCT06057649|No Intervention|control|participants of control group will receive no intervention. they will be instructed to continue with their routine practices
89531626|NCT05910814|Experimental|MI (motor imagery)|Acquired the motor sequence mentally during training
89319649|NCT06057649|Experimental|experimental|Participants of experimental group will perform effleurage abdominal massage
89319650|NCT06056583|Other|Healthy Lactating Women|Healthy Lactating Women will be studied on 3 study days and serve as their own control.
89319651|NCT06054204|Experimental|lateral bony window in maxillary sinus|a displaced root in maxillary sinus which will be removed through a rectangular bony window will be done on the lateral wall of sinus using piezo-electric device after elevation of a full thickness mucoperiosteal flap, then the bony window will be repositioned, and the flap will be sutured.
89319652|NCT06053515|Experimental|Rosie the Chatbot Group|"Participants in the Rosie the Chatbot Group will be taking a pre-test health survey, mid-test health survey, and post-test health survey. In addition, they will be expected to actively use the chatbot app by asking questions related to maternal and infant health and selecting thumbs up or thumbs down to provide feedback for questions' response and using the features (video library, resources page, frequently asked questions (FAQ), and daily syllabus)."
89319653|NCT06053515|No Intervention|Book Club Group|Participants in the Book Club Group will be taking a pre-test health survey, mid-test health survey, and post-test health survey. In addition, they will receive a monthly children's book, which they are expected to read with baby if parenting or individually if pregnant.
89319654|NCT06043414|Active Comparator|Triclosan-coated barbed suture group|The active arm of the study will including patients randomized to abdominal fascial closure with using triclosan-coated barbed (STRATAFIX™ Symmetric PDS™, Johnson & Johnson) suture after emergency exploratory laparotomy.
89319655|NCT06043414|Placebo Comparator|Non-barbed suture group|The control arm of the study will including patients randomized to abdominal fascial closure with using non-barbed triclosan-coated suture(PDS™ Plus, Johnson & Johnson) or non-coated polydioxanone (PDS™ II,Johnson & Johnson) suture after emergency exploratory laparotomy.
89319656|NCT06041438|Experimental|BI 1584862 alone (Reference R) - BI 1584862 + itraconazole (Test T)|
89319657|NCT06039293|Experimental|Intervention|Participants will receive 10 cognitive behavioral therapy sessions and 6 physical activity sessions over 12 weeks. Additionally, participants in this group will receive an adapted copy of the American Diabetes Association's 2021 Diabetes and Emotional Health Workbook: A Practical Guide for Health Professionals Supporting Adults with Type 1 and Type 2 Diabetes.
89319658|NCT06039293|Other|Control|Participants in the control group will receive enhanced usual care and will not take part in cognitive behavioral therapy sessions or exercise sessions. Participants in this group will receive an adapted copy of the American Diabetes Association's 2021 Diabetes and Emotional Health Workbook: A Practical Guide for Health Professionals Supporting Adults with Type 1 and Type 2 Diabetes.
89319659|NCT06035718|Experimental|Active tDCS over the dorsolateral prefrontal cortex (DLPFC)|In this group, participants will receive active 2 milliampere (mA) tdcs over the DLPFC (anode on F3 and cathode onF4) for 20 minutes.
89319660|NCT06035718|Active Comparator|Active tDCS over the ventromedial prefrontal cortex (VMPFC)|In this group, participants will receive active 2 mA tdcs over the VMPFC (anode on Fpz and cathode on Cz) for 20 minutes.
89319661|NCT06035718|Sham Comparator|Sham tDCS Stimulation|In this group, participants will receive sham tDCS which will ramp up for 30 s at the beginning of the session and then ramp down and be switched off during the 20-minute stimulation session.
89319662|NCT06035718|Active Comparator|Probiotic supplementation|In this group, participants will consume 2 probiotic supplements (The synbiotics family) daily, for one month.
89319663|NCT06030245||Patients with Clostridioides infection|The following procedures are specific to this test: 8 additional stool swabs (or Fecal Swab in the absence of stool output) to that of the initial diagnosis, plus four saliva swabs. Rectal swabs may cause anal irritation. The patient must also complete a stool collection form.
89319664|NCT06027125|Experimental|Action Observation Therapy group|The patients in the action observation therapy group will be required to observe the upper limb movements or functional actions in video clips (i.e., the observation phase) and to execute what they had observed to the best of their ability (i.e., the execution phase.
89319665|NCT06027125|Experimental|Mirror Therapy Group|During the mirror therapy, the patients were seated in front of a mirror box placed at their midsagittal plane. The affected arm of the participants was placed inside the mirror box, and the unaffected arm was in front of the mirror. The patient was instructed to watch the mirror reflection of the movement performed by his/her unaffected hand carefully and to imagine that the movement was performed by the affected hand.
89319666|NCT06022302|Experimental|High-fiber diet|The high-fiber diet will consist of foods rich in dietary fiber such as coarse vegetables, wholegrain bread, and fruits representing a broad range of dietary fibers aiming for ≈40 g of fiber/10 MJ.
89319667|NCT06022302|Experimental|Low-fiber diet|The low-fiber diet will consist of foods poor in fiber such as white bread and refined foods aiming for ≈10 g of fiber/10 MJ.
89319668|NCT06020443|Other|Patients with a high risk of lung cancer|
89319669|NCT06017128|Experimental|Intervention|The experimental group will consist of individuals who will undergo total hip replacement surgery and receive sexual counseling along with an educational booklet.
89319670|NCT06017128|No Intervention|Control|The control group will be comprised of individuals undergoing total hip replacement surgery without receiving sexual counseling.
89319671|NCT06014801|Experimental|Low intensity|12 mL/kg/hr
89319672|NCT06014801|Active Comparator|Medium intensity|25 mL/kg/hr
89319673|NCT06013345|Active Comparator|Arm P|Patients in arm P will be administered 2-3 mg midazolam IV before the beginning of the procedure, 5-10 mcg sufentanil IV and a loading dose of propofol 0,8-1,0 mg/kg in 2-5 minutes before the start of the ablation phase. During the procedure, boluses of 0,5 mg/kg propofol will be repeated as needed, in case of inappropriate analgosedation, boluses of midazolam and/or sufentanil can also 0be repeated.
89530146|NCT03434041|Active Comparator|Oral Antidepressant plus Intranasal Placebo|Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.
88815129|NCT01685411|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|Patients treated with Allopurinol, Keppra, Busulfan, Cyclophosphamide, Filgrastim, antithymocyte globulin, Tacrolimus, Mycophenolate mofetil and allogeneic hematopoietic stem cell transplant infusion.
89319674|NCT06013345|Experimental|Arm R|Patients in arm R will be administered 2,5 mg loading dose of remimazolam followed by continuous infusion at 0,5 mg/h/kg of ideal body weight (IBW, calculated using the Miller formula) and a dose of ketamine 1 mg/kg IBW 2-5 minutes before the beginning of the ablation phase. In case of inadequate sedation depth, a bolus of 2,5 mg remimazolam can be repeated as needed. If the patient shows signs of pain or discomfort, a single dose of ketamine - 0,5 mg/kg IBW - will be administered, followed by a bolus of 5-10 mcg sufentanil if needed. The continuous infusion will be terminated as the last ablation pulses are delivered.
89319675|NCT06013345|Active Comparator|Arm TIVA (Total Intravenous Anesthesia)|Patients randomised in arm TIVA will be administered light analgosedation with spontaneous ventilation for the first part of the procedure. The analgosedation will be induced and maintained with bolus of 5 mcg sufentanil IV and propofol infusion dosed by TCI system (the target plasma concentration for propofol 1-2 mcg/ml). Before the beginning of the ablation phase, general anesthesia will be induced with one bolus of 5-10 mcg sufentanil (the TCI target 3-7 mcg/ml for induction and 3-5 mcg/ml for the rest of the procedure), and a bolus of rocuronium 0,2-0,4 mg/kg IBW. Then, the airways will be secured with a laryngeal mask (LMA), the patient ventilated (0,4 - 0,45 FiO2, the target EtCO2 30 - 45 mmHg). After the last ablation pulse is delivered, infusion of propofol will be ceased and LMA extracted at the return of consciousness, muscle strength and sufficient spontaneous ventilation. If residual muscle relaxation occurs, sugammadex will be administered.
89319676|NCT06008886|Experimental|Vegan diet|Vegan diet all foods included were of plant sources. During the vegan diet, the participants took 1000 µg of cyanocobalamin twice a week (Harrison Sport Nutrition, Granada, Spain)
89319677|NCT06008886|Active Comparator|Mediterranean diet|In the case of the mediterranean diet, foods of animal sources were also included (animal protein accounted for 60% of total protein intake). In this diet there was a predominance of plant foods; moderate to low consumption of fish, white meat, low-fat dairy and eggs; and very low consumption of red and processed meats, butter, full-fat dairy and sweets.
89319678|NCT06008652|Experimental|DR-0201|Subjects in this arm will receive a single dose of DR-0201
89319679|NCT06008652|Placebo Comparator|Placebo|Subjects in this arm will receive a single dose of placebo
89319680|NCT06005844|Other|Adults with a cerebellar damage|
89319681|NCT06005051|Experimental|mitigator|Test different foods to see their mitigating effect on blood sugars after a rice meal.
89319682|NCT06000566||Pediatric JIA patients|No interventions will be administered
89319683|NCT05999604|Experimental|annual ocrelizumab infusions|
89319684|NCT05999604|Other|semestrial ocrelizumab infusions|
89319685|NCT05999058|Active Comparator|group A|group A higher nasolacrimal duct obstruction
89319686|NCT05999058|Experimental|group B|group B: lower nasolacrimal duct obstruction
89319687|NCT05999058|Experimental|group C|group C: nasolacrimal duct stenosis
89319688|NCT05995223|Experimental|Down syndrome|Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
89319689|NCT05995223|Experimental|control without Down syndrome|This group of age- and sex-matched participants without Down syndrome will undergo the same testing as participants with Down syndrome
89319690|NCT05990361||women with pelvic girdle pain|The subjects who have at least one positive result from Active Straight Leg Raise, and Posterior Pelvic Pain Provocation Tests; and at least two positive results from the Pelvic Compression and Distraction, Patrick Faber, Gaenslen and Long Dorsal Sacroiliac Ligament Palpation tests are classified as with PGP group.
89319691|NCT05990361||women without pelvic girdle pain|The subjects who have not at least one positive result from Active Straight Leg Raise, and Posterior Pelvic Pain Provocation Tests; and at least two positive results from the Pelvic Compression and Distraction, Patrick Faber, Gaenslen and Long Dorsal Sacroiliac Ligament Palpation tests are classified as without PGP group.
89319692|NCT05989724|Experimental|Dose escalation, Cohort 1|"Drug: SON-DP~1 participant or 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 1 at dose level 1 once per week in 28-day cycle, for up to 6 cycles."
89319693|NCT05989724|Experimental|Dose escalation, Cohort 2|"Drug: SON-DP~1 participant or 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 2 at dose level 2 once per week in 28-day cycle, for up to 6 cycles."
89319694|NCT05989724|Experimental|Dose escalation, Cohort 3|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 3 at dose level 3 once per week in 28-day cycle, for up to 6 cycles.
89319695|NCT05989724|Experimental|Dose escalation, Cohort 4|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 4 at dose level 4 once per week in 28-day cycle, for up to 6 cycles.
89319696|NCT05989724|Experimental|Dose escalation, Cohort 5|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 5 at dose level 3 twice per week in 28-day cycle, for up to 6 cycles.
89319697|NCT05989724|Experimental|Dose escalation, Cohort 6|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 6 at dose level 4 twice per week in 28-day cycle, for up to 6 cycles.
89319698|NCT05989724|Experimental|Dose escalation, Cohort 7|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 7 at dose level 5 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
89319699|NCT05989724|Experimental|Dose escalation, Cohort 8|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 8 at dose level 6 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
89319700|NCT05989724|Experimental|Dose escalation, Cohort 9|Drug: SON-DP 3 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion in the cohort 9 at dose level 7 either once per week or twice per week (FINAL SCHEDULE) in 28-day cycle, for up to 6 cycles.
89319701|NCT05989724|Experimental|Dose escalation, Cohort 10|Drug: SON-DP Up to 12 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion at the RP2D-1 dose level using either once per week or twice per week (FINAL SCHEDULE), for up to 6 cycles.
88815130|NCT05395286|Experimental|Innovation Lab Group|Randomized to attend the Innovation Lab
89319702|NCT05989724|Experimental|Dose escalation, Cohort 11|Drug: SON-DP Up to 12 participants with solid tumor will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level using either once per week or twice per week (FINAL SCHEDULE), for up to 6 cycles.
89319703|NCT05989724|Experimental|Dose expansion, Arm 1|Drug: SON-DP Up to 18 participants with breast cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level using the Final Schedule, for up to 6 cycles.
89319704|NCT05989724|Experimental|Dose expansion, Arm 2|Drug: SON-DP Up to 18 participants with pancreatic cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
89319705|NCT05989724|Experimental|Dose expansion, Arm 3|Drug: SON-DP Up to 18 participants with ovarian cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
89319706|NCT05989724|Experimental|Dose expansion, Arm 4|Drug: SON-DP Up to 18 participants with colorectal cancer will be treated with SON-DP by 90-minute IV infusion at the RP2D dose level, for up to 6 cycles.
89319707|NCT05986773|Active Comparator|group FF|"Group FF will receive a doubled dose Furosemide i.v.~The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v.~Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection."
89319708|NCT05986773|Active Comparator|group FM|"Group FM will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o.~The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v.~Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection. Metolazone will be administered orally."
89319709|NCT05986773|Active Comparator|group FA|"Group FA will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v.~The first standard dose Furosemide i.v. should be administered according to the current guidelines: (i) diuretic-naïve patients should receive Furosemide 40 mg i.v.; (ii) patients on a maintenance oral diuretic treatment should receive the equivalent dose i.v.~Study medications will be used according to the prescribing information: Furosemide will be administered as an intravenous injection. Acetazolamide (500mg) will be administered intravenously as a short infusion."
89319710|NCT05986279|Experimental|Rehab|6 weeks of vestibular physical therapy guided by the use of the MINDGAPS decision support system
89319711|NCT05986279|No Intervention|Observational|Normative data development of performance on vestibular measures following mTBI
89319712|NCT05985603|Experimental|CIMT Group|In this group of patients CIMT technique will be used for treatment
89319713|NCT05985603|Experimental|Mirror Therapy Group|patient will perform movements in semi-reclined and sitting positions with the mirror placed between the two lower extremities.
89319714|NCT05984095|Active Comparator|SELF|All the participants in the SELF group were asked to participate in 10 sessions of 45 minutes of pelvic floor training and exercises, once every 5 days. The exercises were available in pre-recorded videos and the participants were allowed to access it when and where they preferred, respecting the requested frequency. No supervision was provided during the trainings.
89319715|NCT05984095|Experimental|REMOTE|All the participants in the REMOTE group were asked to participate in 10 sessions of 45 minutes of pelvic floor training and exercises, once every 5 days. The exercises were shown and monitored remotely during a one-to-one videocall with a physiotherapist.
89319716|NCT05964621||Pancreatic cancer patients undergoing pancreatic cancer resection|Perioperative laboratory examinations will follow institutional guidelines. These will include, but will not be limited to full blood count, conventional coagulation tests, liver function, and kidney function tests. Moreover, for the purpose of this study, the following parameters will also be obtained; vWF, factors VIII and XI, D-dimers, fibrinogen, platelets activation (multiplate), adams-13, anti-Xa and high sensitivity troponin. All samples will be obtained via puncture from a peripheral vein. Blood samples will obtained at three time points; preoperatively before induction to GA (01), early postoperatively in PACU (02) and postoperatively before discharge (10 days, 03). Of note, at 30 days our patients will undergo an evaluation for asymptomatic DVT with a US triplex scanner. In addition, any thromboembolic episode (deep vein thrombosis, pulmonary embolism) will also be recorded.
89319717|NCT05962424|Experimental|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
89319718|NCT05960253|Active Comparator|PENG block group|
89319719|NCT05960253|Experimental|L-ESP group|
89319720|NCT05950048|Experimental|Web-based breastfeeding counseling/experimental group|The web-based breastfeeding counseling/experimental group (n =33) will be given the web-based breastfeeding counseling.
89319721|NCT05950048|No Intervention|Control group|It will only take routine treatment and midwifery care.
89319722|NCT05949879|Experimental|Pecan LOW|Participants are given pecans and instructed on how to substitute study foods into their diet to maintain caloric balance.
89319723|NCT05949879|Experimental|Pecan MID|Participants are given pecans and instructed on how to substitute study foods into their diet to maintain caloric balance.
89319724|NCT05949879|Experimental|Pecan HIGH|Participants are given pecans and instructed on how to substitute study foods into their diet to maintain caloric balance.
89319725|NCT05949879|Experimental|CONTROL|Participants are asked to maintain their current habitual diet and avoid any tree nut/peanut consumption for the entire 28-day intervention period.
89319726|NCT05944250|No Intervention|control wound|standard of care dressing and bandages
89319727|NCT05944250|Experimental|matrix treated wounds|wounds treated with Spincare matrix device at monthly intervals or as required at the discretion of the principal investigator
89319728|NCT05943145|Experimental|Group Dance and Movement Training|Group dance and movement sessions
89319729|NCT05939700||Cohort 1|Pregnant or breastfeeding women exposed to mavacamten
88815131|NCT05395286|No Intervention|Control Group|Randomized to NOT attend the Innovation Lab
89319730|NCT05939011|Experimental|Well-formulated ketogenic diet (WFKD)|The researchers aim to enroll 20 healthy adults recruited from Kansas City and surrounding areas for an 8-week WFKD diet intervention. Study personnel will obtain baseline (week 0), mid-point (week 4), and end-of-study (8 weeks) blood samples, anthropometrics, and dietary intake data. Fecal microbiome samples and dual energy x-ray absorptiometry (DXA) are collected at baseline and 8-weeks. Blood samples collected at baseline and 8-week visits will be measured for metabolic biomarkers, inflammatory biomarkers, and RNA. The blood sample collected at the 4-week visit will include glucose, insulin, insulin resistance, and beta-hydroxybutyrate to track diet adherence and adjust the diet as needed.
89319731|NCT05934682||Children submitted to surgery|We will follow children submitted to surgery until hospital discharge or until 30 days after surgery.
89319732|NCT05934409|Active Comparator|Control group|without T2D according to Diabetes Canada diagnostics criteria:
89319733|NCT05934409|Experimental|group with Type 2 diabetes|with T2D according to Diabetes Canada diagnostics criteria:
89319734|NCT05924646|Experimental|Moderate Dietary Salt Plus Additional Salt|6 grams of salt in slow release capsules combined with 6 grams of salt in the diet.
89319735|NCT05924646|Placebo Comparator|Moderate Dietary Salt Alone|6 grams of microcrystalline cellulose in slow release capsules combined with 6 grams of salt in the diet.
89319736|NCT05923177|Experimental|The tested injected doses of [123I] I-(HE)3-G3 3000 μg|"At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced"
89319737|NCT05918120|Experimental|Home Sleep Apnea Test|Patients will undergo assessment for obstructive sleep apnea using a home sleep apnea test.
89319738|NCT05918120|Active Comparator|In-laboratory Polysomnography|Patients receive standard of care for diagnosing obstructive sleep apnea, which is in-laboratory polysomnography.
89319739|NCT05916495|Experimental|Hybrid care arm|Remote review of information collected electronically will be combined with in person visits at a hospital
89319740|NCT05916495|Active Comparator|Standard of care arm|Patients will be seen in person at a hospital clinic.
89319741|NCT05911568||Stroke patients with moderate-to-severe pre-stroke disability|Patients with pre-stroke modified Rankin scale score 3 or 4, presenting with a anterior circulation large vessel occlusion stroke within 24 hours of last known well
89319742|NCT05908214|Experimental|Stroke patients - training group|Participants in this group will take part in a 6-week WPHF NMES training period and plantar flexor neuromuscular function will be assessed before and after training.
89319743|NCT05908214|No Intervention|stroke patients - control group|Participants in this group will keep their daily life activities for 6 weeks and plantar flexor neuromuscular function will be assessed before and after training.
89319744|NCT05891678|No Intervention|Control group (N)|Central retinal artery Doppler in patient with normal ICP
89319745|NCT05891678|Active Comparator|Intervention group (H)|Central retinal artery Doppler in patient with increased ICP
89319746|NCT05865444|Experimental|Values alignment wise intervention|1 hour wise intervention (based on a values alignment approach) consisting on several tasks (online and paper-based tasks) to be completed individually.
89319747|NCT05865444|Active Comparator|Traditional educational intervention|1 hour traditional educational intervention on nutrition and physical exercise. This will also include reading and writing exercises.
89319748|NCT05860725|Experimental|PSA Development (Phase 1)|
89319749|NCT05860725|Experimental|Social Marketing Campaign (Phase 2)|
89319750|NCT05860725|No Intervention|Organizational Stakeholders|Organizational stakeholders from organizations involved in Phase 1 and 2 will take part in a focus group after their respective phases have been completed to learn more about their experience.
89319751|NCT05855850|Experimental|Active H4-coil dTMS treatment|
89319752|NCT05855850|Experimental|Active H7-coil dTMS treatment|
89319753|NCT05845749|Other|Vosoritide|This is a single arm open label study of daily SQ dose of vosoritide
89319754|NCT05836818|Experimental|Question (Q)|Subjects receive no vaccine messaging, but are asked a question about whether they would accept a vaccine
89319755|NCT05836818|Experimental|Messaging (M)|Subjects receive vaccine messaging and are asked a question about whether they would accept a vaccine
89319756|NCT05836818|No Intervention|Non intervention|Usual care
89319757|NCT05832554|Active Comparator|Nasopharyngeal airway|Patients with nasopharygeal airway placed
89319758|NCT05832554|Active Comparator|Orophryngeal airway|Patients with oropharygeal airway placed
89319759|NCT05831605|No Intervention|Control group|Venipuncture without near-infrared light
89319760|NCT05831605|Experimental|Experimental group|Venipuncture with near-infrared light
89319761|NCT05830136|Experimental|Group A|Sodium bicarbonate Ringer's solution group
89319762|NCT05830136|Active Comparator|Group B|Lactate Ringer's solution group
89319763|NCT05824559|Experimental|ME-344 and Bevacizumab|"ME-344 (IV) Cohort 1: Days 1, 8, and 15 of each 28-day cycle. Cohort 2: Days 1 and 15 of each 28-day cycle.~Bevacizumab (IV) Cohorts 1 and 2: Days 1 and 15 of each 28-day cycle."
89319764|NCT05822648|Experimental|Intervention|Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
89319765|NCT05822648|Active Comparator|Control|We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
89319766|NCT05820243|Experimental|Antihistamine|The oral antihistamine condition will consist of fexofenadine (540mg) and famotidine (40mg). Commercially available pills (3 x 180mg fexofenadine and 2 x 20mg famotidine) will be placed within opaque capsules and administered to the participants upon arrival to the laboratory.
89319767|NCT05820243|Placebo Comparator|Placebo|The placebo condition will consist of dextrose in an identical number of opaque capsules as the antihistamine treatment. Total dextrose will be <5g. The capsules will be administered to the participants upon arrival to the laboratory.
89319768|NCT05811585||Patient of a Laparoscopic Gynecologic Surgery|ADEPT administered intraperitoneally as a liquid, used for irrigation throughout the procedure and for final instillation of a suitable amount at the end of the procedure.
89319769|NCT05810051|Experimental|Optimal medical therapy (OMT) plus a program of cardiac rehabilitation (CR)|The intervention group will receive cardiac rehabilitation in addition to lifestyle changes and pharmacological treatment.
89319770|NCT05810051|No Intervention|Optimal medical therapy (OMT)|"The control group will be randomized to lifestyle changes and pharmacological treatment.~In the 7 to 14 days after randomization optimal medical therapy will be started."
89319771|NCT05806203|Active Comparator|Low Intensity plus PT|Participants receive active low intensity shockwave treatment from plus typical physical therapy.
89319772|NCT05806203|Sham Comparator|Sham Shockwave Treatment plus PT|Participant receives sham shockwave treatment plus typical physical therapy.
89319773|NCT05805618|Experimental|KH002|at low dose,150 mg(Cohort 1 ), 20 subjects are dosed Vaccine as experimental at high dose,300mg (Cohort 2), 20 subjects are dosed Vaccine as experimental
89319774|NCT05805618|Placebo Comparator|matching placebo|at low dose,150 mg(Cohort 1 ), 10 subjects are dosed placebo at high dose, 300mg(Cohort 2),10 subjects are dosed placebo
89319775|NCT05805280|Experimental|intravascular ultrasound-guided group|In the intravascular ultrasound-guided group, intravascular ultrasound will be either automatically (1 mm/sec) or manually (5-10 mm/sec) pulled back at a constant speed according to the lesion length. Stent size and length are selected by information acquired from on-line intravascular ultrasound examination, and adjunct high-pressure dilation is performed to achieve stent optimization based on the intravascular ultrasound finding
89319776|NCT05805280|Active Comparator|angiography-guided group|In the angiography-guided group, stent size and length are chosen by visual estimation, and adjunctive high-pressure dilation is performed if an optimal result, defined as angiographic residual diameter stenosis of less than 30% by visual estimation and the absence of angiographically detected dissection, , was not achieved
89319777|NCT05801445|Experimental|Occupational Arm|
89319778|NCT05801445|Active Comparator|Traditional Exercise Arm|
89319779|NCT05792241||Women of reproductive age|Randomly selected women of reproductive age in study communities.
89319780|NCT05780788|Experimental|Canine retraction arm|Canine retraction
89319781|NCT05780372|Experimental|Reduced CTVn2|Patients will receive the reduced neck prophylactic irradiation, only the level of positive lymph nodes and its next level.
89319782|NCT05780372|Active Comparator|Conventional CTVn2|Patients will receive the conventional neck prophylactic irradiation, as suggested by the international guideline.
89319783|NCT05775263||A-NRP|
89319784|NCT05775263||TA-NRP|
89319785|NCT05774873|Experimental|IBI334 E|
89319786|NCT05774873|Experimental|IBI334 D|
89319787|NCT05774873|Experimental|IBI334 C|
89319788|NCT05774873|Experimental|IBI334 A|
89319789|NCT05774873|Experimental|IBI334 F|
89319790|NCT05774873|Experimental|IBI334 B|
89319791|NCT05774691|Active Comparator|Routine protamine administration|Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin.
89319792|NCT05774691|Active Comparator|Selective protamine administration|Selective protamine administration, in case of (threatening) bleeding.
89319793|NCT05759143|Experimental|Nest Refinement Phase|"20 participants and clinicians will complete study procedures as outlined:~Nest portal orientation and access.~Semi-structured, 30-minute interviews. Solicited feedback on content and processes will refine the intervention for a pilot phase."
89319794|NCT05759143|Experimental|Nest Pilot Phase|"10 Participants and 10 clinicians will complete study procedures as outlined:~Baseline survey (participant).~Standard clinic visit.~Nest portal orientation and access (participant and clinician).~Post-visit survey (participant and clinician).~Brief, 30-minute, semi-structured interview (participant and clinician)."
89319795|NCT05756881|Active Comparator|Serum containing 1.5 % w/w of palm-oil derived vitamin E concentrate|Serum containing 1.5 % w/w of palm-oil derived vitamin E concentrate
89319796|NCT05756881|Placebo Comparator|Serum (placebo)|Serum (placebo)
89319797|NCT05754996|Experimental|lactulose plus nifuroxazide|"Nifuroxazide dosing : 800 mg daily in 4 divided doses for 7 days~Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day."
89319798|NCT05754996|Active Comparator|Lactulose alone|Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day.
89319799|NCT05751356|Experimental|TR128|
89319800|NCT05749653|Other|bi-annual CDTI|bi-annual CDTI with high coverage
89319801|NCT05741879|Experimental|Gamified online exercise in a family environment|Strength training Resistance training Flexibility training Basic motor skills training Executive function training
89319802|NCT05741879|Active Comparator|Standard care Non-supervised daily routines/activities|Non-supervised daily routines/activities
89319803|NCT05740176|Experimental|Synergy Disc|The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restore kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a two level discectomy for intractable radiculopathy and/or myelopathy.
89319804|NCT05736185|Experimental|EIT-PEEP strategy|PEEP selected by EIT which remained at 15 min
89319805|NCT05736185|Experimental|Low FiO2-PEEP strategy|PEEP selected by low FiO2-PEEP table which remained at 15 min
89319806|NCT05736185|Experimental|High FiO2-PEEP strategy|PEEP selected by high FiO2-PEEP table which remained at 15 min
89319807|NCT05734274|Experimental|Probiotics Lozenge|Subjects are instructed to take a lozenge twice a day, after brushing, in the morning and the evening.
89319808|NCT05734274|Sham Comparator|Negative control Lozenge|Subjects are instructed to take a lozenge twice a day, after brushing, in the morning and the evening.
89319809|NCT05723406|Experimental|Sugammadex|Sugammadex administration at the end of surgery
89319810|NCT05723406|Placebo Comparator|Placebo|Placebo administration at the end of surgery
89319811|NCT05713227|Active Comparator|Gellan gum|White rice test meal boiled in 356 g water containing 5.5g of gellan to each 185g of uncooked rice (50 g of available carbohydrate). Consumed on Day 1 at the study site, then consumed at home once daily for 7 days, then consumed again once at test site at Day 8
89319812|NCT05713227|Placebo Comparator|Control|White rice test meal boiled in 356 g water without gellan gum (50 g of available carbohydrate). Consumed on Day 1 at the study site, then consumed at home once daily for 7 days, then consumed again once at test site at Day 8
89319813|NCT05711160||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.~All patients have been undergoing CBCT scans for both jaws. Then, intraoral scanned of the dental arches of each patient have been taken using an intraoral scanner. Then measurements were made on digital images (CBCT & IOS) and on plaster models."
89319814|NCT05707923|Experimental|Utterance Type|This study uses a within-participant experimental manipulation. All participants will be exposed to all utterance types (across trials).
89319815|NCT05707000|Experimental|group A, Concentric Muscle Training|leg press, knee flexion, knee extension, Quad drills with 1 RM
89319816|NCT05707000|Experimental|group B, Quadriceps Facilitatory Kinesiotaping|kinesiotaping on the quadriceps muscle in the faciliatory mode
89319817|NCT05705596|Experimental|Sucrose|10% (w/v) sucrose in water
89319818|NCT05705596|Experimental|Hesperetin|7% (w/v) sucrose in water + 50 mg/L Hesperetin
89319819|NCT05705375|Experimental|waterpipe regular smokers|waterpipe regular smokers will be invited for 3 lab visits where they are allocated (random order) to smoke 3 waterpipe different sizes.
89319820|NCT05705219|Experimental|3-dimensional multi-parametric ultrasound imaging (3D-MPUS)|Participants will receive sulfur hexafluoride IV and undergo 3D-MPUS imaging over 20 minutes.
89319821|NCT05704855|Experimental|Combined Exercise + Behavioural Counselling|The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) items each week. Participants will also participate in bi-weekly, 30-40 minute, remotely-delivered behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). The program will be taught by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
89319822|NCT05704855|Active Comparator|Active Control|The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
89319823|NCT05695508|Experimental|Arm A Tec-DRd Induction and Tec-DR Maintenance|Arm A participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC and lenalidomide in maximum 18 cycles of maintenance therapy.
89319824|NCT05695508|Experimental|Arm B Tec-DVRd Induction and Tec-DR Maintenance|Arm B participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide, dexamethasone and bortezomib in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC and lenalidomide in maximum 18 cycles of maintenance therapy.
89319825|NCT05695508|Experimental|Arm C Tec-DR Maintenance|Arm C participants will receive maximum 18 cycles of teclistamab SC injection in combination with daratumumab SC and lenalidomide as maintenance therapy.
89319826|NCT05695508|Experimental|Arm A1 Tec-DRd Induction and Tec-DR Maintenance|Arm A participants will receive teclistamab as subcutaneous (SC) injection in combination with daratumumab SC, lenalidomide and dexamethasone in 6 cycles of induction therapy, followed by teclistamab SC injection in combination with daratumumab SC and lenalidomide in maximum 18 cycles of maintenance therapy.
89319827|NCT05695508|Experimental|Arm C1 Tec-DR Maintenance|Arm C participants will receive maximum 18 cycles of teclistamab SC injection in combination with daratumumab SC and lenalidomide as maintenance therapy.
89319828|NCT05694351|Experimental|Families with type 2 diabetes|Families (n=25) of at least two family members - minimum one adult and one child per family unit (appx. 100 individuals in total) will be included. A convenient study sample will be composed with no restriction to family types - traditional nuclear families, same-sex parenting families, single-parent families, or blended/ step-parent families). Balanced representation of different geographical areas within Region Zealand will be attempted.
89319829|NCT05691647|Experimental|Chronotherapy + treatment as usual|
89319830|NCT05691647|Active Comparator|Treatment as usual|medication, cognitive behavioral therapy, and other psychotherapies.
89319831|NCT05689502|Experimental|Treatment|
89319832|NCT05687383|Experimental|Safe breastfeeding pillow|Safe breastfeeding pillow increase the comfort and safety of postpartum women during breastfeeding, thereby prolonging breastfeeding and ensuring optimal nutrition for the baby
89319833|NCT05687383|Placebo Comparator|Breastfeeding pillow|Providing a comfortable, supportive and safe environment for healthier and breastfeeding for women and babies
89319834|NCT05686473|Experimental|Patient group|Single arm study. The family with child with FASD will act as its own control in the period before intervention starts.
89319835|NCT05675150|Experimental|Intervention|This arm of participants will be receiving expressive arts-based intervention as intervention
89319836|NCT05675150|No Intervention|Wait-list control|This arm of participants will not receive any art-based intervention during the study and are allocated as a wait-list control group
89319837|NCT05670704|Experimental|ARGX-119|Patients receiving ARGX-119 IV or SC
89319838|NCT05670704|Placebo Comparator|Placebo|Patients receiving Placebo IV or SC
89319839|NCT05665140|Active Comparator|Arm A (Control)|"Three cycles of induction (isatuximab, bortezomib, lenalidomide, dexamethasone, I-VRD), followed by standard of care therapy (e.g. stem cell mobilization, and apheresis with a subsequent high-dose melphalan and autologous stem cell transfusion).~Both groups will receive subsequently an isatuximab- and lenalidomide-based maintenance therapy."
89531627|NCT05910814|Experimental|MI+HIIE (motor imagery + high-intensity interval physical exercise)|Acquired the motor sequence mentally and achieve a HIIE before the consolidation
88815937|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Juice|
88815938|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Sauce|
89319840|NCT05665140|Experimental|Arm B (Experimental)|"Three cycles of induction (I-VRD), stem cell mobilization, and apheresis followed by three cycles of consolidation (I-VRD).~Both groups will receive subsequently an isatuximab- and lenalidomide-based maintenance therapy."
89319841|NCT05659849|Experimental|Manual therapy with Neuromuscular training|"Manual physical therapy is intended to improve musculoskeletal function and pain by addressing impaired kinematics of the joint. Passive Joint Mobilization (PJM) was applied to knee distraction and dorsal glides, ventral glides, and patellar glides in all directions, which were applied at a rate of two to three oscillations per second for 1-2 min. Each direction was repeated three to six times.~Neuromuscular training (NEMEX-TJR training program):~(2 times per week for 6 weeks) The neuromuscular training program consists of 3 parts: warming up, a circuit program, and cooling down. The program is performed twice a week for 6 weeks, with each session lasts for 60 minutes."
89319842|NCT05659849|Experimental|Conventional physical therapy with Neuromuscular training|"Physical therapists use a variety of transcutaneous electrical nerve stimulation (TENS) applications to reduce or alleviate pain for individuals with Knee OA. TENS (symmetrical biphasic waveform, frequency 32-50 Hz, pulse width 80 microseconds) for the same amount of time and the same number of days. The TENS electrodes were applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care was taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg.~Neuromuscular training (NEMEX-TJR training program):~(2 times per week for 6 weeks) The neuromuscular training program consists of 3 parts: warming up, a circuit program, and cooling down. The program is performed twice a week for 6 weeks, with each session lasts for 60 minutes."
89319843|NCT05656170|Experimental|Stellate ganglion block arm|This arm will receive a one time bilateral stellate ganglion block with 20 cc bupivacaine (10 cc per side).
89319844|NCT05656170|Sham Comparator|Placebo arm|This arm will receive a one time bilateral injection with 20 cc normal saline(10 cc per side).
89319845|NCT05644795|Active Comparator|Active Comparator: wheat/milk free diet (W/MFD) group|Patients randomized to intervention group will go to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.
89319846|NCT05644795|Placebo Comparator|Placebo Comparator: rice/turkey free diet (R/TFD) group|Patients randomized to control group will go to a 2 months elimination diet (rice and turkey's meat). After 2 months of elimination diet they will crossover to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.
89319847|NCT05644782|Active Comparator|Open wheat challenge group|Before starting the elimination diet (time 0, T0), intervention patients will be evaluated by experienced dermatologists, as well as by physicians with expertise in the field of food intolerance about GI and extraintestinal symptoms related to foods intake. Moreover, all these subjects will be subjected to blood, urine, and stools collections, and to a dietary consult, and a food and symptom's diary will be provided to all patients, which must be filled-in daily. After 2 months of elimination diet (time 1, T1), intervention patients will be evaluated again both clinically and by laboratory techniques, identically to T0. At this time-point, intervention patients will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify (T2int), patients will be valued again both clinically and by laboratory techniques, identically to T0 and T1, and then will end the study.
89319848|NCT05644782|Placebo Comparator|Placebo group|Before starting the elimination diet (time 0, T0), control patients will be evaluated by experienced dermatologists, as well as by physicians with expertise in food intolerance. Moreover, patients will be subjected to blood, urine, and stools collections, and to a dietary consult, and a food and symptom's diary will be provided. After 2 months of elimination diet (time 1, T1), patients will be evaluated, identically to T0. Then, control patients will be asked to repeat the elimination diet, this time removing wheat and all cow's milk products for further 2 months (T2con). Then, patients will be valued again both clinically and by laboratory techniques, identically to T0 and T1. Then, patients will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify (T3con), patients will be valued again, identically to T0, T1 and T2con, and then will end the study.
89319849|NCT05631067|Experimental|BP monitoring arm|Participants will be adults >18 years of age admitted for delivery with a diagnosis of HDP (i.e., chronic hypertension, gestational hypertension, preeclampsia, eclampsia, the HELLP syndrome, or chronic hypertension with superimposed preeclampsia) per the American College of Obstetricians and Gynecologists Criteria.
89319850|NCT05631067|Active Comparator|Control arm|Control participants will be adults >18 years of age with an uncomplicated pregnancy and delivery, and without a diagnosis of HDP.
89319851|NCT05629715|Active Comparator|ROSA|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using the ROSA Knee System.
89319852|NCT05629715|Active Comparator|KneeAlign|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using the KneeAlign navigation system.
89319853|NCT05629715|No Intervention|Conventional|Subjects randomly assigned to this arm will undergo a primary total knee arthroplasty procedure using conventional instrumentation.
89319854|NCT05627440|Experimental|Experimental arm|30 g/day protein supplementation (1 Ensure Max Protein® bottle)
89319855|NCT05627440|Active Comparator|Sham comparator arm|9 g/day protein supplementation (1 Ensure Original® bottle)
89319856|NCT05627440|No Intervention|No intervention arm|0 g/day protein supplementation (no Ensure bottles)
89530147|NCT02680067|Experimental|Developmental arm - Healthy or rheumatoid arthritis subjects|Subjects in the developmental arm will have a minimum of two study visits to determine the optimal conditions for visualizing lymphatic transport in the upper extremities. Concentrations of 0.1 mg/ml of Indocyanine Green (ICG) will be injected intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). An ultrasound of the upper extremities may be performed after the ICG fluorescence is observed. The exam will help identify the location of the lymphatic vessels and nodes in the areas fluoresced.
89319857|NCT05625529||Cohort 1|"Individuals without history of PDAC meeting any of the following criteria:~A. 2+ relatives with PDAC on same side of family; 2 are first degree related to each other and at least 1 is first degree related to subject; age ≥ 50 years or ≤10 years younger than earliest PDAC in family at diagnosis.~B. 2+ first degree relatives with PDAC; age ≥ 50 years or ≤ 10 years younger than earliest PDAC in family at diagnosis.~C. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age ≥ 50 years or ≤ 10 years younger than earliest PDAC in family at diagnosis.~D. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age ≥ 40 years.~E. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age ≥35 years.~F. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age ≥ 40 years."
89319858|NCT05625529||Cohort 2|"Individuals without history of PDAC meeting any of the following criteria:~A. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history; age ≥50 years.~B. Two or more (2+) relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age ≥50 years or ≤10 years younger than earliest PDAC in family at time of diagnosis.~C. One (1) first degree relative with PDAC at age ≤45 years; ≤10 years younger than PDAC diagnosis in family member at time of diagnosis."
89319859|NCT05625529||Cohort 3|A. Individuals meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2); age ≥ 18 years.
89319860|NCT05625529||Cohort 4|A. Individuals without history of PDAC presenting for evaluation who do not meet any criteria for the other cohorts after collection of full family history and/or germline testing, eg. they have only 1 relative with PDAC; age ≥ 18 years.
89319861|NCT05625529||Cohort 5 - Personal history of PDAC|"Individuals with a personal history of PDAC meeting any of the following criteria (age ≥ 18 years for all subgroups):~A. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other.~B. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PRSS1, STK11.~C. Diagnosed with PDAC at ≤ age 45."
89319862|NCT05625529||Cohort 6 - Pancreatic cysts|"Individuals with pancreatic cysts (age ≥ 18 years for all subgroups):~A. Individuals with a pancreatic cystic neoplasm (IPMN) and/or mucinous cystic neoplasm (MCN) and/or PanIN not meeting any criteria for Cohorts 1-3 or 6 (no personal history of PDAC, no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk present in cohorts 1C, 2A, 1D, 1E, and 1F).~B. Individuals with a pancreatic cystic neoplasm (IPMN) and/or MCN and/or PanIN without PDAC and with at least one of the pathogenic or likely pathogenic gene mutations present in cohorts 1C, 2A, 1D, 1E, and 1F and/or a first degree relative with PDAC."
89319863|NCT05625529||Cohort 7 - Acute or chronic pancreatitis|"Individuals with a personal history of pancreatitis meeting any of the following criteria (age ≥ 18 years for all subgroups):~A. Chronic pancreatitis. B. At least 2 episodes of acute pancreatitis."
89319864|NCT05625529||Cohort 8 - PDAC stages I-II or clinical suspicion|"Individuals with one of the following conditions and treatment naïve (age ≥ 18 years for all subgroups):~A. Biopsy-proven, clinical stage I-II PDAC and candidate for surgical resection.~B. Clinical findings suspicious for early stage PDAC prior to biopsy."
89319865|NCT05624060|Active Comparator|Control Group|Pelvic Floor Dysfunction Prevention Training
89319866|NCT05624060|Experimental|Experimental Group 1|Pelvic Floor Dysfunction Prevention Training and Perineal Massage
89319867|NCT05624060|Experimental|Experimental Group 2|Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise
89319868|NCT05623358|Experimental|Pharmacist-led HFrEF medication optimization|
89319869|NCT05623358|Other|Usual care|Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services.
89319870|NCT05620212||RC Group|Recovery College partakers in any way (see description of intervention).
89319871|NCT05620212||Control Group|Participants with similar mental health profile as RC group, but do not participate in an RC. These participants are sampled from the Panel Psychisch Gezien (PPG), monitored by the Trimbos-institute.
89319872|NCT05619328|Experimental|Vitamin B combination tablet (B1, B6, B12)|
89319873|NCT05619328|Placebo Comparator|Placebo tablet|
89319874|NCT05619250|Experimental|Unsupervised home-based exercise group without motivational intervention (UNSUP)|Participants will use a mobile application to perform a home-based training program autonomously, without the face-to-face supervision of a specialist during its execution.
89319875|NCT05619250|Experimental|Unsupervised home-based exercise group with motivational intervention (UNSUP+)|"Participants will use a mobile application to perform a home-based training program autonomously, without the face-to-face supervision of a specialist during its execution. As opposed to the UNSUP group, the UNSUP+ group will receive a motivational intervention."
88806563|NCT01793324||UK|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer during the calendar period from 11 January 2012 - 31 July 2012
88806564|NCT05902299||Before antibiotic susceptibility testing|
88806565|NCT05902299||After antibiotic susceptibility testing|
88806566|NCT05902286|Experimental|OSC+|The 25 participants assigned to the OSC+ condition will complete a five-week intervention for the Osc+ portion of the study using emWave software for biofeedback. There will be one 30-60 minute in-person HRVB session once a week completed at the University Parkway Center. In addition to the in-person session, the participant will complete four 20-minute homework sessions during the following week. The format of five weeks of one weekly session and four homework sessions is effective at helping participants learn and implement breathing and biofeedback skills. The five HRVB session will be based on the Lehrer and colleagues' protocol.
89319876|NCT05619250|Experimental|Supervised center-based exercise group without motivational intervention (SUP)|Participants will perform a center-based training program in small groups with a maximum of 8 participants per session, being supervised by an exercise professional.
89531628|NCT05910814|Experimental|PP+HIIE (physical practice + motor imagery + high-intensity interval physical exercise)|Acquired the motor sequence physically and achieve a HIIE before the consolidation
89319877|NCT05619250|Experimental|Supervised center-based exercise group with motivational intervention (SUP+)|"Participants will perform a center-based training program in small groups with a maximum of 8 participants per session, being supervised by an exercise professional. As opposed to the SUP group, the SUP+ group will receive a motivational intervention."
89319878|NCT05619250|No Intervention|Control group (CON)|Participants will not perform any type of exercise program during the intervention period and will be advised to maintain their usual lifestyle.
89319879|NCT05619094|Experimental|Corrective Exercise|Selective corrective exercise program, 8 weeks
89319880|NCT05619094|No Intervention|Control|Training for proper posture
89319881|NCT05615675|Experimental|Virtual Reality|Patients undergo prone pain procedure with virtual reality distraction
89319882|NCT05615675|No Intervention|Control|Patients undergo prone pain procedure without virtual reality distraction
89319883|NCT05615155|Experimental|i-PRF|The sides of the mouth that will be injected with injectable-Platelets Rich Fibrin
89319884|NCT05615155|Experimental|C-PRF|The sides of the mouth that will be injected with Concentrated-Platelets Rich Fibrin
89319885|NCT05609292||Study group|Infants will get their temperature measured with the liquid crystal thermometer. We are not providing any interventions as they will be in the care of a healthcare team.
89319886|NCT05608343|Active Comparator|Difamilast Ointment|1% Difamilast Ointment
89319887|NCT05608343|Placebo Comparator|Vehicle Controlled|Matching placebo
89319888|NCT05606705|Experimental|Baked Milk|Baked milk introduction into diet
89319889|NCT05606523||Cachectic patients with pancreatic cancer|Measurements and sample collection at one timepoint.
89319890|NCT05606523||Non-cachectic patients with pancreatic cancer|Measurements and sample collection at one timepoint.
89319891|NCT05606523||Healthy volunteers|Measurements and sample collection at one timepoint.
89319892|NCT05603143|Experimental|Obeldesivir|Participants will receive obeldesivir 350 mg twice daily for 5 days.
89319893|NCT05603143|Placebo Comparator|Placebo|Participants will receive placebo twice daily for 5 days.
89319894|NCT05600634||Kidney and skin transplataiton|
89319895|NCT05595421|Experimental|The right cerebellum (anode) and the left OFC (cathode) tDCS|Stimulation sessions will be carried out using a neuroConn DC stimulator (Ilmeneau, GmbH) with two rubber electrodes placed inside two 5 × 7 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). Electrodes will be placed on the basis of the international 10-20 electrodes placement system. The cathode will be placed over the left OFC on the FP1 point according to the EEG international reference. The anode will be placed over the right cerebellum 3 cm below the inion and 1 cm right from the midline. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
89319896|NCT05595421|Experimental|The bilateral pre-SMA (cathode) and right deltoid (reference) tDCS|Stimulation sessions will be carried out using a neuroConn DC stimulator (Ilmeneau, GmbH). The stimulator is connected to two rubber electrodes which are placed inside two sponge electrodes soaked in a saline solution (0.9% NaCl), respectively. The active electrode (cathode) is 5×5 cm and placed on the sagittal midline at 15% of the distance between inion and nasion anterior to Cz (vertex), using the International 10-20 EEG System, to target the bilateral presupplementary motor area (pre-SMA). The reference electrode is 5×7 cm and placed on the lateral surface of the patient's right deltoid. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
89319897|NCT05595421|Experimental|The left OFC (cathode 1), bilateral pre-SMA (cathode 2), and right deltoid (reference) tDCS|Stimulation sessions are carried out using a neuroConn DC stimulator (Ilmeneau, GmbH). The stimulator is connected to a 2 × 1 wire adaptor (Equalizer Box, NeuroConn) that links three rubber electrodes placed inside sponge electrodes soaked in a saline solution (0.9% NaCl) will be applied. One active electrode (the 1st cathode) is 5×5 cm and placed on the sagittal midline at 15% of the distance between inion and nasion anterior to Cz (vertex), using the International 10-20 EEG System, to target the bilateral presupplementary motor area (pre-SMA). The other active electrode (the 2nd cathode) is 5×7 cm and placed over the left OFC on the FP1 point according to the EEG international system. The reference electrode is 5×7 cm and placed on the lateral surface of the patient's right deltoid. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min.
89319898|NCT05590884|Experimental|Age Group 1: patients aged 3 to 23 months|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
89319899|NCT05590884|Experimental|Age Group 2: patients aged 28 days to less than 3 months|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
89319900|NCT05590884|Experimental|Age Group 3: patients aged from birth to 27 days (term newborns)|One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.
89319901|NCT05589766|Placebo Comparator|Placebo|Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (12 weeks).
89319902|NCT05589766|Experimental|Dietary Supplement: NR 1000mg group|Nicotinamide Riboside 1000mg total daily. Administered in capsule form in doses of 500mg twice daily for the duration of the trial (12 weeks).
89319903|NCT05589766|Experimental|Dietary Supplement: NR dose escalation group|Nicotinamide Riboside dose escalation group: 1000mg NR daily in doses of 500mg twice daily (week 1 - week 4), 2000mg NR daily in doses of 1000mg twice daily (week 5 - week 8), 3000mg NR daily in doses of 1500mg twice daily (week 9 - week 12).
89319904|NCT05587374|Experimental|Cadonilimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
89319905|NCT05587374|Active Comparator|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
89319906|NCT05585827|Experimental|Immediate eCBT with concurrent TAU|Those randomized into the this group will get immediate e-CBT with TAU.
89319907|NCT05585827|No Intervention|Delayed eCBT with concurrent TAU|Those randomized to the delayed arm of the study, will receive TAU and wait 14 weeks before receiving the intervention. TAU will include ongoing review by the patient's primary care physician, neurologist and PD nurse. TAU does not preclude clinically indicated adjustments to medication or specialist referrals but physicians are asked to keep medication constant if possible. For patients with PD ordinary treatment includes a multitude of interventions, including pharmacological treatment, speech therapy and physical therapy. Pharmacological interventions include the use of dopaminergic treatments, including levodopa and dopamine agonist use, with adjunct use of monoamine oxidase B-inhibitors.
89319908|NCT05583175|Experimental|Venetoclax plus RIC|Administration with oral Venetoclax plus RIC regimen for allo-HSCT in the elderly patients with myeloid malignancies.
89319909|NCT05582980|Experimental|HD-tDCS (active)|Stimulation will be applied by a battery-operated device (NeuroConn DC Stimulator Plus) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration). To target the left DLPFC, the central electrode (anode) will be placed over International 10-20 electrode position F3, with return peripheral electrodes at Fp1, Fz, C3 and F7. Stimulation will be applied at an intensity of 2 milliamp (mA), 8-sec fade in and 5-sec fade out, for 20 min, two times daily, on 5 consecutive weekdays (total 10 sessions). During each session, the subject has to perform a computerized working memory task (i.e., 2-back task). The two times daily sessions will be separated by at least 2 hours.
89319910|NCT05582980|Sham Comparator|HD-tDCS (sham)|In sham stimulation, the electrode montage and protocol will be the same as the active stimulation, except the 2 mA current will be turned on for 30 sec and then ramped down to 0 mA through the remainder of the 20-min time.
89319911|NCT05565989|Active Comparator|control (MI)|Motivational Interview
89319912|NCT05565989|Experimental|experimental (MI/MBM/II)|Motivational Interview + mindfulness-bases meditation practice + intention implementation
89319913|NCT05553184|Active Comparator|Acute Cold Exposure|3h-acute cold exposure.
89319914|NCT05553184|Experimental|Formoterol with nicotinic acid|"Formoterol fumarate or Oxeze® Turbuhaler®: 48 µg (4 inhalations of 12 µg).~Nicotinic acid or Niacin: repeated doses of 150 MG every 30 minutes, for 3 hours."
89319915|NCT05553184|Experimental|Formoterol without nicotinic acid|Formoterol fumarate or Oxeze® Turbuhaler®: 48 µg (4 inhalations of 12 µg).
89319916|NCT05550623|Experimental|Transfemoral amputation performed with tourniquet application|"Group 1:Randomized to procedure with Tourniquet application Sterile wash to groin and placement of sterile tourniquet. The amputation level approximately 10-15 cm above the upper edge of patella is marked and the anterior and posterior flaps are measured and drawn out.~The leg is lifted, and the tourniquet is inflated. The pressure is set to 250 mmHg. Starting time is noted. Incision through skin, fascia and musculature. The femoral vessels are clamped, cut and ligated. With an oscillating saw the femoral bone is cut, and the leg can be removed The tourniquet is deflated. Tourniquet time is noted. Rest of procedure as listed in arm2~Weight of the leg is noted. Weight of surgical swabs is noted, to estimate intraoperative blood loss."
89319917|NCT05550623|No Intervention|Transfemoral amputation performed without tourniquet application|"Group 2: Randomized to procedure without Tourniquet The amputation level approximately 10-15 cm above the upper edge of patella is marked and the anterior and posterior flaps are measured and drawn out. Incision through skin, fascia and musculature. The femoral vessels are clamped, cut and ligated. With an oscillating saw the femoral bone is cut, and the leg can be removed.~The edge of the femoral bone is rasped smooth. A myodesis is performed, attaching the adductor muscle to the end of the femoral bone. Nervus Ischiadicus is dissected as proximal as possible and protected within a purse string suture to avoid development of neuroma.~Ligation of bleeding vessels. Fascia and skin is closed with sutures. A soft compression bandage is applied to the stump.~Weight of the leg is noted.~Weight of surgical swabs is noted, to estimate intraoperative blood loss."
89319918|NCT05548777||Patients hospitalized for an anticoagulation-related major bleed|
89319919|NCT05544721|Active Comparator|Paravertebral block pre procedure|Subjects will receive a preoperative paravertebral block only
89319920|NCT05544721|Active Comparator|Paravertebral block pre and post procedure|Subjects will receive one paravertebral block, administered preoperatively and one paravertebral block, administered on postoperative day 1
89319921|NCT05530538|Experimental|BrainWeighve Intervention|4-month smartphone-based weight loss intervention for teens based on displacement theory of addictive behaviors
89319922|NCT05527509|Active Comparator|Standard Training Condition (STC)|"The STC has received the standard RCMP Depot Division (Depot) Cadet Training Program as has been provided to cadets prior to June 2022. The STC and the ATC will complete the same standardized self-report assessments, clinical interview assessments, and biometric assessments, and receive the same feedback and reporting based on those assessments."
89530148|NCT02680067|Experimental|Clearance arm - Healthy individuals|Subjects in the clearance arm will have an initial study visit that involves injections of 0.1 mg/ml of Indocyanine Green (ICG) intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). Follow up imaging sessions will occur weekly for three weeks for a minimum of four study visits total.
89530149|NCT03346811|Experimental|Experimental: icotinib|Patients diagnosed with lung cancer with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
89319923|NCT05527509|Experimental|Augmented Training Condition (ATC)|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based cognitive-behavioral intervention designed to cultivate constructive approach-oriented emotional engagement. The 13-week Emotional Resilience Training (ERST) is an adaptation of the UP designed for use as a proactive training course. The ERST frames emotional experiences as natural responses to threat, rather than pathological occurrences to avoid; as such, the ERST is well-suited for mitigating health challenges and the skills may also help PSP to support persons in distress, including other PSP and the community members they all serve. The ERST training materials include an instructor guide, didactic PowerPoints, and a trainee workbook. The ERST was designed for seamless integration with the Cadet Training Program, effective June 2022, which is what creates the augmented training arm (i.e., the ATC).
89319924|NCT05525845|Other|Food-Print Main Arm|Functional Magnetic Resonance Imaging (pCASL-MRI) after Caloric and Volumetric stimulus in lean patients will be performed on all patients in the study
89319925|NCT05525286|Experimental|SOT102|"SOT102 is administered as intravenous infusion over 45 minutes as monotherapy or in combination with established standard of care therapy, every 14 days until the disease progression or intolerance to SOT102. SoC therapy is administered as per approved local standards.~Starting dose of SOT102 is 0.032 mg/kg. Dose levels are to be escalated according modified Fibonacci scheme."
89319926|NCT05523661|Experimental|Dasatinib plus anti-CD19/CD22 CAR-T cells|Administration with oral Dasatinib plus anti-CD19/ CD22 CAR-T cells in the elderly Ph-positive ALL patients.
89319927|NCT05522439|Experimental|Subjects receiving SHR-1703 dose 1|
89319928|NCT05522439|Experimental|Subjects receiving SHR-1703 dose 2|
89319929|NCT05522439|Experimental|Subjects receiving SHR-1703 dose 3|
89319930|NCT05522439|Placebo Comparator|Placebo|
89319931|NCT05516082|Experimental|Lens A|All participants wore Lens A for 15 minutes (Period 1)
89319932|NCT05516082|Experimental|Lens B|All participants wore Lens B for 15 minutes (Period 2)
89319933|NCT05515887|Experimental|Shenqu Xiaoshi Oral liquid|Shenqu Xiaoshi Oral liquid will be taken orally.
89319934|NCT05514899|Experimental|THC first, then CBD|THC 10mg daily for 2 weeks, followed by washout for 2 weeks, followed by CBD 600mg daily for 2 weeks
89319935|NCT05514899|Active Comparator|CBD first, then THC|CBD 600mg daily for 2 weeks, followed by washout for 2 weeks, followed by THC 10mg daily for 2 weeks
89319936|NCT05513300|Experimental|HIIT group|Participants randomized in this group will be assigned to 12 weeks high intensity interval training.
89319937|NCT05513300|Experimental|MICT group|Participants randomized in this group will be assigned to 12 weeks of moderate-intensity continuous training.
89319938|NCT05513300|No Intervention|Control group|
89319939|NCT05509192|Experimental|MTPI group|
89319940|NCT05509192|Active Comparator|Classic Induction group|
89319941|NCT05498779||Non-resectable hepatocellular carcinoma|Patients treated with ablation therapy as first treatment for non-resectable hepatocellular carcinoma.
89319942|NCT05497388|No Intervention|Web for HCV education|
89319943|NCT05497388|Experimental|Serious Game for HCV education|
89319944|NCT05490433|Experimental|robot assisted nipple sparing mastectomy(RNSM)|Robotic nipple sparing mastectomy, robotic mastectomy, hybrid robotic nipple sparing mastectomy, robotic nipple mammary complex and skin sparing mastectomy, robot nipple sparing mastectomy
89319945|NCT05490433|Active Comparator|Conventional nipple sparing mastectomy(CNSM)|Total mastectomy, mastectomy, nipple sparing mastectomy, skin sparing mastectomy, nipple sparing breast resection, open nipple sparing mastectomy, general nipple sparing Mammastectomy, an open-window nipple sparing mastectomy
89319946|NCT05488912||Healthy BMI (20-25 kg/m2, n=30)|A group of 30 Hispanic/Latino adults who are NH residents residing in SNAP-eligible households, and have a BMI between 20 and 25 kg/m2.
89319947|NCT05488912||Overweight/Obese BMI (>28 kg/m2, n=30)|A group of 30 Hispanic/Latino adults who are NH residents residing in SNAP-eligible households, and have a BMI greater than or equal to 28 kg/m2.
89319948|NCT05487807|No Intervention|Standard of Care|This is the baseline group receiving advice to quit.
89319949|NCT05487807|Active Comparator|Nicotine Replacement|This group will receive the standard of care and be prescribed nicotine replacement therapy
89319950|NCT05487807|Active Comparator|Text Messaging|This group will receive the standard of care and receive text message support
89319951|NCT05487807|Active Comparator|Nicotine replacement and text messaging|This group will receive the standard of care, be prescribed nicotine replacement therapy, and receive text message support
89319952|NCT05472194|Experimental|Experimental Condition|Participants allocated to the Experimental condition will be following a cognitive training program using a set of game-based activities specifically developed to train executive functions.
89319953|NCT05472194|Active Comparator|Control Condition|Participants allocated to the Control condition will be following the same sessions of the training program (similar to the Experimental group) while playing with a set of commonly used games within the school context (e.g. puzzles).
89319954|NCT05469971||NCWS patients|"The researchers will enrol NCWS, presenting with IBS and/or dyspepsia-like symptoms, according to the Rome IV criteria (20). These patients were diagnosed by DBPC wheat challenge between January 2010 and June 2022 in three tertiary centers for gluten-related disorders (Department of Internal Medicine, University Hospital of Palermo, Italy; Department of Internal Medicine, Cervello Hospital of Palermo, Italy, and Department of Internal Medicine, Hospital of Sciacca, Agrigento, Italy."
89319955|NCT05469971||Celiac disease|"The researchers will enrol CD patients diagnosed between January 2010 and June 2022 in three tertiary centers for gluten-related disorders (Department of Internal Medicine, University Hospital of Palermo, Italy; Department of Internal Medicine, Cervello Hospital of Palermo, Italy, and Department of Internal Medicine, Hospital of Sciacca, Agrigento, Italy."
89319956|NCT05469971||Blood donors|The researchers will enroll blood donors from the Transfusion Centre of the University Hospital of Palermo, Italy.
89319957|NCT05469958|Experimental|Intervention group|a bundle of hypothermia prevention measures will be applied
89319958|NCT05469958|Active Comparator|Control group|Conventional care with textile blankets under patient demand.
89319959|NCT05466006|Active Comparator|Subepithelial Connective Tissue Graft (SCTG)|Soft tissue augmentation at peri-implant small buccal dehiscence with subepithelial connective tissue graft harvested from the patient's palate
89319960|NCT05466006|Experimental|Volume Stable Collagen Matrix (VCMX)|Soft tissue augmentation at peri-implant small buccal dehiscence with xenogenic volume stable collagen matrix
89319961|NCT05459753|Experimental|Parkinson's Disease|Individuals with idiopathic Parkinson's disease.
89319962|NCT05447377|Experimental|SII Yellow Fever Vaccine Lot A|"SII-YFV Lot A:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot A will be administered concomitantly with an MMR and a Men A vaccine."
89319963|NCT05447377|Experimental|SII Yellow Fever Vaccine Lot B|"SII-YFV Lot B:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot B will be administered concomitantly with an MMR and a Men A vaccine."
89319964|NCT05447377|Experimental|SII Yellow Fever Vaccine Lot C|"SII-YFV Lot C:~SII Yellow Fever vaccine is Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~Diluent: 0.5 mL of sterile water for injection~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of SII-YFV Lot C will be administered concomitantly with an MMR and a Men A vaccine."
89319965|NCT05447377|Active Comparator|STAMARIL®|"STAMARIL is a Live attenuated Yellow Fever Virus (17D-204 Strain) not less than 1000 IU/dose produced in specified pathogen-free chick embryos.~Solvent: Sodium Chloride 2.0 mg; Water for injections up to 0.5 mL.~In this arm a total of 554 participants will be enrolled. All participants will receive a single dose of STAMARIL will be administered concomitantly with an MMR and a Men A vaccine."
89319966|NCT05443035|Experimental|Antimicrobial PDT and Papacarie Deproteination Group|The participants will receive selective chemical-mechanical removal of carious dentinal tissue around the walls of the cavity using a curette, followed by the application of antimicrobial PDT and deproteination with Papacárie DuoTM.
89319967|NCT05443035|Experimental|Antimicrobial PDT group and deproteination with NaClO 5% group|The participants will receive selective removal of carious dentinal tissue using a curette, followed by application of antimicrobial PDT and deproteination with NaClO 5%.
89319968|NCT05443035|Experimental|Control group|The participants will receive selective removal of carious dentinal tissue using a curette.
89319969|NCT05440942|Experimental|Part 1 Schedule A: TR^2 Dose Escalation/De-Escalation|"Participants in this group will receive Trametinib, Ruxolitinib and Retifanlimab in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD). Participants will receive Trametinib and Ruxolitinib for two weeks on (Days 1-14) and two weeks off (Days 15-28) and Retifanlimab on Day 8 of a 28-day cycle. Doses will be administered as follows:~Dose Level -1A: Trametinib 1 mg orally (PO), Ruxolitinib 5 mg PO, Retifanlimab 500 mg intravenously (IV);~Starting Dose Level 1A: Trametinib 1.5 mg PO, Ruxolitinib 10 mg PO, Retifanlimab 500 mg IV;~Dose Level 2A: Trametinib 2 mg PO, Ruxolitinib 10 mg PO, Retifanlimab 500 mg IV;~Dose Level 3A: Trametinib 2 mg PO, Ruxolitinib 15 mg PO, Retifanlimab 500 mg IV."
89319970|NCT05440942|Experimental|Part 1 Schedule B: TR^2 Alternate Schedule|Participants in this group will receive the MTD determined in Part 1 Schedule A on a continuous dosing cycle: Trametinib and Ruxolitinib on Days 1-28 and Retifanlimab on Day 8 of a 28-Day Cycle.
89319971|NCT05440942|Experimental|Part 2: TR^2 Expansion Cohort|Participants in this group will receive Trametinib, Ruxolitinib and Retifanlimab at the most appropriate dose and schedule determined in Part 1. Participants will continue to receive treatment as long as receiving clinical benefit or until disease progression.
89319972|NCT05440266|Active Comparator|First: half-sine wave stimulation; Second: rectangular shaped stimulation|"First appointment:~Intracutaneously applied electrical 25 ms half-sine wave stimulation with 2 Hz frequency.~Second appointment:~Intracutaneously applied electrical 500 µs rectangular shaped stimulation with 2 Hz frequency."
89319973|NCT05440266|Active Comparator|First: rectangular shaped stimulation; Second: half-sine wave stimulation|"First appointment:~Intracutaneously applied electrical 500 µs rectangular shaped stimulation with 2 Hz frequency.~Second appointment:~Intracutaneously applied electrical 25 ms half-sine wave stimulation with 2 Hz frequency."
89319974|NCT05437575|Experimental|Ketamine Hydrochloride|2 blinded doses 2.5mg/ml ketamine hydrochloride in separately sealed pre-filled syringes Subjects will be administered the first dose over approximately 2 minutes via slow IV push. Pain assessment following administration will be obtained and recorded every 15 minutes. Redosing may occur after 15 minutes if indication for pain management remains and there are no adverse events
89319975|NCT05437575|Active Comparator|Fentanyl Citrate|2 blinded doses 10mcg/ml in separately sealed pre-filled syringes Subjects will be administered the first dose over approximately 2 minutes via slow IV push. Pain assessment following administration will be obtained and recorded every 15 minutes. Redosing may occur after 15 minutes if indication for pain management remains and there are no adverse events
89319976|NCT05436665|Active Comparator|UT-DSAEK|Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty refers to the use of a corneal endothelial/Descemet graft with a thin layer of stroma (<110um) attached.
89319977|NCT05436665|Active Comparator|DMEK|Descemet membrane endothelial keratoplasty refers to the use of a corneal endothelial/Descemet graft with no layer of associated stroma (15-20um thick)
89319978|NCT05434819|Experimental|Surgical Atrial Fibrillation Ablation Group|Surgeon will perform left atrial ablation during patient's cardiac surgery procedure.
89319979|NCT05434819|No Intervention|No Surgical Atrial Fibrillation Ablation Group|Surgeon will not perform left atrial ablation during the patient's cardiac surgery procedure.
89319980|NCT05429996||Individuals with hypermobile EDS|Skin biopsy collection
89319981|NCT05429996||Individuals with classical EDS|Skin biopsy collection
89319982|NCT05429827|Placebo Comparator|Normal saline|Injection of 2 ml normal saline into a myofascial trigger point.
89319983|NCT05429827|Experimental|hypo-osmolar dextrose solution|Injection of 2 ml 5% dextrose into a myofascial trigger point.
89319984|NCT05429827|Experimental|hyper-osmolar dextrose solution|Injection of 2 ml 15% dextrose into a myofascial trigger point.
89319985|NCT05425446|Experimental|SAD Cohort 1|All randomized patients will receive one dose of either DONQ52 Dose A or placebo
89319986|NCT05425446|Experimental|SAD Cohort 2|All randomized patients will receive one dose of either DONQ52 Dose B or placebo
89319987|NCT05425446|Experimental|SAD Cohort 3|All randomized patients will receive one dose of either DONQ52 Dose C or placebo
89319988|NCT05425446|Experimental|SAD Cohort 4|All randomized patients will receive one dose of either DONQ52 Dose D or placebo
89319989|NCT05425446|Experimental|MAD Cohort 1|All randomized patients will receive multiple dose of either DONQ52 Dose E or placebo
89319990|NCT05425446|Experimental|MAD Cohort 2|All randomized patients will receive multiple dose of either DONQ52 Dose F or placebo
89319991|NCT05425446|Experimental|MAD Cohort 3|All randomized patients will receive multiple dose of either DONQ52 Dose G or placebo
89319992|NCT05419947|Experimental|Fixed dose 3 hours|Fixed dose 2.5 mg with IV administration at a time greater than 3 hours before surgery.
89319993|NCT05419947|Experimental|Fixed dose 30 min|Fixed dose 2.5 mg with IV administration during the immediate preoperative period (15-30 minutes before surgery).
89319994|NCT05419947|Experimental|Weight-adjusted dose 3 hour|Weight-adjusted dose (0.05 mg/kg of total body weight) with IV administration greater than 3 hours before surgery.
89319995|NCT05419947|Experimental|Weight-adjusted dose 30 min|Weight-adjusted dose (0.05 mg/kg of total body weight) with IV administration during the immediate preoperative period (15-30 minutes before surgery).
89319996|NCT05418556|Active Comparator|Conventional Arm|After PCI, patients are prescribed aspirin at a daily dose of 100 mg PO plus a P2Y12 inhibitor [clopidogrel or ticagrelor or prasugrel according to the clinical diagnosis] for 12 months after the index PCI.
89319997|NCT05418556|Experimental|Tailored Arm|The antiplatelet regimens post-PCI are 1-month DAPT (aspirin plus clopidogrel) followed by 11-months clopidogrel alone for CCS, and 3-months DAPT (aspirin plus P2Y12 inhibitor [ticagrelor, prasugrel]) followed by 9-months P2Y12 inhibitor alone for ACS.
89319998|NCT05411614|Experimental|Convergent Hybrid Ablation with Left Atrial Appendage Exclusion|"Staged Convergent Hybrid Ablation Procedure~Stage 1 - Minimally-Invasive Surgical Epicardial Ablation Procedure +/- concomitant LAA exclusion.~Stage 2 - Endocardial Catheter Ablation"
89319999|NCT05411614|Active Comparator|Standard Endocardial Catheter Ablation|Standard endocardial catheter ablation
89320000|NCT05409352|Experimental|Self-administered acupressure|The entire intervention will last 12 weeks, including a one-on-one, 90-min instructional session at week 1 and a one-hour follow-up visit at week 2, which are conducted by a trained traditional Chinese medicine practitioner. Participants will be instructed to perform self-acupressure on the acupoints according to individualized protocol once a day. Participants will be instructed to maintain self-practice after the intervention.
89320001|NCT05409352|Active Comparator|Aerobic exercise|The 12-week aerobic exercise program consists of a one-on-one, 90-min instructional session at week 1 and a one-hour follow-up visit at week 2, which are conducted by a trained exercise specialist. Participants will be advised to perform aerobic exercise of moderate intensity 3 times per week for 30 minutes each time. Accumulating 90 min of exercise per week through more frequent short bouts (e.g. 10-20 min daily) are allowed during the first week of each chemotherapy cycle due to increased symptom burden. Participants will be instructed to maintain self-practice after the intervention.
89320002|NCT05399602|Experimental|Study group A|Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anestezia. Before surgery patients undergo lumbar puncture or external lumbar drainage placement to confirmate the diagnosis and responsivity to VP shunt placement.
89320003|NCT05399602|Active Comparator|Study group B|Patients without diagnosed hydrocephalus undergoing short spinal surgery without affecting dural sac (e.g. anterior cervical discectomy and fusion or lumbar disc herniation or lumbar decompression) in general anestezia.
89320004|NCT05395858||Hemophilia A patients|Patients will be identified via standard medical charts or electronic medical records (EMRs).
89320005|NCT05393817||Low-dose group|Infants receiving low dose caffeine citrate (up to 10mg/kg/day)
89320006|NCT05393817||High dose group|Infants receiving high dose caffeine citrate (exceeding 10mg/kg/day)
89320010|NCT05384275|No Intervention|No intervention: Standard Oxygen Therapy|Standard oxygen therapy arm patients will be given 30-40% inspired O2 and flow 2-6 l/min via nasal prongs or non-rebreathing mask (not humidified and not heated) post extubation. Monitoring of saturations, respiratory rate and arterial gases will happen 15 minutes post extubation and then as per local policy thereafter. If saturations < 93% then FiO2 will be increased as per respiratory escalation protocol. Standard oxygen therapy will be given for a minimum of 16 hours post extubation.
89320011|NCT05384275|Active Comparator|High-Flow Nasal Therapy|High-flow nasal therapy arm patients will be given AIVRO 2 high flow oxygen therapy machines post extubation, start at 30-40% inspired O2 and flow 30 l/min then up to 50 l/min over 5-10 min. Monitoring of saturations, respiratory rate and arterial gases will happen after 15 minutes post extubation and then as per local policy thereafter. If saturations < 93% then increase FiO2 as per respiratory escalation protocol. High flow nasal therapy will be given for a minimum of 16 hours post extubation.
89320012|NCT05371691|Experimental|Myobrace group|Myobrace appliance will be used for children who have Cl.II div.a malocclusion
88811648|NCT01368653|Experimental|Standard treatment+practice quitting|In this arm, participants receive standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling.
88814092|NCT02461758|Other|Standard dose influenza vaccine (SDIV)|"This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
89320013|NCT05371691|Experimental|Twin-block group|Twin-block appliance will be used for children who have Cl.II div.a malocclusion
89320014|NCT05366413|Experimental|Pain management strategies|"Participants will receive early referral to an anesthesia-trained interventional pain management specialist evaluated for pain management strategies.~Participants will complete surveys every 2 months and will have the option of tracking their pain at home using a secure smartphone application.~Participants will be followed on the study for 4 months."
89320015|NCT05366114||New patients at the GoodHope EDS clinic at Toronto General Hospital|All patients seen in the EDS clinic are eligible for inclusion, regardless of their presenting diagnosis or the results of their assessments.
89320016|NCT05363514|Experimental|Low Dose Naltrexone|Low Dose Naltrexone 4.5mg OD PO. Capsules are masked and provided in blister packs.
89320017|NCT05363514|Placebo Comparator|Placebo|Microcrystalline cellulose 4.5mg OD PO. Capsules are masked and provided in blister packs.
89320018|NCT05349955|Experimental|Intensive guideline algorithm implementation|SGLT2i or GLP-1RA recommended in priority in subjects at very high/high CV risk. The targets of intervention will be achieved at HbA1C <7%, blood pressure <130/80mmHg， LDL-c<1.8mmol/L at very high CV risk or <2.6mmol/L at high CV risk patients, antiplatelet as secondary prevention of ASCVD.
89320019|NCT05349955|Active Comparator|Conventional guideline algorithm implementation|Treatment based on the current approaches implemented by local physicians(primary care physicians). Guideline based education and consults will be conducted to primary care physicians.
89320020|NCT05345249|Experimental|ESPB with ropivacaine|Patients in the experimental group will receive locoregional analgesia via ESPB with injectate consisting of ropivacaine 0.375 mg/mL with no additives, two times 30mL bilaterally at the transverse processs of the T12-vertebra (total dose of 225 mg).
89320021|NCT05345249|Placebo Comparator|ESPB with placebo|Patients in the placebo group will receive an injection performed as the procedure of ESPB with injectate consisting of sodiumchloride 0.9% with no additives, two times 30mL bilaterally at the transverse processs of the T12-vertebra.
89320022|NCT05344313|Experimental|Sarcopenic patients|Ensure Plus Advance + resistance training (Prehab) Rehabilitation 2months post surgery
89320023|NCT05344313|No Intervention|Healthy individuals|"To make meaningful comparison of muscle quality, 10 healthy non-sarcopenic individuals from the same age range would also be recruited and will undergo muscle quality assessment using MuscleSound® once upon recruitment so that an objective comparison for IMAT can be made with our sarcopenic study cohort. This is to aid the study team to identify normal IMAT vs an IMAT for sarcopenic individuals. Any improvement of our cohort's muscle quality can be benchmarked against healthy muscle quality so that more meaningful comparison can be made. This control group would not be undergoing surgery, nor will they have any ONS supplied."
89320024|NCT05338242|Experimental|Real-Time Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
89320025|NCT05338242|No Intervention|No Feedback|Participants will have exposure levels monitored by the same device, but it will only display the date/time and will not provide real-time feedback.
89320026|NCT05336097|Experimental|Intervention group|"Participants will receive support from participation coaches trained in Pathways to Empowerment (PTE).~These participation coaches received a four-day training program with two weeks in between each training day, allowing them to immediately implement their acquired set of knowledge and skills. At the end of the training program, participation coaches had to successfully pass an end assignment to become PTE-certified.~In order to ensure the implementation of PTE, the training will be supplemented with a learning cycle. This cycle consists of two workshops on poverty and stress, and of on-the-job coaching. The coaching is tailored to the wishes and needs of the team."
89320027|NCT05335876|Experimental|Intravenous (IV) & Intrathecal (IT) Onasemnogene Abeparvovec|Patients who received OAV101 IT or OAV101 IV in AveXis/ Novartis or Novartis Gene Therapies Phase I to IIIb clinical trials
89320028|NCT05330052|Experimental|Agilik|The participant will be provided custom knee orthoses (the Agilik) to trial in this study
89320029|NCT05323240|Experimental|Filtered air exposure|Subjects will be randomly exposed to three consecutive days of filtered air exposure arm in a double-blind cross-over fashion in an exposure chamber, and exposures will be separated by a minimum of 13 days from the PM2.5 arm.
89320030|NCT05323240|Experimental|PM exposure|Subjects will be randomly exposed to three consecutive days of PM2.5 exposure arm in a double-blind cross-over fashion in an exposure chamber, and exposures will be separated by a minimum of 13 days from the filtered air arm.
89320031|NCT05299359|Experimental|TAK-019 Main Part|TAK-019 0.5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm
89320032|NCT05299359|Experimental|TAK-019 Extension Part|TAK-019 0 .5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm. The participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will receive a second single booster vaccination of TAK-019 by intramuscular injection.
89320033|NCT05294848|Experimental|Gaze-Contingent Feedback Training (toward threat)|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the soldier will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracker, the participant will be instructed to view matrices of faces as he chooses, as described above in the assessment task. The music chosen by the participant will play only when he is looking at threatening faces and it will stop when he looks at neutral faces. Thus, a change in viewing patterns is expected by implementing operant conditioning principles.
89530150|NCT03250585||Sickle Cell Patients with Acute Chest Syndrome|Sickle cell patients with active acute chest syndrome (ACS) from which samples of EBC and plasma will be collected during acute illness within 48 hours of admission with or diagnosis of ACS (Time point 1) in 3 sessions each 1 hour apart (Time point 1a, 1b, and 1c), and 2 weeks after discharge when have returned to steady-state (Time point 2). Time point 2 samples will serve as control (baseline) samples.
89530151|NCT04503239||Prediabetes (both IGT and IFG)|Device: G6 Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89320034|NCT05294848|Active Comparator|RT-Based Attention Bias Modification (toward threat)|"A dot-probe task of 160 trials. Trials begins with a fixation cross (+), on which the participant is asked to focus (500ms). Then two face stimuli (one angry one neutral) are presented above and below the fixation cross (500ms). After the stimuli disappear, a target probe (right- or left-pointing arrowhead) appears in place of one of the face stimuli. The participant is asked to indicate which target probe was presented using a predetermined key. The target probe will remain on the screen until response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the threat location (angry face). Thus, over multiple trials, learning is expected to occurs such that the threatening face predicts the location of the target probe, thereby achieving the desired change in attention pattern."
89320035|NCT05294848|Placebo Comparator|Neutral Control|This condition is also based on the dot-probe task (see Active Comparator) with a fundamental difference. In this task, only neutral faces will be displayed, and therefore, while participants are exposed to the same task parameters, there will be no attention training and there will be no exposure to threat stimuli.
89320036|NCT05290155|Experimental|Anti-CD7 CAR T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
89320037|NCT05287321|Experimental|Aspirin 100mg + Hydroxychloroquine 200mg|Aspirin 100mg 1T daily PO + Hydroxychloroquine 200mg 1T daily PO
89320038|NCT05286788|Experimental|Stratum 1 and Stratum 2|"Stratum 1: Patients with progressive or recurrent adamantinomatous craniopharyngiomas following radiation therapy.~Stratum 2: Patients with measurable adamantinomatous craniopharyngioma who have undergone surgery but have not previously received radiation therapy. Progressive disease is allowed but not required"
89320039|NCT05284812|No Intervention|Negative control population group|In population I, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) and BCG pure protein derivative (BCG-PPD) skin test results were negative.The type I population did not take chemical drugs and was not vaccinated, and was only used as immunogenicity control.
89320040|NCT05284812|Other|Sentinel group|In Population Ⅱ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. First, 5 people aged 18-59 years were selected for low dose injection, 5 people aged 18-59 years were selected for high dose injection, 5 people aged ≥60 years were selected for low dose injection, and 5 people aged ≥60 years were selected for high dose injection.The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
89320041|NCT05284812|Experimental|Low-dose group|In population Ⅲ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅲ population were injected Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02).The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
89320042|NCT05284812|Experimental|High-dose group|In population Ⅳ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅳ population were injected High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02).The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
89320043|NCT05284812|Experimental|3 dose of High-dose group|In population Ⅴ, 40 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅴ population were injected 3 dose of High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) and 3 dose of Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo.The first, third, and sixth doses of the subjects were High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), and the second, fourth, and fifth doses were Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo. Each dose is 2 weeks apart.
89320044|NCT05284812|Placebo Comparator|Placebo group|In population Ⅵ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅵ population were injected Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo.The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
89320045|NCT05284812|Active Comparator|Adjuvant group|In population Ⅶ, 20 subjects were considered to be recombinant mycobacterium tuberculosis fusion protein (EC) was positive. The type Ⅶ population were injected High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02).The subjects received a total of 6 doses of the vaccine, 1 dose every 2 weeks.
89320046|NCT05283382|Experimental|Cannabidiol|600 mg Cannabidiol Isolate Gel Capsules / participant. One-time dose.
89320047|NCT05283382|Placebo Comparator|Placebo|Same number of placebo capsules / participant. One-time dose.
89320048|NCT05262335|Experimental|Experimental: Experimental group 1|Initial treatment: Anlotinib + Oxaliplatin + Capecitabine. Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
89320049|NCT05262335|Experimental|Experimental: Experimental group 2|Initial treatment: Anlotinib + Cisplatin + Paclitaxel/ Docetaxel. Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
89320050|NCT05262335|Experimental|Experimental: Experimental group 3|Initial treatment: Anlotinib + Standard first-line chemotherapy Maintenance treatment (after 6 cycles): Anlotinib + Capecitabine
89320051|NCT05246930||Subjects with a diagnosis of vocal cord dysfunction|Subjects with a confirmed or suspected diagnosis of vocal cord dysfunction (also called inducible laryngeal obstruction). Some subjects will have concomitant diagnosis of asthma.
89320052|NCT05246930||Subjects with diagnosis of asthma|Subjects with physician-diagnosed asthma. Some subjects will have concomitant diagnosis of vocal cord dysfunction.
89320053|NCT05243459|Experimental|Gaze-Contingent Feedback Training|In the task, 30 different matrices, each consisting of 16 faces, will be presented. Each matrix includes 8 angry faces and 8 neutral, 8 women and 8 men, and the locations are counterbalanced between matrices. The participants are asked to view the matrices in any way they choose, and the eye-tracking camera records their viewing location relative to the stimuli presented on the screen. At the beginning of each training session, the veteran will choose to which music he would like to listen during the 12-minute session from a diverse list of music. After calibrating the eye-tracking technology, the veteran will be instructed to view the matrices of faces as he chooses, as described above in the assessment task. The music chosen by the veteran will play only when s/he is looking at neutral faces and it will stop when s/he looks at threatening faces.
89530152|NCT04503239||Type 2 Diabetes on 1 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89320054|NCT05243459|Active Comparator|RT-Based Attention Bias Modification|"The task consists of 160 trials. Each trial begins with a centrally-presented fixation cross (+), on which the participant is asked to focus for 500ms. When it disappears, two stimuli will be presented 1.5cm above and below the previous fixation cross for 500ms. After the stimuli disappear, a target probe (right- or left-pointing arrowhead) will appear in place of one of the stimuli, and the participant will be asked to indicate which target probe is presented by pressing the respective key. The target probe will remain on the screen until the participant's response, after which a new trial will begin.~Participants are instructed to identify the probe type as quickly and accurately as possible.~In the training task, all of the target probes will appear in the neutral face location. Thus, over multiple trials, learning occurs that the threatening face predicts the location of the target probe, thereby achieving the desiring change in attention patterns."
89320055|NCT05243459|Placebo Comparator|Non-Contingent Feedback Training|This condition is based on the aforementioned eye-tracking task with a fundamental change - The music chosen by the veteran will play continuously without any reinforcement for looking at threat or neutral faces.
89320056|NCT05210114|Experimental|Skin Hydration Sensor|
89320057|NCT05206305|Experimental|AD Patients|Patients with Alzheimer's Disease, as verified by positive A(beta)-PET and/or CSF tau/A(beta) biomarkers, who will receive one hour daily gamma frequency sensory stimulation from the investigational device for an 8 week period.
89320058|NCT05205460|Experimental|Home-based telehealth exercise training|After graded exercise testing, the participants will receive a single, individual, face-to-face physical activity promotion counseling session (15-20minutes). Then, the participants will start a home-based telehealth exercise training program (30minutes/session, 3 sessions/week for 12weeks, with a total of 36 sessions) combined with heart rate sensing clothes. Exercise type: brisk walking, jogging, or stationary ergometer exercise.
89320059|NCT05205460|Active Comparator|Education and self-exercise|"After graded exercise testing, the participants will receive a single, individual, face-to-face physical activity promotion counseling session (15-20minutes).~Then, the patients will receive weekly reminders and monthly outpatient follow-ups during the exercise program."
89320060|NCT05202119|Active Comparator|Active stimulation|Active stimulation at 2mA
89320061|NCT05202119|Sham Comparator|Sham stimulation|
89320065|NCT05174273|No Intervention|Participants with a confirmed diagnosis of MDD receiving TAU|Eligible and consenting patients will be assigned 1:1 to receive either FMT from a healthy donor or continuing on their usual medication for MDD, i.e., treatment as usual (TAU). This arm will continue to receive their usual anti-depressant.
89320066|NCT05174273|Active Comparator|Participants with a confirmed diagnosis MDD who will receive FMT + TAU|Eligible and consenting patients will be assigned 1:1 to receive either FMT from a healthy donor or continuing on their usual medication for MDD, i.e., treatment as usual (TAU). This arm will be assigned to receive FMT provided by healthy donors.
89320067|NCT05174273|No Intervention|Participants with a confirmed diagnosis of MDD + IBS assigned to continue with TAU|
89320068|NCT05174273|Active Comparator|Participants with a confirmed diagnosis of MDD + IBS assigned to receive FMT + TAU|
89320069|NCT05174273|No Intervention|Participants with a confirmed diagnosis IBS only receiving TAU|
89320070|NCT05174273|No Intervention|Healthy Controls|Data from healthy comparison (HC) participants will be drawn from another completed research study. Healthy comparison participants who will best match the patient population enrolled in the current trial and who consented to data sharing will be selected.
89320071|NCT05171569|Experimental|Virtual Care with Remote Automated Monitoring|Patients randomized to the PVC-RAM-3 intervention will take biophysical measurements with the RAM technology, complete a daily recovery survey, complete video visits with a virtual care clinical team, and take wound photos during the 14 days after discharge. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician.
89320072|NCT05171569|No Intervention|Standard Care|Standard post surgical care per treating institution.
89320073|NCT05139888|Experimental|Single wavelength light (red) only|Arm 1 will test the core technology of the ToeFX system; this study reproduces methods well-described in the literature. After application of the formulation, nails affected by onychomycosis are exposed to red light at a wavelength of 630-660 nm intensity of 200 mW/cm2.
89320074|NCT05139888|Experimental|Dual wavelength light (red/blue)|Some research has shown that exposure to mild blue light can have anti-inflammatory effects that would improve patient onychomycosis outcomes. We will assess whether inclusion of blue light in the protocol affects the clinical outcome.
89320075|NCT05126823|Experimental|ACT face-to-face + app|Combines face-to-face ACT sessions with non-face-to-face activities and resources (mobile applications)
89320076|NCT05126823|Active Comparator|ACT face-to-face|face-to-face ACT sessions
89320077|NCT05126823|No Intervention|Waitlist|Waitlist group. After the second assessment of the two ACT groups (at post-treatment) this group will receive the face to face ACT intervention.
89320078|NCT05122871|Experimental|Scape room|
89320079|NCT05122871|Active Comparator|Simulation|
89320080|NCT05120843|Other|Intervention Arm|This intervention will combine care coordination and motivational interviewing strategies.
89320081|NCT05104528|Other|Non-invasive cardiometry|"OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3 A technique for the non-invasive determination of SV, CO, cardiac index, stroke index and HR along with other hemodynamic parameters such as preload (Thoracic Fluid Index), afterload and others.~The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other above-mentioned parameters."
89320082|NCT05098795|Experimental|Peer-delivered Behavioral Activation|Adults 18 years or older on MOUD or referred to MOUD will receive Behavioral Activation (BA) an evidence-based intervention (EBI) by trained Peer Recovery Coaches (PRC)
89320083|NCT05096247|Experimental|Treatment with RF Device|Subjects in this arm of the study will be treated with the radiofrequency device, and will receive up to 4 treatments on the face.
89320084|NCT05096247|Experimental|Treatment with IPL and RF Device|Subjects treated in this arm of the study will receive 2 treatments with just the radiofrequency device and then 2 treatments with both the radiofrequency and the IPL laser.
89320085|NCT05092945|Active Comparator|Subject with Type 2 Diabetes- cold exposure|3-hour cold exposure: Protocol B
89320086|NCT05092945|Experimental|Subject with type 2 Diabetes- cold exposure and nicotinic acid|3-hour cold exposure with oral nicotinic acid: Protocol A
89320087|NCT05092945|Active Comparator|Subject without Type 2 Diabetes- cold exposure|3-hour cold exposure: Protocol B
89320088|NCT05092945|Experimental|Subject without type 2 Diabetes- cold exposure and nicotinic acid|3-hour cold exposure with oral nicotinic acid: Protocol A
89320089|NCT05088889|Experimental|study arm|"Study treatments include SBRT (Stereotactic radiation therapy) to one primary/metastatic tumor (3 fractions of 8Gy) , and ipilimumab (1mg/kg every six weeks) + nivolumab (360mg every three weeks) .~Every 8 weeks patients will be assessed for response; responders will continue ipilimumab + nivolumab until disease progression, non-responders will receive very low dose radiation (2Gy single fraction to metastatic lesions of choice) prior to continuing ipilimumab + nivolumab ."
89320090|NCT05078723|Experimental|CYP2C19*2 and CYP2C19*3 Variants|The group of participants has been genotyped to have the CYP2C19*2 and/or CYP2C19*3 variant during the first part of the study. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the wild-type CYP2C19 study subjects.
89320091|NCT05078723|Experimental|Wildtype CYP2C19|The group of participants has been genotyped to have wild-type CYP2C19. The participants will consume 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract) and be asked to swish 5 times and swallow. All participants will then provide breath samples over the course of 2 hours. The breath sample outcomes will be compared to those of the CYP2C19*2 and/or CYP2C19*3 study subjects.
89320092|NCT05073380|Experimental|Control|Outdoor play is an essential component of childhood development, including supporting children's cognitive, physical, emotional, and social growth. Currently, the YMCA early learning and child care centres (ELCCs) host children within childcare settings, with outdoor playtime governed by institutional regulations.
89320093|NCT05073380|Sham Comparator|Intervention|"The PRO-ECO intervention to increase the quality of outdoor play involves four primary components:~Modifying YMCA GV's outdoor play policies The ELCC policy on outdoor play requirements and procedures will be modified in conjunction with YMCA management.~ECE training ECEs will undergo training delivered by YMCA of Southwestern Ontario that includes the importance of outdoor risky play, along with other online training tools along with resources on supporting outdoor play. There will also be ongoing as-needed supportive training and mentorship provided by YMCA senior managers and research team, along with peer mentorship and support.~ELCC outdoor space modification This includes designing and implementing tailored modifications for each centre's outdoor play space developed by landscape architecture students.~Parent engagement We will host parent-engagement events and opportunities to increase knowledge of the importance of outdoor play."
89320094|NCT05070377|Experimental|Intervention|The ActTeens Program will include interventions in three different context: (1) structured physical activity sessions by physical education (school), (2) self-monitoring plus goal setting by pedometer (out-of-school), and (3) healthy lifestyle guidance (social support). The structured PA will be developed in PE lessons, twice a week, with twenty-minute each lesson (40 min·week) To promote active behavior out-of-school will be used a pedometer plus goals setting where each adolescent of the intervention group will receive their own goal (based on the number of steps measured in the baseline week) outlining the goals to achieve weekly. To improve healthy behavior will be sent by WhatsApp® messages about healthy eating and regular PA for the intervention and parents groups.
89320095|NCT05070377|No Intervention|Control|The control group participated in usual practice (regularly scheduled PE and postcurricular school sport) for the duration of the study .
89320096|NCT05069155|No Intervention|Control|Participants will receive a wearable device (e.g. FitBit) but no other interventions during the intervention or follow-up periods.Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and time in the study.
89320097|NCT05069155|Experimental|Gamification|"Intervention participants will receive a wearable device (e.g. FitBit) and will enter a game designed with behavioral economics concepts to address predictable barriers to behavior change during a 12-week intervention period.~At the end of the 12 week intervention period, participants will enter a 6 week follow-up period during which interventions will cease but passive data collection of step counts will continue. Participants will also complete milestones within the study, such as the cognition and function assessment during weeks 1- 2, and 15-16. Participants will complete an end-of-study questionnaire on their experience with the wearable device and intervention design."
89320098|NCT05065567|Active Comparator|haloperidol|these patients will receive 5mg IM haloperidol
89320099|NCT05065567|Active Comparator|droperidol|these patients will receive 2.5mg IV droperidol
89320100|NCT05065567|Active Comparator|ondansetron|these patients will receive 8mg IV ondansetron
89320101|NCT05060731|Active Comparator|Oral iron supplementation|Patients randomized to receive oral ferrous sulfate, ca. 200-300 mg every day for 3 months.
89320102|NCT05060731|Active Comparator|Intravenous iron supplementation|Patients randomized to receive one dose of 1000 mg intravenous ferric carboxymaltose.
89320103|NCT05053438|Active Comparator|Intensive Multidisciplinary Intervention (Standard Care)|Children with a history of chronic food refusal will be randomized to receive the standard of care. The standard of care for tube wean is to accomplish the balance between enteral supplementation and oral intake, the tube feeding regimen will follow the schedule of therapeutic meals (e.g., mid-day supplementation occurs after morning therapeutic meals).
89320104|NCT05053438|Experimental|Intensive Multidisciplinary Intervention (Standard Care) + Hunger provocation (Rapid Tube Wean)|"Children with a history of chronic food refusal will be randomized to receive the experimental arm that combines standard care with rapid tube wean.~All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use regular tube wean sheet to provide credit for oral intake for remainder of admission."
89320105|NCT05052476|Experimental|Open label Bactecal® D Liquid 1 dose|Patients will receive 1 dose of Bactecal® D Liquid by day which corresponds to 2 ml of product
89320106|NCT05052476|Experimental|Open label Bactecal® D Liquid 2 doses|Patients will receive 2 doses of Bactecal® D Liquid by day which correspond to 4 ml of product.
89320107|NCT05047679|Experimental|Perioperative Pain Neuroscience Education|Patients in the experimental treatment group will receive Perioperative Pain Neuroscience Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
89320108|NCT05047679|Active Comparator|Perioperative Biomedical Education|Patients in the control treatment group will receive Perioperative Biomedical Education, including a preoperative session 3 days before the surgery, access to an educational web application and a postoperative session 2 days following the surgery. Both education sessions will be face-to-face and will last approximately 60 minutes.
89320109|NCT05044013|Experimental|JomPrEP App Group|Participants in the JomPrEP group will be provided with full app access and will be encouraged to use all features of the app.
89320110|NCT05044013|Active Comparator|Control Group|Participants in the control group will receive the JomPrEP app with major intervention features inactivated.
89320111|NCT05039229|Experimental|Nozzles (NZ)|Intervention with the aim of reducing bioaerosol exposure for the employees, targeting alteration of nozzles or nozzle function along the production line.
89320112|NCT05039229|Experimental|Cleaning of surfaces (CS)|Intervention with the aim of reducing bioaerosol exposure for the employees while cleaning their personal operating areas (work benches and part of production lines) during work operations or while cleaning floor areas.
89320113|NCT05039229|No Intervention|Control (CTR)|Work is to be carried out as usual without any intervention measures. Follow-up according to the same schedule as for the other intervention groups.
89320114|NCT05036447|Experimental|DM1-Ex|Moderate-heavy resistance exercise of one leg in DM1-patients
89320115|NCT05036447|No Intervention|DM1-Rest|Control leg (i.e. no exercise) in DM1-patients
89320116|NCT05036447|Experimental|Ctrl-Ex|Moderate-heavy resistance exercise of one leg in healthy participants
89320117|NCT05036447|No Intervention|Ctrl-Rest|Control leg (i.e. no exercise) in healthy participants
89320118|NCT05019742|Experimental|Placebo|2 placebo tablets, 1 in the morning and 1 in the evening, daily for 8 weeks. After 8 weeks, optional randomization to 1 of 2 SPH3127 daily treatment arms for an additional 10 months
89320119|NCT05019742|Experimental|SPH3127 50 mg|"1 50 mg SPH3127 tablet in the morning and 1 placebo tablet in the evening daily for 8 weeks.~After 8 weeks, optional continuation of daily treatment for an additional 10 months."
89320120|NCT05019742|Experimental|SPH3127 100 mg|"1 50 mg SPH3127 tablet in the morning and 1 50 mg SPH3127 tablet in the evening daily for 8 weeks.~After 8 weeks, optional continuation of daily treatment for an additional 10 months."
89320121|NCT04996472|Experimental|Sensitivity to phonological rules: Adults|Arm 1: Single Feature Pattern; Arm 2: OR/Disjunction Pattern
89320122|NCT04996472|Experimental|Sensitivity to semantic category cues: Adults|Arm 1. Referential cue during OR learning.
89320123|NCT04995692|Experimental|Telehealth Education for Asthma Connecting Hospital and Home (TEACHH)|New model of patient-centered asthma education
89320124|NCT04995692|Active Comparator|Standard Care (SC) Comparison Group|Standard inpatient asthma education per hospital protocol.
89320125|NCT04989335|Experimental|Bisantrene combined with Fludarabine and Clofarabine|"Bisantrene 250 mg at final concentration of 0.5 mg/mL will be administrated by intravenous (IV) infusion, delivered by a controlled-rate programmable pump via a central line over 2 hours.~Fludarabine (generic) and Clofarabine (generic) are commercially available as injection for intravenous infusion.~The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo) and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each daily FluCloXan treatment in the following sequence:~First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2~Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes~Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours."
89320126|NCT04987879|Experimental|Exercise Arm 1|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 750 MET-min/wk for 3-5 days per week, 22-45 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
89320127|NCT04987879|Experimental|Exercise Arm 2|Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 1,000 MET-min/wk for 3-5 days per week, 30-60 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.
89320128|NCT04987879|No Intervention|Standard of Care|This group will receive best NASH clinical practices counseling at baseline and end-of-trial in accordance with NAFLD clinical practice guidelines and be reinforced by handouts from the American Liver Foundation.
89320129|NCT04986631|Experimental|Topiramate|Individuals will receive 75 mg of topiramate daily. The dose will start at 25 mg daily for the first week. The second week participants will receive 50 mg daily. Starting at week 3 participants will take 75 mg daily.
89530153|NCT04503239||Type 2 Diabetes on 2 or more OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89530154|NCT04503239||Type 2 Diabetes using Basal insulin with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89530155|NCT04503239||Type 2 Diabetes in GLP-1 with or without OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89320130|NCT04984226|Experimental|Sodium bicarbonate 16 weeks|Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.
89320131|NCT04984226|Placebo Comparator|placebo 16 weeks|Microcrystalline cellulose
89320132|NCT04979494||Post cardiac surgery|Patients admitted to ICU right after cardiac surgery with or without cardiopulmonary bypass, usually with cardiac shock.
89320133|NCT04979494||Sepsis and septic shock|Patients admitted to ICU with the major complication of sepsis or septic shock.
89320134|NCT04979494||Control|Patients admitted to ICU for post-surgery monitor in case of complications due to their baseline health condition(e.g. coronary artery disease, hypertension and so on), but without severe shock.
89320135|NCT04970446|Active Comparator|FMT arm|Anaerobically prepared, freeze-thawed faecal microbiota transplantation
89320136|NCT04970446|Placebo Comparator|Placebo arm|Placebo liquid formulation (normal saline, glycerol, food colorant)
89320137|NCT04963777|Experimental|Prebiotic|Oligofructose-enriched inulin
89320138|NCT04963777|Placebo Comparator|Placebo|Maltodextrin
89320139|NCT04958304||Moderna COVID-19 Vaccine in Pregnant Women|The Moderna COVID-19 Vaccine Pregnancy Registry will collect primary data from pregnant women who have received the Moderna COVID-19 vaccine and their healthcare providers (HCPs).
89320140|NCT04946864|Experimental|single arm|APG2575
89320141|NCT04946864|Experimental|combination arm|APG2575+palbociclib i
89320142|NCT04940572|Experimental|Depakine (VPA)|"Depakine Chrono 500 mg (VPA)~VPA will be administered orally:~From D1 to D3: During the first week 10-15 mg sodium valproate/kg bodyweight per day will be taken daily.~From D3 to W156: The dose will be increased every 3 days in steps of 10 mg sodium valproate/kg bodyweight per day with VPA plasma concentration monitoring until the total daily dose corresponding to the optimal plasma level between 40 and 100 mg/l (ie, 300 to 700 micromol/l) is reached, till the 156 weeks corresponding to the end of treatment (EOT) visit.~The total daily dose will be taken in one or two doses during meals."
89320143|NCT04939012|Experimental|MyPath Intervention|At the first visit participants randomized to this arm receive MyPath contraceptive decision tool.
89320144|NCT04939012|Active Comparator|Standard of Care|At the first visit participants randomized to this arm receive standard of care contraceptive counseling.
89320145|NCT04932291|Experimental|vafidemstat 1.2mg|Vafidemstat is administered as capsules.
89320146|NCT04932291|Placebo Comparator|placebo|Placebo is administered as capsules.
89320147|NCT04919980|Experimental|Treatment|MV replacement with Innovalve MR system
89320148|NCT04916977||FD patients|
89320149|NCT04908709|Experimental|Diagnostic (sMRI)|Patients undergo sMRI over less than 1 hour within 7 days prior to start of standard of care radiation therapy and at 10 weeks.
89320150|NCT04908709|Active Comparator|Group 2|Patients will undergo 3-4 sMRI scans at baseline prior to RT, 1 month, 4 months, and 7 months after RT, and/or at any time of suspected tumor recurrence.
89320151|NCT04905225||Ascending aortic replacement|Ascending aortic replacement in ascending aortic aneurysm in men and women
89320152|NCT04904536|Experimental|Study Medication Arm|6-monthly supplies of atorvastatin 40mg on top of standard care for a period of 12 months.
89320153|NCT04904536|Active Comparator|Standard Care Arm|Standard care for a period of 12 months.
89320154|NCT04902937||premenopausal patients|
89320155|NCT04902937||postmenopausal patients|
89320156|NCT04895280|Other|Group 1 (marcaine)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine
89320157|NCT04895280|Experimental|Group 2 (ketorolac)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
89320158|NCT04895280|Other|Group 3 (kenalog)|4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1. Group 3 is standard of care
89320159|NCT04881318|Experimental|Waist-High Compression Tights and Medications|Participants will wear the waist-high compression garment while taking their regularly prescribed medications. This arm will evaluate the effects of waist-high compression garment treatment together with medications that modulate heart rate and blood pressure. This arm will also include control measurements before the garment is put on and after the garment is removed.
89320160|NCT04881318|Experimental|Waist-High Compression Tights and No Medications|Participants will wear the waist-high compression garment while holding their regular medications that modulate heart rate and blood pressure (beta-blockers, midodrine, ivabradine, stimulants). This arm will look at the effectiveness of waist-high compression without medications. This arm will also include control measurements before the garment is put on and after the garment is removed.
89320161|NCT04881318|Experimental|Abdominal Compression Garments and Medications|Participants will wear the abdominal compression garment while taking their regularly prescribed medications. This arm will evaluate the effects of abdominal compression garment treatment together with medications that modulate heart rate and blood pressure. This arm will also include control measurements before the garment is put on and after the garment is removed.
89320162|NCT04881318|Experimental|Abdominal Compression Garments and No Medications|Participants will wear the abdominal compression garment while holding their regular medications that modulate heart rate and blood pressure (beta-blockers, midodrine, ivabradine, stimulants). This arm will look at the effectiveness of abdominal compression without medications. This arm will also include control measurements before the garment is put on and after the garment is removed.
89320163|NCT04877197|Experimental|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
89530156|NCT04503239||Type 2 Diabetes using intense insulin treatment-Multiple Dail|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89320164|NCT04877197|Active Comparator|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
89320165|NCT04875533|Experimental|20vPnC/Saline|20vPnC and saline
89320166|NCT04875533|Active Comparator|13vPnC/PPSV23|13vPnC and PPSV23
89320167|NCT04869163|Active Comparator|red meat consumers|Consumes red meat 3 times a week
89320168|NCT04869163|Experimental|non-red meat consumers|Consumes a non-red meat comparison product 3 times a week
89320169|NCT04868799||ATRT|Patients <18 years with an ATRT having frozen samples
89320170|NCT04868240|Experimental|Concurrent Training Group|The experimental group will perform 16-weeks of the concurrent training exercise.
89320171|NCT04868240|No Intervention|Control Group|Maintain their usual habits/activities, including not participate in any type of physical exercise.
89320172|NCT04867057|Experimental|Experimental: Trichomylin for SAD|18 out of 24 subjects were randomized to receive Trichomylin in a single dose.
89320173|NCT04867057|Placebo Comparator|Placebo Comparator: Placebo for SAD|6 out of 24 subjects were randomized to receive placebo in a single dose.
89320174|NCT04867057|Experimental|Experimental: Trichomylin for MAD|13 out of 17 subjects were randomized to receive Trichomylin in multiple doses.
89320175|NCT04867057|Placebo Comparator|Placebo Comparator: Placebo for MAD|4 out of 17 subjects were randomized to receive Placebo in multiple doses.
89320176|NCT04855370|Experimental|Patients diagnosed with Pulmonary Embolism|Patients requiring intensive care unit (ICU) level care with a confirmed diagnosis of pulmonary embolism (PE) by computed tomography (CT) angiogram or endobronchial ultrasound (EBUS) prior to or within 4 hours of initiation of any PE therapy or intervention.
89320177|NCT04854551|Experimental|Placebo, Then Naltrexone|Participants first received placebo capsules each day in a blister pack for 5 days. After a washout period of at least 3 days, they then received naltrexone capsules (matching placebo capsules) at 25mg/day for days 1 and 2 and then 50mg/day for days 3-5 for 5 days.
89320178|NCT04854551|Experimental|Naltrexone, Then Placebo|Participants first received naltrexone capsules each day in a blister pack for 5 days. Days 1 and 2 were at 25mg/day, and days 3-5 were at 50mg/day. After a washout period of at least 3 days, they then received placebo capsules (matching naltrexone capsules) for 5 days.
89320179|NCT04844502|No Intervention|Control Group|Frequent life activities.
89320180|NCT04844502|Experimental|Intervention Group|Protocol of physical exercises
89320181|NCT04817254|Experimental|Arm 1|Nivolumab + Ipilimumab 1mg/kg + TMZ
89320182|NCT04817254|Experimental|Arm 2|Nivolumab + Ipilimumab 3mg/kg + TMZ
89320183|NCT04805879|Active Comparator|FMT capsules|"Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool and each containing 0.67 ml of pelleted intestinal microbes.~PArticipants will recieve a loading dose of 60 capsules over 3 consecutive days followed by a booster dose of 20 caspules 1 month after and a second similar booster dose a month after that"
89320184|NCT04805879|Placebo Comparator|Placebo oral Capsules|Placebo casules are inactive capsules that look and weigh the same as the Active FMT caspules. Participants will follow the same schedule as the Active arm.
89320185|NCT04802746|Experimental|Sequence ABC in Part A|Study participants randomized to this arm will receive Staccato Placebo (A) and two fixed doses of Staccato alprazolam Dose 1 (B) and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
89320186|NCT04802746|Experimental|Sequence BCA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato alprazolam Dose 2 (C), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
89320187|NCT04802746|Experimental|Sequence CAB in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato Placebo (A), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
89320188|NCT04802746|Experimental|Sequence ACB in Part A|Study participants randomized to this arm will receive Staccato Placebo (A), Staccato alprazolam Dose 2 (C), and Staccato alprazolam Dose 1 (B) at pre-specified time points during 3 separate Treatment Periods in Part A.
89320189|NCT04802746|Experimental|Sequence BAC in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 1 (B), Staccato Placebo (A), and Staccato alprazolam Dose 2 (C) at pre-specified time points during 3 separate Treatment Periods in Part A.
89320190|NCT04802746|Experimental|Sequence CBA in Part A|Study participants randomized to this arm will receive Staccato alprazolam Dose 2 (C), Staccato alprazolam Dose 1 (B), and Staccato Placebo (A) at pre-specified time points during 3 separate Treatment Periods in Part A.
89320191|NCT04802746|Experimental|Staccato alprazolam in Part B|Study participants randomized to this arm will receive Staccato alprazolam at pre-specified time points in Part B.
89320192|NCT04802746|Placebo Comparator|Staccato placebo in Part B|Study participants randomized to this arm will receive Staccato placebo at pre-specified time points in Part B.
89320193|NCT04800822|Experimental|PF-07284892 monotherapy|Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors
88811759|NCT01380197|Active Comparator|Randomizing particiipants to Morphine|Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
88811760|NCT01380197|Active Comparator|Randomization to Nubain|Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
88814093|NCT04372784|Active Comparator|EGD with Balloon Dilatation|Esophagogastroduodenoscopy with balloon dilatation
89320194|NCT04800822|Experimental|PF-07284892 in combination with lorlatinib (Part 2)|Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC
89320195|NCT04800822|Experimental|Expansion Phase (Cohort 1)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib
89320196|NCT04800822|Experimental|Expansion Phase (Cohort 2)|PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib
89320197|NCT04800822|Experimental|Expansion Phase (Cohort 3)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with prior BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)
88806567|NCT05902286|Sham Comparator|OSC-|"Similarly, for the Osc- procedures, the client will be required to complete a five-week intervention. Participants will be instructed that the purpose of this portion of the study is to decrease their breathing oscillations. A program was designed by Yoo and colleagues that gives feedback regarding a calmness score which reflects a better score (i.e., higher) when participants breathe in a pattern that elicits less variability (i.e., less oscillations). They will be asked to complete four 20-minute homework assignments at home and asked to come up with techniques to decrease their heart rate."
88806568|NCT05902273||septic shock patients|mechanically ventilated septic shock patients
89320198|NCT04800822|Experimental|Expansion Phase (Cohort 4)|PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi
89320199|NCT04800822|Experimental|Expansion Phase (Cohort 5)|PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)
89320200|NCT04800822|Experimental|PF-07284892 in combination with encorafenib and cetuximab (Part 2)|Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC
89320201|NCT04800822|Experimental|PF-07284892 in combination with binimetinib (Part 2)|Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors
89320202|NCT04781257||Household contacts with co-prevalent/incipient TB|Household contacts diagnosed with active TB at baseline/during the study period
89320203|NCT04781257||Household contacts staying healthy|Household contacts without active TB who remain healthy throughout the study
89320204|NCT04779697|Experimental|GLP-1a|GLP-1a Semaglutide target dose of 1.2 mg administered weekly over 12 weeks
89320205|NCT04779697|Placebo Comparator|Placebo|Placebo pen administered weekly over 12 weeks
89320206|NCT04758065|Active Comparator|1-Goup: Control group|Home-based cervical therapeutic exercise and manual therapy.
89320207|NCT04758065|Experimental|2-Group: Radial pressure waves Group|Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves.
89320208|NCT04757545|Active Comparator|HM-PRO intervention|The intervention group will have a predetermined nurseled consultation planned to assess medical status and symptom control at 0, 6 and 12 months. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients.
89320209|NCT04757545|No Intervention|Standard outpatient follow-up care|The control group will receive standard care in the outpatient clinic. The patient has a predetermined consultation appointment at the hospital one time a year with a doctor to evaluate medical status and symptom control.
89320210|NCT04750577|Placebo Comparator|Placebo|
89320211|NCT04750577|Experimental|Dose group 1: BI 685509|Low dose
89320212|NCT04750577|Experimental|Dose group 2: BI 685509|Low dose followed by up-titration to medium dose.
88806569|NCT05902260|Experimental|Nutritional intervention|Subjects should consume two 200 mL bottles of study product per day
89320213|NCT04750577|Experimental|Dose group 3: BI 685509|Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.
89320214|NCT04746638|Experimental|Prostate cancer|At least five (5) evaluable subjects with prostate cancer.
89320215|NCT04746638|Experimental|Breast cancer|At least five (5) evaluable subjects breast cancer.
89320216|NCT04746183|Experimental|CST-2 EIDD-2801 Phase Ib|EIDD-2801 (also known as MK-4482, molnupiravir). Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.
89320217|NCT04746183|No Intervention|CST-2 Control|Phase 1b only (standard of care)
89320218|NCT04746183|Placebo Comparator|CST-2 Placebo|Phase II placebo blinded controlled
89320219|NCT04746183|Experimental|CST-3A Nitazoxanide|Phase Ia Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur
89320220|NCT04746183|Experimental|CST-5 VIR-7832 Phase I|Phase I: Single doses of VIR-7832 will be administered by intravenous (IV) infusion. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated.
89320221|NCT04746183|Active Comparator|CST-5 VIR-7831 Phase II|Phase II: 500 mg dose of VIR-7831 will be given by IV infusion.
89320222|NCT04746183|Placebo Comparator|CST-5 Placebo Phase I|Phase I: placebo blinded controlled
89320223|NCT04746183|Experimental|CST3B Nitazoxanide|Phase II experimental arm.
89320224|NCT04746183|No Intervention|CST3B Control|Standard of care
88806570|NCT05902247|Experimental|225Ac-PSMA I&T|225Ac-PSMA I&T
89320225|NCT04746183|Experimental|CST6 IV Favipiravir|IV Favipiravir twice daily for 7 days. Starting dose 600 mg twice daily. Dose escalation to 1200 mg twice daily, 1800 twice daily, 2400 twice daily.
89320226|NCT04746183|No Intervention|CST6 Control|Standard of care
89320227|NCT04746183|Experimental|CST-2 EIDD-2801 Phase II|"EIDD-2801 (also known as MK-4482, molnupiravir).~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
89320228|NCT04746183|Experimental|CST-8 Phase I Molnupiravir + Paxlovid®|Molnupiravir 800mg Twice a day (BD) in combination with Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required. The dose of Paxlovid® will be fixed for all cohorts.
89320229|NCT04746183|No Intervention|CST-8 Phase I Molnupiravir + Paxlovid® Control|Standard of care
88806571|NCT05902221|Active Comparator|Antibiotic treatment backbone alone|Amoxicillin or moxifloxacin to the investigator's discretion
88806572|NCT05902221|Experimental|Antibiotic treatment backbone + rifampicin|Amoxicillin or moxifloxacin to the investigator's discretion + RIMACTAN
89320230|NCT04746183|Active Comparator|CST-5 VIR-7832|Phase II: 500 mg dose of VIR-7832 will be given by IV infusion.
89320231|NCT04746183|Placebo Comparator|CST-5 Placebo Phase II|Phase II: placebo blinded controlled
89320232|NCT04737460|Experimental|AAV9/CLN7|"AAV9/CLN7 is an intrathecally administered AAV9-based gene therapy vector that expresses the fully functional form of MFSD8 under the control of a synthetic promoter. AAV9/CLN7 is designed to achieve stable, potentially life-long expression of MFSD8 in non-dividing cells.~The first participant will receive a low dose of 5X1014 vg, subsequent participants will receive a higher dose of 1x1015 vg of the AAV9/CLN7 agent."
89320233|NCT04726787|Experimental|Bridging Radiotherapy|Disease areas requiring effective long-term control will receive full-dose radiotherapy (20-30Gy/5-15#); other areas will receive low dose (4Gy/2#)
89320234|NCT04723758|Experimental|GI Genius-assisted colonoscopy (GGC)|In the GGC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure, except that at some point prior to commencing withdrawal of the colonoscope, a member of the endoscopy staff will turn on the GI Genius machine. This will remain operational from the time it is switched on until the end of the procedure.
89320235|NCT04723758|Active Comparator|Standard Colonoscopy (SC)|In the SC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure.
89320236|NCT04722588|No Intervention|Control period|The control period is represented by standard care procedures, which are similar in all three EDs: Patients cared for in the EDs receive treatment from ED physicians and nurses, and no pharmacists are involved in any of the EDs.
89320237|NCT04722588|Experimental|Intervention period|"During the intervention period, clinical pharmacists will be present in the EDs from 08.00 - 19.00 Monday to Friday.~The ED pharmacists will collaborate with the interdisciplinary team and perform the following tasks as appropriately as possible and by prioritized need; medication history taking, medication reconciliation, medication review, drug therapy recommendations, guidance on drug administration, medication information and counseling to patients/next of kin and health care personnel and communication about medications and changes in medication regimes. Standardized procedures, like the integrated medicines management (IMM) methodology, will be applied where possible. How, when and which task will be performed for each patient cannot be predetermined, but must be performed according to patient's needs and eventual time constraints."
89320238|NCT04722003|Experimental|4CMenB|Participants will receive two doses (0.5 mL each) of 4CMenB vaccine on Day 1 and Day 29. Each single dose of vaccine will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=40
89320239|NCT04722003|Placebo Comparator|Placebo|Participants will receive two doses (0.5 mL each) of placebo injections (saline) on Day 1 and Day 29. Each single dose of placebo will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=10
89320240|NCT04720911|Experimental|In-person TASCS|This intervention is designed to assess the TASCS app administered via an in-person clinician in the ED, with follow-up telephone calls by a clinician
89320241|NCT04720911|Active Comparator|Telehealth TASCS|This comparison condition is designed to assess the telehealth modality of TASCS in the ED (in contrast to in-person clinician modality), with follow-up telephone calls by a clinician
89320242|NCT04720911|Active Comparator|Self-administered TASCS|This comparison condition is designed to assess the self-administered modality of TASCS (in contrast to clinician modality), with follow-up telephone calls by a clinician
89320243|NCT04719286|Experimental|Intervention group|The intervention is the use of the MinSafeStart mobile application. The app utilizes the Pregnancy-Unique-Quantification-of-Emesis-24 (PUQE-24) scale to categorize the women's NVP severity (e.g. mild, moderate, or severe) on a daily basis, and visualizes the fluctuations over time in a graph. Each woman will have their own personal graph based on the information they put in. They will also be able to see how their symptoms are compared to an average graph. The women will get treatment advice based on their PUQE-24 scale, e.g. dietary and lifestyle advice for mild symptoms and referral to see the doctor for moderate and severe symptoms.
89320244|NCT04719286|No Intervention|Control group|Standard care.
89320245|NCT04718220|Placebo Comparator|Unexposed (SARS-CoV-2 negative) cohort|Women who do not experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
89320246|NCT04718220|Active Comparator|Exposed (SARS-CoV-2 positive) cohort|Women who experience laboratory-confirmed SARS-CoV-2 infection during pregnancy.
89320247|NCT04713917|Active Comparator|Gel Group|Two applications of HA gel (Mucogyne®) per week during one year.
89320248|NCT04713917|Experimental|Laser Group|Laser CO2 for vulvovaginal area during 2 sessions (15 min) at visits D0 and M6.
89320249|NCT04713917|Experimental|HA Injection Group|Injection of 1 mL of HA at D0 and M6 (DESIRIAL®).
89320250|NCT04703270||Exposed|Expectant mothers with a positive nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation regardless of antibody status.
89320251|NCT04703270||Seropositive|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation but positive IgM/IgG antibodies against SARS-CoV-2.
89320252|NCT04703270||Unexposed|Expectant mothers with a negative nasopharyngeal swab for SARS-CoV-2 at any point during pregnancy from 24 weeks gestation and negative IgM/IgG antibodies against SARS-CoV-2.
89320253|NCT04693884|Experimental|High THC, Smoked|
89320254|NCT04693884|Experimental|High THC, Vaporized|
88811761|NCT00862784|Experimental|IMC-1121B (ramucirumab) + mFOLFOX-6|This regimen will be repeated every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
88811762|NCT00864032|Experimental|Phase I|
88811763|NCT00820664|Active Comparator|17β-estradiol 2.0 milligrams|Estrace 2.0 mg tablet
89320255|NCT04693884|Experimental|High CBD, Smoked|
89320256|NCT04693884|Experimental|High CBD, Vaporized|
89320257|NCT04692233|Experimental|Qigong|The entire intervention will last 16 weeks, including 1-hour supervised training sessions twice a week during weeks 1 to 8 (training; 16 hours), and 1-hour supervised weekly follow-up sessions during weeks 9 to 16 (follow-up; 8 hours). The sessions will be supervised by an experienced qigong master. Throughout the intervention period, participants will be asked to self-practice BQ for 30 minutes twice a week from weeks 1 to 8, and then three times a week from weeks 9 to 16 (20 hours).
89530157|NCT04503239||Type 2 Diabetes in MDI or basal insulin plus GLP-1|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89320258|NCT04692233|Active Comparator|Light flexibility exercise|The control group will practice light flexibility exercise without any abdominal breathing and meditation techniques. The duration and frequency of supervised sessions and self-practice will be identical to the qigong sessions. The supervised sessions will be conducted by a certified exercise trainer.
89320259|NCT04688736|Experimental|Placebo|Each recruited subject will oral 8mg placebo 20 minutes before blood transfusion.
89320260|NCT04688736|Active Comparator|Chlorpheniramine|Each recruited subject will oral 8mg chlorpheniramine 20 minutes before blood transfusion.
89320261|NCT04685655|No Intervention|COVID-19 therapy according to center standard alone|
89320262|NCT04685655|Active Comparator|Therapeutic plasma exchange and COVID-19 therapy according to center standard|
89320263|NCT04685616|Active Comparator|ABVD +/- ISRT|"2 x 28 day cycles of ABVD: Doxorubicin 25mg/m^2 IV days 1 & 15 Bleomycin 10000 IU/m^2 days 1 & 15 Vinblastine 6mg/m^2 days 1 & 15 Dacarbazine 375mg/m^2 days 1 & 15~PET-CT after 2 cycles will determine subsequent treatment:~Deauville score 1-3 (PET CMR): 1 further cycle of ABVD then follow up Deauville score 4 (PET positive): 2 further cycles of ABVD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial."
89320264|NCT04685616|Experimental|A2VD +/- ISRT|"2 x 28 day cycles of A2VD: Doxorubicin 25mg/m^2 IV days 1 & 15 Brentuximab vedotin 1.2mg/kg (max 120mg) days 1 & 15 Vinblastine 6mg/m^2 days 1 & 15 Dacarbazine 375mg/m^2 days 1 & 15 Filgrastim (or equivalent haematopoietic growth factor) for 5-7 days from day 2 and day 16 (or single dose of peg-filgrastim on days 2 & 16)~PET-CT after 2 cycles will determine subsequent treatment:~Deauville score 1-3 (PET CMR): 1 further cycle of A2VD then follow up Deauville score 4 (PET positive): 2 further cycles of A2VD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial."
89320265|NCT04682665||Experimental|Patients randomized to the experimental arm of the EMT2 trial, receiving Icosapent Ethyl (EPA-EE) according to the EMT2 protocol.
89320266|NCT04682665||Placebo comparator|Patients randomized to the placebo comparator arm of the EMT2 trial, receiving placebo capsules according to the EMT2 protocol.
89320267|NCT04681417|Experimental|Study 1: Melphalan or Melphalan + Topotecan|Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
89320268|NCT04681417|Other|Study 2: Etoposide, carboplatin and vincristine|Neoadjuvant chemotherapy involves 2 to 6 cycles of combined etoposide, carboplatin and vincristine in association with ophthalmologic treatments.
89320269|NCT04676958|Placebo Comparator|Placebo|380 mg capsule/day micro-crystalline cellulose
89320270|NCT04676958|Active Comparator|Vitamin K2|380 mg capsule/day micro-crystalline cellulose including 240ug/day Vitamin K2
89320271|NCT04672941||COPD patients|"COPD patients switching from Tiotropium monotherapy to dual therapy with Tiotropium bromide plus Olodaterol.~All eligible Chronic Obstructive Pulmonary Disease (COPD) patients who had recently switched (within one week) from tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with tiotropium bromide plus olodaterol (Spiolto® Respimat®), in the Greek private and public sector pulmonary offices and clinics. The follow-up period was 3 months. Participants were visited at baseline (Visit 1) and at 3 months after baseline visit (Visit 2)."
89320272|NCT04670679|Experimental|Dose Escalation (Part A): ERAS-601 monotherapy|ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
89320273|NCT04670679|Experimental|Dose Escalation (Part B): ERAS-601 monotherapy|ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
89320274|NCT04670679|Experimental|Dose Escalation (Part C): ERAS-601 monotherapy|ERAS-601 will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent.
89320275|NCT04670679|Experimental|Dose Escalation and Dose Expansion (Part D): ERAS-601 in combination with cetuximab|ERAS-601 will be administered in sequential ascending doses with cetuximab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC).
89320276|NCT04670679|Experimental|Dose Escalation and Dose Expansion (Part E): ERAS-601 in combination with pembrolizumab|ERAS-601 will be administered in sequential ascending doses with pembrolizumab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or non small cell lung cancer (NSCLC).
89320277|NCT04669093|Experimental|Placebo|All participants will participate in two sessions, one with a placebo suggestion that matches the participant's motivational style, and one with placebo suggestion that does not match their motivational style, in a pseudo-random order.
89320278|NCT04669093|Experimental|Control|Each session will also include a control phase, in which the same cream will be applied, and participants will be instructed that the cream has no analgesic effects.
89320279|NCT04659031|Experimental|Cohort D1|Single Dose 0.1 mg / kg ABC008
89320280|NCT04659031|Experimental|Cohort D2|Single Dose 0.5 mg / kg ABC008
89320281|NCT04659031|Experimental|Cohort D3|Single Dose 2.0 mg / kg ABC008
89320282|NCT04659031|Experimental|Cohort D4|Single Dose 5.0 mg / kg ABC008
89320283|NCT04659031|Experimental|Cohort D5|X.X mg / kg ABC008
89320284|NCT04659031|Experimental|Cohort 6|Single 2.0 mg / kg ABC008
89320285|NCT04659031|Experimental|MAD Phase Cohort 1|Multiple Dose 0.1 mg / kg ABC008 every 8 weeks
89320286|NCT04659031|Experimental|MAD Phase Cohort 2|Multiple Dose 0.5 mg / kg ABC008 every 8 weeks
89320287|NCT04659031|Experimental|MAD Phase Cohort 3|Multiple Dose 2.0 mg / kg ABC008 every 8 weeks
89320288|NCT04658368||Control|Participants with a history of major limb amputation at the University of Wisconsin (UW) that did not undergo TMR
89320289|NCT04658368||Retrospective TMR|Participants with a history of major limb amputation that underwent primary or secondary TMR with attending plastic surgeon at UW
89320290|NCT04658368||Prospective Secondary TMR|Participants who are scheduled to undergo secondary TMR at the UW
89320291|NCT04658368||Prospective Primary TMR|Participants who are scheduled to undergo primary TMR at the UW
89320292|NCT04650841|Experimental|Naloxone Group|Participants will receive 4mg naloxone nasal spray.
89320293|NCT04650841|Experimental|Saline Group|Participants will receive saline in the nasal spray.
89320294|NCT04632810|Experimental|Ketogenic low energy diet|Ketogenic low energy diet for 8 weeks
89320295|NCT04632810|Active Comparator|non-Ketogenic low energy diet|non-Ketogenic low energy diet for 8 weeks
89320296|NCT04625673|Active Comparator|Group A|Group A will wear the OsciPulse device for the first 3 hours then switch to the standard IPC device for the second 3 hours.
89320297|NCT04625673|Active Comparator|Group B|Group B will wear the standard IPC device for the first 3 hours then switch to the OsciPulse device for the second 3 hours.
89320298|NCT04624100||All consecutive patients with primary ventral or incisional hernia|
89320299|NCT04609787|Experimental|All participants|Quantitative sensory testing will be completed and current pain levels obtained. 20-minutes of immersive virtual reality will be completed, and then complete quantitative sensory testing again. We will compare pre-IVR quantitative sensory testing with post IVR levels.
89320300|NCT04599972|Experimental|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
89320301|NCT04599972|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
89320302|NCT04599933|Experimental|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
89320303|NCT04599933|Placebo Comparator|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
89320304|NCT04584892||Haemophilia A|Patients enrolled will have Haemophilia A (any severity), needing turoctocog alpha prophylactic therapy.
89320305|NCT04577300|Experimental|Dual Implantation|Two NT-501 devices will be implanted in the study eye.
89320306|NCT04577300|Experimental|Single Implantation|One NT-501 device will be implanted in the study eye.
89320307|NCT04577300|Sham Comparator|Sham Implantation|No NT-501 devices will be implanted in the study eye.
89320308|NCT04570475|Experimental|vitamin D+multivitamin|
89320309|NCT04570475|Active Comparator|placebo+multivitamin|
89320310|NCT04566523||Control Group|Chronic respiratory patients who undergo a home-based exercise training program with a rehabilitation coach supervision.
89320311|NCT04566523||Tele Group|Chronic respiratory patients who undergo a home-based exercise training program online.
89320312|NCT04564989||HPV+ OPSCC Patients|Patients with p16+ squamous cell carcinoma of the oropharynx (or unknown primary) who will receive definitive cancer treatment.
89320313|NCT04558918|Experimental|LNP023 200mg b.i.d.|Iptacopan 200mg b.i.d. hard gelatin capsule. After 24 weeks of LNP023 200mg b.i.d. treatment in the Randomized Treatment Period, participants had the option to enter the Extension Treatment Period to receive an additional 24 weeks of LNP023 200mg b.i.d.
89320314|NCT04558918|Active Comparator|Anti-C5 antibody|In the Randomized Treatment Period patients randomized to receive Anti-C5 antibody continued with the same stable regimen of Anti-C5 antibody therapy as they had received prior to randomization. For eculizumab (administered as intravenous infusion every 2 weeks), the maintenance dose was a fixed dose, whereas for ravulizumab (administered as intravenous infusion every 8 weeks), the maintenance dose was based on body weight. After 24 weeks of Anti-C5 antibody treatment in the Randomized Treatment Period, participants had the option to enter the Extension Treatment Period to receive 24 weeks of LNP023 200mg b.i.d.
89320315|NCT04555330|Experimental|Visual Feedback|Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level and motivation to move. This information will be visible to the health personnel, the patients and visitors.
89320316|NCT04555330|Other|Control Group|The participants in the non-exposed cohort will receive usual hospital care and be provided with a sensor collecting data on activity level during hospitalisation.No feedback on physical activity is provided.
89320317|NCT04550689|Active Comparator|Xenograft|
89320318|NCT04550689|Active Comparator|Allograft|
89320319|NCT04545398|Experimental|Pasture-raised|The meal contains grass/pasture fed beef
89320320|NCT04545398|Experimental|Grain-fed|The meal contains grain-fed beef
89320321|NCT04545398|Placebo Comparator|Meat Alternative|The meal contains a meat alternative
89320322|NCT04545398|Experimental|Lamb|The meal contains lamb
89320323|NCT04531514|Experimental|Sensitivity to phonological rules & referents OR: Toddlers|OR condition
89320324|NCT04531514|Experimental|Sensitivity to phonological rules & referents FR: Toddlers|Family Resemblance condition
89320325|NCT04524533|Experimental|Intervention group|Participants randomized into the intervention arm will watch smoking cessation videos (ready to quit or not ready to quit) during a dental cleaning clinic visit, receive a brochure about EBTs, and participate in a 4-week text message program which consists of automated and tailored text messages to motivate EBT utilization. After the 4-week program, the intervention group will receive monthly assessment text messages.
89320326|NCT04524533|Active Comparator|Control group|Participants randomized into the control arm will watch a control video during a dental hygiene visit and receive a brochure about EBTs, and a 4-week assessment-only text message program.
89320327|NCT04514003||SARS-CoV-2 PCR positive cases|Antibody tests will be performed every 6 months for 2 years
89320328|NCT04514003||SARS-CoV-2 PCR negative cases|Antibody tests will be performed at baseline
89320329|NCT04514003||Population controls|A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.
89320330|NCT04503681|Active Comparator|Standard introduction video|
89320331|NCT04503681|Experimental|Enhanced compassion video|
89320332|NCT04501939|Experimental|Cirmtuzumab + Venetoclax|All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.
89320333|NCT04500041|Active Comparator|Casting|Subjects will be treated with serial casting
89320334|NCT04500041|Active Comparator|Bracing|Subjects will be treated with full-time orthotics (braces)
89320335|NCT04498910|Experimental|1500 milligrams (mg) LY3451838|Participants received a single intravenous (IV) dose of 1500 mg LY3451838.
89320336|NCT04498910|Placebo Comparator|Placebo|Participants received a single IV dose of placebo.
89320337|NCT04496349|Experimental|APG-115 monotherapy|APG-115 will be given alone
89320338|NCT04496349|Experimental|APG-115 + APG-2575 combination|APG-115 is given in combination with APG-2575
89320339|NCT04461327|Experimental|Major Depressive patients|"3 groups:~Women having recently attempted suicide (less than 72 hours).~Women having a past suicide attempt (more than 72 hours).~Women without lifetime history of suicidal behaviour."
89320340|NCT04454073||Bipolar patients|In euthymic state or with mild to moderate symptoms
89320341|NCT04447131||COVID-19|Confirmation of the diagnosis of COVID-19 by laboratory method (RT-PCR and / or positive serology for SARS-CoV-2 - COVID group).
89320342|NCT04447131||Healthy Individuals|Asymptomatic and with negative SARS-CoV-2 serology
89320343|NCT04447131||Respiratory symptoms but negative for COVID-19|Negative for SARS-CoV-2. But with respiratory symptoms
89320344|NCT04442802|Experimental|Long time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 6 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
89320345|NCT04442802|Active Comparator|Short time balloon inflation|During the endovascular intervention the angioplasty balloon will be inflated for 3 minutes to treat the occlusive-stenotic femoropopliteal arterial lesion
89320346|NCT04440345|Experimental|IBI362|"Participants received dose 1 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 2 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 3 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 4 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 5 level of IBI362 administered as multiple subcutaneous doses."
89320347|NCT04440345|Placebo Comparator|placebo|Participants received matching placebo dose regiments by subcutaneous injection
89320348|NCT04439344|Experimental|Treatment (binimetinib)|Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89320349|NCT04439110|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89320350|NCT04422184|Experimental|SEN GROUP|Sensodyne Repair and Protect - NOVAMIN technology
89320351|NCT04422184|Experimental|REG GROUP|Dentalclean Daily Regenerator - REFIX technology
89320352|NCT04422184|Experimental|REGK GROUP|Dentalclean Daily Regenerator - REFIX technology + potassium citrate
89320353|NCT04416568|Experimental|Solid Tumor (Stratum 1)|"Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles~Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle~Patients with INI1-negative relapsed or refractory extracranial solid tumors"
89320354|NCT04416568|Experimental|CNS (Stratum 2)|"Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles~Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle~Patients with INI1-negative relapsed or refractory CNS tumors"
89320355|NCT04408716|Experimental|Ablation Index Guided High-Power Short-Duration Group|For patients assigned to undergo AF ablation with ablation index guided high-power short-duration strategy, point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
89320356|NCT04408716|Active Comparator|Standard Radiofrequency Ablation Group|For patients assigned to undergo AF ablation with standard radiofrequency ablation group, point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
89320357|NCT04392167|Experimental|a/LCI-OCT Imaging of the Esophagus|
89320358|NCT04389749|Experimental|CPM|The experimental group will have a CPM applied in the PACU immediately post-op and it will be utilized while the patient is awake in bed for 2 hours on and 2 hours off, when not mobilizing with Physical Therapy (PT). The experimental group will also have traditional PT, including sessions 1 to 3 times a week.
89320359|NCT04389749|No Intervention|No CPM|The control group will have typical care, including working with physical therapy 1 to 3 times a week.
89320360|NCT04380038|Active Comparator|Dupilumab|The dupilumab dose regimen selected for this study (300 mg q2w after an initial loading dose of 600 mg)
89320361|NCT04380038|Placebo Comparator|Placebo|A harmless substance that looks like the study drug, but which should have no effect. The placebo formulation used in this study contains all the ingredients present in the active drug, except the active ingredient (IL-4α antibody). Therefore, the risk related to this formulation should be no greater than the risk associated to the active drug.
89320362|NCT04378049|Active Comparator|Standard total knee arthroplasty|Participants who are randomized to the control group will undergo TKA according to local standard of care. The choice of implant and use of bone cement will be recorded but left to the surgeon's discretion according to their standard practice.
89530158|NCT04503239||Type 2 Diabetes on 0 OAD|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89530159|NCT04503239||High Risk to Develop Prediabetes / Type 2 Diabetes|Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
89530160|NCT03250741|Active Comparator|Rotigotine 4 mg|Rotigotine transdermal patches 4 mg
89530161|NCT03250741|Placebo Comparator|Placebo|Placebo transdermal patches
89320363|NCT04378049|Experimental|Robot-assisted partial knee arthroplasty|Participants with isolated medial or isolated lateral compartment OA who are randomized to the intervention group and have one affected knee compartment will receive a robot-assisted unicompartmental knee arthroplasty (UKA). If the patient has medial or lateral OA plus patellofemoral OA they will receive a bicompartmental knee arthroplasty (BiKA) consisting of a two simultaneous UKAs. The partial knee replacement procedures will be performed using the Mako RIO robotic arm (Stryker) according to the manufacturer's instructions. The choice of implant and use of bone cement will be recorded but will be left to the surgeon's discretion. Surgeons will resurface the patella if the patellar cartilage meets Outerbridge grade 3 or 4 criteria
89320364|NCT04358406|Placebo Comparator|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
89320365|NCT04358406|Active Comparator|Rhu-pGSN|Recombinant human plasma gelsolin reconstituted for slow bolus injection.
89320366|NCT04334057||Patients with haemophilia A|New patients who have not previously been exposed to Esperoct® (Turoctocog alfa pegol or N8-GP in clinical trials) are eligible for this study.
89320367|NCT04328662||Cohort 1: Participants with RRMM|Participants diagnosed with relapsed or refractory multiple myeloma (RRMM) who have received at least one dose of ixazomib plus lenalidomide - low dose dexamethasone (IRd) treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
89320368|NCT04328662||Cohort 2: Participants with NDMM, RRMM, and Non-myeloma|Participants diagnosed with NDMM who have received at least one dose of ixazomib-based regimen treatment, diagnosed with RRMM who have received at least one dose non-IRd ixazomib-based regimens treatment, and diagnosed with non-myeloma who have received at least one dose of ixazomib-based regimens treatment, will be observed prospectively. Data will be collected from study sites such as clinical departments and pharmacies in hospitals as a part of routine clinical visits of participants to evaluate effectiveness and safety information.
89320369|NCT04321525|Active Comparator|Cognitive-behavioral therapy (CBT)|Individual Cognitive Behavioral Therapy
89320370|NCT04321525|Experimental|Personal construct therapy (PCT)|Individual Personal Construct Therapy
89320371|NCT04321525|Experimental|Personal construct therapy with virtual reality (PCT-VR)|Individual Personal Construct Therapy with an immersive virtual reality app
89320372|NCT04321356||Stryker Triathlon PCR TKA|Subjects implanted with a Stryker Triathlon PCR TKA
89320373|NCT04321356||Stryker Triathlon PS TKA|Subjects implanted with a Stryker Triathlon PS TKA
89320374|NCT04321356||Zimmer Persona PCR TKA|Subjects implanted with a Zimmer Persona PCR TKA
89320375|NCT04321356||Zimmer Persona PS TKA|Subjects implanted with a Zimmer Persona PS TKA
89320376|NCT04316338|Experimental|Active intermittent theta-burst stimulation (iTBS)|6 weeks of iTBS delivered at 80% resting motor threshold will be delivered to personalized regions in the prefrontal cortex based on each individual's functional connectivity.
89320377|NCT04314492|Experimental|Intracapsular tonsillectomy with coblation|(Total) Intracapsular tonsillectomy (ICTE) with coblation
89320378|NCT04311619|Experimental|Major Depression Disorder Participants|Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the [11C]UCB-J radiotracer before and after Repetitive Transcranial Magnetic Stimulation (rTMS) treatment
89320379|NCT04293783|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 two tablet by mouth 1 time per day
89320380|NCT04293783|Placebo Comparator|Placebo|Placebo two tablet by mouth 1 times per day
89320381|NCT04274010|Other|Crohn's capsule|Single-arm non-randomised study, all participants will undergo MRE, ileo-colonoscopy and Crohn's capsule.
89320382|NCT04265638|Experimental|Exercise|
89320383|NCT04265638|No Intervention|Usual Care|
89320384|NCT04260802|Experimental|Drug: Dose Escalation|Escalating doses of OC-001 administered intravenously (IV)
89320385|NCT04260802|Experimental|Drug: Combination: Tumor Type 1|Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
89320386|NCT04260802|Experimental|Drug: Combination: Tumor Type 2|Doses of OC-001 administered by IV in combination anti-PD-1 or anti-PD-L1 Antibody (Ab)
89320387|NCT04260022|Experimental|Cohort A|
88811764|NCT00820664|Active Comparator|17β-estradiol 0.5 milligrams|Estrace 0.5 mg tablet
88811765|NCT00820664|Placebo Comparator|3|Placebo
89320388|NCT04260022|Experimental|Cohort B|
89320389|NCT04260022|Experimental|Cohort C|
89320390|NCT04260022|Experimental|Cohort D|
89320391|NCT04257175|Experimental|Cyclophosphamide, Flodarabine,CAR-T cells|"The appropriate participants will undergo lymhopheresis to collect lymphocytes from PBMC peripheral blood. CAR T CD19 cells will be produced. The participants will receive cyclophosphamide 300 mg / m² and flodarabine 30 mg / m² lymphodeplition intravenously daily for 3 days.~The CAR-T CD19 cells will be given on the 5 to 7 day post lymphodeplition ."
89320392|NCT04247880|Experimental|Mentees|This arm consists of apprentice-level, female-identifying construction workers who will receive active mentorship (the intervention) for two years from trained journey-level mentors.
89320393|NCT04247880|No Intervention|Control Apprentices|This arm consists of apprentice-level, female-identifying construction workers who will not receive mentorship.
89320394|NCT04227678|Other|Control group- A0|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g Oral Glucose Tolerance Test (OGTT) glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);~A0: without heparin administered"
89320395|NCT04227678|Other|LPLD group-A0|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;~A0: without heparin administered"
89320396|NCT04227678|Other|Control group-A1|"Control group: Healthy subjects with fasting glucose < 5.6, 2-hour post 75g OGTT glucose < 7.8 mmol/l and HbA1c < 5.8%; fasting TG < 1.5 mmol/l);~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
89320397|NCT04227678|Other|LPLD group-A1|"LPLD group: LPL deficient subjects with history of fasting TG > 5 mmol/l and homozygote or compound heterozygote for a LPL-gene mutation;~A1: with an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours starting 15 minutes before ingestion of liquid meal."
89320398|NCT04223765|Experimental|CAR.k.28/CAR.k.4-1BB|Up to 12 patients will receive a single infusion of CAR.k.28. The starting dose will be 2.5x10^5 cells/kg of each product. Up to 3 dose levels of CAR.k.28 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 8 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and bendamustine. Patients with a known history of intolerance to bendamustine may be considered for lymphodepletion with fludarabine and cyclophosphamide.
89320399|NCT04203056|Experimental|AL-LAI: Long-Acting Injectable Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: For patients assigned to the AL-LAI (aripiprazole lauroxil- long-acting injections), initiation of AL-LAI will begin with a one-day initiation regimen (using AL-NCD IM (aripiprazole lauroxil NanoCrystal Dispersion)). Subsequent dosing of AL-LAI will be flexible based on clinician judgment. Treatment with AL-LAI can be initiated at a dose of 441mg or 661mg (administered monthly), 882mg (administered monthly or every 6 weeks), or 1064mg (administered every 2 months). Note: These dosages are not assigned levels of the intervention and dosage levels may be changed at any time throughout the 12-month intervention based on clinical need and clinician judgement. Starting dosages do not indicate separate treatment conditions.
89320400|NCT04203056|Active Comparator|ARI-ORAL: Aripiprazole Oral Antipsychotic|Patients successfully completing the Stabilization period will be randomized to one of the two medications groups: Patients assigned to the oral medication condition will continue with ARI-ORAL. ARI-ORAL dosage will be flexible and dosage will be at the discretion of the treating psychiatrist. Patients discontinuing ARI-ORAL study drug after Randomization to oral antipsychotic medication, can remain in active treatment and follow-up within the study, and may be prescribed any of a number of first-line oral antipsychotics.
89320401|NCT04193228||People with distal hereditary motor neuropathy|This is a single arm, feasibility study
89320402|NCT04182750|Experimental|Intervention group|Pharmacist consultation in early pregnancy (gestation week <12)
89320403|NCT04182750|No Intervention|Control group|Standard care.
89320404|NCT04180722|Experimental|Intervention|Participants will receive multi-component Virtual Transition Intervention facilitated through the aTouchAway™ platform including the usual care provided by specialist HMV programs.
89320405|NCT04180722|No Intervention|Control|Usual care will be delivered in accordance with the Canadian Thoracic Society (CTS) clinical practice guidelines and includes scheduled face-to-face clinic visits with the ventilator team with the ventilator team within the first month of starting HMV and then every 3, 6, or 12 months depending on medical stability with additional telephone calls/email contact for equipment trouble shooting and management of intercurrent illnesses as needed.
89320406|NCT04166149||University of Maryland|Pancreas and pancreas kidney patients enrolled at University of Maryland. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
89320407|NCT04166149||University of Wisconsin|Pancreas and pancreas kidney patients enrolled at University of Wisconsin. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
89320408|NCT04166149||Georgetown University|Pancreas and pancreas kidney patients enrolled at Georgetown University. Determine if dd-cfDNA exists in PTA, SPK, and PAK transplant recipient's blood by taking blood specimens at months 1-4, 6, 9, and 12 in the first year post transplant, and quarterly (month 15, 18, 21, 24) in the second year post transplant.
89320409|NCT04158141|Experimental|Arm I (Step 1: chemotherapy, P/D: Step 2: no treatment)|"STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.~STEP 2: Patients receive no treatment."
89320410|NCT04158141|Experimental|Arm II (Step 1: chemotherapy, P/D, Step 2: IMRT/PBS)|"STEP 1: Patients undergo P/D then within 4 to 8 weeks receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1. Patients may instead receive pemetrexed IV over 10 minutes and cisplatin or carboplatin IV over 60 minutes on day 1 then undergo P/D within 4 to 8 weeks after chemotherapy. The order of surgery and chemotherapy is at the discretion of the treating physician.~STEP 2: Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions IMRT or PBS proton therapy 5 days per week over 6 weeks."
89320411|NCT04132310||MINT Participants|Up to 60 MINT maternal participant are linked with 60 infant participants, and 60 partner participants.
89320412|NCT04113993|Experimental|Oral Bazedoxifene|Oral Bazedoxifene dosed at 40 mg daily
89320413|NCT04113993|Placebo Comparator|Placebo|Identically packaged placebo capsule daily
89320414|NCT04107064|Experimental|Neurodiversity at Work (NaW) Group|Individuals in this group will receive a 6-week Autism at Work pre-employment training. Upon onboarding, each individual will be supported by a team manager, a team buddy, a peer mentor, a job/life skills coach, a vocational rehabilitation counselor, and a personal counselor. Ongoing support for members of support circles will be provided during the 12 weeks immediately after onboarding.
89320415|NCT04107064|Experimental|Neurodiversity at Work - Delayed Start (NaW-DS)|Participants in this group will receive typical orientation for neurotypical employees after onboarding. The support of peer mentor, job/life skills coach, vocational rehabilitation counselor, and a personal counselor will start 6 months after onboarding. Managers, co-workers, team buddies and mentors for all recruited and hired employees in both groups will receive the same specialized training to enhance their abilities to work with individuals with ASD.
89320416|NCT04090528|Experimental|Arm 1: One DNA vaccine|"100 µg pTVG-HP administered intradermally (i.d.) days 1, 8 plus 200 mg Pembrolizumab, administered intravenously on day 1 of 21-day cycles (for 8 cycles)~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 of 21-day cycles x 4 cycles"
89531629|NCT05910814|Experimental|SD + PP (sleep deprivation + physical practice)|One night of sleep deprivation prior physical motor acquisition with PP and consolidation
89320417|NCT04090528|Experimental|Arm 2: Two DNA vaccines|"100 µg pTVG-AR administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 1, 2, 5, and 6 alternating with 100 µg pTVG-HP administered intradermally (i.d.) on days 1, 8 plus 200 mg Pembrolizumab administered intravenously day 1 of 21-day cycles, for cycles 3, 4, 7, and 8.~Following cycle 8, subsequent 21-days cycles: Pembrolizumab 200 mg IV day 1 of 21-day cycles~In the event of PSA rise (25% increase over cycle 9 day 1, minimum of 2 ng/ml), and no evidence of radiographic progression, participants will receive 4 additional vaccine booster cycles: 100 µg pTVG-AR i.d days 1, 8 + 200 mg pembrolizumab IV day 1 of q 21-day cycles, for cycles 1 and 2 followed by 100 µg pTVG-HP i.d. days 1, 8 + 200 mg pembrolizumab IV day 1 in 21-day cycles, for cycles 3 and 4"
89320418|NCT04086797|Experimental|IQP-AE-103|2 capsules after 3 main meals per day (total 1980 mg)
89320419|NCT04086797|Placebo Comparator|Placebo|2 capsules after 3 main meals per day
89320420|NCT04084340|Experimental|Anodal tDCS + Exercises therapies|"Real transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes, 2mA"
89320421|NCT04084340|Sham Comparator|Sham tDCS + Exercises therapies|"Sham transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes (30 seconds ON), 2mA"
89320422|NCT04077632|Experimental|tDCS (anodal)|Real transcranial direct current stimulation tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
89320423|NCT04077632|Sham Comparator|tDCS (sham)|Sham transcranial direct current stimulation tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).
89320424|NCT04058652|Experimental|TENS therapy|the first step would be to administer the biologic medication in one thigh without the use of TENS therapy. Biologic medications are administered in two doses, with one in each thigh. Administering the first biologic medication injection is done to establish a control, or baseline, for how painful the injection experience is. The second step would be a study team member applying two to four TENS unit pads (made of adhesive gel) to the skin of subject's other thigh approximately two centimeters from the site where injection of the biological medication takes place. There will be no extra injection of biologic medication during this procedure. The prescribed dose will be used one time, split into two legs (which is the standard protocol for administration). The device will be turned on during the injection of the medication. Immediately after both steps, the subject will be given a brief survey to determine your pain level. The subject's involvement would last roughly 10-15 minutes.
89320425|NCT04055129||Birth Control|Hormone levels controlled with subject on birth control pill
89320426|NCT04055129||Non-Birth Control|Hormone (estrogen) levels not controlled but monitored for levels of estrogen at two points in menstrual cycle (Follicular and ovulatory phases)
89320427|NCT04052373|Experimental|Peri-implantitis treatment with implantoplasty|Open flap debridement with implantoplasty treatment
89320428|NCT04052373|Active Comparator|Peri-implantitis treatment without implantoplasty|Open flap debridement withput implantoplasty treatment
89320429|NCT04050813|Experimental|Control|"The program is performed 2 times per week using resistance equipment in a physiotherapy clinic. Each session consists of on 2-legged loaded exercises for hamstring, quadriceps, gluteus maximun and core. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 4 exercises.~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 set of 12-repetition maximum (12RM), in week 1 and 2; 3 set of 10 RM, in week 3 and 4; 4 set of 10RM, in weeks 5 and 6; and 4 set of 8RM, in weeks 7 to 8."
89320430|NCT04050813|Experimental|Intervention|Experimental: Inertial flywheel resistance training The program is performed 2 times per week using resistance equipment in a physiotherapy clinical. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 16 repetition maximum (RM) with moment inertia 0.05 m² from week 1-2, 24 repetition maximum (RM) with moment inertia = 0.10 m² from week 3 to 4. 32 repetition maximum (RM) with moment inertia = 0.10 m² from week 5 to 6 and 32 repetition maximum (RM) with moment inertia = 0.13 m² in a flywheel hamstring curl devise.
89320431|NCT04035213|Experimental|Behavior of Sleep Course|A semester-long course focused on sleep improves college students' sleep patterns over one semester. The listed aims of this course are to: 1) provide students with a comprehensive understanding of sleep; 2) afford an overview of the multiple ways sleep impact health, performance and well-being; and 3) to assist students in discovering how their own sleep-wake patterns impact their day to day functioning.
89320432|NCT04035213|No Intervention|Control|Students from other upper level departmental courses with content that does not include a focus on or discussion of sleep
89320433|NCT04032522||Intervention Arm (A)|Half of the health facilities will implement the intervention package. All mothers will be tested using PoC-VL at delivery and all HIV-exposed infants will be offered PoC-EID at birth and week 4-8. Newborns found to be HIV-positive will be offered immediate ART. Neonatal ART initiation will be supported at birth by trained nurses/midwives, and approved and supervised by local doctors from the affiliated HIV CTC. Following ART initiation infants will be referred for consolidated ART management to their paediatric HIV clinic following local procedures. Newborns testing HIV-negative will be offered postnatal prophylaxis (PNP) or enhanced postnatal prophylaxis (ePNP), depending on clinical risk factors, the maternal VL and country guidelines. Mothers with HIV-RNA >1000 copies/mL will receive immediate referral information for ART initiation if not on ART or enhanced ART counselling, with follow up virologic testing and switch of ART regimen as applicable at their local HIV clinic.
89320434|NCT04032522||Control Arm (B)|The other half of the health facilities will implement the standard of care (SoC). Enrolled mothers will not receive immediate PoC VL at delivery, but infants deemed to be at high risk using clinical criteria (e.g. no or late initiation of maternal ART) will be offered ePNP. EID testing will follow the national algorithm with testing at 4-8 weeks, followed by referral for immediate ART initiation for all HIV-infected infants. As PoC EID testing is expected to be nationally implemented on a programme level we will facilitate the availability of PoC testing at these sites.
89320435|NCT04029363|Other|Single arm|Single arm, non-randomized
89320436|NCT04025463|Other|Intervention|Hybrid type II effectiveness/implementation study design - pre-post design with each participant serving as his or her own control.
89320437|NCT04017130|Experimental|Part 1: Dose Escalation|"Weekly Dosing Intravenous (IV) infusion of MT-0169 every 7 days: Days 1, 8, 15, and 22 in a 28-day treatment cycle.~Every 2 Weeks IV infusion of MT-0169 every 14 days: Days 1 and 15 in a 28-day treatment cycle with escalating doses starting at the MTD/RP2D determined by the weekly dose escalation cohort.~Patients will continue to receive treatment until progressive disease, unacceptable toxicity or withdraw from the study for other reasons. Decision to escalate/deescalate/stay on the same dose/discontinue MT-0169 will be based on number of DLTs per number of patients enrolled at each dose level as predetermined by the mTPI-2 statistical model. Subsequent doses will be determined by the frequency and severity of adverse events in previous cohorts. The investigator and sponsor review of available safety, PK, pharmacodynamics, and efficacy data in the previous cohorts will also be factored in the decision."
89320438|NCT04016168||Patients with DILD|Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
89320439|NCT04008173||Male|Non-interventional patient registry
89320440|NCT04008173||Female|Non-interventional patient registry
89320441|NCT04008173||Kidney Disease|Non-interventional patient registry
89320442|NCT04008173||Diabetes|Non-interventional patient registry
89320443|NCT04008173||Elderly|Non-interventional patient registry
89320444|NCT04004403|Experimental|Alternate day fasting|"These participants will consume 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
89320445|NCT04004403|Experimental|Exercise|These participants will participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
89320446|NCT04004403|Experimental|Combination alternate day fasting plus exercise|"These participants will consume 600 kcal on the fast day and eat ad libitum at home on alternating feed days. They will also participate in a supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax."
89320447|NCT04004403|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits.
89320448|NCT04000035|Experimental|Health in work|The interdisciplinary Health in work intervention consists of three information sessions over the course of one year, with work place processes in between. In the meetings, structured health information about musculoskeletal- and mental disorders is given and put in the context of working and the specific workplace. It is an integrated intervention where information is given together by both healthcare- and NAV-personnel.
89320449|NCT04000035|Active Comparator|Regular work place measures|Regular work place measures offered by NAV workplace service. Those are interventions given by NAV personnel without healthcare involvement and can be varying.
89320450|NCT03998462|Active Comparator|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
89320451|NCT03998462|Placebo Comparator|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
89320452|NCT03972371|Experimental|Treatment Group|The ProVee Urethral Expander is implanted into the prostatic urethra to treat BPH symptoms
89320453|NCT03969953|Experimental|Rivaroxaban|Rivaroxaban 2.5mg, twice daily.
89320454|NCT03969953|Placebo Comparator|Placebo|Matched placebo, twice daily.
89320455|NCT03949270|No Intervention|Usual Care|Patients in the usual care arm will not receive any text messages.
89320456|NCT03949270|Experimental|BETA-Text Intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages.
89320457|NCT03943680|Experimental|PRGF|Post-extraction socket grafted with PRGF-Endoret
89320458|NCT03943680|Active Comparator|ABB|Post-extraction socket grafted with anorganic bovine bone (ABB)
89320459|NCT03922087||Control Group|The pregnancy women without any diseases.
89320460|NCT03922087||Disease Group|The pregnancy women with cardio-metabolic and endocrinic disorders such as gestational diabetes, obesity, hypertension, thyroid diseases, anemia and other cardio-metabolic diseases.
89320461|NCT03865524|Experimental|Experimental|Total knee arthroplasty implanted with GPS navigation system.
89320462|NCT03865524|Active Comparator|Control|Total knee arthroplasty implanted with standard guides.
89320463|NCT03857945|Active Comparator|Mobility Device Training Group|Patients receiving preoperative mobility device(s) training before surgery
89320464|NCT03857945|No Intervention|No Mobility Device Training Group|Patients not receiving preoperative mobility device(s) training before surgery
89320465|NCT03848481|Experimental|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV for 12 weeks
89320466|NCT03848481|Placebo Comparator|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo for 12 weeks
89320467|NCT03831035||15 patients and both parents.|The patients are aged 12 months or under hospitalized in the ICU suffering from multiple congenital malformations and/or neurologic symptoms.
89320468|NCT03829501|Experimental|KY1044 monotherapy phase 1|KY1044 monotherapy dose escalation
89320469|NCT03829501|Experimental|KY1044 and atezolizumab phase 1|KY1044 and atezolizumab combination dose escalation
89320470|NCT03829501|Experimental|KY1044 monotherapy phase 2|KY1044 monotherapy
89320471|NCT03829501|Experimental|KY1044 and atezolizumab phase 2|KY1044 and atezolizumab combination
89320472|NCT03825120||Women from original OVA cohort|
89320473|NCT03805932|Experimental|Moxetumomab - Dose Escalation 30 mcg/kg|Arm 1 Moxetumomab Pasudotox-tdfk + Rituximab
89320474|NCT03805932|Experimental|Moxetumomab - Dose Expansion 40 mcg/kg|Arm 1 and Arm 2 Moxetumomab Pasudotox-tdfk + Ruxience
89320475|NCT03803787|Experimental|QT/RT + Budesonide|Patients are receiving chemotherapy (QT) and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
89320476|NCT03803787|No Intervention|QT/RT + No medication|Patients are receiving chemotherapy (QT) and radiotherapy (RT) without intervention therapy and followed during 12 months.
89320477|NCT03803787|Experimental|Target drug/RT + Budesonide|Patients are receiving target therapy and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
89320478|NCT03803787|No Intervention|Target drug/RT + No medication|Patients are receiving target treatment and radiotherapy (RT) without intervention therapy and followed during 12 months.
89320479|NCT03787745|Active Comparator|Ischemic postconditioning|In addition to state of the art primary PCI in patients with TIMI0-1 ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed, however thrombectomy will not be allowed
89320480|NCT03787745|Placebo Comparator|Conventional|State of the art primary PCI in patients with TIMI0-1 will be performed, however thrombectomy will not be allowed
89320481|NCT03774186|Active Comparator|Sensor-augmented pump therapy (SAPT)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor but there will be no automated insulin adjustments made by the system.
89320482|NCT03774186|Experimental|Hybrid closed-loop therapy (HCL)|Pregnant women with T1D with use an insulin pump and a continuous glucose monitor with automated insulin adjustments made by the system, but continued meal boluses from the women.
89320483|NCT03759639|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
89320484|NCT03759639|No Intervention|Post-Treatment Washout|After both the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
89320485|NCT03748017|Placebo Comparator|Placebo-Control Supplement|12 participants will receive a placebo-control supplement per daily oral feeding.
89320486|NCT03748017|Active Comparator|Streptococcus-Containing Probiotic Supplement|12 participants will receive a powdered probiotic containing 7.77 billion colony-forming units (CFU) of L. acidophilus, 8.25 billion CFU of B. lactis, and 2 billion CFU of S. salivarius bacteriocin-like inhibitory substance (BLIS) K12 per daily oral feeding.
89320487|NCT03724409|Experimental|Cohort 1|Subject will be administered 2.96 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
89320488|NCT03724409|Experimental|Cohort 2|Subject will be administered 3.33 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
89320489|NCT03724409|Experimental|Cohort 3|Subject will be administered 3.7 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
89320490|NCT03724409|Experimental|Cohort 4|Subject will be administered 4.17 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
89320491|NCT03724409|Experimental|Cohort 5|Subject will be administered 4.44 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
89320492|NCT03724409|Experimental|Cohort 6|Subject will be administered 5.18 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
89320493|NCT03711617||CKD-ND|patients with non-dialysis CKD
89320494|NCT03711617||CKD-MHD|patients with maintenance hemodialysis
89320495|NCT03711110|Experimental|Primary prevention strategy|Intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care.
89320496|NCT03711110|Other|Secondary prevention strategy (control)|Current clinical practice: cardiac care is based on the onco-hematologist criteria.
89320497|NCT03694834|Experimental|Single Arm - Pembrolizumab|Single dose of Pembrolizumab 200mg IV administered prior to hysterectomy and surgical staging.
89320498|NCT03689894|Experimental|Ibrutinib plus Rituximab|"Rituximab~*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)~Ibrutinib~420 mg (140 mg capsule x3) by mouth daily~May be given beyond 3-6 months (for maintenance)."
89320499|NCT03681275|Experimental|Tofacitinib|Patient will receive two days treatment with tofacitinib prior to the surgery.
89320500|NCT03681275|Placebo Comparator|Placebo|Patient will receive two days treatment with placebo prior to the surgery.
89320501|NCT03677063|No Intervention|Dressing|"It is the historical cohort which is composed of patients over 18 years of age treated by peritoneal dialysis in the nephrology department of Universty Hospital of Caen Normandie. Patients with the same non-inclusion criteria as the experimental group will not be included. The data will be extracted from the Registry of Peritoneal Dialysis of French Language. The number of patients included from the register can not be fixed in advance; this number will correspond to the 4-year follow-up at the start date of the study to ensure at least two years of patient follow-up~Usually care~First dressing 5 or 10 days after the pose of the catheter :~Cleaning emergence with antiseptic soap~Rinsing with saline~Drying~Application of a hazelnut mupirocin on the exit-site~Application of an occlusive dressing on the exit-site Then, care is the same. Exit-site care is performed daily if the patient takes a shower or twice a week."
88806573|NCT05902195|Experimental|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|All participants in the intervention group will receive the intervention (PVI) in addition to usual care. PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
88806574|NCT05902195|Active Comparator|Control|All participants in the control group will receive usual stroke care services such as medical or health services offered by the hospitals or community-based organisations.
88814094|NCT04372784|Experimental|EGD with Balloon Dilatation and Cryotherapy|Esophagogastroduodenoscopy with balloon dilatation and cryotherapy
88814095|NCT04376996||General cohort|General population cohort aged 0-100 years from Slovenia
89320502|NCT03677063|Experimental|No dressing|No application of sterile dressing at the exit-site of periotoneal dialysis catheter for all patients (30 days after the placement of the peritoneal dialysis catheter)
89320503|NCT03666676|Active Comparator|Normal Hearing|Signal processing to improve intelligibility
89320504|NCT03666676|Active Comparator|Mild hearing loss|Signal processing to improve intelligibility
89320505|NCT03666676|Active Comparator|Moderate hearing loss|Signal processing to improve intelligibility
89320506|NCT03663452|Active Comparator|Prolonged exposure training|
89320507|NCT03663452|Experimental|TACTICS|
89320508|NCT03655860|Experimental|SIMEOX|Use of the device SIMEOX to exhale
89320509|NCT03640754|Active Comparator|Experimental: G-CSF|Intervention: G-CSF given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Filgrastim
89320510|NCT03640754|Placebo Comparator|Comparator: Placebo/Saline|Intervention: Placebo/saline given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Saline
89320511|NCT03637998|Experimental|PROPEL|The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.
89320512|NCT03567330|Experimental|Experimental|Family-based attachment-focused intervention for families where parent/caregiver is within 12 months of first diagnosis of a stage I-III solid tumor cancer.
89320513|NCT03567330|Active Comparator|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions.
89320514|NCT03564314|Experimental|SUPPORT AKI Clinical Decision Support|Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
89320515|NCT03564314|No Intervention|Control|Usual care provided to patients with AKI on surgical units.
89320516|NCT03551951||Patients having surgery|Cancer patients undergoing surgery will have test for circulating tumor cells, DNA alterations
89320517|NCT03551951||Patients not having surgery|"Cancer patients not undergoing surgery (but potentially other treatments) will have test for circulating tumor cells, DNA alterations.~Lung cancer screening subjects"
89320518|NCT03551951||Healthy subjects|Healthy control subjects will have test for circulating tumor cells, DNA alterations
89320519|NCT03551509|No Intervention|Control Group|Patients randomly assigned into the control group will undergo open or arthroscopic rotator cuff repair using the surgeon's standard practice. No ECM graft will be used.
89320520|NCT03551509|Active Comparator|Treatment Group|Patients randomly assigned into the treatment group will undergo open or arthroscopic rotator cuff repair and the surgeon will use the ArthroFLEX® ECM graft to augment the repair. ECM scaffold grafts are indicated for the reinforcement of soft tissues repaired by sutures or suture anchors during tendon repair surgery, including rotator cuff.
89320521|NCT03551509|Other|Crossover Group|Patients initially randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
89320522|NCT03543553||SZ|Individuals with a diagnosis of schizophrenia
89320523|NCT03543553||HC|Healthy control participants
89320524|NCT03537742|Experimental|alirocumab|alirocumab 150mg subcutaneous every other week for one year following start of study drug
89320525|NCT03537742|Placebo Comparator|placebo|placebo to match alirocumab every other week for one year following start of study drug
89320526|NCT03537482|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
89320527|NCT03516279|Experimental|Treatment (pembrolizumab, dasatinib, imatinib, nilotinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and dasatinib, imatinib mesylate, or nilotinib PO as clinically indicated per the treating physician. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients with detectable MRD after course 18 continue pembrolizumab and dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity. Patients with UMRD at any time before course 18 discontinue pembrolizumab after course 18 and continue dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity.
89320528|NCT03511846|Experimental|Oral capsaicin|
89320529|NCT03511846|Sham Comparator|Oral capsaicin and Medical Air|
89320530|NCT03511846|Experimental|Oral Capsaicin and Low Flow Oxygen|
89320531|NCT03511846|Experimental|Oral capsaicin and High Flow Oxygen|
89320532|NCT03511846|Experimental|Topical capsaicin|
89320533|NCT03511846|Sham Comparator|Topical capsaicin and Medical Air|
89320534|NCT03511846|Experimental|Topical capsaicin and Low Flow Oxygen|
89320535|NCT03511846|Experimental|Topical capsaicin and High Flow Oxygen|
89320536|NCT03511846|Experimental|Intranasal capsaicin|
89320537|NCT03511846|Sham Comparator|Intranasal capsaicin and Medical Air|
89320538|NCT03511846|Experimental|Intranasal capsaicin and Low Flow Oxygen|
89320539|NCT03511846|Experimental|Intranasal capsaicin and High Flow Oxygen|
89320540|NCT03511846|Experimental|Cold water irrigation|
89320541|NCT03511846|Sham Comparator|Cold water irrigation and Medical Air|
89320542|NCT03511846|Experimental|Cold water irrigation and Low Flow Oxygen|
89320543|NCT03511846|Experimental|Cold water irrigation and High Flow Oxygen|
89320544|NCT03507751||Meropenem|Patients who require meropenem and CRRT during ICU (intensive care unit) stay
89320545|NCT03503799||Observational Group|Patients with primary invasive breast cancer, Stage I/II; ER positive, HER2 (human epidermal growth factor receptor 2) negative, N0-N1, T1-T3, tested with EndoPredict®, age over 18 years, informed consent
89320546|NCT03473223|Experimental|CSL112|Apolipoprotein A-I [human]
89320547|NCT03473223|Placebo Comparator|Placebo|25% albumin solution diluted to 4.4%
89320548|NCT03466502|No Intervention|No oral vancomycin|
89320549|NCT03466502|Experimental|Oral vancomycin 125 mg twice daily|
89320550|NCT03466502|Experimental|Oral vancomycin 125 mg daily|
89320551|NCT03458312|No Intervention|Family and Network support measurements|"The perceived 'Family support' and 'Caregiver burden' (FNC) will be measured among 30 families.~Test time points:~Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52)"
89320552|NCT03458312|Experimental|Family and network consultations|Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
89320553|NCT03453996|Experimental|Intervention|Cardiologists will receive computerized clinical decision support information for CI-AKI prevention for patients identified above the median (> 5%) risk of AKI based on the NCDR risk prediction model for CI-AKI.
89320554|NCT03453996|Other|Control|Usual care.
89320555|NCT03453112|Experimental|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler (NEXThaler)
89320556|NCT03453112|Active Comparator|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with Hydrofluoroalkane ( HFA) -134a propellant.
89320557|NCT03449095|Experimental|Alcohol Administration|A moderate dose of alcohol (Target BAC .08%)
89320558|NCT03449095|No Intervention|Control Beverage Administration|Participants consume a non-alcoholic beverage
89320559|NCT03442374|Experimental|Exercise|A single bout of moderate intensity lumbar extensor muscle exercise.
89320560|NCT03442374|No Intervention|Non-exercise|No exercise intervention.
89320561|NCT03441204|Active Comparator|LTOT 24 h/day (intervention)|Long-term oxygen therapy (LTOT) prescribed 24 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
89320562|NCT03441204|Active Comparator|LTOT 15 h/day (control)|Long-term oxygen therapy (LTOT) prescribed 15 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
89320563|NCT03424993|Experimental|Dietary Sodium Restriction|Daily habitual dietary sodium intake < 2000mg
89320564|NCT03424993|Sham Comparator|Control|Routine habitual dietary sodium intake >3400mg
89320565|NCT03415555|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
89320566|NCT03415555|Experimental|PCA|Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose. ESP will not be done in this arm.
89320567|NCT03392987|Experimental|OTL-200 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-200 gene therapy. Subjects will also receive conditioning regimen with busulfan.
89320568|NCT03367923|Experimental|Arm I (exercise counseling, Fitbit, phone call)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive a short phone call at 2, 4, 6, and 8 weeks, and at 4 and 5 months to discuss the average number of daily steps over the past 2 weeks and to encourage a goal of a 10% increase over the next 2-4 week time period.
89320569|NCT03367923|Experimental|Arm II (exercise counseling, Fitbit, email/text)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive an electronic communication (email/text) of their choice at 2, 4, 6, and 8 weeks, and at 4 and 5 months stating the average number of daily steps over the past 2 weeks and encouraging a goal of a 10% increase over the next 2-4 week time period.
89320570|NCT03362554|Experimental|Intervention|
89320571|NCT03362554|No Intervention|Control|
89320572|NCT03357159|Experimental|cyclophosphamide and ATLG|The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.
89320573|NCT03346096|Experimental|Thiotepa|Thiotepa for reduce toxicity and improve outcome following transplantation
89320574|NCT03332316|Placebo Comparator|DEXA0|Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
89320575|NCT03332316|Experimental|DEXA1|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
89320576|NCT03332316|Experimental|DEXA2|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
89320577|NCT03332316|Experimental|DEXA4|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
89320578|NCT03310710|Experimental|treatment with Viabahn BX stent|Treatment with Viabahn BX stent as branch device in fenestrated EVAR
89530162|NCT03122093||CD-DIET Gluten-Free Diet Group|This former randomized control trial (RCT) group received a gluten-free education and continued support from a dietitian for a 1-year period via the CD-DIET Study (NCT01566110)
89530163|NCT03122093||CD-DIET Gluten-Containing Diet Group|This former RCT group did not receive a gluten-free education and 1-year support from a dietitian via the CD-DIET Study (NCT01566110), but rather a single gluten-free education session upon exiting the study.
89320579|NCT03292861|Active Comparator|Thymoglobulin®|"Thymoglobulin® (Genzyme) [rabbit anti-thymocyte globulin (ATG)] is a purified pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes. This immunosuppressive product contains polyclonal cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.~In addition, there will be maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation"
89320580|NCT03292861|No Intervention|No induction therapy|Patients qualifying for the study will be randomized before the transplantation surgery in a 1:1 ratio to either Thymoglobulin® or no treatment.
89320581|NCT03290040||Metropolit Cohort|Danish birth cohort of men born in 1953 in the Metropolitan area of Copenhagen. These test-persons are divided into two groups based on performance in cognitive tests at late midlife compared to young adulthood; Positive expected performance and negative expected performance and sampled from a birth cohort of 11.532 men.
89320582|NCT03290040||Herlev Hospital, Memory Clinic|Persons from the Memory Clinic at Herlev Hospital. These subjects are diagnosed with either MCI or AD.
89320583|NCT03283930|Experimental|Active ABMT|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the control invention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
89320584|NCT03283930|Placebo Comparator|Placebo|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the control invention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
89320585|NCT03266575|Active Comparator|Pulmonary Rehabilitation|Participants will participate in formal Pulmonary Rehabilitation Exercise program
89320586|NCT03266575|Active Comparator|Home based program|Participants will participate in a Home based Exercise program
89320587|NCT03255018|Experimental|Participants with Gray-zone Lymphoma (GZL) or Extranodal Diffuse Large B-cell Lymphomas (DLBCL)|Participants with gray-zone lymphoma (GZL) or extranodal DLBCL relapsed from or refractory to prior therapy with an anthracycline-based regimen
89320588|NCT03246750|Experimental|B-MAD chemotherapy|Brentuximab Vedotin, Methotrexate, L-Asparaginase, and Dexamethasone
89320589|NCT03231241||Episodic Headache|Participants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
89320590|NCT03231241||Chronic Headache|Participants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
89320591|NCT03231241||Control|Participants reporting fewer than two headaches per year. No interventions
89320592|NCT03216733|Experimental|COMBO|PCI with COMBO stent
89320593|NCT03216733|Active Comparator|ORSIRO|PCI with ORSIRO stent
89320594|NCT03204188|Experimental|Ibrutinib, Fludarabine, and Pembrolizumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Ibrutinib, Fludarabine, and Pembrolizumab combination therapy will be administered in participants with High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur. Fludarabine will be administered intravenously only on cycle -2 at 25mg/m^2 x5 days. Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
89320595|NCT03185702||Patients with Turner Syndrome|Chromosomal diagnosis and typical features
89320596|NCT03185702||Unaffected controls|Normal females and unaffected family members
89320597|NCT03179930|Experimental|Entinostat and Pembrolizumab|patients will be assigned to receive therapy with entinostat given by mouth once weekly and pembrolizumab given intravenously every 3 weeks
89320598|NCT03162913|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry powder.
89320599|NCT03162913|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo powder.
89320600|NCT03159754|Experimental|Early Appendectomy|
89320601|NCT03159754|Experimental|Interval Appendectomy|
89320602|NCT03159754|Experimental|No Appendectomy|
89320603|NCT03155347|Experimental|Tocilizumab + MTX|Participants will receive tocilizumab SC injections Q2W along with MTX orally every week (QW) for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase, irrespective if they achieve or do not achieve DAS28 low activity (DAS28-ESR <= 3.2).
89320604|NCT03155347|Experimental|Tocilizumab + Placebo Matched to MTX|Participants will receive tocilizumab SC Q2W along with placebo matched to MTX for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
89320605|NCT03155347|Active Comparator|Placebo Matched to Tocilizumab + MTX|Participants will receive placebo matched to tocilizumab along with MTX orally QW for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
89320606|NCT03155074|Experimental|High-Intensity Training|
89320607|NCT03155074|No Intervention|Usual Care|
89320608|NCT03083964|Active Comparator|Usual Care|Usual care involves a lifestyle coaching intervention delivered in primary care sites.
89320609|NCT03083964|Experimental|Priming|Priming involves usual care plus just in time reminder messages related to mindful eating and physical activity.
89320610|NCT03072771|Experimental|ASCT + BEAM + Blinatumomab|"Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below, other conditionings are allowed:~carmustine is typically given intravenously (IV) at a dose of 300 mg/m^2 on Day -7~etoposide is typically given IV at a dose of 100 mg/m^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)~cytarabine is typically given IV at a dose of 100 mg/m^2 BID on Days -6, -5, -4, and -3 (8 doses)~melphalan is typically given IV at a dose of 140 mg/m*2 on Day -2~Auto-SCT will take place on Day 0 as per institutional guidelines~Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR or PR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks)."
89320611|NCT03024775|Active Comparator|Active Comparator 1|Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
89320612|NCT03024775|Active Comparator|Active Comparator 2|Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
89320613|NCT03024775|Placebo Comparator|Placebo 1|Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.
89320614|NCT03024775|Placebo Comparator|Placebo 2|Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.
89320615|NCT03017716|No Intervention|IBP patients on standard therapy|IBP patients on standard therapy.
89320616|NCT03017716|Active Comparator|IBP patients on standard therapy and GFD|IBP patients on standard therapy and GFD
89320617|NCT03000530|Experimental|Part A: SAGE-217|Participants received SAGE-217, 30 milligrams (mg), oral solution, once daily for 14 days, as tolerated.
89320618|NCT03000530|Placebo Comparator|Part B: Placebo|Eligible participants received matching placebo capsules once daily for 14 days.
89320619|NCT03000530|Experimental|Part B: SAGE-217|Eligible participants received SAGE-217, 30 mg, oral capsules, once daily for 14 days.
89320620|NCT02978781|Experimental|Part A: SAGE-217 Oral Solution|Participants received SAGE-217 10 mg oral solution on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7 with food in the morning.
89320621|NCT02978781|Experimental|Part A: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7, orally, with food in the morning.
89320622|NCT02978781|Placebo Comparator|Part B: Placebo|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 matching placebo for 7 days beginning on Day 8 with food in the morning.
89320623|NCT02978781|Experimental|Part B: SAGE-217 Capsules|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 for 7 days beginning on Day 8 with food in the morning.
89320624|NCT02978781|Experimental|Part C: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2, 30 mg on Day 3, orally, with food in the evening. Beginning on Day 4 through Day 14, participants received a 40-mg total daily dose (administered as 10 mg with food in the morning and 30 mg with food in the evening).
89320625|NCT02967263||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
89320626|NCT02943057|Experimental|2% guttae Ganciclovir|2% guttae Ganciclovir 5 times a day for 6 weeks
89320627|NCT02918201|Experimental|topical tranexamic acid|tranexamic acid solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
89320628|NCT02918201|Placebo Comparator|placebo control|Saline solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
89320629|NCT02910323||Experimental group|Patients with a history of Cluster Headaches and other TACs, or Trigeminal Neuralgia.
89320630|NCT02910323||Family/Healthy Controls|Healthy volunteer controls and family members may be enrolled for identification of genetic mutations.
89320631|NCT02862938|Experimental|NT-501 ECT Implant|"On eligible participants that are randomized to this group, the NT-501 Investigational product will be implanted in the study eye, and participants will be followed for 24 months.~The investigational treatment, NT-501 ECT, provides intravitreal sustained release of soluble ciliary neurotrophic factor (CNTF) receptor after intraocular implantation."
89320632|NCT02862938|Sham Comparator|Sham|To maintain masking, participants randomized to this group receive sham surgery and will be followed for 12 months. Following analysis of the 6 month data, if the open label extension (OLE) is not triggered, patients in the control group will continue on the original study schedule timeline trough month 24. If OLE is triggered participants will be offered the NT-501 ECT investigational product and will followed for additional 12 months.
89320633|NCT02804126|Experimental|TAP (transversus abdominis plane)|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
89320634|NCT02804126|Experimental|QL (quadratus lumborum)|Ultrasound-guided quadratus lumborum block at the end of cesarean section
89320637|NCT02751866|Active Comparator|Active supplement, low carbohydrate|Whole fruit berry powder, low carbohydrate diet
89320638|NCT02751866|Placebo Comparator|Placebo, Control|placebo powder, higher carbohydrate diet
89320639|NCT02726711|Experimental|Trimethaphan|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the trimethaphan infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
89530164|NCT03122093||CD-DIET Ineligibles/Refusals|This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
89320640|NCT02726711|Placebo Comparator|Placebo|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the placebo (saline) infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
89320641|NCT02677064||Patients with Acute Leukemia (Arm A)|Follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
89320642|NCT02677064||Patients with MDS and MPN (Arm B)|Follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
89320643|NCT02677064||Patients with Acute Leukemia or MDS/MPN who Relapse After First Allografts (Arm C)|Follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
89320644|NCT02670213||NovoThirteen®|
89320645|NCT02556736|Experimental|Group 1|Single intravitreal injection of RST-001
89320646|NCT02551679|Active Comparator|ACP-01|Injection into lower extremity
89320647|NCT02551679|Placebo Comparator|Placebo|Injection into lower extremity
89320648|NCT02549092|Active Comparator|Optimized Medical Treatment (OMT)|"Participants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.~Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG."
89320649|NCT02549092|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"Participants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.~The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day.~Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG."
89320650|NCT02543281|Active Comparator|aCRT Off|The adaptive CRT algorithm will be turned off for the CRT device implanted in the patients in this arm.
89320651|NCT02543281|Experimental|aCRT On|The adaptive CRT algorithm will be turned on for the CRT device implanted in the patients in this arm.
89320652|NCT02543281|No Intervention|Registry arm|Participants who are not eligible for the randomization because of the implantation of the device that is not capable of delivering aCRT. The team of clinical care providers makes such a clinical decision acting in the patient's best interests.
89320653|NCT02458989|Active Comparator|Scalpel|Use of a scalpel as a first incision during thyroid operation.
89320654|NCT02458989|Experimental|Electrocautery|Use of an electrocautery as a first incision during thyroid operation.
89320655|NCT02458040||Biomarker-positive patients|
89320656|NCT02458040||Biomarker-negative patients|
89320657|NCT02458040||All patients|
89320658|NCT02457338|Experimental|Supplement Group|This group will receive probiotic B. infantis supplementation, plus standard care and lactation consultation.
89320659|NCT02457338|No Intervention|Control Group|This group will receive standard care plus lactation consultation only.
89320660|NCT02429791|Active Comparator|Participants receiving CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 milligrams (mg) + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
89320661|NCT02429791|Experimental|Participants receiving DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
89320662|NCT02422797|Active Comparator|Participants receiving CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 milligrams (mg) + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
89320663|NCT02422797|Experimental|Participants receiving DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
89320664|NCT02414321||Fontan group|"Right heart catheterization:~pulmonary artery OCT analysis~dobutamine stress test~pulmonary vascular response test (nitric oxide)~trans-thoracic echocardiography"
89320665|NCT02414321||Control group|"Right heart catheterization:~- pulmonary artery OCT analysis"
89320666|NCT02414321||PAH group|"Right heart catheterization:~- pulmonary artery OCT analysis"
89320667|NCT02287129|Experimental|Non-Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Carboplatin Paclitaxel Radiation Biopsy
89320668|NCT02287129|Active Comparator|Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Biopsy
89320669|NCT02283229|Active Comparator|Active|Newborns with preventive caring advices
89320670|NCT02283229|Placebo Comparator|Surveillance|Newborns with normal caring advices
89320671|NCT02248064|No Intervention|Fixed flow oxygen COPD|The 6MWT will done on the patients usual fixed flow ambulatory oxygen in this arm.
89320672|NCT02248064|Experimental|Auto-titrating arm COPD|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
89320673|NCT02248064|No Intervention|Fixed flow oxygen Pulmonary Fibrosis (IPF)|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
89320674|NCT02248064|Experimental|Auto-titrating arm Pulmonary Fibrosis (IPF)|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
89320675|NCT02237183|Experimental|Arm I (iloprost QID)|Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
89320676|NCT02237183|Placebo Comparator|Arm II (placebo QID)|Patients receive placebo via inhalation using a nebulizer QID for 60 days.
89320677|NCT02237183|Experimental|Arm III (iloprost BID)|Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
89320678|NCT02237183|Placebo Comparator|Arm IV (placebo BID)|Patients receive placebo via inhalation using a nebulizer BID for 60 days.
89320679|NCT02232386|Experimental|Treatment|"Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Treatment duration with Ibrutinib will be based on what comes first of the following three options:~Treatment until progression or toxicity~Treatment until MRD negativity for 6 months~Treatment for 6 years. Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1."
89320680|NCT02214836|Experimental|Kidney stones|"Device: Verasonics Data Acquisition System (VDAS)~Other Names:~Verasonics Data Acquisition System (VDAS) Verasonics Ultrasound Engine Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified.~Subjects in this arm will be imaged by ultrasound by the VDAS. Stone location and size will be determined and compared to clinical determination of stone location and size."
89320681|NCT02196961|No Intervention|Observation|After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
89320682|NCT02196961|Experimental|Nivolumab|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
89320683|NCT02181738|Experimental|Nivolumab (Cohort A, B, C and D)|"Cohort (A, B, C): Nivolumab: Specified dose on specified days~Cohort (D): Nivolumab: Specified dose on specified days + Doxorubicin: Specified dose on specified days + Vinblastine: Specified dose on specified days + Dacarbazine: Specified dose on specified days"
89320684|NCT02126982||Clopidogrel hydrogen sulfate (CHS)|Clopidogrel hydrogen sulfate, 75 mg / day
89320685|NCT02126982||Clopidogrel Besylate (CB)|Clopidogrel Besylate , 75 mg / day
89320686|NCT02042807|Placebo Comparator|Placebo|placebo arm
89320687|NCT02042807|Active Comparator|MCS® 15 mg/day|MCS® soft capsule
89320688|NCT02042807|Active Comparator|MCS® 30 mg/day|MCS® soft capsule
89320689|NCT01971957||Sjogren-Larsson syndrome|There are no cohorts for this study.
89320690|NCT01960933|Active Comparator|Culprit lesion revascularization|Only the culprit lesion is treated whereas other study lesions are left un-treated.
89320691|NCT01960933|Active Comparator|Full revascularization|Culprit lesion is treated initially and all other lesions with diameter stenosis angiographically >50% and FFR <0.80 are treated in a separate procedure within the index hospitalization. Stenoses > 90% are treated without prior FFR.
89320692|NCT01942603||Observation|
89320693|NCT01942603||Complete Lymfnode Dissection|
89320694|NCT01915615||Hypertrophic cardiomyopathy|"None - this is an observational study.~Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after index cardiac magnetic resonance imaging and blood draw for genetics and biomarkers"
89320695|NCT01848951||Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
89320696|NCT01848951||TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
89320697|NCT01817127||Main Study|Women enrolled in this cohort of the study will collect their breast milk, infant urine and stool, and their urine and stool samples. Blood and saliva will be collected from these participants by study personnel.
89320698|NCT01817127||Gestational Diabetes Mellitus Cohort|Women who have been diagnosed with gestational diabetes mellitus, type 2 diabetes mellitus or impaired glucose tolerance will be enrolled in this cohort. Participants will be asked to report their fasting and postprandial blood glucose levels if they are monitoring these outcomes at home with a glucometer.
89320699|NCT01817127||Fresh Milk Cohort|Women enrolled in this cohort will provide fresh milk samples (stored in the refrigerator and picked up by study personnel within 1 hour of collection) for analysis of glycan composition and gene expression of glycan metabolizing enzymes of somatic cells in milk.
89320700|NCT01817127||RNA Milk Fat Cohort|Women enrolled in this cohort must have given birth to sons and will collect a fresh milk sample for transcriptomic analysis compared against non-human primate milk.
89320701|NCT01817127||Skin Study|This cohort includes mothers and their infants who will provide milk and infant stratum corneum cells to act as the control group for a different study designed to investigate skin function in premature infants.
89320702|NCT01817127||BMMI Project|Subjects enrolled in this cohort will be part of the control group for the BMMI Project.
89320703|NCT01811329|Active Comparator|Palm fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and protein powder.
89320704|NCT01811329|Experimental|Palm fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
89320705|NCT01811329|Active Comparator|Dairy fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and protein powder.
89320706|NCT01811329|Experimental|Dairy fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
89320707|NCT01803633|Experimental|Cheese|Cheese sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain medium cheddar cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, high oleic sunflower oil, high polyunsaturated fatty acids (PUFA) sunflower oil, and canola oil.
89320708|NCT01803633|Active Comparator|Vegan cheese|Non-dairy cheese alternative sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain vegan cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, cream of tartar, high oleic sunflower oil, high PUFA sunflower oil, and palm oil.
89320709|NCT01481883|Experimental|Raloxifene Hydrochloride 120mg oral per day|120mg raloxifene plus antipsychotic drug
89320710|NCT01481883|Placebo Comparator|Placebo tablet - one per day|Lactose pill plus antipsychotic medication
89320711|NCT01478932|Experimental|Diaphragmatic Breathing Retraining|In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
89320712|NCT01478932|Placebo Comparator|Health Promotion|In-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
89320713|NCT01430390|Experimental|Biological/Genetically Modified T cells|Utilizing our initial trial experience, it was amended to include three (3) expansion cohorts. Cohort 1: patients with CD19+ relapse/refractory (R/R) B cell malignancies occurring after allogeneic/autologous HSCT or solid organ transplant (SOT) infusion occurring following conditioning chemotherapy. Cohort 2:patients with CD10+ high risk B cell malignancies eligible for autologous HSCT followed by 19-28z CRA EBV-CTLs (auto-HSCT preparative regimen serves as conditioning chemotherapy. Cohort 3: patients with CD19+ high risk B cell malignancies eligible for allogeneic HSCT followed by consolidative 19-28z CAR EBV-CTLs (allo-HSCT preparative regimen serves as conditioning chemotherapy) Each expansion cohort has a target accrual of 6 patients treated with fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose.
89320714|NCT01409109||Patient volunteers|This group is comprised of persons with Schizophrenia and Schizoaffective.
89320715|NCT01409109||Healthy volunteers|This group is comprised of individuals who have no current or past psychiatric diagnosis.
89320716|NCT01202344|Other|Restenosis|Patients who have restinosis immediately following angioplasty.
89320717|NCT01202344|Other|No Restenosis|Patients who do not have restinosis immediately following angioplasty.
89320718|NCT01145209|Experimental|FO Arm (fludarabine and ofatumumab)|For patients with non-high risk FISH changes
89320719|NCT01145209|Experimental|FCO Arm (fludarabine, cyclophosphamide, and ofatumumab)|For patients with high risk FISH changes
89320720|NCT01144494|Active Comparator|Intraocular pressure lowering drug|Eyedrops for lowering intraocular pressure
89320721|NCT01144494|Placebo Comparator|Artificial Tears|Lubricated eye drops
89320722|NCT00977691|Experimental|Cohort 1|PBSC transplant with no post-transplant cyclophosphamide (PT-Cy)
89320723|NCT00977691|Experimental|Cohort 2|PBSC transplant with 50 mg/kg post-transplant cyclophosphamide (PT-Cy)
89320724|NCT00977691|Experimental|Cohort 3|PBSC transplant with 100 mg/kg post-transplant cyclophosphamide (PT-Cy)
89320725|NCT00924482|Other|Single Arm - Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
89320726|NCT00718198||Pre-protocol group|Group admitted 1 (one) month before CPOE protocol changes were made
89320727|NCT00718198||Post-protocol group|Group admitted 1 (one) year after CPOE protocol changes were made
89320728|NCT00697684|No Intervention|Cohort 1|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
89320729|NCT00697684|Experimental|Cohort 2|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
89320730|NCT00697684|Experimental|Cohort 3|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
89320731|NCT00697684|Experimental|Cohort 4|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
89320732|NCT00686946||NRAMP|Participants take their antipsychotic medication as prescribed by their clinical treating teams.
89320733|NCT00514865|Experimental|Experimental 1|1-2 mg of ONO-2333
89320734|NCT00514865|Experimental|Experimental 2|5-10 mg of ONO-2333
89320735|NCT00514865|Placebo Comparator|Placebo|placebo comparator
89320736|NCT02252302|Active Comparator|Resting in diesel exhaust following salbutamol inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
89320737|NCT02252302|Placebo Comparator|Resting in diesel exhaust following placebo inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.
89320738|NCT02252302|Active Comparator|Cycling in diesel exhaust following salbutamol inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.
89320739|NCT02252302|Placebo Comparator|Cycling in diesel exhaust following placebo inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo
89320740|NCT02252302|Sham Comparator|Resting in filtered air following salbutamol inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.
89320741|NCT02252302|Placebo Comparator|Resting in filtered air following placebo inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.
89320742|NCT02252302|Sham Comparator|Cycling in filtered air following salbutamol inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.
89320743|NCT02252302|Placebo Comparator|Cycling in filtered air following placebo inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo
89320744|NCT02131714|Active Comparator|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
89320745|NCT02131714|Placebo Comparator|lifestyle counseling|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character.
89320746|NCT02135926|Active Comparator|Best medical care|Best clinical care in dedicated stroke unit
89320747|NCT02135926|Active Comparator|Thrombectomy|All subjects randomly assigned to the thrombectomy arm, except those with rapidly improving neurologic symptoms or no angiographic evidence of occlusion, will be treated with the endorsed study devices (stent retriever).
89320748|NCT02131792|Experimental|Lateral Rectus Muscle Slanted Recession|Slanted recession of the lateral rectus muscle for the intermittent exotropia with convergence weakness
89320749|NCT02136082|Experimental|Asha Support + Training|Asha Support + Training: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
89320750|NCT02136082|Experimental|Asha Support + Food|Asha Support + Food 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; and c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
89320751|NCT02136082|Experimental|Asha Support + Training + Food|Asha Support + Training + Food: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
89320752|NCT02136082|Active Comparator|Asha Support Only|Asha Support Only 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
89320753|NCT02129140||Hernia graft/mesh|Hernia repair patients implanted with biologic hernia graft during surgery
89320754|NCT02131870|Active Comparator|L plantarum DSM 9843|
89320755|NCT02131870|Placebo Comparator|Placebo|
89320756|NCT03550768||MDP|ERCP was performed by trainees or trainers. Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location. All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate. Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate. Pancreatic duct stent placement was performed at the discretion of the endoscopists.
89320757|NCT01367236|Active Comparator|standard care|"treatment with:~atazanavir 300 mg daily~ritonavir 100 mg daily~tenofovir 245 mg daily*~emtricitabine 200 mg daily* * as the fixed dose combination Truvada™"
89320758|NCT01367236|Active Comparator|Novel therapeutic approach|"darunavir 800 mg daily~ritonavir 100 mg daily~lamivudine 300 mg daily**~abacavir 600 mg daily**~maraviroc 150 mg once daily ** as the fixed dose combination Kivexa ™"
89320759|NCT02129218|Experimental|Cohort 1: Low glycemic load with standard diet|Patients follow a low glycemic load diet with a standard dietary intervention for 12 weeks.
89320760|NCT02129218|Experimental|Cohort 2: Low glycemic load with intensified diet|Patients follow a low glycemic load diet with intensified dietary intervention for 12 weeks.
89320761|NCT02129218|Active Comparator|Cohort 3: Medium glycemic load with standard diet|Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.
89320762|NCT02129218|Active Comparator|Cohort 4: Medium glycemic load with intensified diet|Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks.
89320763|NCT02252614|Active Comparator|Naproxen sodium codein|Preoperative Naproxen sodium codein administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
89320764|NCT02252614|Experimental|Paracetamol codein|Preoperative paracetamol codein administrered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
89320765|NCT02252614|Placebo Comparator|Placebo tablet|Preoperative placebo tablet administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
89320766|NCT02260570|Experimental|Functional MRI Arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
89320767|NCT03681951|Experimental|Part 1: Dose Escalation - GSK3145095 monotherapy|In Part 1, advanced or metastatic PDAC will be enrolled. Part 1 will be using escalating doses of GSK3145095 (total daily dose of 100 mg, 200 mg, 400 mg, 800 mg, and 1600 mg) orally as monotherapy for up to 2 years. For each dose level, subjects will receive a single dose of half the total daily dose on Day 1; and as BID (total daily dose divided in two equal doses) starting from Day 2.
89320768|NCT03681951|Experimental|Part 2: Dose Escalation - GSK3145095 + pembrolizumab|In Part 2, subjects with selected solid tumors, including but not limited to, PDAC, NSCLC, TNBC and/or melanoma will be enrolled. Part 2 will be using GSK3145095 combination escalation to start at least one dose level below the highest dose of GSK3145095 shown to be safe in Part 1, orally BID for up to 2 years along with pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W) for up to 2 years.
89320769|NCT03681951|Experimental|Part 3: Dose Expansion - GSK3145095 + pembrolizumab|In Part 3, subjects with selected solid tumors will be enrolled. Part 3 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with pembrolizumab 200 mg IV Q3W for up to 2 years.
89320770|NCT03681951|Experimental|Part 4: Dose Expansion - GSK3145095 + anticancer agent|In Part 4, subjects with selected solid tumors will be enrolled. Part 4 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with combination of additional anticancer agents.
89320771|NCT02131948|Experimental|Intranasal insulin|40 IU of intranasal insulin
89320772|NCT02131948|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
89320773|NCT02129296|Active Comparator|hemiosphere® BALLOON|Balloon filled with air according to the manufacturing company orders 600 or 720 ml air
89320774|NCT02129296|Active Comparator|Fluid filled balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
89320775|NCT02136316|Experimental|ASP7962 low dose|
89320776|NCT02136316|Experimental|ASP7962 medium dose|
89320777|NCT02136316|Experimental|ASP7962 high dose|
89320778|NCT02136316|Placebo Comparator|Placebo|
89320779|NCT02136394||Severe/moderate acid reflux|
89320780|NCT02136394||Mild/absent acid reflux|
89320781|NCT02132026|Active Comparator|Alendronic Acid|50 patients will receive once weekly Alendronic Acid tablets (70mg).
89320782|NCT02132026|Placebo Comparator|Alendronic Acid placebo|25 patients will receive alendronic acid placebo tablets.
89320783|NCT02132026|Active Comparator|Denosumab|50 patients will receive 6 monthly denosumab injections
89320784|NCT02132026|Placebo Comparator|Denosumab Placebo|25 patients will receive a 6 monthly placebo injection.
89320785|NCT02540811|Experimental|dCELL® ACL Scaffold|
89320786|NCT02136472||Subfertile women|"Women who visit the fertility clinic of the Maastricht University Medical Centre who start with a basic fertility work-up. Women diagnosed with an unexplained subfertility or with (signs of) a decreased ovarian reserve are asked for further participation in the study of the cardiovascular profile.~As a control group parous women with an uncomplicated pregnancy more than 6 months ago will be asked for participation."
89320787|NCT03735771|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
88806575|NCT05902182|Experimental|ConvaFoam Dressings|All participants skin areas will be assessed and allocated a dressing based upon the investigator's clinical judgement. They will receive either ConvaFoam Border, Silicone or Non-Adhesive for up to 2 weeks as an addition to their standard pressure injury prevention protocol.
89320788|NCT03735771|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
89320789|NCT03735771|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
89320790|NCT03735771|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
89320791|NCT02136550|Experimental|Smoking cessation|36 smokers will participate in the study and will be evaluated at baseline, 6 months e 12 months of the smoking cessation program. If they quit the program, they will be asked to continue the study.
89320792|NCT02509455||Normal 1|SwayStar device used 1st, Sensoro used 2nd
89320793|NCT02509455||Normal 2|Sensoro device used 1st, SwayStar used 2nd
89320794|NCT02132104|Experimental|amnion graft in severe IUA|patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
89320795|NCT02132104|Sham Comparator|non-amnion graft in severe IUA|patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
89320796|NCT02136628|Experimental|RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
89320797|NCT02136628|No Intervention|Control|Conventional midline mass closure technique. Upon completion of the surgical procedure was the closure of abdominal wall which will be made with the number 0 monofilament PDS, starting with knot at one end of the wound, continuous with continuous súrgete, moving each point to a centimeter away from the other. Each point will be a distance of one centimeter from the edge of the fascia. At the opposite end of the wound the same procedure was initiated and found the two suture lines at the midpoint of the wound will proceed to tying the two sutures with 4 square knots.
89320798|NCT03681405|Experimental|Group I (eMMB)|Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery.
89320799|NCT03681405|Active Comparator|Group II (AC)|Participants will receive caring attention. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.
89320800|NCT02129374|Experimental|Direct repair of pars defect|The pars defect was repaired with 4.5mm cortical screw.
89320801|NCT02129374|No Intervention|Conservative treatment|The pars defect of spondylolysis was not repaired with cortical screw.
89320802|NCT02129452||CDR (Clinical dementia rating) 0|10 participants complaining subjective memory problem and acquiring CDR 0
89320803|NCT02129452||CDR 0.5|10 participants complaining subjective memory problem and acquiring CDR 0.5
89320804|NCT02129452||CDR 1|10 participants with mild cognitive impairment and acquiring CDR 1
89320805|NCT02129452||CDR 2|10 participants with moderate to severe cognitive impairment and acquiring CDR 2
89320806|NCT00174785|Experimental|Dronedarone 400mg bid|Dronedarone 400mg tablets twice daily (bid)
89320807|NCT00174785|Placebo Comparator|Placebo|matching placebo tablets
89320808|NCT03681093|Experimental|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily orally
89320809|NCT03681093|Experimental|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily orally
89320810|NCT03681093|Placebo Comparator|Placebo|Placebo once daily orally
89320811|NCT03735615|Experimental|chronic obstructive lung disease|
89320812|NCT03735615|Experimental|healthy control|
89320813|NCT00166517|Experimental|1|RotaTeq
89320814|NCT00166517|Placebo Comparator|2|Placebo
89320815|NCT00166439|Experimental|Treatment (ROAD)|The treatment regimen included oxaliplatin with rituximab, cytarabine, and dexamethasone (ROAD); specifically, rituximab 375 mg/m^2 IV on days 1, 8,15, and 22 (cycle 1 only); dexamethasone 40 mg PO/IV days 2-5; oxaliplatin 130 mg/m^2 IV over 2 hours on day 2; cytarabine 2000 mg/m^2 IV in 250 mL of D5W over three hours x two doses on days 2-3. The second dose of cytarabine was to be given no sooner than 12 hours after the first dose and no later than 24 hours after the conclusion of the first dose. This permitted outpatient administration if desired. Patients were provided pegfilgrastim 6 mg SC on day 4. A cycle was 21 days.
89320816|NCT01074671|Other|No control arm|There is no control arm as part of the study design.
89320817|NCT01075997|Experimental|A cell phone tips|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone. The group will be asked to check blood sugar on a schedule determined by their providers. The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed. The group will have the A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
89320818|NCT01075997|Active Comparator|B no cell phone tips|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider. The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed. The group will have A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
89320819|NCT01074749|Active Comparator|Optisense lead|Patients with an Accent pacemaker and an OptiSense atrial lead
89320820|NCT01074749|Active Comparator|Tendril lead|Patients with an Accent pacemaker and a Tendril atrial lead
89320821|NCT02531555|Active Comparator|Group M|Mechanical periodontal treatment (Group M): Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
89320822|NCT02531555|Experimental|Group L|Pocket disinfection with diode laser (Group L): Subgingival irradiation with a GaAlAs diode laser (CHEESE®, Gigaa Laser, China) was applied to residual pockets each for 20 sec in continious mode. The diode laser had a wavelenght of 810 nm and power output of 1 W for subgingival irradiation (Maximum output power of device was 7 W). Diode laser application was performed parallel to root surface by a 200 µm fiber tip inserted at the bottom of periodontal pocket and slowly moved from apical to coronal direction in a sweeping motion without local anesthesia.
89320823|NCT02531555|Experimental|Group M+L|Combined treatment (Group M+L): Following mechanical periodontal treatment, pocket irradiation with diode laser was performed as mentioned above.
89320824|NCT01074827|Experimental|Treadmill group|Specific gait training on treadmill
89320825|NCT01074827|Experimental|Strength training group|Eight weeks of intensive strength training
89320826|NCT01074905|Active Comparator|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
89320827|NCT01074905|Active Comparator|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
89320828|NCT01074905|Experimental|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
89320829|NCT01076309||Tamsulosin|Patients taking tamsulosin
89320830|NCT01076309||Non-tamsulosin|Patients not taking tamsulosin.
89320831|NCT02126254|No Intervention|Control group|Control group will be treated in the cardiology and internal medicine departments according to the guidelines for the management of Heart Failure
89320832|NCT02126254|Active Comparator|Hemodynamic group|Hemodynamic group patients will be examined in the cardiology and internal medicine departments and treated according to the NICaS system in addition to current guidelines. Patients in this group will be tested within 12 hours from hospitalization and thereafter on an everyday basis until discharge
89320833|NCT01074983||Written standard of care|
89320834|NCT01074983||Usual practice pattern|
89320835|NCT01076387|Active Comparator|open radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
89320836|NCT01076387|Active Comparator|robotic-assisted radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
89320837|NCT00138671|Active Comparator|Subcutaneous Insulin|
89320838|NCT00138671|Experimental|Inhaled Insulin|
89320839|NCT01075061|Other|healthy volunteers|healthy volunteers
89320840|NCT01075061|Other|Kallmann|Kallmann syndrome patients
89320841|NCT01075061|Other|Congenital Mirror Movement|patients with CMM
89320842|NCT01075139|Experimental|Brief Motivational Intervention|Subjects in this condition met one-on-one with a counselor for 30 minutes. Subjects received personalized feedback regarding their current physical activity levels and fruit/vegetable intake. Counselors used a motivational interviewing style to try to help resolve ambivalence about changing their current behaviors.
89320843|NCT01075139|Active Comparator|Educational information|Subjects in this condition received general educational information about the benefits associated with physical activity and fruit/vegetable intake.
89320844|NCT01075295|Experimental|Lifestyle Intervention|
89320845|NCT01075295|Active Comparator|TAU|
89320846|NCT01367158|Experimental|3ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
89320847|NCT01367158|Experimental|2ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
89320848|NCT01367158|Experimental|3ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
88806576|NCT05902143||Experimental Group|children with Specific Learning Disorder
89320849|NCT01367158|Experimental|2ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
89320850|NCT01367158|Experimental|3ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of the same in current study
89320851|NCT01367158|Experimental|2ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of Tdap in current study
89320852|NCT01367158|Experimental|3ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of the same in current study
89320853|NCT01367158|Experimental|2ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of Tdap in current study
89320854|NCT01367158|Active Comparator|3B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of the same in current study
89320855|NCT01367158|Active Comparator|2B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of Tdap in current study
89320856|NCT01367158|Active Comparator|1ACWY|One dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine followed by one dose of placebo and one dose of Tdap in current study
89320857|NCT00130637|Experimental|Daclizumab|IV daclizumab
89320858|NCT03550456||ECC, ECC with CLE, speech therapy|"After the standard diagnostic (spirometry, body plethysmography, exhaled NO, skin prick test) all patients with dyspnea while exercising undergo exercise challenges in a cold chamber (ECC).~In case of a positive reaction in the ECC the patients get asthma medication (ICS/LABA combination).~Both groups negative and positive should fill out a symptom diary and the next visit will be booked 6 weeks later.~If they still have dyspnea while exercising with ICS/LABA combination or hat a negative ECC the patients undergo an ECC with continuous laryngoscopy. In case of an EILO diagnosis patients will be sent to speech therapy and checked at a follow up visit.~All patients and their parents should complete questionnaires for symptoms and quality of life at every visit."
89320859|NCT01077245|Experimental|MIYA-BM|MIYA-BM Fine Granules (CBM588)
89320860|NCT01077245|Placebo Comparator|Placebo|Placebo Fine Granules (without CBM588)
89320861|NCT02136706|No Intervention|10/30 min rest/stress|Rest and stress T99m-MPI obtained 10 minutes and 30 minutes after tracer injection. After the myocardial perfusion imaging the investigators will have 10 minute waiting period to take images and then wait the 30 minutes, standard of care to take the images.
89320862|NCT01077479|Experimental|Metformin|
89320863|NCT03549676|Experimental|HSCT patients with refractory GVHD|Patients will accept FilmArray Gastrointestinal (GI) panel test before pre-treatment of HSCT and 28±3 days post-HSCT. Patients will receive 50ml fecal microbiota from unrelated healthy donors through nasojejunal tube and monitored under gastroscopy. Patients receiving FMT treatment will be followed for at least 6 months. The ideal follow up time is 2 year. Stool and blood samples will be serially collected and tested (before pre-treatment, 1/3/6/12 months after FMT).
89320864|NCT02136784|Experimental|morphine sulfate|30mg, single dose,
89320865|NCT02136784|Experimental|hydrocodone|10mg single dose
89320866|NCT02136784|Experimental|hydromorphone HCI|4mg single dose
89320867|NCT02136784|Experimental|oxycodone|10 mg single dose
89320868|NCT02136784|Experimental|buprenorphine|4 mg single dose
89320869|NCT02136784|Placebo Comparator|oral tablet placebo|single dose
89320870|NCT02136784|Placebo Comparator|sublingual tablet placebo|single dose
89320871|NCT02136940|Experimental|AMA0076 0.1%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
89320872|NCT02136940|Experimental|AMA0076 0.25%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
89320873|NCT02136940|Experimental|AMA0076 0.50%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
89320874|NCT02136940|Placebo Comparator|Placebo|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
89320875|NCT02137018|Active Comparator|laparotomy with PPL mesh implantation|control group: laparotomy with PPL mesh implantation (traditional method)
89320876|NCT02137018|Experimental|laparotomy with PPL fixation by BP|laparotomic surgery with PPL mesh fixation by BP (new fixing method)
89320877|NCT02137018|Active Comparator|laparoscopy with PPL mesh implantation|control group: laparoscopy with PPL mesh implantation (traditional method)
89320878|NCT02137018|Experimental|laparoscopy with PPL fixation by BP|laparoscopic surgery with PPL mesh fixation by BP (new fixing method)
89320879|NCT03679767|Experimental|Melanoma: retifanlimab 500 mg|Participants with melanoma received retifanlimab 500 milligrams (mg) every 4 weeks (Q4W), administered by intravenous (IV) infusion over 30 minutes on Day 1 of each 28-day cycle.
89320880|NCT03679767|Experimental|NSCLC: retifanlimab 500 mg|Participants with non-small cell lung cancer (NSCLC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.
89320881|NCT03679767|Experimental|UC: retifanlimab 500 mg|Participants with urethelial carcinoma (UC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.
89320882|NCT03679767|Experimental|RCC: retifanlimab 500 mg|Participants with renal cell carcinoma (RCC) received retifanlimab 500 mg Q4W, administered by IV infusion over 30 minutes on Day 1 of each 28-day cycle.
89320883|NCT02129530|Experimental|Community Social Mobilization Program|A manualized intervention developed with Sonke Gender Justice Network using a workshop intervention manual and a community mobilization toolkit will be used.
89320884|NCT02129530|No Intervention|Control Arm|The Control Arm does not receive the Community Mobilization Intervention
89320885|NCT02129686|Experimental|Immediate Acupuncture Group|"Immediate acupuncture arm will receive acupuncture 3 times per week during week 1 and week 2, then 2 times per week from week 2 to week 8 for a total of 18 sessions. The crossover will take place after 8th week.~The immediate acupuncture arm will enter a follow-up phase without acupuncture for 8 weeks from week 9 to week 16, while the standard usual care will be provided."
89320886|NCT02129686|Active Comparator|Delayed Acupuncture Group|The patients on the usual care/delayed acupuncture arm will continue their standard usual care with their physicians and care team. The crossover will take place after 8th week. After crossover, the patients initially on the usual care/delayed acupuncture arm will receive the identical acupuncture protocol but a less frequent schedule from week 9 to week 16: 2 times per week at week 9, then 1 time per week from week 10 to week 16 for a total of 9 sessions
89320887|NCT02129764|Experimental|Prednisone|Prednisone will be given 30mg/day for 2 weeks and then tapered off.
89320888|NCT02129764|Active Comparator|Allopurinol|Allopurinol will be given 100 mg/day initially, and then titrated to 200 mg/day.
89320889|NCT00130247|Experimental|2EHRZ/2HR arm|Daily treatment with isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.
89320890|NCT00130247|Active Comparator|2EHRZ/4HR arm|Daily treatment with Isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.
89320891|NCT02129842||Atrial Fibrillation|
89320892|NCT03678285|Experimental|HIFRT Workout|Consecutive completion of; 1 mile run, 100 pull ups, 200 push-ups, 300 bodyweight squats, 1 mile run.
89320893|NCT02129920||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation and treated with rivaroxaban
89320894|NCT02129998||Standard IVF/ICSI treatment|
89320895|NCT03735459|Experimental|Patient reminder|"Patient Oriented SCORAD (PO-SCORAD): Assess severity of eczema.~Adherence Questionnaire (AQ): Assess adherence to eczema treatment plan provided to them by their healthcare provider.~Family Dermatology Life Quality Index (FDLQI): Assess impact of the participant's eczema on the family's quality of life.~Enrollment: Participants will complete FDLQI and PO-SCORAD.~Week 1, 2, and 4: Participants will complete PO-SCORAD and AQ.~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
89320896|NCT03735459|No Intervention|No patient reminder/control|"Participants in arm 2 are not sent text messages, and will not be asked to complete questionnaires 1, 2, and 4 weeks post enrollment. Participants will be asked to complete questionnaires during enrollment and 6 weeks post enrollment.~Enrollment: Participants will complete FDLQI and PO-SCORAD.~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
89320897|NCT02252926|Active Comparator|Bupivacaine lozenge|The patients can take up to eight 25 mg bupivacaine lozenges (max. every second hour in the awake hours) a day for seven days. The patients can use concomitant systemic pain treatment (e.g. morphine).
89320898|NCT02252926|Other|Standard treatment|The patients will be treated with the currently used standard pain treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin). The anesthetics are being administered at the physician's discretion.
89320899|NCT03550300||Participants with CMT|Participants with CMT1A, CMT1B, CMT2A or CMTX1
89320900|NCT03550300||Control participants|Control participants
89320901|NCT02253004|Experimental|Active|Cilostazol 200 mg single dose
89320902|NCT02253004|Placebo Comparator|Placebo|Placebo capsule
89320903|NCT03735381|Active Comparator|Intervention 1: pedometer|"Minimum intervention:~Use of pedometer watch from 12 to 32 GW~Recommendations of physical activity"
89320904|NCT03735381|Experimental|Intervention 2: pedometer+goal+reminds|"Maximum intervention:~Use of pedometer from 12 to 32 GW~Recommendations of physical activity~Information about get a goal of 11000 steps/day~Reminds the goal every two weeks."
89320905|NCT03735381|No Intervention|Control: without pedometer|Women receive some recommendations of physical activity during pregnancy. They do not use the pedometer during pregnancy
89320906|NCT02252458|Experimental|Fentanyl high dose|Fentanyl 10mcg/kg of bodyweight
89320907|NCT02252458|Active Comparator|Fentanyl low dose|Fentanyl 1mcg/kg of bodyweight
89320908|NCT02132182||Patients newly diagnosed with osteosarcoma|Blood draw
89320909|NCT04032171|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
89320910|NCT04032171|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
89320911|NCT02130076||Stop|Patients with stable RA stopping TNF inhibition
89320912|NCT02130076||Continue|Patients with stable RA continuing TNFi therapy
89320913|NCT02137174|Active Comparator|Home and school visits|
89320914|NCT02137174|No Intervention|Control|
89320915|NCT03549988||Control|"The group will receive current standard of care as the usual practice of the attending physician. Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on the baseline visit and month 6, 12 and month 18.~When endoscopy is performed biopsies should be taken and the endoscopic and histologic assessment will be recorded. If a fecal calprotectin is measured, every effort should be made to use the IBDoc with the result being sent to the central primary investigator via the IBDoc Web Portal. However, should a different fecal calprotectin measure be used, this will be recorded as part of the study documentation and will be included in the study data."
89320916|NCT03549988||Intervention: FC measurements with IBDoc|"Fecal Calprotectin (FC) measurements with IBDocTM home kits will be performed by participants in the intervention group every 2 months until final visit.~Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on baseline visit and month 6, 12 and month 18."
89320917|NCT03735303|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
89320918|NCT03735303|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
89320919|NCT03735303|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
89320920|NCT03735303|Experimental|control group|no intervention was given
89320921|NCT02137330|Experimental|Obalon Arm|Children swalowed up to 3 intragastric balloons
89320922|NCT02137330|No Intervention|Dietary and lifestyle changes Arm|
89320923|NCT02137408|Active Comparator|200 mg docosahexaenoic acid|Participants will be randomized to 200 mg of docosahexaenoic acid (DHA) administered PO daily (1-200mg capsule of DHA). This is a standard dose used in prenatal vitamins. Participants will be supplemented by mouth daily between 18-20 weeks gestation through 6 weeks post-partum.
89320924|NCT02137408|Active Comparator|1000 mg docosahexaenoic acid|Participants will be randomized to 1000 mg of docosahexaenoic acid (DHA) administered PO daily (5- 200mg capsules of DHA). Participants will be supplemented daily PO between 18-20 weeks gestation through 6 weeks post-partum.
89320925|NCT02130154||Young males|Healthy, Lean, Caucasian, Young males
89320926|NCT02130154||Old males|Healthy, Lean, Caucasian, Older males
89320927|NCT02130232|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve the lower bound of the GWG range recommended by the Institutes of Medicine (IOM) for a given prepregnancy BMI category (i.e., 11 lbs for obese women and 15 lbs for overweight women). The pregnancy lifestyle intervention will be delivered by trained study dieticians via individual counseling sessions: 2 in-person and 11 telephone sessions delivered on a weekly basis, followed by telephone sessions delivered every other week through the end of pregnancy.
89320928|NCT02130232|Active Comparator|Usual Care|Usual Medical Care
89320929|NCT02132260|Experimental|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.)
89320930|NCT02132260|Active Comparator|Naftin® Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2%
89320931|NCT02132260|Placebo Comparator|Placebo Topical Cream|Placebo Topical Cream
89320932|NCT02130310|Experimental|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 3 treatments, or until ulcer closure, whichever occurs first.
89320933|NCT02130310|Placebo Comparator|Placebo injection|The placebo will be administered by injecting normal saline at each centimeter of the ulcer bed.
89320934|NCT02130388|Other|Renal Insufficiency|Based on creatinine clearance
89320935|NCT02130388|Other|Renal Sufficiency|Based on creatinine clearance
89530165|NCT03255811|Experimental|The dosage regimen|The chemotherapy response rate reached the maximum after 14-28 days, apatinib, 750 mg (QD), once a day, half an hour after meal (daily dosing time should be as same as possible), with warm boiling water delivery service. 28 days for a dosing cycle.
89320936|NCT02137564|Experimental|Treatment (gamma secretase inhibitor PF-03084014)|Patients receive gamma secretase inhibitor PF-03084014 PO BID on days 1-21. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with PR, CR, or SD at the end of 4 courses may receive an additional 4 courses of gamma secretase inhibitor PF-03084014 in the absence of disease progression or unacceptable toxicity.
89320937|NCT02137642|Active Comparator|RM-131|
89320938|NCT02137642|Placebo Comparator|Placebo|
89320939|NCT02132338|Experimental|The Education Health Program|Intervention forth knowledge and attitudes necessary for self-care
89320940|NCT02132416|Active Comparator|Surgical management|Operative fixation of unstable thoracic cage injuries and chest wall deformity. Thoracic Epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
89320941|NCT02132416|Active Comparator|Conservative management|Conservative management of unstable thoracic cage injuries and chest wall deformity. Thoracic epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
89320942|NCT00137423|Experimental|SU011248 (sunitinib)|Single-arm study
89320943|NCT02137720|Experimental|Telephonic Diabetes Self-Management Support|This group receives all the Educational Print Materials received by the comparison condition plus telephone calls from a health educator to provide tailored diabetes self-management training and support. Participants with significant emotional distress at baseline also receive additional calls focused on distress management.
89320944|NCT02137720|Active Comparator|Educational Print Materials|Participants randomized to this arm will receive print materials on diabetes, glycemic control, self-management, and distress/depression.
89320945|NCT02137798|Experimental|CARTOUNIVU|Radiofrequency catheter ablation of atrial fibrillation will be performed using fluoroscopy image integrated 3-dimentional electroanatomical mapping system
89320946|NCT02137798|Active Comparator|CARTO3|Radiofrequency catheter ablation of atrial fibrillation will be performed using 3-dimentional electroanatomical mapping system without fluoroscopy image integration technique
89320947|NCT01077557||No HIV infection|Subjects without HIV infection (Group 1) are adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. A 3:1 match of subjects without HIV infection to a subject with HIV infection will occur. Each member of the comparator group without HIV infection will be matched on gender, month/year of IHCIS enrolment, and duration of enrollment to the respective study subject with HIV infection.
89320948|NCT01077557||HIV infection with no antiretroviral (ARV) drug exposure|HIV infection with no ARV drug exposure (Group 2) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have no pharmacy dispensing for ARV drugs.
89320949|NCT01077557||HIV infection with ARV drug exposure|HIV infection with ARV drug exposure (Group 3) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have at least one pharmacy dispensing for an HIV antiretroviral drug.
89320950|NCT02132494|Experimental|Physical activity|60 minutes of daily physical activity during one school year
89320951|NCT02132494|No Intervention|Control|
89320952|NCT02130700|Experimental|Chemotherapy-Naive Patients|VT-464: given orally twice daily in 28-day cycles
89320953|NCT02130700|Experimental|Previous Chemotherapy Patients|VT-464: given orally twice daily in 28-day cycles
89320954|NCT02130700|Experimental|AR Positive 1 - 9% TNBC|VT-464: given orally once daily in 28-day cycles
89320955|NCT02130700|Experimental|Male ER Positive|VT-464: given orally once daily in 28-day cycles
89320956|NCT02130700|Experimental|AR Positive >10% TNBC|VT-464: given orally once daily in 28-day cycles
89320957|NCT02130778|Active Comparator|Saline infusion|infusion of saline
89320958|NCT02130778|Active Comparator|Saline infusion with GLP1|infusion of saline with GLP1
89320959|NCT02137954|Active Comparator|lidocaine|Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day
89320960|NCT02137954|Placebo Comparator|placebo|
89320961|NCT02138032|Experimental|Gains Framed Message|gains framed visual fridge magnet and information sheet about smoking cessation (benefits of quitting smoking)
89320962|NCT02138032|Experimental|Loss Framed Message|loss framed visual fridge magnet and information sheet about smoking cessation (losses of continued smoking)
89320963|NCT02786836|Experimental|13C-Methacetin Testing|All patients enrolled into the ALFSG Registry with the duration of illness <26 weeks with (1) severe acute liver injury; International Normalized Ratio (INR) ≥2.0) and not related to acetaminophen overdose, with no evidence of hepatic encephalopathy (HE); and (2) acute liver failure; INR ≥1.5 with presence of any degree of HE will perform the Breath Test.
89320964|NCT02130856|Experimental|Neonatal Kit|The neonatal kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Lady Health Workers will be equipped with a hand held electric scale to identify low birth weight newborns.
89530166|NCT03255889|Active Comparator|Active|Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
89530167|NCT03255889|Placebo Comparator|Placebo|Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
88806577|NCT05902143||Control Group|children with typically developing children
88806578|NCT05902091|Experimental|Exercising participants|Participants will receive 4 weeks of neurophysiology-based intervention, forty-five minutes of individual session, twice a week.
88806579|NCT05902078|Experimental|Eldecalcitol|Participants receive oral eldecalcitol 0.75μg daily for 12 months
89320965|NCT02130856|No Intervention|Control (Standard care)|"In the control arm, Lady Health Workers will visit the home according to the regular schedule (same as in the intervention clusters) and will deliver the standard post-natal care consisting of:~be present at delivery (though not conduct the delivery) and thorough examination of newborn and mother post delivery~check mother for vaginal bleeding and abnormal blood pressure and make referral to nearest health facility as appropriate~refer any newborn with congenital anomaly or evidence of asphyxia~if unable to attend delivery for any reason, visit within first 24 hours post delivery~assess newborn in first month of life during visits and provide basic treatment for acute respiratory infections, pneumonia, and diarrhea in the home~encourage breastfeeding"
89320966|NCT02138188||T1D patients on CSII|Patients affected by Type 1 Diabetes on insulin pump therapy
89320967|NCT02132728|No Intervention|Control group|In the group with 11 volunteers, the control group did no change in normal food intake.
89320968|NCT02132728|Experimental|Flaxseed group|In this group with 14 volunteers, they received 50% carbohydrate, 31% fat, 19% protein and 60 g of flaxseed powder / day during the period of study.
89320969|NCT02132728|Experimental|Rice and low carb group|In this group with 13 volunteers, they received 35% carbohydrate, 46% fat, 19% protein and 60g of raw rice powder / day during the period of study.
89320970|NCT02132728|Experimental|Flaxssed and low carb group|In this group with 14 volunteers, they received 32% carbohydrate, 47% fat, 21% protein and 60 g of flaxseed powder / day during the period of study.
89320971|NCT02130934||childhood cancer survivors|Cardiac 3D MRI
89320972|NCT02131012|Experimental|Celecoxib|1-4 mg intravitreal injection ofCelecoxib
89320973|NCT03550690||Large Volume Paracentesis|Patient has repeated large volume paracentesis for recurrent ascites secondary to cancer
89320974|NCT03550690||Semi-permanent drain|Patient has a semi-permanent drain (Rocket Indwelling Pleural Catheter) placed for recurrent ascites secondary to cancer
89320975|NCT02132806|Experimental|OFD with piezosurgery|Open flap debridement with Piezosurgery
89320976|NCT02132806|Experimental|OFD with piezosurgery+biomaterial|Open flap debridement with Piezosurgery with biomaterial mp3
89320977|NCT02132806|Experimental|OFD with piezosurgery+mp3+bracket|Open flap debridement with Piezosurgery with biomaterial mp3 + bracket
89320978|NCT00137267|Experimental|Arm 1|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
89320979|NCT00137267|Active Comparator|Arm 2|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
89320980|NCT03549910|Experimental|Early use of APRVplus protocol in ARDS|physiology-driven APRVplus protocol
89320981|NCT03549910|Other|Low tidal volume ventilation|Low tidal volume lung protective ventilation
89320982|NCT01077635||HIV-1 infected children aged 6 ≤ 18 years|HIV-1 infected children aged 6 ≤ 18 years currently or having ever been exposed to FPV/RTV; this is the indicated group for the licensed dose in the paediatric population.
89320983|NCT02138422|Placebo Comparator|Placebo|Placebo administered intravenously every 2 weeks
89320984|NCT02138422|Active Comparator|Xilonix|Xilonix administered intravenously every 2 weeks
89320985|NCT02132962|Active Comparator|Healthy controls|Amino acid infusion
89320986|NCT02132962|Active Comparator|Cirrhosis|Amino acid infusion
89320987|NCT02138500|Experimental|Cohort 1: PF-06372865 10 mg|
89320988|NCT02138500|Experimental|Cohort 2: PF-06372865 TBD dose|
89320989|NCT02138500|Experimental|Cohort 3: PF-06372865 TBD dose|
89320990|NCT01561768|Experimental|Group 1|
89320991|NCT01561768|Experimental|Group 2|
89320992|NCT01561768|Experimental|Group 3|
89320993|NCT01561768|Experimental|Group 4|
89320994|NCT01561768|Experimental|Group 5|
89320995|NCT01561690|Experimental|ARRY-502|
89320996|NCT01561690|Placebo Comparator|Placebo|
89320997|NCT00137111|Other|1|
89320998|NCT00137111|Other|2|
89320999|NCT02133040||T3 > 4 nmol/l|Acute hyperthyroidism with a T3 > 4 nmol/l
89321000|NCT02138656|Active Comparator|Best standard care only - not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice.~Parents aware that infant is not receiving chiropractic treatment"
89321001|NCT02138656|Sham Comparator|Best Standard Care and Sham - Blind|Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus sham chiropractic treatment. Parents unaware of whether infant is receiving real treatment or sham.
89321002|NCT02138656|Experimental|BSC & Chiropractic - Not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents aware that infant is receiving chiropractic treatment."
88806580|NCT05902078|Active Comparator|Calcitriol|Participants receive oral calcitriol 0.5μg daily for 12 months
89321003|NCT02138656|Experimental|BSC & Chiropractic - Blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents not aware that infant is receiving chiropractic treatment."
89321004|NCT02133118||Patients on metformin mono-therapy who receive add-on|
89321005|NCT02138812|Experimental|BAY1161909 + Paclitaxel|Participants received oral doses of BAY1161909 starting from 0.75 mg twice daily, from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in combination with weekly intravenous paclitaxel on D1, D8, and D15 of the 28-day cycles. For single-dose Pharmacokinetic (PK) cohort: in Cycle 1, participants received a single oral dose of 6 mg BAY1161909 on C1D1 with no BAY1161909 dosing for the remainder of Cycle 1.
89321006|NCT02133274|No Intervention|Standard oncologic care|Standard oncologic care
89321007|NCT02133274|Experimental|Early Palliative Care|A first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
89321008|NCT02133274|Experimental|Psychosocial plus early Palliative Care|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy plus early palliative care. Regarding the early Palliative Care, a first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
89321009|NCT02138968|Experimental|Multidimensional intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
89321010|NCT02138968|No Intervention|Usual care|Usual care
89321011|NCT02253082|Active Comparator|OctaplasLG®|replacement to bleeding
89321012|NCT02253082|Placebo Comparator|Standard fresh frozen plasma|replacement to bleeding
89321013|NCT00136955|Experimental|irinitecan/cisplatin|experimental arm consists of patients who receive irinotecan/cisplatin
89321014|NCT02261038|Other|Kanekasu radiographs|No drugs or devices are used in this study. Commonly available radiological techniques such as radiographs and CT are used. All patients undergo a CT of the knee and a special radiograph (Kanekasu technique).
89321015|NCT02133430|Experimental|Bispectral index (BIS) group|Bispectral index as measured by a BIS Processor is used to guide doses of anesthetic for maintaining the BIS values of 40-60
89321016|NCT02133430|No Intervention|Control group|Clinical signs is used to guide doses of anestheitics.
89321017|NCT05579002||Children with unilateral upper limb malformation|Children born between 2006 and 2012, with a unilateral upper limb deformity. These children are regularly followed at CEREFAM for a unilateral upper limb deformity. During their follow-up, they were fitted with different upper limb prostheses. During a consultation with one of the CEREFAM physicians, they requested a Hero Arm prosthesis following the marketing and reimbursement in France in 2019.
89321018|NCT02133586|Placebo Comparator|Clean Air - O3|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
89321019|NCT02133586|Experimental|NO2-O3|"Day #1: Two-hour exposure to 500ppb nitrogen dioxide with intermittent exercise.~Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
89321020|NCT02133586|Placebo Comparator|Clean Air - NO2|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
89321021|NCT02133586|Experimental|O3 - NO2|"Day #1: Two-hour exposure to 300ppb ozone with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
89321022|NCT02139202|Other|Full Program|"The intervention will (1) use the GlowCaps, a remote monitoring and reminder pill bottle; (2) be assigned an engagement advisor from the study team; (3) be asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence for the first three months; and (5) will determine their preferences for Way to Health platform communication methods during the study.~The group receiving the program intervention will also have their claims data analyzed for the 1 months post-enrollment."
89321023|NCT02260726|Experimental|Surgical group|Subjects already scheduled to undergo surgical correction of a symptomatic cam-type hip impingement deformity. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound investigation prior to surgery.
89321024|NCT02260726|Other|Control|Asymptomatic subjects with normal hip morphometry, as determined by MRI. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound imaging.
89321025|NCT00135707|Experimental|Dietary Supplement/Vitamins|1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.
89321026|NCT00135707|Placebo Comparator|Placebo for Vitamin C and Vitamin E|Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.
89321027|NCT05578768||training phase|The study procedures for both cohorts are the same.
89321028|NCT05578768||validation phase|The study procedures for both cohorts are the same.
89321029|NCT03548740||Group A|
89321030|NCT03548740||Group B|
89321031|NCT02252692|Active Comparator|Enalapril|Renitec® 2 x 5 mg tablets administered at once, to be entirely swallowed with 240 ml water
89321032|NCT02252692|Experimental|Enalapril ODMT|10 x 1mg of Enalapril ODMT, swallowed entirely with 240ml of water
89321033|NCT02252692|Experimental|Enalapril ODMT dispersed|10 x 1mg of Enalapril ODMT, dispersed on tongue
89321034|NCT03548662|Experimental|Platelet-Rich Plasma Protein (PRP) Group|Subjects in this group will receive PRP injection into tear site, followed by rehabilitative exercise
89321035|NCT03548662|Active Comparator|Hyaluronic Acid Group|Subjects in this group will receive one injection with hyaluronic acid followed by rehabilitative exercise
89321036|NCT05578534||High CO2 gap (Pcv-aCO2 > 6 mmHg)|Patients had high PCO2 gaps before initial resuscitation
89321037|NCT05578534||Normal CO2 gap (Pcv-aCO2 ≤6 mmHg)|Patients had normal PCO2 gaps before initial resuscitation
89321038|NCT05578534||Responsive (15% increase in CI or stable MAP was achieved)|Patients who respond to initial resuscitation with 15% increase in CI
89321039|NCT05578534||Non-responsive (< 15% increase in CI or a stable MAP was not achieved)|Patients who do not respond to initial resuscitation with less than 15% increase in CI
89321040|NCT05578534||Survivors|Patients who survived after 28 days
89321041|NCT05578534||Non survivors|Patients who do not survive within 28 days
89321042|NCT02139514|Active Comparator|Virtual Reality Social Cognition Training|Virtual Reality Social Cognition Training
89321043|NCT02139514|No Intervention|Control|Participants in the Control condition will be offered treatment following the Control condition.
89321044|NCT03966209|Experimental|treatment|JS001（PD-1 inhibitor）, 240mg I.V. Q3W,
89321045|NCT02139670||pregnant womens|
89321046|NCT02252770|Active Comparator|Nitric oxide supplement arm|During this arm, subjects will receive a lozenge with nitric oxide supplement
89321047|NCT02252770|Placebo Comparator|Placebo Arm|During this arm, subjects will receive placebo
89321048|NCT01077791|Experimental|original cognitive therapy|
89321049|NCT01077791|No Intervention|no intervention|
89321050|NCT05578456|Experimental|prednisone and aspirin|
89321051|NCT05578456|Placebo Comparator|placebo|
89321052|NCT02133820|Active Comparator|12 hourly capsule fasted|4 mg 12 hourly capsule - strong pain killer fasted
89321053|NCT02133820|Active Comparator|12 hourly capsule fed|4 mg 12 hourly capsule - strong pain killer fed
89321054|NCT02133820|Experimental|12 hourly capsule with antagonist fasted|4 mg 12 hourly capsule strong painkiller with antagonist fasted
89321055|NCT02133820|Experimental|12 hourly capsule with antagonist fed|4 mg 12 hourly capsule strong painkiller with antagonist fed
89321056|NCT05578378|Experimental|CLAG arm|Cladribine (5 mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.
89321057|NCT05578378|Active Comparator|Control arm|"Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen;~a high-dose methotrexate-based regimen"
89321058|NCT00129623|Experimental|1|
89321059|NCT00129623|Placebo Comparator|2|
89321060|NCT02139748|Active Comparator|Dental Implant & ADM|Dental implant placement plus simultaneous grafting use one layer of ADM.
89321061|NCT02139748|Experimental|Dental Implant & ADM & bone xenograft|Dental implant placement plus simultaneous grafting use one layer of ADM with bovine xenograft.
89321062|NCT02139904|Placebo Comparator|Active Symptom Control|Active symptom control includes palliative care and standard care methods used to manage symptoms
89321063|NCT02139904|Active Comparator|Vinorelbine|Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).
89321064|NCT02133976|Active Comparator|cognitive therapy|Cognitive therapy will be delivered to decrease pain interference
89321065|NCT02133976|Active Comparator|mindfulness training|Mindfulness training will be delivered to decrease pain interference
89321066|NCT02133976|Active Comparator|behavior therapy|Behavior therapy will be delivered to decrease pain interference
89321067|NCT02133976|Active Comparator|treatment as usual|Subjects will engage in their usual care for low back pain.
89321068|NCT05578222|Experimental|treatment group|All patients who met the inclusion criteria and did not meet the exclusion criteria were enrolled in the treatment group
89321069|NCT05578144|Experimental|Patient decision aids group|shared decision making with using patient decision aids. (SDM group)
89321070|NCT05578144|No Intervention|Control group|oral explanation. (Non-SDM group)
89321071|NCT02134132|Active Comparator|platelet rich plasma|The patients with diabetic foot ulcer who receive PG treatment.
89321072|NCT02134132|Placebo Comparator|Placebo|The patients with diabetic foot ulcer who receive placebo.
89321073|NCT03548506|Active Comparator|STN_O|Omnidirectional Deep Brain Stimulation of STN
89321074|NCT03548506|Experimental|STN_D|Directional Deep Brain Stimulation of STN
89321075|NCT05578066|Experimental|Intervention group|"The experimental group will be composed by aproximately 8 CESFAM with 36 Primary Health Care providers that are currently employed with a total of 288 providers per arm. And some PHC users that have received care there for Mental Health Abuse Issues in the three months prior to study participation.~The interventions include a comprehensive, 18-month, recovery-oriented anti-stigma intervention is composed by five components.~Developing a Team of Local Champions~Analysis of Internal Policies, Procedures and Protocols~Raising Awareness~Innovative Contact-Based Education~Recovery based Arts.~Teams of leaders developed as part of the first component will assist the research team with the implementation of the anti-stigma intervention at their respective CESFAM."
89321076|NCT05578066|No Intervention|Control group|"The control group will be composed by aproximately 8 CESFAM with 36 Primary Health Care providers that are currently employed with a total of 288 providers per arm. And some PHC users that have received care there for Mental Health Abuse Issues in the three months prior to study participation.~Data will be collected from this group in order to generate an integrated analysis with the information recolected from the intervention group."
89321077|NCT00129545|Experimental|WATCHMAN|Implant of WATCHMAN Left Atrial Appendage Closure Technology
89321078|NCT00129545|Active Comparator|Warfarin control|Subjects are treated with current standard of care Oral Anticoagulation Therapy with Warfarin
89321079|NCT00129545|Other|Roll-in|Implant of WATCHMAN Left Atrial Appendage Closure Technology. Up to 3 non-randomized subjects per site, these subjects were not included in the primary analysis.
89321080|NCT03549364|Experimental|Endurance race|"baseline investigations with CT and lab tests~the same CT and lab tests < 24h after an endurance race~CT and lab tests again about 1-2weeks after the race"
89321081|NCT03549286||pregnant women in the first trimester ultrasound consultation|Participation in the study will be offered to all pregnant patients, presenting for their first trimester ultrasound consultation in the obstetrics and gynecology department of the University Hospital of Reims. The study includes the consultations of all the certified doctors of the Maternity Department of the Reims University Hospital carrying out the first trimester ultrasounds. It will concern all the ranges of consultation regardless of the doctor who performs the consultation.
89321082|NCT02134288|Active Comparator|Belatacept|Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12. Then continue at 5mg/kg every 4 weeks throughout the completion of the study.
89321083|NCT02134288|Active Comparator|Everolimus|Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day 3.
89321084|NCT00129467|Experimental|methylphenidate + SSRI|During the 18-day blind treatment period, subjects will be prescribed methylphenidate 5-10 mg twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram. Subjects who respond to methylphenidate treatment will have the option of continuing on methylphenidate, up to 15 mg bid, and an antidepressant in the 6 week open label portion of the study.
89321085|NCT00129467|Placebo Comparator|Placebo + SSRI|During the 18-day blind treatment period, subjects will be prescribed placebo 1-2 capsules twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram.
89321086|NCT02140138|Experimental|Arm A (i.d. vaccinations with needle free injection device)|"Duration: Patients in Arm A will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
89321087|NCT02140138|Experimental|Arm B (i.d. vaccination by conventional injection)|"Duration: Patients in Arm B will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the medial part of the upper arms and thigh~Dose: 2 x 160 μg mRNA per injection (2 x 200 μL), equals 320 μg mRNA per RNActive® drug product component"
89321088|NCT02140138|Other|Arm C (i.d. vaccination with needle free injection device)|"Duration: Patients in Arm C will receive no vaccination before radical prostatectomy. After surgery high risk or very high risk patients will be offered to receive 6 vaccinations with CV9104 at week 8, 9, 10, 12, 14 and 16 after surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
89321089|NCT02140216||Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
89321090|NCT02140216||Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
89321091|NCT02140216||No blood transfusion|Patients undergoing elective spine surgery receiving no blood transfusion.
89321092|NCT00129311|Experimental|1|Selegiline
89321093|NCT00129311|Placebo Comparator|2|Placebo
89321094|NCT03548350|Experimental|Intervention|"The experimental group will participate in a 24 week multi-component programme that includes four strands:~A physical literacy programme focusing on core elements of strength, agility, speed, balance and flexibility. Delivered by external facilitators for one hour per week over 16 weeks of the programme (2 x8week blocks).~'Golden Mile' - pupils and teachers participate 15min walk/run a min of 2 times per week~After schools club (not compulsory) featuring mind-set component delivered by external facilitators~Healthy kidz app with reward system"
89321095|NCT03548350|No Intervention|Control|The control group will continue doing physical activity including physical education as is normal for their school
89321096|NCT01076621||A|
89321097|NCT02140294|Experimental|Polymeric nutritional supplement|
89321098|NCT02140294|Active Comparator|Standard Nutritional Treatment|
89321099|NCT03965819|Experimental|Randomized to consume Pain Bloc-R, Acetaminophen, then placebo|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Investigational Natural Health Product in Study Period 1, Comparator in Study Period 2, and Placebo in Study Period 3.
89321100|NCT03965819|Experimental|Randomized to consume Acetaminophen, Placebo, then Pain Bloc-R|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Comparator in Study Period 1, Placebo in Study Period 2, and the Investigational Product in Study Period 3.
89321101|NCT03965819|Experimental|Randomized to consume Placebo, Pain Bloc-R, then Acetaminophen|Each study product will be consumed as 2 capsules daily for 7 days. Randomized to consume Placebo in Study Period 1, Investigational Product in Study Period 2, and Comparator in Study Period 3.
89321102|NCT02134366|Experimental|Clobazam|Subjects who are assigned the clobazam treatment group will receive a 10mg loading dose followed by a maintenance dose of 5-25 mg bid starting 12 hrs after the loading dose. If subjects are found to have failed to respond to treatment with clobazam, the physician investigator has the ability to either start another AED or increase the dose of clobazam depending on the clinical situation. Subjects still being treated with clobazam at discharge will be given a 30 day supply of clobazam.
89321103|NCT02134366|Active Comparator|Clonazepam|Subjects who are assigned to the clonazepam treatment group will receive a dose of 1-2mg clonazepam dose tid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
88806581|NCT05902065|Experimental|AVR Treadmill training with C-Mill|"Participants (N=30) will undergo the AVR Treadmill training intervention with 5 AVR applications named Nature Island, stepping stones, walking area: obstacles avoidance, and track."
88806582|NCT05902065|Active Comparator|Conventional Treadmill training with C-Mill|"Participants (N=30) will undergo the Traditional Treadmill intervention."
89321104|NCT02134366|Active Comparator|Lorazepam|Subjects who are assigned to the lorazepam treatment group will receive a 1-2mg dose of lorazepam qid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
89321105|NCT03965975|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated urine cups. The urine sample was then sent the Lab and tested sequentially; first by the golden standard techniques used by the Lab (first intervention) and by the S-There device (comparative device - second intervention).
89321106|NCT01077947|Active Comparator|Functional anesthetic discography|"The patients disc levels for surgical treatment will be based exclusively on their Functional anesthetic discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~Loss of disc signal intensity on T-2 weighted sagittal MR images.~Loss of disc height on sagittal MR images.~Patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery by research personnel. Patients will be asked to complete questionnaires before their discography and at every follow-up visit."
89321107|NCT01077947|Active Comparator|Provocative Discography|"The patients disc levels for surgical treatment will be based exclusively on their Provocative Discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~Loss of disc signal intensity on T-2 weighted sagittal MR images.~Loss of disc height on sagittal MR images.~The control disc, in the case provocative discography group must appear normal on the MRI - must have preserved disc height and central disc signal intensity on T-2 weighted images. The provocative discography will be performed using the standard IASP criteria. The patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery."
89321108|NCT02134444|Experimental|Experimental Group|Experimental group will receive the assigned intervention which is a game-based rehabilitation program delivered at home.
89321109|NCT02134444|Active Comparator|Control group|Control group will receive a vestibular rehabilitation program which will include the Herdman gaze stabilization exercises and balance training program.
89321110|NCT01078025||transvaginal hybrid cholecystectomy|
89321111|NCT01078025||laparoscopic cholecystectomy|
89321112|NCT00133991|Experimental|R-CVP + HiCy|Protocol intervention consists of two fifteen-day cycles of cyclophosphamide (Cy), vincristine (V), prednisone (P), rituximab (R), with filgrastim support. CNS intervention consists of three days of cytarabine and hydrocortisone and one day of methotrexate (with leucovorin support) for each cycle. After those two cycles, rituximab and high-dose cyclophosphamide (HiCy) will be given.
89321113|NCT02784106|Placebo Comparator|Placebo: Double-Blind Treatment Period|
89321114|NCT02784106|Experimental|M2951: Double-Blind Treatment Period|
89321115|NCT02784106|Experimental|Placebo/M2951: Open Label Extension Period|
89321116|NCT02784106|Experimental|M2951/M2951: Open Label Extension Period|
89321117|NCT03549208|Experimental|LBVE01|Multivalent pneumococcal conjugate vaccine
89321118|NCT03549208|Experimental|LBVE02|Multivalent pneumococcal conjugate vaccine
89321119|NCT03549208|Active Comparator|Prevnar13|Multivalent pneumococcal conjugate vaccine Prevnar13
89321120|NCT02134600|Experimental|Omega-3 enriched fruit juice|Single arm study: Omega-3 enriched fruit juice in increasing dosage
89321121|NCT02140450|Active Comparator|Timolol|Timolol eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
89321122|NCT02140450|Active Comparator|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
89321123|NCT02140450|Active Comparator|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
89321124|NCT02140450|Active Comparator|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
89321125|NCT02140450|Sham Comparator|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
89321126|NCT05577598|Active Comparator|Subjects in this arm will receive active stimulation.|The Medtronic DBS system will be implanted in subjects in both study arms. Stimulation will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
89321127|NCT05577598|Sham Comparator|Subjects in this arm will receive sham stimulation with DBS being turned off.|The Medtronic DBS system will be implanted in subjects in both study arms. Stimulation will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
89321128|NCT05577520|Experimental|Small particle group (SPG)|SPG (n=10): MSA using 250 to 1000 µm size ABBM particles (Osteodens®, Pharmatrix, Argentina) as bone substitute.
89321129|NCT05577520|Experimental|Large particles group (LPG)|LPG (n=10): MSA using 1000 to 2000 µm size ABBM particles (Osteodens®, Pharmatrix, Argentina) as bone substitute.
89321130|NCT02134678|Experimental|self-system therapy|self-system therapy for depression
89321131|NCT02134678|Active Comparator|cognitive therapy|cognitive therapy for depression
89321132|NCT03549832|Active Comparator|sof/sim/dac|Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin
89321133|NCT03549832|Active Comparator|sof/omb/parit|Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin
89321134|NCT03548974|Active Comparator|Interventiongroup1|passive, motor-driven movement therapy followed by intermittent active and passive training
89321135|NCT03548974|Active Comparator|Interventiongroup2|intermittent active and passive training followed by no intervention
89531630|NCT05910814|Experimental|SD+PP+HIIE (sleep deprivation + physical practice + high-intensity interval physical exercise)|One night of sleep deprivation prior physical motor acquisition and HIIE before consolidation
89531631|NCT05900128|Active Comparator|Intervention|asthmatic patients who receive the educative intervention
89531632|NCT05900128|Placebo Comparator|no intervention|asthmatic patients who don't receive the educative intervention
88814096|NCT00921518|Placebo Comparator|Normal Saline|This group will receive isotonic saline at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
89321136|NCT03548272|Experimental|BiOSS LIM C|"Intervention: Percutaneous coronary intervention (PCI) with BiOSS LIM C stent implantation.~The BiOSS LIM C® is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 µm) releasing sirolimus (1.4 µg/mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids (PGLA). The degradation of the polymer lasts approximately 8 weeks. The BiOSS LIM C® stent consists of two main separate parts with different diameters: wider proximally, and distally smaller. The proximal part is always a bit shorter than the distal one (avg. 1 mm)."
89321137|NCT03548272|Active Comparator|regular 2nd generation DES|"Intervention: Percutaneous coronary intervention (PCI) with regular drug-eluting stent implantation (rDES).~rDES well-tested and available on the market. Xience, Orsiro, Resulte Integrity"
89321138|NCT02134834|Experimental|Ascending single dose of OP0595|
89321139|NCT02134834|Placebo Comparator|Normal Saline|
89321140|NCT05577052|Experimental|Test group|Metastatic vertebrae treated with SBRT
89321141|NCT05577052|Other|Control group|Conventional radiation dose to vertebral metastases
89321142|NCT03767608||Patients with type 2 diabetes mellitus|Patients diagnosed with T2DM according to the ADA
89321143|NCT03767608||Lean healthy controls|Lean healthy controls
89321144|NCT03548194|Experimental|BNC210|Administered orally b.i.d. for 5 days.
89321145|NCT03548194|Placebo Comparator|Placebo|Administered orally b.i.d. for 5 days.
89321146|NCT02140528|Experimental|Mesenchymal stem cell receipients|Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.
89321147|NCT02140528|Placebo Comparator|Placebo|Placebo injection in the site of fracture in patients with tibia fracture.
89321148|NCT02134990|Experimental|Oshadi D and Oshadi R with Docetaxel|Oshadi D and Oshadi R anti cancer agents with Docetaxol chemotherapy
89321149|NCT02140606|Experimental|Cafusertib Hydrochloride + Cytarabine|Cafusertib (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c. Patient to receive escalating dose of cafusertib hydrochloride.
89321150|NCT05576818|No Intervention|Control group|this group will include 33 patients who will receive their standard dopamine replacement therapy for 3 months
89321151|NCT05576818|Active Comparator|Synbiotic group|this group will involve 33 patients who will receive Synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers 2 sachets daily together with their standard dopamine replacement therapy for 3 months
89321152|NCT02260960|Experimental|Omega-3|Reesterified Triglyceride form omega 3
89321153|NCT02260960|Placebo Comparator|Placebo|safflower oil
89321154|NCT02135068|Experimental|CL and exercise with proactive snacking|Subject will consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
89321155|NCT02135068|Active Comparator|CL and exercise without proactive snacking|Subject will not consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
89321156|NCT02135224|Active Comparator|Fentanyl|20 microgram per hour
89321157|NCT02135224|Placebo Comparator|Normal saline|0.4 ml per hour
89321158|NCT03548896|Experimental|Dental Implants|Dental implants Titanium SLA treated surface of different dimensions according to the specific needs of the patient
89321159|NCT03548896|Experimental|Resorbable membrane|Resorbable membrane Cross link collagen membrane from porcine animal with a measure of 15 x 25 mm
89321160|NCT03548896|Experimental|Allograft|Allograft Bone from human source that is administered in a dosage of 1 cc per patient
89321161|NCT02135380|Other|Autologous Stromal Vascular Fraction|Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
89321162|NCT02135380|Other|Autologous Adipose Derived MSCs|3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
89321163|NCT02135380|Active Comparator|Control|"corticosteroids i.e. Prednisolone ≤10mg/day or ≤20 mg every alternate day~Immunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day~Antioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.~Pirfenidone at dose upto 1200 to 1800 mg/day"
89321164|NCT05509270|No Intervention|Control|No additional pro-vaccination intervention - some patients are currently targeted for flu vaccination messages due to a non-machine learning-based assessment that they are at high risk for complications, but are not told that they are at high risk or that they have been targeted
89321165|NCT05509270|Experimental|Letter only|This group will receive a letter telling them they are at high risk for flu and complications
89321166|NCT05509270|Experimental|Patient portal only|This group will receive a patient portal message telling them they are at high risk for flu and complications
89321167|NCT05509270|Experimental|SMS only|This group will receive an SMS telling them they are at high risk for flu and complications
89321168|NCT05509270|Experimental|Patient portal + SMS|This group will receive a patient portal message and an SMS telling them they are at high risk for flu and complications
89321169|NCT05509270|Experimental|Letter + Patient portal + SMS|This group will receive a letter, a patient portal message, and an SMS telling them they are at high risk for flu and complications
89321170|NCT03548038||Bariatric surgery patients|All subjects will be patients scheduled for bariatric surgery. There is only one arm in this study.
89321171|NCT02135458|Experimental|Telemonitoring|Home-based patient management using AUTONOM@DOM telemonitoring system to record and transmit heart rate, blood pressure and weight; along side conventional care (patient therapeutic education or personalised care program)
89321172|NCT02135458|Active Comparator|Conventional care|Conventional care including patient therapeutic education or personalised care program
89321173|NCT02785900|Experimental|33A + HMA|33A plus azacitidine or decitabine
89321174|NCT02785900|Active Comparator|placebo + HMA|placebo plus azacitidine or decitabine
89321175|NCT00127205|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.
89321176|NCT00127205|Active Comparator|Arm II|Patients receive oral clodronate once daily for 35 months.
89321177|NCT00127205|Experimental|Arm III|Patients receive oral ibandronate once daily for 35 months.
89321178|NCT05575960|Experimental|Interpersonal Psychotherapy|"Interpersonal Psychotherapy according to the manuals by Klerman et al. (1984) for patients 18 or above, and Interpersonal Psychotherapy for Adolescents according to the manual by Mufson (2004) for patients under 18.~Klerman, G., Weissman, M. M., Rounsaville, B., & Chevron, E. (1984). Interpersonal psychotherapy of depression. Basic Books.~Mufson, L. (2004). Interpersonal psychotherapy for depressed adolescents. Guilford Press."
89321179|NCT02785588|Other|3.0 T Neonatal MRI scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
89321180|NCT05575882|Active Comparator|Investigational product (BI 479 V1)|"The study product or placebo will be applied twice daily on a clean and dry skin for 120 days. Follow 3-6-9 method as follows: for babies (6 months to 24 months) use 3 pumps for the whole body (1 pump for face, 1 pump for trunk and arms and 1 pump for lower limbs), for children from 25 months: use 6 pumps for the whole body (1 pump for face, 3 pumps for trunk and arms and 2 pumps for lower limbs) and for children with height greater than 1.5 meters: use 9 pumps for the whole body (1 pump for face, 1 pump for chest, 1 pump for back, 1 pump per arm (x2) and 2 pumps per leg (x2). It will be applied from inclusion visit simultaneously with topical treatment in the following order: first the study product or placebo on the whole body followed by the topical treatment on the flare-up areas."
89321181|NCT05575882|Placebo Comparator|Placebo (BI 006)|Same instructions of use as active comparator.
89321182|NCT02135770|Experimental|Unfractionated Heparin|Low dose unfractionated Heparin 10 unit/kgBW/hour continuous infusion
89321183|NCT02135770|Placebo Comparator|Placebo|Normal saline packed in same form with trial drugs.
89321184|NCT05478850||Radiotherapy under anesthesia|
89321185|NCT03761290||Pseudphypoparathyroidism type 1A (PHP1A)|Case
89321186|NCT03761290||Pseudopseudohypoparathyroidism (PPHP)|Case
89321187|NCT03761290||Controls|Matched control group
89321188|NCT05454202||Non-communicating|Non-communicating (Glasgow ≤ 10) end-of-life patient hospitalized in palliative care (age ≥ 18 years old)
89321189|NCT04846114|Active Comparator|Control group (Cg)|"The control group (Cg) comprised 20 procedures performed in patients not on OAT.~Buccal and palatal-lingual flaps were repositioned and sutured with simple stitches using 5/0 monofilament nylon yarn, and a dry gauze was applied for 30 minutes."
89321190|NCT04846114|Experimental|Tranexamic acid group (TXAg)|TXAg group comprised 20 procedures performed in patients OAT. Buccal and palatal-lingual flaps were repositioned and sutured as in the Cg plus compression on the wound for 30 minutes using a gauze soaked in the contents of a 500mg ampoule of TXA, after which a new gauze soaked in the contents of a 500mg ampoule of TXA was applied for two hours.
89321191|NCT04846114|Experimental|Bismuth subgallate group (BSg)|BSg group comprised 20 procedures performed in patients OAT. At the moment of surgery, the contents of an anestube (1.8 ml) were mixed with a sufficient amount of BS powder to obtain a paste similar in consistency to tooth-paste (29). A thin layer of the paste was applied on the bone ridge, and buccal and palatal-lingual flaps were then repositioned and sutured as in the Cg. compression on the wound with a dry gauze for 30 minutes, after which a new dry gauze was placed for another two hours.
89321192|NCT04846114|Experimental|Dry gauze group (DGg)|DGg group comprised 20 procedures performed in patients OAT. Buccal and palatal-lingual flaps were repositioned and sutured as in the Cg plus compression on the wound with a dry gauze for 30 minutes, after which a new dry gauze was placed for another two hours.
89321193|NCT04814524|Experimental|Group 1 (VR, Fitbit)|Beginning postoperative day 1, patients use VR over 30 minutes up to 4 times daily on weekdays and 2 times daily on weekends, and wear Fitbit daily with a goal of 2,000 steps until the day of discharge, or until 14 days after surgery. Pre and post-VR pain scores will be obtained for each VR use. Sleep data may also be evaluated from Fitbit devices.
89321194|NCT04814524|Experimental|Group 2 (VR)|Beginning postoperative day 1, patients use VR over 30 minutes up to 4 times daily on weekdays and 2 times daily on weekends until the day of discharge or until 14 days after surgery. Pre and post-VR pain scores will be obtained for each VR use.
89321195|NCT04814524|Experimental|Group 3 (Fitbit)|Beginning postoperative day 1, patients wear Fitbit daily with a goal of 2,000 steps until the day of discharge or until 14 days after surgery. Sleep data may also be evaluated from Fitbit devices.
89321196|NCT04814524|Active Comparator|Group 4 (questionnaire)|Patients do not use VR or wear Fitbit.
89321197|NCT01560754|Experimental|Transdermal nicotine patch|Subjects will apply a combination of 7 or 14 mg nicotine transdermal patches until reaching their highest well tolerated dose of 7 to 28 mg/day.
89321198|NCT01560754|Placebo Comparator|Transdermal placebo patch|Subjects will apply a combination of 7 or 14 mg placebo transdermal patches until reaching their highest well tolerated dose.
89321199|NCT03547336|Experimental|Theranova 400 Dialyzer|In-center hemodialysis (in HD mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
89321200|NCT03547336|Active Comparator|FX800|In-center hemodialysis (in HDF mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
89321201|NCT03547804|Experimental|experimental arm|apatinib 500 mg qd;The dose was later reduced from 500 mg to 250 mg per day based on a recommendation of the principal investigator to reduce the adverse events.Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
89321202|NCT01076465|Experimental|Lifestyle counselling|Educational intervention, monitoring of clinical status, monitoring of treatment adherence
89321203|NCT01076465|Active Comparator|Comparator|Usual care
89321204|NCT01064037|Experimental|Arm 1|
89321205|NCT01064037|Experimental|Arm 2|
89321206|NCT01064037|Experimental|Arm 3|
89321207|NCT01064037|Placebo Comparator|Arm 4|
89321208|NCT03547648|Active Comparator|Group I ( 30 cm H2O)|Patients will be applied 30 cm H2O peak airway pressure manually at the end of the surgery
89321209|NCT03547648|Active Comparator|Group II( 40 cm H2O)|Patients will be applied 40 cm H2O peak airway pressure manually at the end of the surgery
89321210|NCT03547648|Active Comparator|Group III(50 cm H2O)|Patients will be applied 50 cm H2O peak airway pressure manually at the end of the surgery
89321211|NCT03735225|Experimental|IV Dasiglucagon|Dasiglucagon 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
89321212|NCT03735225|Experimental|SC 0.6 mg Dasiglucagon|Dasiglucagon 0.6 mg administered SC as a single dose
89321213|NCT03735225|Placebo Comparator|IV Placebo|Placebo 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
89321214|NCT05373238||Early Discharge|< discharge before 24 hours
89321215|NCT05373238||Late Discharge|discharge after 24 hours
89321216|NCT02217267|Placebo Comparator|Placebo group|Normal Saline 50 ml intravenous infusion in 1 hour once a week 4 times
89321217|NCT02217267|Active Comparator|Lidocaine group|Lidocaine 3mg/kg in Normal Saline to 50 ml intravenous infusion in 1 hour once a week 4 times
89321218|NCT05338372|Experimental|Two days forest therapy|
89321219|NCT05338372|Experimental|Three days forest therapy|
89321220|NCT05334628|Active Comparator|Preoperative Erector Spinae Plane Block|In the preoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 30 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
89321221|NCT05334628|Active Comparator|Postperative Erector Spinae Plane Block|In the postoperative period, under general anesthesia, after the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 30 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
89321222|NCT03670641|Experimental|Insulin and CGM Intervention|10 individuals with newly diagnosed type 2 diabetes will be started on basal (glargine) bolus (lispro) insulin therapy for up to 4 weeks with titrations guided by continuous glucose monitor (Dexcom G6) to achieve euglycemia and then insulin stopped after 4 weeks with hopes of diabetes remission.
89321223|NCT03621111|Experimental|Adherence plan|At the discharge, the hospital pharmacist will complete the medication reconciliation and assess the patient's medications. All patients enrolled will undergo three interventions in order to improve medication adherence: counseling, pill counts and self-questionnaire. The adherence plan concerns 6 classes of drugs recommended by the European Society of Cardiology in acute myocardial infarction. The adherence plan is performed by the community pharmacists. The hospital pharmacist will complete the discharge care form for the community pharmacist who has in charge the patient. Each patient will be scheduled for the first meeting with his community pharmacist within one month from the hospital discharge; afterward the adherence plan will be submitted every 3 months.
89321224|NCT03621111|No Intervention|Control group|All the patients discharged from the cardiological ward between September 2017 and February 2018 with a primary diagnosis of acute myocardial infarction has been enrolled in the control arm. These patients have been discharged with the current standard therapy and without any adherence plan performed by the community pharmacists. The investigators will collect the data from the administrative pharmaceutical databases throughout 12 months from the hospital discharge.
89321225|NCT02253706|Active Comparator|Low flow nasal oxygen supplementation|Low flow nasal oxygen supplementation as per routine standard of care(control arm)
89321226|NCT02253706|Experimental|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35
89321227|NCT04029519|Experimental|PN40082|All subjects in this study will receive one open-label treatment with PN40082.
89321228|NCT03546400|Other|methylphenidate HCl ERCT|methylphenidate HCl ERCT
89321229|NCT05666583|Experimental|Intervention Group|Within the scope of the research, the art of marbling was made by the art expert, accompanied by a total of 5 sessions ney concerts for 10 weeks, with two-week intervals. The art application was made to last 20-30 minutes before the patients received chemotherapy. The scales were administered to the individuals in the intervention groups three times in total.
89321230|NCT05666583|Experimental|Control Group|No treatment was applied to the control group. The scales were administered to the individuals in the control groups three times in total.
89321231|NCT03547258||AML patients|Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)
88806583|NCT05902039||CADASIL patients|"Inclusion Criteria:~Patients with CADASIL confirmed by gene or/and skin biopsy.~The age range is 20-70 years old.~There is no contraindication to MRI examination, and the informed consent is signed.~exclusion criteria：~Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases.~CADASIL is not confirmed.~There are contraindications to examination or refusal to sign the informed consent."
88806584|NCT05902039||Healthy controls|"Inclusion Criteria:~The age range is 20-70 years old.~There is no contraindication to MRI examination, and the informed consent is signed.~exclusion criteria：~Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases.~There are contraindications to examination or refusal to sign the informed consent."
88806585|NCT05902013|Active Comparator|Video|using video laryngoscopy for endotracheal intubation
88806586|NCT05902013|Active Comparator|Direct|using direct laryngoscopy
89321232|NCT03735147|Experimental|All children|Administration of live attenuated influenza vaccine (LAIV)
89321233|NCT03669861|Experimental|Abatacept|To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD
89321234|NCT00127127|Experimental|Vorinostat 100 mg|During Cycle 1, participants receive a single oral dose of vorinostat 100 mg on Day 1 in a fasted state, Day 3 in a fed state, and Day 19 in a fed state. On Days 5-18, participants receive vorinostat 100 mg twice daily, in the morning and evening. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
89321235|NCT00127127|Experimental|Vorinostat 200 mg|During Cycle 1, participants receive a single oral dose of vorinostat 200 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive vorinostat 200 mg twice daily, in the morning and evening. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
89321236|NCT00127127|Experimental|Vorinostat 400 mg|During Cycle 1, participants receive a single oral dose of vorinostat 400 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive a single oral dose of vorinostat 400 mg once-daily in the morning. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle will be 26 days.)
89321237|NCT00127127|Experimental|Vorinostat 500 mg|During Cycle 1, participants receive a single oral dose of vorinostat 500 mg on Day 1 in a fasted state; on Day 3 in a fed state; and on Day 19 in a fed state. On Days 5-18, participants receive a single oral dose of vorinostat 500 mg once-daily in the morning. If participants do not match to the discontinuation criteria, they can continue the same dose level therapy on the Cycle 2 and subsequent cycles.(Each cycle will be 26 days.)
89321238|NCT04708210|Experimental|Phase Ia Dose-Escalation Stage: IBI319|
89321239|NCT05571904|Experimental|the thick STSG group|For the patients in the thick STSG group, the surgeons harvested thick STSGs which were larger than recipient sites. The extra skin was punctured and stretched to cover the donor site (the novel technique).
89321240|NCT05571904|Active Comparator|the thin STSG group|For the patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with thin STSGs which were harvested from other parts of the patients.
89321241|NCT03669549|Experimental|Nevanimibe hydrochloride|Ascending dose level of oral nevanimibe hydrochloride beginning with 500 mg BID up to 2000 mg BID
89321242|NCT03758092||SGA vs AGA infants|infants, born at term (37+0/41+3 week gestation), aged 24 months, with a birth weight <10th percentile or between 10th and 90th percentile for sex, gestational age, and birth order, according to Italian neonatal anthropometric charts
89321243|NCT05668767|Experimental|study group|Single-arm Surufatinib Durvalumab EP/EC
89321244|NCT05570032|Experimental|virtual reality training|In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
89321245|NCT00126659|Experimental|Group I (cytoreductive nephrectomy and sorafenib tosylate)|"Patients undergo cytoreductive nephrectomy on day 1. Patients then receive oral sorafenib twice daily on days 15-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
89321246|NCT00126659|Experimental|Group II (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-7. Patients undergo cytoreductive nephrectomy on day 8. Patients then receive oral sorafenib twice daily on days 22-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
89321247|NCT00126659|Experimental|Group III (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-28. Patients undergo cytoreductive nephrectomy on day 29. Patients then receive oral sorafenib twice daily on days 43-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
89321248|NCT03735069|Experimental|IPT (Indirect pulp treatment) group|In this group, complete caries excavation from the dentin-enamel junction will be done. Caries near the pulp will be removed with caution until the remaining dentin shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material will be placed (Vitrebond; St.Paul, MN), followed by resin-modified glass ionomer (RMGI) build-up material (Vitremer; St. Paul, MN), and the final restoration of choice for MIH involved teeth; a preformed Stainless Steel Crown (SSC).
89321249|NCT03735069|Experimental|Cvek/partial pulpotomy group|"In this group, partial pulpotomy will be attempted first, inflamed pulp tissue will be removed until healthy pulp tissue is reached (2-4mm depth), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated twice if required; otherwise, cervical pulpotomy will be done.~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be placed in the pulp chamber (2-3mm thickness), a moist cotton pellet will be placed and Intermediate Restorative Material (IRM) to ensure setting. Patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
89321250|NCT03735069|Experimental|Cervical pulpotomy group|"In this group, a cervical pulpotomy procedure will be done where all pulp chamber tissue shall be removed until healthy pulp tissue is reached, as indicated by bleeding from all canals and arrest of hemorrhage upon pressure (for maximum 6 minutes).~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be mixed according to manufacturer instructions and will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with Intermediate Restorative Material (IRM), the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
89321251|NCT03966599|Active Comparator|Lateral position|The patient position was changed to lateral during surgery
89321252|NCT03966599|Active Comparator|prone position|The patient position was changed to prone during surgery
89321253|NCT03547570|Experimental|Heavy shoulder resistance training|Progressive heavy shoulder resistance training performed twice a week at the physiotherapy clinic under supervision, while once weekly training at home will be recommended.
89321254|NCT03669081|Experimental|Toradol and Lyrica|Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
89321255|NCT03669081|Placebo Comparator|Placebo and Standard of Care|Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
89321256|NCT05264350|Experimental|Viiral® Nasal Spray group|The nasal spray to be administrated twice daily for 8 weeks.
89321257|NCT05264350|Active Comparator|Isotonic Saline Nasal Spray|The nasal spray to be administrated twice daily for 8 weeks.
89321258|NCT03734913|Experimental|Part 1|Participants with advanced solid tumors including basal cell carcinoma and medulloblastoma, regardless of SMO or Gli1 alteration status.
89321259|NCT03734913|Experimental|Part 2 Cohort A|Participants with Adenocarcinoma of Esophagogastric Junction with SMO or Gli1 protein overexpression alteration.
89321260|NCT03734913|Experimental|Part 2 Cohort B|Participants with basal cell carcinoma, small cell lung cancer, neuroendocrine neoplasm and glioblastoma with SMO or Gli1 protein overexpression alteration.
89321261|NCT03547492|Experimental|Language Intervention|"1. Baseline LENA recording 2. Review language curriculum and motor curriculum with study personnel 2. Direct linguistic feedback of baseline LENA recording 4. 2nd LENA recording completed and analyzed 5. Direct or mailed linguistic feedback of 2nd LENA recording 6. 16- Weekly text messages 7. 4 month LENA recording with mailed linguistic feedback 8. 12 month LENA recording with mailed linguistic feedback~Assessments:~Ages and Stages Questionnaire at 4 and 12 months~Maternal Peabody Picture Vocabulary test at 4 months~Edinburgh Post-partum Depression Scale at 4 months~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a book at each interaction."
89321262|NCT03547492|Active Comparator|Motor Control|"Baseline LENA recording~Review motor curriculum with study personnel~2nd LENA recording completed and analyzed~4- monthly text messages~4 month LENA recording~12 month LENA recording with mailed linguistic feedback of all recordings~Assessments:~Ages and Stages Questionnaire at 4 and 12 months~Maternal Peabody Picture Vocabulary test at 4 months~Edinburgh Post-partum Depression Scale at 4 months~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a toy at each interaction."
89321263|NCT02253940|Experimental|Dose Group 1 - low dose|Treatment sequences ABC / CAB / BCA
89321264|NCT02253940|Experimental|Dose Group 2 - high dose|Treatment sequences DE / ED
89321265|NCT04617964||IUGR|sample of 40 pregnant women affected by intrauterine growth restriction (IUGR) Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
89321266|NCT04617964||NORMAL|Ssample of 40 healthy pregnant women Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
89321267|NCT05567380||Methotrexate|Patients newly diagnosed with active Rheumatoid Arthritis and receiving lowest effective dosage of Methotrexate as initial therapy.
89321268|NCT05567380||Methotrexate + JAK Inhibitors|Patients diagnosed with active Rheumatoid Arthritis and have shown intolerance or inadequate response to Methotrexate so JAK Inhibitor (Barcitinib) was added at 4mg/day orally to their therapy.
89321269|NCT05567380||Methotrexate + TNF Inhibitors|Patients diagnosed with active rheumatoid arthritis and have shown intolerance or inadequate response to Methotrexate so TNF Inhibitor was added to their therapy (either Golimumab at 50mg subcutaneous injection/m, or Etanercept at 50mg subcutaneous injection/wk)
89321270|NCT02253472|Experimental|Deep Brain Stimulation|Stimulation is on.
89321271|NCT02253472|Sham Comparator|Placebo|Stimulation is off.
89321272|NCT02253550|Experimental|Cirrhosis|Patients with confirmed presence of cirrhosis will received 12 weeks of treatment with Sofosbuvir and Simeprevir
89321273|NCT02253550|Experimental|Non-Cirrhotic|Patients with confirmed absence of cirrhosis will received 8 weeks of treatment with Sofosbuvir and Simeprevir
89321274|NCT03547180|Active Comparator|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
89321275|NCT03547180|Active Comparator|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
89321276|NCT03547180|Other|In-vivo exposure therapy|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
89321277|NCT05203432|Experimental|Red Light Intervention|Repeated Low-Level Red-Light Therapy
89321278|NCT05203432|Active Comparator|Low concentration atropine|0.01% atropine
89321279|NCT03546244|Experimental|musical treadmill|4-week daily musical treadmill training, consisting in two session, 20 minute per session
89321280|NCT03546244|Active Comparator|traditional session|4-week daily traditional treadmill training, consisting in two session, 20 minute per session
89321281|NCT02253628|Experimental|Trial 1|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
89321282|NCT02253628|Experimental|Trial 2|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
89321283|NCT02253628|Experimental|Trial 3|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
89321284|NCT02253628|Experimental|Trial 4|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
89321285|NCT03667053|Experimental|dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
89321286|NCT03667053|Placebo Comparator|placebo|Single fixed dose (s.c.injection) of placebo
89321287|NCT03667053|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
89321288|NCT04589728||Study group|All patients being observed during the study duration.
89321289|NCT05557240|Experimental|NeoPep Vaccine1and 2 plus polyICLC concurrent to TMZ|
89321290|NCT03734835|Active Comparator|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
89321291|NCT03734835|Placebo Comparator|control|no supplementation
89321292|NCT03734835|Active Comparator|flaxseed|30 grams flaxseed
89321293|NCT03734835|Active Comparator|hesperidin|1000 mg hesperidin as two capsules
89321294|NCT05533996|Other|Pregnant women prior to 14 weeks|"The sonographic examination will be conducted as an additional part after completing anatomical survey. . For the most accurate measurements, we will reduce the image depth to decrease the margin of error. We will conduct an initial abdominal sweep in all participants from the xiphoid to the umbilicus to detect the area of maximum pre-peritoneal fat thickness. Then, we will measure the maximum pre-peritoneal fat thickness and minimum subcutaneous fat thickness.~Furthermore, all measurements will be conducted after inspiration to avoid its generated tension with the transducer just touching the skin avoiding compression of the subcutaneous fat. Two measurements will be taken to investigate the inter-observer effect. Then, BFI will be calculated using the following formula: BFI = pre-peritoneal fat (mm) x subcutaneous fat (mm) / Height (cm). Results will be communicated to the site primary investigator. The treating obstetrician will be blinded to these results."
89321295|NCT04062292||Obstructive lung diseases group|"Having been diagnosed with obstructive pulmonary disease,~No acute exacerbation or infection in the past 1 week, Being between the ages of 18 and 65,"
89321296|NCT04062292||Healthy group|Age and sex matched healthy subjects without orthopedic and chronic diseases
89321297|NCT05172388|Active Comparator|Real purification|Air purifier turned on.
89321298|NCT05172388|Sham Comparator|Sham purification|Air purifier turned off.
89321299|NCT05156008|No Intervention|Group A|"Patient on the operating room, before primary hip or knee arthroplasty, will have his or her cannula inserted by standard palpation of vein under strict aseptic measures. Application of tourniquet on upper arm, palpation of vein, disinfection of skin and insertion of cannula. After two unsuccessful punctures, UGVA operator will step in and perform insertion of cannula with ultrasound.~Medical staff will note:~number of attempts~time to obtain vascular access~type of cannula~DIVA score"
89321300|NCT05156008|Other|Group B|"Patient on the operating room, before primary hip or knee arthroplasty, will have his or her cannula inserted by ultrasound guided vascular access under strict aseptic measures. With or without tourniquet applied on upper arm operator will prescan vasculature of arm to choose applicable vein. After disinfection of skin optimal vein is on plain part of arm and cannula must not end in flection (elbow, wrist) of arm.~Medical staff will note:~number of attempts, if 2 attempts fail, another operator will perform insertion~time to obtain vascular access~diameter of vein~type of cannula~DIVA score"
89321301|NCT05152732|Experimental|VGB-R04|Single intravenous (i.v.) infusion of VGB-R04 Intervention: Gene Therapy / Gene Transfer
89321302|NCT03631407|Experimental|Vicriviroc QD at Dose Level 1 (150 mg) + Pembrolizumab (200 mg)|Participants receive vicriviroc 150 mg tablets per os (PO) every day (QD) of each 21-day cycle up to 35 cycles and pembrolizumab 200 mg as a 30-minute intravenous (IV) infusion on Day 1 of each 21 day cycle up to 35 cycles (cycle length: 21 days).
89321303|NCT03631407|Experimental|Vicriviroc QD at Dose Level 2 (250 mg) + Pembrolizumab (200 mg)|Participants receive vicriviroc 250 mg tablets PO QD of each 21-day cycle up to 35 cycles and pembrolizumab 200 mg as a 30-minute IV infusion on Day 1 of each 21 day cycle up to 35 cycles (cycle length: 21 days).
89321304|NCT03547102|Active Comparator|Cherry concentrate|8 weeks supplementation with montmorency cherry concentrate
89321305|NCT03547102|Placebo Comparator|Placebo concentrate|8 weeks supplementation with placebo isoenergetic cherry concentrate
89321306|NCT03547024|Experimental|Part 1: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail on Day 1 followed by JNJ-55308942 high dose once daily from Day 3 to Day 14 and a single dose of drug cocktail on Day 12.
89321307|NCT03547024|Experimental|Part 2: JNJ-55308942 + Levonorgestrel/Ethinyl Estradiol|Participants will receive a single dose of levonorgestrel/ethinyl estradiol alone on Day 1 followed by JNJ-55308942 high dose once daily on Days 5 to 18 and a single dose of levonorgestrel/ethinyl estradiol on Day 14.
89321308|NCT03547024|Experimental|Part 3: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail alone on Day 1 followed by JNJ-55308942 low dose once daily on Days 3 to Day 14 and a single dose drug cocktail on Day 12.
89321309|NCT03639909||MSA-P|Patients with multiple systeme atrophy (MSA) with predominant parkinsonism (MSA-P) had evaluation of cardiovascular function and sweating function
89321310|NCT03639909||PD patients|Parkinson's disease (PD) patients had evaluation of cardiovascular function and sweating function
89321311|NCT05115994||Hypertensive OSA patients, high PAP compliance|Hypertensive OSA patients using their PAP device for at least 4 hrs/night
89321312|NCT05115994||Hypertensive OSA patients, low PAP compliance|Hypertensive OSA patients using their PAP device for less than 4 hrs/night
89321313|NCT05115994||Intra oral device treatment|Hypertensive OSA patients treated with IOD
89321314|NCT05115994||Untreated OSA hypertensive patients|Hypertensive OSA patients not using PAP or IOD
89321315|NCT05115994||Hypertensive patients without OSA|Control population from QregPV without OSA
89321316|NCT03734757|Experimental|Trimodality|PET-CT with fluorocholine and MRI
89321317|NCT03739125|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
89321318|NCT03739125|Placebo Comparator|Placebo|Placebo
89321319|NCT04019704|Experimental|AXS-05|AXS-05 (bupropion and dextromethorphan) oral tablets
89321320|NCT04019704|Placebo Comparator|Placebo|Placebo oral tablets to match AXS-05
89321321|NCT01310049|Experimental|LP0058 oral solution (0.050 mg/mL)|LEO 32731
89321322|NCT01310049|Experimental|LP0058 oral solution (0.200 mg/mL)|LEO 32731
89321323|NCT01310049|Placebo Comparator|LP0058 oral solution (placebo)|Placebo
89321324|NCT01310049|Experimental|LP0058 capsule 1-120 mg|LEO 32731
89321325|NCT01310049|Placebo Comparator|LP0058 capsule (placebo)|Placebo
89321326|NCT03739047|Experimental|Desensitization with flipped spoon|Children in this study will receive behavioral feeding treatment. This arm will include desensitization.
89321327|NCT03739047|Placebo Comparator|flipped spoon|Children in this study will receive behavioral feeding treatment.
89321328|NCT03738969||Laparotomy group|Patients in this group accepted laparotomic radical hysterectomy for cervical cancer.
89321329|NCT03738969||Laparoscopy group|Patients in this group accepted laparoscopic or robotic radical hysterectomy for cervical cancer.
89321330|NCT03546166|Experimental|TREATMENT|
89321331|NCT03738891|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen.
89321332|NCT04012996|Experimental|Investigational|Two-level prodisc C SK and/or prodisc C Vivo
89321333|NCT04012996|Active Comparator|Control|Two-level Mobi-C device
89321334|NCT03630393|Experimental|Pressure 6 mmHg|Pneumoperitoneum Pressure 6 mmHg
89321335|NCT03630393|Active Comparator|Pressure 15 mmHg|Pneumoperitoneum Pressure 15 mmHg
89321336|NCT02253784|Active Comparator|Group I (ISB-P)|Four nerve blocks with perineural injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
89321337|NCT02253784|Active Comparator|Group II (ISB-S)|Four nerve blocks with systemic injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
89321338|NCT02253784|Active Comparator|Group III (ISB-C)|Four nerve blocks without dexamethasone
89321339|NCT03734445|Experimental|Vitamin supplement|Effervescent tablets containing Vitamin C, Vitamin D and zinc
89321340|NCT03734445|Placebo Comparator|Placebo|Effervescent tablets not containing Vitamin C, Vitamin D and zinc
89321341|NCT04554472||Study group|Patients with a distal radius fracture requiring surgery who meet the exclusion and inclusion criteria
89321342|NCT01310205||Hepatitis C treatment|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
89321343|NCT01310205||non cirrhotic subjects|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
89321344|NCT03546946|Experimental|Gaze-Contingent Music Reward Training|GCMRT for eight 20-minute sessions - twice per week over 4 weeks.
89321345|NCT03546946|Placebo Comparator|Control Training|Passive viewing task with continuous music for eight 20-minute sessions - twice per week over 4 weeks.
89321346|NCT03546946|No Intervention|No-Train Group|No active training.
89321347|NCT03546868|Experimental|Ulcerative Colitis|Patients with ulcerative colitis undergoing [18F]FSPG PET/CT scan
89321348|NCT03546868|Experimental|Crohn's disease|Patients with Crohn's disease undergoing [18F]FSPG PET/CT scan
89321349|NCT03738813|Experimental|Treatment Group|"The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.~In Treatment Group, the movements will be performed using Gloreha ARIA. Gloreha Aria is a sensor-based therapy device designed for motor recovery of impaired upper limb. Gloreha Aria is equipped with sensors that can detect any movements in space: the software processes and displays them on the screen."
89321350|NCT03738813|Active Comparator|Participants Usual Care (PUC)|The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.In Control Group, these activates will be performed without any device.
89321351|NCT03993106|Experimental|Study Drug|All study participants will receive sEphB4-HSA through a needle in a vein in their arm for an hour in an outpatient clinic. All study participants will receive two doses of study drug on Days 1 and 15 of each 4 week cycle.
89321352|NCT03738735|No Intervention|Control|Patients will receive standard of care lactated ringer's solution for the arthroscopic irrigation during surgery.
89321353|NCT03738735|Experimental|Intervention|Patients will receive hyperosmolar saline for the arthroscopic irrigation during surgery.
89321354|NCT03734367|Active Comparator|Emotional abilities training program|Intervention program on emotional abilities that will be carried out for 10 hours distributed over 5 weeks, in two and a half hour session. The work methodology will be eminently practical, working in groups including real case analysis and interactive simulation
89321355|NCT03734367|No Intervention|Control group|Control group that will not receive the training program on emotional abilities but usual care.
89321356|NCT03734133|Experimental|Foot orthoses|Different foot orthoses
89321357|NCT03738657||Screening|Olfactory screening
89321358|NCT03738657||On Study|Taste testing
89321359|NCT03983980|Experimental|Tapinarof (DMVT-505) Cream Group|Tapinarof cream, 1%, applied once daily
89321360|NCT03983980|Placebo Comparator|Vehicle Cream Group|Vehicle cream applied once daily
89321361|NCT03628599|Experimental|TOTAL1|Delefilcon A contact lenses worn bilaterally (in both eyes) for 4 weeks in a daily disposable modality
89321362|NCT03628599|Active Comparator|1-DAY|Senofilcon A contact lenses worn bilaterally for 4 weeks in a daily disposable modality
89530168|NCT01842035|Experimental|Regadenoson|"Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.~--------------------------------------------------------------------------------"
89321363|NCT03545776||Educational program|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course that will be preceded by a pre-test evaluation and followed by delayed post-test evaluations.~Training will be followed by an online teaching consisting on additional questions and answers quizzes based on the 10 educational goals already described elsewhere.~In order to avoid any risk of intrasite contamination, all the learners benefiting from the training in the same department will be trained in a uniform time, with respect to the training schedule regarding post-test evaluations (day-1, day-15 and day-30). A final evaluation will be performed at day-90 after beginning of the training course."
89321364|NCT03733821||CUD patients on HF-rTMS treatment|Patients fulfilling the Diagnostic and Statistical Manual of Mental Disorders - 5 (DSM 5) criteria for Cocaine Use Disorder undergoing a High Frequency rTMS protocol stimulating over the left dorsolateral prefrontal cortex (DLPFC).
89321365|NCT03546790|Experimental|Flavor 1|Grape flavored tobacco cigar wrapper
89321366|NCT03546790|Experimental|Flavor 2|Chocolate flavored tobacco cigar wrapper
89321367|NCT03546790|Experimental|Flavor 3|Tobacco flavored tobacco cigar wrapper
89321368|NCT03546088|Experimental|awake naso-tracheal intubation|The patients with obstructive oro and hypo-pharynx tumours will have their airway secured through awake fiberoptic naso-tracheal intubation with light sedation and topical anaesthesia with lidocaine. The sedation will be provided in small boluses until the desired level will be achieved not exceeding 0.05 mg/kg of midazolam and 3 mcg/kg fentanyl. The dose of lidocaine will be to a maximum of 7 mg/kg. The reinforced intubating tube will be lubricated with lidocaine gel.
89321369|NCT04531618|Experimental|Family Nurture Intervention (FNI)|Receives a FNI session over Zoom in the Well Baby Nursery and 3 subsequent Zoom sessions over the next 3 months.
89321370|NCT04531618|No Intervention|Standard of Care (SC)|SC receives the regular standard of care in the Well Baby Nursery and no intervention.
89321371|NCT05163184||Laparotomy|Patients undergoing laparotomy
89321372|NCT05070052|Experimental|Group CBT|9 group sessions lasting 75-90 minutes each. CBT starts with psychoeducation about emotions, their primary functions, and how our emotions can affect the way we think and behave. They next learn about behavioral strategies that can help them manage or overcome difficult emotions. Group members also complete gradual exposure exercises, which involve engaging with activities that elicit negative emotions. Finally, group members are taught cognitive skills to help them cope with difficult/stressful thoughts.
89321373|NCT05070052|Experimental|Group MBCT|9 group sessions lasting 75-90 minutes each. The focus of sessions 1 through 4 will be learning to bring greater awareness to the present moment, on purpose, and nonjudgmentally. Appropriate responding is the focus of sessions 5 through 8. All skills are reviewed in session 9.
89321374|NCT05056480||Parents/caregivers|Parents/caregivers of children <20 years old who received interdisciplinary care coordination within the Pediatric Complex Care Integration (PCCI) program
89321375|NCT05056480||Clinical staff|PCCI care management staff participating in implementation of the PCCI program
89321376|NCT03875950|Experimental|Training intervention|In this cluster randomized control trial design, the experimental arm refers to the 12 study sites that are randomly assigned to receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
89321377|NCT03875950|No Intervention|Standard of care control|In this randomized cluster randomized control trial design, the no intervention arm refers to the 12 study sites that are randomly assigned not to receive the clinician training intervention. Instead, these study sites will receive the standard of care, which is no standardized patient actor training, for health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
89321378|NCT05123248|Experimental|Blinded Group|Participants in the blinded group will be wearing the sensor for 14 days without a reader. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
89321379|NCT05123248|Experimental|Unblinded Group|Participants in the non-blinded group are required to wear the sensor for 14 days with an open reader. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
89321380|NCT05046028|Experimental|Test|50 patients with squamous cell head cancer over 18 years of age, receiving chemoradiation therapy, receiving 3 bottles (х 200 ml) of ONS with Protein Oncosensation with a neutral taste throughout the course of treatment.
89321381|NCT05046028|Active Comparator|Prospective Control group|50 patients over 18 years of age with squamous cell carcinoma of the head and neck, receiving chemoradiation therapy, receiving standard nutritional therapy with a neutral taste throughout the course of treatment.
89321382|NCT05046028|Sham Comparator|Retrospective Control group|60 patients who received chemoradiotherapy earlier with standard nutritional support.
89321383|NCT04427722||MPS-Flex Total Knee Joint Prostheses|Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.
89321384|NCT03866980|Experimental|AK105 plus Carboplatin and Pemetrexed|Subjects receive AK105 200 mg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
89321385|NCT03866980|Placebo Comparator|Placebo plus Carboplatin and Pemetrexed|Subjects receive placebo intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
89321386|NCT03866980|Experimental|AK105 plus anlotinib|Subjects receive AK105 200 mg intravenously (IV) plus Anlotinib 12mg/d PO D1-14, Q3W until progression.
89321387|NCT02253862|Experimental|Sequential treatment|
89321388|NCT03546010|Experimental|Oculometric and neuropsychological tests|Oculometric tests and neuropsychological tests
89321389|NCT03627195|Experimental|DSP-1349M|Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)
89321390|NCT03627195|Placebo Comparator|Placbo|placebo injection
89321391|NCT03738345|Experimental|Oxygenation on hypoxemia patients|Adult patients with hypoxemia will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then patients will be placed on high flow nasal cannula (HFNC), HFNC flow will be titrated based on the hospital's policy or protocol and patient's comfort, patient's clinical effects on oxygenation will be monitored and recorded during the titration process.
89321392|NCT03738345|Experimental|Lung expansion on healthy volunteer|Adult healthy volunteers will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then they will be placed on HFNC, HFNC flow will be increased sequentially by research protocol and their comfort, subjects' lung expansion effects in different flow will be quantified by Electrical impedance tomography (EIT), a noninvasive assessment tool. Their comfort will also be assessed using a visual scale.
89321393|NCT01063803|Experimental|Arm 1: ATN-103_30mg|
89321394|NCT01063803|Experimental|Arm 2: ATN-103_80 mg|
89321395|NCT03738111|Experimental|TG02 Citrate|TG02 citrate capsules given orally.
89321396|NCT03738033||use of the educational platform|Before the hand-on practice and assessements, the participants use the platform for learning.
89321397|NCT03738033||without use of the educational platform|Before the hand-on practice and assessements, the participants did not use the platform for learning.
89321398|NCT03776656|Experimental|Allopurinol|Oral administration of Allopurinol (Zyloric®) for 12 months without exceeding 400 mg / day in children and 900 mg / day in adults, with dosage adjustment in case of renal failure
89321399|NCT03733743|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
89321400|NCT03733665||Heart failure patients|All patients in NICOR's National Heart Failure Audit will be matched to those in NHS Digital's HES database who have a 4-character primary diagnosis of I50.0-I50.9.
89321401|NCT03545698|Active Comparator|Telehealth Intervention|
89321402|NCT03545698|No Intervention|Non-Telehealth Intervention|
89321403|NCT03737877|Experimental|Diet modification|
89321404|NCT03733587|Experimental|Cyclophosphamide and GX-I7|Cyclophosphamide and determined dose of GX-I7 of each cycle
89321405|NCT00126581|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89321406|NCT00126581|Experimental|Arm II (erlotinib hydrochloride, paclitaxel, carboplatin)|Patients receive erlotinib hydrochloride as in arm I. Patients also receive paclitaxel IV over 1-3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of treatment, patients may continue to receive erlotinib hydrochloride alone as above.
89321407|NCT03704584|Active Comparator|Treatment Group (corticosteroid injection plus lidocaine)|Treatment Group (corticosteroid injection plus lidocaine) subjects will receive (Methylprednisolone acetate injectable suspension and Lidocaine HCl) for their upper extremity condition
89321408|NCT03704584|Other|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (Methylprednisolone acetate injectable suspension) for their upper extremity condition
89321409|NCT03662997|Active Comparator|Five-layer vs Hydropolymer|Bordered Five-layer Foam Dressing for 2 weeks, followed by Hydropolymer Foam Dressing for 2 weeks.
89321410|NCT03662997|Active Comparator|Hydropolymer vs Five-layer|Hydropolymer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
88806587|NCT05901948||Asherman Patients|Patients diagnosed with Asherman syndrome based on patient complaint of hypomenorrhea or amenorrhea and hysterosalpingography.
88806588|NCT05901935|Experimental|DP303c|Eligible patients will be treated with DP303c at 3.0 mg/kg every 3 weeks.
88806589|NCT05901935|Active Comparator|Trastuzumab combined with vinorelbine/capecitabine|Eligible patients will be treated with trastuzumab IV on day 1 and oral capecitabine twice daily on days 1-14 every 3 weeks, or patients will be treated with trastuzumab IV on day 1 and vinorelbine IV over on days 1 and 8 every 3 weeks.
88806590|NCT05901844|Other|Perform two different tests on the same sample|The same sample is diagnosed using a Raman analyzer firstly and then diagnosed by paraffin pathology.
88806591|NCT05901779|Experimental|Probiotic Group|PG (probiotic group) patients received probiotic capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. The intervention begins from the completion of preoperative chemotherapy to the seventh day after surgery.
89321411|NCT03662997|Active Comparator|Five-layer vs Hydrocellular|Bordered Five-layer Foam Dressing for 2 weeks, followed by Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks.
89321412|NCT03662997|Active Comparator|Hydrocellular vs Five-layer|Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
89321413|NCT03677284|Experimental|Intervention group|"Information brochure about daily time management, frequent problems, and suggested strategies to manage them.~Time assistive product. Time assistive products for time perception are products making the passage of time visible and understandable, to know for how long to perform an activity or how long to wait until the next activity starts e.g a time log.~Time assistive products for time orientation includes the use of schedules, calendars and other visual aids to promote orientation to the time of the day, week, or year.~Time assistive products for time management would compensate for deficits in time management and focus on self-scheduling skills."
89321414|NCT03677284|Active Comparator|Control group|Information brochure about daily time management, frequent problems, and suggested strategies to manage them.
89321415|NCT03648879|Experimental|1/Arm 1 - Upper white-light endoscopy and confocal endoscopic microscopy|Upper white-light endoscopy and confocal endoscopic microscopy
89321416|NCT03737721|Experimental|Avelumab and Radical radiotherapy|Single-arm combining Avelumab with radical radiotherapy.
89321417|NCT03733431|Active Comparator|Standard dose vagal stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
89321418|NCT03733431|Active Comparator|High dose vagal stimulation|A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)
89321419|NCT03733431|Sham Comparator|Sham stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
89321420|NCT04945876|No Intervention|Control group|"Participants is encouraged to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. No further follow up except for testing at 12 weeks and six months.~After the completion of the study the control group will be offered a session of individual exercise and diet guidance as well as a period of digital follow-up as needed."
89321421|NCT04945876|Experimental|Intervention group|Participants will receive a session of individual exercise and diet guidance with focus on goals and motivation for diet and exercise and help to overcome any barriers for self-efficacy. They will also receive an activity tracker and an introduction on how to use it. Further they will receive a monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise. The participants can also send sms if they have questions during the follow-up period. They will be encouraged to continue to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. If needed they can get help to find suitable exercise groups in their own municipality. The Garmin wristband will be used to facilitate daily activity and continuing exercise at recommended intensity level at home. Participants who are malnourished, or at risk of malnutrition, will receive specific guidance session on nutrition.
89321422|NCT03546634|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
89321423|NCT03546634|Experimental|Two-dose schedule for Sabin IPV|Subjects first dose IPV vaccinate at 4 months of age, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
89321424|NCT03756376||IRRIV and RFR|Enrolled patients will receive IRRIV test and RFR assessment. RFR will be evaluated through a protein loading test. (1.2 g of protein/Kg of body weight) performed with cooked beef. The RFR was then defined as the difference between the highest CrCl obtained after the protein load and the baseline CrCl measured on rest conditions. Concerning the IRRIV test, a weight of 10% of the patient's body weight is applied on the abdominal wall. RRIs is recorded in a middle interlobular artery, every minute for 10 minutes during the echo-renal stress test. The lowest RRI reached is taken as reference (stress RRI). The IRRIV is defined as the percentage difference between baseline RRI and stress RRI
89321425|NCT02254096|Experimental|BIRT 1696 BS|single escalating dose phase
89321426|NCT02254096|Experimental|BIRT 1696 BS + GFJ|single dose grapefruit effect arm
89321427|NCT02254096|Experimental|BIRT 1696 BS + HFM|single dose food effect arm
89321428|NCT02254096|Placebo Comparator|Placebo|
89321429|NCT03661983|Experimental|Open Label Stabilization Phase: Aripiprazole|Participants began treatment with aripiprazole at a 2.0 mg/day dose, with the dose titrated to 5.0 mg/day after 2 days. Subsequent dose adjustments were based on the participant's weight to achieve optimum control of tics up to the maximum recommended doses based on the United States Labeling, up to Week 8 and then continued on the most stabilized dose up to minimum Week 14 or maximum Week 20. Participants who met stabilization criteria were randomized to Double-blind Randomization Phase.
89321430|NCT03661983|Experimental|Double Blind Phase: Aripiprazole Full Dose|Participants who met stabilization criteria and randomized to receive full dose of aripiprazole i.e. 5 mg or 10 mg for <50 kg participants,and 10 mg or 20 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
89321431|NCT03661983|Experimental|Double Blind Phase: Aripiprazole Half Dose|Participants who met stabilization criteria and randomized to receive half dose of aripiprazole i.e. 2 mg or 5 mg for <50 kg participants, and 5 mg or 10 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
89321432|NCT03661983|Placebo Comparator|Double Blind Phase: Placebo|Participants who met randomization criteria and randomized to receive aripiprazole matching-placebo tablets, 2 daily, orally, up to 12 weeks in Double-Blind Phase.
89321433|NCT02783170|Other|Simultaneous vaccination arm|In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
89321434|NCT02783170|Other|Sequential vaccination arm|In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
89321435|NCT03646305|Experimental|Verbally repeat body-related thoughts|A cognitive defusion strategy in which participants repeat a target unwanted thought out loud and as quickly as possible for 60 seconds.
89321436|NCT03646305|Experimental|Sing negative body-related thoughts|A cognitive defusion strategy in which participants sing a target unwanted thought to the tune of 'twinkle, twinkle' for 60 seconds
89321437|NCT03646305|No Intervention|Verbally repeat body-unrelated thoughts|"A control condition in which participants repeat the phrase I am talking out loud and as quickly as possible for 60 seconds."
89321438|NCT03646305|No Intervention|Sing body-unrelated thoughts|"A control condition in which participants sing the phrase I am singing to the tune of 'twinkle, twinkle' for 60 seconds"
89321439|NCT04913272|Experimental|KT-301 (formerly US-APR2020)|Patients in this group will be administered KT-301 (formerly US-APR2020) orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals, (for a total daily dose of 90 Billion CFUs).
89321440|NCT04913272|Placebo Comparator|Placebo|Patients in this group will be administered placebo orally at 2 capsules per day for six months. The frequency will be one capsule in the morning and one capsule in the evening, after meals.
89530169|NCT03260101||one group, ApoGraft Follow up Study|Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
88806592|NCT05901779|No Intervention|Control Group|CG (Control Group) patients receive blank control management.
88806593|NCT05901766|Experimental|Iodine Containing Multiple Micronutrient (UNIMAP)|UNIMAP 1 tablet po once daily from birth to 6 months postpartum
89321441|NCT04300426|Experimental|ACHIM by gastroduodenoscopy|"Intestinal microbiota (acronym ACHIM - anaerobically cultured human intestinal microbiota) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml, containing approximately 10^9 bacteria / ml.~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
89321442|NCT04300426|Placebo Comparator|Placebo by gastroduodenoscopy|"ACHIM culture media (no bacteria) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml.~Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study."
89321443|NCT02782780|Experimental|CBTi|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep as well as to work with the patient toward altering sleep habits to increase sleep propensity and regularity. Specifically, participants will receive 8 weekly individual sessions of CBTi according to the VA CBTi protocol. The investigators will follow the semi-structured approach to treatment described in the VA CBTi protocol, which allows the case conceptualization to drive the order in which treatment components are introduced.
89321444|NCT02782780|No Intervention|Monitor Only|Study participants who are randomized to the Monitor Only (MO) control group will be followed for 8 weeks of usual care (i.e., they will be advised to continue doing whatever they were doing to manage their GWI and insomnia symptoms without change dosage or frequency of treatment). Participants randomized to the Monitor Only condition will have the option of receiving CBTi delivered by telephone, at no cost to them, upon completion of post-study procedures.
89321445|NCT02254018|Experimental|bivatuzumab mertansine|single dose escalation
89321446|NCT03545620||Difficult intubation,|Patients who underwent surgery under general anesthesia will be follow up. Patients predicted difficult intubation/airway or established difficult intubation/airway after anesthesia induction will be included. Which rescue technique will be used after unsuccessful direct laryngoscopy will be recorded.
89321447|NCT03461536|Active Comparator|Clinical Decision Support|Participants in this arm will receive the study intervention, the clinical decision support.
89321448|NCT03461536|No Intervention|Usual care|Participants in this arm will not receive the the clinical decision support tool.
89321449|NCT03396952|Experimental|Treatment (pembrolizumab, ipilimumab, aspirin)|Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
89321450|NCT03378934|Experimental|Berberine Arm|In the Berberine Arm, patients will receive berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
89321451|NCT03378934|Active Comparator|Control Arm|In the Control Arm, patients will receive standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
89321452|NCT00126503|Experimental|Treatment (bevacizumab and sorafenib tosylate)|"Phase I: Patients receive sorafenib PO twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of sorafenib and bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive sorafenib PO once daily on days 1-28 and bevacizumab IV over 90 minutes on days 1 and 15 at the MTD in the absence of disease progression or unacceptable toxicity."
89321453|NCT03546478|Experimental|99mTc-ABH2 SPECT/CT|The patients were injected with 370±54 MBq of 99mTc-ABH2 in one dose intravenously and underwent SPECT/CT scan 90-270 min later.
89321454|NCT03545932|Experimental|Hydrogymnastics|Hydrogymnastics Program
89321455|NCT00126425|Experimental|123I-mIBG (meta-iodobenzylquanidine|Single dose
89321456|NCT03545854|Experimental|T3 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T3 vertebral level
89321457|NCT03545854|Experimental|T3 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T3 vertebral level
89321458|NCT03545854|Experimental|T3 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T3 vertebral level
89321459|NCT03545854|Experimental|T12 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T12 vertebral level
89321460|NCT03545854|Experimental|T12 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T12 vertebral level
89321461|NCT03545854|Experimental|T12 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T12 vertebral level
89321462|NCT03545854|Experimental|L4 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the L4 vertebral level
88806594|NCT05901766|No Intervention|Routine care|Routine clinical care includes recommendation for iron folic acid for women with anemia
88806595|NCT05901727||HIV treatment survey participants|HIV treatment patients eligible to be enrolled in the patient survey
89321463|NCT03545854|Experimental|L4 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the L4 vertebral level
89321464|NCT03545854|Experimental|L4 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the L4 vertebral level
89321465|NCT00126191|Experimental|Low Risk|"Low-risk patients receive 3 cycles of regimen A.~Regimen A:~Rituximab (375 mg/m^2) on Days 1 and 3. Cyclophosphamide (800 mg/m^2) on days 1 and 2. Vincristine (1.4 mg/m^2) on days 1 and 10. Doxorubicin (50 mg/m^2) on Day 1. Methotrexate (3000 mg/m^2) on Day 10. Intrathecal Cytarabine (50mg) will be given on Day 1 and intrathecal methotrexate (12mg) will be given on Days 1 and 10.~Leucovorin on days 11 and 12.~Rituximab is given on Days 1 and 3 in cycle 1, and on Day 1 of all other cycles."
89321466|NCT00126191|Experimental|High Risk|"High-risk patients receive 4 alternating cycles of regimens A and B (A-B-A-B).~Regimen A (as described earlier).~Regimen B:~Rituximab (375mg/m^2) on Day 1. Ifosfamide (1500mg/m^2) on Days 1-5. Mesna (275 mg/m^2) on Days 1-5. Etoposide (60mg/mg^2) on Days 1-5. Cytarabine (2 gm/m^2) twice a day on Days 1 and 2. Intrathecal methotrexate (12mg) on Day 5, and intrathecal methotrexate (50mg) on Day 3 (also on Day 1 for patients with central nervous system involvement)."
89321467|NCT03753178||patients|70 participants presented with clinical and motor electrophysiological evidence of common peroneal neuropathy at the fibular neck
89321468|NCT03753178||controls|70 controls
89321469|NCT03250078||FAMILIAL PANCREATIC CANCER and/or GENE MUTATION|An inherited genetic syndrome associated with Pancreatic Cancer and/or with a strong family history of Pancreatic Cancer.
89321470|NCT03545542|Experimental|Neuroblastoma group|"10 children with neuroblastoma. Inclusion after verification of diagnosis and informed consent.~Sampling of fecal microbiome (Initial microbiome, microbiome under chemotherapy, final microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds, fecal volatile organic compounds under chemotherapy and final fecal volatile organic compounds) and breath organic volatile compounds (initial breath organic compounds, breath volatile organic compounds under chemotherapy and final breath volatile organic compounds).~Samples will be taken after verifying diagnosis before initiation of chemotherapy, 1 week after completion of each cycle and 3 weeks after the end of chemotherapy."
89321471|NCT03545542|Other|Control group|"10 children without gastro-intestinal or pulmonary disease as age and sex matched controls to the neuroblastoma group. Patients will be recruited from paediatric surgery. Inclusion after informed consent.~Sampling of fecal microbiome (initial fecal microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds) and breath organic volatile compounds (initial breath volatile organic compounds).~Samples will be taken as age and sex matched controls for the neuroblastoma group. Sampling will be done once after obtaining informed consent."
89321472|NCT00124943|Experimental|10 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 10 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesion) or balloon angioplasty (in-stent restenosis lesions).
89321473|NCT00124943|Experimental|22 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 22 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
89321474|NCT00124943|Experimental|35 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 35 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
89321475|NCT00124943|Experimental|45 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 45 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
89321476|NCT00124709|Experimental|1|Pimecrolimus
89321477|NCT00124709|Active Comparator|2|Corticosteroid
89321478|NCT01078181|Active Comparator|banded gastric bypass|Banded gastric bypass (circular anastomosis 21mm) using the A.M.I. B-Band (Soft Gastric Bypass Band)
89321479|NCT01078181|Active Comparator|non-banded gastric bypass|non-banded gastric bypass (circular anastomosis 21mm)
89321480|NCT01076699|Active Comparator|Group taking 0.075 mg RVX-100|This group is taking 0.075 mg RVX-100
89321481|NCT01076699|Active Comparator|Group taking 0.125 mg RVX-100|This group is taking 0.125 mg RVX-100
89321482|NCT01076699|Active Comparator|0.250 mg RVX-100|This group is taking 0.250 mg RVX-100
89321483|NCT01076699|Placebo Comparator|placebo|This group is taking a placebo
89321484|NCT01076777|Experimental|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
89321485|NCT01076777|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
89321486|NCT01076933|Experimental|rTMS|rTMS sessions
89321487|NCT01076933|Sham Comparator|control|sham rTMS (control)
89321488|NCT04139434|Experimental|Dose Escalation Phase: LP-108 monotherapy|"Three to 6 subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-108 on a once daily schedule for 28 days (a Cycle) starting at a dose of 100 mg."
89321489|NCT04139434|Experimental|Dose Expansion Phase: LP-108 in combination with azacitidine|"Three to 6 subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-108 on a once daily schedule for 28 days (a Cycle) starting at a dose of 100 mg in combination with azacitidine at 75 mg/m2."
89321490|NCT03134716||Clinical follow-up|Clinical follow-up of MS-patients for 5 years. PET imaging data with PK11195 and TMSX only in baseline and with UCB-J at 5 years
89321491|NCT03134716||Healthy controls|comparison of healthy controls' and MS patients' PET imaging data with PK11195 and TMSX only in baseline and with UCB-J at 5 years
89321492|NCT04133038||Children consulting|Children consulting in the expert center for food difficulties.
89321493|NCT04133038||Pierre Robin sequence|Children with Pierre Robin sequence following for food difficulties.
89321494|NCT04133038||Cardiac malformations|Children with cardiac malformations followed for food difficulties.
89321495|NCT04133038||Oesophageal atresia|Children with oesophageal atresia followed for food difficulties.
89321496|NCT04133038||Cleft lip and palate|Children with cleft lip and palate followed for food difficulties.
89321497|NCT04133038||Autism spectrum disorders|Children followed for congenital pathology that cause food difficulties.
89321498|NCT04133038||Ex-prematurity < 32 AG|Children born premature followed for food difficulties.
89321499|NCT04133038||Chromosomal anomalies|Children with chromosomal anomalies followed for food difficulties.
89321500|NCT02143258|Experimental|Neurointerventional|Stenting of the venous sinus is the neuro-interventional treatment that is being offered to patients with idiopathic intracranial hypertension that are refractory to medical management.
88806596|NCT05901727||Provider survey participants|HIV treatment providers eligible to be enrolled in the provider survey
89321501|NCT03058354||Group TIVA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
89321502|NCT03058354||Group GA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
89321503|NCT02933242|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy
89321504|NCT02143336|Experimental|Subcuticular suture|Subcuticular suture (absorbable) for skin closure
89321505|NCT02143336|Active Comparator|Skin staples|Standard skin staples for wound closure
89321506|NCT03545152|No Intervention|comparison group|No procedure conducted between the pre- and the post-test evaluations, and they received an abridged version of the training after the post-test session.
89321507|NCT03545152|Experimental|exercise group|The exercise program will include instructions on how to read the program, complete the activities, record their sessions, and exercise safely at first day. To promote incorporating exercising in their daily life routine during the 24-week period, we provided 2 group-based (5-8 participants with 2 instructors at community centers, 60' each) and one home-based (with the exercise program VCD and manual to bring home, 30') exercise program.
89321508|NCT03545152|Experimental|cognitive training group|Consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
89321509|NCT02254564||Positive Scrapings|Skin scrapings that are positive for scabies
89321510|NCT02254564||Negative Controls|collect negative controls from patients in whom tinea (superficial fungal infection) was clinically suspected. Samples from patients with demodex folliculitis (a mite that is commonly found in oil glands on the face) are also intended to be used as negative controls as well.
89321511|NCT03545074|Experimental|Mindfulness Spanish|The MAPs program was developed at UCLA (Winston & Smalley, 2010 and Lopez-Maya, 2016) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
89321512|NCT03545074|Experimental|Mindfulness English|The MAPs program was developed at UCLA (Winston & Smalley, 2010) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
89321513|NCT03545074|Active Comparator|Health Education Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
89321514|NCT03545074|Active Comparator|Health Education English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
89321515|NCT02143570|Experimental|Darifenacin + Physiotherapy|Patients allocated to this group will receive Darifenacin 7.5mg daily in addition to physiotherapy for 12 weeks. This dose may be increased up to 7.5mg twice daily in follow-up visits in cases of refractory symptoms.
89321516|NCT02143570|Active Comparator|Physiotherapy|Patients allocated to this arm will receive a tailored pelvic floor exercise programme in addition to a matching placebo pill.
89321517|NCT02780284|Experimental|Physical activity intervention|Subjects at higher risk of developing colorectal cancer will maintain the current level of activity during the first 4 weeks and exercise 150 minutes per week during the last 4 weeks. During the entire study, subjects will wear a Fitbit device on their wrist.
89321518|NCT05084482||Adult patients admitted to Intensive Care Unit (ICU)|Eligible patients are scored by E-PRE-DELIRIC at admission and PRE-DELIRIC 24 hours after admission.
89321519|NCT00108862|Experimental|Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of tuberculosis (TB) treatment.
89321520|NCT00108862|Active Comparator|Deferred ART|The intervention is the strategy of initiating ART after 8 to 12 weeks of TB treatment.
89321521|NCT02143804|Experimental|CG0070|oncolytic virus genetically modified to express GM-CSF
89321522|NCT03544996||TD Insulin Pilot|Test of novel transdermal insulin (TD Insulin) formulations
89321523|NCT00564850|Experimental|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|
89321524|NCT02143882|Experimental|LAIV|All children will receive LAIV, currently available as the marketed product Fluenz
89321525|NCT02143960|Active Comparator|Velashape III device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation
89321526|NCT02143960|Active Comparator|Noninvasive Cryolipolysis Device|A noninvasive device that reduces fat by freezing fat cells
89321527|NCT02144038|Experimental|Phase Ib: LGH447 + BYL719|Dose-escalation, LGH447 in combinatinon with BYL719
88806597|NCT05901727||Time and motion observation participants|HIV treatment providers eligible to be enrolled in the time and motion observation study
89321528|NCT02144038|Experimental|Phase II: LGH447 + BYL719|LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
89321529|NCT02144038|Experimental|Phase II: LGH447 alone|LGH447 alone (dosing according to single-agent RDE)
89321530|NCT00108628|Experimental|Arm 1|Imagery Rehearsal Therapy
89321531|NCT00108628|Active Comparator|Arm 2|Sleep and Nightmare Management
89321532|NCT02144116|Experimental|Experimental group|Patients with fibromyalgia included in a dance-movement therapy programme
89321533|NCT02144116|Active Comparator|Control group|Patients with fibromyalgia who receive a standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
89321534|NCT02715856|Active Comparator|Group I (standard follow up, physical activity measurement)|Patients undergo standard face-to-face follow up visits at 2, 6, 12, and 24 weeks after surgery. Patients also undergo a physical activity assessment over 15 minutes.
89321535|NCT02715856|Experimental|Group II (mobile surveillance)|Patients undergo standard face-to-face follow up visits as in Group I. Patients also undergo mobile surveillance comprising use of a mobile device application to send photos and videos to study staff and engage in video conferences at 3, 7, 13, and 25 weeks after surgery.
89321536|NCT02688166||Breast Cancer|Breast cancer patients who are undergoing internal mammary lymph node radiation
89321537|NCT02688166||Lung Cancer, thymic cancer or mesothelioma|"Non-surgical Stage III non-small cell lung cancer patients undergoing mediastinal nodal irradiation with curative intent using concurrent chemotherapy~Any lung cancer, thymic cancer or mesothelioma patient getting either chemoradiation or radiation alone wherein heart gets radiation exposure"
89321538|NCT02144194|Experimental|Maintenance treatment|"Initial treatment Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles~Followed by:~Oral Vinorelbine 60mg/m2 D1, D8 or 80mg/m2 D1, D8 (dose schedule at investigator's discretion) Every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue"
89321539|NCT02144194|Experimental|Observation arm|"Initial treatment: Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles~Patients in the observation arm will not be administered any treatment after Vinorelbine-Docetaxel"
89321540|NCT02140684||eNO monitoring|Patients undergoing eNO monitoring at the index prescription date
89321541|NCT02140684||No eNO monitoring|
89321542|NCT02140918|Experimental|Fludrocortisone 100 μg|"100 μg/day (25 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
89321543|NCT02140918|Experimental|Fludrocortisone 200 μg|"200 μg/day (50 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
89321544|NCT02140918|Experimental|Fludrocortisone 400 μg|"400 μg/day (100 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
89321545|NCT02140918|Placebo Comparator|Placebo|"Placebo (four times daily) during 5 days~Investigations the sixth day"
89321546|NCT00108160|Active Comparator|Mupirocin Ointment [Treatment]|Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
89321547|NCT00108160|Placebo Comparator|Polyethylene Glycol Ointment [Placebo]|Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
89321548|NCT02140996|Experimental|Ad-sig-hMUC-1/ecdCD40L vector vaccine|Experimental: Ad-sig-hMUC-1/ecdCD40L vector vaccine This trial has six cohorts with 3 subjects planned for each cohort. Subjects in the 1st cohort will receive 1 dose of vaccine injection at the lowest planned dose of the vector, 1 x 10^9 VP. If none of the patients in the 1st cohort experience Dose limiting toxicity (DLT), a 2nd cohort will receive 1 dose of 1x10^10 VP. If none of the patients in the 2nd cohort experience DLT, the dose escalation will continue with the 3rd cohort receiving 1 doses of 5 x 10^10 VP per injection. The patients in the 4th cohort will receive 1 injection of 1x10^11 if no DLT occurs in the preceding cohort. Additional patients will be added to cohort 5 or 6 if DLTs are encountered in the first 3 patients tested in each of these cohorts.
89321549|NCT03544528|Experimental|Regeneration|This treatment aims to regenerate pulp-like tissue within the root canal space after inducing an influx of stem cells from the apical papilla that results in reestablishment of pulp protective functions.
89321550|NCT03544528|No Intervention|Apexification|Traditional method. The application of Mineral Trioxide Aggregate (MTA) as an artificial apical barrier; also refer as the MTA apical plug method.
89321551|NCT02254174|Experimental|Tiotropium/Salmeterol|
89321552|NCT02254174|Active Comparator|Serevent® Diskus®|
89321553|NCT02254174|Active Comparator|Spiriva®|
89321554|NCT02254174|Active Comparator|Spiriva® and Serevent® Diskus®|
89321555|NCT02144272|Experimental|LY3114062 (SC)|LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg.
89321556|NCT02144272|Experimental|LY3114062 (IV)|LY3114062 given once intravenous (IV).
89321557|NCT02144272|Placebo Comparator|Placebo|Placebo (sodium chloride injection) given as a single SC dose.
89321558|NCT01366846|Experimental|Peanut avoidance after continuous peanut consumption|These participants were the peanut consumption group of the ITN032AD (LEAP) study
89321559|NCT01366846|Experimental|Continued peanut avoidance|These participants were the peanut avoidance group of the ITN032AD (LEAP) study
89321560|NCT02144350|Experimental|Intervention|patients will undergo daily hyperbaric oxygen sessions in addition to IV steroids for 10 days.
89321561|NCT02144350|Sham Comparator|Sham|Patients will undergo sham hyperbaric air sessions in addition to IV steroids for 10 days
89321562|NCT03752710||Acute primary angle closure|
89321563|NCT03752710||Acute secondary angle closure induced by LS|
89321564|NCT03752710||Cataract|
89321565|NCT03752710||Primary chronic angle closed glaucoma|
89321566|NCT03545230|Experimental|"children who recieved Four Not Techniques surgery"|":Four Not Techniques"
89321567|NCT02141152||gastric cancer|This study will recruit a total of 130 gastric cancer patients. It is expected to recruit about 250 gastric cancer patients per year. Since the incidence of each mutation is low, the different types of mutations are assumed to be mutually exclusive. So, about 30% of these patients are expected to have a mutation with a target drug. Overall response (OR) is the primary endpoint of this study. OR rate (ORR) will be compared between the group (called targeted group) of patients who have a mutation with a target drug and that (called untargeted group) of patients who have no mutation. The ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 gastric cancer patients, about 39 patients will belong to the targeted group and about 91 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 89% of power. The study on gastric cancer will take 7 months for patient accrual.
89321568|NCT02141152||colorectal cancer|This study will recruit a total of 130 colorectal cancer patients. It is expected to recruit about 300 colorectal cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The median ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 colorectal cancer patients, about 33 patients will belong to the targeted group and about 97 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on colorectal cancer will take about 6 months for accrual.
89321569|NCT02141152||biliary tract cancer/pancreatic cancer|This study will recruit a total of 78 biliary tract cancer/pancreatic cancer patients. It is expected to recruit about 100 biliary tract cancer/pancreatic cancer patients per year. About 20% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 35% for the targeted group and about 5% for the untargeted group. With N=78 biliary tract cancer/pancreatic cancer patients, about 16 patients will belong to the targeted group and about 62 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
89321570|NCT02141152||Rare cancer|Rare cancer is hepatocellular carcinoma, melanoma and neuroendocrine tumor. This study will recruit a total of 87 hepatocellular carcinoma/rare cancer patients. It is expected to recruit about 150 biliary tract cancer/pancreatic cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 30% for the targeted group and about 5% for the untargeted group. With N=87 biliary tract cancer/pancreatic cancer patients, about 22 patients will belong to the targeted group and about 65 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 86% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
89321571|NCT02141152||genitourinary cancer|
89321572|NCT02141230|Experimental|Alli® 60 mg|Participants purchasing Alli®
89321573|NCT02141386|Experimental|Treatment A|plasticity-based, adaptive, computerized cognitive remediation (PACR)
89321574|NCT02141386|Active Comparator|Treatment B|"Ordinary Computer Games (an active control condition)"
89321575|NCT02144428||Cow's milk allergy|Subjcets with a sure diagnosis of cow'a milk allergy on exclusion diet
89321576|NCT02314702||Revision Total Hip Arthroplasty|Single study group previously implanted with a PROFEMUR® L Revision Femoral Stem
89321577|NCT02144506|Experimental|T&E|"Home-based exercises program T&E.This exercise program proposes 50 exercises with a booklet, cards and an electronic tablet. The participants choose their exercises on the basis of a rating scale of perception of exercise difficulty."
89321578|NCT02144506|Active Comparator|OTAGO|"Programm OTAGO is a home-based exercises program."
89321579|NCT02165410|Experimental|Eye tracking and RMI|
89321580|NCT00108082|Experimental|Carvedilol CR|Carvedilol controlled release (CR) 20 to 80 mg once daily (OD) plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study. (In the protocol, carvedilol CR was referred to as carvedilol modified-release [MR].)
89321581|NCT00108082|Experimental|Atenolol|Atenolol 50 to 100 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
89321582|NCT00108082|Experimental|Lisinopril|Lisinopril 10 to 40 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
89321583|NCT02144662|Experimental|Ranibizumab|Ranibizumab
89321584|NCT02141698|Experimental|Cohort 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
89321585|NCT02141698|Experimental|Cohort 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
89321586|NCT02141698|Experimental|Cohort 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
89321587|NCT02141698|Experimental|Cohort 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
89321588|NCT02141698|Experimental|Cohort 5: TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once on Day 1.
89321589|NCT02141698|Experimental|Cohort 6: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
89321590|NCT02141698|Experimental|Cohort 7: TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once on Day 1.
89321591|NCT02141698|Experimental|Cohort 8A: Food-effect|TAK-438 20 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
89321592|NCT02141698|Experimental|Cohort 8B: Food-effect|TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 1.
89321593|NCT02141698|Experimental|Cohort 9: TAK-438 Multiple Dose 1|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
89321594|NCT02141698|Experimental|Cohort 10: TAK-438 Multiple Dose 2|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
89321595|NCT02141698|Experimental|Cohort 11: TAK-438 Multiple Dose 3|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
89321596|NCT02141698|Experimental|Cohort 12: Ethnic Bridging|TAK-438 tablets, dose 1, orally, on Days 1-7 of Period 1, followed by a 4-week washout period followed by TAK-438 tablets, dose 2, orally, Days 1-7 of Period 2, followed by a 4-week washout period, followed by esomeprazole tablets, 40 mg, orally, on Days 1-7 of Period 3. TAK-438 doses to be determined from data collected in Cohorts 9-11.
89321597|NCT02141698|Placebo Comparator|Cohorts 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1
89321598|NCT02141698|Placebo Comparator|Cohorts 9-11: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, where available, if required.
89321599|NCT02144740|Other|NWT-03, then placebo|4 weeks 2g NWT-03 followed by placebo , separated by a 4wk wash-out period
89321600|NCT02144740|Other|Placebo, then NWT-03|4 weeks placebo followed by 2g NWT-03, separated by a 4wk wash-out period
89321601|NCT03544450|Experimental|Psychosocial counselling + Enhanced usual care (EUC)|This arm receives psychosocial counselling from the counsellor as well as enhanced usual care from health worker
89321602|NCT03544450|Active Comparator|Enhanced Usual Care (EUC)|This arm receives enhanced usual care from health worker
89321603|NCT02141776|Sham Comparator|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
89321604|NCT02141776|Active Comparator|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
89321605|NCT02147782||control|Healthy people from physical examination centers are recruited as controls.
89321606|NCT02147782||CKD1|"with clinical one or more symptoms and signs of kidney injury listed as below：~Urinary albumin ( urinary albumin excretion rate≥30 mg/24 h.albumin-creatinine ratio≥3mg/mmol)~urinary sediments abnormality~renal tubular lesions~renal histological abnormalities~abnormal structure showed by imaging~history of renal transplantation~GFR≥90（ml/min/1.73m²)"
89321607|NCT02147782||CKD2|with clinical symptoms and signs of kidney injury, and 60<=GFR<=89（ml/min/1.73m²)
89321608|NCT02147782||CKD3|with clinical symptoms and signs of kidney injury, and 30<=GFR<=59（ml/min/1.73m²)
89321609|NCT02147782||CKD4|with clinical symptoms and signs of kidney injury, and 15<=GFR<=29（ml/min/1.73m²)
89321610|NCT02147782||CKD5|with clinical symptoms and signs of kidney injury, and GFR<15（ml/min/1.73m²)
89321611|NCT02147860|Placebo Comparator|Sensor Augmented Pump Therapy|Each camp participant will be randomized to full day and night CLC or sensor augmented pump therapy for up to 7 days/6 nights. The subject will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
89321612|NCT02147860|Experimental|Diabetes Assistant (DiAs) with USS Virginia|"With the use of the UVA Artificial Pancreas (DiAs), the study will assess safety and feasibility and are not powered for statistical significance. These studies are intended to train staff on system function and obtain data regarding safe and feasible system use.~Camp participants will be randomized to either closed-loop control using the DiAs or sensor-augmented pump therapy only. These studies would generate up to 120 days of closed-loop data and 120 comparable days of open-loop data."
89321613|NCT02144818|Active Comparator|GnRH agonist|
89321614|NCT02144818|Active Comparator|hCG|
89321615|NCT02144818|Active Comparator|dual triggering: GnRH agonist and hCG|
89321616|NCT02147938||1: early conversion from Prograf® to Advagraf®|patients converted during the first 6 months post-transplantation
89321617|NCT02147938||2: late conversion from Prograf® to Advagraf®|patients converted between 6 and 12 months post-transplantation
89321618|NCT02148016|Experimental|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
89321619|NCT02148016|Active Comparator|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
89321620|NCT02148016|Experimental|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
89321621|NCT02148016|Active Comparator|PRK only (Traditional Technique)|PRK alone will be performed.
89321622|NCT03543982|Experimental|Oral probiotic product|
89321623|NCT02148094|Experimental|Truvada|Participants will be initiated on PrEP and asked to select one of two PrEP delivery options. Participants will return to the study site every three months for an additional follow-up visit. At follow-up visits, participants will receive HIV testing and counselling, pregnancy testing, syndromic screening for STIs, and clinical diagnosis of adverse events. Those who test HIV-positive will be discontinued on PrEP, exited from the study and referred for HIV care and treatment. Those who have an adverse event will be clinically evaluated to determine whether they should suspend PrEP use and will be provided with the appropriate management for the adverse event. Participants who test HIV-negative will receive patient-centred counselling around PrEP.
89321624|NCT02148172|Active Comparator|Standard Plyometric Training|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice delivered at a standard dosage of sets and repetitions.
89321625|NCT02148172|Experimental|Plyometric Training with BWS|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice with a treatment volume of sets and repetitions that exceeds standard practice. Higher number of practice trials will be completed with body weight support (BWS) to reduce load. Participants will start at 30 percent of body weight and will be slowly weaned away over time.
89321626|NCT03543904|Experimental|Pre-operative physiotherapy education|Pre-operative education regarding post-operative physiotherapy intervention and post-operative physiotherapy intervention in children with abdominal surgery
89321627|NCT03543904|Experimental|Post-OP PT without Pre-OP education|Post-operative physiotherapy intervention without pre-operative education in children with abdominal surgery
89321628|NCT02148328|Experimental|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly (injection of a substance into a muscle) on Day 1 in healthy participants.
89321629|NCT02148328|Active Comparator|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
89321630|NCT02148328|Experimental|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
89321631|NCT02148328|Active Comparator|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
89321632|NCT03544918||Patients with long QT syndrome.|Patents with Long QT syndrome hospitilized. To be followed over time with no intervention. Observational study.
89321633|NCT03544918||Patients in Telemark with normal QT time|Patients in Telemark with normal QT time. To be followed over time with no intervention. Observational study.
89321634|NCT03544840|Experimental|Dynamic Standing Device|Home program using the Upsee
89321635|NCT03544762|Experimental|18F-FES PET|PET/CT
89321636|NCT02142010|Other|paclitaxel liposome injection plus cisplatin|
89321637|NCT02142088|Other|Glucose Monitoring|Each patient will undergo simultaneous Glucose monitoring with 2 devices. One is GlySure's intervascular continuous measurement sensor (test device) introduced through a CVC, and the other measures glucose intermittently from repeated venous blood samples drawn through an indwelling ventflon style catheter
89321638|NCT02142166|Experimental|SAB analysis|"Patients with acute aneurysmal SAH, confirmed by CT or MRI, or lumbar puncture~Daily (21 days) analysis of Biomarker in serum, in liquor and in micro-dialysate"
89321639|NCT02142166|Experimental|Control|"Patients who undergo a lumbar puncture for myelography as part of the investigation of a cervical or lumbar foraminal stenosis without cranial or myeläre pathology -or- Patients who receive perioperative prophylactic lumbar drainage without cranial or myeläre pathology~Single analysis of Biomarker in serum and liquor"
89321640|NCT02144896|Experimental|Ankle splinting|Older adults will have one leg randomly assigned to ankle splinting for 4 weeks. The non-splinted leg will serve as the control.
89321641|NCT02144896|No Intervention|No Ankle Splinting|The non splinted leg will serve as the control
89321642|NCT02148406|Experimental|Arm I (YST intervention)|Patients undergo YST intervention comprising four individualized, 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation during outpatient chemotherapy sessions in weeks 2, 4, 6, and 8. Patients practice awareness - noticing the current state and establishing relaxed breathing for 5 minutes; movement - 7 minutes of gentle movements coordinated with the breath (such as raising and lowering the arms); breathing practice - 3 minutes of inhaling cool air as if through a straw; and meditation - 5 minutes of focus on letting go of physical and mental tension. Patients review a handout describing the YST and to encourage patients to practice daily with strategies to increase adherence to home practice. Patients also receive an audio recording of the YST and devices to play the recording and are asked to keep a home practice log.
89321643|NCT02148406|Active Comparator|Arm II (attention control)|Patients attend four 30-minute sessions with an interventionist in weeks 2, 4, 6, and 8. During these sessions, patients are encouraged to discuss their experiences while receiving chemotherapy and do not receive instruction of movement, meditation or breathing practices. Patients will also be asked to write brief diary entries daily at home.
89321644|NCT02144974||Patients undergoing total pelvic exenteration|Patients undergoing total pelvic exenteration for gynecological malignancies and reconstruction of the pelvic floor with a TMG flap.
89321645|NCT02142244|Experimental|Near infra red sentinel node biopsy|Sentinel node biopsy adding indocyanine green injection at the tumor/biopsy site during the surgical procedure to the standard technique (blue die and lymph scintigraphy) and near infra red light for fluorescence. The indocyanine green saline solution - 5mg diluted in 10ml. will be injected in 4 points around the biopsy site - 4ml each - total 0.8mg - single procedure.Near infra red lens and camera will be used to detect the fluorescence and localize the sentinel node for biopsy.
89321646|NCT02145052|Active Comparator|Continuous suture|0 non-looped PDS using a tapered needle starting at the superior and the inferior portions of the wound. Fascia is then approximated with at least 1cm distance from the edge of the fascia and 1cm advancement. The two sutures are then knotted in the center with 8 square knots.
89321647|NCT02145052|Active Comparator|Interrupted Suture|Using a tapered needle, 0 non-looped PDS interrupted figure of eight suture 1cm from the edge and advancing 1cm between each suture.
89321648|NCT02142400|Experimental|DS-1093|Group 1 will receive 10mg, group 2 will receive 25mg of DS-1093
89321649|NCT02142400|Placebo Comparator|placebo|placebo to match DS-1093 dosage
89321650|NCT02142478||Adapted scheme|Participants referred by their GP practices to Centre A will take part in the Adapted Exercise for Health (EFH) scheme.
89321651|NCT02142478||Standard scheme|Participants referred by their GP practices to Centre B will take part in the Standard Exercise for Health (EFH) scheme.
89321652|NCT02148484|Experimental|1|Prolonged exposure for adolescents
89321653|NCT02148484|Active Comparator|2|Client centered therapy
89321654|NCT02148562||Chronic Hepatitis B|Diagnosis of Hepatitis B related liver disease in a pre-advanced stage
89321655|NCT02148562||End stage liver disease|Diagnosis of advanced liver disease related to Hepatitis B
89321656|NCT03543826|Other|Subjects undergoing orthopedic or abdominal surgery|Subjects undergoing orthopedic or abdominal surgery requiring neuromuscular blockade. Subjects all receive the neuromuscular blockade drug Rocuronium based on study protocol. Depending on depth of block (subjectively assessed by TOF response), Neostigmine, Sugammadex, or no reversal drug is used to reverse block prior to extubation.
89321657|NCT03543748|Experimental|TMS|The Transcranial Magnetic Stimulation course consisted of daily sessions of 2,000 stimuli for the left DLPFC (50 trains of 40 stimuli at 10 Hz for 10 days),
89321658|NCT03543748|Sham Comparator|SHAM|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
89321659|NCT02148640|Experimental|CT-P13|Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)
89321660|NCT02148640|Active Comparator|INX|Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion
89321661|NCT02142556|Experimental|Quetiapine XR|Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR.
89321662|NCT02145130|Experimental|denovoDerm|Autologous tissue-engineered dermal substitute
89321663|NCT02145130|Experimental|denovoSkin|Autologous tissue-engineered dermo-epidermal skin substitute
89321664|NCT02145286|Experimental|Radiation Therapy|Stereotactic Body Radiation Therapy
89321665|NCT02142634|Experimental|A|Budesonide granules 9 mg
89321666|NCT02142634|Placebo Comparator|B|Placebo granules
89321667|NCT02145442|Experimental|Obex|Obex®, two oral sachets daily during three months.
89321668|NCT02254798||Transplanted patients|No intervention Prospective registration of patients receiving an allogeneic hematopoietic stem cell transplant
89321669|NCT02142790|Experimental|paclitaxel liposome injection weekly|paclitaxel liposome injection 100mg/m2 administered by intravenous on day1 and day8 of a 21-day cycle for at least 4cycles or till progression or intolerable
89321670|NCT02142790|Experimental|paclitaxel liposome injection every 3 weeks|paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a 21-day cycle for at least 4cycles or till progression or intolerable
89321671|NCT02145520|Experimental|Magnesium sulfate|Magnesium sulfate. Single dose intravenous over one hour.
89321672|NCT02145520|Placebo Comparator|placebo|"Treatment will be delivered to enrolled patients as currently practice in PEC (Epinephrine nebulization +5%hypertonic saline with/without dexamethasone).~•All patients will be randomized to receive either Magnesium sulfate over 1 hour or placebo.•Bronchiolitis severity score (BSS) will be recorded at 0, 4, 8, 12, 16,20,24,36,48,60,72 hours, and on discharge."
89321673|NCT02145598|Experimental|Lenalidomide|Lenalidomide 10mg/day
89321674|NCT02145598|Placebo Comparator|Placebo|Placebo
89321675|NCT02145832|Experimental|Fluconazole|"Fluconazole Kabi, Fresenius 2mg/ml~Fluconazole will be administered at a loading dose of 25 mg/kg on the first day and followed by a maintenance dose of 12 mg/kg or 20 mg/kg once daily, depending of corrected gestational age (GA) at the beginning of treatment:~12 mg/kg/day for neonates corrected GA (GA + postnatal age) < 30 weeks~20 mg/kg/day for neonates corrected GA (GA + postnatal age) ≥ 30 weeks~The infusion will last two hours."
89321676|NCT02145832|Experimental|Micafungin|"Mycamine 50mg - 10 mg/mL of micafungin~Micafungin will be administered as a loading dose of 15 mg/kg on the first day of treatment and followed by a maintenance dose of 10 mg/kg once daily.~The infusion will last two hours."
89321677|NCT02149030|Active Comparator|A1|A1) Cytological screening in A1 and A3. Frequent information of screening results for cytology and/or HPV DNA at the ages of 22 (cytology only), 25 and 30.
89321678|NCT02149030|No Intervention|A2|A2) infrequent information of screening results, only at the age 30 years.
89321679|NCT02149030|Other|A3|A3) Cytological screening in A1 and A3. With at least 1000 participants is enrolled for interim safety analysis when the 1992 birth cohort is 25 years of age and cytology results are being revealed.
89321680|NCT02149186|Experimental|Rehabilitation|
89321681|NCT00104728|Experimental|Neoadjuvant ZD1839 Preoperative Therapy|"The ZD1839 250-mg tablet will be taken once a day, every day about the same time. It can be taken with or without food.~At the time of surgery, investigators will collect tissue from the participant's tumor once it has been removed. This tissue will be used to study the effect of ZD1839 on tumor growth."
89321682|NCT02145910|Experimental|WBRT + Vemurafenib|Patients undergo WBRT once daily (QD) for 10 doses
89321683|NCT02145910|Experimental|SRS + Vemurafenib|Patients undergo SRS (gamma knife, tomotherapy, cyberknife, or megavoltage LINAC radiation therapy) on day 1
89321684|NCT02145988|Experimental|DLBS1033|DLBS1033 tablet is administered at the dose of 490 mg, one tablet three times daily, every day for twelve weeks of study period
89321685|NCT02145988|Placebo Comparator|Placebo|Placebo tablet is administered one tablet three times daily, every day for twelve weeks of study period
89321686|NCT02781844|Experimental|A/B or B/A|Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2
89321687|NCT02781844|Experimental|C/B or B/C|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2
89321688|NCT02781844|Experimental|D/E or E/D|Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2
89321689|NCT02781844|Experimental|F/E or E/F|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2
89321690|NCT03544684|Experimental|Control day with no exercise|glycaemic profile will be assessed using continuous glucose monitors following a single 24-hour period in which participants performed no exercise
89321691|NCT03544684|Experimental|High intensity interval training (HIT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of high-intensity interval training (HIT) in the morning under fasted conditions
89321692|NCT03544684|Experimental|moderate intensity continuous training (MICT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of moderate-intensity continuous training (MICT) in the morning under fasted conditions
89321693|NCT03544294||Group|Consecutive patients treated with very thin stents on ULM and bifurcation
89321694|NCT02146222|Experimental|Arm I (high dose X-82, docetaxel)|Patients receive high dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15. Beginning course 2, patients also receive docetaxel IV over 60 minutes on day 1.
89321695|NCT02146222|Experimental|Arm II (low dose X-82, docetaxel)|Patients receive low dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15 and docetaxel IV as in Arm I.
89321696|NCT02151370||Cohort|
89321697|NCT03741322||Infants ages 3-24 months with respiratory infections|
89321698|NCT02146300|Experimental|Allergen and xylometatsolin|Two separate exposure sessions: 1) nasal birch pollen exposure 2) nasal xylometazoline exposure
89321699|NCT02146456|No Intervention|Colloid|During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.
89321700|NCT02146456|Experimental|Tranexamic acid|"During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.~In addition, 1 g of tranexamic acid in 100 ml normal saline is administered intravenously over 30 min after finishing the procedure of hip implant insertion."
89321701|NCT02151760|Experimental|18F-DCFPyL|
89321702|NCT02146534|Experimental|fampridine|extended release fampridine 10mg BID PO for 14 weeks
89321703|NCT02146534|Placebo Comparator|placebo|placebo pill BID PO for 14 weeks
89321704|NCT02151916|Experimental|Dental care, AG, MI & fluoride varnish|The intervention comprises four components; provision of dental care to the mother during pregnancy (2nd trimester), preventive treatment with fluoride varnish to the teeth of children, and two behavioral interventions, namely oral health anticipatory guidance and motivational interviewing with the caregiver/mother.
89321705|NCT02151916|Other|Delayed intervention|Three fluoride varnish applications to the teeth of children and oral health anticipatory guidance and motivational interviewing for the caregiver when the child is aged 24, 30 and 36 months. Dental care also will be offered to the mothers/caregivers in the delayed intervention group when their children are aged 2 to 3 years old. Before the children are aged 2 years, standard dental care will be the comparator, which usually involves provision of dental care only if the participant is in pain.
89321706|NCT02146612||Group Receiving Supplement|Amino acid supplement group
89321707|NCT02146690|Other|osteopathic manipulative treatment|newborns will receive osteopathic manipulative evaluation and treatment during the entire period of hospitalization plus usual care
89321708|NCT02146690|Other|sham|newborns will receive sham treatment for the entire period of hospitalization plus usual care
89321709|NCT02146690|Other|usual care|newborns allocated in the usual care arm will receive standard care only
89321710|NCT02152072||medical students|
89321711|NCT02146846||Imatinib, CML|Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study
89321712|NCT02152150|Experimental|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content)
89321713|NCT02152150|Active Comparator|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content)
89321714|NCT02152228|Experimental|Oral Parathyroid Hormone (1-34)|Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)
89321715|NCT02147002|Active Comparator|omega 3 acids 1|Patients with CKD stage I (GFR 90 and more ml/min/1,73 m2)
89321716|NCT02147002|Active Comparator|omega 3 acids 2|Patients with CKD stage II (GFR 80-89 ml/min/1,73 m2)
89321717|NCT02147002|Active Comparator|omega 3 acids 3|Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2)
89321718|NCT02147002|Active Comparator|omega 3 acids 4|Patients without diabetes mellitus, hypertensions,CKD with normal level of creatinine in serum
89321719|NCT02152306|Experimental|Fimasartan and Amlodipine|Combination of Fimasartan and Amlodipine
89321720|NCT02152306|Active Comparator|Fimasartan|Fimasartan Monotherapy
89321721|NCT02261116|Experimental|Telmisartan|
89321722|NCT02261116|Active Comparator|Candesartan|
89321723|NCT02261116|Placebo Comparator|Placebo|
89321724|NCT02254720|Experimental|BEA 2180 BR IV|Rising doses
89321725|NCT02254720|Placebo Comparator|Placebo|
89321726|NCT02254720|Experimental|BEA 2180 BR inhalation|
89321727|NCT02152462|Other|Exergaming|Exercise Intervention: Participants in the Wii Fit exergaming group will have a goal of 150 min/wk of moderate intensity exercise for the last 5 mo of the 6 mo intervention. Heart rate (HR) monitors will quantify exercise intensity. Participants will exercise at a HR equal to 45-65% of their VO2max. Participants will be instructed by the exercise physiologist on how to achieve the required HR. The training will consist of 3 days/wk of supervised Wii Fit physical activity. Exercise duration will increase gradually from 75 to 150 min/wk by wk 477. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. Participants will complete daily exercise diaries recording the type and duration of physical activity, and HR.
89321728|NCT02152462|No Intervention|Control|Control Group: After baseline testing the control group will be asked to maintain their current daily activities for the duration of the study. The control group will have the option to exercise at the Wii Fit stations following their completion of the study. They will receive the same measures as the exercise group.
89321729|NCT02147080|Experimental|Tailored Intervention|Subject has access to the tailored web intervention
89321730|NCT02147080|Active Comparator|Skin Cancer Foundation Website|Subject has access to the pre-existing Skin Cancer Foundation website
89321731|NCT02147080|No Intervention|Assessment Only Condition|Subjects will only complete assessments
89321732|NCT03542968|Experimental|4D magnetic resonance imaging|MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).
89321733|NCT03542968|Sham Comparator|2D magnetic resonance imaging|MRI, 2D imaging, acquisition and analysis of 2D cardiac MRI
88806598|NCT05901727||HIV testing survey participants|Individuals presenting for HIV testing eligible to be enrolled in the HIV testing survey
89321734|NCT02152618|Experimental|Treatment|
89321735|NCT02152618|No Intervention|Comparison|
89321736|NCT02147470|Other|prerenal AKi, acute tubular necrosis and hepatorenal syndrome|All subjects will undergo CEUS with the use of Definity to measure renal blood flow. At the same time clinical tools (urine output, response to volume expansion, urine sodium, urine output, fractional excretion of sodium and urea and urine microscopy) will be used to differentiate between prerenal AKI, ATN and HRS. the quantity and patterns of RBF measured by CEUS will be compared between these three groups.
89321737|NCT02152774|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
89321738|NCT02152774|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
89321739|NCT02147548|Experimental|etifoxine (Anxiolytic)|etifoxine, 100 mg, a single oral intake
89321740|NCT02147548|Active Comparator|lorazepam|lorazepam, 2 mg, a single oral intake
89321741|NCT02147548|Placebo Comparator|Placebo|2 capsules of Placebo, a single oral intake
89321742|NCT02152852|Experimental|Community Health Worker Intervention|Community Health Worker Intervention-home visits from community health workers providing education and support for self-management of type 2 diabetes, resources for diabetes control, and assistance in effective communication with medical providers
89321743|NCT02152852|No Intervention|Usual Care Control Group|Usual Care Control Group- Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support diabetes self-management (such as classes and support groups) and educational pamphlets.
89321744|NCT02152930|Active Comparator|Supervised Exercise Therapy|Standard treatment: Supervised Exercise Therapy during 12 weeks
89321745|NCT02152930|No Intervention|Controlled group|
89321746|NCT02147704|Other|Goup I|Group I: Fimasartan 60 mg in a low-sodium intake period --> Fimasartan 60 mg in a high-sodium intake period
89321747|NCT02147704|Other|Group II|Group II: Fimasartan 60 mg in a high-sodium intake period --> Fimasartan 60 mg in a low-sodium intake period
89321748|NCT02775916|Experimental|CDZ173|Capsule
89321749|NCT02775916|Placebo Comparator|Placebo|Capsule matching Placebo
89321750|NCT02153008||Symptomatic population for GAS|This study is a diagnostic study to aid in the detection of Strep throat. No intervention or medication is a part of this study.
89321751|NCT02155582|Experimental|Arm 1|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients
89321752|NCT02155582|Experimental|Arm 2|45 mg and 60 mg for the diabetic patients
89321753|NCT03739918||patients with adrenal masses|patients with adrenal mass managed by adrenalectomy
89321754|NCT02155816|Placebo Comparator|Placebo|MCT (medium chain triglyceride)
89321755|NCT02155816|Experimental|Omega 3|Omega-3 fatty acid ethyl esters, 2 soft gels of total 1000mg (660mg EPA +340mg DHA)/day.
89321756|NCT02155816|Experimental|Omega 7 + 3|210mg of Omega-7 fatty acid and 1000mg (660mg EPA +340mg DHA) of Omega-3
89321757|NCT03542890||Baska Mask|It has a non-inflatable cuff, which is moulded to take up the shape of the supraglottic airway, potentially reducing the risk of oropharyngeal tissue and/or nerve damage induced by cuff over inflation, a known complication with other supraglottic airways.
89321758|NCT03542890||I-gel|The I-gel is a single use (SADs) composed of a soft ,gel-like, non-inflatable cuff made from a thermoplastic elastomer. It has a widened , flattened stem with a rigid bite block that acts as a buccal stabilizer to reduce axial rotation and mal-positioning and a port for gastric tube insertion. It is a latex free device that does not require digital insertion into mouth of patient.
89321759|NCT02153242||Supra Ventricular Tachycardia (SVT)|Patients undergoing SVT studies
89321760|NCT02155894|Experimental|Disease control, Telemedicine, doctor|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a doctor at week 13, 26, 39.
89321761|NCT02155894|Experimental|Disease control, Telemedicine, nurse|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a nurse at week 13, 26, 39.
89321762|NCT02155894|No Intervention|Usual care|Usual care: control of disease activity with consultations in the outpatient clinic.
89321763|NCT02153320|Experimental|HBsAg + adjuvant 1 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 1 in study 287615 (NCT00508833).
89321764|NCT02153320|Experimental|HBsAg + adjuvant 2 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 2 in study 287615 (NCT00508833).
89321765|NCT02153320|Experimental|HBsAg + adjuvant 3 Group|Single blood sample taken from subjects who had received GSK candidate vaccines containing HBsAg together with an adjuvant 3 in study 287615 (NCT00508833).
89321766|NCT00122681|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.
89321767|NCT00122681|Active Comparator|Havrix Group|Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrix™-based investigational formulation) at Months 0, 1 and 6.
89321768|NCT02774278|Experimental|Erlotinib|Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.
89321769|NCT02155972|Active Comparator|Bifidobacterium infantis|Bifidobacterium infantis (Align) 10.00 million cfu capsule once daily
89321770|NCT02155972|Placebo Comparator|Placebo|Placebo capsule once daily
89321771|NCT02153554|Experimental|Trained|Training civil servants in Medellin (Colombia) on attention to violence against women.
89321772|NCT02153554|No Intervention|Non trained|
89321773|NCT02156050|Active Comparator|OBLOO device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
89321774|NCT02156050|Experimental|BBLOO Device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
89321775|NCT03733275|Experimental|local anesthetic group|local aensthetic group receive preopetaive lidocaine spray and lidocaine-bupivacine mixture-soaked nasal pacing after nasal reduction surgery
89321776|NCT03733275|Placebo Comparator|control group|control group receive preoperative normal saline spray and normal saline-soaked nasal packing after nasal reduction surgery
89321777|NCT02255188||Graft type - PCL|PCL - polycaprolactone
89321778|NCT02255188||Graft type - PCL/ gelatin|polycaprolactone/ gelatin/poorly permeable layer;
89321779|NCT02255188||Graft type - PLGA/PCL/gelatin|PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer
89321780|NCT02255188||Graft type - nylon 6|
89321781|NCT03542422|Experimental|Apatinib|Apatinib 500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
89321782|NCT01077011|Experimental|Lubricant eye drop|Lubricant eye drop
89321783|NCT01077011|Active Comparator|GenTeal Gel|GenTeal Gel
89321784|NCT02153866|Placebo Comparator|rotavirus|vaccinate one dose rotavirus vaccine for each of 700 participants aged 8~9months
89321785|NCT02153866|Placebo Comparator|measles-rubella|vaccinate one dose measles-rubella vaccine for each of 350 participants aged 8~9 months.
89321786|NCT02153866|Placebo Comparator|measles-mumps-rubella|vaccinate one dose measles-mumps-rubella vaccine for each of 350 participants aged 8~9 months.
89321787|NCT02153866|Experimental|rotavirus, measles-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-rubella vaccine for each of 700 participants aged 8~9 months.
89321788|NCT02153866|Experimental|rotavirus, measles-mumps-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-mumps-rubella vaccine for each of 700 participants aged 8~9 months.
89321789|NCT00122135|No Intervention|Patients without Values Inventory (VI)|Clinic encounter w/physician & patient and/or surrogate - Patients who did not receive the VI prior to their physician clinic encounter
89321790|NCT00122135|Experimental|Patients with Values Inventory (VI)|Clinic encounter w/physician & patient and/or surrogate - Patients who completed the VI prior to their physician clinic encounter
89321791|NCT02156128|Experimental|Cogmed|Participants in a 3,5 week vocational rehabilitation program (containing cognitive therapy and physical exercise) are instructed to use a computer-based working memory training program (named CogMed) each weekday (5 days a week) for 5 weeks. Each training session consists of 8 different tasks and lasts 40-50 minutes.
89321792|NCT02156128|Active Comparator|Control group|These subjects will participate in the vocational rehabilitation program for 3,5 weeks. The program includes cognitive therapy (ACT) and physical activity, but no working memory training.
89321793|NCT03645057|Experimental|Crisaborole|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
89321794|NCT03645057|Active Comparator|Tacrolimus 0.03%|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
89321795|NCT04863430|Experimental|Apatinib with chemotherapy|Apatinib with oxaliplatin and S-1 treatment
89321796|NCT02156206||123 women line|Women who call the 123 emergency line and have also immediate services from the 123 women emergency line
89321797|NCT02156206||No treatment|Women who call the 123 emergency line and do not have immediate services from the 123 women emergency line
89321798|NCT00132041|Other|All Patients|patients with cirrhosis undergoing solitary or repetitive percutaneous RFA treatment sessions for the treatment of HCC.
89321799|NCT05665881|Experimental|Ephedrine|Ephedrine group: receive ephedrine (configured concentration 2 mg/mL). The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
89321800|NCT05665881|Experimental|Phenylephrine|Phenylephrine group: receive intravenous infusion of phenylephrine (configured concentration 0.1 mg/mL) The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
89321801|NCT05665881|Experimental|norepinephrine|norepinephrine group: intravenous infusion of norepinephrine (configured concentration of 6 μg/ml).The individualized blood pressure control target was a 20% increase in baseline blood pressure, and the target blood pressure value was used as the basis for adjusting the dosing or pumping rate.
89321802|NCT02154100|Experimental|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
89321803|NCT02154100|Placebo Comparator|Placebo|12 weeks tart cherry juice taken in two doses of 240 ml per day.
89321804|NCT03730077|Experimental|18F-MISO PET/CT Test Retest|Up to 5 of the 30 intended subjects will participate in a test-retest group that will undergo a second 18F-FMISO scan. Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
89321805|NCT03730077|Experimental|18F-MISO PET/CT|The investigators anticipate enrolling up to 30 subjects who will undergo 18F-FMISO PET/CT.Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
89321806|NCT01582841|Experimental|MSI testing|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI following surgery. Those with MSI-H results will receive a genetic counseling informational call.
89321807|NCT01582841|No Intervention|Usual care|These patients will be treated as usual by their oncologist and medical team. These patients receive a follow up letter a year after randomization, alerting them to the availability of clinical Lynch Syndrome screening.
89321808|NCT03729921|Active Comparator|gastric variceal obturation|gastric variceal obturation
89321809|NCT03729921|Experimental|gastric variceal ligation|gastric variceal ligation
89321810|NCT02156284|Experimental|Empathic behaviour by nurses|Patients who received empathic behaviour was performed by a trained nurse.
89321811|NCT01077089||Transported TBI patients|Traumatically brain injured patients undergoing in-hospital transport.
89321812|NCT02154178|Experimental|Biomarker group|"Intervention group, in which the duration of empirical antifungal therapy will be based on the results of biomarkers.~Biomarker group"
89321813|NCT02154178|No Intervention|Control group|Control group, in which the duration of empirical antifungal therapy will be based on international recommendations (14 days).
89321814|NCT01078649|Experimental|Debio 1143 (AT-406)|Open label study. All patients participating in the study will receive Debio 1143 (AT-406).
89321815|NCT02154256|Experimental|Increasing incentives|The investigators will offer incentives to users that begin low, and get higher over time.
89321816|NCT02154256|Experimental|Decreasing incentives|The investigators will offer incentives to users that start high, and decrease over time.
89321817|NCT02154256|Experimental|Stable incentives|The investigators will offer incentives that stay stable over time.
89321818|NCT02154256|No Intervention|Usual care control|The investigators will offer incentives that are identical to the incentives normally offered by the investigators' partner company.
89321819|NCT03965663|Experimental|Trans-tibial Amputees|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living
89321820|NCT03965663|Experimental|Trans-tibial Amputees with TSR|Unilateral Trans-tibial Amputees that use vibro-tactile feedback for six months in daily living. The subjects underwent a functional nerv-transfer surgery prior to participation, where the proximal part of the sural nerv was to the distal part of the saphenous nerv.
89321821|NCT02156362|Other|follow up|
89321822|NCT03643575|Experimental|Treatment A: Vicks Cough Syrup for Chesty Coughs|Vicks Cough immediate-release (IR) syrup 15 mL (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
89321823|NCT03643575|Experimental|Treatment B: Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 ml (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
89321824|NCT03643575|Experimental|Treatment C: Organ-I- NR tablet|Organ-I- NR 200 mg guaifenesin tablet every 4 hours x 3 doses with 240 mL of water after an overnight fast
89321825|NCT03965507||The group with sacroiliac joint dysfunction|The patient with sacroiliac joint dysfunction in lumbar disc hernia
89321826|NCT03965507||The group without sacroiliac joint dysfunction|The patient without sacroiliac joint dysfunction in lumbar disc hernia
89321827|NCT02768194|Experimental|Test Product (0.454% stannous fluoride)|Participants will use dentifrice containing 0.454% stannous fluoride. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
89321828|NCT02768194|Active Comparator|Reference Product (0.76% sodium monofluorophosphate)|Participants will use dentifrice containing 0.76% sodium monofluorophosphate. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
89321829|NCT02768194|Other|Negative Control (Mineral water)|Participants will use commercially available mineral water. Appliances brushed ex situ in mineral water twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in mineral water. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
89321830|NCT01582919|Experimental|Participant from AMI cohort|
89321831|NCT01582919|Active Comparator|Participant from 3Ccohort|
89321832|NCT03732183|Experimental|Podcast SMART-3RP|"The mind body intervention is delivered by podcast and material posted online. All session content will be audio recorded into 15-min audio-recordings that will be delivered on a podcast platform. During the course of the 4-week program, one new podcast session will be delivered every day."
89321833|NCT02254954|Experimental|Macitentan in combination with RT & TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
89321834|NCT00130793|Experimental|zoster vaccine live (Oka/Merck) refrigerated formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose-urea (PGSU) stabilizer (~45,000 plaque-forming units [PFU]), 1 subcutaneous 0.65-mL injection
89321835|NCT00130793|Active Comparator|zoster vaccine live (Oka/Merck) frozen formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose (PGS) stabilizer (~57,000 PFU), 1 subcutaneous 0.65-mL injection
89321836|NCT02154334|Experimental|Cohort 1|One Intranasal spray of 14 milligram (mg) esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A). Two intranasal sprays of 50 microgram (mcg) mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg at time -1 hour prior to 1 intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg on Day 16 in Period 2 (Treatment B).
89321837|NCT02154334|Experimental|Cohort 2: Sequence 1|One Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A) and pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 2 (Treatment C).
89321838|NCT02154334|Experimental|Cohort 2: Sequence 2|Pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1 (Treatment C) and 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 2 (Treatment A).
89321839|NCT01078883||Lung cancer|Patients with primary stage IIIb and IV lung cancer
89321840|NCT02156440|Placebo Comparator|Placebo|Placebo capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
89321841|NCT02156440|Experimental|SierraSil Joint Formula 14|SierraSil Joint Formula 14 capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
89321842|NCT01078961|Experimental|Dose Escalation|
89321843|NCT02156518|Experimental|Vocal Function Exercises|Vocal Function Exercises
89321844|NCT02156518|Active Comparator|Vocal hygiene|Vocal hygiene
89321845|NCT01077167|Experimental|1|
89321846|NCT03818399|Experimental|overdose patients|subjects that receive acute administration of SUBOXONE sublingual film in the ED followed by SUBLOCADE administration in the ED and referral to an affiliated outpatient treatment clinic, and receive monthly SUBLOCADE injections for 6 months in the context of outpatient treatment.
89321847|NCT02154646|Experimental|LY2157299 + Gemcitabine|150 mg LY2157299 is administered orally twice daily for 14 days followed by 14 days without study drug (28 day cycle.) Gemcitabine 1000 milligram per square meter will be administered intravenously (IV) on Days 8, 15, and 22 in each cycle (28 day cycle). Participants may continue to receive treatment until discontinuation criteria are met.
89321848|NCT03642873|Experimental|Treatment A|Guaifenesin (Humibid®) single extended release 1200 mg tablet administered with 240 mL of room temperature water under fasted conditions.
89321849|NCT03642873|Experimental|Treatment B|Hydrocodone Bitartrate of 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals administered with 240 mL of room temperature water in the fasted state.
89321850|NCT03642873|Experimental|Treatment C|Hydrocodone Bitartrate 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals and guaifenesin (Humibid®) 1200 mg ER administered with 240 mL of room temperature water in the fasted state.
89321851|NCT01079819|Active Comparator|A1 (BMS-708163)|
89321852|NCT01079819|Placebo Comparator|A2 (Placebo)|
89321853|NCT01079819|Active Comparator|B1 (BMS-708163)|
89321854|NCT01079819|Placebo Comparator|B2 (Placebo)|
89321855|NCT02156596|Active Comparator|Intravenous NSAI|patients received 100 mg of ketoprofen (NSAID) by IV root and in parallel 3 nebulisation of serum saline (SS) over 30 minutes.
89321856|NCT02156596|Experimental|Nebulised Morphine|patients received 3 nebulisation of morphine (5 mg each) and in parallel 50 ml of SS by IV root over 30 minutes.
89321857|NCT03729843||CBCT and intraoral digital radiography|simulated bone defects will be detected and measured by 2 techniques using CBCT and using intraoral digital radiography and the all measurements will be compared with the gold standard real measurements on the dry jaws
89321858|NCT03965429||Donor|In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor.
89321859|NCT03965429||Receiver|Systematic longitudinal collection of blood samples for any patient receiving an allogeneic CSH transplant in our facility, regardless of donor category selected and type of graft used
89321860|NCT02156752|Experimental|ACT|Behavioral weight loss plus techniques from Acceptance and Commitment Therapy
89321861|NCT02156752|Active Comparator|SR|Behavioral weight loss plus self-regulation techniques
89321862|NCT02156752|Active Comparator|WLO|Behavioral weight loss plus cooking tips and demonstrations
89321863|NCT01079117|Active Comparator|Sevre-Long™|slow release oral morphine
89321864|NCT01079117|Active Comparator|Methadone|Methodone
89321865|NCT04992286|Experimental|people aged 65 years or more|men or women, age Superior to 65 years
89321866|NCT03732963|Placebo Comparator|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
89321867|NCT03732963|Active Comparator|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
89321868|NCT02154724|Other|aDBS|The aDBS (adaptive Deep Brain Stimulation) device is applied both in aDBS and in DBS modality, for two hours in random order for two days. The aDBS can be programmed to deliver aDBS controlled by local fields potential or conventional DBS.
89321869|NCT03818321|Experimental|Methenamine Hippurate with Cranberry|Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
89321870|NCT03818321|Placebo Comparator|Placebo with Cranberry|"Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.~Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016."
89321871|NCT02154802|Experimental|video: community member|Participant watches video of a community member
89321872|NCT02154802|Experimental|video: physician|Participant watches video of a physician
89321873|NCT02154802|Experimental|video: choice of video|Participant can choose to watch video of either the community member of the physician
89321874|NCT02154802|No Intervention|no video|
89321875|NCT03616977|Experimental|LY900014 U-200|Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
89321876|NCT03616977|Experimental|LY900014 U-100|Single SC dose of LY900014 U-100 in two of four study periods.
89321877|NCT02767570|Experimental|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback. The goal of the training is to encourage participants to adopt an altered foot progression angle in an attempt to alter the distribution of forces crossing the knee joint. Training will occur once a week for six weeks. This will be followed by a 46-week home and community-based walking program to practice and internalize the new personalized, gait pattern and to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to enhance internalization of the new foot progression angle.
89321878|NCT02767570|Experimental|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback. The goal of the training is to encourage participants to maintain a consistent foot progression angle in an attempt to minimize the variability in the forces crossing the knee joint. Training will occur once a week, for 6 weeks. This will be followed by a 46-week home and community-based walking program to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to maintain foot progression angle consistency.
89321879|NCT03732885|Experimental|densah burs drilling group|maxillary sinus floor elevation during implant placement using Densah burs
89321880|NCT03732885|Experimental|Summers osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
89321881|NCT02156986||9 month old infant|
89321882|NCT02156986||12 month old infant|
89321883|NCT02156986||18 month old toddler|
89321884|NCT02156986||24 month old toddler|
89321885|NCT02156986||36 month old toddler|
89321886|NCT04996719|Experimental|Rapamycin|find safe doses for patients who have heart failure with preserved ejection fraction
89321887|NCT02154880||HIV positive under 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
89321888|NCT02154880||HIV negative under 50 yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
89321889|NCT02154880||HIV positive over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
89321890|NCT02154880||HIV negative over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
89321891|NCT03816761|Experimental|Fast-acting insulin aspart, default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with default tmax setting (t65 = 65 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
89321892|NCT03816761|Experimental|Fast-acting insulin aspart, non-default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with non-default tmax setting (t50 = 50 minutes, t40 = 40 minutes or t30 = 30 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
89321893|NCT05665413|Experimental|strocking technique|
89321894|NCT05665413|Experimental|ergon technique|
89321895|NCT03639831|Experimental|Active group|Proprietary, standardized botanical extract
89321896|NCT03639831|Placebo Comparator|Placebo group|Placebo (maltodextrin)
89321897|NCT02157142|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
89321898|NCT01079273|Active Comparator|Vaccine|All Subjects enrolled in this study will receive the study vaccine (single-arm)
89321899|NCT02154958||Unexplained infertility|
89321900|NCT02157220|Experimental|Randomised group 1|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
89321901|NCT02157220|Experimental|Randomised group 2|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
89321902|NCT02770612|Other|Post-cesarean delivery mothers|"Identify eligible women on post-operative day 3. A physician member of the study team will approach participants with study information and consent forms.~After informed consent is obtained, the participant will be taken through a 10 minute shared decision making session (intervention). The participant will then have the opportunity to ask questions, following which they will indicate the number of prescription opioid tablets to be discharged with (primary outcome)~The next contact will be at two weeks after discharge, at which time a member of the study team will contact the participant and administer a brief telephone survey with questions pertaining to perceived pain over time, pain management methods, opioid/pain medication consumption/disposal, and satisfaction with postoperative pain control.~A chart review will be performed by physicians in the research group on participants to gather information on demographics, indications for surgery, etc."
89321903|NCT03542110|Active Comparator|Alirocumab 150 MG/ML subcutaneous injection|Alirocumab 150 mg subcutaneously every 2 weeks
89321904|NCT03542110|Placebo Comparator|Matching Placebo subcutaneous injection|Matching placebo subcutaneously every 2 weeks
89321905|NCT03542032|Other|jaw-thrust|"the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
88806599|NCT05901701|Experimental|LASER group|Group A: Patients received applications of low-level laser therapy using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.
88806600|NCT05901701|Active Comparator|Splint group|Group B: Patients received hard occlusal splints (Michigan splints), used for 3 months during sleeping then the patient stops using it and told to only wear it if discomfort return usually during stressful times.
88806601|NCT05901571|Sham Comparator|sham-acupuncture/placebo-pill|sham-acupuncture protocol plus escitalopram placebo
89321906|NCT03542032|No Intervention|classic group|"In the classic group, the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place. This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
89321907|NCT03542734||Individuals with SVDs|Individuals with at least one following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
89321908|NCT03542734||Individuals without SVDs|Individuals without any following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
89321909|NCT03542656|Experimental|amyloid PET|PET/CT
89321910|NCT02155036|No Intervention|Usual care|Usual care
89321911|NCT02155036|Active Comparator|Exercise|exercise intervention
89321912|NCT03575871|Experimental|PF-04965842 100 mg|
89321913|NCT03575871|Experimental|PF-04965842 200 mg|
89321914|NCT03575871|Placebo Comparator|Placebo|
89321915|NCT03736486||Type 2 Diabetes|Male and female adults of Hispanic and/or Latino heritage with an established diagnosis of Type 2 diabetes.
89321916|NCT02157454|Experimental|Website access|Two-week access to the colorectal cancer module of the website www.krankheitserfahrungen.de
89321917|NCT02157454|No Intervention|Control|Participants who are randomized to the control group don't have access to the website until they have finished the last questionnaire at 6 weeks follow up.
89321918|NCT02155192||Cohort 1|Participants who participated in NCT01483599 (X-PLORE) study.
89321919|NCT02155192||Cohort 2|Participants who participated in NCT00267969 (PHOENIX 1) study.
89321920|NCT02155192||Cohort 3|Participants who participated in NCT00307437 (PHOENIX-2) study.
89321921|NCT02155192||Cohort 4|Participants who participated in NCT00454584 (ACCEPT) study.
89321922|NCT02155270|Active Comparator|Precut|A corneal precut of 600µm will be performed.
89321923|NCT02155270|Active Comparator|Stab incision|A stab incision without corneal precut will be performed.
89321924|NCT03543670|Experimental|Oncoxin-Viusid|
89321925|NCT02155348|Active Comparator|Multifocal group|Bilateral cataract surgery with implantation of multifocal IOLs
89321926|NCT02155348|Active Comparator|Monovision|Bilateral cataract surgery with monovision
89321927|NCT02157688||case|Patient with a folliculitis Decalvans
89321928|NCT02157688||control|Control without folliculitis decalvans
89321929|NCT02155426||Treatment|Treatment: Chemotherapy or targeted therapy
89321930|NCT02157766|Active Comparator|MNP with Asthma: Mindfulness Based Stress Reduction|
89321931|NCT02157766|No Intervention|MNP w/ Asthma: Wait List Control|
89321932|NCT02157766|Active Comparator|MNP, no asthma - Mindfulness Based Stress Reduction|
89321933|NCT02157766|Active Comparator|MNP, no asthma: Health Enhancement Program|
89321934|NCT02157766|No Intervention|MNP, no asthma - Wait List Control|
89321935|NCT02157766|Active Comparator|Long Term Meditator|
89321936|NCT03736408||1. Group without Pain - TMJ disorders symptoms|1. The symptoms concerning joints were: the type of sound symptoms (clicking or popping), their frequency and the phase of the movement of lowering and lifting the jaw during which they occurred, occurrence of the tension type headache or back pain. Hypertension of the mastication muscles is frequently connected with a parafunction activity like grinding or clenching the teeth, which cause abnormal pressure on the joints
89321937|NCT03736408||2. Group with Pain and symptoms TMJ disorder|The pain form of the disease is manifested by spontaneous pain in the preaural region, accompanied by pain or tenderness of the mastication muscle. Pain that appears during palpation examination of temporomandibular joints is frequently not related to inflammation of the soft tissue around the temporomandibular joints, as it is claimed by several authors of the paper. The cause of this problem is a long-term overload of soft tissue causally associated with excessive muscle tension, that sometimes even persists for years
89321938|NCT02155504|Experimental|ASP3700 single ascending dose cohort|Part 1
89321939|NCT02155504|Placebo Comparator|Placebo single ascending dose cohort|Part 1
89321940|NCT02155504|Experimental|ASP3700 alone|Part 2
89321941|NCT02155504|Active Comparator|ASP3700 and itraconazole|Part 2
89321942|NCT02149498||Parkinson Disease (PD)|Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause)
89321943|NCT02149498||Healthy Controls|Healthy individuals
89321944|NCT03543592|Other|3 dimensional power Doppler|100 women suffering post-menopausal bleeding (occurred after at least 12 months of amenorrhea) will be included in the study and 3 dimensional ultrasonography and Doppler will be done for them
89321945|NCT03642717||Subjects diagnosed with type 2 diabetes mellitus|
89321946|NCT03729531|Active Comparator|Conventional|The perivascular tissue is stripped off when harvesting the vein, and saline will be used to distend the vein to check for leakage.
89321947|NCT03729531|Experimental|No-touch|The vein will be harvested by frequency electrotome and the perivascular tissue will be preserved, the vein will not be distended.
89321948|NCT02766478|Experimental|Genistein|Participants with and without diabetes will receive 60 mg/day oral genistein (30 mg taken twice daily) for 12 weeks.
89321949|NCT02766478|Placebo Comparator|Placebo|Participants with and without diabetes will receive placebo taken twice daily for 12 weeks.
88806602|NCT05901571|Active Comparator|sham-acupuncture/escitalopram|sham-acupuncture protocol plus escitalopram
88806603|NCT05901571|Active Comparator|active acupuncture/placebo-pill|acupuncture protocol plus escitalopram placebo
89321950|NCT03729375|Experimental|10cc Patients|Intervention: Group 1 will receive 10cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
89321951|NCT03729375|Active Comparator|20cc Patients|Intervention: Group 2 will receive 20cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
89321952|NCT02149576|Active Comparator|LDCT Surveillance Program Group|This cohort will follow a strict schedule of Low Dose Computed Tomography Imaging scans and clinical visits 3, 6, and 12 months after surgery. At each encounter, a history, physical examination, and review of the LDCT results will be performed. Patients with normal clinical and imaging findings will proceed to the next scheduled clinical encounter. Patients with abnormal findings will be managed according to predetermined algorithms.
89321953|NCT02149576|Other|Historical Control Group|The control group will be a retrospective cohort taken from 1-year before the implementation of the LDCT surveillance program. The post-operative follow-up of these participants was not standardized, but rather left up to the discretion of the individual surgeons, and involved chest radiograph imaging as opposed to Low Dose Computed Tomography.
89321954|NCT03732027|Active Comparator|Transversus Abdominis Block [TB] group|Patients will receive Surgical Transversus Abdominis Plane Block
89321955|NCT03732027|Active Comparator|Rectus Sheath Block [RB] group|Patients will receive Surgical Rectus Sheath Block
89321956|NCT03541954|Other|Patient with pelvic or perineal pain with sensitization|Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria > 5)
89321957|NCT03541954|Other|Patient with pelvic or perineal pain without sensitization|Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria < 5)
89321958|NCT02159326|Experimental|Arm1|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
89321959|NCT02159326|Experimental|Arm2|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment, a single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
89321960|NCT02255266||A|
89321961|NCT02766400|Experimental|Guided Training|"Guided training is a rehabilitation training approach that maximizes the expertise of the patient, by teaching patients to identify and prioritize activities, identify barriers to performing activities, generate their own strategies for addressing these barriers, and apply this process through iterative practice. Guided training equips patients with practical skills that have the potential to generalize beyond activities addressed during the intervention program to novel problematic activities that arise after the intervention program, thereby promoting long-term independence."
89321962|NCT02766400|Active Comparator|Directed Training|Directed training is a rehabilitation approach that maximizes the expertise of the rehabilitation practitioner. Rehabilitation practitioners identify and prioritize problematic activities, identify barriers to performing these activities, generate strategies to address these barriers and instruct patients in these strategies, and repeat the process with a variety of problematic activities identified during the rehabilitation program. Directed training promotes independence with training activities, however the benefits of direct training are likely to be activity-specific (i.e., only promote improvement on the trained activity) and not generalizable to other daily activities. This therapist-directed approach is currently the method used most frequently in acute rehabilitation.
89321963|NCT00104650|Active Comparator|IV Bisphosphonates q 4 weeks|This is an open-label randomization to receive IV bisphosphonate (administered per package insert) every 4 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will receive AMG 162 180mg (SC) every 4 weeks.
89321964|NCT00104650|Experimental|180 mg AMG 162 (SC) q 12 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 12 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 12 weeks.
89321965|NCT00104650|Experimental|180 mg AMG 162 (SC) q 4 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 4 weeks during the treatment phase. If subject is enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 4 weeks.
89321966|NCT02157922|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and of placebo the second period
89321967|NCT02157922|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
89321968|NCT02158156|Experimental|Excercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
89321969|NCT03732807|Experimental|Sequence A|Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
89321970|NCT03732807|Experimental|Sequence B|Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
89321971|NCT03732807|Experimental|Sequence C|Maintenance dose #1 given QD for 48 weeks
89321972|NCT03732807|Experimental|Sequence D|Maintenance dose #2 given QD for 48 weeks
89321973|NCT03732807|Experimental|Sequence E|Maintenance dose #3 given QD for 48 weeks
89321974|NCT03732807|Experimental|Sequence F|Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
89321975|NCT03732807|Experimental|Sequence G|Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks
89321976|NCT00104416|Placebo Comparator|Placebo|
89321977|NCT00104416|Experimental|lamotrigine (LAMICTAL) extended-relesase|
89321978|NCT02158312|Experimental|transcranial direct current stimulation|bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, for 20 minutes
89321979|NCT02158312|Placebo Comparator|sham stimulation|same as the experimental stimulation condition but only for 2 minutes
88806604|NCT05901571|Experimental|active acupuncture/escitalopram|acupuncture protocol plus escitalopram
88806605|NCT05901454|Other|intervention arm|yellow fever vaccine arm (all participants receive the standard yellow fever vaccine (Stamaril)
88806606|NCT05901441|Experimental|H1 group|H1 group will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine
88806607|NCT05901441|Experimental|H2 group|H2 group will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine
88806608|NCT05901441|Experimental|H3 group|H3 group will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine
88806609|NCT05901441|Active Comparator|SF group|SF group will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine
88806610|NCT05901402|Experimental|The experimental group|The experimental group performed aerobic resistance exercise during pregnancy every day.
88806611|NCT05901402|No Intervention|The control group|The control group was given traditional nursing.
88806612|NCT05901389|Experimental|lidocaine|Patients in this group will receive continuous lidocaine infusion via closed chest drainage tube. The pulse infusion speed is 1ml / 30min, and the continuous infusion speed was 2ml / h.
89321980|NCT02159638|Other|comparisson CGM accuracy|Each patient will have both subcutaneous tissue CGM sensors (Guardian Enlite sensor and Dexcom G4 Platinum sensor) inserted at the same time. The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose
89321981|NCT03732729|Experimental|Massage chair|lifestyle modification education(once)+ Using massage chair
89321982|NCT03732729|No Intervention|Control|lifestyle modification education(once)
89321983|NCT02158390|Experimental|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
89321984|NCT02158390|No Intervention|Community treatment as usual|Children access educational and speech-language interventions available to them through schools and community resources.
89321985|NCT03639987|Experimental|Group 1|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
89321986|NCT03639987|Experimental|Group 2|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
89321987|NCT02158468|Active Comparator|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion).
89321988|NCT02158468|Active Comparator|Postconditioning|4 cycles of postconditioning (30s ischemia, 30s reperfusion) after primary PCI/stenting
89321989|NCT02158468|No Intervention|Control group|Standard infarction treatment without conditioning intervention
89321990|NCT03729297|Experimental|cabozantinib|cabozantinib 60 mg tablets OD
89321991|NCT02149888|Experimental|Tenofovir/emtricitabine|MSM receiving once daily TDF/FTC-based (Truvada®) pre-exposure prophylaxis
89321992|NCT03729219|Experimental|ETVAX|Contains inactivated Tetravalent ETEC vaccine, 10 ug Double-mutant heat-labile toxin (dmLT) and effervescent power for oral solution administered twice 14 (plus minus 7) days intervals.
89321993|NCT03729219|Placebo Comparator|Placebo|Effervescent power for oral solution administered wice 14 (plus-minus 7) days intervals
89321994|NCT03639675|Experimental|NVG patients|Japanese patients with neovascular glaucoma
89321995|NCT03543436|Experimental|Intravenous temocillin|Intravenous temocillin 2g/intravenously/8h or renally adjusted equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h)
89321996|NCT03543436|Active Comparator|Intravenous meropenem or imipenem|Intravenous meropenem or imipenem 1g/Intravenously /8h ORAE in 15-30 min infusion. Then switch to oral therapy
89321997|NCT03732651|Experimental|non-pulsatile blood flow|
89321998|NCT03732651|Experimental|pulsatile blood flow|
89321999|NCT03729141|Experimental|Added Cholesterol|
89322000|NCT03729141|Active Comparator|No Added Cholesterol|
89322001|NCT02149966|Experimental|AG-348|Multiple oral doses of AG-348
89322002|NCT02149966|Placebo Comparator|Placebo|Multiple oral doses of placebo.
89322003|NCT03729063|Experimental|Twice daily expired CO measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
89322004|NCT03729063|Active Comparator|Control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
89322005|NCT02159716|Experimental|Metastatic Pancreatic (ductal) adenocarcinoma (PDA)|
89322006|NCT02159716|Experimental|Serious Epithelial Ovarian Cancer|
89322007|NCT02159716|Experimental|Malignant Epithelial Pleaural Mesothelioma|
89322008|NCT01310361|Experimental|Amoxicillin|Once-daily Therapy for Streptococcal Pharyngitis With Amoxicillin
89322009|NCT01310361|Active Comparator|Benzathin Penicillin G|Once-daily Therapy for Streptococcal Pharyngitis With Intramuscular Benzathin Penicillin G
89322010|NCT02159794|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
89322011|NCT03541798|Active Comparator|Traditional sitting position|"Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
89322012|NCT03541798|Experimental|Harmstring stretch position|"the patients sit up from supine position with the legs remaining on the operating table, knees are maximally extended.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
89322013|NCT03541798|Experimental|Squatting position|"the patients sit up from supine position with the legs remaining on the operating table, hips and knees are maximally flexed .~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
89322014|NCT05665803|Experimental|Pediatric rotary files|Biomechanical preparation will be done using pediatric rotary file system (Kedo-SG blue file system). D1 and E1 files will be used at 300 rpm and 2.4 N/cm torque.
89322015|NCT05665803|Active Comparator|Manual flare files|Biomechanical preparation will be done using manual flare files (Mani) No. 15-35.
89322016|NCT03635775|Experimental|Anodal ipsilesional Active tDCS|Anodal tDCS (excitatory) applied to the lesioned hemisphere. Participant must have lesioned hemisphere MEP.
89322017|NCT03635775|Experimental|Cathodal contralesional Active tDCS|Cathodal tDCS (inhibitory) applied to the non-lesioned hemisphere. Participant must have lesioned hemisphere MEP.
89322018|NCT03635775|Experimental|Anodal contralesional Active tDCS|Anodal tDCS (excitatory) applied to the non-lesioned hemisphere. Participant must not have lesioned hemisphere MEP.
89322019|NCT03635775|Sham Comparator|Sham tDCS|Sham tDCS applied in one of the above configurations
89322020|NCT02150122|Experimental|10 micrograms (400 IU) vitamin D3|Participants will be given a daily supplement containing 10 micrograms (400 IU) vitamin D3 to take for 5 months.
89322021|NCT02150122|Experimental|20 micrograms (800 IU) vitamin D3|Participants will be given a daily supplement containing 20 micrograms (800 IU) vitamin D3 to take for 5 months.
89322022|NCT02150122|No Intervention|Placebo|Participants will be given a placebo, similar in appearance to the vitamin D3 tablets, to take for 5 months.
89322023|NCT03610581|Experimental|Regimen 1: Single Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a dose of adenovirus serotype 26 (Ad26)-human papillomavirus (HPV)16 or HPV18 (Ad26.HPV16 or Ad26.HPV18) as prime immunization and a dose of Modified Vaccinia Ankara (MVA)-HPV16/18 (MVA.HPV16/18) as boost immunization.
89322024|NCT03610581|Experimental|Regimen 2: Double Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a double dose of Ad26.HPV16 or Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
89322025|NCT03610581|Experimental|Regimen 3: Ad26.HPV16/Ad26.HPV18 mix and MVA.HPV16/18|Participants will receive a mix of Ad26.HPV16/Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
89322026|NCT03610581|Placebo Comparator|Control: Placebo|Participants will receive matched placebo as prime and boost immunizations.
89322027|NCT03731793|Placebo Comparator|Placebo Group|Placebo. For 90 days one capsule/day.
89322028|NCT03731793|Experimental|Intervention Group|600 mg/day of non-animal Chondroitin Sulphate. One capsule/day for 90 days.
89322029|NCT03610269|Experimental|INVSENSOR00026|All enrolled subjects receive INVSENSOR00026 Pulse CO-Oximeter and sensor for the noninvasive measurement of hemoglobin (SpHb).
89322030|NCT03728907|Active Comparator|Audiologist-adjusted first|This arm will complete the field trial with the audiologist-adjusted fitting first, followed by the user-adjustment fitting.
89322031|NCT03728907|Experimental|User-adjusted first|This arm will complete the trial with the user-adjusted fitting first followed by the audiologist-adjusted fitting.
89322032|NCT03728829||Trastuzumab+TP neoadjuvant chemotherapy|100 cases of patients with stage II-III HER2+ breast cancer will be assigned participants to neoadjuvant treatment regimen, including Trastuzumab combined with Docetaxel and Carboplatin. 5-10 ml peripheral blood will be collected from each patient and formalin fixed paraffin embedded (FFPE) blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals before and after neoadjuvant therapy. The genomic characteristics between patients achieved pCR and non-pCR will be analyzed. The clinically actionable mutations for future therapy instructions will be identified.
89322033|NCT00121667|Experimental|Saxagliptin + Metformin (A)|Pioglitazone 15-45 mg (as needed for rescue)
89322034|NCT00121667|Experimental|Saxagliptin + Metformin (B)|Pioglitazone 15-45 mg (as needed for rescue)
89322035|NCT00121667|Experimental|Saxagliptin + Metformin (C)|Pioglitazone 15-45 mg (as needed for rescue)
89322036|NCT00121667|Placebo Comparator|Placebo+ Metformin (D)|Pioglitazone 15-45 mg (as needed for rescue)
89322037|NCT02954601|Active Comparator|Placebo|Placebo (fish oil)
89322038|NCT02954601|Active Comparator|Dose1|Dose 1 ORMD-0801 (qd)
89322039|NCT02954601|Active Comparator|Dose2|Dose 2 ORMD-0801 (bid)
89322040|NCT02954601|Active Comparator|Dose 3|Dose 3 ORMD-0801 (tid)
89322041|NCT03633903|Active Comparator|Mindfulness|Mindfulness: Eight sessions, twice per week over four weeks. Surveys administered prior to each session.
89322042|NCT03633903|No Intervention|Control|Treatment as usual (i.e., pharmacotherapy, psychotherapy, etc.) for the four week duration with twice weekly surveys administered.
89322043|NCT03728751|Experimental|study group|Study group receiving dry needling and pupil diameter will be studied up to 23 minutes after needle placement.
89322044|NCT01310439||ADHD adolescents and adults|30 adolescents and adults diagnosed with Combined-subtype AD/HD
89322045|NCT03607695|Experimental|Gait training|1 hour walking exercise on a treadmill
89322046|NCT03732573|Experimental|Intervention Group|This group will receive 9 text messages over 3 weeks. Messages will be based on goal-setting in the first week, goal-operating in the second week, and self-monitoring in the third week.
89322047|NCT03732573|No Intervention|Control Group|Participants in this group will receive no messages during the intervention period.
89322048|NCT03728439|Experimental|Before|LED applications at the beginning, with a dose of 8 J/cm2, will be performed shortly after the blood collections, with a maximum period of 10 minutes, in which the participants of the other groups should remain in rest passive. At the end of these 10 minutes, a 5 minute warm up will be performed and then the tests will be started.
89322049|NCT03728439|Experimental|Interval|The LED therapy applied in the tests interval will be performed after the first block of tests, with a maximum duration of 10 minutes and dose of 8 J/cm2. Then the second block of maximum tests will be performed.
89322050|NCT03728439|Experimental|After|LED applications at the end will be performed 10 minutes after the second battery of tests, also with 8 J/cm2 and in the same muscles irradiated in the other moments of application.
89322051|NCT03728439|No Intervention|Baseline|On that day, participants will not receive any intervention.
89322052|NCT05666037|Experimental|Intervention group|The intervention group will receive mobile health intervention.
89322053|NCT05666037|No Intervention|Control group|The control arm will be received the existed current health delivery approach, not received mobile health sending message service.
89322054|NCT03557775|Experimental|Inspiratory Muscle Strength Training|"The participants in the IMST arm will receive, in addition to standard of care voice therapy, inspiratory muscle strength training (IMST).~The IMST intervention will consist of 5 sets of 5 breaths in the inspiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal inspiratory pressure (MIP). MIP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
89322055|NCT03557775|Experimental|Expiratory Muscle Strength Training|"The participants in the EMST arm will receive, in addition to standard of care voice therapy, expiratory muscle strength training (EMST).~The EMST intervention will consist of 5 sets of 5 breaths in the expiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal expiratory pressure (MEP). MEP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
89322056|NCT03557775|Active Comparator|Voice Exercises|The participants in the voice exercises group will receive standard of care voice therapy with a speech language pathologist, once a week during four weeks, plus daily practices.
89322057|NCT00121199|Experimental|Treatment (CHOP, rituximab, bevacizumab)|Patients receive rituximab IV, bevacizumab IV over 30-90 minutes, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1. Patients also receive oral prednisone on days 1-5. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
89322058|NCT03964805|Active Comparator|group A|Embryo culture at 20% O2
89322059|NCT03964805|Active Comparator|group B|Embryo culture at 5% O2
89322060|NCT03964805|Active Comparator|group C|Embryo culture at 5% O2 and at 20% O2
89322061|NCT03728283|Active Comparator|Conventional Implant placement|conventional implant placement following the manufacturer's instructions
89322062|NCT03728283|Experimental|Implant and Connective tissue grafting|implant placement in combination with connective tissue grafting
89322063|NCT03728205|Experimental|Observational|All 10 pilot subjects will be taking yoga
89322064|NCT03725865|Experimental|iNSC treatment group|
89322065|NCT01079897|Active Comparator|Atopiclair|
89322066|NCT01079897|Experimental|EHK02-01|Ectoine containing cream
89322067|NCT00119015|Placebo Comparator|Fluticasone propionate + Placebo|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Placebo - 10 mg po daily for 2 weeks"
89322068|NCT00119015|Active Comparator|Fluticasone propionate + Montelukast|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)~Montelukast - 10 mg po daily for 2 weeks"
89322069|NCT01981850|Experimental|Stage 1: Cohort 1 Weekly|Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
89322070|NCT01981850|Experimental|Stage 1: Cohort 1 Every 4 Weeks|Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
89322071|NCT01981850|Experimental|Stage 1: Cohort 2 Weekly|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
89322072|NCT01981850|Experimental|Stage 1: Cohort 2 Every 4 Weeks|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
89322073|NCT01981850|Experimental|Stage 2: Cohort 1 0.3mg/kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
89322074|NCT01981850|Experimental|Stage 2: Cohort 2 3mg/kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
89322075|NCT01981850|Experimental|Stage 2: Cohort 3 10mg /kg Every 4 Weeks|Participants will be treated with single agent RO7490677 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
89322076|NCT03557307|Experimental|Benralizumab|Benralizumab subcutaneous injection
89322077|NCT00104104|Experimental|15 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks
89322078|NCT00104104|Experimental|30 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.
89322079|NCT03557151|Active Comparator|Usual Care|Usual Care participants will receive the same excellent multidisciplinary care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is < 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
89322080|NCT03557151|Experimental|Transdisciplinary Care-In Person & Telehealth|In addition to all elements of Usual Care, TC-IP participants will have follow-up clinic visits in-person or by telehealth at approximately 3 month intervals during the study that will consist of simultaneous involvement of an advanced practice nurse, dietitian and psychologist who will see the parent and adolescent together. TC team members will have passed a competency exam following completion of a training course on each of the TC team professional disciplines.
89322081|NCT02150200|Other|A group : Conventional hospitalization|Patients discharged after 3 days hospital stay after laparoscopic hysterectomy
89322082|NCT02150200|Experimental|B group : shorter stay|Patients going home within 24 hours discharged the first day after laparoscopic hysterectomy.
89322083|NCT03725787|Experimental|CuroCell S.A.M. ® pro mattress|Mattresses of eligible participants will be replaced by a static air pressure redistribution mattress (CuroCell S.A.M. ® Pro).
89322084|NCT02158624|Experimental|Ranibizumab|
89322085|NCT00115739|Experimental|Imatinib|Patients will be treated with Imatinib (Gleevec) 400 mg two times a day for eight weeks after which radiologic imaging will be obtained to assess response. Patients who attained a complete response will be treated with four additional weeks of Imatinib. Patients who attain a partial response or stable disease will be treated until a complete response is attained, or until disease progression. All patients with progression of disease will be taken off the study. Patients continuing on the study, will undergo radiologic imaging every eight weeks following their initial response assessment. All patients will be followed until death.
89322086|NCT03639519|Experimental|Ascorbic acid|Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.
89322087|NCT03639519|Placebo Comparator|Placebo group|will not be given ascorbic acid , instead a placebo will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers (CRP, ESR and differential TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.
89322088|NCT02255344||ST-Elevation Myocardial Infarction|Consecutive patients of any gender between 18 and 90 years old, diagnosed with ST-Elevation Myocardial Infarction according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
89322089|NCT02255344||Non ST Segment Elevation|Consecutive patients of any gender between 18 and 90 years old, diagnosed with Non ST Segment Elevation (NSTEMI/ Unstable angina) according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
89322090|NCT01079429||MGUS or SMM|Patients with Monoclonal gammopathy of undetermined significance or smoldering myeloma
89322091|NCT02158702|Experimental|Pomalidomide and Dexamethasone|"PO pomalidomide 4mg from D1-21 and PO dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~PO or IV cyclophosphamide 300mg/m2 on D1, 8 and 15 can be added at the discretion of the treating physician to induce added response under the following circumstances: 1) If there is less than a MR after 3 cycles in the absence of disease progression, or 2) If there is disease progression within the first 3 cycles of Pomalidomide and Dexamethasone treatment.~Patients will be assessed every 28 days (+/-10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
89322092|NCT01347086|Experimental|BI 207127 NA (low dose)|Single dose of BI 207127 NA
89322093|NCT01347086|Placebo Comparator|Matching placebo (low dose)|Single dose of matching placebo
89322094|NCT01347086|Experimental|BI 207127 NA (medium dose)|Single dose of BI 207127 NA
89322095|NCT01347086|Placebo Comparator|Matching placebo (medium dose)|Single dose of matching placebo
89322096|NCT01347086|Experimental|BI 207127 NA (high dose)|Single dose of BI 207127 NA
89322097|NCT01347086|Placebo Comparator|Matching placebo (high dose)|Single dose of matching placebo
89322098|NCT02150278|Experimental|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
89322099|NCT01079507||adult acute lymphoblastic leukemia|Patients were diagnosed as adult acute lymphoblastic leukemia.
89322100|NCT02158780|Experimental|Scrotal Orchidopexy|Single incision
89322101|NCT02158780|Other|Inguinal Orchidopexy|Double Incision (Standard)
89322102|NCT03605745|Experimental|Treatment|Prostatic Vapor Ablation with Rezum
89322103|NCT02150356|Experimental|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
89322104|NCT02150356|Placebo Comparator|Control|Diet based on refined cereal products for a period of 8 weeks.
89322105|NCT03725709||All patients|spinal anesthesia
89322106|NCT01761890||CML patients|
89322107|NCT02150434|Sham Comparator|Compressed Air|compressed air delivered at a fixed flow of 2 L/min
89322108|NCT02150434|Active Comparator|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
89322109|NCT02150434|Experimental|Automated oxygen titration|oxygen at a variable flows delivered by the FreeO2
89322110|NCT02160028|Active Comparator|Standard information|This group is given anesthetics and standard information before dental treatment about the anesthetics.
89322111|NCT02160028|Experimental|Extended information|This group is given anesthetics and extended information before dental treatment about the anesthetics.
89322112|NCT03246152|Experimental|Bevacizumab group|Monthly intravitreal injection of 2.5 mg of Bevacizumab for at least 3 consecutive months. This is followed by treat and extend regimen after resolution of macular edema.
89322113|NCT03571581|Experimental|Mindfulness Training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
89322114|NCT03541564|Experimental|BMS-986165 Dose 1 oral administration|BMS-986165 therapeutic single dose
89322115|NCT03541564|Experimental|BMS-986165 Dose 2 oral administration|BMS-986165 supratherapeutic single dose
89322116|NCT03541564|Active Comparator|Moxifloxacin Dose 3 oral administration|Moxifloxacin positive control single dose
89322117|NCT03541564|Placebo Comparator|Placebo Dose 4 oral administration|Placebo single dose
89322118|NCT00115349|Experimental|L1/DFO|Deferoxamine (DFO) and deferiprone (L1) combination therapy
89322119|NCT00115349|Active Comparator|DFO|Deferoxamine (DFO) monotherapy
89322120|NCT04804696|Experimental|TPC treatment|Neoadjuvant treatment of toripalimab, paclitaxel and cisplatin
89322121|NCT03727815|Experimental|Mindfulness Pain Management Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target pain management through mindfulness.
89322122|NCT03727815|Experimental|Mindfulness Self Esteem Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target self esteem through mindfulness.
89322123|NCT03727815|No Intervention|Non-intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
89322124|NCT04753528|Experimental|Group A|Personalized stimulation parameters and amplitude
89322125|NCT04753528|Experimental|Group B|Personalized stimulation amplitude
89322126|NCT04753528|Active Comparator|Group C|Non-personalized stimulation
89322127|NCT00115037|Experimental|Phase 1 Liberal Response|From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 5 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
89322128|NCT00115037|Experimental|Phase 1 Stringent Response|From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 2 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
89322129|NCT00115037|Experimental|Phase 2 nalt and tele for responders|Phase 2: Naltrexone and telephone counseling for responders.
89322130|NCT00115037|Experimental|Phase 2 nalt, MM and CBI for NR|Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).
89322131|NCT00115037|Placebo Comparator|Phase 2 placebo, MM and CBI for NR|Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR)
89322132|NCT00115037|Experimental|Phase 2 naltrexone for responders|Phase 2: Naltrexone and TAU for phase 1 responders.
89322133|NCT02160106|Experimental|TEW-7197|Dose Escalation of TEW-7197: TEW 7191 tablets will be given once daily (QD) or twice daily (BID) for 5 days followed by 2 days without treatment in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
89322134|NCT03964961|Experimental|Functional massage|
89322135|NCT03964961|Active Comparator|Conventional massage|
89322136|NCT02254876|Active Comparator|Standard physical therapy program|Standard physical therapy program is delivered for four rehabilitation sessions for a period of about 45 minutes each.
89322137|NCT02254876|Experimental|NeuroMuscular Taping (NMT)|"NeuroMuscular Taping is delivered in addiction to the Standard Treatment for four rehabilitation sessions. The sessions were spaced apart about five days to ensure the optimum adhesion of the NMT."
89322138|NCT03214640|Active Comparator|Palpation with spinal block (Group C-P)|insertion will be identified by palpation using conventional landmarks (spinous process and iliac crest) for placement of spinal block for cesarean delivery
89322139|NCT03214640|Active Comparator|Palpation with neuraxial block (Group L-P)|the needle insertion site for the neuraxial block will be identified with palpation for labor analgesia, using the spinous process and iliac crest for reference
89322140|NCT03214640|Experimental|Rivanna Accuro Ultrasound Device with spinal block (Group C-R)|insertion will be identified with Rivanna Accuro U/S device for placement of spinal block for cesarean delivery
89322141|NCT03214640|Experimental|Rivanna Ultrasound Device with neuraxial block (Group L-R)|insertion will be identified with Rivanna Accuro U/S device for placement of neuraxial block (combined spinal epidural) for labor analgesia
89322142|NCT04800094|Experimental|Investigational Ultrasound Imaging for Liver Fat Quantification|
89322143|NCT03214406|Experimental|Arm & Hammer Advance White Brilliant Sparkle (Test product)|2X daily brushing for 12 weeks with Arm & Hammer Advance White Brilliant Sparkle (Test product). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
89322144|NCT03214406|Active Comparator|Crest Cavity Protection Regular Toothpaste (Negative Control)|2X daily brushing for 12 weeks with Crest Cavity Protection Regular Toothpaste (Negative Control). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
89322145|NCT02150512|Experimental|Transpulmonary thermodilution (TPTD)|The intervention group (TPTD guided therapy) follows a fluid resuscitation protocol based on stroke volume variation (SVV) and extravascular lung water (EVLW). Initial trigger for fluid loading when circulatory insufficiency is present will be SVV.
89322146|NCT02150512|Active Comparator|Surviving Sepsis Guidelines (SSG)|The standard group (SSG guided therapy) follows a fluid resuscitation protocol based on the Surviving Sepsis Campaign recommendations. Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg).
89322147|NCT03727659|Experimental|SHADE therapy + CONNECT FaceBook support|SHADE is a 10-week, 10-session, computerized CBT/MET intervention for Cannabis Use Disorder and depression. At each visit, a study clinician meets with participants for a 'check-in' session, which includes: review of homework; plans for completing homework; suicide risk and mood assessment. The CONNECT FB intervention component will facilitate social support for between-session homework and CBT skills practice for managing depression and preventing relapse, and bolstering motivation to change. Daily posts will be delivered. Only those participating in the study will know about the existence of this group and will be able to access it. A weekly real-time, Facebook chat session will be held to provide feedback concerning homework practice or answer questions.
89322148|NCT01310517||Radial Coronary Angiography|The subjects enrolled in this study will be adults referred for radial coronary angiography with left ventriculography for clinical indications.
89322149|NCT03731481|Experimental|CHIP - Urban|Participants randomized by urban location of residence to receive CHIP Lifestyle Medicine program intervention.
89322150|NCT03731481|Experimental|CHIP - Rural|Participants randomized by rural location of residence to receive CHIP Lifestyle Medicine program intervention.
89322151|NCT03731481|Experimental|FPD2- Urban|Participants randomized by urban location of residence to receive FPD2 Lifestyle Medicine program intervention.
89322152|NCT03731481|Experimental|FPD2 - Rural|Participants randomized by rural location of residence to receive FPD2 Lifestyle Medicine program intervention.
89322153|NCT03213938|Experimental|Acupuncture|The participants in the acupuncture group will receive treatment that consists of 20 acupuncture sessions over an 8-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Sanyinjiao (SP6), Zhongliao (BL33), Shenshu (BL23), and Huiyang (BL35), were selected as acupoints protocol. SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL32 is in the sacral region, in the second posterior sacral foramen; BL33 is in the third posterior sacral foramen; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
89322154|NCT03213938|Sham Comparator|Sham acupuncture|The participants in the sham acupuncture group will receive shallow needling at bilateral sham BL23, BL33, BL35 and SP6. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-15 mm to the lateral of corresponding acupuncture and not above a meridian line (15mm to BL23, BL33 and BL35; 10mm to SP6). The Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be inserted with a depth of 2-3 mm without any manipulation.
89322155|NCT03604497|Experimental|beacon alerts|active intervention - participants are receiving alerts to warn them about distracted pedestrian behavior near intersections
89322156|NCT03604497|No Intervention|no alerts baseline|baseline - participants do not receive any alerts on their mobile smartphone when near intersections
89322157|NCT03604497|Other|no alerts retention|retention phase - alerts have stopped after active intervention and behavior is monitored to test retention of learned behavior
89322158|NCT02160340||Vitreomacular adhesion|Male or female subjects aged over 40 years with vitreomacular adhesion
89322159|NCT03725631|Experimental|Biopsy proven NAFLD patients|150 subjects who are diagnosed with NAFLD with biopsy from September 2016 to October 2018.
89322160|NCT02159014|Experimental|Phase 1|Facilitated group-based physical activity (aerobic dance), online physical activity (video based aerobic dance) and nutritional intervention (nutritional education, cooking skill training, access and use of NHS Change4Life Eat Well web resource).
89322161|NCT02159014|Active Comparator|Phase 2|Self-paced online physical activity (video based aerobic dance) intervention and use of NHS Change4Life Eat Well web resource.
89322162|NCT02160418|No Intervention|Control|36 Participants will be sent a new toothbrush and will be asked to use it in place of their current brush. They also receive twice daily reminders via sms to brush their teeth.
89322163|NCT02160418|Experimental|Financial Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. They will also be offered financial incentives twice a day to brush their teeth.
89322164|NCT02160418|Experimental|Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
89322165|NCT02160418|Experimental|Financial and Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice daily they receive financial incentives to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
89322166|NCT03725553|Experimental|Intramyometrial Vasopressin|the experimental group received a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
89322167|NCT03725553|Placebo Comparator|Placebo|the placebo group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)immediately after delivery, as soon as the umbilical cord was clamped.
89322168|NCT03213626|Experimental|Cabozantinib + erlotinib|
89322169|NCT02159092|Experimental|Contingency Management|Monetary incentives are given for submitting negative saliva cotinine tests.
89322170|NCT02159092|No Intervention|Fixed Rate Control|Fixed amounts of payments are provided for submitting saliva samples
89322171|NCT03604341|Experimental|Gestational age up to 10w0d - Dronabinol|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
89322172|NCT03604341|Placebo Comparator|Gestational age up to 10w0d - Placebo|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
89322173|NCT02160496|Active Comparator|20% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 20% protein, 30% fat and 50% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
89322174|NCT02160496|Active Comparator|27% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 27% protein, 30% fat and 43% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
89322175|NCT02160496|Active Comparator|35% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 35% protein, 30% fat and 35% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
89322176|NCT03637634||NPC survivors|Survivors of NPC, diagnosed under 21 years of age, between 1990 and 2030. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
89322177|NCT03637634||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine the consistency of findings between data sources.
89322178|NCT03636698||Chorioamnionitis Group|preterm infants were born to mothers with chorioamnionitis
89322179|NCT03636698||Control Group|preterm infants were born to mothers without chorioamnionitis
89322180|NCT02160574|Active Comparator|ZuraPrep|ZuraPrep will be compared statistically to ZuraPrep without IPA and both to the Positive Control (0.1% Sodium Lauryl Sulfate). The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.
89322181|NCT03620552|Experimental|18F-S16 injection and PET/CT scan|The subjects were intravenously injected with 370MBq 18F-S16 and underwent PET/CT scan immediately after the injection.
89322182|NCT02150590|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
89322183|NCT02150590|Placebo Comparator|Sham oxygen|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
89322184|NCT05181566|Experimental|Modular dual mobility group|A group of patients who underwent total hip replacement arthroplasty using a modular dual mobility cup
89322185|NCT05181566|Active Comparator|Conventional group|A group of patients who underwent total hip replacement arthroplasty using a conventional acetabular cup
89322186|NCT03603639|Experimental|Placebo, E2730 40 mg, E2730 120 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
89322187|NCT03603639|Experimental|E2730 40 mg, E2730 120 mg, Placebo|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
89322188|NCT03603639|Experimental|E2730 120 mg, Placebo, E2730 40 mg|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
89322189|NCT03603639|Experimental|Placebo, E2730 120 mg, E2730 40 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
89322190|NCT03603639|Experimental|E2730 40 mg, Placebo, E2730 120 mg|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
89322191|NCT03603639|Experimental|E2730 120 mg, E2730 40 mg, Placebo|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
89322192|NCT02159170|Experimental|NGF|injection of 50 µl NGF, once into the left volar forearm and injection of 50 µl NaCl (sodium chloride) once into the right volar forearm
89322193|NCT01186640|Experimental|FCM-A followed by A-maintenance|First treatment phase: Chemoimmunotherapy A-FMC maximum 4 cycles. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c.
89322194|NCT03727503|Other|group/cohort|operated patients from cardiac surgery. Once they arrived in the ICU, we will measure PPV with the capstesia and the PICCO device at baseline, and after a volume expansion of 500 ml of crystalloid.
89322195|NCT04949516|Experimental|Mono Antiplatelet and Colchicine Therapy|Aspirin-free, single P2Y12 inhibitor (prasugrel or ticagrelor) and colchicine treatment
89322196|NCT00114959|Experimental|Homoharringtonine + Imatinib Mesylate|Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous infusion daily on Days 1-5 of each 4 week treatment cycle, and imatinib mesylate (Gleevec) by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML.
89322197|NCT02778100|Experimental|Nasal Glucagon (NG) - Common Cold|Cohort 1 - Nasal Glucagon (NG) administered once in participants with a common cold.
89322198|NCT02778100|Experimental|Nasal Glucagon (NG) - Symptom-Free|Cohort 1 - NG administered once in participants who have recovered from a common cold.
89322199|NCT02778100|Experimental|NG - Common Cold+Oxymetazoline|Cohort 2 - NG administered once in participants with a common cold who are taking oxymetazoline.
89322200|NCT02159248|Experimental|Tolfenamic acid + gemcitabine + radiation|
89322201|NCT00118157|Experimental|Treatment (lapatinib, tamoxifen)|Patients receive lapatinib ditosylate PO daily and tamoxifen citrate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89322202|NCT02160652||Patients|Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.
89322203|NCT02762500|Experimental|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily for 8 weeks
89322204|NCT02762500|Placebo Comparator|Placebo PO QD|Matching placebo by mouth once daily for 8 weeks
89322205|NCT03543202|Experimental|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
89322206|NCT03543202|Active Comparator|Local infiltration anesthesia|will receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
89322207|NCT03543202|Sham Comparator|Intravenous patient control analgesia|will not receive any regional anethetic intervention will receive intravenous patient controlled analgesia
89322208|NCT03552549|Experimental|PEG-Intron|Participants with stage III node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years post-surgery.
89322209|NCT03552549|Experimental|INTRON A|Participants with stage III node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units [MIU]/m^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m^2 three times per week) for 48 weeks post-surgery.
89322210|NCT00117845|Experimental|Denileukin Diftitox in ATL|Denileukin Diftitox in adult T-cell leukemia (ATL) Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
89322211|NCT02761642|Experimental|Epoetin Beta|Anemic breast cancer participants will receive epoetin beta treatment for 12 weeks.
89322212|NCT03621033|Other|non-transparent cap-assisted endoscopic intubation|we do not use transparent cap-assisted endoscopic intubation.
89322213|NCT03621033|Other|transparent cap-assisted endoscopic intubation|we use transparent cap-assisted endoscopic intubation in the second insertion.
89322214|NCT01310595|Experimental|Manual mobilization on cervical spine|Manual mobilization given on cervical spine with infra-red therapy and self exercise and advice pamphlet.
89322215|NCT01310595|Active Comparator|Infra-red radiation therapy|Infra-red radiation therapy with self exercise pamphlet given to patients with chronic mechanical neck pain.
89322216|NCT00113555|Experimental|Experimental|Open Label Study, ACT (Adjustable Continence Therapy)
89322217|NCT02150668|Experimental|HOPS Intervention|School counselors deliver HOPS intervention to students during the school day. This includes 16, 20-minute sessions with the student and two joint family meetings.
89322218|NCT02150668|Active Comparator|HSI Intervention|School counselors deliver the HSI intervention which focuses on improving focus and efficiency of work completion. This consists of 16, 20-minute sessions, with the student and two joint family meetings.
89322219|NCT03731403|Experimental|MI Varnish|
89322220|NCT03731403|Active Comparator|Profluorid Varnish|
89322221|NCT02150746||Pancreatic Cancer CTC|Peripheral/Central Venous Blood Draw Peritoneal Wash
89322222|NCT03189524|Experimental|Part I: 160 mg BID|"Safety Evaluation: Two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily [BID]) administered in the morning and at night, or 320 mg (once daily [QD]), and a 3+3 design was adopted for Part I of the study to determine recommended Phase 2 dose (RP2D)."
89322223|NCT03189524|Experimental|Part I: 320 mg QD|"Safety Evaluation: Two regimens of zanubrutinib 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and a 3+3 design was adopted for Part I of the study to determine RP2D."
89322224|NCT03189524|Experimental|Part II: 160 mg BID|Dose Expansion: The RP2D determined in Part I was used in Part II to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL).
89322225|NCT02150824|Experimental|BI 187004 low dose mono QD|patient to receive one tablet containing low dose of BI 187004 or matching placebo
89322226|NCT02150824|Experimental|BI 187004 medium dose mono QD|patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo
89322227|NCT02150824|Experimental|BI 187004 high dose mono QD|patient to receive one tablet containing high dose of BI 187004 or matching placebo
89322228|NCT02150824|Experimental|BI 187004 high dose QD add on|patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose
89322229|NCT03600909|Experimental|Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias (Arm A) will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.6-0.8 mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
89322230|NCT03600909|Experimental|Intermediate risk patients|Patients 18 years old or younger with MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8-1.0mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
89322231|NCT03600909|Experimental|High risk patients|Patients 19 years old or older with marrow aplasia or MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.4mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
89322232|NCT03742024||Children and adolescents|Children and adolescents between the ages of 4 and 17 years old (inclusive)
89322233|NCT03727269|Experimental|Wii Fit Training Experimental Group|receiving Wii fit based abdomino-pelvic training
89322234|NCT03727269|Active Comparator|Conventional Training Control Group|receiving conventional pelvic floor exercises.
89322235|NCT03741868||Stage IV non-small cell lung cancer|60 - stage IV non-small cell lung cancer patients will be recruited through the Wake Forest Baptist Comprehensive Cancer Center to complete the quantitative portion of the study. We will use purposive sampling to assure representation of patients at different stages in immunotherapy (i.e., initiating treatment, anticipating scan results, after onset of immune-related side effects).12-15 of the 60 patients who complete the survey and who express interest in providing feedback on programs and participating in future research will be recruited to complete the qualitative portion of the study
89322236|NCT02151136|Experimental|24% sucrose + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml 24% sucrose will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
89322237|NCT02151136|Placebo Comparator|Sterile water + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml sterile water will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
89322238|NCT03212690|Experimental|Mechanically ventilated subjects|Subjects receiving invasive mechanical ventilation (Duration of ventilation <=48 hours) will be evaluated using standard care investigations.
89322239|NCT05390216|Experimental|Partial capsule decortication|
89322240|NCT05390216|No Intervention|Without partial capsule decortication|
89322241|NCT01314482|Experimental|Minocycline|
89322242|NCT03188120||Spiriva Respimat group|
89322243|NCT02895945|Experimental|BAX 802 in Surgery|Participants who are undergoing major or minor elective surgical, dental, or other invasive procedures.
89322244|NCT02777554|Experimental|Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD|Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2.
89322245|NCT02777554|Experimental|Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID|Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2.
89322246|NCT02777554|Experimental|Part 2: Sequence 1|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal."
89322247|NCT02777554|Experimental|Part 2: Sequence 2|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal."
89322248|NCT02777554|Experimental|Part 2: Sequence 3|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet under fasted conditions."
89322249|NCT02777554|Experimental|Part 2: Sequence 4|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions."
89322250|NCT02160886|Experimental|Child-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the children themselves, using the Swedish version of the Perceived Efficacy and Goal Setting System (PEGS).~A PEGS interview will be performed with the children. The children identifies tasks they find difficult to perform and prioritize three tasks, they want to perform better, as goals for intervention."
89322251|NCT02160886|Experimental|Parent-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the parents using the Canadian Occupational Performance Measure (COPM).~Using the COPM interview technique, the parents are encouraged to talk about an ordinary day to identify occupational performance issues their child is not able to perform. Identified performance issues are rated for importance and the parents selects the three most important issues as goals for intervention."
89322252|NCT03220178|Experimental|CANKADO active|CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome.
89322253|NCT03220178|Other|CANKADO inform|CANKADO inform stands for a CANKADO-based eHealth service with a personal login. For the patient , on-site surveys without feedback functions and a dosing tracker to document daily drug intake will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from home, but they will only get text information about their disease and treatment. Further features will be unavailable.
89322254|NCT03550209|Experimental|LCPUFA Oil Supplement, Low Dose|25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
89322255|NCT03550209|Experimental|LCPUFA Oil Supplement, Medium Dose|50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
89322256|NCT03550209|Experimental|LCPUFA Oil Supplement, High Dose|75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
89322257|NCT03550209|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
89322258|NCT02161042||fresh blood Transfusion|
89322259|NCT02161042||Old blood transfusion|
89322260|NCT03725241|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
89322261|NCT03725241|Experimental|Experimental: Glutathione|Intervention: Dietary Supplement: Glutathione supplement
89322262|NCT03725163|Experimental|Treatment|This arm will begin treatment immediately after completing the initial intake assessment.
89322263|NCT03725163|Other|Waitlist Control|Participants assigned to the waitlist control condition will begin a 12-week waiting period after completing the initial intake assessment before starting treatment.
89322264|NCT03032510|Experimental|Eravacycline (Intravenous)/Levofloxacin (Oral)|
89322265|NCT03032510|Active Comparator|Ertapenem (Intravenous)/Levofloxacin (Oral)|
89322266|NCT03727035||Group I|Group I :40 Generalized chronic periodontitis subjects without type II diabetes mellitus
89322267|NCT03727035||Group II|Group II: 40 Generalized chronic periodontitis subjects diagnosed with type II diabetes mellitus
89322268|NCT03599349|Experimental|Microfocused ultrasound w/ visualization|Each subject to receive a full face and neck area treatment using a standard 800 line treatment with set energy levels (0.90 joules for the 4-4.5mm transducer, 0.30 joules for the 7-3.0mm/7-3.0N transducers and 0.75 joules for the 7-4.5mm transducer)
89322269|NCT02161120|Active Comparator|Traditional rye bread|As part of habitual diet participants are expected to consume 100-200 grams of traditional Finnish rye bread daily
89322270|NCT02161120|Experimental|Low-FODMAP rye bread|As part of habitual diet participants are expected to consume 100-200 grams of low-FODMAP rye bread daily
89322271|NCT02161198|Experimental|Y-75|volunteers receive 3 packages twice a day up to 14 weeks
89322272|NCT02161198|Placebo Comparator|Placebo|volunteers receive 3 packages twice a day up to 14 weeks
89322273|NCT03022292|Experimental|IAI Treatment|Intravitreal injection of aflibercept 2 mg/0.05 ml at baseline, week 4, week 8, week 16, week 24, week 36, and week 48. Additional injections can be administered during the remaining visits on an as needed basis per Primary Investigator (PI) discretion based on the presence of any intraretinal or subretinal fluid on OCT, heme visualized on examination, reduction of BCVA by 5 or more ETDRS letters, or evidence of either increased area, density, or activity of the brush border of the neovascularization on OCT-angiography. There will be a minimum of 21 days between subsequent injections. Each subject will therefore receive a minimum of 7 injections and up to a maximum of 13 injections throughout the study period.
89322274|NCT02161276|Experimental|TNTL capsule and Placebo|3-4 capsules 3 times a day Used before meals
89322275|NCT03599193|Experimental|DFD-03 Lotion|DFD-03 Lotion will be applied to the affected areas twice daily for 1 minute and rinsed off. 29 subjects will be enrolled into this arm.
89322276|NCT03599193|Active Comparator|Tazorac Cream|Tazorac Cream will be applied to the affected areas once daily and left on for ~12 hours. 29 subjects will be enrolled into this arm.
89322277|NCT02161354|Experimental|2mg dose of NTC-510 or placebo|Subjects will be dosed with 2 mg of NTC-510 or placebo.
89322278|NCT02161354|Experimental|4 mg dose of NTC-510 or placebo|Subjects will be dosed as a split dose of 2 mg followed by 2 mg an hour later of NTC-510 or placebo.
89322279|NCT02161354|Experimental|6 mg dose of NTC-510 or placebo|Subjects will be dosed with 6 mg of NTC-510 or placebo.
89322280|NCT02161354|Experimental|2 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 2mg of NTC-510A or placebo
89322281|NCT02161354|Experimental|4 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 4 mg of NTC-510A or placebo
89322282|NCT02161354|Experimental|6 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 6 mg of NTC-510A or placebo
89322283|NCT02161432|Experimental|Treatment A|single dose of BI 187004 in fasted state
89322284|NCT02161432|Experimental|Treatment B|single dose of BI 187004
89322285|NCT02161432|Experimental|Treatment C|single dose of BI 187004 in fed state
89322286|NCT03166124|Experimental|Elderly Adults LY900014|Single, subcutaneous (SC) 15-U dose of LY900014 in the elderly adult group.
89322287|NCT03166124|Active Comparator|Elderly Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in in the elderly adult group.
89322288|NCT03166124|Experimental|Younger Adults LY900014|Single, SC 15-U dose of LY900014 in the younger adult group.
89322289|NCT03166124|Active Comparator|Younger Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in the younger adult group.
89322290|NCT03567291|Experimental|TEV-50717- Part A|All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.
89322291|NCT03567291|Experimental|TEV-50717- Part B RW|TEV-50717 is administered during Part B Randomized Drug Withdrawal (RW) 2-week period.
89322292|NCT03567291|Placebo Comparator|Placebo- Part B RW|Placebo is administered during Part B Randomized Drug Withdrawal (RW) 2-week period only.
89322293|NCT02777242|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate administered subcutaneously once each week. Auto-injection of QST 50 mg or 75 mg or 100 mg [Device: QuickShot® Testosterone (QST)]
89322294|NCT03212144|Experimental|High Intensity Interval Training then Peanut Consumption|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
89322295|NCT03212144|Experimental|Peanut Consumption then High Intensity Interval Training|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
89322296|NCT02163070|Experimental|whey drink|consumption of 220 milliliters of whey drink three times a week,
89322297|NCT02163070|Experimental|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
89322298|NCT02163070|Experimental|vitaminE|consumption of 400 milligrams of vitamin E three times a week,
89322299|NCT02163070|No Intervention|D- control|control group: no intervention,
89322300|NCT02748200|Experimental|external beam radiotherapy: Dose level 1|57.6 Gray (Gy) (20 x 2.88 Gy, 5 fractions/week, 4 weeks)
89322301|NCT02748200|Experimental|external beam radiotherapy: dose level 2|60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks)
89322302|NCT02748200|Experimental|external beam radiotherapy: dose level 3|62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks)
89322303|NCT02151214|Experimental|Parenteral nutrition|Parenteral nutrition will be administered to the patients
89322304|NCT02151214|No Intervention|Normal per os nutrition|The patients will eat orally
89322305|NCT03484520|Experimental|Venetoclax + Dinaciclib|Venetoclax and dinaciclib will be administered in combination. Different combinations of dose levels for venetoclax and dinaciclib will be explored.
89322306|NCT03566979|Experimental|Test naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX)
89322307|NCT03566979|Active Comparator|Commercial naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two commercial naproxen sodium 220 mg tablets
89322308|NCT03566979|Active Comparator|Commercial naproxen sodium liquid gels capsule|Single dose of 440 mg of naproxen sodium administered as two 220 mg commercial liquid gels capsules
89322309|NCT03566979|Placebo Comparator|Placebo tablet|Single dose of two Placebo tablets
89322310|NCT00116831|Active Comparator|Glipizide|oral anti-diabetic medication
89322311|NCT00116831|Experimental|rosiglitazone maleate|oral anti-diabetic medication
89322312|NCT02777086|Experimental|StaySafe|Participants are asked to complete 12 brief, self-administered tablet computer sessions designed to improve decision-making around health risk behaviors. Sessions typically take about 10 minutes each to complete and are scheduled prior to or after probationer group or individual appointments at their probation facility. Sessions are scheduled about once per week.
89322313|NCT02777086|No Intervention|Comparison|Participants are asked to complete baseline, 3-month and 6-month surveys but are not asked to complete StaySafe sessions or other alternate activities.
89322314|NCT03549429|Experimental|TegadermTM on R eye, EyeGard® on L eye|Patients will get TegadermTM on Right eye, EyeGard® on Left eye
89322315|NCT03549429|Experimental|TegadermTM on L eye, EyeGard® on R eye|Patients will get TegadermTM on Left eye, EyeGard® on Right eye
89322316|NCT02161510|Experimental|Part I: MK-2248 200 mg (Panel A)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
89322317|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel B)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
89322318|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel C)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days.
89322319|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel D)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
89322320|NCT02161510|Experimental|Part II: MK-2248 200 mg (Panel E)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
89322321|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel F)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
89322322|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel G)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
89322323|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel H)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
89322324|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel I)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
89322325|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel J)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
89322326|NCT02161588|Experimental|Semaglutide|
89322327|NCT02161588|Placebo Comparator|Placebo|
89322328|NCT02163148||Public Speaking Anxiety|Intervention to be administered: One speech exposure session.
89322329|NCT03727672||Tension type headache patients|30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
89322330|NCT03727672||Migraine patients|30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016.
89322331|NCT03727672||age matched controls|30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives
88806613|NCT05901389|Placebo Comparator|normal saline|Patients in this group will receive continuous normal saline infusion via closed chest drainage tube. The pulse infusion speed is same as the lidocaine group.
88806614|NCT05901376||Gastric Cancer|
88806615|NCT05901376||Control|
89322332|NCT02161666||Patients|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
89322333|NCT02161666||Controls|Age, sex and BMI-matched healthy controls
89322334|NCT02161744|Experimental|ADSCs administration|Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.
89322335|NCT02784704|Experimental|Eravacycline|
89322336|NCT02784704|Active Comparator|Meropenem|
89322337|NCT03727516||patients undergone elbow surgery|Patients undergone elbow surgery at routine follow up at 2 or 6 months
89322338|NCT03541096|Experimental|Winter Swimmers|4 Months of supervised winter swimming.
89322339|NCT03541096|Placebo Comparator|Control group|No winter swimming activities.
88806616|NCT05901363|Experimental|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy
88806617|NCT05901363|Active Comparator|laparoscopic common bile duct exploration and laparoscopic cholecystectomy|
88806618|NCT05901337|Active Comparator|Cupping therapy with Convential medical treatment|Cupping therapy with Convential medical treatment
88806619|NCT05901337|Active Comparator|Convential medical treatment|Convential medical treatment
88806620|NCT05901324|Experimental|Maintenance therapy with lenalidomide as the maintenance therapy for patients with PCNSL or PVRL|
88806621|NCT05901272|Other|Implementation strategy bundle 1|Local clinical champion and learning collaborative.
88806622|NCT05901272|Other|Implementation strategy bundle 2|Local clinical champion, learning collaborative, and external facilitation.
89322340|NCT03731338||Reassured and discharged|patients who are reassured and discharged after first attendance
89322341|NCT03731338||Further diagnostic testing|Patients who went on to have further diagnostic testing
89322342|NCT02166658|Experimental|Single Arm|Patients receive Cabazitaxel 25 mg/m2 i.v. infusion. This trial is a single arm trial.
89322343|NCT03566823|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
89322344|NCT03566823|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
89322345|NCT03566823|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
89322346|NCT02163304|Active Comparator|Artificial Sweetner|Artificial Sweetener
89322347|NCT02163304|Placebo Comparator|Tasteless Solution|12 oz tasteless solution
89322348|NCT02163304|Active Comparator|Sucrose|12 oz 75 g sucrose beverage
89322349|NCT03540472|Experimental|efficiency of tacrolimus on PRCA|"A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
89322350|NCT05241548|Experimental|Intervention Group|Ridge augmentation of horizontally deficient alveolar ridge in aesthetic zone by BMAC on PCL scaffold
89322351|NCT02166736|Experimental|Instantaneous wave-free ratio (iFR)|
89322352|NCT02166736|Active Comparator|Fractional Flow Reserve (FFR)|
89322353|NCT02166814|Experimental|Fimasartan and Rosuvastatin|Combination of Fimasartan and Rosuvastatin
89322354|NCT02166814|Active Comparator|Fimasartan|Fimasartan monotherapy
89322355|NCT02166814|Active Comparator|Rosuvastatin|Rosuvastatin monotherapy
89322356|NCT01310283|No Intervention|control group|Conventional pediatric dental care.
89322357|NCT02161822|Experimental|Simvastatin|single arm : Simvastatin
89322358|NCT02163382|Experimental|Neurovent Monitor XIII|1 hour Ventilation with NAVA
89322359|NCT03549117|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
89322360|NCT03549117|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH nasal strips placebo nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
89322361|NCT03183908|Active Comparator|Adjuvanted influenza vaccine (FLUAD®)|In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.
89322362|NCT03183908|Active Comparator|High-dose influenza vaccine (Fluzone® HD)|In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.
89322363|NCT03724851|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Pembrolizumab will be administered as a dose of 200 mg every 3weeks.
89322364|NCT03724773|Active Comparator|Long-Arm Cast|Reduction and long-arm cast application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
89322365|NCT03724773|Active Comparator|Sugar-Tong Splint|Reduction and sugar-tong splint application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
88806623|NCT05901233|Experimental|RS-LRT|
89322366|NCT03731325|Experimental|Episodic Future Thinking Group|The experimental group (N=20 families; N=40 total) will receive the Episodic Future Thinking (EFT) intervention. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now [Atance].
88806624|NCT05901233|Experimental|RS-VISTA|
88806625|NCT05901207||Case|
89322367|NCT03731325|Placebo Comparator|Healthy Thinking Group|The placebo group (N=20 families; N=40 total) will receive the Healthy Thinking (HT) intervention. HT encourages individuals to focus on the nutritional characteristics of food and the healthy benefits of physical activity.
89322368|NCT03565887|Experimental|RVL-1201 ophthalmic solution 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
89322369|NCT03565887|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
89322370|NCT03183518|Experimental|Test Product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
89322371|NCT03183518|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
89322372|NCT00116753|Active Comparator|Degarelix 240@40/240@40 (1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9.
89322373|NCT00116753|Active Comparator|Degarelix 240@40/240@60(1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9.
89322374|NCT00116753|Active Comparator|Degarelix 240@40/240@60(1,4,7,10)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10.
89322375|NCT00113399|Other|Radiotherapy and chemotherapy|Radiotherapy/paclitaxel/cisplatin/filgrastim
89322376|NCT00113399|Other|Chemotherapy|Cisplatin/fluorouracil/paclitaxel/docetaxel
89322377|NCT01326611|Active Comparator|Clarithromycine Group: Active Comparator|Drug: Clarithromycin intravenous clarithromycin (10 mg/kg twice a day for 10 days)
89322378|NCT01326611|Placebo Comparator|Placebo Group: Placebo Comparator|Drug: D5W Dose given daily, IV same volume that Clarithromycin would be to equal 10 mg/kg for first 10 days.
89322379|NCT01082783||patients with acute media infarct|
89322380|NCT01082783||controls with cardiovascular risks|
89322381|NCT01326689|Experimental|KW-2246|
89322382|NCT01326689|Placebo Comparator|Placebo|
89322383|NCT00113087|Active Comparator|Enalapril|Enalapril (angiotensin converting enzyme inhibitor)
89322384|NCT00113087|Placebo Comparator|Placebo|Placebo (Ora-Plus and Ora-Sweet)
89322385|NCT01082861|Experimental|HPV&HBV vaccin|HPV&HBV vaccin
89322386|NCT01082861|Experimental|HPV vaccination|HPV vaccination
89322387|NCT01082861|Experimental|HBV vaccination|HBV vaccination
89322388|NCT00112463|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
89322389|NCT01083017||chlorthalidone|
89322390|NCT01083017||motivational invervention|motivational interview(s) vs. repeated calls vs. no particular intervention
89322391|NCT01083017||standardized anti-hypertensive treatment|
89322392|NCT01066481|Experimental|PF-01913539 5 mg three times daily|PF-01913539 5 mg three times daily for 6 months
89322393|NCT01066481|Experimental|PF-01913539 20 mg three times daily|PF-01913539 20 mg three times daily for 6 months
89322394|NCT01066481|Placebo Comparator|Placebo|Placebo three times daily for 6 months
89322395|NCT03548415|Placebo Comparator|Placebo|Participants received placebo by subcutaneous injection (SC) once every 4 weeks for 16 weeks.
89322396|NCT03548415|Experimental|Cohort A: IONIS GHR-LRx, 60 mg|Participants received IONIS GHR-LRx, 60 milligrams (mg), SC, once every 4 weeks for 16 weeks.
88806626|NCT05901194|Experimental|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight < or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
88806627|NCT05901181|Experimental|Laughter Yoga Group|When we look at the literature, the Laughter Yoga practice is held between 2 weeks and 10 weeks, once a week, 5 times a week, 2 weeks and lasting approximately 25-45 minutes. In this study, the intervention will be implemented within 8 weeks. To the women who constitute the intervention group; After giving short-term self-care training in Menopause for 8 weeks, relaxation will be applied after the practice of Laughter yoga, which starts with breathing exercises, warm-up exercises, childlike games and has different exercises in each session. The research will be carried out in the Famagusta Municipality Development Academy, in a bright hall where women can take a U shape, everyone will be face to face, and will not be disturbed during the application.
88806628|NCT05901181|No Intervention|Control Group|Routine care was given to the control group
89322397|NCT03548415|Experimental|Cohort B: IONIS GHR-LRx, 80 mg|Participants received IONIS GHR-LRx, 80 mg, SC, once every 4 weeks for 16 weeks.
89322398|NCT03548415|Experimental|Cohort C: IONIS GHR-LRx, 120 mg|Participants received IONIS GHR-LRx, 120 mg, SC, once every 4 weeks for 16 weeks.
89322399|NCT03548415|Experimental|Cohort D: IONIS GHR-LRx, 160 mg|Participants received IONIS GHR-LRx, 160 mg, SC, once every 4 weeks for 16 weeks.
89322400|NCT00112385|Active Comparator|Etanercept|Subjects randomized to Etanercept will be provided with syringes contain 50 mg and will be injected subcutaneously once a week for 52 weeks.
89322401|NCT00112385|Placebo Comparator|Placebo|Subjects will be given syringes containing placebo. Injections will be given subcutaneously, one time per week for 52 weeks.
89322402|NCT03548337|Active Comparator|13vPnC with 2-PE from a MDV|Multi Dose Vial with preservative
89322403|NCT03548337|Active Comparator|13vPnC without 2-PE in a PFS|Pre Filled Syringe without preservative
89322404|NCT03596151|Experimental|Click Device|One self collected vaginal swab for Click Device testing. Three health care provider collected vaginal swabs for comparator testing.
89322405|NCT03724617|Experimental|stem cell therapy|
89322406|NCT03547635|Experimental|AMNIOEXCEL Plus Amniotic Membrane|
89322407|NCT03547635|Active Comparator|A Marketed Comparator|
89322408|NCT03547635|Other|Standard of Care|
89322409|NCT03731169|Active Comparator|TDM Only|This is the standard of care trial arm. Patients receive voriconazole dosages according to the product monograph. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
89322410|NCT03731169|Experimental|Genotyping + TDM|After ascertaining CYP2C19 genetic status, the participants will be categorized as having either the ultra-rapid metabolizer (URM), extensive metabolizer (EM), heterozygous extensive metabolizer (HEM) or poor metabolizer (PM) phenotype. They will receive an experimental dosage regimen based on their phenotype. receive the following dosing regimen until TDM is conducted on day 4. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
89322411|NCT03724539|Experimental|STRIPA intervention|"GPs in the intervention group will perform a STRIPA analysis for each of their 8-10 patients after the recruitment of the patient into the OPTICA trial, so that the results can be discussed in the next consultation and a shared decision-making can be performed.~STRIPA is a structured method to perform pharmacotherapy optimization. The STRIPA intervention in the OPTICA trial consists of 4 steps:~recording medication and diagnoses in STRIPA (upload from data from the 'Family medicine ICPC Research using Electronic medical records' (FIRE) database)~structured drug review through the GP based on the STRIPA with the integrated STOPP/START criteria~shared decision-making between GP and patient with possible adaptation of the recommendation~follow-up through study team"
89322412|NCT03724539|Sham Comparator|Sham intervention|Patients in the control group will receive a sham intervention, which consists of a usual medication review by their GP as well as a shared decision making of the latter.
89322413|NCT03731091|Experimental|Calcipotriene/ betamethasone dipropionate topical foam|Topical foam once daily for 4 weeks (28 days)
89322414|NCT03731091|Active Comparator|Enstilar®|Topical foam once daily for 4 weeks (28 days)
89322415|NCT03731091|Placebo Comparator|Placebo|Topical foam once daily for 4 weeks (28 days)
89322416|NCT03726801|Experimental|Stratum C|"N 32 C~Women who are going to be mastectomized, conservate surgery and ostomy who attend the health education together with their immediate family member prior to surgery"
89322417|NCT03726801|Placebo Comparator|Stratum E|"N 32 E~Patients who are going to be subjected to a mastectomized, conservate surgery and ostomy who come alone to the health education prior to surgery"
89322418|NCT03133676|Experimental|KA34 Active Drug|KA34 active drug in the dose range of 50 - 400 ug per knee
89322419|NCT03133676|Placebo Comparator|Placebo|Placebo is the formulation for KA34.
89322420|NCT03182738|Experimental|Intervention|VIP app that delivers HIV-related symptom strategies
89322421|NCT03182738|Sham Comparator|Control|VIP app without HIV-related symptom strategies
89322422|NCT03547167|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
89322423|NCT03547167|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
89322424|NCT03726645|Active Comparator|Study group|Allogeneic fecal microbiota transplantation (from donor)
89322425|NCT03726645|Placebo Comparator|Control group|Autologous fecal microbiota transplantation (own stool)
89322426|NCT03560739|Other|OMB 20mg PFS abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on abdomen
89322427|NCT03560739|Other|OMB 20mg AI abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on abdomen
89322428|NCT03560739|Other|OMB 20mg PFS thigh|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on thigh
89322429|NCT03560739|Other|OMB 20mg AI thigh|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on thigh
89322430|NCT03724461|Active Comparator|High intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg is established as control.
89322431|NCT03724461|Active Comparator|Light intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes light-moderate intensity resistance training (12 weeks) and the other leg is established as control.
89322432|NCT03724461|Experimental|High vs Light intensity (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg undergoes light-moderate intensity resistance training.
89322433|NCT03724461|Experimental|High intensity (Acute)|Analysis of the effects of one High Intensity resistance training session, with a crossover design.
89322434|NCT03724461|Experimental|Light intensity (Acute)|Analysis of the effects of one Light-moderate Intensity resistance training session, with a crossover design.
89322435|NCT03724383|No Intervention|Control|Participants in the control arm will receive standard care.
89322436|NCT03724383|Experimental|Intervention|Participants in the intervention group will receive risk factor management consultations and take part in 1-hour biweekly diet classes and stress management classes for the first 3 months. This will be followed by 3 months of 1-hour biweekly high intensity interval training exercise classes. At the 6-month time point, participants will be prescribed a home based exercise program and will have the option of participating in weekly group walking sessions. During the final 6 months, participants will use a step/activity tracker to track their steps and heart rate.
89322437|NCT01310673|Active Comparator|Allopurinol|
89322438|NCT01310673|Placebo Comparator|Placebo|
89322439|NCT03726567|Active Comparator|Bariatric surgery group|Patients who are undergoing bariatric surgery for weight loss
89322440|NCT03726567|No Intervention|Non bariatric surgery group|Patients who are undergoing abdominal surgery for non-weight loss reasons
89322441|NCT05665257|Experimental|Inspiratory muscle training|Participants in the intervention group were using a handheld device, Powerbreathe K3, aiming at increasing inspiratory muscle strength by applying an inspiratory resistance. They were instructed to use it twice a day for at least 14 days. Starting load was based on the baseline assessment of the participant's inspiratory muscle strength and increased during the intervention period.
89322442|NCT05665257|Sham Comparator|Mini-PEP|Participants in the control arm were instructed to use a handheld PEP-device traditionally used to facilitate deep breathing. The PEP-device does not provide any inspiratory resistance and therefore, it was considered a sham treatment. The control group were also instructed to use the device twice a day for at least two weeks.
89322443|NCT03730935|Experimental|Intervention|Respiratory muscle endurance training (30 minutes of volitional hyperpnoea at a target ventilation of 60-70% of the individual maximal voluntary ventilation for 5 days per week for 4 weeks).
89322444|NCT03730935|Sham Comparator|Sham|Sham training will be performed 5 times a week for 4 weeks using a mock asthma inhaler filled with 5.5 mg lactose powder. Subjects will be instructed to inhale the powder according to inhaler instructions and to then perform one full inspiration to total lung capacity using custom-made, low resistance tubing, which elicits minimal resistance to breathing.
89322445|NCT00101686|Experimental|Modified Bolus 5-FU/LV with Irinotecan|
89322446|NCT00101686|Experimental|FOLFIRI + bevacizumab|
89322447|NCT00101686|Experimental|miFL + bevacizumab|
89322448|NCT00101686|Experimental|Infusional 5-FU/LV with Irinotecan|
89322449|NCT00101686|Other|Oral Capecitabine with Irinotecan|
89322450|NCT02166892|Active Comparator|Normal weight|Normal weight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
89322451|NCT02166892|Active Comparator|Overweight children|Overweight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
89322452|NCT02163460|Experimental|Drain|In group 1(Drain), a 4.8 mm diameter continuous closed-suction tubular drain : was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
89322453|NCT02163460|Experimental|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
89322454|NCT02166970|Experimental|Single stent deployment|Metallic stent deployment in hilar obstruction. Insertion of metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
89322455|NCT02166970|Active Comparator|Multiple stent deployment|Metallic stent deployment in hilar obstruction. Insertion of multiple metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
89322456|NCT02163616|Experimental|PPH Treatment|800mcg sublingual misoprostol
89322457|NCT02162056|Experimental|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffold for coronary artery disease.
89322458|NCT02163772|Experimental|Intracordal hyaluronate injection (HI)|The intervention of Intracordal hyaluronate (Restylane) injection is given in this group No other therapies are given
89322459|NCT02163772|No Intervention|Conservative management (CM)|In this arm, only observation is arranged. No therapy is given.
89322460|NCT00101452|Experimental|S-adenosyl-l-methionine (SAMe)|A natural substance
89322461|NCT00101452|Active Comparator|2. Escitalopram|A selective serotonin reuptake inhibitor (SSRI)
89322462|NCT00101452|Placebo Comparator|3. placebo|Sugar pill- contains no active ingredients
89322463|NCT02167126|Experimental|Kinesio Taping|Kinesio Taping was applied as experimental group.
89322464|NCT02167126|Placebo Comparator|Micropore|Micropore Tape was used as placebo tape
89322465|NCT02163850|Experimental|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
89322466|NCT02163850|Active Comparator|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
89322467|NCT02162134|Other|no chewing gum.|the no chewing gum group was control and receive no chewing gum postoperatively. While they received all other medications like anesthesia, antibiotics etc
89322468|NCT02162134|Experimental|sugar free chewing gum|sugar free chewing was given to patients 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started.
89322469|NCT02162134|Experimental|sugared chewing gum|sugared chewing gum will be given 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started
89322470|NCT02164006|Experimental|TGR-1202 + brentuximab vedotin|TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin
89322471|NCT02162212|Active Comparator|ADA guideline Instructed|The control intervention will be instruction in basic wellness activities according to the American Diabetes Association guidelines
89322472|NCT02162212|Experimental|Optimized Shoulder Movement Program|"The experimental intervention is the Optimized Shoulder Movement Program. Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation, and active shoulder motion based on the participant's baseline activity count ."
89322473|NCT02167360|Experimental|Single Arm|
89322474|NCT03540784|No Intervention|Control group|usual care treatment
89322475|NCT03540784|Experimental|Nutrition|high-protein nutrition therapy
89322476|NCT03540784|Experimental|EMS+Nutrition|WB-EMS Training (2x/week á 20 min) + high-protein nutrition therapy
89322477|NCT02164084|Experimental|SB204|SB204 8% topically twice daily for 4 days and once on Day 5
89322478|NCT02164084|Placebo Comparator|Vehicle Gel|Vehicle Gel topically twice daily for 4 days and once on Day 5
89322479|NCT02164162|Experimental|Experimental group|"Participants received 12 sessions of robotic assisted body weight-supported treadmill training on the Lokomat. Training occurred approximately 3 days/ week for 4 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support.~Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session."
89322480|NCT02164162|Active Comparator|Control group|Participants received 20 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 4 weeks, and each training session lasted 1 hour .Patients allocated to the Control Group performed a general exercise program and a conventional gait training with a 5-minute rest between them. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long.
88806629|NCT05901142|Experimental|Exercise-based multi-phasic, multi-modal intervention|An exercise-based multi-phasic (pre-surgery and post-surgery) and multi-modal (exercise, targeted physiotherapy, dietary advice, and psychological coping and behaviour change) intervention
89322481|NCT02167438|Experimental|Investigational|Application of the Hem-Avert device.
89322482|NCT02167438|No Intervention|Control|No Application of the Hem-Avert device.
89322483|NCT02167516|Experimental|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
89322484|NCT02167516|Active Comparator|glucosamine sulfate capsule|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
89322485|NCT03546621|Experimental|Arm A|Myrcludex B, 2 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
89322486|NCT03546621|Experimental|Arm B|Myrcludex B, 5 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
89322487|NCT03546621|Experimental|Arm C|Myrcludex B, 10 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
89322488|NCT03546621|Active Comparator|Arm D|tenofovir treatment for 48 weeks
89322489|NCT02761330|Active Comparator|Etomidate + ECT|General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
89322490|NCT02761330|Experimental|Ketamine + ECT|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
89322491|NCT02761330|Sham Comparator|Ketamine alone|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.
89322492|NCT02164474|Experimental|High-Intensity Interval Training (HIIT)|Participants will perform a series of high-intensity intervals with an interval length of 60-seconds at 90% of peak aerobic capacity workload, and a rest length of 60-seconds.
89322493|NCT02164474|Active Comparator|Moderate-Intensity Continuous Exercise|Participants will engage in exercise at 45% of peak aerobic capacity workload.
89322494|NCT02162290|Experimental|Interval exercise|Exercise bouts in low and high intensities
89322495|NCT02162290|Experimental|Continuous exercise|Exercise continuously with moderate intensity
89322496|NCT02162524|No Intervention|No Exercise Control|Healthy Living Group
89322497|NCT02162524|Active Comparator|Aerobic Exercise Group|Persons are aerobically exercising.
89322498|NCT03559257|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC).
89322499|NCT03559257|Placebo Comparator|Placebo|Placebo administered SC.
89322500|NCT03540316|Active Comparator|Two short implants and 2 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and Low level laser therapy (LLLT) for 2 minutes .
89322501|NCT03540316|Active Comparator|Two short implants and 4 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
89322502|NCT03540316|Active Comparator|Four short implants and 2 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
89322503|NCT03540316|Active Comparator|Four short implants and 4 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 4 minutes .
89322504|NCT02167672||Consumers|Women who have had a Hysterectomy in the previous 2 years
89322505|NCT02167672||Doctors|Obstetricians and Gynaecologists
89322506|NCT03726411|Experimental|periodontitis group|in this group, prolactin in GCF will be assessed at baseline and after 3 months of receiving non-surgical periodontal treatment
89322507|NCT03726411|No Intervention|control group|in this group of systemically and periodontally healthy participants, prolactin in GCF will be assessed at baseline only
89322508|NCT03723993|Placebo Comparator|Control group|control group will have non inflated cuff around the arm.
89322509|NCT03723993|Active Comparator|RIPC group|Inflated cuff will be done systematically and regularly
89322510|NCT02892513|Experimental|Active Stimulation|Participants will have active percutaneous auricular neurostimulation for 5 days during and after elective surgery.
89322511|NCT02892513|Sham Comparator|Sham Percutaneous Neurostimulation|Participants will have inactive device worn for 5 days during and after elective surgery.
89322512|NCT03726255||Stromal Vascular fraction|31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)
89322513|NCT03726255||Autologous mesenchymal stem cells|9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)
89322514|NCT03726255||Allogenic mesenchymal stem cells|12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)
89322515|NCT03730857|Active Comparator|olanzapine|olanzapine has a dose of 10 to 20 mg daily for 12 weeks
89322516|NCT03730857|Active Comparator|risperidone|risperidone at a dose of 4 to 6 mg daily for 12 weeks
89322517|NCT03730857|Active Comparator|paliperidone|paliperidone at a dose of 6 to 12 mg daily for 12 weeks.
89322518|NCT03726177|Active Comparator|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
89322519|NCT03726177|Active Comparator|aspirin 81 mg plus placebo|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
89322520|NCT03723837|Active Comparator|Study Arm A|Children {Age > 24 months and who received a single dose Inactivated Polio Vaccine (IPV) at the time of routine immunization} in this arm will receive an IPV (0.5ml) intramuscularly at the time of enrolment in the trial
89322521|NCT03723837|Active Comparator|Study arm B|Children {Age 7-12 months and have not received any IPV till date of enrolment} in this arm will receive an Inactivated Polio Vaccine, IPV (0.5 ml) intramuscularly at the time of enrolment in the trial and a repeat dose of IPV (0.5 ml) after 1 month
89322522|NCT03726099|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy containing esomeprazole, amoxicillin, tetracycline and furazolidone.
89322523|NCT03723759|Experimental|Group A|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation D, faster aspart 100 U/mL, formulation B, formulation A, formulation C, formulation E.~The dosing visits will be separated by wash-out periods (2-21 days)."
89322524|NCT03723759|Experimental|Group B|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation C, formulation B, formulation D, formulation E, formulation A, faster aspart 100 U/mL.~The dosing visits will be separated by wash-out periods (2-21 days)."
89322525|NCT03723759|Experimental|Group C|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation E, formulation C, formulation A, formulation B, faster aspart 100 U/mL, formulation D.~The dosing visits will be separated by wash-out periods (2-21 days)."
89322526|NCT03723759|Experimental|Group D|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation A, formulation D, formulation C, faster aspart 100 U/mL, formulation E, formulation B.~The dosing visits will be separated by wash-out periods (2-21 days)."
89322527|NCT03723759|Experimental|Group E|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~faster aspart 100 U/mL, formulation A, formulation E, formulation D, formulation B, formulation C.~The dosing visits will be separated by wash-out periods (2-21 days)."
89322528|NCT03723759|Experimental|Group F|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation B, formulation E, faster aspart 100 U/mL, formulation C, formulation D, formulation A.~The dosing visits will be separated by wash-out periods (2-21 days)."
89322529|NCT03558555|Active Comparator|Oral Acetaminophen|Patients who are randomized to have oral acetaminophen will take oral acetaminophen preoperatively and receive saline intraoperatively.
89322530|NCT03558555|Active Comparator|Acetaminophen IV Soln|Patients randomized to IV acetaminophen will receive IV acetaminophen after induction of general anesthesia and will take placebo pills preoperatively.
89322531|NCT03726021|Experimental|experimental arm|Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.
89322532|NCT03730779|Experimental|O2 recieving|Patients who receive hyperoxia
89322533|NCT03725943|Experimental|Healthy adults|Dreem
89322534|NCT03541317|Experimental|Stage 1: Optimal First Line Implementation Strategy|"All schools enrolled will first be randomized to an optimal first line treatment in order to compare REP vs. REP + Coaching. Schools assigned to Stage 1 treatment REP will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation. Schools assigned to Stage 1 treatment REP + Coaching will receive the REP components plus weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
89322535|NCT03541317|Experimental|Stage 2: Added Value of Providing Facilitation|"After 2 months, schools will be assessed to determine whether they could benefit from augmenting their current strategy with a step-up strategy called Facilitation. Schools identified as potentially benefiting will be re-randomized to compare the added value of augmenting their current strategy with Facilitation, compared to continuing with their same strategy. Stage 2 treatment strategy: step-up will include provision of an additional implementation strategy called Facilitation. A full-time Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support school professionals in strategic thinking and leadership skills to address organizational barriers. Sites receiving Facilitation will receive regular calls for up to a minimum of 10 weeks from the Facilitator. All schools will also continue to receive their first line treatment (i.e. REP or REP + Coaching)."
89322536|NCT03730623|No Intervention|Control group|Usual care. Conservative management of IC
89322537|NCT03730623|Experimental|Intervention|Supervised exercise
89322538|NCT05665023|Experimental|Bevacizumab + modified FOLFIRINOX|Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
89322539|NCT03723525|Experimental|Package of HIV care|Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI), Rapid antiretroviral therapy (ART) initiation and Enhanced adherence support.
89322540|NCT03723525|Experimental|Standard HIV care|Screening and management of common OIs, basic health assessment (CD4, viral load and other tests), ARV drugs and follow up.
89322541|NCT03557931|Experimental|ASP4345 50 milligram (mg)|Participants on stable doses of antipsychotic medication received ASP4345 50 mg, capsules, orally, once daily for 12 weeks.
89322542|NCT03557931|Experimental|ASP4345 150 mg|Participants on stable doses of antipsychotic medication received ASP4345 150 mg, capsules, orally, once daily for 12 weeks.
89322543|NCT03557931|Placebo Comparator|Placebo|Participants on stable doses of antipsychotic medication received ASP4345 placebo matching capsules, orally, once daily for 12 weeks.
89322544|NCT03522675|Other|NeoMatriX and Two Comparators|NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)
89322545|NCT03722199|Experimental|Healthy persons|In this interventional study the investigators ask the patient (healthy persons) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
89322546|NCT03722199|Experimental|Persons with essential hypertension|In this interventional study the investigators ask the patient (persons with essential hypertension) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
89322547|NCT03722199|Experimental|Persons with type 2 diabetes|In this interventional study the investigators ask the patient (persons with type 2 diabetes) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
89322548|NCT00294047|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
89322549|NCT00294047|Placebo Comparator|Aluminium Hydroxide Group|Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
89322550|NCT03977987||The treatment group|Pregnant women with high HBV DNA level > 2*10^6 IU/ml who agree to receive the antiviral treatment during the late pregnancy.
89322551|NCT03977987||The control group with high HBV DNA level|Pregnant women with high HBV DNA level > 2*10^6 IU/ml who decline to receive the antiviral treatment during the late pregnancy.
89322552|NCT03977987||The control group with low HBV DNA level|Pregnant women with high HBV DNA level < 2*10^6 IU/ml
89322553|NCT03977675|Experimental|Ketamine 0.3 mg/kg|Subjects are assigned to receive a dose of 0.3 mg/kg of Ketamine.
89322554|NCT03977675|Experimental|Ketamine 0.5 mg/kg|Subjects are assigned to receive a dose of 0.5 mg/kg of Ketamine.
89322555|NCT03977675|Experimental|Ketamine 0.7 mg/kg|Subjects are assigned to receive a dose of 0.7 mg/kg of Ketamine.
89322556|NCT03977831|Active Comparator|Open Radical Cystectomy (ORC)|Open radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an iliac conduit urinary diversion is performed.
89322557|NCT03977831|Active Comparator|Robot-assisted Radical Cystectomy (iRARC)|Robot-assisted radical cystectomy includes in both genders removal of the bladder and distal ureters as well as pelvic lymphadenectomy. In men the procedure includes removal of the prostate and seminal vesicles and in women removal of the uterus, ovaries, urethra and part of the vagina. Lastly, for both genders an intracorporeal iliac conduit urinary diversion is performed.
89322558|NCT03977519|Experimental|MA group|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used at EX-B8,BL32,SP8,and SP6.
89322559|NCT03977519|Active Comparator|TENS group|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used to stimulate the area along the lower borders of the ribs and the upper borders of the hip crests on both sides.The parameters of the electric acupuncture apparatus：Continuous wave,the frequency is 100Hz, the current intensity is 2.5mA-5mA.
89322560|NCT01066559|Experimental|High flux polymethylmetacrylate membrane|
89322561|NCT01066559|Active Comparator|Polysulfone membranes|
89322562|NCT00293813|Placebo Comparator|3|Placebo for denosumab and placebo for alendronate
89322563|NCT00293813|Experimental|1|denosumab and placebo for alendronate
89322564|NCT00293813|Active Comparator|2|Placebo for denosumab and alendronate
89322565|NCT01066715|Placebo Comparator|Placebo|
89322566|NCT01066715|Experimental|XOMA 052|
89322567|NCT00293579|Experimental|Pemetrexed|pemetrexed 500 mg/m2 administered iv, every three weeks, for 6 cycles
89322568|NCT00293423|Experimental|Phase 1: Vaccine|Patients received 25 micrograms of HSPPC-96 bi-weekly or weekly for the first 4 vaccinations followed by biweekly injections.
89322569|NCT00293423|Experimental|Phase 2: Vaccine|Treatment consisted of 25 mcg of HSPPC-96 weekly for at least 4 weeks, followed by biweekly injections (pending vaccine availability) for up to 52 weeks from the date of surgical resection.
89322570|NCT01066949|Active Comparator|Support and discussion|The Support and Discussion protocol will consist of two integrated components: (a) brief educational materials presented at the start of each session, and (b) group leader facilitated discussion following presentation of the educational materials.
89322571|NCT01066949|Experimental|Behavioral Self management|Self-Regulation group sessions will be generally highly leader-directed though participants will be regularly encouraged to share their experiences dealing with the dialysis regimen. A consistent attempt will be made to focus all group discussion on self-regulatory principles as they relate to treatment adherence.Session material utilized by group-leaders will be highly structured and detailed across the seven sessions.
89322572|NCT01080287||Migraineurs with & w/out auras having orthostatic intolerance|Subjects between ages 18 and 65, having ICHD-II classification of migraine with or without aura, having symptoms of orthostatic intolerance
89322573|NCT01080287||Migraineurs with or without auras|Subjects between ages 18 and 65 having ICHD-II classification of migraine with or without auras
89322574|NCT03538743|Placebo Comparator|Placebo|
89322575|NCT03538743|Experimental|PF-06882961 30 mg|
89322576|NCT03538743|Experimental|PF-06882961 100 mg|
89322577|NCT03538743|Experimental|PF-06882961 300 mg|
89322578|NCT03538743|Experimental|PF-06882961 600 mg|
89322579|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 5|
89322580|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 6|
89322581|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 7|
89322582|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 8|
89322583|NCT03521817|Experimental|Alcohol|Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat; (minus the ~240 kcals from ethanol). The Etoh group will consume a 30% energy restriction diet that will also include ~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila).
89322584|NCT03521817|Active Comparator|No Alcohol|No Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat).
89322585|NCT03538431|Experimental|Buspirone|These subjects will receive buspirone prior to engaging in the driving simulation.
89322586|NCT03538431|Experimental|Unmedicated|These subjects will take no medication prior to engaging in the driving simulation
89322587|NCT03521193|Experimental|Migraine evaluation in PFO patients|Patients symptomatic for migraine with/o aura and addressed to patent foramen ovale closure (Occlutech Figulla Flex II PFO occluder device) for a previous ischemic event, will receive dual antiplatelet therapy (DAPT) for 2 months after procedure and aspirin alone subsequently. Patients will undergo evaluation of platelet reactivity, serotonin and cytokines before PFO closure with a dedicated device and at 6 months follow-up and these results compared to those of a control, group of healthy subjects treated with aspirin alone
89322588|NCT03521193|No Intervention|healthy subjects on aspirin treatment|12 healthy subjects on 100 mg aspirin daily will be compared to PFO patients in terms of platelet reactivity, serotonin and cytokines
89322589|NCT00293267|Experimental|1|raltegravir potassium
89322590|NCT00293267|Placebo Comparator|2|Placebo
89322591|NCT03520959|Placebo Comparator|Placebo|A sequential regimen of LV305-matching placebo and G305-matching placebo.
89322592|NCT03520959|Experimental|CMB305|A sequential regimen of LV305 and G305.
89322593|NCT03730545|Experimental|EIN group|Enteral formula including not only basic energy components, but also immune components such as omega-3 fatty acids, glutamine (Gln), arginine (Arg), and nucleotide.
89322594|NCT03730545|Active Comparator|SEN group|Enteral formula including only basic energy components.
89322595|NCT03977441|Placebo Comparator|control group|treated with Pramipexole 0.75mg/d（0.25mg tid)+placebo 25mg qn *2weeks than Pramipexole 0.75mg/d（0.25mg tid)+placebo 50mg qn * 10 weeks
89322596|NCT03977441|Experimental|experimental group|treated with Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine25 mg qn *2weeks than Pramipexole 0.75mg/d（0.25mg tid)+Agomelatine 50mg qn * 10weeks
89322597|NCT03537261|Experimental|CPI-Parent Training|Will receive one-day (6-hour) training in P-CPI including the use of nonverbal, paraverbal, verbal, and physical intervention techniques.
89322598|NCT03537261|No Intervention|Waitlist Control|"Will not receive active P-CPI training during the experimental treatment interval.~NOTE: The waitlist group will be offered the P-CPI training session after the treatment group completes their follow-up measures."
89322599|NCT01080365|Experimental|1|Commercial Tablet
89322600|NCT01080365|Experimental|2|Clinical Tablet
89322601|NCT03536949|Experimental|RVL-1201 Ophthalmic Solution, 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
89322602|NCT03536949|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
89322603|NCT01080443|Active Comparator|Cellcept® 250 mg Capsule|
89322604|NCT01080443|Experimental|Mycophenolate Mofetil Capsule 250 mg|
89322605|NCT01067183|Experimental|breathing and biofeedback device|This group of physicians were trained in the use of the relaxation breathing technique and the biofeedback device, and then used this portable stress reduction tool on a daily basis with twice weekly visits with the research team. After the 28 day RCT, they were invited to continue to use the device at their discretion during a trial extension from day 28-56 to see if any effect measured was maintained.
89322606|NCT01067183|No Intervention|control arm|This group did not undergo training in the breathing technique and use of the PSMD during the RTC trial day 0-28, but were visited twice weekly by the research team to collect outcome data. During the trial extension Day 28-56, this group did undergo a 1 hr training session with the PSMD and invited to use it at their discretion over the 28 days. Effectiveness outcome data (day 28-56) was collected at day 56.
89322607|NCT03639441|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
89322608|NCT03639441|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
89322609|NCT01067261|Experimental|TMNS and pelvic floor muscle training|This group will receive both the normal pelvic floor muscle training and the TMNS vibration therapy following their radical prostatectomy. Treatment with TMNS will start before the surgery and continue 6 weeks after the surgery.
89322610|NCT01067261|Active Comparator|Pelvic floor muscle training only|This group will receive the normal pelvic floor muscle training after prostatectomy only.
89322611|NCT03588741|Experimental|Turoctocog alfa|
89322612|NCT00111917|Experimental|Infliximab|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
89322613|NCT00111917|Placebo Comparator|Placebo|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
89322614|NCT03730389|Experimental|EPVL Group|In treatment group, patients were given one to three sessions of External Physical Vibration Lithecbole therapy in two weeks. These patients were also instructed to drink a minimum of 2500 ml water daily and take more exercise.
89322615|NCT03730389|No Intervention|Traditional Group|patients with 4-10mm ureteral stone, were treated by traditional treatment methods, including drinking a minimum of 2500 ml water daily and taking more exercise.
89322616|NCT01067417|Active Comparator|Hydroxychloroquine|
89322617|NCT01067417|Placebo Comparator|Placebo|
89322618|NCT03520569|Active Comparator|Octreotide- Euglycemia|octreotide is 30 ng/kg/min x 240 min insulin 0.15mU/kg/min x 240 min Dextrose 20% at variable rate to maintain euglycemia for 240 min
89322619|NCT03520569|Active Comparator|Octreotide - Euglycemia- insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 330 min
89322620|NCT03520569|Active Comparator|Octreotide- hyperglycemia|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 330 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
89322621|NCT03520569|Active Comparator|Octreotide- hyperglycemia - insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
89322622|NCT01067495|Experimental|Exercise|
89322623|NCT03722043|Experimental|Parenting Program|"All study participants will receive our parenting program curriculum. There will not be a control group.~The parenting program will include the topics of mindful parenting strategies, emotional regulation, positive discipline, and positive parenting/attachment. Participants will be provided skills to develop strategies for each of the modules. Each session will contain elements of group troubleshooting and practice in-session. Practice at home will be assigned so that participants can continue to practice and implement these skills and strategies in their homes.~The program is taken from a published, empirically based program called Everyday Parenting: A Professional's Guide to Building Family Management Skills written by Thomas Dishion, Elizabeth Stormshak, and Kathryn Kavanagh."
89322624|NCT03721887|Experimental|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
89322625|NCT03721887|Sham Comparator|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
89322626|NCT00111839|Active Comparator|Pemetrexed Alone|Participants will receive pemetrexed 50 milligrams per square meter (mg/m^2) intravenous (IV) infusion every 3 weeks until disease progression (PD) or the occurrence of unacceptable toxicity.
89322627|NCT00111839|Experimental|Pemetrexed Plus Matuzumab 800 mg per Week|Participants will receive pemetrexed 50 mg/m^2 IV infusion every 3 weeks in combination with matuzumab 800 milligrams (mg) IV infusion once every week. Treatment will continue until PD or the occurrence of unacceptable toxicity.
89322628|NCT00111839|Experimental|Pemetrexed Plus Matuzumab 1600 mg Every 3 Weeks|Participants will receive pemetrexed 50 mg/m^2 IV infusion every 3 weeks in combination with matuzumab 1600 mg IV infusion every 3 weeks. Treatment will continue until PD or the occurrence of unacceptable toxicity.
89322629|NCT03723291|Active Comparator|Arm A|The current best standard of care [rehabilitation exercises]
89322630|NCT03723291|Experimental|Arm B|The current best standard of care [rehabilitation exercises] + the experimental intervention
89322631|NCT01080521||Observational (cognitive function during chemotherapy)|Patients receive standard chemotherapy. Treatment repeats for 6 courses. Patients complete neurocognitive evaluations (Patient Assessment and Own Functioning scale and HeadMinder Custom Research Tool) and quality-of-life assessments (Hospital Anxiety and Depression Scale, FACT-O, and FACT/GOG-Ntx subscale) at baseline, before the fourth course of chemotherapy, at 3 weeks after the sixth course of chemotherapy, and at 6 months after the sixth course of chemotherapy.
89322632|NCT00111761|Experimental|Part 1: Panitumumab + IFL|Panitumumab (2.5 mg/kg once weekly for up to 48 weeks or until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan, 5-fluorouracil (5-FU)and leucovorin (IFL chemotherapy regimen)
89322633|NCT00111761|Experimental|Part 2: Panitumumab + FOLFIRI|Panitumumab (2.5 mg/kg once weekly until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan/5-FU/leucovorin chemotherapy (the FOLFIRI regimen)
89322634|NCT03519867|Experimental|1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced neuromuscular blockade (NMB) reaches 1 to 2 PTCs.
89322635|NCT03519867|Experimental|2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322636|NCT03519867|Experimental|3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322637|NCT03519867|Experimental|4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322638|NCT03519867|Experimental|5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322639|NCT03519867|Experimental|6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322640|NCT03519867|Experimental|7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322641|NCT03519867|Experimental|8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322642|NCT03519867|Experimental|9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322643|NCT03519867|Experimental|10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
89322644|NCT01080599|Experimental|conventional pubic approach|
89322645|NCT01080599|Experimental|inguinal approach|
89322646|NCT03519087|Experimental|Interdisciplinary Evaluation|Participants will receive an Interdisciplinary Evaluation for Nonarthritic Hip Disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care.
89322647|NCT03519087|No Intervention|Standard Evaluation|Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.
89322648|NCT03519087|Experimental|Posture and Movement Training|Participants will receive six training sessions with a physical therapist over a 3-week period.
89322649|NCT03519087|No Intervention|3-week Wait Period|Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.
89322650|NCT03519087|Other|Observational Arm|Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.
89322651|NCT01067651|Active Comparator|Plaster of Paris (POP)|
89322652|NCT01067651|Active Comparator|semi-rigid fiberglass softcast (SRF, 3M Scotchcast)|
89322653|NCT03721809|Other|macrophage activation syndrome secondary to bacterial sepsis|Patients hospitalized in medical intensive care for macrophage activation syndrome secondary to bacterial sepsis
89322654|NCT03721809|Other|bacterial sepsis/septic shock|Patients hospitalized in medical intensive care for sepsis / septic shock
89322655|NCT03977285|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
89322656|NCT03977285|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
89322657|NCT03977285|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
89322658|NCT03730311|Experimental|Elpida 120 mg once weekly|elsulfavirine 120mg or placebo orally once weekly for 4 weeks
89322659|NCT03730311|Experimental|Elpida 200 mg once weekly|elsulfavirine 200mg or placebo orally once weekly for 4 weeks
89322660|NCT03730311|Experimental|Elpida 280 mg once weekly|elsulfavirine 280mg or placebo orally once weekly for 4 weeks
89322661|NCT04883931|Experimental|Intervention group|With in 48-72 hour after birth, infants will receive 0.5 ml breast milk for own mother as a eye drop twice in a day until the discharge or need for laser coagulation. Fresh milk was used as eye drop ( not exceed 6 hours after milking).
89322662|NCT04883931|Placebo Comparator|Placebo group|With in 48-72 hour after birth, infants will receive 0.5 ml 0.9% normal saline as a eye drop twice in a day until the discharge or need for laser coagulation.
89322663|NCT02763046|Experimental|Secukinumab - delayed NSAID tapering|"Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind.~NSAID tapering allowed from Week 4 (delayed tapering)."
89322664|NCT02763046|Experimental|Secukinumab - early NSAID tapering|"Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind.~NSAID tapering allowed from Week 4 (early tapering)."
89322665|NCT02763046|Placebo Comparator|Placebo|"Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20).~NSAID tapering allowed from Week 4."
89322666|NCT02164552||Vitamin D3 pills|Vitamin D3 (cholecalciferol) supplementation (50,000 IU/week for 8 weeks) followed by 1000 IU/day for 16 weeks
89322667|NCT02164552||Placebo pill|Placebo pills will be given 1 per week for 8 weeks followed by 1 per day for 16 weeks
89322668|NCT03518073|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of placebo once every four weeks (Q4W) for 100 weeks.
89322669|NCT03518073|Experimental|Zagotenemab 1400 mg|Participants received IV infusion of 1400 milligram (mg) zagotenemab Q4W for 100 weeks.
89322670|NCT03518073|Experimental|Zagotenemab 5600 mg|Participants received IV infusion of 5600 mg zagotenemab Q4W for 100 weeks.
89322671|NCT03725800||Aspirin|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using aspirin for mono-antiplatelet therapy.
89322672|NCT03725800||Clopidogrel|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using clopidogrel for mono-antiplatelet therapy.
89322673|NCT03725800||ASIDE|Patients(aged ≥18 years) who have undergone PCI between 1 and 1.5 years, currently alive and is using ASIDE for mono-antiplatelet therapy.
89322674|NCT02759692|Active Comparator|Group 1 (Test/Control/Test)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL / TEST wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
89322675|NCT02759692|Active Comparator|Group 2 (Control/Test/Control)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST / CONTROL wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
89322676|NCT02164630|Experimental|Hope Therapy|Patients assigned to this arm will receive Hope Therapy in three individual intervention sessions. Intervention will be administered by an experienced therapist.Training focuses on effective goal setting and augmenting hopeful thinking.
89322677|NCT02164630|Other|Pain Education|Patients assigned to this arm will receive Pain Education in three individual intervention sessions. Intervention will be administered by an experienced therapist. Training will focus on understanding TMD-related pain and learning pain management techniques.
89322678|NCT02167750|Placebo Comparator|Cherry flavored beverage - Mix 1|Mix 1 flavored still beverage
89322679|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 2|Mix 2 flavored still beverage with phytochmicals and caffeine
89322680|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 3|Mix 3 flavored still beverage with phytochemicals and caffeine
89322681|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 4|Mix 4 flavored still beverage with phytochemicals and caffeine
89322682|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 5|Mix 5 flavored still beverage with phytochemicals and caffeine
89322683|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 6|Mix 6 flavored still beverage with caffeine
89322684|NCT03586167|Experimental|LID014341|LID014341 contact lenses worn bilaterally (in both eyes) for 30 days on a daily wear basis
89322685|NCT03586167|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally for 30 days on a daily wear basis
89322686|NCT02167828|Experimental|Social Support|Participants will be trained to give one another ongoing, theory-based but personally-tailored advice, recommendations, and support to encourage entry to HIV medical care, remaining in care, and adhering to medication regimens when they are prescribed. The intervention's intent is to increase mutual support, positive attitudes, intentions, plans, and collective self-efficacy for care engagement.
89322687|NCT02167828|No Intervention|No Intervention|Participants in this arm will not receive an intervention.
89322688|NCT03722979|Other|All patients|
89531633|NCT05879250|Experimental|Cohort I (WP1066, radiation)|Patients whose tumor was completely removed at the time of initial surgery receive WP1066 PO for 6 weeks during routine radiation therapy, and then for twelve 28-day cycles on study. Patients also undergo MRI and collection of blood samples throughout the trial.
89322689|NCT02164708|Experimental|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
89322690|NCT03730233|Active Comparator|Tension-free|Hiatal hernia repair by tension-free mesh closure
89322691|NCT03730233|Active Comparator|Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
89322692|NCT02164786||Acute severe disease|
89322693|NCT03639597|Experimental|Study device|VytronUS Ablation System
89322694|NCT02162836|Experimental|Cohort 1|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
89322695|NCT02162914|Active Comparator|Regorafenib/active|Subjects randomized to be treated with Regorafenib (active product) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
89322696|NCT02162914|Placebo Comparator|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib (placebo) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
89322697|NCT03540940|Experimental|zero positive end expiratory pressure|
89322698|NCT03540940|Experimental|Positive end expiratory pressure|
89322699|NCT03540862||NPV|a hospital-based maintenance NPV program including NPV support, breathing training and an educational program (relaxation techniques, and home pacing walking exercise) in daily clinical practice. Patients received NPV with breathing training via the cuirass ventilator (Philips Respironics Lifecare NEV-100) settings for 60 min. The ventilator was set to control model with frequency of 12 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot) and delivered negative pressures ranging -20 to -30 cm H2O. In the NPV group, patients underwent the hospital-based NPV once every week as the maintenance program.
89322700|NCT03540862||Control|If patients do not wish to enter the hospital-based NPV program, they are placed in the control group and are trained to perform breathing training, relaxation techniques and home pacing walking exercise.
89322701|NCT02762578|Experimental|IDegAsp BID|
89322702|NCT02762578|Active Comparator|BIAsp 30 BID|
89322703|NCT02167984||at term newborns|Infant with GE >=37w
89322704|NCT02167984||preterm newborns|Infant with GE <37w
89322705|NCT03540628|No Intervention|Placebo Arm|The control arm of our randomized trial will receive a second pressor agent, hydrocortisone and standard of care to care for septic shock. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
89322706|NCT03540628|Experimental|Thiamine and Vitamin C administration Arm|The experimental arm will receive a second pressor agent and hydrocortisone, plus thiamine and vitamin C along with the standard of care. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
89322707|NCT02168218|Experimental|high protein|20% protein diet
89322708|NCT02168218|Active Comparator|low protein|7.5% protein diet
89322709|NCT02168296|Placebo Comparator|No added Plant-based ingredient|No Plant-based ingredient added to starchy meal
89322710|NCT02168296|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
89322711|NCT02168296|Active Comparator|High dose added to starchy meal|Plant-based ingredient in high dose added to starchy meal
89322712|NCT02168296|Active Comparator|Low dose added to liquid|Plant-based ingredient in low dose added to liquid
89322713|NCT02168296|Active Comparator|High dose added to liquid|Plant-based ingredient in high dose added to liquid
89322714|NCT02168374|Experimental|Chlorhexidine - CHX|Deciduous teeth were filled with GIC containing 1.25% chlorhexidine.
89322715|NCT02168374|Experimental|Doxycycline - DOX|Deciduous teeth were filled with GIC containing 4.5% doxycycline.
89322716|NCT02168374|Placebo Comparator|Glass ionomer cement - GIC|Deciduous teeth were filled with GIC without chlorhexidine or doxycycline.
89322717|NCT02170948|Experimental|Dex 0.5|Ropivacaine and Lidocaine plus Dexmedetomidine (0.5mg/kg) plus Normal Saline
89322718|NCT02170948|Experimental|Dex 1.0|Ropivacaine and Lidocaine plus Dexmedetomidine (1.0mg/kg) plus Normal Saline
89322719|NCT03540550|Experimental|Dietary intervention|
89322720|NCT02171026|Experimental|Dabigatran etexilate + Amiodarone|
89322721|NCT02171026|Active Comparator|Amiodarone|
89322722|NCT02261194|Experimental|Self-Care Tools|The tool binder includes 3 core tools and 4 supplemental tools. The tools that will be provided include a variety of self-care approaches to manage depression including audio-visual, internet, and paper-based tools that might appeal to individuals with different learning styles. The 3 core tools consist of the Antidepressant Skills Workbook, a Mood Monitoring Tool, and a DVD on depression.
89322723|NCT02261194|No Intervention|Delayed Self-Care Tools|This group will receive the self-care tools at the conclusion of the study.
89322724|NCT02168530|Placebo Comparator|Placebo|
89322725|NCT02168530|Experimental|Vismodegib|
89322726|NCT02168608|Experimental|Remote ischemia precondition|patients in this arm accepted RIPC procedure after induction of anesthesia
89322727|NCT02168608|Experimental|None remote ischemia precondition|patients in this arm didn't accept RIPC procedure after induction of anesthesia
89322728|NCT02165020|Experimental|Rectal toxicities after prostate hypofractionated radiotherapy|Rectal toxicities after prostate hypofractionated radiotherapy with hyaluronic acid
89322729|NCT03514641|Other|Sequence 1|Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
89322730|NCT03514641|Other|Sequence 2|Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
89322731|NCT03514641|Other|Sequence 3|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
89322732|NCT03514641|Other|Sequence 4|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
89322733|NCT02168764|Experimental|Treatment|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
89322734|NCT02168764|Active Comparator|Control|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
89322735|NCT03539224|Experimental|Dolutegravir (DTG) + Lamivudine (3TC)|Eligible subjects will receive one 50 mg tablet of DTG plus 300 mg 3TC tablet orally once daily upto 48 weeks
89322736|NCT02171182||Qutenza patients w/ post-operative peripheral neuropathic pain|
89322737|NCT03722901||Late preterm infants|34 weeks and 0-6 days gestational age
89322738|NCT03722901||Moderate preterm infants|32 weeks and 0-6 days gestational age
89322739|NCT03722901||Reference|Term infants 9m/39-40
89322740|NCT00100828|Experimental|Irinotecan|
89322741|NCT02165098|Experimental|Cariprazine PR tablet B|Cariprazine prolonged release tablet B - fed
89322742|NCT02165098|Experimental|Cariprazine PR tablet A|Cariprazine prolonged release tablet A - fed
89322743|NCT02165098|Experimental|Cariprazine capsule|Cariprazine capsule - fasted
89322744|NCT02165098|Experimental|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
89322745|NCT02165098|Experimental|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
89322746|NCT02171338|Other|Antibiotic treatment based on PCT-level|"Information regarding the PCT-levels in the intervention group is available to the treating doctor and the test subjects are randomized for treatment based on the level of PCT (PCT algorithm).~With a PCT ≥0.25 µg/l and ≥0.10 µg/l for pneumonia and AECOPD respectively antibiotic treatment is advised to be started."
89322747|NCT02171338|No Intervention|Control|"Test subjects randomized for standard treatment (control group) are treated in accordance with the existing treatment guidelines of Holbaek Hospital.~PCT-level will be measured but the treating doctor has no access to the result."
89322748|NCT02171416|Placebo Comparator|Placebo|Placebo s.c every 7 days
89322749|NCT02171416|Experimental|Rilonacept 160mg|Rilonacept s.c every 7 days
89322750|NCT03540082|Active Comparator|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
89322751|NCT03540082|No Intervention|Control|Written instructions will be provided on the correct way to fall without physical practice.
89322752|NCT03540082|Other|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
89322753|NCT02165176|Experimental|10mg acute oral cannabis|10mg acute oral cannabis
89322754|NCT02165176|Experimental|25mg acute oral cannabis|25mg acute oral cannabis
89322755|NCT02165176|Experimental|50mg acute oral cannabis|50mg acute oral cannabis
89322756|NCT02165254|Other|high dose tai chi intervention|
89322757|NCT02165254|Other|standard dose tai chi intervention|
89322758|NCT02168920|Experimental|Aripiprazole, 2 mg/day|
89322759|NCT02168920|Experimental|Aripiprazole, 3 mg/day|
89322760|NCT02168920|Experimental|Aripiprazole, 6 mg/day|
89322761|NCT02168920|Placebo Comparator|Placebo|
89322762|NCT02171494|Experimental|IVAX warfarin|Treatment A: IVAX warfarin
89322763|NCT02171494|Active Comparator|BMS coumadin|Treatment B: BMS coumadin tablets
89322764|NCT02165332|Placebo Comparator|Part 1: Placebo|Saline solution, given as a minimum of a 2 hour infusion
89322765|NCT02165332|Experimental|Part 1: RO7033877|Single ascending dose
89322766|NCT02165332|Experimental|Part 2: RO7033877|Single-dose 4-way crossover
89322767|NCT02171572|Experimental|Dabigatran etexilate low|
89322768|NCT02171572|Experimental|Dabigatran etexilate high|
89322769|NCT02168998|No Intervention|No clown|Routine venipuncture without distraction
89322770|NCT02168998|Active Comparator|Clown|A medical clown is present in the procedure room during venipuncture
89322771|NCT04662112|Experimental|NASOX|Liposomal irinotecan+S-1+oxaliplatin
89322772|NCT03539146|Active Comparator|Control yogurt|Treatment with a control yogurt with cascara but no dietary fiber.
89322773|NCT03539146|Experimental|Yogurt with fiber|Treatment with yogurts containing cascara and 3%, 7% and 13% of dietary fiber.
89322774|NCT02169076|Active Comparator|CRT-On|Cardiac Resynchronization Therapy enabled on ICD/Pacemaker device
89322775|NCT02169076|Sham Comparator|CRT-Off|Cardiac Resynchronization Therapy disabled on ICD/Pacemaker device
89322776|NCT02255578|Other|IVF treatment|Fertility, as determined by egg quality parameters, as well as metabolic parameters, will be assessed following Endobarrier treatment in PCOS during IVF treatment.
89322777|NCT02255578|Other|clomiphene citrate treatment|Ovulation rate in response to clomiphen citrate after Endobarrier treatment in PCOS.
89322778|NCT02169154|Experimental|Diclofenac Sodium/Menthol Gel|1% diclofenac sodium + 3% menthol
89322779|NCT02169154|Active Comparator|Diclofenac Gel|1% diclofenac sodium + 0.09% menthol
89322780|NCT02169154|Active Comparator|Menthol Gel|3% menthol
89322781|NCT02169154|Placebo Comparator|Placebo Gel|0.09% menthol
89322782|NCT02169154|Active Comparator|Voltaren Gel|1% diclofenac sodium
89322783|NCT02169154|Placebo Comparator|Sodium lauryl sulfate|0.2% Sodium lauryl sulfate
89322784|NCT02169154|Placebo Comparator|Saline|0.9% saline
89322785|NCT02169232|Active Comparator|Videolaryngoscope|Intubation by videolaryngoscope
89322786|NCT02169232|Active Comparator|Fiberoptic|Intubation by fibroscope
89322787|NCT05142670|Experimental|task-oriented training individualized by the gravity perception|The training in the experimental group emphasizes the active use of intact or relatively preserved verticality perception to facilitate reestablishing vertical position of the participants. Additionally, a target such as an interesting person/object or an object with interesting music is used to direct the subject to accomplish a task in order to temporally desist from pathological pushing behavior.
89322788|NCT05142670|Active Comparator|visual feedback treatment|The training in the control group emphasizes the active use of visual feedback to facilitate reestablishing vertical position of the participants.
89322789|NCT00100048|Experimental|600 mg monotherapy|MK0518 600 mg twice daily
89322790|NCT00100048|Experimental|400 mg monotherapy|MK0518 400 mg twice daily
89322791|NCT00100048|Experimental|200 mg monotherapy|MK0518 200 mg twice daily
89322792|NCT00100048|Experimental|100 mg monotherapy|MK0518 100 mg twice daily
89322793|NCT00100048|Placebo Comparator|placebo monotherapy|Placebo to MK0518 twice daily
89322794|NCT00100048|Experimental|600 mg combo therapy|MK0518 600 mg + tenofovir + lamivudine
89322795|NCT00100048|Experimental|400 mg combo therapy|MK0518 400 mg + tenofovir + lamivudine
89322796|NCT00100048|Experimental|200 mg combo therapy|MK0518 200 mg + tenofovir + lamivudine
89322797|NCT00100048|Experimental|100 mg combo therapy|MK0518 100 mg + tenofovir + lamivudine
89322798|NCT00100048|Active Comparator|EFV combo therapy|efavirenz + tenofovir + lamivudine
89322799|NCT02171650|Experimental|BIBW 2992|
89322800|NCT02165566|Experimental|Regular-insulin,|regular-insulin or lispro-insulin at 0.04 units/kg/hour continuous infusion crossover and random assignement
89322801|NCT02165566|Experimental|Lispro insulin|patients randomly assigned in a crossover way to one of the 2 treatments
88816001|NCT02467491|Other|Physical Activity group|All the participants enrolled in the study will be part of the physical activity group in which they will perform a scheduled exercise program for 4 weeks using a new physical activity technology called Jintronix.
89322802|NCT02171728|Experimental|BIBW 2992|dose escalation
89322803|NCT02169388|Experimental|Probiotic|Microbial composition using Probiotic，3 capsules / times, 2 times / day for 4 weeks
89322804|NCT02169388|Placebo Comparator|placebo|Microbiota modulation using placebo，3 capsules / times, 2 times / day for 4 weeks
89322805|NCT02165644|Experimental|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with current standard of care which is Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
89322806|NCT02165644|Active Comparator|Standard of care|Subjects will receive only standard of care for subarachnoid hemorrhage which will include Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
89322807|NCT02171806|Experimental|BI 1744 CL multiple rising doses|
89322808|NCT02171806|Placebo Comparator|Placebo|
89322809|NCT02171806|Experimental|BI 1744 CL medium dose, females|
89322810|NCT02165800|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
89322811|NCT02165800|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
89322812|NCT02171962|Experimental|Zilver® PTX® VI|
89322813|NCT03539926|Experimental|Lit-control®pH Meter|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
89322814|NCT03539926|Placebo Comparator|Reactive strips|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.
89322815|NCT02169544||RA patients who are prescribed Abatacept|Abatacept
89322816|NCT02169544||Patients who are prescribed other RA treatments|
89322817|NCT02165878||Children and adolescent|children and adolescent CKD patients of any etiology
89322818|NCT02165956|Experimental|New Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
89322819|NCT02165956|Active Comparator|Standard Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
89523426|NCT03124667|Experimental|Gaming Condition|The games group will visit the lab on 5 separate occasions, for 2 hours each, to complete training sessions (playing seated and standing computerized games), and then complete 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
88816002|NCT01106456|Experimental|All Nations Breath of Life (ANBL)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
89523427|NCT03124667|Active Comparator|Video Condition|The videos group will visit the lab on 5 separate occasions, for 2 hours each, to view health and educational YouTube videos, and then view 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
89523428|NCT03124277|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
89322820|NCT03539770||AIS|Adolescent idiopathic scoliosis subjects undergoing posterior spinal fusion.
89322821|NCT03539770||Control|Children without scoliosis
89322822|NCT02166034|Experimental|garden intervention|Schools assigned to the garden intervention receive raised bed garden kits and access to a toolkit of garden-based curriculum
89322823|NCT02166034|No Intervention|Control|Wait-list control (no garden intervention + lessons) until end of the study.
89322824|NCT02172118|Experimental|severely renally impaired patients|
89322825|NCT02172118|Experimental|healthy volunteers|
89322826|NCT02166112||Permacol mesh placement|No intervention performed
89322827|NCT02261272|Experimental|CBT for insomnia|Cognitive-behavioral therapy for insomnia
89322828|NCT02261272|Active Comparator|Sleep Hygiene|Psychoeducational intervention based on standard sleep hygiene advices
89322829|NCT02261350|Experimental|Food Fortification|Food Fortification
89322830|NCT02261350|Experimental|Oral Nutritional Supplements|Oral Nutritional Supplements - Fortisip Compact
89322831|NCT02261350|No Intervention|Usual Care|
89322832|NCT02166190|Experimental|Radiofrequency Ablation (EndoHbp probe)|Radiofrequency Ablation using EndoHPB Probe
89322833|NCT02166190|Active Comparator|Stenting only|Stenting only
89322834|NCT02169700|Experimental|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling.
89322835|NCT02169700|Sham Comparator|Sham Ischemic compression. Dry Needling|Sham Ischemic compression was carried out after dry needling.
89322836|NCT02169700|No Intervention|Control group|No intervention. Control group
89322837|NCT02169778|Experimental|Intermittent energy restricted diet|The intermittent energy restricted group will undergo 3 nonconsecutive days of partial fasting per week. During the 3 days of partial fasting, participants will be asked to consume a very-low calorie diet (VLCD) providing 550kcal/day for women and 650kcal/day for men. The VLCD products provide 110kcal/pack and include a variety of shakes, smoothies and soups. For the feeding days a diet matching energy needs will be prescribed, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
89322838|NCT02169778|Experimental|Continuous energy restricted diet|The continuous energy restricted group will be prescribed a low calorie diet (LCD) with 33% energy restriction, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. The diets' macronutrient composition of the two groups will be matched (50% carbohydrates, 20% protein and 30% fat).
89322839|NCT02169856|Other|control group|"control group was not given any EFTs (emotional freedom techniques) therapy for postoperative nausea and vomiting.~Following medications were given to both groups. details are in respective interventions.~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
89322840|NCT02169856|Experimental|EFTs study group|"EFTs (emotional freedom techniques) was applied to the patietns. one session of 5 to 10 min at 6 hours postoperatively.~Following medications were given to both groups. details are in respective interventions.~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
89322841|NCT02169934|Experimental|Radiolabeled TRV130|
89322842|NCT02170012|Experimental|Cohort 1-PF-06743649 or placebo|
89322843|NCT02170012|Experimental|Cohort 2-PF-06743649 or placebo|
89322844|NCT02170012|Experimental|Cohort 3-PF-06743649 or placebo|
89322845|NCT02170012|Experimental|Cohort 4-PF-06743649 or placebo|
89322846|NCT02170012|Experimental|Cohort 5-PF-06743649 or placebo|
89322847|NCT02170246|No Intervention|Antiretroviral Therapy (ART) only|Acute HIV-infected subjects (n=7) will be randomly assigned to a group that will receive antiretroviral therapy (the current standard of care for HIV patients) for 72 weeks.
89322848|NCT02170246|Experimental|ART + Telmisartan|Acute HIV-infected subjects (n=14) will be randomly assigned to a group that will receive treatment with telmisartan in addition to ART. Subjects will receive 40mg telmisartan daily for 4 weeks, followed by 80mg telmisartan daily for 44 weeks, to be taken in conjunction with ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily. After telmisartan is stopped, subjects will continue to take ART for an additional 24 weeks (total 72 weeks).
89322849|NCT02170324|Experimental|GLP-1 agonism group|Exenatide injection 10 ug twice daily for 10 days subcutaneously.
89322850|NCT02170324|Placebo Comparator|Placebo group|0.9 % sodium choride 0.1 ml twice daily for 10 days subcutaneously.
89322851|NCT02170402|Experimental|Previously Treated Patients (PTPs)|"PTPs will participate sequentially with:~Part 1: Pharmacokinetic parameters of ADVATE measured in subset of 24 participants, consisting of:~12 adults (>12 years of age)~12 children (≤12 years of age)~Part 2: On-demand treatment with ADVATE for 6 months~Part 3: Prophylaxis regimen with ADVATE for 6 months"
89322852|NCT03538990|Experimental|DASH Eating Pattern|The DASH eating pattern meals prepared for study participants will strictly follow DASH meal planning guidelines published by National Heart, Lung, and Blood Institute of the National Institutes of Health. During the intervention phase of the study, all participants will exclusively consume prepared meals and provided beverages which will be delivered to participants' homes. Meals will be planned and prepared based on individual participant energy needs and dietary restrictions by a Registered Dietitian at the Georgia Clinical and Translational Science Alliance (CTSA) Bionutrition Unit located at Emory University.
89322853|NCT02172196|Experimental|Treatment sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5~Treatment C: Sitagliptin once daily from day 1 to 5"
89322854|NCT02172196|Experimental|Treatment sequence CAB|"Treatment C: Sitagliptin once daily from day 1 to 5~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5"
89322855|NCT02255968|Experimental|EDP-788|Multiple doses with dose escalation to continue in successive cohorts
89322856|NCT02255968|Placebo Comparator|Placebo|Multiple doses with dose escalation to continue in successive cohorts
89322857|NCT02172274|Experimental|[14C]-BI 10773 - oral solution|
89322858|NCT02172352|Experimental|Ba 679 BR low dose|
89322859|NCT02172352|Placebo Comparator|Placebo inhalation powder|
89322860|NCT02172352|Experimental|Ba 679 BR middle dose|
89322861|NCT02172352|Experimental|Ba 679 BR high dose|
89322862|NCT02166268|Active Comparator|Avanz Phleum pratense|Avanz Phleum pratense 15,000 SQ+ (standardised quality), suspension for subcutaneous injection.
89322863|NCT02166268|Placebo Comparator|Placebo|Placebo, suspension for subcutaneous injection.
89322864|NCT02757352|Experimental|Q2W Ixekizumab|"Participants received a starting dose of 80 or 160 milligram (mg) of ixekizumab given subcutaneously (SC) at week 0 followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 52 during the double-blind period.~Inadequate responders (IR) as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
89322865|NCT02757352|Experimental|Q4W Ixekizumab|"Participants received a starting dose of 80 or 160 mg of ixekizumab given SC at week 0 followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 52 during the double-blind period.~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label week 16 and 44."
89322866|NCT02757352|Placebo Comparator|Placebo|"Participants received placebo as 2 SC injections Q2W to week 52 during double-blind period.~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
89322867|NCT02172430|Experimental|Tiotropium|
89322868|NCT02172430|Active Comparator|Oxitropium bromide|
89322869|NCT02166424|Active Comparator|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
89322870|NCT02166424|Placebo Comparator|olive oil|2880mg olive oil daily
89322871|NCT02170558||Patients implanted w/TM-Ardis|Patients who are receiving a TM-Ardis implant for degenerative disc disease will have a CT scan immediate post op (2 weeks) and again at 6 months to determine if fusion can be assessed with the study metal reduction software. Will utilize TM- Ardis implant and Metal Reduction CT software
89322872|NCT02172508|Experimental|Tiotropium|
89322873|NCT02172508|Placebo Comparator|Placebo|
89322874|NCT02166502||Nevirapine|The patients in this study are newborn infants clinically prescribed combination antiretroviral treatment with nevirapine for prevention of mother-to-child HIV transmission.
89322875|NCT02174692|Experimental|Elderly|"Exercise One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 minutes rest between sets"
89322876|NCT02174692|Experimental|Young|"Exercise~One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 minutes rest between sets"
89322877|NCT02172586|Experimental|Telmisartan|
89322878|NCT02172586|Experimental|Telmisartan + Hydrochlorothiazide|
89322879|NCT02172586|Active Comparator|Losartan|
89322880|NCT02172586|Active Comparator|Losartan + Hydrochlorothiazide|
89322881|NCT03538522|Experimental|Low-dose N-831(Traneurocin)- 10 mg QD|Oral administration of 10 mg of NA-831 (Traneurocin) per day for 24 weeks
89322882|NCT03538522|Experimental|Medium-dose NA-831(Traneurocin)- 20 mg QD|Oral administration of 20 mg of NA-831(Traneurocin) per day for 24 weeks
89322883|NCT03538522|Experimental|High-dose NA-831(Traneurocin)- 40 mg QD|Oral administration of 40 mg of NA-831(Traneurocin) per day for 24 weeks
89322884|NCT03538522|Placebo Comparator|Placebo|Oral administration of placebo per day for 24 weeks
89322885|NCT02170636|Experimental|Period 1: BIBR 1048 MS + Pantoprazole|"Five treatments with oral administration of 50 mg BIBR 1048 MS (bid for 3 days) and 40 mg Pantoprazole (bid). Randomised sequence.~BIBR 1048 MS Capsule E with pantoprazole; BIBR 1048 MS Capsule F with pantoprazole; BIBR 1048 MS Capsule G with pantoprazole; BIBR 1048 MS Tablet H with pantoprazole; BIBR 1048 MS Drinking solution with pantoprazole"
89322886|NCT02170636|Experimental|Period 2: BIBR 1048 MS|"Three treatments (fixed sequence) with oral administration of 50 mg BIBR 1048 MS (bid for 3 days).~BIBR 1048 MS Capsule E without pantoprazole;~BIBR 1048 MS Tablet H without pantoprazole;~BIBR 1048 MS Drinking solution without pantoprazole"
89322887|NCT02255734|Active Comparator|Zovirax|
89322888|NCT02255734|Experimental|Virless|
89322889|NCT02170714||ASC|Consecutive children hospitalized for an episode of acute ASC, defined as a PUCAI > 65. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms. A follow-up of 2 years for the colectomy risk was evaluated for all patients.
89322890|NCT02174770|Experimental|ACL BFR group|This group is patients with post-op from ACL reconstruction who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
89322891|NCT02174770|Active Comparator|ACL Standard Therapy|This group is patients with post-op from ACL reconstruction who are randomized into the standard therapy arm. They will receive ACSM guided-strength training as part of their post-operative physical therapy program.
89322892|NCT02174770|Other|Chronic Muscle Weakness|This is a crossover group where all subjects will be randomized to begin with either standard or blood flow restriction therapy for 4 weeks. After completion of the initial training, each subject will be switched to the opposite in an AB/BA crossover design.
89322893|NCT02174770|Experimental|Knee Arthroscopy BFR|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
89322894|NCT02174770|Active Comparator|Knee Arthroscopy Standard|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the standard physical therapy arm. They will receive ACSM-guided strength training as part of their post-operative physical therapy program during normal post-op rehab.
89322895|NCT02170792|Experimental|BIBR 1048 MS with ranitidine|Low, medium or high dose in combination with ranitidine
89322896|NCT02170792|Experimental|BIBR 1048 MS without ranitidine|Low, medium or high dose
89523429|NCT03124277|Other|Control group|Best local diet
89523430|NCT03270917|Other|Open|Open liver surgery
89523431|NCT03270917|Other|Laparoscopy|Laparoscopic liver surgery
89322897|NCT02172898||Heavily Drinking Controls|Heavy alcohol drinking will be defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months and within the 6 weeks prior to study enrollment. Heavy drinkers, who have just become abstinent within prior 2 weeks, including those we convince to seek treatment as part of the recruiting process, are eligible for enrollment. Control subjects must meet the following criteria: (1) AST, ALT, and total bilirubin levels must be within normal range; (2) no prior history of known alcoholic liver disease; and (3) absence of hepatosplenomegaly (from physical examination or radiographic imaging) or stigmata of liver disease.
89322898|NCT02172898||Subjects with AH|Diagnosis of AH will be established on published criteria based on history of heavy alcohol consumption (defined as > 40 grams per day on average in women and > 60 grams per day on average for men for a minimum of 6 months and within the 6 weeks prior to study enrollment), clinical evaluation and appropriate laboratory testing (as defined as total bilirubin > 2 mg/dL and AST > 50 U/L). When diagnosis of AH remains in question, a liver biopsy (if clinically feasible and subject has no contraindications) will be required. We plan to enroll patients with AH in special population infected with hepatitis B (HBV), hepatitis C (HCV), or HIV.
89322899|NCT02174926|Active Comparator|Conservative treatment|Written lifestyle guidance and fiber supplements
89322900|NCT02174926|Experimental|Elective laparoscopic sigmoid resection|
89322901|NCT02172976|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery
89322902|NCT02172976|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery
89322903|NCT04588480|Experimental|BNT162b2|BNT162b2 (intramuscular injection)
89322904|NCT04588480|Placebo Comparator|Placebo|Placebo (intramuscular injection)
89322905|NCT02178280|No Intervention|unresectable hilar cholangiocarcinoma|control group
89322906|NCT02178280|Experimental|liver transplantation|liver transplantation combined with neoadjuvant radiochemotherapy
89322907|NCT02178514|Experimental|Formula Feeding group by BabyNes Nutrition System|In this arm, all infants will be fed with BabyNes Nutrition System since enrollment until 12 month of age
89322908|NCT02178514|No Intervention|Breastfeeding group|used as reference to compare with formula feeding group
89322909|NCT02173132|Active Comparator|acetyl-L-carnitine|2 g acetyl-L carnitine twice a day for 90 days
89322910|NCT02173132|Placebo Comparator|sugar pill|Placebo twice a day for 90 days
89322911|NCT02175082|Active Comparator|Forced exercise cycling|Cycling exercise at approximately 90 rpm
89322912|NCT02175082|Active Comparator|Self-selected pace cycling|Cycling at self selected rate, with same aerobic level as forced cycling group
89322913|NCT03538366|Experimental|Donor FMT|Fecal transplant from unrelated, healthy volunteers
89322914|NCT02175160|Experimental|Braking and functionality with right knee osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right knee osteoarthritis
89322915|NCT02175160|Experimental|Braking and functionality with right knee arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right total knee arthroplasty
89322916|NCT02173210||Prior preterm birth|Pregnant women with a prior preterm birth, eligible to receive 17 hydroxyprogesterone caproate (17OHPC)
89322917|NCT03538288|Experimental|Twenty sessions of rTMS|Twenty sessions of rTMS will be applied to treatment seeking participants.
89322918|NCT02756650|Experimental|Canakinumab|Canakinumab was administered monthly
89322919|NCT02173288|Active Comparator|Standard medical therapy|Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.
89322920|NCT02173288|Active Comparator|Midodrine group|Standard medical therapy (n-15) with Midodrine 7.5 mg thrice a day
89322921|NCT02173288|Active Comparator|Tolvaptan group|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day
89322922|NCT02173288|Experimental|Tolvaptan plus midodrine arm|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day and Midodrine 7.5 mg thrice a day
89322923|NCT02173366|Experimental|Change Club Intervention|
89322924|NCT02178670|Placebo Comparator|non-cancer stem cell vaccine|There is no cancer stem cell vaccine in this group
89322925|NCT02178670|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89322926|NCT02178670|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89322927|NCT02178670|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
89322928|NCT02178748|Experimental|Group 1|Group 1 (Schistosoma mansoni uninfected): 12-24 BCG-vaccinated volunteers with no helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
89322929|NCT02178748|Experimental|Group 2|Group 2 (Schistosoma mansoni infected): 12-24 BCG-vaccinated volunteers with helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
89322930|NCT02178826|Experimental|Rapid Maxillary Expansion|A Rapid Maxillary Expander will be fitted and the palate will be expanded approximately 5mm.
89322931|NCT02178826|Placebo Comparator|Placebo group|A Sham appliance is fitted and activated for 10-14 days. The patients in this group will after it has been revealed they were randomized into the placebo group have a true Rapid Maxillary Expander fitted and the palate will be expanded approximately 5 mm.
89322932|NCT02175238|Experimental|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
89322933|NCT02175238|Active Comparator|BI 691751 fasted|single dose BI 691751 in fasted state
89322934|NCT02175316|Experimental|Experimental: EECP for DOMS|All enrolled subjects will receive EECP treatment Delayed Onset Muscle Soreness.
89322935|NCT02175394|Active Comparator|Microgynon®|Microgynon® once daily during period 1 (day 1 to day 14)
89322936|NCT02175394|Experimental|Microgynon® and BI 1356|Microgynon® combined with BI 1356, once daily during period 2 (day 15 to day 21)
89322937|NCT02173600|Experimental|Group-level Intensive Dietary Counselling|Active learning through 4-6 60-minute sessions workshop, enrolling 8-12 people each time.
89322938|NCT02173600|Active Comparator|Individual-level Intensive Dietary Counselling|Individualised dietary counselling delivered at the health-care point
89322939|NCT02178904||Suspected Coronary Artery Disease|Subjects with symptoms suspicious of obstructive CAD who are referred for non-emergent clinically-indicated invasive coronary angiography or stress-rest MPI. Intervention: Procedure/Surgery: CT and stress test
89322940|NCT02173678|Experimental|COMBIVENT® HFA|
88806630|NCT05901129|Active Comparator|SPSIPB|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle. PCA device was also performed to this group with the same protocol which was detailed in control arm.
89322941|NCT02173678|Active Comparator|COMBIVENT® CFC|
89322942|NCT02173678|Placebo Comparator|Placebo HFA-MDI (metered dose inhaler)|
89322943|NCT02256124|Experimental|Lamotrigine|"Lamotrigine during 28 consecutive weeks:~8 weeks dose-increase phase: from 25mg once daily to 100mg twice daily~18 weeks target-dose phase: 100mg twice daily~2 weeks decline-phase: 100mg once daily."
89322944|NCT02256124|Placebo Comparator|Placebo|Placebo tablets during 28 consecutive weeks, with identical appearance to lamotrigine tablets, mimicking the lamotrigine dosing schedule.
89322945|NCT02173756|Experimental|oral morphine gel|1 mg / ml of Morphine hydrochloride, presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
89322946|NCT02173756|Placebo Comparator|placebo gel|1 mg / ml of Placebo gel that is presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
89322947|NCT00102466|Experimental|Vildagliptin|
89322948|NCT00102466|Active Comparator|Gliclazide|
89322949|NCT02173834|Other|Lean subjects|Lean, young, healthy, Caucasian, male subjects
89322950|NCT02173834|Other|Obese subjects|Obese, Young, Healthy, Caucasian, male subjects
89322951|NCT02178982||standard treatments of ARDS|
89322952|NCT02178982||protocol treatment of ARDS|
89322953|NCT02175550|Experimental|NR CC|
89322954|NCT02179060||Cooling group|The RhinoChill® cooling is started as soon as possible to the patients with Cardiac arrest, and before the return of spontaneous circulation
89322955|NCT02179060||Control group|Standard care, no cooling during pre-hospital care
89322956|NCT04620928|Experimental|Concept Retrieval|Patients will be given behavioral intervention, and their brain activity recorded.
89322957|NCT02256046|Experimental|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
89322958|NCT02175706|Active Comparator|Resolute Integrity®|The coating of Resolute Integrity consists of zotarolimus as antiproliferative agent and the BioLinx® polymer system. This polymer system consists of a blend of three different polymers: (1) the hydrophobic C10 polymer, which aids in the control of drug release; (2) the hydrophilic C19 polymer, which supports biocompatibility; and (3) polyvinyl pyrro-lidinone, which increases the initial drug burst and enhances the elution rate.
89322959|NCT02175706|Active Comparator|Promus Element®|"Promus Element utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation.~Promus Element is composed of the Element platform, a thin fluoropolymer coating, and Everolimus."
89322960|NCT02173912|Experimental|Sequence 1|"Single-dose crossover~Test: CJ-30059~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg~Once daily Oral administration with at least 14 days of washout period"
89322961|NCT02173912|Experimental|Sequence 2|"Single-dose crossover~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg~Test: CJ-30059~Once daily Oral administration with at least 14 days of washout period"
89322962|NCT02173990|Experimental|Aflibercept-FOLFIRI|On day 1 of each cycle patients will receive aflibercept followed by irinotecan, 5-FU and leucovorin (FOLFIRI regimen). This treatment will be repeated every 2 weeks until RECIST progression or intolerance.
89322963|NCT02255812|Placebo Comparator|200 mL tap water|Single intragastric instillation of 200 mL tap water via nasogastric tube
89322964|NCT02255812|Active Comparator|2 g citric acid|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
89322965|NCT02255812|Active Comparator|2 g salt|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
89322966|NCT02255812|Active Comparator|0.017 g quinine|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
89322967|NCT02255812|Active Comparator|1 g monosodium glutamate|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
89322968|NCT02255812|Active Comparator|25 g glucose|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
89322969|NCT02179138|Other|TFV 1% Gel|TFV 1% gel with the user-filled paper applicator
89322970|NCT02175784|Experimental|ipragliflozin group|oral
89322971|NCT02175784|Experimental|placebo group|oral
89322972|NCT02256280|Experimental|S Group|Sugammadex 2 or 4 mg/kg iv once at the end of surgery
89322973|NCT02256280|Active Comparator|N Group|Neostigmine 0.05 or 0.07 mg/kg (+ atropine 0.02 mg/kg) iv once at the end of surgery
89322974|NCT02174068|Experimental|paracetamol|drug interaction between paracetamol and nefopam in healthy volunteers.
89322975|NCT00101608|Experimental|1|
89322976|NCT02175862||Trauma patients before PS-HEMS|"The before period was between december 1 2009 to april 30 2010 (five months)."
89322977|NCT02175862||Traume patients after PS-HEMS|"The after period was between may 1 2010 to april 30 2011 (12 months)."
89322978|NCT02174146|Other|non-surgical therapy|non-surgical periodontal therapy with ultrasonic scalers and periodontal curettes
89322979|NCT02179216|Active Comparator|Hydration|•Group 1: First day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl). Second day, Orthostatic Hypotension test with venous contention in the morning.
89322980|NCT02179216|Active Comparator|Venous contention|•Group 2: First day, Orthostatic Hypotension test after implementation of venous contention in the morning. Second day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl).
89322981|NCT02175940||Myopic Choroidal Neovascularization patients|
89322982|NCT02175940||Control patients undergoing cataract surgery|
89322983|NCT02174224|Experimental|SMC + BI + Case Management|This arm will include all interventions in Standard Medical Care + Brief Intervention Arm. Case management will also be given to this arm. General needs based assessments will be conducted by the outreach worker. These assessments will be done at the hospital or at the youth's home, whichever they prefer. This assessment tool addresses education, vocational training, employment, housing, medical insurance, follow-up care and pro-social activities. Although each youth in this arm will receive the same needs-based assessment, individual youth will have variable needs, which will guide each unique and individualized case management plan.
89322984|NCT03537430|Other|TNT Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent TNT uniportal VATS mediastinal tumor resection
89322985|NCT03537430|Other|Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent traditional uniportal VATS mediastinal tumor resection
89322986|NCT02176096|Experimental|Glycosade|
89322987|NCT02179294|Active Comparator|Pethidine|Pethidine is pain relief in labour
89322988|NCT02179294|Active Comparator|Remifentanil|Remifentanil intravenous patient controlled analgesia
89322989|NCT02176174||White|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
89322990|NCT02176174||Black|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
89322991|NCT02176174||South Asian|Self-reported ethnic group of South Asian, using the United Kingdom Census categories, as recorded in electronic health records.
89322992|NCT02176174||Mixed/Other|Self-reported ethnic group of Mixed or other, using the United Kingdom Census categories, as recorded in electronic health records.
89322993|NCT02179372|Experimental|Eicosapentaenoic acid|Subject with Cronn's Disease and/or Ulcerative colitis in clinical remission will receive 2 g/day of eicosapentaenoic acid for 6 months
89322994|NCT02179372|Placebo Comparator|Medium chain fatty acid (placebo)|Subjects with Crohn's Disease and/or Ulcerative colitis will be receive 2 g/day of medium chain fatty acid for 6 months
89322995|NCT02174380|No Intervention|Passive Household Contact Evaluation|Passive case finding refers to the current National TB program of voluntary self-reporting of symptomatic patients to the health system for diagnosis of TB and initiation of effective chemotherapy
89322996|NCT02174380|Experimental|Active Household Contact Evaluation|The intervention program includes households visits of all newly diagnosed TB cases enrolled in TB treatment within a DISA NTP clinic in SJL district. During the home visit health staff will evaluate all household contacts for symptoms of active TB. Any person reporting cough for >14 days will be asked to provide a spot sputum for microscopy and referred to the clinic for chest x-ray and clinical evaluation. All household contacts ≤19 years will be referred to the clinic for chest x-ray, pediatric clinical evaluation and initiation of treatment for active or latent TB as required. Counseling including TB infection control practices and importance of diagnosis and treatment completion for TB cases will be provided to household members.
89322997|NCT02176252|Experimental|AZD1722|Dose escalation from 5 mg to 90 mg BID
89322998|NCT02174458||Bariatric Surgery only|Patients after Bariatric Surgery but no secondary reconstructive procedures
89322999|NCT02174458||Body Contouring surgery|Post-bariatric patients and patients with no history of bariatric surgery but after natural weight loss
89323000|NCT02174536|Active Comparator|Decidual Stromal cell therapy|Decidual stromal cell therapy (approximately 1x10^6 cells/kg) for hemorrhagic cystitis in addition to Misoprostol therapy (0,2mg, 3 times/day) on two occasions at weekly intervals.
89323001|NCT02174536|Placebo Comparator|Placebo|Receives placebo (masked i.v. infusion, same amount as an infusion of decidual stromal cells) in addition to Misoprostol therapy (0,2mg, 3 times/day).
89323002|NCT02174614|Active Comparator|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
89323003|NCT02174614|Experimental|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment
89323004|NCT02174614|Experimental|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized games 3 times per week for the first 4 weeks.
89323005|NCT02179450||Blepharospasm|Patients suffering from Blepharospasm
89323006|NCT02179450||Cervical Dystonia|Patients suffering from cervical dystonia
89323007|NCT02179450||Bilateral facial palsy|Patients suffering from bilateral facial palsy of inflammatory origin
89323008|NCT02179450||Healthy Control|Control subjects
89323009|NCT02179528|Active Comparator|etoposide,maintenance therapy|etoposide,25mg qd d1-20，repeat every 28 days
89323010|NCT02179528|No Intervention|blank control|blank control
89323011|NCT02176330|Active Comparator|Usual care|ePAQ-PF followed by a face to face consultation.
89323012|NCT02176330|Experimental|Virtual Clinic|ePAQ-PF followed by a telephone consultation.
89323013|NCT02179606|Experimental|Dermalax Implant Plus|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
89323014|NCT02179606|Active Comparator|Restylane Sub-Q|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
89323015|NCT02176564||Chronic obstructive pulmonary disease|Patients with COPD treated with inhaled bronchodilators
89323016|NCT02182102|Experimental|BIBF 1120 + Pemetrexed|
89323017|NCT02176720|No Intervention|Standard diagnostics without PET|Standard of care brain imaging modalities, predominantly MRI
89323018|NCT02176720|Experimental|FDOPA PET-CT|PET-CT with administration of FDOPA as an experimental radiopharmaceutical. This arm includes standard of care imaging plus FDOPA PET-CT
89323019|NCT02182180||Protocol participants|All participants enrolled on the protocol
89323020|NCT04494568|Experimental|HIFU intervention|patients will benefit of an HIFU Treatment of their rectal endometriosis
89323021|NCT02176876|Experimental|GS-5745|Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.
89323022|NCT02176876|Placebo Comparator|Placebo to match GS-5745|Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.
89323023|NCT02179684|Experimental|Early surgery|Patienst with Bell´s Palsy with an early surgical intervention (< 3month), according to 'baby-sitter' method
89323024|NCT02179684|Active Comparator|Conventional treatment and follow-up|Patienst with Bell´s Palsy treated with conventional treatment and standardized physiotherapy according to Jaqueline Diels model.
89323025|NCT02179762|Experimental|Arm I (moderate intensity exercise)|Patients perform moderate intensity exercise on a stationary bike for 20-50 minutes, three days a week for 16 weeks.
89323026|NCT02179762|Experimental|Arm II (HIIT exercise on a standard stationary bike)|Patients perform HIIT exercise on a standard stationary bike, three days a week for 16 weeks.
89323027|NCT02179762|Experimental|Arm III (HIIT exercise on a cybercycle)|Patients perform HIIT exercise on a cybercycle using racing or other games, three days a week for 16 weeks.
89323028|NCT02179840|Active Comparator|Intravenous|Anesthesia is maintained via intravenous agents. Mechanical ventilation adjustment will be performed.
89323029|NCT02179840|Active Comparator|Inhalational|Anesthesia is maintained via inhalational agents. Mechanical ventilation adjustment will be performed.
89323030|NCT02182258|Placebo Comparator|Placebo|
89323031|NCT02182258|Active Comparator|BIBF 1120 intravenous|
89323032|NCT02182258|Experimental|BIBF 1120 capsule|
89323033|NCT02182336|Experimental|BI 201335 NA|
89323034|NCT02176954|Experimental|Test A, Test B, Comparator|The subjects first test Coloplast Test A followed by Coloplast Test B and finally Comparator.
89323035|NCT02176954|Experimental|Test A, Comparator, Test B|The subjects first test Coloplast Test A followed by Comparator and finally Coloplast Test B.
89323036|NCT02176954|Experimental|Test B, Test A, Comparator|The subjects first test Coloplast Test B followed by Coloplast Test A and finally Comparator.
89323037|NCT02176954|Experimental|Test B, Comparator, Test A|The subjects first test Coloplast Test B followed by Comparator and finally Coloplast Test B.
89323038|NCT02176954|Experimental|Comparator, Test A, Test B|The subjects first test Comparator followed by Coloplast Test A and then Coloplast Test B
89323039|NCT02176954|Experimental|Comparator, Test B, Test A|The subjects first test Comparator followed by Coloplast Test B and then Coloplast Test A.
89323040|NCT02182414|Active Comparator|BI 207127 NA (TF-I)|trial part 1: 800 mg BI 207127 NA Trial formulation I (TF-I)
89323041|NCT02182414|Experimental|BI 207127 NA (TF-II)|trial part 1: 800 mg BI 207127 NA Trial formulation II (TF-II)
89323042|NCT02182414|Experimental|BI 207127 NA delayed release|trial part 1: 800 mg BI 207127 NA TF-II, delayed release
89323043|NCT02182414|Experimental|BI 207127 NA extended release (10% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (10% Hydroxypropyl methyl cellulose (HPMC))
88816003|NCT01106456|Experimental|Nontailored (NT)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
89323044|NCT02182414|Experimental|BI 207127 NA extended release (15% PEO)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (15% Polyethylene oxide (PEO))
89323045|NCT02182414|Experimental|BI 207127 NA extended release (20% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (20% HPMC)
89323046|NCT02182414|Experimental|BI 207127 (TF-II), fed|trial part 2
89323047|NCT02182414|Experimental|BI 207127 (TF-II), fasted|trial part 2
89323048|NCT02177110||Study|Patients who have fresh frozen and FFPE tissue taken prior to treatment
89323049|NCT02177110||Control|Fresh frozen tissue and FFPE tissue is available
89323050|NCT02182570|Experimental|WAL 801 CL|
89323051|NCT02182648|Experimental|etomidate group|infusion of etomidate at 2 minutes before anesthesia induction
89323052|NCT02182648|Active Comparator|propofol group|infusion of propofol at 2 minutes before anesthesia induction
89323053|NCT02182648|Active Comparator|sevoflurane group|inhale sevoflurane for anesthesia induction and maintenance
89323054|NCT02182726||MOBEC|
89323055|NCT02179996|Active Comparator|Three vaccine injections|Infants in this study arm will receive three vaccine injections at two, three and four months after birth (vaccine: DTP-pertussis-Hib).
89323056|NCT02179996|Experimental|Two vaccine injections|Infants in this study arm will receive two vaccine injections at two and four months after birth (vaccine: DTP-pertussis-Hib).
89323057|NCT02180074||I|Women without PAD (ABI >1.0 and <1.4) or CAD, and < 2 risk factors for cardiovascular disease (to serve as healthy controls)
89323058|NCT02180074||II|Women without PAD (ABI>1.0 and <1.4) or CAD and > 2 risk factors for cardiovascular disease
89323059|NCT02180074||III|Women with PAD as defined by ABI <0.9 and a coronary angiogram without any significant coronary artery disease.
89323060|NCT02180074||IV|Women with CAD without PAD, as defined by >50% stenosis by coronary angiography and ABI >1.0 and <1.4.
89323061|NCT02180074||V|Women with both CAD and PAD.
89323062|NCT04466098|Experimental|Mesenchymal Stromal Cells|Three fixed doses of MSC approximately 48 hours apart.
89323063|NCT04466098|Placebo Comparator|Placebo|Three fixed doses of placebo control approximately 48 hours apart.
89323064|NCT02180152|Experimental|Postprandial walk|
89323065|NCT02180152|No Intervention|sedentary pregnant women|
89323066|NCT02177188|Experimental|Haemorrhage simulation|
89323067|NCT03536650|Experimental|DMR procedure|
89323068|NCT02177344|Experimental|Low dose of ipratropium bromide|
89323069|NCT02177344|Experimental|High dose of Ipratopium bromide|
89323070|NCT02177344|Active Comparator|Atrovent|
89323071|NCT02177344|Placebo Comparator|Placebo|
89323072|NCT03536494|Experimental|Mirabegron intervention|Review the use of mirabegron and its discontinuation
89323073|NCT03536494|No Intervention|Control group|Usual care
89323074|NCT02180308||PET/MRI|Patient receives PET/MRI
89323075|NCT02177422|Experimental|Telmisartan|
89323076|NCT02180386|Experimental|Experimental group|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
89323077|NCT02182882|Experimental|GINSANA|
89323078|NCT02182882|Placebo Comparator|Placebo|
89323079|NCT02182960|Experimental|Ibuprofen|
89323080|NCT02182960|Active Comparator|Brufen|
89323081|NCT05141968|Experimental|Vitamin D supplements group|Group A: is the interventional group that supplemented with vitamin D tablets contain 2000 IU once time daily with a meal, for 3 months of intervention.
89323082|NCT05141968|No Intervention|Control group|Group B: is the control group, that did not receive any supplements.
89323083|NCT00110357|Active Comparator|Group A|1-12 years old
88816004|NCT03013634|Experimental|Dexmedetomidine Group|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
89323084|NCT00110357|Active Comparator|Group B|13-18 years old
89323085|NCT02183038|Experimental|Meloxicam low & Placebo|
89323086|NCT02183038|Experimental|Meloxicam high & Placebo|
89323087|NCT02183038|Active Comparator|Naproxen sodium & Placebo|
89323088|NCT01067807|Experimental|Proellex Formulation 1|25 mg Proellex Gelucire and PEG (original formulation)
89323089|NCT01067807|Experimental|25 mg Proellex Formulation 2|25 mg Proellex coated with MCC
89323090|NCT01067807|Experimental|25 mg Proellex Formulation 3|25 mg Proellex blended with MCC
89323091|NCT01067807|Experimental|50 mg Proellex Formulation 3|50 mg Proellex blended with MCC
89323092|NCT02752906|Experimental|MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine-primed adolescents (greater than or equal to [>=] 15 to less than [< ]18 years) or adults (>= 18 years) received a single dose of a MenACYW Conjugate vaccine on Day 0.
89323093|NCT02752906|Active Comparator|Menactra®|Healthy, meningococcal- vaccine-primed adolescents (>= 15 to < 18 years) or adults (>= 18 years) received a single dose of Menactra ® vaccine on Day 0.
89323094|NCT01067963|Experimental|Behavioral-education/counseling|"Computer assisted education and telephone counseling using motivational interviewing.~Computer assisted education and motivational interviewing"
89323095|NCT01067963|Placebo Comparator|Group talks/social chat|Group session talks on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
89323096|NCT01068041|Placebo Comparator|A|Placebo
89323097|NCT01068041|Active Comparator|B|250mg active ingredient
89323098|NCT01068041|Active Comparator|C|500mg active ingredient
89323099|NCT01068041|Active Comparator|D|1000mg active ingredient
89323100|NCT02180464|Experimental|LAS41004|Topical application of approximately 2 - 6 mg/cm2 to an area of 20 - 300 cm2, each once daily
89323101|NCT02180464|Active Comparator|control|Topical application of approximately 2 - 6 mg/cm2 of IMPs 1 and 2 to an area of 20 - 300 cm2, each once daily
89323102|NCT02180542||Ischemic stroke patients|Patients admitted with ischemic stroke from march 2012 to april 2014
89323103|NCT02180620|Experimental|No exercise|participants will remain sedentary during testing
89323104|NCT02180620|Experimental|Meal then exercise|45 min of resistance training will be performed after a standard meal
89323105|NCT02180620|Experimental|exercise then meal|45 min of resistance training will be performed prior to a standard meal
89323106|NCT02180698|Experimental|Treatment (TLR4 agonist GLA-SE, radiation therapy)|Patients receive TLR4 agonist GLA-SE intratumorally once weekly for 8 weeks. Within 2 weeks of starting treatment, patients also undergo radiation therapy over 2 weeks for a total of 5-6 fractions.
89323107|NCT00293033|Placebo Comparator|Placebo|Placebo
89323108|NCT00293033|Experimental|BEMA™ Fentanyl|BioErodible MucoAdhesive (BEMA) Fentanyl
89323109|NCT02180776|Active Comparator|Group A|Patients assigned to group A wore the Summit 456 TLSO (intervention) for four weeks in phase 1 of the study, followed by four weeks of observation (control) in phase 2.
89323110|NCT02180776|Placebo Comparator|Group B|Patients assigned to group B started four weeks of observation (control) in phase 1, followed by four weeks of summit 456 TLSO (intervention) in phase 2 of the study.
89323111|NCT02183116|Experimental|Meloxicam|
89323112|NCT02183194|Experimental|Lutonix Paclitaxel Drug Coated Balloon|
89323113|NCT02756182|Experimental|Urodynamics with AC and WP|Patients underwent a conventional urodynamics study utilizing a single catheter technique
89323114|NCT02183272|Active Comparator|Intranasal Ketamine|0.2 mg / kg dose of intranasal ketamine for treatment of suicidality will be given in two separate doses on the day of admission to the hospital.
89323115|NCT02183272|Placebo Comparator|Intranasal Saline Placebo|0.2 mg / kg dose saline intranasal will be given in two separate doses on the day of hospital admission.
89323116|NCT02177500|Experimental|Telmisartan + hydrochlorothiazide and matching placebo|
89323117|NCT02177500|Experimental|Telmisartan and matching placebo|
89323118|NCT02183350|Experimental|BI 1356 BS - single rising dose|
89323119|NCT02183350|Placebo Comparator|Placebo|
89323120|NCT04289597||Obese patients|Obese patients with BMI>30
89323121|NCT02180854|Experimental|Intervention (8 hours)|EWS every 8 hours
89323122|NCT02180854|Active Comparator|Control (12 hours)|EWS every 12 hours
89323123|NCT01068119|Experimental|Same-day discharge|Same-day discharge following PCI
89323124|NCT03537898|Active Comparator|Lactated Ringer's|Patients in a MICU block randomized to lactated Ringer's will receive lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
89323125|NCT03537898|Active Comparator|Normosol|Patients in a MICU block randomized to Normosol will receive Normosol-R pH 7.4 whenever isotonic intravenous fluid administration is ordered by the treating provider.
89323126|NCT01080833|Active Comparator|ERCP mechanical simulator practice|Trainees who are offered ERCP Mechanical Simulator (EMS) training in addition to routine training (study group)
89323127|NCT01080833|No Intervention|No ERCP mechanical simulator practice|Trainees undergoing routine ERCP training only (control group).
89323128|NCT02183428|Experimental|BI 1356|"Treatment sequence AB_C or C_AB~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by~Treatment B: 1 day of combined treatment of BI1356 and glyburide~Treatment C: 1 day of treatment with glyburide alone"
89323129|NCT02183428|Active Comparator|Glyburide|"Treatment sequence AB_C or C_AB~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by~Treatment B: 1 day of combined treatment of BI1356 and glyburide~Treatment C: 1 day of treatment with glyburide alone"
89323130|NCT01080911|Experimental|spinal morphine 0.05 mg|spinal morphine 0.05 mg plus 0.5% heavy marcaine 3.5 ml
89323131|NCT01080911|Active Comparator|spinal morphine 0.1 mg|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
89323132|NCT02183506|Active Comparator|Metformin|
89323133|NCT02183506|Experimental|BI 1356 BS and metformin|Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9)
89323134|NCT01068197|Experimental|Low glycemic load dietary plan|"The subjects and their parents will be given instructions, and specific examples, to lower the glycemic load of their diets by replacing high-GI sources of carbohydrates with low-GI food sources, replacing energy from carbohydrate with energy from protein and fat, and attempt to balance meals and snacks with low-GI carbohydrate, proteins and low-fat food sources. The objective will be to achieve macronutrient composition for the low-GL diet of 45-50% low-GI carbohydrates, 20-25% protein, and 30-35% fat. All subjects will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized low-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
89323135|NCT01068197|Active Comparator|Low fat diet|"For the low fat diet, subjects and their parents will be given instructions, and specific examples, to lower the fat content of their diet. The composition of the low-fat diet will be targeted to achieve 55-60% carbohydrates (with no discrimination by their glycemic index), 15-20% protein and 25-30% fat. All recruited children will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized high-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
89323136|NCT02177656|No Intervention|Usual care|Patients in the usual care group received six patient educational materials in the hospital, a baseline and follow-up phone call by blinded research assistants.
89323137|NCT02177656|Experimental|MI tailored intervention|The MI intervention was provided by a heart failure specialist nurse. The nurse conducted a home-based motivational interviewing intervention followed up by three phone calls over the course of 90 days. The intervention began with a conversation about the participant's self-identified goals. In the home intervention, the nurse focused on self-care areas that the participant identified as high priority. During the home-based intervention, the participant also set specific goals, which the nurse followed up with and reinforced over the follow-up phone calls.
89323138|NCT02177734|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 1 at a 21 day interval
89323139|NCT02177734|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 2 at a 21 day interval
89323140|NCT02177734|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 3 at a 21 day interval
89323141|NCT02177734|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 4 at a 21 day interval
89323142|NCT02177734|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3277509A H7N9 vaccine formulation 5 at a 21 day interval
89323143|NCT02177734|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
89323144|NCT02183584|Experimental|Rifampicin and Linagliptin|
89323145|NCT02180932|Experimental|periodontal disease|Saliva samples
89323146|NCT03537040|Other|Method of Levels|Talking therapy- duration and frequency of sessions to be determined by participant
89323147|NCT02181010|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in low-income, urban, minority neighborhoods. Intervention components will occur at the policy level; food wholesaler level; small food retail outlet level; neighborhood level; household level.
89323148|NCT02181010|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
89323149|NCT03823703|Experimental|Miricorilant- 900 mg|Participants received 900 mg miricorilant (6 miricorilant tablets of 150 mg) orally once daily.
89323150|NCT03823703|Experimental|Miricorilant- 600 mg|Participants received 600 mg miricorilant (4 miricorilant tablets of 150 mg and 2 placebo tablets) orally once daily.
89323151|NCT03823703|Placebo Comparator|Placebo|Participants received 6 placebo tablets orally once daily.
89323152|NCT05141812||ACLR group|ACLR participants would be 7 months post surgery
89323153|NCT05141812||healthy control group|Healthy uninjured participants who are actively engaged in gaelic football or hurling.
89323154|NCT02181088|Experimental|Group 1 (ChAd63 RH5 low dose)|1 dose of ChAd63 RH5 5 x 10^9 vp intramuscularly
89323155|NCT02181088|Experimental|Group 2A (ChAd63 RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly
89323156|NCT02181088|Experimental|Group 2B (ChAd63 RH5 full dose and MVA RH5 low dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 1 x 10^8 pfu 8 weeks later intramuscularly
89323157|NCT02181088|Experimental|Group 2C (ChAd63 RH5 full dose and MVA RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 2 x 10^8 pfu 8 weeks later intramuscularly
89323158|NCT01080989|Other|health screening and clinical diagnosis and treatment for p|The study project can be divided into two parts: (1) health screening for the community and (2) clinical diagnosis and treatment for patients at National Referral Hospital (NRH) in Solomon islands.
89323159|NCT01068275|Active Comparator|Lumbar plexus catheter|
89323160|NCT01068275|Active Comparator|femoral nerve catheter|
89323161|NCT01068275|Active Comparator|single-shot femoral block|
89323162|NCT02181166|Experimental|kinesiotherapy + High voltage electrical stimulation|Same protocol group kinesiotherapy + high voltage electrial stimulation with two rectangular electrodes (3x5 cm) active silicon-carbon and an electrode rectangular dispersive (10x18cm) aluminum wrapped with a damp felt in water. The active electrodes are positioned in central myofascial trigger point of the upper trapezius muscle after application of water soluble gel. The dispersive electrode was placed in the lumbar region. The following parameters will be use: frequency of 10 Hz, twin pulses of 20μs to 100ms between pulses and the maximum voltage tolerated by voluntary until the motor threshold (visible muscle contraction) to increase every five minutes, totaling 30 minutes of stimulation. The negative polarity will be use.
89323163|NCT02181166|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: These exercises involve stretching of the cervical, anterior and posterior chain of the upper trunk and active mobilization of the cervical, shoulder movements of flexion, extension, abduction and adduction of the shoulder and upper limb. The exercises lasted 50 minutes, with 10 minutes of walking, and stretching was performed with two repetitions of 20 seconds, and active mobilization exercises of three sets of eight repetitions and final relaxation of 10 minutes were performed.
88811766|NCT05237024||Physiology Monitoring|The study's objective is to test the hypothesis that immune system activation and subsequent systemic inflammation can be detected through continuously tracking multiple bio signals including physiologic variables (ECG, skin temperature and their derivatives) and behavioral variables (activity and sleep from accelerometers) collected during routine activities of daily living using wearable biosensors.
89323164|NCT02181166|Experimental|kineshioterapy + isquemic compression|The same protocol group kinesiotherapy + ischemic compression in central myofascial trigger point of the upper trapezius muscle. This procedure was performed for 90 seconds.
89323165|NCT02183662|Experimental|BI 224436|
89323166|NCT02183662|Placebo Comparator|Placebo|
89323167|NCT02183740|Experimental|Multifaceted educational program|"A multifaceted educational program for nursing home staff consisting of:~One seven hours educational meeting (interactive workshop) conducted in the nursing home. Theoretical input and case-base discussions considering guidelines for nurse led assessment og interventions of patients fecal incontinence.The content will be made available as educational material.~Recruitment of one local opinion leader per nursing home unit.~Seven educational outreach meetings (1 hour 30 minutes per meeting) during the three months intervention period."
89323168|NCT02183740|No Intervention|Control|The control arm will not receive any educational program and will continue with usual care. Data with information about ordinary care will be gathered as part of the data collection procedure in the study.
89323169|NCT01068353|Placebo Comparator|Placebo|
89323170|NCT01068353|Experimental|Etanercept|
89323171|NCT02177890|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve
89323172|NCT02177890|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation - stimulator attached to the ear but rotated 180 degrees so that it is not stimulating the vagus nerve.
89323173|NCT01083095|Active Comparator|3 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
89323174|NCT01083095|Active Comparator|6 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
89323175|NCT01083095|Active Comparator|9 +/- 1 bite|Volunteers were exposed to mosquito biting for 15 min
89323176|NCT02183818||Healthy nonsmokers|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
89323177|NCT02183818||Smokers with COPD|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
89323178|NCT02183896|Experimental|Platelet-rich plasma (PRP)|Intra-articular injections in the hip of autologous platelet-rich plasma (PRP) at week 1 and 2 post-operatively. Dose 5 mL. PRP is derived from the patient's own blood.
89323179|NCT02183896|Placebo Comparator|Saline|Intra-articular injections in the hip of saline, solution week 1 and 2 post-operatively. Dose: 5 mL at each injection.
89323180|NCT01081067||Control|Routine cow milk-based infant formula
89323181|NCT01081067||Investigational|Cow milk-based infant formula containing probiotics
89323182|NCT05141734||BPPV (benign paroxysmal positional vertigo)|VOR gains were measured by vHIT in both the study group and the control group. The SPV values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
89323183|NCT05141734||Control|VOR gains were measured by vHIT in both the study group and the control group. The SPV values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
89323184|NCT00109577|Placebo Comparator|2|Placebo comparator, 6 placebo capsules three times a day
89323185|NCT00109577|Experimental|1|nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.
89323186|NCT02183974|Experimental|Peptest|44 children at the age between 1 to 7 years diagnosed with bilateral or unilateral OME who underwent adenoidectomy and myringotomy with insertion of ventilation tube. Effusion was collected and analysed using Peptest, which contains monoclonal antibodies targeted against pepsin. Result of the Peptest was stated as positive (2 lines), negative (1 line) and invalid (no line).
89323187|NCT02177968||Elderly fallers or non-fallers|characteristics of these groups
89323188|NCT01083251|Experimental|Peg + Vitamin D|Treatment arm with vitamin D will be treated first with vitamin D supplement for 3 months before the initiation of antiviral therapy. Vitamin D levels will be measures at baseline and three months after. The serum vitamin D-25-OH levels should be > 32 ng/ml before the initiation of antiviral treatment). HBV DNA levels will be also measure at baseline and after 3 months of mono therapy with vitamin D
89323189|NCT01083251|Active Comparator|Peginterferon|
89323190|NCT01083251|Active Comparator|Sebivo|Nucleotide Analog Telbivudine 600 mg daily
89323191|NCT01083251|Active Comparator|entecavir + vitamin d|baraclude 1 mg x1/ day + vitamin d
89323192|NCT02184052||Meloxicam|
89323193|NCT01083329|Placebo Comparator|placebo|for 16 weeks
89323194|NCT01083329|Active Comparator|nicotinic acid|"for 16 weeks :~week 1 = 375 mg per day,~week 2 = 500 mg per day,~week 3 = 750 mg per day,~week 4 = 1000 mg per day,~week 5 = 1500 mg per day,~weeks 6 to 16 = 2000 mg per day."
89323195|NCT03537820||before nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, before nurses formation and installation of a noise warning device
89323196|NCT03537820||after nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, after nurses formation and installation of a noise warning device
89323197|NCT02181244|Experimental|Egg, one a day, for breakfast|The intervention consists in feeding the subjects egg, one a day for breakfast during 5 weeks. At the end of the intervention, blood will be obtained to measure plasma lipids, glucose, insulin and inflammatory markers. All measurements will be finished 24 weeks after the intervention is finished. All data will be reported 1 year after completion of the study.
89323198|NCT02181244|Experimental|Oatmeal, one cup a day|In this arm, subjects will consume oatmeal for a period of 5 weeks. Blood samples will be taken and different parameters will be measured including plasma lipids, glucose, insulin and inflammatory markers. All these measurements will be finished 24 weeks after completion of the study. All data will be reported 1 year after completion of the study.
89323199|NCT01083407|Experimental|0.12% Chlorhexidie Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
89323200|NCT01083407|Placebo Comparator|Toothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
89323201|NCT01068431|Active Comparator|trico bandage|Leg lymphedema stage 2-3
89323202|NCT01068431|Experimental|juxta fit compression device|leg lymphedema stage 2/3
89323203|NCT05141656||Single arm|Patients diagnosed as pancreatic tumor will considered to be enrolled regardless of specific pathologic subtypes expect for metastasis of pancreas. Baseline data and treatment information will be collected under fully informed consent.
89323204|NCT03977051||Focus group|Focus group to explore immunosuppressant medication adherence in kidney transplant patients
89323205|NCT02181322|Experimental|Meloxicam - low dose, fasted|
89323206|NCT02181322|Experimental|Meloxicam - medium dose, fasted|
89323207|NCT02181322|Experimental|Meloxicam - high dose, fasted|
89323208|NCT02181322|Experimental|Meloxicam - high dose, fed|
89323209|NCT03976817||SA-AVR group|Patients who underwent the supra-annular aortic valve replacement (SA-AVR) technique in our institution between December 2010 and December 2017 were retrospectively reviewed.
89323210|NCT02184130|Experimental|TMS|
89323211|NCT02184286|Experimental|Nevirapine + Saquinavir-sgc|
89323212|NCT02178124|Experimental|dosage 1|drug : 9 people(87.5mg/25cm2) placebo : 3 people(0mg/25cm2)
89323213|NCT02178124|Experimental|dosage 2|"dosage2 period 1 : oral administration drug : 12 people(10mg)~dosage 2 period 2: transdermal administration drug : 9 people(175mg/50cm2) placebo : 3 people(0mg/50cm2)"
89323214|NCT02030314|Experimental|chlorthalidone, resistant high blood pressure|if Furosemide dose is 40 mg per day, start Chlorthalidone 12.5 mg per day if Furosemide dose is 80 mg per day, start Chlorthalidone 25 mg per day
89323215|NCT02184364|Experimental|Low dose of Klimadynon®|
89323216|NCT02184364|Experimental|Medium dose of Klimadynon®|
89323217|NCT02184364|Experimental|High dose of Klimadynon®|
89323218|NCT02184364|Active Comparator|Oestrofeminal®|
89323219|NCT02184364|Placebo Comparator|Placebo|
89523432|NCT03375125|Experimental|Probiotic|L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289), dose of 2x10^8 Colony Forming Units (CFU). One lozenges will be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day
89523433|NCT03375125|Placebo Comparator|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
88816005|NCT03013634|Placebo Comparator|Normal saline Group|Equal volume normal saline substitute for dexmedetomidine
89323220|NCT02181478|Experimental|Treatment (intra-osseous UCB with hMSC co-transplant)|"REDUCED INTENSITY CONDITIONING (RIC):~Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.~Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.~GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.~TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0."
89323221|NCT02181712|Experimental|Mesenchymal Stem cells|Subjects who have never received Mesenchymal Stem Cells
89323222|NCT02181712|Experimental|Booster Mesenchymal Stem Cells|Subjects who have previously received Mesenchymal Stem Cells
89323223|NCT02755090|Experimental|Nitrous oxide and IV saline|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
89323224|NCT02755090|No Intervention|Standard Care (IV Sedation and Oxygen)|Within the IV sedation group, women will receive 100mcg fentanyl and 2mg midazolam at least two minutes prior to initiation of the procedure. This group will also receive 100% oxygen by a scented face mask. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
89323225|NCT00109343|Experimental|1|Group 1: ProQuad™ (V221) + PREVNAR™ (pneumococcal 7-valent conjugate vaccine) followed by ProQuad™ (Day 91)
89323226|NCT00109343|Experimental|2|Group 2: PREVNAR™ followed by ProQuad™ (Day 43) followed by ProQuad™ (Day 133)
89323227|NCT00109343|Experimental|3|Group 3: ProQuad™ followed by PREVNAR™ (Day 43), followed by ProQuad™ (Day 91)
89323228|NCT02185690|Other|Binimetinib efficacy/safety|"This is a Phase I/Ib, open-label, dose-escalation, multi-center, non-randomized study designed to evaluate the safety and tolerability of oral Binimetinib in combination with carboplatin and pemetrexed.~Phase I part A standard 3+3 dose-escalation will be used to determine the maximum administered dose (MAD) and the RP2D for the combination in subjects with advanced non-squamous lung carcinoma.~Phase Ib part Once RP2D has been identified, an expansion cohort will be accrued; these patients will be stratified by KRAS genotype.~The RP2D will be expanded by enrolling additional patients, stratified by KRAS genotype, to a total of 30 patients eligible for the safety set (including those treated at the same dose combination in the dose-escalation phase of the study who are eligible for the safety set) to be evaluated for safety, tolerability, pharmacokinetics and biologic activity of MEK162."
89323229|NCT03536806|Placebo Comparator|Placebo Comparator: Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. After drug administration the patient will be observed for 2 hours after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
89323230|NCT03536806|Experimental|Experimental: canrenone|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After administration of canrenone: dose 200 mg (1 ampule a 10 ml) within 2-3 minutes the patient will be observed for 2 hours after the dose with exit ECG and BP measure taken at the end of observation.
89323231|NCT00108485|Active Comparator|Extended release niacin|Extended release niacin 1500-2000 mg daily versus placebo comparator
89323232|NCT00108485|Placebo Comparator|Placebo|Placebo tablets
89323233|NCT02256514|Experimental|Daily oral dose of hepcortespenlisimut-L|Hepcortespenlisimut-L (V5) (850 mg pill) to be administered once per day for the duration of study
89323234|NCT05123339||Case group|Marfan disease according to Ghent criteria revised in 2010 with dural ectasia Patients followed at the CNMR in Bichat Adults ≥18 years old and ≤ 55 years old (to limit the incidence of degenerative lumbar pathologies) No history of lumbar surgery <1 year and without specific pathologies of the spine (tumor, infection, trauma, fracture, inflammatory rheumatism)
89323235|NCT05123339||Control group|Marfan disease according to Ghent criteria revised in 2010 without dural ectasia Patients followed at the CNMR in Bichat Adults ≥18 years old and ≤ 55 years old (to limit the incidence of degenerative lumbar pathologies) No history of lumbar surgery <1 year and without specific pathologies of the spine (tumor, infection, trauma, fracture, inflammatory rheumatism)
89323236|NCT02256592|Experimental|Fecal microbiota transplant (FMT)|Donor fecal suspension will be delivered during colonoscopy to HIV+ individuals.
89323237|NCT02181946|Experimental|Fluconazole with and without Nevirapine|
89323238|NCT02184598|Placebo Comparator|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
89323239|NCT02184598|Experimental|Cognitive training|Cognitive training with 6 different games each of which gets progressively more difficult as children obtain proficiency.
89323240|NCT00107783|No Intervention|Control|No treatment
89323241|NCT00107783|Experimental|Nitisinone-treated|Subjects received nitisinone 2 mg orally, once daily.
89323242|NCT05127694|Experimental|Vestibular Rehabilitation Group|Investigators applied vestibular rehabilitation in this group. This group was consist of 15 participants. After the evaluation investigators gave the patients repetitive vestibular exercises for 4 weeks and in the first week investigators performed canalith repositioning procedure depending on the affected canal. If affected posterior semicircular canal investigators applied Epley maneuver. If affected horizontal semicircular canal also applied barbeque roll maneuver.
89323243|NCT05127694|No Intervention|Pharmacological Control Group|Investigators did not apply any treatment in this group. Participant in this group just used medications doctor-prescribed.
89323244|NCT01068899||Children|healthy children
89323245|NCT01068899||Adult|healthy adults
89323246|NCT02184676|Other|Children born to mother/father with type 1 diabetes|
89323247|NCT01083563||RA inadequate response to methotrexate|Individuals with rheumatoid arthritis who have had an inadequate response to methotrexate and will be starting on an anti-TNF agent.
89323248|NCT01083563||RA inadequate response to anti-TNF.|Individuals with rheumatoid arthritis who have had an inadequate response to an anti-TNF and will be be given a rituximab infusion.
89323249|NCT02030392|Experimental|Intervention group|"IG participation in the cognitive-behavioral program Stop the pain with Happy Pingu. The program compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each)."
89323250|NCT02030392|Active Comparator|Active control group|CG participation in an information and education control group (physical well-being, health and gastrointestinal tract). The program of the control group compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each).
89323251|NCT01083719|Experimental|FDG-PET|A comparison of FDG-PET versus MRI based target volume delineation in glioblastoma and the role of FDG-PET/CT in the alteration of MRI based target volumes.
89323252|NCT02185768|Experimental|DC-BEADS + Idarubicin|Chemoembolization with DC BEAD loaded with idarubicin
89323253|NCT02958202|Experimental|BMN 044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
89323254|NCT02958202|Experimental|BMN 044 IV 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
89323255|NCT02958202|Experimental|BMN 044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
89323256|NCT02182024|Experimental|Dabigatran high dose in healthy subjects|healthy subjects with a creatinine clearance of >80 mL/m
89323257|NCT02182024|Experimental|Dabigatran high dose in mild renal impairment|patients with a creatinine clearance of >50 up to 80 mL/min
89323258|NCT02182024|Experimental|Dabigatran high dose in moderate renal impairment|patients with a creatinine clearance of >30 up to 50 mL/min
89323259|NCT02182024|Experimental|Dabigatran high dose in severe renal impairment|patients with a creatinine clearance of up to 30 mL/min
89323260|NCT02182024|Experimental|Dabigatran low dose in haemodialysis patients|patients requiring haemodialysis
89323261|NCT00095303|Experimental|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
89323262|NCT00095303|Active Comparator|Treatment as Usual (TAU)|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
89323263|NCT03536260|Active Comparator|Immediate implant with Xenograft|
89323264|NCT03536260|Active Comparator|Immediate implant with Nanobone|
89323265|NCT02190136|Active Comparator|Protein whole foods|Ingestion of 20-25 grams per serving consumed 4-6 times per day; 1 within an hour of waking in the morning and the other 2.5-3 hours apart during the day.
89323266|NCT02190136|Experimental|Protein Resistance Exercise Training|Ingestion of 4-6 protein-rich meals per day and 3 times per week of resistance functional training.
89323267|NCT02190136|Experimental|Protein Stretching/Yoga Training|Ingestion of Protein-rich diet 4-6 meals/day and stretching/yoga training 3 times per week
89323268|NCT02184754||MEI|
89323269|NCT02185846|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
89323270|NCT02185846|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San.Ve Tic. A. Ş., Turkey, one tablet, once
89323271|NCT02184832|Experimental|Low tryptophan diet|2 days of a low tryptophan diet
89323272|NCT02184832|Experimental|High tryptophan diet|2 days of a high tryptophan diet
89323273|NCT02256670|Experimental|Text Message Application Intervention|The study intervention will include a mobile phone two-way text message application. Each prompt described below will generate either a yes (Y)/no (N) or ABCDE(F) response from patients. Each response will generate further prompts resulting in either notification for providers to call patients or relevant phone numbers for patients to call for assistance.
89323274|NCT03537352||Surgical Disorders|"A. Surgical Disorders:~Current Hospitalization at the Surgical Inpatient Department or at the Inpatient Department of Otorhinolaryngology or at the Inpatient Department of Cardiology OR~Current Follow-up at the Surgical Outpatient Department or at the Outpatient Department of Otorhinolaryngology or at the Outpatient Department of Cardiology due to a disorder for which any appropriate surgical treatment (surgery) is a treatment option."
89323275|NCT03537352||Non-Surgical General Medical Disorders|"Current Hospitalization at the Internal Medicine Inpatient Department or at the Inpatient Department of Cardiology OR~Current Follow-up at the Internal Medicine Outpatient Department or at the Outpatient Department of Cardiology due to a disorder for which surgery is not a treatment option and any appropriate drug or non-drug treatment excluding surgery is a treatment option."
89323276|NCT00105521|Placebo Comparator|Placebo|Participants will receive placebo matched to sarizotan tablet orally twice daily up to Week 12.
89323277|NCT00105521|Experimental|Sarizotan 2 milligrams per day (mg/day)|Participants will receive sarizotan 2 milligrams (mg) per day (given in 2 divided daily doses) up to Week 12.
89323278|NCT00105521|Experimental|Sarizotan 4 mg/day|Participants will receive sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.
89323279|NCT00105521|Experimental|Sarizotan 10 mg/day|Participants will receive sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.
89323280|NCT04238260|Active Comparator|Usual Physical Therapy Care|Physical Therapists continue usual care
89323281|NCT04238260|Experimental|Enhanced Physical Therapy Usual Care|Best practice implemented
89323282|NCT01083797|Other|dexmedetomidine, chloral hydrate|sedation with dexmedetomidine or chloral hydrate on separate occasions in the same patients
89323283|NCT02190292||PANS group|All current Swedish cases investigated with the Cunningham panel (approximately 150 individuals) will be invited to participate in the study. 50 of these will be re-assessed with the Cunningham panel.
89523434|NCT03099863|Placebo Comparator|Standard Care|Standard cystoscopy with normal saline solution.
89323284|NCT02190292||Psychiatric controls|60 individuals with psychiatric disorder (eg. ADHD, autism spectrum disorder, psychosis, major depression, obsessive-compulsive disorder) will be recruited.
89323285|NCT02190292||Healthy controls|25 age and sex matched children to the PANS group will be recruited.
89323286|NCT01083875|Experimental|0.5% amlexanox oral rinse|Patients treated with an oral rinse containing the active 0.5% amlexanox
89323287|NCT01083875|Placebo Comparator|Vehicle|Patients treated with an oral rinse containing no active
89323288|NCT04325464|Experimental|PEAR-003A|Digital Therapeutic
89323289|NCT01068977|Experimental|Stage I|
89323290|NCT01068977|Experimental|Stage II|
89323291|NCT01068977|Experimental|Stage III|
89323292|NCT02190370|Experimental|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
89323293|NCT03964103|Experimental|gQ-lab daily|
89323294|NCT03964103|Placebo Comparator|Placebo|
89323295|NCT02184910||gastritis and pepsinogen|
89323296|NCT02185924|Experimental|CONTINUOUS FEMORAL BLOCK AND PARECOXIB|Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib
89323297|NCT02185924|Placebo Comparator|CONTINUOUS FEMORAL BLOCK AND PLACEBO|Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%
89323298|NCT02185066|Experimental|Group 1|"Single-dose crossover~Reference: Atorvastatin 20mg and Metformin XR 500mg~Test: CJ-30056 20/500mg~Once daily Oral administration with 7days of washout period"
89323299|NCT02185066|Experimental|Group 2|"Single-dose crossover~Test: CJ-30056 20/500mg~Reference: Atorvastatin 20mg and Metformin XR 500mg~Once daily Oral administration with 7days of washout period"
89323300|NCT01081223|Experimental|TVI-Brain-1|Cancer vaccine plus immune adjuvant Biological/vaccine Other
89323301|NCT02186002|Experimental|Group 1|A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo.
89323302|NCT02186002|Experimental|Group 2|A single oral dose of 50 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 50 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
89323303|NCT02186002|Experimental|Group 3|A single oral dose of 200 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 200 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
89323304|NCT02186002|Experimental|Group 4|A single dose of 500 mg ACT-451840 or placebo to be administered to subjects in the fasted state, followed by an observation period of 4 days. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 500 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
89323305|NCT02186002|Experimental|Group 5|A single oral dose of 1000 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 1000 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
89323306|NCT02186002|Experimental|Group 6|A single oral dose of ACT-451840 or placebo to be administered to subjects in the fed state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. The dose of ACT-451840 to be determined on the basis of the pharmacokinetic results for the previous groups
89323307|NCT01069055|Placebo Comparator|Placebo Control|Group I (Placebo Control) 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
89323308|NCT01069055|Active Comparator|Lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
89323309|NCT01069055|Active Comparator|Paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
89323310|NCT02185144|Experimental|PATH for Triples (PFT)|The Nurse Health Navigator (NHN) meets at least weekly with the experimental participants to implement the adherence component of PFT using approaches tailored to the communication and comprehension of the person that includes memory aids, education regarding side effects and other treatment aspects, engagement with participants' social networks and treatment providers, and active community outreach. PFT will be implemented for 6 months and participants will be followed for an additional 3 months to allow examination of potential decay of the intervention after it is withdrawn.
89323311|NCT02185144|Placebo Comparator|Treatment as Usual (TAU)|Participants in the the Treatment as Usual (TAU) group receive usual treatment after inpatient care.
89323312|NCT02531009||Healthy|Approximately 10 healthy adults will be enrolled into this study
89323313|NCT02531009||SSc|Participants with dcSSc and lcSSc
89323314|NCT02190448|Experimental|study herbal tea|Supplementation of 3-5, 8 oz cups of study tea daily for 4 weeks.
89323315|NCT02190448|Placebo Comparator|herbal placebo tea|Supplementation of 3-5, 8oz cups of tea daily for 4 weeks.
89323316|NCT01083953|Experimental|Sevoflurane|1 arm will receive sevoflurane at varying concentrations at which extubation is attempted according to the Dixon up and down method
89323317|NCT01083953|Experimental|Desflurane|1 arm will receive desflurane at varying end tidal concentration at which extubation will be attempted according to Dixon up and down method
89323318|NCT02190526|Experimental|Mesalazine(asacol 800 mg)|patients receive asacol (800 mg/TDS) and a placebo agent similar to amitriptyline (10 mg/HS) for 8 weeks
89323319|NCT02190526|Experimental|Amitriptyline|patients receive amitriptyline (10 mg/HS) and a placebo like asacol (800 mg/ TDS) for 8 weeks
89323320|NCT02190526|Placebo Comparator|placebo group|patients receive placebo like asacol (800 mg/TDS) and placebo similar to amitriptyline (10 mg/HS) for 8 weeks
89323321|NCT01084031|Experimental|propofol|
89323322|NCT02186080|Experimental|Gemigliptin|Gemigliptin 50mg qd added to subjects current diabetes treatment
89323323|NCT02186080|Placebo Comparator|Placebo|Placebo (identical in appearance to gemigliptin)
89323324|NCT01084109|Active Comparator|1|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
89323325|NCT01084109|Active Comparator|2|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
89323326|NCT02185222|Experimental|Cholecalciferol 100 000 UI (Unité Internationale)|Oral solution in single-dose : 100 000 UI per month
89323327|NCT02185222|Placebo Comparator|Placebo|Oral solution in single-dose per month
89323328|NCT01084187|Active Comparator|vardenafil on demand|four sexual attempts with 20 mg vardenafil during next four weeks
89323329|NCT01084187|Placebo Comparator|placebo|placebo of vardenafil during four weeks
89323330|NCT01084187|Active Comparator|daily vardenafil|10 mg of vardenafil each day during four weeks
89323331|NCT03536182|Active Comparator|Arm A: Carbon ion radiotherapy|"The dose calculation algorithms used in Japan and Europe (local effect model, LEM) are different, so the total dose must be modified to ensure consistency~Japan : 55.2 GyE in 4.6 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of each CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose.~European: . Patients treated in Europe should receive 57.6 GyE in 4.8 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose. This evaluation will occur in the LEM system"
89323332|NCT03536182|Active Comparator|Arm B: Photon radiotherapy|50.4-56 Gy in 1.8-2.0 Gy per fraction in 28 fractions delivered 5 days a week. The plan should be normalized such that 100% of the PTV receives at least 48.9 Gy (i.e. 97% of 50.4 Gy). In addition, 100% of the GTV should receive at least 50.4 Gy. The maximum dose allowed to a point volume (0.03 mL) is 115% of the prescribed dose.
89323333|NCT03964025|Experimental|Cardioskin™ and 3-lead Holter recorder|This is single-arm study. All subjects will receive the investigational device (Cardioskin™) and comparator device (3-lead Holter recorder).The subject will be wearing both the Cardioskin™ and 3-lead Holter recorder for a period of 24 hours, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
89323334|NCT02185300|Experimental|Sequence ABCDE|Subject will be administered treatments in the sequence ABCDE where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 minutes(mins), re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 minutes, re-dispersed, and then taken by subject
89323335|NCT02185300|Experimental|Sequence BCDEA|Subject will be administered treatments in the sequence BCDEA where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
89323336|NCT02185300|Experimental|Sequence CDEAB|Subject will be administered treatments in the sequence CDEAB where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
89323337|NCT02185300|Experimental|Sequence DEABC|Subject will be administered treatments in the sequence DEABC where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
89323338|NCT02185300|Experimental|Sequence EABCD|Subject will be administered treatments in the sequence EABCD where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
89323339|NCT02185378|Active Comparator|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
89523435|NCT03099863|Active Comparator|Neosporin G. U. Irrigant|Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
89323340|NCT02185378|Active Comparator|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
89323341|NCT02190760|Active Comparator|Group I (ISB-P)|Interscalene block with perineural injection of dexamethasone 0.1 mg/kg
89323342|NCT02190760|Active Comparator|Group II (ISB-S)|Interscalene block with systemically injection of dexamethasone 0.1 mg/kg.
89323343|NCT02190760|Active Comparator|Group III - ISB-C|Interscalene block without adjuvant.
89323344|NCT03536104||Controls|"This group will include healthy person."
89323345|NCT03536104||Parkinson's patient|This group will include Parkinsonian patients
89323346|NCT03536104||patients with a related disease.|This group will include patients with a related disease.
89323347|NCT02190838|Experimental|Dacarbazine with Metformin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Metformin 850 mg BID.
89323348|NCT02190838|Experimental|Dacarbazine and Melatonin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Melatonin 3 mg before sleep daily.
89323349|NCT02190838|Active Comparator|Dacarbazine|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days
89323350|NCT02185456|No Intervention|Healthy|Patients with no history of bacterial vaginosis. These women will be monitored monthly and with daily self swabs.
89323351|NCT02185456|Active Comparator|G1 BV in clinical & molecular remission|Patients will receive standard of care intervention, oral metronidazole 500 mg twice a day for 7 days. They will then be monitored to confirm that initial BV treatment was effective by Nugent and Amsel, and by the qPCR test (LbRC). These will be monitored with monthly visits and daily self swabs. Those who recur with symptomatic BV may enroll in the B2 arm for more aggressive treatment.
89323352|NCT02185456|Experimental|G2. Molecular conversion subarm|Half of G1 patients who convert to poor qPCR test results while remaining asymptomatic will be randomized into this G2 arm and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days, with continued monthly visits and daily swabs.
89323353|NCT02185456|Active Comparator|B1 Initially poor qPCR responders|The B1 arm are patients who enter remission after standard of care treatment, oral metronidazole 500 mg twice a day for 7 days, but who have poor initial qPCR scores. Half of such patients will be randomized into B1, half into B2. B1 patients will be monitored with monthly visits and via daily swabs, but will receive no further treatment while BV negative. Patients who recur with BV may enroll as B2 patients for more aggressive treatment.
89323354|NCT02185456|Experimental|B2 BV Remission to conversion|A subgroup of B1 patients who convert to consistently poor qPCR scores during the study (conversion) will be randomized into Arm B2 and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days. These patients will continue monthly visits and daily self swabs. B2 patients who recur with symptomatic BV will be dropped from the study and given other options for therapy.
89323355|NCT02186158|Experimental|Vitamin C|Each patient of this group will be received a direct intravenous injection of 2,5 ml ascorbic acid twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, ascorbic acid's capsules produced by the University Hospital Bordeaux's central pharmacy to keep the double blind way of this study will be given at patient at the morning and at the lunchtime.
89323356|NCT02186158|Placebo Comparator|Placebo|Each patient of this group will be received a direct intravenous injection of 2,5 ml NaCl 9% twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, mannitol's capsules produced by the University Hospital Bordeaux's central pharmacy will be given at patient at the morning and at the lunchtime.
89323357|NCT02186236||Lung and Colorectal cancer patients|Eligible people who consent to participation will provide urine (both in lung cancer and colorectal cancer) and blood (in lung cancer only) samples at pre-specified times.
89323358|NCT02186314|Active Comparator|Apical stimulation|Pacemaker Biotronik: apical stimulation
89323359|NCT02186314|Active Comparator|Bifocal stimulation|Pacemaker Biotronik: bifocal stimulation
89323360|NCT02030548||acute CABG|patients undergoing acute CABG with or without valve replacement during dual antiplatelet therapy
89323361|NCT02185612|No Intervention|Control|Participants will be randomized to a 1 year wait list. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
89323362|NCT02185612|Experimental|Savings program|Participants will be randomized to the EARN.org online savings program for 6 months. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
89323363|NCT02186392|No Intervention|Control department|The control department where the conventional light is installed.
89323364|NCT02186392|Experimental|Circadian Light luminaries|The department where the special circadian light is installed. The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
89323365|NCT02190994|No Intervention|A. Normal function, non-GC replacement|No glucocorticoid replacement will be given perioperatively.
89323366|NCT02190994|Active Comparator|B. Normal function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
89323367|NCT02190994|Active Comparator|C. Impaired function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
89523436|NCT03375047|Experimental|Low Dose|8 mg MRT5005
89523437|NCT03375047|Experimental|Low/Mid Dose|12 mg MRT5005
89523438|NCT03375047|Experimental|Mid Dose|16 mg MRT5005
89323368|NCT02190994|Active Comparator|D. Impaired function, high-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1 and day 2. 60mg hydrocortisone at day 3; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet per day, since postoperative day 3.
89323369|NCT03536338|Active Comparator|Control|Sit-to-stand training alone
89323370|NCT03536338|Experimental|Treatment|Sit-to-stand training combined with Spinal Stimulation
89323371|NCT02193568|Experimental|Arm I (light sedation)|Patients receive light sedation (awake) and undergo craniotomy.
89323372|NCT02193568|Active Comparator|Arm II (intubated general anesthesia)|Patients receive intubated general anesthesia and undergo craniotomy.
89323373|NCT02191072|Experimental|omalizumab|omalizumab 300mg subcutaneously once
89323374|NCT02186548|Active Comparator|Closed surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo closed surgical exposure, which is an intervention to correct the position of PDC:s.
89323375|NCT02186548|Active Comparator|Open surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo open surgical exposure, which is an intervention to correct the position of PDC:s.
89323376|NCT02186626|Experimental|WN/DEN4Δ30 Vaccine|Participants will receive one dose of the WN/DEN4Δ30 vaccine at study entry and one dose at Day 180.
89323377|NCT02186626|Placebo Comparator|Placebo|Participants will receive one dose of the placebo at study entry and one dose at Day 180.
89323378|NCT02191150||Cohort 1|Patients with CKD
89323379|NCT02186704||ICD with DX system|Implantable cardioverter-defibrillator recipients with DX system
89323380|NCT02186704||Dual chamber ICD|Dual chamber implantable-cardioverter-defibrillator recipients (retrospective cohort from IMPACT study)
89323381|NCT02186704||Single chamber ICD|Single chamber implantable cardioverter-defibrillator recipients (retrospective cohort from Cornell registry)
89323382|NCT02191228|Experimental|Group 1|Linagliptin in subjects with normal renal function
89323383|NCT02191228|Experimental|Group 2|Linagliptin in patients with mild renal insufficiency (RI)
89323384|NCT02191228|Experimental|Group 3|Linagliptin in patients with moderate RI
89323385|NCT02191228|Experimental|Group 4|Linagliptin in patients with severe RI
89323386|NCT02191228|Experimental|Group 5|Linagliptin in patients with end-stage renal disease (ESRD)
89323387|NCT02191228|Experimental|Group 6|Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)
89323388|NCT02191228|Experimental|Group 7|Linagliptin in patients with normal renal function and T2DM
89323389|NCT02186782|Active Comparator|Clomiphene citrate-Estradiol group|Women will receive clomiphene citrate and estradiol
89323390|NCT02186782|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate and placebo
89323391|NCT02186860|Experimental|CAR-T cells|Targeting CD19
89323392|NCT02187094|Placebo Comparator|Placebo|One capsule of placebo administered as a single dose.
89323393|NCT02187094|Experimental|2 mg TC-6499|One capsule of 2 mg TC-6499 administered as a single dose.
89323394|NCT02187094|Experimental|5 mg TC-6499|One capsule of 5 mg TC-6499 administered as a single dose.
89323395|NCT02187094|Experimental|10 mg TC-6499|One capsule of 10 mg TC-6499 administered as a single dose.
89323396|NCT02187250|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 2x1000 mg BID per os.
89323397|NCT02187250|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0,6mg sc once per day for one week and increased to 1,2mg sc one per day.
89323398|NCT02187250|Active Comparator|roflumilast|In the roflumilast group roflumilast was initiated at a dose of 500 mg BID per os.
89323399|NCT02191384|Experimental|Orcinoside 25mg per day|
89323400|NCT02191384|Experimental|Orcinoside 50mg per day|
89323401|NCT02191384|Experimental|Orcinoside 100mg per day|
89323402|NCT02191384|Experimental|Orcinoside 200mg per day|
89323403|NCT02191384|Experimental|Orcinoside 400mg per day|
89323404|NCT02191384|Experimental|Orcinoside 600mg per day|
89323405|NCT02191384|Placebo Comparator|placebo|
89323406|NCT02191462|Experimental|Niagen 100mg|1 Niagen capsule (1 x 100 mg capsule) and 9 Placebo capsules
89323407|NCT02191462|Experimental|Niagen 300mg|3 Niagen capsules (3 x 100mg capsule) and 7 Placebo capsules
89323408|NCT02191462|Experimental|1000mg Niagen|10 Niagen capsules (10 x 100mg capsule)
89323409|NCT02191540|Experimental|Abnoba Viscum F 20mg|
89323410|NCT02187328|Experimental|Grapefruit juice|12.5 OZ Grapefruit juice: Subject will ingest grapefruit juice 12.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon prior to their evening visit
89323411|NCT02187328|Placebo Comparator|Apple juice|10.5 OZ Apple juice: Subject will ingest apple juice 10.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon 3 hours prior to their evening visit.
89323412|NCT02187406|No Intervention|Control|
89323413|NCT02187406|Experimental|Traditional ankle athletic taping|Described by Purcell and Schuckman (2009)
89323414|NCT02187406|Experimental|modified ankle athletic taping|Described by Montag and Asmussen (1992)
89323415|NCT03535480|Experimental|G-CSF|Only receives G-CSF subcutaneously five days for stem cell mobilization
89323416|NCT03535480|Experimental|ASCOT|Receives G-CSF subcutaneously five days and then plasmapheresis for hematopoietic stem cell collection and catheterism for infusion in ovarian artery
89323417|NCT02187484|Experimental|Single rising doses of BIBR 277|
89323418|NCT02191852|Experimental|Seresis®|2 capsules per day for a period of 16 consecutive weeks
89323419|NCT02256748|Experimental|BIRT 2584 XX + Midazolam|"BIRT 2584 XX: Multiple doses for 12 days (bid on days 1 and 2, qd from days 3 to 12)~Midazolam: Administration on days -2, 1, 3, and 12"
89323420|NCT02187562|Experimental|Meloxicam/Aspirin|Meloxicam days 1-10 / Aspirin days 5-10
89323421|NCT02187562|Active Comparator|Aspirin|Aspirin 2 days
89523439|NCT03375047|Experimental|Mid/High Dose|20 mg MRT5005
89523440|NCT03375047|Experimental|High Dose|24 mg MRT5005
89523441|NCT03375047|Placebo Comparator|Placebo Comparator|Normal Saline 0.9% USP
89523442|NCT03375047|Experimental|Daily Dose|20 mg MRT5005 delivered in 5 consecutive daily doses of 4mg
89323422|NCT02187640|Experimental|Self-administered acupressure|A 10-day self-administered acupressure program was implemented by the participants who were adult psychiatric in-patients and randomly assigned into this treatment group. The patients would receive a 3-session training of this therapy conducted by a qualified acupressure therapist and each session lasted about an hour. They would be assessed by the trainer to ensure that they are able to identify the five acupoints and applied a constant and an appropriate pressure on each acupoint before actual implementation.
89323423|NCT02187640|Sham Comparator|Sham control group|Sham control group: Patients would receive 3-session training and be assessed by the trainer. However, they would be trained to locate five non-acupoints adjacent to the actual acupoints and with minimal pressure applied.
89323424|NCT02192086|Experimental|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
89323425|NCT02192086|Active Comparator|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
89323426|NCT02187718|Other|SNPGA|Sentinel Node Procedure under General Anaesthesia
89323427|NCT02187718|Other|SNPLA|Sentinel Node Procedure under Local Anaesthesia
89323428|NCT02193724||Retinoblastoma|Participants identified with heritable retinoblastoma will undergo a skin biopsy or blood draw to collect cells for processing and analysis.
89323429|NCT02187796||Normal Cognition|HIV+ individuals with no detectable neurocognitive impairment
89323430|NCT02187796||ANI (asymptomatic neurocognitive impairment)|"HIV+ individuals where impairment involves at least two cognitive domains, and results in neuropsychological testing performance at least 1 Standard Deviation (SD) below the appropriate mean age/education norm for:~Information processing speed~Sensory/motor skills~Short-term and long-term memory~Ability to learn new skills and solve problems~Attention, concentration, and distractibility~Logical and abstract reasoning functions~Ability to understand and express language~Visual-spatial organization Visual-motor coordination~Planning, synthesizing and organizing abilities"
89323431|NCT02187796||MCD (Mild Cognitive Disorder)|HIV+ individuals with cognitive impairment same as ANI but patient or caregivers report that cognitive deficit interferes with mental acuity, work efficiency, home making or social activity
89323432|NCT02187796||HAD (HIV-associated dementia)|"HIV+ individuals where impairment involves at least two cognitive domains and results in neuropsychological testing at least 2 SD below the appropriate mean age/education norm for:~Information processing speed~Short-term and long-term memory~Ability to learn new skills and solve problems~Attention, concentration, and distractibility~Logical and abstract reasoning functions~Ability to understand and express language~Visual-spatial organization Visual-motor coordination~Planning, synthesizing and organizing abilities Cognitive impairment significantly interferes with work, home life, social activities or ADL's."
89323433|NCT02187796||Healthy Controls (HIV-)|Our P300 COGNISION apparatus has been used only in subjects over the age of 60, whereas our participants in the HAND study will all be younger than 60. So, we cannot use COGNISION normative data base for comparison. We will add 10 HIV- healthy controls to our planned 40 HIV+ subjects. These HIV- participants will be age- and gender-matched to the HIV- Asymptomatic Neurocognitive Impairment (ANI) patients, and will undergo all the same assessments
89323434|NCT03535168|Experimental|Dose 1 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.
89323435|NCT03535168|Experimental|Dose 2 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 2 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 2 of BAY1902607 will be given only once.
89323436|NCT03535168|Experimental|Dose 3 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 3 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 3 of BAY1902607 will be given only once.
89323437|NCT03535168|Experimental|Matching placebo|Part 1: From Day 1 until Day 12 the matching placebo will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, matching placebo will be given only once.
89323438|NCT03535168|Experimental|BAY1902607+Matching Placebo|"Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1902607+matching placebo"
89323439|NCT03535168|Experimental|Matching Placebo+BAY1902607|"Part 2:~Randomized crossover design in cough patients Matching placebo+4 different doses of BAY1902607"
89323440|NCT02192242|Experimental|Acute ischemic pain|acute ischemic pain was induced by treadmill testing in all patients investigated
89323441|NCT02192320|Experimental|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone: 0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
89323442|NCT02192320|Active Comparator|Atorvastatin|Atorvastatin: 20 mg (every evening orally) for 5 weeks
89323443|NCT02187874|Active Comparator|early umbilical cord occlusion|Cord clamping will be performed before 30 seconds after delivery, annoting the exact time of clampage and initiating reanimation and postnatal care procedures as usual. 60 second after delivery of the new born, 10 IU of Oxytocin will be administered intramuscularly.
89523443|NCT03374969|Experimental|Attachment and Biobehavioral Catch-Up|
89523444|NCT03374969|Active Comparator|Developmental Education for Families|
89323444|NCT02187874|Experimental|delayed umbilical cord occlusion|"One of the paediatricians will hold the newborn ( in vaginal deliveries between 20-30 cm under the mother, in C-sections between the legs of the mother) until clamping of the umbilical cord is indicated by a second paediatrician who will be controlling the time and overall state of the baby. The baby will be wrapped during this time in a thermal blanket in a flexed lateral decubitus position to minimise stress and heat loss. Time of clamping: after 30 to 60 seconds( preferably 60). If loss of the baby's wellbeing is suspected, the paediatrician will assess the newborn's heart rate , stopping the procedureif this falls under 100ppm, initiating at that moment the necessary reanimation procedures.~60 second after the delivery of the new born 10 IU of oxytocin will be administered intramuscularly."
89323445|NCT02193802|Other|Endoscopy|"CHANCE is a single arm study: all patients will undergo one capsule endoscopy ( PillCam® COLON 2 capsule and PillCam Crohn's) of the whole intestine AND one ileocolonoscopy.~The patients will be then treated according to the preference of their physician and a second capsule endoscopy AND an ileoconoscopy will be performed 6 at 12 months later.~Both exams will be evaluated locally by two independent investigators and all the recorded films will be evaluated and compared by four central readers."
89323446|NCT02187952|Experimental|Behavioral feeding intervention|Behavioral feeding intervention will be conducted as usual. The intervention will not be altered for purposes of the study.
89323447|NCT02187952|No Intervention|Waitlist control|
89323448|NCT02188030|Active Comparator|Group Exercise Training (GET).|Group Exercise Program. The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum 12. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
89323449|NCT02188030|Active Comparator|Individual Exercise Training|Individual Exercise Program. The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al. and Sundstrup et al . During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
89323450|NCT04870216||Medical student|Medical student aged more than 18, presenting menstrual cycles, and agreeing to participate in the study.
89323451|NCT02192476|Active Comparator|conventional|15 participants are allotted in this arm and each participants received conventional neuro rehabilitation programme 5 days a week for 6 weeks.
89323452|NCT02192476|Experimental|intervention|15 participants allotted in this arm and each participants received California tri-pull taping method along with conventional neuro rehabilitation was given 5 days a week for 6 weeks
89323453|NCT04870138|Experimental|Mixed FA7527/FA1090|Bacterial inoculum containing a mixture of equivalent numbers of the isogenic LptA mutant and wild-type (WT) strain administered once to the anterior urethra. N= up to 25
89323454|NCT04870138|Experimental|Mutant FA7527|Bacterial inoculum containing only the isogenic LptA mutant N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
89323455|NCT04870138|Experimental|Wild-type FA1090|Bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
89323456|NCT03536026|Experimental|Bronchoscopic evaluation and biopsy|-Bronchoscopy will be performed by pulmonary and/or critical care fellows who have performed fewer than 10 bronchoscopies (inexperienced bronchoscopists) under direct supervision by an attending Interventional Pulmonologist. The inexperienced bronchoscopist will attempt to navigate to the targeted peripheral pulmonary lesion without virtual bronchoscopic navigation, using only standard axial CT images as a reference. The attending physician will directly observe, but will provide no guidance during this period, which will last no longer than 10 minutes. If the lesion is located and confirmed with radial probe endobronchial ultrasound prior to 10 minutes, biopsies will be performed as per routine clinical practice. If the 10 minute time period elapses prior to localization of the peripheral pulmonary lesion, virtual bronchoscopic navigation will be used.
89323457|NCT02188186|Active Comparator|Conventional treatment|"Initial dual combination therapy with sulfonylurea and metfomin. Dose of sulfonylurea (glimepride 2-8 mg) and metfomin (500-2550 mg) can be ecalated at investigator's discreition at every visit.~Insulin therpy can be added as a rescue therapy at investigator's discreition."
89323458|NCT02188186|Experimental|Initial triple combination treatment|"Initial dual combination therapy with metformin, sitagliptin (Januvia 100 mg), and lobeglitazone (Duvie 0.5 mg).~Insulin therpy can be added as a rescue therapy at investigator's discreition."
89323459|NCT02192632|Experimental|Epiduo- dermatologist's detailed instruction|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into detailed instruction for application of epiduo from dermatologist
89323460|NCT02192632|Experimental|Epiduo- drug insert only gruop|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into drug insert only group
89323461|NCT02192632|Placebo Comparator|BPO group|After randomly assigned to side of BPO application, patients apply BPO during 12 week
89323462|NCT03535090||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
89323463|NCT02257060|Experimental|Endocardial Ablation|
89323464|NCT03535870|Experimental|Fluticasone propionate/salmeterol|fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) twice a day by inhalation throughout the study
89323465|NCT03535870|Active Comparator|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
89323466|NCT03535870|Placebo Comparator|Placebo|placebo inhaled powder twice a day by inhalation throughout the study
89323467|NCT02192710|Active Comparator|Hypnovel® (midazolam)|Midazolam oral intake before anesthesia
89323468|NCT02192710|Experimental|Electronic tab|
89323469|NCT02188342|Experimental|HIT exercise training|
89323470|NCT02188420|Experimental|Latency minus 3ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
89323471|NCT02188420|Experimental|Latency minus 5ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
89323472|NCT02188420|Experimental|Latency minus 7ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
89323473|NCT02188420|Active Comparator|Latency plus 100ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency + 100ms), known to have no effect, where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
89323474|NCT02752048|Experimental|TAS-205（Low dose group）|Low dose group：Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (6.67-13.33 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
89323475|NCT02752048|Experimental|TAS-205（High dose group）|High dose group: Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (13.33-26.67 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
89323476|NCT02752048|Placebo Comparator|Placebo|Placebo group: Oral administration of tablets for 24 weeks, BID after meal
89323477|NCT02188498||Polysomnography with Holter monitoring|Patients will undergo resting electrocardiogram (ECG) test at the beginning of the night and be monitored by a Holter device for the duration of the sleep study.
89323478|NCT02188654|Experimental|Metformin|500 mg metformin
89323479|NCT02188654|Placebo Comparator|Placebo|500 mg of placebo tablets
89323480|NCT02192944|Active Comparator|Chloroquine|Chloroquine base 600 mg single dose
89323481|NCT02192944|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose
89323482|NCT02193022|Experimental|Miltefosine|
89323483|NCT02188732|Experimental|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
89323484|NCT02188732|Active Comparator|CBHH+SMT|"CBHH+SMT Community-Based Health Home (CBHH) PLUS Self-Management Training (SMT) of I-IMR~I-IMR integrates psychiatric illness self-management with strategies for medical illness self-management . The psychiatric component includes psychoeducation about illness and treatment, cognitive behavioral approaches to increase medication adherence, training and relapse prevention, teaching coping skills to manage persistent symptoms, and social skills training. The medical illness component consists of an individually tailored curriculum focused on managing physical illnesses using parallel skills and strategies taught for psychiatric illness self-management, as well as a nurse health care manager to facilitate coordination of necessary preventive and ongoing health care. The I-IMR curriculum consists of 10 modules delivered by an I-IMR specialist through eight months of weekly sessions customized to the specific needs and disorders of each client."
89323485|NCT02188732|Active Comparator|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW)
89323486|NCT02188810|Active Comparator|Group 1|Single dose of control vaccine (a single dose of 0.5 mL TIV).
89323487|NCT02188810|Experimental|Group 2|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 0.5x PAL, i.e. 30 μg).
89323488|NCT02188810|Experimental|Group 3|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 1x PAL, i.e. 60 μg).
89323489|NCT02188810|Experimental|Group 4|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 2x PAL (i.e., 120 μg).
89323490|NCT02188810|Experimental|Group 5|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 4x PAL (i.e., 240 μg).
89323491|NCT02188810|Experimental|Group 6|Single dose of the test article (0.125 mL of TIV with 4x PAL i.e., 240 μg).
89323492|NCT02030704||Atherosclerotic Plaque|
89323493|NCT02188888||Tachycardic patients|Patients will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg.
89323494|NCT02188966|Experimental|Geographical Information System|Availability of Geographical Information System data from ambulances destined for the Emergency Department of Regional Hospital Horsens.
89323495|NCT02194036|Experimental|Learning oriented physiotherapy|Learning oriented physiotherapy is a treatment approach based on knowledge from neuroscience and particularly aimed to curb physical symptoms and ailments, but also to regain a sense of better physical balance and mental control. Therapy sessions are normally given every 2 weeks with individual homework lessons between. The therapy will last between 6 to 12 months depending on learning process and individual needs.
89323496|NCT02194036|Active Comparator|Widely Recognized Psychiatric Treatment|Standard Outpatient Treatment within the Psychiatric clinic
89323497|NCT02189044|Other|exercises; muscle strength|Evaluate the effects of Pilates exercises on respiratory muscle strength in elderly women before and after eleven weeks of training
89523445|NCT03374813|Experimental|MimetikOss|Ridge preservation bone grafting after tooth extraction
89323498|NCT02030782|Active Comparator|Usual Care|Patients received usual care through primary care, enhanced by provider education regarding depression evaluation and management (1-2 hour training, plus study manual)
89323499|NCT02030782|Experimental|Quality Improvement for Depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
89323500|NCT03535402|Other|open label treatment|single arm with patients receiving 200 mg SC twice a week of sarilumab
89323501|NCT04519138|Experimental|Endodrill Model X|Three consecutive samples will be taken using the Endodrill Model X instrument.
89323502|NCT04519138|Active Comparator|Endoscopic ultrasound guided fine-needle aspiration/biopsy|Three consecutive samples will be taken using the the standard method fine-needle aspiration/biopsy.
89323503|NCT02189200|Active Comparator|Oat bran group|oat bran (40g per day)
89323504|NCT02189200|Placebo Comparator|Placebo group|refined rice flour (40g per day)
89323505|NCT02194114|Experimental|Dietary Protein Intake|One treatment Arm; Protein Diet: All patients will be fed the following five diets, in random order, each for 17-19 days: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
89323506|NCT03535246|Experimental|Single arm|EIE cells to treat cancer.
89323507|NCT02030626|Experimental|active rTMS or active tDCS or placebo|Active rTMS (10 Hz) of the motor cortex followed by active tDCS (2 mA) of the motor cortex or conversely
89323508|NCT02030626|Placebo Comparator|Sham rTMS followed by tDCS (or conversely)|Placebo rTMD followed by placebo tDCS or conversely
89323509|NCT02256826|Experimental|Group A|
89323510|NCT02256826|Experimental|Group B|
89323511|NCT02189278|Experimental|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
89323512|NCT02189278|No Intervention|Treatment as usual|Treatment as usual control.
89323513|NCT03535012||Reconstruction using an implant|Immediate 2 stage implant based breast reconstruction after mastectomy. All expanders are placed in the subpectoralis muscle using ADM as a sling. After expansion of the tissue expander change to the permanent implant is performed.
89323514|NCT03535012||Reconstruction using abdominal tissue|immediate free DIEP flap breast reconstruction after mastectomy. DIEP(deep inferior epigastric perforator) free flap was prepared and transferred to the breast pocket. Microanastomosis was done under the microscopic magnification. On sitting position, free flap was inset into breast pocket with confirming of satisfactory inflammatory fold.
89323515|NCT03535792|Active Comparator|Fentanyl/Hyperbaric Bupivacaine|"Group F:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1 ml fentanyl (50μg) and will have Tibial internal fixation."
89323516|NCT03535792|Active Comparator|Nalbuphine/Hyerbaric Bupivacaine|"Group N:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1ml nalbuphine hydrochloride (1.6 mg); (nalufin 20 mg in 1 ml ampoule, Amoun Pharmaceutical Co. Cairo, Egypt) and will have Tibial internal fixation."
89323517|NCT02189356|Experimental|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
89323518|NCT02189356|Other|contol group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
89323519|NCT02193100||13C-glucose|experimental (13C-glucose)
89323520|NCT02193100||No glucose|control (no glucose)
89323521|NCT03535714|Active Comparator|MANTR-a group|"Patients who are in the MANTR-a group attend the MANTR-a treatment program, which consists of 20 once-weekly therapy sessions. Caregivers can be invited to 2 sessions. After 20 weeks, therapy continues with four monthly booster-sessions. In sum, each patient (whose bodyweight is above the 3rd BMI percentile) can attend 24 therapy sessions. In patients whose bodyweight is below the 3rd BMI percentile treatment will be extended to 30 once-weekly and 4 monthly booster sessions. Besides therapy the patients are in nutritional consultation by a dietician and under regular medical care to monitor the physical health and weight gain.~Patients who who have already an existing psychotherapy are attached to the control group."
89323522|NCT03535714|No Intervention|control group|Patients of the control group receive treatment as usual (TAU). It consists of medical care and monitoring, psychotherapy in a single or family setting, parents counselling and dietetics.
89323523|NCT02193256|Active Comparator|Varenicline plus Prazosin|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Prazosin: 1mg for 3 days, then 3mg for 4 days (Week 1), (2) 6mg for 3 days, then 8mg for 4 days (Week 2), and (3) 8mg (Week 3).
89323524|NCT02193256|Placebo Comparator|Varenicline plus Placebo|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Placebo: placebo will be given instead of prazosin (Weeks 1-3)
89323525|NCT03535558||Cohort 1: FQ With Uncomplicated Sinusitis or Bronchitis|A target cohort which includes participants exposed to an oral fluoroquinolone (FQ) with an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
89523446|NCT03374813|Active Comparator|Bio-Oss|Ridge preservation bone grafting after tooth extraction
88819284|NCT05449041||Glaucoma patients|Patients diagnosed with Glaucoma of both gender; passed the age of 18 years; without any other eye disease; suffering from other know serious disease but have a health situation in accordance with expectations related to the age.
89523447|NCT03374735|Experimental|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
89323526|NCT03535558||Cohort 2: FQ With Uncomplicated Acute Urinary Tract Infection|A target cohort which includes participants exposed to an oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
89323527|NCT03535558||Cohort 3: AZ with Uncomplicated Acute Sinusitis or Bronchitis|A comparator cohort which includes participants exposed to oral azithromycin (AZ) with a qualifying indication of uncomplicated acute sinusitis or bronchitis and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
89323528|NCT03535558||Cohort 4: ST with Uncomplicated Acute Urinary Tract Infection|A comparator cohort which includes participants exposed to oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
89323529|NCT02189434||Cytoreductive surgery|Patients having undergone cytoreductive surgery with or without HIPEC will have serum procalcitonin lab draws
89323530|NCT02193334|Active Comparator|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
89323531|NCT02193334|Placebo Comparator|Placebo|Intrathecal injection of placebo starting at 72 hours since the injury and repeating weekly 5 times
89323532|NCT02189512|Other|brain death organ donors|cases - blood sampling
89323533|NCT02189512|Other|abdominal aortic aneurysm repair|controls - blood sampling
89323534|NCT04443478||Laparoscopic Surgery|Lower Mediastinal Lymphadenectomy should be finished via laparoscopic method.
89323535|NCT04443478||Open Surgery|Lower Mediastinal Lymphadenectomy should be finished via open method.
89323536|NCT02189590|Experimental|air-Q|Patients will receive the air-Q with size based on manufacturer recommendations of body weight
89323537|NCT02189590|Experimental|i-gel|Patients will receive the i-gel with size based on manufacturer recommendations of body weight
89323538|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to 1 hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
89323539|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
89323540|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
89323541|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
89323542|NCT02193412|Experimental|patients|"noxious stimulus~change in operating table slope: head-down tilt position~change in operating table slope: head-up tilt position"
89323543|NCT02189824|Experimental|Infusion of partially matched unrelated donor cells|
89323544|NCT02189902|Active Comparator|4000 IU/d of D3 by mouth for 12 weeks|4000 IU/d of D3 by mouth for 12 weeks
89323545|NCT02189902|Experimental|7000IU/d of D3 by mouth for 12 weeks|7000IU/d of D3 by mouth for 12 weeks
89323546|NCT02194192|Experimental|Group E|Ephedrine 10 mg in Normal Saline 10 ml
88816006|NCT02980094|Placebo Comparator|Milk Control group(C)|Using a randomized block design, 25 institutionalized elderly to receive the milk 3 times per day produced by lactating cows fed with the following diet, one of the group is control (C), without vitamin E, selenium, sunflower oil in the cow's food.
89323547|NCT02194192|Active Comparator|Group O|Ondansetron 8 mg in Normal saline 10 ml
89323548|NCT02194192|Placebo Comparator|Group P|Normal saline 10 ml
89323549|NCT02194270|Experimental|Ambroxol hydrochloride - soft pastille|
89323550|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - low dose|
89323551|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - high dose|
89323552|NCT02189980|Placebo Comparator|Saline & nasal clip|Saline and nasal clip inhaled post-operatively
89323553|NCT02189980|Experimental|Aromatherapy blend & nasal clip|Aromatherapy blend and nasal clip inhaled post-operatively
89323554|NCT02190058|Experimental|DS-1971a|DS-1971a suspension, up to 4650mg/day
89323555|NCT02190058|Placebo Comparator|placebo|matching DS-1971a suspension
89323556|NCT02194348|Experimental|BIBN 4096 BS - in single rising doses|
89323557|NCT02194348|Placebo Comparator|Placebo|
89323558|NCT02257216|Active Comparator|Sequence 1: Treatment/Treatment|Treatment/Treatment- consists of Vayarin® for 8 weeks followed by 8 weeks of additional treatment with Vayarin®
89323559|NCT02257216|Active Comparator|Sequence 2: Placebo/Treatment|Placebo/Treatment- consists of Placebo for 8 weeks followed by 8 weeks of treatment with Vayarin®
89323560|NCT02257216|Placebo Comparator|Sequence 3: Placebo/Placebo|Placebo/Placebo- consists of Placebo for 8 weeks followed by 8 weeks of additional treatment with Placebo
89323561|NCT02194426|Experimental|MP0250|"see section intervention description below"
89323562|NCT02195908|Experimental|Single point PC6|"choose single point: Neiguan(PC6).Neiguan(PC6): On the anterior aspect of the forearm,between the tendons of the palmaris longus and the flexor carpi radialis, 2 B-cun proximal to the palmar wrist crease.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
89323563|NCT02195908|Experimental|Single point CV12|"choose another single point Zhongwan（CV12）. Zhongwan(CV12): On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line. Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
89323564|NCT02195908|Experimental|Matching points PC6+CV12|"Choose both Neiguan point(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
89323565|NCT02195908|Active Comparator|only antiemetic|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.
89323566|NCT02197000|Experimental|DIM-Avail 100mg|women will receive DIM 100mg*1/d, a nutritional supplement for 24 months.
89323567|NCT02197312|Other|NobelProcera Bridge Shaded Zirconia|posterior region
89323568|NCT02194504|No Intervention|No dietary advice|No dietary intervention
89323569|NCT02194504|Experimental|Dietary advice, Targeted|12-wk dietary advice
89323570|NCT02194504|Experimental|Dietary advice, Western|12-wk dietary advice
89323571|NCT02197390|Experimental|Health Care plus Public Health|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs). The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
89323572|NCT02197390|Experimental|Health Care|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs).
89323573|NCT02197390|Experimental|Public Health|The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
89323574|NCT02197390|Experimental|Control|No intervention.
89323575|NCT02196064||Safety of the three-drug combination TDF/FTC/RPV|A total of 176 patients will be included in this study, as well as 352 patients naive for RPV who initiated any ART that does not include RPV, who will serve as control group.
89323576|NCT02196142|Active Comparator|Cortisol first, Placebo second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
89323577|NCT02196142|Active Comparator|Placebo first, Cortisol second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
89323578|NCT03534856|Experimental|Mindfulness meditation|Two weeks of short, daily guided mindfulness meditations were provided.
89323579|NCT02257294|Placebo Comparator|Control Arm|two placebo vials
89323580|NCT02257294|Active Comparator|Arm A|Alteplase 10mg and placebo vial
89323581|NCT02257294|Active Comparator|Arm B|Alteplase 10mg and alteplase 10mg
89323582|NCT03534388|Other|Prospective Subjects|
89323583|NCT02194660||M- main hospital|Patient enrolled in the main hospital
89323584|NCT02194660||B- Beihu branch|Patients enrolled in the Beihu branch
89323585|NCT04308694|Experimental|Pharmacy-based methadone treatment|Participants will have their usual methadone dose administered and dispensed at a participating pharmacy. All other methadone services including counseling, drug testing, and medical services will be delivered as usual at the Methadone Program.
89323586|NCT03534778||patients undergoing neck dissection|all patients undergoing neck dissection
89323587|NCT02196298|Experimental|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
89323588|NCT02196298|Active Comparator|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
89323589|NCT03534310|Active Comparator|Lifestyle modification|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive
89323590|NCT03534310|Experimental|Lifestyle modification plus Liraglutide 3 mg|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive. The patients will also receive Liraglutide 3 mg daily sc.
89323591|NCT03534310|Active Comparator|Sleeve Gastrectomy|The patients will undergo laparoscopic sleeve gastrectomy
89323592|NCT02194894|Active Comparator|NAFLD patients|Twenty patients with NAFLD will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
89323593|NCT02194894|Active Comparator|Healthy controls|Twenty healthy controls will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
89323594|NCT02197468||Probiotics|"Preterm infants given probiotics: GA 24-27 weeks/Birth weight < 1000 g~Preterm infants not given probiotics: GA 28-31 weeks/Birth weight 1000-1500 g~Full-term infants not given probiotics (control)"
89323595|NCT02196454|No Intervention|Vaccine Information Statement|Study participants will receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
89323596|NCT02196454|Experimental|Video & Vaccine Information Statement|Participants will view an educational video about the HPV vaccine with a male or female narrator. Participants will also receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
89323597|NCT03534622|Experimental|Delafloxacin|"Dosing will be initiated on Day 1. All participants will receive 300-mg delafloxacin as a~1-hour intravenous infusion every 12 hours (± 15 minutes) for a total of 7 doses."
89323598|NCT02194972|Experimental|soluble dietary fiber|pectin, a kind of soluble dietary fiber
89323599|NCT02194972|No Intervention|Placebo|Placebo
89323600|NCT02197546|Other|acupuncture plus local anesthesia|Bilateral acupuncture with 1.5 mm long indwelling fixed needles
89323601|NCT02197546|No Intervention|Local anesthesia alone|Standard therapy - local anesthesia alone without acupuncture
89323602|NCT02197702|Placebo Comparator|Placebo|2 ml identical placebo taken by mouth at baseline and 3.5 months.
89323603|NCT02197702|Active Comparator|Vitamin D|Vitamin D (100,000IU) given in a 2 ml oral dose at baseline and 3.5months.
89323604|NCT03533920|Experimental|UNI-DEB|
89323605|NCT04213300||Low carbohydrate dietary group|"Participants n = 23~Participants:~Male, female or unspecified gender;~18 years of age or over;~Type 1 diabetes for ≥1 year from diagnosis date and~Individuals who administer insulin using multiple daily injections."
89323606|NCT02196532||migraine group|Patients with migraine
89323607|NCT02196532||healthy control|Sex- and agematched healthy subjects
89323608|NCT02031016|Active Comparator|Fentanyl|"fentanyl bolus injections on an as needed base, next to the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
89323609|NCT02031016|Active Comparator|Remifentanil|remifentanil, starting with 0.15 ug/Ideal Body Weight(IBW)(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
89323610|NCT02196610||HEALTHY SUBJECTS group|A group of 20 healthy staff volunteers identified from the Division of Nephrology, Dept. of Medicine and the Kidney Research Centre at the Ottawa Hospital Research Institute will be invited to participate. Measurements of arterial stiffness will be performed by Applanation tonometry. Healthy status will be defined by a self-reporting questionnaire obtained over the phone prior to enrolment and 2 subsequent non-invasive measurements of arterial blood pressure (BP) prior to testing. Subjects will be included if diastolic BP is ≤ 90 mm Hg and systolic BP ≤ 140 mm Hg on 2 consecutive measurements.
89323611|NCT02196610||END-STAGE RENAL DISEASE (ESRD) group|A group of 20 patients with stage 5 Chronic Kidney Disease (estimated glomerular filtration rate <15 ml/min/m2), who attend chronic hemodialysis treatments at The Ottawa Hospital (TOH) will be invited to participate. Measurements of arterial stiffness will be performed in this group by Applanation tonometry.
89323612|NCT02031094||Major resection|Patients undergoing resection of >3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
89323613|NCT02031094||Minor resection|Patients undergoing resection of </= 3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
89323614|NCT02031172||Subjects with Dry Eye Disease|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
89323615|NCT02031172||Subjects with Sjogren's Syndrome|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
89323616|NCT02031172||Healthy Controls|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
89323617|NCT02195284|Experimental|Sub-study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler
89323618|NCT02195284|Experimental|Sub-study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI (metered-dose inhaler) or use MDI first and then ELLIPTA inahler
89323619|NCT02195284|Experimental|Sub-study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA inhaler
89323620|NCT02197936||Peristalsis adenomyosis|with adenomyosis
89323621|NCT02197936||Peristalsis control|No adenomyosis
89323622|NCT00095147|Active Comparator|Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB])|Days 1-365
89323623|NCT00095147|Active Comparator|Infliximab + MTX (DB)|Days 1-365
89323624|NCT00095147|Placebo Comparator|Placebo + MTX (DB)|Days 1-197
89323625|NCT00095147|Experimental|Placebo + MTX switched to abatacept + MTX (DB)|Participants received placebo plus methotrexate for days 1-197, and abatacept plus methotrexate for days 198-365
89323626|NCT00095147|Experimental|Abatacept (open-label)|Days 365 to 729 All participants receive Active Drug
89323627|NCT02198014|Experimental|Manual Therapy group|We employed joint traction, passive muscle stretching and isometric exercises, active resisted and proprioception exercises. The treatment in this group consisted of two sessions per week for one hour each.
89323628|NCT02198014|Experimental|Educational gruop|"This group received educational sessions and home exercises. The exercises are aimed at improving quadriceps strength, flexibility, range of motion and knee proprioception.~Each educational session of 90 minute every two weeks, with exercises daily home"
89323629|NCT02198014|No Intervention|Control group|The control group (group C) did not receive any treatment. The patients of this group were assessed by the same reviewers and under the same conditions as the subjects of the two intervention groups.
89323630|NCT02198092||Patient Group FAP|"Clinical diagnosis of familial adenomatous polyposis (FAP).~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients. Blood draws in FAP patients should always be accompanied by blood draws in their family member controls.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
89323631|NCT02198092||Patient Group Lynch Syndrome|"Clinical diagnosis of Lynch Syndrome, also known as HNPCC.~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
89323632|NCT02198092||Patient Group MAP / MYH|"Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps.~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. The follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
89323633|NCT02198092||Control Group (FAP Genetically-Related)|"Genetically related family member of enrolled FAP patient.~Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative.~The patients of the control group participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating FAP patients.~If colectomy is performed in a FAP patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.~Blood draws in FAP patients should always be accompanied by blood draws in their family member controls."
89323634|NCT02198170|Experimental|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period
89323635|NCT02198170|Experimental|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
89323636|NCT02198248|Experimental|Low-dose glucocorticoid|"Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months. If a patient fails to achieve BVAS=0, an investigator can postpone the procedure of stopping prednisolone (prednisolone 5mg/day x 2 weeks, 4mg/day x 2 weeks, 3mg/day x 4 weeks, 2mg/day x 4 weeks, 1mg/day x 4 weeks, then off prednisolone). Once starting the procedure, prednisolone must be off after 16 weeks. Patients will also receive rituximab (375mg/m2/w x4).~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy."
89323637|NCT02198248|Active Comparator|High-dose glucocorticoid|"Prednisolone will be commenced with dose of 1.0mg/kg/day and will be tapered to 10mg/day within 6 months. Patients will also receive rituximab (375mg/m2/w x4).~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy. There's no limitation by the protocol regarding further prednisolone tapering."
89323638|NCT02195596|Experimental|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center. A fitness expert nurse is responsible for monitoring the performance and adapt to the physical condition of the patient.Each exercise session consists of warming up time period, period of work and back to calm. Exercise intensity during the work period increases progressively as the program progresses. Aerobic exercise is performed on a cycle ergometer or treadmill.Muscle strength exercises and joint mobility are performed with dumbbells and ankle weights adapted to each patient."
89323639|NCT02195596|Active Comparator|Low intensity aerobic exercise+strength|The control group performed an exercise program similar to intervention but at low intensity that is below 35 or 40% of heart rate reserve (HRR).
89323640|NCT02031328|Experimental|Stereotactic Ablative Radiation|Stereotactic Ablative Radiation 26 Gy in 2 fractions, once weekly to prostate
89323641|NCT01084343|Active Comparator|Panel 1|Subjects in this panel receive the low dose of vaccine (10 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
89323642|NCT01084343|Active Comparator|Panel 2|Subjects in this panel receive the high dose of vaccine (50 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
89323643|NCT02198560||Normal (Eyes without pathology)|
89323644|NCT02195752||Prescribed Compounded Pain Cream|The study is limited to patients who have been prescribed treatment with a topical compounded pain cream as a component of their ordinary care by a qualified physician.
89323645|NCT01084421|Experimental|Computer based intervention|Participants receive content about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general.
89323646|NCT01084421|No Intervention|Wait list control group|Participants will receive the computer based intervention at 3 months follow-up
89323647|NCT01069133|Experimental|Rifaximin|
89323648|NCT02198638|Other|Patients or healthcare workers|
89323649|NCT01069211||ER expression : Low|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 3 or 4 point of total Allred score.
89323650|NCT01069211||ER expression : Intermediate|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 5 or 6 point of total Allred score.
89323651|NCT01069211||ER expression : High|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 7 or 8 point of total Allred score.
89323652|NCT02198716|Other|Drug eluting stent|Percutaneous coronary intervention
89323653|NCT02198716|Other|Bare Metal Stent|Percutaneous Coronary Intervention
89323654|NCT03976583|Active Comparator|Cpp-acp|MI paste Self-administration of the product by the patient once in the evening. A pea-size amount of the product should be applied per arch, using a dry finger or cotton pellet to distribute it evenly across all teeth and to work it into the interdental spaces. The product was then retained in the mouth for 1-3 min, and manipulated around the teeth using the tongue, before being expectorated and patient should not rinse it until 30 min.
89323655|NCT03976583|Experimental|Pearl powder|Pure pearl powder in the form of gel Self-administration of the product should be used once daily (in the evening), after a 2 min manual tooth brushing. .Participants were explicitly instructed to apply the gel by his finger allover the teeth and not to rinse their mouths after application and not to eat or drink for at least 30 min.
89323656|NCT02198326|Experimental|BIBN 4096 BS - in single rising doses|
89323657|NCT02198326|Placebo Comparator|Placebo|
89323658|NCT03976427|Experimental|Guided Imagery|Participants will listen to a guided imagery recording
89323659|NCT01081379||pre-conception immunity|pre-conception immunity- pregnant women with CMV seropositive
89323660|NCT01081379||primary CMV infection|primary CMV infection- pregnant women with primary CMV infection (defined as CMV IgG sero-conversion, the presence of low avidity IgG antibodies or the presence of IgM with no previous IgG antibodies).
89323661|NCT02198482|Active Comparator|Daunorubicin, Cytarabine (DA)|"DA~Induction I:~Daunorubicin 60 mg/m² i.v., d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-7~Induction II:~Daunorubicin 50 mg/m² i.v. d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-5~Consolidation therapy:~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT due to comorbidities, high HCT-CI or patient wish will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine (MiDAC).~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. infusion on day 1.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC may be given prior to alloHSCT."
89323662|NCT02198482|Experimental|Volasertib, Daunorubicin, Cytarabine|"VDA~Induction I~Volasertib i.v., d1~Daunorubicin 60 mg/m² i.v., d 2-4~Cytarabine 100 mg/m² cont. i.v., d 2-8 Induction II~Volasertib i.v., d1~Daunorubicin 50 mg/m² i.v. d 2-4~Cytarabine 100 mg/m² cont. i.v., d 2-6~Consolidation therapy:~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (V-MiDAC).~Volasertib i.v., d1~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 2. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 2.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 2-4 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 2-4 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with V-MiDAC may be given prior to alloHSCT."
89323663|NCT02198482|Experimental|Daunorubicin, Cytarabine, Volasertib|"DAV~Induction I~Volasertib i.v., d7~Daunorubicin 60 mg/m² i.v., d 1-3~Cytarabine 100 mg/m² i.v., d 1-7 Induction II~Volasertib i.v., d5~Daunorubicin 50 mg/m² i.v. d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-5~Consolidation therapy:~Patients with genetic fav. risk and those patients not eligible for alloHSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (MiDAC-V).~Volasertib i.v., d4~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 1.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC-V may be given prior to alloHSCT."
89323664|NCT03961841|Active Comparator|Chemoradiation|weekly 5-Fu and oxaliplatin
89323665|NCT03961841|Experimental|FLOT|Eight perioperative chemotherapy cycles
89323666|NCT03961841|Experimental|FOLFOX|Twelve perioperative chemotherapy cycles
89323667|NCT01086917|Experimental|Group 1|to receive a dose of 2,500 PfSPZ Challenge
89323668|NCT01086917|Experimental|Group 2|to receive a dose of 10,000 PfSPZ Challenge
89323669|NCT01086917|Experimental|Group 3|to receive a dose of 25,000 PfSPZ Challenge
89323670|NCT02195830|Other|Single arm - Ultrasound|All participants will have an Ultrasound measurement of their inferior vena cava at enrolment as described in the intervention
89323671|NCT02201134|Other|sevoflurane|
89323672|NCT02206438|Experimental|1)C-LMA group|
89323673|NCT02206438|Active Comparator|2)Air-Q group|
89323674|NCT05261932||The accuracy of expert with or with-out AI|
89323675|NCT05261932||The accuracy non-expert with or with-out AI|
89323676|NCT02257606|No Intervention|Control group (persons with MS)|no training
89323677|NCT02257606|Experimental|Experimental group (persons with MS)|Robot-assisted training
89323678|NCT03967912|Experimental|MOVE UP for Caregivers|12-week lifestyle intervention focusing on diet and activity
88816007|NCT02980094|Experimental|Milk Antioxidant group(A)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diet: control (C) +vitamin E+ selenium (A).
89323679|NCT02206516|Experimental|patients|Stimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
89323680|NCT02206594|Experimental|Descemetorhexis|
89323681|NCT02201368|Experimental|Triheptanoin|
89323682|NCT02201368|Active Comparator|MCT (Medium-Chain Triglycerides)|
89323683|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
89323684|NCT02198872|Experimental|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
89323685|NCT02198872|Active Comparator|Land Group|Patients of this group perform physical training on bicycle.
89323686|NCT02206750|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
89323687|NCT02206750|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
89323688|NCT02198950||ICU patients|all patients admitted into the ICU
89323689|NCT02201602|Experimental|Gliclazide|Gliclazide, 80 mg tablet, half to maximal dose, 3 weeks
89323690|NCT02201602|Active Comparator|Glibenclamide|Glibenclamide, 5 mg tablet, half to maximal dose, 3 weeks
89323691|NCT02201680||parents and children|Anxiety tests
89323692|NCT02257996|Experimental|Interventional Group|Online Systematic Brief Psychodynamic Psychotherapy
89323693|NCT02257996|No Intervention|Control Group|Waiting list
89323694|NCT02201836|Active Comparator|One time music therapy session|One time music therapy session which consists of music meditation, including as assessment/evaluation of confined body breathing function as expressed through drawing and coloring post music imagery session. This is followed by an entrainment wind playing/breath expansion music therapy intervention. At the end of the session, the subjects are given a donated wind instrument for play at home.
89323695|NCT02201836|Active Comparator|Weekly group music therapy intervention|The weekly group music therapy intervention consists of children and teens using guided visualization and expressing their fears and or fantasies related to breathing with one another. This is followed by creative music improvisations with part-playing on flutes, slide whistles, recorders and melodicas.
89323696|NCT02201836|No Intervention|Control|
89323697|NCT02199106|Experimental|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Intervention: Left temporal verum cTBS"
89323698|NCT02199106|Experimental|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Intervention: Left temporal placebo cTBS"
89323699|NCT02206906||Study Participants|All participants who meet eligibility requirements and who consent to participation will use an incentive intervention model.
89323700|NCT02201914|Experimental|Clomiphene citrate|
89323701|NCT02201914|Experimental|Daily FSH and LH plus Cetrorelix|
89323702|NCT02201914|Experimental|Triptorelin plus daily FSH and LH|
89323703|NCT02202070|Experimental|Botox injection first, followed by placebo|50 units Botox injection in masseter and temporalis muscles in the first 3 months, then second injection of normal saline at placebo in second 3 months
89323704|NCT02202070|Experimental|Placebo injection first, followed Botox|Injection of normal saline at placebo in first 3 months, then 50 units Botox injection in masseter and temporalis muscles in the second 3 months.
89323705|NCT05261698|Active Comparator|Arms|Control group: in control group moist heating pads along with TENS shall be applied on neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed.
89323706|NCT05261698|Experimental|Assigned Interventions|Experimental group: in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
89323707|NCT02202148||alcohol withdrawal|
89323708|NCT02202226|Experimental|Lu AF35700 oral solution (1 mg/mL)|Planned daily doses range from 5 mg/day to 30 mg/day for 3 weeks. Weekly doses up to 75 mg/week for 3 weeks.
89323709|NCT02202226|Placebo Comparator|Matching placebo|Oral solution
89323710|NCT02207140|Experimental|probiotic|HOWARU Restore
89323711|NCT02207140|Placebo Comparator|placebo|microcrystalline cellulose
89323712|NCT03533140|Active Comparator|DUCEST Neurostimulator V Group A|
89323713|NCT03533140|Sham Comparator|DUCEST Neurostimulator V Group B|
89323714|NCT05261542||normal colorectal epithelium|Tissue samples from normal colorectal epithelium are collected during colectomy in every colorectal cancer patient
89323715|NCT05261542||cancer colorectal epithelium|Tissue samples from colorectal cancer are collected during colectomy in every colorectal cancer patient
89323716|NCT02199262|Experimental|control groupe|agitation diagnosis and management according to implemented guidelines= reminder implementation
89323717|NCT02199262|Experimental|music intervention + reminder|agitation diagnosis and management according to implemented guidelines+ music intervention
89323718|NCT02199262|Experimental|reflexology + reminder|agitation diagnosis and management according to implemented guidelines + reflexology
89323719|NCT02207296|Other|PVI group|Fluid optimisation using PVI
89323720|NCT02207296|No Intervention|Control group|Standard care using a hemodynamic protocol during general anesthesia
89323721|NCT02202304|Experimental|Chlorhexidine/Thymol varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush by painting it over the surfaces of these teeth."
89323722|NCT02202304|Placebo Comparator|Placebo varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush and painting it on all the surfaces of these teeth.."
89323723|NCT02207452|Other|Salbutamol + Ipratropium|Treatment period 1: Salbutamol 5mg nebulised, single Dose. Treatment period 2: Ipratropium 500mcg nebulised, single dose.
89323724|NCT02207452|Other|Ipratropium + Salbutamol|Treatment period 1: Ipratropium 500mcg nebulised, single dose. Treatment period 2: Salbutamol 5mg nebulised, single Dose.
89323725|NCT02202382|Placebo Comparator|non-V + P group|no surgery and placebo (12 weeks)
89323726|NCT02202382|Active Comparator|V + P group|Surgery with placebo (12 weeks)
89323727|NCT02202382|Active Comparator|non-V + KRG group|no surgery with KRG (korean red ginseng, 1.5 gm daily 12weeks)
89323728|NCT02202382|Experimental|V + KRG group|Surgery with KRG (1.5 gm daily 12weeks)
89323729|NCT03533062|Active Comparator|trigonal sparing botox injection|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area excluding trigone in other arm Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).•then after 6 months postoperative anticholinergics administration .
89323730|NCT03533062|Active Comparator|trigonal involved|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area including the trigone .Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).then after 6 months postoperative anticholinergics administration .
89323731|NCT02751502|Experimental|Bimanual-to-unimanual device home training program|
89323732|NCT02751502|No Intervention|Conventional non-device home training program|Subjects receive 6 weeks of ongoing usual and customary care schedule of home physical and occupational therapy as usual and customary care independent of the study.
89323733|NCT02207686||von Hippel-Lindau disease|Patients with von Hippel-Lindau disease who have had at least one vHL-related tumor removed
89323734|NCT02202694|Experimental|Intervention|Culturally Adapted Cognitive Behavior Therapy
89323735|NCT02202694|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
89323736|NCT02207764|Experimental|Reiki Intervention|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
89323737|NCT02207764|No Intervention|nursing presence control|Each patient in the control group will receive usual care including the study nurse presence for the 15-minute period.
89323738|NCT02199340|Experimental|Cystic fibrosis|"iStep exercise test~CPET exercise test"
89323739|NCT02199340|Active Comparator|Healthy control|- iStep exercise test
89323740|NCT02207842||Volatile anesthesia exposure|
89323741|NCT02207842||No volatile anesthesia exposure|
89323742|NCT02202928|Sham Comparator|Chemo-radiotherapy|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will just regularly follow up.
89323743|NCT02202928|Experimental|DC-CIK|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will receive 3 cycles of autologous tumor lysate pulsed DC-CIK treatment.
89323744|NCT02207920|Experimental|Group 1|"At study entry and Month 1, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid."
89323745|NCT02207920|Experimental|Group 2|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
89323746|NCT02207920|Experimental|Group 3|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
89323747|NCT02207920|Experimental|Group 4|At study entry and Months 1, 3, and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
89323748|NCT02203084||Children with Chronic Medical Conditions|The Social Determinants Questionnaire will be administered to the three groups of children with chronic diseases (cystic fibrosis, diabetes mellitus type I, or chronic renal insufficiency). The questionnaire questions will be asked by a research assistant. Each participant will have the same general and background information questions then will have questions specific to their chronic medical condition.
89323749|NCT02207998|Experimental|Homeopathic complex and physiotherapy|"Homeopathic complex and physiotherapy: (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of 168 tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist."
89323750|NCT02207998|Placebo Comparator|Placebo and physiotherapy|"Placebo and Physiotherapy: Placebo will comprise of 168 unmedicated lactose tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist ."
89323751|NCT03532984||adults aged 20-29|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
89323752|NCT03532984||adults aged 30-39|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
89323753|NCT03532984||adults aged 40-49|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
89323754|NCT03532984||adults aged 50-59|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
89323755|NCT03532984||adults aged 60-69|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
89323756|NCT03532984||adults aged 70-79|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
89323757|NCT03532984||adults aged 80+|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
89323758|NCT03532984||geriatric patients|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
89323759|NCT02208154|Active Comparator|Standard care|"Standard infection prevention measurements will be implemented before the baseline period and carried out throughout the entire trial. They consist of:~Chlorhexidine 2% body washings (CHX-BW) for all ICU patients. The face and neck of the patient will not be cleansed with Chlorhexidine to prevent irritation of the eyes and face.~A hand hygiene improvement program (HHIP) based on the program designed by the World Health organisation (WHO).~Standard oropharyngeal care consists of oral washing with sterile water (3-4 times daily) and tooth brush twice daily."
89323760|NCT02208154|Experimental|Chlorhexidine oral care (CHX-Oro)|Chlorhexidine digluconate oromucosal gel 1%, 2cm, to be administered 4 times daily, during invasive mechanical ventilation.
89323761|NCT02208154|Experimental|Selective oropharyngeal decontamination|Selective oropharyngeal decontamination (SOD) mouth paste containing colistin and tobramycin in a 2% concentration and nystatin 1 x 10^5 units, dosage 0.5g , to be administered 4 times daily during the entire period of invasive mechanical ventilation.
89323762|NCT02208154|Experimental|Selective digestive decontamination|Selective digestive decontamination (SDD), suspension via the nasogastric tube containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u., dosage 10ml, to be administered together with SOD (see above) 4 times daily during entire period of mechanical ventilation.
89323763|NCT03532906|Active Comparator|TAP block|Patients receive the injection of local anaesthetic into the right abdominal wall (TAP block) together with the injection of local anaesthetic into the surgical wounds.
89323764|NCT03532906|Other|Control|Patients receive the injection of local anaesthetic into the surgical wounds only.
89323765|NCT02208232||MC 6125 AS IOL|cataract surgery with implantation of intraocular lens MC 6125 AS in one eye
89323766|NCT03533530|Active Comparator|No electrical source imaging (ESI)|In all patients, the multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, except for ESI.
89323767|NCT03533530|Experimental|Low-density ESI (LD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using LD EEG recordings.
89323768|NCT03533530|Experimental|High-density ESI (HD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using HD EEG recordings.
89323769|NCT02208622|Experimental|Study 1: Whey Supplement Day 1|Children in this arm received the whey supplement as part if their diet on day 1.
89323770|NCT02208622|Experimental|Study 1: Whey Supplement Day 2|Children in this arm received whey supplement as part of their diet on day 2.
89323771|NCT02208622|Experimental|Study 2: Whey Supplement|Children in this arm received a whey supplement as part of their diet.
89323772|NCT02208622|No Intervention|Study 2: Control|Children in this arm did not receive a whey supplement as part of their diet.
89323773|NCT02257762|Experimental|Lipid-based nutrient supplement (LNS)|LNS added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
89323774|NCT02257762|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge, eaten over 6 months, age 6-12 months to age 11-17 months
89323775|NCT02257762|Active Comparator|Sprinkles|Sprinkles added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
89323776|NCT02257762|No Intervention|Control|Plain borbor and thereafter family foods, eaten over 6 months, age 6-12 months to age 11-17 months
89323777|NCT02199418|Experimental|Paclitaxel and Cisplatin|"Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.~Trastuzumab (only for human epidermal growth factor receptor-2(HER2)-positive patients): Loading dose: 4 mg/kg, Maintenance dose: 2 mg/kg, day 1 q day 8 for 16 weeks. Post-surgery: up to a total duration of 1 year"
89323778|NCT02208700|Experimental|Oxepa|Other: Therapeutic nutrition with EPA, GLA and antioxidants.
89323779|NCT02208700|Active Comparator|Jevity 1.5|Other: Jevity 1.5 Complete Balanced Nutrition with Fiber .
89323780|NCT02208778|Experimental|Duloxetine|Duloxetine 30 mg a day (2 weeks), then 60 mg a day (4weeks), taken by mouth
89323781|NCT02208778|Placebo Comparator|Placebo (for Duloxetine)|Sugar pill: 1 capsule a day (2 weeks), then 2 capsules a day (4 weeks) taken by mouth
89323782|NCT02208778|Experimental|Remifentanil|Intravenous infusion with maximum estimated plasma target of 1.0 ng/ml, during less than 20 minutes
89323783|NCT02208778|Placebo Comparator|Placebo (for Remifentanil)|Intravenous infusion of normal saline, during less than 20 min
89323784|NCT02203318||control|healthy children with normal bilateral testis
89323785|NCT02203318||undescended palpable testis|patient whose affected testis is not descended to the normal position but palpable and exist intact in the upper area
89323786|NCT02203318||non-paplpable testis|patient whose affected testis is not palpable during the physical examination
89323787|NCT02203396|Experimental|Severe Aplastic Anemia|Drug: rabbit ATG, Cyclosporine, Levamisole
89323788|NCT02208856|Placebo Comparator|Placebo|
89323789|NCT02208856|Experimental|BIBR 796 BS food effect|
89323790|NCT02208856|Experimental|BIBR 796 BS|
89323791|NCT02208934|Experimental|PBF-999 (5 mg)|5 mg of PBF-999
89323792|NCT02208934|Experimental|PBF-999 (10 mg)|10 mg of PBF-999
89323793|NCT02208934|Experimental|PBF-999 (20 mg)|20 mg of PBF-999
89323794|NCT02208934|Experimental|PBF-999 (40 mg)|40 mg of PBF-999
89323795|NCT02208934|Placebo Comparator|Placebo|Placebo for the 5, 10, 20 and 40 mg dose
89323796|NCT02203552|Experimental|Arm I (minocycline hydrochloride)|Beginning 1 week prior to chemotherapy, patients receive minocycline hydrochloride orally PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
89323797|NCT02203552|Placebo Comparator|Arm II (placebo)|Beginning 1 week prior to chemotherapy, patients receive placebo PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
89323798|NCT02203708|Active Comparator|BPD prevention|Supportive Program for Mother with BPD (SuPMother-B) : BPD mothers participate to prevention program in groups or/and house calls.
89323799|NCT02203708|No Intervention|Usual care of BPD mothers|BPD mothers don't participate to Supportive Program (SuPMother-B).
89323800|NCT02199808||7-9 year olds|These are children who are between 7 and 9 years old when they are tested.
89323801|NCT02199808||10-12 year olds|These are children who are between 10 and 12 years old when they are tested.
89323802|NCT02209012||ALA|Subjects who received ALA in CP0108
89323803|NCT02209012||Vehicle|Subjects who received Vehicle in CP0108
89323804|NCT02031406|No Intervention|Usual care|No extra post-discharge pharmacist counseling is explicitly provided to patients, although some patients may receive it depending on their care setting
89323805|NCT02031406|Experimental|Post-discharge pharmacist counseling|Patients will receive post-discharge telephonic pharmacist counseling at around 72 hours after hospital discharge.
89323806|NCT02209090|Experimental|maternal modified sims position|"Women in this group will adopt the modified Sims position, lying on the side of the foetal back.~This position is maintained for the greater part of labour, at least 40 minutes, every hour. The mother can use other positions during resting time of no more than 20 minutes each hour, but never use a lateral position against the side of the foetal back."
89323807|NCT02209090|Sham Comparator|maternal free positions|Women can adopt the position they wish and which is most comfortable, except for lateral positions which can only be used for a maximum of 20 minutes each hour to avoid confounding factors.
89323808|NCT02199886|Experimental|BIBH 1|dose escalation: 0.5, 2, 10 or 20mg/m**2, 7 days prior to surgery
89323809|NCT02209168||Infertile Indian Population|200 Infertile Indian population
89323810|NCT02209168||Infertile arabian population|200 Infertile Arabian population
89323811|NCT02209168||Infertile caucasian population|200 Infertile Caucasian population
89323812|NCT02209246|Experimental|Intervention|The intervention group will be comprised of patients who will complete the PROMIS- CAT for pain interference, pain behavior and physical function prior to the encounter with the physician and then will complete the MISS-21 after the encounter.
89323813|NCT02209246|Experimental|Control|The control group will complete the PROMIS- CAT for pain interference, pain behavior and physical function after the encounter and after completing a satisfaction questionnaire (MISS-21).
89323814|NCT03533296|Experimental|Children|Children who receive elective surgery under general anesthesia and are supported by mechanical ventilation
89323815|NCT02203864|Experimental|BIBW2 with IL-2 secreting cell line|
89323816|NCT02203864|Experimental|BIBW2 without IL-2 secreting cell line|
89323817|NCT02209324|Experimental|ASP2151|
89323818|NCT02209402|No Intervention|Usual Care|
89323819|NCT02209402|Experimental|Exercise Training|
89323820|NCT02203942||Vaginal Infections (BV, VVC, trich)|NAAT testing Amsel criteria Nugent score yeast culture TV culture
89323821|NCT02200198|Active Comparator|Inspiratory group|Inspiratory muscle training
89323822|NCT02200198|Sham Comparator|Sham group|Sham training
89323823|NCT02200198|Experimental|Expiratory group|Expiratory muscle training
89323824|NCT03532672|Experimental|Acute fasting|Participants will fast overnight for 10 hours (resting period), consume a santdardized breakfast, and fast during daily activities (active period) for another 10 hours.
89323825|NCT02209480|Experimental|Alexander Technique|5 lessons of AT, each lasting up to 45 minutes, weekly intervals The lessons aimed at sensory awareness of everyday movements and movement sequences, such as sitting, walking, lying, or lifting in order to replace habitual patterns using conscious control; and different techniques were applied, such as demonstration, verbal instructions, hands on techniques and others
89323826|NCT02209480|Active Comparator|Heat pad application|5 treatments by means of a heat pad, 15-0 minutes, sitting or lying position, quiet room Heat pad: Zapp-Sack® contained certain grains and a ginger extract, and could be heated up in the microwave.
89323827|NCT02209480|Active Comparator|guided imagery|guided imagery relaxation technique , 45 minutes, 5 sessions in weekly rhythm including body scan, breathing relaxation, visualization
89323828|NCT02200354|Experimental|pemetrexed with bevacizumab|pemetrexed rechallenge with bevacizumab pemetrexed (500mg/m2 day1) bevacizumab (15mg/kg day1)
89323829|NCT02209558|No Intervention|Standard Written Sternal Precautions|"Patients will receive education that is the standard of care at North Shore Long Island Jewish Health Systems in their post-operative sternal precautions."
89323830|NCT02209558|Experimental|Visual Sternal Precautions|"Patients will receive both standard of care written sternal precautions, as well as visual sternal precautions."
89323831|NCT02200432|No Intervention|Control|The study's current rule-based CTHC system is embedded within the Decide2Quit.org web service. Control smokers will receive the current Decide2Quit.org system, including informational web pages, an interactive quit plan, plus pushed email messages. The messages will be selected using the current rule-based CTHC system. The CTHC selects messages based on decision rules (e.g: readiness to quit, gender) using information from a smoker's baseline profile. Participants will receive one message per day for 30 days
89323832|NCT02200432|Experimental|Intervention|The PERSPeCT intervention smokers will receive all components of the Decide2Quit.org web service, but persuasive email messages will be selected by the PERSPeCT recommender system developed in Aim 2. PERSPeCT will use data (see Figure 1) to predict messages that would be most influential to the participant. Intervention smokers will receive one PERSPeCT-generated message per day for 30 days. With each message rating, the PERSPeCT system will further adapt to patient preferences.
89323833|NCT02209714|Experimental|BIIF 1149 BS|
89323834|NCT02209714|Placebo Comparator|Placebo|
89323835|NCT02200588||Patients|Patients followed in the First Episode Psychosis Clinical Program (PAFIP) with psychotic disorder
89323836|NCT02200588||Controls|Healthy subjects without psychotic disorder
89323837|NCT02200744||Dislocation reduction using propofol|
89323838|NCT05263414|Active Comparator|Active tVNS|In the active tVNS session, tVNS will be delivered via a programmable stimulation unit connected to two titan ear electrodes mounted on a gel frame. Active tVNS will be delivered over the cymba conchae of the left ear for a 70 minutes session. Stimulation intensity will be set at an intensity corresponding to individual sensitivity threshold. The intensity of the stimulation will be gradually increased in order to reach the intensity of stimulation with a ramping-up phase of 30 secs. During the stimulation, participants will perform the tasks. At the end of the stimulation session participants will be asked to report possible side effects occurring during tVNS and to rate their feeling on several visual analogue scales.
89323839|NCT05263414|Sham Comparator|Sham tVNS|In the sham tVNS session tVNS will be delivered via a programmable stimulation unit connected to two titan ear electrodes mounted on a gel frame. Sham tVNS will be delivered over the left lobe auricle area, which is free from cutaneous vagal innervation. It will last 70 minutes. Stimulation intensity will be set at the intensity corresponding to the individual sensitivity threshold, as it will be defined on the left ear lobe. The intensity of the stimulation will be gradually increased to reach the intensity of the stimulation with a ramping up phase of 30 secs. During the sham stimulation, the tasks will be performed. At the end of the stimulation session participants will be asked to report possible side effects occurring during tVNS and to rate their feeling on several visual analogue scales.
89323840|NCT02204020|Experimental|5-azacytidine|5-aza SC or IV 32mg/m2 - 75mg/m2 (based on dose escalation)
89323841|NCT02200822|No Intervention|non-intervention arm|continuation of neurohumoral blocker therapy based on maximum tolerated guideline recommended dose (this group is the control arm for as well withdrawal of beta blocker therapy as withdrawal of RAAS blocker therapy)
89323842|NCT02200822|Active Comparator|withdrawal of beta blockers|"Intervention arm with systematic withdrawal of beta blocker therapy at a reverse sequence of guideline recommended uptitration.~(this group is the experimental arm for beta blocker withdrawal. This group receives no intervention with regards to the withdrawal of RAAS blockade). Per 2 weeks:~bisoprolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop~metoprolol: 200 mg/d → 100 mg/d → 50 mg/d → 25 mg/d → stop~nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop~carvedilol: 50 mg bid → 25 mg bid → 12,5 mg bid → 6,25 mg bid → stop"
89323843|NCT02200822|Active Comparator|withdrawal of RAAS blockers|"intervention arm with systematic withdrawal of spironolactone followed by withdrawal of ACE-I/ARB at a reverse sequence of guideline recommended uptitration (this group receives no intervention regarding the withdrawal of beta blockers. This group is the experimental arm for withdrawal of RAAS blockers)~first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop~after 2 weeks stop spironolactone/eplerenone start withdrawal of ACE-I/ARB per two weeks:~captopril: 50 mg tid→25 mg tid→12,5 mg tid→6,25 mg tid→stop~enalapril: 10 mg bid→5 mg bid→2,5 mg bid→1,25 mg bid→stop~lisinopril: 20 mg/d→10 mg/d→5 mg/d→2,5 mg/d→stop~ramipril: 10 mg/d→5 mg/d→2,5 mg/d→1,25 mg/d→stop~candesartan: 32 mg/d→16 mg/d→8 mg/d→4 m/d→stop~valsartan: 160 mg bid→80 mg bid→40 mg bid→20 mg bid→stop"
89323844|NCT02200822|Active Comparator|withdrawal of RAAS - and beta blockers|"intervention arm with systematic withdrawal of spironolactone, secondly ACE-I/ARB and finally beta blockers. (this group is the experimental group for both study interventions (withdrawal of beta blockers and RAAS blockers)~First: spironolactone/eplerenone cfr reduction schedule supra~After 2 weeks of stop spironolactone withdrawal of ACE-I or ARB cfr reduction schedule supra~After 2 weeks of stop ACE-I/ARB withdrawal of beta blocker cfr reduction schedule supra"
89323845|NCT05252962|Experimental|marine collagen peptide production process I|standardized to 10 g provided as single dose. Orally applied in water.
89323846|NCT05252962|Experimental|marine collagen peptide production process II|standardized to 10 g provided as single dose. Orally applied in water.
89323847|NCT05252962|Experimental|marine collagen peptide fish source I|standardized to 10 g provided as single dose. Orally applied in water.
89323848|NCT05252962|Experimental|marine collagen peptide fish source II|standardized to 10 g provided as single dose. Orally applied in water.
89323849|NCT02200900|Active Comparator|Group 1 ( CPAP followed by HFNC)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on CPAP first followed by HFNC.
89323850|NCT02200900|Active Comparator|Group 2 (HFNC followed by CPAP)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on HFNC first followed by CPAP.
89323851|NCT05240872|Active Comparator|Group A|Platelet Rich Plasm (PRP) injection group
89323852|NCT05240872|Active Comparator|Group B|Autologous Blood injection (ABI) group
89323853|NCT02204332|Experimental|Cabazitaxel|"Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).~Besides, patient will be treated with BSC."
89323854|NCT02204332|Other|Best Supportive Care|Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).
89323855|NCT02209792|Placebo Comparator|Placebo|
89323856|NCT02209792|Experimental|BIRB 796 BS, low dose|2 x 5 mg b.i.d.
89323857|NCT02209792|Experimental|BIRB 796 BS, medium dose 1|20 mg b.i.d.
89323858|NCT02209792|Experimental|BIRB 796 BS, medium dose 2|2 x 5 mg + 20 mg b.i.d.
89323859|NCT02209792|Experimental|BIRB 796 BS, high dose|3 x 20 mg b.i.d.
89323860|NCT05238454|Experimental|Cohort 1: SCTV01C|
89323861|NCT05238454|Active Comparator|Cohort 1: Sinopharm inactivated COVID-19 vaccine|
89323862|NCT05238454|Experimental|Cohort 2: SCTV01C|
89323863|NCT05238454|Active Comparator|Cohort 2: Comirnaty|
89323864|NCT02204488|Active Comparator|Total Joint Arthroplasty|Total Joint Arthroplasty
89323865|NCT02204488|Active Comparator|Trapeziectomy|Trapeziectomy
89323866|NCT02209870||E-checklist group|The patients after CPR team using E-checklist system
89323867|NCT05222542||Patients after aneurysmal subarachnoid hemorrhage|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
89323868|NCT02220634|Experimental|Regadenoson|Intravenous infusion of the A2A agonist regadenoson has a preferential vasodilator effect on pulmonary vasculature that is comparable to iNO, the current gold standard for pulmonary vasoreactivity studies.
89323869|NCT02204644|Experimental|Flumatinib mesylate tablets|Flumatinib mesylate tablets 600mg qd for 12 months
89323870|NCT02204644|Active Comparator|Imatinib mesylate tablets|Imatinib mesylate tablets 400mg qd for 12months
89323871|NCT02204722|Experimental|Group B|the group who has more than 10% of the BCR-ABL(IS) level for three months will receive 600mg/day of Imatinib after three months.
89323872|NCT02204722|Experimental|Group A|the group who has more than 10% of the BCR-ABL(IS) level for three months will maintain the dose, 400mg/day of Imatinib, after three months.
89323873|NCT02204800||Small clear cell renal tumors (Wild Type)|No specific chromatin remodeling gene (CRG) alteration
89323874|NCT02204800||Small clear cell renal tumors (Mutant)|Specific chromatin remodeling gene (CRG) alteration
89323875|NCT02210572|Experimental|Bimuno Galacto-oligosaccharide|Dietary intervention
89323876|NCT02210572|Placebo Comparator|Low- FODMAPs diet|Dietary intervention
89323877|NCT02204878|Placebo Comparator|A|1ml of saline was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. 1ml saline Q12h will be given within 72 hours after surgery
89323878|NCT02204878|Experimental|AT|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
89323879|NCT05263024||left atrial appendage clip|Cardiac valvular patients complicated with atrial fibrillation need cardiac valvular surgery, according to the patient's wishes, cardiac auricular clamp at the same time
89323880|NCT05263024||Left atrial appendage treated with conventional methods|Valvular heart disease with atrial fibrillation requires valvular heart surgery and left atrial ligation
89323881|NCT02204956|Experimental|Sustained Care|A 40-minute, in-hospital motivational counseling session about smoking cessation, 8 Interactive Voice Response (IVR) phone calls and/or texts over 90 days, including the possibility of a warm transfer to a telephone tobacco quit line and up to 8-weeks of free transdermal nicotine patches.
89323882|NCT02204956|Active Comparator|Usual Care|A brief 5-10 minute tobacco education session that all hospitalized smokers will receive, delivered by a hospital nurse. During this session, they will be provided with written handouts describing the stages of readiness for change in quitting, self-monitoring of smoking, self-management of smoking situations, relapse prevention, managing stress, other quitting tips and use of nicotine replacement therapy.
89323883|NCT02258230|Active Comparator|2D mode LSC|2D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
89323884|NCT02258230|Active Comparator|3D mode LSC|3D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
89323885|NCT02258230|Active Comparator|2D mode PVR|2D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
89323886|NCT02258230|Active Comparator|3D mode PVR|3D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
89523448|NCT03374579|Experimental|CO2 gap|The patients will receive fluid bolus and observe changes in co2 gap and gap/ ratio in them.
89523449|NCT03374501|Experimental|2 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 2 tablets of Sugardown™
89323887|NCT02258308|Experimental|CHW intervention|"The CHW intervention is in-home education and support by a community health worker (CHW). At the first home visit, the CHW assesses the participant's knowledge and skills related to asthma self-management, current status of the child's asthma, and resources and support for asthma self-management using a baseline questionnaire. The CHW will inspect the home environment using an Environmental Home Checklist to identify environmental triggers that can cause asthma symptoms and affect asthma control. The CHW makes up to three follow-up visits and two telephone visits during the year the participant is in the study. Participants receive resources to help them control asthma: vacuum cleaner, dust covers for a pillow and mattress and a green cleaning kit with cleaning supplies."
89323888|NCT02258308|No Intervention|control|The control group receives standard asthma care, as provided by a primary health care provider. When the intervention period is over, the control group receives one visit with a CHW and the resources provided to the intervention group participants.
89323889|NCT02210728|Active Comparator|Medication only|Stimulant medication (methylphenidate or amphetamine product approved for clinical use in Canada), with dose optimized for each patient based on report of efficacy and side effects.
89323890|NCT02210728|Active Comparator|Cognitive behavioral therapy + medication|Patients are first titrated to an optimal dose of stimulant medication. They then undergo the 12 weeks of group cognitive behavioral therapy.
89323891|NCT02210728|Experimental|Cognitive behavioral therapy alone|12 weeks of structured group cognitive behavioral therapy, focusing on acquisition of skills in organization, time management, goal attainment, cognitive restructuring, stress management, anger management, impulse control, self-esteem, and relationship management.
89323892|NCT02220868|Other|Sofossbuvir, Riabvirin, Stribild|Open-Label SIngle Arm of Sofosbuvir, Ribavirin and Stribild
89323893|NCT02210962|Experimental|essential fatty acids|The experimental treatment is a food supplement containing fish oil. The daily dose of 4 capsules provides 1320 mg of eicosapentaenoic acid and 880 mg of docosahexaenoic acid, 26 weeks intervention
89323894|NCT02210962|Placebo Comparator|olive oil|Placebo capsules contain olive oil and trace amount of fish oil to assure comparable taste, 26 weeks intervention
89323895|NCT02220946|Active Comparator|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. Each patient received a 20 minute session once a week for total 8 sessions
89323896|NCT02220946|Placebo Comparator|plasebo|sham electrical stimulation
89323897|NCT02211430|Experimental|Cognitive-Behavioral Counseling (CBC)|Cognitive-Behavioral Counseling (CBC) consists of two 45-minute on-site intervention sessions (session 1 and 3), one 15 minute on-site session (session 2), and one 15-minutes phone session (booster session).
89323898|NCT02211430|Active Comparator|Best Practice (BP) Control|Best Practice (BP) Control Condition consists of two 10-15 min, on-site intervention sessions (session 1 and 3), one brochure pick-up (session 2), and receipt of a newsletter by mail (booster session).
89323899|NCT02221024|Experimental|Flushing every 24 hours|Flushing with positive pressure with normal saline every 24 hours
89323900|NCT02221024|Active Comparator|Flushing every 12 hours|Flushing with positive pressure with normal saline every 12 hours
89323901|NCT02212522||Isis-Diab patients|French T1D patients with genetic data (GWAS), and environmental data (questionnaire and environmental databases), clinical data
89323902|NCT02212522||Isis-Diab controls|French control population with genetic data (GWAS) and environmental data (questionnaire and environmental databases
89323903|NCT02221102|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30
89323904|NCT02221102|Experimental|edoxaban 30mg|Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30
89323905|NCT02221102|Experimental|edoxaban 60mg|Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30
89323906|NCT02213302|Placebo Comparator|Isotonic serum|placebo administration
89323907|NCT02213302|Active Comparator|Midazolam|midazolam intravenous administration 0.02mg/kg
89323908|NCT02221180|Experimental|Treatment Sequence ABDC|Treatment A (1 immediate release (IR) fixed dose combination [FDC] tablet containing canagliflozin 150 milligram [mg] and metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89323909|NCT02221180|Experimental|Treatment Sequence BCAD|Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89523450|NCT03374501|Experimental|4 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 4 tablets of Sugardown™
89523451|NCT03374501|Placebo Comparator|Soft drink|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink
89523452|NCT03374423|Active Comparator|intercostal nerve group|pulsed radiofrequency on intercostal nerves (2-5)
88811767|NCT05237024||Physiology & Immune Monitoring|A limited sub-study including 30 individuals enrolled in the primary study (not retrospective group) will incorporate serial blood draws relative to the vaccine doses. The purpose of the serologies and immunoassays is to explore the correlation an individual's development of a vaccine-induced immune response with changes in the continuous physiologic data surrounding the immunization process.
89323910|NCT02221180|Experimental|Treatment Sequence CDBA|Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89323911|NCT02221180|Experimental|Treatment Sequence DACB|Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
89323912|NCT02221258|Experimental|FURESTEM-RA Inj.+DMARDs|FURESTEM-RA Inj. 1. 2.5x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 2. 5.0x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 3. 1.0x10^8 stem cells+DMARDs after registration
89323913|NCT02205112|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL, intravenous administration, once daily for 7~14 days
89323914|NCT02205112|Active Comparator|Levofloxacin 500mg|Levofloxacin: 500mg/100mL, intravenous administration, once daily for 7~14 days
89323915|NCT02213770||Intervention group|Group that followed high- intensity interval training program in TEX study.
89323916|NCT02213770||Control group|Followed up on a regular basis for HTx recipients in Norway.
89323917|NCT02205190|Other|Treatment AB|"Treatment A (1 day) → wash-out(7days) → Treatment B (1 day)~Treatment A : Fimasartan and Rosuvastatin~Treatment B : Fimasartan/Rosuvastatin combination"
89323918|NCT02205190|Other|Treatment BA|"Treatment B (1 day) → wash-out(7days) → Treatment A (1 day)~Treatment A : Fimasartan and Rosuvastatin~Treatment B : Fimasartan/Rosuvastatin combination"
89323919|NCT02221336|Placebo Comparator|Non-MONARCA II system|Use of smartphone for normal communicative purposes only. No self-monitoring and no feedback loop.
89323920|NCT02221336|Experimental|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
89323921|NCT05236816|Experimental|Healthy|Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
89323922|NCT02257918|Experimental|Group 1|N = 70 subjects receive single oral dose , 2000 mg of AZD0914
89323923|NCT02257918|Experimental|Group 2|N =70 subjects receive single oral dose , 3000 mg of AZD0914
89323924|NCT02257918|Active Comparator|Group 3|N = 40 subjects receive single intramuscular dose, 500 mg of ceftriaxone
89323925|NCT02216578|Experimental|cabozantinib|cabozantinib 60 mg oral daily
89323926|NCT05262868|Active Comparator|Active|Magnetic stimulus intensity of 80% of the motor threshold applied at the frequency of 20 Hz over the left DLPFC with a total number of pulses of 1200 / treatment session for a total of 5 sessions /week for 3 consecutive weeks
89323927|NCT05262868|Placebo Comparator|Sham|"Sham procedure implies the use of a sham coil of exactly the same dimension and appearance as the one used for the effective treatment. This sham coil is made for research purposes by the producing company and used in accordance with the instructions for use, which explicitly mention it (cf. instruction manual page 34: Stimulation Coil DuoMAG 70BFP (70BFP1, 70BFP2), typical use for blinded studies)."
89323928|NCT02205268|Experimental|Neurofeedback training|20 sessions of near infrared spectroscopy neurofeedback training to increase activation to bilateral prefrontal cortex. Two sessions per week.
89323929|NCT02205346||no treatment|no treatment
89323930|NCT05262790||PNS group|The patients with prominently negative symptoms (PNS) had a greater score on the negative than on the positive subscale of the PANSS, a negative symptoms score > 20, and at least one of items from PANSS negative symptoms scale ≥ 4 points
89323931|NCT05262790||PPS group|The patients with predominantly positive symptoms (PPS) had a greater score on the positive than on the negative subscale of the PANSS
89323932|NCT05262790||Control|Healthy control
89323933|NCT02221414|Experimental|Treatment A (FDC)|
89323934|NCT02221414|Active Comparator|Treatment B (single agents)|
89323935|NCT02221492|Active Comparator|granulocyte colony-stimulating factor alone|G-CSF administered up to 8 days
89323936|NCT02221492|Experimental|granulocyte colony-stimulating factor plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
89323937|NCT05164978|Experimental|DEP combine with PD-1 antibody|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 1.5mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; sintilimab injection 200mg day 4. This regimen was repeated after 2 weeks.
89323938|NCT02751424|Experimental|GSK3342830 single dose in Part 1|Enrolled subject will receive single escalation dose of GSK3342830. The escalating doses will be evaluated in six cohorts as A- 250 mg, B-500 mg, C-1000 mg, D-2000 mg, E-4000 mg, and F-=<6000 mg. In each cohort 6 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 36 subjects will receive GSK3342830. Dose escalation will be based on evaluation of the preceding dose levels in the study.
89323939|NCT02751424|Placebo Comparator|Placebo single dose in Part 1|Enrolled subject will receive single escalation dose of placebo. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 12 subjects will receive placebo.
89523453|NCT03374423|Active Comparator|dorsal root ganglion group|pulsed radiofrequency on dorsal root ganglion (2-5)
89523454|NCT03374345|Experimental|SDT group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
89523455|NCT03374345|Placebo Comparator|Placebo group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
89523456|NCT04175873|No Intervention|Group C|Control group.
89323940|NCT02751424|Experimental|GSK3342830 repeat Dose in Part 2|Enrolled subject will receive repeat escalating dose of GSK3342830. GSK3342830 as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. The escalating doses will be evaluated in three cohorts as G-1000 mg, H-2000 and I-4000 mg. In each cohort 8 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 24 subjects will receive GSK3342830. The starting dose and maximum dose may change based on clinical safety and PK findings in Part 1 or earlier doses in Part 2 respectively.
89323941|NCT02751424|Placebo Comparator|Placebo repeat Dose in Part 2|Enrolled subject will receive repeat escalation dose of placebo. Placebo as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 6 subjects will receive placebo.
89323942|NCT02221570|Active Comparator|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
89323943|NCT02221570|Placebo Comparator|Placebo|placebo of baclofen
89323944|NCT02217358|Experimental|NBI endoscopy|150 patients with suspected lesion in larynx and hypopharynx on standard ENT white light endoscopy examination will undergo NBI endoscopy in order to compare the outcomes of these two examination methods
89323945|NCT05163652|Experimental|3 months after two doses|group 1：the third does was given 3 months after two doses CoronaVac group 2：the third does was given 3 months after two doses BBIBP-CorV group 3：the third does was given 3 months after one does CoronaVac and one does BBIBP-CorV
89323946|NCT05163652|Experimental|4 months after two doses|group 1：the third does was given 4 months after two doses CoronaVac group 2：the third does was given 4 months after two doses BBIBP-CorV group 3：the third does was given 4 months after one does CoronaVac and one does BBIBP-CorV
89323947|NCT05163652|Experimental|5 months after two doses|group 1：the third does was given 5 months after two doses CoronaVac group 2：the third does was given 5 months after two doses BBIBP-CorV group 3：the third does was given 5 months after one does CoronaVac and one does BBIBP-CorV
89323948|NCT05163652|Experimental|6 months after two doses|group 1：the third does was given 6 months after two doses CoronaVac group 2：the third does was given 6 months after two doses BBIBP-CorV group 3：the third does was given 6 months after one does CoronaVac and one does BBIBP-CorV
89323949|NCT02205502|Experimental|Lidocaine|"Proper amount of lidocaine will be injected lacerated wound.~dosage form: fluid~dosage: not exceeding 1mg/kg~frequency: once~duration: n/a"
89323950|NCT02205502|Placebo Comparator|Normal saline|Normal saline will be used as a placebo for lidocaine
89323951|NCT02219698|Experimental|Symptomatic treatment|
89323952|NCT02205580|Experimental|Sufentanil infusion rate 0.02μg•kg-1•h-1|Sufentanil infusion rate 0.02μg•kg-1•h-1 lasted for 48 hours
89323953|NCT02205580|Experimental|Sufentanil infusion rate 0.03μg•kg-1•h-1|Sufentanil infusion rate 0.03μg•kg-1•h-1 lasted for 48 hours
89323954|NCT02205580|Experimental|Sufentanil infusion rate 0.04μg•kg-1•h-1|Sufentanil infusion rate 0.04μg•kg-1•h-1 lasted for 48 hours
89323955|NCT05262634||study group: iron deficiency|Pregnant women with a documented iron deficiency in the first trimester
89323956|NCT05262634||control group: normal iron status|Pregnant women with normal hematological parameters and iron status in the first trimester
89323957|NCT02221726|Experimental|JNJ-35684-AAA-023: 5.5 cm^2 Patch|
89323958|NCT02221726|Experimental|JNJ-35684-AAA-023: 44 cm^2 Patch|
89323959|NCT02221804|Experimental|COPD - reduced activity levels|COPD patients who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
89323960|NCT02221804|Experimental|Healthy - reduced activity levels|Healthy age-matched controls who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
89323961|NCT02221804|No Intervention|COPD - unchanged activity levels|
89323962|NCT02221960|Experimental|Monotherapy Arm|MEDI6383
89323963|NCT02221960|Experimental|Combination Arm|MEDI6383 and MEDI4736
89323964|NCT02220010|Experimental|Pancreatic stent|If POPF grade B or C is detected on post operative day 3 or more, a pancreatic stent is endoscopically positioned in the pancreatic duct.
89323965|NCT02220010|No Intervention|Drain only|If POPF grade B or C is detected on post operative day 3 or more, only the per-operatively placed drain is used as treatment
89323966|NCT05262478||Alpha-D cervical disc prosthesis|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
89323967|NCT02220088|Experimental|TAI of FOLFOX|Retreatment With Transcatheter arterial infusion of oxaliplatin , fluorouracil, and leucovorin
89323968|NCT02220088|Active Comparator|Sorafenib|treatment with sorafenib
89323969|NCT02205658||Autism|Individuals, aged 18-95 years, with a pre-existing diagnosis of Autism Spectrum Disorder with or without a co-morbid diagnosis of Sensory Processing Disorder.
89323970|NCT02205658||Sensory Processing|Individuals, aged 18-95 years, with a pre-existing diagnosis of Sensory Processing Disorder with no co-morbid diagnosis of Autism Spectrum Disorder
89323971|NCT02205658||Typical|Typically functioning individuals aged 13-95 years
89323972|NCT05097040|Experimental|Acceptance and commitment therapy (ACT) group|A total of 7 ACT sessions individually guided by a trained coach through Zoom videoconferencing
89323973|NCT05097040|No Intervention|Control group|Care as usual
89323974|NCT02220166|Experimental|Triticum monococcum|60 days of daily administration of 100 grams of water biscuits of Triticum monococcum
89323975|NCT02220244|Experimental|MD1003|MD1003 100mg capsule, 1 capsule TID for 12 months
89323976|NCT02220244|Placebo Comparator|Placebo|Placebo capsule, 1 capsule TID for 6 months, then switch to MD1003 100mg capsule, 1 capsule TID for 6 months
89323977|NCT02222038|Other|skin biopsy|4mm punch biopsy
89323978|NCT02222116|Experimental|MGuard Prime|MGuard Prime
89323979|NCT02222116|Active Comparator|Control|BMS or DES
89323980|NCT02205736|Other|Living Room Visit participants|Latino women who received breast health education while attending a Living Room Visit.
89323981|NCT02220400|Experimental|Ketamine|Ketamine infusion group
89323982|NCT02220400|Placebo Comparator|Placebo|Normal saline infusion
89323983|NCT02205892|Active Comparator|Lupeol|
89323984|NCT02205892|Placebo Comparator|Vehicle|
89323985|NCT05228626|Placebo Comparator|Standard of care plus placebo arm|Will contain standard of care plus placebo
89323986|NCT05228626|Experimental|Stanadard of care plus COVIDEX arm|Will contain the standard of care plus the intervention given for 3 times daily for seven days
89323987|NCT02224768||HCP and Patient inclusion|"HCP inclusion - HCP Experience with treatment of patients with study compound who have been exposed to risk minimization tools~Patient inclusion - Patients treated with study compound as per label who have been exposed to the risk minimization materials"
89323988|NCT05262166|No Intervention|Epidural Fentanyl group:|Epidural Fentanyl group: using an epidural catheter technique with epidural catheter set, and at L1-2 insertion level directed up to cover up to T6 sensory level, 5ml of bupivacaine 0.5%plus 50 micrograms fentanyl in a total volume of 40 ml added saline 0.9% (epidural injection of bolus of total Volume of 15 ml of 0.0625%bupivacaine with 1.25Mcg/ml fentanyl) then for next G anaesthesia hours to run in a 3-5 ml/h epidural infusion rate.
89323989|NCT05262166|Experimental|Intrathecal dexmedetomidine group:|Intrathecal dexmedetomidine plus heavy bupivacaine then general A
89323990|NCT02205970|Active Comparator|TENS active|TENS (interactive): frequency (90 and 150 pps) and pulse duration (300 and 400μs)
89323991|NCT02205970|Sham Comparator|TENS sham|Placebo lasting 35 minutes.
89323992|NCT02206126|Experimental|Energy restriction group|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
89323993|NCT02206126|No Intervention|Control group|The control group was advised not to change their food intake.
89323994|NCT02206204|Experimental|Group A|Subjects in Group A receive selexipag on Days 3 to 23 and moxifloxacin-matching placebo on Days 2 and 24. Selexipag administered orally, twice a day, for 21 days according to the following multiple dose up-titration regimen: 400 μg on Days 3-5, 600 μg on Days 6-8, 800 μg on Days 9-11, 1000 μg on Days 12-14, 1200 μg on Days 15-17, 1400 μg on Days 18-20, and 1600 μg on Days 21-23 (only morning dose on Day 23).
89323995|NCT02206204|Experimental|Group B1|Subjects in Group B1 receive 400 mg moxifloxacin, orally on Day 2 and moxifloxacin-matching placebo, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
89323996|NCT02206204|Experimental|Group B2|Subjects in Group B2 receive moxifloxacin-matching placebo, orally on Day 2 and 400 mg moxifloxacin, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
89323997|NCT02222194||VAM|"Patients with operable and resectable cT1-2-selected T3 cN1cM0 NSCLC undergo VAM for mediastinal lymph node staging. After VAM, patients without tissue proof of N2/3 disease at surgical staging undergo a VATS or thoracotomy with systematic lymph node dissection during the same anaesthesia or at a later stage.~Sensitivity, NPV and accuracy of staging with VAM will be calculated. Provided N2 lymph node metastases are proven by VAM the patient goes off study protocol and can further be assessed/treated according to local clinical practice."
89323998|NCT05073016|Active Comparator|Finger Taping Task + iTBS intermittent group|Finger Taping Task + iTBS Daily application group: the group receives these applications every other day for 5 sessions.
89323999|NCT05073016|Active Comparator|Finger Taping Task intermittent Group|Finger Taping Task intermittent application group: the group receives the application every other day for 5 sessions.
89324000|NCT02222350|Experimental|DS-8500a 10mg once daily|10mg DS-8500a tablet given orally once daily
89324001|NCT02222350|Experimental|DS8500a 75 mg once daily|75mg DS-8500a tablet given orally once daily
89324002|NCT02222350|Placebo Comparator|placebo to match DS-8500a tablet|placebo matching DS-8500a tablet
89324003|NCT02222428|Experimental|BI 1744 CL/BI 54903 XX FDC|
89324004|NCT02222428|Active Comparator|BI 54903 XX|
89324005|NCT02222428|Active Comparator|BI 1744 CL|
89324006|NCT02222506|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for diabetic foot ulcers.
89324007|NCT02231242|Experimental|Intrathecal Autologous Bone Marrow TNC|Procedure/Surgery: Intrathecal Autologous Bone Marrow TNC. Other Names: Autologous Stem Cell Transplantation Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) (10mcgr/kg of body weight) for 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the autologous TNC concentrate of 10 mL will be infused intrathecally.
89324008|NCT02231242|No Intervention|Control group|"Patients will be evaluated with the Gross Motor Functional Classification System initially, at one, three and six months, and then cross to the intervention arm."
89324009|NCT02225236|Experimental|Classroom Intervention|The intervention focuses on training executive functioning (e.g., working memory and inhibition) and metacognition (i.e., the ability to predict, check, monitor, coordinate and control cognitive operations) using play activities and structured language and reinforcement.
89324010|NCT02225236|No Intervention|No treatment control|No intervention
89324011|NCT02225314|Experimental|Brain Fitness|Brain Fitness is a computer-based cognitive training programs designed to augment auditory processing speed and accuracy over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
89324012|NCT02225314|Experimental|InSight|InSight is a computer-based cognitive training programs designed to augment visual processing and working memory over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
89324013|NCT02225314|Active Comparator|Active Control|An active control arm is necessary to model practice effects in an untreated group. Participants in this group will view and complete quizzes on a computerized learning program designed to improve knowledge about literature, art, and history.
89324014|NCT02231320||Chronic Obstructive Pulmonary Disease patients|
89324015|NCT02222584||IBD group|patients with with inflammatory bowel disease who are visiting the out-patient clinic of severance hospital from July 2014 to February 2015
89324016|NCT02222662|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
89523457|NCT04175873|Experimental|Group M|Music group.Preoperative 1 hour and during the operation of Classical Turkish Music (Acemaşiran makam) listening group
89324017|NCT02222662|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
89324018|NCT04719520|No Intervention|traditional method|radio and telephone to notify the patient's family to the operating room
89324019|NCT04719520|Experimental|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
89324020|NCT02225470|Experimental|Arm A, E7389 (Eribulin Mesylate)|The eribulin mesylate dose will be 1.4 mg/m2 administered as an intravenous bolus over 2 to 5 minutes on Days 1 and 8 of each 21-day cycle.
89324021|NCT02225470|Active Comparator|Arm B, Vinorelbine injection|The vinorelbine dose will be 25 mg/m2 administered as an intravenous bolus on Days 1, 8, and 15 of each 21-day treatment cycle.
89324022|NCT02222974|Experimental|BIIR 561 CL|
89324023|NCT02222974|Placebo Comparator|Placebo|
89324024|NCT02906488||Patients with Parkinson's Disease|
89324025|NCT02259166|Experimental|EHFP+|Group receiving the intervention EHFP+, in addition to MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
89324026|NCT02259166|No Intervention|Control|MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
89324027|NCT02225548|Experimental|Selegiline and Tadalafil|Tadalafil 2.5mg for 4 weeks then oral selegiline 5mg daily for 2 weeks then increased to 5mg twice daily for 2 more weeks
89324028|NCT02259244|Experimental|Mediterranean diet+physical activity|Mediterranean diet based on 1573 kcal/day with the goal of consumption of 30 ml/day of olive oil, 56g/week of nuts, 3-4 servings/week of fish, 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat
89324029|NCT02259244|Active Comparator|Hypolipemic reduction diet+physical activity|Hypolipemic reduction diet based on 1287 kcal/day with the goal of consumption of 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat, non-fat or low-fat dairy products
89324030|NCT02231554|Experimental|Feldenkrais|The Feldenkrais method is a self education method that uses the somatic sensory-motor learning to enhance the functions of people in daily life activities through the awareness of their motor habits and the experience of more efficient alternatives.
89324031|NCT02231554|Active Comparator|Back School|The Back School teaches the patient, with theoretical and practical knowledge, how to defend his own back from the pain and how to prevent their disease, considering awareness and education as important parts of the therapeutic process .
89324032|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 1|Two 150-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of CC-486 on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
89324033|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 1|One 300-mg tablet of oral CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
89324034|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by two 150-mg tablets on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
89324035|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 1, followed by one tablet of 300-mg oral CC-486 under fasted conditions on PK dosing Day 2; if PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine of Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
89324036|NCT02225626|Experimental|BI 1060469 fed|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administr
89324037|NCT02225626|Experimental|BI 1060469 fasted|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
89324038|NCT02223130|Experimental|Intervention Group|Participants will attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys. After their baseline interview and before their first follow-up interview, participants attend the Intervention Group, which consist of 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who uses Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions, and behaviors in response to stressful/discrimination experiences.
89324039|NCT02223130|No Intervention|Waitlist Control|"Participants are not given the Intervention Group while they are enrolled in the study. Instead, they only attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys.~After they have completed the study, participants from the first two cohorts are offered the option of attending an intervention group that is identical in content to the intervention group being studied.The third cohort is offered the intervention group after they have completed the first follow-up but before they complete the final follow-up due to timing and budgetary restraints. No data is collected and no incentives are given during these intervention groups."
89324040|NCT02223286||ASGES (Treatment Group)|Patients who received a Corus CAD or Age/Sex/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
89324041|NCT02223286||Non-ASGES (Control Group)|Patients who underwent usual care testing and did not receive a Corus CAD or Age/SEX/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
89324042|NCT02225782|Active Comparator|1.0 mg alteplase (tPA)|1.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
89324043|NCT02225782|Experimental|2.0 mg alteplase (tPA)|2.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
89324044|NCT02231788|Experimental|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab.(Telmisartan/S-Amlodipine) 40/2.5mg
89324045|NCT02231788|Active Comparator|Telmitrend®Tab. 80mg|Telmitrend®Tab.(Telmisartan) 80mg
89324046|NCT02225938||Intensive care survivors|Patients surviving an admission to an intensive care unit
89324047|NCT02231866|Experimental|Group 1|cAd3-EBO at 2x10(10)PU IM
89324048|NCT02231866|Experimental|Group 2|cAd3-EBO at 2x10(11)PU IM
89324049|NCT02231866|Experimental|Group 3|cAd3-EBO at 2x10(11)PU IM boost of Ebola DNA WT vaccine (VRC 206 participants)
89324050|NCT02231866|Experimental|Group 4A|cAd3-EBOZ at 1x10(10)PU IM
89324051|NCT02231866|Experimental|Group 4B|cAd3-EBOZ at 1x10(11)PU IM
89324052|NCT02231866|Experimental|Group 5|cAd3-EBO at 2x10(11)PU IM
89324053|NCT02231944|Experimental|Replenine®-VF|
89324054|NCT02226094|Experimental|DWT device dose A|Deep Wave Trabeculoplasty (DWT) dose A (10 second spot treatments).
89324055|NCT02226094|Active Comparator|Ellex Tango SLT machine|Selective Laser Trabeculoplasty (SLT)
89324056|NCT02226094|Sham Comparator|DWT Sham|Deep Wave Trabeculoplasty (DWT) but device not applied to ocular surface.
89324057|NCT02226094|Experimental|DWT device dose B|Deep Wave Trabeculoplasty (DWT) dose B (20 second spot treatments).
89324058|NCT02858908|Experimental|Cohort 1 - Tideglusib|1000 mg tideglusib, orally, once daily
89324059|NCT02858908|Experimental|Cohort 2 - Tideglusib|400 mg tideglusib, orally, once daily
89324060|NCT02258620|Experimental|dinitrate isosorbide (intra venous)|dinitrate isosorbide by continuous intra venous injection (1 à 5 mg/h)
89324061|NCT02258620|Experimental|dinitrate isosorbide (intra arterial)|dinitrate isosorbide 5 mg by direct administration intra arterial
89324062|NCT02258620|Experimental|nitroglycerine (transdermic)|nitroglycerine dermal patch15 mg/24h soit 67,2 mg/21 cm2
89324063|NCT02232100|Experimental|10AMG|Attentional bias modification group - 10 training sessions
89324064|NCT02232100|Placebo Comparator|10ACG|Attentional control group - 10 placebo sessions
89324065|NCT02232100|Experimental|18AMG|Attentional bias modification group - 18 training sessions
89324066|NCT02232100|Placebo Comparator|18ACG|Attentional control group - 18 placebo sessions
89324067|NCT02223598|Experimental|Dose Escalation - CB-5083|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with lymphoid hematological malignancies
89324068|NCT02223598|Experimental|Dose Expansion - CB-5083, Dexamethasone|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with relapsed and refractory multiple myeloma; in addition, subjects who develop progressive disease at the end of Cycle 1, or beyond, may receive their current dose of CB-5083 in combination with oral or IV low dose Dexamethasone (40 mg)
89324069|NCT02223598|Experimental|Dose Expansion - CB-5083|CB-5083 will be administered orally, daily, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with diffuse large B-cell lymphoma (DLBCL) or Waldenstrom Macroglobulinemia, if such arm is opened, per Sponsor
89324070|NCT02258698||Elective on-pump cardiac surgery|Observation of perioperative Insulin resistance in patients undergoing elective on-pump cardiac surgery (CABG and/or valve repair)
89324071|NCT02226250|Experimental|3 Placebo Beverages|Sugar beverage 2 hr before meal and with meal and 2 hr after meal
89324072|NCT00094835|Experimental|Paclitaxel + Carboplatin + Motesanib|Chemotherapy naïve participants received paclitaxel 200 mg/m^2 and carboplatin chemotherapy administered by intravenous (IV) infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort and up to 125 mg once daily was used in subsequent cohorts. A cycle was defined as the 3 weeks plus the time to recover from toxicity, if encountered.
89324073|NCT00094835|Experimental|Panitumumab + Motesanib|Participants with no more than one prior chemotherapy regimen for NSCLC received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort, up to 125 mg once daily was used in subsequent cohorts.
89324074|NCT00094835|Experimental|Panitumumab + Paclitaxel + Carboplatin + Motesanib|"Chemotherapy naïve participants received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, paclitaxel 200 mg/m^2 and carboplatin chemotherapy administered by IV infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter.~Participants were enrolled in this arm once a safe and tolerable dose of motesanib was established."
89324075|NCT02232256|Experimental|CALPXT96|"1st treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)~2 week wash out period~2nd treatment period: 4 weeks placebo (two capsules hs at bedtime)"
89324076|NCT02232256|Placebo Comparator|Placebo|"1st treatment period: 4 weeks placebo (two capsules hs at bedtime)~2 week wash 'out' period~2nd treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)"
89324077|NCT02226328|Experimental|Propofol sedation|"Refract bolus propofol sedation as monotherapy administered by a sedation-trained nurse endoscopist.~Induction with 10-60 mg bolus, repeated every 45-60 sec. until moderate sedation.~Maintenance with 10-20 mg of propofol in case of discomfort."
89324078|NCT02226328|Active Comparator|Midazolam and Fentanyl sedation|"1-2 mg of Midazolam with 0.025-0.05 mg of fentanyl for induction 10 prior to procedure initiation.~Maintenance with 1 mg Midazolam in case of discomfort."
89324079|NCT02530931|Experimental|patients with Meniere's disease|
89324080|NCT02226016|Experimental|Ptosis|Device (measurement of levator strength in patients with upper lid ptosis)
89324081|NCT02226406|Experimental|Legs Cycloergometer Group (A)|Patients randomized in this group will do 10 minutes of legs cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
89324082|NCT02226406|Experimental|Hands Cycloergometer Group (B)|Patients randomized in this group will do 10 minutes of hand cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
89324083|NCT02226406|Experimental|Walk in place (C)|Patients randomized in this group will do 10 minutes of active walk in place. Continuously evaluated with electric impedance tomography.
89324084|NCT03962699||Obese patients selected for bariatric surgery|Normospermic obese patients ((BMI>40), aged 20-50 years) who will undergo Bariatric surgery.
89324085|NCT03962699||Control Group: Non obese volunteers|Normospermic obese patients ((BMI>40), aged 20-50 years
89324086|NCT03962777|Experimental|oil pulling|patients used oil pulling therapy for 4 days
89324087|NCT03962777|Active Comparator|chlorhexidine|patients used chlorhexidine digluconate for 4 days
89324088|NCT04464538|Placebo Comparator|Health information|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
89324089|NCT04464538|Experimental|Group education session and individualised coaching (online)|Participants assigned to the WALC-R intervention will attend a virtual baseline educational group session which will include a maximum of five people. The aim of the sessions will be to introduce the basics of the benefits of walking for exercise and why exercise is beneficial, as well as to give information, support and motivation to help participants to independently walk more in their daily routines.The group session will also include goal setting, in which participants will be encouraged to set their own daily walking targets to increase their habitual levels of walking. All participants will be given a pedometer to self-monitor how far they walk and a diary to record activity context throughout the intervention daily. Participants will meet briefly (20-30 minutes) via the internet with an assigned coach every 2 weeks.
89324090|NCT02226484|Experimental|Quercetin|Two 250 mg capsules of oral quercetin (Q) twice-a-day (BID) one hour before meals with a glass of water for 6 weeks.
89324091|NCT04453852|Experimental|Group A|Spike antigen (25ug) + 15 mg Advax-2 adjuvant
89324092|NCT04453852|Placebo Comparator|Group B|Saline
89324093|NCT02226640||Non-Diabetic Lean Athletes|Athletes with a Body Mass Index (BMI) less than or equal to 25 kg/m2.
89324094|NCT02226640||Non-Diabetic Lean No Diabetes History|Adults with a BMI < 25 kg/m2 and no family history of diabetes
89324095|NCT02226640||Non-Diabetic Lean Yes Diabetes History|Adults with a BMI < 25 kg/m2 and family history of diabetes
89324096|NCT02226640||Non-Diabetic Obese|Adults with BMI greater than or equal to 30 kg/m2.
89324097|NCT02226640||Non-Diabetic Obese Female PCOS|Female adults with BMI > 30 kg/m2 and Polycystic Ovarian Syndrome (PCOS).
89324098|NCT02226640||Diabetic No Medication|Have diabetes and currently receiving no medication or early treatment with one medication. Some participants receiving insulin may also be included in this study
89324099|NCT02226640||Diabetic GAD Ab+|Have diabetes with Latent Autoimmune Diabetes in Adults (LADA).
89324100|NCT02226640||Diabetic With NASH|Have diabetes with Nonalcoholic Steatohepatitis (NASH), which is chronic liver disease with fat in the liver, inflammation, and damage not associated with drinking alcohol.
89324101|NCT02223676|Experimental|Intervention|Clinical pharmacists conduct medication history
89324102|NCT02223676|No Intervention|Control|standard procedures for admission is followed
89324103|NCT02226718||questionnaire|
89324104|NCT00094757|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg
89324105|NCT00094757|Experimental|Sitagliptin 200 mg|Sitagliptin 200 mg
89324106|NCT00094757|Placebo Comparator|Placebo/Pioglitazone|Placebo/Pioglitazone
89324107|NCT04388020|Experimental|Test Arm|
89324108|NCT02223832|Experimental|ACT-128800|"A single oral dose of 40 mg ACT-128800 will be administered as~1 capsule given in the fasted state in the morning"
89324109|NCT02223910|Active Comparator|Motor Cortex|Feedback training of functional connectivity between motor cortex and the rest of the brain
89324110|NCT02223910|Placebo Comparator|Control region|Feedback training of functional connectivity between medial prefrontal cortex of healthy hemisphere and the rest of the brain
89324111|NCT01081457|Active Comparator|ON|Stimulator switched ON
89324112|NCT01081457|Sham Comparator|OFF|Stimulator switched OFF
89324113|NCT02223988|Experimental|subglottic secretion drainage|
89324114|NCT02226952|Experimental|Group 1|BILN 2061 W, medium dose, in patients with genotype 1, minimal fibrosis
89324115|NCT02226952|Experimental|Group 2|BILN 2061 W, high dose, in patients with genotype 1, minimal fibrosis
89324116|NCT02226952|Experimental|Group 3|BILN 2061 W, high dose, in non-genotype 1 patients, minimal fibrosis
89324117|NCT02226952|Experimental|Group 4|BILN 2061 W, low dose, in patients with genotype 1, minimal fibrosis
89324118|NCT02226952|Experimental|Group 5|BILN 2061 W, medium dose, in patients with genotype 1, advanced fibrosis
89324119|NCT02226952|Placebo Comparator|Placebo|
89324120|NCT02224066|Experimental|Ticagrelor|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
89324121|NCT02224066|Active Comparator|Aspirin/Clopidogrel|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
89324122|NCT02224066|No Intervention|Registry arm|Patients with normal-on-treatment platelet reactivity (PRU < 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.
89324123|NCT02232334|Experimental|Osteopathic manual treatment|Global Osteopathic Manual treatment: each subject will be treated according to what restrictions or areas of poor mobility are found individually. No two subjects will receive the same overall treatment.
89324124|NCT02232334|No Intervention|Control--no change in current treatment of subject|The population will act as their own control prior to intervention of osteopathy, their will be a control period where the subject maintains current treatment of their gastroparesis. During that period they will fill out the GCSI measuring tool at the beginning of the control period and at the end. Those measurements will be compared to the GSCI results during the intervention period.
89324125|NCT04682470||All patients|
89324126|NCT02232490|Experimental|hepcortespenlisimut-L|Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC
89324127|NCT02232490|Placebo Comparator|placebo|placebo
89324128|NCT02227030|Experimental|BIIB 722 CL single rising dose|
89324129|NCT02227030|Experimental|BIIB 722 CL cross over|
89324130|NCT02227030|Placebo Comparator|Placebo solution|
89324131|NCT02227030|Placebo Comparator|Placebo tablet|
89324132|NCT02227186|No Intervention|Control arm|No school-located influenza vaccination clinic
89324133|NCT02227186|Experimental|School-located influenza vaccination clinics|School-located influenza vaccination clinics
89324134|NCT04378114|Experimental|Subjects with diabetes wearing Guardian™ Sensor (3). C algorithm applied retrospectively|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one frequent sample test (FST). C sensor algorithm applied retrospectively to raw sensor data.
89324135|NCT04378114|Experimental|Subjects with diabetes wearing Guardian™ Sensor (3). Zeus algorithm applied retrospectively|Subjects wear Guardian™ Sensor (3) over 7 days and undergo one FST. Zeus sensor algorithm applied retrospectively to raw sensor data.
89324136|NCT02224222||Patients undergoing vascular procedures|Including all non-interventional surgical procedures, excluding varix surgery
89324137|NCT02224222||Patients undergoing cardiac procedures|Including all non-interventional surgical procedures, excluding HTX
89324138|NCT02224300|Experimental|Education|"Intervention group will receive the ELC for six weeks (15.9. - 26.10.2014) and comparison group will not receive it.~Members of the intervention group in will work in teams of 10 nurses with weekly questions (released in Mondays) based on patient-description existing in Moodle. One member of the team will send the solutions to questions once a week (in Thursdays) Moodle. Researcher will download the model-answer to Moodle once a week (in Fridays) and nurses will compare their answer to model answer (self-evaluation)."
89324139|NCT00082433|Experimental|A|
89324140|NCT00082433|Active Comparator|B|
89324141|NCT00094445|Experimental|Curcumin|Oral curcumin daily for eight weeks, starting dose 8 gm per day.
89324142|NCT03961763|Active Comparator|omega-3 supplement|This group will receive a daily dose of 4g EPA+DHA (which is the recommended safe tolerable upper intake level of omega-3 supplements for healthy individuals) for eight weeks.
89324143|NCT03961763|Placebo Comparator|Placebo|This group will receive a daily dose of 4g olive oil placebo for eight weeks.
89324144|NCT01081535|Experimental|ketorolac|
89324145|NCT01081535|Experimental|fentanyl|
89324146|NCT03741257|Active Comparator|Group A|Received Hypertonic saline 3% as resuscitation fluid.
89324147|NCT03741257|Active Comparator|Group B|Received Hypertonic saline 1.8% as resuscitation
89324148|NCT01087229|Experimental|equimolar oxygen-nitrous oxide mixture|"equimolar oxygen-nitrous oxide mixture~Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture."
89324149|NCT01087229|Placebo Comparator|Placebo|Patients randomized to this arm will have the placebo.
89324150|NCT00082355|Experimental|Alteplase (r-tPA)|Patients with DVT of lower extremity will receive up to 4 treatments low dose (<10 mg/day) intraclot injections of alteplase. Intention is to evaluate safety and efficacy of this treatment, and durability of outcomes (for 6 months)in 25 patients.
89324151|NCT01084577|Active Comparator|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
89324152|NCT01084577|Active Comparator|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
89324153|NCT00094055|Experimental|Axitinib [AG-013736]|
89324154|NCT01084811||chronic rhinosinusitis with nasal polyps|
89324155|NCT01084811||chronic rhinosinusitis without nasal polyps|
89324156|NCT01084811||Control group|
89324157|NCT02531165|Experimental|Morphine|"Pre-hospital Ticagrelor 180 mg loading dose orally.~Morphine, initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required.~Aspirin 500 mg loading dose orally (or intravenously).~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.~Primary PCI."
89324158|NCT02531165|Experimental|Fentanyl|"Pre-hospital Ticagrelor 180 mg loading dose orally.~Fentanyl, initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required.~Aspirin 500 mg loading dose orally (or intravenously).~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.~Primary PCI."
89324159|NCT01084889||symptomatic genital descensus|"Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention.~Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally."
89324160|NCT01084967||Healthy lean control group|"The healthy lean controls consisted of age-, sex- and geography-matched young volunteers, or golden standard lean controls from China Cardiometabolic Disease and Cancer Cohort Study (4C Study).~Healthy volunteers:~BMI:18.5-22.9kg/m2;~Age:14-30 years old;~To be proved normal by the examinations of liver and kidney function,blood lipids profile,FBG, PBG, fasting insulin and HbA1c.~Controls from 4C Study:~17.0≤BMI≤23.0kg/m2 and waist circumference <85cm for males and <80cm for females;~1.8≤LDL-c≤3.4mmol/l;~FBG<6.1, PBG<7.8;~HOMA-IR<2.5;~BP <140/90mmHg;~eGFR>60mL/(min·1.73 m2), ALT<40IU/L, AST<40IU/L;~Excluding the history of hyperthyroidism, digestive system diseases, malignant tumors, infectious diseases (hepatitis B) and other systemic wasting diseases; Severe dysfunction of heart, lung and kidney;~Not using antihypertensive, hypoglycemic and lipid-lowering drugs；~No history of smoking."
89324161|NCT01084967||obesity group|"BMI ≥30kg/m2;~Age:14-30 years old; obesity group 4000, lean healthy control group 4000"
89324162|NCT00099983|Active Comparator|Risperidone|1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
89324163|NCT00099983|Placebo Comparator|Sugar Pill|Placebo 1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
89324164|NCT00099359|Experimental|A|Standard of care ( Zidovudine only)
89324165|NCT00099359|Experimental|B|Standard of care (Zidovudine) plus Nevirapine
89324166|NCT00099359|Experimental|C|Standard of Care (Zidovudine) plus 2 weeks of Epivir and Nelfinavir
89324167|NCT00092495|Experimental|1|100% Formulation qHPV Vaccine
88811768|NCT01380743|Experimental|Cohort 1, Duvoglustat 50 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 50 milligram (mg) oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
89324168|NCT00092495|Experimental|2|60% Formulation qHPV Vaccine
89324169|NCT00092495|Experimental|3|40% Formulation qHPV Vaccine
89324170|NCT00092495|Experimental|4|20% Formulation qHPV Vaccine
89324171|NCT01085123|Experimental|1|PET 1: baseline, PET 2: 10 mg Zomig® Rapimelt, PET 3: 5 mg ZOMIG® Rapimelt, PET 4 2.5 mg ZOMIG® Rapimelt
89324172|NCT00092417|Experimental|1|Higher Potency Dose
89324173|NCT00092417|Experimental|2|Lower Potency Dose
89324174|NCT00091949|Active Comparator|Pioglitazone|pioglitazone
89324175|NCT00091949|Placebo Comparator|Placebo|inactive substance
89324176|NCT02258542|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
89324177|NCT02258542|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
89324178|NCT00091793|Experimental|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
89324179|NCT00091793|Placebo Comparator|Placebo|Placebo given day 1, month 6, month 12 and month 18
89324180|NCT00098813|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of unacceptable toxicity or disease progression.
89324181|NCT01081613||AUY922|Patients with estrogen receptor (ER) positive, hormone therapy refractory breast cancer.
89324182|NCT02227264|Experimental|Cinacalcet|"Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.~Second intervention: Parathyroid adenomectomy."
89324183|NCT02227342|Experimental|Fecal Microbiota Transplantation|serial Fecal Microbiota Transplantation
89324184|NCT02224378|Experimental|peep induced CVP|
89324185|NCT02224378|Active Comparator|passive leg raising(PLR)|
89324186|NCT02227420|Experimental|Anakinra|Anakinra 100mg s.c. x 5
89324187|NCT04772248||Patients treated with Tofacitinib|Real-World Evidence (RWE) and RCT-Duplicate
89324188|NCT04772248||Patients treated with TNF inhibitors|Real-World Evidence (RWE) and RCT-Duplicate
89324189|NCT00090857|Experimental|Letrozole|Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
89324190|NCT00090857|Placebo Comparator|Placebo|Participants in this arm received 1 tablet per day which contained the inert ingredients from the letrozole tablet, for a duration of 12 months; followed by an optional 5 years of letrozole.Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
89324191|NCT02227498|Experimental|Effect of Argus II on Functional Vision|All subjects enrolled in the study will be implanted with the Argus II Retinal Prosthesis. To evaluate safety and effectiveness of Argus II on visual function.
89324192|NCT01775644||Metastatic Colorectal Cancer Participants|"Administration of treatment will be as used in normal daily routine under local labelling in 4 subgroups- participants with liver and/or lung metastases, potentially resectable after a response to a systemic therapy and clinically operable; participants with tumor related symptoms, risks for complications or fast progression for whom quick proliferation control is needed; asymptomatic participants (indolent tumor) without the option of a metastases resection (no pressure for remission) for whom the aim of the therapy is proliferation control and participants without classification."
89324193|NCT02227576|Experimental|Romiplostim|Romiplostim lyophilized formulation is a white, solide cake that is reconstituted with sterile water for injection.
89324194|NCT04259086|Experimental|DAXI 40 U GL / 32 U FHL / 48 U LCL|DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL), & Lateral Canthal Lines (LCL)
89324195|NCT04243486|Experimental|UHE-105 Shampoo|UHE-105 Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
89324196|NCT04243486|Placebo Comparator|Vehicle Shampoo|Vehicle Shampoo applied topically once daily to psoriatic lesions on the scalp for up to four (4) weeks
89324197|NCT00090779|Active Comparator|IT arm|IT (immediate treatment) arm participants received emtricitabine/tenofovir disoproxil fumarate once daily and lopinavir/ritonavir twice daily
89324198|NCT00090779|No Intervention|DT arm|DT (deferred treatment) arm participants received no treatment
89324199|NCT01085279|Experimental|Non-ablative fractional laser|"In each patient, one side of the face was treated with non-ablative fractional laser in four-five sessions.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
89324200|NCT01085279|Active Comparator|Triple topical therapy|"In each patient, one side of the face was treated with triple topical therapy (Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1%) during 15 weeks.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
89324201|NCT02531243|Experimental|CALMS|12 session family therapy using multi-user biofeedback games
89324202|NCT01081691|Experimental|001|CNTO 5825 0.1 mg/kg single dose Intravenously (IV) or matching placebo
89324203|NCT01081691|Experimental|002|CNTO 5825 0.3 mg/kg single dose IV or matching placebo
89324204|NCT01081691|Experimental|003|CNTO 5825 1 mg/kg single dose IV or matching placebo
89324205|NCT01081691|Experimental|004|CNTO 5825 3 mg/kg single dose IV or matching placebo
89324206|NCT01081691|Experimental|005|CNTO 5825 10 mg/kg single dose IV or matching placebo
89324207|NCT01081691|Experimental|006|CNTO 5825 For atopic patient:10 mg/kg single IV dose or matching placebo
89324208|NCT01081691|Experimental|007|CNTO 5825 For atopic patient: 3 mg/kg single dose SC or matching placebo
89324209|NCT00098345|Experimental|Caprelsa (vandetanib) 300 mg|Daily oral dose of Caprelsa (vandetanib) 300mg
89324210|NCT03962387||Atopic Dermatitis|
89523458|NCT02872727||Air France Company's Employees Working|Observational cohort : Air France Company's Employees Working in the Marseilles and Paris Airports having Respiratoy health, biological investigations
89523459|NCT03374111|Experimental|Experimental group|15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd) ， taken once daily for 8 weeks
89324211|NCT03963713|Experimental|Stereotactic radiotherapy|"In this study, the metastases were treated with Stereotactic radiotherapy（SBRT）.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).~Stereotactic radiotherapy"
89324212|NCT03963713|Experimental|Conventionally-fractionated image- guided Intensity modulated|In this study, the metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
89324213|NCT03963635||Lyme Infected|Subjects presenting with suspected Lyme Disease
89324214|NCT03963635||Controls|Subjects with no known Lyme Disease, past or present
89324215|NCT01085669||VEPTR patients|Children treated with VEPTR Implants for severe spinal or thoracic deformities
89324216|NCT03962621|Active Comparator|2940 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
89324217|NCT03962621|Active Comparator|1064 nm group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 1064 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
89324218|NCT03962621|Experimental|Combined treatment group|Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm or 1064 nm laser (Fotona, Slovenia, EU) alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser. The patients received three treatment sessions with monthly intervals between each session.
89324219|NCT03962075|Other|laparoscopic paravaginal repair|"patient enrolled in this arm were offered laparoscopic paravaginal repair by Using a 10mm laparoscope, video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique All cases received diclofenac potassium 100 mg and meperidine hydrochloride 50 mg intramuscular with anesthesia recovery and 12 hours later second dose of diclofenac potassium was given. Also 40-60 mg Enoxaparin was given 6-12 hours postoperatively as subcutaneous injection.~Foley's catheter was removed 6 hours postoperative"
89324220|NCT01085747||Plastic stent|
89324221|NCT01085747||Covered SEMS|
89324222|NCT01081847|Active Comparator|Group A|Montanide ISA 720 Dose by peptide 50ug
89324223|NCT01081847|Active Comparator|Group B|Montanide ISA 51 Dose by peptide 50ug
89324224|NCT01081847|Active Comparator|Group C|Montanide ISA 720 Dose by peptide 100ug
89324225|NCT01081847|Active Comparator|Group D|Montanide ISA 51 Dose by peptide 100ug
89324226|NCT01081847|Placebo Comparator|Group E|Control Group. no peptide. Isotonic saline solution
89324227|NCT01081925||Congestive heart failure|Patients suffering from sudden worsening of congestive heart failure
89324228|NCT02224456|Experimental|Tenofovir|Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.
89324229|NCT02224534|Experimental|Ticagrelor and Clopidogrel.|The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
89324230|NCT02224534|Active Comparator|Clopidogrel|The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
89324231|NCT02227732|Other|New Indwelling Pleural Catheter|
89324232|NCT02227888|Experimental|N91115|Every 12 hour oral dosing of 50 mg N91115 for 14 days
89324233|NCT02227966|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
89324234|NCT02227966|Sham Comparator|sham-YBand (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
89324235|NCT02258776|Active Comparator|Pomegranate Extract|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate extract on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
89324236|NCT02258776|Active Comparator|Pomegranate Juice|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate juice on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
89324237|NCT02258776|Placebo Comparator|Placebo|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of placebo on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
89324238|NCT04174612|Active Comparator|Standard clinical treatment|"Patients will complete 3+7 + Midostaurin induction course."
89324239|NCT04174612|Experimental|Experimental treatment|"The experimental arm will provide 2 main modifications compared to standard:~i) immediate switch to intensified induction with high-doses Cytarabine (on days 5, 6 and 7 of induction) ii) early allocation to high-risk disease category to be refined according to ELN stratification and post induction MRD status"
89324240|NCT00097721|Experimental|E7389|
89324241|NCT02228044|Experimental|Prevention Program|This is a cognitive-behavioral substance abuse, suicide, and HIV prevention program delivered in a workshop format to adolescent participants and their parents/legal guardians.
89324242|NCT02228044|No Intervention|Assessment Only|
89324243|NCT01082003|Other|Permanent Implant|Trental and Vitamin E for 6 months
89324244|NCT01082003|Other|Tissue Expander|Trental and Vitamin E for 6 months
89324245|NCT03963791|Experimental|Eggshell powder gel|prepared from eggshell powder. applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
89324246|NCT03963791|Active Comparator|CPP-ACP crème|CPP-ACP crème (GC Tooth Mousse). applied on the tooth surfaces twice daily (after breakfast and before bedtime) after brushing the teeth.
89324247|NCT02232958|Experimental|Hyperbaric Oxygen treatment|administration of 100% Oxygen at 2 Atmospheres Absolute for 1 hour 1 daily, 5 days a week for 2 weeks
89324248|NCT01082237|Active Comparator|escitalopram|All subjects will receive escitalopram (ESC), brand name Lexapro (Forest Laboratories, Inc., New York) throughout the study. Dosing will start at 5 mg/d, be titrated to 10 mg after 4 days, and continue at 10 mg/d thereafter; an additional dose titration to 20 mg will be pursued at week 8 for those not significantly better (<50% improvement on IDS-30 at week 8 visit) and as tolerated.
89324249|NCT02228122|Experimental|Aquacel® Ag+ Extra|
89324250|NCT03963323|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
89324251|NCT03963323|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
89324252|NCT01082471|Experimental|M6G|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
89324253|NCT01082471|Active Comparator|Morphine|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
89324254|NCT03553498|Experimental|IV hydromorphone and IV acetaminophen|"1000 mg IV acetaminophen administered over 5-10 minutes~1 mg hydromorphone administered over 5-10 minutes"
89324255|NCT03553498|Placebo Comparator|IV hydromorphone and placebo|"100 ml IV normal saline administered over 5-10 minutes~1 mg hydromorphone administered over 5-10 minutes"
89324256|NCT01589393|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post injury to day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting day 6 post injury.
89324257|NCT01589393|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo 36-48 hours post traumatic injury until day 5, then standard of care (DVT prophylaxis with Enoxaparin) starting on Day 6.
89324258|NCT02228200|Experimental|Nurse-led care|Subjects in the nurse-led care arm received nurse-led care and routine care.
89324259|NCT02228200|Active Comparator|Routine care|Subjects in the routine care arm received routine care provided by the study hospital.
89324260|NCT01589471|Experimental|Botox-A|Intra-rectal (or intra-colic) injection of 100 U of Botox-A
89324261|NCT00096941|Experimental|Pertuzumab|Participants received the same dose of pertuzumab that they received in their parent Phase II trial, either 420 mg or 1050 mg, intravenously on Day 1 of every 3 week cycle until disease progression.
89324262|NCT03548116|Sham Comparator|Group 1|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
89324263|NCT03548116|Experimental|Group 2|Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
89324264|NCT03548116|Experimental|Group 3|Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
89324265|NCT03548116|Sham Comparator|Group 4|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
89324266|NCT03548116|Experimental|Group 5|Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
89324267|NCT03548116|Experimental|Group 6|Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
89324268|NCT03548116|Sham Comparator|Group 7|Individuals will receive sham non-imaging mode ultrasound with a disconnected probe (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
89324269|NCT02228278|Experimental|Group A|Group A will receive the typical clinic visits plus daily text messages
89324270|NCT02228278|Other|Group B|Group B will act as the control and will receive the typical clinic visits.
89324271|NCT00096785|Active Comparator|A1|
89324272|NCT00096785|Active Comparator|A2|
89324273|NCT04070170|Experimental|Low-level laser therapy and no orthodontic force|No orthodontic force. Laser is applied on the first day and the premolars is extracted after 24 hours
89324274|NCT04070170|Experimental|Low-level laser therapy and application of orthodontic force|Orthodontic force and Laser is applied on the first day and the premolars is extracted after 24 hours
89324275|NCT04070170|Active Comparator|Orthodontic force only|Orthodontic force is applied and the premolars is extracted after 24 hours, with no laser therapy
89324276|NCT04070170|Experimental|Low-level laser therapy and orthodontic force|Orthodontic force and Laser is applied and the orthodontic tooth movement is evaluated
89324277|NCT04070170|Active Comparator|Orthodontic force with no laser therapy|Orthodontic force is applied and the orthodontic tooth movement is evaluated, with no laser therapy
89324278|NCT01326767|Active Comparator|Paclitaxel dosing according to SmPC|
89324279|NCT01326767|Experimental|Individualized pharmacokinetically driven paclitaxel dosing|In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient. In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.
89324280|NCT02228434|Experimental|Tailored intervention group|"For the monitoring session, physical activity was assessed by accelerometer and dietary was assessed by diary. Based on the monitoring information, the individual tailored prescription, including the normative feedback and process feedback, were formed and delivered to children and parents. Children were encouraged to modify the behaviors according to the prescription.~Then, next monitoring circle was followed. In total, 7 monitoring round were completed."
89324281|NCT02228434|Experimental|Happy 10 exercise group|All the schools participating in this group were encouraged to take two Happy 10 sessions on each school day.
89324282|NCT02228434|Experimental|Nutrition education group|The nutrition intervention was mainly conducted based on the nutrition knowledge through health education lectures given by researchers. The lectures were given for eight times to students and twice to parents. Each lecture session lasted no less than 40 min.
89324283|NCT02228434|No Intervention|Control group|Receive no intervention
89324284|NCT03963479|Active Comparator|Magnesium-Vitamin B6|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
89324285|NCT03963479|Placebo Comparator|Placebo|Magnesium (50mg) for ages 1-3 years (100mg) for ages 4-8 years (200mg) for ages 9-12 years Vitamin B6 (25mg) for ages 1-3 years (50mg) for ages 4-8 years (100mg) for ages 9-12years
89324286|NCT02228512|Active Comparator|1|Treatment naive PEL (main cohort)
89324287|NCT02228512|Active Comparator|2|Treatment na(SqrRoot) ve large cell lymphoma arising in KSHV-MCD
89324288|NCT02228512|Active Comparator|3|Previously treated KSHV-NHL
89324289|NCT01082627|Experimental|Somatostatin+common daily practice|
89324290|NCT01082627|Placebo Comparator|common daily practice|
89324291|NCT03515044|Experimental|Cohort 1 40 mg Rifaximin SSD once daily|40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
89324292|NCT03515044|Experimental|Cohort 2 40 mg Rifaximin SSD twice daily|40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
89324293|NCT03515044|Experimental|Cohort 3 80 mg Rifaximin SSD once daily|80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
89324294|NCT03515044|Experimental|Cohort 4 80 mg Rifaximin SSD twice daiy|80 mg Rifaximin sustained extended release (SER) rifaximin SSD twice daily (BID) and lactulose
89324295|NCT03515044|Experimental|Cohort 5 Placebo twice daily|SSD placebo twice daily (BID) and lactulose
89324296|NCT01082705|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
89324297|NCT01082705|Experimental|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine administered once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
89324298|NCT03963557||Healthy participants|BMI 5th percentile to less than the 85th percentile
89324299|NCT03963557||Overweight/Obese participants|BMI 85th percentile or more
89324300|NCT01582997|Experimental|Dose Escalation Part|Dose escalation will be conducted to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 . The dose may be escalated to the overseas recommended phase III dose.
89324301|NCT02228746|Experimental|Alpha-galacto-oliosaccharides|
89324302|NCT02228746|Placebo Comparator|Placebo|
89324303|NCT01090349|Experimental|Direct Alerts ON|Direct Alerts in implantable device were turned on
89324304|NCT01090349|Active Comparator|Direct Alerts OFF|Direct Alerts in implantable device were turned off
89324305|NCT01090505|Experimental|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2|Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy
89324306|NCT01090505|No Intervention|surgery|Procedure/Surgery: Gastrectomy with D2 dissection
89324307|NCT01085981|Active Comparator|GRAS ingredients cream|"The study will be placebo controlled double blind study which will require two office visits after informed consent and sensitivity testing done with the study cream on the day of recruitment.~On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit Then placebo or active cream will be applied and the pt restudied. the same process is repeated another day with the second arm cream."
89324308|NCT01085981|Placebo Comparator|placebo cream then doppler study|
89324309|NCT03950752|Experimental|Bagels with optimized composition in fatty acids|Participants will consume three bagels with an optimized composition in fatty acids and without oil palm in only one day.
89324310|NCT03950752|Active Comparator|Bagels with conventional composition in fatty acids|Participants will consume three bagels with a conventional composition in fatty acids in only one day.
89324311|NCT02258854|Experimental|Dose 2 gevokizumab|
89324312|NCT02031562|Active Comparator|Chiropractic|Chiropractic
89324313|NCT02031562|Active Comparator|Physical therapy|Physical therapy
89324314|NCT03938038|Active Comparator|Serial ultrasound assessments for GDT|
89324315|NCT03938038|Active Comparator|Usual care|
89324316|NCT03345082|Experimental|0.5 mg ranibizumab with 2.0 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
89324317|NCT03345082|Experimental|0.5 mg ranibizumab with 0.5 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
89324318|NCT03345082|Sham Comparator|0.5 mg ranibizumab with sham|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
89324319|NCT02228902|Active Comparator|ferrous fumarate|12 patients receive ferrous fumarate, 12 patients receive ferrous gluconate
89324320|NCT02228902|Active Comparator|ferrous gluconate|12 patients receive ferrous fumarate and 12 patients receive ferrous gluconate
89324321|NCT03313882||donor|donor: normal heart samples from donor
89324322|NCT03313882||ICM|ICM: heart samples with ischemic cardiomyopathy
89324323|NCT03313882||NICM|NICM: heart samples with non-ischemic cardiomyopathy
89324324|NCT03288454|Experimental|Cohort 1|ciraparantag (60 mg)
89324325|NCT03288454|Experimental|Cohort 2|ciraparantag (120 mg)
89324326|NCT03288454|Experimental|Cohort 3|ciraparantag (30 mg)
89324327|NCT03288454|Placebo Comparator|Placebo|placebo (saline for injection)
89324328|NCT03285178|Experimental|IW-1701 (Olinciguat) 2 mg|After a single-blind treatment with placebo once daily (QD) for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received 1 mg olinciguat QD Week 1 and 2 mg olinciguat QD Weeks 2-12 under the original protocol, Amendment 1, Amendment 2, and Amendment 3.
89324329|NCT03285178|Experimental|IW-1701 (Olinciguat) 4 mg|After a single-blind treatment with placebo QD for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received 2 mg olinciguat QD Week 1 and 4 mg olinciguat QD Weeks 2-12 under the original protocol, Amendment 1, Amendment 2, and Amendment 3.
89324330|NCT03285178|Experimental|IW-1701 (Olinciguat) 6 mg|After a single-blind treatment with placebo QD for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received 3 mg olinciguat QD Week 1 and 6 mg olinciguat QD Weeks 2-12 under the original protocol, Amendment 1, Amendment 2, and Amendment 3.
89324331|NCT03285178|Experimental|IW-1701 (Olinciguat) 18 mg|After a single-blind treatment with placebo QD for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received 6 mg olinciguat QD Days 1-7, 12 mg olinciguat QD Weeks 1-3, and 18 mg olinciguat QD Weeks 4-12 under protocol Amendment 4 and later.
89324332|NCT03285178|Placebo Comparator|Placebo|After a single-blind treatment with placebo QD for 14 to 17 days of the Screening period and before the first dose of double-blind study drug on Day 1, participants received placebo treatment QD for 12 weeks.
89324333|NCT00090545|Experimental|First Stage - disease progression|"The first stage was to rule out the probability of 4 month progression free survival.~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
89324334|NCT00090545|Experimental|Second Stage - increased accrual|"Due to prostatic specific antigen and radiographic discordance during the first stage, the protocol was amended to allow accrual to a second stage.~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
89324335|NCT02829814|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
89324336|NCT02829814|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
89324337|NCT03916042|Experimental|Reproxalap (0.25% Novel Formulation) QID to BID|
89324338|NCT03916042|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
89324339|NCT02229058|Experimental|Albumin Bound Paclitaxel plus S-1|Abraxane 120 mg/m2, D1,D8;S-1 40~60mg QD D1-D14,every 3 weeks until disease progress or intolerable toxicity.
89324340|NCT03249376|Experimental|Lumateperone|Lumateperone 42 mg (ITI-007 60 mg tosylate) administered once daily every evening for 6 weeks
89324341|NCT03249376|Placebo Comparator|Placebo|Placebo administered once daily every evening for 6 weeks
89324342|NCT03224650||Surgical|Patients treated surgically for spinal metastases
89324343|NCT03224650||Non-operative|Patients treated non-operatively for spinal metastases
89324344|NCT03224650||Expectant|Patients receiving no treatment for spinal metastases
89324345|NCT03887026|Experimental|NKT Low Dose|NKT single dose - Low
89324346|NCT03887026|Experimental|NKT High Dose|NKT single dose - High
89324347|NCT03887026|Placebo Comparator|Placebo|Placebo single dose
89324348|NCT02229292|Active Comparator|Tranexamic acid|The active comparator consists of an intravenously administered bolus injection of 10ml of 100mg/ml tranexamic (1g in total) given as a single dose, after the onset of anesthesia, prior to surgery.
89324349|NCT02229292|Placebo Comparator|Saline|The placebo consists of an intravenously administered bolus injection of 10 ml of 9mg/ml sodium chloride given as a single dose after the onset of anesthesia, prior to surgery.
89324350|NCT02229370||ECAA|all patients diagnosed with an extracranial carotid artery aneurysm
89324351|NCT02229448||IgG4 UKN diagnosis|who ever been found with IgG4 sub class in blood sample or in his byposy
89324352|NCT02233114|Experimental|Yogic exercises|Yogic exercises for lung disorders
89324353|NCT02233114|Active Comparator|physiotherapy|Physiotherapy during the yogic exercises
89324354|NCT02229526|Active Comparator|Low dose fish oil|
89324355|NCT02229526|Placebo Comparator|Low dose olive oil|
89324356|NCT02229526|Experimental|High dose fish oil|
89324357|NCT02229526|Placebo Comparator|High dose olive oil|
89324358|NCT02229604|Experimental|EA group|Patients choose this group will receive EA as a combination. Beside of EA, participants could receive oral medicine as the same as that of the drug group. The EA regimen has two point formulae, i.e. A (BL33) and B (ST25, EX-CA1 and RN4). The two formulae will be used alternatively. One session will last for 20 minutes, 5 sessions per week for the first 4 weeks and 3 sessions per week later (44 sessions in all).
89324359|NCT02229604|Active Comparator|drug group|Hormone replacement therapy (HRT), DHEA and herb decoction are allowed to be used for this group. Treatment course is not fixed. Immunosuppressive agents are not allowed.
89324360|NCT00070109|Experimental|Trabectedin 1.3 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. A cohort of 6 patients will be enrolled at the 1.3 mg/m2 dose level.
89324361|NCT00070109|Experimental|Trabectedin 1.5 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Six toxicity-evaluable patients are assigned this treatment.
89324362|NCT00070109|Experimental|Trabectedin at 1.5 mg/m2 to assess efficacy in Ewing sarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89324363|NCT00070109|Experimental|Trabectedin at 1.5 mg/m2 - assess efficacy in rhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89324364|NCT00070109|Experimental|Trabectedin 1.5 mg/m2 - assess efficacy in nonrhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
89324365|NCT01086059||Cohort 1 - Exposure cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have used adalimumab in the first trimester of pregnancy for any length of time from the date of conception.
89324366|NCT01086059||Cohort 2 - Matched Diseased Comparison Cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have not used adalimumab or any TNF antagonist in pregnancy.
89324367|NCT01086059||Cohort 3-Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used adalimumab or any TNF antagonist at any time in pregnancy nor have they been exposed to any known human teratogen during pregnancy.
89324368|NCT01086059||Cohort 4 - Registry Group|Pregnant women who have used adalimumab for any length of time following the first day of the last menstrual period until the end of pregnancy who do not meet Cohort 1 inclusionary criteria.
89324369|NCT00090233|Experimental|1|RotaTeq
89324370|NCT00090233|Placebo Comparator|2|Placebo
89324371|NCT00069953|Experimental|ChemoRT and selective surgery|Induction therapy of fluorouracil, cisplatin, paclitaxel, and pegfilgrastim OR filgrastim, then chemoradiotherapy of concurrent cisplatin and fluorouracil with external beam radiotherapy (RT), followed by selective salvage therapy.
89324372|NCT01090583||Cesarean Delivery Patients|
89324373|NCT03771040|Experimental|Masitinib (titration to 6.0 mg/kg/day)|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
89324374|NCT03771040|Placebo Comparator|Placebo|Participants receive matched placebo
89324375|NCT02229682|Experimental|Mild-dose IMRT|"Experimental: Mild-dose of 46Gy with IMRT~Drug:~gemcitabine：1250mg/m2 (iv drip) on days 1, oxaliplatin: 85 mg/m2 (iv drip) on day 1, and pegaspargase: 2500 IU/m2 (intramuscular injection) on day 1. Cycle is repeated every 14 days~IMRT： IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions."
89324376|NCT02807428|Experimental|AYX1 Injection 660 mg/6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery.
89324377|NCT02807428|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
89324378|NCT02750800||Adalimumab and AbbVie Care 2.0|Adalimumab administered via subcutaneous (SC) injection for 12 months according to the approved EMA label and Hungarian financial protocols and supportive services via the AbbVie Care 2.0 patient support program
89324379|NCT05633056|No Intervention|Enhanced standard of care|"Care from trained and supported physicians, nurses, and social workers who have received repeated trainings from study staff on medical and behavioral aspects of DR-TB HIV care, which will be documented in terms of date, attendance, and content~All participants who receive care as inpatients will receive an orientation to DR-TB treatment in form of a group session designed to impart key behavioral information and health knowledge about the disease, treatment, and skills to obtain optimal outcome.~Discharge counselling session will be conducted prior to discharge.~Study participants will complete study assessments at baseline (enrollment) and monthly for the first six months."
89324380|NCT05633056|Other|Psychosocial support|"In addition to Arm 1~Participants will participate in individual counseling aligned with their monthly clinic visit.~Individual counseling will use motivational interviewing (MI) techniques, based on the 4-part engaging, focusing, evoking and planning approach for each participant.~Home visits will be conducted (if warranted/consented for by the participant) by the same trained counselors known to patients.~Adherence support groups will be facilitated by counselors trained in group facilitation methods; group curriculum will include 6 sessions (monthly, gender specific, structured adherence support groups) that focus on practical topics.~Discharge planning (if inpatient)~Community treatment planning (if outpatient)"
89324381|NCT05633056|Other|mHealth|"In addition to Arm 1~Participants will receive x 2 portable Wisepill devices. (x1 for MDR-TB treatment and x1 for ART).~A Wisepill device is an RT2000 cellular-enabled electronic pill boxes using 2G/3G cellular network.~Participants will select a text message reminder from a guided menu of choices and receive a weekly text message encouraging adherence.~Participants will receive a study call to support regular adherence. Participants will be assessed weekly. Less than 85% observed/expected doses will be considered at risk for non-adherence and the intervention will be increased."
89324382|NCT05633056|Other|mHealth and Psychosocial support|Combination of Arm 2 and Arm 3.
89324383|NCT02258932||Continuous subcutaneous insulin infusion|This group will consist of patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
89324384|NCT02229760|Experimental|TPV/r (Tipranavir co-administered with low dose ritonavir)|
89324385|NCT02229838|Experimental|BIBB 1464 MS single rising dose fed|
89324386|NCT02229838|Experimental|BIBB 1464 MS tablet fasted|
89324387|NCT02229838|Active Comparator|BIBB 1464 MS solution fasted|
89324388|NCT02229838|Placebo Comparator|BIBB 1464 MS placebo|
89324389|NCT02229994||Adults patients with chronic respiratory diseases|"- 200 adult patients with chronic respiratory diseases will be studied longitudinally and transversely (follow-up: 6 months) in 12 centres.~Sample 1 (n=110 patients) with COPD~Sample 2 (n=30 patients) with Diffuse interstitial lung diseases~Sample 3 (n=30 patients) with Pulmonary Arterial Hypertension primary or secondary (post embolic .....).~Sample 4 (n=30 patients) Adult with Cystic fibrosis"
89324390|NCT03688906||Cohort A|"Blood and stool specimen collection.~Study samples must be collected prior to any treatment."
89324391|NCT03688906||Cohort B|"Blood and stool specimen collection.~Samples must be collected prior to performing bowel preparation for the colonoscopy."
89324392|NCT03688906||Cohort C|"Blood and stool specimen collection.~Study samples must be collected prior to any treatment."
89324393|NCT05615506|Experimental|patients|suction diathermy adenoidectomy
89324394|NCT01329562|Active Comparator|Treximet|"Subjects randomized to Group A will be provided with 1 tablet of Treximet to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
89324395|NCT01329562|Placebo Comparator|Placebo|"Subjects randomized to Group B will be provided with 1 tablet of placebo to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
89324396|NCT00069641|Experimental|Idursulfase weekly (0.5 mg/kg)|
89324397|NCT00069641|Experimental|Idursulfase every other week (0.5 mg/kg)|
89324398|NCT00069641|Placebo Comparator|Placebo|
89324399|NCT01086293||Patients exposed to Saxagliptin|
89324400|NCT01086293||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
89324401|NCT02230228|Experimental|ALK-001 capsules|
89324402|NCT01090661|Experimental|mipomersen IV (supra-therapeutic dose)|200 mg of mipomersen IV / placebo SC
89324403|NCT01090661|Experimental|mipomersen SC (therapeutic dose)|200 mg of mipomersen SC / placebo IV
89324404|NCT01090661|Active Comparator|moxifloxacin IV|400 mg of moxifloxacin IV / placebo SC
89324405|NCT01090661|Placebo Comparator|placebo|Placebo IV / placebo SC
89324406|NCT02230462|Experimental|Viewing of cancer excision defect|Patients in this arm of the study will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
89324407|NCT02230462|No Intervention|No viewing of cancer excision defect|Patients in this arm of the study will not be invited to view their cancer excision defect prior to its reconstruction.
89324408|NCT01086449|Experimental|Group A|
89324409|NCT02233348||ASD group|Subjects with DSM-IV ASD diagnosis
89324410|NCT02233348||Control group|Controls without lifetime ASD or a family history of ASD
89324411|NCT05585476|Experimental|Laser + Regenerative topical treatment|"The treatments used in this arm are the following:~º Microfractionated laser treatment of C02, through the AcupulseDuo generator of the company Lumenis®. The treatment regimen would consist of three sessions in total with periodicity of 4 weeks, between the first and the second, and 6 weeks between the second and third. The application of laser energy will be carried out by vaginal and vulvar terminals. The dose applied will consist of monopulse shots distributed throughout the vaginal mucosa and vulvar skin of 10 mJ of energy and at a density of 10%.~nd Topical treatment: It consists of the application of XCM® intim of the company Mucosa Innovations. The route of administration would be vulvo-vaginal. The dose applied would be 2 ml of total product every 12 hours during 36 months."
89324412|NCT05585476|Active Comparator|Regenerative topical treatment|In this arm, only the regenerative treatment of XCM® intim of the company Mucosa Innovations will be used. The route of administration would be vulvo-vaginal. The dose applied would be 2 ml of total product every 12 hours. The total duration of treatment would be 36 months.
89324413|NCT05563480|Experimental|TQB2618+Pempulimab+Chemotherapy|Induction therapy: TQB2618 injection + Penpulimab injection + Gemcitabine hydrochloride injection + cisplatin injection; Maintenance treatment: TQB2618 injection +Penpulimab injection; 21 days as a treatment cycle.
89324414|NCT05563480|Active Comparator|Penpulimab + Chemotherapy|Induction therapy: Penpulimab injection + Gemcitabine hydrochloride injection + cisplatin injection; Maintenance treatment: Penpulimab injection; 21 days as a treatment cycle.
89324415|NCT05563480|Experimental|TQB2618+Pempulimab|TQB2618 injection combined with Penpulimab injection, 21 days as a treatment cycle.
89324416|NCT05546398||Physicians|Office-based cardiologists (OBCs) and lipid management specialists (LMSs) who are qualified for study participation regarding experience in lipid management therapy and treating a sufficient number of patients.
89324417|NCT05546398||High and Very High Cardiovascular Patients|Patients at high and very high cardiovascular risk as assessed by the office-based cardiologists and lipid management specialists with hypercholesterolemia or mixed dyslipidemia who received a prescription of bempedoic acid 180 mg fixed dose combination with ezetimibe 10 mg (FDC).
89324418|NCT05509348|Experimental|Phase 1: ADAPT Workshop|2 - day long in-person workshops (7 hours each day). Workshops are 2 weeks apart.
89324419|NCT05509348|Experimental|Phase 1: ADAPT Online|3 weeks are given to complete 12 online modules using a secure website. Online modules include skill video, practice video, summary sheets, mindfulness audio and exercise video, printable handouts and motivation questionnaire.
89324420|NCT05509348|Experimental|Phase 2: ADAPT Group|3 - 2 hour long in-person group sessions. Group sessions are consecutive weeks.
89324421|NCT05509348|Experimental|Phase 2: ADAPT Individual|3 - 1 1/2 hour in-person individual sessions. Sessions are consecutive weeks.
89324422|NCT05485636||degenerative lumbar scoliosis postoperative group|"This group contains patients who have undergone spinal surgery for degenerative lumbar scoliosis.~No interventions are designed to be administered."
89324423|NCT05472766|Active Comparator|Early resumption of anticoagulation|The standard of care DOAC at appropriate standard dose assigned by the MRP will start at day 30 +/- 7 after diagnosis of acute or chronic subdural hematoma.
89324424|NCT05472766|Active Comparator|Delayed resumption of anticoagulation|The standard of care DOAC at appropriate standard dose assigned by the MRP will start at day 90 +/- 14 after diagnosis of acute or chronic subdural hematoma.
89324425|NCT05461924||long-segment HSCR|Aganglionosis of non-rectosigmoid HSCR can extend to the descending colon, transverse colon, ascending colon, but not to the terminal ileum
89324426|NCT05461924||rectosigmoid HSCR|Aganglionosis confined to the rectosigmoid
89324427|NCT03653026|Experimental|Upadacitinib 45 mg|Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 additional weeks in the open-label extension period.
89324428|NCT03653026|Placebo Comparator|Placebo|Participants received placebo matching to upadacitinib once daily for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 weeks in the open-label extension period.
89523460|NCT03374111|Placebo Comparator|Control group|a Simulate Agent of Colla corii asini granule， similar in size, shape，color and taste to Colla corii asini granule, taken once daily for 8 weeks
89324429|NCT02232568|Experimental|Feedback Arm|Orthopedic surgeons in the Feedback Arm will receive monthly reports providing individualized data on compliance with the FOCUS trial RBC transfusion guideline (pretransfusion Hb <8 g/dL for hip surgery patients in the postoperative period.) Feedback data will be anonymized, but surgeons will be able to see their own data in comparison with their peers.
89324430|NCT02232568|No Intervention|Control Arm|Orthopedic surgeons in the Control Arm will not receive any feedback on their use of RBC transfusion in hip surgery patients.
89324431|NCT02232724|Experimental|Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
89324432|NCT01329328|No Intervention|CONTROL|NO VIBRATION EXERCISE
89324433|NCT01329328|Experimental|VIBRATION EXERCISE|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIOS, MILAN, ITALY
89324434|NCT01329328|Experimental|VIBRATION EXERCISE PLUS RADIOFREQUENCY ADMINISTRATION|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIO, MILAN, ITALY PLUS LOCAL ADMINISTRATION OF RADIOFREQUENCY
89324435|NCT02234440|Experimental|Metformin|Metformin- 500 mg once daily as a starting dose, can be escalated to 2 g/day to control diabetes
89324436|NCT02234440|Active Comparator|Insulin|
89324437|NCT02234518|Experimental|High quantity fiber food product|
89324438|NCT02234518|Experimental|Low quantity fiber food product|
89324439|NCT02234518|Placebo Comparator|Placebo|
89324440|NCT02230618||Ryzodeg™|
89324441|NCT04852354||Pediatric tumor patients undergoing neurosurgery|Samples of tumor tissue, blood, CSF, saliva, skull, and dura will be taken during neurosurgery from tumor patients meeting the inclusion criteria.
89324442|NCT04852354||Parents of tumor patients|Saliva samples will be taken from parents of pediatric tumor patients meeting the inclusion criteria.
89324443|NCT04852354||Non-tumor patients|Blood and CSF samples will be taken from non-tumor pediatric patients meeting the inclusion criteria.
89324444|NCT02230774||medical staff|Nurses and doctors oncall
89324445|NCT01337986|Active Comparator|Group B: Dalfampridine First|Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
89324446|NCT01337986|Active Comparator|Group A: Dalfampridine Second|Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks
89324447|NCT02262520|Experimental|Treatment A: Digoxin|Digoxin tablet by mouth on specified days
89324448|NCT02262520|Experimental|Treatment B: Apixaban and Digoxin|Apixaban and Digoxin tablets by mouth on specified days
89324449|NCT04626310|Experimental|Dialectical behavior therapy - emotion regulation skills training|Dialectical behavior therapy - emotion regulation skills training
89324450|NCT04626310|Experimental|Dialectical behavior therapy - interpersonal effectiveness skills training|Dialectical behavior therapy - interpersonal effectiveness skills training
89324451|NCT04626310|Active Comparator|Non-skills-oriented interpersonal psychotherapy group|Non-skills-oriented interpersonal psychotherapy group
89324452|NCT04623268||Adult offspring|Adult female and male offspring to AAA patients 45-80 years of age at inclusion Children to detected AAA patients. Found in the Multigeneration registry
89324453|NCT04623268||Control group|Matched women and men, without parents with AAA. Matched in the Swedish Multigeneration registry
89324454|NCT05255926|Experimental|68Ga-pentixafor and 18F-FDG PET/CT|Investigators recruit patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies. Then patients undergo 68Ga-pentixafor and 18F-FDG PET/CT imaging in one week.
89324455|NCT02262598|Experimental|Telmisartan/HCTZ fixed dose|
89324456|NCT02262598|Active Comparator|Telmisartan and HCTZ monocomponents|
89324457|NCT02603614|Experimental|Cenderitide-Placebo|"Infusion Period A: Cenderitide Infusion Period B: Placebo~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
89324458|NCT02603614|Experimental|Placebo-Cenderitide|"Infusion Period A: Placebo Infusion Period B: Cenderitide~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
89324459|NCT02234674|Active Comparator|Standard intensive CDP|This arm is the controlled group ; patients in that group will undergo a current practice performed in the lymphology unit.
89324460|NCT02234674|Experimental|Stendo group|This arm contitutes the group where the Stendo pulsating suit sessions are investigated in the frame of the CDP in replacement of the pressotherapy sessions.
89324461|NCT01337674|Experimental|Panel A: MK-4618 + Met → PBO + Met|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
89324462|NCT01337674|Experimental|Panel A: PBO + Met → MK-4618 + Met|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
89324463|NCT01337674|Experimental|Panel B: MK-4618 + Amlo → PBO + Amlo|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
89324464|NCT01337674|Experimental|Panel B: PBO + Amlo → MK-4618 + Amlo|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
89324465|NCT02600494|Experimental|40 mg ITI-007 (Lumateperone)|40 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
89324466|NCT02600494|Experimental|60 mg ITI-007 (Lumateperone)|60 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
89324467|NCT02600494|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
89324468|NCT02262676||Rivaroxaban|Patients with Atrial fibrillation treated with Rivaroxaban
89324469|NCT02234830|Experimental|Exoseal closure device|Closure device for femoral artery access closure
89324470|NCT02234830|Active Comparator|Angio-Seal closure device|Closure device for femoral artery access closure
89324471|NCT02233582|Experimental|ibuprofen plus ascent to high altitude|subjects randomized to this arm will take ibuprofen 200 mg 3 times daily during ascent and at altitude.
89324472|NCT02233582|Placebo Comparator|sugar pill plus ascent to high altitude|subjects randomized to this arm will receive the placebo
89324473|NCT02580370|Experimental|Dose A|Botulinum toxin type A
89324474|NCT02580370|Placebo Comparator|Dose B|Placebo comparator
89324475|NCT02233660|Experimental|Physical Therapy Group.|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
89324476|NCT02233660|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
89324477|NCT02233816|Experimental|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
89324478|NCT02233816|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
89324479|NCT02233816|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
89324480|NCT02233816|Placebo Comparator|Placebo|A single dose of Placebo
89324481|NCT02234908|Experimental|Contacts|Contacts are the household contacts of confirmed TB and drug-resistant TB patients.
89324482|NCT02234908|Other|Index|Index subjects are confirmed TB and drug-resistant TB patients who distribute referral cards to their household contacts.
89324483|NCT02234986|Experimental|ENMD-2076|ENMD-2076, oral capsule Once daily dose 250 mg/day
89324484|NCT02259556|Experimental|anti-CD30 CAR T cells|Patients receive CART30 cell infusions with an escalation dose.
89324485|NCT02259634|Experimental|Patient Navigation|Intensive Patient Navigation with Motivational Interviewing and Health Education for 8 months 18 month follow-up
89324486|NCT02259634|No Intervention|Treatment as Usual|Case Management and Medical Care as provided by the Coming Home Program at Mount Sinai St. Luke's Institute of Advanced Medicine, Morningside Clinic
89324487|NCT02750410|Experimental|Dulaglutide|Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
89324488|NCT02750410|Placebo Comparator|Placebo|Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.
89324489|NCT02750332|Experimental|Treatment Sequence A (Fed) - B (Fasted)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89324490|NCT02750332|Experimental|Treatment Sequence B (Fasted) - A (Fed)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
89324491|NCT02233894||Chronic obstructive pulmonary disease patients|
89324492|NCT02233972|Experimental|Midazolam and Ginkgolides Meglumine Injection|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Ginkgolides Meglumine Injection: 25mg, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
89324493|NCT02233972|Placebo Comparator|Midazolam and placebo|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Placebo: Sodium Chloride Injection, 250 ml, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
89324494|NCT02234050|Experimental|Trabectedin|Patient will be treated with trabectedin
89324495|NCT02234050|Other|Local standard of care|Treatment in the control arm is left to the discretion of the investigator, according to the local standard of care.
89324496|NCT01337596|Experimental|Single dose 1 milligram (mg) LY2951742|Administered single subcutaneous injection
89324497|NCT01337596|Experimental|Single dose 5 mg LY2951742|Administered single subcutaneous injection
89324498|NCT01337596|Experimental|Single dose 25 mg LY2951742|Administered single subcutaneous injection
89324499|NCT01337596|Experimental|Single dose 75 mg LY2951742|Administered single subcutaneous injection
89324500|NCT01337596|Experimental|Single dose 200 mg LY2951742|Administered single subcutaneous injection
89324501|NCT01337596|Experimental|Single dose 600 mg LY2951742|Administered single subcutaneous injection
89324502|NCT01337596|Placebo Comparator|Single dose placebo|Administered single subcutaneous injection
89324503|NCT01337596|Placebo Comparator|Multiple dose placebo|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
89324504|NCT01337596|Experimental|150 mg LY2951742|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
89324505|NCT02234206|Experimental|Chandrakanthi choornam|"Chandrakanthi Choornam (CKC) - 12gm in milk~OD dose; Oral route~3 Months - duration~Intervention Drug: Chandrakanthi Choornam (CKC)"
89324506|NCT02235220|Experimental|Composite resin restoration|A canine guidance is reestablished by additive composite resin restorations of the canine cusp.
89324507|NCT02262910|Experimental|ES414|Cohorts 1-3 of the dose escalation stage of the study (Stage 1) will test weekly doses of 0.2 mcg/kg to 2 mcg/kg. Cohorts 4-9 of the dose escalation stage of the study (Stage 1) will test continuous infusion at flat doses of 25 mcg to 300 mcg per day delivered continuously over 24 hours. The maximum tolerated dose from Stage 1 of the study will be further examined in Stage 2. Patients in cohorts 1-3 will receive ES414 weekly via intravenous (IV) infusion during the first three 28-day cycles and then on Day 1 and 15 of each subsequent cycle until disease progression, intolerable toxicity occurs, or the patient withdraws consent. Patients in cohorts 4-9 will receive ES414 as a continuous IV infusion for 6 months until disease progression, intolerable toxicity occurs, or the patient withdraws consent.
89324508|NCT05155696|Experimental|Kefir probiotic drink|Daily kefir for 6 weeks.
89324509|NCT05155696|Placebo Comparator|placebo comparator|Daily non-fermented dairy based equivalent drink for 6 weeks.
89324510|NCT02263066||Group 1|Chinese hemophilia A pediatric patients with medical records who had accepted regular prophylaxis, totally/partially with rFⅧ between Nov. 1st 2007 and May 31st 2013
89324511|NCT05102344|Active Comparator|Psychosocial Treatment as Usual|Participants assigned to the active comparator arm will receive active non-pharmacological treatment utilizing behavioral social skills training strategies previously found to be effective in reducing symptoms of ADHD and improving social skills for children with ADHD
89324512|NCT05102344|Experimental|Animal Assisted Intervention|Participants assigned to the experimental arm will receive active non-pharmacological treatment utilizing behavioral social skills training strategies previously found to be effective in reducing symptoms of ADHD and improving social skills for children with ADHD accompanied by live therapy dogs
89324513|NCT02235376||critical care|
89324514|NCT02263144||histologically-verified <10mm polyps|histologically-verified <10mm polyps, analyzed by virtual chromo-endoscopy using FICE Fujifilm Technology
89324515|NCT02554396|Experimental|PRX-100|PRX-100 ophthalmic solution
89324516|NCT02554396|Placebo Comparator|Placebo|saline solution
89324517|NCT02235532|Experimental|Foramen Herbal Aloe toothpaste|test group was asked to brush the teeth with Foramen Herbal Aloe toothpaste for 30 days once a day.
89324518|NCT02235532|Active Comparator|use of fluoride toothpaste (signal)|use of a fluoride toothpaste (signal) in control group once a day for 30 days .
89324519|NCT00069095|Experimental|XELOX (oxaliplatin+capecitabine)|Patients in the 2-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
89324520|NCT00069095|Experimental|XELOX (oxaliplatin+capecitabine) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
89324521|NCT00069095|Active Comparator|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)|Patients in the 2-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
89324522|NCT00069095|Active Comparator|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.
89324523|NCT00086411|Experimental|1: Bup+MM|bupropion and MM counseling with placebo patch
89324524|NCT00086411|Experimental|2 Bup+Mayo|bupropion and Mayo counseling with placebo patch.
89324525|NCT00086411|Placebo Comparator|3 Patch+MM|patch and MM counseling with placebo pills
89324526|NCT00086411|Experimental|4 Patch+Mayo|patch and Mayo counseling with placebo pills
89324527|NCT03961997|Other|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
89324528|NCT03961997|Other|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
89324529|NCT03961997|Other|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
89324530|NCT01086527|Experimental|SLCO2B1{NM_007256.2}:c.[935G>A] + [=]|Individuals in this group will be homozygous for SLCO2B1{NM_007256.2}:c.[935G>A].
89324531|NCT01086683|Experimental|Intervention group|
89324532|NCT01086683|No Intervention|Control group|Wait list control group: The control group received usual care including clinical control visits but no systematic rehabilitation activities.
89324533|NCT00068237|Experimental|Surgery + Transfer + Radiation|Submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes followed by post-operative radiation therapy.
89324534|NCT01086839|Experimental|sodium chloride 6%|"Cross-Over! experimental (days 1 - 28), then Wash-Out (28 days),then placebo comparator (days 57 - 85)."
89324535|NCT01086839|Placebo Comparator|sodium chloride 0,9%|"Cross-Over! placebo comparator (days 1 - 28), then Wash-Out (28 days),then experimental (days 57 - 85)."
89324536|NCT01090817|Experimental|Mesenchymal stromal cells|Mesenchymal stromal cells administered weekly for 4 weeks
89324537|NCT03956381||THR with OPS system-TriFit TS/Trinity combination|Hip prosthesis combination: TriFit TS stem/ Trinity cup implanted by Surgeon 1 via a posterolateral approach according to their standard of practice.
89324538|NCT03956381||THR with OPS system-MetaFix/Trinity combination|Hip prosthesis combination: MetaFix stem/ Trinity cup implanted by Surgeon 2 via a direct anterior approach according to their standard of practice.
89324539|NCT01094015|Active Comparator|Lidocaine-Prilocaine cream|
89324540|NCT01094015|Placebo Comparator|placebo|
89324541|NCT01090895|Active Comparator|Vitamin C|Vitamin C infusion
89324542|NCT01090895|Placebo Comparator|Placebo|Saline solution
89324543|NCT03956303|Active Comparator|Plain Levobupivacaine (Chirocaine (% 0.5)|Levobupivacaine 8 mg (Chirocaine (% 0.5)) + 20 mcg fentanyl Chirocaine Plain
89324544|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 40|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 40 Chirocaine Heavy 40
89324545|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 60|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 60 Chirocaine Heavy 60
89324546|NCT03956303|Active Comparator|Levobupivacaine (Chirocaine % 0,75) + dextrose 80|Levobupivacaine 8 mg (Chirocaine % 0,75) + 20 mcg fentanyl + dextrose 80 Chirocaine Heavy 80
89324547|NCT01094093|Experimental|Part B|Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).
89324548|NCT01094093|Experimental|Part A|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.
89324549|NCT01094249|Experimental|001|divalproex sodium ER/paliperidone ER Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
89324550|NCT03957785|Experimental|Alter G treatment|All participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.
89324551|NCT03957785|Active Comparator|Traditional Gait Training|All participants practiced one session a day TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using FAC-tailored physiotherapist assistance, to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). Physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions.
89324552|NCT03957785|Active Comparator|Healthy Control|ll participants practiced one session a day of AlterG (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the gait training was performed.The HC initially practiced the device at the same BWS and S administered to the patients. BWS and S were reduced progressively and increased, respectively, across the AlterG sessions in keeping with patients progresses.
89324553|NCT01094405|Experimental|EBV Vaccine|
89324554|NCT00055601|Experimental|Pelvic RT + paclitaxel + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with paclitaxel and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with paclitaxel and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
89324555|NCT00055601|Experimental|Pelvic RT + fluorouracil + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with fluoruracil and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with fluoruracil and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
89324556|NCT01094483|Experimental|1|PN400 + ASA
89324557|NCT01094483|Placebo Comparator|2|Placebo + ASA
89324558|NCT01583621|No Intervention|Placebo|Placebo group
89324559|NCT01583621|Experimental|Supplementation arm 1|cholecalciferol 18000 U/month for 4 months
89324560|NCT01583621|Experimental|supplementation arm 2|cholecalciferol 60000 U/month for 4 months
89324561|NCT01583621|Experimental|Supplementation arm 3|cholecalciferol 120000 U/month for 4 months
89324562|NCT03806231|Experimental|Outpatient Cervical Ripening|Patients randomized to the outpatient cervical ripening arm will come in for a scheduled visit in Labor and Delivery prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be monitored for 2 hours and sent home after a the following are present: (1) reactive non-stress test (NST) (2) category 1 tracing x 2 hours (3) no vaginal bleeding (4) normal maternal vital signes (5) intact bag of water (BOW) and (6) less than 1 contraction every 10 minutes at the time of discharge. The patient will remove the insert the following morning prior to her scheduled induction.
89324563|NCT03806231|Active Comparator|Inpatient Cervical Ripening|The patient will be admitted into the Labor and Delivery unit prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be watched with continuous fetal monitoring for 2 hours. The patient remains hospitalized and the following morning the induction will be started per Intermountain Healthcare protocol.
89324564|NCT01091051|Active Comparator|Ustekinumab|Ustekinumab S/C 45mg or 90mg depending on patient's weight or placebo injection. 10 with PPPP and 10 with PPP will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
89324565|NCT01091051|Placebo Comparator|Placebo|Placebo S/C (Sodium Chloride). 10 with PPPP and 10 with PPP will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
89324566|NCT01091129|Experimental|Treatment|Treatment with the miraDry System in both axilla
89324567|NCT01327079|Experimental|Group 1|"Gestational age less than 29 weeks We will substitute for one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
89324568|NCT01327079|Experimental|Group 2|"Gestational age greater then 29 weeks We will substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
89324569|NCT01091207|Experimental|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
89324570|NCT01094639|Placebo Comparator|Supragingival prophylaxis|Plaque removal
89324571|NCT01094639|Active Comparator|Scaling root planing|SRP+oral hygiene
88816008|NCT02980094|Experimental|Milk Oil group(O)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
89324572|NCT01094873|Experimental|Arm A, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 14 and 1 dose Ad6NSmut 5 x 10^8vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
89324573|NCT01094873|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 14 and 1 dose Ad6NSmut 5 x 10^9vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
89324574|NCT01094873|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
89324575|NCT01094873|Experimental|Arm A, group 4|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 2 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 12, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
89324576|NCT01094873|Experimental|Arm A, group 5|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 14 and 18, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 28, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
89324577|NCT01094873|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 2 and 6, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 16, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
89324578|NCT01094873|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 4 and 1 dose Ad6NSmut 5 x 10^8vp at week 14.~Patients: 2"
89324579|NCT01094873|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 4 and 1 dose Ad6NSmut 5 x 10^9vp at week 14.~Patients: 2"
89324580|NCT01094873|Experimental|Arm B, group 3|"Interventions: AdCh3NSmut; Ad6NSmut.~1 dose AdCh3NSmut 2.5 x 10^10vp at week 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 14.~Patients: 4"
89324581|NCT01091285|Active Comparator|Single Balloon Catheter|Cervix Ripening is achieved by a single balloon catheter. Further induction by cytotec or/amniotomy and pitocin
89324582|NCT01091285|Active Comparator|Double balloon catheter|Cervix Ripening is achieved by a double balloon catheter. Further induction by cytotec or/amniotomy and pitocin
89324583|NCT01094951|Other|ENGAGE|"In stage 1, study investigators will train Neighborhood House caseworkers to screen their clients for depressive symptoms.~In stage 2, study investigators will train Neighborhood House caseworkers to use the ENGAGE intervention in referring their clients to mental health services"
89324584|NCT01583699|Experimental|Endomicroscopy|All patients included into the study will undergo endomicroscopy of the upper GI-tract.
89324585|NCT01095029|Experimental|Off/Off|Pacemaker status: Bilateral Off for four weeks before first PET scann.
89324586|NCT01095029|Experimental|On/On|Pacemaker status: Bilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
89324587|NCT01095029|Experimental|On/Off|Pacemaker status: Unilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
89324588|NCT01095107|Other|Control Arm = Decreased Energy Density|Decreased energy density = 35-50 grams of fat per day between meals and snacks
89324589|NCT01095107|Other|Treatment Arm = Increased Energy Density|increased increased energy density : Intake > 50 grams of fat per day between meals and snacks
89324590|NCT00054275|Experimental|Erlotinib Plus Docetaxel|
89324591|NCT01095185|Experimental|Standard therapy + Simvastatin|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated until achieve maximum tolerated dose)~Simvastatin (20 mg for 15 days and after 40 mg/day until the end of the study)"
89324592|NCT01095185|Placebo Comparator|Standard therapy + placebo|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated maximum tolerated dose).~Placebo"
89324593|NCT01583777|Experimental|Belinostat|Open Label
89324594|NCT01091441||Patients with heart failure|Patients hospitalized for acute heart failure
89324595|NCT00053417|Placebo Comparator|1|Placebo control, twice a day (b.i.d.)
89324596|NCT00053417|Experimental|2|10 milligram (mg) fampridine b.i.d.
89324597|NCT00053417|Experimental|3|15 mg fampridine b.i.d.
89324598|NCT00053417|Experimental|4|20 mg fampridine b.i.d.
89324599|NCT00052715|Experimental|poly-ICLC Newly diagnosed GBM|"Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy~Intramuscular injection~Drug Poly-ICLC"
89324600|NCT03955601|Experimental|TBI free Haploidentical HSCT|Recipients will receive a reduced intensity conditioning regimen of ''Fludarabine'' 30 mg/m2 IV daily from day -7 to -3, ''Cyclophosphamide'' 14.5-30 mg/kg IV daily on day -6 and -5 , ''rabbit Antithymocyte globulin'' 5 mg /kg/day from day -6 to day-3; ''Busulphan'' IV 3.2 mg per kg/day in 02 divided doses on day -3 and day-2, ''Granulocyte Colony Stimulating factor primed Bone marrow harvest'' and/OR ''PBSC'' graft on day 0 and day +1 respectively and Graft versus host disease prophylaxis with ''post-transplant cyclophosphamide'' administered at a dose of 50mg/kg/day given daily on days +3 and +5 post-transplant and ''cyclosporine'' from day +5, ''mycophenolate mofetil'' from day+5 to day+35.
89324601|NCT01095263|Experimental|Sham then Stimulation|
89324602|NCT01095263|Experimental|Stimulation then Sham|
89324603|NCT01095341||THP|THP: patients undergoing parathyroidectomy according to tertiary hyperparathyroidism
89324604|NCT01095341||Other causes|patients with hyperthyroidism not caused by parathyroidectomy
89324605|NCT01091597|Active Comparator|usual ablation|Wide-area circumferential ablation of the pulmonary veins
89324606|NCT01091597|Experimental|Box isolation of the pulmonary veins|Single Box lesion set encompassing all four pulmonary veins and the posterior wall of the left atrium.
89324607|NCT00051311|Other|Donor|Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
89324608|NCT00051311|Experimental|Recipient|Recipients will receive induction chemotherapy (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.
89324609|NCT01095419|No Intervention|Control|Patients were seated in a chair for the same period then those from MT group, but did not receive intervention
89324610|NCT01095419|Experimental|Massage Therapy|Patients in the postoperative period of coronary artery bypass graft surgery, which receive intervention for 3 consecutive days
89324611|NCT01091753|Placebo Comparator|morning administration group|
89324612|NCT01091753|Experimental|nocturnal administration group|
89324613|NCT00049673|Experimental|Arm I|Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.
89324614|NCT00049673|No Intervention|Arm II|Patients undergo observation.
89324615|NCT00049127|Experimental|Phase II (Group 1)|Patients receive imatinib mesylate PO, at the MTD determined in phase I, BID for 4 weeks.
89324616|NCT00049127|Experimental|Phase II (Group 2)|Patients receive standard-dose imatinib mesylate PO BID for 4 weeks.
89324617|NCT00066365|Experimental|Group 1 (unilateral recurrence) - Sargramostim and thoractomy|Patients receive initial inhalation therapy inhaled sargramostim (GM-CSF) twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure thoracotomy on day 22. Beginning on day 29, or as soon as possible thereafter, patients begin post-thoracotomy inhalation therapy for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
89324618|NCT00066365|Experimental|Group 2 (bilateral recurrence) - Sargramostim and thoractomy|Patients may be enrolled on study either before or after the first thoracotomy procedure. For the first thoracotomy, patients undergo surgical procedure unilateral thoracotomy. Patients receive initial inhalation therapy inhaled GM-CSF, as soon as possible after recovery from first thoracotomy, twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure contralateral thoracotomy on day 22. Beginning on day 29, or as soon as possible, patients begin post-thoracotomy inhalation therapy as above for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
89324619|NCT00048581|Active Comparator|Abatacept|Short Term Portion of Study
89324620|NCT00048581|Placebo Comparator|Placebo|Short Term Portion of Study
89324621|NCT00048581|Active Comparator|Abatacept (Long Term)|"Long Term Portion of Study:~All participants receive Active Drug"
89324622|NCT00048347|Experimental|Avonex|Interferon-beta1a (Avonex) 30 µg IM every week for 12 weeks
89324623|NCT03955523|Experimental|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation >5% VO2peak for at least 3 minutes of exercise.
89324624|NCT03955523|Experimental|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
89324625|NCT03955523|No Intervention|Control (doing nothing)|Non-exercise trial day The protocol of the non-exercise trial day is identical to that of the exercise trial day, except that exercise is substituted by 30 min of quiet sitting in a lounge area (e.g. reading, working or watching a movie on an electronic device) without further engagement with other people.
89324626|NCT03957629|Active Comparator|TDF group|93 patients would receive treatment of oral medication of tenofovir disoproxil fumarate (TDF) 300mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
89324627|NCT03957629|Active Comparator|Combination group|93 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg once per week and meanwhile oral medication of tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive oral medication of TDF 300 mg once per day from 49 to 96 weeks.
89324628|NCT01091909|Experimental|post-extraction wound healing|53 individuals with diabetes and 29 controls, without diabetes, were followed for 60 days after dental extractions, and were examined after 3, 7, 21, and 60 postoperative days.
89324629|NCT00065507|Experimental|A1|
89324630|NCT00065507|Active Comparator|A2|
89324631|NCT01095575|Active Comparator|group 1|NS preoperatively and MO postoperatively
89324632|NCT01095575|Active Comparator|group 2|MO preoperatively and NS postoperatively
89324633|NCT03954977|Experimental|Ultrasound vs Radiograph|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
89324634|NCT03954821||control group|control group in which all of them present pronated foot without tratment
89324635|NCT03954821||experimental group|Group in which they have been treated with prefabricated plantar insoles to stop pronation
89324636|NCT00065429|Experimental|BB-10901, 5mg/m2 - Phase I|
89324637|NCT00065429|Experimental|BB-10901, 10 mg/m2 - Phase I|
89324638|NCT00065429|Experimental|BB-10901, 20 mg/m2 - Phase I|
89324639|NCT00065429|Experimental|BB-10901, 40 mg/m2 - Phase I|
89324640|NCT00065429|Experimental|BB-10901, 60 mg/m2 - Phase I & Phase II|Phase I and Phase II were consecutive and sequential. Different patients received the 60mg/m2 dose in Phase I and in Phase II.
89324641|NCT00065429|Experimental|BB-10901, 67.5 mg/m2 - Phase I|
89324642|NCT00065429|Experimental|BB-10901, 75 mg/m2 - Phase I|
89324643|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
89324644|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
89324645|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
89324646|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
89324647|NCT01095809|Experimental|bevacizumab|intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.
89324648|NCT01095809|Experimental|triamcinolone acetonide|intravitreous triamcinolone 2 mg, frequency: 3 months
89523461|NCT03373955||Immunotherapy,chemotherapy,radiotherapy|Pembrolizumab will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent.The peripheral blood will be collected at 3 weeks,2 months, 6 months,an average of 1 year
89324649|NCT00048035|Experimental|Cohort 1 (RO0503821 [0.25/150 1x/week])|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) intravenously (IV) using a dose conversion factor of 0.25/150 microgram (mcg)/kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 62.50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89324650|NCT00048035|Experimental|Cohort 2 (RO0503821 [0.25/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.25/150 mcg/kg of the previous weekly ESA dose, (equal to 62.50% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89324651|NCT00048035|Experimental|Cohort 3 (RO0503821 [0.4/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89324652|NCT00048035|Experimental|Cohort 4 (RO0503821 [0.4/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89324653|NCT00048035|Experimental|Cohort 5 (RO0503821 [0.6/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89324654|NCT00048035|Experimental|Cohort 6 (RO0503821 [0.6/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
89324655|NCT01092221|Experimental|Allopurinol|
89324656|NCT01092221|Placebo Comparator|Placebo|
89324657|NCT00047879|Other|Glioblastoma multiforme stratum|Glioblastoma multiforme is one of the most common and aggressive types of brain tumor.
89324658|NCT00047879|Other|Anaplastic Glioma Stratum|Anaplastic glioma is a type of brain tumor that develops from star-shaped glial cells that support nerve cells. Anaplastic oligodendroglioma is a malignant type of brain tumor sensitive to treatment with chemotherapy and radiotherapy.
89324659|NCT03954665|Active Comparator|Baseline Testing|Baseline testing for a 10km cycle time trial and a 30s Wingate cycle test.
89324660|NCT03954665|Experimental|Dietary Supplement: Exogenous Ketone Salt|Ketone salt supplementation (0.6-0.8g•kg-1•d-1) 7-days. Participants will perform two exercise performance tests (a 10km cycle time trial and a 30s Wingate cycle test on separate days) after supplementation.
89324661|NCT01095965|Experimental|Lifestyle education|Nutrition education comprised of 4 components: Curriculum (8 weeks), follow-up meetings (4 monthly plus 2-bimonthly), education materials for use at home and vegetable gardening demonstrations.
89324662|NCT01096043|Placebo Comparator|Placebo|Each Strata of the study will have a placebo control. In strata A, the chance of getting active drug is 4 out of 5, in Strata B the chance of getting active drug is 3 ot of 4, and in Strata C, the chance of getting active Drug is 4 out of 5. In the event that a patient is allocated to receive placebo, the treatment may be stopped if the patient's condition fails to improve or worsens during the placebo infusion.
89324663|NCT01096043|Experimental|Strata 1 CXL-1020|Patients assigned to CXL-1020 in strata one will have their dose increased from the initial dose 2 times during the study period. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
89324664|NCT01096043|Experimental|Strata 2 CXL-1020|In strata 2, patients who are assigned to active treatment will receive one of up to 3 possible fixed dose levels of CXL-1020 for a period of 6 hours. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
89324665|NCT01096043|Experimental|Strata 3 CXL-1020|In strata 3, patients assigned to receive CXL-1020 will receive a fixed dose of CXL-1020 for 6 hours, and then the dose may be increased or decreased, based on the investigators assessment of the patient. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
89324666|NCT00064337|Experimental|Treatment|"MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70.~Mobilization and SC Collection:~MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis.~Amyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection).~Conditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion >/= 3.5 x 10^6 CD34+ cells/kg IV Day 0.~Maintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year."
89324667|NCT01096121|Placebo Comparator|2|
89324668|NCT01096121|Experimental|1|Enalapril
89324669|NCT00064259|Experimental|Treatment (oblimersen sodium)|"Phase I: Patients receive oblimersen IV continuously on days 1-7, fluorouracil IV continuously on days 4-8, and cisplatin IV on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 12 patients are treated at the MTD.~Phase II: Patients receive treatment as in phase I with oblimersen at the MTD."
89324670|NCT03954197|Experimental|Without injection group|no injection used as priming
89324671|NCT03954197|Active Comparator|hCG group|hCG used as priming
89324672|NCT03954197|Active Comparator|GnRHa group|GnRH agonist used as priming
89324673|NCT00044213|Active Comparator|EDTA + high dose vitamin|Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
89324674|NCT00044213|Placebo Comparator|EDTA + high dose vitamin placebo|Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
89324675|NCT00044213|Placebo Comparator|EDTA placebo + high dose vitamin|Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
89324676|NCT00044213|Placebo Comparator|EDTA placebo + high dose vitamin placebo|Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.
89324677|NCT00064025|Experimental|Treatment (medroxyprogesterone)|"Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before surgical hysterectomy.~A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72 hours after medroxyprogesterone therapy, and during surgery for gene expression arrays."
89324678|NCT01091987|Experimental|Non-pharmacological approach of insomnia|Non-pharmacological approach of insomnia based on cognitive-behavioural techniques (education on sleep, sleep hygiene, stimulus control, cognitive techniques)
89324679|NCT03957395|Experimental|scs high-frequency|high-frequency stimulation
89324680|NCT03957395|Experimental|scs tonic|tonic stimulation
89324681|NCT03957395|Experimental|scs burst|burst stimulation
89324682|NCT03957395|Placebo Comparator|scs off|off stimulation
89324683|NCT03957239|Experimental|Cranberry Beverage|Four prepackaged juice boxes (4.23 oz each) containing a whole milled cranberry beverage for 2 weeks
89324684|NCT03957239|Placebo Comparator|Placebo Group|Four prepackaged juice boxes (4.23 oz each) containing a cranberry-flavored beverage for 2 weeks
89324685|NCT01092299|Experimental|Cohort 1 (2 arms)|Period 1: randomized to either fasting IR or ER1. Period 2: Cross-over to either IR or ER1. Period 3: ER1 in fed conditions.
89324686|NCT01092299|Experimental|Cohort 2 (2 arms)|Period 1: randomized to either fasting IR or ER2. Period 2: Cross-over to either IR or ER2. Period 3: ER2 in fed conditions.
89324687|NCT01092299|Experimental|Cohort 3( 2 arms)|Period 1: randomized to either fasting IR or ER3. Period 2: Cross-over to either IR or ER3. Period 3: ER3 in fed conditions.
89324688|NCT01092299|Experimental|Cohort 4 (2 arms)|Period 1: randomized to either fasting IR or MR4. Period 2: Cross-over to either IR or MR4. Period 3: MR4 in fed conditions.
89324689|NCT01092299|Experimental|Part 2: Extended/Modified release|Extended/Modified release capsule to be determined
89324690|NCT01092299|Placebo Comparator|Part 2: Placebo|
89324691|NCT01092377|Experimental|DHA/EPA capsules and iron tablet|
89324692|NCT01092377|Experimental|DHA/EPA and placebo tablet|
89324693|NCT01092377|Placebo Comparator|placebo capsules & placebo tablet|
89324694|NCT01092377|Experimental|iron tablet and placebo capsules|
89324695|NCT01096277|Active Comparator|Sitagliptin|100 mg sitagliptin per day for 2 weeks
89324696|NCT01096277|Placebo Comparator|Placebo|1 placebo tablet per day for 2 weeks
89324697|NCT01096277|No Intervention|Healthy Control|Healthy control subjects
89324698|NCT01584167|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
89324699|NCT01584167|Active Comparator|EMCOOLS Flex.Pads|Passive surface cooling with 10 EMCOOLS Flex.Pads (Emergency Medical Cooling Systems AG, Wien, Austria)
89324700|NCT01096355|Experimental|Group A|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3 and 8-10.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
89324701|NCT01096355|Experimental|Group B|"Patients receive oral RO4929097 once daily on days 1-7.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
89324702|NCT01096355|Experimental|Group C|"Patients receive oral RO4929097 once daily on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
89324703|NCT01096355|Experimental|Group D|"Patients receive oral RO4929097 once daily on days 1, 8, and 15.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
89324704|NCT01096355|Experimental|Group E|"Patients receive oral RO4929097 once daily on days 1, 4, 8, 11, 15, and 18.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
89324705|NCT01096355|Experimental|Group F|"Patients receive oral RO4929097 once daily days 1-5, 8-12, and 15-19.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
89324706|NCT01096433|Experimental|CPAP|The subjects introduced with CPAP treatment
89324707|NCT03956927||patients|Insulin-dependent diabetic patients who have participated in a full TPE program (3 sessions)
89324708|NCT03953963|Experimental|Intra-Abdominal Mesenteric Fat Extraction Group|All enrolled patients will undergo the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery.
89324709|NCT01096511||Group 1|
89523462|NCT02814695|No Intervention|Control|First fraction was control, 0.1ml of liquefied semen mixed with 0.1ml Ham's F10 medium and incubated at 37o C for 30 minutes.
89324710|NCT01092455||Citrasate and heparin reduction|Sequential hemodialysis treatment study in which all enrollees move through four (4) separate treatment phases. Results from the separate phases will be compared to standard bicarbonate dialysis with standard does of heparin.
89324711|NCT03954275||Critically ill patients with a CrCl24h|Patients admitted to any intensive care unit (surgical, medical or cardiac) and having at least one 24h creatinine clearance measurement available.
89324712|NCT02263222|Experimental|MDT-10013|Subjects will receive MDT-10013.
89324713|NCT02264782|Experimental|Group I (PreView)|Patients complete PreView, the Video Doctor plus Provider Alert, over 45 minutes on an iPad in the waiting room before a doctor visit.
89324714|NCT02264782|Active Comparator|Group II (educational video)|Patients watch a video about healthy lifestyles including information about exercise and healthy eating over 45 minutes on an iPad in the waiting room before a doctor visit.
89324715|NCT02264860|Other|Nutritional Supplements Zinc and SAMe|All men subjects will be started on 30 mg/day and women will be started on 25mg of elemental zinc plus 1600 mg/day of SAMe.
89324716|NCT02264938|No Intervention|Observation|Patients with AREDS category 2 and 3 AMD are observed during 1 year
89324717|NCT02264938|Active Comparator|Antioxidant|Patients with AREDS category 2 and 3 AMD are enrolled to take daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid [DHA] 540mg + eicosapentaenoic acid [EPA] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg) during 1 year.
89324718|NCT02235766||CRT candidates patients|In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection fraction equal or less than 35% will be considered eligible to participate in this observational study.
89324719|NCT02542384|Active Comparator|CR845 IV 1 mcg/kg|CR845 IV solution will be supplied in 2 mL glass vials.Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
89324720|NCT02542384|Active Comparator|CR845 IV 0.5 mcg/kg|CR845 solution will be supplied in 2 mL glass vials. Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
89324721|NCT02542384|Placebo Comparator|Placebo IV|Placebo will be supplied in matched vials containing the same volume of buffer but with no active drug. It will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
89324722|NCT02511886|Experimental|Arbaclofen Placarbil (AP)|Orally administered Arbaclofen Placarbil (AP) sustained release (SR) tablets
89324723|NCT02511886|Placebo Comparator|Placebo|Subjects remain on placebo for entire study
89324724|NCT02235844|Experimental|Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells
89324725|NCT00043979|Experimental|Arm 1- Sibling Donors|Donors (n = 30) were matched first degree relatives who were eligible to donate peripheral blood stem cells.
89324726|NCT00043979|Experimental|Arm 2 - Recipients|Recipients (n=30) were enrolled to receive peripheral blood stem cells (PBSC) and receive either cyclosporine or tacrolimus and sirolimus for graft versus host disease (GVHD) prophylaxis.
89324727|NCT04188808|Experimental|Popliteal artery aneurysm|Asymptomatic popliteal artery aneurysm patients will undergo surgery with a femoropopliteal/femorodistal bypass
89324728|NCT04188808|Active Comparator|Peripheral artery disease|Patients with peripheral artery disease defined as (ankle - brachial index, ABI <0.5 or typical symptoms); intermittent claudication (IC), or resting pain and/or minor tissue loss. Will undergo surgery with a femoropopliteal/femorodistal bypass
89324729|NCT02265016||Patients with CAD|Patients with stable coronary artery disease
89324730|NCT02265016||Patients with ACS|Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI
89324731|NCT02265016||healthy control group|healthy control group without clinical apparent arteriosclerosis
89324732|NCT01436032|Experimental|N1539 15 mg|
89324733|NCT01436032|Experimental|N1539 30 mg|
89324734|NCT01436032|Active Comparator|Ketorolac|IV
89324735|NCT01436032|Placebo Comparator|Placebo|IV
89324736|NCT01436032|Experimental|N1539 7.5mg|
89324737|NCT01092533|Experimental|Mycophenolate sodium + Prednisolone|Mycophenolate sodium 1440 mg/day Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
88811769|NCT01380743|Experimental|Cohort 2, Duvoglustat 100 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 100 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
89324738|NCT01092533|Active Comparator|Prednisolone|Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
89324739|NCT02472418|Experimental|DFN-15 120 mg (treatment A)|DFN-15 120 mg (treatment A)
89324740|NCT02472418|Experimental|DFN-15 240 mg (treatment B)|DFN-15 240 mg (treatment B)
89324741|NCT02472418|Placebo Comparator|Placebo (treatment C)|Placebo (treatment C)
89324742|NCT01092611|Other|Group A|Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study
89324743|NCT01092611|Other|Group B|Subjects who were administered placebo in primary studies and who accepted to participate in this study
89324744|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 1|
89324745|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 2|
89324746|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 1|
89324747|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 2|
89324748|NCT01624636|Placebo Comparator|Placebo|
89324749|NCT01624636|Experimental|LFG316: 10 mg/kg (2 doses in cohort 1)|
89324750|NCT01624636|Experimental|LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2).|
89324751|NCT03953885|Experimental|Fire needle group|Participants in experimental group will receive Fire needle therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
89523463|NCT02814695|Experimental|Vit E supplementation|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
89324752|NCT03953885|Placebo Comparator|Fire needle placebo group|Participants in experimental group will receive Fire needle placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.
89324753|NCT01092689|Experimental|PhIP|Prior to surgery, consented subjects will ingest a capsule containing [14C]PhIP. This amount of [14C]PhIP (84 micrograms PhIP; 15.6 micro-curies) is equivalent to that in 2 very well done grilled/barbecued chicken breasts (Sinha 1995); the amount of radioactivity is equivalent to the dose received in a commercial airline flying at 30,000 ft. for 5 h (HPS 2007) or to the amount received during a typical chest x-ray.
89324754|NCT01425970|Experimental|25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 1
89324755|NCT01425970|Experimental|50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 2
89324756|NCT01425970|Experimental|100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 3
89324757|NCT01425970|Placebo Comparator|Placebo + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 4
89324758|NCT01425970|Experimental|100 mg INX-08189 + Ribavirin|PART B Arm 1
89324759|NCT01425970|Experimental|200 mg INX-08189 + Ribavirin|PART B Arm 2
89324760|NCT01425970|Experimental|Daclatasvir + INX-08189 100 mg|PART B Arm 3
89324761|NCT01425970|Experimental|Daclatasvir + INX-08189 200 mg|PART B Arm 4
89324762|NCT01425970|Experimental|Daclatasvir + INX-08189 50 mg + Ribavirin|PART B Arm 5
89324763|NCT01583855|Active Comparator|Manual ablation|Patients will have their ablation performed manually.
89324764|NCT01583855|Active Comparator|Ablation using remote catheter system|Ablation for atrial fibrillation using the Amigo remote catheter system
89324765|NCT02265094|Experimental|Patients|Electroencephalography and neuropsychological tests in children with autism
89324766|NCT02265094|Experimental|Control|Electroencephalography and neuropsychological tests in children without autism
89324767|NCT03135496||Surgery with CEC|
89324768|NCT03135496||Without CEC|
89324769|NCT01619332|Experimental|LEZ763|Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
89324770|NCT01619332|Placebo Comparator|Placebo|Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
89324771|NCT01619332|Active Comparator|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
89324772|NCT02265172|Experimental|Physiotherapy screening|"Screening consisted of a 60-min appointment including assessment, diagnosis and management. The patients received advice regarding ergonomics, exercises and/or treatment when needed. Management options were;~Referral for orthopaedic surgeon consultation.~Referral back to the patient's General Practitioner.~Referral for further investigation.~Referral to the physiotherapy or the occupational therapy clinic."
89324773|NCT02265172|Active Comparator|Standard practice (orthopaedic surgeon)|"Appointment was 15 min, including assessment, diagnosis and management. The patients received advice, prescriptions or injections when needed. Management options were;~Referral for orthopaedic intervention.~Referral back to the patient's General Practitioner.~Referral for further investigation.~Referral to the physiotherapy or the occupational therapy clinic."
89324774|NCT02265250||Asymptomatic, CACS <300|"5 asymptomatic subjects with low CVD risk, defined as recent coronary artery calcium score (CACS) <300~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers)"
89324775|NCT02265250||Asymptomatic, CACS ≥300|"5 asymptomatic subjects with increased CVD risk, defined as a recent coronary artery calcium score (CACS) ≥300~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
89324776|NCT02265250||Stable angina|"5 subjects with stable angina and evidence of coronary atherosclerosis based on a recent invasive or CT coronary angiogram~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
89324777|NCT02265250||Recent acute MI|"5 subjects with a recent acute myocardial infarction (within 1 month) and evidence of coronary atherosclerosis based on invasive or CT coronary angiogram~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
89324778|NCT01616524|Experimental|Arm 1: pegIFNλ + Ribavirin + Placebo matching Daclatasvir|
89324779|NCT01616524|Experimental|Arm 2: pegIFNλ + Ribavirin + Daclatasvir|
89324780|NCT01616524|Experimental|Arm 3: pegIFNα-2a + Ribavirin + Placebo matching Daclatasvir|
89324781|NCT02263378|Experimental|supplement|
89324782|NCT02263378|Placebo Comparator|not intervention|
89324783|NCT02265328|Experimental|Bovine colostrum + prednisolone|"Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.~Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. If Lilli score > 0.45 after 7 days, then GC would be stopped and patients will be counselled for liver transplantation.~Oral Bovine colostrum (200 ml (20 gram) TDS × 2 months."
89324784|NCT02265406|Experimental|Ceftriaxone|
89324785|NCT02265406|Placebo Comparator|Sodium Chloride|
89324786|NCT01421056|Experimental|CHF 5074 1x|oral tablet, multidose
89324787|NCT01421056|Experimental|CHF 5074 2x|oral tablet, multidose
89324788|NCT01421056|Experimental|CHF 5074 3x|oral tablet, multidose
89324789|NCT02263456|Active Comparator|Current Factor IX|
89324790|NCT02263456|Experimental|Replenine®-VF|
89324791|NCT02263534|Experimental|minisling|patients in this arm will undergo single incision minisling
89324792|NCT02263534|Sham Comparator|tension free vaginal tape|patients in this arm will undergo tension free vaginal tape
89324793|NCT01418092|Placebo Comparator|Placebo|Capsules for oral administration
89324794|NCT01418092|Experimental|ALKS 37|Capsules for oral administration
89324795|NCT01416064|Other|Molindone|Extension study, all subjects will be given Molindone at different (established) dosage levels based on the patient's weight, response and investigator discretion.
89324796|NCT01594216|Experimental|First Stage|Ruxolitinib at 25 mg orally, twice daily and Exemestane, 25 mg orally once daily
89324797|NCT01594216|Experimental|Second Stage|Ruxolitinib at 15 mg orally, twice daily and Exemestane, 25 mg orally once daily
89324798|NCT01411150|Experimental|Creatine|
89324799|NCT02263612||Danish Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
89324800|NCT02263690|Active Comparator|Group Drops|"proparacaine 0.5% drops (Group Drops)~Patients from group Drops received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.~Patients from Group Drops received a second drop of proparacaine 0.5%, 5 minutes after the drop of povidone iodine 5%."
89324801|NCT02263690|Active Comparator|Group SC|"proparacaine 0.5% drops plus subconjunctival lidocaine (Group SC)~Patients from group SC received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.~For the patients from Group SC, a subconjunctival bleb of anesthesia was created by injecting 0.4 ml of lidocaine 1% into the subconjunctival space, posteriorly to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-ml syringe."
89324802|NCT02263690|Active Comparator|Group Gel|"Lidocaine gel 2% on the eye (Group Gel)~Patients from Group Gel received 1 mL of 2% lidocaine gel on the eye before receiving the drop of povidone iodine 5%.~For the patients from Group Gel, 1 mL of 2% lidocaine gel was applied on the eye before receiving the drop of povidone iodine 5%."
89324803|NCT02265562|Experimental|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
89324804|NCT02265562|Placebo Comparator|Placebo|60 minutes before the surgery 2 tablets of placebo tablets inserted rectally
89324805|NCT01407874|Experimental|Placebo|Placebo + Allopurinol 200mg
89324806|NCT01407874|Experimental|Ulodesine (BCX4208) 5mg|BCX4208 5mg + Allopurinol 200 mg
89324807|NCT01407874|Experimental|Ulodesine (BCX4208) 10mg|BCX4208 10mg + Allopurinol 200mg
89324808|NCT02263768|Other|Group 1 - Recall Interval of 12 months|"Oral clinical conditions:~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
89324809|NCT02263768|Other|Group 2 - Recall Interval of 18 months|"Oral clinical conditions:~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
89324810|NCT02265640|Experimental|BIIL 284 BS boli - fasted|
89324811|NCT02265640|Experimental|BIIL 284 BS boli - fed|
89324812|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fasted|
89324813|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fed|
89324814|NCT01399684|Experimental|MEGF0444A + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A + mFOLFOX-6 (oxaliplatin, folinic acid, and 5-fluorouracil) regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles (Cycle = 14 days) and 5-fluorouracil, folinic acid, bevacizumab and MEGF0444A will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
89324815|NCT01399684|Placebo Comparator|Placebo + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A matching placebo + mFOLFOX-6 regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles and 5-fluorouracil, folinic acid, bevacizumab and placebo will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
89324816|NCT01397968|Experimental|YKP3089|
89324817|NCT01397968|Placebo Comparator|Placebo|
89324818|NCT01397578|Experimental|Part 1: Subcutaneous cohort exp|
89324819|NCT01397578|Experimental|Part 2: Intravenous cohort exp|
89324820|NCT01397578|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
89324821|NCT01397578|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous injection
89324822|NCT03135418|Experimental|Intervention|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
89324823|NCT03135418|Sham Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift a will be used to create an immersive visual environment.Patient will be watching the premade scenarios without interaction. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire, Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
89324824|NCT01395004|Experimental|Active Drug - GSK2110183|This was an open-label study of oral GSK211083 administered at the maximum tolerated dose of 125 mg once daily.
89324825|NCT01549834|Experimental|ABT-126 Low Dose|low dose
89324826|NCT01549834|Experimental|ABT-126 High Dose|high dose
89324827|NCT01549834|Placebo Comparator|sugar pill|Placebo
89324828|NCT02265718||(Amyloid Negative)|
89324829|NCT02265718||Amyloid Positive|
89324830|NCT02263846||Postmenopausal group|Patients at the age ≥ 60 years with more than one year of menopause, or patients having undergone bilateral oophorectomy.
89324831|NCT02263846||Premenopausal group|Patients with regular menses during recent 3 months and having never received luteinizing hormone-releasing hormone analogue therapy.
89324832|NCT01389700|Experimental|SAR279356 dose 1|SAR279356 dose 1, single administration
89324833|NCT01389700|Experimental|SAR279356 dose 2|SAR279356 dose 2, single administration
89324834|NCT01389700|Placebo Comparator|Placebo|Matching placebo, single administration
89324835|NCT01540864|Experimental|HPP404 35 mg|
89324836|NCT01540864|Experimental|HPP404 50 mg|
89324837|NCT01540864|Placebo Comparator|Placebo|
89324838|NCT01384630|Other|Single group|
89324839|NCT01381666|Experimental|INS316|inhalation via nebulizer given for 2 doses for 60 minutes each
89324840|NCT01381666|Placebo Comparator|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
89324841|NCT01540630|Experimental|CNV1014802|
89324842|NCT01540630|Placebo Comparator|Placebo|
89324843|NCT02266030|Experimental|Cilostazol|Cilostazol 100-200 mg qd
89324844|NCT02266030|Active Comparator|Aspirin|Asprin 100mg qd for active comparator
89324845|NCT01535950|Experimental|LFG316|
89324846|NCT01535950|Sham Comparator|Sham|
89324847|NCT01527916|Placebo Comparator|sugar pill|
89324848|NCT01527916|Active Comparator|donepezil|
89324849|NCT01527916|Experimental|ABT-126 Low Dose|low dose
89324850|NCT01527916|Experimental|ABT-126 Middle Dose|middle dose
89324851|NCT01527916|Experimental|ABT-126 high dose|high dose
89324852|NCT01373086|Experimental|LFF269 low dose|LFF269 low dose + Matching Placebo to Eplerenone 50mg during 4 week double blind period
89324853|NCT01373086|Experimental|LFF269 high dose|LFF269 high dose + Matching Placebo to Eplerenone 50mg
89324854|NCT01373086|Active Comparator|Eplerenone|Eplerenone 50mg twice daily + matching placebo of LFF269
89324855|NCT01373086|Placebo Comparator|Placebo|Placebo of LFF269 high dose + Placebo of Eplerenone 50 mg
89324856|NCT01521598|Experimental|SKL11197|This arm is the experimental drug (SKL11197) arm. Patients will be randomized to this arm.
89324857|NCT01521598|Placebo Comparator|Placebo|This arm is the placebo comparator arm. Patients will be randomized to this arm.
89324858|NCT01519804|Experimental|MetMAb+paclitaxel+platinum|
89324859|NCT01519804|Active Comparator|Placebo+paclitaxel+platinum|
89324860|NCT02263924|Experimental|Experimental: Tocotrienol|Mixed tocotrienol 200mg twice a day for 6 months
89324861|NCT02263924|Placebo Comparator|Placebo (for tocotrienol)|Placebo capsules, 1 capsule twice a day for 6 months
89324862|NCT02266186|Experimental|Internet CBT|Intervention:Internet-based cognitive behavioural therapy.
89324863|NCT02266186|Active Comparator|Traditional CBT|Intervention:Traditional CBT given by a therapist following given modules.
89324864|NCT02266186|No Intervention|Care as usual|Childbirth preparation according to local routine
88811770|NCT01380743|Experimental|Cohort 3, Duvoglustat 250 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 250 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
89324865|NCT04476394|Experimental|1|Administered orally once
89324866|NCT02264002|Experimental|Cilobradine low dose 1|
89324867|NCT02264002|Experimental|Cilobradine low dose 2|
89324868|NCT02264002|Experimental|Cilobradine medium dose|
89324869|NCT02264002|Experimental|Cilobradine high dose 1|
89324870|NCT02264002|Experimental|Cilobradine high dose 2|
89324871|NCT02264002|Active Comparator|Metoprolol succinate|1 tablet on day 1, day 2 followed by two tablets from day 3 to day 14
89324872|NCT02264002|Placebo Comparator|Placebo|
89324873|NCT02264080|Experimental|WAL2014|
89324874|NCT02264080|Placebo Comparator|Placebo|
89324875|NCT01517776|Experimental|Cilengitide and metronomic temozolomide|Cilengitide 1800 mg/m² i.v. twice weekly and Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
89324876|NCT01364662|Experimental|1|
89324877|NCT01364662|Experimental|2|
89324878|NCT01364662|Experimental|3|
89324879|NCT01364662|Experimental|4|
89324880|NCT01517698|Experimental|RO4917523 0.5 mg|
89324881|NCT01517698|Experimental|RO4917523 1.5 mg|
89324882|NCT01517698|Placebo Comparator|Placebo|
89324883|NCT02266264|Experimental|100 milligrams of hydrocortisone|100 milligrams per day of hydrocortisone is the starting dosage.
89324884|NCT02266264|Active Comparator|200 milligrams of hydrocortisone|200 milligrams per day of hydrocortisone is the starting dosage.
89324885|NCT01516918|Experimental|Quadruple Regimen|All subjects will receive active study drugs (quadruple regimen: VX-222, telaprevir,Peg-IFN, and RBV) for a fixed treatment duration of 24 weeks.
89324886|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg
89324887|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg
89324888|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg
89324889|NCT01508026|Experimental|Nebivolol Low Dose|Nebivolol Monotherapy 5 mg
89324890|NCT01508026|Experimental|Nebivolol High Dose|Nebivolol Monotherapy 20 mg
89324891|NCT01508026|Experimental|Valsartan Low Dose|Valsartan Monotherapy 80 mg
89324892|NCT01508026|Experimental|Valsartan High Dose|Valsartan Monotherapy 160 mg
89324893|NCT01508026|Placebo Comparator|Placebo|Dose Matched placebo
89324894|NCT01357642|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of E004, QID, with 4-6 hr intervals
89324895|NCT01357642|Placebo Comparator|Arm P|Placebo comparator as 2×Placebo QID, with 4-6 hr intervals
89324896|NCT01357642|Active Comparator|Arm A|Active comparator, Primatene Mist, 2×220 mcg/inhalation, QID, with 4-6 hr intervals
89324897|NCT03135340|Experimental|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
89523464|NCT02814695|Experimental|Yeast supplementation|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) Yeast extraction and incubated at 37o C for 30 minutes.
89324898|NCT03135340|Active Comparator|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
89324899|NCT01356160|Active Comparator|Arm 1|RGT with GS-5885 30 mg QD + GS-9451 200 mg QD + PEG/RBV
89324900|NCT01356160|Placebo Comparator|Arm 2|RGT with GS-5885 30 mg QD + GS-9451 placebo QD + PEG/RBV
89324901|NCT02264158|Experimental|Telmisartan high|
89324902|NCT02264158|Experimental|Telmisartan low|
89324903|NCT02264158|Active Comparator|Lacidipine high|
89324904|NCT02264158|Active Comparator|Lacidipine low|
89324905|NCT02264158|Experimental|Telmisartan+Lacidipine|
89324906|NCT02264158|Placebo Comparator|Placebo|
89324907|NCT01349998|Experimental|Safety Population|
89324908|NCT02266498|Experimental|BIBB 515 BS after a standard breakfast|
89324909|NCT02266498|Active Comparator|BIBB 515 BS|
89324910|NCT01345006|Experimental|MA09-hRPE|Patients will undergo subretinal injection of MA09-hRPE
89324911|NCT02264236|Experimental|P10s-PADRE vaccine|Subjects will be immunized by administration of either three or four doses of P10s-PADRE vaccine over a six-week period at a dose level of 500 micrograms (µg) per injection depending on the slandered of care therapy they receive for their lung cancer.
89324912|NCT02264314|Experimental|Intervention|This group received an audiological rehabilitation program with a tele-educative intervention boost
89324913|NCT02264314|Placebo Comparator|Control|This group received no intervention
89324914|NCT01476904|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of epinephrine inhalation, QID, with 4-6 hr intervals
89324915|NCT01476904|Placebo Comparator|Arm P|Arm P is a placebo comparator consisting of 2× 0 mcg of placebo inhalations, QID, with 4-6 hr intervals
89324916|NCT01476904|Active Comparator|Arm A|Arm A is an active comparator, Primatene Mist, consisting of 2× 220 mcg/inhalation, QID, with 4-6 hr intervals
89324917|NCT01337752|Experimental|BHQ880 + bortezomib and dexamethasone|
89324918|NCT01337752|Placebo Comparator|BHQ880 Placebo + bortezomib and dexamethasone|
89324919|NCT01333540|Experimental|Active|Escalating Doses of TD-1211
89324920|NCT01333540|Placebo Comparator|Placebo|
89324921|NCT02266654|Experimental|Prehospital-directed therapy arm|Patients who are hypotensive or whose lactate is ≥ 2.5, prehospital providers will provide a notification to the receiving hospital (Hospital Notification), establish an IV, and provide 1 liter normal saline (NS) bolus of IV fluids. An additional 1 liter normal saline bolus will be given for systolic blood pressure less than 100. Patients who have a history of end-stage renal disease or congestive heart failure would receive only 20 milliliters/kilogram of fluid. If the patient remains hypotensive, Emergency Medical Services will continue providing fluids as is standard of care.
89324922|NCT02266654|Experimental|Control Arm|Prehospital providers will obtain a point of care lactate, establish an IV, and provide IV fluids as judged necessary.
89324923|NCT02266732|Other|Interscalene block|
89324924|NCT02266732|Other|Femoral block|
89324925|NCT02264392|Active Comparator|Ultrasound Guided|Ultrasound Guided Incision and Drainage- Patients will undergo ultrasound guided drainage of the abscess using bedside ultrasound
89324926|NCT02264392|Active Comparator|Blind I&D|Blind Incision and Drainage- Patients will undergo drainage of the abscess using physical exam.
89324927|NCT02264470||Patients with clinical stroke|All patients with stroke, 18 years or older, are asked for participation.
89324928|NCT01318642|Active Comparator|Placebo + Gemcitabine|Arm 2: AMG479-placebo IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle
89324929|NCT01318642|Experimental|AMG 479 20 mg/kg + Gemcitabine|ARM 1: AMG 479 20mg/kg IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle.
89324930|NCT01318252|Experimental|AL-54478|AL-54478 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
89324931|NCT01318252|Active Comparator|Latanoprost|Latanoprost 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
89324932|NCT01318252|Placebo Comparator|Vehicle|AL-54478 Vehicle, single dose, followed 7 days later with 14 days of once daily dosing
89324933|NCT04476160|Experimental|Cinnamon|In this group, children will receive an intervention with 3000mg / day cinnamon along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
89324934|NCT04476160|No Intervention|Control|In this group, children will receive a placebo intervention along with diet and physical activity recommendations according to the WHO guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to corroborate the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects.
89324935|NCT01315210|Experimental|D-Ribose|
89324936|NCT01315210|Placebo Comparator|Placebo|
89324937|NCT01313572|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson
89324938|NCT01313572|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with the active comparator: adenosine.
89324939|NCT01474798|Experimental|RA-18C3|
89324940|NCT01470664|Experimental|FST-100|
89324941|NCT01470664|Experimental|FST-100 (Component #1)|
89324942|NCT01470664|Placebo Comparator|FST-100 Vehicle|
89324943|NCT01305538|Other|Arm 1 BMS-954561 40mg or 80mg|"Arm description: BMS-954561 40mg or 80mg three times daily (TID) to Placebo OR Placebo to 40mg or 80mg TID.~Arm type: Active to Placebo or Placebo to Active (cross-over)"
89324944|NCT01305538|Other|Arm 2 BMS-954561 150mg or 300mg|"Arm description: BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Arm type: Active to Placebo or Placebo to Active(cross-over)"
89324945|NCT02265484|Experimental|Lactulose + Rifaximin + Bromocriptine|
89324946|NCT02265484|Active Comparator|Lactulose+Rifaximin+Placebo|
89324947|NCT02264626|Experimental|acutely ill patients|administration of remifentanil at the infusion rate by 0.025 μg kg-1 min-1 to a maximum of 0.10 μg kg-1 min-1.
89324948|NCT01304524|Experimental|VGX 3100|
89324949|NCT01304524|Placebo Comparator|Placebo|
89324950|NCT01302886|Experimental|BHQ880|
89324951|NCT01300858|Experimental|EGEN-001|
89324952|NCT02264704|Experimental|High intensity exercise|High intensity exercise Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks.
89324953|NCT02264704|Experimental|Moderate intensity exercise|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks.
89324954|NCT02264704|No Intervention|Usual Care|Participants receive usual medical care.
89324955|NCT02266966|Experimental|F2695|Single dose - 2 capsules / Day on Day 1 and Day 8
89324956|NCT02266966|Placebo Comparator|placebo|Single dose - 2 capsules / Day on Day 1 and Day 8
89324957|NCT02267044|Active Comparator|Ropivacaine Single Shot Block|Single Shot Interscalene block patients will receive a single shot of 30ml of 0.5% Ropivacaine prior to surgery
89324958|NCT02267044|Active Comparator|Ropivacaine Continuous block|Continuous Interscalene block patients will receive a shot of up to 30ml of 0.5% Ropivacaine and then a catheter is placed. The catheter is secured with Dermabond and Tegaderm. Once surgery is complete, the catheter is connected to a pain ball system which holds 400ml of 0.2% Ropivacaine local anesthetic. The rate is locked in at 8ml/hr. Catheter is pulled once the pain ball is empty.
89324959|NCT02267122|Experimental|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound.
89324960|NCT02267122|Experimental|Mupirocin ointment application|After placing the staples, a Mupirocin ointment application was placed covering the wound.
89324961|NCT02267122|No Intervention|Conventional dressing|After placing the staples, a conventional dressing, without application of any special gauze or ointment, was placed covering the wound
89324962|NCT01261312|Experimental|Daily Regimen|"SGI-110 daily x5 dosing on a 28-day course~SGI-110 daily x10 dosing on a 28-day course"
89324963|NCT01261312|Experimental|Weekly Regimen|"SGI-110 weekly dosing for three weeks on a 28-day course~SGI-110 twice weekly dosing for three weeks on a 28-day course"
89324964|NCT02267200||reversible PAH group|reversible PAH was defined as sPAP decreasing to 40 mmHg after follow-up more than 6 months through echocardiography.
89324965|NCT02267200||irreversible PAH group|irreversible PAH was defined as 6 months after surgery through echocardiography ，the sPAP remaining 40 mmHg or up
89324966|NCT01255696|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
89324967|NCT01255696|Placebo Comparator|Placebo|Excipients for ALV003 absent the experimental compounds
89324968|NCT02267434|Experimental|Low dose AFFITOPE® PD03A + Adjuvant|"4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
89324969|NCT02267434|Experimental|High dose AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
89324970|NCT02267434|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
89324971|NCT01254370|Experimental|Catioprost|
89324972|NCT01254370|Active Comparator|Travatan Z|
89324973|NCT01254136|Experimental|Treatment A - INCB007839 300mg BID|This is a single arm, open label study in which all patients will receive a single dose of the investigational product INCB007839 in combination with a standard regimen of trastuzumab and vinorelbine.
89324974|NCT02268292|Experimental|Bicycle Exercise|Bicycle Exercise for 12 weeks
89324975|NCT04476004|Experimental|experimental group|EMG group
89324976|NCT04476004|Active Comparator|control group|exercise group
89324977|NCT02268370|Other|Dasatinib|"This research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib.~Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years.~If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years.~If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib."
89324978|NCT00039377|Experimental|Treatment (imatinib mesylate, chemotherapy, PBSCT)|See Detailed Description.
89324979|NCT01092845|Experimental|PF-04457845 followed by placebo|
89324980|NCT01092845|Experimental|Placebo followed by PF-04457845|
89324981|NCT01096745|Experimental|Gemcitabine/Cisplatin|
89324982|NCT01096745|Experimental|S-1/Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
89324983|NCT03953729|Experimental|Group 1:Ibuprofeno|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
89523465|NCT02814695|Experimental|Vit C supplementation|fractions (Vit. C. 1,2,3), 0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02, 0.04, 0.06 mg/ml) Vitamin C respectively and incubated at 37o C for 30 minutes.
89523466|NCT03420781|Placebo Comparator|Treatment Period: Placebo|Placebo-matching relamorelin injected subcutaneously twice daily for up to 40 weeks.
89523467|NCT03420781|Experimental|Treatment Period: Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 40 weeks.
89324984|NCT03953729|Placebo Comparator|Group 2: Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
89324985|NCT03953651||Patients|Patients admitted in the emergency department presenting a myocardial oxygenation imbalance and are therefore at risk for Myocardial Infarction (MI) type 2.
89324986|NCT01096901|Active Comparator|Comprehensive behavioral weight loss|The group will be implemented to induce a 6% weight loss over 3 months. The lessons will follow protocols from the Look AHEAD trial and Diabetes Prevention Program. This behavioral program has been shown to promote long-term weight loss and a reduction in diabetes and cardiovascular risk factors, and is based on the social cognitive theory.
89324987|NCT01096901|No Intervention|Education and Support Control group|Participants in this group will receive support and education about healthy eating and activity with lessons based on the Look AHEAD support and education control condition. Participants will attend monthly closed group meetings and meetings will be designed to promote retention but not weight loss.
89324988|NCT03953495|Experimental|Better Together|Participants will be recruited with e-mail, print, and social media announcements and advertisements distributed through the professional contacts and networks of the investigators. The experimental group will consist of randomly assigned volunteers who meet the eligibility requirements (i.e., same-sex female couple over the age of 18 who lives in Central Appalachia).
89324989|NCT01093001|Active Comparator|Lead size|The pacemaker lead will be < or = to 7Fr. The ICD lead will be 9 Fr.
89324990|NCT01093001|Active Comparator|RV Lead position|50 patients will be randomized to RV apex lead placement.
89324991|NCT01093001|Active Comparator|Mid-Septum Lead position|50 patients will be randomized to RV mid-septum lead placement.
89324992|NCT01093001|Active Comparator|CS lead position|50 patients will have lead placed in the CS
89324993|NCT03953339|Active Comparator|no release|no release of the suprascapular nerve during arthroscopic repair of a rotator cuff tendon repair
89324994|NCT03953339|Experimental|release|arthroscopic release of the suprascapular nerve according to the established, standard technique during arthroscopic repair of a rotator cuff tendon repair
89324995|NCT03953573||Women post-delivery|
89324996|NCT01583933|Experimental|Essix retainer|
89324997|NCT01583933|Active Comparator|Hawley retainer|"Hawley retainer is a device composed of an acrylic base with built-in hooks and a labial arch wire 0.022 x0.036 and attached to the teeth. Its metal component consists of two adams hooks positioned from the first permanent molar right to left, a labial bow that progresses from lingual superface to distal of canine to integrate with the acrylic base."
89324998|NCT01584011||Middle ear disease|
89324999|NCT01097135|No Intervention|Standard surgical skin preparation|
89325000|NCT01097135|Active Comparator|Standard Surgical Skin Preparation with Duraprep|standard surgical skin prep
89325001|NCT01093079||Laparoscopic partial nephrectomy|
89325002|NCT01093079||Open Partial nephrectomy|
89325003|NCT00154102|Experimental|Cetuximab Plus FOLFIRI|
89325004|NCT00154102|Active Comparator|FOLFIRI Alone|
89325005|NCT01280344|Experimental|0.03 mg/kg BID|Ipamorelin 0.03 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
89325006|NCT01280344|Experimental|0.06 mg/kg BID|Ipamorelin 0.06 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
89325007|NCT01280344|Experimental|0.06 mg/kg TID|Ipamorelin 0.06 mg/kg, TID (3 investigational drug infusions)
89325008|NCT01280344|Placebo Comparator|Placebo|Matching placebo, TID (3 placebo infusions)
89325009|NCT01269658|Experimental|Azithromycin ophthalmic solution, 1%|
89325010|NCT01269658|Placebo Comparator|Vehicle|
89325011|NCT02268604|Experimental|BIIB 722 CL|
89325012|NCT02268604|Placebo Comparator|Placebo|
89325013|NCT01263886|Experimental|AVE8062 and combination|"Day 1: AVE8062~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
89325014|NCT01263886|Placebo Comparator|Placebo|"Day 1: placebo~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
89325015|NCT02267590||MCL: 80-100 samples from 60- 70 patients|Mantle Cell lymphoma patients
89325016|NCT02267590||CLL: 15-20 samples from 10-15 patients|Chronic lymphocytic leukaemia patients
89325017|NCT01233700|Experimental|Motivational Interviewing|Subjects will receive two, individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on assisting subjects to delineate their reasons for or against proceeding with living organ donation and assisting subjects to resolve any lingering concerns about their decisions regarding donation.
89325018|NCT01233700|Active Comparator|Enhanced Standard Care|Subjects will receive two individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on providing educational information to subjects regarding healthy lifestyle issues (healthy eating, diet, exercise, quitting smoking).
89325019|NCT01233700|No Intervention|Standard Care|Subjects will receive the standard care and education provided by the Living Donor Program at their medical center.
89325020|NCT02267668|Experimental|STEP arm|"The Baseline Evaluation Session will include formal neuropsychological evaluation, postural stability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).~Intervention includes exercise tolerance evaluations, 3 times per week exercise by physical therapist. Self report of symptoms and exertion."
89325021|NCT02267668|Active Comparator|Control|"The Baseline Evaluation Session will include formal neuropsychological evaluation, posturalstability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).~Control protocol includes instructions for stretching, instructions for restricting physically demanding activity during first 3 weeks of study; instructions for light, self-guided daily exercise in last 3 weeks of study. Self report of symptoms and exertion."
89325022|NCT01229644|Experimental|Cohort A|Adult newly diagnosed glioma (both low and high grade) patients, who are able to to take Crenolanib (CP-868,596) for at least 3 days prior to surgical resection.
89325023|NCT01229644|Experimental|Cohort B|Adult patients with recurrent high grade glioma, including patients treated with bevacizumab. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
89325024|NCT01229644|Experimental|Cohort C|Adult patients with biopsy proven low grade glioma who have residual measurable disease. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
89325025|NCT02267902|Experimental|Part 1|Single oral therapeutic dose of 5mg DA-1229 as a tablet + An IV dose of 20㎍ [14C]-DA-1229
89325026|NCT02267902|Experimental|Part 2|Single oral therapeutic dose of 5mg [14C]-DA-1229
89325027|NCT01226290|Experimental|VizAblate treatment|VizAblate System: subject acts as her own control
89325028|NCT02267980|Active Comparator|Group SK|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.
89325029|NCT02267980|Placebo Comparator|Group SS|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Patients in Group SS (n=30) received saline in the same manner.
89325030|NCT01225666|Experimental|Weekly low dose|MOD-4023
89325031|NCT01225666|Experimental|Weekly middle dose|MOD-4023
89325032|NCT01225666|Experimental|Weekly high dose|MOD-4023
89325033|NCT01225666|Experimental|Every-other week dose|MOD-4023
89325034|NCT01225276|Experimental|Dosage Arm 1|NewGam 10% 0.4 g/kg
89325035|NCT01225276|Experimental|Dosage Arm 2|NewGam 10% 1.0 g/kg
89325036|NCT01225276|Experimental|Dosage Arm 3|NewGam 10% 2.0 g/kg
89325037|NCT01225276|Placebo Comparator|Dosage Arm 4|Placebo 0.9% Saline
89325038|NCT02268136|Experimental|BIII 890 CL|single increasing doses
89325039|NCT02268136|Placebo Comparator|Placebo|
89325040|NCT01224262|Experimental|Fluzone + 0.45 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg)
89325041|NCT01224262|Experimental|Fluzone + 1.8 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg)
89325042|NCT01224262|Active Comparator|Fluzone|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
89325043|NCT04475458||LANDMARK|The children who underwent circumcision received general anesthesia plus dorsal penis nerve block performed by the surgeon with a landmark technique.
89325044|NCT04475458||ULTRASOUND|The children who underwent circumcision received sedation (in spontaneous breathing) plus ultrasound-guided dorsal penis nerve block.
89325045|NCT01222702|Experimental|Cadazolid 250 mg|Subjects received 250 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
89325046|NCT01222702|Experimental|Cadazolid 500 mg|Subjects received 500 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
89325047|NCT01222702|Experimental|Cadazolid 1000 mg|Subjects received 1000 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
89325048|NCT01222702|Active Comparator|Vancomycin 125 mg|Subjects received one vancomycin capsule (125 mg) four times daily and reconstituted placebo-matching cadazolid suspension twice daily for 10 days
89325049|NCT01204762|Experimental|Part A Arm 1: pegIFN (180 μg)|
89325050|NCT01204762|Active Comparator|Part A Arm 2: pegIFNα-2a|
89325051|NCT01204762|Experimental|Part B: pegIFN lambda + Entecavir|
89325052|NCT04475068||Moderate to severe ARDS patients due to COVID-19 infection|Mechanically ventilated patients with moderate to severe ARDS due to COVID-19 infection admitted to the COVID Intensive Care Unit of Rebagliati Hospital.
89325053|NCT02235922|Experimental|Dual task training|Dual task training
89325054|NCT02235922|Experimental|Conventional training|Conventional training
89325055|NCT02236078|Experimental|High dose isoniazid|INH 900 mg daily to be administered orally for 6 days (600 mg for patients weighing <45 kg)
89325056|NCT01198834|Placebo Comparator|Placebo Patch|Treatment with Placebo Patch
89325057|NCT01198834|Experimental|MRX-7EAT Patch|Treatment with MRX-7EAT Patch
89325058|NCT01198834|Experimental|Lidocaine Patch|Treatment with Lidocaine Patch
89325059|NCT01198834|Experimental|Etodolac Patch|Treatment with Etodolac Patch
89325060|NCT01193140|Experimental|Arm A|
89325061|NCT04474756|Experimental|Mandibular Advancement Devices Narval™|The tested device Narval™ will be a custom-made adjustable bi-block mandibular advancement device, that is made with semi-rigid plastic materials (bio-compatible polymer) and customized using a high-precision computer-aided design (CAD)/computer-aided manufacturing (CAM) ) (ResMed, Narval CC™). The Mandibular Advancement Devices will be gradually adjusted to provide mandibular advancement over a 15-mm range. Each Mandibular Advancement Device will be ﬁtted by a dental specialist with an initial advancement of about 60 % of maximal jaw protrusion. During titration, mandibular advancement will be adjusted at the discretion of the dental specialist.
89325062|NCT04474756|Active Comparator|Mandibular Advancement Devices TALI ™|"The control device TALI ™ is a mandibular advancement orthesis, customized and manufactured by the laboratoire TALI, of the bi-bloc type consisting of rigid gutters thermo-formed on the plaster dental arches and articulated by two links of variable size allowing to adjust the advance in steps of 1 millimeter. This orthesis is manufactured on molding from bio-compatible plastic materials. The different sizes of rods proposed allow mandibular advances of 4 mm to 16 mm. Two clinical studies evaluated the effectiveness of the AMC / AMO orthosis (initial version of the TALI orthesis, with non-curved links) in patients with OSA. They have already demonstrated the effectiveness of the TALI orthesis by decreasing AHI and drowsiness; most patients preferred to use the orthesis (76.4% vs. 9.1%)11."
89523468|NCT03420781|Experimental|Randomized Withdrawal Period: Placebo then Relamorelin 10 μg|Participants who received placebo-matching relamorelin injected subcutaneously twice daily for 40 weeks, followed by relamorelin 10 μg injected twice daily for up to 6 weeks in the Randomized Withdrawal (RW) Period.
89325063|NCT03951064|Experimental|Optimal PEEP|The waveforms of airway pressure (Paw), esophageal pressure (Pes), and transpulmonary pressure (Ptp) will be visualized on the ventilator. Ptp is obtained from Paw - Pes. PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP). Measurements will be obtained daily and adjustments to PEEP will occur daily. PEEP will be reduced below Optimal PEEP in the setting of hemodynamic compromise (requiring increasing vasoactive medications for blood pressure support).
89325064|NCT03951064|Active Comparator|ARDSNet High PEEP|PEEP in the control group will be determined by High PEEP ARDSnet PEEP/FiO2 table. Titration of PEEP will occur when clinically indicated by partial pressure of oxygen (PaO2) or oxygen saturation (SpO2), and FiO2. The investigators chose the High PEEP table based on the clinical suspicion that obese patients may require higher PEEP levels on average than non-obese patients to balance the additional pressure of their chest wall. In addition, EPVent2, a study of esophageal balloon PEEP titration in patients with ARDS utilized the High PEEP table. Patients with moderate and severe ARDS benefit from higher levels of PEEP.
89325065|NCT01192906|Experimental|1|
89325066|NCT01192906|Experimental|2|
89325067|NCT01192906|Placebo Comparator|3|
89325068|NCT01189396|Experimental|T|Four doses of A006 taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
89325069|NCT01189396|Active Comparator|R|Four doses of Proventil-HFA taken in 30 minute intervals. Doses will have an escalating number of inhalations (2, 2, 4, and 8 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
89325070|NCT01189396|Placebo Comparator|P|Four doses of Placebo DPI taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 0 mcg.
89325071|NCT05626972|Active Comparator|Tenecteplase (TNK)|Drug: Alteplase (tPA) Dose: 0.9 mg/kg Route: Intravenous (IV) infusion
89325072|NCT05626972|Active Comparator|Alteplase (tPA)|Drug: Tenecteplase (TNK) Dose: 0.25 mg/kg Route: Intravenous (IV) bolus injection
89325073|NCT01187836|Experimental|TRV120027|
89325074|NCT01187836|Placebo Comparator|Placebo|
89325075|NCT02268760|Experimental|BILN 2061 ZW single rising doses|
89325076|NCT02268760|Placebo Comparator|Placebo|
89325077|NCT02268760|Experimental|BILN 2061 ZW fixed dose fed|
89325078|NCT02268760|Active Comparator|BILN 2061 ZW fixed dose fasted|
89325079|NCT01095562|Experimental|ABT-126 Dose 1|
89325080|NCT01095562|Experimental|ABT-126 Dose 2|
89325081|NCT01095562|Placebo Comparator|Sugar Pill|
89325082|NCT01174732|Experimental|T1|A006 albuterol inhalation powder, 120 mcg/inhalation, 1 inhalation
89325083|NCT01174732|Experimental|T2|A006 albuterol inhalation powder 180 mcg/ inhalation, 1 inhalation
89325084|NCT01174732|Experimental|T3|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
89325085|NCT01174732|Experimental|T4|A006 albuterol inhalation powder 180 mcg/inhalation, 2 inhalations
89325086|NCT01174732|Placebo Comparator|P|Placebo, 2 inhalations
89325087|NCT01174732|Active Comparator|R1|Proventil 90 mcg/inhalation, 2 inhalations
89325088|NCT01174732|Active Comparator|R2|Proventil 90 mcg/inhalation, 4 inhalations
89325089|NCT01077700|Experimental|ABT-288 Dose 1|low dose of ABT-288
89325090|NCT01077700|Experimental|ABT-288 Dose 2|high dose of ABT-288
89325091|NCT01077700|Placebo Comparator|Sugar Pill|inactive substance
89325092|NCT02236234|Experimental|Vaccine|one group with HPV vaccine
89325093|NCT02268838|Experimental|50 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 1, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
89325094|NCT02268838|Experimental|100 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 2, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
89325095|NCT02268838|Experimental|200 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
89325096|NCT02268838|Experimental|400 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 8, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
89325097|NCT02268838|Experimental|200 mg E6007 fed condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fed condition. Drug administration on 1 day (Day 1).
89325098|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.100 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Otamixaban (0.080 mg/kg bolus followed by 0.100 mg/kg/h infusion)~Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Placebo (for Eptifibatide)"
89325099|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.140 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Otamixaban 0.080 mg/kg bolus followed by 0.140 mg/kg/h infusion)~Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Placebo (for Eptifibatide)"
89325100|NCT01076764|Active Comparator|UFH + Eptifibatide|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Placebo (for Otamixaban)~Drug B: UFH (60 IU/kg bolus followed by 12 IU/kg/h infusion)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Eptifibatide (180 mcg/kg bolus followed by 2 mcg/kg/min infusion)"
89325101|NCT02269072|Active Comparator|Testosterone|Testosterone cream applied daily
89325102|NCT02269072|Placebo Comparator|Placebo|Identical placebo cream applied daily
89325103|NCT01071850|Experimental|ASP1941 lowest dose|oral tablet
89325104|NCT01071850|Experimental|ASP1941 low dose|oral tablet
89325105|NCT01071850|Experimental|ASP1941 high dose|oral tablet
89325106|NCT01071850|Experimental|ASP1941 highest dose|oral tablet
89325107|NCT01071850|Active Comparator|Metformin|oral tablet
89325108|NCT01071850|Placebo Comparator|Placebo|oral tablet
89325109|NCT01071226|Experimental|Stratum 1|Patients receiving an unrelated donor or partially matched related donor.
89325110|NCT01071226|Experimental|Stratum 2|For the patient's whose donors are haploidentical or a 2 antigen mismatched where one of the mismatches includes DRB1
89325111|NCT03758404|Experimental|Low dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single low dose AAV CNGA3
89325112|NCT03758404|Experimental|Intermediate dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single intermediate dose AAV CNGA3
89325113|NCT03758404|Experimental|High dose adeno-associated virus (AAV) CNGA3|Subretinal administration of a single high dose AAV CNGA3
89325114|NCT02269228|Experimental|Asasantin ER|Administered once daily (days 1 to 7), followed by twice daily administration (days 8 to 14)
89325115|NCT02269228|Experimental|Asasantin ER, administered twice daily from day 1 to day 14|
89325116|NCT02269228|Placebo Comparator|Placebo|
89325117|NCT03722212|Other|Prospective patients|The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.
89325118|NCT03722212|Other|Retrospective patients|Patients with confirmed Glut1DS diagnosis Already diagnosed patients are included retrospectively as well as patients with pending diagnosis at inclusion (inconsistent biological or genetic data).
89325119|NCT01167244|Experimental|BMS-690514|
89325120|NCT05624320|Experimental|single center open label, single arm study with no control and no randomization|Investigators will enroll 30 presbyopic patients between the ages of 40-55 years old who have undergone successful contact lens fitting in single-use, daily, contact lenses between the spectacle lens powers of -4.00 -to +1.00, in both eyes for best distance correction by the primary investigator
89325121|NCT01037062|Experimental|Entecavir|
89325122|NCT03687502|Experimental|Experimental|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, up to 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
89325123|NCT03654976|Experimental|Active treatment|Subject's ICS or ICS/LABA background medication plus HDM SLIT-tablet
89325124|NCT03654976|Placebo Comparator|Placebo|Subject's ICS or ICS/LABA background medication plus placebo oral tablet
89325125|NCT02269306|Experimental|clomiphen citrate(cc)|Initial CC doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles.
89325126|NCT01167166|Experimental|rigosertib|Patients will receive 2400 mg dose of rigosertib as a intravenous continuous infusion over 24 hours for 72 to 120 consecutive hours every 2 weeks for the first 4 weeks then will receive oral rigosertib at a 560 mg twice-daily dose as capsules taken continuously.
89325127|NCT02269384|Sham Comparator|No History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
89325128|NCT02269384|Active Comparator|History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
89325129|NCT02236468|Experimental|new EHFP|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
89325130|NCT02236468|Experimental|old EHFP+WASH|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication since 2014
89325131|NCT02236468|Other|new EHFP+WASH|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014 + WASH/malaria behavior change communication since 2014
89325132|NCT02236468|Other|old EHFP+WASH+LNS distribution|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication and distribution of LNS since 2014
89325133|NCT01035502|Experimental|Elacytarabine plus idarubicin|
89325134|NCT01030432|Experimental|Phase 2a: Arm 1|
89325135|NCT01030432|Placebo Comparator|Phase 2a: Arm 2|
89325136|NCT01030432|Experimental|Phase 2b: Arm 1|
89325137|NCT01030432|Placebo Comparator|Phase 2b: Arm 2|
89325138|NCT02269462||Pregnant women - efavirenz|Pregnant women taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health
89325139|NCT02269462||Nursing mothers - efavirenz|Nursing mothers taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
89325140|NCT02269462||Pregnant women - nevirapine|Pregnant women taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health
89325141|NCT02269462||Nursing mothers - nevirapine|Nursing mothers taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
89325142|NCT02261506|Active Comparator|7 days|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
89325143|NCT02261506|Active Comparator|14 days|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
89325144|NCT02269540|Experimental|Sertraline and n-acetylcysteine|Sertraline and n-acetylcysteine for seven weeks of treatment
89325145|NCT02269540|Experimental|Citalopram and n-acetylcysteine|Citalopram and n-acetylcysteine for seven weeks of treatment
89325146|NCT02269540|Experimental|Existing medication treatment & NAC|Existing depression medication treatment and n-acetylcysteine for seven weeks of treatment
89325147|NCT02261584|Experimental|Microwave Thermal Coagulation|MW ablation performed either laparoscopically or percutaneously is a safe, effective, and minimally invasive technique for the management of hypersplenism in patients with liver cirrhosis. It may significantly increase platelet count and white blood cell (WBC) count and improve hepatic blood supply with fewer complications. Ablating more than 40% of the splenic parenchyma may yield better long term results. This method may provide a new and promising minimally invasive alternative for treating hypersplenism.
89325148|NCT02261584|Experimental|Partial Splenic Embolization Catheter|Partial splenic embolization (PSE), which was first performed by Spigos et al in 1979, has been considered first-line therapy for hypersplenism in many institutions, and has been proposed as an effective alternative to splenectomy for improving peripheral blood cell counts. However, PSE is associated with many complications, including intermittent fever, abdominal pain, nausea, vomiting, post-embolization syndrome, splenic abscess, splenic rupture, pneumonia, refractory ascites, pleural effusion and gastrointestinal bleeding. To ensure a sustained and long-term increase in platelet and leucocytic counts, the splenic infarction rate needs to be greater than 50% (8). Thus, severe complications can ensue.
89325149|NCT05621122||Omnivours|100 subjects (comparison group)
89325150|NCT05621122||Vegans|50 subjects, adults aged over 18 years, voluntarly participating in this observational study
89325151|NCT05621122||Lacto-ovo-vegetarians|50 subjects, adults aged over 18 years, voluntarly participating in this observational study
89325152|NCT05621122||Pesco-vegetarians|50 subjects, adults aged over 18 years, voluntarly participating in this observational study
89325153|NCT05621122||Pro-vegetarians|50 subjects, adults aged over 18 years, voluntarly participating in this observational study
89325154|NCT02269618|Active Comparator|Control group (Group A)|The patients will be followed in the usual care manner by GPs and by routine specialist visits, if needed
89325155|NCT02269618|Other|Intervention group (Group B)|"Group B (Home-based intervention): the patients will be followed at home for 4 months by nurse and therapist and will perform an individual rehabilitative program. The interventions will be:~Home-based telehealth program~Home-based rehabilitation"
89325156|NCT01023880|Experimental|1|CEP-18770
89325157|NCT02269696|Experimental|Metoprolol|Metoprolol infusion
89325158|NCT02269696|Placebo Comparator|Normal saline|Equal volume of saline.
89325159|NCT03135184|Experimental|HDL Therapeutics PDS-2™ System|Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
89325160|NCT05613400|Experimental|Simvastatin 10mg/day|One simvastatin 10mg-tablet and one placebo tablet with the shape of ezetimibe 10mg each day.
89325161|NCT05613400|Active Comparator|Ezetimibe 10mg/day|One ezetimibe 10mg-tablet and one placebo tablet with the shape of simvastatin 10mg each day.
89325162|NCT03134950|Experimental|ADAPT|Aim to Decrease Anxiety and Pain Treatment (ADAPT) is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions are in person with a trained psychologist and the following 2-4 sessions are web-based. Each web-based session is followed by phone support.
89325163|NCT03134950|No Intervention|Medical Treatment as Usual|Medical treatment as usual
89325164|NCT02261662|Experimental|Ribavirin and Betamethasone|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
89325165|NCT02261662|Experimental|Betamethasone alone|Topical steroids alone will be used; Betamethasone.
89325166|NCT02269774|Other|Pulmonary vein isolation|Intra-thoracic pressure swings induced by breathing manoeuvres during standard catheter-ablation procedure. Catheter-based electrical mapping and pressure in the left atrium and pulmonary veins during standard catheter-ablation procedure. Only patients with an apnea-hypopnea index > 5/h and documented premature atrial beats during the Mueller manoeuvre will be eligible for the catheter-based electrical mapping. Follow-up after 1 year for atrial fibrillation recurrence.
89325167|NCT02269774|No Intervention|No intevention|Intra-thoracic pressure swings induced by breathing manoeuvres during ECG-monitoring. Only patients with an apnea-hypopnea index < 5/h and no premature atrial beats during the Mueller manoeuvre will be assigned to the no intervention arm.
89325168|NCT02261740|Experimental|Yoga Therapy Group|Participants will attend twice-weekly group yoga classes and be instructed to practice yoga at home one additional hour a week, using a written manual.
89325169|NCT01016782|Experimental|Test|Test product that contains active pharmaceutical ingredient
89325170|NCT01016782|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
89325171|NCT01016782|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
89325172|NCT02269852|Experimental|trivalent seasonal influenza vaccine|"Northern hemisphere 2013-2014 trivalent seasonal influenza vaccine~60 infants: two-dose regimen with a 28-day interval;~60 adults: single-dose regimen;~60 seniors: single-dose regimen;"
89325173|NCT02269930|Experimental|Group 1|Treatment Sequence 1: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41 Treatment Sequence 2: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29
89325174|NCT02269930|Experimental|Group 2|Treatment Sequence 1: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29 Treatment Sequence 2: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41
89325175|NCT02261896|Experimental|Placebo|1 intravenous dose followed by 1 oral dose each 12 hours (complete 3 days)
89325176|NCT02261896|Active Comparator|Antibiotic|Ciprofloxacin 400 mg intravenous one dose followed by ciprofloxacin 500 mg oral each 12 hours (complete 3 days)
89325177|NCT02262052|Other|Phase 4 cohort study|MRDTI
89325178|NCT02270008|Active Comparator|Pelvic floor training|The intervention group will undergo an in-person standardized training session by a trained nurse practitioner. The intervention is the pelvic floor training session. They will then be asked to continue muscle training at home at regular intervals and asked to log their exercises on a standardized exercise diary that is provided to them.
89325179|NCT02270008|No Intervention|Literature-only group|The literature-only group will receive a pamphlet with instructions for pelvic floor muscle exercises; however, no in-person training will be administered.
89523469|NCT03420781|Experimental|Randomized Withdrawal Period: Relamorelin 10 μg then Relamorelin 10 μg|Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by relamorelin injected twice daily for up to 6 weeks in the RW Period.
89523470|NCT03420781|Experimental|Randomized Withdrawal Period: Relamorelin 10 μg then Placebo|Participants who received relamorelin 10 μg injected subcutaneously twice daily for 40 weeks, followed by placebo-matching relamorelin injected twice daily for up to 6 weeks in the RW Period.
89325180|NCT00035555|Experimental|Belatacept: More intensive (MI) regimen|The MI regimen was designed to achieve projected serum trough concentrations of belatacept of approximately 20 μg/mL through Day 99, and approximately 5 μg/mL through Day 183 (10 mg/kg on Days 1, 5, 15, 29, 43, 57, 71, 85, 113, 141, and 169). After Day 169, patients were reallocated and dosed to achieve projected trough serum concentrations of approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 197). Those patients who received belatacept every 8 weeks received placebo infusions on scheduled treatment dates between infusions of active drug to maintain the blind between treatment regimens. Patients initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the patient was able to tolerate medications by mouth. Corticosteroids given daily.
89325181|NCT00035555|Experimental|Belatacept: Less intensive (LI) regimen|The LI regimen was designed to achieve projected trough serum concentrations of belatacept of approximately 20 μg/mL through Day 29, and approximately 5 μg/mL through Day 99 (10 mg/kg on Days 1, 15, 29, 57 and 85). After Day 85, these subjects were reallocated and dosed to achieve projected trough serum concentrations of either approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 113). Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
89325182|NCT00035555|Experimental|Cyclosporine regimen|The initial daily dose was 7±3 mg/kg. Subsequent doses were adjusted to maintain a predefined range of serum concentrations: 1st month, target level 150-400 ng/mL; after 1st month, target level of 150-300 ng/mL. Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
89325183|NCT01087385||Troponin T elevation|
89325184|NCT01087385||No troponin T elevation|
89325185|NCT01087463|Experimental|single arm|In this single arm study, the Quantum nailing system will be used in all patients.
89325186|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 40 units|
89325187|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 80 units|
89325188|NCT01097369||Anti-rasburicase antibodies|
89325189|NCT01097447||Ciprofloxicine or Vigamox or other|up to qid till epithelialized.
89325190|NCT01097447||Topical Nonsteroidal (Acular, Acuvail, Voltaren Xibrom|up to qid for up to 5-10 days postop
89325191|NCT01097447||Topical steroid (FML, Pred Forte, Flarex|qid for up to 8 weeks
89325192|NCT03953105||Resusci Baby|Resusci Baby used for the simulated emergency scenario
89325193|NCT03953105||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
89325194|NCT01097525|Active Comparator|Wavefront guided (WFG) PRK|
89325195|NCT01097525|Active Comparator|WFG LASIK|
89325196|NCT01097525|Active Comparator|Wavefront optimized (WFO) PRK|
89325197|NCT01097525|Active Comparator|WFO LASIK|
89325198|NCT01097681|Experimental|Normal renal function group|oral
89325199|NCT01097681|Experimental|Mild renal impairment group|oral
89325200|NCT01097681|Experimental|Moderate renal impairment group|oral
89325201|NCT01087697|Experimental|Implanted with NUC|Patients who have been implanted with the Neo-Urinary Conduit
89325202|NCT01087853|Active Comparator|Phase A1: Plasmalyte|Plasmalyte
89325203|NCT01087853|Active Comparator|Phase A2: 0.9% Saline|0.9% Saline
89325204|NCT01087853|Active Comparator|Phase B1: PlasmaVolume|PlasmaVolume
89325205|NCT01087853|Active Comparator|Phase B2: Voluven|Voluven
89325206|NCT01088009|Experimental|early add-on|
89325207|NCT01088009|Active Comparator|SOC|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
89325208|NCT01088009|Other|De-novo combination|patients in this arm will receive oral lamivudine 100mg and adefovir 10mg for 104 weeks
89325209|NCT03894046|Experimental|Part A - Group 1|"Part A was the pivotal, assessor-blind, randomized, comparative portion of the study in patients with documented ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), ventilated pneumonia (VP), or bacteremia.~Part A - Group 1 (experimental): 1.0 g sulbactam/1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h) plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h"
89325210|NCT03894046|Active Comparator|Part A - Group 2|Part A - Group 2 (control group): 2.5 mg/kg colistin IV infused over 30 minutes every 12 hours (after an initial loading dose of colistin 2.5 to 5 mg/kg) plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h.
89325211|NCT03894046|Experimental|Part B - Group 3|"Part B (Group 3) was the open-label, supportive portion of the study that included patients known to have HABP, VABP, VP, and/or bacteremia infections associated with ABC organisms resistant to colistin or polymyxin B, who failed a colistin or polymyxin B regimen prior to study entry or were on acute renal replacement therapy, and patients with infections due to colistin- or polymyxin B-resistant ABC with sources of infection other than HABP, VABP, VP, and/or bacteremia.~Part B - Group 3: 1.0 g ETX2514/1.0 g sulbactam IV infused over 3 hours q6h plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h."
88816009|NCT02980094|Experimental|Milk Antioxidant and oil(AO)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control C+sunflower oil+vitamin E+selenium (AO) .
89325212|NCT02271490|Active Comparator|micoinjection according to classical protocole|incubation of sperm in incubation medium
89325213|NCT02271490|Experimental|incubation in follicular fluid|incubation of sperm in follicular fluid prior to microinjection
89325214|NCT04475614|No Intervention|informative|The patients in this group received only verbal and written information about their condition.
89325215|NCT04475614|Experimental|oral probiotics|The patients in this group, beside verbal and written information about their condition, received also oral probiotics. They were instructed to melt one lozenge in the mouth in the evening, after tooth brushing and flossing, for one month.
89325216|NCT04475614|Experimental|low level laser treatment|The patients in this group, beside verbal and written information about their condition, received a total of ten low level laser treatments, for ten days consecutively excluding weekends.
89325217|NCT04475614|Experimental|B-vitamin injections|The patients in this group, beside verbal and written information about their condition, received a total of nine B vitamin injections, every other day, intra muscular.
89325218|NCT02262208|Other|Patients with type 2 diabetes|
89325219|NCT02262208|Other|Healthy|
89325220|NCT02262286||Brain Injury|Brain Injury
89325221|NCT02262286||Control|Healthy, or Head Trauma, or Orthopedic Trauma, or Poly-Trauma
89325222|NCT01154374|Experimental|MEBO Wound Ointment|Topical application twice daily
89325223|NCT01154374|Active Comparator|Standard of Care (sterile saline moistened gauze)|Topical application twice daily
89325224|NCT02262442|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
89325225|NCT02262442|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
89325226|NCT02271724||CIDP/MMN newly diagnosed (drug naive)|"Patients, who are suspected to suffer from CIDP or MMN, will undergo a lumbar puncture as a part of the diagnostic procedure. We expect to include 5-10 patients.~Lumbar puncture Blood sample"
89325227|NCT02271724||CIDP/MMN treated|"All patients with established CIDP in maintenance treatment with SCIG or IVIG are recruited from local registries at the outpatient clinic at Department of Neurology, Aarhus University Hospital.~We expect that 10-15 patients with CIDP and MMN treated with SCIG or IVIG eligible for inclusion. Furthermore, we expect to include 10 CIDP and MMN patients in maintenance therapy from the outpatient clinics at Department of Neurology, Odense University Hospital and Department of Neurology, Aalborg University Hospital."
89325228|NCT02271724||Other peripheral neuropathies|Patients who are diagnosed with other causes of peripheral neuropathies than CIDP. We expect to include 20 patients
89325229|NCT02271724||Syptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study plus healthy controls. We expected to include 40-50 symptomatic controls
89325230|NCT01143064|Active Comparator|Progesterone|
89325231|NCT01143064|Placebo Comparator|Lipid emulsion without progestrone|
89325232|NCT05247502||ICU patients without Acute Kidney Injury|"Intensive care unit (ICU) patients who do not develop acute kidney injury (AKI) during their stay.~AKI will be defined by KDIGO stage 1.~The baseline serum creatinine (sCr) measurement will be defined as the sCr at admission if the corresponding estimation of glomerular filtration rate (GFR) by CKD-EPI formula is at least 90ml/min/1.73m2. Otherwise, the most recent sCr measured from 7-365 days prior to admission will be used. If there is no sCr measurement available from this period, it will be estimated using a reverse CKD-EPI formula for a GFR of 75 ml/min/1.73m2.~No intervention is foreseen out of the observation of data relative to kidney function during ICU stay, at 3 month and 12 month of ICU admission.~There will be no biological sample collection."
89325233|NCT05247502||ICU patients with transient Acute kidney injury|"Transient AKI will be defined as a complete renal recovery within 48 hours after the start of AKI.~Complete renal recovery will be defined as a return to within 25% of the baseline serum creatinine measurement. TIf several AKI episodes occur during the patient's ICU stay, only the longest episode will be considered.~No intervention is foreseen out of the observation of data relative to kidney function during ICU stay, at 3 month and 12 month of AKI start.~There will be no biological sample collection."
89325234|NCT05247502||ICU patients with persistent Acute kidney injury|"If the AKI episode lasts longer than 48 hours, it will be classified as persistent AKI. If several AKI episodes occur during the patient's ICU stay, only the longest episode will be considered.~No intervention is foreseen out of the observation of data relative to kidney function during ICU stay, at 3 month and 12 month of AKI start.~There will be no biological sample collection."
89325235|NCT00033371|Active Comparator|Arm I: Celecoxib and Placebo|Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
89325236|NCT00033371|Experimental|Arm II: Celecoxib and Eflornithine|Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
89325237|NCT01001338|Experimental|RDEA594 200 mg qd|RDEA594 200 mg qd plus allopurinol qd
89325238|NCT01001338|Experimental|RDEA594 200 mg, 400 mg qd|"RDEA594 200 mg then 400 mg qd plus allopurinol qd.~Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
89325239|NCT01001338|Placebo Comparator|Matching Placebo|"RDEA594 matching placebo qd plus allopurinol qd, then allopurinol qd alone in open label period.~Patients on allopurinol qd alone were discontinued after protocol amendment 16 dated 07 October 2015."
89325240|NCT01001338|Experimental|RDEA594 600 mg qd|"RDEA594 200 mg then 400 mg then 600 mg plus allopurinol qd~Patients on lesinurad 600 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
89325241|NCT01093313|Experimental|Attention training|
89325242|NCT01093313|Active Comparator|Cognitive therapy|
89325243|NCT03952949|Experimental|Default|Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
89325244|NCT03952949|Active Comparator|Nutrition Education|Participants in the nutrition education condition were instructed to read a brief education brochure before online grocery shopping.
89325245|NCT01097759||LigaSure|LigaSure is a vascular sealing device that can seal the hemorrhoidal plexus during hemorrhoidectomy (surgery)
89325246|NCT01097759||Stapler|Circular stapler that removes excess loose tissue above the anus and interrupts the blood supply during hemorrhoidal surgery
89325247|NCT03952715|Experimental|Evoked pain training|
89325248|NCT03952715|Experimental|Control|
89325249|NCT01137526|Experimental|ABT-384 Dose 1|
89325250|NCT01137526|Experimental|ABT-384 Dose 2|
89325251|NCT01137526|Active Comparator|donepezil|
89325252|NCT01137526|Placebo Comparator|placebo|
89325253|NCT00993382|Experimental|Celivarone 50 mg|Celivarone, 50 mg once daily up to 10-15 days before the common study end date
89325254|NCT00993382|Experimental|Celivarone 100 mg|Celivarone, 100 mg once daily up to 10-15 days before the common study end date
89325255|NCT00993382|Experimental|Celivarone 300 mg|Celivarone, 300 mg once daily up to 10-15 days before the common study end date
89325256|NCT00993382|Active Comparator|Amiodarone|Amiodarone, 600 mg once daily for 10 days (loading dose) then 200 mg once daily up to 10-15 days before the common study end date
89325257|NCT00993382|Placebo Comparator|Placebo|Matching placebo once daily up to 10-15 days before the common study end date
89325258|NCT00081731|Active Comparator|Optimal Medical Therapy|Optimal anti-hypertensive therapy
89325259|NCT00081731|Experimental|Stenting|Stent procedure plus optimal anti-hypertensive therapy
89325260|NCT00911248|Experimental|PTC299|PTC299 administered at 100 mg/dose twice per day
89325261|NCT00909766|Active Comparator|Panel A|
89325262|NCT00909766|Active Comparator|Panel B|
89325263|NCT00909766|Active Comparator|Panel C|
89325264|NCT00909766|Active Comparator|Panel D|
89325265|NCT00909766|Active Comparator|Panel E|
89325266|NCT00909766|Active Comparator|Panel F|Low Dose
89325267|NCT00909766|Active Comparator|Panel G|High Dose
89325268|NCT00909766|Placebo Comparator|Panel H|
89325269|NCT05628610|Experimental|Tislelizumab combined with radiotherapy|
89325270|NCT05628610|Experimental|Tislelizumab combined with chemotherapy|
89325271|NCT00079937|Experimental|Omalizumab|Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
89325272|NCT00079937|Placebo Comparator|Placebo|Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
89325273|NCT00909610|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg dosed in second period.
89325274|NCT00909610|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.
89325275|NCT00909298|Experimental|1|TTP889 300 mg
89325276|NCT00909298|Placebo Comparator|2|TTP889 Placebo
89325277|NCT03961607|Experimental|Painless Photodynamic Therapy(P-PDT) group|The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid#ALA#cream for 30min. A repeat treatment was administered once weekly for a maximum of 3 weeks.
89325278|NCT03961607|Active Comparator|Conventional Photodynamic Therapy(C-PDT) group|The conventional photodynamic therapy(C-PDT) group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 50 J/cm2) after applying 5% 5-aminolevulinic acid cream for 1.5h.A repeat treatment was administered once weekly for a maximum of 3 weeks.
89325279|NCT00908752|Active Comparator|Brivanib|Adjuvant treatment with TACE Therapy
89325280|NCT00908752|Placebo Comparator|Brivanib Placebo|Placebo adjuvant treatment with TACE Therapy
89325281|NCT03126110|Experimental|Phase 1 Group A: INCAGN01876 1.0 mg/kg Q2W + nivolumab 240 mg Q2W|Participants received INCAGN01876 1.0 milligrams per kilogram (mg/kg) administered intravenously (IV) every 2 weeks (Q2W) in combination with nivolumab 240 mg administered IV Q2W.
89325282|NCT03126110|Experimental|Phase 1 Group A: INCAGN01876 3.0 mg/kg Q2W + nivolumab 240 mg Q2W|Participants received INCAGN01876 3.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
89325283|NCT03126110|Experimental|Phase 1 Group A: INCAGN01876 5.0 mg/kg Q2W + nivolumab 240 mg Q2W|Participants received INCAGN01876 5.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
89325284|NCT03126110|Experimental|Phase 1 Group A: INCAGN01876 10.0 mg/kg Q2W + nivolumab 240 mg Q2W|Participants received INCAGN01876 10.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
89325285|NCT03126110|Experimental|Phase 1 Group B: INCAGN01876 1.0 mg/kg Q2W, then nivolumab 240 mg Q2W|Participants received INCAGN01876 1.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by INCAGN01876 1.0 mg/kg Q2W in combination with nivolumab 240 mg administered IV Q2W starting at Cycle 3.
89325286|NCT03126110|Experimental|Phase 1 Group B: INCAGN01876 3.0 mg/kg Q2W, then nivolumab 240 mg Q2W|Participants received INCAGN01876 1.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by INCAGN01876 1.0 mg/kg Q2W in combination with nivolumab 240 mg administered IV Q2W starting at Cycle 3.
89325287|NCT03126110|Experimental|Phase 1 Group B: INCAGN01876 5.0 mg/kg Q2W, then nivolumab 240 mg Q2W|Participants received INCAGN01876 5.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by INCAGN01876 5.0 mg/kg Q2W in combination with nivolumab 240 mg administered IV Q2W starting at Cycle 3.
89325288|NCT03126110|Experimental|Phase 1 Group C: INCAGN01876 1.0 mg/kg Q2W + ipilimumab 1 mg/kg Q6W|Participants received INCAGN01876 1.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV every 6 weeks (Q6W).
89325289|NCT03126110|Experimental|Phase 1 Group C: INCAGN01876 3.0 mg/kg Q2W + ipilimumab 1 mg/kg Q6W|Participants received INCAGN01876 3.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.
89325290|NCT03126110|Experimental|Phase 1 Group C: INCAGN01876 5.0 mg/kg Q2W + ipilimumab 1 mg/kg Q6W|Participants received INCAGN01876 5.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.
89325291|NCT03126110|Experimental|Phase 1 Group D: INCAGN01876 + Nivolumab + Ipilimumab|Participants received INCAGN01876 1.0 mg/kg administered IV Q2W in combination with nivolumab 3 mg/kg administered IV Q2W and ipilimumab 1 mg/kg administered IV Q6W.
89325292|NCT03126110|Experimental|Phase 2 Group C2 PD-1/PD-L1: INCAGN01876 300 mg + ipilimumab 1 mg/kg|Participants with programmed cell death protein/programmed cell death ligand 1 (PD-1/PD-L1) relapsed melanoma received INCAGN01876 300 mg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.
89325293|NCT03126110|Experimental|Phase 2 Group F GC: INCAGN01876 300 mg + nivolumab 240 mg|Participants with gastric cancer (GC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
89325294|NCT03126110|Experimental|Phase 2 Group F SCCHN INCAGN01876 300 mg + nivolumab 240 mg|Participants with squamous cell carcinoma of the head and neck (SCCHN) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
89325295|NCT03126110|Experimental|Phase 2 Group F CC: INCAGN01876 300 mg + nivolumab 240 mg|Participants with cervical cancer (CC) received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
89325296|NCT03126110|Experimental|Phase 2 Group F PD-1/PD-L1: INCAGN01876 300 mg + nivolumab 240 mg|Participants with PD-1/PD-L1 relapsed melanoma received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
89325297|NCT03126110|Experimental|Phase 2 Group F Biopsy: INCAGN01876 300 mg + nivolumab 240 mg|Participants with gastric cancer, squamous cell carcinoma of the head and neck, cervical cancer, or PD-1/PD-L1 relapsed melanoma who had tumor lesions that were amenable to percutaneous biopsy received INCAGN01876 300 mg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.
89325298|NCT01088087|Placebo Comparator|Colostrum|
89325299|NCT01088087|No Intervention|Sugar pill|
89325300|NCT00908128|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
89325301|NCT00908128|Active Comparator|CellCept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
89325302|NCT05628454|Experimental|EBUS-TBNSP|The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.
89325303|NCT05628454|Experimental|EBUS-TBNA|The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.
89325304|NCT05628454|Experimental|EBUS-TBNCS|The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
89325305|NCT00906334|Experimental|800 mg/m^2 ON 01910.Na|800 mg/m^2 ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 48 hours (i.e. 2 consecutive 24-hour infusions) every week for the first 3 weeks of 4-week cycle.
89325306|NCT00906334|Experimental|1800 mg ON 01910.Na|1800 mg ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 72 hours (i.e., 3 consecutive 24-hour infusions) every 2 weeks for the first four 2-week cycles and every 4 weeks afterwards.
89325307|NCT00905164|Experimental|Test First|Topiramate Capsules, 25 mg
89325308|NCT00905164|Active Comparator|Reference First|Topamax® Capsules, 25 mg
89325309|NCT05344118||Parents|Parents of children undergoing orthopedic surgery
89325310|NCT05628298||Experimental group|Women in their 2nd and 3rd trimester of pregnancy who have significant pregnancy related pain (>5/10). Subjects will be allowed to use the device during labor and one month postpartum.
89325311|NCT00978016|Experimental|arbaclofen placarbil-Cohort 1|"arbaclofen placarbil 20 mg QD with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
89325312|NCT00978016|Experimental|arbaclofen placarbil-Cohort 2|"arbaclofen placarbil 40 mg QD with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
89325313|NCT00978016|Experimental|arbaclofen placarbil-Cohort 3|"arbaclofen placarbil 20 mg BID with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
89325314|NCT00978016|Experimental|arbaclofen placarbil-Cohort 4|"arbaclofen placarbil 30 mg BID with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
89325315|NCT00978016|Placebo Comparator|Placebo-Cohort 5|"Placebo dose with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
89325316|NCT03181958|Experimental|NHFOV|"neonates assigned to NHFOV will be started with the following boundaries:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment, similar to what is done in endotracheal high frequency oscillatory ventilation targeting a FiO2≤25-30%. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90%-95%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-12Hz). c)Inspiratory time 50% (1:1).d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2o; amplitude will be titrated according to PaCO2."
89325317|NCT03181958|Active Comparator|NCPAP|Neonates assigned to the CPAP group were initiated on a pressure of 5 cmH2O. CPAP can be raised in steps of 1 cmH2O up to 8 cmH2O. If this is not enough to maintain SpO2 between 90% and 95%, FiO2 will be added up to 0.40.
89325318|NCT03181958|Experimental|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of 15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec(according to clinicians' evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at 30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
89325319|NCT05628220|Other|Cohort of motion sickness|one group of patient
89325320|NCT05258240|Other|Virtual Reality|Virtual reality workout session will be for about 50 minutes in which warm-up exercise will be for 5 minutes including relaxed breathing, selected exercises for dynamic balance and static balance will take 40 minutes of the session in which games; tilt city, soccer heading, table tilt game, and penguin tilt will be used for dynamic balance training. For static balance training games will be torso leg curl and single leg extension. After that 5 minutes will be given for cools down.
89325321|NCT05258240|Other|Conventional Physical Therapy|Conventional physical therapy will be provided to this group for 50 minutes, with one minute of rest for every five minutes of exercise. Warm-up for 5 minutes, balancing-drills for 40 minutes, and cools down for five minutes. The session will include; slow and deep breathing exercise for about 3 minutes, patient will be asked to move both ankle joint to its complete range of movement for about five minutes, posture training for balance includes standing from sitting for five times, shifting the weight of the body while standing at one place for five times, move the body to the side and forward to aim the objective set by the therapist for five times, lift or raise the heels for five times of both foot for 20 seconds for each rise, to stand on one foot for 15 seconds, five times, to stand on one foot and bend the knee for about 15 seconds, five times. Wobble board preparation gait training and spot marching will be performed for about 5 to 6 minutes each.
89325322|NCT05240222|Experimental|Theory-informed pre-implementation enhancement strategies (SC-PIES)|The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and subsequent follow-up consultation. The content of SC-PIES was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
89325323|NCT05240222|Sham Comparator|Active control|Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
89325326|NCT01129648|Placebo Comparator|BCX4208 placebo + Allopurinol placebo|Administered daily for 21 days.
89325327|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 100mg|Administered daily for 21 days.
89325328|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 200 mg|Administered daily for 21 days.
89325329|NCT01129648|Active Comparator|BCX4208 Placebo + Allopurinol 300 mg|Administered daily for 21 days.
88806631|NCT05901129|No Intervention|Control|Control group patients were not subjected to any block or local infiltration anesthesia (local anesthetic administration around the incision). Their postoperative pain was relieved with tramadol (intravenous analgesic drug) administration by using patient-controlled analgesia (PCA) device. Patient-controlled analgesia was achieved with tramadol hydrochloride at a concentration of 4 mg per 1 ml with the PCA device. The PCA device was configured to administer the patients boluses of 10 mg tramadol hydrochloride with a lockout time of 20 minutes, allowing a maximum of 4 pushes per hour. The total dose was standardized for all patients with a maximum daily dose of 400 mg and a maximum dose of 100 mg tramadol hydrochloride every 6 hours.
89325330|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol Placebo|Administered daily for 21 days.
89325331|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 100 mg|Administered daily for 21 days.
89325332|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 200 mg|Administered daily for 21 days.
89325333|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 300 mg|Administered daily for 21 days.
89325334|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol placebo|Administered daily for 21 days.
89325335|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 100 mg|Administered daily for 21 days.
89325336|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 200 mg|Administered daily for 21 days.
89325337|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 300 mg|Administered daily for 21 days.
89325338|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol Placebo|Administered daily for 21 days.
89325339|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 100 mg|Administered daily for 21 days.
89325340|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 200 mg|Administered daily for 21 days.
89325341|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 300 mg|Administered daily for 21 days.
89325342|NCT05235698||Patients with long COVID diagnosis|Ophthalmological examinations performed as part of the care Addition of GlycoCheck for the study
89325343|NCT04438720|Active Comparator|Extended Release Nifedipine Tablets（Adalat® GITS）|Extended Release Nifedipine reference formulation at a single dose of 30 mg
89325344|NCT04438720|Experimental|Extended Release Nifedipine Tablets|Extended Release Nifedipine test formulation at a single dose of 30 mg
89325345|NCT00973024|Experimental|JNJ-42160443 1 mg|
89325346|NCT00973024|Experimental|JNJ-42160443 3 mg|
89325347|NCT00973024|Experimental|JNJ-42160443 6 mg/3mg|
89325348|NCT00973024|Experimental|JNJ-42160443 10 mg|
89325349|NCT01314638||Single group|Single group, Identical investigations for all subjects
89325350|NCT03165110|Experimental|Users of the Onyx Blood Glucose Meter/ app System at home|Participants have a diagnosis of either type 1 or type 2 diabetes for at least 6 months and use insulin.
89325351|NCT05239676|Experimental|Treatment of Lymphoma|Refractory and relapsed malignant lymphoma
89325352|NCT05459662|Placebo Comparator|Oat based porridge|Oat based porridge prepared with 64g of oat, 200ml of milk and 10 g of honey by the participant and consumed orally daily for 14 days as breakfast replacement
89325353|NCT05459662|Active Comparator|Enriched plant-based meal|Enriched plant-based meal pots (400 g) mixed with 25g of seeds and nuts consumed orally daily for 14 days as breakfast replacement
89325354|NCT00079781|Active Comparator|Treatment Group|Group of subjects who have undergone RNS® System implantation who are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the blinded Evaluation Period. Stimulation is enabled during the first month post-implant and may continue throughout the subject's participation in the study.
89325355|NCT00079781|Sham Comparator|Sham Group|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the blinded Evaluation Period. Stimulation is enabled after transition into the Follow-Up Period (5th month post-implant) and may continue for the remainder of the subject's participation in the study.
89325356|NCT00079781|Other|Open Label Group|Group of subjects who have undergone RNS® System implantation who were not randomized or blinded to therapy status during the Evaluation Period. Stimulation may have been enabled during the first month post-implant and may have continued throughout the subject's participation in the study.
89325357|NCT05628064|Experimental|1C70 to Pro-Flex XC|Transtibial amputees randomized to start with 1C70 and cross over to Pro-Flex XC
89325358|NCT05628064|Experimental|Pro-Flex XC to 1C70|Transtibial amputees randomized to start with Pro-Flex XC and cross over to 1C70
89325359|NCT03176966|Active Comparator|Vitamin E then Ropinirole|Patients will be provided with vitamin E, 400 international units (IU), at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to Ropinirole. Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
89325360|NCT03176966|Active Comparator|Ropinirole then Vitamin E|Patients will be prescribed ropinirole at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to vitamin E, 400 international units (IU). Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
89325361|NCT03961451||Group With Recommendations (GAR)|Patients in the GAR group will receive several recommendations and will have access to an online tool to increase motivation to engage in physical activity.
89325362|NCT03961451||Control Group (GC)|No recommendation given
89325363|NCT04474444||Hear and treat|phone call, treatment, not attended
89325364|NCT04474444||See and treat|Ambulance crew attended
89325365|NCT03175562|Experimental|Test product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
89325366|NCT03175562|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
89325367|NCT03957317|No Intervention|Control|Subjects in this group do not receive an eye mask or ear plugs, and receive standard of care (including pain control modalities). The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
89325368|NCT03957317|Experimental|Intervention|Subjects in this group receive an eye mask and ear plugs in addition to standard of care for pain control. The subjects will receive a Richards-Campbell Sleep Questionnaire (RCSQ) survey for each night they spend in the Surgical ICU, as well as a modified Family Satisfaction in the Intensive Care Unit (FS-ICU) survey upon discharge from the ICU.
89325369|NCT03961373|Active Comparator|Standard Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2 lymphadenectomy
89325370|NCT03961373|Experimental|Experimental Group|Neoadjuvant chemotherapy + surgical gastrectomy with D2plus lymphadenectomy
89325371|NCT05172466|Experimental|BeCare application|individuals with relapsing-remitting MS (RRMS) on Natalizumab therapy
89325372|NCT00079391|Experimental|allogeneic hematopoietic SCT|allogeneic hematopoietic stem cell transplantation (SCT) using Nexell Isolex system
89325373|NCT03209570|Experimental|TENA Identifi with sensor wear data|All individuals in this arm will receive care planning using TENA Identifi sensor wear data
89325374|NCT03209570|Active Comparator|TENA Identifi without sensor wear data|All individuals in this arm will receive care planning without using TENA Identifi sensor wear data
89325375|NCT00902200|Placebo Comparator|Vehicle|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
89325376|NCT00902200|Experimental|AR-12286 0.05%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
89325377|NCT00902200|Experimental|AR-12286 0.1%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
89325378|NCT00902200|Experimental|AR-12286 0.25%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
89325379|NCT01097837||Epilepsy|Cohort is comprised of women with epilepsy between 18 and 47.
89325380|NCT03209492||Leuprorelin acetate|Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
89325381|NCT01097993|Experimental|1 = Tested product|
89325382|NCT01097993|Active Comparator|2 = Control product|
89325383|NCT01093391|Placebo Comparator|BARE METAL STENT|BARE METAL STENT - STENT CRONUS
89325384|NCT01093391|Experimental|DRUG ELUTING STENT|STENT INSPIRON WITH SIROLIMUS
89325385|NCT05160662|No Intervention|Women with BMI>=35 (2019-2020)|Pregnant women with BMI>=35 delivered at the hospital 2019-2020
89325386|NCT05160662|Experimental|Women with BMI>=35 (2021-2023)|Pregnant women with BMI>=35 delivered at the hospital 2021-2023
88816010|NCT02530515|Experimental|Treatment (ex vivo autologous lymph node lymphocytes)|Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.
89325387|NCT00894868|Experimental|Vildagliptin|
89325388|NCT00894868|Placebo Comparator|Placebo|
89325389|NCT05158010|Other|HELIX's follow-up|
89325390|NCT03956693|Experimental|HEADS: UP|HEADS: UP is group-based mindfulness intervention based on the original mindfulness based stress reduction course, but adapted for people affected by stroke.
89325391|NCT01098149|Active Comparator|AFB stand alone|Patients are switched in AFB treatment, without blood volume control.
89325392|NCT01098149|Active Comparator|BD and BVC|Patients are switched into bicarbonate dialysis with Blood Volume Control
89325393|NCT01098227||RSV positive subjects|Subjects admitted to Winthrop University Hospital with lower viral respiratory infection and RSV positive status by DFA and/or Viral culture
89325394|NCT01098227||RSV negative subjects|Subjects admitted to Winthrop University Hospital with a lower viral respiratory infection and RSV status negative by DFA and viral culture. these subjects may be positive for other viruses detected by DFA or viral culture (Adenovirus, Influenza A or B, Metapneumovirus or parainfluenza) or not
89325395|NCT01098227||Control group|Children in the same age range without respiratory conditions and who are well enough to perform the test from the out patient setting
89325396|NCT01122784|Active Comparator|Group 1|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 182
89325397|NCT01122784|Active Comparator|Group 2|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 182
89325398|NCT01122784|Active Comparator|Group 3|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 121
89325399|NCT01122784|Active Comparator|Group 4|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 121
89325400|NCT03208244|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet
89325401|NCT01088165|Experimental|Adalimumab treatment group|
89325402|NCT01088165|Active Comparator|Fumaric acid esters treatment group|
89325403|NCT05159804||Carotid plaque length|Patients underwent coronary angiography and carotid ultrasonography simultaneously
89325404|NCT00892762|Experimental|Travoprost APS|Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
89325405|NCT00892762|Active Comparator|XALATAN|Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
89325406|NCT01088321||Patients initiating abatacept|
89325407|NCT01088321||Patients initiating other biologic disease-modifying drugs|
89325408|NCT01088321||Pts initiate non-biologic disease-modify anti-rheumatic drugs|
89325409|NCT05158946|Experimental|Intervention Group|Participants in the intervention group received Future Oriented Group Training in addition to their treatment as usual.
89325410|NCT05158946|No Intervention|Control Group|Participants in the control group received their treatment as usual.
89325411|NCT00890968|Experimental|Triamcinolone Acetonide (TAC) DuraPeel|
89325412|NCT00890968|Placebo Comparator|Placebo|
89325413|NCT01098383|Placebo Comparator|Placebo for AChEI and Choline|
89325414|NCT01098383|Experimental|AChEI and Choline|Acetyl-choline Esterase Inhibitor and Choline supplements
89325415|NCT00890890|Experimental|Avagacestat (50 mg)|
88816216|NCT02384382|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
89325416|NCT00890890|Placebo Comparator|Placebo|
89325417|NCT00964990|Experimental|001|JNJ-42160443 SC injection (1 3 or 10 milligrams) once every 28 days
89325418|NCT00964990|Placebo Comparator|002|Placebo SC injection once every 28 days
89325419|NCT03175172|Experimental|Experimental|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
89325420|NCT01093547|Active Comparator|Dianeal only|Patients in Dianeal during the daily exchanges and randomised to Dianeal during the long-dwell exchange
89325421|NCT01093547|Active Comparator|Dianeal; Extraneal long-dwell exchange|Patients in Dianeal during the daily exchanges and randomised to Extraneal during the long-dwell exchange
88816217|NCT01178528|Experimental|Ivabradine|7.5 mg bd
88816218|NCT01178528|Active Comparator|Carvedilol|up to 25 mg bd
88816219|NCT01178528|Experimental|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
89325422|NCT03089996|Experimental|Piezocision|Piezocision-assisted canine retraction x Control (split mouth design)
89325423|NCT03089996|Experimental|Corticotomy|Corticotomy-assisted canine retraction x Control (split mouth design)
89325424|NCT03089996|Experimental|Piezocision x Corticotomy|Piezocision-assisted retraction x Corticotomy-assisted retraction (split mouth design)
89325425|NCT03089996|Experimental|Micro-osteoperforations|Micro-osteoperforations-assisted upper incisors retraction
89325426|NCT03089996|No Intervention|Control|Upper incisors retraction not associated with any clinical intervention to accelerate tooth movement
89325427|NCT00961090|Other|Single-Arm|Single-Arm All subjects received 20mg/kg of Aminolevulinic Acid diluted in 50cc of water, orally, approximately 3 hours prior to surgery.
89325428|NCT01088477||Breast cancer patients with acquired anti-hormonal resistance|
89325429|NCT05456074||Patients with TRCC|
89325430|NCT05456074||Patients with other rare kidney tumors|
89325431|NCT03961139|Experimental|Continuous feeding (CF)|"Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~Feed volume increment per day is as per departmental protocol and same as comparator arm."
89325432|NCT03961139|Active Comparator|Bolus feeding (BF)|"Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes.~Feed volume increment per day is as per departmental protocol and same as experimental arm."
89325433|NCT01088555|Active Comparator|Control group|Healthy subjects with no history of kidney stones, heart liver or kidney disease, not pregnant /lactating.
89325434|NCT01088555|Active Comparator|Stone formers|History of calcium containing kidney stones, hypercalciuria on previous urine tests, no heart /liver / kidney disease, not pregnant/lactating
89325435|NCT03172364|Experimental|Test product 1|All the participants in this arm will receive test product 1 (micellar cleanser) at home twice a day (morning and evening) for 21 (±2) days.
89325436|NCT03172364|Experimental|Test product 2|All the participants in this arm will receive test product 2 (micellar foaming cleanser) at home twice a day (morning and evening) for 21 (±2) days.
89325437|NCT04474210|Experimental|Part A: Group 1|Participants with severe renal impairment and/or kidney failure (estimated glomerular filtration rate [eGFR] less than [<] 30 milliliter[mL]/minute but not yet on hemodialysis) will receive a single oral dose of JNJ-56136379.
89325438|NCT04474210|Active Comparator|Part A: Group 2|Healthy participants with normal renal function (eGFR greater than or equal to [>=] 90 mL/minute), will receive a single oral dose of JNJ-56136379.
89325439|NCT04474210|Experimental|Part B: Group 3 (Optional)|Participants with mild renal impairment (eGFR: 60 to 89 mL/minute) will receive a single oral dose of JNJ-56136379.
89325440|NCT04474210|Experimental|Part B: Group 4 (Optional)|Participants with moderate renal impairment (eGFR: 30 to 59 mL/minute) will receive a single oral dose of JNJ-56136379.
89325441|NCT04474210|Experimental|Part B: Group 5 (Optional)|Participants with kidney failure (eGFR: <15 mL/minute and on hemodialysis; pharmacokinetic [PK] to be evaluated during non-dialysis days) will receive a single oral dose of JNJ-56136379.
89325442|NCT00078767|Experimental|TF-CBT + sertraline|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus Sertraline provided in dosage titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 50mg/day to a maximum dosage of 150 mg/day
89325443|NCT00078767|Active Comparator|TF-CBT +placebo|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus placebo identical to Sertraline, provided in pill form and titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 1 to 3 pills/day (identical in appearance to 50 to 150mg/day of Sertraline)
89325444|NCT04474288||Person Under Investigation (PUI)|PUI's are subjects who were admitted to the hospital with symptoms suspicious for COVID-19.
89325445|NCT04474288||Asymptomatic Person under Screening (APS)|APS's are those patients who do NOT meet the criteria to be a suspect COVID- 19 patient but are being tested because they are being admitted, are required for testing by state mandate, or are having a procedure, etc.
89325446|NCT03208088|Experimental|Sequence 1|etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental)
89325447|NCT03208088|Experimental|Sequence 2|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator)
89325448|NCT03208088|Experimental|Sequence 3|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental)
89325449|NCT03208088|Experimental|Sequence 4|etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental)
89325450|NCT03208088|Experimental|Sequence 5|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental)
89325451|NCT03208088|Experimental|Sequence 6|etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental / etafilcon A Test Lens 1 (experimental)
89325452|NCT03208088|Experimental|Sequence 7|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental)
89325453|NCT03208088|Experimental|Sequence 8|etafilcon A Test Lens 1 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental / etafilcon A Test Lens 3 (experimental)
89325454|NCT03208088|Experimental|Sequence 9|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental / etafilcon A Control Lens (Active Comparator) /etafilcon A Test Lens 4 (experimental)
89325455|NCT03208088|Experimental|Sequence 10|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental / etafilcon A Control Lens (Active Comparator)
89325456|NCT00889486|Placebo Comparator|Placebo|Four placebo capsules taken orally once per day for 28 days
89325457|NCT00889486|Experimental|10 mg TZP-102|One 10 mg TZP-102 Capsule and three placebo capsules taken orally once per day for 28 days
89325458|NCT00889486|Experimental|20 mg TZP-102|Two 10 mg TZP-102 Capsules and two placebo capsules taken orally once per day for 28 days
89325459|NCT00889486|Experimental|40 mg TZP-102|Four 10 mg TZP-102 Capsules taken orally once per day for 28 days
89325460|NCT00078377|Experimental|1|Armodafinil 250 mg
89325461|NCT00078377|Experimental|2|Armodafinil 150 mg
89325462|NCT00078377|Placebo Comparator|3|Placebo
89325463|NCT01107496|Experimental|SPN-812|viloxazine, oral, 300mg, tid, 6 weeks
89325464|NCT01107496|Placebo Comparator|Placebo|placebo, oral, tid, 6weeks
88816220|NCT03012854|Experimental|short-myotomy|Short-POEM for patients with esophageal achalasia
88816221|NCT03012854|Active Comparator|long-myotomy|Long-POEM for patients with esophageal achalasia
89325465|NCT05085314|Experimental|Ngenuity digital 3D microscope|
89325466|NCT05085314|Active Comparator|Conventional microscope|
89325467|NCT01098617||hemorrhage|The patients who had bleeding induced by endoscopic sphincterotomy
89325468|NCT00886600|Placebo Comparator|1|Placebo
89325469|NCT00886600|Experimental|2|losartan 50 mg q.d.
89325470|NCT00886600|Experimental|3|losartan 100 mg q.d.
89325471|NCT00886600|Experimental|4|losartan 50 mg b.i.d.
89325472|NCT02591654|Experimental|Pembrolizumab and FLT|Subjects will receive WB-DW MRI and FLT PET to assess disease burden after receiving pembrolizumab.
89325473|NCT01098695|Experimental|EcoFIT offered|
89325474|NCT01098695|No Intervention|No Feedback or services offered|
89325475|NCT03134872|Experimental|SHR-1210+Chemotherapy|Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
89325476|NCT03134872|Active Comparator|Chemotherapy|Subjects receive pemetrexed 500 mg/m^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
89325477|NCT03952481|Experimental|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
89325478|NCT05135312|Other|Etanercept|50mg etanercept subcutaneously twice weekly for 3 months, followed by once weekly for another 3 months for a total duration of 6 months or 24 weeks.
89325479|NCT01098773||patients requiring ventilation|
89325480|NCT01098773||patients who weaned permanently|
89325481|NCT00885196|Experimental|AEB071 200 mg BID|
89325482|NCT00885196|Experimental|AEB071 400 mg OD|
89325483|NCT00885196|Experimental|AEB071 300 mg BID|
89325484|NCT00885196|Placebo Comparator|Placebo BID|
89325485|NCT03172130|Experimental|Straight CPAP|Patients randomized to straight CPAP will receive 10 cm of air pressure, or as determined by the results of polysomnography, for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
89325486|NCT03172130|Sham Comparator|Sham CPAP|Patients randomized to sham CPAP will receive 1-2 cm of air pressure for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
89325487|NCT03956771|Experimental|Real neurofeedback|Two sessions of neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
89325488|NCT03956771|Sham Comparator|Sham neurofeedback|Two sessions of placebo/control neurofeedback training during 2 weeks (2 distinct days; 36 min per session).
89325489|NCT00881452|Active Comparator|CM-AT|CM-AT (Luminenz-AT)- 900mg CM-AT, pancreatic enzyme concentrate (720mg)
89325490|NCT00881452|Placebo Comparator|Placebo|Placebo 900mg (Sucanate (98% w/w), Citric Acid (2% w/w)
89325491|NCT04512170|Experimental|A single dose HEC585（pilot trial arm）|Healthy subjects receive a single dose of HEC585
89325492|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 1）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
89325493|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 2）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
89325494|NCT04512170|Experimental|Single and Mulltiple doses HEC585（ Part 1, Cohort 3）|Healthy subjects receive Single and multiple doses of HEC585 or matching placebo
89325495|NCT04512170|Experimental|Single dose of HEC585 （Part 2，Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
89325496|NCT04512170|Experimental|two-period study at 400 mg dose group (part 3，Fed)|Healthy subjects receive Single/multiple doses of HEC585 or matching placebo in two cycles.
89325497|NCT01098929||Congenital Diaphragmatic Hernia (CDH)|Individuals affected with congenital diaphragmatic hernia (CDH)
89325498|NCT01098929||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
89325499|NCT05210816|Experimental|ACT|''Acceptance and Commitment Therapy (ACT) Based Intervention Program was applied to the intervention group.
89325500|NCT05210816|No Intervention|Control|Only data collection was carried out. No attempt was made by the researcher during the study.
89325501|NCT03952325|Experimental|Cohort 1, Arm A: Tesetaxel plus nivolumab|
89325502|NCT03952325|Experimental|Cohort 1, Arm B: Tesetaxel plus pembrolizumab|
89325503|NCT03952325|Experimental|Cohort 1, Arm C: Tesetaxel plus atezolizumab|
89325504|NCT03952325|Experimental|Cohort 2: Tesetaxel|
89325505|NCT03952325|Experimental|Cohort 3: Tesetaxel|
89325506|NCT04473898|Sham Comparator|Patient Education Group|Information training about COViD-19 and its symptoms, hygiene education, family education
88816222|NCT03012854|Experimental|full-thickness myotomy|Full-thickness-POEM for patients with esophageal achalasia
89325507|NCT04473898|Experimental|Aerobic Training Group|Teaching and regular follow-up of aerobic exercises shown online
89325508|NCT04473898|Experimental|Aerobic + Respiratory Training Group|Teaching and regular follow-up of aerobic and respiratory exercises shown online
88816223|NCT03012854|Active Comparator|circular myotomy|Circular-POEM for patients with esophageal achalasia
89325509|NCT01583153|Active Comparator|Hospital Inpatient Rehabilitation (HI)|
89325510|NCT01583153|Active Comparator|Hybrid Home Programme (HO)|
89325511|NCT04473586|Other|Sample tested in less than one-hour|Buccal samples will be collected and analyzed on the Spartan Cube CYP2C19 System immediately (<1hr). The Spartan Cube CYP2C19 results will be compared with bi-directional sequencing results generated by a third part from a saliva sample collected from the same subject.
89325512|NCT04473586|Other|Samples tested greater than 24 hours|Buccal samples will be collected, stored and then analyzed on the Spartan Cube CYP2C19 System greater than 24 hours after collection. The Spartan Cube CYP2C19 results will be compared with bi-directional sequencing results generated by a third part from a saliva sample collected from the same subject.
89325513|NCT01583231|No Intervention|No Prewash|Level 1: participants will be swabbed, then application of brushless scrub, swabbed again
89325514|NCT01583231|Experimental|Prewash|Level 2: participants will be swabbed, perform a wash with soap and water for 1 minute, dry, apply brushless scrub, swabbed again
89325515|NCT05197868|Active Comparator|Intubation with traditional laryngoscope|Participants will be required to intubate the manikin by using a traditional laryngoscope
89325516|NCT05197868|Experimental|Intubation with a straight blade video laryngoscope|Participants will be required to intubate the manikin by using a straight blade video laryngoscope
89325517|NCT05197868|Experimental|Intubation with hyper-angulated video laryngoscope|Participants will be required to intubate the manikin by using a hyper-angulated video laryngoscope
89325518|NCT00948142|Active Comparator|Linezolid|600 mg BID
89325519|NCT00948142|Experimental|CEM-102 Regimen A|
89325520|NCT00948142|Experimental|CEM-102 Regimen B|
89325521|NCT00947518|Experimental|Chlorhexidine skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
89325522|NCT00947518|Placebo Comparator|Saline skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing normal saline
89325523|NCT00947518|No Intervention|No skin cleansing|No skin application
89325524|NCT00945802|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
89325525|NCT00945802|Active Comparator|ciprofloxacin 0.3%, dexamethasone 0.1%|
89325526|NCT01105624|Experimental|azithromycin ophthalmic solution, 1%|
89325527|NCT01105624|Experimental|rewetting drops|
89325528|NCT01102660|Other|Treatment Sequence 1|
89325529|NCT01102660|Other|Treatment Sequence 2|
89325530|NCT01102660|Other|Treatment Sequence 3|
89325531|NCT01102660|Other|Treatment Sequence 4|
89325532|NCT03135106|Experimental|Treatment A: Erdafitinib alone|Participants will receive single 4 milligram (mg) oral dose of erdafitinib on Day 1 in a fasted state.
89325533|NCT03135106|Experimental|Treatment B: Erdafitinib + Fluconazole|Participants will receive 400 mg fluconazole once daily orally from Day 1 to Day 11 in a fasted state and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 400 mg fluconazole dose.
89325534|NCT03135106|Experimental|Treatment C: Erdafitinib + Itraconazole|Participants will receive 200 mg itraconazole once daily orally from Day 1 to Day 11 and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 200 mg itraconazole dose.
89325535|NCT00872014|Experimental|15mg/ kg cohort|AMG 386 15mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
89325536|NCT00872014|Experimental|10 mg/kg cohort|AMG 386 10mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
89325537|NCT00870688||1|epilepsy patients
89325538|NCT00870454|Experimental|001|Carisbamate 800 mg/d 200 mg/d twice daily titrated up to 400 mg twice daily as tolerated by Week 3
89325539|NCT00870454|Experimental|002|Carisbamate 1 200 mg/d 200 mg/d twice daily titrated up to 600 mg twice daily as tolerated by Week 3
89325540|NCT00870454|Active Comparator|003|Pregabalin 300 mg/d 75 mg/d twice daily for Week 1 followed by 150 mg twice daily for the remainder
89325541|NCT00870454|Placebo Comparator|004|Placebo Placebo capsules twice daily
89325542|NCT00869986|Experimental|Dirucotide|
89325543|NCT00869986|Placebo Comparator|Placebo|
89325544|NCT05096962||Arm IKEM|"Arm IKEM (Institute for Clinical and Experimental Medicine) is represented by two subcohorts:~participants with chronic illness (adults only), which are part of the research project of the Institute of Clinical and Experimental Medicine (the expected number of participants in the study - 3 000)~healthy subjects from the Study of Czech Academy of Science, who are following up in the Institute of Clinical and Experimental Medicine (the expected number of subjects in the study - 2000) The subjects will be contacted based on the Hospital study database."
89325545|NCT05096962||Arm FTN|Arm FTN (Thomayer University Hospital) is represented by the healthcare staff of the Hospital (the expected number of subjects in the study - 1800).
89325546|NCT05096962||Arm Olomouc|"Arm Olomouc is represented by participants, who participated in the Study Herd Immunity Study SARS-CoV-2-CZ-Preval in May 2020 and at the same time subjects who will be willing to participate in this study. The involvement of subjects from two localities is expected:~Olomouc~Litovel, Uničov and Červenka. The expected number of subjects in the study is approximately 2500."
89325547|NCT00869128|Other|Placebo First|Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).
89325548|NCT00869128|Other|Circadin first|Subjects were treated for 3 weeks with 1 tablet per night of 2 mg melatonin (Circadin) and then with placebo.
89325549|NCT00866476|Experimental|Vaccine-recipients|
89325550|NCT00866476|Placebo Comparator|Placebo|
89325551|NCT00866242|Experimental|Challenge-recipients|
89325552|NCT00945646|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
89325553|NCT00945646|Placebo Comparator|vehicle|
89325554|NCT00945490|Experimental|NX-1207|
89325555|NCT00945490|Placebo Comparator|Placebo|
89325556|NCT00077675|Experimental|Telavancin|
89325557|NCT00077675|Active Comparator|Standard of care for cSSSI|cSSSI - comlicated skin and skin structure infections
89325558|NCT00934180|Experimental|Ondansetron|Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
89325559|NCT00934180|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg OD Tablet (test) dosed in second period
89325560|NCT02576444|Experimental|Group 1|Patients with cholangiocarcinoma harboring IDH 1/2 tumors will be treated with olaparib. Patients with tumors harboring mutation in HDR genes will be treated with olaparib.
89325561|NCT02576444|Experimental|Group 2|Patients with tumors harboring PTEN, PIK3CA, AKT, or ARID1A mutations or other molecular aberrations leading to dysregulation of the PI3K/AKT pathway will be treated with AZD5363 plus olaparib.
89325562|NCT02576444|Experimental|Group 3|Patients with tumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53 will be treated with AZD1775 plus olaparib. TP53 mutations must be found on the TP53 mutation eligibility list.
89325563|NCT02576444|Experimental|Group 4|Patients with tumors harboring mutations in HDR genes, including ATM, CHK2, APOBEC, MRE11 complex, will be treated with AZD6738 and olaparib.
89325564|NCT02530775|Active Comparator|instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion with use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
89325565|NCT02530775|Active Comparator|non-instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion without the use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
89325566|NCT00929968|Placebo Comparator|Placebo to VAK694|
89325567|NCT00929968|Experimental|VAK694|
89325568|NCT00929968|Active Comparator|Fluticasone propionate|
89325569|NCT01099007|Active Comparator|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
89325570|NCT01099007|Experimental|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
89325571|NCT04957160||Cohort 1|
89325572|NCT04957160||Cohort 2|
89325573|NCT00929188|Experimental|001|JNJ-42160443 Type=1 unit=mg number=10 form=solution for injection route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
89325574|NCT00929188|Placebo Comparator|002|Placebo Form=solution for injection route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
89325575|NCT03957083|Active Comparator|Oxytocin 0.5IU|Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89325576|NCT03957083|Active Comparator|Oxytocin 1IU|Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89325577|NCT03957083|Active Comparator|Oxytocin 2IU|Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89325578|NCT03957083|Active Comparator|Oxytocin 3IU|Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89325579|NCT03957083|Active Comparator|Oxytocin 4IU|Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89325580|NCT03957083|Active Comparator|Oxytocin 5IU|Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
89325581|NCT04945616|Experimental|group A： Aspirin + Clopidogrel + placebo or SHR2285 (dose 1)|
89325582|NCT04945616|Experimental|group B ：Aspirin + Clopidogrel + placebo or SHR2285 (dose 2)|
89325583|NCT04945616|Experimental|group C： Aspirin + Ticagrelor + placebo or SHR2285|
89325584|NCT00858052|Experimental|breast augmentation|breast implant
89325585|NCT03956459|Other|Patients with a cancer|
89325586|NCT00855712|Experimental|Organ Care System|
89325587|NCT00855712|Active Comparator|Cold cardioplegia solution|
89325588|NCT05210842||Lumen apposing metal stent|All patients who had a lumen-proximating stent implanted are included.
89325589|NCT00850174|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
89325590|NCT00850174|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
89325591|NCT00849862|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra 750 mg Tablet (reference) dosed in second period
89325592|NCT00849862|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
89325593|NCT05341648|Experimental|Experimental Group|Aerobic Training for 3 days/week with 40-70% Intensity for 6 Weeks
89325594|NCT05341648|Placebo Comparator|Control group|Home plan: Positioning, Breathing Exercises, Muscle Relaxation, and Flexibility exercises for 6 weeks
89325595|NCT00077207|Experimental|Treatment (carboplatin, vincristine sulfate, temozolomide)|Induction therapy: Patients receive carboplatin IV (175/m2) over 1 hour on days 1, 8, 15, and 22; vincristine IV (1.5 mg/m2) on days 1, 8, 15, 22, 29, and 36; and oral temozolomide (200 mg/m2) on days 43-47. Four weeks after the completion of induction therapy, patients achieving stable or responding disease proceed to maintenance therapy. Maintenance therapy: Patients receive carboplatin (175/m2) and temozolomide (200 mg/m2) as in induction therapy and vincristine IV ((1.5 mg/m2) day 1 of weeks 10,11,12. Treatment repeats every 10 weeks for a total of 6 courses in the absence of disease progression.
89325596|NCT05627284|Experimental|Stoma reversal with bio-mesh placement|
89325597|NCT01099085|Active Comparator|XP/simvastatin|Capecitabine/cisplatin + simvastatin
89325598|NCT01099085|Placebo Comparator|XP/placebo|Capecitabine/cisplatin + placebo
89325599|NCT05296018|Experimental|Mandala|Mandala coloring page
89325600|NCT05296018|No Intervention|Control group|Routine maintenance will be applied
89325601|NCT03206918|Experimental|Zanubrutinib|
89325602|NCT01093703|No Intervention|Conventional Therapy|In the conventional therapy group, no medication changes other than the ones needed to achieve target awake average SBP will be undertaken. Time at which patients are taking their BP medications will be recorded.
89325603|NCT01093703|Active Comparator|Intensive Therapy|In the intensive therapy group, BP medications will be adjusted to both control awake average systolic BP to target and to cover the overnight period in an attempt to control nocturnal hypertension.
89325604|NCT01088867|Other|Acupuncture|14 weeks of electroacupuncture therapy.
89325605|NCT04504994|Experimental|exclusion BPD|cyberball exclusion condition - BPD patients
89325606|NCT04504994|Experimental|over-inclusion BPD|cyberball over-inclusion condition - BPD patients
89325607|NCT04504994|Experimental|exclusion healthy controls|cyberball exclusion condition - healthy controls
89325608|NCT04504994|Experimental|over-inclusion healthy controls|cyberball over-inclusion condition - healthy controls
89325609|NCT01093781|Experimental|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
89325610|NCT03206216|Experimental|Group A - Painful CIPN|Participants with painful chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
89325611|NCT03206216|Active Comparator|Group B - Painless CIPN|Participants with painless chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
89325612|NCT03961217||Gynecological Cases|"Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy at~Radiumhemmat, Karolinska University Hospital and~Jubileumskliniken at Sahlgrenska University Hospital in Sweden."
89325613|NCT03961217||Prostate Cases|Prostate Cancer survivors treated with radiotherapy for localized prostate cancer at Sahlgrenska University Hospital, Gothenburg, Sweden
89325614|NCT03961217||Gynecological Rehab Cases|Gynecological Cancer survivors with treatment induced survivorship syndroms treated pelvic radiotherapy
89325615|NCT01088945|Experimental|Enhanced Discharge Process|Caregivers of these infants will receive individual coaching in order to enhance their understanding of their infant's problems and enhance their knowledge and skills to care for their fragile infants.
89325616|NCT01088945|Active Comparator|Standard Discharge Process|These infants will receive the hospital's current standard of care for the discharge of fragile infants from the NICU.
89325617|NCT05257642|Experimental|Cognitive Change Groups|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on cognitive change. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements.
89325618|NCT05257642|Experimental|Mindfulness Groups|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on mindfulness and relaxation. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements
89325619|NCT05257642|Experimental|Positive bias Group|The participants in this group will complete the pre-test measurements, then they will receive a level of the REThink Game that focuses on problem-solving. After playing the game they will receive an experimental task Cyberball and complete the post-test measurements
89325620|NCT05257642|No Intervention|Control Group|The participants in this group will complete the pre-test measurements, then they will receive an experimental task Cyberball and complete the post-test measurements
89325621|NCT03952247|Experimental|Single Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
89325622|NCT03952247|Active Comparator|Conventional Multi Use Bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
89325623|NCT05627050|Experimental|AR Training System|The subjects follow the daily rehabilitation training program designed by clinical and healthcare team. The system will monitor their movement and provide feedbacks to the users. The clinicians/healthcare workers can provide feedbacks and guidance to correct their movements and postures.
89325624|NCT02530229||Periprosthetic joint infection|Patients with suspected periprosthetic joint infection of the hip, knee and shoulder
89325625|NCT02530229||Septic arthritis|Patients with suspected septic arthritis of a native joint of the hip, knee and shoulder
89325626|NCT01093859|Experimental|PRX-105 Infusion|
89325627|NCT03169244|Active Comparator|Bupropion|Bupropion extended release
89325628|NCT03169244|Placebo Comparator|Placebo|Placebo oral tablet
89325629|NCT01099163|Experimental|3g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, 100 IU vitamin E
89325630|NCT01099163|Active Comparator|3 g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, vitamin E placebo
89325631|NCT01099163|No Intervention|3 g MCT + vit E placebo|3 g MCT AND other diabetes medication currently prescribed to participant, 100 IU vitamin E placebo
89325632|NCT02486042|Active Comparator|Standard of Care (Standard Nutrition)|Infants in this group will receive standard lipids (predominantly Omega-6 fatty acids).
89325633|NCT02486042|Experimental|Omegaven|Infants in this group will receive lipid supplementation with omega-3 fatty acids.
89325634|NCT00920764|Active Comparator|A|
89325635|NCT00920764|Active Comparator|B|
89325636|NCT00920764|Active Comparator|C|
89325637|NCT00920764|Placebo Comparator|D|
89325638|NCT05376046||Sickle cell disease|"Confirmed sickle cell disease withHaemoglobin profile was determined by high performance liquid chromatography (HPLC) (Variant II Biorad, California, United States), by capillary electrophoresis on Capillarys 3 Octa® (Kit hydragel hémoglobine Sebia, Lisses, France) and iso-electrofocalisation.~Patients were included during injury evaluation in our tertiary centre."
89325639|NCT05376046||Healthy|25 healthy controls matched on age and gender
89325640|NCT03034304|Experimental|MASCT-I alone or in combination with chemical drugs or in combination with PD-1 antibody|"Group 1: MASCT-I alone;~Group 2: Advanced urothelial carcinoma and cholangiocarcinoma treatment with MASCT-I alone,Advanced soft tissue sarcoma and osteosarcoma treatment with MASCT-I alone or combination with ifosfamide. In the event of disease progression, treatment with MASCT-I +PD1 antibody;~Group 3: Advanced metastatic or recurrent urothelial carcinoma, soft tissue sarcoma/osteosarcoma, and cholangiocarcinoma that progressed after first line chemotherapy were treated with MASCT-I combined with PD1 antibody;~Group 4: Recurrent metastatic solid tumors that had failed previous treatment with PD1 antibody were treated with MASCT-I + PD1 antibody;~Group 5: Untreated advanced soft tissue sarcom treatment with MASCT-I+AI (Adriamycin+ifosfamide);~Group 6: Untreated advanced urothelial carcinoma treatment with MASCT-I+GP/GC(Gemcitabine+cisplatin/ Gemcitabine+carboplatin);"
89325641|NCT00918814|Experimental|LIPO-102|LIPO-102
89325642|NCT00918814|Experimental|Placebo|Placebo
89325643|NCT00917020|Experimental|Active: CO2 Gas|
89325644|NCT00917020|Placebo Comparator|Inactive Placebo Gas|
89325645|NCT00914602|Active Comparator|Treatment Period A|Treatment Period A: Sinemet® 25-100 treatment After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
89325646|NCT00914602|Experimental|Treatment Period B|Multiple-Dose XP21279 (with Lodosyn®) treatment. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
89325647|NCT00914290|Other|IPX056-Baclofen IR-IPX056|Following 2 weeks of run-in period, subjects were randomized to IPX056 and Placebo IR for 2 weeks and then to Baclofen IR and Placebo IPX056 for 2 weeks.
89325648|NCT00914290|Active Comparator|IPX056-IPX056-Baclofen IR|Following 2 weeks of run-in period, subjects were randomized to Baclofen IR and Placebo IPX056 for 2 weeks and then to IPX056 and Placebo IR for 2 weeks.
89325649|NCT04710524|Placebo Comparator|Placebo|orally administer placebo BID for 13 weeks except on Day 91 subject receive a single dose
89325650|NCT04710524|Experimental|FM101 150 mg BID|orally administer FM101 150mg BID for 13 weeks except on Day 91 subject receive a single dose
89325651|NCT04710524|Experimental|FM101 300 mg BID|orally administer FM101 300mg BID for 13 weeks except on Day 91 subject receive a single dose
89325652|NCT04473118||Healthcare workers|All healthcare workers exposed directly or not to suspected or infected COVID-19 patients such as nurse; paramedic; senior physician; resident/ trainee physician; respiratory therapist; perfusionist; physiotherapist; dietitian; technician lab; technician imaging; pharmacist; occupational therapist; speech therapist
89325653|NCT00057941|Experimental|Arm I (anastrozole, gefitinib)|Patients receive oral anastrozole and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89325654|NCT00057941|Experimental|Arm II (fulvestrant, gefitinib)|Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89325655|NCT01099319|Experimental|Renalof|
89325656|NCT01099319|Placebo Comparator|Placebo|
89325657|NCT03005522|Placebo Comparator|placebo|dosed with placebo
89325658|NCT03005522|Active Comparator|intervention|10mg oral dexamethasone
89325659|NCT02998736|Experimental|Intervention|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
89325660|NCT02998736|No Intervention|Control|No intervention in the perioperative period
89325661|NCT00075881|Experimental|Treatment (bortezomib)|"INDUCTION TREATMENT: Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TREATMENT: Patients who complete induction treatment without progressive disease receive bortezomib IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~REINDUCTION TREATMENT: Patients who progress while on maintenance treatment receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
89325662|NCT00840268|Experimental|HPGG 0.25%|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
89325663|NCT00840268|Placebo Comparator|HPGG Vehicle|Hydroxypropyl Guar Galactomannan Vehicle, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
89325664|NCT00838630|Experimental|1|
89325665|NCT00838630|Active Comparator|2|
89325666|NCT02996474|Experimental|Pembrolizumab and Decitabine for treatment of Acute Myeloid Leukemia|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Up to eight cycles of pembrolizumab will be given during the initial induction phase. Each cycle is 21 days. Decitabine will be administered at a dose of 20 mg/m^2 by intravenous infusion over approximately 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7) for treatment relapsed/refractory AML.
89325667|NCT00821002|Experimental|Plug placement|
88809623|NCT00722072|Experimental|Fulvestrant/ Sorafenib|"Fulvestrant: A loading dose will be administered intramuscularly to all subjects during cycle 1 of treatment as follows:~500 mg IM on Day 1~250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of Fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or unacceptable toxicity occurs requiring discontinuation.~Sorafenib: Subjects will take Sorafenib 800 mg/day administered as 400 mg bid (twice daily)each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until unacceptable toxicity occurs."
89325668|NCT03667924|Experimental|PorchLight Project Intervention Group|Participants in the intervention group will receive home-based support and respite services from PorchLight Project trained Senior Companion volunteers of the Lutheran Social Services of Minnesota.
89325669|NCT03134794|Experimental|Educational Intervention|"Education intervention using the TLS. The active group will received an educational intervention applying proven concepts in medical education (cognitive reflection/checklist, traffic light system (TLS). Previous research showed that TL food labels prompted individuals to consider their health and to make healthier choices. A color-coded system influences the valuation process in favor of healthier choices by interfering with automatic decisions and triggering the re-evaluation process (Ena, Krajbich et al Judgement and DM 2016).~The TLS is being implemented to facilitate the identification of patients at risk of developing a clinical and radiological progression that could result in escalation of therapy."
89325670|NCT03134794|No Intervention|Control|Usual Care. The control group will make therapeutic decisions without being exposed to the educational intervention as part of the current standard practice.
89325671|NCT00820924|Experimental|LAPATINIB|LAPATINIB 1500MG ORAL ONCE DAILY
89325672|NCT00820300|Experimental|Punctal plug|
89325673|NCT00814372|Experimental|MBX-102 400|
89325674|NCT00814372|Experimental|MBX-102 600|
89325675|NCT00814372|Placebo Comparator|Placebo|
89325676|NCT00814372|Active Comparator|Actos|30-45 mg
89325677|NCT05042050|Experimental|A-iMAPS Intervention|Participants will receive six sessions of Attachment-focused iMAgery therapy for PSychosis. They will be randomised to different baseline lengths (two to five assessment sessions)
89325678|NCT03134638|Experimental|Dose Escalation|Dose escalation phase to explore maximum tolerated dose across two dosing schedules. SY-1365 will be administered intravenously weekly and twice-weekly for 3 weeks of each 4-week cycle
89325679|NCT03134638|Experimental|Advanced Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 3 prior lines of therapy (SY-1365 single agent)
89325680|NCT03134638|Experimental|Relapsed Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 1 prior line of therapy including a platinum-based regimen (SY-1365 + carboplatin)
89325681|NCT03134638|Experimental|Clear Cell Ovarian Cancer|Patients with clear cell ovarian cancer previously treated with ≥ 1 prior line of therapy (SY-1365 single agent)
89325682|NCT03134638|Experimental|Advanced Solid Tumors|Biopsy cohort of approximately 20-30 patients with advanced solid tumors from whom pre- and post-treatment biopsies will be obtained (SY-1365 single agent)
89325683|NCT03134638|Experimental|HR+ breast cancer|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy (SY-1365 + fulvestrant)
89325684|NCT03205046|Experimental|Part 1 continuous dose for vistusertib|acalabrutinib daily + vistusertib daily
89325685|NCT03205046|Experimental|Part 1 intermittent dose for vistusertib|acalabrutinib daily + vistusertib 5 days on and 2 days off
89325686|NCT04884698|Experimental|Phrenic nerve stimulation with Stimit Activator|
89325687|NCT04855526|Experimental|Occasional Users - High THC and High CBD Dose|People who smoke marijuana occasionally will be given a dose of high THC high CBD marijuana at the study visit
89325688|NCT04855526|Experimental|Occasional Users - High THC and No CBD Dose|People who smoke marijuana occasionally will be given a dose of high THC and no CBD marijuana at the study visit
89325689|NCT04855526|Experimental|Occasional Users - No THC and No CBD Dose|People who smoke marijuana occasionally will be given a dose of marijuana that contains no THC or CBD
89325690|NCT04910360||ICU patients with severe COVID-19 pneumonia|Without using any intervention, this group has been included in the study to research certain genetic dispositions determining the severity of the COVID-19 pneumonia
89325691|NCT04910360||Random population|This group has been included as a control group to compare the genetic predisposition of ICU patients with severe COVID-19 pneumonia with the normal population.
89325692|NCT04874168|Active Comparator|In the TAP group (Group A )|"after completion of surgery, bilateral ultrasound-guided TAP block was performed .~Description of the intervention: a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used ;A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
89325693|NCT04874168|Active Comparator|In the infiltration group (Group B )|at the end of surgery, 40 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (20 mL in each of the upper and lower sides) by the obstetrician before skin closure.
89325694|NCT04874168|Placebo Comparator|In placebo group (Group C )|routine analgesic was administered and recorded .
89325695|NCT02339090|Experimental|Somavaratan|Participants will receive somavaratan 3.5 milligrams (mg)/kilogram (kg) subcutaneous (SC) bolus injection twice monthly for 12 months.
89325696|NCT02339090|Active Comparator|rhGH|Participants will receive commercially available rhGH (genotropin) 34 micrograms (μg)/kg once daily SC bolus injection for 12 months.
89325697|NCT04868318|Experimental|VHP(very-high protein) group|In VHP(very-high protein) group, we will provide pre-digested formula of 37% protein to the experimental group for at least 3 days to up to 7 days.
89325698|NCT04868318|Active Comparator|SHP(standard-high protein) group|SHP(standard-high protein) group is the control group, standard-high protein formula (16% of energy) would be given to the control group for at least 3 days to up to 7 days.
89325699|NCT02947646|Experimental|BabyGentleStick™ ON, then BabyGentleStick™ OFF|Experimental intervention, then Active Comparator.
89325700|NCT02947646|Experimental|BabyGentleStick™ OFF, then BabyGentleStick™ ON|Active Comparator, then Experimental intervention.
89325701|NCT04774484|Experimental|All subjects will be in one arm|Both Lean and Obese, End-Stage Renal Disease (ESRD) patients and normal volunteers will be in one arm, that will receive the High Intensity Interval Training intervention.
89325702|NCT02926352|Experimental|Extinction Training with LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear domain. 15 minutes after fear extinction, participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system; to stimulate the vmPFC). Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
89325703|NCT02926352|Active Comparator|Extinction Training with Sham LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear. 15 minutes after fear extinction, participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
89325704|NCT02926352|Experimental|LLLT alone|Participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). F3 corresponds with the left dorsolateral prefrontal cortex and F4 corresponds with the right dorsolateral prefrontal cortex. Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
89325705|NCT02926352|Sham Comparator|Sham LLLT alone|Participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
89325706|NCT02171078||Alliance for Clinical Trials Database|Use existing data from clinical trials sponsored by one of the leading cancer cooperative groups to evaluate how risk of recurrence and side effects of treatment vary based on patient and cancer characteristics.
89325707|NCT02171078||National Cancer Database|Use existing data to evaluate the effectiveness of the latest imaging technology for detecting recurrence and improving survival in patients previously treated for breast cancer.
89325708|NCT02171078||Stakeholder Engagement|Engage cancer survivors, providers, and health outcomes researchers in the development of an improved patient-centered approach to guide post-treatment care, as well as identification of the highest priority strategies for prospective randomized trials.
89325709|NCT04655300||Group 1|
89325710|NCT04655300||Group 2|
89325711|NCT04655300||Group 3|
89325712|NCT04655300||Group 4|
89325713|NCT04655300||Group 5|
89325714|NCT04655300||Group 6|
89325715|NCT03331562|Active Comparator|pembrolizumab & paricalcitol|pembrolizumab 200 mg IV q 3 weeks and paricalcitol 25 mcg IV 3 xs per week
89325716|NCT03331562|Placebo Comparator|pembrolizumab & placebo|pembrolizumab 200 mg IV q 3 weeks & placebo- normal saline IV 3 xs per week
89325717|NCT02152124||Controlled on LA-SMSA|Patients with controlled acromegaly on long-acting somatostatin analogs
89325718|NCT02152124||Controlled on LA-SMSA and pegvisomant|Patients with controlled acromegaly on long-acting somatostatin analogs and pegvisomant
89325719|NCT02152124||Controlled after surgery|Controlled acromegaly patients without need for medical therapy after surgery
89325720|NCT02152124||Healhy controls|Healthy volunteers
89325721|NCT02152124||Uncontrolled on LA-SMSA|Patients with uncontrolled acromegaly (i.e. with serum IGF-1 levels above age-specific thresholds and/or symptoms due to active acromegaly (e.g. excessive sweating, arthralgia)) on LA-SMSA monotherapy in maximal dosage
89325722|NCT00814294|Placebo Comparator|1; Placebo|Patients receive a sugar pill.
89325723|NCT00814294|Experimental|2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Patients receive Oral HDV-Insulin (U-5).
89325724|NCT00814294|Experimental|3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Patients receive Oral HDV-Insulin (U-15).
89325725|NCT05441228|Experimental|Group A|Group A receives virtual reality through Oculus Quest 2. Beat saber application will be used to improve upper limb's motor function of stroke patients. Total 1 hour session will be provided to each patient for 5 days a week. Total period 4 weeks
89325726|NCT05441228|Other|Group B|Group B receives mirror therapy through mirror therapy box. Total 1 hour session will be provided to each patient for 5 days a week. Total period 4 weeks
89325727|NCT04438642|Other|conventional ceramic onlay with shoulder finishline|tooth that need ceramic onlay restoration, a conventional cavity will be prepared with shoulder finishline.
89325728|NCT04438642|Experimental|conservative ceramic onlay preparation buttjoint with bevel|tooth that need ceramic onlay restoration, a conservative cavity will be prepared with butt joint with bevel finishline.
89325729|NCT02038634|Active Comparator|Unguided injections|Corticosteroid injection (betamethasone) without ultrasound guidance.
89325730|NCT02038634|Active Comparator|Ultrasound-guided injections|Corticosteroid injections (betamethasone) under ultrasound guidance.
89325731|NCT00808288|Experimental|PF-00610355|
89325732|NCT00808288|Experimental|PF- 00610355|
89325733|NCT00808288|Experimental|PF - 00610355|
89325734|NCT00808288|Placebo Comparator|Placebo|
89325735|NCT00808288|Active Comparator|Salmeterol|
89325736|NCT03636308|Experimental|AS：Nanoparticle albumin-bound paclitaxel，S-1|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle.~S-1 is orally administered (BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle."
89325737|NCT03636308|Active Comparator|AG：Nanoparticle albumin-bound paclitaxel，Gemcitabine|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8 of each 21 day cycle.~Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21 day cycle."
89325738|NCT04438486|Active Comparator|dietary advice|
89325739|NCT04438486|Experimental|dietary advice+ Barely Green|
89325740|NCT03476980|Active Comparator|Randomized to Umbilical Cord Milking at birth|Milking the umbilical cord towards the infant at a speed of 20cm/2seconds at birth.
89325741|NCT03476980|Active Comparator|Randomized to Delayed Cord Clamping at birth|Delayed clamping of the umbilical cord at birth.
89325742|NCT00836056|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
89325743|NCT00836056|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
89325744|NCT03200912|Active Comparator|Picato|Picato® (ingenol mebutate) gel, 0.15% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
89325745|NCT03200912|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.15% [Test]
89325746|NCT03200912|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
89325747|NCT00806806|Placebo Comparator|Placebo|
89325748|NCT00806806|Experimental|SKY0402|
89325749|NCT00799552|Placebo Comparator|Placebo|
89325750|NCT00799552|Experimental|RX-10045|
89325751|NCT00835666|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
89325752|NCT00835666|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
89325753|NCT00835588|Experimental|Pantoprazole|Pantoprazole Sodium 40 mg DR Tablet (test) dosed in first period followed by Protonix® 40 mg DR Tablet (reference) dosed in second period
89325754|NCT00835588|Active Comparator|Protonix®|Protonix 40 mg DR Tablet (reference) dosed in first period followed by Pantoprazole Sodium 40 mg DR Tablet (test) dosed in second period
89325755|NCT03200366|Active Comparator|Tailored DVD|Tailored digital video disc (DVD)
89325756|NCT03200366|Active Comparator|Tailored DVD + Patient Navigation|Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
89325757|NCT03200366|No Intervention|Usual Care|Care normally provided by a nurse in the endoscopy department of the healthcare system
89325758|NCT00713518|Active Comparator|Arm 1 ranibizumab|0.5 mg ranibizumab intravitreal injection given every 4 weeks from baseline to Week 12
89325759|NCT00713518|Experimental|Arm 2 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg PF-04523655 given by intravitreal injection every 2 weeks from Week 4 to Week 12
89325760|NCT00713518|Experimental|Arm 3 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg PF-04523655 given by intravitreal injection evey 4 weeks to Week 12
89325761|NCT00713518|Experimental|Arm 4 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given by intravitreal injection every 4 weeks from Week 4 to Week 12
89325762|NCT00713518|Experimental|Arm 5 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg of PF-04523655 (30 minutes later) given in combination every 4 weeks from baseline to Week 12
89325763|NCT03134482|Experimental|In vitro maturation (IVM)|"hCG primed in vitro maturation (IVM) procedure Gonadotropin is not used in this patient group If the endometrial thickness in 6mm or more and the mean diameter of largest follicle is 11 mm or less on menstrual cycle day 9 to 12 on ultrasonography, oocyte retrieval is planned two days later.~Recombinant hCG injection (priming) is given 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization.~The biochemical pregnancy is confirmed by serum beta hCG 15 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
89325764|NCT03134482|Active Comparator|Minimal stimulation IVF|"minimal stimulation IVF procedure These patients are stimulated with 150 or less IU of recombinant Follicle-stimulating hormone (FSH) from menstrual cycle day 3 in GnRH antagonist protocol.~If the mean diameters of two or more follicles are 17mm or more, oocyte retrieval is planned two days later.~Recombinant hCG is triggered 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization if needed.~The biochemical pregnancy is confirmed by serum beta hCG 14 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
89325765|NCT00795418|Experimental|CAD106|
89325766|NCT00795418|Placebo Comparator|Placebo|
89325767|NCT04560296|Experimental|Community-based E-Health Program|The intervention group will consist of 80 participants who will engage in Community-based E-Health Program.
89325768|NCT04560296|Active Comparator|usual self-management and follow up with doctors/nurse|The participants will receive the usual self-management and follow up with doctors/nurse as planned.
89325769|NCT00712426|Active Comparator|A|Randomized to receive creatine monohydrate (up to 40 grams daily)
89325770|NCT00712426|Placebo Comparator|B|Randomized to receive placebo (up to 40 grams daily)
89325771|NCT04468958|Experimental|10mg/kg SAB-185|10mg/kg SAB-185 in normal (0.9%) saline; concentration 4mg/mL (0.4%)
89325772|NCT04468958|Experimental|25mg/kg SAB-185|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
89325773|NCT04468958|Experimental|25mg/kg SAB-185 x 2 doses|25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%). Cohort 3 will receive a second 25mg/kg dose of SAB-185 7 days (+/-2) after the first treatment.
89325774|NCT04468958|Experimental|50mg/kg SAB-185|50mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)
89325775|NCT04468958|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
89325776|NCT04540718|No Intervention|Control|Participants in this group continues with their sedentary behavior
89325777|NCT04540718|Active Comparator|Exercise only|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and will sit in the exercise laboratory for 15 minutes whilst the experimental group uses the sauna.
89325778|NCT04540718|Experimental|Exercise and sauna|Participants in this group performs exercise 3 times a week (150 minutes total) according to the recommended exercise guidelines and incorporates sauna bathing (heat therapy) immediately after exercise.
89325779|NCT00708292|Experimental|Single Agent AUY922|
89325780|NCT00708292|Experimental|AUY922 + Bortezomib|
89325781|NCT00708292|Experimental|AUY922 + Bortezomib + Dexamethasone|
89325782|NCT03636620|Active Comparator|TACE group|Transcatheter arterial chemoembolization
89325783|NCT03636620|Experimental|TACE+RFA/MV group|Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
89325784|NCT00699790|Experimental|A1|
89325785|NCT00699790|Placebo Comparator|A2|
89325786|NCT04505462|Experimental|Study diet|7-day therapeutic diet intervention as experimental group
89325787|NCT04505462|No Intervention|Usual diet|7-day usual diet as control group, no dietary intervention in this group, participants consumed their habitual diet
88816251|NCT02568345|Experimental|sugammadex ED90|"Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).~The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg."
88816252|NCT03010124|Other|Patients with ovarian cancer|
89325788|NCT05429216|Experimental|mEMR-C group|In mEMR-C group, enrolled patients will receive modified EMR-C without submucosal injection.
89325789|NCT05429216|Active Comparator|ESD group|In ESD group, enrolled patients will receive the standard treatment modality of ESD to remove the rectal NET
89325790|NCT00790660|Experimental|ASP1941 Lowest Dose|Oral
89325791|NCT00790660|Experimental|ASP1941 Low Dose|Oral
89325792|NCT00790660|Experimental|ASP1941 Medium Dose|Oral
89325793|NCT00790660|Experimental|ASP1941 High Dose|Oral
89325794|NCT00790660|Placebo Comparator|Placebo|Oral
89325795|NCT01330082|Experimental|Photodynamic therapy|will be treated by PDT using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
89325796|NCT01330082|Experimental|Light-emitting diode Irradiation|will be treated only by using Light-emitting diode(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark)
89325797|NCT01330082|Experimental|applying photosensitizer|will be treated only by toluidine blue O
89325798|NCT00835354|Experimental|1|
89325799|NCT00835354|Active Comparator|2|
89325800|NCT01330160||cohort of stroke patients|patients, over 40 years old and without dementia, displaying an hemorrhagic or an ischemic stroke, with a sus-tentorial localization, and included 72h before the onset of symptoms
89325801|NCT00698230|Experimental|Treatment A - INCB013739 & Metformin|INCB013739 5 mg QD and Metformin
89325802|NCT00698230|Experimental|Treatment B - INCB013739 & Metformin|INCB013739 15 mg QD and Metformin
89325803|NCT00698230|Experimental|Treatment C - INCB013739 & Metformin|INCB013739 50 mg QD and Metformin
89325804|NCT00698230|Experimental|Treatment D - INCB013739 & Metformin|INCB013739 100 mg QD and Metformin
89325805|NCT00698230|Experimental|Treatment E - INCB013739 & Metformin|INCB013739 200 mg QD and Metformin
89325806|NCT00698230|Placebo Comparator|Treatment F - Placebo|Matching placebo
89325807|NCT04433468|Active Comparator|RIPC|
89325808|NCT04433468|No Intervention|Control|
89325809|NCT01330238|Active Comparator|Zoledronic acid|Single infusion of 5 mg zoledronic acid I.V.
89325810|NCT01330238|Placebo Comparator|Placebo|Single infusion of 100 ml isotonic NaCl-solution I.V.
89325811|NCT00790426|Experimental|FGFR3 wild type|
89325812|NCT00790426|Experimental|FGFR3 mutant|
89325813|NCT01330472|Active Comparator|Xanax XR tablets 3 mg (sourced from Caugus)|Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE)
89325814|NCT01330472|Experimental|Xanax XR tablets 3 mg (sourced from Barceloneta),|Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST)
89325815|NCT00697918|Experimental|001|RWJ-333369100 mg to 400 mg twice daily
89325816|NCT00835276|Experimental|1|
89325817|NCT00835276|Active Comparator|2|
89325818|NCT03344536|Experimental|fulvestrant and Debio 1347|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter. Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated. The dosage in the phase 2 portion will be the MTD/RP2D determined in the phase 1b portion.
89325819|NCT01759238|Experimental|Chemoradiation|Chemoradiation with different radiotherapy regimes (depending on location and size of irradiated lesions; e.g. conventional radiotherapy with a total dose of 35 Gy, delivered in 2.5Gy fractions for 14 days or intensity-modulated and image-guided radiotherapy with a total dose of 40 Gy, delivered in 4.0 Gy fractions for 10 days or 3-8 fractions with 8-15 Gy) combined with bevacizumab (7.5mg/kg day 1) and capecitabine (825mg/m2 bid on day 1-5, 8-12 and 15-19)
89325820|NCT00697762|Placebo Comparator|003|Placebo tablet twice daily for 12 weeks
89325821|NCT00697762|Experimental|002|RWJ-333369 200 mg tablet twice daily for 12 weeks
89325822|NCT00697762|Experimental|001|RWJ-333369 100 mg tablet twice daily for 12 weeks
89325823|NCT03299062|Active Comparator|Parkinson's Disease with Voice Dysfunction Patients|• Twenty people with Parkinson's Disease requiring evaluation of voice dysfunction by an Ear, Nose, and Throat (ENT) doctor
89325824|NCT03299062|Active Comparator|Other Neurodegenerative Disorders with Voice Dysfunction|• Twenty people with other neurodegenerative disorders requiring evaluation of voice dysfunction by an ENT doctor.
89325825|NCT03299062|Placebo Comparator|Voice Dysfunction|Twenty people with voice tremor and/or presbylarynx, but no evidence of Parkinson's other neurodegenerative disease, requiring evaluation of voice dysfunction by an ENT doctor.
89325826|NCT00835042|Experimental|1|
89325827|NCT00835042|Active Comparator|2|
89325828|NCT03291340||Cognitively normal elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
89325829|NCT03291340||Cognitive impaired elderly|TCD agitated saline right-to-left shunt study TCD cerebrovascular reactivity study
89325830|NCT03290248|Placebo Comparator|Vehicle|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
89325831|NCT03290248|Active Comparator|B 244 1x (low dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
89325832|NCT03290248|Active Comparator|B244 4x (mid dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
89325833|NCT04680520|Experimental|Best practice skin care advice booklet plus emollient (Doublebase Gel® or Diprobase Cream®)|Use of emollient (Doublebase Gel® or Diprobase Cream®) plus best practice skin care advice. The advice is given in the form of a booklet containing advice on skin care. This will contain information on avoiding soap etc. It will also explain how to apply the emollient i.e. in the direction of the hair, all over the child's skin daily for the first year of life. Intervention group will receive both emollients and parents are asked to choose their preferred.
89325834|NCT04680520|Active Comparator|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
89325835|NCT04667962||Hospital service change|This group is composed of caregivers who changed hospital service during COVID-19 health crisis.
89325836|NCT04667962||No hospital service change|This group is composed of caregivers who have not changed hospital service during COVID-19 health crisis.
89325837|NCT00834964|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
89325838|NCT00834964|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
89325839|NCT03239938|Experimental|Modern pain neuroscience approach|Modern pain neuroscience approach
89325840|NCT03239938|Active Comparator|Usual care evidence-based physiotherapy|Usual care physiotherapy
89325841|NCT03070522|Active Comparator|Placebo|Placebo
89325842|NCT03070522|Active Comparator|Treatment|Prednisone
89325843|NCT00783406|Experimental|PF- 00610355|
89325844|NCT00783406|Experimental|PF-00610355|
89325845|NCT00783406|Experimental|PF -00610355|
89325846|NCT00783406|Placebo Comparator|Placebo|
89325847|NCT03038854|Experimental|Test GUM|This group will drink a test toddler growing up milk (GUM) with higher amounts of key nutrients
89325848|NCT03038854|Active Comparator|Standard GUM|This group will drink a standard toddler growing up milk (GUM)
89325849|NCT03038854|Placebo Comparator|Comparator Group|This group will drink liquid full fat cows' milk
89325850|NCT03038854|No Intervention|Population Group|This group will eat and drink their usual foods with no interventions.
89325851|NCT00834574|Experimental|1|
89325852|NCT00834574|Active Comparator|2|
89325853|NCT04879966||UC cohort|the patiente of Moderate to Severe Ulcerative Colitis who recieved infliximab(IFX) or corticosteroids(CS) as induction therapy would be enrolled in this cohort
89325854|NCT00834418|Experimental|Leflunomide|Leflunomide 20 mg Tablet
89325855|NCT00834418|Active Comparator|Arava™|Arava™ 20 mg Tablet
89325856|NCT04621318|Experimental|SB16|SB16 (proposed denosumab biosimilar)
89325857|NCT04621318|Active Comparator|EU Prolia|EU sourced Prolia (denosumab)
89325858|NCT04621318|Active Comparator|US Prolia|US sourced Prolia (denosumab)
89325859|NCT00834340|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
89325860|NCT00834340|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
89325861|NCT00683722|Experimental|Prochymal™|Participants received Prochymal™ a total of 400×10^6 cells, intravenous (IV) infusions on Days 0, 30, 60, and 90.
89325862|NCT00683722|Placebo Comparator|Placebo|Participants received placebo-matching IV infusions on Days 0, 30, 60 and 90.
89325863|NCT04473274|Experimental|Pioglitazone group|Participants will receive pioglitazone 15mg to 30mg daily oral or enteral during hospitalization for up to 30 days in addition to standard of care
89325864|NCT04473274|No Intervention|Matching cohort group|Participants will standard of care
89325865|NCT02935270||Stroke Survivors|Individuals who have experienced a unilateral hemispheric stroke
89325866|NCT00679588|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery (placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind)
89325867|NCT00679588|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium (placebo for Semuloparin sodium 8 hours after surgery to maintain the blind)
89325868|NCT00151996|Experimental|Methylphenidate + SPD503|
89325869|NCT00151996|Experimental|Amphetamine + SPD503|
89325870|NCT02889874|No Intervention|A: Radiation Therapy & endocrine therapy|Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).
89325871|NCT02889874|Experimental|B: No Radiation Therapy (ET only)|Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.
89325872|NCT00831532|Experimental|Normal|Healthy Volunteers
89325873|NCT00831532|Experimental|Mild Hepatic Impairment|Mild hepatic impairment patients
89325874|NCT00831532|Experimental|Moderate hepatic Impairment|Moderate Hepatic Impairment Patients
89325875|NCT00831532|Experimental|Severe Hepatic Impairment|Severe Hepatic Impairment Patients
89325876|NCT00830206|Experimental|Azithromycin (test)|Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
89325877|NCT00830206|Active Comparator|Zithromax® (reference)|Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in second period
89325878|NCT04472962|Active Comparator|Low-carbohydrate-high-protein pre-exercise meal|
89325879|NCT04472962|Active Comparator|High-carbohydrate-low-protein pre-exercise meal|
89325880|NCT05388994|Experimental|Exercise|The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
89325881|NCT00829504|Experimental|1|
89325882|NCT00829504|Active Comparator|2|
89325883|NCT00779428|Experimental|A1|
89325884|NCT00829426|Experimental|Alprazolam|Alprazolam 3mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
89325885|NCT00829426|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (reference) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
89325886|NCT00152464|Experimental|Levocetirizine (LCTZ)|0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.
89325887|NCT00152464|Placebo Comparator|Placebo (PBO)|Placebo was administered as oral drops twice daily.
89325888|NCT00827008|Experimental|1, verum|
89325889|NCT04472806|Experimental|chemotherapy+Endostar+Toripalimab(JS001)|
89325890|NCT00674440|Experimental|Subjects who had PET and surgery|Children diagnosed with hyperinsulinism who have failed other non-surgical interventions and are candidates to be scheduled for surgery for partial pancreatectomy. Eligible children will undergo PET imaging with F-DOPA prior to surgery.
89325891|NCT00773344|Experimental|A1|
89325892|NCT02742766|Experimental|Part 1 - GSK3008356 single dose and multiple doses|Healthy subjects will receive GSK3008356 in morning as single dose or multiple doses of 5 milligrams (mg), 10 mg, 30 mg,45 mg, 75 mg, 90 mg, 125, 180 mg, 200 mg, 250 mg total daily dose or matching placebo in eleven sequential cohorts while receiving a standard fat meal. The initial dosing for the first cohort will be staggered so that 2 subjects will be dosed as sentinel subjects. Provided there are no safety concerns, the remainder of the subjects scheduled for the cohort may be dosed. Eight subjects will be enrolled in each cohort.
89325893|NCT02742766|Experimental|Part 2 - GSK3008356 14 day repeat dose|Healthy subjects will receive GSK3008356 or matching placebo, as 14 daily doses in the three sequential cohorts. Subjects in cohort 1 will receive their daily dose in morning, while subjects in cohort 2 and cohort 3 will receive their daily dose in evening. In all the three cohorts, Day 1 and day 14 dosing will occur while receiving a standard fat meal in morning. Eight subjects will be enrolled in each cohort.
89325894|NCT02742766|Experimental|Part 3 - GSK3008356 28 day repeat dose|Obese subjects will receive GSK3008356 or matching placebo, as 28 daily doses in the three parallel cohorts. Cohort 1 will evaluate 1 dose strength of GSK3008356 (or matching placebo) administered as morning doses. Cohorts 2 and 3 will evaluate 2 dose strengths (1 per cohort) of GSK3008356 (or matching placebo) administered in the evening. Ten subjects will be enrolled in each cohort.
89325895|NCT01858948|Experimental|Quetiapine plus Omega|Patients will be randomized to EPA+DHA supplements (OmegaRx) at fixed dose of 3.0 g/day (EPA: 2.0 g, DHA: 1.0 g; 5 capsules/d) for 24 weeks.
89325896|NCT01858948|Placebo Comparator|Quetiapine plus Placebo|Patients will be randomized to similar in shape an color placebo supplements (corn oil)
89325897|NCT00770848|Other|Phase 1b - AMG 102|Phase 1b is an open-label study with AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed, will be administered by IV Q3W in combination with MP.
89325898|NCT00770848|Experimental|Phase 2 Arm A - AMG 102 + MP|AMG 102 safe dose level in phase 1b in combination with MP, will be administered by IV Q3W.
89325899|NCT00770848|Placebo Comparator|Phase 2 Arm C- PLACEBO|Placebo in combination with MP, will be administered by IV Q3W.
89325900|NCT00770848|Experimental|Phase 2 Arm B - AMG 102 + MP|Safe dose level in phase 1b of AMG 102 + MP will be administered by Q3W
89325901|NCT00672412|Experimental|1|Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
89325902|NCT00672412|Experimental|2|Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
89325903|NCT01468922|Experimental|A/Combination pazopanib plus ARQ 197 (Tivantinib)|Combination pazopanib plus ARQ197 at doses established during escalation phase
89325904|NCT01381094|Experimental|AKB-6548 240 mg|
89325905|NCT01381094|Experimental|AKB-6548 370 mg|
89325906|NCT01381094|Experimental|AKB-6548 500 mg|
89325907|NCT01381094|Experimental|AKB-6548 630 mg|
89325908|NCT01381094|Placebo Comparator|Placebo|
89325909|NCT01330550|Experimental|high fiber sugar free biscuit.|High fiber sugar free biscuit will regulate Blood sugars.
89325910|NCT01315184|Experimental|Recovery Line Support System|Patients assigned to the Recovery Line Support System will be trained on the system and provided 24-hr access to the system for a four week period, provided with a Recovery notebook, and given reminder calls to contact the system.
89325911|NCT01315184|No Intervention|Treatment as Usual|Patients assigned to the TAU condition will receive any services provided by their buprenorphine provider and any additional services that their provider refers or recommends that patients attend. No additional services will be provided by the study.
89325912|NCT01315262|Active Comparator|Viagra 100 mg daily|
89325913|NCT01315262|Active Comparator|Viagra 100mg on demand|
89325914|NCT03197558|Other|Tube insertion using Tube Delivery System (TDS)|Active Tymbion iontophoresis and tube insertion using the TDS
89325915|NCT03197324|Active Comparator|Digoxin Alone first, then Digoxin With Bexagliflozin|
89325916|NCT03197324|Active Comparator|Digoxin with Bexagliflozin, then Digoxin alone|
89325917|NCT01330706|Experimental|Sterile Saline solution|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
89325918|NCT01330784||hMG-HP|Patients with a condition
89325919|NCT03162614|Active Comparator|AduFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.
89325920|NCT03162614|Experimental|2PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.
89325921|NCT03162614|Experimental|PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.
89325922|NCT03162614|Experimental|Adu2Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.
89325923|NCT03162614|Active Comparator|Adu1Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.
89325924|NCT03162614|Other|Control Group|Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.
89325925|NCT03160898|Experimental|Reldesemtiv 150 mg twice daily|Patients in this arm took 1 reldesemtiv 150 mg oral tablet and 2 matching placebo tablets every 12 hours for 12 weeks.
89325926|NCT03160898|Experimental|Reldesemtiv 300 mg twice daily|Patients in this arm took 2 reldesemtiv 150 mg oral tablets and 1 matching placebo tablet every 12 hours for 12 weeks.
89325927|NCT03160898|Experimental|Reldesemtiv 450 mg twice daily|Patients in this arm took 3 reldesemtiv 150 mg oral tablets every 12 hours for 12 weeks.
89325928|NCT03160898|Placebo Comparator|Placebo|Patients in this arm took 3 placebo oral tablets every 12 hours for 12 weeks.
89325929|NCT01330940|Placebo Comparator|Water drinking|32 ounces of water/24 hours
89325930|NCT01330940|Active Comparator|orange soda drinking|32 ounces orange soda
89325931|NCT01331096||Anesthetic drugs manually administrated|
89325932|NCT01331096||Automated anesthesia delivery system|
89325933|NCT01331174|Experimental|High dose PSW groups|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W. These settings were based on the fact that applications with mean power below 20W minimize the thermal effects
89325934|NCT01331174|Placebo Comparator|Placebo|A placebo group was also established, in which the PSW device was turned on but kept in stand-by mode during 19 minutes without any electrical current being applied in the patients
89325935|NCT01331174|No Intervention|Control|The control group was composed of patients that were not submitted to any form of treatment and all patients were instructed to maintain their daily activities
89325936|NCT01331252|Experimental|supine body position|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
89325937|NCT01331252|Experimental|semi-recumbent|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
89325938|NCT03193736|Experimental|implant|
89325939|NCT04071704||Patients|Patients who have been or are being treated for sarcoma.
89325940|NCT04071704||Health care professionals|Health care professionals with extensive experience in sarcoma care (medical oncologists, radiation oncologists, surgical oncologists, orthopaedic surgeons, nurse specialists, psychologists, physiotherapists)
89325941|NCT04014998|Experimental|Virtual Reality|Virtual Reality + Exercise
89325942|NCT04014998|Other|Exercise|Exercise Only
89325943|NCT01235936|Experimental|AKB-6548|
89325944|NCT01156220|Experimental|female|"The healthy female volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2."
89325945|NCT01156220|Experimental|male|"The healthy male volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2"
89325946|NCT01021202|Experimental|Early tracheostomy|Percutaneous dilation tracheostomy < 72h on mechanical ventilation
89325947|NCT01021202|Experimental|Late tracheostomy|Percutaneous dilation tracheostomy > 10 days on mechanical ventilation
89325948|NCT01331330|Active Comparator|Group B|Low Programming
89325949|NCT01331330|Experimental|Group A|Normal Programming
89325950|NCT03192488|Experimental|Cetirizine/Hypoxia|Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
89325951|NCT03192488|Placebo Comparator|Placebo/Normoxia|Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
89325952|NCT03192488|Placebo Comparator|Placebo/Hypoxia|Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
89325953|NCT01642004|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
89325954|NCT01642004|Experimental|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
89325955|NCT03975530|Experimental|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it. At 6 months postpartum, and upon completion of the intervention, participants in the treatment group will be asked to participate in brief semi-structured phone interviews.
89325956|NCT03975530|Active Comparator|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
89325957|NCT03264560|Active Comparator|Synchronous Telepsychiatry (STP) group|
89325958|NCT03264560|Experimental|Asynchronous Telepsychiatry (ATP) group|
89325959|NCT01331486|Placebo Comparator|Placebo|Placebo capsule
89325960|NCT01331486|Active Comparator|Low dose|
89325961|NCT01331486|Active Comparator|Mid dose|
89325962|NCT01331486|Active Comparator|High dose|
89325963|NCT00042289||DRV/RTV 600 or 800 or 900/100mg b.i.d. then 800 or 900/100mg b.i.d. then 600/100mg b.i.d.|"HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received:~darunavir/ritonavir (DRV/RTV) 600/100 mg twice daily (b.i.d.) or 800/100 mg b.i.d. until 30 weeks gestation; then 800/100 mg b.i.d. until postpartum hospital discharge; then 600/100 mg b.i.d. after postpartum hospital discharge until 2 week postpartum PK samples are drawn.~OR darunavir/ritonavir twice daily 600/100 mg b.i.d. or 900/100 mg b.i.d. until 30 weeks gestation; then 900/100 mg b.i.d. until postpartum hospital discharge; then 600/100 mg b.i.d. after postpartum hospital discharge until 2 week postpartum PK samples are drawn."
89325964|NCT00042289||DTG 50mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received dolutegravir (DTG) 50 mg once a day (q.d.).
89325965|NCT00042289||TAF 25mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 25 mg q.d. without cobicistat or ritonavir boosting.
89325966|NCT00042289||TAF 10mg q.d. w/COBI|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 10 mg q.d. with cobicistat (COBI).
89325967|NCT00042289||TAF 25mg q.d. w/COBI or RTV boosting|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received tenofovir alafenamide fumarate (TAF) 25 mg q.d. with cobicistat (COBI) or ritonavir (RTV) boosting.
89325968|NCT00042289||EVG/COBI 150/150mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received elvitegravir/cobicistat (EVG/COBI) 150/150 mg q.d
89325969|NCT00042289||DRV/COBI 800/150 mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d.
89325970|NCT00042289||ATV/COBI 300/150 mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d.
89325971|NCT00042289||EFV 600 mg q.d. (outside THA)|HIV-infected pregnant women ≥ 20 weeks gestation NOT on tuberculosis treatment who received efavirenz (EFV) 600 mg q.d. (Participants outside of Thailand only)
89325972|NCT00042289||EFV 600mg q.d. and at least one 1st line TB drug|"HIV-infected pregnant women ≥ 20 weeks gestation who received efavirenz (EFV) 600mg q.d.and TB treatment with at least one of the following TB drugs at study entry:~rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w."
89325973|NCT00042289||LPV/RTV 800/200mg b.i.d. and at least one 1st line TB drug|"HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV) 800/200mg b.i.d. and TB treatment with at least one of the following TB drugs at study entry:~rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w."
89325974|NCT00042289||No ARVs and at least two 1st line TB drugs|"HIV-uninfected pregnant women ≥ 20 weeks gestation who received at least two of the following first line TB drugs at study entry:~rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w."
89325975|NCT00042289||At least two 2nd line TB drugs w/ or w/out ARVs|"HIV-infected and HIV-uninfected pregnant women ≥ 20 weeks gestation who received at least two of the following second line TB drugs at study entry:~Injectable agents:~kanamycin~amikacin~capreomycin~Fluoroquinolones:~moxifloxacin~levofloxacin~ofloxacin~Oral bacteriostatic second-line agents:~ethionamide/prothionamide~terizidone/cycloserine~para-aminosalicylic acid (PAS)~Other agents:~high dose INH~bedaquiline~clofazamine~delamanid~linezolid~pretomanid"
89325976|NCT00042289||DRV/COBI 800/150mg q.d. or ATV/COBI 300/150mg q.d with 30-35ug EE|HIV-infected women 2-12 weeks (14-84 days) post-delivery who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d. or atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol
89325977|NCT00042289||DRV/COBI 800/150mg q.d. or ATV/COBI 300/150mg q.d with ENG|HIV-infected women 2-12 weeks (14-84 days) post-delivery who received darunavir/cobicistat (DRV/COBI) 800/150 mg q.d. or atazanavir/cobicistat (ATV/COBI) 300/150 mg q.d. postpartum and starting etonogestrel (ENG) implant
89325978|NCT00042289||EFV 600mg q.d. with 30-35ug EE|HIV-infected women 2-12 weeks (14-84 days) post-delivery who received efavirenz (EFV) 600mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
89325979|NCT00042289||ATV/RTV/TFV 300/100/300mg q.d. with 30-35ug EE|HIV-infected women 2-12 weeks (14-84 days) post-delivery who received atazanavir/ritonavir/tenofovir (ATV/RTV/TFV) 300/100/300 mg q.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
89325980|NCT00042289||NVP 200mg b.i.d|HIV-infected pregnant women ≥ 26 weeks gestation who received nevirapine (NVP) 200 mg twice a day
89325981|NCT00042289||APV 1200mg b.i.d|HIV-infected pregnant women ≥ 26 weeks gestation who received amprenavir (APV) 1200mg twice a day
89325982|NCT00042289||ABC 300mg b.i.d|HIV-infected pregnant women ≥ 20 weeks gestation who received abacavir (ABC) 300mg twice a day
89325983|NCT00042289||LPV/RTV Arm 1: 400/100mg b.i.d|HIV-infected pregnant women ≥ 26 weeks gestation who received lopinavir/ritonavir (LPV/RTV) 400/100mg twice a day
89325984|NCT00042289||IDV/RTV Arm 1: 800/100mg b.i.d|HIV-infected pregnant women ≥ 26 weeks gestation who received indinavir/ritonavir (IDV/RTV) 800/100 mg twice a day
89325985|NCT00042289||FPV/RTV 700/100mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received fosamprenavir/ritonavir (FPV/RTV)700/100mg twice a day
89325986|NCT00042289||LPV/RTV Arm 2: 400/100mg b.i.d. then 533/133mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received Kaletra (LPV/RTV) 400/100 mg twice a day until 30 weeks gestation, then 533/133 mg twice a day until results of postpartum PK evaluation were available
89325987|NCT00042289||ATV/RTV Arm 1: 300/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received atazanavir/ritonavir (ATV/RTV) 300/100 mg once a day
89325988|NCT00042289||DDI 400mg or 250mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received didanosine delayed release (Videx® EC) (DDI) 400 mg once a day if weight > 60 kg; 250 mg once a day if weight < 60 kg
89325989|NCT00042289||FTC 200mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received emtricitabine (FTC) 200 mg once a day
89325990|NCT00042289||TFV 300mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir (TFV) 300 mg once a day
89325991|NCT00042289||TFV/ATV/RTV Arm 1: 300/300/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir/atazanavir/ritonavir (TFV/ATV/RTV) 300/300/100 mg once a day
89325992|NCT00042289||NFV Arm 1: 1250mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received nelfinavir (NFV) [625 mg tablets] 1250 mg twice a day
89325993|NCT00042289||EFV 600mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received efavirenz (EFV) 600 mg once a day
89325994|NCT00042289||TPV/RTV 500/200mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received tipranavir/ritonavir (TPV/RTV) 500/200 mg twice a day
89325995|NCT00042289||LPV/RTV Arm 3: 400/100mg b.i.d. then 600/150mg b.i.d. then 400/100mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV) tablets 400/100 mg [2 tablets] twice a day until 30 weeks gestation, then 600/150 mg [3 tablets] twice a day until postpartum hospital discharge; and 400/100 mg [2 tablets] twice a day after postpartum hospital discharge, until 2 week postpartum PK sample is drawn
89325996|NCT00042289||RAL 400mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received raltegravir (RAL) 400 mg twice a day
89325997|NCT00042289||ETR 200mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received etravirine (ETR) 200mg twice a day
89325998|NCT00042289||MVC 150 or 300mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received maraviroc (MVC)150 mg or 300 mg twice a day
89325999|NCT00042289||DRV/RTV 800/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received darunavir/ritonavir (DRV/RTV) 800/100 mg once a day
89326000|NCT00042289||DRV/RTV 600/100mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received darunavir/ritonavir (DRV/RTV) 600/100 mg twice a day
89326001|NCT00042289||ATV/RTV Arm 2: 300/100mg q.d. then 400/100mg q.d. then 300/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received atazanavir/ritonavir (ATV/RTV) 300/100 mg once a day until 30 weeks gestation then 400/100 mg once a day until postpartum hospital discharge; then 300/100 mg once a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
89326002|NCT00042289||TFV/ATV/RTV Arm 2: 300/300/100mg q.d. then 300/400/100mg q.d then 300/300/100mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received tenofovir/atazanavir/ritonavir (TFV/ATV/RTV) 300/300/100 mg once a day until 30 weeks gestation; then 300/400/100 mg once a day until postpartum hospital discharge; then 300/300/100 mg once a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
89326003|NCT00042289||NFV Arm 2: 1250mg b.i.d. then 1875mg b.i.d. then 1250mg b.i.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received nelfinavir (NFV) [625 mg tablets] 1250 mg twice a day until 30 weeks gestation; then 1875 mg twice a day until postpartum hospital discharge; then 1250 mg twice a day after postpartum hospital discharge until 2 week postpartum PK samples drawn
89326004|NCT00042289||IDV/RTV Arm 2: 400/100mg q.d. (only THA)|HIV-infected pregnant women ≥ 20 weeks gestation who received indinavir/ritonavir (IDV/RTV) 400/100 mg twice a day only to participants enrolling in Thailand
89326005|NCT00042289||LPV/RTV Arm 4: 400/100mg b.i.d. then 600/150mg b.i.d. then 400/100mg b.i.d. (only African sites)|HIV-infected pregnant women ≥ 20 weeks gestation who received lopinavir/ritonavir (LPV/RTV, Alluvia tablets) 400/100 mg [2 tablets] twice day until 30 weeks gestation; then 600/150 mg [3 tablets] twice a day until postpartum hospital discharge; then 400/100 mg [2 tablets] twice a day after postpartum hospital discharge until 2 week postpartum PK sample drawn only to participants enrolling in Uganda
89326006|NCT00042289||RPV 25mg q.d.|HIV-infected pregnant women ≥ 20 weeks gestation who received rilpivirine (RPV) (25 mg q.d.)
89326007|NCT00042289||NVP 200mg b.i.d. and RIF and at least one 1st line TB drug|"HIV-infected pregnant women > 20 weeks gestation who received nevirapine (NVP) 200 mg b.i.d AND rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w. and at least one of the following drugs at study entry:~ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.~isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.~pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w."
89326008|NCT00042289||ATV/RTV/TFV 300/100/300mg q.d. with ENG|HIV- infected women 2-12 weeks postpartum who received atazanavir/ritonavir/tenofovir (ATV/RTV/TFV) 300/100/300 mg q.d. postpartum and starting postpartum etonogestrel (ENG) implant
89326009|NCT00042289||LPV/RTV 400/100 b.i.d. with 30-35ug EE|HIV- infected women 2-12 weeks postpartum who received lopinavir/ritonavir (LPV/RTV) 400/100 b.i.d. postpartum and starting combined oral contraceptives formulated with 30-35 μg ethinyl estradiol (EE)
89326010|NCT00042289||LPV/RTV 400/100 b.i.d. with ENG|HIV- infected women 2-12 weeks postpartum who received lopinavir/ritonavir (LPV/RTV) 400/100 b.i.d. postpartum and starting postpartum etonogestrel (ENG) implant
89326011|NCT00042289||EFV 600mg q.d. with ENG|HIV-infected women 2-12 weeks postpartum who received efavirenz (EFV) 600mg q.d. postpartum and starting postpartum etonogestrel (ENG) implant
89326012|NCT03953911|Active Comparator|Control: Mobile Clinic Only|The middle school assigned to the control arm will receive a visit by a mobile clinic every 6 months only. The school will follow normal protocol for HPV vaccination awareness. Parents will be made aware of the mobile clinic per normal school newsletters and mailers.
89326013|NCT03953911|Experimental|Mobile Clinic plus Educational Sessions|The middle school assigned to the Mobile Clinic every 6-mos or month plus Educational Sessions arm will receive visitation of a mobile clinic providing free HPV vaccination among other school-related vaccines once every 6-months or once a month. Parents will be made aware of the mobile clinic per normal school newsletters and mailers. In addition, parents will be provided with free weekly educational sessions about the HPV Vaccine as a cancer-prevention effort.
89326014|NCT03952117|Active Comparator|Active tDCs|Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. The cathode will be positioned facing the primary motor cortex area and the anode over the contralateral supraorbital area.
89326015|NCT03952117|Sham Comparator|Sham tDCS|Sham stimulation will be delivered to the motor cortex using a sham tDCS device that delivers a direct current for 10 seconds at the beginning and end of tDCS to provide sensory experiences similar to active stimulation.
89326016|NCT01099033||Hiatal/Paraesophageal hernia patients|patients with hiatal or paraesophageal hernias
89326017|NCT01099033||control group|patients without hiatal or paraesophageal hernias who are undergoing crural dissection for heller myotomy, or who are undergoing gastric bypass surgery
89326018|NCT01584193|Experimental|US-guided subclavian vein puncture|
89326019|NCT01584193|Active Comparator|Cephalic vein dissection|
89326020|NCT02886728|Experimental|Filgotinib 200 mg + MTX|Filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
89326021|NCT02886728|Experimental|Filgotinib 100 mg + MTX|Filgotinib 100 mg + placebo to match filgotinib 200 mg + MTX up to 20 mg
89326022|NCT02886728|Experimental|Filgotinib 200 mg Monotherapy|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match MTX
89326023|NCT02886728|Active Comparator|MTX Monotherapy|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
89326024|NCT00039871|Experimental|Overall study population|
89326025|NCT01096693|Placebo Comparator|Saline Placebo|In this arm, the response in forearm blood flow to incremental doses of Urocortins 2, 3 and Substance P will be studied co infused with saline placebo.
89326026|NCT01096693|Active Comparator|Response to Urocortin infusion in presence of Astressin 2B|This arm studies the response to intra arterial infusion of incremental doses of Urocortins 2, 3 and Substance P in the presence or absence of a selective antagonist - Astressin 2B.
89326027|NCT03951181|Experimental|LEAP-MS Intervention|This is a single arm study.
89326028|NCT00015457|Experimental|cervical dystonia|cervical dsytonia patinets
89326029|NCT01331564|Experimental|electronic intervention group 2|(e-intervention 2) receives a behavioral intervention through a website during pregnancy and until 18 months postpartum
89326030|NCT01331564|Experimental|electronic intervention group 1|(e-intervention 1) receives a behavioral intervention through a website during pregnancy. During the postpartum period this arm receives the same non-weight-related information as the control arm
89326031|NCT01331564|Placebo Comparator|Control|
89326032|NCT01331642||Observation|Patients with Gaucher disease or high-grade suspicion for Gaucher disease
89326033|NCT01331720||FSH:LH 1:1 - Treatment Group A|"Patients with a condition~LH (luteinizing hormone)"
89326034|NCT01331720||FSH:LH 3:2 - Treatment Group B|Patients with a condition
89326035|NCT01331720||FSH:LH 3:1 - Treatment Group C|Patients with a condition
89326036|NCT01331720||FSH:LH 3:0 - Treatment Group D|Patients with a condition
89326037|NCT01331720||Initially FSH:LH 3:0 and on S6 FSH:LH 1:1 - Treatment Group E|Patients with a condition
89326038|NCT03564470|Experimental|Chidamide|Chidamide will be added to chidamide arm Ph-like ALL(CRLF2 high-expression, CRLF2/EPO/JAK2 rearrangement, JAK/IL-7R/SH2B3 mutation, etc).
89326039|NCT03564470|Experimental|Dasatinib|Dasatinib at a dose of 100mg/day will be added to Dasatinib arm of Ph-like ALL (CRKL high-expression, ABL1 or ABL2 or CSFR1 or PRGFRB rearrangement, etc).
89326040|NCT01574144||AVIVO™ PiiX Patch Monitor System|Heart failure patients monitored continuously for 30 days post-discharge.
89326041|NCT03685760|Experimental|Reiki|Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
89326042|NCT03685760|Sham Comparator|Sham Reiki|Sham Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily sham Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
89326043|NCT03685760|No Intervention|Usual Care|Twice per day, 30 minutes apart, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data. Usual care will also involve a 5-day period.
89326044|NCT03191630|Experimental|Control|This arm includes participants randomized to the control group who will use activity trackers (Fitbits) only, and not receive the SystemCHANGE intervention.
89326045|NCT03191630|Experimental|Intervention|This are includes participants randomize to the intervention group who will receive the combination of the SystemCHANGE TM and activity tracker intervention
89326046|NCT03191552|Experimental|SPIO 2 hours|"All children will be hospitalized for 2 weeks and will receive conventional exercise therapy including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks 2 hours a day.~SPIO 2 hours group will receive conventional exercise therapy with the garment on for 2 hours."
89326047|NCT03191552|Experimental|SPIO 6 hours|SPIO 6 hours group will receive conventional exercise therapy with the garment on for 2 hours and worn SPIO 4 hours more in addition to 2 hour of wear during exercise therapy.
89326048|NCT03191552|Active Comparator|Control(conventional exercises)|Control group will only receive conventional exercise therapy (for two hours a day) including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks
89326049|NCT03191396|Experimental|Semaglutide|Half the study participants are randomised to receive semaglutide
89326050|NCT03191396|Active Comparator|Liraglutide|Half the study participants are randomised to receive liraglutide
89326051|NCT01331798|Experimental|Test: TissuGlu Adhesive|Patients received the TissuGlu Adhesive Treatment
89326052|NCT01331798|Active Comparator|Control|Control Arm received no TissuGlu- Standard of Care received.
89326053|NCT03509636|Experimental|Treatment|Fluzoparib capsule
89326054|NCT01331876|Experimental|reference therapy|20 OCD patients following 15 sessions of the reference CBT (Bouvard,2006)
89326055|NCT01331876|Experimental|experimental therapy|20 OCD patients following 15 sessions of reference CBT associated with a new psychopedagogic task developed by our team.
89326056|NCT03664934|Experimental|Patients, Neck-specific exercises|Patients before and after neck-specific exercises, subgroup to NCT01528579 with additional measures
89326057|NCT03664934|No Intervention|Healthy controls|Healthy controls, no treatment
89326058|NCT01333670|Experimental|Prontosan wound irrigation solution|
89326059|NCT01333670|Active Comparator|Standard care|
89326060|NCT00007345|Experimental|Peripheral T-cell Lymphoma (PTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
89326061|NCT00007345|Experimental|Cutaneous T-cell Lymphoma (CTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
89326062|NCT01571102|Active Comparator|physiotherapy|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
89326063|NCT01571102|No Intervention|Rest|
89326064|NCT01571102|Active Comparator|Home exercises|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
89326065|NCT01584271|Active Comparator|2 Dex-Otic ear drops|Dex-Otic(R) ear drops are used for pain relief and treating ears of AOE patients. It contains: Dexamethasone Sodium Phosphate 1 mg; Neomycin sulfate 5 mg; Polymyxin B sulfate 10,000 units. It
89326066|NCT01584271|Experimental|3 Ear Comfort(TM) ear drops|Natural Ear comfort(TM) ear drops contains Chamomile extract and Thyme oil in anhydrous glycerin for pain relief and ear healing.
89326067|NCT01584271|Active Comparator|1 Otidin(R) ear drops|Otidin(R): Ear drops containing Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin for pain relief in AOE patients.
88816253|NCT02570139|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
89326068|NCT03405662|Active Comparator|Acitve PBM|This arm will receive active photobiomodulation (PBM), delivered with the Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
89326069|NCT03405662|Sham Comparator|Sham PBM|This arm will not receive active photobiomodulation (PBM). Instead, they will use a sham Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
89326070|NCT02530099|No Intervention|Control group|Receive no training.
89326071|NCT02530099|Experimental|CN-group|Receive basic camera navigation training.
89326072|NCT02530099|Experimental|Procedure-group|Receive training on a laparoscopic procedure.
89326073|NCT02530567|Experimental|Intervention|"The measurement of portosystemic pressure gradient will be performed before liver biopsy.~Then liver biopsy is performed. The MRI was performed on the day of biopsy or within one week around the completion of the biopsy.~The MRI machine used is the Siemens 3T."
89326074|NCT01333748|Experimental|patients group|Patients with ovarian and/or breast cancer
89326075|NCT01333748|Other|control population|control population without history of breast and/or ovarian cancer
89326076|NCT01331954|Experimental|HIFU|
89326077|NCT00031447|Placebo Comparator|Placebo|
89326078|NCT00031447|Experimental|Acyclovir|
89326079|NCT01099189||Observed cohort|All patients recruited. Observed for clinical outcomes
89326080|NCT03949543|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with large lunch intervention
89326081|NCT03949543|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with large dinner intervention
89326082|NCT01102933||Unselected post-myocard infarct patients|Patients diagnosed with MI at Uppsala University Hospital
89326083|NCT01099345||Group 1 - OAB with DO+|Subjects that DO+ nocturia
89326084|NCT01099345||Group 2- OAB with DO-|Subjects that DO- nocturia
89326085|NCT01103011|Experimental|ND0611 dose 1, ND0611 dose 2, placebo|
89326086|NCT03948997|Experimental|Treatment group|Patients with port wine stains receive PDL (1.5-10ms, 11-12.5J/cm2) with a treatment range of approximately 10*10cm2
89326087|NCT03948997|No Intervention|No treatment group|Patients with port wine stains have not been treated with PDL treatment
89326088|NCT01101139|Experimental|Experimental|Single injection of Sugammadex 0.25 mg/kg
89326089|NCT01101139|Placebo Comparator|Placebo comparator|Single injection of Saline 0.9%
89326090|NCT00006409|Experimental|School-based intervention|TAAG health education included six lessons in each of 7th and 8th grades designed to enhance behavioral skills known to influence physical activity. TAAG physical education classes promoted moderate-vigorous physical activity for at least 50% of class time and encouraged teachers to promote physical activity outside of class. In conjunction with community partners, programs that were promoted outside of school included Dance Dance Revolution, after-school step aerobics class, before-school open gym, basketball camp, touch football, and weekend canoe programs. TAAG promotions used a social marketing approach to promote awareness of and participation in activities through media and promotional events.
89326091|NCT00006409|No Intervention|Control group|
89326092|NCT01099423|Active Comparator|Immediate nephrectomy|Surgery followed by Sunitinib
89326093|NCT01099423|Experimental|Deferred nephrectomy|Sunitinib (3 cycles) followed by surgery followed by Sunitinib
89326094|NCT00006289|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive placebo for 5 weeks and then Neurotropin for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
89326095|NCT00006289|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 5 weeks and then placebo for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
89326096|NCT01099501|Active Comparator|Oxepa|Oxepa (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
89326097|NCT01099501|Active Comparator|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
89326098|NCT01099657|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis for chronic pain
89326099|NCT01099657|Experimental|Virtual Reality Distraction|Virtual Reality Distraction for Chronic Pain
89326100|NCT05625841|Experimental|Honey|Each pack of 10 grams of honey after three meals a day.
89326101|NCT05625841|Experimental|Honey and propolis|Each pack contains 0.7ml of propolis + 9.3g of honey after three meals a day.
89326102|NCT05625841|Placebo Comparator|Usual care|General routine oral care.
89326103|NCT01101217|Placebo Comparator|placebo|placebo for 6 weeks
89326104|NCT01101217|Active Comparator|zinc|zinc sulfate 220 mg per day orally for 6 weeks
89326105|NCT01099735||CPAP, Manometry|Patients undergoing Manometry before weight loss surgery
89326106|NCT01101373||1|All subjects who received BAC for treatment resistant depression between 2000 and 2009
89326107|NCT01099813||Inpatients assessed for critical care|Patients admitted to Critical Care Units participating in the ICNARC CMP programme who have been assessed at any time on a ward prior to ICU admission by a critical care decision maker (e.g. the CCOT or any member of the medical staff on duty for the unit)
89326108|NCT02530021||Heart rate monitor|"Hospitalized patients with chest pain and suspected ischemic heart disease who are candidates for non invasive exercise stress test by their treating physician.~The patients will perform a one hour heart rate variability monitoring prior to the stress test."
89326109|NCT00005947|Active Comparator|sipuleucel-T|
89326110|NCT00005947|Placebo Comparator|Placebo|
89326111|NCT01103401|Active Comparator|Tobramycin/Dexamethasone|
89326112|NCT01103401|Active Comparator|Tobramycin/Dexamethasone plus Ketorolac tromethamine|
89326113|NCT00005047|Experimental|Arm I: M-VAC x 3|Patients with altered (+) p53, reconsented to randomization, randomized to three cycles of MVAC
89326114|NCT00005047|No Intervention|Arm II: Observation|Patients with altered (+) p53, reconsented to randomization, randomized to observation
89326115|NCT00005047|No Intervention|Arm III: Observation|Patients with unaltered (-) p53
89326116|NCT00005047|No Intervention|Arm IV: Observation|Patients with altered (+) p53, patients did not consent to randomization
89326117|NCT01099891|Experimental|EGF|
89326118|NCT01099891|Placebo Comparator|Placebo|
88809624|NCT04385186|Experimental|Convalescent plasma+Support treatment selected by the hospital|Participants will receive two doses of ABO - Rh compatible inactivated convalescent plasma, each one of 200 mililiters (mL), with a 24-hour interval via transfusion, for a final volume of 400 mL, meanwhile they continue to receive the supportive treatment chosen by the hospitals, according to each institutional protocol.
88809625|NCT04385186|Active Comparator|Support treatment selected by the hospital|The best support treatment selected by the hospital, according to each institutional protocol. Due to the ongoing development of knowledge of pathophysiology and scientific evidence of the available alternatives, it will be selected at the time of treatment.
89326119|NCT01584427|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch.
89326120|NCT01584427|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans
89326121|NCT01103635|Experimental|Arm I|Patients receive tremelimumab over 1 hour on day 1 and CD40 agonist monoclonal antibody CP-870,893 IV over 30 minutes on days 2, 22, 43, and 64. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
89326122|NCT03948841||Neuroendocrine tumor|Patients with liver metastasis from neuroendocrine tumor
89326123|NCT01584505|Experimental|CHF5993 HFA pMDI dose 1, BID|CHF5993 HFA pMDI dose 1, BID
89326124|NCT01584505|Experimental|CHF5993 HFA pMDI dose 2, BID|CHF5993 HFA pMDI dose 2, BID
89326125|NCT01584505|Active Comparator|CHF1535 HFA pMDI + Placebo|CHF1535 HFA pMDI BID plus placebo BID
88809626|NCT04385420|Experimental|ATR-002 100 mg (SAD)|100 mg ATR-002 once (morning)
88809627|NCT04385420|Experimental|ATR-002 300 mg (SAD)|300 mg ATR-002 once (morning)
88809628|NCT04385420|Experimental|ATR-002 600 mg (SAD)|600 mg ATR-002 once (morning)
88809629|NCT04385420|Experimental|ATR-002 900 mg (SAD)|900 mg ATR-002 once (morning)
88809630|NCT04385420|Placebo Comparator|Placebo (SAD)|Placebo once (morning)
88809631|NCT04385420|Experimental|ATR-002 100 mg (MAD)|100 mg ATR-002 once daily (morning) for 7 days
88809632|NCT04385420|Experimental|ATR-002 300 mg (MAD)|300 mg ATR-002 once daily (morning) for 7 days
88809633|NCT04385420|Experimental|ATR-002 600 mg (MAD)|600 mg ATR-002 once daily (morning) for 7 days
88809634|NCT04385420|Placebo Comparator|Placebo (MAD)|Placebo once daily (morning) for 7 days
88809635|NCT00737360|Experimental|1|
88809636|NCT01279148||Biopsy/Ablation - CONTROL GROUP|The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again.
88809637|NCT01279148||Biopsy/Ablation - STUDY GROUP:|"The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will then be un-blinded and shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure, and if clinically indicated, a verification CT computed tomography scan will be taken with the needle in place and, sent to the PercuNav. Radiation dosage, due to CT imaging, will also be recorded."
88809638|NCT01276106|Experimental|AC-201, 25mg|25mg BID for 24 weeks
88809639|NCT01276106|Experimental|AC-201, 50mg|50mg BID for 24 weeks
88809640|NCT01276106|Experimental|AC-201, 75mg|75mg BID for 24 weeks
88809641|NCT01276106|Placebo Comparator|Placebo|Placebo BID for 24 weeks
88809642|NCT01275170|Experimental|Panel A Mild Renal Impairment|Participants with an eGFR of >50 to <80 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
88809643|NCT01275170|Experimental|Panel B Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel A and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
88809644|NCT01275170|Experimental|Panel C Moderate Renal Impairment|Participants with an eGFR of 30 to 50 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
88809645|NCT01275170|Experimental|Panel D Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel C and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
88816254|NCT02570139|Active Comparator|ConvaTec Sensi-Care Protective Barrier|Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.
89326126|NCT03949075|Experimental|Enalapril treatment|
89326127|NCT03949075|Placebo Comparator|Placebo treatment|
89326128|NCT03951727|Other|Endovascular treatment for PAD|Single group study (1 arm)
89326129|NCT01101529|Placebo Comparator|Standard antiemetic therapy plus placebo|Standard anti-emetic prophylaxis consisting of 1/dexamethasone 6 mg daily during the chemotherapy days and 2/tropisetron (Navoban)5 mg daily during chemotherapy and 2 days after
89326130|NCT01101529|Experimental|aprepitant (Emend)|Aprepitant given orally 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after as an addition to standard antiemetic therapy as in the placebo arm.
89326131|NCT01584583||blood pressure monitor|Cuff circumference:22cm-36cm
89326132|NCT01584583||stethoscopy|Cuff circumference: 22cm-36cm
89326133|NCT00003901|Experimental|Surgery|"All patients undergo complete lymph node sampling or dissection. A small portion of rib is removed at this time. Some patients may have primary tumor completely removed.~Lymph nodes and bone marrow from the rib section are examined for occult metastases using immunohistochemical staining methods and standard staining methods.~Patients are followed at 1, 4, 8, and 12 months, every 6 months for 2 years, and then annually for 2 years."
89326134|NCT01584661||Compliance with nutritional care|"The Inclusion criteria comprise patients who were treated nutritionally with food enrichment supplements during their hospitalization in Bait Balev and were discharged to their homes with dietary recommendations. Participants who are willing to participate will sign an informed consent form. For patients with cognitive impairment or dementia, as reported in their medical records, their formal primary caregiver or proxy will sign the informed consent form."
89326135|NCT00003895|Experimental|gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
89326136|NCT00003895|Experimental|gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
89326137|NCT05623891|Experimental|177Lu-Anti-ED-B mAbs|Patients will receive a tracer (5 mg, IV) dose of 177Lu (10 mCi) labeled anti-ED-B mAbs(177Lu-B5-IgG4)
89326138|NCT01100047|Experimental|1|
89326139|NCT01100047|Placebo Comparator|2|
89326140|NCT01100125|Experimental|sitagliptin|
89326141|NCT01100125|Active Comparator|insulin dose increase|
89326142|NCT01100203|Active Comparator|Treatment|
89326143|NCT01100203|No Intervention|Control|
89326144|NCT03948685|Experimental|Carvedilol SR|Carvedilol SR 8mg, 16mg, 32mg
89326145|NCT03948685|Placebo Comparator|Placebo|Placebo
89326146|NCT01584973||cruciate ligament group|
89326147|NCT01584973||control group|
89326148|NCT01585051|Active Comparator|vitamin D|Intervention: Intramuscular injection of 300 000 U of 25(OH)vitamin D
89326149|NCT01585051|Placebo Comparator|placebo|administration of 0.9 % NaCl as a placebo
89326150|NCT01103791|Experimental|Cohort 1|Docetaxel-PNP 20mg/m2
89326151|NCT01103791|Experimental|Cohort 2|Docetaxel-PNP 35mg/m2
89326152|NCT01103791|Experimental|Cohort 3|Docetaxel-PNP 45mg/m2
89326153|NCT01103791|Experimental|Cohort 4|Docetaxel-PNP 60mg/m2
89326154|NCT01103791|Experimental|Cohort 5|Docetaxel-PNP 75mg/m2
89326155|NCT01103791|Experimental|Cohort 6|Docetaxel-PNP 90mg/m2
89326156|NCT03948607||Adult ADHD|Adult ADHD patients without current comorbidity and treatment.
89326157|NCT03948607||Healthy controls|Healthy controls without ADH, paired in age and gender.
89326158|NCT03800173|Experimental|Galidesivir|Galidesivir IV infusion
89326159|NCT03800173|Placebo Comparator|placebo|Placebo IV infusion
89326160|NCT05614687|Experimental|Community-informed art-based programme (CiAbP)|The CiAbP sessions will cover relevant aspects of art, such as poetry, spoken words, painting, drawing, literature, and music, in tackling trauma and negative attitudes towards ex-offenders reintegration.
89326161|NCT05614687|Active Comparator|Government intervention involving media messages|It will involve media messages from the National Orientation Agency devoid of CiAbP and other media sources on materials such as health and public awareness.
89326162|NCT01103947|Active Comparator|EcoAnesthesia Mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. This group will receive the EcoAnesthesia Mask first."
89326163|NCT01103947|Active Comparator|Standard mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. Patients in this arm will receive the standard mask first."
89326164|NCT00003631|Experimental|Arm I|(0-1 adverse prognostic factors): Patients receive ifosfamide by 24 hour infusion on day 2. Carboplatin is administered on day 2. Etoposide IV is administered once daily on days 1-3. Patients then receive filgrastim (G-CSF) subcutaneously or IV on days 5-12. Patients receive another course of ICE chemotherapy 2-3 weeks after the first course.
89326165|NCT00003631|Experimental|Arm II|(2 adverse prognostic factors): Patients receive the first course of ICE as in Arm I
89326166|NCT00003631|Experimental|Arm III|Arm III (3 adverse prognostic factors): Patients receive cyclophosphamide IV daily for 2 days, then G-CSF beginning on day 4 until blood stem cells are collected
89326167|NCT00003535|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89326168|NCT00003511|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89326169|NCT01327417||Depressed|Patients with Major Depressive Disorder
89326170|NCT01327417||Healthy Controls|
88816255|NCT02410200|Experimental|BG00012|Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
89326171|NCT01101607|Active Comparator|Pediatric Emergency Physician|Patients randomized to Pediatric Emergency Physician Group will have their fracture reduced by a Pediatric Emergency Physician
89326172|NCT01101607|Active Comparator|Orthopaedic physician|Patients to be randomized to Orthopaedic physician Group will have their fracture reduced by an Orthopaedic Physician
89326173|NCT00003499|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89326174|NCT00003487|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89326175|NCT03950947|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis and randomization to the intervention group, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug, CE0086).
89326176|NCT03950947|Sham Comparator|Sham-Control|In the presence of a significant right coronary artery stenosis, and randomization to the sham-procedure: right IMA will be selectively intubated using an appropriate catheter. Angiography of the RIMA and the pericardiacophrenic branch will be performed.
89326177|NCT01101685|Active Comparator|Escitalopram|7 days dosing at 10mg per day
89326178|NCT01101685|Placebo Comparator|Placebo|7 days dosing at 10mg daily
89326179|NCT01101763||All Subjects|Healthy males
89326180|NCT00003475|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89326181|NCT01104181|Experimental|swab and brush or swab and swab|we will determine which collection method is superior
89326182|NCT00003457|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89326183|NCT01100281||PSP (Progressive supranuclear palsy)|
89326184|NCT01100281||FTD (Frontotemporal lobar degenerative)|
89326185|NCT01100281||Alzheimer's disease|
89326186|NCT00030901|Active Comparator|L-selenomethionine|L-selenomethionine (Selenium)one tablet by mouth daily for 3 years.
89326187|NCT00030901|Placebo Comparator|L-selenomethionine placebo|L-selenomethionine placebo one tablet by mouth daily for 3 years
89326188|NCT03950869|Experimental|Negative Expectations|Expectations on the severity and frequency of intrusions are increased while expectations on the controllability of intrusions are decreased.
89326189|NCT03950869|Experimental|Positive Expectations|Expectations on the severity and frequency of intrusions are decreased while expectations on the controllability of intrusions are increased.
89326190|NCT03950869|No Intervention|No Expectation Manipulation|Expectations on the severity and frequency of intrusions and on the controllability are neither increased nor decreased.
89326191|NCT01104259|Experimental|Treatment (veliparib with cisplatin and vinorelbine tartrate)|Patients receive veliparib PO BID on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV over 1 hour on day 1 and vinorelbine ditartrate IV over 10-20 minutes on days 1 and 8. Treatment repeats every 21 days for 6-10 courses in the absence of disease progression or unacceptable toxicity. Treatment with veliparib alone may continue in the absence of disease progression or unacceptable toxicity.
89326192|NCT01104337|Experimental|Paracetamol 2g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 2g/d
89326193|NCT01104337|Experimental|Paracetamol 3g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 3g/d
89326194|NCT01104337|Placebo Comparator|Placebo|9 patients on stable warfarin therapy received a 10-day regimen of placebo
89326195|NCT00003199|Experimental|Arm I|See Detailed Description.
89326196|NCT01327261|Experimental|Levodopa + benserazide (test formulation)|A randomized-sequence, open-label, 2-period crossover study assessing relative bioavailability of two drug products containing the association levodopa + benserazide.
89326197|NCT01327261|Active Comparator|Levodopa + benserazide (reference formulation)|
89326198|NCT03950713|Experimental|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|Participants in the intervention group received the MBSR-T in addition to routine care.
89326199|NCT03950713|No Intervention|Routine care|The control group received the routine care provided in facilities, including routine check-ups at diabetes clinics as necessary.
89326200|NCT00030823|Experimental|Vaccine|Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.
89326201|NCT01101919|Experimental|CP-690,550 Dose Group|
89326202|NCT03951571|Experimental|Anlotinib Gruop|
89326203|NCT03951571|Placebo Comparator|Placebo Group|
89326204|NCT03951415|Experimental|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
88816256|NCT02494323|Experimental|Functional Electrical Stimulation|Dual channel stimulation of the peroneal nerve to improve dropfoot
88816257|NCT01143272|Active Comparator|Saccharomyces boulardii|Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
88816258|NCT01143272|Placebo Comparator|Microcristallin cellulose|Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
89326205|NCT03948451|Experimental|[14C]AZD5718 Oral Suspension|One 200 mg dose of [14C]AZD5718 Oral Suspension
89326206|NCT00001849|Experimental|Patients with Cushing Syndrome|Patients receive various types of radiologic or nuclear medicine scans to identify tumor
89326207|NCT03950479||primiparous group|women who will give birth to their first baby
89326208|NCT02530255|Placebo Comparator|Placebo|Study subjects receiving placebo: Intervention - two capsules, one morning and one night for one year; placebo for cycloastragenol
89326209|NCT02530255|Active Comparator|cycloastragenol|Study subjects receiving cycloastragenol: Intervention - cycloastragenol; oral capsules 8mg. per day (two capsules) one in the morning and one at night for one year.
89326210|NCT03947905|Experimental|Type of visit|Single arm, non-randomized crossover design. All patients will receive both types of visits virtual and physical, and after assessments are made, participants will be classified by physicians into low, moderate or high risk for intervention.
89326211|NCT01100515|Experimental|Experimental arm|Hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) followed by 4 hours of normobaric oxygen therapy
89326212|NCT01100515|Active Comparator|Control|6 hours course of normobaric oxygen therapy via a face full mask
89326213|NCT01100593|Active Comparator|1.75 inch catheter length|Length of catheter to be used
89326214|NCT01100593|Active Comparator|2.5 inch catheter length|length of catheter to be used
89523471|NCT03385291|Experimental|patients with disorders of consciousness|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
89523472|NCT03385291|Experimental|healthy control group|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
89326215|NCT01102075|Experimental|Electroacupuncture|The Electroacupuncture therapy protocol included a total of 12 acupuncture points at the CV12,CV6, bilateral ST25, SP15, SP14,LI4, LI11, ST36, ST44. All acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Abdominal acupuncture points were inserted horizontally 6~6.5cm in depth and the others were inserted vertically 2~2.5cm in depth until patient can feel De-Qi. All acupuncture points were stimulated electrically with a frequency of 24 Hz an intensity of 0.27-1.3mA(tolerable strength) with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks by practitioner who had had 6 years of acupuncture training and 3 more years of clinical experience.
89326216|NCT01102075|Sham Comparator|Sham electroacupuncture procedure|The Sham electroacupuncture therapy protocol(Non-acupoint, No electrical stimulation)included the same number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment, but superficially at non acupuncture points 15 mm to the lateral of each acupuncture point was treated. The points were not stimulated electrically, but the sound of the pulse generator was heard by the participants. (Lee SH, LeeBC 2009) Those receiving EA or SEA therapy were treated on alternate days to prevent crosstalk among groups, which could have compromised the blinded study design.
89326217|NCT01102075|No Intervention|Waiting list|No treatment was done for waiting group, but could receive same treatments as Electroacupuncture group after the end of trial.
89326218|NCT03950089||Patients with Central Serous Chorioretinopathy|
89326219|NCT03950089||Healthy patients|
89326220|NCT01102153||Coolgard|invasive cooling
89326221|NCT01102153||ArcticSun|non-invasive (surface) cooling
89326222|NCT01104571|Other|Part 1: Control|No peri-operative therapy given
89326223|NCT01104571|Experimental|Part 1: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
89326224|NCT01104571|Experimental|Part 1: lapatinib|Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery
89326225|NCT01104571|Other|Part 2: Control|No peri-operative therapy
89326226|NCT01104571|Experimental|Part 2: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
89326227|NCT01104571|Experimental|Part 2: lapatinib-trastuzumab combination|Lapatinib 1000mg/day p.o. continuously for 28 days, in combination with trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery. Both drugs should start 11 days (+2 or -1 day) before the scheduled surgery.
89326228|NCT01100671||Healthy patients|
89326229|NCT03947593||Households with children under 13|Interviews conducted with the parent or guardian of a child or children under age 13.
89326230|NCT03947593||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own for five or more hours a week.
89326231|NCT03947593||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
89326232|NCT03947593||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
89326233|NCT01102309|Experimental|Experimental Group (EG)|Group assigned to robot plus conventional therapy
89326234|NCT01102309|Active Comparator|Control Group (CG)|Group assigned to conventional therapy only
89326235|NCT03947047||Placenta Accreta|Women found to have abnormal placentation (any degree of placenta accreta) during the cesarean section.
89326236|NCT03947047||No Placenta Accreta|Women found to have normal placenta separation during the cesarean section.
89326237|NCT03950323|Experimental|patients operated on for parotid tumor|All consecutive patients operated on for parotid tumor.
89326238|NCT01104649|Experimental|Riluzole|Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
89326239|NCT01104649|Placebo Comparator|Placebo comparator|Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
89326240|NCT01104727|Active Comparator|Multi port|4-Ports Cholecystectomy (4PC): a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
89326241|NCT01104727|Active Comparator|Single port|"Single-Port Cholecystectomy (SPC): a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
89326242|NCT01327729|Active Comparator|YPEG-IFN α-2a one week|this arm will be treated with: YPEG-IFN α-2a 180mcg/ week for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
89326243|NCT01327729|Active Comparator|YPEG-IFN α-2a Ten days|this arm will be treated with: YPEG-IFN α-2a 180mcg/10 days for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
89326244|NCT01327729|Active Comparator|YPEG-IFN α-2a two weeks|"The third group will be treated with:~YPEG-IFN α-2a 180mcg/ 2 weeks for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks."
89326245|NCT01104805|Experimental|Therapeutic Education System (TES)|Participants randomized to this arm will replace approximately 2 hours of Standard Treatment with the Therapeutic Education System (TES) (comprised of a web-based version of the Community Reinforcement Approach and contingency management).
89326246|NCT01104805|Other|Treatment-as-Usual (TAU)|Participants randomized to TAU will receive standard treatment offered and prescribed, as usual, in the outpatient substance abuse treatment program.
88816259|NCT02383056|Sham Comparator|Sham Group (Group 1)|This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
89326247|NCT01342952|Experimental|Ambrisentan|Open label, flexible dosing from 2.5 mg to 10 mg (not to exceed 0.25 mg/kg) per day
89326248|NCT01105429|Active Comparator|BMS-820132 (0.3 mg) or Placebo|
89326249|NCT01105429|Active Comparator|BMS-820132 (1.0 mg) or Placebo|
89326250|NCT01105429|Active Comparator|BMS-820132 (3 mg) or Placebo|
89326251|NCT01105429|Active Comparator|BMS-820132 (10 mg) or Placebo|
89326252|NCT01105429|Active Comparator|BMS-820132 (30 mg) or Placebo|
89326253|NCT01105429|Active Comparator|BMS-820132 (75 mg) or Placebo|
89326254|NCT01105429|Active Comparator|BMS-820132 (150 mg) or Placebo|
89326255|NCT01105429|Active Comparator|BMS-820132 (300 mg) or Placebo|
89326256|NCT01105429|Active Comparator|BMS-820132 (TBD) or Placebo|
89326257|NCT01105507|Experimental|canakinumab arm|
89326258|NCT01104883|Experimental|Adductor-Canal-Blockade|Adductor-Canal-Blockade with ropivacaine
89326259|NCT01104883|Placebo Comparator|Adductor-Canal-blockade with saline|Adductor-Canal-blockade with isotonic saline
89326260|NCT01104961|Experimental|Contact Lens Packaging Solution #1|Test solution - contact lens packaging solution
89326261|NCT01104961|Experimental|Contact lens packaging solution #2|Test solution - contact lens packaging solution
89326262|NCT01104961|Placebo Comparator|Balanced salt solution|Control solution
89326263|NCT04371380|Experimental|OLI phase followed by Injection phase|Participants will be administered cabotegravir at a dose of 30 mg plus rilpivirine dose of 25 mg once daily with meal on Day 1 to Day 28 in OLI phase. There will be 10 to 14 days wash out period after OLI. This will be followed by an injection phase, wherein participants will receive 600 mg cabotegravir long acting given as one 3 milliliter (mL) IM injection plus 900 mg rilpivirine long acting given as one 3 mL IM injection on Day 1.
89326264|NCT03950011||ERP|Any patient requiring oncologic surgery, including hysterectomy or curettage, posterior pelvectomy, conventional laparoscopic or assisted robotic surgery, or laparotomy for cervical or cervical cancer or ovarian cancer, body or cervix uterus and ovaries as well as benign pathologies or borderline malignancy.
89326265|NCT04333784||exercise with BFR|Patients with rotator cuff tendinopathy will perform the exercises with a pneumatic cuff and blood flow restricted.
89326266|NCT04333784||Control|Patients with rotator cuff tendinopathy will perform the exercises without a pneumatic cuff.
89326267|NCT01105585|Experimental|ZCB00 IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens (IOL) randomly assigned to one eye, with AcrySof Natural IQ (SN60WF) IOL in the fellow eye for contralateral implantation
89326268|NCT01105585|Active Comparator|SN60WF IOL|AcrySof Natural IQ (SN60WF) intraocular lens (IOL) randomly assigned to one eye, with Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens in the fellow eye for contralateral implantation
89326269|NCT04321928|Other|Group A|General health education arm.
89326270|NCT04321928|Other|Group B|Personalized health education arm.
89326271|NCT01332032||Reminder Letter|"A letter sent to women reminding them that are coming due or overdue for a mammogram. It contains a reminder that their primary care provider (PCP) recommends mammography screening every 1-2 years. It urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. Repeat Booster letters will be sent in subsequent years to those failing to get a mammogram."
89326272|NCT01332032||Reminder Call|"A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a mammogram within 2 weeks, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offer to schedule a mammogram for her. Repeat Booster letters will be sent and repeat scheduler calls made in subsequent years to those failing to get a mammogram."
89326273|NCT01332032||Counselor Call|"A reminder letter as above is sent first. If a woman does not call in to schedule a mammogram within 2 weeks, a second letter is sent along with a mammography educational booklet. The second letter also reiterates a reminder that her PCP recommends screening every 1-2 years, and offers a special number to call to schedule. If a woman does not schedule within 8-10 days, a counselor will call. The protocol script included tailored barriers counseling, correction of misinformation and motivational interviewing. Repeat booster letters will be sent and repeat counselors calls made in subsequent years to those failing to get a mammogram. techniques. Average calls last 20-30 minutes."
89326274|NCT04291196|Experimental|Immersive Virtual Reality|Patients will be immersed in the ECT experience using VR-ECT 360o video (VR-ECT).
89326275|NCT04291196|Other|Standard Treatment|Patients will receive standard preparation for their ECT session.
89326276|NCT01333904|Experimental|PUR118|
89326277|NCT01341080|Experimental|Varenicline|
89326278|NCT01341080|Placebo Comparator|Sugar pill|
89326279|NCT02886884|Experimental|Pilot Phase 20 million allogeneic hMSCs|Participants in this group will receive one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
89326280|NCT02886884|Experimental|Pilot Phase 100 million hMSCs|Participants in this group will receive one peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
89326281|NCT02886884|Experimental|Randomized Phase 20 million allogeneic hMSCs|Participants in this group will receive one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
89326282|NCT02886884|Experimental|Randomized Phase 100 million allogeneic hMSCs|Participants in this group will receive one peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
89326283|NCT01333982|Experimental|Referral compliance|Health workers will receive a basic maternal, newborn and child health training under the MNCS programme. Newborn sepsis management training will be organised for the study. The Bangladesh Perinatal Society (BPS) will take the lead in developing and implementing the training programme with support from Saving Newborn Lives (SNL) and other partners.Referral slips will be used in the intervention unions for all the sick newborns identified so that they seek care on a timely fashion.
89326284|NCT01333982|Experimental|Neonatal sepsis|Existing health delivery systems in the community level in managing neonatal sepsis.
89326285|NCT01334060|No Intervention|CML HLA A2-|
89326286|NCT01334060|No Intervention|AML HLA A2-|
89326287|NCT01334060|Experimental|AML HLA A2+|
89326288|NCT01334060|Experimental|CML HLA A2+|
89326289|NCT04253834|Active Comparator|Incentive Spirometer Control Arm|Participants assigned to use the incentive spirometer after surgery.
89326290|NCT04253834|Experimental|GO2 Mouthpiece|Participants assigned to use the Bidirectional Oxygenation Valve (GO2 Mouthpiece) after surgery.
89326291|NCT04130828|Experimental|Thrice-weekly group|Ferrous fumarate 200 mg PO PC Thrice-weekly
89326292|NCT04130828|Active Comparator|Thrice-daily group|Ferrous fumarate 200 mg PO PC Thrice-daily
89326293|NCT01332110|Experimental|Knee abduction moment-reducing footwear|Footwear that is known to decrease knee abduction moments of force in healthy subjects. May include orthotics, or footwear that allows relative movement between the heel section of the outsole and rest of the shoe.
89326294|NCT01332110|Placebo Comparator|Control footwear|Standard, off-the-shelf running shoes with no mechanical modifications.
89326295|NCT01332344||Asthma patients treated with inhaled corticosteroids|Asthma subjects newly prescribed inhaled corticosteriods
89326296|NCT01334138|Experimental|4-week diet, low in sodium|The study subjects go on a 4-week diet, low in sodium.
89326297|NCT01240694|Experimental|CEP-33457|Participants will receive 200 micrograms (mcg) of CEP-33457
89326298|NCT03635918|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a benchmark HSAT monitor.
89326299|NCT01332422||Pediatric patients prescribed ADOAIR|Pediatric patients with asthma prescribed ADOAIR during study period
89326300|NCT01334294||1. Received therapy for CNV|
89326301|NCT03162224|Experimental|First-line Recurrent/Metastatic (1L R/M) Platinum Non-refractory|Participants with recurrent or metastatic disease and were non-refractory to neoadjuvant/adjuvant platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then every 8 weeks (Q8W) and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then every 4 weeks (Q4W) until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.
89326302|NCT03162224|Experimental|1L R/M Platinum Refractory|Participants with R/M disease and were refractory to neoadjuvant/adjuvant platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then Q8W and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then Q4W until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.
89326303|NCT03162224|Experimental|Second-line (2L) + R/M|Participants with R/M disease and were treated with 1 or more lines of platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then Q8W and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then Q4W until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.
89326304|NCT01334372|No Intervention|Treatment as Usual|Treatment as usual (TAU) outpatient care will consist of existing outpatient clinical practices utilized in the Mental Health Clinic.
89326305|NCT01334372|Experimental|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
89326306|NCT00904046|Experimental|Pioglitazone|For 60 Aim 2 Subjects Only - Pioglitazone (Actos)
89326307|NCT00904046|Placebo Comparator|Placebo|For 60 Subjects in Aim 2 Only - Placebo for Pioglitazone
89326308|NCT00867464||Observational (long term follow-up)|Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.
89326309|NCT01332734||severe sepsis and septic shock|
89326310|NCT03423524|Experimental|Arm: Investigational Device|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. consisting of hydrophobic material"
89326311|NCT00582842||1|Men with prostate cancer
89326312|NCT00582842||2|Men with prostate cancer
89326313|NCT01332890|Experimental|Sequence 1|
89326314|NCT01332890|Experimental|Sequence 2|
89326315|NCT01332890|Experimental|Sequence 3|
89326316|NCT01332890|Experimental|Sequence 4|
89326317|NCT01332890|Experimental|Sequence 5|
89326318|NCT01332890|Experimental|Sequence 6|
89326319|NCT03326492||Patients bitten by a snake|"Any patient over 5 years old going to a participating center for curative care following a snake bite.~Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient."
89326320|NCT01524536|Other|Steroid Challenge|A single oral dose of prednisone (1 mg/kg rounded to the nearest 5mg) was administered to all participants. The following day, participant began glucocorticoid therapy of prednisone 30 mg oral daily for one week followed by a standardized taper until a minimally effective dose was achieved or participant tapered to prednisone 5 mg oral daily.
89326321|NCT00537134|No Intervention|Conservative|Conservative management (watchful observation)
89326322|NCT00537134|Active Comparator|Endovascular|Endovascular treatment
89326323|NCT01315418|Active Comparator|1 = Tested product|
89326324|NCT01315418|Sham Comparator|2 = Control product|
89326325|NCT00533468|Experimental|Active Drug|Active 4% Lidocaine topical cream (LMX4 cream) applied under occlusive dressing
89326326|NCT00533468|Placebo Comparator|Placebo|Placebo Cream made on same run at factory but without active Lidocaine 4% drug
89326327|NCT02886338|Experimental|capsule endoscopy examination|Capsule endoscopic examination for the esophagus, stomach and duodenum.
89326328|NCT01334528||OEF/OIF Veterans mTBI|Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans with a history of mild traumatic brain injury (mTBI) with persistent self-reported symptoms.
89523473|NCT03386695|Other|Education by Pamphlets|Half of the women in each group will be provided an information pamphlet on the risk factors, methods of early detection, prevention, signs and symptoms of cervical cancer and how to use the self samplers at home.
88809646|NCT01275170|Experimental|Panel E Severe Renal Impairment|Participants with an eGFR <30 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
89326329|NCT01333124|Experimental|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
89326330|NCT03130790|Experimental|Varlititib+mFOLFOX6|
89326331|NCT03130790|Placebo Comparator|Placebo+mFOLFOX6|
89326332|NCT01333202|Experimental|Fresh lime|Those who were randomly assigned to receive fresh lime were instructed to use it every time they began to crave cigarettes and as often as they needed. Fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible. All participants in this group had to report the number of fresh lime slices used per day in the self-report card.
89326333|NCT01333202|Active Comparator|Nicotine gum|"The dosage of nicotine gum used in this group was primarily based on the participants' FTND scores. Those with FTND score of 4 or above were given 4-mg nicotine gum. The 2-mg gum was assigned only to light smokers. Appropriate gum use by chew and park technique was instructed to all subjects in this group. They were advised to use the gum whenever they began to crave a cigarette but not to exceed more than 20 pieces per day. All participants in this group also had to report the total number pieces of gum used per day in the self-report card. Like the lime use group, phone calls were also made every 2-3 days during the initial month of study to remind them of technique and record keeping."
89326334|NCT03035630|Experimental|Avelumab then Sunitinib for Investigational Arm A|"First-Line Medication:~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects will have a mandatory an inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
89326335|NCT03035630|Experimental|Sunitinib then Avelumab for Investigational Arm B|"First-Line Medication:~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects will have a mandatory inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
89326336|NCT01333280|Experimental|Double Trouble (DTR) group|Double Trouble in Recovery groups
89326337|NCT01333280|Active Comparator|Treatment as usual|Treatment as usual while on a waiting list for DTR groups
89326338|NCT00004124|Active Comparator|bicalutamide, goserelin|androgen deprivation
89326339|NCT00004124|Experimental|bicalutamide, goserelin, mitoxantrone, prednisone|androgen deprivation plus mitoxantrone, prednisone
89326340|NCT01330004||Hemodialysis patients|
89326341|NCT02697422|Experimental|Peer health coach intervention group|Eligible participants will be randomly assigned to receive a home-visit peer health coach intervention to promote health outcomes and behavior change among Veterans with multiple cardiovascular disease (CVD) risk factors.
89326342|NCT02697422|No Intervention|Control group|Participants who meet the same eligibility criteria as participants in the intervention group will be randomly assigned to receive no intervention. Participants will continue to receive their regular, usual primary care.
89326343|NCT01334684|Other|Metformin|"At study entry, all oral hypoglycemic agents will be discontinued for 5 days and then metformin (2,550 mg/daily) will be given for 3 months. Fasting plasma glucose will be measured at baseline and 3 months after metformin treatment. Patients will be stratified according to the median value of metformin efficacy as indicated by fasting glucose change after metformin treatment (i.e. baseline fasting glucose minus 3-month fasting glucose).~So, two subgroups of patients will be obtained, defined as relatively high responders (individual fasting glucose change > median value) or relatively low responders (individual fasting glucose change < median value) to metformin monotherapy."
89326344|NCT01334762|Experimental|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
89326345|NCT01334762|Active Comparator|CC/IUI|Patients received 100 mg CC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
89326346|NCT01341548|Active Comparator|Civamide Nasal Solution 0.01%|
89326347|NCT01341548|Placebo Comparator|Vehicle Solution|
89326348|NCT01334840|Experimental|BW|Bicarbonated mineral water without meal
89326349|NCT01334840|Experimental|BW with meal|Bicarbonated mineral water with meal
89326350|NCT01334840|Active Comparator|CW|Mineral water low in mineral content (control) without meal
89326351|NCT01334840|Active Comparator|CW with meal|Mineral water low in mineral content (control) with a meal
89326352|NCT00383552|Experimental|MF/F MDI 100/10 mcg BID|
89326353|NCT00383552|Experimental|MF MDI 100 mcg BID|
89326354|NCT00383552|Experimental|F MDI 10 mcg BID|
89326355|NCT00383552|Placebo Comparator|Placebo BID|
89326356|NCT01335074|Experimental|Temsirolimus + Sorafenib|
89326357|NCT01337414|Experimental|VMS diary booklet|
89326358|NCT01337414|Active Comparator|Usual Care (e.g. Amsler grid monitoring)|
89326359|NCT01337492|Experimental|Sorafenib|
89326360|NCT01337570|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
89326361|NCT01337570|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
89326362|NCT01337648||TBI prior to stem cell transplantation|
89326363|NCT01337726|Active Comparator|Illness Management Only|
89326364|NCT01337726|Experimental|Combined Psychotherapy & Illness Management|
89326365|NCT05186246|Experimental|Experimental Combination Cream Group|Subjects were randomized to have combination cream to be applied on one side of the face twice daily post fractional CO2 laser. The subjects were evaluated on day 3 and day 7 post fractional CO2 laser. Combination cream consisted of Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate cream
89326366|NCT05186246|Placebo Comparator|Placebo comparator|Subjects were randomized to have placebo cream to be applied on the other side of the face twice daily post fractional CO2 laser. Placebo cream were packaged in identical-looking containers with combination cream. The subjects were evaluated on day 3 and day 7 post fractional CO2 laser.
89326367|NCT03158012|Active Comparator|Active treatment|
89326368|NCT03158012|Placebo Comparator|Placebo treatment|
89326369|NCT01337804|Experimental|Zegerid-Prilosec|Participants receive Zegerid in Period 1 and Prilosec in Period 2, with a 10- to 21-day washout between study drug administrations.
89326370|NCT01337804|Experimental|Prilosec-Zegerid|Participants receive Prilosec in Period 1 and Zegerid in Period 2, with a 10- to 21-day washout between study drug administrations.
89326371|NCT05182736|Experimental|TRAIL intervention|"The TRAIL program is comprised of a multi-tier system of strategies:~Universal Strategies (delivered school-wide),~Targeted Strategies (delivered to the target grade level in the evaluation sample)~Intensive Strategies (delivered to select at-risk students)"
89326372|NCT05182736|No Intervention|Control|"Students in the comparison schools receive the normal ninth grade health curriculum, Reproductive and Health Safety Education."
89326373|NCT01776424|Experimental|Rivaroxaban 2.5mg + Aspirin 100mg|Participants received rivaroxaban 2.5 mg twice daily (bid) and aspirin 100 mg once daily (od). All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a proton pump inhibitor (PPI), were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
89326374|NCT01776424|Experimental|Rivaroxaban 5mg + Aspirin Placebo|Participants received rivaroxaban 5 mg bid and aspirin placebo od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
89326375|NCT01776424|Active Comparator|Rivaroxaban Placebo + Aspirin 100mg|Participants received rivaroxaban placebo bid and aspirin 100 mg od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
89326376|NCT00642148|Active Comparator|Seretide|
89326377|NCT00642148|Placebo Comparator|Placebo|Placebo tablet
89326378|NCT00642148|Experimental|GW856553|
89326379|NCT00767416|Experimental|Cohort 1 MEDI-559|MEDI-559
89326380|NCT00767416|Placebo Comparator|Cohort 1 Placebo|Placebo
89326381|NCT00629980|Experimental|1|
89326382|NCT00629980|No Intervention|2|
89326383|NCT00629590|Experimental|1|
89326384|NCT00629590|No Intervention|2|
89326385|NCT00766324|Experimental|A|
89326386|NCT00766324|Experimental|B|
89326387|NCT00626704|Experimental|Arm 1|AMG 655 + Doxorubicin
89326388|NCT00626704|Placebo Comparator|Arm 2|Placebo + Doxorubicin
89326389|NCT00765700|Active Comparator|Ketoprofen 10% Cream|"Topical Ketoprofen 10% Cream~1gram three times daily for 7 days"
89326390|NCT00765700|Placebo Comparator|Placebo|"Topical placebo cream~1gram three times daily for 7 days"
89326391|NCT00626236|Experimental|Treatment 1|
89326392|NCT00626236|Experimental|Treatment 2|
89326393|NCT00626236|Experimental|Treatment 3|
89326394|NCT00626236|Experimental|Treatment 4|
89326395|NCT00626002|Experimental|1|
89326396|NCT02280694|Experimental|capecitabine, cyclophosphamide, methotrexate, celecoxib|"The Investigational Product: Route and Dosage Form Ambulatory/oral, continuous but not uniform, DAILY treatment~Tab. CYCLOPHOSPHAMIDE 50mg, 1X1/day ONLY days 1-5 / week; At evening only (at the end of meal)~Tab. CAPECITABINE 500mg, fixed dose of 1500mg/day (1000mg at morning + 500mg at evening) ONLY on days 1-5 / week; At morning AND at evening (at the end of meals)~Tab. METHOTREXATE 2.5mg, 1x2/day ONLY on days 6-7/week; At morning AND evening (one hour before meal)~Tab. CELECOXIB 200 mg, 1x2/day EVERY day (at the end of meal)"
89326397|NCT02280772|Experimental|Glucomannan|Glucomannan orally, 3g/day (in three divided doses), for 12 weeks
89326398|NCT02280772|Placebo Comparator|Maltodextrin|Maltodextrin orally, 3g/day (in three divided doses), for 12 weeks
89326399|NCT02280850|Experimental|Guanxin Shutong Capsule|3 capsules once, tid, Oral Duration: 4 weeks
89326400|NCT02280850|Placebo Comparator|Placebo Capsule|"Placebo capsule and Guanxin Shutong Capsule the same appearance are made by SHAANXI BUCHANG PHARMACEUTICAL CO.,LTD.~3 capsules once, tid, Oral Duration: 4 weeks"
89326401|NCT02280928|Experimental|Single-task motor training group|The participants will receive only balance training which will progress from stance activities, to stance activities plus hand manipulation, then gait activities, and finally gait activities plus hand manipulation.
89326402|NCT02280928|Experimental|Single-task cognitive training group|The participants will receive cognitive training that will involve executive function, attention, and working memory.
89326403|NCT02280928|Experimental|Dual-task motor-cognitive training group|The participants assigned to the dual-task motor-cognitive training group will receive the same exercises as single-task motor training while simultaneously performing secondary tasks as those in the single-task cognitive training group.
89326404|NCT02280928|Experimental|Dual-task cognitive-cognitive training group|The participants in the dual-task cognitive-cognitive trainings group will receive two cognitive tasks at the same time.
89326405|NCT00667654|Experimental|100-200 µg CNTX-4975|single dose
89326406|NCT00667654|Experimental|300-425 µg CNTX-4975|Total dose delivered as two separate lower doses
89326407|NCT00667654|Experimental|600-700 µg CNTX-4975|Total dose delivered as two separate lower doses
89326408|NCT00667654|Experimental|800 µg CNTX-4975|Total dose delivered as two separate lower doses
89326409|NCT00667654|Experimental|900-1000 µg CNTX-4975|Total dose delivered as two separate lower doses
89326410|NCT02272972||Retrospective group|One x-ray image per patient is assessed by the surgeon. The surgeon undergoes an educational intervention (video/poster) and applies the achieved knowledge during the second assessment of the same image. The intervention is not administered to patients, only to an image.
89326411|NCT02272972||Prosp.group (Application of knowledge)|No direct intervention at the patient. The surgeon applies the achieved knowledge during the performance of the fluoroscopy in the operating room. This image is assessed.
89326412|NCT02273830|Active Comparator|oxygen adjusted|oxygen adjusted to get SpO2> 90% during the walking test
89326413|NCT02273830|Placebo Comparator|control group|oxygen at 3L/min
89326414|NCT03134560|Active Comparator|With vein display instrument|Vein cannulation was done after the vein display instrument displays the veins using infrared
89326415|NCT03134560|No Intervention|Without vein display instrument|vein cannulation was done without any vein display instrument
89326416|NCT02281006|Experimental|Treated ear|Trans-tympanic injection of a sodium thiosulfate gel
89326417|NCT02281006|No Intervention|Control ear|No intervention
89326418|NCT00758290|Active Comparator|A|
89326419|NCT00758290|Experimental|B|
89326420|NCT02281162||Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
89326421|NCT02281162||No Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
89326422|NCT03799627|Experimental|Vadadustat|The initial dose of Vadadustat (300, 450, or 600 milligrams [mg]) will be based upon the dose of Epoetin Alfa dose participants had received prior to Vadadustat treatment
89326423|NCT03799627|Experimental|Vadadustat TIW|Participants randomized to Vadadustat (Main and erythropoiesis-stimulating agent [ESA] hyporesponder parallel studies) who complete a once-daily dosing regimen treatment period and meet eligibility criteria for transition to three times weekly (TIW) dosing will switch to TIW dosing
89326424|NCT03799627|Active Comparator|Epoetin Alfa|Epoetin Alfa
89326425|NCT02274142|Experimental|Restorations with Encapsulated material|Restorations performed with encapsulated glass ionomer cement (EQUIA - GC Corp). Capsules with glass ionomer will be activated and applied after selective carious tissue removal in primary molars.
89326426|NCT02274142|Active Comparator|Restorations with Hand-Mixed material|Restorations will be performed with hand-mixed glass ionomer cement (Fuji IX - GC Corp) after selective carious tissue removal in primary molars.
89326427|NCT00756574|Active Comparator|1. Surgical|surgical mask
89326428|NCT00756574|Active Comparator|2. N95 Respirator|N95 respirator
89326429|NCT00752050|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
89326430|NCT00752050|Placebo Comparator|2|Preservative-free Saline - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
89326431|NCT02275390|Experimental|Nurse-led Psycho-education [SPBB: Self-learning program]|"The Nurse-led Psychoeducation Program is comprised of eight 2-hour sessions held at every two weeks (over 4 months). The program consists of five themes: (a) orientation and engaging and understanding of mental health/illness, its related behaviors and community support resources; (b) working collaboratively and empowering and minimizing resistance and challenges using motivational interviewing approach; (c) effective interpersonal and communication skills; (d) strategies in coping with mental illness, sleep hygiene and allaying anxiety; and (e) self-review and evaluation and establishing a realistic plan for future.~[Note: The participants in the SPBB will complete the self-help and problem-solving manual (5 modules) for caregivers of people with psychotic disorders over 20 weeks, together with an orientation, understanding about psychosis and its care and 4 review sessions.]"
89326432|NCT02275390|Active Comparator|Usual Psychiatric Outpatient Care|"Routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study~[Note: for SPBB trial, routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study]"
89326433|NCT03798769|Experimental|Supportive Oncology Care at Home|"The Supportive Oncology Care at Home intervention entails the following:~patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers for phone calls and home visits by Medically Home based on a clinician-derived algorithm~scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
89326434|NCT02276014|Other|Supplement A|Beta-carotene 7mg formulation A
89326435|NCT02276014|Other|Supplement B|Beta-carotene 7mg formulation B
89326436|NCT02276014|Other|Supplement C|Beta-carotene 7mg formulation C
89326437|NCT01105039||lap. hernia repair|undergoing laparoscopic groin hernia repair
89326438|NCT02276170||Aminophylline per standard of care|
88809647|NCT01275170|Experimental|Panel F Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel E and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
88816260|NCT02383056|Experimental|Treatment group (Group 2)|This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
89326439|NCT02277496|Experimental|HC toolkit intervention students|HC students will receiveeExperimental wellness education via a toolkit approach to address the 2010 Dietary Guidelines for reducing obesity in youth. The specific recommendations include: 1) reducing intake of sugary beverages, 2) increasing intake of fruits and vegetables, 3) increasing frequency of eating breakfast, 4) decreasing fast and junk food choices, 5) increasing physical activity to 1 hour/day, and 6) decreasing screen time to 2 hours per day.
89326440|NCT02277496|No Intervention|Comparison Schools|During the 2014-2015 school year, control schools were utilized to compare outcomes.
89326441|NCT01102387|Experimental|LAS41003|
89326442|NCT01102387|Active Comparator|LAS189962|
89326443|NCT01102387|Active Comparator|LAS189961|
89326444|NCT02277808|Active Comparator|Respirgard II|Determination of pulmonary deposition
89326445|NCT02277808|Active Comparator|Isoneb|Determination of pulmonary deposition
89326446|NCT01105663||Sedated, Intubated, Morphine|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
89326447|NCT01105663||Sedated, Intubated, Midazolam|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
89326448|NCT03949699|Other|Resistance Training|. Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down. Performance during exercise sessions will be monitored by study staff who will progress the participant to exercises of greater intensity (increasing number of repetitions, sets, or resistance load; on an individual basis over the 8-week intervention period according to the participant's level of readiness). This progression will also be guided by a strength training protocol. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise
89326449|NCT02281240||With hemostatic complications|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
89326450|NCT00625612|Placebo Comparator|2|
89326451|NCT00625612|Experimental|1|Denufosol Tetrasodium (INS37217) Inhalation Solution
89326452|NCT01105195|Active Comparator|DuraPrep|
89326453|NCT01105195|Active Comparator|ChloraPrep|
89326454|NCT01105741||Active Crohn's disease - single arm|Active Crohn's disease, a decision is made to start treatment with adalimumab.
89326455|NCT01105819|Other|Standard oral care with chlorhexidine|The control group will receive a standard oral care. This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed
89326456|NCT01105819|Active Comparator|Lactobacillus plantarum 299|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
89326457|NCT00749788|Experimental|1|JTT-302, 200 mg
89326458|NCT00749788|Experimental|2|JTT-302, 400 mg
89326459|NCT00749788|Placebo Comparator|3|Matching placebo tablets
89326460|NCT00749632|Active Comparator|1|
89326461|NCT00749632|Active Comparator|2|
89326462|NCT00749632|Active Comparator|3|
89326463|NCT01105273|Experimental|HAPLO|
89326464|NCT00748852|Experimental|1|JTT-302, 400 mg
89326465|NCT00664378|Experimental|I|CYT997
89326466|NCT01102543||Premature babies < 28 GA|
89326467|NCT01102543||Premature babies > 28 & < 32 weeks GA|
89326468|NCT00743938|Experimental|A1|
89326469|NCT00743938|Active Comparator|B2|
89326470|NCT03947203|No Intervention|Pamphlet|Provided with only a pamphlet containing educational material about oral health
89326471|NCT03947203|Experimental|Social media|Provided pamphlet containing educational material about oral health and will have access to a private Facebook group, where we will share informational messages and content relating to oral health
89326472|NCT01105897||Surgically treated endometriosis patients|Women scheduled for operation on suspected endometriosis in two study hospitals specialized in the surgical treatment of endometriosis between January 2005 - December 2007 (Päijät-Häme Central Hospital) and January 2008 - December 2008 (Helsinki University Hospital).
89326473|NCT02529865|Experimental|ADRCs and Adipose tissue|Periurethral injection of autologous adipose derived regenerative cells and adipose tissue
89326474|NCT01584739|Experimental|AZD8683|
89326475|NCT01584739|Placebo Comparator|Placebo to AZD8683|
89326476|NCT01105351|Active Comparator|folic acid plus B6 and B12|folic 400 µg plus vitamin B12 plus B6
89326477|NCT01105351|Placebo Comparator|Folic acid|folic acid alone
89326478|NCT00662506|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy, IMRT)|See Detailed Description
89326479|NCT03947359|Other|Participants with a thoracic diameter < 75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
89326480|NCT03947359|Other|Participants with a thoracic diameter >75 cm|Measurement of liver stiffness before and after a standardized meal with different probes
89326481|NCT03947125||knee applied group|the patients with buprenorphine patch applied to painful knee joint in knee osteoarthritic patients
89326482|NCT03947125||chest applied group|the patients with buprenorphine patch applied to anterior chest wall in knee osteoarthritic patients
89326483|NCT00658762|Experimental|PD 0332334 225 mg BID|
89326484|NCT00658762|Experimental|PD 0332334 300 mg BID|
89326485|NCT00658762|Active Comparator|Paroxetine 20 mg q am|
89326486|NCT00658762|Placebo Comparator|Placebo BID|
89326487|NCT04023409||Severe COPD patients|Patients with severe COPD who are referred to the UMCG for a consultation on lung transplantation or bronchoscopic lung volume reduction.
89326488|NCT00658372|Experimental|PD 0332334 225 mg BID|
89326489|NCT00658372|Experimental|PD 0332334 300 mg BID|
89326490|NCT00658372|Active Comparator|Paroxetine 20 mg QD|
89326491|NCT00658372|Placebo Comparator|Placebo BID|
89326492|NCT01584817|No Intervention|normal education|patients in this arm was educated about bowel preparation on the day of reservation by nurse for 15 minutes and meanwhile a booklet was also sent to them.
89326493|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
89326494|NCT03946657|Active Comparator|The Inhalation Group|Sevoflurane (1 minimum alveolar concentration [MAC]) were used in the Inhalation group for the maintenance of anesthesia.
89326495|NCT03946657|Active Comparator|The TIVA (total intravenous anesthesia) Group|Propofol infusion (4-8 mg/kg of total body weight/h) were used in the TIVA group.
89326496|NCT00616798|Experimental|3|
89326497|NCT00616798|Placebo Comparator|4|
89326498|NCT00616798|Experimental|1|
89326499|NCT00616798|Experimental|2|
89326500|NCT01106053|Experimental|Pramipexole|Open-label trial of pramipexole.
89326501|NCT05626543|Experimental|Intervention|Participants in the Intervention arm will receive Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs based intervention.
89326502|NCT05626543|No Intervention|Control|The control will work normally with intervention. The intervention material will be provided to the controls once the follow-up surveys are conducted after the intervention is given to the intervention arm.
89326503|NCT00616330|Experimental|1|clindamycin phosphate/butoconazole nitrate
89326504|NCT00616330|Active Comparator|2|clindamycin phosphate
89326505|NCT00616330|Active Comparator|3|butoconazole nitrate
89326506|NCT03949933|Experimental|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
89326507|NCT04856683||Patients with endocrine and metabolic diseases|Patients with endocrine and metabolic diseases (hypothalamic-pituitary-gonadal and adrenal diseases, type 2 diabetes mellitus and bone diseases)
89326508|NCT00615940|Experimental|1|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with WX-671 once daily by mouth, Days 1-21 inclusive.
89326509|NCT00615940|Experimental|2|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with placebo once daily by mouth, Days 1-21 inclusive.
89326510|NCT01584895|Experimental|Rehab|Patients randomized into early cardiac rehabilitation
89326511|NCT01584895|No Intervention|Control|No cardiac rehabilitation until after 6 week post assessment.
89326512|NCT00612742|Experimental|testosterone gel|1% testosterone transdermal gel
89326513|NCT00612742|Placebo Comparator|placebo gel|placebo transdermal gel
89326514|NCT04839211|Experimental|Inspiratory muscle training|High-intensity interval-based inspiratory muscle training
89326515|NCT04839211|Sham Comparator|Sham inspiratory muscle training|Unloaded inspiratory muscle training
89326516|NCT01106131|Experimental|CKD-501 0.5mg|
89326517|NCT01106131|Active Comparator|Pioglitazone 15mg|
89326518|NCT01327807||Cystinsosis patients|Those with a diagnosis of cystinosis.
89326519|NCT00612664|Active Comparator|Arm 1|0.1 mg/kg every 3 weeks
89326520|NCT00612664|Active Comparator|Arm 2|1 mg/kg every 3 weeks
89326521|NCT00612664|Active Comparator|Arm 3|1 mg/kg every 6 weeks
89326522|NCT00612664|Active Comparator|Arm 4|5 mg/kg every 3 weeks
89326523|NCT01328197|Experimental|Treovance|
89326524|NCT00743002|Experimental|TT223 with Metformin and/or TZD|TT223 as a treatment for Type 2 diabetes is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
89326525|NCT00743002|Placebo Comparator|Placebo with Metformin and/or TZD|Placebo as a comparator is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
89326526|NCT03944863||POEM + Antibiotic prophylaxis|Cefazolin: 2g or Amoxicillin - clavulanic acid: 1g x 3 during 7 days
89326527|NCT03944863||POEM + No antibiotic prophylaxis|
89326528|NCT01102621||case-control, head and neck cancer with radiotherapy|The group of exposed individuals had to be patients with disease-free survival interval of at least two years subsequent to treatment for head and neck cancer by means of radiotherapy alone or in combination, in which the auditory system was included in the field of irradiation.
89326529|NCT01102621||case-control, head an neck cancer without radiotherapy|The group of non-exposed individuals (control group) had to be patients who had not undergone oncological treatment that put their hearing at risk and who were age-matched (2 years). This group was formed by individuals who had had pelvic tumors or skin tumors and who had only undergone local surgery to remove their tumors, and by female volunteers from the hospital. All of these individuals were asked whether they would be willing to participate in a study, without knowing in advance whether they had any previous hearing problems or complaints.
89326530|NCT00741442|Experimental|1|RDEA806 400 mg qd
89326531|NCT00741442|Experimental|3|RDEA806 400 mg bid
89326532|NCT00741442|Placebo Comparator|2|Placebo QD
89326533|NCT00741442|Placebo Comparator|4|Placebo BID
89326534|NCT01102699|Experimental|Filgrastim, G-CSF|Single s.c. dose of G-CSF (300 microg)
89326535|NCT04720339|Experimental|Experimental arm|
89326536|NCT00603616|Placebo Comparator|1|Placebo pills
89326537|NCT00603616|Active Comparator|2|Rifaximin
89326538|NCT04704037|Active Comparator|Arm 1: Minimally enhanced usual care|See intervention/treatment description
89326539|NCT04704037|Experimental|Arm 2: Guideline implementation tool|See intervention/treatment description
89326540|NCT02280070|Active Comparator|SOX (S-1 + L-OHP)|"S-1 (80 mg/m2, p.o.) (day1-14）, L-OHP (130 mg/m2)(day 1): repeated every 3 weeks until 4 courses or meet discontinuation criteria.~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
89326541|NCT02280070|Active Comparator|mFOLFOX6|"L-OHP (85 mg/m2) and l-LV (200 mg/m2) by IV infusion drip for 2hr at day 1. 5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards (day 1-2: repeated every 2 weeks until 6 courses or meet discontinuation criteria.~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
89326542|NCT05626309|Experimental|Qizhu Yuling Prescription|Qizhu Yuling Prescription
89326543|NCT05626309|Placebo Comparator|Placebo Comparator|Simulation agent of Qizhu Yuling Prescription Group
89326544|NCT01106209||Prematurely born infants in the NICU|Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤1500 grams or <30 weeks gestational age at birth
89326545|NCT01106209||Healthy term infants|Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery
89326546|NCT01106209||Infants having surgery at <1 year old|Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery within the first year of life
89326547|NCT01106365|Experimental|prefrontal cortex (PFC)|rTMS with the H-coil to the prefrontal cortex (PFC)
89326548|NCT01106365|Active Comparator|motor cortex|rTMS with the H-coil to the motor cortex
89326549|NCT01106365|Sham Comparator|sham treatment|sham treatment
89326550|NCT03949309||Eligible patients|All eligible patients discharged from hospital for Acute Myocardial Infarction (AMI) or acute decompensation of Chronic Heart Failure (CHF)
89326551|NCT05626075|Experimental|group Low Myopia|"Patients with low myopia aging more than 15 years old~All patients are with visual acuity (uncorrected, with habitual correction, and best spectacle correction).~There is no restrictions on the range and regularity of keratometry"
89326552|NCT05626075|Experimental|group high myopia|"Patients with high myopia aging more than 15 years old~All patients are with visual acuity (uncorrected, with habitual correction, and best spectacle correction).~There is no restrictions on the range and regularity of keratometry"
89326553|NCT05626075|Experimental|group Hypermetropia|"Patients with hypermetropia aging more than 15 years old~All patients are with visual acuity (uncorrected, with habitual correction, and best spectacle correction).~There is no restrictions on the range and regularity of keratometry"
89326554|NCT05626075|Experimental|group mixed astigmatism|"Patients with mixed astigmatism aging more than 15 years old~All patients are with visual acuity (uncorrected, with habitual correction, and best spectacle correction).~There is no restrictions on the range and regularity of keratometry"
89326555|NCT03845491||SR Classic|SR (Trevo®]) + BGC (FlowGate2] or Merci)
89326556|NCT03845491||SR Combination|"SR (Trevo) + Asp Cath (AXS Catalyst DAC, Vecta) ± Pump~+ LS (AXS Infinity LS, AXS Infinity LS Plus)~or~SR (Trevo) + Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2 or Merci)"
89326557|NCT03845491||Direct Aspiration|"Asp Cath (AXS Catalyst DAC, Vecta) ± Pump + LS (AXS Infinity LS, AXS Infinity LS Plus)~or~Asp Cath (AXS Catalyst DAC) ± Pump + BGC (FlowGate2, Merci)"
89326558|NCT03944551|Experimental|Bubble CPAP|
89326559|NCT03944551|Other|Standard Therapy|
89326560|NCT01108783|Experimental|Bilastine|
89326561|NCT01108783|Active Comparator|Desloratadine|
89326562|NCT01108783|Placebo Comparator|Placebo|
89326563|NCT03795103|Experimental|Patients achieving neuromuscular electrical stimulation|LEPAD patients achieving a 12-week program of neuromuscular electrical stimulation. Group of arteriopathic patients who will perform electrostimulation sessions at home and independently. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
89326564|NCT03795103|Other|Control|Group of artriopathic patients who will maintain their usual drug management. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
89326565|NCT03795103|Other|Healthy volunteers|Ancillary study. Participants will perform a precise program of walking sessions performed outdoors and independently and the same biological parameters as those assessed in arteriopathic patients will be assessed
89326566|NCT03778411||cACLD|200 people with compensated advanced chronic liver disease who have not undergone liver transplant
89326567|NCT03778411||cACLD-post transplant|100 people with compensated advanced chronic liver disease who have previously undergone liver transplant
89326568|NCT02743780|Experimental|MGV354|Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days
89326569|NCT02743780|Placebo Comparator|Placebo|Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days
89326570|NCT01106443|Active Comparator|Total Thyroidectomy - CLND|Total thyroidectomy without central lymph node dissection.
89326571|NCT01106443|Experimental|Total Thyroidectomy +CLND|Total thyroidectomy with central lymph node dissection.
89326572|NCT01106443|Experimental|Hemi-thyroidectomy + CLND|Hemi-thyroidectomy with central lymph node dissection.
89326573|NCT01106443|Active Comparator|Hemi-thyroidectomy - CLND|Hemi-thyroidectomy without central lymph node dissection.
89326574|NCT03740971|Experimental|Guideline-based therapy+RIC|RIC is given twice a day with 200mmHg pressure.
89326575|NCT03740971|Active Comparator|Guideline-based therapy|
89326576|NCT02280148|Experimental|Endoscopy of Intravenous Anesthesia|20-70 year-old volunteers who hold legitimate licenses were recruited to have gastroscopy or colonoscopy under intravenous anesthesia with propofol
89326577|NCT01111435||Individuals with Multiple Sclerosis|
89326578|NCT00602602|Experimental|GemOx and Bev, then chemoradiation, then surgery|"Gemcitabine 1000 mg/m2 over 100 min on day 1 every 2 weeks~Oxaliplatin 85 mg/m2 over 2 hours on day 2 every 2 weeks~Bevacizumab 10 mg/kg over 90 minutes on day 1 every 2 weeks. Infusion duration may be shortened in subsequent courses if tolerated.~One cycle is 2 weeks. Chemoradiation to begin prior to 4 weeks from last dose of Gem. Between 4 and 6 weeks following chemoradiotherapy, patients will undergo re-staging with CT or MRI and CA 19-9. If there is no evidence of disease progression, the patient will be referred to the surgeon for re-evaluation and consideration of surgical intervention"
89326579|NCT01208779||1|Women with estrogen receptor positive breast cancer already receiving treatment with an aromatase inhibitor (AI) will be enrolled in the study
89326580|NCT03946735|Experimental|Intervention study|Cognitive Behavioural Therapy for social anxiety
89326581|NCT03946735|Experimental|Social anxiety|
89326582|NCT04177654||Cambodia|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
89326583|NCT04177654||Bangladesh|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
89326584|NCT04177654||Vietnam|The group of school-aged children from Vietnam who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
89326585|NCT04177654||Lao PDR|The group of school-aged children from Lao PDR who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
89326586|NCT04177654||Ghana|The group of school-aged children from Ghana who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
89326587|NCT04177654||Senegal|The group of school-aged children from Senegal who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
89326588|NCT04177654||Rwanda|The group of school-aged children from Rwanda who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
89326589|NCT04177654||Haiti|The group of school-aged children from Haiti who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
89326590|NCT01108861|Experimental|Endoprosthesis|GORE VIABAHN® Endoprosthesis
89326591|NCT01108861|Active Comparator|Plain old balloon angioplasty|Plain old balloon angioplasty
89326592|NCT02281396|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
89326593|NCT02281396|Experimental|2.5IU/ml in humans aged 21-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
89326594|NCT02281396|Active Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
89326595|NCT02281396|Active Comparator|2.5IU/ml in humans(from 21-60 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
89326596|NCT03944395|Other|Assisted Partner notification services|Voluntary assisted partner notification (VAPN) services will be offered at facilities according to a stepped wedge design. Once VAPN services are activated at a facility, HIV positive individuals will be offered four options (3 voluntary assisted partner notification options and 1 standard of care option) for inviting their contacts, which they can choose to accept or decline.
89326597|NCT04471480|Experimental|group A，TCCA|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +anlotinib 10mg, PO, d1-14, q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab plus anlotinib for maintenance therapy until PD or intolerable toxicity
89326598|NCT04471480|Experimental|group B，TCC|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab for maintenance therapy until PD or intolerable toxicity
89326599|NCT04471480|Other|group C，TC|paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w
89326600|NCT04471948|Experimental|Fractional picosecond laser 1,064 nm laser|1 arm The subjects with enlarged pores were treated with fractional picosecond laser 1,064 nm laser
89326601|NCT00657826|Experimental|19mm arotic valve implant|Single arm study for patients who require a smaller valve size of the ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm.
89326602|NCT02880956|Placebo Comparator|Placebo|Placebo for ABBV-8E12 every 4 weeks for 96 weeks
89326603|NCT02880956|Experimental|ABBV-8E12 300 mg|ABBV-8E12 300 mg every 4 weeks for 96 weeks
89326604|NCT02880956|Experimental|ABBV-8E12 1000 mg|ABBV-8E12 1000 mg every 4 weeks for 96 weeks
89326605|NCT02880956|Experimental|ABBV-8E12 2000 mg|ABBV-8E12 2000 mg every 4 weeks for 96 weeks
89326606|NCT00656890|Placebo Comparator|2|sterile saline for injection
89326607|NCT00656890|Experimental|1|MDX-1100 for injection
89326608|NCT01106521|Experimental|PBSI|PBSI is a form of accelerated partial breast irradiation involving the insertion of 103-palladium stranded seeds under ultra-sound guidance and light sedation after CT planning in lieu of whole breast adjuvant radiotherapy.
89326609|NCT01111513|Active Comparator|Continuous femoral block|Patients receive a continuous femoral block for 48 hours and they have patient controlled analgesics.
89326610|NCT01111513|Active Comparator|Single dose femoral block|Patients receive a single dose femoral block and have patient controlled analgesics.
89326611|NCT01111513|Active Comparator|Patient controlled analgesics|Patients do not receive a femoral block. They only have patient controlled analgesics.
89326612|NCT01106599|Experimental|A|
89326613|NCT01111591|No Intervention|2. Bile duct cancer - control|Bile duct cancer patients do not administration of COX inhibitor
89326614|NCT01111591|Experimental|3. Pancreas cancer - experimental|Pancreas cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
89326615|NCT01111591|No Intervention|4. Pancreas cancer - control|Pancreas cancer patients do not administration of COX inhibitor
89326616|NCT01111591|Experimental|Bile duct cancer - experimental|Bile duct cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
89326617|NCT02281474|Active Comparator|150mg dosing|This arm will take 150mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
89326618|NCT02281474|Active Comparator|300mg dosing|This arm will take 300mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
89326619|NCT04630561|Experimental|Intervention Group|Subjects will participate in a 15 minute postural intervention program 2-3 times per week
89326620|NCT04630561|No Intervention|Control Group|Subjects will NOT participate in any postural intervention.
89523474|NCT03386695|Other|Health education programme|Half of the women in each group will be invited to specially organised camps in their neighbourhood for Health Education and distribution of self samplers.
89326621|NCT01111669|Experimental|Tranexamic Acid|Patients in the tranexamic acid (TA) group will receive a bolus of TA, prepared according to patient weight (15mg / kg loading dose). The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation for the duration of the operation.
89326622|NCT01111669|Placebo Comparator|Normal Saline|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution as the intervention group. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of normal saline for the duration of the operation.
89326623|NCT02281630|Experimental|KWA-0711 High dose|
89326624|NCT02281630|Experimental|KWA-0711 Low dose|
89326625|NCT02281630|Placebo Comparator|Placebo|
89326626|NCT01108939|Experimental|Antimalarial treatment|
89326627|NCT01108939|Sham Comparator|Observation|
89326628|NCT00654706|Experimental|Sertindole|
89326629|NCT00654706|Active Comparator|Quetiapine|
89326630|NCT03741049||Consultants|
89326631|NCT03741049||Trainee anaesthetists|
89326632|NCT03741049||Paramedics|
89326633|NCT03741049||Students|
89326634|NCT02280382|Other|Femmeze®|Femmeze® will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
89326635|NCT00651508|Experimental|Single Arm 25mg/m2|KOS-1584 25mg/m2
89326636|NCT03944473|Active Comparator|neostigmine|Neostigmine is the acetylcholinesterase inhibitor most commonly used in pharmacologically reversing the effects of neuromuscular blockers [8]. Reversal of NMB is facilitated by increasing acetylcholine levels at nicotinic skeletal muscle-binding sites.
89326637|NCT03944473|Experimental|sugammadex|Sugammadex is a modified gamma-cyclodextrin, the first of a new class of drugs called selective relaxant binding agents, with an unusually high affinity for rocuronium. This medication offers an alternate mechanism of action to antagonize the effects of steroidal neuromuscular blockade agents.
89326638|NCT03944317|Active Comparator|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
89326639|NCT03944317|Active Comparator|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
89326640|NCT02280538|Experimental|Intra-Articular Hyaluronic Acid|"hylan G-F 20 (high molecular weight hyaluronic acid):~intra-articular administration~6 mL~administered every 6 months~for 2 years"
89326641|NCT02280538|Placebo Comparator|Placebo|"Saline solution:~intra-articular administration~6 mL~administered every 6 months~for 2 years"
89326642|NCT01111747|Experimental|PRP|In this group PRP will be used in the patellar tendon donor site.
89326643|NCT01111747|Sham Comparator|Control|In this group PRP will not be aded to the patellar tendon donor site
89326644|NCT02281708|No Intervention|low risk|low risk; observation
89326645|NCT02281708|No Intervention|high risk; observation group|high risk: observation
89326646|NCT02281708|Experimental|high risk; adjuvant chemotherapy group|high risk. vinorelbine plus cisplatin
89326647|NCT02281786|Experimental|Cohort 1|8 volunteers (6 active, 2 placebo)
89326648|NCT02281786|Experimental|Cohort 2|8 volunteers (6 active, 2 placebo)
89326649|NCT02281786|Experimental|Cohort 3|8 volunteers (6 active, 2 placebo)
89326650|NCT02281786|Experimental|Cohort 4|8 volunteers (6 active, 2 placebo)
89326651|NCT02281786|Experimental|Cohort 5|8 volunteers (6 active, 2 placebo)
89326652|NCT02281786|Experimental|Cohort 6|8 volunteers (6 active, 2 placebo)
89326653|NCT01111903|Experimental|lenalidomide|Phase II: lenalidomide 20 mg/day in continuous regimen. Phase I: lenalidomide 25 mg/day 21 days/28 + carboplatin AUC 5 + caelyx 30 mg/m2
89326654|NCT02281942|Experimental|Yoga|Sequential movements in coordination to the breath cycle followed by seated and supine postures to release muscle tension.
89326655|NCT02281942|Placebo Comparator|Education|A series of 30-minute recordings focused on different aspects of healthy living (e.g. diet, stress).
89326656|NCT02280616|Experimental|Low dose budesonide tablet|
89326657|NCT02280616|Experimental|High dose budesonide tablet|
89326658|NCT02280616|Experimental|High dose budesonide suspension|
89326659|NCT02280616|Placebo Comparator|Placebo|
89326660|NCT01109017||Norditropin®|
89326661|NCT02283424|Active Comparator|chemotherapy|Carboplatin,350mg/m2,1/3weeks Docetaxel,75mg/m2,1/3weeks
89326662|NCT02283424|Experimental|Icotinib|Icotinib, 125mg,3/D,2years
89326663|NCT01109095|Experimental|HER.CAR CMV-specific CTLs|Subject will be assigned a dose level at study entry.
89326664|NCT02283502|Experimental|Intervention: MRgHIFU, Surgery|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
89326665|NCT03946267|Experimental|IFCG = Infracyanine Green stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 ml of low-concentration (0.5 mg/mL, 0.05%) IFCG injected over the macular area with the infusion line closed.
89326666|NCT03946267|Experimental|BBG = Brilliant Peel stained eyes|After removal of core and posterior cortical vitreous and hyaloid stained with 0.2 ml triamcinolone acetonide 40 mg/mL, on the basis of the previous randomization the ILM is stained with 0.2 mL BBG at a concentration of 0.25 mg/mL (0.025%) injected over the macular area with the infusion line closed.
89326667|NCT02283580|Experimental|Single limb resistance training|"Low load, high-repetitive resistance training.~single limb at a time (e.g., one arm or one leg)~elastic bands"
89326668|NCT02283580|Active Comparator|Two limb resistance training|"Low load, high-repetitive resistance training.~two limbs at a time (e.g., both arms or both legs)~elastic bands"
89326669|NCT03942601|Active Comparator|Group 1 - temsirolimus injection|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
89326670|NCT03942601|Active Comparator|Group 2 - temsirolimus and dexamethasone injection|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
89326671|NCT04538833|Experimental|monosialic ganglioside|On the days -1, 1, and 2 of albumin-bound paclitaxel application, 80 mg of monosialic ganglioside were applied (monosialic ganglioside was a single infusion)
89326672|NCT04538833|Placebo Comparator|Placebo|The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel application, (placebo as a single infusion)
89326673|NCT00595426|Experimental|1. YM150 Dose X, twice daily|
89326674|NCT00595426|Experimental|2. YM150 Dose Y, once daily|
89326675|NCT00595426|Experimental|3. YM150 Dose Y, twice daily|
89326676|NCT00595426|Experimental|4. YM150 Dose Z, once daily|
89326677|NCT00595426|Active Comparator|5. Warfarin|various doses
89326678|NCT03946501||clinical research visit|
89326679|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (600 mg, bolus)|
89326680|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (75 mg daily)|
89326681|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (600 mg, bolus)|
89326682|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (75 mg, daily)|
89326683|NCT01106755|Experimental|hemiparetic gait|gait training on ground level
89326684|NCT02282098|Experimental|Active Colchicine|The intervention group will receive colchicine 0.6 mg twice daily orally for 3 months
89326685|NCT02282098|Placebo Comparator|Placebo Colchicine|The control group will receive colchicine placebo 0.6mg twice daily orally for 3 months.
89326686|NCT00584974|Experimental|0.5 mg SEP-225289|0.5 mg SEP-225289
89326687|NCT00584974|Experimental|2.0 mg of SEP-225289|2.0 mg of SEP-225289
89326688|NCT00584974|Active Comparator|Venlafaxine|150 mg Venlafaxine
89326689|NCT00584974|Placebo Comparator|Placebo|placebo
89326690|NCT01107067|Experimental|testosterone replacement therapy|
89326691|NCT03942445|Experimental|Control patients|
89326692|NCT03942445|Experimental|Chronic ischemia|
89326693|NCT03942445|Experimental|Acute ischemia|
89326694|NCT02282176|Experimental|Azithromycin|10mg/kg azithromycin IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
89326695|NCT02282176|Placebo Comparator|Placebo|Placebo IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
89326696|NCT01209013|Experimental|Medlight PDT Balloon|
89326697|NCT01209091||No treatment|
89326698|NCT00580216|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 7 weeks followed a maintenance dosing adjusted according to the age and to the renal function for a minimum total treatment duration of 6 months.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or overdosage)."
89326699|NCT00580216|Active Comparator|Warfarin|Warfarin, INR-adjusted dose, for a minimum total treatment duration of 6 months.
89326700|NCT01209247|Active Comparator|patient treated by fluoroquinolone|patient treated by fluoroquinolone. Nasal, rectal and pharyngeal swabs
89326701|NCT01209247|Placebo Comparator|patient not receiving FQ treatment|reference group of patients not receiving FQ treatment, but hospitalized in the same wards at the same time
89326702|NCT01109251|Other|Intervention group|Group of patients presenting a non controlled AHT or a masked AHT, benefiting from an optimised caring at visit 0.
89326703|NCT01109251|Other|Control group|Patients presenting a non controlled AHT(persistent AHT, AHT necessiting an adaptation of the treatment by the generalist) with information of the generalist on the necessity of obtaining the tensional control according the HAS recommendations
89326704|NCT03944239|Experimental|retinal pigment epitheliums transplantation|Transplant clinical-grade hESC derived retinal pigment epitheliums into subretinal of patients with retinitis pigmentosa.The dosage is 150000.
89326705|NCT03944083||ADHD with and without DMDD|ADHD with DMDD versus ADHD without DMDD. Observational study at referral and after 6 and 12 months.
89326706|NCT01109329|Experimental|HMPV challenge virus|Participants will receive the HMPV challenge virus.
89326707|NCT01107145|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
89326708|NCT01107145|Experimental|Artemether-Lumefantrine|Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
88809648|NCT01275170|Experimental|Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)|Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).
88816261|NCT02409732|Experimental|PDT|PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
89326709|NCT01107145|Active Comparator|Chloroquine|Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
89326710|NCT03944005|Active Comparator|Study Group|Spinal Anesthesia + ACB continuous catheter+ iPACK + Sham LIA
89326711|NCT03944005|Sham Comparator|Comparator Group|Spinal Anesthesia + LIA + Sham Blocks
89326712|NCT02910973|Active Comparator|Vagus Nerve Stimulation|Device: Vagus nerve stimulation Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
89326713|NCT02910973|Sham Comparator|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
89326714|NCT01209403|No Intervention|No treatment|
89326715|NCT01209403|Active Comparator|Glukose-infusion|Glucose-infusion during hemodialysis
89326716|NCT01209403|Active Comparator|Glucose-insulin infusion|Glucose-insulin infusion during hemodialysis
89326717|NCT01112215|Active Comparator|azathioprine|
89326718|NCT01112215|Active Comparator|Enteric-coated Mycophenolate Sodium|
89326719|NCT01112371|Experimental|Contractubex|
89326720|NCT01112371|No Intervention|Non treatment|
89326721|NCT02283736|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one tablet containing Lactobacillus rhamnosus SP1 per day during 3 months.
89326722|NCT02283736|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
89326723|NCT04473196|Active Comparator|Weightbearing|Immediate weightbearing after surgery
89326724|NCT04473196|Active Comparator|Non weightbearing|nonweightbearing x 6 weeks post surgery
89326725|NCT01107223|Experimental|Training to antibiotic prescription|Physicians randomized in the education group attended a two days seminar focussed on evidence-based guidelines on antibiotic use in respiratory tract infections.
89326726|NCT01107223|Placebo Comparator|control|
89326727|NCT02286388|Experimental|Partial excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
89326728|NCT02286388|Active Comparator|Complete excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
89326729|NCT02286388|Experimental|Antibacterial dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
89326730|NCT02286388|Active Comparator|Conventional dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
89326731|NCT00501202|Placebo Comparator|002|placebo twice daily for 4 weeks
89326732|NCT00501202|Experimental|001|RWJ-333369 (carisbamate) 200 mg tablet twice daily for 4 weeks
89326733|NCT00500812|Experimental|0.3 mg|Subjects Receiving 0.3 mg Cethrin
89326734|NCT00500812|Experimental|1 mg|Subjects receiving 1 mg Cethrin
89326735|NCT00500812|Experimental|3 mg|Subjects receiving 3 mg Cethrin
89326736|NCT00500812|Experimental|6 mg|Subjects receiving 6 mg Cethrin
89326737|NCT00500812|Experimental|9 mg|Subjects receiving 9 mg Cethrin
89326738|NCT02283892|Experimental|Checklist|2 checklists available for consultation by the attending physician: (1) dyspnea evaluation checklist and (2) cough evaluation checklist. The checklists are available on computers and mobile devices (smartphone, PDA or tablet computer).
89326739|NCT02283892|Active Comparator|Conventional assessment|Evaluation of patients reporting dyspnea or cough made by the attending physician, without the use of the checklists for dyspnea or cough evaluation.
89326740|NCT02286544|Active Comparator|Salmonella typhi vaccine|0.5 mL Salmonella typhi vaccine
89326741|NCT02286544|Experimental|Salmonella typhi vaccine + oxygen|0.5 mL Salmonella typhi vaccine + 6l/min oxygen
89326742|NCT02286544|Experimental|S. typhi vaccine + oxygen + Atorvastatin|0.5 mL Salmonella typhi vaccine + 6l/min oxygen + 80mg Atorvastatin
89326743|NCT02282254|Active Comparator|Single-hormone closed-loop strategy|
89326744|NCT02282254|Active Comparator|Dual-hormone closed-loop strategy|
89326745|NCT00574132|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
89326746|NCT00574132|Placebo Comparator|Placebo Control|infusion every 13 weeks for a total of 6 infusions.
89326747|NCT00574132|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
89326748|NCT01337882|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
89326749|NCT01337882|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
89326750|NCT01338116|Experimental|Management by TREAT/PCR|The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly.
89326751|NCT01338116|No Intervention|Usual management|Patients will be managed by physicians as in regular clinical practice.
89326752|NCT01335152|Experimental|Web-based workbook|Participants will use one chapter of the web-based workbook each week for 10 weeks. The workbook consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
88809649|NCT01275170|Experimental|Panel H Healthy Volunteers|A subset of healthy control participants were matched specifically to participants in Panel G and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
88809650|NCT01272596||Multiple Sclerosis Patients|Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
89326753|NCT01335152|No Intervention|Waitlist control group|Participants will no intervention for the first 10 weeks of the study and then will receive the web-based intervention.
89326754|NCT00384904|No Intervention|A1|
89326755|NCT00384904|Experimental|A2|
89326756|NCT00384904|Experimental|A3|
89326757|NCT00384904|No Intervention|B1|
89326758|NCT00384904|Experimental|B2|
89326759|NCT00384904|Experimental|B3|
89326760|NCT05182424|Experimental|Myndlift BPT Immediate Treatment|After the completion of consent, a battery of baseline assessments will be completed by the parent. Children will not be involved in the study assessment or interventions-only parents/caregivers. Parent(s) will be emailed baseline and post-treatment assessment surveys through Qualtrics to complete. Following completion of baseline assessment, study staff will meet with the parent via Zoom to review any questions with the consent and review and discuss questions/issues with the baseline assessment. Following completion of the post-treatment assessment, study staff will meet with the parent via Zoom to review and discuss questions/issues with the post-treatment assessment. Following this review, the post-treatment interview will be completed. Having study staff present has been found useful by parents should they have any questions or concerns about items on surveys.
89326761|NCT05182424|Other|Waitlist Control Group|Following completion of consent and baseline assessment, parent participants randomly assigned to the waitlist condition will be requested to wait for a period of 12 weeks before accessing the program, modules, and receiving therapist support. They will be required to answer the time 2 (at 12 weeks following completion of the baseline assessment) assessment prior to starting the process. The time 2 assessment for the waitlist condition is identical to the post-treatment assessment for participants in the Myndlift BPT group except that questions related to experience with Myndlift BPT will not be included.
89326762|NCT00569062|Experimental|Arm 1|GW856553X 7.5mg BID for 6 weeks
89326763|NCT00569062|Placebo Comparator|Placebo|Placebo to match, BID, 6 weeks
89326764|NCT01335386|Experimental|KLYX|
89326765|NCT01335386|Active Comparator|Glycerine|
89326766|NCT00568594|Experimental|1|
89326767|NCT00568594|Placebo Comparator|2|
89326768|NCT01338350|Experimental|1|
89326769|NCT01338350|Placebo Comparator|2|
89326770|NCT05182268||endoscopic ear surgery group(EES)|
89326771|NCT05182268||microscopic ear surgery group(MES)|
89326772|NCT00496132|Experimental|1|
89326773|NCT05182190|Active Comparator|Control - White bread|Commercial white bread in a 50 gram available carbohydrate dose
89326774|NCT05182190|Active Comparator|Control - whole black beans|Whole boiled black beans (Zenith) in a 50 gram available carbohydrate dose
89326775|NCT05182190|Experimental|Knife Mill pasta|Heat treated black bean flour made with standard Knife Mill techniques
89326776|NCT05182190|Experimental|Combined pasta|Black bean flour with medium protein made with novel compression/decompression mill
89326777|NCT05182190|Experimental|Cyclone pasta|Black bean flour with lower protein made with novel compression/decompression mill
89326778|NCT00384358|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
89326779|NCT00384358|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
89326780|NCT00384358|Other|C|Control: Surgical fixation
89326781|NCT01338428|Active Comparator|Brochure|
89326782|NCT01338428|Experimental|Enhanced AAA Sexual Assault Education|
89326783|NCT00383578|Experimental|Vildagliptin|
89326784|NCT00383578|Active Comparator|Metformin|
89326785|NCT01341704|Experimental|MSP3-LSP/AlOH|Synthetic polyprotein of 96 amino acids (186-276 in 3D7 strain) manufactured by solid-phase synthesis by SYNPROSIS, France; lyophilized product was formulated extemporaneously with aluminum hydroxide (Reheis). 30 microgram per dose; three dose schedule on study day 0, 28 and 56 for primary series
89326786|NCT01341704|Placebo Comparator|Control|Primary series: Verorab Rabies vaccine; Secondary/Booster series: 0.9% NaCL/Normal Saline
89326787|NCT00383422|Experimental|1|
89326788|NCT00383422|Active Comparator|2|
89326789|NCT03635528|Experimental|Test 1\Test 2\Control 2\Test 3\Control 1\Test 4\Test 5|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326790|NCT03635528|Experimental|Test 2\Test 3\Test 1\Test 4\Control 2\Test 5\Control 1|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326791|NCT03635528|Experimental|Test 3\Test 4\Test 2\Test 5\Test 1\Control 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326792|NCT03635528|Experimental|Test 4\Test 5\Test 3\Control 1\Test 2\Control 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326793|NCT03635528|Experimental|Test 5\Control 1\Test 4\Control 2\Test 3\Test 1\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326794|NCT03635528|Experimental|Control 1\Control 2\Test 5\Test 1\Test 4\Test 2\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326795|NCT03635528|Experimental|Control 2\Test 1\Control 1\Test 2\Test 5\Test 3\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326796|NCT03635528|Experimental|Test 5\Test 4\Control 1\Test 3\Control 2\Test 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326797|NCT03635528|Experimental|Control 1\Test 5\Control 2\Test 4\Test 1\Test 3\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326798|NCT03635528|Experimental|Control 2\Control 1\Test 1\Test 5\Test 2\Test 4\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326799|NCT03635528|Experimental|Test 1\Control 2\Test 2\Control 1\Test 3\Test 5\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326800|NCT03635528|Experimental|Test 2\Test 1\Test 3\Control 2\Test 4\Control 1\Test 5|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326801|NCT03635528|Experimental|Test 3\Test 2\Test 4\Test 1\Test 5\Control 2\Control 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326802|NCT03635528|Experimental|Test 4\Test 3\Test 5\Test 2\Control 1\Test 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
89326803|NCT02286622|Experimental|Renal Impairment|Eight (8) subjects with ESRD on HD will receive one 18 mg dose of deflazacort.
89326804|NCT02286622|Experimental|Healthy Volunteers|Eight (8) healthy subjects with estimated creatinine clearance (CLcr) ≥ 90 mL/min. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the ESRD cohort. Subjects will receive one 18 mg dose of deflazacort.
89326805|NCT00486538|Experimental|Single arm|One oral dose daily
89326806|NCT02283970||BAV and aortic regurgitation|BAV Diagnosis, Aortic Regurgitation with surgical indication (according to current clinical guidelines or best clinical practice), normal ascending aorta
89326807|NCT02283970||BAV and Ascending aorta dilatation|BAV diagnosis, no or trivial Aortic Regurgitation, ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice)
89326808|NCT02283970||BAV, aortic regurgitation and dilatation|BAV diagnosis, Aortic Regurgitation and ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice).
89326809|NCT02283970||BAV with aortic stenosis in pts>60yrs|BAV diagnosis, Aortic stenosis with surgical indication (according to current clinical guidelines or best clinical practice). Normal ascending aorta
89326810|NCT01338584|Experimental|Pelvic floor muscle training, post prostatectomy|Pelvic floor muscle training will be taught on the day of admission
89326811|NCT00564928|Experimental|IPI-504: Group A|No Prior treatment for prostate cancer with cytotoxic chemotherapy (adjuvant or neoadjuvant chemotherapy is acceptable if completed >2 years prior to study)
89326812|NCT00564928|Experimental|IPI-504: Group B|"Must have evidence of radiographic metastatic disease~Must have been treated with a docetaxel-based chemotherapy regimen for HRPC with a minimum of 2 cycles with either PSA or RECIST defined radiographic progression during or witin 60 days of completeing docetaxel based chemotheraph or be intolerant of docetaxel-based chemotherapy~No more than three prior chemotherapies regimens for HRPC"
89326813|NCT01338662||Group A-1|"study enroll number 3n+1 (N=0,1,2...)~initial treatment- amantadine~add levodopa when the patient become to need further treatment."
89326814|NCT01338662||Group A-2|"study enroll number 3n+2 (N=0,1,2...)~initial treatment: amantadine~add dopamine agonist when the patient become to need further treatment."
89326815|NCT01338662||Group B|"study enroll number 3n+3 (N=0,1,2...)~initial treatment: dopamine agonist~add levodopa when the patient become to need further treatment. but cannot use amantadine"
89326816|NCT00564226|Experimental|SSR240600C Dose Level 1|
89326817|NCT00564226|Experimental|SSR240600C Dose Level 2|
89326818|NCT00564226|Experimental|SSR240600C Dose Level 3|dose level 3
89326819|NCT00564226|Active Comparator|Tolterodine|
89326820|NCT00564226|Placebo Comparator|Placebo|
89326821|NCT03635684|Experimental|SC Acetaminophen|Palliative Care or Geriatric Patients who receive subcutaneous Acetaminophen for pain or fever relief
89326822|NCT00563680|Experimental|Exploratory Cohort|If a total of two or more responses (partial and complete) in EFTs/DSRCTs are documented in this or the ongoing phase 1 study (20050118), then the study will allow enrollment of up to 10 additional EFT/DSRCT subjects who have been exposed to prior anti-IGF-1R targeting therapy.
89326823|NCT00563680|Experimental|Main Cohort|Subjects with relapsed Ewing's Family Tumors (EFTs) and Desmoplastic Small Round Cell Tumors (DSRCTs) who have not received prior anti-IGF-1R therapy will receive AMG 479 at 12mg/kg.
89326824|NCT02286700|Active Comparator|Desonide Group|Group randomly receiving desonide cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
89326825|NCT02286700|Experimental|Amino Acid Group|Group randomly receiving amino acid moisturizing cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
89326826|NCT01315964|Active Comparator|plant stanol ester|3 grams of plant stanol esters per day in a margarine product as part of daily diet for 6 months
89326827|NCT01315964|Placebo Comparator|Placebo|a margarine product as part of daily diet, which is not containing plant stanol esters
89326828|NCT02286778|Active Comparator|Acetogenins|Dietary Supplement: Acetogenins BID for 12 months
89326829|NCT02286778|Placebo Comparator|Placebo|Dietary Supplement: No Acetogenins BID for 12 months
89326830|NCT02286778|No Intervention|Control|Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.
89326831|NCT01338896|Experimental|Sequence A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1)
89326832|NCT01338896|Experimental|Sequence B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1)
89326833|NCT00560482|Active Comparator|A|
89326834|NCT00560482|Placebo Comparator|B|
89326835|NCT05185544||neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma|neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
89326836|NCT00382096|Experimental|Vildagliptin + Metformin Dose 1|
89326837|NCT00382096|Experimental|Vildagliptin + Metformin Dose 2|
89326838|NCT00382096|Active Comparator|Vildagliptin|
88809651|NCT04385654|Experimental|Neoadjuvant toripalimab plus axitinib|Toripalimab (240 mg,ivgtt,q3w) combined with Axitinib (5 mg,po,bid) was treated for 6 weeks and underwent surgery within 2-4 weeks
88809652|NCT01272674|Active Comparator|exercise training|4 weeks of supervised physical exercise training
88809653|NCT01272674|No Intervention|control|sedentary lifestyle
88809654|NCT01272674|No Intervention|healthy control|
88809655|NCT00400634|Experimental|1|Intracerebral administration of CERE-120
88809656|NCT00400634|Sham Comparator|2|Sham Neurosurgery
88816347|NCT04431843|Placebo Comparator|Placebo|Spirulina maxima extract for 0 g/day
88816348|NCT04431765|Active Comparator|Patient for Eye Movement desensitization Reprocessing therapy|Patient with post-traumatic Stress Disorder will receive Eye Movement Desensitization reprocessing therapy
89326839|NCT00382096|Active Comparator|Metformin|
89326840|NCT05172284||Psoriasis|
89326841|NCT05172284||Psoriatic arthritis|
89326842|NCT05172284||Atopic dermatitis|
89326843|NCT05172284||Chronic urticaria|
89326844|NCT05172284||Suppurative hydrosadenitis|
89326845|NCT05172284||Systemic lupus erythematosus|
89326846|NCT05172284||Acne vulgaris|
89326847|NCT05172284||Rosacea|
89326848|NCT05172284||Seborrheic dermatitis|
89326849|NCT05172284||Contact dermatitis|
89326850|NCT05172284||Chronic eczema of the hands|
89326851|NCT05172284||Vitiligo|
89326852|NCT00482092|Placebo Comparator|Placebo|Participants will receive matching placebo administered as intravenous (IV) infusions.
89326853|NCT00482092|Active Comparator|Prochymal® - Low dose|Participants will receive a total dose of Prochymal® 600 x 10^6 cells, IV infusion, on four days, once daily.
89326854|NCT00482092|Active Comparator|Prochymal® - High dose|Participants will receive a total dose of Prochymal® 1200 x 10^6 cells, IV infusion, on four days, once daily.
89326855|NCT01335776|Experimental|Cognitive Behavior Therapy|Cognitive Behavior Therapy for insomnia consists of stimulus control therapy, sleep restriction therapy, cognitive therapy and relaxation.
89326856|NCT01335776|Experimental|Mindfulness-Based Stress Reduction|The program consists of three primary components: theoretical material related to relaxation, meditation, and the mind-body connection; experiential practice of meditation and yoga and home based practice; group process focused on problem solving and support.
89326857|NCT00379990|Experimental|GW274150 60 mg once daily for 28 days|60 mg GW274150 taken once daily for 28 days
89326858|NCT00379990|Active Comparator|Prednisolone 7.5 mg once daily for 28 days|7.5 mg prednisolone taken once daily for 28 days
89326859|NCT00379990|Placebo Comparator|Placebo once daily for 28 days|Placebo taken once daily for 28 days
89326860|NCT01341860||controls|control group with a BMI of less thatn 25kg/m2
89326861|NCT01341860||obese group|Obese patients with BMI 25-30 kg/m2
89326862|NCT01339130|Other|behavioral and physiological tests|Computerized tests and Electrophysiological measurements
88806632|NCT05901116|Other|SPSIPB|SPSIPB is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle. Tramadol (intravenous analgesic drug) at a concentration of 4 mg per 1 ml was administered with patient-controlled analgesia (PCA) device (max dose: 400 mg /day)
89326863|NCT00377182|Active Comparator|PEGASYS with COPEGUS|
89326864|NCT00377182|Experimental|RO5024048 1500mg in combination with PEGASYS|
89326865|NCT00377182|Experimental|RO5024048 3000mg in combination with PEGASYS|
89326866|NCT00377182|Experimental|RO5024048 in combination with PEGASYS and COPEGUS|
89326867|NCT01341938|Active Comparator|Lozenge Self Help: self help materials & lozenge NRT.|Self-help materials + Commit® nicotine lozenges (4 mg)
89326868|NCT01341938|Experimental|Lozenge Assisted Self-help: lozenge NRT, phone counseling, & self help materials|Self-help materials + Commit® nicotine lozenges (4 mg) + Phone counseling
89326869|NCT01341938|Experimental|Assisted Self-Help: self-help materials & phone counseling without lozenges|Self-help materials + Phone counseling
89326870|NCT02284048|Placebo Comparator|control|nitrate,beta blocker
89326871|NCT02284048|Active Comparator|ticagrelor|ticagrelor 90mg qd
89326872|NCT05185232||Patients with complex congenital heart disease|Complex congenital heart disease will be defined by previously published classification including those listed in the American heart association/ American college of cardiology guidelines for the care of adults with congenital heart disease.
89326873|NCT05185232||Patients with non-complex congenital heart disease|Non-complex congenital heart disease will be defined by previously published classification including those listed in the American heart association/ American college of cardiology guidelines for the care of adults with congenital heart disease.
89326874|NCT00374296|No Intervention|1|Elderly (≥65 years) untreated arm
89326875|NCT00374296|Experimental|2|Relapsed/Refractory Arm
89326876|NCT00547066|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously.
89326877|NCT01315496|Experimental|Imunoglobulin G|The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
89326878|NCT01315496|Placebo Comparator|Placebo control|The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
89326879|NCT02286856|Other|control group|Usual care followed bij diet intervention after 6 months
89326880|NCT02286856|Active Comparator|intervention group|diet intervention
89326881|NCT01339208|Experimental|Telemedicine Diabetes Intervention|
89326882|NCT00544960|Experimental|1|AT-101 and docetaxel
89326883|NCT00544960|Placebo Comparator|2|placebo and docetaxel
89326884|NCT01339286|Experimental|atomoxetine|
89326885|NCT01339364|Active Comparator|Didactic Lecture|
89326886|NCT01339364|Experimental|Lecture plus Case Disscussion|
89326887|NCT01339364|Experimental|Lecture plus Small Group Education|
89326888|NCT00468442|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplants and maintenance immunosuppressive therapy.
89326889|NCT01339442|Experimental|Dose Level 1 - Phase 1A|"BKM120 80 mg PO daily.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
89326890|NCT01339442|Experimental|Dose Level 2 - Phase IA|"BKM120 100 mg PO daily.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
89326891|NCT01339442|Experimental|Phase IB|"BKM120 (dose to be determined in Phase IA)PO 5 days on/ 2 days off per week.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
89326892|NCT01339442|Experimental|Cohort C|"BKM120 (dose determined in Phase IA) PO daily.~Fulvestrant 500 mg IM on Day 1 and Day 15 during Cycle 1 then monthly on Day 1 of subsequent cycles."
89326893|NCT02286934|Experimental|Carvedilol|"Day 1 to 3 : Carvedilol 12.5 mg qd~Day 4 to 8 : Carvedilol 25 mg qd~Day 9 to 11 : Carvedilol 12.5 mg qd~Isoproterenol Sensitivity Test~Day 0, 1.5h post-dose Injection of isoproterenol 4 times (0.25, 0.5, 1, 2 ug/mL), time interval of 10 minutes.~Day 1, 8, 1.5h post-dose Injection of isoproterenol 4 times (5, 10, 20, 40 ug/mL), time interval of 10 minutes.~Measure change of heart rates after 1, 2, 3 minutes post injection of isoproterenol."
89326894|NCT02282410|Experimental|ADVATE standard prophylaxis|This study is a prospective, open-label, interventional, multicenter study in a total of 15 PTPs with hemophilia A (FVIII≤2 %).The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
89326895|NCT01339520|Experimental|Scorecard|Score of points for variables.
89326896|NCT01339520|No Intervention|Control|Standard of care for diabetes subjects
89326897|NCT02287012||Pre-Plerixafor era|The first era (Pre-Plerixafor era) will be defined as a two year period immediately preceding commercialization of plerixafor in Europe, (e.g., June 1, 2007 through June 1, 2009).
89326898|NCT02287012||Plerixafor era|The second era (Plerixafor era) will be defined as July 1, 2010 through July 1, 2012).
89326899|NCT02287168|Experimental|dissemination of cancer cells|conversion of negative result of pre-gastrectomy peritoneal washing cytology to positive cytology after gastrectomy
89326900|NCT02287168|Experimental|elimination of cancer cells|elimination of peritoneal cancer cells occurred before (pre-gastrectomy peritoneal washing cytology) or after gastrectomy (post-gastrectomy peritoneal washing cytology) by intra operative peritoneal lavage ('post-lavage peritoneal washing cytology)
89326901|NCT01339598|Sham Comparator|Sham transcranial direct current stimulation|
89326902|NCT01339598|Active Comparator|Transcranial direct current stimulation|
89326903|NCT01339598|Active Comparator|Different transcranial direct current stimulation montage|
89326904|NCT00540358|Active Comparator|Arm G/C|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
89326905|NCT00540358|Experimental|Arm G/C/I|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
89326906|NCT04469504|Experimental|PREHAB|
89326907|NCT04469504|Active Comparator|control group|
89326908|NCT00462202|Experimental|Sulodexide|Open label extension to original trial
89326909|NCT01335854|No Intervention|Usual Care|Usual care for 3 months. This consists of a phone call after one week of treatment, and clinic appointments at the sleep center following one month and three months of CPAP treatment.
89326910|NCT01335854|Experimental|Web-Access to CPAP Data|Usual care and web-based access to CPAP adherence data for 3 months. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website.
89326911|NCT01335854|Experimental|Web-Access to CPAP Data & Incentive|Usual care and web-based access to CPAP data for 3 months with financial incentives. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website. Financial incentive terminated after 1 week.
89326912|NCT02287246|Experimental|Extended-Release liposomal bupivacaine|20mL Extended-release liposomal bupivacaine injected into the posterior vaginal wall following surgery
89326913|NCT02287246|Active Comparator|Placebo (normal saline)|20mL normal saline injected into the posterior vaginal wall following surgery
89326914|NCT02682836|Experimental|single arm|Walk with Ease physical activity intervention
89326915|NCT04470544|Placebo Comparator|Placebo + Standard of Care|Standard of Care will be defined by the investigators in collaboration with the sponsor on the basis of the best available evidence at the time of study initiation with placebo.
89326916|NCT04470544|Experimental|Camostat + Standard of Care|Patient will receive SOC tablets and Camostat mesilate 200 mg four times a day after each meal with Standard of Care treatment.
89326917|NCT00535366|Experimental|Tiotropium+salmeterol+fluticasone|
89326918|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide low|
88816349|NCT04431765|Placebo Comparator|patients for Trauma-Centred Cognitive and Behavioural Therapy|Patients with post-traumatic Stress Disorder will receive Trauma-Centred Cognitive and Behavioural Therapy
89326919|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide high|
89326920|NCT00535366|Placebo Comparator|Placebo|
89326921|NCT02282488|Experimental|Group 1: Low protein formula|Low protein formula
89326922|NCT02282488|Experimental|Group 2: high protein formula|High protein formula
89326923|NCT02282488|No Intervention|Group Breastfeeding|Breastfeeding
89326924|NCT00369070|Experimental|A|AMG 706 125 mg once daily (QD) and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
89326925|NCT00369070|Experimental|B|AMG 706 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
89326926|NCT00369070|Active Comparator|C|Bevacizumab 15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
89326927|NCT02284204|Active Comparator|Midazolam and Ketamine|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
89326928|NCT02284204|Experimental|Midazolam, Ketamine and Sevoflurane|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). After fifteen minutes of this drug administration, the investigators start to provide sevoflurane, through a nasal hood, in an initial concentration of 0.1%, with 0.1% increment every 30 seconds, until a final expired concentration between 0.3 and 0.4%.
88816350|NCT02406612|Experimental|X-Seal 6F Vascular Closure Device|The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
89326929|NCT01352416|Active Comparator|CABG surgery with Ranolazine|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
89326930|NCT01352416|Placebo Comparator|CABG surgery with placebo|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
89326931|NCT01352416|Active Comparator|Heart Valve surgery with Ranolazine|Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
89326932|NCT01352416|Placebo Comparator|Heart Valve surgery with placebo|Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.
89326933|NCT00531622|Experimental|Saredudant/Escitalopram|Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks
89326934|NCT00531622|Active Comparator|Placebo and Escitalopram|Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks
89326935|NCT00531622|Placebo Comparator|Placebo|Placebo for saredutant and Placebo for Escitalopram once daily for one week during the screening phase and for a maximum of 8 weeks during the active phase
89326936|NCT02282644|Experimental|CellSearch|
89326937|NCT00359476|Experimental|1|
89326938|NCT04470466|Active Comparator|short pulse and Q-switched ND-YAG laser with topical carbon|
89326939|NCT04470466|Active Comparator|Fractional CO2 Laser|
89326940|NCT00450970|Experimental|1|Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of platinum (IV) compounds that are absorbed by the oral route. The lipophilic properties of these compounds, and hence their absorption, are largely determined by the nature of the axial acetate ligands.
89326941|NCT00450970|Experimental|2|Prednisone (17 alpha, 21-dihydroxypregna-1, 4-diene-3, 11, 20-trione) is commercially formulated as the acetate salt (prednisone 21-acetate). It is a biologically inert glucocorticoid, which is converted to active prednisolone in the liver.
89326942|NCT00449878|Experimental|Liprotamase|"Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units).~Open Label Period: Liprotamase administered orally with each of three meals and two snacks daily for 21 days.~Double Blind Treatment Period: Administered orally with each of three meals and two snacks daily for 6 days.~Second Open Label Period: Administered orally with each of three meals and two snacks daily for 7 days."
89326943|NCT00449878|Placebo Comparator|Placebo|Double Blind Treatment Period: Placebo (microcrystalline cellulose) administered orally with each of three meals and two snacks daily for 6 days.
89326944|NCT02282800||Case group|Case group include patients with generalized AgP were the tissue samples taken to analyse the number of vitamin D receptor present.
89326945|NCT02282800||Control group|Ethnically matched, systemically and periodontally healthy individuals were included in control group were also gingival tissue taken for analysis of number of receptors present in nucleus and cytoplasm
89326946|NCT02287324|Active Comparator|Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine
89326947|NCT02287324|Placebo Comparator|Manual Contact|Manual contact to suboccipital region of the cervical spine for 5 minutes
89326948|NCT02282878|Experimental|High/Low Sodium Diet|All MS patients will receive 2 weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
89326949|NCT02282878|Active Comparator|High/Low Sodium Diet Control|Age matched controls will receive two weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
89326950|NCT05208034|No Intervention|single-dose group|Women in single-dose group were administered a single-dose of intramuscular methotrexate as 50 mg/m2 on day-zero (the start of treatment).
89326951|NCT05208034|Experimental|two-dose group|Women allocated to two-dose group were administered intramuscular methotrexate as 50mg/m2 at day-zero and 7 while measurement of β-hCG was ordered at day-14.
89326952|NCT02284282|Active Comparator|Spinal injection|Patients receive spinal injection Bupivacaine/Morphine
89326953|NCT02284282|Placebo Comparator|Subcutaneum injection|Placebo subcutaneum injections
89326954|NCT02284360|Experimental|Group A: Low dose|"Each volunteer in group A will receive both Verum and Placebo.~The Verum lyophilized APOSEC™ is derived from 12.5*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
89326955|NCT02284360|Experimental|Group B: High dose|"Each volunteer in group B will receive both Verum and Placebo.~The Verum lyophilized APOSEC™ is derived from 25*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
89326956|NCT00359086|Experimental|1|
89326957|NCT02284438|Other|Biofilm formation on ETT|Three different endotracheal tubes uses on intubated mechanical ventilated patients will after extubation be examined regarding biofilm, structure and presence of microbes on the ETTs The different tubes will be used during consecutive time periods The study does not include any interventions concerning the treatment of these critically ill patients
89326958|NCT04471558||Music group|A part of the care is realized with music.
89326959|NCT04471558||Control group|The entire care is realized without music.
89326960|NCT02282956|Experimental|study group|single shot, posterior tibial nerve block with 5 ml of Ropivacaine 0,75% before surgery postoperative PCA pump with morphine and droperidol (DHBP®) for the next 24 hours.
89326961|NCT02282956|Other|controll Group|After surgery: standard analgesic treatment by PCA (patient controlled analgesia) pumps with morphine and Droperidol (DHBP®) for the next 24 hours.
89326962|NCT02282566|Placebo Comparator|Protein-nutrition beverage - Placebo|: 8 oz protein-nutrition beverage 1
89326963|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 2|8 oz protein-nutrition beverage 2
89326964|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 3|8 oz protein-nutrition beverage 3
89326965|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 4|8 oz protein-nutrition beverage 4
89326966|NCT02283034|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
89326967|NCT02283034|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
89326968|NCT02284594|Experimental|text message|Receipt of series of text messages regarding influenza vaccination
89326969|NCT02284594|No Intervention|usual care|
89326970|NCT04470856|Experimental|septic shock patients|"Intubated patients with septic shock receive an end-expiratory occlusion test (EEOT) and, after the test, they receive a 500 ml-fluid challenge.~During these phases the carotid doppler changes will be recorded."
89326971|NCT02287558|Experimental|Pomalidomide|Pomalidomide will be supplied as 1.0 mg, 2.0 mg, 3.0 mg and 4.0 mg capsules for oral administration. The principal investigator will determine whether intrapatient dose escalation is indicated based on the response of the patient's bleeding during the first 30 days of therapy. If dose escalation is indicated, pomalidomide will be increased by 1 mg/month at the investigator's discretion to a maximal dose of 5 mg/day.
89326972|NCT04470076|Experimental|neoadjuvant afatinib combination with chemotherapy|"Neoadjuvant treatment (chemotherapy+afatinib) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment (including dynamic 18F-FDG PET/CT) will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3) Adjuvant treatment (afatinib): Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the first week (+ 7 days) from surgery and up to 2 years."
89326973|NCT00445198|Experimental|Phase 1 and Phase 2a|
89326974|NCT00443326|Experimental|AMG 714|AMG 714 will be given as a multiple dose regimen
89326975|NCT00345748|Active Comparator|Abatacept 2 mg/kg|
89326976|NCT00345748|Active Comparator|Abatacept 10 mg/kg|
89326977|NCT00345748|Placebo Comparator|Placebo|
89326978|NCT00439738|Experimental|valsartan/HCTZ|
88806633|NCT05901103|Active Comparator|SPSIPB|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle. PCA device was also performed to this group with the same protocol which was detailed in control arm.
88806634|NCT05901103|No Intervention|Control|Control group patients were not subjected to any block or local infiltration anesthesia (local anesthetic administration around the incision). Their postoperative pain was relieved with tramadol (intravenous analgesic drug) administration by using patient-controlled analgesia (PCA) device. Patient-controlled analgesia was achieved with tramadol hydrochloride at a concentration of 4 mg per 1 ml with the PCA device. The PCA device was configured to administer the patients boluses of 10 mg tramadol hydrochloride with a lockout time of 20 minutes, allowing a maximum of 4 pushes per hour. The total dose was standardized for all patients with a maximum daily dose of 400 mg and a maximum dose of 100 mg tramadol hydrochloride every 6 hours.
88806635|NCT05901090|Active Comparator|M-TAPA block|Patients had bilateral M-TAPA block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
88806636|NCT05901090|Active Comparator|TAP block|Patients had bilateral TAP block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery for postoperative pain control.
88806637|NCT05901090|No Intervention|Control|Control group patients were not subjected to any block or local infiltration anesthesia. Their postoperative pain was relieved with tramadol (intravenous) administration.
88806638|NCT05901064|Active Comparator|Harmonic Focus|Patients that are operated with Harmonic Focus
88806639|NCT05901064|Active Comparator|Diathermy|Patients that are operated with conventional diathermy
88806640|NCT05901038||Cardiac patients (group 1)|Patients with prior myocardial infarction, percutaneous coronary intervention (PCI), cardiac ablation or cardiac surgery, attending a reimbursed cardiac rehabilitation programme in the cardiology department of the UZA.
88816730|NCT05612477|No Intervention|No Autotransfusion|patients in this arm will have their salvaged and washed RBCs discarded.
89326979|NCT00439738|Active Comparator|HCTZ +Amlodipine|
89326980|NCT00435916|Experimental|1|
89326981|NCT03134170|No Intervention|No intervention|The no intervention group will serve as control group. This group will receive standard care and will be an active comparator. At the end of the study they may join the intervention group
89326982|NCT03134170|Other|Intervention group|The intervention group will be seen by a pharmacist iin addition to their normal provider. The pharmacist will provide medication therapy review of the patient's therapy. The pharmacist will make recommendations to make revisions in the patient's therapy.
89326983|NCT00524056|Experimental|001|Carisbamate two 100 mg tablets twice per day
89326984|NCT00524056|Placebo Comparator|002|Placebo two placebo tablets twice per day
89326985|NCT00523042|Experimental|A|
89326986|NCT00523042|Active Comparator|B|
89326987|NCT03794362||Local Anesthetics|Lidocaine
89326988|NCT03794362||N-methyl-D-aspartate Antagonists|Ketamine
89326989|NCT03794362||SNRIs|Duloxetine
89326990|NCT03794362||Alpha-2 adrenergic agonists|Dexmedetomidine
89326991|NCT03794362||Oral Analgesics|NSAIDs, acetaminophen
89326992|NCT03794362||Non-pharmacologic interventions|Acupuncture
89326993|NCT00338104|Experimental|40% Glargine|Patients will receive a dose of glargine insulin equal to 40% of insulin drip rate.
89326994|NCT00338104|Experimental|60% Glargine|Patients will receive a dose of glargine insulin equal to 60% of insulin drip rate.
89326995|NCT00338104|Experimental|80% Glargine|Patients will receive a dose of glargine insulin equal to 80% of insulin drip rate.
89326996|NCT00519142|Placebo Comparator|1|metformin + placebo for mitiglinide
89326997|NCT00519142|Experimental|2|metformin + mitiglinide three times a day with meals
89326998|NCT00519142|Experimental|3|metformin + mitiglinide two times a day with morning and evening meal, placebo for mitiglinide with midday meal
89326999|NCT02284672|Placebo Comparator|control|"After preoxygenation for 3 minutes, normal saline would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
89327000|NCT02284672|Experimental|dexmedetomidine|"After preoxygenation for 3 minutes, dexmedetomidine would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
88806641|NCT05901038||Coached sporters with 12-week training schedule (group 2)|Sporters attending a sports cardiology consultation and following a 12-week training schedule at Sport Medical Centre Nottebohm.
89327001|NCT03134014|No Intervention|Breakfast Skipping (BS)|The BS group will continue to skip breakfast.
89327002|NCT03134014|Active Comparator|Normal Protein Breakfast (NP)|The NP groups will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The NP breakfasts will be 11% protein (10 g protein), 63% CHO, and 26% fat
89327003|NCT03134014|Active Comparator|High Protein Breakfast (HP)|The HP group will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The HP breakfasts will be 34% protein (30 g protein), 40% CHO, and 26% fat.
89327004|NCT00336934|Experimental|Arm I|Patients receive oral pomegranate extract daily.
89327005|NCT00336934|Placebo Comparator|Arm II|Patients receive oral placebo daily.
89327006|NCT02287714|Active Comparator|Instep without Gastrocnemius Recession|Patient will receive an instep plantar fascial release but not a gastrocnemius recession.
89327007|NCT02287714|Experimental|Instep with Gastrocnemius Recession|Patient will receive an instep plantar fascial release as well as a gastrocnemius recession.
89327008|NCT00334828|Experimental|1|
89327009|NCT00334828|Placebo Comparator|2|
89327010|NCT00425464|Experimental|Synchrony® Dual Optic Intraocular Lens|
89327011|NCT00425464|Active Comparator|Standard Monofocal Intraocular Lens|
89327012|NCT02283190|Experimental|Ewwinase|Six doses of Erwinase given three times weekly (Monday-Wednesday-Friday) for two weeks. Possible dose levels used are 20.000 IU/m2/day, 25,000IU/m2/day, and 30,000IU/m2/day.
89327013|NCT00333502|Experimental|CRLX101 (formerly known as IT-101)|CRLX101 dosing per protocol dose escalation cohorts to MTD, then expansion cohort treated at MTD of CRLX101 15mg/m2
89327014|NCT05982704|Experimental|tixagevimab/cilgavimab (Group 1)|tixagevimab/cilgavimab at a dose of 150+150 mg
89327015|NCT05982704|Experimental|tixagevimab/cilgavimab (Group 2)|tixagevimab/cilgavimab at a dose of 300+300 mg
89327016|NCT05982704|Active Comparator|regdanvimab group|regdanvimab at a dose of 40 mg/kg body weight
89327018|NCT05982639|Other|one-lung ventilation|Usual care. One lung ventilation will be provided using a Carleans type double lumen orotracheal tube.
89327019|NCT05982639|Experimental|two-lung ventilation and use of pneumothorax with CO2.|Two lung ventilation will be provided using a single lumen orotracheal tube and CO2-induced pneumothorax
89327020|NCT05982626|Experimental|68Ga/131I-SGMIB-5F7|68Ga/131I-SGMIB-5F7, single dose
88816731|NCT05610449||Testing Done Simple Antigen test in Symptomatic Subjects (Nasal swab)|
89327021|NCT05982613||General|This research is an observational study. There was no control and experimental group.
89327022|NCT05982535|Experimental|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
89327023|NCT05982535|Active Comparator|Physiogel Stability Intensive Cream MD|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
89327024|NCT05982522|Experimental|Experimental Group|IN10018 + nab-paclitaxel + Tislelizumab in previously-treated NSCLC
89327025|NCT05982522|Active Comparator|Control Group|Nab-paclitaxel + Tislelizumab in previously-treated NSCLC
89327026|NCT05982509|No Intervention|No intervention|Control group: 10 people without treatment
89327027|NCT05982509|Experimental|Treatment|Study Group: 10 People Applying EasyDew Regen MD Cream
89327028|NCT05982483|Experimental|ESP cohort|Randomized to receive the ultrasound-guided ESP block.
89327029|NCT05982483|Active Comparator|Usual care cohort|Randomized to usual care as dictated by the treating emergency physician
89327030|NCT05982470|Experimental|treatment group|"Estradiol gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application)* in combination with progesterone soft capsules 100mg once daily (oral) for 12 months~Note :~* Usage and dosage of estradiol gel: A dose of ruler is applied to the skin of the arm, shoulder, head and neck, abdomen, thigh or face every morning or evening. It is dry about two minutes after application. It is non-irritating, colorless, or milky white and tasteless, and is best used after bathing."
89327031|NCT05982470|Placebo Comparator|control group|"Estradiol placebo gel 2.5g (containing 17β estradiol 0mg) once daily (percutaneous application) *in combination with progesterone placebo soft capsules(containing progesterone 0mg) 100mg once daily (oral) for 12 months~Note :~* Usage and dosage of estradiol placebo gel : A dose of ruler is applied to the skin of the arm, shoulder, head and neck, abdomen, thigh or face every morning or evening. It is dry about two minutes after application. It is non-irritating, colorless, or milky white and tasteless, and is best used after bathing."
89327032|NCT05982457|Experimental|virtual reality group|After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and the students will be provided to wear them. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously. Cervical dilatation and effacement application will be watched using virtual glasses. Then, the students will be asked to use their hands to touch the perineum of the woman and make the image transparent, and it will be ensured that they watch the cervix structures again. Each student will use the virtual glasses for an average of 20-25 minutes.
89327033|NCT05982457|No Intervention|Model group|After the introduction and briefing, the students will be provided to perform cervical dilatation and effacement application on the model in accordance with the Cervical Dilatation and Effacement Learning Guide with each student in the laboratory environment.
89327034|NCT05982444|Other|patient treated by rezum procedure|patients had benign prostatic hyperplasia and treated by rezum procedure from 2 to 4 years included in the study
89327035|NCT05982431|Experimental|exercise group|60-minutes exercise program, three times a week on alternate days for 12 successive weeks.
89327036|NCT05982431|Experimental|placebo kinesiology taping plus exercise group|Kinesiology taping was used, however the strain was zero. Before each exercise session, the tape was changed every two days while the patients were present.
89327037|NCT05982431|Experimental|kinesiology taping plus exercise group|putting no stress on the opposite end and a 50% stretch from the top of the big toe to the heel along the back of the heel. After applying a 50% stretch from the top of the big toe to the second horizontal little strip between the big toe and second toe, place the ends below the toe diagonally with no stress.
89327038|NCT05982418|Experimental|3D Printed Models|This cohort will consist of 54 prospective cases whereby patient-specific 3D printed models will be available to the surgeon during RARP for manipulation.
89327039|NCT05982418|Experimental|3D Virtual Models|This cohort will consist of 54 prospective cases whereby 3D virtual models will be available to the surgeon during RARP for manipulation using Innersight Labs platform.
89327040|NCT05982379|Experimental|Intervention|This study was carried out with two groups. Technology Based Motivation Program were used for the intervention group.
89327041|NCT05982379|No Intervention|Control|No application was made to the control group, standard procedure was followed.
89327042|NCT05982366|Experimental|Distal transradial approach|Distal transradial approach as the default strategy
89327043|NCT05982366|Active Comparator|Conventional transradial approach|Conventional transradial approach as the default strategy
89327044|NCT05982314|Experimental|Gamma-PN3 50 mcg|In GPNV-001 participants will have received 2 doses of 50 mcg Gamma-PN3 at intervals of 4 weeks
89327045|NCT05982314|Experimental|Gamma-PN3 250 mcg|In GPNV-001 participants will have received 2 doses of 250 mcg Gamma-PN3 at intervals of 4 weeks
89327046|NCT05982314|Experimental|Gamma-PN3 1000 mcg|In GPNV-001 participants will have received 2 doses of 1000 mcg Gamma-PN3 at intervals of 4 weeks
89327047|NCT05982314|Active Comparator|Pneumovax 23|In GPNV-001 participants will have received one 0.5ml dose of Pneumovax-23 followed by saline placebo 4 weeks later
89327048|NCT05982314|Active Comparator|Prevenar-13|In GPNV-001 participants will have received one 0.5ml dose of Prevenar-13 followed by saline placebo 4 weeks later
89327049|NCT05982314|Placebo Comparator|Placebo|In GPNV-001 participants will have received two doses of 0.5 ml saline placebo at intervals of 4 weeks.
89327050|NCT05982301|Experimental|Nab-POF|Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
89327051|NCT05982288|Experimental|Intensive care nurses|"Type of Study: It will be conducted in a single-center, randomized controlled experimental design. A clinical trial number will be obtained before starting the study.~Location of the Study: The research will be conducted in the Anesthesiology and Reanimation Clinic of Antalya Kepez State Hospital."
89327052|NCT05982249|Experimental|Hypnosis (H)|Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten bone marrow (BM) examinations at the hematology institute. The length of the recording is about 7 minutes.
89327053|NCT05982249|Experimental|Virtual reality (VR)|Patients will be connected to a VR device that will transmit to the patient's choice a 3D screen and soothing noise for about 7 minutes.
89327054|NCT05982249|Experimental|Combined hypnosis and virtual reality (VRH)|Patients will hear the same 7-minutes hypnotic script by earphones and simultaneously be connected to the VR device that will show the 3D screen without soothing noise.
89327055|NCT05982249|No Intervention|Control (C)|
89523475|NCT03386461|Experimental|Exercise + Omega 3 supplementation|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly (Senior Fitness, and Faculty of Physical Education and Sport). Subjects will take 5 capsules od Calanus oil (containing approx. 250 mg EPA and DHA per day).
88806642|NCT05901038||Sporters without 12-week training schedule (group 3)|Sporters attending a sport medical check-up at S.P.O.R.T.S. (i.e., a multidisciplinary centre of expertise within UZA), but without standardized 12-week training schedule.
89327056|NCT05982223|Experimental|Integrative oncology|All patients will be followed up by a haemato-oncologist. The frequency and type of visits and exams will be determined by National Comprehensive Cancer Network (NCCN) guidelines, patients' symptoms and physician's clinical judgement. Patients recruited to the intervention arm will receive, on top of the defined conventional medicine follow-up, integrative oncology intervention including emotional treatments (counseling, spiritual guidance), complementary medicine (acupuncture, herbal supplements, mind-body, touch and/or movement therapies) or both. The type and frequency of these interventions will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
89327057|NCT05982223|No Intervention|Conventional medicine only|All patients will be followed up by a haemato-oncologist. The frequency and type of visits and exams will be determined by NCCN guidelines, patients' symptoms and physician's clinical judgement.
89327058|NCT05982210|No Intervention|Control Group|The Control Group does not have any interventions applied.
89327059|NCT05982210|Experimental|Intervention Group|The Intervention Group will take part in the experimental process. A clinical practice protocol about breathing exercises and diaphragm and ribs manual therapy will be applied, in a total duration of 15 minutes, twice a week during eight weeks.
89327060|NCT05982197|Active Comparator|Curcuma longa oral gel group|
89327061|NCT05982197|Active Comparator|Standard treatment group|
89327062|NCT05982145||Patients who are 60 years old and over|Patients who are 60 years old and over had a questionary and a measure of their leg's length
89327063|NCT05982145||Patients with / or had venous leg ulcers|Patients with / or had venous leg ulcers actually have individual interviews
89327064|NCT05982145||Caregivers who treat patients with venous leg ulcers (except nursing homes)|Caregivers who treat patients with venous leg ulcers (except nursing homes) actually have individual interviews
89327065|NCT05982145||Caregivers in nursing homes for dependant elderly people and institutions like hospital|Caregivers in nursing homes for dependant elderly people and institutions like hospital actually have focus groups
89327066|NCT05982119|Other|Patients with DMD/FSHD or control subjects|"Patients and control subjects will be included over a one-year study period. Patients will be examined by a neuropaediatrician or neurologist and perform standardized assessments (timed tests, motor function tests, and strength tests) at baseline, 6 and 12 months. Patients will be asked to wear the device during one year.~Control subjects will be examined by a physician and perform the same tests than those for ambulant patients at baseline and 12 months. Control subjects will be asked to wear the device for two months (one month at inclusion, one month 11 months after inclusion)."
89327067|NCT05982106|Experimental|TQ05105 Tablets (fasted)|TQ05105 tablets was administered on fasted state in the first cycle for Group A and the second cycle for Group B.
89327068|NCT05982106|Experimental|TQ05105 Tablets (fed)|TQ05105 tablets was administered on fed state in the second cycle for Group A and the first cycle for Group B.
89327069|NCT05982067|Experimental|mindfulness-based physical exercie|The participants will receive about 70-min MIPE program twice a week, which will be conducted in a hybrid way, a combination of face-to-face and at home by a qualified mindfulness therapist and a sport coach.
89327070|NCT05982067|Placebo Comparator|Health education|Health education consisting of discussion provided by a registered nurse will be conducted as a control of socialization and interaction.
89327071|NCT05982028|Experimental|Pit picking group|Minimally invasive pilonidal cyst surgery.
89327072|NCT05982028|Experimental|Excision group|Radical surgical pilonidal cyst excision without suturing
89327073|NCT05982002|Active Comparator|Control group|Group A: (Control group)20 post menopausal women received moderate intensity aerobic exercise in addition to energy restricted diet 2time/week for 6 -weeks
89327074|NCT05982002|Experimental|Shock wave group|Group B: (shock wave group)20 post menopausal women received the same intervention as in group A and 12 sessions of shockwave on abdomen twice/week for 6 -weeks
89327075|NCT05981989|Experimental|Epidural electrical stimulation (EES)|Subjects will be implanted with 16-electrode epidural array in the C6-T1 area of the spinal cord. After surgery, subjects will undergo a structured program of physical rehabilitation and electrical stimulation.
89327076|NCT05981976|Experimental|Abatacept Treatment A|
89327077|NCT05981976|Experimental|Abatacept Treatment B|
89327078|NCT05981950||Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
89327079|NCT05981872|Experimental|post covid-19 patients with neurological symptoms as study group|•Study group (A) will receive cognitive rehabilitation (Rehacom ) for 30 minutes and selected physical therapy program(that included aerobic, strength, and balance training for 30 minutes, with total duration 60 minutes. 3 sessions per week for 12 weeks.
89327080|NCT05981872|Active Comparator|post covid-19 patients with neurological symptoms as control group|"Control group (B) which will include 18 patients who will receive only selected physical therapy program (that included aerobic, strength, and balance training ).~The treatment will conducted for 60 minutes, 3 sessions per week for 12 weeks"
89327081|NCT05981820|Experimental|HIIT group|"This group will only participate Wingate-based HIIT training.~In the first three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes~Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set~Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes~Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets"
89327082|NCT05981820|Experimental|HIIT + creatine group|The HIIT + creatine group will participate the same Wingate-based HIIT training in addition to consume 10 g of creatine supplementation. Participants in this group will use 10 g of creatine monohydrate by dissolved in 200 ml of water. Creatine supplementation will be taken in two doses of five grams, 30 minutes before and after training.
89327083|NCT05981807||Transgender population|Cohort of transgender people (man to woman and woman to man)
89327084|NCT05981781|Active Comparator|ultrasound guided peng block in paediatric hip surgery|Patients will receive US-guided PENG block with 0.5 ml/kg of bupivacaine 0.25% after induction of general anaesthesia.
89327085|NCT05981781|Active Comparator|ultrasound guided caudal epidural block in paediatric hip surgery|Patients will receive US-guided caudal block with 0.5 ml/kg of bupivacaine 0.25% after induction of general anaesthesia.
89327086|NCT05981742|Active Comparator|Group 1 (M)|25 Patients administered Metformin (Glucophage) Tablets of 500 mg per oral twice daily for 90 days duration.
89327087|NCT05981742|Active Comparator|Group 2 (D)|25 Patients administered Cabergoline (Pergoline) Tablets of 0.5 mg dose per oral once weekly for 90 days duration.
89327088|NCT05981742|Active Comparator|Group 3 (MD)|25 Patients administered Metformin (Glucophage) Tablets of 500 mg per oral twice daily and Cabergoline (Pergoline) Tablets of 0.5 mg dose per oral once weekly for 90 days duration.
89327089|NCT05981729|Experimental|Technology enhanced stroke rehabilitation|Supported use of stroke rehabilitation technology
89327090|NCT05981690|Experimental|Therapist guided, parent-led CBT for preadolescent children with OCD|6 to 8 sessions of therapist guided, parent-led CBT for preadolescent children with OCD
89327091|NCT05981677||NSSI|
89327092|NCT05981677||HC|
89327093|NCT05981651||training session|A total of 150 facial expression videos of healthy volunteers and facial palsy patients were collected as a training set for the algorithm
89327094|NCT05981651||test set|A total of 50 cases of healthy volunteers and patients with facial palsy were used as the test set for the algorithm
89327095|NCT05981638|Other|Group WM (Water+mobilization)|All patients were randomized according to a table created on a computer using the closed-envelope method.Patients in the WM group (water+mobilization) were given water and mobilized
89327096|NCT05981638|Other|Group WR(water+rest)|All patients were randomized according to a table created on a computer using the closed-envelope method. Patients in the WR group (water+rest) were given water and stay in rest
89327097|NCT05981638|Other|Group AR(apple juice+rest)|All patients were randomized according to a table created on a computer using the closed-envelope method. Patients in the AR group (apple juice+rest) were given apple juice and stay in rest
89327098|NCT05981638|Other|Group AM (apple juice+mobilization)|All patients were randomized according to a table created on a computer using the closed-envelope method. Patients in the AM group (apple juice+mobilization) were given water and mobilized
89327099|NCT05981625|Experimental|Giomer varnish containing surface pre-reacted glass fillers|Giomer-based varnish is a light-curable varnish/desensitizer. The surface pre-reacted glass (S-PRG) filler is a bioactive trilaminar structure with a multifunctional glass core embedded in resin matrix. It can release and recharge fluoride ions. When it becomes in contact with the oral fluids, it starts to bind to the collagen fiber and release six different types of ions like fluoride, calcium, phosphate that help in the formation of apatite crystals and seal the open dentinal tubules with a long-lasting effect Brand name: S_PRG (Shofu-Japan)
89327100|NCT05981625|Active Comparator|Bioactive Glass Air Polishing|Bioactive glass powder delivered by standalone air polishing system, is a bioactive material that reacts with saliva to deposit Hydroxycarbonate Apatite crystals (HCA), which is very strong and resilient. The continuous release of calcium ions promotes constant protection and long lasting seal of the tubules. Using the air polishing delivery system helps to provide a huge amount of calcium and phosphate particles at the exposed surface of the tooth. Moreover, the air pressure aids in pushing these particles inside the dentinal tubules to a considerable depth. Air polishing using such powder provides a bifunctional advantage of occluding the dentinal tubules. However, there is limited clinical trials testing the efficacy of the bioactive glass powder air polishing system in minimizing the dentin hypersensitivity
89327101|NCT05981612||NSSI|
89327102|NCT05981612||HC|
89327103|NCT05981586|Experimental|SPEED|Speed tests are typically used solely to measure an athlete's linear speed capabilities. Track sprinters have been shown to accelerate continuously through at least 50m during a 100m sprint event.
89327104|NCT05981586|Experimental|BALANCE|"The person performing the test must maintain their balance on one leg, while using the other leg to reach as far as possible in 8 different directions. The person (standing on his/her left leg for example) must reach in 8 different positions, once in each of the following directions: anterior, antero medial, medial, posteromedial, posterior, posterolateral, lateral and anterolateral.~The reliability of the SEBT as being moderate to good"
89327105|NCT05981586|Experimental|AGILITY|The T-Test is one of the most important agility Test, used in a lot of different sports all around the world. The test is a combination of different sport specific pattern as forward, lateral, and backward movements
89327106|NCT05981560|Experimental|Closed Chain Exercise|closed chain exercise plan given to the participant of this group
88806643|NCT05901012|Experimental|60mg of N,N-Dimethyltryptamine|One inhaled dose of 60mg of vaporized DMT.
89327107|NCT05981560|Experimental|Neuromuscular Training Exercise|Neuromuscular training plan given to the participants of this group
89327108|NCT05981495||TB Suspects|TB Suspects recruited to this study will have blood drawn in a single visit.
89327109|NCT05981482||Stroke survivors|Individuals who have survived a stroke
89327110|NCT05981404|Experimental|Low calorie and low carbohydrate meals with β-glucan.|On day 1, a low-calorie breakfast will be consumed at the metabolic investigation laboratory at New Lister Building (NLB) of Glasgow Royal Infirmary but low carbohydrate lunch and low-calorie dinner at home. On day 2, breakfast and lunch will be consumed at the laboratory and, prior to the breakfast, 1000mg of paracetamol will be taken, blood samples, breath hydrogen tests, appetite questionnaires will be obtained for 7 hours after the completion of breakfast. 3g β-glucan will be consumed with each meal on both days.
89327111|NCT05981404|Experimental|Low calorie and low carbohydrate meals with placebo.|On day 1, a low-calorie breakfast will be consumed at the metabolic investigation laboratory at New Lister Building (NLB) of Glasgow Royal Infirmary but low carbohydrate lunch and low-calorie dinner at home. On day 2, breakfast and lunch will be consumed at the laboratory and, prior to the breakfast, 1000mg of paracetamol will be taken, blood samples, breath hydrogen tests, appetite questionnaires will be obtained for 7 hours after the completion of breakfast. 3g cellulose will be consumed with each meal on both days.
89327112|NCT05981378||Native Amazonian group|Amazonian people that belongs to a indigenous community located in the Peruvian Amazon
89327113|NCT05981378||Urban Amazonian mestizos group|Amazonian mestizo people that lives on a urban district in the Peruvian Amazon
89327114|NCT05981339|Sham Comparator|Control Group|In the control group, diaphragmatic breathing exercises will be performed together with the physiotherapist. Osteopathic manual therapy techniques will be applied as sham. The physiotherapist will not touch the appropriate anatomical points while performing the loosening.
89327115|NCT05981339|Experimental|Study Group|In addition to breathing exercises, sacral release and bladder mobilization, which are osteopathic manual therapy techniques, will be applied to the patients in the study group.
89327116|NCT05981326|Experimental|cohort: triple negative breast cancer|"Standard drug: Neoadjuvant treatment : Weekly paclitaxel + carboplatin + pembrolizumab (TCP) followed by EC90 *4 pembrolizumab~Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite"
89327117|NCT05981326|Experimental|cohort: HER2+ breast cancer|"Standard drug:~EC100 followed by docetaxel + trastuzumab or EC100 followed by paclitaxel + trastuzumab Docetaxel + carboplatin + trastuzumab *6 folowed by trastuzumab alone~Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite"
89327118|NCT05981326|Experimental|cohort: ER/PR+ /HER2- breast cancer|"Standard drug: EC100 paclitaxel or EC100 docetaxel~Procedure: supplementary biopsy at inclusion + centralized blood samples and questionnaires at evaluation visite"
89327119|NCT05981313||Hemophilia Group|The viscoelastic properties (tone, stiffness, elasticity) of the lower extremity muscles (Vastus Medialis Obliquus, Rectus Femoris, Vastus Lateralis, Biceps Femoris, Tibialis Anterior, Gastrocnemius) of hemophilia patients who meet the study criteria will be evaluated with the MyotonPro device (Myoton Ltd).
89327120|NCT05981313||Control Group|The viscoelastic properties (tone, stiffness, elasticity) of the lower extremity muscles (Vastus Medialis Obliquus, Rectus Femoris, Vastus Lateralis, Biceps Femoris, Tibialis Anterior, Gastrocnemius) of healthy children meeting the study criteria will be evaluated with the MyotonPro device (Myoton Ltd).
89327121|NCT05981287|Experimental|Task-oriented activities based on NDT (TOA-NDT) principle and Conventional Physical Therapy|The experimental group undergo conventional physical therapy and additional task-oriented activities based on NDT (TOT-NDT) principle 10 - 36 sessions in 5-8 weeks, 2 to 6 days per sessions.
89327122|NCT05981287|Active Comparator|Gross motor task training and Conventional physical therapy (CPT)|This group will receive conventional physical therapy and additional gross motor task training 10-36 sessions in 5-8 weeks, 2 to 6 days per sessions.
89327123|NCT05981261|Other|Experimental pain|Experimental pain
89327124|NCT05981248|Experimental|the MIED+TAU group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
89327125|NCT05981248|No Intervention|the TAU-only group|treated as usual
89327126|NCT05981222||Osteo Match cage|Patients undergoing posterior lumbar interbody fusion with Osteo Match Cages
89327127|NCT05981222||Peek Cage|Patients undergoing posterior lumbar interbody fusion with PEEK Cages
89327128|NCT05981157|Experimental|Anrotinib plus Tirelizumab arm|Subjects receive anrotinib plus tirelizumab
89327129|NCT05981079|Experimental|Model-based dosing regimen|Drug: Piperacillin Sodium and Tazobactam Sodium for Injection. Dosing regimen: GA<28 weeks: 30 mg/kg, Q8H; 28 weeks ≤GA<34 weeks: 50 mg/kg，Q8H.
89327130|NCT05981079|Active Comparator|Empirical dosing regimen|Drug: Piperacillin Sodium and Tazobactam Sodium for Injection. Dosing regimen: 90 mg/kg，Q8H.
89327131|NCT05981066|Experimental|IPM511 monotherapy|3+3 dose excalation. Paticipants will receive two cycle (QWX4 per cycle) IPM511 injection，I.M injection
89327132|NCT05981014|Experimental|Phase I and phase II: Chemotherapy + LNL treatment|Participants in both phase I and phase II portions receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by neoadjuvant LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.
88806644|NCT05901012|Placebo Comparator|Placebo-like|One inhaled dose of 1mg of vaporized DMT.
89327133|NCT05981014|Active Comparator|Phase II: Chemotherapy|The single-arm phase I study did not have this arm. Participants in phase II portion receive two cycles of doxorubicin or epirubicin, plus cyclophosphamide (AC or EC), followed by four-cycles of nab-paclitaxel as neoadjuvant therapy prior to definitive surgery. The choice of doxorubicin or epirubicin should be the same as the prior neoadjuvant chemotherapy.
89327134|NCT05981001|Experimental|Phase I and phase II: LNL treatment + Camrelizumab + Chemotherapy|Participants in both phase I and phase II portions receive LNL treatment, which consists of non-myeloablative lymphocyte depleting regimen of chemotherapy with cyclophosphamide and fludarabine, followed by infusion of LNL and interleukin-2. After LNL treatment, participants receive camrelizumab PLUS one of two background chemotherapy regimens at investigator's discretion: (1) nab-paclitaxel, OR (2) gemcitabine/carboplatin.
89327135|NCT05981001|Active Comparator|Phase II: Camrelizumab + Chemotherapy|The single-arm phase I study did not have this arm. Participants in phase II portion receive camrelizumab PLUS one of two background chemotherapy regimens at investigator's discretion: (1) nab-paclitaxel, OR (2) gemcitabine/carboplatin.
89327136|NCT05980988|Experimental|Probiotic group|2B CFU/capsule/day BLa80, before meals； Storage: Store in a cool, dry place without sun exposure.
89327137|NCT05980988|Placebo Comparator|placebo|Maltodextrin, one capsule/day, before meals； Storage: Store in a cool, dry place without exposure to the sun.
88806645|NCT05900999|Experimental|Survivors of stroke in early stages of recovery|
88806646|NCT05900921|Experimental|Experimental: Trilaciclib+Chemotherpy+Tislelizumab|"Participants received Trilaciclib (240mg/m2) in combination with Paclitaxel (175mg/m2), Cisplatin (AUC=5), and Tislelizumab (200mg) treatment, every 3 weeks for up to 4-6 cycles (Induction).~Following induction, patients will receive trilaciclib with tislelizumab for every 3 weeks"
88816732|NCT05610449||Testing Done Simple Antigen test in Asymptomatic Subjects (Nasal swab)|
88816733|NCT05599178||Term gestation|
89327138|NCT05980975|Experimental|Coffee group (Group 1)|Then, at the 4th hour, 8th hour and 12th hour of the surgery, the patients in the coffee group received 10 gr. granulated coffee.
89327139|NCT05980975|Experimental|Hot water group (Group 2)|The patients in the hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of the operation.
89327140|NCT05980975|No Intervention|Control group (Group 3)|No application was made to the control group.
89327141|NCT05980962|Active Comparator|Group 1 (Anteriorization group)|Symmetrical Anteriorization of the inferior oblique muscle
89327142|NCT05980962|Experimental|Group 2 (Resction group)|Asymmetrical Anteriorization of the inferior oblique muscle, where an additional resection of the inferior oblique was done for the eye with the larger deviation
89327143|NCT05980897|Experimental|Naming Treatment|Participants will complete three sessions of baseline probe testing (40 treatment items) occurring virtually on three consecutive days prior to treatment onset. Participants will then complete 10 sessions of therapy scheduled five days a week for two weeks, all occurring virtually. The treatment approach for this study will be a hierarchical, cueing-based treatment for naming.
89327144|NCT05980884|Experimental|L-Carnitine supplementation|Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days. During the intervention, participants are asked to collect urine sample and dietary record each day. Blood and fecal samples will be collected before and after the intervention. Each participant needs to complete a food frequency questionnaire.
89327145|NCT05980871|Active Comparator|single-dose ceftriaxone plus doxycycline|single-dose ceftriaxone (1g intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days)
89327146|NCT05980871|Active Comparator|single-dose BPG plus doxycycline|single-dose BPG (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days)
89327147|NCT05980845|Active Comparator|Assigned Interventions|It was explained to the patients in the nature sounds group that nature sounds would be played for 30 minutes in three HD sessions for one week, starting from the beginning of the session. Afterwards, the patients were informed about the usage of the Mp3 player and in-ear headphones, they were demonstrated that they could adjust the volume to the level they desired, and it was stated that they should not detach the headphones until the 30-minute recording was over. The patients listened to nature sounds for 30 minutes in three HD sessions for one week under the supervision of the researcher.
89327148|NCT05980845|No Intervention|Control Group|"Patients in the control group were not intervened by the researcher during the HD sessions. Before the first HD session started, the Descriptive Characteristics Form and Trait Anxiety Scale were performed by the researcher while the patients were in the waiting room. Then, in every three HD sessions for one week, when the patients went to their beds, their vital signs were measured and recorded on the Vital Signs Monitoring Form and the State Anxiety Scale was administered just before the HD treatment session was started. Then, the vital signs of the patients were measured and recorded on the Vital Signs Monitoring Form at the 30th minute, 1st, 2nd, 3rd hour of the HD session and immediately after the end of the HD session. At the same time, the State Anxiety Scale was performed again immediately after the end of the HD session. The patient was then transferred out of the unit."
89327149|NCT05980832|Experimental|Experimental Group 1|It will consist of 10 patients who have received psychosocial skills training by the staff of the center, and a 6-week peer-supported psychosocial skills training will be given by the peer-leaders trained by the researcher psychiatric nurse.
89327150|NCT05980832|Experimental|Experimental Group 2|It will consist of 10 patients who have not received psychosocial skills training by the staff of the center, and a 6-week peer-supported psychosocial skills training will be given by the peer-leaders trained by the researcher psychiatric nurse.
89327151|NCT05980832|No Intervention|Control Group 1|It will consist of 10 patients who have received psychosocial skills training by the center staff and no intervention will be applied.
89327152|NCT05980832|No Intervention|Control Group 2|It will consist of 10 patients who have not received psychosocial skills training by the center staff and no intervention will be applied.
89327153|NCT05980832|Other|Peer Practitioner Training|It is the group in which psychosocial skills training will be given to 4 patients with chronic mental disorders by a researcher psychiatric nurse.
89327154|NCT05980819|Experimental|All Volunteers|All volunteers will partake in this educational study at the same timepoints, there will be no blinding, but there will be an unbiased recruitment effort
89327155|NCT05980780|No Intervention|The control group|no intervention
89327156|NCT05980780|Experimental|video game group|Children in this group will play a video game for disease management
89327157|NCT05980780|Experimental|Education booklet group|Children in this group will read an educational booklet for disease management.
89327158|NCT05980741|No Intervention|control group|Traditional nursing services are provided to the control group, based on functional nursing. The nurses in the ward are assigned to complete different tasks according to their responsibilities, technical knowledge and skills. These tasks are including carrying out health education to the patients, introducing the admission guidelines and ward conditions, informing patients of basic knowledge on diseases, treatment, and nursing, monitoring patient vital signs and so on. The basic medical inspection and care are conducted appropriately. The patients are instructed on the compliance and precautions required during the perioperative period. The wound and drainage are checked regularly after the operation.
89327159|NCT05980741|Experimental|study group High-quality nursing|High-quality nursing is provided to the study group based on primary nursing. Nurses in primary nursing take responsibility for the total care of a patient and are accountable for his/her care over 24 h a day from the patient's admission to discharge. In this case, nurses have more time to communicate with patients and to establish the nurse-patient relationship. In addition, high-quality nursing offers effective nursing measures to patients in terms of multiple aspects and dimensions through planning patient-centered nursing care, strengthening the perioperative nursing since admission, and fully implementing the nursing responsibility system.
88806647|NCT05900921|Active Comparator|Active Comparator: Chemotherpy+Tislelizumab|"Participants received Paclitaxel (175mg/m2), Cisplatin (AUC=5), and Tislelizumab (200mg) treatment, every 3 weeks for up to 4-6 cycles (Induction).~Following induction, patients will receive tislelizumab for every 3 weeks until PD"
88806648|NCT05900830|Active Comparator|common educational methods|this group will receive common educational methods
89327160|NCT05980741|Experimental|study group Clinical Care Pathway|The clinical care pathway will be implemented immediately after admission. With the patient as the center of the nursing intervention, a flowable form is chosen to ensure that patients could receive effective nursing interventions throughout the entire hospitalization from the day of admission to the final discharge. In addition to primary care, the present program also unifies the management of nursing resources with the establishment of a highly qualified and professionally competent nursing team. The team members would cooperate with each other and give full play to their respective initiatives, with the common goal of improving the quality of care. The severity of illness, psychological status, and family and social environment in each patient differ, so individualized care plans are developed for each case.
89327161|NCT05980741|Experimental|study group Roy Adaptation Model|the Roy Adaptation Model (RAM) offers a comprehensive framework to guide nursing care for patients with chronic diseases. The RAM group receives standard care supplemented with interventions based on the RAM model. Negative emotions measured by the Hospital Anxiety and Depression Scale (HADS), pain intensity by the Visual Analog Scale (VAS), and HRQoL by the 36-Item Short Form Health Survey (SF-36) are measured at the preoperative visit (T0), at 30 days (T1), and at 3 months of (T2) follow-up.
89327162|NCT05980715|Experimental|Arm 1（PD-1）|Radiotherapy free treatment: the experimental group took PD-1 inhibitor maintenance regimen.
89327163|NCT05980715|Active Comparator|Arm 2（radiotherapy）|conventional radiotherapy (chemoradiotherapy) regimen, and received comprehensive treatment according to the guidelines (radiotherapy or platinum-based concurrent chemoradiotherapy as stipulated in the guidelines).
89327164|NCT05980676|No Intervention|Control|The control group will be told that they can work a WOW routine on their own, with the opportunity to complete the intervention after completing the 4-week follow-up assessment.
89327165|NCT05980676|Experimental|No-Coach|This is a fully automated intervention. The No-Coach group will complete an online activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. They will not be able to reply to the emails for support.
89327166|NCT05980676|Experimental|Coached|This is a semi-automated intervention. The Coached group will complete an online activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. Prompts will be added to the end of each email such that these participants can respond to give feedback, ask questions, and receive additional support from a (human) coach.
89327167|NCT05980663|Experimental|Active group|Participants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management.
89327168|NCT05980663|Active Comparator|Active control|Participants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).
89327169|NCT05980663|No Intervention|Control group|Participants receive personalized advice on proper nutrition for a reduction diet in which they use common food.
89327170|NCT05980637|Active Comparator|Shaoyao Gancao Decoction with Addition|11g of Shaoyao Gancao Decoction with Addition granules twice daily for 4 weeks
89327171|NCT05980637|Placebo Comparator|Placebo|11g of placebo granules twice daily for 4 weeks
89327172|NCT05980611||copd patients with high upper airway symptoms|"The SNOT22 nasal subdomain (SNOT22nasal) consists of seven questions (no. 1-5 + 7-8), which include: need to blow nose, sneezing, runny nose, nasal obstruction, loss of smell or taste, post-nasal discharge and thick nasal discharge. the total SNOT22 has been found to have a median score of 7 points in healthy volunteers"
89327173|NCT05980611||copd patients with low upper airway symptoms|"The SNOT22 nasal subdomain (SNOT22nasal) consists of seven questions (no. 1-5 + 7-8), which include: need to blow nose, sneezing, runny nose, nasal obstruction, loss of smell or taste, post-nasal discharge and thick nasal discharge. the total SNOT22 has been found to have a median score of 7 points in healthy volunteers"
89327174|NCT05980455|Active Comparator|Control Sleep Cycle|Baseline device programming parameters will be used during study participation. No modification to Enterra™ device programming will be in effect during waking or sleeping hours.
89327175|NCT05980455|Experimental|Arm 1 Sleep Cycle|"Device programming parameters participants have at enrollment will be used during waking hours.~During sleeping hours, the Enterra™ device will cycle through modified programming over the course of 6 hours. Each hour, the Enterra™ device will deliver 30 minutes of reduced stimulation, followed by 30 minutes of waking hours stimulation. At the end of the 6-hour sleep cycle, the Enterra™ device will return to waking hours programming."
89327176|NCT05980455|Experimental|Arm 2 Sleep Cycle|"Device programming parameters participants have at enrollment will be used during waking hours.~During sleeping hours, the Enterra™ device will cycle through modified programming over the course of 8 hours. Each hour, the Enterra™ device will deliver 45 minutes of reduced stimulation, followed by 15 minutes of waking hours stimulation. At the end of the 8-hour sleep cycle, the Enterra™ device will return to waking hours programming."
89327177|NCT05980390||Active vitiligo|
89327178|NCT05980390||Stable vitiligo|
89327179|NCT05980390||Normal controls|
89327180|NCT05980364|Experimental|Experimental group|
89327181|NCT05980364|No Intervention|Control group|
89327182|NCT05980338|Active Comparator|control group|The patients are placed in supine position with knee preparation using an iodine-based product and drape in a sterile manner Then the ground pad of the radio frequency machine will be placed in the other leg (we used the Neurotherm NT1100 re generator) All the patients will be monitored by ECG, noninvasive blood pressure and pulse oximetry The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ). this group will receive radio frequency alone .
89327183|NCT05980338|Experimental|study group|this group will pass through the all steps but after the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve.
89327184|NCT05980208||Inetetamab|Inetetamab-based treatment for first-line treatment of HER2-positive MBC
89327187|NCT05979597|Active Comparator|Group SFIB (Suprainguinal fascia iliaca block)|In the patient lying in the supine position, a high-frequency linear probe is inserted under sterile conditions, using an in-plane technique, 1 cm cephalad of the inguinal ligament with a needle. Using hydro-dissection, the fascia iliaca is separated from the iliac muscle and a space is created where the needle can be advanced cranially, and the procedure will be completed by injecting local anesthetic into this space.
89327188|NCT05979597|Active Comparator|Group SFIB+dexa (Suprainguinal fascia iliaca block+dexamethasone)|In the patient lying in the supine position, a high-frequency linear probe is inserted under sterile conditions, using an in-plane technique, 1 cm cephalad of the inguinal ligament with a needle. Using hydro-dissection, the fascia iliaca is separated from the iliac muscle and a space is created where the needle can be advanced cranially, and the procedure will be completed by injecting local anesthetic+dexamethasone into this space.
89327189|NCT05979363|Experimental|VRD-based Regimen Combined With BCMA CART|"VRD：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle.~Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10^6 anti-BCMA CAR+T cells/kg.~Participants will receive VRD-based induction, BCMA CAR-T infusion, VR consolidation, VR maintenance."
89327190|NCT05979272|Active Comparator|TAU-only|Treatment as usual
89327191|NCT05979272|Experimental|TAU + TECH|Treatment as usual, plus TECH app
89327192|NCT05979038|Experimental|Metformin arm|In this arm patients will administrate metformin 500 mg three times a day together with the standard care of sepsis.
89327193|NCT05979038|No Intervention|Control Arm|In this arm patients will receive the standard care of sepsis only
89327194|NCT05978947|Experimental|Microfluidic Chip Method|The Sperm Separation Device - ZyMōt Multi 850µL device (ZyMōt Fertility, Inc) will be used. The microfluidic chamber will be used based on the manufacturer's instructions. 850 μL of the semen sample will be added to the inlet port of the device and 750 μL of fertilization media will be added to the outlet port. The device will then be incubated in 6% CO2 at 37°C. After 30 minutes, 500 μL of the prepared sample at the outlet port will be removed and pipetted into a labelled test tube. The final volume will be adjusted to 1mL for sperm counting.
89327195|NCT05978947|Active Comparator|Density Gradient Centrifugation Method|After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 500 μL. The final volume will be adjusted to 1mL for sperm counting.
89327196|NCT05978921|Experimental|Intervention group|"An additional strength training programme will be carried out for 12 weeks with 2 sessions per week. The sessions will last approximately 50 minutes and will be divided into 3 distinct parts: The first part will consist of a warm-up with a part of aerobic exercise that will last approximately 15 minutes. This will be followed by the main part of strength training with a circuit of 6 exercises (3 series x 12 repetitions) which will last approximately 25 minutes.~Finally, there will be a cool down phase with breathing exercises to allow people to recover."
89327197|NCT05978921|Sham Comparator|Control group|Subjects in the control group will continue with their normal life and carry out all the activities they have been doing previously.
89327198|NCT05978219|Experimental|Patients with MDD with insomnia|"Diagnosed MDD patients with insomnia problems will be approached and enrolled from NIMH, Dhaka.~Trial medications will be self-administered and treatment regimen will be continued until serious adverse effect develops or for 42 days, whichever occurs sooner.~Patients will receive mirtazapine at 15-30 mg/day (tablet form, once or twice daily, orally) from start. Depending on the response, doses might be increased at 2 weeks up to 45 mg/day for mirtazapine.~The clinical trial for each patient will last for 42 days. Clinical data will be collected at the beginning - Day 0 and then on Day 14 and Day 42 of the trial by face-to-face interview. A clinical follow up will be provided to trial patients on Day 28 of the trial over telephone. Research psychiatrists will also conduct follow up, medication and side effect monitoring and overall management of the patients."
89327199|NCT05977335||Orthostatic Intolerance Patients|
89327200|NCT05976984||Medicaid enrollees|Medicaid enrollees age15 years or older 2016-2020
88806649|NCT05900830|Experimental|play based program|this group will get the combined selected physical and occupational therapy program
88806650|NCT05900817|Experimental|antivet arm|Teeth treated will be isolated first then Vaseline will be placed on gingival sulcus before placing dental dam., patient will be seated at a 45 degree angle. Five drops of Antivet in the plastic mixing well that comes. Then ANTIVET solution will be applied over the tooth's surface using a well condensed cotton pellet (approximately a 3 mm diameter). When the cotton pellet is pigmented by the tooth's staining, it will be changed for a new one. This process may take about 1 to 5 minutes per tooth, It should take no longer than 15 minutes from the moment the solution contacts the tooth's surface
89327201|NCT05976399|Active Comparator|Manual lymph drainage group|The patients, who had filled out their pain diary before and submitted a consent form, were first evaluated before the treatment and then they lay on their back with their neck area open, paying attention to the protection of their privacy. Hand strokes, one of the basic techniques applied for treatment, were planned in accordance with the anatomy and physiology of the lymphatic system. MLD was applied to the lateral neck and face region in 5-7 repetitions so that the lymph collectors could give an adequate reaction to the application. The treatment was performed 2 days a week for 6 weeks, with a total of 12 sessions. Each session lasted 45 minutes.
88809657|NCT01273064|Experimental|CTS-1027 60 mg + ribavirin + peglyated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg.
89327202|NCT05976399|Active Comparator|Connective tissue massage group|"In participants in the CTM group, the treatment was started with the sacral region called the basic region and the whole back was treated. Pulls in the interscapular region were more intense than in other regions. After the interscapular region, the cervical, clavicular, and facial regions were also included in the treatment. The applications first started with the basic region and then progressed to the lower thoracic, scapular, and interscapular regions. Then, the cervical and clavicular regions were treated. In each region, the applications were performed three times on each of the right and left sides. While positioning the patients, we paid attention to their privacy and the temperature of the room where the treatment was carried out. A total of 12 sessions, which were conducted 2 days a week and took 6 weeks, were performed."
89327203|NCT05976204||ToF primary repair|Patients who underwent ToF primary repair from January 2020 until December 2022
89327204|NCT05975489|Experimental|Caffeine 3mg/kg intake|A dose of 3 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test.
89327205|NCT05975489|Experimental|Caffeine 6mg/kg intake|A dose of 6 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test.
89327206|NCT05975489|Placebo Comparator|Placebo intake|A dose of 3 mg/kg of placebo (Cellulose, Guinama, Valencia, Spain) was ingested before the beginning of each test.
89327207|NCT05970874||pregnant covid 19 patients|pregnant covid 19 patients
89327208|NCT05969691|Experimental|Validation of IDH1 mutations from the radiomics model|In this experiment, we validate the accuracy of radiomics model for IDH1 prediction by puncturing typical targets of gliomas, gene sequencing and quantitative gene analysis.
89327209|NCT05966675|Experimental|Conduction System Pacing|Patients who receive Conduction System Pacing in form of Left Bundle Branch Area Pacing or His Bundle Pacing.
89327210|NCT05966675|Active Comparator|Standard Pacing Method|Patients who receive currently standard pacing method with exact type of ventricular pacing depending upon left ventricular ejection fraction (LVEF): right ventricular pacing in case of LVEF >= 40% or biventricular pacing if LVEF is determined to be less than 40%, as per current ESC guidelines.
89327211|NCT05964231|Experimental|Heat-treated PS23|Lactobacillus paracasei PS23 heat-treated
89327212|NCT05964231|Placebo Comparator|Placebo|microcrystalline cellulose
89327213|NCT05963854||SC|Food Waste Tracking Survey and Curbside over 2 consecutive weeks
89327214|NCT05961579|Experimental|Barrier Renew Cleanser, Barrier Renew PM Moisturizer, and mineral sunscreen.|Enrolled subjects will all receive Barrier Renew Cleanser, Barrier Renew PM Moisturizer, and mineral sunscreen. Cleanser and Barrier Renew PM moisturizer will be used twice daily. Mineral sunscreen will be used every morning and throughout the day as indicated.
89327215|NCT05947539|Experimental|Kisoboka Mukwano Intervention (treatment)|A brief couples-based intervention using motivational interviewing, peer navigation, and behavioral economic approaches to target intimate partner violence, alcohol use, and HIV care engagement.
89327216|NCT05947539|Active Comparator|Screening & Referral (control)|Brief feedback on intimate partner violence and alcohol use (males), referrals for these conditions, and briefly discuss the importance of HIV care engagement and adherence.
89327217|NCT05947201|Experimental|AK104+cisplatin+albumin paclitaxel+fluorouracil|AK104 (10 mg/kg d1), in combination with cisplatin (20 mg/m2 on d1-3) and albumin paclitaxel (100mg/m2 on d1,d8), fluorouracil (600 mg/m2 on d1-5) Q3W, intravenously
89327218|NCT05946174|Experimental|Outpatient clinic/community participants receiving exercise sessions and meals (A1)|Outpatient clinic/community participants receiving intervention Set A (exercise sessions and meals over approximately 12 weeks)
89327219|NCT05946174|No Intervention|Outpatient clinic/community participants receiving control/usual care (A2)|Outpatient clinic/community participants receiving control/usual care
89327220|NCT05946174|Experimental|Step-down community hospital participants receiving exercise sessions and meals (B1)|Step-down community hospital participants receiving Intervention Set B (exercise sessions and meals over approximately 3 weeks)
89327221|NCT05946174|No Intervention|Step-down community hospital participants receiving control/usual care (B2)|Step-down community hospital participants receiving control/usual care
89327222|NCT05946174|Experimental|Acute hospital participants receiving meals (C1)|Acute hospital participants receiving Intervention Set C (meals over approximately 3 weeks)
89327223|NCT05946174|No Intervention|Acute hospital participants receiving control/usual care (C2)|Acute hospital participants receiving control/usual care
89327224|NCT05926310|Experimental|Exoskeleton assisted ambulation|"Phase 1: Five participants will undergo a training programme with the TWIICE Rise 0.0 two times a week for up to 6 weeks for a total of 6 sessions.~Phase 2: Ten participants will undergo a training programme with the TWIICE Rise 1.0 two times a week for up to 20 weeks for a total of 24 sessions."
88806651|NCT05900817|Active Comparator|opulsture arm|They were isolated with a rubber dam and then a fine-grit, water-cooled diamond bur was applied to the stained and white opaque enamel region for five to 10 seconds to enable penetration of the gel into the enamel. An approximately 1-mm- thick layer of 6.6% hydrochloric acid slurry with silicone carbide microparticles (Opalustre, Ultradent Products Inc, South Jordan, UT, USA) was applied to the affected tooth surfaces.
89327225|NCT05914389|Experimental|Standard chemotherapy control cohort|Patients with locally advanced colon cancer who met the inclusion criteria received two cycles of Capecitabine and Oxaliplatin （Capox） regimen chemotherapy and were evaluated by enhanced CT. Patients with more than 20% regression of maximum diameter of colon tumor in enhanced CT image will be randomly assigned to the Standard chemotherapy control cohort and continued with two more cycles of Capox chemotherapy. Then, these patients will receive curative surgery for colon cancer.
89327226|NCT05914389|Experimental|Enhancement regimen of combined Anti-PD-L1 monoclonal antibody|Patients with locally advanced colon cancer who met the inclusion criteria received two cycles of Capecitabine and Oxaliplatin （Capox） regimen chemotherapy and were evaluated by enhanced CT. Patients with more than 20% regression of maximum diameter of colon tumor in enhanced CT image will be randomly assigned to the Enhancement regimen of combined Anti-PD-L1 monoclonal antibody and continued with two more cycles of Capox chemotherapy along with the reduced dosage of Anti-PD-L1 monoclonal antibody. Then, these patients will receive curative surgery for colon cancer.
89327227|NCT05914389|Experimental|Enhancement regimen of combined lactobacillus and Anti-PD-L1 monoclonal antibody|Patients with locally advanced colon cancer who met the inclusion criteria received two cycles of Capecitabine and Oxaliplatin （Capox） regimen chemotherapy and were evaluated by enhanced CT. Patients with more than 20% regression of maximum diameter of colon tumor in enhanced CT image will be randomly assigned to the Enhancement regimen of combined lactobacillus and Anti-PD-L1 monoclonal antibody and continued with two more cycles of Capox chemotherapy along with the reduced dosage of Anti-PD-L1 monoclonal antibody and Clostridium butyricum. Then, these patients will receive curative surgery for colon cancer.
89327228|NCT05909267|Experimental|L-dopa/Carbidopa followed by placebo|Participants will receive first L-dopa/Carbidopa (100/25 mg), and then placebo.
89327229|NCT05909267|Experimental|Placebo followed by L-dopa/Carbidopa|Participants will receive first placebo, and then L-dopa/Carbidopa (100/25 mg).
89327230|NCT05906589|Experimental|Inulin|The participant will be asked to administer the provided doses of 8g inulin twice daily.
89327231|NCT05906589|Experimental|Inulin + psyllium|The participant will be asked to administer the provided doses of 8g inulin + 3.5g psyllium twice daily.
89327232|NCT05906589|Placebo Comparator|Maltodextrin|The participant will be asked to administer the provided doses of 8g maltodextrin twice daily.
89327233|NCT05901480|Experimental|Treatment Arm|Patients with OTOF mutation-related deafness
89327234|NCT05890573|Experimental|Bailing capsule group|Bailing capsule group:6 Bailing capsules,po, tid,12 weeks.
89327235|NCT05890573|No Intervention|Blank group|Blank group:no anti-fibrosis treatment is given.
89327236|NCT05886140|Experimental|Carrilizumab with albumin-binding paclitaxel|All enrolled patients received carrilizumab combined with albumin-binding paclitaxel.
89327237|NCT05884710|Experimental|Exercise Group|Foot core exercises consist of 4 movements; short foot exercise, towel curls, toe spread and squeeze, balance board training
89327238|NCT05884710|Active Comparator|Control Group|Conventional Physiotherapy Program
89327239|NCT05877677|Placebo Comparator|Placebo drink|consume 1 bottle per day
89327240|NCT05877677|Experimental|Polygonatum kingianum extract drink|consume 1 bottle per day
89327241|NCT05874258|Experimental|Real-PL + Real-NIBS (tDCS)|Participant will receive 30 training sessions with real PL and real NIBS (tDCS): 3-4 sessions per week, about 1 hour per session
89327242|NCT05874258|Experimental|Real-PL + Sham-NIBS (tDCS)|Participant will receive 30 training sessions with real PL and sham NIBS (tDCS): 3-4 sessions per week, about 1 hour per session
89327243|NCT05874258|Placebo Comparator|Placebo-PL + Sham-NIBS (tDCS)|Participant will receive 30 training sessions with placebo PL and sham NIBS (tDCS): 3-4 sessions per week , about 1 hour per session
89327244|NCT05870319|Experimental|SKB264 by IV infusion on Days 1 and 15 of each 4-week cycle;|
89327245|NCT05870319|Active Comparator|pemetrexed+ carboplatin or on Day 1 of each 3-week cycle, with 4 cycles chemo|
89327246|NCT05869422|Placebo Comparator|Placebo|placebo tablet containing no iron
89327247|NCT05869422|Experimental|Low Dose Iron|low-dose tablet containing 6mg of iron
89327248|NCT05863364|No Intervention|control group|Group A: Patients in the control group were administered only conventional therapy
89327249|NCT05863364|Experimental|the low-dose rifaximin treatment group|Group B
89327250|NCT05863364|Experimental|the conventional dose rifaximin treatment group|Group C
89327251|NCT05859321|Experimental|virtual reality|virtual reality exercises will be administered along with routine physiotherapy
89327252|NCT05859321|Active Comparator|Routine Physiotherapy (treatment as usual)|transcutaneous electrical nerve stimulation,Heat Therapy, Stretching and strengthening exercises with Cycling will be administered
89327253|NCT05853679|Experimental|Lumoral Treatment (Study group)|"A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. The study group shall receive the Lumoral treatment -device, Lumorinse -tablets and instructions for their use.~All subjects shall receive new electric toothbrushes, standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss."
89327254|NCT05853679|Other|Control group|A complete clinical intraoral examination shall be performed for all subjects. Same demographic and clinical data will be obtained from subjects in both arms. All subjects shall receive new electric toothbrushes, standard oral hygiene instructions for the use of an electric toothbrush, interdental brush, and dental floss.
89327255|NCT05833438|Experimental|VEN+AZA-5|Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
89327256|NCT05833386|Active Comparator|Silodosin group|all patients will receive oral silodosin 8 mg orally for 0ne week prior to surgery
89327257|NCT05833386|Active Comparator|Non premedicated group|None of this group will receive alpha blocker prior to surgery
89327258|NCT05824533|Experimental|TKA with onlay patella button|Total knee arthroplasty (TKA) with a patella placed with the use of the CORI based on pre-operative 4DCT images of the knee.
89327259|NCT05824533|Active Comparator|TKA without onlay patella button|Total knee arthroplasty (TKA) placed with the use of the CORI based on pre-operative 4DCT images of the knee.
89327260|NCT05816824|Experimental|Symptom Monitoring Telerehabilitation (Intervention) Group|The intervention group will be followed up with the same protocol plus symptom monitoring software called PhysioAnalyst which provides visual feedback. The video exercises given to the participants will include Williams, McKenzie exercises and core strengthening exercises.
89327261|NCT05816824|Active Comparator|Telerehabilitation (Control) Group|The control group will receive video exercise-based rehabilitation protocol with telerehabilitation without visual feedback. The video exercises given to the participants will include Williams, McKenzie exercises and core strengthening exercises.
89327262|NCT05816252|Experimental|Cohort 1 EGFR wild-type and ALK fusion genes negative (PD-L1 TPS ≥ 1 %)|SKB264 (Dose Level 1) + Pembrolizumab
89327263|NCT05816252|Experimental|Cohort 2 EGFR wild-type and ALK fusion genes negative (PD-L1 TPS ≥ 1 %)|SKB264 (Dose Level 2) + Pembrolizumab
89327264|NCT05816252|Experimental|Cohort 3 EGFR wild-type and ALK fusion genes negative|SKB264 (Dose Level 3) + Pembrolizumab + Carboplatin
89327265|NCT05816252|Experimental|Cohort 4 EGFR wild-type and ALK fusion genes negative|SKB264 (Dose Level 1) + Pembrolizumab + Carboplatin
89327266|NCT05816252|Experimental|Cohort 5 EGFR sensitizing mutation|SKB264 (Dose Level 3) + Carboplatin
89327267|NCT05816252|Experimental|Cohort 6 EGFR sensitizing mutation|SKB264 (Dose Level 1) + Carboplatin
89327268|NCT05816252|Experimental|Cohort 7 EGFR 19del or L858R Mutation|SKB264 (Dose Level 1) + Osimertinib
89327269|NCT05816252|Experimental|Cohort 8 EGFR 19del or L858R Mutation|SKB264 (Dose Level 2) + Osimertinib
89327270|NCT05815069|Experimental|[18F]AlF-NOTA-pentixather|No special preparation such as fasting and fasting is required before the examination. The radiotracer 18F-AlF-NOTA-pentiaxther PET/CT (dose 4.81 MBq/Kg body weight) was injected intravenously according to the patient's body weight, and the drug was synthesized by the Department of Nuclear Medicine of Sichuan Provincial People's Hospital immediately before the examination. Before the examination, patients were instructed to urinate as many times as possible to reduce the possible influence of the residual radiotracer in the renal pelvis and calyces on the image quality. The whole-body PET/CT examination from the top of the skull to the root of the thigh was performed using a PET/CT examination instrument (Siemens Biograph mCT Flow) 50-60 minutes after the injection of radiopharmaceuticals. Flow Motion flow scanning technology with a matrix of 128x128 and a layer thickness of 3 mm was used. all PET images were reconstructed iteratively.
89327271|NCT05812794|Experimental|Transcranial Direct Current Stimulation (tDCS)|
89327272|NCT05801172|Active Comparator|A (NSAID)|ketoprofen 100 mg intravenously 30 min. pre-office hysteroscopy
89327273|NCT05801172|Active Comparator|B (A+infiltration anesthesia)|ketoprofen 100 mg intravenously 30 min. pre-office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure
89327274|NCT05801172|Active Comparator|C (A+paracervical block)|ketoprofen 100 mg intravenously 30 min. pre-office hysteroscopy 20 ml 1% lidocaine in pericervical administration at the start of the procedure
89327275|NCT05795686|Other|"Patients of program AVanCer"|"Patients included in program AVanCer"
89327276|NCT05770479|Experimental|ME-CCT Booster Training|3-4 Sessions of ME-CCT Booster Training
89327277|NCT05770479|Other|Treatment as Usual|Treatment as Usual
89327278|NCT05765929|Experimental|Non-operative treatment|Non-operative treatment based on weightbearing radiographs
89327279|NCT05758818|Placebo Comparator|A = Placebo (negative control)|"Dosage Form: Capsules~Route of Administration: Oral~The placebo and milademetan will be identical in appearance."
89327280|NCT05758818|Active Comparator|B = Moxifloxacin (positive control)|"Dosage Form: Tablets~Route of Administration: Oral~Dosage: 400 mg"
89327281|NCT05758818|Experimental|C = Milademetan|"Drug: Milademetan~Dosage:~Part 1: 300, 330, 360 mg. Part 2: 260 mg single oral dose or higher, as determined in Part 1."
89327282|NCT05757648|Experimental|Buffered Anesthetic|Patients will be randomized to one side of the mouth getting the buffered anesthetic and the other side of the mouth to the non-buffered anesthetic.
89327283|NCT05757648|Active Comparator|Non-buffered Anesthetic|Patients will be randomized to one side of the mouth getting the buffered anesthetic and the other side of the mouth to the non-buffered anesthetic.
89327284|NCT05753254|No Intervention|Baseline session|Baseline measurements will be performed in the same schedule as measurements in the three other arms. In the baseline session, participants are in classroom before starting any firefighting exercise
89327285|NCT05753254|Experimental|Firefighting exercises without fire|Firefighting equivalent work, with exercises performed in a clean environment, without fire (no ambient temperature, soot or smoke). This type of exercise usually precedes or complements the training under real fire conditions.
89327286|NCT05753254|Experimental|Firefighting under wood fire|Firefighting under wood fire, with exposure to ambient heat, smoke and soot. This is the most common training scenario used in the training centres. The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models
89327287|NCT05753254|Experimental|Firefighting under gas fire|Firefighting under gas fire, with exposure to ambient heat, and expectably less smoke and soot than with wood fire. These conditions are used in some Danish training centres, with logistical advantages (ease of turning or putting out the fire and managing the fire fuel) and unknown effect relating to exposure prevention (smoke and soot). The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models
89327288|NCT05748613|Experimental|Computerized Anxiety Sensitivity Treatment|"CAST is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated anxiety sensitivity (AS), particularly the amplification of cognitive stress symptoms including perceived confusion and memory problems. CAST is a fully computerized, 1-hour intervention containing video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension, introduction and practice with interoceptive exposures). Procedures draw heavily on standard CBT techniques; AS, a core vulnerability for anxiety and depression is targeted using these procedures. In CAST, participants are informed that the primary purpose of the presentation is to highlight healthier, more productive, and effective ways of dealing with stress. Through participation in the intervention, people learn adaptive long-term strategies for tolerating, coping with, and effectively reducing distress and negative emotions."
89327289|NCT05748613|Placebo Comparator|Health Education Control|HEC is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, exercise, stress management as well as other healthy lifestyle tips. To match the interactive components in the CAST condition, behavior tracking and goal-setting are included in HEC. The HEC protocol has been used in prior studies as a control condition for CAST to account for intervention modality and time. HEC is perceived positively, with high rates of acceptability. Importantly, HEC is inert with respect to the proposed mechanism of action (AS).
89327290|NCT05744544||External Oblique Intercostal Block Group|Sensory Assessment and Regression Rate will be performed on the anterolateral abdominal wall after EOIB. (external oblique intercostal block)
89327291|NCT05744544||modified-TAPA block|Sensory Assessment and Regression Rate will be performed on the anterolateral abdominal wall after m-Tapa. (modified- thoracoabdominal nerves block through perichondrial approach)
89327292|NCT05730231|Experimental|Early time-restricted eating with calorie restriction|Participants will follow calorie restriction with early day time-restricted eating protocol with three planned meals from 8:00 AM to 4:00 PM.
89327293|NCT05730231|Experimental|Mid-day time-restricted eating with calorie restriction|Participants will follow calorie restriction with mid-day time-restricted eating protocol with three planned meals from 1:00 PM to 9:00 PM.
89327294|NCT05730231|Experimental|Daily calorie restriction|Participants will follow daily calorie restriction protocol with three planned meals from 8:00 AM to 9:00 PM.
89327295|NCT05728827|Experimental|Anti-gravity treadmill + Blood Flow Restriction training|
89327296|NCT05728827|Active Comparator|Anti-gravity treadmill|
89327297|NCT05712824|Experimental|V-LAP™ System|Heart failure subjects - Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home and will be trained on the use of the device for self-management.
89327298|NCT05704946|Experimental|experiment group|The patients will be given a standard brand of lavender oil by the researcher, and they will be informed about how to use it (they should drop 2 drops of lavender oil on the right side of their pillow and 2 drops on the left side of their pillow every evening for a month after discharge).
89327299|NCT05704946|No Intervention|control group|Standard care will be applied.
89327300|NCT05674877|Placebo Comparator|Opioid-based group (OB)|".Patients in the opioid-based group will receive placebo boluses and infusions of saline.~The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows:~Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg"
89327301|NCT05674877|Active Comparator|Opioid sparing group (OS)|"Patients in the Opioid Sparing group will receive a loading dose of dexmedetomidine (1µg/kg over 10 minutes). This will be followed by a fixed continuous maintenance infusion of 0.5µg/kg/hour. Furthermore, a single induction analgesic dose of 0.5 mg/kg ketamine will be given to all patients in the OS group. This will be followed by 0.25 mg/kg/h continuous maintenance infusion. Dexmedetomidine and ketamine infusions will be stopped 30 minutes prior to the conclusion of surgery.~The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows:~Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg in the two study groups."
89327302|NCT05673694|Experimental|EG017|"70 subjects: Part Ia 10 subjects: A total of 3 dose groups of 6 mg/day, 18 mg/day, 24 mg/day are planned. Once a day, each treatment cycle was administered for 28 days.~Part Ib 60 subjects: A total of 2 dose groups of 18 mg/day, 24 or 12mg/day are planned. Once a day, each treatment cycle was administered for 28 days."
89327303|NCT05670288||Spinal Cord Injury|Patients who have had an acute spinal cord injury in the past 72 hours
89327304|NCT05662917||Palliative care patients|"Palliative care patients~Suffering from a serious and progressive illness (whatever it is)~Hospitalized in a palliative care unit or followed at home by the hospital's mobile palliative care team"
89327305|NCT05660161|Experimental|Nanofracture|"The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care."
89327306|NCT05643391|Experimental|Single arm|"The treatment will include 1 preparatory angiography followed by treatment at a maximum 2 weeks interval. Dosimetry MRI will be performed just before and immediately after treatment. SPECT CT will be performed three days after treatment.~The activity of 166Ho that must be administered to a patient will depend on the tumor perfusion and absorbed dose linked to this activity.Q-SuiteTM 2.0 will be used, more precisely a dosimetry software to perform an optimal compartmental predictive dosimetry:~- minimum 150 Gy to the tumor, maximum 60 Gy to non-tumoral liver, maximum 30 Gy lung shunt fraction."
89327307|NCT05616299|Experimental|BrightPoint Epidural|Subjects will receive an epidural using the BrightPoint device concurrent with usual LOR technique using the same epidural needle, sterile saline, syringe, etc.
89327308|NCT05616299|No Intervention|Normal Epidural|Subjects will have an epidural placed in usual manner with LOR technique using the same epidural needle, sterile saline, syringe etc. but without use of the BrightPoint device.
89327309|NCT05593536|Experimental|Group 1 (biological nurturing)|In biological feeding, the mother takes a semi-sitting position and the baby lies face down on the mother's breast and belly, with every part of her body in contact with the mother.
89327310|NCT05593536|Experimental|Group 2 (classic breastfeeding)|In classical breastfeeding, the mother holds her baby in her arms and breastfeeds while she is in a sitting position.
89327311|NCT05593536|No Intervention|Group 3 (control)|The mother will breastfeed her baby as she wishes.
89327312|NCT05588414|Other|Indocyanine Green fluorescence method as first step|Systematic double identification of the sentinel lymph node, by sequential use of ICG fluorescence technique as first step followed by isotopic technique.
89327313|NCT06098716|No Intervention|Education|The Education condition package will consist of Canada's PA guidelines, information about the benefits of child and adult PA, and a breakdown of ways for the parent to help their child achieve this PA.
89327314|NCT06098716|Experimental|Self Regulation|"The SR condition will receive all of the same education material as the standard condition in addition to skill training content (how to plan for family PA) based on our prior family trials. Families will be instructed to plan for when, where, how, and what PA will be performed, and to create back-up plans commensurate with the creation of action and coping planning"
89523476|NCT03386461|Placebo Comparator|Exercise + placebo|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly. Subjects will take 5 capsules od placebo per day (provided by Calanus oil company, containing sunflower oil).
89327315|NCT06098716|Experimental|Identity & Family Functioning|The ID condition will receive the same content as the other groups but with two additional virtual workshop sessions. Session 1 involves only the parent(s) and focuses on parental support identity. The content is based on the behaviour change principles of self-identity theory that should lead to increases in self-identity.97-100 This session's activities include: 1) bringing awareness to the concept of identity and being a role model, 2) an activity on finding the meaning and value of parental support of child PA, 3) an activity on setting prioritization rules around parental support for child PA in comparison to other parenting responsibilities and values (brainstormed), 4) developing an affirmation for parental support self-talk, and 5) planning ways to visually demonstrate the parental support identity for self-categorization (e.g., on social media, pictures in frames101)
89327316|NCT06098664||Low score group (DNN-score = 0 - 10%)|The inclusions will be stratified to the deep neural network (DNN) score. The study will enrol 20 patients in each group.
89327317|NCT06098664||Medium score group (DNN-score = 10 - 50%)|The inclusions will be stratified to the deep neural network (DNN) score. The study will enrol 20 patients in each group.
89327318|NCT06098664||High score group (DNN-score = 50 - 100%)|The inclusions will be stratified to the deep neural network (DNN) score. The study will enrol 20 patients in each group.
89327319|NCT06098651|Experimental|DCR-STAT3|DCR-STAT3
89327320|NCT06098638|Active Comparator|control group|Group (A) included 27 overweight breastfeeding woman who received nutritional recommendation and faradic current stimulation on the abdominal surface for 12 weeks, while group
89327321|NCT06098638|Experimental|exercise group|Group (B) 27 overweight breastfeeding women, who received the same nutritional recommendation and faradic current stimulation on the abdominal surface plus exercise training (aerobic + resisted) for 12 weeks.
89327322|NCT06098625|Experimental|Empagliflozin|Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
89327323|NCT06098625|Active Comparator|Linagliptin|Linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
89327324|NCT06098599|Experimental|Doxorubicin hydrochloride liposome injection(LY01612)|20mg/10mL, 50mg/m2, intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial.
89327325|NCT06098599|Active Comparator|Doxorubicin hydrochloride liposome injection(CAELYX®)|20mg/10mL, 50mg/m2, intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial
89327326|NCT06098534|Experimental|"Hospi'Senior group"|Patients admitted to the Hospi'Senior room benefit from the innovative technologies available in this room. Patients benefit from standard care throughout their hospital stay.
89327327|NCT06098534|Experimental|"Conventional room group"|Patients admitted to a conventional room receive the standard care throughout their hospital stay.
89327328|NCT06098495||infertile women (unexplained, tubal, mild male factor)|women belonging to couples selected for homologous IVF due to an unexplained, tubal or mild male factor
89327329|NCT06098495||fertile women|women without any infertility history who are attempting to conceive naturally
89327330|NCT06098495||infertile women (ovarian factor)|women selected for homologous IVF for different reason og chohort 1
89327331|NCT06098495||recurrent pregnancy loss|women affected by idiopathic recurrent pregnancy loss
89327332|NCT06098352|Experimental|PEBL Continuous Performance Task|Participants will take the PEBL Continuous Performance Task, a 14 minute attention test requiring participants to press the space bar when certain letters are shown on the screen.
89327333|NCT06098326|Experimental|CyFluATG|Patients who receive with cyclophosphamide, fludarabine, and antithymocyte globulin (CyFluATG) for allogeneic hematopoietic cell transplantation
89327334|NCT06098313|Experimental|PTCy|Patients who receive post-transplantation cyclophosphamide
89327335|NCT06098287|Active Comparator|Intervention (Exhaust-only ventilation)|A study group with a continuous exhaust-only ventilation system
89327336|NCT06098287|Active Comparator|Intervention (Central-fan-integrated-supply ventilation)|A study group with an intermittent central-fan-integrated-supply ventilation system and air filtration upgrades
89327337|NCT06098287|Active Comparator|Intervention (Balanced energy recovery ventilation)|A study group with a continuous balanced energy recovery ventilation system and air filtration upgrades
89327338|NCT06098261|Experimental|Test (T)-Reference (R)|In this trial, 40 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group A: Test (T)-Reference (R), The washout period (dosing interval) between doses will be at least 7 days. After fasting for at least 10 hours.
89327339|NCT06098261|Experimental|Reference (R)-Test (T)|In this trial, 40 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group B: Reference (R)-Test (T), The washout period (dosing interval) between doses will be at least 7 days. After fasting for at least 10 hours.
89327340|NCT06098248|Experimental|Patients already scheduled for brain tumor surgery|The biological specimens (hereafter referred to as 'tissue') and/or images to be used in this trial must be collected from patients who are male or female and ≥ 19 years of age, and the patient is suspected to have a brain tumor and has been scheduled for neurosurgery with a potential tumor resection. There will be up to three (3) tissue sample types assessed for each participant: 1- center-of-tumor, 2- normal tissue (collected from inevitable standard resection), and 3- margin tissue. Tissues will be removed as part of the standard neurosurgical procedure. Resected tissue will be cleaned, stained, and imaged ex-vivo using cCeLL. Image recordings of sample tissue using cCeLL - Ex vivo are taken and the obtained data is stored.
89327341|NCT06098222|Experimental|Slow breathing exercise training|Slow breathing exercise training will be given to patients in the experimental group. After discharge, patients will be asked to do slow breathing exercises twice a day for 10 minutes every day for eight weeks. Daily and/or weekly online, weekday, weekend, daytime, evening, video phone calls will be made with patients who are discharged at the end of the training to practice the slow breathing exercise every day according to the patients' demand. It will be provided that breathing exercises will be performed together with a video call in the form of a conference call. Patients will be asked to take measurements a total of two days a week, one day on weekdays and one day on weekends, in the morning, after a light breakfast, at least five minutes of rest and breathing exercises. Pulse and blood pressure measurements at home on weekdays will be asked to be measured Decouply from breathing exercise, and on weekends before and after breathing exercise.
89327342|NCT06098222|No Intervention|Control group|In the control group, patients will be shown and told self-blood pressure and pulse measurement at home at discharge. A reminder text message will be sent to the mobile phones of patients for blood pressure and pulse measurement at home. The control group will also be asked to perform their own blood pressure and pulse monitoring at home and record a Self-Monitoring Form (for the Control group).During home follow-up, patients will be sent reminder text messages to their mobile phones two days a week. According to the request of patients, daily and/or weekly online, weekdays, weekends, daytime, evening, phone calls will be made to measure pulse and blood pressure values two days a week.
89327343|NCT06098183|Experimental|Whey protein isolate, then Non-caloric placebo|Participants will randomly consume a whey protein isolate (Dymatize ISO-100) mixed with 6 oz of water prior to exercise. After a minimum of 48 hrs they will consume a non-caloric placebo (6 oz of water) prior to exercise.
89327344|NCT06098183|Placebo Comparator|Non-caloric placebo, then Whey protein isolate|Participants will randomly consume a non-caloric placebo (6 oz of water) prior to exercise. After a minimum of 48 hrs they will consume a whey protein isolate (Dymatize ISO-100) mixed with 6 oz of water prior to exercise.
89327345|NCT06098131|Experimental|Sliding Technique Group|When the participants achieved the final sympathetic slump position , the therapist will move the foot of the participant into full plantar flexion as they moved their head into maximal flexion.
89327346|NCT06098131|Experimental|Tension Technique Group|When the participants achieved the final sympathetic slump position , the therapist will move the foot of the participant into full plantar flexion as they moved their head into maximal extension.
89327347|NCT06098131|No Intervention|Control Group|In this group the participants will be requested to position themselves on the plinth in supine line position. All participants in this group will not receive any intervention and they will be instructed to remain in this position for 20 minutes.
89327348|NCT06098092|Experimental|Long-term Blood pressure and Heart rate monitoring with reference digital tonometer and smartwatch|Measurement of a non-invasive Blood pressure and Heart rate using a reference medical grade digital tonometer Omron and a smartwatch Samsung Galaxy Watch during 20-40 days every morning and evening.
89327349|NCT06098066||control|
89327350|NCT06098066||ECIC bypass|
89327351|NCT06098066||CEA|
89327352|NCT06098066||CAS|
89327353|NCT06098053|Experimental|Group A|Muscle energy technique was given to this group
89327354|NCT06098053|Active Comparator|Group B|Muscle energy technique along with interferential therapy was given to this group
89327355|NCT06098040|Experimental|group 2 - FGM continuous|Patients will be asked to wear the sensor FreeStyle Libre2 continuously
89327356|NCT06098040|Experimental|group 3 - FGM intermittent|will be asked to wear the sensor FreeStyle Libre2 intermittently
89327357|NCT06098040|Active Comparator|group 1- SMBG|Patients will be asked to test capillary blood glucose as recommended by subjects' usual provider
89327358|NCT06098027|Experimental|[14C]CS0159|Single oral dose of 4mg [14C]CS0159
89327359|NCT06098014|Active Comparator|Thalidomide group|Thalidomide group
89327360|NCT06098014|Placebo Comparator|Placebo group|Placebo group
89327361|NCT06098001|Active Comparator|Low dose fiber|Dose esacalation design
89327362|NCT06098001|Active Comparator|High dose of fiber|Dose escalation design which is one arm with low and followed by high dose
89327363|NCT06097975|Experimental|Experimental arm|
89327364|NCT06097936||HPV Patients|
89327365|NCT06097923|Experimental|Active fluid management with BIA monitoring|For assessment of fluid status, a commercial portable BIA device (InBody M20®, InBody Corp., Seoul, Korea) was measured. Baseline BIA data were collected at the time of ICU admission, and BIA measurements were performed daily for 3days for all participants. The participants in active fluid management with BIA monitoring arm received fluid supplementation targeting specific range of ECW ratio by BIA (0.390-0.406). If a patient with dehydrated status indicated by the ECW ratio was less than 0.390, a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte). If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered. Changes in the ECW ratio were measured at one hour after initial intervention for fluid adjustment, and the investigators determined whether additional intervention was needed according to results of changes. These processes continued until the ECW ratio was within the normal range (0.390-0.406).
89327366|NCT06097923|Experimental|Conventional fluid management without BIA monitoring|"For assessment of fluid status, a commercial portable BIA device with 5-kilohertz, 50-kilohertz, and 250-kilohertz alternating current (InBody M20®, InBody Corp., Seoul, Korea) was measured. Baseline BIA data were collected at the time of ICU admission. Thereafter, BIA measurements were performed daily for 3 days for all participants.~The participants in conventional fluid management without BIA monitoring arm underwent conventional fluid management without specific targets of ECW ratio by BIA."
89327367|NCT06097884|Experimental|Main study intervention- Salt substitute|Replacing usual salt with salt substitute in school meals
89327368|NCT06097884|Placebo Comparator|Main study control- Usual salt|Using usual salt in school meals
89327369|NCT06097884|Experimental|Ancillary study intervention- Meal tray|Replacing bowls with trays in school cafeteria
89327370|NCT06097884|Placebo Comparator|Ancillary study control- Bowl|Using bowls in school cafeteria
89327371|NCT06097845|Experimental|Transcranial Ultrasound|Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices currently used in routine clinical practice.
89327372|NCT06097832|Experimental|NXC-201 CAR-T|"The dose escalation phase will include the following doses:~Cohort 1 - 450×10^6 CAR-positive (CAR+) T cells (3 patients) Cohort 2 - 800×10^6 CAR-positive (CAR+) T cells (3 patients) The dose expansion phase will include a dose of 800×10^6 CAR-positive (CAR+) T cells (3 or more patients)"
89327373|NCT06097806||Low-flow anesthesia group|In this group, ventilation parameters is adjusted to have fresh gas flow/minute ventilation ratio below 0.5
89327374|NCT06097806||High-flow anesthesia group|In this group, ventilation parameters is adjusted to have fresh gas flow/minute ventilation ratio above 1.0
89327375|NCT06097780|Placebo Comparator|Placebo|Arm 1: Nine intravenous placebo administrations in twelve months.
89327376|NCT06097780|Experimental|Intravenous NestaCell® administrations|Arm 2: Nine intravenous NestaCell® administrations in twelve months.
89327377|NCT06097767|Other|Control group|It includes preterm infants with respiratory distress syndrome aged 32 weeks-35 weeks receives regular intervention for RDS
89327378|NCT06097767|Active Comparator|Caffeine-treated group|It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
89327379|NCT06097754|Experimental|Ketone group|Ketone esters will be provided
89327380|NCT06097754|Placebo Comparator|Control|Ketone placebo will be provided
89327381|NCT06097741|Other|MRI sequence|patients receive an MRI
89327382|NCT06097715|Active Comparator|patient group|patients which previosly diagnosed with chronic liver diseases or presented with manifestations of chronic liver diseases
89327383|NCT06097715|Active Comparator|control group|children in the same age and sex of the patient group and presented to Sohag Universty Hospital due to any complaint rather than hepatic and gastrointestinal disease.
89327384|NCT06097637|Experimental|underwater endoscopic mucosal resection|underwater endoscopic mucosal resection for resection of big pedunculated colorectal polyps
89327385|NCT06097637|Active Comparator|hot snare polypectomy|hot snare polypectomy for resection of big pedunculated colorectal polyps
89327386|NCT06097624|Experimental|Exercise|The exercises will be applied three times a week for four weeks. Each exercise is going to start with 10 repetitions and 1 set in the first session, and the exercises will be revised at the beginning of each week. Resistance will gradually be increased, and after four weeks, 3 sets of 10 repetitions will be targeted.
89327387|NCT06097624|No Intervention|Control|After a waiting period of four weeks, the participants will be contacted for reevaluation, and at the end of the assessment, an individual home exercise program will be created for them.
89327388|NCT06097585||SGLT2I Group|the case group that will receive SGLT2I in the treatment
89327389|NCT06097585||non - SGLT2I Group|the control group that will not receive SGLT2I in the treatment
89327390|NCT06097572|Experimental|Peanut|Participants with possible allergy to peanut
89327391|NCT06097572|Experimental|Cow's Milk|Participants with possible allergy to cow's milk
89327392|NCT06097546||Breast cancer patients|Newly diagnosed patients with breast cancer
89327393|NCT06097546||Benign lesions|Diagnosed patients with benign breast lesions
89327394|NCT06097546||Control|apparently healthy individuals with matched age and sex
89327395|NCT06097533|Experimental|Cannabisextrakt Avextra 10/10 Lösung|Solution with tetrahydrocannabinol and cannabidiol
89327396|NCT06097533|Placebo Comparator|Placebo|Sesame oil, Ph.Eur. Linseed oil, Ph.Eur
89327397|NCT06097429||study group|COVID-19 confirmed cases with positive PCR test in the first week of diagnosis
89327398|NCT06097429||control group|healthy volunteers, persons with no history nor symptoms suggestive of COVID-19 with negative COVID -19 PCR test and no CT Chest changes suggestive of COVID-19 infection.
89327399|NCT06097377||ToF|
89327400|NCT06097377||Controls|
89327401|NCT06097338||MAFLD patients|MAFLD patients undergoing weight loss surgery
89327402|NCT06097338||healthy volunteers|healthy volunteers
89327403|NCT06097286|Active Comparator|external oblique intercostal plane block|
89327404|NCT06097286|Active Comparator|erector spinae plane block|
89327405|NCT06097286|No Intervention|control group|
89327409|NCT06097221|Experimental|Advance-group|The group will recieve 8 hours of psychotherapy with focus on advancing sleep timing, besides their treatment as usual.
89327410|NCT06097221|Active Comparator|Control-group|Treatment as usual at the outpaitent unit.
89327411|NCT06097208||Intervention Group|Children who attended kindergartens actively delivering a community-based health promotion and obesity prevention intervention
89327412|NCT06097208||No-intervention Group|Children who attended usual care kindergartens
89327413|NCT06097182|Experimental|Postbiotic, colonic delivery|n=25, 250mg postbiotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)
89327414|NCT06097182|Active Comparator|Postbiotic, regular administration|n=25, 250mg postbiotic once daily in a regular uncoated vegan gelatine capsule
89327415|NCT06097182|Placebo Comparator|Placebo|n=25, 250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
89327416|NCT06097143|Experimental|Flowable Giomer|Patients with conservative carious class I occlusal cavities will be treated with Shofu™ Beautifil Injectable X, Shofu Dental Corp., Japan flowable composite Novel bio-active flowable resin containing nano S-PRG (Surface Pre-Reacted Glass ionomer).
89327417|NCT06097143|Experimental|Nano-filled Flowable Composite with S-PRG barrier coat|Patients with conservative carious class I occlusal cavities will be treated with Filtek™ Z350 XT 3M ESPE, USA Flowable composite: Conventional resin-based nano-filled flowable composite which will then be coated with Shofu™ PRG Barrier Coat, Shofu Dental Corp., Japan.
89327418|NCT06097143|Active Comparator|Nano-Filled Flowable Composite|Patients with conservative carious class I occlusal cavities will be treated with Filtek™ Z350 XT 3M ESPE, USA Flowable composite: Conventional resin-based nano-filled flowable composite.
89327419|NCT06097117||one group undergoes multiplex PCR|treatment will be started according targeted antibiotics
89327420|NCT06097117||the other group undergoes simple culture and sensitivity|empirical antibiotics will be started until results appear and according results ,treatment will be completed or shifted to another treatment or be narrowed ,later on detect outcome of both groups.
89327421|NCT06097091|Active Comparator|Self-Management Education|Participants in the control group will receive an SME via weekly video calls over 6 weeks.
89327422|NCT06097091|Experimental|Pain Neuroscience Education|Participants in the experimental group will receive a 6-week PNE program.
89327423|NCT06097065||Non pregnant people with prediabetes or diabetes|Non pregnancy meeting the diagnosis of prediabetes or diabetes.
89327424|NCT06097065||Non pregnant people with normal glucose tolerance|Non pregnant population with normal Oral Glucose Tolerance Test results.
89327425|NCT06097065||pregnant people with gestational diabetes mellitus|Pregnant people who meet the diagnosis of gestational diabetes.
89327426|NCT06097065||pregnant people with normal glucose tolerance|Pregnant people with normal Oral Glucose Tolerance Test results.
89327427|NCT06097013||Prolonged disorders of consciousness|Admission criteria for patients with prolonged disorders of consciousness Inclusion Criteria
89327428|NCT06097013||Acute disorders of consciousness|Admission criteria for patients with acute disorders of consciousness Inclusion Criteria
89327429|NCT06097000|Experimental|Powered Exoskeleton Group|Rehabilitation exercises with powered exoskeletons
89327430|NCT06097000|No Intervention|Traditional Group|Rehabilitation exercises without the use of powered exoskeletons
89327431|NCT06096987|Experimental|Electronic medical record portal video group|Assigned to receive videos regarding electronic medical record portals and information shared in electronic medical record portals
89327432|NCT06096987|Active Comparator|General adolescent health video group|Assigned to receive videos regarding general adolescent health issues
89327433|NCT06096974|Experimental|Dose Escalation and Expansion|Dose escalation of YL-17231 to determine maximum tolerated dose.Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of YL-17231 to recommend Phase 2 regimens
89327434|NCT06096961|Experimental|Mothers using baby scent|Mothers in the experimental group will be given baby clothes that their babies will wear for 12 hours and will be asked to smell these clothes during the milking process. The work will continue for four days. Saliva cortisol test and mother-infant attachment scale will be applied on the first day and the last day.
89327435|NCT06096961|No Intervention|Mothers who do not use baby scent|Mothers in the control group will express milk without any intervention. The works will continue for 4 days. Saliva cortisol test and mother-baby attachment scale will be applied on the first day and the last day.
89327436|NCT06096948|Experimental|NEXPOWDER-ENDOHS|Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
89327437|NCT06096909|Experimental|experimental group|intensive lipid lowering therapy
89327438|NCT06096909|Active Comparator|control group|conventional lipid lowering therapy
89327439|NCT06096896||single-group with MWA|334 patients with confirmed or suspected eHCC as indicated by EOB-MRI were to be included in this study in a population with high or extremely high-risk of hepatocellular carcinoma in chronic liver disease. Then Microwave ablation (MWA) was performed under EOB-MRI guidance in patients with confirmed or suspected eHCC.
89327440|NCT06096831||Post-Stroke patients at chronic phase living in the community|The data will be extracted from medical records of all people who are at least one year after a stroke, live in the community and are insured by Health maintenence Organization (HMO).In the first part we expect to extract data of approximately 40,000 patients . In the second part, a sub sample of 240 patients will be recruited to answer standardized questionnaires. In the third part, a sub-sample from part 2, of 20 people will be interviewed.
89327441|NCT06096753||Test Group|The Test Group will include patients rehabilitated according to the full-arch method (Columbus Bridge ProtocolTM) with immediate loading for at least 6 months prior to the first nocturnal recording using Bruxoff®.
89327442|NCT06096753||Control Group|The Control Group will include healthy subjects and volunteers awaiting implant-prosthetic rehabilitation of intercalated edentulism (i.e. single-tooth gap) who have natural dentition up to the first molar.
89327443|NCT06096701||Intervention|Intervention group will receive blood pressure (BP) cuffs. The BP cuff is connected in a Health Insurance Portability and Accountability Act-compliant fashion to the patient's medical record, allowing for documentation and communication with the nurse and the care team. Alerts are triggered if a patient has not checked her BP for 3 days or when readings fall outside a specific threshold (high or low BP alerts). Based on these alerts, the nurse follows up with these patients and reminds them to take a reading. The nurse will also notify participants with elevated BP values to repeat their BP and will contact the participants by phone to discuss symptoms and antihypertensive medications. Patients will be managed based on a clinical algorithm for initiation of antihypertensive medications without the need for an outpatient visit if considered appropriate by the clinical provider.
89327444|NCT06096701||Historical or Concurrent controls|Individuals who had hypertensive disorders during pregnancy but who did not receive the BP cuffs will serve as the control group.
89327445|NCT06096688||FAP without treatment with NSAIDs|Patients with the Hereditary Cancer Syndrome known as Familial Adenomatous Polyposis (FAP) undergoing upper or lower endoscopy/surgery without treatment with NSAIDs
89327446|NCT06096688||FAP on treatment with NSAIDs|Patients with the Hereditary Cancer Syndrome known as Familial Adenomatous Polyposis (FAP) undergoing upper or lower endoscopy/surgery on treatment with NSAIDs
89327447|NCT06096688||HNPCC without treatment with NSAIDs|Patients with the Hereditary Cancer Syndrome known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) undergoing lower endoscopy/surgery without treatment with NSAIDs
89327448|NCT06096688||HNPCC on treatment with NSAIDs|Patients with the Hereditary Cancer Syndrome known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) undergoing lower endoscopy/surgery on treatment with NSAIDs
89327449|NCT06096688||Other Hereditary Colorectal Cancer Syndromes|Other Hereditary Colorectal Cancer Syndromes undergoing lower endoscopy/surgery
89327450|NCT06096688||Average-risk population|Average-risk population undergoing lower endoscopy/surgery in the lower gastrointestinal tract.
89327451|NCT06096662|Experimental|Experimental: Treatment group|"Participants will receive 35 hours of training, twice a week in ten weeks using Verb Network Strenghtening Treatment (VNeST).~Treatment will be administered by a speech-language pathologist thought an online platform."
89327452|NCT06096662|No Intervention|Control group|"Participants in the control group will not receive speech-and-language treatment targeting word-finding.~Treatment for word finding will be provided by a speech-language pathologist after participation to the study."
89327453|NCT06096649|Experimental|Topical Vehicle + Zinc Di-(dibutyryl lisinate)|Topical cream containing Zinc Di-(dibutyryl listinate)
89327454|NCT06096649|Placebo Comparator|Topical Vehicle|Topical cream
89327455|NCT06096636||Study participants|Participants will complete survey and dietary assessment.
89327456|NCT06096285||Preserved ratio impaired spirometry (PRISm)|People with post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ≥ 0.70 and FEV1 and/or FVC < 80% predicted, or FEV1/FVC ≥ lower limit of normal (LLN) and FEV1 < LLN.
89327457|NCT06096285||COPD Stage 0|People who had COPD-related risk factor exposure (e.g. cigarette smoke) and/or presented with respiratory symptoms (e.g. chronic cough, and/or sputum production) whereas with normal pulmonary function.
89327458|NCT06096285||Pre-COPD|People (importantly, of any age) who had respiratory symptoms (e.g. cough, sputum production, dyspnea, and/or exacerbation) with or without detectable structural (e.g. thoracic computed tomography (CT) emphysema, small and/or large airway impairments) and/or functional (e.g. low diffusion capacity for carbon monoxide (DLCO), hyperinflation, small airway obstruction, and/or accelerated FEV1 decline) abnormalities, in the absence of airflow limitation, and who might (or not) develop persistent airflow limitation (i.e. COPD) over time.
89327459|NCT06096285||Early COPD|People who were younger than 50 years with ten or more pack-years smoking history and any of these abnormalities: i) early airflow limitation (post-bronchodilator FEV1/FVC < LLN), ii) compatible thoracic CT abnormalities, iii) rapid decline in FEV1 (> 60 ml/year) that was accelerated relative to FVC.
89327460|NCT06096285||Young COPD|COPD patients with post-bronchodilator FEV1/FVC < 0.70 diagnosed in the 20-50 year age range.
89327461|NCT06096285||Mild COPD|COPD patients with post-bronchodilator FEV1/FVC < 0.70 and FEV1 ≥ 80% predicted.
89327462|NCT06096285||Controls|People who were not belonged to any of above six early COPD status, and with pre- and post-bronchodilator FEV1/FVC ≥ 0·70, and with post-bronchodilator FEV1/FVC ≥ LLN.
89327463|NCT06095843|Active Comparator|implants in free vascularized fibular flap|placement of dental implants in free fibular flaps after mandibular reconstruction
89327464|NCT06095843|Active Comparator|implants in non-vascularized iliac crest grafts|placement of dental implants in non-vascularized iliac crest grafts after mandibular reconstruction
89327465|NCT06095037|Experimental|Intervention|Mindful yoga
89327466|NCT06095037|Active Comparator|Control|Psychoeducation
89327467|NCT06094751|Experimental|ACT Guide for Insomnia|Participants will complete 2 modules of an online Acceptance and Commitment Therapy (ACT) Guide designed to focus on insomnia among college students. Module 1 will be available to participants at the start of week 1 and throughout the course of the study. Module 2 will become available at the start of week 3 and participants will have access throughout the study
89327468|NCT06094751|No Intervention|Waitlist|Participants randomized into the waitlist condition will not have access to the ACT Guide for Insomnia until the conclusion of their time in the study (8 weeks after randomization).
89327469|NCT06093828|Other|Single-arm|Single-arm: subjects with Tricuspid valve regurgitation who meet the study eligibility criteria
89327470|NCT06093815|Experimental|Arm 1|Subjects in Arm 1 will receive injections of biostimulatory products (Radiesse, Sculptra, Ellanse, HArmonyCa) at 3 timepoints (six months, three months and two weeks) prior to removal of redundant abdominal tissue.
89327471|NCT06093815|Experimental|Arm 2|Subjects in Arm 2 will receive injections of 1 of 2 selected biostimulatory products (Radiesse or Sculptra) at 1 timepoint (6 months) prior to removal of redundant abdominal tissue.
89327472|NCT06093802|Experimental|DISE-guided treatment group|"DISE findings will be documented and obstruction scored per pediatric DISE criteria. Clinically relevant obstruction is defined as >50% at minimum one site. (Adeno-)tonsillotomy will be performed if corroborative DISE suggests tonsil/adenoid obstruction; if not, no surgery will be performed.~This approach is maintained despite other identified obstruction sites, which will be assessed at a later stage."
89327473|NCT06093802|Active Comparator|Non-DISE-guided treatment group|"DISE findings will be documented, and video material will be saved for later assessment.~Patients will be operated according to current guidelines (s.o.), regardless of perioperative DISE findings, i.e. tonsillotomy +/- adenoidectomy."
89327474|NCT06093789||Group PT-PADC|patients who will receive sedoanalgesia for the oocyte retrieval procedure.
89327475|NCT06093776||Case Series|Prospective: Case Series The investigators will complete ioveraº system training (i.e., cadaveric demonstration) and work with our local surgical team to develop an effective procedure. The technique will then be refined and considered fully developed with three consecutive successful placements. Data reporting to the sponsor will occur once data for the first five successful interventions and the subsequent 14-day follow-ups are completed. Adverse event reporting to the IRB will occur in accordance with GCP standards. Due to the small sample size and short duration, patients lost to follow-up will be an indication for additional enrollment. No more than 10 total subjects will be enrolled.
89327476|NCT06093763|Active Comparator|Patients with symptomatic malunion of distal radius receiving bone grafting|Open wedge corrective osteotomy and plate fixation with harvesting and using bone from the iliac crest.
89327477|NCT06093763|Active Comparator|Patients with symptomatic malunion of distal radius receiving none bone grafts|Open wedge corrective osteotomy and plate fixation without harvesting and using bone from the iliac crest.
89327478|NCT06093737|Experimental|COPE Intervention|Is a three session brief group psychoeducational intervention. Session 1 is 4 hours, Session 2 and 3 are 1.5 hours. It is delivered in groups of 8-15 people with sessions spaced 1 month apart.
89327479|NCT06093737|Active Comparator|House Meeting Control|Is a 1.5 hour group meeting delivered in groups of 8-15 people spaced 1 month apart.
89327480|NCT06093724|Experimental|Anatomy reorganization after vaginoplasty in transgender women (MtF)|The research consists of adding to the usual MtF transgender patient undergoing vaginoplasty care course, static and dynamic perineo-pelvic MRI before, and at 6 and 24 months. The aim is to assess perineo-pelvic static's evolution, based on the appearance of a rectocele.
89327481|NCT06093698|Experimental|single arm|A-337dosage: 0.05, 0.15, 0.3, 0.6, 0.9, 1.2, 1.5 μg/kg/d
89327482|NCT06093659|Experimental|Product use sequence ABECD|Subjects use Product A on Day 1, Product B on Day 2, Product E on Day 3 and Product C on Day 4 and Product D on Day 5.
89327483|NCT06093659|Experimental|Product use sequence BCADE|Subjects use Product B on Day 1, Product C on Day 2, Product A on Day 3 and Product D on Day 4 and Product E on Day 5.
89327484|NCT06093659|Experimental|Product use sequence CDBEA|Subjects use Product C on Day 1, Product D on Day 2, Product B on Day 3 and Product E on Day 4 and Product A on Day 5.
89327485|NCT06093659|Experimental|Product use sequence DECAB|Subjects use Product D on Day 1, Product E on Day 2, Product C on Day 3 and Product A on Day 4 and Product B on Day 5.
89327486|NCT06093659|Experimental|Product use sequence EADBC|Subjects use Product E on Day 1, Product A on Day 2, Product D on Day 3 and Product B on Day 4 and Product C on Day 5.
89327487|NCT06093646|Experimental|Ebola+D intervention|Ebola+D intervention will include psycho-education, Problem Solving Therapy, antidepressant medication and referral to a supervising specialist mental health worker.
89327488|NCT06093516|Experimental|Optimal Precision Tinted Lenses (PTL)|"The participant is asked to describe any perceptual distortion and discomfort of the text in the colorimeter.~At each of the 12 hues in turn the saturation of colour is increased from white to modest saturation (30) and after 5s returned to white. The participant is asked to compare the coloured text with the white and report any differences in the distortion/discomfort.~At the best of the 12 hues, the participant adjusts the saturation to optimise the clarity and comfort of the text (comfort is more important than clarity).~At this saturation, the hue is adjusted by small amounts and re-optimised. The saturation is then minimised.~At the re-optimised hue/saturation, the brightness is reduced to assess its effects on comfort. If the lower brightness is preferred the saturation is increased slightly to see if the high brightness is better tolerated."
89327489|NCT06093516|Experimental|Sub-Optimal Precision Tinted Lenses (PTL)|"The sub-optimal colour will be chosen as a colour of similar saturation to the optimal colour but differing in u'v' colour space by 0.07. Two colours of equal radial distance from the optimal colour will be considered. The colour that shares the name of the optimal colour or appears most similar will be chosen.~After colorimetry, participants will choose a spectacle frame. Two pairs of PTLs will be made up by the manufacturing opticians, one to the optimal colour and the other to a slightly sub-optimal colour."
89327490|NCT06093503|Experimental|Telisotuzumab Vedotin and Osimertinib|Participants will receive telisotuzumab vedotin every 2 weeks in combination with osimertinib, until disease progression or unacceptable toxicity.
89327491|NCT06093503|Experimental|Standard of Care|Participants will receive standard of care chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed as prescribed by the physician), until disease progression or unacceptable toxicity.
89327492|NCT06093477|Placebo Comparator|5mg Liquid Placebo|Participants will take a placebo of 5mg syrup, complete surveys, and wear an actigraphy device during the specified study period.
89327493|NCT06093477|Experimental|5mg Liquid Melatonin|Participants will take 5mg of melatonin in liquid form, complete surveys, and wear an actigraphy device during the specified study period.
89327494|NCT06093464|Experimental|Group A- Natural Compound A to Natural Compound B|"Cycle 1 (4 weeks): use diffused Natural Compound A (like an essential oil) in a diffuser every night when sleeping~Cycle 2 (4 weeks): will not use compounds/diffuser (wash-out period)~Cycle 3 (4 weeks): use diffused Natural Compound B (like an essential oil) in a diffuser every night when sleeping~Cycle 4 (4 weeks): will not use compounds/diffuser (post-intervention observation period)~This study has incomplete disclosure; interested individuals will be told that there is incomplete disclosure. There will be 2 natural compounds; the compounds are like essential oils and are commercially available. They will be used as intended with diffusers. To prevent any bias, the study team will not tell the participant what compounds are being studied during the time of consent and participation. There will be a debriefing session after the participant is done participating, to tell them about the compounds and to answer any questions."
89327495|NCT06093464|Experimental|Group B- Natural Compound B to Natural Compound A|"Cycle 1 (4 weeks): use diffused Natural Compound B (like an essential oil) in a diffuser every night when sleeping~Cycle 2 (4 weeks): will not use compounds/diffuser (wash-out period)~Cycle 3 (4 weeks): use diffused Natural Compound A (like an essential oil) in a diffuser every night when sleeping~Cycle 4 (4 weeks): will not use compounds/diffuser (post-intervention observation period)~This study has incomplete disclosure; interested individuals will be told that there is incomplete disclosure. There will be 2 natural compounds; the compounds are like essential oils and are commercially available. They will be used as intended with diffusers. To prevent any bias, the study team will not tell the participant what compounds are being studied during the time of consent and participation. There will be a debriefing session after the participant is done participating, to tell them about the compounds and to answer any questions."
89327496|NCT06093451|Experimental|Dexmedetomidine|Participants with moderate agitation will receive sublingual dexmedetomidine 120 mcg as needed. Participants with severe agitation will receive dexmedetomidine 180 mcg as needed.
89327497|NCT06093451|Active Comparator|Lorazapem|Participants with moderate agitation will receive oral lorazapam 2 mgas needed. Participants with severe agitation will receive oral lorazapam 2 mg as needed.
89327498|NCT06093438|Experimental|Induction immunotherapy and chemotherapy|Patients enrolled in this arm would receive neoadjuvant immunotherapy and chemotherapy before definitive chemoradiation
89327499|NCT06093425|Active Comparator|TST001|TST001
89327500|NCT06093425|Placebo Comparator|Placebo|Placebo
89327501|NCT06093412||unilateral epidural anesthesia (UEA) group|Patients were divided into two groups based on the type of anesthesia they received; a UEA group (n = 42) and a combined spinal epidural anesthesia (CSEA) group (n = 64).
89327502|NCT06093412||combined lumbar and epidural anesthesia (CSEA) group|Patients were divided into two groups based on the type of anesthesia they received; a UEA group (n = 42) and a combined spinal epidural anesthesia (CSEA) group (n = 64).
89327503|NCT06093399|Experimental|Deep Brain Simulation (DBS) System|The DBS device will be turned on to compare stutter to when the device was off (which would be the control).
89327504|NCT06093373||Comparison|
89523477|NCT03386305|Experimental|EnvarsusXR arm|Patients are converted to once daily EnvarsusXR (study drug). The patients continue taking this medication for 9 months of the study. Initial dosage will be 0.8 times the total daily dose of tacro bid, due to higher bioavailability. All subsequent dose adjustments will be based on maintenance of target tacro trough levels within range of 5-12 ng/ml.
89327505|NCT06093360||flapless group|Patients were treated in 1-2 sessions within a period of 7 days, with a minimum of 90 minutes per session. Implant-supported restorations were unscrewed and modified if they were not cleansable. After local anesthesia, a periodontal ultrasonic stainless-steel tip was used for supra- and sub-mucosal mechanical debridement . Next, a Columbia 4R/4L curette was used around the implant in a circular motion until a bone exposure of 2-3 mm was achieved. Mucosal curettage was performed. After obtaining access to the implant surface, ultrasonic instrumentation was repeated and air polishing with an erythritol powder was applied submucosally with the aim of a periodontal probe. Hydrogen peroxide 3% was used to irrigate the implant surface for 2 minutes, followed by a rinse with saline. Systemic antibiotics, when prescribed, were metronidazole or azithromycin.
89327506|NCT06093308|Experimental|Elderly subjects|elderly subjects with underlying diseases.
89327507|NCT06093243||"women of childbearing age group"|women of childbearing age with or without endometriosis
89327508|NCT06093230|Experimental|Group A|mild liver function impairment group
89327509|NCT06093230|Experimental|Group B|moderate liver function impairment group
89327510|NCT06093230|Experimental|Group C|normal liver function subject group
89327511|NCT06093204||Patients with eosinophilic esophagitis|Pediatric patients with a sure diagnosis of eosinophilic esophagitis
89327512|NCT06093204||Sex and age matched healthy controls|Matched healthy controls for age and gender, without eosinophilic esophagitis
89327513|NCT06093165|Other|A|Primary radiotherapy 54Gy/30 fractions
89327514|NCT06093165|Other|B|Any other dose and fractionation for primary radiotherapy than 54gy/30 fractions.
89327515|NCT06093152||Before salbutamol|Participants before the administration of salbutamol
89327516|NCT06093152||After salbutamol|Participants after the administration of salbutamol
89327517|NCT06093139|Active Comparator|Active|Probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules alongside additional potato starch as a filler).
89327518|NCT06093139|Placebo Comparator|Placebo|Placebo capsule (placebo consisted of the same capsules filled with potato starch)
89327519|NCT06093087|Experimental|SAIF|patients will be treated with kyphoplasty surgery combined with pedicular screw-assisted internal fixation for vertebral augmentation
89327520|NCT06093087|Active Comparator|BKP|patients will be treated with balloon kyphoplasty surgery for vertebral augmentation
89327521|NCT06093061|Experimental|MAINTENANCE STUDY TREATMENT|EBV DNA ≥4000 copies/mL OR N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA detectable after 3 cycles of IC.
89327522|NCT06093035||patients with neurogenic bladder|Female patients of childbearing age with neurogenic bladder secondary to spina bifida and multiple sclerosis
89327523|NCT06093035||healthy patients|Female patients of childbearing age without neurogenic bladder secondary to spina bifida and multiple sclerosis
89327524|NCT06092983|Experimental|HS-10383 (Multiple doses)|Escalating doses of HS-10383 administered orally once daily for a week in healthy participants.
89327525|NCT06092983|Placebo Comparator|HS-10383 Placebo (Multiple doses)|Escalating doses of HS-10383 Placebo administered orally daily for a week in healthy participants.
89327526|NCT06092944|Experimental|continuous RISS group|Patients were given continuous RISS plane block in addition to patient controlled intravenous analgesia.
89327527|NCT06092944|Experimental|single RISS group|Patients were given single RISS plane block in addition to patient controlled intravenous analgesia.
89327528|NCT06092944|Active Comparator|PCIA group|Patients were given patient controlled intravenous analgesia.
89327529|NCT06092905||Pregnant women with symptomatic common bile duct stones|Pregnant women with symptomatic common bile duct stones
89327530|NCT06092853||systemically and periodontally healthy (CG)|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses.
89327531|NCT06092853||systemically healthy and periodontitis (PG)|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
89327532|NCT06092853||Metabolic syndrome and periodontally healthy (MG)|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
89327533|NCT06092853||Metabolic syndrome and periodontitis (MPG)|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
89327534|NCT06092840|Experimental|Transform Burn|Participants were supplied with one bottle of study product (Transform Burn) for each visit, labeled with their participant number. They were required to take the product consisting of 4 capsules per day, taken on an empty stomach at least 30 minutes prior to eating each morning, 5 days on Monday through Friday. Product was taken at the beginning of each visit, except for Week 0 visit for a total of 12 weeks and bottles were returned at each visit.
89327535|NCT06092827|Experimental|Physical activity|Adults 18 to 75 with an active diabetic foot ulcer
89327536|NCT06092775||RA group|DEXA scan X_rays lumber, dorsal spine
89327537|NCT06092775||AS group|DEXA scan X_rays lumber, dorsal spine
89327538|NCT06092775||Control group|DEXA scan X_rays lumber, dorsal spine
89327539|NCT06092762|Experimental|AK120 300mg|AK120 loading dose 600mg, then 300mg subcutaneous injection every 2 weeks thereafter until week 14.
89327540|NCT06092762|Experimental|AK120 450mg|AK120 loading dose 600mg, then 450mg subcutaneous injection every 2 weeks thereafter until week 14.
89327541|NCT06092736|Experimental|Compound Danshen Dropping Pills|Treatment group: Compound Danshen Dropping Pills (Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day, 20 capsules each time.
89327542|NCT06092736|Placebo Comparator|Placebo|Placebo group: placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
89327543|NCT06092723|Experimental|Lactococcus lactis subsp. lactis, LY-66|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
89327544|NCT06092723|Experimental|Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
89327545|NCT06092723|Experimental|Lactococcus lactis subsp. lactis, LY-66+Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
89327546|NCT06092723|Placebo Comparator|Placebo|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
89327547|NCT06092697|Experimental|3D printed PEEK|Indirect dental restoration
89327548|NCT06092697|Experimental|Milled PEEK|Indirect dental restoration
89327549|NCT06092697|Active Comparator|Hybird resin composite|Indirect dental restoration
89327550|NCT06092684|Experimental|BT-KTM-I|Patients received 0.5mg/kg BT-KTM-I during anesthesia induction period. Patients received 0.5mg/kg/h BT-KTM-I during anesthesia maintenance period.
89327551|NCT06092684|Active Comparator|Ketanest®S|Patients received 0.5mg/kg Ketanest®S during anesthesia induction period. Patients received 0.5mg/kg/h Ketanest®S during anesthesia maintenance period.
89327552|NCT06092671|Experimental|Family-Centered group (F group)|Both children and parents received family-focused anesthesia strategies.
89327553|NCT06092671|No Intervention|Routine group (R group)|The child received clinical standard preoperative education and anesthesia induction. It is recommended to give sedatives (such as oral midazolam or dexmedetomidine nasal drops, etc.) before surgery. The child was not accompanied by the parents during the anesthesia induction period and the awakening period.
89327554|NCT06092658||No Intervention|No Intervention
89327555|NCT06092645|Experimental|surufatinib plus Cadonilimab|Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cardonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle
89327556|NCT06092619|Experimental|Intervention Group|Patients under Vojta Therapy intervention
89327557|NCT06092619|Active Comparator|Control Group|Patients under regular physiotherapy intervention
89327558|NCT06092567|Experimental|Group A (Oblique Incremental Placement Techniique)|In this interventional group, a Nanohybrid composite resin Nexcomp (Meta Biomed, Korea) was placed using an oblique incremental technique with increments not exceeding 2 mm in thickness.
89327559|NCT06092567|Experimental|Group B (Bulk-fill Placement Technique)|In this group, a composite Beautifil-Bulk Restorative (SHOFU dental) was utilized for restorative purposes using a bulk-fill technique with a thickness of 4 mm.
89327560|NCT06092541|Experimental|Intervention group: pericervical anesthesia|Intervention group: pericervical anesthesia
89327561|NCT06092541|Active Comparator|Control group: nitrous oxide anesthesia|Control group: nitrous oxide anesthesia
89327562|NCT06092515|Experimental|Fermented High Zinc Wheat Flour Flatbread|Participants in this arm will receive fermented whole wheat flatbreads made from wheat variants with a high zinc content, ranging. These flatbreads are prepared through traditional fermentation methods.
89327563|NCT06092515|Experimental|Unfermented High Zinc Wheat Flour Flatbread|Participants in this arm will receive unfermented whole wheat flatbreads made from wheat variants with a high zinc content. These flatbreads provide a source of bioavailable zinc without the fermentation process.
89327564|NCT06092515|Experimental|Fortified Wheat Flour flatbread|Participants in this arm will receive flatbreads made from whole wheat flour fortified post-harvest to contain a zinc content
89327565|NCT06092515|Active Comparator|Low Zinc Wheat flatbread|Participants in this arm will receive whole wheat flatbreads made from wheat variants with a low zinc content
89327566|NCT06092502|Active Comparator|Traditional Physiotherapy Program|This group included strengthening exercises will be applied, including various joint movements and strengthening exercises applied in physiotherapy clinics.
89327567|NCT06092502|Experimental|Traditional Physiotherapy Program and Graded Motor Imagery Therapy|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
89327568|NCT06092476|Active Comparator|DMR procedure|Patients receive Revita® DMR Treatment Paradigm 1. After unblinding at 24 weeks, they receive retreatment.
89327569|NCT06092476|Sham Comparator|Sham procedure|Patients receive a sham procedure. After unblinding takes place at 24 weeks, patients receive a Revita® DMR Treatment Paradigm 1. 48 weeks after initial sham (= 24 weeks after first DMR) patients may receive retreatment, if they want to.
89327570|NCT06092463||Preterm infants|"Infants will be included just after birth after obtained consent based on written and verbal information. Fecal samples will be collected from day 1 of life and weekly for the following weeks until discharge to investigate the composition of the fecal microbiome in relation to the development of NEC and the effect of medical therapy.~In case of development of NEC with the need for surgery the affected intestine will be resected and stomas will be established. Samples of fecal content and tissue is collected from intestine proximal and distal to divided intestine. At time of reversal of stomas, again tissue will be collected both proximal and distal from division to investigate the development of the intestine during early life as well as potential nutritional effects on intestinal maturity. Infants who do not undergo surgery serve as controls, those who are treated for NEC with antibiotics only, will be included in a sub analysis comparing the microbiome of infants who need surgery."
89327571|NCT06092463||Newborn and children up to 1 year of age|Infants with congenital malformations will have to undergo scheduled surgery to resect and/or anastomose the affected area of the intestine and some will receive a stoma that needs later reversal. At primary surgery fecal samples and intestinal tissue will be collected proximal and distal to the pathology. In cases with a stoma, and when the child will undergo later reversal surgery, tissue samples from the proximal and distal ends of the intestine will be collected together with fecal samples.
89327572|NCT06092450||MIBC|patients with pathologically confirmed MIBC after radical cystectomy
89327573|NCT06092437|Experimental|Tailored, Urine sodium guided, intensified diuretic strategy|
89327574|NCT06092437|Active Comparator|Usual care|
89327575|NCT06092424|Active Comparator|Investigations at High altitude (HA, 2840m)|PAP and other hemodynamics assessed by echocardiography and blood gases near their living altitude in Quito at 2840m
89327576|NCT06092424|Experimental|Investigations at Low altitude (LA, sea level)|PAP and other hemodynamics assessed by echocardiography and blood gases after the first and second night at LA (sea level)
89523478|NCT03386305|Active Comparator|Standard of care arm|Post Liver Transplant patients take Tacrolimus twice daily as a part of standard of care. Those participating in the study will continue to take tacrolimus twice daily, as apart of their regular care. As a part of the study, they will complete the medication adherence and quality of life instruments.
89327577|NCT06092398|Experimental|PRP and PRFG in anal fistula|the tract fistula was cleaned with betadine 10% before PRP and PRFP were applied. Then, 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. The operation time was about 20-30 minutes, the clot formation usually takes about 8 minutes, but the anesthesia was extended to 20 minutes to make sure a complete clot in the place
89327578|NCT06092385||Patients with chronic liver disease and histologically proven cirrhosis|
89327579|NCT06092385||Control subjects with no signs of cirrhosis|
89327580|NCT06092372|No Intervention|Control|Participants in the control group will be asked to fill out online surveys and book appointments for blood sample collection and weight measurements at the beginning and at the end of the study. In addition, participants will be asked to report their weight two more times during the study (in months 2 and 4) with an online survey that will be sent via the MyBiobank portal. The participation in the study ends with another personal visit to the clinic for blood sampling and weight measurement six months after registration. No other personal advice or support is provided to this group.
89327581|NCT06092372|Experimental|Diet Intervention|Participants in the diet intervention group will be asked to fill out online surveys and book appointments for blood sample collection and weight measurements at the beginning and at the end of the study. After visiting the clinic for the first time, each participant will be contacted to start a diet coaching program and to obtain an activity tracking device. In addition, each participant will be asked to report their weight two more times during the study (in months 2 and 4) with an online survey that will be sent to them via the online portal of the study (OmaBiopankki portal). The study participation ends with another personal visit to the clinic for blood sampling and weight measurement six months after registration.
89327582|NCT06092320|Experimental|Simulation - Didactic Lecture Group|This group will start with a Simulation and debrief followed by a didactic lecture afterwards. They will then complete a simulation 2 months later.
89327583|NCT06092320|Experimental|Didactic Lecture - Simulation Group|This group will start with a didactic lecture and then complete a simulation and debrief. They will then complete a simulation 2 months later.
89327584|NCT06092307|Experimental|Chronic pancreatitis|adult patients aged 18-65 years with a diagnosis of chronic pancreatitis
89327585|NCT06092294|Experimental|Tactical training in numerical superiority and numerical inferiority|"Participants will carry out a specific training program, with the objective of improving both offensive and defensive Tactical-Technical Actions (ATT) that will allow the increase of effectiveness indexes (EI) (offensive and defensive). The formats through which will train are Small Sided Games (SSGs) and ATT 2 against 1, 3 against 2 and 4 against 3 alternating them during the week (SSGs on Tuesdays and ATT on Thursdays).~The characteristics of this training program are: training frequency 5 times/week, plus 1 competition on weekends, frequency of stimulation of the SSGs and ATT of numerical superiority and numerical inferiority 2 times/week, the specific training time assigned to the development of these formats and exercises will be 30 to 42 minutes/training session and will be carried out after the warm-up."
89327586|NCT06092294|Active Comparator|Conventional training in numerical equality|"On the other hand, the CG participants will perform conventional training. In the present study, conventional training is defined as ATTs performed in equal numbers in 1 against 1, 2 against 2 and 3 against 3 formats. Likewise, coaches will be asked not to carry out additional specific training with these formats, nor of SSGs or offensive or defensive ATT in numerical superiority and inferiority, specifically in 2 against 1, 3 against 2, or 4 against 3 formats, during the time of the study, to avoid confusion biases due to possible co-interventions. This CG training program will include individual, couples, and groups of three ATTs .~The characteristics of this training program are: training frequency 5 times/week, 1 official competition on weekends, frequency of ATT stimulation in 1v1, 2v2 and 3v3 formats is 2 times/week, the specific training time allocated will be 40 minutes per training session and will be performed after the warm-up."
89327587|NCT06092268|Experimental|Treatment Part A: SHR-A2009 for injection in combination with Almonertinib Mesilate Tablets|
89327588|NCT06092268|Experimental|Treatment Part B: SHR-A2009 for injection in combination with Adebrelimab Injection|
89327589|NCT06092255|Experimental|Preventive radiotherapy irradiation SVZ group|GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
89327590|NCT06092242|Experimental|TAS-102 combined with bevacizumab|
89327591|NCT06092229|Active Comparator|Palpation|digital palpation used to identify the cricothyroid membrane
89327592|NCT06092229|Experimental|Ultrasonography|Ultrasonography (TACA approach) used to identify the cricothyroid membrane
89327593|NCT06092203||Patients|Pediatric patients who underwent treatment for utrollithiasis.
89327594|NCT06092203||Control|Cross-matched group of healthy children.
89327595|NCT06092190||Group A|
89327596|NCT06092190||Group B|
89327597|NCT06092177|Experimental|Test group|The group will include patients who undergo periodontal surgery with virtual reality distraction
89327598|NCT06092177|Experimental|Control group|The group will include patients who undergo periodontal surgery without virtual reality distraction
89327599|NCT06092151|Experimental|Silver Diamine Fluoride|SDF treatment for caries in the primary teeth of children included
89327600|NCT06092151|Active Comparator|Usual Care|Usual care determined by child's dentist for caries in their primary teeth
89327601|NCT06092138|Experimental|Wearable Device Group|The Wearable Device Group uses wearable devices to perform rehabilitation exercises using the provided strategies. It includes the application of IoT technology to build a cloud platform combining software and hardware, using the spine sensors described in this project to collect behavioral data (it is recommended that they be worn during working hours every day for no less than 7 hours/week), and using end-to-end AI algorithms for health monitoring; the visualized data is synchronized to the spine health platform for real-time viewing and analysis by both doctors and patients. Through cell phone software and internet platform, spine health files are established to realize convenient and efficient communication between patients and professional doctors.
89327602|NCT06092138|No Intervention|Traditional group|The Traditional intervention group used traditional interventions, i.e., routine patient education, guidance on rehabilitation exercises, and tips on proper lifestyle habits.
89327603|NCT06092125||Alzheimer's Disease (AD)|The study will collect PET/MR multimodal imaging data, including brain structure, cerebral perfusion, brain function, glucose metabolism, and Aβ deposition, from 100 healthy volunteers, 250 patients with MCI, and 300 patients with AD. Abnormal changes in imaging biomarkers will be analyzed quantitatively, specifically for AD, to determine the specific quantitative threshold for diagnosing AD using 18F-FDG PET and 18F-AV-45 PET and establish imaging biomarkers for early diagnosis of AD. Longitudinal follow-up will be conducted to analyze multimodal imaging data dynamically and discover imaging biomarkers for early prediction of subjective cognitive decline (SCD), MCI, and AD progression.
89327604|NCT06092125||Parkinson's Disease (PD)|The study aims to collect PET/MR multimodal imaging data from 250 patients with rapid eye movement sleep behavior disorder (RBD) and 300 patients with Parkinson's disease (PD) across multiple centers. The imaging data will include brain structure, brain iron deposition, brain function, glucose metabolism, and vesicular monoamine transporter levels, among other imaging biomarkers. Abnormal changes in these imaging biomarkers will be analyzed quantitatively to determine the specific quantitative threshold for diagnosing PD using 18F-FDG PET and 18F-AV-133 PET and establish imaging biomarkers for early diagnosis of PD. Longitudinal follow-up will be conducted to dynamically analyze the multimodal imaging data and discover imaging biomarkers for early prediction of RBD and PD progression.
89327605|NCT06092125||Epilepsy(EP)|The study aims to collect PET/MR multimodal imaging data from 550 patients with epilepsy across multiple centers. The imaging data will include brain structure, brain function, glucose metabolism, and microglial cell activity, among other imaging biomarkers, to identify abnormal changes characteristic of epilepsy. Key features will be quantitatively analyzed to determine the specific quantitative threshold for diagnosing epilepsy using 18F-FDG PET and 18F-DPA714 PET and establish imaging biomarkers for epilepsy diagnosis. Using pathological results as the gold standard, the analysis of imaging data from lesions and surrounding brain tissue aims to discover imaging biomarkers that differentiate lesions from normal brain tissue and establish imaging markers for precise localization of epilepsy lesions.
89327606|NCT06092125||Malignant Brain Tumors(MBT)|A total of 550 patients with malignant brain tumors (gliomas, metastatic tumors, and lymphomas) were collected from multiple centers for PET/MR multimodal imaging of brain structure, brain function, glucose metabolism, and amino acid metabolism, analyzing the characteristic abnormal changes in imaging markers. Using pathological results as the gold standard, specific quantitative threshold values for diagnosing different pathological types of malignant brain tumors using 18F-FDG PET and 18F-FET PET were determined, establishing imaging biomarkers for the diagnosis of malignant brain tumor pathology. Analysis of imaging data of the tumor and surrounding brain tissue revealed imaging markers for distinguishing tumors from surrounding normal brain tissue, enabling precise localization of malignant brain tumors.
89327607|NCT06092112|Experimental|CD-801 treatment|The subjects with advanced HCC will be treated by CD-801 through the hepatic artery injection.
89327608|NCT06092086|Experimental|CROWN Criteria (CC) Cohort、Compassionate use (CU) Cohort|
89327609|NCT06092073|Experimental|RIFPB group|Patients will receive bilateral Recto-Intercostal Fascial Plane Block (RIFPB) using 20 mL of bupivacaine 0.25% on each side.
89327610|NCT06092073|No Intervention|Control group|Patients will not receive the block.
89327611|NCT06092060|Experimental|the group GS|probiotic treatment group, ca. 20 participants
89327612|NCT06092060|Placebo Comparator|the group GP|placebo group, ca. 20 participants
89327613|NCT06092047|Experimental|UTAA09 cells for infusion|Off-the-shelf γδT cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day-7~Day-2.
89327614|NCT06092034|Experimental|RP-A501|One planned dose of RP-A501 in cohorts of subjects with a confirmed diagnosis of Danon Disease.
89327615|NCT06091267|Experimental|ASTX727 and IV Decitabine|Cycle1：ASTX727 tablets, oral, 1 tablet/day for 5 days；Cycle2：IV Decitabine, 20 mg/m^2, is administered for 1 hour at a time for 5 days；≥ Cycle 3：ASTX727 tablets, oral, 1 tablet/day for 5 days
89327616|NCT06091267|Active Comparator|IV Decitabine and ASTX727|Cycle1：IV Decitabine, 20 mg/m^2, is administered for 1 hour at a time for 5 days； Cycle2：ASTX727 tablets, oral, 1 tablet/day for 5 days；≥ Cycle 3：ASTX727 tablets, oral, 1 tablet/day for 5 days
89327617|NCT06091267|Experimental|ASTX727|ASTX727 tablets, oral, 1 tablet/day for 5 days；
89327618|NCT06090968|Experimental|Umbilical cord milking|20 cm of umbilical cord would be milked towards the infant with intact umbilical cord. The cord milking will be done four times. The entire procedure can be done in 15-20 seconds
89327619|NCT06090968|Active Comparator|Immediate cord clamping|clamping the umbilical cord as soon as possible (average 30 seconds)
89327620|NCT06090734|Experimental|My Voice|"Intervention arm patients will complete the patient version of 'My Voice' at least once every 3 months for 1 year or until they pass away (whichever is earlier).~Caregivers of patients in the intervention arm will complete the caregiver version of 'My Voice' at least once every 3 months for 1 year (or until the patient passes away, whichever is earlier)."
89327621|NCT06090734|No Intervention|Control|Control arm patients and caregivers will receive usual care.
89327622|NCT06090578|Experimental|TabCAT-Brain Health Assessment|Primary care providers concerned that their patients are exhibiting signs of cognitive decline based on patient, informant (family), or provider concerns will refer them for a TabCAT-BHA assessment and follow-up care.
89327623|NCT06090578|No Intervention|Usual Care|Patients in the control practices will continue with usual care workflows.
89327624|NCT06090513||Control/Standard|Standard patient group: advanced cancer patients receiving limited and acceptable care without access to advanced genetic testing tools or expertise; patients at facility prior to deployment of TSO500, ELIA, and molecular tumor boards.
89327625|NCT06090513||Test group|Same patient population at the same facility after deployment of TSO500, ELIA, and molecular tumor board support.
89327626|NCT06090474|Experimental|NDC-002|"In Period 1, Two tablets of NDC-002C are repeatedly administered once a day for seven days to reach a steady state of NDC-002C. There is a seven-day washout period between Period 1 and Period 2.~In Period 2, after repeated administration of one tablet of NDC-002A once a day for seven days, one tablet of NDC-002B is administered repeatedly once a day for eight days to reach a steady state of NDC-002B.~In Period 3, after the completion of Period 2 administration and without a washout period, one tablet of NDC-002B and two tablets of NDC-002C administered repeatedly in combination once a day for seven days."
89327627|NCT06090383||Adolescents with CP and typically developed adolescents.|
89327628|NCT06090240|Experimental|Motivational Interview|Older adult-family member dyads in this arm will receive an MI-based education intervention our team developed.
89327629|NCT06090240|No Intervention|Self-learning|Older adult-family member dyads in this arm will receive a self-learning ACP educational material developed by the Hong Kong Hospital Authority.
89327630|NCT06090084||Multiple Sclerosis|Multiple sclerosis patients
89327631|NCT06090084||Healthy Controls|Healthy subjects
89327632|NCT06090019|Experimental|Control group|Nursing interns students learned the routine nursing care of children on mechanically ventilation to prevent VAP by PICU nurses staff.
89327633|NCT06090019|Experimental|Study group|Nursing interns students received comprehensive education about VAP care bundle prevention by self-instructional module through the researchers.
89327634|NCT06089928|Active Comparator|fixation free|sandwich osteotomy with Interpositional graft without fixation.
89327635|NCT06089928|Active Comparator|conventional sandwich osteotomy|sandwich osteotomy with Interpositional graft with fixation.
89327636|NCT06088823||No paresthesia|Patients that had no registration of post-operative paresthesia in hand or lower arm after cardiac surgery
89327637|NCT06088823||Paresthesia|Patients that had one o more registrations of post-operative paresthesia in hand or lower arm after cardiac surgery
89327638|NCT06086938|Active Comparator|active TBS group|active TBS combined with speech language therapy
89327639|NCT06086938|Sham Comparator|sham TBS group|sham TBS combined with speech language therapy
89327640|NCT06086379|Experimental|CCT-C|10-week Compensatory Cognitive Training Group
89327641|NCT06086379|Active Comparator|HCE|10-week Holistic Cognitive Education Group
89327642|NCT06086301|Experimental|PICTURE-THIS services|This group receives a Run-In Phase followed by outpatient transitional care management (up to 8 visits over 3 months), activity-based rehabilitation (up to 10 visits over 3 months), and social support for patients and families (ongoing screening and referral). They will also undergo outcome assessments at discharge, 3 and 6 months.
89327643|NCT06086301|Active Comparator|Enhanced Usual Care|Enhanced Usual Care (EUC) control group will rececive a Run-in Phase followed by an informational brochure with regular assessments on the same schedule as the PICTURE-THIS group (i.e., discharge, 3 and 6 months)
89327644|NCT06085963|Placebo Comparator|Control group|"20 subjects will be challenged with both a dissolved placebo-tablet and 0.9% saline solution. This provocation will be performed as a one-sided blinded challenge which will demonstrate that the NAC is truly negative.~Subjects will be randomized to dissolved placebo-tablet or saline solution in a cross over design. 10 subjects will start with dissolved placebo-tablet and 10 will start with 0.9% saline solution. After 30 minutes the subjects will switch to receive a challenge with the other solution. This will ensure negative reactivity to the excipients and challenge as a method. The placebo solution will be prepared the same as way as the active ITULAZAX® stock solutio"
89327645|NCT06085963|Active Comparator|Birch group|NAC will be applied to 70 patients with birch pollen allergy. Subjects will initially receive a NAC with 0,9% saline solution to ensure negative reactivity to the challenge as method. If negative after 30 minutes NAC will continue with one puff (1x0.1 ml) dissolved ITULAZAX® (1 SQ-Bet/ml) in each nostril.
89327646|NCT06085807||Patients with ADPKD|The participants will receive a survey.
89327647|NCT06085807||Family members of patients with ADPKD|The family members of participants will receive a survey.
89327648|NCT06085742|Other|CMC orally|All agents in CMC are oral and conform to a 3-week = 1 cycle regimen. All subjects will receive Cyclophosphamide 60mg/m2 PO once a day (21 continuous days) Methotrexate 10mg/m2 PO BID on days 1, 8, and 15 Capecitabine 825mg/m2 PO BID on days 1-14
89327649|NCT06085300|Experimental|sentence recast in Spanish only|A trained, bilingual SLP will treat the targeted structure at a rate of ~ 1 recast per minute, for 16 hours spread over 9 weeks to obtain a planned dose of 912-1008 recasts (960 +/- 5%). Following evidence on enhanced conversational recasting, the SLP will obtain the child's attention before recasting and systematically vary the lexical items in the recasts. Children receiving monolingual Spanish therapy will have the entire treatment session conducted in Spanish.
89327650|NCT06085300|Experimental|sentence recast in English only|A trained, bilingual SLP will treat the targeted structure at a rate of ~ 1 recast per minute, for 16 hours spread over 9 weeks to obtain a planned dose of 912-1008 recasts (960 +/- 5%). Following evidence on enhanced conversational recasting , the SLP will obtain the child's attention before recasting and systematically vary the lexical items in the recasts. Children receiving monolingual English therapy will have the entire treatment session conducted in English.
89327651|NCT06085300|Experimental|sentence recast - Bilingual (Spanish+English) intervention|Treatment will differ from monolingual therapy in that the child will be seen by two SLPs in keeping with one-person one-language models. This allows us to ensure that the dose in each language is controlled and supports the use of both languages evenly in therapy. Sessions will alternate between English-only therapy and Spanish-only therapy - thus the child will receive 8 hours of therapy treating the selected target in English and 8 hours treating the selected target in Spanish. A child in bilingual therapy will receive approximately 456-504 (480 +/- 5%) recasts in each language for a total of 912-1008 recasts combined.
89327652|NCT06085222|Experimental|Emotional Engagement Distress Tolerance Intervention|The experimental intervention (single 2.5 hour session) is comprised of video-delivered psychoeducation, adaptive skill practice, and emotional exposure. During exposure, a sequence of percussive sounds accompanied by a visual depiction of the participant's skin conductance level during exposure will be presented at the moment the participant's skin conductance returns to the relaxation baseline value. These images/sound will be intermittently sent to the participant's smart phone during the smart phone portion of the intervention.
89327653|NCT06085222|Placebo Comparator|Health Education Intervention|The health education control intervention is a single 2.5 hour computerized session. It is comprised of audio-narrated videos on healthy habits and self-care in the domains of sleep, nutrition, hygiene, and physical exercise. The same sequence of percussive sounds used in the Emotional Engagement Distress Tolerance Intervention is presented alongside summary slides presenting key points on healthy habits and self-care. These images/sound will be intermittently sent to the participant's smart phone during the smart phone portion of the intervention.
89327654|NCT06085040|Experimental|Intervention|
89327655|NCT06084897|Experimental|Consolidation radiotherapy|This treatment group will be receive radiotherapy on the basis of standard first-line treatment, after all planned cycles of chemotherapy combined with PD-1 inhibitor completed.
89327656|NCT06084897|Experimental|Salvage radiotherapy|This treatment group will be receive salvage radiotherapy on the basis of standard first-line treatment, when disease progressed and salvage radiotherapy is recommended by multidisciplinary team.
89327657|NCT06084767|Experimental|Malignant tumors|This arm investigated the clinical value of 68Ga-TCR-FAPI PET/CT in suspected malignant tumors.
89327658|NCT06084689|Experimental|Cohort A: soft-tissue sarcomas|Soft-tissue sarcomas
89327659|NCT06084689|Experimental|Cohort B: Solid tumors|Solid tumors [non-small cell lung cancer (NSCLC) or triple negative breast cancer (TNBC) or MMS colorectal cancer (MSS-CCR) or biliary tract cancer (BTC)]
89327660|NCT06083649|Experimental|Experimental group A (AI Group: EG-A)|The AI group scanned their own mouths at home once a week for 6 months, with each scan taking approximately 5 min. After scanning, they uploaded the results to the AI system for evaluation. The AI system then selected and sent a message to each patient depending on their intraoral conditions.
89327661|NCT06083649|Experimental|Experimental group B (AI and health counseling group: EG-B)|The AI and health counseling group scanned their own mouths at home once a week for 6 months, with each scan taking approximately 5 min. After scanning, they uploaded the results to the AI system for evaluation. The EG-B received both AI-assisted DM and real-person oral health counseling and advice from a counselor, who assessed their oral hygiene conditions on the basis of their scanning results and then provided individualized counseling, such as pointing out unclean teeth and offering suggestions on cleaning tools.
89327662|NCT06083649|No Intervention|No Intervention: Control group (CG)|the control group(CG) only have standard oral hygiene education
89327663|NCT06081348|Active Comparator|Sertraline|
89327664|NCT06081348|Placebo Comparator|Placebo|
89327665|NCT06080919|Experimental|DCB-PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention will undergo DCB-PCI under IVUS guidance and angio-derived coronary phisiology assessment. Angiographic follow-up with IVUS evaluation will be performed 3 months after the index procedure.
89327666|NCT06080893||Ferric Carboxymaltose - Administrated Group|"Patients eligible for inclusion who received preop FCM intravenous therapy~FCM will be administered intravenously at preop 24th hour according to weight and preop hgb level"
89327667|NCT06080893||Ferric Carboxymaltose - Not Administrated Group|Patients eligible for inclusion who are not received preop FCM intravenous therapy
89327668|NCT06079645|Active Comparator|Triamcinolone acetonide (2mg/ml) injections through syringes and needles|Triamcinolone at a concentration of 2mg/ml will be injected on one side of the randomized vulva using a syringe and needle.
89327669|NCT06079645|Active Comparator|Triamcinolone acetonide (40mg/ml) through microinjections with needles|Triamcinolone at a concentration of 40mg/ml will be injected on the other side of the randomized vulva using a tattoo machine.
89327670|NCT06079502|Experimental|Neuromuscular Electrical Stimulation group|Thirty patients will receive a supervised program of intradialytic NMES two times per week for 16weeks with medical treatment.
89327671|NCT06079502|Experimental|resistive training group|Thirty patients will receive a supervised program of intradialytic resistive training two times per week for 16weeks with medical treatment.
89327672|NCT06075862||Patients with lumbar spinal stenosis|Patients diagnosed with lumbar spinal stenosis and referred to operation. Balance will be measured once in this group before operation, and four times again after operation.
89327673|NCT06075407||Fluid responder|All patients will undergo a volume expansion test or fluid challenge according to standard protocol. The volume expansion test will be performed with an intravenous infusion of 0.9% sodium chloride (500mL) within 15 minutes. The patient becomes a fluid responder if SV increases by > 10% after the fluid challenge.
89327674|NCT06075407||Fluid non-responder|All patients will undergo a volume expansion test or fluid challenge according to standard protocol. The volume expansion test will be performed with an intravenous infusion of 0.9% sodium chloride (500mL) within 15 minutes. The patient becomes a fluid responder if SV increases by > 10% after the fluid challenge (21). If the patient becomes a fluid non-responder, vasopressor infusion or inotrope will start.
89327675|NCT06075004|Active Comparator|Periarticular Local Anesthetic Infiltration|60 mL of 0.25% bupivacaine with 5ug/mL epinephrine will be deposited under direct vision during surgery at the periarticular level before wound closure.
89327676|NCT06075004|Experimental|Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block|"45 mL of 0.25% bupivacaine with 5ug/mL epinephrine will be deposited under direct vision during surgery at the posterior periarticular level before wound closure.~After wound closure, an ultrasound-guided pericapsular nerve group block of the hip will be performed using ten mL of 0.5% bupivacaine with 5ug/mL epinephrine."
89523479|NCT03386227|No Intervention|Prophylactic antibiotics|Current standard of care in our practice for a fresh in vitro fertilization cycle is to administer one dose of 1 gram oral azithromycin on day one of the IVF cycle start to both the male and female partner. In cases of same-sex couples, only the female undergoing the embryo transfer receives prophylaxis. This will serve as our control arm entitled: prophylactic antibiotics.
89523480|NCT03386227|Experimental|No antibiotic prophylaxis.|Couples randomized to the no-antibiotic treatment group will not be prescribed oral antibiotic prophylaxis.
89327677|NCT06073561|Experimental|Underwater mucosectomy|"Every colonoscopy should be performed with a high definition colonoscope, such as Olympus series Q185 or Q190 with virtual chromoendoscopy by NBI (Olympus Inc., Tokyo, Japan) or Fujifilm EC-760R-V/L or EC-760Z-V/L with virtual chromoendoscopy by LBI (Fujifilm Group, Japan).~A study investigator or a senior endoscopy fellow under their direct supervision should perform all procedures.~The U-EMR procedure should include the following steps: CO2 should be completely removed, and the bowel lumen filled with normal saline using a water jet pump (OFP-2, Olympus Medical System or similar) until the lesion is totally immersed in water. The lesion and 2-3 mm of normal surrounding mucosa should be resected using electrocauterization (VIO 200D Endocut Q Effect 3; ERBE Electromedizin, Tübingen, Germany)."
89327678|NCT06073210|Experimental|Therapeutic exercise plus motor imagery|This group will perform a therapeutic exercise programme (aerobic and strength training) to which motor imagery training will be added.
89327679|NCT06073210|Experimental|Therapeutic exercise plus action observation|This group will perform a therapeutic exercise programme (aerobic and strength training) to which action observation training will be added.
89327680|NCT06073210|Active Comparator|Therapeutic exercise|This group will perform a therapeutic exercise programme (aerobic and strength training) to which sham action observation training will be added.
89327681|NCT06072326|Experimental|Treatment order 1|Subjects will start with 4 weeks of Ambrisentan in treatment period 1. In period 2 subjects will receive Sotagliflozin. In period 3 subjects will receive a combination of Ambrisentan and Sotagliflozin. Between treatment periods there is a 4-week wash-out.
89327682|NCT06072326|Experimental|Treatment order 2|Subjects will start with 4 weeks of Ambrisentan in treatment period 1. In period 2 subjects will receive a combination of Ambrisentan and Sotagliflozin. In period 3 subjects will receive Sotagliflozin. Between treatment periods there is a 4-week wash-out.
89327683|NCT06072326|Experimental|Treatment order 3|Subjects will start with 4 weeks of Sotagliflozine in treatment period 1. In period 2 subjects will receive a combination of Ambrisentan and Sotagliflozine. In period 3 subjects will receive Ambrisentan. Between treatment periods there is a 4-week wash-out.
89327684|NCT06072326|Experimental|Treatment order 4|Subjects will start with 4 weeks of Sotagliflozine in treatment period 1. In period 2 subjects will receive Ambrisentan. In period 3 subjects will receive a combination of Ambrisentan and Sotagliflozin. Between treatment periods there is a 4-week wash-out.
89327685|NCT06072326|Experimental|Treatment order 5|Subjects will start with 4 weeks of a combination of Ambrisentan and Sotagliflozin in period 1. In period 2 subjects will receive Ambrisentan. In period 3 subjects will receive Sotagliflozin. Between treatment periods there is a 4-week wash-out.
89327686|NCT06072326|Experimental|Treatment order 6|Subjects will start with 4 weeks of a combination of Ambrisentan and Sotagliflozin in period 1. In period 2 subjects will receive Sotagliflozin. In period 3 subjects will receive Ambrisentan. Between treatment periods there is a 4-week wash-out.
89327687|NCT06062056|Experimental|Intervention|Behavioral health clinicians will use motivational interviewing with eligible patients to address vaccine hesitancy
89327688|NCT06062056|No Intervention|Control|Control sites will adhere to standard practice in behavioral health sessions (i.e., no discussions about vaccination)
89327689|NCT06057428||Patients with lumbar spinal stenosis|Patients diagnosed with lumbar spinal stenosis and referred to operation. Measurements of activity levels will be undertaken before operation, and compared to after operation.
89327690|NCT06057298|Experimental|Cytoreductive surgery and patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|"Preliminary laparoscopic exploration of the whole abdominal cavity is performed to stage the peritoneal disease, and obtain samples of peritoneal tumor to confirm the diagnosis of colorectal peritoneal metastases, and develop tridimensional cell cultures (organoids).~Preoperative systemic chemotherapy (s-CT) is performed at the discretion of treating medical oncologists, according to current guidelines.~Cytoreductive surgery and patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC) is scheduled within 6 weeks and at least 4 weeks after the completion of preoperative s-CT (at least 6 weeks after the last administration of bevacizumab). Cytoreductive surgery is aimed at removing all the macroscopic tumor by means od peritonectomy procedures and organ resections, as needed."
89327691|NCT06056752|Experimental|Patients with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia|A conditional chemotherapy regimen of fludarabine and cyclophosphamide will be administered, followed by investigational therapy, QH103 Cells
89327692|NCT06056323|Experimental|HB0045|HB0045 IV every 3 weeks (q3w)
89327693|NCT06054126||T2DM with good CCC|T2DM was diagnosed according to the criteria of the American Diabetes Association. The diagnosis of CTO was made if at least one lesion was angiographic 100% occlusion. Coronary collateral circulation development was graded according to the Cohen-Rentrop method, grade 2 (partial filling of the epicardial segment by collateral vessels); grade 3 (complete filling of the epicardial artery by collateral vessels) were defined as good coronary collateral circulation.
89327694|NCT06054126||T2DM with poor CCC|T2DM was diagnosed according to the criteria of the American Diabetes Association. The diagnosis of CTO was made if at least one lesion was angiographic 100% occlusion. Coronary collateral circulation development was graded according to the Cohen-Rentrop method, grade 0 (no filling of any collateral vessels) and grade 1 (filling of side branches of the artery to be perfused by collateral vessels without visualization of the epicardial segment) were defined as poor coronary collateral circulation.
89327695|NCT06053554|Other|Sulcus|On the day baseline examination, the first eye to be operated is randomised to receive a 3p-IOL implantation in the capsular bag (group 1) or a 3p-IOL haptics in the ciliary sulcus with the IOL optic tucked in the capsular bag (group 2). The second eye to be operated receives the other method. The eye with the lower visual acuity is operated first, in case of identical visual acuity values the for the patient subjective worse eye is operated first. This procedure is clinical standard.
89327696|NCT06053554|Other|In the bag|On the day baseline examination, the first eye to be operated is randomised to receive a 3p-IOL implantation in the capsular bag (group 1) or a 3p-IOL haptics in the ciliary sulcus with the IOL optic tucked in the capsular bag (group 2). The second eye to be operated receives the other method. The eye with the lower visual acuity is operated first, in case of identical visual acuity values the for the patient subjective worse eye is operated first. This procedure is clinical standard.
89327697|NCT06051448|Active Comparator|Promoting Resilience in Stress Management (PRISM)|
89327698|NCT06051448|Active Comparator|Clinical-focused narrative (CFN)|
89327699|NCT06048627|Active Comparator|Mouthwash Test|
89327700|NCT06048627|Experimental|Mouthwash Experimental|
89327701|NCT06044363|Experimental|Satir group|Participants in the intervention group will receive a 10-session Satir model intervention.
89327702|NCT06044363|No Intervention|Control group|Participants in the control group will receive care as usual.
89327703|NCT06039436||ATG group|Patients in the ATG group will be treated with conditioning regimen containing ATG 2mg/kg on day -7 prior to transplant.
89327704|NCT06032949|Other|Vialize|Vialize is a lyophilized dehydrated complete human placental membrane allograft.
89327705|NCT06029348|Experimental|Paced Auditory Serial Addition Task|For the Paced Auditory Serial Addition Task, volunteers are presented with single digit numbers (1-9), and are instructed to add any given number to the previously presented number, and call out the answer. Volunteers are told that their performance is being monitored by research assistants. Volunteers are provided with a signaling device that they can use to discontinue testing. Lastly, participants will be asked to complete brief questionnaires to assess their levels of experienced threat, challenge, valence, arousal, and sense of control.
89327706|NCT06028945|Experimental|Group 1: VR-ET|Group 1 will receive the VR-ET for up to 10 days while in the EMU and complete a set of questionnaires at the first visit and after the last day of VR. A researcher will conduct a short exit interview with participants about their experience during their second visit. There will be a one-month follow-up phone interview with a researcher and participants will complete a final set of questionnaires.
89327707|NCT06028945|Active Comparator|Group 2: Neutral Game|"Group 2 will have access to a VR device with a neutral game for up to 10 days while in the EMU and complete a set of questionnaires at the first visit and after the last day of VR. A researcher will conduct a short exit interview with participants about their experience during their second visit. There will be a one-month follow-up phone interview with a researcher and participants will complete a final set of questionnaires."
89327708|NCT06024590|Active Comparator|Group A: irrigation with Irrisept™|Group A: standard of care wound treatment with 150 mL of IrriseptTM irrigation of the wound at each follow up visit.
89327709|NCT06024590|Active Comparator|Group B: irrigation or irrigation with normal saline|Group B: standard of care wound treatment with 150 mL ration of normal saline irrigation of the wound at each follow up visit.
89327710|NCT06021197|Experimental|NMDAE|An NMDA enhancer
89327711|NCT06021197|Placebo Comparator|Placebo|Placebo
89327712|NCT06015438|Experimental|Home Exercise EP Group|Participants in this group will follow an at home personalized EP for up to 12 weeks.
89327713|NCT06015438|Active Comparator|Short EP Group|Participants in this group will be enrolled in the short EP program.
89327714|NCT06009094|Experimental|VC005 Low Dose groups|
89327715|NCT06009094|Experimental|VC005 median-A Dose groups|
89327716|NCT06009094|Experimental|VC005 median-B Dose groups|
89327717|NCT06009094|Experimental|VC005 high Dose groups|
89327718|NCT06009094|Placebo Comparator|VC005 Placebo groups|
88809658|NCT01273064|Experimental|CTS-1027 30 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 30 mg, supplied in a blinded kit containing one bottle of 30 mg tablets, and one bottle of placebo tablets (in order to maintain blind). One tablet from each of the bottles is taken twice daily, for a total daily dose of 60 mg of CTS-1027.
89327719|NCT06004531|Experimental|Health Promoting|The survey will be organized so health promoting behavioral scale questions will be asked first concerning personal wellbeing. This will be followed by eco-friendly behavior scale questions involving one's concern for the wellbeing of the planet. After this, there will be two surveys concerning loneliness and eco-anxiety before the intervention.
89327720|NCT06004531|Experimental|Eco-friendly behavior|The survey will be organized so eco-friendly behavior scale questions involving one's concern for the wellbeing of the planet will be asked first. This will be followed by health promoting behavioral scale questions concerning personal wellbeing. After this, there will be two surveys concerning loneliness and eco-anxiety before the intervention.
89327721|NCT06003673|Experimental|Neoadjuvant therapy group|Participants will receive a combination treatment of Tislelizumab, Lenvatinib, and Transarterial Chemoembolization (TACE).
89327722|NCT06002438|Experimental|Egg powder|15g egg powder per day for 24 weeks
89327723|NCT06002438|Active Comparator|Corn powder|15g corn powder per day for 24 weeks
89327724|NCT06001320|Experimental|Letermovir group (study group)|Letermovir 480 mg once daily
89327725|NCT06001320|Other|Historically matched AA kidney transplant recipients who received valganciclovir|Compare outcomes to a historical group of 50 AA kidney transplant recipients who have received valganciclovir prophylaxis
89327726|NCT05995093||non-DIC group|
89327727|NCT05995093||pre-DIC group|
89327728|NCT05995093||overt-DIC group|
89327729|NCT05995093||DIC group|
89327730|NCT05994729|Experimental|Candidates to RDN with ascertained CMD|Patients that are candidates to receive RDN for resistant/difficult to control hypertension, who also have documented coronary microvascular dysfunction
89327731|NCT05992922|Experimental|IC265 Ophthalmic Solution 1%|1 drop will be instilled in each eye twice daily.
89327732|NCT05992922|Placebo Comparator|Placebo Ophthalmic Solution (Vehicle)|1 drop will be instilled in each eye twice daily.
89327733|NCT05991999|Experimental|The Study Group|800-meter swimming performance tests were administered to all swimmers prior to the measurement. The study group started to do stretch exercises every day for 6 weeks. At the end of six weeks, performance tests and myoton measurements were administered and analyzed for both groups.
89327734|NCT05991999|Active Comparator|The Control Group|800-meter swimming performance tests were administered to all swimmers prior to the measurement. The control group just continued their regular training for 6 weeks. At the end of six weeks, performance tests and myoton measurements were administered and analyzed for both groups.
89327735|NCT05991908|Experimental|Flu-Bu2-Mel140|Patients receive fludarabine, busulfan and melphalan as conditioning regimen
89327736|NCT05991908|Active Comparator|Flu-Bu4|Patients receive fludarabine and busulfan as conditioning regimen
89523481|NCT05237635|Experimental|Threshold estimates|Descriptive case-scenarios
89523482|NCT05237635|Active Comparator|Alternative threshold estimates|Descriptive case-scenarios
89327737|NCT05990699|Experimental|Intervention group|"patients will under routine hospital care as well as MBRP. This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network."
89327738|NCT05990699|No Intervention|control group|patients with substance use disorder who will be under routine hospital care.
89327739|NCT05989958|Experimental|HepaCure|Patients will receive Hepacure treatment on top of DPMAS
89327740|NCT05988983||OTC users|Participants using the oral contraceptive pill purchased over the counter
89327741|NCT05988983||Rx users|Participants using the oral contraceptive pill received by a prescription
89327742|NCT05984628|Experimental|human umbilical cord mesenchymal stem cells|"Injection of human umbilical cord mesenchymal stem cells (hUCMSC) into the donor site.~Dosage of stem cell preparation: Calculated based on the area of the donor site, with a cell count of 1X10^5cells/cm2.~Administration method: The cells are prepared as an injectable suspension using a blank solvent for stem cells at a concentration of 1X10^6 cells/ml (0.1 ml/cm2).~Timing of administration: Administered immediately after completion of the donor site harvesting procedure.~Treatment duration: The stem cell administration is a single dose, administered at the specified timing as described above"
89327743|NCT05984628|Placebo Comparator|blank solvent|"Injection of an equal volume of blank solvent for suspension of stem cells into the donor site.~Dosage of Control group preparation: Calculated based on the area of the donor site.~Administration method: Injection of an equal volume of blank solvent for suspension of stem cells into the donor site.~Timing of administration: Administered immediately after completion of the donor site harvesting procedure.~Treatment duration: The Control group administration is a single dose, administered at the specified timing as described above"
89327744|NCT05970588|No Intervention|Wait-list Control Group|Fitted with inclinometers/accelerometers at week 0 and week 4 of the intervention period for 7 consecutive days of wear. Measures of cognition and blood pressure regulation will occur at these same timepoints. Daily activities of participants will not be restricted if patients are assigned to the control group.
89327745|NCT05970588|Experimental|Intervention Group|Fitted with inclinometers/accelerometers at week 0 and week 4 of the intervention period for 7 consecutive days of wear. Measures of cognition and blood pressure regulation will occur at these same timepoints.
89327746|NCT05967676|Experimental|Patient group|athletes who have suffered a sports injury
89327747|NCT05965180||Biopsy|Patients will be identified once prostate biopsies have been scheduled. Once enrolled on trial, patients will undergo standard biopsy procedure as per clinical care. During this biopsy, research measurements will be completed using the fine needle photoacoustic probe.
89327748|NCT05960656|Experimental|Empagliflozin|Administration of Empagliflozin 25mg administered at time zero.
89327749|NCT05960656|Placebo Comparator|Placebo/Control Group|Administration of placebo for empagliflozin 25mg administered at time zero.
89327750|NCT05959694|Experimental|TQB3909 tablets|Oral administration, 400mg or 600 mg, once a day, and 28 days is a treatment cycle. Continue medication until the disease progresses or intolerant toxicity appears.
89327751|NCT05948098|Experimental|Facilitated Tucking Position|"Prior to the procedure, parents will be informed about facilitated tucking position practices.Heel blood will be drawn from newborns after facilitated tucking position practices are performed. The pain of newborns will be evaluated with the Neonatal Pain Diagnostic Scale (NIPS) before, during and after the procedure. Practice:~For the facilitated tucking position, the lower and upper extremities of the newborn will be kept in lateral flexion and close to the midline. Meanwhile, the researcher's hand will be gently held on the baby's head and the other hand on the baby's hips, without restricting the baby's movements. The facilitated tucking position will be given one minute before the heel blood collection and will be maintained for one minute during and after the blood collection."
89327752|NCT05948098|Experimental|Gentle Human Touch|"Before the procedure, parents will be informed about gentle human touch practice. After Gentle human touch practice, heel blood will be taken from newborns. The pain of newborns will be evaluated with the Neonatal Pain Diagnostic Scale (NIPS) before, during and after the procedure. Practice:~For the Gentle human touch practice, the researcher will place one hand on the newborn's top (head) above the brow line and the other hand on the lower abdomen covering the baby's waist and hips. Gentle human touch practice will be started 10-15 minutes before the procedure and will continue throughout the process and until 15 minutes after the end of the process."
89327753|NCT05948098|No Intervention|Control Group|"During the heel blood collection, no procedures other than routine procedures applied in the clinic will be applied. The pain of newborns will be evaluated with the Neonatal Pain Diagnostic Scale (NIPS) before, during and after the procedure."
89327754|NCT05943678||Healthy controls|negative controls
89327755|NCT05943678||Pompe Disease patients|
89327756|NCT05943678||McArdle Disease patients|positiv controls
89327757|NCT05937269|Experimental|Advanced Pneumatic Compression|Subjects who present with dermal lymphatic backflow will be asked to complete a session of advanced pneumatic compression therapy each day at home.
89327758|NCT05937269|Active Comparator|Standard-of-Care|Subjects who present with dermal lymphatic backflow will continue under standard-of-care surveillance of lymphedema and will only receive treatment if they are diagnosed with head and neck cancer-acquired lymphedema.
89327759|NCT05937269|Other|No Dermal Backflow|Subjects who do not present with dermal lymphatic backflow at enrollment will be monitored at subsequent visits and if/when dermal lymphatic backflow is observed will be randomized into either Advanced Pneumatic Compression or Standard-of-Care arm.
89327761|NCT06217718|Experimental|Telenursing Interventions Group|Participants in this group will receive five hours of face-to-face empowerment training. After the training, the experimental group will be monitored remotely by the researcher nurse via tele-nursing interventions for 12 weeks. Participants will be given a pulse oximeter, symptom diary, action plan, oxygen saturation-pulse monitoring chart. Participants will be asked to measure their oxygen saturation and pulse once a day for 12 weeks and record it on the chart. Participants will also be asked to record their complaints in their symptom diary. Participants will be called by the researcher every two weeks (on Thursdays) and informative and reminding text messages prepared specifically for the disease will be sent to the participants three times a week for 12 weeks. Participants will be able to reach the researchers by phone whenever they need.
89327762|NCT06217718|No Intervention|No Intervention Group|Participants in this group will be given a pulse oximeter, symptom diary, action plan, oxygen saturation-pulse monitoring chart. No intervention will be taken.
89327763|NCT06217666|Experimental|PCX-12|PCX-12 is an experimental immunotherapy drug that is injected into the pancreatic cancer one time in attempt to stimulate the patient's immune system to fight the cancer.
89327764|NCT06217653|Experimental|İntervention|"Intervention Group: A mother-baby yoga video prepared by the researchers was sent to the mothers in the intervention group. Before the mothers yoga practice, a 10-minute training was given about mother-baby yoga. Mothers were asked to do yoga at least 3 times a week for 4 weeks. Counseling and follow-up of the process were carried out by a researcher by calling the mothers once a week.~Mothers were asked to choose the most suitable time of the day for the baby and herself, to have the baby fed at least 45 minutes before yoga, and to practice in a calm and dim environment, listening to music or white noise of her choice. Approximately one yoga session is 20 minutes.~It was monitored once a week for 4 weeks, a total of 4 times. Postnatal Breastfeeding Self-Efficacy Scale-Short Form, Mother-Infant Attachment Scale, and Sleep Diary were administered to mothers at each follow-up."
89327765|NCT06217653|No Intervention|Control|Data Collection Form, Postnatal Breastfeeding Self-Efficacy Scale-Short Form, Mother-Infant Attachment Scale, and Sleep Diary were administered to mothers.It was monitored once a week for 4 weeks, a total of 4 times. Postnatal Breastfeeding Self-Efficacy Scale-Short Form, Mother-Infant Attachment Scale, and Sleep Diary were administered to mothers at each follow-up.
89327766|NCT06217640||Patients with Heart Failure|Patient diagnosed with heart failure with reduced ejection fraction (HFrEF): EF less than or equal to 40% and heart failure with preserved EF (HFpEF): EF is greater than or equal to 50%.
89327767|NCT06217640||Healthy Control|older people without HF.
89327768|NCT06217614|Active Comparator|(Manuka honey-green tea- ginger) interventional arm|• (Manuka honey-green tea- ginger) will topically be applied to the oral mucosa as oral rinse 3 times per day to treat xerostomia.
89327769|NCT06217614|Placebo Comparator|Saline mouthwash control group|Patients in the control arm followed the same protocol with normal saline rinses in the same bottles 3 times per day for xerostomia
89327770|NCT06217601|Experimental|Treatment status|To account for immortal time bias, each subject will be created with two clones at time zero and assigned each of the two clones to either treatment or no-treatment status, respectively. The treatment status in each evaluative endpoint (i.e., 3-month, 6-month, and 12-month) is defined as subjects who have received the digital intervention for the respective length of time since the time zero during which the intervention has just commenced.
89327771|NCT06217601|Placebo Comparator|No-treatment status|To account for immortal time bias, each subject will be created with two clones at time zero and assigned each of the two clones to either treatment or no-treatment status, respectively. The corresponding no-treatment status is defined as subjects who have not received the digital intervention for the corresponding length of time.
89327772|NCT06217536|Experimental|Phase 1b, Cohort 1 (Extremity and Trunk Sarcoma)|Participants will receive up to 3.2 mg/m^2 of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 2 weeks of pre-operative radiation given as 35 Gy in 5 fractions (gross tumor volume (GTV)) with fractions administered at least every other day starting on cycle 2 for participants with extremity and trunk sarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
89327773|NCT06217536|Experimental|Phase 1b, Cohort 2 (Extremity Myxoid Liposarcoma)|Participants will receive up to 3.2 mg/m^2 of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 2 weeks of pre-operative radiation given as 35 Gy in 5 fractions (gross tumor volume (GTV)) with fractions administered at least every other day starting on cycle 2 for participants with extremity myxoid Liposarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
89327774|NCT06217536|Experimental|Phase 1b, Cohort 3: Retroperitoneal Sarcoma|Participants will receive up to 3.2 mg/m^2 of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 6 weeks of pre-operative conventional external beam radiation therapy given as 45-50.4 Gy delivered over 25-28 fractions starting on cycle 1 for participants with retroperitoneal sarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
89523483|NCT05237323|Experimental|main group|Group 1 included 25 patients who received mycophenolate mofetil 2 g per day per os and methylprednisolone in an average starting dose 24 [24; 32] mg per day per os and standard drug therapy for heart failure (beta-blockers, angiotensin converting enzyme inhibitors or angiotensin II receptor blocker, mineralocorticoid receptor antagonist angiotensin receptor-neprilysin inhibitor (if required), diuretics (if required)).
89327775|NCT06217536|Experimental|Phase 2, Cohort 1: Extremity and trunk sarcoma|Participants will receive the maximum tolerated dose of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 2 weeks of pre-operative radiation given as 35 Gy in 5 fractions (gross tumor volume (GTV)) with fractions administered at least every other day starting on cycle 2 for participants with extremity and trunk sarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
89327776|NCT06217536|Experimental|Phase 2, Cohort 2: Extremity myxoid liposarcoma|Participants will receive the maximum tolerated dose of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 2 weeks of pre-operative radiation given as 35 Gy in 5 fractions (gross tumor volume (GTV)) with fractions administered at least every other day starting on cycle 2 for participants with extremity myxoid Liposarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
89327777|NCT06217536|Experimental|Phase 2, Cohort 3: Retroperitoneal sarcoma|Participants will receive the maximum tolerated dose of neoadjuvant lurbinectedin IV once every cycle (a cycle is 21 days) in combination with 6 weeks of pre-operative conventional external beam radiation therapy given as 45-50.4 Gy delivered over 25-28 fractions starting on cycle 1 for participants with retroperitoneal sarcoma. Non-investigational surgery will take place 4-6 weeks after completion of radiation therapy. Participants with metastatic disease at the time of study enrollment may be able to continue study treatment for 2 years from the time of initiating treatment. Participants with localized disease at the time of study enrollment may continue study treatment for approximately 3 months AND then be followed on-study surveillance.
89327778|NCT06217510|Experimental|Test Brace|A 3D printed brace designed automatically from a digital twin of the participant.
89327779|NCT06217497|Experimental|Experimental Group|After the patients in the experimental group were informed verbally and in writing and consented to participate in the study, the Patient Information Form, the Piper Fatigue Scale (PFS), and the Pittsburgh Sleep Quality Index (PSQI) were applied in the first interview and the initial readings were obtained. The researcher received training on a classical massage from an expert massage therapist before the foot massaging application. Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI.
89327780|NCT06217497|No Intervention|Control Group|Patients in the control group were not subjected to any intervention other than routine HD treatment and nursing care. The first readings were obtained by applying the Patient Information Form, PFS and PSQI at the first interview, and the second and third measurement values were obtained by repeating the PFS and PSQI at the end of the second and fourth weeks.
89327781|NCT06217484||Parkinson Disease|Participants with Parkinson Disease; Single group.
89327782|NCT06217458|Experimental|Interventional Group|Patients with mammographically newly detected ductal in situ carcinoma who undergo surgery at CHC Rijeka in 2024, 2025, and 2026 (consecutively), who agree to have a CEM performed prior to surgery as part of the diagnostic work-up in addition to standard mammography, and who agree to participate in the examination. Group number: 50 patients.
89327783|NCT06217458|No Intervention|Historical Control|Patients diagnosed with ductal in situ carcinoma who underwent surgery at CHC Rijeka in the period from 2019 to 2024 and whose clinical data are available in the prospectively managed clinical registry for breast diseases at CHC Rijeka and in the Hospital Information System (IBIS). Group number: 50 patients.
89327784|NCT06217445|Experimental|HIFU plus exercises|"A physician or technician first cleans the target area.~They may apply a topical anesthetic cream before starting.~The physician or technician then applies an ultrasound gel.~The HIFU device is placed against the skin.~Using an ultrasound viewer, the physician or technician adjusts the device to the right setting.~Ultrasound energy is then delivered to the target area in short pulses for roughly 30 to 90 minutes.~The device is removed."
89327785|NCT06217445|Experimental|doubled chin exercises|"Straight jaw jut~Ball exercise~Pucker up~.~Tongue stretch~Neck stretch~Bottom jaw jut"
89327786|NCT06217432|Experimental|Morning exercise|Three sessions per week of targeted resistance exercise targeting the quadriceps muscles performed between 6:00 and 8:00 for 12 weeks.
89327787|NCT06217432|Experimental|Late afternoon exercise|Three sessions per week of targeted resistance exercise targeting the quadriceps muscles performed between 16:00 and 18:00 for 12 weeks.
89327788|NCT06217432|No Intervention|Healthy control|Healthy individuals without tendinopathy as controls for the transcriptomics and proteomics analyses.
89327789|NCT06217419|No Intervention|Trial 1 - control group|On site visit every 3 months as for SoC
89327790|NCT06217419|No Intervention|Trial 1 - PROMs + spirometer group|On site visit every 6 months. Monthly remote PROMs evaluation + portable spirometer measurement to remotely monitor the disease.
89327791|NCT06217419|No Intervention|Trial 2 - control group|Monthly on site visit and paper PROMs.
89327792|NCT06217419|No Intervention|Trial 2- Social Network Chatbot|PROM answered remotely weekly + monthly on site, first by themselves with the aid of Chatbot on the electronic forms and then under direct supervision of the clinicians.
89327793|NCT06217419|No Intervention|Trial 2- Phonebot|PROM answered remotely weekly + monthly at hospital, first by themselves with the aid of Phonebot on the electronic forms and then under direct supervision of the clinicians.
89327794|NCT06217419|No Intervention|Trial 2 - Mobile app|PROM answered remotely weekly + monthly at hospital, first by themselves with the aid of Mobile app on the electronic forms and then under direct supervision of the clinicians.
89327795|NCT06217419|No Intervention|Trial 3 - asthma + CRSwNP Spirometer|Airflow monitoring recorded remotely with Spirometer every 2 weeks + on site visit every 2 month to compare wearable device with the standard one.
89327796|NCT06217419|Experimental|Trial 3 - asthma + CRSwNP RFID|Airflow monitoring with RFID (daily) + on site visit every 2 months to compare wearable device with the standard one.
89327797|NCT06217406|Experimental|ACYCLOVIR|Intravenous acyclovir (ACYCLOVIR )
89327798|NCT06217406|Placebo Comparator|PLACEBO|saline bags
89327799|NCT06217393|Experimental|Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals|Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)
89327800|NCT06217393|Active Comparator|Active Control group - Itopride Hydrochloride 50 mg film|
89327801|NCT06217380|Experimental|Masimo SafetyNet Alert (MSNA)|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive Masimo SafetyNet Alert (MSNA)
89327802|NCT06217367|Experimental|50 mg Diphenhydramine|
89327803|NCT06217367|Experimental|10 mg Loratadine|
89327804|NCT06217367|Experimental|5 mg Desloratadine|
89327805|NCT06217367|Placebo Comparator|Placebo (Sugar pill)|
89327806|NCT06217354|Active Comparator|Group A: Parturient with BMI ≥ 30 kg/m2.|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. [PabalVR, Ferring AG, Baar, Switzerland]).
89327807|NCT06217354|Other|Group B: Parturients with BMI < 30kg/m2 (control group)|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. [Pabal, Ferring , Baar, Switzerland]).
89327808|NCT06217341||emergence agitation group|Patients in the emergence agitation group are patients who are observed to be agitated during recovery according to the Richmond agitation sedation scale after anesthesia.
89327809|NCT06217341||calm group|The calm group will consist of patients whose agitation scale is below +2 during recovery.
89327810|NCT06217302|Active Comparator|Sotagliflozin|Oral sotagliflozin at a dose of 200 mg (one tablet) per day for three years followed by a 2-month wash-out period.
89327811|NCT06217302|Placebo Comparator|Placebo|Oral tablets similar to sotagliflozin tablets but containing no active drug (one tablet per day for three years followed by a 2-month wash-out period).
89327812|NCT06217263|Experimental|Vibration|After coronary artery bypass graft surgery, patients will receive routine monitoring, pharmacological treatment and nursing care in the unit where the research is conducted. The vibration device will be placed in the upper quadrant proximal to the patient's drain tube entrance. Care will be taken to ensure that the point where the vibration device is placed is the same as the vibration device placement point in the vibration and cold application group. 10 minutes after the application, the patient's skin temperature will be measured and the vibration device will be pulled above the chest tube insertion area.
89327813|NCT06217263|Experimental|Vibration & Cold application|After coronary artery bypass graft surgery, patients will receive routine monitoring, pharmacological treatment and nursing care in the unit where the research is conducted. Cold gel pack will be placed around the patient's chest tube insertion area. In order to optimize the effect of cold, the cold application will not exceed 20 minutes and the temperature of the skin will not fall below 12 ℃. At the 10th minute of cold application, the vibration device will be placed proximal to the chest tube, over the upper area of the cold gel pack. At the 20th minute of the application, the patient's skin temperature will be measured and the cold applied vibration device will be pulled above the chest tube insertion area.
89327814|NCT06217263|No Intervention|Control|After coronary artery bypass graft surgery, patients will receive routine monitoring, pharmacological treatment and nursing care in the unit where the research is conducted. In the control group, the processes and monitoring in the application groups will be continued in the same period without the application.
89327815|NCT06217237||AD FDT DBL GROUP|All participants will undergo an MRI session. The MRI protocol will include the clinical diagnostic protocol defined within the Network and research sequences as specified above (T1 3D, DTI, FLAIR 3D, QSM).
89327816|NCT06217237||CONTROL GROUP|All participants will undergo an MRI session. The MRI protocol will include the clinical diagnostic protocol defined within the Network and research sequences as specified above (T1 3D, DTI, FLAIR 3D, QSM).
89327817|NCT06217224|Active Comparator|Preventative photobiomodulation therapy arm only in methotrexate weeks.|The application of preventive photobiomodulation therapy (PBMT) will be carried out on the day of methotrexate infusion (D1) and until the patient reaches a serum concentration equal to or less than 0.3 mmol/L.
89327818|NCT06217224|Experimental|Preventive photobiomodulation therapy arm in the weeks of methotrexate, cisplatin and doxorubicin.|The application of preventive photobiomodulation therapy will be performed on the days of doxorubicin infusion and cisplatin and on the day after the doxorubicin infusion; on the day of the methotrexate infusion and until the patient reaches a serum concentration equal to or less than 0.3 mmol /L.
89327819|NCT06217211|Experimental|Remolacha|beet juice
89327820|NCT06217211|Placebo Comparator|Placebo|
88809659|NCT01273064|Experimental|CTS-1027 15 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 15 mg (supplied in a blinded kit containing one bottle each of of 5 mg and 10 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 30 mg.
88809660|NCT01273064|Active Comparator|placebo + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus placebo (supplied in a blinded kit containing two bottles of placebo tablets). One tablet is taken from each of the placebo bottles twice daily, for a total daily dose of 4 tablets.
89327821|NCT06217172|Other|Intervention Group|RHEUPP App follow-up
89327822|NCT06217172|Other|Control Group|Usual follow-up
89327823|NCT06217133|No Intervention|control group|The analysis of heart rate variability will be carried out in theIn the control group (NT), data collection will be carried out in the Rooming Room in a single reference collection lasting 20 minutes, and analyzed in 4 5-minute intervals. Newborns will be full term and will be in the supine position, lying in the common crib and resting. All collections for this group will be carried out in the afternoon on a day to be agreed with the mother or responsible companion.
89327824|NCT06217133|Active Comparator|CPAP Group|The analysis of heart rate variability will be carried out in the in the CPAP group, conventional and in the bubble CPAP.
89327825|NCT06217107|Experimental|C3 Coach plus H360x|Arm 1 will have 80 participants who will receive four weekly goal setting sessions with coach consisting of 45 min-1 hour recorded sessions. They will then receive another 4 sessions every 2 weeks, followed by three monthly goal setting sessions. Baseline surveys will be collected, in addition to surveys taken at 3 and 6 months.
89327826|NCT06217107|Active Comparator|C3 Coach plus Health360x and micro-learning|Arm 2 will have 80 participants who will receive four weekly goal setting sessions with coach consisting of 45 min-1 hour recorded sessions, in addition to periodic micro-learning content delivered via an online technology platform. They will then receive another 4 sessions every 2 weeks, followed by three monthly goal setting sessions. Baseline surveys will be collected, in addition to surveys taken at 3 and 6 months. This arm will have learning augmented by micro-learning to test effectiveness in enhancing engagement and promoting retention of educational content.
89327827|NCT06217094|Experimental|NP-101|
89327828|NCT06217055|Experimental|remimazolam based MAC group|remimazolam based monitored anesthesia care
89327829|NCT06217055|Active Comparator|inhalation general anesthesia group|general anesthesia with sevoflurane
89327830|NCT06217042|Experimental|HR070803+Oxaliplatin+5-FU/LV|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
89327831|NCT06217042|Active Comparator|GX|gemcitabine; capecitabine
89327832|NCT06217016|Experimental|ICCAUT Group|Patients undergoing laparoscopic/robotic rectal cancer TME surgery will undergo bladder training. The bladder training include intermittent catheter clamping and active urination to facilitate complete bladder emptying each time the catheter is released, which we called ICCAUT strategy. The training will commence at 9:00 am on the first postoperative day, and the catheter will be removed at 9:00 am on the second postoperative day.
89327833|NCT06217016|Other|Free Drainage Group|Patients undergoing laparoscopic/robotic rectal cancer TME surgery will have their urinary catheter kept open postoperatively, and the catheter will be removed at 9:00 am on the second postoperative day.
89327834|NCT06217003|Experimental|trilaciclib|Screening of eligible subjects for inclusion and application of trilaciclib before undergoing perioperative chemotherapy
89327835|NCT06216977|Experimental|Clear Liquids Arm|
89327836|NCT06216977|Active Comparator|Standard Of Care|
89327837|NCT06216951||Patients with symptomatic pulpitis|vital permanent molars with symptomatic pulpitis in patients aged between 7-70
89327838|NCT06216925|Experimental|#BabyLetsMove|For 24 weeks, participants will wear a Fitbit activity tracker (continually) and receive interactive self-monitoring and tailored feedback text messages (twice per week), tailored skills training texts and materials (once per week), and peer health coaching (once every other week). In addition, the participants will receive ancillary healthy food to allay food insecurity, nutritional counseling, and clinical care referrals once every three months.
89327839|NCT06216925|Active Comparator|WIC Antenatal Care|The participants will receive ancillary healthy food to allay food insecurity, nutritional counseling, and clinical care referrals once every three months.
89327840|NCT06216886|Experimental|OnabotulinumtoxinA|Intradermal injections will be placed in the affected trigeminal territories according to a specific facial map that we have developed.
89327841|NCT06216886|Placebo Comparator|Saline|The same procedure will be followed as above, but saline will be injected instead of onabotA
89327842|NCT06216873||multiple trauma|multiple trauma patients sent to emergency room for further evaluation are included
89327843|NCT06216821|Active Comparator|Standard DAPT therapy|Standard DAPT therapy for 12 mouths
89327844|NCT06216821|Experimental|OPT-CAD score guided de-escalation DAPT therapy|Patients at moderate to high risk of ischemic events assessed by the OPT-CAD score will receive DAPT therapy for 3 months followed by P2Y12 inhibitor monotherapy for 9 months; Patients at low risk of ischemic events assessed by the OPT-CAD score will receive DAPT for 1 month follow by P2Y12 inhibitor monotherapy for 11 months.
89327845|NCT06216782||Non-small cell lung cancer patients receiving neoadjuvant therapy|Patients diagnosed with non-small cell lung cancer who received neoadjuvant therapy.
89327846|NCT06216782||Small cell lung cancer patients receiving neoadjuvant therapy|Patients diagnosed with small cell lung cancer who received neoadjuvant therapy.
89327847|NCT06216756|Experimental|Osteochondral transplant on the femoral condyle|Eligible and enrolled patients will receive one or more cryopreserved osteochondral allograft core as part of their osteochondral transplant procedure
89327848|NCT06216743|Experimental|Imaging cohort|Patients participating in pilot study who will receive an additional MRI-scan, cineMRI and cineCT scan.
89327849|NCT06216730|Other|single arm cohort study|Since this is a single arm cohort study the outcomes will be descriptive
89327850|NCT06216691|Other|Coach-guided smartphone delivered CBT program|All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
89327851|NCT06216678|Experimental|Healthy Diet + Cottonseed Oil (CSOD)|Healthy dietary pattern containing 40g/day/2000 kcal of cottonseed oil (CSO)
89327852|NCT06216678|Active Comparator|Healthy Diet + Fatty Acid-Matched Plant Oils (FAMD)|Healthy dietary pattern containing 40g/day/2000 kcal of a blend of plant oils comprising a fatty acid profile that matches the CSOD but devoid of CSO
88809661|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control treatment in IBS treatment
88809662|NCT01279382|Other|Hypnotherapy (HYP)|HYP was given to a subgroup of patients as intervention in IBS treatment
89327853|NCT06216678|Active Comparator|Healthy Diet + PUFA:SFA Ratio-Matched Plant Oil (P:S-MD)|Healthy dietary pattern containing 40g/day/2000 kcal of plant oil that is lower in polyunsaturated fatty acids (PUFA) and saturated fatty acids (SFA) than the CSOD, but with a matched PUFA:SFA ratio and devoid of CSO.
89327854|NCT06216587|Placebo Comparator|Placebo group|
89327855|NCT06216587|Experimental|Probiotic group|
89327856|NCT06216548|Active Comparator|Delayed Enhanced Primary Care (E-PRIME) Group|Children will receive usual care before receiving E-PRIME intervention.
89327857|NCT06216548|Experimental|Early Enhanced Primary Care (E-PRIME) Group|Subjects of this arm will receive E-PRIME intervention at the start of enrollment.
89327858|NCT06216535|Placebo Comparator|Placebo|Participants will receive an inactive placebo by mouth using the same administration schedule as for escitalopram.
89327859|NCT06216535|Active Comparator|Escitalopram|Participants will take oral escitalopram 10 mg per day for two weeks, followed by oral escitalopram 20 mg per day for 22 weeks.
89327860|NCT06216496|Experimental|Dynamic test|
89327861|NCT06216483|Placebo Comparator|No PDM Alert|No PDM alert will be placed on subject's record
89327862|NCT06216483|Experimental|PDM Alert|PDM alert will be placed on subject's record
89327863|NCT06216457||Group 1: LVO|Subjects with Methinks NCCT algorithm detecting ICA, M1, and M2 occlusions.
89327864|NCT06216457||Group 2: ICH|Subjects with Methinks NCCT algorithm detecting ICHs.
89327865|NCT06216457||Group 3: Controls|Subjects with final diagnosis confirmed not to be Stroke (i.e. stroke mimic) or any type of stroke not determined to be: LVO (ICA, M1 or M2) or ICH.
89327866|NCT06216444|Experimental|Remimazolam Tosilate for Injection（5mg）|
89327867|NCT06216444|Experimental|Remimazolam Tosilate for Injection（10mg）|
89327868|NCT06216418|Experimental|BRFS-18G-S100WH|
89327869|NCT06216418|Active Comparator|MINT Lift FINE+|
89327870|NCT06216392|Experimental|Experimental: GR1802|GR1802 injection 300mg every two weeks for 52-week treatment.
89327871|NCT06216392|Placebo Comparator|Placebo|Placebo every two weeks for 16-week treatment. Crossover to GR1802 injection for another 36 weeks
89327872|NCT06216379||Preterm|Children born before 37 gestational weeks
89327873|NCT06216379||Term|Children born after 37 weeks of gestation
89327874|NCT06216340|Placebo Comparator|Control group|Placebo and diet-exercise therapy
89327875|NCT06216340|Experimental|Intervention group|10mg of Henagliflozin and diet-exercise therapy
89327876|NCT06216327|Experimental|intervention arm|There is a single intervention arm with no comparator for this pilot study
89327877|NCT06216314|Active Comparator|Heart rate (HR)|Three physiological zones were established according to the results of the treadmill test. The HR group completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. Runners trained 4 times a week.
89327878|NCT06216314|Experimental|Race pace based approach (RP)|For the race pace based approach (RP), intensity zones were established by calculating the percentage of the average speed achieved in the 7-km time trial (TT) and 3 zones were established. Kenneally's model was used to determine the race intensity zones by analyzing 7-km TT performance. Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace. Runners trained 4 times a week.
89327879|NCT06216314|Experimental|Heart rate + heart rate variability (HRV)|The HR+HRV group completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. Runners trained 4 times a week.
89327880|NCT06216301|Experimental|Arm 1: NovoTTF-200T, Pembrolizumab, and Platinum-based Chemotherapy|Subjects in this arm receive three treatments - TTFields using the NovoTTF-200T device, pembrolizumab, and platinum-based chemotherapy.
89327881|NCT06216301|Active Comparator|Arm 2: Pembrolizumab and Platinum-based Chemotherapy|Subjects in this arm receive two treatments - pembrolizumab and platinum-based chemotherapy.
89327882|NCT06216262|Active Comparator|Control group|1450 ppm fluoride toothpaste
89327883|NCT06216262|Active Comparator|Arginine|toothpaste containing arginine
89327884|NCT06216262|Active Comparator|Novamin|toothpaste containing novamin
89327885|NCT06216262|Active Comparator|Propolis|toothpaste containing propolis
89327886|NCT06216262|Active Comparator|Casein Phosphopeptide Amorphous Calcium Phosphate|Dental cream containing casein phosphopeptide amorphous calcium phosphate
89327887|NCT06216262|Active Comparator|Potassium Nitrate|mouthwash containing potassium nitrate
89327888|NCT06216236|Experimental|Kinect intervention system combined with aerobic exercise training|Kinect intervention system combined with aerobic exercise training
89327889|NCT06216236|No Intervention|aerobic dance training|aerobic exercise at home.
89327890|NCT06216223|Active Comparator|laser|laser ablation of anal diseases in inflammatory bowel patients
89327891|NCT06216223|Sham Comparator|traditional surgery|traditional surgery for anal diseases in inflammatory bowel patients
89327892|NCT06216210||Group (A)|Opioid-free anesthesia group
89327893|NCT06216210||Group (B)|Opioid-containing anesthesia group.
89327894|NCT06216197|Other|The FENT Group|Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).
89327895|NCT06216197|Other|The DEX Group|The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
89327896|NCT06216184||CRI|Patients with suspected catheter-related infection (CRI) and with one central venous catheter for at least 7 days were included. The area under the curve (AUC) of the Maki technique, the vortexing technique and the combination of both techniques for the diagnosis of catheter tip colonization (CTC) and diagnosis of catheter-related bloodstream infection (CRBSI) were compared.
89327897|NCT06216158|Active Comparator|Arm A: Iberdomide|36 months of oral iberdomide administration; In cycle 1, dexamethasone is added as pre-medication
89327898|NCT06216158|Experimental|Arm B: Iberdomide plus isatuximab|36 months of oral iberdomide plus subcutaneous isatuximab administration; In cycle 1, dexamethasone is added as pre-medication
89327899|NCT06216132|Experimental|BIOPIN-6 active implant|3 sequential cohorts receiving 4.8, 9.6, or 14.4 g BIOPIN 6 implanted into a subcutaneous pocket in the upper abdominal wall.
89327900|NCT06216132|Placebo Comparator|BIOPIN-6 placebo implant|The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.
89327901|NCT06216106||patients undergone prepectoral breast reconstruction|As the retrospective nature of this study, we have no exlusion criterias. We included all the patients with prepectoral breast reconstruction with polyurethane covered implants. We also included patients underwent postoperative radiation therapy (50 patients) and 20 patients with history of previous radiotherapy
89327902|NCT06216093|Experimental|RSV-1|
89327903|NCT06216093|Experimental|RSV-2|
89327904|NCT06216093|Placebo Comparator|Normal Saline|
89327905|NCT06216080||OCT-BIO-CVC cohort|Adult critically ill patients (> 18 years of age) exposed to central venous catheter for at least two calendar days
89327906|NCT06216067||Group 1 (Operating Room #1) CALLISTO eye|Group 1 (Operating Room #1) will have preoperative measurements with the IOL Master 700 and lens selection will be based on Veracity. The subjects in group 1 will have LenSx surgery and placement of the lens will be based on the CALLISTO eye.
89327907|NCT06216067||Group 2 (Operating Room #2) Wavetec AnalyzOR|Group 2 (Operating Room #2) will also have preoperative measurements with the IOL Master700, but lens selection will be based on the Wavetec AnalyzOR. The subjects in group 2 will have LenSx surgery and placement of the lens will be based on the Wavetec AnalyzOR.
89327908|NCT06216054|Experimental|LPM3770164|LPM3770164 sustained-release tablets will be administrated with multiple doses from 5mg to 30mg on day 1~10
89327909|NCT06216054|Placebo Comparator|Placebo|LPM3770164 sustained release tablet simulant will be administrated on day 1~10
89327910|NCT06216041|Experimental|IMM-H014 /Placebo(single dose) 12.5 mg (Cohort 1)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
89327911|NCT06216041|Experimental|IMM-H014 /Placebo((single dose) 37.5 mg Cohort(Cohort 2)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
89327912|NCT06216041|Experimental|IMM-H014 /Placebo(single dose) 75 mg (Cohort 3)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
89327913|NCT06216041|Experimental|IMM-H014 /Placebo(single dose) 125 mg(Cohort 4)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
89327914|NCT06216041|Experimental|IMM-H014 /Placebo(single dose and food effect) 175mg (Cohort 5)|"Period 1 (Day1 to Day4): Group A and Group B receive IMM-H014 /Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day11): Group A and Group B receive IMM-H014 /Placebo under the fed or fasting condition ,respectively on Day8."
89327915|NCT06216041|Experimental|IMM-H014 /Placebo(single dose) 225 mg (Cohort 6)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
89327916|NCT06216041|Experimental|IMM-H014 /Placebo(single dose) 275mg (Cohort 7)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
89327917|NCT06216041|Experimental|IMM-H014 /Placebo(single dose) 325 mg (Cohort 8)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition.
89327918|NCT06216041|Experimental|IMM-H014 /Placebo(multiple dose) tentative 37.5 mg(Cohort 9)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
89327919|NCT06216041|Experimental|IMM-H014 /Placebo(multiple dose) tentative 75 mg(Cohort 10)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
89327920|NCT06216041|Experimental|IMM-H014 /Placebo(multiple dose) tentative 125 mg(Cohort 11)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
89327921|NCT06216041|Experimental|IMM-H014 /Placebo(multiple dose) tentative 175 mg(Cohort 12)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
89327922|NCT06216041|Experimental|IMM-H014 /Placebo(multiple dose) tentative 225 mg(Cohort13)|IMM-H014 /Placebo tablets administered orally once daily under fasted condition for 7 Days(a total of 7 doses).
89327923|NCT06216015|Experimental|Exercise training group|The training programs will encompass three phases, with a gradual progression in both intensity and duration. Each phase will span a duration of four weeks, culminating in a comprehensive 12-week training regimen.
89327924|NCT06216015|No Intervention|Control group|Control group will continue their usual care without exercise interventions.
89327925|NCT06216015|Active Comparator|Continue exercise|Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will include individuals who choose to persist with their exercise routine.
89327926|NCT06216015|Active Comparator|Discontinue exercise|Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will comprise individuals who opted not to continue their exercise routine.
89327927|NCT06216002|Experimental|TOF nerve stimulation|Patient receive TOF nerve stimulation in recovery room after surgery
89327928|NCT06215989|Experimental|Treatment group|Patients are randomized within 48 hours after diagnosis of ACS, and on the day of randomization, eligible patients undergo standard treatment plus colchicine (0.5mg qd from 1st month to 12th month).
89327929|NCT06215989|Placebo Comparator|Placebo group|Patients are randomized within 48 hours after diagnosis of ACS, and on the day of randomization, eligible patients undergo standard treatment plus placebo (1 tablet qd from 1st month to 12th month).
89327930|NCT06215976|Active Comparator|Metformin|(39) patients taking metformin (500 mg twice daily) with cisplatin (70 mg/m2) and gemcitabine (1000 mg/m2) (GC) protocol
89327931|NCT06215976|No Intervention|Control|(39) patients taking cisplatin (70 mg/m2) gemcitabine (1000 mg/m2) (GC) protocol without metformin
89327932|NCT06215950|Experimental|Intravenous of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89327933|NCT06215950|Experimental|intraperitoneal injection of CD70-targeted CAR-T|Infusion of CD70-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89327934|NCT06215924|Active Comparator|'Reverse Kegel' exercise group|In addition to the training given by the physician, patients will be taught the 'Reverse Kegel' exercise. The 'Reverse Kegel' exercise is an exercise that is used to relax the pelvic floor muscles. To practice the exercise, patients will be asked to lie in a supine position with a support under the knees. In this position, patients will be asked to relax the pelvic floor muscles while breathing through their nose, maintain this movement for 5 seconds, and tighten the pelvic floor muscles while exhaling. Patients will be advised to do this exercise for 5 sets, 10 repetitions during the day. On the day of the training, initial evaluations will be made to the patients before the exercise training is given. Evaluations will be repeated at the end of the second and fourth week.
88809663|NCT01279382|Other|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
88809664|NCT01279460||CKD Cohort of patients with renal insufficiency|patients with renal insufficiency grade II-IV
88809665|NCT01272986|Placebo Comparator|Healthy patients|
89327935|NCT06215924|Experimental|'Postisometric Relaxation Technique' group|In addition to training given by the physican, internal digital Postisometric Relaxation method will be applied to the patients in this group from the anal region. Application will be made to the muscles where muscle spasm, movement restriction and pain are detected. The patient will be asked to perform a contraction against the digital resistance with maximum force and maintain this contraction for 5 seconds, actively relax after 5 seconds. During relaxation, stretching will be applied for 30 seconds by digitally supporting the movement of the pelvic floor muscles. The process will be performed with 5 repetitions. The application will be made 2 days a week for 4 weeks. On the day of the training, initial evaluations will be made to the patients before the exercise training is given.Evaluations will be repeated at the end of the second and fourth week.
89327936|NCT06215898|No Intervention|Control Group|Patients with Parkinson's Disease who were in the control group did not receive any interventional application.
89327937|NCT06215898|Experimental|Exercise Group (LSVT-Big protocol)|Patients with Parkinson's disease who were in the exercise group have completed a four-week supervised aerobic exercise protocol via Tele-rehabilitation.
89327938|NCT06215885||Subsolid nodules group|Patients with pulmonary subsolid nodules were identified by CT examination and intended for surgical treatment. All participants will undergo chest CT, genomic, and proteomic tests to identify related biomarkers and establish a clinical diagnostic model for the invasiveness of subsolid nodules.
89327939|NCT06215885||Volunteers group|Healthy volunteers.
89327940|NCT06215872|Active Comparator|Upper Extremity Exercises Group|Participants will treated exercises with focused on upper extremity especially wrist muscles.
89327941|NCT06215872|Experimental|Myofascial Chains Exercises Group|Participants will treated exercises with focused on whole body especilly myofascial chains.
89327942|NCT06215872|No Intervention|Control Group|Participants will do any exercises. They will join only assessment sessions.
89327943|NCT06215846|Experimental|BioTTT001 injection|BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10^9 viral particle (VP) ,5×10^10 VP and 5×10^11 VP based on the 3+3 dose escalation principle.
89327944|NCT06215807|Active Comparator|Femtosecond laser arcuate keratotomy|femtosecond laser arcuate keratotomy will be designed using Donnenfeld nomogram.
89327945|NCT06215807|Active Comparator|Toric intraocular lens implantation|The Toric IOL power and alignment axis were calculated using the online calculator available at https://www.tecnistoriccalc.com
89327946|NCT06215768|Experimental|Dexemedetomidine group A|Patients aged( 2_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous dexmedetomidine 0.5 μg/kg
89327947|NCT06215768|Experimental|Midazolam group B|Patients aged( 2_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous midazolam 0.1 mg/kg
89327948|NCT06215716|Experimental|EFX 28 mg|
89327949|NCT06215716|Experimental|EFX 50 mg|
89327950|NCT06215716|Placebo Comparator|Placebo|
89327951|NCT06215664|Experimental|Singularities Game|Singularities is an online game.
89327952|NCT06215664|Active Comparator|Psychoeducation Readings|Psychoeducation Readings is a Qualtrics-delivered program.
89327953|NCT06215651|Experimental|Cadonilimab and lenvatinib|the combination therapy of Cadonilimab and Lenvatinib for conversion treatment in unresectable hepatocellular carcinoma
89327954|NCT06215638|Experimental|Bortezomib|
89327955|NCT06215625|Experimental|Stroke: TIGER group|Participants in the TIGER (tenodesis-induced-grip exoskeleton robot) group will operate the TIGER system. They will undergo a 30-minute home-based training program twice a day, 5 days a week for 4 weeks.
89327956|NCT06215625|Active Comparator|Stroke: TOT group|Participants in the TOT (task-oriented training) group will receive task-oriented training as home program. They will undergo a 30-minute home-based training program twice a day, 5 days a week for 4 weeks.
89327957|NCT06215625|Experimental|Spinal cord injury: TIGER group|Participants in the TIGER (tenodesis-induced-grip exoskeleton robot) group will operate the TIGER system. They will undergo a 40-minute home-based training program once a day, 5 days a week for 4 weeks.
89327958|NCT06215625|Active Comparator|Spinal cord injury: TOT group|Participants in the TOT (task-oriented training) group will receive task-oriented training as home program. They will undergo a 40-minute home-based training program once a day, 5 days a week for 4 weeks.
89327959|NCT06215573|Experimental|Melatonin supplementation|5mg melatonin supplement from Ritual Inc's BioSeries
89327960|NCT06215573|Placebo Comparator|Placebo supplementation|Placebo supplement from Ritual Inc.
89327961|NCT06215560||Usual Care|Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.
89327962|NCT06215560||CDS Alert|"Providers will see a pop-up alert within the electronic health record (EHR) when they initiate an opioid or benzodiazepine prescription without recording use of the prescription drug monitoring program (PDMP) database.~Alerts do not appear with patients with oncology or sickle cell diagnoses, or hospice discharge orders."
89327963|NCT06215547|Other|The Medtronic Enterra II Model 37800 Neurostimulator|It is powered by a hermetically sealed hybrid cathode silver vanadium oxide (HCSVO) single-cell battery. To further protect the neurostimulator components from body fluids, the electronics and power source are hermetically sealed within an oval-shaped titanium shield. The neurostimulator case has an external insulating coating to prevent skeletal muscle stimulation at the neurostimulator implant site. An uninsulated area on one side of the neurostimulator (etched identification side) forms the indifferent electrode. The uninsulated side should be positioned away from muscle tissue. The neurostimulator has a self-sealing connector assembly with a corrosion-resistant titanium alloy body & titanium setscrews. Securing the lead system requires the use of a torque wrench which is packaged with the neurostimulator.
89327964|NCT06215521|Experimental|Pirtobrutinib|Pirtobrutinib a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
89327965|NCT06215521|Placebo Comparator|Placebo|Placebo (matched to Pirtobrutinib) a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
89327966|NCT06215521|Active Comparator|Moxifloxacin|Moxifloxacin a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
89327967|NCT06215482||"A-N group (Anxious-Non-anxious group)"|Upon admission, participants filled out a Anxiety Disorder Screening Scale, this group scored <10 points
89327968|NCT06215482||"N-N group (Non-anxious-Non-anxious group)"|Upon admission, participants filled out a Anxiety Disorder Screening Scale, this group scored ≥10 points
89327969|NCT06215456|No Intervention|Control|The control group will be treated according to local protocol. Unless contra-indicated, patients experiencing moderate to severe anxiety before undergoing ICA may receive preprocedural oxazepam (10 mg, oral) at the day care unit and diazepam (5 mg, intravenous) before arterial puncture at the catheterization room at nurses and physicians discretion. In patients planned for coronary function testing, benzodiazepines are withheld per protocol.
89327970|NCT06215456|Active Comparator|Virtual Reality therapy|The VR intervention group will receive two sessions of VRH in addition to standard care. Before starting the first guided session in this study, patients can use VR during the waiting time using SyncVR Relax & Distract (SyncVR Medical, Utrecht, The Netherlands). Subsequently, the first session of VRH is administered at the day-care unit 20 minutes prior to the procedure. After the first session patients is transported to the catheterization room, where the treatment team have the possibility to introduce themselves to the patients. The second session of VRH is administered during arterial access puncture in the catheterization room, starting 5 minutes prior to puncture and terminating when the diagnostic or guiding coronary catheter is in position. The rest of the procedure will be continued without VR.
89327971|NCT06215430|Experimental|Period 1: Probe Drug Cocktail|Caffeine, omeprazole, and warfarin administered as a single dose of probe drug cocktail along with vitamin K (tablets) in the morning on Day 1 followed by a fast of at least 10 hours pre dose and 2 hours post dose.
89327972|NCT06215430|Experimental|Period 2: LOXO-305 + Probe Drug Cocktail|"LOXO-305 will be administered orally once daily for 14 consecutive days in the morning. On Day 15, LOXO-305 will be coadministered with caffeine, omeprazole and warfarin administered orally as a single dose of probe drug cocktail, along with vitamin K.~There will be a washout period of 5 days between administration of the probe drug cocktail on Day 1 (Period 1) and the first dose of LOXO-305 on Day 6 (Period 2)."
89327973|NCT06215417|Experimental|HDA|Human dermal allograft (LifeNet Health Arthroflex graft)
89327974|NCT06215417|Active Comparator|Regeneten|Bovine collagen patch xenograft (Smith & Nephew Regeneten)
89327975|NCT06215391|No Intervention|commercial mask|Noninvasive ventilation delivered through a conventional mask as usual care
89327976|NCT06215391|Experimental|3d printed mask|"The customized mask will be obtained by merging the scanned surface with the base mask design using CAD 3D SolidWorks software, also available in the unit. In patients with edentulism, leak areas will be evaluated without dental prostheses.~3D Printing~Personalized oronasal masks will be manufactured following this procedure:~Design and manufacture of molds for each type of base mask and the personalized mold of the scanned surface, using stereolithography technology with suitable biocompatible resin such as BioMed Clear or White from FormLABS.~Manual injection of a biocompatible resin with a Shore A hardness of 18, such as SORTA-Clear™ 18, by joining the two molds. This Shore A hardness will provide appropriate elasticity for this type of mask, perfectly adapting to each patient's unique facial characteristics."
89327977|NCT06215378|Experimental|Systematic heparine antagonization with protamine sulphate|Complete reversal of the Heparin administered during the TAVI achieved through the infusion of a protamine solution until the ACT returns to its baseline level.
89327978|NCT06215378|No Intervention|No Systematic heparine antagonization with protamine sulphate|No administration of protamine solution unless a participant encounters a bleeding event requiring a surgery or percutanous intervention.
89327979|NCT06215339|Experimental|group where diet education is given|"Patients in the experimental group were given face-to-face diet education by the researcher in the waiting room for approximately 15 minutes and an Information Brochure was given.~Pre-training (pre-test) for hemodialysis patients Data collection tools were applied. All data collection tools were applied to these patients, except for the structured Patient Information Form for post-training measurements (intermediate measurement) 1 month after the training was given."
89327980|NCT06215339|No Intervention|Control group|No treatment was performed on hemodialysis patients in this group. Only data collection forms were applied to the patients before the study (pretest), at the 1st week (intermediate measurement/1st measurement) and at the end of the study. (8th week) 3 times in total for 8 weeks.
89327981|NCT06215313|Experimental|Patients with PTSD|Patients with PTSD will be randomly assigned to either EMDR or IR. They will receive two 75-minute sessions of either EMDR or IR each week, with one additional coaching session in both conditions (EMDR and IR).
89327982|NCT06215313|Experimental|Patients with depression|Patients with depression will be randomly assigned to either EMDR or IR. They will receive two 75-minute sessions of either EMDR or IR each week, with one additional coaching session in both conditions (EMDR and IR).
89327983|NCT06215313|Experimental|Patients with PTSD and depression|Patients with PTSD and depression will be randomly assigned to either EMDR or IR. They will receive two 75-minute sessions of either EMDR or IR each week, with one additional coaching session in both conditions (EMDR and IR).
89327984|NCT06215300||genotype GG|GG
89327985|NCT06215300||genotype AG/АА|AG/АА
89327986|NCT06215287||Exjade Prescribers/HCP receiving Educational Materials|HCPs prescribing Exjade in the EU/EEA provided with Exjade Educational Materials
89327987|NCT06215248||LEAD|LEAD diagnosis confirmed by by ankle-brachial index (≤0,9 or >1,3) or angiography. Fontaine I-IV class symptoms.
89327988|NCT06215248||Controls|Matched with LEAD group's patients as much as possible for age, sex, smoking history, hypertension, diabetes, coronary artery disease.
89327989|NCT06215235||Persons involved in BLT|Persons with ID and staff who are involved in BLT. Either by receiving BLT, or by prescribing or facitating BLT.
89327990|NCT06215222||Healthy patients|Healthy Patients
89327991|NCT06215222||IBS/Functional GI diasease|Patients with IBS or Functional GI disease (bloating, diarrhea, constipation)
89327992|NCT06215209||ultra-low tidal volume group|ARDS patients with ultra-low tidal volume ventilation
89327993|NCT06215170|No Intervention|Control|General Instructions on Opioid Disposal
89327994|NCT06215170|Active Comparator|Treatment|General Instructions on opioid disposal Device: SafeMedWaste Opioid Disposal Kit
89327995|NCT06215157|Active Comparator|Flotrac Group|In this group,an arterial catheter was inserted preoperatively. An indwelling radial artery catheter was connected to the hemodynamic monitoring system (EV1000; Edward Lifesciences Corp., Irvine, CA, USA) via FloTrac™ (Edwards Lifesciences Corp.) sensors.
89327996|NCT06215157|Experimental|BioZ Group|In this group,haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™) monitoring.
89327997|NCT06215092||Developmental learning disorder|Children above 5 years old, with formal diagnosis of Developmental learning disorder.
89327998|NCT06215092||Disorder of intellectual development, mild|Children above 5 years old, with formal diagnosis of Disorder of intellectual development, mild.
89327999|NCT06215092||Attention deficit hyperactivity disorder|Children above 5 years old, with formal diagnosis of Attention deficit hyperactivity disorder (ADHD).
89328000|NCT06215092||Autism spectrum disorder|Children above 5 years old, with formal diagnosis of Autism spectrum disorder (ASD).
89328001|NCT06215092||Learning difficulties|Children above 5 years old, with difficulties in reading and/or writing without formal diagnosis of Developmental learning disorder.
89328002|NCT06215092||Control group|Children above 5 years old without formal diagnosis of neurodevelopmental disorders.
89328003|NCT06215079|Active Comparator|active transcranial magnetic stimulation in stroke patients with complex regional pain syndrome|The intermittent theta-burst stimulation (iTBS) intensity for patients, applied under doctor supervision for a total of 5 days over one week (from Monday to Friday), will be set at 70% of the resting motor threshold. Stimulation will consist of bursts at a frequency of 50 Hz, with 3 bursts every 10 seconds, each burst lasting 2 seconds, totaling 600 bursts. Subsequently, the resting motor threshold will be adjusted to 80%, and a total of 2000 bursts will be delivered at a frequency of 10 Hz, repeated every 30 seconds, each lasting 10 seconds.
89328004|NCT06215079|Sham Comparator|sham transcranial magnetic stimulation in stroke patients with complex regional pain syndrome|Similar protocol will be applied and sham transcranial magnetic stimulation treatment will be given with a sham coil to the sham group.
89328005|NCT06215079|Placebo Comparator|conventional rehabilitation program in stroke patients with complex regional pain syndrome|Only a conventional rehabilitation program consisting of discontinuous ultrasound, transcutaneous electrical nerve stimulation (TENS), and contrast bath, formed by 5 sessions, will be applied to this group.
89328006|NCT06215066|Active Comparator|Modified Progressive Muscle Relaxation Group (MPMR)|
89328007|NCT06215066|Active Comparator|Virtual Reality Group (VR)|
89328008|NCT06215053|Other|group 1|Following induction of anesthesia, ESP block will be performed before the surgery begins
89328009|NCT06215053|Other|group 2|An ESP block will be performed before waking the patient at the end of surgery.
89328010|NCT06215040||Asymptomatic common bile duct stone|
89328011|NCT06215027|Experimental|Dance|Dance
89328012|NCT06215014|Experimental|Handgrip training|Participants will perform isometric handgrip training 3 days per week for a month.
89328013|NCT06215014|No Intervention|Control|Participants will not perform isometric handgrip training for a month.
89328014|NCT06215001|Experimental|EFL Positive - intervention|Patients with Expiratory flow limitation will undergo a positive end-expiratory pressure trial to assess the level of positive end-expiratory pressure that eliminates the Expiratory Flow limitation. Positive end-expiratory pressure will be therefore set according to this value.
89328015|NCT06215001|Active Comparator|EFL Positive - control group|Patients with Expiratory flow limitation will undergo a positive end-expiratory pressure trial to assess the level of positive end-expiratory pressure that eliminates the Expiratory Flow limitation. Positive end-expiratory pressure will be set at a fixed level of 4 cmH2O.
89328016|NCT06215001|No Intervention|EFL negative patients|Patients with negative positive end-expiratory pressure test (no expiratory flow limitation) will be treated according to the current evidence and followed up for 7 days after surgery to evaluate the incidence of pulmonary postoperative complications.
89328017|NCT06214988|Experimental|selective approach to defunctioning stoma|With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.
89328018|NCT06214988|No Intervention|routine use of defunctioning stoma|With randomisation to this control arm (systematic approach), a defunctioning stoma is constructed using the marked stoma site. A loop ileostomy is fashioned using an ileal loop close to the ileocecal valve, while a loop colostomy can be derived from either the transverse or a redundant left colon.
89328019|NCT06214975|Active Comparator|EXOPULSE Mollii Suit Stimulation Active|This will be the EXOPULSE Mollii Suit Active Stimulation. Stimulation will go on for 60 minutes while control unit is on for 60 minutes
89328020|NCT06214975|Sham Comparator|EXOPULSE Mollii Suit Stimulation Sham|This will be the EXOPULSE Mollii Suit Sham Stimulation. Stimulation will go on for 1 minute then it turns off while the control unit will remain on for total of 60 minutes.
89328021|NCT06214949|Experimental|Personalized Repetitive Transcranial Magnetic Stimulation|
89328022|NCT06214949|Experimental|Sham Personalized Repetitive Transcranial Magnetic Stimulation|
89523484|NCT05237323|Active Comparator|control group|Group 2 included 25 patients who received azathioprine at an average dose of 150 [75; 150] mg per day per os and methylprednisolone in an average starting dose 24 [24; 32] mg per day per os and standard drug therapy for heart failure (beta-blockers, angiotensin converting enzyme inhibitors or angiotensin II receptor blocker, mineralocorticoid receptor antagonist angiotensin receptor-neprilysin inhibitor (if required), diuretics (if required))
89328025|NCT06214884|Experimental|Mindfulness for All (MFA) Group|"This intervention program named MINDFULNESS FOR ALL (MFA) developed on the conceptual basis of traditional mindfulness programs. Its formal structure resembles the traditional mindfulness programs, but it has been tailored to meet the needs and demands of employees.The MFA will take place in a group setting with 10-15 participants per cluster. Due to participants' convenience, the delivery mode of each intervention session would be conducted online. At the end of session, they will be provided the task and supplementary materials (e-book, short audio, and video) to be apply after the session.~The modules will be delivered by two trainees. Both trainees have received the certificates from the mindfulness-based strategic awareness training course. Participants in the intervention group will be joining the modules for 5 sessions weekly for 60-minute/session. Details on the modules can be referred in the Supplement material."
89328026|NCT06214884|Active Comparator|Wait-list control group|The wait-list control group will receive their training two weeks after interventional group complete their training. There will be a 90-minute online training session aimed at introducing participants to mindfulness in general and encouraging them to practice mindfulness by teaching several techniques. There will be no potential harm occurs among the subjects in the wait-list control group.
89328027|NCT06214858|Experimental|（Trial group）-SHEN211 tablets|"part 1：Four dose groups were set up: 110mg,330mg, 550mg and 770mg, each group was intended to include 2 subjects and was administered orally. SHEN211 tablets in the corresponding dose group were given on fasting in the morning of D1. PK blood collection and related tests were completed on day 8 (D8), PK and safety tests were completed on day 10 (D10), and telephone follow-up was performed on day 14 (D14±1).~part 2：Two dose groups were set up with 8 subjects in each group. In the first dose group, 330mg SHEN211 tablets D1 and 110mgSHEN211 tablets D2 ~ D5 were taken orally once a day (QD). The second dose group was taken orally 660mg SHEN211 tablets on D1 and 220mg SHEN211 tablets from D2 to D5, once a day (QD). PK samples were collected before and after administration, and safety observation was performed up to 8 days after the last administration."
89328028|NCT06214858|Placebo Comparator|（Placebo group）-placebo tablets|"part 1：Four dose groups were set up: 110mg,330mg, 550mg and 770mg, each group was intended to include 2 subjects and was administered orally. placebo tablets in the corresponding dose group were given on fasting in the morning of D1. PK blood collection and related tests were completed on day 8 (D8), PK and safety tests were completed on day 10 (D10), and telephone follow-up was performed on day 14 (D14±1).~part 2：Two dose groups were set up with 8 subjects in each group. In the first dose group, 330mg placebo tablets D1 and 110mg placebo tablets D2 ~ D5 were taken orally once a day (QD). The second dose group was taken orally 660mg placebo tablets on D1 and 220mg placebo tablets from D2 to D5, once a day (QD). PK samples were collected before and after administration, and safety observation was performed up to 8 days after the last administration."
89328029|NCT06214858|Experimental|（Food influence group）-SHEN211 tablets|The dose of SHEN211 tablets 330mg was intended to be selected in this experiment. Subjects in group A took SHEN211 tablets 330mg orally on an empty stomach in the morning of the first day of the experiment (the first cycle). On the morning of the 12th day of the trial (the second cycle), SHEN211 tablets 330mg were taken orally once, 30min after starting to eat a high-fat high-calorie meal; Subjects in group B took SHEN211 tablets 330mg orally once in the morning of the first day of the trial (the first cycle) when they started to eat A high-fat and high-calorie meal for 30min, and took SHEN211 tablets 330mg orally in the morning of the 12th day of the trial (the second cycle) on an empty stomach.
89328030|NCT06214845|Experimental|Automated REX|Automated REX
89328031|NCT06214845|Active Comparator|Manual REX|First manual REX will be performed as soon as possible after randomisation, and the patient will be re-assessed every 24 hours (repeated manual REX will be allowed in case of clinical worsening after 24 or 48 hours or in the absence of clinical improvement after 72 hours)
89328032|NCT06214754|Active Comparator|Intravascular high-pressure cutting balloon catheter|
89328033|NCT06214754|Active Comparator|Boston Scientific Corporation|
89328034|NCT06214728|Placebo Comparator|MINST|Minimally invasive non-surgical treatment (MINST): Using mini five curettes and ultrasonic devices with precise tips , the root surfaces were cleaned reaching to the base of the pocket, avoiding excessive root surface smoothing and gingival curettage.
89328035|NCT06214728|Active Comparator|MINST+HA|Minimally invasive non-surgical technique (MINST) with application of Hyaluronıc Acid gel: Using mini five curettes and ultrasonic devices with precise tips , the root surfaces were cleaned reaching to the base of the pocket, avoiding excessive root surface smoothing and gingival curettage. HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus.
89328036|NCT06214702||Study group|Patients with diastolic blood pressure (DBP) after the 20th GW up ≥140 or 90 mmHg without proteinuria.
89328037|NCT06214702||Control Group|Patients were normotensive at the 20th GW.
89328038|NCT06214598|Experimental|AI Diet|Personalised diet rich in whole grains high in fibres, vegetables (particularly leafy greens and tomatoes), polyphenol-rich fruits (berries), and n-3 FAs foods (fatty fish, nuts, seeds and oils)
89328039|NCT06214598|Active Comparator|Supplements|2 gel capsules/d of fish oil (FO) + 3 gel capsules/d of evening primrose oil (EPO), containing 600 mg EPA, 400 mg DHA and 351 mg GLA + Standard diet: 55% carbohydrate, 15% protein and 30% fats
89328040|NCT06214598|Placebo Comparator|Placebo|Standard diet: 55% carbohydrate, 15% protein and 30% fats + placebo capsules
89328041|NCT06214260||Endometriosis|Women suggested endometriosis by clinical presentations & imaging and scheduled for surgical treatment (laparotomy/laparoscopy) at the age of 18-45 years having regular menstrual cycles will be recruited. Finally laparoscopy and histology confirmed endometriosis cases will be eligible for the final analysis.
89523485|NCT05226715|Experimental|Intervention|Received a bilateral, lower extremity manipulation series
88806652|NCT05900804|Experimental|Intervention Group|"On the 3rd postoperative day, patient information form, patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied in the patient room. Afterwards, the training prepared in line with the fracture liaison service model will be verbally explained to the patients and then the booklet prepared by taking expert opinion will be given to the patients.~3rd week patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied in orthopedics and traumatology outpatient clinic.~3rd month patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied at home visit."
89328042|NCT06214260||Healthy groups|Control subjects at the age of 18-45 years, who have regular menstrual cycles and self-reported no history suggestive of a diagnosis of endometriosis will be recruited.
89328043|NCT06214182||Group T1|T1 is before CPB.
89328044|NCT06214182||Group T2|T2 is 2 hours after CPB.
89328045|NCT06214182||Group T3|T3 is 3 days after CPB.
89328046|NCT06214091|Experimental|Gastrointestinal decompression group|
89328047|NCT06214091|Placebo Comparator|Control group|
89328048|NCT06213961|Experimental|arm trained with pecha kucha|Before basic life support training is given to students, an introductory characteristics form and basic life support skill questions will be applied (pre-test). Skill questions will be administered immediately after the PK training presentation, which includes basic life support skills, is given to the students (Posttest 1), and 4 weeks later.
89328049|NCT06213961|No Intervention|control arm|Before basic life support training is given to students, an introductory characteristics form and basic life support skill questions will be applied (pre-test). Immediately after the traditional powerpoint training presentation, which includes basic life support skills, is given to the students (Posttest 1), the skill questions will be administered again 4 weeks later.
89328050|NCT06213649|Experimental|Topical steroids|Participants in this arm will receive anti-amoebic therapy plus topical steroids.
89328051|NCT06213649|Placebo Comparator|Topical placebo|Participants in this arm will receive anti-amoebic therapy plus topical placebo.
89328052|NCT06213441|Experimental|arm trained with pecha kucha|Before the patient is discharged from the clinic, the data collection form and scales will be administered to the patient (pre-test). Pecha kucha (PK) training presentation will be shown to the patient via mobile phone before the patient leaves the clinic and will also be shared via WhatsApp via the phone numbers they use. While the PK training presentation is approximately 5-7 minutes, the time to fill out the scales is approximately 10-15 minutes. 4 weeks after the training, the scale will be administered to the participants again via an online survey (posttest).
89328053|NCT06213441|No Intervention|control arm|The data collection form and scales will be applied to the patient before the patient is discharged from the clinic (pre-test). Routine training is provided by the wound and stoma care nurse before the patient is discharged from the clinic. The scale will be administered to the patient again via an online survey 4 weeks after discharge (posttest).
89328054|NCT06213155|Experimental|Cryoneurolysis|
89328055|NCT06213155|Sham Comparator|Stimulation|
89328056|NCT06213038|Experimental|Dose Level 1|SKG0106 One-Time Intraocular Injection Dose Level 1
89328057|NCT06213038|Experimental|Dose Level 2|SKG0106 One-Time Intraocular Injection Dose Level 2
89328058|NCT06213038|Experimental|Dose Level 3|SKG0106 One-Time Intraocular Injection Dose Level 3
89328059|NCT06213012|Active Comparator|Transcutaneous Spinal Stimulation (TSS)|Spinal Stimulation delivered over the skin using a research stimulator with conventional surface electrodes during research visits.
89328060|NCT06213012|Sham Comparator|Sham|Sham Stimulation delivered over the skin using a research stimulator with conventional surface electrodes during research visits. Sham stimulation will be delivered using the intensity of stimulation set as during active sessions of ESS, but then gradually decreased down to zero in approximately 30 s. There will be 5-10 minute breaks interspersed between intervals of stimulation, and will vary according to the individual's tolerance and fatigue levels
89328061|NCT06213012|Experimental|Epidural Spinal Stimulation (ESS)|Stimulation delivered internally using an implanted device operated by an external control (only used during research visits).
89328062|NCT06211933|Experimental|HIFU intervention|HIFU intervention
89328063|NCT06211283|Experimental|Treatment A, Orfiril long, 500 mg prolonged release minitablets|fasting
89328064|NCT06211283|Experimental|Treatment B, Orfiril long, 500 mg prolonged release minitablets|fed
89328065|NCT06211283|Active Comparator|Treatment C, Ergenyl chrono 500 mg prolonged release tablets|fasting
89328066|NCT06211283|Active Comparator|Treatment D, Ergenyl chrono 500 mg prolonged release tablets|fed
89328067|NCT06209125|Other|study group|use new device for treatment of class II malocclusion
89328068|NCT06209086|Active Comparator|incisal capped twin block|"The incisal capped Twin Block, which was used for the first group composed of two parts. The upper part had labial bow over labial surface of upper anterior teeth using Adam and ball clasps for retention.~The lower part included ball clasp between lower anterior teeth and Adam clasp on lower first premolar with the additional modifications:~The lower incisors were capped with acryl.~lower incisors were relieved from the lingual side with wax."
89328069|NCT06209086|Active Comparator|skeletal anchored twin block|"This appliance was constructed as the modified Twin Block used for the incisal capped appliance in addition to the following modifications:~Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally."
89328070|NCT06206291|Active Comparator|Methadone CBD|CBD capsules (BSPG Laboratories) in two dosing periods for a total of 8 weeks.
89328071|NCT06206291|Placebo Comparator|Methadone Placebo|Matching placebo.in first dosing period and CBD 400mg in second dosing period
89328072|NCT06206291|Active Comparator|Buprenorphine CBD|CBD capsules (BSPG Laboratories) in two dosing periods for a total of 8 weeks.
89328073|NCT06206291|Placebo Comparator|Buprenorphine Placebo|Matching placebo.in first dosing period and CBD 400mg in second dosing period
89328074|NCT06206031|Experimental|"Intraosseous ultrasonography"|All subjects of each sub-protocol receive identical intervention (single group assignment for each of 2 sub-protocols).
89328075|NCT06203912|Experimental|Treatment (cyclophosphamide, dexamethasone, TiNK, isatuximab)|Patients receive cyclophosphamide IV on day 1, dexamethasone PO on days 1-4, TiNK IV on day 8, and isatuximab IV on days 8 and 15 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy during screening and on study, as well as optionally during follow up. Patients undergo ECHO during screening and blood sample collection throughout the study.
89328076|NCT06203028|Experimental|Experimental Group|The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.
89328077|NCT06203028|No Intervention|Control Group|The Cyberbullying Awareness Training program will not be applied to students in the control group.
89328078|NCT06199271|Experimental|Treatment group|Patients with resectable locally advanced head and neck squamous carcinoma cell carcinoma receive adebrelimab plus dalpiciclib before surgery.
89328079|NCT06192888|Experimental|Participants with Mantle Cell Lymphoma|Participants will be diagnosed with relapsed, refractory (R/R) mantle cell lymphoma (MCL) with prior BTK inhibitor (BTKi) failure
89328080|NCT06188039|Experimental|Patients undergoing open aortic surgery with sinus rhythm|Arm to validate SVC-CI during open aortic surgery with special focus of predicting FR during aortic cross clamping (n=50).
89328081|NCT06188039|Experimental|Patients undergoing laparotomy and high PEEP|Arm designed to validate SVC-CI during laparotomy, ventilated with high PEEP levels (8-10cmH2O). PEEP will be raised transiently during measurements (n=50).
89328082|NCT06188039|Active Comparator|Patients undergoing laparotomy with standard ventilatory settings|Arm designed as an active comparator with standard (protective) ventilatory settings (n=50). Tidal volumes (Vt) will be set for 8ml/kg.
89328083|NCT06182644|Experimental|Positron-labeled FAPI PET/CT|Imaging was performed 60 minutes after injection of 5mci Positron-labeled FAPI tracer
89328084|NCT06178783|Experimental|Brensocatib Treatment Sequence ADBC|Participants will taste and expectorate Dose 1 of each brensocatib formulation across the 4 treatment administrations (Treatments A, B, C, and D), orally on Day 1 in the sequence ADBC.
89328085|NCT06178783|Experimental|Brensocatib Treatment Sequence BACD|Participants will taste and expectorate Dose 1 of each brensocatib formulation across the 4 treatment administrations (Treatments A, B, C, and D), orally on Day 1 in the sequence BACD.
89328086|NCT06178783|Experimental|Brensocatib Treatment Sequence CBDA|Participants will taste and expectorate Dose 1 of each brensocatib formulation across the 4 treatment administrations (Treatments A, B, C, and D), orally on Day 1 in the sequence CBDA.
89328087|NCT06178783|Experimental|Brensocatib Treatment Sequence DCAB|Participants will taste and expectorate Dose 1 of each brensocatib formulation across the 4 treatment administrations (Treatments A, B, C, and D), orally on Day 1 in the sequence DCAB.
89328088|NCT06172881|Experimental|Distance Visual Acuity|Visual acuity will be measured while participant's wear study lenses.
89328089|NCT06166901|Experimental|AcrySof IQ PanOptix IOL - Non Toric|Implantation with AcrySof IQ PanOptix non toric IOL in both eyes 3-5 years prior to enrollment
89328090|NCT06166901|Experimental|AcrySof IQ PanOptix IOL - Toric|Implantation with AcrySof IQ PanOptix IOL in both eyes 3-5 years prior to enrollment, with at least one of the eyes implanted with a toric AcrySof IQ PanOptix IOL
89328091|NCT06166056|Experimental|Experimental: CHF6333|"CHF6333 active (Part I - SAD): once daily inhaled single dose of CHF6333 at each period (three dose levels for HVs and one dose level for BE subjects).~CHF6333 active (Part II - MD): once daily inhaled multiple dose of CHF6333 for 28 days consecutive days (two dose levels for BE subjects)."
89328092|NCT06166056|Placebo Comparator|Placebo comparator: CHF6333 Placebo|"CHF6333 placebo (Part I - SAD): once daily inhaled single dose of placebo matching CHF6333 at each period.~CHF6333 placebo (Part II - MD): once daily inhaled multiple dose of placebo matching CHF6333 for 28 days consecutive days."
89328093|NCT06165419|Experimental|SBRT to the spine|
89328094|NCT06154291|Experimental|Dose Escalation part then Expansion part|"Dose Escalation part: Six dose levels are planned: 1.5; 3; 6; 12; 16 and 20mg/kg~Expansion part: Up to 7 cohorts (1 cohort for one selected solid tumor type) could be investigated:~Cohort E1: Non-small cell lung cancer (NSCLC) Cohort E2: Gastro-esophageal adenocarcinoma Cohort E3: Colorectal cancer (CRC) Cohort E4: Pancreatic cancer Cohort E5: Sarcoma Cohort E6: Triple-negative breast cancer (TNBC) Cohort E7: Ovarian cancer"
89328095|NCT06142669||Revision Total Knee Arthroplasty|Single study group with either newly or previously implanted subjects with the EVOLUTION® Revision Tibia and EVOLUTION® Revision STEMMED CS Femur with the EVOLUTION® MP CS Insert.
89328096|NCT06138808||Stereoelectroencephalography (SEEG)|Participants undergoing SEEG as part of standard of care.
89328097|NCT06138808||Control Group|Participants not undergoing SEEG as part of standard of care.
89328098|NCT06128590|Experimental|Experimental: Photobiomodulation (Group A)|Participants will receive photobiomodulation therapy immediately before local anesthesia, in the same place where the puncture will be performed for pterygomandibular anesthesia.
89328099|NCT06128590|Sham Comparator|Control: Laser Sham (Group B)|The participants will be treated in the same way as in group A. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same place as described for the experimental group, but the equipment will be switched off. So that the participant does not identify the group to which they belong, the device's activation sound (beep) will be simulated by the device itself, which makes the beep sound by pressing the activation button only once. After this, pterygomandibular anesthesia will be carried out in the same way.
89328100|NCT06127459|Experimental|Parental Guidance+Virtual Reality Game|
89328101|NCT06127459|No Intervention|Control Group|This group implement the rehabilitation plan drawn up in specialized medical care (treatment as usual).
89328102|NCT06119074|Experimental|Gifted Savings|Participants in the treatment group will receive an unconditional Gifted Savings account with $2,000 of assets ($100 USD available upon enrollment; $500 USD available for emergency use each year for two years).
89328103|NCT06119074|No Intervention|No Gifted Savings|Participants in the control group will not receive a Gifted Savings account.
89328104|NCT06116006|Other|Subjects with 3 experimental conditions|"3 types of upper limb pointing movements:~movements with robot assistance~movements without robot assistance~movements with robot resistance"
89328105|NCT06114043|Other|Operation|60 participants will be operated for mild to moderate hallux valgus deformity
89328106|NCT06114043|Other|Conservative|60 participants will be treated conservatively with a wide shoe
89328107|NCT06109831|Experimental|SHR-1918|
89328108|NCT06109831|Placebo Comparator|SHR-1918 placebo|
89328109|NCT06100770||Aveir AR Leadless Pacemaker|This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.
89523486|NCT05226715|No Intervention|Control|30 seconds of lying supine on a chiropractic bench (control) without manual manipulation
89328110|NCT06100770||Single-Chamber Atrial Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber atrial pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study.
89328111|NCT06072755||Critically ill adults|Inpatient adults who require internal jugular venous central line and radial arterial line
89328112|NCT06062420|Experimental|Dostarlimab Monotherapy|
89328113|NCT06062420|Experimental|Sub study 1: Dostarlimab and Belrestotug|
89328114|NCT06062420|Experimental|Sub study 2: Dostarlimab and GSK6097608|
89328115|NCT06062420|Experimental|Sub study 3: Dosarlimab and Belrestotug and GSK6097608|
89328116|NCT06038539|Experimental|Treatment Arm A: PERT-IJS plus trastuzumab, carboplatin and docetaxel|"Part 1 (Cycle 1 to 6):~Initial loading dose of PERT-IJS is 840 mg administered as an approximately 60-minute IV infusion followed every 3 weeks by a maintenance dose of 420 mg administered as an IV infusion over a period of approximately 30 to 60 minutes.~Trastuzumab: Initial dose of trastuzumab is 8 mg/kg administered as approximately 90-minute IV infusion followed every 3 weeks by 6 mg/kg IV infusion over 30 to 90 minutes Carboplatin: Area Under the Curve (AUC) 6 for Cycles 1 to 6 Docetaxel: 75 mg/m2 by IV infusion every 3 weeks for Cycles 1 to 6~Part 2 (Cycle 7 - till end of 1 year from Cycle 1 day 1):~Initial loading dose of PERT-IJS is 840 mg administered as approximately 60-minute IV infusion followed every 3 weeks by a maintenance dose of 420 mg administered as an IV infusion over a period of approximately 30 to 60 minutes.~Trastuzumab: As mentioned in part 1"
89328117|NCT06038539|Active Comparator|Treatment Arm B: EU-Perjeta plus trastuzumab, carboplatin and docetaxel|"Part 1 (Cycle 1 to 6):~Initial loading dose of EU- Perjeta is 840 mg administered as approximately 60-minute IV infusion followed every 3 weeks by a maintenance dose of 420 mg administered as an IV infusion over a period of approximately 30 to 60 minutes.~Trastuzumab: Initial dose of trastuzumab is 8 mg/kg administered as approximately 90-minute IV infusion followed every 3 weeks by 6 mg/kg IV infusion over 30 to 90 minutes Carboplatin: Area under the curve 6 for Cycles 1 to 6 Docetaxel: 75 mg/m2 by IV infusion every 3 weeks for Cycles 1 to 6~Part 2 (Cycle 7 onwards till end of 01 year from Cycle 1 day 1):~The patients will be re-randomized (1:1) to receive EU- Perjeta + trastuzumab or PERT-IJS + trastuzumab.~Initial loading dose of PERT-IJS is 840 mg administered as approximately 60-minute IV infusion followed every 3 weeks by a maintenance dose of 420 mg administered as an IV infusion over a period of approximately 30 to 60 minutes.~Trastuzumab: As mentioned in part 1"
89328118|NCT06033014|No Intervention|Control|The one-year mortality prediction, calculated by the PM Heart algorithm, will not be available to the physician.
89328119|NCT06033014|Experimental|Intervention|The one-year mortality prediction, calculated by the PM Heart algorithm, will be available to the physician.
89328120|NCT06031077||Cardiologist Assessed Conditions.|The consultant Cardiologist will decide on the various types of presentations and symptoms that will be use full in generating this study.
89328121|NCT06030154|Experimental|Amplification of Positivity Therapy|AMP-A will involve 12, one-hour weekly therapy sessions completed one-on-one with a therapist. The sessions and between-session homework will focus on amplifying positive thoughts, emotions, and behaviors to address anxiety/depression and alcohol use.
89328122|NCT06030154|Active Comparator|Cognitive Behavioral Therapy|The CBT intervention will involve 12, one-hour weekly therapy sessions completed one-on-one with a therapist. The sessions and between-session homework will focus on monitoring of the relationship between thoughts, emotions, and alcohol use.
89328123|NCT06023706|Experimental|Capsaicin 179 mg cutaneous patch|"Capsaicin 179 mg cutaneous patch.~1 patch applied once for 1 hour at inclusion visit."
89328124|NCT06023706|Placebo Comparator|Capsaicin low concentration patch|"Capsaicin 0.04 cutaneous patch.~1 patch applied once for 1 hour at inclusion visit"
89328125|NCT06011681||Depression|Seniors diagnosed with late life depression or with a concern of late life depression.
89328126|NCT06011681||Mild cognitive impairment|Seniors with self-reported decline in cognitive function or with a diagnosis of mild cognitive impairment.
89328127|NCT06011681||Healthy controls|Seniors with no neurological or psychiatric symptoms or conditions.
89328128|NCT05970549|Experimental|IRRAflow with Active Fluid Exchange arm|The analysis of the IRRAS catheter will occur prospectively if it is determined the patient meets the enrollment criteria.
89328129|NCT05970549|Active Comparator|Retrospective analysis of traditional external ventricular drains|The retrospective analysis will be performed on the last 60 traditional external ventricular drains.
89328130|NCT05958381|Experimental|Transcranial direct current stimulation|"Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.~Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10"
89523487|NCT03394261|Experimental|Patient Decision Aid|Patients in this arm will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
89523488|NCT03394261|No Intervention|Record-only control group|Treatment records of patients receiving treatment in the same clinic in the prior 3 months will be abstracted for comparison purposes.
88806653|NCT05900804|No Intervention|Control group|"On the 3rd postoperative day, patient information form, patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied in the patient room.~Week 3 patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied in orthopedics and traumatology outpatient clinic.~3rd month patient follow-up form, Edmonton frailty scale, kinesiophobia causes scale and care dependency scale will be applied at home visit. Afterwards, the training prepared in line with the fracture liaison service model will be verbally explained to the patients and then the booklet prepared by taking expert opinion will be given to the patients."
88806654|NCT05900739|Experimental|Intervention 1: Virtual Campus|This group received 7 sessions (one every 7 days) of one hour through moodle virtual campus (webinar) to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
89328131|NCT05958381|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
89328132|NCT05958303|Experimental|Antioxidant Cocktail|The first dose will be 500 mg vitamin C, 200 IU vitamin E, and 300 mg of alpha lipoic acid 120 minutes before MRI. The second dose will be 500 mg vitamin C, 400 IU vitamin E, and 300 mg of alpha lipoic acid 60 minutes before MRI.
89328133|NCT05958303|Active Comparator|Placebo|Placebo 120 minutes before MRI, followed by another dose of placebo 60 minutes before MRI.
89328134|NCT05941000|Experimental|CGM paired with behavior change technique interventions, physical activity intervention first|Participants in this arm will receive a continuous glucose monitor and they will receive two behavior change technique interventions via daily text messages over the course of eight weeks, in a series of four, two-week blocks. In the first two-week block, they will receive the physical activity behavior change technique intervention. In the second and third two-week blocks, they will receive the mood behavior change technique intervention. In the fourth two-week block, they will receive the physical activity behavior change technique intervention.
89328135|NCT05941000|Experimental|CGM paired with behavior change technique interventions, mood intervention first|Participants in this arm will receive a continuous glucose monitor and they will receive two behavior change technique interventions via daily text messages over the course of eight weeks, in a series of four, two-week blocks. In the first two-week block, they will receive the mood behavior change technique intervention. In the second and third two-week blocks, they will receive the physical activity behavior change technique intervention. In the fourth two-week block, they will receive the mood behavior change technique intervention.
89328136|NCT05940337||Elderly|
89328137|NCT05940337||Young adults|
89328138|NCT05934695||Mild lymphedema (stage 1)|International Society of Lymphology lymphedema severity stage 1, characterized by swelling with pitting, normal skin and tissue turgor. Participants assigned to this group will have mild swelling and tightness of the arm.
89328139|NCT05934695||Moderate lymphedema (stage 2)|International Society of Lymphology lymphedema severity stage 2, characterized by swelling with pitting as well as skin and tissue changes such as dermal thickening. Participants assigned to this group will have moderate swelling and tightness of the arm as well as skin changes without distortional warty-overgrowth or elephantiasis folds.
89328140|NCT05934695||Severe lymphedema (stage 3)|International Society of Lymphology lymphedema severity stage 3, characterized by swelling with non-pitting, and warty-overgrowth or elephantiasis folds of skin. Participants assigned to this group will have severe swelling and tightness of the arm with warty overgrowth of skin.
89328141|NCT05927415|Experimental|Mild renal impairment|Patients with 60 <= eGFR <90
89328142|NCT05927415|Experimental|Moderate renal impairment|Patients with 30 <= eGFR <60
89328143|NCT05927415|Experimental|Severe renal impairment|Patients with eGFR <30
89328144|NCT05927415|Experimental|Normal renal function|Patients with eGFR >=90
89328145|NCT05927090||Ascending Aorta Replacement (AAR) with or without Hemiarch Repair|Patients who will require a conservative prosthetic replacement of the ascending aorta with or without hemiarch.Patients who required a concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis
89328146|NCT05927090||Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)|Patient who will require the extensive procedure including ascending aorta replacement associated to root replacement with or without sparing of the aortic valve
89328147|NCT05927090||Ascending Aorta Replacement with Total Arch Replacement (TARP)|Patient who will require the extensive procedure including ascending aorta replacement associated to TARP
89328148|NCT05927090||Root and Ascending Aorta Replacement with Total Arch Replacement|Patient who will require the extensive procedure including root and ascending aorta replacement associated to TARP
89328149|NCT05919108|Active Comparator|Treatment A (endocrine therapy)|Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
89328150|NCT05919108|Experimental|Treatment B (endocrine therapy, neratinib)|Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
89328151|NCT05915572|Experimental|Mulligan Mobilization Technique Plus Traditional Physical Therapy Program|"Mulligan Mobilization Technique in addition to traditional physical therapy program (myofascial release, capsular stretching ex. strengthening ex. and ROM ex.) 3 sessions per week for 6 weeks. The therapist applied passive accessory glide to increase shoulder flexion, abduction, external rotation as the patient moved the arm actively in the desired direction with in a pain free range with dosage: 3 sets for 10 repetitions with 1 minute rest between sets. 3 times a week for 6 weeks.~Traditional physical therapy will include chin tucks, shoulder shrugs, shoulder circle, scapular retraction/adduction and shoulder ROM exercises, including shoulder flexion and abduction to improve glenohumeral & scapulothoracic motion and shoulder extension & adduction with moderate resistance and shoulder internal/external rotation with approximately two sets of 15 repetitions."
88806655|NCT05900739|Experimental|Intervention 2: Facebook|This group received 25 educational impacts (2-5 per week - during 7 weeks) through a private group of facebook. Activities were: posts, stories and Facebook Lives as workshops (recorded)
89328152|NCT05915572|Experimental|Traditional Physical Therapy Program|Traditional physical therapy program (myofascial release, capsular stretching ex. strengthening ex. and ROM ex.) 3 sessions per week for 6 weeks. Traditional physical therapy will include chin tucks, shoulder shrugs, shoulder circle, scapular retraction/adduction and shoulder ROM exercises, including shoulder flexion and abduction to improve glenohumeral & scapulothoracic motion and shoulder extension & adduction with moderate resistance and shoulder internal/external rotation with approximately two sets of 15 repetitions.
89328153|NCT05913752|Other|Healthy Subjects - Part A|Part A: Single dose (~ 24 ) Healthy Volunteers: At least four consecutive ascending dose cohorts (20 mg, 40, 80 and 160 mg) will be included in this part of the study in accordance with a pre-defined dose escalating scheme. In each cohort, 6 HVs will receive a single dose of investigation medicine product (CMND-100) starting with the lowest dose of 20 mg. Once dosed, the subjects will be sampled for PK for 24 hours following dosing and will be monitored for drug effects with a physical examination at the end of 24 hours after dosing and daily monitored for safety for a period of 1 week following dosing. Assuming no serious adverse reactions or limiting toxicity (grade 2 and higher) in up to 2, subjects are observed in this dose level, then the next 6 subjects are treated with the next escalated dose, in accordance with a pre-defined dose escalating scheme. The DSMB will review results and guide doses to be studied in Parts B, C and D.
89328154|NCT05913752|Other|AUD Subjects - Part B|Single dose (~12): After DSMB review of part A, binge drinking/AUD subjects will be enrolled in at least 2 consecutive ascending single dose cohorts using the highest tolerable doses from Part A. The first cohort (n=6) will start with the lower ascending dose and sampled for PK for 24 hours following dosing and will be monitored for drug effects with a physical examination at the end of 24 hours after dosing and daily monitored for safety for a period of 1 week following dosing. Assuming no serious adverse reactions or limiting toxicity are observed in this dose level, then the next 6 subjects are treated with the next escalated dose. At the end of this part, real time PK data from the dose cohorts will be collected and analyzed. PK and safety information from this part of the study and from Part A will be reviewed by the DSMB and will guide the dose to be studied in Part D.
89328155|NCT05913752|Placebo Comparator|AUD Subjects - Part C|Multiple dose (18) HVs: Once Part A has been completed, the data analysed and approved by the DSMB, Part C will be initiated. This part will consist of a repeated-dose cohort based on the higher tolerable dose found in Part A. HVs will be randomized into either the treatment or the placebo arm at a ratio of 2:1 (12 subjects treated with the investigation product and 6 subjects receiving placebo) and will receive the drug/placebo at a daily basis for a total of 10 consecutive days. Each subject will be sampled for PK for 24 hours after first and last dosing and will be daily monitored for drug effects and safety throughout the study period and until 1 week after the last dosing. Real time PK data will be collected and results analysed (as defined in Section 5.2). The PK and safety information gathered from in this part of the study will be evaluated by the DSMB and will guide the dose to be studied in Part D of this study.
89328156|NCT05913752|Other|AUD Subjects - Part D|Multiple dose (18) subjects with binge drinking/AUD: Once Part B and Part C has been completed, the data analyzed and approved by the DSMB, Part D will be initiated. This part will consist of a repeated-dose cohort, based on the higher tolerable dose found in Part C and considering the dose effects found in Part B. Subjects will be randomized into either the treatment or the placebo arm at a ratio of 2:1 (12 subjects treated with the investigation product and 6 subjects receiving placebo) and will receive the drug/placebo at a daily basis for a total of 10 consecutive days. Each subject will be sampled for PK for 24 hours after first and last dosing and will be daily monitored for drug effects and safety throughout the study period and until 1 week after the last dosing. The PK and safety information gathered from in this part of the study will be evaluated by the DSMB.
89328157|NCT05912634||Conservative Type A Aortic Dissection Repair (TAAD-R)|The Conservative procedure will include patients receiving ascending aortic root sparing replacement with or without the implantation of the aortic hemiarch
89328158|NCT05912634||Extensive Type A Acute Aortic Dissection Repair (TAAD-R)|The extensive procedure will include patients receiving ascending aorta replacement associated to TARP
89328159|NCT05912608||Conservative Type A Acute Aortic Dissection Repair (TAAAD-R)|All conservative TAAAD-R will be performed through a median sternotomy. The conservative TAAAD-R will include patients receiving valve-sparing root procedures and recipients of ascending aortic root sparing replacement if the intima separation extended into the sinuses resulting in commissural collapse.When necessary, the hemiarch technique will be used with a limited extension of the conservative procedure by resection of all the aortic tissue up to the left common carotid artery and which will be dictated according to the presentation of the lesion.
89328160|NCT05912608||Extensive Type A Acute Aortic Dissection Repair (TAAAD-R)|All extensive TAAAD-R will be performed through a median sternotomy.The extensive TAAAD-R will include patients receiving replacement of the aortic root and total arch replacement procedures (TARP)
89328161|NCT05903859|Experimental|Full dose group|Participants in this group will receive the full dose of probenecid for a total of 90 days.
89328162|NCT05903859|Experimental|Half dose group|Participants in this group will receive half the dose of probenecid for a total of 90 days.
89328163|NCT05903859|Placebo Comparator|Control-placebo group|Participants in this group will receive a placebo dose (No active ingredient) for a total of 90 days.
89328164|NCT05902741|Experimental|Resilience, Stress, and Ethnicity (RiSE) program|"Resilience, Stress, and Ethnicity (RiSE) program is an 8-session weekly group-based intervention that integrates cognitive-behavioral strategies focused on the biopsychosocial impact of racism, racial identity development, and empowerment. RiSE has three primary components:~processing and sharing experiences related to race based stress,~psychoeducation on the biopsychosocial impact of racism,~skill building and empowerment."
88806656|NCT05900739|Experimental|Intervention 3: Instagram|This group received 35 educational impacts (4-6 per week - during 7 weeks) through a private account of instagram. Activities were: posts, stories and Instagram Lives as workshops (recorded)
88806657|NCT05900739|No Intervention|Control|Information about Mediterranean Diet was provided but no activities nor interventions took place.
88806658|NCT05900726|Experimental|Pelvipower chair|
88806659|NCT05900726|Sham Comparator|Sham stimulation|
88806660|NCT05900492||previous 1 cesarean section|patient who had her first Cesarean section
88806661|NCT05900492||previous 2 cesarean sections|patient who had her second Cesarean sections
89328165|NCT05902741|Active Comparator|Health Education Program (HEP)|Health Education Program
89328166|NCT05901467|Experimental|kisspeptin, GnRH|IV administration of kisspeptin 112-121; one bolus. IV administration of GnRH; one bolus.
89328167|NCT05884476|Experimental|REST + TAU|Veterans in this condition will complete the REST intervention and be expected to remain engaged in their standard course of health care as described in the TAU condition.
89328168|NCT05884476|Other|TAU|Veterans in this condition will be expected to engage in their standard course of heath care.
89328169|NCT05844527|Experimental|MRG-001|MRG-001 will be administered subcutaneously at 0.01 mL/kg bodyweight 3 times per week for 3 weeks.
89328170|NCT05844527|Placebo Comparator|Saline|Placebo will be administered subcutaneously at 0.01 mL/kg bodyweight 3 times per week for 3 weeks.
89328171|NCT05837585|Experimental|Air quality sensors|The experimental group will use the air quality sensors during 2 weeks pre-test and 12 weeks trial period.
89328172|NCT05824988||Patients with MAC lung disease|
89328173|NCT05809830|Experimental|LB-100 plus doxorubicin|"LB-100 will be administered during the first 3 days of each cycle (days 1, 2, and 3) at RP2D as a 2-hour intravenous infusion (with 500 mL of physiological saline solution), every 3 weeks (21-day cycles until progression or intolerance).~Doxorubicin will be administered only once (day 1) of each cycle at RP2D as a 20-minute infusion after completion of LB-100, every 3 weeks (up to a maximum of 6 x 21-day cycles)."
89328174|NCT05809830|Active Comparator|Doxorubicin alone|Control: Doxorubicin will be administered only once (day 1) of each cycle at RP2D as a 20-minute infusion every 3 weeks (up to a maximum of 6 x 21-day cycles).
89328175|NCT05800431|Experimental|Non-invasive Neuromodulation|The non-invasive neuromodulation experimental group, made up of 20 participants, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
89328176|NCT05800431|No Intervention|Control group (CG)|Conventional care will be performed without interrupting their normal activity.
89328177|NCT05785962|Experimental|Intervention group for people with brain damage|"Other: Vojta The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
89328178|NCT05785962|Experimental|Intervention group for people without brain damage|"Other: Vojta The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
89328179|NCT05766423|No Intervention|Usual Care|"Usual care includes:~The normal standard clinical practices at the participating practice.~No specific materials to promote PATTERN, and no additional materials that include adherence assessments or care alert notifications."
89328180|NCT05766423|Active Comparator|The PATTERN Intervention|"The intervention components include:~An adherence assessment completed by participants ahead of a regularly scheduled clinic visit.~Care alert notifications directed to a nurse pool and/or member of the clinical care team."
89328181|NCT05758753|Experimental|Stage I Neurotrophic Keratopathy|Clinical findings of corneal hyperplasia and irregularity, scattered small facets of dried epithelium, decreased nerve density as assessed by in vivo confocal microscopy (IVCM), and decreased corneal sensation.
89328182|NCT05758753|Experimental|Stage II Neurotrophic Keratopathy|Clinical findings of corneal epithelial defect with smooth and rolled edges, decreased nerve density as assessed by in vivo confocal microscopy (IVCM), and decreased corneal sensation.
89328183|NCT05758753|Experimental|Dry Eye Disease|Symptoms of dry eye disease for at least 3 months, supported by clinical finding of decreased tear film break-up time or ocular surface staining. Normal corneal sensation.
89328184|NCT05758753|Experimental|Healthy Individuals|Absence of any ocular symptoms, absence of surface findings (including corneal or conjunctival staining, corneal scar or surgical wound), and normal corneal sensation.
89328185|NCT05721781|Experimental|Participants receiving a dental cleaning and oral hygiene instruction|Participants randomized to this arm will receive a standard dental cleaning and education on proper toothbrushing and flossing technique and asked to follow these toothbrushing and flossing techniques for the duration of the study period. They will receive periodic phone call reminders to maintain these practices during the study period.
89328186|NCT05721781|No Intervention|Control|Participants randomized to this arm will be instructed to continue with their usual oral hygiene practices for the duration of the study period.
89328187|NCT05716035|Experimental|tocilizumab|Participants will receive tocilizumab 8mg/Kg administered intravenously (IV) on weeks 1,5,9 and 13 of the open-lable period.
89328188|NCT05685433|Experimental|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
89328189|NCT05665634|Experimental|All participants|
89328190|NCT05662462|Active Comparator|ACHIEVE Intervention|The intervention includes a multi-component, including a mobile health (mHealth) application (app), provider dashboard, DEXCOM continuous glucose monitoring (CGM), and care team coaching for medical and social needs. The intervention group will also receive standard of care as described below.
88806662|NCT05900492||previous 3 or more cesarean sections|patient who had 3 or more Cesarean sections
89328191|NCT05662462|No Intervention|Standard of care|Standard of care includes prenatal visits, self-monitored blood glucose, and certified diabetes care and education specialist support.
89328192|NCT05656014||Patients with knee osteoarthritis|Adult patients 50 years of age or older diagnosed with knee osteoarthritis according to American College of Rheumatology criteria
89328193|NCT05646316|Experimental|Arm 1 (sentinel lymph node mapping)|Patients receive ICG dye via injection and undergo sentinel lymph node mapping during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping cannot be completed. Successful mapping requires no additional removal of lymph nodes. Patients also undergo imaging as clinically indicated.
89328194|NCT05646316|Experimental|Arm 2 (sentinel lymph node mapping, pelvic lymphadenectomy)|Patients receive ICG dye via injection and undergo sentinel lymph node mapping during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care. Patients also undergo imaging as clinically indicated.
89328195|NCT05641285||Otosight, Otoscope, and Tympanogram|Prospective study using a convenience sample. There will be no group assignment or randomization. There is no intervention planned and therefore, no placebo group or use of controls.
89328196|NCT05625724|Experimental|Aspirin|Low-dose Aspirin: 150mg, daily, oral route, at bedtime, initiated between 9 and 14 weeks of gestation, until 35 (+6) weeks of gestation, or in the event of earlier delivery, until the onset of labor.
89328197|NCT05625724|Placebo Comparator|Control|Matching placebo administrated daily, oral route, at bedtime, initiated between 9 and 14 weeks of gestation, until 35 (+6) weeks of gestation, or in the event of earlier delivery, until the onset of labor.
89328198|NCT05615337|Experimental|Mindfulness-based stress reduction - MBSR|Traditional MBSR curriculum
89328199|NCT05615337|Active Comparator|Health Promotion Program - HPP|the HPP has the same structure of MBSR, but training different components, not including mindfulness practice.
89328200|NCT05614895|Experimental|Cohort 1|Bacteremia participants without pneumonia and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
89328201|NCT05614895|Experimental|Cohort 2|Participants with hospital-acquired bacterial pneumonia (HABP) and who are not mechanically ventilated at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
89328202|NCT05614895|Experimental|Cohort 3|Participants with mechanical ventilation at screening will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
89328203|NCT05614895|Experimental|Cohort 4|Participants with mechanical ventilation who have a bronchoalveolar lavage (BAL) planned as a part of routine practice will be enrolled in this cohort. Participants will receive RO7223280 on Day 1.
89328204|NCT05609669|Experimental|CADENCE program pilot|
89328205|NCT05605639|Experimental|Phrenic nerve anesthetics infiltration|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
89328206|NCT05605639|Placebo Comparator|Physiological serum infiltration|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
89328207|NCT05592418|Experimental|Ampligen / rintatolimod|Subjects will receive rintatolimod (intravenous [IV]), up to 400 mg twice weekly for 12 weeks.
89328208|NCT05592418|Placebo Comparator|Placebo / Saline|Subjects will receive placebo / normal saline (intravenous [IV]), up to 160 mL twice weekly for 12 weeks.
89328209|NCT05591677|Active Comparator|Active iTBS + active DCS 50mg/day|Active iTBS (600 pulses), 5 days/week x 4 weeks + active DCS 50mg/day x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
89328210|NCT05591677|Active Comparator|Active iTBS + active DCS 100mg/day|Active iTBS (600 pulses), 5 days/week x 4 weeks + active DCS 100mg/day x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
89328211|NCT05591677|Placebo Comparator|Active iTBS + placebo|Active iTBS (600 pulses), 5 days/week x 4 weeks + placebo x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
89328212|NCT05591339|Experimental|BCG vaccine|"Participants that are randomized in the active arm will receive an adult 0.1 ml dose of BCG vaccine (e.g. BCG-Denmark or BCG-Japan) in the skin covering the left upper deltoid muscle. Two doses will be given, 4 weeks apart.~Intervention: Biological BCG-vaccine."
89328213|NCT05591339|Placebo Comparator|Placebo|Placebo will be 0.1 ml sterile 0.9 % NaCl, which has a similar color as the resuspended BCG vaccine. Two placebo doses will be given, 4 weeks apart.
89328214|NCT05587699|Experimental|Group - A1(Part 1)|CKD-843 A 45mg
89328215|NCT05587699|Experimental|Group - A2(Part 2)|CKD-843 A 45mg
89328216|NCT05587699|Experimental|Group - B1(Part 1)|CKD-843 A 55mg
89328217|NCT05587699|Experimental|Group - B2(Part 2)|CKD-843 A 55mg
89328218|NCT05587699|Active Comparator|Group - R(Part 1)|CKD-843-R
89328219|NCT05572736|Experimental|Conduction system pacing|Patients will be randomized 1:1 to either conduction system pacing or biventricular pacing.
89328220|NCT05572736|Active Comparator|Biventricular pacing|Patients will be randomized 1:1 to either conduction system pacing or biventricular pacing.
89328221|NCT05551429||Patients with Acute Coronary Syndrome|The study sample will comprise acute coronary syndrome patients admitted to Gazi University Faculty of Medicine, Cardiology Department, Coronary Intensive Care Unit because of one or more of the diagnoses of acute ST-elevation myocardial infarction (MI), acute non-ST elevation MI and unstable angina pectoris. Patients who are hemodynamically stable and have no signs of residual ischemia after acute care will be informed by the cardiologist about the study. After the inclusion process, patients will be evaluated in terms of clinical characteristics, muscle strength, quality of life, and health literacy. They will be given detailed information about CR and an appointment will be made four weeks later for starting the exercise program. In the follow-up, the Cardiac Rehabilitation Barriers Scale-Turkish Version will be applied to those who do not participate in the initial exercise program.
89328222|NCT05549505|Experimental|ARV-471 monotherapy|ARV-471 taken once daily until surgical resection
89328223|NCT05549505|Active Comparator|Anastrozole monotherapy|Anastrozole 1mg taken once daily until surgical resection
89328224|NCT05542381|Experimental|Loteprednol|1 drop of Loteprednol is administered immediately after the intravitreal injection in this treatment arm.
89328225|NCT05542381|Placebo Comparator|Artificial tears|1 drop of artificial tears is administered immediately after the intravitreal injection in this treatment arm. This arm acts as a negative control.
89328226|NCT05542147|Experimental|Fenofibrate|1 tablet per day per 12 weeks
89328227|NCT05542147|Placebo Comparator|Placebo|1 tablet per day per 12 weeks
89328228|NCT05527093|Experimental|Patients with focal temporal lobe epilepsy for at least one year, drug-resistant|
89328229|NCT05523700|Experimental|Interventional Arm|Use of Mobile Application
89328230|NCT05523700|No Intervention|Control Arm|Routine care and symptom management
89328231|NCT05501769|Experimental|ARV-471 and Everolimus|ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
89328232|NCT05497791|Experimental|Experimental Transcranial Laser and Electrical Stimulation|Hemiplegics treated with transcranial laser stimulation (on) associated with neuromuscular electrical stimulation (NMES) (on)
89328233|NCT05497791|Placebo Comparator|Placebo|Hemiplegics treated with placebo transcranial laser stimulation (off) associated with NMES (on)
89328234|NCT05488652|No Intervention|Control|no intervention
89328235|NCT05488652|Experimental|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
89328236|NCT05466955|Experimental|Free eye glasses for un or under-corrected myopia|Free eyeglasses for the correction of uncorrected myopia will be provided to participants at the time of enrolment into the intervention group.
89328237|NCT05466955|No Intervention|Control-No treatment|Participants in the control period will not have glasses but the SW-CRT design means that all trial participants with uncorrected myopia will receive free glasses by the trials' completion, and no participant will have glasses withheld after being diagnosed with un- or under-corrected myopia.
89328238|NCT05464173|Experimental|SAF|endocrinotherapy（doctor's choice） According to the drug insert abemaciclib 150mg or 100mg bid, Chidamide 10-30mg biw.
89328239|NCT05453357||iGlucose Remote Glucose Monitoring|Patients will be provided with the iGlucose monitor at baseline data collection.
89328240|NCT05452304|Experimental|Part 1a - Cohort 1: AZD7798 dose 1|A total of 6 subjects will receive single ascending doses of AZD7798.
89328241|NCT05452304|Experimental|Part 1a - Cohort 2: AZD7798 dose 2|A total of 6 subjects will receive single ascending doses of AZD7798.
89328242|NCT05452304|Experimental|Part 1a - Cohort 3: AZD7798 dose 3|A total of 6 subjects will receive single ascending doses of AZD7798.
89328243|NCT05452304|Experimental|Part 1a - Cohort 4: AZD7798 dose 4|A total of 6 subjects will receive single ascending doses of AZD7798.
89328244|NCT05452304|Experimental|Part 1a - Cohort 5: AZD7798 dose 5|A total of 6 subjects will receive single ascending doses of AZD7798.
89328245|NCT05452304|Experimental|Part 1a - Cohort 6: AZD7798 dose 6|A total of 6 subjects will receive single ascending doses of AZD7798.
89328246|NCT05452304|Experimental|Part 1a - Cohort 7: AZD7798 dose 7|A total of 6 subjects will receive single ascending doses of AZD7798.
89328247|NCT05452304|Experimental|Part 1b - Cohort 8: AZD7798 dose 8|A total of 6 subjects will receive repeat doses of AZD7798.
89328248|NCT05452304|Experimental|Part 1a - Spare Cohort 9: AZD7798 dose 9|A total of 6 subjects will receive a single ascending dose of AZD7798.
89328249|NCT05452304|Experimental|Part 2 - Cohort 10: AZD7798 + AZD7798|A total of 4 subjects will receive a single dose on Day 1 followed by a single dose on Day 15.
89328250|NCT05452304|Experimental|Part 2 - Cohort 11: Placebo + AZD7798|A total of 2 subjects will receive placebo on day 1 followed by AZD7798 on day 15.
89328251|NCT05452304|Experimental|Part 2 - Cohort 12: AZD7798 + Placebo|A total of 2 subjects will receive AZD7798 on day 1 followed by placebo on day 15.
89328252|NCT05452304|Experimental|Placebo: Part 1a and Part 1b|A total of 2 subjects per cohort will receive placebo.
89328253|NCT05452304|Experimental|Part 3a - Cohort 12: AZD7798|A total of 6 subjects will receive single ascending doses of AZD7798.
89328254|NCT05452304|Experimental|Part 3b - Cohort 13: AZD7798|A total of 6 subjects will receive single ascending doses of AZD7798.
89328255|NCT05452304|Experimental|Placebo: Part 3a and Part 3b|A total of 2 subjects per cohort will receive placebo.
89328256|NCT05444231|Experimental|Brain Training A|This group will access one type of online brain-health oriented training.
89328257|NCT05444231|Active Comparator|Brain Training B|This group will access a distinct type of online brain-health oriented training.
89328258|NCT05444231|Active Comparator|Brain Training C|This group will access a distinct type of online brain-health oriented training.
89328259|NCT05443347|Experimental|Structured exercise|Adolescents randomized to the exercise will participate in a supervised structured exercise program (walking on a treadmill, cycling on a stationary bicycle, etc.) and expend an equivalent of 400 kcals/session (approximately 45-60 min/session) on three days/week. We will follow the protocol of Mentor Dr. Joseph Donnelly, with exercise prescriptions progressing from 150 kcal/session at intervention onset to reach the target exercise energy expenditure (EEEx) (400 kcal/session) at the end of month 3. EEEx will be assessed at baseline and monthly during the intervention to determine the duration of treadmill exercise required to achieve the EEEx goals. All supervised exercise will occur at the CCHLN on a treadmill with heart rate, speed, and grade monitored by an exercise specialist every five minutes.
89328260|NCT05443347|Active Comparator|Newsletter control|"Adolescents randomized to the newsletter control will receive with biweekly newsletters with parenting tips, sample praise statements, and age-appropriate activities and recipes identical to what has been used by others (Epstein et al., 2008), including existing group-based interventions with overweight/obese adolescents."
89328261|NCT05439655|Experimental|Epilepsy|patients with drug resistant epilepsy undergoing a surgical evaluation in the epilepsy monitoring unit
89328262|NCT05397678|Experimental|BCG-Denmark|Infants randomized to receive BCG-Denmark at discharge from the Maternity Ward will receive one 0.05 ml infant dose of Mycobacterium bovis BCG live-attenuated BCG-AJ vaccine by intradermal injection in the left deltoid region. Dependent on national supply, oral polio vaccine will be co-administered.
89328263|NCT05397678|Active Comparator|BCG-Bulgaria|Infants randomized to receive BCG-Bulgaria at discharge from the Maternity Ward will receive one 0.05 ml infant dose of Mycobacterium bovis BCG live-attenuated BCG-Bulgaria vaccine by intradermal injection in the left deltoid region. Dependent on national supply, oral polio vaccine will be co-administered.
89328264|NCT05396742|Experimental|Cohort 1|Participants received a single dose of ravulizumab SC 400 (milligrams) mg .
89328265|NCT05396742|Experimental|Cohort 2|Participants received a single dose of ravulizumab SC 500 mg/rHuPH20 10000 units.
89328266|NCT05396742|Experimental|Cohort 3|Participants received a single dose of ravulizumab SC 1000 mg/rHuPH20 20000 units.
89328267|NCT05396742|Experimental|Cohort 4|Participants received a single dose of ravulizumab SC 2000 mg/rHuPH20 40000 units.
89328268|NCT05396742|Experimental|Cohort 5|Participants received a single dose of ravulizumab intravenously (IV) 400 mg.
89328269|NCT05380934|Experimental|TQH3821 Tablets (Single Administration Dose)|TQH3821 tablets, Single administration
89328270|NCT05380934|Placebo Comparator|TQH3821 Placebo Tablets (Single Administration Dose)|TQH3821 placebo tablets, Single administration
89328271|NCT05380934|Experimental|TQH3821 Tablets (Food Effect)|TQH3821 tablets, 2 sequential periods (fasting and fed)
89328272|NCT05380934|Placebo Comparator|TQH3821 Placebo Tablets (Food Effect)|TQH3821 placebo tablets, 2 sequential periods (fasting and fed)
89328273|NCT05380934|Experimental|TQH3821 Tablets (Multiple Administration Dose)|TQH3821 tablets once every 12 hours for 7 times during the continuous administration phase.
89328274|NCT05380934|Placebo Comparator|TQH3821 Placebo Tablets (Multiple Administration Dose)|TQH3821 placebo tablets once every 12 hours for 7 times during the continuous administration phase.
89328275|NCT05380934|Experimental|TQH3821 Tablets + Methotrexate Tablets|Take Methotrexate Tablets once in the first cycle, take TQH3821 Tablets once every 12 hours in the second cycle for 6 times, and then TQH3821 Tablets + Methotrexate Tablets once in the third cycle.
89328276|NCT05380934|Placebo Comparator|TQH3821 Placebo Tablets + Methotrexate Tablets|Take Methotrexate Tablets once in the first cycle, take TQH3821 placebo tablets once every 12 hours in the second cycle for 6 times, and then TQH3821 placebo tablets + Methotrexate Tablets once in the third cycle.
89328277|NCT05351775|Experimental|Interventional AF detection arm|The patients will be monitored during index hospitalization according normal practice and additionally with a bed sensor, smartphone app, and patch-holter ECG. In addition, patients will have PDL monitoring device during hospitalization. During the index hospitalization, patients will download the CardioSignal app to their own smartphone or if patient does not have a smartphone one can be provided to the patient by the study group. Patients are asked to do the first recordings at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period. When discharged home, the study subject will have the bed sensor for home-based use up to 3 months. If the average pulse rate in the bed sensor recordings have increased with 20% or the device has recorded rhythm irregularity lasting over 5 minutes (could be longer to reduce false alarms), a 12-lead ECG will be taken, and in the case of a normal ECG, a 7-day Holter monitoring is performed.
89328278|NCT05351775|No Intervention|Standard of care treatment arm|Patient will be followed as in routine clinical practice.
89328279|NCT05302817|Experimental|Standard-of-care Radiation Therapy for lung cancer using HXe MRI for diagnosis.|Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study, where they will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. However, for this part of the study, subjects will still follow the standard-of-care radiation treatment plan. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.
89328280|NCT05302817|Experimental|Guided Radiation Therapy for lung cancer using HXe MRI for functional lung avoidance and diagnosis.|Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study. They will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. Patients will follow radiation therapy optimized for functional lung avoidance. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.
89328281|NCT05299723|Experimental|Phase A - open label single-arm|"All Phase A participants randomized to the home-based CC intervention will be use a light visor to administer bright light therapy in the morning for 30 minutes after waking up (BLT), and use orange-colored glasses for blue light blocking at night from 8:00 pm until going to sleep (BLB)."
89328282|NCT05299723|Experimental|Phase B - active CC treatment|For all Phase B participants randomized to the active CC group, BLT will occur each morning after awakening and will last for 30 minutes and BLB at night from 8:00 pm until going to sleep throughout the 4-week intervention period. Participants in the CC group will also receive a sleep hygiene education.
89328283|NCT05299723|Active Comparator|Phase B - sleep hygiene education control group|All Phase B participants randomized to the control group will receive a sleep hygiene education alone at the start of the 4 week monitoring period.
89328284|NCT05286827|Experimental|Arm 1|Olaparib, taken orally, twice daily
89328285|NCT05262101|Experimental|TQB2858 injection|TQB2858 injection (1800mg intravenous(iv), on day 1 of every 3 weeks)
89328286|NCT05227677|Experimental|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals and the anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
89328287|NCT05227677|Active Comparator|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals，but investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
89328288|NCT05178745||Cohort 1|Patients with metastatic colorectal cancer and liver metastases treated with FOLFIRI plus aflibercept after failure of an oxaliplatin-based regimen
89328289|NCT05178537||AAS users|current og previous use of AAS
88806665|NCT05899699|Experimental|DAP/FLU ME|Acne vulgaris patients treated with the optimized topical combination ME contain DAP-FLU.
88806666|NCT05899699|Active Comparator|Adapalene .1% gel|Acne vulgaris patients treated with standard therapy of Adapalene.
88806667|NCT05899530|Active Comparator|Conventional expander|Expansion using conventional orthodontic expander(hyrax)
88806668|NCT05899530|Experimental|Invisalign|Expansion with Invisalign appliance
89328290|NCT05166603|Experimental|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
89328291|NCT05166603|No Intervention|Usual Care|Patients receive usual care
89328292|NCT05162131|Experimental|1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)|PB2452 Infusion
89328293|NCT05162131|Experimental|1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)|PB2452 Infusion
89328294|NCT05162131|Experimental|1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
89328295|NCT05162131|Experimental|2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
89328296|NCT05162131|Experimental|3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
89328297|NCT05162131|Experimental|4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
89328298|NCT05162131|Experimental|5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg + 90 mg bid for a total of 5 doses
89328299|NCT05146440|Experimental|PM14 in monotherapy and in combination with radiotherapy in STS and other solid tumors|"Cohort A : Phase I. PM14 24-h IV 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort B: Phase I. PM14 3-h IV infusion 3 d 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort E: PM14 at RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort F: PM14 at the RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort C: Phase I: PM14 at the RP2D, 21-d cycles in combination with radiotherapy, up to PD or toxicity. Dexamethasone recommended. Radiation therapy 3Gy/f 10 d. Phase II: PM14 at RP2D with radiation therapy.~Cohort D: Phase I: PM14 at the RP2D, 3 x 21-d cycles in neoadjuvant setting, in combination with radiotherapy. Dexamethasone recommended. Radiation therapy 1.8Gy/f 25 d. Phase II: PM14 at RP2D with radiation therapy."
89328300|NCT05135091|Experimental|NRTX-1001 (Stage 1)|Up to 10 subjects.
89328301|NCT05135091|Experimental|NRTX-1001 (Stage 2)|Up to 20 subjects.
89328302|NCT05135091|Sham Comparator|Sham Comparator (Stage 2)|Up to 10 subjects.
89328303|NCT05125003|Experimental|FITBI|Reinforcement-based learning procedures delivered via telehealth in 16 remote-delivered treatment sessions - 13 weekly and 3 booster treatment sessions over 6 month period.
89328304|NCT05125003|Active Comparator|Parent Education|Information relevant to parenting a young child with ASD (e.g. parent advocacy, developmental changes in ASD, treatment options) delivered via telehealth in 15 remote-delivered treatment sessions -12 weekly and 3 booster treatment sessions over 6 month period.
89328305|NCT05108688|Active Comparator|Mirtazapine Therapy group (M group)|
89328306|NCT05108688|Active Comparator|Sumatriptan Therapy group (S group)|
89328307|NCT05108688|Placebo Comparator|Control group ( C group)|
89328308|NCT05099965|Active Comparator|Vaccine Group|60 participants will receive CMV-MVA Triplex® containing 5 x 108 plaque-forming unit (pfu) ±0.5 x 108 pfu of MVA Vaccine Encoding CMV Antigens by intramuscular (IM) deltoid injections.
89328309|NCT05099965|Placebo Comparator|Placebo Group|30 participants will receive a volume of placebo (7.5% Lactose in phosphate-buffered saline [PBS]) that matches the volume of the active vaccine injection by IM deltoid injections.
89328310|NCT05083416|Experimental|A: Prolonged Nightly Fasting|"Participants will be educated on Prolonged Nightly Fasting (PNF) and the mycircadianapp. Participants be allowed to choose any 10-hr period that falls between 6 AM- 6 PM, as feeding period. Participants will be recommended to follow study diet guidelines, eat to satiety and not count calories. Participants will be allowed to have water, beverages (<4 kcal) during the fasting period."
89328311|NCT05083416|Active Comparator|B: Regular Eating pattern|Participants will follow a traditional eating pattern with no time restrictions.
89328312|NCT05079841|Experimental|Intrapartum nipple stimulation|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or stimulate by hand (intervention) to induce labor.
89328313|NCT05079841|Active Comparator|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor.
88809666|NCT01272986|Active Comparator|Asymptomatic myocardial Ischemic patients|
88809667|NCT01272986|Active Comparator|Acute Coronary Syndrome Patients|
88809668|NCT01272908|Experimental|Single arm|
89328314|NCT05074056|Experimental|Ketorolac|A double-blinded number of children will get one dose of intravenous 0.5 mg/kg (max dose 30mg) ketorolac intraoperatively.
89328315|NCT05074056|Placebo Comparator|Placebo|A double-blinded number of children will get one dose of intravenous placebo intraoperatively.
89328316|NCT05071183|Experimental|TPX-0005 + Trametinib|"TPX-0005 + Trametinib Dose Escalation and Dose Expansion~Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC"
89328317|NCT05049122|Experimental|Dupilumab|Dupilumab every 2 weeks (q2w). Dosing interval may be changed from q2w to q4w at week 24
89328318|NCT05001568|Experimental|Optimized Providence brace|The braces will be designed using optimization and finite element analysis.
89328319|NCT05001568|Active Comparator|Conventional Providence brace|The braces will be designed by an orthotist using the conventional design method.
89328320|NCT04990128|Experimental|Bone marrow aspirate concentrate|Bone marrow that is aspirated then concentrated using a device.
89328321|NCT04990128|Active Comparator|Triamcinolone|Triamcinolone is a corticosteroid.
89328322|NCT04987931||Primary population: Talazoparib-treated patients with HER2- ABC with gBRCA1/2m|HER2-negative ABC patients with gBRCA1/2 mutations treated with talazoparib monotherapy initiated on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
89328323|NCT04980482|Experimental|Cohort A, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
89328324|NCT04980482|Experimental|Cohort A, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks."
89328325|NCT04980482|Experimental|Cohort B, Group 1|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
89328326|NCT04980482|Experimental|Cohort B, Group 2|"AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:~NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks."
89328327|NCT04974749|Experimental|REPLAGAL|Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight, infusion, intravenously every other week (EOW) for 52 weeks.
89328328|NCT04969263|Experimental|mRNA-1273 vaccine (Pfizer/BioNTech)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Pfizer/BioNTech will receive a third dose of the the same vaccine.~Administration: One dose administered intramuscularly, upper arm."
89328329|NCT04969263|Experimental|mRNA-1273 vaccine (Moderna)|"The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Moderna will receive a third dose of the same vaccine.~Administration: One dose administered intramuscularly, upper arm."
89328330|NCT04964063|Other|Sensodyne Fresh Mint Toothpaste|"Participants will be asked to follow commercial tube instructions as recommended for sensitivity relief: Apply at least a 1-inch strip of the product onto a soft bristle toothbrush. Brush teeth thoroughly for at least 1 minute twice a day (morning and evening), and not more than 3 times a day, or as recommended by a dentist or doctor. Make sure to brush all sensitive areas of the teeth. Minimize swallowing, Spit out after brushing."
89328331|NCT04959812|Experimental|Sufentanil|Sufentanil (30 microgram tablet) will be administered via a sublingual pill
89328332|NCT04959812|Placebo Comparator|Placebo|Placebo will be administered via a sublingual pill
89328333|NCT04928508|Experimental|OK-1 capsule|OK-1 (oral, BID) within a 21-days cycle
89328334|NCT04919395|Experimental|Clip device removal|
89328335|NCT04919395|Active Comparator|Standard of Care removal|
89328336|NCT04914390|Experimental|Tislelizumab + Anlotinib + Chemotherapy|Participants receive Tislelizumab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + AT regimen (Q3W) x 6 cycles as neoadjuvant therapy prior to surgery.
89328337|NCT04903977|Experimental|Impedance spectroscopy|ONIRY examination
89328338|NCT04887935|Experimental|Dapagliflozin|"Dapagliflozin will be initiated once daily approximately 6 weeks prior to planned prostatectomy~Dapagliflozin will be given at 10 mg by mouth once daily for 4 weeks (days 1-28) prior to prostatectomy."
89328339|NCT04887662|No Intervention|Control|The control group will be asked to follow their usual diet, but will receive print materials about a diet for cardiovascular health.
89328340|NCT04887662|Experimental|Fermented vegetable|The fermented vegetable group will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week for 8 weeks.
89328341|NCT04871139|Experimental|Diagnostic (iodine-based contrast, CEM)|Patients receive iodine-based contrast agent IV and the undergo CEM over 10-15 minutes.
89328342|NCT04870944|Experimental|Treatment (CBL0137)|Patients receive CBL0137 IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy at baseline, ECHO prior to cycle 1, and as clinically indicated undergo collection of blood samples throughout the trial.
89328343|NCT04869111|Experimental|Online SMART Intervention & Stress Solutions|Strategic Memory Advanced Reasoning Training (SMART) teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance
89328344|NCT04869059|Experimental|Transcranial direct current stimulation|20 minutes of 1 milliamp transcranial direct current stimulation to presupplementary motor area for 15 sessions
89328345|NCT04869059|Sham Comparator|Sham transcranial direct current stimulation|20 minutes of sham transcranial direct current stimulation to presupplementary motor area for 15 sessions
89328346|NCT04851691|Experimental|EHR CDS tool|Multi-pronged electronic health record (EHR) clinical decision support (CDS) tool intervention to reduce physician prescriptions of new antipsychotic medications among older adults with ADRD
89328347|NCT04851691|Experimental|Control|Physicians will not receive intervention and perform duties as usual.
89328348|NCT04775706|Experimental|HM15912 0.5 mg/kg, 1.0mg/kg, 1.5mg/kg Active|
89328349|NCT04775706|Placebo Comparator|Matching Placebo|
89328350|NCT04765059|Experimental|Treatment Arm A|All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin ([AUC] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
89328351|NCT04765059|Placebo Comparator|Treatment Arm B|All randomized patients will receive placebo QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
89328352|NCT04760847|Experimental|Intermittent Fasting|Patients in Group A will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day.
89328353|NCT04760847|Active Comparator|Control|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast.
89328354|NCT04742205|Active Comparator|tranexamic acid|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
89328355|NCT04742205|Placebo Comparator|Sodium Chloride|Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
89328356|NCT04724447|Experimental|Valganciclovir|900 milligrams (mg) valganciclovir (VGCV) to be taken orally once per day for 8 weeks.
89328357|NCT04724447|Placebo Comparator|Placebo|Placebo equivalent of 900 milligrams (mg) VGCV to be taken orally once per day for 8 weeks.
89328358|NCT04704583|Experimental|Treatment group (active)|Individuals in this group will start treatment after the initial assessment, without a delay.
89328359|NCT04704583|Active Comparator|Wait-list control group|Individuals in this group will start treatment after the initial assessment, with a delay of thirteen weeks.
89328360|NCT04682392|Active Comparator|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|This group will use Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction for rehab.
89328361|NCT04682392|Active Comparator|Non Delfi PTS Personalized Tourniquet System for Blood Flow Restriction Group|Standard post operative ACL rehab without Blood flow restriction
89328362|NCT04665947|Experimental|[177Lu]Lu DOTA-ABM-5G dose escalation therapy study|Patients will be undergo [68Ga]Ga DOTA-5G PET/CT scans to confirm eligibility for the [177Lu]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of [68Ga]Ga DOTA-5G PET/CT will be offered therapy. Escalating doses of 25-200 mCi of [177Lu]Lu DOTA-ABM-5G will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.
89328363|NCT04665947|Experimental|Recommended Phase 2 dose [177Lu]Lu DOTA-ABM-5G therapy study|Patients will be undergo [68Ga]Ga DOTA-5G PET/CT scans to confirm eligibility for the [177Lu]Lu DOTA-ABM-5G therapy.10 patients will be enrolled in the dose expansion cohort and recieve the highest dose achieved in the [177Lu]Lu DOTA-ABM-5G dose escalation therapy study
89328364|NCT04662710|Experimental|Lenvatinib + Pembrolizumab + Chemotherapy|Participants receive lenvatinib administered orally (PO) every day (QD) in combination with pembrolizumab intravenously (IV) every 6 weeks (Q6W) plus chemotherapy with either capecitabine and oxaliplatin (CAPOX) or chemotherapy with 5-FU, leucovorin, and oxaliplatin (mFOLFOX6). Induction with lenvatinib 8 mg QD plus pembrolizumab (400 mg Q6W) plus chemotherapy (CAPOX or mFOLFOX6) will be administered for 2 cycles (approximately 12 weeks), followed by consolidation with lenvatinib 20 mg QD plus pembrolizumab (400 mg Q6W) for 16 cycles. A cycle is 6 weeks (42 days).
89328365|NCT04662710|Experimental|Chemotherapy|Participants receive chemotherapy with either CAPOX Q3W or mFOLFOX6 Q2W. A cycle is 6 weeks (42 days).
89328366|NCT04658680|Experimental|BCG available at first health facility contact|Infants living in catchment areas of HFs randomized to opening of BCG vial if just 1 eligible child is present.
89328367|NCT04658680|No Intervention|Usual availability of BCG at health facilities|Infants living in catchment areas of HFs randomized to BCG availability according to the per usual restricted vial opening policy aiming at reducing vaccine wastage. This entails that BCG vaccination is commonly only available on specific predefined days where a BCG vial will only be opened if several children are present.
89328368|NCT04642079|Experimental|Cohort 1: =>15 through 23 months of age|20vPnC
89328369|NCT04642079|Experimental|Cohort 2: 2 through 4 years of age|20vPnC
89328370|NCT04642079|Experimental|Cohort 3: 5 through 9 years of age|20vPnC
89328371|NCT04642079|Experimental|Cohort 4: 10 through 17 years of age|20vPnC
89328372|NCT04641962|Experimental|Phase 2: Low dose ASP0367|Participants will receive ASP0367 once daily in the morning for 2 weeks.
89328373|NCT04641962|Experimental|Phase 2: High dose ASP0367|Participants will receive ASP0367 once daily in the morning for 2 weeks.
89328374|NCT04641962|Placebo Comparator|Phase 2: Placebo|Participants will receive placebo once daily in the morning for 2 weeks.
89328375|NCT04641962|Experimental|Phase 3: ASP0367|Participants will receive ASP0367 once daily in the morning for up to 52 weeks.
89328376|NCT04641962|Placebo Comparator|Phase 3: Placebo|Participants will receive placebo once daily in the morning for up to 52 weeks.
89328377|NCT04641962|Experimental|Open Label Extension: ASP0367|Participants will receive ASP0367 once daily in the morning for 24 weeks.
89328378|NCT04633421|Experimental|PRECISe protocol EN (8g protein/100kcal)|Enteral (EN) feed with 8 grams protein per 100 kcal (2.0 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
89328379|NCT04633421|Active Comparator|PRECISe protocol EN (5g protein/100kcal)|Enteral (EN) feed with 5 grams protein per 100 kcal (1.3 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
89328380|NCT04629495|Active Comparator|RAPA (rapamycin) treatment group|Subjects will receive active drug
89328381|NCT04629495|Placebo Comparator|Placebo group|Subjects will receive placebo
89328382|NCT04618081||Participants with FL or MZL|Patients who have been diagnosed with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who receive R2 combination therapy with revlimid and rituximab for the first time.
89328383|NCT04604665|Experimental|High frequency postural change|"Repositioning or rotation of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency. It has to be performed on each patient between an interval less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to the right lateral, supine, left lateral, supine, or prone position to supine position. The repositioning will be provided until a patient is discharged from ICU, die or begin ambulation. When providing each repositioning, avoid dragging the patient, the shear, and the friction to increase UPP risk. This must be applied to avoiding massage. Patients in any position should use pressure-reducing items such as pillows."
89328384|NCT04604665|Active Comparator|Conventional care|Repositioning or rotation of patients hospitalized will be the conventional or usual care. Units in this group are not going to receive any intervention. Will be only observed in their current intervention of repositioning.
89328385|NCT04587687|Experimental|Treatment (brentuximab vedotin, bendamustine)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and bendamustine IV over 60 minutes on days 1 and 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who respond to combination treatment and do not experience excessive toxicity may continue to receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
89328386|NCT04572451|Experimental|Nivolumab (Anti-PD-1) + BMS-986253 (Anti-IL-8) + SBRT|480 mg intravenous nivolumab (BMS-936558-01) every 4 weeks + 2,400 mg intravenous BMS-986253 (Anti-IL-8) every 2 weeks + Stereotactic Body Radiotherapy (SBRT)
89328387|NCT04559048||FK506-treated group|In FK506-treated group, the patients who underwent liver transplant are treated with FK506 immunosuppressive therapy.
89328388|NCT04559048||control group without FK506 treatment|In control group, the patients who underwent liver transplant are treated without FK506.
89328389|NCT04547543|Other|Video consultation|Patients in this group will have a continuous positive pressure follow-up visit by videoconsultation
89328390|NCT04547543|No Intervention|Face-to-face consultation|Patients in this group will have a continuous positive pressure follow-up visit by face-to-face consultation
89328391|NCT04496947|Experimental|Stress Reduction|8 week stress reduction course
89328392|NCT04496947|No Intervention|Control|No intervention
89328393|NCT04495621|Experimental|MEN1611|MEN1611 + Cetuximab
89328394|NCT04493645|Active Comparator|Standard of Care (SOC)|Participants will be randomized to receive standard of care rehabilitation (SOC) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the SOC group for 24 months following completion of their assigned SOC intervention.
89328395|NCT04493645|Experimental|Foot Intensive Rehabilitation (FIRE)|Participants will be randomized to receive foot intensive rehabilitation (FIRE) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the FIRE group for 24 months following completion of their assigned SOC intervention.
89328396|NCT04474379|Experimental|Strategy Training|Consists of 8-90 minute sessions over 8 weeks. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the therapist teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based) and instructs in their use before and during the training games. In sessions 3-8, the tester tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. After completing the training games, the therapist and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the therapist helps the participant develop written action plans to do so. Plans and goals are reviewed and modified, if necessary, at each session.
89328397|NCT04474379|No Intervention|Process Training|Consists of 8, 90 minute sessions over 8 weeks. In sessions 1 and 2, the therapist teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3-8, the tester tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the therapist. Feedback on accuracy is provided after each training game. This is typical of a process training approach and expects that practice of the training tasks will improve prospective memory ability per se or that participants will develop effective strategies for completing prospective memory tasks on their own. At the end of each session, the therapist reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Goals are reviewed and modified if necessary.
89328398|NCT04470453|Experimental|Patients with active rheumatoid arthritis|30 patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
89328399|NCT04470453|Experimental|Patients with rheumatoid arthritis into remission|30 patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
89328400|NCT04458909|Experimental|Arm I (nivolumab, gemcitabine, cisplatin, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 30-60 minutes or carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After 4 weeks, patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89328401|NCT04458909|Active Comparator|Arm II (gemcitabine, cisplatin, carboplatin)|Patients receive gemcitabine and cisplatin or carboplatin as in Arm I.
89328402|NCT04450173|Experimental|Treatment (obinutuzumab, venetoclax, ibrutinib)|Patients receive obinutuzumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, and 24. Patients also receive venetoclax PO QD on days 1-28 (days 4-28 of cycle 1) and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
89328403|NCT04446182|Experimental|Treatment: all patients|Patients will self-administer itacitinib every morning regardless of food. ECP will be administered twice weekly on consecutive days for 8 weeks per institutional standards. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule and itacitinib will be continued at the assigned dose level. After six cycles of therapy, itacitinib may be tapered at the treating investigator's discretion as described below.
89328406|NCT04420195|Experimental|Envarsus XR|Envarsus XR to be initiated once patient is tolerating oral medications
89328407|NCT04420195|Experimental|IR tacrolimus (historical control)|Historical cohort of patients maintained on IR tacrolimus following transplant
89328408|NCT04383925|Experimental|BCG-Japan|Infants randomized to receive BCG-Japan at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Japan (Tokyo BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination.
89328409|NCT04383925|Active Comparator|BCG-Russia|Infants randomized to receive BCG-Russia at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
89328410|NCT04376593|Experimental|18F-αvβ6-BP|Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe.
89328411|NCT04363801|Experimental|Part A First Line Treatment|Part A patients will receive IV DKN-01 (300 mg) on Days 1 and 15, IV tislelizumab (200 mg) on Day 1, IV oxaliplatin (130 mg/m2) on Day 1, and oral capecitabine (1000 mg/m2 twice daily [BID]) on Days 1-15 of each 21-day cycle. Part A is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
89328412|NCT04363801|Experimental|Part B1 Second Line Treatment|"Part B patients will receive IV DKN-01 (300 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
89328413|NCT04363801|Experimental|Part B2 Second Line Treatment|"Part B patients will receive IV DKN-01 (600 mg) on Days 1 and 15 and IV tislelizumab (200 mg) on Day 1 of each 21-day cycle.~Patients enrolled in Part B are required to have DKK1-high (H-score ≥ 35) G/GEJ adenocarcinoma (pre-screen biopsy) and must have had only 1 prior systemic therapy for locally advanced/metastatic disease (platinum + fluoropyrimidine-based therapy; ±HER2 therapy if applicable). Patients may have received prior neoadjuvant or adjuvant therapy."
89328414|NCT04363801|Active Comparator|Part C Control First Line Treatment|Part C control patients will receive only tislelizumab in combination with chemotherapy regimen (CAPOX or mFOLFOX6). Part C is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
89328415|NCT04363801|Experimental|Part C Experimental First Line Treatment|Part C experimental patients will receive DKN-01 in combination with tislelizumab and chemotherapy regimen (CAPOX or mFOLFOX6). Part C is restricted to patients who have not had prior systemic therapy for locally advanced or metastatic disease. Patients may have received prior neoadjuvant or adjuvant therapy as long as it was completed without disease recurrence for at least 6 months.
89328416|NCT04336150|Experimental|Hypopressive exercisesE|"Hypopressive exercises described according to Dr. Caufriez~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~Hypopressive exercises according to the original method described by Dr. Caufriez, which is based on performing the hypopressive maneuver in 33 postures that he described (1,2)."
89328417|NCT04336150|Experimental|Hypopressive exercises&PFM contraction|"Hypopressive exercises + active pelvic floor muscle contraction:~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~Hypopressive exercises according to the original method described by Dr.Caufriez, which is based on performing the hypopressive maneuver in 33 postures he described, plus the active contraction of the pelvic floor muscles (PFM) during the hypopressive maneuver."
89328418|NCT04336150|Experimental|Hypopressive maneuver|"Hypopressive maneuver:~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~Hypopressive maneuver with transabdominal ultrasound biofeedback."
89328419|NCT04336150|Experimental|Hypopressive maneuver&PFM contraction|"Hypopressive maneuver + pelvic floor muscles contraction:~Anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity).~Hypopressive maneuver plus active contraction of the pelvic floor muscles with transabdominal ultrasound biofeedback."
89328420|NCT04334798|Experimental|PFM&electro&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the pelvic floor muscles (PFM) will be performed using intravaginal palpation and electrostimulation, together with biofeedback (BFB).
89328421|NCT04334798|Experimental|PFM&BFB|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with biofeedback (BFB).
89328422|NCT04334798|Experimental|PFM&electro&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation and electrostimulation, together with transabdominal ultrasound biofeedback (BFB).
89328423|NCT04334798|Experimental|PFM&transabdominal US|An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with transabdominal ultrasound biofeedback (BFB).
89328424|NCT04330781|Experimental|Intervention group|N=123
89328425|NCT04330781|Active Comparator|Control group|N=31
89328426|NCT04329494|Experimental|Arm I (PIPAC, doxorubicin, cisplatin)|Patients with ovarian, uterine, or gastric cancer, undergo PIPAC with doxorubicin IP, followed by cisplatin IP. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
88809669|NCT01271504|Active Comparator|Phase Ib: Cohort 1,2, and 3|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
89328427|NCT04329494|Experimental|Arm II (PIPAC, oxaliplatin, leucovorin, fluorouracil)|Patients with colorectal or appendiceal cancer undergo PIPAC with oxaliplatin IP. For cycles 2 and 3, patients receive leucovorin IV over 10 minutes and fluorouracil IV over 15 minutes 1-24 hours before undergoing PIPAC. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
89328428|NCT04329494|Experimental|Arm III (PIPAC, mitomycin, FOLFIRI)|Patients with colorectal or appendiceal cancer who have undergo at least 4 months (or 8 cycles) of first-line standard of care chemotherapy but have not progressed on second line chemotherapy undergo PIPAC with mitomycin IP. Patients also receive standard of care irinotecan IV over 90 on day 1, leucovorin IV over 30 minutes on day 1, and fluorouracil IV on days 1-2 during weeks 2, 4, 8, 10, 14 and 16. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
89328429|NCT04329104|Experimental|Dose-escalation study: Arm 1: 5 mg/kg of CIS43LS|Participants will receive 5 mg/kg of CIS43LS on Day 0. Once all participants in Arm 1 reach Day 7 post-infusion, if no safety concerns have arisen, dosing will begin for Arm 2.
89328430|NCT04329104|Experimental|Dose-escalation study: Arm 2: 10 mg/kg of CIS43LS|Participants will receive 10 mg/kg of CIS43LS on Day 0. Once all participants in Arm 2 reach Day 7 post-infusion, if no safety concerns have arisen, dosing will begin for Arm 3.
89328431|NCT04329104|Experimental|Dose-escalation study: Arm 3: 40 mg/kg of CIS43LS|Participants will receive 40 mg/kg of CIS43LS on Day 0. After the last participant in Arm 3 reaches Day 7 safety follow-up, an interim safety evaluation will be performed before enrollment begins for the Efficacy study.
89328432|NCT04329104|Experimental|Efficacy study: Arm 1: 10 mg/kg of CIS43LS|Participants will receive 10 mg/kg of CIS43LS on Day 0
89328433|NCT04329104|Experimental|Efficacy study: Arm 2: 40 mg/kg of CIS43LS|Participants will receive 40 mg/kg of CIS43LS on Day 0.
89328434|NCT04329104|Placebo Comparator|Efficacy study: Arm 3: Placebo|Participants will receive placebo on Day 0.
89328435|NCT04309227|Experimental|Traditional High-Intensity Training|Participants will perform their training at ~70% of their 1-repetition maximum, as traditionally advocated in strengthening literature. Each of the diagnoses (RA, OA, myositis) will have a High-Intensity arm.
89328436|NCT04309227|Experimental|Low Intensity plus Blood Flow Restriction Training|Participants will perform their training at ~30% of their 1-repetition maximum, and will have blood flow partially occluded (60-70%) to the training limb. Each of the diagnoses (RA, OA, myositis) will have a Low-Intensity plus Blood Flow Restriction arm.
89328437|NCT04309227|No Intervention|Control|Each of the diagnoses (RA, OA, myositis) will have a control arm. The control groups will be evaluated at time 0, 4 weeks, and 8 weeks but will not receive intervention.
89328438|NCT04295733||Cohort 1|Hematopoietic Stem Celi Transplant (HSCT) patients
89328439|NCT04295733||Cohort 2|HIV infected subjects
89328440|NCT04295733||Cohort 3|Patients candidates for / in treatment with biological drugs such as monoclonal antibodies anti CD-20 (rituximab or ocrelizumab)
89328441|NCT04260464|Experimental|PF-06700841 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
89328442|NCT04260464|Experimental|PF-06700841 Normal Renal Function|This arm includes participants with normal renal function who will receive a single oral dose of 30 mg PF-06700841 on Day 1
89328443|NCT04260464|Experimental|PF-06700841 Moderate Renal Impairment|This arm includes participants with moderate renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
89328444|NCT04260464|Experimental|PF-06700841 Mild Renal Impairment|This arm includes participants with mild renal impairment who will receive a single oral dose of 30 mg PF-06700841 on Day 1
89328445|NCT04246372|Experimental|On Treatment|Tofacitinib 5mg oral tablets twice daily for 16 weeks
89328446|NCT04232124|Experimental|Hypertension Management Model|Aim 1. Execute a smaller version of the LA Barbershop BP Study through the new Nashville network as the test case for: A) recruiting regular patrons with uncontrolled HTN, B) conducting a research protocol and evaluating a HTN intervention; and C) creating a local registry of potential subjects as platform for enrolling black men in future research studies.
89328447|NCT04204967|Experimental|transdermal fentanyl|transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
89328448|NCT04204967|Active Comparator|IV Remifentanil alone|remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit
89328449|NCT04203316|Experimental|Treatment (enasidenib)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and/or biopsy and collection of blood on study.
89328450|NCT04159012|Experimental|Active transcranial direct current stimulation|Active transcranial direct current stimulation (tDCS), delivered at 2 mA and for 30 minutes, on sequential weekdays, for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
89328451|NCT04159012|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS), which will ramp up to 2 mA over 17 s, and then ramp down to and remain at 0.3 mA for the remainder of the 30 minute session. The short period of active stimulation is included to stimulate the somatic sensations of active therapy. The trickle current at 0.3 mA is necessary to measure electrode contact and prevent investigators from deducing that the device is no longer active. Participants will receive the sham therapy on sequential weekdays for a total of 30 sessions. Participants will continue to receive their usual pharmacotherapy and psychotherapy.
88806669|NCT05898516|Experimental|Usual Practice + JoyPop|Participants will be monitored through the existing wait-list practices, which involve regular phone calls to check in and assess functioning, and will receive access to the JoyPop app for 4 weeks.
88809670|NCT01271504|Active Comparator|Phase II: Arm 1; E7050 + Sorafenib|Phase II: Arm 1; E7050 + 400 mg Sorafenib Arm 2; 400 mg Sorafenib
88809671|NCT02144714|Experimental|SB5|SB5, single dose of 40 mg via subcutaneous injection (study drug)
89328452|NCT04158362|Experimental|Standard Chemotherapy regimen|"* Paclitaxel: administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle.~OR~* Capecitabine: given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks."
89328453|NCT04158362|Experimental|Standard Endocrine therapy (ET) regimen + Abemaciclib|"* Letrozole: continuous orally administration of 2.5 mg/day (1 tablet/day) OR anastrozole continuous orally administration of 1 mg/day (1 tablet/day) in combination with oral abemaciclib 150 mg (BID: twice a day) continuous for patients NSAI naïve or relapsing >1 year after the end of adjuvant ET.~OR~* Fulvestrant: 500 mg intramuscular on D1-D15-D29 (loading dose). Then 500 mg every 28 days (maintenance dose) with oral abemaciclib 150 mg BID continuous for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.~For women with a non-menopausal status at inclusion, a concomitant Luteinizing hormone-releasing hormone (LH-RH) agonist will be administered in combination with ET every 28 days. The LH-RH agonist drug to be used will be left to the investigator's choice."
89328454|NCT04145258|Other|WHO TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
89328455|NCT04145258|Other|WHO TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
89328456|NCT04145258|Other|Intensified TBM treatment + placebo|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
89328457|NCT04145258|Other|Intensified TBM treatment + aspirin|"Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d~W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d."
89328458|NCT04140734|Experimental|Hard Palate|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use hard palate
89328459|NCT04140734|Active Comparator|Autologous Ear Cartilage|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use autologous ear cartilage
89328460|NCT04140734|Active Comparator|Porcine Acellular Dermal Matrix|Some patients who will already be undergoing lower eyelid retraction repair with a spacer graft will be randomized to use porcine acellular dermal matrix
89328461|NCT04125134|Experimental|Hypertonic Saline Responders|Subjects who qualify as hypertonic saline responders will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
89328462|NCT04125134|Experimental|Hypertonic Saline Non-responders|Subjects who qualify as hypertonic saline non-responders will be dispensed the same instructions and treatment as the Hypertonic Saline Responders. They will be instructed to instill 1-2 drops of preservative-free Refresh Optive Advanced Lubricant Eye Drops, which are available over the counter, into each eye twice a day for 28 days.
89328463|NCT04104256|Experimental|Alert 1|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
89328464|NCT04104256|Experimental|Alert 2|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
89328465|NCT04104256|Experimental|Alert 3|Pre-op clinic physicians will be confronted with nudge #1 if they attempt to place an order for a pre-op test during the pre-op encounter.
89328466|NCT04104256|Experimental|Control|Pre-op clinic physicians will not receive interventions and perform duties as usual.
89328467|NCT04086771|Experimental|Intervention Group (Navigation)|Participants will be contacted by CHAs by phone one week after giving informed consent and completion of the baseline survey. CHAs will contact participants once a week for up to 10 weeks (a maximum of 10 attempts or until a clinic appointment is made, whichever comes first). Using the TIMS© message library, the CHAs will engage participants in conversations about breast and cervical cancer screening and navigate the participants to overcome any barriers to screening and motivate them to make a clinic appointment. Personal messages from mothers to daughters and vice versa and screening reminder notecards will be sent at 12-months (T3). At 18-months (T4), CHAs will follow-up with navigation group participants who reported completing a mammogram during the navigation process. Screening completion will be measured by self-report and confirmed via medical record check.
89328468|NCT04086771|Placebo Comparator|Control Group (Information only)|Participants will be mailed an informational brochure on mammography and Pap testing one week after enrollment into the study. At 3-months post enrollment, CHAs will conduct a follow-up phone call with each participant to assess mammogram and/or Pap testing completion (primary outcomes). At 12-months (T3) post enrollment, CHAs will contact all control group participants by phone to confirm a scheduled appointment or screening completion. For those who completed a mammogram within the 12 months since enrollment, generic screening reminder notecards will be sent by mail. At 18-months (T4), CHAs will follow-up with those control group participants who reported scheduling a mammogram, Pap smear, or both at the 12-month (T3) time point.
89328469|NCT04083612|Other|Standard of care - ixekizumab|Patient will continue to receive ixekizumab according to standard of care dosing regimen, i.e. loading dose first (160 mg) at week 0; 80 mg every 2 weeks until week 12, then 80 mg every 4 weeks
89328470|NCT04080661|Experimental|Standard of care - secukinumab|Patients will continue to receive secukinumab according to the standard dosing schedule: subcutaneous injections once a week for 5 weeks, then every 4 weeks (300 mg).
88809672|NCT02144714|Active Comparator|EU sourced Humira®|EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
88809673|NCT02144714|Active Comparator|US sourced Humira®|US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
88809674|NCT01279538|Experimental|ASKP1240 lowest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
89328471|NCT04080648|Other|Standard of case - guselkumab|Patients will continue to receive guselkumab according to the standard dosing schedule; subcutaneous injection of 100 mg at weeks 0 and 4 and then every 8 weeks
89328472|NCT04030559|Experimental|Treatment (niraparib)|Patients receive niraparib PO QD on days 1-28. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Following completion of treatment, patients then undergo standard of care surgery.
89328473|NCT04028921||Normal weight, active|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, >=60 min/day of moderate/vigorous physical activity.
89328474|NCT04028921||Normal weight, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=5th to <75th for age/sex, <60 min/day of moderate/vigorous physical activity.
89328475|NCT04028921||Overweight/obese, active|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, >=60 min/day of moderate/vigorous physical activity.
89328476|NCT04028921||Overweight/obese, sedentary|Male and female adolescents (age 14-17 years), BMI percentile >=85th to <99th for age/sex, <60 min/day of moderate/vigorous physical activity.
89328477|NCT04010630|No Intervention|control group|The physicians will resuscitate the patients according to the current critical care medicine guidelines.
89328478|NCT04010630|Experimental|Sodium bicarbonate group|Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion
89328479|NCT04000529|Experimental|TNO155 in combination with spartalizumab|TNO155 in combination with spartalizumab
89328480|NCT04000529|Experimental|TNO155 in combination with ribociclib|TNO155 in combination with ribociclib
89328481|NCT03981718|Active Comparator|Group: Standard|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive fat grafting procedure per standard of care during their 2nd stage breast reconstruction.
89328482|NCT03981718|Experimental|Group: Experimental|Breast cancer subjects with current injury to irradiated skin at the post-mastectomy site will receive their fat grafting procedure until 6 months after their 2nd stage breast reconstruction.
89328483|NCT03952637|Experimental|1|In Stage 1, up to 5 Type II subjects will receive 1.5E13 vg/kg of the gene transfer agent, and two Type II subjects will receive 4.5E13 vg/kg of the gene transfer agent. In Stage 1, up to 3 Type I subjects will receive 1.5E13 of the gene transfer agent (Cohort 1) and then up to 3 subjects will receive 4.5E13 of the gene transfer agent (Cohort 2).
89328484|NCT03952637|Experimental|2|Following the last Stage 1 subject s 6 months visit, data will be reviewed, and Stage 2 dosing and assessments will be determined. If Stage 2 dosing is to proceed, it will be reflected in a protocol amendment.
89328485|NCT03932773|Sham Comparator|Sham rTMS + CPT|30 minutes of sham repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) prior to each Cognitive Processing Therapy (CPT) session
89328486|NCT03932773|Active Comparator|Active rTMS + CPT|30 minutes of 1 Hz rTMS to rDLPFC prior to each CPT session
89328487|NCT03932773|Active Comparator|Active rTMS Alone|30 minutes of 1 Hz rTMS to rDLPFC at 1 session per week over 12 weeks
89328488|NCT03896503|Active Comparator|Arm I (topotecan hydrochloride )|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II at disease progression. Patients undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Patients may also undergo blood sample collection during screening and on study.
89328489|NCT03896503|Experimental|Arm II (topotecan hydrochloride, M6620)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 and M6620 IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Patients may also undergo blood sample collection during screening and on study.
89328490|NCT03798951|Experimental|Prehabilitation program|The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient. The program will have a duration of, at least, 4 weeks.
89328491|NCT03798951|No Intervention|Control|The patients included in this group will, also, receive a basal evaluation by a physiotherapist, a nutritionist and a psychologist. These patients will not receive a tailored prehabilitation program and will be revaluated the day before surgery.
89328492|NCT03787134|Experimental|2016-0500-Healthy YoungAdults|working memory and attention
89328493|NCT03785028|Experimental|Experimental Arm|Only arm of this basic science study, participants will undergo working memory and attention tasks
89328494|NCT03735745|Experimental|Caucasian, HPV positive, Non Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
89328495|NCT03735745|Experimental|Caucasian, HPV positive, Smoking patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
89328496|NCT03735745|Experimental|Newly diagnosed, African American/Black, HPV negative, Smoking|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
89328497|NCT03735745|Experimental|Young (<40 years old), Oral Cavity (Tongue) patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
89328498|NCT03735745|Experimental|Neoadjuvant PD-1 Blockade patients|Blood, tissue and saliva specimen will be collected. Surveys will be administered.
89328499|NCT03705585|Experimental|Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine prior to routine endoscopic examination. During endoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings might also be obtained.
88809675|NCT01279538|Experimental|ASKP1240 low dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
88809676|NCT01279538|Experimental|ASKP1240 high dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
89328500|NCT03705585|Experimental|Endoscopy, Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine after initial endoscopic exam and specimen collection and prior to a routine follow up endoscopic examination during which additional specimens will be collected.
89328501|NCT03705585|No Intervention|Endoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during endoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum if colonoscopy performed, duodenum if EGD performed).
89328502|NCT03678181|Active Comparator|Information-Only Arm|The HMP 2.0 Information-Only Control Arm will feature a streamlined version of the website that provides tailored information and content for YBLMT. This follows the design of HMP 1.0 where control arm participants had access to HIV-related Knowledge Center articles of the main intervention without access to the engagement features, interactive forums, or doctor Q&A. HIV-negative and sero-unknown participants also will be able to request HIV home test kits. The choice of control arm balances equipoise with research study design; in HMP 1.0, control arm participants also experienced a statistically significant intervention benefit.
89328503|NCT03678181|Experimental|HMP 2.0 Arm|Participants in this experimental arm will receive access to HMP 2.0, an interactive site that includes a Knowledge Center focused on HIV prevention content, interactive forums, and a provider question & answer platform.
89328504|NCT03678181|Experimental|Peer-referred HMP network arm|Participants randomized to Intervention Arm 2 (peer-created network) will be enrolled into a parallel (but separate) version of HMP 2.0. The only difference between the two intervention arms is that the peer-referred HMP network arm will allow participants to refer and enroll 2 peers of their choosing into the study.
89328505|NCT03657069|Experimental|Supportive care (Blossom Smart Expander Technology)|After mastectomy, participants undergo 2-staged IBR with the Blossom Smart Expander Technology comprising of the Blossom syringe assist device connected to the Mentor SPECTRUM adjustable saline breast implant.
89328506|NCT03643510|Experimental|Fulvestrant in Combination with Abemaciclib|Eligible patients will take Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28. Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles. Each cycle will be 28 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, or study termination.
89328507|NCT03639701|Experimental|Open label thymidine and deoxycytidine|All patients will receive open label thymidine and deoxycytidine
89328508|NCT03629990|Experimental|Active ABM + CBT/MET|"Participants in the Active ABM condition will receive approach bias modification (ABM) training sessions aimed at reducing cognitive bias for cannabis cues.~All participants will receive MET/CBT therapy."
89328509|NCT03629990|Sham Comparator|Sham ABM + CBT/MET|"Participants in the Sham ABM condition will undergo similar computerized tasks without the manipulation of response contingencies that target modification of approach bias.~All participants will receive MET/CBT therapy."
89328510|NCT03574545|Active Comparator|Reference VAY736 Drug Product|Powder for solution for injection / infusion
89328511|NCT03574545|Experimental|Test VAY736 Drug Product|Solution for injection
89328512|NCT03542383|Active Comparator|Active HD tDCS|Administer 10 20-minute sessions of 1 mA anodal High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
89328513|NCT03542383|Sham Comparator|Sham HD tDCS|Administer 10 20-minute sessions of sham High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
89328514|NCT03529110|Experimental|Trastuzumab deruxtecan (T-DXd)|Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).
89328515|NCT03529110|Active Comparator|Ado-trastuzumab emtansine (T-DM1)|Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.
89328516|NCT03500874|Experimental|HAI group|Patients will receive systemic chemotherapy on days 1 and 15 using either of the following regimens: mFOLFOX6 (Oxaliplatin 85 mg/m2; Leucovorin 200mg/m2; followed by an infusion of 5-fluorouracil 2.4 g/m2 administered over 46 hours) or mFOLFIRI (Irinotecan 180mg/m2; Leucovorin 200mg/m2; followed by an infusion of 5-fluorouracil 2.4 g/m2 administered over 46 hours) For HAI, FUDR was administered as a continuous infusion of 0.12 mg/kg/day over 14 days via the HAI pump, along with dexamethasone 20 mg, and normal saline was used to fill up the 300ml pump reservoir.
89328517|NCT03500874|Active Comparator|Non-HAI group|Patients will receive systemic chemotherapy on days 1 and 15 using either of the following regimens: mFOLFOX6 (oxalipatin 85 mg/m2 infusion for 3 h, Leucovorin 200 mg/m2 for 3 h and 5-FU 2,400 mg/m2 continuous infusion for 46 h) or mFOLFIRI (Irinotecan 180mg/m2; Leucovorin 200mg/m2; 5-FU 2,400 mg/m2 continuous infusion for 46 h).
89328518|NCT03460158|Experimental|Restylane-L®, Restylane-L® Lyft, and Restylane Silk®|Hyaluronic acid
89328519|NCT03399500|Active Comparator|Usual Case Management (UCM)|Group receives standard case management at the shelter
89328520|NCT03399500|Experimental|UCM + Smartphone|Group receives standard case management and an unlimited smartphone
89328521|NCT03399500|Experimental|Smartphone Based Case Management (SPCM)|Group receives standard case management and an unlimited smartphone with the SPCM app
89328522|NCT03358472|Experimental|Pembrolizumab + Epacadostat|
89328523|NCT03358472|Experimental|Pembrolizumab|
89328524|NCT03358472|Active Comparator|EXTREME|EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil.
89328525|NCT03315390|Experimental|Intervention-group|Narrative Exposure Therapy (NET): for GP-practice adapted version of narrative exposure therapy during 3 sessions (à 45 minutes)
89328526|NCT03315390|Active Comparator|iTAU group|Improved Treatment-as-usual: 3 GP consultations with patients according to guidelines and adapted to patients' needs
89328527|NCT03276546|Experimental|SHARE-D decision tool use|The intervention, a shared decision-making tool ('SHARE-D'), which is a paper-based questionnaire, will be used jointly by a health professional and patient to facilitate decision-making about initiating change in physical activity or diet behaviour
89328528|NCT03253549|Experimental|SMArTVIEW|
88809677|NCT01279538|Experimental|ASKP1240 highest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
89328529|NCT03253549|No Intervention|Standard Care|
89328530|NCT03247309|Experimental|IMA201 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~One dose of IMA201 product will be infused intravenously. Up to four dose levels will be evaluated. At least two patients per cohort will be treated.~Post-infusion of IMA201 product, administration of low-dose recombinant human interleukin-2"
89328531|NCT03195777|Experimental|Single Arm: Observation after Imaging|This is a single-arm study, where subjects will be monitored for development of PTS after baseline non-invasive imaging with FDG PET/CT. The experimental interventIon is the PET/CT imaging.
89328532|NCT03164486|Experimental|18F-αvβ6-BP|Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.
89328533|NCT03132922|Experimental|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|
89328534|NCT03132922|Experimental|Radiation Sub-Study: Autologous genetically modified MAGE-A4c1|
89328535|NCT03099382|Experimental|camrelizumab|
89328536|NCT03099382|Active Comparator|Investigator's Choice of Standard Therapy|Docetaxel or Irinotecan
89328537|NCT02988960|Experimental|Escalating Arm 1: ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
89328538|NCT02988960|Experimental|Escalating Arm 2: ABBV-927|Participants with solid tumors will receive escalating intratumoral (IT) doses of ABBV-927.
89328539|NCT02988960|Experimental|Escalating Arm 3: ABBV-927+ABBV-181|Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
89328540|NCT02988960|Experimental|Escalating Arm 4: ABBV-927+ABBV-181|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
89328541|NCT02988960|Experimental|Escalating Arm 5 (Japan): ABBV-927|Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
89328542|NCT02988960|Experimental|Escalating Arm 6 (Japan): ABBV-927+ABBV-181|Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
89328543|NCT02988960|Experimental|Expansion Arm A: ABBV-927|Additional participants with HNSCC or NSCLC will receive intravenous (IV) doses of ABBV-927.
89328544|NCT02988960|Experimental|Expansion Arm B: ABBV-927+ABBV-181|Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
89328545|NCT02988960|Experimental|Expansion Arm C: ABBV-927+ABBV-181|Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
89328546|NCT02952508|Experimental|Iopofosine I 131, intravenous administration WM|Iopofosine I 131 in Waldenstroms Macroglobulinemia
89328547|NCT02952508|Experimental|Iopofosine I 131, intravenous administration MM|Iopofosine I 131 in Multiple Myeloma
89328548|NCT02952508|Experimental|Iopofosine I 131, intravenous administration CNS Lymphoma|Iopofosine I 131 in Central Nervous System Lymphoma
89328549|NCT02952508|Experimental|Iopofosine I 131 intravenous administration NHL [CLOSED]|Iopofosine I 131 in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma
89328550|NCT02939287|Active Comparator|Aprepitant|aprepitant plus standard anti-emetic regimen
89328551|NCT02939287|Experimental|Olanzapine|olanzapine plus standard anti-emetic regimen
89328552|NCT02939287|Experimental|Aprepitant plus olanzapine|aprepitant and olanzapine plus standard anti-emetic regimen
89328553|NCT02932176||Non-invasive vascular testing|All patients undergoing non-invasive vascular testing will be eligible for this study. The official results will be used to develop the algorithm and to evaluate the accuracy of the algorithm
89328554|NCT02802241|Experimental|open-label placebo|
89328555|NCT02802241|Experimental|double-blind placebo|
89328556|NCT02802241|Experimental|double-blind peppermint oil|
89328557|NCT02802241|No Intervention|no additional treatment|
89328558|NCT02771275|Experimental|Harpoon Medical Device TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
89328559|NCT02748018|Experimental|Hybrid Closed Loop Arm|The HCL Arm will use the MiniMed System (i.e., using Auto Mode) for 6 months during the study period.
89328560|NCT02748018|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump). Each cohort (CSII, MDI, or SAP) will be used as the control arm to be compared to the experimental arm (HCL).
89328561|NCT02714257|No Intervention|Enhanced Usual Care - control group|Participants will receive enhanced usual care by reviewing three printed pamphlets on fall risks and recommendation to exercise. In addition, to maximize patient safety, the investigators will communicate the baseline bone density results (measured by Dual-energy X-ray absorptiometry, DXA) to the patient's primary care provider, and any critical values of a baseline measure.
89328562|NCT02714257|Experimental|Enhanced Usual Care plus Exercise Coaching Intervention|Participants will receive the three printed pamphlets on fall risks and exercising in groups (same as the controls) plus: (1) an exercise program that includes strength, balance, and aerobic exercises; (2) an exercise coach that provides in-person and telephone support/feedbacks to enhance participation in the exercise program; and (3) regular progress reports sent by coaches by fax/Electronic Health Records every 4 months, to communicate the patient's progress.
89328563|NCT02587936|Experimental|Collaborative model|Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator
89328564|NCT02587936|No Intervention|Standard Care|Group to receive regular care
89328565|NCT02564900|Experimental|Part 1 Dose escalation|Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation with overdose control principal.
89328566|NCT02564900|Experimental|Part 2 Dose expansion|Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), HER2 expressing other solid malignant tumor (Part 2d); HER2 expressing breast cancer (Japan only; Part 2e)
89328567|NCT02513914|Experimental|Dural Venous Sinus Stenting|Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.
89328568|NCT02513914|Active Comparator|Cerebrospinal Fluid Shunting|Choice of shunt procedure (ventriculoperitoneal, ventriculoatrial, or lumboperitoneal), catheter laterality, brand and shunt equipment (including shunt catheters and valves), valve settings of programmable shunt valves (when applicable), intrathecal antibiotic administration and the use of stereotactic navigation will be at the discretion of neurosurgeon. Shunt procedures will be performed per the standard of care, under general anesthesia. An optional surgical procedure guidance document will be provided for other sites. Patients will undergo serial physical and neurological examinations for 24 hours post-procedure prior to discharge.
89328569|NCT02470091|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity.
89328570|NCT02437851|Experimental|Treatment (surgery)|Participants undergo therapeutic conventional surgery to remove anal or perianal cancer (SISCCA). Any HSIL remaining is treated with the goal for complete eradication in accordance with clinician and participant preference.
89328571|NCT02432196|Experimental|Harpoon Medical TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
89328572|NCT02329860|Experimental|Apatinib|750 mg orally (p.o.) every day (qd), 28 days as one cycle
89328573|NCT02329860|Placebo Comparator|Placebo|orally (p.o.) every day (qd), 28 days as one cycle
89328574|NCT02269332||Screening Colonoscopy|Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks
89328575|NCT02163733|Other|Fasted|AZD9291 tablets following a period of fasting
89328576|NCT02163733|Other|High-fat meal|AZD9291 tablets following a high-fat meal.
89328577|NCT02079662|Experimental|Arm I (IO interventions)|Patients undergo up to 7 different IO intervention sessions per week during their 6-week course of radiotherapy for between 1 and 3 hours each session, in addition to, up to 6 aerobic training sessions per week and one grocery store trip during the course of the program. IO intervention programs consist of nutritional coaching, behavioral therapy, yoga and meditation practice, resistance training, and a weekly meal sharing and cooking class. Patients then have weekly meetings with the study psychologist on the computer for 6 months, followed by a monthly meeting on the computer from 6-12 months, and 2 hour meetings at all follow-up appointments during the first year after radiotherapy.
89328578|NCT02079662|Active Comparator|Arm II (standard of care)|Patients undergo standard of care.
89328579|NCT02062593|Active Comparator|Coronary angioplasty and optimum medical therapy|Percutaneous coronary intervention and optimal medical therapy
89328580|NCT02062593|Placebo Comparator|Sham procedure and optimum medical therapy|Placebo percutaneous coronary intervention and optimal medical therapy with risk factor modification and anti-anginal therapy
89328581|NCT02027896|Experimental|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
89328582|NCT02027896|No Intervention|Standard surgical care|Surgical hip fracture repair according to the standard timing.
89328583|NCT02023333|Experimental|Regorafenib|This is an open-label, phase II study of regorafenib for patients with metastatic colorectal carcinoma. The treatment will be repeated every week for three weeks on and one week off. Patients will be evaluated for response after every 2 cycles (8 weeks).
89328584|NCT01888913||Adult Women|Adult Women aged 18-50
89328585|NCT01879761||Immunosuppressed|"Immunosuppressed includes patients with any one of the following:~a diagnosis of a hematological malignancy~a diagnosis of HIV~myelosuppressive chemotherapy in the previous 90 days~immune-modulating medications in the previous 90 days"
89328586|NCT01879761||Non-Immunosuppressed|Subject does not fit immunosuppressed criteria
89328587|NCT01726855||dorsal fascial flap|combined with standard modified Kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger palmar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons.
89328588|NCT01726855||standard modified Kessler technique|
89328589|NCT01533337|Other|finger|Free dorsal digital flap transferring is used for reconstruction of soft-tissue defects
89328590|NCT01407263|Experimental|Lymphadenectomy vs. no lymphadenectomy|In patients randomized to standard, only the nodal packet under the external iliac vein and above the obturator nerve will be dissected. For patients randomized to the modified template, the external iliac, hypogastric and obturator fossa nodal groups will be removed.No lymph nodes will be removed in patients randomized to the no PLND arm.
89328591|NCT01407263|Experimental|Transverse versus vertical closure of the port site incision (Closed as of 9/30/2021)|
89328592|NCT01407263|Experimental|One vs. three days of antibiotic prophylaxis (Closed as of 9/30/2021)|
89328593|NCT01407263|Experimental|Hemostatic agent vs. no hemostatic agent|
89328594|NCT01391832|Sham Comparator|Sham rTMS|Sham Treatment Intervention: Device: Repetitive Transcranial Magnet Stimulation (sham treatment)
89328595|NCT01391832|Active Comparator|active rTMS|"Active Repetitive Transcranial Magnet Stimulation treatment~Intervention: Device: Active rTMS of dorsolateral pre-frontal cortex"
89328596|NCT01226316|Experimental|Part A and B Schedule 1, Continuous dosing|Part A: Ascending doses of AZD5363 administered orally, every day to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A.
89328597|NCT01226316|Experimental|Parts A,B,C,D Schedule 2, Intermittent dosing|Part A: Ascending doses of AZD5363 administered orally, twice daily, on a 7-day repeating regimen (4 days on, 3 days off and 2 days on, 5 days off), to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A (4 days on, 3 days off and 2 days on, 5 days off). Part C and D: AZD5363 orally, twice daily on an intermittent regimen (4 days on, 3 days off).
89328598|NCT01226316|Experimental|Parts A and B Schedule 3, Intermittent dosing.|"Part A: Ascending doses of AZD5363 administered orally, twice daily, on an alternative weekly regimen. Initiation of Schedule 3 is dependant on emerging clinical data.~Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A"
89328599|NCT01226316|Experimental|Parts E and F, Intermittent dosing with Fulvestrant|Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment to cessation of therapy combined with background therapy of fulvestrant at its licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter to cessation of therapy.
89328600|NCT00979771|Experimental|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
89328601|NCT00979771|Placebo Comparator|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
89328602|NCT05934305|Experimental|Matter Intervention|This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.
89328603|NCT05934305|Active Comparator|Control Condition|The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
89328604|NCT05929300|Experimental|Yoga|The study design entails randomizing ~34 Veterans who are undergoing RP for PCa to either usual care or a twice-weekly hybrid (in-person and virtual) yoga program that includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-RP yoga. Participants will provide data at three time points: baseline/pre-yoga (T1), completion of~ 4 weeks of pre-RP yoga (T2), and completion of 8 weeks of post-RP yoga (T3). Data collection for the control group will parallel that of the yoga group. Times of data collection are consistent with other yoga trials. Veterans randomized to the intervention will be asked to routinely practice yoga (at least 15 min/day).
89328605|NCT05929300|Active Comparator|Usual Care|"The control group will consist of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it."
89328606|NCT05925465|Active Comparator|Maxillary and mandibular nerve block (MMNB) group|receive bilateral combined maxillary and mandibular nerve block. Three mL of 0.5% isobaric bupivacaine will be injected for each nerve block after negative aspiration of blood.
89328607|NCT05925465|Placebo Comparator|Control (C) group|not receive any nerve block
89328608|NCT05923502||All enrolled patients.|All patient who signed the consent form for participation to the study.
89328609|NCT05922033|Experimental|Patient-led self-titration of insulin|Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.
89328610|NCT05922033|Active Comparator|Standard of care|Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
89328611|NCT05921643||patient with cholesteatoma who has never been operated on|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
89328612|NCT05914038|Experimental|individualized rTMS|Patients will receive individualized repetitive transcranial magnetic stimulation according to lateralization index measured by functional near-infrared spectroscopy
89328613|NCT05914038|Active Comparator|Traditional rTMS|Control group is given traditional rTMS
89328614|NCT05913219||Participants with long-term conditions affecting movement|A total number of 120 people with long-term conditions affecting their movement include people with Parkinson's (N=60), stroke (N=30), those living with arthritis (N=30).
89328615|NCT05913219||Healthy control|A total number of 30 healthy people with no condition impacting their movement and walking ability.
88809678|NCT01279538|Placebo Comparator|Placebo|Participants received a single 30-minute matching placebo infusion on Study Day 1, followed by a 90-day follow-up period.
89328616|NCT05912803|Experimental|Simulated Equestrian Therapy|"The treatment group will receive Simulated Equestrian Therapy using 2 horse simulators (wooden and mechanical). Each participant will undergo a warm-up before phase I and cool-down after phase II.~The treatment will be divided into following 2 phases; Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed every week for 12 weeks in the following manner;~0-2 weeks: Practicing catching and throwing.~3-5 weeks: Placing the ball, and rings on the target.~6-8 weeks: Target hitting on a game of dart.~9-12 weeks: Leaning to the head, feet, and tail of the horse"
89328617|NCT05912803|Active Comparator|Neuro-Motor Therapy|This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child thrice for three weeks. The participants will undergo warm-up before the exercise and cool-down afterwards.
89328618|NCT05910645||Dental Residents in pediatric department|
89328619|NCT05910645||Dental Residents in conservative department|
89328620|NCT05905679|Experimental|Probiotic Arm|
89328621|NCT05905679|Active Comparator|Placebo|
89328622|NCT05904756||Metal framework group|Two sets of patients were made (10 patients/set) using random-generated numbers created by a computer program (Excel sheet). Conventional complete denture will be fabricated first and patient will wear the denture for 3 months. Then 4 implants will be placed according to all in 4 concept.after 3 months of asseointegration,the first 10 participants will recieve metal framework first. After 3 months, patient satisfaction and oral healthy related quality of lifewill be measured.
89328623|NCT05904756||PEKK framework group|metal framework will be replaced by PEKK framework. After another 3 months, measurements will be repeated. The second 10 patients received polyetherketoneketone first, and after 3 months, measurements will be made. Then, polyetherketoneketone framework will be replaced by Metal framework and measurements( Patient satisfaction and oral healty related quality of life) will be repeated after another 3 months in across over design.
89328624|NCT05899361|Experimental|Electromagnetic Guided Laparoscopy + Ultrasound|"This trial will investigate the use of the novel imaging protocol patients who have a confirmed cancer diagnosis in any of the following urologic regions or organs: Bladder, Prostate, Testicle, Ureter, Kidney, Urethra, Penis, and Scrotum.~- This research study involves the use of a standard of care laparoscope and ultrasound probe. The laparoscope and ultrasound probe will have an electromagnetic sensor attached which will assist in the tracking of lymph nodes of interest or organs of interest. It is expected that the entire time to record the data will be less than 10 minutes. standard of care laparoscope and ultrasound probe"
89328625|NCT05894057||Group 1 (reference: midazolam oral syrup or rectal suppository formulations)|Oral syrup or rectal suppository formulation of midazolam prescribed in the Anesthesiology Unit or Emergency Unit of UKBB as current reference formulations in clinical routine.
89328626|NCT05894057||Group 2 (alternative: midazolam oro- dispersible mini-tablet (OMDT) formulation)|ODMT formulation of midazolam prescribed in the Anesthesiology or Emergency Unit at UKBB as a recently introduced alternative formulation in clinical routine.
89328627|NCT05893576|Experimental|R group (reference formulation group)|
89328628|NCT05893576|Experimental|T group (test formulation group)|
89328629|NCT05892991|Active Comparator|standard physical therapy group|this group will receive 4 physical therapy sessions per week for 4 weeks. The session will consist of intermittent neuromuscular inhibition which is composed of 3 manual approaches (positional release, muscle energy technique, and progressive pressure release).
89328630|NCT05892991|Experimental|amplitude modulated frequency (AMF) 130Hz group|"Chattanooga (Intellect© Advanced, USA) multi-current device will be used to apply the IFC sessions. Carrier frequency 4000Hz, 2 pole placement (pre-modulated), the intensity will be raised till the patient feels a strong but comfortable tingling sensation, AMFs 130. Two vacuum electrodes of medium size will be placed at both sides of the trigger point. The duration of the session will be 30 minutes and will be repeated 3 times per week for 4 weeks.~standard physical therapy treatment as in the first group"
89328631|NCT05892991|Experimental|amplitude modulated frequency (AMF) 80Hz group|"Chattanooga (Intellect© Advanced, USA) multi-current device will be used to apply the IFC sessions. Carrier frequency 4000Hz, 2 pole placement (pre-modulated), the intensity will be raised till the patient feels a strong but comfortable tingling sensation, AMFs 80Hz. Two vacuum electrodes of medium size will be placed at both sides of the trigger point. The duration of the session will be 30 minutes and will be repeated 3 times per week for 4 weeks.~standard physical therapy treatment as in the first group"
89328632|NCT05892991|Experimental|amplitude modulated frequency 4Hz group|"Chattanooga (Intellect© Advanced, USA) multi-current device will be used to apply the IFC sessions. Carrier frequency 4000Hz, 2 pole placement (premodulated), the intensity will be raised till muscle twitching is visible under electrodes, AMFs 4 Hz. Two vacuum electrodes of medium size will be placed at both sides of the trigger point. The duration of the session will be 30 minutes and will be repeated 3 times per week for 4 weeks.~standard physical therapy treatment as in the first group"
89328633|NCT05891873||Neurointensive/neurocritical group (N-ICU)|
89328634|NCT05891873||Paediatric intensive/critical group (P-ICU)|
89328635|NCT05879991|Experimental|Part A: BI 1810631 (C-14)|
89328636|NCT05879991|Experimental|Part B: BI 1810631 then BI 1810631 (C-14)|
89328637|NCT05878418|Experimental|Trunk Exercises, Pulmonary Rehabilitation and Pulmonary Care Program + Spinal Orthosis Group|Trunk Exercises, Pulmonary Rehabilitation and Pulmonary Care Program + Toracolumbosacral Spinal Orthosis
89328638|NCT05878418|Active Comparator|Trunk Exercises, Pulmonary Rehabilitation and Pulmonary Care Program Group|Trunk Exercises, Pulmonary Rehabilitation and Pulmonary Care Program
89328639|NCT05877807||Experimental : BACLOFEN|Patient will receive baclofen caps
89328640|NCT05877807||Placebo Comparator : PLACEBO|Patient will receive placebo caps (lactose)
89328641|NCT05877560|Active Comparator|NIBS-OBVAT|8 sessions of non-invasive brain stimulation with 8 weeks of office-based vergence/accommodative therapy.
89328642|NCT05877560|Active Comparator|NIBS|8 sessions of non-invasive brain stimulation only.
89328643|NCT05877560|Sham Comparator|OBVAT|8 sessions of sham stimulation with 8 weeks of office-based vergence/accommodative therapy.
89328644|NCT05876988|Experimental|experimental group|"Electroacupuncture intervention will take about 45 minutes every time. For experimental group, acupuncture points are mainly in the head, limbs and abdomen, and a total of six pairs of electric acupuncture for head. The Montreal Cognitive Assessment (MoCA) serves as the primary outcome. Digit span test will be the secondary outcome for attentional function and working memory. In addition, EORTCQLQ-C30 will be used to examine the quality of life of elderly cancer patients. Functional changes and side eﬀects associated with therapies will be measured using the Functional Assessment of Cancer Therapy (FACT). Most items of these functional assessments are 5-point Likert scale questions. Functional items which would be rated as 3 (quite a bit) or higher and incidences would be signiﬁcantly diﬀerent between the two groups in any assessment point will be extracted for statistical analysis."
89328645|NCT05876988|Placebo Comparator|control group|Electroacupuncture intervention will take about 45 minutes every time. For the control group, acupuncture points are mainly on the head and limbs, only a pair of electric needles for head. The Montreal Cognitive Assessment (MoCA) serves as the primary outcome. Digit span test will be the secondary outcome for attentional function and working memory. The quality of life and multiple functional assessments will also be evaluated.
89328646|NCT05874544|Active Comparator|Tetracycline Bismuth Quadruple Therapy|Vonoprazan 20mg bid, Bismuth Potassium Citrate 110mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
89328647|NCT05874544|Experimental|Rifabutin Triple Therapy|Vonoprazan 20mg bid, amoxicillin 1000mg tid, rifabutin 150mg bid
89328648|NCT05874544|Experimental|Dual Therapy|Vonoprazan 20mg bid, amoxicillin 1000mg tid
89328649|NCT05870241|Experimental|Ga-As Laser|the patients will receive Ga-As Laser and traditional therapy three times a week for three months
89328650|NCT05870241|Experimental|Microcurrent Electrical Stimulation|the patients will receive Microcurrent Electrical Stimulation and traditional therapy three times a week for three months
89328651|NCT05870241|Active Comparator|traditional therapy|the patients will receive traditional therapy three times a week for three months
89328652|NCT05866887|Experimental|Sleep ALL Night|"Participants and parents will complete study procedures as outlined:~Baseline survey completed by participant parent(s).~Introduction to Sleep ALL Night action plan.~Review of psychoeducational website and completion of sleep diary.~Survey completed by participant parent(s)."
89328653|NCT05857761|Sham Comparator|Sham group|participants (n=50) will receive sham rTMS.
89328654|NCT05857761|Active Comparator|Active rTMS treatment|Participants (n=50) will receive active rTMS treatment.
89328655|NCT05857059|Active Comparator|Misoprostol 25 mcg|Participants received misoprostol 25 mcg every 2 hours until the active stage of labour was attained or failed induction was diagnosed
89328656|NCT05857059|Experimental|Misoprostol 50 mcg|Participants received misoprostol 25 mcg matching misoprostol 50 mcg every 2 hours until the active stage of labour was attained or failed induction was diagnosed
89328657|NCT05855681|Experimental|experimental group|patients will receive strengthening exercise for hip rotators and ankle muscles in addition to quadriceps strengthening . stretching exercise for hamstring and calf muscle also will be received
89328658|NCT05855681|Other|control group|patients will receive strengthening exercises for quadriceps and stretching exercise for hamstring and calf muscle.
89328659|NCT05839990|Active Comparator|Surgery|Patients with ascending aortic aneurysm and dlatation who undergo surgical tretment
89328660|NCT05839990|No Intervention|Non-surgery|Patients with ascending aortic dlatation who undergo surveillance
89328661|NCT05835492||Setting 1 - Hospital Readmission Reduction|North Bristol NHS Trust and University Hospitals Bristol and Weston NHS Foundation Trust (hospital readmissions reduction): Using myCOPD to support high risk patients with a primary focus on acute hospital admission discharge bundle following AECOPD. Patients who have been discharged from hospital following an AECOPD diagnosis and assessed in a follow-up clinic, including virtual wards, within 6 weeks can be included.
89328662|NCT05835492||Setting 2 - Pulmonary Rehabilitation|Cornwall Partnership NHS Foundation Trust (increasing community care provision of PR): Using myCOPD to support delivery of PR and self-management in the community.
89328663|NCT05833789||Colonoscopy for colorectal cancer screening|All patients in this group will have their colonoscopy for colorectal cancer screening completed with a legacy colonoscope followed by colonoscopy with the Magnetic Flexible Endoscope (MFE) to determine if the MFE can travel from the rectum to the cecum.
89328664|NCT05832827|Experimental|MK-3475(Pembrolizumab), Lenvatinib, carboplatin, and paclitaxel|Intervention: Carboplatin + paclitaxel + pembrolizumab + lenvatinib for 3 weeks (21 days) as 1 cycle, up to a maximum of 4 cycles in the induction phase. Then, maintenance therapy with pembrolizumab and lenvatinib will be continued until progression or unacceptable adverse events up to 31 cycles.
89328665|NCT05831826||healthy controls|Healthy controls are ≥18 years old, no previous history of SARS-CoV-2 infection, and no previous history of autoimmune diseases. All the HC group were injected with 2 or 3 doses of inactivated SARS-CoV-2 vaccines.
89328666|NCT05831826||the vaccinated patients with ADs|The vaccinated patients with ADs are ≥18 years old, no previous history of SARS-CoV-2 infection, and diagnosed with autoimmune diseases. All the group were injected with the inactivated SARS-CoV-2 vaccines.
89328667|NCT05831826||the unvaccinated patients with ADs|The vaccinated patients with ADs are ≥18 years old, no previous history of SARS-CoV-2 infection, and diagnosed with autoimmune diseases. All the group were not injected with the inactivated SARS-CoV-2 vaccines.
89328668|NCT05828017|Experimental|Participants with Hearing Loss|Individuals with hearing loss that meet the candidacy to wear hearing aids. All interventions are associated with the fitting of binaural hearing aids with various coupling methods. All participants will be assessed under all interventions.
89328669|NCT05825209|Active Comparator|Food-Grown Magnesium|Food-grown magnesium in capsule form - taken as 2 capsules, orally with water 1 hour before sleep.
89328670|NCT05825209|Placebo Comparator|Microcrystalline cellulose|Microcrystalline cellulose in capsule form - taken as 2 capsules, orally with water 1 hour before sleep.
89328671|NCT05815095||Routine practice (control)|In this group, a health professional will assess the infant's neurodevelopmental characteristics through routine practice evaluations, such as motor skills, vocalizations, babbling, and social interactions
89328672|NCT05815095||Use of PREAUT Grid (intervention)|In this group, a health professional will assess the infant's neurodevelopmental characteristics using the PREAUT grid
89328673|NCT05806242||Validation|Elderly in-patients eligible for physiotherapy admitted to IRCCS-INRCA Hospital
89328674|NCT05805007|Experimental|Dose escalation|"Three cohorts of 3 patients each. All the patients enrolled in the study will receive a single subretinal injection in one eye.~Cohort 1: Subretinal administration of a single low dose ZVS203e at Day 0. Cohort 2: Subretinal administration of a single medium dose ZVS203e at Day 0. Cohort 3: Subretinal administration of a single high dose ZVS203e at Day 0."
89328675|NCT05804162|Experimental|Cagrilintide (Arm 1)|Participants will receive 0.6 milligrams (mg) of cagrilintide subcutaneously once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose moxifloxacin placebo at the end of the treatment period will be administered orally.
89328676|NCT05804162|Active Comparator|Cagrilintide Placebo (Arm 2A)|Participants will receive cagrilintide placebo subcutaenously once weekly. In addition, a single dose of moxifloxacin active prior to initiation of treatment and a single dose of moxifloxacin placebo at the end of the treatment period will be administered orally.
89328677|NCT05804162|Active Comparator|Cagrilintide Placebo (Arm 2B)|Participants will receive cagrilintide placebo subcutaneously once weekly. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose of moxifloxacin active at the end of the treatment period will be administered orally.
89328678|NCT05797649||Heart Failure-Associated Pleural Effusion|Patients with pleural effusion with an underlying aetiology of heart failure
89328679|NCT05797649||Non-Heart Failure, Fluid Overload-Associated Pleural Effusion|Patients with pleural effusion with an underlying aetiology of fluid overload excluding heart failure
89328680|NCT05797649||Control group|Patients with pleural effusion due to exudative, or non-fluid overload causes
89328681|NCT05795816|Active Comparator|Testofen|Testofen in capsule form - taken as 2 x 300 mg daily with food (1 in the morning and 1 in the evening)
89328682|NCT05795816|Placebo Comparator|Microcrystalline cellulose|Microcrystalline cellulose in capsule form - taken as per Active comparator
89328683|NCT05790889|Placebo Comparator|Group 1 (Control group)|n= 60. Age= 5-17 months Rabies Vaccine administered on Days 0, 28 and 152.
89328684|NCT05790889|Experimental|Group 2|n=120 Age= 5-17 months First vaccination of RH5.1 10μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 152.
89328685|NCT05790889|Placebo Comparator|Group 3 (Control Group)|n= 60. Age= 5-17 months Rabies Vaccine administered on Days 0, 28 and 56.
89328686|NCT05790889|Experimental|Group 4|n=120 Age= 5-17 months First vaccination of RH5.1 10μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 56.
89328687|NCT05790889|Experimental|Group 5|n=120 Age= 5-17 months First vaccination of RH5.2-VLP 5μg with 50μg Matrix-M will be administered on day 0, followed by a second dose administered on Day 28, followed by a third and final dose at Day 56.
89328688|NCT05789316|Experimental|Ototoxicity Screening Protocol|After enrollment, participants will complete a pre-screening survey. Before their survivorship clinic visit, participants will complete the ototoxicity screening protocol and implementation outcome surveys. During their visit, they will receive counseling on ototoxicity and referral to audiology. After their visit, they will complete the SESMQ and WU-QOLv4 surveys and undergo pure tone audiometry. Each participant will complete this protocol once. The investigators will follow each participant by chart review for at least six months to evaluate for audiologic follow-up.
89328689|NCT05788926|Experimental|Dose escalation of TG6050|Dose escalation with single or repeated administrations of TG6050 by intravenous route in patients with advanced NSCLC.
89328690|NCT05785299|Active Comparator|Double blind placebo controlled challenge test|Introduction of cow's milk by means of an adjusted double blind placebo controlled challenge test
89328691|NCT05785299|Active Comparator|Home introduction test|Introduction of cow's milk by means of a standardized schedule
89328692|NCT05775094|Experimental|Romosozumab|Romosozumab will be given on-label for osteoporosis at 210 mg administered SC once monthly for 12 months in conjunction with antimyeloma therapy.
89328693|NCT05770856||Trauma related infection|
89328694|NCT05766813|Experimental|Lenrispodun 30 mg|Lenrispodun 30 mg tablets administered orally, once-daily.
89328695|NCT05766813|Placebo Comparator|Placebo|Matching tablets administered orally, once daily.
89328696|NCT05763654||Linovera emulsion|No intervention. Routine clinical practice.
89328697|NCT05759793|Experimental|CAR-GPRC5D cells|"The tolerability and safety of CARGPRC5D cells will be assessed according to the 3+3 doseescalation design.There will be three dose levels, 0.5×10^6, 1.0×10^6, 2.0x10^6cells/kg. For each level, 3-6 subjects will be enrolled."
89328698|NCT05756296||Intervention group|Children aged 9 years old with NE-TH meeting study inclusion criteria.
89328699|NCT05756296||Control group|A comparison group of sex and age matched children with no NE-TH meeting similar study inclusion criteria to intervention group. Specific exclusion criteria for matched control group include a previous history of neurodevelopmental delay or disorder, or a traumatic brain injury, and born at term (gestational age ≥37 weeks), or born without neonatal complication.
89328700|NCT05751655||Drowning patients|Process of experiencing respiratory impairment from submersion/immersion in liquid
89328701|NCT05748145|Experimental|Metronidazole treated arm|Administration of Metronidazole for 10 days prior to surgery in CRC patients
89328702|NCT05739214|Experimental|laser sequential mode|All patients received 2 sessions of laser therapy / week with different wavelengths in sequential mode in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care
89328703|NCT05739214|Experimental|laser seperate mode|All patients received 2 sessions of laser therapy / week with different wavelengths in seperate mode in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care
88809679|NCT00741026|Placebo Comparator|Placebo|Placebo
88809680|NCT00741026|Experimental|Olanzapine|Olanzapine 10mg po daily x 3 days
89328704|NCT05739214|Active Comparator|traditional wound care|"Traditional wound care inform of~Wound care treatment~Debridement to remove necrotic tissue~Irrigation of the wound by normal saline~Change dressing daily to protect wound from infection~Foot care~Wash feet daily, dry carefully especially between toe~Avoid extreme temperatures~Inspection daily of foot blisters~Foot wear~Avoid walking bare foot~Properly fitted shoes~Avoid wearing open-toed shoes"
89328705|NCT05735743|No Intervention|Standard of Care|Standard of Care
89328706|NCT05735743|Experimental|Participants receiving intervention|Motivational interviewing intervention
89328707|NCT05718869|Experimental|Treatment (tafasitamab and zanubrutinib)|Patients receive tafasitamab IV and zanubrutinib PO on study. Patients also undergo collection of blood samples on study and undergo CT scan and bone marrow biopsy throughout the trial.
89328708|NCT05714995||hypnosis|patients in the hypnosis group will perform self-hypnosis sessions
89328709|NCT05714995||hypnosis with aromatherapy|patients in the hypnosis with aromatherapy group will perform self-hypnosis sessions with inhalation of an essential oil
89328710|NCT05714631|No Intervention|Standard of care group|Patients in the standard of care will not be receiving any lidocaine or placebo patches. The aim of this group is to control for the placebo effect
89328711|NCT05714631|Placebo Comparator|Placebo group|
89328712|NCT05714631|Experimental|Intervention group|
89328713|NCT05701969|Experimental|Melatonin group|These subjects will receive melatonin
89328714|NCT05701969|Placebo Comparator|Placebo group|These subjects will receive placebo
89328715|NCT05700292|Experimental|High-intensity Interval Training|Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge & knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.
89328716|NCT05700292|Active Comparator|Moderate-intensity continuous training|Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
89328717|NCT05699993|Other|IBI351+ itraconazole|Enrolled subjects were treated with IBI351 on an empty stomach on Day 1. Itraconazole was administered orally once daily after a standardized meal from Day 3 to Day 6. IBI351 and itraconazole were administered simultaneously on an empty stomach on Day 7. On Day 8, itraconazole was orally administered once after a standard meal.
89328718|NCT05699993|Other|IBI351+ dextromethorphan|Enrolled subjects were orally administered dextromethorphan on an empty stomach on Day 1. IBI351 and dextromethorphan were orally administered simultaneously on an empty stomach on Day 3, followed by IBI351 12 hours later.
89328719|NCT05693909|Experimental|Cohort 1|SP-420, 28 mg/kg, three times weekly for 48 weeks
89328720|NCT05693909|Experimental|Cohort 2|SP-420, 56 mg/kg, three times weekly for 48 weeks
89328721|NCT05693909|Experimental|Cohort 3|SP-420, 84 mg/kg, three times weekly for 48 weeks
89328722|NCT05691751|Experimental|limited application|Will go primary unilateral TKA with the tourniquet inflated only during cementation and final components of the prosthesis application
89328723|NCT05691751|Experimental|full-time application|will go unilateral primary TKA with inflating the tourniquet prior to incision and releasing it after closure and compression bandage application
89328724|NCT05691283|Experimental|transcranial direct current stimulation (tDCS), then sham stimulation|Participants receives three weeks of 20-minute tDCS stimulation. After a washout period of 3 months, they then receive three weeks of sham stimulation
89328725|NCT05691283|Experimental|Sham stimulation, then transcranial direct current stimulation (tDCS)|Participants receives three weeks of sham stimulation. After a washout period of 3 months, they then receive three weeks of 20-minute tDCS stimulation
89328726|NCT05688839|Experimental|Jaktinib 100mg BID|Jaktinib hydrochloride tablets, 2 x 50mg dosage, BID
89328727|NCT05688839|Placebo Comparator|Placebo|2 x Placebo tablets, BID
89328728|NCT05688124|Other|IBI351|This cohort investigated the effect of food on the pharmacokinetics of IBI351 in healthy subjects. In a double-crossover design, subjects were enrolled and randomly divided into two test groups A and B. Group A: IBI351 was orally administered to subjects in this group on an empty stomach on Day 1, followed by a high-fat meal on Day 4. Group B: IBI351 was orally administered to subjects in this group after a high-fat meal on Day 1 followed by an empty stomach on Day 4.
89328729|NCT05688124|Other|IBI351+Esomeprazole|Enrolled subjects were orally administered IBI351 with recommended dose on an empty stomach. Esomeprazole were administered orally.
89328730|NCT05686629|Experimental|Jaktinib 100mg BID|Jaktinib hydrochloride tablets, 2 x 50mg dosage, BID
89328731|NCT05686629|Placebo Comparator|Placebo|2 x Placebo tablets, BID
89328732|NCT05681884|Experimental|Group 1|"Subjects will be administered intravitreal faricimab 6 mg every 4 weeks (defined as every 28 days + 7 days and at least 21 days between injections) through week 48. Starting at Week 48, subjects will be treated every 16 weeks (weeks 48, 64 & 80) with an end of study visit at week 96.~Rescue: At any visit after Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial."
89328733|NCT05681884|Experimental|Group 2|"Subjects are seen and observed every 16 weeks. Starting at Week 48, subjects will be administered intravitreal faricimab 6 mg every 4 weeks from week 48 to week 92, (defined as every 28 days ± 7 days and at least 21 days between injections) with an end of study visit at week 96.~Rescue: At any visit before Week 48, if rescue criteria are met, faricimab 6mg will be given every 4 weeks and the subject will continue dosing through the end of the trial."
89328734|NCT05677919|Experimental|Treatment (pirtobrutinib and venetoclax)|Patients receive pirtobrutinib and venetoclax PO on study. Patients also undergo CT, MRI, and PET scans during screening and on study. Patients also undergo bone marrow aspiration and bone marrow biopsy, and collection of blood, tissue, stool, and saliva samples on study.
89328735|NCT05677347|Experimental|Part 1: GSK3923868 or placebo|Participants allocation to GSK3923868 and placebo will be in 3:1 ratio. In treatment period 1, participants will receive GSK3923868 (Dose 1) or Placebo; in treatment period 2, GSK3923868 (Dose 2) or Placebo. There will be a washout period of at least 5 days after each treatment periods.
89328736|NCT05677347|Experimental|Part 2: GSK3923868 or placebo|Participants from Part 1 will be allocated to GSK3923868 and placebo in 3:1 ratio to receive single repeat dose of GSK3923868 (Dose 3) or placebo for 14 days in treatment period 3 with up to 14 days of follow up.
89328737|NCT05672615||Non-Muscle Invasive Bladder Cancer - Bacillus Calmete-Guerin (BCG) intravesical treatments|Participants who are receiving BCG intravesical treatments will be asked to provide research urine samples and blood samples prior to and during their treatment course. Participants will also be asked to complete the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale at the start and throughout the treatment course. Participants will be given a daily mood diary to complete at the following timepoints: 6-week induction treatment, 3-week maintenance treatment, and the 3-month follow-up. The study team will ask permission from participants to utilize excess tissue samples from standard of care procedures and biopsies. Participants' medical history and clinical data will also be collected for the study.
89328738|NCT05672615||Non-Muscle Invasive Bladder Cancer - Chemotherapy intravesical treatments|Participants who are receiving chemotherapy intravesical treatments will be asked to provide research urine samples and blood samples prior to and during their treatment course. Participants will also be asked to complete the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale at the start and throughout the treatment course. Participants will be given a daily mood diary to complete at the following timepoints: 6-week induction treatment, 3-week maintenance treatment, and the 3-month follow-up. The study team will ask permission from participants to utilize excess tissue samples from standard of care procedures and biopsies. Participants' medical history and clinical data will also be collected for the study.
89328739|NCT05659901||Pelizaeus-Merzbacher Disease Participants|Participants will undergo CSF collection and neuroimaging procedures, up to Week 106 as a part of prospective study. Each participant's medical and family history data will be collected retrospectively from available medical notes and charts, from birth up to the end of the study period (up to 26 months).
89328740|NCT05651932|Experimental|KTX-1001|KTX-1001 will be administered orally, daily for 28 days.
89328741|NCT05649306||Patients not receiving a cystectomy - Standard of Care Group|Patients will receive standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
89328742|NCT05649306||Patients not receiving a cystectomy - Additional Education Group|Patients will receive additional education with standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment. Patients will also be asked to complete an attendance diary documenting additional support services utilized. The Attendance Diary will be completed at 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
89328743|NCT05649306||Patients receiving a cystectomy- Standard of Care Group|Patients will receive standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
89328744|NCT05649306||Patients receiving a cystectomy - Additional Education Group|Patients will receive additional education with standard of care treatment. Patients will be asked to complete the Demoralization Scale II and Female Sexual Function Index at baseline, 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment. Patients will also be asked to complete an attendance diary documenting additional support services utilized. The Attendance Diary will be completed at 1-month following treatment, 3-months following treatment, 6-months following treatment, and one-year following treatment.
89328745|NCT05647057|Active Comparator|A: gelofusine + ringers|Prime fluid strategy containing gelofusine and ringers
89328746|NCT05647057|Active Comparator|B: albumin + ringers|Prime fluid strategy containing albumin and ringers
89328747|NCT05647057|Active Comparator|C: ringers + retrograde autologous priming|Prime fluid strategy containing ringers combined with retrograde autologous priming
89328748|NCT05644444|Experimental|Lubricant A and Comparator A|"The comparator will be tested for oral assessment in the tolerance phase only. Tolerance phase includes oral assessment and vaginal assessment. A 7-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment. This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.~Treatment phase includes a 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment."
89328749|NCT05644444|Experimental|Lubricant B and Comparator B|"The comparator will be tested for oral assessment in the tolerance phase only. Tolerance phase includes oral assessment and vaginal assessment. A 7-Day wash-out period followed by 2 visits. Visit 1 will include baseline assessments and application of allocated IP. Visit 2 will consist of clinical assessment. This is conducted on a sub-set of the population enrolled into the arm using the same IP for the treatment phase.~Treatment phase includes a 4-week run-in period followed by 2 visits. Visit 1 will include baseline assessments and provision of allocated IP. Visit 2 will consist of clinical assessment."
89328750|NCT05642975||Suprainguinal Fascia Iliaca Block and Spinal Anesthesia Group|
89328751|NCT05642975||Erector Spinae Plane Block and Spinal Anesthesia Group|
89328752|NCT05642975||Spinal Anesthesia Group (control)|
89328753|NCT05636137||High School Students|The sample of the study consists of high school students who do not have mental disabilities that will prevent them from understanding and answering the questions, aged 15-18 and volunteer to participate in the study, have internet at home and have an individual device that provides internet access.
89328754|NCT05635968|Experimental|Low-dose whole brain irradiation group 1 (4cGy/day)|Low-dose whole brain irradiation with general AD medication treatment (4cGy/day, 2times/1wk, total 24cGy, 6 times/3wks)
89328755|NCT05635968|Experimental|Low-dose whole brain irradiation group 2 (50cGy/day)|Low-dose whole brain irradiation with general AD medication treatment (50cGy/day, 2times/1wk, total 300cGy, 6 times/3wks)
89328756|NCT05635968|Sham Comparator|Sham RT group|Sham RT wtih general AD medication treatment (0cGy/day, 2times/1wk, total 0cGy, 6 times/3wks)
89328757|NCT05634005|Experimental|Ordering Providers Assigned to Visible Clinical Decision Support Alerts|Clinical decision support alert will fire and become visible to the ordering provider in the electronic health record if blood product(s) are ordered out of accordance with guidelines. Information about transfusion guidelines and best practices will be sent to providers prior to starting the study and will be available on an internal website.
89328758|NCT05634005|No Intervention|Ordering Providers Assigned to No Visible Clinical Decision Support Alerts|Clinical decision support alert will not be visible to the ordering provider in the electronic health record if blood product(s) are ordered out of accordance with guidelines. Information about transfusion guidelines and best practices will be sent to providers prior to starting the study and will be available on an internal website.
89328759|NCT05631262|Experimental|SKB264 (Cohort 1)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
89328760|NCT05631262|Experimental|SKB264 (Cohort 2)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
89328761|NCT05631262|Experimental|SKB264 (Cohort 3)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
89328762|NCT05631262|Experimental|SKB264 (Cohort 4)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
89328763|NCT05631262|Experimental|SKB264 (Cohort 5)|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
89328764|NCT05631262|Experimental|Part II Test group|SKB264 will be administered as an intravenous (IV) infusion on Day 1 and Day 15 of each 28-day cycle
89328765|NCT05631262|Active Comparator|Part II Control group|Docetaxel will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle
89328766|NCT05630924|Experimental|SI! Program-NYC Children|Receives 4 month health promotion educational intervention.
89328767|NCT05630924|No Intervention|NYC Elementary School Children|The control group will be participating school children not enrolled in the program
89328768|NCT05629338|Experimental|Cohort 1|Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 1 unit (200 mL) of autologous FrontlineODP.
89328769|NCT05629338|Experimental|Cohort 2|Subjects are to have sufficient plasma withdrawn during a single plasmapheresis collection, in the range of 625 - 800 mL, depending on subject's weight and hematocrit, to allow re-infusion with 2 units (400 mL) of autologous FrontlineODP.
89328770|NCT05629338|Active Comparator|Cohort 3 Arm 3|Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous FrontlineODP and 4 units of autologous control PF24. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 3 will receive 4 units of FrontlineODP during the first infusion visit, and following a 14 day washout period, they would receive 4 units of PF24 during a second visit.
89328771|NCT05629338|Active Comparator|Cohort 3 Arm 4|Subject plasma is withdrawn during 4 plasmapheresis collections, in the range of 625 - 800 mL per collection, a total of approximately 2500 - 3200 mL, depending on subject's weight and hematocrit, to allow re-infusion with 4 units of autologous control PF24 and 4 units of autologous FrontlineODP. Subjects will receive in total 8 units of plasma over the course of 2 infusion visits. Subjects randomized to Arm 4 will receive 4 units of PF24 during the first infusion visit, and following a 14 day washout period, they would receive 4 units of FrontlineODP during the second visit.
89328772|NCT05628194||Men who have sex with men (MSM)|
89328773|NCT05626556|Experimental|older adults|Older adults with mild to moderate chronic illness
89328774|NCT05624853|Experimental|pregabalin sustained release tablet|pregabalin sustained release tablet 150mg qd for 8weeks
89328775|NCT05624853|Active Comparator|pregabalin immediate release capsule|pregabalin immediate release capsule 75mg bid for 8weeks
89328776|NCT05619263|No Intervention|Control|Caregivers who consent to participate, complete a baseline survey, and are assigned to the control arm will receive a four-page handout on Emergency Preparedness published by the Alzheimer's Association that provides tips on preparing for disasters and what to do during and after a disaster. Control participants will complete follow-up surveys at 3 and 6 months, similar to intervention participants.
89328777|NCT05619263|Experimental|Disaster PrepWise-Caregiver Intervention|Caregivers who consent to participate, complete a baseline survey, and are assigned to the intervention arm will receive a Disaster PrepWise-Caregiver program from a trained interventionist and receive a completed household emergency management plan. Control participants will complete follow-up surveys at 3 and 6 months, similar to intervention participants.
89328778|NCT05613244||Patients with Orbital Solitary Fibrous Tumors|
89328779|NCT05611333|Experimental|Physician-Led Remote Exercise Program Intervention|Participants randomized to the intervention arm will attend three 45-minute walking sessions over Zoom per week for 4 weeks. All participants will be asked to wear Fitbit activity trackers to track steps every day and to regularly use blood pressure cuffs to measure blood pressure at home. All participants will also be asked to complete a brief set of surveys at the beginning of the study, after 4 weeks, and after 12 weeks.
89328780|NCT05611333|No Intervention|Control|Participants in the control group will continue with usual care. All participants will be asked to wear Fitbit activity trackers to track steps every day and to regularly use blood pressure cuffs to measure blood pressure at home. All participants will also be asked to complete a brief set of surveys at the beginning of the study, after 4 weeks, and after 12 weeks.
89328781|NCT05608876|Experimental|Single Arm, Open Label|Single or multiple Intratumoural injections of tigilanol tiglate at up to a fixed dose of 3.6 mg/m2 (Body Surface Area [BSA]) per treatment.
89328782|NCT05594433|Experimental|Experimental|Sub cutaneous injection of Lenograstim with blood donation (450ML) after 4 days of mobilization
89328783|NCT05590000|Experimental|Gemini rechargeable Spinal Cord Stimulation (SCS) System|Patients will be implanted with the Gemini rechargeable SCS System
89328784|NCT05589597|Experimental|Cohort 1|E04010 Monotherapy
89328785|NCT05589597|Experimental|Cohort 2|E04010 in combination with nivolumab
89328786|NCT05589597|Experimental|Cohort 3|E04010 in combination with nivolumab
89328787|NCT05586698|Experimental|Group A|57 participant received auricular acupressure at Zero point on the left ear. Heart rate, HRV, and elements of HRV will be recorded every 5 minutes.
89328788|NCT05586698|Experimental|Group B|57 participant received sham acupressure at Zero point on the left ear. Heart rate, HRV, and elements of HRV will be recorded every 5 minutes.
89328789|NCT05581329|Experimental|Group A: acupoints on the left hand|Participants will be received acupuncture at the control acupoint (Yuji - LU10) in the first trial phase, and the second trial phase will be conducted after 07 days at the research acupoint (Houxi - SI3). In each time, skin surface temperature at the neck area will be recorded.
89328790|NCT05581329|Experimental|Group B: acupoints on the right hand|Participants will be received acupuncture at the control acupoint (Yuji - LU10) in the first trial phase, and the second trial phase will be conducted after 07 days at the research acupoint (Houxi - SI3). In each time, skin surface temperature at the neck area will be recorded.
89328791|NCT05579990|Experimental|Meal Delivery|Meal delivery intervention program designed to help low income postpartum women lose weight through weekly meal delivery and behavioral strategies.
89328792|NCT05578040|Experimental|Group A: Left AH13 acupoint (left cervical vertebra)|Participants received sham auricular acupressure by adhesive patches without Vaccaria seed at the left auricular cervical vertebra acupoint and auricular acupressure Vaccaria seed at the left auricular cervical vertebra acupoint after 1 week. At each time, the skin surface temperature of the neck area will be recorded.
89328793|NCT05578040|Experimental|Group B: RIght AH13 acupoint (right cervical vertebra)|Participants received sham auricular acupressure by adhesive patches without Vaccaria seed at the right auricular cervical vertebra acupoint - and auricular acupressure Vaccaria seed at the right auricular cervical vertebra acupoint after 1 week. At each time, the skin surface temperature in the neck area will be recorded.
89328794|NCT05578027|Experimental|Group A: P1M2|19 participants received mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) and the research acupoint (Mingmen) in the first and the second trial phase, respectively. In each trial phase, skin surface temperature at the local stimulated area and the knee area on both sides will be recorded.
89328795|NCT05578027|Experimental|Group B: M1P2|19 participants received mild moxibustion manipulation at the research acupoint (Mingmen) and the control acupoint (the left side Pishu acupoint) in the first and the second trial phase, respectively. In each trial phase, skin surface temperature at the local stimulated area and the knee area on both sides will be recorded.
89328796|NCT05578014|Experimental|Group STD|"19 participant received sham acupuncture at EX-B2 T3 point in right side or acupuncture with tonyfying or dispersing manipulations at Dazhui point, corresponding to 3 times of acupuncture in 14 days, each time is 7 days aparts. In each time, temperature of skin surface at the acupuncture site, the neck and the face will be recorded.~Procedure/Surgery: Acupuncture with disposable acupuncture needles (the size of 0.30 x 25 mm) at EX-B2 T3 point in right side as sham acupoint in the first trial phase. We used the same type of acupuncture needles as aboved to acupuncture at Dazhui with tonifying manipulations in the second trial phase and with dispersing manipulatiuons in the third trial phase."
89328797|NCT05578014|Experimental|Group TDS|"19 participant received acupuncture with tonyfying or dispersing manipulations at Dazhui or sham acupuncture at EX-B2 T3 point in right side, corresponding to 3 times of acupuncture in 14 days, each time is 7 days aparts. In each time, temperature of skin surface at the acupuncture site, the neck and the face will be recorded.~Procedure/Surgery: Acupuncture with disposable acupuncture needles (the size of 0.30 x 25 mm) at Dazhui with tonifying manipulations in the first trial phase and with dispersing manipulatiuons in the second trial phase. We used the same type of acupuncture needles as aboved to acupuncture at EX-B2 T3 point in right side as sham acupoint in the third trial phase."
89328798|NCT05578014|Experimental|Group DST|"19 participant received acupuncture with tonyfying or dispersing manipulations at Dazhui or sham acupuncture at EX-B2 T3 point in right side, corresponding to 3 times of acupuncture in 14 days, each time is 7 days aparts. In each time, temperature of skin surface at the acupuncture site, the neck and the face will be recorded.~Procedure/Surgery: Acupuncture with disposable acupuncture needles (the size of 0.30 x 25 mm) at Dazhui with tonifying manipulations in the first trial phase and with dispersing manipulatiuons in the second trial phase. We used the same type of acupuncture needles as aboved to acupuncture at EX-B2 T3 point in right side as sham acupoint in the third trial phase."
89328799|NCT05573802|Experimental|Part 1 : Dose finding|"Belantamab mafodotin will be administered as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle.~Belantamab mafodotin starting dose:~• 1.4 mg/kg Q8W (i.e., on Day 1 of every other 28-day cycle)~Dose Level +1: 1.9 mg/kg Q8W~Dose Level -1: 1.0 mg/kg Q8W~Dose Level -2: 1.0 mg/kg Q12W~Lenalidomide: 25 mg/d on day 1-21 of every 28-day cycle.~Dexamethasone: 40 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants < 75 years; 20 mg/d on days 1, 8, 15, 22 of every 28-day cycle in participants ≥ 75 years~Nirogacestat: 100 mg twice a day (BID) starting on day -3 and then each day of every other 28-day cycle (i.e., to be given only on cycles where belantamab mafodotin is administered)."
89328802|NCT05569291|Experimental|Automated Coaching Program (ACP)|The ACP will use the application as developed for patients with COPD and tested to be effective in this population (Demeyer et al., 2017). The program includes 1) one-to-one semi-structured interview (V1) with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favorite activities and (coping) strategies to become more active resulting in an individual action plan; 2) step counter (Fitbit; wrist or waist worn) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention; 3) smartphone coaching application, installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient. 4) phone calls by the coaches initiated in pre-defined situations.
88809681|NCT00741104||RA patients|Patients on maintenance therapy for RA with infliximab for >= the past 12 months.
88809682|NCT01273298|Experimental|Bisoprolol|
88809683|NCT01273298|Placebo Comparator|Sugar pill|
89328803|NCT05569291|Experimental|Manual Coaching Program (MCP)|The MCP includes 1) one-to-one semi-structured interview (V1) with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favorite activities and (coping) strategies to become more active resulting in an individual action plan; 2) step counter (Fitbit, wrist or waist worn), that will be linked with a smartphone using the Fitbit application providing direct feedback. Patients can access the Fitbit application if they want to, but they will not receive personal feedback; 3) weekly phone calls by the coaches, interviewing patients on their progress, performance (steps) and feedback. The first goal is based on the physical activity level at the beginning of the coaching intervention (median of 4 days). The individual activity goal (expressed as daily step count) will be revised based on the patient's willingness to increase.
89328804|NCT05568355|No Intervention|Standard Hospital-Based Care Coordination|Patients and families randomized to this arm will receive best practice standard of care hospital-based transition planning in the hospital with routine outpatient care team follow-up post-discharge.
89328805|NCT05568355|Experimental|GET2HOME Intervention|The GET2HOME intervention includes: 1) a pre-discharge telehealth huddle with the family, inpatient team, primary care team, and home care nursing; 2) a visual discharge task tracker (DTT) to monitor progress across care management tasks; and if desired by family and primary care 3) a post-discharge telehealth huddle 2-7 days after discharge with the family, inpatient team, primary care team, and home care nursing
89328806|NCT05562583|Experimental|Intervention (single arm)|5 session self-guided online delivered positive emotion regulation intervention with social components.
89328807|NCT05558215|Experimental|Remote Otago Exercise Program|Individuals with dementia will participate in Otago Exercise Program in their home using video recordings and with safety oversight by their trained care partners.
89328808|NCT05557292|Experimental|Cohort A (Dose Escalation, Recurrent Non-surgical GBM)|Participants will start at dose level 1 (6 mg) of RMC-5552 administered intravenously. Participants will receive RMC-5552 weekly in 21-day cycles until disease progression or unacceptable toxicity.
89328809|NCT05557292|Experimental|Cohort B (Dose Expansion, Recurrent Surgical GBM)|Participants will receive a single dose of RMC-5552 at the RP2D approximately 4 hours prior to participants' scheduled surgical resection as part of standard of care. After recovering from surgery (about 3-6 weeks), participants will continue receiving RMC-5552 weekly in 21-day cycles until disease progression or unacceptable toxicity.
89328810|NCT05557292|Experimental|Cohort C (Dose Expansion, Recurrent Non-surgical GBM)|Participants will be given the RP2D of RMC-5552 weekly in 21-day cycles until disease progression or unacceptable toxicity.
89328811|NCT05553860|Active Comparator|Anterior Protrusive|use of anterior protrusive positioning technique
89328812|NCT05553860|Experimental|Speech Position|use of speech positioning technique
89328813|NCT05553054||Intravenous (IV) drugs|Patient and prepared/administrated/discarded IV drugs data will be collected during 24 hours.
89328814|NCT05551416||EPIGASTRIC|Patients with GC.
89328815|NCT05551416||EDGAR 1|Symptomatic patients subjected to a diagnostic gastroscopy to study the prevalence of premalignant gastric lesions.
89328816|NCT05551416||EDGAR 2|Patients with premalignant gastric lesions and early gastric neoplasias treated by endoscopy resection.
89328817|NCT05551416||Negative control|"Patients from EDGAR 1 without gastric pathology or familial history of this neoplasia."
89328818|NCT05550961||Retrospective Cohort|About 1000 patients with NSCLC pre-treated with innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
89328819|NCT05550961||Prospective Cohort|About 200 patients with NSCLC planned to start an innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
89328820|NCT05546996|No Intervention|Phase A:|Establish suitability of digital video recording system for quantifying CSF drainage into an EVD drainage system.
89328821|NCT05546996|Other|Phase B|Exploratory study to generate initial data on the correlation between FlowSense flow rate measurements (FlowSense Flow Rate) and: A) EVD drainage data, quantified via video recording; B) intracranial pressure (ICP) measurements
89328822|NCT05546242|Experimental|CAB LA + RPV LA Arm|"The first 4 weeks of the treatment differ depending on whether participant opts for direct to injection (DTI) or Oral lead-in (OLI).~DTI: participants will remain on daily oral ART for 4weeks after randomization and will receive the 1st injection of IM CAB LA 600mg+RPV LA 900mg at the Month 1 visit. 2nd injections administered at Month 2, followed by maintenance injections every 2 months (Q2M)~OLI: participants will receive the study intervention in 2 phases:~Participants will receive CAB 30mg+RPV 25mg OD for 4weeks to be taken daily with food. The purpose of the optional OLI Phase is to allow an opportunity for participants to assess tolerability of the combination prior to administration of the injectables. There is no proven benefit to this approach~After 4weeks participants return for the Month 1 visit to receive the 1st IM CAB LA 600mg+RPV LA 900mg injections. The 2nd injections administered at Month 2 and then continuation injections will be administered Q2M"
89328823|NCT05546242|Active Comparator|ART Group|Participants will take a daily oral combination of 2 NRTIs plus DTG 50mg. Ideally, the single tablet fixed-dose combination regimen of (tenofovir disoproxil fumarate [TDF] 300 mg + lamivudine [3TC] 300 mg (or emtricitabine [FTC] 200 mg) + DTG 50 mg) will be used as per local country guidelines up to Month 24. If there are preexisting reasons why TDF or 3TC cannot be used as the NRTI backbone then alternative NRTIs are acceptable. Participants will be permitted to switch daily oral ART drugs in case of toxicity, after discussion with the coordinating center.
89328824|NCT05543122||Breastfeeding women|Either of the following drugs at steady state (Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe).
89328825|NCT05541809|Experimental|Peppermint group|This group will receive peppermint oil aroma
89328826|NCT05541809|Placebo Comparator|Water group|This group will receive water as an aroma oil
89328827|NCT05540392|Experimental|Acupuncture|Acupuncture group will receive 10 treatments of acupuncture over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
89328828|NCT05540392|Experimental|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
89328829|NCT05538169|Experimental|Laser therapy group|There will be 2 weekly applications of a low-level laser diode (Pioon Laser) for a 4-week active treatment period. Thus, a total of 8 therapeutic sessions will be conducted
89328830|NCT05534269|Experimental|Low dose|Already human tested low dose from phase I study
89328831|NCT05534269|Experimental|High dose|First in human dose used for efficacy reasons during phase II
89328832|NCT05532033|Experimental|high flow nasal cannula|Two hours after extubation patients will received high flow nasal cannula oxygenation therapy for 24 hours
89328833|NCT05532033|Active Comparator|Standard oxygen therapy|Two hours after extubation patients will received standard oxygenation therapy for 24 hours
89328834|NCT05531305|Experimental|Study intervention|
89328835|NCT05528744||Proband|Study participants who have suspected or confirmed CAGS based on having a variant of uncertain significance, likely pathogenic variant, or pathogenic variant in ANKRD17 and clinical features of the condition.
89328836|NCT05528744||Unaffected family members|Family members of the proband who do not have an ANKRD17 variant.
89328837|NCT05528172|Experimental|Group A|Participants receive K-321 ophthalmic solution Four times daily(QID) for 12 Weeks followed by a 4 week follow-up period with no treatment.
89328838|NCT05528172|Experimental|Group B|Participants receive K-321 ophthalmic solution Four times daily(QID) for 12 Weeks followed by a 14 week follow-up period with no treatment.
89328839|NCT05528172|Placebo Comparator|Group C|Participants will receive K-321 Placebo ophthalmic solution QID for 12 Weeks followed by a 4 week follow-up period with no treatment.
89328840|NCT05528172|Placebo Comparator|Group D|Participants will receive K-321 Placebo ophthalmic solution QID for 12 Weeks followed by a 14 week follow-up period with no treatment.
89328841|NCT05524753|Experimental|AquOTic|Dose of 10 weeks of aquatic occupational therapy
89328842|NCT05524753|No Intervention|Control|No intervention
89328843|NCT05524688|Experimental|Beta-glucan|500 mg/d of beta-glucan
89328844|NCT05524688|Placebo Comparator|Placebo|500 mg/d of cellulose
89328845|NCT05519696|Experimental|Intervention|This group will receive a 10-week group-based intervention program.
89328846|NCT05519696|Active Comparator|Comparison|The group will receive a 10-week group-based comparison program.
89328847|NCT05517863|Experimental|laser sequential mode|All patients received 2 sessions of laser therapy / week with different wavelengths in sequential mode in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care
89328848|NCT05517863|Experimental|laser seperate mode|All patients received 2 sessions of laser therapy / week with different wavelengths in seperate mode in two consecutive months of treatment aiming complete wound closure , patients received & infrared laser therapy plus traditional wound care
89328849|NCT05517863|Active Comparator|traditional wound care|"(II) Traditional wound care inform of~Wound care treatment~Debridement to remove necrotic tissue~Irrigation of the wound by normal saline~Change dressing daily to protect wound from infection~Foot care~Wash feet daily, dry carefully especially between toe~Avoid extreme temperatures~Inspection daily of foot blisters~Foot wear~Avoid walking bare foot~Properly fitted shoes~Avoid wearing open-toed shoes"
89328850|NCT05517161||Individuals with TBI|
89328851|NCT05502172|Experimental|fish oil|Healthy individuals will be taking the composition of fish-derived oils BioMarine®Medical Immuno & Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.
89328852|NCT05500183|Experimental|PA + CA|a cognitively enriched walking program (Physical Activity (PA)+Cognitive Activity (CA)
89328853|NCT05500183|Active Comparator|PA only|a walking program without cognitive enrichment (Physical Activity (PA) only)
89328854|NCT05500183|No Intervention|control|a passive control group (CG). The passive CG will receive no intervention program.
89328855|NCT05499572||Inbrija followed by Cyclops|During an off episode, patients will demonstrate both inhaler user maneuvers. The researcher will observe whether the steps are followed correctly. The handling time will be recorded as well. To see whether the patients prefer a certain inhaler and to see where this preference comes from, they need to fill in a questionnaire. The questionnaire will be filled in during or directly after the off episode. Dummy inhalers are used, so patients will only inhale air (no medication).
89328856|NCT05499572||Cyclops followed by Inbrija|During an off episode, patients will demonstrate both inhaler user maneuvers. The researcher will observe whether the steps are followed correctly. The handling time will be recorded as well. To see whether the patients prefer a certain inhaler and to see where this preference comes from, they need to fill in a questionnaire. The questionnaire will be filled in during or directly after the off episode. Dummy inhalers are used, so patients will only inhale air (no medication).
89328857|NCT05491759|Experimental|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle The dose will be consumed orally with 250 mL water.
89328858|NCT05491759|Experimental|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle The dose will be consumed orally with 250 mL water.
89328859|NCT05491759|Experimental|Product 3 - Standard Fish Oil Triglyceride|"1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).~The dose will be consumed orally with 250 mL water."
89523489|NCT02520505|Other|Expectant Management: Timed Intercourse|Patients randomized to expectant management will be counseled on timed intercourse and the window in which intercourse should be performed during the randomization phone call. Patients will be encouraged to contact their fertility doctor and the primary investigator if they become pregnant and an estimated date of confinement will be calculated based upon the patient's last menstrual period. Patients will also be notified that they will be contacted at the end of the six month timeframe to inquire as to whether or not they became pregnant.
88806670|NCT05898516|No Intervention|Usual Practice|Participants will be monitored through existing wait-list practices which involve regular phone calls to check in and assess functioning. After 4 weeks in the Usual Practice condition, participants will be offered access to the JoyPop app.
88806671|NCT05897671||study group|retrospective data analysis of patients that underwent after foveal sparing ILM peeling with ILM flap transposition for macular hole repair
88809684|NCT01273376|Experimental|RX-10100 high dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
89328860|NCT05488483||Breast and Melanoma Cohort|Participants with a suspicious finding at breast ultrasonography (BI-RADS 4 suspicious abnormality; BI-RADS 5, highly suggestive for malignancy) who are scheduled for ultrasound-guided breast biopsy will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. We will evaluate MSOT in 10 patients from the Melanoma Surgical Oncology Clinics (Dr. Ariyan, Co-I) with pathologically confirmed ITM following physical exam and biopsy. We will also evaluate MSOT in five melanoma patients with pathologically confirmed IT metastases scheduled for neoadjuvant immunotherapy prior to surgical resection.
89328861|NCT05488444|Experimental|Group 1 (Investigational Group)|Participants will complete an in-depth patient needs checklist to identify patient-specific barriers that could lead to a delay with starting chemotherapy.
89328862|NCT05488444|Experimental|Group 2 (Control Group)|Participants will follow routine clinical care, where chemotherapy start date is determined by the provider and patient.
89328863|NCT05482191|Experimental|Treatment group|Treatment activity on lifestyle interventions will target the dietary and exercise factors of childhood obesity.
89328864|NCT05482191|No Intervention|Usual practice group|No intervention
89328865|NCT05482165|Experimental|Intervention group|The students of this group will receive multi-faceted intervention activities toward weight management.
89328866|NCT05482165|No Intervention|Usual practice group|The students of this group will receive regular health education.
89328867|NCT05481125|Experimental|Clareon/Clareon Toric|Phacoemulsification surgery, followed by implantation with Alcon Clareon Aspheric Hydrophobic Acrylic IOL or Alcon Clareon Aspheric Hydrophobic Acrylic Toric IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
89328868|NCT05481125|Active Comparator|Eyhance/Eyhance Toric|Phacoemulsification surgery, followed by implantation with TECNIS Eyhance IOL or TECNIS Eyhance Toric II IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
89328869|NCT05480566|Experimental|Functional strength training + NMES|The experimental group will receive the standard of care plus functional strength training and quadriceps neuromuscular electrical stimulation. Functional strength training will include lower limb (e.g. rising from chair, heel rises) and upper limb (e.g. push-ups from the chair and against the wall) exercises for 15 min/day. Target levels of dyspnoea and/or perceived exertion will be 4 to 6 in the modified Borg scale. For neuromuscular electrical stimulation, electrodes will be placed longitudinally on the vastus intermedius and vastus medialis and a symmetric biphasic pulse waveform, with a pulse duration of 400ms, a frequency of 50Hz, in cycles of 8s of contraction and 20s of rest, will be used for 30min/day. The highest intensity tolerated by the patient will be used and intensity will be increased every time the patient feels comfortable with increasing the intensity. The device Compex Pro Rehab (CE-0473) will be used.
89328870|NCT05480566|Active Comparator|Standard of care|The standard of care group will receive the common treatment delivered at the hospital, i.e., routine medical treatment and daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.
89328871|NCT05474820|Other|Saliva and serum collection of patients and samples molecules analysis|After periodontal examination, samples were collected from all patients via informing them about procedures. Then all samples were stored at -80 C unto analyses.
89328872|NCT05474820|Other|Periodontal examination|All periodontal indices were measured in six sites in each tooth present in the arch by one calibrated periodontist
89328873|NCT05473533|Placebo Comparator|Arm 1|Placebo
89328874|NCT05473533|Experimental|Arm 2|PRS-220
89328875|NCT05471258|Experimental|Experimental: monopolar dielectric diathermy|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar muscles by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. 3 weekly sessions will be performed for 3 weeks, a total of 9 treatment sessions.
89328876|NCT05471258|Placebo Comparator|Placebo|"The 30 participants in the control group will receive a placebo treatment, consisting of the same execution protocol as the EG, but with a non-emitting device whose software and hardware will be exactly the same as that used in the EG. The intervention will be simulated for 20 minutes.~3 weekly sessions will be held for 3 weeks, a total of 9 treatment sessions."
89328877|NCT05466474|Experimental|Tislelizumab combined with dacarbazine|Tislelizumab combined with dacarbazine in the treatment of advanced melanoma.
89328878|NCT05459012||pregnant women with asthma|
89328879|NCT05458596|Experimental|Screen-based simulation|Screen-based simulation about intimate partner violence against women prepared by researchers will apply to nursing students.
89328880|NCT05448976|Active Comparator|Saliva and serum collection of patients and samples molecules analysis|aliva and serum sampling Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MY,EY) from each participant. Saliva and serum were then stored at -80 °C until analysis.
89328881|NCT05448976|Experimental|Salivary and serum arginine metabolites ADMA and SDMA observation|"IL-6 levels in collected samples were determined by ELISA kits and analyzed according to manufacturers' instructions, with colorimetric assessment performed using a microplate reader at 450 nm with the assay detection range between 7.8 and 500 pg/mL. Concentrations were determined based on the respective assay standard curve. All samples were analyzed in duplicate, and the average was used in subsequent calculations.~Determination of methylated arginine metabolites:~The ADMA, SDMA, homoArg, arginine and L-NMMA levels in saliva and serum were assessed by a liquid chromatography-mass spectrometry (LC MS/MS)* method, which was a modification of the method of Di Gangi et al."
88809685|NCT01273376|Experimental|RX-10100 low dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
88809686|NCT01273376|Placebo Comparator|Placebo|Matching placebo is to be given orally, in tablet form, twice daily, for 8 weeks
88809687|NCT01270958|Experimental|TREATMENT|50 adult patients with Perennial Allergic Rhinities treated with Avamys.
89328882|NCT05448651|Experimental|Active substance 1|UPB-101 Cohort 1
89328883|NCT05448651|Experimental|Active substance 2|UPB-101 Cohort 2
89328884|NCT05448651|Experimental|Active substance 3|UPB-101 Cohort 3
89328885|NCT05448651|Experimental|Active Substance 4|UPB-101 Cohort 4
89328886|NCT05445908|Experimental|SKB264+KL-A167（Part1，TNBC）|Participants received SKB264 followed by KL-A167
89328887|NCT05445908|Experimental|SKB264（Part2，TNBC）|Participants received SKB264
89328888|NCT05445908|Experimental|SKB264+KL-A167（Part2，TNBC）|Participants received SKB264 followed by KL-A167
89328889|NCT05445908|Experimental|SKB264（Part3，HR+/HER2- BC）|Participants received SKB264
89328890|NCT05445908|Experimental|SKB264+KL-A167（Part3，HR+/HER2- BC）|Participants received SKB264 followed by KL-A167
89328891|NCT05439551||Pediatric and adults suspected of acute bacterial or viral infection|ED, Hospital admitted, and urgent care center patients over the age of 90 days, with clinical suspicion of acute bacterial or viral infection.
89328892|NCT05437991|Other|Morphological quantification of low-grade carotid stenosis|Morphological quantification using ECST method and implying two independent observers
89328893|NCT05437978|Experimental|"Adapted Physical Activity (APA) program called Cap Sport Santé 83"|
89328894|NCT05436639|Experimental|SPI-62 dose 1|0.2mg dose level of SPI-62. Active drug by mouth each morning for up to 12 weeks.
89328895|NCT05436639|Experimental|SPI-62 dose 2|0.6mg dose level of SPI-62. Active drug by mouth each morning for up to 12 weeks.
89328896|NCT05436639|Experimental|SPI-62 dose 3|2mg dose level of SPI-62. Active drug by mouth each morning for up to 12 weeks.
89328897|NCT05436639|Experimental|SPI-62 dose 4|6mg dose level of SPI-62. Active drug by mouth each morning for up to 12 weeks.
89328898|NCT05436639|Placebo Comparator|Placebo|Placebo by mouth each morning for up to 12 weeks.
89328899|NCT05436561|Experimental|MBF-RIC|Patients with MBF-RIC as conditioning regimen
89328900|NCT05435573|Active Comparator|Crystalloid group|The patients will receive 1000 mL of ringer's acetate solution (250 mL over 5 minutes starting immediately after intrathecal injection using a pressurizer then 500 mL over 55 minutes then 250 mL over 60 minutes).
89328901|NCT05435573|Active Comparator|Crystalloid-colloid group|Patients will receive 250 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride starting immediately after intrathecal injection then 500 mL of ringer's acetate solution then 250 mL of hydroxyethyl starch
89328902|NCT05425680|Experimental|Core muscle training|specific rehabilitation exercise for improving functional movements
89328903|NCT05424224||patients with depression|patients with depression
89328904|NCT05417061|Active Comparator|Saliva and serum collection of patients and samples molecules analysis|
89328905|NCT05417061|Experimental|Salivary and serum SIRT6, LPXA4 and CASP8 observation|"Saliva and serum samples obtained for each patient were used for cytokine analysis. Prepared samples were analyzed for Lipoxin A4 (LXA4), Caspase 8 (CASP8) and Sirtuin-6 (SIRT6) using commercial ELISA kits~(Elabscience, Houston, Texas, USA and Bioaasay Technology Laboratory (BT-Lab), Shanghai, China, respectively) according to the manufacturer's instructions. The detection limits of ELISA kits were 0.78 - 50ng/ml for LXA4, 0.16 - 10ng/ml for CASP8 and 0.1- 40 ng/ml for SIRT6."
89328906|NCT05413317||Adult patients hospitalized for suspicion of pulmonary embolism recurrence|Patients with at least one of the following symptoms: acute dyspnea or aggravation of chronic dyspnea, chest pain, hemoptysis or syncope
89328907|NCT05409404|Experimental|Aerobic exercise + hot water immersion|3 sessions per week, over an 8 week period, with each session consisting of 30 minutes of aerobic exercise (10 minutes cycling, jogging and rowing) at a power output equivalent to 65-75% of maximal heart rate followed by 30 minutes of whole body hot water immersion at 40°C.
89328908|NCT05409404|Active Comparator|Aerobic exercise + thermoneutral water immersion|3 sessions per week, over an 8 week period, with each session consisting of 30 minutes of aerobic exercise (10 minutes cycling, jogging and rowing) at a power output equivalent to 65-75% of maximal heart rate followed by 30 minutes of whole body water immersion at 34°C.
89328909|NCT05403086|Experimental|Psilocybin|A single moderate-to-high dose of oral psilocybin, plus 4-5 sessions of a brief, existential psychotherapy.
89328910|NCT05403086|Active Comparator|Ketamine|A single low-to-moderate dose of oral liquid ketamine, plus 4-5 sessions of a brief, existential psychotherapy.
89328911|NCT05401487||Adult patient with a severe trauma requiring SMUR activation|Trauma defined by appearance of lesions following a fall, a road accident, a burn or the penetration of a foreign body and regulated by one of the SAMU PACA region centres (84, 83, 13, 04)
89328912|NCT05388136|Active Comparator|Control Arm|"Conventional (standard) FU entails frequent clinical exams and routine imaging (17 visits including a visit at randomization, plus 4 or 7 imaging depending on smoking habits of the participant) during 5 years of FU.~PRO with rating scale is to be completed monthly by the participant, but no alert will be generated and the participating center will not arrange urgent appointment, except in case of self-referral for any reasons."
89328913|NCT05388136|Experimental|Individualized Deintensified Arm|"Individualized de-intensified FU entailing less frequent clinical exams and no routine imaging (11 visits including visit at randomization) without any routinely planned imaging during 5 years of FU.~PRO with rating scale is to be completed monthly by the participant. The PRO result will trigger an alert to the participant and to the site in conditions indicating possible REC/SPM. In case of possible (recurrence or secondary primary malignancy) REC/SPM, an 'open urgent appointment' will be arranged for the participant by the participating centers' team within 2 weeks."
89328914|NCT05385367|Other|Regional anesthetic|Patients only have nerve block with or without sedation
89328915|NCT05385367|Other|General anesthetic|Patients only have general anesthetic
89328916|NCT05385367|Other|Combined general anesthetic and regional anesthetic|Patients have both general anesthetic and regional anesthetic together
88806672|NCT05897151|Experimental|Continuous spinal anesthesia|Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics. Norepinephrine starting dose 0.01 micg/kg/min will be ready for both groups if needed (main arterial pressure < 70 or main arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics.
89328917|NCT05377970|Experimental|Prehabilitation Intervention Program|Patients enrolled in this arm will receive the preabilitation intervention program prior to their surgery to complete
89328918|NCT05377216|Experimental|Stellate ganglion block|All subjects will undergo stellate ganglion block during their VT ablation procedure
89328919|NCT05376566|Active Comparator|Intervention group|Hydrochloric acid (2 M)
89328920|NCT05376566|Placebo Comparator|Control group|Normal saline
89328921|NCT05375474|Experimental|Oral anticoagulation therapy group|Vitamin-K antagonists (warfarin), therapeutic INR: 1.8-2.5
89328922|NCT05375474|Active Comparator|Single antiplatelet therapy group|Aspirin, 75-100mg
89328923|NCT05374460|Sham Comparator|Conscious awareness: No information|Told nothing about the visuo-proprioceptive mismatch. Hand remains hidden beneath mirror that shows visual display. (control)
89328924|NCT05374460|Experimental|Conscious awareness: Explanatory diagram|Told in advance about the visuo-proprioceptive mismatch, which will be explained with a diagram. Hand remains hidden.
89328925|NCT05374460|Experimental|Conscious awareness: Direct vision of hand|Foamboard under mirror removed, making the mirror see-through and the hand directly visible.
89328926|NCT05374460|Sham Comparator|Movement feedback: No feedback|No movement feedback (control)
89328927|NCT05374460|Experimental|Movement feedback: Target hand|Movement feedback about the target hand.
89328928|NCT05374460|Experimental|Movement feedback: Pointing hand|Movement feedback about the pointing hand.
89328929|NCT05371626|Other|Suture-less entropion technique|suture-less technique for cicatricial entropion
89328930|NCT05370807|Experimental|Cohort A|Patients take 2 oral tablets of 40mg of Regorafenib daily.
89328931|NCT05370807|Experimental|Cohort B|Patients take 1 oral tablets of 40mg of Regorafenib daily in combination with BRAF- /MEK- inhibitors dabrafenib/trametinib or encorafenib/binimetinib at the dose they were already taking them.
89328932|NCT05370807|Experimental|Cohort C|Patients take 1 oral tablets of 40mg of Regorafenib daily in combination with encorafenib/binimetinib at the standard dose.
89328933|NCT05367635|Experimental|Phase 1a：Dose escalation|Eleven dose levels are tentatively planned for Phase 1a
89328934|NCT05367635|Experimental|Phase 1b: Dose expansion|The dose of SKB315 for injection in Phase 1b is selected based on the Phase 1a monotherapy dose escalation study.
89328935|NCT05350631|No Intervention|Control|only follow-ups consultations, phone contact and TVE workshop with the AJA mobile team centralized by the IDEC
89328936|NCT05350631|Experimental|Experimental|using a digital tool in addition to follow-ups by consultations, phone contact and PTE workshop with the AJA mobile team centralized by the IDEC
89328937|NCT05347134|Active Comparator|SKB264|5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle.
89328938|NCT05347134|Active Comparator|Eribulin or Capecitabine or Gemcitabine or Vinorelbine|"Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21day cycle.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle."
89328939|NCT05339464|Experimental|Family wellness program- Group 1|This group will begin the family wellness program first; approximately, 5 weeks before group 2. The family wellness program consists of 8 parent-child workshops and text message reminders.
89328940|NCT05339464|Experimental|Family wellness program- Group 2|This group will begin the family wellness program approximately 5 weeks after group 1.The family wellness program consists of 8 parent-child workshops and text message reminders.
89328941|NCT05333965|Experimental|Lens A, Then Lens B|Participants wore Lens A for one month and then crossed over to wear Lens B for one month.
89328942|NCT05333965|Experimental|Lens B, Then Lens A|Participants wore Lens B for one month and then crossed over to wear Lens A for one month.
89328943|NCT05331651|Experimental|Glycopyrronium in Combination With Tropisetron|
89328944|NCT05331651|Placebo Comparator|Normal Saline in Combination With Tropisetron|
89328945|NCT05331157|No Intervention|palpation group|"In lateral decubitus position, the conventional palpation technique will be used to detect the epidural space. The midline will be identified by palpation of the spinous processes. Through the Tuffier's line, L5 spine then, the two intervertebral spaces (L3-4 and L2-3) will be detected and the middle of each intervertebral space will be marked with selection of the widest space.~After sterilization of the patient's skin the needle will be inserted to detect the epidural space by using loss of resistance to saline"
89328946|NCT05331157|Experimental|Ultrasonography group|In lateral decubitus position, a curved array probe will be utilized to scan the sacrum in the longitudinal paramedian plane, then the probe will be moved upwards to detect the L5-S1, L4-5, L3-4 and L2-3 intervertebral spaces then turned 90º to the transverse plane and used to scan L3-4 and L2-3 spaces inside the 2 spaces, midline will be detected by noting the site of spinous processes with selection of the space with the best sonographic image quality. Then skin surface at the middle of the long and short axis of the probe will be marked horizontally. If the 2 spaces have the same image quality, L2-3 space will be chosen for the entrance of epidural needle. After sterilization of the patient's skin the needle will be inserted to detect the epidural space by using loss of resistance to saline
89328947|NCT05328999||Subfertile patients|Males and females between 18 and 50 years of age with subfertility presenting at the fertility center at the Medical University of Graz.
89328948|NCT05328999||Subfertile males with elevated DNA fragmentation index and asthenozoospermia|Males between 18 and 50 years of age with elevated DNA fragmentation index and asthenozoospermia presenting at the fertility center at the Medical University of Graz.
89328949|NCT05323799||Group 1/Seed set 1 - recently diagnosed 'COVID-19 cases|(Group1) and their social network with up to 2 waves of /Key people, will be followed up for 1 month initially with specific monitoring tools before they will transition into ongoing follow up and monitoring as recruitment group 2
89328950|NCT05323799||Group 2/Seed set 2 - people from the general community that are not currently infected with COVID19|'Group 2' that are practicing physical distancing and represent specific key risk groups, and their social network with up to 2 waves of Key people
89328951|NCT05321368|Experimental|LINKED-HEARTS Program|"Patients in the LINKED-HEARTS Program will be trained to measure their blood pressure with an Omron 10 series device using the Sphygmo telemonitoring app. The physician, pharmacist and Community Health Worker will have access to transmit data.~Community Health Workers will provide education on managing blood pressure; reinforce positive blood pressure self-management behaviors; deliver knowledge and skills to promote healthy chronic conditions; assist with linking clinical and administrative services; and link participants with community resources.~The study pharmacist will conduct telehealth visits, optimize pharmacologic therapy. The pharmacists will assess and address medication adherence to improve hypertension and diabetes control."
89328952|NCT05321368|No Intervention|Enhanced Usual Care|Patients in the Enhanced Usual Care Arm, will receive care as usual from their primary care provider and will be trained to measure their blood pressure with an Omron 10 series device. The staff in each participating community health center practice will be trained in blood pressure measurement best practices.
89328953|NCT05318898|Experimental|Regular diet with vegetable protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetable protein sources.
89328954|NCT05318898|Active Comparator|Regular diet with animal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
89328955|NCT05309551|Experimental|Inspiratory Muscle training- Intervention group|Along with standard post-transplant physical therapy, the intervention group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with weekly incremental increases in respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.
89328956|NCT05309551|Sham Comparator|Inspiratory Muscle training - Placebo group|Along with standard post-transplant physical therapy, the placebo group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with no increase of respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.
89328957|NCT05309551|No Intervention|Usual care group|Patients will only participate in standard post-transplant physical therapy.
89328958|NCT05308966||Patient presenting MPS treated with nivolumab and ipilimumab|Adult patients with previously untreated and unresectable Malignant Pleural Mesothelioma (MPM) treated with combination of Nivolumab and Ipilimumab in the setting of the early access program not opposed to the collection of their data
89328959|NCT05304598|Active Comparator|Dexmedetomidine Group|a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes
89328960|NCT05304598|Active Comparator|Control Group|routine awake intubation as per current unit standard of care
89328961|NCT05300139||Patients included in the ULTREC study who had a recurrence of deep vein thrombosis|Patients who have a baseline CDUS diagnosis of recurrent DVT as identified in the ULTREC study.
89328962|NCT05299970|Experimental|fermented porridge|this study arm participant will consume fermented millet porridge, daily
89328963|NCT05299970|Active Comparator|Non-fermented porridge|this study arm participants will consume non-fermented millet porridge, daily
89328964|NCT05299125|Experimental|Single Arm: Therapy consisting of lazertinib plus amivantamab plus chemotherapy|"CYCLE 1 (21-day cycle)~Amivantamab 1400 mg (1750 mg if body weight is >80 kg) IV once weekly + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1~CYCLE 2 (21-day cycle)~Amivantamab 1400 mg (1750 mg if body weight is >80 kg) IV on day 1 + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1~MAINTENANCE CYCLES 3 + (21-day cycle)~Amivantamab 1750 mg (2100 mg if body weight is >80 kg) IV on day 1 + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1"
89328965|NCT05294172|Experimental|KL-A167+Gemcitabine+Cisplatin|subject will receive KL-A167 1200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, 4-6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day,4-6 cycles
89328966|NCT05294172|Placebo Comparator|Placebo+Gemcitabine+Cisplatin|subject will receive placebo every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, 4-6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, 4-6 cycles
89328967|NCT05292534|Active Comparator|Amplification-only|Hearing aid will be fit to prescribed participant hearing loss.
89328968|NCT05292534|Active Comparator|Amplification with added sound|Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated on the hearing aid.
89328969|NCT05292534|No Intervention|No intervention|Participants will return to their original unaided state.
89328970|NCT05275010|Active Comparator|Arm 1: PH FDC SC Administered Using a Handheld Syringe with Hypodermic Needle|
89328971|NCT05275010|Experimental|Arm 2: PH FDC SC Administered Using the On-Body Delivery System|
89328972|NCT05262036|Experimental|Anti-aging Supplement|Mixture (powder) of vitamins and nutrients
89328973|NCT05262036|Placebo Comparator|Placebo excipients|All excipients in powder WITHOUT vitamins and nutrients
89328974|NCT05261321|Active Comparator|Cannabis oil with a high ratio of THC to CBD|Participants will be given a single dose of oral cannabis oil containing 5mg THC and 0.17mg CBD.
89328975|NCT05261321|Active Comparator|Cannabis oil with a high ratio of CBD to THC|Participants will be given a single dose of oral cannabis oil containing 5mg THC and 25mg CBD.
89328976|NCT05261321|Placebo Comparator|Placebo|Participants will be given a single dose of 1 mL placebo (carrier oil with botanical terpenes) via oral route of administration.
89328977|NCT05259982|Experimental|Vital root resection|Root resective surgery aiming to preserve pulp vitality
89328978|NCT05257265|Experimental|High Dose Centanafadine Hydrochloride|328.8 mg total daily dose
89328979|NCT05257265|Experimental|Low Dose Centanafadine Hydrochloride|164.4 mg total daily dose
89328980|NCT05257265|Placebo Comparator|Matching Placebo|
89328981|NCT05256615|Experimental|Diabetes|Participants recruited to this arm have been clinically diagnosed with either gestational, pre- or type 2 diabetes.
89328982|NCT05256615|Experimental|Non-diabetes|Participants recruited to this arm of the study do not have gestational, pre- or type 2 diabetes.
89328983|NCT05255744|Experimental|Whitsundays nasal mask|Participants will be asked to take home the investigational mask to use at night while they sleep in place of their own mask. The participant's therapy and comfort settings will not be altered.
89328984|NCT05255744|Active Comparator|AirFit N30i Quiet mask|Participants will be asked to take home the comparator mask to use at night while they sleep in place of their own mask. The participant's therapy and comfort settings will not be altered.
89328985|NCT05245292|Experimental|3BNC117-LS + 10-1074-LS + N-803|3BNC117-LS dosed at 30 mg/kg IV, day 0 10-1074-LS dosed at 10 mg/kg IV, day 0 N-803 dosed at 6 mcg/kg, SC, 8 doses every 3 weeks (week 1 through week 22)
89328986|NCT05237050|Experimental|Sound therapy associated with relaxation|
89328987|NCT05237050|Active Comparator|Relaxation alone|
89328988|NCT05235971|Experimental|Episodic Future thinking (EFT)|Participants will receive up to 3 messages a day that include assessment and intervention messages.The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.
89328989|NCT05235971|Experimental|Volitional choice (VC)|VC creates structured if-then plans to dismantle context-linked alcohol use. Participants will receive up to 3 messages a day that include assessment and intervention messages.
89328990|NCT05235971|Experimental|Episodic Future thinking plus Volitional choice|Participants will receive both EFT and VC interventions with text messages.
89328991|NCT05235971|Other|Monitoring only|This is a control group in which participants will receive general psychoeducation.
89328992|NCT05235763|Placebo Comparator|Control|A sham activity coach will be installed on the Optilogg system, slightly changing its appearance.
89328993|NCT05235763|Experimental|Intervention|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
89328994|NCT05232279|Experimental|Testofen 300mg|Testofen in capsule form - taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
89328995|NCT05232279|Experimental|Testofen 600mg|Testofen in capsule form - taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
89328996|NCT05232279|Placebo Comparator|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
89328997|NCT05232266|Experimental|Caralluma fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
89328998|NCT05232266|Placebo Comparator|Placebo comparator capsule - Microcrystalline cellulose|A comparator capsule taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
89328999|NCT05230680|Experimental|Arm ACHOP|"Phase I Azacitidine D1-3 + CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone)~Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~Phase II~Azacitidine D-2, -1, 1 + CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone)~6 cycles in total"
89329000|NCT05229718|Active Comparator|Usual Care Model|Patients enrolled in this arm will receive diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center.
89329001|NCT05229718|Active Comparator|Diabetes Collaborative Care Model for Young Adults|Patients enrolled in this arm will receive diabetes care per the diabetes collaborative care model for young adults.
89329002|NCT05215808|Experimental|RBN-3143|RBN-3143 in single ascending dose followed by multiple ascending dose cohorts, randomized 3:1 ratio
89329003|NCT05215808|Active Comparator|Placebo|Placebo randomized in 1:3 ratio with ascending RBN-3143 single and multiple dosing
89329004|NCT05215808|Other|Pantoprazole|Open Label PPI cohort to evaluate concurrent administration of pantoprazole on RBN-3143 pharmacokinetics
89329005|NCT05215808|Other|Midazolam|Open Label DDI Cohort (12 subjects) to evaluate the effect of RBN-3143 on the exposure of midazolam, a sensitive CYP3A4 substrate
89329006|NCT05201586|Active Comparator|Conditional cash transfer|Investigators will randomize 15 patients into this intervention arm. All participants will undergo a semi-structured patient interview about how social needs impact health and self-perceptions of health at the time of enrollment and again in 6 months. All participants will receive a CCT after the first interview.
89329007|NCT05201586|Active Comparator|Control|Investigators will randomize 15 patients into this control arm. All participants will undergo a semi-structured patient interview about how social needs impact health and self-perceptions of health at the time of enrollment and again in 6 months.
89329008|NCT05198895|Experimental|Open-label, single arm with identical assessment of both biomarkers for all participants|All participants will have their glycated nail keratin assessed by infrared and blood HbA1c levels measured via an assay (based on finger prick blood drop sample)
89329009|NCT05187650|Experimental|Ekso and FES|Participants will train for 8 weeks, 3 times per week (i.e. 24 sessions in total) for 30 minutes effective training time per session using the EksoNR powered exoskeleton combined with gait-synchronized FES using the FES RehaMove2.
89329010|NCT05187650|Active Comparator|Ekso without FES|Participants will train for 8 weeks, 3 times per week (i.e. 24 sessions in total) for 30 minutes effective training time per session using the EksoNR powered exoskeleton without applying FES.
89329011|NCT05179408|Experimental|Telerehabilitation|Telerehabilitation intervention consisting of exercise training, education, and behavioral support
89329012|NCT05179408|No Intervention|Control|No intervention arm, with assessment of functional and patient-reported outcomes only
89329013|NCT05172089||Diabetic Foot Ulcer parent study|405 clinically diagnosed Diabetic Foot Ulcer (DFU) patients who are suspected to be infected will be recruited . Wound swab for culture obtained. Baseline digital imaging of target wound(s). SF-12 Health survey, Visual Analogue Pain scale, Cardiff wound impact questionnaires. Wound site evaluation including TcOM/TBI/ankle brachial index (ABI) will be completed for subjects with wounds below the knee, if not already completed per standard of care within the previous 12 months. Hemoglobin A1c point of care testing will be drawn for diabetic subjects who do not have an A1c available within 90 days prior to enrollment; 3mm biopsy tissue or debrided tissue will be collected. Ideally, two tissue samples will be obtained; the subject's medical records will be reviewed and followed for up to 16 weeks or until their wound has closed, whichever comes first. The research staff will also call the patient or care facility as needed to check for wound closure.
89329014|NCT05172089||Imaging sub study- 30 subjects|"All of the above items will be performed in this arm in addition to the below:~Wound perfusion will also be measured by laser speckle imaging (LSI) using the Pericam PSI-NR instrument (Perimed Inc.). PeriCam PSI is a non-invasive non-contact device providing two-dimensional imaging of peripheral tissue blood perfusion. Reduced blood flow may lead to insufficient tissue oxygenation and, thus, assessment of peripheral vascular function has several clinical applications. The PeriCam PSI System is FDA 510(k) (#K063586) approved instrument imaging of peripheral tissue blood perfusion. The additional Pericam imaging for perfusion will be performed only in a small pilot cohort of n=40 patients at an IU site to compare this imaging modality with established modalities such as TcOM/TBI/ABI measurements performed within this study."
89329015|NCT05172089||Alzheimer and/or related dementia|"All items in the group: Diabetic Foot Ulcer Parent study will be performed plus:~15 patients that currently have an open chronic wound and are clinically diagnosed with Alzheimer's Disease or Related Dementias (AD/ADRD) will be recruited for this additional cohort."
89329016|NCT05170269|Experimental|BT097|Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
89329017|NCT05167695|Experimental|Habit-based Sleep Health Intervention (HABITs)|"Participants in this condition participate in the HABITs intervention which includes 3x50-minute weekly sessions followed by 6x30-minute weekly sessions.~Participants in this group will not receive the texts discussed below."
89329018|NCT05167695|Experimental|Habit-based Sleep Health Intervention plus text messages (HABITs+texts)|"Participants in this condition participate in the HABITs intervention which includes 3x50-minute weekly sessions followed by 6x30-minute weekly sessions.~Additionally, participants in this group will receive the text messaging intervention."
89329019|NCT05161338|Experimental|FROZEN EMBRYO TRANSFER|Women who undergo an artificial cycle for frozen embryo transfer and receive luteal phase support.
89329020|NCT05160441|Experimental|Platelet Rich Plasma Injection Group|Minimum 2cc Leukocyte Poor Platelet Rich Plasma
89329021|NCT05160441|Active Comparator|Corticosteroid Injection Group|5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
89329022|NCT05160441|Experimental|Delayed Platelet Rich Plasma Injection Group upon Corticosteroid Injection Failure|If a participant does not have any benefit from the corticosteroid injection by the six-week follow-up time point, then that participant will be eligible for a platelet rich plasma injection.
89329023|NCT05153772|Experimental|Pb212-DOTAMTATE|investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine tumors in PRRT naive patients (Cohort 1) and previous PRRT patients (Cohort 2)
89329024|NCT05151120||Group A: Hyperthyroid|30 patients will be included and divided into three categories: A1: 10 patients with suppressed TSH, around 0.01 milli-international unit/liter (mIU/L) A2: 10 patients with TSH values between 0.01 - 0.1 mIU/L A3: 10 patients with TSH values between 0.1 - 0.4 mIU/L
89329025|NCT05151120||Group B: Euthyroid|30 Patients (under treatment) with TSH values between 0.4 - 4 mIU/L will be included
89329026|NCT05151120||GROUP C: Hypothyroid|40 patients will be included and divided into two categories: C1: 20 patients with TSH values between 4 - 50 mIU/L C2: 20 patients with TSH values > 50 mIU/L up to 100 mIU/L. Even distribution (if possible).
89329027|NCT05144308|Experimental|Patients operated with a TECNIS® Eyhance Toric II 1-piece posterior chamber lens|For at least one eye : Planned cataract surgery with placement of a TECNIS® Eyhance Toric II 1-piece posterior chamber lens
89329028|NCT05144048|Active Comparator|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
89329029|NCT05144048|Experimental|Induction of labour with oral misoprostol, outpatient setting|These women are observed 2 hours after they receive one dose of oral misoprostol before they leave the maternity unit.
89329030|NCT05143632|No Intervention|Intermittent NIBP monitoring|Oscillometric intermittent (3 mins) noninvasive blood pressure monitoring
89329031|NCT05143632|Experimental|ClearSight|Continuous non invasive hemodynamic monitoring
89329032|NCT05138822|Experimental|GSK3882347 + Placebo|Participants will be administered GSK3882347 plus placebo.
89329033|NCT05138822|Active Comparator|Nitrofurantoin+ Placebo|Participants will be administered nitrofurantoin plus placebo.
89329034|NCT05133024|Active Comparator|beetroot juice|Brand: BEET IT sport NITRATE 400 concentrated beetroot shot (James White Drinks Ltd.) Dosage regimen: 7 shots of 70 mL, once daily in the morning, on 7 consecutive days before surgery
89329035|NCT05133024|Placebo Comparator|nitrate-depleted beetroot juice|Brand: BEET IT sport NITRATE 400 nitrate-depleted concentrated beetroot shot (James White Drinks Ltd.) Dosage regimen: 7 shots of 70 mL, once daily in the morning, on 7 consecutive days before surgery
89329036|NCT05132283|Experimental|Urologic Lymphadenectomy in AMIGO|Participants will undergo Lymphadenectomy per standard of care with the navigation systems (3D Slicer and Monaco) used to locate the abnormal lymph node(s).
89329037|NCT05124301|Experimental|Perceptual learning|Reaching task in which visual information about target finger position is offset to induce a change in perception of the finger.
89329038|NCT05124301|Active Comparator|Control|Reaching task with accurate visual information.
89329039|NCT05122052||Women with cancer|Patients with cancer of any site and stage defined as feminine both from the biological (female sex) and psychosocial point of view (feminine gender)
89329040|NCT05122052||Men with cancer|Patients with cancer of any site and stage defined as masculine both from the biological (male sex) and psychosocial point of view (masculine gender)
89329041|NCT05113901|Active Comparator|Methylprednisolone taper|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM <90° at 8 weeks
89329042|NCT05113901|Placebo Comparator|Placebo taper|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM <90° at 8 weeks
89329043|NCT05109702|Other|Placebo Run-in|Participants self-administered placebo ocular drops, twice daily (BID) in both eyes for 14 days in the Placebo Run-in Period.
89329044|NCT05109702|Experimental|0.25% Tanfanercept Ophthalmic Solution|Participants self-administered tanfanercept 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, BID for up to 8 weeks in Treatment Period.
89329045|NCT05109702|Placebo Comparator|Placebo|Participants self-administered tanfanercept placebo (vehicle solution) solution as topical ophthalmic drops, BID for up to 8 weeks in Treatment Period.
89329046|NCT05099978||NGS analysis of ctDNA|"This study consists of 6 cohorts; cervical cancer(n=100), ovarian clear cell cancer(n=50), nasopharyngeal cancer(n=96), ovarian cancer(n=100), breast cancer(n=100), endometrial cancer(n=60).~In each cohort, the blood samples will be collected within 2weeks after registration. ctDNA will be extracted from blood samples and somatic gene abnormalities will be analyzed using NGS, PCR, and Sanger sequencing. In addition, the analysis of DNA methylation and RNA sequencing may be performed to obtain information related to gene expression."
89329047|NCT05099159|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
89329048|NCT05099159|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
89329049|NCT05092477|Experimental|Integrated Intervention|4 intervention sessions over 6 months using an educational and counseling intervention developed by the study team.
89329050|NCT05092477|Active Comparator|Control|Attention Control group - Supportive counseling for DM management
89329051|NCT05092321|Experimental|Aquatic Occupational Therapy|Group-based aquatic occupational therapy with 1:1 swim buddy for safety.
89329052|NCT05092022|Experimental|Requested self-sampled HPV test|This group will receive the self-sampled HPV test. Included with the test are the test instructions, a lab requisition form, and a pre-paid mailer so that it can be sent back to the lab for testing. Results of the test will be shared with the participant.
89329053|NCT05089929||Endoflip 2.0|The investigators will perform FLIP topography (Endoflip 2.0) analysis on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
89329054|NCT05085873|Experimental|Sodium oxybate|
89329055|NCT05085873|Active Comparator|Midazolam|
89329056|NCT05077605|Experimental|Functional residual capacity|Functional residual capacity measure during and after extubation
89329057|NCT05076747|Experimental|Cardiovascular training|Cardiovascular training will comprise 4 weeks of moderate-to-vigorous continuous training followed by 4 weeks of progressive high-intensity interval training (HIIT) performed on recumbent steppers. This intervention will be performed in addition to the conventional standard therapy sessions. We will start with very moderate intensities and prepare participants for higher intensities. Introducing HIIT will allow us to use higher intensities over short bursts of exercise interspersed with periods of active rest. HIIT is more effective than continuous training to increase BDNF and we have shown that even a single bout of HIIT reduces interhemispheric imbalances in excitability and improves motor learning in chronic stroke.
89329058|NCT05076747|Active Comparator|Standard Therapy|Will comprise 8 weeks of the control protocol that includes regular sessions of physiotherapy, occupational therapy, and speech therapy.
89329059|NCT05069142|Experimental|Intervention group|15 participants will be randomly selected to the intervention group. These individuals will receive six weeks of pre-operative exercise instruction and education, as well as six weeks of graduated post-operative exercise instruction, beginning at three weeks post-op with the surgeons clearance.
89329060|NCT05069142|No Intervention|Control group|15 participants will be randomly selected to the control group. This group will receive pre-operative education in the form of videos regarding the procedure and pain. They will not receive exercise instruction.
89329061|NCT05064111||All subjects|The experimental conditions will include a standard prostate biopsy using an FDA-approved ultrasound machine with application of the experimental (non-FDA approved) image fusion software.
89329062|NCT05056129|Experimental|Sensor-controlled digital game (SCDG)|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
89329063|NCT05056129|Active Comparator|Sensors-only|The control group will receive only the weight monitoring and physical activity sensors
89329064|NCT05043454|Experimental|Vascular Density Improvement in Hypertensive Participants|Participants will undergo baseline visits and follow-up visits to include neurocognitive testing, VO2 max testing (graded exercise test), blood draws, and retinal scans. Potential subjects must pass an exercise stress test with 12-lead ECG, and training sessions (exercise protocol). Standardized neurocognitive tests assessing functions such as memory and attention will be administered and retinal scans will be conducted. The at-home exercise intervention will be supervised via the Polar beat/flow applications by study personnel. Subjects will engage in cardiovascular exercise with heart rate monitoring on 4 days per week for a total of 10 weeks.
89329065|NCT05034250||Women with infertility|The patient suffers from primary or secondary infertility, defined as the inability to conceive despite frequent unprotected sexual intercourse for at least 12 months.
89329066|NCT05034250||Women with recurrent miscarriage|The patient suffers from recurrent miscarriage, defined as three or more consecutive miscarriages before the 20th gestation week with the same partner.
89329067|NCT05034250||Healthy controls|The woman does neither suffer from infertility/sterility nor from recurrent miscarriage and is also otherwise healthy with regular cycles.
89329068|NCT05028283|Experimental|participants|patients with atrophic acne scars on the cheeks who will reviewing the dermatological clinics at the Dermatology and Venereology Hospital at least 69 patients they will be undergo fat grafting for one session and will be follow up for 6 months after the procedure
88806673|NCT05897151|Active Comparator|General anesthesia|After establishing of ASA monitoring, a wide bore cannula (18Gague) will be inserted. Induction will be done by fentanyl (2 mcg/kg), titrating dose. of propofol according to patient hemodynamic response and atracurium (0.5 mg/kg) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
88806674|NCT05897138|Experimental|Lenvatinib plus Tislelizumab|
88806675|NCT05895903|Active Comparator|Screw expansion group|threadform screw expanders with special condensing burs for lateralization and compaction of bone while simultaneously placing dental implants
88806676|NCT05895903|Active Comparator|Osseodensification group|special drills to expand narrow alveolar ridges.These drills share similar advantages with osteotomes in terms of greater tactile sensitivity, faster speed, and low heat generation, all of which help to maintain healthy bone and enhance implant osseointegration.
89329069|NCT05026372|Experimental|Mindfulness + Compassion (MC)|For participants randomized to the MC condition will focus on compassion and creating positive emotions. This session will include techniques such as guided visualizations and a loving kindness meditation that are intended to facilitate connection with their partners. During this session, couples will also learn the ground rules of mindful and compassionate listening and sharing, as they will be asked to engage in an emotional disclosure task. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
89329070|NCT05026372|Experimental|Mindfulness + Gratitude (MG)|Session 2 for participants randomized to group MG will focus on gratitude. Participants will be taught to reflect on things, events, and people which they are grateful for via a gratitude meditation. Couples will share their experiences of practicing gratitude. The instructor will remind the couple of ground rules prior to the emotional disclosure exercise and facilitate if necessary during the sharing. Each member of the couple will take turn in sharing with and listening to their partner. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
89329071|NCT05026372|Experimental|Mindfulness + Value-Based Living (MV)|Session 2 for participants randomized to group MV will focus on learning strategies to live life according to their values. They will first engage in a reflection exercise to help identify their values, and then complete a worksheet. Couples will brain storm together strategies to ensure that their lives reflect their self-identified values. The instructor will go over the homework assignment. The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
89329072|NCT05026372|No Intervention|Attention Control (AC)|For participants randomized to the AC condition, both sessions will focus on discussing issues and themes that emerge for couples, such as communication and perceived supportiveness. Utilizing a reflective listening approach, the interventionist will focus on encouraging participants to share concerns related to their daily experiences. Unlike in the MC, MG, and MV groups, the interventionist will not offer advice, support (other than reflective listening) or any other tools to participants. Additionally, the interventionist will not probe for deep emotional disclosure. Please see the appendix for the session outline. We believe a control group that discusses daily relationship-related concerns serves as an excellent comparison condition in this study since it is viewed as credible by participants and equates for time and attention as well as nonspecific treatment effects such as those provided through social interactions.
89329073|NCT05022758||Participants treated with rivaroxaban|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation [OAC] therapy use in the January 2013 to December 2014) and newly initiated on rivaroxaban (defined as the index date) during the enrollment period from January 2015 to December 2017.
89329074|NCT05022758||Participants treated with warfarin|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation [OAC] therapy use in the January 2013 to December 2014) and newly initiated on warfarin (defined as the index date) during the enrollment period from January 2015 to December 2017.
89329075|NCT05011084|Experimental|Game Ready Cryotherapy with Compression Group|Post-operative treatment will involve using a Game Ready ® unit
89329076|NCT05011084|Active Comparator|Control Cryotherapy Group|Post-operative treatment will involve using the standard of care cryotherapy (i.e., traditional ice packs without compression).
89329077|NCT05009771||IV-PCA group|Patients receiving intravenous patient-controlled analgesia (IV-PCA) will be allocated to IV-PCA group.
89329078|NCT05009771||IV-PCA + NALDEBAIN group|Patients treated with the combination of IV-PCA and intramuscular injection of dinalbuphine sebacate will be allocated to IV-PCA + NALDEBAIN group.
89329079|NCT05009771||NALDEBAIN group|Patients injected with dinalbuphine sebacate intramuscularly will be allocated to NALDEBAIN group.
89329080|NCT05007938|Experimental|Icotinib + Befotertinib|"Icotinib（125 mg orally, three times daily）~Befotertinib（25 mg orally, three times daily）"
89329081|NCT05003258|Other|Patients with RVO|Dexamethasone Intravitreal Implant is used in patients with Macular ar edema due to retinal vein occlusion either from the start or after unsatisfactory response to anti - VEGF
89329082|NCT04991389|Experimental|Phase 1 - Contrast 129Xe MRI ages 5-18|The research team will collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Phase contrast MRI of inhaled gas. (4) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
89329083|NCT04991389|Experimental|Phase 2 - Contrast 129Xe MRI ages 3-18|The research team plans to collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.
89329084|NCT04989751||LGMD patients|
89329085|NCT04981925|Experimental|MBSR treatment|
89329086|NCT04977986|Experimental|ZYN002 - transdermal gel|Pharmaceutically manufactured. Cannabidiol is formulated as a clear gel for transdermal delivery.
89329087|NCT04977986|Placebo Comparator|Placebo transdermal gel|Placebo is formulated as a clear gel for transdermal delivery.
89329088|NCT04959201|Experimental|NMDAE plus Antioxidant agent (AO)|An NMDA enhancer plus a drug with antioxidant property
89329089|NCT04959201|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
89329090|NCT04946994|Experimental|High intensity interval training|
89329091|NCT04946994|Active Comparator|Continuous moderate intensity exercise|
89329092|NCT04939545|Experimental|Experimental Intervention Ropivacain|Ropivacain Fresenius 0.2% is a solution for infusion/ injection and will be continuously administered with an elastomer pump through the surgically placed intercostal catheter (ICC) between parietal pleura and fascia endo-thoracica at the level of surgical incision for a maximum of 72 hours at an initial standard flow rate setting of 6 ml/h using 2 mg/ml ropivacaine. In case pain exceeds 7 on NRS later than 2 hours after skin closure the flow rate will be adjusted on 8 ml/h. Furthermore, Ropivacain Fresenius 0.2% will be provided in a 20 ml glass vial for flushing the infusion line and subpleural administration.
89329093|NCT04939545|Placebo Comparator|Control Intervention Placebo|Placebo (NaCl 0.9% B. Braun) is an isotonic solution for infusion and will be continuously administered with an elastomer pump through the surgically placed intercostal catheter (ICC) between parietal pleura and fascia endo-thoracica at the level of surgical incision for a maximum of 72 hours at an initial standard flow rate setting of 6 ml/h using NaCl 0.9%. In case pain exceeds 7 on NRS later than 2 hours after skin closure the flow rate will be adjusted on 8 ml/h. Furthermore, NaCl 0.9% will be provided in a 20 ml glass vial for flushing the infusion line and for subpleural administration, which will be prepared by the hospital pharmacy.
89329094|NCT04939038|Active Comparator|Control Arm|Standard wound care for diabetic wound ulcer
89329095|NCT04939038|Experimental|Immediate revascularization|Patient will have revascularization 0 - 7 days after initial wound assessment and then receive standard wound care for diabetic wound ulcer
89329096|NCT04925973|Experimental|Treatment arm|Tofacitinib 10mg PO BID
89329097|NCT04919954|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 7 doses of tebipenem, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours following the last dose.
89329098|NCT04919954|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 doses of tebipenem, followed by sampling of interstitial tissue fluid by a microdialysis probe inserted in a thigh over 8 hours following the last dose.
89329099|NCT04919408|Experimental|Patients scheduled for cesarean section under spinal anesthesia|Patients scheduled for cesarean section under spinal anesthesia ASA I and II according to The ASA Physical Status Classification System
89329100|NCT04915352|Experimental|Adult dust mite allergenic rhinitis patients|Nasal Provocation Test administration (725 Dermatophagoides pteronyssinus (5.000 SBE/ml) dosage form: Lyophilisate and solvent for nasal drops, suspension dosage and frequency: 3 nasal sprays at 3 different concentrations per year: 50, 500 and 5000 SBE / ml for 3 years Duration: 36 months
89329101|NCT04907721|Experimental|Measuring glucagon sensitivity in humans|Participants will be subjected to two experimental days.
89329102|NCT04903522|Experimental|Depressive patients|Patients suffering from major depressive disorder with anxiety symptoms
89329103|NCT04902846||Control (no kidney injury)|Patients who receive ICI but no develop kidney injury
89329104|NCT04902846||Case (kidney injury)|Patients who receive ICI and develop kidney injury
89329105|NCT04902092|Active Comparator|High Intensity Physical Training|12-week, 36 session, cardiorespiratory-focussed physical exercise program delivered by an accredited exercise physiologist
89329106|NCT04902092|Active Comparator|Low Intensity Physical Training|12- week, 36 session, strength-focussed physical exercise program delivered by an accredited exercise physiologist
89329107|NCT04901286|No Intervention|Seated Rest|Behavioral: Seated Rest In the seated rest control condition, participants will sit on the bike for 30 minutes. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
89329108|NCT04901286|Active Comparator|Exercise Only|Behavioral: Exercise Only In the exercise-only condition, participants will complete a total of 30-minutes on the stationary bike. This will include a) 5-min warm-up at low resistance, b) 20 minutes of moderate-vigorous intensity cycling, and c) a 5-min cool-down at low resistance. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes.
89329109|NCT04901286|Experimental|Exercise + Non-Immersive Virtual Reality|"Behavioral: Exercise + Non-Immersive Virtual Reality In the exercise with non-immersive Virtual Reality condition, participants will complete a total of 30-minutes on the stationary bike while watching a video on an iPad. The cycling session will be identical to that in the Exercise Only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, a YouTube video called 360° VR Cycling Newport Back Bay Sunset [30 MIN - NO MUSIC]) will play on an iPad placed on the front of the bike. Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
89329110|NCT04901286|Experimental|Exercise + Immersive Virtual Reality|"Behavioral: Exercise + Immersive Virtual Reality In the exercise with immersive virtual reality condition, participants will complete a total of 30-minutes on the stationary bike while wearing Oculus Quest 2 goggles. The bout of cycling will be identical to the prescription given in the exercise only condition (5-min warm-up, 20 minutes of moderate-vigorous intensity cycling, and 5-min cool down). During cycling, the Oculus YouTubeVR app will play a 360° version of the YouTube video called 360° VR Cycling Newport Back Bay Sunset [30 MIN - NO MUSIC]). Interaction with researchers will be kept at a minimum, similar to that in other sessions. Heart Rate will be recorded every two minutes and perceived exertion will be reported every four minutes."
89329111|NCT04890873|Experimental|ERX1000|"ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension~Proposed dose level for Part A: 4 mg and 8 mg~Proposed dose level for Part B: 4 and 8 mg. The dose administered will not exceed the highest dose administered in Part A."
89329112|NCT04890873|Placebo Comparator|Placebo|Reference product: Magnesium hydroxide carbonate powder prepared in an oral suspension
89329113|NCT04889105|Other|Performance evaluation|Preliminary performance evaluation to refine the Smart MOVE! intervention.
89329114|NCT04889105|Active Comparator|Smart MOVE!|Participants will be enrolled in the multi-component Smart MOVE! intervention for 12 weeks.
89329115|NCT04889105|Placebo Comparator|Usual care|Participants will receive general walking advice for 12 weeks.
89329116|NCT04887805|Experimental|Treatment (pembrolizumab, lenvatinib mesylate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and lenvatinib mesylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89329117|NCT04878432|Experimental|MBG453 (sabatolimab) + HMA|MBG453 + HMA (azacitidine, decitabine, or INQOVI (oral decitabine))
89329118|NCT04878263|Active Comparator|Control group|
89329119|NCT04878263|Experimental|FIL-EAS ic group|
89329120|NCT04877782||Healthy older participants|Healthy older participants receiving both stimulation conditions (experimental and placebo) randomized across scanning sessions.
89329121|NCT04876222|Active Comparator|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
89329122|NCT04876222|No Intervention|Subacute CAG|The patient is triaged to the coronary care unit (CCU) for rhythm surveillance, and additional diagnostics, and in case there is found indication for CAG, it is planned for the coming day in daytime (12-24 hours after cardiac arrest). Revascularization is performed if indicated according to guidelines.
89329123|NCT04875442|Experimental|Memowave emitting sound|Patients worn Memowave during one night, and the device emits sounds to increase slow brain signals
89329124|NCT04875442|Placebo Comparator|Memowave not emitting sound|Patients worn Memowave during one night, and the device doesn't emit sounds
89329125|NCT04874974|Experimental|Metacognitive and Defusion Training|All participating patients are allocated to the same five-week experimental group therapy, which consists of three different modules (Module I: Psychoeducation on cognitive processes and rational of the therapy - week 1; Module II: Metacognition - week 2+3; Module III: Cognitive Defusion - week 4+5). Group therapy will start with a psychoeducation session of 60 minutes in the first week and will then take place twice a week with each session lasting 60 minutes.
89329126|NCT04861636|Experimental|HealthTRAC|Both the standard behavioral weight control (SBWC) and HealthTRAC interventions include 4 months of intensive treatment, followed by monthly maintenance sessions for a 12-month program. SBWC includes attention to diet and activity coupled with behavioral modification strategies. HealthTRAC integrates these key constructs with an emotion regulation intervention with documented efficacy in teens.
89329127|NCT04861636|Active Comparator|Standard Behavioral Weight Control (SBWC)|4 months of intensive treatment focused on attention to diet and activity coupled with behavioral modification strategies, which is then followed by monthly maintenance sessions for a 12-month program.
89329128|NCT04858191||Pediatric PCD|Pediatric participants with PCD
89329129|NCT04853329|Experimental|PartA- Arm A|"Arm A 1-6 subjects will be enrolled at dose levels of CPO107 at (1, 3, 6, 12, 20 mg/kg).~Each subject group will receive multiple cycles of a weekly dose of CPO-107 (1 cycle=21 days=3 treatments)."
89329130|NCT04853329|Experimental|PartA- Arm B|Arm B will explore a 3 weekly schedule in which a single dose is administered every 3 weeks (1 cycle=21 days=1 treatment). The starting dose for Arm B will be the dose level below the Arm A level that provides an equivalent dose over a 3-week period.
89329131|NCT04853329|Experimental|Part B|Part B with either: second or greater relapse OR refractory patients, as defined by not achieving a CR after 2 cycles of a standard first line chemoimmunotherapy regimen or not achieving a CR following 1 cycle of a second line chemotherapy regimen.
89329132|NCT04840017|Experimental|Study group I|excessive body weight and flat feet
89329133|NCT04840017|Experimental|Study group II|normal body weight and flat feet
89329134|NCT04840017|No Intervention|Study group III|control, healthy children
89329135|NCT04834024|Experimental|Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|
89329136|NCT04834024|Active Comparator|lenalinomide|
89329137|NCT04832503||Group 1|The PROMPT-treated group will include 12 children with idiopathic CAS. The pre-treatment assessment is aimed at evaluating the baseline speech and language level and at treatment planning. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided in order to shape speech movements, to give information on sequencing and timing, and to introduce constraints for the reduction of the degrees of freedom at the articulators' level in favour of motor control. In a PROMPT session the syllables, words and phrases are produced within a communicative context in play. Speech motor goals are, as soon as possible, integrated in goals for language and functional communication.
89329138|NCT04832503||GROUP 2|The LNSOM-treated group will include 12 children with idiopathic CAS. The pre-treatment assessment is aimed at evaluating the baseline speech and language level and at the treatment planning. None of the SLTs treating this group are PROMPT trained. According to the standard care methods used in Italy, the intervention consists of a linguistic and articulatory approach that includes auditory discrimination of phonemic categories at the syllable and word level and non-speech oral motor exercises. Receptive and expressive lexicon and morphosyntax are targeted depending on the children's linguistic profile.Differently from the PROMPT, selection of speech sounds to be targeted, is based on developmental speech sounds acquisition rather than motor criteria. According to this treatment approach, the motor goal is usually identified with the placement of the main articulator involved in the production of a speech sound.
89329139|NCT04827368||Crohns Disease|
89329140|NCT04827368||Ulcerative Colitis|
89329141|NCT04827368||Non-IBD|
89329142|NCT04826367|Experimental|Exercise Group (EG)|"The participants in the EG will perform relaxation exercises in groups of up to 8 people, 3 days a week for 6 weeks via WhatsApp (© 2020 WhatsApp, Inc.) or Zoom (© 2012-2020 Zoom Video Communications, Inc.) applications. Relaxation exercises will be performed with the Progressive Relaxation Exercises (PRE) technique defined by Jacobson et al.[11] Tele-rehabilitation sessions will last approximately 40 minutes of each, accompanied by a physiotherapist who has 8 years of experience in the field of oncological rehabilitation."
89329143|NCT04826367|No Intervention|Control Group (CG)|Participants in this group will have a brochure with simple exercises (relaxation exercises involving the upper and lower extremities) in sitting and lying positions. They will be advised to be as active as possible at home and to take mild walks at home. Any supervised exercise program will not apply to participants in the CG. If the participants apply any regular exercise program within 6 weeks, the participants in this group will be excluded from the study.
89329144|NCT04823923|Other|Patients without renal insufficiency under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
89329145|NCT04823923|Other|Patients without renal insufficiency under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
89329146|NCT04823923|Other|Patients with moderate renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
89329147|NCT04823923|Other|Patients with moderate renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
89329148|NCT04823923|Other|Patients with severe or terminal stage renal impairment under pazopanib|Pazopanib is taken daily, for a minimum of 3 months, according to the medical prescription.
89329149|NCT04823923|Other|Patients with severe or terminal stage renal impairment under cabozantinib|Cabozantinib is taken daily, for a minimum of 3 months, according to the medical prescription.
89329150|NCT04815785|Experimental|A single set of test|The experimental apparatus consisted of artificial aortic valve, transporter and loading system
89329151|NCT04814693|Experimental|Interventional arm|Subjects randomized to the control device arm will undergo treatment with the EndoRotor System, which is a powered debridement tool intended for use in endoscopic procedures to resect and remove necrotic debris during direct endoscopic necrosectomy (DEN) for walled-off necrosis. The system consists of capital components including a power console, roll stand, vacuum pump, and foot control; as well as disposable components including a single-use catheter, purge kit, and suction bag. The EndoRotor System has CE-Mark 613797 and is cleared for use by the FDA in the United States.
89329152|NCT04814693|Active Comparator|Control arm|Subjects randomized to the control device arm will undergo conventional DEN as per the standard of care. Investigators will choose conventional DEN instruments according to their preference.
89329153|NCT04811014|Experimental|MOUD induction and behavioral interventions among opioid-dependent youths|Induction into medication for opioid use disorder (MOUD) treatment and behavioral interventions
89329154|NCT04808518||Bx reg group|
89329155|NCT04808518||non-Bx reg group|
89329156|NCT04808037|Experimental|Cohort 1, First Part|12 patients are anticipated to receive Belantamab Mafodotin 2.5 Q8W = 2.5 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
89329157|NCT04808037|Experimental|Cohort 2, First Part|12 patients are anticipated to receive Belantamab Mafodotin 1.9 Q8W = 1.9 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
89329158|NCT04808037|Experimental|Cohort 3, First Part|12 patients are anticipated to receive Belantamab Mafodotin 1.4 Q8W = 1.4 mg/kg on Day 1 of every other 28-day cycle, in combination with Lenalidomide and Dexamethasone
89329159|NCT04808037|Experimental|Group A, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.~In this Arm the ocular toxicity will be graded according to the Dose Modification Guidelines for Corneal-Related Adverse Events Associated with belantamab mafodotin"
89329160|NCT04808037|Experimental|Group B, Second Part|"15 patients are anticipated to receive Belantamab Mafodotin in the Recommended Phase 2 Dose, in combination with Lenalidomide and Dexamethasone.~In this Arm the ocular toxicity will be graded according to the Dose modification guidance based on visual acuity"
89329161|NCT04802265||ILM peeling|ILM is peeled during epiretinal membrane surgery
89329162|NCT04802265||without ILM peeling|ILM is not peeled during epiretinal membrane surgery
89329163|NCT04801303|Experimental|Friedreich's Ataxia patients|"Friedreich's Ataxia patients that will receive treatment with Calcitrol 0.25mcg/24h for a year.~During the clinical trial:~The effects of Calcitriol in the neurological symptoms of Friedreich's Ataxia patients will be evaluated before starting the treatment and after a year. The following scales will be used: SARA scale, 9-Hole Peg test, 8 meters walking test, PATA velocity test and Quality of life test with the SF36 questionnaire.~The changes in the Frataxin's levels during the treatment with Calcitriol will be measured: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment."
89329164|NCT04785443|Experimental|ICG group|Patient receiving 2 or 3 intraoperative injections of indocyanine green.
89329165|NCT04785443|Other|Control group|Patient benefiting from the traditional surgical act
89329166|NCT04771260||Case study #1|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329167|NCT04771260||Case study #2|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329168|NCT04771260||Case study #3|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329169|NCT04771260||Case study #4|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329170|NCT04771260||Case study #5|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329171|NCT04771260||Case study #6|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329172|NCT04771260||Case study #7|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329173|NCT04771260||Case study #8|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329174|NCT04771260||Case study #9|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329175|NCT04771260||Case study #10|There will be no intervention. There will be 10 separate case studies, to identify how care for fibromyalgia is being delivered in each case study, and to identify models of care.
89329176|NCT04727684|Active Comparator|Agonist Group (long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
89329177|NCT04727684|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
89329178|NCT04727671|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
89329179|NCT04727671|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
89329180|NCT04724486|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
89329181|NCT04724486|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
89329182|NCT04724343|Active Comparator|Agonist Group (Long protocol):|The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
89329183|NCT04724343|Experimental|Antagonist Group (Flexible protocol):|The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).
89329184|NCT04713007|Experimental|Group 1|Supportive Care Materials and Resources
89329185|NCT04713007|Experimental|Group A|Ted Talks/Educational videos
89329186|NCT04704024|Experimental|Pregnant Women - Tenofovir|Women will be randomized to early initiation (enrollment at 14-28 weeks pregnant) vs standard initiation (at 28 weeks pregnant) of tenofovir disoproxil fumarate (TDF) 300 mg daily oral medication until delivery.
89329187|NCT04704024|Placebo Comparator|Newborn Infants - Lamivudine|Infants exposed to HBV at birth will be randomized to receive oral lamivudine post-exposure prophylaxis or matching placebo. Medication will be administered twice daily for 6 months.
89329188|NCT04701450||conventional|consent for anaesthesia is obtained as part of a conversation with physical attendance
89329189|NCT04701450||telephonic|consent for anaesthesia is obtained telephonically
89329190|NCT04701450||digital|a digital survey and video information is used to inform the patient about the anaesthetic procedure
89329191|NCT04699747|Experimental|Multiple sclerosis|F-18 3F4AP PET Scan
89329192|NCT04699747|Active Comparator|Healthy controls|F-18 3F4AP PET Scan
89329193|NCT04699461|Experimental|Loncastuximab Tesirine|Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles.
89329194|NCT04699461|Active Comparator|Idelalisib|Participants will be administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks.
89329195|NCT04685343|Experimental|fMRI and laboratory pain induction|
89329196|NCT04683796|Experimental|100% APRP|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
89329197|NCT04683796|Active Comparator|100% AS|Patients will be instructed to apply every 2 hours (8 times/day). The currently used bottle will be required to store at 4 C for 24 hours, and the remaining bottles at -20 C in a freezer until day of use.
89329198|NCT04682522|Active Comparator|Metronidazole|Metronidazole 250 mg three times a day
89329199|NCT04682522|No Intervention|Standard care|Standard post-operative care, which may or may not include post-operative antibiotics
89329200|NCT04663204|Experimental|Sparsentan|Sparsentan will be administered once daily, starting at a dose of 200 mg (two 100 mg oral capsules) for the first 2 weeks of the study. Patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg (one 400 mg tablet). Patients who do not tolerate the target dose will have their dose reduced back to 200 or 100 mg/day; throughout the study, patients will be maintained on the maximum allowed dose of sparsentan they can tolerate. All patients will be treated with sparsentan for a total of 110 weeks.
89329201|NCT04651348|Experimental|MIL95|
89329202|NCT04649411|Experimental|Ferric citrate|Participants aged 12 to <18 years and 6 to <12 years will receive ferric citrate for 24 weeks at a starting dose based on body weight categories.
89329203|NCT04649411|Active Comparator|Standard of care|Participants aged 12 to <18 years and 6 to <12 years will receive standard of care treatment for 24 weeks.
89329204|NCT04642365|Experimental|Part I|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682 with a fixed dose of Atezolizumab, every three weeks (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
89329205|NCT04642365|Experimental|Part II|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I. Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab.
89329206|NCT04642365|Experimental|Part III (Exploratory)|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I and if clinical activity is seen in this trial or in the single agent study (WP41188). Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab at the dosing regimen established in Part I.
89329207|NCT04640025|Experimental|itacitinib|Participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. Participants who are receiving ruxolitinib under parent protocol INCB39110-209 may continue to receive it as described in that protocol.
89329208|NCT04636268|Experimental|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
89329209|NCT04634838|Other|MedCu Antibacterial Wound Dressings with Copper Oxide|Wound dressings impregnated with copper oxide microparticles will be applied in wounds treated with antibacterial wound dressings with silver that their sizes were not reduced by at least 50% during three weeks of treatment.
89329210|NCT04620070|No Intervention|Conventional|In the Netherlands, out-of-hospital cardiac arrest (OHCA) is managed by paramedics. In this study, in the conventional arm, OHCA is managed by a physician of the Helicopter Emergency Medical Services (HEMS), but without the possibility of prehospital ECPR.
89329211|NCT04620070|Experimental|Intervention group|OHCA managed by the physician of the HEMS team, but with the possibility of prehospital ECPR.
89329212|NCT04617886|Experimental|Sadness condition|
89329213|NCT04617886|Experimental|Happiness condition|
89329214|NCT04617678|Active Comparator|Prospective Prehabilitation|Prospectively enrolling patients into a prehabilitation program for head and neck cancer.
89329215|NCT04617678|No Intervention|Prospective Control|Prospectively enrolling patients to a control arm with no intervention.
89329216|NCT04617327|Experimental|Experimental : Short Course Pre-operative RadiothErapy|"As part of the planning process, you need to undergo a CT Simulation.It is special type of CT scan used to measure and design the radiation fields to precisely target the tumor.It is done at the Radiation Oncology Department at the MUHC. Some patients may be asked to also undergo an MRI Simulation, and the CT simulation. You may asked to provide a blood sample to ensure good kidney function prior to the CT and MRI scans. Both CT and MRI simulations are considered standard of care.~Once the simulation studies are done, there is about a 2 week waiting period for radiation planning prior to starting the radiation treatments.~The hypofractionation technique will be delivering five fractions (one fraction delivered every 2nd day) of 7 Gy daily of external beam radiotherapy (EBRT) over a period of one and half weeks for a total of 35 Gy. The treatment should last approximately 30 minutes. Once treatments are done, there is a 4 to 6 week wait for surgery."
89329217|NCT04601337||Brachial plexus and/or nerve transfer surgery patients|Patients set to undergo brachial plexus reconstruction or nerve transfer surgery that are 18 years or older.
89329218|NCT04600921|Active Comparator|Ertugliflozin|The subject will receive Ertugliflozin 5mg.
89329219|NCT04600921|Placebo Comparator|Placebo|The subject will receive Placebo 5mg.
89329220|NCT04586413||Non-hospitalised post-COVID-19 patients|This cohort will have had a confirmed positive test for COVID-19 or antibody test confirming they had COVID-19 but they were not hospitalised for this
89329221|NCT04586413||Hospitalised post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised but were not in an Intensive Care Unit
89329222|NCT04586413||Intensive care post-COVID-19 patients|This cohort will have a confirmed diagnosis of COVID-19 and been hospitalised in an Intensive Care Unit
89329223|NCT04575636|Other|Lymphedema patients|MRL examination in lymphedema patients
89329224|NCT04575636|Other|Healthy volunteers|MRL examination in healthy volunteers
89329225|NCT04571216|Experimental|NFL-101 Dose 1|50 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on
89329226|NCT04571216|Experimental|NFL-101 Dose 2|100 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on
89329227|NCT04571216|Placebo Comparator|Placebo|The placebo will consist of two syringes containing 1 mL of dilution solution, two injections at day 1, two injections at day 8, optional injections later on
89329228|NCT04559373|Experimental|Virtual Reality and Field Practice Training (VRFT)|Participants will engage in a 4-week VRFT intervention that comprises of 1-hour training sessions, 3 times/week.
89329229|NCT04554914|Experimental|EBV+ PID LPD|Participants with R/R or newly diagnosed EBV+ PID LPD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel.
89329230|NCT04554914|Experimental|EBV+ AID LPD|Participants with R/R or newly diagnosed EBV+ AID LPD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel.
89329231|NCT04554914|Experimental|EBV+ CNS PTLD|Participants with R/R or newly diagnosed EBV+ CNS PTLD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel.
89329232|NCT04554914|Experimental|EBV+ PTLD (inappropriate for first-line therapy or CD20-negative)|Participants with EBV+ PTLD for whom standard first-line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, will receive IV tabelecleucel.
89329233|NCT04554914|Experimental|EBV+ sarcoma, including LMS, or smooth muscle tumors|Participants with newly diagnosed EBV+ sarcoma for whom the standard first-line therapy is inappropriate, including LMS or smooth muscle tumor, will receive IV tabelecleucel.
89329234|NCT04554290||positive temporal artery biopsy|all adult patients with significant inflammation shown on temporal artery biopsy
89329235|NCT04550780||The study population|The study population will comport all beneficiaries in the national French SNDS database who were prescribed mepolizumab and for whom health resource use data is available for the 12 months preceding and following a first filled prescription for mepolizumab.
89329236|NCT04547985|Placebo Comparator|Placebo|24 randomized patients will take placebo daily for 8 weeks.
89329237|NCT04547985|Active Comparator|Naltrexone|24 randomized patients will take naltrexone daily for 8 weeks
89329238|NCT04539093||End-stage heart failure patients requiring lvad support|Patients with end-stage heart failure with reduced ejection fraction, requiring mechanical circulatory support.
89329239|NCT04535609|Experimental|Mavodelpar|Once daily
89329240|NCT04535609|Placebo Comparator|Matched placebo|Once daily
89329241|NCT04523194||Acute Coronary Syndrome|Patients diagnosed with acute coronary syndrome.
89329242|NCT04523194||Stable Angina|Patients diagnosed with stable angina.
89329243|NCT04521855||Caregivers|Caregivers (family environment or close entourage) for adults and children with cerebral palsy.
89329244|NCT04512690|Experimental|Epidural electrical stimulation of the cervical spinal cord|Individuals with prior subcortical stroke and hemiparesis of the upper extremity.
89329245|NCT04505436|Experimental|HM15211|
89329246|NCT04505436|Placebo Comparator|Placebo|
89329247|NCT04504721|Experimental|Light therapy group|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
89329248|NCT04504721|No Intervention|Waiting list group|Participants who are randomly assigned into the waiting list group will be told that they are on a waiting list to be enrolled in the study. Participants will be provided with light therapy after the first posttest outcome assessments are completed.
89329249|NCT04498221|Experimental|Imaging Phase|During routine examination under anaesthetic 4 x peritumoural injection of Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
89329250|NCT04498221|Experimental|Surgical Phase|Excision of contralateral nodes identified on imaging *(fhSPECT or SPECT/CT*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
89329251|NCT04494074|Experimental|Fever Control by external cooling|External cooling during 48 hours to obtain normothermia
89329252|NCT04494074|No Intervention|Fever respected, no cooling|Fever respect without any antipyretic therapy
89329253|NCT04486066|Experimental|Mindfulness-Based Stress Reduction (MBSR)|In MBSR, participants meet for 2 hours per week for 8 weeks in a video group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
89329254|NCT04486066|Experimental|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 sessions in a video group format, while retaining all essential elements.
89531634|NCT05879250|Experimental|Cohort II (WP1066, radiation, surgery)|Patients whose tumor was not fully removed at the time of initial surgery receive WP1066 PO for 6 weeks during routine radiation therapy on study. Patients may then undergo possible surgery or open biopsy if eligible, followed by twelve 28-day cycles of WP1066 PO on study. Patients also undergo MRI and collection of blood samples throughout the trial.
89329255|NCT04486066|Other|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
89329256|NCT04481581|Experimental|Intervention arm- Oxygen titration with electronic alerts|Oxygen titration will be done based on electronic alerts and decisions support tool by Respiratory Therapists, if FiO2=> 0.4 and SpO2 =>94% for more than 45 minutes
89329257|NCT04481581|No Intervention|Control Arm- Oxygen titration by one time physician orders|Oxygen titration will be done ventilator management guidelines for the medical intensive care unit. Titration is done by one-time orders.
89329258|NCT04479722|Experimental|Microport CardioAdvance LAAC system|Subject implant Microport CardioAdvance LAAC system to occlude LAA through percutaneous intervention.
89329259|NCT04479722|Active Comparator|Watchman LAAC system|Subject implant Watchman LAAC system to occlude LAA through percutaneous intervention.
89329260|NCT04467957|Experimental|CF Cohort|16 Cystic Fibrosis Patients will undergo MRI imaging before and 6 months after initiation of triple-combination modulator therapy. Initiation of triple -combination modulator therapy will be determined by clinician and family prior to study enrollment. Hyperpolarized Xenon 129 will be administered through inhalation at two MRI imaging study visits.
89329261|NCT04467957|Experimental|Control Cohort|10 Healthy control study participants matched for age and gender will undergo one MRI imaging study visit. Hyperpolarized Xenon 129 will be administered through inhalation at one MRI imaging study visit.
89329262|NCT04467905|Placebo Comparator|Placebo|Patients will receive a total of 200 μL of placebo ((i.e. 100 μL in each nostril) via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.
89329263|NCT04467905|Experimental|Etripamil|Patients will receive a total of 200 μL of etripamil Nasal spray 70 mg via the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged. Instructions on device usage will be provided.
89329264|NCT04458168|Experimental|Recently completed treatment|25 women who have just completed treatment
89329265|NCT04458168|Experimental|No recurrence of ovarian cancer for at least one year|25 women who have not experienced a recurrence of their ovarian cancer at least one year after their initial diagnosis
89329266|NCT04458168|Experimental|Recurrence of ovarian cancer|25 women who have experienced a recurrence of their ovarian cancer after primary treatment
89329267|NCT04452825|Experimental|Cancer and Aging: Reflections for Elders (CARE) Intervention|Session content and timing was developed and confirmed in our qualitative work (Expert Panel) and the CARE pilot study. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
89329268|NCT04452825|Experimental|Social Work and Supportive Counseling (SWSC)|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
89329269|NCT04441086|Experimental|eMotion|The eMotion intervention is based on feasibility testing of the successful in-person program with critical refinement to improve accessibility. eMotion has undergone subsequent content validity testing with intervention development, self-management, cardiovascular health, and health information technology delivery experts. eMotion teaches a carefully selected repertoire of emotion regulation strategies well suited for aging rural adults following a first cardiac event in tandem with usual cardiac rehabilitation. The intervention helps patients recognize their emotions, balance emotional and physical wellbeing, and implement emotion regulation strategies effectively. Intervention provided in addition to usual cardiac rehabilitation.
89329270|NCT04441086|Active Comparator|Healthy living active control|Healthy living strategies based on American Heart Association education. Intervention provided in addition to usual cardiac rehabilitation.
89329271|NCT04441086|No Intervention|Usual care|Usual cardiac rehabilitation with no additional intervention.
89329272|NCT04417946|Experimental|PrEP Messages|The peer leaders and the study staff will post PrEP related health messages
89329273|NCT04417946|Active Comparator|Health messages|The peer leaders and study staff will post general health messages that are not related to sexual health.
89329274|NCT04417621|Experimental|LXH254 + LTT462|
89329275|NCT04417621|Experimental|LXH254 + trametinib|
89329276|NCT04417621|Experimental|LXH254 + ribociclib|
89329277|NCT04399551|Experimental|Participants with HIV infection|HIV-infected participants will receive CAB LA + RPV LA regimen for a month of oral lead in (OLI) at Day 1 followed by CAB LA + RPV LA injections at Months 1 and 2 and every 2 months (Q2M) thereafter.
89329278|NCT04399551|Other|Staff study participants (SSP)|Staff study participants will be randomized to receive standard implementation support (Arm-S; through visit(s) with the medication lead in their country, education on the medication, and patient and staff education/support materials) or through enhanced implementation support (Arm-E; through the addition of continuous quality improvement during the study).
89329279|NCT04395222|Experimental|ATG Group I|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen.~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
89531635|NCT05867368|Active Comparator|Standard HABIT|Children will receive hand arm bimanual intensive therapy the way it is typically delivered. Children will receive 40 hrs of one-on-one bimanual therapy, delivered as play. Activities will be self-selected, but all options will require both hands to succeed.
89329280|NCT04395222|Experimental|ATG Group II|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen.~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
89329281|NCT04395222|Experimental|ATG Group III|"Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen.~Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
89329282|NCT04395222|Experimental|ATG Group IV|"Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)~Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.~Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.~Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen."
89329283|NCT04376762|Experimental|Fibrinogen Concentrate|Fibrinogen Concentrate (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM).
89329284|NCT04376762|Active Comparator|Cryoprecipitate|. Cryoprecipitate (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM).
89329285|NCT04362995||SARS-CoV-2 Infection|St. Jude Children's Research Hospital employees with SARS-CoV-2 infection
89329286|NCT04362995||Controls|St. Jude Children's Research Hospital employees uninfected with SARS-CoV-2 infection
89329287|NCT04362995||Long Term Follow Up (LTFU)|Subset of participants who participated in the original SJTRC study and agree to continue in LTFU
89329288|NCT04362696|Experimental|active stimulation|
89329289|NCT04362696|Sham Comparator|sham stimulation|
89329290|NCT04358055|Experimental|WET® gel|"At the screening/baseline visit (Visit 1, Day 1), eligible patients will be assigned to treatment with WET® gel, at the dose of 3-4 nasal applications/day (according to necessity), 1or 2 puff/nostril, for maximum 14 days.~Treatment will be administered according to patient's need without any relation with the time of the day (i.e. day time or night time administration), however within a maximum of 4 applications/day, which must include one administration in the morning upon awakening and one administration in the evening before retiring to bed."
89329291|NCT04356716|Active Comparator|Standard of Care Sildenafil|Medical record review for participants that are prescribed Sildenafil off-label as part of standard of care treatment for disease.
89329292|NCT04356716|Active Comparator|Sildenafil|Participants are prescribed sildenafil 40-80 mg daily.
89329293|NCT04353232||DANCAVAS trial|"We performed a population-based, parallel-group, randomized, controlled trial involving men 65 to 74 years of age living in 15 Danish municipalities. The participants were randomly assigned in a 1:2 ratio to undergo screening (the invited group) or not to undergo screening (the control group) for subclinical cardiovascular disease. Randomization was based on computer-generated random numbers and stratified according to municipality.~A total of 46,611 participants underwent randomization. After exclusion of 85 men who had died or emigrated before being invited to undergo screening, there were 16,736 men in the invited group and 29,790 men in the control group; 10,471 of the men in the invited group underwent screening (62.6%). In intention-to-treat analyses, after a median follow-up of 5.6 years, 2106 men (12.6%) in the invited group and 3915 men (13.1%) in the control group had died."
89329294|NCT04353232||VIVA trial|In this randomised controlled trial, we randomly allocated (1:1) all men aged 65-74 years living in the Central Denmark Region to screening for abdominal aortic aneurysm, peripheral arterial disease, and hypertension, or to no screening. We based allocation on computer-generated random numbers from 1 to 100 in blocks of 1067 to 4392, stratified by 19 municipalities. Only the non-screening group and the investigator assessing outcomes were masked. We invited participants who were found to have abdominal aortic aneurysm or peripheral arterial disease back for confirmation and eventual initiation of relevant pharmacological therapy. We further offered participants with abdominal aortic aneurysm annual control or surgical repair. We referred participants with suspected hypertension to their general practitioner. The primary outcome was all-cause mortality, assessed 5 years after randomisation. This trial is registered at ClinicalTrials.gov, number NCT00662480.
89329295|NCT04348396||Elderly patients affected by COVID-19|The group taken into consideration consists of elderly patients hospitalized with diagnosed COVID-19.
89329296|NCT04345731|No Intervention|Condition 1 - Control|"We note that our within subjects experimental design, in which each subject receives all treatments, is not well suited to this system of reporting. Thus we are defining arms as the label treatments we are evaluating. This label is the control label treatment which represents the current, legally required over-the-counter labeling standard."
89329297|NCT04345731|Experimental|Condition 2 - Highlighted|This condition will involve a novel method of presenting critical active ingredient, drug/drug, and drug/diagnosis information with highlighting.
89329298|NCT04345731|Experimental|Condition 3 - FOP warning label|This condition will involve presenting critical drug/drug, and drug/diagnosis information in a novel Front-of-Pack (FOP) warning label.
89329299|NCT04345731|Experimental|Condition 4- FOP+Highlighting label|This condition will combine both the highlighting and FOP labeling interventions from conditions 2 and 3. Note: Across the four arms we are essentially doing a 2 (highlighting/no highlighting) by 2 (front of pack warning/ no front of pack warning) within subjects design.
89329300|NCT04343235|Experimental|labetalol + furosemide|labetalol + furosemide
89329301|NCT04343235|Active Comparator|labetalol only|labetalol only
89329302|NCT04340180|Experimental|Subjects with enhancing breast lesions|
89329303|NCT04338321|Experimental|Esketamine Arm|Participants will receive treatment with esketamine nasal spray (28 milligram [mg] [initial dose for elderly participants 65 to 74 years of age and adults of Japanese ancestry; may be used throughout the study in these populations; may be uptitrated in 28 mg increments], 56 mg [initial dose for adult participants aged 18 to 64 years and may be used for all age groups throughout the study], or 84 mg [maximum dose esketamine nasal spray may be uptitrated to]) twice-weekly with a flexible dose regimen from Day 1 until Week 4, once weekly from Week 5 to Week 8 and once-weekly or once every 2 weeks from Week 9 to Week 32 in combination with continuing serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI).
89329304|NCT04338321|Active Comparator|Comparator Arm|Participants will continue to take their current SSRI/SNRI augmented with quetiapine extended release (XR) as per the Summary of Product Characteristics (SmPC) (or local equivalent, if applicable). In adult participants aged 18 to 64 years, the initial dose is 50 mg/day on Days 1-2, 150 mg/day on Days 3-4 [lowest effective dose]; a further dose increase to 300 mg/day on Day 5 and onward will be based on individual participant evaluation. In elderly participants aged 65 to 74 years, the initial dose is 50 mg/day on Days 1-3, 100 mg/day on Days 4-7, and 150 mg/day on Day 8; a further dose increase to 300 mg/day will be based on individual participant evaluation no earlier than Day 22.
89329305|NCT04322955|Experimental|Treatment with cabozantinib and nivolumab with nephrectomy|"All study participants will receive the same study medications, cabozantinib and nivolumab. The study drug, nivolumab, will be administered through an IV infusion every 4 weeks and cabozantinib will be administered orally daily. Initially participants will receive study treatment for 12 weeks. The cabozantinib will then be stopped prior to the nephrectomy. Initially patients enrolled on the study will be assigned to cohort 1.~Patients who are assigned to cohort 1 will be treated with cabozantinib until 21 days prior to surgery. A patient in cohort 1 will be evaluable for assessment of the cabozantinib washout interval (evaluable patients) if they~complete at least 10 of the 14 scheduled cabozantinib doses in the two week period prior to stopping cabozantinib AND~have surgical resection of the primary tumor.~In cohort 2, subjects will receive cabozantinib until 14 days prior to nephrectomy."
89329306|NCT04308681|Experimental|IPF Dose 1 + Post Treatment Follow-up or OTE|IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
89329307|NCT04308681|Experimental|IPF Dose 2 + Post Treatment Follow-up or OTE|
89329308|NCT04308681|Placebo Comparator|IPF Placebo + Post Treatment Follow-up or OTE|
89329309|NCT04308681|Experimental|PF-ILD Dose 1 + Post Treatment Follow-up or OTE|PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
89329310|NCT04308681|Experimental|PF-ILD Dose 2 + Post Treatment Follow-up or OTE|
89329311|NCT04308681|Placebo Comparator|PF-ILD Placebo + Post Treatment Follow-up or OTE|
89329312|NCT04303780|Experimental|AMG 510|
89329313|NCT04303780|Active Comparator|Docetaxel|
89329314|NCT04302168|Active Comparator|Choline Supplement Group|Choline Supplement 470 mg twice daily for total of 8 weeks.
89329315|NCT04302168|Placebo Comparator|Placebo Group|Placebo pill twice daily for total of 8 weeks.
89329316|NCT04299490|Experimental|Sleep Continuity Disruption|The Sleep Continuity Disruption condition will be conducted on two consecutive nights. An 8-hour sleep opportunity period will be disturbed by several forced awakenings at random intervals during which no sleep is permitted.
89329317|NCT04299490|Experimental|Sleep Fragmentation|The Sleep fragmentation condition will be conducted on two consecutive nights. Subjects are provided an 8-hour sleep opportunity during which their sleep will be disturbed by microarousals that simulate sleep apnea.
89329318|NCT04299490|Active Comparator|Undisturbed Sleep|An 8-hour period of undisturbed sleep is permitted on each night.
89329319|NCT04294225|Experimental|Treatment (anastrozole, letrozole)|Patients receive anastrozole PO QD for 56-70 days (8-10 weeks). Patients with E1 >= 1.3 pg/ml and E2 >= 0.5 pg/ml continue to receive anastrozole PO QD for another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
89329320|NCT04284488|Experimental|APG-1387 in combination with Toripalimab|
89329321|NCT04283448|Experimental|Lentil|0.66 cups lentils
89329322|NCT04283448|Sham Comparator|Control|0.0 cups lentils
89329323|NCT04270058||Cohort 1|Cohort 1 will be pregnant patients who have been exposed to at least 1 dose of TEGSEDI within 25 weeks prior to conception or during pregnancy.
89329324|NCT04270058||Cohort 2|Cohort 2 will be pregnant patients who have hATTR-PN, who were not exposed to TEGSEDI or have not received TEGSEDI within the previous 25 weeks prior to conception.
89329325|NCT04261127|Experimental|experimental arm|"The analysis of phenotypic data in RADIAL and the analysis of DNA (analysis of the Friedreich gene ± PMDA panel) will be performed for all patients in order to meet the main objective and the secondary objectives.~Specifically for the secondary objectives (N ° 3, 4 and 5), randomization via eCRF (electronic case report form) will be performed for the interpretation of genetic analyzes (PMDA panel) without inducing any change for the patients. This randomization, by block and by center, will allow the attribution of one of the following two groups:~Control group: interpretation of genetic analyzes without the use of RADIAL;~Experimental group: interpretation of genetic analyzes using RADIAL.~Genome analysis (secondary objective n ° 6) will be carried out for all the patients who remained without diagnosis at the end of the first part, and for whom the DNA of relatives is available."
89523490|NCT02520505|Active Comparator|Supraovulation + IUI|Women randomized to super ovulation (SO) will be treated according to a standard protocol under the care of their staff physician and fertility nurses. The patient will be treated with 100mg/day of clomiphene citrate starting on day 3 of the menstrual cycle and ending on day 7. Intrauterine insemination will be performed 36 hours after the hCG surge (follicle rupture) by inserting a catheter through the cervix of the patient in dorsal lithotomy position.
89523491|NCT03380767|Experimental|POC group|In this group, patients will be treated according to the information gathered by TEG or ROTEM assays.
89329326|NCT04259996||MODIFIED NATURAL CYCLE|"The term 'modified natural cycle' refers to a natural cycle in which ovulation is triggered by exogenous hCG administration in order to provide optimal timing scheduling embryo transfer. In contrast to the natural cycle, the applied hCG may lead to a different luteal phase profile. Luteal phase support is common clinical practice in those cycles.~On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
89329327|NCT04259996||STIMULATED CYCLE|"On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
89329328|NCT04259970|Experimental|Phase 1|Phase 1 will include implementation of a centralized analysis program of repeated 129Xe MRI scanning in CF patients with mild lung disease to define the intra-subject variability of the primary outcome ventilation defect percentage (VDP). Patients will undergo baseline 129Xe MRI scanning and repeated measurements the same day, as well as at 28 days (± 7 days). Phase 1 will establish the intra-subject reproducibility to facilitate future use of 129Xe MRI in multi-site studies. Furthermore, the reproducibility limits defined will inform the overall design of future studies and will compare to established pulmonary function and multiple-breath washout testing (via measurement of the lung clearance index, LCI).
89329329|NCT04259970|Experimental|Initiation of CFTR Modulator|Phase 2 will be an observational study of patients assessed before and after the clinical initiation of triple-combination modulator therapy (after presumed FDA and Health Canada approval). The primary endpoint for Phase 2 is the change of VDP after 28 days of triple-combination modulator therapy. Within Phase 2, this study will also address how highly-effective modulator therapies affect lung function trajectories by measuring 129Xe MRI at 28 days (± 7 days), 6 months (± 28 days), and 12 months (± 28 days) after start of therapy (paralleling time points of the PROMISE study). Finally, to understand how 129Xe MRI can be used in combination with existing measures of lung function (e.g. spirometry, multiple breath washout), the investigators will directly compare the repeated data collected in both Phase 1 and Phase 2 to these established measures of lung function that are currently used in observational and interventional studies.
89329330|NCT04257136|Experimental|Treatment|Treatment with VBI-S
89329331|NCT04236986|No Intervention|Baseline [11C]PBR28 PET Scan|Subjects will complete a 120-minute baseline [11C]PBR28 PET scan.
89329332|NCT04236986|Experimental|Post-LPS [11C]PBR28 PET Scan|Subjects will complete a second120-minute [11C]PBR28 PET scan 3-hours after LPS administration (1.0ng/kg; IV)
89329333|NCT04226456|No Intervention|Control|"Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
89329334|NCT04226456|Experimental|N-acetylcysteine|"Experimental arm (Arm B):~0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.~Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)~Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease."
89329335|NCT04211922|Experimental|Alkotinib 400mg QD|400mg orally once daily. Take Alkotinib at least 1 hour before or at least 2 hours after a meal.
89329336|NCT04206072|Experimental|D-0316|D-0316 (75 mg or 100 mg orally, once daily), in accordance with the randomization schedule.
89329337|NCT04206072|Active Comparator|Icotinib|Icotinib (125 mg orally, three times daily), in accordance with the randomization schedule.
89329338|NCT04174755|Experimental|Semaglutide 0.25/0.5/1 mg plus standard of care|
89329339|NCT04174755|Other|Standard of care alone|
89329340|NCT04168866|Experimental|Surgery|Patients who choose operations will have surgery performed to remove the appendix laparoscopically, through 3 or 4 small incisions. All patients in the operative group will receive standard perioperative antibiotics. They will also have the abscess(es) drained during the same surgery if there is one present. In some cases, the operation may be too difficult to perform laparoscopically, so an open appendectomy will be performed, involving a longer incision to remove the appendix. In some cases, both laparoscopic and open are performed. The surgeon may also choose to remove a section of the intestine with the appendix or perform additional procedures.
89329341|NCT04168866|Active Comparator|Non-operative management|If a patient chooses non-operative management and if an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
89329342|NCT04162951|Experimental|Ordinary approach group|The patients in this group will receive ordinary ultrasound-guided thoracic paravertebral block. by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
89329343|NCT04162951|Experimental|Retro-laminar approach group|The patients in this group will be receive real ultrasound-guided Retrolaminar thoracic paravertebral block by local anesthetic mixture at a volume of 0.2 ml/kg composed of plain bupivacaine 0.25% and Fentanyl 2 ug/ml.
89329344|NCT04162847|Experimental|Mobile Coached Intervention|This group will receive access to the mobile intervention for 6 months. They will be assigned to the primary program (i.e., anxiety, depression, or eating disorders) they screen positive for. If a person screens positive for more than one disorder, they will be given the choice of which program they want to start with. They will also be provided preventive interventions for anxiety, depressive, or eating of disorders they may not have but be at risk for. After two weeks in the program, the coach will assign the components presumed to be essential to intervention effects for comorbid disorder(s) and risk factors.
89329345|NCT04162847|No Intervention|Referral to Counseling Center|This group will receive information about how to make an appointment at their counseling center and will be encouraged to do so.
89329346|NCT04162327|Experimental|Ia stage - IBI315 Dose escalation|
89329347|NCT04162327|Experimental|Ib stage - IBI315 monotherapy|
89329348|NCT04157517|Experimental|Phase 1b SA Dose Escalation|Modakafusp alfa 0.1 to 6 milligram per kilogram (mg/kg), infusion, intravenously, once on Day 1 of each 21-days treatment cycle for up to 1 year.
89329349|NCT04157517|Experimental|Phase 2 Safety Lead-in Dose Expansion: Modakafusp Alfa + Pembrolizumab|"Melanoma with primary resistance to prior anti-PD1, acquired resistance to prior anti-PD1 or naïve to anti-PD1.~Modakafusp alfa, infusion, intravenously, once on Day 1 of each 21-days treatment cycle and pembrolizumab 400 mg infusion, intravenously, once every 6 weeks for up to 2 years. The starting dose of modakafusp alfa for dose expansion safety lead-in phase will be the RP2D determined in the previous Phase 1b dose escalation phase."
89329350|NCT04157517|Experimental|Phase 2 Dose Expansion: Modakafusp Alfa + Pembrolizumab (Melanoma With Primary Resistance)|Melanoma With Primary Resistance to prior anti-PD1. Modakafusp alfa, infusion, intravenously, once on Day 1 of each 21-days treatment cycle and pembrolizumab 400 mg infusion, intravenously, once every 6 weeks for up to 2 years, in participants with unresectable/metastatic cutaneous melanoma with primary resistance to no more than 2 prior lines of anti-PD1 containing treatments in the metastatic setting. The dose of modakafusp alfa for dose expansion phase will be the modakafusp alfa RP2D in combination with pembrolizumab determined in the previous Phase 2 dose expansion safety-lead in phase.
89329351|NCT04157517|Experimental|Phase 2 Dose Expansion: Modakafusp Alfa + Pembrolizumab (Melanoma With Acquired Resistance)|Melanoma With Acquired Resistance to prior anti-PD1. Modakafusp alfa, infusion, intravenously, once on Day 1 of each 21-days treatment cycle and pembrolizumab 400 mg infusion, intravenously, once every 6 weeks for up to 2 years, in participants with unresectable/metastatic cutaneous melanoma with acquired resistance to no more than 2 prior lines of anti-PD1 containing treatments in the metastatic setting. The dose of modakafusp alfa for dose expansion phase will be the modakafusp alfa RP2D in combination with pembrolizumab determined in the previous Phase 2 dose expansion safety lead-in phase.
89329352|NCT04157517|Experimental|Phase 2 Dose Expansion: Modakafusp Alfa + Pembrolizumab (Melanoma naïve to anti-PD1)|Modakafusp alfa, infusion, intravenously, once on Day 1 of each 21-days treatment cycle and pembrolizumab 400 mg infusion, intravenously, once every 6 weeks for up to 2 years, in participants with unresectable/metastatic cutaneous melanoma naive to prior line of anti-PD1 containing treatments in the metastatic setting. The dose of modakafusp alfa for dose expansion phase will be the modakafusp alfa RP2D in combination with pembrolizumab determined in the previous Phase 2 dose expansion safety lead-in phase.
89329353|NCT04149795||Clinical psychologists in Germany|Clinical psychologists in Germany currently working with patients with mental disorders
89329354|NCT04149782||Patients enrolled in differentiated service delivery models|
89329355|NCT04149782||Patients not enrolled in DSD models|
89329356|NCT04145427|Experimental|Low Carbohydrate Diet|This arm will be randomized to low carbohydrate diet
89329357|NCT04145427|Active Comparator|Standard Dietary Advice Control Group|This arm will be randomized to control diet
89329358|NCT04138680|Experimental|Active Biofeedback|The patients in the active group will receive one active biofeedback training session.
89329359|NCT04138680|Sham Comparator|Sham Biofeedback|The patients in the sham group will receive one sham biofeedback training session.
89329360|NCT04125043||RRT Group|Pediatric patients undergoing ocular screening tests
89329361|NCT04124432|Experimental|Active cannabis without nicotine|Smoked cannabis containing 10mg THC + No nicotine/tobacco
89329362|NCT04124432|Experimental|Active cannabis with own brand cigarettes|Smoked cannabis containing 10mg THC + ad-libitum use of preferred brand cigarettes
89329363|NCT04124432|Experimental|Active cannabis with low nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
89329364|NCT04124432|Experimental|Active cannabis with high nicotine e-cigarette|Smoked cannabis containing 10mg THC + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
89329365|NCT04124432|Experimental|placebo cannabis with own brand cigarettes|Smoked placebo cannabis + ad-libitum use of preferred brand cigarettes
89329366|NCT04124432|Experimental|Placebo cannabis with low nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of low nicotine content E-Cig (3% nicotine JUUL)
89329367|NCT04124432|Experimental|Placebo cannabis with high nicotine e-cigarette|Smoked placebo cannabis + ad-libitum use of high nicotine content E-Cig (5% nicotine JUUL)
89329368|NCT04110301|Experimental|MIL62 + Lenalidomide|MIL62 plus Lenalidomide
89329369|NCT04108377|Experimental|Roflumilast|Roflumilast 500mcg by mouth, once daily, for 70 days (10 weeks).
89329370|NCT04108377|Placebo Comparator|Placebo|Placebo by mouth, once daily, for 70 days (10 weeks).
89329371|NCT04094324||Children and youth at obesity clinic|Children 11-18 who are patients at obesity clinics in region Skåne SUS.
89329372|NCT04094324||Children and youth at a pediatric gastrointestinal clinic|Children 11-18 who are patients at a gastrointestinal clinic i region Skåne SUS.
89329373|NCT04084678|Experimental|Ralinepag|Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the individual maximum tolerated dose (maximum dose of 1400 mcg)
89329374|NCT04084678|Placebo Comparator|Placebo|Matching placebo tablets (oral)
89329375|NCT04080440|Active Comparator|Standard of care|Clinicians decide whether to extubate or not following their ICU protocol
89329376|NCT04080440|Experimental|Extubation readiness clinical score|Clinicians decide whether to extubate or not following the extubation readiness clinical score
89329377|NCT04069572|Experimental|Vibrotactile Stimulation|
89329378|NCT04069572|Sham Comparator|Sham Stimulation|
89329379|NCT04066881|Experimental|Group A|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm~1 tab of Truvada (0-26 weeks)"
89329380|NCT04066881|Experimental|Group B|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm~1 tab of Truvada (0-26 weeks)"
89329381|NCT04066881|Placebo Comparator|Group C:|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.~1 tab of Truvada (0-26 weeks)"
89329382|NCT04066881|Active Comparator|Group D|"278 participants will receive DNA-HIV-PT123 vaccine and AIDSVAX® B/E protein at weeks 0, 4, 24 and 48.~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml of AIDSVAX® B/E will be injected into the deltoid muscle of the right arm~1 tab of Descovy (0-26 weeks)"
89329383|NCT04066881|Experimental|Group E|"278 participants will receive DNA-HIV-PT123 and CN54gp140+MPLA-L at weeks 0 and 4, then MVA and CN54gp140+MPLA-L at weeks 24 and 48~1ml of DNA-HIV-PT123 will be injected into the deltoid muscle of the left upper arm~1ml (1x108 pfu) of MVA will be injected into the deltoid muscle of the left upper arm~0.4mL containing a mixture of 100mcg CN54gp140 and 5mcg MPLA-L will be injected into the deltoid muscle of the right upper arm~1 tab of Descovy (0-26 weeks)"
89329384|NCT04066881|Placebo Comparator|Group G|"278 participants will receive Sodium Chloride 0.9% (Normal Saline) placebo at weeks 0,4,24, and 48~The volume will be matched to the vaccine at 1ml for DNA, MVA and AIDSVAX® B/E, but 0.4ml for CN54gp140 in MPLA-L. Participants will be randomly divided in a 1:1 ratio to receive 1ml in each arm at the four timepoints or 1ml in the left arm and 0.4ml in the right arm at the four timepoints.~1 tab of Descovy (0-26 weeks)"
89329385|NCT04066868|Experimental|PRO active|
89329386|NCT04066868|Active Comparator|PRO not active|
89329387|NCT04066036||Study Population|The study will enroll a total of 1,000 ART-experienced participants from the study sites in Uganda and South Africa who are being transitioned to TLD from non-nucleoside reverse transcriptase-based antiretroviral therapy.
89329388|NCT04058717|Experimental|NNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
89329389|NCT04058717|Experimental|NNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with normal nicotine content (NNC) cigarettes (11.6 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid.
89329390|NCT04058717|Experimental|VLNC cigarettes + High Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with high nicotine e-liquid.
89329391|NCT04058717|Experimental|VLNC cigarettes + Zero Nicotine Containing E-cigarette|Participants are provided with very low nicotine content (VLNC) cigarettes (0.2 mg nicotine/cigarette) plus e-cigarette with zero nicotine e-liquid
89329392|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 1)|
89329393|NCT04028973|Experimental|Evaluation of fatigue level in BPCO patients (condition 2)|
89329394|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 1)|
89329395|NCT04028973|Active Comparator|Evaluation of fatigue in control patients (condition 2)|
89329396|NCT04020419|Experimental|Pediaberry group|PediaBerry™ is a proprietary blend powdered berry extracts
89329397|NCT04020419|Placebo Comparator|Placebo|Placebo: powdered sugar plus McCormick Color from Nature Food Colors Berry and Sky Blue powdered food color (https://www.mccormick.com/spices-and-flavors/extracts-and-food-colors/food-colors/color-from-nature-assorted-food-color ).
89329398|NCT04013568|Active Comparator|Group 1 - Agree to Exercise Program|12-week exercise program
89329399|NCT04013568|No Intervention|Group 2 - Declines Exercise Program|Same biometric and biomarker assessment at as Group 1 (at baseline, after 12 weeks and annually) however they will not participate in the exercise sessions
89329400|NCT04004312|Experimental|Single Fraction SBRT in the treatment of prostate cancer|Prior to treatment, a hydrogel spacer will be inserted between the recutm and prostate. A urinary catheter will also be inserted in the bladder. A single dose of 19Gy will be delivered with an IMRT technique. The treatment should last approximately 30 minutes. After the treatment, the urinary catheter will be removed.
89329401|NCT03999424|Experimental|Autologous human Schwann cells|All participants will receive autologous human Schwann cells harvested from their own sural nerve.
89329402|NCT03987958||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for AML.~The decision to treat with venetoclax has been made independently from this observational study before participants are offered the opportunity to participate in this study."
89329403|NCT03970746|Experimental|Cohort A1|PDC*lung01 Low Dose
89329404|NCT03970746|Experimental|Cohort A2|PDC*lung01 High Dose
89329405|NCT03970746|Experimental|Cohort B1|PDC*lung01 Low Dose added to SoC, i.e., anti-PD-1 treatment
89329406|NCT03970746|Experimental|Cohort B2|PDC*lung01 High Dose added to SoC, i.e., anti-PD-1 treatment
89329407|NCT03961815|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
89329408|NCT03961815|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
89329409|NCT03959943||Innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction with additional sensory nerve coaptation.
89329410|NCT03959943||Non-innervated LTP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral lateral thigh perforator (LTP) flap breast reconstruction without sensory nerve coaptation.
89329411|NCT03957421|Experimental|Aquatic exercise is more beneficial than land based exercise|use of aquatic exercise will be evaluated for individuals with stroke
89523492|NCT03380767|Experimental|Conventional group|In this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)
89329412|NCT03956810|Experimental|On-demand transportation|Women randomized to the intervention group will be able to contact the transportation broker via telephone, web portal, or the broker's mobile application. In addition to the current trips provided by their Medicaid managed care organization , women assigned to the intervention group will be provided with extra trips to the pharmacy and grocery store or food bank.
89329413|NCT03956810|Active Comparator|Usual transportation|Women assigned to the usual care group will receive the usual transportation services from their Medicaid managed care organization.
89329414|NCT03952936|Other|Mobility|Self comparison of data from pre-post intervention.
89329415|NCT03948217|Active Comparator|L1|regimen L1 has overall higher intensity, higher color temperature and less light fluctuations
89329416|NCT03948217|Active Comparator|L2|regimen L2 has lower intensity, lower color temperature and more light fluctuations.
89329417|NCT03945019|Experimental|CT-P13 SC|
89329418|NCT03945019|Placebo Comparator|Placebo SC|
89329419|NCT03929627||Group 1 - Medical personnell|Group 1 consists of 70 participants belonging to medical staff of the Medical University of Vienna/University Hospital of Vienna and is divided into subgroups consisting of medical technical assistants, nurses, assistant physicians and physicians.
89329420|NCT03929627||Group 2 - Control|Group 2 consists of 70 participants and is recruited from the General non-medical staff of the Austrian Federal Ministry of Defence and Sports, Austrian Armed Forces.
89329421|NCT03929081|Experimental|Inference Based Approach (IBA)|The IBA treatment, a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly. The IBA model is based on the assumption that patients with OCD feel the need to perform compulsive acts because they misjudge the actual state of affairs, for example fearing that an appliance is on when it is visibly off. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the patient's attention from observable reality. IBA teaches patients how to defend themselves against the absorbing and confusing effect of obsessive reasoning processes and how to stay in touch with reality by actively relying on the sensory information of the very moment. As a consequence, the patient realizes that any compulsive act is superfluous and feels able to omit it.
89329422|NCT03929081|Active Comparator|Cognitive Behavior Therapy (CBT)|In the control condition, the patients will receive twenty 45-minutes sessions of CBT consisting of self-guided exposure in vivo with response prevention (ERP) and cognitive therapy (CT), both standardized according to evidence-based session-by-session protocols, containing standardized forms for exercises and homework assignments.
89329423|NCT03929081|No Intervention|No intervention (healthy controls)|The healthy control group will receive no intervention.
89329424|NCT03921788||Group 1|Patients with venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
89329425|NCT03921788||Group 2|Patients without venous pelvic pain. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
89329426|NCT03921788||Group 3|Volunteers without pain syndromes of any location. Pain measurement using a visual analogue scale, the study of calcitonin gene-related peptide and substance P (ELISA)
89329427|NCT03910673|Experimental|2-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 2 hours after start of third infusion dose. n = 6
89329428|NCT03910673|Experimental|30-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 30 minutes after start of third infusion dose. n = 6
89329429|NCT03910673|Experimental|5-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 5 hours after start of third infusion dose. n = 6
89329430|NCT03910673|Experimental|75-Minute Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 75 minutes after start of third infusion dose. n = 6
89329431|NCT03910673|Experimental|8-Hour Group|ZTI-01 administered as 1-hour IV infusions (+10 minute window) given every 8 hours for three doses. Each dose comprised of 200 mL (6 g) of fosfomycin disodium. Bronchoscopy and bronchoalveolar lavage (BAL) performed 8 hours after start of third infusion dose. n = 6
89329432|NCT03906071|Experimental|Nivolumab and Sitravatinib|Nivolumab will be administered by intravenous infusion over 30 minutes at 240 mg every 2 weeks or at 480 mg every 4 weeks. Sitravatinib capsules will be administered orally, once daily.
89329433|NCT03906071|Active Comparator|Docetaxel|Docetaxel will be administered by intravenous infusion at 75 mg/m2 over 1 hour every 3 weeks.
89329434|NCT03898453|Experimental|Group EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
89329435|NCT03898453|Other|Group Control : support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
89523493|NCT03385213||Relapse|Patients who suffered colorectal cancer relapse after curative surgery
89523494|NCT03385213||Remission|Patients who get remission after curative surgery
88806677|NCT05895253|Active Comparator|Control-Vibration|Participants were assessed before and after 60 days of no additional intervention to any ongoing treatment, after seven days of washout, and after receiving 60 days of vibrotactile ground-contact feedback.
89523495|NCT03380689|Experimental|SIRB2|Biweekly combination therapy with S-1, Irinotecan, and Bevacizumab
89523496|NCT03380611|Experimental|Wakame|Subjects will receive capsules containing wakame
89523497|NCT03380611|Experimental|Spirulina|Subjects will receive capsules containing spirulina
89329436|NCT03895450|Experimental|Aerobic Exercise Protocol (AEP)|Symptom threshold will be determined at baseline and repeated every 3 weeks using the Buffalo Concussion Treadmill Test. Briefly, there will be an initial 4min warm up at 1.7mph. The protocol will start with treadmill speed se to 3.3 mph and 0.0% incline. Each subsequent minute, the incline will increase by 1.0% to a max of 15%. At 15% grade, if the participant is still able to continue, treadmill speed will increase by 0.4mph each minute. Heart rate (HR) and rating of perceived excretion (RPE Borg scale) will be measured every minute. The test will be terminated upon symptom exacerbation at which time HR and RPE will be recorded. Every 3 weeks the symptom threshold test will be repeated for all participants and exercise prescription will be adjusted accordingly.
89329437|NCT03895450|Placebo Comparator|Stretching Protocol (SP)|The exercise testing for the stretching protocol to determine exercise prescription will be the same as described above.
89329438|NCT03886675|Experimental|carbon-dioxide|Flushing of stent-grafts in TEVAR with carbon-dioxide
89329439|NCT03886675|Active Comparator|Saline|Flushing of stent-grafts with saline
89329440|NCT03875690|Experimental|Experimental group|
89329441|NCT03875690|Placebo Comparator|Control group|
89329442|NCT03874845|Experimental|Mindfulness-Based Cognitive Therapy|Participants will have 8 weeks of group therapy and will be asked to do MBCT exercises for approximately 20-30 minutes on 5 or more days/week.
89329443|NCT03874845|Active Comparator|Muscle Relaxation Therapy (MRG)|Participants will have 8 weeks of group therapy participants and will be asked to do MRG exercises for approximately 20-30 minutes on 5 or more days/week.
89329444|NCT03868956|Experimental|Diagnostic strategy|Colour doppler ultrasound (CDUS) with or without D-dimer test to rule-in or rule-out deep vein thrombosis recurrence
89329445|NCT03866408|Active Comparator|Immediate weight loss - placebo|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
89329446|NCT03866408|Placebo Comparator|Deferred control group - placebo|After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
89329447|NCT03866408|Active Comparator|Immediate weight loss - pioglitazone|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
89329448|NCT03866408|Active Comparator|Deferred group - pioglitazone|"After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period.~At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone."
89329449|NCT03848286|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
89329450|NCT03842137|Active Comparator|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
89329451|NCT03842137|Sham Comparator|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
89329452|NCT03842085|Experimental|MBS301|Drug: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
89329453|NCT03837106|Experimental|Rehabilitation program|Home and supervised exercise program specific to musicians. Injury prevention and management education program specific to musicians.
89329454|NCT03837106|No Intervention|No intervention|Control group, no intervention
89329455|NCT03836209|Experimental|Arm A|"Induction: Daunorubicin, cytarabine and gilteritinib. Depending on response, second cycle of Induction may be given.~Consolidation: High-dose cytarabine and gilteritinib."
89329456|NCT03836209|Active Comparator|Arm B|"Induction: Daunorubicin, cytarabine and midostaurin. Depending on response, second cycle of Induction may be given.~Consolidation: High-dose cytarabine and midostaurin."
89329457|NCT03829514|Experimental|Fenofibrate|Single arm. Participants will take study medication
89329458|NCT03794687||Distal Radial Artery|Left heart catheterization via the distal radial artery (dorsal aspect of the hand at the base of the thumb).
89329459|NCT03787173|No Intervention|Manual standard ventilator settings|Inspiratory trigger set at 2 l/min, Expiratory trigger set at 25% of peak inspiratory flow
89329460|NCT03787173|Active Comparator|Manual optimized ventilator settings|Inspiratory trigger and Expiratory trigger settings optimized by investigator
89329461|NCT03787173|Experimental|Automated ventilator settings|Inspiratory trigger and Expiratory trigger settings automatized
89329462|NCT03783325|Other|UV Counseling|Evaluate the effectiveness of dosimetry feedback on sun exposure behaviors, attitudes, and awareness in patients diagnosed with melanoma.
89329463|NCT03783325|Experimental|Visual Analysis - UV Photo|Assess the relationships between UV camera score, silicone mold of a skin patch, phenotypic evaluation and sun-exposure behaviors. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
89329464|NCT03783325|Experimental|Biological Sample|Determine the relationship between measures of sun exposure and genomic characteristics of tumors in melanoma patients. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
89329465|NCT03781167|Experimental|ABBV-951 Low Dose Subgroup|After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was < 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.
89329466|NCT03781167|Experimental|ABBV-951 High Dose Subgroup|After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.
89329467|NCT03771313|Other|PK/PD|Open-label prospective study with participants receiving treating physician-approved intravenous ceftaroline, dosed according to current recommendations. Blood samples collected at baseline, 1 hour, 1.5 hours, 3 hours, and 6 hours after infusion.
89329468|NCT03748134|Experimental|Randomized Part: Experimental: Sintilimab + chemotherapy|"Sintilimab in combination with investigator's choice of chemotherapy~TP regimen: Cisplatin + paclitaxel~or~CP regimen: Cisplatin + fluorourcil"
89329469|NCT03748134|Active Comparator|Randomised Part: Active Comparator: Placebo + chemotherapy|Placebo in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil
89329470|NCT03748134|Experimental|Open-label part: Sintilimab+ chemotherapy|Sintilimab in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil
89329471|NCT03727802|Experimental|TRK-250|
89329472|NCT03727802|Placebo Comparator|Placebo|
89329473|NCT03726320|Experimental|Intervention Group|A decision aid along with decision coaching on PSA screening from a Community Health Worker (CHW). The intervention will be administered directly prior to the participant's appointment with their provider.
89329474|NCT03726320|Active Comparator|Control Group|A decision aid along with CHW interaction on dietary and lifestyle modification to serve as an attention control. The intervention will be administered directly prior to the participant's appointment with their provider.
89329475|NCT03720912|Experimental|Online Family Education Modules|Patients will receive online family education modules.
89329476|NCT03720912|No Intervention|Control|Patients will not receive any intervention.
89329477|NCT03702582|Experimental|Rivaroxaban|"Rivaroxaban: Direct inhibitor of Factor Xa, an enzyme that stimulates the formation of thrombin from prothrombin (A critical step in both the intrinsic and extrinsic aspects of the coagulation cascade)~Dosage form: Per Os (Oral)~Dosage and Frequency: 20 mg every evening with the evening meal (No titration requirements). For patients with decreased glomerular filtration rate (GFR between 15 ml/min and 50 ml/min), dosing will be decreased to 15 mg every evening with the evening meal.~Duration: 30 days (Possibility of continuation after post-operative cardiology clinic visit)"
89329478|NCT03702582|Active Comparator|Warfarin|"Warfarin: Competitive inhibitor of vitamin K epoxide reductase complex 1, an important enzyme in the activation pathway for vitamin K dependent coagulation factors~Dosage form: Per Os (Oral)~Dosage and Frequency: Initial dose of 2 - 5 mg nightly after the evening meal (QHS) with appropriate titration to goal INR 2.0 - 3.0 (Initial dose based on weight, age, gender, co-morbidities and concurrent medications). INR will be checked daily to weekly depending on stability of dosing and medication regimen.~Duration: 30 days (Possibility of continuation after post-operative Cardiology clinic visit)"
89329479|NCT03701711|Experimental|Lenalidomide escalation and expansion|Among the participants who will be receiving lenalidomide, the first 12 participants will be in the dose escalation phase; with the subsequent 8 participants anticipated to receive dose expansion.
89329480|NCT03689712|Experimental|GC4419 (avasopasem manganese) 90 mg|
89329481|NCT03689712|Placebo Comparator|Placebo|
89329482|NCT03686683|Experimental|Treatment Group: Sipuleucel-T|Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion. Subjects randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals.
89329483|NCT03686683|No Intervention|Control Arm: Active Surveillance|Subjects randomized to the control arm will be followed on Active Surveillance described in the schedule of events.
89329484|NCT03680508|Experimental|TSR-022 (Cobolimab) and TSR-042 (Dostarlimab)|Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89329485|NCT03679624|Experimental|Cohort A - Ibrutinib naive|Cohort A will consist of subjects who are ibrutinib naïve and appropriate for ibrutinib based treatment. Treatment naïve subjects will be eligible to enroll in this cohort. All subjects in this cohort will receive ibrutinib plus daratumumab
89329486|NCT03679624|Experimental|Cohort B - Ibrutinib response plateau|Cohort B will consist of subjects who have had at least 6 months of exposure to single agent ibrutinib and who have demonstrated an IgM response plateau defined by two IgM measurements, at least 8 weeks apart that have changed <15% from the previous mark. All subjects in this cohort will receive ibrutinib plus daratumumab
89329487|NCT03659669||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label.
89329488|NCT03658772|Experimental|Cohort 1|Single Agent run-in with grapiprant and then combination treatment of grapiprant and pembrolizumab.
89329489|NCT03658772|Experimental|Cohort 2|Participants will be treated with grapiprant in combination with pembrolizumab.
89329490|NCT03658343|Experimental|T2* Imaging|Participants undergo T2* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.
89329491|NCT03625323|Experimental|1st line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
89329492|NCT03625323|Experimental|2nd line NSCLC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
89329493|NCT03625323|Experimental|HNSCC|"Eftilagimod alpha: 30 mg every 2 weeks for the first 8 cycles (1 cycle = 3 weeks) and every 3 weeks thereafter (starting cycle 9).~Pembrolizumab: 200 mg every 3 weeks."
89329494|NCT03623945||Cohort A|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III or IV invasive breast cancer, will be invited to participate. Stage I, II and III participants will be further categorized into high-risk and low-risk. For the purposes of this study, participants with at least one of the following will be considered high-risk; any triple negative cancer, any grade III cancer, lymph node involvement, tumor greater than 2cm, or any patient receiving cytotoxic chemotherapy.
89523498|NCT03380611|Placebo Comparator|Control|Subjects will receive capsules containing microcrystalline cellulose
89329495|NCT03623945||Cohort B|"Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign but high-risk pathology, will be invited to participate. This includes, but is not limited to, atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), flat epithelia atypia or phylloides.~Accrual to Cohort B is complete."
89329496|NCT03623945||Cohort C|Patients who have recently had an abnormal mammogram, followed by a breast biopsy and diagnosed with a benign tumor, will be invited to participate. This includes, but is not limited to, fibroadenoma, papilloma, fibrocystic changes and Pseudoangiomatous stromal hyperplasia (PASH). Accrual to Cohort C is complete
89329497|NCT03623945||Cohort D|Patients who have had a normal screening mammogram within the last 6 months will be invited to participate. Accrual to Cohort D is complete.
89329498|NCT03623945||Cohort E|"Patients who have recently had an abnormal mammogram, followed by a breast biopsy and an initial diagnosis of Stage I, II, III invasive breast cancer.~Patients who have recently had an abnormal mammogram, followed by a breast biopsy, and diagnosed with a benign but high-risk pathology.~Cohort E has 3 sub-groups. For the purposes of this study, participants with a breast cancer will be categorized as E1-malignant high risk, of E2-malignant low risk.~Patients who have recently had an abnormal mammogram, followed by a breast biopsy, and diagnosed with a benign but high-risk pathology, will be invited to participate.~These patients will be considered E3-benign high-risk."
89329499|NCT03580564|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
89329504|NCT03565588|Experimental|Education session with fixed incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs to the health facility with payments conditional on being circumcised.
89329505|NCT03565588|Experimental|Education session with lottery incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs but with conditional lottery financial incentives.
89329506|NCT03565588|No Intervention|Control arm|No intervention will be administered to the control arm
89329507|NCT03546374|Experimental|Primary Cohort|Patients with a history of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal atrial fibrillation) who are undergoing concomitant cardiac surgery
89329508|NCT03539900|Experimental|NB Medication|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
89329509|NCT03539900|Placebo Comparator|Placebo|Placebo will be inactive and taken daily in pill form.
89329510|NCT03527719|Experimental|Experimental Group|Village-doctor-led multifaceted intervention
89329511|NCT03527719|No Intervention|Control Group|Village doctors in usual care group will not receive hypertension management training or support. However, they will be trained in standardized BP measurement. Participants in control group will receive their usual care from village doctors or primary care physicians in township hospitals
89329512|NCT03493529||Normal Weight|BMI: Between 18.50 and 29.99 kg/m2
89329513|NCT03493529||Obesity Clas I|BMI between 30 and 34.99 Kg/m2
89329514|NCT03493529||Obesity Clas II|BMI between 35 and 39.99 Kg/m2
89329515|NCT03493529||Obesity Clas III|BMI> 40 Kg/m2
89329516|NCT03489980||Ambulatory consultation waiting room|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form before a medial consultation with hospital practitioner.
89329517|NCT03489980||Hemodialysis service|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during hemodialysis.
89329518|NCT03489980||Day hospitalization service : psychiatry|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during day hospitalization.
89329519|NCT03484546||folicular|Women who will undergo endometrioma cystectomy in her follicular phase of menstrual period.
89329520|NCT03484546||ovulatory|Women who will undergo endometrioma cystectomy in her ovulatory phase (12-14th day of mestrual period cycle for women regular period) of menstrual cycle.
89329521|NCT03484546||luteal|Women who will undergo endometrioma cystectomy in her luteal phase of menstrual period.
89329522|NCT03480191|Experimental|Patients|
89329523|NCT03428581|Experimental|ALND with ARM +/- LVB|Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.
89329524|NCT03428581|Active Comparator|ALND without ARM +/- LVB|Axillary Lymph Node Dissection (ALND)
89329525|NCT03421340|Other|ERC Arm|After screening examination and confirmed presence of non-complex bile duct stone by image, patients will be randomly assigned by stratified randomization to Electroscopic Retrograde Cholangioscopy (ERC) treatment.
89329526|NCT03421340|Other|DSC Arm|After screening examination and confirmed presence of non-complex bile duct stone by imagine, patients will be randomly assigned by stratified randomization to fluoroscopy/radiation-free direct solitary cholangioscopy (DSC).
89329527|NCT03402945|Active Comparator|Arm 1|"cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day"
89523499|NCT03380533|Active Comparator|Buprenorphine Patch|"Buprenorphine 10mg Patch + Placebo Tablet + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
89523500|NCT03380533|Active Comparator|Tramadol Tablet|"Placebo Patch + Tramadol 50mg Tablet + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
89329528|NCT03402945|Active Comparator|Arm 2|"cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days."
89329529|NCT03402945|Active Comparator|Arm 3|"cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
89329530|NCT03402945|Active Comparator|Arm 4|"cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
89329531|NCT03399552|Experimental|Avelumab|The treatment will consist of one dose of avelumab every other week as well as a short course of SBRT after the first two doses of avelumab.
89329532|NCT03395522|Experimental|Device|ITind device implant
89329533|NCT03359902|Experimental|Initial tVNS|This group will receive transcutaneous vagal nerve stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
89329534|NCT03359902|Experimental|Initial Sham|This group will receive sham stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
89329535|NCT03355573|Experimental|Bimekizumab|Subjects will receive bimekizumab up to 4 years.
89329536|NCT03341364|Experimental|ACT group treatment|Participants receiving the ACT-based group therapy.
89329537|NCT03341364|Active Comparator|ACT individual|Participants receiving individual ACT-based therapy.
89329538|NCT03328507|Experimental|BLI4900|BLI4900 Bowel Preparation
89329539|NCT03328507|Active Comparator|PEG Control|Polyethylene glycol-based bowel preparation
89329540|NCT03312231|Experimental|Group 1|3.75 mcg of H7N9 vaccine with PBS diluent plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
89329541|NCT03312231|Experimental|Group 2|7.5 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
89329542|NCT03312231|Experimental|Group 3|15 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
89329543|NCT03312231|Experimental|Group 4|15 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
89329544|NCT03312231|Experimental|Group 5|45 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
89329545|NCT03307356|Experimental|Uterine Transplantation|Women will undergo extensive medical and psychological screening. Five women that meet all inclusion and exclusion criteria will undergo ovarian stimulation, oocyte retrieval and will create embryos that will be stored for future use. Women will then undergo uterine transplantation from a donor. Following transplant women will be closely monitored for complications (including infection and rejection). If no complications arise, or complications that do arise can be treated, attempts at pregnancy will begin approximately 6 months after transplant. Pregnancy in the setting of uterine transplant requires directly placing embryos directly into the uterus.
89329546|NCT03307057|Experimental|Social Communication Growth Charts (SCGC)|Infants with a sibling who is diagnosed with ASD, who are randomized to receive the Social Communication Growth Charts (SCGC) intervention.
89329547|NCT03307057|No Intervention|Usual care|Infants with a sibling who is diagnosed with ASD, who are randomized to receive usual care.
89329548|NCT03307057|Experimental|Parent-Implemented (P-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a parent-implemented (P-I) condition of a naturalistic developmental behavioral intervention (NDBI) based on the Early Social Interaction model.
89329549|NCT03307057|Experimental|Clinician-Implemented (C-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a clinician-implemented (C-I) condition NDBI based on a hybrid model.
89329550|NCT03303612|Other|EP-based approach/pacemaker implant|"Subjects will undergo an EP study prior to hospital discharge and will receive a pacemaker implantation if the HV interval is ≥65 msec.~In the case where the electrical slowdown is not confirmed by the electrophysiological study, the participant will not have a pacemaker implantation."
89329551|NCT03303612|Other|Compared transcutaneous cardiac monitor|Subjects will undergo a minimum of 72 hour ECG monitoring in hospital and receive transcutaneous monitoring prior to hospital discharge for a duration of 30 days.
89329552|NCT03300180|No Intervention|Control|The patients in this group will receive no AD screening
89329553|NCT03300180|Active Comparator|Screening Only|The patients in this group will receive screening for AD. Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic and some information about local clinical resources for them to peruse regarding follow-up care. The patient's PCP is also be notified of the screening results via EHR message.
89329554|NCT03300180|Experimental|Collaborative Dementia Care Program|The patients in this group will receive screening for AD, Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic. Also, the family member will receive two follow-up phone calls. One from the COADS Study Coordinator and one from a care coordinator at the Aging Brain Care Program (ABC). This phone call will include an opportunity for the family to ask questions and a conversation about the program and diagnostic evaluation and management. Dyads have the option to refuse the follow-up visit. The patient's PCP is also be notified of the screening results via EHR message,
89329555|NCT03294590|Experimental|Oral health text messages (OHT)|Participants in this arm will receive the OHT parent targeted text messages to reduce caries and improve oral health behaviors among low income families visiting community-based, urban pediatric clinics.
89329556|NCT03294590|Active Comparator|Child wellness text messages (CWT)|Participants in this arm will receive the CWT parent targeted text messages to improve child wellness (e.g., reading time, safety) among low income families visiting community-based, urban pediatric clinics.
89329557|NCT03292731|Experimental|hydroxyprogesterone caproate 500 mg|For safety assessment of the 500 mg dose, subjects will be randomized to the 500 mg dose of 17-OHPC.
89329558|NCT03292731|Active Comparator|hydroxyprogesterone caproate 250 mg|For safety assessment of the 500 mg dose, subjects will be randomized to the 250mg dose of 17-OHPC.
89329559|NCT03292731|Active Comparator|Ancillary cohort 250 mg dose|Receiving 250 mg as part of routine care
89329560|NCT03277313|Experimental|Epoch 1|Pediatric participants with PIDD who were on IV or non-HYQVIA SC treatment with immunoglobulin were enrolled and treated with HYQVIA SC with a dose or interval ramp-up period of up to six weeks. HYQVIA dose was planned to be equivalent to 100% (± 5%) of pre-study treatment. Dose frequency was one treatment interval of one week, then one treatment interval of two weeks for participants who were planned to be treated every three weeks, and one more treatment interval of three weeks for participants who were planned to be treated every four weeks.
89329561|NCT03277313|Experimental|Epoch 2|Epoch 1 was followed by Epoch 2 with HYQVIA treatment infusions given once every 3 or 4 weeks, depending on the participant's previous IV dosing schedule (for IV pretreated participants) and at the discretion of the investigator and participant (for SC-pretreated participants) up to approximately 36 months.
89329562|NCT03239340|Experimental|Osimertinib|An oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer
89329563|NCT03206073|Experimental|1/Arm A1 Pexa-Vec + Durvalumab|Pexa-Vec escalation dose levels + Durvalumab
89329564|NCT03206073|Experimental|2/Arm A2 Pexa-Vec +Durvalumab|Maximum tolerated dose (MTD) of Pexa-Vec after the MTD is established +Durvalumab
89329565|NCT03206073|Experimental|3/Arm B1 Pexa-Vec + Durvalumab +Tremelimumab|Pexa-Vec escalation dose levels + Durvalumab +Tremelimumab
89329566|NCT03206073|Experimental|4/Arm B2|MTD of Pexa-Vec after the MTD is established+Durvalumab + Tremelimumab
89329567|NCT03194308|Other|HIV-uninfected women|A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
89329568|NCT03193801|Experimental|Failing mitral transcatheter valve|Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
89329569|NCT03179540|Experimental|non-operative management|Patients with low rectal cancer who have achieved a complete clinical response following chemoradiotherapy will undergo active follow-up with regular clinical visits, physical exam, endoscopy and imaging assessments at regular intervals for 2 years to assess for tumour re-growth or spread to the liver and lungs
89329570|NCT03138603|Experimental|Metoprolol|Metoprolol group, 3-intravenous doses of 5mg metoprolol tartrate (over 15-minutes), and oral dose(s) of 25mg metoprolol approximately every 8 hours postoperatively for up to 3-days (or 72 hrs).
89329571|NCT03138603|Placebo Comparator|Placebo|Placebo comparator group, up-to-three intravenous doses of placebo comparator (over 15-minutes), and oral dose(s) of a placebo comparator approximately every 8 hours postoperatively for up to 3-days (or 72 hrs).
89329572|NCT03061890||Prematurity and Respiratory Outcomes Program (PROP)|extant, NIH-supported preterm birth cohort NCT01435187
89329573|NCT03061890||Trial of Late Surfactant (TOLSURF)|extant, NIH-supported preterm birth cohort NCT01022580
89329574|NCT03061890||NICU Hospital Exposures and Long-Term Health (NICU-HEALTH)|extant, NIH-supported preterm birth cohort NCT01963065
89329575|NCT03061890||Preterm Erythropoietin Neuroprotection Trial (PENUT)|extant, NIH-supported preterm birth cohort NCT01378273
89329576|NCT03034356|Experimental|Levetiracetam, Then Placebo|4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).
89329577|NCT03034356|Experimental|Placebo, Then Levetiracetam|4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).
89329578|NCT03001362|Experimental|Radical External Beam RT for Colorectal Ca|A single arm consisting of: Radical external beam RT dose of 54 Gy in 30fx with radiosensitizing chemotherapy as per institutional standard
89329579|NCT02973997|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 cycles.
89329580|NCT02962063|Experimental|Esophageal Cancer|This is a phase Ib/II trial of durvalumab (MEDI4736), a monoclonal antibody against programmed death ligand-1 (PD-L1)), and tremelimumab, an anti-CTLA-4 antibody, in combination with chemoradiation for patients with locally advanced (TanyN+M0 or T3-4NanyM0) esophageal or gastroesophageal (GE) junction adenocarcinoma.
89329581|NCT02941926|Experimental|Ribociclib + letrozole+goserelin/leuprolide|Participants received ribociclib (orally taken, 3 weeks on/1 week off) in combination with letrozole (orally taken once daily). For men and premenopausal women, either goserelin was given as an injectable subcutaneous implant or leuprolide was given as an intramuscular injection.
89329582|NCT02905578|Experimental|Ascorbate group|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Pharmacological ascorbate: 75 grams, three times weekly for 4 weeks"
89329583|NCT02905578|Active Comparator|Control|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Each cycle has 1 rest week"
89329584|NCT02902107|Experimental|surgical resection and intraoperative radiation therapy (IORT)|Brachytherapy will be administered using the CivaSheet, a novel permanent LDR palladium-103 (Pd-103) planar brachytherapy device that is applied directly to the surgical resection bed.
89329585|NCT02890485|Experimental|Glute Dry Needling|Receives dry needling to their gluteal muscles in addition to standard physical therapy treatment.
89329586|NCT02890485|Experimental|Quad Dry Needling|Receives dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
89329587|NCT02890485|Sham Comparator|Glute Sham Dry Needling|Receives sham dry needling to their gluteal muscles in addition to standard physical therapy treatment.
89329588|NCT02890485|Sham Comparator|Quad Sham Dry Needling|Receives sham dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
89329589|NCT02890485|Active Comparator|Control|Receives only standard physical therapy treatment.
89329590|NCT02846415|Experimental|PID group|Experimental group receiving the Play Intervention for Dementia
89329591|NCT02846415|No Intervention|Wait-list control group|Participants will receive usual care offered by the day care centre, including health and social services, and meals, etc.
89329592|NCT02780024|Experimental|Registered one arm study|Two weeks of neo-adjuvant Metformin+Temozolomide followed by accelerated hypofractionation using an IMRT technique+TMZ & Metformin followed by TMZ, and Metformin as adjuvant component.
89329593|NCT02688868|Experimental|new specifications (Diameter 2.25mm)of Firehawk stent|Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
89329594|NCT02688842|Experimental|treatment group|Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems
89329595|NCT02657837||Cystic Fibrosis|Children 2.5 to 18 years old with confirmed diagnosis of cystic fibrosis
89329596|NCT02657837||Children with other respiratory disease|Children 2.5 to 18 years old with confirmed diagnosis of respiratory disease including but not limited to asthma, transplant, and sickle cell anemia.
89329597|NCT02657837||Healthy Children|Children and adults 2.5 to 30 years old with no history of chronic disease
89329598|NCT02640313|Experimental|18F-choline PET-MR imaging|"Intervention: 18F-choline PET-MR imaging.~Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose.~Procedure: dynamic and static 18F-choline PET-MR."
89329599|NCT02571621||Patients intubated with Combitube|Patients with Combitube intubation undergoing general anesthesia with ASA class I and II
89329600|NCT02535312|Experimental|Arm A (methoxyamine, pemetrexed disodium, cisplatin)|Patients receive methoxyamine PO QD on days 1-4, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
89329601|NCT02535312|Experimental|Arm B (methoxyamine, pemetrexed disodium)|Patients receive methoxyamine PO QD on days 1-4 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
89329602|NCT02520180|Experimental|Firehawk™ stent system|MicroPort Firehawk™ stent system
89329603|NCT02520180|Active Comparator|Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
89329604|NCT02485639|Experimental|Influenza Virus Vaccine Inactivated|All study participants received licensed inactivated influenza vaccine intramuscularly (IM) on Day 0.
89329605|NCT02455648|Experimental|ESD/EMR plus Cell Sheet|Patients receive both mucosal buccal biopsy and insertion of cell sheets during/after ESD/EMR
89329606|NCT02455648|Sham Comparator|ESD/EMR|patients receive both mucosal biopsy but no placement of cell sheets during/after ESD
89329607|NCT02418949|Experimental|Cyproheptadine + AMP|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
89329608|NCT02418949|Placebo Comparator|Placebo for Cyproheptadine + Stretching|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
89329609|NCT02418949|Active Comparator|Cyproheptadine + Stretching|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
89329610|NCT02418949|Active Comparator|Placebo for Cyproheptadine + AMP|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
89329611|NCT02397434|Experimental|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
89329612|NCT02387255||Normal Volunteers|60 normal volunteers will be recruited. Each volunteer will undergo a single MRE scan (with Resoundant driver System ) of their abdominal aorta.
89329613|NCT02387255||Patients with AAA|Fifty to sixty five patients with AAA will be recruited. These patients will undergo MRE (with Resoundant driver system) of their AAA every six months for three years, or until the study ends or until the time of surgical repair or death due to rupture of AAA or other causes.
89329614|NCT02387255||Open Surgical Repair Patients|Fifty to sixty five patients patients undergoing open surgical repair will be recruited and undergo MRE (with Resoundant driver system) prior to surgery
89329615|NCT02383433|Experimental|Treatment (regorafenib, gemcitabine hydrochloride)|Patients receive regorafenib PO QD on days 1-21 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89329616|NCT02373774|No Intervention|Standard Anatomic Palpation Technique|Participants randomized to this group will receive standard of care treatment with providers using the palpation technique to select an interspace to perform lumbar puncture.
89329617|NCT02373774|Experimental|Pre-Procedural Ultrasound|Participants randomized to this group will receive an ultrasound of the interspace selected via the palpation method prior to performance of the lumbar puncture to determine measurements of appropriate angle and depth and evaluation of any overlying vasculature.
89329618|NCT02336074|Active Comparator|Control|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total)
89329619|NCT02336074|Experimental|Intervention|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total) Plus ChAdV63.HIVconsv prime (post-randomisation week 00) and MVA.HIVconsv boost (post randomisation week 08 day 1) vaccines; followed by a 28-day course of vorinostat (10 doses in total).
89329620|NCT02313272|Experimental|HFSRT with Pembrolizumab and Bevacizumab|Hypofractionated Stereotactic Irradiation (HFSRT). Pembrolizumab intravenous (IV) infusion every 3 weeks. Bevacizumab administered intravenously every 2 weeks.
89329621|NCT02303821|Experimental|Phase 1b: Dose Escalation 1|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising an R3 backbone of dexamethasone, mitoxantrone, PEG asparaginase, and vincristine.~Subjects will have a 1 week carfilzomib single agent Lead in Window prior to the Induction Cycle.~Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
89329622|NCT02303821|Experimental|Phase 1b: Dose Escalation 2|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising a VXLD backbone of vincristine, dexamethasone, PEG asparaginase, and daunorubicin.~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy and then have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
89329623|NCT02303821|Experimental|Phase 2: Aged ≥ 12 months at screening|"All subjects aged ≥ 12 months at screening.~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 4 week cycle of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine) if subjects showed no disease progression at the end of the Induction Cycle."
89329624|NCT02303821|Experimental|Phase 2: Aged < 12 months at screening|"All subjects aged < 12 months at screening.~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.~Subjects will receive a modified 5 week cycle (based on Interfant-06) of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 5 week cycle (modified based on Interfant-06) of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if subjects showed no disease progression at the end of the Induction Cycle."
89329625|NCT02254031|Experimental|bivatuzumab mertansine|dose escalation
89329626|NCT02254005|Experimental|single dose escalation|
89329627|NCT02231931|Experimental|A (Reference 1) Digoxin|1 tablet as single dose, fasted
89329628|NCT02231931|Experimental|B (Reference 2) Furosemide|oral solution, as single dose, fasted
89329629|NCT02231931|Experimental|C (Reference 3) Metformin hydrochloride|1 film-coated tablet as single dose, fasted
89329630|NCT02231931|Experimental|D (Reference 4) Rosuvastatin|1 film-coated tablet as single dose, fasted
89329631|NCT02231931|Experimental|E (Test) 1|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
89329632|NCT02231931|Experimental|F (Test 2)|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (2 film-coated tablets), Rosuvastatin (1 film-coated tablet), fasted
89329633|NCT02231931|Experimental|G (Test 3)|Digoxin (1 tablet), Furosemide (2.0 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
89329634|NCT02229825|Experimental|Duloxetine 60 mg|Duloxetine 60 mg
89329635|NCT02229825|Experimental|Duloxetine 120 mg|Duloxetine 120 mg
89329636|NCT02162823||Pancreatic cancer|Patients with pancreatic cancer and age&sex-matched controls without any cancer from a distinct population area (district of Stockholm). Patients with pancreatic cancer will be subjected to pancreatic surgery
89329637|NCT02078245||Familial pancreatic cancer patients|Individual with ten fold higher risk to develop pancreatic cancer.
89329638|NCT02057718|Experimental|LUM001 (Maralixibat)|Participants will receive LUM001, also known as Maralixibat (MRX) twice a day (BID).
89329639|NCT02024243||Venous leg ulcers|Patients visiting the Indiana University Health Comprehensive Wound Center, with a chronic venous leg ulcer(s), who qualify based on the study inclusion and exclusion criteria, will be involved in a 14-week (98 days) longitudinal observational study. All subjects in this arm will have wound measurements, photographs for digital planimetry to measure wound area, and two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) on days day 0, 14, and 28. Biopsies will not be taken if the wound has closed by day 14 or 28. Patient charts will be reviewed 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed.
89329640|NCT01920737|Experimental|Leukemia Patients|"The treatment plan has 6 treatment cycles. The cycle names are listed in the following order:~Induction Phase I - Induction Phase II - Intensification I - Re-induction I - Intensification II - Re-induction II Each cycle is given over a period of 4-6 weeks and the interval between them can range between 1-3 weeks. Based the patients medical condition, the doctor may decide to change the timing of the drugs, the interval between the drugs in a cycle, or the interval between the cycles. After receiving all cycles you will continue with a 36 months treatment part that is called Maintenance."
89329641|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
89329642|NCT01914406|Active Comparator|continuous moderate training|Continued exercise 45 min.
89329643|NCT01852890|Experimental|50g Ascorbate|"This arm is the initial starting dose. The first study participant will be assigned the 50g ascorbate arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 50 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
89329644|NCT01852890|Experimental|75g Ascorbate|"If the 50g arm is tolerated, the study opens the 75g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 75 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
89329645|NCT01852890|Experimental|100g Ascorbate|"If the 75g arm is tolerated, the study opens the 100g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 100 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
89329646|NCT01852890|Experimental|25g Ascorbate|"This study arm will only be used if participants cannot tolerate the 50g arm. If participants cannot tolerate 50 grams of Ascorbate, the 25g arm is opened.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 25 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
89329647|NCT01843413|Experimental|Treatment (SRS)|Patients undergo SRS guided by CT and MRI.
89329648|NCT01788774|Other|Risperidone ISM 50mg|Three different single doses will be evaluated
89329649|NCT01788774|Other|Risperidone ISM 75mg|Three different single doses will be evaluated
89329650|NCT01788774|Other|Risperidone ISM 100mg|Three different single doses will be evaluated
89329651|NCT01757730||Altered Stiffness|Tissue stiffness will be evaluated in subjects those with disease conditions where stiffness changes from normal. These studies will be repeated for reproducibility.
89329652|NCT01757730||Healthy Volunteers|Tissue stiffness will be evaluated in normal subjects to determine the normal values. These studies will be repeated for reproducibility.
89329653|NCT01755975|Experimental|Romidepsin and Lenalidomide|This will be a multicentered, open label, phase Ib/IIa trial of romidepsin and lenalidomide in patients with relapsed or refractory lymphomas or multiple myeloma. Lenalidomide will be provided in accordance with the Celgene Corporation's Revlimid REMS® program. Per standard Revlimid REMS® program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, and all research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS® program. Only enough lenalidomide for one cycle of therapy will be supplied to the patient each cycle.
89329654|NCT01752491|Experimental|15g Ascorbate|"During radiation therapy:~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.~Ascorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
89329655|NCT01752491|Experimental|25g Ascorbate|"If the 15g arm is tolerated, the study opens the 25g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
89329656|NCT01752491|Experimental|50g arm|"If the 25g arm is tolerated, the study opens the 50g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
89329657|NCT01752491|Experimental|62.5g|"If the 50g arm is tolerated, the study opens the 62.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
89329658|NCT01752491|Experimental|75g Ascorbate|"If the 62.5g arm is tolerated, the study opens the 75g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
89329659|NCT01752491|Experimental|87.5g Ascorbate|"If the 75g arm is tolerated, the study opens the 87.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
89329660|NCT01750281|Experimental|Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
89329661|NCT01750281|Experimental|Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 60 mg/m2 intravenously administered on day 1 of each 21 day cycle.
89329662|NCT01750281|Experimental|Placebo twice daily + Docetaxel 75 mg/m2|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
89329663|NCT01608152||Group I (focus group)|Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.
89329664|NCT01608152||Group II (access to the game)|Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.
89329665|NCT01494662|Active Comparator|Cohort 1|"Patients With Progressive Brain Metastases~Intervention: HKI-272 (Neratinib)340 mg orally, once daily."
89329666|NCT01494662|Active Comparator|Cohort 2|"Patients Who Are Candidates For Craniotomy.~Intervention: HKI-272 (Neratinib) 240 mg orally, once daily.~Surgical resection (biopsy).~Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib."
89329667|NCT01494662|Active Comparator|Cohort 3a/3b|"Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.~Cohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest."
89329668|NCT01494662|Active Comparator|Cohort 4a/4b/4c|"Cohort 4a will be made up of participants with previously untreated brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.~Cohort 4b will be made up of participants with progressive brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.~Cohort 4c will be made up of participants with progressive brain metastases and prior T-DM1. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks."
89329669|NCT01366833|Active Comparator|Self-expanding stent alone|All patients in Arm A will receive self-expanding stent alone
89329670|NCT01366833|Experimental|Brachytherapy and Stent therapy|
89329671|NCT01205061|Experimental|Emervel Deep Lidocaine|NLFs (Nasolabial Folds) were injected with Emervel Deep Lidocaine (20 mg/mL with 0.3% lidocaine).
89329672|NCT01205061|Active Comparator|Juvederm Ultra Plus|NLFs were injected with Juvéderm Ultra Plus (24 mg/mL).
89329673|NCT01180881||Proton Radiation Patients at MGH|Pediatric brain and central nervous system (CNS) tumor patients treated with proton beam radiation therapy
89329674|NCT01108237|Other|TruMatch™ Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch™ Personalized Solutions
89329675|NCT01108237|Other|Historical Control|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional and CAS surgical techniques without TruMatch™ instrumentation.
89329676|NCT00888459|Active Comparator|active|Self-help counseling material and 4 mg nicotine lozenges
89329677|NCT00888459|Placebo Comparator|2|self help counseling material and placebo nicotine lozenges
89523501|NCT03386149|Experimental|Experimental Group|In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
89329678|NCT00793884||Diabetes Education|Latino individuals with diabetes who are attending the Emory Latino Diabetes Education Program (ELDEP) will be followed in order to collect outcomes on clinical measurements. The class curriculum follows the American Association of Diabetes Educators (AADE) seven self-care behaviors: healthy eating, being active, monitoring, medication use, problem-solving and healthy coping. Program participants attend an initial 3 hour diabetes education class conducted in Spanish and then are invited to return to monthly follow-up sessions covering topics of meal planning, exercise, medications and complications. The follow-up sessions include activities such as dance lessons, cooking demonstrations, and sharing.
89329679|NCT00736450|Experimental|Arm I|See Detailed Description
89329680|NCT00611351|Experimental|Unrelated Donor Allogeneic|Matched unrelated donor allogeneic stem cell transplantation with a conditioning regimen of targeted busulfan, cyclophosphamide and thymoglobulin.
89329681|NCT00590993||1 - MRSI / MRI|
89329682|NCT00572936|Other|Latanoprost/Dorzolamide/Timolol|The participants received latanoprost at night and vehicle in the morning for two weeks, then 6 week washout, then Dorzolamide BID for two weeks, then 6 week washout, then Timolol BID for two weeks. The order in which the participants received the three different drugs was random.
89329683|NCT00571662|Experimental|Cohort I|Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day
89329684|NCT00436254|Experimental|Arm I|Patients receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months in the absence of disease progression or unacceptable toxicity.
89329685|NCT00310765|Active Comparator|Pregabalin 150 or 300 mg daily for severe abdominal pain from adhesions|Patients were randomly assigned to active drug 75-150 mg of pregabalin po BID for 7 weeks followed by a 1 week wash out phase and then were given 150 mg of pregabalin BID for an additional 4 weeks. Daily pain and sleep scores were reported by the patient throughout the study.
89329686|NCT00310765|Placebo Comparator|Look alike placebo 150 or 300 mg daily for severe abdominal pain from adhesions|Patients were randomly assigned to look alike placebo 75 or 150 mg po BID for 7 weeks followed by a 1 week wash out phase and then were given 150 mg of pregabalin BID for an additional 4 weeks. Daily pain and sleep scores were reported by the patient throughout the study.
89329687|NCT05548335|Other|Ocular Ultrasound|This arm includes all patients enrolled who will have an ocular ultrasound with two different probes for a total of four ultrasounds.
89329688|NCT05538520|Experimental|Traditional Pilates|"5 stretching exercises will be performed, followed by 15 strengthening exercises (5 for core, 5 for lower limbs and 5 for upper limbs), all in a series of 10 repetitions, 3x-week, for 8 weeks, maintaining an effort level 7-8 on the Omni-Scale. Below are the exercises and equipment used.~1) Stretching the Chain Posterior (Reformer); 2) Front Splits Modified (Reformer); 3) Stomach Massage (Reformer); 4) Stretches Front (Barrel); 5) Back Stretches: Quadriceps Stretch (Barrel); 6) Bridge (Mat with Magic Circle); 7) The Hundred (Mat with Swiss ball); 8) Teaser (Mini Barrel); 9) Swan (Mini Barrel); 10) Swimming (Mini Barrel); 11) Footwork Double Leg Pumps (Chair); 12) Pump One Leg Front (Chair); 13) Forward Lunge (Chair); 14) Wall Side (Wall with Swiss ball and dumbbells); 15) Tower (Cadillac); 16) Arms Pulling Up (Cadillac); 17) Rowing Front: Hug a Tree (Cadillac); 18) Arm Pulling Down (Wall Unit); 19) Horizontal Arm Pulling (Wall Unit); 20) Extension Arm Up (Wall Unit)."
89329689|NCT05538520|Experimental|Pilates without stretching|"15 strengthening exercises will be performed (the same performed by the TP group), all in a series of 10 repetitions, 3x-week, for 8 weeks, maintaining an effort level 7-8 on the Omni-Scale. Below are the exercises and equipment used.~1) Bridge (Mat with Magic Circle); 2) The Hundred (Mat with Swiss ball); 3) Teaser (Mini Barrel); 4) Swan (Mini Barrel); 5) Swimming (Mini Barrel); 6) Footwork Double Leg Pumps (Chair); 7) Pump One Leg Front (Chair); 8) Forward Lunge (Chair); 9) Wall Side (Wall with Swiss ball and dumbbells); 10) Tower (Cadillac); 11) Arms Pulling Up (Cadillac); 12) Rowing Front: Hug a Tree (Cadillac); 13) Arm Pulling Down (Wall Unit); 14) Horizontal Arm Pulling (Wall Unit); 15) Extension Arm Up (Wall Unit)."
89329690|NCT05534672|Experimental|Rapamycin arm|Each patient randomized to the rapamycin arm will receive rapamycin in liquid. The rapamycin will be administered in individually calculated doses depending on the body surface of participants
89329691|NCT05534672|Placebo Comparator|Placebo arm|The patients assigned to the placebo arm will receive placebo in liquid, analogically to the rapamycin group.
89329692|NCT05513573|Experimental|HLX07+HLX10+chemotherapy|
89329693|NCT05513573|Experimental|Placebo+HLX10+chemotherapy|
89329694|NCT05507424|Active Comparator|Prone Positioning During Delayed Cord Clamping|Newborns delivered between 25w+0d and 29w+6d gestation who have been randomized in 1:1 fashion to prone positioning during routine delayed cord clamping.
89329695|NCT05507424|Active Comparator|Supine Positioning During Delayed Cord Clamping|Newborns delivered between 25w+0d and 29w+6d gestation who have been randomized in 1:1 fashion to supine positioning during routine delayed cord clamping.
89329696|NCT05498675||Sacubitril/valsartan group|Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
89329697|NCT05498675||ACEI/ARB group|"Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
89329698|NCT05482126||Deep Brain Stimulation Surgery Patients|The investigators will seek to enroll people with Parkinson's disease (PD) who have been approved for deep brain stimulation surgery (DBS) as part of their routine clinical
89329699|NCT05482126||Healthy controls|The investigators will seek to enroll a cohort of age- and sex-matched healthy individuals to act as a control group. This group will NOT undergo DBS surgery
89329700|NCT05472363|Experimental|Non-Stroke Subjects|Subjects will receive up to 30 minutes of focal simulation with either TMS or tDCS administered to one brain location within standard safety protocols
89329701|NCT05472363|Experimental|Stroke Subjects|Subjects will receive up to 30 minutes of focal stimulation with either TMS or tDCS administered to one brain location within standard safety protocols
89329702|NCT05457218|Experimental|Whey protein|This arm will be given a supplemental dose of whey protein (0.25 g/kg body weight)
89329703|NCT05457218|Experimental|IPC80|This arm will be given a supplemental dose of IPC80, an insect-derived protein source (0.25 g/kg body weight)
89329704|NCT05457218|Experimental|Whole Buffalo Powder|This arm will be given a supplemental dose of Whole Buffalo Powder, an insect-derived protein source (0.25 g/kg body weight)
89329705|NCT05436327|Other|Geriatric Assessment (GA)|Clinical staff undergo training in GA and are provided with facilitation and support for one year as they implement GA among older adult patients (65+) considering chemotherapy and their care partners/caregivers.
89329706|NCT05431946||Palliative Care arm|"Intervention by Advance care planning (ACP) conversation:The goal is the identification, assessment, and treatment of physical, psychosocial, or spiritual symptoms and problems.~Advance care actions:These are the actions taken to fulfill the advance care plan and can include, but are not limited to:treatments: pharmacological, psychosocial (priest, psychologist, etc.) referrals: rehabilitation, specialized palliative care team, hospice, etc.~communication initiatives with relatives, primary care, public authorities"
89329707|NCT05431946||Non-participating arm|Will continue standard of care
89329708|NCT05428059|Experimental|application group|In addition to standard care, training and consultancy will be provided with a mobile application.
89329709|NCT05428059|No Intervention|control group|Standard care will be given
89329710|NCT05427279|Placebo Comparator|Placebo|This arm will be given a placebo (20g maltodextrin with 50mg vitamin C)
89329711|NCT05427279|Experimental|Hydrolized Collagen|This arm will be given Hydrolized Collagen (20g with 50mg vitamin C)
89329712|NCT05427279|Experimental|PrimaColl|This arm will be given PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
89329713|NCT05427279|Experimental|Whey Protein|This arm will be given whey protein (20g with 50mg vitamin C)
89329714|NCT05424770|Experimental|experiment group|During the 3 weeks in which the subjects related to pain control are explained, the standard lecture (explanation with ppt presentation) will be made as in the normal course of the course. Afterwards, puzzle activities prepared by the researcher will be implemented and students will be actively involved in the process.
89329715|NCT05424770|No Intervention|control group|During the 3 weeks in which the subjects related to pain control are explained, the standard lecture (explanation with ppt presentation) will be made as in the normal course of the course.
89329716|NCT05413070||Lowest Performing Practices|This is the group of 5 to 10 primary care practices that incurred the highest amount of low-value back pain imaging based on claims data reports. This group will receive the survey and the intervention (brief training sessions in existing quality improvement meetings, performance reports, etc.).
89329717|NCT05413070||Highest Performing Practices|This is the group of 5 primary care practices that incurred the lowest amount of low-value back pain imaging based on claims data reports. This group will only receive the survey.
89329718|NCT05411016|Placebo Comparator|Placebo|
89329719|NCT05411016|Experimental|KK4277|
89329720|NCT05390528|Experimental|Experimental Group(phase Ia)|Phase 1a uses accelerated titration design and Bayesian optimal interval (BOIN) design to investigate the safety of HLX301 and determine MTD.Six dose levels of 0.25 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 20mg/kg are planned for dose finding.
89329721|NCT05389098|Experimental|Experimental|eat-hands type food mode
89329722|NCT05389098|Active Comparator|Control|Usual food administration
89329723|NCT05388799|Experimental|application group|Before the operation, training will be given in line with the training brochure prepared by the researcher in the outpatient clinic and the printed version of the training brochure will be given to the patient. The training will be repeated by calling the patients the day before the surgery.
89329724|NCT05388799|No Intervention|control group|Standard care will be applied.
89329725|NCT05377372|Experimental|Breastfeeding Intervention Group|Ten mother-infant dyads will be recruited to a six-month, community-based intervention aimed to promote sustained breastfeeding for at least six months among mothers of infants with sickle cell disease. The intervention will include an online, social media-based support group, online educational modules, monthly in-person educational sessions, access to free breast pump rentals, and monthly peer-led home visits by certified Vanderbilt-affiliated Maternal Infant Health Outreach Specialists. We obtain whole blood specimens for analysis of oxidative stress and inflammation at 3, 6, 12 and 24 months.
89329726|NCT05377372|Other|Observation Group|A 24 month observation of 10 mother-infant dyads affected by sickle cell disease that initiate breastfeeding. These dyads will observed for breastfeeding exclusivity/dosage and duration. We obtain whole blood specimens for analysis of oxidative stress and inflammation at 3, 6, 12 and 24 months.
89329727|NCT05374057|Experimental|Chiropractic Spinal Manipulative Therapy (CSMT)|A specific contact, high-velocity, low-amplitude, spinal thrust manipulation directed to spinal biomechanical dysfunction in the cervical and/or thoracic spinal column, as diagnosed by standard chiropractic tests, in accordance with their clinical judgment.
89329728|NCT05374057|Sham Comparator|CSMT sham manipulation|A broad non-specific contact, low-velocity, low-amplitude sham push manoeuvre in a non-therapeutic directional line.
89329729|NCT05374057|Active Comparator|Ibuprofen|Ibuprofen 600mg, 3 times daily for 12 days.
89329730|NCT05374057|Sham Comparator|Placebo medication|Placebo medication, x 3 times daily for 12 days.
89329731|NCT05363189||No venons augmentation|Retrospective group of patients who have not received venous augmentation during their operation.
89329732|NCT05363189||Venous augmentation|Retrospective group of patients who have received venous augmentation during their operation.
89329733|NCT05363189||ERAS protocol|Retrospective group operated according to the traditional ERAS (enhanced recovery after surgery) protocol
89329734|NCT05363189||Sahlgrenska recovery protocol|Prospective group operated according to the Sahlgrenska recovery protocol.
89329735|NCT05360381|Experimental|Phase 1a dose-escalation stage|"Phase 1a uses the 3+3 design, to investigate the safety and determine the MTD of HLX35. Seven dose levels of 0.015 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg are planned for dose finding. Enrollment will continue until a maximum of 42 patients are enrolled"
89329736|NCT05360381|Experimental|Phase 1b dose-expansion stage|Patients with sqNSCLC (EGFR H score≥200) will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX35. Phase 1b dose expansion will include 15-20 per-protocol treated patients, as defined above, in each of the two expansion cohorts.
89329737|NCT05352516|Experimental|Treatment group|
89329738|NCT05352516|Active Comparator|Control group|
89329739|NCT05345613|Experimental|Tranexamic Acid group|standard solution for injection with TXA and without adrenaline
89329740|NCT05345613|Placebo Comparator|Standard therapy group|standard solution for injection including adrenaline
89329741|NCT05341661|Active Comparator|Active|The active arm patients undergo the Butterfly device procedure.
89329742|NCT05341661|Sham Comparator|Sham Comparator|The sham control arm patients undergo a rigid cystoscopy procedure.
89329743|NCT05341661|Other|Cross over|Sham arm patient is allowed to crossover and undergo the Butterfly procedure
89329744|NCT05338905|Experimental|Group A (quality of life questionnaire)|Patients complete a quality of life questionnaires over 10-15 minutes BIW during standard of care radiation therapy and QW for the first month after completing standard of care radiation therapy course, and then once monthly for 6 months.
89329745|NCT05338905|Active Comparator|Group B (standard symptom management)|Patients receive standard symptom management QW during standard of care radiation therapy and for 6 months after completing radiation therapy course.
89329746|NCT05336500|Experimental|Pilates method exercises associated with education to keep the abdomen relaxed|The group will receive guidance to perform the exercises in a relaxed and smooth way
89329747|NCT05336500|Active Comparator|Pilates method exercises associated with education to keep the abdomen contracted|The group will receive guidance on the specific activation of the center of strength (the powerhouse)
89329748|NCT05330520|Experimental|Patients Who Completed 12 Months of Follow-Up Post Butterfly Implantation|Continuation study for Study BM-011-IL
89329749|NCT05324566||Patients with ECG-capable Apple Watch|Patients who own an Apple Watch series 4 or later willing to record and upload personal ECGs to our study App
89329750|NCT05296031|Active Comparator|Drug Eluting Stent (DES)|Drug Eluting Stent (DES). Zilver PTX.
89329751|NCT05296031|Placebo Comparator|Bare Metal Stent (BMS)|Bare Metal Stent (BMS). Zilver Flex
89329752|NCT05258071|Experimental|Pirepemat dose 1|Pirepemat tablets, dose 1 (mg), 2 tablets t.i.d. for 84 days.
89329753|NCT05258071|Experimental|Pirepemat dose 2|Pirepemat tablets, dose 2 (mg), 2 tablets t.i.d. for 84 days.
89329754|NCT05258071|Placebo Comparator|Placebo|Placebo tablets, 2 tablets t.i.d. for 84 days.
89329755|NCT05251558|Experimental|Telerehabilitation (TR)|Self PNF exercises determined for facial muscles (M. Frontalis, M. Orbicularis Oculi, M. Orbicularis Oris, M. Risorius etc.) will be applied.
89329756|NCT05251558|Active Comparator|Conventional Education Program (CEP)|Education will be given to cases with Bell's Palsy. Some exercises will be suggested in front of the mirror. Patients will be advised to gently massage upwards with their fingertips after applying a warm towel with a towel on the facial muscles.
89329757|NCT05240976|Experimental|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
89329758|NCT05240976|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
89329759|NCT05240352|Experimental|active tDCS|
89329760|NCT05240352|Sham Comparator|sham tDCS|
89329761|NCT05222516|Experimental|OM-85|Daily administration of OM-85 (Broncho-Vaxom) 3.5 mg capsules
89329762|NCT05222516|Placebo Comparator|Placebo|Daily administration of Placebo capsules
89329763|NCT05222100||Women without breast implants|Women without breast implants participating in the mammography screening program.
89329764|NCT05222100||Women with breast implants|Women with breast implants participating in the mammography screening program.
89329765|NCT05194930|Experimental|The ABC of Insomnia (Acceptance and the Behavioral Changes to|This is the new treatment arm that is being compared to CBT-I, standard treatment for insomnia.
89329766|NCT05194930|Active Comparator|Cognitive-Behavioral Therapy for Insomnia|This is the standard treatment for insomnia that is being compared to the new treatment (ABCI).
89329767|NCT05166954||LSG group|Laparoscopic sleeve gastrectomy (LSG) performed as a treatment for obesity
89329768|NCT05166954||RYGB group|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity
89329769|NCT05156580||Obese hypertensive group|Patients who were diagnosed with obesity (body mass index (BMI)≥28kg/m2) and hypertension (systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥ 140/90 mmHg).
89329770|NCT05156580||Overweight hypertensive group|Overweight patients (24 kg/m2≤BMI≤28 kg/m2) diagnosed with hypertension (SBP/DBP≥140/90 mmHg).
89329771|NCT05156580||Lean hypertensive group|Lean patients (BMI ≤ 24 kg/m2) diagnosed with hypertension (SBP/DBP ≥ 140/90 mmHg).
89329772|NCT05144997|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
89329773|NCT05139043|Active Comparator|Arm I (standard dose dexamethasone)|Patients receive standard dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive standard dose dexamethasone IV before and after the surgery. Patients receive standard dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.
89329774|NCT05139043|Experimental|Arm II (lower dose dexamethasone)|Patients receive lower dose dexamethasone PO q 12 h for 3 days. On the day of surgery, patients receive lower dose dexamethasone IV before and after the surgery. Patients receive lower dose dexamethasone IV q 12 h on days 1-3 post surgery and tapered dexamethasone PO q 12 h on days 4-14 in the absence of disease progression or unacceptable toxicity. Additional doses of dexamethasone are given if needed.
89329775|NCT05102214|Experimental|Phase 1a dose-escalation stage|Phase 1a uses the Bayesian optimal interval (BOIN) design, to investigate the safety and determine the MTD of HLX301. Six dose levels of 0.25 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 15 mg/kg are planned for dose finding. Intra-patient dose escalation is not permitted. Enrollment will continue until a maximum of 30 patients are enrolled.
89329776|NCT05102214|Experimental|Phase 1b dose-expansion stage|Patients with NSCLC will be enrolled in two expansion cohorts, at doses equal to or lower than the MTD, to better characterize the safety, tolerability, PK variability, and preliminary efficacy of single-agent HLX301. Phase 1b dose expansion will include 20 per-protocol treated patients, as defined above, in each of the two expansion cohorts.
89329777|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort A|20 per-protocol treated patients with non-small cell lung cancer (NSCLC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
89329778|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort B|20 per-protocol treated patients with gastric/esophagogastric junction adenocarcinoma (GC/EGJ), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
89329779|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort C|20 per-protocol treated patients with head and neck squamous cell carcinoma (HNSCC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
89329780|NCT05102214|Experimental|Phase 2 clinical expansion stage: Cohort D|20 per-protocol treated patients with urothelial carcinoma (UC), with PD-L1 expression, progression after one or two prior systemic anti-tumor regimens, and who have failed or are intolerant to standard therapy, or for whom no standard therapy is available, will be enrolled and treated in phase 2 at RP2D.
89329781|NCT05097651|Experimental|CBD|Participants will receive oral liquid cannabidiol
89329782|NCT05097651|Placebo Comparator|Placebo|Participants will receive an inert oral liquid
89329783|NCT05093153||Waldenström's macroglobulinemia cohort patient|Adult patients diagnosed with Waldenström's Macroglobulinemia
89329784|NCT05092815|Experimental|HLX208|Participants receive HLX208 450mg bid po
89329785|NCT05078099|Experimental|Study arm - Binocular CureSight|Using binocular treatment device 90 min a day 5 times a week for 12 weeks following by 90 min a day 3 times a week for additional 12 weeks
89329786|NCT05074693|Experimental|EASE App|EASE is a intervention designed to address anxiety and depression symptoms in its users through the use of educational videos, tailored messages, and interoceptive exercises designed to help the user overcome negative feelings of stress.
89329787|NCT05074693|Other|INSIGHT (Control) APP|The Insight app provides users with educational videos on mindfulness and meditation techniques.
89329788|NCT05049421||Patients following CABG|Recruitment amongst patients enrolled in SWEDEGRAFT RCT at Aarhus University Hospital scheduled for follow-up
89329789|NCT05041868|Experimental|Study group|The program comprises the practice of warm-up, muscle strengthening with free weights and with their own body weight against the action of gravity for the main muscular groups, balance control training, aerobic training, and relaxation exercises. The proposal consists of 3 weekly sessions, for 12 consecutive weeks.
89329790|NCT05038904|Experimental|Acalabrutinib|Participants will be given acalabrutinib (four doses of 100 mg of acalabrutinib to be taken orally twice daily).
89329791|NCT05026853|Experimental|PRO Integration into Clinical Practice|PRO scores will be shared with patients and healthcare providers (HCPs) via an emailed report card
89329792|NCT05026853|No Intervention|Usual Care|Patients and HCPs will not receive an emailed PROMIS score report. PROMIS scores, however, will be available in the EMR as usual.
89329793|NCT05000034|Experimental|Patients|
89329794|NCT04996251|Experimental|subcutaneous infiltration pre-incision|Marcaine (bupivacaine) injected in the umbilical port site subcutaneously, while in the other 4 sites injection under direct visualization
89329795|NCT04996251|Experimental|subcutaneous infiltration post-incision|local anesthetic infiltrated subcutaneously at the end of the procedure after trocar removal and after skin closure with suture
89329796|NCT04989868|Experimental|Trans-Nasal Afferent Loop Decompression Arm|Patients will receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.
89329797|NCT04989868|Active Comparator|No Trans-Nasal Afferent Loop Decompression Arm|Patients will NOT receive trans-nasal afferent loop decompression after pancreaticoduodenectomy.
89329798|NCT04976387|Experimental|Group 1: Hydrocodone/Acetaminophen and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
89329799|NCT04976387|Experimental|Group 2: Ibuprofen and Hydrocodone/acetaminophen|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
89329800|NCT04976387|Experimental|Group 3: Ibuprofen and Acetaminophen|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control~If pain is not controlled after 60 minutes then can take Acetaminophen 650mg every 6 hours as needed for additional pain control."
89329801|NCT04969107|Active Comparator|transanal TME (taTME)|patients with rectal cancer receiving transanal TME
89329802|NCT04969107|Active Comparator|abdominal TME (abTME)|patients with rectal cancer receiving open, laparoscopic or robotic TME
89329803|NCT04951336|Experimental|Mushrooms|Drug: FoTv The dosage of FoTv is 8 capsules three times a day for 4 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary. Should swallowing capsules be an issue, they can be opened and dispensed into water or juice for easy ingestion.
89523502|NCT03386149|Active Comparator|Control Group|In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
89329804|NCT04951336|Placebo Comparator|Placebo|Placebo: organic brown rice The dosage of Placebo is 8 capsules three times a day for 4 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary. Should swallowing capsules be an issue, they can be opened and dispensed into water or juice for easy ingestion.
89329805|NCT04941872|Experimental|68Ga-DOTA-2P(FAPI)2 PET/CT|Each subject receive a single intravenous injection of and 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
89329806|NCT04939415|Experimental|modified Qing Fei Pei Du Tang|encapsulated modified Qing Fei Pai Du Tang
89329807|NCT04939415|Placebo Comparator|Placebo|Organic brown rice
89329808|NCT04926766|Experimental|SHF-WBI|Patients with an indication for whole breast irradiation will receive 5.2 Gy in 5 fractions to whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
89329809|NCT04917302|Experimental|NMDAE plus Anti-inflammatory Agent (AIFA)|An NMDA enhancer plus a drug with anti-inflammatory property
89329810|NCT04917302|Placebo Comparator|NMDAE plus Placebo|An NMDA enhancer plus Placebo
89329811|NCT04915755|Experimental|Cohort1:Participants with tBRCAmut HER2-breast cancer(Independent of HR status,including HR+andTNBC)|Eligible participants will receive either Niraparib or Placebo.
89329812|NCT04915755|Experimental|Cohort 2: Participants with tBRCAwt TNBC|Eligible participants will receive either Niraparib or Placebo.
89329813|NCT04897321|Other|Treatment Phase|During the treatment phase, the participant receives an infusion of the B7-H3-CAR T cells that were made in the Collection and Manufacturing Phase. Chemotherapy is given for several days prior to the cellular infusion. Patients are then monitored for possible side effects, as well as effects of the treatment on their cancer.
89329814|NCT04879823|Experimental|Dexamethasone|"IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup.~Patients will also receive acetaminophen and ibuprofen. Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days.~Patients and parents/caregivers will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. Families will also be asked daily to check symptoms that were experienced by the child and their child's current comfortable diet. The diary will be completed by post-operative day 14. The diary will be returned via email, mail, or a post-operative appointment at the main hospital."
89329815|NCT04879823|Placebo Comparator|Placebo|"An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.~Patients will also receive acetaminophen and ibuprofen. Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days.~Patients and parents/caregivers will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. Families will also be asked daily to check symptoms that were experienced by the child and their child's current comfortable diet. The diary will be completed by post-operative day 14. The diary will be returned via email, mail, or a post-operative appointment at the main hospital."
89329816|NCT04879524||Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|100 units of Botulinum toxin type A (Botox, Allergan, Ireland) injection into the puborectalis muscle to each side of the midline, achieving a total of 200 units
89329817|NCT04872413|Experimental|Screening (biospecimen collection)|Patients undergo blood, saliva or tissue sample collection for mRNA analysis and drug efficacy testing. Patients assigned treatment per the results are followed every 1 cycle of therapy for 1 year, every 2 months for 1 year, every 4 months for 1 year then every 6 months thereafter.
89329818|NCT04864522|Experimental|SLAMF7 FPBMC|Participants will undergo apheresis to collect cells to make SLAMF7 fresh peripheral blood mononuclear cells (FPBMC). These cells will be activated in the lab to fight against multiple myeloma. About 3-4 days after apheresis, participants will start receiving infusions of SLAMF7 FPBMC. Throughout treatment, participants will have blood taken for labs, to check disease status and also to look at immune response. Study treatment will stop if the participant has disease progression.
89329819|NCT04844918|Experimental|Tirzepatide Regimen A|Tirzepatide Regimen A administered subcutaneously (SC)
89329820|NCT04844918|Experimental|Tirzepatide Regimen B|Tirzepatide Regimen B administered subcutaneously (SC)
89329821|NCT04844918|Placebo Comparator|Placebo|Placebo administered SC
89329822|NCT04835493|Experimental|Intervention|Intervention individuals will receive the 12-month diabetes TIME program
89329823|NCT04835493|Other|Enhanced Usual Care (EUC)|We will define EUC as usual clinical care, which consists of diabetes management provider encounters (mean quarterly) plus monthly individual appointments with a pharm-Ds or nutritionists as clinically indicated. In addition, clinics offer multiple other individual and group opportunities. In addition for the EUC arm, we will provide three quarterly, 1-hour classes (nutrition medications, exercise). The classes will be led by a research-staff trained, bilingual healthcare professional e.g., nurse. EUC individuals will not have contact with CHWs.
89329824|NCT04826354|Experimental|Rosuvastatin|Rosuvastatin 20mg
89329825|NCT04826354|Active Comparator|Rosuvamibe|Rosuvastatin plus ezetimibe 10/5
89523503|NCT03301441||Migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine (Classification into migraine without or with aura)
89329826|NCT04805502|Experimental|Aerobic Exercise (AE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The AE group will exercise on aerobic machines (i.e. treadmill, elliptical, bicycle) for all of their sessions."
89329827|NCT04805502|Experimental|Resistance Exercise (RE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The RE group will perform 12-15 repetitions of 10-12 resistance exercises in a circuit, for 3 sets with rest period of 30-60 seconds between sets as needed.[100] Seated isokinetic exercise using Cybex machines will target all major muscle groups. Light dumbbells and resistance bands will be used if the participant is unable to lift the minimal load on Cybex machines. Core exercises will be performed at the end of the session (i.e. seated side bends)."
89329828|NCT04805502|Experimental|Combination Exercise (AERE)|"All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.~The AERE group will switch between AE exercise and RE; for this group, RE exercises will consist of 1 set of 12-15 repetitions of 4 resistance exercises, then 5 minutes of AE, then repeated repeat with different exercises.[106-108] The investigators will also calculate the metabolic minutes per week (METmin/wk) of all participants in order to account for potential differences in energy expenditure based on activity, though the dose of 150 min/wk at moderate intensity is held constant between exercise groups."
89329829|NCT04805502|No Intervention|Control (no exercise)|The Control group will participate in weekly sessions that focus on stretching, breathing, and healthy lifestyle.
89329830|NCT04785690|Experimental|CureSight|eye-tracking-based
89329831|NCT04785690|Active Comparator|Patching|occlusive deprivation
89329832|NCT04781998|Experimental|liraglutide 3 mg (Saxenda®) once-daily|
89329833|NCT04770610|Experimental|OT-101 alone|Atropine Sulfate 0.01% Ophthalmic Solution through year 4
89329834|NCT04770610|Experimental|OT-101 plus vehicle|Atropine Sulfate 0.01% Ophthalmic Solution through year 3 followed by vehicle for 1 year
89329835|NCT04770610|Placebo Comparator|Vehicle|Vehicle (Investigational Product minus active ingredient) through year 4
89329836|NCT04745143|Experimental|NMDAE|An NMDA enhancer
89329837|NCT04745143|Placebo Comparator|Placebo|Placebo
89329838|NCT04708613||Former Professional Football Players|Former professional football players who played in at least 3 professional seasons, with at least 3 games each season.
89329839|NCT04708613||Control Groups|Friends and brothers of the Former Professional Football Player group.
89329840|NCT04698785|Experimental|Regorafenib and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib and best supportive care followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
89329841|NCT04698785|Placebo Comparator|Placebo and best supportive care|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo and best supportive care followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
89329842|NCT04694820|Experimental|Text message intervention|Six month text message intervention
89329843|NCT04673825|Experimental|Intervention: patient initiated care + telemonitoring|Patients in the intervention group will only have a scheduled outpatient visit at baseline and after 1 year. Patients will answer questionnaires and have routine blood tests done before every visit. At 6 months, there will be a remote monitoring check-up and results will be checked by the physician. If indicated, a telephone or video call can take place or a physical visit can be planned. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
89329844|NCT04673825|No Intervention|Control group|The standard care group will have a scheduled outpatient visit at baseline and after 1 year, and in between as usual, scheduled at the discretion of the treating rheumatologist. Prior to each visit, patients complete questionnaires in SpA-Net and have routine blood tests done. Patients from either arm will be instructed that at any time, they may contact the rheumatology department and extra visits can be scheduled. During the COVID-pandemic, outpatient visits may also take place through telephone or video calls.
89329845|NCT04667247|Experimental|Mushrooms|Fomitopsis officinalis and Trametes versicolor
89329846|NCT04667247|Placebo Comparator|Placebo|Organic brown rice
89329847|NCT04664738|Experimental|10 % PEP only|Cohort 1: Subjects will receive 10% PEP to the skin graft donor wound.
89329848|NCT04664738|Experimental|20% PEP only|Cohort 2: Subjects will receive 20% PEP to the skin graft donor wound
89329849|NCT04664738|Experimental|20% PEP and TISSEEL|Cohort 3: Subjects will receive 20% PEP and TISSEEL to the skin graft donor wound.
89329850|NCT04635345|Experimental|Vibrator Therapy + dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel) plus an external vibrator.
89329851|NCT04635345|Active Comparator|Dilator/standard therapy|Patient will receive standard therapy (initial appointment, referral for womens health physiotherapy or psychosexual counselling as standard, together with vadinal dilators and lidocaine gel).
89329852|NCT04601402|Experimental|GEN-001 with avelumab|"Dose Escalation Cohort includes patients with advanced or metastatic solid tumors who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination) will be enrolled. 3 or 6 patients will be enrolled per escalating or de-escalating dose levels.~Dose Expansion Cohort includes patients with advanced or metastatic NSCLC, SCCHN, and UC who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)will be enrolled."
89329853|NCT04551287||Training dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Artificial Intelligence Cervical Cancer Screening (AICS).
89329854|NCT04551287||SYSMH internal validation dataset|11,468 eligible individuals' slides for the cervical cytology screening collected from the Sun Yat-sen Memorial Hospital (SYSMH, Guangzhou, China) between January 2016 and January 2020, were randomly assigned to the training dataset (n = 9,316) and the internal validation dataset (n = 2,152) in order to train and validate the Artificial Intelligence Cervical Cancer Screening (AICS).
89329855|NCT04551287||TAHGMU external validation dataset|600 slides from 600 eligible individuals were obtained in the Third Affiliated Hospital of Guangzhou Medical University (TAHGMU, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Artificial Intelligence Cervical Cancer Screening (AICS).
89329856|NCT04551287||GWCMC external validation dataset|600 slides from 600 eligible individuals were obtained in Guangzhou Women and Children Medical Center (GWCMC, Guangzhou, China) between January 2016 and January 2020, which was used to validate the Artificial Intelligence Cervical Cancer Screening (AICS).
89329857|NCT04551287||Prospective validation dataset|A prospective validation dataset was conducted to distinguish the diagnostic performance of the cytopathologists, AICS, and AICS-assisted cytopathologists, in which 2,780 eligible slides from 2,780 individuals were obtained and prospectively labeled between August 28, 2020 and October 16, 2020 at SYSMH.
89329858|NCT04551287||Randomized controlled trial|A prospective randomized controlled trial was conducted to compare the performance of the cytopathologists, AICS, and AICS-assisted cytopathologists in SYSMH. Here, 618 slides were collected between August 13, 2020, and December 14, 2020, to build the SYSMH randomized controlled trial. The remaining 608 slides after quality control were randomly assigned (1:1:1) to the AICS group (n = 201), the cytopathologists group (n = 203), and the AICS-assisted cytopathologists group (n = 204).
89329859|NCT04545710|Experimental|Single Arm, POC|"Single arm, POC Safety and Efficacy~Osimertinib 80 mg QD Abemaciclib 150mg BID"
89329860|NCT04533581|Experimental|ME-401|
89329861|NCT04530981|Experimental|Repaglinide 0.5 mg + Ripretinib 150 mg QD|A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.
89329862|NCT04526561|Active Comparator|Breast reconstruction TDAP|Breast reconstruction performed with TDAP
89329863|NCT04526561|Active Comparator|Breast reconstruction latissimus dorsi|Breast reconstruction performed with latissimus dorsi
89329864|NCT04526561|Active Comparator|Breast reconstruction with DIEP|Breast reconstruction performed with a deep inferior epigastric artery perforator flap
89329865|NCT04520178|Active Comparator|Low-dose 5HTP|50mg 5-HTP in combination with 50mg carbidopa
89329866|NCT04520178|Active Comparator|High-dose 5HTP|100mg 5-HTP in combination with 50mg carbidopa
89329867|NCT04520178|Sham Comparator|Carbidopa|50mg carbidopa only
89329868|NCT04520178|Placebo Comparator|Placebo|Placebo comparator
89329869|NCT04516434|Experimental|Intraurethral Electrical Stimulation|"This procedure is specific to the urethral stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the urethra and positioned with the electrode contact 10-14 mm from the bladder neck to stimulate the proximal urethra. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be 2-20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to the proximal urethra at strong desire to void during cystometry. The participant will then be given permission to void at maximum cystometric capacity with continuous intraurethral stimulation."
89329870|NCT04516434|Experimental|Intravesical Electrical Stimulation|This procedure is specific to the bladder stimulation arm. A sterile stimulation catheter (custom, 7-French) will be placed in the bladder through the urethra and the electrode contacts will be positioned to be floating within the bladder. A single return electrode will also be placed on the abdominal skin above the pubic bone. Stimuli will be delivered as 0.2 ms charge-balanced biphasic rectangular current pulses. Stimulation frequency will be set at 20 Hz and amplitude will be adjusted individually to 80% of the maximum tolerable intensity. Electrical stimulation will be applied to bladder sensory nerves for up to 60 minutes prior to the start of urodynamic studies.
89329871|NCT04511988|Experimental|Experimental|blood sample (20 ml) and biopsy
89329872|NCT04501874|Active Comparator|EMB-001 Active|EMB-001 Combination product of 720 mg metyrapone/24 mg oxazepam mg by mouth twice per day for 12 weeks followed by a 1 week taper
89329873|NCT04501874|Placebo Comparator|EMB-001 Placebo|EMB-001 Placebo by mouth twice per day for 12 weeks followed by a 1 week taper
89329874|NCT04500769|Experimental|Acute Resistance Exercise|Participants will perform four exercises: squat, knee extension, leg press, and lat pulldown at 80% of 1-RM determined during a previous visit.
89329875|NCT04487262|Active Comparator|Day O chest tube removal|"Chest tubes maybe removed ten hours after arrival at the intensive care provided standardized removal criteria are fulfilled:~blood loss through chest tubes less than 200 ml during the last four hours~no air leak~the patient extubated and mobilized It remains at the discretion of the attending cardiac surgeon to postpone chest tube removal in cases of increased bleeding risk, due to circumstances which develop during the perioperative period"
89329876|NCT04487262|Active Comparator|Day 1 chest tube removal|"Chest tubes are removed in the early morning of the first postoperative day, provided standardized removal criteria are fulfilled:~blood loss through chest tubes less than 200 ml during the last four hours~no air leak~the patient extubated and mobilized It remains at the discretion of both the attending surgeon and anestesiologist to remove chest tubes prematurely in cases of drain-induced, severe analgetic resistant, intractable pain resistant to analgetic treatment."
89329877|NCT04470037|Experimental|DAAOI-P|DAAOI-P 250-1500mg
89329878|NCT04470037|Placebo Comparator|Starch pill|
89329879|NCT04446377|Experimental|LAM-002A|LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days
89329880|NCT04446377|Placebo Comparator|Placebo|(microcrystalline cellulose) in 5 capsules BID for 10 days
89329881|NCT04440761||Troponin rise/ diagnosis of MINOCA|This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients diagnosed with MINOCA among all patients with coronary artery disease.
89329882|NCT04420221|Experimental|Half dose non-adj Group 1a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1.
89329883|NCT04420221|Placebo Comparator|Placebo Group 1b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
89329884|NCT04420221|Experimental|Full dose non-adj Group 2a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1
89329885|NCT04420221|Placebo Comparator|Placebo Group 2b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
89329886|NCT04420221|Experimental|Half dose adj Group 3a|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1.
89329887|NCT04420221|Placebo Comparator|Placebo Group 3b|Subjects aged 18 to 50 at the time of first vaccination who receive 1 dose of placebo (saline) at Day 1.
89329888|NCT04420221|Experimental|Full dose adj Group 4a|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61)
89329889|NCT04420221|Placebo Comparator|Placebo Group 4b|Subjects aged 18 to 50 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
89329890|NCT04420221|Experimental|Vaccine Group 5a|Subjects aged 18 to 64 at the time of first vaccination who receive a series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61).
89329891|NCT04420221|Placebo Comparator|Placebo Group 5b|Subjects aged 18 to 64 at the time of first vaccination who receive a series of 2 doses of placebo (saline) given approximately 2 months apart (Days 1 and 61).
89329892|NCT04418427|Experimental|1|6E11 vg/eye ADVM-022 +/- aflibercept 2mg IVT
89329893|NCT04418427|Experimental|2|2E11 vg/eye ADVM022 +/- aflibercept 2mg IVT
89329894|NCT04418427|Active Comparator|3|Aflibercept 2mg IVT
89329895|NCT04416165|Experimental|Experimental: 68Ga-DOTA-FAPI-04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
89329896|NCT04398368|Experimental|Prevention (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride intravesically for at least 1 hour at the time of RNU.
89329897|NCT04383210|Experimental|Cohort 1|"A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
89329898|NCT04383210|Experimental|Cohort 2|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
89329899|NCT04383210|Experimental|Cohort 3|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
89329900|NCT04380363|Experimental|Honda Walk Assist (HWA) Group|Participants utilize HWA device at home for 2 months according to prescribed settings.
89329901|NCT04380363|Active Comparator|Control Group|Participants complete prescribed exercise program at the Shirley Ryan AbilityLab gym for 2 months.
89329902|NCT04378959|Experimental|Lidocaine patch first|This group will receive up to 3 lidocaine patches for 4 weeks, followed by placebo patches after a 1-3 week washout period.
89329903|NCT04378959|Placebo Comparator|Placebo patch first|This group will receive up to 3 placebo patches for 4 weeks, followed by lidocaine patches after a 1-3 week washout period.
89329904|NCT04364087||Infertile PCOS women|All Vietnamese, infertile women, diagnosed with PCOS according to the Rotterdam criteria (2003) at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study.
89329905|NCT04359446|Other|Stent under-expansion with NC Balloon|
89329906|NCT04359446|Other|Stent under-expansion with Laser Excimer + NC Balloon|
89329907|NCT04347213||omnivors|Participants who habitually consume all food groups in their diet.
89329908|NCT04347213||vegetarian|Participants who habitually avoid meat in their diet.
89329909|NCT04347213||vegan|Participants who habitually avoid all animal source food in their diet.
89329910|NCT04347213||low-carbohydrate high-fat diet|Participants who habitually avoid carbohydrate in their diet.
89329911|NCT04320368||Alzheimer's disease cohort|"Aged 40-100 years old (≥ 40 years old, ≤ 100 years old).~Diagnosed with AD according to Alzheimer disease diagnostic criteria following NINCDS-ADRDA 1984 or NIA-AA 2011 guideline.~Had adequate hearing, vision and comprehension and verbal expression to complete the cognitive assessments.~Had at least 3 years of education.~Signed informed consent."
89329912|NCT04320368||Post-stroke cognitive observation cohort|"Aged 40-100-years old (≥ 40 years old, ≤ 100 years old).~Cerebral infarction is diagnosed according to World Health Organization diagnostic criteria and was the first symptomatic onset.~The time from onset to enrollment was less than 7 days.~Had adequate hearing, vision and comprehension and verbal expression to complete the cognitive assessments.~Had at least 3 years of education.~Signed informed consent."
89329913|NCT04320368||A cohort of people with normal cognitive function|"Aged 40-100 years old (≥ 40 years old, ≤ 100 years old).~The patients are cognitively normal and able to live and work independently~Had adequate hearing, vision and comprehension and verbal expression to complete the cognitive assessments.~Had at least 3 years of education.~Signed informed consent."
89329914|NCT04310930|Active Comparator|Intensive Therapy A|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin AND clofazimine.
89329915|NCT04310930|Experimental|Intensive Therapy B|Following Randomisation 1, Participants will receive inhaled amikacin (IA), IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin AND clofazimine.
89329916|NCT04310930|Experimental|Intensive Therapy C|Following Randomisation 1, Participants will receive intensive drug therapy in the form of IV amikacin, IV tigecycline, IV cefoxitin/imipenem + oral azithromycin/oral clarithromycin.
89329917|NCT04310930|Active Comparator|Consolidation A|Oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
89329918|NCT04310930|Experimental|Consolidation B|Inhaled amikacin (IA), oral clofazimine + oral azithromycin/oral clarithromycin in combination with one to three of the following oral antibiotics: oral linezolid, oral co-trimoxazole, oral doxycycline, oral moxifloxacin, oral bedaquiline (adults only), oral rifabutin.
89329919|NCT04297995|Experimental|Part 1: HLX10 Plus HLX07 (stage 1L)|3 mg/kg of HLX10 every two weeks infusion combined with 600 mg HLX07 weekly
89329920|NCT04297995|Experimental|Part 1: HLX10 Plus HLX07 (Stage 1H)|3 mg/kg of HLX10 every two weeks infusion combined with 800 mg HLX07 weekly
89329921|NCT04297995|Experimental|Part 2: HLX10 Plus HLX07 Plus Chemotherapy|HLX10 (300 mg) Plus HLX07 (1000 mg) Plus Cisplatin (100 mg/m2) Plus 5-FU (1000 mg/m2/day, 1-4 days). Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles of chemotherapy.
89329922|NCT04297995|Placebo Comparator|Part 2: HLX10 Plus HLX07 Placebo Plus Chemotherapy|HLX10 (300 mg) Plus HLX07 Placebo (1000 mg) Plus Cisplatin (100 mg/m2) Plus 5-FU (1000 mg/m2/day, 1-4 days). Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles of chemotherapy.
89329923|NCT04292405||Heart Failure Patients|Simultaneous recordings of cardiac acoustic biomarkers (CABs) by the Wearable Cardioverter Defibrillator and the AUDICOR AM
89329924|NCT04292275|Experimental|Digital Health Tools + Standard of Care|
89329925|NCT04292275|Other|Standard of Care|
89329926|NCT04275297|Experimental|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
89329927|NCT04275297|Placebo Comparator|Attention Control|The attention control condition consists of 8 weekly telephone calls with a study interventionist. Sessions will occur via scheduled telephone calls and follow a structured procedure. Telephone calls are designed to monitor symptoms and overall wellness. Each week, participants will be asked about current symptoms, flare patterns, and physical and emotional wellbeing.
89329928|NCT04247282|Experimental|Arm A, Cohort 1 Bintrafusp Alfa (M7824) (Days 1, 15)|M7824 (Days 1, 15)
89329929|NCT04247282|Experimental|Arm B, Cohort 1 M7824 + TriAd Vaccine (ETBX-011, ETBX-051 & ETBX-061) (Day 1)|M7824 + TriAd vaccine (ETBX-011, ETBX-051 and ETBX-061) (Days 1)
89329930|NCT04247282|Experimental|Arm C, Cohort 1 M7824 + TriAd Vaccine (Day 1) + N-803 (Day 1)|M7824 + TriAd vaccine (Day 1) + N-803 (Day 1)
89329931|NCT04224688|Experimental|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
89329932|NCT04224688|Placebo Comparator|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
89329933|NCT04204122|Experimental|Arm 1: Eye treated with Vigamox|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
89329934|NCT04204122|Placebo Comparator|Arm 2: Eye treated with placebo|-The participant will be instructed to use one drop from each bottle four times per day for 7 days
89329935|NCT04200456|Experimental|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
89329936|NCT04200456|Placebo Comparator|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
89329937|NCT04196413|Experimental|GD2-CAR T|"Rolling-6 dose escalation design will test GD2-CAR T cells in subjects with H3K27M-mutant DIPG.~GD2CART will be administered in escalating doses on Day 0 in hospitalized subjects with either DIPG or spinal DMG~Intravenously~Dose Level -1: 3x10^5 transduced T cells/kg(± 20%)~Dose Level 1: 1x10^6 transduced T cells/kg (± 20%)~Dose Level 2: 3x10^6 transduced T cells/kg (± 20%)~Intracerebroventricularly, without conditioning lymphodepletion chemotherapy~Dose Level -1: 10x10^6 transduced T cells (±20%)~Dose Level 1: 30x10^6 transduced T cells (±20%)~Dose Level 2: 50x10^6 transduced T cells (±20%)~Dose Level 3: 100x10^6 transduced T cells (±20%)~Intracerebroventricularly after administration of conditioning lymphodepletion chemotherapy regimen with cyclophosphamide and fludarabine~Dose Level -1: 10x10^6 transduced T cells (±20%)~Dose Level 1: 30x10^6 transduced T cells (±20%)~Dose Level 2: 50x10^6 transduced T cells (±20%)"
89523504|NCT03301441||Non migrainers|Patients experiencing an acute brain infarction complicating the occlusion of the internal carotid artery or the first or second segment of the middle cerebral artery. Migraine status determined by the validated French short questionnaire ef-ID Migraine A short questionnaire validating the absence of migraine
89523505|NCT03269695|Experimental|PF-06687234|PF-06687234 subcutaneous (SC) weekly (QW) x 12 doses
89329938|NCT04189965|Other|Pilot group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses to validate it.~The subject will also have headphones and different shouts or noises will be broadcast and he will have to rate the level of dislike of each sound stimulation."
89329939|NCT04189965|Other|Experimental group|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses. He will also have headphones and different shouts or noises will be broadcast and an electric stimulation glove to study in humans the mechanisms of long-term memory of pain by exploring the parallel between memory of pain and memory of a traumatic event.~3 sessions of stimulation will be done (D0, D2 and D30)"
89329940|NCT04189965|Other|Experimental subgroup|"Subjects are volunteers of 18 to 50 years of age that have given consent and that are affiliated to a social security. Overall, subjects must be in good health (no chronic pain, neuropathy or cardiac/respiratory issues etc.) and (for women) non-pregnant.~The subject will be seated in an armchair. He will be asked to explore the virtual environment using virtual reality glasses. He will also have headphones and different shouts or noises will be broadcast and an electric stimulation glove to study in humans the mechanisms of long-term memory of pain by exploring the parallel between memory of pain and memory of a traumatic event.~3 sessions of stimulation will be done (D0, D2 and D30)"
89329941|NCT04167917|Experimental|NTX-301|
89329942|NCT04164732|Experimental|LCZ696 at doses of 50mg, 100mg and 200mg b.i.d|randomized in a 1:1 ratio: LCZ696 to placebo
89329943|NCT04164732|Placebo Comparator|Placebo to LCZ696|randomized in a 1:1 ratio: LCZ696 to placebo
89329944|NCT04145011|Experimental|COOLIEF Cooled Radiofrequency Probe|Cooled radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
89329945|NCT04145011|Active Comparator|Conventional (Standard) Radiofrequency Probe|Standard (non-cooled) radiofrequency energy will be delivered to the study subjects' knee to ablate culprit sensory nerves and reduce knee pain
89329946|NCT04133233|Experimental|active treatment|"IL-2 (ILT-101) Sub-cutaneous~1 million UI/j"
89329947|NCT04133233|Placebo Comparator|placebo|placebo Sub-cutaneous The Placebo used is a sterile powder that will be produced by the CMO (AMATSI, France).
89329948|NCT04117932|Experimental|"Arm ustekinumab"|Patients with bullous pemphigoid, treated using ustekinumab in association during 8 weeks with superpotent topical corticosteroids
89329949|NCT04110743|Other|delayed imaging acquisition|10 mCi of 18F fluorodeoxyglucose (FDG) will be injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The IV line will be removed after dynamic acquisition. The dynamic scan will be preceded by ultra low-dose (1.298 mSv) CT scan to provide information for attenuation correction for the PET data. At 90 minutes, 3-, 6-, 9- and 12-hours, a static whole-body scan for 20 minutes will be acquired on EXPLORER. Prior to the 90-minute scan a low-dose CT (7.44 mSv) will be obtained both for anatomic localization and for attenuation correction purposes. Prior to each of the later time-points (3-, 6-, 9- and 12-hours), an ultra low-dose (1.298 mSv) CT scan will be acquired. This scan will be for attenuation correction purposes only. Following the 12-hour scan, the participant's study visit will be completed. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
89329950|NCT04110743|Other|low FDG dose imaging|0.5 mCi of 18F-FDG (1/20th of the standard dose) will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. The dynamic scan will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction. The standard 20-minute EXPLORER scan obtained at 90 minutes will be obtained after a low dose CT (7.44 mSv) for attenuation and co-localization. The standard 20-minute EXPLORER scan obtained at 3 hours will be preceded by an ultra-low-dose CT scan (1.298 mSv) for attenuation correction only. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
89329951|NCT04110743|Other|comparison PET images reconstructed using CT-based attenuation|10 mCi of 18F-FDG will be hand injected through the IV and a 60-minute dynamic scan will begin on EXPLORER. Prior to the dynamic scan, an ultra-low-dose CT scan (1.298 mSv) will be acquired for attenuation correction purposes only. At 90 mins, a low dose non contrast enhancement CT (7.44 mSv) will be acquired vertex to toes. Iodinated contrast (150 cc of iodine Omnipaque 350) will then be intravenously injected (through the same IV placed to inject FDG) at 3 ml/sec while the patient remains still on the scanner and a second low-dose CT will be acquired. Finally, a 20-minute PET acquisition will be performed. The IV line will be removed after completion of the study. MRI Brain will be also obtained after PET/CT scanning for anatomic correlation.
89329952|NCT04055220|Experimental|Regorafenib|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by regorafenib followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
89329953|NCT04055220|Placebo Comparator|Placebo|"Treatment will be divided in 28 days cycles, including a 21-day period of treatment by placebo followed by a 7-day period of rest.~In case of toxicity, dose can be reduced or treatment interrupted according to Specific Product Characteristics (SPC).~Patients can receive up to a maximum of 13 cycles (maximum treatment period : 12 Months)."
89329954|NCT04033354|Experimental|A|HLX10 + chemotherapy (carboplatin nab paclitaxel)
89329955|NCT04033354|Placebo Comparator|B|Placebo + chemotherapy (carboplatin nab paclitaxel), After 1st PD, the subject will be unblinded by the investigator and be continued with HLX10 monotherapy
89329956|NCT03963427|Other|Irradiated women|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap.
89329957|NCT03963427|Other|Non-irradiated women|Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
89523506|NCT03269695|Placebo Comparator|Placebo|PF-06687234 matched Placebo SC QW x 12 doses
89523507|NCT01098331|Other|Arm Rx1: Radical Prostatectomy|Arm Rx1: Radical Prostatectomy
89523508|NCT01098331|Other|Arm Rx2: Brachytherapy|Arm Rx2: Brachytherapy
89329958|NCT03952403|Experimental|Part 1-Cohort 1 (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
89329959|NCT03952403|Experimental|Part 2-Arm A (HLX10+HLX04+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
89329960|NCT03952403|Experimental|Part 2-Arm B (HLX10+HLX04 placebo+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 and HLX04 placebo on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
89329961|NCT03952403|Active Comparator|Part 2-Arm C (HLX10 placebo+HLX04 placebo+Carboplatin+Pemetrexed)|Participants will receive IV infusion of HLX10 placebo and HLX04 placebo on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
89329962|NCT03950492|Experimental|OUD DBS|This is a single arm study. Participants will be followed in an inpatient service for two weeks to gather baseline data followed by DBS placement and up to 6 weeks inpatient for clinical stabilization and DBS titration. All participants will then be followed twice a week for 12 weeks in the outpatient setting and then once a week for a total of 52 weeks post-titration.
89329963|NCT03899831|Experimental|Function-Based Elopement Treatment (FBET)|Participants in this group will receive Function-Based Elopement Treatment (FBET) for 16 weeks.
89329964|NCT03899831|Active Comparator|Parent Education Program (PEP)|Participants in this group will take part in a parent education program (PEP) for 16 weeks.
89329965|NCT03838146|No Intervention|Non-Exercise Control|This group will come in regularly for measurements, but will not have an exercise intervention. If necessary for retention of participants, then we will meet with controls 3 times a week to stress reduction techniques.
89329966|NCT03838146|Experimental|Resistance Type of Exercise|This group will participate in resistance exercise intervention 3 times per week from enrollment to delivery.The resistance training (RT) group will perform three sets of 12-15 repetitions of 10-12 resistance exercises in a circuit, with rest of 30-60 seconds between sets as needed. Participants will use a combination of Cybex machines (Cybex International, Medway, MA), resistance bands, and free weights. Routines will change every 3 weeks to add variety and improve compliance.
89329967|NCT03838146|Experimental|Combination Type of Exercise|This group will participate in combination (aerobic+resistance) exercise intervention 3 times per week from enrollment to delivery. The combination (CT) group will alternate between resistance and aerobic exercises. Participants will perform 4.5 minute bouts of aerobic exercise and perform four resistance exercises of 12-15 repetition that vary between aerobic bouts[17-19]. The aerobic exercise bouts will be performed on the aerobic machine of the participant's choosing as described above. The resistance routine will follow similar guidelines as the resistance group.
89329968|NCT03838146|Experimental|Aerobic Type of Exercise|This group will participate in aerobic exercise intervention 3 times per week from enrollment to delivery. The aerobic training (AT) group will perform a continuous aerobic exercise of their choosing (e.g., treadmill, ellipticals, stairs, Zumba, or outside walking/jogging). Participants' ability to choose an aerobic activity that they are comfortable with and enjoy is intended to improve compliance.
89329969|NCT03826927||AF and cerebrovascular event|patients with AF and recent (< 3 month) stroke or transient ischaemic attack (TIA) or intracranial haemorrhage (ICH) with or without pre-existing oral anticoagulation, in whom treatment with NOACs or VKAs is initiated or continued for prevention of ischemic events
89329970|NCT03806621||Rotational Atherectomy|
89329971|NCT03775161|Experimental|V-LAP™ System|Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home
89329972|NCT03766685|Experimental|Bimekizumab-SS|Subjects will receive assigned bimekizumab dose regimen using a prefilled safety syringe (SS).
89329973|NCT03766685|Experimental|Bimekizumab-AI|Subjects will receive assigned bimekizumab dose regimen using an auto-injector (AI).
89329974|NCT03756480||Case Group|"Clinical or surgical diagnosis of Endometriosis, patients undergoing surgical management~100 participants"
89329975|NCT03756480||Control Group|"No diagnosis of Endometriosis, Patients undergoing Laparoscopic Tubal Ligation~35 participants"
89329976|NCT03748784|Experimental|Dose 1|6E11 vg of ADVM-022
89329977|NCT03748784|Experimental|Dose 2|2E11 vg of ADVM-022
89329978|NCT03727776|Experimental|H.P. Acthar ®|Subjects will self-administer subcutaneous injections of 80 units of adrenocorticotropic hormone analog starting on post-operative day 1 for twice a week until week 8.
89329979|NCT03727776|No Intervention|Controls|Subjects will be managed per the standard of care.
89329980|NCT03704103|Experimental|iSage for adjustment of insulin|The provider will prescribe the iSage app to the subject and choose a treatment algorithm within the app to make insulin dose adjustments.
89329981|NCT03704103|No Intervention|Conventional management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet.
89329982|NCT03654274|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 80 weeks.
89329983|NCT03606161|Experimental|Supportive care (nrTMS)|Between 1-7 days after standard of care surgery, participants undergo 10 nrTMS sessions over 30 minutes each over 3 weeks.
89329984|NCT03533686|Experimental|Single-Sided Deafness Adult (Aim1) Group|Adult participants with single-sided deafness and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
89329985|NCT03533686|Experimental|Conductive Hearing Loss Adult (Aim 2) Group|Adult participants with conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
89329986|NCT03533686|Experimental|Adhear followed by BAHA (Aim 3) Group|Pediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
89329987|NCT03533686|Experimental|BAHA followed by Adhear (Aim 3) Group|Pediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
89329988|NCT03533686|Experimental|Pediatric Unilateral Conductive Hearing Loss (Aim 3a) Group|Pediatric participants (aged 2-17 years) and their parents with unilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system for 2 weeks (plus up to 90 days).
89329989|NCT03533686|Experimental|Pediatric Bilateral Conductive Hearing Loss (Aim 3b) Group|Pediatric participants (aged 2-17 years) and their parents with bilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system. Participants who are fitted bilaterally will receive 2 Adhear systems (one for each ear) for 2 weeks (plus up to 90 days) at Visit 1. Participants who are fitted unilaterally will receive 1 Adhear system for 2 weeks (plus up to 90 days) at Visit 1, afterwards, will be fitted bilaterally at Visit 2 and receive the Adhear system for both ears for another 2 weeks (plus up to 90 days) for a total of 4 weeks (plus up to 180 days).
89329990|NCT03517293|Experimental|Aerobic Exercise Intervention|Aerobic Exercise training 50 minutes of moderate intensity exercise, 3 times per week from ~16-40 weeks of pregnancy
89329991|NCT03517293|No Intervention|Control|usual daily activities - not exercise, not elevating heart rate
89329992|NCT03492372||Spine patients|Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures.
89329993|NCT03490357|Active Comparator|Control - Transversus Abdominus Plane Block|Standardized ERAS regional nerve block
89329994|NCT03490357|Experimental|Quadratus Lumborum Block|Quadratus lumborum nerve block
89329995|NCT03463187|Experimental|80mg SHR-1314-Part A|SHR-1314 80mg, subcutaneously
89329996|NCT03463187|Experimental|160mg SHR-1314-Part A|SHR-1314 160mg, subcutaneously
89329997|NCT03463187|Experimental|240mg SHR-1314-Part A|SHR-1314 240mg, subcutaneously
89329998|NCT03463187|Experimental|40mg SHR-1314 (Part B)|SHR-1314 40mg, subcutaneously
89329999|NCT03463187|Experimental|80mg SHR-1314 (Part B)|SHR-1314 80mg, subcutaneously
89330000|NCT03463187|Experimental|160mg SHR-1314 (Part B)|SHR-1314 160mg, subcutaneously
89330001|NCT03463187|Experimental|240mg SHR-1314 (Part B)|SHR-1314 240mg, subcutaneously
89330002|NCT03463187|Experimental|SHR-1314 Placebo (Part B)|SHR-1314 Placebo, subcutaneously
89330003|NCT03417882|Experimental|Cohort 1|All subjects will have newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
89330004|NCT03403686||Controls|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require that the subject must carry the diagnosis of healthy control.
89330005|NCT03403686||Diabetic no retinopathy|Patients with diabetes but with no evidence of diabetic retinopathy
89330006|NCT03403686||Diabetic with mild retinopathy|Diabetics with mild non proliferative diabetic retinopathy (NPDR).
89330007|NCT03403686||Diabetic with moderate retinopathy|Diabetics with moderate NPDR
89330008|NCT03403686||Diabetics with severe retinopathy|Diabetic with severe NPDR.
89330009|NCT03403686||Diabetics with proliferative diabetic retinopathy (PDR)|Diabetics with proliferative diabetic retinopathy (PDR)
89330010|NCT03386864||Control|Control
89330011|NCT03386864||Insulin Resistant|Insulin Resistant
89330012|NCT03386864||Type 2 Diabetes|Type 2 Diabetes
89330013|NCT03363581||Gastric bypass|Obese patients due to undergo gastric bypass surgery
89330014|NCT03363581||Control|Healthy free-living individuals
89330015|NCT03330457|Experimental|Cohort 1 Bertrixaban/Andexanet|Andexanet 800 mg, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
89330016|NCT03330457|Experimental|Cohort 1 Bertrixaban/Placebo|Placebo, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
89330017|NCT03330457|Experimental|Cohort 2 Bertrixaban/Andexanet|andexanet 800 mg administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
89330018|NCT03330457|Experimental|Cohort 2 Bertrixaban/Placebo|Placebo administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
89523509|NCT03231085|Active Comparator|Ferrous fumarate or ferrostrane|"The oral treatment should begin 21 days before surgery.~Recommended Dosage ferrous fumarate according to the SPC in force:~5 to 8 kg: 2 cd rases / d or 200mg of ferrous fumarate~8 to 10 kg: 3 cd rases / d or 300mg of ferrous fumarate~10 to 12kg: 4 cd rases / d or 400mg of ferrous fumarate~Ferrostrane ® (syrup) Laboratory TEOFARMA SRL Either 34mg of iron per teaspoon~Recommended dosage according to the SPC in force:~Infant 5 to 8 kg (about 1 to 6 months): 2 teaspoons a day,~Infant from 8 to 12 kg (about 6 to 30 months): 3 teaspoons a day."
89330019|NCT03286556|Experimental|Autoantibody Reductive Therapy|"Therapeutic Plasma Exchange (TPE) consisting of 1x estimated plasma volume exchanges for 3 successive days (1-3) and then, after a one day interval to enable equilibration of autoantibodies between intra- and extra-vascular spaces, again on days 5, 6, 9, 11, 13, and 15.~Rituximab: One gm i.v. will be administered on day 6 and day 15 after completion of the TPE on those days.~Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19~All subjects in this trial, including patients in this arm, will receive identical empiric antibiotics and steroids. The steroid dose is: Prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 6 and 15, as a premedication prior to the rituximab."
89330020|NCT03286556|Active Comparator|Treatment as Usual (TAU)|The same steroid regimen as described for the experimental arm, i.e., prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent), and methylprednisolone 100 mg i.v. administered on days 6 and 15, as well as empiric antibiotics.
89330021|NCT03236909|Experimental|Single-arm|Single-arm, repeated-measures study design with all subjects receiving a MED-EL cochlear implant
89330022|NCT03234881|Active Comparator|MOVE!|Weight management delivered as Treatment-as-Usual
89330023|NCT03234881|Experimental|MOVE!+CBT|Weight management delivered as Treatment-as-Usual plus use of a short duration, low-intensity CBT for recurrent binge eating.
89330024|NCT03198572|Experimental|Berberine|Berberine was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
89330025|NCT03198572|Placebo Comparator|Placebo|Placebo was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
89330026|NCT03192436|Active Comparator|Real Ultrasound|The subjects will receive real ultrasound intervention.
89330027|NCT03192436|Sham Comparator|Sham Ultrasound|The subjects will receive sham ultrasound intervention.
89330028|NCT03178331||Grade 1 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
89330029|NCT03178331||Grade 5 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
89330030|NCT03152318|Experimental|Arm A- rQNestin|"Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
89330031|NCT03152318|Experimental|Arm B- rQNestin+CPA|"Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Cyclophosphamide one intravenous injection 2 days prior to procedure.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
89330032|NCT03152318|Experimental|Arm C- Multiple Dose rQNestin|"Arm C includes up to 6 intratumoral repeated doses of rQNestin34.5v.2, first in a cohort receiving 10^8 pfus per time point, followed by a cohort receiving 10^9 or 10^7 pfus per time point.~Arm C adds 2 cohorts of 12 subjects in an open-label clinical trial of rQNestin34.5v.2 administered at two dose levels~The injections are planned for days 0, 15, 30, 60, 90, and 120~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent."
89330033|NCT03148379|Experimental|Customized patient instruments|Experimental group: Patients randomized into this group will undergo surgery utilizing single-use Efficiency Instruments with patient-specific technique (MyKnee® patient-matched cutting blocks)
89330034|NCT03148379|Active Comparator|Traditional metal instruments|Control Group: Patients will undergo conventional surgical technique
89330035|NCT03135834|Experimental|Group 1 (ACWY Naive subjects, MenABCWY/Saline)|ACWY Naive subjects, MenABCWY/Saline
89330036|NCT03135834|Experimental|Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)|ACWY Naive subjects, rLP2086/MenACWY-CRM
89330037|NCT03135834|Experimental|Group 3 (ACWY Experienced subjects, MenABCWY/Saline)|ACWY Experienced subjects, MenABCWY/Saline
89330038|NCT03135834|Experimental|Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)|ACWY Experienced subjects, rLP2086/MenACWY-CRM
89330039|NCT03130777|Experimental|TPVR - Main Cohort|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Commander Delivery System.
89330040|NCT03130777|Experimental|TPVR - PDS Registry|Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Pulmonic Delivery System (PDS).
89330041|NCT03083704|Experimental|Cohort 1|
89330042|NCT03083704|Experimental|Cohort 2|
89330043|NCT03083704|Experimental|Cohort 3|
89330044|NCT03083704|Experimental|Cohort 4|
89330045|NCT03083704|Experimental|Cohort 5|
89330046|NCT03083704|Experimental|Cohort 6|
89330047|NCT03083704|Experimental|Cohort 7|
89330048|NCT03083704|Experimental|Cohort 8|
89330049|NCT03083704|Experimental|Cohort 9|
89330050|NCT03083704|Experimental|Cohort 10|
89330051|NCT03083704|Experimental|Cohort 11|
89330052|NCT03021928|Experimental|72 hours (Day 3-4)|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 72 (+/-24) hours correlates to starting treatment on Day 3-4.
89330053|NCT03021928|Experimental|132 hours (Day 6)|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 132 (+/- 12) hours correlates to starting treatment on Day 6.
89330054|NCT03021928|Experimental|228 hours (Day 10)|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 228 (+/- 12) hours correlates to starting treatment on Day 10.
89330055|NCT03021928|Experimental|324 hours Day 14.|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 324 (+/- 12) hours starts Day 14.
89330056|NCT03010358|Experimental|Treatment (entospletinib, obinutuzumab)|Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of the first cycle, and on day 1 of subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity.
89330057|NCT02995850|Experimental|anti-cancer drug|
89330058|NCT02989935|Experimental|Fluticasone vilanterol bronchodilator|"Inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, bronchodilator,using standard dry powder inhaler.~Interventions include ventilation, parasternal EMG, and phrenic magnetic stimulation."
89330059|NCT02936089|Experimental|Low risk group|Patients with KIT-ASXL1- (non-mutation, NM) and acquiring main molecular response (MMR) after two cycles of consolidation.
89330060|NCT02936089|Experimental|Intermediate risk group|Patients with KIT+/ASXL1+ (single mutation, 1M) and acquiring MMR after two cycles of consolidation.
89330061|NCT02936089|Experimental|High risk group|Patients with KIT+ASXL1+ (two mutations ,2M) or without acquiring MMR after two cycles of consolidation.
89330062|NCT02721654|Experimental|Plasma-Lyte 148®|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
89330063|NCT02721654|Active Comparator|0.9% sodium chloride|Following randomisation, each study participant will receive either Plasma-Lyte 148® or 0.9% saline alone for all resuscitation episodes and for all compatible intravenous crystalloid therapy while in ICU (for up to 90 days).
89330064|NCT02694679|No Intervention|Random 0|The CBNH intervention will be delivered to 0% of population targeted households in the village.
89330065|NCT02694679|Active Comparator|Random 5|The CBNH intervention will be delivered to a random 5% of targeted households in the village.
89330066|NCT02694679|Active Comparator|Random 10|The CBNH intervention will be delivered to a random 10% of targeted households in the village.
89330067|NCT02694679|Active Comparator|Random 20|The CBNH intervention will be delivered to a random 20% of targeted households in the village.
89330068|NCT02694679|Active Comparator|Random 30|The CBNH intervention will be delivered to a random 30% of targeted households in the village.
89330069|NCT02694679|Active Comparator|Random 50|The CBNH intervention will be delivered to a random 50% of targeted households in the village.
89330070|NCT02694679|Active Comparator|Random 75|The CBNH intervention will be delivered to a random 75% of targeted households in the village.
89330071|NCT02694679|Active Comparator|Random 100|The CBNH intervention will be delivered to a random 100% of targeted households in the village.
89330072|NCT02694679|No Intervention|Friendship 0|CBNH 0% of population targeted
89330073|NCT02694679|Experimental|Friendship 5|The CBNH intervention will be delivered to 5% of households identified through friendship nomination.
89330074|NCT02694679|Experimental|Friendship 10|The CBNH intervention will be delivered to 10% of households identified through friendship nomination.
89330075|NCT02694679|Experimental|Friendship 20|The CBNH intervention will be delivered to 20% of households identified through friendship nomination.
89330076|NCT02694679|Experimental|Friendship 30|The CBNH intervention will be delivered to 30% of households identified through friendship nomination.
89330077|NCT02694679|Experimental|Friendship 50|The CBNH intervention will be delivered to 50% of households identified through friendship nomination.
89330078|NCT02694679|Experimental|Friendship 75|The CBNH intervention will be delivered to 75% of households identified through friendship nomination.
89330079|NCT02694679|Experimental|Friendship 100|The CBNH intervention will be delivered to 100% of households identified through friendship nomination.
89330080|NCT02657577||WIC staff|WIC staff is eligible to complete the WIC staff online survey if the individual is at least 18 years of age and have been employed at a WIC Clinic or DHH in Louisiana for at least 6 months in the past 2 years.
89330081|NCT02657577||WIC clients|WIC client is eligible to complete the WIC client online survey if the individual is at least 18 years of age and received WIC services during pregnancy or postpartum or have had a child who received WIC services in the past 2 years.
89330082|NCT02621476|Experimental|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
89330083|NCT02621476|Experimental|Usual care|Usual care
89330084|NCT02596100|Experimental|Tablet|80mg immediate release tablet
89330085|NCT02596100|Experimental|Capsule|80mg immediate release capsule
89330086|NCT02466217||1: AID groups|Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes (CAPS)/TNF-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes
89330087|NCT02466217||2: Control groups|knee arthritis, hip arthritis, muscular dystrophy, healthy subject
89330088|NCT02396810|Placebo Comparator|No intra-operative MRI|Patients undergo transsphenoidal surgery without an intra-operative MRI.
89330089|NCT02396810|Experimental|intra-operative MRI|Patients undergo transspheonidal surgery followed by intra-operative MRI.
89330090|NCT02280161||Ancillary-Correlative (germ-line mutation analysis)|Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the investigator for germ-line mutation analysis.
89330091|NCT02207725|Experimental|Andexanet|Andexanet (antidote)
89330092|NCT02207725|Placebo Comparator|Placebo|Placebo
89330093|NCT02119689||Diabetic Patients|Mild, Moderate and Severe Retinopathy
89330094|NCT02119689||Healthy Controls|Age and sex matched Healthy Controls
89330095|NCT01788410||Cryoablation under image guidance|Patients with facet joint disease, or compressed or damaged nerve roots causing pain in the head, neck or spine. Procedures performed with MRI Seednet Cryotherapy System (Galil Medical).
89330096|NCT01782352|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
89330097|NCT01782352|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
89330098|NCT01782352|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
89330099|NCT01782352|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
89330100|NCT01765868|Experimental|Single Arm Oral and IV Betrixaban|
89330101|NCT01647763|Experimental|HAL/RAR|hemorrhoidal artery ligation with rectoanal repair
89330102|NCT01647763|Active Comparator|Stapled hemorrhoidopexy|"procedure for prolapse and hemorrhoids (PPH)~Resection using a circular stapler"
89330103|NCT01641718|Experimental|Single sided glue|Mesh is fixed with Tisseel for single sided inguinal hernias.
89330104|NCT01641718|Active Comparator|Single sided stapled|Mesh is fixed with staples for single sided inguinal hernias.
89330105|NCT01641718|Other|Bilateral glue right|"For bilateral inguinal hernias mesh on the right side is fixed with Tisseel, on the left with staples.~Experimental treatment and active comparator in the same patient."
89330106|NCT01641718|Other|Bilateral glue left|"For bilateral inguinal hernias mesh on the left side is fixed with Tisseel, on the right with staples.~Experimental treatment and active comparator in the same patient."
89330107|NCT00968799|Experimental|HIPEC treatment|"Cytoreduction~Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin~Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).~If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).~Perfusion is performed with the open or Coliseum technique for 90 min."
89330108|NCT00751231|Active Comparator|Arm 1|300mg or 600mg loading dose of Clopidogrel followed by once daily dosing of 75 mg Clopidogrel for up to 120 days.
89330109|NCT00751231|Experimental|Arm 2|IV bolus of PRT060128 prior to PCI and twice daily administration of 50 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
89330110|NCT00751231|Experimental|Arm 3|IV bolus of PRT060128 prior to PCI and twice daily administration of 100 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
89330111|NCT00751231|Experimental|Arm 4|IV bolus of PRT060128 prior to PCI and twice daily administration of 150 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
89330112|NCT00521209|Experimental|Clinic 1 - intervention|Clinic 1 will feature the Self-Care Stimulating Disease Prevention Program (SCSDPP) intervention
89330113|NCT00521209|Other|Clinic 2 - no intervention|Clinic 2 will continue with standard procedures no intervention
89330114|NCT00345553||1|Biliary atresia subjects who have their native liver
89330115|NCT00345553||2|Biliary atresia subjects who have had a liver transplant
89330116|NCT00061828||Biliary Atresia|Infants presenting with cholestasis who are diagnosed with biliary atresia.
89330117|NCT00061828||Non-Biliary Atresia|Infants presenting with cholestasis without a diagnosis of biliary atresia.
89330118|NCT00332956|Active Comparator|Group 1|Volunteers will be vaccinated with 80 mcg rF1V vaccine on Study Days 0 , 28, 182
89330119|NCT00332956|Active Comparator|Group 2|Volunteers will be vaccinated with 80 mcg of rF1V vaccine at Study Days 0, 56, 182
89330120|NCT00332956|Active Comparator|Group 3|Volunteers will be vaccinated with 160 mcg rF1V vaccine given on Study Days 0, 28, 182
89330121|NCT00332956|Active Comparator|Group 4|Volunteers will be vaccinated with 160 mcg rf1V vaccine on Study Days 0, 56, 182
89330122|NCT04471324|Experimental|EBUS cryo probe|Patients receive a transbronchial cryobiopsy using an eBUS cryo probe
89330123|NCT04471012|Experimental|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~The experimental group was given a Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet during their first counseling session."
89330124|NCT04471012|No Intervention|Standard Care|The progress of the participants in the control group was tracked routinely without any specific implementation. At the end of the study, the control group was also given the same booklet.
89330125|NCT00324220|Experimental|1|MGCD0103 oral administration 3 times per week.
89330126|NCT02283346|Experimental|HDR Brachytherapy + EBRT|HDR brachytherapy + hypofractionated EBRT
89330127|NCT02284750|Experimental|Two-stenting technique|Percutaneous coronary intervention with DK crush, or culotte technique
89330128|NCT02284750|Active Comparator|Provisional stenting technique|Percutaneous coronary intervention with Provisional stenting technique. Stenting of the side branch was required if TIMI flow was <3, or ≥ type B dissection after kissing balloon inflation.
89330129|NCT00323518|Placebo Comparator|1|placebo
89330130|NCT00323518|Experimental|2|30 mcg/kg velafermin
89330131|NCT00323518|Experimental|3|10 mcg/kg velafermin
89330132|NCT00323518|Experimental|4|60 mcg/kg velafermin
89330133|NCT02287792|Experimental|18-FDG PET/CT scan|All patients will undergo a whole body PET/CT scan
89330134|NCT00417118|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 8 weeks
89330135|NCT00417118|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily in the morning for a maximum of 8 weeks
89330136|NCT00417118|Placebo Comparator|Placebo|Placebo for one week during the run in period and for a maximum of 8 weeks during the active period
89330137|NCT02883452|Active Comparator|Cohort 1: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks (Part 1)
89330138|NCT02883452|Experimental|Cohort 2: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every 2 weeks (Part 1)
89330139|NCT02883452|Experimental|Cohort 3: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every 2 weeks (Part 1)
89330140|NCT02883452|Experimental|Cohort 4: CT-P13 SC 240 mg|CT-P13 SC (Infliximab), 240 mg by SC injection every 2 weeks (Part 1)
88806678|NCT05895253|Active Comparator|Vibration-Control|Participants were assessed before and after receiving 60 days of vibrotactile ground-contact feedback, after seven days of washout, and after 60 days of no additional intervention to any ongoing treatment.
88806679|NCT05895162|Experimental|JUVIA zinc-containing vaginal gel and Fluconazole|JUVIA zinc containing vaginal gel group. Receive oral fluconazole treatment (150 mg) and after that participants will use a zinc containing- vaginal gel for 12 weeks.
88806680|NCT05895162|Active Comparator|Fluconazole|Control group. Receive oral fluconazole treatment.
88806681|NCT05891951|Experimental|B-Carotid ultrasound guided fluid therapy|Participants will use carotid ultrasound to assess volume status. If volume is insufficient, fluid therapy will be selected until volume is sufficient, anesthesia will be then induced. If volume is sufficient, anesthesia will be directly induced.
88806682|NCT05891951|No Intervention|C-No intervention|No carotid ultrasound will be used to assess the volume status of the patients, and anesthesia will be directly induced.
88806683|NCT05884125|Experimental|Brief Electrical Stimulation Therapy|Single, 10 minute dose of electrical stimulation delivered to the injured nerve during surgical intervention.
88806684|NCT05884125|No Intervention|Standard of Care|Surgical intervention for repair of peripheral nerve injury.
88806685|NCT05879731||Participants|"Potential participants for the study will be approached by phone on the day prior to their surgery. Details of the study will be explained to the potential participant by a member of the study team, who will also verify inclusion/exclusion criteria. The morning of the surgery, co-investigators will meet the patients to address any concerns. Written informed consent will be obtained by a member of the study team who is not a member of the patient's treating team.~Participants will then receive the interventions described in the ''Interventions'' section."
88806686|NCT05877326|Active Comparator|Perioperative anesthesia with a BIS target of 35|Anesthesia with a BIS target of 35
88806687|NCT05877326|Active Comparator|Perioperative anesthesia with a BIS target of 55|Anesthesia with a BIS target of 55
88806688|NCT05871489||Lesotho Cohort|200 patients receiving an all-oral shorter regimen in Lesotho under routine program conditions.
88806689|NCT05871489||Peru Cohort|50 patients receiving an all-oral shorter regimen in Peru under routine program conditions.
88806690|NCT05871489||Kazakhstan Cohort|550 patients receiving an all-oral shorter regimen in Kazakhstan under routine program conditions.
88806691|NCT05871346|Experimental|Complementary Feeding Counseling|Complementary feeding counseling to the mother-child pairs, in the intervention clusters, will be given by trained women development army (WDA) team leaders. The intervention process will have two components; training of WDA leaders, and counseling of mothers. Counselors' training will be given centrally by the principal investigator. During counseling, WDA leaders will use a counseling guide, which is prepared in Amharic, the local and the national language. The counseling guide contains seven key messages; complementary feeding: at 6 months, from 6-8 months, from 9-11 months, from 12-23 months, hygiene, breast feeding a sick child greater than 6 months, and signs that require mothers' special care of their children. Starting the children's 6 months of age, participants in the intervention group will receive in group counseling at convenient places, and individual counseling at each mother-child pair's home every month for 9 consecutive months (a total of 9 months follow up).
88806692|NCT05871346|Experimental|Routine Complementary Feeding Counseling|Participants in the control clusters will receive the routine complementary feeding counseling, which is offered by heath extension workers and other health professionals.
88806693|NCT05868694||Group 1|Patients suspected of having obstructive apnea
88806694|NCT05855304|Experimental|manual therapy|
88806695|NCT05855304|Experimental|Kinesiology taping|
88806696|NCT05851326|Experimental|Active Sonodyn Therapy (Treatment Group)|Patients will remain on treatment for 3 weeks and will activate their device 3 times a day for 10 minutes each.
88806697|NCT05851326|Sham Comparator|Sham Therapy (Control Group)|Patients will remain on sham treatment for 3 weeks and will activate their device 3 times a day for 10 minutes each.
88806698|NCT05850793|Experimental|Sensorimotor Exercise Training|Sensorimotor exercise content has been prepared based on previous sensorimotor, balance and proprioceptive studies in the literature. It is organized as a structured traditional exercise program + SM training content.
88806699|NCT05850793|Experimental|Progressive Motor Imagery Training|In order to sequentially activate the cortical motor networks and improve cortical organization, a literature-supported program including the components of AMI training (first stage laterality training, second stage motor imagery and third stage mirror therapy) was prepared and a six-week structured exercise program suitable for knee joint treatment + AMI training was prepared.
88806700|NCT05850793|Active Comparator|Conventional Exercise Training|A 6-week program was prepared from traditional treatment exercises based on previous studies in knee osteoarthritis. It consists of progressive muscle strengthening of Quadriceps, Hamstrings and gluteals and also stretching exercises.
88806701|NCT05837000|Experimental|Dexmedetomidine|0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
88806702|NCT05837000|Experimental|Ketamine|0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
88806703|NCT05837000|Experimental|Magnesium sulphate|0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
88806704|NCT05833139|Experimental|BI 1810631 (R) followed by BI 1810631 + itraconazole (T)|
88806705|NCT05821504|Experimental|Plyometric High-Intensity Interval Training|This group performed high-intensity interval training consisting of body-weight, plyometric exercises involving jumping.
89330141|NCT02883452|Experimental|Arm 1: CT-P13 SC 120/240 mg|CT-P13 SC (Infliximab), either 120 mg or 240 mg every 2 weeks by SC injection (Part 2)
89330142|NCT02883452|Active Comparator|Arm 2: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks up to Week 22. CT-P13 IV was switched to either 120 mg or 240 mg of CT-P13 SC (Infliximab) treatment, and further doses with CT-P13 SC were given up to Week 54. (Part 2)
89330143|NCT00508066|Experimental|Arm 1|Subjects in arm 1 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse 0.25 - 0.5% (according to patient's weight) Bupivacaine at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
89330144|NCT00508066|Placebo Comparator|Arm 2|Subjects in arm 2 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse normal saline at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
89330145|NCT01336010|Experimental|Group A - 8 weeks therapy|8 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 2 weeks of therapy.
89330146|NCT01336010|Experimental|Group B - 16 weeks therapy|16 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 4 weeks of therapy.
89330147|NCT01336010|Experimental|Group C - 24 weeks therapy|24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 6 weeks of therapy.
89330148|NCT01336010|Experimental|Group D - 32 weeks (gt1) or 24 weeks (gt 2/3)|32 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy.
89330149|NCT01336010|Experimental|Group E - 48 weeks (gt 1) or 24 weeks (gt 2/3)|48 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 2/3).
89330150|NCT01336010|No Intervention|Untreated Group|Observation only. No treatment for hepatitis C administered. Subjects who have undetectable HCV RNA at baseline, do not wish to commence treatment or are ineligible for treatment.
89330151|NCT00321412|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
89330152|NCT00321412|Experimental|1|AST-120, 2 gram sachets
89330153|NCT01336088|Experimental|ADX48621|
89330154|NCT01336088|Placebo Comparator|ADX48621 Matching Placebo|
89330155|NCT02549144|Experimental|High fat/cholesterol diet|High-fat/high-cholesterol (HFHC) normocaloric diet for 14 days.
89330156|NCT02549144|Experimental|Low fat/cholesterol diet|Low-fat/low-cholesterol (LFLC) normocaloric diet for 14 days.
89330157|NCT02207504|Experimental|crizotinib and enzalutamide|"A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.~Crizotinib- given orally daily-28 day cycle~Enzalutamide- given orally daily-28 day cycle"
89330158|NCT00151372|Experimental|Treatment Adherence Intervention|In the Treatment Adherence Intervention group, a study therapist regularly meets with subjects in order to identify obstacles to depression and chronic obstructive pulmonary disease treatment adherence and to help the participant overcome those obstacles.
89330159|NCT00151372|Active Comparator|Enhanced Care|In the Enhanced Care group, physicians providing aftercare will be informed in writing of the patients' diagnosis but will receive no clinical instructions by the research team.
89330160|NCT01342016|Experimental|tacrolimus group|tacrolimus capsule + leflunomide placebo
89330161|NCT01342016|Active Comparator|leflunomide group|tacrolimus placebo + leflunomide tablet
89330162|NCT00318214|Experimental|1|
89330163|NCT00318214|Placebo Comparator|2|
89330164|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
89330165|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 30 μg|split-virion, non-adjuvanted H1N1 vaccine of 30 μg.
89330166|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 45 μg|split-virion, non-adjuvanted H1N1 vaccine of 45 μg.
89330167|NCT01336166|Placebo Comparator|Placebo control|Placebo control
89330168|NCT04470310|Active Comparator|glimepiride|glimepiride 1mg monotherapy and glimepiride 2mg monotherapy
89330169|NCT04470310|Active Comparator|alogliptin|alogliptin 25mg monotherapy
89330170|NCT04470310|Active Comparator|alogliptin - pioglitazone|Alogliptin 25mg+pioglitazone 15mg combination
89330171|NCT02083250|Experimental|Treatment (vorinostat, chemotherapy, SCT)|"CONDITIONING REGIMEN: Patients receive vorinostat PO QD, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -6 to -3. Patients receiving a transplant from a HLA-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to -1.~TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0."
89330172|NCT01336244|Experimental|GLPG0778 ascending doses|Multiple ascending doses for 13 days, ranging from 50 mg twice daily upto a maximum to be determined during escalation.
89330173|NCT01336244|Placebo Comparator|Placebo|Twice daily for 13 days, matching the scheme of the multiple ascending dose.
89330174|NCT00315640|Experimental|Anecortave Acetate 3 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
89330175|NCT00315640|Experimental|Anecortave Acetate 15 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
89330176|NCT00315640|Experimental|Anecortave Acetate 30 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
89330177|NCT00315640|Other|Anecortave Acetate Vehicle|
89330178|NCT00411892|Experimental|A|
89330179|NCT00411892|Active Comparator|B|
89330180|NCT01336322|Active Comparator|Metformin|Metformin 850 mg bid
89330181|NCT01336322|Active Comparator|Sitagliptin|Sitagliptin 100 mg qd
89330182|NCT01336322|Active Comparator|Sitagliptin+Metformin|Sitagliptin 100 mg qd plus Metformin 850 mg bid
89330183|NCT01033916|No Intervention|STRICT Glucose Control (80-120 mg/dL)|The STRICT arm of the study will have a target Blood Glucose level ranging from 80-120 mg/dL. This is currently the standard of care for post CABG patients.
89330184|NCT01033916|Active Comparator|LIBERAL (Target Glucose:121-180 mg/dL)|
89330185|NCT01339676|Experimental|1|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
89330186|NCT01339676|Placebo Comparator|2|Identically appearing once weekly peroral capsules
89330187|NCT00315250|Experimental|[123I]β-CIT|To assess B-CIT and SPECT imaging
89330188|NCT04848428|Experimental|Online Mindfulness-based intervention|Four weekly sessions are planned. The first session will focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
89330189|NCT04848428|Active Comparator|Online standardized education|In addition to usual care, the CG will have access to one 15-minute standardized educational online session on persistent post-surgical pain, how pain and stress may interact and their potential impact on recovery.
89330190|NCT00407914|Experimental|1|Aquamid
89330191|NCT00407914|Active Comparator|2|Restylane
89330192|NCT01339754|Experimental|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
89330193|NCT00313768|Active Comparator|B|Standard of care chemotherapy
89330194|NCT00313768|Experimental|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
89330195|NCT01339988|Experimental|Busulfan/Cyclophosphamide|
89330196|NCT05160350|Active Comparator|Probiotic|Familact 2 plus (Zist takhmir pharmaceutical company, Iran), one capsule per day
89330197|NCT05160350|Placebo Comparator|Placebo|Similar capsule in shape and size (Zist takhmir pharmaceutical company, Iran), one capsule per day
89330198|NCT01342250|Experimental|Conventional plus hUC-MSCs treatment (low dose)|
89330199|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （medium dose）|
89330200|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （high dose）|
89330201|NCT00406588|Experimental|1|
89330202|NCT00406588|Placebo Comparator|2|
89330203|NCT05184686|Active Comparator|noise(low-level) and RF(low-level)|
89330204|NCT05184686|Active Comparator|noise(high-level) and RF(low-level)|
89330205|NCT05184686|Active Comparator|noise(high-level) and RF(high-level)|
89330206|NCT05184686|Active Comparator|noise(low-level) and RF(high-level)|
89330207|NCT01342328|Placebo Comparator|Control|For this arm, the volunteer subject will receive a saline infusion during the sleep session.
89330208|NCT01342328|Experimental|Dexmedetomidine (DEX)|For this arm, the volunteer subject will receive a DEX infusion for sedation during the sleep session.
89330209|NCT01342328|Experimental|Propofol|For this arm, the volunteer subject will receive a propofol infusion for sedation during the sleep session.
89330210|NCT05184608|Experimental|Cycling combined with cognitive tasks|
89330211|NCT05184608|Active Comparator|Cycling|
89330212|NCT01336400||PGD-FISH|"Following couples opting for preimplantation genetic diagnosis on the basis of FISH:~couples suffering a complex chromosomal rearrangement (CCR)~couples with X-linked recessive disorders~couples that carry a balanced chromosomal rearrangement"
89330213|NCT01336400||PGD-PCR|"Following couples opting for preimplantation genetic diagnosis on the basis of PCR:~-couples at risk for the transmission of monogenic diseases"
89330214|NCT05184530||Statin Group|AMI patients with Statin therapy.
89330215|NCT05184530||Ezetimibe Group|AMI patients with Statin plus Ezetimibe therapy.
89330216|NCT05184530||PCSK9i Group|AMI patients with Statin plus PCSK9i therapy.
89330217|NCT05184530||Triple Group|AMI patients with Statin plus Ezetimibe plus PCSK9i therapy
89330218|NCT05184374|Experimental|subcutaneous injection of gonadorelin is facilitated by GnRH pump|After non-dose GnRH stimulation test on day 1, GnRH pump pulse subcutaneous injection of gonadorelin on the next day until one month.
89330219|NCT00312286|Experimental|1|
89330220|NCT00312286|Experimental|2|
89330221|NCT00312286|Experimental|3|
89330222|NCT00312286|Experimental|4|
89330223|NCT00312286|Experimental|5|
89330224|NCT00312286|Experimental|6|
89330225|NCT00312286|Experimental|7|
89330226|NCT00312286|Placebo Comparator|8|
89330227|NCT00312286|Placebo Comparator|9|
89330228|NCT00312286|Placebo Comparator|10|
89330229|NCT00312286|Placebo Comparator|11|
89330230|NCT05187494|Other|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine 2% with Epinephrine 1:80000, Korea) will be performed and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
89330231|NCT05187494|Experimental|EMLA cream only|The palatine mucosa will be dried with a cotton ball 2*2 and then 0,2 g of Emla cream will be applied for 3 minutes . During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
89330232|NCT05187494|Experimental|chemical permeability enhancer DMSO with EMLA cream|The palatine mucosa will be dried with a cotton ball and then EMLA cream will be mixed with a permeability enhancer in the laboratory of pharmaceutical industries at the Faculty of Pharmacy at Damascus University according to the following: Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes. During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
89330233|NCT05187494|Experimental|Oral patches with EMLA Cream|The palatine mucosa will be dried with a cotton ball and then 0.2 g of EMLA cream 5% will be applied by using an oral patch 14*14 mm for 3 minutes. During this period and the following measures (face expressions ( Wong-Baker Faces) heart rate and oxygen rate and FLACC pain scale) will be recorded to determine the reaction of the child.
89330234|NCT05187494|Experimental|Micro-needle patches dissolved with EMLA Cream|The palatine mucosa will be dried with a cotton ball 2*2 and then 0.2 g of EMLA cream 5% will be applied by using an micro-needle patch 14*14 mm, 0,25 micron for 3 minutes.
89330235|NCT00312052|Experimental|E5555 50 mg|Participants received one 50 mg E5555 and two 100 mg placebo tablets, once orally daily for 24 weeks.
89330236|NCT00312052|Experimental|E5555 100 mg|Participants received one 50 mg placebo, one 100 mg E5555 and one 100 mg placebo tablets, once orally daily for 24 weeks.
89330237|NCT00312052|Active Comparator|E5555 200 mg|Participants received one 50 mg placebo and two 100 mg E5555 tablets were taken orally once daily for 24 weeks.
89330238|NCT00312052|Placebo Comparator|Placebo|Participants received one 50 mg placebo and two 100 mg placebo tablets, once orally daily for 24 weeks.
89330239|NCT01342562|Experimental|DXM-bupivacaine|
89330240|NCT01342562|Placebo Comparator|saline-bupivacaine|
89330241|NCT00404014|Active Comparator|AL-208|1 dose of 300 mg
89330242|NCT00404014|Placebo Comparator|Placebo|
89330243|NCT01315652|Experimental|Auto DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
89330244|NCT01315652|Active Comparator|Comorbidities treatment|
89330245|NCT01315730|Experimental|Device: Tactile Stimulation|"A new medical grade device (FDA - category exempt) has been newly designed and built at the University of Mississippi within the departments of Communication Sciences & Disorders, Exercise Science, and Computer and Electrical Engineering. The device records either sound waves (via a small standard microphone) or three dimensional accelerometer data from the throat of a stuttering subject. This data is digitally signal processed, and fed back to the user in the form of a small vibrating disk/film that can be held between the fingers or mounted on the skin. This feedback data does not require the subject to attend to the incoming signal."
89330246|NCT01315808||Low risk group|Patients will be stratified based on risk factors significantly contributing to diabetes type 2.
89330247|NCT01315808||Intermediate risk group|
89330248|NCT01315808||High risk group|
89330249|NCT02287870|Experimental|Chloroprocaine Group|Epidural anesthesia with 3% chloroprocaine.
89330250|NCT02287870|Active Comparator|Lidocaine Group|Epidural anesthesia with 2% lidocaine.
89330251|NCT05157230|Experimental|exercise|volunteers in this group do shoulder/arm exercises after vaccine injection and fill in the pain diary
89330252|NCT05157230|No Intervention|no-exercise|volunteers in this arm only completed the pain diary without any intervention
89330253|NCT02287948||MS subjects group|Multiple sclerosis subjects wiht mild-moderate gait disability with EDSS score not higher than 5.5
89330254|NCT02287948||Healthy subjects group|Healthy subjects age-matched with multiple sclerosis subjects.
89330255|NCT01340456|Experimental|Rifampicin 10 mg QD|
89330256|NCT01340456|Experimental|Rifampicin 20 mg QD|
89330257|NCT01340456|Experimental|Rifampicin 100 mg QD|
89330258|NCT00110422|Experimental|A1|
89330259|NCT00110422|Active Comparator|B1|
89330260|NCT05156528|Experimental|Experimental group|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine, 0.5ml/dose, 2 doses with an interval of 30 days.
89330261|NCT05156528|Placebo Comparator|Placebo group|Aluminium phosphate adjuvant, 0.5ml/dose, 2 doses with an interval of 30 days.
89330262|NCT00305656|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28.
89330263|NCT01342718|Experimental|GJS/Duolac7S|GJS: Real herbal extract granule/Duolac7S: Real probiotics
89330264|NCT01342718|Placebo Comparator|GJS-P/Duolac7S|GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
89330265|NCT01342718|Placebo Comparator|GJS/Duolac7S-P|GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics
89330266|NCT01342718|Placebo Comparator|GJS-P/Duolac7S-P|GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
89330267|NCT01336946|Experimental|health promotion program|Psycho education and behavioural group sessions and supervised walking sessions will be performed.
89330268|NCT01336946|No Intervention|Control group|No intervention will be performed in this control group.
89330269|NCT01337024||Control group|Healthy volunteers, examined with ECG without any treatment (controls)
89330270|NCT01337024||100 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 100 units BoNT/A
89330271|NCT01337024||300 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 300 units BoNT/A
89330272|NCT02284984|Experimental|Rituximab with belimumab|Rituximab 1000mg on day 0 and day 14 Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks.
89330273|NCT01337102|Other|Physician to receive results|Arm 1 Physician to receive the results of the Lung QoL scale
89330274|NCT01337102|Other|Physician Does Not Receive Results|Arm 2 Physician does not receive the results of the Lung QoL scale
89330275|NCT00305188|Experimental|Xaliproden (SR57746A)|
89330276|NCT00305188|Placebo Comparator|Placebo|
89330277|NCT01340534|Experimental|Oxygen 80% FIO2|Group of 181 patients that will receive supplemental oxygen 80% FIO2 during surgery (cesarean) and two hours after the procedure.
89330278|NCT01340534|Placebo Comparator|Use of air (no oxygen during surgery)|Group of 181 patients that will not receive supplemental oxygen during surgery (cesarean).
89330279|NCT02285218||1) Normal control|metabolically healthy with no obesity
89330280|NCT02285218||2) dyslipidemia|high triglyceride levels or LDL-C levels
89330281|NCT02285218||3) type 2 diabetes|defined in 'inclusion criteria'
89330282|NCT02285218||4) non-alcoholic fatty liver disease|defined in 'inclusion criteria'
89330283|NCT01340690|Active Comparator|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension each day. Each 4ml suspension bag includes 400mg eicosapentaenoic acid (EPA), 40mg docosahexaenoic acid (DHA), 5.4 mg gamma-linolenic acid (GLA), 80 mg magnesium, 5 mg zinc and consists of linseed oil, xylitol, sea fish oil with high portion of omega-3-acids, magnesium citrate, vegetable oil, orange flavour, evening primrose oil, zink gluconate, soya lecithin, citric acid, acesulfame k (E950)
89330284|NCT01340690|Placebo Comparator|placebo suspension|2 bags of Esprico (R) placebo suspension. Includes no ω-3 fatty acids, no ω-6 fatty acids, no magnesium and no zinc, but other vegetable oils, orange flavor, etc.
89330285|NCT00095290|Experimental|A1|
89330286|NCT00095290|Placebo Comparator|A2|
89330287|NCT05183750|Other|Adult with isolated medial compartmental knee osteoarthtitis|
89330288|NCT05183594|Experimental|TSupport group|"Subjects will receive TSupport 4 sachets (5 grams/sachet) orally twice daily. Morning dose and evening dose should be administrated at about the same time every day and irrelevant to meals.~Supportive care duration: 24 weeks."
89330289|NCT01340846|Experimental|Part A|Warfarin dosed at 15mg
89330290|NCT01340846|Experimental|Part B|Ketoconazole dosed at 400mg
89330291|NCT01340846|Experimental|Part C|Gemfibrozil dosed at 600mg
89330292|NCT01340846|Experimental|Part D|GSK2118436 dosed alone
89330293|NCT02285296|No Intervention|control arm|usual care
89330294|NCT02285296|Experimental|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
89330295|NCT01337180||Main study group|"Inclusion criteria: Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both administrative/office workers and workers in the production and maintenance departments will be invited to participate. Non-smokers and smokers and male and female workers will be included in the main study group (study A).~Sputum part of study: nonsmokers."
89330296|NCT00398710|Experimental|Perifosine|Patients will receive perifosine orally at 150 mg daily after food for 28-d cycles.
89330297|NCT01342874||Inositol group|Inositol dietary exposure 4000 mg/day
89330298|NCT01342874||Control group|folic acid 400 mcg/day
89330299|NCT00397696|Experimental|[123I] 5-IA|To assess [123I] 5IA and SPECT imaging
89330300|NCT01337258||Men at increased risk for Prostate Cancer (PCA)|
89330301|NCT00397228|Experimental|ALTROPANE®|ALTROPANE® dosing
89330302|NCT02603809|Placebo Comparator|Placebo|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
89330303|NCT02603809|Experimental|Aprocitentan 5 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
89330304|NCT02603809|Experimental|Aprocitentan 10 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
89330305|NCT02603809|Experimental|Aprocitentan 25 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
89330306|NCT02603809|Experimental|Aprocitentan 50 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
89330307|NCT02603809|Active Comparator|Lisinopril 20 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
89330308|NCT01341002|Experimental|SCVO2 < 70%|guidelines transfusion + SCVO2 < 70%
89330309|NCT01341002|Active Comparator|currently intervention|guidelines transfusion
89330310|NCT00396448|Experimental|CP-945,598 Treatment B|
89330311|NCT00396448|Experimental|CP-945,598 Treatment A|
89330312|NCT00396448|Placebo Comparator|Placebo|
89330313|NCT01341158|Experimental|Experimental arm|
89330314|NCT05183438||patients with metachronous colorectal adenomas|
89330315|NCT05183438||patients without metachronous colorectal adenomas|
89330316|NCT00393952|Experimental|1|FlutiForm 250/10
89330317|NCT00393952|Active Comparator|2|FlutiForm 100/10
89330318|NCT00393952|Active Comparator|3|Fluticasone 250
89330319|NCT00393952|Active Comparator|4|Formoterol 10
89330320|NCT00393952|Placebo Comparator|5|Placebo
89330321|NCT01341236|Active Comparator|continuous nutrition|
89330322|NCT01341236|Active Comparator|bolus nutrition|
89330323|NCT02285374|Experimental|Arm 1|Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus Dolutegravir 50mg (one tablet) once daily
89330324|NCT02285374|Experimental|Arm 2|Atripla (efavirenz 600mg, emtricitabine 200mg, tenofovir 245mg) one tablet once daily, or Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus efavirenz 600mg one tablet once daily for 4 weeks. At week 4, efavirenz is switched to Dolutegravir 50mg (one tablet) once daily
89330325|NCT00391066|Active Comparator|1|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
89330326|NCT00391066|Experimental|2|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
89330327|NCT01112449|Experimental|Low dose selenized-yeast|200 µg/day of selenized-yeast (SY)
89330328|NCT01112449|Experimental|selenomethionine|The second group will receive 200 µg/day of selenomethionine (SM)
89330329|NCT01112449|Placebo Comparator|Placebo|no active medication.
89330330|NCT01112449|Experimental|High dose selenized-yeast|The fourth group will receive 285 µg/day of selenized-yeast (SY).
89330331|NCT01341392|Experimental|CKD-501 0.5mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
89330332|NCT01341392|Experimental|CKD-501 Amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
89330333|NCT01341392|Experimental|Amlodipine 10mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
89330334|NCT03946189||P/F less than 100|Patients receiving mechanical ventilation with paO2/FiO2 less than 100
89330335|NCT03946189||P/F between 100 and 200|Patients receiving mechanical ventilation with paO2/FiO2 between 100 and 200
89330336|NCT03946189||P/F between 200-300|Patients receiving mechanical ventilation with paO2/FiO2 between 200 and 300
89330337|NCT05186792||myco well participants|Retrospective analysis of patient records. No new patients recruited.
89330338|NCT01328509||Sepsis|Patients with sepsis
89330339|NCT01328509||Control|Patients with no clinical evidence of sepsis, but who are critically ill
89330340|NCT03635762|Experimental|Be In Charge|behavioral + nutrition education program
89330341|NCT01109407||patients with MGUS or SMM|patients with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM)
89330342|NCT04390958|Experimental|Neoadjuvant chemotherapy group|Total 6 perioperative chemotherapy composed of nab-paclitaxel, cisplatin and capecitabine every 21 days
89330343|NCT03946033|Other|Single arm|All participants are included in the same arm. Immunoscore Colon Test is applied on a tumor sample and the result is kept secret. In the Multidisciplinary Meeting evaluating the adjuvant therapy of the participant, a first therapeutic decision is taken, then Immunoscore result will be disclosed and the Multidisciplinary Meeting will take a second decision.
89330344|NCT02285452|Active Comparator|Thorax wrap with ginger flour (Zingiberis Rhizoma plv.)|Thorax wrap with ginger flour, duration max. 20 minutes
89330345|NCT02285452|Active Comparator|Thorax wrap with mustard flour (Sinapis nigrea semen)|Thorax wrap with mustard flour, duration max 20 minutes
89330346|NCT02285452|Placebo Comparator|Thorax wrap with warm water (placebo)|Thorax wrap with warm water (placebo), duration: 20 minutes
89330347|NCT05136950|Experimental|Secondary in-the-bag IOL fixation group|In-the-bag IOL fixation is the experimental arm
89330348|NCT05136950|Active Comparator|Secondary ciliary sulcus IOL fixation group|Ciliary sulcus IOL fixation is the control arm
89330349|NCT02285608|Experimental|PIMM/SAM|Partnership in Medication Management (PIMM): The nurse and the attending physician will meet with the patient and ask how s/he administers medication at home (i.e., blister pack). Initial education session: the nurse will teach the patient about his/her medications, dosage, purpose, when and how to take them. Nurse and patient will establish reminders to take his/her medication. Following the education session, patients will be required to notify the nurse when it is time to take their medications, where their medications are, dosage, purpose and side effects. Self-Administered Medication (SAM): Patients will transition to SAM once the clinical team feels that no further medication changes are required. SAM is also the model that the participants will follow after discharge.
89330350|NCT02285608|No Intervention|Standard Prescribing Practice(SPP)|Standard prescribing practice (SPP): medication administration will proceed as standard practice. Patients will not receive a personalized medication training. The nurse will administer the patient's medications. However, patients are encouraged to ask any questions regarding his/her medications.Patients will not be provided with any tool to help them to remember when to take their medications. The nurse will record the patient's knowledge regarding his/her medications.
89330351|NCT03943459|No Intervention|Control|20 Patients on placebo
89330352|NCT03943459|No Intervention|Atorvastatin|20 patients treated with atorvastatin 80 mg/day
89330353|NCT03943459|Experimental|Quercetin|20 patients treated with quercetin 500 mg/day
89330354|NCT04832438|Experimental|9-ING-41 plus carboplatin|Patients will receive 9-ING-41 (15 mg/kg IV on Day 1 and Day 4) in addition to carboplatin (AUC 5 IV on Day 1) each of a 21-day cycle
89330355|NCT01209481|Experimental|Nutritional education|
89330356|NCT01209481|No Intervention|control|
89330357|NCT05182970|Active Comparator|Metformin on top of standard care|Metformin will be prescribed by the Investigator at the study site and dispensed at pharmacy of choice by the patient. Metformin will be recommended to be gradually titrated to minimize gastrointestinal side effects with a start dose of 500 mg 1x1 for 1 week and thereafter 500 mg 1x2 with an individualised target dose of 2000 mg daily depending on tolerability. The goal is to a have minimal dose of 500 mg 1x2. Patients will be informed to stop medication in events of sever nausea, vomiting or dehydration according to standard practice. The threshold for metformin titration or adding another drug during follow-up is recommended to be assessed individually by the Investigator at the study site, responsible for the patient. Patients with eGFR <60 cannot be included in the MIMET study. If GFR is between 30-45 ml/min during the study, metformin should be reduced to 1000 mg daily. Metformin is contraindicated if GFR <30 ml/min. Standard care will be the same as in the control arm.
89330358|NCT05182970|No Intervention|Standard care alone|Standard care according to national guidelines. In Sweden there is no pharmacological intervention recommended for individuals with prediabetes at present. Standard care includes diet and life-style advice, which will be given to both groups in the same manner according to local routines, based on the present guidelines. Secondary preventive treatment includes physical activity, participating in exercise program, dietary habits, BMI and or waist circumference, smoking and EQ-5D will be followed in accordance with the routinely reported SWEDEHEART-SEPHIA variables.
89330359|NCT01209559||air-Q Intubating Laryngeal Airway|
89330360|NCT01209559||LMA FastrachTM or ILMA|
89330361|NCT01315886|Experimental|SL Fentanyl conversion|"Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication~Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes."
89523510|NCT03231085|Experimental|Ferric carboxymaltose|The single intravenous treatment the day of the inclusion. Dosage according to: 15mg / kg iron (to dilute in 3 ml / kg of Nacl 0.9% (SSI), to pass in 15 minutes.
89523511|NCT03118921|Experimental|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software
89523512|NCT03385135|Active Comparator|Allopurinol group|Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks
89330362|NCT04441294|Experimental|ACE-Plus|"ACE-Plus is a one-on-one dual-session intervention for males aged 16 to 20 within foster care or preventive services settings which promotes condom use and knowledge of dual methods of contraception. The goal of ACE-Plus is to promote correct and consistent condom use of male latex condoms during penile-vaginal sex and to promote male engagement (e.g., discussion, decision-making) with their female partners in the use of female-centered contraception methods.~Session one focuses on correct and consistent condom use for purposes of HIV/STD prevention including information and activities that address teen pregnancy prevention. Session two, which occurs within 10 to 14 days of the first session, promotes dual-method contraceptive use. Both sessions are one hour."
89330363|NCT04441294|No Intervention|On Track|On Track was the alternative program provided to males randomly assigned to the control group. On Track seeks to assist participants in identifying their aptitudes and preferences regarding their careers and their values associated with employment, and to provide tools to prepare them for the work setting and future job interviews. Participants learn how to identify attitudes, values, preferences, and challenges surrounding a career path, receive an understanding of the documents required for employment, and develop an initial employment strategy and action plan. Trained foster care agency staff deliver the curriculum to participating youth in two one-on-one sessions at agencies. Each session is one hour in length. Session two occurs 10 to 14 days after session one.
89330364|NCT04441450|Experimental|[14C]ICP-022|Subjects will take a single of 150mg 100μCi of [14C]ICP-022.
89330365|NCT05251220||10 women with objectively confirmed vulvovaginal atrophy|10 women with objectively confirmed vulvovaginal atrophy (genitourinary menopausal syndrome
89330366|NCT05251220||37 women with 1-2 degree prolapse of the vaginal walls combined with stress urinary incontinence|37 women with 1-2 degree prolapse of the vaginal walls combined with stress urinary incontinence
89330367|NCT05251220||7 with vaginal relaxation syndrome|7 with vaginal relaxation syndrome
89330368|NCT05251220||6 with vulvar lichen sclerosus|6 with vulvar lichen sclerosus
89330369|NCT03942367|Experimental|Group A (Active Device Group)|Patients will receive a fully functioning vPatch device, pre-configured to deliver stimulation intensity according to the subjective motor threshold intensity reported by the Patients. Pre-configured stimulation intensity cannot be changed by the Patient.
89330370|NCT03942367|Sham Comparator|Group B (Sham Device Group)|Patients will receive a vPatch device pre-configured to deliver the sensory electrical stimulation according to the subjective sensory threshold that is ineffective for muscle activation. Pre-configured stimulation intensity cannot be changed by the Patient.
89330371|NCT05251142|Experimental|Plyometric training|Jumps in place. Standing jumps. Multiple hops and jumps. Box drills. Depth jumps.
89330372|NCT05251142|Active Comparator|General exercises|Dumbbell Squat, Dumbbell Alternating Bench Press, Straight Arm Pulldowns, Dumbbell Front Raises, Reverse Flyes, Overhead Tricep Extensions, Dumbbell Bicep Curls, Jackknife Crunches, Oblique Crunches, External Rotation
89330373|NCT01209637|No Intervention|control|standard care of coronary artery diseases incl. recommended home based exercise 3x/week
89330374|NCT01209637|Active Comparator|Exercise training|exercise training for 4 weeks at 70% of ischemia free individual threshold within a rehabilitation care center
89330375|NCT01209637|Active Comparator|intensive exercise training|intensive exercise training incl. interval training
89330376|NCT01343654|Experimental|Text messaging|Participants randomized to this arm will receive a mobile phone if needed, and the 12 week personalized text messaging/EMA intervention
89330377|NCT01343654|Active Comparator|Treatment as usual|Participants randomized to this arm will receive treatment as usual in the ID clinics and in the communities for nonadherence and drug use problems
89330378|NCT03133468|Experimental|Part 1: AJM347|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of AJM347, respectively, administered in the fasted state on Day 1.
89330379|NCT03133468|Placebo Comparator|Part 1: Placebo|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of matching placebo, respectively, administered in the fasted state on Day 1.
89330380|NCT03133468|Experimental|Part 2: Low-dose AJM347|"Caucasian and Japanese participants will receive a low dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 6 sequential treatment periods."
89330381|NCT03133468|Experimental|Part 2: High-dose AJM347|"Caucasian and Japanese participants will receive a high dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 2 sequential treatment periods (the frequency and timing with respect to meals will be determined after review of the data from the low-dose AJM347 groups)."
89330382|NCT03133468|Experimental|Part 3: AJM347|Caucasian and Japanese participants will be randomized to receive one of three single doses of AJM347 on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
89330383|NCT03133468|Placebo Comparator|Part 3: Placebo|Caucasian and Japanese participants will be randomized to receive one of three single doses of matching placebo on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
89330384|NCT01343732|No Intervention|healthy volunteeres|this arm will undergo only EEG measurement
89330385|NCT01343732|Active Comparator|real - low frequency|this arm will receive DTMS treatment with low frequency
89330386|NCT01343732|Active Comparator|real - high frequency|this arm will receive DTMS treatment with high frequency
89330387|NCT01343732|Sham Comparator|sham - low / high frequency|this arm will receive DTMS sham treatment with low or high frequency
89330388|NCT00065728|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
89330389|NCT03945877||English-speaking Community Members|Survey respondents
89330390|NCT03945877||Spanish-speaking Community Members|Survey respondents
89330391|NCT03945877||Arabic-speaking Community Members|Survey respondents
89330392|NCT00064714|Experimental|Group 1|Group 1 will receive immunosuppression and AC2993; then immunosuppression only
89330393|NCT00064714|Experimental|Group 2|Group 2 will receive AC2993 only; then neither immunosuppression nor AC2993
89330394|NCT00064714|Experimental|Group 3|Group 3 will receive immunosuppression and AC2993; then immunosuppression and AC2993
89330395|NCT00064714|Experimental|Group 4|Group 4 will receive AC2993 only; then AC2993 only
89330396|NCT03943771|Experimental|Virtual modelization group|Patients having their kidney modelized in three dimensions on a software
89330397|NCT03943771|Experimental|Printed modelization group|Patients having their kidney modelized and printed in three dimensions
89330398|NCT03943771|Sham Comparator|Control group|No kidney model
89330399|NCT04771598|Experimental|İntervention|Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
89330400|NCT04771598|Other|Control|Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
89330401|NCT01109485|Experimental|Olopatadine|Olopatadine hydrochloride ophthalmic solution 0.1%
89330402|NCT01112605||otherwise healthy persons|healthy persons, no major trauma or surgery of ankle or calves, no bone or muscle disease, age 18-60
89330403|NCT00292396|Active Comparator|1|Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks
89330404|NCT00292396|Active Comparator|2|Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks
89330405|NCT00292396|Active Comparator|3|Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks
89330406|NCT00292396|Active Comparator|4|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks
89330407|NCT00292396|Active Comparator|5|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks
89330408|NCT00292396|Placebo Comparator|6|placebo, 12 doses
89330409|NCT03942289|Experimental|Healthy controls|
89330410|NCT03942289|Experimental|Parkinson disease|
89330411|NCT02285764|Experimental|Nutritional Supplement|One 237 ml oral supplement consumed two times a day; Not commercially available.
89330412|NCT02285764|Other|Standard of Care|As determined by the study site
89330413|NCT03976999|Experimental|Biological collection|"For all the patients include in the studie :~Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~Tissue samples (tumor tissue and healthy tissue) collected during the surgery~In parallel to this biological collection, standardized clinical data will be entered into a database"
89330414|NCT00284128|Experimental|ilepatril (2.5 mg ) once daily|AVE7688 oral administration
89330415|NCT00284128|Experimental|ilepatril (10 mg) once daily|AVE7688 oral administration
89330416|NCT00284128|Experimental|ilepatril (35 mg) once daily|AVE7688 oral administration
89330417|NCT00284128|Experimental|ilepatril (50 mg) once daily|AVE7688 oral administration
89330418|NCT00284128|Other|Losartan-potassium (100 mg) once daily|oral administration
89330419|NCT01107691|Experimental|Resistance training|1 set of progressive resistance training per session
89330420|NCT01107691|Experimental|3 sets per session|3 sets of progressive resistance training per session
89330421|NCT01107691|No Intervention|Control|Non exercise control group
89330422|NCT03941977|Experimental|Surgery|Group evaluated with MRI and submitted to the percutaneous introduction of cannula for bone grafting
89330423|NCT01209715|Placebo Comparator|Matching Placebo|Participants will be treated with placebo twice a day for 3 weeks.
89330424|NCT01209715|Active Comparator|Fluticasone/salmeterol|Participants will be assigned to inhaled fluticasone/salmeterol twice a day for 3 weeks.
89330425|NCT02288026||Arm I|Patients undergo lobectomy
89330426|NCT02288026||Arm II|Patients undergo a wedge resection or anatomical segmentectomy
89330427|NCT01112761|Experimental|Healthy Subjects|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
89330428|NCT01112761|Experimental|Athletes with history of concussion|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
89330429|NCT02288104|Other|needle based confocal endomicroscopy|The patient, scheduled for a standard liver or kidney percutaneous biopsy or ablation will undergo a needle-based confocal laser endomicroscopy procedure during the procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
89330430|NCT01207375|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
89330431|NCT01207375|Placebo Comparator|Placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
89330432|NCT01109563|Active Comparator|Computer Check-In Control|The Computer Check-In gives the participant contact with the research therapist, an assessment of marijuana use and the current impact of use, and a reminder about optional support sessions.
89523513|NCT03385135|No Intervention|No Allopurinol group|Optimal medical therapy alone
89523514|NCT00462943|Experimental|OMA|"Omacetaxine mepesuccinate (OMA) Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days for up to six cycles.~Omacetaxine mepesuccinate (OMA) Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days for up to 24 months."
89523515|NCT04475185|Experimental|MakAir|
89330433|NCT01109563|Experimental|Marijuana Check-Ins|The MCI, a MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
89330434|NCT01107769||VISIONAIRE™|Total knee arthroplasty with VISIONAIRE™ patient-matched cutting blocks
89330435|NCT01107769||Standard Instrumentation|Total knee arthroplasty with standard instrumentation
89330436|NCT01207531||Survival Group|
89330437|NCT01207531||Death group|
89330438|NCT00277810|Experimental|A|
89330439|NCT00277810|Experimental|B|
89330440|NCT00277810|Experimental|C|
89330441|NCT01207609|Experimental|Laparoscopic Gastric Plication|Collect data prospectively on the safety and efficacy of the Laparoscopic Gastric Plication operation for 50 patients with Severe or Morbid Obesity
89330442|NCT02286232|Experimental|Stretching exercise|A series of 12 standardized, weekly stretching exercise classes will be held at the Wilton Family YMCA, designed for people with chronic low back pain unaccustomed to stretching. Participants will be asked to practice the identical routine of that week's stretching exercise class on off days and will be given handouts and CD's to assist in this.
89330443|NCT02286232|Active Comparator|Self-care book|The Back Pain Helpbook (Moore JE, Lorig K, Von Korff M, Gonzalez VM, Laurent DD. The Back Pain Helpbook. Reading, MA: Perseus Books; 1999)provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
89330444|NCT03942133|Experimental|entrance placement of adductor canal catheter|
89330445|NCT03942133|Experimental|middle point placement of adductor canal catheter|
89330446|NCT02288260||Part A|PATIENTS RECEIVED THE STANDARD MEDICAL CARE AS DETERMINED BY THE TREATING CARDIOLOGIST
89330447|NCT02288260||Part B|Patients on ticagrelor at the time of discharge from hospital
89330448|NCT03740893|No Intervention|Cohort A (standard care reference cohort)|
89330449|NCT03740893|Experimental|Cohort B (AZD6738 monotherapy)|
89330450|NCT03740893|Experimental|Cohort C (olaparib monotherapy)|
89330451|NCT03740893|Experimental|Cohort D (durvalumab monotherapy)|
89330452|NCT03945955|Experimental|Melatonin|
89330453|NCT03945955|Placebo Comparator|Placebo|
89330454|NCT01209793|Experimental|Dose 1|(3:1, active: placebo)
89330455|NCT01209793|Experimental|Dose 2|(3:1, active: placebo)
89330456|NCT01209793|Experimental|Dose 3|(3:1, active: placebo)
89330457|NCT01209793|Experimental|Dose 4|(3:1, active: placebo)
89330458|NCT01209793|Experimental|Dose 5|(3:1, active: placebo)
89330459|NCT02288338|Experimental|1(Lipitor®>Ezetrol®>Lipitor®, Ezetrol®)|"Three treatment~atorvastatin calcium 40mg will be administration to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
89330460|NCT02288338|Experimental|2(Ezetrol®>Lipitor®, Ezetrol®>Lipitor®)|"Three treatment~ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
89330461|NCT02288338|Experimental|3(Lipitor®, Ezetrol®>Lipitor®>Ezetrol®)|"Three treatment~atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
89330462|NCT02288338|Experimental|4(Lipitor®>Lipitor®, Ezetrol®>Ezetrol®)|"atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
89330463|NCT02288338|Experimental|5(Ezetrol®>Lipitor®>Lipitor®, Ezetrol®)|"ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
89330464|NCT02288338|Experimental|6(Lipitor®, Ezetrol®>Ezetrol®>Lipitor®)|"atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
89330465|NCT00388960|Experimental|Amrubicin|Amrubicin 45mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
89330466|NCT00388960|Experimental|Amrubicin plus Cisplatin|Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> IV day 1 of each 21-day cycle until disease progression.
89330467|NCT00388960|Active Comparator|Cisplatin plus etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 each 21-day cycle until disease progression.
89330468|NCT03941899|Other|QLB II|Quadratus Lomborum Blocck II type will be performed before robot-assisted laparoscopic radical prostatectomy
89330469|NCT02288416|Active Comparator|Group I (standard of care)|Patients receive standard of care following LCS consisting of routine visits and telephone contact with the LCS program nurse practitioner and coordinator.
89330470|NCT02288416|Experimental|Group II (video-based intervention)|Patients undergo a video-based intervention prior to undergoing LCS. Patients watch a 5-minute video that focuses on preparing patients for LCS by providing information on the following: program team and contact information; reason to be screened; screening eligibility; how screening is performed; what to expect on the day of screening; what to expect after screening; what to expect if result is positive; what to expect if result is negative; and risks of screening. Patients also receive an educational handbook. Patients with positive scans (a Lung-RADS 3 or 4) receive additional brochure and nursing support within 1 week after notification of scan results.
89330471|NCT03945331|Experimental|TESS|Transcutaneous Electrical Spinal Stimulation (TESS), used during all training sessions.
89330472|NCT03945331|Experimental|EES|TESS, used during the initial 6-month training period, followed by Epidural Electrical Stimulation (EES) during the final 6-month training period.
89330473|NCT02286310|Experimental|Group A|Kinetic Chain Exercises
89330474|NCT02286310|Active Comparator|Group B|Traditional Exercises
89330475|NCT03945487|Experimental|Comprehensive treatment plus UC-MSC treatment|
89330476|NCT03945487|Other|Comprehensive treatment|
89330477|NCT02529787|Experimental|A Test|Test drug (Doxirazole) 1 capsule contains 60 mg of Dexlansoprazole
89330478|NCT02529787|Active Comparator|B Reference|Reference drug (Dexilant) 1 capsule contains 60 mg of Dexlansoprazole
89330479|NCT01328275||1|long-term follow-up of HIV-infected patients on ART
89330480|NCT00267592|Experimental|enzyme-inducing antiseizure drug|A single-arm study with all subjects assigned to one treatment (radiation + temozolomide + talampanel) but subjects receiving concomitant anti-seizure drugs which could increase study drug elimination had a slightly modified dose/schedule of study drug. The primary endpoint is analyzed as a single group.
89330481|NCT01328353|No Intervention|control group|Control group arm follows usual care
89330482|NCT01328353|Experimental|Intervention group arm 1|Intervention group arm 1 receives aprn/telephone care coordination
89330483|NCT01328353|Experimental|Intervention group arm 2|Intervention group arm 2 receives aprn/telephone/video care coordination
89330484|NCT04469998|Experimental|AXR-270 Low Dose|AXR-270 Low Dose administered once daily
89330485|NCT04469998|Experimental|AXR-270 High Dose|AXR-270 High Dose administered once daily
89330486|NCT04469998|Placebo Comparator|AXR-270 Vehicle|AXR-270 Vehicle administered once daily
89330487|NCT01109797|Experimental|Transition Social Behavioral Intervention|
89330488|NCT01109797|Experimental|Diabetes Transition Clinic|
89330489|NCT01210105||Macintosh #3 Laryngoscope|
89330490|NCT01210105||Glidescope|
89330491|NCT01210105||Ambu Pentax AWS|
89330492|NCT01210105||McGrath|
89330493|NCT01210105||Airtraq|
89330494|NCT01210105||Storz C-MAC|
89330495|NCT03530644|Experimental|RSP-14|"Comparative study of two Investigational Medical Devices (WM3.4NR and P0.1)~Optical data will be obtained from T1D over a dynamic glycemic range. Data will be paired with references."
89330496|NCT03530566||Pnk group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, scheduled bariatric surgery within 3 months will be treated with PnK® Method
89330497|NCT03530566||Control group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, treated with standard diet 3 moths prior bariatric surgery
89330498|NCT03942055||B-line score ≥7|"Patients with B-line score ≥7 at the end of the surgical procedure.~The Sonosite Edge II Ultrasound device will be used.~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
89330499|NCT03942055||B-line score <7|"Patients with B-line score <7 at the end of the surgical procedure.~The Sonosite Edge II Ultrasound device will be used.~The B-line score will be partially based on the simplified 4-sector lung ultrasound scoring protocol used by Phillip Enghard at el. The Enghard study showed a closed correlation between the number of B-lines per intercostal space and EVLW Index measurements."
89330500|NCT01112839|Active Comparator|Less Intensive Group|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
89330501|NCT01112839|Experimental|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
89330502|NCT03943069|Experimental|Patient with PSP|Patient who will be admitted with primary spontaneous pneumothorax.
89330503|NCT04252495|Experimental|Subjects with moderate hepatic impairment (Group 1)|
89330504|NCT04252495|Experimental|Healthy subjects (Group 2)|
89330505|NCT03530488|Active Comparator|Lidocaine group|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline 5 minutes before hystroscopy
89330506|NCT03530488|Placebo Comparator|control group|intrauterine and intracervical instillation of 19 ml normal saline 5 minutes before hystroscopy
89330507|NCT02529709|Experimental|High-protein meal condition|
89330508|NCT02529709|Active Comparator|High-monounsaturated fat meal condition|
89330509|NCT05202028|Experimental|Classic abdominal massge|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Classic abdominal massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
89330510|NCT05202028|Experimental|Connective tissue massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
89330511|NCT05202028|Experimental|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
89330512|NCT03945253|Experimental|ASP8374-dose A|Participants will receive dose A of ASP8374 solution intravenously on day 1 of every 3-week cycle.
89330513|NCT03945253|Experimental|ASP8374-dose B|Participants will receive dose B of ASP8374 solution intravenously on day 1 of every 3-week cycle.
89330514|NCT00262990|Experimental|Patupilone|
89330515|NCT00262990|Active Comparator|doxorubicin|
89330516|NCT01112995|Experimental|Probiotic|subjects will be given a pill formulation of a probiotic Lactobacillus rhamnosus to be taken once a day.
89330517|NCT01112995|Placebo Comparator|Sugar pill|placebo identical to the active product will be given
89330518|NCT03942523|Experimental|School Children|School children will be administered with behavioral change communication sessions as an intervention
89330519|NCT01108315|Experimental|Intervention|The participant used the web and/or phone-based PRO reporting symptoms to enter symptoms twice a week at minimum.
89330520|NCT01108315|No Intervention|Usual Care|The participants on this arm do not record their symptoms. They report symptoms as they would under usual care.
89330521|NCT03941821||G/P treatment|Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment
89330522|NCT01210261|Active Comparator|Autoset S8|Single night auto-titrating CPAP treatment using the reference device (Resmed Autoset S8) with polysomnographic monitoring
89330523|NCT01210261|Experimental|Somnilink SPAP|Single night auto-titrating CPAP treatment using the test device with polysomnographic monitoring
89330524|NCT01109953||Breath-Hold PET/CT image|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both.
89330525|NCT01110031|Experimental|Treatment|Six months treatmet with ofatumumab will be given to subjects with chronic lymphocytic leukemia.
89330526|NCT02741596|Experimental|Rollover Participants|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
89330527|NCT02741596|Experimental|Non-rollover Participants|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
89330528|NCT01110109||Continuous Suctioning|Anesthesia staff will suction secretions continuously at 20 mmHg with a safety stop of 5 seconds every 30 minutes.
89330529|NCT01110109||Intermittent Suctioning|Anesthesia staff will suction secretions intermittently using an intermittent suction regulator. The regulator will be set to suction at 100-150 mmHg. The regulator has a preset cycle of intermittent suctioning for 15 seconds with an 8 second pause.
89330530|NCT01110265|Placebo Comparator|placebo training|
89330531|NCT01110265|Experimental|attention training|
89330532|NCT03941665|Experimental|Gelronate|Tested new medical device
89330533|NCT03941665|Active Comparator|Aloevera|Current product used by the medical center
89330534|NCT01210339|Experimental|1|Treatment A (Clopidogrel 9 days), at least 14 days wash-out, Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days)
89330535|NCT01210339|Experimental|2|Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days), at least 14 days wash-out, Treatment A (Clopidogrel 9 days)
89330536|NCT03147248|Active Comparator|Cohort 1: CT-P13 IV 3 mg/kg|CT-P13 Intravenous (IV) (Infliximab), 3 mg/kg by IV infusion every 8 weeks (Part 1)
89330537|NCT03147248|Experimental|Cohort 2: CT-P13 SC 90 mg|CT-P13 Subcutaneous (SC) (Infliximab), 90 mg by SC injection every other week (Part 1)
89330538|NCT03147248|Experimental|Cohort 3: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week (Part 1)
89330539|NCT03147248|Experimental|Cohort 4: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every other week (Part 1)
89330540|NCT03147248|Experimental|Arm 1: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week with placebo intravenous infusion at Weeks 6, 14 and 22 (Part 2)
89330541|NCT03147248|Active Comparator|Arm 2: CT-P13 IV 3 mg/kg|CT-P13 IV (Infliximab), 3 mg/kg by IV infusion every 8 weeks with placebo subcutaneous injection at Week 6 and every 2 weeks thereafter up to Week 28 (Part 2)
89330542|NCT03945097||Letters|Education program focuses on learning letters.
88806706|NCT05821504|Experimental|Cycling High-Intensity Interval Training|This group performed high-intensity interval training consisting of cycling exercise.
88806707|NCT05821296|Other|Crystal Peel|2.5 ml of Crystal peel applied up to 3 coats and performed 3 times in the study (i.e: at Day 15, Day 36 and Day 57.
89330543|NCT03945097||Language|Education program focuses on language comprehension.
89330544|NCT01113073|Experimental|Elective open heart surgery|Patients who had undergone elective open heart surgery
89330545|NCT02288494||hypoalbuminemia|The primary purpose was to describe the acid base balance of ICU patients with severe hypoalbuminemia using Stewart's approach for acid base disorders, before and after an human albumin perfusion
89330546|NCT05251064|Active Comparator|Suture|Standard suture wound closure
89330547|NCT05251064|Active Comparator|Adhesive wound closure device|Clozex wound closure device
89330548|NCT05251064|Active Comparator|Adhesive wound closure device with zip ties|Zipline wound closure device
89330549|NCT05719012|Experimental|UC-MSCs|UC-MSCs
89330550|NCT05719012|Placebo Comparator|Placebo|0.9% Normal Saline
89330551|NCT03796039|Experimental|Standing and Social Intervention|Participants be exposed to an additional 100 minutes of standing per week. Participants will do this by standing for 20 minutes Monday through Friday.
89330552|NCT03796039|No Intervention|Control Group|Control group will receive social visits, but no exposure to standing
89330553|NCT01343810|Experimental|Meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The experimental arm will be randomly assigned to practice meditation immediately following the emotional stress task in the lab during the post-MBSR lab visit.
89330554|NCT01343810|Active Comparator|No meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The active comparator arm will be randomly assigned to not practice meditation, but rather listen to a non-meditative audio track of equal length, immediately following the emotional stress task in the lab during the post-MBSR lab visit.
89330555|NCT05717452|Experimental|Blueberry drink|
89330556|NCT05717452|Placebo Comparator|Placebo drink|
89330557|NCT01344044|Active Comparator|BCI treatment|BCI treatment will commence during the week of the Baseline.
89330558|NCT01344044|Other|Wait-list control|BCI treatment will commence 8 weeks after Baseline
89330559|NCT01344044|Experimental|BCI pilot arm|This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious.
89330560|NCT02288572|Active Comparator|Lactobacillus plantarum PCS 26|Dosage: 1.000.000.000 Colony Forming Units (CFU) per day in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
89330561|NCT02288572|Placebo Comparator|Placebo|Only vehicle components in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
89330562|NCT02288650|Experimental|Liberal group|Early refeeding
89330563|NCT02288650|Sham Comparator|Control group|Refeeding in the day case ward (usual practice)
89330564|NCT01207921|Experimental|Arm 1|"Lenalidomide 15 mg/day Cycle 1 (28 days).~If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.~If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day."
89330565|NCT05725486|Experimental|n-3 PUFA|Intake of n-3 PUFAs enriched chicken meet for three weeks
89330566|NCT05725486|Experimental|Control|Intake of regular chicken meet for three weeks
89330567|NCT01108393|Experimental|Agomelatine A|
89330568|NCT01108393|Placebo Comparator|Placebo|
89330569|NCT03532594|Other|Standard Care|At the conclusion of cardiopulmonary bypass, protamine administration will be undertaken at surgical request. For patients in the control group, protamine will be dosed on a 1:1 ratio according to the total dose of heparin initially required to establish a therapeutic activated clotting time (ACT) (i.e. if 30,000 IU were required prior to initiating cardiopulmonary bypass, then the protamine dose will be 300mg).
89330570|NCT03532594|Experimental|Algorithm|For patients in the intervention group, protamine will be administered according to the PRODOSE algorithm, which has been incorporated into an Excel spread sheet for ease of use (Microsoft Corporation).
89330571|NCT01207999||Group A|Subjects diagnosed with invasive cervical cancer
89330572|NCT01113151|No Intervention|Washout|
89330573|NCT01113151|Active Comparator|Mablet|
89330574|NCT01113151|Placebo Comparator|Placebo|
89330575|NCT03530410||Patients with intragastric balloon|Patients who will receive an intragastric balloon placement for weight loss
89330576|NCT01210417||Trauma victims|All prehospital traumatic patients enrolled by our Helicopter Emergency Medical System (HEMS)
89330577|NCT03530332|Experimental|Treatment|
89330578|NCT03530332|No Intervention|Control|
89330579|NCT01113229|Experimental|Misoprostol|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two misoprostol tablets taken orally (400µg) following cord clamp
89330580|NCT01113229|Placebo Comparator|PLACEBO|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two placebo tablets taken orally following cord clamp.
89330581|NCT03530176|Experimental|single arm|18F-NaF (sodium Flouride ) is a radio-pharmaceutical used to image skeletal pathology, including primary and secondary neoplasms. Despite US Federal Drug Administration (FDA) approval and 18F-NaF being listed in the US Pharmacopeia, 18F-NaF is not currently approved by Health Canada for use as a cardiac imaging tracer. Therefore, a concurrent Health Canada Clinical Trial Application is being submitted to ensure its availability. Intervention on single arm: A dose of 18F-NaF (200 - 400 MBq) will be injected intravenously at rest. After a 60 minute, an ECG-gated PET acquisition will be performed centered over the heart for 20 minutes. A CT coronary calcium score examination will also be performed on a dedicated CT scanner and the Agatston and volume scores calculated according to standards.
89330582|NCT03942679|Other|PRPinjection group|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 201
88806708|NCT05820321|Active Comparator|Experimental (Beetroot juice NO3)|8-day supplementation with beetroot juice rich in NO3 (400mg) during 8 days.
88806709|NCT05820321|Placebo Comparator|Placebo (Beetroot juice without NO3)|8-day supplementation with beetroot juice NO3 depleted during 8 days.
88806710|NCT05794880|Experimental|Alpha/Beta T cell depletion (TCD) plus CD19+ depletion|Alpha beta T cell and B cell depleted allogeneic transplantation with individualized dosing of ATG for patients with hematologic malignancies
88806711|NCT05786287||Conditioned Medium (CM)|2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell injected into peribulbar
88806712|NCT05786287||UC-MSC + NaCl|1.8 ml cell preparations are suspended in physiological NaCl until it reaches a 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension injected into peribulbar
89330583|NCT03942679|Other|physiotherapy group|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks
89330584|NCT02288728|Experimental|Group B (double-track anastomosis)|Patients in the Group B will received the double-track anastomosis with proximal gastrectomy.
89330585|NCT02288728|Other|Group A (Gastric tube anastomosis)|Patients in the Group A (Gastric tube anastomosis) will take the gastric tube anastomosis with proximal gastrectomy.
89330586|NCT01110343|Active Comparator|mindfulness intervention group|Mindfulness intervention is a formatted curriculum based on Mindfulness based stress reduction techniques which have proven effective in reducing stress related to pain, everyday living and medical and psychiatric disorders.
89330587|NCT01110343|Active Comparator|conventional parent support group|a 6 week behavioral program, with weekly 1.5 hour sessions with a trained parent mentor, 3 monthly booster sessions and follow-up.
89523516|NCT04436965|Experimental|Standard nutrition therapy|Dynamic nutrition assessment will be performed to patients. If malnutrion happened, patients would receive oral nutritional supplements (ONS) first, then feeded with nasal feeding tube or PEG when ONS wasn't enough. If all the these enteral nutrition methods couldn't make up for patient's nutritional deficiencies, parenteral nutrition would be considered.
89330588|NCT03151304|Experimental|Stage 1a and 1b open-label pracinostat plus azacitidine|"open-label single arm pracinostat plus azacitidine. Pracinostat: 45 mg administered orally 3 days each week for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.~In later cycles (i.e., after Cycle 4), pracinostat dose reduction to 45 mg orally 3 days each week × 2 weeks (instead of 3 weeks) or dose interruption is allowed to manage toxicity such as fatigue, gastrointestinal toxicity, or myelosuppression.~Azacitidine: 75 mg/m2 for 7 days of each 28-day cycle. Administration will occur by subcutaneous (SC) injection, or IV infusion if SC injections are not tolerated, on one of two schedules:~Schedule 1 - daily therapy on Days 1 through 7~Schedule 2 - 5-2-2 schedule in which subjects receive azacitidine for 5 consecutive days (Days 1 through 5) with rest on Days 6 and 7, and resume azacitidine dosing the first two days of the next week (Days 8 and 9) of each 28-day cycle"
89330589|NCT03532438||NTM patient group|NTM lung disease patients living together
89330590|NCT01208077||Acute CHF|"Recurrent or worsening (within 3 days) shortness of breath as the primary presenting ED complaint~Initial treating ED physician impression that the worsening dyspnea is most likely caused by decompensated CHF~Known history of physician diagnosed CHF~Natriuretic peptide (BNP, MR-pro ANP, NT pro BNP) level will be ordered by the treating physician as part of the patient's work up"
89330591|NCT01208077||Acute Stroke Syndrome|"Onset of abnormal neurological symptoms consistent with possible stroke, within the prior 24 hours, as the primary ED complaint~Initial treating ED physician impression that the abnormal neurological symptoms/signs are most likely caused by an acute stroke syndrome~Non contrast head CT will be ordered by the treating physician as part of the patient's work up"
89330592|NCT01208077||Acute Systemic Infection|"Any combinations of acute (within 3 days) symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection~Blood cultures and/or a blood lactate will be ordered by the treating physician as part of the patient's work up"
89330593|NCT02288884|Active Comparator|Silver containing dressing|Subjects will have a silver containing dressing (Acticoat PostOp) applied at the time of elective cesarean section.
89330594|NCT02288884|Placebo Comparator|Standard dressing|Subjects will have a standard dressing (OpSite PostOp) applied at the time of elective cesarean section.
89330595|NCT01208155|Experimental|1|Fostamatinib 50 mg tablet x 2
89330596|NCT01208155|Experimental|2|Fostamatinib 100 mg tablet (batch 1)
89330597|NCT01208155|Experimental|3|Fostamatinib 100 mg tablet (batch 2)
89330598|NCT01208155|Experimental|4|Fostamatinib 100 mg tablet (batch 4)
89330599|NCT03530020|Active Comparator|monolithic zirconia crowns|Monolithic zirconia attracts many dentists worldwide due to its excellent mechanical properties, biocompatibility and appreciate aesthetics
89330600|NCT03530020|Experimental|lithium silicate crowns|A lithium silicate glass ceramic is newly introduced to the market. After crystallization, it exhibits an ideal combination of aesthetics and strength with translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns.
89330601|NCT02288962|Experimental|cabergoline|"Target dose for cabergoline is 2 mg/week.The medication is administered in the evening to minimize side effects. If intolerable side effects occur despite this, it may be necessary to treat with a lower dose than 2 mg per week.~Treatment scheme: 0.5 mg x 1 per week the first 2 weeks, then 0.5 mg x 2 per week the next 2 weeks, then 1 + 0.5 mg per week the next 2 weeks, then 1 mg x 2 per week (target dose) for the rest of the study"
89330602|NCT02288962|No Intervention|observation|visits and controls as usual
89330603|NCT01210573||Device adjustment|Advanced or suspected advanced heart failure. Most are anticipated to have severely depressed ejection fraction (<30% and typically <20%), but patients with preserved ejection fraction and either hypertrophy or restrictive cardiomyopathy will also be eligible. Patients pulmonary hypertension, on any therapy (other than diuretics alone), are also felt to be at high risk of developing right heart failure and may also be included. Patients who have already undergone LVAD or cardiac transplant are also considered to have advanced heart failure and are eligible to participate, regardless of the severity of their symptoms at the time of enrollment.
89330604|NCT01328119|Other|hemodialysis patients|conventional hemodialysis patients
89330605|NCT03942991|Active Comparator|2% Mepecaine-L|infiltration injection of 2% Mepivacaine
89330606|NCT03942991|Experimental|4% Artpharmadent|infiltration injection of 4% Articaine
89330607|NCT03532204|Experimental|Chemotherapy + SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
89330608|NCT03532204|Active Comparator|Chemotherapy|Patients will receive chemotherapy as initially scheduled
89330609|NCT03532126||Dermal filler for midface deficit|There will be one group in this study, the actual treatment group.
89330610|NCT01208311||Patients with Hepatitis C Cirrhosis|Patients with Hepatitis C Cirrhosis
89330611|NCT03529864|Experimental|Exercise therapy|The participants took part in a progressive exercise therapy program for 9 consecutive weeks, once a week. This consisted of group sessions with 8 or 9 students, with each session lasting 60 minutes, supervised by the principal researcher
89330612|NCT03529864|No Intervention|Control|The CG did not receive any type of information or instructions apart from the general information sheet on the progress of the study, attached to the informed consent form
89330613|NCT01208467||Basic science (DNA analysis)|DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
89330614|NCT05725330|Experimental|Intervention Group|Application of data collection forms for the initial evaluation. Teaching the use of mobile games, monitoring the use of mobile games in the experimental group by the researcher for six weeks, and applying data collection forms to the patients in the sixth week.
89330615|NCT05725330|No Intervention|Control Group|Application of data collection forms for the initial evaluation. Application of data collection forms to the patients in the sixth week. No intervention will be made to the patients in the control group other than the routine education given in the diabetes outpatient clinic.
89330616|NCT01113307||Hard to heal wounds|
89330617|NCT04469608|Experimental|TCM clinical daycare model for depression patients|Tai Chi and Acupuncture and Yoga and Mindfulness
89330618|NCT04469608|No Intervention|Depression patients|Tai Chi and acupuncture and yoga and mindfulness are not added
89330619|NCT01210885|Experimental|Group I: Investigational MenABCWY Formulation 1|
89330620|NCT01210885|Experimental|Group II: Investigational MenABCWY Formulation 2|
89330621|NCT01210885|Experimental|Group III: Investigational MenABCWY Formulation 3|
89330622|NCT01210885|Experimental|Group IV: Investigational MenABCWY Formulation 4|
89330623|NCT01210885|Active Comparator|Group V: Active comparator investigational MenB|
89330624|NCT01210885|Active Comparator|Group VI: Active comparator MenACWY|
89330625|NCT03529708|Experimental|SBRT boost|Standard radiotherapy (3D conformal, urgent palliative radiotherapy) plus stereotactic body radiotherapy (SBRT) boost
89330626|NCT01210963||SENSIMED Triggerfish|
89330627|NCT03941041|Experimental|Prenatal Yoga Practice|Pregnant women participating in a yoga course at least 12 session, each session in duration of 90 minutes.
89330628|NCT03941041|No Intervention|Regular Prenatal Care|Pregnant women being treated according to national guidelines
89330629|NCT03529552|Experimental|Patients with anterior cruciate ligament rupture|
89330630|NCT01110577||Traveling cohort|Overweight patients with or without type 2 diabetes or pre-diabetes
89330631|NCT00128128|Active Comparator|Arm 1|Cranberry Juice Cocktail- 4 ounces
89330632|NCT00128128|Active Comparator|Arm 2|Cranberry Juice Cocktail-8 ounces
89330633|NCT00128128|Placebo Comparator|Arm 3|Placebo- 4 ounces
89330634|NCT00128128|Placebo Comparator|Arm 4|Placebo- 8 ounces
89330635|NCT03531970|Experimental|Dexamethasone|lidocaine & Dexamethasone
89330636|NCT03531970|Placebo Comparator|Non-dexamethasone|lidocaine & Placebo
89330637|NCT01211743|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
89330638|NCT01211743|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
89330639|NCT03529474|Experimental|Psychology and Physiotherapy group|The psychological program consists of 4 sessions (2 hours each) comprising psychoeducation, training techniques of psychological management of pain and kinesiophobia resources The physiotherapy program consists of 3 domiciliary sessions per week, including physical exercise and stretching
89330640|NCT03529474|Placebo Comparator|Placebo Comparator: Control group|Usual daily activities
89330641|NCT01211119|Experimental|platelet-rich fibrin, PRF|
89330642|NCT01110655|Experimental|Intravenous hypertonic saline|
89330643|NCT01110655|Experimental|Oral hypertonic saline|
89330644|NCT01211821|Other|metoprolol|Treatment A
89330645|NCT01211821|Experimental|BMS-914392 + metoprolol|Treatment B
89330646|NCT03527836|Active Comparator|Lidocaine|Lidocaine brachial plexus block 0.4 ml/kg of 0.66% solution
88806713|NCT05786287||UC-MSC+CM|1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension injected into peribulbar
88806714|NCT05780450|Experimental|Treatment group|
88806715|NCT05763849|Experimental|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance, food exposure, and body image exposure.
88806716|NCT05763849|Active Comparator|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) focuses on parent-enforced contingencies, increasing value of eating, and decreasing the value of food avoidance.
89330647|NCT03527836|Active Comparator|Bupivacaine|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
89330648|NCT03527836|Active Comparator|Mixture|Mixture brachial plexus block 0.4 ml/kg of 0.33% bupivacaine and 0.33% lidocaine solution
89330649|NCT01110811|Active Comparator|TIF procedure|Transoral Incisionless Fundoplication (TIF)
89330650|NCT01110811|Sham Comparator|Sham procedure|The intervention on the Sham procedure consisted of an upper gastrointestinal endoscopy, or EGD.(esophagogastricduodenoscopy).
89330651|NCT03529240|Experimental|Kinesiology taping|After performing the baseline assessments, kinesiology taping with facilitation technique was applied on bilateral quadriceps and tibialis anterior muscles of children. In both applications, the first and last 5 cm section of the bands were used as anchor and no tension was applied.
89330652|NCT03940885|Active Comparator|Erector spinea plane block group|this group is planned for ultrasound-guided Transversus abdominis plane block
89330653|NCT03940885|Active Comparator|Transversus abdominis plane block|this group is planned for ultrasound-guided Transversus abdominis plane block
89330654|NCT03940885|Placebo Comparator|Control group|standard general anesthesia
89330655|NCT03941431|Experimental|Chinese medicine internal treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin granule two times daily after meals and moving cupping placebo therapy three times per week for 8 weeks.
89330656|NCT03941431|Experimental|Chinese medicine external treatment group|Participants in Chinese medicine internal treatment group will receive Jueyin placebo granule two times daily after meals and moving cupping therapy three times per week for 8 weeks.
89330657|NCT03941431|Experimental|Chinese medicine treatment group|Participants in Chinese medicine treatment group will receive Jueyin granule two times daily after meals, moving cupping therapy and NB-UVB placebo therapy three times per week for 8 weeks.
89330658|NCT03941431|Experimental|Western medicine treatment group|Participants in Western medicine treatment group will receive Jueyin placebo granules two times daily after meals, moving cupping placebo therapy and NB-UVB therapy three times per week for 8 weeks.
89330659|NCT03941431|Experimental|Integrated Chinese and Western Medicine Treatment Group|Participants in Chinese and Western Medicine Treatment Group will receive Jueyin granules two times daily after meals, moving cupping therapy and NB-UVB therapy three times per week for 8 weeks.
89330660|NCT03531424|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
89330661|NCT03531424|Experimental|CTA guided PCI|CTA guided PCI is coronary revascularization based on systematic use of CTA plus coronary angiography.
89330662|NCT05724862|Experimental|Needle-less jet anaesthesia|Infiltration anaesthesia without needle
89330663|NCT05724862|Active Comparator|Conventional injection anaesthesia|Regular infiltration anaesthesia
89330664|NCT01111045|Active Comparator|Arm 1|0.03 mg/ml BMP-7, single intraarticular knee injection
89330665|NCT01111045|Active Comparator|Arm 2|0.1 mg/ml BMP-7, single intraarticular knee injection
89330666|NCT01111045|Active Comparator|Arm 3|0.3 mg/ml BMP-7, single intraarticular knee injection
89330667|NCT01111045|Placebo Comparator|Arm 4|1 ml placebo, single intraarticular knee injection (control)
89330668|NCT03940651|Experimental|Knee Arthroplasty|Surgery to replace the knee joint with prothetic joint
89330669|NCT03940651|Experimental|Hip Arthroplasty|Surgery to replace the hip joint with prothetic joint
89330670|NCT03527758|No Intervention|Standard Invasive intraoperative monitoring|
89330671|NCT03527758|Experimental|Flo TracIQ with HPI software|
89330672|NCT01328665|Experimental|Expressive Writing|Affectionate Writing Intervention for 20 minutes per day, 2 times per week, 6 weeks.
89330673|NCT01328665|No Intervention|No writing|Control Group -- No writing
89330674|NCT03152552|Experimental|LIK066 2.5mg|Eligible participants randomized to this treatment arm received the LIK066 2.5mg dose regimen once daily for 36 weeks.
89330675|NCT03152552|Experimental|LIK066 10mg|Eligible participants randomized to this treatment arm received the LIK066 10mg dose regimen once daily for 36 weeks.
89330676|NCT03152552|Experimental|LIK066 50mg|Eligible participants randomized to this treatment arm received the LIK066 50mg dose regimen once daily for 36 weeks.
89330677|NCT03152552|Active Comparator|Empagliflozin|Participants randomized to this treatment arm received empagliflozin once daily for 36 weeks.
89330678|NCT03152552|Placebo Comparator|Placebo|Participants randomized to this treatment arm received LIK066 matching placebo and empagliflozin matching placebo.
89330679|NCT05724706||Patients with peri-implantitis (PI)|The PI group consisted of 23 patients (9M/14F) with ages ranging from 29 to 66 years (mean 51,91 ± 10,63). This group was selected based on the success criteria of Misch et al. 2008; patients with clinical findings such as bleeding and/or sweeping in their implants, pain or tenderness during function, and exudation in peri-implant tissues, with at least 1 implant with a pocket depth of more than 7 mm and radiographic bone loss of at least 4 mm or more around the implant were included.
89330680|NCT05724706||Patients with marginal bone loss (MBL)|The MBL group consisted of 22 patients (14M /8F) aged between 27 and 67 years (mean 53,00 ± 8,92). This group was based on the success criteria defined by Misch et al. 2008; patients for whom, in the clinical examination of implants, there was no bleeding, non-sweeping, non-mobility, with no exudation history of peri-implant tissues, no pain or sensitivity when in function, and there was at least 1 implant with 2-4 mm radiographic bone loss around the implant were included.
89330681|NCT05724706||Patients with healthy peri-implant tissues (HI)|The HI group consisted of 22 patients(7M/15F) with ages ranging from 29 to 62 years (mean 51,00 ± 8,45). This group was based on the success criteria defined by Misch et al. in 2008: Patients with no history of exudation in the periimplant tissues, no bleeding and suppuration during probing, no pain or sensitivity in function, no mobility, and at least 1 implant with a radiographic bone loss around the implant of less than 2 mm were included.
89330682|NCT05724706||Healthy control (HC)|21 individuals (8M/ 13F) whose ages ranged between 27 and 67 (mean 21.88 ± 11.21 years), who did not have any dental implants, and who were selected among the patient community were included the study as a healthy control group (HC).
89330683|NCT01211275|Experimental|arm 2|axitinib + cisplatin + premetrexed
89330684|NCT01211275|Active Comparator|arm 1|cisplatin + premetrexed
89330685|NCT03529084|Experimental|EGF816|Investigational treatment arm of EGF816 (nazartinib).
89330686|NCT03529084|Active Comparator|Investigator's Choice|Investigator's Choice (erlotinib or gefitinib).
89330687|NCT03942757||observation before educational program|100 preterm infant medical records will be studied in a first part of this observational study
89330688|NCT03942757||Observation after educational program|An educational program will be implemented in the unit after this first period. 100 preterm infant will be included in a second part of this observational study.
89330689|NCT01111201||questionnaires|There will be four versions of the questionnaire, each slightly modified to be more specific toward the treatment paradigms in the respective target patient population (Breast Cancer/ Lymphoma/Autologous Bone Marrow Transplant/ Allogeneic Bone Marrow Transplant). All questionnaire versions will consist of seven sections.
89330690|NCT01114399|Experimental|Standard Broccoli|Standard Broccoli
89330691|NCT01114399|Experimental|High Glucosinolate Broccoli|High Glucosinolate Broccoli
89330692|NCT01114399|Experimental|Peas|Peas
89330693|NCT01111279|Placebo Comparator|Placebo|
89330694|NCT01111279|Experimental|gpASIT+TM|
89330695|NCT01111279|Experimental|gpASIT+TM/adjuvant|
89330696|NCT03527680|Experimental|Lactobacillus rhamnosus|received daily one capsule containing 1.6*107 CFU of Lactobacillus Rhamnosus
89330697|NCT03527680|Placebo Comparator|Placebo|received one placebo capsule per day Infant formula after meal for 28 days
89330698|NCT03151226|Other|capnography monitoring|single arm, all subjects receiving duramorph will receive capnography monitoring
89523517|NCT04436965|Active Comparator|Conventional nutrition therapy|Dynamic nutrition assessment will be performed to patients throughout whole treatment, and symptomatic treatment would be performed if needed.
89523518|NCT04420741|Experimental|Iloprost|Patients randomized to active treatment (n=40 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
89330699|NCT03529006|Active Comparator|Sequent Please Drug Coated Balloon Group|For Sequent Please Group, PCI (percutaneous coronary intervention) PCI procedure with Sequent Please inflation will be performed - drug eluting balloon will be used in the narrowed part of the artery. This method of treatment is one of the standard ones, which is typically used for treatment patients with diagnosis of in stent restenosis, the exact intervention and anesthesia procedures will be performed according to physician's usual practice. For bailout situation Xience stent implantation is possible.
89330700|NCT03529006|Active Comparator|Absorb Stent Group|Absorb scaffold group will be treated by PCI procedure with Absorb BVS implantation - implantation of bioresorbable vascular scaffold (Absorb). Coronary stent implantation for treatment in stent restenosis is one of the standard method of treatment this disease, but Absorb system has not been investigated in this indication yet.
89330701|NCT03528928|Experimental|Surface electrical stimulation|Each subject did a Kegel pelvic floor contraction, had the surface electrical stimulation turned on at highest comfortable intensity, did a Kegel contraction with surface electrical stimulation on, and had second electrical stimulation turned on.
89330702|NCT01208623||2D|2D digital venography images alone
89330703|NCT01208623||3D|3D rotational venography
89330704|NCT01208623||Combine|combined MDCT angiography/venography
89330705|NCT01208701|Active Comparator|Atorvastatin|
89330706|NCT01208701|Placebo Comparator|Placebo|
89330707|NCT03151148|Experimental|TMT Lotion|The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to active TMT will apply 2 grams of TMT to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
89330708|NCT03151148|Placebo Comparator|Placebo Lotion|Placebo lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to placebo will apply 2 grams of placebo to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
89330709|NCT01113619|Experimental|RP-G28|Study Drug RP-G28
89330710|NCT01113619|Placebo Comparator|Placebo|Study Drug Placebo
89330711|NCT03527602|Experimental|Intervention|Endodontic treatment will be performed in maxillary anterior teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with rotary files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
89330712|NCT03527602|No Intervention|Control|In the control group, no foraminal enlargement will be performed.
89330713|NCT01113775||presence of right ventricle dysfunction|
89330714|NCT01113775||absence of right ventricle dysfunction|
89330715|NCT03528850|Experimental|Telehealth|The Telehealth arm will receive daily biometric measurement of blood pressure, heart rate, oxygen saturation and weight. The Telehealth arm will also have weekly virtual visits for the first month after hospital discharge. The Telehealth arm will answer surveys weekly for the first 30 days.
89330716|NCT03528850|No Intervention|Standard of Care|The Standard of Care will receive no interventions but will conduct surveys at enrollment and at the end of 30 days.
89330717|NCT03940573|Experimental|Treatment|All patients fitted with the device.
89330718|NCT03527524|Experimental|exercise with ball|The participant in core stabilization exercise with ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
89330719|NCT03527524|Other|exercise without ball|The participant in core stabilization exercise without ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
89330720|NCT01211353|Experimental|Personalized Drinking Feedback|Personalized feedback on drinking behaviors
89330721|NCT01211353|Active Comparator|Education-Only|Educational information about alcohol
89330722|NCT03528772|Active Comparator|Minoxidil|Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
89330723|NCT03528772|Active Comparator|Glyceryl trinitrate|Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks
89330724|NCT01211431|Active Comparator|Reference|Intrathécale morphine is used for post-cesarean pain control
89330725|NCT01211431|Experimental|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
89330726|NCT01117519|Active Comparator|unbalanced infusion solution|
89330727|NCT01117519|Active Comparator|balanced infusion solution compound|
89330728|NCT03527446|Experimental|Normal Weight|BMI ≥ 18.5 < 25.0 km/m2 Sprint Interval Training
89330729|NCT03527446|Experimental|Individuals living with Obesity|BMI ≥ 30.0 km/m2 Sprint Interval Training
89330730|NCT03938077|Experimental|S4E App intervention|"Youth will receive the S4E intervention via provided iPads. The intervention will last approximately 60. Content includes: (a) storytelling scenarios, (b) drug use and HIV/STI knowledge, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual and drug use risk behaviors and increase HIV self-testing, (e) Near Peer-youth communication, and (f) highlighting prevention principles. The youth will participate in a Near Peer-initiated prevention and risk reduction encounter which includes (a) reinforcement of HIV solutions that youth learned in the S4E app, (b) promotion of HIV self-tests, and (c) linkage to care and prevention services.~Youth have the option to take a HIV self-test. We will determine the acceptability of youth disclosing their results to their Near Peer and linkage to resources.~The research staff will also conduct in-depth qualitative interviews with both youth and Near Peer participants to assess feasibility and acceptability of S4E."
89330731|NCT03938233|Active Comparator|DSME program delivered by community health volunteers|Randomisation will happen in 21 primary care units to offer DSME delivered by lay health workers to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
89330732|NCT03938233|Active Comparator|DSME program delivered by nurses|Randomisation will happen in 21 primary care units to offer DSME delivered by nurses (for comparative effectiveness) to those newly diagnosed with diabetes and those having difficulties with self-managing their diabetes.
89330733|NCT03938233|No Intervention|Usual care(no DSME program)|Randomisation will happen in 21 primary care units where no DSME will be offered to those newly diagnosed with diabetes and/or those having difficulties with self-managing their diabetes.These patients will continue with usual care and will be assessed as the control group.
89330734|NCT05572294|Experimental|Mindfulness and Yoga Therapy|Participants will have access to video-guided mindfulness interventions.
89330735|NCT01114711||Frovatriptan|All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).
89330736|NCT01316822|Experimental|ARRY-382|
89330737|NCT01213381|Experimental|SAR240550|"single cohort: SAR240550~combination cohort: SAR240550 in combination with Gemcitabine and Carboplatin"
89330738|NCT01344122|Active Comparator|KPI training only|Study sites randomized to this arm will receive a knowledge, perceptions and information (KPI) training for community correctional and treatment staff to address knowledge, perceptions, and information regarding local resources about MAT.
89330739|NCT01344122|Experimental|KPI plus OLI|Study sites randomized to this arm will receive the KPI training plus a Organizational Linkage Intervention (OLI) that will: (a) establish a local Pharmacotherapy Exchange Council (PEC) among agencies important for the implementation of MAT in community corrections; (b) facilitate a strategic planning process within the PEC to increase the availability of MAT for opiate and/or alcohol dependent individuals who are on probation/parole; and (c) identify a community corrections coordinator in one of the local agencies to operationalize and implement the strategic plan.
89330740|NCT03531346|Experimental|Hyperosmolarity group|Healthy, young, habitual contact lens wearers with initial increased tear osmolarity (hyperosmolarity)
89330741|NCT03531346|Experimental|Normal osmolarity|Healthy, young, habitual contact lens wearers with initial tear osmolarity reported as normal
89330742|NCT01316978|Experimental|Experimental|Experimental Ibuprofen
89330743|NCT01316978|Active Comparator|Nurofen|Nurofen Meltlets Orodispersible Tablet
89330744|NCT01316978|Active Comparator|Motrin|Junior Strength Motrin Chewable Tablet
89330745|NCT03531268|Active Comparator|PGx testing has clinical utility|These are subjects whose PGx testing is judged to have clinical utility and whose clinical care may be modified. Modifications may include altering doses or types of drugs given based on metabolic profile of the patient.
89330746|NCT03531268|No Intervention|PGx testing has no clinical utility|"These are subjects whose PGx testing is judged to have no clinical utility. Care as usual is provided, and there are no changes in drug selection or dosing based on the results of PGx testing."
89330747|NCT01117597|Active Comparator|low RF exposure level|Intervention with low RF exposure level SAR 1.5 W/kg
89330748|NCT01117597|Sham Comparator|sham RF exposure|Intervention with sham RF exposure
89330749|NCT01117597|Active Comparator|high RF exposure level|intervention with high RF exposure level SAR 6W/kg
89330750|NCT05250752|Other|On treatment|Assigned to oral treatment with dapagliflozin 10 mg for three consecutive days.
89330751|NCT01114009|Experimental|Lung recruitment maneuver|The maneuver briefly increases the alveolar pressure to open recruitable lung (50 cmH2O), sustained with adequate positive end-expiratory pressure(PEEP) after lung recruitment, to avoid derecruitment.
89330752|NCT01114009|Active Comparator|Lung protective strategy|Lung protective strategy group received lung protective strategy without recruitment maneuver
89330753|NCT05724238|Experimental|Traditional Herbal Supplements|Traditional Herbal Supplements (Kuan Sin Yin)
89330754|NCT05724238|Placebo Comparator|Placebo|Placebo starch powder with 10% Kuan Sin Yin
89330755|NCT01344278|Experimental|Lifestyle Counseling|
89330756|NCT01344278|No Intervention|Control|
89330757|NCT04795544|Experimental|cuff inflation by the residual volume|"LMA will be inserted with the initial inflating volume correspondent to residual volume group (RV group):~volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 mL syringe without plunger is connected to the laryngeal cuff for 5 minutes"
89330758|NCT04795544|Experimental|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group)
89330759|NCT04795544|Placebo Comparator|unchanged cuff inflation volume|LMA will be inserted unchanged (NV group): LMA is unpacked and used without inflating or deflating the cuff.
89330760|NCT01211509|Experimental|montelukast sodium|Daily treatment with 10 mg montelukast after diagnosis of fibroproliferative BOS (fBOS) which is the low neutrophilic phenotype within BOS
89330761|NCT01211509|Placebo Comparator|placebo|Lactose monohydricum Ph.Eur.
89330762|NCT02741518|Active Comparator|Treatment Arm|The treatment arm will receive an induction dose of FMT via capsules (30) followed by monthly maintenance oral capsules(12) at week 4 and week 8. Donor Stool from healthy lean donors and placebo material will be obtained from OpenBiome. OpenBiome, is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use
89330763|NCT02741518|Placebo Comparator|Placebo Arm|The placebo group will receive a placebo FMT capsules at the time of their screening colonoscopy followed by monthly intake of oral placebo capsules at week 4 and week 8
89330764|NCT03941119|Experimental|Intervention|The intervention arm will receive a VR-therapy session every 24-72 hours of their stay in the hospital. Participants will view specially designed 360-degree VR films using a Virtual Reality head mounted display for a maximum of 20 minutes per session.
89330765|NCT03941119|No Intervention|Control|The control arm will not receive any VR-therapy sessions during their hospital stay.
89330766|NCT05072600|Experimental|arm 1|All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.
89330767|NCT04441528|Experimental|Lid wipes containing terpinen-4-ol and sodium hyaluronate|The lid wipes will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
89330768|NCT04441528|Active Comparator|Baby shampoo|Baby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
89330769|NCT01117675|Other|Arm I|Arm I: HIV-infected patients controlled through Virtual Hospital
89330770|NCT01117675|Other|Arm II|Arm II: HIV-infected patients controlled through Standard Care
89330771|NCT04440826|Active Comparator|Whole Food Meal|Whole foods meal - grilled cheese and drink meal
89330772|NCT04440826|Experimental|Processed Food Meal|Highly processed foods - grilled cheese and drink meal
89330773|NCT04440826|Experimental|Gluten-Free and Lactose-Free Meal|Gluten-free and lactose-free foods - grilled cheese and drink meal
89330774|NCT01117753|Experimental|OPT-A|OPT-A is an outpatient family-based treatment for co-occurring substance use and internalizing disorders
89330775|NCT01117753|Active Comparator|Treatment as Usual|Treatment as usual in a community based mental health center
89330776|NCT05251792||Primary Angle Clousure Diseases Eyes|Over 40 years old, regardless of gender. Patients diagnosed with PACD (PACG or PAC or PACS) with phakic eyes. Peripheral iridectomy or trabeculectomy, more than 3 months after operation.
89330777|NCT05251792||Matched Eyes|Healthy population matched by sex and age.
89330778|NCT01344512|Experimental|Patients treated with Ceftazidime|
89330779|NCT01344512|Experimental|Patients treated with Ciprofloxacin|
89330780|NCT01344512|Experimental|Patients treated with Voriconazole|
89330781|NCT03941197|Experimental|Ready and Healthy for Kindergarten Family Literacy Program|Ready and Healthy for Kindergarten Family Literacy Program- 8 weekly parent child workshops with text message reminders
89330782|NCT03527368|Experimental|Time-restricted feeding|
89330783|NCT03527368|Other|Usual feeding pattern|Comparison
89330784|NCT05064488|Experimental|Part-1: Evobrutinib + Digoxin + Metformin + Rosuvastatin|
89330785|NCT05064488|Experimental|Part-2: Evobrutinib + Sumatriptan|
89330786|NCT01115023|Experimental|iron group|This group received an iron cooking pot for daily household cooking as an intervention
89330787|NCT01115023|No Intervention|Aluminium group|the subjects in this group were asked to continue cooking in the aluminium pot and not to cook in the iron pot if they possessed one.
89330788|NCT03527290|Experimental|Time Restricted Eating|Participants will be instructed and counseled to incorporate a 12-hour Time Restricted Eating (TRE) regimen that begins upon waking and concludes within a 12-hour period (e.g. if wake at 6:30 AM then all caloric intake occurs between 6:30 AM and 6:30 PM). Water and non-caloric beverages (e.g. herbal tea) outside the period are encouraged as desired. There are no specific content or energy intake changes to the diet counseled or recommended as the focus of the counseling in this arm is timing of eating with innate circadian patterns and developing plans and approaches to follow this plan.
89330789|NCT03527290|Active Comparator|Standard Cardiometabolic Health Diet|Participants will be instructed and counseled with standard clinical dietary guidance for improving cardiometabolic health, where the focus is on the content, specifically a dietary pattern that emphasizes vegetables, fruits, whole grains, legumes, nuts/seeds, low fat dairy, seafood, lean poultry and meat and avoidance of foods with high levels of sodium, added sugars, saturated fats, and trans fats. There is no prescription to reduce energy intake.
89330790|NCT01344590|Active Comparator|saline lock maintenance|Standard saline lock maintenance
89330791|NCT01344590|Experimental|ethanol maintenance|Instillation of 70% pharmaceutical grade ethanol solution into the central line in a volume calculated to fill the catheter lumen and hub.
89330792|NCT01114087|Experimental|1|Patients presenting with chronic myeloid leukaemia or malignant GIST and receiving for the first time a treatment by imatinib, a tyrosin-kinase inhibitor, preceded or not by hydroxyurea therapy for less than one month.
89330793|NCT01344668|Other|Standard Diabetes Education|Standard Diabetes Education
89330794|NCT01344668|Other|Enhanced Diabetes Education|Enhanced Diabetes Education
89330795|NCT01212133||A|
89330796|NCT04286126|Active Comparator|bilateral DMPFC|This arm will receive intermittent theta-burst stimulation to bilateral DMPFC site.
89330797|NCT04286126|Active Comparator|right OFC|This arm will receive continuous theta-burst stimulation to the right OFC site.
89330798|NCT01211587|Experimental|100mg safinamide|Two 50mg tablets of safinamide once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
89330799|NCT01211587|Placebo Comparator|Placebo|Two 50mg tablets of placebo once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
89330800|NCT04269356|Experimental|BMS-986256|
89330801|NCT01117909|Sham Comparator|"Laying of hands plus standard therapy"|Subjects will lie on their back as if they were receiving the joint mobilization treatment and the therapist will place their hands in a position as if to perform the mobilization but no movement will occur. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
89330802|NCT01117909|Experimental|Standard therapy with joint mobilization|This group will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session, in addition to standard therapy. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
89330803|NCT04263974|Experimental|Smartphone Application|"A protocol of exercises and general recommendations based on the current scientific evidence will be provided through a smartphone application. A follow-up of the use of the application will be carried out. The treatment protocol will last 6 months, during which a minimum of 4 weekly sessions of exercises will be carried out at home.~Each pathology will have an unique program of exercises and recommendations."
89330804|NCT04263974|Active Comparator|Conventional Treatment|Those in this group will received the conventional treatment protocol provided within the Andalusian Public Health System. This will consist on the delivery of an exercise program and recommendations using a sheet of paper. Participants will be told to perform the exercises during 6 months, with minimum of 4 weekly sessions of exercise that will be carried out at home.
89330805|NCT03940339|Experimental|Suboccipital myofascial release|Treatment will be given for 3 minutes, 3 days per week for 4 weeks.
89330806|NCT03940339|Active Comparator|Coventional Physiotherapy|Treatment will be given for 3 days per week for 4 weeks
89330807|NCT02529631|Active Comparator|Drug: orlistat 60mg capsules|"A tailored blister-strip for one day contains~three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~six placebo tablets Administration: 3 times daily 2 tablets with each main meal"
89330808|NCT02529631|Active Comparator|Medical device: polyglucosamine|"A tailored blister-strip for one day contains~three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold breakfast are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine"
89330809|NCT04469062|Experimental|Mirikizumab|Mirikizumab administered intravenously (IV) and subcutaneously (SC).
89330810|NCT04469062|Active Comparator|Vedolizumab|Vedolizumab administered IV.
89330811|NCT04469062|Placebo Comparator|Placebo|Placebo administered SC and IV.
89330812|NCT01212211|Experimental|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
89330813|NCT01212211|No Intervention|reference|drug treatment of ten patients will remain unchanged during the three months of inclusion
89330814|NCT03528538|Placebo Comparator|Placebo|
89330815|NCT03528538|Active Comparator|AlphaFen fenugreek 400 mg|This group received 400 mg of fenugreek to be ingested daily for 60 days.
89330816|NCT03528538|Active Comparator|AlphaFen fenugreek 500 mg|This group received 500 mg of fenugreek to be ingested daily.
89330817|NCT01114165|Experimental|SeptiFast Test|Pathogen detection by SeptiFast Test as an adjunct to traditional microbiological assessments including blood culture
89330818|NCT01114165|Active Comparator|Only Conventional Diagnostics|Pathogen detection only by conventional microbiological assessments, e.g. blood culture
89330819|NCT03531190|Experimental|Nutritional supplement (Protein + MIX)|Patients are given: Nutritional Supplement of protein 2-3 times a day + MIX once daily for 35 days
89330820|NCT03531190|Active Comparator|Nutritional supplement (Protein)|Nutritional Supplement of protein as needed 2-3 times a day for 35 days
89330821|NCT03145766|Experimental|Group 1: VRVg-2 Formulation 1|VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.
89330822|NCT03145766|Experimental|Group 2: VRVg-2 Formulation 2|VRVg-2 formulation 2, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
89330823|NCT03145766|Experimental|Group 3: VRVg-2 Formulation 3|VRVg-2 formulation 3, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
89330824|NCT03145766|Experimental|Group 4: VRVg-1|VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
89330825|NCT03145766|Active Comparator|Group 5: Imovax Rabies|Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
89330826|NCT01115179|Active Comparator|Propofol|Propofol anesthesia
89330827|NCT01115179|Active Comparator|Control|Anesthesia with isoflurane alone
89330828|NCT01115179|Active Comparator|Solvent|Anesthesia with isoflurane together with the solvent of propofol (intralipid)
89330829|NCT03531034|Experimental|Hypertensive Women|Group of hypertensive and controlled women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
89330830|NCT03531034|Active Comparator|Normotensive Women|Group of normotensive women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities.
89330831|NCT01213459||Cohort A|Women ≥15 years of age attending out-patient departments for routine cervical screening in the Kingdom of Saudi Arabia.
89330832|NCT04468438||50 patients with LN with regular menstrual cycle|1- First group of50 patients with regular menstrual cycle
89330833|NCT04468438||50 patients with LN with amenorrhea|2- Second group of 50 patients with amenorrhea.
89330834|NCT05250674||Adult women with indication for a breast biopsy procedure after an abnormal CEM or MRI examination.|Adult women presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination and no clear ultrasound or mammography correlation.
89523519|NCT04420741|Placebo Comparator|Isotonic saline|Patients randomized to placebo treatment (n=40 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
89523520|NCT04409041|Experimental|Low-dose naltrexone group|All participants were prescribed low-dose naltrexone at 3mg oral daily.
89523521|NCT03090997|Placebo Comparator|Group 1|vitamin C (500 mg/day/orally) + placebo
89523522|NCT03090997|Placebo Comparator|Group 2|resveratrol (500 mg/day/orally) + placebo
88806717|NCT05747430|Experimental|IRX-101|Subjects randomized to IRX-101 will receive the investigational product, IRX-101.
88806718|NCT05747430|Active Comparator|5% Povidone-iodine|Subjects randomized to this arm will receive the standard of care, Providone-iodine, at a concentration of 5%.
88806719|NCT05747339|Experimental|Tumor treatment vaccine for patients with advanced solid tumors|Tumor treatment vaccine(TTV) would be given deep subcutaneously in the arm or near the tumor.The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88806720|NCT05740475|Experimental|9MW3811 injection|single dose escalation for experimental drug
88806721|NCT05740475|Placebo Comparator|placebo|matching placebo administration for control
88806722|NCT05736861|Experimental|Arm A - Ivermectin 400|"Ivermectin - 7-mg tablets~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg."
88806723|NCT05736861|Placebo Comparator|Arm A - Placebo|"Placebo - appearance and size matched to active study drug.~Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight, matched to active study drug dosing."
89523523|NCT03090997|Active Comparator|Group 3|vitamin C (500 mg/day/orally) + resveratrol (500 mg/day/orally)
89330835|NCT01213537||Patients undergoing clinically indicated CRT implantation|"Patients may be included in the study if they fulfil the following;~Age ≥18 years old~Fulfil the current guidance for the implantation of a CRT device; optimal medical treatment for heart failure, broad QRS complex on electrocardiogram with or without evidence of cardiac dyssynchrony as appropriate, LVEF <35%, functional impairment as defined by an NYHA class of III-IV~Clinically stable with no unplanned admission to hospital for preceding 4 weeks~No changes in medications for heart failure in preceding 4 weeks~Able to read and understand patient information sheet and give informed consent~Patients must be excluded from the study if they fulfil they the following;~On positive pressure treatment for known sleep disordered breathing at the time of inclusion~Other known condition (untreated) likely to significantly disturb sleep eg. Restless legs syndrome, pain from any cause etc.~Pregnancy"
89330836|NCT01344746||Snoring group|"Subjects with snoring and AHI ≥ 20 episodes/h (severe SDB).~Snorers with AHI < 20 episodes/h and ≥ 5 episodes/h (moderate SDB)~Snorers with AHI < 5 episodes/h and ≥ 1 episodes/h (mild SDB)"
89330837|NCT01344746||Non-snoring group|"When testing serum and urinal samples, healthy children without snoring will be chosen as controls.~When testing lymphoid tissue samples, patients with recurrent infectious tonsillitis (at least five tonsillar infections in less than 6 months) but without snoring will be selected as controls before surgery and recruited to the study, because adenotonsillar tissue can't be obtained from normal children for obvious ethical reasons."
89330838|NCT04468282|Experimental|VGB-ST|"Name of the compound: Vigabatrin ORPHELIA Pharma (VGB-ST) Pharmaceutical form: Soluble tablet Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization.~Batch N°: 16.92.042 (expiry date: 31.05.2017)"
89330839|NCT04468282|Active Comparator|Sabril|"Name of the compound: Sabril (vigabatrin) Pharmaceutical form: granules (sachet) Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization.~Batch N°: 6810 (expiry date: 31.05.2019)"
89330840|NCT01115257|Other|group 1|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with vitrectomy
89330841|NCT01115257|Other|panretinalphotocoagulation (group 2)|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with panretinalphotocoagulation
89330842|NCT05057936||Control|Healthy healthcare workers
89330843|NCT05057936||Chronic kidney disease (CKD)|CKD stage 3-5 (eGFR < 60 mL/min/1.73m3)
89330844|NCT05057936||Dialysis patients|CKD stage 5 requiring HD
89330845|NCT05057936||kidney transplant patients|patients receiving kidney transplantation for more than 3 months
89330846|NCT05057936||dialysis patients|CKD patients requring continuos ambulatory peritoneal dialysis
89330847|NCT01121731|Experimental|Interferon α-5|
89330848|NCT01121731|Experimental|Interferon α-5 plus Interferon α-2b|
89330849|NCT01121731|Active Comparator|Interferon α-2b (INTRON® A)|
89330850|NCT03527212|Experimental|SJP-0035 0.001% (ophthalmic solution)|
89330851|NCT03527212|Placebo Comparator|Placebo (ophthalmic solution)|
89330852|NCT01215799|Experimental|Bafetinib|
89330853|NCT05207020|Experimental|Blood sugar levels estimated by analysis of exhaled air|
89330854|NCT01213615||all patients eligible for implantation of a Hancock II Ultra|
89330855|NCT05723848||CIDP patients|CIDP patients with ongoing standard of care IVIG treatment
89330856|NCT03145064|Experimental|Zanubrutinib|Participants received zanubrutinib BID.
89330857|NCT01115335|Active Comparator|Gomco|NMC performed using a Gomco clamp
89330858|NCT01115335|Active Comparator|Mogen clamp|NMC performed using a Mogen clamp
89330859|NCT01115335|Active Comparator|Plastibell|NMC performed using a Plastibell device
89330860|NCT03527134|Experimental|Amantadine treatment|To determine whether amantadine is effective in reducing the occurrence of postoperative cognitive dysfunction.
89330861|NCT03527134|No Intervention|No-treatment|Patients will not receive any treatment.
89330862|NCT01213693|Experimental|ICS/LABA group|Patients assigned to this arm will take bid 50/500 mcg fluticasone/salmeterol combination
89330863|NCT01213693|Active Comparator|LABA group|Patients assigned to this arm will take bid 50 mcg salmeterol
89330864|NCT01344902|Experimental|Hexaminolevulinate|
88806724|NCT05710965|Active Comparator|FRx-001|FRx-001 is a wearable digital intervention that provides therapeutic vibrations to the subjects wrist and scheduled assistive messaging.
89330865|NCT04468750|Experimental|Kinesiotape|Kinesiotape (Nasara, Korea) was applied for three times a week (Monday, Wednesday, and Friday) for three weeks.
89330866|NCT01213771|No Intervention|Preoperative care 2009|Patients are receiving the usual care
89330867|NCT03527056|Experimental|Oral capsule fecal transplantation|Enrolled patients who have screened positive for CRE in the stool will receive fecal transplant via OpenBiome oral capsules. The patient is given 90 minutes to swallow all capsules and does not require any anesthesia or sedation. Stool samples to test for CRE will be taken 10 days and 30 days after the fecal transplant.
89330868|NCT03527056|No Intervention|Observation|Enrolled patients who have screened positive for CRE in the stool will have stool samples to test for CRE taken 10 days and 30 days after initial enrollment.
89330869|NCT01213849|Experimental|200/100 mcg fluticasone furoate/vilanterol|4 inhalations of 50/25 mcg fluticasone furoate/vilanterol
89330870|NCT01213849|Experimental|400/100 mcg fluticasone furoate/vilanterol|4 inhalations of 100/25 mcg fluticasone furoate/vilanterol
89330871|NCT01213849|Experimental|800/100 mcg fluticasone furoate/vilanterol|4 inhalations of 200/25 mcg fluticasone furoate/vilanterol
89330872|NCT03528304|Experimental|Smoking arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking.
89330873|NCT03528304|Experimental|Weight loss arm|As part of the CM intervention women attend visits for smoking and weight loss assessment and are rewarded with prizes for losing some weight.
89330874|NCT03528304|Experimental|Smoking and weight loss arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking and for losing some weight.
89330875|NCT03528304|No Intervention|Control|Women attended clinic visits for smoking status and weight loss assessment.
89330876|NCT03940183|Experimental|Trelagliptin succinate 100 mg|Tablets,100mg per tablet,oral, once a week, 100mg each time, continuous medication for a total of 24 weeks
89330877|NCT03940183|Placebo Comparator|Placebo Oral Tablet|Tablets,N/A,oral, once a week, one tablet each time, continuous medication for a total of 24 weeks
89330878|NCT03530956|Active Comparator|Current prosthesis|A unilateral transtibial amputee will conduct experiments with the current prosthesis
89330879|NCT03530956|Experimental|Novel prosthesis|A unilateral transtibial amputee will conduct experiments with the novel prosthesis
89330880|NCT01115413||young maternal age|maternal age of < 18 years
89330881|NCT01115413||adult maternal age|maternal age >/= 18 years
89330882|NCT01121809|Other|Raltegravir|Raltegravir 400 mg bid
89330883|NCT01121809|Other|Etravirine|Etravirine 200 mg bid
89330884|NCT03530878|Experimental|Hip Arthroscopy (HA)|This approach addresses intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH 3. Furthermore, capsular plication can be performed through HA to reduce instability of the joint.
89330885|NCT03530878|No Intervention|Periacetabular Osteootmy (PAO)|The Bernese periacetabular osteotomy (PAO) remains the gold standard for treatment of symptomatic developmental dysplasia of the hip (DDH) in most patients with closed triradiate cartilage. First developed by Ganz in 1984, this technique utilizes 4 osteotomies to completely mobilize the acetabular fragment 1. Although a technically demanding procedure, it allows optimal correction in all planes and maintains integrity of the posterior column, enabling early weight bearing and mobilization.
89330886|NCT03937687|Placebo Comparator|Placebo|300 mg cellulose
89330887|NCT03937687|Experimental|Caffeine|300 mg caffeine
89330888|NCT03937687|Experimental|Caffeine Combination|150 mg caffeine with 100 mg Dynamine and 50 mg TeaCrine
89330889|NCT01212289||Primary cardiac surgery|Pediatric patients receiving primary cardiac surgery
89330890|NCT01212289||Reoperation|Pediatric patients receiving cardiac surgery reoperation
89330891|NCT03937531|Experimental|Retrograde-fill void trial (RVT)|Subjects will leave the operating room with a urinary catheter inserted. Subjects should be recovered from anesthesia effects (2-3 hours after surgery) before voiding trial. First, the bladder will be completely drained into the Foley bag then the bag will be detached from the catheter. The bladder will be back-filled with sterile water (300 mL). After the catheter is removed, subjects are expected to void at least 2/3 (200 mL) of the total instilled amount within 30 minutes of filling. Post-void residual (PVR) will be measured by both subtraction of the voided volume from 300cc and by using a bladder scanner.
89330892|NCT03937531|Active Comparator|Spontaneous void trial (SVT)|"Subjects will leave the operating room without a urinary catheter. Participants are allowed up to 6 hours after surgery for spontaneous voiding. After voiding, the voided volume will be noted. PVR will be measured using a bladder scanner.~In both groups, if PVR >=100 mL on a bladder scanner, an indwelling urinary catheter will be placed and the actual PVR will be documented. Subjects who failed voiding trial will be instructed to return to clinic within 2-4 days for the second void trial. Prophylactic antibiotics will NOT be given. The time to discharge will be measured for each subject. This will be determined by calculating the time between arrival to the PACU and the time of discharge using documentation from EPIC."
89330893|NCT05128396|Active Comparator|Cognitive Training using Cogmed|Subjects will complete computerized cognitive training with varying degrees of difficulty over 5 weeks.
89330894|NCT05128396|Active Comparator|Awareness (mindfulness) training|Subject participate in mindfulness training. The meditation and tasks will become increasingly more self-directed over the 5 weeks; the degree of guidance will decrease to keep the subjective effort approximately constant and moderately challenging through the 5 weeks.
89330895|NCT05128396|Active Comparator|Physical Exercise Training Using an Interactive Video Platform|Subjects will participate in a structured physical exercise training program that aims to progressively increase their level of activity over the 5 week training period.
89330896|NCT05128396|Placebo Comparator|Low Level of Cognitive Training Using the Cogmed Program|Subjects will complete the same computerized training as the active cognitive arm over the course of 5 weeks, but the main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time.
89330897|NCT01121887|Active Comparator|Standard treatment|
89330898|NCT01121887|Experimental|Motivational Interviewing|
89330899|NCT05110144|Experimental|Duloxetine and Placebo|Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 30mg of Duloxetine plus 30mg Placebo for blinded period 2 (additional 4 week treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89330900|NCT05110144|Experimental|Duloxetine dose escalation|Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 60mg of Duloxetine for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89330901|NCT05110144|Experimental|Amitriptyline and Placebo|Subjects will receive 25mg of Amitriptyline for blinded period 1 (first 4 week treatment period) and 25mg of Amitriptyline plus 30mg Placebo for blinded period 2 (additional 4 week treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89330902|NCT05110144|Experimental|Amitriptyline dose escalation|Subjects will receive 25mg of Amitriptyline for blinded period 1 (first 4 week treatment period) and 50mg of Amitriptyline for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89330903|NCT05110144|Placebo Comparator|Placebo|Subjects will receive 30mg of Placebo for blinded period 1 (first 4 week treatment period) and 60mg of Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).
89330904|NCT01121965|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs
89330905|NCT01121965|Experimental|Early vitrectomy|Pars plana vitrectomy with ILM peeling would be employed when visual symptoms occur.
89330906|NCT04440904||Characteristic of aortic length and body surface mark|The diameters and lengths of blood vessels and the distances on the body surface were measured by three-dimensional reconstruction using related Software on CT Workstation
89330907|NCT01212367|Experimental|Dose Level 1|
89330908|NCT01212367|Experimental|Dose Level 2|This is a dose de escalation.
89330909|NCT01216111|Experimental|6 cycles of PC adjuvant chemotherapy|paclitaxel 80 mg/m2 and carboplatin (area under the curve [AUC]= 2) on day 1, 8, 15 every 28 days for six cycles
89330910|NCT01216111|Active Comparator|3 cycles of FEC followed by 3 cycles of Docetaxel|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
89330911|NCT05072470|Experimental|Experimental|Participants with bilateral moderate to severe sensorineural hearing loss
89330912|NCT01122043||Endoglide|Patients with moderate degrees of corneal decompensation from a variety of disorders which require DSAEK corneal transplantation surgery, with or without concurrent cataract surgery, to restore visual acuity.
89330913|NCT04440748|Experimental|Experimental Group|Participants in the experimental group will perform additional high-intensity therapy on the T-Chair 2.0, which is a newly developed non-CE-marked prototype to train trunk control and sitting balance. This they will do in addition to their normal rehabilitation program.
89330914|NCT04440748|Active Comparator|Control Group|Participants in the control group will execute their normal rehabilitation program.
89330915|NCT01216267|Active Comparator|lansoprazole|lansoprazole for 7 days
89330916|NCT03526978|Experimental|Experimental Group|"The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.~Intervention: investigational sIPV"
89330917|NCT03526978|Active Comparator|Control Group|The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV
89330918|NCT01115647|Experimental|Ready-to-Use Therapeutic Foood (RUSF)|"Caretakers will receive weekly RUSF, 350g, and will be advised to feed it(50 g d-1 or 3 tablespoons/day) in one meal or on demand. These are pre-defined quantities. However, minimum quantities required for a timely (≤15 days) recovery from moderate malnutrition will be determined during the pilot phase.~Besides supplementary food, parents will be provided with the usual nutrition counsels prevailing currently in the health services.Children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
89330919|NCT01115647|Active Comparator|CSB++|"Caretakers will receive weekly CSB++ (450g) rations. Parents will be advised to feed the CSB++ (65g d-1 diluted in 370 g water) in one meal or on demand. These are pre-defined quantities. However, minimum quantities of CSB++ required for a timely (≤15 days) recovery from moderate malnutrition in the area will be determined during the pilot phase. Besides supplementary foods, parents will be provided with the usual nutrition counsels prevailing currently in the health services, i.e. to keep on breastfeeding, to increase diet diversity and to feed frequent snacks.~Feeding practices will be also assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
89330920|NCT01115647|Active Comparator|Children Centered Counseling (CCC)|"The counsellor will spend 1 hour daily (during the 3 first days and then weekly) within the household for identifying enhancing and blocking factors and adapt consequently the treatment strategies in agreement with the caretakers.~As in the other study arms, children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be also assessed in each arm, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members.There will be no dietary supplements intervention, outside normal practices in Burkina."
89330921|NCT04468048||Music|"Subjects will put on headphones containing music from the album Nada Himalaya performed by S. G. Sachchidananda. The music will start playing 10 minutes before the colonoscopy procedure and will stop once subjects have woken up from sedation. Subjects will be instructed to not tell anyone if music is playing from their headphones. Subjects will two questionnaires before the procedure asking about their initial anxiety levels and previous procedure history. Two questionnaires following the procedure will be provide asking about their anxiety levels following the procedure and their overall satisfaction with the procedure."
89330922|NCT04468048||Control|Subjects will put on headphones, but there will be no music playing. Subjects are instructed to not tell anyone if music is playing from their headphones. Subjects will two questionnaires before the procedure asking about their initial anxiety levels and previous procedure history. Two questionnaires following the procedure will be provide asking about their anxiety levels following the procedure and their overall satisfaction with the procedure.
89330923|NCT01216423||Incidence of recent stroke in patients with PFO|
89330924|NCT01216423||Incidence of recent stroke in patients without PFO|
89330925|NCT01118533|Experimental|metallic blades|laryngoscope blade material
89330926|NCT01118533|Active Comparator|plastic laryngoscope blades|Laryngoscope Blade Material
89330927|NCT05462158|Experimental|Available for Members-Text|"Participants will receive a text message that says, Two common kidney tests have been made available for members. By taking them, you could stay ahead of any problems and keep enjoying life. Schedule a doctor visit today to ask about them."
89330928|NCT05462158|Experimental|Checked Health-Text|"Participants will receive a text message that will say, Have you checked your kidney health recently? By taking two common kidney tests, members can stay ahead of any problems and keep enjoying life. Schedule a doctor visit today to ask about them."
89330929|NCT05462158|Experimental|No Text Message|Participants in this group will not receive a text message at all
89330930|NCT01118689|Experimental|MLN0128|
89330931|NCT01122121|Experimental|Combined Radiotherapy and Hormone Therapy|Leuprorelin 11.25 milligram (mg) sustained release (SR), injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin. Radiotherapy 70 +/- 4 Gray (Gy) in 35 fractions at a rate of 5 fractions of 2 Gy per week up to 3 years. An interval of a maximum of 2 weeks is authorized between radiation of the pelvis with 50 Gy (±4) (5 weeks) and radiation of the prostate with an additional 20 Gy.
89330932|NCT01122121|Active Comparator|Hormone Therapy alone|Leuprorelin 11.25 mg SR, injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin.
89330933|NCT04542460|No Intervention|Optimal Medical Treatment|CTO patients receiving optimal medical treatment
89330934|NCT04542460|Active Comparator|Optimal Medical Treatment and PCI|CTO patients receiving PCI in ajunction to optimal medical treatment
89330935|NCT01115725||Gonal-f® prefilled pen|
89330936|NCT03526744|Experimental|marine protein hydrolysate 1234|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
89330937|NCT03526744|Experimental|marine protein hydrolysate 2134|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
89330938|NCT03526744|Experimental|marine protein hydrolysate 3124|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with with up to 7 days-out in between. Random sequence of arms.
89330939|NCT03526744|Experimental|marine protein hydrolysate 4123|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
89330940|NCT01122199|Experimental|Open Label|RAD001+ AMG479
89330941|NCT04514926||Healthy Controls|Participants with no history of asthma or other lung diseases.
89330942|NCT04514926||Asthmatics newly prescribed therapeutic proteins|Participants with asthma, have been newly prescribed therapeutic proteins and have yet to start on those therapeutics at the time of enrollment.
89330943|NCT04514926||Asthmatics already being treated with therapeutic proteins|Participants with asthma who have already started on therapeutic proteins.
89330944|NCT01118923|No Intervention|Washout|
89330945|NCT01118923|Active Comparator|Mablet|
89330946|NCT01118923|Placebo Comparator|Placebo|
89330947|NCT01119079|Placebo Comparator|Standard labor epidural protocol|Standard labor epidural protocol
89330948|NCT01119079|Experimental|10ml Normal Saline prior to lidocaine|
89330949|NCT01119157|Experimental|humoral and cellular immune response|
89330950|NCT01119157|Experimental|reactogenicity|
89330951|NCT05036668|Experimental|ABO809|Participants will receive ABO809 at a single oral dose of 1x10^4 oocysts. Other doses such as 1x10^6 oocysts may be considered to optimize the model
89330952|NCT01119235|Active Comparator|Cohort 1: PF-04531083|
89330953|NCT01119235|Active Comparator|Cohort 2: PF-04531083|
89330954|NCT01119313|Experimental|LAS 41002|
89330955|NCT01119313|Active Comparator|Active|
89330956|NCT01119391||Patients undergoing IVF|Women undergoing an in vitro fertilization cycle
89330957|NCT04467268|Experimental|Sleep extension intervention|"Intervention group participants met with an experienced sleep scientist to discuss and agree changes to their sleep and personal schedules. Discussions lasted 60-90 minutes, were informed by actigraphic sleep assessments from the baseline period, and aimed to increase TST by ≥1 hour/night. The structure and content of the About Sleep, Sleep Hygiene and Thoughts and Sleep components of the online Sleepful application, a self-help sleep management programme. Advice was supported by the provision of self-help booklets addressing sleep hygiene and the management of pre-sleep cognitions which had been successfully trailed in an intervention for insomnia symptoms. Finally, to capitalize on the participant's motivation at recruitment, and optimize adherence, the newly agreed sleep schedule was written into an agreement which the participant was asked to sign, simulating a 'therapeutic contract'. Schedules were reviewed by telephone at the end of the first week and revised if required."
89330958|NCT04467268|No Intervention|Control group|Participants in the control group were asked to continue with their habitual sleep schedule.
89330959|NCT01119469|Experimental|Cognitive Therapy (CT)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include psychoeducation, attention training, cognitive restructuring, behavioral experiments, imagery rescripting and relapse prevention.
89330960|NCT01119469|Experimental|Exposure Therapy (ET)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include change of safety behavior, exposition (in sensu and in vivo), and response prevention.
89330961|NCT01119469|No Intervention|Waiting List (WL)|12 weeks waiting time
89330962|NCT03528148|Experimental|active cycling group|effect of combine cycling and conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
89330963|NCT03528148|Active Comparator|control group|effect of combine conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
89330964|NCT01119547|Experimental|Home exercise|The patients is training at home during 6 v. with an individual exercise program.
89330965|NCT01119547|Experimental|Exercise in group|The patients is doing their individual exercise program in a group.
89330966|NCT02529397|Experimental|Adaptive Working Memory Training|The experimental group will receive working memory training through a commercial computerized program: five weeks of adaptive working memory training concurrently with a behavioral weight loss program. Adaptive working memory training becomes progressively more challenging depending on an individual's performance on a given task. They will attend weekly classes of a behavioral weight loss program.
89330967|NCT02529397|Placebo Comparator|Non-adaptive Working Memory Training|The control group will receive five weeks of non-adaptive (placebo) cognitive training concurrent with the identical behavioral weight loss program as in the experimental group. Non-adaptive cognitive training remains at a constant level.
89330968|NCT01119781|Experimental|peginterferon beta-1a|Single dose of peginterferon beta-1a at either 63 or 125 mcg in renal impaired Participants and healthy volunteers
89330969|NCT01120015|Experimental|Diacerein|diacerein 50mg oD first month, 50 mg BD next 2 months
89330970|NCT03526666||AML, MDS, and CMML patients|Patients with a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
89330971|NCT01122355|Active Comparator|niacin arm|
89330972|NCT01122355|Active Comparator|fenofibrate arm|
89330973|NCT01216579|Placebo Comparator|Reference arm|Asthmatic patients managed as per British Thoracic Society guidelines by symptoms and lung function.
89330974|NCT01216579|Active Comparator|Mannitol managed arm|Group of asthmatic patients managed according to their mannitol challenge.
89330975|NCT03528070|Experimental|Tranilast|
89330976|NCT03525340|No Intervention|Standard of Care|Participants in the standard of care arm will receive no navigation assistance to remain in care. They will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation, but no additional services to remain engaged in care other than what is provided as standard by the clinic.
89330977|NCT03525340|Experimental|Peer Navigation|Participants in the peer navigation arm will meet with a peer navigator at least once per month for nine months in-person, and have at least one other navigator contact per month. Like the standard of care arm, they will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation.
89330978|NCT03935815|Active Comparator|Intervention|"Standard of care pain management plus quadratus lumborum nerve block.~Ropivicaine 0.25% 60 mL will be injected in the fascial plane between the quadratus lumborum muscle and transverses abdominus muscle."
89330979|NCT03935815|Sham Comparator|Control|Standard of care pain management plus a sham procedure.
89330980|NCT03935659|Active Comparator|Standard gauze therapy|The control group will receive a standard sterile gauge dressing over the groin incision. The dressing will be removed on post-operative day #2 and the wound will be inspected for any complications, followed by daily dressing changes and wound inspections until discharge.
89330981|NCT03935659|Experimental|Negative Pressure wound therapy|The intervention group will receive a negative pressure dressing which will be applied in the operating room under sterile conditions. The brand of negative pressure dressing will be based on surgeon preference or center availability. The NPWT dressing will be removed on day 5 postoperatively or at discharge, whichever occurs first, and the groin wound inspected for any evidence of infection or dehiscence, and daily thereafter until discharge.
89330982|NCT04458298|Experimental|Stage I: Cohort A: OP-101 2 mg/kg|Participants will receive a single intravenous (IV) infusion of OP-101 2 milligram per kilogram (mg/kg) on Day 1.
89330983|NCT04458298|Experimental|Stage I: Cohort B: OP-101 4 mg/kg|Participants will receive a single IV infusion of OP-101 4 mg/kg on Day 1.
89330984|NCT04458298|Experimental|Stage I: Cohort C: OP-101 8 mg/kg|Participants will receive a single IV infusion of OP-101 8 mg/kg on Day 1.
89330985|NCT04458298|Placebo Comparator|Stage I: Cohort D: Placebo|Participants will receive a single IV infusion of matching placebo on Day 1.
89330986|NCT04458298|Experimental|Stage II: Cohort E: OP-101 8 mg/kg|Participants will receive a single IV infusion of OP-101 8 mg/kg on Days 1 and 4.
89330987|NCT04458298|Placebo Comparator|Stage II: Cohort F: Placebo|Participants will receive a single IV infusion of matching placebo on Days 1 and 4.
89330988|NCT03935503||Total Extraperitoneal Repair|Laparoscopic Total Extraperitoneal (TEP) method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
89330989|NCT03935503||Lichtenstein repair|Lichtenstein method was performed to repair inguinal hernia . Patients were evaluated preoperatively, at 1 month and 6 months postoperatively, International Sexual Function Index (IFIF), International Prostatic Symptom Score, SF-36 Quality of Life Scale, Visual Analog Pain Scale, Beck Depression Scale, Inguinal Region Discrimination Test ( DT), DN4 Neuropathic Pain Survey, Uroflowmetry and FSH, LH, Total Testosterone levels were evaluated.
89330990|NCT01216657|Experimental|sunitinib|50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
89330991|NCT04400188|Experimental|Experimental A (part 1) : Fluzoparib + temozolomide|
89330992|NCT04400188|Experimental|Experimental B (part 2) : Fluzoparib + temozolomide + SHR-1316|
89330993|NCT03935581|Experimental|ExAblate 4000 System|ExAblate Neuro system to perform AF echo imaging in treatment of Essential Tremor
89330994|NCT03935737||Full dose Chest X-Ray|Subjects will receive a full (standard) dose chest X-ray at Day 1.
89330995|NCT03935737||Low dose Chest X-Ray|Subjects will receive a follow up X-ray at at a lower dose within 3 months after the first dose.
89330996|NCT03935191||Group|Device: Dexcom CGM System
89330997|NCT01122433|Experimental|C-MAC|After a maximum of three failed intubation attempts using direct laryngoscope the C-MAC video laryngoscope is used as an emergency airway device.
89330998|NCT01328899|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
89330999|NCT01214005|Experimental|schizophrenia|Smokers with schizophrenia or schizoaffective disorder
89331000|NCT01214005|Other|non-psychiatric|smokers without psychiatric illness
89331001|NCT03264040||Observation|Patients with Mannosidosis disease or high-grade suspicion for Mannosidosis disease
89331002|NCT03935035|Experimental|internet-Cognitive Therapy for PTSD|This is a single-arm study. All participants will receive the same therapist supported, internet-delivered intervention.
88806725|NCT05710965|Active Comparator|FRx-003|FRx-003 is a wearable digital intervention that provides therapeutic vibrations to the subjects wrist and may include periodic assistive messaging.
88806726|NCT05710965|Active Comparator|FRx-004|FRx-004 is a wearable digital intervention that displays periodic therapeutic assistive messaging.
88806727|NCT05708833|Experimental|intraosseous venous access|intraosseous venous access
89331003|NCT01216891|Experimental|Team-based treatment|
89331004|NCT01115959|Active Comparator|valproic acid|Valproic acid given orally 400mg twice daily
89331005|NCT01115959|Placebo Comparator|placebo|Placebo twice daily for one month
89331006|NCT03936907|Experimental|Orally Disintegrating MGC-ODT Tablet|Administration of a single tablet of Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5mg THC and 5 mg CBD
89331007|NCT03936907|Active Comparator|Sativex®|Sativex® spray X 2 actuations (1 under the tongue and 1 inside the cheek administered within 2 min) - Reference Product [Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 5.4 mg THC and 5.0 mg CBD]
89331008|NCT01116115|Active Comparator|Standard vegetable oil based formula|
89331009|NCT01116115|Active Comparator|InFat™ based infant formula|
89331010|NCT01116115|No Intervention|Breast-fed|
89331011|NCT01217203|Experimental|IPH2101 and lenalinomide|
89331012|NCT01120171|Experimental|1|Cyclofosfamide/Liposomal-encapsulated doxorubicin
89331013|NCT01120327|Experimental|Amlodipine|Amlodipine
89331014|NCT01120327|Placebo Comparator|Placebo|Placebo
89331015|NCT01122589|Experimental|Motivation Interviewing/CBT|
89331016|NCT01122589|Active Comparator|Control|Receive a smoking cessation pamphlet and watch a series of six weekly 30-45 minutes general wellness videos.
89331017|NCT01116271|Experimental|1|Selumetinib (AZD6244) in combination with irinotecan
89331018|NCT01217359|Experimental|Interferon Alfa-2b|Patients will receive a single dose of interferon
89331019|NCT03939715|Active Comparator|DermaPure|
89331020|NCT03939715|Active Comparator|Native Tissue|
89331021|NCT01212601||1|
89331022|NCT01212679|Experimental|nerve growth factor|Patients who underwent TBI will be chosen to receive NGF randomly.
89331023|NCT01212679|Placebo Comparator|Control|Patients who underwent TBI will be chosen to receive nomral saline randomly.
89331024|NCT04466644||The regulars of IVF clinics in the USA|Mainly asymptomatic individuals composed by patients who are attending their regular medical consultation and/ clinic staff of the participant sites, located in two areas of the USA with different pandemic status, and undergoing PCR and ELISA tests for diagnosis of COVID-19 before initiating the work after the lockdown.
89331025|NCT01217593|Experimental|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
89331026|NCT01217593|Active Comparator|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
89331027|NCT03198988|Experimental|General|One arm study: smART Feeding Tube System.
89331028|NCT03193684|Experimental|Treatment|empagliflozin 25 mg per day
89331029|NCT03193684|Placebo Comparator|control|matching placebo 1 pill per day
89331030|NCT01116349|Active Comparator|Surgical treatment|Patients included in the surgical group will have surgery to treat the fracture.
89331031|NCT01116349|Active Comparator|Conservative treatment group|Patients included in the conservative group will be taken to a plaster room where a Hanging Support System(HSS) brace will be installed by a qualified technician.
89331032|NCT01217671|Experimental|Alpha-1 Antitrypsin|
89331033|NCT01217671|Placebo Comparator|Placebo|
89331034|NCT01116505|No Intervention|gluten-containing diet|
89331035|NCT01116505|Active Comparator|Active comparator, gluten-free diet|
89331036|NCT03525184|Placebo Comparator|Normal sleep|A normal sleep condition and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; NS)
89331037|NCT03525184|Placebo Comparator|72-h Sleep restriction with placebo beverage|Sleep restriction (72-h with 2-h of sleep per night) and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; SR),
89331038|NCT03525184|Experimental|72-h Sleep restriction with multi-nutrient beverage|Sleep restriction (72-h with 2-h of sleep per night) and the experimental treatment (1.5 g protein/kg body weight/day + multi-nutrient beverage; SR+).
89331039|NCT01214707||Exercise protocol|No arms are required for this study as all subjects complete the entire protocol
89331040|NCT04316650|Other|SSRI Group|Treated by ISRS at inclusion
89331041|NCT04316650|Other|Anti-androgen Group|Treated by anti-androgen at inclusion
89331042|NCT04316650|Other|No SSRIs or antiandrogen treatment at inclusion|no treatment
89331043|NCT01116583|Active Comparator|Gabapentin|Gabapentin group
89331044|NCT01116583|Placebo Comparator|Placebo|Placebo group
89331045|NCT04315792|Experimental|Endoxifen Arm|Endoxifen enteric-coated tablet (8 mg). Patients will continue treatment with their initial randomized medication for 3 weeks
89331046|NCT04315792|Placebo Comparator|Placebo Arm|Placebo tablets of endoxifen. Patients will continue administration with their initial randomized medication for 3 weeks
89331047|NCT01214785|Active Comparator|Sanitation intervention|
89331048|NCT01214785|No Intervention|Control|
89331049|NCT04302376||Catheter-related thrombosis|The presence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
89331050|NCT04302376||No catheter-related thrombosis|The absence of occlusive or nonocclusive thrombus in the insertion vein ad identified on Doppler and compression ultrasonography and compression ultrasound.
89331051|NCT02529475|Experimental|Gadoteric acid|Gadoteric acid 0.2 mmol/kg
89331052|NCT04284280|Experimental|Early Routine Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) when feeds of 150 ml/kg/day are reached (120Kcal/kg/day)
89331053|NCT04284280|Active Comparator|Selective Fortification|Human Milk Donor Fortifier added to preterm human milk (maternal or donor) only for weight gain less than 15g/kg/day after full feeds of 180 ml/kg/day are achieved (120 Kcal/kg/day). If milk of any infant in the selective fortification group gets fortified the volume will be decreased to 150 ml/kg/day to keep the total caloric intake equal.
89331054|NCT01214863||T3|Model SN60T3 assigned by AcrySof Toric calculator
89331055|NCT01214863||T4|Model SN60T4 assigned by AcrySof Toric calculator
89331056|NCT01214863||T5|Model SN60T5 assigned by AcrySof Toric calculator
89331057|NCT03935347|Experimental|Treatment (cyclophosphamide, fludarabine, pembrolizumab)|Patients receive cyclophosphamide IV over 2 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -2, and pembrolizumab IV over 30 minutes on day -1. At least 24 hours later, patients receive autologous tumor infiltrating lymphocytes LN-145 IV on day 0, and receive aldesleukin IV over 30 minutes for up to 6 doses on days 1-4. Patients then continue receiving pembrolizumab IV over 30 minutes beginning on day 21. Cycles of pembrolizumab repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity.
89331058|NCT04467346|Experimental|Ped-TMZ|Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition.
89331059|NCT04467346|Active Comparator|Temodal capsule|Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. The administration will take place around 8:00 a.m. followed with 240 mL of tap water, in sitting position and under fasting condition
89331060|NCT04845256||SOMAVAC 100 Sustained Vacuum System|New sustained vacuum system
89331061|NCT03939871|Experimental|Single arm|Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.
89331062|NCT03525106|Experimental|Participants: Positive Psychology Intervention|Participants receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
89331063|NCT03525106|Experimental|Caregivers: Positive Psychology Intervention|Caregivers receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
89331064|NCT01122667|Experimental|Part 1 - Panel A|Subjects with severe renal impairment
89331065|NCT01122667|Experimental|Part 1 - Panel B|Healthy matched control subjects
89331066|NCT01122667|Experimental|Part 2 - Panel C|Subjects with moderate renal impairment
89331067|NCT01122667|Experimental|Part 2 - Panel D|Healthy matched control subjects
89331068|NCT01122667|Experimental|Part 2 - Panel E|Subjects with mild renal impairment
89331069|NCT01122667|Experimental|Part 2 - Panel F|Healthy matched control subjects
89331070|NCT03116464|Experimental|Intervention Group|Caregiver and patient with dementia dyads who receive the family intervention.
89331071|NCT03940027|Experimental|ropivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% ropivacaine with 10ml anhydrous alcohol
89331072|NCT03940027|Active Comparator|bupivacaine|The patients will be carried on EUS-CPN with 10ml 0.75% bupivacaine with 10ml anhydrous alcohol
89331073|NCT04221464|Experimental|Tumors and blood collection|"For all the patients include in the study :~Blood samples will be collected at different times : before any treatment, at every surgery, one month after any surgery, at progression.~Tumours and not tumours tissues will be collected at different times : Before any surgery, one month after any surgery~In parallel to this biological collection, standardized clinical data will be entered into a database treatment, at every surgery"
89331074|NCT03635372|Experimental|Alginate|10 cc of Alginate peroral
89331075|NCT03635372|Experimental|Sucralfate|10 cc of Sucralfate peroral
89331076|NCT03635372|Experimental|Hydrotalcite|10 cc of Hydrotalcite peroral
89331077|NCT03939793|Placebo Comparator|Usual Clinical Support|Participants will continue with their usual diabetes care provided by their clinic. Participants will receive a free wireless glucometer on the day of enrollment if they do not already have one.
89331078|NCT03939793|Active Comparator|DFI Alone|Participants will receive a free wireless glucometer on the day of enrollment if they don't already have one. To encourage habit formation, for the first 6 weeks of the trial, participants will be eligible for a daily lottery incentive for every day that they use their glucometer. Investigators will use an approach similar to what we have used in prior DFI trials: the lottery will provide infrequent large payoffs (a 1 in 100 chance of a US$50 reward) and more frequent small payoffs (an 18 in 100 chance of a US $5 reward). Participants who draw the winning lottery number, but did not check their glucose the day prior will receive an automated text or e-mail message informing them what earnings they would have won had they used their glucometer. After 6 weeks, investigators will terminate the lottery but continue to monitor patients' adherence to glucose self-monitoring.
89331079|NCT03939793|Experimental|Hybrid DFI CHW|Participants in the hybrid intervention will receive a wireless glucometer if they don't already have one and financial incentives just as in the DFI intervention. However, any individuals who have low adherence (no self-monitoring) or elevated glucose readings (>300 mg/dL) for >30% of days over any 2 week period in the first 12 weeks of the study will be assigned to receive ongoing community health worker (CHW) support for the duration of the 24-week study period.
89331080|NCT04391036|Experimental|High Eudragit® Film, then Low Eudragit® Film|High (12.8%) Eudragit® content vaginal film, then low (6.4%) Eudragit® content vaginal film
89331081|NCT04391036|Experimental|Low Eudragit® Film, then High Eudragit® Film|Low (6.4%) Eudragit® content vaginal film, then high (12.8%) Eudragit® content vaginal film
89331082|NCT01116817|Experimental|LPV/r monotherapy 400/100 mg twice daily, orally administered|LPV/r monotherapy 400/100 mg twice daily, orally administered
89331083|NCT01116817|Active Comparator|Lumbar puncture|LPV/r 400/100 mg twice daily + 2 NRTI, orally administered.
89331084|NCT01344980|Experimental|Stainless steel MGH|Patients in this study arm will have their flexor tendon laceration repaired using stainless steel suture (size 3-0) in an MGH repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
89331085|NCT01344980|Active Comparator|Polypropylene DOLL|Patients in this study arm will have their flexor tendon laceration repaired using polypropylene suture (size 3-0) in a double-locking loop repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
89331086|NCT01122745||Catheter Group|Patient will have continuous interscalene block for pain relief placed preoperatively. They will go home with the portable pump. Pain score will be tracked via phone and compared with the control or single short group.
89331087|NCT01122745||Single shot group|Patient will have single shot interscalene block and will go home. Pain will be tracked using phone. Pain will be compared with the catheter group.
89331088|NCT05250518|No Intervention|the control group|The control group will receive no prophylaxis of post-procedure bleeding.
89331089|NCT05250518|Experimental|APC group|The APC group will receive prophylaxis of post-procedure bleeding with argon plasma coagulation.
89331090|NCT05250518|Experimental|Clip group|The Clip group will receive prophylaxis of post-procedure bleeding with clip closure.
89523524|NCT03062995|Experimental|Active product: partially hydrolysed formula + synbiotics|partially hydrolysed formula + synbiotics
89523525|NCT03062995|Active Comparator|Control product: standard formula (intact protein)|standard formula (intact protein)
89331091|NCT01122823|Experimental|On-line workshop|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
89331092|NCT05250206|Experimental|Myopia Control Lens|
89331093|NCT03936595|Experimental|Core exercises protocol|Participants will perform 4 core exercises
89331094|NCT03936595|Experimental|Structural exercises protocol|Participants will perform 4 structural (Olympic lifting) exercises
89331095|NCT03936595|Experimental|Accentuated eccentric load exercises protocol|Participants will perform 4 exercises with eccentric loading
89331096|NCT03936595|Other|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
89331097|NCT03787615|Other|The sipIT tools|The wrist-worn sensors used to detect a drinking event (FitBit Versa with custom algorithm), an H2OPal connected water bottle and fluid consumption monitoring mobile applications.
89331098|NCT01345214|Experimental|E|
89331099|NCT01120873|Experimental|Metamin 3D|A randomized, double-blinded and placebo-controlled study
89331100|NCT04070456|Experimental|Intervention sites-Tablet-based SDH tool|All clinicians and primary care teams at a practice that are randomized to the intervention will receive the tablet-based SDH tool.
89331101|NCT04070456|No Intervention|Control sites|Care as usual, no tablet-based SDH tool.
89331102|NCT03110068||Preoperative clinical/imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo contrast-enhanced computed tomography (CECT) and contrast-enhanced ultrasound (CEUS).
89331103|NCT03620396|Experimental|Experimental: Interventional|Group A patients consists of Gingivitis patients whose serum is collected at base line and treated with Scaling and root planing and after three months serum is collected for assessment of Trefoil factor 3.
89331104|NCT03620396|Experimental|Experimental Interventional|Group B patients consists of Periodontitis patients whose serum is collected at base line and treated with Scaling and Root Planing and after three months serum is collected for assessment of Trefoil factor 3.
89331105|NCT03784963|Experimental|Primary Prevention Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
89331106|NCT03784963|Placebo Comparator|Primary Prevention Non-Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
89331107|NCT03784963|Experimental|Secondary Prevention Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
89331108|NCT03784963|Placebo Comparator|Secondary Prevention Non-Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
89331109|NCT04365998|Experimental|BUBOLight® Device|
89331110|NCT04467892|Active Comparator|Group A|. Group A 120 patients, received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
89331111|NCT04467892|Active Comparator|Group B|group B 120 patients, included received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
89331112|NCT04269668|Active Comparator|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
89331113|NCT04269668|Experimental|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
89331114|NCT03934879|Experimental|Gateway Academy|For this study, Gateway Academy students will participate in the FitClub intervention. They will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
88806728|NCT05708833|Active Comparator|peripheral venous access|Limiting use of intraosseous access (intraosseous access possible after 3 attempts of peripheral venous access)
88806729|NCT05707273|Experimental|Treatment (CD19-CAR T cells)|Patients undergo T cell leukapheresis, receive fludarabine and cyclophosphamide IV, and then receive CD19-CAR T cell infusion IV on study.
89331115|NCT03934879|Active Comparator|Control School|Other comparable school will be added as a control school, in which regular school activities will be provided.
89331116|NCT04258826|Experimental|LY3154207|LY3154207 administered orally in one of two study periods.
89331117|NCT04258826|Placebo Comparator|Placebo|Placebo administered orally in one of two study periods.
89331118|NCT03939403|Experimental|7-days pill free interval|
89331119|NCT03939403|No Intervention|5-days pill free interval|
89331120|NCT01122979|Experimental|group 1: insulin glargine + insulin glulisine|insulin glargine once daily + glulisine at meal times
89331121|NCT01122979|Active Comparator|group 2 NPH insulin + regular insulin|NPH insulin (isophane insulin) (2 or more divided doses) + regular insulin at meal times
89331122|NCT05227040|Experimental|Nintendo Ring Fit Adventure Exergame Group|Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
89331123|NCT05227040|No Intervention|Control group|
89523526|NCT03385915||TAVI cohort|Patients who underwent transcatheter aortic valve implantation for aortic valve stenosis
89331124|NCT04179110|Experimental|Pembrolizumab and Ramucirumab|Patients with progressive transitional cell carcinoma after treatment with an immune checkpoint inhibitor will receive Pembrolizumab and Ramucirumab.
89331125|NCT04797208|Experimental|Real-Time CGM|This group will have a subcutaneous RT-CGM inserted by a member of the research team. CGM's low and high glucose alerts will be activated. The treating clinical team will be able to remotely monitor glucose data and be notified of low glucose alerts through the linked handset. Hyper- and hypo-glycemia management including insulin dose adjustments by the treating clinical team, will be guided by sensor glucose levels and trends according to written guidelines during the study. Glucose level during and post-hypoglycaemia treatment will be confirmed by capillary blood glucose (CBG) measurements (using the NovaStat® glucometer or similar CE-marked glucose meter).
89331126|NCT04797208|Active Comparator|Capillary blood glucose with masked CGM|This group will have their glucose monitored in hospital using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted by a member of the research team to collect glucose values (glucose values will not be displayed and no glucose alerts will be available). This will removed at the end of the study by the research team.
89331127|NCT04722536||Cervico-isthmic cerclage|Are included in this group the women who underwent cervico-isthmic cerclage between January 1, 2010 and April 1, 2019, in 3 hospitals of the Hospices Civils de Lyon, respecting the inclusion and exclusion criteria, to assess the primary and secondary outcomes before and after performing the cerclage.
89331128|NCT03524950|No Intervention|no dexmedetomidine|
89331129|NCT03524950|Experimental|high dose dexmedetomidine|
89331130|NCT03524950|Experimental|low dose dexmedetomidine|
89331131|NCT03936673|Experimental|atrophic kidney|Patients diagnosed with unilateral obstructed kidney with RRF 10% or less underwent application of percutaneous nephrostomy tube on affected side.
89331132|NCT03524872|Active Comparator|Original CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and original (Sweden&Martina) CAD/CAM abutments.
89331133|NCT03524872|Experimental|Compatible CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and compatible (New Ancorvis) CAD/CAM abutments.
89331134|NCT01121029|Experimental|Hematopoietic stem cells|
89331135|NCT01345370||Stupp protocole|All subjects enrolled must be treated according to the Stupp schedule : surgical resection followed by Temozolomide (TMZ) chemotherapy with concomitant radiotherapy, and then 6 cycles of adjuvant Temzolomide.
89331136|NCT04702802|Experimental|Arm 1; PRO-149|Viscoelastic substance PRO-149 (sodium hyaluronate 3%) in pre-filled syringe to be applied in the ocular anterior chamber during phacoemulsification surgery in an amount sufficient to form the desired intraocular space and allow the technical maneuvers required for the procedure.
89331137|NCT04702802|Active Comparator|Arm 2; Healon® EndoCoat|Viscoelastic substance Healon® EndoCoat (sodium hyaluronate 3%) in pre-filled syringe to be applied in the ocular anterior chamber during phacoemulsification surgery in an amount sufficient to form the desired intraocular space and allow the technical maneuvers required for the procedure.
89331138|NCT04108702|Experimental|VR heart|
89331139|NCT04108702|Sham Comparator|VR control|
89331140|NCT04108702|Active Comparator|Standard control|
89331141|NCT03787303|Experimental|Triiodothyronine (T3)|Following discontinuation of L-thyroxine (T4), triiodothyronine (T3) will be initiated at a 3:1 ratio. The dose will be titrated by the investigator to maintain levels of free T4 < 50% of normal range while maintaining a euthyroid state. Triiodothyronine (T3) tablets for oral administration will be prescribed once or twice daily depending on the total dose. Treatment duration will be approximately 9 months during which time the subjects will continue to be treated and monitored as usual for their metastatic breast cancer. During the study period and at the conclusion of the study period, there will be continuous evaluations of the disease status and thyroid status with the option of resuming the original thyroid replacement or continuation of the triiodothyronine (T3).
89331142|NCT03522766||Healthy volunteers with no urinary tract infections|people who don't experience urinary tract infections
89331143|NCT03522766||Healthy volunteers with urinary tract infections|people who frequently experience urinary tract infections
89331144|NCT03522766||Intermittent catheter users with neurogenic bladder|
89331145|NCT03522766||Intermittent catheter users with enlarged prostate|
89331146|NCT03939559|Experimental|Balance Exercises Group|Balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks. After the four weeks, the exercises should be progressed in the last 4 weeks in the second training session
89331147|NCT03939559|Experimental|Dual Task Based Balance Exercises Group|Dual task based balance exercises group, 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
89331148|NCT02529163|Active Comparator|Late-life Schizophrenia ICP|"The Late-Life Schizophrenia ICP arm will follow a medication algorithm composed of 3 trials and titration schedule with prompts.~First trial is Risperidone (2- 4mg daily).~Second trial: Quetiapine (100 - 400mg daily) OR Aripiprazole (100 - 200mg daily) OR OR Ziprasidone (80mg daily) OR Loxapine (100mg daily)~Third trial: Clozapine (450mg daily) or Olanzapine (20mg daily)~If non compliant depot preparation of: Paliperidone (50 - 150mg monthly), Risperidone (12.5 - 50mg q 2 weeks), Flupentixol (10 - 20mg q 2-3 weeks) or Aripiprazole ( up to 400mg monthly)~Prompts will be given to for non-pharmacological interventions such as:~metabolic monitoring~skin hygiene~pain management~nutritional counseling~counseling"
89331149|NCT02529163|Active Comparator|Treatment as Usual (TAU)|The TAU will not receive any prompts to follow a specific treatment. The TAU group will be treated according to the current standard of care by the treating physician. They will have an opportunity to be offered the same non-pharmacological interventions seen with the ICP group but at the discretion of the treating physician. Pharmacological interventions will include an anti-psychotic medication that is selected at the discretion of treating physician with no set titration schedule or timeline to meet a maximum dosage. Max dosage will be decided by the treating physician.
89331150|NCT01214941|Placebo Comparator|Placebo|
89331151|NCT01214941|Active Comparator|Ticlopidine|
88806730|NCT05706649|Experimental|Plant-based diet|Subjects will receive a handbook on plant-based diet including recipe recommendations. They will follow a strict plant-based diet for 21 day.
89331152|NCT01214941|Active Comparator|Ticlopidine and itraconazole|
89331153|NCT01217905|Experimental|1|
89331154|NCT03934801||The expert panel|"Participation in this study will be proposed to a group of experts, including pulmonologists, endocrinologists, allergists, paediatricians and rheumatologists. Additionally, patient advocacy organization representatives will also be invited.~Experts meeting eligibility criteria (see section below) are invited to participate. Further details are available via the URL link at the end of this declaration."
89331155|NCT03934645||Not In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)=0
89331156|NCT03934645||In Delirium|Intensive Care Delirium Screening Checklist(ICDSC)≥4
89331157|NCT05301634|Active Comparator|Group A|the patients will receive bilateral infraorbital block
89331158|NCT05301634|Active Comparator|Group B|the patients will receive topical intranasal application of bupivacaine
89331159|NCT04170296|Experimental|Cohort 1: Posterolateral Thigh|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
89331160|NCT04170296|Experimental|Cohort 2: Buttocks|EN3835 up to 1.68mg (Collagenase Clostridium Histolyticum)
89331161|NCT01328821|Placebo Comparator|Part A|"Single ascending dose administration of four doses of CTP-499 as tablets under fasting condition.~8 subjects per dose group will be enrolled with a 3:1 randomization of active drug to placebo.~Dose levels: 600mg -> 1200mg -> 1800mg -> 2400mg"
89331162|NCT01328821|Active Comparator|Part B|Part B will consist of a single 400 mg dose of an immediate release capsule of CTP-499 administered under fasting conditions. In Part B 6 subjects will be enrolled.
89331163|NCT01212835|Sham Comparator|no ring|Patients at this group will have RING REMOVED AT THE END OF SURGERY.
89331164|NCT01212835|Active Comparator|RYGBP-Ring|Open Roux-en-Y gastric bypass with a silastic ring which is performed with linear cut stapler 100 mm and a biliopancreatic limb of 60 cm long and a alimentary limb of 100 cm long. All patients will have a 6.5 cm silastic ring located at the middle of the pouch above of the gastroenteroanastomosis.
89331165|NCT01123135|Active Comparator|Vaginal ERT|Vaginal ERT cream 1 gm at bed time 3 times a week
89331166|NCT01123135|Placebo Comparator|Placebo|1gm of placebo at bed time 3 times a week
89331167|NCT03939325||first group|patient who exposed to frequency 60 shock wave per min
89331168|NCT03939325||second group|patient who exposed to frequency 80 shock wave per min
89331169|NCT03939325||third group|patient who exposed to frequency 100 shock wave per min
89331170|NCT04001894|Experimental|Ticagrelor|To observe the safety and efficacy of standard-dose ticagrelor in Chinese patients with Stable Coronary Artery Disease
89331171|NCT04001894|Active Comparator|Clopidogrel|To observe the safety and efficacy of standard-dose clopidogrel in Chinese patients with Stable Coronary Artery Disease
89331172|NCT03995264|Experimental|Ultrasound group|Ultrasound-guided radial artery cannulation
89331173|NCT03995264|Placebo Comparator|Palpation group|Radial artery cannulation with palpation technique
89331174|NCT03936283|Experimental|Lifestyle Intervention|
89331175|NCT03936283|No Intervention|Usual Care|
89331176|NCT01317290|Experimental|linseed oil; young|ALA rich linseed oil to younger subjects (18-35 years)
89331177|NCT01317290|Experimental|linseed oil; older|ALA rich linseed oil to older, normalweight subjects (BMI <25, age 49-69 years)
89331178|NCT01317290|Experimental|linseed oil older, overweight|ALA-rich linseed oil to older, normalweight subjects (BMI >25, age 49-69 years)
89331179|NCT01317290|Experimental|olive oil|n3-PUFA free control oil to normalweight subjects (BMI <25)
89331180|NCT04065568|Experimental|Intervention group|The patient will receive conventional out patient rehabilitation after discharge to the home after stroke. In addition an individualized training program with gamified excercises for motor function will be set and followed up by clincians using video communication, as part of the DISKO-tool. Patients are instructed to train self sufficiently 5 days a week and will be supervised by the treating physiotherapist. The intervention will last for 6 weeks.
89331181|NCT04065568|No Intervention|Control group|Conventional rehabilitation in primary care after discharge to the home after stroke.
89331182|NCT01121341|Experimental|EVOH|Procedure: Endoscopic vein with an open CO2 system harvesting
89331183|NCT01121341|Active Comparator|OVH|Procedure: Conventional vein harvesting
89331184|NCT01212913|Experimental|group 1: Basal plus|Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)
89331185|NCT01212913|Active Comparator|group 2: Biphasic insulin|Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL < Pre-meal blood glucose (dinner and breakfast).
89331186|NCT05371366|Experimental|Experimental group|Patients with ASD assigned to experimental group will receive the novel ASD occluder (ReAces)
89331187|NCT05371366|Active Comparator|Control Group|Patients with ASD assigned to control group will receive the normal occluder
89331188|NCT01345526|Experimental|Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream|
89331189|NCT01345526|Placebo Comparator|Metastatic colorectal cancer, Doxycycline, Cream|
89331190|NCT04100798|Experimental|Entire Papilla Preservation (EPP) technique|A minimally invasive surgical technique that involves using a vertical incision away from the defect area in order to preserve the integrity of the related interdental papilla and elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
89523527|NCT03385915||SAVR cohort|Patients who underwentsurgical aortic valve replacement for aortic valve stenosis
89523528|NCT03374033|No Intervention|NUTR (Nutrition) 0_STIMUL(Stimulation) 0|Standard Nutrition and no Physical Stimulation
89331191|NCT04100798|Active Comparator|Modified Minimally invasive Surgical Technique (M-MIST)|A minimally invasive surgical technique that involves using a horizontal interdental incision that extends to the buccal aspect of the two teeth adjacent to the intraosseous defect then elevating a full thickness flap then using microsurgical instruments to properly debride the intraosseous defect before closing the flap
89331192|NCT04050124|Experimental|Promogran Prisma|Following standard of care split thickness skin grafting, patients randomized to the intervention group will receive Promogan Prisma as the primary contact dressing at the donor grafting site.
89331193|NCT04050124|Active Comparator|Standard of care (SOC) dressings|
89331194|NCT03939247|Other|"Conventional PT treatment (CPT)"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching;
89331195|NCT03939247|Experimental|"CPT + Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an active Tecaretherapy is also provided during the sessions
89331196|NCT03939247|Sham Comparator|"CPT + Placebo Tecare"|All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an inactive Tecaretherapy is also provided during the sessions
89331197|NCT04044508|Active Comparator|Interventional diet|A modified ketogenic diet (with the composition found in the pilot study, 75%fat, 15% protein, 10% carbohydrates)
89331198|NCT04044508|Placebo Comparator|Placebo diet|A placebo diet (over 100 g of carbohydrates per day)
89331199|NCT01345604|Placebo Comparator|Saline|
89331200|NCT01345604|Active Comparator|Ropivicaine|
89331201|NCT01218217|Experimental|SQ109 75 mg|75 mg SQ109 monotherapy daily
89331202|NCT01218217|Experimental|SQ109 150 mg|150 mg SQ109 daily
89331203|NCT01218217|Experimental|SQ109 300 mg|300 mg SQ109 daily
89331204|NCT01218217|Experimental|SQ109 150 mg + RIF|150 mg SQ109 + RIF standard dose daily
89331205|NCT01218217|Experimental|SQ109 300 mg + RIF|300 mg SQ109 + RIF standard dose daily
89331206|NCT01218217|Active Comparator|RIF Mono|Standard dose Rifampicin monotherapy daily
89331207|NCT03934723|Active Comparator|Control|This arm will consist of healthy overweight and obese individuals who are physically inactive and do not have clinically diagnosed depression or depression symptoms.
89331208|NCT03934723|Experimental|Antidpressants|This arm will consist of healthy overweight and obese adults who are physically inactive and who are diagnosed with clinical depression and have been taking antidepressant medications for at least 1 year.
89331209|NCT01345760||Basal Cell Carcinoma|
89331210|NCT01345760||Squamous Cell Carcinoma|
89331211|NCT01345760||Actinic Keratosis|
89331212|NCT01345760||healthy non-lesional skin|
89331213|NCT03522532|Experimental|Amalgam (Amg)|Amalgam was sealed in 8-K2 patients and 6-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
89331214|NCT03522532|Experimental|Tetric EvoCeram (TEC)|Tetric EvoCeram was sealed in 12-K2 patients and 5-K5 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
89331215|NCT03522532|Experimental|Beautifil (BF)|Beautifil was sealed in 15-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
89331216|NCT03522532|Experimental|Zinc phosphate cement (ZPhC)|"Zinc phosphate cement was sealed in 7-K2 patients, 4-K3 patients, 1-K4 patients and 2-K5 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
88806731|NCT05705856||intravenous maintenance at early stage|Participants who have evidence of high activity clinically, biochemically or endoscopically : HBI ≥8, inflammatory markers significantly increased (CRP > 5mg/L, fecal calprotectin> 200mg/g), SES-CD≥ 7, will get multiple intravenous injections of Ustekinumab maintenance after induction.
88806732|NCT05705856||intravenous escalation when poor response|Participants who experience a loss of response or poor response to 90 mg Ustekinumab standard therapy will receive Ustekinumab intravenously at regular interval or at shorten interval.
88806733|NCT05699668|Experimental|older premature children born at a term ≤28 weeks of amenorrhea without dysplasia bronchopulmonary|OCT Angiography
88806734|NCT05699668|Experimental|older premature children born at a term ≤28 weeks of amenorrhea with dysplasia bronchopulmonary|OCT Angiography
88806735|NCT05699668|Experimental|patients in the control group without prematurity without BPD|OCT Angiography
88806736|NCT05698654|Experimental|Fasting-mimicking diet (FMD)|The fasting-mimicking diet (FMD) group, will be instructed on the benefits and use of the fasting-mimicking diet and how it should be used. This group will have to perform the fasting-mimicking diet once every 3 months (3 cycles in 6 months).
88809688|NCT01270880|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89331217|NCT03522532|Experimental|Zinc polycarboxylate cement (ZPoC)|"Zinc polycarboxylate cement was sealed in 5-K2 patients, 4-K3 patients and 5-K4 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
89331218|NCT03522532|Experimental|Glass ionomer cement (GIC)|"Glass ionomer cement was sealed in 11-K2 patients, 2-K3 patients and 1-K5 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
89331219|NCT03945422|Experimental|Treatment Arm|Subject will receive AccuTite/FaceTite and Morpheus8 treatment
89331220|NCT01121419||Neuroblastoma|
89331221|NCT03895580|No Intervention|Group 1|Medical nutrition therapy session with no further dietary counseling throughout the study.
89331222|NCT03895580|Experimental|Group 2|Medical nutrition therapy session plus in-store point-of-purchase (POP) education.
89331223|NCT03895580|Experimental|Group 3|Medical nutrition therapy session plus combined in-store/online point-of-purchase (POP) education.
89331224|NCT03522454|Experimental|Intervention group|Intervention group: Combination of a protein-rich oral nutritional supplement consumed twice daily for 4 weeks pre-TAVR and 12 weeks after the patient is discharged home post-TAVR, and a home-based supervised exercise program that combines walking and weight-bearing exercises to build strength and balance performed for 12 weeks after the patient is discharged home post-TAVR.
89331225|NCT03522454|No Intervention|Lifestyle counselling group|Lifestyle counselling group: Recommendation to perform moderate-intensity aerobic activity at least 30 minutes 5 days per week as tolerated and eat a balanced diet based on the AHA/ACC Guideline on Lifestyle Management.
89331226|NCT01215019|Active Comparator|Arm 1|20% Mannitol
89331227|NCT01215019|Active Comparator|Arm 2|3% sodium chloride
89331228|NCT03795428|Experimental|Pemziviptadil (PB1046) Injection-OL Active Drug-Up-Titration to Stable Dose|Pemziviptadil (PB1046) Injection: Regardless of dose assignment, all subjects will be up-titrated in 0.2 mg/kg weekly increments, beginning with 0.4 mg/kg at Week 1, to the target dose of 1.2 mg/kg or higher depending on safety and tolerability.
89331229|NCT01116973|Other|CICC comparison with PICC|All patients will be having CVP reading taken from the CICC
89331230|NCT01116973|Other|PICC group|The transition to the PICC, a 5.0-French, 18-gauge double lumen PICC (BARD, Power PICC Solo Catheter with Tip Location Stylet; Salt Lake City, UT) will be inserted
89331231|NCT01215331|Active Comparator|Insulin|Rapid acting insulin and long acting insulin
89331232|NCT01215331|Experimental|Oral Hypoglycemic Agents|Metformin + glyburide + insulin if needed
89331233|NCT03772184|Active Comparator|cervical inversion|
89331234|NCT03772184|No Intervention|no cervical inversion|
89331235|NCT03526276|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
89331236|NCT03526276|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
89331237|NCT03526276|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
89331238|NCT04972916|Other|Patient Navigation-based Tobacco Harm Reduction Intervention|All participants will receive a smoking cessation educational brochure and patient navigation intervention delivered over 2 months.
89331239|NCT01218295|Experimental|Respiratory muscle training|Patients assigned to this arm train the respiratory muscles by means of normocapnic hyperpnea.
89331240|NCT01345916|Experimental|CHF 1535 100/6 NEXT Dry Powder Inhaler®|CHF1535 100/6 NEXT DPI® 1 inhalation bis in day (b.i.d) (daily dose BDP 200/FF 12 µg)
89331241|NCT01345916|Active Comparator|CHF1535 100/6 pMDI|CHF1535 100/6 pressurisedMeterDoseInhaler 1 inhalation b.i.d (total daily dose BDP 200/FF 12 µg)
89331242|NCT01345916|Active Comparator|beclomethasone dipropionate DPI|beclomethasone dipropionate 100 µg DPI, 1 inhalation b.i.d (total daily dose BDP 200 µg)
89331243|NCT01123291|Active Comparator|routine follow-up coronary angiography|routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
89331244|NCT01123291|Active Comparator|clinical follow-up|no routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
89331245|NCT05158634||Cerebral Palsy|"Inclusion Criterias: Being diagnosed with Cerebral Palsy. Volunteer. Be between the ages of 6-18. Being at level 1 and level 2 according to Gross Motor Function Classification System (GMFCS) (Level 1 and 2).~To have the cognitive skills to understand and apply the evaluation parameters.~Exclusion Criterias: Cognitive impairment of participants diagnosed with Cerebral Palsy. Participants diagnosed with Cerebral Palsy have vision or hearing problems. Participants diagnosed with Cerebral Palsy must have a history of trauma such as botox or muscle relaxation operation and/or fracture at least 6 months before participating in the study."
89331246|NCT03934489|Experimental|PERSIST|Participants will receive Partnered Emotion Regulation Skills Intervention and Support.
89331247|NCT03934489|Active Comparator|Facilitated Peer Support|Participants will undergo a 12-week group intervention, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
89331248|NCT04466254|Experimental|Arm A|CPGJ602 325mg/m2 IV Q2W； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks.
89331249|NCT04466254|Experimental|Arm B|CPGJ602 400 mg/m2 IV in the first infusion， then 250mg/m2 followed per every week； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks
89331250|NCT04466254|Active Comparator|Arm C|cetuximab 400 mg/m2 IV in the first infusion， then 250mg/m2 followed per every week； mFOLFOX6 therapy starts on day 1 and ends on day 2, then repeats every 2 weeks
89331251|NCT01345994|Experimental|Acupuncture - local|acupuncture on forearm only
89331252|NCT01345994|Experimental|acupuncture - distal|acupuncture on both arm and leg
89331253|NCT04466176|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89331254|NCT04466176|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
89331255|NCT03939013|Experimental|Xpert HCV VL, sof/dac (local standard of care therapy)|Use of Cepheid GeneXpert HCV VL device as diagnostic tool to test for HCV RNA for diagnosis of chronic hepatitis C infection, for assessment of sustained virological response at 12 weeks post treatment completion
89331256|NCT01346150||Stratum A -Typical SCID|Typical Severe Combined Immunodeficiency (SCID), Adenosine Deaminase-Deficient ADA SCID, and X-linked SCID (XSCID) who received a transplant
89331257|NCT01346150||Stratum B - Atypical SCID|Leaky SCID, Omenn Syndrome, and Reticular Dysgenesis who received a transplant
89331258|NCT01346150||Stratum C - SCID w/Non-HCT Treatments|SCID who received Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) or gene therapy
89331259|NCT01215409||Group 1|
89331260|NCT03936205|No Intervention|Control|
89331261|NCT03936205|Experimental|Dexmedetomidine|
89331262|NCT04686266|Experimental|ViCCY: Health Information + Health Coaching|This group will receive 10 front-loaded sessions of virtual health coaching by trained Health Coaches over 6 months with content based on the theoretical framework our prior research. Sessions are provided using tablets. Initially, sessions are weekly to build the relationship, but the frequency of sessions decreases over time
89331263|NCT04686266|No Intervention|Health Information|Caregivers in the Health Information group are asked to spend at least 30 minutes weekly using the computer tablet provided to you by the study team to access recommended websites
89331264|NCT03939091|Other|Ultrasonography|Renal Ultrasonography
88809689|NCT01270802|Active Comparator|Tenofovir/emtricitabine/efavirenz|Tenofovir/emtricitabine/efavirenz
88809690|NCT01270802|Experimental|Tenofovir/emtricitabine plus raltegravir|Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine plus raltegravir
89331265|NCT04674020|Experimental|Single-Arm|Erenumab packed in a SureClick® Autoinjector Pen (AI).
89331266|NCT01215487||1 - Chronic Myelogenous Leukemia Patients|Patients will be selected from patients referred to the primary hospital site for treatment and assessment. The patients will be approached by the physicians and or the study research nurse to consider participation in the study. Patients may be selected by participating off-site hospital centres and may be enrolled at those collaborating centres.
89331267|NCT03522376||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic obstructive pulmonary disease, stable clinically, has no infection or acute exacerbation in the previous four weeks, and can cooperate with the measurements of this study, loaded inspiratory muscle test.
89331268|NCT01213069||all 5000 subjects|this is a purely descriptive study with one group
89331269|NCT03524716|Experimental|Fitbit and Text Messages|Participants randomized to this arm receive print materials and a Fitbit Flex 2 at baseline and daily text messages for 12 weeks.
89331270|NCT03524716|No Intervention|Usual Care|Participants randomized to usual care receive print materials at baseline.
89331271|NCT01123525|Experimental|Adenosine cardioplegia|Adenosine cardioplegia
89331272|NCT01123525|Active Comparator|Control|Standard hyperkalemic cardioplegia
89331273|NCT03522220|Experimental|3D Super Mario Game Condition|3D navigation video game intervention
89331274|NCT03522220|Active Comparator|2D Super Mario Game Condition|Video game intervention without 3D navigation
89331275|NCT03522220|Active Comparator|Kindle Device|No 3D navigation
89331276|NCT03368144|Experimental|ClearLumen II Peripheral Thrombectomy System|Patients treated with the ClearLumen II Peripheral Thrombectomy System
89331277|NCT01215565|Experimental|patient treated|patient who receive sunitinib
89331278|NCT05128058|Experimental|Cohort 1|Subjects will be dosed with 50 mg Ritlecitinib on Day 1 and followed up till Day 3
89331279|NCT05128058|Experimental|Cohort 2|Subjects will be dosed with 200 mg Ritlecitinib on Day 1 and followed up till Day 3
89331280|NCT03526198|Experimental|Group 1 (adult)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
89331281|NCT03526198|Experimental|Group 2 (elderly)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
89331282|NCT01121497|Experimental|Physostigmine|Colonoscopy sedation with or without physostigmine
89331283|NCT03526120|Experimental|Pistachio diet|Incorporates 44 g (1 serving) of pistachios into a daily diet
89331284|NCT03526120|No Intervention|Control|No pistachio consumption
89331285|NCT01213147|Experimental|clomiphene citrate,pregnancy,poor responders|Woman in clomiphene citrate arm are administered 100mg/day oral from day 3 of menstrual cycle until day 7 of cycle
89331286|NCT01213147|Active Comparator|buserelin,pregnancy,poor responder|women in control arm are administered Buserelin buserelin 50 µg SC twice a day from cycle day 2 of menstrual cycle
89331287|NCT03143816|Active Comparator|Technosphere insulin (TI, Afrezza) -Treatment arm|Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG ( post prandial blood glucose)
89331288|NCT03143816|No Intervention|Insulin Aspart ( Novolog) -Control arm|Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals.
89331289|NCT01123681||Ventilator associated pneumonia|
89331290|NCT01123681||No pneumonia|
89331291|NCT04646564|Active Comparator|control arm|standard of care
89331292|NCT04646564|Experimental|study arm|radiotherapy + standard of care
89331293|NCT01117129|Experimental|A|
89331294|NCT01117129|Placebo Comparator|B|
89331295|NCT01123759|Active Comparator|Tilapia|Subjects are fed 6 oz tilapia once a week for 3 months
89331296|NCT01123759|Active Comparator|Salmon|Subjects fed 6 oz salmon once a week for 3 months
89331297|NCT01218373|Active Comparator|Intervention Group: HOMESWEETHOME services|Monitoring and alarm handling services. eInclusion services. Domotica services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
89331298|NCT01218373|Placebo Comparator|Control Group: No HOMESWEETHOME services|Normal care.
88809691|NCT01273454||001|OROS Hydromorphone 8 16 32 mg once a day for 4 weeks
88809692|NCT01270256|Active Comparator|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
89331299|NCT03934411|Experimental|Tramadol treatment|
89331300|NCT03934411|Placebo Comparator|Placebo treatment|
89331301|NCT01346384||intracuff pressure N2O|measured intracuff pressure of LT with N2o during operative period
89331302|NCT01124461||Brain Tumor|Brain neoplasms, malignant
89331303|NCT04631120|Active Comparator|Standard of Care|The proposed arm will involve an initial assessment using the Clinical Dementia Rating (CDR) Scale and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score for patients and Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard educational material from the AA and Association for the Advancement of Retired Persons (AARP). Two phone sessions with a study nurse will occur post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment; a summary of these and professional education on national evidence-based guidelines will be mailed to the patient's PCP of record. Education provided in this arm will be both patient- and caregiver-centered.
89523529|NCT03374033|Experimental|NUTR 0_STIMUL +|Standard Nutrition and Physical Stimulation
89523530|NCT03374033|Experimental|NUTR +_STIMUL 0|Enhanced Nutrition, and no Physical Stimulation
89523531|NCT03374033|Experimental|NUTR +_STIMUL +|Enhanced Nutrition and Physical Stimulation
89523532|NCT04446169||SARS-CoV 2 Patients|Patients with previous nasopharyngeal swab positive for SARS-CoV-2, subsequently negativeized in two detections
89331304|NCT04631120|Experimental|Integrated Dementia Practice Unit Arm|"The integrated practice unit design is a coordinated, team-based, comprehensive, technology enabled, family focused care delivery design comprised of:~Dementia Central: Nurses, physicians, psychologists, social workers, and other relevant healthcare providers that will meet monthly to review participants progress and issues. Telehealth visits would facilitate home care.~Dementia Mobile: A nurse and lay health educator team will perform monthly visits, conduct assessments of subjects and provide education/coaching.~Dementia Link: Technologies that facilitate communication between Dementia Central and Dementia Mobile and foster proactive collaboration/coaching for study subjects include an mHealth software that allows for real time intervention/communication between professional teams and dyads, combined with management of dyads for multiple parameters like health metrics, behavioral measures and stress management and a portal tailored to specific clinical needs."
89331305|NCT01218451|Experimental|Group 1|Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
89331306|NCT01218451|Experimental|Group 2|Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
89331307|NCT01218451|Active Comparator|Group 3|Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
89331308|NCT04967144||Carpal Tunnel syndrome|.Patients with carpal tunnel syndrome
89331309|NCT04967144||Control subjects|Healthy subjects
89331310|NCT04467580|Experimental|Patients with stenosing CD|Patients with stenosing CD will be recruited in each investigation center, during a preoperative consultation for an already decided and planned intestinal resection (digestive surgery or hepato-gastro department) -enterology).
89331311|NCT01123837|Active Comparator|D5LR|In the treatment group, a 250cc bolus over 2 hrs of D5LR will be initiated prior to the end of surgery and continued in PACU.Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning
89331312|NCT01123837|Active Comparator|lactated ringers|In the control group, a 250cc bolus over 2 hrs of LR will be initiated prior to the end of surgery and continued in PACU. Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning.
89331313|NCT03524638|Active Comparator|ARM A|Colorectal surgery with administration of Visbiome
89331314|NCT03524638|Active Comparator|ARM B|Colorectal Surgery alone
89331315|NCT01346930|Experimental|Macitentan|Macitentan tablet, 10 mg, once daily
89331316|NCT01219153|Experimental|Extended high dose letrozole regimen /GnRH antagonist|
89331317|NCT01219153|Active Comparator|Short low dose letrozole regimen /GnRH antagonist|
89331318|NCT04466020||Patients with Chronic Breathlessness|Patients with Chronic Breathlessness
89331319|NCT03635450|Experimental|First cohort of 3 subjects enrolled|The first cohort of three patients will receive a single dose in the first 48 postnatal hours.
89331320|NCT03635450|Experimental|Second cohort of 3 subjects enrolled|If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
89331321|NCT01117285|Active Comparator|3-day post-graduate course|3-day post-graduate course on the use of the COTiD program in clinical practice
89331322|NCT01117285|Experimental|Combined implementation strategy|The combined implementation strategy
89331323|NCT03526042|Experimental|Losartan|AT1R-ab effect can be blocked with the use of angiotensin-II receptor blockers. The participants will receive losartan.
89331324|NCT03526042|Active Comparator|Enalapril|Angiotensin converting enzyme inhibitors are indicated in the management of active lupus nephritis but do not block the effect of AT1R-Ab.
89331325|NCT01316432|Experimental|SQ Bolus Cenderitide|
89331326|NCT01316432|Experimental|SQ Infusion Cenderitide|24 hour SQ infusion of cenderitide
89331327|NCT01316432|Placebo Comparator|Placebo|24 hrs of SQ placebo infusion
89331328|NCT01124539|Experimental|AR-67|
89331329|NCT03141788|Other|3M Clear Aligner|Clear Aligner for Orthodontic Treatment
89331330|NCT03869554|Experimental|Renal disease|detection of Fabry disease
89331331|NCT01347164|Experimental|Life coaching sessions|6 2-hour counseling session with trained therapist/counselor. The sessions deal with coping and stress reduction as well as sexual health.
89331332|NCT01347164|Active Comparator|HIV counseling session|One 60-minute counseling session, based on standard HIV counseling content.
89331333|NCT03873038|Experimental|Part 1, Panel A: MK-2060 (8 mg)|Participants will receive a single 8-mg dose of MK-2060 via intravenous (IV) infusion.
89331334|NCT03873038|Experimental|Part 1, Panel B: MK-2060 (20 mg)|Participants will receive a single 20-mg dose of MK-2060 via IV infusion.
89331335|NCT03873038|Experimental|Part 1, Panel C: MK-2060 (40 mg)|Participants will receive a single 40-mg dose of MK-2060 via IV infusion.
89331336|NCT03873038|Experimental|Part 2: MK-2060 (25 mg)|Participants will receive three doses of up to 25 mg MK-2060 via IV infusion in the first week (Week 1), followed by a single dose of up to 25 mg MK-2060 via IV infusion weekly for 3 weeks (Weeks 2-4).
89331337|NCT03873038|Placebo Comparator|Part 1 (Panels A, B, C) and Part 2: Placebo|Part 1: Participants will receive a single dose of placebo via IV infusion. Part 2: Participants will receive three doses of placebo via IV infusion in the first week and then a single dose of placebo via infusion weekly for 3 weeks (Weeks 2-4).
89331338|NCT01347242|Experimental|study treatment|autologous CD34 positive cells transduced with a lentiviral vector containing the human WAS gene
89523533|NCT02615951|Other|Nutrient transporters study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of nutrient transporters expression
89331339|NCT03781375|Placebo Comparator|Methotrexate + Placebo|Participants received placebo subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
89331340|NCT03781375|Experimental|Methotrexate + Etanercept|Participants received 0.4 mg/kg etanercept subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
89331341|NCT01123915|Experimental|Opal-HIV-Gag(c)|Opal-HIV-Gag(c) administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
89331342|NCT01123915|Placebo Comparator|Diluent|Administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
89331343|NCT01123993|No Intervention|Lifestyle counselling|
89331344|NCT03938779|Experimental|Pelvic Floor Muscle Training (PFMT)|Experimental group will perform for 4 months a PFMT
89331345|NCT03938779|Experimental|Pad test|The experimental and control group will perform the pad test twice. At the beginning of the evaluation and 4 months after the PFMT. The modified pad test, has the durability of a workout (2h30min)
89331346|NCT03938779|No Intervention|Kings Health Questionnaire|Kings Health Questionnaire to assess the impact of urinary incontinence on quality of life of women. Both groups will complete the questionnaire.
89331347|NCT03938779|No Intervention|perineometer|Both groups will perform perineometry at baseline and 4 months after
89331348|NCT03938623||Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
89331349|NCT03938623||Control|General Practitioners not using the patient-centered approach
89331350|NCT03779503|Active Comparator|midafilcon A|Subjects will be randomized to wear midafilcon A 1 day for one week of daily wear during the study.
89331351|NCT03779503|Active Comparator|somofilcon A|Subjects will be randomized to wear somofilcon A 1 day for one week of daily wear during the study.
89331352|NCT01124071|Active Comparator|Korean Diet|Provision of 2 Korean meals per day, 6 days per week
89331353|NCT01124071|Active Comparator|Western Diet|Lifestyle counseling, dietary advice, grocery vouchers
89331354|NCT01117363|Experimental|Rye porrige breakfast|
89331355|NCT01117363|Active Comparator|Refined wheat reference bread breakfast|
89331356|NCT01218529|Experimental|Whole Brain Radiation Therapy (WBRT) + lapatinib|Whole Brain Radiation Therapy (30Gy in 10 fractions) and lapatinib 1250mg once daily for 2 weeks followed by lapatinib treatment 1500mg once daily for 4 weeks.
89331357|NCT03938467|Experimental|Antiseptic Cleanser|Standard prophylaxis will be administered by Irrisept patients as would individuals in the control group. In addition, these Irrisept study subjects will be supplemented with the use of Irrisept irrigation by the study surgeon during the patient's surgical procedure. Standard times for irrigation will include immediately after incision through the dermal layer, and immediately prior to implantation of any prosthetic components. Final irrigation will be performed just prior to closure of the deltopectoral interval.
89331358|NCT03938467|No Intervention|Standard of Care Prophylaxis|Standard prophylaxis includes use of chlorhexidine wipes (Sage cloth) the night before and morning of surgery on the surgical site over the anterior shoulder.
89331359|NCT03933943|Experimental|LY3361237|LY3361237 administered subcutaneously (SC)
89331360|NCT03933943|Placebo Comparator|Placebo|Placebo administered SC
89331361|NCT01218607|Placebo Comparator|Placebo|
89331362|NCT01218607|Active Comparator|Active|
89331363|NCT01219231|Experimental|Exercise|
89331364|NCT01219231|Placebo Comparator|Placebo|
89331365|NCT01219309|Active Comparator|Omega 3/6 treatment|
89331366|NCT01219309|Placebo Comparator|Placebo|
89331367|NCT01213303||Blood donors|Evaluation of cardiovascular risk factors, oxidative stress and fatty acid metabolism in a cohort of blood donors
89331368|NCT01218685||Health adults|
89331369|NCT01218685||Health children|
89331370|NCT01218685||Pregnants|
89331371|NCT01218685||Elderly over 65 years old|
89331372|NCT01218685||HIV patients|
89331373|NCT01218685||Kidney transplant|
89331374|NCT01218685||Oncologic patients|
89331375|NCT01218685||Rheumatologic adult patients|
89331376|NCT01218685||Rheumatologic children patients|
89331377|NCT01222039|Experimental|Conventional treatment plus high dose: 3x10e6 cells / Kg.|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
89331378|NCT01222039|Experimental|Conventional treatment plus low dose: 1x10e6 cells / Kg|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
89331379|NCT03933709|No Intervention|Follow-up Group (FG)|dietary surveillance and conventional therapy
89331380|NCT03933709|Active Comparator|Control Group (CG)|deworming and WHO diet
89331381|NCT03933709|Experimental|Intervention Group (IG)|deworming and the Nutritional Support System (NSS)
89331382|NCT03931993|Placebo Comparator|Treatment Group 1|Six 1.0mL placebo injections (2% w/v L-tyrosine)
89331383|NCT03931993|Experimental|Treatment Group 2|Six 1.0mL injections of Grass MATA MPL 900, 2700, 8000, 8000, 8000, and 8000 SU
89331384|NCT03933787|Placebo Comparator|mannitol in a tablet|two tablets containing mannitol in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
89331385|NCT03933787|Active Comparator|Saxagliptin in a tablet|two tablets containing each 5 mg of Saxagliptin in a blister: one tablet provided to each volunteer in a blister 16 hours before the trial and one tablet provided two hours before the clinical trial
89331386|NCT01124773||Previous HT use and cognition|Women who were aged 50-54 at the time of randomization into the WHI hormone trials.
89331387|NCT01124851|Experimental|Arm 1|ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days
89331388|NCT01124851|Experimental|Arm 2|ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days
89331389|NCT01124851|Experimental|Arm 3|ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days
89331390|NCT01124929|Active Comparator|Arm 1: Category I treatment for 6 months|Anti-tuberculosis drugs
89331391|NCT01124929|Active Comparator|Arm 2: Category I treatment for 9 months|Anti-tuberculosis drugs,
89331392|NCT01219465|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
89331393|NCT01329055||Hemodialysis patients|
89331394|NCT03934333|Experimental|A/B (BDA MDI/Pulmicort)|For each participant, the BDA MDI/Pulmicort Flexhaler DPI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP will be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
89331395|NCT03934333|Experimental|B/A (Pulmicort/ BDA MDI)|For each participant, the Pulmicort Flexhaler DPI / BDA MDI will be administered as a single dose (2 inhalations) on Day 1 of the respective treatment period per the assigned treatment sequence. The IMP should be administered in the morning, at approximately the same time of day throughout the study (±30 minutes).
89331396|NCT01124227|Sham Comparator|Standard Care|
89331397|NCT01124227|Active Comparator|2 Icodextrin PD changes / day|
89331398|NCT01124227|Active Comparator|1 Icodextrin PD change/day|
89331399|NCT03931915|Experimental|TAK-385|TAK-385 40 mg administered orally once daily before breakfast + Leuprorelin placebo administered subcutaneously once every 4 weeks
89331400|NCT03931915|Active Comparator|Leuprorelin acetate|TAK-385 placebo administered orally once daily before breakfast + Leuprorelin acetate 1.88 mg / 3.75 mg administered subcutaneously once every 4 weeks
89331401|NCT01218763||ICD patients|Candidates may come from the investigator's general population, who require DR ICD or CRT-D therapy for primary or secondary ICD indication and meet all study eligibility criteria
89331402|NCT01125007|Active Comparator|toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
89331403|NCT01125007|Experimental|medium toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
89331404|NCT01222429|Active Comparator|diet following American Diabetes Association guidelines|Participants will follow diets based on ADA guidelines. This group will also receive weekly nutrition classes.
89331405|NCT01222429|Experimental|vegan diet|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
89331406|NCT03932071|Experimental|experimental group|
89331407|NCT03932071|No Intervention|control group|
89331408|NCT03931759|Active Comparator|Diabetes mellitus|patients with diabetes mellitus
89331409|NCT03931759|No Intervention|non-Diabetes mellitus|patients without diabetes mellitus
89331410|NCT01218841|Experimental|Fish oil lipid emulsion|Parenteral lipid emulsion composed by fish oil which is rich in the omega-3 polyunsaturated fatty acids eicosapentanoic and docosahexanoic.
89331411|NCT01218841|Active Comparator|MCT/LCT lipid emulsion|Parenteral lipid emulsion containing 50% of medium-chain triglycerides and 50% of soybean oil
89331412|NCT01124383|Active Comparator|General anesthesia|
89331413|NCT01124383|Active Comparator|Local anesthesia with sedation|
89331414|NCT01222663|Other|Standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
89331415|NCT01222663|Experimental|Hemoperfusion|standard therapy + 2 sessions of hemoperfusion within the first 24 hours
89331416|NCT01218919||Brio DBS System|Eligible subjects in this study will be screened to confirm that they meet the strict guidelines for advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication followed by bilateral surgery to implant the Brio™ deep brain stimulation system
89331417|NCT03928873|Experimental|Low energy ESWT|"Low energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks)"
89331418|NCT03928873|Experimental|High energy ESWT|"High energy ESWT (using LITEMEDLM-ESWT-mini System with 1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks)"
89331419|NCT03928873|Sham Comparator|Sham treatment|All participants will receive sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks.
89331420|NCT03928951||Patients suffering from urinary infection|Patients consulting in one of Toulon - La Seyne sur Mer hospital emergency departments because of urinary infection
89331421|NCT01125085|Other|131I-L19SIP RIT in Combination with WBRT|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
89331422|NCT01125241|Experimental|Wuling capsule|
89331423|NCT01125241|Placebo Comparator|Placebo|
89331424|NCT01125319|Other|patients Hemophagocytic lymphohisticytosis group|
89331425|NCT01125319|Other|group control patient|
89331426|NCT01125319|Other|healthy control group|
89331427|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 75 mmHg|Before skin incision
89331428|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 100 mmHg|Before skin incision
89331429|NCT03931837|Experimental|Tourniquet: Systolic blood pressure + 150 mmHg|Before skin incision
89331430|NCT01225939|Experimental|1|Single Oral dose AZD8329 tablet (fasting)
89331431|NCT01225939|Experimental|2|Single Oral dose AZD8329 solution (fasting)
89331432|NCT01225939|Experimental|3|Single Oral dose AZD8329 tablet (Fed)
89331433|NCT03928483|Experimental|Modified WW Food program|Participants will be assigned to a SmartPoints budget and number and types of ZeroPoint foods.
89331434|NCT01219543|Experimental|Part A|Daily dosing of AZD1480 to the patients with solid tumours excluding HCC
89331435|NCT01219543|Experimental|Part B|BID dosing of AZD1480 to the patients with advanced HCC (Child-Pugh A to B7)
89331436|NCT01219543|Experimental|Part C|BID dosing of AZD1480 to the patients with solid tumours excluding HCC
89331437|NCT01219543|Experimental|Expansion|BID dosing of AZD1480 to the patients with EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available.
89331438|NCT01125397|Experimental|Behavioral Intervention|
89331439|NCT01125397|No Intervention|Control|These participants will be randomized to receive no behavioral intervention prior to bariatric surgery.
89331440|NCT01219621|Active Comparator|DDD Long AVD|
89331441|NCT01219621|Experimental|safeR|
89331442|NCT01222819|Experimental|IV filgrastim|as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg) in bolus IV injection, as per manufacturer's recommendations.
89331443|NCT01222819|Active Comparator|SC filgrastim|given as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg)
89331444|NCT01222897|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
89331445|NCT01222897|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
89331446|NCT03150056|Experimental|GSK525762 + Abiraterone (+ Prednisone) (Arm A)|
89331447|NCT03150056|Experimental|GSK525762 + Enzalutamide (Arm B)|
89331448|NCT01329367|Active Comparator|Control group|"Control group: Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
89331449|NCT01329367|Experimental|Protein group|"Protein group: Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
89331450|NCT01329367|Experimental|Antioxidant group|"Antioxidant group: Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
89331451|NCT01222975|Experimental|1|Risperidone orally disintegrating tablets of Ranbaxy Laboratories, Ltd
89331452|NCT01222975|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
89331453|NCT01129063|Experimental|Sequence clopidogrel 75 / 75 / 300 mg|"Period 1: clopidogrel 75 mg single dose~Period 2: clopidogrel 75 mg single dose~Period 3: clopidogrel 300 mg single dose~Each intake is at around 8:00 AM under fasted conditions."
89331454|NCT03928561|Experimental|1 - Active air cleaner then Placebo|Exposure to cat allergen in the presence of active air cleaners then placebo. 3-week wash-out period between the two exposures.
89331455|NCT03928561|Experimental|2 - Placebo then active air cleaner|Exposure to cat allergen in the presence of placebo then active air cleaners. 3-week wash-out period between the two exposures.
89331456|NCT01317368|Active Comparator|TAP block|"TAP block with Ropivacaine~Wound infiltration with Saline"
89331457|NCT01317368|Active Comparator|Wound infiltration|"TAP block with Saline.~Wound infiltration with Ropivacaine."
89331458|NCT01317368|Placebo Comparator|Placebo|"TAP block with Saline.~Wound infiltration with Saline."
89331459|NCT01329445||DeNovo NT patient|Patients who have received or who are scheduled to receive a DeNovo NT graft for repair of 1-2 knee cartilage lesions.
89331460|NCT02887040|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
89331461|NCT02887040|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for 104 weeks. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
89331462|NCT01219699|Experimental|BYL719|In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
89331463|NCT01219699|Experimental|BYL719 + fulvestrant|In post-menopausal patients with estrogen receptor positive locally advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
89331464|NCT03933319|Experimental|PLD in combination with trastuzumab|"Trastuzumab: administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.~pegylated liposomal doxorubicin(PLD):administered at dose of 35mg/m2 IV once every 21 days."
89331465|NCT04587440|Experimental|Patient|"All patients will have a clinical examination before surgery and another 3 months after surgery, each including :~A medical examination~3 pelvic inclination measurements (1 sitting, 1 lying and 1 standing). These measurements will be done by ultrasound devices.~2 EOS X-rays (1 standing and 1 sitting) of the lower limbs and spine~Harris hip score~Pain quantification thanks to an EVA scale~hand-ground distance"
89331466|NCT01223053|Active Comparator|Active|Topical ketoprofen 10% Cream
89331467|NCT01223053|Placebo Comparator|Placebo Cream|Placebo Cream
89331468|NCT04561700|Experimental|Reporting of sucking patterns captured by Instrumented Bottle|Weekly reporting on objective measurements of sucking activity during oral feeding
89331469|NCT04561700|Sham Comparator|Control|Weekly reporting on traditional measurements of sucking activity during oral feeding (no objective measurements reported)
89331470|NCT01223131|Experimental|Insulin glargine|injection once daily at bedtime
89331471|NCT01223131|Active Comparator|NPH insulin|injection once daily at bedtime or twice daily in the morning and at bedtime
89331472|NCT04543526||Obese patients|Obese patients eligible for standard laparoscopic or robot-assisted laparoscopic RYGB surgery.
89331473|NCT03933241|Experimental|experiment group|nasal irrigation after transsphenoidal surgery for pituitary tumor
89331474|NCT03933241|No Intervention|matched group|without nasal irrigation after transsphenoidal surgery for pituitary tumor
89331475|NCT02763956|Experimental|Gelstix|The intradiscal insertion of the GelStix™ Nucleus Augmentation Device.
89331476|NCT02763956|Placebo Comparator|Placebo|Intradiscal saline solution (1 mL NaCl 0.9%) injection.
89331477|NCT01125553|Experimental|IDegAsp B|
89331478|NCT01125553|Experimental|IDegAsp F|
89331479|NCT01347320|No Intervention|No preoperative MRI|control arm of the study
89331480|NCT01347320|Active Comparator|MRI group|preoperative MRI
89331481|NCT01125631|Experimental|PF-04360365 8.5 mg/kg|
89331482|NCT01125631|Placebo Comparator|Placebo|
89331483|NCT01347398|Experimental|MicroMESAM|Sleep study made by MicroMESAM system
89331484|NCT01347398|Active Comparator|PSG|Sleep study made by PSG (polysomnography)
89331485|NCT01329133|Active Comparator|DBS of subthalamic nucleus|
89331486|NCT01329133|Active Comparator|DBS of ventral striatum|
89331487|NCT01347476||patients older than 70 years|
89331488|NCT01347476||patients 70 years or younger|
89331489|NCT03928249|Active Comparator|Grupo A|Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks
89331490|NCT03928249|Placebo Comparator|GRUPO B|group B (n = 20) will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg / d placebo for 12 weeks
89331491|NCT03635294|Experimental|Blood sample|Blood sample for analyses
89331492|NCT02640664|Experimental|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
89331493|NCT02640664|Experimental|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
89331494|NCT02640664|No Intervention|Laser therapy|Laser therapy
89331495|NCT03222830|Experimental|RIF group|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
89331496|NCT01226251||Healthy adults|Subjects consulting a bad breath clinic at the Department of Periodontology, KULeuven
89331497|NCT01317446|Experimental|amine fluoride/stannous fluoride|Amine fluoride/stannous fluoride mouthrinse in addition to mechanical oral hygiene
89331498|NCT01317446|No Intervention|No rinsing|Mechanical oral hygiene only
89331499|NCT03928171|Experimental|Intra-abdominal pressure of 8 mmHg|The laparoscopy insufflator is set to a pressure of 8 mmHg
89331500|NCT03928171|Experimental|Intra-abdominal pressure of 12 mmHg|The laparoscopy insufflator is set to a pressure of 12 mmHg
89331501|NCT03928171|Experimental|Intra-abdominal pressure of 16 mmHg|The laparoscopy insufflator is set to a pressure of 16 mmHg
89331502|NCT01226329|Experimental|RQP-MH|Participants in the intervention arm will receive three Patient Activation and Self-Management education sessions, plus a fourth booster session if they show difficulty mastering the content of the first three trainings.
89331503|NCT01226329|Active Comparator|Comparison Group|"Participants in this arm will receive a pamphlet in either Spanish or English called Managing Your Mental Health Care."
89331504|NCT03207620||smoker asthmatics|"Asthma control questionnaire (ACQ) score~Spirometry~Sputum cytology"
89331505|NCT03207620||non-smoker asthmatics|"Asthma control questionnaire (ACQ) score~Spirometry~Sputum cytology"
89331506|NCT01223209|Experimental|LTX-315|The dose range of 0,25-2.0 mg/ML LTX-315 will be used. In combination with a fixed dose of GV-1001.
89331507|NCT04108312||Autism Spectrum Disorders|
89331508|NCT04108312||Typical Control|
89331509|NCT02529241|Experimental|Group 1: LCB01-0371|Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg
89331510|NCT02529241|Experimental|Group 2: LCB01-0371|Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg
89331511|NCT02456012|Experimental|The D group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg twice daily for 36 weeks.
89331512|NCT02456012|Experimental|The S group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg once daily for 36 weeks.
89331513|NCT02456012|No Intervention|The C group|The cohort control group includes patients from a previous study who had peptic ulcer bleeding and Rockall scores ≥ 6 but who did not receive esomeprazole or other proton pump inhibitors after 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment.
89331514|NCT01226407|Experimental|Single Arm for CG200745|any progrossive solid cancer
89331515|NCT01317524|Experimental|Homogenized Milk|900 mL homogenized milk is consumed within a mixed meal
89331516|NCT01317524|Experimental|Unhomogenized Milk|900 mL unhomogenized milk is consumed within a mixed meal
89331517|NCT01317524|Experimental|Skimmed Milk|900 mL skimmed milk and 44 g of butter are consumed within a mixed meal
89331518|NCT03932929|Experimental|Scotchbond universal adhesive (etch-and-rinse)|Acid etch (enamel&dentin)+adhesive agent Intervention: Device: Adhesive agent
89331519|NCT03932929|Experimental|Scotchbond universal adhesive (selective-etch)|Acid etch (only enamel)+adhesive agent Intervention: Device: Adhesive agent
89331520|NCT03932929|Experimental|Scotchbond universal adhesive (self-etch)|Adhesive agent Intervention: Device: Adhesive agent
89331521|NCT02468596|Experimental|Patients|Patients suffering from anti-MAG neuropathy
89331522|NCT00812006|Experimental|A|Treatment Sequence A: rizatriptan, rizatriptan, placebo
89331523|NCT00812006|Experimental|B|Sequence B: rizatriptan, placebo, rizatriptan
89331524|NCT00812006|Experimental|C|Sequence C: placebo, rizatriptan, rizatriptan
89331525|NCT03133234||EGFR T790M Patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI
89331526|NCT01125787|Experimental|ofatumumab + bendamustine|
89331527|NCT01220011|Experimental|NO INTERVENTION|
89331528|NCT01220011|Active Comparator|fetoscopic laser|
89331529|NCT04541498||Population of Poland|Exposure to short term long term effects of air pollution and climate change
89331530|NCT04541498||Patients with Acute Coronary and Cerebral Syndromes|Exposure to short term long term effects of air pollution and climate change
89331531|NCT03524482|Experimental|Path2Quit|Culturally specific text message intervention
89331532|NCT03524482|Active Comparator|SmokeFreeText|The National Cancer Institute's publicly available, standard text messaging program for tobacco cessation
89331533|NCT01220089|Active Comparator|Standard maintenance|During months 7 to 18, individuals in the Standard Maintenance condition will receive informational handouts by mail (or e-mail) regarding weight maintenance.
89331534|NCT01220089|Active Comparator|Intensified Maintenance|"During months 7 to 18, individuals in the Intensified Maintenance condition will continue to have monthly in-person visits with the weight loss counselor (Weight Coach)."
89331535|NCT03145532|Experimental|Real tDCS plus robotic training|Children will receive 20 min of real tDCS stimulation per session, followed by robotic training for 1 hr.
89331536|NCT03145532|Sham Comparator|Sham tDCS plus robotic training|Children will receive 20 min of sham tDCS stimulation per session, followed by robotic training for 1 hr.
89331537|NCT01129219|Experimental|Usual care|Subjects in the control group were asked to maintain their current lifestyle. No restrictions were placed on their exercise activities.
89331538|NCT03132038|Experimental|Nivolumab|Nivolumab will be given every two weeks for a maximum of one year (12 cycles) at a dose of 3 mg/kg to be administered as a 60 minute IV infusion
89331539|NCT02298712||Observation|Patients with Hurler disease or high-grade suspicion for Hurler disease
89331540|NCT01129375|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
89331541|NCT01129375|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
89331542|NCT01129375|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions"
89331543|NCT01129375|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
89331544|NCT03635138|Experimental|Adhesives Cu/Zn nanoparticles doped|Adhesive dopped with Zn Oxide + Cu nanoparticles in a ( 5% / 0.2% concentration )
89331545|NCT03635138|Active Comparator|Adhesive control|Adhesive conventional
89331546|NCT03928405|Experimental|Virtual reality group|The subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT). The virtual reality group was trained with games selected from different categories such as balance and aerobic exercises with Nintendo Wii virtual reality device for 6 weeks, 1 session 30 min, 2 times a week. In the control group, no treatment was performed during this period and routine medical treatments were continued. In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control.
89331547|NCT03928405|No Intervention|Control Group|The sociodemographic characteristics of the subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT).the control group was reevaluated at the end of the 6th week after the initial evaluation. After the study was completed, training was given to the volunteers from the control group.
89331548|NCT04625062|Experimental|Visual-acoustic biofeedback|Visual- acoustic biofeedback treatment (behavioral) administered via telepractice
89331549|NCT04625062|Experimental|Motor-based treatment|Motor-based articulation treatment administered via telepractice
89331550|NCT01352624|Experimental|Experimental|$teps for Achieving Financial Empowerment ($AFE)
89331551|NCT01352624|No Intervention|Usual Care|Veterans in control arm will receive usual care at VA
89331552|NCT03931447|Experimental|Cohort 1: JNJ-72537634 Dose 1 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a single day (SD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1.
89331553|NCT03931447|Experimental|Cohort 2: JNJ-72537634 Dose 2 or Placebo (Part 1 - SD)|Each participant will receive pretreatment with oral antibiotic; followed by a SD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1.
89331554|NCT03931447|Experimental|Cohort 3: JNJ-72537634 Dose 1 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a multiple day (MD) study intervention of JNJ-72537634 at dose 1 or placebo after overnight fast on Day 1 for 14 consecutive days.
89331555|NCT03931447|Experimental|Cohort 4: JNJ-72537634 Dose 2 or Placebo (Part 2 - MD)|Each participant will receive pretreatment with oral antibiotic; followed by a MD study intervention of JNJ-72537634 at dose 2 or placebo after overnight fast on Day 1 for 14 consecutive days.
89523534|NCT02615951|Other|Chemokine receptors study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of chemokine receptors expression
89523535|NCT02615951|Other|Genes study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of genes expression
89331556|NCT06130098|Active Comparator|control group|"Training by the clinical nurse before discharge. Prepare an educational brochure and give it to patients. Application of patient information form, EQ-5D-5L Quality of Life and Oxford Knee Score Scale During the routine check-up in the first week, evaluates the development of complications without knowing which group the patient is in.~Within the first week and at the end of the fourth week, the wound site is evaluated by the physician for the development of complications, . Patients who cannot come for a check-up should send a photo of the wound area to the researcher via WhatsApp application, and the photo will be forwarded to the clinician who performed the surgery and the physician will record the complication situation. It is planned to receive complication development and wound site evaluation results from the physician system.~At the end of the fourth and sixth weeks after discharge, the EQ-5D-5L and OKS scale must be filled in again by the patients."
89331557|NCT06130098|Active Comparator|experimental group|"Active Comparator: experimental group Providing education to patients by preparing a pre-discharge education brochure. You will be contacted by phone at the end of the first, second, third and fourth weeks after discharge.~Application of the patient information form, EQ-5D-5L Quality of Life and Oxford Knee Score Scale. Evaluation of the wound site in terms of complications at the end of the first and fourth weeks. It is planned to receive complication development and wound site evaluation results from the system.~After the first check-up, a call is made at the end of the first week after discharge.~Providing training on the subjects included in the training brochure during the first phone call~In the fourth meeting, tele-nursing service was provided through the Telephone Counseling Protocol~Refilling of the EQ-5D-5L quality of life and Oxford Knee Score scale by patients at routine check-up at the end of the fourth and sixth weeks after discharge"
89331558|NCT06130085|No Intervention|Infants Continuing on amino acid based formula after 6 months elimination|
89331559|NCT06130085|Active Comparator|Infants receiving partially hydrolyzed formula after 6 months of elimination diet|
89331560|NCT06130072|Active Comparator|Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil|Group 2 including 20 patients with hydrosalpinx refaired for hysteroscopic tubal occlusion prior to IVF using iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil.
89331561|NCT06130072|Active Comparator|Hysteroscopic tubal occlusion using only iso-amyl- 2-cyanoacrylate|Group 1 including 25 patients with hydrosalpinx refaired for hysteroscopic tubal occlusion prior to IVF using iso-amyl- 2-cyanoacrylate .
89331562|NCT06130059|Experimental|Low dose colchicine|Low dose colchicine 0.5 mg once a day orally for 3 months
89331563|NCT06130059|Placebo Comparator|Placebo|Placebo once a day orally for 3 months
89331564|NCT06130046||OLT|Observation of MR-proADM levels at protocol timepoints to predict main (DGF and AR) and secondary (surgical complications, infections, others) complications after liver transplantation at our Institution.
89331565|NCT06130046||KT|Observation of MR-proADM levels at protocol timepoints to predict main (DGF and AR) and secondary (surgical complications, urological complications, infections, others) complications after kidney transplantation at our Institution.
89331566|NCT06130007|Experimental|Neoadjuvant Treatment with Trastuzumab in Combination with Platinum-Based Doublet|A first-line chemotherapy regimen for oral squamous cell carcinoma involves combining paclitaxel with platinum agents. PD-1 antibodies have shown promise in cases where the cancer has recurred, metastasized, or didn't respond to platinum-based treatments. Research is ongoing on using immune induction therapy with surgery or chemoradiotherapy for locally advanced, resectable oral squamous cell carcinoma. Trastuzumab, in combination with standard chemotherapy, is being explored as an induction treatment for patients needing mandibulectomy due to tumor proximity to the mandible. This study is a prospective, single-arm, single-center Phase II explora.
89331567|NCT06129994||Study Group|Participants will complete the observational study over the 15 day study period
89331568|NCT06129981|Experimental|Imaginary exposure therapy augmented by vocal feedback in patients fulfilling the criteria for PTSD|
89331569|NCT06129955|Experimental|Pucotenlimab combined with Lenvatinib as neoadjuvant therapy|Pucotenlimab combined with Lenvatinib as neoadjuvant therapy
89331570|NCT06129942|Placebo Comparator|Dim light group|treated with the placebo device which operates with one intensity of 300 lux * 1 month
89331571|NCT06129942|Experimental|Bright light group|treated with the experimental device which operates with one intensity of 10,000 lux * 1 month
89331572|NCT06129851|Experimental|Arm A (relugolix, brachytherapy, external beam radiation)|Patients receive relugolix PO QD. Cycles repeat every 3 months for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions. Patients undergo bone scan, CT or MRI or PSMA PET scan during screening. Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
89331573|NCT06129851|Experimental|Arm B (relugolix, brachytherapy, external beam radiation)|Patients receive relugolix PO QD. Cycles repeat every 3 months for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 30 to 180 days after start of relugolix, patients undergo brachytherapy and external beam radiation over 25 fractions. Patients undergo bone scan, CT or MRI or PSMA PET scan during screening. Patients also undergo DEXA scan and may optionally undergo blood sample collection throughout the trial.
89331574|NCT06129838||Healthy participants|Healthy participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer [11C]-CS1P1. Participants will then undergo a brain [11C]-CS1P1 PET scan
89331575|NCT06129838||Participants with cognitive impairment (Alzheimer's disease)|Participants with cognitive impairment will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer [11C]-CS1P1. Participants will then undergo a brain [11C]-CS1P1 PET scan
89331576|NCT06129812||resectable PDAC with no contact to major vessels (R-no contact)|
89331577|NCT06129812||resectable PDAC with contact PV/SMV of ≤180° (R-contact)|
89331578|NCT06129812||borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)|
89331579|NCT06129799||paradoxical LF-LG AS|
89331580|NCT06129799||conventional LF-LG AS|
89523536|NCT02615951|Other|Protein surface study|Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure of protein surface expression
89331581|NCT06129734|Experimental|Low dose maintenance chemotherapy|Participants will receive low dose chemotherapy as a maintenance therapy post-transplant. Participants must enroll by post-transplant day 40. Treatment will consist of once weekly 5 mg/m2 decitabine followed by 400 mg venetoclax orally approximately 6 hours afterwards. Participants will continue maintenance therapy for one year or unacceptable toxicity. Participants will otherwise receive post Allogeneic hematopoietic stem cell transplant (alloSCT) care and disease monitoring as per institutional standards.
89331582|NCT06129708|Experimental|Group (A) Aquatic Exercise Group|They participated in an aqua aerobic exercise program, 3 days per week, for 8 weeks
89331583|NCT06129708|Experimental|Group (B) Aerobic Exercise Group|They participated in an aerobic exercise program on a treadmill, 3 days per week, for 8 weeks.
89331584|NCT06129669||Debridement after radiotherapy|Debridement after radiotherapy
89331585|NCT06129669||Debridement after trauma|Debridement after trauma
89331586|NCT06129669||Reconstructive surgery using a fasciocutaneous flap|Reconstructive surgery using a fasciocutaneous flap
89331587|NCT06129669||Reconstructive surgery using a muscle flap|Reconstructive surgery using a muscle flap
89331588|NCT06129669||Reconstructive surgery using a osseous flap|Reconstructive surgery using a osseous flap
89331589|NCT06129669||Vaginaplasties|Vaginaplasties using a peritoneum flap or colon interposition
89331590|NCT06129669||Phalloplasties|Phalloplasties
89331591|NCT06129669||Finger replantation|Finger replantation
89331592|NCT06129656||Cardiac Amyloidosis|Patients with diagnosed cardiac amyloidosis being treated at Leipzig University Hospital.
89331593|NCT06129630|Active Comparator|Control Group (CG)|Control Group (CG), which received their usual sessions of conventional occupational therapy.
89331594|NCT06129630|Experimental|Experimental Group (EG)|Experimental Group (EG), which received therapy with Nintendo Switch, plus their conventional occupational therapy sessions.
89331595|NCT06129617|Active Comparator|Hemodialysis|Patients receiving hemodialysis therapy mit Fresenius 5008
89331596|NCT06129617|Experimental|ADVOS|Patients receiving ADVOS therapy with ADVOS multi
89331597|NCT06129565|Experimental|Q-collar Intervention|All patients with low-pressure hydrocephalus that qualify for the study and agree to participate will receive the Q-collar for intervention
89331598|NCT06129513|Active Comparator|Whey protein isolate|Following a bout of bilateral resistance exercise, participants will ingest 32 g protein from whey protein isolate
89331599|NCT06129513|Experimental|Plant-blend isolate|Following a bout of bilateral resistance exercise, participants will ingest 32 g protein from a novel plant-blend protein isolate
89331600|NCT06129500|Experimental|CBT for mood driven, problematic, impulsive behaviours|All participants will be offered the 12 week CBT intervention
89331601|NCT06129474|Experimental|DROPIT Intervention|The study intervention is a patient-centred PPI deprescribing intervention aiming to guide GPs and patients through the process of safely deprescribing inappropriate PPIs.
89331602|NCT06129474|No Intervention|Usual Care|The reference or control arm will receive usual care. This means that the GPs and patients in this group will conduct their clinical practice as per usual, without receiving the intervention from the study team.
89331603|NCT06129461|Experimental|Treatment|The intervention group will participate in a single-session, self-guided online intervention imparting skills grounded in Acceptance and Commitment Therapy. The one-hour workshop guides participants through evidence-based exercises, brief video clips, and reflection activities designed to clarify values and teach skills to foster acceptance, defusion, and present-moment awareness.
89331604|NCT06129461|No Intervention|Control|Participants in the control group will not receive any intervention; they will complete assessments on the same schedule as the intervention group (baseline, 1 month, at full term)
89331605|NCT06129409|Experimental|NT-0796|BID
89331606|NCT06129409|Placebo Comparator|Placebo|BID
89331607|NCT06129396|Experimental|Aerobic exercise group|The aerobic exercise consists of: (1) 5 min warm-up exercise, (2) 20 min aerobic exercise with heart rate (HR) at target zone (one research assistant will be onsite to monitor whether the HR is around the range of moderate intensity), and (3) 5 min cool-down exercise.
89331608|NCT06129396|Active Comparator|Video-watching group|The video-watching group will be asked to watch a nature documentary for 30 mins
89331609|NCT06129370|Experimental|Software, then Standard|Participants will use the medication dosage software to calculate and prepare intravenous medications during the initial run through of pediatric case scenarios. Then, they will use standard clinical practice (Lexicomp and manual calculator) during the second run through of pediatric case scenarios.
89331610|NCT06129370|Experimental|Standard, then Software|Participants will use standard clinical practice (Lexicomp and manual calculator) to calculate and prepare intravenous medications during the initial run through of pediatric case scenarios. Then, they will use the medication dosage software during the second run through of pediatric case scenarios.
89331611|NCT06129357||Diagnosis of gingivitis|60
89331612|NCT06129357||Diagnosed as periodontal healthys|60
89331613|NCT06129357||Diagnosis of periodontitis|60
89331614|NCT06129331||AS-CA without amyloid-specific treatment|Patients with no amyloid-specific treatment
89331615|NCT06129331||AS-CA with amyloid-specific treatment|Patients receiving newly available amyloid-specific drugs
89331616|NCT06129318|Experimental|Clinical Pharmacist Led Pharmaceutical Care|In addition to usual care services, the intervention group was provided with pharmaceutical care by a clinical pharmacist.
89331617|NCT06129318|No Intervention|Control Group|Usual Care
89331618|NCT06129253||Cross-Sectional Survey|There are total 14 CSS groups among 8 participating countries: Bangladesh has 3 groups for CSS (urban CSS, rural CSS, displaced population CSS); Pakistan has 3 groups for CSS (urban CSS, rural CSS, commercial sex worker population CSS); Nepal has 1 nationally representative CSS; Sierra Leon has 1 rural CSS; Tanzania has 2 groups for CSS (pastoralists CSS, displaced population CSS); Ghana has 1 urban CSS; Zambia has 1 group for urban & rural representative CSS; DR Congo has 2 groups for CSS (population representative sample for urban and rural CSS, displaced population CSS)
89331619|NCT06129253||Longitudinal Study|There are total 11 LS groups: Bangladesh has 2 LS groups (married women up to 25 years-old & 26-35 years old); Sierra Leone has 2 LS groups (Young girls subject to child marriage/early pregnancy & general population); Tanzania has 2 LS groups (fishing, mining/tuck stop community & general population) Other 5 countries have 1 LS group in each country.
89331620|NCT06129253||Qualitative Study|The qualitative sub-studies in five selected countries (Bangladesh, Nepal, Pakistan, Sierra Leone, DR Congo) will follow and draw on findings from the CSS, focusing on girls and women of different age strata as well as community members (including boys and men) and key informants in the health care system in each study site. Qualitative study methods will vary depending on the site and CSS findings, but will include both individual in- depth interviews (IDIs) (up to ~ 30 individuals per site), key informant interviews as well as multiple focus group discussions (FGDs) with ~6-8 participants/group. Detailed qualitative study methodology will be developed separately as another study protocol and adapted according to the procedures for each site.
89331621|NCT06129227|Experimental|Dual-task training|Mobility tasks performed in conjunction with cognitive tasks
89331622|NCT06129227|Active Comparator|Single-task training|Separate cognitive and mobility exercises
89331623|NCT06129227|Active Comparator|Control group|Upper limb strengthening and flexibility exercises
89331624|NCT06129201||Training group|Experimental group: population of initially diagnosed nasopharyngeal carcinoma [600 people]; Control group: 2400 healthy individuals+nasopharyngeal disease patients+other tumors.
89331625|NCT06129201||Validation group|Validation group: Experimental group: Nasopharyngeal cancer population [400 people]; Control group: 1600 healthy individuals+patients with nasopharyngeal diseases+other tumors.
89331626|NCT06129162|Active Comparator|Group I: Control Group|Use a conventional syringe to inject anesthetic solution by the inferior alveolar nerve block (IANB) technique. Also, use a conventional syringe to inject anesthetic solution by buccal infiltration (BI) technique.
89331627|NCT06129162|Experimental|Group II: STA group|Use STA Wand® (CCLA) to inject anesthetic solution by the inferior alveolar nerve block (IANB) technique. Also, use STA Wand® (CCLA) to inject anesthetic solution by buccal infiltration (BI) technique.
89331628|NCT06129162|Experimental|Group III: Star pen group|Use a Star Pen device to inject anesthetic solution by the inferior alveolar nerve block (IANB) technique. Also, use a Star Pen device to inject anesthetic solution by buccal infiltration (BI) technique.
89331629|NCT06129136|Active Comparator|Nature-based exposure by biodiversity component in lotion.|This group uses regularly the lotion with added natural biodiversity component. The component is mimicking natural exposure to Finnish forest soil and it contains high microbial diversity. The microbes are inactivated.
89331630|NCT06129136|Placebo Comparator|Placebo group using colored lotion.|This group uses regularly the same vehicle lotion than Nature exposure group, with the difference that the biodiversity component has been replaced with safe coloring ingredients to give the same brownish color than in the other group's lotion. Coloring ingredients are iron oxides that are common in foods and cosmetics: C.I.7791, C.I.77492, C.I. 774499.
89331631|NCT06129123|Experimental|Intervention|"Participants will be asked to complete a 30-minute intervention that is accessible on a mobile device, delivered via a webpage, and personalized to their individual vaping behavior and beliefs (based on the baseline surveys). The intervention will contain personalized normative feedback (PNF), Motivational Enhancement (ME), and education.~Participants will complete assessments at baseline as well as 2-weeks, 4-weeks, and 8-weeks post randomization."
89331632|NCT06129123|No Intervention|Waitlist Control|Participants will complete assessments at baseline as well as 2-weeks, 4-weeks, and 8-weeks post randomization. They will not receive the intervention during the active study phase, lasting 8 weeks. Participants will have the option to access the intervention once this active study phase is over.
89331633|NCT06129110|Experimental|Diet Weight Loss|Low calorie meal replacement shakes
89331634|NCT06129110|No Intervention|Delayed Intervention|Normal feeding
89331635|NCT06129071|Experimental|US block of maxillar nerve|"Extraoral ultrasound-guided block of the maxillary nerve will be performed using an ultrasound device. After visualisation of the pterygomandibular space, of the maxillary artery and the mandibular nerve next to it, at a depth of 2-4 cm, the detection of the maxillary artery is confirmed by Color Doppler. A needle enters between the coronoid and condylar processes, using the out of plane technique, near the maxillary artery, and after negative aspiration, local anesthetic levobupivacaine (0,5%, 2 mL) combined with triamcinolonacetonid (2mL)."
89331636|NCT06129006|Active Comparator|group A shoulder anterior capsular infiltration plus hydrodilatation with steroids.|25 patients with frozen shoulders treated with ultrasound-guided shoulder anterior capsular infiltration plus hydrodilatation with steroids.
89331637|NCT06129006|Active Comparator|groupB shoulder anterior capsular infiltration plus hydrodilatation with hyalase.|25 patients with frozen shoulders treated with ultrasound-guided shoulder anterior capsular infiltration plus hydrodilatation with hyalase.
89331638|NCT06128993|Experimental|Transcoronary cooling and dilution|Intervention with transcoronary cooling and dilution
89331639|NCT06128993|Placebo Comparator|Standard of care|Routine clinical care
89331640|NCT06128980|No Intervention|Standard of Care|Patients will be treated with GDMT for heart failure during the trial follow-up of 1 year.
89331641|NCT06128980|Active Comparator|Weaning|Patients will be weaned from GDMT in a sequential order.
89331642|NCT06128967|Placebo Comparator|Placebo|Placebo talc pills of same shape, color, weight dispensed in coded bottles. Each bottle contains 120 pills
89331643|NCT06128967|Active Comparator|Fluvoxamine 100 mg|Fluvoxamine maleate 100 mg pills dispensed in coded bottles. Each bottle contains 120 pills
89331644|NCT06128967|Active Comparator|Metformin XR 750 mg|Metformin 750 mg Extended release pills dispensed in coded bottles. Each bottle contains 120 pills
89331645|NCT06128941|Experimental|Normobaric hypoxia (SRH)|Participants will carry out training sessions in a normobaric hypoxia chamber at a simulated altitude of 3000 meters (FiO2 14.5%)
89331646|NCT06128941|Experimental|Hypoventilation (SRH-VLH)|Participants will be asked to exhale to residual functional capacity, immediately before starting each sprint, and to hold their breath until the end of the sprint
89331647|NCT06128941|Active Comparator|Normoxia (SRN)|Participants will carry out training sessions in normoxia (FiO2 20.9%)
89331648|NCT06128902|Experimental|intervention group|COPD patients
89331649|NCT06128902|No Intervention|Control group|COPD patients
89331650|NCT06128863|Other|single arm|"Systemic therapy with pembrolizumab and eftilagimod alpha is given concurrently with radiotherapy.~Surgery is scheduled 5-6 weeks after completion of radiotherapy."
89331651|NCT06128850||Peri-implantitis|
88809693|NCT01270256|Placebo Comparator|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
89331652|NCT06128850||Peri-implant mucositis|
89331653|NCT06128850||Peri-implant health|
89331654|NCT06128824||Patients with probable CAA and cSS or fSAH|Patients with probable CAA and cortical superficial siderosis (cSS) or focal subarachnoid haemorrhage (fSAH)
89331655|NCT06128824||Patients with probable CAA without cSS or fSAH|Patients with probable CAA and intracerebral hemorrhage (ICH; micro- or macrohemorrhage) but without cSS or fSAH
89331656|NCT06128811|Experimental|Group 1|Participants who will receive rubber dam isolation followed by DryShieled will be considered group 1.
89331657|NCT06128811|Active Comparator|Group 2|Participants who will receive DryShieled followed by rubber dam isolation will be considered group 2.
89331658|NCT06128798|Experimental|Oral Impact|Immunonutrition enriched with omega-3 fatty acids, arginine, nucleotides, and soluble fibre. Main source of protein is arginine and casein.
89331659|NCT06128798|Active Comparator|Nutren Optimum|A balanced nutritional supplement that enhance body natural defence and support recovery during illness.
89331660|NCT06128785|Experimental|Electroacupuncture group|The acupuncture will be performed within 6 hours after surgery Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37), All acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to an electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation was given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal discharge or until the fourth day.
89331661|NCT06128785|Sham Comparator|Sham EA group|In order to achieve maximum patient blindness, both groups will use adhesive pads, and the sham acupuncture needle will have the same appearance as the traditional needle, with a blunt tip (Suzhou Medical Supplies Factory, specification 0.25×40mm), lifting and inserting and twisting, but not piercing the adhesive pad. The output wire of the special sham electroacupuncture apparatus is cut in the middle, and the appearance is as usual; that is, the electroacupuncture apparatus shows an on state, but is not actually energized; the electroacupuncture points, acupuncture time points, frequency, retention time, and duration of treatment are the same as the intervention group, and the patients are informed that it is an effective light current input and may not feel stimulation, but the current is output. All study patients will be treated independently and separately to ensure that patients will not come into contact with each other.
89331662|NCT06128785|No Intervention|Conventional control group|Routine perioperative management will be given, postoperative fluid and nutritional support, correction of acid-base imbalance, electrolyte disorders, anti-infection, hemostasis and other symptomatic management.
89331663|NCT06128720|Experimental|Open Label|Participants will get Hyperbaric oxygen therapy for 20 days to determine best methods for full trial.
89331664|NCT06128720|Experimental|Active Hyperbaric Oxygen|Participants will get Hyperbaric oxygen therapy for 20 days.
89331665|NCT06128720|Placebo Comparator|Sham Hyperbaric Oxygen|Participants will get a Sham Hyperbaric oxygen therapy for 20 days
89331666|NCT06128707||Chronic Motion sensitivity group|Participants with a self-reported history of chronic motion sensitivity and who scored greater than or equal to the 30th percentile on the Motion sickness susceptibility questionnaire short form.
89331667|NCT06128707||Non-Chronic Motion sensitivity Group|Participants without a self-reported history of chronic motion sensitivity and who scored less than or equal to the 25th percentile on the Motion sickness susceptibility questionnaire short form.
89331668|NCT06128694|Experimental|ONS (oral nutrition supplement) group|ONS will be consumed 3 times a day, for 8 weeks. Per serving/sachet ONS (±81g) contains 350 kcal of energy, 9 g of fat, 20 g of protein, 48 g of carbohydrates, 400 mg of DHA (Docosahexaenoic acid), 300 mg of EPA (Eicosapentaenoic Acid) 0.92 g of Omega-3, 1 g of L-Valine, 2.1 g of L-. Isoleucine 1.1 g, L-Leucine 2.1 g, Sodium 75 mg, 12 vitamins and 9 minerals. Consumed as a morning snack (between breakfast and lunch); afternoon snack (between lunch and dinner) and evening snack (before bedtime). Subject will also received dietary counseling for 8 weeks
89331669|NCT06128694|No Intervention|Control group|only received dietary counseling for 8 weeks without ONS supplementation.
89331670|NCT06128681||Mediastinal open group|Mediastinal opening technique was performed with intraairway ultrasound guidance
89331671|NCT06128681||Non-mediastinal open group|Diagnosis and treatment are routinely performed without any manipulation of the mediastinum
89331672|NCT06128668|Experimental|Yoga|Yoga will be aplicated
89331673|NCT06128668|No Intervention|Control|Yoga will not be aplicated
89331674|NCT06128603||LPD group|Cases who had underwent laparoscopic pancreaticoduodenectomy
89331675|NCT06128577|Experimental|Sarcopenia group|After completing screening, 30 subjects in the sarcopenia group received a 3-month intensive intervention consisting of an intensive nutritional intervention and an individually designed exercise intervention. Nutritional and exercise prescriptions were co-designed through a nutritionist and rehabilitation physician.
88809694|NCT01273532|Experimental|001|tapentadol (CG5503) ER 50-mg TRF 100 mg TRF single oral dose
88809695|NCT01273532|Experimental|002|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
88809696|NCT04386434|Experimental|Active for Life|The Active Life intervention includes structured walking, functional circuit training, stretching and behavior/educational components.
89331676|NCT06128577|No Intervention|Normal control group|
89331677|NCT06128525|Experimental|Treatment (TMA, radical prostatectomy)|Patients undergo MRI/US fusion guided transperineal targeted TMA and then undergo standard of care RP same day or at 30 days post-TMA on study. Patients may undergo planning mpMRI of prostate prior to TMA. Patients also undergo blood sample collection at screening and post RP.
89331678|NCT06128486|Experimental|Yung Sheng 55% Color Contact Lens|
89331679|NCT06128473|Experimental|Yung Sheng 38% color contact lens|
89331680|NCT06128434|Experimental|zinc carbonate nano-hydroxyapatite toothpaste|Biorepair toothpaste with 20 wt% zinc carbonate nano-hydroxyapatite
89331681|NCT06128434|Experimental|8% arginine toothpaste|Colgate Sensitive Pro-Relief™ with pro-argin technology
89331682|NCT06128434|Active Comparator|Fluoride toothpaste|Signal cavity fighter toothpaste with Sodium Monofluorophosphate
89331683|NCT06128408||schizophrenia|
89331684|NCT06128395||Aspirin 81 mg for Frozen Embryo Transfer (FET)|Subjects were prescribed Aspirin 81 mg to be started on the third day of their menstrual cycle in preparation for their FET.
89331685|NCT06128395||Aspirin 162 mg for Frozen Embryo Transfer (FET)|Subjects were prescribed Aspirin 162 mg to be started on the third day of their menstrual cycle in preparation for their FET
89331686|NCT06128278|Experimental|(1) S-equol, (2) Placebo|
89331687|NCT06128278|Experimental|(1) Placebo, (2) S-equol|
89331688|NCT06128252|Experimental|Taurine + Serplulimab + investigator's choice chemotherapy|Taurine + Serplulimab + XELOX or Taurine + Serplulimab + FLOT
89331689|NCT06128252|Active Comparator|Serplulimab + investigator's choice chemotherapy|Serplulimab + XELOX or Serplulimab + FLOT
89331690|NCT06128213|Experimental|NRX101 Treatment arem|oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone)
89331691|NCT06128200|Active Comparator|Active|Subjects in this arm will undergo treatment with the NEUROMARK device.
89331692|NCT06128200|Sham Comparator|Sham|Subjects in this arm will undergo the procedure with a Sham device. Sham control participants will be offered the option to receive active treatment after the 90-day follow-up provided they still meet all eligibility criteria.
89331693|NCT06128187|Active Comparator|Control Group|Participants will undergo a conventional upper extremity rehabilitation program for 45 minutes daily, 5 days a week, for 6 weeks. After the conventional rehabilitation program, 30 minutes of virtual reality training for the upper extremity will be applied.
89331694|NCT06128187|Active Comparator|Study Group|Participants will undergo a conventional upper extremity rehabilitation program for 45 minutes a day, 5 days a week, for 6 weeks. In addition to the conventional rehabilitation program, dual-task training will be provided with a 30-minute virtual reality training program. Cognitive tasks will be given in addition to virtual reality training as dual-task training.
89331695|NCT06128148|Experimental|JYP0322|In adult patients with Ros-1 solid positive tumor progressed after standard of care.
89331696|NCT06127732|Experimental|Phytosterol|Participants received diet plus phytosterols (2.6 g of phytosterols per day) prescribed and supplied in 650 mg gelatin capsules, to be used four capsules a day along with meals(Fitocor®, Farmoquímica, Brazil) and divided into two meals.for 12 weeks.
89331697|NCT06127732|No Intervention|Control: diet alone|Participants received diet alone recommended for 12 weeks.
89331698|NCT06127576||paraboloid geometry double and triple dental abutment-implant|
89331699|NCT06127173|Active Comparator|(group ZEEP)|children will receive mask ventilation with PEEP level 0 cmH2O.
89331700|NCT06127173|Experimental|(group PEEP 3)|children will receive mask ventilation with PEEP level 3 cmH2O.
89331701|NCT06127173|Active Comparator|(group PEEP 5)|children will receive mask ventilation with PEEP level 3 cmH2O.
89331702|NCT06126783|Experimental|IBI311|The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
89331703|NCT06126536|Experimental|Group 1: Crestal Maxillary Sinus Floor Elevation using Osseodensification:|A crestal incision will be made towards the palate for better wound closure. A conservative flap will be raised, extending beyond the alveolar crest to minimize complications. In cases with 4-6mm ridge height and a need for 3mm vertical depth, a narrow densifying bur will be used, followed by wider burs to elevate the sinus membrane. The Densah® Bur will compact graft material to lift the membrane without penetrating the sinus floor. The osteotomy will be filled with bone graft substitute, and the final bur will apically propel the graft for vertical augmentation. Implant placement follows confirmation via radiography.
89331704|NCT06126536|Experimental|Group 2: Lateral Maxillary Sinus Floor Elevation|"In the Lateral technique, a crestal incision and mucoperiosteal flap will expose the sinus's lateral wall. A bony window is created, and when removable, sinus elevation curettes are used to elevate the sinus floor cautiously. Membrane perforations are covered with a resorbable collagen membrane if needed. Implant osteotomies follow standard protocol.~Graft material mixed with saline is gently packed into the sinus to achieve the desired bone height. A resorbable membrane is placed on the window's outer surface, and the flap is sutured for primary closure."
89331705|NCT06126406|Experimental|Intravenous of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 3-10x10^6 cells/kg
89331706|NCT06126406|Experimental|intraperitoneal injection of CEA-targeted CAR-T|Infusion of CEA-targeted CAR-T cells by dose of 1-10x10^6 cells/kg
89331707|NCT06126068|Active Comparator|first arm - Loading dose of magnesium sulfate|This arm received Loading dose of magnesium sulfate only. those that developed complication in each arm were managed according to departmental protocol.
89331708|NCT06126068|Active Comparator|2. Pritchard regimen|This arm received the full dose of magnesium sulfate regimen by Pritchard. those that developed complication in each arm were managed according to departmental protocol also.
89331709|NCT06125613|Experimental|Experimental|Double pulse TMS method used to investigate the influence of the pIPS on M1 excitability. We set the ST intensity to evoke a 1mV MEP in the first dorsal interosseous muscle. The SC is applied at 90% of the MT on the pIPS. Our study involves two phases: Resting Phase: 10 single ST and 10 SC+ST doublets with a 4ms interstimulus interval. ST intensity is set to evoke a 1mV MEP, and SC is at 90% of the motor threshold. Movement Phase: Subjects perform a specific hand movement in response to colored light signals (green or red) projected on a screen. A brief but non-painful stimulus may coincide with the red signal to induce a fear response. A test stimulus (ST) or SC+ST doublet is delivered with a 500ms delay after each signal, allowing us to explore corticocortical influences during motor programming. 40 stimulations in total are delivered during this phase. Note that only 40 trials will be performed, and there will be no painful stimuli.
89331710|NCT06124378|Experimental|Tislelizumab combined with Oxaliplatin and Capecitabine cohort|"Patients with locally advanced colon cancer who met the inclusion criteria received two or four cycles of Tislelizumab combined Capecitabine and Oxaliplatin regimen chemotherapy and were evaluated by enhanced CT. Then, these patients will receive curative surgery for colon cancer.~Interventions:~Drug: Oxaliplatin,130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles.~Drug: Capecitabine, Oral Capecitabine 1000 mg/m2 twice daily from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles.~Drug: Tislelizumab, 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. Procedure: Colectomy"
89331711|NCT06122909|Experimental|Group VTI|Group VTI (n=45): will receive resuscitation guided by LVOT-VTI variation after PLR test.
89331712|NCT06122909|Active Comparator|Group IVC|Group IVC (n=45): will receive resuscitation guided by IVC diameter variation after PLR test.
89331713|NCT06122636|Experimental|Experimental group|An envelope with the same packaging, size, shape and color will be given, it will only differ from the placebo in that it will contain the active ingredient of the intervention which is Lactobacillus Rhamnosus GG, Lactobacillus casei, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium infantis and Lactobacillus bulgaricus.Experimental group
89331714|NCT06122636|Placebo Comparator|Placebo group|The placebo will be given in an envelope with the same packaging, size, shape and color of contents as the intervention of interest, except that the placebo will not contain the active ingredient of the intervention
89331715|NCT06120426||Total en bloc spondylectomy for spinal oligometastases|Based on the medical history, physical signs, and imaging examination results, a definitely diagnosis of spinal oligometastasis tumor was made and perform a Total en bloc spondylectomy.
89331716|NCT06120426||Separation surgery combined with radiotherapy for spinal oligometastases|Based on the medical history, physical signs, and imaging examination results, a definitely diagnosis of spinal oligometastasis tumor was made and perform a Separation surgery. After surgical recovery, take a radiotherapy.
89331717|NCT06117254|Active Comparator|Communication Counseling|Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including tips on environmental modification and communication repair strategies.
89331718|NCT06117254|Experimental|Hearing Aids|Individuals randomized to this group will receive communication counseling as well as hearing aids set to provide a low level of amplification.
89331719|NCT06117254|Experimental|Hearing Aids with Remote Microphones|Individuals randomized to this group will receive communication counseling as well as hearing aids set to provide a low level of amplification and remote microphones that can be used in some situations to improve the signal-to-noise ratio.
89331720|NCT06113354|Experimental|MRace Arm|Single-arm study of MRace Implant and Delivery System to treat severe mitral regurgitation All enrolled patients will receive the study device
89331721|NCT06112080||Normal Breath Sound Cohort|"32 patients ages 4-10, 16 patients ages 11-17)~Admitted for a non-respiratory complaint~Normal breath sounds on screening examination"
89331722|NCT06112080||Wheeze Cohort|"(106 patients ages 4-10, 53 patients ages 11-17)~Admitted for pathologic process that may lead to wheezing (e.g., asthma)~Presence of wheeze on screening examination"
89331723|NCT06108752|Experimental|Scapular Stabilization Exercises|Scapular stabilization exercises along with the hot pack and cervical active range of motion exercises
89331724|NCT06108752|Experimental|Thoracic Extension Exercises|Thoracic extension exercises along with the hot pack and cervical active range of motion exercises
89331725|NCT06108687|Experimental|Experiment|"In cold water applications, 50 cc bottles with plastic spray heads will be used. New materials will be used for each patient. Interventions will be carried out by the researcher and. Cold water kept in the refrigerator at +4 degrees will be placed in 50 cc spray bottles for the experimental group and will be sprayed orally to the patients 3 times an hour in the postoperative period. The spray will be applied to the patient's mouth, upper palate, top of the tongue, right inner cheek, and left inner cheek.~Patients will be given approximately 0.5 mL of water via spray in each application."
89331726|NCT06108687|No Intervention|Control|Spray application will not be applied to patients in the control group.
89331727|NCT06088355|Experimental|HV-PDAE: High Volume Partnered Dance Aerobic Exercise|HV-PDAE classes will meet 5 times a week for 90 minute sessions for 3 weeks at onset of trial and then every 4 weeks for a year. All participants will receive 112.5h of training. PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
89331728|NCT06088355|Active Comparator|MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise|MV-PDAE: MV classes will meet biweekly for 52 weeks for 65-minute sessions. All participants will receive 112.5h of training. . PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
89331729|NCT06088355|Active Comparator|MV-WALK: Moderate Volume Walking|MV-WALK (65-minute sessions): WALK will control for the walking that participants in PDAE do and will also take place in groups to control social effects of intervention. Walking for exercise expends 3 METS, like PDAE. (Knaggs et al., 2011) 65 minute sessions will consist of 15 minutes of warmup exercises, 45 minutes of walking with breaks ad libitum, and a 5-minute cool down. Setting will be a designated, safe, non-cluttered area for walking- indoors or outdoors. This protocol is in line with recommendations for gait training to improve gait parameters, i.e., 2-3 days per week, for 30-60 minutes and with evidence that light-moderate intensity walking programs can lead to gains in gait parameters.
89331730|NCT06086691|Experimental|Strength Training|Strength training exercises along with caffeine supplementation
89331731|NCT06086691|Active Comparator|Endurance Training|Endurance training exercises along with caffeine supplementation
89331732|NCT06086171|Experimental|Methadone|Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
89331733|NCT06086171|Placebo Comparator|Placebo|Standard saline solution administered intravenously at the induction of anaesthesia
89331734|NCT06084026||Neuromuscular Disease|Patients with confirmed neuromuscular disease
89331735|NCT06084026||Control|Participants who do not have or are not expected to have neuromuscular disease
89331736|NCT06066437|Experimental|LeadIn: Treatment with 177Lu rhPSMA-10.1|Participants will receive 177Lu rhPSMA-10.1 alone.
89331737|NCT06058650|Experimental|Part I (technetium Tc-99m sestamibi, MBI)|Patients receive technetium Tc-99m sestamibi IV and undergo MBI on study.
89331738|NCT06058650|Experimental|Part II (technetium Tc-99m sestamibi, MBI, biopsy)|Patients receive technetium Tc-99m sestamibi IV and undergo MBI. Patients whose breast lesions of interest are visualized on MBI then undergo breast biopsy using the Stereo Navigator accessory.
89331739|NCT06054113|Experimental|Blinatumomab|Participants will receive up to 5 cycles of blinatumomab (cycle is 42 days), including a 28-day continuous intravenous infusion (CIVI) of blinatumomab and a 14-day treatment free interval.
89331740|NCT06031727|Experimental|HG202|
89331741|NCT06023563|Experimental|Virtual reality active video gaming|The participants in this group will engage in VR active gaming using Nintendo Switch Sports under supervision via Zoom, for 6 sessions over 2 weeks.
89331742|NCT06023563|Active Comparator|Standard balance exercises|The participants in this group will engage in standard physical therapy exercises for balance and walking under supervision via Zoom, for 6 sessions over 2 weeks.
89331743|NCT06022146|Experimental|1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month|12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
89331744|NCT06022146|Active Comparator|3HR regimen of isoniazid and rifampicin once daily for three months|3HR regimen of isoniazid and rifampicin once daily for three months
89331745|NCT06012578|Experimental|ISM5411|
89331746|NCT06012578|Placebo Comparator|Placebo|
89331747|NCT06009237|Experimental|Part 1: Han-Chinese Participants ABBV-903|Han-Chinese participants will receive a single dose of ABBV-903.
89331748|NCT06009237|Experimental|Part 1: Japanese Participants ABBV-903|Japanese participants will receive a single dose of ABBV-903.
89331749|NCT06009237|Experimental|Part 1: Placebo|Participants will receive a single dose of Placebo for ABBV-903.
89331750|NCT06009237|Experimental|Part 2: Japanese Participants ABBV-903|Japanese participants will receive ABBV-903 daily for 10 days.
89331751|NCT06009237|Experimental|Part 2: Japanese Participants Placebo|Japanese participants will receive placebo daily for 10 days.
89331752|NCT06002958|No Intervention|FEP Providers|Approximately 20 FEP providers (clinicians and peer support specialists) affiliated with first episode psychosis (FEP) clinics in North Carolina (OASIS, SHORE, Encompass, Eagle, AEGIS) will be recruited to share their perspectives of barriers and facilitators in implementing and integrating a digital intervention in clinical practice. They will be asked to complete a survey examining their perspective and beliefs at three time points (baseline, 6 months, and 12 months) as well as a qualitative interview based on the Consolidated Framework for Implementation Science at 12 months.
89331753|NCT06002958|Experimental|FEP Clients|Approximately 50 individuals experiencing FEP and receiving services from FEP clinics (OASIS, SHORE, Encompass, Eagle, AEGIS) or their step down care clinics (STEP and TIDES) will be recruited to participate in a digital platform, Horyzons, for 12 months as part of their clinical care. Participants will have access to and encouraged to use the therapeutic content as well as the moderated online community network during their time engaging with the platform. They will be asked to complete a small battery of measures at baseline, 6-months, 12 months, and 3 month follow-up.
89331754|NCT06002932|Active Comparator|Conventional arm|As per the conventional treatment process, this strategy treats both the main vessel and the branch vessel with stents. The decision among Crush (Mini-crush), DK-Crush, Cullotte, TAP, and T-stenting is left to the discretion of the treatment provider.
89331755|NCT06002932|Experimental|PROVISION-DEB arm|As a principal, the treatment regime will be composed of the stent treatment in the main blood vessel and a drug-eluting balloon in a branch vessel. The order of the treatments done to the main vessel and the branch vessel shall be at the discretion of the treatment provider. Also, at the discretion of the treatment provider, a bail-out stenting can still be performed, depending on the condition of the branch vessel following a drug-eluting balloon treatment. However, bail-out stenting is recommended if there is a TIMI flow disorder, severe coronary artery exfoliation (National Heart, Lung, and Blood Institute type D, E, or F), or significant residual stenosis.
89331756|NCT06000488|No Intervention|Control|No intervention
89331757|NCT06000488|Experimental|Reflective Writing Workshop Sessions (RWW)|Participants will participate in three 75-minute RWW sessions scheduled to take place after students finish their 1st, 3rd, and 5th clinical rotations during the study period. reflective writing workshops
89331758|NCT05998928|Experimental|Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells|Patients will receive lymphodepletion chemotherapy with fludarabine (30 mg/m2 body surface area) plus cyclophosphamide (300 mg/m2 body surface area) for 3 consecutive days during D-7 to D-3, followed by the infusion of BCMA-GPRC5D CAR-T cells at a single dose of 4.0×10^6/kg ± 50%/kg for one day.
89331759|NCT05995600|Experimental|Clopidogrel-based antiplatelet therapy group|"Clopidogrel 75 mg daily~Patients assigned to this group will be permitted to use additional antiplatelet drugs other than clopidogrel at the investigator's discretion."
89331760|NCT05995600|Active Comparator|Warfarin group|Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
89331761|NCT05990426|Experimental|FAST Group|The FAST intervention will consist of one week of alternate day fasting (ADF) using the sandwich model at the start of each cycle of chemotherapy, for a total of 6 weeks of ADF. Patients will be instructed on how and what they may consume on fasting days.
89331762|NCT05990426|No Intervention|Control Group|Participants in the control arm will be instructed to eat as desired throughout their entire chemotherapy treatment course. Control group participants will not receive any special study- related instructions or direction regarding food and drinks consumed during chemotherapy.
89331763|NCT05978778|Other|controlled group|Nine children will be randomly allocated to control group who receive only pre-hand writing skills.
89331764|NCT05978778|Experimental|Experimental group|Nine children will be randomly allocated to experimental group who receive active video gaming along with pre-hand writing skills.
89331765|NCT05976880|Active Comparator|Conventional treatment of isometric hand grip training exercises|In control group, conventional treatment perform by using isometric hand grip training exercises (putty grip and squeeze exercise, thumb pinch z strengthening exercises, isometric Hooks exercises, rubber band abduction and c thumb exercises) for 3times a week in one month.
89331766|NCT05976880|Experimental|Conventional treatment along with power ball training|In experimental group, 3sessions per week and total 12 training sessions in a month will be perform. In this session, conventional treatment perform with power ball exercise should be done for 3 minutes in a day, where power ball can initially alleviate the pain, then make them feel strong and in the end persons feel strengthen with pain free movements. Before start training with a power ball, hand held dynamometer will use prior to the first session, on 7th session of training and after 12th training session. So that changes in hand grip strength can be measured by dynamometer.
89331767|NCT05975775||ambulatory patient cohort|Patients with prostate cancer for whom an ambulatory laparoscopic radical prostatectomy has been validated at a multidisciplinary consultation meeting.
89331768|NCT05968937|Active Comparator|Vaginal baclofen suppository|Baclofen 20mg in Supposibase F vaginal suppository daily per vagina
89331769|NCT05968937|Placebo Comparator|Vaginal placebo suppository|Supposibase F vaginal suppository daily per vagina
89331770|NCT05968794|Experimental|Cerclage|A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.
89331771|NCT05968794|No Intervention|Standard care|The comparator will be standard treatment according to the current Dutch (NVOG) guideline from 2018, which is to not perform or offer an intervention such as vaginal cerclage. This is in line with the standard care in the participating hospitals in Belgium.
89331772|NCT05962177|Experimental|Relapsing-remitting Multiple sclerosis benefiting from a moderately effective treatment|Moderately effective treatment includes interferon beta, glatiramer acetate, Teriflunomide, dimethyl Fumarate and monomethyl fumarate n= 175 patients
89331773|NCT05962177|Experimental|Relapsing-remitting Multiple sclerosis benefiting from a highly effective treatment|Highly effective treatment includes Natalizumab, Ocrelizumab, Rituximab, Ofatumumab, Fingolimod and Cladribine n= 175 patients
89331774|NCT05962177|Experimental|Untreated relapsing-remitting Multiple sclerosis|Patients untreated for relapsing-remitting Multiple sclerosis n= 50 patients
89331775|NCT05956353|Experimental|Stories for Change: Prevention (S4C) intervention|Participants who are due or overdue for cancer screening will receive the digital storytelling intervention and complete a cross-sectional survey to assess intervention acceptability, socio-behavioral constructs, and theory-based constructs.
89331776|NCT05954845|Experimental|colonic biopsies|participants will have colonic biopsies taken following a colonoscopy/rectosigmoidoscopy previously indicated for spinal cord injured patients.
89331777|NCT05951543|Experimental|plyometric group|Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.
89331778|NCT05951543|Other|dynamic balance group control group|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
89331779|NCT05947214|Experimental|Myofascial Decompression Therapy|15 minute's moist heat will be given first. Patient was lied prone on couch with their upper torso unclothed, covered with massage oil than placed cup on skin and suction will created in cups by pump.
89331780|NCT05947214|Experimental|Positional Release technique|Positional Release technique (PRT) is apply after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 900 and adds slight flexion or extension to fine-tune.
89331781|NCT05930561|Experimental|4D-150 Part 1 Dose Confirmation Dose Level 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89331782|NCT05930561|Experimental|4D-150 Part 1 Dose Confirmation Dose Level 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89331783|NCT05930561|Experimental|4D-150 Part 2 Dose Expansion Dose Level 1|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89331784|NCT05930561|Experimental|4D-150 Part 2 Dose Expansion Dose Level 2|4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
89331785|NCT05930561|Active Comparator|4D-150 Part 2 Dose Expansion Control|Aflibercept at a fixed regimen will be administered.
89331786|NCT05929274|Experimental|Active Comparator - real tDCS|real tDCS: anodal transcranial direct current stimulation were delivered over the left DLPF cortex in patients
89331787|NCT05929274|Sham Comparator|Sham Comparator - sham tDCS|sham transcranial direct current stimulation were delivered over the left DLPF cortex in patients.
89331788|NCT05924438|Experimental|Treatment Group 1|Delstrigo
89331789|NCT05924438|Other|Treatment Group 2|KOCITAF
89331790|NCT05923346|Experimental|Glutlearn|
89331791|NCT05916794|Experimental|: Modified Cervical Retraction Exercises (MCRE)|The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head positions. Hold each position for 20 sec with 8 to 10 repetitions
89331792|NCT05916794|Experimental|Motor Control therapeutic exercise(MCTE)|The MCTE will used is based on retraining the cervical muscles and included four exercises
89331793|NCT05915715|Experimental|McGill stabilization exercise|The patients performed the corresponding exercises 3 days a week and 10 repetitions of each exercise for a period of 6 weeks and a rest interval of 2 minutes between exercises
89331794|NCT05915715|Experimental|Proprioceptive neuromuscular facilitation technique|The total duration of RS will be of approximately 33 minutes
89331795|NCT05915689|Experimental|Myofascial arm pull technique|subjects in this group will be treated with myofascial arm pull technique
89331796|NCT05915689|Experimental|Post Isomeric relaxation technique|subjects in this group will be treated with post isometric relaxation technique
89331797|NCT05915325|Experimental|Physical training|Supervised patient-tailored intensity-modulated physical training
89331798|NCT05910983|Experimental|Patients receiving ThuLEP surgery only|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for ThuLEP to treat their urinary symptoms. No Botox injections will be given.
89331799|NCT05910983|Experimental|Patients receiving ThuLEP surgery + Intravesical Botox Injections|50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for ThuLEP to treat their urinary symptoms. Botox injections will be given during the surgery.
89331800|NCT05906953|Experimental|HG004|
89331801|NCT05905835|Experimental|Cryoablation Balloon|The Synaptic Cryo Balloon will be used to isolate all targeted pulmonary veins.
89331802|NCT05903729|Experimental|neurodevelopmental therapy group|in this group patients wil be treated with task oriented activities using neurodevelopmental therapy principles. This group will receive therapy session for 1 hour 6 days a week and for 8 weeks. total sessions will be 48. this group will receive task oriented neurodevelopmental therapy for 30 mins and next 30 mins it will receive conventional treatment.
89331803|NCT05903729|Experimental|conventional physiotherapy group|in this group patients will be treated with conventional physiotherpy treatment protocol. this group will receive therapy session for one hour, 6 times in a week for 8 weeks. total therapy sessions will be 48. this group will receive 30 mins conventional physiotherapy treatment and 30 mins task oriented neurodevelopmental therapy.
89331804|NCT05903534|Active Comparator|Pediatric Endurance and Limb Strengthening Program (PEDALS) Group|In this group patients will performed pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention was performed 60 min per day, 3 times per week, for a total of 24 sessions, within a 8 week period. The longer session duration was designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program was performed prior to cycling.
89331805|NCT05903534|Active Comparator|Lower Limb Strength Training Group|In this group patients will performed lower limb strengthening intervention was performed 3 times per week, for a total of 24 sessions, within a 8 week period using the functional strength training (for eccentric, concentric, and isometric contraction), plyometric exercises (including jumping), and balance training. Before each training session, there was a warm-up period with 5 to 10 minutes of dynamic activities (eg, jogging). After training, there was a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals, after each training session, there was a rest interval to prevent muscle fatigue and injury
89331806|NCT05903508|Active Comparator|Functional task training Group.|In this group patients will performed functional task training program was performed including non-walking (i-iii) and walking activities: (i) standing from a seated position; (ii) reaching for an object overhead, which required ankle plantar flexion from the standing position, and returning to the initial position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and down stairs; and (v) walking on flat surfaces and ramps. for 8 weeks, 50 minutes per day, 3 times per week. The individual session lasted approximately 10 minutes including the rest intervals.
89331807|NCT05903508|Active Comparator|functional therapy program|In this group patients will performed functional therapy program as goal directed training to optimize the child to practice goal including stand when turning around between chair, cycles 5m on stationary bicyle on smooth surface, kicking a ball during 8 weeks, the children practiced a goal in 50 mintute per day and 3 times a week.
89331808|NCT05881772|Active Comparator|Experimental 1|It will be applied a dose of 30J (180J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
89331809|NCT05881772|Active Comparator|Experimental 2|It will be applied a dose of 60J (360J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
89331810|NCT05881772|Active Comparator|Experimental 3|It will be applied a dose of 90J (540J per leg) of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence Maxx, São Paulo, Brazil) on quadriceps muscle.
89331811|NCT05881772|Placebo Comparator|Placebo group|The placebo treatment will be performed with the equipment HTM® (model Fluence Maxx, São Paulo, Brazil) turned off.
89331812|NCT05867329|Experimental|Methylprednisolone|Methylprednisolone Intravenous (IV) 30 milligram (mg) twice a day (BID)
89331813|NCT05867329|Experimental|Methylprednisolone plus Upadacitinib|Methylprednisolone IV 30mg BID plus Upadacitinib 45mg every day.
89331814|NCT05867329|Experimental|Oral Upadacitinib|Upadacitinib 30 mg BID
89331815|NCT05867329|Experimental|Methylprednisolone then Cyclosporine|Methylprednisolone IV 30 mg BID Stage 1 and if determined to be a non-responder to Methylprednisolone, patient will receive rescue Cyclosporine (2milligram/kilogram (mg/kg) per day aiming for levels 200-400 nanograms per milliliter (ng/mL)) in addition to continuing Methylprednisolone for stage 2.
89331816|NCT05867329|Experimental|Methylprednisolone then Upadacitinib|Methylprednisolone IV 30mg twice a day Stage 1 and if determined to be a non-responder to Methylprednisolone, patient will receive rescue Upadacitinib 30mg BID in addition to continuing Methylprednisolone for stage 2
89331817|NCT05867329|Experimental|Oral Upadacitinib then Methylprednisolone|Oral Upadacitinib 30mg BID for stage 1 then for patients that are non-responders, add rescue Methylprednisolone IV 30mg twice a day in addition to continuing Upadacitinib for stage 2.
89331818|NCT05867329|Experimental|Oral Upadacitinib then Methylprednisolone plus cyclosporine infusion|Upadacitinib 30 mg BID for stage 1. If a patient is a non-responder to Upadacitinib 30 mg, then the study team will stop Upadacitinib and initiate Methylprednisolone IV 30mg twice a day plus Cyclosporine (2 milligram/kilogram (mg/kg) per day aiming for levels 200-400 nanograms per milliliter (ng/mL)) for stage 2.
89331819|NCT05867329|Experimental|Methylprednisolone plus Upadacitinib then cyclosporine|Methylprednisolone IV 30mg BID and Oral Upadacitinib 45mg everyday stage 1 and then Cyclosporine 2 mg/kg per day aiming for levels 200-400ng/mL for stage 2.
89331820|NCT05867329|Experimental|Methylprednisolone plus Upadacitinib then increased Upadacitinib|Methylprednisolone IV 30mg BID and Oral Upadacitinib 45mg everyday stage 1 and if determined to be a non-responder to Methylprednisolone and 45 mg Oral Upadacitinib, patient will receive rescue Upadacitinib 30mg BID in addition to continuing Methylprednisolone for stage 2.
89331821|NCT05855863|Experimental|Ginkgo Ketone Ester Tablets Treatment Group|Ginkgo Ketone Ester Tablets (Styron), taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic therapy continuously administered for 6 months
89331822|NCT05855863|Placebo Comparator|control group|placebo combined with conventional hypoglycemic therapy for 6 months
89331823|NCT05839405||Non Allergic|Recruited patients whose medical records indicate they are not allergic to the foods they were in clinic for
89331824|NCT05839405||Mild Allergic|Recruited patients whose medical records indicate they are allergic to the foods they were in clinic for, but only to a mild degree where they would be expected to experience mild, non-life threatening symptoms on exposure to the allergen
89331825|NCT05839405||Severe Allergic|Recruited patients whose medical records indicate they are allergic to the foods they were in clinic for, to a severe degree where they would be expected to experience severe symptoms on exposure to the allergen
89331826|NCT05830565||Food Supplement|Single dose of food Supplement Based on L-theanine, Passionflower and Rhodiola Extracts
89331827|NCT05805033|Experimental|Ultra-polished zirconia abutment|
89331828|NCT05805033|Experimental|Machined zirconia abutment|
89331829|NCT05805033|Active Comparator|Titanium abutment|
89331830|NCT05771961|Active Comparator|Rotational Atherectomy|Patients who are scheduled to have rotational atherectomy will be labeled in this group; patients in this group will have invasive and non-invasive microvascular testing before and after the rotational atherectomy procedure.
89331831|NCT05771961|Active Comparator|Conventional Stenting|Patients who are scheduled to have conventional stenting will be labeled in this group; patients in this group will have invasive and non-invasive microvascular testing before and after the conventional stenting procedure.
89331832|NCT05769257|Experimental|Single Arm|Single Arm Safety and Feasibility Study of IS-001 with 20 mg in Multiple Injections
89331833|NCT05723172|Active Comparator|active tACS|40 mins tACS for 10 consecutive daily sessions
89331834|NCT05723172|Sham Comparator|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
89331835|NCT05704478|Active Comparator|Intervention|Participants will be administered the drug vericiguat
89331836|NCT05704478|Placebo Comparator|Control|Participants will be administered a placebo
89331837|NCT05700019|Other|Control - Standard Advertisements|In the control condition, participants will view 3 advertisements for alcohol (shown in random order) that do not mention breast cancer awareness or charities. Advertisements will be real social media posts used by alcohol companies, modified only to remove dates, likes/comments, and references to specific geographic locations.
89331838|NCT05700019|Experimental|Pinkwashed Advertisements|In the pinkwashed condition, participants will view 3 advertisements for alcohol (shown in random order) that associate the alcohol company with breast cancer awareness or research (e.g., indicate that a portion of sales will be directed to a breast cancer-related foundation). Advertisements will be real social media posts used by alcohol companies, modified only to remove dates, likes/comments, and references to specific geographic locations.
89331839|NCT05697627|Experimental|Computerized cognitive training (CCT) using EndeavorRx|Exciting, youth-friendly computer game, EndeavorRx engages and trains cognitive control across component processes of attention, response inhibition, shifting and working memory.
89331840|NCT05694832|Experimental|Expressive writing weekly session|Weekly, 1-hour sessions of creative writing, discussion and social support, in a group setting via videoconference for a total of 4 sessions.
89331841|NCT05694715|Experimental|Cohort 1 (Niraparib, Irinotecan)|Participants will receive a starting dose of 100 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
89331842|NCT05694715|Experimental|Cohort 2 (Niraparib, Irinotecan)|Participants will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
89331843|NCT05694715|Experimental|Cohort 3a (Niraparib, Irinotecan)|Participants weighing < 77 kg will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
89331844|NCT05694715|Experimental|Cohort 3b (Niraparib, Irinotecan)|Participants weighing >= 77 kg will receive a starting dose of 300 mg of niraparib on days 1-7 each 21-day cycle, and 100 mg/m^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
89331845|NCT05694715|Experimental|Cohort 4a (Niraparib, Irinotecan)|Participants weighing < 77 kg will receive a starting dose of 200 mg of niraparib on days 1-7 each 21-day cycle, and 150 mg/m^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
89331846|NCT05694715|Experimental|Cohort 4b (Niraparib, Irinotecan)|Participants weighing >= 77 kg will receive a starting dose of 300 mg of niraparib on days 1-7 each 21-day cycle, and 150 mg/m^2 of irinotecan on day 1 of each 21 day cycle until unacceptable toxicity, disease progression or participant withdrawal.
89331847|NCT05693649|Experimental|Arm 1A: Usual Care|Patients assigned to the Usual Care arm will receive current usual care and will not receive direct patient outreach or any visit-based interventions from this trial.
89523537|NCT02615951|Other|Protein surface & genes data validation|"Blood sampling from 10 patients vith RA and 10 control patient for biological analysis and measure for validation of the data from protein surface study and genes study arms analysis."
89331848|NCT05693649|Experimental|Arm 2A: Colonoscopy Only and No Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm will not receive visit-based interventions.
89331849|NCT05693649|Experimental|Arm 2B: Colonoscopy Only and Visit-Based Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion.
89331850|NCT05693649|Experimental|Arm 3A: Sequential Choice and No Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm will not receive visit-based interventions.
89331851|NCT05693649|Experimental|Arm 3B: Sequential Choice and Visit-Based Nudge/Text|Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion.
89331852|NCT05677659|Experimental|VGL101|Solution administered via Intravenous Infusion (IV)
89331853|NCT05674747|Experimental|Group A-Weekly x 4wk|"Subjects will receive treatment on Day 0 and then weekly in the first month followed by monthly treatment to Month 6 (9 treatments).~Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months."
89331854|NCT05674747|Experimental|Group B-Biweekly x4wk|"Subjects will receive treatment on Day 0 and then every two weeks in the first month followed by monthly treatment to Month 6 (7 treatments).~Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months."
89331855|NCT05674747|Experimental|Group C-Biweekly x 24wks|"Subjects will receive treatment on Day 0 and then once every two weeks in the first six months (12 treatments).~Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months."
89331856|NCT05667103|Experimental|Embotrap stent retriever|
89331857|NCT05667103|Active Comparator|Other stent retriever without endochannel|
89331858|NCT05655832|Experimental|COPD cohort|
89331859|NCT05655832|Experimental|Calibration participants cohort|
89331860|NCT05639595|Experimental|Intervention|The designated health center staff will receive a web interface that will allow them to offer job aid for supervision, including real-time information about VHSGs' performance in the form of process indicators and coverage of MCH services. The tool will also support health center staff in their daily tasks, such as high-risk patient tracking, low-supply-inventory alerts, supply chain management, electronic health records, vital events tracking, and automatic calculation of performance-based incentives and motivation for VHSGs. The mobile application will be offered to two female VHSGs from each of the 200 villages connected to their respective health centers in the intervention arm. The mobile application will provide job aid to VHSGs for scheduling home visit tasks, including ANC, home-based newborn care, reporting outcomes of pregnancies, and follow-up visits of complicated cases.
89331861|NCT05639595|No Intervention|Control|All villages under the health center's catchment areas in the control arm will continue to receive the MCH standard care provided by the government and other local and international non-governmental organizations (NGOs) and facilitated by VHSGs. VHSGs in both intervention and control arms will receive refresher training on maternal, neonatal, and childcare to avoid ethical issues that may arise and to ensure that change in outcomes in the intervention arm is due only to i-MoMCARE, but not the VHSGs MCH training.
89331862|NCT05623995|Experimental|Treatment arm|Participants will receive PCSK9 inhibitors added to guideline recommended statin therapy.
89331863|NCT05623995|Active Comparator|Control arm|Patients will continue to taking guideline recommended statin therapy.
89331864|NCT05608252|Experimental|Phase 1 Dose Escalation|"During 28 day/4 week study cycle, participants will receive:~VS-6766 2x weekly for 3 out of the 4 week cycle~Abemaciclib 2x daily~Fulvestrant on day 1 of each study cycle (and day 15 of cycle 1 only)"
89331865|NCT05608252|Experimental|Phase 2 Dose Expansion|Participants will receive VS-6766 with abemaciclib and fulvestrant at the recommended phase II doses determined in the phase I portion of the study.
89331866|NCT05606913|Experimental|IBI362 6.0mg|①2mg, SC, once a week* 4weeks; ②4mg, SC, once a week* 4weeks；③6mg, SC, once a week* 20weeks.
89331867|NCT05606913|Experimental|dulaglutide|1.5mg, SC, once a week* 28weeks
89331868|NCT05606913|Experimental|IBI362 4.0mg|2mg, SC, once a week* 4weeks; ②4mg, SC, once a week* 24weeks.
89331869|NCT05603572|Experimental|Oral experimental arm|Oral administration (KAT-101) taken once per day for 4 consecutive days out of 7 (4 days on / 3 days off weekly). Each cycle is 28 days. Treatment will continue for up to 12 cycles until progressive disease (PD), unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
89331870|NCT05603572|Experimental|IT experimental arm|IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or computed tomography (CT) guidance once a week (on Day 1 weekly). Each cycle is 28 days. Treatment will continue for up to 2 cycles until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
89523538|NCT04446013|Experimental|Group General Anesthesia|C-Section under general anesthesia
89523539|NCT04446013|Experimental|Grup Spinal Anesthesia|C-Section under spinal anesthesia
89523540|NCT03373799|Experimental|Group 1|Video-Based Rehabilitation Group
89331871|NCT05603572|Experimental|Oral + IT experimental arm|Once optimal oral and IT dose are determined, oral + IT will be administered as follows: oral administration (KAT-101) will be taken once per day for 4 consecutive days out of 7 (4 days on / 3 days off weekly). Treatment will continue for up to 12 cycles (each cycle 28 days). IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or CT guidance once a week (on Day 1 weekly). Treatment will continue for up to 2 cycles (each cycle 28 days) until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
89331872|NCT05601037|Experimental|Axilla dissection + Lymphevenous Anastomosis|Surgical bypass between lymphatic vessel and vein
89331873|NCT05601037|No Intervention|Standard surgery|Standard surgery
89331874|NCT05598710||Group 1|Group who have pigtail 5-26
89331875|NCT05598710||Group 2|Group who have pigtail 6-26
89331876|NCT05598710||Group 3|Group who have pigtail 5-28
89331877|NCT05598710||Group 4|Group who have pigtail 6-28
89331878|NCT05587582||Observational (Family Behaviors)|"PRIMARY OBJECTIVES:~I. Use direct observation of medication administration in the home to understand common episode-level barriers and identify the most impactful behavioral parenting skills for intervention.~II. Use daily diary methods to identify contextual barriers to adherence and identify intervention components to help parents anticipate barriers and plan strategies to promote successful adherence.~OUTLINE:~Participants complete a survey over 15-20 minutes at baseline. Family behaviors before, during and after the administration of medication to the child are video-recorded over 40-45 minutes. Participants receive MEMS electronic pill bottle to use for 2 weeks and complete daily survey over 5 minutes for 14 days."
89331879|NCT05562440|Experimental|Focus Group Discussion on breast cancer risk prediction report|Woman population with no breast cancer who received the dummy report result
89331880|NCT05561647||GATTEX: Participants|Participants who have taken GATTEX in the 60 days prior to survey implementation are eligible to participate in this Risk Evaluation and Mitigation Strategy (REMS) survey for up to 10 years via internet, telephone, and paper.
89331881|NCT05561647||GATTEX: Healthcare Providers (Prescribers)|HCPs (adult and pediatric) in the United States (US) who have prescribed GATTEX at least once regardless of their completion of the voluntary GATTEX REMS training are eligible for participation in this REMS survey for up to 10 years via internet, telephone, and paper.
89331882|NCT05551585|Experimental|Real TPS treatment group|"Participants with MDD will receive TPS treatment lasting for 4 weeks (3 sessions per week).~A follow-up assessment will be scheduled 3 months after the last REAL treatment day.~MRI measurements will be conducted before the start of treatment (within one week before treatment start), as well as after the last treatment day (within one week post-treatment)"
89331883|NCT05551585|Sham Comparator|Sham TPS treatment|"Participants will receive sham TPS treatment lasting for 4 weeks (3 sessions per week, as done previously.~After treatment end and completed assessments, the study will be unblinded and participants in the sham treatment arm will receive real TPS.~A follow-up assessment will be scheduled 3 months after the last REAL treatment day.~MRI measurements will be conducted before the start of treatment (within one week before treatment start), as well as after the last treatment day (within one week post-treatment),"
89331884|NCT05528952|Experimental|Experimental Arm (Arm A)|Atezolizumab + Bevacizumab + UCPVax
89331885|NCT05528952|Other|Control Arm (Arm B)|Atezoliumab + Bevacizumab
89331886|NCT05527782|Experimental|induction mTPF|"4 CYCLES OF INDUCTION mTPF: Docetaxel 40 mg/m2 iv day 1, Cisplatin 40 mg/m2 iv day 1, Leucovorin 400 mg/m2 iv followed by Fluorouracil (5FU) bolus 400 mg/m2 iv day 1, 5FU 1000 mg/m2 iv day 1-2, q2w. Primary neutropenic fever prophylaxis with GCSFs x 3 days~CONCURRENT CHEMORADIOTHERAPY WITH 2 CYCLES OF CISPLATIN 100mg/m2 iv q3w"
89331887|NCT05527652|Experimental|Self-Supporting Nasopharyngeal Airway (ssNPA)|
89331888|NCT05527652|No Intervention|Standard of Care|Waitlist control group: While waiting, participants will continue to receive the treatment they would have had before which will likely include being placed on the waiting list for positive airway pressure (PAP). After a period of being on the waitlist (8 weeks) there is an option to cross-over to the device arm.
89331889|NCT05508308|Active Comparator|Manual oxygen control|Oxygen therapy delivered with bCPAP as per standard practice, except for the addition of continuous pulse oximetry. Nursing staff will make manual adjustments to Fraction of Inspired Oxygen (FiO2) provided to infants on bCPAP. Oxygen saturations (SpO2) will be monitored by continuous pulse oximetry, and nurses asked to target the range of SpO2 91-95%. Pulse oximeter alarms will be set to alert nurses to periods of hypoxaemia (SpO2<88%) and hyperoxaemia (SpO2>96%).
89331890|NCT05508308|Experimental|OxyMate Automated Oxygen Control|Automated control of oxygen therapy partnered with bCPAP delivered as per standard practice. The automated oxygen control set-up (OxyMate) will consist of: continuous pulse oximetry input, a computer algorithm (VDL1.1) that calculates changes to delivered FiO2 based on the input SpO2, and a mechanism to automatically effect changes to delivered FiO2. The system will target an SpO2 of 93% (mid-point of the target range). There will be several embedded safety mechanisms, including the ability to manually over-ride OxyMate at any stage. Pulse oximeter alarms will be as for the manual control arm, with additional automated system alarms in place.
89331891|NCT05506579|Experimental|Intervention group|Exercises for knees, lower back and hip/groin in an expanded warm up program. In addition, the warm up program will include pelvic floor muscle training (PFMT). The warm up program will in total take approximately 12-15 minutes to conduct each training.
89331892|NCT05506579|No Intervention|Control group|No intervention.
89331893|NCT05493111|Experimental|AR-15512 Ophthalmic Solution (0.003%)|0.003% AR-15512 to be administered BID for 365 days. Both eyes will be treated.
89331894|NCT05493111|Placebo Comparator|Vehicle|AR-15512 vehicle to be administered BID for 365 days. Both eyes will be treated.
89331895|NCT05491915|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 leads placed in the back of their neck, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
89331896|NCT05481697|Experimental|UWL and GRAIL Galleri Testing|"Enrolled participants will have an initial blood sample taken and record their weights weekly on a FitBit Aria scale for three years to detect for UWL~Those who unintentionally lost lost ≥5% from their baseline weight will be identified and have a GRAIL Galleri blood test, physical examination, imaging, and cancer screenings to test for malignancy"
89331897|NCT05481463|Experimental|surufatinib combined with TAS-102|Surufatinib 250mg,TAS-102 35mg/m2
89331898|NCT05474417||Cystic Fibrosis Carrier Group|Participants who have been identified as Cystic Fibrosis Carriers via previous genetic testing.
89331899|NCT05474417||Control Group|Participants who have been identified as not being Cystic Fibrosis Carriers via previous genetic testing.
89331900|NCT05467865|Experimental|Experimental, nutrition education program|
89331901|NCT05467865|No Intervention|control group|
89331902|NCT05465876|Experimental|EVUSHELD|
89331903|NCT05464927||Participants pre CDT|"Participants with lipedema~Biologically Female~Age range = 18-80 years~BMI range = 18 to 40 kg/m2~BMI range = 18 to 40 kg/m2"
89331904|NCT05464927||Controls|"Participants without lipedema~Biologically Female~Age range = 18-80 years~BMI range = 18 to 40 kg/m2"
89331905|NCT05464927||Participants post CDT|"Participants with lipedema~Biologically Female~Age range = 18-80 years~BMI range = 18 to 40 kg/m2~BMI range = 18 to 40 kg/m2"
89331906|NCT05457023||Collegiate Women Soccer Players|National Collegiate Athletic Association (NCAA) players.
89331907|NCT05454956|Experimental|BID Dosing|TP-03, lotilaner ophthalmic solution, 0.25% administered topically twice a day and TP-03 vehicle administered once a day to maintain masking for approximately 85 days
89331908|NCT05454956|Experimental|TID Dosing|TP-03, lotilaner ophthalmic solution, 0.25% administered topically three times a day for approximately 85 days
89331909|NCT05454371|Experimental|Sample collection|This is a prospective study in which urine samples will be collected from healthy volunteers and urine samples and a blood sample from cancer patients with breast- or prostate cancer. The participants will be asked to provide a urine sample collected with the ColliPee® device and fill out an online questionnaire to collect usability data.
89331910|NCT05410236|Experimental|Experimatal|Learning anatomy with 3D bronchial tree model.
89331911|NCT05410236|No Intervention|Control group|Learning anatomy without 3D bronchial tree model.
89331912|NCT05385887|Active Comparator|Antibiotic treatment|Two kinds of antibiotics: Ciprofloxacine 500mg 2dd & Metronidazole 500mg 3dd
89331913|NCT05385887|Placebo Comparator|Placebo|Placebo tabletes
89331914|NCT05383378|Experimental|si-544|The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo.
89331915|NCT05383378|Placebo Comparator|Placebo|The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo.
89331916|NCT05382312|Experimental|Participants receiving GSK3036656+bedaquiline|
89331917|NCT05382312|Experimental|Participants receiving GSK3036656+delamanid|
89331918|NCT05382312|Experimental|Participants receiving bedaquiline+delamanid|
89331919|NCT05382312|Experimental|Participants receiving RIFAFOUR e-275|
89331920|NCT05382312|Experimental|Participants receiving GSK3036656+BTZ-043|
89331921|NCT05369221|Experimental|ReSpace™|The subjects who meet all the inclusion criteria and do not meet any of the exclusion criteria will be enrolled in this study. Subjects will undergo placement of ReSpace™ hydrogel.
89331922|NCT05327387|Experimental|model-based electrical brain stimulation|
89331923|NCT05324397|Experimental|Experimental: Treatment|Subjects will undergo treatment with the NEUROMARK System
89331924|NCT05308537|Experimental|Mindful Compassion Care Program|The MCCP comprises six regular 1 hour and 30-minute sessions and 1 all-day class lasting 4 hours and 30 minutes.
89331925|NCT05308537|No Intervention|Waiting List|
89331926|NCT05281159|No Intervention|Standard of Care|This group will receive a standard SMS text message indicating that they have a MyChart message from their provider about CRC screening and should follow a link to be screened.
89331927|NCT05281159|Experimental|"Risk Information"|This group will receive an SMS text message highlighting their risk for CRC.
89331928|NCT05281159|Experimental|"Risk Information + Action"|This group will receive an SMS message highlighting their risk for CRC and the importance of taking quick action.
89331929|NCT05275790|Experimental|Vestal active device|10 subjects to receive an active device plus a diet plan for 12 weeks.
89331930|NCT05275530|No Intervention|Standard of Care|"No Intervention-Standard Care~UCLA Health has a mailed FIT outreach program. This group will receive standard FIT mailer protocol. They will receive a tailored MyChart message indicating the importance of CRC screening and not be presented with a choice for screening modalities."
89331931|NCT05275530|Experimental|FIT Choice|This group will receive a tailored message via MyChart with information about CRC screening and using the FIT kit for noninvasive screening. They will then have to actively choose if they want CRC screening with a FIT kit vs no screening. If they opt for screening, the investigators will mail them a FIT kit.
89331932|NCT05275530|Experimental|Colonoscopy Choice|This group will receive a tailored message via MyChart with information about CRC screening and colonoscopy for CRC screening. They will then have to actively choose if they want CRC screening with a colonoscopy vs no screening. If they opt for screening, the investigators will direct them to our patient navigators to get scheduled for a colonoscopy.
89331933|NCT05275530|Experimental|Dual Choice|This group will receive a tailored message via MyChart with information about CRC screening and using either the FIT kit or colonoscopy for CRC screening. They will then have to actively choose if they want CRC screening with a FIT kit, a colonoscopy, or no screening. If they opt for screening, the investigators will either mail them a FIT kit or direct them to our patient navigators to schedule a colonoscopy, depending on their choice.
89331934|NCT05264558|Experimental|Test and treat|This group will receive POC HCV viral load testing via a fingerstick using the Xpert HCV Viral load finger stick point of care test (Cepheid) in addition to the standard of care whole blood conventional laboratory based HCV PCR viral load testing. Participants who return a positive POC HCV viral load result will be provided with Epclusa on the same day as result. Follow up management will be determined by results received from standard of care blood. Service level data will be investigated to estimate HCV targeted treatment numbers prior to intervention arms implementation. Service level data will be measured post intervention periods.
89523541|NCT03373799|Active Comparator|Group 2|Physiotherapist-Supervised Rehabilitation Group
89523542|NCT04446091|Experimental|Two-drug group|Camrelizumab:200mg,iv,Q2W; Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
89331935|NCT05264558|Other|General Practitioner Refresher and Clinic in reach|Perform hepatitis C education for GP and clinic staff at primary health services; on hepatitis testing and treatment at a service level will offer the opportunity to tailor education to the requirements of the clinic and staffing needs.Service level data will be investigated to estimate HCV targeted treatment numbers prior to intervention arms implementation. Service level data will be measured post intervention period
89331936|NCT05264558|Other|Incentive and Peer intervention in HCV care cascade|Assess the effectiveness in primary health services of engaging people in hepatitis C testing, and retention throughout the care cascade whilst employing innovative techniques including incentives and peer recruitment.Service level data will be investigated to estimate HCV targeted treatment numbers prior to intervention arms implementation. Service level data will be measured post intervention period
89331937|NCT05241405|Experimental|Qiseng|200 mg/capsule of P. quinquefolius extract, i.e. 30 mg of ginsenosides, associated with 30 mg of vitamin C extracted from Camu Camu berry
89331938|NCT05241405|Placebo Comparator|Placebo|neutral microgranules of Qiseng® excipients without P. quinquefolius or Camu Camu extract
89331939|NCT05219812|Experimental|Group 1 (BAY2395840 - placebo)|Participants will be randomly assigned to treatment regimen of double-blind BAY2395840, and after an interim single blind period for washout will switch to double-blind placebo.
89331940|NCT05219812|Experimental|Group 2 (Placebo - BAY2395840)|Participants will start with a treatment regimen of double-blind placebo, and after an interim single blind period for washout will switch to double-blind BAY2395840.
89331941|NCT05207605|Experimental|Rhythmic Stabilization (RS)|The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended
89331942|NCT05207605|Experimental|McKenzie technique|McKenzie exercises will be guided to conduct four extension exercises and three flexion exercises.
89331943|NCT05200962|Experimental|Active tDCS group|The experimental arm receives real (or active) electrical stimulation for 20 minutes
89331944|NCT05200962|Sham Comparator|sham tDCS group|The sham arm receives sham (or no real) intervention in which stimulation lasts for 30 seconds and ends afterward.
89331945|NCT05197257|Experimental|Men with pathologically proven prostate adenocarcinoma|The intervention is a PET scan with the radiolabelled PSMA ligand, 68Ga-PSMA-11. The PET may be combined with a CT scan as a PET/CT or an MRI scan as PET/MRI. 68Ga-PSMA-11 PET/CT will be acquired using a modern digital GE PET/CT scanner or a modern digital PET / MRI scanner.
89331946|NCT05194410|Experimental|Intervention|6 months of virtual, team-based exercise
89331947|NCT05194410|Other|Control|3 months of usual exercise and then 3 months of virtual, team-based exercise
89331948|NCT05180513|Other|Teleconference Mindfulness Intervention Group|MBSR training program that has been adapted for use via Zoom teleconferencing and for cultural relevancy
89331949|NCT05180513|Other|Smartphone App Mindfulness Intervention Group|MBSR training program that has been adapted for use via smartphone app and for cultural relevancy
89331950|NCT05180513|No Intervention|Waitlist Control Group|No intervention; control group
89331951|NCT05179369|No Intervention|Standard Care|Participants randomized to standard care will be offered prenatal and postpartum care in accordance with site-specific procedures based on AAP and ACOG Guidelines for Perinatal Care. The initial intake appointment, involving a comprehensive visit with physical exam, medical and psychosocial history, laboratory testing, and education would optimally occur in the 1st trimester. Subsequent prenatal visits, per ACOG, is monthly for the first 28 weeks, biweekly for weeks 28-36, and weekly after 36 weeks. More frequent visits may be offered to women at high risk. In addition, some sites may offer supports such as nutritional counseling, childbirth education, and case management. A comprehensive postpartum care visit would typically occur within the first 6 weeks of birth, involving a physical examination, lab tests, and immunizations.
89331952|NCT05179369|Experimental|Standard Care with Well-Mama Intervention|Participants will receive standard perinatal care plus the Well Mama intervention, including the Well Mama Checklist, assistance from a Community Doula Navigator, and virtual support groups.
89331953|NCT05158972||Dymista®|Dymista® (Azelastine hydrochloride and Fluticasone propionate) nasal spray as prescribed within routine clinical practice
89331954|NCT05158166|Experimental|Administration of Daxi|Injectible daxibotulinumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) is an investigational botulinum toxin type A which has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and cervical dystonia and may offer longer-lasting results when compared with onabotulinumtoxinA. Dosage will be same number of units as prior Botox A dose.
89331955|NCT05156905|Experimental|Cirmtuzumab + Docetaxel|There is only one treatment arm on this study. The combination of cirmtuzumab + docetaxel will be administered on one treatment arm. Treatment will cirmtuzumab will be administered initially as a loading dose alone on days 1, 15, and 29 of cycle 1. Following the loading, cirmtuzumab will be given on Day 1 of every 21-day cycle starting on Cycle 2 to up to Cycle 7 corresponding with concurrent docetaxel administration. Following discontinuation or completion of docetaxel, treatment with cirmtuzumab will be continued Day 1 of every 28 cycle until disease progression, toxicity or study withdrawal. Docetaxel will be administered on day 1 of every 21-day cycle starting Cycle 2 for up to 6 cycles.
89331956|NCT05153564|Experimental|One-sequence cross-over arm|
89331957|NCT05138458|Experimental|Cohort 1 and Cohort 3|MT-101
89331958|NCT05138458|Experimental|Cohort 2 and Cohort 4|MT-101 preceded by conditioning (lymphodepleting) chemotherapy
89331959|NCT05137899|Experimental|Neoadjuvant Atezolizumab/Bevacizumab|• Arm 1: neoadjuvant atezolizumab 1200 mg IV q3weeks x 4 cycles, and bevacizumab 15 mg/kg IV q3weeks x 4 cycles
89331960|NCT05137899|Experimental|Neoadjuvant SBRT|• Arm 2: neoadjuvant stereotactic body radiation therapy (SBRT), target volume 30 40 Gy, in 6-8 Gy per day over five days, delivered every other day
89523543|NCT04446091|Experimental|Three-drug group|Camrelizumab:200mg,iv,Q3W; Irinotecan:150mg/m2,iv 30~90min,d1,Q3W Fruquintinib:5mg,po.qd,Day1~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1~21, repeat every 28 days;
88809697|NCT00744380|Active Comparator|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4) as other sedatives are down titrated. Daily awakenings are used.
89331961|NCT05127304||Tiotropium bromide/Olodaterol (TIO/OLO)|Chronic Obstructive Pulmonary Disease (COPD) patients with ≥30 consecutive days with TIO/OLO initiated during the patient identification period of 01 June 2015 to 30 November 2019 and ≥40 years of age as of the year of the index date. The index date was the date of the TIO/OLO pharmacy claim that started the ≥30 consecutive days with the medication.
89331962|NCT05127304||Fluticasone furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)|Chronic Obstructive Pulmonary Disease (COPD) patients with ≥30 consecutive days with FF/UMEC/VI initiated during the patient identification period of 01 June 2015 to 30 November 2019 and ≥40 years of age as of the year of the index date. The index date was the date of the FF/UMEC/VI pharmacy claim that started the ≥30 consecutive days with the medication.
89331963|NCT05121909|Experimental|Prototype 1 Mouthwash|Participants will brush their teeth using Colgate (registered [R]) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 milliliters (mL) of the Prototype 1 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89331964|NCT05121909|Experimental|Prototype 2 Mouthwash|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 2 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89331965|NCT05121909|Experimental|Prototype 3 Mouthwash|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Prototype 3 Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89331966|NCT05121909|Active Comparator|Listerine (R) Cool Mint (R) Antiseptic Mouthwash (Positive Control)|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the Listerine Cool Mint Antiseptic Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89331967|NCT05121909|Active Comparator|5 Percent (%) Hydroalcohol Mouthwash (Negative Control)|Participants will brush their teeth using Colgate (R) Cello Toothbrush and Colgate (R) Cavity Protection Toothpaste twice daily and rinse with 20 mL of the 5% Hydroalcohol Mouthwash for 30 seconds, twice a day following brushing on Day 0 under supervision and up to 12 weeks unsupervised at home.
89331968|NCT05072418||Children with dyslexia|
89331969|NCT05072418||Non-dyslexic children|
89331970|NCT05066230|Experimental|KSI-301 - Treatment Group A|Intravitreal injection of KSI-301 (5 mg): three initiating doses, and then every 24 weeks through Week 92
89331971|NCT05066230|Sham Comparator|Treatment Group B|Sham injection on the same schedule as Treatment Group A
89331972|NCT05059717|Experimental|Diagnostic (standard of care MRI, MR DENSE MRI)|Patients undergo standard of care MRI and then undergo an MRI of the liver using MR DENSE imaging sequences over 60-90 minutes. Healthy volunteers undergo MRI of the liver using DENSE imaging sequences.
89331973|NCT05052944||Cochlear implant recipients|Patients with single-sided deafness undergoing cochlear implantation
89331974|NCT05048875|Experimental|JNJ-64281802|"There are two cohorts and three groups in each cohort. Cohort 1 consists of Group 1a, Group 1b and Group 2. Cohort 2 consists of Group 3, Group 4, and Group 5. Within each group, participants will either be randomized to receive study drug or placebo.~Four participants will be enrolled in Group 1a before enrolling the remaining participants to Group 1b (12 participants) and Group 2 (14 participants) in Cohort 1.~Based on the interim analysis results of Cohort 1, three groups for Cohort 2 were created. Eight participants will be enrolled in each of the three groups (Group 3, Group 4, and Group 5)."
89331975|NCT05048875|Placebo Comparator|Placebo|"There are two cohorts and three groups in each cohort. Cohort 1 consists of Group 1a, Group 1b and Group 2. Cohort 2 consists of Group 3, Group 4, and Group 5. Within each group, participants will either be randomized to receive study drug or placebo.~Four participants will be enrolled in Group 1a before enrolling the remaining participants to Group 1b (12 participants) and Group 2 (14 participants) in Cohort 1.~Based on the interim analysis results of Cohort 1, three groups for Cohort 2 were created. Eight participants will be enrolled in each of the three groups (Group 3, Group 4, and Group 5)."
89331976|NCT05027230|Experimental|Consecutive doses of low-dose of STSP-0601|
89331977|NCT05027230|Experimental|Consecutive doses of high-dose of STSP-0601|
89331978|NCT05017753|Active Comparator|Control group|Standard-of-care medical treatment.
89331979|NCT05017753|Experimental|Intervention group|Thoracentesis in addition to standard-of-care medical treatment.
89331980|NCT05016609|Experimental|POC HCV antibody group (Arm A)|This group will receive POC HCV antibody testing via fingerprick using the OraQuick HCV antibody test (OraSure) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
89331981|NCT05016609|Experimental|POC HCV RNA group (Arm B)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will receive POC HCV viral load testing via fingerstick using the Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Follow up and management of any treatment will be through usual standard-of-care. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
89331982|NCT05016609|Experimental|Test and treat group (ArmC)|This group will receive POC HCV antibody testing using the OraQuick HCV antibody test. Participants in this group who return a positive POC HCV antibody result will be provided a starter pack of HCV treatment (epclusa). POC tests results will be confirmed through standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. HCV RNA positive participants will continue treatment. Participants in this group will also fill out a short behavioural questionnaire and a clinical questionnaire.
89331983|NCT05016609|No Intervention|Control|This group will receive the standard of care for HCV testing and treatment. Participants in this group will fill out a short behavioural questionnaire and a clinical questionnaire.
89331984|NCT05015894|Experimental|NNC0480-0389|All participants will be administered a single s.c. dose of 18 mg NNC0480-0389
89331985|NCT05015491|Experimental|Noom Healthy Weight Program|"The Noom platform uses a cognitive behavioral approach to weight loss that integrates set content with interaction with live coaches to support client efforts at behavior change. The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. It has 52 weeks of curriculum with 1-3 articles to read per day (Reading level: Grade 6-8)."
89331986|NCT04993287|Experimental|Pilot|45 eligible HF patients
89331987|NCT04991454|Other|end-stage pulmonary hypertension .|subjects with end-stage PH that currently on the waitlist for lung transplant
89331988|NCT04991454|Other|following pulmonary arterial hypertension subjects|Following pulmonary arterial hypertension subjects upto 24 months
89331989|NCT04988308|Placebo Comparator|Part 1 (Group 1): Placebo|Participants will receive placebo subcutaneously (SC) at Week 0 through Week 15. At Week 16, participants will cross over to receive bermekimab dose 1 SC every week thereafter through Week 31.
89331990|NCT04988308|Active Comparator|Part 1 (Group 2): Adalimumab|Participants will receive adalimumab 160 milligrams (mg) SC at Week 0, placebo SC at Week 1, followed by adalimumab 80 mg SC and placebo SC at Weeks 2 and 3. Participants will then receive adalimumab 40 mg SC and placebo SC at Week 4 and every week thereafter through Week 31.
89331991|NCT04988308|Experimental|Part 1 (Group 3): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC and placebo SC at Week 0, followed by bermekimab dose 1 SC at Week 1 and every week thereafter through Week 31.
89331992|NCT04988308|Placebo Comparator|Part 2 (Group 1): Placebo|Participants will receive placebo SC from Week 0 through Week 11. At Week 12, participants will cross over to receive bermekimab dose 1 SC weekly through Week 31.
89331993|NCT04988308|Experimental|Part 2 (Group 2): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 31.
89331994|NCT04988308|Experimental|Part 2 (Group 3): Bermekimab Dose 1|Participants will receive bermekimab dose 1 SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 1 SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.
89331995|NCT04988308|Experimental|Part 2 (Group 4): Bermekimab Dose 2|Participants will receive bermekimab dose 2 SC and placebo SC at Week 0 and every week thereafter through Week 11. From Week 12, participants will receive bermekimab dose 2 SC and placebo SC every other week thereafter through Week 30. During weeks in which bermekimab is not administered, participants will receive placebo SC through Week 31.
89331996|NCT04959851||Participants With Inflammatory Bowel Disease (IBD)|Participants diagnosed with moderately to severely active IBD (UC or CD) who are initiating or currently ongoing vedolizumab intravenous induction treatment or maintenance intravenous treatment in accordance with the current Summary of Product Characteristics (SmPC) along with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.
89331997|NCT04915534|Other|Women - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
89331998|NCT04915534|Other|Men - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
89331999|NCT04915534|Other|Women - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
89332000|NCT04915534|Other|Men - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
89332001|NCT04904562|Active Comparator|Treatment|Angiotensin II administered as an intravenous (IV) infusion will be increased every 5 minutes by 5-10ng/kg/min increments up to 80ng/kg/min
89332002|NCT04904562|Placebo Comparator|Control|Intravenous (IV) infusion (saline)
89332003|NCT04904354|Experimental|Paroxysmal atrial fibrillation|Subjects schedule for a de novo ablation of paroxysmal atrial fibrillation
89332004|NCT04904354|Experimental|Persistent atrial fibrillation|Subjects schedule for a de novo ablation of persistent atrial fibrillation
89332005|NCT04887584|Experimental|Group 1|"Order of treatments:~A: Control diet B: Low pulse diet C: High pulse diet"
89332006|NCT04887584|Experimental|Group 2|"Order of treatments:~A: Control diet C: High pulse diet B: Low pulse diet"
89332007|NCT04887584|Experimental|Group 3|"Order of treatments:~B: Low pulse diet A: Control diet C: High pulse diet"
89332008|NCT04887584|Experimental|Group 4|"Order of treatments:~B: Low pulse diet C: High pulse diet A: Control diet"
89332009|NCT04887584|Experimental|Group 5|"Order of treatments:~C: High pulse diet A: Control diet B: Low pulse diet"
89332010|NCT04887584|Experimental|Group 6|"Order of treatments:~C: High pulse diet B: Low pulse diet A: Control diet"
89332011|NCT04862910|Experimental|Kinect Based Virtual Reality Training|Kinect-Based Virtual Reality Training 30 Minutes walk outdoor Routine Medication and routine diet will be continued.
89332012|NCT04862910|Other|Control Group|30 Minutes walk outdoor Regular active life style Routine diet and routine Medication
89332013|NCT04849364|Experimental|Arm 1|"Arm 1a: Patients who are ctDNA-positive and harbor a genomic target. DNA repair pathway = talazoparib + capecitabine (CLOSED)~Arm 1b: Patients who are ctDNA-positive and harbor a genomic target. Immunotherapy pathway = pembrolizumab + capecitabine (CLOSED)~Arm 1c: Patients who are ctDNA-positive and harbor a genomic target. PI3K Pathway = inavolisib + capecitabine ---> +/- standard of care pembrolizumab~Arm 1d: Patients who are ctDNA-positive and harbor a genomic target. DNA Repair + Immunotherapy = talazoparib + capecitabine +/- standard of care pembrolizumab"
89332014|NCT04849364|Active Comparator|Arm 2|Arm 2 subjects have plasma ctDNA positive but do not have a genomically driven treatment option. Treatment of physician's choice will be given with consideration for capecitabine and pembrolizumab. Dose, schedule and duration of treatment to be determined by treating physician.
89332015|NCT04849364|Active Comparator|Arm 3|Arm 3 subjects have plasma ctDNA negative. Treatment of patient and physician's choice will be given with consideration for capecitabine and pembrolizumab. Dose, schedule and duration of treatment to be determined by treating physician.
89332016|NCT04845542|Experimental|ReStoreD|8-week intervention that is remotely delivered, consisting of psychoeducation and positive psychology activities. Participants complete two activities individually and two together each week.
89332017|NCT04845542|No Intervention|Waitlist-control|Participants will be waitlisted for 8 weeks.
89332018|NCT04812418|Experimental|Group (A)|120 mg of eschscholtzia extract and 50 mg of valerian extract by tablet, without support 28 days
89332019|NCT04812418|Placebo Comparator|Group (B)|Placebo 28 days
89332020|NCT04798885|No Intervention|Enhanced usual care|Participants will be informed about typical Post Concussion Symptoms and the process of typical recovery as well as given reassurance concerning the prognosis. Advice concerning the use of pain relief medication will also be provided.
89332021|NCT04798885|Experimental|GAIN 2.0 intervention|An eight-week, interdisciplinary intervention program based on principles from cognitive behavioural therapy (CBT) and gradual return to activities.
89332022|NCT04797156|Experimental|High Dose Intravenous TXA (hTXA group)|Patients assigned to hTXA group will receive 50mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
89332023|NCT04797156|Experimental|Low Dose Intravenous TXA (lTXA group)|Patients assigned to lTXA group will receive 20mg/kg IV TXA loading dose with a 5mg/kg/hr maintenance dose, and normal saline poured over 5 minutes at the wound prior to closure.
89332024|NCT04797156|Placebo Comparator|Combined Intravenous and Topical TXA group (cTXA group)|Patients assigned to cTXA group will received 20mg/kg V TXA loading dose with a 5mg/kg/hr maintenance dose, and 2g topical TXA poured over 5 minutes at the would prior to closure
89332025|NCT04789902|Experimental|Hospital site 1|This site will provide usual ED care during the control period which will last for the first six months of the study. After six months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
89332026|NCT04789902|Experimental|Hospital site 2|This site will provide usual ED care during the control period which will last for the first 12 months of the study. After 12 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
89332027|NCT04789902|Experimental|Hospital site 3|This site will provide usual ED care during the control period which will last for the first 18 months of the study. After 18 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
89332028|NCT04789902|Experimental|Hospital site 4|This site will provide usual ED care during the control period which will last for the first 24 months of the study. After 24 months this site will begin transitioning to the SurgeCon management platform which they will use until the end of the study.
89332029|NCT04776148|Experimental|lenvatinib+pembrolizumab|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week (Q6W) Cycle for up to 18 cycles (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily until progressive disease.
89332030|NCT04776148|Active Comparator|standard of care treatment (regorafenib OR TAS-102)|Participants receive regorafenib 160 mg via oral tablet once daily on Days 1 through 21 of each 4-week cycle OR TAS-102 (trifluridine and tipiracil hydrochloride) 35 mg/m^2 via oral tablet twice a day on Days 1 through 5 and Days 8-12 of each 4-week cycle until progressive disease.
89332031|NCT04753190|Placebo Comparator|Dim Room Light Control|Participants in the dim room light control group will not receive any bright light exposure.
89332032|NCT04753190|Experimental|Morning Bright Light Only (MBL)|"Participants in the morning bright light (MBL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive mornings in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
89332033|NCT04753190|Experimental|Afternoon Light Only (ABL)|"Participants in the afternoon bright light (ABL) group will receive a 3-h bright light exposure from 2 light boxes on 3 consecutive afternoons in the laboratory. Bright light will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
89332034|NCT04753190|Experimental|Morning + Afternoon Light (MBL+ ABL)|"Participants in the morning bright light + afternoon bright light (MBL+ ABL) group will receive bright light from 2 light boxes on 3 consecutive days in the laboratory. The morning exposure will be 1.5 h and the afternoon exposure will be 1.5 h. Bright light exposures will be timed for each individual based on their baseline sleep schedule to shift the circadian timing system earlier (phase advance)."
89332035|NCT04737109|Experimental|Phase I De-Escalation Cohort: ADT + Ipatasertib + Darolutamide|Cycle 0 Days 1-7: Ipatasertib Monotherapy + Androgen Deprivation Therapy (ADT) Cycle 1+: Ipatasertib + Darolutamid + ADT
89332036|NCT04737109|Experimental|Phase II: ADT + Ipatasertib + Darolutamide|All Cycles: Ipatasertib + Darolutamide + ADT
89332037|NCT04669028|Experimental|NE3107|Hard gelatin capsule containing 20 mg micronized NE3107 drug substance blended with common excipients for oral formulations
89332038|NCT04669028|Placebo Comparator|placebo|Hard gelatin capsule containing only common excipients for oral formulations
89332039|NCT04662801|Experimental|Behavioral Weight Loss|
89332040|NCT04662801|Experimental|Behavioral Weight Loss + Medication|
89332041|NCT04634773|Experimental|Group 1: Early Degeneration ('Disease')|Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.
89332042|NCT04634773|Active Comparator|Group 2: No Degeneration ('Healthy')|Those who have posterior subluxation of the humeral head and show no signs of degeneration.
89332043|NCT04632940|Experimental|Pamrevlumab|Pamrevlumab 35 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
89332044|NCT04632940|Placebo Comparator|Placebo|Matching placebo IV every 2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally for up to 52 weeks
89332045|NCT04629352|Experimental|Verum Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
89332046|NCT04629352|Placebo Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|Each SCZ patient will receive twice-daily for 5-days, 10-sessions course of tDCS [anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2]. For Sham-tDCS, no current will be delivered beyond initial ramp-up time.
89332047|NCT04621643|Experimental|digital cognitive behavioral therapy (dCBT-I)|
89332048|NCT04621643|Active Comparator|Patient education about sleep (PE)|
89332049|NCT04617028|Experimental|Jaktinib|Participants will receive Jaktinib plus placebo to match Hydroxycarbamide.
89332050|NCT04617028|Active Comparator|Hydroxycarbamide|Participants will receive Hydroxycarbamide plus placebo to match Jaktinib.
89332051|NCT04589325|Experimental|Ixekizumab|
89332052|NCT04589325|Placebo Comparator|Placebo|
89332053|NCT04584632|Experimental|EVSS|Efemoral Vascular Scaffold System (EVSS)
89332054|NCT04582669|Placebo Comparator|Sodium Chloride 0.9%|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
89332055|NCT04582669|Active Comparator|Intralesional Triamcinolone 10 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
89332056|NCT04582669|Experimental|Intralesional Triamcinolone 20 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
89332057|NCT04582669|Experimental|Intralesional Triamcinolone 40 mg/mL|Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
89332058|NCT04563130|Experimental|Cryocompression|Patients will be randomized to receive cryocompression on one hand and foot using ice bags and compression socks.
89332059|NCT04563130|No Intervention|Control|Patients will be randomized to receive no intervention on the opposite hand and foot.
89332060|NCT04560309|Experimental|Glutamine|Intravenous L-alanyl-L-glutamine 0.5 mg/kgbw
89332061|NCT04560309|Placebo Comparator|Control|Intravenous NaCl 0.9%
89332062|NCT04550182|Experimental|Individual positioning schedule|Pressure ulcer prevention cares are provided according to the positioning schedule for every patient.
89332063|NCT04550182|No Intervention|Standard care|Pressure ulcer prevention cares are provided according to usual practice of the ICU. Frequency and modality of positioning applied to the patients are collected.
89332064|NCT04535986|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
89332065|NCT04535986|Placebo Comparator|Arm 2|Placebo Nebulized BID
89332066|NCT04522375|Experimental|FP-045|The study will enroll a total of 6 young adult/adolescent patients progressing through three dose levels, followed by a minimum of 8 and up to 12 pediatric patients progressing through up to three dose levels.
89332067|NCT04495972|Active Comparator|Experimental arm: Intestinimonas|Intestinimonas in capsules
89332068|NCT04495972|Placebo Comparator|Placebo arm: Placebo|Placebo in capsules
89332069|NCT04465240|Experimental|Virtual reality simulation of neighborhood disadvantage|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood representative of disadvantage they were assigned to. Then they will watch a video again during a recovery period.
89332070|NCT04465240|Active Comparator|Virtual reality simulation of neighborhood affluence|Participants will attend one study session. They will watch a video during a baseline rest period. Participants will be assigned to navigate and explore the virtual neighborhood, representative of affluence they were assigned to. Then they will watch a video again during a recovery period.
89332071|NCT04456270||Primary care patients with current asthma|Male and female primary care patients aged ≥18 years of age with clinically diagnosed asthma.
89332072|NCT04450264|Other|Breast Cancer Education Program|
89332073|NCT04420754|Experimental|Cohort -1|AIC100 CAR T Cell Dose Level -1 (Flat Dose): 1 x 10e6 CAR T cells
89332074|NCT04420754|Experimental|Cohort 1|AIC100 CAR T Cell Dose Level 1 (Flat Dose): 1 x 10e7 CAR T cells
89332075|NCT04420754|Experimental|Cohort 2|AIC100 CAR T Cell Dose Level 2 (Flat Dose): 1 x 10e8 CAR T cells
89332076|NCT04420754|Experimental|Cohort 3|AIC100 CAR T Cell Dose Level 3 (Flat Dose): 5 x 10e8 CAR T cells
89332077|NCT04420754|Experimental|Cohort 2.5|AIC100 CAR T Cell Dose Level 2.5 (Flat Dose): 2.5 x 10e8 CAR T cells. The interim step-down dose of Cohort 2.5 may be evaluated, if needed, based on ongoing safety and efficacy data.
89332078|NCT04420754|Experimental|Cohort 4|AIC100 CAR T Cell Dose Level 4 (Flat Dose): 7.5 x 10e8 CAR T cells. The proposed escalation dose of Cohort 4 may be evaluated, if needed, based on ongoing safety and efficacy data.
89332079|NCT04406714|Experimental|Trial Mailed FIT Intervention - Age Group 50-75|Subjects randomized to this arm are 50-75 years of age and eligible for CRC screening using FIT per electronic health record at either of two FQHCs. Only subjects who are 50-75 years of age are randomized to this arm. Subjects who are 50-75 cannot be randomized to Arm 3 or Arm 4.
89332080|NCT04406714|No Intervention|Trial Usual Care - Age Group 50-75|Subjects randomized to this arm are 50-75 years of age and eligible for CRC screening using FIT per electronic health record at either of two FQHCs. Only subjects who are 50-75 years of age are randomized to this arm. Subjects who are 50-75 cannot be randomized to Arm 3 or Arm 4.
89332081|NCT04406714|Experimental|Sub-study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49|Subjects randomized to this arm are 45-49 years of age and eligible for CRC screening using FIT per electronic health record at one FQHC. Only subjects who are 45-49 years of age are randomized to this arm. Subjects who are 45-49 years of age cannot be randomized to Arm 1 or Arm 2 of the main trial.
89332082|NCT04406714|Active Comparator|Sub-study Mailed FIT Comparator Plain Envelope - Age Group 45-40|Subjects randomized to this arm are 45-49 years of age and eligible for CRC screening using FIT per electronic health record at one FQHC. Only subjects who are 45-49 years of age are randomized to this arm. Subjects who are 45-49 years of age cannot be randomized to Arm 1 or Arm 2 of the main trial.
89332083|NCT04400565|Experimental|Recovery group|The recovery program has 2 phases and consists of 20 classes, 1.5 hour per class and one class per week. We will introduce concepts of recovery and personal strengths in phase 1. Then, we will help participants to set goals and implement their plans in phase 2. Participants will fill out all questionnaires during the recruitment meeting.They will fill out the same questionnaires plus the course satisfaction survey in the end of phase 1 and 2. Six months later, participants will receive a follow-up interview and fill out the questionnaires again.
89332084|NCT04400565|No Intervention|Control group|The control group will receive a spiritual book and complete the questionnaires at the same time as the recovery group.
89332085|NCT04368702|Experimental|Phase I - Gastric Cancer|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
89332086|NCT04368702|Experimental|Phase I - Breast Cancer|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
89332087|NCT04368702|Experimental|Phase I - Mantle Cell Lymphoma|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
89332088|NCT04368702|Experimental|Phase I - Larynx|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
89332089|NCT04368702|Experimental|Phase I - Bladder|"The research study procedures include:~Screening for eligibility~Study treatment including evaluations~MR-image guided radiation will be administered per disease site standards.~Follow up visits~Questionnaires"
89332090|NCT04356755|Experimental|AdMSC|Subcutaneous injections of cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma
89332091|NCT04356755|Placebo Comparator|Placebo|Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma
89332092|NCT04325789|No Intervention|Group 1 Control|Group 1 will serve as the control and undergo routine rotator cuff repair with suture anchors without the nanofiber scaffold.
89332093|NCT04325789|Active Comparator|Group 2 Scaffold|Group 2 will undergo rotator cuff repair with suture anchors and incorporation of the nanofiber scaffold.
89332094|NCT04317118||Neurodevelopmental|Individuals between 8 and 17 years old with neurodevelopmental disorders
89332095|NCT04259801|Experimental|NNC0480-0389 and semaglutide|"Part 1: 6 subjects will receive a single subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.~Part 2: 12 subjects will receive 4 doses of s.c. NNC0480-0389 co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c semaglutide."
89332096|NCT04259801|Experimental|NNC0480-0389 and placebo (semaglutide)|"Part 1: 4 subjects will receive a single dose of s.c. NNC0480-0389 co-administered with semaglutide placebo.~Part 2: 4 subjects will receive 4 doses of s.c. NNC0480-0389, co-administered with semaglutide placebo after 8 weeks of dosing with semaglutide placebo."
89332097|NCT04259801|Active Comparator|Placebo (NNC0480-0389) with semaglutide|"Part 1: 2 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with s.c. semaglutide.~Part 2: 4 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with s.c. semaglutide, after 8 weeks of dosing with s.c. semaglutide"
89332098|NCT04259801|Placebo Comparator|Placebo (NNC0480-0389) with placebo (semaglutide)|"Part 1: 3 subjects will receive a single dose of placebo (NNC0480-0389), co-administered with semaglutide placebo.~Part 2: 2 subjects will receive 4 doses of placebo (NNC0480-0389), co-administered with semaglutide placebo, after 8 weeks of dosing with semaglutide placebo."
89332099|NCT04202549|Experimental|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy
89332100|NCT04187196|Experimental|Sedation with propofol group|Participants in this group will be randomized to sedation with bolus dosing of propofol for cardioversion.
89332101|NCT04187196|Experimental|Sedation with methohexital group|Participants in this group will be randomized to sedation with bolus dosing of methohexital for cardioversion.
89332102|NCT04166474|Experimental|Dolutegravir|
89332103|NCT04162184|Other|Health Educator Intervention|As the population of focus in this study is diverse, including men and women regardless of pregnancy desire, the primary focus for the intervention for this study will be education, particularly for men. All participants that enroll in the study will be offered the intervention. The study health educator will use the PATH (Parenthood/Pregnancy Attitude, Timing, and How) framework questions to initially guide the conversation. Depending on the participant's desires, the educator will provide education on other topics such as sexually transmitted infections (STIs) and we will also navigate to clinical services as needed. The health educator will use a study manual to guide all intervention activities including engagement. Additionally, the health educator will collect data on intervention outreach, engagement, topics discussed, participant needs and outcomes.
89332104|NCT04137952|Experimental|deterministic visual error gain|"Day1(Pretest):~stabilometer stance, 3 times/1 min~air pillow stance, 3 time/30 sec~poture-supraposture dual task, 3 times/1 min~Day2 to Day5:~Exp.group:27 times of posture tracking with high visual error gain.~Control group:27 times of posture training with normal visual error gain.~Day6 (Posttest):~stabilometer stance, 3 times/1 min~air pillow stance, 3 time/30 sec~poture-supraposture dual task, 3 times/1 min"
89332105|NCT04137952|Experimental|stochastic visual noise|"Day1(Pretest):~stabilometer stance, 3 times/1 min~air pillow stance, 3 time/30 sec~poture-supraposture dual task, 3 times/1 min~Day2 to Day5:~Exp.group A:27 times of posture training with posture tracking signal-to-noise ratio=2:1.~Exp.group B:27 times of posture training with posture tracking signal-to-noise ratio=4:1.~Control group:27 times of posture training with normal visual error gain.~Day6(Posttest):~stabilometer stance, 3 times/1 min~air pillow stance, 3 time/30 sec~poture-supraposture dual task, 3 times/1 min"
89332106|NCT04137952|Experimental|intermittent visual gain|"Day1 (Pretest):~stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec~stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec.~stabilometer stance with wearing flash glasses (clear), 4 times/45 sec~air pillow stance, 8 times/1 min~Day2 (training section):~Exp. group:Posture tracking with wearing flash glasses (low frequency with opaque ratio 50%), 12 times/45 sec.~Control group:Posture tracking with wearing flash glasses (clear), 12 times/45 sec.~Day3 (Posttest):~stabilometer stance with wearing flash glasses (low frequency with opaque ratio 50%), 4 times/45 sec~stabilometer stance with wearing flash glasses (high frequency with opaque ratio 50%), 4 times/45 sec~stabilometer stance with wearing flash glasses (clear), 4 times/45 sec~air pillow stance, 8 times/1 min"
89332107|NCT04091971|Experimental|Depressed adults with current MDD|Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.
88809698|NCT00744380|Experimental|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)as other sedatives are down titrated. Daily awakenings are used.
89332108|NCT04021238|Experimental|Perflutren Lipid Microsphere or Lumason|Patients with suspected kidney cancer and planned surgery will be imaged using contrast-enhanced ultrasound with either perflutren or Lumason.
89332109|NCT04019873||Subjects receiving 2DR treatment|Data will be collected from HIV positive male or female adult subjects who have started 2DR with an integrase inhibitor plus a reverse transcriptase inhibitor from 2014.
89332110|NCT04003454|Other|Nontargeted Screening|The nontargeted HCV screening arm will consist of implementing non-risk-based rapid opt-out HCV screening.
89332111|NCT04003454|Other|Targeted Screening|"The targeted HCV screening arm will consist of implementation of risk-based rapid opt-out HCV screening using current recommendations for HCV screening by the CDC, USPSTF, and AASLD-IDSA. Targeted HCV screening will consist of offering HCV testing to those identified with the following specific risk characteristics, adapted from the above recommendations: born between 1945 - 1965 (birth cohort); injection drug use (IDU); intranasal drug use;tattoo or piercing in an unregulated setting; or blood transfusion or organ recipient before 1992."
89332112|NCT03988608|Experimental|Eltrombopag|Subjects will start eltrombopag treatment at 25 mg/day since Day 1.
89332113|NCT03955887||Experimental|Patients with severe acute lung disease requiring mechanical ventilation
89332114|NCT03955887||Control|Patients receiving routine bronchoalveolar lavage for a pathology not suspected of acute infection
89332115|NCT03950609|Experimental|Treatment (lenvatinib, everolimus)|Patients receive lenvatinib PO daily and everolimus PO daily on days 1-28. Treatments repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89332116|NCT03949387|Experimental|FES Cycling Exercise|FES cycling will involve systematic, transcutaneous electrical stimulation of the leg muscles to produce leg-cycling movement. The intensity and duration of training will be prescribed based on guidelines for aerobic exercise training for persons with MS and from the American College of Sports Medicine, and will progressively increase across 24 weeks. Participants will be encouraged to actively cycle at a minimum cadence of ~40-50 rpm, at 40-60% VO2peak for between 10-50 minutes. The intensity of stimulation will be adjusted per leg muscle group based on sensory tolerance with the goal of maintaining pedaling action and target heart rate over the entire session. At each session, we will record the distance traveled, energy expended, power output, resistance, heart rate and rating of perceived exertion (RPE).
89332117|NCT03949387|Placebo Comparator|Passive Leg Cycling|Passive leg cycling will involve movement of the participant's legs by the cycle ergometer motor without electrical stimulation. The duration of training will follow the same schedule as the FES cycling condition and the same data will be recorded at each session. The passive cycling condition will include the same exposure with the training facility, the exercise equipment (i.e. RT300 cycles), and the research staff (i.e. social contact and attention) as with the FES cycling condition.
89332118|NCT03943901|Experimental|Split Dose R-CHOP|"Each cycle is 28 days and consists of one A treatment on Day 1 and one B treatment on Day 15 for 6 cycles~Day 1 (A part of cycle)~Rituximab 375 mg/m2 IV (or biosimilars Ruxience or Truxima)~Cyclophosphamide 375 mg/m2 IV~Doxorubicin 25 mg/m2 IV~Vincristine 1 mg IV~Prednisone 50 mg (Days 1-5) PO~Pegfilgrastim (supportive care) 6 mg on Day 2 (24 hours after completion of chemotherapy) or filgrastim daily as institutionally indicated (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor.~Day 15 (B part of cycle)~Cyclophosphamide 375 mg/m2 IV~Doxorubicin 25 mg/m2 IV~Vincristine 1 mg IV~Prednisone 50 mg (Days 15-19) PO~Pegfilgrastim (supportive care) 6 mg on Day 16 (24 hours after completion of chemotherapy) or filgrastim daily as institutionally indicated (starting 24 hours post completion of chemotherapy), or institutional standard granulocyte stimulating factor."
89332119|NCT03925220|Experimental|Substance Use Prevention Intervention|Parents will be given a handbook specific to the gender of their child that provides information and advice communication and substance use prevention. Parents will then participate in a one-hour session with an interventionist where the main points in the handbook will be reviewed and they will fill out an action plan on how to make changes in communication about substances with their child. The interventionist will also provide parents with a referral packet. Two weeks after the live session, participants will have a half-hour follow-up phone call with the same study interventionist. For the home-based component, parents will receive two messages each week with reminders and tips that reinforce the information covered in the handbook. Finally, participants will receive a magnet about the importance of family meals that they will be instructed to put on their refrigerators.
89332120|NCT03925220|Active Comparator|Nutrition, Physical Activity, and Weight Talk Comparison|"For the comparison condition, after the baseline assessment, parents will receive a handbook on nutrition and physical activity entitled: Healthy Eating & Physical Activity Across Your Lifespan: Helping your Child - Tips for Parents. This handbook, which is adapted from the handbook developed by the National Institute of Diabetes and Digestive and Kidney Diseases and the Weight Control Information Network, is approximately the same length as the intervention handbook and is available in English and Spanish. It is given with an insert on reducing weight talk and weight teasing in the family. Parents will also receive a magnet with a message about nutrition and exercise. To control for contact time, these participants will meet live with a study staff member two weeks after receiving the handbook, complete an action plan, and have the 30-minute call, as well as receive two text messages twice per week for 13 weeks with tips and reminders from the comparison handbook and insert."
89332121|NCT03902613|Experimental|Lurasidone|Open-label treatment with lurasidone within the dose range of 20-60 mg daily
89332122|NCT03888612|Experimental|ARV-110|"Part A: Oral tablet(s), once or twice daily in 28 day cycles~Part B: Oral tablet(s), once or twice daily in 28 day cycles"
89332123|NCT03854071|Other|Group 1|Heart failure patients with preserved ejection fraction
89332124|NCT03854071|Other|Group 2|Heart failure patients with reserved ejection fraction
89332125|NCT03854071|Other|Group 3|Patients with pulmonary hypertension
89332126|NCT03854071|Other|Group 4|Patients with acute myocardial infarction
89332127|NCT03854071|Other|Group 5|Patients with suspected but not treated coronary artery disease
89332128|NCT03854071|Other|Group 6|Healthy Volunteers
89332129|NCT03845894|Active Comparator|Liposomal Bupivacaine Interscalene brachial plexus (ISB)|
89332130|NCT03845894|Active Comparator|Bupivacaine with adjuvants ISB|
89332131|NCT03787589|Experimental|Exercise Intervention|Participants in this arm will receive standard of care along with the exercise prescription intervention
89332132|NCT03787589|No Intervention|Standard of Care|This group will receive standard of care treatment including regular verbal encouragement to exercise (monthly) by dialysis unit staff.
89332133|NCT03753919|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks up to 4 cycles followed by durvalumab 1500 mg every 4 weeks until disease progression, unacceptable toxicity or patients' decision.
88809699|NCT00744692|Experimental|RIC Cord Blood Transplant|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
89332134|NCT03658954|Active Comparator|Advice|Participants receive only web-based sleep hygiene advice
89332135|NCT03658954|Experimental|Advice + Self-monitoring|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring
89332136|NCT03658954|Experimental|Advice + Self-monitoring + Feedback|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring + sleep/alcohol data feedback
89332137|NCT03654768|Active Comparator|Arm I (bosutinib, dasatinib, nilotinib, imatinib)|Patients receive bosutinib PO daily or dasatinib PO daily or nilotinib PO BID or imatinib PO daily on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89332138|NCT03654768|Experimental|Arm II (ruxolitinib phosphate, dasatinib, nilotinib, imatinib)|Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID or imatinib PO daily on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
89332139|NCT03616145|Experimental|Osteopathic Manipulative Treatment (OMT)|Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
89332140|NCT03616145|Sham Comparator|Light Touch|Participants assigned to the light touch comparator arm will receive 30 minutes of light touch procedures designed to be credible but minimally effective. The procedures for the light touch arm are adapted from the methodology established in the North Texas Chronic Low Back Pain Trial, and have been used successfully by the PI as a comparator arm numerous times in the past (e.g., in the OSTEPAThic Trial). Subjects assigned to receive light touch will be treated in positions similar to subjects receiving OMT. Light touch will target each of the 15+ anatomic regions for approximately 1 ½ to 2 minutes each to appropriately control for time, attention, and physical contact. Light touch hand placement will be over the same areas of the body contacted in the OMT protocol, but involve virtually no motion of a meaningful nature, such a range of motion testing which could have therapeutic effect.
89332141|NCT03616145|No Intervention|Standard of Care Only|Subjects will continue their usual care and will visit the UCSD for the 4 assessment sessions only, during their course of study participation.
89332142|NCT03615599||Seventh-day Adventists|This is a prospective cohort study of 96,000 members of the Seventh-day Adventists Church in the United States and Canada age 30 and older at the time of enrollment who are proficient in English language.
89332143|NCT03590249|Experimental|Osteopathic Manipulative Treatment (OMT)|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
89332144|NCT03590249|No Intervention|No Intervention|Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.
89332145|NCT03564613||HIV positive pregnant women|Data from approximately 250 HIV positive pregnant women with exposure to DTG from potential investigational sites across Europe will be included.
89332146|NCT03508908|No Intervention|Observation Period|HIV testing will only be done if ordered by the primary care clinician. Individuals diagnosed with HIV who have not yet notified partners will be offered assisted partner notification at a 6-week visit.
89332147|NCT03508908|Active Comparator|Intervention Period|Combination intervention with HIV-1 RNA testing followed by rapid tests if positive for HIV diagnosis, immediate ART if diagnosed, assisted partner notification with HIV-1 RNA testing of partners, and PrEP for uninfected partners in discordant relationships.
89332148|NCT03439631|Active Comparator|Tiered OR Satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
89332149|NCT03439631|Other|Status Qou OR satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
89332150|NCT03422731|Experimental|Cohort I (TMLI+FLT/TMLI)|Patients may undergo optional fluorothymidine F-18 PET scan over 2 hours at baseline, on days 30 and 100, at 1 year, and at time of relapse. Patients undergo DECT and water-fat MRI scan over 30 minutes at baseline, on days 30 and 100, at year 1, and at time of relapse. Patients also undergo collection of bone marrow and blood samples at baseline, on days 30 and 100, and at 1 year. Patients undergo fluorothymidine F-18 PET, DECT, and water-fat MRI as in TMLI+FLT.
89332151|NCT03422731|Active Comparator|Cohort II (TBI)|Patients undergo collection of bone marrow at baseline, day 30, time of relapse, and at 1 year.
89332152|NCT03402906|Experimental|Family-Clinician Collaboration|Participants are dyads of a stroke survivor and their family member. Family members will work closely with the Clinician to understand the status and goals of the stroke survivor, and family members will integrate Family-Mediated Treatment Procedures into their time spent with the stroke survivor at home.
89332153|NCT03401099|Active Comparator|Radiofrequency ablation of CTI|Radiofrequency ablation of CTI (cavo-tricuspid isthmus), which is the 'conventional' treatment of atrial flutter
89332154|NCT03401099|Active Comparator|Cryoballoon PVI|Cryoballoon PVI (Pulmonary Vein Isolation), which is the 'novel treatment'
89332155|NCT03299842|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
89332156|NCT03281564||Essure®|Patients with laparoscopic removal of Essure®
89332157|NCT03279185||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
89332158|NCT03249181|Experimental|Dolutegravir|"Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs"
89332159|NCT03249181|Active Comparator|Standard of Care (EFV + 2 NRTI backbone)|Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).
89332160|NCT03237611|Experimental|low dose aprepitant or fosaprepitant|In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards
89332161|NCT03233542|Experimental|Panic Disorder: CBT|Participants with Panic Disorder randomized to this arm will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
89332162|NCT03233542|No Intervention|Panic Disorder: Waiting list|After the pre-treatment testing session, participants with Panic Disorder randomized to this arm will wait a length of time equivalent to that for the pre/post-treatment duration for the Panic Disorder: Cognitive Behaviour Therapy arm (approx. 3 months), before returning to the post-treatment assessment. After completing all the study procedures, participants in this arm receive also the manualised Cognitive Behaviour Therapy treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
89332163|NCT03233542|Other|Anxious Control Group: CBT|All participants in the Anxious Control Group will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for their diagnosed anxiety disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
89332164|NCT03104374|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
89332165|NCT03104374|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 56 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
89332166|NCT03104374|Placebo Comparator|Placebo then Upadacitinib 15 mg|"Period 1: Participants receive placebo once daily for 24 weeks followed by upadacitinib 15 mg once daily for 32 weeks.~Period 2: Participants will continue to receive upadacitinib 15 mg once daily."
89332167|NCT03104374|Placebo Comparator|Placebo then Upadacitinib 30 mg|"Period 1: Participants receive placebo once daily for 24 weeks followed by upadacitinib 30 mg once daily for 32 weeks.~Period 2: Participants will continue to receive upadacitinib 30 mg once daily."
89332168|NCT03100656|Other|Anorexia nervosa I|Anorexia nervosa with BMI <=17.5 kg/m² or BMI >17.5 kg/m² with regular binge-purge episodes
89332169|NCT03100656|Other|Anorexia nervosa II|Anorexia nervosa with BMI > 18.5 kg/m² for at least 12 months.
89332170|NCT03100656|Other|Controls|Healthy control women
89332171|NCT03099850||Chronic Pancreatitis|
89332172|NCT03073941|Active Comparator|Persona CR Total Knee System|All patients randomized into this group will have the Intervention: Persona total knee system
89332173|NCT03073941|Active Comparator|NexGen CR Total Knee System|All patients randomized into this group will have the Intervention: Nexgen total knee system
89332174|NCT03054363|Experimental|Phase 1b|Tucatinib 300 mg PO BID, palbociclib 125 mg PO daily 21 days on and 7 days off, and letrozole 2.5 mg PO daily on a 28 day cycle length.
89332175|NCT03054363|Experimental|Phase II|Tucatinib 300 mg BID; palbociclib 75 mg PO daily 21 days on, 7 days off; letrozole 2.5 mg PO daily.
89332176|NCT03043313|Experimental|Cohort A: Tucatinib + Trastuzumab|Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
89332177|NCT03043313|Experimental|Cohort B: Tucatinib + Trastuzumab|Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
89332178|NCT03043313|Experimental|Cohort C: Tucatinib Monotherapy|Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.
89332179|NCT03042104|Experimental|TAVR|Transcatheter aortic valve replacement (TAVR)
89332180|NCT03042104|No Intervention|CS|Clinical surveillance (CS)
89332181|NCT02962570|Experimental|Only Arm|"Two minutes: Intervention: Device: On Demand Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Two minutes intervention: Device: Traditional, Always-On, Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Repeat until the end of the surgical procedure"
89332182|NCT02953067|Active Comparator|Open reduction and internal fixation|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
89332183|NCT02953067|Active Comparator|Primary Arthrodesis|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
89332184|NCT02953067|Active Comparator|Conservative treatment|Non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
89332185|NCT02939976|Active Comparator|Single Vessel Disease|Standard of care comparator for those subjects with single vessel coronary artery disease. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
89332186|NCT02939976|Experimental|Multi-vessel Disease, Culprit Vessel Only|Subjects randomized to revascularization of infarct related artery only. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
89332187|NCT02939976|Experimental|Multi-vessel Disease, Complete Revascularization|Subjects randomized to complete revascularization. Complete revascularization of all diseased arteries with Medtronic Resolute family of stents; Use of Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology to determine which arteries to stent; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
89332188|NCT02834780|Experimental|H3B-6527 (escalation and expansion)|Hepatocellular Carcinoma
89332189|NCT02829957|Active Comparator|Rivaroxaban|
89332190|NCT02829957|Active Comparator|Apixaban|
89332191|NCT02817958|Experimental|A-Adjuvant Chemotherapy TIP|Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapy TIP modified bilateral lymphadenectomy 4 cycles every 21 days
89332192|NCT02817958|Experimental|B-Neoadjuvant Chemotherapy TIP|fine needle biopsy or sentinel node + neoadjuvant chemotherapy TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days
89332193|NCT02736565|Experimental|Cohort -1|0.02mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
89332194|NCT02736565|Experimental|Cohort 0|0.03mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
89332195|NCT02736565|Experimental|Cohort 1|0.04mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
89332196|NCT02736565|Experimental|Cohort 2|0.06mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
89332197|NCT02736565|Experimental|Cohort 3|0.08mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
89332198|NCT02736565|Experimental|Cohort 4|0.10mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
89332199|NCT02736565|Experimental|Cohort 5|0.125mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
89332200|NCT02736565|Experimental|Cohort 6|0.156mg/kg pbi-shRNA™ EWS/FL/I1 Type 1 Lipoplex
89332201|NCT02727972|Other|Cognitive Testing|Cognitive assessments
89332202|NCT02727972|Active Comparator|Magnetic Resonance Imaging|All subjects will have one MRI with a possibility of one functional MRI (fmri).
89332203|NCT02727972|Active Comparator|Positron Emission Tomography|All subjects will have PET scan using FPEB or ABP688.
89332204|NCT02710370||Controls|Patients who meet criteria for gastric bypass surgery, and do not have a documented history of Type 1 or Type 2 Diabetes.
89332205|NCT02710370||Participants with Type 2 Diabetes|Patients who meet criteria for gastric bypass surgery, and have a documented history of Type 2 Diabetes.
89332206|NCT02707471|Experimental|SM-AET|a self-management intervention for enhancing skills to improve adherence and reduce symptom interference (SM-AET) (active intervention group)
89332207|NCT02707471|Other|general health education Intervention|general health education Intervention (control group)
89332208|NCT02564484||Neuropathy|Adult survivors who developed persistent treatment-related neuropathy.
89332209|NCT02564484||Control|Adult survivors who did not develop persistent treatment-related neuropathy.
89332210|NCT02377726|Experimental|Internet self-help with support|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules. Patients will have access to Alkoholhjälpen counselor support through secure comments at every module they complete.
89332211|NCT02377726|Experimental|Internet self-help|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules.
89332212|NCT02377726|Active Comparator|Information|Brief information on resources that can be accessed through the open access website Alkoholhjälpen: Information on alcohol and health, where and how to find treatment and an internet discussion forum.
89332213|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 30 mg BID|Subjects are randomized to receive 30 mg twice daily of enoxaparin.
89332214|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 40 mg QD|Subjects are randomized to receive 40 mg once daily of enoxaparin.
89332215|NCT02236689|Active Comparator|Arthroscopic tennis elbow release|This group will have arthroscopic tennis elbow release through a standard, two-portal technique,
89332216|NCT02236689|Placebo Comparator|Non Operative|control group will not undergo a second portal or muscle release.
89332217|NCT02119702||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
89332218|NCT02119702||Uninfected Cohort|Perinatally HIV-exposed but uninfected participant at or beyond their 18th birthday at enrollment. May have horizontally-acquired HIV infection.
89332219|NCT02069782|Experimental|Home visiting|Home visiting programs in the United States grew from three major approaches that first became prominent in the 1960s: visits by public health nurses to promote infant and child health in disadvantaged families, Head Start home visiting to promote school readiness in hard-to-reach families, and home-based family support to promote positive parenting and prevent child abuse in high-risk families. All of these approaches sought to foster early childhood health and development by intervening in the home to support and improve socialization, health, and education practices.Today, home visiting is seen as a particularly important strategy for high-risk families who may be difficult to engage in other services.
89332220|NCT02022436|Active Comparator|contrast ultrasound for patients with AAA|Contrast ultrasound
89332221|NCT02022436|Active Comparator|contrast ultrasound for patients without arterial disease|contrast enhanced ultrasound
89332222|NCT01984346|Experimental|Convergent Procedure|Procedure/Surgery: Convergent Procedure using EPi-Sense-AF Guided Coagulation System with Endocardial Catheter Ablation Treatment
89332223|NCT01984346|Active Comparator|Standalone Endocardial Catheter Ablation|Procedure/Surgery: Endocardial Catheter Ablation Treatment
89332224|NCT01860339||Gene-expanded (GE)|Children at risk for HD who have a CAG repeat length of 40 and above.
89332225|NCT01860339||Gene Non-Expanded (GNE)|Children at risk for HD who have a CAG repeat length of 39 or less
89332226|NCT01787409|Experimental|Treatment (cholecalciferol)|Vitamin D sufficient patients receive no intervention. Vitamin D insufficient patients receive cholecalciferol PO once weekly for 12 weeks and then once monthly for a total of 36 months.
89332227|NCT01661660|Active Comparator|Control subjects|Control subjects were people with memory complaints coming for a consultation and prevention.
89332228|NCT01661660|Experimental|Predementia / MCI patients|Subjects at predementia stage or MCI stage
89332229|NCT01661660|Experimental|Dementia patient|Subjects at demential stage
89332230|NCT01442363|Experimental|BLI-1300 (low dose)|Investigational Product (10%) Ointment
89332231|NCT01442363|Experimental|BLI-1300 (high dose)|Investigational Product (20%) Ointment
89332232|NCT01442363|Placebo Comparator|placebo|Placebo Ointment
89332233|NCT01418014||Infected Cohort|Perinatally HIV-infected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment, engaged in care with ART treatment history available.
89332234|NCT01418014||Uninfected Cohort|HIV-uninfected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment born to HIV-infected mothers.
89332235|NCT01393171|Active Comparator|Polypropylene Mesh|Site-specific cystocele repair with polypropylene mesh augmentation
89332236|NCT01393171|Placebo Comparator|Anterior Colporrhaphy|Anterior vaginal prolapse repair with anterior colporrhaphy with no graft.
89332237|NCT01393171|Active Comparator|Porcine Dermis|Site-specific cystocele repair with porcine dermis augmentation
89332238|NCT01338389|Experimental|CITICOLINE|Daily oral administration of 800 mg citicoline
89332239|NCT01338389|Placebo Comparator|Placebo|Daily oral administration of placebo
89332240|NCT01310023||Static Cohort- closed to enrollment and follow-up|HIV-uninfected children < 12 years of age at the time of enrollment, born of HIV-infected mothers
89332241|NCT01310023||Dynamic Cohort|HIV-uninfected children born of HIV-infected mothers enrolled from prior to birth through ≤ 72 hours of age
89332242|NCT01310023||Reference Cohort- closed to enrollment and follow-up|HIV-uninfected children born to a mother HIV uninfected at the time of the child's birth enrolled at 1, 3, 5, or 9 years of age(± 3 months) at the time of the study visit
89332243|NCT01310023||Young Adult Cohort- closed to enrollment and follow-up|Former Dynamic and Static Cohort participants ≥ 18 years of age.
89332244|NCT01186198||MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Patients requiring initial balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis will be included.
89332245|NCT00886301|Other|1|obese or overweight patients with fatty liver or ectopic fat
89332246|NCT00541047|Experimental|RADICALS-RT: Early RT|
89332247|NCT00541047|Experimental|RADICALS-RT: Salvage RT|
89332248|NCT00541047|Experimental|RADICALS-HD: Radiotherapy Alone|
89332249|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 6 months|
89332250|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 24 months|
89332251|NCT00307281||Registry|10 pack year tobacco smoking history required, current or former smokers accepted.
89332252|NCT01352702|Experimental|Arm 1|Dabigatran Therapy
89332253|NCT01352702|Active Comparator|Arm 2|Phenprocoumon Therapy
89332254|NCT03525730|No Intervention|Control|This group receives no intervention.
89332255|NCT03525730|Experimental|Valproic acid|This group receives valproic acid (enteric) for 14 days.
89332256|NCT03525730|Experimental|Pyrimethamine|This group receives pyrimethamine for 14 days.
89332257|NCT03525730|Experimental|Valproic acid and Pyrimethamine|This group receives valproic acid and pyrimethamine for 14 days.
89332258|NCT01223443|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
89332259|NCT01223443|No Intervention|Standard medical treatment|
89332260|NCT01352780|No Intervention|usual care|Motivational interviewing
89332261|NCT03525652|Active Comparator|Therapeutic vaccine|Therapeutic vaccine will be prepared ex vivo using the peripheral mononuclear cells from the patients and the vaccine (as maturated dendritic cells) will be infused back to the patients in 3 times with a 2-week interval.
89332262|NCT03525652|Experimental|Therapeutic vaccine plus PD-1 knockout|Therapeutic vaccine and PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the vaccine (as maturated dendritic cells) and maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
89332263|NCT03525652|Active Comparator|PD-1 knockout T cells|PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
89332264|NCT03772327|Experimental|Routine counseling + AdhereTech bottle|"Participants will receive routine medication adherence counseling and be given the AdhereTech smart bottle with reminders."
89332265|NCT03772327|Active Comparator|Routine counseling|Participants will receive routine medication adherence counseling.
89332266|NCT02290054|Sham Comparator|Control|A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
89332267|NCT02290054|Experimental|Treated|"A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Auriculotherapy is performed while the patient is sleeping but before thoracic incision.~Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles."
89332268|NCT01223521|Experimental|Immediate intrauterine contraception|IUD (either Cu-IUD or LNG-IUS) inserted immediately after abortion.
89332269|NCT01223521|No Intervention|Control group|Post-abortal contraception is prescribed by the hospital but on the responsibility of the patient.
89332270|NCT02298634||Observation|Patients with Farber disease or high-grade suspicion for Farber disease
89332271|NCT03931525|Experimental|Radiofrequency therapy with drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
89332272|NCT03931525|Active Comparator|Radiofrequency Therapy without drug delivery 30 days interval|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 30 days.
89332273|NCT03931525|Experimental|Radiofrequency therapy with drug delivery 15 days|Group that will be treated with Fractional Radiofrequency plus a regerative drug at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
89332274|NCT03931525|Active Comparator|Radiofrequency therapy without drug delivery 15 days|Group that will be treated with Fractional Radiofrequency at the Gluteus or Abdomen level during 4 sessions with an interval of 15 days.
89332275|NCT01352936||Experimental Group|
89332276|NCT01352936||Control Group|
89332277|NCT02290132||highly aggressive T cell tumors|The study is to research the outcome of Rabbit Anti-human Thymocyte Globulin (ATG)based myeloablative conditioning regimen after allo-HSCT in patients with highly aggressive T-cell tumors.
89332278|NCT01353014|Experimental|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genetic information.
89332279|NCT01353014|Active Comparator|General dietary recommendations|This group will receive general dietary recommendations for caffeine, vitamin C, sugar and sodium from recognized health institutions (caffeine: Health Canada; sugar: the World Health Organization; vitamin C and sodium: the Institute of Medicine).
89332280|NCT03927937|Experimental|AUTOTRANSPLANTATION TOOTH|
89332281|NCT02204098|Active Comparator|Cohort 1:Neoadjuvant endocrine therapy alone|"Will be treated with standard of care adjuvant endocrine therapy as determined by their treating physician~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy"
89332282|NCT02204098|Experimental|Cohort 2:Neoadjuvant endocrine + mammaglobin-A DNA vaccine|"Will be treated with standard of care adjuvant endocrine therapy~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)~All study injections will be administered using a TriGrid electroporation device"
89332283|NCT02204098|Active Comparator|Cohort 3: Neoadjuvant chemotherapy alone|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in cohort 3"
89332284|NCT02204098|Experimental|Cohort 4: Neoadjuvant chemotherapy + mammoglobin-A DNA vaccine|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)~All study injections will be administered using a TriGrid electroporation device~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in either cohort 4"
89332285|NCT03109262|Experimental|Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans|All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans
89332286|NCT01220245|Experimental|Heparin-bonded endoluminal fempop bypass|Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass
89332287|NCT01220245|Active Comparator|Surgical femoro-popliteal bypass|Surgical femoro-popliteal bypass.
89332288|NCT02290210|Placebo Comparator|Placebo|Placebo x 2weeks
89332289|NCT02290210|Placebo Comparator|URC102 0.25mg|0.25mg URC102 x 2weeks
89332290|NCT02290210|Experimental|URC102 0.5mg|0.5mg URC102 x 2weeks
89332291|NCT02290210|Placebo Comparator|URC102 1.0mg|1.0mg URC102 x 2weeks
89332292|NCT02290210|Placebo Comparator|URC102 2.0mg|2.0mg URC102 x 2weeks
89332293|NCT03931135|Active Comparator|Dexamethasone|
89332294|NCT03931135|Active Comparator|Cyclizine|
89332295|NCT01125865|Active Comparator|SEMS|Self-expandable metallic stent will be inserted for the malignant hilar obstruction.
89332296|NCT01125865|Active Comparator|DLS|DoubleLayer plastic stent (Olympus) will be inserted for malignant hilar obstruction.
89332297|NCT01353092|Experimental|Active PEMF twice daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
89332298|NCT01353092|Active Comparator|Active PEMF once daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
89332299|NCT01226641|Experimental|Telemedecine|CPAP treatment with telemedicine system
89332300|NCT01226641|Active Comparator|Standard Care|Standard care, including CPAP
89332301|NCT01353170|Experimental|Prevalent hd patients|Patients undergoing three consecutive cross-over hd session with 3 different dialysate calcium concentrations
89332302|NCT01220323|Active Comparator|direct current stimulation|The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm.
89332303|NCT01220323|Sham Comparator|sham stimulation|
89332304|NCT01223677|Active Comparator|rumination focused CBT|RFCBT-group. This group training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, group discussion, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
89332305|NCT01223677|Active Comparator|rumination focused CBT (online)|The online training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
89332306|NCT01223677|No Intervention|No training control group|No training control group. Participants within this condition received no treatment, but only filled out the outcome measures at each measurement period.
88806737|NCT05698654|Experimental|Longevity diet and Fasting-mimicking diet (LD + FMD)|This group will undergo both nutritional interventions (LD + FMD); the nutritionist will provide information on the longevity diet andpotential the fasting-mimicking diet, highlighting the advantages of following them. The subjects will be instructed to follow 3 FMD cycles (one cycle every 3 months as for arm 1) combined with the longevity diet plan. The longevity diet includes parts unrelated to diet and involving physical exercise.
89332307|NCT01125943|Experimental|Acetylcholine|Intra-arterial infusion of acetylcholine in two increasing dosages during 5 minutes each during the intra-arterial infusion of bevacizumab
89332308|NCT01125943|Experimental|Nitroprusside|Infusion of two increasing dosages of nitroprusside during 5 minutes each during the continuous infusion of bevacizumab
89332309|NCT03927859|Active Comparator|Mailing Letter|Patients assigned to this arm, in which a letter is mailed out will receive 2 pamphlets in the mail. One pamphlet described the teleophthalmology program and the other pamphlet was designed by the Canadian Association of Ophthalmologists and describes what DR is and why screening is important. The letter will also contain contact information about the closest TOP to the area of the PCP practice.
89332310|NCT03927859|Active Comparator|Phone call|"Administrative staff on site of each practice will contact all patients assigned to this arm by a phone call.~The patient will be informed that they are calling from the family health practice that the patient belongs to. The reason for the call will be that the patient has been identified as somebody who is likely overdue for a screening test. Patients will be asked if they have had a screening test done recently, and if not, they will be offered an appointment. Patients that refuse an appointment, will be politely probed for reasons and attempts will be made to provide them with information on potential solutions to these barriers (e.g. patients working 9-5 on weekdays will be informed that they can access TOP on evenings). The call will also be used as an opportunity to inform patients about the importance of screening.Three attempts will be made to reach each patient. Only a single voicemail message will be left, when the possibility is available."
89332311|NCT03927859|Active Comparator|Mail + Phone call|Patients assigned to this arm will first have letters mailed out to them (identical to the ones mailed out in the letter only arm). A week later, the letter will be followed up by a phone call as per the phone only arm. Patients will be asked if they have already booked, and if not, will be provided with information about the program as per the phone call script in the phone only arm.
89332312|NCT03927859|No Intervention|Control|No intervention will be offered to patients in this arm.
89332313|NCT01129453|Experimental|Vaccine-recipients|
89332314|NCT01129453|Placebo Comparator|Placebo|
89332315|NCT01223755|Experimental|Sirolimus|
89332316|NCT01223755|Active Comparator|conventional therapy|
89332317|NCT02290288|Active Comparator|SSF|1. vaginal surgery arm (SSF)
89332318|NCT02290288|Active Comparator|LSC|laparoscopic surgery arm (LSC)
89332319|NCT01126021|Active Comparator|Control|Given access to mental exercises but receives no rewards for use.
89332320|NCT01126021|Experimental|Atomistic|Each individual is awarded for his or her individual participation
89332321|NCT01126021|Experimental|Altruistic|Participants are paired and rewarded according to the other individual's participation.
89332322|NCT01126021|Experimental|Team-based|Teams compete against each other and receive rewards according to relative participation.
89332323|NCT02290600||type 1 diabetes|type 1 diabetes with continuous glucose monitor (CGM)
89332324|NCT03930901|Other|Intervention|Children in this group were examined for intestinal parasites and then treated accordingly. Then, health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), & nail clipper).
89332325|NCT03930901|No Intervention|Control|Children in this group were examined for intestinal parasites and then treated accordingly. They were follow up for 6 months.
89332326|NCT02290678|Experimental|Intervention|Participate in a two day Adventure-based Programming retreat and team building exercises.
89332327|NCT01220479|No Intervention|Control Healthy|
89332328|NCT01220479|No Intervention|Control Diabetic|
89332329|NCT01220479|Experimental|Exercise Diabetic|
89332330|NCT01220479|Experimental|Exercise Healthy|
89332331|NCT01126177|Placebo Comparator|Placebo|Placebo once daily for 14 days
89332332|NCT01126177|Experimental|SNG001|
89332333|NCT03680092|Experimental|Cyclophosphamide and abatacept|The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
89332334|NCT03680092|Active Comparator|methotrexate and tacrolimus|The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus
89332335|NCT03671044|Experimental|Nanosomal Docetaxel Lipid Suspension - 75 mg/m2|Experimental: NDLS for Injection, 75 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 75 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
89332336|NCT03671044|Experimental|T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Experimental: NDLS for Injection, 100 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
89332337|NCT03671044|Active Comparator|R, Taxotere® (100 mg/m2)|Active Comparator: Taxotere® Injection Concentrate Docetaxel Injection Concentrate; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
89332338|NCT03740425||Transfusion|Patients requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
89332339|NCT03740425||No Transfusion|Patients not requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
89332340|NCT03072134|Experimental|Unresectable disease|Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
89332341|NCT03072134|Experimental|Resectable disease|Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
89332342|NCT01223833||tamoxifen|100 postmenopausal women with early breast cancer treated with tamoxifen in the adjuvant setting
89332343|NCT01223833||aromatase inhibitors|200 postmenopausal women with early breast cancer treated with an aromatase inhibitor in the adjuvant setting
89332344|NCT02290756|Active Comparator|Parenting program and toolkit|The intervention arm of the study will have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy and the parenting program delivered to the newborn for 12 months.
89332345|NCT02290756|Other|Control- toolkit|The control arm of the study will only have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy.
89332346|NCT05790096|Active Comparator|Reference Drug - Granulokine®|"Reference Drug - Granulokine® is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.~Granulokine® will be administered at a daily dose of 5 μg/kg of body weight, exclusively subcutaneously, according to randomization."
89332347|NCT05790096|Experimental|Test Drug - Filgrastine®|"Test Drug -~Filgrastine® is presented in boxes containing vials containing 1 mL of solution for injection and 300 µg of filgrastim.~Filgrastine® will be administered at a daily dose of 5 μg/kg of body weight, exclusively subcutaneously, according to randomization."
89332348|NCT05790083|Experimental|Body Lotion BNO 3732 + Intensive Care BNO 3731|
89332349|NCT05790070|Placebo Comparator|Placebo|3g/ twice daily (separated by ~12 hours) cellulose placebo for 14 days
89332350|NCT05790070|Experimental|Betaine Supplementation|3g/twice daily (separated by ~12 hours) betaine anhydrous for 14 days
89332351|NCT05790018|Experimental|Experiment|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
89332352|NCT05790018|No Intervention|Control|The researcher will apply the questionnaires and scales in the pre-test to the pregnant woman included in the control group, and no other intervention will be applied. 37-38 to the pregnant women in the control group. The final test will be done weekly.
89332353|NCT05789966|No Intervention|Control Group|The control group will receive a Fitbit device
89332354|NCT05789966|Experimental|Intervention Group - Genetic Risk Estimate+health coaching|Genetic: Genetic Risk Estimate The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated as well.
89332355|NCT05789966|Experimental|Intervention Group - Genetic Risk Estimate + Fitbit Functions+health coaching|"Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well."
89332356|NCT05789914|Experimental|Small Intestinal Submucosa Membrane|
89332357|NCT05789914|Active Comparator|Bio-guide|
89332358|NCT05789888||Study group|The study group consisted of 75 people (46 women and 29 men) with gender (BMI=30.0-39.9 kg/m2).
89332359|NCT05789888||Control group|The control group included 41 people (31 women and 10 men) with normal weight (BMI=18.5-24.9 kg/m2).
89332360|NCT05789875|Experimental|Intervention|All YLWH who choose to enroll in the study will receive access to AiCure, the mobile health application. The participants will be asked to use the app for 3 months, during which the investigators will assess the feasibility and acceptability of AiCure.
89332361|NCT05789849|Experimental|Blood Pressure Collection|This study has only 1 arm; investigational NIBP measurements will be collected using a NIBP Auscultatory Algorithm with alternating NIBP measurements collected using a reference sphygmomanometer.
89332362|NCT05789810|Experimental|Manuel pressure group|10-second manual pressure was applied on the insulin injection area. The injection point was pressed by the diabetes nurse's right thumb over the site until resistance was felt and the pressure was then maintained for 10 seconds before the insulin injection. Then insulin injection was administered.
89332363|NCT05789810|Experimental|ShotBlocker group|ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
89332364|NCT05789810|Experimental|Control group:|No intervention was performed to reduce pain and fear.
89332365|NCT05789719|Experimental|autoSTEM-OA 400|400x10^6 autologous MSC(AT)s in autologous fat
89332366|NCT05789719|Experimental|alloSTEM-OA 400|400x10^6 allogeneic MSC(AT)s in autologous fat
89332367|NCT05789719|Experimental|autoSTEM-OA 800|800x10^6 autologous MSC(AT)s in autologous fat
89332368|NCT05789719|Experimental|alloSTEM-OA 800|800x10^6 allogeneic MSC(AT)s in autologous fat
89332369|NCT05789719|Experimental|autoSTEM-OA 1600|1600x10^6 autologous MSC(AT)s in autologous fat
89332370|NCT05789719|Experimental|alloSTEM-OA 1600|1600x10^6 allogeneic MSC(AT)s in autologous fat
89332371|NCT05789706|Experimental|Intervention Arm|Patients will have Dayamed Arthur a novel intelligent medication adherence platform installed on their smartphone and configured with their pharmacy data providing accurate prompts and reminders to patients to take medications as directed In addition to the prompts patient all auditable information will be relayed to their PACT CPS through a provider dashboard allowing for timely and directed clinical intervention. Dayamed Arthur will provide automated alerts to the patients care team in specific scenarios.
89332372|NCT05789706|No Intervention|Standard of Care Arm|Study subjects will be counseled on medication adherence and strategies to remember how to take their medications correctly. Study subjects will then be followed as clinically indicated by their clinical care team.
89332373|NCT05789680||Parathyroid carcinoma among patients undergoing surgical treatment of primary hyperparathyroidism|All adult (18 years old and older) patients registered in EUROCRINE® database that underwent surgery for primary hyperparathyroidism and received histopathologic diagnosis of parathyroid carcinoma from 2015 till 2021 will be included
89332374|NCT05789459||Stapler group|closure with a stapler
89332375|NCT05789459||Hand-sewn group|closure with suture
89332376|NCT05789186|Experimental|Test group|CAVO aromatherapy patch at 3% concentration （continue sniffing for 15 minutes ）and Fluoxetine Hydrochloride mimetic （20mg/tablet，once a day，10mg each time）
89332377|NCT05789186|Active Comparator|Positive drug group|CAVO aromatherapy patch at 0.1% concentration（continue sniffing for 15 minutes ） and Fluoxetine hydrochloride tablet （20mg/tablet，once a day，10mg each time)
89332378|NCT05789186|Sham Comparator|Blank control group|Concentration 0.1% CAVO aromatherapy patch（continue sniffing for 15 minutes）and fluoxetine hydrochloride mimetic（20mg/tablet，once a day，10mg each time）
89332379|NCT05789160|Experimental|the MIED group|provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
89332380|NCT05789160|No Intervention|the waiting-list group|no treatment.
89332381|NCT05789108|Other|Biomarkers and long term complications in DVT patients|Patients with DVT will be enrolled in the study during their hospitalization at the ED. The enrolled patients will have 4 follow-up visits, 1) during the first 14 days after diagnosis, 2) after 3 months, 3) after 12 months and 4) 24 months after the time of diagnosis.
89332382|NCT05789030|Experimental|Group I|Patients are treated with Diprospan (1mL im) and then with iguratimod (25mg bid) for 12 months
89332383|NCT05789030|Experimental|Group II|Patients are treated with Diprospan (1mL im) and then with leflunomide (10-20mg qd) for 12 months.
89332384|NCT05789030|Experimental|Group Ⅲ|Patients are treated with prednisone (20 mg qd and taper to ≦ 5mg in 3 months) and leflunomide (10-20mg qd) for 12 months.
89332385|NCT05789017|Experimental|Group I|Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 4 months. Afterwards, patients are treated with low dose mycophenolate (0.5-1g/day) during remission maintenance period for 9 months.
89332386|NCT05789017|Experimental|Group II|Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 4 months. Afterwards, patients are treated with leflunomide (10-20 mg/day) during remission maintenance period for 9 months.
89332387|NCT05788991|Experimental|Dequalinium chloride|Dequalinium chloride 10 mg vaginal tablets
89332388|NCT05788991|Active Comparator|Metronidazole|Metronidazole 500 mg oral tablets
89332389|NCT05788913|Active Comparator|Reference Drug|Healthy participants using intravenous Heparin Sodium Injection, USP (Fresenius Kabi) to assess the pharmacodynamic profile
89332390|NCT05788913|Experimental|Test Drug|Healthy participants using intravenous Heparin Test to assess the pharmacodynamic profile
89332391|NCT05788900|Active Comparator|Reference Drug|Healthy participants using intravenous Heparin Sodium Injection, USP (Fresenius Kabi) to assess the pharmacodynamic profile
89332392|NCT05788900|Experimental|Test Drug|Healthy participants using intravenous Heparin Test to assess the pharmacodynamic profile
89332393|NCT05788835|Experimental|DEB-TACE-HAIC|Drug-eluting bead transarterial chemoembolization Sequential with FOLFOX-based chemotherapy hepatic artery infusion
89332394|NCT05788835|Active Comparator|DEB-TACE|Drug-eluting bead transarterial chemoembolization
89332395|NCT05788822|Experimental|MVA treated group|Oocytes in this groups will be cultured with MVA
89332396|NCT05788822|No Intervention|Control group|Oocytes in this groups will be culture without MVA
89332397|NCT05788770|Experimental|FEops HEARTGuided transcatheter aortic valve implantation|
89332398|NCT05788770|No Intervention|Standard transcatheter aortic valve implantation (no FEops HEARTGuide)|
89332399|NCT05788744|Experimental|A: Experimental|Patients will receive surveillance with liver enzymes, CA 19-9, history, clinical evaluation of signs of recurrence (e.g. weight loss, abdominal pain or fatigue) in combination with analysis of plasma ctDNA (90 ml blood drawn per visit) every 3 months until disease progression or up to 36 months. If plasma ctDNA is positive the patient will have a CT scan (thorax and abdomen) and EUS every 3 months for 2 years and then every 6 months until disease recurrence or up to 36 months. If plasma ctDNA is negative the patient will have CT scan of thorax and abdomen and EUS every 6 months until disease recurrence or up to 36 months. Plasma eccDNA will be determined at the same time as ctDNA but a positive eccDNA result will not be informed to the patients.
89332400|NCT05788744|No Intervention|B: Control|Patients will receive surveillance until recurrence according to current Danish guidelines with liver enzymes, history and clinical evaluation every 3 months for two years and then every 6 months until 36 months. If an increase in liver enzymes is seen or clinical signs of recurrence (e.g. weight loss, abdominal pain or fatigue) patients will have a CT scan of thorax and abdomen. Blood samples (90 ml blood per visit) will be collected at the same time points as blood is drawn for liver enzymes (i.e. every 6 months until 36 months) for later analysis at the end of study of plasma ctDNA and eccDNA. These measurements will serve to enable post-trial comparison of oncological outcomes for the two arms.
89332401|NCT05788705|Active Comparator|"apigenin and glycyrrhizin"|Patients will receive one capsule contains 10 mg of apigenin (Matricaria chamomilla L extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months
89523544|NCT04445935|Active Comparator|Standard treatment|"In this arm the patients will be treated according to our standard anticoagulation protocol.~The patients will not be treated with Bivalirudin (the investigational drug)."
88806738|NCT05698654|No Intervention|Control Group|Participants in this arm will undergo the same testing as the intervention groups but will be instructed to continue their usual diet. Participants belonging to the control arm will be given an opportunity to follow a 6-month additional LD program starting at the end of 6 months. This trial makes use of a control group to provide robust evidence on the effects of nutritional interventions on the primary and secondary endpoints.
89332402|NCT05788705|Active Comparator|"boswellic acid and glycyrrhizin"|Patients will receive one capsule contains 200 mg boswellic acid (Boswellia serrata extract) and one capsule contains glycyrrhizin 50(licorice extract) twice daily for 6 months
89332403|NCT05788705|Placebo Comparator|"placebo"|Patients will receive daily two capsules contain placebo for 6 months
89332404|NCT05788614|Experimental|RSA-RV-30|
89332405|NCT05788614|Experimental|RSA-RV-0|
89332406|NCT05788562||Experimental group|Incorporate blood gas analysis indicators in D1-D7, after birth,1 week before and on the day of onset of early complications
89332407|NCT05788562||Control group|Incorporate blood gas analysis indicators in D1-D7,D14,D28after birth and the day of diacharge
89332408|NCT05788549|Experimental|Progressive Relaxation Group|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. The first application was done face to face with the researcher. Individuals were asked to perform subsequent applications at home.Educational booklet describing the progressive relaxation exercises with pictures was given to individuals, and a video prepared by the researcher was uploaded to their mobile phones. Individuals were asked to practice progressive relaxation exercises every day, at least once a day, in a quiet and peaceful environment for 30-minute sessions. The researcher sent reminder SMS messages to individuals twice a week for eight weeks to encourage regular practice of the progressive relaxation exercises. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed
89332409|NCT05788549|Placebo Comparator|Relaxative Music Group|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. Individuals were asked to perform subsequent applications at home.Individuals were provided with a relaxing music file prepared by the researcher and were asked to listen to it at least once a day for 30 minutes in a quiet and calm environment. The researcher also sent reminder SMS messages twice a week for eight weeks to remind individuals. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed to listen to the relaxing music regularly. At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
89332410|NCT05788549|No Intervention|Control Group|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting.The members of this group have not undergone any intervention and continued their routine maintenance, treatment, and follow-up.At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
89332411|NCT05788471|Active Comparator|Conventional treatment group|Twenty patients will receive conventional treatment in the form of superficial heat, ultrasound with freq of 1 MHz, pulsed mode 1:4 for 5 min and stretching exercise to lumbrical muscles of the hand.
89332412|NCT05788471|Experimental|Neurodynamic mobilization therapy group|Twenty patients will receive neurodynamic mobilization therapy (upper limb tension test 1) in addition to conventional treatment.
89332413|NCT05786261|Experimental|experimental group MIRT|Task 1a: Assessing the effect of MIRT on cortical plasticity tested with rPAS Task 1b: Assessing the effect of MIRT on structural cortical plasticity and brain connectivity tested with MRI Task 1c: Assessing the effect of MIRT on movement-related beta modulation Task 1d: Assessing the effects of MIRT on motor skills formation with reaching tasks Task 1e: Assessing the effects of MIRT on EEG correlates of motor skills formation Task 2a: Assessing the effect of MIRT on muscle synergies during gait Task 2b: Assessing the effect of MIRT on muscle synergies during reaching movements Task 3a: Assessing the effect of MIRT on sleep microstructure
89332414|NCT05786261|Active Comparator|control group|EEG con task, Gait Analysis, fMRI, rTMS,
89332415|NCT05785936||Highly sensitized and desensitized kidney transplanted group|Patient that were HLA desensitized for kidney transplantation
89332416|NCT05785936||Highly sensitized and non-desensitized kidney transplanted group|Patient that were not HLA desensitized for kidney transplantation but were highly sensitized and received a kidney graft due to local priority system
89332417|NCT05785936||Healthy donors|
89332418|NCT05784389|Experimental|Low PRAL diet|Experimental: Low PRAL diet Crossover design: 1 arm consisting of three consecutive periods of two weeks (control, intervention and follow up).
89332419|NCT05771415||Grannum placental maturity grade 0 and 1 (low maturity level|Women with low placental maturity grade (group 1, Grannum 0-1)
89332420|NCT05771415||Grannum placental maturity grade 2 and 3 (high maturity level)|Women with high placental maturity grade (group 2, Grannum 2-3)
89332421|NCT05770076|Active Comparator|Probiotic lysate (postbiotic and metabiotic) group|oral, 2 capsules per day (BID) for 3 month treatment
89332422|NCT05770076|Placebo Comparator|Placebo group|placebo, oral, 2 capsules per day (BID) for 3 month treatment
89332423|NCT05769270|Experimental|Peer Navigation and Coping Skills|Participants will receive peer navigation and coping skills to increase PrEP use.
89332424|NCT05769270|Sham Comparator|Treatment as usual|Participants will receive referrals to PrEP and services.
89332425|NCT05755282|Other|Spectrum Advanced Hand Sanitizer Foam|Half of participants will apply Spectrum Advanced Hand Sanitizer Foam followed by Purell Advanced Hand Sanitizer Foam
89332426|NCT05755282|Other|Purell Advanced Hand Sanitizer Foam|Half of participants will apply hand Purell Advanced Hand Sanitizer Foam followed by Spectrum Advanced Hand Sanitizer
89332427|NCT05748769|Experimental|UL group|SIngle session of practicing RM sequence with the UL towards illuminating switches
89332428|NCT05748769|Active Comparator|Switches observation - SO group|Single session of observation of sequence of illuminating switches
89332429|NCT05748769|Active Comparator|(Nature observation -NO group|Single session of observation of nature movies
88806739|NCT05689125|Experimental|Railroaded bougie|An endotracheal tube is loaded onto a bougie posterior to the placement of the bougie into the trachea.
88806740|NCT05689125|Other|Preloaded bougie|An endotracheal tube is loaded onto a bougie prior to initiating laryngoscopy.
89332430|NCT05747807|Experimental|Percutaneous intradiscal radiofrequency|"Standard monitoring ,prone position, sterile prepped and draped No sedation, Fentanyl 0.5-2 mcg/kg IV as needed ATB prophylaxis: ceftriaxone 1 g IV Performed by interventional pain physician, under fluoroscopic guidance 2% lidocaine 5 ml LA using Flextrode introducer kit, Boston Scientific Corporation Using an extrapedicular approach ipsilateral to the prolapse, the Flextrode cannula is advanced to the posterior disc.~The Flextrode electrode is inserted through the cannula. Sensory (50Hz) and motor (2Hz) stimulation, 3 Volts amplitude and 1msec pulse width. Confirm no sensory/motor response.~Lateral, AP, and oblique x-ray views are used to confirm the active tips are fully within the disc Thermal RF: temp 80 ◦C, 4 min Ceftriaxone 75 mg intradiscal injection via the cannula"
89332431|NCT05743140||CMD group, Non-CMD group|CMD group: participants whose CaIMR shows ≥25U. Non-CMD group: participants whose CaIMR less than 25U.
89332432|NCT05730504|Experimental|Mobile app-based self-guided interventions|Participants have access to self-guided, app-based mobile psychological interventions grounded in Cognitive Behavioral Therapy, meditation, mindfulness, journaling, as well as audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
89332433|NCT05730504|No Intervention|No interventions|Participants don't have access to app-based mobile psychological interventions
89332434|NCT05698563|Other|Patient group|Patients with rheumatoid arthritis and forefoot pain.
89332435|NCT05698563|Other|Control group|Patients with other rheumatic diseases and absence of forefoot pain.
89332436|NCT05697471|Experimental|Dienogest|
89332437|NCT05697471|Active Comparator|Danazol|
89332438|NCT05695482|Experimental|Neuromuscular exercise training (NMT)|"The 6-week exercise intervention consists of group sessions of Neuromuscular training supervised by a researcher 3 times per week. Participants will be familiarized with the exercises on a separate day prior to testing.~Each session consists of a 5-minute submaximal warm-up followed by 25 minutes of NM training with closed kinetic chain exercises.~Every 2 weeks, there will be a progression that will be achieved by increasing the level of difficulty of each the exercise. We will take into consideration when an exercise is performed with appropriate sensorimotor control, quality of the performance, minimal exertion and control of the movement. Participants will be given special equipment including a step measuring 20 cm in height, an uneven surface, a slider and an elastic tubing medium load (green) from Thera BandTM, (Akron, Ohio, USA)."
89332439|NCT05695482|Experimental|Progressive Resistance Training (PRT)|"The 6-week exercise intervention consists of group sessions of progressive resistance training supervised by a researcher 3 times per week. Participants will be familiarized with the exercises on a separate day prior to testing.~Each session consists of a 5-minute submaximal warm-up followed by 20 minutes of PRT with an open kinetic chain (no weight-bearing exercises) targeting the abductors' muscles of the hip joint. The exercise intensity will be monitored by the researcher, as determined by the patient's ability to complete three sets of 8-12 repetitions for a given exercise and a Borg Rating of Perceived Exertion (RPE) of 6-8.~Every 2 weeks, there will be a progression achieved by changing the resistance in line with guidelines provided by the American College of Sports Medicine with an elastic tubing heavy load (grey) from Thera BandTM, (Akron, Ohio, USA)"
89332440|NCT05677828||Antagonist - SMART|Women who have had a SMART IVF stimulation cycle with Letrozole after a failed antagonist IVF stimulation cycle between 2010 and 2020.
89332441|NCT05677828||Antagonist - Antagonist|Women who have had an antagonist stimulation IVF cycle after a previously failed antagonist IVF stimulation cycle between 2010 and 2020.
89332442|NCT05670561|Experimental|Esketamine-PCIA(patient controlled intravenous analgesia)|PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.
89332443|NCT05670561|Active Comparator|Sufentanil-PCIA(patient controlled intravenous analgesia)|PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.
89332444|NCT05662566||Chronic pain|Patients with chronic pain and fixed opioid use, undergoing laparotomy with epidural anesthesia as a part of the postoperative analgesic strategy
89332445|NCT05662566||No chronic pain|Patients without chronic pain and without fixed opioid use, undergoing laparotomy with epidural anesthesia as a part of the postoperative analgesic strategy
89332446|NCT05659641|Experimental|Branch-type intraoperative stent system with double branch structure|"Learning curve case group~Experimental: Beijing PerMed branch-type intraoperative stent system with double branch structure."
89332447|NCT05659641|Experimental|Single Branch Structure Stent Graft System single group|Beijing PerMed single branch intraoperative stent system
89332448|NCT05659641|Other|CRONUS® Stent Graft System In Surgical Operation|Control group：CRONUS® Stent Graft
89332449|NCT05658653|No Intervention|Standard Practice|The Control group treats their simulated patients using standard practice and has no introduction to the new CDMT test.
89332450|NCT05658653|Experimental|Chronic Disease Management Test (CDMT)|The intervention will receive information regarding the CDMT test and will be given the test results, whether selected or not, in Round 2 of CPV administration.
89332451|NCT05652218|Experimental|Sequence 1|LB-CRT - Left Bundle Cardiac Resynchronization Therapy, Participants will spend 3 months in this group
89332452|NCT05652218|Experimental|Sequence 2|BiV-CRT - Biventricular Pacing Cardiac Resynchronization Therapy. Participants will spend 3 months in this group
89332453|NCT05650463|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns with darker skin types using Picterus JP.
89332454|NCT05647980|Experimental|TACTIC|"Participants in the TACTIC intervention will be provided a 3-step approach, i.e.~an online information video to inform patients about the cardiovascular risks of antipsychotic use and the procedures of the multidisciplinary meeting~a multidisciplinary meeting with their general practitioner, the primary care nurse, a psychiatrist, and an experience expert to discuss cardiovascular risk and side effect and to provide personalised treatment options~a consultation with their general practitioner to translate treatment options into an individualised treatment plan including lifestyle and medication treatment and monitoring frequency, based on shared-decision making"
89332455|NCT05647980|No Intervention|Care as usual|Care as usual, i.e. renewal of prescriptions for antipsychotics by the general practitioner without multidisciplinary treatment advice and without the use of scheduled and structured monitoring visits.
89332456|NCT05645796|Active Comparator|Fixed group|They received a fixed amount of contrast media prior to CT scan
89332457|NCT05645796|Active Comparator|body composition tailored group|They received a body tailored amount of contrast media prior to CT scan
89332458|NCT05642598|Experimental|Pivot for Vape|A commercially available mobile phone app and program for vaping cessation
89332459|NCT05640297|Experimental|KMC with Massage therapy|Preterm low birth weight babies who will get KMC will also receive massage therapy
89332460|NCT05640297|No Intervention|KMC only|Preterm low birth weight babies who will get KMC only
89332461|NCT05635877|Experimental|Experimental:Esmolol|The treatment group was given esmolol 0.5mg/kg load, 10μg /kg/min continuous pump; Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was >3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
89332462|NCT05635877|Placebo Comparator|Placebo Comparator:normal saline(0.9%)|The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was >3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
89332463|NCT05633940|Experimental|Implementation|The centers that implement PCBH.
89332464|NCT05633940|No Intervention|No implementation|Control centers that do not implement PCBH.
89332465|NCT05629832|Experimental|PTP group|
89332466|NCT05629832|No Intervention|Control group|
89332467|NCT05621512|Experimental|Intervention|"The intervention implies a letter of invitation for a session between the employee, the department manager, and a midwife concerning workplace risk assessment and agreement on feasible work adjustments if necessary. A second session within gestational week 26-28 is scheduled to follow-up and readjust if necessary. A systematic frame for sessions is developed by the research team and conclusions from the sessions are registered within a piloted standardized template.~The employee and the manager can initiate contact with the midwife at any time, e.g in case of new symptoms or discomfort and need for support or guidance. If sick leave is considered, a new session is recommended and may be scheduled at any time.~To ensure transparency of guidance and workplace adjustments for other relevant healthcare professionals, the employee is asked to inform her general practitioner (GP) and midwife of the program."
89332468|NCT05621512|No Intervention|Usual practice|"Hospital pregnancy policy is usual practice and implies a meeting between the pregnant employee and her manager concerning an individual risk assessment. A risk assessment-template can be downloaded from the hospital website.~If minimizing potential risks by adjustments is not possible the employee should be redeployed. If redeployment is not possible the pregnant employee may be absent due to pregnancy related symptoms.~The pregnant employee is requested to inform her GP about agreements."
89332469|NCT05596006|Experimental|ASIMOMMY®|"Experimental:~2 capsules of ASIMOMMY, orally one times daily from days 1 to 7"
89332470|NCT05596006|Active Comparator|Domperidone|Domperidone capsule, one capsule, orally three times daily from days 1 to 7
89332471|NCT05596006|Placebo Comparator|Placebo|Identical 2 capsules of placeb, orally one times daily from days 1 to 7
89332472|NCT05586529|Experimental|Cholecalciferol group|patients will recieve one dose of Vitamin D 200000 IU PO at the time of admission
89332473|NCT05586529|No Intervention|Control|Patients will not recieve any vitamin D before admission
89332474|NCT05575284||Robot-assisted urological surgery|Patients with programmed robot-assisted urological surgery
89332475|NCT05574088|Experimental|apical patency|30 patients will be in apical patency group
89332476|NCT05574088|No Intervention|Control group ( non apical patency)|30 patients will be in control group ( non apical patency)
89332477|NCT05570591|Active Comparator|Active laser|Application of the active 2RT sub threshold laser
89332478|NCT05570591|Sham Comparator|Sham laser|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant)
89332479|NCT05568329|Experimental|Hearing Aid Signal Processing|"Each subject will listen to recordings of music processed by seven different hearing aid brands set to the default Speech in Quiet program and the default Music program. Recordings (hearing aid brand x program x music sample) will be randomized from trial to trial."
89332480|NCT05561582|Experimental|High Intensity Exercise|Participants will complete a knee extension exercise with weight equivalent to 75% of their 1-repetition maximum for 3 sets of 10 repetitions.
89332481|NCT05561582|Experimental|Low Intensity Exercise|Participants will complete a knee extension exercise with weight equivalent to 30% of their 1-repetition maximum for 3 sets of 10 repetitions.
89332482|NCT05561582|No Intervention|Quiet Rest|Participants will sit quietly for two minutes, three times.
89332483|NCT05555745|Experimental|Audio-based behavioral activation intervention|This intervention consists of two audio-based sessions delivered one week apart. The first session lasts approximately 30 minutes, and the second session lasts approximately 15 minutes. The sessions are audio recordings. The first session introduces behavioral activation and provides instruction for how to schedule and engage in positively reinforcing activities. The second session recaps the principles of behavioral activation and guides participants through methods of troubleshooting. After each session, participants are asked to create an activity schedule for the coming week. Then, each day in the week following each session, participants receive an email with a survey asking them to report on their activity and mood in the previous day.
89332484|NCT05555745|Active Comparator|Audio-based self-monitoring intervention|This intervention consists of two audio-based sessions delivered one week apart. The first session lasts approximately 30 minutes, and the second session lasts approximately 15 minutes. The sessions are audio recordings. The first session introduces information about emotion and provides instruction for how to track emotion using self-monitoring. The second session provides more information about emotion and recaps instructions for self-monitoring. Each day in the week following each session, participants receive an email with a survey asking them to report on their mood in the previous day.
89332485|NCT05555303|Other|Amikacin|
89332486|NCT05551286|Experimental|Young Adults Taking Action|The programme is person-centered, goal-oriented, and peer-based and is structured around a 5-day residential stay, an online follow-up after five weeks and a 2-day residential follow-up stay after ten weeks.
89523545|NCT04445935|Experimental|Bivalirudin arm|The patients will be anticoagulated according to the institutional HIT-protocol which uses Bivalirudin as anticoagulant.
89332487|NCT05550935|Experimental|HFNC Group|Healthy subject will perform one Constant Work-Rate Exercise Test at respiratory compensation point as determined by a cardiopulmonary exercise test with High Flow Nasal at 60L/min (without additional oxygen)
89332488|NCT05550935|Sham Comparator|Control Group|Healthy subject will perform one Constant Work-Rate Exercise Test at respiratory compensation point as determined by a cardiopulmonary exercise test with High Flow Nasal at 2L/min (without additional oxygen)
89332489|NCT05549752|Active Comparator|Flecainide|
89332490|NCT05549752|Active Comparator|Amiodarone|
89332491|NCT05546892|Experimental|Full bowel preparation (MBP+OA)|"Rifaximin 400 mg twice daily for three days prior to surgery~Day prior to surgery:~17.00 - 18.00 Macrogol-3350 - 100 g Natrium sulfate - 7,5 g Natrium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Natrii ascorbate - 5,9 g Clear fluids - 1000 ml~18.00 - 19.00 Clear fluids 500 ml~19.00 - 20.00 Macrogol-3350 - 100 g Natrium sulfate - 7,5 g Natrium chloride - 2,691 g Potassium chloride - 1,015 g Ascorbic acid - 4,7 g Natrii ascorbate - 5,9 g Clear fluids - 1000 ml~20.00 - 21.00 Clear fluids 500 ml"
89332492|NCT05546892|Active Comparator|No bowel preparation|No bowel preparation (enema of not more then 500 ml is allowed prior or during surgery)
89332493|NCT05540691|Experimental|group 1|Intraoperative intervention with noise-canceling earphones was performed to isolate the noise
89332494|NCT05540691|No Intervention|group 2|After general anesthesia, the intervention of wearing noise-canceling earphones was not given
89332495|NCT05539859|Experimental|Experimental Arm|Endoscopic surgery
89332496|NCT05539859|Active Comparator|Control Arm|Medical management
89332497|NCT05538286|Experimental|transcranial ultrasonography through sonolucent cranioplasty|All surgical procedures and implants in this protocol are standard of care.
89332498|NCT05537116|Experimental|Personalized Feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
89332499|NCT05537116|Experimental|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
89332500|NCT05537116|Active Comparator|Information only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
89332501|NCT05535192|Active Comparator|HEALTH EDUCATION AND SUPPORT CONTROL GROUP|The research study procedures include screening for eligibility and a baseline visit to collect measurements and questionnaires. After the baseline appointment, participants randomized into the Heath Education Support Program will receive a tablet from the study that is pre-loaded with material to help support them during chemotherapy. The tablet materials will include supportive care and resources that focus on movement (light stretching and gentle yoga), soothing music, meditation/mindfulness, and recipes/cooking demos. Participants in this arm will be asked to fill out questionnaires at the start of each chemotherapy cycle to indicate any side effects from chemotherapy and the amount of time they spend engaging with the tablet. At the end of participants' chemotherapy, they will be asked to complete end-of-study measures.
89332502|NCT05535192|Experimental|THRIVE: EXERCISE INTERVENTION WITH PROTEIN INTAKE SUPPORT|The research study procedures include screening for eligibility and a baseline visit to collect measurements and questionnaires. After the baseline appointment, participants randomized into the THRIVE Exercise and Diet Intervention will work with a coach to gradually build exercise and stay active during chemotherapy treatment. Participants will work with an exercise coach to reach the muscle strengthening and aerobic exercise goals of the study. Participants will also consult with a dietician to ensure adequate protein intake during the study. Participants in this arm will be asked to fill out questionnaires at the start of each chemotherapy cycle to indicate any side effects from chemotherapy. At the end of participants' chemotherapy, they will be asked to complete end-of-study measures.
89332503|NCT05532345||Development group, retrospectively collecting|The training set includes 80% of the development dataset from Beijing Friendship Hospital (Retrospectively collecting DILI 649 cases and AIH 180 cases in total)
89332504|NCT05532345||Validation group, retrospectively collecting|"The internal validation group includes 20% of the development dataset from Beijing Friendship Hospital (Retrospectively collecting DILI 649 cases and AIH 180 cases in total).~External validation groups include Fifth Medical Center of Chinese PLA Medical Center(Retrospectively collecting DILI 585 cases and AIH 400 cases in total), Beijing You'an Hospital (Retrospectively collecting DILI 266 cases and AIH 100 cases in total) and additional seven tertiary hospitals throughout China (Retrospectively collecting DILI 182 cases and AIH 92 cases in total, including Tianjin Second People's Hospital, Heilongjiang Provincial Hospital, Affiliated Hospital of Qingdao University, the First Affiliated Hospital of Xiamen University, Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous Region, Lanzhou University Second Hospital, Qinghai Provincial People's Hospital)."
89332505|NCT05532345||Real-World validation group, prospectively and retrospectively collecting|Real-World validation data will be prospectively and retrospectively collected from Beijing Friendship Hospital (78 cases for DILI and 51 cases for AIH)
89332506|NCT05502354|Experimental|patients with TDT removal guided by postoperative CRP trajectory|
89332507|NCT05499832|No Intervention|Best Medical Treatment (standard of care)|Patients will receive standard of care as per current ESO guidelines.
89523546|NCT03373643|Experimental|Patient suspected for NAFLD|
88806741|NCT05689125|Active Comparator|Stylet|A stylet is placed within an endotracheal tube prior to initiating laryngoscopy.
88806742|NCT05689125|No Intervention|Naked endotracheal tube|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation without assistance of stylet or bougie.
88806743|NCT05684939||cancer patients and cancer survivors|answer to an online questionnaire
89332508|NCT05499832|Experimental|Intra-arterial Tenecteplase|Patients will receive intra-arterial administration of Tenecteplase using a standard approved microcatheter.
89332509|NCT05494164|Experimental|Study group|Nigella sativa nasal oil drops
89332510|NCT05494164|Other|Control group|standard treatment
89332511|NCT05487703||Clinical characteristics|clinical characteristics of adult patients with Rheumatoid Arthritis (RA) initiating tofacitinib
89332512|NCT05485857|Experimental|Arrangement group|Experimental group: After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterwards, close the abdomen.
89332513|NCT05485857|No Intervention|No arrangement group|No arrangement group: After completing the routine operation of laparoscopic-assisted colorectal cancer surgery, the abdomen was closed directly.
89332514|NCT05483972|Experimental|Whole Prediabetes Diet Intervention|The diet intervention will consist of weekly food deliveries for a total of 2-weeks. The intervention will consist of a weekly individual counseling sessions led by the team's registered dietitian nutritionist (RDN). Prior to beginning the intervention, an initial individual and/or family meeting with the RDN will be scheduled. The focus of the meeting will be for the RDN to provide information about diet instruction, meal preparation/planning, and individual and family goal setting. Meetings can occur in person, via a secure zoom videoconference, or via telephone (per participant preference) and must take place with the index parent present, as they will be responsible for taking the lead of the diet intervention or relaying the information to the primary caregiver/spouse/partner in the household who is responsible for meal preparation/cooking. Child/adolescent participants will be instructed by the RDN on how to record their dietary intake (as age-appropriate) using a food diary.
89332515|NCT05467059||Nap-modulated participants|Patients with rises of tinnitus intensity after taking a nap or after a short period of sleep. If possible with a characteristic ON/OFF tinnitus (sometimes they have a tinnitus for several days and then stop for several days also). This condition is determined by previous questionnaire.
89332516|NCT05466942|Other|Controled Hypoxia - Healthy volunteer|Male and female subjects, ranging in pigmentation from light to dark
89332517|NCT05461456|Experimental|OP2101|Treatment with Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
89332518|NCT05460650|Experimental|Receives app|All women in the study will receive access to the app.
89332519|NCT05459779|Experimental|Electric wheelchair with activated assistance module|This condition will be achieved in a standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance, in a random order established upstream.
89332520|NCT05459779|Other|Electric wheelchair with assistance module not activated|This condition will be achieved in a standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activated assistance, in a random order established upstream.
89332521|NCT05455814|Experimental|Wellness and Meditation-Based Intervention|Shambhavi Mahamudra Kriya: a multi-component 21-minute meditation that incorporates a combination of different breathing patterns and meditative components.
89332522|NCT05455814|No Intervention|Control|Control Group: selected to be age, gender and education level matched with the intervention group and will be asked to continue their daily routine while completing surveys at each timepoint.
89332523|NCT05441930|Experimental|Levofloxacin Ocular Implant|Biphasic levofloxacin antibiotic implant
89332524|NCT05441930|Active Comparator|Control|Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
89332525|NCT05438732|Experimental|SING-IMT Implanted|the implanted eye will be the study eye which receives the SING-IMT. Implantation will occur during routine cataract surgery using a proprietary delivery system (loading cartridge and injector), via an approximately 6.5mm incision
89332526|NCT05435118|No Intervention|EMONO (usual care administered to all the children undergoing painful procedures)|Use of the Equimolar Mixture of Oxide Nitrous and Oxygen (EMONO) with facial mask. In the hospital EMONO is administered to all the children for procedure pain control.
89332527|NCT05435118|Experimental|EMONO + audiovisuals tool|Use of the Equimolar Mixture of Oxide Nitrous and Oxygen (EMONO) with facial mask and vision of audiovisual toll with smartphone or tablet. The intervention is represented by the audiovisual tool.
89332528|NCT05424068|No Intervention|Standard best cancer practice|All participants (intervention arms 1 and 2, and control) will receive usual oncology care by their health care providers which includes recommendations for general aerobic and resistance exercise. Participants in the control group will be of recommended to work towards the recommended 90 minutes moderate to vigorous aerobic exercise, and two days a week of large muscle group strength training as recommended by the ACSM. A general brochure will be provided to all control participants providing education in line with current standard of care. This safety precautions noted these will be indicated brochure will have an open text field on the back which will allow the kinesiologist to provide and general advice at each time point. If there are particular here. Participants in all study arms may also be referred by treating health care providers to usual supportive care or early palliative care services at any time deemed necessary, and will be recorded as part of monthly data collection.
89523547|NCT03385057|Active Comparator|Ibuprofen Arm|
89523548|NCT03385057|Active Comparator|Acetaminophen|
89523549|NCT02051309|Experimental|Guanfacine 6mg/day ER|Guanfacine 6mg/day extended release
88806744|NCT05672173|Experimental|Treatment (nivolumab, ibrutinib, chemotherapy, liso-cel)|Patients receive ibrutinib PO, nivolumab IV, fludarabine IV, cyclophosphamide IV, and liso-cel IV on study. Patients also undergo apheresis, PET/CT, biospecimen collection, and bone marrow biopsy on study. Patients may receive low-moderate intensity chemotherapy in combination with the study induction therapy per treating physician discretion with approval of study principal investigator.
89523550|NCT02051309|Placebo Comparator|Placebo|Placebo matching capsule
89523551|NCT03373565|Active Comparator|Radial|Coronary angiography using radial approach
89523552|NCT03373565|Experimental|palmar|Coronary angiography using palmar approach
89332529|NCT05424068|Experimental|In-person Intervention arm|The in-person intervention arm is an 8-week program and four week short maintenance period. This includes 1 hr of in-person, group-based exercise guided by a qualified exercise professional followed by 1 hr of in-person, group based, self-management education provided by a rehabilitation expert to occur immediately following the exercise session. Each participant is given a FitBit® to track steps, heart rate and sleep. Each site (i.e., Toronto and Vancouver) will run independent, in-person exercise and educational programs based on local referrals. Self management sessions include 8 high priority topics for advanced cancer patients including: 1) goal setting, 2) managing pain, 3) reducing fatigue and improving sleep, 4) boosting brain health, 5) eating and cooking for wellness, 6) managing emotions, 7) being mindful, and 8) planning for the future. Education sessions will be run by local experts at each site.
89332530|NCT05424068|Experimental|Virtual Intervention arm|The virtual intervention arm will be an 8-week program plus four week short maintenance period but will include two separate 1 hour sessions per week. This includes: 1) 60 minutes of virtual, group-based, synchronous exercise over a virtual secure platform; and, 2) A separate 60 min virtual synchronous education session provided on a separate day (to prevent virtual fatigue). 3) Encouragement to participate in a home program the other days of the week, striving for the recommended 90 min of moderate to vigorous aerobic exercise and 2 days of week or resistance exercise. The virtual intervention group will combine participants across both study locations and run sessions when sufficient numbers are recruited. Self-management education content will be unchanged to the in-person sessions but conducted over a virtual platform (i.e., videoconferencing) with participants also attending virtually.
89332531|NCT05415527|Other|patients with inoperable high-grade ovarian carcinoma|Evaluation of sarcopenia in patients with inoperable high-grade ovarian carcinoma as part of optimised management
89332532|NCT05405829|Active Comparator|Control group|Conventional information received by caregivers. The speech therapist comes to the room to pass the Volume viscosity exploratory method test (V-VST) Test and after confirming dysphagia, informs the patient of the test result and delivers a booklet of recommendations.
89332533|NCT05405829|Experimental|Intervention group|A 45-minute session, hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
89332534|NCT05394727|Experimental|Needle-free injection first group|Use needle-free syringe for insulin injection in patients for 2 weeks, then replace it with conventional insulin pen injection for another 2 weeks.
89332535|NCT05394727|Other|Traditional insulin pen first group|Use conventional insulin pen for insulin injection in patients for 2 weeks, then replace it with needle-free syringe injection for another 2 weeks.
89332536|NCT05391243|Other|Follicular phase|LLETZ performed during the follicular phase of the menstrual cycle
89332537|NCT05391243|Other|Luteal phase|LLETZ performed during the luteal phase of the menstrual cycle
89332538|NCT05378048|Experimental|PDO-guided treatment|"A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO."
89332539|NCT05378048|Experimental|standard of care|the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
89332540|NCT05376540|Other|Direct gallbladder injection|2.5 mg of ICG will be injected directly into gallbladder intraoperatively.
89332541|NCT05376540|Other|2.5 mg intravenously|2.5 mg will ICG will be injected intravenously 1 hour prior to surgery.
89332542|NCT05376540|Other|2.5 mg intravenously + direct gallbladder injection|2.5 mg ICG will be injected intravenously 1 hour prior to surgery and another 2.5 mg ICG will be injected directly into the gallbladder intraoperatively.
89332543|NCT05376540|Other|5 mg intravenously|5 mg ICG will be injected intravenously 0-8 hours prior to surgery.
89332544|NCT05374837|No Intervention|Control group|The control group will not receive any intervention. After the endline data collection is completed, the intervention will be delivered to the control group.
89332545|NCT05374837|Experimental|Infant and young child feeding (IYCF) voice messaging intervention|The voice messaging intervention group will receive voice/text messages for a period of 16 weeks.
89332546|NCT05344898|Experimental|Subscap Tenotomy|
89332547|NCT05344898|Experimental|Subscap Repair|
89332548|NCT05336162|Experimental|Patients with non-cavitated pits and fissures in permanent molars will be treated with BeautiSealant|Young adults (16-22 y) who have existing pits and fissures that are anatomically deep and caries susceptible or with Stained pits and fissures with minimum decalcification of opacification and no softness at the base of the fissure (ICDAS 1 and 2).
89332549|NCT05336162|Active Comparator|Patients with non-cavitated pits and fissures in permanent molars will be treated with UltraSeal XT|Young adults (16-22 y) who have existing pits and fissures that are anatomically deep and caries susceptible or with Stained pits and fissures with minimum decalcification of opacification and no softness at the base of the fissure (ICDAS 1 and 2).
89332550|NCT05332860||Immediate Extubation or IE|patients were extubated in the operating room (OR) or in 6 hours after surgery
89332551|NCT05332860||Early Extubation or EE|patients were extubated within 6-48 hours of admission to the ICU
89332552|NCT05332860||Delayed Extubation or DE|patients were extubated sometime after 48 hours or not extubated
89332553|NCT05324553||Tissue Collection|Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
88806745|NCT05660096|No Intervention|Patient with Cerebral Palsy, no intervention|Gait analysis of cerebral palsy patients without any intervention.
89332554|NCT05324553||Blood Collection|Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional testing
89332555|NCT05324553||Buccal Swab|Buccal swab may be requested, if necessary, to generate germline data.
89332556|NCT05323370||Patientes with lymphangioleiomyomatosis|no intervention administered. Recruitment in pneumology department
88806746|NCT05660096|Active Comparator|Patient with Cerebral Palsy, with sleeve|Gait analysis of cerebral palsy patients while wearing neural sleeve.
89332557|NCT05323370||Patientes with tuberous sclerosis complex without Lymphangioleiomyomatosis|no intervention administered. Recruitment in neurology department
89332558|NCT05323370||Healthy women volunteers|no intervention administered. Recruitment in clinical investigation centre
89332559|NCT05322525|Experimental|ON101 Cream|"Single arm of VLU group for ON101 Cream~Test drug:~Name: ON101~Dosage form: Topical cream~Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~Dosing schedule: Apply once a day"
89332560|NCT05321771|Experimental|Family caregiver application of HELP principles|The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. The patient will be assessed daily by means of the Confusion Assessment Method (CAM) and the 4 'A's test (Arousal, Attention, Abbreviated Mental Test - 4, Acute change) (4AT) to determine delirium incidence.
89332561|NCT05311150|Active Comparator|Narrow band imaging bronchoscopy|The narrow band imaging mode uses two narrow bands of light with wavelengths of 390-445 nm and 530-550 nm.
89332562|NCT05311150|Active Comparator|White light bronchoscopy|The white light bronchoscopy mode uses the entire range of white light wavelengths, 400-700 nm.
89332563|NCT05305521||Injectable TSFE|partially edentulous patients needing unilateral sinus floor elevation (residual crestal height <5 mm) for the placement of a single implant
89332564|NCT05301907||Health Care Professionals (HCPs)|HCPs who prescribe, monitor and oversee the management / or provide in person medical supervision of patients on Mayzent (siponimod).
89332565|NCT05301907||Patients/Caregivers|Patients/Caregivers of patients who are taking Mayzent (siponimod) to treat their MS and according to the prescription of their neurologists across EU markets that will be included in the launch program
89332566|NCT05295342|Experimental|Girls-only intervention arm|Schools in this arm will receive only the girls intervention.
89332567|NCT05295342|Experimental|Girls and Boys intervention arm|Schools in this arm will receive both the girls and boys intervention.
89332568|NCT05295342|Active Comparator|Control|The control arm will receive the standard school-based Life Orientation curriculum.
89332569|NCT05295238|Experimental|Compass Course|Four groups of up to 12 participants (48 total) will receive the study intervention during Spring and Fall 2022. All participants will complete study questionnaires before and after the sessions.
89332570|NCT05285969|Experimental|Motivational interview|Motivation Interview program with standard care
89332571|NCT05285969|Active Comparator|Standard care group|Standard care
89332572|NCT05274412|Active Comparator|Control group|Participants in this group will receive protocolized hemodynamic management based on advanced hemodynamic monitoring and dynamic parameters.Keep pulse pressure variation >12%; keep cardiac index >2L/min/cm^2; keep mean arterial pressure > 65mmHg.
89332573|NCT05274412|Experimental|HPI group|Participants in this group will receive protocolized hemodynamic management based on advanced hemodynamic monitoring, hypotension prediction index (HPI), and dynamic parameters.Keep HPI <85; pulse pressure variation >12%; keep cardiac index >2L/min/cm^2; keep mean arterial pressure > 65mmHg.
89332574|NCT05273970|Experimental|Behavioral testing under intracranial monitoring|Patients will undergo behavioral tasks while being monitored by intercranial electrodes
89332575|NCT05273216||Observational Study (no different study arms)|Prospective, longitudinal, multicenter, observational study to investigate hemodynamic changes (by TCD and perfusion MRI) and blood biomarkers as predictors of reperfusion injury / intracranial hemorrhage after stroke thrombectomy of the anterior cerebral circulation
89332576|NCT05268926|Placebo Comparator|Placebo|
89332577|NCT05268926|Active Comparator|Dapagliflozin 10mg/day|
89332578|NCT05267366|Experimental|Chemothreapy with PD-1 inhibitor and bevacizumab|PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Carboplatin 5 AUC /cisplatin 75 mg/m2, iv day 1 Pemtrexed 500 mg/m2, iv day 1 Bevacizumab 15 mg/m2, iv day 1 as induction therapy every 21 days a cycle for 4 cycles, PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Bevacizumab 15mg/m2, iv day 1 every 21 days a cycles as maintenance treatment for 31 cycles or 2 years.
89332579|NCT05267366|Active Comparator|Chemothreapy with PD-1 inhibitor|PD-1 inhibitor (pembrolizumab) 200mg iv day 1 Carboplatin 5 AUC /cisplatin 75 mg/m2, iv day 1 Pemtrexed 500 mg/m2, iv day 1 as induction therapy every 21 days a cycle for 4 cycles, PD-1 inhibitor (pembrolizumab) 200mg iv day 1 every 21 days a cycles as maintenance treatment for 31 cycles or 2 years.
89332580|NCT05267288|Experimental|afatinib plus bevacizumab|afatinib 40mg oral continually bevacizumab 15mg/kg, iv day 1, every 21days until disease progression, untolerated toxicities of patient death.
89332581|NCT05266118||Former ICU patients|Participants is former ICU patients, immediately after transferred from ICU to a hospital ward. At least one of these criteria is needed for the participation in the study: ICU stays > 24 hours; ventilatory support; transferals to other ICU < 24 hours; continuous infusion of vasoactive substances. In addition, to be included, the patients must be more than 18 years of age; understand and be able to write and read Norwegian; be able to communicate verbally; not have a manifest cognitive deficit; and not being readmitted to ICU < 72 hours
89332582|NCT05246605|Experimental|From supine to prone to supine position|Prone position
89332583|NCT05223530||Prevention of Pre-eclampsia and Intrauterine Growth Restriction (PREDO)|"The PREDO study is a cohort study that was started in 2005 in the Helsinki metropolitan area and Northern Karelia. In 2005-2009, it recruited a total of 4,777 women in the early pregnancy. Almost all subjects participated in stress monitoring during pregnancy. In addition, some mothers participated in either genetic, ultrasound, or drug research to develop methods for predicting and preventing pre-eclampsia and fetal growth retardation, and for identifying related factors.~Some key objectives have been to determine whether the physical and mental well-being of the pregnant women could be relevant with hereditary factors for the course of pregnancy and the subsequent physical and mental development and health of the child.~The previous follow-up phases have been performed 2 weeks and 6 months after the birth in 2006-2011 and at the age of approximately 2-6 and 7-12 years. More than 2,500 families participated in the most recent follow-up phase. Now it is 11-17 years of follow-up."
89523553|NCT00372073|Active Comparator|Arm 1 with seliciclib|Oral seliciclib at 1200mg b.i.d. for 3 consecutive days as an outpatient beginning on day 1 every 2 weeks for 3 cycles as run-in. Patients (randomized) continue on treatment if derived clinical benefit during run-in period.
88806747|NCT05659056|Experimental|Pyrotinib, trastuzumab, paclitaxel-albumin|
89332584|NCT05223530||Finnish Gestational Diabetes Prevention (RADIEL)|"The RADIEL study is a randomized multicenter study that was launched in 2008 in Helsinki, Espoo, Vantaa and Lappeenranta. Between 2008 and 2011, we recruited a total of 729 women for gestational diabetes prevention research. Subjects either planned to become pregnant or were in early pregnancy at the time of the study. Subjects were randomized to either receive diet and exercise intervention (active group) or to continue with normal counseling follow-up (control group). Study visits occurred every three months before pregnancy (if recruited before pregnancy), once in each trimester of pregnancy, and at 6 weeks, 6 months, and 12 months after delivery. The effectiveness of the intervention was measured with a variety of metrics.~In 2013-2017, we invited mothers and children who participated in the RADIEL study to a 5-year follow-up of the project, and nearly 350 mother-child pairs participated. Now it is 11-17 years of follow-up."
89332585|NCT05218629|Experimental|Anlotinib， PD-1inhibitor|Anlotinib 8-14 mg, oral, once a day for 14 days every 3 weeks. PD-1 inhibitor (Pembrolizumab) 200mg iv day1, every 3 weeks
89332586|NCT05214651|Experimental|novel double row group|This is the experimental group, and 26 participants will be enrolled, a novel double row technique will be using to repair the large - massive rotator cuff tears in in this group.
89332587|NCT05214651|Active Comparator|suture bridge double row group|This is the control group, and 26 participants will be enrolled, a suture bridge double row technique will be using to repair the large - massive rotator cuff tears in in this group in routine.
89332588|NCT05205785|Experimental|Human Milk Oligosaccharide (HMO) mix|The HMO blend to be used in this trial is a mix of the three milk oligosaccharides produced by fermentation of lactose. The blend is provided as white powder and mixed in a single serve stick packs containing 5.5 g of HMOs. The final product contains less than 0.03 g lactose per serving. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
89332589|NCT05205785|Placebo Comparator|Placebo|The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
89332590|NCT05205330|Experimental|30 mg (Dose Level 1)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 30 mg twice a day for 14 days
89332591|NCT05205330|Experimental|90 mg (Dose Level 2)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days
89332592|NCT05205330|Experimental|180 mg (Dose Level 3)|14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 180 mg twice a day for 14 days
89332593|NCT05203653|Experimental|All participants|All participants will undergo two separate testing sessions
89332594|NCT05200182|Other|Study A|Validation of the reward system-related fMRI task, as determined by an increased activation on the brain reward structure (striatum) under the task.
89332595|NCT05200182|Experimental|Study B - Neurofeedback|"The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the volunteer will have to increase the brain activity of his/her dlPFC using a visual gauge representing the activity level of his/her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
89332596|NCT05200182|Sham Comparator|Study B - Control|In the control group with neurofeedback sham, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy the participant tries to implement is not correlated with the visual feedback provided by the gauge.
89332597|NCT05196763|Experimental|Supplemental Nutrition Assistance Program-Education|"This group will receive the core content of the Supplemental Nutrition Assistance Program-Education over the 10-week intervention period."
89332598|NCT05196763|No Intervention|Control|"This group will not receive the Supplemental Nutrition Assistance Program-Education during the intervention period nor throughout the study (1 year)."
89332599|NCT05191667|Experimental|Patients with unresectable locally advanced/locally recurrent esophageal cancer|Patients will receive AN0025 orally once daily (QD) and chemoradiotherapy followed by the maintenance of AN0025
89332600|NCT05185128|No Intervention|Control arm|Typically developing control participants will undergo cognitive assessments and MRI imaging 16 weeks apart with no intervention in between.
89332601|NCT05185128|Experimental|Patient arm|Both ASD and SSD participants will undergo cognitive assessments and MRI imaging pre- and post- the 16-week PEERS social skills intervention.
89332602|NCT05182710|Experimental|Stress Inoculation Training|Intervention Arm
89332603|NCT05182710|Active Comparator|Alternative Training|Best practice/control
89332604|NCT05177653|Experimental|GIPRA|
89332605|NCT05177653|Experimental|GLP-1RA|
89332606|NCT05177653|Experimental|GIPRA + GLP-1RA|
89332607|NCT05177653|Placebo Comparator|Saline|
89332608|NCT05172323|Experimental|3DCT-guided group|PCI guided with 3DCT results and IVUS
89332609|NCT05172323|Placebo Comparator|Angiography-guided group|PCI guided by operator and IVUS
89332610|NCT05164718|Experimental|Exercise group|
89332611|NCT05164718|Other|Control group|
89332612|NCT05156515|Experimental|Imaging cohort|All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-THP-APN09 PET/CT scans.
89332613|NCT05152524|Experimental|Treatment|Mechanical thrombectomy with Tigertriever 13 EVT + MM (without thrombolysis).
89332614|NCT05152524|No Intervention|Control|Medical Management alone (without thrombolysis).
89332615|NCT05140187|Experimental|CMV-TCR-T cells|The patients with CMV infection after HSCT will receive one to three infusions of donor-derived CMV-TCR-T cells, with the escalated dose ranging from 1×10^3/kg to 5×10^5/kg CMV-TCR-T cells per dose.
89332616|NCT05112263|Active Comparator|Group A|Group A: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks
89332617|NCT05112263|Experimental|Group B|Oral Tofacitinib 10 mg TDS for 3 days, and then 10 mg BD to complete 8 weeks followed by 5 mg BD till follow-up (14 weeks)
89332618|NCT05104281|Experimental|study drug|osimertinib 80 mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days
89332619|NCT05098015|Experimental|Intervention|8-session group intervention to train participants to engage in HIV prevention advocacy.
89332620|NCT05098015|No Intervention|Usual care control|Participants will receive HIV usual care, and no added intervention.
89332621|NCT05092282||TBI Patients|TBI participants 13 to 45 years of age, recruited from patients at a clinical research facility who present with head trauma. Clinical evaluation for the patient can be positive (target condition present) or negative (target condition absent) for mTBI. Enrollment is to occur within 2 weeks of the incident injury.
89332622|NCT05092282||Controls|Participants should not be part of the Intended Use Population. Subjects that present to the hospital, clinic or emergency department, either as a patient or non-patient, with no history of head trauma.
89332623|NCT05076591|Experimental|IMM2902|"IMM2902 Phase 1a Dose escalation: 0.03, 0.1, 0.25, 0.5, 1.0, 1.5, and 2.0 mg/kg through intravenous administration weekly up to 48 weeks.~Phase 1b Dose expansion: A disease-specific dose expansion study in patients with locally advanced (unresectable) and/or metastatic breast with HER2-overexpression (Cohort 1) or HER2-low (Cohort 2), gastric/esophageal/gastroesophageal junction (GEJ) cancer with HER2-overexpression (Cohort 3) or HER2-low (Cohort 4) and other solid tumors with HER2-overexpression (Cohort 5) is aimed at further defining safety and characterizing efficacy. Dose expansion is through intravenous administration weekly up to 48 weeks."
89332624|NCT05072249||lay person provided with take home naloxone|Naloxone all forms
89332625|NCT05070338|Experimental|Guideline-Based Nudges|
89332626|NCT05070338|Experimental|Peer-Based Nudges|
89332627|NCT05070338|No Intervention|Control|
89332628|NCT05067868|Experimental|Replagal|Participants with fabry disease will receive Replagal 0.2 milligram per kilogram (mg/kg) intravenous infusion on Day 1 and every 2 weeks up to Week 51.
89332629|NCT05054296|Active Comparator|Group I (education exercise packet, FitBit)|Patients receive general education exercise packet with instruction to exercise regularly for up to 150 minutes weekly. Patients also wear a FitBit daily over 16 weeks.
89332630|NCT05054296|Experimental|Group II (exercise program FitBit)|Patients participate in supervised and self-directed exercise sessions over 60 minutes BIW for up to 16 weeks. Patients also wear a FitBit daily over 16 weeks.
89332631|NCT05048017|Experimental|Regorafenib plus PD-1 inhibitor|"Regorafenib (BAY 73-4506, Stivarga®) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF).~Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma.~Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers.~Pembrolizumab (Keytruda) the programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells."
89332632|NCT05046951|Active Comparator|Web arm|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
89332633|NCT05046951|Active Comparator|Print Arm|The Should I Screen print-based education (included with this IRB protocol) will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
89332634|NCT05040984||solifenacin|
89332635|NCT05040984||mirabegron|
89332636|NCT05038930|Experimental|Intervention protocol|"Phase 1. The patient will be positioned in a supine position for 20 minutes on the Sara Combilizer®. When necessary, the head of the patient can be elevated to a maximum of 30 degrees during the 20 minutes baseline measurements.~Phase 2. The patient will be positioned in a seated position for 10 minutes with the trunk and head elevated to at least 70 degrees.~Phase 3. The patient will be moved to the standing position for 20 minutes with an elevation angle of the Sara Combilizer of at least 70 degrees. If patients become haemodynamically unstable during the seated or standing position, they will be returned to the supine position, and the intervention will be terminated.~Phase 4. The patient is returned to the phase 1 position (supine). Further measurements are made for at least 20 minutes."
89332637|NCT05038930|No Intervention|Sedentary protocol|The sedentary protocol will follow the same four phases as the intervention protocol only the patient will remain in the supine position on the Sara Combilizer®. Ideally, no interventions will occur during the 70-minute protocol. If medications are given or other interventions are necessary, this will be registered.
89332638|NCT05032885|Experimental|A|48-72 hours after hospital admission, following the baseline assessment of the patient, they will begin to receive physiotherapy treatment with respiratory techniques and motor training, adapted at all times to the clinical situation of the patient, until hospital discharge. If the patient's clinical condition worsens, treatment will be temporarily suspended until the patient improves to allow resumption of treatment.
89332639|NCT05032885|No Intervention|B|48-72 hours after admission to the hospital, after the patient's baseline assessment, the patient will not receive physiotherapy and the usual referral to the Rehabilitation Service for physiotherapy treatment of hospitalized patients will be followed, if the patient's physician considers it necessary and requests it.
89332640|NCT05032378||People with movement disorders|Adults with acquired movement disorders secondary to neurological injury.
89332641|NCT05032378||Professionals|Professionals providing physical or occupational therapy to participants with acquired movements disorders.
89332642|NCT05032274|Experimental|Single group|The study will include one group and each participant will perform home-based exercise for 8-weeks.
89332643|NCT05022602|Experimental|Imagio|Imagio Grayscale only probe and Imagio Duplex probe in ultrasound only and OA modes
89332644|NCT05017272|Active Comparator|Opioid Addiction Recovery Support (OARS)|Data collected post-implementation of OARS in conjunction with medication for opioid use disorder (MOUD) at study sites.
89332645|NCT05017272|No Intervention|Treatment as Usual|Data collected at baseline before OARS in conjunction with MOUD is implemented at study sites.
89332646|NCT05009459|Experimental|eVIS + Treatment as usual (interdisciplinary pain rehabilitation program)|Participant takes part of the unit´s program with an addition of eVIS. eVIS consists of objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
89332647|NCT05009459|No Intervention|Treatment as usual (interdisciplinary pain rehabilitation program)|Participant takes part of the unit´s program with an addition of daily self-report of pain intensity (0-10), affect of pain on daily activities (0-10), and pharmacological consumption.
89332648|NCT05005533||Mild and Moderate Severe Group|Individuals with Chronic Obstructive Pulmonary Disease with a Forced Expiratory Volume greater than 50% of the expected value
89332649|NCT05005533||Severe and Very Severe Group|Individuals with Chronic Obstructive Pulmonary Disease whose Forced Expiratory Volume is less than 50% of the expected value
89332650|NCT04981912|Experimental|Arm A|HDMP + rituximab as a means of debulking prior to initiating venetoclax.
89332651|NCT04974879|Experimental|study drug|osimertinib oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
89332652|NCT04974866|Experimental|study drug|EGFR TKIs
89332653|NCT04972773|Experimental|MM + standard-therapy intervention group|In addition to receiving standard-therapy, participants will be asked to practice MM using a MM app for at least 10 minutes per day from weeks 0 to 8.
89332654|NCT04972773|No Intervention|Standard-therapy control group|Participants randomized to the standard-therapy control group will receive their typical in- or out-patient therapy. This is expected to include small doses of MM.
89332655|NCT04969640||infective keratitis|50 cases with infectious keratitis (any age) either received medical treatment or not, attending to our department will be included in the study.
89332656|NCT04944615|Experimental|Intravascular ultrasound guidance|"All targeted CTO lesions will be examined and documented using a commercially available IVUS catheter (Opticross HD) according to its instructions (if not contraindicated, preoperative vasodilation with nitroglycerin to prevent spasm).~IVUS examination must be performed at least once before and after stent implantation."
89332657|NCT04944615|Active Comparator|Angiographic guidance|The patient will choose the appropriate length and diameter of the stent to be implanted by visual estimation. All commercially available drug-eluting stents (except first-generation DES, such as Taxus, Excel, Partner, Firebird, etc.) can be used. DES with high quality clinical evidence is strongly recommended. The type, diameter, and length of the stent are determined by the surgeon. The stent length should be selected to ensure complete coverage of the CTO lesion. If dissection is present, additional stents are implanted. Repeat angiograms were performed immediately after surgery in the same view as before surgery.
89332658|NCT04933058|Experimental|Opioid-free anesthesia|"IV propofol 1-1.5 mg/kg~IV acetaminophen 1000mg~IV dipyrone 1000mg~IV lidocaine 1mg/kg~IV dexacort 4mg~PR diclofenac 50 mg"
89332659|NCT04933058|Active Comparator|Opioid-supplemented anesthesia|"IV propofol 1-1.5 mg/kg~IV fentanyl 1.5 mcg/kg~IV dipyrone 1000mg~IV lidocaine 1mg/kg~IV dexacort 4mg~PR diclofenac 50 mg"
89332660|NCT04929821|Other|Study Device Treated Group|Treated with the study device, UNITY-B Biodegradable Balloon-Expandable Biliary Stent System.
89332661|NCT04928612|Experimental|Part A -CBP-1018 Dose escalation/Part B- CBP-1018 monotherapy|"Part A: CBP-1018 administrated iv Q 2 W (4 weeks/cycle), utilizing accelerated titration at lower doses (0.03 mg/kg and 0.06 mg/kg) and an i 3+3 design at following doses (0.08 mg/kg,0.10 mg/kg,0.12 mg/kg and 0.14 mg/kg, etc.), respectively.~Part B：Further evaluate the efficacy and safety profile of CBP-1018 in 4 tumor-specific cohorts.Cohort 1 (Metastatic castration resistant prostate cancer, mCRPC)；(Advanced renal cell cancer, RCC); Cohort 3 (Advanced lung squamous cell cancer, LSCC); Cohort 4 (Other advanced solid tumors)."
89332662|NCT04925492|Experimental|Finding Optimal Scan Timing|Group A will receive two PET scans after the radiotracer injection to learn the best timing of the scan for the rest of the people in the study during participant's baseline state. Participants will receive another injection of the radiotracer during a sickle cell crisis and have one PET scan. Receive an optional injection and perform another PET scan 12 months after your sickle cell crisis if there were technical problems the previous scans.
89332663|NCT04925492|Experimental|Scan at Determined Optimal Timepoint|Group B participants will receive an injection of the radiotracer and undergo only one PET scan during a baseline state. Participants will receive another injection of the radiotracer during a sickle cell crisis and have one PET scan. Receive an optional injection and perform another PET scan 12 months after your sickle cell crisis if there were technical problems the previous scans.
89332664|NCT04918810|Experimental|Arm 1: Intermittent docetaxel treatment|suspend docetaxel prior to cycle 4, recommencement based on mGSTP1 monitoring
89332665|NCT04918810|Active Comparator|Arm 2: Standard of Care docetaxel treatment|Docetaxel administered as per Standard of Care: as per clinician recommendation
89332666|NCT04904861|Experimental|Videoconference Intervention group|Brief group videoconferencing attachment-based intervention (sessions once a week for 4 weeks)
89332667|NCT04904861|Active Comparator|Control group|Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks)
89332668|NCT04880395|Experimental|Experimental : Dolutegravir plus Lamivudine|DOVATO: Dolutegravir 50mg/lamivudine 300 mg, FDC, 1 coformulated tablet QD
89332669|NCT04880395|Active Comparator|active comparator : TDF/XTC plus Dolutegravir (XTC stands for lamivudine OR emtricitabine)|"Unit Dose:~TDF/FTC 300/200 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD OR~TDF/3TC 300/300 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD"
89332670|NCT04870593|Experimental|Community receives buddy and gossip treatment, individual informed directly (arm (1))|"(i) Individual elder given vaccination information.~(ii) Individual elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated.~(iii) Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders and to encourage their communities to use the buddy system to get elders vaccinated."
89332671|NCT04870593|Experimental|Community receives buddy and gossip treatment, individual not informed directly (arm (2))|Individual elder lives in community with elders in arm (1).
89332672|NCT04870593|Experimental|Community receives gossip treatment, individual informed directly (arm (3))|"(i) Individual elder given vaccination information.~(ii) Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders."
89332673|NCT04870593|Experimental|Community receives gossip treatment, individual not informed directly (arm (4))|Individual elder lives in community with elders in arm (3).
89332674|NCT04870593|Experimental|Community receives buddy treatment, individual informed directly (arm (5))|"(i) Individual elder given vaccination information.~(ii) Individual elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
89332675|NCT04870593|Experimental|Community receives buddy treatment, individual not informed directly (arm (6))|Individual elder lives in community with elders in arm (5).
89332676|NCT04870593|Experimental|Community receives information, individual informed directly (arm (7))|Individual elder given vaccination information.
89332677|NCT04870593|Experimental|Community receives information, individual not informed directly (arm (8))|Individual elder lives in community with elders in arm (7).
89332678|NCT04849013|Placebo Comparator|Placebo + Placebo|
89332679|NCT04849013|Active Comparator|Mescaline-100 + Placebo|
89332680|NCT04849013|Active Comparator|Mescaline-200 + Placebo|
89332681|NCT04849013|Active Comparator|Mescaline-400 + Placebo|
89332682|NCT04849013|Active Comparator|Mescaline-800 + Placebo|
89332683|NCT04849013|Active Comparator|Mescaline-800 + Ketanserin|
89332684|NCT04836416||Young Adult/Normal|Age 18-35, BMI 18.5-24.9
89332685|NCT04836416||Young Adult/Overweight and Obese|Age18-35, BMI greater than 25.0
89332686|NCT04836416||Adult/Normal|Age 36-50, BMI 18.5-24.9
89332687|NCT04836416||Adult/Overweight and Obese|Age 36-50, BMI greater than 25.0
89332688|NCT04836416||Older Adult/Nornal|Age 51-65, BMI 18.5-24.9
89332689|NCT04836416||Older Adult/Overweight and Obese|Age 51-65, BMI greater than 25.0
89332690|NCT04824768|Experimental|Experimental group|30 min session of Tecar Therapy with functional massage on the rectus femoris, and gastrocnemius. Tecar therapy in the resistive modality (80W) on lower back and hamstrings and in rectus femoris and gastrocnemius with resistive mode (100-120W), and then in capacitive mode(180-200VA)
89332691|NCT04824768|Sham Comparator|Control group|30 min session of Tecar Therapy with functional massage on the rectus femoris, and gastrocnemius. Sham stimulation was provided by only turn on the device but dose is 0.
89332692|NCT04812665||Qualitative sub-study (SS1)|One group of caregivers (n = 10) will engage with the mHealth solution during 1 month. Subsequently, an individual semi-structured interview with each of the participants will proceed to gather user experience qualitative information.
89332693|NCT04812665||Quantitative sub-study (SS2)|A different group of caregivers (n = 55) will engage with the mHealth solution during 3 months. As elaborated in the following sections, a quantitative approach will be adopted to assess different emotional, behavioral and growth parameters before and after engaging with the mHealth solution (pre-post design).
89332694|NCT04808245|Experimental|Standard patient cohort|"All fifteen patients will receive in total 11 doses of H3K27M peptide vaccine starting with standard radiotherapy (RT) and 14 doses of the human anti-PD-L1 antibody Atezolizumab/ Tecentriq® (every three weeks, q3w) starting four weeks after completion of RT. The first 3 vaccines will be given bi-weekly (q2w) in combination with RT. One dose of vaccination will be given at the beginning of recovery (RE) period following RT. Vaccines 5-11 (q6w) will be initiated with Atezolizumab after completion of RE. The H3K27M peptide vaccine is administered in combination with topical Imiquimod that serves as an adjuvant.~For safety reasons, the first three patients will be enrolled sequentially: Each patient will receive the first vaccination at the earliest 28 days after the previous patient has received the first vaccination."
89332695|NCT04799119|Experimental|DAID dog training|'Do As I Do' (DAID) dog training employs operant conditioning to train dogs to copy the behavior of their owner upon hearing the verbal cue 'Do it', similar to teaching a dog the rules behind the game 'Simon Says'. Once this rule has been established and generalized, something that can be achieved in dogs by practicing with only 3-6 initially learned behaviors, owners can demonstrate new actions and use the cue 'Do it' to prompt a matched, imitative, behavioral response.
89332696|NCT04799119|No Intervention|Control|No intervention (waitlisted and will be provided with the experimental condition post-study completion).
89332697|NCT04798430|Experimental|LIB003 (lerodalcibep)|300 mg monthly (Q4W) by subcutaneous injection
89332698|NCT04793581|Other|Single Arm|Single-arm study
89332699|NCT04791423|Experimental|Single dose of GRAd-COV2|1 single IM dose of GRAd-COV2 2 x 10^11 vp plus 1 dose of saline placebo after 21 days
89332700|NCT04791423|Experimental|Double dose of GRAd-COV2|2 repeated (21 days apart) IM dose of GRAd-COV2 1 x 10^11
89332701|NCT04791423|Placebo Comparator|Placebo|Two doses of saline placebo on day 1 and day 22
89332702|NCT04790513|Experimental|LIB003 (lerodalcibep)|300 mg SC Q4W
89332703|NCT04790513|Active Comparator|evolocumab|420 mg SC Q4W
89332704|NCT04790513|Active Comparator|alirocumab|300 mg SC Q4W
89332705|NCT04788459|Experimental|0.5 mg PB|"0.5 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 1 mg~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
89523554|NCT00372073|Placebo Comparator|Arm 2 with placebo control|Randomized to placebo after run-in period.
89332706|NCT04788459|Experimental|1 mg PB|"1 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 2 mg~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
89332707|NCT04788459|Experimental|2 mg PB|"2 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 4 mg~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29"
89332708|NCT04788459|Experimental|2 mg P|"2 mg P (Prime) - Total dose: 2 mg~IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1"
89332709|NCT04786353||COVID positive kids|Children with at least one positive SARS-CoV-2 test.
89332710|NCT04786353||Controls|Children with no positive SARS-CoV-2 test.
89332711|NCT04777071|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/CT, PET/MR)|Patients receive gallium Ga 68-labeled PSMA-11 IV then undergo PET/CT or PET/MR scan over 2-4 minutes per bed position at baseline. Patients receiving systemic therapy undergo an additional 68Ga-PSMA-11 PET/CT or PET/MR scan 12 weeks after initiating therapy.
89332712|NCT04772937|Other|LLETZ group|LLETZ (large loop excision of the transformation zone) is one of several possible surgical interventions for treating cervical dysplasia.
89332713|NCT04772937|Other|LEEP group|LEEP (loop electrosurgical excision procedure) is one of several possible surgical interventions for treating cervical dysplasia.
89332714|NCT04771572|Experimental|Dose Escalation Phase|Phase 1a dose-escalation will begin with group 1 and proceed until DLT is observed and MTD is established, or until an RP2D is established. Subjects enrolled in the dose cohorts will follow the 3+3 study design, starting with an accelerated step-up dosing schedule (with a starting dose of 20 mg, 50 mg, 100 mg once daily) until they reach the designated target dose (50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg). Once the MTD or RP2D is established for group 1, the phase 1a dose escalation can proceed for group 2. The starting dose level for group 2 will be one dose level below the MTD or RP2D established for group 1.
89332715|NCT04771572|Experimental|Dose Expansion Phase|Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups. One or more RP2D may be explored. Definition of these cohorts will be accomplished by protocol amendment, and in light of emerging data from Phase 1a.
89332716|NCT04757233|Other|Single arm|Intervention: GlucoType Single arm study; all participants assigned to use the intervention
89332717|NCT04749771|Experimental|Filming Interactions to Nurture Development (FIND)|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly sessions lasting 30-45 minutes. The process begins with an initial session in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
89332718|NCT04749771|Active Comparator|The Healthy Toddler Program (HTP)|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 sessions each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
89332719|NCT04740398|Experimental|Ia stage - CBP-1008 Dose escalation/ Ib stage - CBP-1008 monotherapy|"Ia:Patients will receive CBP-1008 IV infusion every 2 weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.~Ib:Patients will receive CBP-1008 RP2D IV infusion every two weeks until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue."
89332720|NCT04732923|Experimental|Experimental arm|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks~STEP 2 : monitoring at 6 months after cardiac rehabilitation program~STEP 3 : monitoring at one year after cardiac rehabilitation program"
89332721|NCT04725708|Experimental|normoxy|"Group 1(n=50) FiO2%40, PaO2<180 ve PaO2≥80mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored.~An rSO2 less than 45% triggered an alarm, the anesthesiologist timed the event, and after 60 seconds initiated an intervention protocol means; PaO2 levels were checked, PaO2> 100 mmHg was achieved, if not improved, pump blood flow, mean arterial pressure were increased, if there is still no response and hematocrit <20%, patients were scheduled for erythrocyte transfusion until the rSO2 was restored to at least 60% at both probes.In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months."
89332722|NCT04725708|Experimental|hyperoxia|Group 2(n=50) FiO2%100, PaO2≥180mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored..In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months.
89332723|NCT04723212||Younger healthy adults|Healthy subjects in the age group of 18-30 years old, and without history of any neurological condition
89332724|NCT04723212||Older healthy adults|Healthy subjects aged 55 years and older, and without history of any neurological condition
89332725|NCT04721561||Chronic stroke patients|Patients who are at least 6 months after a first unilateral stroke
89332726|NCT04721561||Healthy controls|Healthy subjects with no history of any neurological condition and who are in the same age group as the chronic stroke patients
89332727|NCT04699253||Consenting participants|Patients meeting the eligibility criteria and are using the SanaCoach heart failure during the study period.
89332728|NCT04699253||Consenting non-participants|Patients meeting the eligibility criteria but do not wish to use the SanaCoach heart failure and only fill-in an anonymized questionnaire once, without any follow-up.
89332729|NCT04664790|Active Comparator|Hyperbaric Oxygen|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week.
89332730|NCT04664790|Active Comparator|Cognitive training|Neuropsychologist guided cognitive training.
89332731|NCT04646837|Experimental|Experimental Arm|Durvalumab 1000 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IB-IIIA NSCLC adult patients followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 15000mg Q4W for 8 months
89332732|NCT04646174|Experimental|Multi-component Behavioral Treatment|This treatment consists of nine weekly phone-based individual treatment sessions, 45-60 minutes each, delivered by a trained study therapist.
89332733|NCT04646174|Experimental|Self-guided Treatment|This treatment consists of self-help materials from the American Lung Association that address evidence-based smoking cessation and self-management strategies.
89332734|NCT04635072|Experimental|Stabilised Whole Rice Bran (SWRB)|"Patients with mild AD will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, one time per day.~Patients with moderate disease will be instructed to use SWRB as a cleanser as above. In addition, they will also use SWRB as an emollient after constituting it into a paste as in instructions, apply at night and leave it overnight."
89332735|NCT04634396|Other|Experimental TACTICs|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACICS. Participants will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1 hour sessions by a trained interventionalist
89332736|NCT04623125|Experimental|Spaced Repetition|Two weeks (10 sessions) of online picture-naming training with 60 words.
89332737|NCT04600167|Experimental|Isoniazid and Rifapentine (INH-RPT)|Participants in intervention arm will receive an oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
89332738|NCT04600167|Placebo Comparator|Control|Participants in the control arm will receive placebo once weekly for 12 weeks.
89332739|NCT04592328||Patients planned for elective open cardiac surgery|
89332740|NCT04591652|Experimental|99mTc-MIRC208 SPECT/CT scan|The cancer patients will be injected with14.8 MBq/kg body weight, and 2h later, SPECT/CT scan will be performed.
89332741|NCT04590690|Experimental|Roux-en-y gastric bypass subjects|"Inclusion Criteria: Age 18-70. Participants pre-Roux-en-y gastric bypass (RYGB) who are approved and planned for Roux-en-y gastric bypass surgery in the Bariatric Surgery Center at the UCM.~Exclusion Criteria: Patients with primary kidney diseases, kidney stone disease, or kidney impairment (eGFR < 90). Patients with known bladder voiding problems.~Participants will complete a diet record and a 24-hour urine collection both before and after surgery.~Participants will consume a 3 day fixed diet and present to the clinical research center for timed blood and urine draws. They will do this before and twice after (1 month and 1 year) surgery."
89332742|NCT04590690|Experimental|Sleeve gastrectomy subjects|"Inclusion Criteria: Age 18-70. Participants pre-sleeve gastrectomy who are approved and sleeve gastrectomy in the Bariatric Surgery Center at the UCM.~Exclusion Criteria: Patients with primary kidney diseases, kidney stone disease, or kidney impairment (eGFR < 90). Patients with known bladder voiding problems.~Participants will complete a diet record and a 24-hour urine collection both before and after surgery.~Participants will consume a 3 day fixed diet and present to the clinical research center for timed blood and urine draws. They will do this before and twice after (1 month and 1 year) surgery."
89332743|NCT04582734|Experimental|Intervention group - cognitive behavioral therapy|The intervention consists of three parts: 1) screening of hospitalised and outpatient cardiac patients at four university hospitals using the Hospital Anxiety and Depression Scale (HADS), scores ≥8 are invited to participate. (2) Assessment of type of anxiety by Structured Clinical Interview for DSM Disorders (SCID). (3) Investigator-initiated randomised clinical superiority trial with blinded outcome assessment, with 1:1 randomisation to cognitive-behavioural therapy (CBT) performed by a cardiac nurse with CBT training, plus usual care or usual care alone.The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
89332744|NCT04582734|No Intervention|Usual Care group|The usual care group (control group) will receive usual care which consists cardiac disease control and treatment.
89332745|NCT04578769|Active Comparator|conventional myotomy|conventional myotomy for achalasia type I, II and III
89332746|NCT04578769|Experimental|short myotomy|modified myotomy (short myotomy) for achalasia type I and II
89332747|NCT04578769|Experimental|full-thickness myotomy|modified myotomy (full-thickness myotomy) for achalasia type I and II
89332748|NCT04578769|Experimental|tailored myotomy|modified myotomy (tailored myotomy) for achalasia type III
89332749|NCT04576585|Experimental|Appetite lexicon training group|They will get appetite lexicon training in week three.
89332750|NCT04576585|Active Comparator|taste Lexicon training|They will get taste lexicon training In week three.
89332751|NCT04574115|Experimental|Study Eye|study eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens.
89332752|NCT04574115|Active Comparator|Control Eye|Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).
89332753|NCT04549597|Experimental|Cohort 1: Straight Switch|Patients stop taking phosphate binders and start tenapanor 30 mg twice daily
89332754|NCT04549597|Experimental|Cohort 2: Decrease Phosphate Binder by 50%|Decreases phosphate binder dose by at least 50% with the ability to switch the binder regiment from thrice daily (TID) to BID or once a day and initiates tenapanor 30 mg BID
89332755|NCT04549597|Experimental|Cohort 3: Phosphate Binder Naive|Phosphate binder naive patients are enrolled as Cohort 3 and receive tenapanor with a starting dose of 30 mg/BID
89332756|NCT04542863|Experimental|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo 18F-DX600 PET/CT scans.
89523555|NCT03373487|Experimental|Early-intervention group|Patients follow the evidence-based cognitive rehabilitation program ReMind, which is provided via an iPad. It incorporates psychoeducation, strategy training and retraining. The intervention commenced 3 months after surgery and patients were advised to spend 3 hours per week on the program for 10 weeks.
89332757|NCT04522284|Experimental|CURATE.AI|"- Cohort 1: Capecitabine in solid tumours. In this cohort, participants will receive the treatment in three-week cycles. Only the dose of capecitabine will be modulated with CURATE.AI, based on measurements of the tumour marker (CEA/CA19-9). CT scans for radiological assessment will be performed according to standard of care, usually after every 2 to 3 cycles of chemotherapy for Cohort 1 only.~Cohort 2: Ibrutinib in Waldenström macroglobulinaemia In this cohort, participants will receive the treatment in four-week cycles. The total cumulative dose of Ibrutinib will be modulated with CURATE.AI, based on measurements of the tumour marker (IgM paraprotein)."
89332758|NCT04512976|Experimental|24 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
89332759|NCT04512976|Experimental|30 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
89332760|NCT04512976|Experimental|38 deg C environment|Subjects will exercise for 60 minutes in a 24 deg C environment while being exposed to each of the following cooling modalities: no cooling, fan only, skin wetting only, and a combination of a fan and skin wetting.
89332761|NCT04490564||HNSCC, NSCLC, melanoma Patients|The study population are subjects with a confirmed diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), who are going to receive PD-1 inhibitor nivolumab or ii) metastatic Non-Small Cell Lung Cancer (NSCLC), who are going to receive PD-1 inhibitor, e.g. nivolumab, pembrolizumab or iii) metastatic melanoma, who are going to receive PD-1 inhibitor, e.g. nivolumab, embrolizumab. The selected inclusion/exclusion criteria have been set to include in the performance study appropriate population of interest, as broad as possible, but to exclude these subjects that have another current malignancy or any history of recent malignancy within 3 years.
89332762|NCT04490564||Healthy volunteers|In case of healhty volunteers, only peripheral blood samples will be collected.
89332763|NCT04489888|Experimental|Pembrolizumab + Carboplatin + Paclitaxel|Participants will receive pembrolizumab plus carboplatin plus paclitaxel. Pembrolizumab will be administered via intravenous (IV) infusion at a dose of 200 mg on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Carboplatin will be administered via IV infusion at area under curve (AUC) 5 mg/mL/minute on Day 1 of each 21-day cycle for up to 6 cycles (up to ~4 months). At investigator's choice, paclitaxel will be administered via IV infusion at a dose of 100 mg/m^2 on Day 1 and Day 8 of each 21-day cycle for up to 6 cycles (up to ~4 months) or at a dose of 175 mg/m^2 on Day 1 of each 21-day cycle for up to 6 cycles (up to ~4 months).
89332764|NCT04483856|Experimental|DermoRelizema cream|The treatment will be applied since about 7 (±3) days prior to RT start and will continue until 14 days post RT end
89332765|NCT04483856|Active Comparator|Dexeryl|The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
89332766|NCT04481334|Experimental|One group|One group pre-test, post-test design
89332767|NCT04480814||Metastatic Breast Cancer|"The study population are subjects with a confirmed diagnosis of ER+/HER2 metastatic Breast Cancer patient before the treatment initiation.~The selected inclusion/exclusion criteria have been set to include in the performance study appropriate population of interest, as broad as possible, but to exclude these subjects that have another current malignancy or any history of recent malignancy within 3 years."
89332768|NCT04480814||Healthy volunteers|In case of healthy volunteers only peripheral blood samples will be collected.
89332769|NCT04443309|Experimental|Lenvatinib plus Camrelizumab|"Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
89332770|NCT04437433|Experimental|Atogepant 60 mg|Taken once daily
89332771|NCT04412369||Study group|Patients with COVID-19 and cardiac Troponin elevation
89332772|NCT04407611|No Intervention|Conventional modality|Control arm. Conventional modality entails telephone disclosure of genetic results by a licensed genetic counselor.
89332773|NCT04407611|Experimental|Online modality|Online self-guided modality entails return of genetic results directly to participants, with optional genetic counselor follow-up via telephone.
89332774|NCT04400110|Experimental|Short treatment group|Amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 5 consecutive days
89332775|NCT04400110|Active Comparator|Standard treatment group|amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 10 consecutive days
89332776|NCT04394689|Active Comparator|MRV-SC|A standard, single dose of Measles Rubella vaccine delivered subcutaneously with a needle and syringe
89332777|NCT04394689|Experimental|MRV-MNP|A single dose of Measles Rubella vaccine delivered intradermally with a microneedle patch
89332778|NCT04368078|Experimental|Toripalimab plus Lenvatinib|"Lenvatinib is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.~Toripalimab is a recombinant anti-human PD-1 monoclonal antibody."
89332779|NCT04364763|Experimental|RBT-9 (90 mg)|RBT-9 (90mg) will be administered intravenously over a 120-minute period on Day 1.
89332780|NCT04364763|Placebo Comparator|Placebo|0.9% sodium chloride (normal saline) will be administered intravenously over a 120-minute period on Day 1.
89332781|NCT04347616|Experimental|NK cells without IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. NK cells administration will not be followed by sc IL-2. N=3.
89332782|NCT04347616|Active Comparator|NK cells with low dose IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. IL-2 will be administered in a fixed dose of 3.0 x 10^6 units starting 4 hours after NK cell infusion and given every other day for 6 doses in total. N=3
88806748|NCT05654649|Placebo Comparator|Group C|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
89332783|NCT04347616|Active Comparator|NK cells with higher dose IL-2|On day 0, patients will receive a fixed dose of 1.0-3.0 x 10^9 allogeneic UCB-NK cells. Prior to NK cell infusion, patients will receive cyclophosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy. IL-2 will be administered in a fixed dose of 6.0 x 10^6 units starting 4 hours after NK cell infusion and given every other day for 6 doses in total. N=6
89332784|NCT04320264||Low oxidizers/high lactate|Individuals with low aerobic oxidation
89332785|NCT04320264||High oxidizers/low lactate|Individuals with high aerobic oxidation
89332786|NCT04320264||Obese|Severely obese scheduled for surgery
89332787|NCT04304326|Experimental|Intervational|"FT: Functional training with elastic band Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group.~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
89332788|NCT04304326|Experimental|Arms and Interventions|"Resistance exercise with weight training machines. Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
89332789|NCT04269837|Experimental|Supportive Care (sexual health counseling)|Patients receive sexual health counseling prior to starting and at the completion of radiation.
89332790|NCT04249778|Experimental|Dapagliflozin|Patients admitted with exacerbation of chronic heart failure by clinical and radiologic features randomized to receive 10 mg of dapagliflozin, once daily for 26 weeks.
89332791|NCT04249778|Placebo Comparator|Placebo|Patients admitted with exacerbation of chronic heart failure by clinical and radiologic features randomized to receive a placebo to match 10 mg of dapagliflozin, once daily for 26 weeks.
89332792|NCT04247815|Experimental|ATI-450 plus Methotrexate|ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate
89332793|NCT04247815|Placebo Comparator|Placebo plus Methotrexate|Placebo oral tablet BID with a stable weekly dose of Methotrexate
89332794|NCT04236102|Experimental|EGFR, KRAS, BRAF Lung adenocarcinoma LBC|Will use residual material from existing LBC cytology samples sent to the laboratory. Routine testing will take priority. Cases identified as non small cell lung carcinoma will have the residual LBC sample tested on the Idylla platform for EGFR, KRAS and BRAF. The EGFR, KRAS and BRAF mutation results obtained using the routine diagnostic procedure (FFPE samples) will be compared to those produced using the LBC samples.
89332795|NCT04236102|Experimental|KRAS Pancreatic adenocarcinoma|Will involve testing archived FFPE clot samples from confirmed pancreatic adenocarcinoma patients since 2014 (Approximately 20 cases per year). KRAS testing will be performed using the Idylla platform to establish if there is a KRAS codon 12 mutation present in 94% percent of the cases reported at RCHT. Patients will have consented to the use of their tissue at the time of procedure. Prospectively new patients diagnosed with pancreatic adenocarcinoma will have KRAS testing on the FFPE clot made as part of the routine diagnostic work up and KRAS testing on the LBC sample.
89332796|NCT04236102|Experimental|EGFR, KRAS, BRAF Blood plasma|Will involve a blood sample being taken at the time of the procedure from patients that have a clinical suspicion of having lung or pancreatic cancer. The single blood sample will be taken from the cannula inserted for the procedure. The blood sample will be processed using the Biocartis Idylla ™ circulating tumour cell cartridges (EFGR, KRAS and BRAF for lung and KRAS for pancreas).
89332797|NCT04227522|Experimental|Arm A (Rucaparib)|Rucaparib treatment (starting dose 600 mg, twice daily) after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
89332798|NCT04227522|Placebo Comparator|Arm B (Placebo)|Placebo treatment after receiving Bevacizumab for 12 to 15 months. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
89332799|NCT04225845|Experimental|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
89332800|NCT04225845|Experimental|Phone therapy plus cash transfer|Weekly phone calls by lay trained personnel to deliver problem solving therapy. Combined with a one-time cash transfer of Rs.1000.
89332801|NCT04225845|Experimental|Cash transfer|One-time cash transfer of Rs.1000.
89332802|NCT04225845|No Intervention|Control|Control group.
89332803|NCT04211168|Experimental|Toripalimab Plus Lenvatinib|"Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.~Lenvatinib is a novel angiogenesis inhibitor which targets multiple tyrosine kinases， including vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT."
89332804|NCT04205942|Experimental|Plasma|regular treatment with Argon Plasma Jet according to manufacturer's instructions, 8 times within 14 days
89332805|NCT04205942|Sham Comparator|Placebo|Sham-treatment with Argon Plasma Jet, Plasma producing electric field switched off - no Plasma is produced, just argon gas as effluent, 8 times within 14 days
89332806|NCT04196257|Experimental|BP1001-A monotherapy|Dose escalation of BP1001-A monotherapy
89332807|NCT04196257|Experimental|BP1001-A and Paclitaxel|Dose expansion of selected dose of BP1001-A with paclitaxel
89332808|NCT04195438|Other|Intervention Arm|CO and ABG Testing Arm
89332809|NCT04193553|Experimental|Lenvatinib + Best Supportive Care|
89332810|NCT04193553|Placebo Comparator|Placebo + Best Supportive Care|
89332811|NCT04183101|Experimental|Aliskiren treatment|Patients will be randomized to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for 6 months. After 6 months the patients will be switched to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for the coming 2,5 years.
88806749|NCT05654649|Active Comparator|Group D|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
89332812|NCT04183101|Active Comparator|Enalapril treatment|Patients will be randomized to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for 6 months. After 6 months the patients will be switched to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for the coming 2,5 years.
89332813|NCT04167683||Cohort 1 - Patients referred to myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
89332814|NCT04167683||Cohort 2 - Patients referred to non myeloablative HSCT|These patients will undergo 5 assessments: a baseline-assessment 3-4 week prior to conditioning treatment, at discharge (in-patients) or at day +28 after stem cell infusion (out-patients) and follow-up assessments at 3 months, 6 months and 12 months.
89332815|NCT04155632|Experimental|N-acetylcysteine + Theta Burst Stimulation|
89332816|NCT04155632|Sham Comparator|N-acetylcysteine + Sham Theta Burst Stimulation|
89332817|NCT04155632|Experimental|Placebo + Theta Burst Stimulation|
89332818|NCT04155632|No Intervention|Placebo + Sham Theta Burst Stimulation|
89332819|NCT04142073||Children under 18 years of age|
89332820|NCT04117841||Arm I: Prospective from diagnosis|Patients have been enrolled and followed since diagnosis will be placed into Arm I.
89332821|NCT04117841||Arm II: Prior treatment at centre|Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.
89332822|NCT04117841||Arm III: Prior treatment at outside centre|Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.
89332823|NCT04073134|Active Comparator|Evolocumab|Participants will receive evolocumab 140 mg subcutaneous injections once every 2 weeks.
89332824|NCT04073134|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injections once every 2 weeks.
89332825|NCT04069962|No Intervention|Control group|Patients in the control group will receive CGA coordinated by the oncology team as standard of care, including geriatric recommendations for interventions communicated to the treating physician (eg. referral to the social worker, psychologist, dietician).
89332826|NCT04069962|Experimental|Intervention group|Patients in the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching.
89332827|NCT04034485|Experimental|LIB003 (lerodalcibep)|300 mg SC Q4W
89332828|NCT04034485|Active Comparator|evolocumab|420 mg SC Q4W
89332829|NCT04010071|Experimental|axitinib plus toripalimab|"Axitinib (Inlyta, Pfizer Inc.) is a novel oral angiogenesis inhibitor that selectively targets vascular endothelial growth factor (VEGFR) 1, 2 and 3.~Toripalimab (Shanghai Junshi Biosciences Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody."
89332830|NCT03992339|Experimental|ATG-010|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.
89332831|NCT03988920|Experimental|Tenapanor w/Sevelamer|Tenapanor will be administered QD or BID and sevelamer can be added to achieve desired serum phosphorus level
89332832|NCT03988920|Experimental|Sevelamer w/Tenapanor|Sevelamer will be administered QD, BID or TID and tenapanor will be added to achieve desired serum phosphorus level and sevelamer dose will be decreased as needed
89332833|NCT03968133|Experimental|Probiotic|Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5*10^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10^9 CFU/gram) per day.
89332834|NCT03968133|Placebo Comparator|Placebo|Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
89332835|NCT03968029|Experimental|Suturing meniscal augmented|Non-vascularised area meniscus tear was sutured and bone marrow was injected under a protective collagen membrane (ChondroGide)
89332836|NCT03968029|Active Comparator|Suturing meniscal|Non-vascularised area meniscus tear was only sutured
89332837|NCT03957369||Adult naive HIV positive individuals|HIV-diagnosed subjects, older than 18 years, with no prior exposure to antiretroviral drugs.
89332838|NCT03925402||Ertapenem|Patients who received ertapenem as an empirical antibiotic
89332839|NCT03925402||Other carbapenems|Patients who received carbapenems other than ertapenem as an empirical antibiotic
89332840|NCT03897361|Experimental|"Gene Therapy with CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)"|"This is a single arm study without randomization. Eligible subjects will receive the final product: CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)."
89332841|NCT03892577||Patients with advanced hepatobiliary tumors|"2000 patients with advanced hepatobiliary tumors will be enrolled and the enroll patients should be treat with any type of the following three treatment program:~Monotherapy or combination therapy with the targeted drug related to genetic variation of the subject;~Treatment with pan-target anti-angiogenic drugs, such as sorafenib, regorafenib, lenvatinib, apatinib, etc;~Immunotherapy or immunotherapy combined with targeted therapy or (and) chemotherapy."
89332842|NCT03886025|Experimental|Combined anodal tDCS and cognitive training|Combined anodal tDCS and cognitive training. Anodal tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). Anodal tDCS will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration of each tDCS session will be 20 minutes.
89332843|NCT03886025|Sham Comparator|Combined sham tDCS and cognitive training|Combined sham tDCS and cognitive training. Sham tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). For sham tDCS, the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each tDCS session will be 20 minutes.
89523556|NCT03373487|Other|Waiting-list control group|The waiting-list control group will be offered the same cognitive rehabilitation program after they have undergone all study assessments one year after surgery.
88806750|NCT05654324|Experimental|Pregnant women|Pregnant women aged 18-40, 20-40 weeks of gestation.
89332844|NCT03875079|Experimental|Part I Safety Run in: RO6874281 + Pembrolizumab|"Cohort 1.1 (CPI naive and experienced melanoma participants):~Participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2 (CPI experienced melanoma participants only):~Participants will receive RO6874281 in combination with Pembrolizumab via an induction and maintenance schedule for RO6874281: QW three times (D1, D8, D15) followed by Q3W dosing (D22 and subsequent). Pembrolizumab is to be administered Q3W, starting on Day 1. Participants will be observed for 2 pembrolizumab cycles (ie: 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part III of this study."
89332845|NCT03875079|Experimental|Part II Expansion: RO6874281 + Pembrolizumab|Part II will start once all participants in Part I Cohort 1.1 have completed the observation period. Approximately 34 participants will receive RO6874281 in combination with Pembrolizumab every 3 weeks (Q3W) and will be observed for 2 cycles (ie: 6 weeks).
89332846|NCT03875079|Experimental|Part III Expansion: RO6874281 + Pembrolizumab|Part III will start once all participants in Part I Cohorts 1.1 and 1.2 have completed the observation period. Approximately 80 participants will be randomised to receive RO6874281 in combination with Pembrolizumab in either a Q3W or QW/Q3W schedule.
89332847|NCT03866252|Experimental|Treatment Arm|Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.
89332848|NCT03866252|Active Comparator|Control Arm|Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.
89332849|NCT03813342|Experimental|Multichannel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 4 channels of visual information, each of which represents a joint angle (right and left hips, right and left knees).
89332850|NCT03813342|Experimental|Single Channel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 1 channel of visual information that encompasses information from 4 lower limb joint angles (right and left hips, right and left knees).
89332851|NCT03780751|Experimental|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
89332852|NCT03780751|Experimental|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
89332853|NCT03780751|No Intervention|Waitlist|Participants will receive no immediate treatment but will be able to choose either MIND or COPE after a six months waiting period.
89332854|NCT03747601|Experimental|Temporal Interference (TI) Stimulation|Temporal Interference stimulation applied to the head via standard electrodes
89332855|NCT03719495||Cohort 1|Pre-menopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
89332856|NCT03719495||Cohort 2|Postmenopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
89332857|NCT03719495||Cohort 3|Pre-menopausal women initiating tamoxifen after standard of care local-regional therapy after surgery +/- radiation.
89332858|NCT03719495||Cohort 4|Pre-menopausal women initiating ovarian suppression plus aromatase inhibition after surgery +/- radiation.
89332859|NCT03719495||Cohort 5|Postmenopausal women initiating endocrine therapy with aromatase inhibition after standard of care surgery +/- radiation.
89332860|NCT03688451|Experimental|Intrathecal rituximab|Cohort 1: 10 mg dose, day 1 chemotherapy cycles 2-5 Cohort 2: 20 mg dose, day 1 chemotherapy cycles 2-5
89332861|NCT03687528||Patient with minor head injury trauma|The emergency protocol for antiplatelet inhibitors treated patient with head injury trauma and meeting others NICE criteria involves a clinical exam followed by a CT-scanner.
89332862|NCT03664752|Experimental|IDP-120 Gel|IDP-120 Gel, once-daily application
89332863|NCT03664752|Placebo Comparator|IDP-120 vehicle gel|IDP-120 vehicle gel, once daily application
89332864|NCT03664739|Experimental|IDP-120 Gel|IDP-120 Gel, once-daily application
89332865|NCT03664739|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
88806751|NCT05654324|Active Comparator|Non-Pregnant|Being a non-pregnant woman who is in the same age range as the experimental group.
88806752|NCT05608759|Experimental|single arm|4 weeks of multimodal pre-rehabilitation
89332866|NCT03626064|Other|PROMPT Participants|80 participants who are homeless or at-risk for homelessness, smoke tobacco, and identify as People Who Use Drugs in Ottawa.
89332867|NCT03590028|Experimental|Early Nephrology Consult (ENC)|The ENC will be a structured consultative note that will provide detailed recommendations around issues such as Differential Diagnosis, Drug Dosing and Volume Status. The research ENC will have a daily follow-up with documented recommendations.
89332868|NCT03590028|Active Comparator|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
89332869|NCT03587922|Experimental|Treatment Arm|Single arm study with treatment of Fantom scaffold
89332870|NCT03570099||Prospective Naloxone cohort|The prospective cohort consists of study subjects receiving Naloxone nasal spray in the distribution program.
89332871|NCT03570099||Historical control cohort|Data from the historical control cohort will be collected from national registries years 2013-2017.
89332872|NCT03550417||2011 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010.
88806753|NCT05589337|Experimental|Baduanjin intervention group|Participants randomized to Baduanjin intervention group receive health education plus a Baduanjin training program. The Baduanjin training program was a 16-week, instructor-led group training program that offers breathing training as a core skill.
89332873|NCT03550417||2013 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010. Comparison of 2011, 2013 cohorts & July16/June17.
89332874|NCT03550417||July2016/Jun17 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010 & 2014. Comparison of 2011, 2013 cohorts & July16/June17.
89332875|NCT03541720|Experimental|Injection of 18F-DA|18F-DA will be injected into a vein in the arm or leg, or via central venous access line.
89332876|NCT03529396|Experimental|1a: Chloroquine + 5th-day Primaquine|[ARM HALTED PREMATURELY DUE TO SAFETY CONCERNS]
89332877|NCT03529396|Experimental|1b: Chloroquine + 8-week Primaquine|26 G6PD deficient patients. Directly observed therapy.
88806754|NCT05589337|Active Comparator|Health education control group|Participants randomized to the health education control group only receive health education and no additional training program.
89332878|NCT03529396|Active Comparator|1c: Chloroquine + 12-week Chloroquine|26 G6PD deficient patients. Control group in terms of safety. Directly observed therapy.
89332879|NCT03529396|Active Comparator|2: Standard chloroquine + primaquine|52 G6PD normal patients. Control group in terms of efficacy. Directly observed therapy.
89332880|NCT03479593||CMR and OCT in NSTEMI patients with MVD|NSTEMI patients with multi vessel disease
89332881|NCT03462407|Experimental|DAID|Trained assistants will help participants train their dog to engage in imitation based dog training, using positive reinforcement training (operant conditioning) focused on physical activities.
89332882|NCT03462407|Active Comparator|Dog walking|Trained assistants will help children train their dog to walk on a loose leash (eliminate pulling behavior) during this period using positive training techniques. The focus of this group will be on appropriate walking behavior to facilitate enjoyable independent dog-walking at home.
89332883|NCT03462407|No Intervention|Control|This group will all own family dogs but will not participate in either intervention during year 1. All participants assigned to the waitlist will be offered the DAID intervention the subsequent summer.
88806755|NCT05567237|Active Comparator|Microcurrent alone (MC)|This group will receive a live microcurrent device and they will not be engaged in any resistance training exercises.
89332884|NCT03449602|Experimental|Mini-thoraoscopy|The mini-thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 5.5 mm and a working channel diameter of 3.5 mm.
89332885|NCT03449602|Active Comparator|Conventional rigid thoracoscopy|The rigid thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 10 mm and channel internal diameter of 5 mm.
89332886|NCT03436784|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
89332887|NCT03436784|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
89332888|NCT03436563|Experimental|Treatment (M7824)|Patients receive M7824 IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity (Cohorts A,B, and C) or for six doses in patients with detectable circulating tumor DNA (ctDNA) following resection of all known liver metastases (Cohort D).
89332889|NCT03432819|Experimental|Siempre Seguiré|We will conduct a small randomized controlled trial (RCT), testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
89332890|NCT03432819|No Intervention|Control|Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.
89332891|NCT03426254|Experimental|Injections Subcutaneously Talazoparib|"Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Auto-Injector delivers a single dose of 1 mg Talazoparib injection (subcutaneous)"
89332892|NCT03426254|Active Comparator|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89523557|NCT03373409|Experimental|Albuterol DPI 90mcg|Participants will receive albuterol 90mcg via the albuterol DPI
89523558|NCT03373409|Experimental|Albuterol DPI 180mcg|Participants will receive albuterol 180mcg via the albuterol DPI
88806756|NCT05567237|Active Comparator|Microcurrent with exercise (MC + RT)|This group will receive a live microcurrent device and they will follow an exercise programme of 2 training sessions per week for 6 weeks (12 sessions in all)
89332893|NCT03411031|Active Comparator|A: Elotuzumab + Lenalidomide at 25 mg|"Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule."
89332894|NCT03411031|Active Comparator|B: Elotuzumab + Lenalidomide at 10 mg|"Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule."
89332895|NCT03358017|Active Comparator|ARM A - standard NACT|Standard anthracyclines/taxanes based neoadjuvant chemotherapy chosen by the investigator and administered according to clinical practice, for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
89332896|NCT03358017|Experimental|ARM B - standard NACT + Zol + atorvastatin|Standard anthracyclines/taxanes based neoadjuvant CT chosen by the investigator and administered according to clinical practice + Zoledronate 4 mg i.v. every 3-4 weeks and Atorvastatin 80 mg/die administered for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
89332897|NCT03289351|No Intervention|2-drug Therapy|ceftriaxone/metronidazole
89332898|NCT03289351|Experimental|1-drug Therapy|piperacillin-tazobactam
89332899|NCT03280667|Experimental|Pembrolizumab plus Denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D, continued until disease progression or prohibitive toxicity
89332900|NCT03272347|Experimental|Islatravir 0.25 mg|Participants will be treated once daily (QD) with 0.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
89332901|NCT03272347|Experimental|Islatravir 0.75 mg|Participants will be treated QD with 0.75 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to DOR/3TC/TDF for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
89332902|NCT03272347|Experimental|Islatravir 2.25 mg|Participants will be treated QD with 2.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to DOR/3TC/TDF for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
89332903|NCT03272347|Active Comparator|DOR/3TC/TDF|Participants will be treated QD with placebo to islatravir, placebo to DOR, placebo to 3TC, and a fixed dose combination of DOR/3TC/TDF consisting of 100 mg DOR + 300 mg 3TC + 300 mg TDF for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only DOR/3TC/TDF QD open label up to Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
89332904|NCT03259568|Experimental|Dose-response TMS - Intensity = 20%RMT|"Four levels of TMS intensity (here, 20% of Resting Motor Threshold), titrated to each individual, tested within the MRI.~Outcome measures include accuracy, RT, and BOLD signal."
89332905|NCT03259568|Experimental|Dose-response TMS - Intensity = 40%RMT|"Four levels of TMS intensity (here, 40% of Resting Motor Threshold), titrated to each individual, tested within the MRI.~Outcome measures include accuracy, RT, and BOLD signal."
89332906|NCT03259568|Experimental|Dose-response TMS - Intensity = 80%RMT|"Four levels of TMS intensity (here, 80% of Resting Motor Threshold), titrated to each individual, tested within the MRI.~Outcome measures include accuracy, RT, and BOLD signal."
89332907|NCT03259568|Experimental|Dose-response TMS - Intensity = 120%RMT|"Four levels of TMS intensity (here, 120% of Resting Motor Threshold), titrated to each individual, tested within the MRI.~Outcome measures include accuracy, RT, and BOLD signal."
89332908|NCT03251300|Experimental|group A|daytime dosing of mirabegron
89332909|NCT03251300|Active Comparator|group B|nighttime dosing of mirabegron
89332910|NCT03228693|Active Comparator|Group 1|Baseline lesional and non-lesional biopsies and re-biopsy 6-8 weeks later with intralesional triamcinolone injections at 9-10, 12-16, and 24-32 weeks.
89332911|NCT03228693|Active Comparator|Group 2|Baseline lesional biopsy and re-biopsy at 6-8 weeks with intralesional triamcinolone injections at 3-4, 9-10, 12-16, and 24-32 weeks
89332912|NCT03228693|Active Comparator|Group 3|Baseline lesional and non-lesional biopsy and re-biopsy 3-4 months later with intralesional triamcinolone injections at 18-20 and 24-32 weeks.
89332913|NCT03228693|Active Comparator|Group 4|Baseline lesional biopsy and re-biopsy at 3-4 months with intralesional triamcinolone injections at 3-4, 6-8, 18-20 and 24-32 weeks.
89332914|NCT03228693|Active Comparator|Group 5|Normal patient skin (surgical or adjacent to other biopsy) from subjects with no self-reported history of keloids.
89332915|NCT03228693|Other|Earlobe Keloid|Complete excision of an earlobe keloid measuring > 10mm will be taken.
89332916|NCT03198039|Experimental|Group 1|Meditation twice daily for at least two weeks prior to surgery and for four weeks after surgery
89332917|NCT03198039|Experimental|Group 2|Meditation twice daily for four weeks after surgery
89523559|NCT03373409|Active Comparator|Albuterol HFA MDI|Participants will receive albuterol 180mcg via the HFA MDI inhaler
89332918|NCT03198039|No Intervention|Group 3|Control group - will undergo surgery and subsequent hospital stay according to the current standard of care, which does not include meditation
89332919|NCT03167723|Experimental|28 French chest tube for hemothorax|28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
89332920|NCT03167723|Experimental|14 French chest tube for hemothorax|14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
88806757|NCT05567237|Sham Comparator|Sham alone (SH)|This group will receive a sham microcurrent device and they will not be engaged in any resistance training exercises.
88806758|NCT05567237|Sham Comparator|Sham with exercise (SH + RT)|This group will receive a sham microcurrent device and they will follow an exercise programme of 2 training sessions per week for 6 weeks (12 sessions in all)
88806759|NCT05560100||Patients|Must have participated in >= 1 session of dry needling treatment and not be a healthcare provider.
88806760|NCT05560100||Dry Needling Experts|"(1) Must have >= 5 years of clinical practice performing dry needling and at least ONE of the following secondary criteria:~Certification in Dry Needling~Completion of a manual therapy fellowship that included dry needling training~>= 1 total scholarly product (poster presentation, author of a peer-reviewed publication) involving the use of dry needling"
88819285|NCT05449041||Glaucoma controlls|Gender- and age-matched controls to the Glaucoma patients, passed the age of 18 years without any eye diseases; not suffering from other know serious disease and have a health situation in accordance with expectations related to the age.
89332921|NCT03108690|Experimental|TDM and CI.|Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.
89332922|NCT03108690|No Intervention|Control|Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.
89332923|NCT03107533||Video recording of clinical visit|Investigators will enroll patients from the Department of Orthopedic Surgery for enrollment. The shared decision group will provide staff for data analysis.
89332924|NCT03103152|Experimental|High dose Aspirin & Vitamin D|Aspirin high dose (300mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
89332925|NCT03103152|Experimental|High dose Aspirin, Vitamin D placebo|high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
89332926|NCT03103152|Experimental|Low dose Aspirin , Vitamin D|Low dose aspirin (100mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
89332927|NCT03103152|Placebo Comparator|Low dose Aspirin, Vitamin D placebo|Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
89332928|NCT03103152|Experimental|Aspirin Placebo, Vitamin D|Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil
89332929|NCT03103152|Experimental|Aspirin placebo, Vitamin D placebo|Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil
89332930|NCT03084822|Experimental|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
89332931|NCT02986243|Experimental|Treatment|Subjects receive a diet plan and exercise regimen.
89332932|NCT02937285|Active Comparator|Standard care|Interferon alone
89332933|NCT02937285|Experimental|Experimental group|Mitoxantrone for 6 month followed by interferon
89332934|NCT02878785|Experimental|Phase 1: Decitabine and Talazoparib Combo|"Phase 1:~Decitabine by IV daily for 5 days every 28 days. Talazoparib orally daily days 1-28.~The 'outer layer' of this nested dose escalation trial will escalate the dose of the two drugs by sequentially going through dose levels 1-6 in the table found in the protocol. The standard algorithm of the 3+3 design will be applied."
89332935|NCT02878785|Experimental|Phase 2: Decitabine and Talazoparib Combo|"Phase 2:~Recommended Phase 2 Dose (RP2D) The MTD of the combination of decitabine with a dose of talazoparib of at least 0.25 mg is defined as the maximal tolerated dose of decitabine studied - and for that dose level, combined with the maximum dose of talazoparib for which the incidence of DLT was less than 33% in 6 participants treated and this will be chosen as the recommended Phase 2 dose (RP2D). Among potential combined dose levels at MTD, available pharmacodynamic data (PARP trapping) will also be considered in the choice of RP2D, as will any significant indications of differences in clinical efficacy"
89332936|NCT02878785|Active Comparator|Phase 2 Arm A|Adult patients with AML who are thought not to be likely to tolerate or respond to standard chemotherapy
89332937|NCT02878785|Active Comparator|Phase 2 Arm B|Adult patients with AML that has not responded to previous treatment or has come back after responding to previous treatment
89332938|NCT02878785|Active Comparator|Phase 2 Arm C|Adult patients previously treated with a DNA methyltransferase inhibitor (decitabine, azacitidine or guadecitabine)
89332939|NCT02825576|Active Comparator|Sugammadex group|Sugammadex 2mg/kg intravenously at completion of surgery.
89332940|NCT02825576|Active Comparator|Neostigmine/Glycopyrrolate group|Neostigmine 50mcg/kg plus Glycopyrrolate 10mcg/kg intravenously at completion of surgery.
89332941|NCT02771990|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
89332942|NCT02771990|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
89332943|NCT02660645||Blue Light Cystoscopy with Cysview®|Bladder cancer patients who have undergone Blue light cystoscopy with Hexaminolevulinate hydrochloride (Cysview®) 100mg in 50 milliliters (mL) reconstituted solution instilled intravesically into bladder prior to cystoscopy in operating room (OR). Retention time: 1-3 hours. The Karl Storz D-Light C Photodynamic Diagnostic (PDD) system is used for the cystoscopy procedure at the OR examination.
89332944|NCT02512003|Experimental|Fantom Treatment group|
89332945|NCT02435316|Active Comparator|Group 1|Group 1 will receive 1 hour of compare-contrast basic science teaching of cell recognition to enhance recognition of those photographs, followed by 1 hour Case vignette-based teaching of cell recognition 2 weeks later
89332946|NCT02435316|Active Comparator|Group 2|Group 2 will receive 1 hour of Case vignette-based teaching of cell recognition followed by compare-contrast basic science teaching of cell recognition 2 weeks later
89332947|NCT02315196|Experimental|Treatment (doxil, carboplatin, surgery, paclitaxel)|"NEOADJUVANT: Patients receive pegylated liposomal doxorubicin hydrochloride* IV over 90 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~ADJUVANT: Patients undergo definitive surgery at the discretion of the treating physician. Patients then receive paclitaxel IV over 60 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.~*NOTE: If there is a shortage of pegylated liposomal doxorubicin hydrochloride, patients receive epirubicin hydrochloride IV over 15-20 minutes on day 1."
89332948|NCT02276885|Experimental|PBI Radiotherapy 6 Gy|Prone partial breast irradiation of 6 Gy x 5 over 5 days, on five consecutive days
89332949|NCT02276885|Experimental|PBI Radiotherapy 8 Gy|Prone partial breast irradiation of 8 Gy x 3 over 5 days, every other day
89332950|NCT02165670||Ischemic heart disease|Patients undergoing percutaneous coronary intervention (PCI)
89332951|NCT02059005|Experimental|Specialized Community Disease Management|Specialized Community Disease Management
89332952|NCT02059005|Active Comparator|Treatment As Usual|Treatment as Usual: standard post-hospital discharge with medical monitoring.
89332953|NCT01917877|Experimental|study group|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
89332954|NCT01917877|Active Comparator|control|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
89332955|NCT01845311|Experimental|ReZolve2 Treatment Group|
89332956|NCT01693263||brachiocephalic fistula placed|Subjects are being asked to participate in this study because they have end-stage renal disease and they are undergoing dialysis, and their doctor has recommended that they will have brachiocephalic fistula placed for their dialysis access.
89332957|NCT01693263||Sub-study participants|As part of this study there is an additional sub-study. The researchers would like to collect more information about the vascular access from 50 subjects. For the purposes of this sub-study the following will take place: Intravenous Ultrasound (IVUS) and Hand Held Doppler
89332958|NCT01672463|Experimental|All patients|All participants enrolled in this study
89332959|NCT01570296|Experimental|Gefitinib and BKM120|"Patients with NSCLC who progress on treatment with single-agent EGFR TKI (e.g., gefitinib or erlotinib), and meet the clinical definition of EGFR TKI resistance (Jackman et al., 2010):~A tumour that harbours an EGFR mutation known to be associated with drug sensitivity~Previous objective clinical benefit from treatment with an EGFR TKI~Patients should have systemic progression of disease (by RECIST) while on continuous treatment with gefitinib or erlotinib. Patients that have previously progressed on EGFR TKI (not in the preceding line of treatment) may also be enrolled and will receive gefitinib and BKM120 sequentially.~Patients with any solid tumour-type and activated PI3 kinase pathway and historically known to over express EGFR may also be recruited.~Once the RP2D is reached, an expansion cohort of 40 patients will be accrued for extended safety experience and to ascertain preliminary activity."
89332960|NCT01393821|Experimental|Arm I (lotion)|Patients apply menadione topical lotion BID for 28 days.
89332961|NCT01393821|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo lotion BID for 28 days.
89332962|NCT01277029||lower urinary tract symptoms|
89332963|NCT00993460||Normal body weight|Female subjects, ages 21-65 yrs, with BMI of 21-27 kg/m2 with normal glucose tolerance.
89332964|NCT00993460||Roux-en-Y gastric bypass|Female subjects ages 21-65 with insulin resistance and scheduled for Roux-en-Y gastric bypass at Vanderbilt University Medical Center will be studied before and 4-6 weeks after surgery.
89332965|NCT00804713|Experimental|All study participants|Subjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
89332966|NCT00611598||1|second primary lung cancer
89332967|NCT00611598||2|single primary lung cancer
89332968|NCT00496873|Experimental|Cytoxan + Rituxan + Nipent|Cytoxan 600 mg/m^2 on Day 1 of 21-day cycle. Rituxan 375 mg/m^2 on Day 1 of 21 Day Cycle. Nipent 4 mg/m^2 on Day 1 of 21 Day Cycle.
89332969|NCT00492778|Experimental|Arm I (brachytherapy, radiation therapy)|Patients undergo EBRT to the pelvis daily on days 1-5 for 5 weeks. After completion of EBRT, patients undergo intracavitary low-dose rate or high-dose rate brachytherapy or low-dose rate interstitial brachytherapy.
89332970|NCT00492778|Experimental|Arm II (brachytherapy, radiation therapy, cisplatin)|Patients undergo EBRT as in Arm I and receive cisplatin IV over 1-2 hours on days 1, 8, 15, 22, and 29. Patients then undergo brachytherapy as in Arm I.
89332971|NCT00430313|Experimental|Electro-Stimulation (Active Site)|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
89332972|NCT00430313|Experimental|Electro-Stimulation (Inactive Site)|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
89332973|NCT01226875|Active Comparator|A (Narrow focus, LP)|A (Narrow focus): stone is in lower pole of kidney and SWL using narrow focus on lithotripter
89332974|NCT01226875|Active Comparator|B (Wide focus, LP)|B: stone is in lower pole of kidney and SWL using wide focus on lithotripter
89332975|NCT01226875|Active Comparator|C (Narrow focus, no LP)|C: stone is in no-lower pole of kidney and SWL using narrow focus on lithotripter
89332976|NCT01226875|Active Comparator|D (Wide focus, no LP)|D: stone is in no-lower pole of kidney and SWL using wide focus on lithotripter
89332977|NCT03931369|Experimental|Tolvaptan test|15 MG pill administered tolvatan once, one day
89332978|NCT00359216|Experimental|Mometasone furoate nasal spray|
89332979|NCT00359216|Placebo Comparator|Placebo nasal spray|
89332980|NCT01226953|Active Comparator|Arm 1|
89332981|NCT01226953|Active Comparator|Arm 2|
89332982|NCT02290912|Experimental|Treatment|Health education program; informational website, experiential classes in various help domains, custom smart phone application, and wearable technology
89332983|NCT02290912|No Intervention|Control|No intervention
89332984|NCT01220635|Experimental|Skill Group Program|Positive Thoughts and Actions Program
89332985|NCT01220635|Active Comparator|Individual Support Program|Measure of Adolescent Potential for Suicide (MAPS) - modified
89332986|NCT04525430|Experimental|Group 1|only childbirth education group
89332987|NCT04525430|Experimental|Group 2|childbirth education and was subjected to a birth plan group
89332988|NCT04525430|No Intervention|Group 3|standard care group
88806761|NCT05560100||Policy Experts|"An individual who has a degree in bioethics with at least ONE of the following criteria:~>= 5 years of experience in obtaining informed consent or an advanced graduate degree in bioethics~Has served on ethics related committee in a healthcare institution or healthcare society/professional association~Is or has been a member of a state licensing board"
89332989|NCT03521752|Experimental|Experimental|Performed a specific program exercises (resistance training, balance, coordination and flexibility) during 4 weeks.
89332990|NCT03521752|No Intervention|Control|The control group wasn't subjected to any intervention
89332991|NCT03932851||HBsAg(+) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA). The newborns born to HBV-infected pregnant women were divided into HBV DNA-negative group, low-viral group, and high-viral group according to HBV DNA status. The HBV infection status of these newborns was counted in July, and the different viral loads were tested. The impact of HBV mother-to-child transmission.
89332992|NCT03932851||HBsAg(-) pregnant woman|Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA).
89332993|NCT01348022||Xience V stent|unprotected Left Main Coronary Artery stenting treated with Xience V stent
89332994|NCT02290990|Experimental|Multiple Sclerosis patients|Patients with MS
89332995|NCT02290990|Experimental|Insomnia patients|Patients with insomnia
89332996|NCT02290990|Experimental|Health professionists|Health professionists as healthy volunteers
89332997|NCT02290990|Active Comparator|Waiting list MS|pw MS filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
89332998|NCT02290990|Active Comparator|Waiting list arm Insomnia|pw INS Insomnia Subject filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
89332999|NCT02290990|Active Comparator|Waiting list arm Health professionists|Health professionist filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated.
89333000|NCT01223989|Experimental|group bread|group who received an hypocaloric balanced diet including bread
89333001|NCT01223989|Active Comparator|group without bread|group who received a hypocaloric balanced diet with exclusion of bread
89333002|NCT01239550|Experimental|Insulin Detemir Treatment|"Insulin detemir treatment: Insulin detemir will be administered subcutaneously, once daily. Dose ranges from approximately 0.1 U/kg up to 0.6 u/kg or higher. The dosing regimen will employ a strategy similar to the 303algorithm, where, with close interaction with study personnel (rather than self-titration), bedtime insulin dosing will be titrated up by 3 units until AM fasting sugars within the prescribed protocol range are achieved (90-110 mg/dl). Subjects will have contact with study personnel on weekly basis for glycemia monitoring and adjustments. Similarly, documented hypoglycemia (blood sugars less than 70) will trigger a dose reduction, and it is expected that with weight loss, tolerable insulin dosages will drift downward. The treatment period is 24 weeks."
89333003|NCT01239550|No Intervention|Comparator: No insulin|"The main hypothesis is that diabetes can be changed  with early and careful insulinization capturing effects on brain function ultimately leading to weight loss. . Seek to determine in a quantitative manner whether insulin detemir restores brain dopamine neurotransmission, a control group not treated with insulin is required. The strength of this study is our ability to test the specific molecular (D2R, DAT, functional MRI responses) and integrated output (functional brain responses, mood, cognitive function, reward responses etc.) of CNS dopaminergic pathways in order to shed unprecedented light upon mechanisms of detemir action in obesity and diabetes."
89333004|NCT01353326|Active Comparator|Cementless Hip Resurfacing|Patients randomized into the Cementless Hip Resurfacing Group will have their hip resurfaced with the cementless Cormet / Corin Hip Resurfacing System.
89333005|NCT01353326|Active Comparator|Cemented Hip Resurfacing|Patients randomized into the Cemented Hip Resurfacing Group will have their hip resurfaced with the cemented Conserve Plus Total Resurfacing Hip System.
89333006|NCT01220713|Experimental|Treatment 1--1.5 atm abs|
89333007|NCT01220713|Experimental|Treatment 2--2.0 atm abs|
89333008|NCT01220713|Sham Comparator|Placebo--equivalent to breathing air|
89333009|NCT03524014||HEV-infected patients with hepatitis|
89333010|NCT03524014||HEV-infected patients with neurological features|
89333011|NCT03524014||HEV-infected patients with kidney features|
88806762|NCT05560100||Legal Experts|"An individual who is an attorney and who has had training in health law as evidenced by at least ONE of the following criteria:~Evidence of training based on ONE of the follow:~Concentration/Certification in Health Law~L.L.M in health or medical law~SJD in health law~Experience in litigating medical malpractice cases involving failure to obtain informed consent~Published scholarship on informed consent in an academic journal (>= 1)"
88806763|NCT05525806|No Intervention|Control Group|Control group treats their simulated patients using standard practice and have no introduction to the new LynxDx test.
88806764|NCT05525806|Experimental|Intervention Group 1|Intervention Group 1 will receive information regarding the LynxDx rest and will be given the test results, whether selected or not, in Round 2 of CPV administration.
88806765|NCT05525806|Experimental|Intervention Group 2|Intervention Group 2 will receive information regarding the LynxDx test and will be given the test results if selected in Round 2 of CPV administration.
88806766|NCT05519111|Experimental|Dronabinol|BID for 8 weeks. Dosage will be individualized per patient. In days 1-4 of the study each patient will be titrated from 5mg bid to a minimum dose of 2.5 mg bid to a maximum dose of 10 mg bid depending on patient preference.
88806767|NCT05519111|Placebo Comparator|Placebo|A placebo comparator
88806768|NCT05517941|Experimental|active cycle breathing exercise|patients will receive Active cycle of breathing techniques daily for 2 weeks
89333012|NCT02291068|Other|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy.
89333013|NCT03721328|Experimental|Experimental|Joint irrigation with vancomycin and tobramycin
89333014|NCT03042416|Experimental|18F-DOPA scan|18F-DOPA (4 MBq/kg, minimum 110 MBq, maximum 600 MBq) intravenous. Single-dose 20-80 minutes prior to PET/CT scan of brain or whole body (depending on specific imaging protocol for patient).
89333015|NCT03927469||Hospitalisation group|The patients who were hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
89333016|NCT03927469||Re-hospitalisation group.|The patients who were re-hospitalized in the hospital between January 2015 and July 2018, according to ICD 10 code; hemiplegia (G81), flaccid hemiplegia (G81.0), hemiplegia, unspecified (G81.9), Spastic hemiplegia (G81.1) scanned from the hospital database.
89333017|NCT03523936|Active Comparator|Prebiotic|
89333018|NCT03523936|Placebo Comparator|Placebo|
89333019|NCT01353404|Experimental|fenofibrate 65mg, fed condition, per oral|
89333020|NCT01353404|Experimental|fenofibrate 65mg, fasting condition, per oral|
89333021|NCT01353404|Active Comparator|fenofibrate 160mg, fed condition, per oral|
89333022|NCT01220791|Active Comparator|Follicular Medrol|In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
89333023|NCT01220791|Placebo Comparator|No medrol group|Patients will receive only Antagonist protocol for IVF as usual
89333024|NCT03521284||Mothers with education program during their mat|
89333025|NCT03521284||Mothers without education program during their mat|
89333026|NCT04499456|Active Comparator|Control|Waiting list control receiving the PNF after the last assessment
89333027|NCT04499456|Experimental|Single PNF|Receives PNF after the first assessment only
89333028|NCT04499456|Experimental|Boosted PNF|Receives PNF after every assessment
89333029|NCT03930667|Active Comparator|clips|Closure of the appendix stump with hem-o-lok clips
89333030|NCT03930667|Experimental|knotting|Closure of the appendix stump with intracorporal knotting.
89333031|NCT02291146|Experimental|LA Sprouts intervention|"The intervention classes will be taught during a 90-minute session once a week for 12 weeks. Participants will receive a 45-minute gardening lesson, taught by a Master Gardener (supervised by Dr. Gatto). This lesson will include learning how to plant, maintain and harvest various fruits and vegetables. Supplementing the gardening lesson, a USC nutrition educator, with help from various graduate students (supervised by PI Dr. Davis), will lead a 45-minute cooking activity and nutrition education lesson. Every participant will participate in the cooking activity and sample the food. The program will include lessons on growing crops that have cultural significance to Latino youth such as nopales, beans, corn and squash (the latter three crops are commonly referred to as the three sisters)."
89333032|NCT02291146|No Intervention|control|Approximately 200 students in the second region who are enrolled in LA's Best will serve as control participants. After the 12-week intervention is conducted and all post-testing measures are collected on controls, a vegetable/fruit garden will be built at both control schools and the LA Sprouts program will be taught to all 3rd, 4th and 5th graders in LAs Best and their parents at the control school as a delayed intervention.
89333033|NCT01126411|No Intervention|control|control group / no immunoadsorption
89333034|NCT01126411|Active Comparator|immunoadsorption|immunoadsorption
89333035|NCT04495166|Experimental|Motherly app with brief psychotherapy|Participants in this arm will receive intervention via Motherly 1.0, an app that delivers behavioral activation strategies and psychoeducational content to promote changes in sleep, nutrition, and physical activity habits. It has also functionalities that help participants to engage in prenatal care, breastfeeding, and social support, and to stimulate child development. In addition will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
89333036|NCT04495166|Active Comparator|Educational app (Active control)|Participants in this arm will have access to a psychoeducational app (active control) which delivers content about gestation, maternal health and mental health, and child development. In addition, they will undergo will undergo brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation.
89333037|NCT02291224|Other|Control|The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
89333038|NCT02291224|Experimental|Intervention|"Enrollment~Interactive multimedia platform focused on DP strategies.~Intervention arm counseling by a health care provider to select DP strategy.~Intervention arm counseling and skill-building by a nurse educator (NE) on correct, consistent use of DP strategy.~Booster counseling by an NE via phone at 3 weeks and 5 months after both the enrollment visit and the 6 month visit.~6 month visit~Abbreviated version of the interactive multimedia platform on DP strategies and adherence.~Intervention arm counseling by an NE to reinforce skills for correct, consistent use of DP strategy.~Interim visits: Participants may visit the clinic at any time. If intervention group members visit the clinic for STI treatment or to switch birth control method, providers and/or NEs will follow structured counseling guides. If they have an interim visit for another reason, they will receive the clinic standard of care."
89333039|NCT03775681|Experimental|Device feasibility (Laryngeal Mask Airway, ERCP)|Patients wear Laryngeal Mask Airway after receiving general anesthesia and falling asleep. Patients then undergo standard of care endoscopic retrograde cholangiopancreatography. Patients also complete a 5-minute interview following ERCP procedure.
89333040|NCT01353482|Active Comparator|Phase II only - Arm I|If the patient is randomised into the Vorinostat arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle plus the dose of Vorinostat determined in the phase I study.
89333041|NCT01353482|Placebo Comparator|Phase II only - Arm 2|If the patient is randomised into the placebo arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle with the placebo for the same number of days as in the vorinostat arm.
89333042|NCT03774823|Experimental|Freeze Plus|Subjects in this arm will receive treatment using RF and PEMF
89333043|NCT03774823|Experimental|Ultrasound|Subjects in this arm will receive treatment using ultrasound
89333044|NCT01346462|Experimental|PaCT|The Patient-Centered Transition Arm
89333045|NCT01346462|No Intervention|Control|Control group patients will receive routine care from the admitting hospital, including routine patient management, and discharge planning.
89333046|NCT01348178||developmental dysplasia of the hip, PAO|All patients who underwent periacetabular osteotomy from 1999-2007 at the University Hospital of Aarhus
89333047|NCT01129843|Experimental|Directly observed home based daily iron therapy|Village volunteers will provide directly observed home based daily iron supplementation( ferrous sulphate) to enrolled anemic women in the experimental arm
89333048|NCT01129843|Active Comparator|Clinic driven unsupervised daily iron therapy|In the control group of villages, clinic driven unsupervised iron ( ferrous sulphate) supplementation will be offered on monthly basis to anemic women for 3 months
89333049|NCT01353560||New patients of Osher Clinical Center|
89333050|NCT01129999|Experimental|Cognitive-Behavioral Therapy|
89333051|NCT01129999|Experimental|Hypnotherapy|
89333052|NCT01348256|No Intervention|Observation|Observation after standard treatment
89333053|NCT01348256|Experimental|Dendritic cells vaccine|Adjuvant treatment with dendritic cells vaccine after standard treatment
89333054|NCT03930589|Placebo Comparator|Standard of care|no intervention will occur in the standard of care arm
89333055|NCT03930589|Active Comparator|Remote Ischemic Conditioning|Remote ischemic conditioning using BP cuff on left arm
89333056|NCT01353638|Other|Arm A|Arm A includes 14 patients. In treatment period 1, arm A receives standard PDF with the interventional drug alanyl-glutamine-dipeptide as add-on. As it is a cross-over study design, in treatment period 2, group A receives standard PDF without add-on.
89333057|NCT01353638|Other|Arm B|Arm B includes 14 patients who in treatment period 1 receive standard PDF without the investigational drug. As it is a cross-over study design, in treatment period 2 arm B receives standard PDF with alanyl-glutamine-dipeptide as add-on.
89333058|NCT01227109||With infection|This group consist of cancer patients with a bacterial infection
89333059|NCT01227109||Without infection|This is a group of cancer patients without infection
89333060|NCT02291380|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose, dextran and gelatin.
89333061|NCT02291380|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but includes sucrose, dextran and gelatin.
89333062|NCT01353716|Experimental|Cohort 1|Healthy subjects matched to the renal impaired subjects by gender, age and body mass index to the renal impaired subjects. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
89333063|NCT01353716|Experimental|Cohort 2|Subjects with severe renal impairment. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
89333064|NCT03927625|Experimental|Cohort 1|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.16 g/min for 60 minutes.
89333065|NCT03927625|Experimental|Cohort 2|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.31 g/min for 60 minutes.
89333066|NCT03927625|Experimental|Cohort 3|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The second cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.63 g/min for 60 minutes.
89333067|NCT03927625|Experimental|Cohort 4|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The third cohort of patients will receive ascorbate-meglumine at a dose administration rate of 1.25 g/min for 60 minutes.
88806769|NCT05517941|Experimental|incentive spirometer|patients will receive incentive spirometer and active cycle breathing daily for 2 weeks
89333068|NCT04481672|Experimental|Magnesium Sulfate|"Starting the night before surgery participants will receive intravenous infusion of magnesium over approximately 36 hours. Dosage amounts will vary among participants as the study is determining the highest dose of magnesium that can be administered safely without severe or unmanageable side effects. The first 5 participants of the study will all receive the same dose of magnesium. The decision to test other doses of magnesium in 5 additional participants will depend on magnesium levels and dose tolerance outcomes in the first 5 participants.~Participants will be followed for 4 days and undergo blood test to measure magnesium levels at the time of hospital admittance, the morning prior to the surgery, twice immediately after surgery, and twice a day for 3 days after the surgery."
89333069|NCT01126567||High Sampling Rate|Samples will be obtained at a high rate
89333070|NCT01126567||Low Sampling Rate|Samples will be obtained at a low rate
89333071|NCT01224067|Active Comparator|Quetiapine|Quetiapine (dosage 50mg to 300mg + sertraline)Experimental
89333072|NCT01224067|Placebo Comparator|Placebo|Participant will receive placebo for 8 weeks.
89333073|NCT01343030||Patients with implants|Patients with silicone implants and fat grafting.
89333074|NCT02529085|Experimental|Infants with PWS|Blood samples for the bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour
89333075|NCT02529085|Other|control group|Blood samples for the bank in children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
89333076|NCT04465552||Hospitalized COVID-19 Patients|
89333077|NCT01126645|Other|local ablation group|Local ablation group: Potentially curative treatment of early HCC includes surgical resection and local ablation (RFA, PEI, BT). Recurrence rates after such approaches are reported to amount to 50% at 3 years and 70% at 5 years. Tumor recurrence may be either due to de novo development of new primary tumors or due to intrahepatic (unrecognized) metastases. Prevention of recurrence after local ablation is an important strategy to improve overall survival. So far, adjuvant chemoembolization and chemotherapy have not proven to be effective in preventing recurrences. There is, however, a strong rationale to assume that sorafenib will be of value in the adjuvant treatment of HCC as sorafenib has a dual mechanism of action (inhibition of tumor proliferation and antiangiogenesis) and has proven efficacy in HCC.
89333078|NCT01126645|Active Comparator|palliative treatment group|"Radioembolization has been reported to be effective in patients with unresectable HCC with preserved liver function from a number of trials. Successful downstaging of disease rendering patients eligible for potentially curative therapies, and even histologically confirmed complete responses of unresectable HCC, have repeatedly been reported providing the rationale to evaluate SIRT+sorafenib in comparison to sorafenib alone.~The impact of cirrhosis as a concomitant disease in most patients with HCC is that it limits the ability of many patients to tolerate chemotherapy and is an independent cause of death in HCC patients. Thus, the historical difficulty in demonstrating an effect of therapy on survival in patients with advanced-stage, unresectable HCC (the majority). A new therapy that is effective in controlling hepatic disease, is less toxic than traditional chemotherapy, and improves the quality of life for patients in the advanced stages of HCC could represent an alternative."
89333079|NCT01348334|Active Comparator|Vypromesh®(Ethicon,USA)|Vypromesh®(semiabsorbable multiflament mesh;non-absorbable Polypropylene+absorbable Poliglactin)
89333080|NCT01348334|Active Comparator|Ultrapromesh®(Ethicon,USA)|Ultrapromesh®(semiabsorbable monofilament mesh;non-absorbable Polypropylene+absorbable polyglecaprone).
89333081|NCT01348334|Active Comparator|Prolene light mesh®(Johnson&Johnson,USA)|Prolene light mesh®(cpp-Condensed monofilament non absorbable polypropylene mesh)
89333082|NCT03133078|Experimental|Exercise: step-down test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
89333083|NCT03133078|Experimental|Exercise: side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
89333084|NCT01224223||acute asthma exaecerbtion patients|Patients experiencing acute exacerbation of their asthma
89333085|NCT01224223||chronic asthma group|Two groups are being enrolled. The first group is chronic asthma patients with FEV1 below 80% and FEV1/FVC ratio reduced by 5%
89333086|NCT01343186|Other|Arm 1|
89333087|NCT01343186|Other|Arm 2|
88806770|NCT05513157||Chronic stroke patients with knee hyperextension|Chronic stroke patients with a maximum knee extension angle of less than 0 degrees in movement analysis
89333088|NCT01343186|Other|Arm 3|
89333089|NCT01343186|Other|Arm 4|
89333090|NCT02291458|Experimental|L-arginine|Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.
88806771|NCT05513157||Chronic stroke patients without knee hyperextension|Chronic stroke patients with a maximum knee extension angle greater than 0 degrees in movement analysis
88806772|NCT05503407|Experimental|Baseline V-RESOLVE score-guided PCI|"Lesions with baseline V-RESOLVE <14 scores would undergo either jailed wire technique or provisional two-stent strategy;~Lesions with baseline V-RESOLVE ≥14 scores would undergo either jailed balloon technique or elective two-stent strategy."
89333091|NCT02291458|Placebo Comparator|Placebo|Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.
89333092|NCT01329289|Experimental|SOM230 with Bortezomib and Dexamethasone|
89333093|NCT01317914|Experimental|Dietary instruction on Gluten Free Diet|
89333094|NCT02291536|Experimental|tetrahydrocannabinol|oral administration of 10mg of tetrahydrocannabinol, once
89333095|NCT02291536|Experimental|cannabidiol|oral administration of cannabidiol, 600mg, once
89333096|NCT02291536|Placebo Comparator|placebo|oral administration of placebo, once
89333097|NCT01317992|Experimental|Ibudilast|To receive ibudilast 40mg twice daily for 8 weeks.
89333098|NCT01317992|Placebo Comparator|Placebo|To receive placebo twice daily for 8 weeks.
88806773|NCT05503407|Placebo Comparator|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
88806774|NCT05465525|Placebo Comparator|Control group|Patients will be operated under general anesthesia.
89333099|NCT03927547|Experimental|Inclined Sleep|Inclined mattress at 15 degrees
89333100|NCT03927547|No Intervention|Flat Sleep|Plane mattress
88806775|NCT05465525|Active Comparator|Quadratus Lumborum Block Group|Patients will receive ultrasound-guided quadratus lumborum block type III bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
88806776|NCT05465525|Active Comparator|Erector Spinae Plane Block Group|Patients will receive ultrasound-guided erector spinae plane block bilaterally with 30 ml of bupivacaine 0.25% on each side, totally 60 ml of bupivacaine 0.25% followed by general anesthesia.
89333101|NCT01227343||Female Smokers|Healthy females who smoke 10-30 cigarettes per day for the past 2 years and meet criteria for nicotine dependence.
89333102|NCT01227343||Female Non-smokers|Healthy females who do not currently smoke cigarettes.
89333103|NCT01227343||Male Smokers|Healthy males who smoke 10-30 cigarettes per day for the past 2 years and who meet criteria for nicotine dependence.
89333104|NCT01227343||Male - Non-Smokers CLOSED|WE ARE NO LONGER RECRUITING MALE NON-SMOKERS
89333105|NCT01348412|Experimental|ARM A|Hepatic artery infusion through an implanted arterial catheter of the combination of raltitrexed (3 mg/m ²) and oxaliplatin (100 mg/m ²) every 21 days.
89333106|NCT01348412|Active Comparator|ARM B|Intravenous standard chemotherapy.
89333107|NCT01128127|Experimental|Multifaceted intervention 1|psycho-educational workshop + audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
89333108|NCT01128127|Experimental|Multifaceted intervention 2|audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
89333109|NCT01128127|Active Comparator|Control|usual intervention
89333110|NCT01353794||Group 1|
89333111|NCT01224301|Experimental|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have access to school-based flu vaccine clinics and 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
89333112|NCT01224301|Experimental|School based flu vaccine: Low intensity|Interventions: Parents in low intensity schools have access to school-based flu vaccine clinics and less than 3 communications from schools about influenza illness, influenza vaccine, and school based clinics.
89333113|NCT01224301|No Intervention|Standard of Care|Control Schools did not have any in school seasonal influenza vaccine clinics. Parents of children in control schools got no notification from the schools and sought seasonal influenza vaccines for their children as they normally would.
89333114|NCT01353872|Experimental|Sports Drinks|3 drinks : Nutrattente (before each match) / Nutraperf (during each match) / Nutrarecup (after each match)
89333115|NCT01353872|Placebo Comparator|Placebo|3 drinks : Nutrattente placebo (before each match) / Nutraperf placebo(during each match) / Nutrarecup placebo (after each match)
89333116|NCT01221025|Experimental|parecoxib|Parecoxib, a water-soluble prodrug of valdecoxib, is a high-selective COX-2 inhibitor that is first available for intravenous administration.
89333117|NCT01224379|Other|"Arm1: topping off system"|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
89333118|NCT01224379|Other|Arm 2: monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
89333119|NCT03149042||CCTA|Patients who are scheduled for clinically mandated elective invasive coronary angiography (ICA) at Buffalo General Hospital.
89333120|NCT01221103|Experimental|DOT|Combination of dexamethasone, ofatumumab and bendamustine
89333121|NCT03521206|Experimental|Intervention group|"The ACP+ programme aims to improve or establish advance care planning (ACP) in the day-to-day routine of staff working in nursing homes.~The intervention implementation period has a total duration of 8 months and is divided into:~a four-month preparation and training phase. During this phase the ACP reference persons will attend a two-day training given by the ACP trainers. Other staff will receive training by the reference persons on conducting ACP conversation or recognizing triggers for an ACP conversation in nursing home residents.~A four-month follow-up phase in which ACP conversations are held with residents. Additional training sessions will be organized to give more in-depth knowledge to the ACP reference persons."
88806777|NCT05460299|Experimental|Telko plus conventional physical therapy (CPT)|All patients received 15-minute CPT, three times a week, for four weeks. The patients in the experimental group received 15-minute Telko at the end of each CPT session.
88806778|NCT05460299|Active Comparator|Conventional physiotherapy|All patients received 15-minute CPT, three times a week, for four weeks.
88806779|NCT05435482|Experimental|LHE-led|Participants will receive 1) LHE outreach/support (2 small group educational sessions via Zoom and 2 individual follow-up calls), 2) COVID-19 at-home antigen test kits, and 3) a written and a video guide to using a test kit
88806780|NCT05435482|Active Comparator|Instruction only|Participants will receive 1) COVID-19 at-home antigen test kits and 2) a written and a video guide to using a test kit
89333122|NCT03521206|No Intervention|Control group|The staff of nursing homes in the control group will receive no additional training next to any standard education or continuous training. After the intervention and follow-up measures are finished, all nursing homes in the control group will be offered a shortened version of the ACP+ training programme as well as all ACP+ training materials.
89333123|NCT03706898|Experimental|Elpida® fasting|Elpida® 20 mg single dose fasting
89333124|NCT03706898|Experimental|Elpida® after meal|Elpida® 20 mg single dose after meals
89333125|NCT03706898|Experimental|Elpida® (in subjects with mild hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with mild hepatic impairment (Child - Pugh Class А)
89333126|NCT03706898|Experimental|Elpida® (in subjects with moderate hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with moderate hepatic impairment (Child - Pugh Class B)
89333127|NCT03706898|Experimental|Elpida® & sofosbuvir & daclatasvir|Drug-drug interactions of sofosbuvir 400 mg + daclatasvir 60 mg and Elpida® 20 mg, single dose fasting
89333128|NCT03706898|Experimental|Elpida® & dolutegravir|Drug-drug interactions of dolutegravir 50 mg and Elpida® 20 mg, single dose fasting
89333129|NCT03927313|Active Comparator|Standard of care anti-tubercular therapy|Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).
89333130|NCT03927313|Experimental|Intensified anti-tubercular therapy|"Standard of care anti-TB therapy as described in Arm 1,~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days)."
89333131|NCT03927313|Experimental|Intensified anti-tubercular therapy plus aspirin|"Standard of care anti-TB therapy as described in Arm 1,~Plus additional 25 mg/kg rifampicin (total dose rifampicin 35 mg/kg orally for the first 56 days of treatment) and linezolid ( 1,200 mg orally daily for first 28 days reduced to 600 mg daily for next 28 days),~Plus aspirin (1000mg orally daily for the first 56 days of Tuberculous Meningitis treatment)"
89333132|NCT03523234|Experimental|surgery group|
89333133|NCT03523234|Placebo Comparator|control group|
89333134|NCT01343420|Active Comparator|Dog Hair Extract, ALK-Abelló, Inc.|
89333135|NCT01353950||Adult Cystic Fibrosis Patients|Adults with Cystic Fibrosis will be followed longitudinally for 2 years
89333136|NCT03133312|Experimental|Chlorhexidine Gluconate|Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
89333137|NCT03133312|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
89333138|NCT01128205||Diagnosed for 6 months or more|
89333139|NCT01354184|Experimental|CRD007 10 mg tablet|
89333140|NCT01354184|Experimental|CRD007 25 mg tablet|
89333141|NCT01354184|Experimental|CRD007 40 mg tablet|
89333142|NCT01354184|Placebo Comparator|CRD007 matching placebo tablet|
89333143|NCT01130155||Mwanza Region|Households, and patients presenting at public health facilities in Mwanza Region
89333144|NCT01130155||Mbeya Region|Households, and patients presenting at public health facilities in Mbeya Region
89333145|NCT01130155||Mtwara Region|Households, and patients presenting at public health facilities in Mtwara Region
89333146|NCT02291692|Active Comparator|Paravertebral blockade|Paravertebral blockade
89333147|NCT02291692|No Intervention|Paracetamol|The patients was given 15 mg/kg of paracetamol.
89333148|NCT01318148|Experimental|Caspofungin|
88806781|NCT05428202|Experimental|GN 037 cream|"Healthy volunteers will receive GN037 cream in 2 to 1 ration~Application will be done twice daily, to selected area of body on the fore arm:~Increasing dosages of dosages: Low dose to a 5 cm2 skin area, Medium dose to15 cm2 skin area, High dose to 30 cm2 skin area~Psoriatic patients will receive GN037 cream Aplication twice daily, to a selected body target lesion High dose 30 cm2"
88806782|NCT05428202|Placebo Comparator|Placebo Cream|"Placebo cream will be applied in 2 to 1 ratio twice daily, to selected area of fore arm.~Low dose to 5 cm2 skin area, Medium dose 15 cm2 skin area, High dose 30 cm2 skin area"
88806783|NCT05427474|No Intervention|standard protocol of manaegement|traumatic brain injury protocol in Emergency ICU without adding propranolol or gabapentin
89333149|NCT03740347||Juvenile idiopathic arthritis and chronic pain|Patients followed for juvenile idiopathic arthritis and chronic pain in Necker Hospital
89333150|NCT03521128|Experimental|the radiological tubal blockage group|
89333151|NCT03521128|Active Comparator|the laparoscopic salpingectomy group|
89333152|NCT01354262|Experimental|Lower dose vitamin D|Fixed daily doses of 600 IU vitamin D oral supplementation.
89333153|NCT01354262|Experimental|Higher dose vitamin D|50,000 IU supplementation bi-monthly.
89333154|NCT01354262|No Intervention|Control Group|Patients will be followed from baseline to 12 and 24 week follow up. Patients do not receive any research treatment or intervention beyond the standard care of their diabetes. This group are patients with normal levels of Vitamin D.
89333155|NCT03932617||fluid responders|
89333156|NCT03932617||fluid non responders|
89333157|NCT03521674|Other|Foley catheter|Foley catheter will be inserted through the cervical os and it will be filled with 40 ml saline. After insertion gentle traction will be applied for cervical ripening. Pregnancy termination will be achieved.
89333158|NCT03521674|Other|Double-balloon catheter|Double-balloon catheter will be inserted through the cervical os and both baloons will be filled with 40 ml saline. No traction will be applied. Pregnancy termination will be achieved.
89333159|NCT01343498|Experimental|BEZ235|
89333160|NCT01221259|Experimental|Drug E2212|
89333161|NCT01221259|Placebo Comparator|Placebo|
89333162|NCT03521050||implanted defibrillator lead|patients having an ICD implanted and having follow-up at the investigators center
89333163|NCT01348568|Experimental|Low glycemic index diet with canola oil bread|Subjects will be given whole wheat bread which includes canola oil, and advised to follow a diabetic diet using low glycemic index foods.
89333164|NCT01348568|Active Comparator|high fiber diet|Subjects will be given whole wheat bread, and advised to follow a healthy high fiber diabetic diet.
89333165|NCT01221337|Other|haemodialyzer EVODIAL-haemodialyzer VIE|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
89333166|NCT01221337|Other|haemodialyzer VIE-haemodialyzer Evodial|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
89333167|NCT01354340|Experimental|Limicol simple dose|
89333168|NCT01354340|Experimental|Limicol double doses|
89333169|NCT01354340|Placebo Comparator|Placebo|
89333170|NCT01130233|Experimental|robotic|robotic assisted rectal resection
89333171|NCT01130233|Active Comparator|laparoscopic|laparoscopic rectal resection
89333172|NCT03496012|Experimental|BIIB111 High Dose|Participants will receive a single administration of high dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
89333173|NCT03496012|Experimental|BIIB111 Low Dose|Participants will receive a single administration of low dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
89333174|NCT03496012|No Intervention|Untreated Control Group|Participants will receive no sham surgery or study medication.
89333175|NCT01348646|Other|Lifestyle counseling|
89333176|NCT01128283||Sepsis|Patients with severe sepsis
89333177|NCT01128283||Non-infected|ICU patients without evidence of infection
89333178|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fasted|Single dose phenylephrine HCl extended release tablet administered under fasted conditions on Day 1 in one of four study periods
89333179|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fed|Single dose phenylephrine HCl extended release tablet administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
89333180|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fasted|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered under fasted conditions on Day 1 in one of four study periods
89333181|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fed|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
89333182|NCT03520972|Experimental|PB-119 75ug|PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
89333183|NCT03520972|Experimental|PB-119 150ug|PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
89333184|NCT03520972|Experimental|PB-119 200ug|PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
89333185|NCT03520972|Placebo Comparator|placebo|placebo injection subcutaneously injected once-weekly for 12 weeks
89333186|NCT03774433|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
89333187|NCT02289040||Children undergoing cardiac surgery|Paediatric patients (<17 years with a body weight >2000g) undergoing cardiac surgery for congenital heart disease with extracorporeal circulation
88806784|NCT05427474|Active Comparator|propranolol group|addding propranolol to the traumatic brain injury protocol in Emergency ICU
88806785|NCT05427474|Active Comparator|combined propranolol and gabapentin|adding propranolol and gabapentin to the traumatic brain injury protocol in Emergency ICU
88806786|NCT05424211|Experimental|Music group|the group using the music therapy mobile application
89333188|NCT02289118||Diagnostic Imaging|[18F]T807 imaging tracer.
89333189|NCT01224535|Experimental|Maize porridge with Amaranth|Maize porridge enriched with amaranth grain flour at 70:30 maize/amaranth ratio (80g/day)
89333190|NCT01224535|Active Comparator|Maize flour with multiple micronutrients|Maize porridge fortified with a multiple micronutrient powder (MixMe™)
89333191|NCT01224535|Placebo Comparator|Maize Porridge|Plain maize porridge group
89333192|NCT02291770|Active Comparator|Mesenchymal stem cells (MSC)|"Patients with newly diagnosed cGvHD receive primary treatment plus MSC:~MSC+prednisone+cyclosporine;~MSC+prednisone+tacrolimus;~MSC+prednisone+mycophenolate mofetil."
89333193|NCT02291770|Placebo Comparator|Placebo|"Patients with newly diagnosed cGvHD receive primary treatment:~Placebo+prednisone+cyclosporine;~Placebo+prednisone+tacrolimus;~Placebo+prednisone+mycophenolate mofetil."
89333194|NCT03927235|Sham Comparator|the freezing time of 3s|Transbronchial cryobiopsy in the freezing time of 3s
89333195|NCT03927235|Experimental|the freezing time of 4s|Transbronchial cryobiopsy in the freezing time of 4s
89333196|NCT03927235|Experimental|the freezing time of 5s|Transbronchial cryobiopsy in the freezing time of 5s
89333197|NCT03927235|Experimental|the freezing time of 6s|Transbronchial cryobiopsy in the freezing time of 6s
89333198|NCT02289196|Experimental|Vx-006: 0,5mg|Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks
89333199|NCT02289196|Experimental|Vx-006: 1mg|Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks
89333200|NCT02289196|Experimental|Vx-006: 5mg|Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks
89333201|NCT02289196|Experimental|Vx-006: 10mg|Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks
89333202|NCT02291926|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
89333203|NCT01221493|Experimental|Cryo biospy|
89333204|NCT02289274|Experimental|NVP-1203|NVP-1203
89333205|NCT02289274|Active Comparator|Eperisone SR tab. + and Airtal tab.|Eperisone HCl and aceclofenac
88806787|NCT05424211|No Intervention|control group|the group that received routine care and treatment
88806788|NCT05418647|Experimental|high dialysate Na|They will receive high dialysate sodium (Na = 141 mmol/L) for 8 weeks.
89333206|NCT01224613|Active Comparator|Intanza - self-administered|Self-administered intradermal influenza vaccine
89333207|NCT01224613|Active Comparator|Intanza - nurse-administered|Nurse-administered intradermal influenza vaccine
89333208|NCT03932695|Active Comparator|High dose Milk peptides|2800mg of whey protein hydrolysates single dose
89333209|NCT03932695|Active Comparator|Low dose Milk peptides|1400mg of whey protein hydrolysate Single dose and 6 weeks intervention
89333210|NCT03932695|Placebo Comparator|Placebo|maltodextrin
89333211|NCT03522922|Active Comparator|Dermaroller arm|Patients received a series of six treatments by dermaroller at 4 weeks interval and no topical anti scar treatment in between sessions.
89333212|NCT03522922|Active Comparator|Dermaroller + topical Vit. C arm|Patients received a series of six treatments by dermaroller at 4 weeks interval with the same maneuver and instructions as first group and each session was followed by immediate application of topical vitamin C serum plus once daily application in between sessions.
89333213|NCT03522922|Active Comparator|Topical Vit. C arm|Patients received once daily topical vitamin C serum capsule at night for six months. With monthly evaluation.
89333214|NCT03930433|Active Comparator|Nebivolol group|Oral Nebivolol 5mg / day (2 weeks) -> 10mg / day (10 weeks)
89333215|NCT03930433|Placebo Comparator|Diltiazem group|Oral Diltiazem 90mg / day (2 weeks) -> 180mg / day (10 weeks)
89333216|NCT03930433|Placebo Comparator|Nebivolol+Diltiazem group|Oral Nebivolol 2.5mg / day + Oral Diltiazem 45mg / day (2 weeks) -> Oral Nebivolol 5mg / day + Oral Diltiazem 90mg / day (10 weeks)
89333217|NCT03520894|Experimental|Neoadjuvant radiotherapy arm|Early breast cancer patients eligible for breast conservative surgery will undergo neoadjuvant radiotherapy with Cyberknife robotic system
89333218|NCT01585519|No Intervention|(Group 1) Low Apple Diet|
89333219|NCT01585519|Experimental|(Group 2) 2 High Apples|
89333220|NCT01585519|Experimental|(Group 3) 2 Low Apples|
89333221|NCT01585519|Experimental|(Group 4) 2 x 4.4g apple granules|
89333222|NCT01585519|Experimental|(Group 5) 2 x Apple Extract Capsules|
89333223|NCT01221571|Experimental|AFM13|IV (intravenous) infusion, dose escalation
89333224|NCT01224769||bendamustine +/- rituximab|
89333225|NCT02289430|Experimental|Crestor+Ezetrol|rosuvastatin+ezetimibe
89333226|NCT02289430|Active Comparator|Ezetrol|ezetimibe
89333227|NCT02289430|Active Comparator|Crestor|rosuvastatin
89333228|NCT03930511|No Intervention|PADL at the beginning of PR|First assessment of patients starting Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
89333229|NCT03930511|Experimental|PADL at discharge of PR|Assessment of patients at discharge of Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
89333230|NCT03930511|No Intervention|PADL at 6 months follow-up|Half-a-year reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
89333231|NCT03930511|No Intervention|PADL at 1 year follow-up|Yearly reassessment of patients on Pulmonary Rehabilitation, including a 4 day time telemonitoring of physical activity on daily life, 6 minute walk test, International Physical Activity Questionnaire (IPAQ), EuroQoL, mMRC, COPD Assessment Test (CAT), London Chest Activity of Daily Living (LCADL) and Hospital Anxiety and Depression Scale (HADS).
89333232|NCT02289508||acute decompensated heart failure|Patients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
89333233|NCT02289508||compensated heart failure|compensated heart failure (cHF) is defined as the existence of heart failure in the absence of any acute exacerbation but which may either include typical chronic symptoms and signs or may be asymptomatic but with evidence of cardiac dysfunction i.e. a reduced ejection fraction.
89333234|NCT02289508||non-heart failure patients|Non-heart failure patients (nHFp) are a patient control group with suspected heart failure but who after further assessment are found not to meet the criteria. Such patients may subsequently be found to have COPD, anaemia, over transfusion. As the purpose of this study is to assess the potential value of USCOM parameters in the assessment of patients with possible heart failure in the clinical setting, it is important to include patients without heart failure.
89333235|NCT02289508||healthy controls|Healthy controls are subjects with not acute or chronic illness.
89333236|NCT01224847|Active Comparator|Tetracaine gtt|Pre-Intravitreal injection - 1 gtt Tetracaine topically
89333237|NCT01224847|Active Comparator|Tetraciane gtt + Lidocaine pledget|1 gtt Tetracaine pre-IVT injection + application Lidocaine pledget to injection site
89333238|NCT01224847|Active Comparator|Cocaine gtt alone|1 gtt pre-IVT injection
89333239|NCT02289586|Active Comparator|hypoxemia, central airway stenosis.|"Inclusion Criteria:~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
89333240|NCT02289586|Experimental|hypoxemia, central airway stenosis|"Inclusion Criteria:~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
89333241|NCT03740581|Active Comparator|Intensive|New anti-diabetic drug regimen with (mandatory) Insulin >= 3 times per day
89333242|NCT03740581|No Intervention|Conventional|Old anti-diabetic drug regimen with or without Insulin (<3 times per day) to be continued as before
89333243|NCT01329211||Gastroparesis Patients|
89333244|NCT01329211||Gastroparesis Patients' Caregivers|
89333245|NCT02289664|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
89333246|NCT02289664|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89333247|NCT03874897|Experimental|CAR-CLDN18.2 T-Cells|The subjects enrolled will be sequentially assigned to the corresponding dose level.
89333248|NCT02294188|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
89333249|NCT02294188|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
89333250|NCT01127035|Experimental|SLIT|sublingual immunotherapy biologically standardized
89333251|NCT01127035|Placebo Comparator|placebo|same preparation of SLIT without the allergen
89333252|NCT03520816|Experimental|Burn Physiotherapy Protocol Group|Patients in the treatment group have been received to the physiotherapy programme from the first day of their stay in the hospital.
89333253|NCT03520816|No Intervention|Control Group|The control group consisted of patients who could not receive physiotherapy due to various reasons.
89333254|NCT01127113|Active Comparator|SPIO-labelled mononuclear cells|
89333255|NCT01127113|Placebo Comparator|Unlabelled mononuclear cells|
89333256|NCT01127113|Active Comparator|SPIO alone|
89333257|NCT02294266|Experimental|Mephedrone and alcohol|"Mephedrone 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
88806789|NCT05418647|Experimental|low dialysate Na|They will receive low dialysate sodium (Na = 136 mmol/L) for 8 weeks.
89333258|NCT02294266|Active Comparator|Mephedrone|"Mephedrone 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
89333259|NCT02294266|Active Comparator|Alcohol|"Lactose 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
89333260|NCT02294266|Placebo Comparator|Placebo|"Lactose 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
89333261|NCT01227733||Breast Tumor|Breast Tumor Blocks
89333262|NCT03521440|Experimental|Psychomotor Massage|Participants will be randomly allocated to individual sessions, and will receive two 30-minute individual sessions per week, for 8 weeks.
89333263|NCT03521440|Experimental|Progressive Muscle Relaxation|Participants will participate in 30-minute group sessions, twice a week, for 8 weeks.
89333264|NCT03521440|No Intervention|Waiting List|Participants will maintain their daily routines through the experimental intervention period. After finishing all periods of data collection, participants will be invited to participate in one of the interventions previously offered to the experimental groups.
89333265|NCT02294344|Experimental|DFPP&CTX|double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP&CTX)
89333266|NCT02294344|Active Comparator|cyclophosphamide|cyclophosphamide(CTX) pulse therapy
89333267|NCT03926455|Experimental|Typhax 0.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
89333268|NCT03926455|Experimental|Typhax 2.5 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
89333269|NCT03926455|Experimental|Typhax 10 mcg|Vaccine was administered IM on Days 0 and 28 (n=9).
89333270|NCT03926455|Active Comparator|Typhim Vi 25 mcg|Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
89333271|NCT03926455|Placebo Comparator|Placebo (saline)|Placebo control was administered IM Days 0 and 28 ( n=9)
89333272|NCT03520738|Other|Chronic Kidney Disease|"Blood and urinary samples on the following patients:~10 Stage 1 and 2 CKD patients 10 patients 6 weeks after graft 10 patients on maintenance dialysis."
89333273|NCT03520738|Other|Pseudoxanthoma elasticum (PXE)|"Blood and urinary samples on the following patients:~10 patients with pseudoxanthoma elasticum (PXE) with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
89333274|NCT03520738|Other|Hypophosphatasia (HPP)|"Blood and urinary samples on the following patients:~4 patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
89333275|NCT01127191||Military|
89333276|NCT02289976|Active Comparator|femoral condyle|Core decompression of the talar avascular necrosis followed by free microvascular femoral condyle grafting
89333277|NCT02289976|Active Comparator|core decompression|Core decompression and nonvascularized autograft from the iliac crest
89333278|NCT01130311|Experimental|Cholecalciferol (Vitamin D)|Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
89333279|NCT01130311|Placebo Comparator|SALINE, INTRAMUSCULAR INJECTION|NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial
89333280|NCT03520582||Volunteers|Cohort of 10 healthy subjects. The tube will be placed and removed by a gastroenterologist experienced in performing endoscopic postpyloric tube placement. Secondly, a second tube will be placed and removed.
89333281|NCT03520582||Mechanically ventilated ICU|Cohort of 20 mechanically ventilated intensive care patients requiring a placement of a postpyloric feeding tube on clinical indications.
89333282|NCT03926377|Other|Clobetasol propionate treatment|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
89333283|NCT03132688||children < 2 years old|Children under 2 years of age who received intravenous propofol during general anesthesia.
89333284|NCT01227811|Active Comparator|Enablex(R) 15 mg , single dose|
89333285|NCT01227811|Experimental|Darifenacin 15 mg tablets, single dose|
89333286|NCT01225081|Experimental|ASP group|ASP1941 and pioglitazone
89333287|NCT01225081|Placebo Comparator|Placebo group|placebo and pioglitazone
89333288|NCT02294422|Experimental|2. LOR and aneroid manometer group|after inflating the endotracheal tube (ETT) cuff using a loss of resistance syringe (BD Epillor LOR), the LOR syringe is left attached to the pilot balloon and and any excess pressure will be passively released until the plunger stops drawing back.
89333289|NCT02294422|Placebo Comparator|1. PBP and aneroid manometer group|The anaesthesia care provider shall inflate the ETT cuff via the pilot balloon with small volumes of air as he/she 'feels ' for the pressures in the pilot balloon to a pressure he/she thinks is just enough. An aneroid manometer (VBM, Germany. Accurate in the range 0-120 cmH2O +-2 cmH2O) shall then be attached by the investigator and measurement of the pressure taken.
89333290|NCT02298166|Placebo Comparator|Standard arm|chemotherapy (MC) in combination with placebo
89333291|NCT02298166|Experimental|Experimental arm|chemotherapy (MC) in combination with crenolanib
89333292|NCT02298244|Active Comparator|PV isolation + GP Ablation|
88806790|NCT05414396|Experimental|Supportive care (EML program)|Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.
89333293|NCT02298244|Active Comparator|PV isolation + GP ablation + Pulmonary GP ablation|
89333294|NCT03932149|Experimental|Experimental Group|Real stimulation
89333295|NCT03932149|Sham Comparator|Control Group|Sham stimulation
89333296|NCT03520426|Experimental|Votiva RF|Patients will undergo radiofrequency treatment using the Votiva FormaV and FractoraV hand pieces, using the device's standard protocol. Patients will have 3 treatments spaced 3-4 weeks apart and two follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
89333297|NCT03520426|Sham Comparator|Votiva RF Sham|Patients will undergo the acts of receiving radiofrequency treatment with the Votiva FormaV and FractoraV hand pieces, but no direct energy will be applied. Patients will have 3 treatments spaced 3-4 weeks apart and 2 follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
89333298|NCT01127269|Experimental|Insulin Glargine|"Patients will receive insulin glargine titrated based on standard of care as recommended by the ADA/EASD Consensus Algorithm. Step 1: insulin glargine initiation regimen for insulin naive patients/ Switch to insulin glargine for patient already treated with basal insulin.~Step 2: the insulin dosage of patients will be titrated according to the ADA/EASD Consensus Algorithm."
89333299|NCT02294578||Lung Cancer|Patients with biopsy proven lung cancer
89333300|NCT02294578||Controls|Patients with lung lesions suspicious for the presence of cancer and with cancer excluded after further diagnostic study
89333301|NCT03932227|Other|Cardioskin-Holter|Subjects in the randomized group A, start by wear the Cardioskin during 24h, and after wear the Holter during 24h.
89333302|NCT03932227|Other|Holter-Cardioskin|Subjects in the randomized group B, start by wear the Holter during 24h, and after wear the Cardioskin during 24h.
89333303|NCT02298400|Active Comparator|Acuvue®Oasys® Lenses(senofilcon A)|Acuvue® Oasys® Lenses (senofilcon A) contact lenses
89333304|NCT02298400|Active Comparator|Bausch + Lomb PureVision (balafilcon A)|30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
89333305|NCT02298400|Active Comparator|Clariti® 1-Day (Somofilcon A)|Clariti® 1-Day (Somofilcon A) contact lenses
88806791|NCT05377736|Experimental|Molecular testing|Descriptive and explorative study including identical molecular analyses applied to all included patients
89333306|NCT03930355||Transfused|Patients who received blood transfusion in the perioperative period
89333307|NCT03930355||Non transfused|Patients who did not receive blood transfusion in the perioperative period
89333308|NCT03514654|Active Comparator|Mastectomy +/- reconstruction|Either a simple mastectomy or skin sparing mastectomy technique will be used. Women in this arm will be offered either immediate or delayed breast reconstruction according to standard practice. Reconstructions will be followed by chemotherapy and/or endocrine therapy as determined by local clinicians . Chest wall and/or regional nodal radiotherapy will be prescribed according to local centre policy.
89333309|NCT03514654|Active Comparator|Therapeutic Mammoplasty|"Therapeutic Mammoplasty (TM) comprises well-established surgical techniques involving volume displacement using breast reduction techniques, or volume replacement to maximize the volume of tissue that can be excised resulting in effective local control whilst maximizing cosmetic outcomes. This group will either have one disease site lumpectomy in the case of multifocal tumours or distant disease site lumpectomies in multicentric cancers."
89333310|NCT03929965|Experimental|advanced solid tumors with FGFR alteration|
89333311|NCT02298478|Experimental|Group without support by the therapist|"Intervention group that do the NO-FEAR Airlines program and does not receive support by the therapist."
89333312|NCT02298478|Experimental|Group with support by the therapist|"Intervention group that do the NO-FEAR Airlines program and receives support by the therapist (a brief weekly five-minutes call)."
89333313|NCT02298478|Other|Waiting list control group|"Control group that could access the NO-FEAR Airlines program after waiting for 6 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
89333314|NCT01127425|Active Comparator|1|Intervention: Surgery: laparoscopic sigmoid resection without fast track postoperative care
89333315|NCT01127425|Active Comparator|2|Intervention: Surgery: conventional (open) sigmoid resection without fast track postoperative care
89333316|NCT02298556||Hypertensive patients|Hypertensive patients with elevated heart rate and type 2 diabetes mellitus
89333317|NCT03929809||Adult Single-sided deafness|Adult subjects with unilateral single-sided deafness at least 6 months (to ensure stability of hearing loss), but no greater than 10 years will be implanted with a MED-EL Synchrony Cochlear Implant.
89333318|NCT01221883|Placebo Comparator|Placebo|Placebo capsule in ER, identical follow up like those in the active arm.
89333319|NCT01221883|Experimental|Diazepam|10 mg of Diazepam mg orally at ER only (a single administration)
89333320|NCT02294656|Experimental|RANIBIZUMAB|Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
89333321|NCT02294656|Active Comparator|TRIAMCINOLONE ACETONIDE|Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
89333322|NCT01225237|Experimental|ramosetron group|
89333323|NCT01225237|Placebo Comparator|Placebo group|
89333324|NCT03517930|Experimental|Test treatment|Healthy adult subjects under fasted conditions
89333325|NCT03517930|Active Comparator|Reference treatment|Healthy adult subjects under fasted conditions
89333326|NCT02292316|Experimental|Fall with fracture|Fall with fracture in the last 6 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
89333327|NCT02292316|Sham Comparator|controls|Fall without fracture in the last 12 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
89333328|NCT03932383|Experimental|Modified CPAP|Single arm cohort study of modified mask
89333329|NCT02294812|Active Comparator|Control, cognitive training|Participants in the control arm will receive cognitive training for cognitive abilities not affected by age-related hearing loss.
89333330|NCT02294812|Experimental|Experimental, cognitive training|Participants in the experimental arm will receive cognitive training for cognitive abilities affected by age-related hearing loss.
89333331|NCT02294812|Active Comparator|Active Control, crossword training|Participants in this group will undergo crossword puzzle training. The purpose of this group is control for any effects that may be due to engaging in cognitive training.
89333332|NCT01130467||Normal control|
89333333|NCT01130467||pure ADHD|
89333334|NCT01130467||ADHD with comorbidity|
89333335|NCT02294890||Fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
89333336|NCT02294890||No fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
89333337|NCT03517774|Experimental|3D Printed Socket|All participants will received a 3D Printed Prosthetic
89333338|NCT01128439||1|
89333339|NCT03517696|Active Comparator|Membrane Sweeping|Membrane sweeping
89333340|NCT03517696|No Intervention|Control|Routine vaginal exam
89333341|NCT03930043||Health Control|
89333342|NCT03930043||Non-gastrointestinal Lymphoma|
89333343|NCT03930043||Gastric Lymphoma|
89333344|NCT03930043||Intestinal Lymphoma|
89333345|NCT02295046|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
89333346|NCT02295046|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
89333347|NCT03926221|Experimental|PBC_I plus TranS-C|The Parent Behavior Change Intervention (PBC-I) is a behavioral intervention intended to teach parent behavior change techniques to better support their adolescents to improve sleep health behavior. The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
89333348|NCT03517618|Experimental|S-1 + leucovorin|Single arm
89333349|NCT03929887||KORNERSTONE|"Glomerulonephritis (GN) such as Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), Membranous nephropathy (MN), and Immunoglobulin A nephropathy (IgAN)~Participants enrolled in KORNERSTONE with a biopsy proven GN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
89333350|NCT02295124|Active Comparator|Oxycodone|Patients will be prescribed oxycodone 10mg (5mg if > age 65) every 2 hours as needed for post-operative pain management in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
89333351|NCT02295124|Active Comparator|Hydromorphone|Patients will be prescribed hydromorphone 2mg (1mg if > age 65) every 2 hours as needed in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
89333352|NCT03925051|Experimental|CMAB807|60mg by subcutaneous injection once on the first day.
89333353|NCT03925051|Active Comparator|Prolia®|60mg by subcutaneous injection once on the first day.
89333354|NCT03514576|Experimental|Pasireotide75|75 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
89333355|NCT03514576|Experimental|Pasireotide150|150 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
89333356|NCT03929731||Polypoidal Choroidal Vasculopathy RCT|Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T&E studies
89333357|NCT02298790|Experimental|Early Meals|Meals are eaten early in the wake episode
89333358|NCT02298790|Experimental|Late Meals|Meals are eaten late in the wake episode
89333359|NCT01128517|Experimental|Bahavioral|Education about complementary food given to mothers
89333360|NCT02299024|No Intervention|Control|Patients in this arm are discharged from the Northwestern Emergency Department with standard communication about their prescribed opioid pain medication from their care providers. They are called for a follow up survey 4-7 days after their visit.
89333361|NCT02299024|Experimental|Dual Modality Educational Intervention|"Patients in this arm are discharged from the ED with an additional information sheet about their prescribed opioid pain medication, via the intervention titled Additional Opioid Information. The sheet is read aloud to them by a research assistant. They are called 4-7 days later for a follow up survey."
89333362|NCT03929419|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
89333363|NCT03929419|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
89333364|NCT02299102|Other|Jamshidi Manual Standard Device|The Jamshidi manual standard device will be randomized for use on the right or left iliac crest
89333365|NCT02299102|Other|OnControl Powered Ported Device|The OnControl power ported device will be used on the opposite iliac crest
89333366|NCT01228279|Active Comparator|DIANEAL|One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
89333367|NCT01228279|Active Comparator|EXTRANEAL|The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
89333368|NCT03514342||Interscalene brachial plexus block|Ultrasound-guided interscalene brachial plexus block with 25 ml to 30 ml of 0.75% ropivacaine
89333369|NCT01228045|Experimental|Trastuzumab in Combination with TS-ONE and cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
89333370|NCT03514264|Experimental|GUTTA PERCHA and AHPLUS cement (group A)|43 patients will undergo endodontic treatment with obturation with AHPlus cement and Gutta-Percha cones. This treatment will be performed in 2 sessions. First intervention: endodontic instrumentation and introduction of intra-canal medication that will remain in the tooth for 4 weeks. Second intervention: removal of intracanal medication and filling with cement and gutta percha AHPlus.
89333371|NCT03514264|Experimental|PBS CIMMO cement (group B)|43 patients will undergo endodontic treatment with PBS CIMMO® cement (single material).This treatment will be performed in 1 session.Single intervention: endodontic instrumentation and cement filling PBS CIMMO.
89333372|NCT02292394|Experimental|Multicomponent Cognitive Behavioral Telephone Intervention|In this study, we will apply a telephone intervention that is a modified version of a brief prevention intervention for depressed caregivers that previously was applied in person in a group format during five 90-minute sessions (Vazquez et al., 2014). During the intervention, participants will be trained in various behavioral and cognitive abilities such as increasing pleasant activities, self-reinforcement, relaxation techniques, assertive communication, strategies to increase social contacts and social skills, and strategies to increase positive thoughts and decrease depressive ones.
89333373|NCT02292394|Experimental|Telephone Intervention Pleasant Activities|This intervention is also a modified version of a protocol described by Vazquez et al. (2014). However, in this case, we will specifically focus on the behavioral activation components of the multicomponent cognitive-behavioral telephone intervention. This intervention will also be structured in groups and administered by phone in five 90-minute sessions.
89333374|NCT02292394|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms. The use of such treatments will be recorded.
89333375|NCT03929497|Experimental|Lu AF11167|
89333376|NCT03514030||positive|serum AQP4-antibody is positive
89333377|NCT03514030||negtive|serum AQP4-antibody is negtive
89333378|NCT03925909|Experimental|Eriomin 200 mg|The volunteers will receive one capsule containing 200 mg eriocitrin
89333379|NCT03925909|Experimental|Eriomin 400 mg|The volunteers will receive one capsule containing 400 mg eriocitrin
89333380|NCT03925909|Experimental|Eriomin 800 mg|The volunteers will receive one capsule containing 800 mg eriocitrin
89333381|NCT03925909|No Intervention|Placebo|The volunteers will receive a capsule containing corn starch (placebo)
89333382|NCT03517462|Experimental|Ivermectin|Single dose directly observed treatment with Ivermectin 3Mg Tab (150 ug/kg) delivered orally.
89333383|NCT03929653||Advanced Refractory Solid Tumors|Patients with advanced refractory solid tumors receive personalized therapy with the guidance of Molecular Tumor Board after the NGS(next generation sequencing).
89333384|NCT03925129|Experimental|TENS|
89333385|NCT03925129|Sham Comparator|Sham TENS|
88806792|NCT05363345|Experimental|Vortic Catch V basket catheter|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter following endoscopic papillary large balloon dilation.
89333386|NCT02295202|Experimental|CPAP|CPAP: Continuous Positive Airway Pressure - Device used for treating OSA during sleep.
89333387|NCT02295202|Placebo Comparator|Placebo|Nasal Strips
89333388|NCT06142734|Other|mini-incision open dismembered pyeloplasty|Open surgery
89333389|NCT06142734|Other|Laparoscopic dismembered pyeloplasty|Minimally invasive surgery
89333390|NCT06142721||ITW Group|3D gait analysis was applied to children with idiopathic toe walking. Static, kinematic and kinetic walking parameters were evaluated.
89333391|NCT06142721||DCP Group|3D gait analysis was applied to diparetic children who were able to walk independently. Static, kinematic and kinetic walking parameters were evaluated.
89333392|NCT06142721||Healthy Group|3D gait analysis was applied to healthy children. Static, kinematic and kinetic walking parameters were evaluated.
89333393|NCT06142708|Experimental|Dual trigger (GnRH-agonist plus hCG)|Participants in this arm will be administered a GnRH-agonist trigger plus hCG (dual trigger) for final maturation
89333394|NCT06142708|Active Comparator|Gn-RH-agonist only trigger|Participants in this arm will be administered a GnRH-agonist trigger only for final maturation
89333395|NCT06142643|Experimental|Device under investigation|
89333396|NCT06142617|Experimental|experimental group|Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks. Osimertinib will be the sequential treatment strategy at progression until resistance develops.
89333397|NCT06142604|Experimental|Flecainide|Participants randomized to the flecainide arm will be prescribed a single 300mg dose of oral flecainide, to be given as soon as possible after study randomization. Rate controlling drugs will be prescribed and titrated to achieve a heart rate of less than 100 beats per minute and symptom minimization.
89333398|NCT06142604|No Intervention|No flecainide|Participants randomized to the no flecainide arm will not be prescribed flecainide. Rate controlling drugs will be prescribed and titrated to achieve a heart rate of less than 100 beats per minute and symptom minimization.
89333399|NCT06142591|Active Comparator|Group A (10mg oxycodone)|The burn wound was covered with a three-layer sterile dressing. The first layer was a dressing soaked in Octanisept (a solution of octenidine dihydrochloride and phenoxyethanol) with 10mg Oxycodone, the second dressing with paraffin, and the third dry dressing. Octenisept (Schulke&Mayer Poland, 1000ml) is a disinfectant liquid. The 1 gram of Octenisept contains 1 mg of octenidine dihydrochloride and 20 mg of Phenoxyethanol.
89333400|NCT06142591|Active Comparator|Group B (20mg oxycodone)|The burn wound was covered with a three-layer sterile dressing. The first layer was a dressing soaked in Octanisept (a solution of octenidine dihydrochloride and phenoxyethanol) with 20mg Oxycodone, the second dressing with paraffin, and the third dry dressing. Octenisept (Schulke&Mayer Poland, 1000ml) is a disinfectant liquid. The 1 gram of Octenisept contains 1 mg of octenidine dihydrochloride and 20 mg of Phenoxyethanol.
89333401|NCT06142578|Experimental|Device under investigation|
89333402|NCT06142565|Experimental|Olfactory training with nose plugs|Participants will complete olfactory training with scented nose plugs.
89333403|NCT06142565|Active Comparator|Olfactory training with household odors|Participants will complete olfactory training with odors found in their household.
89333404|NCT06142500|Experimental|Patients with testicular cancer|Patient with testicular cancer
89333405|NCT06142500|Active Comparator|First-degree family members of patients with testicular cancer|First-degree family members of patients with testicular cancer
89333406|NCT06142487|Experimental|Silk Pillowcase|100% Mulberry Silk Pillowcase used every night
89333407|NCT06142487|Active Comparator|Cotton Pillowcase|100% Cotton Pillowcase used every night
89333408|NCT06142474|No Intervention|acute decompensated HF Patients|acute decompensated HF Patients 2：1，have 50 Patients control and 100 Patients randomly assigned empagliflozin or dapagliflozin
89333409|NCT06142474|Experimental|empagliflozin 10mg|acute decompensated HF Patients 2：1,have 50 Patients control and 100 Patients randomly assigned empagliflozin or dapagliflozin ,3 days before ventilator weaning in a ratio of 1:1.empagliflozin 10 mg once daily
89333410|NCT06142474|Experimental|dapagliflozin 10mg|acute decompensated HF Patients 2：1,have 50 Patients control and 100 Patients randomly assigned empagliflozin or dapagliflozin ,3 days before ventilator weaning in a ratio of 2:1. dapagliflozin 10 mg once daily
89333411|NCT06142448|Experimental|Responders|
89333412|NCT06142448|No Intervention|Non-responders|
89333413|NCT06142435||Controls|Participants should not be part of the Intended Use Population. Subjects that present to the hospital, clinic, or emergency department, either as a patient or non-patient, with no history of head trauma and, are 18-45 years of age.
89333414|NCT06142435||TBI-Suspected Patients|TBI participants 18-45 years of age, recruited from patients at a clinical research facility who present with head trauma. Clinical evaluation for the patient can be positive (target condition present) or negative (target condition absent) for mTBI. Testing will occur on Day-0, Day-14, and Day-30.
89333415|NCT06142422|Experimental|experimental group with intermittent Theta Burst Stimulation|The procedure under study is the use of a stimulation device to perform intermittent Theta Burst Stimulation treatment on the precuneus to treat resistant schizophrenia. Targeting requires a neuronavigation device.
88806793|NCT05363345|Active Comparator|ordinary basket catheter|Common bile duct stones (≧ 10 mm) are removed by using ordinary basket catheter following endoscopic papillary large balloon dilation.
89333416|NCT06142422|Placebo Comparator|control group with placebo stimulation|"In the control group, stimulation is simulated using a Sham or placebo coil. The stimulation device is the same as for the experimental group, only the coil differs."
89333417|NCT06142370|Other|Positive LCV|A patient who tests positive by clinical exam of a LCV.
89333418|NCT06142344|Experimental|Ho-166 radioembolization|Patients will undergo standard procedures for holmium radioembolization
89333419|NCT06142318|Experimental|Pirfenidone group|Calculate from 2 weeks before the start of radiotherapy: week 1: pirfenidone 200mg, tid; week 2: pirfenidone 400mg tid; during radiotherapy: pirfenidone 600mg tid.
89333420|NCT06142318|Placebo Comparator|Control group|Calculate from 2 weeks before the start of radiotherapy: week 1: placebo 200mg, tid; week 2: placebo 400mg tid; during radiotherapy: placebo 600mg tid.
89333421|NCT06142279|Other|COVID +|participant with a positive SARS-CoV-2 PCR test
89333422|NCT06142279|Other|COVID -|participant with a negative SARS-CoV-2 PCR test
89333423|NCT06142266|Active Comparator|Intervention group|The intervention group (n=60) will undergo a 12-week pulmonary rehabilitation program. This program will consist of twice-weekly supervised exercise sessions, including aerobic training and resistance exercises targeting the lower limbs.
89333424|NCT06142266|Active Comparator|Control group|The control group (n=60) will receive usual medical care according to guidelines, which may include bronchodilator/anti-inflammatory therapy but no formal pulmonary rehabilitation.
89333425|NCT06142253|Experimental|WATER+CT|This is 8-month long two phase intervention consisting of: 1) 6 months of aquatic exercise followed by 2) 2 months of cognitive training.
89333426|NCT06142253|Other|Usual Care|This arm consists of psychoeducation regarding brain health and healthy lifestyles.
89333427|NCT06142240|Active Comparator|programe at the health centre|Subjects who are included in the study will perform a therapeutic exercise programme which will have a duration of 8 weeks and 2 sessions per week of 1h duration. Participants assigned to the supervised group will perform the programme at the health centre
89333428|NCT06142240|Experimental|programe at the health home|Subjects who are included in the study will perform a therapeutic exercise programme which will have a duration of 8 weeks and 2 sessions per week of 1h duration. Participants assigned to the to the home group will receive telematic supervision (via videoconference).
89333429|NCT06142227|No Intervention|Control Group|Routine dental treatment will be applied to the control group. No action will be taken.
89333430|NCT06142227|Experimental|Experimental Group|Before dental treatment, the child will be read a story book with pictures of the dental clinic.
89333431|NCT06142214||Endometriosis- Case group|Patients between the ages of 18-45, who applied to the Gynecology outpatient clinic of Etlik City Hospital and were followed up in our hospital, who were suspected of endometriosis on ultrasound or MRI or CT, and who were operated and whose postoperative pathology was compatible with endometriosis will be included in the study.
89333432|NCT06142214||Healthy patients-Control|Patients who underwent bilateral tubal ligation in our Gynecology Clinic and who did not have any pelvic pathology will be included as the control group.
89333433|NCT06142201||JT001|
89333434|NCT06142201||No anti-SARS-CoV-2 treatment|
89333435|NCT06142188||Relmacabtagene Autoleucel|Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
89333436|NCT06142175||Relmacabtagene Autoleucel|Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
88806794|NCT05355792|Experimental|Single tooth restorations|A single, open-label group with patients in need of single tooth restorations will receive an OmniTaper EV implant system available in the following sizes: diameter 3.4, 3.8, 4.5 and 5.5 mm and lengths 8, 9.5, 11, 13, 15 and 18 mm.
89333437|NCT06142162||control|healthy children
89333438|NCT06142162||sepsis-1|children with sepsis on the 1 day
89333439|NCT06142162||sepsis-7|children with sepsis on the 7 day
89333440|NCT06142162||severe bacterial infection|children with severe bacterial infection
89333441|NCT06142162||severe viral infection|children with severe viral infection
89333442|NCT06142136|Active Comparator|Vitamin D3 sublingual sprayable microemulsion.|Total participants: 34 participants Duration: 30 days.
89333443|NCT06142136|Active Comparator|Vitamin D3 oil droplets.|Total participants: 33 participants Duration: 30 days.
89333444|NCT06142136|Active Comparator|Vitamin D3 capsules.|Total participants: 32 participants Duration: 30 days.
89333445|NCT06142123|Experimental|Group A|"Group A will be treated with 3-D Ankle Mobility Exercises with combined isotonic (agonist) technique at ankle joint. Two diagonal (D2) Flexion-Extension patterns from the PNF leg patterns will be used.~Both the techniques will be first performed in prone lying against the resistance of the therapist and then in crook lying.~The patients will receive Intervention consisting 14 sets (7 sets for each 3-D extension-flexion [1 set (1 min) = exercise 30sec + rest 30 sec]) performed for 15 minutes thrice per week for four weeks"
89333446|NCT06142123|Experimental|Group B|Group B will be treated with Eccentric Heel Drop Training and Conventional physiotherapy treatment All patients will be treated once daily with 10 sets of 15 repetitions with a frequency of 2sec per repetitions and an interval of 30 sec between each set of Eccentric Heel drop training, 4 days a week for four weeks
89333447|NCT06142084|Experimental|Dietary Intervention Sequence 1 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333448|NCT06142084|Experimental|Dietary Intervention Sequence 2 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333449|NCT06142084|Experimental|Dietary Intervention Sequence 3 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333450|NCT06142084|Experimental|Dietary Intervention Sequence 4 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333451|NCT06142084|Experimental|Dietary Intervention Sequence 5 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333452|NCT06142084|Experimental|Dietary Intervention Sequence 6 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333453|NCT06142084|Experimental|Dietary Intervention Sequence 7 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333454|NCT06142084|Experimental|Dietary Intervention Sequence 8 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333455|NCT06142084|Experimental|Dietary Intervention Sequence 9 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333456|NCT06142084|Experimental|Dietary Intervention Sequence 10 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333457|NCT06142084|Experimental|Dietary Intervention Sequence 11 (Meals: Pea protein (2x), Oat protein (2x), Protein-free (1x))|"The participant will consume the below mentioned meals in a random order on five different study days (one on each visit):~Protein meal: pea protein, low bioavailability~Protein meal: pea protein, high bioavailability~Protein meal: oat protein, low bioavailability~Protein meal: oat protein, high bioavailability~Protein-free meal"
89333458|NCT06141980|Experimental|Study group (DWP16001 0.3 mg)|DWP16001 0.3mg, Tablets, Orally, Once daily
89333459|NCT06141954|Active Comparator|Ultrasound|Effect of ultrasound therapy on sacroiliac joint pain in woman postpartum
89333460|NCT06141954|Active Comparator|Low level laser|Effect of low level laser therapy on sacroiliac joint pain in woman postpartum
89333461|NCT06141941|Other|CGM|A CGM device (Dexcom sensor and transmitter) will be placed by research personnel upon presentation to Labor and Delivery unit.
89333462|NCT06141928|Other|Functional Recovery|
88806795|NCT05348681|Experimental|RIST4721 400 mg|RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks
88806796|NCT05348681|Placebo Comparator|Placebo|Placebo: 4 placebo tablets once daily for 12 weeks
89333463|NCT06141915|Experimental|Aerobic training and diet protocol group|30 patients received aerobic training and diet protocol for 12 weeks.
89333464|NCT06141915|Experimental|Aerobic training group|30 patients will receive aerobic training for 30 minutes, three times per week for 12 weeks.
89333465|NCT06141915|Active Comparator|Diet protocol group|30 patients will receive diet protocol for 12 weeks.
89333466|NCT06141863||Group 1|no disability and mild disability
89333467|NCT06141863||Group 2|moderate and severe disability
89333468|NCT06141837||Included|Patient hospitalized between 01/03/20 and 31/05/21 in an intensive care unit of the Nancy University Hospital for at less 48 h for COVID-19 acute respiratory distress syndrome and presenting a positive sample for P. aeruginosa during his stay in the intensive care unit.
89333469|NCT06141811||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-302
89333470|NCT06141811||Vehicle sheet|Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-302
89333471|NCT06141785|Experimental|Nutritional Intervention|Patients with Cancer treated with palliative chemotherapy.
89333472|NCT06141785|No Intervention|Historical control|"Patients with Cancer treated with palliative chemotherapy.~Historical Control cohort following current clinical practise, where nutritional treatment is not systematically implemented but patients can be referred to a clinical dietitian after clinical assessment by the treating physician or nurse."
88806797|NCT05347784||Patients without postoperative complications|
89333473|NCT06141772|Experimental|Kinetics of circulating tumor DNA|
89333474|NCT06141759|Experimental|Intervention group|Schroth Best Practice Exercises and Cheneau braces. There were 18 sessions, each lasting 90 minutes, a total of 6 weeks for the exercise training.
89333475|NCT06141759|No Intervention|Control Group|For six weeks, no application was made.
89333476|NCT06141707||Group I|G1 is comprised of 20 parents in charge of children and adolescents with SRBDs who will participate in pilot study.
89333477|NCT06141707||Group II|G2 132 parents in charge of children and adolescents with and without SRBDs who will answer the final version of the protocol. This group will include 66 parents in charge of participants with SRBDs and 66 parents in charge of participants without SRBDs.
89333478|NCT06141707||Group III|G3 is the group that will be used to test the reliability of the Arabic Pediatric Sleep Questionnaire (APSQ); 33 parents in charge will be randomly selected among the 66 parents in charge of subjects with SRBDs in G2.
89333479|NCT06141694|Experimental|Endovascular Robotic Navigation|
89333480|NCT06141655|Experimental|QIV-HD vaccine|EFLUELDA, Suspension for injection, one dose
89333481|NCT06141655|Active Comparator|QIV-SD vaccine|INFLUVAC TETRA, Suspension for injection, one dose
89333482|NCT06141629|Active Comparator|Accu-Chek Aviva Expert.|Accu-Chek Aviva Expert. This is a glucometer with boluscalculator.
89333483|NCT06141629|Placebo Comparator|Accu check Nano|Accu check Nano
89333484|NCT06141616|Sham Comparator|Control group|Sessions once a week, covering information about the pathophysiology of asthma, medication instructions, self-monitoring techniques, environmental control techniques, and prevention strategies for children, adolescents, and families. They will also receive physical activity recommendations, as well as information about the importance and benefits of being physically active and maintaining a healthy lifestyle. The sessions will feature educational and playful videos, presentations, and participants will be able to clarify their doubts about the topic addressed.
89333485|NCT06141616|Experimental|Experimental group|Rehabilitation program performed 3x/week. Each session will last 60 minutes, with a minimum interval of 24 hours, for a period of three months. The main focus of the intervention is aerobic training, which will be carried out in three stages, treadmill with a warm-up (10 minutes), load (20 minutes), and cool-down (5 minutes). With an initial intensity of 65% of the maximum load obtained in the incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 115%, keeping dyspnea and fatigue values between 4 and 6, according to the modified Borg scale. In addition, we will do a circuit focused on aerobic activities, maintaining target heart rate during its performance for 20 minutes. When necessary, supplemental oxygen will be provided during training. Volunteers in this group will receive a bronchodilator dose before starting each day's session. This group will hold educational sessions as well.
89333486|NCT06141590|Experimental|UI068|
89333487|NCT06141590|Experimental|UIC202205, UIC202206|
89333488|NCT06141577|Experimental|UI059|
89333489|NCT06141577|Active Comparator|UIC202201|
89333490|NCT06141564||Early stage HCC|
89333491|NCT06141564||Compensated cirrhosis|
89333492|NCT06141564||Chronic hepatitis without cirrhosis|
89333493|NCT06141538||Experimental group|Adequate and regular anticoagulant therapy. Anticoagulation therapy is determined based on the patient's CHADS₂ or CHA₂DS₂-VASc score. Anticoagulant medications include vitamin K antagonists, novel oral anticoagulants (NOACs), and aspirin.
89333494|NCT06141538||Control group|Patients who have not received regular or continuous anticoagulation therapy due to poor compliance or other reasons.
89333495|NCT06141525|Experimental|RIC group|In the RIC group, patients will undergo RIC training in the 3 days before and 7 days after the CABG surgery.
89333496|NCT06141525|No Intervention|Control group|In the control group, a blood pressure cuff, same as the cuff in the RIC group, will be placed on both upper arms of the patients but only pressurized to 60 mmHg. The rest of the procedures will be the same.
89333497|NCT06141447|Experimental|Oxytocin|Participants receive 40 units IV oxytocin in 1000 mL of normal saline at the time of tenaculum placement for D&E.
89333498|NCT06141447|Placebo Comparator|Placebo|Participants receive 1000 mL of normal saline alone at the time of tenaculum placement for D&E.
89333499|NCT06141434||Pregnancies where the mother has type 1 diabetes|We will observe the risk for islet autoimmunity in the offspring where the mother has type 1 diabetes. There is no intervention in this study.
89333500|NCT06141434||Pregnancies where the mother does not have type 1 diabetes|We will observe the risk for islet autoimmunity in the offspring where the mother does not have type 1 diabetes, but the baby's father or full sibling does. There is no intervention in this study.
89333501|NCT06141421||RWS study for SP CR Surgeries da Vinci SP Surgical System(SP1098)|
89333502|NCT06141408|Experimental|Intervention|This is the arm engaging in the stigma-reduction and support-increasing activities.
89333503|NCT06141408|No Intervention|Comparison|This is the arm not engaging in the stigma-reduction and support-increasing activities.
89333504|NCT06141382|Experimental|English Language-Sensory based narrative intervention|This experimental group participants will receive sensory based intervention in English language.
89333505|NCT06141382|Active Comparator|English Language-Narrative intervention|This Control group participants will receive narrative intervention in English language.
89333506|NCT06141382|Experimental|Urdu Language-Sensory based narrative intervention|This experimental group participants will receive sensory based narrative intervention in Urdu language.
89333507|NCT06141382|Active Comparator|Urdu Language-Narrative intervention|This control group participants will receive narrative intervention in Urdu language.
89333508|NCT06141382|Experimental|Bilingual-Sensory based narrative intervention|This experimental group participants will receive sensory based narrative intervention in both English and Urdu language.
89333509|NCT06141382|Active Comparator|Bilingual-Narrative intervention|This control group participants will receive narrative intervention in both English and Urdu language.
89333510|NCT06141356||Healthy participants|"Drug: [18F]Florbetazine ([18F]92). A dosage of 10 mCi +/- 20% of Florbetazine will be injected by a PET-certified medical professional followed by 5ml 0.9% sodium chloride (normal saline) flush.~Drug: [11C]PIB. A dosage range between 6.0-20.0 mCi of PIB will be injected by a PET-certified medical professional followed by 5ml 0.9% sodium chloride (normal saline) flush."
89333511|NCT06141356||Patients with cognitive impairment|"Drug: [18F]Florbetazine ([18F]92). A dosage of 10 mCi +/- 20% of Florbetazine will be injected by a PET-certified medical professional followed by 5ml 0.9% sodium chloride (normal saline) flush.~Drug: [11C]PIB. A dosage range between 6.0-20.0 mCi of PIB will be injected by a PET-certified medical professional followed by 5ml 0.9% sodium chloride (normal saline) flush."
89333512|NCT06141343||Veillonella atypica FB0054|Active ingredient dietary supplement group
89333513|NCT06141343||Placebo|No active ingredient
89333514|NCT06141330|Experimental|Vitamin D|
89333515|NCT06141330|Active Comparator|Placebo|
89333516|NCT06141304|Experimental|Plerixafor plus DLI|DLI will be given to the participants three days after chemotherapy, and plerixafor will be administrated ten days post DLI.
89333517|NCT06141291|Other|Old 1|1. Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
89333518|NCT06141291|Experimental|Old 2|"Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.~Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects."
89333519|NCT06141291|Other|Young|1. Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
89333520|NCT06141278|Experimental|Intervention|Stakeholder-based participatory research will be conducted after CFIR-ERIC mapping activities to focus on partnerships, engagement, co-learning, and developing interventions incorporating interventions on existing practices. Three workshops will be held to reach agreements on the intervention tools, the implementation structure, the data collection procedures and the study audit process among the research team, local policymakers, and implementers. The participants and contents of each workshop are shown in Table 1. At the end of the workshop series, the implementation team from each county prepared a proposed intervention plan describing the steps needed to achieve their goals within a set timeline. The agreed plan of action considered their constraints and how to overcome those barriers.
89333521|NCT06141278|No Intervention|Control|Usual care
89333522|NCT06141265|Experimental|Niraparib|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
89333523|NCT06141226|Experimental|TQB2450 +Anlotinib+Docetaxel|TQB2450（1200mg intravenous(iv). 3 weeks using a(q3w), day 1(d1)）+Anlotinib administered PO at day 1-14 every 3 weeks+Docetaxel（75mg/square meter intravenous(iv). 3 weeks using a(q3w), day 1(d1)）
89333524|NCT06141226|Placebo Comparator|TQB2450 +Androtinib Placebo+Docetaxel|TQB2450 Injection（1200mg intravenous(iv). 3 weeks using a(q3w), day 1(d1)）+Anlotinib capsule placebo administered PO at day 1-14 every 3 weeks+Docetaxel Injection（75mg/square meter intravenous(iv),q3w, d1）
89333525|NCT06141213||Normal fetal chromosomes|"This group will consist of participants with confirmed normal fetal chromosomes.~Fetal membrane thickness measurements will be taken at enrollment and may be followed up with subsequent measurements throughout the pregnancy.~The data from this group will serve as the control for comparison with the chromosomal abnormality group."
89333526|NCT06141213||Abnormal fetal chromosomes|"This group will include participants whose fetuses have been diagnosed with chromosomal abnormalities.~These participants will also have their fetal membrane thickness measured at the same gestational age as the control group to ensure consistency.~The comparison of fetal membrane thickness between this group and the control group will be a primary focus of the study."
89333527|NCT06141200|Experimental|Study Group (Arm 1)|"The patient will receive NW Roselle capsules 1000 mg and placebo tablets. Patients will take two capsules of NW Roselle and one placebo tablet orally BID on an empty stomach with plenty of water 15 minutes before meals or one hour after meals.~A total dose of 2000 mg of NW Roselle will be administered per day."
89333528|NCT06141200|Active Comparator|Control Group (Arm 2)|"Captopril 25 mg tablets will be used. The patient will receive placebo capsules and Captopril 25 mg tablets. Patients will take two placebo capsules and one Captopril 25 mg tablet orally BID on an empty stomach with plenty of water 15 minutes before meals or one hour after meals.~A total dose of 50 mg of Captopril will be administered per day."
89333529|NCT06141187|Active Comparator|Vertebroplasty|Polymethyl-methacrylate (PMMA) cement is prepared and injected slowly into the vertebral body under constant bi-plane fluoroscopy
89333530|NCT06141187|Sham Comparator|Sham vertebroplasty|A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.
89333531|NCT06141161||group A,|group A (controlled bronchial asthma patients)
89333532|NCT06141161||group B|group B(uncontrolled bronchial asthma patients)
89333533|NCT06141148||group A,|group A ( Pulmonary Tuberculosis).
89333534|NCT06141148||group B|group B ( Extra pulmnary Tuberculosis).
89333535|NCT06141135|Experimental|Experimental Arm - Transfer of Best Quality, Euploid Blastocyst|Transfer of best quality, PGTA normal (euploid) blastocyst.
89333536|NCT06141135|No Intervention|Control Arm - Transfer of Untested, Best Quality Blastocyst|Transfer of Untested, Best Quality Blastocyst
89333537|NCT06141122|Experimental|The booklet group|The research protocol was explained during the colonoscopy appointment, and patients, when they agreed to follow their diet according to the recipe booklet, were accepted as part of the patient intervention group.
89333538|NCT06141122|No Intervention|control|The control group consists of patients who prepared for colonoscopy with the standard low-residue diet list without being given a recipe booklet.
89333539|NCT06141109|Experimental|MB07133+Sintilimab|"The test is divided into 2 stages： fist stage is dose escalation：Sintilimab 200mg，MB07133 injection is divided into three dosage groups: 600mg/m2/day, 1200mg/m2/day, and 1800mg/m2/day.~second stage Dose expansion：Sintilimab 200mg+MB07133 1800mg/m2/day"
89333540|NCT06141096|Experimental|MB07133 600mg/m2/day|
89333541|NCT06141096|Experimental|MB07133 1200mg/m2/day|
89333542|NCT06141096|Experimental|MB07133 1800mg/m2/day|
89333543|NCT06141083|Placebo Comparator|Placebo chewable tablets|
89333544|NCT06141083|Experimental|TCI188 Probiotic chewable tablets|
89333545|NCT06141070|Active Comparator|A, standard systemic therapy|Standard systemic chemoimmunotherapy
89333546|NCT06141070|Experimental|B, Radiotherapy + systemic therapy|Standard systemic chemoimmunotherapy and radiation to all known lesions
89333547|NCT06141057|Experimental|Group 1: Delayed regimen|12 volunteers receiving three doses of 10 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
89333548|NCT06141057|Experimental|Group 2: Delayed Fractional Regimen|12 volunteers receiving two doses of 50 µg RH5.1 with 50 µg of Matrix-M on days 0, 28 and one dose of 10 µg RH5.1 with 50 µg of Matrix-M on day 182 via intramuscular (IM) injection in the deltoid region of the non-dominant arm
89333549|NCT06141044|No Intervention|Drainage|Patients undergoing distal pancreatectomy with surgical drainage.
89333550|NCT06141044|Experimental|No drainage|Patients undergoing distal pancreatectomy without surgical drainage.
89333551|NCT06141018|Active Comparator|Cross-linked intra-articular hyaluronic acid|Cross-linked intra-articular hyaluronic acid (90 mg 3 ml cross-linked hyaluronic acid)
89333552|NCT06141018|Placebo Comparator|Placebo|Intra-articular isotonic saline solution (3 ml 0.9% isotonic saline) at the same dose as the treatment arm
89333553|NCT06141005|Experimental|Ultrathin bronchoscopy with intratumoral washing|Each subject suspected or diagnosed of lung cancer will undergo bronchoscopic procedure for generic alteration with Next Generation Sequencing.
89333554|NCT06140992||Site-Specific Therapy Group|These patients with cancer of unknown primary received site-specific therapy that matched the particular site predicted by the DNA methylation classifier.
89333555|NCT06140992||Empirical Therapy Group|These patients with cancer of unknown primary received empirical therapy that didn't match the particular site predicted by the DNA methylation classifier.
89333556|NCT06140979|Experimental|Test Group|The patients in the test group will be given a visual focus game to play, and the treatment will be required at least 5 times per week for 2 weeks, with each session lasting 30 minutes.
89333557|NCT06140979|Sham Comparator|Control Group|The patients in the control group were given an animated video of the game that had no therapeutic effect, and the video will be required at least 5 times per week for 2 weeks, with each session lasting 30 minutes.
89333558|NCT06140953|Experimental|control group (conventional treatment)|control group Weight reduction and life style modification(modification in diet like decrease lipids intak).pateints will recieve their conventional therapy
89333559|NCT06140953|Experimental|interventions: drug trimetazidine|trinetazidine group Weight reduction and life style modification and receive (trimetazidine) 20 mg three times dialy for 24 weeks plus their conventional treatment
89333560|NCT06140914||CRT|Heart failure patients that receive a CRT
89333561|NCT06140914||Control|Heart failure patients treated with medicines, without a CRT indication.
89333562|NCT06140628|Active Comparator|Formulation containing MLYAAT-1002® Composition|After the Fotana4D Pro® treatment, daily use of the formulation for 28 days: apply one pump of the formulation to the treated side of the face in the morning and evening, respectively.
89333563|NCT06140628|Placebo Comparator|Blank formulation without MLYAAT-1002® Composition|After the Fotana4D Pro® treatment, daily use of the blank formulation for 28 days: apply one pump of the blank formulation to the control side of the face in the morning and evening, respectively.
89333564|NCT06140446|Experimental|FeverApp group|Use af a self-care FeverApp (containing fever advices and a monitoring function for their child with an uncomplicated URTI), additional to standard advices of the GP.
89333565|NCT06140446|Experimental|DMT group|Use of a self-care decision making tool (to choose a herbal medicinal product for their child with an uncomplicated URTI), additional to standard advices from their GP.
89333566|NCT06140446|No Intervention|Control group|Just standard advices from the GP for their child with an uncomplicated URTI.
89333567|NCT06140420|Placebo Comparator|Placebo Comparator: Placebo|24 randomized patients will take placebo daily for 8 weeks.
89333568|NCT06140420|Active Comparator|Active Comparator: Naltrexone|24 randomized patients will take naltrexone daily for 8 weeks
89333569|NCT06139029|Experimental|Patients in Group-A were nebulized with 3% normal saline|Patients in Group-A were nebulized with 3% normal saline 3 times a day at intervals of 8 hours until they improved enough for discharge
89333570|NCT06139029|Experimental|patients in Group-B were nebulized with steroid and salbutamol with 0.9% normal saline|patients in Group-B were nebulized with steroid (beclomethasone dipropionate 400 μg/day in 3 divided doses) and salbutamol with 0.9% normal saline 3 times a day at intervals of 8 hours until they improved enough for discharge
89333571|NCT06138626|Experimental|Alert active|Anesthesia provider will see alert when fresh gas flow is excessive
89333572|NCT06138626|No Intervention|Alert inactive|Anesthesia provider will not see alert when fresh gas flow is excessive
89333573|NCT06138275|Experimental|Elranatamab|Elranatamab subcutaneous injections at pre-determined doses, administered at the following timepoints during each 28-day cycle: Cycle 1: Days 1, 4, 8, 15, and 22; Cycle 2: Days 1, 8, 15, and 22 ; Cycles 3-6: Days 1 and 15
89333574|NCT06137872|Experimental|Music Group|During the non-stress test shooting, the music group was allowed to listen to music via headphones once for at least 20 minutes.
89333575|NCT06137872|Experimental|Control Group|No application was made and non-stress test shooting was performed.
89333576|NCT06137846|Experimental|Peri-mucositis|Dental implant has peri-implant mucositis
89333577|NCT06137846|Placebo Comparator|Healthy|Dental implant does not have peri-implant mucositis
89333578|NCT06137638|Experimental|ENA-001 Treatment Arm|ENA-001 consisting of continuous infusion of a loading dose of 2.0 mg/kg/hr for 20 minutes followed by a maintenance dose of 1.1 mg/kg/hr.
89333579|NCT06137638|Placebo Comparator|Placebo Treatment Arm|Matching placebo for ENA-001 will consist of the solution that is used as diluent for ENA-001. Placebo will be administered similarly consisting of continuous infusion of a loading dose of 2.0 mg/kg/hr for 20 minutes followed by a maintenance dose of 1.1 mg/kg/hr.
89333580|NCT06137586|Experimental|Infusion of GIP[1-42], GIP[1-30] or placebo|This is a single arm study. All participants will go through all five experimental days in a randomized order. The interventions are A) 4pmol/kg/min GIP[1-42] B) 8pmol/kg/min GIP[1-42] C) 4pmol/kg/min GIP[1-30] D) 8pmol/kg/min GIP[1-30] E) Saline (placebo)
89333581|NCT06137378|No Intervention|A - Control|"Standard-Arm:~Short Induction (IC-1):~T = Docetaxel 75 mg/m^2 i.v. day 1 P = Cisplatin 75 mg/m^2 i.v. day 1 Response evaluation will be performed in week 4 after IC-1 by endoscopic estimation of tumor-surface shrinkage (ETSS) to select nonresponders for early total laryngectomy (TL). Responders receive further 2 cycles TP followed by radiotherapy (RT) starting week 11.~ETSS < 30% (Nonresponder):~- TL + adjuvant RT or chemo-radiotherapy (CRT) according the decision of the tumor board~ETSS >=30% (Responder):~2 further TP cycles (IC-2 in week 5-7 and IC-3 in week 8-10; same doses as IC-1) Radiotherapy (RT) is accelerated IMRT with concomitant boost with total dose of 69.6 Gy applied over 5.5 weeks to all tumor localizations; clinically non-affected neck levels receive 51.6 Gy.~* protocol is according exactly to the DeLOS-II protocol arm A in Dietz et al. Ann Oncol. 2018 Oct 1;29(10):2105-2114"
89333582|NCT06137378|Experimental|B - KEYTRUDA®|"Intervention arm aka Experimental-Arm:~Treatment same as for patients randomized into the standard arm A + application of KEYTRUDA® (pembrolizumab), i.v., in 3-week cycle (q3w) 200 mg, starting day 1; for 17 cycles (12 months). Treatment with pembrolizumab will continue in the experimental arm regardless of ETSS status after IC-1 in both responders and laryngectomized nonresponders, independent from subsequent decision on adjuvant therapy after TL."
89333583|NCT06137053||Exposed group|Standard treatment for SLE + Telitacicept 160 mg qw
89333584|NCT06137053||Control group|Standard treatment for SLE
89333585|NCT06135142|Experimental|Connective Tissue Massage Group|The patient was positioned in sitting position and their feet were supported.The basic region consisted of short and long strokes to the anterior superior iliac spine, the sacrolumbar angle, the ilium, L5 to T12, the pectoral muscles.After,the transition was made to the lower thoracic region.Short strokes were applied from lateral to medial on the latissimus dorsi muscle.Short strokes were executed between the transverse processes of the vertebrae from T12 to T7.Following this,long strokes were initiated from the axilla and continued up to the vertebrae.Finally,long strokes continued beneath the scapular angles.At the end of the lower thoracic region massage,the pectoral muscles were subjected to three stroking motions.After concluding the massage of the lower thoracic region,the application was finalized with long strokes performed subcostally and under the iliac crest.
89333586|NCT06135142|Experimental|Classic Massage Group|The patient positioned themselves face down with their upper clothing removed. The massage initiation involved employing a general stroking motion. Commencing from the sacrolumbar region, paravertebral long sweeping strokes were executed bilaterally, progressing upwards along the vertebrae's lateral edges. In the area spanning from the lumbothoracic boundary to the gluteals, a general stroking motion was iterated thrice. Subsequently, the erector spinae, latissimus dorsi, and gluteus maximus muscles were sequentially subjected to a series of actions: three cycles of stroking, followed by three cycles of kneading, concluding with three more cycles of stroking. As a concluding step, the initial general stroking movements were replicated thrice prior to finalizing the massage session.
89333587|NCT06135142|Active Comparator|Control Group|The standardized physiotherapy program included the application of superficial thermal heat, transcutaneous electrical nerve stimulation (TENS) and therapatic Ultrasound. TENS at a frequency of 100 Hz (250-μsec pulses) was applied for 15 min using two 4- to 6-cm electrodes placed bilaterally on each side of the spinous process of the L4 to S1 vertebrae with thermal therapy. While the TENS application was in progress, the heat treatment was also applied. Topical moist heat treatment at 40°C applied directly on the skin to increase both tissue temperature and blood flow. Then, continuous ultrasound was applied at an intensity of 1.5 to 2.5 W/cm2 for a period of 5 minutes.
89333588|NCT06134726||RA group|
89333589|NCT06134726||Control group|
89333590|NCT06134037||Aminophylline|Patients who received Aminophylline bolus (4 mg/kg) at Burst Suppression occurence during induction of general anesthesia conducted with Eleveld TCI model
89333591|NCT06134037||Not Aminophylline|Patients who did not received Aminophylline bolus (4 mg/kg) at Burst Suppression occurence during induction of general anesthesia conducted with Eleveld TCI model
89333592|NCT06132919|Experimental|MC2-25 cream|MC2-25 cream will be applied daily for 12 weeks
89333593|NCT06132919|Experimental|MC2-25-vehicle|MC2-25 vehicle will be applied daily for 12 weeks
89333594|NCT06127186||Study group|Patients reporting for primary care assessment because of URTI.
89333595|NCT06124053|Experimental|Group Voice Therapy|"In this research, a total of eight sessions of group voice therapy will be applied as the intervention approach. It is planned that each group will consist of three participants. Participants will be evaluated before the intervention, after the intervention, at the third-month follow-up assessment, and at the sixth-month follow-up assessment. Both formal and informal assessment tools have been preferred for the evaluation. Researchers will collect case histories and demographic information. For the acoustic assessment of the participants, voice recordings will be obtained through the ComputerizedSpeech Lab (CLS) program. GRBAS scores will be conducted by the researchers, while Pediatric Voice Handicap Index (pVHI) and Pediatric Voice Related Quality of Life (pVRQOL) scales will be filled out by parents."
89333596|NCT06124053|Active Comparator|Individual Voice Therapy|"In this research, a total of eight sessions of individual voice therapy will be implemented as the intervention approach. Participants will be evaluated before the intervention, after the intervention, at the third-month follow-up assessment, and at the sixth-month follow-up assessment. Both formal and informal assessment tools have been chosen for the evaluation. Researchers will collect case histories and demographic information. For the acoustic assessment of the participants, voice recordings will be obtained through the CLS program. GRBAS scores will be conducted by the researchers, while pVHI and pVRQOL scales will be filled out by parents or guardians."
89333597|NCT06124053|Active Comparator|Vocal Hygiene Education|"Participants will receive a one-session vocal hygiene training. Participants will be evaluated twice: once before the vocal hygiene training and again 8 weeks after the vocal hygiene training. Both formal and informal assessment tools have been preferred for the evaluation. Researchers will collect case histories and demographic information. For the acoustic assessment of the participants, voice recordings will be obtained through the CLS program. GRBAS scores will be conducted by the researchers, while pVHI and pVRQOL scales will be filled out by parents."
89333598|NCT06121648|Experimental|Water Group|Static and dynamic balance, breathing, combined breathing and movement activities.
89333599|NCT06121648|Active Comparator|Land Group|Intervention program focused on balance and gait.
89333600|NCT06112262|Experimental|Heparin and Hirudin|Anticoagulant in Hemodialysis
89333601|NCT06108024|Active Comparator|SM-020 gel 1.0%|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
89333602|NCT06108024|Placebo Comparator|Vehicle gel|Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
89333603|NCT06107023|Experimental|Intervention Group|action observation and upper extremity activities
89333604|NCT06107023|Sham Comparator|Control Group|sham action observation and upper extremity activities
89333605|NCT06106659|Experimental|forearm|Mini midline catheter forearm placement.
89333606|NCT06106659|Other|upper arm|Mini midline catheter upper arm placement
89333607|NCT06106646||Offspring of smokers who received Vitamin C|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo.
89333608|NCT06106646||Offspring of smokers who received Placebo|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo.
89333609|NCT06106646||Offspring of non-smokers|
89333610|NCT06103994|Experimental|Intervention|Multistrain probiotic
89333611|NCT06103994|Placebo Comparator|Placebo|Placebo
89333612|NCT06098196||Aminophylline|Patients who received Aminophylline bolus (4 mg/kg) at the end of general anesthesia conducted with Eleveld or Schnider TCI model (this model was chosen at anesthesiologist's discretion)
89333613|NCT06098196||Not Aminophylline|Patients who did not received Aminophylline bolus (4 mg/kg) at the end of general anesthesia conducted with Eleveld or SchniderTCI model (this model was chosen at anesthesiologist's discretion
89333614|NCT06086561|Experimental|Feasibility Assessment Cohort|Non-invasive device data acquisition; study is not interventional
89333615|NCT06082466|Active Comparator|Conventional Autologous Bypass|
88806798|NCT05347784||Patients with postoperative complications|
89333616|NCT06082466|Active Comparator|FRAMED Infrainguinal Venous Bypass|
89333617|NCT06081439||patients|310
89333618|NCT06081439||controls|120
89333623|NCT06076538||Patient diagnosed with incidental solid renal mass|All patients at our institution who are diagnosed with indeterminate solid SRM and without prior treatment for the tumor, renal biopsy or contraindication to PET/MRI can be included in the study. This will be a prospective, non-randomized, non-blinded observational study. Patients will then be managed following the standard of care.
89333624|NCT06058897|Experimental|Experimental|MRI, eye-tracking and cognitive exams will be completed by subjects.
89333625|NCT06047886|Experimental|Treatment population|"Patients status post allogeneic hematopoietic stem cell transplantation for a neoplastic hematologic disorder with the need of a CD34 selected stem cell boost for graft failure or low graft function will receive a CD34 selected hematopoietic stem cell infusion with or without preceding conditioning.~Fludarabine 25 mg/mq day 1 - 5 + 2 Gray Total body irradiation depending on clinician's discretion (with the addition of cyclophosphamide 14.5 mg/kg for two doses for haploidentical or matched unrelated donor with at least one major HLA mismatch). Recommendation to use a conditioning regimen include complete loss of donor chimerism, trilineage cytopenias."
89333626|NCT06045494|Active Comparator|Meiji Yogurt Group|"Meiji LG21 yogurt: 180 g/bottle, main ingredients:~Raw milk, water, sugar, skim milk powder, food additives (hydroxypropyl distarch phosphate, pectin), cream, whey protein powder, food flavor, Lactobacillus grigi, Lactobacillus bulgaricus, Streptococcus thermophilus."
89333627|NCT06045494|No Intervention|Blank Control Group|No interventional product for this arm
89333628|NCT06045026|Other|Anti-sensitivity toothpaste|Participants will use the anti-sensitivity toothpaste according to the instructions on the commercial pack and their normal oral healthcare habits for 24 weeks.
89333629|NCT06043596|Experimental|SafeSpace Sexual Health|The proposed intervention is a 10-week app-based program, SafeSpace Sexual Health. SafeSpace Sexual Health will be implemented using a secure, anonymous mobile app that uses authentic stories to engage young people with sexual health information and resources. The program addresses healthy relationships, anatomy and physiology, identity, adolescent development, STIs/HIV, pregnancy and reproduction, decision-making, personal safety, communication, and accessing healthcare. Each lesson includes a story written by youth with lived experience, two to three key facts developed by sexual health experts, a reflection prompt, and two to three reputable resources.
89333630|NCT06043596|Active Comparator|SafeSpace General Health|Participants in the control condition will participate in a 10-week app-based general health program, SafeSpace General Health. Lessons address general health topics including self-care, stress, sleep, nutrition, physical activity, substance use, driving and seatbelt use, and social media. Each lesson contains 2-3 key facts created by public health experts and reputable resources. Similar to SafeSpace Sexual Health, youth will receive SafeSpace General Health over 10 weeks, although SafeSpace General Health includes one lesson per week and does not contain youth stories or reflection prompts.
89333631|NCT06039735||Patients diagnosed with previous untreated multiple myeloma|Patients diagnosed multiple myeloma by bone marrow cytology without previous chemotherapy and/or hematopoietic stem cell transplantation
89333632|NCT06033430|Experimental|True dry needling of the hypertrophic scar tissue|Participants with hypertrophic linear scar tissue in the true dry needling group will undergo authentic dry needling interventions targeted at the scar tissue, in conjunction with routine physiotherapy.
89333633|NCT06033430|Sham Comparator|Sham dry needling of the hypertrophic scar tissue|In the sham dry needling group, participants presenting with hypertrophic linear scar tissue will receive superficial dry needling of the skin, performed at a location distinct from the scar tissue. This will be administered alongside routine physiotherapy.
89333634|NCT06030414|Experimental|Sentinel Cohort|
89333635|NCT06030414|Experimental|Main Cohort Group 1|
89333636|NCT06030414|Experimental|Main Cohort Group 2|
89333637|NCT06030414|Experimental|Main Cohort Group 3|
89333638|NCT06030258|Experimental|Experimental group|IN10018 in combination with Tislelizumab, carboplatin and etoposide as the first-line treatment in ES-SCLC.
89333639|NCT06030258|Active Comparator|Control group|Tislelizumab in combination with carboplatin and etoposide as the first-line treatment in ES-SCLC
89333640|NCT06021886||patient without scar|history of euploid embryo transfer
89333641|NCT06021886||patient with cs scar no Niche|history of euploid embryo transfer
89333642|NCT06021886||patient with cs scar with niche|history of euploid embryo transfer
89333643|NCT06019793|Experimental|DBS for Chronic Pain|
89333644|NCT06019403||People without musculoskeletal pain|People who do not suffer from musculoskeletal pain (neck pain, low back pain and/or temporomandibular pain), with or without a healthy lifestyle behavior.
89333645|NCT06019403||People with musculoskeletal pain|People suffering from musculoskeletal pain (neck pain, low back pain and/or temporomandibular pain), with or without a healthy lifestyle behavior.
89333646|NCT06017895|Experimental|doxepin solution|Patients received a doxepin solution spray to the posterior pharyngeal wall 10 minutes before eating. At least 12 hours later, when the swallowing-induced pain score ≥4, a placebo spray was administered to the posterior pharyngeal wall 10 minutes before eating.
88806799|NCT05340673|Experimental|Arm I (Aquaphor)|Beginning on day 1 of radiation therapy, patients apply Aquaphor BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.
88806800|NCT05340673|Experimental|Arm II (Miaderm)|Beginning on day 1 of radiation therapy, patients apply Miaderm BID, but not within the four hours before EBRT, to the irradiated field until 2 weeks following completion of EBRT.
88806801|NCT05322837||Intervention|
88806802|NCT05320406|Active Comparator|Arm I (radiation therapy alone)|Patients undergo definitive radiation therapy alone (IMRT, SBRT, proton therapy, brachytherapy) in the absence of disease progression or unacceptable toxicity.
88806803|NCT05320406|Experimental|Arm II (radiation therapy plus leuprolide)|Patients undergo radiation therapy as in Arm I and receive leuprolide SC or IM every 3 or 6 months. Treatment continues for 6 to 12 months (depending on risk) in the absence of disease progression or unacceptable toxicity.
88806804|NCT05320406|Experimental|Arm III (radiation therapy plus relugolix)|Patients undergo radiation therapy as in Arm I and receive relugolix PO QD. Treatment continues for 6 to 12 months (depending on risk) in the absence of disease progression or unacceptable toxicity.
88806805|NCT05312151|Experimental|COMP360 Psilocybin|25 mg COMP360 Psilocybin
88809700|NCT00744848|Active Comparator|Bupivacaine HCl|"100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
88809701|NCT00744848|Other|SKY0402|"300 mg SKY0402 in a 40-mL injection volume.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
89333647|NCT06017895|Placebo Comparator|placebo|Patients received a placebo spray to the posterior pharyngeal wall 10 minutes before eating. At least 12 hours later, when the swallowing-induced pain score ≥4, a doxepin solution spray was administered to the posterior pharyngeal wall 10 minutes before eating.
89333648|NCT06014905|Experimental|Hyperpolarized 13C pyruvate, Magnetic Resonance Imaging|Participants will receive a single research MR imaging using HP 13C pyruvate, intravenously injected at a rate of 5 ml/second followed by a 20-ml saline flush at 5 ml/second. Safety monitoring, including vital signs and symptom monitoring will be performed for 30 minutes after dosing is completed, 1 to 3 days after dosing, and up to 30 days post scanning procedure. During the follow-up period, study personnel will obtain clinical data from the participants' medical records.
89333649|NCT06012825||Physical Activity (PA) Round 1|All enrollees will have the opportunity to attend virtual PA sessions.
89333650|NCT06012825||Physical Activity Round 2|This second cohort is the 2nd round of intervention, which allows participants to enroll for another round, and/or newly recruited patients will have the opportunity to participate.
89333651|NCT05999266||Rheumatoid Arthritis Patients with Knee Pain|In patients with knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest.
89333652|NCT05999266||Rheumatoid Arthritis Patients without Knee Pain|In patients without knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest.
89333653|NCT05992675||AONDA contact lenses|Lotrafilcon A contact lenses worn in a 30-day, continuous wear modality (lenses worn continuously including overnight) over a period of approximately 3 years
89333654|NCT05992675||PV2 contact lenses|Balafilcon A contact lenses worn in a 30-day, continuous wear modality (lenses worn continuously including overnight) over a period of approximately 3 years
89333655|NCT05988931|Active Comparator|Web Program + App|Brief intervention web program (rooted in Motivational Interviewing) recommended at enrollment with parent/caregiver recommended to download and use app (with strategies to talk to youth about drinking prevention).
89333656|NCT05988931|Active Comparator|Web Program + App + Text Messages|Brief intervention web program (rooted in Motivational Interviewing) recommended at enrollment with parent/caregiver recommended to download and use app (with strategies to talk to youth about drinking prevention) plus youth receive 8 weeks of text messages.
89333657|NCT05988086|Active Comparator|Group 1: platelet rich fibrin|Group 1: This will include 12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone.
89333658|NCT05988086|Active Comparator|Group 2:collagen membrane|Group 2: This will include 12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.
89333659|NCT05987943|Other|healing.recurrence of oroanral fistula|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
89333660|NCT05981196||Liver Transplant Patients|Subjects with end-stage liver disease and being referred for transplant evaluation will fill out questionnaires about their background, emotions, and behaviors.
89333661|NCT05979818|Experimental|Propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy|Patients receive propranolol hydrochloride PO BID, pembrolizumab IV over 30 minutes of day 1 and chemotherapy IV. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
89333662|NCT05963737|Experimental|Experimental arm|The initial PS level is set up based on VT/PBW (6-8ml/kg) and RR (20-30 breaths/min) when patients are enrolled in the experimental arm. The following steps need to be repeated every 2 hours for 48 hours. Step 1: 3 times short EIOs (2-3s) are performed. At least 1 minute between each occlusion. PMI is calculated as the mean value of 3 measured values. Step 2: Clarify whether PMI is in the target range (PMI 0-2cmH2O). If yes, keep this PS level. If not, implement step 3. Step 3: A downward or upward PS setting adjustment is performed at a 1cmH2O interval. Every PS level is maintained for 3-5 minutes. PMI is measured again and step 3 is repeated until the PMI target is reached. Step 4: supplemental adjustment: PS setting needs to be returned to the previous level if the patient presents the following signs: VT < 4 ml/Kg, RR > 35 breaths/min, respiratory acidosis, respiratory distress, VT > 10ml/Kg, Pplat > 30 cmH2O, respiratory alkalosis.
89333663|NCT05963737|No Intervention|Control arm|Patients randomized to the control arm need to continue to accept the traditional ventilation strategy which is VT/PBW (6-8ml/kg) and RR (20-30breaths/min) guide PS setting.
88806806|NCT05300815||Dry Needling Experts|"Experts will be defined as adult individuals with a high level of knowledge within the area of patient safety and adverse events related to dry needling which will be confirmed using the following eligibility criteria:~(1) Must have >= 5 years of clinical practice performing dry needling and at least ONE of the following secondary criteria:~Certification in Dry Needling~Completion of a manual therapy fellowship that included dry needling training~>= 1 total scholarly product (poster presentation, author of a peer-reviewed publication) involving the use of dry needling~Eligible participants will be identified through existing professional networks and social media/internet-based searching. They will be recruited worldwide and be aged 18 or above, able to read and write in English, and willing to provide signed informed consent."
89333664|NCT05956327|Experimental|Intervention Group|Aerobic endurance training on a bicycle ergometer
89333665|NCT05956327|Active Comparator|Control Group|Flexibility, strengthening and balance training
89333666|NCT05952479||Undernutrition|Undernutrition is defined as weight-for-age z-score (WAZ), height-for-age z-score (HAZ), and weight-for-height z-score (WHZ) of WHO growth chart standards < -2.00 SD
88806807|NCT05299073|Experimental|MB09 (denosumab biosimilar)|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
88806808|NCT05299073|Active Comparator|US-sourced Xgeva|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
88806809|NCT05299073|Active Comparator|EU-sourced Xgeva|Sterile vial 120mg/1.7mL, Single dose, 35mg SC
88806810|NCT05277025||Fibromyalgia|Participants who fulfill the 1990 and 2011 American College of Rheumatology Criteria for FM.
88806811|NCT05277025||Rheumatoid Arthritis|Participants who fulfill the 2010 American College of Rheumatology (ACR)-European League against rheumatism (EULAR) classification criteria for RA.
89333667|NCT05952479||Normal nutrition|Normal nutrition is defined as weight-for-age z-score (WAZ), height-for-age z-score (HAZ), and weight-for-height z-score (WHZ) of WHO growth chart standards in the range of +2 and -2.00 SD
89333668|NCT05951894||Hypertension|This group consists of obese adolescents with hypertension, defined as systole blood pressure >130 mmHg or diastole blood pressure >85 mmHg, or both
89333669|NCT05951894||Non-hypertension|This group consists of obese adolescents without hypertension
88806812|NCT05277025||Healthy Volunteers|Participants who do not have significant pain/fatigue/anxiety/depression.
88806813|NCT05264194|Active Comparator|Patients receiving subcuticular suturing|Sutures will be hidden underneath skin
88806814|NCT05264194|Active Comparator|Patients receiving transcutaneous suturing|Sutures will be on your skin
89333670|NCT05951894||Normal (non-obese)|This group consist of normal subjects (non-obese)
89333671|NCT05950360||rock climbers (healthy group)|Climbers without shoulder pain
89333672|NCT05950360||rock climbers (shoulder pain group)|Climbers with shoulder pain
89333673|NCT05940103|Experimental|Mixed Reality Simulation|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
89333674|NCT05933096|Experimental|Breakfast 1|Breakfast 1 is composed of 500 ml of water, mixed with 50 mg of ICG
89333675|NCT05933096|Experimental|Breakfast 2|Breakfast 2 is composed of 200ml of yoghurt, mixed with 50 mg of ICG
89333676|NCT05933096|Experimental|Breakfast 3|Breakfast 3 is composed of two slices white toast, two fried eggs and 30 g of jam, mixed with 50 mg of ICG
89333677|NCT05930444||Normal participants|Healthy individuals who have no concerns related to their eyes.
89333678|NCT05930444||Patients with Eye-related Chief Complaints|Individuals who have specific concerns or issues related to their eyes, which they consider as the main reason for seeking medical attention or making a complaint.
89333679|NCT05930106|Active Comparator|Group Intraoperative fluid ratio|The intraoperative fluid ratio will determine fluid administration. This ratio is calculated by dividing the sum of subcutaneous infiltration and intravenous fluid by the total aspirate volume. Depending on the aspiration volume, it will be maintained at 1-1.4.
89333680|NCT05930106|Experimental|Group Carotid Artery Peak Velocity Variation|Patients will be given a fluid maintenance rate of 1.5 ml/kg/h. To determine fluid responsiveness, the carotid artery peak velocity variation (ΔVPeak-CA) will be measured before, during, and after the procedure. If the ΔVPeak-CA goes above 15%, the patient will receive a fluid bolus of lactated ringer solution at a rate of 4-6 ml/kg over 10-15 minutes, and the team will re-measure fluid responsiveness 10 minutes after each ΔVPeaK-CA.
89333681|NCT05926674|Experimental|Myofascial Release|"Myofascial release (MFR) is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.~Myofascial release will be provided to each subject assigned to the experimental group by the primary investigator (PI). The participant will be positioned in prone and the MFR will be applied along the lumbar paraspinals bilaterally for five minutes per side."
89333682|NCT05926674|Sham Comparator|Light Touch Contact|Sham treatment will be provided to each subject assigned to the control group by the designated co-investigator. The sham treatment of light touch will be applied to the lumbar paraspinals in the same fashion as noted above. This form of light touch contact is not therapeutic and is meant to only mimic a manual therapy technique.
89333683|NCT05920915|Placebo Comparator|Group K|Group K: Control group; 30 seconds (sec) will be waited before the vascular access is opened, no additional action will be taken.
89333684|NCT05920915|Experimental|Group M|Group M: Cold application group; Just before the vascular access was opened, a marble plaque was placed on the carotid (2-3 cm above the clavicle, on the sternocleidomastoid muscle (SCM) 2-3 cm above the clavicle) in the bilateral neck region, 4x5 cm in size, for 30 seconds.
89333685|NCT05920915|Sham Comparator|Group S|Group S: Sham group; Before the vascular access is opened, a marble plaque of 4x5 cm with a polar sheath on it will be applied bilaterally to the neck region of the patients for 30 seconds.
89333686|NCT05919134|Experimental|Group 1 - probiotic|"The use of Streptococcus salivarius M18 containing tablets (Dentoblis, registration number: AM.01.06.01.003.R.000061.07.20; 15.07.2020, MEDICO DOMUS, d.d.o.; 18116, Nis, Serbia)) once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: basic active ingredients - Streptococcus salivarius M18 (≥5×108 CFU in 1 tablet), Vitamin D (320 IU (8 mcg) in 1 tablet); excipients - isomalt (sweetener), magnesium stearate (vegetable), mint flavoring."
89333687|NCT05919134|Placebo Comparator|Group 2 - placebo|"The use of placebo tablets once a day for 4 weeks (before bedtime after evening brushing).~Ingredients: isomalt (sweetener), magnesium stearate (vegetable), mint flavoring."
89333688|NCT05918198|Experimental|Ven+CAG|Venetoclax plus CAG regimen
89333689|NCT05917210|Experimental|Peer navigation strategy for TB Education and Counseling (TB-EC)|peer-navigation strategy for TB-EC in adults and adolescents with and without HIV starting TB treatment at clinics in Uganda
89333690|NCT05917210|Active Comparator|Standard TB-EC|standard TB-EC in adults and adolescents with and without HIV starting TB treatment at clinics in Uganda
89333691|NCT05914467|No Intervention|Standard of care|Participants receive teicoplanin on discretion of the doctor
89333692|NCT05914467|Experimental|Model Informed Precision Dosing (MIPD) guided Therapeutic Drug Monitoring(TDM)|Participants start on standard of care dosing. After 2 days blood samples will be analysed and exposure will be determined using MIPD. Wherever necessary dose adjustments will be made.
89333693|NCT05910398|Active Comparator|continuous pyrotinib|pyrotinib 400 mg, orally once daily for one year
89333694|NCT05910398|Experimental|intermittent pyrotinib|pyrotinib 400 mg, 14 days on and 7 days off, every 21 days for 17 cycles
89333695|NCT05908474|Active Comparator|iowater fibre Group|This exclusive blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%* of your recommended daily fibre intake and 100%* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
88806815|NCT05247346|Experimental|probe-based endoscopic Raman and scattering measurements of GI tissue|probe-based integrated Raman spectroscopy and scattering measurements of BE and colorectal tissue during GI endoscopy
89333696|NCT05908474|Placebo Comparator|Volvic Placebo control Group|This is the equivalent placebo control water that it is matching the energy values
89333697|NCT05906173|Experimental|Mixed Reality Simulation|Participants in the experimental arm will be introduced to workplace training modules through an Augmented Reality (AR) headset.
89333698|NCT05905640|No Intervention|Control arm- Usual PrEP care pathway|At clinics that will serve as contemporaneous control clinics, eligible persons will receive PrEP according to the current client flow, which typically involves multiple room consultations. Quality improvement strategies will be promoted throughout the implementation period.
89333699|NCT05905640|Other|Intervention Arm- One Stop PrEP care pathway|In a one-stop arm, the number of client consultation rooms in the PrEP care pathway will be reduced to a single consultation room. All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider. Quality improvement strategies will be promoted throughout the implementation period.
89333700|NCT05894798|Experimental|Intervention|The acupuncture nurse holds the child by the hand and speaks to it calmly for about a minute. The children receive acupuncture at point LI 4 in the grip of the thumb on the upper side of the hand, bilaterally, with a sterile disposable needle with dimensions 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
89333701|NCT05894798|No Intervention|Controll|The children in the control group do not receive acupuncture. However, they spend the same amount of time with the acupuncture nurse, are addressed and are touched in the same way as the children in the intervention group, but do not get stung.
89333702|NCT05891613|Active Comparator|Control Breast Treatment Group: Bupivacaine Hydrochloride|Subjects undergoing breast reduction surgery will receive standard 0.25% Bupivacaine Hydrochloride in one breast.
89333703|NCT05891613|Experimental|Treatment Breast Treatment Group: Liposomal (Exparel) Bupivacaine|Subjects undergoing breast reduction surgery will receive a mixture of liposomal (Exparel) bupivacaine with plain 0.25% bupivacaine hydrochloride in contralateral breast.
89333704|NCT05890625|Experimental|InT-mAp|
89333705|NCT05890625|Active Comparator|Control group|
89333706|NCT05883150|Experimental|Nebulized Midazolam|
89333707|NCT05883150|Active Comparator|Intranasal Midazolam|
89333708|NCT05880862|Experimental|Pelvic Floor Muscle Training|A 12-week, 6 visit, outpatient program of physical therapist delivered behavioral and pelvic floor muscle training (PFMT)
89333709|NCT05880862|Active Comparator|Mirabegron|Individually titrated Mirabegron, starting at 25 mg daily and increased to 50 mg daily at 6-weeks, during the 12-week intervention period.
89333710|NCT05880862|Active Comparator|Trospium Chloride|A 12-week course of Trospium -extended release, 60mg once daily.
89333711|NCT05880823||Prospective|All patients for whom the decision has been made to have the Synergy Disc system implanted and give informed consent will be enrolled in this study, following country-specific requirements.
88806816|NCT05242146|Experimental|GB5121|GB5121 orally twice per day (BID)
89333712|NCT05880823||Retrospective|Patients who have previously received the Synergy Disc system in the last ten years are eligible for inclusion in the retrospective data collection; a waiver of consent, or an informed consent, for the retrospective data collection from the medical records of the implanting surgeon will be sought per country-specific regulations.
89333713|NCT05877339||Osteoartritis|Patients with osteoarthritis among the participants
89333714|NCT05877339||Fibromyalgic Disease|Patients with fibromyalgia among the participants
89333715|NCT05877339||Control Group|Healthy people
89333716|NCT05876156|Experimental|VRPT then Traditional PT|Participants will receive Virtual Reality assisted Physical Therapy sessions (VRPT) in the first Physical Therapy (PT) session and will receive traditional Physical Therapy sessions (standard care) in the second Physical Therapy session under the supervision of the accredited physical therapist.
89333717|NCT05876156|Experimental|Traditional PT then VRPT|Participants will receive traditional Physical Therapy (PT) sessions (standard care) in the first Physical Therapy session and receive Virtual Reality assisted Physical Therapy sessions (VRPT) in the second Physical Therapy session under the supervision of the accredited physical therapist.
89333718|NCT05876065|Experimental|capecitabine and cyclophosphamide (XC)|capecitabine and cyclophosphamide as maintenance therapy every 3 weeks
89333719|NCT05876065|Active Comparator|physician's choice|Any physician's choice as maintenance therapy (except for XC regimen).
89333720|NCT05870839|Experimental|VXCO-100 Group 1|Participants 18-55 years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection
89333721|NCT05870839|Experimental|VXCO-100 Group 2|Participants 18-55 years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection
89333722|NCT05870839|Experimental|VXCO-100 Group 3|Participants 18-55 years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection
89333723|NCT05870839|Experimental|VXCO-100 Group 4|Participants 56+ years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection
89333724|NCT05870839|Experimental|VXCO-100 Group 5|Participants 56+ years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection
89333725|NCT05870839|Experimental|VXCO-100 Group 6|Participants 56+ years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection
89333726|NCT05866666||Cardiac Function Monitoring|Subjects scheduled for cardiac catheterization will undergo measurement with the Cardiac Performance System non-invasive device for a brief period before the catheterization procedure.
89333727|NCT05866003|Active Comparator|Active conventional tDCS plus CCFES|The conventional tDCS montages involves placing the surface anode electrode on the scalp of the lesioned hemisphere and the surface cathode electrode on the scalp of the non-lesioned hemisphere. TDCS will deliver a low current while participants are undergoing CCFES-mediated functional task practice.
89333728|NCT05866003|Active Comparator|Active unconventional tDCS plus CCFES|The unconventional tDCS montages involves placing the surface anode electrode on the scalp of the non-lesioned hemisphere and the surface cathode electrode on the scalp of the lesioned hemisphere. TDCS will deliver a low current while participants are undergoing CCFES-mediated functional task practice.
89333729|NCT05866003|Sham Comparator|Sham tDCS plus CCFES|The sham tDCS montages involves placing the surface electrodes on the scalp over the lesioned and the non-lesioned hemisphere. TDCS will not be delivered during CCFES-mediated functional task practice.
89333730|NCT05862506|Experimental|The Daily Mile|The intervention consisted of walking, jogging or running for ~ 15 min (~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
89333731|NCT05862506|No Intervention|Control Group|This group will be received only the physical education lessons and it will be followed-up equally to compare outcomes in the future.
89333732|NCT05862025|Other|Echocardiography intervention|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
89333733|NCT05860192|Experimental|Virtual Reality|Each patient undergoes to a virtual reality session of mindfullness. This lasts about 30 minutes.
89333734|NCT05858086|Active Comparator|Conventional Postoperative Physical Therapy Clearance|Patients will be evaluated and cleared by physical therapy after total joint replacement surgery prior to home discharge
89333735|NCT05858086|Experimental|Preoperative Physical Therapy, Postoperative Ambulation with Nursing|Patients will receive gait/stair training from physical therapy prior to total joint arthroplasty, then ambulate with nursing postoperatively prior to home discharge
89333736|NCT05857332|Experimental|SG1906|SG1906 monotherapy intravenous (IV) infusion - Biweekly doses
89333737|NCT05856552|Experimental|CBT home visits|Community resource persons will visit the elderly women once per week to deliver cognitive behavioral therapy for six weeks, followed by monthly boosters.
88806817|NCT05236023|No Intervention|Control group|Group receiving care as usual before the intervention takes place
89333738|NCT05856552|Experimental|CBT home visits and group activities|Community resource persons will visit the elderly women once per week to deliver cognitive behavioral therapy for six weeks, followed by monthly boosters. The elderly women and their families will also be invited to join weekly hour-long group activities for 6 weeks. Group activities will be administered by community resource persons in community spaces.
89333739|NCT05856552|No Intervention|Control|Control group
89333740|NCT05856552|Experimental|Group activities|The elderly women and their families will be invited to join weekly hour-long group activities for 6 weeks. Group activities will be administered by community resource persons in community spaces.
88806818|NCT05236023|Experimental|Intervention group|Group receiving zero separation and couplet care
89333741|NCT05851677||RC48-ADC|RC48-ADC for breast cancer
89333742|NCT05850091|Placebo Comparator|Group A|Participants will receive placebo daily
89333743|NCT05850091|Active Comparator|Group B|Participants will receive rosuvastatin 20mg daily and placebo daily
89333744|NCT05850091|Active Comparator|Group C|Participants will receive colchicine 0.6mg daily and placebo daily
89333745|NCT05850091|Active Comparator|Group D|Participants will receive rosuvastatin 20mg daily and colchicine 0.6mg daily
89333746|NCT05826899|Active Comparator|oat protein-based iron delivery system1|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
89333747|NCT05826899|Active Comparator|oat protein-based iron delivery system2|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
89333748|NCT05826899|Active Comparator|oat protein-based iron delivery system3|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
89333749|NCT05826899|Active Comparator|oat protein-based iron delivery system4|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
89333750|NCT05826899|Active Comparator|oat protein-based iron delivery system5|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
89333751|NCT05826899|Active Comparator|oat protein-based iron delivery system6|Each subject will complete the six iron absorption studies in which they will receive supplemental iron doses of 4 mg iron from the six products: (i) Fe-oat 1 alone, (ii) Fe-oat 1 with 30 mL acai puree with honey, (iii) Fe-oat 2 alone, (iv) Fe-oat 2 with 30 mL acai puree with honey, (v) FeSO4 alone, (vi) FeSO4 with 30 mL acai puree and honey.
89333752|NCT05826782|Active Comparator|A|The treated group
89333753|NCT05826782|Placebo Comparator|B|The placebo group
89333754|NCT05826184|Experimental|Time restricted eating|Individuals will eat between 12-8pm ad libitum, fasting from 8-12pm.
89333755|NCT05826184|Experimental|TRE+ prebiotic supplement|Individuals will eat between 12-8pm ad libitum, fasting from 8-12pn with the addition of a prebiotic fiber supplement with the first eating bout of the day.
89523560|NCT03380065|Active Comparator|Late deflation of TR band|"first 3ml of air removed from the TR band after TWO hour of sheath removal. Then, 3ml of air removed every 15minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then wait for another 15minutes for the next deflation."
89333756|NCT05825924|Active Comparator|Study Arm A: Electronic Cigarettes (18mg/ml)|Participants randomized to study arm A will be provided a free e-cigarette and sufficient nicotine cartridges (18 mg/ml) supply to last till next in person visit. Participants will be instructed to use the device ad libitum one week before their quit day to familiarize themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the e-cigarette exclusively for the next 12 weeks. Smokers often take 10 to 15 puffs over the course of 5 to 8 minutes, repeating this pattern with each cigarette. On the other hand, users of EC may periodically use it throughout the day, and they may or may not take their puffs like those of traditional cigarettes
89333757|NCT05825924|Active Comparator|Study Arm B: 21 mg nicotine patches|Participants randomized to study arm B will be provided 21 mg nicotine patches supply to last till next in person visit. Participants will use the nicotine patch daily for one week before their quit day to familiarize themselves with its use. On their designated quit day they will stop smoking and use nicotine patches daily for the next 12 weeks. Usually a full-strength patch (15-22 mg of nicotine) daily for four weeks is suggested for use in majority of the smokers, followed by a lower strength patch (5-14 mg of nicotine) for an additional four weeks, depending on their body size and smoking habits
89333758|NCT05811728|Experimental|Low level laser therapy|
89333759|NCT05811728|Placebo Comparator|Control|
89333760|NCT05809271|Experimental|MDMA with booster|MDMA followed by MDMA
89333761|NCT05809271|Experimental|MDMA without booster|MDMA followed by placebo
89333762|NCT05809271|Placebo Comparator|Placebo|Placebo followed by placebo
89333763|NCT05801601|Experimental|Many Ways of Being|In the experimental arm, Equimundo's Many Ways of Being program will be implemented. Youth will receive eight two-hour sessions or 16 one-hour sessions over four to eight weeks for a total of 14 hours and 40 minutes of programming.
89333764|NCT05801601|Active Comparator|A career readiness program|In the comparison arm, a curriculum focused on career readiness will be implemented. Youth will receive eight two-hour sessions or 16 one-hour sessions over four to eight weeks for a total of 14 hours and 40 minutes of programming.
89333765|NCT05790733|Active Comparator|Standard|"When the patient is in the conventional arm, the nurse of the service will place the NGS according to the recommendations of the French Health Authorities on the management of the induced pain. The patient is seated at 90 degrees. The nurse takes its landmarks on the NGS to be able to install the NGS at the correct landmark (it takes the NGS and measures nose-ear, ear-stomach).~This arm involves the use of the 5% Xylocaine nebulizer spray and a single-use cannula.~The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia."
89333766|NCT05790733|Experimental|Hypnosis|"Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics.~As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products.~The installation of the SNG with hypnosis will be carried out according to the protocol set out in appendix 4.~In the hypnosis arm, there will be none local anesthesia."
89333767|NCT05790720|Experimental|Intervention|Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed. Two models will be created and compared retrospectively: BIS (Eleveld Validation) and EEG Frontal Marker (New model).
89333768|NCT05785533|Experimental|Smartphone App|The mobile app will allow recording of study outcomes (pain using the vNRS and functional outcomes using the ASKp) and house an interactive educational component to provide daily reminders on pharmacological (ibuprofen and acetaminophen) and non-pharmacological (ice, elevation, and range of motion exercises) for pain management and when to return to activity. The app will collect pain scores using the verbal Numeric Rating Scale (vNRS) and functional outcomes using the Activities Scale for Kids (ASKp) scores on days 3, 5, 7, 10, 12, and 14. The ASKp will be completed by the child with assistance from the caregiver.
89333769|NCT05785533|Active Comparator|Standard of Care|The standard of care group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity identical to the information contained in the mobile app. They will download onto their smartphone device a Data Collection App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, and pain using the vNRS and ASKp scores on days 3, 5, 7, 10, 12, and 14. The ASKp will be completed by the child with assistance from the caregiver.
89333770|NCT05783258|Experimental|CAF+tSCTG|15 sites will be treated.The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the level of the maxillary tuberosity. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
89523561|NCT03380065|Active Comparator|Early deflation of TR band|"First 2ml of air is removed from the TR band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then push the 2ml of air back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
88806819|NCT05221398||Immune checkpoint inhibitors based adjuvant therapy|Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.
88806820|NCT05221398||Without adjuvant therapy|Patients in this arm will not receive any adjuvant therapy.
88806821|NCT05213221|Experimental|Treatment group|Envafolimab, Lenvatinib and TACE
89333771|NCT05783258|Active Comparator|CAF+L-PRF|15 sites will be treated.The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm,2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession. Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa. The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of bone.A partial thickness dissection will be performed in the apical portion of the flap to obtain complete passivation.The L-PRF membranes will be realized centrifuged venous blood collected in two 10-ml sterile tubes at 3000 rpm for 10 minutes and squeezing the fibrin clot. L-PRF membranes will be superimposed to crete a double layer of about 2 mm thickness.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
89333772|NCT05765734|Experimental|TAS3351 Part A (Dose Escalation)|Dose escalation will assess the safety and determine the recommended phase 2 dose and regimen of TAS3351 administered orally.
89333773|NCT05765734|Experimental|TAS3351 Part B (Dose Expansion)|TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose determined in Part A.
89333774|NCT05765734|Experimental|TAS3351 Part C (Phase 2)|To assess efficacy of TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose.
89333775|NCT05761639|Experimental|Telerehabilitation, Education and Telephone Monitoring.|"The effects of a physical exercise program and educational component with telephone follow-up mediated by cardiac telerehabilitation in patients with heart failure on functional capacity, depression and health-related quality of life will be determined.~Each participant will be given a polar FT4 brand frequency monitor to record their HR, an OMRON brand digital blood pressure monitor to monitor blood pressure and the conventional Borg scale will be used for perception of exertion during exercise."
89333776|NCT05761639|Experimental|conventional rehabilitation and Education|The effects of a physical exercise program and a conventional educational component in patients with heart failure on functional capacity, depression and health-related quality of life will be determined. The development of this program will be carried out in person guided by a physiotherapist specializing in cardiac and pulmonary rehabilitation.
89333777|NCT05761639|Experimental|Telerehabilitation and Education|"To determine the effects of a physical exercise program and a conventional educational component mediated by cardiac telerehabilitation in patients with heart failure on functional capacity, depression, and health-related quality of life~Each participant will be given a polar FT4 brand frequency monitor to record their HR, an OMRON brand digital blood pressure monitor to monitor blood pressure and the conventional Borg scale will be used for perception of exertion during exercise."
89333778|NCT05747157|Experimental|Administration of Metabolically Armed CD19 CAR-T cells|Patients undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with cyclophosphamide and fludarabine before CAR-T cells infusion. A dose of metabolically armed CD19 CAR-T cells will be infused on day 0.
89333779|NCT05743868|Experimental|IR participants with standardized dinner|"Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention.~Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed."
89333780|NCT05743868|Experimental|IR participants with standardized dinner and premeal exercise|"Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention.~DNL will be assessed in all participants after a single day with short bouts of premeal exercise with a standardized dinner.~Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed."
89333781|NCT05737706|Experimental|Phase 1/1B|Dose Escalation/Evaluation
89333782|NCT05737706|Experimental|Phase 2|MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC, PDAC, CRC, Other Solid Tumors
89333783|NCT05734495|Experimental|PIRTOBRUTINIB + VENETOCLAX|"Participants will receive:~Standard of care bone marrow aspirate & biopsy within 90 days of Cycle 1 Day 1.~Computed Tomography (CT) scan of chest, pelvis & abdomen within 90 days of Cycle 1 Day 1.~Electrocardiogram at screening.~Cycle 1~Electrocardiogram.~Day 1-28: Predetermined dose of Pirtobrutinib 1x daily.~Cycle 2~-Day 1-28: Predetermined dose Pirtobrutinib & Venetoclax 1x daily. Tumor lysis syndrome (TLS) prophylaxis, predetermined dose Allopurinol at least 72 hrs prior to 1st administration of Venetoclax and dose escalation at Day 8 & Day 15.~Cycles 3-24~Day 1-28: Predetermined dose of Pirtobrutinib & Venetoclax 1x daily.~Electrocardiogram: Cycles 3, 6, 9,12,15,18,21,24~CT scan of chest, pelvis & abdomen: Cycles 7, 13, End of Treatment if extramedullary disease at baseline unresolved in previous CT scan~Standard of care bone marrow aspirate and biopsy: Cycles 7, 13, End of Treatment~Follow up every 12 wks for 4 yrs."
89333784|NCT05717621|Experimental|Test Arm|VTD-101 ointment
89333785|NCT05715996|Experimental|mixed reality guided localization group|Application of mixed reality technique for percutaneous lung nodule localization.
88806822|NCT05181228|Experimental|Intervention Group (Web-based family-centered empowerment program intervention)|Intervention group participants will receive the web-based family-centered empowerment intervention for 10 weeks.
89333786|NCT05715996|No Intervention|Computerized tomography (CT) guided localization group|Computerized tomography (CT) guided percutaneous lung nodule localization.
89333787|NCT05708703||Study cohort|Individuals receiving treatment for metastatic breast cancer or advanced stage ovarian cancer, will complete a baseline survey, install a mobile app on their smartphone to track daily activities, short daily surveys, and a study end survey
89333788|NCT05703217|Active Comparator|classical physical therapy and rehabilitation program|In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
89333789|NCT05703217|Active Comparator|virtual reality assisted walking and balance exercise program|C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds.
89333790|NCT05703035|Active Comparator|waiting group during staple firing|In this group, the amount of bleeding, bleeding points, postoperative drain amount and laboratory values will be monitored during the operation.
89333791|NCT05703035|Active Comparator|staple firing group without waiting for a certain time|In this group, no further intervention will be made, and the same treatment will be given as the 1st group and comparison will be made.
89333792|NCT05695495|Experimental|Randomized|Subjects will be administered intravenous DMT in 4 different bolus doses or placebo in randomized, counter-balanced order. The bolus applications will be separated by one hour.
88806823|NCT05181228|No Intervention|Control Group|No intervention was applied to the control group.
89333793|NCT05695495|Experimental|Dose ecalation|Subjects will be administered a placebo and a maximum of 5 DMT bolus doses in an escalating dose order. The bolus applications will be separated by one hour.
89333794|NCT05685615|Experimental|BV100 (200 mg) plus Polymyxin B|BV100 (200 mg q12h) infused over 2 hours plus Polymyxin B (12 500-15 000 IU/kg) infused over 1h
89333795|NCT05685615|Experimental|BV100 (300 mg) plus Polymyxin B|BV100 (300 mg q12h) infused over 2 hours plus Polymyxin B (12 500-15 000 IU/kg) infused over 1h
89333796|NCT05685615|Active Comparator|Best Available Therapy|Best Available Antibiotic Therapy to Treat CRAB
89333797|NCT05685615|Experimental|Part B: BV100 plus BAT|BV100 (300 mg q12h) infused over 2 hours plus Best Avaialble Therapy to Treat Colistin resistant CRAB
89333798|NCT05684718|Experimental|BV100 Plus Itraconazole|A total 2 doses of BV100 and 14 doses of itraconazole will be administered to each participant per specified dosing schedule
89333799|NCT05684705|Experimental|BV100|7 doses of BV100 (q12h)
89333800|NCT05683717|Experimental|Dose Escalation for TT-01488|TT-01488 tablets will be administered once daily in a 28-day cycle in increasing strength in order to determine the recommended dose for dose expansion.
89333801|NCT05683717|Experimental|Dose Expansion for TT-01488|TT-01488 tablets will be administered once daily in 28-day cycles to verify the safety and preliminary efficacy as observed in the dose escalation cohorts.
89333802|NCT05669339|Experimental|Irinotecan, Sonidegib, and Sorafenib|Subjects will be assigned to a dose of each drug following a 3 + 3 design
89333803|NCT05660408|Experimental|RNA-LP vaccine|
89333804|NCT05655546|Other|Intervention Arm|Participants in this group will complete the baseline study activities, as described above. Additionally, participants will be instructed to create a Cue Health account and download the Cue Health App. Using the app and the 10 Cue Health COVID-19 molecular tests that are provided (or Cue Health Flu+COVID molecular tests if available and FDA authorized), the participant will perform tests after exposure or if symptoms arise. Participants can also use the test for close contacts who are exposed to COVID-19 and/or have symptoms. If COVID-19 infection occurs, participants will have access to telemedicine to discuss further with a healthcare professional. When clinically indicated, medication for the treatment of COVID-19 (and/or Influenza in case of Cue Health Flu+COVID test availability) will be prescribed and delivered to the participants' delivery address. Participants can also seek care through other healthcare providers or not seek care, at their discretion.
89333805|NCT05655546|No Intervention|Control Arm|Participants in the control group will complete the baseline study activities, as described above. If symptoms arise or COVID-19 infection occurs, participants will test and seek care as they normally would.
89333806|NCT05650658|Active Comparator|His/Left Bundle Branch Pacing (His/LBBP)|"Patients with LVEF≤35% at entry will receive a His/LBB defibrillator which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular ICD lead, and an endocardial His-bundle or left bundle branch pacing lead directly pacing the intrinsic conduction system.~Patients with LVEF 36-50% at entry will receive His/LBB pacemaker which includes implantation of two leads, an endocardial right atrial lead, and an endocardial His-bundle or left bundle branch pacing lead directly pacing the intrinsic conduction system."
89333807|NCT05650658|Active Comparator|Biventricular Pacing (BiVP)|"Patients with LVEF≤35% at entry will receive a BiV defibrillator which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular ICD lead, and and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~Patients with LVEF 36-50% at entry will receive BiV pacemaker which includes implantation of three leads, an endocardial right atrial lead, an endocardial right ventricular pacing lead, and and an epicardial left ventricular lead implanted in a branch of the coronary sinus."
89523562|NCT03384979|Placebo Comparator|TBW protocol|Patients will receive a contrast agent dose based on their TBW as a standard clinic protocol.
89523563|NCT03384979|Experimental|LBW protocol|Patients will receive a contrast agent dose based on their calculated LBW.
89333808|NCT05648864|Experimental|Viamigo intervention|All eligible and consenting dyads will be asked to participate in the Viamigo intervention (mobile application), consisting of three main components: (1) a face-to-face technology training session of 60 minutes, (2) a 3-month period of using the Viamigo intervention with support phone calls of approximately 5 minutes by the coordinating investigator once every two weeks, and (3) an evaluation phone call of 5-10 minutes.
89333809|NCT05648721|Experimental|Mobile health application|Use of GDM application for GDM management
89333810|NCT05648721|Other|Control|Regular follow-up without the GDM application
89333811|NCT05628311|Experimental|IBI362 4.0 mg|"①2mg, subcutaneously (SC), once a week* 4weeks;~②4mg, SC, once a week* 44weeks."
89333812|NCT05628311|Experimental|IBI362 6.0 mg|"①2mg, SC, once a week* 4weeks;~②4mg, SC, once a week* 4weeks；~③6mg, SC, once a week* 40weeks."
89333813|NCT05628311|Placebo Comparator|placebo|"placebo, SC, once a week* 24weeks;~2mg, SC, once a week* 4weeks;~4mg, SC, once a week* 4weeks；~6mg, SC, once a week* 16weeks."
89333814|NCT05623111|Active Comparator|Incobotulinumtoxin-A|100 units of incobotulinumtoxin-A in 5ml of sterile saline around both distal ischial nerves.
88806824|NCT05157178|Experimental|4 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 4 week interval between the two doses.
88806825|NCT05157178|Experimental|8 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 8 week interval between the two doses.
89333815|NCT05623111|Placebo Comparator|Placebo|5ml sterile saline with small amounts of human albumin and sucrose (identical to binding agents in active vials)
89333816|NCT05612178|Experimental|3BNC117-LS and 10-1074-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) at weeks 0, 20 and 40.
89333817|NCT05612178|Placebo Comparator|Placebo|Participants will receive three intravenous infusions of placebo (Sterile Saline) at weeks 0, 20 and 40.
89333818|NCT05598645|Experimental|Thulium Fibre Laser (TFL)|Patients randomized to this arm will undergo treatment using the TFL.
89333819|NCT05598645|Experimental|MOSES Holmium Laser|Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.
89333820|NCT05596240|Experimental|Dry Needling|Individuals with shoulder pain will receive dry needling to the two to four most tender points in the infraspinatus based on examiner palpation
89333821|NCT05596240|Placebo Comparator|Sham Dry Needling|Individuals with shoulder pain will receive sham dry needling to two points in the muscle belly of the infraspinatus near the insertion and below the midpoint of the spine of the scapula
89333822|NCT05595941|Experimental|TELEYOG'AVC Group|The subjects of the experimental group will be invited to participate in 60-minute tele-yoga sessions, twice a week, for 12 weeks. The sessions will take place via the Zoom videoconference software, in small groups (maximum 5 people) in order to adapt the practice to the possibilities of each subject. In addition, an additional weekly session, independently at home, will be recommended to participants, accompanied by a pre-recorded video support hosted on YouTube.
89333823|NCT05595941|No Intervention|Wainting list Group|The subjects in the control group will be asked not to change their habits during the entire experimental phase (T0-T1). They will be able to benefit in turn from the tele-yoga program (free of charge), if they wish, once the evaluations in T1 are completed.
89333824|NCT05591079|Experimental|1.4mg CS0159|One tablet daily for 12 weeks
88806826|NCT05157178|Active Comparator|12 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 12 week interval between the two doses.
89333825|NCT05591079|Experimental|2mg CS0159|One tablet daily for 12 weeks
89333826|NCT05591079|Placebo Comparator|PLACEBO|One tablet daily for 12 weeks
89333827|NCT05583903|Experimental|Virtual Reality Software Usability in Healthy Volunteers Age 18-35 Years|Healthy volunteers between the ages of 18 and 35 years will utilize the ReCognition virtual reality software
89333828|NCT05583903|Experimental|Virtual Reality Software Usability in Healthy Volunteers Age 60 or Greater Years|Healthy volunteers 60 years of age and older will utilize the ReCognition virtual reality software
89333829|NCT05580965|No Intervention|control group|Routine procedure
89333830|NCT05580965|Experimental|Group A|1 min pressure applied
89333831|NCT05580965|Experimental|Group B|3 min pressure applied
89333832|NCT05580965|Experimental|Group C|5 min pressure applied
89333833|NCT05569915|Experimental|Trauma Expressive Writing|In the trauma condition, we ask participants to write about a traumatic experience, prompting them to write their very deepest thoughts and feelings about the most traumatic experience of their entire life or an extremely important stressful, upsetting, or emotional issue that has affected them.
89333834|NCT05569915|Experimental|Stigma Expressive Writing|In the stigma condition, we ask participants to write about an experience of stigma, prompting them to write about their very deepest thoughts and feelings about the most difficult or painful experience of stigma or bias (e.g., prejudice, bullying, rejection, discrimination) based on one or more of their identities (e.g., race/ethnicity, gender identity, sexual identity, religion) that they have faced.
89333835|NCT05569915|Placebo Comparator|Control|In the control condition, we ask participants to write about their day, prompting them to write about what they did yesterday from the time they got up until the time they went to bed.
89333836|NCT05562492|Experimental|Closed-loop insulin delivery (CamAPS FX)|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) A smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data.~Participants will use the closed-loop system for the next 26 weeks at home"
89333837|NCT05562492|Active Comparator|Conventional insulin therapy with CGM|Usual insulin therapy (injections or pump) and study CGM for 26 weeks at home.
89333838|NCT05553613|Active Comparator|ticagrelor arm|The ticagrelor arm will receive (180 mg loading dose during the first 12 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day)
89333839|NCT05553613|Active Comparator|clopidogrel arm|The clopidogrel arm will receive (a 300 mg loading dose during the first 12 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day).
89333840|NCT05550662|Experimental|Single arm|Participants will inhale hyperpolarized 129Xe gas.
89523564|NCT03379987|Experimental|PVB morphine|
89333841|NCT05548855||Heart Transplant or Cardiac Assist Device|Female and male patients with confirmed diagnosis of Danon disease based on a genetic test positive for a mutation in LAMP2 For living patients who underwent heart transplantation or placement of a cardiac assist device, and for deceased patients, at least 1 MRI or echo assessment prior to heart transplantation/cardiac assist device placement or death.
89333842|NCT05548855||No Intervention|Female and male patients with confirmed diagnosis of Danon disease based on a genetic test positive for a mutation in LAMP2 for living patients (who have not undergone heart transplantation or placement of a cardiac assist device), availability of at least 6-month cardiology follow-up data
89333843|NCT05540535||Bilateral Symmetrical Hearing Loss|"Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderate, moderately-severe, severe, or profound sensorineural HL in the past three month and on.~Moderate hearing will be defined as a PTA between 41-55dB HL (0.5-4 kHz) in the better ear, moderately-severe hearing will be defined as a PTA between 56-70dB HL (0.5-4 kHz) in the better ear, severe HL will be defined as a PTA between 71-90dB HL (0.5-4 kHz) in the better ear and profound HL will be defined as a PTA above 90+dB HL (0.5-4 kHz) in the better ear. Asymmetry of HL will be defined as a difference in PTA that is greater than dB between ears or a difference greater than/equal to 20 dB at two contiguous frequencies or greater than/equal to 10 dB at three contiguous frequencies between ears."
89333844|NCT05540535||Control participants with normal hearing.|Normal hearing will be defined as a PTA below 25dB (0.5-4 kHz) bilaterally. Subjects above 65 years of age, with symmetric ARHL in the high frequencies (>3K), with unaided PTA < 40 dB (0.5-4KHz) will be included in the control group as well.
89333845|NCT05537090|Experimental|BV100 Plus Midazolam|A total 2 doses of midazolam and 9 doses of BV100 will be administered to each participant per specified dosing schedule
89333846|NCT05518903|Experimental|Diagnostic (gallium GA 68 FAPi-46, PET/CT)|Patients receive 68Ga-FAP-46 IV, then allow 60 minutes for 68Ga-FAPI-46 uptake. Patients then undergo PET/CT scans over 30 minutes at baseline (before SOC therapy), up to 2 scans approximately 8 weeks apart (at SOC re-staging visits), and a then a scan within 4 weeks of SOC surgical resection, if applicable.
89333847|NCT05509933|Experimental|Budesonide|
89333848|NCT05509933|No Intervention|nothing|
89333849|NCT05500326|Experimental|Intervention|All participants will received one dose of oral 3mg Ivermectin tablet
89333850|NCT05496751|Experimental|Low amount, low intensity exercise|exercise dose (amount and intensity) will be controlled.
89333851|NCT05496751|Experimental|Low amount, high intensity exercise|exercise dose (amount and intensity) will be controlled.
89333852|NCT05496751|No Intervention|Control|no exercise intervention
89333853|NCT05496751|Experimental|High amount, high intensity exercise|exercise dose (amount and intensity) will be controlled.
89333854|NCT05495451|Experimental|Mediterranean diet and Personalized training|"36 participants will participate to the following lifestyle changes for 6 months:~Behavioral: Lifestyle changes Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet.~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
89333855|NCT05495451|Active Comparator|Intermittent Fasting Intervention|Between 3 and 6 months, 24 participants (on a total of 36) will progressively integrate intermittent fasting 16:8 (5 times/week for 12 weeks) and 20:4 (2 times/week for 4 weeks)
89333856|NCT05491655|Experimental|High intensity His bundle pacing|"After implantation of the device there will be a 1-month run-in period that the device will be programmed to deliver His bundle pacing therapy during this period at 3.5V/1msec.~After one month these patients will continue to receive active pacing treatment with 3.5V/1msec."
89333857|NCT05491655|Sham Comparator|Back up only ventricular pacing|"After implantation of the device there will be a 1-month run-in period that the device will be programmed to deliver His bundle pacing therapy during this period at 2V/1msec.~After one month these patients will receive back up only pacing (pacemaker programmed to VVI 30 bpm or AAI(R)-DDD(R) 50bpm) for 6 months."
89333858|NCT05491239|Active Comparator|Thoracic epidural analgesia|See intervention description
89333859|NCT05491239|Experimental|Continuous regional paravertebral block|See intervention description
89333860|NCT05491239|Experimental|Single shot intercostal nerve block|See intervention description
89333861|NCT05478174|Experimental|HSK3486|HSK3486 for general anesthesia induction
89333862|NCT05478174|Active Comparator|Propofol|Propofol for general anesthesia induction
89333863|NCT05477628|Placebo Comparator|Control Group|Participants who are randomized to the control group will receive usual care from their health care practitioners.
89333864|NCT05477628|Experimental|Intervention Group|"Participants who are randomized to Intervention Group will receive one of three possible scenarios: 1) Childcare Navigator Support, 2) Breastfeeding support via Lactation Consultant, 3) both Childcare Navigator Support and Breastfeeding support via Lactation."
89333865|NCT05470998|No Intervention|control group|this group will include 25 patients who will receive their standard therapy for 3 months
89333866|NCT05470998|Active Comparator|L-Arginine group|this group will include 25 patients who will receive L-Arginine 0.1-0.2 g/kg/day and their standard therapy for 3 months
89333867|NCT05467098|Experimental|Individuals with and without Shoulder Pain|"Individuals with shoulder pain will receive dry needling to the two to four most tender points in the infraspinatus based on examiner palpation~Individuals without shoulder pain will receive dry needling to two points in the muscle belly of the infraspinatus near the insertion and below the midpoint of the spine of the scapula"
89333868|NCT05465408|Experimental|Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention|Participants will have two (2), 60 minute, individual sessions with a nurse practitioner via videoconferencing (in person or via telephone) and complete three (3) questionnaires at the time of enrollment, 1-month post-baseline, and 3-months post-baseline.
89333869|NCT05461573|Experimental|Part A - An investigation of the efficacy, safety, and tolerability of LPRI-CF113|All subjects enrolled in the study will participate in Part A of the study. Part A of the study will investigate the efficacy, safety, and tolerability of LPRI-CF113.
89333870|NCT05461573|Experimental|Part B - The effect of LPRI-CF113 on bone mineral density in a subgroup age 18-45|A subgroup of subjects from Part A that are age 18-45 and without further exclusion criteria to Part B will be enrolled in Part B of the study. Part B of the study will investigate the effects of LPRI-CF113 on bone mineral density.
89333871|NCT05459987|Experimental|Intervention|"Behavioral: Lifestyle changes Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
89333872|NCT05456334|Experimental|Pulsed dye laser-mediated photodynamic therapy|After curretage light-sensitizer (methyl aminolaevulinate cream) was applied on the lesions and covered with an occlusive plastic foil for 2-3-h incubation. Then a local lidocaine anaesthetic spray was applied. The lesions were illuminated with 30% overlapping pulsed laser double-stacked pulses (, energy 7 J/cm2, spot size 7 mm, pulse duration 10 ms, wavelength 595 nm and dynamic cooling 2/3).
89333873|NCT05456334|Active Comparator|Conventional photodynamic therapy|After curretage a light-sensitizer (methyl aminolaevulinate cream) was applied on the lesions and covered with an occlusive plastic foil for 2-3-h incubation. Then a local lidocaine anaesthetic spray was applied. The lesions were illuminated with a red LED light for 7-8 min (exposure 75 J/cm2, wavelength 630 nm).
89333874|NCT05456334|Experimental|Ablative fractional laser- mediated daylight photodynamic therapy|After curretage lidocaine anaesthetic spray was applied on the whole treatment area. Lesions were treated with an ablative fractional CO2-laser (19 W, Dot mode, spacing 1000 µm, stack 3, scanning dwell time 1800 µs, repeat 0.5 s). A thin layer of light sensitizer (methyl aminolaevulinate cream) was applied on the treatment area. The patients were asked to move outdoors (temperature >10C, no rain, June-August) or to our adPDT-room (IndoorLux®, wavelength 350-750 nm, 15-25 000 lux) within 30 minutes, for the 2h-illumination.
89333875|NCT05456334|Active Comparator|Daylight photodynamic therapy|After curretage lidocaine anaesthetic spray was applied on the whole treatment area. A thin layer of light sensitizer (methyl aminolaevulinate cream) was applied on the treatment area. The patients were asked to move outdoors (temperature >10C, no rain, June-August) or to our adPDT-room (IndoorLux®, wavelength 350-750 nm, 15-25 000 lux) within 30 minutes, for the 2h-illumination.
89333876|NCT05456321|Active Comparator|Cognitive Training and Active tDCS|5 sessions of computerized executive functioning training - plus active tDCS (also 5 sessions).
89333877|NCT05456321|Sham Comparator|Cognitive Training and Sham tDCS|5 sessions of computerized executive functioning training - plus sham tDCS (also 5 sessions).
89333878|NCT05456126||Term infants|The inclusion criteria for term infants are: gestational age 37-42 weeks, birth weight >2,500 grams, aged 2-4 months, and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
89333879|NCT05456126||Preterm infants|The inclusion criteria for preterm infants are: gestational age <37 weeks, birth weight <2,500 grams, aged 2-4 months (corrected for prematurity), and no congenital/genetic abnormalities. Their mothers are older than 20 years of age, have no history of alcohol or drug abuse, and are married or live with fathers.
89333880|NCT05453916|Experimental|Nitazoxanide|patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
89333881|NCT05453916|Active Comparator|Rifaximin|patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days.
89333882|NCT05451680|Experimental|Negative-pressure treatment|A negative pressure wound dressing is placed over the skin graft. Patients are started on compression therapy after surgery, unless there are contraindications, and standard oral and written postoperative immobilization and other treatment instructions are given.
89333883|NCT05451680|Active Comparator|Conventional treatment|A conventional antimicrobial wound dressing is placed on top of the graft. Patients are started on compression therapy after surgery, unless there are contraindications, and standard oral and written postoperative immobilization and other treatment instructions are given.
89333884|NCT05448638|Experimental|transversus thoracic muscle plane block+pectoral nerves block|the combination of transversus thoracic muscle plane and pectoral nerves blocks
89333885|NCT05448638|Active Comparator|pectoral nerves block|the pectoral nerves block only
89333886|NCT05443555|Active Comparator|Intervention: Gabapentin|Participants randomized to the intervention group will receive active gabapentin for 3 months and brief (5-minute) evidence-based counseling for alcohol use.
89333887|NCT05443555|Placebo Comparator|Control: Placebo|Participants randomized to the control group will receive placebo capsules, identical in appearance to gabapentin, and the same brief (5-minute) one-time evidence-based counseling for alcohol use as the intervention group.
89333888|NCT05427708|Experimental|Interoceptive Exposure (IE)|Participants assigned to the interoceptive exposure condition will receive twice-weekly 90-minute in-person treatment sessions for four weeks. This treatment will include education about anxiety and factors that maintain anxiety symptoms. In addition, participants will be asked to perform exercises designed to activate potentially distressing - but harmless - bodily sensations that are commonly associated with stress and anxiety. Participants will also be encouraged to practice these exercises daily at home.
89333889|NCT05427708|Experimental|Capnometry-Guided Respiratory Intervention (CGRI)|If assigned to this condition, participants will be expected to complete twice-daily 17-minute tablet-assisted breathing exercises at home for four weeks. They will also receive brief phone check-ins with their study therapist weekly to review progress and troubleshoot any problems they may be experiencing. Last, these participants will have access to a paced-breathing app that provides audio recordings to maintain specified breathing rates for up to 10 minutes.
89333890|NCT05427708|Active Comparator|Psycho-Education (PsyEd)|If assigned to the psycho-education condition, participants will undergo once-weekly 20-minute video conferencing session with a therapist for four weeks. During these sessions, they will be provided information about the nature and causes of anxiety-related disorders and learn tips for coping with anxiety symptoms when they arise. At the end of their sessions with the therapist, they will receive handouts that will help reinforce what they've learned.
89333891|NCT05426109|Experimental|Peanut snacks|Participants will be provided and consume an extra 500 kcal/day of peanut-containing snacks for 10 weeks.
89333892|NCT05426109|Active Comparator|No peanut-containing snacks|Participants will be provided and consume an extra 500 kcal/day of snacks without peanuts or peanut-containing foods for 10 weeks.
89333893|NCT05419063|Experimental|weight loss program|Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress. The weight loss program will provide asynchronous support (information, automated texting feedback, tailored emails) for adopting and maintaining lifestyle-based strategies for safe and effective weight loss.
88806827|NCT05131425|Experimental|Cognitive Behavioral Intervention|The experimental condition is a CBT intervention which focuses on developing 1) emotion regulation skills, 2) somatic management skills individually tailored for sensory and regulatory needs; 3) cognitive strategies such as individualized helpful thoughts and mantras (I can do it); and 4) graded exposure (e.g., facing fears).
89333894|NCT05410340|Active Comparator|Preterm group 1|To analize the brain activation and oxigenation using the Vojta Therapy
89333895|NCT05410340|Active Comparator|Preterm Group 2|To analize the brain activation and oxigenation using massotherapy
89333896|NCT05410340|Placebo Comparator|Term group 1|To analize the brain activation and oxigenation using the Vojta Therapy
89333897|NCT05410340|Placebo Comparator|Term group 2|To analize the brain activation and oxigenation using massotherapy
89333898|NCT05394766|No Intervention|Does not receive access to Omada Health program|Participants manage hypertension with usual care alone.
89333899|NCT05394766|Experimental|Receives access to Omada Health program|In addition to usual care, participants will gain access to the Omada Program, an online program that offers lifestyle self-management support for hypertension. Participants will be assigned a health coach and a hypertension specialist via Omada's secure app. Participants will receive hypertension education and resources and communicate with their care team through asynchronous, in-app messaging features. Participants will receive digital tools that connect with the Omada app to help track their food intake, physical activity, and blood pressure (BP). Participants who also have diabetes will receive a digital blood glucose meter and/or a continuous glucose monitor as well. The care team will support patients with lifestyle self-management support, adherence to their current medication regimen, improved BP control, and use of monitors for self-management of their BP and/or blood glucose values.
89333900|NCT05394610|Active Comparator|Active Treatment|The Sana Device is an externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies. The device is externally communicating only. The Sana Device will be administered at least twice daily, with one treatment session being just prior to bedtime. Additional PRN sessions with the Sana device will be allowed at the subject's discretion.
89333901|NCT05394610|Sham Comparator|Sham Arm|The sham treatment device was designed to copy the look and feel of the Sana therapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and ound but should offer no therapeutic effect to the level of the Sana Device. The sham device will run on the same headset, use a matched intensity of light/audio and used on the same schedule as the Sana treatment.
89333902|NCT05393726|Experimental|Suprainguinal Fascia Iliaca Block group|Patients will receive ultrasound-guided suprainguinal fascia iliaca block injection 40 ml of bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.
89333903|NCT05393726|Experimental|Lumbar Erector Spinae Plane Block group|Patients will receive ultrasound-guided lumber erector spinae plane block (L-ESPB) injection 40ml bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.
89333904|NCT05393726|No Intervention|control group|Patients underwent surgery under general anesthesia and received the perioperative routine protocol of analgesia by using I.V. fentanyl (1µg/kg), with elevation of mean arterial blood pressure for more than 20% of their baseline values, additional bolus doses of fentanyl 0.5 µg /kg.
89333905|NCT05386173||Fetal intervention group|Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria
89333906|NCT05386173||Fetal non-intervention group|Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria which are identical with the criteria in the Fetal intervention group
89333907|NCT05384678|Experimental|DMT 0.6 mg/min|
89333908|NCT05384678|Experimental|DMT 1.2 mg/min|
89333909|NCT05384678|Experimental|DMT 1.8 mg/min|
89333910|NCT05384678|Experimental|DMT 2.4 mg/min|
89333911|NCT05384678|Placebo Comparator|Placebo|
89333912|NCT05384678|Experimental|DMT 1.2 mg/min + dose titration|
89333913|NCT05378490||Intravenous thrombolysis (IVT)|All patients treated with IVT in the acute stroke care pathway 2012-2025
89333914|NCT05378490||Intracerebral hemorrhage (ICH)|All patients with intracerebral hemorrhage 2012-2019
89333915|NCT05378490||Acute ischemic stroke (AIS) and Intracerebral hemorrhage (ICH)|All patients with acute ischemic stroke or intracerebral hemorrhage 2015-2017
89333916|NCT05378490||Stoke care pathway|All patients admitted to the stroke care pathway (ischemic stroke, intracerebral hemorrhage, transient ischemic attack and stroke mimics) 2015-2017
89333917|NCT05378490||Endovascular treatment|All stroke patients treated with endovascular treatment 2012-2025
89333918|NCT05378490||Cerebellar hematoma (cICH)|All patients with cerebellar hematoma 2008-2019
89333919|NCT05378152|Active Comparator|Pipelle biopsy|This group will undergo an endometrial biopsy performed using a Pipelle catheter in the usual manner performed according to the physician either with or without a speculum and with or without a tenaculum. Local anaesthetic block may or may not be used as per clinical judgement.
89333920|NCT05378152|Sham Comparator|No Pipelle biopsy|This group will undergo a sham procedure where a speculum is inserted into the vagina and then removed.
89333921|NCT05369234|Experimental|Cohort 1--Arm 1|Aloe Vera Juice + Standard of Care Treatments Swish and spit ¼ cup (2 ounces) of 100% aloe vera juice 3 times per day, 7 days per week as first line treatment, standard of care agents added as needed
89333922|NCT05369234|Active Comparator|Cohort 1--Arm 2|Standard of Care Treatments Use salt and baking soda rinses, Magic Mouthwash, Carafate, etc.
89333923|NCT05369234|Experimental|Cohort 2--Arm 1|Aloe Vera Juice + Standard of Care Treatments Drink ¼ cup (2 ounces) of 100% aloe vera juice 3 times per day, 7 days per week as first line treatment, standard of care agents added as needed
89333924|NCT05369234|Active Comparator|Cohort 2-- Arm 2|Standard of Care Treatments Use salt and baking soda rinses, Magic Mouthwash, Carafate, etc.
89333925|NCT05364125|Experimental|Treatment arm|Olfactory training by neurological chemosensory stimulation using aromatic substances delivered via diffusers. Four aromatic substances will be used. Each substance will be given for 20 seconds sequentially, providing a total of 80 seconds of olfactory stimulation three times per day for 3 months.
89333926|NCT05364125|Placebo Comparator|Control arm|Same diffuser will be given to control group. All of the four essential oils will be replaced by normal saline using the same packing. Same treatment regime of 20 seconds for each diffuser three times per day for 3 months will be instructed to control group patients.
89333927|NCT05362526|Experimental|HFOT (High flow with tracheostomy interface)|Patient will be placed on heated humidified high flow after surgery.
89333928|NCT05362526|Active Comparator|COT (Conventional Oxygen Therapy)|Pt will be placed on conventional oxygen therapy after surgery.
89333929|NCT05360290|Active Comparator|CTC positive|
89333930|NCT05360290|Other|CTC negative|
89333931|NCT05340855|Experimental|Facebook Intervention|In Phase 3, all participants will receive the same intervention.
89333932|NCT05340023||Patient with suspicion of Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH)|"right cardiac catheterization (usual practice)~a blood sample (inclusion for all patients with suspicion)~if diagnosis of Chronic thromboembolic pulmonary hypertension confirmed a another bood sample at 6 months"
89333933|NCT05330182|Experimental|Sentinel Cohort|
89333934|NCT05330182|Active Comparator|LMN-201|
89333935|NCT05330182|Placebo Comparator|Placebo|
89333936|NCT05326880|Experimental|Study Group (SG)|Receive new zirconia implant: Straumann® PURE 2-piece Ceramic Implant (tissue level), ZLA
89333937|NCT05326880|Active Comparator|Control Group (CG)|Receive standard titanium implant: Straumann® Bone Level Implant, Titanium, SLA
89333938|NCT05326100|Active Comparator|Conventional Therapy (CPT) Group|Each session will include vestibular exercises, customized to address the participant's symptoms of vestibular dysfunction and functional ability.
89333939|NCT05326100|Active Comparator|CAREN Group|The CAREN group will undergo vestibular physical therapy that will include virtual environment (VE) applications on the CAREN.
89333940|NCT05326100|Experimental|Augmented Reality (AR) Group|The AR group will undergo vestibular physical therapy that will include VE applications on the AR HMD.
89333941|NCT05325242|Experimental|Elbow Artery Embolization (EAE)|Patients will undergo EAE with Embozene microspheres (75 micron). The microspheres will be delivered in a saline-contrast medium solution and will be delivered to the arteries supplying the areas of the patient's pain.
89333942|NCT05322655||infants living in low-income neighborhoods of Nairobi|62 infants between 0 and 12 months age
89333943|NCT05322655||infants living in middle-income neighborhoods of Nairobi|62 infants between 0 and 12 months age
89333944|NCT05322655||infants living in low-income neighborhoods of Kisumu|62 infants between 0 and 12 months age
89333945|NCT05322655||infants living in middle-income neighborhoods of Kisumu|62 infants between 0 and 12 months age
89333946|NCT05310461|Experimental|Early transcatheter or surgical aortic valve replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
89333947|NCT05310461|Other|Control Intervention|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention.
89333948|NCT05303428|Experimental|LIFU, fMRI Cognitive|fMRI resting and cognitive tasks performed after LIFU application to known brain region of interest or active sham region (within participant all conditions tested).
89333949|NCT05298761|Experimental|Lignocain|I/V lignocain 1.5mg per kg given to participants in state dose
89333950|NCT05298761|Experimental|nalbuphine|I/v nalbuphine 0.1mg per kg given to participants in stat dose
89333951|NCT05297318|Experimental|hypotension prediction index guided|Patients receiving hypotension prediction index guided. In this group, they will be alerted when the index exceeded 85 (range 0 to 100) indicating the later occurrence of MAP< 65mmHg for at least minutes and a treatment protocol based on advanced hemodynamic parameters recommended vasopressor or inotrope, fluid administration, or observation.
89333952|NCT05297318|Sham Comparator|without hypotesion prediction index guided|Patients will receive usual care during the operation without hypotension prediction index alerted.
89333953|NCT05293470||Piqray|Patients prescribed with Piqray
89333954|NCT05290233|Experimental|TRE+RT|Participants will confine eating between either 10am-6pm or 12-8pm and fast from 6pm-10am or 8pm-12pm daily combined with 3-4 days of supervised resistance training per week.
89333955|NCT05290233|Active Comparator|TRE+AT|Participants will confine eating between either 10am-6pm or 12-8pm and fast from 6pm-10am or 8pm-12pm daily combined with 3-4 days of supervised aerobic training per week.
89333956|NCT05288868|Experimental|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
89333957|NCT05288868|No Intervention|Caregiver Satisfaction|Caregivers who accompany their children with autism to the clinic will be surveyed for their comfort scores before and after the study participants' educational intervention
89333958|NCT05286255|Experimental|Allogeneic Mesenchymal Stromal Cell infusion|Intravenous infusion of 1.25-1.5 x 10^6 cells/kg with a maximal dose of 100 x 10^6 cells on days 1 and 3 after study enrollment.
89333959|NCT05281211|Experimental|Preoperative Nutrition+Exercise|Preoperative nutrition and exercise pre-habilitation followed by major liver resection.
89333960|NCT05281211|No Intervention|Upfront Surgery|Upfront major liver resection.
89333961|NCT05276011|Active Comparator|Active Treatment (TG-C)|TG-C at 1.0 x 10e7 cells per single 2 mL intraarticular injection
89333962|NCT05276011|Active Comparator|Active Treatment 2 (TG-C)|TG-C at 3.0 x 10e6 cells per single 2 mL intraarticular injection
89333963|NCT05276011|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
89333964|NCT05262530|Experimental|BNT142|
89333965|NCT05259410|Experimental|Time restricted eating|Participants will eat all food within the same self selected 8 hour window daily.
89333966|NCT05259410|No Intervention|Standard care|Current standard care is to eat enough calories and protein to maintain weight and lean mass.
89333967|NCT05259410|Experimental|Med TRE|Participants will eat a mediterranean style diet within the same self selected 8 hour window daily.
89333968|NCT05253807|Experimental|Cohort A: Squamous NSCLC|Participants with squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
89333969|NCT05253807|Experimental|Cohort B: Non-squamous NSCLC|Participants with non-squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
89333970|NCT05239429|Experimental|Transcendental Meditation Technique|Participants are trained on the use of the Transcendental Meditation Technique. They will perform the technique twice a day for 20-minutes per session.
89333971|NCT05239429|No Intervention|Lifestyle-as-usual (control)|There is no change to the participants daily schedule and lifestyle.
89333972|NCT05233033|Experimental|Phase 1a Dose Escalation|
89333973|NCT05233033|Experimental|Phase 1b Dose Expansion MYD88MT|KT-413 given at the RP2D identified in Phase 1a Dose Escalation in patients with MYD88 mutant DLBCL.
89333974|NCT05233033|Experimental|Phase 1b Dose Expansion MYD88WT|KT-413 given at the RP2D identified in Phase 1a Dose Escalation in patients with MYD88 wild type DLBCL.
89333975|NCT05219435|Experimental|Nivolumab plus Ipilimumab|Patients will receive maintenance therapy with 4 cycles of Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg every three weeks (Q3W)(induction phase) followed by Nivolumab 480 mg every 4 weeks (Q4W)(consolidation phase) until unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
89333976|NCT05212870||Low back and neck pain group with experience of Covid-19|
89333977|NCT05212870||Low back and neck pain group without experience of Covid-19|
89333978|NCT05211635|Experimental|Vitamin D|Vitamin D3 capsule 50 µg
89333979|NCT05211635|Placebo Comparator|Placebo|Placebo capsule with identical appearance to the experimental drug
89523565|NCT03379987|Active Comparator|PVB bupivacaine|
89333980|NCT05204680|Experimental|Aerobic Exercise|"The participant will work with the physical therapist on an exercise regimen and first session will be supervised with the therapist. Exercise protocols will include a 15-minute warmup and cooldown session as well. To allow for increased participation and accessibility, the means of aerobic exercise will not be restricted and any safe mechanism of exercise will be allowed e.g., treadmill, stationary bike, etc.~Subjects will be provided an activity monitor (Phillips HealthBand Monitor) for the duration of study participation and receive training on how to use it, including marking events with start and stop of exercise sessions and tracking heart rate. The device can track type of activity as well as cardio fitness index and VO2max."
89333981|NCT05195788|Experimental|Intervention|Participants assigned to the Intervention group will undergo a cardiac rehabilitation program. The program will combine individualized aerobic and muscle strengthening exercises, comprising three sessions per week to be conducted in person at the EPIC center and at home, for a duration of three months. All sessions will be prepared by a certified kinesiologist.
89333982|NCT05195788|No Intervention|Control|Participants assigned to the control group will be encouraged to remain at the usual level of physical activity for the duration of the study. At the end of the study, they will gain free access to the same cardiac rehabilitation program provided to the intervention group.
89333983|NCT05175092|Experimental|Intent to Treat: LDLT|Living Donor Liver Transplantation
89333984|NCT05175092|No Intervention|Control Group|Enrolled but does not receive LDLT
89333985|NCT05173597||Patients receiving treatment with Follitropin-delta|The included patients are adult women from the routine clinical care settings with indication for ovarian stimulation with follitropin delta in a GnRH-antagonist protocol who are making a first treatment attempt IVF or ICSI. This study is intended to be conducted in non-vulnerable population. No vulnerable subjects will be enrolled in the study.
89333986|NCT05167266|Experimental|Cognitive psychoeducation|"1) The cognitive intervention is a 4-session, psycho-educative, integrative and multidimensional intervention designed to prevent post-acute cognitive symptoms. Each individual session will last 90' and will concern a specific cognitive domain:~Cognition in covid, fatigue and sleep~Working memory and attentional functioning~Executive functioning~Memory functioning~The structure of the sessions will be similar: (1) explanation about (dys)functioning of processes associated to the domain of interest: (2) identification of problems in daily life translated into functional objectives (e.g. keeping papers organized; scheduling activities to avoid fatigue); (3) discovery and application of (meta)cognitive strategies.~Material (videos, tips,…) will be provided that the patients can consult when needed. The patients will have a diary to complete to explain when they applied the content of the intervention in daily life, and how successful it was."
89333987|NCT05167266|Active Comparator|Affective psychoeducation|"2) The affective intervention is also a psychoeducation program based on four sessions, in which different strategies and resources will be proposed to increase self-efficacy for emotion management:~Recognizing emotions and affective states~Accepting and communicating emotions and difficulties~Accepting the uncertainty associated with difficulties~Behavioural activation~Material (videos, tips,…) will be provided that the patients can consult when needed. The patients will have a diary to complete to explain when they applied the content of the intervention in daily life, and how successful it was."
89333988|NCT05164094|Experimental|Part A: mRNA-1189 Dose Level 2|Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
89333989|NCT05164094|Experimental|Part A: mRNA-1189 Dose Level 3|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
89333990|NCT05164094|Experimental|Part A: mRNA-1189 Dose Level 4|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
89333991|NCT05164094|Placebo Comparator|Part A: Placebo|Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
89333992|NCT05164094|Experimental|Part B: mRNA-1189 Dose Level 1|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
89333993|NCT05164094|Experimental|Part B: mRNA-1189 Dose Level 2|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
89333994|NCT05164094|Experimental|Part B: mRNA-1189 Dose Level 3|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
89333995|NCT05164094|Experimental|Part B: mRNA-1189 Dose Level 4|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
89333996|NCT05164094|Placebo Comparator|Part B: Placebo|Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
89333997|NCT05159596|Experimental|In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by Spanish-speaking caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
89333998|NCT05159596|Sham Comparator|Limited In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by Spanish-speaking caregivers (N=60) in their homes. Only monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm."
89333999|NCT05159583|Experimental|In-Home Technology System|"The full system [(a) 1 advanced gateway with a dual-SIM cellular connection to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by rural caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
89334000|NCT05159583|Sham Comparator|Limited In-Home Technology System|"The full system [(a) 1 advanced gateway with a dual-SIM cellular connection to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by rural caregivers (N=60) in their homes. Only monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm."
89334001|NCT05159557|Experimental|In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 1 Apple Watch to detect falls and activity outside the home] will be self-installed by caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
89334002|NCT05159557|Sham Comparator|Limited In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights], with the exception of the Apple Watch that those in the experimental condition receive will be self-installed by caregivers (N=60) in their homes. Only monitoring of the water leak and associated warnings will be activated remotely for those participants who have been randomly assigned to this limited (sham comparator) arm."
89334003|NCT05159375|Experimental|Elio (supplement under investigation)|2.4g of Elio administered orally daily with the first meal of the day for a 17 day period
89334004|NCT05159375|Placebo Comparator|Placebo|2.4g of SMCC administered orally daily with the first meal of the day for a 17 day period
89334005|NCT05137821|Experimental|non tested comparative group|two sealed new implants as a control
89334006|NCT05137821|Experimental|Er: YSGG laser tested group|24 infected implants divided into four subgroups that will be decontaminated by Er: YSGG laser in various peri-implant defects
89334007|NCT05132296|Experimental|GROUP I (CLIP)|Patients undergo 60 minute sessions of nutrition education for 12 weeks and behavioral intervention 26 weeks. Patients receive FitBit and undergo physical activity for 30-60 minutes 5 days a week (aerobic activity) and 2 days a week (resistance training).
89334008|NCT05132296|Active Comparator|GROUP II (usual care)|Patients have access to all usual care supportive services.
89334009|NCT05131555|Placebo Comparator|1: Placebo|lactose
89334010|NCT05131555|Experimental|H1 blockade|540 mg Fexofenadine
89334011|NCT05131555|Experimental|H2 blockade|40 mg Famotidine
89334012|NCT05126030|Experimental|Primary Cohort|Device: Topaz TTVR system
89334013|NCT05119296|Experimental|Pembrolizumab 200 mg|Participants will receive pembrolizumab (Keytruda) 200 mg administered by IV infusion every 3 weeks. Participants will remain on study and receive pembrolizumab for the nominal duration of treatment (35 cycles, approximately 2 years) or until there is evidence of disease progression by RECIST, unacceptable toxicity, withdrawal of consent, or discontinuation of the trial for any other reason.
89334014|NCT05118113|Other|Healthy donors|
89334015|NCT05111847|Active Comparator|Short-term Baseplate|
89334016|NCT05111847|Active Comparator|Long-term Baseplate|
89334017|NCT05101031||Denver Health Medical Center|SV machine will be attached if hypotensive and in the emergency department
89334018|NCT05089201|Experimental|Animal-assisted interaction (AAI)|Dogs and handlers will visit with patients for 20 minutes and discuss semi-scripted topics.
89334019|NCT05089201|Active Comparator|Conversational interaction|Handlers will have a 20 minute semi-scripted conversation with patients.
89334020|NCT05089201|No Intervention|Treatment as usual|Patients will receive treatment as usual.
89334021|NCT05085366|Experimental|mRNA-1647|Participants will receive mRNA-1647 vaccine by intramuscular (IM) injection on Day 1, Day 57, and Day 169.
89334022|NCT05085366|Placebo Comparator|Placebo|Participants will receive mRNA-1647 vaccine matching placebo by IM injection on Day 1, Day 57, and Day 169.
89334023|NCT05065710|Experimental|ZL-1211 monotherapy|
89334024|NCT05065554|Experimental|ACALABRUTINIB + RITUXIMAB/BIOSIMILAR|"Acalabrutinib and rituximab (or biosimilar) with be contained in the treatment regimen.~Acalabrutinib will be administered twice daily, with 28 consecutive days defined as a treatment cycle. Acalabrutinib will be administered for 48 cycles or until disease progression or unacceptable toxicity.~Rituximab will be administered on Days 1, 8, 15, and 22 of Cycles 1 and 4. Participants will have study visits every cycle for cycles 1-6, then every 3 cycles, with the next visit at Cycle 9, then C12, C15, etc.~Participants will continue acalabrutinib until disease progression or intolerable adverse effect develops. They will be followed for up to 2 years after completion of 48 cycles of treatment or until death"
89334025|NCT05061992|Experimental|Lactulose|
89334026|NCT05061992|No Intervention|No treatment|Subjects will complete baseline and outcome assessments at 28 days and no intervention or placebo will be prescribed.
89334027|NCT05058417|Experimental|Empagliflozin group|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
89334028|NCT05058417|Placebo Comparator|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
89334029|NCT05030623|Experimental|Tadalafil|
89334030|NCT05030623|Placebo Comparator|Placebo|
89334031|NCT05026736|Experimental|Treatment (sintilimab)|Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue to receive treatment at the discretion of the treating physician.
89334032|NCT05026645||adult inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
89334033|NCT05026645||Infant inflicted by a CBRNE weapon|Part of the population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
89334034|NCT05026645||Women inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
89334035|NCT05026645||Men inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
89334036|NCT05026645||Elderly inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
89334037|NCT05026645||Diagnosed with chronic disease(s) inflicted by a CBRNE weapon|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system.
89334038|NCT05026645||Clinician (adult) whom performs his/her clinical interventions|Clinician (adult) whom performs his/her clinical interventions while integrating competences in protections and decontamination. Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system. This is the case of when the clinician is required to ensure safety toward his/her patient while performing his/her interventions & procedures.
89334039|NCT05026645||Clinician (adult) injured by duties circumstances|Part of the Population is being studied includes any individual who was affected by CBRNE attacks and needed an intervention of the healthcare system. This is the case of when the clinician becomes inflicted by a CBRNE weapon while intervening toward contaminated patient due to any failure in protection and decontamination.
89334040|NCT05014581|Experimental|Pre-emptive vasopressor|Pre-emptive continuous infusion of norepinephrine during intubation
89334041|NCT05014581|No Intervention|No vasopressor|No pre-emptive administration of vasopressors
89334042|NCT05009082|Active Comparator|Arm 1|Chemotherapy followed by maintenance with niraparib
89334043|NCT05009082|Active Comparator|Arm 2|Chemotherapy in combination with bevacizumab followed by maintenance with bevacizumab and niraparib
89334044|NCT05000710|Experimental|study arm|"Study treatments include:~Durvalumab at D1 and q4w + Tremelimumab at C1D1 and C4D1. Radiotherapy 11 fractions (start at D21)."
89334045|NCT04995536|Experimental|Treatment (radiation therapy, CAS3/SS3)|Patients undergo radiation therapy on days 1 and 2 tumor-bearing lymph node, and receive CAS3/SS3 intratumorally on days 2, 4, 16, and 18. Patients assigned to dose level 3 also receive CAS3/SS3 intratumorally on days 9, 11, 23, and 25.
89334046|NCT04994652|Experimental|Videolaryngoscope|Intubation attempted with C-MAC videolaryngoscope
89334047|NCT04994652|Active Comparator|Standard laryngoscope|Intubation attempted with standard laryngoscope
89334048|NCT04992052|Active Comparator|Treatment arm|This arm will have bone wax applied to the exposed cancellous surfaces of the bone.
89334049|NCT04992052|No Intervention|Control Arm|This arm will serve as the control group. Bone wax will not be used in this group.
88819570|NCT05451381|Experimental|Propofol group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group (PR):~continuous infusion of propofol using a syringe pump at the dose of 1-1.5 mg / kg / h"
89334050|NCT04977908|Experimental|Fully closed-loop system with ultra-rapid Lispro insulin|"The fully closed-loop system (CamAPS HX) will consist of:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm~Cloud upload system to review CGM/insulin data.~Participants will use ultra-rapid Lispro insulin in the closed-loop system"
89334051|NCT04977908|Active Comparator|Standard insulin pump therapy with CGM|"Participants will use their own insulin pump and usual insulin throughout this study period.~The CGM will be the Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)"
89334052|NCT04976153|Experimental|aSMDC|Autologous skeletal muscle derived cells for the treatment of urge fecal incontinence
89334053|NCT04976153|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product
89334054|NCT04961047|Experimental|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
89334055|NCT04961047|Active Comparator|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
89334056|NCT04934293|Experimental|Arm A_ first with RV then without|Use of the virtual reality headset from the first week of proton therapy
89334057|NCT04934293|Experimental|Arm B- first without RV than with|Use of the virtual reality headset from the second week of proton therapy
89334058|NCT04924322|Experimental|Enoxaparin (Older Children Prophylactic)|Prophylactic dose of enoxaparin for older children 1-17 years old.
89334059|NCT04924322|No Intervention|Control (Older Children)|Usual care without placebo for older children 1-17 years old.
89334060|NCT04924322|Experimental|Enoxaparin (Infants Therapeutic High Anti-Xa Target)|Therapeutic dose of enoxaparin for infants <1 year old with anti-Xa target of >0.5-1 IU/mL.
89334061|NCT04924322|Experimental|Enoxaparin (Infants Therapeutic Low Anti-Xa Target)|Therapeutic dose of enoxaparin for infants <1 year old with anti-Xa target of 0.2-0.5 IU/mL.
89334062|NCT04924322|No Intervention|Control (Infants)|Usual care without placebo for infants <1 year old.
89334063|NCT04909125|Active Comparator|Hypofractionation Arm|40Gy / 15 fractions, 2.67Gy per fraction, over 3.5 week (9 fractions per fortnight)
89334064|NCT04909125|Other|Standard /Conventional fractionation Arm|50Gy / 25 fractions, 2Gy per fraction, over 5.5 week (9 fractions per fortnight)
89334065|NCT04830501|Experimental|Dose Escalation|This study adopts an accelerated titration design (ATD) and utilizes an accelerated dose escalation phase in order to minimize suboptimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD.
89334066|NCT04821466|Experimental|Virtual Reality Headset|VR headset, programmed with a selection of 7 wellbeing programs to identify if use will improve participants wellbeing
89334067|NCT04814823||Adult healthy subjects|Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state
89334068|NCT04807517|Experimental|Buspirone|Subjects will receive buspirone 2.5 mg each morning at the start of the trial. The dose will be increased by 2.5 mg per week in two divided doses daily depending on effectiveness and tolerability. The optimal dose will be reached by week 12 of treatment. The minimum starting dose will be 2.5 mg and the maximum total daily dose will be 30 mg. Medication will be dosed twice daily due to the short half-life (2-3 hours) of this medication.
89334069|NCT04798352|Experimental|LUTONIX(R)035 drug-coated balloon catheter|
89334070|NCT04798352|Experimental|RANGER TM drug-coated balloon catheter|
89334071|NCT04789551||Multiple Sclerosis Stable Conditions|Multiple sclerosis patients presenting for a routine clinic visit.
89334072|NCT04789551||Multiple Sclerosis Acute Flare Up|Multiple sclerosis patients admitted to the hospital with acute symptoms.
89334073|NCT04789551||Control patients|Patients without any immunological diseases who present for elective surgery.
89334074|NCT04785365|Other|Experimental: ATL001|Patients who have previously received ATL001 in a clinical trial will be evaluated in this trial for long-term safety and clinical activity.
89334075|NCT04785365|Other|Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001|Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001
89334076|NCT04776928|Experimental|Provider-level push report notifications|Push reports will be sent via using a secure email client. The email will be sent to the email address provided to the study team by the surgeon or site.
89334077|NCT04776928|No Intervention|No intervention|Sites who did not sign Exhibit B-1.
89334078|NCT04751071|Active Comparator|Roflumilast|Roflumilast 500 µg tablet plus standard therapy
89334079|NCT04751071|Placebo Comparator|Placebo|placebo tablet plus standard therapy
89334080|NCT04731168|No Intervention|Control|
89334081|NCT04731168|Experimental|MAD|Patients will have a mandibular advancement device during the first postoperative night
89334082|NCT04726280|Experimental|10 ml single-shot injection|"In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
89334083|NCT04726280|Active Comparator|20 ml single-shot injection group|"In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots.~Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution."
89334084|NCT04708717|Experimental|Stimulation Rate|
89334085|NCT04708717|Active Comparator|Electrode Location|
89334086|NCT04697225|Experimental|weight loss program|
89334087|NCT04677972|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 28 days, with 84-day followup
89334088|NCT04677972|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 28 days, with 84-day followup
89334089|NCT04676217|Active Comparator|FDP|Face down positioning
89334090|NCT04676217|Experimental|NSP|"No positioning named non-supine positioning. Participants are to avoid recumbent positioning."
89334091|NCT04661189|Experimental|Multidomain intervention|The multidomain intervention will combine a remote monitoring of home-based cognitive training with physical exercise training for 6-month.
89334092|NCT04661189|Experimental|Physical exercise intervention|The physical exercises intervention will include the remote monitoring of physical exercise training for 6-month.
89334093|NCT04648293||Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. Improvement in hemodynamics is exhibited by an increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
89334094|NCT04648293||No Improvement in Hemodynamics|Over the course of a patient's hospitalization, data will be collected on patients from the initiation to completion of hemodynamic monitoring with the Starling monitor in a wide variety of clinical settings, and for different diagnoses. No Improvement in hemodynamics is exhibited by no increase in both Cardiac Output and Stroke Volume observed at 12 hour intervals from time of monitoring until completion.
89334095|NCT04647227|Other|Hemophilia A and B Cases|SEVENFACT® has been approved for the treatment of bleeding events in individuals with hemophilia A or B with inhibitors. This study is intended to further investigate the safety and tolerability of SEVENFACT in participants with hemophilia A or B with inhibitors in the presence or absence of prophylactic therapies. Dosing will be at the discretion of the attending physician, and each participant will be supplied with the equivalent of nine 75 µg/kg doses, which aligns with the recommended dosing schedule as provided in SEVENFACT's United States Prescribing Information (USPI). In the event of a bleeding episode (BE), the participant will either self-administer the correct dose under the guidance of the treating investigator or the dose will be administered at a treatment facility.
89334096|NCT04634877|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by pembrolizumab 400 mg IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of pembrolizumab, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
89523566|NCT02730793|Active Comparator|Standard Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
89523567|NCT02730793|Experimental|Study Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
89334097|NCT04634877|Placebo Comparator|Placebo + Chemotherapy|Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
89334098|NCT04625972|Experimental|AZD7442|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
89334099|NCT04625972|Placebo Comparator|Placebo|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
89334100|NCT04605198|Experimental|Modified Mindfulness-based Stress Reduction|
89334101|NCT04605198|Active Comparator|Health Promotion Attention Control|
89334102|NCT04593550||Observational (BrainCheck, 3D-CAM, EEG)|Patients undergo cognitive function assessment BrainCheck over 10 minutes before surgery, day 1 after surgery, and day 2 after surgery (if patients are still admitted to the hospital) and 3D-confusion assessment over 10 minutes BID on day 1 after surgery and day 2 after surgery (if patients are still admitted to the hospital). Patients also undergo EEG during surgery and collection of blood samples 30-60 minutes after surgery.
89334103|NCT04592978|Experimental|Pain-Alcohol Personalized Feedback Intervention|
89334104|NCT04592978|Active Comparator|Control Personalized Feedback Intervention|
89334105|NCT04591106||Group 1|50 healthy subjects and 50 subjects with NAFLD between ages of 6-17 years old. Each subject will receive 1 MRI/MRE exam. The MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.
89334106|NCT04591106||Group 2|"60 subjects with Liver Disease and Fibrosis between ages of 1 month - 40 years old.~Each subject will receive 1 MRI/MRE exam. The MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations."
89334107|NCT04591106||Group 3|15 healthy infants between 1 week - 6 months old and their mothers; 15 at-risk infants (mother had gestational diabetes) between 1 week - 6 months old and their mothers. Each infant will receive 1 MRI scan.
89334108|NCT04583774|Other|Anorexia Nervosa Group|Participants with anorexia nervosa
89334109|NCT04583774|Other|Healthy Control Group|Participants who are considered to be healthy controls
89334110|NCT04572048|Other|Single-day NRP training|This group will follow the single-day NRP training course that is currently the standard. It usually takes 8 hours to complete this training course and the nurses are released from their clinical duty to attend the training course.
89334111|NCT04572048|Experimental|Longitudinal one year NRP Training|This group will follow the longitudinal NRP training course. The longitudinal NRP training course will consist of nine 30-minute modules that will be taught every 6-8 weeks over a period of one year. The nurses will attend the different modules of the training course at their work place and during their work shift so they will have to be released from their clinical duty only 30 minutes at a time.
89334112|NCT04557618|Experimental|Auricular VNS Stimulation|Participants receive twice daily auricular vagal nerve stimulation
89334113|NCT04557618|Sham Comparator|Sham Auricular VNS Stimulation|Participants will have an auricular vagal nerve stimulator applied twice daily, without the stimulation applied
89334114|NCT04533022|Experimental|C21|
89334115|NCT04526418|Experimental|24/7 EEG™ SubQ System|To demonstrate the electrographic seizure recording effectiveness of the 24/7 EEG™ SubQ system by comparison to simultaneous inpatient video-EEG data.
89334116|NCT04520152|Experimental|Treatment group|Bronchoscopic LTD placement
89334117|NCT04519645|Experimental|Lacosamide|Study participants randomized to this arm will receive lacosamide (LCM) as an intravenous infusion in the Treatment Period and may continue to receive lacosamide in the Extension Period. Participants should be switched to oral dosing of LCM as soon as medically possible during the Extension Period.
89334118|NCT04519645|Active Comparator|Active Comparator|Study participants randomized to this arm will receive Active Comparator chosen based on standard of care (StOC) in the Clinical Practice in the Treatment Period and may continue to receive in the Extension Period.
89334119|NCT04513288|Experimental|Experimental group|Enteral administration of citrulline for 5 days. L-citrulline (Protéocit®). This commercial form consists only of L-citrulline. Each patient will receive 10 grams per day in 2 doses (1 stick/ 12H = 5 grams / 12H). These sticks contain a powder to be resuspended in 50 mL of water for injection (ppi) for 1 stick. They will be delivered in a 50 mL syringe allowing administration of the product through the nasogastric tube. The solution will be prepared just before administration.
89523568|NCT03385837||Heart Failure Patients|Cardiac Rehabilitation in Advanced Heart Failure Patients
89334120|NCT04513288|Placebo Comparator|Control group|Enteral administration of iso-nitrogenous placebo for 5 days. The placebo used will consist of a mixture of 4 non-essential amino acids. 5 g of L-citrulline provides 1.2 g of nitrogen. For the mixture to be iso-nitrogenous, each of the 4 amino acids will need to provide 0.3 g of nitrogen. The mixture will therefore consist of 21.6% alanine, 32.3% aspartate, 18.2% glycine and 27.9% proline for a total of 8.83 g of amino acids per sachet. 2 administrations (2 sticks) daily for 5 days.
89334121|NCT04512560|Experimental|Structured Remote Surgical Coaching|Participants randomized to the intervention group will participate in a 3-month SRSC program in addition to CST. Participants will be asked to provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon prior to the coaching session. Each coach will review the video recording and will identify key themes for discussion. Coaching sessions will be structured using the modified PRACTICE model, will be conducted outside of the clinical environment, and will employ facilitative coaching methods to encourage participants to define specific intra-operative problems and conceptually troubleshoot various solutions.
89334122|NCT04512560|Active Comparator|Conventional Surgical Training|Participants randomized to the control group will continue of their usual general surgery residency training including attending scheduled teaching sessions, and continuing with assigned responsibilities on the ward and in the OR.
89334123|NCT04508322|Active Comparator|Group 1|Early treatment HGA (9 years)
89334124|NCT04508322|Active Comparator|Group 2|Late treatment HGA (11 years)
89334125|NCT04508322|Active Comparator|Group 3|Treatment FA
89334126|NCT04507425|Active Comparator|Not Intubated|Patients admitted with a trauma injury who do not need to be intubated to receive treatment. Intubated means putting a tube down your throat to keep your airway from collapsing. Participants will be randomized to receive one of the three interventions in this arm.
89334127|NCT04507425|Active Comparator|Intubated Patients Undergoing Extubation|Patients admitted with a trauma injury who had to be intubated for treatment of their injury. Interventions administered after the tube is extubated (removed from throat). Participants will be randomized to receive one of the three interventions in this arm.
89334128|NCT04491409||Observational (standard of care, medical chart review)|Patients undergo standard of care treatment and their medical records are reviewed at 30 days and at 1 year after surgery.
89334129|NCT04491383|Experimental|Tocovid Suprabio (HOV-12020)|200mg, twice 1 day, 12 months
89334130|NCT04491383|Placebo Comparator|Placebo|200mg, twice 1 day, 12 months
89334131|NCT04488315|Experimental|The dexamethasone lipid microsphere plus ropivacaine group|
89334132|NCT04488315|Active Comparator|The ropivacaine alone group|
89334133|NCT04482647|Experimental|Supportive Care (video, breathing techniques, meditation)|Patients view an instructional video on breathing techniques and meditation. Patients then perform breathing techniques over 3 minutes and meditation over 2 minutes BID for 28 days.
89334134|NCT04469036|No Intervention|Telephone consultation|Telephone consultation to a pediatric trauma specialist
89334135|NCT04469036|Experimental|Virtual Pediatric Trauma Center|The Virtual Pediatric Trauma Center (VPTC), uses live video, or telehealth, to bring the expertise of a Level I pediatric trauma center virtually to patients at a hospital emergency department.
89334136|NCT04464005|Experimental|Pads with cold magnesium sulfate 33% solution|
89334137|NCT04464005|Placebo Comparator|Pads with cold water|
89334138|NCT04459013||Patient of the orthodontic consultation|
89334139|NCT04456816|Experimental|100 mg AP1189|100 mg AP1189. The treatment is a 12-weeks treatment. Each daily dose will be administered as a tablet
89334140|NCT04456816|Experimental|Placebo|Placebo. The treatment is a 12-weeks treatment. Each daily dose will be administered as a tablet
89334141|NCT04442048|Experimental|IMM-101|The treatment regimen with IMM-101 will be one 1.0 mg (= 0.1 mL) dose given on Day 0, followed by a second dose of 0.5 mg (= 0.05 mL) on Day 14 (-2/+5 days), and a third Dose of 0.5 mg (= 0.05 mL) on Day 45 (+/-14 days)
89334142|NCT04442048|Active Comparator|Observation|
89334143|NCT04429503|Active Comparator|aflibercept Q8|Administered every 8 weeks after a loading phase
89334144|NCT04429503|Experimental|High-Dose aflibercept Q12|Administered every 12 weeks after a loading phase
89334145|NCT04429503|Experimental|High-Dose aflibercept Q16|Administered every 16 weeks after a loading phase
89334146|NCT04408924|Experimental|200 milligram (mg) Abemaciclib Twice Daily|Participants received 200 mg abemaciclib administered orally twice daily on a continuous dosing schedule (28-day cycle) until symptomatic and/or radiographic progression, unacceptable toxicity, or until another discontinuation criterion is met.
89334147|NCT04400487|Experimental|Voxelotor|Participants will receive voxelotor at 1500 mg
89334148|NCT04385277|Experimental|Treatment (temozolomide, irinotecan, dinutuximab)|Patients receive temozolomide PO or via enteral tube daily and irinotecan IV over 90 minutes daily on days 1-5, dinutuximab IV over 10-20 hours daily on days 2-5, sargramostim SC or IV over 2 hours daily on days 6-12, and isotretinoin PO BID on days 8-21. Patients undergo MUGA during screening. Patients also undergo MRI, or CT, I23I-MIBG, or FDG-PET, BM aspiration, and BM biopsy on study. Treatment repeats every 28 days for up to 5 cycles (up to 6 cycles for isotretinoin only) in the absence of disease progression or unacceptable toxicity.
89334149|NCT04379011|Experimental|Brivaracetam Group|Participants in this arm will receive the investigational drug, Brivaracetam.
89334150|NCT04379011|Placebo Comparator|Control Group|Participants in this arm will receive a placebo.
89334151|NCT04375332|Experimental|HARPOON™ Beating Heart Mitral Valve Repair System|Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System
89334152|NCT04373720|Experimental|Diagnostic (MRE, standard of care MRI)|Patients undergo MRE over 10 minutes and then undergo standard of care MRI of the brain with and without contrast at baseline. Within 4 weeks after the initial MRI and MRE scans, patients may undergo standard of care biopsy to check the status of the disease. Within 48 hours after biopsy, patients undergo standard of care MRI to check the status of the disease. Patients who do not undergo biopsy undergo standard of care MRI 4-8 weeks after MRE scan to check the status of the disease.
89334153|NCT04346563|Experimental|Kinesio tape, functional correction applying|The experimental group, trained by Certified Kinesio tape researcher will attache the kinesio tape. Attaching the kinesio tape by using functional correction techniques, apply tape from the front of the acromion process to the spinous process T10 on both sides, providing 50% of the tape's tension (Kase, 2003, Han JT et al) to create a scapular retraction.
89334154|NCT04346563|Placebo Comparator|Placebo Kinesio taping apply|Apply kinesio tape without tension.
89334155|NCT04342715||Patients|Patients who have a diagnosis of visceral leishmaniasis and will be treated with SSG/PM
89334156|NCT04342715||Control|Healthy volunteers
89334157|NCT04333823|Experimental|Intervention (Dapagliflozin)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
89334158|NCT04333823|Placebo Comparator|Control (Placebo)|Dapagliflozin 5mg tablet taken by mouth once daily for 16 weeks
89334159|NCT04332393|Experimental|metformin group|
89334160|NCT04332393|No Intervention|No treatment group|
89334161|NCT04293757|Experimental|Rotational angio|Patients that will undergo 3D rotational angiography before cryoballoon ablation
89334162|NCT04293757|No Intervention|No rotational angio|Patients that will receive no preprocedural imaging before cryoballoon ablation
89334163|NCT04291976|Experimental|back-to-back HDWLE|Similar to single-pass HDWLE, with a second segmental inspection after the first examination in the same session. Equipment is similar to 1.
89334164|NCT04291976|Active Comparator|single-pass HDWLE|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
89334165|NCT04291976|Active Comparator|Chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or 0.3% indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two arms.
89334166|NCT04280796|Experimental|Substudy 1|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 1 an operant learning paradigm will be implemented to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement and vice versa.~Primary objectives:~To develop psychophysical methods that allow the independent assessment of sensory-discriminative and emotional-motivational pain responses and~to show that emotional-motivational and sensory-discriminative pain components can be dissociated~Secondary objective:~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in how strongly sensory-discriminative and emotional-motivational pain responses can be dissociated"
89334167|NCT04280796|Experimental|Substudy 2|"All participants will perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other. No arms will perform. In addition, in Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients.~Primary objective:~To demonstrate that in chronic pain patients, emotional-motivational pain responses are increased relative to sensory-discriminative pain responses~Secondary objective:~To assess whether fear of pain, fear-avoidance beliefs, pain catastrophizing, and sensation seeking as personality traits can explain variations in the present dissociation of sensory-discriminative and emotional-motivational pain responses in chronic pain patients"
89334168|NCT04280796|Experimental|Substudy 3|"All participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component. No arms will perform.~Primary objective:~To assess whether metacognition on pain perception are involved and subjective ratings of perceived pain and how metacognition relates to pain intensity.~Secondary objective:~To assess whether confidentiality as a personality trait , pain catastrophizing, and skin conductance responses are related to metacognition in pain."
89334169|NCT04258254|Experimental|Multimodal|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in tasks requiring interpersonal synchrony, multilimb coordination (asymmetrical and ipsi/contralateral motions), and balance. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
89334170|NCT04258254|Active Comparator|General Movement|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in structured physical activity focused on flexibility, strength, and endurance. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
89334171|NCT04258254|Active Comparator|Standard of Care|Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in seated play focused on reading, building, and art-craft activities. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
89334172|NCT04254263|Experimental|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
89334173|NCT04254263|No Intervention|No Pyrotinib|Observation follow-up
89334174|NCT04251702||Healthy Low-Risk Individuals in Labor|Healthy laboring individuals with a Singleton Term fetus in the Vertex position. Patients requiring medical management of diabetes or hypertension will be excluded.
89334175|NCT04247594|Experimental|Period 1|1500 mg per day
89334176|NCT04247594|Experimental|Period 2|2000 mg per day
89334177|NCT04247594|Experimental|Period 3|2500 mg per day
89334178|NCT04247594|Experimental|Period 4|3000 mg per day
89334179|NCT04247191|Experimental|P-Chat|The P-Chat is a brief individually delivered intervention
89334180|NCT04247191|Experimental|PBI|The PBI is a handbook developed by the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
89334181|NCT04247191|Experimental|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above.
89334182|NCT04247191|No Intervention|Control|This group will only complete assessments and will not receive any intervention.
89334183|NCT04234347|Active Comparator|Long Axis approach|Utilize the longitudinal orientation when placing an USGPIV.
89334184|NCT04234347|Active Comparator|Short axis approach|Utilize the transverse orientation when placing an USGPIV.
89334185|NCT04231331|Placebo Comparator|Placebo|All patients will receive placebo in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
89334186|NCT04231331|Active Comparator|Ertugliflozin|All patients will receive ertugliflozin 5 mg qd in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
89334187|NCT04219696|Active Comparator|1 session|Participants will complete one 45-minute session of reactive balance training. Participants will experience 40-60 perturbations during this session. Participants will also complete 5 45-minute 'traditional' balance training sessions.
89334188|NCT04219696|Experimental|3 sessions|Participants will complete three 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session. Participants will also complete 3 45-minute 'traditional' balance training sessions.
89334189|NCT04219696|Experimental|6 sessions|Participants will complete six 45-minute sessions of reactive balance training. Participants will experience 40-60 perturbations during each session.
89334190|NCT04214587||baseline assessment group|n=150 patiënts for baseline assessment
89334191|NCT04214587||clinical need for reintervention group|n=20-30 patiënts for re-bronchoscopy
89334192|NCT04214587||clinical stable controls|n=20 stable treated control patiënts
89334193|NCT04211571|Experimental|MCO group|Hemodialysis using Theranova 400 dialyzer
89334194|NCT04211571|Active Comparator|High-flux group|Hemodialysis using high-flux dialyzer (Fx CorDiax 80; Fresenius Medical Care)
89334195|NCT04205266|Experimental|IV Iron|Will receive 2 infusions of 510mg of ferumoxytol, administered over 15 minutes, 3-8 days apart
89334196|NCT04205266|Active Comparator|Oral Iron|Will receive 325mg ferrous sulfate tablets daily for 60 days
89334197|NCT04193579|Experimental|Language Treatment Arm|An infant participant randomized to the language treatment arm will be played recordings of his/her mother's voice 2-3 hours daily in the intermediate care nursery until discharge.
89334198|NCT04193579|Sham Comparator|Control Treatment Arm|An infant participant randomized to the control treatment arm will receive standard of care. Standard of care does not include being played recordings of his/her mother's voice while admitted to the intermediate care nursery. However, an infant randomized to the control treatment will have the same auditory equipment placed in his/her isolette or crib as an infant randomized to the Language Treatment Arm.
89334199|NCT04176198|Experimental|TP-3654|
89334200|NCT04176094|Experimental|16 hour schedule|All residents assigned to an ICU randomized to a 16h overnight schedule will complete 16h overnight calls not preceded by an 8h daytime shift.
89334201|NCT04176094|Active Comparator|24 hour schedule|All residents assigned to an ICU randomized to a 24h overnight schedule will complete 24h shifts when scheduled for overnight calls (8h daytime shift followed by a 16h overnight call).
89334202|NCT04173169|Active Comparator|Pre-IVF Treatment with 60 day course of oral GnRH antagonist|For those who agree to be randomized, subjects will be randomized to elagolix 200mg BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who do not want to be randomized while choose elagolix.
89334203|NCT04173169|Other|Pre-IVF Treatment with 60 day course of Placebo or SOC IVF|For those who agree to be randomized, subjects will be randomized to placebo, BID. The medication will be taken orally and subjects will be counseled to take the medication at the same time each day. This arm will also include participants who want to continue their ongoing or planned IVF and follow standard of care (SOC) (SOC IVF) if they do not want to delay the IVF procedure.
89334204|NCT04157972|Active Comparator|SIMEOX|Participants will have to perform 20 minutes of SIMEOX. Passive exhalation is required using the SIMEOX, starting from tidal volume and going until achieving residual volume.
89334205|NCT04157972|Active Comparator|PEP|Participants will have to perform 20 minutes of PEP. Active exhalation is required using a PEP device, starting from tidal volume and going until achieving residual volume.
89334206|NCT04150601|Active Comparator|Spontaneous slow vital capacity|Participants will have to perform a slow vital capacity according to the guidelines, from total lung capacity to residual volume
89334207|NCT04150601|Active Comparator|SIMEOX|Participants will have to perform a passive exhalation using the SIMEOX, starting from total lung capacity and going until achieving residual volume
89334208|NCT04150601|Active Comparator|PEP|Participants will have to perform an active exhalation using a PEP device, starting from total lung capacity and going until achieving residual volume
89334209|NCT04127331|Active Comparator|Routine|Patients who are scheduled for routine outpatient surgery.
88806828|NCT05131425|Other|Treatment as Usual|The TAU condition will serve as the control condition and participants' medication use and outside therapies will be tracked monthly. Following completion of the 16-week wait period, the TAU group will be invited to enroll in FYF:ASD/ID.
88806829|NCT05123040|Experimental|Ruxolitinib;hCG (Pregnyl®) ;Corticosteroids|"Ruxolitinib 10 mg by mouth twice daily (with dose adjustments as indicated) through day 56, followed by taper~hCG (Pregnyl®) 2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses (total 17 doses through day 56)~Corticosteroids (Prednisone, or IV methylprednisolone equivalent)~Dose level 1 (starting dose) = 1 mg/kg~Dose level 2 = 0.5 mg/kg~Dose level 3 = 0.25 mg/kg~Dose level 4 = 0.1 mg/kg~Dose level 5 = 0 mg/kg"
88806830|NCT05106569||SUNY Upstate|One of 2 ALS certified treatment centers in USA expected to recruit 50 subjects.
88806831|NCT05106569||Atrium Health|One of 2 ALS certified treatment centers in USA expected to recruit 50 subjects.
89334210|NCT04127331|Active Comparator|Urgent|Patients who are scheduled for urgent surgery.
89334211|NCT04127331|Active Comparator|Emergent|Patients who are scheduled for emergency surgery.
89334212|NCT04126525|Experimental|neoadjuvant pyrotinib|pyrotinib 400mg qd trastuzumab 4mg/kg loading dose, then 2mg/kg qw palitaxel 80mg/m^2, d1, 8, 15, 22 cisplatin 25mg/m^2, d1, 8, 15 every 28 days
89334213|NCT04118595|Experimental|Full Intervention (Video + Telecare + PCP communication)|Patients in this arm will watch an interactive pain management video; receive a pain assessment phone call and be given medication and behavioral pain management strategy recommendations; and an index visit and telecare summary will be shared with patient's primary care provider.
89334214|NCT04118595|Experimental|Video-only Intervention|Patients in this arm will watch an interactive pain management video.
89334215|NCT04118595|No Intervention|Usual Care|Patients will receive the typical care provided by medical personnel for their acute pain.
89334216|NCT04103645|Experimental|Treatment arm|Vactosertib intra-patient dose finding cohort.
89334217|NCT04103281||Sepsis Patients|
89334218|NCT04103281||Control Patients|
89334219|NCT04103268||Sepsis|
89334220|NCT04103268||Control|
89334221|NCT04101149||Group 1|Patients with high clinical suspicion of familial hypercholesterolemia. No intervention.
89334222|NCT04099901|Experimental|Anakinra|Dosage form: intravenous. Dosage: 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
89334223|NCT04099901|Placebo Comparator|Placebo|Dosage form: intravenous. Dosage: not applicable. Frequency: once daily. Duration: 15 days (day -2 until day +12).
89334224|NCT04099368|Experimental|Auditory|Group receives training on listening to musical pitch differences between sounds as the first component of a crossover trial. The intervention is the listening exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
89334225|NCT04099368|Active Comparator|Visual|Group receives training on visual differences between objects on a computer screen as the first component of a crossover trial. This is a control measure for the auditory training exercises. Exercises are completed daily as 30-minute sessions for 4 weeks. Hearing assessment outcomes of speech comprehension in background noise and of musical pitch sensitivity are conducted at baseline and at midpoint and endpoint.
89334226|NCT04092686|Experimental|SEP-363856 75mg|SEP-363856 75mg dosed once daily
89334227|NCT04092686|Experimental|SEP-363856 100mg|SEP-363856 100mg dosed once daily
89334228|NCT04092686|Placebo Comparator|Placebo|Placebo dosed once daily
89334229|NCT04062630|Active Comparator|Standard care|Multilevel Lumbar Fusion Surgery
89334230|NCT04062630|Experimental|Standard Care + iFuse 3-D|Multilevel Lumbar Fusion Surgery with additional placement of iFuse 3-D in a trajectory parallel to the S2AI screws
89334231|NCT04042961|Experimental|Reactive balance training|
89334232|NCT04042961|Active Comparator|Aerobic and strength training|
89334233|NCT04037475|Placebo Comparator|Control (placebo)|The patients will receive an agent with the same vehicle as methylene blue to mimic irrigation with the photosensitizer and the laser will be switched off at the time of application. The placebo PDT procedures will be performed on the lesion: Application of methylene blue placebo with a carpule syringe and needle (with stop and without bevel) inside the lesions; 1 minute of pre-irradiation will be expected. The irradiations will be performed with the same device positioned in the same way and at the same time of application, however, the laser will be turned off. The beep sound will be recorded and turned on during application to blind treatment to the patient. The patient will receive a catheter with acyclovir cream and will be advised to spread on the lesions four times a day for 7 days, which will be their return for reevaluation. It will be washed in abundance with saline (saline solution) until the total removal of the placebo from the photosensitizer.
89334234|NCT04037475|Experimental|experimental group|Patients will be treated with photodynamic therapy and will receive a placebo ointment simulating acyclovir cream. If the lesions are in the vesicle phase, they will be ruptured with a sterile needle. The methylene blue solution at 0.005% concentration will be gently placed on the lesions. Application of methylene blue on the lesions.1 minute of pre-irradiation will be expected. The irradiations will be performed with the Laser Duo® with a wavelength of 660 nm, with a power of 100 mW(milliwatts), the energy density of 300 J / cm², with the energy of 3 J (joules) in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each lesion with energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. Patients will receive a tube with a placebo cream simulating aciclovir and the same will be advised to spread the cream 4 times per day for 7 days.
89334235|NCT04031300|Experimental|RSP-20|Subjects will perform daily measurements on the IMD (Prototype 0.5) in addition to capillary reference measurements for 48 days.
89334236|NCT04029194|Experimental|Treatment|
89334237|NCT04029194|No Intervention|Control|
89334238|NCT04028479||Validation Cohort|Patients enrolled into the study to allow validation of a specific element, process, or endpoint. Validation will be done showing concordance with traditional interventional trial standards.
89334239|NCT04028479||Analysis Cohorts|Patient who are enrolled into the study to allow analysis to determine any association, effect, or benefit. Cohorts can be determined prospectively and/or retrospectively for data already collected, Cohorts are identified to highlight collection of information on patients who are already receiving any treatment or testing as determined by the physician and patient independent of this study. Because many analysis cohorts will be determined in patients already enrolled in the study, this group is inclusive of many different sub-groupings or specific analysis cohorts of patients.
88806832|NCT05097235||t0, t1|acute low back pain, inclusion criteria.
89334240|NCT04028479||Retrospective Chart Review Cohorts|"This arm will use retrospective data obtained through systematic chart review on previously seen patients to compare, contrast, or enhance the efforts of the prospective arms. Because most RWD has been traditionally obtained through retrospective methods, this is also considered the control arm. Data in this arm will be collected without any patient identifiers. This arm is optional."
89334241|NCT04026295|Experimental|Short burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of SBLTT
89334242|NCT04026295|Active Comparator|Traditional Locomotor Treadmill Training (TLTT)|TLTT will consist of walking at steady-state speeds. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of TLTT
89334243|NCT04020055|Experimental|Cohort 1: Severe Renal Impairment|All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.
89334244|NCT04020055|Experimental|Cohort 2: End-Stage Renal Disease|All hemodialysis subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat). Subjects will take 1 migalastat capsule orally with water every other week.
89334245|NCT04014140||Patients with multi-vessel coronary artery disease (MVCAD)|iFR measurements will be taken pre-operatively during the invasive coronary angiography.
89334246|NCT03999164|Experimental|Moderate to Severe Traumatic Brain Injury|All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
89334247|NCT03960164|Experimental|Patient group|The group of patients included in the study following inclusion criteria with local (wound) and systemic test values prior and after to the application of the DRPM.
89334248|NCT03954704|Experimental|Phase 1a, Part A - Dose Escalation|Part A will consist of dose escalation by an accelerated dosing design and a 3+3 dose escalation scheme. Participants will receive escalating dose levels dalutrafusp alfa of up to 45 mg/kg on Day 1 of each 2-week cycle (Q2W) until the participant meets study treatment discontinuation criteria or for up to 1 year.
89334249|NCT03954704|Experimental|Phase 1a, Part B - Flat Dose Regimen|Part B will consist of 3 adaptive cohorts. Based on PK, pharmacodynamics, and safety results from the Part A study, participants will be administered a flat dose of dalutrafusp alfa on Day 1 of each cycle QW, Q2W and/or every 3 weeks (Q3W) until the participant meets study treatment discontinuation criteria or for up to 1 year.
89334250|NCT03954704|Experimental|Phase 1b, Cohort 1 (Gastric Cancer)|"Safety run-in: A standard 3+3 dose escalation design will be used to determine the DLT and MTD or RP2D of dalutrafusp alfa in combination with mFOLFOX6. The planned starting dose of dalutrafusp alfa will be targeted to achieve the exposure at -1 dose of RP2D monotherapy (Q2W) determined from Phase 1a. Dalutrafusp alfa will be administered in combination with mFOLFOX6.~Post safety run-in: Approximately 70 participants will be enrolled to receive dalutrafusp alfa at the dose level determined from the safety run-in period, in combination with mFOLFOX6 regimen.~Participants will receive dalutrafusp alfa on Day 1 of each 14-day cycle up to 2 years until PD, or unacceptable toxicity, substantial noncompliance with study procedures or study drug, study discontinuation or withdrawal from study. Participants will also receive mFOLFOX6 regimen Q2W for up to 12 cycles."
89334251|NCT03954704|Experimental|Phase 1b, Cohort 2 (Paired Biopsy)|Participants will receive dalutrafusp alfa at the dose level determined from Phase 1a Q2W until the participants meets study treatment discontinuation criteria or for up to 1 year.
89334252|NCT03947164|Other|Case group|"Case :~- Patient operated at Rennes University Hospital of anterior POP and / or posterior POP via vaginal and / or abdominal way.~POPs will be classified in stages 2-4 using the ICS classification;~Without urinary incontinence associated effort (eliminated by the interrogation);~Registered to a health insurance system;~Having received information on the protocol and giving informed written consent."
89334253|NCT03947164|Other|Control group|"Control:~Patient operated at the Rennes University Hospital for a vaginal or abdominal hysterectomy for a benign reason.~No POPs and no urinary incontinence eliminated during the interrogation and clinical examination.~Registered to a health insurance system;~Having received information on the protocol and giving informed written consent."
89334254|NCT03944902|Experimental|Cohort 1: Dose Escalation using Niraparib and CB-839|The first phase will be a 3+3 design, 3 participants will be enrolled in the first cohort with a fixed dose of Niraparib and CB-839, 600 mg. If there are no dose limiting toxicities (DLT), 3 additional participants will be enrolled in the next cohort (CB-839, 800mg). If 1 of the 3 in the first cohort experiences DLT's, then the additional participants will be enrolled in the same cohort (CB-839, 600mg).
89334255|NCT03944902|Experimental|Cohort 2: Dose Escalation using Niraparib and CB-839|If there are no DLT's, 3 additional participants will be enrolled in the next cohort with a fixed dose of Niraparib and CB-839, 800mg.
89334256|NCT03944902|Experimental|Cohort 3: Expansion with Maximum Tolerated Dose (MTD)|Patients in this expansion cohort will continue study treatment with the MTD until they experience disease progression, unacceptable toxicity or withdraw consent. Patients who discontinue study treatment for reasons other than Progressive-Free Survival (PFS) will continue to have PFS follow-up visits every 2 months for the first 6 months after treatment, and every 3 months until disease progression, death, or start of another anticancer therapy.
89334257|NCT03933735|Experimental|Arm A: Dose Escalation|Up to 15 cohorts of participants receiving sequentially ascending doses of TNB-383B are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified.
89334258|NCT03933735|Experimental|Arm B: Dose Expansion Dose A|An expansion cohort will be enrolled at the recommended phase 2 Dose A.
89334259|NCT03933735|Experimental|Arm B: Dose Expansion Dose B|An expansion cohort will be enrolled at the recommended phase 2 Dose B.
89334260|NCT03933735|Experimental|Arm E: Monotherapy Once Every 4 Weeks (Q4W)|An expansion cohort will be enrolled at the recommended phase 2 Dose A.
89334261|NCT03933735|Experimental|Arm F: Monotherapy Dose C|An expansion cohort will be enrolled at the recommended phase 2 Dose C.
89334262|NCT03923101||Patients with Keratoconus|Aim is to include as many Keratoconus patients as possible with the intention to elucidate how the disease begins and develops during lifetime.
89334263|NCT03922412|Active Comparator|plantar block|Short lasting sciatic nerve block (mepivacaine 1% 200mg) and long lasting plantar block (ropivacaine 0,5% 25mg + 2mg dexamethasone) with distal deep peroneal block (ropivacaine 0,5% 2ml).
89334264|NCT03922412|Active Comparator|Sciatic popliteal block|Long lasting sciatic nerve block (ropivacaine 0,5% 100mg + 2mg dexamethasone)
89334265|NCT03917186|Active Comparator|Group sevoflurane|Administration under labelling conditions
89334266|NCT03917186|Experimental|Group desflurane|Administration under labelling conditions
89334267|NCT03917043|Experimental|APG-2449|APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 30-40 patient at the MTD/RP2D dose level.
89334268|NCT03916419|Experimental|Safety lead-in: Chemoradiation + Durvalumab|"The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events.~Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of treating physician) for up to 12 months."
89334269|NCT03916419|Experimental|Phase II: Chemoradiation + Durvalumab|-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every 2 weeks or 4 weeks (timeline at the discretion of the treating physician) for up to 12 months.
89334270|NCT03916003|Experimental|PQ7|high dose primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
89334271|NCT03916003|No Intervention|standard care|As per national guidelines for P. falciparum treatment
89334272|NCT03907020|Experimental|Meabolic Availabiliy of Barley|Healthy adult men
89334273|NCT03904264|Experimental|Hearing Aid Study|Measure the reduction in tinnitus handicap when mild amplification through receiver-in-the-canal hearing aids is provided to adults with bothersome tinnitus and normal hearing thresholds.
89334274|NCT03904264|No Intervention|VA Clinician Interviews|Document the opinions, procedures, and rationale used clinically to make decisions regarding fitting mild amplification for tinnitus on Veterans with bothersome tinnitus and normal hearing thresholds. The data for this arm of the study will be collected via telephone interview.
89334275|NCT03898973|Other|Study Phase|Participants will be given the current year's a quadrivalent inactivated influenza vaccine (IIV)
89334276|NCT03894618|Experimental|SL-279252|Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated
89334277|NCT03894241|Experimental|Sedentary condition|
89334278|NCT03894241|Experimental|Moderate-intensity continuous training|
89334279|NCT03894241|Experimental|Cooperative-high-intensity interval training|
89334280|NCT03891823|Experimental|MitraClip|"Study of MitraClip in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
89334281|NCT03891823|Active Comparator|Medical Therapy|"Study of medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
89334282|NCT03884296|Other|Study Phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
89334283|NCT03872102||Aim 1: Develop a biomarker of PD disease progression rate|"For Aim 1, we will enroll PD subjects spanning a range of progression rates that have been tracked at UT Southwestern Medical Center.~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data and known data on clinical progression using statistical techniques to determine a biomarker that associates with progression rate."
89334284|NCT03872102||Aim 2: Develop a biomarker to distinguish between PD, PSP, MSA|"For Aim 2, we will recruit subjects with PD, MSA, and PSP. We will also recruit healthy age/sex-matched controls. All subjects will complete a series of clinical assessments at three different time points, roughly 6-8 months apart:~Levodopa Equivalent Daily Dose~Parkinson disease questionnaire~Schwab and England ADL Scale~MDS-UPDRS (PD and healthy controls only)~UMSARS (MSA subjects only)~PSPRS (PSP subjects only)~Multimodal neuroimaging will be acquired from each subject. We will evaluate imaging data from the participants along with prospectively collected information on clinical progression using statistical techniques to determine a biomarker that associates with the differentiation of PD, MSA, and PSP."
89334285|NCT03868579|Experimental|Observational (pleuroscopy, medical chart review)|Patients undergo biopsy of the lining of the lung using pleuroscopy. Medical chart of patients is also reviewed.
89334286|NCT03861299|Experimental|Awake craniotomy|Cortical stimulation is performed with a bipolar electrical stimulator. The Boston naming test and repetition of words is done in cooperation with a neuropsychologist/linguist, who will inform the neurosurgeon of any kind of speech arrest or dysarthria. When localizing the motor and sensory cortex, the patient is asked to report any unintended movement or sensation in extremities or face. Functional cortical areas are marked with a number. When the tumour margins or white matter is encountered or when on regular neuronavigation the eloquent white matter tracts are thought to be in close proximity, subcortical stimulation (biphasic currents of 8-16 mA, pulse frequency 60 Hz, single pulse phase duration of 100 microsec., 2-second train) is performed to localize functional tracts.
89334287|NCT03861299|Active Comparator|Craniotomy under general anesthesia|Trephination and tumour resection are performed without any additional neuro-psychological monitoring or brain mapping, guided by STEALTH-neuronavigation.
89334288|NCT03857529|Experimental|conventional tDCS concurrent with CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
89334289|NCT03857529|Experimental|unconventional tDCS concurrent with CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
89334290|NCT03857529|Experimental|conventional tDCS preceding CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
89334291|NCT03857529|Experimental|unconventional tDCS preceding CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
89334292|NCT03857529|Sham Comparator|sham tDCS with CCFES|sham tDCS preceding and concurrent with CCFES
89334293|NCT03845712|Experimental|doxecitine and doxribtimine|This is an open label study with all participants in a single arm. Study participants will take doxecitine and doxribtimine up to a maximum of 800 mg/kg/day (400 mg/kg/day doxecitine and 400 mg/kg/day doxiribtimine).
89334294|NCT03835182|Active Comparator|Ultrasound group|Thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The ultrasound group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and ultrasound 1MHz frequency (ten minutes) applied to the lower back, abdominal and lower back muscle strengthening exercises.
89334295|NCT03835182|Active Comparator|Short wave diathermy group|The short wave diathermy group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The short wave diathermy group will be treated with a hotpack (20minutes), transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and short wave diathermy at a frequency of 27.12MHz (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
89334296|NCT03835182|Other|Control group|The control group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The control group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
89334297|NCT03825822|Experimental|ImPaC Resource Intervention (INT)|The INT arm will receive the 7-step web-based ImPaC intervention to use over 6 months. The intervention is divided into the Plan Stage and the Change Stage. The Plan Stage (steps 1-4) is expected to be completed in 1 month. The Change Stage (steps 5-7) is expected to be completed in 1-2 months. We anticipate that Change Teams will be able to complete 2 cycles of change over the 6-month intervention period.
89334298|NCT03825822|Other|Standard Practice (SP)|The SP arm will continue as usual with their unit or institutional standard pain practices and any strategies that they would normally use to improve them (e.g. new staff orientation).
89334299|NCT03825380|Experimental|T4032|
89334300|NCT03825380|Active Comparator|Lumigan®|
89334301|NCT03786939|Other|On-pump CABG.|On-pump CABG.
89334302|NCT03786939|Other|Off-pump CABG.|Off-pump CABG.
89334303|NCT03786939|Other|Pump-assisted CABG.|Pump-assisted CABG.
89334304|NCT03761732|Experimental|PTSD lay-led group treatment program|The group will go through the Islamic Trauma Healing Program
89334305|NCT03759288|Experimental|(Stage 1) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
89334306|NCT03759288|Experimental|(Stage 1) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
89334307|NCT03759288|Placebo Comparator|(Stage 1) Placebo|Intravenous placebo on Days 1, 29, and 57, followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
89334308|NCT03759288|Experimental|(Stage 2) Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
89334309|NCT03759288|Experimental|(Stage 2) Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous on Day 85 and every 4 weeks through Week 48
89334310|NCT03759288|Active Comparator|(Stage 2) Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50
89334311|NCT03679546|Experimental|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
89334312|NCT03679546|Experimental|Vedolizumab|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
89334313|NCT03676439|Active Comparator|Treated Arm: Magnetic Spinal Stimulation plus PKT|Three months of kinesthetic and phoniatric treatment, and Magnetic Spinal Stimulation, 80% of the cervical muscles's motor threshold, 100 pulses at 10Hz, lasting 10 seconds, repeated during 30 minutes, twice a week for 3 months on cervical lateral location, focalized on the Lateral Spinal Cord.
89334314|NCT03676439|Placebo Comparator|Sham comparator|They will receive kinesthetic and phoniatric treatment, and during 3 months,with equal periodicity, they will receive a sensible false magnetic stimulation, of equal localization that other arm, with insufficient intensity, to blind clinical experience.
89334315|NCT03667027||Patients undergoing LTx with respiratory failure (cases)|Patients are receiving a respiratory support modality (mechanical ventilation and/or extracorporeal life support) as a bridge to lung transplantation (LTx).
89334316|NCT03667027||Patients undergoing LTx without prior respiratory support|Patients undergoing lung transplantation but do not require prior bridging respiratory support.
89334317|NCT03667027||Elective thoracic surgical patients|Patients undergoing elective thoracic surgery for planned lung or esophageal resection.
89334318|NCT03653390|Experimental|EnhanceWellness for Disability (EW-D)|Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
89334319|NCT03653390|Active Comparator|Wellness Education|Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
89334320|NCT03653390|No Intervention|Control|Participant continues with their lives as they normally would.
89334321|NCT03653247|Experimental|BIVV003|Participants will receive plerixafor as subcutaneous (SQ) administration followed by myeloablative conditioning therapy with intravenous (IV) busulfan. BIVV003 will then be administered as a 1-time IV infusion of autologous Cluster of Differentiation 34 + Hematopoietic Stem/Progenitor Cell (CD34+HSPC) transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNAs) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus.
89334322|NCT03600649|Experimental|Myxoid Liposarcoma|Twice-daily administration of oral seclidemstat
89334323|NCT03600649|Experimental|Sarcomas with FET-family translocations, including demoplastic small round cell tumors|Twice-daily administration of oral seclidemstat
89334324|NCT03600649|Experimental|Ewing sarcoma, combination therapy|Twice daily administration of seclidemstat in combination with cyclophosphamide and topotecan
89334325|NCT03589482|Experimental|EIT algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the EIT algorithm, which selects a PEEP at which both collapse and hyperdistention are minimized.
89334326|NCT03589482|Active Comparator|ExPRESS algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the ExPRESS algorithm, which is a method that targets a tidal volume of 6 ml/kg predicted body weight and then titrates PEEP until plateau airway pressure reaches 28 cm H2O.
89334327|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for six weeks.
89334328|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
89334329|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement are for completing the counseling call.
89334330|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokeFreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
89334331|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive the following: 1-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Patch treatment will consist of a 4 week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). The Financial Incentives are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for 6 weeks.
89334332|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Nicotine Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
89523569|NCT02855125|Active Comparator|TAS-114 + S-1|Participants received 400 milligrams (mg) of TAS-114 tablets orally twice daily (BID) along with 30 milligrams per meter square (mg/m^2) of S-1 capsule BID for 2 weeks (Day 1 to 14), followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 51 weeks).
89334333|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). No SmokefreeTXT text messaging in support of cessation will be offered proactively. The Financial Incentives for treatment engagement are for completing the counseling call.
89334334|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
89334335|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination:4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). The Financial Incentives for treatment engagement are for completing each of the four counseling calls and for staying enrolled in the SmokefreeTXT program for six weeks.
89334336|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
89334337|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
89334338|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
89334339|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive: 4-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each counseling call will last approximately 20 min. Patch treatment will consist of a 4 week supply of over-the-counter (OTC) nicotine patches (21 mg for if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4 week supply of OTC nicotine lozenges (2-mg dose for those who do not smoke within 30 min of waking; 4-mg dose for those who smoke within 30 min of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). Financial Incentives are for completing each of the 4 counseling calls and for staying enrolled in SmokefreeTXT for 6 weeks.
89334340|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for 6 weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
89334341|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenge, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
89334342|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
89334343|NCT03505346|Experimental|percutanous coronary intervention(PCI)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after intervention
89334344|NCT03505346|Experimental|Coronary artery bypass-graft(CABG)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after interventionintervention
89334345|NCT03481998|Experimental|Cohort 1 (Part 1)|Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
89334346|NCT03481998|Experimental|Cohort 2 (Part 1)|SHR6390 (TBD), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
89334347|NCT03481998|Experimental|SHR6390 + Letrozole or anastrozole (Part 2)|SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
89334348|NCT03481998|Experimental|SHR6390 + Fulvestrant Cohort 3 (Part 1)|SHR6390 (at protocol defined dose levels), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
89334349|NCT03481998|Experimental|SHR6390 + Fulvestrant Cohort 4 (Part 1)|SHR6390 (TBD), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
89334350|NCT03473769|Experimental|Vital Signs at 2 Hours + CAM-ICU|enhanced vital sign and delirium monitoring in patients for who the per-sepsis algorithm reaches alert threshold.
89334351|NCT03473769|No Intervention|No Intervention|No intervention. Patient treated per standard of care.
89334352|NCT03394612|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
89334353|NCT03393039|Experimental|Behavioral|Negative Affect Task
89334354|NCT03390283||Observational (Online survey)|Participants complete online survey on an iPad over 20 minutes.
89334355|NCT03366844|Experimental|Pembrolizumab with RT Boost|"Study drug plus tumor boost before standard of care treatment"
89334356|NCT03261050|Experimental|Body Project Treatment|An 8-session group-delivered eating disorder treatment that seeks to reduce valuation of the thin ideal and eating disordered behaviors used to pursue this ideal.
89334357|NCT03261050|Active Comparator|Interpersonal Psychotherapy|An 8-session group-delivered eating disorder treatment that seeks to improve interpersonal functioning because this is theorized to maintain eating pathology.
89334358|NCT03249207|Active Comparator|IL-1Ra twice daily|
89334359|NCT03249207|Placebo Comparator|Placebo twice daily|
89334360|NCT03196180|Experimental|Treatment (topical fluorouracil, imiquimod)|Patients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle.
89334361|NCT03193567|Experimental|HEKT cell|Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
89334362|NCT03174197|Experimental|Adjuvant phase (temozolomide, atezolizumab)|Patients receive temozolomide PO on days 1-5 and atezolizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
89334363|NCT03174197|Experimental|Concurrent phase (temozolomide, atezolizumab, RT)|Patients receive temozolomide PO daily on days 1-42 and atezolizumab IV over 30-60 minutes on day 1, 15, 29, and 42. Patients undergo RT 5 days per week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
89334364|NCT03170440|Experimental|Noninvasive nerve stimulation type I|This group will receive one type of nerve stimulation
89334365|NCT03170440|Active Comparator|Noninvasive nerve stimulation type II|This group will receive second type of nerve stimulation
89334366|NCT03164980|Experimental|Arm A|PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
89334367|NCT03164980|Experimental|Arm B|"Carboplatin/PLD~Carboplatin/Gemcitabine~Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first."
89334368|NCT03093155|Active Comparator|Ixabepilone|Ixabepilone 20 mg/m2 days 1, 8, 15 Q 28 days
89334369|NCT03093155|Experimental|Ixabepilone + Bevacizumab|"Ixabepilone 20 mg/m2 days 1, 8, 15~+ Bevacizumab 10 mg/kg days 1, 15 Q 28 days"
89334370|NCT03070340|Experimental|Breast MRI and Contrast Enhanced Mammography (CEDM)|Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy
89334371|NCT03069378|Experimental|Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu|Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.
89334372|NCT03050736|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
89334373|NCT02967848||Patients with Cancers in Liver|Adult patients with primary liver cancer or liver metastases from any other histology who will be measured before and after Radiotherapy by '99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green and Liver Elasticity.
89334374|NCT02958072|Experimental|LeucoPatch|Treatment with usual ulcer care and LeucoPatch once weekly up til 24 weeks or until healing.
89334375|NCT02958072|Active Comparator|Usual care followed by LeucoPatch|Usual care weekly for 12 weeks, if the ulcer persist after the12 weeks LeucoPatch treatment will be started for up to 12 weeks or until healing.
89334376|NCT02957825|No Intervention|Control|Routine monitoring
89334377|NCT02957825|Experimental|Continuous wireless monitoring|Continuous wireless monitoring
89334378|NCT02937571|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone|"Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 45 or 56 mg/m2 per dose, days 8, 9, 15, and 16.~Cycles 2- up to 12: Carfilzomib 45 or 56 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16~Cycles 1- up to 12: Lenalidomide 25 mg/day, days 1-21 every 28 days~Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23~Cycles 5- up to 12: Dexamethasone 10 mg/dose, days 1, 2, 8, 9, 15, 16, 22 and 23"
89334379|NCT02919072|Experimental|Chloroprocaine|Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
89334380|NCT02919072|Active Comparator|Ropivacaine|Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
89334381|NCT02911571|Experimental|MMprofiler SKY92|Eligible patients will have their bone marrow biopsy sample analyzed for the prognostic MMprofiler SKY92 gene signature
89334382|NCT02880293|Experimental|Patients will undergo donor/recipient bone marrow|All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
89334383|NCT02874014|Experimental|Hypofractionation Proton beam therapy|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
89334384|NCT02780297||Primary Hyperoxaluria Patients|Patients with confirmed diagnosis of Primary Hyperoxaluria.
89334385|NCT02780297||Dent Disease Patients|Patients with confirmed diagnosis of Dent Disease.
89334386|NCT02780297||Cystinuria Patients|Patients with confirmed diagnosis of Cystinuria.
88806833|NCT05096702||Tafenoquine (TQ)|Patients aged ≥16 years, G6PD activity ≥ 6.1 IU/gHb, not pregnant or breastfeeding, will receive single-dose TQ in addition to standard blood schizonticidal drug.
89334387|NCT02780297||APRT deficiency Patients|Patients with confirmed diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)
89334388|NCT02780297||Lowe Syndrome or Dent 2 patients|Patients with confirmed diagnosis of Lowe Syndrome or Dent 2.
89334389|NCT02780297||Dent 1 carriers|Patients with confirmed diagnosis of Dent 1. Dent 1 carriers
89334390|NCT02780297||Enteric Hyperoxaluria Patients|Patients with confirmed diagnosis enteric hyperoxaluria.
89334391|NCT02739035|No Intervention|MUA alone|Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
89334392|NCT02739035|Experimental|MUA with dexamethasone and celecoxib|For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
89334393|NCT02730039||Cancer Care Providers|"Provider will attend a MCPT two-day intensive workshop that will include:~Didactic Components~Experiential Exercises~Simulated patient role plays with actors~Provider completes MCPT Workshop Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)~MCP Core Competency Trainer rated Assessment~MCP Pre & Post Workshop Knowledge Assessment~MCPT Session Evaluation Assessment Provider will participate in training follow-up calls & webinars for approximately 6 -12 months following completion of MCPT workshop.~Provider will have ongoing access to MCPT Website with a discussion board, training resources and materials for clinical care.~Provider will complete follow-up assessment at 3, 6, 9, & 12 months post-training~Training Update~Goal Evaluation Form~MCP Core Competency Self-Assessment MCPT POST-WORKSHOP IMPLEMTATION (OPTIONAL)"
89334394|NCT02710123|Experimental|Aerobic Exercise|Participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during the Buffalo Concussion Treadmill Test (BCTT). The script will ask the participant to exercise one a day for 20 minutes at 80% of HRT. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Sub-Threshold exercise prescription
89523570|NCT02855125|Active Comparator|S-1 (Monotherapy)|Participants received 30 mg/m^2 of S-1 capsules BID for 2 weeks (Day 1 to 14) followed by 1 week recovery period (Day 15 to 21) in each 21 days cycle, until progressive disease (PD), occurrence of intolerable side effects, removal by the Investigator, or withdrawal of consent (maximum treatment duration: 38 weeks).
88806834|NCT05096702||Daily primaquine (PQ) for 7 days|Patients aged ≥ 6 months, with G6PD activity between 4.1 and 6.0 IU/gHb, not pregnant or breastfeeding for < 1 month, will receive daily PQ in addition to standard blood schizonticidal drug.
88806835|NCT05096702||Weekly primaquine for 8 weeks|Patients aged ≥ 6 months, with G6PD activity ≤ 4.0 IU/gHb, not pregnant or breastfeeding for < 1 month, will receive weekly once-a-week PQ for eight weeks in addition to standard blood schizonticidal drug.
89334395|NCT02710123|Placebo Comparator|Stretching Exercise|Participants will receive a prescription for stretching exercises that they will be asked to do daily. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Structured stretching exercise prescription.
89334396|NCT02682355||Study cohort|Patients receiving IV polymyxin B for treatment of bacteremia and/or urinary tract infection and/or respiratory tract infection (including tracheobronchitis) or sepsis
89334397|NCT02663934|Experimental|Exercise (EXS)|All EXS sessions will be at an exercise facility at the WUSTL medical campus. Sessions will be offered weekdays. Each session will start with range of motion exercises. Participants will follow an individualized exercise training prescription based on baseline cardiovascular testing. Individual aerobic exercise intensity is based on % of maximum heart rate achieved during the baseline cardiorespiratory fitness test. The target exercise HR will start at 50% and progress to 85% HR reserve. During aerobic exercise, a battery-operated HR monitor will monitor HR. Exercise intensity & duration will be increased as the participant acclimates to the exercise prescription. Adaptation is determined when a given exercise intensity yields a lower HR than prior sessions conducted at the same intensity.
89334398|NCT02663934|Active Comparator|Social Interaction Stretching (SIS)|This group will serve as a control group against which to gauge the effects of aerobic and resistance training on cognitive function. Participants in this group will follow the same schedule and format as the EXS group. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program. These SIS participants will receive instructions on stretching, range of motion, limbering, and toning; but the intensity will be far less than that achieved in the EXS classes. Activities will focus on flexibility enhancement. As the participant's level of flexibility increases, stretches with increasing levels of difficulty will be incorporated into the program.
89334399|NCT02657434|Experimental|Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed|Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
89334400|NCT02657434|Active Comparator|Arm B (Carboplatin or Cisplatin + Pemetrexed)|Participants received IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
89334401|NCT02656290|Experimental|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Pulmonary valve replacement
88806836|NCT05070533|Active Comparator|Individual treatment|The strength and balance activities of the LiFE program will be carried out. Participants will receive 7 home visits and will be given the support material for the manual (diptychs, pictures, etc.).
88806837|NCT05070533|Experimental|Groupal treatment|The strength and balance activities of the LiFE program will be carried out. Participants will be invited to participate in groups of about 8 - 12 people in community venues.
89334402|NCT02560181|Other|HDR whole gland salvage treatment|Locally recurrent prostate cancer Whole gland HDR brachytherapy administered Whole gland dose=10.5Gy x 2 fractions delivered one week apart GTV dose=13.5Gy x 2 fractions delivered one week apart
89334403|NCT02557321|Experimental|Phase 1b|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
89334404|NCT02557321|Experimental|Phase 2 (Arm 1)|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
89334405|NCT02557321|Active Comparator|Phase 2 (Arm 2)|Pembrolizumab (2 mg/kg every 3 weeks)
89334406|NCT02555839||Pomalidomide and Dexamethasone|Pomalidomide 4mg capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
89334407|NCT02555839||Pomalidomide, Bortezomib and Dexamethasone|Cycle 1-8: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle until progression or unacceptable toxicity; from cycle 9 onwards: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 8, 9 of a 21 day cycle until progression or unacceptable toxicity
89334408|NCT02543879|Experimental|Dose Escalation FT-1101|Following a 3+3 dose escalation strategy, the first cohort of patients will be administered FT-1101 at 10 mg, oral capsules, once weekly on a continuous basis. Subsequent cohorts dose and frequency will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will continue until the MTD is determined.
89334409|NCT02543879|Experimental|Dose Expansion FT-1101|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 3 Expansion cohorts of up to 20 patients each will be treated with the RP2D of FT-1101
89523571|NCT02845531|Experimental|ICD implantation and optimal medical therapy|
88806838|NCT05067543||Tornier Perform Humeral System - Stem|Partial or total shoulder arthroplasty using the Tornier Perform Humeral Stem.
88806839|NCT05066724|Experimental|Centanafadine|Participants will receive centanafadine sustained release (SR) tablets, orally at a TDD of 400 milligrams (mg), administered as 200 mg doses, BID, approximately 4 to 6 hours apart, for a total of 7 weeks.
88806840|NCT05041855|Experimental|Community based childhood obesity intervention|A novel family-inclusive childhood obesity treatment program consisting of 12 family group sessions delivered in English and Spanish by health educators at community recreation centers, followed by three group booster sessions occurring every 6 months.
89334410|NCT02543879|Experimental|Dose Escalation FT-1101 + azacitidine|Following a 3+3 dose escalation strategy, the first cohort of AML/MDS patients will be administered FT-1101 at approximately 50% or lower than the MTD identified for the single agent FT-1101. Subsequent cohorts dose will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will not exceed the dose determined to be the single agent MTD for that schedule.
89334411|NCT02543879|Experimental|Dose Expansion FT-1101 + azacitidine|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 1 Expansion cohorts of up to 20 AML/MDS patients each will be treated with the RP2D of FT-1101 in combination with azacitidine.
89334412|NCT02514512|No Intervention|Standard SABR|Patients receive standard treatment
89334413|NCT02514512|Experimental|MLC Tracking SABR|Patients are treated with MLC tracking
89334414|NCT02441322|Experimental|Methods to identify treatment response|The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
89334415|NCT02390284|No Intervention|Abnormal PERG Untreated|Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
89334416|NCT02390284|Experimental|Abnormal PERG Treated|"Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%.~Drugs could be:~Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation.~If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure."
89334417|NCT02390284|No Intervention|Normal|Patients with a normal PERG test that will go through the study under observation.
89334418|NCT02387229|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg, orally, once daily, preferably at the same time of the day throughout the study.
89334419|NCT02387229|Active Comparator|standard of care|standard of care
89334420|NCT02362438|Experimental|10X|Highest dose in the escalation scheme
89334421|NCT02362438|Experimental|1X|Lowest dose in the escalation scheme
89334422|NCT02362438|Experimental|3.3X|2nd dose increase in escalation scheme
89334423|NCT02362438|Experimental|5X|3rd dose increase in escalation scheme
89334424|NCT02303015||Danish germ cell cancer patients|Danish patients with germ cell cancer diagnosed from 1984 to 2007.
89334425|NCT02255149|Experimental|Bone/Mesh|Allograft and Titanium mesh will be used to grow jaw bone vertically.
89334426|NCT02206841||NAFLD|Patients with suspected nonalcoholic fatty liver disease will be screened. Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained. In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed. A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis. Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study. Several serum and plasma samples are collected of patients and stored for future analysis such as targeted SNP arrays, super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, metabolomics, fecal microbiome, metabolite, metagenome/metatranscriptome analyses.
89334427|NCT02199015|Experimental|Spasticity, Cerebral Palsy|To perform a Lateral spinal cord surgical implant of electrodes for electrical neuromodulation of a cohort of selectyed patients with refractory Spastic Cerebral Palsy To compare spasticity and speech trouble´s evolution on a cohort of treated patients, by evaluating their pre and post operative status into one year follow up.
89334428|NCT02195206||Healthy|Adult
89334429|NCT02189031||Upper Extremity Amputee|Robust custom tactor to facilitate embodiment and proprioception
89334430|NCT02189031||Able Bodied|Bypass tactor
89334431|NCT02127567|Experimental|Online writing tool|Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
89334432|NCT02127567|Other|writing with no specific support.|The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.
89334433|NCT02112734|Active Comparator|vitamin D|400 IU /daily cholecalciferol/vitamin D
89334434|NCT02112734|Placebo Comparator|placebo|carrier formulation minus vitamin D
89334435|NCT01990352|Experimental|Pegylated liposomal doxorubicin|The enrolled patients will be treated with pegylated liposomal doxorubicin at 30mg/m2 every 21 days.
89523572|NCT02845531|Active Comparator|optimal medical therapy|
89523573|NCT02827279|Other|Patients|Mesure of emotional induction by eye tracking on Patient with Pervasive Developmental Disorders (PDD)
89334436|NCT01852370|Experimental|BOLT+BMT|All patients will receive a double lung transplant followed by a hematopoietic stem cell transplant. The lungs and stem cells are from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
89334437|NCT01802567|Experimental|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
89334438|NCT01742403|Experimental|R/T gating kV intrafraction monitoring|"Intervention: Recruitment will be performed in 2 phases:~Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction)."
89334439|NCT01742143||Phase I: Refinement|10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSKC
89334440|NCT01742143||Phase II, Arm 1: Usual and Customary Care (U&C)|Participants in this group will receive the same referrals on social and economic resources as ICCAN group.
89334441|NCT01742143||Phase II, Arm 2: ICCAN-IO|Arm 2 will consist of everything in Arm 1
89334442|NCT01661959||Non-Operative|
89334443|NCT01661959||Operative|
89334444|NCT01583920|Experimental|Focal salvage HDR prostate brachytherapy|
89334445|NCT01473628|Experimental|Arm I (radiation therapy and rituximab)|Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab IV over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
89334446|NCT01473628|Experimental|Arm II (radiation therapy and observation)|Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
89334447|NCT01443910||behavior, supportive|receiving information about behavior with supportive provider communication
89334448|NCT01443910||behaviors, directive|receiving information about behavior with directive provider communication
89334449|NCT01443910||genetics, directive|receiving information about genetics with directive provider communication
89334450|NCT01443910||genetics, supportive|receiving information about genetics with supportive provider communication
89334451|NCT01409200|Experimental|Arm I (antiandrogen therapy, axitinib, surgery)|Patients receive antiandrogen therapy per standard care and axitinib PO BID for 4 months. Patients then undergo radical prostatectomy and pelvic lymph node dissection.
89334452|NCT01409200|Active Comparator|Arm II (antiandrogen therapy, surgery)|Patients receive antiandrogen therapy per standard care for 4 months and then undergo radical prostatectomy and pelvic lymph node dissection.
89334453|NCT01193842|Experimental|Arm A (VR-DA-EPOCH)|Patients receive vorinostat PO QD on days 1-5; rituximab IV on day 1; etoposide IV over 24 hours, doxorubicin hydrochloride IV over 24 hours, and vincristine sulfate IV over 24 hours on days 1-4; prednisone PO daily on days 1-5; and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89334454|NCT01193842|Experimental|ARM B (DA-R-EPOCH)|Patients receive rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and cyclophosphamide as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
89334455|NCT01026077||Fibromyalgia/prospective pregnancies|Women taking Savella during pregnancy. Register prospectively, provide verbal consent.
89334456|NCT00855465|Experimental|Riociguat (Adempas, BAY63-2521)_individual dose titration|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
89334457|NCT00855465|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks
89334458|NCT00756769||1|Patients with SLE
89334459|NCT00756769||2|Related unaffected controls
89334460|NCT00756769||3|Unrelated unaffected controls
89334461|NCT00680264||Operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level Curve >40 degrees on sitting film, A spinal fusion is being undertaken and the patient/family is proceeding with the spinal fusion (with any level of distal fusion).
89334462|NCT00680264||Non-operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level, Curve >40 degrees on sitting film, A spinal fusion is not being undertaken either because the family has refused surgery or because it is not recommended at this point.
89334463|NCT00591552|Active Comparator|Group A|Electrocautery used for dissection.
89334464|NCT00591552|Active Comparator|Group B|Harmonic Scalpel used for dissection
89334465|NCT00098475|Active Comparator|Arm I (lenalidomide, dexamethasone)|Patients receive lenalidomide PO QD on days 1-21 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20.
89334466|NCT00098475|Experimental|Arm II (lenalidomide, low-dose dexamethasone)|Patients receive lenalidomide and acetylsalicylic acid as in Arm I and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
89334467|NCT00098475|Active Comparator|Arm III (thalidomide, dexamethasone)|Patients with no response after treatment on Arm I: Patients receive thalidomide PO QD on days 1-28 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20
89334468|NCT00098475|Experimental|Arm IV (thalidomide, low-dose dexamethasone)|Patients with no response after treatment on Arm II: Patients receive thalidomide as in arm III and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
89523574|NCT02827279|Other|Healthy volunteers|Mesure of emotional induction by eye tracking on People without disorders
89334469|NCT00003468|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89334470|NCT03929575|Placebo Comparator|Placebo of calcium|Participants will consume 250 mg of calcium
89334471|NCT03929575|Experimental|Rhodiola|Participants will consume 250 mg of Rhodiola
89334472|NCT03929575|Experimental|Rhodiola and Cordyceps|Participants will consume a combination of 250 mg of Rhodiola and 225 mg of Cordyceps
89334473|NCT02292472|Experimental|Medytoxin®|Botulinum toxin type A
89334474|NCT02292472|Placebo Comparator|Normal Saline|Normal Saline
89334475|NCT03517384|Experimental|I-CBT for Body Dysmorphic Disorder|All participants will receive our Internet-Cognitive Behavioral Therapy treatment for Body Dysmorphic Disorder.
89334476|NCT02299180|No Intervention|Control arm|The control arm patients will not take part in ACP discussions and documentation, but will continue to receive usual care.
89334477|NCT02299180|Experimental|Intervention (ACP) arm|The patient and his/her family members will be referred to an ACP facilitator and will undergo ACP as an ongoing process, integrated with patient's care, from the facilitator, in coordination with a coordinator/nurse, and treating physician. The ACP facilitator will be certified in providing ACP and will possess sufficient knowledge of the risks, benefits, and harms of treatments and procedures available to the patient. The ACP facilitator will be supported by the physician with the specialized knowledge of treatment options, especially with regards to prognosis. Family members will be encouraged to be present during the ACP discussion so that the whole family unit will be able to explore goals, values and beliefs towards the patient's medical care.
89334478|NCT03519958||EGFR NSCLC Progressed on EGFR TKI|Patients with EGFR NSCLC who have progressed following EGFR TKI therapy will undergo plasma-tissue testing
89334479|NCT01131247|Experimental|ofatumumab + bendamustine|
89334480|NCT03513874|Experimental|Metformin + Insulin|
89334481|NCT03513874|Active Comparator|Insulin alone|
89334482|NCT05170516|Experimental|Experimental Group A|In experimental group A, 4°C saline irrigation was used for removal of the bone surrounding the right or left third molars.
89334483|NCT05170516|Experimental|Experimental Group B|In experimental group B, 10°C saline irrigation was used for removal of the bone surrounding the right or left third molars.
89334484|NCT05170516|Active Comparator|Control Group A|In control group A, room temperature saline was used for the other side extractions of patients whose impacted tooth was extracted under 4 °C saline irrigation on one side.
89334485|NCT05170516|Active Comparator|Control Group B|In control group B, room temperature saline was used for the other side extractions of patients whose impacted tooth was extracted under 10 °C saline irrigation on one side.
89334486|NCT01228357|Experimental|SSRI treated group|SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline
89334487|NCT01228357|Active Comparator|non-SSRI treated group|non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
89334488|NCT03517306||Beijing|No interventions
89334489|NCT03517306||Ningxia|No interventions
89334490|NCT03517306||Wenzhou|No interventions
89334491|NCT03517306||Changzhou|No interventions
89334492|NCT01228123|Active Comparator|CVVH arm|
89334493|NCT01228123|Active Comparator|IHD arm|
89334494|NCT03519880|Experimental|Custom Mask Interface|Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.
89334495|NCT03929263|Experimental|Real-time fMRI neurofeedback|All participants will receive neurofeedback from the target region (no sham condition).
89334496|NCT03929107|Experimental|Intervention group|In this group, patients will be treated with Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T, and the safety and efficacy will be evaluated.
89334497|NCT01329523||Subjects with AD|Subjects with a diagnosis of dementia
89334498|NCT01329523||Family Members|Younger biological family members of the patients with dementia
89334499|NCT01329523||Control Group|Individuals without dementia matched in age to the patients with a dementia diagnosis
89334500|NCT01128673||Body Cooled|Infants undergoing total body cooling for HIE
89334501|NCT01128673||HIE,Selective Head Cooled|Infants undergoing head cooling for HIE
89334502|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
89334503|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
89334504|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
89334505|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
89334506|NCT02292550|Experimental|Ribociclib 300 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
89334507|NCT03929185||Tumor affected|Patients affected by colorectal cancer who underwent to surgical resection in Sant'Anna Hospital in Cona (Ferrara)
89334508|NCT03929185||Control|Healthy people aged 20-35 years old without risk factors for colorectal cancers who voluntarily participated to the study
89334509|NCT03925519||non-obese|non-obese diabetic patients (n= 25, BMI ≤ 30 kg/m2) were subjected to supervised aerobic exercise
89334510|NCT03925519||obese group|obese diabetic group (n= 25, BMI ≥ 30 kg/m2)
89334511|NCT02295436|Experimental|1-mg group|Twelve healthy young subjects were administered a single oral dose of 1 mg minodronic acid tablets at day 1 and then received repeated oral doses of minodronic acid (1 mg) once daily for 7 days (day 3 to day 9).
89334512|NCT02295436|Experimental|2-mg group|Twelve healthy young subjects were administered a single oral dose of 2 mg minodronic acid tablets.
89334513|NCT02295436|Experimental|4-mg group|Twelve healthy young subjects were administered a single oral dose of 4 mg minodronic acid tablets under fasting state at period 1.After a washout period of 8 days, they received the same dosage under fed conditions (administrated 30 minutes before high-fat breakfast).
89334514|NCT02295436|Experimental|1-mg elderly group|Twelve healthy elderly subjects were administered a single oral dose of 1 mg minodronic acid tablets.
89334515|NCT03925363|Active Comparator|Active|Participants will be given a mobile-app where they will get feedback from the device based on their physical activity (feedback app)
89334516|NCT03925363|Sham Comparator|Control|Participants will be given a mobile-app that does not give feedback back, but the app will register physical activity (blind app).
89334517|NCT03517150|Experimental|Experimental group|This group will use an oral appliance for treatment of obstructive sleep apnea. The oral appliance is custom-made and its titration is attained by means of progressive mandibular advancement that incrementally moves the mandible forward. This group of patients will use the oral appliance for 45 days.
89334518|NCT03517150|Active Comparator|Control group|This group will use a single adjustable silicone appliance in maxillar for 45 days, in order to compare to the experimental group.
89334519|NCT03925285|Experimental|IV fluorescent tracer bevacizumab-800CW|Patients will be administered with 10 or 25 bevacizumab-800CW.
89334520|NCT03924505|Experimental|Implementation Manual and External Facilitation|This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.
89334521|NCT03924505|Active Comparator|Implementation Manual - only|This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.
89334522|NCT03929341|Experimental|CCTA first approach with Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test and have Cardiac Link pathway activated for expedited cardiology referral.
89334523|NCT03929341|Experimental|CCTA first approach without Cardiac Link|Patient will undergo Coronary Computed Tomography Angiography as the first test, but Cardiac Link pathway will not be activated.
89334524|NCT03929341|Active Comparator|Usual Care with Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, and have Cardiac Link pathway activated for expedited cardiology referral.
89334525|NCT03929341|Active Comparator|Usual Care without Cardiac Link|Patient will undergo the usual diagnostic test ordered by their family physician as the first test, but Cardiac Link pathway will not be activated.
89334526|NCT04464694|Experimental|Ranibizumab|Single intravitreal injection of ranibizumab (0.5 mg) 3~7 days before vitrectomy
89334527|NCT04464694|Sham Comparator|Sham injection|Sham injection 3~7 days before vitrectomy
89334528|NCT03924349|Experimental|ICG clip|Three clips are fixed in three directions (120 degrees apart) at the distal of the lesion (just distal) before surgery
89334529|NCT02292628|Experimental|Mesenchymal stem cells|Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.
89334530|NCT02292628|Placebo Comparator|Ringer lactate solution|Ringer lactate solution
89334531|NCT03924271|Experimental|ONCOLOGY|Patient with a cancer
89334532|NCT01130779|Experimental|tarceva|continuation of tarceva
89334533|NCT03740269||oral health educational program|poster for oral health education program for a group of egyptian school girls
89334534|NCT03519724|Experimental|SUG|
89334535|NCT03519724|Active Comparator|NEO|
89334536|NCT02292862||MG Main Group|lymph node and blood sampling
89334537|NCT01130935||1|
89334538|NCT03516916||Australia|Patients with a permanent colostomy after curative surgery for rectal cancer
89334539|NCT03516916||Brazil|Patients with a permanent colostomy after curative surgery for rectal cancer
89334540|NCT03516916||China|Patients with a permanent colostomy after curative surgery for rectal cancer
89334541|NCT03516916||Denmark|Patients with a permanent colostomy after curative surgery for rectal cancer
89334542|NCT03516916||Egypt|Patients with a permanent colostomy after curative surgery for rectal cancer
89334543|NCT03516916||Israel|Patients with a permanent colostomy after curative surgery for rectal cancer
89334544|NCT03516916||Lithuania|Patients with a permanent colostomy after curative surgery for rectal cancer
89334545|NCT03516916||the Netherlands|Patients with a permanent colostomy after curative surgery for rectal cancer
89334546|NCT03516916||Portugal|Patients with a permanent colostomy after curative surgery for rectal cancer
89334547|NCT03516916||Russia|Patients with a permanent colostomy after curative surgery for rectal cancer
89334548|NCT03516916||South Africa|Patients with a permanent colostomy after curative surgery for rectal cancer
89334549|NCT03516916||Spain|Patients with a permanent colostomy after curative surgery for rectal cancer
89334550|NCT03516916||Sweden|Patients with a permanent colostomy after curative surgery for rectal cancer
89334551|NCT03516916||Turkey|Patients with a permanent colostomy after curative surgery for rectal cancer
89334552|NCT03516916||the United Kingdom|Patients with a permanent colostomy after curative surgery for rectal cancer
89334553|NCT01131091|Other|Group A|Subjects with end stage renal disease (ESRD) who are receiving hemodialysis treatment
89334554|NCT01131091|Other|Group B|Subjects with severe renal impairment
89334555|NCT01131091|Other|Group C|Subjects with moderate renal impairment
89334556|NCT01131091|Other|Group D|Subjects with mild renal impairment
89334557|NCT01131091|Other|Group E|Healthy subjects
89334558|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 0.75% (w/w) MTC896 Gel
89334559|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel twice daily|Subjects will apply topically twice daily 0.75% (w/w) MTC896 Gel
89334560|NCT02293018|Experimental|1.5% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 1.5% (w/w) MTC896 Gel
89334561|NCT01228201|Experimental|Aerboic interval training|
89334562|NCT01228201|Active Comparator|Moderate continuous training|
89334563|NCT03920449|Active Comparator|Botulinum toxin injection|
89334564|NCT03920449|Active Comparator|Posterolateral internal sphincterotomy|
89334565|NCT02295514|Experimental|PTP1B dosage|PTP1B dosage during sepsis
89334566|NCT03920059|Placebo Comparator|FD arm|MMF will be prescribed at a starting dose of 1.5 g/day and increased to 2 g/day at week 4 (if body weight ≥ 45 kg) and continue the same dose until week 24. After week 24, MMF will be lowered to 1.5 g/day.
89334567|NCT03920059|Active Comparator|CC Arm|MMF will be prescribed at a starting dose of 1.5 g/day. MPA-C0 (trough) level will be measured weekly and MMF dose will be increased by 500 mg/day every week until the MPA-C0 level ≥ 3 mg/L or the MMF dosage is 3000 mg/day. After achieving the targeted MPA-C0 level, the MMF dose adjustment will be allowed only if the MPA-C0 levels are lower than 3 mg/L for two consecutive monitoring visits. After week 12, MMF will be maintained at the same dose until week 48
89334568|NCT03519568|Experimental|Combination inoculation group|GroupⅠ: HepB:3 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old GroupⅡ: MPSV-A:1 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old, MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR and EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old GroupⅣ: JE-Land EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old
89334569|NCT03519568|Active Comparator|Separate inoculation control group|GroupⅠ: HepB:3 third dose was injected at 6 months old GroupⅡ: MPSV-A:1 was injected at 6 months old, then MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR was injected at 8 months old GroupⅣ: JE-L was injected at 8 months old
89334570|NCT03519568|Active Comparator|EV71 inoculation control group|GroupⅠ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅡ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅢ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅣ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old
89334571|NCT01132027|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
89334572|NCT01132027|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
89334573|NCT03136484|Experimental|Semaglutide + canagliflozin placebo|
89334574|NCT03136484|Active Comparator|Canagliflozin + semaglutide placebo|
89334575|NCT02295592|Experimental|group A( TSTstarr+ group)|"TSTstarr+ is a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
89334576|NCT02295592|Active Comparator|group B ( PPH group)|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
89334577|NCT03519490|Placebo Comparator|Single Vision Hybrid Contact Lens|Subjects will wear the Duette single vision hybrid contact lens.
89334578|NCT03519490|Experimental|Multifocal Hybrid Contact Lens|Subjects will wear the Duette hybrid multifocal contact lens with the near center design in one eye and the distance center design in the other eye with a crossover at every six months.
89334579|NCT03919591|Other|Open Label Pilot|Open Label Pilot Study. All subjects will receive the viral challenge inoculum.
89334580|NCT01132105||Normal subjects|Adults normal hearing and vestibular function subjects
89334581|NCT02295670|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
89334582|NCT02295670|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
89334583|NCT01132183|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
89334584|NCT01132183|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
89334585|NCT03519334||Chronic health condition group/study|People with any of the following chronic health conditions: Diabetes, Chronic obstructive Pulmonary Disease, Major Depression, Dysthymia, Migraine, Back & Neck Pain, Cancer, Ischemic Heart Disease
89334586|NCT03519334||Expert consultation group/study|Relevant contacts from advocacy organizations operating at European level for the professional integration of people with chronic health conditions.
89334587|NCT03923881|Experimental|Study group|Patients with oral squamous cell carcinoma that have been included in ICON-study and are scheduled for treatment of neck
89334588|NCT03516682|No Intervention|Usual Care|Parents will receive usual care for their child at Kaiser Permanente Colorado. This includes recommendations for well child visits at 2, 4, 6 and 12 months of age as well as automated reminders for age eligible children to receive the flu shot during flu season.
89334589|NCT03516682|Experimental|Reminders|Parents randomized to the reminder arm will receive automated reminders to complete a 6 month and 12 month vaccine visit for their child. They will receive 2 reminders before the child is 6 and 12 months of age and 2 reminders after their child is 6 and 12 months of age. Reminders will not occur if they have received vaccines within the eligible time frame to receive a vaccine or have a visit scheduled. After randomization, participants in the intervention arm will have an opportunity to provide their preference on how they receive reminders (text, phone and/or email). Participants not providing a preference will receive text reminders. If a child is randomized into the study after the child is 7 months of age, the parent will only be eligible for reminders for the 12 month vaccine visit.
89334590|NCT03924115|Experimental|Group Total|This group of patients was chosen at random. They are patients who receive the full PST as intervention, that is, they receive a Smartphone with the AFAM-Health application with all the contents of the PST and data plan for 1 year.
89334591|NCT03924115|Experimental|Group Partial|This group of patients was chosen at random under the criteria of parity with group A. They are patients who receive partial PST as intervention, that is, they only receive video capsules reproduced in the CESFAM waiting room as educational content.
89334592|NCT03924115|No Intervention|Group Control|This group of patients is the control group, that is, they do not receive any type of intervention additional to the one they already receive from their CESFAM.
89334593|NCT02295748|Experimental|Deflazacort|0.9 mg/kg oral deflazacort (between 2 to 12 x 6mg tablets based on body weight) will be administered daily.
89334594|NCT03923803||Chronic obstructive pulmonary disease|patients with acutely exacerbated Chronic obstructive pulmonary disease admitted in chest department Assiut university hospital ,30 patients who revealed sputum culture and inflammatory markers suggesting infection exacerbation will be followed up
89334595|NCT03923569|Other|Alzheimer's Disease patients group|This group contains the 31 (anticipated) participants with a diagnosis of Alzheimer's disease
89334596|NCT03923569|Other|Healthy control group|This group contains the 31 (anticipated) age and sex -matched healthy controls
89334597|NCT02295826|Experimental|Dabigatran therapy|150 mg BID for 30 days (dose modification - reduced to 110mg BID in patients >80 years of age and/or an eGFR of 30-50 ml/min)
89334598|NCT02295826|Active Comparator|Acetylsalicylic Acid thereapy|325 mg loading dose then 81 mg/day for 30 days
89334599|NCT03923647||Laparoscopy and CT scan|Usage of laparoscopy after inflation of co2 infra umbilical
89334600|NCT01348724|Experimental|[14C] NKTR-118|
89334601|NCT03519022|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
89334602|NCT03519022|Active Comparator|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Cocaine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
89334603|NCT01131403||BW= using baby wipes and CW= using cotton wool|
88806841|NCT05041855|Active Comparator|Primary care based childhood obesity intervention|A healthy lifestyle counseling intervention delivered by trained primary care providers and health educators at visits occurring every 3 months.
88806842|NCT05017454|Experimental|sodium valproate group|Group 1 will be treated with the optimized sodium valproate-loaded nanospanlastic dispersion, twice daily on the affected areas of the scalp for 3 months
89334604|NCT01131403||wet wipe, cotton wool|Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.
89334605|NCT03518944||occult premature ovarian insufficiency|Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two occasion >4 weeks apart
89334606|NCT01228669|Experimental|A|
89334607|NCT01228669|Experimental|B|
89334608|NCT01228669|Placebo Comparator|C|
89334609|NCT01354574|Experimental|High Glycemic Index meals|Three days of run-in diet with meals containing high glycemic index carbohydrates followed by test day with breakfast meal containing high glycemic index carbohydrates.
89334610|NCT01354574|Experimental|Low Glycemic Index meals|Three days of run-in diet with meals containing low glycemic index carbohydrates followed by test day with breakfast meal containing low glycemic index carbohydrates.
89334611|NCT02293252|Experimental|Interventional group|Remote patient monitoring system (Motiva)
89334612|NCT02293252|No Intervention|Control group|Best medical treatment according to the guidelines of the European Society of Cardiology (ESC)
89334613|NCT03923257|Experimental|PRRT with 177Lu-DOTA-tyr3-OCTREOTATE|"177Lu-DOTA-tyr3-OCTREOTATE (177Lu-DOTATATE) and amino acid will be administered intravenously (IV) on Day 1 of each of four treatment cycles, 8 weeks apart.~This study will consist of children and adolescents ages 1-20 years with relapsed or refractory neuroendocrine tumors and pheochromocytoma or paraganglioma. Children and adolescents with neuroendocrine tumor, pheochromocytoma or paraganglioma will not have had any previous endoradiotherapy with 90Y-DOTATOC, 131I-MIBG, or 177Lu-DOTATATE."
89334614|NCT01348802|Experimental|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
89334615|NCT01348802|Placebo Comparator|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
89334616|NCT03516526|Other|All patients in this study|Patients treated with natalizumab with a minimum of 1 year, without signs of disease activity (relapses, new T2 lesions on MRI) for a minimum of 1 year.
89334617|NCT01354730||Exposed cohort|The woman received AdimFlu-S (A/H1N1) vaccination between 2009/10 and 2010/02. The woman was pregnant at the time of vaccination.
89334618|NCT01354730||Unexposed cohort|The woman was gestation after April 2009.
88806843|NCT05017454|Active Comparator|topical steroid group|Group 2 will be treated with the marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
89334619|NCT02295982|Placebo Comparator|Laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo laparoscopic nephrectomy within standarized technique
89334620|NCT02295982|Active Comparator|Hand assisted laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo hand assisted laparoscopic nephrectomy
89334621|NCT02293330|Experimental|C group|continuous infusion of levobupivacaine
89334622|NCT02293330|Experimental|B group|Intermittent bolus infusion of levobupivacaine
89334623|NCT01228825||CABG without CPB|Patients undergoing coronary artery bypass graft (CABG) without Cardiopulmonary bypass ( CPB)
89334624|NCT01228825||CABG with CPB|Patients undergoing coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB)
89334625|NCT01348880|Experimental|Arm1|
89334626|NCT01348880|Placebo Comparator|Arm2|
89334627|NCT03516448|Active Comparator|the Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d Gan Fu Le Tablets，6 tablets,po,tid
89334628|NCT03516448|Placebo Comparator|the placebo group|the placebo Gan Fu Le Tablets，6 tablets,po,tid
89334629|NCT03923179|Experimental|pyrotinib+Etoposide|
88806844|NCT05013424|Experimental|OnabotulinumtoxinA|Participants will receive one dose of OnabotA X administered as 5 injections to the corrugator and procerus muscles on Day 1.
88806845|NCT04999215|Experimental|Main arm|F-choline intravenous injection
89334630|NCT01357226||All patients over the age of 18|
89334631|NCT02293408||Component 1|Component 1 involved an evaluation of the clinical characteristics of MPS IIIB in participants based on a retrospective chart review to collect information on demographics, clinical history, diagnostic tests, treatments, clinical chemistry and hematology test results, physical examination findings, anthropometric data, radiology results, and supportive interventions performed over a period of up to 6 weeks.
89334632|NCT02293408||Component 2|Component 2 involved a longitudinal evaluation of the course of disease progression in a subset of participants considered to be at risk of rapid disease progression, who, after completing Component 1, were to be prospectively followed for a period of at least 1 year (Longitudinal Follow-Up) and up to 3 years total (Extended Follow-Up).
89334633|NCT03923413||patients with chronic heart failure without LVAD support|patients with chronic heart failure without LVAD support
89334634|NCT03923413||patients with end-stage heart failure with LVAD support|patients with end-stage heart failure with LVAD support
89334635|NCT01348958|Experimental|Post-operative knee replacement|Subjects that have had a hemi knee replacement of one knee at least 8 weeks ago had the post-operative knee scanned using the orthopedic hip application and the Lunar orthopedic knee application.
89334636|NCT01357304|Experimental|Group treatment and PAR|
89334637|NCT01357304|No Intervention|Usual care|
89334638|NCT02296060|Experimental|6 minutes walking test|
89334639|NCT01318304||Pregnant, HIV- negative|This cohort has completed accrual as of 12/28/11.
89334640|NCT01318304||Pregnant, HIV-positive|
89334641|NCT01318304||Non-pregnant, HIV-negative|This cohort has completed accrual as of 12/28/11.
88806846|NCT04991025|Experimental|Participants with resectable stage II-III lung cancers (Adenocarcinoma)|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + nivolumab + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
89334642|NCT01318304||Non-pregnant, HIV-positive|This cohort has completed accrual as of 12/28/11.
89334643|NCT03518788|Experimental|Pleur-X|Placement of a permanent drainage under local anesthesia
89334644|NCT03518788|Experimental|pleurodesis|Pleurodesis with talc in VATS
89334645|NCT01318460|Active Comparator|Levosimendan|Patients treated with prophylactic administration of levosimendan
89334646|NCT01318460|Placebo Comparator|Placebo group|Patients managed with placebo administration
89334647|NCT03516370|Experimental|study group|Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
89334648|NCT03516370|Placebo Comparator|control group|Control site received placebo i.e distilled water as a mixture after scaling and root planning.
89334649|NCT01318616|Experimental|Training group|
89334650|NCT02299726|Experimental|Active|spironolactone
89334651|NCT02299726|Placebo Comparator|Placebo|matching placebo to active study drug
89334652|NCT03518710|Experimental|Children with NF1|"One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :~Neuropsychological evaluation~Evaluation of the reading assistance technique"
89334653|NCT02299804|Experimental|High dose arm|Have included the Levophencynonate Hydrochloric 1.5mg bid.
89334654|NCT02299804|Experimental|Low dose arm|Have included the Levophencynonate Hydrochloric 1.0mg bid.
89334655|NCT02299804|Placebo Comparator|Placebo arm|Have no any active component
89334656|NCT01354808|Active Comparator|DAPT|
89334657|NCT01354808|Experimental|TAPT|
89334658|NCT03518632|Active Comparator|Control group|
89334659|NCT03518632|Experimental|Interval training 1|
89334660|NCT03518632|Experimental|Interval training 2|
89334661|NCT01354886|Experimental|FSH-GEX 25 IU|25 IU single dose
89334662|NCT01354886|Experimental|FSH-GEX 75 IU|75 IU single dose
89334663|NCT01354886|Experimental|FSH-GEX 150 IU|150 IU single dose
89334664|NCT01354886|Experimental|FSH-GEX 300 IU|300 IU single dose
89334665|NCT01354886|Active Comparator|Gonal-f|150 IU single dose
89334666|NCT01354886|Active Comparator|Bravelle|150 IU single dose
89334667|NCT01354886|Placebo Comparator|Placebo|single dose
89334668|NCT02299882|Experimental|Vancomycin|Patient will receive Vancomycin powder to the incision just before skin closure
89334669|NCT02299882|No Intervention|no vancomycin|Patient will be randomized to either vancomycin powder or no vancomycin powder. This arm the patient will not have the powder placed in the incision before skin closure.
89334670|NCT01355042||Severe Sepsis and Septic Shock|
89334671|NCT01355042||Other Critical Ill with or without Shock|Severe Trauma, Neurological Injury, Other Shock (not Septic)
89334672|NCT02293486|No Intervention|Control|Arm that followed all the protocols with the exception of the pomegranate juice intake.
89334673|NCT02293486|Experimental|Pomegranate Juice|Arm that followed all the protocols and the pomegranate juice intake.
89334674|NCT02293486|Experimental|Pomegranate Juice Dilution|Arm that followed all the protocols and the pomegranate juice dilution (1:1) intake.
89334675|NCT01355120|Experimental|a human immunoglobulin|Four infusions (i.v.) of 3mg/kg Ipilimumab in week 1, week 4, week 7 and week 10
89334676|NCT02299960||HFpEF|patients with heart failure with preserved ejection fraction
89334677|NCT02299960||HFrEF|patients with heart failure with reduced ejection fraction
89334678|NCT02299960||AH|patients with hypertension
89334679|NCT02299960||Nephropathy|patients with diabetic nephropathy
89334680|NCT02300038|Active Comparator|Lidocaine (Xylocaine) 0.5%|Injection of 1ml after mixing Lidocaine 10 mg/ml 1 ml +1 ml NaCl was administrated perineuromally
89334681|NCT02300038|Placebo Comparator|Lidocaine (Xylocaine) 10 mg/ml 0.01%|Injection of 1 ml from 10 mg/ml 1 ml lidocaine Xylocaine +10 ml Nacl was adminsitrated perineuromally
89334682|NCT01355198|Experimental|Cysteine/glycine|Subjects will be studied before and after receiving oral cysteine (as n-acetylcysteine) and glycine for 2 weeks
89334683|NCT01355276|Experimental|1|
89334684|NCT01355276|Active Comparator|2|
89334685|NCT02293564|Experimental|gevokizumab|
89334686|NCT03922711|Experimental|Pridopidine Dose 1|Dose 1 (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period
89334687|NCT03922711|Experimental|Pridopidine Dose 2|Dose 2 for (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period
89334688|NCT03922711|Placebo Comparator|Placebo|Matching placebo (oral capsule) for 16 weeks
89334689|NCT03637010|Other|Breakfast in the Classroom|Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
89334690|NCT03518554|Experimental|JAB-3068 (SHP2 inhibitor)|Daily oral administration of JAB-3068
89334691|NCT01357382|No Intervention|low fat diet|replace high fat, energy dense foods with foods rich in whole grains, fruits and vegetables. The macronutrient distribution of this diet will be approximately 55% carbohydrate, 15% protein and 30% fat. Individuals will also be instructed to reduce sodium intake to < 2300 mg / day and in individuals with hypertension, < 1500 mg / day.
89334692|NCT01357382|Experimental|low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' to increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
89334693|NCT03922633|Experimental|Cohort 1 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
89334694|NCT03922633|Experimental|Cohort 1 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
89334695|NCT03922633|Experimental|Cohort 2 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
89334696|NCT03922633|Experimental|Cohort 2 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
89334697|NCT03922633|Experimental|Cohort 3 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
89334698|NCT03922633|Experimental|Cohort 3 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
89334699|NCT03922633|Experimental|Cohort 4 Group A: E3112 + Placebo|E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
89334700|NCT03922633|Experimental|Cohort 4 Group B: Placebo + E3112|Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.
89334701|NCT02296294|Active Comparator|Fluid Therapy|"Intravenous isotonic fluid therapy of Elo-mel® (Fresenius Kabi Austria) at a rate of 0,50ml/kg/min for one hour.~Body Composition Monitoring every 10 minutes for 6hours."
89334702|NCT02296294|Placebo Comparator|Zero Therapy|Body Composition Monitoring every 10 minutes for 6hours. No intravenous fluid therapy
89334703|NCT02296372|Other|SOFA <7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score < 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
89334704|NCT02296372|Other|SOFA >7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score > 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
89334705|NCT01128751|Active Comparator|Embol-X|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
89334706|NCT01128751|Active Comparator|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
89334707|NCT01128751|No Intervention|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
89334708|NCT01355354|Experimental|1|Digoxin
89334709|NCT01355354|Experimental|2|Fostamatinib
89334710|NCT03928795||neonates with acute acidosis|neonates with Cord blood gases measured immediately after birth inferior to 7.15
89334711|NCT03928795||neonates with a normal ph|neonates with Cord blood gases measured immediately after birth of at least 7.15
89334712|NCT01715324|Experimental|Growth Hormon|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication and will receive 2.5 mg of Adjuvant Growth Hormon (Saizen) daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering.
89334713|NCT01715324|No Intervention|Control|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication without Adjuvant Growth Hormon (Saizen).
89334714|NCT03513172|Active Comparator|Brimonidine Pre-Administration During First Visit|
89334715|NCT03513172|Active Comparator|Brimonidine Pre-Administration During Second Visit|
89334716|NCT03518476|Experimental|Intervention arm|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
89334717|NCT03518476|Active Comparator|Control arm|Non-tobacco related training or education sessions will delivered to pharmacists in the control group.
89334718|NCT01355432||Propofol|
89334719|NCT01132261|Active Comparator|1|brain preservation diet
89334720|NCT01132261|No Intervention|2|
89334721|NCT01349270|Experimental|immunoglobulin|patient who received monthly 2g/kg cure of intravenous Immunoglobulin during 6 months
89334722|NCT01349270|Active Comparator|prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
89334723|NCT03513094|Experimental|Without and With Transversus Abdominis|"Without:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, without transversus abdominis contraction.~With:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, with 50% MVIC transversus abdominis contraction."
89334724|NCT01132339||Enhanced MR (case group)|those with an exposure to gadolinium-based contrast agent
89334725|NCT01132339||Unenhanced MR (control group)|those without an exposure to gadolinium-based contrast agent
89334726|NCT01132339||Unenhanced CT (control group)|those without an exposure to iodine-containing contrast agent
89334727|NCT01132339||Enhanced CT (case group)|those with an exposure to iodine-containing contrast agent
89334728|NCT01128907||1|Hematological neutropenic patients at high risk of Invasive Aspergillosis with persistent fever and an opportunist infection suspicion.
89334729|NCT01128907||2|Patients without hematological illness and without Invasive Aspergillosis suspicion.
89334730|NCT01355666|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
88819571|NCT05451381|Experimental|Dexmedetomidine group|"Patient sedation after cardiac surgery at the intensive care unit.~Sedation group Dexmedetomidine (DEX):~continuous infusion of Dexmedetomidine using a syringe pump at the dose of 0.5-1.0 mcg/ kg / h"
89334731|NCT01225627|Experimental|Coordinated discharge|Patients will receive support by discharge coordinator for activities associated with discharge and immediate post-discharge care.
89334732|NCT01225627|Placebo Comparator|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
89334733|NCT01355744||Spider bite patients|All patients treated for an actual spider bite by a Swiss physician during study period.
89334734|NCT03515980|Experimental|Mild hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh A score 5 to 6 points
89334735|NCT03515980|Experimental|Moderate hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh B score 7 to 9 points
89334736|NCT03515980|Experimental|Severe hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh C score 10 to 15 points
89334737|NCT03515980|Experimental|Normal hepatic function|Based on Hepatic Function Impairment as defined by the investigator
89334738|NCT01132417||Multidrug resistant (MDR)bacterial strains|
89334739|NCT01355822|Placebo Comparator|Placebo|
89334740|NCT01355822|Experimental|PETN|Pentalong, Actavis Germay: 80 mg twice a day
89334741|NCT03922399|Other|Laser and Surgery in patients with major burn scars|Evaluating patients with major burn scar after laser and surgical treatments Multiple-directions evaluation, including senior plastic resident, young resident, professional burn surgeons, senior nurse with burn scar, one non-medical patients(usually patients' family and friends)
89334742|NCT01355900|Other|I tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after bone cement set.
89334743|NCT01355900|Other|II tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
89334744|NCT01355900|Other|III tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after wound closure
89334745|NCT01355900|Other|IV control group|Do not use volume loading test. Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
89334746|NCT01131481|Other|AcrySof MA50BM,AVS Model X-60|AcrySof MA50BM, AVS Model X-60
89334747|NCT03513016|Experimental|Part A: UBX0101|Part A: UBX0101, single intra-articular injection, ascending dose
89334748|NCT03513016|Placebo Comparator|Part A: Placebo|Part A: Placebo, single intra-articular injection, ascending dose
89334749|NCT03513016|Experimental|Part B: UBX0101|Part B: UBX0101, single intra-articular injection, fixed dose
89334750|NCT03513016|Placebo Comparator|Part B: Placebo|Part B: Placebo, single intra-articular injection, fixed dose
89334751|NCT02347202|Experimental|Online counseling via Zoom teleconferencing|Each participant will be assigned a random number which is linked to group assignment. The numbers will be assigned consecutively to participants as they enroll. All caregivers in the treatment group will receive 6 counseling sessions in 4 months, using teleconferencing. The first session will be an individual session. The caregiver will be asked to select family members to participate in the next 4 sessions. The 4 family sessions will be followed by another individual session with the spouse/partner caregiver. The counselor will send the primary caregiver an email to be forwarded to family members with instructions on how to access the TTDC training on using the teleconferencing technology. All caregivers in the control group will be able to call the counselor for resource information and support.
89334752|NCT02347202|Other|Telephone support as needed|All caregivers in the control group will be able to call the counselor for resource information and support as needed.
89334753|NCT02300194|Active Comparator|Topic Morphine|Use of topic morphine for treatment of procedure associated pain
89334754|NCT02300194|Placebo Comparator|Placebo|Use of topic hydrogel (placebo) for treatment of procedure associated pain
89334755|NCT01225705|Experimental|Raltegravir|45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine
89334756|NCT01225705|Active Comparator|Atazanavir/ritonavir|45 patients will receive open label atazanavir/ritonavir
89334757|NCT03512938|Active Comparator|Non-smoker Group|This group included non-smoker generalized aggressive periodontitis patients.
89334758|NCT03512938|Experimental|Smoker Group|This group included smoker generalized aggressive periodontitis patients.
89334759|NCT03922867|No Intervention|Control Group|Subjects with receive standard of care for management of insomnia in subjects with fibromyalgia
89334760|NCT03922867|Active Comparator|Intervention Group|Subjects will receive standard of care and additionally complete the online cognitive behavior therapy program
89334761|NCT04465006|Experimental|Hippotherapy Simulator Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
88806847|NCT04991025|Experimental|Participants with resectable stage II-III lung cancers (squamous cell carcinoma)|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + nivolumab + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
89334762|NCT04465006|Experimental|Conventional Exercise Group|Getting a diagnosis of stroke by a specialist physician, Being between the ages of 18-65, Having a stroke history of 3- 36 months, To be able to sit without support while both soles are in contact with the floor, To be able to walk independently with or without using walking aid, To be able to understand and follow audio and visual warnings, Scoring 24 points or more from the Mini Mental State Exam.
89334763|NCT01357538|Active Comparator|Posiformin 2 %|Eye ointment applied to the eye lid
89334764|NCT01357538|Placebo Comparator|Placebo|corresponding vehicle, eye ointment applied to the eye lid
89334765|NCT01128985|Experimental|001|Canagliflozin 50 mg 50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
89334766|NCT01128985|Experimental|002|Canagliflozin 100 mg 100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
89334767|NCT01128985|Experimental|003|Canagliflozin 300 mg 300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
89334768|NCT01128985|Placebo Comparator|004|Placebo matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
89334769|NCT03518398|Experimental|IPL group|IPL 9-13 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
89334770|NCT03518398|Sham Comparator|sham-IPL group|IPL 0 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
89334771|NCT01604876|Experimental|light condition 1 + day night structure|exposure to 10.000 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
89334772|NCT01604876|Active Comparator|light condition 2 + day night structure|exposure to 200 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
89334775|NCT03512860|Experimental|E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B)|Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration.
89334776|NCT03512860|Experimental|E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A)|Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP).
89334777|NCT01357694|Experimental|psychotherapeutic contacts|
89334778|NCT01357694|No Intervention|control group|
89334779|NCT03923335||high-risk group|patients with any of the four genes hypermethylated
89334780|NCT03923335||low-risk group|patients with none of the four genes hypermethylated
89334781|NCT03512782|No Intervention|CONTROL|
89334782|NCT03512782|Experimental|INTERVENTION|
89334783|NCT02528695|Active Comparator|Healthy euglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during an euglycemic clamp
89334784|NCT02528695|Active Comparator|healthy hypoglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
89334785|NCT02528695|Experimental|Type 2 diabetes hypoglycemic clamp|In 5 type 2 diabetes patients, an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
89334786|NCT03574454|Other|Phase 1 - Mixed Scan Data Training Set|Machine learning (ML): A mixed data set of 200 WB-MRI scans comprising scans obtained from 40 healthy volunteers (scanned for the purposes of the study), 40 previously acquired inactive myeloma WB-MRI scans and 120 previously acquired active myeloma WB-MRI scans, in which machine learning and convolutional neural networks will be trained to recognise healthy marrow, treated inactive previous myeloma and active myeloma. An algorithm will be developed for testing in phase 2.
89334787|NCT03574454|Other|Phase 2 - Mixed Scan Data Validation Set|Machine Learning (ML): A mixed data set of 353 WB-MRI scans as that comprising 50 healthy volunteers (scanned for the purposes of the study), and previously acquired scans from 303 myeloma patients, 100 of whom have inactive disease and 203 of whom have active myeloma. The scans will be read by radiologists in random order either with or without the support of for the detection of active myeloma. The diagnostic performance of the radiology reads with or without the machine learning support will be measured against an expert panel reference standard.
89334788|NCT03574454|Other|Phase 3 - Disease Burden Paired Data Set|Machine Learning (ML): Approximately 200 paired WB-MRI scans from 100 patients (scanned at baseline with active disease and then post treatment) will be used to develop a machine learning tool to quantify the burden of disease. The machine learning algorithm will then be tested on a further additional set of 60 patients who previously had two WB-MRI scans comprising paired baseline (with active disease) and post treatment scans. The agreement of radiology readers to evaluate the burden of disease will be measured against the reference standard (expert panel) with and without machine learning support.
89334789|NCT02296762|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
89334790|NCT02296762|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
89334791|NCT03515902|Experimental|mouthguard|Mouthguard arm is application of mouthguard while swimming
89334792|NCT03515902|Experimental|mouthguard with desensitizing toothpaste|Mouthguard with desensitizing toothpaste arm is application of mouthguard with desensitizing toothpaste containing 8% arginine and calcium carbonate while swimming
89334793|NCT01132573|Experimental|Treatment (entinostat and clofarabine)|"Patients receive entinostat PO on days 1 and 8 and clofarabine IV over 2 hours on days 3-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity (only for patients >= 60 years of age with newly diagnosed ALL or ABL who are unable or unwilling to tolerate standard multi-agent chemotherapy and patients with relapsed or refractory ALL or ABL).~Patients 40-59 years of age with newly diagnosed ALL receive standard multi-agent induction chemotherapy beginning on day 11. Patients >= 21 years of age in their first relapse with sensitive disease begin initiation of allogeneic transplant after one course of entinostat and clofarabine."
89334794|NCT02877680|Experimental|Intervention|Smartphone app for parents to track adolescents' strength behaviors related to living with and managing type 1 diabetes, including regular feedback to parents and training about how to recognize and reinforce positive behaviors in teens.
89334795|NCT02877680|No Intervention|Usual Care|Usual diabetes care and study-related data collection, without use of app during the study period. They will be offered an opportunity to try the app and share their feedback with the study team after completing follow-up data collection.
89334796|NCT02293720|Experimental|EndoBarrier Device|Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.
89334797|NCT01131559|Active Comparator|Lisdexamfetamine|Drug
89334798|NCT01131559|Placebo Comparator|Placebo|Drug
89334799|NCT03922009|Experimental|Virtual Reality group|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
89334800|NCT03922009|No Intervention|control group|General routine care
89334801|NCT03518320|Experimental|TAR-200 and Nivolumab Combination|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 is placed into the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed. In combination, subjects are dosed intravenously with a Nivolumab Injection [Opdivo] within 3 days of TAR-200 placement. Subjects will receive four consecutive 21-day dosing cycles of the combination of TAR-200 and Nivolumab prior to radical cystectomy.
89334802|NCT01134289|Active Comparator|lumbar sympathetic block|Unilateral lumbar sympathetic blockade using chirocaine
89334803|NCT01134289|No Intervention|contralateral side|
89334804|NCT02300272||Typically healthy older adults|Adults 65 years and older with only common late-life medical conditions who will complete a screening that includes a Polysomnograph and assessment that includes Actiwatch.
89334805|NCT01231789|Sham Comparator|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
89334806|NCT01231789|Experimental|RIPC treatment|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
89334807|NCT02300350|Experimental|Treatment A|0.5 mg single-dose oral digoxin administration
89334808|NCT02300350|Experimental|Treatment B|400 mg oral LX4211 qd administration
89334809|NCT02300350|Experimental|Treatment C|0.5 mg single-dose oral digoxin administration + 400 mg oral LX4211 qd administration
89334810|NCT01349348|Experimental|Tolvaptan 15mg|Tablet;15mg/tab
89334811|NCT01349348|Experimental|Tolvaptan 7.5mg|Tablet;7.5mg/tab
89334812|NCT01349348|Placebo Comparator|Placebo|Tolvaptan 0mg/tab
89334813|NCT02300428||1-year cohort|"Patients with at least 1 prescription of any oral iron preparation in the last 2 years and who have at least 1 year of follow up data post-prescription.~It is anticipated that ca. 123,000 patients in CPRD fulfil this criteria."
89334814|NCT02300428||10-year cohort|"All pre-menopausal women (18-45 years old) with at least 1 prescription of one ferrous iron salt (i.e. sulphate, fumarate and gluconate) since January 2000.~It is anticipated that ca. 299,000 patients in CPRD fulfil this criteria."
89334815|NCT01356056||Kinesia HomeView Monitoring|Uses Kinesia HomeView at home once per week
89334816|NCT01356056||Control|Assessed in the clinic every 4 weeks using traditional methods
89334817|NCT01131637|Experimental|rhNRG-1|recombinant human neuregulin-1
89334818|NCT01131637|Placebo Comparator|placebo|placebo
88819765|NCT05350059|Experimental|High Intensity Focused Ultrasound (HIFU) treatment to breast cancer|High-Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer prior to surgical resection
88819766|NCT05349903|Experimental|Rice flour|Rapidly digestible control
88819767|NCT05349903|Experimental|Alternanoligosaccharide 15|
89334819|NCT03515746|Active Comparator|Exergaming2D|The participants will practise grab and grasp through exergaming in virtual environment (VE) on a laptop computer. During the task, they will sit in a comfortable chair in front of the screen.
89334820|NCT03515746|Active Comparator|Exergaming3D|The participants will practise grab and grasp through exergaming in virtual environment (VE) in 3D VE using Oculus Rift CV1 3D goggles. During the task, they will sit in a comfortable chair with head-mounted 3D display.
89334821|NCT02293876|Sham Comparator|Eye drop|Eye drop LACRIBELL® - two drops each eye, three times a day, after eye cleansing.
89334822|NCT02293876|Sham Comparator|Ocular gel|Ocular gel LIPOSIC® applied three times a day at the lower palpebra from medium line to the lateral border.
89334823|NCT02293876|Sham Comparator|Glad wrap|Occlusion of the orbital area with a Glad wrap, turning the area into a moisture chamber.
89334824|NCT02293876|No Intervention|Control group|Ocular cleansing three times a day.
89334825|NCT03919201|Sham Comparator|Control group|No exercise intervention
89334826|NCT03919201|Experimental|Resistance band exercise intervention|Exercise intervention group (resistance band exercise training for 12 weeks, 5x per week, for 60 minutes per day).
89334827|NCT03141086|Experimental|Group 1|LML134, then placebo
89334828|NCT03141086|Experimental|Group 2|Placebo, then LML134
89334829|NCT03518164|Other|Allograft|Bone graft
89334830|NCT03518164|Other|Autograft|Bone from iliac crest
89334831|NCT01134367||1|Patients with GERD
89334832|NCT02296996|Experimental|Dabrafenib + trametinib|Single arm study with dabrafenib + trametinib combination therapy
89334833|NCT01329601|Experimental|Cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
89334834|NCT01329601|Active Comparator|Booklet-based training|Home based training of episodic memory using paper-pencil exercizes
89334835|NCT02297074|Experimental|Ordinary White Bread|Ordinary white bread bread is characterised by a white crumb with regular soft alveoli and a slightly soft thin crust.
89334836|NCT02297074|Experimental|Precooked-Frozen White Bread|Precooked-Frozen white bread is characterized by white crumb with regular soft alveoli and bright crusty crust
89334837|NCT02297074|Experimental|Candeal-flour White Bread|Candeal-flour white bread has a thick crust of between one and two millimetres, which is smooth and crisp, golden to light brown in colour and which tastes of toasted cereal. The crumb of the bread is white and its texture is smooth, spongy and consistent, with little regular alveolus and with an intense cereal aroma with a pleasant and slightly sweet taste
89334838|NCT02297074|Experimental|Alfacar White Bread|Alfacar white bread is made according to its protected designation of origin and protected geographical indication (D.O. Alfacar, Granada, Spain). The bread has a creamy white, flexible and soft crumb, with many randomly scattered holes. The crust is medium-thick to thick, golden, slightly shiny and quite smooth
89334839|NCT02297074|Experimental|Organic Wholemeal Bread|The Organic wholemeal bread only includes organic whole grain flours as the unique difference compared with the Ordinary bread. The resulting dark brown bread is characterized by compact crumb free of alveoli and hard thin crust
89334840|NCT02297074|Active Comparator|Glucose|Glucose is used to calculate glycemic index, glycemic load and insulinemic index
89334841|NCT01356134||Multiple sclerosis and or Ehlers-Danlos|Patients with suspected or confirmed cases of Ehlers Danlos Syndrome and or Multiple Sclerosis
89334842|NCT01356134||Age matched normals|Age matched normals
89334843|NCT02297152|Other|FLIP HOLE|The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation
89334844|NCT02270840|Active Comparator|CRT-D|Patients currently implanted with a single or dual chamber pacemaker or ICD will be upgraded to CRT.
89334845|NCT02270840|No Intervention|Only ICD|"In the ICD arm, choosing single or dual chamber device is based upon the investigator's discretion.~Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only)."
89334846|NCT01228981||Type-2 Diabetic Retinopathy|
89334847|NCT02300506||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg, and enrolled in study GLI01S.
89334848|NCT03921853|Active Comparator|Active comparator|Control group with obesity under Resistant Training
89334849|NCT03921853|Experimental|Experimental group with morbid obesity|Experimental group with morbid obesity under Resistant Training
89334850|NCT03512626|Experimental|Multifocal IOL (OptiVis)|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.~The randomly assigned IOL (in this arm: a hybrid (refractive-diffractive) multifocal IOL (OptiVis, Aaren Scientific) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
89334851|NCT03512626|Active Comparator|Monofocal IOL|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.~The randomly assigned IOL (in this arm: a monofocal IOL (AR40e, AMO) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
89334852|NCT03620240|Experimental|Sleep Education|Half of the participants are randomly assigned to the Sleep Education group. These participants will undergo 4 weekly class-based lesson, during which they are educated about sleep.
89334853|NCT03620240|No Intervention|Control|Half of the participants are randomly assigned to the Control group. These participants undergo 4 weekly class-based lessons, during which they are educated about health-related topics, but not about sleep.
89334854|NCT01357928||Healthy Volunteers|
89334855|NCT02294110||diabetes mellitus|spinal anesthesia
89334856|NCT02302300|Experimental|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
89334857|NCT02302300|No Intervention|Control Group|Standard preparation
89334858|NCT01283438|Experimental|Barricaid Device|Intervention: Barricaid Device
89334859|NCT01283438|Active Comparator|Standard of Care|Standard (Limited) Discectomy Only
89334860|NCT03512548|Experimental|Part 1 Period 1|Part 1 Period 1: Relacorilant 350mg will be given once on Day 1
88806848|NCT04989686||Cyclosporine A|"Males and females <18 years of age~Weight greater than 5 kg~Receiving cyclosporine A as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of cyclosporine A for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
88806849|NCT04989686||Tacrolimus|"Males and females <18 years of age~Weight greater than 5 kg~Receiving tacrolimus as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of tacrolimus for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
89334861|NCT03512548|Experimental|Part 1 Period 2|Part 1 Period 2: Itraconazole 200mg will be given for three days
89334862|NCT03512548|Experimental|Part 1 Period 3|Part 1 Period 3: Relacorilant 350mg will be given once with concomitant itraconazole and itraconazole will continue for three additional days
89334863|NCT03512548|Experimental|Part 2 Period A|Part 2 Period A: Relacorilant 300mg will be given once daily for 10 days
89334864|NCT03512548|Experimental|Part 2 Period B|Part 2 Period B: Relacorilant 300mg will be given once daily in combination with itraconazole 200mg once daily for 10 days
89334865|NCT03919357||Verbal|Passing of a specialized questionnaire on verbal disorders
89334866|NCT03919357||Non-verbal|Passing of a specialized questionnaire on non verbal disorders
89334867|NCT03919357||Attention|Passing of a specialized questionnaire on attention disorders
89334868|NCT03919357||Complaint about learning|Passing of a specialized questionnaire on learning disorders
89334869|NCT02300584|Experimental|Prototype Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
89334870|NCT02300584|Experimental|Field Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Based on the feedback from the prototype program, the videos may vary. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
89334871|NCT03515668|Experimental|Ritalin|20 mg Ritalin, 90 min before testing
89334872|NCT03515668|Placebo Comparator|Control|Identical size/taste placebo pill, 90 min before testing
89334873|NCT01356212|Experimental|Regimen A: Ketorolac tromethamine (Gentle Sniff - Upright)|Gentle sniff-inhalation with the volunteer upright for dosing and imaging
89334874|NCT01356212|Experimental|Regimen B: Ketorolac tromethamine (Vigorous Sniff - Upright)|Vigorous sniff-inhalation with the volunteer upright for dosing and imaging
89334875|NCT01356212|Experimental|Regimen C: Ketorolac tromethamine (Gentle Sniff - Semi-supine)|Gentle sniff-inhalation with the volunteer semi-supine for dosing and imaging
89334876|NCT02302378|Active Comparator|Taylor's approach|This arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
89334877|NCT02302378|Active Comparator|Lumbar approach|This arm will have the procedure of spinal anesthetic performed via a paramedian 'Lumbar approach' at interspace L3-L4. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
89334878|NCT03919279|Experimental|active arm with active tVNS for 1 month|
89334879|NCT01356368|Experimental|Cisplatin,Docetaxel,Gemzar, Premetrexed|Patients will receive treatment for up to six cycles of the assigned regimen unless there is disease progression or unacceptable toxicities. After treatment, the patients will be seen every 2 months for the first year, then every 3 months for the second year and every 6 months afterwards.
89334880|NCT03921697||Parkinson Disease Patients|"Patients with PD will be recruited at Fondazione Policlinico Universitario Gemelli and Fondazione Don Gnocchi ONLUS in Rome. All included patients will be affected by idiopathic PD. Clinical data will be acquired by a trained neurologist.~We will remotely monitor 300 patients through wearable sensors. Subjects will be instructed to wear the sensor for 14 consecutive days."
89334881|NCT03515590|Experimental|Emulsion with solid droplets|Emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
89334882|NCT03515590|Experimental|Emulsion with liquid droplets|Emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
89334883|NCT01349426|Experimental|LigaSure|"Arm 1~Patients undergoing lung surgery"
89334884|NCT01349426|Active Comparator|Automatic Staplers|"Arm 2~Patients undergoing lung surgery"
89334885|NCT02302456|Experimental|TXA|Intravenous administration of 1g of tranexamic acid within 2 minutes after birth and prophylactic oxytocin administration
89334886|NCT02302456|Placebo Comparator|Placebo|Intravenous administration of placebo within 2 minutes after birth and prophylactic oxytocin administration
89334887|NCT01356446|No Intervention|before surgical checklist|
89334888|NCT01356446|Active Comparator|after implementation surgical checklist|
89334889|NCT02300662|Experimental|Cycle Ergometer|Conventional physiotherapy and cycle ergometer 20 minutes, at 20 cycles per minute, once per day for as long as they remain on invasive mechanical ventilation
89334890|NCT02300662|Sham Comparator|Conventional Physiotherapy|Upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method and manual bronchial hygiene exercises.
89334891|NCT01131715||Study group|Patients who are included in the pharmacist follow-up procedure
89334892|NCT01356524|Active Comparator|Supplementary progesterone|Women with mid-luteal progesterone levels that are less than 15 ng/dl will receive higher doses of supplementary progesterone
89334893|NCT01356524|No Intervention|No additional progesterone|No additional progesterone given to women with mid-luteal progesterone levels below 15 ng/dl
89334894|NCT02302534|Experimental|patients|"2 groups with MRI :~- 8 right thoracic AIS participants (Cobb angle between 20 and 40°)"
89334895|NCT02302534|Experimental|controls subjects|- 8 healthy controls (no clinical scoliosis)
88819768|NCT05349903|Experimental|Waxy potato starch|
88819769|NCT05349903|Experimental|Combination of waxy potato starch and epigallocatechin gallate (EGCG)|
88819770|NCT05349903|Experimental|Combination of chickpea flour and epigallocatechin gallate (EGCG)|
89334896|NCT01232023|Experimental|100mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
88819771|NCT05349903|Experimental|Inulin|
89334897|NCT01232023|Experimental|200mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
89334898|NCT01232023|Experimental|400mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
89334899|NCT01232023|Experimental|800mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
89334900|NCT01318772||Fluoroscopy and Angiography Procedure|Patient that have been scheduled for routine diagnostic fluoroscopy and angiography procedures by their physician.
89334901|NCT02300740|Experimental|low dose|500 mg nicotinamide riboside oral
89334902|NCT02300740|Experimental|high dose|1000 mg nicotinamide riboside oral
89334903|NCT05401981|No Intervention|Standard care|Clinician not given any cards about the patient's story.
89334904|NCT05401981|Experimental|Story checklist|Clinician given a card with talking points in the form of a checklist about the patient's story.
89334905|NCT01318850|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes and Reeder, 2005)
89334906|NCT01318850|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
89334907|NCT01318850|Other|Healthy Controls|Healthy controls
89334908|NCT02300818|Active Comparator|Pulsed Electromagnetic Field Therapy|"Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.~PEMF has also proved to be beneficial in vision acuity of patients with low vision. In 50 per cent of the cases, values improved. Patients with vision acuity of 0.2 diopters showed improvement from 46 before treatment to 75 after treatment.~Different studies on varied diseases have proved that Pulsed Electromagnetic Field Therapy (PEMF) treatment is a safe, non-invasive and effective option for curing ocular conditions."
89334909|NCT02300818|Active Comparator|Seawater eyedrops|instantly soothes and clears the eye irritation caused by pollution, pollen, smoke, etc. It is a very practical system for eye daily hygiene · enables efficient therapeutic help in basic eye conditions such as: · · internal and external stye blepharitis and keratoconjunctivitis · · Conjuntiviti Episcleritis and scleritis
89334910|NCT01349504||Mesalmine|
89334911|NCT02302612|Experimental|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE disease management program.
89334912|NCT02302612|Active Comparator|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
89334913|NCT01134445|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
89334914|NCT01358006|Experimental|001|JNJ-40411813 Cohort 1: Type=2 to 3 unit=mg number=200 to 300 form=capsule route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.,JNJ-40411813 Cohort 2: Type=up to 7 unit=mg number=up to 700 mg form=capsule route=oral use. Capsule(s) taken in the fed state.
89334915|NCT02297386|Experimental|[18F] DIHYDRO-TESTOSTERONE PET|"The diagnostic intervention of this study is the use of FDHT PET in localized prostate cancer. Patients will undergo a 30 minute dynamic scan of the pelvis followed by a whole body scan of approximately 30-minutes duration. The dynamic scan will be optional, but strongly encouraged. PET scanning will preferably be done on the GE Discovery STE PET/CT scanner or the equivalent generation of scanner. The PET scans are routinely quantitative, that is corrected for attenuation and scatter and adjusted for system sensitivity and providing parametric images in terms of standardized uptake values (SUV) (= μCi found/gm tissue / μCi injected/gm body mass)."
89334916|NCT04464616|Placebo Comparator|control group|spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + normal saline (0.5 ml).
89334917|NCT04464616|Experimental|Dexmedetomidine group):|spinal anesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 5 μg dexmedetomidine in a volume of (0.5 ml).
89334918|NCT04464616|Experimental|Dexamethasone group|spinal anaesthesia with 10 mg hyperbaric bupivacaine 5% (2 ml) + 25 μg fentanyl (0.5 ml) + 2 mg dexamethasone in a volume of 0.5 ml).
89334919|NCT01356680|Active Comparator|Arm A|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IF-RT irrespective of FDG-PET results after chemotherapy
89334920|NCT01356680|Experimental|Arm B|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IN-RT if FDG-PET is positive after chemotherapy; 2 cycles BEACOPPescalated plus 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
89334921|NCT01229995|Active Comparator|Prefabricated Abutment|
89334922|NCT02300896|Experimental|Intervention|Group-based exercise training during hospitalization Procedure: Exercise training. Individual program training 5 days a week during hospitalization
89334923|NCT02300896|No Intervention|Control|Usual care including rehabilitation when necessary
89334924|NCT03918967|Experimental|CT-G11|CT-G11 Experimental Drug
89334925|NCT03918967|Experimental|CT-G20|CT-G20 Experimental Drug
89334926|NCT03918967|Placebo Comparator|CT-G11 Placebo|
89334927|NCT03918967|Placebo Comparator|CT-G20 Placebo|
89334928|NCT03477890|Active Comparator|Intervention group (coronary function test results disclosed)|Coronary function tests are measured and disclosed to the clinician for re-evaluation of the initial diagnosis and treatment as compared with initial angiography. The intervention involves measurement of FFR, CFR, IMR and RRR in a major coronary artery followed by reactivity testing using incremental doses of acetylcholine (10-4 Molar (M), 10-5 M, 10-6 M) to assess endothelial function, bolus of ACh (10-4 M; 100 micrograms) for vasospasm, followed by glyceryl trinitrate (300 micrograms). FFR will be measured in all arteries with a diameter >=2.5 mm and a stenosis 40% to 90% in severity. Endotypes are based on criteria for abnormal coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, vasospastic angina, microvascular angina, mixed (ie both vasospastic and microvascular disorders), endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
89334929|NCT03477890|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking and protocol adherence is prospectively monitored.
89334930|NCT04464850|Experimental|Intravenous iron|Iron sucrose 200 mg every 2 weeks Folic acid 5 mg/day B6 10 mg/day
89334931|NCT04464850|Active Comparator|Oral iron|Ferrous fumarate 600 mg/day Folic acid 6.5 mg/day B6 15 mg/day
89334932|NCT03921463||caesarean section|
89334933|NCT03921463||vaginal delivery|
89334934|NCT01356758||Psoriasis topical treatment|Psoriasis topical treatment. No systemic drugs.
89334935|NCT01356758||Psoriasis biological treatment|Psoriasis biological treatment. Anti-Tnf and anti-il12/23.
89334936|NCT01356758||Severe atopic dermatitis|Severe atopic dermatitis
89334937|NCT01356758||Control|No intervention. No inflammatory skin disease.
89334938|NCT01229137||Right Ventricular Cohort|Right Ventricle wtih SRD-1 conversion
89334939|NCT01229137||Left Ventricular Cohort|Left Ventricle with SRD-1 conversion
89334940|NCT01229137||Right Atrium Cohart|Right atrium cohort with SRD-1 conversion
89334941|NCT03510832||STEMI patients undergoing Emergent PCI|
89334942|NCT01356836||Good-poor collateral|Patients who had good and poor collaterals formed 2 groups
89334943|NCT01356836||Good collateral, Poor collateral|
89334944|NCT02529007|Active Comparator|Standard|These patients have standard colonoscopy performed
89334945|NCT02529007|Experimental|Endocuff|These patients have colonoscopy performed with the endo-cuff attached to the end of the colonoscope
89334946|NCT01358084|Experimental|Arm A: NGR-hTNF + Best Supportive Care|NGR-hTNF + Best Supportive Care
89334947|NCT01358084|Placebo Comparator|Arm B: Placebo + Best Supportive Care|Placebo + Best Supportive Care
89334948|NCT04464382|Experimental|Outpatient appendectomy|"Patients with acute uncomplicated appendicitis that require emergency appendectomy. The intervention will be the classic.Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed.~Patients after surgery will go to the anesthetic recovery room without requiring hospital admission. The degree of satisfaction of the quality of the service and the care that must be completed before discharge and after surgery will be recorded.~1 phone review call will be made per month +/- 30 days in order to assess the safety and satisfaction of the procedure."
89523575|NCT02791321|Other|Patients with ADS-MR|Patients presenting Autism Spectrum Disorder and mental retardation who are evaluated for their ADS severity, their adaptative and intellectual functioning, psychiatric and somatic comorbidities
89334949|NCT04464382|Active Comparator|Hospitalization appendectomy|"Patients with acute uncomplicated appendicitis that require emergency appendectomy. The intervention will be the classic.Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed.~Patients after surgery will go to the anesthetic recovery room and then be admitted to hospital beds, to be discharged within approximately 12 hours.~1 phone review call will be made per month +/- 30 days in order to assess the safety and satisfaction of the procedure."
89334950|NCT02297464|Experimental|Eggs - 2 per day for breakfast|Participants will consume 2 eggs per day for breakfast for 4 weeks of the study.
89334951|NCT02297464|Experimental|Oatmeal - 1 packet per day for breakfast|Participants will consume 1 packet of oatmeal per day for breakfast for 4 weeks of the study.
89334952|NCT01134523|Active Comparator|Group A: EC-T regimen|
89334953|NCT01134523|Experimental|Group B: ET regimen|
89334954|NCT01349738||Positive Group|Positive for ASB
89334955|NCT01349738||Negative Group|Negative for ASB
89334956|NCT03515434|Active Comparator|ESP Block|Ultrasound-guided Erector spinae plane (ESP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
89334957|NCT03515434|Active Comparator|TAP Block|Ultrasound-guided Transversus abdominis plane (TAP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
89334958|NCT03515434|Sham Comparator|Control|The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
89334959|NCT05401747|Other|Healthy lifestyle intervention|All cases will be assessed before and after intervention for cognitive changes.
89334960|NCT01358162|Experimental|SQ109|300 mg of SQ109, orally, given daily for 14 consecutive days
89334961|NCT01358162|Placebo Comparator|Placebo|Placebo given orally, daily for 14 consecutive days
89334962|NCT02302768|Placebo Comparator|Placebo|Patients randomized to receive same pharmaceutical form (capsule) used for the two Semet groups, with the same excipients but the active drug.
89334963|NCT02302768|Active Comparator|80-Semet|Patients randomized to receive selenomethionine at 80 mcg per day.
89334964|NCT02302768|Active Comparator|160-Semet|Patients randomized to receive selenomethionine at 160 mcg per day.
89334965|NCT03921775|Experimental|Treatment group A|IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance
89334966|NCT03921775|Active Comparator|Treatment B|IV pumping of propofol at 120~150mg/kg/h for anesthesia induction and 3~12mg/kg/h for anesthesia maintenance
89334967|NCT01356992|Active Comparator|Clexane® (enoxaparin - Sanofi)|
89334968|NCT01356992|Experimental|Versa® (enoxaparin - Eurofarma)|
89334969|NCT02297542|Active Comparator|Flu Vaccine SD|Fluzone Standard Dose Influenza Vaccine
89334970|NCT02297542|Active Comparator|Flu Vaccine HD|Fluzone High Dose Influenza Vaccine
89334971|NCT03739879|Experimental|Inspiratory muscle training (IMT)|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
89334972|NCT01350050|Active Comparator|articaine|Pharyngeal anesthesia with articaine 4% or placebo should randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of Articaine 4%solution or placebo (NaCl 0,9%) will be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with articaine (or placebo) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
89334973|NCT01350050|Placebo Comparator|placebo|Pharyngeal anesthesia with placebo or articaine 4% should be randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of placebo or Articaine 4% solution should be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with placebo(or articaine) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
89334974|NCT03918889|Experimental|dexmedetomidine|patients receive dexmedetomidine infusion
89334975|NCT03918889|Experimental|midazolam|patients receive midazolam infusion
89334976|NCT01357070|Active Comparator|Brocco-sprout homogenate|
89334977|NCT01357070|Sham Comparator|Alfalfa sprout homogenate|
89334978|NCT02297620||Suglat group|
89334979|NCT01134679|Experimental|Phone calls|Disease management with close patient follow-up, using phone calls.
89334980|NCT03739801|Experimental|Treatment (ramucirumab, liposomal irinotecan[MM-398])|Patients receive ramucirumab IV over 30 minutes and MM-398 IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89334981|NCT03512236|Experimental|BC Pram Ins|Single subcutaneous injection of BC Pram Ins + injection of placebo (0.9% NaCl) to ensure the double dummy
89334982|NCT03512236|Active Comparator|Symlin® and Humulin®|Simultaneous subcutaneous injections avec pramlintide and human insulin
89334983|NCT03512236|Active Comparator|Humalog®|Single subcutaneous injection of lispro + injection of placebo (0.9% NaCl) to ensure the double dummy
89334984|NCT01230073|Active Comparator|ICD traditional follow-up|ICD with traditional follow-up in the outpatient clinic
89334985|NCT01230073|Active Comparator|Home-Monitoring|Home-Monitoring
89334986|NCT01229293|Experimental|Resurfacing Total Hip Arthroplasty|A hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint. Articular surface replacement ASR, DePuy posterolateral approach used (RTHA)
89334987|NCT01229293|Active Comparator|Standard Total Hip Arthroplasty (THA)|A standard 28 mm head uncemented THA
89334988|NCT02301052|Placebo Comparator|placebo|placebo topical cream 2 cc twice daily for 3 weeks
89334989|NCT02301052|Active Comparator|Anti-hemorrhoid topical cream drug|Anti hemorrhoid topical cream as a standard drug 2 cc twice daily for 3 week
89334990|NCT02301052|Active Comparator|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
89334991|NCT01134835|Experimental|IMP Pioglitazone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
89334992|NCT01134835|Placebo Comparator|Placebo|Placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
89334993|NCT02297776||CPC score 1 to 2|The patients with CPC score 1 to 2 judged half a year after cardiac arrest
89334994|NCT02297776||CPC scores 3 to 5|The patients with CPC score 3 to 5 judged half a year after cardiac arrest
89334995|NCT03920917|Experimental|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm second or third cryoballoon catheter will be used.~Esophageal temperature will be monitored to prevent esophageal injury.~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and cryoablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
89334996|NCT03920917|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
89334997|NCT03510676|Experimental|NiTiDES|Single arm
89334998|NCT03918733|Experimental|surgical treatment|surgical treatment of failed root canal treated teeth following secondary root canal treatment.
89334999|NCT03918733|Experimental|Non surgical retreatment|Non surgical retreatment of failed root canal treated teeth
89335000|NCT03511924|Experimental|Intradialytic resistance training|During the 12-week intradialytic training plan subjects will be performed 3 to 5 sets of 3 different lower extremities exercises, each set will consist of 12 up to 18 repetitions of a single exercise. Subjects will take 1 to 2 minutes rest between each set. The resistance training will be realized 3 times per week and will be performed during haemodialysis therapy.
89335001|NCT03511924|No Intervention|Control programme|Control subjects will receive no intervention during the 12-weeks of the experiment. Through the 12-week control period, all participants will be instructed to maintain a standard treatment regimen and to maintain their customary dietary and physical activity patterns.
89335002|NCT02303002|Experimental|Dose A|Dose A: Botulinum Toxin Type A
89335003|NCT02303002|Experimental|Dose B|Dose B: Botulinum Toxin Type A
89335004|NCT02303002|Experimental|Dose C|Dose C: Botulinum Toxin Type A
89335005|NCT02303002|Active Comparator|Dose D|Dose D: Botulinum Toxin Type A
89335006|NCT02303002|Placebo Comparator|Dose E|Dose E: Placebo
89335007|NCT02297854|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
89335008|NCT02297854|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., San Francisco
89335009|NCT05401669|Experimental|Trans-radial artery access|
89335010|NCT05401669|Active Comparator|Trans-femoral Artery access|
89335011|NCT03515356|Experimental|MI-Walk Intervention|"Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.~In addition, subjects will receive 8-weeks of motivational enhancement therapy- and a home-based aerobic walking intervention. Motivational interviewing will be delivered with concurrent feedback and motivational techniques in 30-45-minute sessions at intervention orientation (T1), 2 weeks (T3), and 4 weeks (T4)."
89335012|NCT03515356|Active Comparator|PA Education Alone|Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.
89335013|NCT05401591|Active Comparator|Milk protein|
89335014|NCT05401591|Experimental|Whole cell chlorella|
89335015|NCT05401591|Experimental|Cracked cell chlorella|
89335016|NCT05401591|Experimental|Spirulina|
89335017|NCT03515278|Experimental|suprascapular nerve block (SCNB) group|"SCNB with physiotherapy. Suprascapular nerve block: Ultrasound-guided SCNB by 3 c.c. 1% lidocaine with 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
89335018|NCT03515278|Active Comparator|intra-articular corticosteroid injection (IACI) group|"IACI with physiotherapy. Intra-articular steroid Injections: Receive intra-articular corticosteroid injection.Ultrasound-guided IACI with 3c.c. 1% lidocaine and 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
89335019|NCT01230151|Active Comparator|Clinical|Stimulation settings predetermined clinically (Clinical)
89335020|NCT01230151|Experimental|Model|stimulation settings derived from a patient-specific computer-based model (Model)
89335021|NCT03511768|Experimental|18F-AlF-NOTA-octreotide PET/CT|One injection of the radioligand 18F-AlF-NOTA-octreotide
89335022|NCT01134991|Placebo Comparator|Topical Minocycline Foam FXFM244 Placebo|Minocycline Foam FXFM244 Placebo
89335023|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 1%|Minocycline Foam FXFM244, 1%
89335024|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 4%|Minocycline Foam FXFM244, 4%
89335025|NCT02303080|Placebo Comparator|Control (WPM 0)|400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
89335026|NCT02303080|Active Comparator|WPM 30|400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
89335027|NCT02303080|Active Comparator|WPM 50|400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
89335028|NCT02303080|Active Comparator|MC 50|400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
89335029|NCT01135147|Experimental|Diet|Patients treated with diet and physical therapy for the entire 6 months of the study
89335030|NCT01135147|Active Comparator|Surgery|Patients undergoing adenotonsillectomy at some point of the study period
89335031|NCT03515200|Experimental|Treatment|"This study will be done in two parts: Part 1: Dose escalation and Part 2: Dose expansion.~In Part 1 - Dose escalation: Patients that lack Ph+ or Ph-like ALL, palbociclib, initially at 50mg/m2/day, 40% of the adult MTD, will be administered on Days 1-5 and 11-15, and escalated based on tolerability. If our highest dosing of 100mg/m2/day is tolerated, we will have a final dose level that receives an additional 10 days of palbociclib (Days 1-5, 11-15, and 21-30).~For patients that are Ph+ or have Ph-like ALL that are also receiving dasatinib or ruxolitinib: palbociclib, initially at 75mg/m2/day, 60% of the adult MTD, will be administered on Days 1-5 and 11-15 and escalated based on tolerability.~In Part 2 - Dose expansion: After determination of dose in Part 1, an additional 10 patients will be enrolled to confirm tolerability."
89335032|NCT03918265|Experimental|Efficiency of tacrolimus on autoimmune cytopenia|"A prospective research of the tacrolimus efficiency on refractory autoimmune cytopenia patients. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
89335033|NCT03920839|Experimental|INCMGA00012 + gemcitabine/cisplatin|
89335034|NCT03920839|Experimental|INCMGA00012 + pemetrexed/cisplatin|
89335035|NCT03920839|Experimental|INCMGA00012 + pemetrexed/carboplatin|
89335036|NCT03920839|Experimental|INCMGA00012 + paclitaxel/carboplatin|
89335037|NCT01131793|Experimental|RF Guidewire|
89335038|NCT03135548|Experimental|Spesolimab (low dose)|
89335039|NCT03135548|Experimental|Spesolimab (high dose)|
89335040|NCT03135548|Placebo Comparator|Placebo|
89335041|NCT01135225|Active Comparator|PROMUS(TM) Element(TM) Coronary Stent|PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent System
89335042|NCT01135225|Experimental|Evolution Coronary Stent A|Evolution Everolimus-Eluting Monorail Coronary Stent System
89335043|NCT01135225|Experimental|Evolution Coronary Stent B|Evolution Everolimus-Eluting Monorail Coronary Stent System
89335044|NCT02297932|Experimental|Strength training|The intervention will consist of a Home-based Resistant Training Intervention. Participants randomized to the home-based progressive resistance training (PRT) condition and will be provided with a training manual, an exercise log book, and resistance training equipment. The training manual will consist of a detailed description of the exercises to be performed and how to progress over 4-months. The exercise logbook will allow participants to provide a detailed recording of each training session. Home-based PRT equipment will consist of elastic bands (Thera-Band®, Hygenic Corporation, Akron, OH) and weighted vests.
89335045|NCT02297932|Active Comparator|Stretching|Individuals in the comparator group will participate in a four month home-based stretching program developed by the National Multiple Sclerosis Society (NMSS). They will be provided text-based materials and asked to provide a weekly log book. In efforts to equate the attention received, individuals will come to KF at the same frequency as those receiving the PRT intervention and will also engage in the same number of sessions to assess their adherence to the program.
89335046|NCT02301130|Experimental|mogamulizumab + MEDI4736 (Durvalumab)|"During Parts 1 and 2, mogamulizumab and MEDI4736 (Durvalumab) are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1A to 4A, increased doses of mogamulizumab and MEDI4736 (Durvalumab) are administered.~Part 2 (Cohort Expansion Phase)~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
89335047|NCT02301130|Experimental|mogamulizumab + tremelimumab|"During Parts 1 and 2, mogamulizumab and tremelimumab are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1B to 4B, increased doses of mogamulizumab and tremelimumab are administered.~Part 2 (Cohort Expansion Phase)~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
89335048|NCT03920605|Active Comparator|Peginterferon alfa group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
89335049|NCT03920605|Active Comparator|Combination group|50 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week and meanwhile oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 48 weeks. Then they would receive treatment of oral TDF 300 mg once per day from 49 to 144 weeks.
89335050|NCT01361360||control|
89335051|NCT01361360||hypercapnia|
89335052|NCT02301208|Active Comparator|Low dose cisplatin arm|concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
89335053|NCT02301208|Active Comparator|High dose cisplatin arm|concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
89335054|NCT02301208|Experimental|Low dose nedaplatin arm|concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
89335055|NCT02301208|Experimental|High dose nedaplatin arm|concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
89335056|NCT01230229|Active Comparator|Stenting|Active treatment group
89335057|NCT01230229|Placebo Comparator|Conservative treatment|Best medical treatment
89335058|NCT03511612|Other|Pattern A|Intervention : Each subject has 3 measurements of ABI starting with oscillometric device and then using the Doppler method.
89335059|NCT03511612|Other|Pattern B|Intervention : Each subject has 3 measurements of ABI starting with Doppler method and then using oscillometric device.
89335060|NCT01135303|Experimental|VistaO2 device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
89335061|NCT01132963|Experimental|Outdoor Shoes|Patient will be asked to do balance tests while wearing outdoor shoes.
89335062|NCT01132963|Active Comparator|Pillow Paws Slippers|Patient will be asked to complete balance tests while wearing standard hospital issue 'Pillow Paw' slippers on their feet
89335063|NCT02298010||Adjuvant chemotherapy group|Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.
89335064|NCT02298010||Only surgery group|Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy
89335065|NCT03510520|Experimental|Medium Cut-Off Haemodialysis (Theranova)|Participants will receive medium cut-off haemodialysis treatment for 6 months in total (3 times per week treatment).
89335066|NCT03510520|Active Comparator|On-Line Haemodiafiltration|Participant will remain on their usual on-line haemodiafiltration (HDF) treatment for the 6 month study duration (3 times per week treatment).
89335067|NCT01131871|Active Comparator|Standard Behavioral Weight Loss Intervention|
89335068|NCT01131871|Experimental|Enhanced Weight Loss Intervention|
89335069|NCT05091398|Active Comparator|Group I|ultrasound-guided erector spinae block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
89335070|NCT05091398|Active Comparator|Group II|ultrasound-guided paravertebral block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
89335071|NCT05091398|Active Comparator|Group III|ultrasound-guided intercostal nerve block on T4 and T6 levels after the anesthesia induction and turning the patient in the lateral position
89335072|NCT02303314|Other|Drug: Trigonella Foenum-graecum|in this group patients use Trigonella Foenum-graecum seed extract twice daily.
89335073|NCT02303314|Other|Drug: Placebo|in this group patients use placebo twice daily.
89335074|NCT02528929|Active Comparator|At-risk serology|Gluten-free diet
89335075|NCT02528929|Active Comparator|Not at-risk serology|Gluten-free diet
89335076|NCT05189678||frailty group|Modified Frailty index score greater than or equal to 0.21
89335077|NCT05189678||non-frailty group|Modified Frailty index score is less than 0.21
89335078|NCT01229605|Experimental|Single Arm|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
89335079|NCT03515122||Persons with Spinal cord injury (SCI)|The total population of a specified group of persons with traumatic SCI will be invited to participate.
89335080|NCT03515122||Matched control group|A matched control group of the general population at a ratio of 3-4 to each person with SCI will be recruited from the Swedish Cardiopulmonary and Bioimage Study.
89335081|NCT01319006|Experimental|GSK1278863A 100mg (X90=13um)|single dose
89335082|NCT01319006|Experimental|GSK1278863A 100mg (x90=29Um)|single dose
89335083|NCT01319006|Experimental|GSK1278863 100mg (X90=41um)|single dose
89335084|NCT05401435|Experimental|Blood pressure and heart rate measurement|Resting blood pressure and heart rate measurement regularly one value in the morning and evening for 28 days. The volunteer measures the parameters simultaneously on both devices (smartwatch and digital tonometer). In total, each participant will undergo this measurement 56 times.
89335085|NCT03511456||FLLDH-PELD|Extraforaminal LDH patients received PELD operation
89335086|NCT01232101|Active Comparator|covered self expandable metallic stents|Patients with bile malignant bile duct strictures are randomized to covered or uncovered stent
89335087|NCT01232101|Active Comparator|Uncovered self expandable metallic stent|
89335088|NCT01319084||ARMES group|Surgeons who watch Tilepro program before da Vinci Robotic Surgery.
89335089|NCT01319084||normal group|Surgeons who do not watch Tilepro program before da Vinci Robotic Surgery.
89335090|NCT03511300|Placebo Comparator|Standard Instructions|Participants will receive standard instructions for cognitive tasks.
89335091|NCT03511300|Experimental|Goal Setting Instructions|Participants will receive goal-setting instructions for cognitive tasks.
89335092|NCT01358240|Experimental|Econazole Nitrate Foam 1%|Study medication
89335093|NCT01358240|Placebo Comparator|Vehicle Foam|Placebo medication
89335094|NCT01358240|Active Comparator|Econazole Nitrate Cream 1%|Econazole Nitrate Cream 1%
89335095|NCT01358240|Sham Comparator|Placebo Cream|Placebo Cream
89335096|NCT01131949|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
89335097|NCT01131949|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
89335098|NCT03511222|Experimental|Dose Escalation: Vorolanib + Nivolumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level.~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
89335099|NCT03511222|Experimental|Dose Escalation: Vorolanib + Pembrolizumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level~Patients receiving pembrolizumab will get it on an outpatient basis as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 200 mg on Day 1 of each 21-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
89335100|NCT03511222|Experimental|Vorolanib + Nivolumab (Small Cell Lung Cancer)|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at 300 mg daily~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
89335101|NCT01230385|Experimental|Lersivirine 500 mg QD fasted (wet granulated tablet)|
89335102|NCT01230385|Experimental|Lersivirine 500 mg QD fed (wet granulated tablet)|
89335103|NCT01230385|Experimental|Lersivirine 750 mg QD fasted (wet granulated tablet)|
89335104|NCT01230385|Experimental|Lersivirine 750 mg QD fed (wet granulated tablet)|
89335105|NCT01230385|Active Comparator|Lersivirine 500 mg QD fasted (dry granulated tablet)|
89335106|NCT01350206|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
89335107|NCT01350206|Experimental|TACE group|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
89335108|NCT04464148|Experimental|Pregnenolone 250 BID > Pregnenolone 400 BID|For week 0-5 participants will receive pregnenolone 250 mg twice a day (total 500 mg/day). For weeks 6-8 participants will receive 400 mg twice a day (800 mg/day), if the drug is well tolerated.
89335109|NCT01230463|Active Comparator|15 mg ketorolac IV|
89335110|NCT01230463|Active Comparator|30 mg ketorolac IV|
89335111|NCT01358318|Placebo Comparator|Control|
89335112|NCT01358318|Experimental|Soy Protein|
89335113|NCT01358318|Experimental|Soy Fiber|
89335114|NCT01358318|Experimental|Soy Protein and Soy Fiber|
89335115|NCT04464460|Experimental|Cohort 1: TAK-671 Low Dose|TAK-671 low dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
89335116|NCT04464460|Experimental|Cohort 2: TAK-671 High Dose|TAK-671 high dose or TAK-671 placebo-matching, infusion over a 90-minute period, intravenously, once on Day 1.
89335117|NCT03920371|Experimental|gamma camera imaging|hand held camera
89335118|NCT01358396||HBA1c|
89335119|NCT03510364|Experimental|Dietary intervention|All participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days.
89335120|NCT01135615|Other|Sevelamer|
89335121|NCT01135615|Other|calcium acetate|
89335122|NCT01358474||PD Subjects|Subjects diagnosed with Parkinson's disease (PD)
89335123|NCT01358474||At-risk for PD|Subjects at-risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations)
89335124|NCT01358474||Healthy Controls|Healthy volunteers
89335125|NCT03511144|Active Comparator|Measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
89335126|NCT03511144|Active Comparator|Ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
89335127|NCT01229683||Shoulder Surgery|Patients will be given an interscalene nerve block and then strength and sensation of the hand and forearm will be tested to determine if the block is helping to anesthetize these areas.
89335128|NCT01361516|Experimental|Intravenous sedation, General anaesthesia|IV sedation-ESWL under spontaneous respiration GA - ESWL under controlled respiration
89523576|NCT02781025||Oligometastatic Disease|Patients with oligometastatic cancer, defined as biopsy proven disease involving at least one organ other than the primary tumor organ. Regional lymph node metastases are not considered metastatic.
89523577|NCT02678533|Experimental|Fanconi anemia|G-CSF and Plerixafor
89335129|NCT03920137|Active Comparator|Active- UP-ST|The intervention will be the UP-ST therapy sessions. Treatment will be delivered using the new UP-ST protocol that will be developed in Phase I by integrating components of smoking cessation treatments (e.g. using the nicotine patch) with the theoretical model and treatment components of the existing UP treatment protocol, which includes both a therapist14 and patient12 manual. The UP-ST will maintain the same focus on transdiagnostic mechanisms of change as in the original UP, but will be adapted to integrate the smoking cessation focus and concurrent use of NRT. Thus, the investigators can successfully adapt and develop the new UP-ST to be delivered in eight 90-minute sessions and will be able to incorporate content from each of the 8 modules of the UP in the new UP-ST protocol.
89335130|NCT03920137|Experimental|Control- Standard|The Intervention will be the standard therapy sessions. Participants will receive a standard smoking cessation treatment based on the most recent clinical practice guideline from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence19. The investigative team has considerable expertise in developing and evaluating behavioral and pharmacological treatments for smoking cessation. Treatment will be delivered in eight, 90-minute sessions over an eight-week period.
89335131|NCT03739957|Experimental|BPCO Media Kit|The kit is composed of a Bluetooth pulse oximeter and an APP for Android system downloadable from Google Play and installed on the Android smartphone of the patient from version 4.1 on.
89335132|NCT03132610|Active Comparator|Experimental group|Conventional Therapy + Xiyanping injection(andrographolide sulfonate)
89335133|NCT03132610|Placebo Comparator|control group|Conventional Therapy + Xiyanping injection simulation/andrographolide sulfonate simulation(0.9% normal saline)
89335134|NCT01133041|Experimental|NBI observation|
89335135|NCT01133041|Experimental|i-Scan observation|
89335136|NCT02301442|Experimental|Exercise + behaviour change intervention|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + behaviour change intervention will be delivered by physiotherapists between weeks 1 and 11.
89335137|NCT02301442|Active Comparator|Exercise + control education|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + control education intervention will be delivered by physiotherapists between weeks 1 and 11.
89335138|NCT01350284|Experimental|Dietary supplementation|3g of cinnamon or placebo control were added to a test-meal.
89335139|NCT02298088|Active Comparator|Ticagrelor 180 mg|Patients assigned to Ticagrelor will receive oral Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
89335140|NCT02298088|Active Comparator|Clopidogrel|"Patients will take the 300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.~For patients with > 75 years the recommended load dose is 75 mg instead 300 mg."
89335141|NCT01133119|Active Comparator|Treatment Group 1|
89335142|NCT01133119|Experimental|Treatment Group 2|
89335143|NCT01350362|Experimental|Tideglusib 1000 mg Q.D.|Group dosed with 1000 mg once daily for 26 weeks/extension
89335144|NCT01350362|Experimental|Tideglusib 1000 mg Q.O.D.|Group dosed with 1000 mg once every other day for 26 weeks/extension
89335145|NCT01350362|Experimental|Tideglusib 500 mg Q.D.|Group dosed with 500 mg once daily for 26 weeks/extension
89335146|NCT01350362|Placebo Comparator|Placebo|Once daily administration for 26 weeks/extension
89335147|NCT01133197||controls|No hand arthritis
89335148|NCT01133197||CMC Arthritis|Patients with arthritis
89335149|NCT01361750|Experimental|gastirc tube group|conduit will be perfomed by narrowed gastric tube
89335150|NCT01361750|No Intervention|control group|conduit will be traditional subtotal stomach without any surgical modification
89335151|NCT01230541|Placebo Comparator|Placebo|Placebo
89335152|NCT01230541|Active Comparator|Udenafil|Udenafil daily tablet
89335153|NCT01361828||Patients with choroidal neovascularization|CNV due to Age-Related Macular Degenerations and Myopia were included.
89335154|NCT01361906|No Intervention|Untreated control|Untreated control
89335155|NCT01361906|Experimental|Sensomotoric training|Treatment with Sensomotoric training
89335156|NCT01229761|Active Comparator|infant cotrimoxazole|
89335157|NCT01229761|Placebo Comparator|infant placebo|
89335158|NCT01229761|Active Comparator|exclusive breastfeeding for 6 months|
89335159|NCT01229761|Active Comparator|exclusive breastfeeding for 12 months|
89335160|NCT03510286||Pregnant women|Pregnant women attending ANC clinics in Techiman Holy Family Hospital and Kintampo North and South districts (all hospitals and clinics inclusive where ANC services are provided) are the primary participant group- primarily women of reproductive age. Pregnant women attending routine ANC will be enrolled. In addition to routine ANC, pregnant women will be tested with the Test-it™ PrCr Urinalysis Strips. Pregnant women are a potentially vulnerable population whose participation in this research is necessary given the target use case for this diagnostic tool: providing reliable and accurate point of care screening of proteinuria in ANC settings. The legal age of consent in Ghana is 18 years and women under the age of 18 will not be recruited for this study.
89335161|NCT01358552||Néevo®/NéevoDHA®|Subjects who have been prescribed Néevo/NéevoDHA® daily.
89335162|NCT01229839|Experimental|infusion group|Infusion of anticancer agent followed by Embolization
89335163|NCT01229839|Experimental|lipiodol chemotherapy group|Infusion of mixture of anticancer agent and lipiodol followed by Embolization
89335164|NCT01350440|Experimental|IVIG|Intravenous Immune Globulin
89335165|NCT03514810|Placebo Comparator|Sertralin & Ketoprofen in MDD|To compare the median of Beck Depression Inventory-II (BDI-II) score of MDD patients after treatment with sertralin (50mg) daily+placebo and after treatment with combination of (sertralin & ketoprofen) for two months.
89335166|NCT03514810|Experimental|Interleukins in MDD after treatment|Some Interleukines level were estimated before and after treatment with sertralin 50 mg in combination with either placebo or ketoprofen 100mg daily.
89335167|NCT01137409||Suspected or Diagnosed with Coronary artery disease|All patients with suspected or previously diagnosed coronary artery disease
89531636|NCT05867368|Experimental|HABIT-VR|Children will receive hand arm bimanual intensive therapy, however, it will be through the use of custom virtual reality games. Children will receive 40 hrs of one-on-one bimanual therapy, delivered through the virtual reality games. Activities will be self-selected, but all games have a task constraint, requiring both hands to succeed.
89335168|NCT02306434|Active Comparator|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
89335169|NCT02306434|Other|Standard care-Counselling|Counselling for childbirth fear is given by the antenatal care midwife and by specially trained midwives working in collaboration with obstetricians at approximately 3-5 face to face counselling sessions. Often a visit to the delivery unit is included in the program and a care plan for the coming birth.
89335170|NCT01233193|Experimental|Intervention|The intervention group receive an pharmacist intervention (health education, Home Blood Pressure Monitoring and Referral to physician as needed) This group will be followed for 6 months
89335171|NCT01233193|No Intervention|Control|The control group receive usual care in the community pharmacy
89335172|NCT01232179|Active Comparator|conventional prp|
89335173|NCT01232179|Active Comparator|targeted PRP|
89335174|NCT01137487|Other|residual gastric volume|
89335175|NCT01137487|Other|residual gastric volume not monitored|
89335176|NCT02301598|Experimental|FS-ALK|Femtosecond laser-assisted maximum thickness anterior lamellar keratoplasty (FS-ALK) was performed for 11 eyes of 11 patients with advanced keratoconus and 2 eyes of 2 patients with superficial corneal scattering.
89335177|NCT03510130|Experimental|Routine leg movement|Intervention group- In the second stage of labor, attending physician or nurse will help the participant in routine leg movements every 20-30 minutes.
89335178|NCT03510130|No Intervention|Control group|Control group which includes women during the second stage of labor with no intervention (routine leg movement).
89335179|NCT05401123|Experimental|Comparison of Breast Milk Content in Mothers Using a Expressing Pump and Milking by Hand|"Randomization In order to ensure similarity between groups; Stratified block randomization was used to assign the women in the sample group to the experimental and control groups. According to the stratified block randomization method, the imbalances that may occur in the experimental and control groups are limited. In this method, block randomization is performed within each stratum after stratification according to risk factors (Akın & Koçoğlu, 2017; Kanık, Taşdelen & Erdoğan, 2011). Since the mode of delivery affects the content of breast milk, women will be divided into two layers as vaginal delivery and cesarean section in terms of delivery type (Table 1).~In order to determine the strata group of the woman who was found to meet the research criteria and accepted to participate in the study, a list of assignments was created through the website www.randomizer.org by making 6 blocks with a combination of 4 .~Experiment: A Control: B"
89335180|NCT02301676|Active Comparator|General anesthesia & Control|"After the surgery, the patients are discharged from the hospital, investigators will check the postoperative cognitive function 4 times: 1weak, 3months, 6months, 1 year later using the intervention Korean version of telephone interview for cognitive status (TICS). The test will be administered to spouse simultaneously by telephone."
89335181|NCT02301676|Active Comparator|Sevoflurane & Propofol & Dexmedetomidine|The anesthetic methods are divided into the following 3 kinds: Sevoflurane, Propofol, Dexmedetomidine. These anesthetic drugs are used in general anesthesia generally.
89335182|NCT01137565|Experimental|AMG 853|
89335183|NCT01137565|Placebo Comparator|Placebo|
89335184|NCT02301754|Experimental|INVAC-1|"INVAC-1 at escalating doses of 100, 400 and 800 µg will be given as a single agent by intradermal injection (Q 4 weeks x 3 cycles), always combined with electroporation.~Each patient will receive 3 cycles, unless motivated treatment interruption."
89335185|NCT03510052|Other|Diet Modification Pilot Program|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
89335186|NCT01133353|Experimental|Tetrabenazine MR|
89335187|NCT01133353|Placebo Comparator|Placebo|
89335188|NCT01135927|Experimental|A|
89335189|NCT01135927|Active Comparator|B|
89335190|NCT02301910|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
89335191|NCT02301910|Active Comparator|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~55 to <60 30 mg 6 ml~60 to <70 35 mg 7 ml~70 to <80 40 mg 8 ml~80 to <90 45 mg 9 ml~90 50 mg 10 ml"
89335192|NCT01585753||Arm 1|NRTI and PI
89335193|NCT01585753||Arm 2|Maraviroc + PI
89335194|NCT01585753||Arm 3|maraviroc + NRTI
89335195|NCT02306512|Active Comparator|Standard vs. IF MART-1|"Samples removed with MMS within the first 3 mm margin from the tumor will be the first section. They will be processed as a conventional H&E frozen section and section stained with IHC MART-1. Samples removed with MMS within 3-6 mm from tumor margin will be the second section. They will be processed with fluorescent MART-1 antibodies. Based on the pre-defined characteristics MMS surgeon will evaluate each MART-1 immunofluorescent section as no evident melanoma or possible melanoma or present melanoma. Dermatopathologist will secondarily review each section scoring them in the same manner. If standard H&E, IHC, or immunofluorescence is recorded as present melanoma or possible melanoma a third section from 6-9mm will have the same procedure described before."
89335196|NCT02306512|Active Comparator|IF MART-1 versus IF cocktail|In the second arm of the study, assuming that immunofluorescence with MART-1 proves to be superior or at least equivocal to regular MART-1 IHC, the same method will be applied, but the control sections will be stained with fluorescent MART-1 antibodies and compared to a section stained with a cocktail of fluorescent melanocytic antibodies.
89335197|NCT01137721||Pre-Hydroxyurea - subjects with SCD|Patients with a diagnosis of HbSS (sickle cell anemia) or HbS/ß0-thalassemia (beta thalassemia) who will be treated with hydroxyurea therapy.
89335198|NCT01137721||Sibling control|Sibling control with no diagnosis of HbSS or HbS/ß0-thalassemia.
89335199|NCT01137721||Observational - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia.
89335200|NCT01137721||Pre-transfusion - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia who will be treated with transfusion therapy.
89335201|NCT03509818|Experimental|Plyometric|Effects of plyometric acute exercise
89335202|NCT03509818|Experimental|Aerobic|Effects of aerobic acute exercise
89335203|NCT01136005|Experimental|dexpanthenol 5% cream|dexpanthenol 5% cream
89335204|NCT01136005|Active Comparator|cetomacrogol cream|a vehicle
89335205|NCT03507868||Group 1|Periodontally healthy individuals
89335206|NCT03507868||Group 2|Chronic periodontitis patients
89335207|NCT05400967|Experimental|68Ga-FAPI PET/CT for scan and 177Lu-EB- FAPI for therapy|All patients diagnosed with metastatic tumors underwent 68Ga-FAPI PET/CT scan. If the PET/CT showed high FAPI expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-FAPI for therapy.
89335208|NCT02306590|Experimental|Study Intervention|High caloric fatty diet for drinking (100% lipids, 4.5 kcal/ml) 405 kcal/90 ml/day in addition to daily food intake and standard of care; corresponding to an additional intake of 45 g fat per day
89335209|NCT02306590|Placebo Comparator|Placebo|Placebo drinking solution 8 kcal/90ml/day in addition to daily food intake and standard of care
89335210|NCT01233271|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
89335211|NCT03917953|Experimental|Arm I|Patients receive transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
89335212|NCT03917953|Sham Comparator|Arm II|Patients receive sham transcutaneous electrical acupoint stimulation therapy twice weekly for 4 weeks.
89335213|NCT03509740|Experimental|tramadol|Intravenous 100 mg tramadol in 100 ml saline with slow infusion over 10 minutes.
89335214|NCT03509740|Active Comparator|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion over 10 minutes.
89335215|NCT01136083|Experimental|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
89335216|NCT01136083|Active Comparator|Control group|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
89335217|NCT03507712|Active Comparator|Symmetrical IO weakening.|Same surgery in both eyes
89335218|NCT03507712|Active Comparator|Asymmetrical IO weakening.|Different amounts or different surgery in each eye
89335219|NCT03918187|Experimental|bupivacaine|12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
89335220|NCT03918187|Active Comparator|nalbuphine|12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
89335221|NCT03918187|Active Comparator|midazolam|12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .
89335222|NCT02302144|Experimental|Early Multi-Ex-PD|Immediately following enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
89335223|NCT02302144|Experimental|Late Multi-Ex-PD|Three months after enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
89335224|NCT01233349|Experimental|Litramine|
89335225|NCT01233349|Placebo Comparator|Placebo|
89335226|NCT05472181|Active Comparator|rTMS (Repetitive TMS)|The rTMS group will receive 30 minutes of excitatory rTMS (i.e., 60 trains of 10 Hz pulses for 5 second with over 120% of motor threshold) over SMA combined with speech training (for 25 seconds during the 60 inter-train intervals) for five sessions
89335227|NCT05472181|Sham Comparator|Sham|The sham group will receive 30 minutes of sham rTMS (no magnetic stimulation) over SMA combined with speech training (for 25 seconds during the 60 inter-train intervals) for five sessions.
89335228|NCT03507634|Active Comparator|Opioid Based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl and Sevoflurane.
89335229|NCT03507634|Active Comparator|Opioid Free Anesthesia|General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine and Sevoflurane.
89335230|NCT03917875|No Intervention|Control|
89335231|NCT03917875|Experimental|PFI|
89335232|NCT03507556|Experimental|Triple paste and induced bleeding|The triple paste is a mixture of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol will be used and next visit intracanal bleeding will be induced
89335233|NCT01232257|Experimental|Healthy volunteers|
89335234|NCT01232257|Experimental|CKD patients|Patients with CKD stage 3-4 (GFR 15-60 ml/min)
89335235|NCT01232257|Experimental|Hemodialysis patients|
89335236|NCT01232257|Experimental|Peritoneal dialysis patients|
89335237|NCT03509662|Placebo Comparator|Placebo group|Group 1 will be treated with placebos for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
89335238|NCT03509662|Active Comparator|Vitamin C - 3 gr/day|Group 2 will be treated with 1.5 gr Vitamin C b.i.d. (3 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
89531637|NCT05866770|Other|U8 then N8|Participants in this arm receive U8 followed by N8
89531638|NCT05866770|Other|N8 then U8|Participants in this arm receive N8 followed by U8
88806850|NCT04989686||Sirolimus|"Males and females <18 years of age~Weight greater than 5 kg~Receiving sirolimus as the standard of care~Has scheduled/anticipated blood draw to quantify the concentration of sirolimus for clinical indications~Parental/guardian permission (informed consent), and subject's assent if applicable."
89335239|NCT03509662|Active Comparator|Vitamin C - 10 gr/day|Group 3 will be treated with 5 gr Vitamin C b.i.d. (10 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
89335240|NCT01137799|Experimental|001|JNJ-39393406 10mg nanosuspension (sort of liquid formulation) once daily (single dose)
89335241|NCT01137799|Experimental|002|JNJ-39393406 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
89335242|NCT01137799|Experimental|003|JNJ-39393406 50mg nanosuspension (sort of liquid formulation) once daily (single dose)
89335243|NCT01137799|Experimental|004|JNJ-39393406 100mg nanosuspension (sort of liquid formulation) once daily (single dose)
89335244|NCT01137799|Experimental|005|JNJ-39393406 200mg nanosuspension (sort of liquid formulation) once daily (single dose)
89335245|NCT01137799|Placebo Comparator|006|placebo Once daily (single dose)
89335246|NCT02306668||Ocular surface discomfort|There are no interventions with this observational study
89335247|NCT03505138|Experimental|Group intervention|Conventional management for COPD will take place in our health care system more telematics intervention.
89335248|NCT03505138|Active Comparator|Group control|Is performed only conventional management of COPD in our health care system.
89335249|NCT02303626|Experimental|BCX4161 300 mg three times daily|Three BCX4161 capsules (100 mg) and two placebo capsules to be taken three times daily by mouth
89335250|NCT02303626|Experimental|BCX4161 500 mg three times daily|Five BCX4161 capsules (100 mg) to be taken three times daily by mouth
89335251|NCT02303626|Placebo Comparator|Placebo three times daily|Five placebo capsules to be taken three times daily by mouth
89335252|NCT05456347|Experimental|High-protein animal diet.|Low-calorie and high-protein diet (35% of total calories), mostly of protein coming from animal sources (75% of total protein).
89335253|NCT05456347|Experimental|High-protein vegetal diet.|Low-calorie and high-protein diet (35% of total calories), mostly of protein coming from plant sources (75% of total protein).
89335254|NCT02311426||Norway|"500 consecutive patients with stroke from the stroke units at the University Hospital of North Norway located in the cities Narvik, Harstad and Tromsø.~At baseline 155 patients with first ever stroke were registered. At 3 and 12 months follow-up 135-155 patients were enrolled."
89335255|NCT02311426||Denmark|500 consecutive patients from the stroke unit at Århus Hospital in Denmark. At baseline 402 patients with first ever stroke were included. At 3 and 12 months follow-up 318/ 170 patients were enrolled.
89335256|NCT01137877|Active Comparator|Infant Formula #1|Milk-based Infant Formula Powder
89335257|NCT01137877|Experimental|Investigational Infant Formula #1|Investigational Milk-based Infant Formula Powder
89335258|NCT01137877|Experimental|Investigational Infant Formula #2|Investigational Milk based infant formula powder
89335259|NCT01137877|Active Comparator|Human Milk|Reference group
89335260|NCT03504982|Experimental|Treatment 1|Treatment sequences: A*-B-C-D
89335261|NCT03504982|Experimental|Treatment 2|Treatment sequences: D-A-B-C*
89335262|NCT01133431|Experimental|CKD-501 + Glimepiride -> CKD-501 placebo + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
89335263|NCT01133431|Experimental|CKD-501 placebo + Glimepiride -> CKD-501 + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
89335264|NCT03507478|Experimental|BPI1000013|Subjects suffering from pain associated with plantar fasciitis or general heel pain
89335265|NCT05610007|Experimental|Prilocaine|50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume)
89335266|NCT05610007|Active Comparator|bupivacaine|12.5, 5 mg hyperbaric 0.5% bupivacaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume)
89335267|NCT03507400|Experimental|non-waiting list group|Intervention: Introvision: mental and emotional self-regulation
89335268|NCT03507400|Experimental|waiting list group|"Intervention: Introvision: mental and emotional self-regulation~Introvision is teached to participants of the waiting-list group at least 6 weaks or more after first group"
89335269|NCT02306746|Experimental|TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
89335270|NCT02306746|Active Comparator|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
89335271|NCT01232413|Placebo Comparator|Treatment A|Placebo
89335272|NCT01232413|Experimental|Treatment B|ASP1941 low dose
89335273|NCT01232413|Experimental|Treatment C|ASP1941 high dose
89335274|NCT01232413|Active Comparator|Treatment D|Moxifloxacin
89335275|NCT02303782|Experimental|OTX015 + azacitidine|
89335276|NCT02303782|Experimental|Azacitidine|
89335277|NCT01233505|Experimental|Treatment (veliparib, capecitabine, oxaliplatin)|Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89335278|NCT02311504||DiabCheck ophta OCTplus|persons with diabetes undergoing OCT examination
88806851|NCT04985487||Brolucizumab|Patients prescribed with brolucizumab in the approved indication
89335279|NCT01138033|Experimental|Part 1|Part 1 - dose escalation; starting dose 80 mg BID
89335280|NCT01138033|Experimental|Part 2|Part 2 - Dose expansion phase of the study at the maximum tolerated dose and schedule identified in Part 1 in patients with tumors known to over express FAK
89335281|NCT01138033|Experimental|Part 3|Part 3 - Characterize the biologically active dose range by analysis of PD markers in skin, hair and in tumor tissue in subjects with solid tumors amendable to biopsy and know to over express FAK
89335282|NCT01138033|Experimental|Part 4|Part 4 - Explore further the safety, PK, tolerability and anti-tumor activity of GSK2256098 in subjects with relapsed glioblastoma multiforme (GBM).
89335283|NCT01138033|Experimental|Part 5|Part 5 will investigate the time course, the extent of an apparent change in the PK of GSK2256098 following repeated dosing, and screen for potential CYP3A induction as a possible mechanism of reduced systemic exposure of GSK2256098 at Day 15 and later time points.
89335284|NCT02303860|Experimental|Panel 1|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
89335285|NCT02303860|Experimental|Panel 2|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
89335286|NCT03917563|Experimental|Intervention group|WATCHMAN LAA occluder treatment
89335287|NCT03134222|Experimental|Lanraplenib 30 mg|Lanraplenib + filgotinib placebo for 48 weeks
89335288|NCT03134222|Experimental|Filgotinib 200 mg|Filgotinib + lanraplenib placebo for 48 weeks
89335289|NCT03134222|Placebo Comparator|Placebo|Filgotinib placebo + lanraplenib placebo for 12 weeks
89335290|NCT03134222|Experimental|Placebo to Lanraplenib 30 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive lanraplenib + filgotinib placebo in a blinded fashion through Week 48.
89335291|NCT03134222|Experimental|Placebo to Filgotinib 200 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive filgotinib + lanraplenib placebo in a blinded fashion through Week 48.
89335292|NCT04463602|Experimental|Desidustat + Standard of Care|"Test: Desidustat + Standard of care~Desidustat 100 mg for the duration of 14 days along with the recommended standard of care at the time of conduct of trial."
89335293|NCT04463602|Active Comparator|Standard of Care|"Control: Standard of care~Standard of care treatment for the duration of 14 days at the time of conduct of trial."
89335294|NCT01230619|Experimental|RV568 treatment group|
89335295|NCT01230619|Placebo Comparator|Placebo treatment group|
89335296|NCT03917719|Experimental|Dose 1|Edasalonexent 100mg/kg/day. Capsules taken by mouth three times per day.
89335297|NCT03507322||Ultrasound texturization|Application of ultrasound texturization (2D/3D ultrasound scanning)
89335298|NCT04925180||Physicians|Physicians who have recently prescribed (e.g., within previous 12 months) CPA monotherapy will be invited to complete a brief web-based questionnaire regarding their knowledge of the revised summary of product characteristics (SmPC) and the direct healthcare professional communication (DHPC).
89335299|NCT03509428|No Intervention|Control|Usual care plus additional monitoring
89335300|NCT03509428|Experimental|SRETP|Structured Responsive Exercise Training Programme (SRETP) prior to surgery
89335301|NCT03509428|Experimental|Psychological support|Psychological support prior to surgery
89335302|NCT03509428|Experimental|SRETP and psychological support|Structured Responsive Exercise Training Programme (SRETP) and psychological support prior to surgery
89335303|NCT01133509|Other|gardisil|gardisil
89335304|NCT02306902|Experimental|Test|Fenofibrate Capsules, USP 130 mg
89335305|NCT02306902|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
89335306|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV -|n=12
89335307|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV -|n=12
89335308|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV -|n=12
89335309|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV -|n=12
89335310|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV +|n=12
89335311|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV +|n=12
89335312|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV +|n=12
89335313|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV +|n=12
89335314|NCT01350518|Placebo Comparator|Study prepared meals and placebo|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will not receive any fiber (Benefiber) supplementation in their TrueLemon mixture.
89335315|NCT01350518|Active Comparator|Nutritional Counseling with fiber|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions will focus on knowledge, self-regulation, motivation, experience and environment. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture .
89335316|NCT01350518|Placebo Comparator|Nutrition counseling and placebo|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions (interventions) will focus on knowledge, self-regulation, motivation, experience and environment.Participants will receive no fiber supplementation in their TrueLemon mixture .
89335317|NCT01350518|Active Comparator|Study prepared meals and fiber|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture.
89335318|NCT02306980|Experimental|Colostrum|Colostrum administration
89335319|NCT02306980|No Intervention|Control|Routine care
89335320|NCT01358786|No Intervention|no quilting sutures but drains|
89335321|NCT01358786|Experimental|quilting sutures and drains|
89335322|NCT01358786|Experimental|quilting sutures but no drains|
89335323|NCT01230697||Sofanenib and Hypophosphatemia|Patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with Sorafenib
89335324|NCT01361984|Experimental|Brovana (nebulized arformoterol)|Brovana (nebulized arformoterol) treatment for 2 weeks
89335325|NCT01361984|Experimental|Serevent (Salmeterol dry powder inhaler)|Serevent (Salmeterol dry powder inhaler) treatment for 2 weeks
89335326|NCT02311660|Experimental|vagus nerve stimulation|Patients will have an implanted vagus nerve stimulation device.
89335327|NCT01136239|Placebo Comparator|Placebo|Placebo (600mg twice daily)
89335328|NCT01136239|Active Comparator|N-acetylcysteine|N-acetylcysteine (600mg twice daily)
89335329|NCT02303938|Experimental|physical exercise|Patients will exercise three times per week for 6 months home-based exercise intervention. Session duration will vary between 20 minutes and 45 minutes.
89335330|NCT02303938|No Intervention|Active control group|Patients in the active control group will be advised to walk regularly based on brochures from 30minutenbewegen.nl
89335331|NCT01230775|Experimental|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
89335332|NCT01230775|Placebo Comparator|Placebo|"Week 1:~x1 tablet/d of Placebo will be administered in week 1.~Placebo:~x1 tablet/d of placebo will be administered in week 2.~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
89335333|NCT02311738|Experimental|High intensity training group|"HIE will consist of the following:~10 minute warm up at 70% of maximal heart rate.~4 minute exercise intervals at 90-95% of maximal heart rate.~4 minute interval bouts repeated 4 times.~Between each bouts there will be a 3 minute active recovery at 70% of maximal heart rate~After all four bouts are completed; 5 minute cool-down at 70% of maximal heart rate."
89335334|NCT02311738|Experimental|Moderate intensity training group|"MIE will consist of the following:~10 minute warm up at 50% of maximal heart rate.~35 minutes exercise at 70% of maximal heart rate.~4 minute cool-down at 50% of maximal heart rate."
89335335|NCT03504904|Experimental|Internet-delivered ACT and CFT|8 week, guided internet- delivered acceptance and commitment therapy (ACT) and compassion focused therapy (CFT)
89335336|NCT03504904|No Intervention|Wait list control group|Wait list control group, received treatment at later point.
89335337|NCT01136317|Experimental|Omeprazole|
89335338|NCT01136317|Experimental|Rabeprazole|
89335339|NCT01136317|Placebo Comparator|Placebo|
89335340|NCT02304016|Experimental|Pelvic floor physical therapy|
89335341|NCT02304016|No Intervention|Observatoin|
89335342|NCT02311816||Infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
89335343|NCT02311816||No infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
89335344|NCT05393947|Experimental|patient aducation|It is planned to provide education to patients about the side effects of chemotherapy.
89335345|NCT05393947|No Intervention|observation|While training the patients in the intervention group, observations will be made on the patients in the experimental group.
89335346|NCT02307214|Other|Coronary X syndrome|BaroReflex Sensitivity, endothelial function measurement
89335347|NCT02307214|Other|Tako-tsubo cardiomyopathy|BaroReflex Sensitivity, endothelial function measurement
89335348|NCT02307214|Other|Healty Volunteers|BaroReflex Sensitivity, endothelial function measurement
89335349|NCT03917641|Experimental|Patients after Oculoplastic surgery|"Each participant will use one compression with Khat leaves and another standard compression and will decide on which eye to use which compression.~The compressions will be used for 10 minutes per every waking hour in the first 2 days post-op.~The patient will take pictures of both his eyes in days 1,3 and 7 post operative days."
89335350|NCT03507244|Experimental|Group 1,Intra-pemetrexed, radiotherapy|The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 10 mg, plus dexamethasone 5 mg, once per week, 5-8 times, 4-7 weeks in total) and radiotherapy. Radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on magnetic resonance imaging, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40-50 Gy.
89335351|NCT01136395|Active Comparator|LD kidney transplantation, ABOi|Living donor (LD) kidney transplantation, ABO incompatible (ABOi); Immunosuppressive treatment: Tacrolimus (Tacr)/ Mycophenolate sodium (MPS), Basiliximab induction, Rtx induction
89335352|NCT01136395|Active Comparator|LD kidney transplantation, ABOc|Living donor (LD) kidney transplantation, ABO compatible (ABOc); Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
89335353|NCT01136395|Active Comparator|DD kidney transplantation|Deceased donor (DD) kidney transplantation, ABO compatible; Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
89335354|NCT02304094|Experimental|manipulation|Those in the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique. They will be asked to return once each week for a further five weeks. At each visit the VAS and PTM measurements shall be repeated, as will the manual manipulation. They shall also be asked to return for a review in the sixth week.
89335355|NCT02304094|Active Comparator|Steroid|Those randomised to the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine. They shall then be asked to return for review in six weeks. A second injection may be offered at this point if clinically indicated.
89335356|NCT01138345||Treatment w/Surgery|Breast Cancer survivors treated with surgery with or without radiation.
89335357|NCT01138345||Treatment w/endocrine therapy|Breast Cancer survivors treated with surgery with or without radiation plus endocrine therapy.
89335358|NCT01138345||Treatment w/ chemotherapy|Breast Cancer survivors treated with surgery with or without radiation and chemotherapy with or without endocrine therapy.
89335359|NCT03507166|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
88811771|NCT01380743|Experimental|Cohort 4, Duvoglustat 600 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 600 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
89335360|NCT01136473||congenital cataract or aphakic glaucoma|children with congenital cataract or aphakic glaucoma
89335361|NCT03507088|Experimental|fulvestrant|500mg fulvestrant on days 0, 14, 28 and every 28 days thereafter Fluoroestradiol-PET is performed at baseline and after 28 days
89335362|NCT01233583||Betamethasone/Calcipotriol (Dovobet)|patients in whom decision to treat with Dovobet by their dermatologist
89335363|NCT01233583||Acitretin (neotigason)|patients in whom decision to treat with neotigason by their dermatologist
89335364|NCT01233583||narrow-band UVB|patients in whom decision to treat with narrow band UVB by their dermatologist
89335365|NCT01233583||Anti TNF-alpha|patients in whom decision to treat with anti TNF-alpha(adalimumab-etanercept-infliximab) by their dermatologist
89335366|NCT02312050|Experimental|GCS-100 1 mg|Dose level 1 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
89335367|NCT02312050|Experimental|GCS-100 3 mg|Dose level 2 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
89335368|NCT02312050|Experimental|GCS-100 9 mg|Dose level 3 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
89335369|NCT02312050|Placebo Comparator|Normal Saline Solution 0.9%|Placebo - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
89335370|NCT03504748|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
89335371|NCT03504748|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
89335372|NCT01230853|Active Comparator|Active Comparator: A|
89335373|NCT01230853|Placebo Comparator|Placebo Comparator A|
89335374|NCT01230853|Active Comparator|Active Comparator: B|
89335375|NCT01230853|Placebo Comparator|Placebo Comparator B|
89335376|NCT02304172|Active Comparator|Thunderbeat (Group A)|Patients submitted to thyroidectomy with the use of the Thunderbeat device.
89335377|NCT02304172|Active Comparator|Harmonic (Group B)|Patients submitted to thyroidectomy with the use of the Harmonic scalpel device
89335378|NCT02304250|Active Comparator|Group D|Group D: dexamethasone group
89335379|NCT02304250|Placebo Comparator|Group S|Group S: saline group
89335380|NCT01133587|Experimental|admissions contract|"contract regarding patient-guided admissions"
89335381|NCT01133587|Active Comparator|wait list control|1 year on waiting list
89335382|NCT03504670|Experimental|Early amniotomy|Women randomized to early amniotomy will have their membranes ruptured in usual fashion using an amniotomy hook when the cervix is less than 4cm dilated. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. Prior to amniotomy, the obstetric provider will assess whether or not the fetal head is engaged. If the fetal head is not engaged (applied to the cervix), amniotomy will be deferred. The patient will be examined every 2 hours until amniotomy can be safely performed (in keeping with our institutional standard of care to examine women every 2-4 hours in labor).
89335383|NCT03504670|Experimental|Late amniotomy|Women randomized to late amniotomy will have their membranes ruptured once the cervix reaches at least 4cm dilation. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. If the cervix fails to reach 4cm dilation 12 hours following cervical ripening, amniotomy will be performed.
89335384|NCT02312128|Active Comparator|Early Mobilisation|"receives a removable plastic cast for one week and is allowed to move the wrist directly postoperative.~Interventions:~Range of Motion measurement (ROM),~Grip strength measurement,~VAS Score according to the visual analogue scale ().~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.~X- Rays in two planes.~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
89335385|NCT02312128|Active Comparator|Cast Group|"receives a non removable cast for 5 weeks~Interventions:~Range of Motion measurement (ROM),~Grip strength measurement,~VAS Score according to the visual analogue scale ().~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.~X- Rays in two planes.~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
89335386|NCT05198635||Group 1|
89335387|NCT05198635||Group 2|
89335388|NCT01136551|Active Comparator|IR formulation|Healthy volunteers will receive imediate release formulation of Huperzine A (0.4mg)
89335389|NCT01136551|Experimental|CR 1|"CR formulation~Healthy volunteers will receive controlled release formulation 1 of Huperzine A (0.4mg)"
89335390|NCT01136551|Experimental|CR 2|"CR formulation~Same volunteers will receive controlled release formulation 2 of Huperzine A (0.4mg)"
89335391|NCT01233739|Placebo Comparator|Placebo|
89335392|NCT01233739|Experimental|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
89335393|NCT02304328||No clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients without clinical signs of brain herniation syndrome
89335394|NCT02304328||Clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients with clinical signs of brain herniation syndrome
89335395|NCT03132142|Experimental|Capsaicin|Capsacin (8%) patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
89335396|NCT03132142|Experimental|Trans-cinnamaldehyde|Trans-cinnamaldehyde (10%, dissolved in 90% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
89335397|NCT03132142|Experimental|L-menthol|L-menthol (40%, dissolved in 96% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
89335398|NCT03132142|Placebo Comparator|Vehicle patch|Inert vehicle patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
89335399|NCT03509272|No Intervention|Control Group|
89335400|NCT03509272|Experimental|remote monitoring group|
89335401|NCT03917329|Other|ACT and PBS group workshop|The intervention in this study is an Acceptance and Commitment Therapy (ACT) and Positive Behaviour Support (PBS) group workshop for parents and education staff of children with intellectual disabilities.
89335402|NCT03509194||Pediatric liver disease patients|Comparison of outcome of pediatric liver disease and prognostic functional liver test results and gene expression in liver biopsies.
89335403|NCT01232647|Active Comparator|Vitamin k1|1.0 mg of vitamin K1 (phylloquinone) and placebo MK4 will be given to one of the treatment arm for 18 months
89335404|NCT01232647|Placebo Comparator|placebo vitamin K1 and MK4|placebo pill of both vitamin K1 and MK4 given for 18 months to the control arm
89335405|NCT01232647|Active Comparator|Menatetrenone MK4|45 mg MK4 given daily and placebo vitamin K1 will be given to one of treatment arm for 18 months
89335406|NCT03504592|Experimental|Glooko App|Glooko application and meter compatibility device (if required)
89335407|NCT03504592|Active Comparator|Traditional Care|Traditional clinic reporting system: paper/MyChart/emailed glucose logs
89335408|NCT03917095|Active Comparator|Mesalazine conventional enema|Participants undergo the conventional enema of Mesalazine Enemas (4g) for one week.
89335409|NCT03917095|Experimental|Mesalazine TET enema|Participants undergo the TET enema of Mesalazine Enemas (4g) for one week.
89335410|NCT03917095|Active Comparator|Compound Glutamine conventional enema|Participants undergo the conventional enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
89335411|NCT03917095|Experimental|Compound Glutamine TET enema|Participants undergo the TET enema of Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
89335412|NCT03917095|Experimental|Compound Glutamine and Mesalazine TET enema|Participants undergo the TET enema of Mesalazine(4g) and Compound Glutamine (24 tablets of the drug were dissolved in 50ml normal saline) for one week.
89335413|NCT03504514|No Intervention|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
89335414|NCT03504514|Experimental|Adapted mechanical ventilation|Mechanical ventilation with parameters specifically modified to improve speech the effect is evaluated with speech trials during different ventilation conditions
89335415|NCT01133743|Experimental|Lenalidomide and Dexamethasone|Lenalidomide target dose of 25 mg PO OD continuously (28-day cycle) using an initial dose escalation period. Oral dexamethasone 12 mg daily on days 1-7, 14 and 21 of each cycle.
89335416|NCT02307604||Brain cancer|Patients with diagnosis of brain cancer at any stage
89335417|NCT01138423|Experimental|Aliskiren|
89335418|NCT01138423|Experimental|Moxonidine|
89335419|NCT01138423|Experimental|Hydrochlorothiazide|
89335420|NCT01138423|Placebo Comparator|Placebo|
89335421|NCT03509038|Experimental|Urinary incontinence before bariatric surgery|All patients with urinary incontinence before bariatric surgery will be addressed for a urodynamic exam
89335422|NCT03506854|Experimental|Normal Renal Function|Subjects with normal renal function will be matched by age (±10 years), weight (± 20%), and gender to the pooled mean values of subjects with the moderate renal impairment. Subjects will receive 1 dose of ISIS 681257.
89335423|NCT03506854|Experimental|Moderate Renal Impairment|Presence of moderate renal impairment (eGFR 30-59 mL/min/1.73m2). Subjects will receive 1 dose of ISIS 681257.
89335424|NCT01136629||Subjects with hyper-pigmented spots|Subjects age 21 to 80 year old, who have elected to undergo a plastic surgery will be enrolled. Subjects will be from Chinese, Malay, Indian or Caucasian ancestry. Subjects will be female or male with a hyper-pigmented spots.
89335425|NCT02312284||Radiotherapy/Chemoradiotherapy|Pre- or postoperative or palliative radiotherapy/chemoradiotherapy based on 5-fluorouracil or Capecitabine +/-Oxaliplatin
89335426|NCT02312284||Surgery|Transabdominal resection or transanal excision
89335427|NCT02312284||Chemotherapy|Pre- or postoperative chemotherapy including 5-fluorouracil/leucovorin with oxaliplatin, Capecitabine, etc
89335428|NCT01138813||1|Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher
89335429|NCT01136707||Patients with rheumatoid arthritis new to Orencia|
89335430|NCT03504358||Analysis before liver resection|Multivariate analysis of predictive factors associated with survival
89335431|NCT03504358||Different risk group|Low-risk group, moderate-risk group, high-risk group
89335432|NCT03504358||Model comparison|Comparison of models in predicting survival
89335433|NCT01136863|Active Comparator|felodipine group, active, pill|felodipine and HCTZ treatment group
89335434|NCT01136863|Placebo Comparator|placebo, no treatment, pill|placebo and HCTZ group
89335435|NCT01138891||Removed breast implants for any reason|
89335436|NCT03961516||Cystic Fibrosis, Pancreatic Sufficient|CF patients with exocrine pancreatic sufficiency
89335437|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, No Insulin|CF patients with exocrine pancreatic insufficiency but not treated with insulin therapy
89335438|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, Treated with Insulin|CF patients with exocrine pancreatic insufficiency who are treated with insulin therapy for CFRD
89335439|NCT01133899|Experimental|GAA-2|2.4 grams of guanidinoacetic acid
89335440|NCT01133899|Experimental|GAA-1|1.2 grams of guanidinoacetic acid
89335441|NCT01133899|Experimental|GAA-4|4.8 grams of guanidinoacetic acid
89335442|NCT01133899|Placebo Comparator|PLACEBO|cellulose
89335443|NCT01231009|Active Comparator|Corticosteroids|Patients receive for 7 days intravenous corticosteroids, dexamethasone, and they continue receiving for 7 days corticosteroids per os
89335444|NCT01231009|Placebo Comparator|Vestibular exercises|Patients perform for 15 days certain vestibular exercises under suspicion of an expert physiotherapist
89335445|NCT03508882|Active Comparator|Preseptal-pretarsal|The Preseptal-pretarsal group will receive injections of Botulinum Toxin Type A 100Unit/Vial (Product) in the preseptal site (Injection pattern A) and Saline Solution for Injection (placebo control) in the pretarsal site for 2 cycles at 3 months apart. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
89335446|NCT03508882|Active Comparator|Pretarsal-preseptal|The Pretarsal-preseptal group will initially receive injections Botulinum Toxin Type A 100Unit/Vial (Product) in the reverse with the intervention at the pretarsal site (Injection pattern B) for 2 cycles at 3 months apart. Groups 1 and 2 will crossover and receive the alternative intervention. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
89335447|NCT03504280|Active Comparator|high dose IM|cholecalciferol 600,000 IU given intramuscularly
89335448|NCT03504280|Active Comparator|high dose oral|cholecalciferol 600,000 IU given orally
89335449|NCT03504280|Active Comparator|low dose oral|cholecalciferol 400,000 IU given orally in 2 divided doses given monthly for 2 consecutive months followed by daily maintenance dose of 1000 IU
89335450|NCT03504202|Experimental|Trimetazidine|
89335451|NCT01232725|Experimental|Donor Human Milk|VLBW infants randomized to be fed donor human milk, fortified as appropriate, for all feedings for which maternal milk is not available, including infants who receive no maternal milk
89335452|NCT01232725|Experimental|Preterm Formula|VLBW infants randomized to receive preterm infant formula for any feedings for which maternal milk is unavailable, including infants receiving no maternal milk
89335453|NCT02307760|Active Comparator|Study Human Milk Fortifier A|Acidified processing method.
89335454|NCT02307760|Experimental|Study Human Milk Fortifier B|Non-acidified processing method.
89335455|NCT03506776|Active Comparator|Education Only Group|The education only group will receive foot self-management education.
89335456|NCT03506776|Experimental|Education and Thermometer Group|The intervention group will receive foot self-management education. Additionally, the intervention group will receive a Commercially Available Infrared Thermometer (CAIT). Education on use of the CAIT will be provided through demonstration using a foot model and CAIT.
89335457|NCT01136941|Experimental|Treatment|Research participants will be administered Zileuton according to the dose escalation/de-escalation schema provided in the protocol.
89335458|NCT02304562|Experimental|UCB Mesenchymal Stem Cells|UCB Mesenchymal Stem Cells treatment of patients with skin injury
89335459|NCT01232803|Active Comparator|2% N-9 gel|Rectal application of 2% N-9 gel
89335460|NCT01232803|Placebo Comparator|HEC placebo gel|Rectal application of HEC placebo gel
89335461|NCT01232803|No Intervention|no-treatment arm|no intervention
89335462|NCT01232803|Experimental|Tenofovir 1% gel|rectal application of Tenofovir 1% gel
89335463|NCT03504046|Experimental|Artificial Pancreas App|After completing a 1 week open-loop run in period, subjects will use the APS APP for a 48-hour period in an observed transitional environment.
89335464|NCT03917017|Experimental|Radiomics and Watson artificial intelligence|
89335465|NCT02304640||Early-stage breast cancer patients|
89335466|NCT02304640||Healthy control|
89335467|NCT01139203|Active Comparator|lamivudine|
89335468|NCT01139203|Active Comparator|lamivudine and adefovir|
89335469|NCT01139203|Active Comparator|entecavir|
89335470|NCT02312362|Experimental|Combined sclerotomy ab interno and phaco|Combined sclerotomy ab interno and phacoemulsification with IOL implantation
89335471|NCT02312362|Active Comparator|Phacoemulsification with IOL implantation|Phacoemulsification with IOL implantation
89335472|NCT05187715|Experimental|Simvastatin with Standard Medical Treatment|Simvastatin 40mg OD plus standard treatment plus standard treatment (excluding Pentoxiphylline)
89335473|NCT05187715|Active Comparator|Placebo with Standard Medical Treatment|Matched placebo plus standard treatment (excluding Pentoxiphylline)
89335474|NCT02312440|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
89335475|NCT02312440|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' prior to skin incision and the second dose at 180' after the first dosage.
89335476|NCT02312440|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
89335477|NCT02307994|Experimental|75IU uFSH|75IU uFSH (Livzon Pharm Group Inc., China) being injected into severe oligospermia patients or azoospermia patients every 3 days for 6 months
89335478|NCT01137019|Active Comparator|Biolimus-eluting stent|
89335479|NCT01137019|Active Comparator|Everolimus-eluting stent|
89335480|NCT02312518|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
89335481|NCT02312518|Other|Usual and Customary Practice|usual and customary practice
89335482|NCT03769753|Experimental|intraoperative use of IRE|Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.
89335483|NCT03508804|Experimental|Lidocaine-prilocaine cream|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the lidocaine-prilocaine cream vaginally using a syringe
89335484|NCT03508804|Placebo Comparator|Placebo cream (pain lucubrating gel)|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the placebo cream vaginally using a syringe
89335485|NCT01137097|Active Comparator|Lateral sentinel group|Lateral sentinel lymph node biopsy with radioisotope
89335486|NCT01137097|No Intervention|No intervention for lateral neck|No lateral sentinel lymph node biopsy with radioisotope
89335487|NCT01232881||Tumor and Serum Collection|"Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.~Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib."
89335488|NCT01231165|Experimental|Amiloride,nitrates,clopidogrel,aspirin,statins|Comparative Efficacious Research
89335489|NCT01231165|Active Comparator|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
89335490|NCT01231243|Active Comparator|35% hydrogen peroxide control|The tooth bleaching will be performed using a high hydrogen peroxide concentration (35%) without light-activation with LED/light device
89335491|NCT01231243|Active Comparator|20% hydrogen peroxide|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) without light activation with a LED/laser device
89335492|NCT01231243|Experimental|35% hydrogen peroxide + light|The tooth bleaching will be performed with a high hydrogen peroxide concentration (35%) associated with LED/laser light activation
89335493|NCT01231243|Experimental|20% hydrogen peroxide + light|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) associated with LED/laser light activation
89335494|NCT02308306||Opioid analgesics|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
89335495|NCT01139281|Active Comparator|Study Group|The Study Group(SG) received Ginkgo biloba extract(GBE761)(240mg/day)plus cisplatin(CDDP)
89335496|NCT01139281|Placebo Comparator|Control Group(CG)|The Control Group received Placebo plus CDDP
89335497|NCT02304718|Experimental|exercise intervention group|Pregnant women randomised to the exercise intervention group will complete three supervised, exercise sessions each week, exercise sessions completed on alternate days, and lasts until they give birth by using a stational bike. And also they will have regular prenatal care.
89335498|NCT02304718|No Intervention|control group|Pregnant women randomised to the control group only have regular prenatal care.
89335499|NCT01233895|Experimental|AVE1642/ AVE1642 with Velcade|
89335500|NCT02304796|Experimental|Unified CBT|Group psychotherapy according to the principles of the Cognitive-Behavioral Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011).
89335501|NCT02304796|Experimental|Combined CBT-DMT|Group psychotherapy combining cognitive-behavioral principles and techniques with dance/movement therapy techniques.
89335502|NCT03503734||Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
89335503|NCT02308384|No Intervention|Before intervention|GPs in this group have not yet received intervention.
89335504|NCT02308384|Experimental|After intervention|GPs in this group have received the intervention.
89335505|NCT02308462|Experimental|CHIMPs intervention|Family-Intervention
89335506|NCT02308462|No Intervention|Control|"The long-term effectiveness of the CHIMPs intervention under conditions of practice will be examined in comparison to a control condition receiving the usual after care (Treatment as usual = TAU); this testing of effectiveness will be performed in due consideration of the health economic aspects.~The treatment as usual implies that families of the control Group receive the Treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every Family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system."
89335507|NCT05523115|Experimental|Heights Smart Supplement|Participants will take the supplement over a 12 week period. There will be both biomarker outcomes and subjective outcomes reported by the participants via questionnaires.
89335508|NCT03503656||CompuFlo|All the consecutive patients undergoing to an epidural catheter placement in Gynecological and Obstetric setting
89335509|NCT02312596|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix
89335510|NCT02312596|Active Comparator|Usual and customary practice|Usual and customary practice
89335511|NCT05521243|Experimental|Placebo + Dream Powder|Participants take the placebo product for two weeks, followed by the Dream Powder intervention product for four weeks.
89335512|NCT05521243|Experimental|Placebo + Dream Powder Extra Strength|Participants take the placebo product for two weeks, followed by the Dream Powder Extra Strength intervention product for four weeks.
89335513|NCT03503500|Experimental|Laid-back breastfeeding|Women will breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves, without following particular procedure to breastfed.
89335514|NCT03503500|Active Comparator|Standard care|Staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast,
89335515|NCT03916861|Experimental|Bioelectrical Impedance|The first group will be monitored by Inbody S20 analysis to measure fluid status. The Bioimpedance will be measured each time prior to hemodialysis session . The value of BIA measurement of more than 0.4 will be considered as edema.
89335516|NCT03916861|Active Comparator|Physicain-guided group|The fluid monitoring will be managed by physician-adjustment by physical examination and fluid balance record . The fluid balance (FB) is the total fluid administered minus the total fluids eliminated over a period of time.
89335517|NCT02308618|Experimental|Traditional Immobilization|45 days of plaster cast immobilization After the immobilization period, subjects received instructions on how to perform a home-based exercise program
89335518|NCT02308618|Experimental|Early mobilization|Six weeks of physical therapy program
89335519|NCT02308618|No Intervention|Control|Subjects had no history of lower limb injury, and were matched in age and anthropometric measurements to subjects that performed physical rehabilitation and to subjects that remained immobilized.
89335520|NCT01139359|Experimental|Single Arm, darinaparsin and CHOP|open label, single arm, unblinded
89335521|NCT02304952|Active Comparator|Eccentric exercise|Conservative treatment with eccentric exercise as self-training
89335522|NCT02304952|Active Comparator|Radiofrequency microtenotomy|A minimally invasive surgery (Topaz) and eccentric exercise as postoperative treatment
89335523|NCT03916471|Experimental|S (SOLYX)|The Solyx™SIS System is an innovative mid-urethral sling single incision system consisting of a 9 cm long polypropylene mesh, whose mid-urethral portion (4 cm) is detanged to potentially resist deformation and to reduce irritation to the urethral wall. Snap-fit to delivery device tip allows for advanced placement control and, therefore, the tensioning through the forward and reverse functions performed with this delivery device.
89335524|NCT03916471|Experimental|O (OBTRYX II)|The Obtryx II System (Halo) is a transobturator sling designed to allow inter-operative adjustability with minimal tissue disruption. It consists of two delivery devices (one patient right and one patient left) and one mesh assembly. The mesh assembly is comprised of a polypropylene knitted mesh with dilator legs and a center tab. At the distal ends of the dilator legs there are association loops designed to be placed in the needle slot of the distal end of the delivery device. The disposable delivery device consists of a handle with a stainless steel needle. The needle is designed to facilitate the passage of the mesh assembly through bodily tissues for placement through the obturator foramen.
89335525|NCT03506620|Placebo Comparator|Control|Subjects will be randomized to receive a single-injection QL block with normal saline (Saline Solution for Injection).
89335526|NCT03506620|Experimental|QL Block|Subjects will be randomized to receive a single-injection QL block with either local anesthetic (0.25% Ropivacaine injection).
89335527|NCT01232959|Experimental|Transvaginal Surgery|Gallbladder will be removed through the vagina
89335528|NCT02305030|Experimental|BIA 9-1067 / Warfarin|BIA 9-1067 capsules of 25 mg or 50 mg Warfarin capsules of 5 mg
89335529|NCT03503422|Experimental|tDCS (anodal) + therapeutic exercises|"Real transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
89335530|NCT03503422|Sham Comparator|tDCS (sham) + therapeutic exercises|"Sham transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
89335531|NCT02305108|Experimental|fascial manipolation and standard|
89335532|NCT02305108|Active Comparator|standard treatment|
89335533|NCT01139437|Experimental|Adults|Adults ages 18 to 49 years of age. Open label.
89335534|NCT01139437|Experimental|Seropositive children - vaccine|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving the HPIV2 vaccine.
89335535|NCT01139437|Experimental|Seronegative infants and children - low dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of the HPIV2 vaccine.
89335536|NCT01139437|Experimental|Seronegative infants and children - standard dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of the HPIV2 vaccine.
89335537|NCT01139437|Placebo Comparator|Seropositive children - placebo|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving a placebo.
89335538|NCT01139437|Placebo Comparator|Seronegative infants and children - low dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of placebo.
89335539|NCT01139437|Placebo Comparator|Seronegative infants and children - standard dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of placebo.
89335540|NCT01137253|Experimental|Trimethaphan|Response to intrabrachial vasodilators during autonomic withdrawal
89335541|NCT01137253|Placebo Comparator|Placebo|Response to intrabrachial vasodilators during saline intravenous (IV) infusion
89335542|NCT02312674|Experimental|Intervention|Patient group which takes daily an adjusted amount of oral nutritional supplements through an intervention period of three months
89335543|NCT02312674|No Intervention|Control|Patients group which takes no oral nutritional supplements
89335544|NCT05493163|Experimental|Catheter-Directed Thrombolysis|"Venous access should be obtained under ultrasound guidance (via the common femoral vein). The use of a double-lumen 8-Fr introducer (single access site) or two 4-Fr introducers (two ipsilateral access sites) is at the discretion of the operator.~After each thrombolytic catheter placement into left and/or right pulmonary artery, a subsequent bolus of 1mg of Alteplase (Actilyse, Boehringer Ingelheim)/catheter is administered, followed by continuous infusion at 1 mg/h/catheter for 9 h (total dose 10mg for unilateral and 20mg for bilateral PE).~Intravenous unfractionated heparin is continued to a target activated partial thromboplastin time (aPTT) of 50-60 s. After the end of local thrombolysis, the catheters are removed and anticoagulation with unfractionated heparin continues."
89335545|NCT05493163|Active Comparator|Standard Anticoagulation|Before randomization, all patients are treated with intravenous unfractionated heparin (to a target aPTT of 70-90 s) or subcutaneous LMWH (the full therapeutic dose). For patients in the CDT group, the anticoagulation treatment was is described above; among CDT patients who received LMWH, the procedure should be postponed for 8 h after the last dose of LMWH. Patients in the standard care group continue therapeutic anticoagulation with either unfractionated heparin or LMWH. Subsequent change for oral anticoagulation is at the discretion of the treating physician (not earlier than 24 hours post-randomization).
89335546|NCT02312752|Other|Intra-epidermal stimulation|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
89335547|NCT01134211|Other|nelfilcon A / filcon II 3|Nelfilcon A contact lenses worn first, with filcon II 3 contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
89335548|NCT01134211|Other|filcon II 3 / nelfilcon A|Filcon II 3 contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
89335549|NCT03506542|Experimental|Ologen (OLO)|Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy
89335550|NCT03506542|Active Comparator|Mitomycin C (MMC)|Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)
89335551|NCT01231477||Volunteers|Healthy volunteers not submitted to anesthesia nor surgery.
89335552|NCT01231477||Sevoflurane Group|This group was submitted to inhalational anesthesia with sevoflurane and otorhinolaryngological surgery.
89335553|NCT01139593||morning dose|women undergoing IVF/ICSi taking their gonadotropin dose in the am
89335554|NCT01139593||evening dose|Women undergoing IVF/ICSI taking their gonadotropin in the evening
89335555|NCT02305186|Experimental|Neodjuvant CRT + Pembrolizumab|Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab
89335556|NCT02305186|Active Comparator|Neoadjuvant CRT|Standard neoadjuvant chemoradiation treatment (CRT) alone
89335557|NCT01137331|Experimental|K301|K301 applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
89335558|NCT01137331|Placebo Comparator|Placebo|Placebo applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
89335559|NCT03506464|Experimental|plantar fasciitis group|Myofascial release technique
89335560|NCT03506464|No Intervention|control group|None of the control group received the treatment
89335561|NCT02305342||Urinary Tract Infections (UTIs)|Uncomplicated UTIs
89335562|NCT01233115||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections
89335563|NCT01231711|Experimental|Vets Prevail|N=50. Participants were recent veterans (deployed after September 11, 2001) of operations in Iraq and Afghanistan who were experiencing depression/distress symptoms at the time of screening (CES-D > 8) but who were not considered to be inappropriate for a health promotion intervention (CES-D > 35 indicating severe depressed mood or exhibiting self-harm risk).
89335564|NCT02312908|Experimental|Clonazepam|Clonazepam 0.5 mg 1 Tablet by mouth, 1/day before sleeping for 4 weeks
89335565|NCT02312908|Placebo Comparator|Placebo|Placebo 1 Tablet by mouth, 1/day before sleeping for 4 weeks
89335566|NCT02305420|Experimental|EmbryoGen/BlastGen|"EmbryoGen and BlasGen media containing GM-CSF 2ng/ml will be used in the experimental arm~The intervention is to use EmbryoGen/BlastGen"
89335567|NCT02305420|Active Comparator|Control|Standard Cook sequential media
89335568|NCT01236235||ARV-naïve HIV patients initiated on ATV/RTV-based therapy|"Anti-retroviral (ARV)-naïve HIV patients initiated on ATV/RTV-based therapy between 2008-2010~One cohort being observed for 3 different countries"
89335569|NCT02308930|Experimental|Vitamins + DHA supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg algal oil (containing 150mg DHA).
89335570|NCT02308930|Other|Vitamins supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg corn oil (free of omega-3 fatty acids).
89335571|NCT02305498|Experimental|Vigorous yoga practice|Supervised vigorous yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
89335572|NCT02305498|Active Comparator|Restorative (gentle) yoga practice|Supervised restorative (gentle) yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
89335573|NCT01233973|No Intervention|control subjects|verbal narrative of advance care planning
89335574|NCT01233973|Experimental|intervention group|video decision aid viewed by subjects
89335575|NCT02309008|Placebo Comparator|placebo|vehicle cream, dermal administration, multiple dosing
89335576|NCT02309008|Experimental|drug|PAC-14028 cream, dermal administration, multiple dosing, dose escalation
89335577|NCT02313064|Active Comparator|CXA-10|single dose of CXA-10 oral formulation
89335578|NCT02313064|Placebo Comparator|CXA-10 placebo|single oral doses of CXA-10 placebo
89335579|NCT05100511|Experimental|Phase I, healthy subjects|General usability of the device is tested with healthy patients. Different commercial electroretinography electrodes are tested to investigate the patient comfort, usability and signal-to-noise ratio when recording fundus image-guided focal electroretinography with the investigational device. Most suitable electrode is selected to phase II.
89335580|NCT05100511|Experimental|Phase II, patients with macular edema or macular degeneration|The usability of the device is tested with patients suffering either from macular edema or macular degeneration. Fundus image-guided focal electroretinography is recorded with the electrode chosen in phase I from two different retinal areas: from an area with macular edema or signs of macular degeneration and from a healthy area (area without macular edema or signs of macular degeneration).
89335581|NCT05094661|No Intervention|Non failure high flow oxygen therapy|The patient is treated with high flow oxygen system throughout the admission in the intermediate respiratory care unit
89335582|NCT05094661|Active Comparator|Non-invasive ventilation (CPAP/BiPAP)|If high flow support fails, the patients will be treated with non-invasive respiratory support.
89335583|NCT02309086|Experimental|Single arm|Autologous dendritic cells transduced with Ad encoding NS3
89335584|NCT02309164|Active Comparator|Acupuncture|acupuncture
89335585|NCT02309164|Sham Comparator|orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
89335586|NCT03508492|Active Comparator|Knee surgeons|Four knee surgeons
89335587|NCT03508492|Active Comparator|Hip surgeons|Six hip surgeons
89335588|NCT03508492|Active Comparator|Cardiac surgeons|6 cardiac surgeons
89335589|NCT03508492|Active Comparator|Colon surgeons|6 colon surgeons
89335590|NCT01234051|Experimental|Docetaxel, oxaliplatin, palliative chemotherapy|
89335591|NCT02309242|No Intervention|Neuropsychological assessment, MRI|This is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex.
89335592|NCT02313142|Experimental|Subjects|
89335593|NCT03109834|Active Comparator|Meal replacement (MR) group|"Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1)~During weight stabilization phase (phase 2) MR counted to food choice option."
89335594|NCT03109834|Other|Control (C) group|"Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1)~During 3-month weight stabilization phase (phase 2) MR counted to food choice option."
89335595|NCT03109834|Active Comparator|Verum group|"Specific micronutrient composition with omega-3 fatty acids (capsules)~Duration: 6-month weight maintenance phase (phase 3)"
89335596|NCT03109834|Placebo Comparator|Placebo group|"Placebo capsules~Duration: 6-month weight maintenance phase (phase 3)"
89335597|NCT04808401|Experimental|Normoxaemia First + Hyperoxia Procedure|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.
89335598|NCT04808401|Experimental|Normoxaemia First + Normoxia Procedure|Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive normoxic concentrations.
89335599|NCT04808401|Experimental|Hyperoxia First + Hyperoxia Procedure|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.
89335600|NCT04808401|Experimental|Hyperoxia First + Normoxaemia Procedure|Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive normoxic concentrations.
89335601|NCT03341962|Experimental|10 mg IMU-838 (Induction)|"Two 5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
89335602|NCT03341962|Experimental|30 mg IMU-838 (Induction)|"Two 15 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
89335603|NCT03341962|Experimental|45 mg IMU-838 (Induction)|"Two 22.5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.~Patients will receive only half of their assigned full dose during the first week of treatment."
89335604|NCT03341962|Placebo Comparator|placebo (Induction)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging.
89335605|NCT03341962|Experimental|10 mg IMU-838 (Maintenance)|Two 5 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
89335606|NCT03341962|Experimental|30 mg IMU-838 (Maintenance)|Two 15 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.
89335607|NCT03341962|Placebo Comparator|placebo (Maintenance)|The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion).
89335608|NCT03341962|Experimental|30 mg IMU-838 (Open-label)|Two 15 mg tablets once daily of IMU-838 or one 30 mg tablet IMU-838 once daily for up to 10 years and up to 3 years in UK sites
89335609|NCT04782817|Experimental|High Flow Nasal Canula Oxygen Therapy|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
89335610|NCT04782817|Active Comparator|Provider Choice Standard Care|Participants be assigned standard provider choice of standard care therapy physician order set.
89335611|NCT01234597|Active Comparator|Arm A: Without Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the treating physician"
89335612|NCT01234597|Experimental|Arm B: Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: the patients are connected to a CGM sensor. Insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the national coordinator based on the data collected in the past previous days of CGM sensor monitoring."
89335613|NCT02313220|Experimental|Dapagliflozin and exenatide|Dapagliflozin 10 mg film-coated tablet once daily and exenatide 2 mg once weekly injection combined treatment for 24 weeks
89335614|NCT02313220|Placebo Comparator|Placebo|Placebo film-coated tablet once daily and placebo once weekly injection combined treatment for 24 weeks
89335615|NCT02313298|Experimental|Stereotactic Body Radiotherapy|An extreme hypofractionated regimen of 36.25Gy in 5 fractions over 10-11 days
89335616|NCT02309320|Experimental|ALX-0171|Inhalation of ALX-0171 during 3 consecutive days
89335617|NCT02309320|Placebo Comparator|Placebo|Inhalation of Placebo during 3 consecutive days
89335618|NCT03739489|Active Comparator|rTMS-PSI|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the posterior superior insula right.
89335619|NCT03739489|Active Comparator|rTMS-M1|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the right primary motor cortex.
89335620|NCT03739489|Active Comparator|rTMS-F3|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the left pre frontal dorsolateral cortex.
89335621|NCT01139749|Active Comparator|Oral isotretinoin|Subjects from treatment arm will be treated with low-dose oral isotretinoin - 20 mg a day, every other day, for six months
89335622|NCT01139749|Active Comparator|salicylic acid and ciclopirox olamine|Subjects from comparison arm will be treated with topical salicylic acid and ciclopirox olamine shampoo
88817589|NCT05727501|Active Comparator|Post isometric relaxation|This Group was treated with baseline treatment of heating for 15min and rehab protocol post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
89335623|NCT03508414|Experimental|Ketogenic diet|
89335624|NCT03508414|Experimental|Intermittent therapeutical fasting|
89335625|NCT03508414|Active Comparator|Control group|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
89335626|NCT01139827||normal|normal group has no diabetes.
89335627|NCT01139827||IGT|IGT group has impaired fasting glucose or impaired glucose tolerance.
89335628|NCT03506230|Experimental|Incentives group|a bonus to buy their medications if they improve their HbA1c
89335629|NCT03506230|No Intervention|Standard group|Will buy their medications as usual
89335630|NCT02309476|Experimental|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
89335631|NCT02309476|Experimental|PASCAL Laser, Green Laser 1 burn|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
89335632|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
89335633|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
89335634|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
89335635|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
89335636|NCT01140607|Experimental|Cohort 1: normal hepatic function: cabazitaxel|"cabazitaxel 25mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
89335637|NCT01140607|Experimental|Cohort 2: mild hepatic impairment : cabazitaxel|"cabazitaxel 20mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
89335638|NCT01140607|Experimental|Cohort 3: moderate hepatic impairment: cabazitaxel|"cabazitaxel 10mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
89335639|NCT01140607|Experimental|Cohort 4: severe hepatic impairment: cabazitaxel|"cabazitaxel 5 mg/m^2 or 10mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
89335640|NCT01140607|Experimental|Cohort 5: normal hepatic function: cabazitaxel and midazolam|"cabazitaxel 25mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).~Midazolam is given orally in single dosing on day -1 and day 1 (crossover)"
89335641|NCT02305810|Experimental|Single arm receiving everolimus|single treatment arm receiving everolimus 10 mg daily
89335642|NCT01139905|Other|1|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour
89335643|NCT03502954|Experimental|ABY-039 IV|
89335644|NCT03502954|Experimental|ABY-039 SC|
89335645|NCT03502954|Placebo Comparator|Placebo IV|
89335646|NCT03502954|Placebo Comparator|Placebo SC|
89335647|NCT01236313||TEE report|Cardiac surgery patients requiring TEE
89335648|NCT03506152||Culture positive|
89335649|NCT03506152||Culture negative|
89335650|NCT03506074||General population|"Adult volunteers (≥18 years of age) selected as part of a project to investigate the role of lifestyle in preventing chronic diseases supported by the Campus Salute association (www.campussalute.it).~All volunteers performed the flavor test as described in Maione et al, Endocrine, 2016 (doi:10.1007/s12020-015-0690-y)."
89335651|NCT02305966|Active Comparator|pressfit humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is -pressfit humerus & non-lateralized glenoid.
89335652|NCT02305966|Active Comparator|pressfit humerus & lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is - pressfit humerus & lateralized glenoid.
88818400|NCT05587335|Experimental|Online|Couples will be assigned into online relationship intervention.
89335653|NCT02305966|Active Comparator|cemented humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component. Therefore, 4 randomization groups will be created and one of them is cemented humerus & non-lateralized glenoid
89335654|NCT02305966|Active Comparator|cemented humerus & lateralized glenoid.|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is cemented humerus & lateralized glenoid.
89335655|NCT02309554|Active Comparator|SILCS Diaphragm alone|Participants will complete a post-coital test cycle with SILCS diaphragm alone.
89335656|NCT02309554|Active Comparator|SILCS Diaphragm with 3% Nonoxynol-9 Gel|Participants will complete a post-coital test cycle with SILCS diaphragm used with 3% nonoxynol-9 gel.
89335657|NCT02309554|Experimental|SILCS Diarphragm with ContraGel|Participants will complete a post-coital test cycle with SILCS diaphragm used with ContraGel.
89335658|NCT01140763||Sysmex's 5-blade cutter.|
89335659|NCT03721471||Frail, non-frail|"Frail Group: Those individuals identified as frail by low hand-grip-strength and/or the Clinical Frailty Scale.~Non-frail Group: Those individuals identified as not frail by hand-grip-strength and/or the Clinical Frailty Scale."
89335660|NCT03709225|Experimental|Music-based meditation|"The music therapy intervention consists of four in-person sessions (45 minutes) over twelve weeks. Content includes:~Introduction to music therapy and mindfulness~Music-based meditation~Using personal music to shift energy, mood, and support relaxation~Mindfulness through active music making~Discuss bringing mindfulness to daily activities"
89335661|NCT03502720||Control Patients|"Data obtained retrospectively from Scaphoid fixation surgeries performed at our center using the standard procedure (no device for guide wire positioning).~This control group should have registered al parameters and variables to be studied."
89335662|NCT03502720||Case Patients|Prospective series of ten patients on which the external 3D guide system will be used.
89335663|NCT01236469||Retrospective Patients|Pediatric (21 years of age or younger) patients who received a CryoValve SG Aortic Valve distributed during the 2000 to 2003 period as an aortic valve replacement.
89335664|NCT02313376|Experimental|GAP3KO|
89335665|NCT02309632|Active Comparator|Pathway 1|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 1
89335666|NCT02309632|Active Comparator|Pathway2|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 2
89335667|NCT05022355||scapulothoracic arthrodesis|"Individuals diagnosed with FSHD who have undergone unilateral or bilateral surgery who meet the inclusion criteria.~application of determined outcome scales on patients"
89335668|NCT05022355||non-operative|"Participants diagnosed with FSHD who have not undergone any surgery, who meet the inclusion criteria.~application of determined outcome scales on patients"
89335669|NCT02309710|Experimental|ShangRing|ShangRing administered to men seeking medical male circumcision
89335670|NCT05000593|Experimental|stem cell treating group|Intra-articular injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 1 week for a total of 3 times.
89335671|NCT01143025|Active Comparator|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
89335672|NCT01143025|Experimental|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
89335673|NCT01143025|Experimental|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
89335674|NCT02309788||RT|Resectable HCC patients adjuvant RT for PVT or NM
89335675|NCT02309788||No RT|Resectable HCC patients adjuvant other treatment for PVT or NM
89335676|NCT03502642|Placebo Comparator|Placebo (P)|Placebo group parturients will receive spinal anesthesia with intrathecal morphine and will have continuous normal saline wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
89335677|NCT03502642|Active Comparator|Ropivacaine (R)|Ropivacaine group parturients will receive spinal anesthesia without intrathecal morphine and will have continuous ropivacaine (Ropivacaina Molteni®) wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
89335678|NCT01140139|Experimental|HIV DNA + Hydroxyurea|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption. The patients also received 500 mg of hydroxyurea daily.
89335679|NCT01140139|Experimental|HIV DNA|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
89335680|NCT01140139|Placebo Comparator|Placebo|PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
89335681|NCT02306278|Placebo Comparator|vitamin capsules|vitamin capsules orally at the night before operation and 2 hours before surgery,respectively
89335682|NCT02306278|Experimental|gabapentin|gabapentin 600mg orally at the night before operation and 2 hours before surgery,respectively
89335683|NCT01140841||Fipamezole ODT|
89335684|NCT01140841||Placebo|
89335685|NCT02313610|Experimental|Qinbudan|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program （2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan table, table, 4, thrice a day, 8 months
89335686|NCT02313610|Placebo Comparator|Control Qinbudan Placebo|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program（2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan Placebo, table, 4, thrice a day, 8 months
89335687|NCT01143103|Experimental|Respiratory therapy with cough assist|
89335688|NCT01143103|Active Comparator|Usual respiratory therapy|
89335689|NCT02313688|Experimental|Group A|Group A: Patients in the Group A will underwent D2 total gastrectomy and with 3±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
89335690|NCT02313688|Experimental|Group B|Patients in the Group B will underwent D2 total gastrectomy and with 5±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
89335691|NCT01234753|No Intervention|Usulal care|Usual care by a visit to physician at the hospital out-patient clinic
89335692|NCT03505918|No Intervention|Standard municipal rehabilitation|Standard care with postoperative rehabilitation at the municipal facility.
89335693|NCT03505918|Experimental|No referral for rehabilitation|No referral for supervised postoperative rehabilitation. Only standard information booklet and advice during hospitalization.
89335694|NCT04645771|Experimental|Microwave ablations|A total of 50 patients with varicose veins of lower extremities treated with microwave ablation catheter were selected to observe their annual venous closure rate and postoperative adverse reactions.
88806852|NCT04979130|Experimental|SC semaglutide|Participants receive a once weekly, subcutaneous, Semaglutide injection for 16 weeks in addition to the participants background metformin monotherapy. The participants in this arm will begin at a 0.25 mg dose during the randomization visit, at week 4 this will be escalated to a 0.5 mg dose and at week 8 it will be escalated again to a 1.0 mg dose if tolerable by the participant. If the participant cannot tolerate the 0.25 mg dose at randomization or the 0.5 mg dose at week 4 they will be withdrawn from the study.
88806853|NCT04979130|Placebo Comparator|Placebo|Participants in this arm will be given a once weekly, subcutaneous, placebo injection matching the Semaglutide experimental arm in addition to their background metformin monotherapy.
89335695|NCT02309866||Genetic Testing|All participants determined eligible for the study will be placed into genetic testing arm.
89335696|NCT03505840||antiphospholipid group|pregnant ladies in the third trimester who have antiphospholipid syndrome
89335697|NCT03505840||control group|pregnant ladies in the third trimester who have no medical disorders with pregnancy
89335698|NCT04961515|Experimental|Phase Ib|"Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 250mg qd will be used for phase II trial.~Orelabrutinib: orally daily Sintilimab: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks (maximum 12 total dose)"
89335699|NCT04961515|Experimental|Phase II|"Participants will receive orelabrutinib and sintilimab at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles.~Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg) Sintilimab: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks"
89335700|NCT03508336||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
89335701|NCT04947787|Experimental|Intervention Group|Participants receive a physical activity referral scheme.
89335702|NCT04947787|Active Comparator|Control Group|Participants receive physical activity advice from general practitioners.
89335703|NCT02310022|Experimental|Drug Omega 3|4g (4 capsules) once a day, administered with food Other name MAT9001
89335704|NCT02310022|Active Comparator|Drug Omega 3 Comparator|4g (4 capsules) once a day, administered with food Other name Omega 3 Active Comparator
89335705|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not.
89335706|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid
89335707|NCT01234129||zoledronic acid|Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid
89335708|NCT03505684|Experimental|CTP group|1,000 mg of collagen tripeptide (CTP) was orally administered per day for 12 weeks.
89335709|NCT03505684|Placebo Comparator|Control group|1,000 mg of placebo (starch) was orally administered per day for 12 weeks
88806854|NCT04957290|Experimental|Part 1: Dose Cohort 1: NOX66 800 mg|
88806855|NCT04957290|Experimental|Part 1: Dose Cohort 2: NOX66 1200 mg|
88806856|NCT04957290|Experimental|Part 1: Dose Cohort 3: NOX66 1600 mg|
88806857|NCT04957290|Experimental|Part 1: Dose Cohort 4: NOX66 2400 mg|
88806858|NCT04957290|Experimental|Part 2: Arm 1: Patients with mCRPC (RP2D NOX66)|
88806859|NCT04957290|Experimental|Part 2: Arm 2: Patients with BC or NSCLC (RP2D NOX66)|
88806860|NCT04956952|Other|Enhanced External Counterpulsation (EECP)|1 hour of treatment with EECP
88806861|NCT04955626|Experimental|10 µg dose|1 dose
88806862|NCT04955626|Placebo Comparator|Placebo|1 dose
88806863|NCT04955626|Experimental|30 µg dose|1 dose
88806864|NCT04955626|Experimental|60 µg dose|1 dose
89335710|NCT02313844|Experimental|Viralym-B|"Partially HLA-matched Viralym-B cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-B/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
89335711|NCT02313922|Experimental|etanercept combined with methotrexate|patients treated with etanercept combined with methotrexate
89335712|NCT02313922|Experimental|etanercept as monotherapy|patients treated with etanercept combined with placebo
89335713|NCT03508180|Experimental|foot reflexology|patients WITH foot reflexology session during chemotherapy treatments
89335714|NCT03508180|Placebo Comparator|platinum-based treatment|Patients WITHOUT ANY foot reflexology session during chemotherapy treatments
89335715|NCT03505606|Active Comparator|Control|Visual acuity tests on control participants
89335716|NCT03505606|Experimental|Amblyopic|Visual acuity tests on amblyopic participants.
89335717|NCT03551977|Experimental|Intervention group|The intervention group will receive the iCanCope with Pain app with all five components: (I) symptom trackers for pain, sleep, mood, physical, and social function; (II) goal setting to improve pain and function; (III) coping toolbox of pain self-management strategies; (IV) social support; (V) age-appropriate pain education
89335718|NCT03551977|Active Comparator|Control group|The control group will receive the iCanCope with Pain control app with only the first self-registration component (I) symptom trackers for pain, sleep, mood, physical, and social function.
89335719|NCT03508102|Experimental|Remifentanil 1 μg kg-1 (R1)|Received remifentanil 1μg/kg when induction of general anesthesia
89335720|NCT03508102|Experimental|Remifentanil 0.5 μg kg-1 (R0.5),|Received remifentanil 0.5μg/kg when induction of general anesthesia
89335721|NCT03508102|No Intervention|saline (control)|Injected the equal volume normal saline when induction of general anesthesia
89335722|NCT03505528|Experimental|Cohort Group|There are five patient cohort groups. Each will receive a progressively higher starting dose of phenelzine sulfate, consecutively. Cohort A will start at 15mg/day and will be increased to 30mg/d by week 2 and further increased to 45mg/d for week 3, which will be maintained throughout the study. Cohort B will start at 45mg/d and will be held constant throughout the Study. Similarly, Cohort C, D & E will start at 60, 75 and 90mg/d, respectively, and will also be held on this dose throughout the study. The decision to escalate the dose for the next cohort will be made on the basis of the number of dose limiting toxicity (DLT) events observed during the first 8 weeks in the preceding cohort group. In addition, all cohort groups will receive a constant dose of Abraxane at 100mg/m2.
89335723|NCT01234909||Atopic dermatitis|Pediatric patients ages 1-18 years old with atopic dermatitis
89335724|NCT02314234||Control group|did not receive muscle relaxant during anesthesia
89335725|NCT02314234||Sugammadex group|received single dose of rocuronium for anesthesia and sugammadex at skin incision
89335726|NCT02306356|Experimental|Interventional|Behavioral: Internet-delivered Cognitive Behavior Therapy
89335727|NCT01234987||Breast cancer|
89335728|NCT01234987||Colon cancer|
89335729|NCT01234987||Lung Cancer|
89335730|NCT03502564|Active Comparator|CBT for ED only|In this arm, participants will receive CBT for ED following intensive ED treatment (see intervention section for description).
89335731|NCT03502564|Experimental|Concurrent CBT for ED and PTSD|In this arm, participants will receive concurrent CBT for ED and PTSD following intensive treatment. (see intervention section for description).
89335732|NCT02310178|Other|Group/Cohort|all of the current bariatric surgeries are allowed in this prospective cohort study
89335733|NCT02310256|No Intervention|Usual care|
89335734|NCT02310256|Active Comparator|Five Plus|Exercise training
89335735|NCT01234285|Experimental|intravenous heparin aPTT 40-50 seconds|Patients 11-15: IV heparin, target aPTT range 40-50 seconds
89335736|NCT01234285|Experimental|intravenous heparin|Patients 26-40: IV heparin, target range aPTT 50-60 seconds
89335737|NCT01234285|Experimental|Intravenous heparin|Patients 41-55 IV heparin, target aPTT range 60-70 seconds
88806865|NCT04946721||1.BMT Patients (Study)|Patients prior to receiving a bone marrow transplant will be recruited during their initial intake prior to their BM transplant through the PI's regularly scheduled appointment with these patients.
88806866|NCT04946721||2.Controls|Patients with no history of eye disease or cancer history
88806867|NCT04935658|Experimental|Virtual Reality Group|in this group, patients will use virtual reality during the oocyte retrieval plus the standard anesthesic procedure (local anesthesia)
88806868|NCT04935658|Sham Comparator|Standard Group|in this group, patients will receive the standard anesthesic procedure during the oocyte retrieval wich is local anesthesia
88806869|NCT04930315|Experimental|neoadjuvant and adjuvant group|Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4 cycles；apatinib：250mg, po, qd, q2w, 3 cycles Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles
88806870|NCT04930315|Active Comparator|adjuvant group|Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 12 cycles
88806871|NCT04927494|Experimental|Black women cervical cancer screening|Participants in this group with receive the Health is Wealth intervention.
89335738|NCT01234285|Active Comparator|sq heparin three times a day|Patients 1-10 will receive subcutaneous heparin three times a day
89335739|NCT03922594||Cameroon|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
89335740|NCT03922594||China|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
89335741|NCT03922594||Ivory Coast|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex and severely disproportionate length or weight according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
89335742|NCT03922594||Sri Lanka|Live newborns with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
89335743|NCT03922594||Vietnam|Fetuses or newborns (still-born, medical abortions or alive) with microcephaly defined as head circumference ≤-3SD according to INTERGROWTH standards for gestational age and sex with abnormal ultrasound and/or clinical examination findings for newborns
89335744|NCT02310334|Experimental|Unguided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the first visit, the participant will partake in an unguided exercise session.
89335745|NCT02310334|Experimental|Guided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the second visit, the participant will partake in a guided exercise session.
89335746|NCT02314312|Experimental|A: investigation arm|De novo kidney transplantation form ECD/AKI donor with Everolimus + low dose cyclosporinA + prednisolone as immunosuppressive regimen
89335747|NCT02314312|Other|B: control arm|De novo kidney transplantation form ECD/AKI donor with standard immunosuppressive regimen
89335748|NCT01585909|Other|Septic Shock|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with septic shock
89335749|NCT01585909|Other|SIRS|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with SIRS
89335750|NCT01585909|Other|healthy/controls|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients without SIRS/septic shock
89335751|NCT02316262|Experimental|TR|All subjects enrolled in this study will undergo pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally.Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle.
89335752|NCT01236625||No adhesiolysis|All patient undergoing elective laparotomy or laparoscopy with no need for adhesiolysis during the procedure.
89335753|NCT01236625||Adhesiolysis|All patient undergoing elective laparotomy or laparoscopy requiring adhesiolysis during the procedure.
89335754|NCT02314390|Experimental|G-MBCT|Group-Mindfulness-Based Cognitive Therapy
89335755|NCT02314390|Experimental|I-MBCT|Individual-Mindfulness-Based Cognitive Therapy
89335756|NCT01234363|Experimental|Magnetic Resonance Elastography, Supersonic Shear Imaging|Magnetic Resonance Elastography and Supersonic Shear Imaging
89335757|NCT01140997|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per Week, with Ribavirin 1000-1200mg/d
89335758|NCT01140997|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per Week, with Ribavirin 1000-1200mg/d
89335759|NCT01140997|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per Week, with Ribavirin 1000-1200mg/d
89335760|NCT01140997|Active Comparator|Group 4|Pegasys 180mcg per Week, with Ribavirin 1000-1200mg/d
89335761|NCT02316418|Experimental|Hairstetics™ anchoring system|Prosthetic hair implantation using the Hairstetics™ anchoring system, followed by attachment of hair extensions.
89335762|NCT03502486|Experimental|Moderate exercise|20 minutes of cycle ergometry at 50 - 60% of heart rate max.
89335763|NCT03502486|Experimental|Intense Exercise|20 minutes of cycle ergometry at 70 - 80% of heart rate max.
89335764|NCT03502486|Active Comparator|Rest|20 minutes of seated reading.
89335765|NCT02310490|Active Comparator|Right Side DermaVeil, Left Side Sculptra|DermaVeil right with left side Sculptra left side
89335766|NCT02310490|Active Comparator|Left Side DermaVeil, Right Side Sculptra|DermaVeil left with left side Sculptra right side
89335767|NCT02316496|Experimental|open label , single arm|cetuximab - irinotecan until progression or unacceptable toxicity
89335768|NCT02528851|Experimental|Higher CPAP|Infants extubated to CPAP level 2cm H2O higher than extubation EAP
89335769|NCT02528851|Active Comparator|Equivalent CPAP|Infants extubated to CPAP equivalent to extubation EAP
89335770|NCT02528773||HIV positive|Persons newly diagnosed with HIV.
89335771|NCT02316574|Experimental|Cognitive Behavioral Coping Skills|Cognitive Behavioral Coping Skills Therapy is an individual psychotherapy for alcohol use disorders that has been previously shown to reduce drinking. The focus of this treatment is the teaching of coping skills for managing alcohol craving and negative emotions as a way to reduce drinking behavior.
89335772|NCT01140529|Experimental|Dexmedetomidine|
89335773|NCT01140529|Active Comparator|Haloperidol|
89335774|NCT01140529|Placebo Comparator|Placebo|
89335775|NCT02310724||TODAY cohort|All subjects randomized to the TODAY clinical trial are eligible to participate in T2P2. The study performs long-term observation only and administers no treatment, care, or management.
89335776|NCT02310880||Low vision (virtual street training)|Low vision subjects trained in virtual streets and observed in real streets
89335777|NCT02310880||Low vision (real street training)|Low vision subjects trained in real streets and observed in real streets
89335778|NCT01235065|Active Comparator|direct laryngoscope|emergency intubation with direct laryngoscopy technique
89335779|NCT01235065|Active Comparator|video laryngoscope|emergency intubation with video laryngoscopy technique
89335780|NCT03501784|Experimental|Novidia Dental bonding and flow|Nobio particles incorporated within Novidia Dental Bonding and Flow.
89335781|NCT03501784|Active Comparator|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
89335782|NCT01143493||Carrier - Other|
89335783|NCT01143493||Carrier hGR N363S Heterozygote|
89335784|NCT01143493||Carrier hGR N363S Homozygote|
89335785|NCT01143493||Carrier hGR9B A3669G Heterozygote|
89335786|NCT01143493||Carrier hGR9B A3669G Homozygote|
89335787|NCT01143493||Control|
89335788|NCT02310958||Children with inguinal hernia|Laparoscopic surgical hernia repair in children aged between 1 day and 16 years
89335789|NCT01141153|Experimental|Oral anticoagulation plus dual antiplatelet therapy|
89335790|NCT01141153|Active Comparator|Dual antiplatelet therapy|
89335791|NCT02316730|Experimental|Sanchi-Tongshu Capsule (Enteric coated pellets)|Sanchi-Tongshu Capsule (Enteric coated pellets) is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.35g/capsule, containing 100mg of panaxatriol saponins (PTS).
89335792|NCT02316730|Active Comparator|Sanchi-Tongshu Capsule|Sanchi-Tongshu Capsule is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.2g/capsule, containing 100mg of panaxatriol saponins (PTS).
89335793|NCT01234441|Sham Comparator|Control|This group of patients will receive a non-nutritive beverage, and no exercise.
89335794|NCT01234441|Active Comparator|Protein|This group of patients will ingest 30 grams of a liquid whey protein supplement during the first hour of their dialysis session
89335795|NCT01234441|Active Comparator|Protein + Exercise|This group will ingest 30 grams of a liquid whey protein supplement as well as exercise for 30-45 minutes during their dialysis treatment
89335796|NCT04463524||Test|They will receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken.
89335797|NCT04463524||Control|They will not receive ECG sensor after initial standard 12-channel ECG record will be taken; they will return after 5 days and after 3 months to assess their hearth rhythm disorders and actions taken.
89335798|NCT02314858|Experimental|Brief Personalized Video (BPV)|Our BPV intervention focuses on augmenting risk perception and reducing optimistic bias by showing the patient a dramatic video of his/her own apnea (which shows them struggle to breathe), as well as by explaining the physiological processes involved in an apneic event. Specific apneic events are highlighted and associated decreases in blood oxygen levels are demonstrated via oxygen saturation recording superimposed on the video. This group will receive educational information about OSA, its consequences and the need for treatment.
89335799|NCT02314858|Active Comparator|Non-Personalized Video (NPV)|NPV will include a video of someone having apnea, but it will not be personalized. This group will receive educational information about OSA, its consequences and the need for treatment.
89335800|NCT02314858|Placebo Comparator|Treatment As Usual (TAU)|The TAU group will receive no special treatment from study interventionist team and will not view a video.
89335801|NCT01235143|Experimental|desflurane anesthesia|maintenance anesthesia with desflurane
89335802|NCT01235143|Active Comparator|sevoflurane|maintenance anesthesia with sevoflurane
89335803|NCT03502252|Experimental|Treatment Group|Semillas de Apego is a group-based psychosocial program for victimized caregivers with children 2 to 5 in Colombia, a country devastated by violence. The program's builds upon scientific evidence on (i) the way in which violence hinders early childhood development and erodes mothers' mental health and their capacity to form nurturing relationships with their children, and (ii) the effectiveness of promoting healthy child-parent attachments to mitigate the effects of toxic stress on toddlers (Lieberman and Van Horn, 2011).
89335804|NCT03502252|No Intervention|Control Group|Centers and participants assigned to the this group continue to have access to the regular early childhood programs offered through the centers to which children are affiliated.
89335805|NCT03293563||Patients|Adult patients with kidney cancer
89335806|NCT02315014|Experimental|whey protein|whey protein micelles
89335807|NCT02315014|Placebo Comparator|placebo|calorie-free placebo
89335808|NCT01238029|Experimental|Capecitabine, Lapatinib, Vinorelbine|
89335809|NCT02315092||Diabetic foot ulcers|Patients who present with diabetic foot ulcers will undergo fluorescence imaging.
89335810|NCT01144897|Experimental|PET Acetate Imaging with Docetaxel|"PET-acetate as an intermediate endpoint in the assessment of response of patients undergoing docetaxel for hormone refractory prostate cancer (HRPC).~Subjects will be treated with docetaxel, 75 mg/m2 every 21 days until disease progression or unacceptable toxicity occurs. Subjects will have two PET acetate scans - one prior to beginning chemotherapy and one approximately 8-9 weeks after chemotherapy has begun."
89335811|NCT03502096|Experimental|100% portion size|100% portion sizes of all foods served (baseline). To-go container and controls received this meal.
89335812|NCT03502096|Experimental|125% portion size|125% of baseline portions served. To-go container and controls received this meal.
89335813|NCT03502096|Experimental|150% portion size|150% of baseline portions served. To-go container and controls received this meal.
89335814|NCT03502096|Experimental|175% portion size|175% of baseline portions served. To-go container and controls received this meal.
89335815|NCT02311036|Other|Comorbidity_Comprehensive Rehabilitation|Charlson Comorbidity Index contains 19 categories of comorbidity and predicts the ten-year mortality for a patient who may have a range of co-morbid conditions Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. For a physician, it is helpful in knowing how aggressively to treat a condition. Higher scores indicating greater comorbidity (patients with a score > 5 have essentially a 100% risk of dying at one year).
89335816|NCT02311036|Other|MRS_Comprehensive Rehabilitation|The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.
89335817|NCT02311036|Other|MMSE_Comprehensive Rehabilitation|The mini mental state examination (MMSE) is the most commonly used instrument for screening cognitive function. This examination is not suitable for making a diagnosis but can be used to indicate the presence of cognitive impairment, such as in a person with suspected dementia or following a head injury. The examination has been validated in a number of populations. Scores of 25-30 out of 30 are considered normal; the National Institute for Health and Care Excellence (NICE) classifies 21-24 as mild, 10-20 as moderate and <10 as severe impairment. The MMSE may not be an appropriate assessment if the patient has learning, linguistic/communication or other disabilities (eg, sensory impairments).
89335818|NCT02311036|Other|BSRS_Comprehensive Rehabilitation|Brief Symptom Rating Scale is a rating scale which a clinician or researcher may use to measure psychiatric symptoms such as depression, anxiety, hallucinations and unusual behavior. Each symptom is rated 1-7 and depending on the version between a total of 18-24 symptoms are scored. The scale is the one of the oldest, widely used scales to measure psychotic symptoms and was first published in 1962.
89335819|NCT01235221|Experimental|BIIB041 (Fampridine-SR)|Participants take 10 mg sustained-release tablets of fampridine twice daily for up to 27 months or until the product is commercially available.
89335820|NCT03505450||Population sample|
89335821|NCT03505450||Purposive Sample|
89335822|NCT03505294|Experimental|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks will be applied."
89335823|NCT03505294|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform.
89335824|NCT03263923|Experimental|Arm 1: Cognitive behavioral skills training & 4 wks online journaling|"Cognitive behavioral skills' training and 4 weeks of online journaling.~Participants receive cognitive behavioral skills training by online video, then participants must complete a 28 day online journal reflecting on the cognitive skills they used to handle various situations."
89335825|NCT03263923|Active Comparator|Arm 2: Reflective journaling training & 4 wks online journaling|"Reflective journaling training and 4 weeks of online journaling.~Participants watch a reflective journaling video and complete a 28 day journal using a different set of prompts to reflect on their days and describe how they handled various situations."
89335826|NCT03139604|Experimental|Itacitinib|Itacitinib plus corticosteroids
89335827|NCT03139604|Placebo Comparator|Placebo|Matching placebo plus corticosteroids
89335828|NCT02311114||Telehomecare patients|Observational fieldwork, in depth interviews and surveys up to 4 times will be conducted.
89335829|NCT02311114||Health care providers|In-Depth interviews, observational fieldwork and one time survey will be conducted.
89335830|NCT02311114||Telehomecare administrators|In depth interviews will be conducted
89335831|NCT02311114||Telehomecare technicians|In-depth interviews, observational fieldwork will be conducted.
89335832|NCT02315404|Placebo Comparator|No cap|enteroscopy performed without a cap
89335833|NCT02315404|Active Comparator|Enteroscopy with a cap|Enteroscopy performed with a CAP fitted to the end of the scope
89335834|NCT03501628|Placebo Comparator|Placebo|"2 servings daily~Serving information:~204 kcal~2.8 g fat~44.4 g carbohydrate~0.4 g protein (0 g L-leucine)"
89335835|NCT03501628|Experimental|L-leucine + maltodextrin|"2 servings daily~Serving information:~200 kcal~2.0 g fat~43.1 g carbohydrate~2.8 g protein (2.8 g L-leucine)"
89335836|NCT03501628|Experimental|Whey protein concentrate|"2 servings daily~Serving information:~184 kcal~3.5 g fat~12 g carbohydrate~26.3 g protein (2.8 g L-leucine)"
89335837|NCT03501628|Experimental|Hydrolyzed whey protein concentrate|"2 servings daily~Serving information:~192 kcal~4.6 g fat~12.2 g carbohydrate~25.4 g protein (2.9 g L-leucine)"
89335838|NCT03501628|Experimental|Soy protein concentrate|"2 servings daily~Serving information:~266 kcal~4.5 g fat~17.2 g carbohydrate~39.2 g protein (2.9 g L-leucine)"
89335839|NCT01350596|Active Comparator|Reference Drug|
89335840|NCT01350596|Active Comparator|Test Drug|
89335841|NCT03139448|Active Comparator|Oxygen via nasal cannula (Standard of Care)|The anesthesia provider will supply oxygen via nasal cannula at oxygen flow rates as per standard of care routine at Vanderbilt University Medical Center.
89335842|NCT03139448|Experimental|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
89335843|NCT02316808|Placebo Comparator|Placebo smoothie|
89335844|NCT02316808|Experimental|Plant stanol ester smoothie|
89335845|NCT04462822|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
89335846|NCT04462822|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
89335847|NCT01350674|Experimental|EBUS|patients undergoing EBUS
89335848|NCT04462510|Experimental|Illioinguinal/Illiohypogastric Block|A single shot 20ml of 0.25% Ropivacaine was used to block illioinguinal/illiohypogastric nerves using ultrasound right before incision was given
89335849|NCT04462510|Experimental|Wound infiltration|Surgeon infiltrated the wound using 20ml of 0.25% Ropivacaine right after the skin was closed.
89335850|NCT01362218|Experimental|Fixed Dose Combination Pill|A fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril Intervention: Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
89335851|NCT01362218|Active Comparator|Simvastatin|Simvastatin given together with the reference drugs ramipril and acetylsalicylic acid
89335852|NCT02315482|Experimental|Group A|after induction of general anesthesia (i) a pneumoperitoneum is induced then (ii) patient is placed in steep trendelenburg position at 25 degrees head down
89335853|NCT02315482|Experimental|Group B|after induction of general anesthesia (i) the patient is placed in steep trendelenburg position at 25 degrees head down then (ii) a pneumoperitoneum is induced
89335854|NCT04568642|Active Comparator|Conventional|Device: conventional FiO2 will be selected by the clinician according to the SpO2 target
89335855|NCT04568642|Experimental|Closed-loop|Device: conventional FiO2 will be selected by the closed-loop algorithm according to the SpO2 target
89335856|NCT02316964|Experimental|Treatment (decitabine, allogeneic NK cells, aldesleukin)|Patients receive decitabine IV over 60 minutes on days -4 to 0 and undergo infusion of allogeneic NK cells on day 0. Beginning 1 hour after infusion allogeneic NK cells, patients also receive aldesleukin SC every other day for 6 doses.
89335857|NCT03501862|Experimental|Mindfulness-based intervention|Intervention: a twelve 1.5 weekly program on mindfulness-based cognitive therapy (psychosis)
89335858|NCT03501862|Active Comparator|Psychoeducation|Intervention: a twelve 1.5 hours weekly program on psychoeducation (psychosis)
89335859|NCT02875340|Experimental|VAL401 treatment|Patients received VAL401 oral formulation once daily according to their level of tolerance (2 mg - 10 mg).
89335860|NCT02315638||Dosed subjects|There is no intervention. This is a observational study monitoring subjects that were dosed with TT-034 in the Tacere B2801001 study,
89335861|NCT03237325|Experimental|SGX942|Patients are randomized 1:1 active/placebo.
89335862|NCT03237325|Placebo Comparator|Placebo|Patients are randomized 1:1 active/placebo.
89335863|NCT03498664|Experimental|EMR-C group|"A plastic cap for mucosectomy (MH-597, Olympus Optical Co., Ltd, Tokyo, Japan) with an outer diameter of 17 mm and a length of 15 mm will be preloaded on the tip of the colonoscope. Inside the distal end of the cap there is a gutter which positions the opened polypectomy snare.~After submucosal injection, the cap will be applied against the lesion which will be aspirated by controlled suction, avoiding excessive protrusion of tissue in order not to trap the muscular layer.~The tissue will then be gripped with the snare and resection will be performed. A specific polypectomy snare which can be adapted into the gutter of the cap will be used (SD-221U-25, Olympus Optical Co., Ltd, Tokyo, Japan)."
89335864|NCT03498664|Active Comparator|EMR-S group|The resection will be performed using a standard polypectomy snare, which diameter will be chosen according to the size of the lesion, after lifting the lesion from the underlying layers with a submucosal injection of liquid.
89335865|NCT01362452|Experimental|Double Umbilical Cord Blood (UCB)|"Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation."
89335866|NCT01362452|Experimental|Single Umbilical Cord Blood (UCB)|"Single UCB unit arm does not start enrollment until Dose Level A2 in the double UCB unit arm has been deemed safe.~Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation"
89335867|NCT04509284|Experimental|Training|Participants with persistent pain after breast cancer treatment will receive 24 sessions of individualized progressive total body resistance training, supervised by a certified strength and conditioning specialist.
89335868|NCT04509284|Other|Control|Participants with persistent pain after breast cancer treatment will be instructed to continue their everyday lifestyle and be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
89335869|NCT02320786|Experimental|CoPILOT|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (one hour, four times per week for three weeks).
89335870|NCT02320786|No Intervention|Standard of Care|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair, consisting of 12 hour protocols in a standard power wheelchair (one hour, four times per week for three weeks).
89335871|NCT01358942||Cohort|
89335872|NCT04462666|Experimental|HZG intervention|During the 5-day treatment period, participants in the Experimental group will receive 10 sacks of experimental granules. They will be instructed to take two sacks per day, one in the morning and one in the evening, in approximately 30 minutes after the meal.. The placebo etoricoxib will also be taken daily in the morning for 5 days.
89335873|NCT04462666|Active Comparator|Etoricoxib intervention|During the 5-day treatment period, participants in the Etoricoxib group will receive 5 Etoricoxib capsules. They will be instructed to take one capsule per day in the morning, at approximately 30 minutes after the meal. The placebo HZKL will also be taken daily in the morning for 5 days.
89335874|NCT04462666|Placebo Comparator|Placebo intervention|During the 5-day treatment period, participants in the Placebo group will receive 10 sacks of placebo HZG. They will be instructed to take two sacks per day, one sack in the morning and one in the evening, at approximately 30 minutes after the meal. And the placebo etoricoxib also be taken daily in the morning for 5 days.
89335875|NCT05170477|Experimental|Apical aptency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically
89335876|NCT05170477|Active Comparator|Non-apical patency|in Gp B apical patency will not be maintained
89335877|NCT01359020|Experimental|Ibuprofen|10 milligram per kilo, oral administration
89335878|NCT01359020|Active Comparator|Acetaminophen|10 milligram per kilo, oral administration
89335879|NCT01359020|Active Comparator|Dipyrone|10 milligram per kilo, oral administration
89335880|NCT03498586|Experimental|Half-normal saline|
89335881|NCT03498586|Active Comparator|Normal saline|
89335882|NCT01359098|Active Comparator|Ciprodex Otic Suspension|Ciprodex Sterile Otic Solution (Alcon, Inc.)
89335883|NCT01359098|Experimental|Ciprodexa Otic Foam|Ciprodexa Otic Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone otic foam)
89335884|NCT02320864||Non-surgical group|Adults who have knee osteoarthritis, but do not elect to have a total knee replacement surgery.
89335885|NCT02320864||Surgical group|Adults who have knee osteoarthritis and elect to have total knee replacement surgery.
89335886|NCT01319240|Experimental|IDegLira|
89335887|NCT01319240|Active Comparator|IDeg|
89335888|NCT01319240|Active Comparator|Lira|
89335889|NCT03498508||Healthcare professionals in Dalarna County Council|Healthcare professionals working in-hospital at the hospitals in Mora, Avesta and Falun, Sweden, n=1473.
89335890|NCT03498508||Healthcare professionals in Region Västmanland|Healthcare professionals working in-hospital at the hospital in Västerås, Region Västmanland, Sweden, n=1571.
89335891|NCT01141387||Patients at the intervention sites|The intervention sites will receive the results of the patient-reported depression severity collected during the phone interviews on a monthly basis. The patients in the intervention arm will be interviewed by phone once per month for 6 months.
89335892|NCT01141387||Patients at the usual care sites|The usual care sites will receive the results of the patient-reported depression severity at the end of the study. Patients in the usual care arm will be interviewed at 3 months and 6 months post study enrollment.
89335893|NCT01359176||Healthy volunteers|
89335894|NCT03498430|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Planned at least 12 patients who meet the entry criteria will receive 60 mg copanlisib as single agent, with dosing on Days 1, 8 and 15 of each 28-day treatment cycle
89335895|NCT03370952|Active Comparator|new approach|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:~Delivery of affected ovary outside the abdominal cavity:~A transverse mini-laparotomy is done (2-3 cm) in the midline 2 cm above the symphysis pubis.~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
89335896|NCT03370952|Active Comparator|Laproscopic ovarian cystectomy|classic laparoscopic ovarian cystectomy
89335897|NCT02315794|Experimental|SPI®ART|in test group after a three month healing period a zirconia abutment was connected to the implant to realize the prosthetic restoration
89335898|NCT02315794|Active Comparator|SPI®EASY|in control group a three month healing period a titanium abutment was connected to the implant for the prosthetic restoration
89335899|NCT03331640|Experimental|OFF|
89335900|NCT03331640|Experimental|FOLFIRI|
89335901|NCT01144975|Active Comparator|XOMA 052|
89335902|NCT01144975|Placebo Comparator|Placebo|
89335903|NCT04463056|Experimental|Elizaria®|International nonproprietary name: eculizumab
89335904|NCT04463056|Active Comparator|Soliris®|International nonproprietary name: eculizumab
89335905|NCT01359332|Experimental|hypothermia|
89335906|NCT01359332|No Intervention|control|
89335907|NCT02315950|Other|Arm 1|Botulinum toxin and cineMRI-UDS
89335908|NCT03113383|Experimental|Primary Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
89335909|NCT03113383|Experimental|Expanded Selection Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
89335910|NCT03319316|Experimental|Cohort 1 - Non-squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
89335911|NCT03319316|No Intervention|Cohort 1 - Non-squamous - Arm B|Patients receive a maintenance treatment of pemetrexed
89335912|NCT03319316|Experimental|Cohort 2 - Squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
89335913|NCT03319316|No Intervention|Cohort 2 - Squamous - Arm B|Patients will have observation
89335914|NCT01350752|No Intervention|Control|"In Cameroon: Existing practice (with microscopy widely available)~In Nigeria: Expected practice (RDTs will be provided with basic instructions)"
89335915|NCT01350752|Active Comparator|Provider Intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment. This involved 1-day training on: 1) Malaria Diagnosis; 2) Rapid Diagnostic Testing; 3) Malaria Treatment. These modules explain that all febrile patients should be tested for malaria; procedures for using an RDT; that confirmed cases of uncomplicated malaria should be treated with an ACT; and test-negative patients should not be given an antimalarial.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment. This involved a 2-day training workshop and support visits. The training covered the following topics: causes and symptoms of malaria; demonstration on how to use an RDT; updated malaria guidelines; and communications skills. The training used a combination of seminars and facilitated small-group work, such as a treatment algorithm game, problem-solving exercises, self-developed participatory drama and role-playing."
89335916|NCT01350752|Active Comparator|Extended intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment AND enhanced provider training on improving quality of care. Clinicians received 3-days of training: the first day was identical to the basic intervention, while the remainder of the course covered three additional modules targeting improvements in quality of care: 4) Adapting to Change; 5) Professionalism; 6) Communicating Effectively.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment AND School-based malaria education intervention (with drama, peer-health education and distribution of health education materials). In addition, teachers and Peer Health Educators were offered support to hold malaria events in which parents, guardians, and other community members could participate in the same types of activities."
89335917|NCT04462978||Non IgE-mediated food allergy|Children with non IgE-mediated food allergy
89335918|NCT01238107|Experimental|High dose|
89335919|NCT01238107|Experimental|Low dose|
89335920|NCT01238107|Placebo Comparator|Placebo|
89335921|NCT02316028|Experimental|decitabine|"administration of decitabine by hepatic arterial infusion~Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~Proposed dose levels:~10 mg/m2 per course~15 mg/m2 per course~20 mg/m2 per course"
89335922|NCT01359488|Experimental|VRS-317 Safety Arm 1|"VRS-317 Single injection SC of dose level 1 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
89335923|NCT01359488|Experimental|VRS-317 Safety Arm 2|"VRS-317 Single injection SC of dose level 2 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
89335924|NCT01359488|Experimental|VRS-317 Safety Arm 3|"VRS-317 Single injection SC of dose level 3 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
89335925|NCT01359488|Experimental|VRS-317 Safety Arm 4|"VRS-317 Two injections SC of dose level 4 (based on 90 kg patient)~Placebo Two SC injection Dose matched to treatment volume"
89335926|NCT01359488|Experimental|VRS-317 Safety Arm 5|"VRS-317 Two injections SC of dose level 5 (based on 90 kg patient)~Placebo Two SC injections Dose Volume matched to active treatment volume"
89335927|NCT01236703||ICU patients|ICU patients (post-operative and none operative patients) will be enrolled in the study. They are followed up until the end of ICU stay or, for a maximum of 60 days.
89335928|NCT02320942|Experimental|Exercise Intervention|At discharge from the inpatient unit, participants will receive a practical introduction by an exercise specialist and enrolled in the 12-week exercise intervention
89335929|NCT01141465||IPDA FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at ≥twice the equivalent BDP-equivalent dose
89335930|NCT01141465||IPDA FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at ≥twice the equivalent BDP-equivalent dose
89335931|NCT01141465||IPDI FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at equivalent BDP-equivalent dose
89335932|NCT01141465||IPDI BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at equivalent BDP-equivalent dose
89335933|NCT01141465||IPDI FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at equivalent BDP-equivalent dose
89335934|NCT01141465||IPDA BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at ≥twice the equivalent BDP-equivalent dose
89335935|NCT01141543||cohort 1|Patients in Cohort 1 will be followed with daily Flowcytometric studies to quantify CXCR4 positive cells.The samples will be obtained before the following doses of FLUDARABINE and BUSULFAN. Eighteen hrs (range 18 -20 hrs) after start of the last dose of FUDARABINE andBUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR
89335936|NCT01141543||Cohort 2|Patients in Cohort 2 will receive the second dose of PLERIXAFOR 24 hrs after the first dose. A PB sample for a CBS and Flowcytometry will be drawn prior to the dose. Nine hrs later a further study sample for Flowcytometry will be obtained prior to administration of the second dose of FLUARABINE and BUSULFAN. Flowcytometric studies will be repeated on day 3 and 4. Eighteen hrs (range 18 - 20 hrs) after start of the last dose of FLUDARABINE and BUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR.
89335937|NCT01141543||cohort 3|Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN
89335938|NCT01141543||Cohort 4|Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
89335939|NCT03300518|Other|pretreatment group|the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
89335940|NCT03300518|Other|control groups|In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
89335941|NCT02317198|Experimental|Intervention|Clopidogrel
89335942|NCT02317198|Active Comparator|Control|Ticagrelor/Prasugrel
89335943|NCT03498274|Experimental|Fitting System|a self-directed hearing screening based on a known algorithm from Audiology Inc. sold in an automated audiogram by Grason Stadler, GSI and a simplified version of the software. The flow of the new software is driven by the end user, but a trained professional should always assist with the fitting. The new software will first perform a hearing screening on the end user and then recommend a hearing aid and prescribe amplification to the hearing aid based on the hearing screening results.
89335944|NCT03498274|Active Comparator|Traditional Fitting System|A traditional fitting method will be used as a control. This system is controlled by a trained professional, who performs the entire fitting without much interaction from the end user. The hearing instruments will be fit with the same settings as the experimental arm.
89335945|NCT01350830|Active Comparator|pre-trasversalis mesh repair group|
89335946|NCT01350830|Active Comparator|trans-inguinal preperitoneal patch group|
89335947|NCT03038347|Experimental|Training|In the training group, participants work six weeks on the training program, one module per week. The modules contain PDF-files with text-based information, video files, case studies with associated questions as well as practical exercises that participants perform independently. The main purpose of this intervention is the improvement of cross-cultural competencies in psychotherapists
89335948|NCT03038347|Active Comparator|Education only|In the education only group, participants work six weeks on a slimmed down version of the training program. The modules only contain text-based information without any exercises. After completion, participants receive access to the practical exercises, case studies and video files as well. Main purpose of the education only group is to determine whether the practical part of the training program can offer additional benefit.
89335949|NCT03038347|No Intervention|Waiting control|Initially, participants do not receive any training contents. After a six week waiting period, they can participate in the training program as well. Modules are equivalent to those of the training group. Purpose of this group is to determine whether the training program is effective.
89335950|NCT03294434||High Grade Glioma|Diffusion tensor Imaging (DTI-MRI) scan to be performed pre-operatively and pre-radiotherapy
89335951|NCT02324374|Experimental|Endocytoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
89335952|NCT01141699||female|Women who live in the Shuang Ho Region of Taipei City. Women can read and write chinese language.
89335953|NCT01359722|Experimental|N-Acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
89335954|NCT01359722|Placebo Comparator|Control|This group will receive only the infusion of saline in the same doses and infusion rate.
89335955|NCT03501472|Experimental|Text-only PWL, immediate post|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
89335956|NCT03501472|Experimental|Text-only PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
89335957|NCT03501472|Experimental|Low-emot PWL, immed post|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
89335958|NCT03501472|Experimental|Low-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
89335959|NCT03501472|Experimental|High-emot PWL, immed posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
89335960|NCT03501472|Experimental|High-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
89335961|NCT01143805|Experimental|Treatment A: Tasocitinib 10 mg oral tablet|
89335962|NCT01143805|Experimental|Treatment B: Tasocitinib 10 mg IV Infusion|
89335963|NCT01362764|Other|001|Abiraterone acetate tablets Type=exact unit=mg number= 250 form=tablet route=oral use as a single dose
89335964|NCT01362764|Other|002|Abiraterone acetate suspension Formulation 1 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
89335965|NCT01362764|Other|003|Abiraterone acetate suspension Formulation 2 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
89335966|NCT01236781|Experimental|Group A: Screening|Group A comprises 500 asymptomatic women with no history of breast cancer who are scheduled for routine screening of the breasts with FFDM.
89335967|NCT01236781|Experimental|Group B: Diagnostic Enriched Population|Approximately 50 asymptomatic women with no history of breast cancer who have been informed of positive (abnormal) findings from a recent (within 30 days) FFDM screening will be recruited to Group B prior to their diagnostic imaging (e.g., diagnostic FFDM and/or ultrasound and/or other).
89335968|NCT04457960|Experimental|JNJ-66525433|Participants will receive JNJ-66525433 in increasing dose level 1 to dose level 4 in Parts 1, 2, and dose level 3 in part 3.
89335969|NCT04457960|Placebo Comparator|Placebo|Participants will receive matching placebo in Parts 1, 2 and 3.
89335970|NCT03498118|Experimental|Transversus Abdominis Plane Block group|after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
89335971|NCT03498118|Active Comparator|Wound Infiltration group|at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure
89335972|NCT01145131|Experimental|Beef steak|
89335973|NCT01145131|Experimental|Minced beef|
89335974|NCT03498040||Patients with or at risk of carcinoid heart disease|"Adult patients with well-differentiated metastatic ileum or bronchial neuroendocrine tumor~Adult patients with carcinoid syndrome or elevated urinary 5HIAA regardless of primary site"
89335975|NCT01362920||Sepsis or Septic shock cohort|
89335976|NCT01362920||Non-sepsis or non-Septic shock cohort|
89335977|NCT03497962||ITU patients|25 patients will be recruited from the Intensive Care Unit/ High dependency unit Inclusion- Adults (>18years) with community acquired pneumonia (CAP).
89335978|NCT03497962||Healthy volunteer|24 healthy adult volunteers will be recruited to establish a comparison data set and to extend the laboratory observations to include other bacterial pathogens.
89335979|NCT01141777|Active Comparator|Spirulina platensis|
89335980|NCT01141777|Placebo Comparator|Soya bean|
89335981|NCT01350986|Experimental|Directive|
89335982|NCT01350986|Active Comparator|Non-Directive|
89335983|NCT03494452||Low back pain - no intervention|Patients who perform sitting occupational activities for at least 4 hours/day and have had low back pain for at least the previous 6 months
89335984|NCT03494452||Healthy - no intervention|Healthy persons who perform sitting occupational activities for at least 4 hours/day
89335985|NCT01235299||Healthy subjects|
89335986|NCT01235299||Subjects suffering from Diabetes mellitus|
89335987|NCT01235299||Subjects suffering from peripheral arterial occlusive disease|
89335988|NCT03501394|Experimental|Single Arm|25 patients with pathologically confirmed invasive breast cancer who will undergo neoadjuvant chemotherapy treatment (NACT) and surgery will be recruited. During the study, patients will receive the standard care and the current study will not alter the care plan offered to them. All patients in the single arm will undergo 4 magnetic resonance imaging scan sessions. Histopathological analysis will be performed on the core biopsy and tumour tissue removed in surgery. Health questionnaire will be completed by each patient.
89335989|NCT05188742|Experimental|Sequence A|mirabegron 50mg OD x 8 weeks, followed by mirabegron 50mg OD and TTNS for 4 weeks, followed by TTNS twice a week x 8 weeks
89335990|NCT05188742|Experimental|Sequence B|TTNS twice a week x 8 weeks, followed by mirabegron 50mg OD and TTNS for 4 weeks, followed by mirabegron 50mg OD x 8 weeks
89335991|NCT02324452|Experimental|heterozygous carrier of DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for one of these SNPs
89335992|NCT02324452|Experimental|wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
89335993|NCT01359800||Treatment-naive HIV+ subjects|
89335994|NCT01359800||HAART-treated HIV+ subjects|
89335995|NCT02324530|Experimental|Lung tumors|Patients with > 1 cm tumor motion simulated using 4DCT with and without CPAP
89335996|NCT02324530|Experimental|Left sided Breast cancer|Patients with heart abutting chest wall will be simulated using 4DCT with and without CPAP
89335997|NCT02324530|Experimental|Abdominal tumors|Patient with liver metastases for SBRT or pancreatic tumors will be simulated using 4DCT with and without CPAP
89335998|NCT03497884|Experimental|Real rTMS (low frequency)|Real rTMS (low frequency) is 1Hz.
89335999|NCT03497884|Sham Comparator|Sham rTMS|Sham rTMS session includes low frequency and high frequency stimulations.
89336000|NCT03497884|Experimental|Real rTMS (high frequency)|Real rTMS (high frequency) is 10Hz.
89336001|NCT01363154|Active Comparator|Mozart K448|Treatment: music exposure to Mozart K448
89336002|NCT01363154|Placebo Comparator|Beethoven's Für Elise|Placebo: music exposure to Beethoven's Für Elise for piano
89336003|NCT01363154|No Intervention|No music exposure|Control: no music exposure
89336004|NCT03501316|Active Comparator|Hand Instrumentation|Root surface debridement using hand instruments.
89336005|NCT03501316|Active Comparator|Ultrasonic Instrumentation|Root surface debridement using ultrasonic scaler.
89336006|NCT01351220|Active Comparator|Basic dissemination|
89336007|NCT01351220|Active Comparator|Organizational dissemination|
89336008|NCT01363232|Experimental|BKM120 + MEK162|
89336009|NCT02321176|Experimental|pharmacokinetics,trans-resveratrol|tissues from the eyes of the surgery of patients who received 1 Longevinex containing 100 mg of trans resveratrol active ingredient brand capsule for three days
89336010|NCT04418882||non septic open fracture|patients having had an open fracture without septic evolution
89336011|NCT04418882||septic open fracture|patients having had an open fracture with septic evolution
89336012|NCT03494296||Open, multi-center, prospective|All enrolled and relapsed patients received D-COP regimen chemotherapy
89336013|NCT01359878|Experimental|Fibrinogen Concentrate|
89336014|NCT01359878|Placebo Comparator|Placebo|Isotonic Saline
89336015|NCT01351298|Placebo Comparator|Saline spray|
89336016|NCT01351298|Experimental|Decongestant|
89336017|NCT01351298|Experimental|Decongestant and local anesthetic|
89336018|NCT02324686|Other|Vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
89336019|NCT01360034|Experimental|Nifedipine|108 patients will receive nifedipine as tocolytic for 48 hours.
89336020|NCT01360034|Experimental|Indomethacin|108 patients will receive indomethacin as tocolytic for 48 hours.
89336021|NCT02321254|Experimental|The RehaARM-Robot|Receive 45 min of robot-assisted therapy for the shoulder and 1 hour of daily standard rehabilitation therapy.
89336022|NCT01363310|Active Comparator|Quetiapine XR|
89336023|NCT01363310|Active Comparator|Escitalopram|
89336024|NCT02321332|Active Comparator|B-ETS|Bilateral simultaneous endoscopic thoracic sympathectomy: bilateral simultaneous T2-T3 ganglionectomy.
89336025|NCT02321332|Active Comparator|S-ETS|unilateral sequential endoscopic thoracic sympathectomy: unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval
89336026|NCT01363466|Experimental|with hysterectomy|
89336027|NCT01363466|No Intervention|without hysterectomy|
89336028|NCT03501004|Experimental|The Acupuncture Group|Sterile acupuncture needles for single use will be used.The intervention is going to be executed using the acupuncture points GV14（Dazhui）and GB20 (Fengchi) for 20 minutes.The acupuncture needles will be inserted to a depth of 0.8 to 1 cm using GV14（Dazhui）and GB20 (Fengchi).
89336029|NCT03501004|Sham Comparator|The Sham Acupuncture Group|Sterile acupuncture needles for single use will be used.The sham acupuncture group's acupuncture needles will be inserted to a depth of 0.1 to 0.2 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points for 20 minutes.
89336030|NCT02317588|Active Comparator|Flax Oil|Flax oil 4 grams of ALA per day for 28 days (4 weeks).
89336031|NCT02317588|Active Comparator|Fish Oil|Fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day for 28 days (4 weeks).
89336032|NCT01363544|Experimental|Neurofeedback|
89336033|NCT01363544|Experimental|Exercise|
89336034|NCT01363544|Active Comparator|methylphenidate|optimum dose of methylphenidate (assessed by a double blind placebo-controlled procedure)
89336035|NCT04462354|Active Comparator|Pancreatogastric anastomosis.|
89336036|NCT04462354|Experimental|Blumgart Anastomosis|
89336037|NCT04462432||Anterior Cruciate Ligament injury and reconstruction group|According to the previous clinical diagnosis, volunteers who has never suffered the Anterior Cruciate Ligament injury.
89336038|NCT04462432||normal control group|According to the previous clinical diagnosis, volunteers who has never suffered the lower extremity sports injuries.
89336039|NCT01363622||SGA|SGA (small for gestational age)
89336040|NCT01363622||LGA|LGA (large for gestational age)
89336041|NCT01363622||AGA|AGA (appropriate-for-gestational-age)
89336042|NCT03257618|Experimental|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
89336043|NCT02317666|Experimental|Medication Review|Structured 5-step multidisciplinary medication review (STRIP method) performed by the pharmacist in collaboration with the general practitioner.
89336044|NCT02317666|No Intervention|Delayed Medication Review|Patients in the control group will not undergo a medication review during the study period (delayed medication review).
89336045|NCT01363778|Experimental|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
89336046|NCT02321410|Other|Imaging of carotid plaque|Patient undergo contrast enhanced ultrasound of the carotid plaque and dynamic contrast-enhanced carotid plaque MRI
89336047|NCT02324998|Experimental|Group A|Olaparib Monotherapy
89336048|NCT02324998|Experimental|Group B|Olaparib in combination with degarelix
89336049|NCT03500926|Active Comparator|hype standard|total hip replacement with standard femoral stem
89336050|NCT03500926|Experimental|hype mini|total hip replacement with short uncemented femoral stem
89336051|NCT02325076|Experimental|Spirodoc|One time during examination at the outpatient unit
89336052|NCT05188430|Active Comparator|Active treatment|Medical Device (Kaptufat®)
89336053|NCT05188430|Placebo Comparator|Placebo|Placebo
89336054|NCT03497650|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb while observing the reflection of the exercising limb in the mirror which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
89336055|NCT03497650|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
89336056|NCT05188352|Experimental|Training group|Patients in the training group received supervised aerobic exercise training on the treadmill with the intensity of 60-75% of maximal VO2 for 40-50 minutes, 3 days a week for 8 weeks. Work-load was gradually increased during the eight-week period. In addition, conventional chest physiotherapy and was instructed to continue their daily physical activity program at home patients in this group.
89336057|NCT05188352|Active Comparator|Control group|Patients in the control group received no aerobic exercise training but were asked to continue their chest physiotherapy and daily physical activity program at home.
89336058|NCT01363856||First ever acute stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
89336059|NCT03500848|Active Comparator|Tacrolimus-based group|Tacrolimus-based immunosuppression regimen: Tacrolimus+MMF and/or steroids
89336060|NCT03500848|Experimental|Sirolimus-based group|Sirolimus-based immunosuppression regimen: Tacrolimus (Tacrolimus elimination 30 (± 5) days post LT)+Sirolimus+MMF and/or steroids
89336061|NCT01351454|Active Comparator|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
89336062|NCT01351454|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
89336063|NCT01360190|Active Comparator|fluoxetine|
89336064|NCT01360190|Placebo Comparator|placebo|
89336065|NCT03500770|Experimental|Transcranial Direct Current Stimulator|The Transcranial Direct Current Stimulator device (tDCS) is a safe technique which poses a non-significant risk to study subjects. This technique uses weak current which is applied by using two electrodes. In the literature, no undesirable or long-lasting side effects due to device have been reported, nor have any participants reportedly abandoned a study due to discomfort.
89336066|NCT01351532|Experimental|Lifestyle counseling, smoking cessation drug|
89336067|NCT01351532|Active Comparator|Lifestyle counseling|
89336068|NCT02321566|Experimental|Treatment Arm|A craniotomy will be performed for the placement of an epidural motor cortex stimulation lead in the context of subjects with chronic facial, upper extremity, and throat pain. If the stimulation is successful during a trial period with externalized lead cabling, the system cabling will be internalized and connected to an internal implantable pulse generator to power and control the system for the duration of the trial.
89336069|NCT01351610|Experimental|Group B|
89336070|NCT01351610|Experimental|Group A|
89336071|NCT02325232|Experimental|Enteroscopy|Capsule endoscopy, double balloon enteroscopy sequential use
89336072|NCT01363934|Experimental|Group A|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
89336073|NCT01363934|Experimental|Group B|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
89336074|NCT01363934|Experimental|Group C|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
89336075|NCT01363934|Experimental|Group D|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
89336076|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by IV|Darbepoetin alfa 30ug/kg once intravenously
89336077|NCT01363934|Experimental|Group H|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
89336078|NCT01363934|Experimental|Group I|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
89336079|NCT01363934|Experimental|Group J|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
89336080|NCT01363934|Experimental|Group K|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
89336081|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by SC|Darbepoetin alfa 30ug/kg once subcutaneously
89336082|NCT02325310|Experimental|Breastfeeding women|70 breastfeeding women meeting all the inclusion criteria and none of the exclusion criteria will be immunized with MMR vaccine in postpartum (before the exit of the maternity)
89336083|NCT01351688|Experimental|AZD3514|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
89336084|NCT03132376|Experimental|Breakfast Preload Drink|"Participants were given isovolumetric drinks, to consume in the morning after an overnight fast, followed by questionnaires asking throughout the day asking participants of their perceived hunger, fullness, desire to eat, and prospective food consumption, and if they would like to eat again. Four hours following consumption, they were given an ad libitum pasta meal to consume.~The drinks consisted of the following:~Water Preload Drink, Whey Protein Isolate Drink, Micellar Casein Protein Drink, Egg White Isolate Protein Drink, and Egg White Concentrate Protein Drink"
89336085|NCT03973112|Experimental|HLX10 3 mg/kg + HLX04 5 mg/kg|HLX10 3 mg/kg + HLX04 5 mg/kg, as second-line treatment or above
89336086|NCT03973112|Experimental|HLX10 3 mg/kg + HLX04 10 mg/kg|HLX10 3 mg/kg + HLX04 10 mg/kg,as second-line treatment or above
89336087|NCT03973112|Experimental|HLX10|HLX10 3mg/kg, as second-line treatment or above
89336088|NCT03973112|Experimental|HLX10+HLX04 1L treatment|HLX10 3 mg/kg + HLX04 10 mg/kg: as first-line treatment
89336089|NCT02321644|Experimental|CC-90001|"Part 1: All subjects will receive the following doses of CC-90001 in the fixed sequence below:~Treatment A: 60 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment B: 160 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment C: 400 mg of CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days"
89336090|NCT02321644|Experimental|CC-90001 2 X 100mg fasted|Treatment D: 2 x 100 mg CC-90001 as Active-Ingredient-in-Capsule, single oral dose administered under fasted conditions.
89336091|NCT02321644|Experimental|CC-90001 1 X 200mg fasted|Treatment E: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fasted conditions
89336092|NCT02321644|Experimental|CC-90001 1 X 200mg fed|Treatment F: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fed conditions (standard high fat breakfast).
89336093|NCT01364012|Experimental|Bevacizumab + Paclitaxel/Carboplatin|Participants will receive bevacizumab on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
89336094|NCT01364012|Active Comparator|Placebo + Paclitaxel/Carboplatin|Participants will receive bevacizumab matching placebo on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab matching placebo on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
89336095|NCT02317900|Experimental|TV005 and rDEN2∆30-7169|Participants will receive one injection of TV005 at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
89336096|NCT02317900|Placebo Comparator|Placebo and rDEN2∆30-7169|Participants will receive one injection of placebo at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
89336097|NCT03497494|Active Comparator|Without hiatal suture|the different distance of pylorus without hiatal suture
89336098|NCT03497494|Active Comparator|With hiatal suture|the different distance of pylorus without hiatal suture
89336099|NCT05188274|Experimental|T92 group|The dose of T92 was calculated based on body weight, orally twice daily. Supportive care duration: 8 weeks
89336100|NCT05188274|Placebo Comparator|Placebo group|The dose of placebo was calculated based on body weight, orally twice daily. Supportive care duration: 8 weeks
89336101|NCT03497416||Anemic|
89336102|NCT03497416||Non-anemic|
89336103|NCT01351844|Active Comparator|Education and exercise intervention|"The intervention module will contain a brief series of slides with a voice-over. An occupational therapist will review recommended exercises."
89336104|NCT01351844|Placebo Comparator|Education and general exercise|"The control module will contain a brief series of slides with a voice-over. A physical therapist with experience in treating breast cancer patients will demonstrate a series of 4-5 general stretching and toning exercises."
89336105|NCT02325388|Experimental|Treatment group with ForeSite PT™ system|Inpatients assigned to the treatment group with the ForeSite PT™ system will have its LCD monitor turned on (i.e., real-time images of interface pressure will be displayed on the monitor) during their enrolment in the trial.
89336106|NCT02325388|No Intervention|Control group|Inpatients assigned to the control group will have the ForeSite PT™ system's LCD monitor turned off and hidden (i.e., real-time images of interface pressure will not be displayed on the monitor). As the ForeSite PT™ system will continue to record interface pressure with the display turned off, this enables patients enrolled in the control group to undergo silent monitoring.
89336107|NCT01360346|Experimental|Enteral Sedation (EN)|Melatonin, Hydroxyzine, and Lorazepam. At every work shift, it will be checked the possibility to decrease the Lorazepam and then the Hydroxyzine dosage to quickly obtain and continuously maintain a RASS level = 0
88806872|NCT04899323||Cohort|Perform a 250cc vascular filling over 10 minutes and then perform a cardiac ultrasound. Repeat the vascular filling followed by the ultrasound as long as the patient is responsive.
88806873|NCT04896801|Experimental|MR-guided prostate stereotactic body radiotherapy|Patients will receive MR-guided RT in 5 fractions over 7 days (daily excluding weekend, i.e. start on Wednesday or Thursday, until Tuesday or Wednesday respectively the week after).
89336108|NCT01360346|Active Comparator|Intravenous Sedation (IV)|Intravenous propofol or midazolam administration at the ICU admission to discharge at the compatible lowest level with harsh ICU environment. At every shift nurses are requested to give intravenous lowest dosage to obtain RASS=0
89336109|NCT03494218|Experimental|vegetative state|patients with vegetative state lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
89336110|NCT03494218|Experimental|minimally conscious state|Patients with minimally conscious state display inconsistent, but reproducible and discernible signs of awareness using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
89336111|NCT03972254|Experimental|Intervention|Caregivers and their child will interact for 10 minutes while being observed and videotaped. Psychoeducation will be provided and goal setting will occur to ensure dyad specific relationship gains are made.
89336112|NCT02317978||Subfertility without polycystic ovarian syndrome|The records of all women with infertility who had IVF/ICSI without polycystic ovarian syndrome (PCO) will be reviewed
89336113|NCT01364246|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Intervention group
89336114|NCT02318056|Experimental|Aquacel® Ag Burn Glove|Application of Aquacel® Ag Burn Glove burn dressing
89336115|NCT02318056|Active Comparator|Mepilex® Transfer Ag|Application of Mepilex® Transfer Ag burn dressing
89336116|NCT02318056|Active Comparator|Xeroform®/Bacitracin®|Application of Xeroform® burn dressing and Bacitracin® topical antibiotic
89336117|NCT02325544|Experimental|CBT+SMC|12 sessions of Cognitive Behavioural Therapy adapted for DS (plus one booster session) plus standardised medical care
89336118|NCT02325544|Active Comparator|SMC|Standardised medical care provide by neurologist and/or psychiatrist
89336119|NCT01351922||A|
89336120|NCT01360424|Experimental|teriparatide|
89336121|NCT04461652|Experimental|New method|One thoracic tube (28fr drainage tube) was inserted through intercostal incision, and one microtubule (7fr × 20cm) was punctured through the middle line of clavicle
89336122|NCT04461652|Placebo Comparator|Traditional method|Two conventional chest tubes (28fr or 24fr) were placed through intercostal incision
89336123|NCT01364324||Gastrectomy|Twenty gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
89336124|NCT01364324||Non-gastrectomy|Twenty non-gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
89336125|NCT01352000|Active Comparator|Usual Care (UC)|Receive Quitline services
89336126|NCT01352000|Active Comparator|Repeated Mailings (RM)|Receive the 8 Forever Free booklets sent by mail at regular intervals over a period of 12 months
89336127|NCT01352000|Active Comparator|Massed Mailings (MM)|Receive all 8 booklets in a single mailing
89336128|NCT01364402|Experimental|Erythropoietin|
89336129|NCT01364402|Placebo Comparator|Placebo|
89336130|NCT02325700||Open aortic repair|145 patients with open aortic repair for abdominal aortic aneurysmal disease (n=139) or abdominal aortic occlusive disease (n=89)
89336131|NCT02325700||Laparoscopic aortic repair|83 patients with Laparoscopic aortic repair for abdominal aortic aneurysmal disease (n=30) or abdominal aortic occlusive disease (n=53)
89336132|NCT03552380|Experimental|Entinostat, Nivolumab and Ipilimumab|"Entinostat: 5mg, 3mg, or 2mg orally (PO) on D1, 8, 15 plus Nivolumab: 3 mg/kg IV D1 and Ipilimumab 1 mg/kg IV D1~Each cycle is 21 days"
89336133|NCT02318290||Critically ill patients|Mechanically ventilated critically ill patients receiveing opiates for more than 96 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opiates
89336134|NCT01317680|Active Comparator|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
89336135|NCT01317680|Placebo Comparator|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy.
89336136|NCT03494062|Experimental|Exercise|Home-based exercise intervention
89336137|NCT03494062|No Intervention|Control|Usual care
89336138|NCT03500536|No Intervention|Waitlist Control|8 weeks of treatment as usual followed by 8 weeks of IntelliCare treatment.
89336139|NCT03500536|Experimental|Experimental|8 weeks of IntelliCare treatment followed by 8 weeks of treatment as usual.
89336140|NCT03452072|Experimental|0.25% Timolol gel under the paraffin gauzes|"Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
89336141|NCT03452072|Active Comparator|Standard of Care dressings|"Vaseline will be applied to wound bed immediately after surgery before dressing is applied~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
89336142|NCT02325778|Experimental|CTI First|CTI ablation prior to left atrial ablation
89336143|NCT02325778|Experimental|CTI second|CTI ablation after left atrial ablation
89336144|NCT03493984|Experimental|Ginger exosomes|
89336145|NCT03493984|Experimental|Aloe exosomes|
89336146|NCT03493984|Experimental|Ginger and aloe exosomes|
89336147|NCT03493984|Placebo Comparator|Placebo|
89336148|NCT03433040|Other|non obese|250mg 17 OHP-C
89336149|NCT03433040|Other|obese - control|250mg 17 OHP-C
89336150|NCT03433040|Experimental|obese|500mg 17 OHP-C
89336151|NCT03493906|Experimental|Intervention|Patient Ambassador Support
89336152|NCT03316430||Patients|Patients coming before 16 weeks of gestation at their first planned prenatal visit at the Hôpital Femme Mère Enfant, who planned to deliver at the Hôpital Femme Mère Enfant
89336153|NCT02318446|Placebo Comparator|Control group|Will receive Oral saccharine tablet daily for 1month along with their existing antiepileptic therapy
89336154|NCT02318446|Experimental|Test group|Will receive Oral Folic acid 1mg tablet daily for 1month along with their existing antiepileptic therapy
89336155|NCT02325934|Active Comparator|Reference|Stribild Standardized breakfast followed by a single dose of STB (whole tablet).
89336156|NCT02325934|Experimental|Intervention I|Stribild, crushed Standardized breakfast followed by a single dose of crushed and suspended STB.
89336157|NCT02325934|Experimental|Intervention II|Stribild, crushed 350 mL of drip feed (type) followed by a single dose of crushed and suspended STB.
89336158|NCT01360658|Experimental|Intravenous immunoglobulins|Intravenous immunoglobulins
89336159|NCT02318680|Experimental|Intervention|Review of follow home visits after discharge from Nykøbing Falster Hospital
89336160|NCT02318680|No Intervention|Control|Standard health care and discharge services
89336161|NCT05143294|Experimental|Modern board and card games group|The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl & Weir, 2018), Kaleidos Junior (Albertarelli, 1997), Sherlock Express (Kermarrec, 2019), Alles Kanone! (Knizia, 2007), Halli Galli (Shafir, 1990), Bananazul (Warsch, 2019), Blurble (Bernard, 2013), La Morada Maldita (Ortiz, 2020), Dice Academy (Gobert, 2019) and Streams (Itsubaki, 2011). Play sessions will be held in subgroups of 3-5 children within the class group. In each session, each subgroup will play two games. The games used in the program have an average duration of approximately 20-30 minutes (filler games). All subgroups will play all games in the program the same number of times with the same rules. The game program will be the same in all participating centers to guarantee the homogeneity of its implementation.
89336162|NCT05143294|No Intervention|Wait-list group|Wait-list. They will do the usual classes without modern board games. At the end of the post-intervention evaluation, the Conectar Jugando game program will be implemented under the same conditions as the experimental group.
89336163|NCT01317758|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
89336164|NCT01317758|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
89336165|NCT01317758|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
89336166|NCT01317758|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus GSK AS03 adjuvant
89336167|NCT01317758|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus GSK AS03 adjuvant
89336168|NCT01317758|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus GSK AS03 adjuvant
89336169|NCT02318758|Active Comparator|Comparison 1|UT-15C 1 mg alone
89336170|NCT02318758|Active Comparator|Comparison 2|UT-15C 1 mg plus ethanol (simultaneously)
89336171|NCT02318758|Active Comparator|Comparison 3|UT-15C 1 mg administered 1 hour before ethanol
89336172|NCT02318758|Active Comparator|Comparison 4|UT-15C 1 mg administered 1 hour after ethanol
89336173|NCT05187806|Experimental|Experimental group|"After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions of 30-60 (mean 45 min) min each. The sessions were structured according to the Behavior Change Stage Identification Form developed by the researcher by making use of the trans-theoretical model and adapting it to diabetic patients. The subject of the first session was Opening, Structuring the Discussion, and Establishing the Agenda; the subject of the second session was Improving Motivation for Change; the subject of the third session was Summarizing, Support, and Talking about the Change; and the subject of the fourth session was Evaluation . The discussions were completed in four weeks, with one discussion held every week. The final test and the Diabetes Self-Management Instrument were applied again to the members of the intervention group in the third month after completion of the MI method sessions."
89336174|NCT05187806|No Intervention|Control group|The control group received routine treatment. The final test and the Diabetes Self-Management Instrument were applied again to the members of the control group in the third month.
89336175|NCT01364636||Acute Heart Failure|Patients admitted to emergency room in Acute Heart Failure at Hospital PróCardíaco and Hospital Universitario Antonio Pedro
89336176|NCT03500146||Normal sexual function|Patients with an overall FSFI score equal to or above 26.5 will be in the normal sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
89336177|NCT03500146||Low sexual function|Female sexual dysfunction is defined as an overall FSFI score below 26.5, patients meeting this criteria will be in the low sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
89336178|NCT01317836||Patients having pancreatic cystic lesion|
89336179|NCT01364714||ICU survivors|Male ICU survivors 12 month after discharge
89336180|NCT01364714||Controls|Age and gender matched controls
89336181|NCT03493594|No Intervention|Control|"Control group will receive standard health care.~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
89336182|NCT03493594|Experimental|Nutrition education program|"The intervention group will receive an early nutrition program for 12 months. Workshops format will be mainly in form of talks and experience sharing groups which run by lactation consultants, nutritionists / dietitians. All classes and workshops will be run for 4-6 times to cater for subjects recruited in different phases.~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
89336183|NCT05187728||adenomyosis group|CSD with adenomyosis
89336184|NCT05187728||non-adenomyosis group|CSD without adenomyosis
89336185|NCT05126056|Active Comparator|Active Comparator|Products that contain plant stanol ester. Product with active ingredient
89336186|NCT05126056|Placebo Comparator|Placebo comparator|Placebo product. Product without active ingredient
89336187|NCT01352234|Experimental|Group A|Acetylsalicylic Acid 160mg administered at bedtime
89336188|NCT01352234|Active Comparator|Group B|Acetylsalicylic Acid 80mg administered at bedtime
89336189|NCT01364792|Experimental|Valaciclovir|The patients in the experimental group will be treated with 4 times 2 grams valaciclovir per day for seven days.
89336190|NCT01364792|Placebo Comparator|Placebo|Patient receives placebo four times a day for seven days.
89336191|NCT02318836|Active Comparator|Normal Hepatic function|
89336192|NCT02318836|Active Comparator|Mild Hepatic Impairment|(Child-Pugh score 5-6)
89336193|NCT02318836|Active Comparator|Moderate Hepatic Impairment|(Child-Pugh score 7-9)
89336194|NCT02318836|Active Comparator|Severe Hepatic Impairment|(Child-Pugh score 10-15)
89336195|NCT01364948|Experimental|Coconut oil application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day starting at 12 hrs of life. Four ml of coconut oil was applied using both hands of the caregiver in four strokes. First stroke was from the clavicles over the chest and abdomen till the groin, second from the front of thighs over the knee and leg upto the sole, the third one from the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back, starting from the upper back, continuing over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life).
89336196|NCT01364948|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
89336197|NCT03493438|Experimental|Relaxation Group|Patients performed Jacobson relaxation technique in supine position. Respiration control and various visual imaging techniques were used during the technique. Relaxation exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
89336198|NCT03493438|Experimental|Proprioceptive Neuromuscular Facilitation Group|Patients exercised with proprioceptive neuromuscular facilitation technique for trunk muscles using chopping and lifting patterns with ritmic initiation PNF exercises were made by the physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
89336199|NCT03493438|Experimental|Core stabilization group|Patients had core stabilization exercises that involved spinal mobility. The patients performed the drawing-in maneuver within various visual imaging techniques during all exercises, especially with respiratory control. Exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
89336200|NCT03493438|Other|control group|Patients in the control group were told the importance of a single session exercise
89336201|NCT01352312|Experimental|Treatment (pentostatin, bendamustine, ofatumumab)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, pentostatin IV on day 1, and ofatumumab IV on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
89336202|NCT03493360|Experimental|Visual feedback|Participants will be asked to perform movements of the low back while looking at a mirror for visual feedback.
89336203|NCT03493360|Active Comparator|No visual feedback|Participants will be asked to perform movements of the low back while the mirrors are covered and no visual feedback is provided.
89336204|NCT02340026|Experimental|Conventional Therapy|"The conventional treatment group will receive traditional, therapist-directed pediatric physical therapy. Therapy will focus on early gait training strategies and encouragement of normal movement patterns for walking and other age-appropriate movements, with manual guidance or correction of atypical movements from the therapist. This group may use assistive devices, orthoses, and may receive static body weight support for gait training. Therapy activities will be performed in blocks of practice, with the specific activities and level of therapist assistance tailored to each child."
89336205|NCT02340026|Experimental|Dynamic Supported Mobility|Children will receive dynamic weight support during all DSM treatment time. The environment will be arranged to encourage active motor exploration, somewhat similar to a play gym for toddlers, to promote the motor variability, engagement, and error experiences that characterize the typical development of upright motor skills and walking. The floor area within 3 feet below either side of the overhead track for a distance of 20 feet (approximately 120 ft2 total) will be defined with colorful thin rubber interlocking mats and arranged with pediatric toys and activities, tailored to the child's interests and to encourage motor skills just beyond his/her current ability. The therapist will minimally assist the child as needed to perform the movements he/she initiates.
89336206|NCT02318914|Experimental|gevokizumab|Solution for subcutaneous injection
89336207|NCT01365026|Experimental|PVS intervention|
89336208|NCT01365026|No Intervention|Control group|
89336209|NCT02319070||Cohort 1|Adult patients with severe Hemophilia A.(25 patients on Secondary Prophylaxis treatment)
89336210|NCT02319070||Cohort 2|Adult patients with severe Hemophilia A.(50 patients on On Demand treatment)
89336211|NCT04463134||Treatment group|They will start pharmacological treatment according to guidelines and sensitivity
89336212|NCT04463134||Observation group|They will not start pharmacological treatment. They will be monitored on symptoms, sputum conversion and radiological progression
89336213|NCT03131960|Experimental|VNS + Rehabilitation (1)|Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation.
89336214|NCT03131960|Active Comparator|Control VNS|Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.
89336215|NCT02939209|Experimental|Hydromorphone|Patients will be given 2 mg hydromorphone (immediate release) in the post anesthetic care unit.
89336216|NCT02939209|Placebo Comparator|Placebo|Patients will be given placebo in the post anesthetic care unit.
89336217|NCT01141855|Experimental|Champix plus counselling|varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration). In combination with Quit SA (5A) telephone counselling service
89336218|NCT01141855|Active Comparator|counselling alone|5A counselling via Quit SA (quitline) telephone counselling service. (maximum 8 phone calls per subject within a 3 month period).
89336219|NCT05091736|Experimental|Subject glucometer measurement|
89336220|NCT01360736|Experimental|Safety Planning - Military (SAFE-MIL)|Brief Safety Planning Using Stanley and Brown (2012) Model
89336221|NCT01360736|No Intervention|E-CARE|Treatment As Usual and Assessment Services of Study; Control Condition
89336222|NCT01236859|Placebo Comparator|placebo|The patients in the placebo group received equal numbers of identical looking placebo 2 h before operation
89336223|NCT01236859|Active Comparator|gabapentin|Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation.
89336224|NCT05073952|Active Comparator|Connective tissue graft|patient in this group will be treated with a flap and a connective tissue graft at the moment of implant placement.
89336225|NCT05073952|Active Comparator|Flapess|patient in this group will be treated with a flapless approach at the moment of implant placement.
89336226|NCT01360814||GROUP A (multidisciplinary intervention)|Patients receive six 90-minute sessions of a multidisciplinary structured intervention comprising physical therapy, education, a cognitive-behavioral intervention, discussion and support, spiritual reflection, and a relaxation exercise over 2-4 weeks. Caregivers are invited to sessions 1, 3, 4, and 6. Patients may also receive brief telephone contact during the 6 month follow-up period.
89336227|NCT01360814||GROUP B (standard medical care)|Patients receive standard medical care only. Patients may also receive brief telephone contact during the 6 month follow-up period.
89336228|NCT03493204|Experimental|Home-delivered, salt restricted|Meal description: salt-restricted (1500 mg to 2000 mg daily), > 2100 kilocalorie, high protein (>80 g daily) in addition to receiving standard pamphlet receipt
89336229|NCT03493204|Active Comparator|Dietary Advice|Standard of care, advice on salt-restriction using standard pamphlet receipt
89336230|NCT03720925|Experimental|TDI treatment|"The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and from between 3 to 6 months after the TDI treatment ."
89336231|NCT01145365|Active Comparator|Combination Therapy Group|Patients in this arm will have surgically established drainage of their Crohns perianal fistulas and/or abscesses (exam under anesthesia (EUA)) done BEFORE beginning medical therapy with Cimzia.
89336232|NCT01145365|No Intervention|Control Group|Patients in this group will begin medical therapy with Cimzia regardless of status of surgically established drainage.
89336233|NCT03225170|Experimental|Self-affirmation (SA) group|"Immediately prior to the scheduled cancer genetic counseling appointment, clients:~completed standardized questionnaires on self-affirmation (SA) intervention that focused on positive values of personal importance. The SA intervention required clients to rank 11 items (artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity) from most important to least important and to elaborate on one that was most important to them and why;~6-item standardized measure of anxiety questionnaire;~after the genetic counseling session, clients were required to fill out a post session questionnaire"
89336234|NCT03225170|Sham Comparator|Control group|"Immediately prior to the scheduled cancer genetic counseling appointment, clients:~completed similar standardized questionnaire as the SA group, with a non-affirming exercise. The non-intervention required clients to rank 11 items (artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity) from most important to least important and to elaborate on the 9th ranked item and why it might be important to someone else;~6-item standardized measure of anxiety questionnaire;~after the genetic counseling session, clients were required to fill out a post session questionnaire"
89336235|NCT01236937|Active Comparator|Bellows-based breath hold biopsy|CT guided biopsy is preformed with the use a bellows-based breath
89336236|NCT01236937|No Intervention|No Bellows-based breath hold.|CT guided biopsy is preformed without the use a bellows-based breath
89336237|NCT04967092|Active Comparator|Modified Xiao-Feng Powder|Modified Xiao-Feng Powder granules will be taken twice daily for 12 weeks
89336238|NCT04967092|Placebo Comparator|Placebo|Placebo granules will be taken twice daily for 12 weeks
89336239|NCT03499834|Experimental|Study Group|26 patients who has successfully undergone the screening criteria will be enrolled for treatment. Immune Killer Cells (IKC) will be administered through Intravenous Injection (I.V.) Frequency: One injection per week, twenty-four injections on-treatment
89336240|NCT01145443||Continuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when a single intensivist was the sole attending physician of record for intervals of 2 weeks (or 1/2 month).
89336241|NCT01145443||Discontinuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when, for intervals of 2 weeks (or 1/2 month), there was a single intensivist who was the primary attending of record during Mondays-Fridays, but cross-covering colleagues took over that role during the weekends.
89336242|NCT02319382|Experimental|2 markers: 18F-DPA-714 and 11C-PE2I|PET with the tracer [18F]DPA-714 and second PET with the tracer [11C]-PE2I. [18F]DPA-714 is a new marker. It allows the macroscopic visualization of active microglia in the brain. [11C]-PE2I allow measures dopaminergic neuronal loss.
89336243|NCT01141933|Other|Usual care|Subjects in this group receive the usual treatment only.
89336244|NCT01141933|Experimental|Individual intervention|Consisting in a 12 weekly sessions with a therapist. Each session lasts 1 hour.
89336245|NCT01141933|Experimental|Group intervention|Consisting in a 12 weekly sessions with two therapists. Number of subjects in each group is from 5 to 10. Each session lasts 2 hours.
89336246|NCT01365104|Experimental|Healthy young|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
89336247|NCT01365104|Experimental|healthy old|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
89336248|NCT03492970|Other|10 adult patients with SMS|Specify the evolution of the nycthemeral cycle of melatonin secretion in adult subjects carrying an SMS Behavioral characterization of adult subjects with SMS Make recommendations on the management of sleep / sleep rhythm disorders and behavior in adult subjects with SMS
89336249|NCT01362374|Experimental|Arm A (Doc + Ipat 100mg)|Participants received ipatasertib at a dose of 100 milligrams (mg) once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336250|NCT01362374|Experimental|Arm A (Doc + Ipat 200mg)|Participants received ipatasertib at a dose of 200mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336251|NCT01362374|Experimental|Arm A (Doc + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336252|NCT01362374|Experimental|Arm A (Doc + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336253|NCT01362374|Experimental|Arm B (mFOLFOX + Ipat 100mg)|Participants received ipatasertib at a dose of 100mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336254|NCT01362374|Experimental|Arm B (mFOLFOX + Ipat 200mg)|Participants received ipatasertib at a dose of 200mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336255|NCT01362374|Experimental|Arm B (mFOLFOX + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336256|NCT01362374|Experimental|Arm B (mFOLFOX + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336257|NCT01362374|Experimental|Arm C (Pac + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336258|NCT01362374|Experimental|Arm C (Pac + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first.
89336259|NCT01362374|Experimental|Arm D (Enza + Ipat 400mg)|Participants received ipatasertib at a dose of 400mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
89336260|NCT01362374|Experimental|Arm D (Enza + Ipat 600mg)|Participants received ipatasertib at a dose of 600mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
89336261|NCT01362374|Experimental|Arm D (Enza + Ipat 400-600mg)|Participants received ipatasertib at a dose of 400-600mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants received both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurred first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
89336262|NCT01142011|Experimental|Belimumab|"The first cycle of Belimumab is a loading cycle of 3 doses over 28 days (days 1, 15, 29).~After the first cycle, additional cycles of belimumab will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles)."
89336263|NCT02319460||Retrospective|Retrospective cohort of adults hospitalized for major bleeding during 2008 to 2013 who receive plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
89336264|NCT02319460||Prospective|Prospective parallel cohort of adults hospitalized for major bleeding during 2014 to 2020 who either receive Kcentra® or plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
89336265|NCT04722952|Experimental|Anti-PD-1 mAb Combined With Azacytidine and HAG regimen|Anti-PD-1 mAb combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen
88811772|NCT01380899||PD Parkinson´s Disrease|We are studying the presence of alpha-synuclein in the epidermis and dermis besides the end nerve terminal. We have several reports until now, and we are following the study because we wish to convince the academic and scientific society over the utility of this study to be close to the molecular diagnosis of this kind of disease.
89336266|NCT05187572|Experimental|Reminiscence Therapy (RT)|The RT program is composed of activities that follow older adults' lifespan (e.g., school, professional life, travelling, holidays and celebrations, historical dates/moments). Such activities allow older adults to revive and share life-changing/significant moments and integrate them into their autobiographical narrative. The program was developed and validated by Gil and colleagues for Portuguese older adults with cognitive decline.
89336267|NCT05187572|Experimental|Cognitive Stimulation (CST)|"The CST intervention was based on the Making a Difference program, specifically developed for older adults with cognitive decline and previously adapted and validated to the European Portuguese language and culture. This program offers a sequence of activities that covers different cognitive domains and promotes older adults' socialization and self-esteem."
89336268|NCT01145599||Type-2 diabetes, NPDR|Type-2 diabetic patients with NPDR.
89336269|NCT01352390|Active Comparator|Control Condition|A basic reminder mailing will prompt each subject to receive a health test as specified on the mailing
89336270|NCT01352390|Experimental|Artwork Prompt Condition|A basic reminder mailing will prompt each subject to give their child a reminder postcard to color
89336271|NCT02319538|No Intervention|Non-surgical treatment only|Control arm. This arm receives standard medical hormone treatment (Thyroxine substitution) only and no surgical intervention.
89336272|NCT02319538|Active Comparator|Total thyroidectomy performed|Surgical arm.The approach for total thyroidectomy will be a complete removal of all visible, and immunological active thyroid tissue with a high accuracy, with a special focus on three sites; 1) The angle where the recurrent laryngeal nerve enters the cricothyroid membrane, 2) The pyramidal lobe and 3) The hilus where the superior vessels are entering the field. Standard Thyroxine supplementation maintained as in the control group.
89336273|NCT01238419|Experimental|Physiotulle|
89336274|NCT01238419|Placebo Comparator|Urgotul|
89336275|NCT01365260|Experimental|MM-II|
89336276|NCT01365260|Active Comparator|DurolaneTM|hyaluronic acid
89336277|NCT03492892|Experimental|Acupuncture|Use real acupuncture treatment for blood pressure management in patients with hypertension
89336278|NCT03492892|Sham Comparator|Sham Acupuncture|Use non-acupoint as the stimulating site in acupuncture for the treatment of hypertension
89336279|NCT03634904|Experimental|Drug Blood sampling|"Drug Blood sampling~Pharmacokinetic study measuring total and free ceftazidime concentrations"
89336280|NCT01235455||Group 1|
89336281|NCT04676698|Experimental|Three Good Things|"Three times weekly for three weeks, participants will receive a text-based survey asking them to type or dictate three good things."
89336282|NCT04676698|Active Comparator|Waitlist Control Arm then Three Good Things|Participants will have surveys in the waiting period for 3 months and then be crossed over to the treatment arm Three Good Things.
89336283|NCT01365338|Placebo Comparator|Placebo|Participants will receive placebo as a single oral dose.
89336284|NCT01365338|Experimental|Cohort 1|Participants will receive 0.075 milligrams (mg) of PF-04958242 as a single oral dose.
89336285|NCT01365338|Experimental|Cohort 2|Participants will receive 0.15 mg of PF-04958242 as a single oral dose.
89336286|NCT04676282||Survey 1 Statin - May cause harm|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm.
89336287|NCT04676282||Survey 1 Stain - May lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may lack benefit.
89336288|NCT04676282||Survey 1 Statin - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm and lack benefit.
89336289|NCT04676282||Survey 1 PPI - May cause harm|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may be causing harm.
89336290|NCT04676282||Survey 1 PPI - May lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may lack benefit.
89336291|NCT04676282||Survey 1 PPI - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a proton pump inhibitor (heartburn) medication. The primary care provider raises the idea of stopping the PPI as it may be causing harm and lack benefit.
89336292|NCT04676282||Survey 2 Statin - May cause harm and lack benefit|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin as it may be causing harm and lack benefit.
89336293|NCT04676282||Survey 2 Statin - Cardiologist|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin previously started by a cardiologist.
89336294|NCT04676282||Survey 2 Statin - Daughter Preference|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient's adult daughter prefers for her to continue the medication.
89336295|NCT04676282||Survey 2 Statin - Husband Stroke|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient's husband previously had a stroke after he stopped his statin.
89336296|NCT04676282||Survey 2 Statin - Flier|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient saw an educational flier about strokes in the waiting room.
89336297|NCT04676282||Survey 2 Statin - Difficulty Maintaining Lifestyle Changes|Participants in this arm will be exposed to a scenario in which a patient takes a statin (cholesterol) medication. The primary care provider raises the idea of stopping the statin but the patient recognizes that they have had difficulty exercising and eating healthier foods.
89336298|NCT01145677|Experimental|Topiramate|
89336299|NCT03499522||Observational group|"80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain.~The inclusion criteria to participate in the present study are patients: with a medical diagnosis of congenital coagulopathies (hemophilia A and B, or von Willebrand's disease); adults; in a prophylactic or on demand regimen with FVIII / FIX concentrates; and that they have signed the informed consent document.~On the other hand, those patients with: neurological or cognitive alterations that impede the comprehension of the questionnaires will be excluded from the study; inability to walk autonomously or with an orthosis; and without access to digital media to complement the measuring instruments."
89336300|NCT03492814|Experimental|Partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
89336301|NCT03492814|Active Comparator|Total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
89336302|NCT01235533|Experimental|N-3 fatty acids|Participants in this arm were received three capsules of n-3 fatty acids. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g。
89336303|NCT01235533|Placebo Comparator|Placebo|Participants in this arm were received three identical capsules per day. All capsules included olive oil.
89336304|NCT03499288||Children and youth with cerebral palsy|Subjects between 1 month and 18 years of age with Cerebral Palsy who visited the coordinating HCP within the past 12 months.
89336305|NCT04089085|Other|One group pilot|The experimental group will receive the intervention, which is an 8-week (30 minute session per week) asthma educational and cognitive behavioral skills program.
89336306|NCT02319616|Experimental|Clobetasol 0.05% ointment|All patients will have one arm assigned to receive the experimental treatment (topical clobetasol 0.05% ointment) applied daily for a period of fourteen days.
89336307|NCT02319616|Placebo Comparator|Placebo|All patients will have one arm assigned to receive the placebo treatment (topical petrolatum ointment) applied daily for a period of fourteen days.
89336308|NCT01142167|Active Comparator|Standard Colonoscopy|Colonoscopy with standard instrument
89336309|NCT01142167|Experimental|Ultra-thin colonoscopy|New prototype scope
89336310|NCT01142245|Active Comparator|oral esomeprazole|"Esomeprazole placebo IV loading bolus~Esomeprazole placebo intravenous infusion for 72 hours~Oral Esomeprazole: 80 mg/Day on Day 1, 2 and Day 3, and the drug will be given as 40 mg q12h."
89336311|NCT01142245|Active Comparator|Intravenous Esomeprazole|"Esomeprazole IV loading bolus 80mg~• Esomeprazole intravenous infusion 8mg/hr for 72 hours"
89336312|NCT02319772|Experimental|BCX4430|BCX4430 administered as an IM injection
89336313|NCT02319772|Placebo Comparator|Placebo|Matched placebo administered as an IM injection
89336314|NCT02319850||Reference Group|18 - 29 years of age; apparently healthy younger participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
89336315|NCT02319850||Comparison Group|55 - 75 years of age; apparently healthy older participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
89336316|NCT01235767|Experimental|ASF supplement pre-pregnancy to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
89336317|NCT01235767|Experimental|ASF Supplement mid-gestation to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
89336318|NCT01235767|No Intervention|Routine prenatal care|Nutrition education and iron-folate supplements during pregnancy
89336319|NCT03499210|Experimental|Investigational group|All subjects will participate in study procedures involving use of the ReWalk ReStore device.
89336320|NCT03499132||General anesthesia (with opioids)|orthopedic surgery plus general anesthesia
89336321|NCT03499132||Epidural anesthesia (without opioids)|orthopedic surgery plus epidural anesthesia (without opioids use)
89336322|NCT03499132||Subarachnoid anesthesia (with opioids)|orthopedic surgery plus subarachnoid anesthesia (plus intrathecal opioid)
89336323|NCT03499132||Regional anesthesia (without opioids)|orthopedic surgery plus regional anesthesia (peripheral nerve block, continous or single shot, without opioid use)
89336324|NCT03499054|No Intervention|control group|Hemodialysis patients in the control group who receive only routine nursing care during hemodialysis
89336325|NCT03499054|Experimental|exercise group|The exercise group are asked to perform breathing exercises during hemodialysis for the study period of 3 months.
89336326|NCT03498976|Other|Pulsed radiofrequency on SE nerve|Single technic
89336327|NCT03498976|Other|Pulsed radiofrequency on SE + CF nerves|Combinated technic
89336328|NCT02319928|Active Comparator|Short-term surveillance|Short-term surveillance. Colonoscopy at 5+10 years in low-risk adenomas or 3+5 years in high-risk adenomas.
89336329|NCT02319928|Experimental|Long-term surveillance|Long-term surveillance. Colonoscopy at 10 years in low-risk adenomas or 5 years in high-risk adenomas.
89336330|NCT01235845|Experimental|DC-DCIK|
89336331|NCT03498898|Active Comparator|Group A|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
89336332|NCT03498898|No Intervention|Group B|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
89336333|NCT03498898|Active Comparator|Group C|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement.
89336334|NCT03498898|No Intervention|Group D|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement
89336335|NCT03842917||Patient starting bevacizumab treatment for cancer|Taken biological samples (urine and blood) and blood pressure measurement on patients starting bevacizumab treatment for cancer
89336336|NCT03498820|Experimental|Analgesia Nociception Index|Intraoperative remifentanil administration guided by the Analgesia Nociception Index
89336337|NCT03498820|Active Comparator|Usual practice|Intraoperative remifentanil administration managed in standard practice
89336338|NCT01142479|Placebo Comparator|herbal A|dilute of (TPE-1) decoction.
89336339|NCT01142479|Experimental|herbal B|TPE-1 decoction (100 ml)
89336340|NCT05158309|Experimental|Capsaicin|Capsaicin condition: in this condition participants received pain using a (5x10 cm) 8% topical capsaicin patch on the volar part of the dominant right forearm.
89336341|NCT05158309|Placebo Comparator|Placebo|Placebo condition: participants received no pain.
89336342|NCT03498742||No SABA users|Asthmatic subjects that did not use short acting beta2 agonists in the last 3 months and being using none agent or ICS, systemic corticosteroids of combined ICS/LABA as relief symptoms agent.
89336343|NCT03498742||SABA users|Most of the asthmatic subjects usually inhale SABA as rescue medication and many times SABA is the only one prescribed treatment for asthma.
89336344|NCT02320006|Active Comparator|True acupuncture plus hydrotubation|The treatment group will receive true acupuncture and hydrotubation,Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performedwithin 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles. The points (points used for every participant of treatment group) include bilateral RN4、CV6、CV3、EX-CA1、ST36、SP6,All the needles will be keep in positions for 30 min.Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk)
89336345|NCT02320006|Sham Comparator|control acupuncture plus hydrotubation|The control group will receive control acupuncture and hydrotubation.Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performed within 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles.Two needles will be inserted in each arm, one in each shoulder and one in each upper arm at nonacupuncture pointsAll the needles will be keep in positions for 30 min. Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk).
89336346|NCT01238497||Registry 1 - SOURCE XT|Registry 1: All patients implanted with a SAPIEN XT valve, via Transfemoral access using NovaFlex (for 23mm and 26mm valve), or via Transapical access using Ascendra2 (23mm, 26mm and 29mm valve)
89336347|NCT01238497||Registry 2 - Ascendra+|Registry 2: All patients implanted with a SAPIEN XT Valve, via Transapical or Transaortic access using Ascendra+ delivery system (23mm, 26mm and 29mm valve)
89336348|NCT01238497||Registry 3 - NovaFlex+ 29 mm|Registry 3: All patients implanted with a SAPIEN XT valve, 29mm only, via Transfemoral access using NovaFlex+
89336349|NCT02320084||HT-1 patients on Orfadin treatment|HT-1 patients on Orfadin (nitisinone) treatment
89336350|NCT02320162|Experimental|Experiential learning|Oral health education using experiential learning (EL)
89336351|NCT02320162|Placebo Comparator|Traditional lecturing|Oral health education using traditional lecturing (TL)
89336352|NCT01145911||Glaucoma patients|Glaucoma patients
89336353|NCT02320240||SNRI Exposure Group|Patients who received a new prescription for an SNRI (duloxetine, venlafaxine, or desvenlafaxine at any dosage) with no prescriptions for either SNRI or SSRI in the prior year.
89336354|NCT02320240||SSRI Exposure Group|Patients who received a new prescription for an SSRI (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline at any dosage) with no prescriptions for either SSRI or SNRI in the prior year.
89336355|NCT01238731||Valve replacement|Patients undergoing valve replacement for severe valve disease will be screened for study entry
89336356|NCT02320318|Experimental|Ibodutant 10 mg|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the ibodutant 10 mg arm will be re-randomised in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
89336357|NCT02320318|Placebo Comparator|Placebo|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.
89336358|NCT03492736|Experimental|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
89336359|NCT03492736|Placebo Comparator|Placebo|30 days placebo taken nightly 1 hour before bed
89336360|NCT01238809||1|
89336361|NCT02320474|Experimental|Aflibercept|
89336362|NCT01238887|Placebo Comparator|microcrystalline cellulose|
89336363|NCT01238887|Active Comparator|Hydroxycitric acid|2800 mg divided in three doses per day
89336364|NCT01238887|Active Comparator|Hydroxycitric Acid|5400 mg divided into three doses per day
89336365|NCT02320552||PD patients|Patients receiving peritoneal dialysis. No intervention
89336366|NCT02320552||HD patients|Patients receiving hemodialysis. No intervention
89336367|NCT03492580||Cohort 1: Canagliflozin|A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).
89336368|NCT03492580||Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)|A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336369|NCT03492580||Cohort 3: Empagliflozin|A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336370|NCT03492580||Cohort 4: Empagliflozin with CVD|A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336371|NCT03492580||Cohort 5: Dapagliflozin|A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336372|NCT03492580||Cohort 6: Dapagliflozin with CVD|A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336373|NCT03492580||Cohort 7: Empagliflozin or Dapagliflozin|A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336374|NCT03492580||Cohort 8: Empagliflozin or Dapagliflozin with CVD|A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336375|NCT03492580||Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA|A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336376|NCT03492580||Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336377|NCT03492580||Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336378|NCT03492580||Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
89336379|NCT01238965|Experimental|Arm I|Patients receive oral panobinostat 3 times a week. Patients also receive leucovorin calcium IV over 2 hours on days 1 and 15 followed by fluorouracil IV continuously over 46 hours on days 1-2 and 15-16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89336380|NCT02320630|Experimental|A|Maintenance treatment group
89336381|NCT02320630|Experimental|B|Combination treatment group
89336382|NCT02320630|Experimental|C|Single drug group
89336383|NCT02506387||Mitraclip patients|Patients with severe mitral regurgitation in whom decision for mitraclip implantation was made by the heart team.
89336384|NCT03492502|Experimental|Allo-SCT patients with GI related GVHD|"Allo-SCT patients above 18 years of age with acute steroid-resistant GI-related GVHD grade III-IV.~The diagnosis of GVHD will be made on clinical grounds (in line with the major associations' recommendations) - the appearance of characteristic mucoid diarrhea within 100 days after Allo-SCT, with or without associated skin/liver involvement. In cases of atypical presentation - we will recommend biopsy or endoscopy for diagnosis. Patients suspected to have Clostridium difficille associated diarrhea will be tested for toxin (CDT).~Steroid-resistant GI-related GVHD will be defined as lack of improvement (same stage) or worsening of GI symptoms after 7 days of steroid therapy (≥ 2 ml/kg of IV methylprednisolone)."
89336385|NCT01236079|Experimental|Assisted Referral & IVR|
89336386|NCT01236079|No Intervention|Usual Care|
89336387|NCT04496908|Active Comparator|Early Amniotomy|Women in the Early AROM group will under amniotomy one hour from Foley Catheter expulsion. Labor augmentation will continue per study protocol. Refer to Appendix A for protocol regimen.
89336388|NCT04496908|Active Comparator|Delayed Amniotomy|Women in the Delayed AROM group will undergo amniotomy at the discretion of the obstetrician or labor provider. No specific instructions will be given.
89336389|NCT01144117|Experimental|Erythropoietin|Erythropoietin treated patients contra placebo.
89336390|NCT03491878|Experimental|3D approach|Three dimensional laparoscopic cholecystectomy including segments IVB and V
89336391|NCT03491878|Active Comparator|open approach|Open cholecystectomy including segments IVB and V
89336392|NCT03756259|Other|Pneumonia perception arm|Caregivers of children under five will be interviewed qualitatively to understand in depth on perception of pneumonia. These will be mothers, fathers and grandmothers of these children. Once the formative research is done, it will inform design of an intervention whereby the caregivers will be recruited to be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject. The LHWs will also be trained on pneumonia case finding which they will manage at their end and refer if required while doing daily field visits.
89336393|NCT01236157||Chest Pain|All patients that call to the SAMU-ACS because of chest pain are included
89336394|NCT01239199|Experimental|Exhaled NO|
89336395|NCT04371640|Active Comparator|Sirolimus|Sirolimus + standard medical care Day 1: 10mg Days 2-7: 5mg
89336396|NCT04371640|Placebo Comparator|Placebo|Placebo + standard medical care Day 1: 10mL Days 2-7: 5mL
89336397|NCT04356196|Experimental|Verapamil group|45 patients will receive 80 mg oral verapamil 3 hours pre-operative
89336398|NCT04356196|Experimental|Bisoprolol group|45 patients will receive Bisoprolol 5mg PO 3 hours preoperative
89336399|NCT04356196|Experimental|placebo group|45 patients will receive placebo tablet PO 3 hours preoperative .
89336400|NCT04338178|Experimental|Experimental intervention|Standard outpatient program, with additional group sessions integrating the experimental intervention : Cognitive Remediation Therapy (CRT), Emotional Skills Training (EST), and Cognitive Behavioral Therapy focused on craving and food addiction (CBT), delivered once a week during 10 weeks.
89336401|NCT04338178|Active Comparator|Standard intervention|Standard outpatient program, with additional group sessions integrating control intervention : multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches, delivered once a week during 10 weeks.
89336402|NCT04289428||A|Not currently on antiviral therapy for HBV and HBV DNA detectable
89336403|NCT04289428||B|Stable on HBV antiviral therapy for at least 3 months with HBV DNA < 20 IU/ml
89336404|NCT02115139|Experimental|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1
89336405|NCT02047981|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.~In Niger during year 3, all communities will be offered azithroymcin."
89336406|NCT02047981|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~In Niger during year 3, all communities will be offered azithroymcin."
89336407|NCT04802356|Experimental|Multiple Myeloma experimental arm|Combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone)
89336408|NCT01239277|Experimental|protein (elderly)|
89336409|NCT01239277|Experimental|protein and carbohydrate (elderly)|
89336410|NCT01239277|Experimental|protein and carbohydrate (young)|
89336411|NCT01239277|Experimental|protein and leucine (elderly)|
89336412|NCT01239433||mechanically ventilated patients|ICU patients on mechanical ventilation. Daily endotracheal suctioning performed to reduce secretions. Data recorded during these therapeutic interventions.
89336413|NCT03774979|Experimental|SHR-1701|intravenous infusion
89336414|NCT03947788|Experimental|Interventional Practices|These clinics, including physicians, clinical and administrative staff, will receive the One Key Question training program, delivered by Power to Decide, via an in-person group training session.
89336415|NCT03947788|No Intervention|Control Practices|These clinics will not receive the OKQ training program during the study period. They will have the opportunity to receive the training after the study period is over.
89336416|NCT01237171||Sub-lobar resection with Cesium-131|All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
89336417|NCT03749746|Active Comparator|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
89336418|NCT03749746|Experimental|Home Blood Pressure Monitoring|In addition to usual care outlined above, each participant will receive a Bluetooth-enabled blood pressure cuff along with a checklist of proper technique and instructions on use. Women will be prompted to measure their BP across the first week of each month during the intervention. Based on guidelines, participants will take their blood pressure in the morning and evening, each time taking two readings separated by one minute.
89336419|NCT03749746|Experimental|Heart Health 4 New Moms|Participants randomized to this group will receive instruction on the use of Heart Health 4 New Moms internet-based lifestyle intervention and home blood pressure monitoring. The internet-based intervention is comprised of four key components: an online curriculum with modules on healthy eating and physical activity, a self-monitoring and tracking program, a registered dietitian will act as a lifestyle coach for participants and a customized online toolbox.
89336420|NCT03696550|Experimental|Cohort 1|"Eravacycline (TP-434) intravenous formulation Eravacycline will be administered as a single 60 minute IV infusion according to age.~Age group (years) Dose (mg/kg) 12 to <18 (Cohort 1) 1.50"
89336421|NCT03696550|Experimental|Cohort 2|"Eravacycline will be administered as a single 60 minute IV infusion according to age.~Age group (years) Dose (mg/kg) 8 to <12 (Cohort 2) 1.75"
89336422|NCT05631769|Experimental|HBR - 1M DAPT|Patients who receive percutaneous coronary intervention for coronary artery disease, and who have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 1 month or 3 month DAPT duration.
89336423|NCT05631769|Active Comparator|HBR - 3M DAPT|Patients who receive percutaneous coronary intervention for coronary artery disease, and who have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 1 month or 3 month DAPT duration.
89336424|NCT05631769|Experimental|LBR - 12M DAPT|Patients who receive percutaneous coronary intervention for coronary artery disease, and who do NOT have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 3 month or 12 month DAPT duration.
89336425|NCT05631769|Active Comparator|LBR - 3M DAPT|Patients who receive percutaneous coronary intervention for coronary artery disease, and who do NOT have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 3 month or 12 month DAPT duration.
89336426|NCT01144273|Active Comparator|0.5% Ropivacaine|group receiving TAP block (0.5% ropivacaine at TAP plane)
89336427|NCT01144273|Placebo Comparator|normal saline|group receiving placebo (saline) at TAP plane
89336428|NCT02528383|Experimental|Vagifem|Postmenopausal women diagnosed with breast cancer, are currently on an anti-estrogen called an aromatase inhibitor and you have agreed to undergo treatment with Vagifem based on your physician's recommendation.
89336429|NCT01146067|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
89336430|NCT01146067|Active Comparator|Exelon|Exelon 1.5 mg capsules of Novartis
89336431|NCT01237249|Active Comparator|MPV followed by Revlimid/Low Dose Dexamethasone (Rd)|Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
89336432|NCT01237249|Experimental|Alternating MPV with Revlimid/Low Dose Dexamethasone|Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)
89336433|NCT01144351|Experimental|ELND002|ELND002 sc injection
89336434|NCT01144351|Placebo Comparator|Placebo|placebo injection
89336435|NCT03646162|Experimental|Veru-944 10 mg|Veru-944 10 mg daily
89336436|NCT03646162|Experimental|Veru-944 50 mg|Veru-944 50 mg daily
89336437|NCT03646162|Placebo Comparator|Placebo|Placebo daily
89336438|NCT05019859|Active Comparator|Intervention|low carb diet
89336439|NCT05019859|No Intervention|Control|traditional low fat diet
89336440|NCT05018533|Experimental|Cohort 1|TAKC-02 0.15mg Single dose
89336441|NCT05018533|Placebo Comparator|Placebo (to Cohort 1)|
89336442|NCT05018533|Experimental|Cohort 2|TAKC-02 0.5mg Single dose
89336443|NCT05018533|Placebo Comparator|Placebo (to Cohort 2)|
89336444|NCT05018533|Experimental|Cohort 3|TAKC-02 1.5mg Single dose
89336445|NCT05018533|Placebo Comparator|Placebo (to Cohort 3)|
89336446|NCT05018533|Experimental|Cohort 4|TAKC-02 5mg Single dose
89336447|NCT05018533|Placebo Comparator|Placebo (to Cohort 4)|
89336448|NCT05018533|Experimental|Cohort 5|TAKC-02 15mg Single dose
89336449|NCT05018533|Placebo Comparator|Placebo (to Cohort 5)|
89336450|NCT05018533|Experimental|Cohort 6|TAKC-02 Multiple dose (low)
89336451|NCT05018533|Placebo Comparator|Placebo (to Cohort 6)|
89336452|NCT05018533|Experimental|Cohort 7|TAKC-02 Multiple dose (high)
89336453|NCT05018533|Placebo Comparator|Placebo (to Cohort 7)|
89336454|NCT04434469|Experimental|Arm A Flat Dose Escalation: RO7297089|Participants in Arm A will receive the target dose of RO7297089 as a flat dose at each scheduled study drug administration visit
89336455|NCT04434469|Experimental|Arm B Split Dose Escalation: RO7297089|Participants in Arm B will receive the first target dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose will be administered at subsequent study drug administration visits.
89336456|NCT04434469|Experimental|Arm C Step Dose Escalation: RO7297089|Participants in Arm C will receive the first cycle of RO7297089 as a single-step dose escalation. The Cycle 1 Day 1 dose will be lower than the target dose. The full target dose will be administered at subsequent study drug administration visits.
89336457|NCT04434469|Experimental|Phase I Expansion Stage: RO7297089|After dose escalation has been completed, approximately 30 patients will be enrolled in the expansion stage. Participants will receive RO7297089 at the recommended phase 2 dose (at or below the maximum tolerated dose).
89336458|NCT02528617|Other|Gaucher Type 1 or 3|Velaglucerase alfa IV 60 units/kg every other week for duration of the study.
89336459|NCT01244347|Experimental|folic acid 4 mg|
89336460|NCT01244347|Active Comparator|folic acid 0.4 mg|
89336461|NCT01239589||1|patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
89336462|NCT01239589||2|patients admitted as for an acute bipolar manic episode and treated with quetiapine XR
89336463|NCT01144429|Active Comparator|100 DPP/mL|Concentration of solution fo s.c. injection: 100 DPP/mL
89336464|NCT01144429|Active Comparator|1000 DPP/mL|Concentration of solution fo s.c. injection: 1000 DPP/mL
89336465|NCT01144429|Active Comparator|5000 DPP/mL|Concentration of solution fo s.c. injection: 5000 DPP/mL
89336466|NCT01144429|Active Comparator|10000 DPP/mL|Concentration of solution fo s.c. injection: 10000 DPP/mL
89336467|NCT01763827|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.
89336468|NCT01763827|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
89336469|NCT01763827|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
89336470|NCT01763827|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
89336471|NCT01763827|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
89336472|NCT01763827|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
89336473|NCT03348514|Experimental|CPX-POM - 30 mg/m^2|
89336474|NCT03348514|Experimental|CPX-POM - 60 mg/m^2|
89336475|NCT03348514|Experimental|CPX-POM - 120 mg/m^2|
89336476|NCT03348514|Experimental|CPX-POM - 240 mg/m^2|
89336477|NCT03348514|Experimental|CPX-POM - 360 mg/m^2|
89336478|NCT03348514|Experimental|CPX-POM - 600 mg/m^2|
89336479|NCT03348514|Experimental|CPX-POM - 900 mg/m^2|
89336480|NCT03348514|Experimental|CPX-POM - 1200 mg/m^2|
89336481|NCT01146145|Experimental|treatment|intravenous morphine titration combined to ketamine
89336482|NCT01146145|Placebo Comparator|placebo|morphine titration alone
89336483|NCT01146535|Experimental|Interferon-alpha|"Interferon-alpha~150 IU lozenges bid for 5 days"
89336484|NCT01146535|Placebo Comparator|maltose|"maltose~200 mg maltose lozenges bid for 5 days"
89336485|NCT01245127|Experimental|Canakinumab|"Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.~Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
89336486|NCT01144585|Experimental|RIPC|those who receive RIPC and RIPoC before and after CPB
89336487|NCT01144585|Placebo Comparator|Control|this group have same pneumatic cuff around their arm, but it is not inflated.
89336488|NCT01239667|Experimental|Life style counseling|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
89336489|NCT01237405||Knee Osteoarthritis|"Unilateral or bilateral knee osteoarthritis on radiograph associated with knee pain on most days of any one-month in the last year in at least one knee.~Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi)."
89336490|NCT01239823|Experimental|Whole Body Vibration Training|The subjects will participate in a 12-week whole body vibration exercise program with 2 sessions (1/2 hour) per week.
89336491|NCT01239823|Experimental|Exercise without vibration|The subjects will participate in a 12-week exercise program with 2 sessions (1/2 hour) per week.
89336492|NCT01732783||Metastatic Colorectal Cancer|Participants with wild-type RAS metastatic colorectal cancer who were receiving panitumumab in combination with chemotherapy.
89336493|NCT03777007|Experimental|Experimental|The application used is build upon the company's category-defining, SPARTA Platform and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
89336494|NCT04355728|Experimental|UC-MSCs Group|Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
89336495|NCT04355728|Placebo Comparator|Control Group|Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
89336496|NCT01693783|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving objective response or stable disease continue to receive maintenance therapy comprising ipilimumab IV over 90 minutes once every 12 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
89336497|NCT04461574|Placebo Comparator|Cervex Brush|
89336498|NCT04461574|Active Comparator|Orcellex Brush|
89336499|NCT04461496|Active Comparator|Hybrid revascularization|50 hybrid procedure
89336500|NCT04461496|Experimental|Full metall jacket|50 total endovascular interventions
89336501|NCT03491644|Active Comparator|Liberal oxygen|"Liberal oxygen administration (to mimic current practice) for the first 24 hours without interruption.~In the trauma bay and during intrahospital transportation this implies administration of a FiO2 of 1.0 for intubated patients and an oxygen flow on a non-rebreather with reservoir of 15 l/min for non-intubated patients. In the operating room, patients will receive a FiO2 of ≥ 0.8 to obtain a saturation of ≥ 98%. Patients admitted to the ICU/PACU/floor will receive and FiO2 of ≥ 0.8 or more to obtain a saturation of ≥ 98% when intubated and for non-intubated patients a non-rebreather with reservoir will be set to 15 l/min."
89336502|NCT03491644|Experimental|Titrated oxygen|"Titrated oxygen administration for the first 24 hours without interruption. Lowest dosage of oxygen possible in order to achieve a saturation of at least 94%, either using mechanical ventilation (intubated patients), a nasal cannula, a non-rebreather or nothing.~A saturation above 94% shall not be aimed for using supplemental oxygen, and thus only patients without oxygen requirement shall have saturations above 94%.~The intervention will only be interrupted in case the saturation becomes unmeasurable - if this happens, the treating physician shall treat the patient as he/she judges best fit. As soon as the saturation is measurable again, the intervention will resume. The treating physician must document and explain the situation."
89336503|NCT02528461||Sofosbuvir|"All patients receiving Sofosbuvir based treatment regimes during the study period will be included in the study.~All patients will receive all interventions (galactose elimination capacity test, gastroscopy, fibroscan), except liver biopsy which the patients may decline to participate in without affecting the participation in the rest of the study. If varices are found during the gastroscopy a liver vein catheterization will be performed."
89336504|NCT01237483|Other|Erbitux Radiotherapy|Radiotherapy during 5 weeks and concurrent Erbitux once a week.
89336505|NCT01239979||Stable, Unstable , control|
89336506|NCT01240057|Placebo Comparator|expectant management during pregnancy|watchful waiting during pregnancy
89336507|NCT01240057|Experimental|fetal endoluminal tracheal occlusion|fetoscopic balloon occlusion at 27 to 29+6 weeks of gestation
89336508|NCT03492268|Experimental|BCMA-CART|Autologous T cells transduced to express anti-BCMA chimeric antigen receptor (CAR)
89336509|NCT01240213|Active Comparator|Vitamin D|2000 IU per day of Vitamin D
89336510|NCT01240213|Placebo Comparator|Placebo|
89336511|NCT02787850|Experimental|CoolSculpting Treatment Cohort A|"Cohort A will be treated on one side of the abdomen (Abdominal side 1) at a protocol-defined temperature for 60 minutes using the CoolMax applicator without the Crown Cooling Insert. The contralateral side (Abdominal side 2) will be treated with the Crown Cooling Insert at a second protocol-defined temperature for 45 minutes.~Each half of the abdominal area will be treated once, for a total of two treatments per subject."
89336512|NCT02787850|Active Comparator|CoolSculpting Treatment Cohort B|"Cohort B will be treated on one side of the abdomen (Abdominal side 1) at a protocol-defined temperature for 45 minutes using the CoolMax applicator with the Crown Cooling Insert. The contralateral side (Abdominal side 2) will be treated with a second protocol-defined temperature for 60 minutes with the Crown Cooling Insert.~Each half of the abdominal area will be treated once, for a total of two treatments per subject."
89336513|NCT03751969|Experimental|HSK3486|"0.4 mg/kg of HSK3486 emulsion injection (containing [14C] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg)~."
89336514|NCT01375777|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
89336515|NCT01375777|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
89336516|NCT01375777|Active Comparator|Ezetimibe|Participants received 10 mg ezetimibe orally once a day for 12 weeks.
89336517|NCT01375777|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89336518|NCT01375777|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89336519|NCT01375777|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
89336520|NCT01375777|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
89336521|NCT01375777|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
89336522|NCT01375777|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
89336523|NCT03712969|Experimental|Intervention group|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
89336524|NCT03712969|No Intervention|Control group|Patients receive conventional adjuvant chemotherapy.
89336525|NCT01245907|Experimental|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
89336526|NCT01245907|No Intervention|Waiting-list/control|No intervention for 10 weeks but the same registrations and diaries and forms as the interventional group
89336527|NCT02431702|Active Comparator|Part-1: Oral Antipsychotics (OAP)|All Participants will receive Paliperidone Extended Release (ER) 1.5 to 12 milligram (mg) or risperidone 1 to 6 mg once daily orally for 2 months. Subjects who tolerate paliperidone ER/risperidone but find it inadequately efficacious after treatment for an adequate duration at an adequate dosage (per clinical judgment), may be switched to another protocol-specified OAP at the discretion of the investigator.
89336528|NCT02431702|Experimental|Part-2: Paliperidone Palmitate (PP)|Participants who will complete Part-1 will be randomized to receive oral Paliperidone Palmitate (PP) treatment. Participants will receive 5 doses of PP1M (paliperidone palmitate once-monthly injection). First dose at a starting dose of 234 mg on Day 1 and thereafter second dose in second week and then, every month up to Day 92. Participants will be subsequently switched to PP3M (paliperidone palmitate three-monthly injection) following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
89336529|NCT02431702|Active Comparator|Part-2: OAP|Participants who will complete Part-1 will be randomized to receive Oral Antipsychotics for 9 months.
89336530|NCT02431702|Experimental|Part-3: PP - PP|Participants who will complete Part-2 (with PP treatment) will continue to receive Paliperidone Palmitate for 9 months.
89336531|NCT02431702|Experimental|Part-3: OAP - Delayed Start Paliperidone Palmitate (PP)|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive PP treatment for 9 months. PP treatment includes PP1M and PP3M. Participants will be subsequently switched to PP3M following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
89336532|NCT02431702|Active Comparator|Part-3: OAP - OAP|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive OAP treatment for additional 9 months.
89336533|NCT03492190||adults|"Select the individual:~Healthy, non-pregnant adults 18-65 years of age, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range and stable weight.~Exclusion criteria: children and elderly (over 65), pregnancy, diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, adults will be eat the bean enrichment of deuterium for availability protein, collected urine, saliva and blood."
89336534|NCT03492190||Children|"Fifty children will be recruited from ages varying from 1 to 3 years and of both sexes. Children who use medications, who do not habitually consume beans, will be excluded and when there is no explicit written authorization from the parents or guardians.~All the children with different status of nutrition will be eaten the beans. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, children will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult)."
89336535|NCT03492190||Elderly|Fifty individuals of both sexes will be recruited, previously evaluated by complete clinical / laboratory examination and medical history. The elderly will be excluded from antiinflammatory, chemotherapeutic, corticoid, allergy and bean aversion or antibiotic therapy. These drugs could interfere with protein bioavailability. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, elderly will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult).
89336536|NCT03491566|Experimental|Clinic Pilates Group|Initial assessments of participants were made and they were taught key components of the Clinical Pilates exercises. Exercises were administered for 4 weeks, 3 days/week, 40-50 minutes/session under the supervision of a physiotherapist. Groups of 9-10 people with similar physical characteristics and fitness level for session times were created. The sessions were started with level 1 exercises requiring more support and less control. Each exercise was repeated 8-10 times; as the physical level of the participants increased, exercises progressed towards level 3 exercises requiring more attention, concentration and control. Each session consisted of an average of 10 minutes warm-up, 20 to 30 minutes of matt and 10 minutes cooling of of Clinical Pilates exercises.
89336537|NCT03491566|Experimental|Aerobic Exercise Group|"Initial assessments of participants were made before the first session. Using an elliptical bicycle or bicycle, or treadmill under the supervision of a physiotherapist, a total of 150 minutes moderate intensity (50-70% of maximal heart rate (HRmax)) aerobic exercise in accordance with the World Health Organization's guideline was applied, 3 days/week (50 mins/session) or 5 days/week (30 mins /session) for 4 weeks. The instruments to be used for the exercises were chosen according to the preference of the individual. HRmax was calculated using the 220-years. For example; at the age of 20 years, the target heart rate was determined as 100-140 beats/min for moderate physical activity in a person with HRmax 200 beats/min."
89336538|NCT03132064||post total knee arthroplasty|The measurements will made for patients before and after total knee arthroplasty to explore the improvements and possible correlation with preoperative pain psychology and hypersensitivity
89336539|NCT03491488|Experimental|Intervention Group|"300 children in the randomly selected crèche classrooms receiving the Brain Games intervention.~The Brain Games intervention we propose in this project is designed to complement and improve current government efforts. Given the importance of executive functioning skills and the high plasticity around age three, early programs like the ones proposed here may be the most effective tool to reduce socioeconomic and intergenerational disparities, and thus nicely complement current social protection policies."
89336540|NCT03491488|No Intervention|Control Group|300 children in the randomly selected creches classrooms receiving the regular Brazilian curriculum.
89336541|NCT02086552|Experimental|Treatment (sonidegib, lenalidomide)|Patients receive sonidegib PO QD on days 1-28 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve sCR, CR, VGPR, PR, MR, or SD (or usCR, uCR, uVGPR, uPR, uMR) continue treatment in the absence of disease progression or unacceptable toxicity.
89336542|NCT01146223||Basic science (correlative studies)|Patient mRNA samples from diagnosis are analyzed via quantitative PCR to measure WT1 and VEGF-1 expression.
89336543|NCT03492034|Active Comparator|IUD during CS|
89336544|NCT03492034|Active Comparator|IUD after puerperium|
89336545|NCT01237561|Experimental|spirometry, patient activation tool|"Receive Portable Spirometer~Spirometry training of staff~Provide clinician with web-based COPD interactive guideline tool~Provide clinician with patient activation tool~Train clinicians (tools, integration into workflow)~Academic Detailing"
89336546|NCT01237561|No Intervention|Usual Care|Spirometer and spirometry training of staff
89336547|NCT03497260|Experimental|Fructose in water first, water only second|Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit
89336548|NCT03497260|Experimental|Water only first, Fructose in water second|Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit
89336549|NCT01146691||Standard staffing model|All patients in participating ICUs during the blocks of time when a single intensivist staffs a participating ICU for a 7 day period. The intensivist will be present during daytime hours, and takes call from home afterwards.
89336550|NCT01146691||24-7 shiftwork staffing model|All patients in participating ICUs during the blocks of time when the 24-7 in-hospital intensivist coverage model is in place. This model is enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am. Call rooms will be provided to allow the night shift intensivist to sleep, if the workload permits.
89336551|NCT02321878||Liraglutide|
89336552|NCT03491410|Placebo Comparator|1|Arm 1: standard Unit´s protocol + placebo
89336553|NCT03491410|Experimental|B|Arm 2: standard Unit´s protocol + aspirin
89336554|NCT01144819||STEMI|Patients with STEMI according to ESC STEMI guidelines: Age above 18 years and able to give written, informed consent to participation in the project.
89336555|NCT00876031|Experimental|O-TIE|oral maintenance therapy with trofosfamide, idarubicin, and etoposide
89336556|NCT00876031|No Intervention|control|
89336557|NCT02321956|Experimental|Ultrasound|Using ultrasound measurement of the subglottic area to choose endotracheal tube size
89336558|NCT02321956|No Intervention|Formula|Using Cole's formula to choose endotracheal tube size
89336559|NCT03491332|Placebo Comparator|group C|general circuit group
89336560|NCT03491332|Active Comparator|group H|warm circuit group
89336561|NCT03491332|Experimental|group SH|new warm circuit group
89336562|NCT02322034|Experimental|Interval Training|Hospital outpatient-based regimen (3 times/week for 24 weeks) exercise program will be performed by cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
89336563|NCT02322034|No Intervention|Controls|CHF patients allocated to the control group (no intervention) will undergo biochemical and hormonal sampling, Doppler-echocardiography, cardiopulmonary exercise stress testing at study enrollment and at 24-week follow-up.
89336564|NCT01146769|Experimental|Pelvic floor exercise|
89336565|NCT01146769|No Intervention|Control|
89336566|NCT02322112|Placebo Comparator|Microcrystalline Cellulose (Control)|Microcrystalline cellulose will be used as a placebo control, as it is known to be an insoluble, non-viscous fiber that is essentially not fermented by the human gut microbiota. However, it is important to note that cellulose does have fermentation potential within the gastrointestinal tract and may be associated with improved health benefits; indicating a role as an active comparator.
89336567|NCT02322112|Experimental|Acacia Gum|Acacia gum is composed largely of arabinogalactan, and is considered to be a relatively non-viscous, soluble fiber this is highly fermented by the gut microbiota and well tolerated.
89336568|NCT02322112|Experimental|Resistant Starch Type 4|Cross-linked phosphorylated resistant starch (type IV) is generally insoluble and with low viscosity; yet it tends to have physiologic properties similar to soluble fibers, such as fermentability.
89336569|NCT02322268|Experimental|Diabetic Cosmos caudatus treated group|Subjects in this arm will receive Cosmos caudatus for 8 weeks.
89336570|NCT02322268|No Intervention|Diabetic control group|Subject in this group will not receive Cosmos caudatus. However, they will be educated for the same calorie intake and lifestyle intervention as in Cosmos caudatus treated group.
89336571|NCT02322346|Placebo Comparator|Group S|Preincisional bilateral peritonsillar infiltration of a total of 6 mL of saline
89336572|NCT02322346|Active Comparator|Group LL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.25% (3 mL to each tonsil).
89336573|NCT02322346|Active Comparator|Group HL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.5% (3 mL to each tonsil).
89336574|NCT01146301|Active Comparator|300 mg Loading dose clopidogrel|
89336575|NCT01146301|Experimental|600 mg Loading dose of clopidogrel|
89336576|NCT04461184|Experimental|Internet wellness intervention for aging|Feasibility components will be evaluated with a 5-point Likert scale may include open ended items for more detailed feedback. Participants will be asked to visit NDSU at the beginning and end of the intervention, and at 1-month follow-up. After written informed consent, each participant will complete a descriptive questionnaire at the beginning of the intervention period, and a health-related questionnaire at the beginning and end of the intervention, and at follow-up that includes self-rated health, current smoking status, smoking history, alcohol use, morbid conditions, functional disability, and depression status. Standing height and waist circumference will be collected with a tape measure. Body weight and composition will be measured with the InBody 570. Anthropometric and body composition assessments will be collected pre, post, and follow up.
89336577|NCT00807859|Experimental|Cohort A1|
89336578|NCT00807859|Experimental|Cohort A3|
89336579|NCT00807859|Experimental|Cohort B1|
89336580|NCT00807859|Experimental|Cohort B3|
89336581|NCT01237639|Experimental|Restrictive Red blood cell Transfusion|Transfusion Trigger of 70g/L with an aim to maintain Hemoglobin between 80-90g/L
89336582|NCT01237639|Active Comparator|Liberal Red blood Cell Transfusion|Transfusion Trigger of 90g/L with an aim to maintain Hemoglobin between 100-110g/L
89336583|NCT03491956|Other|DFPP group|self contrast (before and after DFPP)
89336584|NCT01237717||normotensive subjects|subjects without hypertension, and without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,
89336585|NCT01237717||Hypertensive subjects|"subjects with hypertension,~currently not treated at least within 6 months~without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,"
89336586|NCT03491254||Group A/exposure group|Huaier Granule & biliary drainage
89336587|NCT03491254||Group B/non-exposure group|biliary drainage.
89336588|NCT01246453|Active Comparator|urokinase|
89336589|NCT01246453|Active Comparator|Alteplase|
89336590|NCT03489148|Experimental|Tamarkoz®|A Sufi method to focus, called Tamarkoz®. Participants had met in class twice a week for two and a half hours total for three months. One day of the week, they met for theoretical teachings of Sufism, and for the second day in the week they met with a Tamarkoz® instructor to learn meditation techniques.
89336591|NCT03489148|Active Comparator|Stress Management Resources|The self-care stress management group used the campus resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, and online reading materials for stress management as needed for themselves.
89336592|NCT03489148|No Intervention|Waitlist|The waitlist control group did not receive Tamarkoz® and did not use the stress management resources on campus for the duration of the study.
89336593|NCT02322424||Patients who undergo pancreaticoduodenectomy|
89336594|NCT03497182|Experimental|Breath sample collection|
89336595|NCT03491098|Placebo Comparator|momestone furoate spray first group: will be given|Nasonex spray one puff in each nostril daily for 8 weeks
89336596|NCT03491098|Placebo Comparator|prednisolone sodium phosphate 15mg second group: will be given|Predsol fort tablet three times per day for 1 week then gradual withdrawal over 2 weeks
89336597|NCT03491098|Placebo Comparator|hypertonic sea water solution spray third group: will be given|Nasal spray one puff in each nostril daily for 8 weeks
89336598|NCT02322502|Experimental|desflurane|Suprane® Dose: 0.8 MAC / 4-5 vol. % Mode of administration: inhalation with laryngeal mask One application
89336599|NCT02322502|Active Comparator|sevoflurane|"Sevoflurane:~Dose: 0.8 MAC / 1.2-1.4 vol.% Mode of administration: inhalation with laryngeal mask One application"
89336600|NCT02322502|Active Comparator|propofol|Propofol Dose: 5-7 mg kg-1 h-1 to maintain a BIS index value between 40 and 60 Mode of administration: intravenous One application
89336601|NCT03489070|Active Comparator|Traumastem®|Oxidized nonregenerated cellulose hemostatic agents.Traumastem® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
89336602|NCT03489070|Active Comparator|Surgicel®|Oxidized regenerated cellulose hemostatic agents.Surgicle® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
89336603|NCT02307448|Active Comparator|PRP Group|Patients will receive weekly PRP treatments
89336604|NCT02307448|Placebo Comparator|Standard of Care|Patients will receive weekly standard of care.
89336605|NCT03490786|Experimental|Dose escalation|Single arm dose escalation.
89336606|NCT02445040|Experimental|Babylog VN500 in HFOV mode|Subjects will be treated with HFOV provided by the Babylog VN500 - the investigational device - for up to 14 days.
89336607|NCT03488992|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
89336608|NCT03488992|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
89336609|NCT02322580||Psoriasis patients who receive Enbrel® therapy|
89336610|NCT04461886|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
89336611|NCT03190174|Experimental|Arm 1|"This is an open label, dose-seeking phase 1b study using a defined dose of nivolumab and escalating doses of Nab-Rapamycin (ABI-009) given intravenously.~I. Dose Escalation Phase 1 Part of Study: The study will employ the standard cohort of three design. No intra-patient dose escalation will take place.~II. Expansion Phase 1b Part of Study: Following dose escalation, an additional 22-28 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs."
89336612|NCT03490708|Experimental|Tranilast|Subjects who were treated with tranilast
89336613|NCT00924326|Experimental|1x10^9-1x10^10+ high dose Interleukin-2|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + cryopreserved anti-CD19-CAR PBL
89336614|NCT00924326|Experimental|1x10^9-1x10^10 + high dose Retreat|
89336615|NCT00924326|Experimental|0.5x10^7 cells/kg|
89336616|NCT00924326|Experimental|2.5x10^6 cells/kg|
89336617|NCT00924326|Experimental|1.0x10^6 cells/kg|
89336618|NCT00924326|Experimental|1.0x10^6 cells/kg (Reduced chemo)|
89336619|NCT00924326|Experimental|2.0x10^6 cells/kg (Reduced chemo)|
89336620|NCT00924326|Experimental|6.0x10^6 cells/kg (Reduced chemo)|
89336621|NCT00924326|Experimental|2.0x10^6 cells/kg (Moderate chemo)|
89336622|NCT00924326|Experimental|2.0x10^6 cells/kg (9-12 days culture)|
89336623|NCT03496948|Experimental|TeGeCoach|Home-based exercise program consisting of telephone health coaching, remote walking exercise monitoring based on wearable monitors and intensified primary care.
89336624|NCT03496948|No Intervention|Usual care group (TAU)|Patients randomized to TAU receive written information about courses offered by their statutory health insurance. Health insurance companies offer a variety of courses to encourage regular exercise and to promote lifestyle changes, including SEPs (vascular and cardio exercise), physical therapy, nutritional assistance programs, smoking cessation programs, weight loss programs, and patient education programs for obesity and diabetes.
89336625|NCT03496870|Experimental|Opicapone once daily with Carbidopa/Levodopa|Opicapone administered once daily for 14 days; carbidopa/levodopa administered at set frequency on Study Days 1, 2 & 15
89336626|NCT01365572|Active Comparator|Xience V, drug-eluting stent|randomized implantation for DES restenotic lesion
89336627|NCT01365572|Active Comparator|Endeavor Resolute, drug-eluting stent|randomized implantation for DES restenotic lesion
89336628|NCT01370252||scope technique|
89336629|NCT01370252||open technique|
89336630|NCT01361204|Experimental|Theanine|Experimental Comparator, theanine Taking 4 tablets of theanine two times daily for 16 days Placebo Comparator, sucrose Taking 4 tablets of sucrose two times daily for 16 days
89336631|NCT03131570|Experimental|Group 1|6 months of Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period.
89336632|NCT03131570|Placebo Comparator|Group 2|Placebo followed by Secukinumab. 3 months of placebo followed by 3 months of Secukinumab at a dose of 300 mg with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period.
89336633|NCT02930018|Placebo Comparator|Placebo|Drug vehicle only
89336634|NCT02930018|Experimental|Nerinetide (NA-1), 2.6 mg/kg|
89336635|NCT01361282||Triple Procedure|All qualifying patients will have received DSAEK with concurrent cataract extraction and intraocular lens placement. Data collection will occur between 6-18 months post-operation.
89336636|NCT01370720|Active Comparator|Recoclix (CM&D Pharma Limited)|Recoclix: two tablets per day for 12 weeks
89336637|NCT01370720|Placebo Comparator|Placebo|IBS patients
89336638|NCT01370798|Experimental|promestriene|Children with severe hypospadias treated with promestriene 1%
89336639|NCT01370798|Placebo Comparator|Placebo|Control group, children with severe hypospadias treated with Placebo.
89336640|NCT01370876|Experimental|Oxaliplatin/5-FU|
89336641|NCT01370954||CerefolinNAC®|Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
89336642|NCT01372436||1|children in high-school
89336643|NCT01372436||2|children in primary school
89336644|NCT04327466|Experimental|Osciflow|Crossover sequence of experimental treatment and active comparator.
89336645|NCT04327466|Active Comparator|Highflow|Crossover sequence of experimental treatment and active comparator.
89336646|NCT05191082|Sham Comparator|Control Group (CG)|The palatal wound area will not receive any treatment
89336647|NCT05191082|Experimental|Silk Fibroin Film - SF|The palatal wound area will receive silk fibroin film as a dressing
89336648|NCT05191082|Experimental|Neurotensin-loaded Silk Fibroin Film - SF + NT|The palatal wound area will receive a neurotensin-loaded silk fibroin film as a drug delivery system
89336649|NCT04652882|Experimental|Tasimelteon|
89336650|NCT04652882|Placebo Comparator|Placebo|
89336651|NCT04644536||Granules in long bone & extremities|Filling of post-traumatic or surgically created bone defects
89336652|NCT04644536||Wedges in long bone & extremities|Osteotomies with fixation
89336653|NCT04644536||HA paste in long bone & extremities|Filling of post-traumatic or surgically created bone defects
89336654|NCT04644536||Granules in Spine|Spinal cage filling
89336655|NCT04644536||HA paste in Spine|Spinal cage filling
89336656|NCT01319630||Normal Saline|patients with severe sepsis/septic shock randomized to receive 1500 cc of Normal saline bolus as the resuscitation fluid.
89336657|NCT01319630||Albumin|patients with severe sepsis/septic shock randomized to receive 500 cc of Albumin 5% bolus as the resuscitation fluid.
89336658|NCT01319630||HES|patients with severe sepsis/septic shock randomized to receive 500 cc of Hydroxyethyl starch (HES 130kD) bolus as the resuscitation fluid.
89336659|NCT04230824|Active Comparator|Pre-workout plus and Protein recovery plus|"Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise~Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise"
89336660|NCT04230824|Placebo Comparator|Placebo|Non-caloric powder mixed with water and consumed within 30 minutes prior to exercise and within 15 minutes after exercise
89336661|NCT04230824|No Intervention|Control|This arm will receive no intervention
89336662|NCT01371188||Controls|Healthy male volunteers, non-smokers, 20-40yo, living in the city of Mendonça, São Paulo-Brazil.
89336663|NCT01371188||Sugarcane Workers|Healthy male volunteers, non-smokers, 20-40yo, sugarcane workers, living in the city of Mendonça, São Paulo-Brazil.
89336664|NCT04230434|Experimental|Safety Plan Intervention|The Safety Plan Intervention (SPI) performed in ED or in ambulatory appointment
89336665|NCT01371266|Active Comparator|Honey|60.7 grams daily orally times 14 days
89336666|NCT01371266|Active Comparator|CHO|50 grams daily orally times 14 days
89336667|NCT01371266|Active Comparator|High Fructose Corn Syrup|65.7 grams daily orally times 14 days
89336668|NCT01372514||suspected thromboembolic disease|Patients with thromboembolic disease according to diagnostic tests (MDTC with angiography, scintigraphy V/Q, dimer d, ecografia doppler, etc. ) required by the physician.
89336669|NCT04086758|Experimental|Zolbetuximab|Participants will receive a loading dose-1 of zolbetuximab on Day 1 of Cycle 1, consists of 21 days, followed by subsequent lower dose-2 every 3 weeks until they meet the discontinuation criteria.
89336670|NCT02875028|Experimental|Vorapaxar|subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
89336671|NCT02875028|Placebo Comparator|Placebo|subjects will be treated with 4 empty lactose-starch capsules
89336672|NCT01371344|Experimental|Part A: Heart Transplant (Tacrolimus granules)|In Part A of the study, participants who are heart transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
89336673|NCT01371344|Experimental|Part A: Liver Transplant (Tacrolimus granules)|In Part A of the study, participants who are liver transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
89336674|NCT01371344|Experimental|Part A: Kidney Transplant (Tacrolimus granules)|In Part A of the study, participants who are kidney transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
89336675|NCT01371344|Experimental|Part B: All Participants (Tacrolimus capsules)|In Part B of the study, participants who are heart, kidney or liver transplant recipients and who are converted from tacrolimus granules-based immunosuppression regimen, receive tacrolimus capsules twice daily for 1 month and thereafter receive commercially available tacrolimus capsules.
89336676|NCT03631004|Experimental|olanzapine tablets|PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY
89336677|NCT03631004|Placebo Comparator|Starch tablets|PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY
89336678|NCT01366118|Experimental|TT tailored Ch plus IMRT|
89336679|NCT04342364|Active Comparator|Slush nitrogen|oocytes are randomized to undergo vitrification utilizing slush nitrogen
89336680|NCT04342364|Active Comparator|Liquid Nitrogen|oocytes are randomized to undergo vitrification utilizing liquid nitrogen which is the current standard of care
89336681|NCT01372592||Degenerative|Patients being treated for degenerative spine conditions.
89336682|NCT01372592||Deformity|Patients being treated for a deformity spine condition.
89336683|NCT01372592||Trauma|Patients being treated for a trauma related spine condition.
89336684|NCT04305314||Group 1: PRI > 70%|Compliance with the Enhanced Revovery protocol higher than 70%
89336685|NCT04305314||Group 2: PRI < 70%|Compliance with the Enhanced Revovery protocol lower than 70%
89336686|NCT00943618|Active Comparator|Group 1|Varenicline and Bupropion
89336687|NCT00943618|Placebo Comparator|Group 2|Varenicline and Placebo
89336688|NCT00943618|Placebo Comparator|Group 3|Placebo that looks like varenicline and a placebo that looks like bupropion.
89336689|NCT05150080||cardiotoxicity|subjects with heart failure, coronary artery disease, valvular heart disease, arrhythmia, hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension and pericardial disease after hematopoietic stem cell transplantation.
89336690|NCT05150080||non-cardiotoxicity|subjects with on heart failure, coronary artery disease, valvular heart disease, arrhythmia, hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension and pericardial disease after hematopoietic stem cell transplantation.
89336691|NCT01372670|Experimental|Hydroxyzine|Hydroxyzine given TID
89336692|NCT01372670|Placebo Comparator|Sugar Pill|Placebo given 3 times per day
89336693|NCT02322658|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
89336694|NCT02322658|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
89336695|NCT01366274|Active Comparator|Usual method of MHI|
89336696|NCT01366274|Experimental|Protective MHI|
89336697|NCT03490552|Sham Comparator|group A|include clots which have been extracted by mechanical thrombectomy and with definite stroke etiology and submitted to the RNA analysis in blinded coded label .
89336698|NCT03490552|Experimental|group B|include all clots which have been extracted by mechanical thrombectomy and with unknown stroke etiology and submitted to RNA analysis in cryptogenic label.
89336699|NCT04218656|Experimental|Group A|111 patients with intermittent claudication
89336700|NCT04218656|Experimental|Group B|48 patients with critical limb ischemia with pain at rest and/or foot ulcers
89336701|NCT02322736||WT RAS mCRC|Wild Type RAS metastatic colorectal cancer patients
89336702|NCT04176380|Experimental|Administration of RAPA-201 cells|
89336703|NCT02322970||Intracranial Pressure monitoring|Invasive Intracranial Pressure monitoring will be compared to non invasive intracranial monitoring ( through use of transcranial Doppler ).
89336704|NCT04157426|Experimental|Ultrasound-guided percutaneous electrolysis|
89336705|NCT04157426|Active Comparator|ultrasound-guided dry needling|
88811773|NCT01380899||AP Atypical Parkinsonism|with neurodegenerative disease (proteinopathies) and secondary AP.
89336706|NCT03496714|Active Comparator|PSYED-T|In PSYED-T (psychoeducation on trauma symptoms), participants will receive a psychoeducation handout and watch a related video on common reactions to trauma. Participants in this condition will also receive a rationale stating that both learning about the nature of trauma reactions and monitoring symptoms are important for preventing development of PTSD.
89336707|NCT03496714|Experimental|PSYED-T+SB|Participants in PSYED-T+SB (Combined psychoeducation on trauma reactions and safety behaviors) will receive psychoeducation handouts and videos on the nature of trauma symptoms and the nature of safety behaviors and how to fade them. Participants in this condition will also receive a rationale stating that learning about the nature of trauma reactions and safety behaviors, learning to fade safety behaviors, and monitoring symptoms are important in the prevention of PTSD.
89336708|NCT03496714|No Intervention|Monitoring-only control|The third condition will be a monitoring-only control and thus will receive no psychoeducation information. Participants in the control condition will receive a rationale that monitoring symptoms is important in the prevention of PTSD development.
89336709|NCT03488914|Other|Intervention|
89336710|NCT03488914|Other|Enhanced Treatment as Usual|
89336711|NCT03488836|Active Comparator|race|race rotation protocol
89336712|NCT03488836|Active Comparator|reciproc|reciprocal endodontic treatment group
89336713|NCT01371422|Experimental|A1 (PVB)|PVB technique will be utilized for injection of the anaesthetic under the skin before the procedure.
89336714|NCT01371422|Placebo Comparator|A2 (Placebo)|The placebo is an inactive substance that looks identical to the test intervention but contains no active ingredients and will be administered the same as the PVB by a local skin injection, but no advancement of the needle to the paravertebral space will be made to avoid unnecessary risks.
89336715|NCT05190614||thick-gingiva group|After the insertion of the probe into the facial aspect of the sulcus through the gingival margin, the simple visual method is based on the transparency of the periodontal probe through the gingival margin while probing the buccal sulcus at the midfacial aspect of the tooth. When the outline of the underlying periodontal probe can't be seen through the gingival, the gingival phenotype is considered thick.
89336716|NCT05190614||thin-gingiva group|After the insertion of the probe into the facial aspect of the sulcus through the gingival margin, the simple visual method is based on the transparency of the periodontal probe through the gingival margin while probing the buccal sulcus at the midfacial aspect of the tooth. When the outline of the underlying periodontal probe can be seen through the gingival, the gingival phenotype is considered thin.
89336717|NCT02710084|Experimental|Oxytocin|The first phase of the study will follow a double-blind, placebo-controlled design. Participants randomized to the experimental group will receive intranasal oxytocin in doses of 24 IU, two times daily, for a total of 48 IU. Doses may be reduced by 8 IU/day if safety concerns emerge. During the second phase of the study, all participants will receive oxytocin, in identical doses.
89336718|NCT02710084|Placebo Comparator|Saline|During the first phase, patients randomized to the placebo group will receive intranasal saline solution in doses of 24 IU two times daily, for a total of 48 IU. During the second phase of the study, all participants will receive oxytocin, in identical doses.
89336719|NCT02849990|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
89336720|NCT03488680|Experimental|Intervention group|Behavior change communication
89336721|NCT03488680|No Intervention|Control group|No Behavior change communication
89336722|NCT03490474|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
89336723|NCT03490474|Active Comparator|Pain Free Massage|Participants will receive light touch applied to one myofascial trigger point.
89336724|NCT03490474|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
89336725|NCT03488602|Experimental|F-SPS Intervention|This group will receive the F-SPS intervention.
89336726|NCT03488602|Active Comparator|Enhanced Usual Care (EUC)|This group will receive Enhanced Usual Care (EUC)
89336727|NCT05190536|Experimental|Experimental: Patients in Group 1 undergo Ho:YAG laser|
89336728|NCT05190536|Experimental|Experimental: Patients in Group 2 undergo TFL|
89336729|NCT03496558|Experimental|150 pregnant women with a history of risk|
89336730|NCT03496558|No Intervention|150 healthy pregnant women|
89336731|NCT01366352|Experimental|Arm 1|MNTX tablet
89336732|NCT01366352|Experimental|Arm 2|MNTX tablet
89336733|NCT01366430|Active Comparator|Gefoni manenuver|Gefoni manenuver for Geotropic HC-BPPV
89336734|NCT01366430|Active Comparator|sham maneuver|sham maneuver for geotropic HC-BPPV
89336735|NCT01366430|Active Comparator|barbecue maneuver|barbecue maneuver for geotropic HC-BPPV
89336736|NCT03490396|Experimental|Arm 1 (Gelclair at time of conditioning)|All subjects in study Arm 1 will receive GEL starting on the first day of conditioning.
89336737|NCT03490396|Active Comparator|Arm 2 (Gelclair when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive GEL.
89336738|NCT03490396|Active Comparator|Arm 3 (MMW when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive MMW.
89336739|NCT01371812|Experimental|Cohort 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 150mg, to 600mg, to 1200mg and 1200mg with a FDA high fat/high calorie meal, will be administered over the 13 week long study allowing adequate washout period between doses.
89336740|NCT01371812|Experimental|Cohort 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 300mg, to 900mg, and 1500mg, will be administered over the 13 week long study allowing adequate washout period between doses.
89336741|NCT02449148|Experimental|Intermittent Calorie Restriction|2 days per week fasting with 25 % energy intake and 5 days per week at 100% energy intake
89336742|NCT02449148|Experimental|Continuous Calorie Restriction|daily energy intake of 80 %
89336743|NCT02449148|No Intervention|Healthy Nutrition|general advice on healthy nutrition
89336744|NCT05358782||Implant with peri-implantitis|Implant with progressive marginal bone loss
89336745|NCT05358782||Healthy implant|Implant without any sign of marginal bone loss
89336746|NCT03490162|Experimental|Food Effect|300 mg of DM1157 (2 capsules of 150 mg) orally with high fat diet, n=6, and matching placebo (2 capsules) orally with high fat diet, n=2
89336747|NCT03490162|Experimental|MAD 1|150 mg of DM1157 (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=2
89336748|NCT03490162|Experimental|MAD 2|300 mg of DM1157 (2 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (2 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
89336749|NCT03490162|Experimental|MAD 3|600 mg of DM1157 (4 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (4 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
89336750|NCT03490162|Experimental|MAD 4|900 mg of DM1157 (6 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (6 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
89336751|NCT03490162|Experimental|SAD 1|9 mg of DM1157 (1 capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
89336752|NCT03490162|Experimental|SAD 2|27 mg of DM1157 (3 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (3 capsules) orally with 240 ml of water after an overnight fast, n=2
89336753|NCT03490162|Experimental|SAD 3|81 mg of DM1157 (9 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (9 capsule) orally with 240 ml of water after an overnight fast, n=2
89336754|NCT03490162|Experimental|SAD 4|150 mg of DM1157 (1capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
89336755|NCT03490162|Experimental|SAD 5|300 mg of DM1157 (2 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (2 capsules) orally with 240 ml of water after an overnight fast, n=2
89336756|NCT03490162|Experimental|SAD 6|600 mg of DM1157 (4 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (4 capsules) orally with 240 ml of water after an overnight fast, n=2
89336757|NCT03490162|Experimental|SAD 7|900 mg of DM1157 (6 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (6 capsules) orally with 240 ml of water after an overnight fast (n=2)
89336758|NCT01366508|Other|Visit B|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
89336759|NCT01366508|Other|Visit A|At approximately 13:00 the subject will be given a standard high calorie lunch that the subject is required to finish
89336760|NCT05354648|Active Comparator|Hypoxic-hyperoxic preconditioning (HHP)|HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, and at the last stage, a period of breathing with atmospheric air until the cardio-pulmonary bypass is connected. The anaerobic threshold was determined 72 hours before surgery to establish a safe oxygen concentration in the respiratory gas mixture during the hypoxic phase of preconditioning.
89336761|NCT05354648|Placebo Comparator|Control|The anaerobic threshold was determined, however, patients in the control group were not preconditioned. Mechanical ventilation was carried out with individual settings maintaining the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively), until the cardio-pulmonary bypass was connected.
89336762|NCT05136040|Active Comparator|Group İzobarik bupivakain (5 mg) + fentanil|Patients were given a solution containing 5 mg isobaric bupivacaine + 15 µg fentanyl (1.3 ml)
89336763|NCT05136040|Active Comparator|Group İzobarik bupivakain (7 mg) + fentanil|Patients were givena solution containing 7 mg isobaric bupivacaine + 15 µg fentanyl (1.7 ml)
89336764|NCT03634358|Active Comparator|Bipolar scissors group|Group of male infants undergoing circumcision using bipolar scissors to separate the foreskin
89336765|NCT03634358|Active Comparator|Classic scalpel group|Group of male infants undergoing circumcision using classic scalpel to separate the foreskin, and sutures to control bleeding
89336766|NCT02192762|Experimental|Withdrawal regulation training|Withdrawal coping skills
89336767|NCT02192762|Active Comparator|Relaxation training|Relaxation skills instruction
89336768|NCT02183558|Experimental|OGTT by randomization|Women without risk factors for GDM are offered OGTT in gestational week 28
89336769|NCT02183558|Experimental|OGTT by indication|Women with risk factors for OGTT are offered diagnostic 2 hour OGTT in pregnancy week 28
89336770|NCT03496246|Active Comparator|Group A|patients with vitamin D deficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
89336771|NCT03496246|Active Comparator|Group B|patients with vitamin D insufficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
89336772|NCT03496246|Active Comparator|Group C|patients with normal vitamin D level normal are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
89336773|NCT02017964|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on days 1, 15, and 29; cyclophosphamide IV over 1 hour on days 1-3; methotrexate IV over 24 hours on days 15 and 29; etoposide IV over 60-120 minutes on days 43-45; and carboplatin IV over 1 hour on days 43-45. Treatment repeats every 63 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CONTINUATION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on day 1, cyclophosphamide IV over 1 hour on days 1-3, etoposide IV over 60-120 minutes on days 21-23, and carboplatin IV over 1 hour on days 21-23. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity."
89336774|NCT03131752|Experimental|Intervention Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~The intervention will last 7 days for all the patients. Three phases will be performed: warm up, knee muscle strengthening with elastic bands and stretch/relax."
89336775|NCT03131752|No Intervention|Control Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~Patients will be not receive intervention."
89336776|NCT03131830||Staff of the University Clinic of Tuebingen|Online-based questionnaire
89336777|NCT03131830||Participants of the 9th German Urogynecological Congress|Online-based questionnaire
89336778|NCT03131830||All members of the German Society of Obsetrics and Gynecology|Online-based questionnaire
89336779|NCT03131830||Pregnant women from Tübingen and Heidelberg|Online-based questionnaire
89336780|NCT05129566|Experimental|IOL Clareon AutonoMe|The first group of patients (39 eyes) who received the monofocal IOL Clareon AutonoMe after the phacoemulsification of cataract.
89336781|NCT05129566|Active Comparator|IOL Hoya iSert 251|the second group of patients (39 eyes) who received the monofocal IOL Hoya iSert 251 after the phacoemulsification of cataract
89336782|NCT02450890|Placebo Comparator|Placebo First, then ORADUR®|Placebo once daily for 2 weeks in Period 1 and ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in period 2. (No washout period between two treatment periods)
89336783|NCT02450890|Experimental|ORADUR® First, then Placebo|ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in Period 1 and Placebo once daily for 2 weeks in period 2. (No washout period between two treatment periods)
89336784|NCT05121298|Experimental|Upadacitinib|The administration of upadacitinib 15mg/day
89336785|NCT03496090|Experimental|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
89336786|NCT03496090|Active Comparator|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
89336787|NCT05190380|Experimental|High intensity|"Intervention: Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.Routine physical therapy including TENS, Hot pack and Deep friction massage along with high intensity exercises will also be delivered along with Muscle Energy Technique. Experimental:High intensity will be treated with high intensity exercises in such a way that~1st and 2nd week; resistance training will be of 50% 1RM with 4 sets of 10 repetitions.~3rd and 4th week: resistance training will be of 70% 1RM with 4 sets of 10 repetitions.~5th and 6th week: the training will be of 80% 1RM with 4 sets of 10 repetitions~Last 4 sessions will be:~7th and 8th week: resistance training will be of 80% 1RM with 5 sets of 10 repetitions."
89336788|NCT05190380|Experimental|Low intensity|"Intervention: Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.Routine physical therapy including TENS, Hot pack and Deep friction massage along with Low intensity exercises will also be delivered along with Muscle Energy Technique. Experimental:Low intensity Group B will be treated with low intensity exercise in such a way that,~1st and 2nd week; Resistance training will be of 20% 1RM with 4 sets of 15 reps 3rd and 4th week Resistance training will be of 30% 1RM with 4 sets of 15 reps 5th and 6th week: the training will be of 40% 1RM with 4 sets of 15 reps~Last session will be:~7th and 8th week; Training of 40% 1RM with 5 sets of 15 reps"
89336789|NCT03495934|Experimental|single oral administration of 14C-pracinostat in the fas|
89336790|NCT01981174|Active Comparator|30-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
89336791|NCT01981174|Active Comparator|32-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
89336792|NCT03488368||Supportive-care group|Observation of IgAN patients who received supportive care measures (without additional immunosuppression) during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
89336793|NCT03488368||Immunosuppression group|Observation of IgAN patients who received supportive care measures and additional immunosuppression during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
89336794|NCT03490006|Active Comparator|Paravertebral Block|For this arm, the initial level will be at T3-4 and an out-of-plane technique to guide the needle tip to a point between the costotransverse ligament and the parietal pleura between the visualized transverse processes. Then, a few milliliters of 0.5% ropivacaine will be injected slowly to displace the pleura ventrally as the paravertebral space fills with local anesthetic. After negative aspiration, the rest of 0.5% ropivacaine (total 10 ml) will be injected in 5 ml increments to further fill the paravertebral space. The procedure will then be repeated in the same exact fashion at the T5-6 level. We will observe local anesthetic spread under real-time ultrasound imaging.
89336795|NCT03490006|Experimental|Erector Spinae Plane Block|For this arm, the needle tip will be directed under ultrasound guidance using an in-plane technique towards the T5 transverse process until the needle tip contacts os. Then, a few milliliters of ropivacaine will be injected slowly to separate the plane between the erector spinae muscle and the transverse process. After negative aspiration, the rest of the 0.5% ropivacaine will be injected (total 20ml)
89336796|NCT01956110|Experimental|A|Follitropin Delta (FE 999049)
89336797|NCT01956110|Active Comparator|B|Follitropin Alfa (GONAL-F)
89336798|NCT03489928|Experimental|Oral Misoprostol|50ug po q4h orally, as needed
89336799|NCT03489928|Experimental|Low dose vaginal misoprostol|25-50ug q6h, vaginally, as needed
89336800|NCT03489928|Experimental|Usual vaginal dinoprostone|1-2mg q6h, vaginally as needed
89336801|NCT03488212|Active Comparator|Basic Implementation Intervention|
89336802|NCT03488212|Experimental|Enhanced Implementation Intervention|
89336803|NCT03488212|Active Comparator|Online Treatment; Control Maintenance Intervention|
89336804|NCT03488212|Experimental|Online Treatment; Monthly Lessons & Feedback for Maintenance|
89336805|NCT03488212|Experimental|Online Treatment; Refresher Courses for Maintenance|
89336806|NCT02323282|Other|ropivacine|
89336807|NCT01802086|Active Comparator|Emla-cream|Dose: 1 g Emla-cream, 1 hour.
89336808|NCT01802086|Placebo Comparator|Miniderm cream|Dose: 1 g Miniderm-cream, 1 hour.
89336809|NCT02323360|Experimental|Stereotactic body radiation therapy|HCC after incomplete TAE or TACE treated by SBRT
89336810|NCT02323360|Active Comparator|TACE/TAE|HCC after incomplete TAE or TACE treated by a new cycle of TAE or TACE
89336811|NCT01371890||Intradialytic hypertension|Patients with systolic blood pressure increases > 10 mmHg during 4/6 hemodialysis sessions
89336812|NCT05347316|Experimental|Colchicine|0.5 mg of colchicine daily for 12 months
89336813|NCT05347316|No Intervention|Placebo|Follow-up for 12 months
89336814|NCT03495778|Experimental|Test Granola|50.5 g Test Granola
89336815|NCT03495778|Placebo Comparator|Control Granola|54.3 Control Granola
89336816|NCT01735942|Experimental|Ingenol Mebutate|Ingenol Mebutate applied to one side of face with skin lesions
89336817|NCT01735942|Active Comparator|Cryotherapy|Cryotherapy applied to other side of face with skin lesions
89336818|NCT03489772|Experimental|1 mg ITI-214|Single dose
89336819|NCT03489772|Experimental|10 mg ITI-214|Single dose
89336820|NCT03489772|Placebo Comparator|Placebo|Single dose
89336821|NCT01366664|Experimental|001|Treatment sequence 1 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days)
89336822|NCT01366664|Experimental|002|Treatment sequence 2 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
89336823|NCT05193422|Active Comparator|Phase I: No mask|"Participants, without wearing a face mask, will undergo the following:~Measurement of peak nasal inspiratory flow~Cardiopulmonary exercise testing (CPET) with an ergometric bike at 30% of their predicted maximum workload (Wmax) for 4 minutes, 50% of Wmax for 2 minutes and 70% of Wmax for 1 minute, with continuous oxygen saturation (SpΟ2), heart rate (HR), end-tidal CO2 (EtCO2) and respiratory rate (RR) monitoring.~Spirometry and measurement of nPIF immediately after CPET.~Discomfort assessment using a special scale"
89336824|NCT05193422|Experimental|Phase II: Face mask|"Following nPIF measurement, participants will be asked to wear a standard surgical face mask. A temperature and humidity sensor will also be placed inside the mask. Will follow:~Resting phase, 6 minutes. SpO2, HR, EtCO2 and RR will be monitored.~CPET at 30% of Wmax for 4 minutes, 50% Wmax for 2 minutes and 70% Wmax for 1 minute. SpO2, HR, EtCO2 and RR will be continuously monitored.~Spirometry and measurement of nPIF immediately after CPET.~Discomfort assessment."
89336825|NCT03495622|Experimental|Motivational Interviewing/Text messaging|Home visits by community health worker to deliver motivational interviewing and set up a structured text messaging strategy designed around a pre-determined quit date for smoking cessation.
89336826|NCT03495622|No Intervention|Control|All participants will receive brief verbal advice about the hazards of smoking and the benefits of smoking cessation.
89336827|NCT03495544||Hereditary BC|Pathogenic germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
89336828|NCT03495544||Sporadic BC|Without germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
89336829|NCT05216510|Experimental|Cohort 1|Healthy uninfected/unexposed subjects to SARS-CoV-2
89336830|NCT05216510|Active Comparator|Cohort 2|Subjects who have recovered from SARS-CoV-2 infection
89336831|NCT05216510|Sham Comparator|Cohort 3|Subjects who have received a complete SARS-CoV-2 vaccine course
89336832|NCT03495466|Active Comparator|Local only Anesthesia|The patient will receive local only anesthesia during the first surgery and local with sedation anesthesia for their second surgery.
89336833|NCT03495466|Active Comparator|Local with sedation anesthesia|The patient will receive local with sedation anesthesia during the first surgery and local only anesthesia for their second surgery.
89336834|NCT01366742||HPV Cohort|Sexually active young women aged 12 to 22 years of age without a previous history of CIN. Women are not eligible for entry if pregnant or known immunosuppression.
89336835|NCT05054452|Experimental|Echocardiographic assessment|At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
89336836|NCT01372826|Experimental|NKTR118 Group1|Normal Renal Function
89336837|NCT01372826|Experimental|NKTR118 Group 2|Moderate Renal Function
89336838|NCT01372826|Experimental|NKTR118 Group 3|Severe Renal Impairment
89336839|NCT01372826|Experimental|NKTR118 Group 4|End-Stage Renal Disease
89336840|NCT03488056|Experimental|Test - ICCMS|"The dentists will perform clinical examination on children following the ICCMS sequence:~The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
89336841|NCT03488056|Active Comparator|Control - Standard care SESC|"The clinical sequence in this group will be:~Caries Diagnosis Operative and non-operative treatments Indication of recall interval according to the dentist However, dentists will do that without a schematic guide to follow. They will do as they usually do in their practices."
89336842|NCT01371968|Experimental|alfentanil|patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods
89531639|NCT05866302||Cohort 1: Newly diagnosed chronic GVHD|All subjects will undergo a non-contrast, high resolution CT scan with inspiratory and expiratory imaging, pulmonary function testing (PFT) and serologic biomarker studies upon entry. A total of 300 subjects (200 adults, 100 pediatric) will be enrolled. Patients in cohort 1 who develop CLD prior to the 12-month period will transition to cohort 2 at that time. PFT is recommended every 3 months over a 12 month period. Plasma samples will be collected at entry and at 12 months.
88806874|NCT04894929|Experimental|A. Multi-conponente exercise|"A 6-week therapeutic multi-component physical exercise program will be carried out. The ministerial guide will be followed by carrying out 5 weekly sessions (from Monday to Friday), offering the application through a web link of the weekly programming of the exercises for the patient (type of exercise, video of its execution, number of repetitions and description) having a approximate duration of 40 minutes.~Said sessions will be carried out daily and from the center a call was made at the end of the week to mark the follow-up and resolve any questions related to symptoms"
89336843|NCT05147818||Cases|"200 Diabetic patients of 18 year and older (either type 1or 2) presented by AKI based on KIDIGO Definition & Staging. KDIGO definition of AKI: Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 h, or Increase in serum creatinine to ≥1.5 times baseline that is known or presumed to have occurred within the prior 7 days, or Urine volume <0.5 mL/kg/h for 6 h.~KDIGO staging of AKI: (1) stage 1: Serum creatinine 1.5-1.9 × baseline or ≥0.3 mg/dL (≥26.5 µmol/L) increase / Urine output <0.5 mL/kg/h for 6-12 h (2) stage 2; Serum creatinine 2.0-2.9 × baseline / Urine output <0.5 mL/kg/h for ≥12 h (3) stage 3: Serum creatinine 3.0 × baseline, increase in serum creatinine to ≥4.0 mg/dL (≥353.6 µmol/L), initiation of renal replacement therapy, or, in patients <18 years, decrease in eGFR to <35 mL/min per 1.73 m2 / Urine output <0.3 mL/kg/h for ≥24 h or anuria for ≥12 h ."
89336844|NCT05147818||Controls|200 Diabetic patients of 18 year and older with no AKI (either type 1or 2) Matched to controls in age ,sex
89336845|NCT05193110|Other|CAD/CAM PEEK sub-periosteal implant retaining maxillary fixed prosthesis|4 PEEK sub-periosteal implants were surgically placed for patients demonstrated sever bone loss especially in the posterior region which complicate conventional implant placement for full arch prosthesis.The PEEK framework was fabricated by CAD/CAM method
89336846|NCT05193110|Other|Injection molding PEEK sub-periosteal implant retaining maxillary fixed prosthesis|4 CAD/CAM PEEK sub-periosteal implants were surgically placed for patients demonstrated sever bone loss especially in the posterior region which complicate conventional implant placement for full arch prosthesis.The PEEK framework was fabricated by injection molding technique method.
89336847|NCT04989322|Experimental|Treatment|
89336848|NCT01367054|Experimental|Metformin|500 mg
89336849|NCT03487978||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo 3-tesla resting-state functional MRI.
89336850|NCT03487978||Control|Normal controls without headaches will undergo 3-tesla resting-state functional MRI.
89336851|NCT05146570|Experimental|Aseptic Meningitis|"In all patients cerebrospinal (CSF) fluid will be aspirated following the routine diagnostic procedure. After aspiration CSF will be tested with standard diagnostic tests and experimental diagnostic test (D-lactate).~Immediately after aspiration, 0.5-1 ml of cerebrospinal fluid will be transferred into each of the following vials:~native vial for conventional culture (agar plate & broth)~EDTA vial for the determination of leukocyte count and differential~pediatric blood culture bottle (BacTec PedsPlus/F)~native vial for biomarker detection (D-Lactate)"
89336852|NCT05146570|Experimental|Infective meningitis|"In all patients cerebrospinal (CSF) fluid will be aspirated following the routine diagnostic procedure. After aspiration CSF will be tested with standard diagnostic tests and experimental diagnostic test (D-lactate).~Immediately after aspiration, 0.5-1 ml of cerebrospinal fluid will be transferred into each of the following vials:~native vial for conventional culture (agar plate & broth)~EDTA vial for the determination of leukocyte count and differential~pediatric blood culture bottle (BacTec PedsPlus/F)~native vial for biomarker detection (D-Lactate)"
89336853|NCT03495310|Experimental|Mindfulness|"In this group, children and their parents will receive a mindfulness session once a week, with a duration of 90 minutes, during 8 weeks (sessions will be separated for children and parents). Mindfulness sessions will be coordinated by experts in mindfulness techniques in children and adults respectively from the collaborator Institution Spanish School of Transpersonal Development Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan if necessary. Also a 60-minute walk 3 times a week will be recommended"
89336854|NCT03495310|No Intervention|Control|In this group, children and their parents will receive information regarding what is a healthy diet and physical activity attached to the World Health Organization recommendations. The session will be coordinated by a pediatric endocrinologist. Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan when necessary. Also a 60-minute walk 3 times a week will be recommended
89336855|NCT01372046|Experimental|Enhanced|A external consultant works with the team to develop skills and trains an in-house coach
89336856|NCT01372046|Experimental|Trainer|External consultant provides booster session
89336857|NCT01372046|Experimental|Standard|Receive agency training
89336858|NCT05192018|Experimental|Group A|This group will have their ileostomy reversed after 3 weeks from the index operation. All procedures were performed by the same senior surgeons. The duration of the operation was noted and the ease of reversal of stoma and closure of abdominal wall were assessed on ascale of 0-10 (0 = difficult, 10 = easy) by the operating surgeons.
89336859|NCT05192018|Active Comparator|Group B|This group will be discharged home after the primary colorectal surgery with a defunctioning ileostomy and brought back after an interval of 3 months ,or after completion of their adjuvant therapy, for reversal. All procedures were performed by the same senior surgeons. The duration of the operation was noted and the ease of reversal of stoma and closure of abdominal wall were assessed on ascale of 0-10 (0 = difficult, 10 = easy) by the operating surgeons.
89336860|NCT03487822|Experimental|Path Pain|Path Pain participants will be receiving 8 weekly therapy session by license clinicians trained in the Path Pain intervention. They will also receive 4, 15-minute phone booster sessions, on a monthly basis after their final therapy session. They will also be invited to monthly group educational sessions. Both intervention and usual care participants will be receiving a pain educational booklet.
89336861|NCT03487822|No Intervention|Usual Care with Education|Usual Care with Education (UCE) will receive a pain educational booklet. Following completion of their 24 weeks in the study, they will also be invited to attend the monthly group educational sessions.
89336862|NCT03487822|No Intervention|Provider Feedback|Providers of patients in the study will take part in a short interview on their impressions of the intervention.
89336863|NCT05043064|Active Comparator|Experienced robotic cardiac surgeons|
89336864|NCT05043064|Active Comparator|Cardiac surgeons with limited robotic experience|
89336865|NCT05043064|Active Comparator|Non-cardiac surgeons with limited robotic experience|
89336866|NCT03634514|Experimental|Application of Biomatrop|A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
89336867|NCT03634514|Active Comparator|Application of Hormotrop|A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
89336868|NCT02323438|Active Comparator|Usual Brand (UB) Cigarettes|Usual Brand Cigarette
89336869|NCT02323438|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 29 mg nicotine)
89336870|NCT02323438|Experimental|Electronic Cigarette #2|VUSE® (menthol flavor, 26 mg nicotine)
89336871|NCT02323438|Experimental|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
89336872|NCT01372124|Experimental|NOX-E36|All subjects included in this study will receive the same dose of NOX E36.
89336873|NCT01372904|Experimental|Dexamethasone|
89336874|NCT01372982|Active Comparator|Femara|
89336875|NCT01372982|Experimental|Letrozole|
89336876|NCT02323516|Experimental|Acetylsalicylic acid + loperamide|Acetylsalicylic acid + loperamide
89336877|NCT02323516|Active Comparator|diosmectite + loperamide|Acetylsalicylic acid + loperamide
89336878|NCT05066048||The appendectomy group|
89336879|NCT05066048||Colorectal cancer group|
89336880|NCT05066048||Normal group|
89336881|NCT04625296||Healthcare professional|Communities Health professionals (doctors, nurses, physiotherapist) Working in the city, In metropolitan France, Having managed patients with COVID-19
89336882|NCT05134610|No Intervention|Control|Standard of care for pre- and post-op pulmonary care
89336883|NCT05134610|Experimental|OPEP Therapy|14 days pre- and and post-op OPEP device usage
89336884|NCT03489694||Subjects|Each subject will undergo skin test endpoint titrations with three different testers.
89336885|NCT01367210|Experimental|MARAVIROC, DARUNAVIR/r|"Treatment simplification from a standard combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy"
89336886|NCT01367210|Sham Comparator|current ART with 3 drugs|Patients on HAART with three drugs and HIV RNA below 50 copies/mL
89336887|NCT02323594|Experimental|Group 1: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV pediatric chewable tablet
89336888|NCT02323594|Experimental|Group 2: Daclatasvir|Single oral dose of Daclatasvir (DCV) pediatric chewable tablet and single oral dose of DCV pediatric chewable tablet
89336889|NCT02323594|Experimental|Group 3: Asunaprevir|Single oral dose of Asunaprevir (ASV) tablet, single oral dose of ASV pediatric chewable tablet and single oral dose of ASV pediatric chewable tablets
89336890|NCT02323594|Experimental|Group 4: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV tablets
89336891|NCT01372280|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
89336892|NCT01372280|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
89336893|NCT04866160|Experimental|BI 1291583 low dose|
89336894|NCT04866160|Experimental|BI 1291583 high dose|
89336895|NCT04866160|Placebo Comparator|Placebo|
89336896|NCT04947644|Active Comparator|Thoracic epidural analgesia group|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
89336897|NCT04947644|Experimental|Ultrasound guided continuous erector spinae plane block group|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
89336898|NCT02323672||oral premalignant patients|15 patients suffering from oral premalignant lesions as lichen planus, actinic keratosis, leukoplakia and erythroplakia.
89336899|NCT02323672||oral malignant patients|15 patients suffering from oral malignant lesions
89336900|NCT02323672||control subjects|15 individuals age, gender and periodontal status matched with oral premalignant and malignant patients and not suffering from any oral mucosal lesions or periodontal disease.
88811774|NCT01380899||Control group|Subjects without neurodegenerative disease and apparently good health status with an age that matches the problems groups
88811775|NCT01498601|Experimental|Oral care treatment group|All subjects in the prospective intervention group will receive the same enhanced oral care protocol
89336901|NCT04989842|Active Comparator|Intervention group 1|webbased aftercare
89336902|NCT04989842|No Intervention|Control group|care as usual
89336903|NCT04989842|Active Comparator|Intervention group 2|webbased aftercare
89336904|NCT04989842|Active Comparator|face-to-face aftercare|face-to-face aftercare
89336905|NCT03487744|Active Comparator|Promote without fiber|Lower osmolality enteral tube feed formulation
89336906|NCT03487744|Active Comparator|Osmolite 1.5|Higher osmolality enteral tube feed formulation
89336907|NCT01373060|Experimental|ASP1941 group|
89336908|NCT01373060|Placebo Comparator|placebo group|
89336909|NCT04816630||CBC-Diff Monocyte Volume Width Distribution|Monocyte Distribution Width [MDW] is part of the CBC with Differential. No intervention
89336910|NCT03620084|Experimental|Expiratory Muscle Strength Training (EMST)|Participants will be taught how to use the EMST-150 device. The device has a one-way spring-loaded valve calibrated at different resistances that the user can select. The valve will open when expiratory pressure exceeds the threshold set by the user on the device. This threshold is set at 75% of the individual's maximum expiratory pressure for the session.
89336911|NCT04742140|Active Comparator|group I|each patient injected 0.5ml in each TrPs of saline by the same operator
89336912|NCT04742140|Experimental|group II|each patient injected 0.5ml in each TrPs of magnesium sulphate by the same operator
89336913|NCT04580992||Ajmaline group|
89336914|NCT04590274|Experimental|Regimen|0-400 mg Hydroxychloroquine 0-500 mg Azithromycin 0-50 mg elemental Zinc 0-3,000 mg Vitamin C 0-5,000 IU Vitamin D3 0-1200 mg N-acetylcysteine 0-600 mg Elderberry 0-600 mg Quercetin
89336915|NCT01367288|Experimental|A (Neoadjuvant therapy + Zometa)|Patients will be treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : Zometa 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with Zometa 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
89336916|NCT01367288|Active Comparator|B (Neoadjuvant therapy)|Patients will be treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
89336917|NCT04455178|Experimental|Spironolactone|Spironolactone 20mg once daily
89336918|NCT04455178|Active Comparator|Indapamide|Indapamide 1.5mg once daily
89336919|NCT01372358|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
89336920|NCT01372358|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
89336921|NCT01367366||Mediastinal malignant lymphadenopathy|
89336922|NCT03634046|Experimental|PTED group|Percutaneous transforaminal endoscopic discectomy (PTED). Use German Joimax company production of intervertebral foramen mirror operation system, the prone position, by preoperative X-ray locating the skin into the needle point, intervertebral level away from the spine line 8 ~ 10 cm, 18 g needle insertion, the Kambin security triangle directly through the middle of pathological changes of intervertebral disc. After the success of the puncture, remove the needle core, injection of contrast agent, methylene blue (9:1) mixture disk imaging, replace the godet, slight rotation step by step to insert the expansion sleeve, X-ray perspective to determine work under the correct position. Radiofrequency ablation is used to form nucleus pulposus and fibrous ring and stop bleeding.
89336923|NCT03634046|Active Comparator|RA group|Radiofrequency ablation (RA). Patients in prone position, local infiltration anesthesia, the puncture point for lesion clearance level, is apart from the spine line distance is 8 to 10 cm, in the perspective of the C-shaped arm X-ray machine; After the puncture needle was reached, the needle core was removed and the radiofrequency head was pierced through the puncture channel to the nucleus pulposus. In accordance with the method of melt into the shrinking exit, the intensity of the treatment by band 2, increased to 3 file again, according to the needle round mouth of 2, 4, 6, 8, 10, 12 o'clock to this process is repeated six times.
89336924|NCT04373746|Experimental|10-40 kg|Patients undergoing major surgery that weigh between 10-20 kg.
89336925|NCT04373746|Experimental|40-80 kg|Patients undergoing major surgery that weigh between 40-80 kg.
89336926|NCT01367522|Experimental|Arm 1|
89336927|NCT02446834|Experimental|intensive lifestyle intervention|3 months intensive lifestyle intervention, including low GI diet and exercise.
89336928|NCT02446834|Experimental|GLP-1 Receptor Agonists|3 months GLP-1 Receptor Agonists treatment
89336929|NCT02446834|Experimental|metformin|3 months metformin treatment
89336930|NCT02446834|Experimental|acarbose|3 months acarbose treatment
89336931|NCT02893514|Placebo Comparator|Screening Only (SO)|
89336932|NCT02893514|Experimental|Substance Use Screening and Intervention Tool (SUSIT)|
89336933|NCT03489616|Experimental|Radiotherapy+chemotherapy+ rhGM-CSF|Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be> 4Gy per time（or BED >45Gy） from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.
89336934|NCT03489616|Experimental|Single agent maintenance therapy|Maintenance treatment by single agent in a cycle of 21 days.
89336935|NCT02323828|Experimental|Investigational product|"The investigational products are RS starch cookies (40 g resistant starch) from high amylose maize starch.~Nine young healthy volunteers (males and females) consumed RS rich cookies (40 g RS) in two separate occasions."
89336936|NCT02323828|Placebo Comparator|Placebo|The placebo products are common wheat-maize cookies (2 g RS). Nine young healthy volunteers (males and females) consumed placebo in two separate occasions.
89336937|NCT02323906|Experimental|CC-122 + Fixed-dose Sorafenib|"A dose escalation and expansion clinical study of CC-122 in combination with sorafenib in subjects with unresectable HCC who have received no prior systemic therapy for HCC.~The dose escalation part of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part."
89336938|NCT02323984||Hypoactive Delirium - Delirious|Hypoactive delirious patients presenting with lethargy and sedation and are slow to respond to questions and demonstrate little spontaneous movement. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
89336939|NCT02323984||Hyperactive Delirium - Delirious|Hyperactive delirious patients presenting with restlessness, agitation, hyper vigilance, and occaionally hallucinations. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
89336940|NCT02323984||No Delirium - Nondelirious|Patients not presenting any symptoms of hypoactive or hyperactive postoperative delirium. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
89531640|NCT05866302||Cohort 2: Newly diagnosed chronic lung disease (CLD)|All subjects will undergo a non-contrast, high resolution CT scan with inspiratory and expiratory imaging, pulmonary function testing (PFT) and serologic biomarker studies upon entry. A total of 75 subjects (50 adults, 25 pediatric) will be enrolled. PFT is recommended every 3 months over a 12 month period. Plasma samples will be collected at entry and at 12 months.
89336941|NCT02324062||Pathogenic group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients identified with a mutation in a gene not commonly tested for prior to the advent of multiplex panel testing. This excludes BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH unless a patient tested positive for one of these 9 genes but did not meet clinical criteria for the underlying syndrome (n = 124). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
89336942|NCT02324062||VUS group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients identified with a variant of unknown significance of any gene of any nonBRCA (BRCA1 and BRCA2) or non-Lynch syndrome gene (MLH1, MSH2, MSH6, PMS2 and EPCAM).~Target accrual is 100. These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
89336943|NCT02324062||Negative Group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients who test negative for all the genes tested. Target goal is 50 for Stanford (100 for the study). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
89336944|NCT02324062||No follow-up intervention group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~All other participants who do not meet any of the above criteria or fall into one of these groups after the target goal is met for that group."
89336945|NCT03116828|Experimental|eslicarbazepine acetate (arm 1)|eslicarbazepine acetate (as first add-on)mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
89336946|NCT03116828|Experimental|eslicarbazepine acetate (arm 2)|eslicarbazepine acetate (as later add-on)
89336947|NCT03487510||NO groups|no groups apply.
89336948|NCT03487432|Experimental|OPN NC|Patients receiving a Super High-Pressure NC PTCA Balloon (OPN NC)
89336949|NCT03487432|Experimental|NSE Alpha|Patients receiving a Scoring PTCA Balloon (NSE Alpha)
89336950|NCT01319942||Unresectable hepatoma|Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
89336951|NCT04392232|Experimental|Convalescent Plasma|
89336952|NCT01373138|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
89336953|NCT01373138|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
89336954|NCT03489538||RYGB Patients|Laparoscopic long limb roux-en-Y gastric bypass group. All consecutive patients eligible for bariatric surgery.
89336955|NCT01373216|Experimental|Exenatide|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment
89336956|NCT01373216|No Intervention|Control|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment
89336957|NCT04007146|Experimental|Cardiac Output Measurement|Subject will have a usual cardiac output
89336958|NCT03495076|Experimental|Saline injection|In the saline condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline solution.
89336959|NCT03495076|Sham Comparator|Sham injection|In the sham injection condition, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
89336960|NCT03495076|No Intervention|Control|Participants in the control condition will not receive any kind of pain or pinprick sensation.
89336961|NCT04770974||Urothelial Carcinoma|"Patients over the age of 18 known for urological interventions for the following pathologies will be considered for enrollment in the group of cases:~- Bladder cancer~The exclusion criteria will be:~Age under 18~Pregnancy~Lack of informed consent~Inability to provide informed consent~Patients included in the study, who meet the inclusion criteria, have an operative note for:~Transurethral Resection of Bladder Neoplasia (TURBT)~Radical Cystectomy for Bladder Neoplasia"
89336962|NCT02324140||Minimized extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the minimized extracorporeal circulation (MECC, group 1)
89336963|NCT02324140||Conventional extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the conventional extracorporeal circulation (CECC, group 2)
89336964|NCT02324140||Transcatheter aortic valve implantation, transfemoral access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transfemoral access route
89336965|NCT02324140||Transcatheter aortic valve implantation, transapical access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transapical access route
89336966|NCT03633968|Active Comparator|maxillary sinus lift small antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall. round diamond bur will be used to make small antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
89336967|NCT03633968|Active Comparator|maxillary sinus lift large antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall round diamond bur will be used to make large antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
89336968|NCT01374074||White GERD|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with gastroesophageal reflux disease and do not have Barrett's esophagus."
89336969|NCT01374074||African American GERD|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with gastroesophageal reflux disease and do no have Barrett's esophagus."
89336970|NCT01374074||White BE|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with Barrett's Esophagus."
89336971|NCT01374074||African American BE|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with Barrett's Esophagus."
89336972|NCT03487354|Active Comparator|Single daily dose|
89336973|NCT03487354|Active Comparator|Multiple daily doses|
89336974|NCT04752800|Experimental|active tDCS|"Participants will receive 10 ETCC sessions, for 20 minutes, on alternate days (3 times a week). The electrodes will be positioned on the primary motor cortex (position C3 or C4 according to the international electroencephalogram system - EEG 10/20), with the anode positioned on the affected hemisphere and the cathode on the supraorbital region in the hemisphere contralateral to the injury. The electrodes will be wrapped with sponges of 5 x 7 cm and moistened with saline (NaCl 0.9%).~The current intensity will be 2mA."
89336975|NCT04752800|Sham Comparator|Sham tDCS|The protocol for placebo stimulation will be identical, but the device will stop emitting current 30 seconds after the start of stimulation.
89336976|NCT04461340|Experimental|Group A|20 patients will receive sirolimus ( oral dose of 6 mg on day 1 followed by 2 mg daily for 9 days) plus national standard of care therapy against COVID 19
89336977|NCT04461340|No Intervention|Group B|20 patients will receive only national standard of care therapy against COVID 19
89336978|NCT05154968|Experimental|Sequence 1 (ABCD)|Participants will receive 1 millilitre (ml) subcutaneous (SC) injection of treatment A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at the potential of hydrogen (pH) 5.7) followed by treatments B (higher pain Room Temperature [RT] solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7), C (lower pain refrigerated solution contains mannitol), and D (lower pain RT solution contains mannitol) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
89336979|NCT05154968|Experimental|Sequence 2 (BDAC)|Participants will receive 1 ml SC injection of treatment B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7) followed by treatments D (lower pain RT solution contains mannitol), A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), and C (lower pain refrigerated solution contains mannitol) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
89336980|NCT05154968|Experimental|Sequence 3 (CADB)|Participants will receive 1 ml SC injection of treatment C (lower pain refrigerated solution contains mannitol) followed by treatments A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), D (lower pain RT solution contains mannitol), and B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
89336981|NCT05154968|Experimental|Sequence 4 (DCBA)|Participants will receive 1 ml SC injection of treatment D (lower pain RT solution contains mannitol) followed by treatments C (lower pain refrigerated solution contains mannitol), B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7), and A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
89336982|NCT01903408|Other|Arm 1: Boost to prostate|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate (76.5 Gy) in 34 fractions Arm finished recruitment and follow-up
89336983|NCT01903408|Other|Arm 2: Boost to prostate and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate (76.5 Gy) & pelvic lymph node mets (61.2 Gy) in 34 Fx
89336984|NCT01903408|Other|Arm 3: Boost to prostate bed|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate bed (68 Gy) in 34 fractions Arm finished recruitment and follow-up and is published
89336985|NCT01903408|Other|Arm 4: Boost to prostate bed and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate bed 68 Gy) & lymph node metastases (61.2 Gy) in 34 Fx
89336986|NCT01903408|Other|Arm 5: Boost to lymph node metastases|Patients with previous irradiation of the prostate bed: IMRT of the pelvic lymphatic drainage (46.8 Gy) above the previous treatment fields, SIB to lymph node metastases (63.2 Gy) in 26 Fx
89336987|NCT01373372|Experimental|Functional Dyspepsia cohort|Cohort of subjects with functional dyspepsia
89336988|NCT01373372|Other|Control cohort|Control group of subjects with no functional dyspepsia
89336989|NCT02324218||Diabetes mellitus Group|All the subjects with diabetes mellitus diagnosed with hepatitis B, reported in the CPRD database of UK, from the Year 2000 to 2012.
89336990|NCT02324218||Non-Diabetes mellitus Group|All the subjects with hepatitis B who are diagnosed negative diabetes mellitus, reported in the CPRD database of UK, from the Year 2000 to 2012.
89336991|NCT03877978||Severe traumatized patients|Severe traumatized patients with an Index Severity Score (ISS) ≥ 15 admitted to the trauma center of Edouard Herriot Hospital.
89336992|NCT03494998||Children and young people|Aged 0-16 years
89336993|NCT03993574|Other|Standard Care|The standard care group will receive baseline testing #1, standard care, baseline testing #2 and follow up testing approximately 8 weeks later.
89336994|NCT03993574|Experimental|Experimental|Experimental group will baseline testing #1, standard care, baseline testing #2 however then participate in a 6-week self-management intervention (either generic or vision specific self-management based) and then get 8 week follow up testing.
89336995|NCT03938272|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes Strain HC-1
89336996|NCT04146142|Active Comparator|Transperineal prostate biopsy with antibiotic profylaxis|Cefuroxim 1.5 g will be applied intramuscularly before prostate biopsy
89336997|NCT04146142|Experimental|Transperineal prostate biopsy without antibiotic profylaxis|No antibiotics will be used before or after prostate biopsy
89336998|NCT03494842|Active Comparator|the active TENS group|Transcutaneous nerve stimulation (TENS)
89336999|NCT03494842|Placebo Comparator|the placebo TENS group|Placebo Transcutaneous nerve stimulation (TENS)
89337000|NCT03494764|Active Comparator|5 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
89337001|NCT03494764|Active Comparator|3 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
89337002|NCT03489460|Active Comparator|Receive sleep health messages + GAD|Procedures will be delivered to users of the GAD, individuals who have opted in via their smartphone application, to receive messages about various areas of health.
89337003|NCT03489460|Active Comparator|Sleep message No GAD|For two weeks participants agree to receive sleep health messages and wear the GAD
89337004|NCT03494686|Experimental|LLETZ under local anaesthesia|The LLETZ procedure will be performed under local anaesthesia
89337005|NCT03494686|Active Comparator|LLETZ under general anaesthesia|The LLETZ procedure will be performed under general anaesthesia
89337006|NCT03486028||ASAM Counties/non-computerized|Pre- and 1115-waived counties that are implementing the ASAM. Intervention is adherence to ASAM protocols.
89337007|NCT03486028||ASAM Counties/computerized|Counties using a computerized system to assist in intervention determination according to ASAM protocols. Intervention is adherence to ASAM protocols.
89337008|NCT03486028||Non-ASAM Counties|"Pre- and non-waived control counties that are not implementing the ASAM. Intervention is non-adherence to ASAM protocols."
89337009|NCT03487198|Experimental|Brexpiprazole|2-3 mg/day, once daily for 6 weeks, oral administration
89337010|NCT03487198|Placebo Comparator|Placebo|2-3 mg/day, once daily for 6 weeks, oral administration
89337011|NCT03978754||Patients who visit clinic|Postoperative patients who have undergone axillary surgery for breast cancer and went to clinic due to complaints of upper limb discomfort.（The expected number of subjects in this group is 300）
89337012|NCT03978754||Preoperative breast cancer patients|Preoperative subjects diagnosed with breast cancer were enrolled as non-lymphedema group. （The expected number of subjects in this group is 1300）
89337013|NCT03881020|Experimental|SMART|Silver modified atraumatic restorative treatment group in which advantage Arrest Silver diamine Fluoride 38% (Elevate oral Care, USA ) will be applied to carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
89337014|NCT03881020|Active Comparator|Conventional ART|Conventional atraumatic restorative treatment group in which a sharp excavator will be used to remove caries from carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
89337015|NCT03485872|Experimental|Self-Screening and Referral Information|The intervention will include a combination of self-screening and UI specific information and resources. Older adults in the intervention group will complete a gender specific UI Self-Screening tool. Men will complete the International Consultation on Incontinence Modular Questionnaire (ICIQ) for Males and women will complete the ICIQ for Females. In addition, the intervention group will receive a fact sheet with UI specific information, contact information to the local incontinence clinic and a link to a website with patient incontinence resources and education.
89337016|NCT03485872|Active Comparator|Control Group|Older adults assigned to the control group will receive standard care from their physicians. Standard care may differ from general practitioner to general practitioner. Usual care for urinary incontinence (UI) from general practitioners is generally minimal. Most patients do not tell their physicians about UI, and most physicians do not ask about UI. If this topic does come up during a GP appointment, a patient may be offered no treatment, lifestyle advice (e.g., do not drink before bed), told to do Kegels (but likely not instructed how to do these properly) or in some cases, offered pharmacological therapies (which will be captured in our questionnaire with the participants). But standard of care is unfortunately very often no care.
89337017|NCT03841708|Active Comparator|Pleth Variability Index|In the experimental group patients will be hemodynamically resuscitated in the early phases after ROSC based on the pleth variability index on top of standard non invasive monitoring
89337018|NCT03841708|Placebo Comparator|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG.
89337019|NCT03776188||no groups - observational study|no groups - observational study
89337020|NCT01367600|Experimental|Arm 1|
89337021|NCT03720730|Experimental|Study participants|Patients with a recent history of suicidal crisis (within the last 7 days) will use a smartphone application to evaluate sleep, appetite and social parameters.
89337022|NCT01367678|Experimental|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
89337023|NCT01367678|Experimental|i-Gel|Directly measured mucosal pressures
89337024|NCT03487042|Experimental|Generalized vitiligo patients|"Each patient with generalized vitiligo will be subjected to the following:~One side will be treated by narrow band ultraviolet rays sessions twice weekly for 3 months + topical bimatoprost 0.03% ophthalmic solution solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% ophthalmic solution twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months."
89337025|NCT02150564|Other|Navigation only group|Sonowand system will be used for navigation control arm as well as sononavigation experimental arm.Navigation will be used to plan the craniotomy and throughout the procedure as desired by the operating surgeon. At no point of time however will the Ultrasound be used.
88811776|NCT01498601|No Intervention|Retrospective study group|For comparison purposes, a retrospective chart review of matched in-patient population will reveal pneumonia rates in the same population who did not receive the enhanced oral care protocol.
88811777|NCT01419977|Placebo Comparator|Placebo|Normal saline solution
89337026|NCT02150564|Experimental|SonoRCT Test group|Surgery to resect the tumor with the aid of sononavigation. In addition to the navigation function, the Ultrasound will be available at all times. This study will help in assessing the usefulness sononavigation in improving radicality of resection in malignant gliomas and also to access the accuracy of SonoWand in predicting residue.
89337027|NCT03486886|Experimental|PSMA -PET/CT scanning|
89337028|NCT02137460||Young normal controls|"age : 20 ~ 55~without dementia, MCI, or other major neurological/psychiatric illness"
89337029|NCT02137460||Elderly normal controls|"age : 55 ~ 90~without dementia, MCI, or other major neurological/psychiatric illness"
89337030|NCT02137460||MCI (Mild cognitive impairment)|"age : 55 ~ 90~without major neurological/psychiatric illness~concern regarding a change in cognition, lower performance in episodic memory domains that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
89337031|NCT02137460||AD (Alzheimer's diseases)|"age: 55 ~ 90~National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia"
89337032|NCT03486808|Experimental|Dual stimulation|i) anodal stimulation of left inferior frontal cortex ii) anodal stimulation on left dorsolateral prefrontal cortex
89337033|NCT03486808|Active Comparator|IFG stimulation|anodal stimulation of left inferior frontal cortex
89337034|NCT03486808|Active Comparator|DLPFC stimulation|anodal stimulation on left dorsolateral prefrontal cortex
89337035|NCT03486808|Sham Comparator|Sham stimulation|sham stimulation
89337036|NCT03165916|Experimental|Reconstruction with stent placement|Subjects will undergo biliary reconstruction with stent placement at the anastomosis site.
89337037|NCT03165916|No Intervention|Reconstruction without stent placement|Subjects will undergo biliary reconstruction without stent placement.
89337038|NCT04718948||Patients Positive for Urinary Tract Cancer|"Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention~The group of cases will consist of patients who meet the inclusion and exclusion criteria in the operative note for:~Transurethral Resection of Bladder Neoplasia (TURBT)~Radical Cystectomy for Bladder Neoplasia~Diagnostic ureterorenoscopy and / or laser treatment of ureteral and / or renal pelvis neoplasia~Segmental ureterectomy with or without ureteral reimplantation~Nephroureterectomy with or without bladder cuff excission"
89337039|NCT04718948||Patients Negative for Urinary Tract Cancer|"Patients will undergo urinary cytology, multimodal spectroscopy in urine and urologic surgical intervention~The control group will consist of patients who meet the inclusion and exclusion criteria in the operative note for:~Transurethral Resection of Prostate (TURP)~Other endoscopic treatments of Benign Prostatic Hyperplasia (BPH)~Open interventions of prostatic adenomectomy~Endoscopic lithotripsy interventions of bladder stones or cystotomy with removal of bladder stones~Rigid and / or flexible ureterorenoscopy for the treatment of kidney and / or ureteral stones~Placement of ureteral catheter for ureteral and / or renal stones~Bladder Neck Incision (TUIP)~Endoscopic urethrotomy"
89337040|NCT03115294|Experimental|Study group|Patients undergo procedure with stepwise measurements and ventilator + volume adjustment + iv theophylline Myocardial movement recording using videoscanning
89337041|NCT05154266|Experimental|Mindfulness Programme|Participants randomized to the mindfulness programme were invited to complete a twelve-week programme called 'Taking it Further'.
89337042|NCT05154266|No Intervention|Waitlist Control|Participants randomized to the waitlist control were asked to carry on as usual and were offered the Taking it Further course at a later time. No data was collected when the waitlist control group took part in the TiF programme.
89337043|NCT03485716|Experimental|running under hypoxia - first|running under hypoxia (first day) and normoxia (second day)
89337044|NCT03485716|Active Comparator|running under normoxia - first|running under normoxia (first day) and hypoxia (second day)
89337045|NCT01367756|Experimental|1|
89337046|NCT01367756|Placebo Comparator|2|
89337047|NCT03485638||Cetuximab administration|
89337048|NCT04624958|Experimental|zanubrutinib, rituximab, consolidation chemotherapy and zanubrutinb maintenance|"Part A (Zanubrutinib and Rituximab): Patients receive zanubrutinib on days 1-28 and rituximab on day 1. Treatment cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve CR.~PART B (Consolidation chemotherapy of R-DHAOx): Patients receive R-DHAOx regimen every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Elderly patients (> 65 years old) and patients who achieved CR and minimal residual disease negative after PART B receive zanubrutinb maintenance therapy. Young patients (<65 years old) who achieved CR but minimal residual disease positive after PART B can receive autologous stem cell transplantation and then zanubrutinb maintenance therapy. Patients with PD, SD or PR after PART B quit the trial.~ZANUBRUTINB MAINTENANCE: Patients receive zanubrutinib every day for up to one year."
89337049|NCT03489226|Active Comparator|Capsimax 2 mg|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
89337050|NCT03489226|Placebo Comparator|Placebo|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
89337051|NCT03489226|Active Comparator|Capsimax 4 mg plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
89337052|NCT03489226|Placebo Comparator|Placebo plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
89337053|NCT03067714|Experimental|Active product: partially hydrolysed formula + synbiotics|
89337054|NCT03067714|Active Comparator|Control product: standard formula (intact protein)|
89337055|NCT01374152|Experimental|Perfetti|Cognitive sensory motor training method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
89337056|NCT01374152|No Intervention|conventional rehabilitation|conventional occupational therapy method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
89337057|NCT03485560|Experimental|internvention of Chrinic skin conditions|All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
89337058|NCT03289702|Experimental|CORETOX®|
89337059|NCT03289702|Active Comparator|BOTOX®|
89337060|NCT03126344|Experimental|King Vision video laryngoscope|
89337061|NCT03126344|Experimental|McGrath MAC video laryngoscope|
89337062|NCT03126344|Active Comparator|Macintosh|
89337063|NCT03485482|Experimental|Group Ivabradine|six healthy volunteers will administer Ivabradin tablet only once single 10 mg oral dose
89337064|NCT03485482|Experimental|Group Bisoprolol|six healthy volunteers will administer bisoprolol tablet only once single oral dose of 5mg
89337065|NCT03485482|Experimental|Group combination|six healthy volunteers will administer only once a combination of a single dose of ivabradine 10 mg and bisoprolol 5 mg
89337066|NCT02946424|Experimental|Simvastatin treatment|Simvastatin for one year time period
89337067|NCT02946424|Placebo Comparator|Placebo treatment|Placebo for one year time period
89337068|NCT00783536|Experimental|1|"Clinical and demographic information~Clinical and Laboratory information"
89337069|NCT00783536|Active Comparator|2|"Clinical and demographic information~Clinical and Laboratory information"
89337070|NCT01374230|Experimental|E1 Tibial bearing|All patients undergoing primary total knee replacement surgery will receive a tibial bearing made of E1 polyethylene, which is the material being monitored in this study.
89337071|NCT01367912|No Intervention|Progesterone only group|received a single daily application of vaginal progesterone gel beginning from the day of OPU and continued at least until pregnancy was ruled out by a negative serum ß-hCG measurement performed on the 14th day after embryo transfer with no E2 added
89337072|NCT01367912|Active Comparator|Progesterone+Early Estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
89337073|NCT01367912|Active Comparator|Progesterone+Late estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel
89337074|NCT00349466|Experimental|CF101 1mg|CF101 1 mg given orally every 12 hours for 12 weeks
89337075|NCT00349466|Placebo Comparator|Placebo|Placebo given orally every 12 hours for 12 weeks
89337076|NCT04093466|Experimental|Treatment (CX1003)|Treatment will comprise 2 periods: a 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond).
89337077|NCT03115112|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
89337078|NCT03115112|Active Comparator|Sitagliptin|Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
89337079|NCT03634280|Placebo Comparator|Splinting|Splinting was applied to the patients' ankle in the second group(n=120). Splint were kept on the patients for 5 days for 23 hours a day. In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
89337080|NCT03634280|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 120 participants were taped for a lateral ankle sprain. 50-mm wide and 0.5-mm thick KT was applied to the tendinomuscular meridian around the ankle with three I-shaped tapes. Initially, one I-shaped tape was applied along the course of the tibialis anterior muscle, and another I-shaped tape was then applied to the peroneus longus and brevis muscles. The third I-shaped tape was applied from the abductor digiti minimi muscle and wrapped around the ankle in a figure-of-eight shape to the abductor hallucis muscle, surrounding the ankle over the medial and lateral malleoli. The tape was applied to the skin by applying zero tension, and skin problems were avoided.
89337081|NCT01373528|Experimental|Budesonide|
89337082|NCT03634202|Experimental|IMRT + oral chemotherapy|Radiotherapy = IMRT with SIB. The overall duration of irradiation is 5 to 7 weeks Chemotherapy = oral capecitabine. Chemotherapy is taken in concomitance as radiotherapy days
89337083|NCT05019560|Active Comparator|Group A|"In group A:~The researcher, who supervised the anesthesia, explained the concept of the study to all patients before induction, and then a tourniquet was placed around the dominant arm of the patients after placing a cotton bandage; to be inflated to 200mmHg or 40 mmHg above the systolic blood pressure of the patient; immediately before administration of the muscle relaxant later on.~Patients received inhalation induction using sevoflurane 8% and fentanyl 2 µg/kg was administered intravenously. After loss of consciousness, and BIS value of 50 or less, the tourniquet cuff was inflated then atracurium 0.5 mg/kg was given intravenously and sevoflurane reduced to 2%, then laryngoscopy and intubation were done when action of neuromuscular blocker (NMB) was confirmed by the disappearance of T3,T4. During this time, mask assisted ventilation with 100% oxygen was used to achieve normocapnia"
89337084|NCT05019560|Active Comparator|Group B|"In group B:~The researcher, who supervised the anesthesia, explained the concept of the study to all patients before induction, and then a tourniquet was placed around the dominant arm of the patients after placing a cotton bandage; to be inflated to 200mmHg or 40 mmHg above the systolic blood pressure of the patient; immediately before administration of the muscle relaxant later on.~In group B: propofol 1.5 mg/kg and fentanyl 2 µg/kg were administered intravenously. After loss of consciousness, and BIS value of 50 or less, the tourniquet cuff was inflated and then atracurium 0.5 mg/kg was given intravenously. Propofol infusion 6 mg/kg/hr was started, until action of neuromuscular blocker (NMB) was confirmed by disappearance of T3,T4, then laryngoscopy and intubation were done. The used dosing regimen is according to previous guidelines [8] [9].No inhalational agent was used. Mask assisted ventilation was used to achieve normocapnia."
89337085|NCT01373606|Experimental|Terlipressin|
89337086|NCT03690284|Active Comparator|Conventional Double Lumen Tube|Patient will be intubated with conventional double lumen endotracheal tube for single lung ventilation during thoracic surgery.
89337087|NCT03690284|Experimental|VivaSight Double Lumen Tube|Patient will be intubated with VivaSight double lumen endotracheal tube for single lung ventilation during thoracic surgery.
89337088|NCT03632252|Experimental|Powered ankle prosthesis|We will use data from various sensors to optimize the amount of power provided by custom ankle ankle prosthesis. This is a single session study lasting about 4 hours.
88811778|NCT01419977|Experimental|Dalteparin|5000 unites subcutaneously, Other Name: Fragmin
89337089|NCT03626012|Experimental|Cohort 1: BIIB078 First Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
89337090|NCT03626012|Experimental|Cohort 2: BIIB078 Second Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
89337091|NCT03626012|Experimental|Cohort 3: BIIB078 Third Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
89337092|NCT03626012|Experimental|Cohort 4: BIIB078 Fourth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
89337093|NCT03626012|Experimental|Cohort 5: BIIB078 Fifth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
89337094|NCT03626012|Experimental|Cohort 6: BIIB078 Sixth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
89337095|NCT03626012|Placebo Comparator|Cohorts 1-6: Placebo|Matching placebo will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days (Cohorts 1 through 3) and five maintenance doses on five later days (Cohorts 4 through 6).
89337096|NCT01367990|Experimental|Norepinephrine|
89337097|NCT03556358|Experimental|TX05 (trastuzumab)|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
89337098|NCT03556358|Active Comparator|Herceptin®|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
89337099|NCT01374308|Experimental|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
89337100|NCT01374308|Active Comparator|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
89337101|NCT01368068|Experimental|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial.
89337102|NCT01368068|Active Comparator|Escitalopram|10mg of escitalopram will be taken by participants daily for the duration of the 12 week trial period.
89337103|NCT01368068|Placebo Comparator|Placebo|Placebo arm containing sweetener has been approved and will be used as placebo arm.
89337104|NCT01368146|Experimental|IV Clear™|
89337105|NCT01368146|Active Comparator|Tegaderm CHG™|
89337106|NCT01368146|Placebo Comparator|Control Vehicle Dressing|
89337107|NCT03077204|Other|BIO4 treatment|Patients undergoing 1 or 2-level Anterior Cervical Discectomy and Fusion (ACDF) spine surgery utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
89337108|NCT03633890|Experimental|DaZhu Rhodiola Rosea Capsule|
89337109|NCT03633890|Placebo Comparator|DaZhu Rhodiola Rosea Simulation Capsule|
89337110|NCT01374386|No Intervention|Usual Physical Activity|Participants in this arm are do not have access to Exergames, only usual physical activity at the gym
89337111|NCT01374386|Experimental|Exergaming|Participants in this arm will have access to usual physical activity at the gym as well as access to Exergaming equipment (video games that require physical activity)
89337112|NCT01319708|Experimental|mild ovarian stimulation|100 mg CC by day 2 till 6, plus antagonist plus gonadotrophin 150-200IO until HCG triggering
89337113|NCT01319708|Active Comparator|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses using a GnRH agonist long protocol
89337114|NCT01373684|Experimental|Peginterferon alfa-2a add on|All patients are all currently being treated with long-term NA treatment. PEG-IFN will be given in a dose of 180 μg per week s.c. for a total duration of 48 weeks starting at week 0.
89337115|NCT01373684|Active Comparator|Nucleoside analogue|All patients are all currently being treated with long-term Nucleos(t)ide analogue treatment and will continue using this medication during the duration of the study.
89337116|NCT04485260|Experimental|Part A, Arm 1, Cohort 1|KRT-232 by mouth once daily for Days 1-7, off treatment for Days 8-28 (28 day cycle)
89337117|NCT02891798|Experimental|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)
89337118|NCT02891798|Active Comparator|Bupivacaine Only (control arm)|Patients will receive a nerve block consisting of bupivacaine only.
89337119|NCT01368224|Placebo Comparator|Maltodextrin|
89337120|NCT01368224|Experimental|Lactobacillus paracasei NCC 2461 (ST 11)|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11)
89337121|NCT01368224|Experimental|Lactobacillus paracasei+ Bifidobacterium longum|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11) + 1x1010 CFU of Bifidobacterium longum (NCC3001)
89337122|NCT01374464|Active Comparator|High Volume, High Concentration|
89337123|NCT01374464|Active Comparator|High Volume, Low Concentration|
89337124|NCT01374464|Active Comparator|Low Volume, High Concentration|
89337125|NCT01374464|Active Comparator|Low Volume, Low Concentration|
89337126|NCT01374542||Respiratory endoscopy patients|Patients undergoing respiratory endoscopy at Singapore General Hospital
89337127|NCT02562872|Experimental|Cohort 1 Active DSM265|
89337128|NCT02562872|Placebo Comparator|Cohort 1 Placebo|
89337129|NCT02562872|Experimental|Cohort 2a Active DSM265|
89337130|NCT02562872|Placebo Comparator|Cohort 2a Placebo|
89337131|NCT02562872|Experimental|Cohort 2b Active DSM265|
89337132|NCT02562872|Placebo Comparator|Cohort 2b Placebo|
89337133|NCT01368302|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to normalize threat-related attention biases.
89337134|NCT01368302|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
89337135|NCT02507960|Other|Pilot Study|The patient will undergo a conventional CT simulation in supine position without the breast immobilization cup. The purpose of the CT simulation is-two-fold: 1) the investigators will see if the TB volume can be accurately delineated and if the TB volume is too large for Gamma Pod boost; and 2) the CT images are used for planning the patient's whole breast irradiation. If, after viewing the CT images and the patient is deemed a study candidate and consents, the participants will receive a second CT-sim and the Gamma Pod TB boost treatment on the same day as described below.
89337136|NCT01374620|Experimental|Paclitaxel Dose escalation|"A standard dose escalation strategy will be used including 3 to 6 patients at each dose level (Paclitaxel dose escalation + fixed dose of cyclophosphamide)~+ blood collection"
89337137|NCT01374620|Experimental|Cohort extension|"An additional 10 patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose~+ blood collection"
89337138|NCT01368380|Experimental|Psychological Intervention|
89337139|NCT01368380|No Intervention|Usual care|
89337140|NCT01374698|Active Comparator|Aspirin|All patients who meet the eligibility criteria will be randomized in a 1:1 manner to receive, before the coronary percutaneous procedure, an oral aspirin reload (325 mg)or placebo.
89337141|NCT01374698|No Intervention|No intervention|No intervention
89337142|NCT01373762|Experimental|Exercise Videogame Bike|Families in this group will receive an interactive exercise videogame bike (ie. the Active Cycle) to keep in their home for three months.
89337143|NCT01373762|Other|Stationary Bike|Families will receive a stationary bike to keep in their home for three months. It is required that the family places the stationary bike (Active Cycle without video game controllers) in front of a television.
89337144|NCT01368458|Experimental|Conversion to mono therapy|Conversion from 2 to 1 antipsychotic
89337145|NCT01368458|No Intervention|control|No change in antipsychotics
89337146|NCT01374776|Experimental|intravenous iron carboxymaltose|intravenous iron carboxymaltose infusion
89337147|NCT04947332|Other|Auto-inoculation recipients|Auto-inoculation of wart to be performed
89337148|NCT03118934|Experimental|AOA MF|Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 10 ± 3 days
89337149|NCT03118934|Experimental|DACP MF|Nelfilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
89337150|NCT03118934|Experimental|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
89337151|NCT01374854|Experimental|Stem Cell Infusion|
89337152|NCT01374854|Active Comparator|traditional therapy control|
89337153|NCT01368692|Active Comparator|neutral shoulder|neutral shoulder position during subclavian vein catheterization
89337154|NCT01368692|Experimental|shoulder retraction|position of shoulder retraction during subclavian vein catheterization
89337155|NCT01374932|Experimental|CPAP (see below)|Adult patients with asthma who require treatment with CPAP because of OSAS (RDI> = 20 events per hour). CPAP will be administered according to SEPAR guidelines and tailored to individual characteristics
89337156|NCT03114488|Experimental|Anodal Stimulation|
89337157|NCT03114488|Sham Comparator|Sham Stimulation|
89337158|NCT05197478|Other|COVID 19 positive patients|COVID 19 positive patients receiving inpatient treatment were evaluated.
89337159|NCT05197400|Active Comparator|supine|operation in the supine position
89337160|NCT05197400|Active Comparator|prone|operation in the prone position
89337161|NCT01368770|Experimental|Coronary CTA|Coronary CTA using standard protocols
89337162|NCT01368770|Active Comparator|Stress MPI SPECT|Stress-rest MPI SPECT using standard protocols
89337163|NCT01373840||healthy controls|
89337164|NCT01373840||patients with focal dystonias|
89337165|NCT05197088|Experimental|1 week of tamsulosin|1 week of tamsulosin tablet 400mcg once a night
89337166|NCT05197088|No Intervention|no additional medication|
89337167|NCT01375088|Placebo Comparator|placebo mouth wash|10 patients swish & swallow 15 ml placebo mouth wash for at least 5 min from the first session of radiotherapy until the last session
89337168|NCT01375088|Active Comparator|propolis|10 patients swish & swallow 15 ml propolis mouth wash for at least 5 min from the first session of radiotherapy until the last session
89337169|NCT05197010|Experimental|Home-based exercise program|The subjects will receive 6 weeks of the home exercise program via a smartphone application. The home exercise program sets the exercise intensity to 3 levels (low, medium, and high) according to the disease and consists of 2 stretches, 3 strengthening and/or functional exercises, and a cool-down exercise. The exercise group applies a daily home exercise program (30min/day, 7days/week for 6 weeks).
89337170|NCT05197010|No Intervention|Exercise brochure|This group will be offered a brochure including number of exercises for back or knee.
89337171|NCT01375166||Diabetic retinopathy|Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
89337172|NCT01375166||healthy|healthy control subjects
89337173|NCT03631472|Experimental|RheOx Treatment|RheOx Treatment (i.e., Bronchial Rheoplasty)
89337174|NCT03604874|Active Comparator|low dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 2 mU/min, incrementally increase by 2 mU/min every 30 minutes until achievement of adequate uterine contractions.
89337175|NCT03604874|Experimental|high dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 4 mU/min, incrementally increase by 4 mU/min every 30 minutes until achievement of adequate uterine contractions
89337176|NCT01368926|Experimental|Part 1|
89337177|NCT01368926|Experimental|Part 2|
89337178|NCT05196542|Experimental|mersilene tape arm (ETHICON, polyester 5mm double needle)|Group 1: patients with apical prolapse who will do Sacro hysteropexy using mersilene tape (polyester 5mm tape with double needle)
89337179|NCT05196542|Other|polyproline mesh arm (ETHICON, polyprolene mesh)|Group 2: patients with apical prolapse who will do Sacro hysteropexy using poly-proline mesh
89337180|NCT05196386|Experimental|Patient with targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
89337181|NCT05196386|Other|Patient without targeted pharmaceutical interview|No Specific information about treatment delivered by pharmacist
89337182|NCT01369004|Experimental|Daily self-weighing + feedback/lessons|Participants will be instructed to weigh daily and they will receive a smart scale for daily monitoring of weighing via the website bodytrace.com. They will also receive weekly emailed lessons with content related to behavioral weight control (e.g., How to control portion sizes, How to develop an exercise routine) as well as weekly emailed feedback from a registered dietitian on their daily weighing and weight loss progress.
89337183|NCT01369004|No Intervention|Delayed Intervention Control Group|Participants will receive the same components of the experimental group with the exception of the weekly feedback after the 6-month study period is complete.
89337184|NCT01319786|Other|Low- polyphenol diet|
89337185|NCT01319786|Active Comparator|High-polyphenol diet|
89337186|NCT01369082||CIT Islet Transplantation Recipients|"Subjects who received an islet-cell transplant for Type 1 Diabetes (T1D) while enrolled in one of the Clinical Islet Transplantation (CIT) parent studies and continue to have islet graft function. All subjects will continue immunosuppressive medications under CIT08. Detailed follow-up evaluations including but not limited to islet function will occur on an annual basis.~The immunosuppressive medications (e.g., tacrolimus, sirolimus, cyclosporine, mycophenolate mofetil [MMF], mycophenolic sodium) in this study are obtained by prescription unless provided by the study through the drug distributor. Generic brands are allowed, when available. Antibacterial, antifungal, and antiviral prophylaxis, insulin therapy, and other standard therapies will be provided per site-specific practices."
89337187|NCT03382730|Other|Oral Chlorhexidine Mouth Rinse|Application of chlorhexidine gluconate mouth rinse per unit protocol.
89337188|NCT03382730|Experimental|De-Adoption of Oral Chlorhexidine Mouth Rinse|No application of chlorhexidine gluconate mouth rinse. Oral care bundle.
89337189|NCT03135262|Experimental|Dose-Escalation Cohort: FL|Induction Treatment: Participants will receive either Regimen A or Regimen B. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax (both at maximum tolerated dose [MTD] established from Regimen A) in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
89337190|NCT03135262|Experimental|Dose-Escalation Cohort: DLBCL|Induction Treatment: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. In bridging cohort, participants will receive rituximab on Day 1 of Cycles 1 to 6 and idasanutlin and venetoclax (both at MTD) in Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive obinutuzumab or rituximab (according to study treatment received in the induction) every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
89337191|NCT03135262|Experimental|Expansion Cohort: FL|Induction Treatment: Participants will receive idasanutlin and venetoclax at the RP2D of the selected regimen (Regimen A or B) identified during the dose-escalation phase in combination with obinutuzumab. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
89337192|NCT03135262|Experimental|Expansion Cohort: DLBCL|Induction Treatment: Participants will receive rituximab on Day 1 of Cycles 1 to 6; idasanutlin and venetoclax (both at RP2D) on Days 1 to 5 of Cycles 1 to 6 or rituximab on Day 1 of Cycles 1 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive rituximab every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
89337193|NCT01375244|Experimental|A|Subjects received the Par formulated product.
89337194|NCT01375244|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
89337195|NCT01369160||1|Chronic Transfusion
89337196|NCT01369160||2|hydroxyurea
89337197|NCT01369160||3|matched sibling donor stem cell transplantation (MSD-SCT)
89337198|NCT01369160||4|standard comprehensive care (SCC, control)
89337199|NCT01375322|Active Comparator|Co-Diovan® Group|The starting dose of Co-Diovan® was 1 capsule (contains 1/2 tablet) (valsartan/ hydrochlorothiazide 40 mg/ 6.25 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (valsartan/ hydrochlorothiazide 160 mg/ 25.0 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
89337200|NCT01375322|Experimental|Amtrel® Group|The starting dose of Amtrel® was 1 capsule (contains 1/2 tablet) (amlodipine / benazepril hydrochloride 2.5 mg/ 5 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (amlodipine / benazepril hydrochloride 10 mg/ 20 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
89337201|NCT01369238|Experimental|Bee Venom Acupuncture & zaltoprofen|
89337202|NCT01369238|Active Comparator|zaltoprofen|
89337203|NCT01369238|Active Comparator|Bee Venom Acupuncture|
89337204|NCT03485404|Experimental|VB12+FA|Patients will receive oral supplementation of 0.5mg methylcobalamin, 3/day and 5 mg folic acid, 1/day for 7 days before non-cardiac surgery.
89337205|NCT03485404|Placebo Comparator|Placebo|Patients with receive oral tablets of placebo for folic acid 1/d and placebo for methylcobalamin 3/d, which look exactly like the interventional drugs as oral supplementation for 7 days before non-cardiac surgery.
89337206|NCT03485404|Other|Non-surgical controls|Age and sex-matched community elderly people are included for two sessions of NPB test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCd incidence to rule out learning effect.
89337207|NCT05195294|Experimental|LioCyx-M monotherapy|Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M).
89337208|NCT05195294|Experimental|LioCyx-M + lenvatinib combinational therapy|Patients will receive up to 8 biweekly infusions of HBV antigen specific TCR redirected T cells (LioCyx-M) with daily intake of lenvatinib.
89337209|NCT05195216||individuals with cystic fibrosis|
89337210|NCT05195216||healthy individuals|
89337211|NCT03535194|Experimental|250mg Q4W/250mg Q8W Mirikizumab|Participants received 250 Milligrams (mg) Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
89337212|NCT03535194|Experimental|250mg Q4W/125mg Q8W Mirikizumab|Participants received 250mg Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 125mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
89337213|NCT03535194|Experimental|Placebo/250mg Mirikizumab|Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab.
89337214|NCT03535194|Active Comparator|300mg Secukinumab|Participants received 300mg Secukinumab at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during induction period followed by 300mg Secukinumab Q4W from week 16 to 52 in maintenance period.
89337215|NCT03535194|Experimental|Japan GPP/EP|Participants received 250mg Mirikizumab Q4W in induction period followed by 250mg Q8W in maintenance period by subcutaneous injection.
89337216|NCT03633812||Beta blocker group|ESLD recipients who had beta blocker during more than 1 month before the liver transplantation
89337217|NCT03633812||Non-Beta blocker group|ESLD recipients who had not taken beta blocker more than 3 month before the liver transplantation
89337218|NCT05194904|Active Comparator|group 1|ketorolac group: number = 30 patients , time : after intubation, dose 0.9 mg/kg
89337219|NCT05194904|Active Comparator|group 2|Dexmedetomidine group: number : 30 patients, time : after intubation, dose 1 μg/kg
89337220|NCT05194826|Experimental|Fascia lata membrane|
89337221|NCT05194826|Active Comparator|Connective tissue graft both with xenogenic lamina membrane|
89337222|NCT05194670|Experimental|Acunex Vario AN6V|Patient will receive the enhanced depth of focus IOL during cataract surgery
89337223|NCT05194670|Experimental|Acunex AN6|Patient will receive the monofocal IOL during cataract surgery
89337224|NCT01319864|Experimental|Plerixafor, Dose Escalation|Dose escalation of plerixafor administered intravenously in combination with IV cytarabine and IV etoposide in pediatric patients wtih relapsed/refractory AML/ALL.
89337225|NCT04853654|Experimental|Selective training|selective training on lower extremity for 3 days/week
89337226|NCT04853654|Experimental|Downhill walking|downhill walking training on the treadmill for 2 days/week
89337227|NCT04853654|Experimental|Uphill walking|uphill walking training on the treadmill for 2 days/week
89337228|NCT05194280||Robotic-assisted group|Group of patients that underwent a robotic-assisted donornephrectomy
89337229|NCT05194280||Hand-assisted laparoscopic group|Group of patients that underwent a hand-assisted laparoscopic donornephrectomy.
89337230|NCT05194046|Experimental|Sequence A|"T1→Washout period(D6~14)→ T3→Washout period(D20~28)→ T2~T1: JP-1366 1capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
89337231|NCT05194046|Experimental|Sequence B|"T1 →Washout period(D6~14)→ T2→Washout period(D20~28) → T3~T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
89337232|NCT05194046|Experimental|Sequence C|"T2 →Washout period(D6~14)→ T3→Washout period(D20~28) → T1~T1: JP-1366 1capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
89337233|NCT05194046|Experimental|Sequence D|"T2 →Washout period(D6~14)→ T1→Washout period(D20~28) → T3~T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
89337234|NCT05194046|Experimental|Sequence E|"T3 →Washout period(D6~14)→ T1→Washout period(D20~28) → T2~T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
89337235|NCT05194046|Experimental|Sequence F|"T3 →Washout period(D6~14)→ T2→Washout period(D20~28) → T1~T1: JP-1366 1 capsule, 2 times per 1 day, repetition administration for 5 days~T2: amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days~T3: JP-1366 1 capsule + amoxicillin 500mg 2 capsules + clarithromycin 500mg 1 tablet, 2 times per 1 day, repetition administration for 5 days"
89337236|NCT01369394|Experimental|Tailored information|Individuals assigned to the experimental group will receive individually-tailored educational messages.
89337237|NCT01369394|Active Comparator|Untailored information|Individuals assigned to the control group will receive generic, untailored educational messages.
89337238|NCT05193890||Epilepsy only|Epilepsy only patients who underwent our gene panel and the Clinical exome Solution
89337239|NCT05193890||Intelectual Disability only|Intelectual Disability only patients who underwent our gene panel and the Clinical exome Solution
89337240|NCT05193890||Epilepsy and Intelectual Disability|Intelectual Disability and Epilepsy patients who underwent our gene panel and the Clinical exome Solution
89337241|NCT01369472|Experimental|Dilatrend SR capsule 8mg|
89337242|NCT01369472|Experimental|Dilatrend SR capsule 16mg|
89337243|NCT01369472|Experimental|Dilatrend SR capsule 32mg|
89337244|NCT01369472|Experimental|Dilatrend SR capsule 64mg|
89337245|NCT01369472|Experimental|Dilatrend SR capsule 128mg|
89337246|NCT01375478||Cohort|
89337247|NCT01373996||Wireless|Measuring of invasive arterial blood pressure through HMW10 Wireless System.
89337248|NCT01373996||Wired|Measuring of invasive arterial blood pressure through conventional wired technology.
89337249|NCT01369550|Placebo Comparator|High-oleic sunflower oil-containing foods|Subjects will consume 3 servings of foods containing high-oleic sunflower oil plus 3x500 mg high-oleic sunflower oils softgels per day.
89337250|NCT01369550|Active Comparator|Eicosapentaenoic acid|Subjects will consume 3 x 500 mg eicosapentaenoic acid ethyl ester in softgels plus 3 servings of high-oleic sunflower oil-containing foods per day
89337251|NCT01369550|Experimental|SDA soybean oil-containing foods|Subjects in this arm will consume 3 servings of SDA soybean oil-containing foods plus 3 x 500 mg high-oleic sunflower oil softgels per day.
89337252|NCT03559530||Patients|Patients with microbiologically proven A. baumannii-related osteomyelitis
89337253|NCT05193734|Experimental|Group Pertagen|
89337254|NCT05193734|Active Comparator|Group Control|
89337255|NCT02740972|Experimental|NS-065/NCNP-01 40mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks
89337256|NCT02740972|Experimental|NS-065/NCNP-01 80mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks
89337257|NCT02740972|Placebo Comparator|Placebo|Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment
89337258|NCT05193578|Active Comparator|Semaglutide|"Active Comparator: Semaglutide injection once-weekly~The participants start with Semaglutide given as 0.25 mg subcutaneously per week for 4 weeks. Then, the dose is uptitrated to 0.5 mg subcutaneously per week for 4 weeks, whereafter the highest dose is reached: 1 mg subcutaneously per week until the end of the study (week 30).~Subjects, who experience side effects that hinder a stepwise increase in study drug, will remain at the highest possible tolerated dose for the rest of the study."
89337259|NCT05193578|Placebo Comparator|Placebo|"Semaglutide-Placebo injections once weekly.~The Semaglutide-Placebo pens are produced by Novo Nordisk A/S and resemble the pens containing active drug.~Semaglutide-Placebo pens contain vehicle, i.e. no active drug. Semaglutide-Placebo is administered similarly to semaglutide. That is using the same uptitration regime and volume as the active comparator, Semaglutide.~Subjects, who experience side effects that hinder a stepwise increase in Semaglutide-Placebo, will remain at the highest possible tolerated dose for the rest of the study."
89337260|NCT04834076||Cancer patients|50 cancer patients referred to the Oncology Department, Faculty of medicine, Sohag University.
89337261|NCT04834076||Healthy controls|50 healthy controls will be recruited in the study.
89337262|NCT03486574||Gastric cancer|Pathologically proven diseases after upper gastroendoscopy and biopsy. Previous pathological reports and endoscopic image can be used.
89337263|NCT03486574||non-gastric cnacer|Rull out gastric cancer by upper gastroendoscopy. The results 3 moths before enrollment is available.
89337264|NCT03486496|Experimental|Gefitinib and Berberine|Experimental: Gefitinib and Berberine Patients will be treated with Gefitinib and Berberine. Gefitinib: 250 mg p.o., daily. Berberine: 50 mg p.o., tid.
89337265|NCT03124784|Experimental|RD Disposable Sensors|All subjects are enrolled into the test group and all subjects received the RD Disposable Sensors
89337266|NCT02410330||Group I|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with Therapeutic ultrasound with 20 usec: custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 MI designed for the 1.7 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
89337267|NCT02410330||Group II|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low MI perfusion imaging detected microbubbles within the microvasculature. Treatment will be applied while patient waits for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
89337268|NCT02410330||Group III|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) while few limited diagnostic high MI impulses (n<5 per patient) will be applied to assess myocardial perfusion before and after percutaneous coronary intervention (PCI).
89337269|NCT05186480|Active Comparator|test group|they receive the immune enhancing formula
89337270|NCT05186480|No Intervention|control group|they receive the conventional formula
89337271|NCT02091934|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
89337272|NCT02091934|Active Comparator|Wavefront-optimized PRK|Wavefront-optimized PRK
89337273|NCT01375634|Placebo Comparator|Placebo|Normal saline
89337274|NCT01375634|Experimental|Midazolam|Midazolam
89337275|NCT01987648||All study participants|Included are all patients who 18 years or older, who get an elective craniotomy (no biopsy, no awake surgery, no re-operation) and who are treated at the Department of Neurosurgery
89337276|NCT01369628|Experimental|Arm 1|"1 arm with the 3 following dose regimens:~Regimen 1: Atacicept 25 mg weekly for 12 weeks~Regimen 2: Atacicept 75 mg weekly for 12 weeks~Regimen 3: Atacicept 150 mg weekly for 12 weeks"
89337277|NCT05388448|Experimental|Sanfetrinem cilexetil 1.6 gram 12 hourly|Sanfetrinem cilexetil 1.6g will be given orally 12 hourly for 14 consecutive days.
89337278|NCT05388448|Experimental|Rifampicin 35 mg/kg once daily|Rifampicin 35 mg/kg will be given orally once daily for 14 consecutive days.
89337279|NCT05388448|Experimental|Sanfetrinem cilexetil 3.2 gram once daily|Sanfetrinem cilexetil 3.2 g will be given orally daily for 14 consecutive days.
89337280|NCT05388448|Experimental|Sanfetrinem cilexetil 800 mg 12 hourly|Sanfetrinem cilexetil 800 mg will be given orally 12 hourly for 14 consecutive days.
89337281|NCT05388448|Experimental|Sanfetrinem cilexetil 800 mg 8 hourly|Sanfetrinem cilexetil 800 mg will be given orally 8 hourly for 14 consecutive days.
89337282|NCT05388448|Experimental|Sanfetrinem cilexetil 1.6 gram plus amoxicillin/clavulanic acid 250 mg/125 mg 12 hourly|Sanfetrinem cilexetil 1.6 g plus amoxicillin/clavulanic acid 250 mg/125 mg will be given orally 12 hourly for 14 consecutive days.
89337283|NCT05388448|Experimental|Sanfetrinem cilexetil 1.6 gram 12 hourly plus rifampicin 35 mg/kg once daily|Sanfetrinem cilexetil 1.6 g will be given orally 12 hourly plus rifampicin 35 mg/kg orally once daily for 14 consecutive days.
89337284|NCT01375712|Active Comparator|Fermented milk|Fermented milk containing Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
89337285|NCT01375712|Placebo Comparator|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
89337286|NCT01369862|Placebo Comparator|SPGNH buffer|SPGNH buffer administration by liquid nasal spray
89337287|NCT01369862|Experimental|GHB16L2|Dose level ~7.0 log10 fTCID50/strain/person
89337288|NCT05152498|Experimental|Fu Zheng Jie Du Hua Yu therapy|
89337289|NCT05152498|Experimental|Routine medical care|
89337290|NCT05185466|Experimental|Experimental Group|Experimental Group
89337291|NCT05185466|No Intervention|Control Group|Control Group
89337292|NCT05150470|Other|open label|Single Group Assignment
89337293|NCT01375790|Experimental|Exercise with Whole-body vibration platform|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm). Training volume and intensity we will increase systematically over six weeks according to the overload principle.
89337294|NCT01375790|Active Comparator|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli, during a six weeks training period (3sessions/week). Training volume and intensity we will increase systematically over six weeks according to the overload principle
89337295|NCT05150392|Experimental|Booster immunization 1 year after primary immunization|Subjects C0001-C0400 except C0243 received 1 dose of booster immunization 1 year after primary immunization.
89337296|NCT05150392|Experimental|Booster immunization 2 year after primary immunization|Subjects C0401-C0800 except C0556 received 1 dose of booster immunization 2 years after primary immunization.
89337297|NCT05150392|Experimental|Booster immunization 3 year after primary immunization|Subjects C0801-C1197 received 1 dose of booster immunization 3 years after primary immunization.
89337298|NCT01375868|Experimental|Vaccine Silgard|vaccination with tetravalent antiviral vaccine, 3 doses
89337299|NCT00708994|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
89337300|NCT00708994|Placebo Comparator|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
89337301|NCT03485248|Active Comparator|Beetroot juice|Beetroot Juice cotaining on average 9mmol of nitrate per dose
89337302|NCT03485248|Placebo Comparator|Placebo beet juice (Nitrate depleted)|Beetroot juice nitrate depleted
89337303|NCT05105750|Active Comparator|aspirin 100 mg/d therapy|
89337304|NCT05105750|Experimental|indobufen 200 mg bid therapy|
89337305|NCT03485170|Other|PET|Hemophilia patients receive PET evaluation
89337306|NCT05760014||CAS patients|"CAS patients with a conventional follow-up who will benefit from the hypnosis technique known as Place of Safety on their admission to conventional hospitalization."
89337307|NCT05760014||TEMOINS patients|TEMOINS patients with conventional follow-up who will not benefit from the medical hypnosis technique.
89337308|NCT05152264|Active Comparator|TENS (transcutaneous electrical nerve stimulation)|Patients with endometriosis-related chronic frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) randomized to transcutaneous electrical nerve stimulation as add-on treatment in addition to conventional analgesic treatment. Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
89337309|NCT05152264|Active Comparator|Conventional analgesic treatment|Patients with endometriosis related chronic frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) randomized to conventional analgesic treatment for 8 weeks. After 8 weeks the patients are treated with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
89337310|NCT05152264|Active Comparator|External control group|Patients with endometriosis-related pain that is not frequent or without high pain intensity (< 4 according to Numeric Rating Scale, NRS) constitute an external control group. The patients are treated with transcutaneous electrical nerve stimulation as add-on treatment in addition to conventional analgesic treatment. Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
89337311|NCT05152186|Active Comparator|tranexamic acid|Topical hemostatics as tranexamic acid or hydrogen peroxide in wound before skin closure to decrease perioperative blood loss
89337312|NCT05152186|Active Comparator|Hydrogen peroxide|Topical hemostatics as hydrogen peroxide in wound before skin closure to decrease perioperative blood loss
89337313|NCT05152186|Placebo Comparator|Normal saline|Hemostasis in spine surgery
89337314|NCT05759858||Patients with hepatocellular carcinoma confirmed by pathology.|Patients with hepatocellular carcinoma confirmed by pathology.
89337315|NCT03485092|Active Comparator|Empagliflozin|Empagliflozin 10mg tablets for oral self-administration once daily
89337316|NCT03485092|Placebo Comparator|Placebo Oral Tablet|placebo tablets for oral self-administration once daily
89337317|NCT03481582|Active Comparator|Group without nitroglycerin|They will be subjected to TV ultrasound for folliculometry till maturation of the follicle ≥18mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
89337318|NCT03481582|Experimental|Group with nitroglycerin|They will receive (nitrodermal®) 5 mg (patch) from 2nd day of cycle till maturation of the follicles ≥ 18 mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
89337319|NCT01376102||BONVIVA(ibandronate)|Patients administrated ibandronate injection with postmenopausal osteoporosis
89337320|NCT03109522|Experimental|axillary reverse mapping|Axillary reverse mapping and sentinel lymph node biopsy (ARM/SLNB) or Axillary reverse mapping and axillary lymph node dissection (ARM/ALND)
89337321|NCT03109522|Active Comparator|standard axillary surgery|The control group will have standard sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
89337325|NCT05152030||hyposmic patients|
89337326|NCT05152030||anosmic patients|
89337327|NCT05152030||normosmic group|
89337328|NCT01376180||Subjects prescribed lamotrigine tablet|Subjects with epilepsy prescribed lamotrigine tablet during study period
89337329|NCT05048576|Experimental|Positive auditory cues|Participants will listen to the following auditory cues ~30 seconds apart Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job.
89337330|NCT05048576|Experimental|Negative auditory cues|Participants will listen to the following auditory cues ~30 seconds apart You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet.
89337331|NCT05048576|Experimental|Music|Participants will be allowed to select a streaming music station of their choice.
89337332|NCT05048576|Active Comparator|Silence|Participants will walk in silence while wearing noise cancelling headphones.
89337333|NCT03484858|Other|High glycaemic index meal and exercise|
89337334|NCT03484858|Other|High glycaemic index meal and rest|
89337335|NCT03484858|Other|Low glycaemic index meal and exercise|
89337336|NCT03484858|Other|Low glycaemic index meal and rest|
89337337|NCT03633734|Experimental|Sequential treatment|"One cycle of sequential treatment lasts for 56 days.~Stage 1(28 days): AG regimen. Nab-paclitaxel (Abraxane) 125mg/m^2 + gemcitabine 1000mg/m^2 (days 1, 8, 15, 28)~Stage 2(28 days)：mFolfirinox regimen. Fluorouracil 2400 mg/m^2 continuous intravenous drip 46h + calcium folinate 400 mg/m^2 + irinotecan 135 mg/m^2 + oxaliplatin 68 mg/m^2 (day 1, 15, a total of 28 days).~Repeat the cycle above until progression or intolerance of toxicity."
89337338|NCT03481504|Experimental|ACT-ETP|Cognitive behavioral treatment
89337339|NCT03481504|No Intervention|Usual care|no intervention
89337340|NCT03633656|Experimental|Treatment|Model predictive control recommendation of iron dosing in combination with an erythropoietic stimulating agent.
89337341|NCT03481426|Experimental|Workplace intervention group|Workers with back problems receive both information/advice and participatory workplace intervention organized by Occupational Health Physioterapist.
89337342|NCT03481426|No Intervention|Information and advice group|Workers with back problems receive only information / advice by Occupational Health Physiotherapist, not the workplace intervention.
89337343|NCT01369940||NICHD Fetal Growth Study - Twin Gestations|"Women with dichorionic twin gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2012-2013) in this prospective cohort study.~Intervention: No intervention"
89337344|NCT03484780|Experimental|VisONE ADS|Patients implanted with a VisONE stimulator and leads for receiving continual Synchronized Diaphragmatic Stimulation
89337345|NCT03481348|Experimental|Pharyngeal Electrical Stimulation|PES for 10 minutes per day on 3 consecutive days in addition to standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
89337346|NCT03481348|No Intervention|Control|Standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
89337347|NCT01376258||Patients adherent to 5-alpha reductase inhibitor (5ARI)|Patients with benign prostate hyperplasia (BPH) who are adherent (as measured by a medication possession ratio (MPR)) based on 3 MPR threshold values of 70%, 75% and 80%
89337348|NCT01376258||Patients who are non-adherent to 5ARI therapy|Patients with BPH who are not adherent to 5ARI therapy as measured by 3 MPR threshold values of 70%, 75%, and 80%
89337349|NCT05151952||Cancer patients receiving proton radiation therapy|Cancer patients receiving proton radiation therapy, Registry of cancer patients who receive proton radiation therapy to crack disease and toxicity outcomes.
89337350|NCT04923464||ELX/TEZ/IVA|CF participants who are currently on a stable regimen of commercially available ELX/TEZ/IVA will be evaluated for the performance of wearable technology devices. Wearable devices include a wrist-worn actigraphy sensor and an ambulatory cough monitoring system.
89337351|NCT05151874||Range of movement|Change in passive joint mobility (ROM) of the carpus (flexion-extension) affected by spasticity pattern III during a 20-week follow-up.
89337352|NCT03531840|Experimental|Arm 1/Olaparib|Twice daily oral olaparib
89337353|NCT04915274|Experimental|Adult cancer patients|Patients will be provided with the QuestOnco application for monitoring
89337354|NCT05151796||Aspirin continued within 5 days before surgery|
88811779|NCT01420289|Experimental|HPIPC|High Pressure Intermittent Pneumatic compression (HPIPC)to be performed for 45 minutes twice daily
89337355|NCT05151796||Aspirin discontinued more than 5 days before surgery|
89337356|NCT03481192|Experimental|A group using amnesic substances|"A group of patients admitted for IMV exclusively using amnesic substances. Benzodiazepines, benzodiazepines, tricyclic antidepressants, neuroleptics, antihistamines, other atropine substances, anti-epileptics and opiates.~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
89337357|NCT03481192|Active Comparator|A control group|"A control group that ingested exclusively non-amnesic substances among them most frequently ingested in this context, ie the following classes: level 1 analgesics, antibiotics, serotonergic and noradrenergic antidepressants, oral antidiabetic, thyroid hormones, anti oral coagulant.~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
89337358|NCT04460092|Experimental|"Group A"|"In the first three days, participants in group A will inject 90-degree insulin injections using 5-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 8 mm to inject insulin."
89337359|NCT04460092|Experimental|"GroupB"|"In the first three days, participants in group B will inject 90-degree insulin injections using 8-mm 32-gauge needles. Then, with an interval of one day, in the second three days, they will use 32-gauge needles with a length of 5mm to inject insulin."
89337360|NCT03484624|Experimental|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
89337361|NCT01376336|Experimental|Safe storage device|This arm will be assigned a safe water storage device.
89337362|NCT01376336|No Intervention|Control|This arm of the trial will receive nothing until the end of the trial.
89337363|NCT04604158|Experimental|Elly Mobile Phone Application|
89337364|NCT03633578|Experimental|Interventional group|Patients are asked to walk ont a treadmill in four conditions: with and without distraction (virtual environment) and at different speed (comfortable vs high).
89337365|NCT03110900|Active Comparator|haloperidol + lorazepam|IM haloperidol 5mg + IM lorazepam 2mg + placebo inhaler
89337366|NCT03110900|Experimental|loxapine|Inhaled loxapine 10mg + IM normal saline
89337367|NCT03486262||Lung carcinoma on IPF|Lung carcinoma on IPF
89337368|NCT04459858||rotator cuff lesion|patients treated for traumatic or degenerative rotator cuff lesion
89337369|NCT03896828|Experimental|Sedentary|Sedentary (SED): Participants will remain seated in the lab all-day (7.5 hr).
89337370|NCT03896828|Experimental|Walking Breaks|Walking breaks (WALK): Participants will perform 2-minute walking breaks at 3.1 mph on a treadmill every 30 minutes (7.5 hr).
89337371|NCT03896828|Experimental|Resistance-exercise breaks|"Resistance exercise breaks (RE): Participants will perform 15 squats (1-minute) every 30 minutes. To reduce the risk of injury, standardize squat-depth, and recruit similar muscle groups as walking, the squats performed will be a chair-stand with calf-raise (7.5 hr)."
89337372|NCT05759702||normal weight|normal weight students will be enrolled in this group their BMI range from 5th percentile to less than the 85th percentile on CDC growth chart
89337373|NCT05759702||overweight|overweight students will be enrolled in this group their BMI range from 85th to less than the 95th percentile on CDC growth chart
89337374|NCT05759702||obese|obese students will be enrolled in this group their BMI range from Equal to or greater than the 95th percentile on CDC growth chart
89337375|NCT03894956||Participants with Hidradenitis Suppurativa (HS)|Participants who along with their treating physician have elected for treatment with Humira as per routine clinical practice for the treatment of HS
89337376|NCT03109756|Experimental|Single-dose 5 mg OV101|
89337377|NCT03867734|Experimental|2g Aztreonam|Subjects to receive 2g Aztreonam IM for the treatment of gonorrhea
89337378|NCT03131674|Experimental|Direct treatment|
89337379|NCT03131674|Experimental|Delayed treatment|
89337380|NCT04965844|Experimental|Oxygen close-loop|Four hours period where the fraction of inspired oxygen delivered will be automatically titrated based on SpO2 values.
89337381|NCT04965844|Active Comparator|Manual FiO2 adjustment|Four hours period where the fraction of inspired oxygen delivered will be manually adjusted by the healthcare personnel based on SpO2 values.
89337382|NCT05759624||Hormone replacement therapy with rhGH|
89337383|NCT03484468||femtosecond_laser|participants had there lasik corneal flap creation using femtosecond laser
89337384|NCT03484468||moria_microkeratome|participants had there lasik corneal flap creation using moria microkeratome
89337385|NCT03484390|Experimental|Mindfulness-based stress reduction|The MBSR program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
89337386|NCT03484390|Active Comparator|Wellness Group|The Wellness control group uses a health education manual that provides information on various aspects of health, including diet, physical activity, sleep, stress management, and communication. The manual is used during weekly check-in phone calls for an 8-week period.
89337387|NCT05151016|Experimental|mifepristone|mifepristone tablets，10mg，One tablet daily, oral treatment
89337388|NCT05151016|Active Comparator|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
89337389|NCT01376414||Non specific upper abdominal pain|Cohort is patients who present to the Emergency Department with primary complaint of upper abdominal pain without obvious cause.
89337390|NCT05150860|Active Comparator|At-home testing + household|At-home COVID-19 testing model with active encouragement of household member participation in regular COVID-19 testing part way through the trial
89337391|NCT05150860|Active Comparator|On-site testing + household|On-site COVID-19 testing model with active encouragement of household member participation in regular COVID-19 testing part way through the trial
89337392|NCT05150860|Active Comparator|On-site testing|On-site COVID-19 testing model, no active encouragement of household member participation in COVID-19 testing
89337393|NCT04459390||COVID19 with comorbidities|"Patients with COVID19 with at least one of the following comorbidities:~Hypertension~Diabetes~Cardiovascular disease~Chronic pulmonary disease~Obesity~Chronic liver disease~Chronic kidney disease~Collagen vascular disease~Autoimmune disease~Malignancy"
89337394|NCT04459390||COVID19 without comorbidities|Patients with COVID19 without any of the previously mentioned comorbidities
89337395|NCT01376492||001|Functioning assessment The functioning will be assessed with 2 scales (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
89337396|NCT01376492||002|Quality of sleep assessment The quality of sleep will be assessed with 2 scales (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
89337397|NCT01376570|Experimental|Contingency Management arm|The Contingency Management arm will receive the abstinence-reinforcing contingency management intervention.
89337398|NCT01376570|Active Comparator|Control arm|The Control arm will receive the performance feedback intervention.
89337399|NCT03484234|Experimental|Ultimaster stent|
89337400|NCT03484234|Active Comparator|Xience alpine stent|
89337401|NCT03484156|Experimental|Volunteers|"The Installation of 3PEGASE Sensor in elders volunteers to monitor clinical indicators at home.The instrument is for monitoring functional and cognitive autonomy in frail or disable elderly persons living alone at home.~The volunteers will have 70 years old or more, living alone at home, frail of disable (ADL> or =3) and able to walk by themselves."
89337402|NCT04871360|Experimental|Citrulline group|Group of adolescents supplemented orally with 6 g / day of pure L-citrulline in capsules. The dose will be met by taking four (3 g) capsules in the morning before the first meal and four capsules (3 g) in the evening after the last meal.
89337403|NCT04871360|Placebo Comparator|Placebo group|Group of adolescents supplemented with placebo (carboxymethyl cellulose). The indication for taking will be the same as in the experimental group, four capsules in the morning before the first meal and four capsules at night, after the last meal.
89337404|NCT05153200|Experimental|Upadacitinib(Rinvoq)|Upadacitinib(Rinvoq) 15 mg po daily
89337405|NCT05153200|Active Comparator|Adalimumab(Idacio)|
89337406|NCT01376726|Experimental|Previous HIV Vaccine Trial Participants (Group 1)|"Participants will receive the study vaccine administered as one 0.5 mL intramuscular injection (IM) in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
89337407|NCT01376726|Experimental|No Previous HIV Vaccine Trial (Group 2)|"Participants will receive the study vaccine administered as one 0.5 mL IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
89337408|NCT03477214||Normal|No UI, no OAB conditions. Transvaginal biomechanical and electromyography mapping will be completed.
89337409|NCT03477214||Urinary incontinence|Urinary incontinence conditions. Transvaginal biomechanical and electromyography mapping will be completed.
89337410|NCT03477214||Overactive bladder|Overactive bladder conditions
89337411|NCT03726476|Experimental|Patient Centered pre-op education|Patient centered pre-operative education and patient centered post-operative care.
89337412|NCT03726476|Active Comparator|Routine Pre-op education|Participants will receive routine pre-operative education and post-op will receive a standardized number of narcotics
89337413|NCT03481036|Active Comparator|Non cirrhotic|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg), LDV (90 mg) and DCV (60 mg) per day
89337414|NCT03481036|Active Comparator|Genotype 1,4,5 and 6 with cirrhosis|Sofosbuvir (SOF)+ Ledipasvir (LDV) for 12-weeks + weight based Ribavirin Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and LDV (90 mg) per day
89337415|NCT03481036|Active Comparator|Genotype 2 and 3 with Cirrhosis|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks+ weight based Ribavirin Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and DCV (60 mg) per day
89337416|NCT03477136||First group: semen parameter showing normospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
89337417|NCT03477136||second group: semen parameter asthenozoospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
89337418|NCT03477136||Third group: semen parameter oligozoospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
89337419|NCT03477136||Forth groupsemen parameter: astheno-teratozoospermic,|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
89337420|NCT03477136||Fifth group semen parameter: oligo asthenoteratozoospermia|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
89337421|NCT03483922||chronic hepatitis B|This group will include 50 with hepatitis B subjects and the diagnoses will be based on AASLD practice guideline.
89337422|NCT03483922||HCC Cases|"This group will include 350 in stage 0, stage A, stage B, Stage C+D of hepatocellular carcinoma.~HCC staging will be diagnosed according to EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma"
89337423|NCT03483922||Healthy|This group will include 50 healthy sex and age matched controls.
89337424|NCT03552068|Placebo Comparator|Patients under placebo|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
89337425|NCT03552068|Active Comparator|Patient under clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
89337426|NCT00702988||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) (60 μg, 120 μg and 180 μg)
88811780|NCT01420289|Active Comparator|Excercise|Walking on a graded treadmill for 45 minutes once daily
88811781|NCT01499147|Active Comparator|Arm 1|All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
89337427|NCT00702988||Experimental Group 2|150 IU recFSH
89337428|NCT05759312|Experimental|zimberelimab plus metformin|Patients will start metformin at 1,000mg by mouth once daily during a 7-day induction period prior to starting zimberelimab. The dose will be increased by 500mg every 7 days until reaching the target dose of 2000mg. Zimberelimab will be administered at a fixed dose of 240 mg IV every 14 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity, or withdrawal of consent.
89337429|NCT05152654|No Intervention|Fixation|Total extra peritoneal repair will be performed in this arm for the patients due to unilateral inguinal hernia. The 15x12 cm mesh will be marked with titanium clips from its 4 corners and placed in the hernia area. The mesh will be fixed to the hernia area by the non-absorbable tacker.This method is the method used routinely in the treatment of laparoscopic hernia today.
89337430|NCT05152654|Experimental|Non-Fixation|Total extra peritoneal repair will be performed in this arm for the patients due to unilateral inguinal hernia. The 15x12 cm mesh will be marked with titanium clips from its 4 corners and placed in the hernia area. The mesh will not be detected in any way.
89337431|NCT03446456|Placebo Comparator|Saline|"Under direction of a research team member, participants will self-administer intranasal normal saline shortly before beginning the fMRI experiment.~Investigators, staff, and participants were blinded to the treatment options. Each of the agents will be administrated by means of a nasal spray. Participants will be instructed by a nurse/PI to self-administer the nasal spray as follows: one spray in each nostril alternating sides, 30 seconds apart for a total of two sprays per nostril."
89337432|NCT03446456|Experimental|Arginine vasopressin|Under direction of a research team member, participants will self-administer intranasal vasopressin shortly before beginning the fMRI experiment. The of AVP will be 40IU. The quantity per unit (1 mL) of Arg8-vasopressin synthetic, manufactured by Polypeptide Group Inc. (http://www.polypeptide.com) was 0.323 mg. This amount was diluted in 0.9% sodium chloride (B. Broun Medical Inc.).
89337433|NCT03483688|Experimental|CD19-directed CAR-T cells|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
89337434|NCT03412292|Experimental|MAX-40279|"MAX-40279 is provided as a capsule for oral use at 5mg, 25mg. In the dose-escalation phase, patients will be enrolled sequentially into the 5 dose levels of MAX-40279 designated in this study: 20, 40, 70, 100 and 120 mg/day (3-6 patients per cohort),bid.For each dose level, a single dose of MAX-40279 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).~After completion of the dose escalation, additional patients will be enrolled into dose expansion at the Maximum tolerated dose(MTD), up to 12 patients will be enrolled into expansion cohorts."
89337435|NCT03476902|Experimental|Integrated Mobile Treatment|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
89337436|NCT03396692|Active Comparator|Control Arm|Pain management use intravenous morphine patient-controlled analgesia (PCA)
89337437|NCT03396692|Experimental|Posterior exo-thoracic fascia block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of the posterior exo-thoracic fascia with Ropivacaine
89337438|NCT03396692|Experimental|Paravertebral block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of paravertebral space with Ropivacaine
89337439|NCT04908904|Active Comparator|Cafestol|12 mg cafestol
89337440|NCT04908904|Placebo Comparator|Placebo|Placebo
89337441|NCT03476746|Experimental|LEO 90100 foam|"LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g).~Pilot part: 6 single applications of LEO 90100 foam on Day 1 (for 12 sites in total).~Pivotal part: To be decided based on the result of the pilot part"
89337442|NCT03476746|Active Comparator|Dovobet® ointment|"Pilot part: 6 single applications of Dovobet® ointment on Day 1 (for 12 sites in total).~Pivotal part: To be decided based on the result of the pilot part"
89337443|NCT03633266|Experimental|anti-VEGF|experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF
89337444|NCT03633266|Active Comparator|PRP|Control group: vitreoretinal surgery combined with intraoperative PRP
89337445|NCT03483610|Active Comparator|screening and referral|
89337446|NCT03483610|Active Comparator|behavioral intervention|
89337447|NCT03480958|Active Comparator|ESP group|Erector Spinae Plane Block administered group
89337448|NCT03480958|Active Comparator|TPVB group|Thoracic Paravertebral Block administered group
89337449|NCT03480958|Other|Control Group|No regional anesthesia technique will be applied to control group; but will be provided with iv PCA
89337450|NCT03476668|Active Comparator|RPD PD patients|Right-side affected PD patients. Intervention: MIRT
89337451|NCT03476668|Active Comparator|LPD PD patients|Left-side affected (LPD) PD patients. Intervention: MIRT
89337452|NCT05759234|Experimental|HS248 pieces|"dose escalation period： At this stage, it is planned that HS248 will adopt the traditional 3+3 method of increasing doses at four dose levels of 20 mg, 40 mg, 60 mg and 80 mg. All dosage components are divided into single administration stage and multiple administration stage. After 5 days of observation after single administration, it enters the stage of multiple administration. In the stage of multiple administration, HS248 is administered once a day (qd) for 28 days. a treatment cycle. 33 days after the first administration (the 5-day observation period in the single-administration phase and the first cycle in the multiple-administration phase) is the dose-limiting toxicity (DLT) observation period of this study"
89337453|NCT03480880|Experimental|Group BIS|Thiopentone dosing during induction of anaesthesia based on guidance of Bispectral Index values.
89337454|NCT03480880|No Intervention|Group Clinical|Thiopentone dosing during induction of anaesthesia based on clinical guidance targeted to loss of eyelash reflex or loss of response to noxious stimulus.
89337455|NCT03495102|Active Comparator|Dulaglutide 1.5 mg|Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
89337456|NCT03495102|Experimental|Dulaglutide 3 mg|Dulaglutide 3 mg administered SC once a week.
89337457|NCT03495102|Experimental|Dulaglutide 4.5 mg|Dulaglutide 4.5 mg administered SC once a week.
89337458|NCT03105362|Experimental|Amino Acid-ORS arm|Patients consumed an amino acid based oral rehydration solution (enterade®) as part of their oral rehydration care plan. Enterade® oral rehydration solution volumes varied from patient to patient depending on baseline clinical need.
89337459|NCT05120986||IND/GLY/MF with sensor|Patients prescribed with indacaterol acetate, glycopyrronium bromide and mometasone furoate with sensor
89337460|NCT05120986||IND/GLY/MF without sensor|Patients prescribed with indacaterol acetate, glycopyrronium bromide and mometasone furoate without sensor
89337461|NCT04762238|Experimental|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
89337462|NCT04762238|Sham Comparator|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
89337463|NCT03483532||Lit Control pH Up without cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract without cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
89337464|NCT03483532||Lit Control pH Up with dry cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract with cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
89337465|NCT05198180|Active Comparator|Potassium hydroxide group|Patients with plantar warts will apply topical 30% potassium hydroxide solutions on warts
89337466|NCT05198180|Active Comparator|Hydrogen peroxide group|Patients with plantar warts will use topical 45% hydrogen peroxide solution on warts
89337467|NCT03483454|Experimental|Exercise classes|This group of children and their parents will participate in an exercise class for 8 weeks.
89337468|NCT03483454|Experimental|Home exercise|"This group of children and their parents will participate in exercise at home for 8 weeks. This is currently the standard of care in the weight management clinic (advise to continue increasing activity at home). This group is considered the control group."
89337469|NCT03639402|Experimental|Health education classes|"Intervention consist of 2 rounds. Round 1: Locally selected mothers who have children 1-9 years old are trained by research team (peer mothers). Peer mothers conduct 4 education classes each for approximately 10 eligible mothers in their neighbourhood (fellow mothers).~Round 2: After one month gap one meeting for recapitulation and feedback is conducted by research team for peer mothers. Similarly, peer mothers conduct one meeting with fellow mothers."
89337470|NCT03639402|No Intervention|No health education classes|Community is exposed to health-related information, which is provided by the regular health system of Nepal
89337471|NCT03253172|Placebo Comparator|Placebo|Placebo
89337472|NCT03253172|Experimental|Potassium Chloride|Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride
89337473|NCT03253172|Experimental|Potassium Citrate|Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.
89337474|NCT03483376|Active Comparator|Dental prophylaxis|Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste.
89337475|NCT03483376|Experimental|Dental prophylaxis + aPDT|"Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning, followed by antimicrobial photodynamic therapy (aPDT) to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste. The aPDT protocol is as follows:~Patient will rinse the oral cavity with 20 ml of an aqueous solution of curcumin (photosensitizer; 1.5 g/L) for 30 seconds.~Blue light from a Bluephase 20i curing lamp will be applied perpendicularly for 1 min per tooth (30 seconds on the vestibular side and 30 seconds on the palatal side).~Remaining photosensitizer will be removed using the prophylaxis brush. The aPDT protocol is repeated following a rest period of 10 days."
89337476|NCT03726450|Experimental|Andrositol Plus|all the patients will be treated for three months with a dietary supplement containing Myo-inositol, NAC, Folic acid, selenium, vitamin E, L-Arginine and L-Carnitine
89337477|NCT03243656|No Intervention|historical group|Immunosuppressive therapy (cyclosporine alone ),
89337478|NCT03243656|Active Comparator|case arm|cyclosporine plus an oral dose of Eltrombopag
89337479|NCT03480646|Experimental|CPI-1205 Combination with Enzalutamide|
89337480|NCT03480646|Experimental|CPI-1205 Combination with Abiraterone/Prednisone|
89337481|NCT03559218|Other|Standard of care|Patients undergoing radiation therapy for breast cancer will be provided instructions for radiation dermatitis per institutional standard of care
89337482|NCT03559218|Experimental|KeraStat Cream|Patients undergoing radiation therapy for breast cancer will be provided KeraStat Cream for twice daily application.
89337483|NCT05760872||Placement of an esophageal catheter|In this group we will assess the influence of placing an esophageal catheter on the cortisol levels in HV
89337484|NCT03483142|Experimental|misoprostol group|misoprostol group ( study group ) ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
89337485|NCT03483142|Placebo Comparator|placebo group|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol.
89337486|NCT03726372|Experimental|deep neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given by continuous infusion at a dose that reaction to train of four (TOF) stimulation is depressed to zero
89337487|NCT03726372|Experimental|moderate neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given at a dose by intermittent injection that reaction to train of four (TOF) stimulation is kept 1 to 2
89337488|NCT03104816|Experimental|Acetaminophen IV Soln 10 MG/ML (A)|Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
89337489|NCT03104816|Experimental|PO acetaminophen (B)|Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
89337490|NCT03104816|Active Comparator|Hydromorphone (control arm) (C)|Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.
89337491|NCT04306588|Experimental|Tele-rehabilitation exercise Group|Participants who are suffering from a chronic illness such as COPD or CHF and are referred for tele-rehabilitation intervention at the VA-Houston will be qualified for the purpose of this study.
89337492|NCT02523742|Other|Neuropsychiatric Disorders|Neuropsychiatric Disorders patients
89337493|NCT02523742|Other|Healthy volunteers|control subjects matched to patients by age, sex, socio-cultural level and laterality
89337494|NCT04720976|Experimental|JAB-3312+Pembrolizumab dose escalation|Dose escalation
89337495|NCT04720976|Experimental|JAB-3312+ Binimetinib dose escalation|Dose escalation
89337496|NCT04720976|Experimental|JAB-3312+Pembrolizumab dose expansion|Dose expansion
89337497|NCT04720976|Experimental|JAB-3312+Binimetinib dose expansion|Dose expansion
89337498|NCT04720976|Experimental|JAB-3312+Sotorasib dose escalation|Dose escalation
89337499|NCT04720976|Experimental|JAB-3312+ Osimertinib dose escalation|Dose escalation
89337500|NCT04720976|Experimental|JAB-3312+ Sotorasib dose expansion|Dose expansion
89337501|NCT04720976|Experimental|JAB-3312+ Osimertinib dose expansion|Dose expansion
89337502|NCT03480568|Experimental|alirocumab|Alirocumab 150 mg q 2 weeks for 12 weeks
89337503|NCT04707326||DTG/3TC|HIVRNA suppressed HIV patients who switched to DTG/3TC
89337504|NCT04707326||Triple drug cART|Matched HIVRNA suppressed patients who remained on triple drug cART
89337505|NCT03559062|Other|Placebo|Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
89337506|NCT03559062|Experimental|TEZ/IVA|Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
89337507|NCT03559062|Experimental|Ivacaftor|Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.
89337508|NCT03483064|No Intervention|Control group|Subjects without low back pain to whom the electric current is put but it is not activated.
89337509|NCT03483064|Experimental|Healthy group|Subjects without low back pain to whom the electric current is put but it is activated.
89337510|NCT04979416|No Intervention|Control|No video message
89337511|NCT04979416|Experimental|Video message 1|
89337512|NCT04979416|Experimental|Video message 2|
89337513|NCT04979416|Experimental|Video message 3|
89337514|NCT03039296||One side endoscopic rhizotomy|Endoscopic rhizotomy will be provided only on one back side according pain
89337515|NCT03039296||Both sides endoscopic rhizotomy|Endoscopic rhizotomy will be provided on both back sides according pain
89337516|NCT03726216||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in France
89337517|NCT00204490|Experimental|1|soy isoflavones
89337518|NCT00204490|Placebo Comparator|2|carbohydrates (maltodextrin)
89337519|NCT00089791|Placebo Comparator|Placebo|Placebo administered subcutaneously once every 6 months for 3 years.
89337520|NCT00089791|Experimental|Denosumab 60 mg Q6M|Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
89337521|NCT03633188|Experimental|Patients treated by antibiotherapy|35 Patients treated by antibiotherapy for acute and subacute post-operative implant-associated BJI infections and among them 10 patients with Staphylococcus. aureus treated with antibiotics as part of their standard treatment procedure for metagenomic procedure.
89337522|NCT04939870||PREDIALYSIS GROUP|(n = 48) - patients in the pre-dialysis period (stage G3b-G4 CKD) with moderate or severe decrease in eGFR (eGFR 44-29 ml / min / 1.73 m2),
89337523|NCT04939870||END-STAGE RENAL DISEASE GROUP|patients with ESRD (n=78) - (eGFR <15 ml/min /1.73 m2) undergoing renal replacement therapy. Depending on the method of renal replacement therapy used, two subgroups are distinguished: PD subgroup (n=35) including patients treated by peritoneal dialysis. In this subgroup, initially, due to the treatment technique, two groups were separated, a group (n=15) treated with the automatic peritoneal dialysis (APD) technique, and a group of patients (n = 20) using the technique of continuous cycling peritoneal dialysis (CCPD), HD subgroup (n = 43) including patients treated with repeated hemodialysis. Hemodialysis procedures were performed in each patient three times a week, via an arteriovenous fistula from own or artificial vessels. The duration of hemodialysis was at least 10 hours/week using standard bicarbonate dialysis fluids and polysulfone low-flux dialyzers. The blood flow during hemodialysis was 200-350 ml/min, with an average dialysis fluid flow of 500 ml/min.
89337524|NCT04939870||CARDIOLOGY GROUP|• CARD group (n = 37) - patients with at least one history of cardiovascular events, admitted to hospital for elective angiography, without any signs of impaired kidney function. The studies in this group were to show the changes that occur as a result of diseases of the cardiovascular system and the functioning of the kidneys.
89337525|NCT04939870||HEALTHY VOLUNTEERS|Healthy volunteers, (n = 32) - it was composed of healthy people, with no evidence of impairment in renal function and cardiovascular function in the history and at the time of enrollment in the study.
89337526|NCT05671094|No Intervention|Control group|Standard of care, i.e no specific program prior to surgery.
89337527|NCT05671094|Experimental|Prehabilitation group|A multimodal prehabilitation program including 4 different components (physical, cognitive, nutritional and stress reduction prehabilitation) will be proposed to patients in order for them to participate during four to two weeks pre-operatively.
89337528|NCT03482908|Experimental|Responsive parenting treatment|Early Healthy Lifestyles (EHL) screening tool reported by participants to identify potentially obesogenic parenting practices and child behaviors; data sharing/coordination into electronic health records to inform counseling by trained providers; responsive parenting curriculum delivered by trained WIC nutritionists.
89337529|NCT03482908|No Intervention|Standard Care Control|Standard of pediatric and WIC care
89337530|NCT02881268||Patient with sepsis|Patient hospitalized in intensive care unit
89337531|NCT02881268||Patient without sepsis|Patient hospitalized in intensive care unit
89337532|NCT03558516|Experimental|Magnesium group|The patient will receive magnesium sulfate injection 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed
89337533|NCT03558516|Placebo Comparator|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed
89337534|NCT03476434|No Intervention|group A (HR-WLE)|Two tandem colonoscopies: first inspection was on high-resolution white-light endoscopy from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection also on HR-WLE.
89337535|NCT03476434|Experimental|group B (HR_CE)|two tandem colonoscopies: first inspection was on HR-WLE from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection with panchromoendoscopy on indigo carmine.
89337536|NCT03380455|Experimental|Treatment period A & B|"Treatment period A: Subjects receive a single oral dose of 500 mg lucerastat on Day 1 under fasted conditions.~Treatment period B: From Day 3 to Day 9, subjects receive a b.i.d. (every 12 h) oral dose of 800 mg cimetidine under fasted conditions (Treatment period B1; from Day 3 to Day 5). On Day 6, subjects receive a single oral dose of 500 mg lucerastat concomitantly with the morning dose of 800 mg cimetidine under fasted conditions (Treatment period B2; from Day 6 to Day 10)."
89337537|NCT03557970|Experimental|Treatment (JNJ-40346527)|Participants receive JNJ-40346527 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89337538|NCT03339037|Active Comparator|Hyperbaric oxygen therapy|"60 Hyperbaric oxygen sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). each session 1.5 ATA of 100% oxygen for 1 hour.~1 meter per minute compression and decompression."
89337539|NCT03339037|Sham Comparator|Normobaric air SHAM|"60 sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session at 1 ATA of 21% oxygen (air) for 1 hour.~1 meter per minute compression and decompression. after 3 months, patients will be crossed over and treated with 60 sessions of treatment"
89337540|NCT04804228|Experimental|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis, following the PGM maps described by Travell and Simons. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
89337541|NCT04804228|Active Comparator|Ischemic compression, analytical stretching and postural habits educational dossier|The control group consisting of 40 subjects will undergo an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifid and iliocostal, 1 weekly session for 6 weeks providing a training dossier of postural education in their activities of daily life.
89337542|NCT02815280|Experimental|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
89337543|NCT02815280|Placebo Comparator|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
89337544|NCT01241929|Experimental|video decision aid|Video decision aid arm
89337545|NCT01241929|No Intervention|Usual Care -- Verbal Description Arm|Verbal description of CPR (i.e., without the video).
89337546|NCT05665218||patients undergoing right heart catheterization|
89337547|NCT03723330|Experimental|Plant sterol with a healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided with specific instructions to consume plant sterols-enriched food (contains 2 g plant sterols).
89337548|NCT03723330|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
89337549|NCT03482674|No Intervention|Control Group|The control group will receive standard care as provided by the German statutory health insurance.
89337550|NCT03482674|Experimental|Intervention group|The intervention group receives the DIMINI lifestyle intervention for a period of three months.
89337551|NCT01237795|Experimental|0.01% fluorosurfactant|An experimental formula for denture hygiene containing 0.01% fluorosurfactant.
89337552|NCT01237795|Experimental|1.0% chloramine T|An experimental formula for denture hygiene containing 1.0% chloramine T.
89337553|NCT01237795|Experimental|0.2% chloramine T|An experimental formula for denture hygiene containing 0.2% chloramine T.
89337554|NCT01237795|Active Comparator|Proprietary dentifrice.|A proprietary denture-specific dentifrice.
89337555|NCT01310712|Experimental|oxybutynin|patients will receive in the end of the treatment, 10 mg of oxybutynin a day
89337556|NCT01310712|Placebo Comparator|Placebo|Placebo
89337557|NCT02737930|Experimental|Fluoxetine|20 mg fluoxetine capsule by mouth once daily for 90 days
89337558|NCT02737930|Placebo Comparator|Placebo|Matching placebo
89337559|NCT03723174||Single Arm|baseline data will be calculated before the oral health educational program using gingival index and after 3 months from the intervention
89337560|NCT02719184||Healthy volunteers|
89337561|NCT02719184||COPD GOLD I|Chronic obstructive pulmonary disease
89337562|NCT02719184||COPD GOLD II|Chronic obstructive pulmonary disease
89337563|NCT02719184||COPD GOLD III|Chronic obstructive pulmonary disease
89337564|NCT02719184||A1AT Deficiency|Alpha one anti-trypsin deficiency
89337565|NCT05664984|Experimental|1-face-to-face group|Cognitive rehabilitation intervention was given face-to-face.
89337566|NCT05664984|Experimental|2-tele rehabilitation group|Cognitive rehabilitation intervention was given tele-rehabilitation method.
89337567|NCT01242787|Active Comparator|Entecavir 0.5 mg|Entecavir 0.5 mg
89337568|NCT01242787|Experimental|LB80380|Optimal dose of LB80380 (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
89337569|NCT03476356|Experimental|Group L|This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.
89337570|NCT03476356|Active Comparator|Group C|This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle.
89337571|NCT02611076|Experimental|Stop Smoking for Good Intervention in Spanish|Study II: Stop Smoking for Good Intervention in Spanish (SS-SP) will comprise a series of 10 booklets distributed over 18 months, plus additional monthly contacts via 9 supportive pamphlets developed in Study I. Behavioral: Stop Smoking for Good Intervention in Spanish (SS-SP) Assessments will occur at six-month intervals, through 24 months.
89337572|NCT02611076|Active Comparator|Usual Care|Study II: Usual Care (UC) will comprise a single, Spanish-language, smoking cessation booklet developed by the National Cancer Institute (NCI). Behavioral: Usual care (UC) Assessments will occur at six-month intervals, through 24 months.
89337573|NCT01237873|Experimental|Ali/Amlo|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
89337574|NCT03480412||Follicular Phase|
89337575|NCT03480412||Luteal Phase|
89337576|NCT03723018|Experimental|Meditation - Headspace|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by the commercially available app/website Headspace (provided to participants for free). Participants in this arm will have access to the other meditation arm once they finish the study.
89337577|NCT03723018|Experimental|Meditation - Respite|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by Respite, a website created by the investigators for this study. Participants in this arm will have access to the other meditation arm once they finish the study.
89337578|NCT03723018|No Intervention|Observational|Participants in this arm will not receive any intervention. Their only study activity will be taking online surveys. They will have access to the two meditation arms once they finish the study.
89337579|NCT03476200|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy consisting of fourteen weekly group sessions, one hour and a half each, directed by two clinical psychologist.
89337580|NCT03476200|No Intervention|Control Group|Control Group with no intervention.
89337581|NCT03913663|Active Comparator|study group|20 patient with hemineglect, minimum 6 months post stroke
89337582|NCT03913663|Active Comparator|control group|20 patient with hemineglect, minimum 6 months post stroke
89337583|NCT02534012|Experimental|PVB group|Patients will receive nerve stimulator guided paravertebral block
89337584|NCT02534012|Experimental|GA group|Patients will receive general anesthesia
89337585|NCT05664906|Active Comparator|Intervention Group: Chinese Medicine Oral Rinse and Standard Care|"Prescription and oral rinsing with Chinese Medicine Oral Rinse Formula-I (CMORF-I) which mainly consists of the Nong's concentrated CM granules of Wu Wei Xiao Du Yin and other ingredients.~Standard care will be following the indications provided by patient's western medical doctor.~Patients should not take any other TCM and non-prescribed medication and nutritional supplements during the intervention period."
89337586|NCT05664906|Placebo Comparator|Control Group: Placebo and Standard Care|"Placebo: The placebo consists of an inert substance, made of starch filler, flavor and colorings. It is also manufactured under GMP standard. To ensure blinding, the CMORF-I formula and placebo will be indistinguishable in appearance, smell and favour.~Standard care will be following the indications provided by patient's western medical doctor.~Patients should not take any other TCM and non-prescribed medication and nutritional supplements during the intervention period."
89337587|NCT03131284|No Intervention|Control|Families of newborns whose paediatrician is assigned to the control arm, receive usual education about nutrition and lifestyle, during their child's first two years of life.
89337588|NCT03131284|Experimental|Intensive education.|Families of newborns whose paediatrician is assigned to the intervention arm, receive standardized lifestyle counseling along with educational written material about their child's first two years of life, which corresponds to the experimental treatment.
89337589|NCT01146847|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish tight glycaemic control
89337590|NCT05626387|Active Comparator|Prednisolone alone|Oral prednisolone will be administered over 52 weeks, according to following schedule 0.75 mg/kg x 2 weeks 0.5 mg/kg x 2 weeks 20 mg/day x 4 weeks 15 mg/day x 4 weeks 10 mg/day x 4 weeks 5 mg/day x 10 weeks 5 mg on alternate days x 26 weeks
89337591|NCT05626387|Experimental|Mycophenolate mofetil plus prednisolone|Oral prednisolone will be administered according to the schedule in the prednisolone alone arm. Mycophenolate mofetil will be administered starting from 2 weeks after randomization. It will be initiated at a dose of 500 mg twice daily and will be escalated to 1000 mg twice daily after two weeks.
89337592|NCT03480256|Experimental|SHR6390 combined with pyrotinib|Group A:pyrotinib 400mg qd combined with SHR 6390 100mg qd Group B: pyrotinib 400mg qd combined with SHR 6390 125mg qd Group C: pyrotinib 400mg qd combined with SHR 6390 150mg qd Group D: pyrotinib 400mg qd combined with SHR 6390 175mg qd Group E: pyrotinib 320mg qd combined with SHR 6390 100mg qd
89337593|NCT03722940|Active Comparator|Magnesium sulphate|Group M
89337594|NCT03722940|Placebo Comparator|Na CL 0.9%|group C
89337595|NCT03476122||Disease Group|The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
89337596|NCT03476122||Control Group|The control group will receive Colonoscopy
89337597|NCT01146925|Experimental|CRMD-001-Deferiprone|
89337598|NCT01146925|Placebo Comparator|Placebo|
89337599|NCT04635254|Active Comparator|Halophites-based cream 24 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
89337600|NCT04635254|Active Comparator|Halophites-based cream 48 hours|A 2 gram amount of Halophites-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
89337601|NCT03476044|Active Comparator|Group Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
89337602|NCT03476044|Active Comparator|Group Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
89337603|NCT01250821|Experimental|Ovulation induction|
89523578|NCT02601937|Experimental|Open-label Tazemetostat|"Dose Escalation: Level 1 (Starting Dose) Oral Tazemetostat 240 mg/m^2 BID; Level 2 Oral Tazemetostat 300 mg/m^2 BID; Level 3 Oral Tazemetostat 400 mg/m^2 BID; Level 4 Oral Tazemetostat 520 mg/m^2 BID; Level 5 Oral Tazemetostat 700 mg/m^2 BID; Level 6 Oral Tazemetostat 900 mg/m^2 BID; Level 7 Oral Tazemetostat 1200 mg/m^2 BID~Dose Expansion:~Cohort 1: Oral tazemetostat 1200mg/m2 BID Cohort 2: Oral tazemetostat 520mg/m2 BID Cohort 3: Oral tazemetostat 520mg/m2 BID Cohort 4: Oral tazemetostat 800mg/m2 TID (2400mg/m2/day)"
89337604|NCT05760716||Experiment Group|"The prone position was positioned within the application steps.~The introductory characteristics form of the patients was filled in on the day the patient was included in the study.~Blood gas results and mechanical ventilator respiration indicators were followed up in the PP for 5-10 days and the changes were recorded in the tolerance hours.~Arterial blood gas results, mechanical ventilator values, and ventilator-associated pneumonia status were monitored before the position was applied, during the position and after the patients were placed in the supine position by comparing the groups with and without the prone position.~• Nursing intervention application steps for VAP were followed during the PP and the changes were recorded."
89337605|NCT05760716||Control Group|Routine nursing care was applied without any intervention. 'Patient Information Form', 'Patient Follow-up Charts', 'Clinical Pulmonary Infection Score', 'Braden Pressure Wound Risk Assessment' and 'Ramsey Sedation Scale' were used.
89337606|NCT01253395|Experimental|Strength training|Supervised strength training.
89337607|NCT01253395|Active Comparator|Aerobic exercise|Supervised aerobic exercise.
89337608|NCT05181332||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
89337609|NCT05181332||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
89337610|NCT03475966|Experimental|Prehabilitation|Exercise, nutrition and relaxation techniques all beginning four weeks prior to surgery date.
89337611|NCT03475966|Active Comparator|Rehabilitation|Exercise, nutrition and relaxation techniques all beginning immediately after surgery.
89337612|NCT01147315|Experimental|Hybrid bone substitution|Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow
89337613|NCT04576442|Experimental|Asthma-PASS Intervention|Collaboration with PCPs to optimize management. Community Health Worker (CHW) to ensure PCP plan is followed. Two asthma education sessions with children/caregivers focusing on self-efficacy and physical activity promotion. Promotion of asthma awareness in school. School personnel training in asthma
89337614|NCT04576442|Active Comparator|Asthma Management Comparison Group|Includes two sessions of basic asthma education and PCP notification of child's asthma severity level.
89337615|NCT03493698|Experimental|Treatment A: Midazolam|All subjects will receive a single oral dose of 2 mg Midazolam on Day 1
89337616|NCT03493698|Experimental|Treatment B and C: Inarigivir|All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18
89337617|NCT03493698|Experimental|Treatment D: Inarigivir with Midazolam|All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19
89337618|NCT00839137||no exercise program group|group will continue with current level of activity and will be asked not to start an exercise program. They will be seen in the clinic three times a week for 12 weeks. These visits will be very brief; blood pressure, heart rate, oxygen level and peak flow will be measured at each visit
89337619|NCT00839137||exercise group|will meet three times a week for 12 weeks, following specific exercise program
89337620|NCT02737852|Experimental|Healthy subject|"Healthy subject exposed to Trojan Chameleon Personal Lubricant at least four times weekly for two weeks"
89337621|NCT01148173|Experimental|Systemic and intrathecal chemotherapy|
89337622|NCT03482596|Experimental|Intervention|All participants will follow the personalised multifaceted intervention to reducing/breaking prolonged sitting.
89337623|NCT03722862|Placebo Comparator|Control Arm|Healthy volunteers will continue normal healthy diet with a placebo.
89337624|NCT03722862|Experimental|Low fiber|Healthy volunteers will be randomized to receive 3 grams of Sunfiber.
89337625|NCT03722862|Experimental|High fiber|Healthy volunteers will be randomized to receive 6 grams of Sunfiber.
89337626|NCT05179850||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
89337627|NCT05179850||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is a external validation cohort.
89337628|NCT03131518|Other|E-bicycle|Access to an e-bicycle will be provided.
89337629|NCT03131518|Other|Longtail bicycle|Access to a longtail bicycle will be provided.
89337630|NCT03131518|Other|Traditional bicycle|Access to a traditional bicycle will be provided.
89337631|NCT03720444||MDT (mechanical diagnosis and therapy) method|
89337632|NCT01898312|Experimental|Mifepristone|treatment with oral mifepristone 50 mg every second day for 12 weeks in 30 women with BRCA 1 or 2 mutation
89337633|NCT01898312|Placebo Comparator|TrioBe|treatment with a quarter of a tablet of TrioBe every second day for 12 weeks
89337634|NCT03482518|Experimental|Intervention Group|The intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover with elements in insoles. They will be advised to wear the slipper for 4 hours in the first week and up to 8 hours after that period. Should any part of you feel uncomfortable, the participant should return immediately so that the appropriate adjustments are made in the slipper
89337635|NCT03482518|Sham Comparator|Control group|"The control (sham) group volunteers will receive a pair of custom slippers with perforated synthetic leather cover as those used by GI.~The difference will be that these slippers will not have the elements in the insoles."
89337636|NCT02724319||Left heart catheterization patients|Patients presenting to the UF Health Jacksonville cardiac catheterization laboratory for left heart catheterization for suspected coronary artery disease and intent to undergo percutaneous coronary intervention will be targeted for enrollment and will be genotyped by SpartanRX
89337637|NCT03528174|Experimental|Single Hormone closed loop|Subjects will have glucose managed using the Artificial Pancreas Control system (APC) using insulin only. Insulin will be infused through the Pacific Diabetes Technologies CGM Insulin Infusion system.
89337638|NCT03908671|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with advanced esophageal and non-small cell lung cancers
89337639|NCT03913429|Active Comparator|Control Group|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml."
89337640|NCT03913429|Experimental|Study Group|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side."
89337641|NCT03482440|Placebo Comparator|Placebo|
89337642|NCT03482440|Experimental|Salsalate|
89337643|NCT05660928|Experimental|Intervention|"Eighteen primary care centers will be randomized to the intervention arm, which consists of a multidimensional strategy, with a multidisciplinary approach, for the management of patients with hypertension and diabetes in the primary care setting. It is going to include:~Telehealth tools: clinical decision support system for primary care professionals to support the care of patients with hypertension and diabetes; clinical decision support system to support community health agents (ACS), for use in home visits; asynchronous teleconsultations; telediagnosis for digital electrocardiogram and retinography reports; text messages to patients, to provide information, education, improve adherence to treatment and encourage patients to promote health;~Continued education for health professionals;~Strengthening the educational groups and promotion of lifestyle changes, with a focus on promoting healthy eating and reducing sedentary behavior."
89337644|NCT05660928|No Intervention|Usual care|Seventeen primary care centers will be randomized to usual care.
89337645|NCT04638634|Experimental|CSL760 (low dose)|Administered as an intravenous infusion
89337646|NCT04638634|Experimental|CSL760 (high dose)|Administered as an intravenous infusion
89337647|NCT01253473|Active Comparator|ipratropium/albuterol|1 puff 4 times daily
89337648|NCT01253473|Experimental|Budesonide|budesonide 180 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
89337649|NCT01253473|Experimental|budesonide/formoterol|budesonide/formoterol 160/4.5 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
89337650|NCT01883804|Experimental|Study group|All participants selected to continue with Methyldopa administration.
89337651|NCT01247935|Experimental|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
89337652|NCT01247935|Experimental|transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
89337653|NCT01247935|No Intervention|Control|patient are monitored for pain and discomfort
89337654|NCT05259592|Experimental|Modular Patient Centred CBT (MPC) for CPTSD|MPC (Folke, Friis, Thomsen & Roitmann, 2020) is a treatment programme consisting of up to 32 therapy sessions broken down by five treatment modules (each consisting of six sessions). Prior to the treatment modules, the client completes an intro module (two sessions) focusing on psyhoeducation on CPTSD, individual case formulation and introduction to the further treatment programme. After the intro module (and after each treatment module), the client and therapist jointly decide which treatment module to proceed with based on 'co-decision'. The treatment modules directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares. Each treatment module is structured in such a way that it can be offered alone and independently of the other modules.
89337655|NCT05259592|Active Comparator|Modular CBT for CPTSD without co-decision|Because the study investigates a potentially beneficial effect of including the client directly in treatment decisions (by having the client determine the order of treatment modules together with the therapist), the patient-centred version of the treatment is compared with a control treatment, where the five treatment modules are delivered in a predefined order. The control treatment thus consists of the same treatment components as described above. It is only the aspect of co-decision that has been taken out. Instead, the therapist will just inform the client about the order of treatment modules in the programme. The order of treatment modules in the control treatment will be: 1) Affect dysregulation (6 sessions), 2) Disturbed relationships (6 sessions), 3) Negative self-concept (6 sessions), 4) PTSD symptoms (6 sessions) and 5) Insomnia and trauma-related nightmares (6 sessions).
89337656|NCT03109184|No Intervention|Waitlist Control|Parents and teens enrolled in the study and randomized to the control condition wait until they complete their 3-month and 9-month follow-up surveys before completing the web-based program.
89337657|NCT03109184|Experimental|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
89337658|NCT03480100||Xylometazoline Nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
89337659|NCT03480100||Xylometazoline + Ectoin Nasal Douche|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Douche (END01): 1 spray per nostril 2-6 times per day or as often as required
89337660|NCT02348203|Experimental|Arm I (aspirin, zileuton)|Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
89337661|NCT02348203|Placebo Comparator|Arm II (double placebo)|Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
89337662|NCT03984916|Active Comparator|Hesperidin Pharma|500 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R. The approximate particle size is less than 100 µm for the 90% of the extract, and of 10 µm for 10% of the extract.
89337663|NCT03984916|Active Comparator|Hesperidin Pharma_M|500 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R. The size of 90% of particles is less than 10 µm.
89337664|NCT03984916|Experimental|Cardiose|500 mg of sweet orange extract with more than 90% of the isomer -S. The size of the 90% of particles is less than 10 µm.
89337665|NCT04570904||Early HCWs|Health Care Workers vaccinated early prior to the influenza season
89337666|NCT04570904||Late HCWs|Health Care Workers vaccinated just prior to the influenza season
89337667|NCT04570904||Inpatients|Inpatients recruited for evaluation of new approaches to influenza diagnosis
89337668|NCT03913585|Experimental|Lifestyle intervention|The intervention group comprises ~4800 patients born 1959-1988, living in the municipalities of Haderslev or Middelfart, and affiliated to one of the participating GPs. No control group is included.
89337669|NCT03722706|Experimental|Handbook|handbook provided as an adjunct to standard AD management with a healthcare provider at BCH
89337670|NCT03722706|No Intervention|Control|standard management alone
89337671|NCT03482362|Experimental|Cohort A; KRASmt, BRAFwt, BRAF-like CC|Patients with KRAS mutant and BRAF wildtype colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
89337672|NCT03482362|Experimental|Cohort B; KRASwt, BRAFmt, BRAF-like CC|Patients with KRAS wildtype and BRAF mutant colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
89337673|NCT03479866|Experimental|Dietary intervention|2 week dietary intervention using standardized test meals
89337674|NCT04500470|Experimental|Group A|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
89337675|NCT04500470|Placebo Comparator|Group B|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table vaginal placebo by the patient 12 hours before the procedure
89337676|NCT03482284|Experimental|Monosaccharide 1|Participants receive standardized meals with a defined amount of monosaccharide 1.
89337677|NCT03482284|Experimental|Monosaccharide 2|Participants receive standardized meals with a defined amount of monosaccharide 2.
89337678|NCT03493386|Experimental|Treatment Group A: Part 1|Subjects will be randomized to receive single dose of two tablets of 2 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
89337679|NCT03493386|Experimental|Treatment Group B: Part 1|Subjects will be randomized to receive single dose of 4 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of two tablets of 2 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
89337680|NCT03493386|Experimental|Treatment Group C: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fed state during Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fasted state. There will be a wash-out period of 5 days between the Periods.
89337681|NCT03493386|Experimental|Treatment Group D: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fasted state during period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fed state. There will be a wash-out period of 5 days between the Periods.
89337682|NCT03482206|Experimental|Healthy subjects|Healthy adult volunteers (age 18 or greater) that are not claustrophobic, do not have hyperventilation or panic disorders, not pregnant, have no metal implants and can pass the MRI screening questions.
89337683|NCT04480658|Experimental|Bryophyllum pinnatum|Bryophyllum pinnatum (BP) muscle relaxing substance
89337684|NCT03908203|Other|Treatment Arm|
89337685|NCT03475732|Experimental|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
89337686|NCT03908047||healthy volunteers|
89337687|NCT02528149||patients with renal aneurysm|Patient with one or more renal artery aneurysm (RAA) operated and with tissue; adjacent part and aneurysm; cryopreserved. Blood sample performed at day 1.
89337688|NCT03475654|Experimental|technology-assisted rehabilitation|The experimental group will receive treatment as usual, in addition to training with the Jintronix platform. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
89337689|NCT03475654|Active Comparator|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
89337690|NCT03479788||DM|Observational study. NO intervention
89337691|NCT03479788||non-DM|Observational study. NO intervention
89337692|NCT01253551|Experimental|001|Treatment sequence AB Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
89337693|NCT01253551|Experimental|002|Treatment sequence BA Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
89337694|NCT03633500|Placebo Comparator|Sterile water|Sterile water: Started by six hours of age, In the control arm, 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
88811782|NCT01499147|Active Comparator|Arm 2|All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
89337695|NCT03633500|Experimental|Breastmilk|Breastmilk. This is started at 6 hours of age at the earliest; breast milk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
89337696|NCT03475576|Other|all participants|The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian.
89337697|NCT01251055|Placebo Comparator|Placebo|
89337698|NCT01251055|Experimental|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1 4000 mg/day
89337699|NCT03482128||preAlgorithm|Standard coagulation management of patients undergoing cardiac surgery
89337700|NCT03482128||postAlgorithm|Coagulation management guided by SONOCLOT of patients undergoing cardiac surgery
89523579|NCT03384667|Experimental|MMDT group|
89337701|NCT03478644|Experimental|Experimental Denture Wipe|Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.
89337702|NCT03478644|Placebo Comparator|Tap Water|Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.
89337703|NCT01366898|Experimental|Chemotherapy|
89337704|NCT03916315|Experimental|Transdiagnostic Treatment|Participants in this group will receive from 11 to 17 sessions of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
89337705|NCT03916315|No Intervention|Control group|The participants in this group will not receive the treatment, just waiting list. They will be measured one time and then a second time 3 months after. Calculating when 3 months corresponding to 11-12 sessions will take place in the intervention group.
89337706|NCT03479632|Experimental|Intervention Group|The intervention group will undergo an aerobic walking program using a treadmill, a body-weight support system, and an assistive device.
89337707|NCT03479632|Active Comparator|Control Group|The control group will receive standard physical therapy (PT).
89337708|NCT03482050|Experimental|AstroRx|
89337709|NCT03527550|Experimental|Cognitive Training plus Treatment as Usual|Participants in this arm will receive daily computerized cognitive training sessions during partial hospitalization, in addition to treatment as usual. Cognitive training sessions will alternate between response inhibition training and working memory training.
89337710|NCT03527550|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment As Usual group will receive usual treatment in the partial hospitalization program.
89337711|NCT01248871|Active Comparator|SEVO|sevoflurane-remifentanil/sufentanil combination
89337712|NCT01248871|Active Comparator|SERE|volatile agent only during reperfusion
89337713|NCT01248871|Active Comparator|propofol|propofol-remifentanil/sufentanil
89337714|NCT04458844|Experimental|Fundamental Movement Skill (FMS) Training|Exercise 2 x per week focusing on Fundamental Movement Skill Development
89337715|NCT04458844|Experimental|FMS and strength|Replacement of 50% FMS training with integrated strength training.
89337716|NCT04458844|No Intervention|Control|No intervention.
89337717|NCT03479398||App Condition|Although we will be mostly observing routine practice, we will randomize patients into either an App condition or paper condition. The App condition refers to patients completing routine Cognitive Behavioral Therapy (CBT) worksheets on a mobile application during session. Everything else that occurs in treatment sessions will be consistent with routine care practices.
89337718|NCT03479398||Paper Condition|Although we will be mostly observing routine practice, we do randomize patients into either an App condition or paper condition. The paper condition refers to patients completing routine CBT worksheets on paper (the current standard) during session.
89337719|NCT01251133|Experimental|LBVH0101|
89337720|NCT01251133|Active Comparator|Hiberix|
89337721|NCT03720288|Experimental|Acetazolamide|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the acetazolamide group, he / she will start using the adjuvant medication as acetazolamide drug capsule at the daily dose of 250 mg / day (oral) during the first three days of treatment.
89337722|NCT03720288|Experimental|Placebo|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the placebo group, he / she will start using the placebo drug capsule during the first three days of treatment.
89337723|NCT01147549|Experimental|1|[C14]AZD9668
89337724|NCT03722628||HCC with TTT|Blood sample from all HCC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
89337725|NCT03722628||HCC without TTT|Blood sample from all HCC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
89337726|NCT03722628||LC with TTT|Blood sample from all LC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
89337727|NCT03722628||LC without TTT|Blood sample from all LC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
89337728|NCT03722628||Healthy control|MMP1-genotype polymorphism will be applied on those healthy people to detect which type of mutation occur in healthy rather than diseased.
89337729|NCT03916393|Experimental|PF-06651600 Treatment A|Active pharmaceutical ingredient (API)solution in water
88811783|NCT00823082|Experimental|Antithrombin III treatment group|Preoperative ATIII supplementation administered immediately after anesthesia induction
88811784|NCT00823082|No Intervention|Control group|No preoperative ATIII supplementation administered
89337730|NCT03916393|Experimental|PF-06651600 Treatment B|API in sweetened solution
89337731|NCT03916393|Experimental|PF-06651600 Treatment C|API blend suspension in water
89337732|NCT03916393|Experimental|PF-06651600 Treatment D|API blend suspension in apple sauce
89337733|NCT03916393|Other|Bitrex (Registered) Treatment E|Positive control for bitterness
89337734|NCT03907813|Experimental|liposomal bupivacaine infiltration|Local infiltration of all wound layers with liposomal bupivacaine (Exparel(R)) 20 ml diluted with 70 ml of normal saline to 90 ml for patient with a BMI of 39 and under. If BMI is 40 or more the 20 ml of liposomal bupivicaine will be diluted to 150 ml by adding 130 ml of normal saline
89337735|NCT03907813|Placebo Comparator|Saline infiltration|Local infiltration of all wound layers with saline, using to match the amount. The amount of total fluid is divided into 4 and instilled with 1-2 ml at a time in between fascial layers after fascial closure. Each 1/4 will be instilled laterally (2) and on each side of the incision(2)- extra fluid is placed subcutaneously.
89337736|NCT03916705|Other|single study arm|All enrolled participants will undergo ultrasound evaluation and chiropractic low back spinal manipulation treatment.
89337737|NCT03475056|Experimental|Group 1: cAd3-Marburg vaccine (1x10^10 PU)|cAd3-Marburg vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
89337738|NCT03475056|Experimental|Group 2: cAd3-Marburg vaccine (1x10^11 PU)|cAd3-Marburg vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
89337739|NCT03913507|Experimental|one group : patients with suspicion of cystic fibrosis|
89337740|NCT00938912|Experimental|Lacosamide|Subjects and their caregivers may chose to receive Lacosamide oral solution (syrup) or Lacosamide tablets. The maximum duration of LCM administration will be approximately 2 years.
89337741|NCT03473808|Experimental|therapy + vibration|Imperceptible vibration applied to the wrist during a standardized hand task practice therapy program.
89337742|NCT01148329||Single arm observational study|To evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice
89337743|NCT01251211|Active Comparator|botulinum toxin type A|botulinum toxin type A will be injected subcutaneously in the painful area (maximum 300 units)
89337744|NCT01251211|Placebo Comparator|sodium chloride 9 %|sodium chloride 9 % will be used as a neutral placebo
89337745|NCT03473340|Experimental|Pirfenidone Capsule|"Method of Administration: Oral (capsule)~Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
89337746|NCT03473340|Placebo Comparator|Placebo Capsule|"Method of Administration: Oral (capsule)~Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
89337747|NCT03907267|Experimental|Taurine|
89337748|NCT03907267|Placebo Comparator|Saline|
89337749|NCT01147705|Active Comparator|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks.
89337750|NCT01147705|Placebo Comparator|Placebo|Same number of tablets and appearance as active drug.
89337751|NCT03915847|Active Comparator|Single layer closure|
89337752|NCT03915847|Active Comparator|Double layer closure|
89337753|NCT03915847|Active Comparator|Doble layer closure with trimming|
89337754|NCT05625451|Experimental|20-22 hours of daily total end range time intervention|used the elastic tension digital neoprene orthosis from twenty to twenty-two hours
89337755|NCT05625451|Active Comparator|11-13 hours daily total end range time intervention|used the elastic tension digital neoprene orthosis from eleven to thirteen hours
89337756|NCT03906955|Experimental|Efficacy for Lifestyle PA|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for lifestyle physical activity.
89337757|NCT03906955|Active Comparator|Efficacy for Work-life Balance|Three brief (10-minute) video chats during first three weeks of six weeks of lifestyle physical activity engagement providing information relative to outcome expectations (week 1), self-efficacy (week 2), and self-regulatory strategies (week 3) to enhance self-efficacy for work-life balance.
89337758|NCT01147081|Experimental|Arm 1|
89337759|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase I)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
89337760|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
89337761|NCT03490032|Experimental|Metastatic Prostate Cancer (mPCa) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
89337762|NCT03915457|Experimental|Dry immersion Control Group|5 days of dry-immersion
89337763|NCT03915457|Experimental|Thigh Cuffs intervention|5 days of dry-immersion with thigh cuffs
89337764|NCT03912493|Active Comparator|Control Group|Number of participants in this group is anticipated to be 20. Conventional physiotherapy and rehabilitation methods will be applied to this group. The conventional program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
89337765|NCT03912493|Active Comparator|Study Group|Number of participants in this group is anticipated to be 20. Participants in this group will be receiving conventional physiotherapy and rehabilitation methods and 10 minutes of exercise with the game-based virtual reality system (USE-IT). In the USE-IT system two games will be played for 5 minutes each.
89337766|NCT03722472|Experimental|Single-vial ID93 + GLA-SE|Single-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
89337767|NCT03722472|Active Comparator|Two-vial ID93 + GLA-SE|Two-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
89337768|NCT01250041|Active Comparator|femoral block|
89337769|NCT01250041|Experimental|saphenous block|
89337770|NCT03489720|Experimental|Arm A: Exercise intervention then usual exercise program|8 weeks of exercise intervention followed by 8 weeks of usual exercise program
89337771|NCT03489720|Active Comparator|Arm B: Usual Exercise Program then exercise intervention|8 weeks of usual exercise program followed by 8 weeks of exercise intervention
89337772|NCT03907111|Experimental|Chitosan gauze|100cm^2 Gauze made by chitosan material. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
89337773|NCT03907111|Placebo Comparator|Traditional gauze|100cm^2 Gauze made by traditional cotton yarn. Administrate it on surgical wound after surgery directly. Change it daily with necessary wound care.
89337774|NCT03722394|Experimental|Pain Neuroscience Education|Subjects received a 15-minute verbal, one-on-one Pain Neuroscience Education (PNE) session
89337775|NCT03906799|Experimental|Low OMT-28|Verum, low OMT-28
89337776|NCT03906799|Experimental|Middle OMT-28|Verum, middle OMT-28
89337777|NCT03906799|Experimental|High OMT-28|Verum, high OMT-28
89337778|NCT03906799|Placebo Comparator|Placebo|Placebo
89337779|NCT03912571||Mild Cognitive Impairment (MCI)|Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.
89337780|NCT03912571||Normal Cognition (NL)|Clinical Dementia Rating [CDR] of 0 or Global Deterioration Scale [GDS] of 1-2
89337781|NCT03912727|Experimental|Alpha-lipoic acid|18 patients will receive alpha lipoic acid (thiotacidR) product with their standard therapy.
89337782|NCT03912727|Placebo Comparator|Control|18 patients will receive their standard therapy only.
89337783|NCT03619200||Fallers|"Participants who reported at least one fall in the 12-months follow-up period were categorized as fallers."
89337784|NCT03619200||Non-Fallers|"Participants who did not report any fall in the 12-months follow-up period were categorized as non-fallers."
89337785|NCT01250197|Experimental|Formulation A|AR-12286 Ophthalmic Solution Formulation A
89337786|NCT01250197|Experimental|Formulation B|AR-12286 Ophthalmic Solution Formulation B
89337787|NCT03661567|Experimental|Methylprednisolone|Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
89337788|NCT03661567|Active Comparator|Observation|Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).
89337789|NCT01250275|Experimental|Acute Phase: traditional canola oil|Participants will receive banana bread containing traditional canola oil once weekly during the 5-week schedule
89337790|NCT01250275|Active Comparator|Acute Phase: high oleic canola oil|Participants will receive banana bread containing high oleic canola oil once weekly during the 5-week schedule
89337791|NCT01250275|Active Comparator|Acute Phase: soybean oil|Participants will receive banana bread containing soybean oil once weekly during the 5-week schedule
89337792|NCT01250275|Active Comparator|Acute Phase: high linoleic safflower oil|Participants will receive banana bread containing high linoleic safflower oil once weekly during the 5-week schedule
89337793|NCT01250275|Active Comparator|Acute Phase: coconut oil|Participants will receive banana bread containing coconut oil once weekly during the 5-week schedule
89337794|NCT01250275|Experimental|Chronic Phase: traditional canola oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing traditional canola oil for a total of 8 weeks
89337795|NCT01250275|Active Comparator|Chronic Phase: safflower oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing an oil mixture representing the typical western diet for a total of 8 weeks
89337796|NCT03739138|Experimental|MK-4621 Monotherapy (Arm 1)|Participants receive MK-4621 once a week (Q1W) during each 21-day cycle for a maximum duration of 6 cycles.
89337797|NCT03739138|Experimental|MK-4621 + Pembrolizumab (Arm 2)|Participants receive escalating doses of MK-4621 Q1W during each 21-day cycle for a maximum duration of 6 cycles in combination with pembrolizumab at a fixed dose 200 mg every 3 weeks (Q3W) for a maximum duration of 6 cycles. Participants may continue on treatment with pembrolizumab after Cycle 6 for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621 will be based on safety and tolerability.
89337798|NCT03739138|Experimental|Intrahepatic MK-4621 + Pembrolizumab (Arm 3)|Participants receive MK-4621 as monotherapy on Day 1 only of the first 21-day cycle (run-in phase). After the run-in phase, participants receive escalating doses of MK-4621 Q3W in combination with pembrolizumab at a fixed dose 200 mg Q3W for a maximum duration of 5 cycles (Cycles 2-6). Participants may continue on treatment with pembrolizumab for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621 will be based on safety and tolerability.
89337799|NCT03472326|Experimental|Part 1 Sentinel Cohort 1: GS-9131 60 mg|Treatment experienced participants will receive GS-9131 60 mg in addition to their current failing ARV regimen for a period of 10 days.
89337800|NCT03472326|Experimental|Part 1 Sentinel Cohort 2: GS-9131 180 mg|Treatment experienced participants will receive GS-9131 180 mg in addition to their current failing ARV regimen for a period of 14 days.
89337801|NCT03472326|Experimental|Part 1: Randomized Cohort|Participants will be randomized in 1:1:1:1 so as to receive GS-9131 in 3 active dose levels up to a maximum of 180 mg or Placebo to match GS-9131 in addition to their current failing ARV regimen for a period of 14 days in Part 1.
88811785|NCT01382303|Active Comparator|Pentoxifylline|Pentoxifylline 400mg three times a day
88811786|NCT01382303|Placebo Comparator|Placebo|placebo tablet
89337802|NCT03472326|Experimental|Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV|Participants who complete dosing in Sentinel Cohort 1 of Part 1 and show a reduction in plasma HIV RNA > 0.5 log10 from their pre-GS-9131 baseline value at Day 11 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 60 mg + bictegravir (BIC) 30 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 60 mg + BIC 75 mg + tenofovir alafenamide (TAF) 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
89337803|NCT03472326|Experimental|Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF|Participants who complete dosing in Sentinel Cohort 2 of Part 1 and show a reduction in plasma HIV RNA > 0.5 log10 from their pre-GS-9131 baseline value at Day 15 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
89337804|NCT03912649|Experimental|RemovAid arm|"RemovAid arm -~All subjects have their implant removed by the RemovAid device"
89337805|NCT02737618|Experimental|Healthy subject|"Healthy subjects exposed to Trojan Chameleon Personal Lubricant applied by occlusive patch"
89337806|NCT03472014|Experimental|IMVAMUNE®|Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals
89523580|NCT03384667|Placebo Comparator|Placebo group|
89337807|NCT03906487|Experimental|Intimate partner violence|The women in this arm must have suffered at least two physical aggressions. They will be recruited in the study as part of their coming to the consultation of intentional injury of the medico-legal unit of the University Hospital Toulouse.
89337808|NCT03906487|Active Comparator|Control group|The women in this group are women who have never experienced domestic violence or have experienced a potentially traumatic event. These women will be recruited by a call for volunteers.
89337809|NCT03720132|Experimental|Patients with port catheter: flushing|In patients with a catheter-related blood stream infection (CRBSI) and a port catheter, being treated with vancomycin intravenously, we will flush the catheter with 30 ml of sodium chloride 0.9 % prior to blood sampling to determine vancomycin concentrations, in order to decrease residuel vancomycin in the port.
89337810|NCT04182100|Experimental|P1101|Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated proline-interferon alpha-2b (P1101, ropeginterferon alfa-2b) once every 2 weeks.
89337811|NCT01251523|Active Comparator|PACE Plus|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
89337812|NCT01251523|Active Comparator|PACE|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
89337813|NCT01251523|No Intervention|Control|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
89337814|NCT04174222|Active Comparator|Moderate block|5-10mg rocuronium is administered to maintain train-of-four count 1-2. At the end of surgery, sugammadex 2mg/kg is administered IV for reversal of neuromuscular block.
89337815|NCT04174222|Experimental|Deep block|5-10mg rocuronium is administered to maintain train-of-four count 0, and post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
89337816|NCT01253863|Other|determining damaged tissue|
89337817|NCT03479320|Experimental|Lidocaine group|Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery
89337818|NCT03479320|Placebo Comparator|Placebo|They will receive the same volume of 0.9% of normal saline as calculated for the experimental group
89337819|NCT01147159|Other|Skin Prick Test|
89337820|NCT04112524||Patients from routine treatment|all 30 patients from Routine Treatment, only observational
89337821|NCT03915301||ESPB|Erector spinae plane block group
89337822|NCT03915301||Opioids|Opioid group
89337823|NCT01250353|Experimental|conjunctival autograft|The conjunctival autograft was performed after the pterygium surgery like usual technique.
89337824|NCT01250353|Experimental|latex biomembrane application|The latex biomembrane was applied after pterygium surgery to recover the bare sclera area. This device was closed to conjunctiva with running suture anchored at some places to episclera. The sutures was removed at fourteenth day after surgery.
89337825|NCT03526458|Active Comparator|Holmium:YAG laser: 0.2J&15Hz|Patients are assigned to treat stones with 0.2J&15Hz of the holmium laser.
89337826|NCT03526458|Experimental|Holmium:YAG laser: 0.8J&15Hz|Patients are assigned to treat stones with 0.8J&15Hz of the holmium laser.
89337827|NCT03914989|Experimental|Experimental group|Individuals in this group receive exposure to a higher concentration of essential oil fragrances nightly.
89337828|NCT03914989|Placebo Comparator|Active control group|Individuals in this group receive exposure to a lower concentration of essential oil fragrances nightly.
89337829|NCT01253941|Experimental|Mud Bath therapy|
89337830|NCT01253941|No Intervention|no Mud Bath Therapy|
89337831|NCT03488238|Experimental|ORi sensor|All subjects are enrolled in the test group and receive an ORi sensor during their scheduled, general surgery procedure
89337832|NCT03912415|Experimental|BCD-100|BCD-100 3 mg/kg Q3W
89337833|NCT03912415|Placebo Comparator|Placebo|
89337834|NCT01147783||SimBaby|
89337835|NCT01147783||Infants (1-12 mo)|
89337836|NCT03525834|Experimental|Everolimus|Participants targeted to receive Everolimus tablets 10 mg orally once daily for 48 weeks.
89337837|NCT00925652|Experimental|Lifestyle: Diet|The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
89337838|NCT00925652|Experimental|Lifestyle: Diet+Exericise|The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. The exercise intervention is comprised of a target physical activity goal of 180 minutes of moderate-intensity activity each week. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
89337839|NCT00925652|Experimental|Lifestyle: Diet and Bevicizumab+CM|"The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.~Bevicizumab: 15 mg/kg administered intravenously day 1 of a 3-week cycle for 6 months and day 1 of a 6 week cycle up to 2 years Cyclophosphamide: 50 mg orally each day of a 3-week cycle for 6 months Methotrexate: 2.5 mg orally twice daily of a 3-week cycle for 6 months"
89337840|NCT00925652|Experimental|Lifestyle: Diet+Exericise and Bevicizumab+CM|"The dietary intervention focuses on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. The exercise intervention is comprised of a target physical activity goal of 180 minutes of moderate-intensity activity each week. Patients receive a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.~Bevicizumab: 15 mg/kg administered intravenously day 1 of a 3-week cycle for 6 months and day 1 of a 6 week cycle up to 2 years Cyclophosphamide: 50 mg orally each day of a 3-week cycle for 6 months Methotrexate: 2.5 mg orally twice daily of a 3-week cycle for 6 months"
89523581|NCT02557477|Active Comparator|Active|Participants received 3 capsules of Omega 3/6 fatty acids twice daily
89523582|NCT02557477|Placebo Comparator|Placebo|Participants received 3 capsules of identical placebo (palm oil) twice daily
89337841|NCT03906097|Experimental|intervention|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
89337842|NCT03906097|No Intervention|control|SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).
89337843|NCT03905785|Experimental|Parenting Intervention Group(Samarthan)|Parenting intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
89337844|NCT03905785|No Intervention|Wait list Control group|wait list control group was given no intervention for the trial period. They were offered sam intervention after the intervention was completed in experimental group.
89337845|NCT03915145|Experimental|Kinesio tape group|Kinesio tape application has been applied
89337846|NCT03915145|Sham Comparator|Sham group|Sham kinesio tape application has been applied
89337847|NCT03915145|Other|Control group|No intervention has been applied
89337848|NCT03912025||Mild hemodynamic CHD|"Mild severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses, as outlined in the European Society of Cardiology Section on Sports Cardiology consensus guidelines (Budts W, Borjesson M, Chessa M, van Buuren F, Trindade PT, Corrado D, Heidbuchel H, Web G, Holm J, Papadakis M. 2013).~They define functional parameters such as systolic function, oxygen saturation, rhythm disorders, elevated pressure or volume load, etc. to divide patients into 3 hemodynamic groups. Based on their model, we define mild CHD as ones falling into the group that can train at High Intensity exercise levels."
89337849|NCT03912025||Moderate hemodynamic CHD|"Moderate severity category will be defined in terms of hemodynamic parameters rather than anatomic diagnoses. Based on their model, we define moderate CHD as those that can train at Moderate Intensity."
89337850|NCT05749874|Experimental|berberine group|Berberine hydrochloride plus lifestyle intervention
89337851|NCT05749874|Placebo Comparator|placebo group|Placebo plus lifestyle intervention
89337852|NCT01250431|Experimental|EFT (Emotional Freedom Techniques)|10 sessions of EFT.
89337853|NCT01250431|No Intervention|Wait List|10 week wait period.
89337854|NCT01251679|No Intervention|Control|Control: nutrition, physical activity and smoking cessation education
89337855|NCT01251679|Experimental|Hand washing|Intervention 1: hand washing education and material
89337856|NCT01251679|Experimental|Hand washing and surgical mask|Intervention 2: hand washing education and material AND paper surgical face masks
89337857|NCT03912103|Active Comparator|Interdiciplinary medication review intervention|The clinical pharmacist perform medication review and presents medication interventions orally and written to the physician. The physician perform the changes and inform the patient about the changes. 7 days after intervention the patient receives a follow up phone call from the pharmacist about the medication interventions. If the pharmacist during the follow up phone call identify any complications due to compliance/add on/deprescribing the pharmacist uses motivational conversation to come to a solution.14 days after the beginning of the intervention the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire and measured on a Likert scale (1-5). 30 days after the beginning of the intervention the pharmacist collect an updated medication history. Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group.
89337858|NCT03912103|No Intervention|Control group|Standard treatment without a medication review and follow up related to medication changes (standard treatment).14 days after the enrollment the patients knowledge about their medication and satisfaction with medication information is investigated by a phone questionnaire measured on a Likert scale (1-5). 30 days after the enrollment the pharmacist collect an updated medication history.Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group
89337859|NCT01147861|Placebo Comparator|Placebo|Subjects will receive 2 placebo tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
89337860|NCT01147861|Other|5mg BID|Subjects will receive 1 x 5mg tablet and 1 placebo tablet in the morning, and 1 x 5mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
89337861|NCT01147861|Other|10mg QD|Subjects will receive 2 x 5mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
89337862|NCT01147861|Other|25mg BID|Subjects will receive 1 x 25mg tablet and 1 placebo tablet in the morning, and 1 x 25mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
89337863|NCT01147861|Other|50mg QD|Subjects will receive 2 x 25mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
89337864|NCT04872686|Experimental|Oral and nasal spray to moderately ill COVID-19 positive patient|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: Single
89337865|NCT04872686|Experimental|Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: hourly for 4 hours in a single day
89337866|NCT04872686|Experimental|Oral and nasal spray to healthy volunteer|Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: 3-4 times interval but not more than 4 times a day for 30 days
89337867|NCT04872686|Placebo Comparator|Oral and nasal spray by distilled water to control group|Placebo comparator: Distilled water Dosage form: Oral and Nasal spray will be provided by Distilled water
88818401|NCT01819415|No Intervention|Naive|Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.
89337868|NCT03954106|Experimental|Defibrotide|"Part 1 (lead-in phase) will evaluate a 2.5 mg/kg/dose regimen before escalating to a 6.25 mg/kg/dose regimen.~After the Safety Assessment Committee establishes the recommended phase 2 dose based on dose-limiting toxicities during Part 1, Part 2 will enroll subjects at the recommended phase 2 dose."
89337869|NCT03525444|Placebo Comparator|Placebo|Participants who received placebo matched to VX-445/TEZ/IVA for 24 weeks in the TC treatment period.
89337870|NCT03525444|Experimental|VX-445/TEZ/IVA TC|Participants who received VX-445 200 mg/TEZ 100 mg/IVA150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
89337871|NCT01250587|Experimental|PDC31|
89337872|NCT03924310|Experimental|Arm amputees|This single arm conducts all experiments. In three out of four experiments both interventions (with feedback & without feedback) are used, the fourth experiment does not allow the intervention without feedback.
89337873|NCT01251835|Active Comparator|Sitaxsentan|
89337874|NCT01251835|Experimental|Sitaxsentan plus Rifampin|
89337875|NCT03914911|Experimental|Study Arm|The radiologist will perform a routine ultrasonic guided biopsy procedure using the Smart Biopsy Device, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
89337876|NCT03632876|Active Comparator|Lower Dose Vitamin A|Subjects with SCD-SS in the lower dose Vitamin A arm receive 3000IU of retinyl palmitate daily for 8 weeks.
89337877|NCT03632876|Active Comparator|Higher Dose Vitamin A|Subjects with SCD-SS in the higher dose Vitamin A arm receive 6000IU of retinyl palmitate daily for 8 weeks.
89337878|NCT03632876|No Intervention|Healthy Comparison Arm|Healthy subjects receive no intervention and undergo comparisons to the two vitamin A supplementation arms at baseline.
89337879|NCT01250665||clinically isolated syndrome|In this study the term clinically isolated syndrome (CIS) is defined according to the Task Force on Differential Diagnosis in MS, as a monophasic presentation of neurological symptoms with suspected underlying inflammatory demyelinating disease (Miller 2008).
89337880|NCT01250665||remitting, relapsing MS|remitting relapsing MS according to the criteria by Poser (Poser 1983) or McDonald (McDonald 2001)
89337881|NCT03914755|Experimental|Cohort 1|50 mg twice daily on Days 1-13 and once daily on Day 14
89337882|NCT03914755|Experimental|Cohort 2|150 mg twice daily on Days 1-13 and once daily on Day 14
89337883|NCT03914755|Experimental|Cohort 3|300 mg twice daily on Days 1-13 and once daily on Day 14
89337884|NCT03905317|Experimental|Bevacizumab|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
89337885|NCT03487848|Experimental|Daclatasvir with Sofosbuvir|Specified dose on specified days for specified duration
89337886|NCT03914365|Active Comparator|Ultrasound-guided pudendal nerve block (PNB)|"Standard circumcision under general anaesthesia with ultrasound-guided pudendal nerve block.Pudendal nerve block patients will be positioned dorsally with the legs in the  frog  position (hips in abduction, knees flexed, sole of the feet together). An ultrasound-guided technique will be used as described previously. A linear probe will be positioned horizontally between the ischiatic tuberosity and the rectum. The ischiorectal fossa is then located between these two landmarks. Using a sterile tech-nique, an echogenic 22 gauge, 50 mm block needle will be inserted out of plane on the superior edge of the probe, midline between the ischiatic tuberosity and the rectum. After feeling two distinct fascial  clics  and confirmation of correct needle posi-tioning in the ischiorectal fossa under ultrasound, 0,2 mL/kg (max 10mL) of ropiva-caine 0,25% will be injected under real-time ultrasound-guidance after negative aspiration. The same technique will be repeated on the contralateral side."
89337887|NCT03914365|Active Comparator|Ultrasound-guided penile nerve block (DPNB)|Standard circumcision under general anaes-thesia with ultrasound-guided penile nerve block.Penile nerve block patients will be positioned in the supine position. An ultrasound-guided technique will be used as described previously. A linear probe will be placed transversely at the base of the penis while an assistant applies caudal traction to the penis. The penile neurovascular sheath is then located just above the corpus cavernosum. The dorsal penile nerve, dorsal penile artery and penile deep dorsal vein are visualized deep to Buck's fascia. Using a sterile technique, a 25 gauge, 1,5 inch needle will be inserted in-plane from lateral to medial so that the needle tip is placed into the penile neurovascular sheath, 0,1 mL/kg (max 4 mL) of ropivacaine 0,25% will be injected under real-time ultrasound guidance while retracting the needle so that the local anaesthetic solution spreads bilaterally filling the neurovascular space.
89337888|NCT05662878||Patient Group|Hemiplegic Patients
89337889|NCT05662878||Control Group|Healthy Individuals
89337890|NCT03475420||National Cancer Database|Use existing data to define surveillance strategy in use for patients in this cohort. We will use 10 randomly selected lung cancer resection patients from each accredited institution with stage I-III NSCLC (potentially curative resection) diagnosed in 2006-2007 and with 5 years of complete follow up or reported as deceased before 2012.
89337891|NCT03911635|Experimental|Hypospadias in children|Distal shaft hypospadias at age of 12 years or less
89337892|NCT03719352|Experimental|Deep dry needling|Deep dry needling will be applied in the upper trapezius myofascial trigger point
89337893|NCT03719352|Experimental|Superficial dry needling|Superficial dry needling will be applied in the upper trapezius myofascial trigger point
89337894|NCT03719352|Placebo Comparator|Placebo Gastrocnemius dry needling|A technique simulating dry needling will be applied in the gastrocnemius myofascial trigger point with a needle guard guide tube, without any therapeutic manoeuvre will be applied.
89337895|NCT01251991|Experimental|Combinatorial treatment|
89337896|NCT01251991|Active Comparator|Single treatment: Psyllium husks|
88814097|NCT00921518|Active Comparator|Sodium Bicarbonate|This arm two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
88814098|NCT02461290||Combination Therapy|Rituximab 375mg/m2, on day 1 of each cycle of chemotherapy, total of 8 infusions. Chemotherapy according to standard regimens.
88814099|NCT04376528|Experimental|Cyclosporin A|
89337897|NCT01251991|Active Comparator|Single treatment: Isolated soy protein|
89337898|NCT01251991|Placebo Comparator|Control|
89337899|NCT03719274|Experimental|non-surgical vitamin c depigmentation|locally injected vitamin c is used to depigment the hyperpigmented gingival tissues
89337900|NCT03719274|Active Comparator|surgical depigmentation|the conventional scalpel surgical technique is used to depigment the hyperpigmented gingival tissues
89337901|NCT04458454||Examination of relaxin levels|This is a pilot study of 1 group of patients. The analysis of relaxin levels in serum and follicular fluid obtained on the day of puncture of the follicles in patients undergoing treatment in the IVF protocol is carried out.
89337902|NCT03722316|Experimental|MCI/Mild Dementia|"Twenty participants will be allocated to this arm if they demonstrate mild impairments in cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
89337903|NCT03722316|Active Comparator|Healthy Older Adults|"Participants are allocated to this arm if they demonstrate healthy cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
89337904|NCT03914287|Experimental|Self-myofascial release|Each session will last approximately 15 minutes, with five physiotherapy sessions taking place over a period of 3 months. The Self-Myofascial release protocol for the lower limbs using a Foam Roller and and Solid Ball Massage, adapted to patients with hemophilic ankle arthropathy will include 11 exercises that must be administered bilaterally. A mobile application will be developed where each patient will be able to observe the exercises to be carried out.
89337905|NCT03914287|No Intervention|Control|Patients included in the control group will not receive any physiotherapy intervention. They will continue with their routine prior to the beginning of the study.
89337906|NCT03479164|Experimental|Ultra Low-Dose CT|One non-contrast gated aortic (NCGA) computer tomography scan, a low radiation, non-contrast, low cost CT based study
89337907|NCT03911947|Active Comparator|SaO2 (oxygen status)|Measurment 4 times per day, ABA (acid-bases analyses)
89337908|NCT03911947|Active Comparator|PaO2/FiO2 (respiratory index)|Measurment 4 times per day, ABA (acid-bases analyses)
89337909|NCT03911947|Active Comparator|AB (actual bicarbonat level)|Measurment 4 times per day, ABA (acid-bases analyses)
89337910|NCT03475030|No Intervention|Usual Care|Patients receive usual care and can continue using their existing pharmacy.
89337911|NCT03475030|Experimental|Smart Pillbox|Patients receive pre-filled medication trays from Curant Health Pharmacy or the Brigham and Women's Hospital Outpatient Pharmacy. The smart pillbox in which pre-filled medication trays are housed provide automated medication reminders.
89337912|NCT03524664|No Intervention|"Delayed tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
89337913|NCT03524664|Experimental|"Tuning in to kids intervention"|Children with fetal alcohol spectrum disorder and their parents
89337914|NCT03914677|Experimental|Mecamylamine Oral Tablet|Initial dose - mecamylamine 2.5 mg tablet po 3 hours prior to provocative testing; subsequent dose escalations as needed, to 5 mg and then 7.5 mg, using the same testing methodology.
89337915|NCT03474952|Experimental|Remote ischemic preconditioning (RIPC)|Intervention is remote ischemic preconditioning (RIPC) consists of 4 cycles of 5-min ischemia (using pneumatic cuff pressure of 200 mmHg) and subsequent 5-min reperfusion applied to upper arm.
89337916|NCT03474952|Sham Comparator|Control (Sham-RIPC)|Intervention is Sham-RIPC (ischemia pressure < 10 mmHg) applied to upper arm.
89337917|NCT03914131|Experimental|study group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule 3 tablets per time, 3 times per day, orally, after meals.~Dosage form:Capsule"
89337918|NCT03914131|Placebo Comparator|control group|"Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.~Dosage form:Capsule"
89337919|NCT03777826|Other|Open label (1 arm)|Open label use of study product (post-marketing): PKU Synergy
89337920|NCT03905551|Placebo Comparator|Standard Dialysis|Patients participated in a 7 months exercise trials receiving standard dialysis (at 37oC)
88814100|NCT04376528|Active Comparator|Mycophenolate Mofetil|
89337921|NCT03905551|Experimental|Cold Dialysis|Patients participated in a 7 months exercise trials receiving cold dialysis (at 35oC)
89337922|NCT03479086|Experimental|Topiramate|Topiramate 200mg/day
89337923|NCT03479086|Experimental|Naltrexone|Naltrexone 50mg/day
89337924|NCT03720054|Experimental|MapTrek|Veterans in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so veterans can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
89523583|NCT03379597|Experimental|Probiotics Group|"Probiotics add-on treatment :（live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules, Oral）, each capsule contain more then 1.0*10^7 CFU.~Bifico: 840mg Bid."
89337925|NCT03720054|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the veterans a Fitbit.
89337926|NCT01254097|Placebo Comparator|Probiotic|Participants are provided in double blinded fashion, probiotic given to take with antibiotics prescribed by their provider.
89337927|NCT01254097|Placebo Comparator|Placebo|Participants are provided in double blinded fashion, Look alike placebo given to take with antibiotics prescribed by their provider.
89337928|NCT03521908||Participants treated with apixaban|
89337929|NCT03521908||Participants treated with warfarin|
89337930|NCT05662020|Experimental|The Group of Investigational Vaccine|0.5 mL suspension for injection, each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein.
89337931|NCT05662020|Active Comparator|The Group of Active Control Vaccine|0.5-mL suspension for injection, each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein.
89337932|NCT03905395|Active Comparator|Meditation and mindfulness intervention|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
89337933|NCT03905395|No Intervention|Control group|Women in the no intervention arm will receive no introduction to meditation and mindfulness - only questionnaires at the same time as the intervention group receives questionnaires.
89337934|NCT03913897|Experimental|virtual reality group|The children in the groups were distracted by virtual reality goggles 2 minutes before venipuncture, until the process was over.
89337935|NCT03913897|Experimental|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before the blood collection, until the process was over.
89337936|NCT03913897|No Intervention|control group|No intervention was made to children in the control group
89337937|NCT03474796|Experimental|Novice|
89337938|NCT03474796|Experimental|Expert|
89337939|NCT01252069|Experimental|A|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ended by a drug free period until return of menses.
89337940|NCT01252069|Experimental|B|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets) during 3 periods each ended by a drug free period until return of menses.
89337941|NCT01252225|Active Comparator|Nebulised Lidocaine followed by Placebo throat spray|
89337942|NCT01252225|Active Comparator|Nebulised Placebo followoed by Lidocaine Throat Spray|
89337943|NCT01252225|Placebo Comparator|Nebulised placebo followed by placebo throat spray|
89337944|NCT04459780|Experimental|Group 1 : 20 subjects with plaque psoriasis|Intervention: skin biopsies and blood sample
89337945|NCT04459780|Experimental|Group 2 : 10 subjects with atopic dermatitis|Intervention: skin biopsies
89337946|NCT03914209||EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
89337947|NCT04459702|Experimental|Dual Therapy|Dual Therapy utilizing hydroxychloroquine and azithromycin.
89337948|NCT04459702|Experimental|Quadruple Therapy|Quadruple therapy utilizing hydroxychloroquine, lopinavir, ritonavir, and azithromycin
89337949|NCT01148641||LNS-regular|Lipid-based nutrient supplement, regular (peanut) flavor
89337950|NCT01148641||LNS-cinnamon|Lipid-based nutrient supplement, cinnamon flavor
89337951|NCT03911245||Patients with age equal or older than 40 years|
89337952|NCT03911245||Patients with age less than 40 years|
89337953|NCT03478774|Active Comparator|Control|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, continuous videolaryngoscopy will be performed.
89337954|NCT03478774|Experimental|High flow|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
88814101|NCT04366466|Other|suicide attempt patient who will receive sanitory supervision|The control group will establish the health monitoring
89337955|NCT03478774|Experimental|medium flow|These patients will receive oxygen 10l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
89337956|NCT03478774|Experimental|low flow|These patients will receive oxygen 2l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
89337957|NCT03478774|Experimental|minimal flow|These patients will receive a standard tracheal tubes after induction of general anesthesia, with 100% Oxygen and Minimum-flow 0.25l/min. The measurement period is 15 or 30 minutes.
89337958|NCT03905005||Pre-flexed reconstruction plate|Patients who undergo mandibular reconstruction using a pre-flexed osseosynthesis reconstruction plate along with free-tissue transfer for reconstruction of a mandibular continuity defect.
89337959|NCT03905005||Printed reconstruction plate|Patients who undergo mandibular reconstruction using a 3D-printed reconstruction plate made by selective laser melting (SLM), along with free-tissue transfer for reconstruction of a mandibular continuity defect.
89337960|NCT03574792|Active Comparator|Arm I (gabapentin, methadone, oxycodone)|Participants receive gabapentin PO daily or TID. Participants may also receive methadone PO TID and oxycodone PO every 8 hours as needed. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
89337961|NCT03574792|Experimental|Arm II (gabapentin, methadone, oxycodone, venlafaxine)|Participants receive gabapentin, methadone, and oxycodone as in Arm I and venlafaxine PO BID or venlafaxine hydrochloride extended release daily for up to 12 months in the absence of disease progression or unacceptable toxicity.
89337962|NCT03904849|Active Comparator|Cannabidiol|Cannabidiol 6 mL of 100 mg/mL cannabidiol oral solution per day for 8 days
89337963|NCT03904849|Placebo Comparator|Placebo|Placebo 6 mL oral solution per day for 8 days
89337964|NCT03471676||Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording in children suffering from neuromuscular diseases
89337965|NCT01250743|Experimental|Ascorbic Acid (Vitamin C)|
89337966|NCT03481894|Experimental|Kabiven®|Kabiven is a sterile, hypertonic emulsion in a three chamber container. The separate chambers contain either amino acids with electrolytes, dextrose, or lipid injectable emulsion.
89337967|NCT03481894|Active Comparator|Compounded standard parenteral nutrition|"The control drug will be compounded for each individual patient as prescribed by the physician. Compounding will be performed according to normal hospital procedure which meets the requirements of the United States Pharmacopeial Convention (USP) <797> Pharmaceutical Compounding-Sterile Preparations."
89337968|NCT01147237|Experimental|Single arm study|
89337969|NCT03474562|Experimental|Duowell Tab|Telmisartan 40mg/Rosuvastatin 20mg qd for 24 weeks
89337970|NCT03474562|Active Comparator|Monorova Tab + Amlopin Tab|Rosuvastatin 20mg + Amlodipine 5mg qd for 24 weeks
89337971|NCT01254175|Experimental|rHPIV3cp45 Vaccine|Participants will receive one dose of the rHPIV3cp45 vaccine at baseline and a second dose at Month 6.
89337972|NCT01254175|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of the placebo vaccine at baseline and a second dose at Month 6.
89337973|NCT03474484||np-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) and pulmonary infiltrate on chest X -ray at admission
89337974|NCT03474484||p-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) without pulmonary infiltrate on chest X -ray at admission
89337975|NCT03911479|Experimental|Bariatric Surgery Group|
89337976|NCT03911479|Other|Clinical Threatment|Convencional treatment in a public tertiary outpatients care unit
89337977|NCT03478618|Active Comparator|Group R|30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative.
89337978|NCT03478618|Active Comparator|Group L|30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative.
89337979|NCT04377620|Placebo Comparator|Placebo + Standard of Care (SoC)|Matching Placebo will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
89337980|NCT04377620|Experimental|Ruxolitinib 5mg + Standard of Care (SoC)|Ruxolitinib 5mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
89337981|NCT04377620|Experimental|Ruxolitininb 15mg + Standard of Care (SoC)|Ruxolitinib 15mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
89337982|NCT01148095|Experimental|1|AZD2516 (dose escalating)
89337983|NCT01148095|Placebo Comparator|2|Placebo
89337984|NCT03474328|Experimental|Treatment arm|
89337985|NCT03903367|Active Comparator|control|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
89337986|NCT03903367|Active Comparator|paravertebral block|Bilateral thoracic paraverteberal catheters will be inserted preoperative at level of T4 in order to block thoracic dermatomal levels from T3-T7 and 0.3ml/kg 0.25% bupivacaine bouls dose in each catheter maximum 20 ml in each catheter before induction and testing sensation bilaterally by pinprick and ice after 15-20min from injection then standard GA and after tracheal intubation continuous infusion of 0.1 ml /kg/h 0.25% bupivacaine in each catheter and stopped at the end of the operation , When HR or MBP increased ≥20% from base line readings, increamental dose of fentanyl will be given (2mcg /kg), the catheters will be removed after 24 h.
89337987|NCT02523664|Active Comparator|Hydrocortisone|10 mg hydrocortisone orally
89337988|NCT02523664|Placebo Comparator|Placebo|placebo orally
89337989|NCT01252303|Experimental|Nutrisystem|Group will receive Nutrisystem meals in addition to the behavioral weight loss program.
89337990|NCT01252303|Active Comparator|Control|Group will receive a behavioral weight loss program only.
89337991|NCT02528071||Patients|ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death
89337992|NCT02528071||Control|Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT
89337993|NCT01254253|Experimental|Group a|no severe cardiac perfusion defects
89337994|NCT01254253|Experimental|Gooup b|reversible cardiac perfusion defects
89337995|NCT01254253|Experimental|Group c|irreversible cardiac perfusion defects
89337996|NCT03905161||Myasthenia patients|Danish patients with myasthenia gravis seen at the Department of Neurology, Rigshospitalet
89337997|NCT01252381|Active Comparator|Vitamin D|
89337998|NCT01252381|Placebo Comparator|Calcium tablet|
89337999|NCT05410184|Experimental|Virtual Reality Glasses|Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device.
89338000|NCT05410184|Experimental|Mural Curtain|the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
89338001|NCT05410184|No Intervention|control group|Patients of the control group, will not receive any intervention except for applied routine hospital colonoscopy procedures.
89338002|NCT03522948|Experimental|Open pilot|The intervention is a brief, in-person motivational intervention followed by 4 weeks of text messaging to reduce heavy episodic drinking and sexual risk behavior (unprotected anal intercourse) among men-who-have-sex-with-men.
89523584|NCT03379597|No Intervention|Control Group|No probiotics or dietary fiber group.
89523585|NCT03379597|Experimental|Dietary fiber Group|Prebiotics add-on treatment: dietary fibers compound powder, 30g bid
89523586|NCT03379597|Experimental|Dietary fiber Probiotics group|Dietary fiber and probiotics group: receiving both Bifico 840mg Bid and dietary fiber 30g bid.
89338003|NCT05409014|Experimental|PFMT|The exercises of this protocol were performed at home, but with face-to-face meetings in the first phase of the protocol (awareness) and every 15 days, where the physical therapist taught the new exercises to be performed in the next phase. All protocol meetings were performed by a trained physical therapist/researcher. In situations where it was not possible to hold the meetings in person, due to the Covid-19 pandemic, they were held online through video calls with the responsible researcher. The PFMT protocol lasts for eight weeks and was divided into five phases: awareness, stabilization, strength, potency and potency complement. Each phase is 2 weeks long.
89338004|NCT03911167||RG|RG: robotic group
89338005|NCT03911167||LG|LG:laparoscopic group,
89338006|NCT03911167||OG|OG：open group
89338007|NCT03717168|Active Comparator|Recombinant human growth hormone|Patients who received growth hormone immediately after tracheostomy.
89338008|NCT03717168|Active Comparator|Control|Patients who did not receive growth hormone and followed the conventional weaning trials
89338009|NCT04722926||PJI|Patients having had a PJI
89338010|NCT03719196|Experimental|Reading glass provided|"Randomization took place after conducting the census survey. Participants were selected based on the inclusion criteria.~423 random households were surveyed at the baseline. These households have been given reading glasses free of cost."
89338011|NCT03719196|No Intervention|Non-reading glass|A total of 824 households were surveyed at the baseline survey. Among them, 423 households have been provided reading glasses. The 401 remaining households were not given reading glasses during the baseline survey. The endline survey will be conducted in March 2018. Upon completing the endline survey, the non-reading glasses group will be provided reading glasses.
89338012|NCT03406078|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
89338013|NCT03406078|Placebo Comparator|Placebo|Placebo subcutaneous injection
89338014|NCT03719898|Experimental|Brigatinib|90 mg daily orally for 7 days, then 180 mg daily orally during first cycle; 180 daily orally thereafter during every subsequent cycle. Each cycle has 28 days
89338015|NCT03719118|Experimental|Genotyping group|The patients undergo pretreatment of genotyping for three genes (TPMT, NUDT15 and FTO)
89338016|NCT03719118|Active Comparator|Non-genotyping group|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping.
89338017|NCT04713020|Experimental|Effectiveness of Application Education Intervention|This study hopes that through the intervention of mobile device education programs, it can provide patients with easy access and repeated viewing and learning. It can replace traditional leaflet health education and reduce the workload of clinical nurses. It is hoped that it can effectively improve the self-care knowledge of stroke patients, improve self-efficacy, reduce the symptoms of depression, and increase the satisfaction of education and guidance. Eventually, patients can be prevented from recurring from stroke, and they can coexist peacefully with stroke and have a good quality of life.
89338018|NCT04713020|Other|genaral care|Give patients routine care
89338019|NCT03717090||Patients with PJI|
89338020|NCT03634033|Experimental|MiCAP with IF (Main Study)|MiCAP with Internal Facilitation will receive MiCAP (implementation strategies). Internal facilitators will be waiver site clinicians with exemplary clinical practice and/or supervisory experience, who are expected to be early adopters of CAPABLE; and will be selected by their supervisors.
89338021|NCT03634033|Experimental|MiCAP with IF and EF (Main Study)|MiCAP with Internal Facilitation and External Facilitation will receive MiCAP (implementation strategies) and the addition of external facilitation. The external facilitators will be Super-Champion waiver program site clinicians from prior work who were trained and early adopters of CAPABLE; and will be selected by the research team to perform external facilitation.
89338022|NCT00708448|Experimental|All patients|All participants enrolled.
89338023|NCT05597384|Experimental|Autologous Blood Marker Group|The tattooing was performed at 24-48 hours before the surgery. When the lesion was identified by endoscopy, 2-3 ml of the patient's peripheral venous blood without heparin preparation were injected submucosally at the distal side and proximal side of the lesion using a conventional endoscopic needle without submucosal injection of normal saline.
89338024|NCT05597384|Active Comparator|Intraoperative colonoscopy group|Under general anesthesia with endotracheal intubation, the patient was placed in the modified lithotomy position. After routine laparoscopic exploration, CO2-insufflated intraoperative colonoscopy was performed using a flexible videocolonoscope. Upstream small bowel clamping was applied before intraoperative colonoscopy. During intraoperative colonoscopy, CO2 pneumoperitoneum was maintained by the insufflator so that the laparoscope could guide the colonoscope effectively.
89338025|NCT02892604|Experimental|insulin delivery driven by inControl|"Closed-loop insulin delivery using inControl AP system is assessed for two weeks, 24/7.~Connection of continuous glucose monitoring (CGM) system and insulin pump to inControl AP platform, all wireless and wearable, in free-life conditions Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data."
89338026|NCT03478306|Active Comparator|Arm 1|Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
89338027|NCT03478306|Placebo Comparator|Arm 2|Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
89338028|NCT03103100|Active Comparator|1% Lidocaine|Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine
89338029|NCT03103100|Active Comparator|0.25% Bupivacaine|Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine
89338030|NCT03103100|Active Comparator|Bupivacaine plus Lidocaine|Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.
89338031|NCT03903601||Ischemic changes|Patients with ischemic changes in the brain diagnosed by MRI
89338032|NCT03903601||No ischemic changes|Patients without ischemic changes in the brain diagnosed by MRI
89338033|NCT05233904|Active Comparator|Standard of Care|Patients will be booked for CT simulation and treatment as per the local institution's standard practice.
89338034|NCT05233904|Experimental|Experimental Treatment Workflow|Patients do not require a CT simulation appointment. A radiation treatment appointment will be scheduled on an optical surface guidance-equipped treatment unit as soon as available, but a minimum of 24 hours is required between EBAF processing and fraction 1.
89338035|NCT01148719|Active Comparator|Index group|Patients in the index group receive the diagnostic triage instrument. This includes echocardiographic, electrocardiographic and spirometric measurements and blood testing.
89338036|NCT01148719|No Intervention|Control|Participants receive care as usual.
89338037|NCT05182814|Placebo Comparator|Placebo drink|
89338038|NCT05182814|Experimental|Collagen drink|
89338039|NCT03438006||Cervarix group|Healthy female Chinese subjects aged between 9 and 45 years, vaccinated according to the Prescribing Information (PI) as per routine practice.
89338040|NCT04233632|Active Comparator|FC2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit.
89338041|NCT04233632|Active Comparator|Cupid Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
89338042|NCT04233632|Active Comparator|Cupid 2 Condom|Participants will be randomized to either of the 3 groups and provided with their randomized method at enrolment and at each follow up visit until the final visit
89338043|NCT03131128|Experimental|Mindfulness-based Intervention|2 sessions of diet nutrition education and 6 sessions of Mindfulness-based intervention, 1.5 hours each session.
89338044|NCT03131128|Active Comparator|Health Education Intervention|2 sessions of diet nutrition education and 6 sessions of Health Education, 1.5 hours each session.
89338045|NCT03910855|Experimental|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
89338046|NCT03910855|Active Comparator|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
89338047|NCT03130894||Healthy control|A FPG concentration < 6.1 mmol/l, and a 2-h oral glucose tolerance test (OGTT) plasma glucose concentration < 7.8 mmol/l was considered normal glucose tolerance.
89338048|NCT03130894||Type 2 diabetes|Type 2 diabetes was diagnosed when fasting plasma glucose (FPG) ≥ 7.0 mmol/l, and/or 2-h post-glucose load ≥ 11.1 mmol/l.
89338049|NCT03639168|Experimental|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 25mg/m2 ivgtt D1-3 Chidamide :20mg PO Biw, 2 week on , 1 week off
89338050|NCT01148797|Experimental|Canakinumab|
89338051|NCT03131050|Experimental|High-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
89338052|NCT03131050|Experimental|Low-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) QD; placebo (1 ml saline, i.m.) QD; escitalopram （10 mg/d p.o.）QD
89338053|NCT03131050|Placebo Comparator|Placebo add-on therapy|Placebo (1 ml saline, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
89338054|NCT03719820||Intracranial Atherosclerosis|First-ever stroke patients attributed to intracranial artery stenosis (> 50% or occlusion) who receive aggressive medical management
89338055|NCT04206020|Placebo Comparator|Placebo Comparator: SkQ1 Vehicle|Vehicle for SkQ1 Ophthalmic Solution
89338056|NCT04206020|Active Comparator|SkQ1|SkQ1 Ophthalmic Solution
89338057|NCT03910699|Active Comparator|Two-row anastomosis|Colorectal anastomosis is created with a two-row circular surgical stapler
89338058|NCT03910699|Experimental|Three-row anastomosis|Colorectal anastomosis is created with a three-row circular surgical stapler
89338059|NCT03478228|Experimental|Multi-Sensory Training (MST)|Multi-Sensory Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
89338060|NCT03478228|Active Comparator|Wrist Stabilisation Training (WT)|Wrist Stabilisation Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
89338061|NCT03902899|Experimental|Intervention-arm|"All endoscopists employed by 9 semi-randomly chosen hospitals in the Netherlands will be exposed to an educational intervention (oral presentation): an oral awareness training which will be delivered twice, first in 2014 and then in 2016/2017.~In total 38 endoscopists are included from these 9 hospitals."
89338062|NCT03902899|No Intervention|Control arm|A random set of 100 endoscopists will be selected ass a reference group. These 100 endoscopists were unaware of the present study, and were thus blinded for their allocation.
89338063|NCT03466086|Experimental|Test/Control|Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order
89338064|NCT03466086|Experimental|Control/Test|Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.
89338065|NCT05632952||A|120 patients affected by Incisional Hernia with size between 3 to 10 cm, undergoing Intraperitoneal Onlay Mesh with the closure of defect
89338066|NCT01252459|Experimental|Arm A: AA-PET based target volume delineation|Experimental intervention (Arm A): High-precision re-irradiation. Target volume delineation based on AA-PET.
89338067|NCT01252459|Active Comparator|Arm B: T1Gd-MRI based target volume delineation|Control intervention (Arm B): High-precision re-irradiation. Target volume delineation based on T1Gd-MRI.
89338068|NCT03719742|Experimental|Sponsor Test Products|"Baby Bee Foaming Cleanser(at least once daily)~BB Baby Ultra Gentle Lotion (twice daily)"
89338069|NCT04963010|No Intervention|standard withdrawal colonoscopy|Observation of conventional colonoscopy
89338070|NCT04963010|Experimental|second forward view|second forward view examination of the proximal colon
89338071|NCT03718962|Active Comparator|needling|needling + phototherapy
89338072|NCT03718962|Placebo Comparator|phototherapy|phototherapy
89338073|NCT01254799|Placebo Comparator|Placebo|Women in this arm will receive identical Placebo capsules twice daily for 5 days
89338074|NCT01254799|Active Comparator|Doxycycline|Women in this arm will receive 100 mg doxycycline capsules twice daily for 5 days
89338075|NCT05548010||Subjects|Patients >18years old with scheduled operation
89338076|NCT05548010||Healthcare Professionals (HCP)|HCP of the enrolled subjects
89338077|NCT03718806|Experimental|Regimen A|3 g zoliflodacin oral suspension; oral administration after an overnight fast
89338078|NCT03718806|Experimental|Regimen B|3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
89338079|NCT03718806|Experimental|Regimen C|4 g zoliflodacin oral suspension; oral administration after an overnight fast
89338080|NCT03718806|Experimental|Regimen D|4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
88814102|NCT04366466|Experimental|Suicide attempt patient who will participate to PEPS Program|The intervention group will test the program of Promotion of Commitment to Care for the Prevention of Suicidal Recidivism.
89338081|NCT03911011|Active Comparator|Fresh air|2 litres of fresh air
89338082|NCT03911011|No Intervention|no fresh air|no supply of fresh air
89338083|NCT03716856|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
89338084|NCT01149187||IGRA in solitary pulmonary nodules|Inpatients who undergo percutaneous needle biopsy for diagnosis of pulmonary nodules in Seoul National University hospital for six months are going to be included. Patients who are not tolerable for PCNB or do not agree the enrollment of study will be excluded.
89338085|NCT03902977|Experimental|Arm A|quilting
89338086|NCT03902977|Active Comparator|Arm B|conventional suture
89338087|NCT04024904|No Intervention|control group|In the control group, the patient received the standard pharmacologic intravenous sedation before the regional anaesthesia (2 mg midazolam + 5 µg de sufentanil) without VRHD (Virtual Reality Hypnosis Distraction).
89338088|NCT04024904|Experimental|VRHD1|In the study group VRHD (Virtual Reality Hypnosis Distraction) 1, the patient received the VHRD technique during the peripheral nerve block and received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
89338089|NCT04024904|Experimental|VRHD2|In the study group VRHD (Virtual Reality Hypnosis Distraction) 2, the patient received the VHRD technique for the first time before the regional procedure and a second time during the peripheral nerve block. The patient received a pharmacologic intravenous sedation only if the patient's asked for it or if the patient shows some discomfort (behavioural pain scale score >3).
89338090|NCT03904459||cases|Children with juvenile idiopathic arthritis
89338091|NCT03904459||controls|healthy children
89338092|NCT03910543|Experimental|Patients with Cutaneous Sarcoidosis|Patients with cutaneous sarcoidosis that may also have also have internal organ sarcoidosis
89338093|NCT03910543|Experimental|Patients with Granuloma Annulare|Patients with granuloma annulare that is long-standing and/or widespread
89338094|NCT01148953|Active Comparator|ALN-TTR01|
89338095|NCT01148953|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
89338096|NCT03101462|Active Comparator|Group 1|One dose of 0.5 mL Licensed Inactivated Influenza Vaccine (IIV) on Day 0
89338097|NCT03101462|Active Comparator|Group 2|One dose of 0.5 mL Licensed Live Attenuated Influenza Vaccine (LAIV) on Day 0
89338098|NCT03902587||Cervical Elastography|During each sonogram in which cervical lengths are measured, 5 additional cervical indices will be collected using Samsung's E-cervix technology. Each index will then be separated based on characteristics to create a nomogram for singletons, twins, and those with interventions already in place (i.e. cerclage and/or progesterone) at the time of their E-cervix assessment.
89338099|NCT01252537||Initiation of antituberculosis therapy|Patients initiating treatment for tuberculosis with and without HIV co-infection in primary health care centres in Ethiopia
89338100|NCT01254955||organ transplant patients|
89338101|NCT01254955||healthy controls|
89338102|NCT03910309||1 or 2 level TLIF candidates|Any subject determined to ALREADY be a candidate for 1 or 2 level transforaminal interbody fusion surgery
89338103|NCT03904537|Experimental|PD1-TIL combined with chemotherapy|Participants would received anti-PD-1 antibody-activated TILs after the final adjuvant chemotherapy.
89338104|NCT04505384|Experimental|Left bundle branch pacing|Left bundle branch pacing
89338105|NCT04505384|Active Comparator|Biventricular pacing|Biventricular pacing
89338106|NCT03904303|Experimental|Geloprep|Novel and patented Polyethylene glycol 3350 mixture
89338107|NCT03904303|Active Comparator|Moviprep|Standard of care Polyethylene glycol 3350 mixture
89338108|NCT03902665|Experimental|Allogeneic hematopoietic stem cell transplantation|Day -6, -5 Thiotepa 5 mg/kg/day . Day -4 to -3 Busulfan i. v 3,2 mg/kg/day and fludarabine i.v. 50 mg/m2 /day Day -2 fludarabine i.v. 50 mg/m2 Day -1 Rest Day 0 Begin cyclosporine; Infusion of T cell replete bone marrow transplant Day 1 Begin mycophenolate mofetil Day 3 and 5 Cyclophosphamide 50 mg/kg IV and Mesna Day 6 G-colony stimulating factor
89338109|NCT01149265|Experimental|Online support group|
89338110|NCT01149265|Active Comparator|Expressive writing|
89338111|NCT01252615|Experimental|patient only|Patient with the ICD is involved in the intervention
89338112|NCT01252615|Experimental|patient and partner|patient with the ICD and intimate partner are involved in the intervention
89338113|NCT03902275|Experimental|Quantra|Evaluation of bloodsamples using the Quantra and Multiplate device
89338114|NCT03902275|Active Comparator|Control|Evaluation of bloodsamples using the ROTEM and Multiplate device
89338115|NCT03902743|Experimental|Intervention group|Participants will receive an Anticipatory Care Plan
89338116|NCT03902743|No Intervention|Control group|Usual care
89338117|NCT03903913|Experimental|Dose Escalation Study|"Subjects will receive up to three inhaled doses of S- 1226. Each dose will be administered over a 2-minute treatment period (with a minimum 2-minute break between treatments) with a nebulizer as follows.~Three S-1226 formulations will be tested sequentially:~S-1226(4%) is composed of 3 mL PFOB and 4% CO2~S-1226(8%) is composed of 3 mL PFOB and 8% CO2~S-1226(12%) is composed of 3 mL PFOB and 12% CO2~Each formulation will be administered by inhalation for a period of 2 minutes.The nebulizer will be filled with 3 mL of PFOB. The nebulizer is connected to a compressed medical gas mixture consisting of either 4%, 8% or 12%, CO2. A driving pressure of 20 psi will be used, producing a gas flow rate of 9 L/min."
89523587|NCT05173909|Experimental|group H|BIS closed-loop target controlled infusion group with BIS value of 55
89338118|NCT03903913|Experimental|Daily Dosing Study|"Eligible subjects will receive S-1226 twice daily for 5 consecutive days. Subjects will receive up to three doses of S-1226 in the morning and afternoon, administered over three 2-minute periods with a Circulaire nebulizer, filled with one of the dosages outlined below, depending on the safety and tolerability data gathered from the dose escalation study for that particular subject.~S-1226(4%) is composed of 3 mL PFOB and 4% CO2~S-1226(8%) is composed of 3 mL PFOB and 8% CO2~S-1226(12%) is composed of 3 mL PFOB and 12% CO2"
89338119|NCT03903991||Thoracotomy|All patients needing pulmonary surgery under thoracotomy
89338120|NCT01252771|Experimental|PKM report and algorithm|Phosphate kinetic modeling was performed and displayed in graphical form laboratory results and an estimated phophorus protein ratio
89338121|NCT03904225|Experimental|tegio|Tegio 60mg bid d1-28 q6wks was administered until disease progression, unacceptable toxicity,or over 12monthes within 3monthes after curative chemoradiation
89338122|NCT03904225|No Intervention|control|patients was oberved
89338123|NCT01149031|Active Comparator|low level laser therapy, using a probe|"The treatment will be done by using a LLL-probe touching several areas of the vulvar vestibule, according to the selected protocol.~Every patient will be treated twice weekly for 6 weeks."
89338124|NCT01149031|Placebo Comparator|Placebo|The patients will be treated with placebo-probe, according to the same protocol
89338125|NCT03910231|Placebo Comparator|Placebo|Placebo
89338126|NCT03910231|Experimental|15mg Tolvaptan|15mg Tolvaptan
89338127|NCT03910231|Experimental|30mg Tolvaptan|30mg Tolvaptan
89338128|NCT03902353|Other|Adults without diagnosis of PH|Adults without diagnosis of PH carrying an heterozygous EIF2AK4
89338129|NCT03902197|Experimental|CD19 hsCAR-T|This cohort will be administrated by T cells transduced with lentivirus vectors expressing CD19 hsCAR
89338130|NCT01255033||Pulmonary surgical patients|Patients submitted for scheduled lung surgery requiring one-lung ventilation
89338131|NCT02527915|Experimental|Mental Health eConsults|Primary care clinics that will receive the eConsults intervention at the start of the study.
89338132|NCT02527915|Active Comparator|Usual care|"Primary care clinics that will deliver care as usual for nine months, and will receive the eConsults intervention nine months subsequent to the eConsults intervention clinics."
89338133|NCT03902119|Experimental|INIBY tool|Patients will undergo a single treatment session consisting of applying a suboccipital muscle inhibition technique using the so-called INYBI tool. The treatment session will last approximately 5 minutes
89338134|NCT03902119|Active Comparator|Manual suboccipital inhibition|Patients will receive a single treatment session consisting of the use of the manual suboccipital muscles inhibition technique.The treatment session will last approximately 5 minutes
89338135|NCT03901885|Other|Major women operated for deep endometriosis|Major women operated for deep endometriosis at the Lyon Sud Hospital Center (CHLS) of the Hospices Civils de Lyon (HCL).
89338136|NCT01149109|Experimental|lomustine (CCNU) + temozolomide (TMZ) and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day
89338137|NCT01149109|Active Comparator|temozolomide and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2
89338138|NCT03903757||Obese subjects with and without T2D|
89338139|NCT03903757||control subjects|
89338140|NCT03903679|Active Comparator|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway supreme during the septal surgery.
89338141|NCT03903679|Sham Comparator|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
89338142|NCT03902041||Treatment Group|The patients will receive Eltrombopag treatment after transplantation at d1.
89338143|NCT03902041||Control Group|The patients will not receive Eltrombopag treatment after transplantation.
89338144|NCT05667415|Experimental|disulfiram and cisplatin|Cisplatin combined with disulfiram chemotherapy
89338145|NCT05667415|Active Comparator|standard cisplatin|Cisplatin chemotherapy alone
89338146|NCT03903445|Experimental|MaPa Kids|"Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids) Parenting training for parents of children aged 2-9~Program length: 8 consecutive weekly sessions~Incentive: PHP 500 or approximately £7 per participant~Participants: N=15 per group"
89338147|NCT03903445|Experimental|MaPa Teens|"Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens) Parenting training for parents of children aged 10-17~Program length: 9 consecutive weekly sessions~Adult Incentive: PHP 500 or approximately £7 per participant~Child incentive: PHP 300 or approximately £4 per participant~Participants: N=15 per group"
89338148|NCT01586143|Experimental|transbuccal paracetamol 125 mg|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
89338149|NCT01586143|Placebo Comparator|placebo|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
89338150|NCT03909841||DM|DM without DPN (Diabetic Peripheral Neuropathy)
89338151|NCT03909841||DPN|DM with DPN (Diabetic Peripheral Neuropathy)
89338152|NCT03909841||DPN-P|DM with DPN-P (Diabetic Peripheral Neuropathic Pain)
89523588|NCT05173909|Experimental|group L|BIS closed-loop target controlled infusion group with BIS value of 45
89523589|NCT03379519|Experimental|Multi-domain Attention Training (MAT)|Training sessions of the MAT group is 45 minutes/day, 3 sessions/week, for 12 weeks (36 sessions).
89338153|NCT01252927|Experimental|ASIST intervention|The gatekeeper training intervention group received the Applied Suicide Intervention Skills Training (ASIST) 10.0 in addition to TAU. ASIST is a two-day (fourteen hour), intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The intervention was offered to students on a weekend and was conducted by three senior ASIST trainers and one junior trainer, with two trainers assigned to each training group.
89338154|NCT01252927|No Intervention|Control group: training as usual|Training as usual consisted of didactic teaching and a tutorial with case-based examples around suicide risk factors in their first year of medical school. Third- and fourth-year students may also have the opportunity to practice their skills with real patients during their clerkship rotations or in the emergency department.
89338155|NCT01256359|Experimental|Docetaxel and AZD6244|Docetaxel with AZD6244
89338156|NCT01256359|Experimental|Docetaxel and Placebo|Docetaxel without AZD6244
89338157|NCT01256437|Experimental|ointment Threolone|Treatment with topical application of combined anti inflammatory and anti bacterial agent.
89338158|NCT01256437|Active Comparator|ointment Synthomycine|ointment once daily for 1 month
89338159|NCT01256437|Placebo Comparator|Aqua cream|
89338160|NCT02873936|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
89338161|NCT02873936|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + stable dose of permitted csDMARD(s)
89338162|NCT02873936|Placebo Comparator|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
89338163|NCT03901651|Active Comparator|Standard colonoscopy|"Patients submitted for screening, surveillance or diagnostic colonoscopy. A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location. Polyps will be removed before the second procedure."
89338164|NCT03901651|Experimental|Retroview colonoscopy|"The same group of patients. A second colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the first colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
89338165|NCT02527993|Experimental|Glucobay|Tablet Glucobay (acarbose) 50 mg x 6 daily for 7 days.
89338166|NCT02527993|Experimental|Januvia|Tablet Januvia (sitagliptin) 100 mg orally O.D for 7 days.
89338167|NCT02527993|Experimental|Verapamil|Tablet Verapamil 120 mg orally O.D for 7 days.
89338168|NCT02527993|Experimental|Victoza|Subcutaneous injection of Victoza (liraglutide) 0,6-1,2 mg O.D for three weeks.
89338169|NCT02527993|Experimental|Signifor|Subcutaneous injection of Signifor (pasireotide) 300 µg as a single dose prior to a meal tolerance test.
89338170|NCT03901417|Active Comparator|Non-ablative Fractional Laser|Non-ablative fractional laser (brand name Fraxel Restore) only on one half of the face.
89338171|NCT03901417|Active Comparator|Non-ablative Fractional Laser Plus Microneedling|Non-ablative fractional laser (brand name Fraxel Restore) in combination with a microneedling device (SkinPen) on the other half of the face.
89338172|NCT03901495|Experimental|Diaana|"The patient fullfill Diaana~The resident physician takes connaissance of the Diaana summary~The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)~The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
89338173|NCT03901495|No Intervention|Control|"The resident physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)~The senior physician see the patient in consultation. He establishes his DD without having access to the complementay exams (blood tests, x-ray, ...)"
89338174|NCT01256515|Experimental|Health Education Training Group 1|One form of health education training
89338175|NCT01256515|Active Comparator|Health Education Training Group 2|Another form of health education training
89338176|NCT03909373||Cohort|patients with carpal tunnel syndrome
89338177|NCT01253239||TECNIS/ReZoom|Patients who received a TECNIS multifocal IOL in one eye and a ReZoom multifocal IOL in the opposite eye.
89338178|NCT01253239||TECNIS/TECNIS|Patients who received TECNIS multifocal IOLs in both eyes
89338179|NCT01150435||Maintenance Medication D, S- Methadon|
89338180|NCT01150435||Maintenance Medication S- Methadon|
89338181|NCT01150435||Buprenorphine|
89338182|NCT01150435||Buprenorphine+ Naloxone|
89338183|NCT01150513|Active Comparator|EC-T|
89338184|NCT01150513|Experimental|TP|
89338185|NCT03908983|Experimental|Implanted Patients|Implantation of Kalios Device
89338186|NCT03908827|Experimental|Active BMAC treatment|60 mL of bone marrow will be aspirated from the iliac crest of each subject in the active treatment group. The bone marrow aspirate (BMA) will be centrifuged using a single spin protocol such that the red blood cells are minimized and the total nucleated and platelet cells are concentrated into a 12 mL volume of bone marrow aspirate concentrate (BMAC).
89338187|NCT03908827|No Intervention|Wait List Control|Participants will continue with their usual treatment, inclusive of medications or conservative treatments and will continue with activity guidelines as previously provided by clinical staff whilst awaiting joint arthroplasty
89338188|NCT05416502||Passage Observed|Enrolled patients whose stone and ureter diameters are obtained and their stone passage was successful during the follow-up.
89338189|NCT05416502||Passage Not Observed|Enrolled patients whose stone and ureter diameters are obtained and their stone passage was not successful during the follow-up.
89523590|NCT03379519|Active Comparator|Passive information activities (PIA)|The training sessions of PIA is the same as MAT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions).
88818402|NCT01819415|Active Comparator|Anti-VEGF plus AREDS-1 supplementation.|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.
89523591|NCT05173363||Older adults with frailty and mild cognitive impairment|
89523592|NCT03379441|Experimental|Experimental|"Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week cycle until:~PD,~unacceptable toxicity,~investigator choice,~patients IC withdrawal,~up to a maximum of 24 months (35 administrations) Experimental"
89338190|NCT03898141|Experimental|Animal-assisted placebo condition (AAPL)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream.~Additionally, they will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high de-gree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Therefore, the distance between participant and dog will always be the same. However, partici-pants will still be able to see the dog."
89338191|NCT03898141|Placebo Comparator|Placebo only (PO)|"Participants will receive verbal information that they are receiving an analgesic cream (i.e. Anti-dolor, containing Lidocain ), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
89338192|NCT03898141|Experimental|Dog only (DO)|"Participants will be told that a dog will be present during the experiment to examine whether animals can be present during experimental studies or if they are too big of a distraction. Prior to the pain assessment, participants are allowed to greet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. During the experiment the dog will be lying in the room with some distance to avoid further physical interaction.~After the introduction of the dog, participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements"
89338193|NCT03898141|No Intervention|No dog, no placebo (ND)|Participants will participant will have the verbal information that the applied cream only moisturizes the skin to allow accurate pain measurements.
89338194|NCT03901027|Experimental|Parents of children with chronic illnesses|psycho-educational intervention for parents
89338195|NCT01149499|Experimental|Valacyclovir|Test 1000 mg Valacyclovir Tablet
89338196|NCT01149499|Active Comparator|Valtrex|Reference Listed 1000 mg Valtrex Tablet
89338197|NCT04919798|Experimental|Urinating with NIBED first, without NIBED second|Urinating with NIBED first, without NIBED second
89338198|NCT04919798|Experimental|Urinating without NIBED first, with NIBED second|Urinating without NIBED first, with NIBED second
89338199|NCT03900871|Experimental|Experimental group|
89338200|NCT03900871|Placebo Comparator|Control group|
89338201|NCT01149577|Experimental|Schizophrenia patients|The study population of 25 schizophrenia patients constituted the active arm of the study.
89338202|NCT01150669||Observational|Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model.
89338203|NCT03894007|Experimental|A: Experimental|"Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide + atezolizumab. In total seven courses of preoperative treatment. Response evaluations after course four.~Postoperatively, if pathologic complete response, patients receive 14 courses of adjuvant trastuzumab every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
89338204|NCT03894007|Active Comparator|B: Standard|"Four courses of docetaxel or paclitaxel + carboplatin + trastuzumab sc + pertuzumab given every third week followed by three courses of epirubicin + cyclophosphamide. In total seven courses of preoperative treatment. Response evaluations after course four.~Postoperatively, if pathologic complete response patients receive 14 courses of adjuvant trastuzumab (combined with pertuzumab in case of high-risk disease features) every third week. If no pCR patients receive 14 courses of T-DM1 every third week."
89338205|NCT01150747||Risk of positive chlamydia|"current, untreated endocervical C. trachomatis infection~mucopurulent cervicitis on pelvic examination~Sexual contact with a male partner recently diagnosed with C. trachomatis, and/or non-gonococcal urethritis"
89338206|NCT01150825||STEMI|Patients with ST segment elevation myocardial infarction, verified by elevated troponin levels
89338207|NCT01150825||NSTEMI|Patients with non-ST segment elevation myocardial infarction, verified by elevated levels of troponin
89338208|NCT01255189|Experimental|Device: near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements
89338209|NCT03900481|Experimental|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive
89338210|NCT05416034|Experimental|Use of the ATLAS 2030 exoskeleton at home|Children with Spinal Muscular Atrophy Type II will received robot assisted gait therapy with the ATLAS 2030 exoskeleton at their homes 5 days a week during two months in 60 minutes sessions
89338211|NCT03900559|Experimental|"NO-FEAR Airlines program with still images"|"Intervention group that uses NO-FEAR Airlines program with still images to carry out the exposure."
89338212|NCT03900559|Experimental|"NO-FEAR Airlines program with still and navigable images"|"Intervention group that uses NO-FEAR Airlines program with still and navigable images to carry out the exposure."
89338213|NCT03900559|No Intervention|Waiting list control group|"Participants of this group are able to access NO-FEAR Airlines program after 6 weeks of waiting period.~After that period, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (only still images or still + navigable images)."
89523593|NCT03379441|No Intervention|Observation|
89338214|NCT04811066|Experimental|Anodal tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
89338215|NCT04811066|Experimental|Cathodal tDCS|Cathodal electrode (35 cm2 sponge electrode) placed over C3. Anodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
89338216|NCT04811066|Sham Comparator|Sham tDCS|Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. Stimulation was phased in for 30 seconds up to 2 mA and then switched off. Stimulation was again phased in for 30 seconds following 20 minutes of no stimulation.
89338217|NCT03900325|Experimental|Nimacimab|2.5 mg/kg
89338218|NCT03900325|Placebo Comparator|Placebo|0.9% sodium chloride
89338219|NCT01255267||Acute coronary syndrome patients|
89338220|NCT01255267||Chronic coronary artery disease patients|
89338221|NCT01255267||Healthy control|
89338222|NCT01258309|Experimental|1|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
89338223|NCT01258309|Active Comparator|2|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
89338224|NCT03893851|Experimental|ICC-T|Interactions Competencies with Children - for Teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
89338225|NCT03893851|No Intervention|Control|The control schools do not receive any intervention
89338226|NCT01256827||ranibizumab in MARINA/ANCHOR|Exudative AMD patients previously enrolled in the ranibizumab treatment arms of the MARINA or ANCHOR studies with subsequent enrollment into the HORIZON extension study.
89338227|NCT01256905|Experimental|Armodafinil|
89338228|NCT03900091||Cases with clinical meningitis|Patients aged 0-12 years with suspected CNS infection, at the pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda.
89338229|NCT03900091||Control subjects|Patients aged 0-12 years, visiting the outpatient pediatric clinics at Mbarara Regional Referral Hospital or Holy Innocents Children's Hospital, Mbarara, Uganda, with fever clinically considered non-severe.
89338230|NCT05667337|Experimental|CLP-PEG-MPC DALK|Subjects having successfully undergone implantation of CLP-PEG-MPC implant using DALK technique
89338231|NCT05667337|Active Comparator|HDC PKP|Subjects having undergone DALK conversion to PKP using a human donor cornea tissue
89338232|NCT01151839|Active Comparator|Surgery Alone|
89338233|NCT01151839|Active Comparator|Neoadjuvant chemoradiation followed by surgery|
89338234|NCT03900013|Experimental|Injectable Platelet Rich Fibrin (i-PRF) with DFDBA|"In i-PRF assigned group, 10 cc of blood per intraosseous defect will be collected right after administering the anaesthesia and will be processed according to the technique proposed by Choukroun et al., 2017 (centrifuged at 700 rpm, for 2-3 minutes). The yellow part will be collected using a syringe and added to a cup that contains the bone grafting material.~The i-PRF consolidated bone graft will placed into the intraosseous defect."
89338235|NCT03900013|Active Comparator|Demineralized Freeze-Dried Bone Allograft (DFDBA) alone|After debridement and intraoperative recordings, in the control group, the bone graft material will be placed in the intraosseous defect without overfilling.
89338236|NCT03893227||Patients|Patients with chronic upper airway inflammation
89338237|NCT03893227||Healthy control|Healthy controls without chronic upper airway inflammation
89338238|NCT03899935||Group A: obese patients|Obese patients undergoing laparoscopic surgery for endometriosis
89338239|NCT03899935||Group B: non-obese patients|Non-obese patients undergoing laparoscopy for endometriosis
89338240|NCT01586299|Experimental|ibuprofen|
89338241|NCT01586299|Active Comparator|acetaminophen|
89338242|NCT01257061|Experimental|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g
89338243|NCT01257061|Active Comparator|Group 2|Dexchlorpheniramine maleate 10 mg/g
89338244|NCT01151917||Bilio-pancreatic diversion|Each subject is own control
89338245|NCT01149811||Fipamezole ODT Cohort 1|
89338246|NCT01149811||Fipamezole ODT Cohort 2|
89338247|NCT05099809||Hyperthermia|"Patients with locally advanced cancers reporting to Department of Radiotherapy at MGIMS who fulfil the eligibility criteria would be included in the study. Depending on the ongoing departmental protocols for various tumors the patients could be treated with either:~Radiotherapy and Hyperthermia~Concurrent chemoradiotherapy and hyperthermia~Neoadjuvant chemotherapy and hyperthermia followed by surgery and/or radiotherapy Hyperthermia would be delivered using a shortwave diathermy unit operating at 27.1 MHz.~Tumour response would be evaluated using RECIST criteria 1.1 while the acute and late morbidities would be scored as per CTCAE v5.0 guidelines. Outcome measures for each site would be undertaken and evaluated in terms of~Locoregional disease control~Disease free survival~Overall Survival~Acute morbidity~Late morbidity"
89338248|NCT02874794|Experimental|LCZ696 (sacubitril/valsartan)|minimum dose: 24/26mg, BID, oral, tablet maximum dose: 97/103mg, BID, oral, tablet All patients will begin on Dose Level 1 (24/26mg) and will be titrated every two weeks to target Dose level 3 (97/103mg). LCZ696 tablets will be provided for the 12-week open label extension.
88814103|NCT02461134|Experimental|Ponesimod|Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.
89338249|NCT02874794|Active Comparator|Enalapril|minimum dose: 2.5mg, BID, oral, tablet maximum dose: 10 mg, BID, oral tablet All patients will begin on Dose Level 1 (2.5mg) and will be titrated every two weeks to target Dose level 3 (10mg).
89338250|NCT01149889|Experimental|active stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
89338251|NCT03897283|Experimental|Anlotinib + TQB2450|TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89338252|NCT01258465|Active Comparator|Pivotal Response Training|A naturalistic behavioral intervention designed to facilitate verbal communication.
89338253|NCT01258465|Active Comparator|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to facilitate communication via picture icons.
89338254|NCT03897517|Experimental|Proprietary Botanical Blend|Proprietary Botanical Blend - Dietary supplement with alpha amylase and sucrase inhibitory activity. 2 capsules
89338255|NCT03897517|Placebo Comparator|Placebo|Non/minimally nutritive nonactive material: rice flour. 2 capsules
89338256|NCT04776902|Other|Study Group|All patients will be enrolled in one arm
89338257|NCT03900169||Stemi patient|Stemi patient who underwent Ppci
89338258|NCT03899779|Active Comparator|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
89338259|NCT03899779|Experimental|Online hypnotherapy|12 weeks treatment with online hypnotherapy
89338260|NCT03899779|Active Comparator|Online psychoeducation|12 weeks treatment with online psychoeducation
89338261|NCT03102710|Experimental|tDCS Enhancement|In this group, the transcranial direct current stimulation (tDCS) stimulates the areas of the brain being examined in this study to increase their activity.
89338262|NCT03102710|Experimental|tDCS Inhibition|In this group, the transcranial direct current stimulation (tDCS) inhibits the areas of the brain being examined in this study to decrease their activity.
89338263|NCT03102710|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) does not provide real stimulation though you will not know this until your debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
89338264|NCT01149967|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
89338265|NCT01149967|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
89338266|NCT05505409|Experimental|pirfenidone group|CTD-ILD patients treated with pirfenidone、glucocorticoid and immunosuppressant.
89338267|NCT05505409|Active Comparator|No-pirfenidone group|CTD-ILD patients treated with glucocorticoid and immunosuppressant,without pirfebidone
89338268|NCT04770740|Active Comparator|Experimental: Vitamin K2|Patients with COVID-19 who get our dietary supplement vitamin K2, three tablets of 333mcg a day, for 14 days or until discharge, whichever occurs earlier.
89338269|NCT04770740|Placebo Comparator|Control: Placebo|Patients with COVID-19 who get placebo as control, three tablets a day, for 14 days or until discharge, whichever occurs earlier.
89338270|NCT01258543||Non-specific back pain|
89338271|NCT05415878|Other|Tall RCW|
89338272|NCT05415878|Other|Short RCW with contralateral lift|
89338273|NCT03896971|Experimental|Thrombopoietin mimetic plus immunosuppressive therapy|The intervention group will be given cyclosporin A plus thrombopoietin (TPO) mimetic starting with 50 mg orally daily that would be increased or decreased according to response, for 3-months. Patients will be kept on weekly follow up visits and assessed by peripheral hemogram .
89338274|NCT03896971|No Intervention|Immunosuppressive therapy|A comparative group will be collected retrospectively and treated with cyclosporin A alone as standard.
89338275|NCT01151059|Other|Group 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
89338276|NCT01255345||Adult females with CPP living in Denmark|
89338277|NCT03899545|Experimental|Serratus Plane Block|Serratus plane block will be applied after induction of general anesthesia.
89338278|NCT03899545|Active Comparator|Serratus Plane Block plus Pectoral I block|Serratus plane plus pectoral I block will be applied after induction of general anesthesia.
89338279|NCT05415332||Cardiogenic shock patients|"We will collect patient's demographic information, medical history, vital signs, cardiac arrest, the maximum dose of the drug at shock treatment and whether mechanical circulatory support devices are inserted, indicators of deterioration and improvement of shock.~For follow-up observations, only prospective subjects are examined for results and administrative information conducted by visiting an outpatient at the time of one, six, one, two, three, four, and five or more years after the shock."
89338280|NCT05415332||Patients hospitalized in cardiovascular intensive care unit|we will collect patient's demographic information, medical history related to cardiovascular disease, and vital signs on the admission date to the cardiovascular critical care unit.
89338281|NCT01258621|Experimental|Laparoscopic Distal Pancreatectomy|
89338282|NCT03893149|Experimental|Active-Start intervention|Supervised exercise training
89338283|NCT03893149|No Intervention|Control group|No-exercise
89338284|NCT04323020|Experimental|Comatose cardiac arrest patients|Comatose cardiac arrest patients will be undergoing CT perfusion test
89338285|NCT03893071|Experimental|Hydroxypropyl-β-cyclodextrin IV|Hydroxypropyl-β-cyclodextrin will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
89338286|NCT01258699|Experimental|3|BK-C-0701 480mg
89338287|NCT01258699|Experimental|2|BK-C-0701 320mg
89338288|NCT01258699|Active Comparator|1|Thioctacid HR tab 600mg
89338289|NCT04298138|Experimental|Low dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single low dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
89338290|NCT04298138|Experimental|Medium dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single medium dose (0.5 mL of 1.4 x 10^4 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
89338291|NCT04298138|Experimental|High dose DENV-3-LVHC|Dengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single high dose (0.5 mL of 1.4 x 10^5 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
89338292|NCT01258777|Experimental|001|200 mg golimumab or placebo Single dose of 200 mg subcutaneously
89338293|NCT01258777|Experimental|002|400 mg golimumab or placebo Single dose of 400 mg subcutaneously
89338294|NCT03899389||Acute Coronary Syndrome (ACS)|Patients with STEMI or NSTEMI infarction, who were admitted to the hospital with chest pain.
89338295|NCT03899389||Stable Angina (SA)|Patients with stable angina who were scheduled for conventional coronary angiography.
89338296|NCT03899389||Control Group (CON)|Healthy control group responding by age and gender to examined groups.
89338297|NCT03632564|Experimental|Stimulation Arm|REVIVIEW dichoptic audio-visual stimulation
89338298|NCT01257295|Placebo Comparator|control|No additions of fiber to a breakfast meal
89338299|NCT01257295|Active Comparator|low viscous, low gelling|low viscous, low gelling fibre added to breakfast meal
89338300|NCT01257295|Active Comparator|high viscous, low gelling|high viscous, low gelling fibre added to breakfast meal
89338301|NCT01257295|Active Comparator|low viscous, high gelling|low viscous, high gelling fibre added to breakfast meal
89338302|NCT01257295|Active Comparator|high viscous, high gelling|high viscous, high gelling fibre added to breakfast meal
89338303|NCT01257295|Active Comparator|fibre supplement|high viscous, high gelling fibre is added, not to the breakfast meal, but as supplement
89338304|NCT03304028|Other|Refusal Group|"Refusal Questionnaires Intervention:~Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal."
89338305|NCT03304028|Other|Interventionnal Group|Connected Devices for 3 months (36 patients will be equipped with CDs-spirometer, oxymeter, scales, podometer watch and AURA device for sleep quality and analyze) Educationnal Intervention Connected Devices for 12 months Interviews
89338306|NCT01151995||Remote plus on-site|Subjects will have remote source document verification performed 2-4 weeks prior to study monitors scheduled visit and any variables that were not able to be verified remotely will be verified on-site.
89338307|NCT01151995||On-site monitoring|Traditional source document verification will be performed when study monitor is on site
89338308|NCT03896893|No Intervention|Standard of Care|Routine bathing and skin care as per hospital practice
89338309|NCT03896893|Experimental|1% chlorhexidine gluconate (CHG)|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays (total of 8 days CHG application)
89338310|NCT03896893|Experimental|Emollient therapy|Aquaphor skin cream applied from the neck down daily on weekdays (total of 8 days emollient application)
89338311|NCT03896893|Experimental|1% CHG plus emollient therapy|1% aqueous CHG applied from the neck down with cotton swabs daily on weekdays followed immediately by Aquaphor skin cream (total of 8 days CHG application plus emollient application)
89338312|NCT01257373||patiens with Firebird 2 stent|The group of 1300 patients, in which only Fireibrd2 stent is implanted, will be collected. All inclusive patients should be definitely diagnosed type 2 diabetic mellitus （DM）, either before or during the present hospitalization and with complex coronary lesion.
89338313|NCT02527837|Active Comparator|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
89338314|NCT02527837|Placebo Comparator|Placebo|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
89338315|NCT03899233|Active Comparator|Fractional CO2 laser combined with Tranexamic acid|one side of the face of all participants will be subjected to low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond for 3 sessions every 6 weeks. In addition to Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, on the 2nd and the 4th week of each laser session. With total treatment time for each patient of 4 months and another month free of sessions for followup.
89338316|NCT03899233|Active Comparator|Tranexamic acid alone|the other side of the face of all participants will be subjected Tranexamic acid intradermal microinjections using tranexamic acid 500mg/5ml ampoules, the dose of 1ml syringe with 100mg/ml with maximum of 4ml per session, every 2 weeks for 4 months then another month free of sessions for followup.
89338317|NCT03101150|Active Comparator|400 IU Vitamin D3|400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.
89338318|NCT03101150|Experimental|4000 IU Vitamin D3|4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.
89338319|NCT03898999||Older adult|Individuals belonging to the population group of the elderly (60 years or more)
89338320|NCT03899311||PSMF cohort|The cohort is instructed to follow a protein-sparing modified fast diet and is given standard health care in the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital.
89338321|NCT01255501|Experimental|NI-0701|
89338322|NCT01255501|Placebo Comparator|Placebo|
89338323|NCT01255579|Active Comparator|SF|Extrafine Fluticasone/Salmeterol
89338324|NCT01255579|Active Comparator|FB|Extrafine Formoterol and beclometasone HFA
89338325|NCT03898609|Experimental|Low-fat diet|20% fat 20% protein 60% carbohydrate
89338326|NCT03898609|Experimental|Low-carbohydrate diet|45% fat 20% protein 35% carbohydrate
89338327|NCT04908644|Experimental|MS-20 oral solution|Oral Solution 8 c.c per day divided twice daily (BID) for 12 weeks.
89338328|NCT04908644|Placebo Comparator|Placebo|Oral Solution 8 c.c per day divided twice daily (BID) for 12 weeks.
89523594|NCT02479321|No Intervention|Control group|Hemodynamic optimization according to the standards of perioperative monitoring of our center. In the intraoperative period hemodynamic monitoring will be done by management of blood pressure, heart rate and oxygen saturation
89523595|NCT02479321|Experimental|GDT noninvasive monitoring group|GDT based on noninvasive monitoring System ClearSight® and Platform EV Clinic 1000®
89523596|NCT02464345|Experimental|HAPIFED|HAPIFED therapy
89338329|NCT03898921|Experimental|Stereotactic Body Radiotherapy (SBRT)|The planned target volume (PTV) was constructed by adding a 5-mm geometric uncertainty margin around the clinical target volume (CTV). The dose-volume constraints used during SBRT planning are fairly standardized: care was taken to ensure that at least 700 cm3 of normal liver parenchyma was exposed to <15 Gy over the course of SBRT, consistent with published recommendation. Radiotherapy dose was prescribed to the isodose surface covering 99.5% of the PTV, typically 75% to 85% of the maximum PTV dose, accepting regional underdosing when necessary to satisfy normal tissue limits.
89338330|NCT03898921|Active Comparator|Radiofrequency Ablation (RFA)|"Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain safe margin. CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition."
89338331|NCT03101930|Experimental|liraglutide|Subjects in the liraglutide group will receive subcutaneous liraglutide (0.6 mg/d for one week, 1.2 mg/d for one week, and then 1.8 mg/d for 12 weeks) and oral placebo.
89338332|NCT03101930|Active Comparator|sitagliptin|Subjects in the sitagliptin group will receive subcutaneous placebo daily and sitagliptin 100 mg/d orally for 14 weeks.
89338333|NCT03101930|Active Comparator|hypocaloric diet|Subjects in the hypocaloric diet group will be given a caloric goal designed to achieve a weight loss similar to that expected in the liraglutide treatment arm based on his or her resting energy expenditure. Subjects will be provided counseling and written instructions on how to achieve their daily caloric goal, including use of their own mobile phone applications to monitor caloric intake. To assure compliance with the prescribed caloric goal, subjects will meet with the study dietitian every other week for problem solving and review of diet intake logs.
89338334|NCT03898765|Experimental|Experimental：Dry blood spot screening|
89338335|NCT03898687|Other|MAGMEN arm|Patients with melanoma of the extremities included in the protocol. SLNB will be performed with the addition of magtrace (SPIO) injection, 0.2 ml around previous scar. The patients will undergo MRI of the involved basin (Axilla-groin)and receive the SpIO injection the day before SLN biopsy. A separate SPIO MRI will be performed before the operation. All patients will receive all 3 methods for SLN identification as described in the protocol.
89338336|NCT04239950|Placebo Comparator|Placebo|Placebo, orally, twice daily after breakfast and dinner for 12 weeks.
89338337|NCT04239950|Experimental|Ethyl Icosapentate 1.8g|Ethyl Icosapentate 0.9g, orally, twice daily after breakfast and dinner for 12 weeks.
89338338|NCT04239950|Experimental|Ethyl Icosapentate 3.6g|Ethyl Icosapentate 1.8g, orally, twice daily after breakfast and dinner for 12 weeks.
89338339|NCT01255657|Experimental|ABT-806 Arm|
89338340|NCT01255735||Vocal nodules|Two groups of children who are hoarse and have vocal nodules will be examined to see whether voice therapy is effective as a treatment strategy
89338341|NCT01255813|Placebo Comparator|Placebo|
89338342|NCT01255813|Experimental|Sub-perception|
89338343|NCT01255813|Experimental|Full Stimulation|
89338344|NCT05415254|Experimental|treatment group|calcitriol 0.25ug daily for 10 days + COVID-19 routine treatment
89338345|NCT05415254|No Intervention|control group|COVID-19 routine treatment
89338346|NCT03898375|Experimental|VR-enhanced treadmill walking|Participants will be tested during 4 sessions of 20 minutes treadmill walking.
89338347|NCT01255969|No Intervention|Control|
89338348|NCT01255969|Experimental|Exercise|Patients in this arm will undergo to personalized exercise program.
89338349|NCT01256047|Active Comparator|group A|preoperative immunonutrition
89338350|NCT01256047|No Intervention|group B|ordinary diet
89523597|NCT02464345|Active Comparator|CBT-E|CBT-E therapy
89523598|NCT03379363||Pediatric Cushing Syndrome Patients|Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
89338351|NCT02928848|Experimental|Real tDCS|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
89338352|NCT02928848|Sham Comparator|Sham tDCS|Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of real tDCS.
89338353|NCT01150201|Experimental|Aliskiren|Aliskiren
89338354|NCT01150201|Active Comparator|Losartan|ARB
89338355|NCT05269550|Experimental|Men with high intermediate to very high risk protstate cancer|
89338356|NCT01256125||Allogene MSCs transplantation|Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
89338357|NCT01256125||control|only medical treatments were performed in patients with chronic liver diseases.
89338358|NCT02928770|Experimental|Nastent|A baseline sleep study is obtained from the subject, without wearing the device. The individual wears the device at home for at least 7 nights, and then returns to the sleep lab for an in-laboratory sleep study while wearing the device.
89338359|NCT01256203|Experimental|Sunscreen|Solar Protection Formula SPF® 60 will be applied on the skin of each subject. Applications will be followed by photobiological testings to assess skin protection.
89338360|NCT05087485|Experimental|Basic science|This group will be exposed to a written learning content that includes both the presentation and underlying reason of dermoscopic criteria
89338361|NCT05087485|Experimental|visual criteria|This group will be exposed to a written learning content that includes only the presentation of dermoscopic criteria
89338362|NCT03889327|Experimental|Cognitive Feedback and Psychoeducation (CFP)|Participants assigned to the cognitive feedback and psychoeducation (CFP) treatment group will watch a brief video integrating both neuropsychological test feedback and psychoeducation. The computerized intervention will cover MS disease-related information, define objective cognition, explain neuropsychological assessment, and inform patients of their cognitive test performance outcomes. The CFP intervention will also define and explain perceived cognition and subjective measures of cognition, and compare objective performance on neuropsychological tests to a subjective measure of perceived cognition. The intervention will also discuss emotion, attention, and misattribution related to PCI. The proposed intervention will incorporate expert testimony on MS disease course and related symptomology and interpretations of neuropsychological test performance.
89338363|NCT03889327|Active Comparator|Healthy Eating Habits (HEH)|The control group, healthy eating habits (HEH) group, will watch a brief psychoeducational video of same length in time as the treatment group. The control intervention will include information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The proposed control intervention will include expert testimony from a nutritionist and expert dietician.
89338364|NCT01259947|Experimental|Lippia alba|
89338365|NCT01257451|Experimental|Vildagliptin|
89338366|NCT01257451|Placebo Comparator|Placebo|
89338367|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, low-fat|
89338368|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, medium-fat|
89338369|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, high-fat|
89338370|NCT01257529|Other|Pregabalin immediate release, 300 mg|Reference Treatment
89338371|NCT03896113|Experimental|Celecoxib|Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery will receive celecoxib 400 mg twice a day, for 15 days before the curative surgery for their endometrial cancer. The patients will undergo an endometrial biopsy at the inclusion and during the surgery.
89338372|NCT01257685||Control Group|Normal group
89338373|NCT01257685||NAFLD Group|NAFLD in the present study was defined a value of LAI <5 HU using an unenhaned CT.
89338374|NCT03100838|Experimental|Nifedipine (Generic)|1 x 60 mg Nifedipine extended-release tablet
89338375|NCT03100838|Active Comparator|Nifedipine (Brand)|1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet
89338376|NCT03100838|Active Comparator|Nifedipine (Generic) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg Nifedipine extended-release tablet on day 7
89338377|NCT03100838|Active Comparator|Nifedipine (brand) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet on day 7
89338378|NCT03895957|Experimental|Group 1: VR Mind+|Virtual Reality Exposure Therapy VR Mind+
89338379|NCT03895957|Experimental|Group 2: VR Mind|Virtual Reality Exposure Therapy VR Mind
89338380|NCT03895957|Active Comparator|Control group: CBT|Cognitive Behavioral Therapy
89338381|NCT03892681|Other|contrast agents for liver MRI|
89338382|NCT04031144|Experimental|Ultrafiltration|Ultrafiltration is applied at the end of cardiopulmonary bypass. Maximal clot formation (MCF) of ROTEM-EXTEM tracing is reduced before applying the ultrafiltration.
89338383|NCT01260025|Experimental|PEDylated Recombinant Human Endostatin|PEDylated Recombinant Human Endostatin
89338384|NCT03892837|Active Comparator|Control group|Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
89338385|NCT03892837|Experimental|PRP group|Procedure/Surgery: PRP PRP treatment following the conventional treatment Slow spray / inject autogenous PRP to cover the wound of stenosis. Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
89338386|NCT04363580||Patients|Children consulting for an assessment of central auditory skills
89338387|NCT03892525|Experimental|treatment|
89338388|NCT05418452|Experimental|metformin|will receive split-crest technique by ultrasonic bone surgery with implant placement and PRF mixed with 1% metformin gel
89338389|NCT05418452|No Intervention|control|will receive split-crest technique by ultrasonic bone surgery with implant placement without gap filling.
89338390|NCT01257841|Placebo Comparator|Fasting alone|
89338391|NCT01257841|Active Comparator|Fasting plus leptin|
89338392|NCT04346888|Experimental|HBM9161 (680mg and 340 mg)|Subcutaneous injection; Blinded: HBM9161 680mg; Open-label: HBM9161 340mg;
89338393|NCT04346888|Experimental|HBM9161 (340 mg)|Subcutaneous injection; Blinded: HBM9161 340mg; Open-label: HBM9161 340mg;
89338394|NCT04346888|Placebo Comparator|Placebo, HBM9161 (340 mg)|Subcutaneous injection; Blinded: Placebo; Open-label: HBM9161 340mg;
89338395|NCT01153399||1|Patients with Non Small Cell Lung Cancer, visiting hospital oncology clinics
89338396|NCT01260103|Active Comparator|Temozolomide (TMZ)|Study subjects receive TMZ for 13 cycles
89338397|NCT01260103|Experimental|ANP Therapy|Escalating doses of ANP therapy are given daily for 52 weeks.
89338398|NCT03480750|Experimental|trientine with chemotherapy|trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1
89338399|NCT05207384|Active Comparator|Ozone (O2-O3) group|Ultrasound (US)-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
89338400|NCT05207384|Other|Corticosteroid group|US-guided injection will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
89338401|NCT03892447|Experimental|Alprostadil|Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
89338402|NCT03892447|Active Comparator|Sodium Ferulate|Sodium Ferulate 2~6mg/kg.d,iv,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
89338403|NCT03718650|Experimental|Scans, Surgical Resection and Assessment|Pre-surgery scans, surgical resection and post-surgery pathological assessment. All patients will receive standard of care imaging and blood tests. If suitable, non-standard of care abdominal MRI imaging will be done. 16-24 hours prior to surgery, patients will be administered a single dose of 0.5 g/m^2 pimonidazole (HydroxyProbe).
89338404|NCT01152073|Placebo Comparator|Placebo|Study participants whose drink formulation contains no active ingredients but will appear and taste similar to the two other formulations. This will form the control formulation
89338405|NCT01152073|Active Comparator|Second Formulation|Study participants' drink formulation will include Red Yeast Rice 600mg, Niacin 12.5mg, Phytosterol esters 650mg, L-Carnitine 150mg, vitamin C 500mg, and Co-Q-10 25mg.
89338406|NCT01152073|Active Comparator|Third Formulation|The third formulation will be identical to the second, but without the Red Yeast Rice.
89338407|NCT03716700||Cohort 1|Cohort1 will include the participants who have been transitioned to CUVITRU at the time of enrollment in the study.
89338408|NCT03716700||Cohort 2|Cohort 2 will include participants 6 months (±2 weeks) after CUVITRU initiation.
89338409|NCT03716700||Cohort 3|Cohort 3 will include participants 12 months (-1 or +2 months) after CUVITRU initiation.
89338410|NCT05250596|Experimental|Colchicine and Atorvastatin|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge plus Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
89338411|NCT05250596|Active Comparator|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
89338412|NCT03719664|Experimental|Cohort 1: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
89338413|NCT03719664|Experimental|Cohort 2: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
89338414|NCT03719664|Active Comparator|Control Arm 1: Baseline ART|Subjects continuing on baseline ART
89338415|NCT03719664|Experimental|Cohort 3: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
89338416|NCT03719664|Experimental|Cohort 4: albuvirtide & 3BNC117|albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks
89338417|NCT03719664|Experimental|Optimal Dose: albuvirtide & 3BNC117|albuvirtide and 3BNC117 every 2 or 4 weeks
89338418|NCT03719664|Active Comparator|Control Arm 2: Baseline ART|Subjects continuing on baseline ART
89338419|NCT04788914|Other|Active bamboo charcoal|In this proposal, investigators aim to determine the therapeutic impact of a carbonaceous oral adsorbent made of activated bamboo charcoal (ABC) with/without probiotics on the endothelial/vascular function, CV outcome and mortality in CKD patients with PAD. In addition, investigators hypothesize that circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota. Investigators also hypothesize that the administration of ABC could normalize the dysbiosis of gut microbiota, dysregulated circulating lncRNAs and metabolome that are linked to adverse CV/limb outcomes in CKD patients with PAD.
89338420|NCT04788914|Other|Probiotics|The therapeutic impact of probiotics on circulating long noncoding RNA (lncRNA) expression profiles and metabolome may serve as a sensitive and reliable biomarker to predict the adverse CV outcomes and death in CKD patients with established PAD. In addition, it is hypothesized that circulating lncRNAs and linked to adverse CV outcomes in CKD patients with PAD are associated with dysbiosis of gut microbiota.
89338421|NCT03888859|Experimental|Intravenous (i.v.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intravenous (IV) infusion
89338422|NCT03888859|Experimental|Intra-hepatic artery (i.a.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intra-hepatic artery (IA) infusion
89338423|NCT03888859|Experimental|Intratumoral Injections (i.t.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intratumoral injections (i.t.) infusion
89531670|NCT05801653|Experimental|Oat meal 1|The test portion is based on 30 gram available carbohydrates with added x amount oat betaglucan. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning
89338424|NCT03716622|Active Comparator|bismuth-clarithromycin-containing group|Patients in bismuth-clarithromycin-containing group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 500mg po bid for 14d
89338425|NCT03716622|Experimental|bismuth-furazolidone-containing quadruple group|patients in bismuth-furazolidone-containing quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 240mg po bid, and furazolidone (Liteling) 100mg po bid for 14d
89338426|NCT03889015|Active Comparator|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
89338427|NCT03889015|Experimental|probiotic yogurt|Probiotics are live microorganisms that confer oral health benefits by adhering to the oral mucosa and surface of teeth as a part of the biofilm thus preventing the adhesion, colonization, and proliferation of cariogenic bacteria inhibiting the formation of pathogenic plaque
89338428|NCT03714126||HF patients|HF patients will use the Cordio Medical app to record in their hospital visits and at home.
89338429|NCT01152151|Active Comparator|Postal reminders|Postal reminders
89338430|NCT01152151|Active Comparator|Electronic reminders|Electronic reminders
89338431|NCT04926740|Experimental|Ringer's lactate|The intervention is administration of IV Ringer's lactate. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
89338432|NCT04926740|Active Comparator|Normal saline|The comparator is administration of IV normal saline. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
89338433|NCT01153477|No Intervention|TAU|This group is the control group by which we are comparing our intervention. This group will not receive an intervention from us but will continue to be treated at the Intensive Outpatient facility from which we recruited them.
89338434|NCT01153477|Experimental|Counseling (TMAC-E)|This telephone based intervention includes six factors to improve our extended treatment model: Incentive component; Patient choice; Provision of cell phones to those who need them; Social support and community resources; Positive recovery factors; and Outreach following dropout.
89338435|NCT05418374|Active Comparator|Group A|18G epidural needle will be inserted intrathecally at the level of L4-L5. After insertion of the Tuohy needle, the subarachnoid space is found and the bevel is directed downward, and the spinal catheter is passed 2-3 cm into the subarachnoid space. After confirmation of aspiration cerebral spinal fluid through the catheter, an initial dose 2.5 mg (0.5 ml) of plain bupivacaine 0.5%(manufactured by sunny medical ) will be injected.
89338436|NCT05418374|No Intervention|Control group|traditional spinal anesthesia will be done with a 25G pencil point spinal needle at the level of L4-L5 with injection of 12.5 mg (2.5ml) of bupivacaine 0.5%. By adjusting the head level, T10 sensory block will be targeted
89338437|NCT01153555||Intermediate coronary lesions|"Diagnostic device: FFR~Diagnostic device: IVUS RF~At participating centers, FFR and IVUS are standard of care diagnostic procedures for patients with intermediate (40-80% angiographic stenosis by visual estimate). Both modalities were used regularly for such patients whether or not they are participants in this clinical study. In FIRST, the decision to perform percutaneous coronary intervention (PCI) was left to the discretion of the investigator, and was not dictated by the clinical protocol."
89338438|NCT02673320|Experimental|Early surgery|Early surgery within 48 hours
89338439|NCT02673320|Other|Delayed surgery|Delayed surgery at 15 days
89338440|NCT01152229||nuisance bleeding|
89338441|NCT01152229||alarming bleeding|
89338442|NCT01152229||maintenance therapy|
89338443|NCT03639012|Active Comparator|Carbohydrate loading|Patients to receive an oral preoperative carbohydrate drink
89338444|NCT03639012|No Intervention|No Carbohydrate loading|Current standard of care
89338445|NCT03895723|Experimental|Minimally Invasive surgery|the intevention of Minimally Invasive procedure contains laparoscopic and robotic liver resection
89338446|NCT03895723|Other|Open surgery|the open surgery means traditional open surgery for liver resection
89338447|NCT04895462||Ischemic Stroke and COVID-19|Ischemic stroke patients with COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)
89338448|NCT04895462||Control group: Ischemic Stroke without COVID-19|Ischemic stroke patients without COVID-19 receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment)
89338449|NCT03892213|Other|Benznidazole and E1224|Benznidazole and E1224
89338450|NCT03412734|Experimental|Chlorhexidine group|
89338451|NCT03412734|Active Comparator|Iodine group|
89338452|NCT04313114|Active Comparator|PRIME CRC|Patients will receive a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; as well as plain language, literacy appropriate handouts on the CRC screening test they choose - colonoscopy or FIT. Patients will also receive automated reminder calls and texts for both screening options to encourage screening.
89338453|NCT04313114|Active Comparator|Enhanced Usual Care|Patients will receive a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; as well as plain language, literacy appropriate handouts on the CRC screening test they choose - colonoscopy or FIT. Patients will receive no reminder calls.
89338454|NCT03888781||With Left Ventricular Remodeling|By Echocardiography
89338455|NCT03888781||Without Left Ventricular Remodeling|By Echocardiography
89338456|NCT03888703|Experimental|Treatment|
89338457|NCT03888703|No Intervention|Control|
89338458|NCT01153789|Experimental|Patients orthoptic rehabilitation|Children with vertigo-headache and vergence disorders
89338459|NCT01153789|Other|Control Orthoptic diagnostic|Healthy controls
89338460|NCT01260259|Experimental|Remote Ischemic Preconditioning (RIPC)|
89338461|NCT01260259|Sham Comparator|Control|
89338462|NCT03892135||Physicians|3 paediatricians and 3 rheumatologists
89338463|NCT03892135||Parents|Parents
89338464|NCT03892135||Children|Children
89338465|NCT01259167||BACK group|training with a traditional protocol of Therapeutic Physical Exercise
89338466|NCT01259167||"Group C."|Control group with sedentary people undergoing usual care.
89338467|NCT01259167||JOBA group|training with JOBA® Core Trainer
89338468|NCT01260337|Active Comparator|Diabetes Support and Education (DSE)|
89338469|NCT01260337|Experimental|Portion controlled diet (PCD)|behavior modification
89338470|NCT03895177|Experimental|low kVp high mAs CT group|doing pancreatic CT with 80 kVp tube current with more than 500 mA tube current for the evaluation of pancreatic cancer resectability
89338471|NCT03891979|Experimental|Pembrolizumab + Antibiotics|Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.
89338472|NCT01257997||Healthy subjects|18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body mass index from 20 to 27.
89338473|NCT01260415|Experimental|Folfox/Folfiri, Panitumumab|Eligible patients will recieved chemotherapy/panitumumab for 2 months (4 cycles) pre-operatively and 4 months post-operatively, plus a further 6 months of pantimumab post-chemotherapy
89338474|NCT02374814|Active Comparator|Rabies vaccine IM 3 dose|Intramuscular injection: 1mL at 0, 7 and 21 days. An additional 1 mL intramuscular dose at day 365
89338475|NCT02374814|Experimental|Rabies vaccine ID 3 dose|Intradermal injection: 0.1mL at 0, 7 and 21 days. A single intramuscular 1 mL dose at day 365
89338476|NCT02374814|Experimental|Rabies vaccine IM 2 dose|Intramuscular injection: 1mL at 0, 7 days. An additional 1 mL intramuscular dose at day 365
89338477|NCT02374814|Experimental|Rabies vaccine ID 2 dose|Intradermal injection: 0.1mL at 0, 7 days. A single intramuscular 1 mL dose at day 365
89338478|NCT02374814|Placebo Comparator|Placebo IM 1 dose|Albumin and saline comparator, Intramuscular injection: 1mL
89338479|NCT02374814|Placebo Comparator|Placebo ID 1 dose|Albumin and saline comparator, Intradermal injection: 0.1mL
89338480|NCT03892057|Experimental|Internet-based Positive Psychological Intervention|The investigator's culturally-tailored internet-based Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
89338481|NCT03892057|No Intervention|Attention Control Group|Participants will complete computerized surveys to document the frequency of positive and negative emotions experienced in daily life. The attention control group will be given the option to access our positive psychological intervention and associated content via the web at the conclusion of the 12-week data collection phase.
89338482|NCT01153945||Hypothyroid|
89338483|NCT01153945||Non hypothyroid|
89338484|NCT01153945||Healthy subjects|
89338485|NCT03888625|Active Comparator|Group A: Conventional ILM peeling|peeling with complete removal of the internal limiting membrane (ILM)
89338486|NCT03888625|Active Comparator|GroupB: Inverted ILM Peeling|the inverted ILM peeling technique, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
89338487|NCT04608344|Experimental|Sequence AB|Participants will receive atorvastatin (ATV) 40 mg tablet on Day 1, followed by a washout period of 1 day, and then pravastatin (PRA) 40 mg + rosuvastatin (ROS) 10 mg tablets on Day 3 in Treatment A, Period 1. In Treatment B, Period 2 participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 12 and PRA 40 mg + ROS 10 mg tablets on Day 14. Period 1 and Period 2 will be separated by a washout period of 3 days.
89338488|NCT04608344|Experimental|Sequence BA|Participants will receive filgotinib 200 mg tablet once daily for 11 days, with ATV 40 mg on Day 6 and PRA 40 mg + ROS 10 mg tablets on Day 8 in Treatment B, Period 1. In Treatment A, Period 2 participants will receive ATV 40 mg tablet on Day 18, followed by a washout period of 1 day and PRA 40 mg + ROS 10 mg tablets on Day 20. Period 1 and Period 2 will be separated by a washout period of 6 days.
89338489|NCT01154023|Experimental|stimulus control therapy|Focuses on strengthening the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, and developing a consistent sleep-wake pattern
89338490|NCT01154023|Experimental|sleep restriction therapy|Sleep restriction therapy consolidates sleep by restricting the amount of time spent in bed and limiting sleep to a specific time period .
89338491|NCT01154023|Experimental|multi-component intervention|Combines stimulus control and sleep restriction: strengthen the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, develop a consistent sleep-wake pattern, consolidate sleep by restricting the amount of time spent in bed and limit sleep to a specific time period
89338492|NCT01153867|Experimental|Schema Focused Therapy|Participants will receive Schema Focused Therapy
89338493|NCT03895021|Experimental|Intervention|This multifaceted, adapted program focuses preventing falls through balance and strength exercises, teachings from guest experts (e.g., PT, Pharmacist, vision) and at-home safety education. Participants attended weekly 2-hour group sessions (8 -12 persons) over the course of 8 weeks delivered in Spanish by trained Hispanic/Latino personnel in two communities in Wisconsin.
89338494|NCT03895255|Active Comparator|IMA high ligation with routine SFM|Inferior mesenteric artery is ligated close to its origin. Splenic flexure is always mobilized.
89338495|NCT03895255|Experimental|IMA skeletonization and low ligation with selective SFM|Inferior mesenteric artery is ligated below the origin of left colic artery. Splenic flexure is mobilized only if needed.
89338496|NCT03891433|Active Comparator|Carbapenems group|Meropenem (1g intravenously every 8 hours or adjusted to renal function) or Ertapenem (1g intravenously every 24 hours or adjusted to renal function) by 10 days.
89338497|NCT03891433|Active Comparator|Piperacillin/tazobactam.|Piperacillin / Tazobactam (4.5gr intravenously every 6 hours or adjusted to renal function) by 10 days.
89338498|NCT03895333||study group|women with hearing loss and osteoporosis will develop the study group.
89338499|NCT03895333||control group|women who have hearing loss but have no osteoporosis will constitute the control group.
89338500|NCT03895411|Experimental|Sotalol|Oral sotalol 2.5mg/kg/time, per 12h. Combination therapy: betaloc
89338501|NCT03895411|Active Comparator|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h Combination therapy: betaloc
89338502|NCT01154179|No Intervention|Normocaloric feeding|This control group will receive energy and protein intakes as recommended by the use of Schofield equations, as is current practice (100% of requirements)
89338503|NCT01152619|Experimental|1|
89338504|NCT01152619|Experimental|2|
89338505|NCT01152619|Placebo Comparator|3|
89338506|NCT01152619|Placebo Comparator|4|
89338507|NCT03891589|Experimental|Optimized CF with Taburia|The intervention groups consisted of promotion of optimized complementary feeding with home fortification (taburia) one sachet per week
89338508|NCT03891589|Experimental|Optimized CF only|The intervention groups consisted of promotion of optimized complementary feeding without home fortification (taburia)
89338509|NCT03891589|Experimental|Taburia|The intervention groups consisted of provision taburia home fortification three sachet per week
89338510|NCT03891589|No Intervention|Control|No intervention but gave a standard education from primary health center
89338511|NCT03888313||Patients participating in the pretreatment group consultation|Patients who chosse to participate in a group consultation (with other patients also in the process of undergoing surgery for colorectal cancer).
89338512|NCT03888547|Experimental|OT-HAWP|"The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules:~Week 1: Sleep Hygiene Week 2: Fatigue Management Week 3: Cancer-related cognitive impairments Week 4: Stress Management Each session will last 1.5 hours (45 minutes of group education and 45 minutes of individual modifications and strategy recommendations."
89338513|NCT02527525|Experimental|Stepped Care|150 subjects will be randomized to the stepped care intervention. All 150 participants will be assigned a parent coach after randomization to stepped care condition. At the child's next follow up clinic visit participants who have elevated depression scores OR who's child has not met A1c target will move on to Step 2 of the intervention- 5 sessions with a study interventionist. At the following child's clinic visit, participants can either remain in Step 1, move to Step 2, or if needed, move on to Step 3- using a continuous glucose monitor for 1 week followed by a meeting with a certified diabetes educator and a diabetes team clinical psychologist.
89338514|NCT02527525|No Intervention|Usual Care|Participants randomized to usual care will participate in regular diabetes clinic visits and diabetes education, as they would have done without participation in this study.
89338515|NCT03894943|Experimental|General|All subjects will undergo ordinary surgical treatment for their lumbar disc herniation. Experimentally, all subjects participating in the study will receive PET/CT scans and sensory testing as specified below.
89338516|NCT01259323|Experimental|Cohort 1|
89338517|NCT01259323|Experimental|Cohort 2|
89338518|NCT01259323|Experimental|Cohort 3|
89338519|NCT01589575||Spouses|This group of relatives includes the spouses of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
89338520|NCT01589575||Other relatives|This group of relatives includes the non-spouse relatives of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
89338521|NCT03891277|Active Comparator|Ferrous succinate|Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
89338522|NCT03891277|Placebo Comparator|placebo|placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
89338523|NCT03888157||Liraglutide|Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.
89338524|NCT03890965|Experimental|Experimental|Adult patients with chronic sequelae in the upper limb after neurological damage
89338525|NCT03887923|Experimental|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
89338526|NCT03887845||Open gastrointestinal surgery|All patients enrolled in this group would undergo open gastric and colorectal resection surgery.
89338527|NCT03887845||Laparoscopic gastrointestinal surgery|All patients enrolled in this group would undergo laparoscopic gastric and colorectal resection surgery.
89338528|NCT01154413|Experimental|Intensive education of the doctor/nursing team on the protocol|
89338529|NCT01154413|No Intervention|Without intervention in the team|
89338530|NCT01154491|Placebo Comparator|Placebo|Two placebos: placebo for ferric carboxymaltose and placebo for erythropoietin
89338531|NCT01154491|Experimental|FE|Ferric carboxymaltose and placebo for erythropoietin
89338532|NCT01154491|Experimental|EPOFE|Ferric carboxymaltose and erythropoietin
89338533|NCT01260571|Experimental|Benzoyl Peroxide and Sulfur|Topical Medications containing benzoyl peroxide and sulfur
89338534|NCT03887689|Experimental|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
89338535|NCT03894865|Experimental|urban school|Male students from selected urban schools undergo screening for idiopathic scoliosis
89338536|NCT03894865|Experimental|countryside schools|Male students from selected countryside schools undergo screening for idiopathic scoliosis
89338537|NCT01151527||Sporadic (idiopathic) or familial interstitial pneumonia|We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).
89338538|NCT03894709|Experimental|The family-centered care model|Interventions include a family-centered approach to interdisciplinary care and a family caregiving-training component to enhance family caregivers' competence in providing post-operative care and handling behavioral problems of adults with cognitive impairment. The interdisciplinary care model consists of geriatric consultation, continuous rehabilitation, and discharge planning. The family-centered approach involves family caregivers using a structured guide to assess the condition of the hip-fractured patient with cognitive impairment. Habits, daily routines, preferences, behavioral problems and environmental safety and stimuli are explored. The strengths, weakness, and resources of the family are assessed. The behavioral problems and symptoms to target are identified. Both the research nurse and the caregiver will then collaborate on a tentative plan to minimize the behavioral problems.
89338539|NCT03894709|No Intervention|Usual care|During hospitalization, patients receive health teaching for exercise while still in bed. Physical therapy usually starts only for those who received arthroplasty of hip replacement. Physical therapists train patients to use a walker and get in/out of bed through consultation. Usually, patients are discharged from the hospital without home assessment, nor are in-home programs provided for rehabilitation or nursing care. The usual care does not involve interdisciplinary care protocols, continuity of care, or specific care for hip-fractured patients with cognitive impairment.
89338540|NCT02527603|Experimental|Spaso Method|Randomized for Sp method + 1 initial dose of 50mg dexketoprofen IM or 25mg Oral
89338541|NCT02527603|Experimental|Boss-Holzach-Matter Method|Randomized for BHM method +1 initial dose of 50mg dexketoprofen IM or 25mg Oral
89338542|NCT01259479|Experimental|1|Dose escalation, continuous treatment without DLTs
89338543|NCT03894475|Active Comparator|Sequence A|Patient would first perform an examination with handheld spirometer (AioCare), followed by measurements with the reference spirometer (MGC)
89338544|NCT03894475|Active Comparator|Sequence B|Patient would first perform an examination with the reference spirometer (MGC), followed by measurements with handheld spirometer (AioCare)
89338545|NCT01260727|Experimental|Group 1|Participants will receive PENNVAX-G vaccine administered by intramuscular injection (IM) via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
89338546|NCT01260727|Experimental|Group 2|Participants will receive PENNVAX-G vaccine administered via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
89338547|NCT01260727|Experimental|Group 3: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
89338548|NCT01260727|Placebo Comparator|Group 3: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via Biojector 2000 needless device in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
89338549|NCT01260727|Experimental|Group 4: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
89338550|NCT01260727|Placebo Comparator|Group 4: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
89338551|NCT03887611||thyroid nodules|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of thyroid surgery or thyroid biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
89338552|NCT03890809|Experimental|Normal liver function|Single dose
89338553|NCT03890809|Experimental|Mild liver impairment|Single dose
89338554|NCT03890809|Experimental|Moderate liver impairment|Single dose
89338555|NCT03890809|Experimental|Severe liver impairment|Single dose
89338556|NCT01151683|Active Comparator|Magnesium|Magnesium chelate 600 mg per day
89338557|NCT01151683|Placebo Comparator|Placebo|Placebo 4 capsules per day
89338558|NCT03891121|Experimental|Occlusal splint|Patients were treated with occlusal splint.
89338559|NCT03891121|Experimental|Botulinum toxin|Patients were treated with botulinum toxin injection.
89338560|NCT03891121|Experimental|Both|Patients were treated with occlusal splint and botulinum toxin injection together.
89338561|NCT01154569|Active Comparator|Post Roux-en-Y gastric bypass|Post-bypass receiving a single dose of azithromycin
89338562|NCT01154569|Active Comparator|Controls|BMI and sex matched. Have not undergone surgery
89338563|NCT03891043|Placebo Comparator|Group A, Placebo group|Placebo consisted in a pill of 100 micrograms of starch, to be taken twice a day.
89338564|NCT03891043|Experimental|Group B, Selenium group|Selenium consisted in a pill of 100 micrograms, to be taken twice a day.
89338565|NCT03894397|Experimental|Stimulation of left BNST|
89338566|NCT03894397|Experimental|Stimulation of right BNST|
89338567|NCT03894397|Experimental|Stimulation of bilateral BNST|
89338568|NCT03894397|Placebo Comparator|Stimulation OFF|
89338569|NCT01152775|Placebo Comparator|No Media|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
89338570|NCT01152775|Experimental|Yes Media Newly Diagnosed Breast Cancer Pts|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
89338571|NCT03890341|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-64530440|Participants will receive single oral dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and midazolam 2 mg with under fed conditions (high fat meal) on Day 1 followed by JNJ-64530440 2,000 mg on Days 6 under fasted conditions ; JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg under fed conditions on Day 13; JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) from Days 14 to 18; single oral dose of JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg on Day 19 under fed conditions (high fat meal); and JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) on Days 20 to 22.
89338572|NCT03890653|Experimental|Performance-Based Financing|At least one primary healthcare centre per ward and one General Hospital per selected LGA (in 50% of LGAs in each of the 3 states) and one secondary hospital per State will be contracted by the State Primary Health Care Development Agency ) , to deliver specified services at an agreed price. Selection of which services to focus on is based on priorities identified by the Federal Government of Nigeria and the states in 2010-2015. Initial prices for each service were based on shadow prices of providing the service and have been adjusted based on implementation experience.
89338573|NCT03890653|Experimental|Decentralized Facility Financing|In the other half of the LGA's in each treated state, at least one facility per ward will receive Decentralized Facility Financing (DFF) or equivalent financing that is not be linked to any service delivery targets. These payments would be made on a quarterly basis.
89338574|NCT03890653|No Intervention|Control|This is a pure control arm with no additional interventions.
89338575|NCT01260805|Active Comparator|Reference Drug|
89338576|NCT01260805|Active Comparator|Test Drug|
89338577|NCT01259557|Experimental|Botulinum toxin type A(Meditoxin®)|
89338578|NCT01152853|Experimental|single arm|PF00299804 treatment arm
89338579|NCT03894085|Experimental|GAD group|"General anxiety disorder(GAD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~Paroxetine (20-40mg) treatment for 4 weeks"
89338580|NCT03894085|Experimental|PD group|"Panic disorder(PD) patients meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~Paroxetine (20-40mg)treatment for 4 weeks"
89338581|NCT03894085|Experimental|SAD group|"Social anxiety disorder(SAD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~Paroxetine (20-40mg)treatment for 4 weeks"
89338582|NCT03894085|Experimental|OCD group|"Obsessive-compulsive disorder (OCD)meet the diagnostic criteria of the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)~MRI scan and evaluation of clinical symptoms at baseline and 4 weeks~Paroxetine(40-80mg) treatment for 4 weeks"
89338583|NCT03894085|No Intervention|Healthy controls|MRI scan at baseline and no drugs treatment
89338584|NCT03890575|Experimental|Airway Stent for Malignant Stricture|Patients with malignant stricture were implanted with covered metallic segmented stent modified with 3D printing.
89338585|NCT05075707|No Intervention|control group|Participants will receive the descriptive medication by neurologist
89338586|NCT05075707|Experimental|electromagnetic group|Participants will receive the descriptive medication by neurologist in addition to electromagnetic therapy. Electromagnetic therapy will be applied for 20 min/session for three days each week for two months.
89338587|NCT05075707|Experimental|low laser therapy group|Participants will receive the descriptive medication by neurologist in addition to low laser therapy. Low laser therapy will be applied for 20 min/session for three days each week for two months.
89338588|NCT03890263|Experimental|Opioid deprescribing and self-management|
89338589|NCT01155349|Experimental|InSight Brain Fitness|
89338590|NCT01155349|Placebo Comparator|No contact-control|
89338591|NCT01152931|Active Comparator|COHORT A= Amodiaquine + Artesunate|Amodiaquine will be administered orally at 10mg/kg daily for 3days. Artesunate 50mg will be administered orally daily for 3days.For subjects >6months< 1 years 4mg/kg daily for 3 days
89338592|NCT01152931|Active Comparator|cohort B= Lumefantrine +Artemether|Artemether 20mg/Lumefantrine 120mg fixed combination administered daily for 3 days
89338593|NCT01152931|Experimental|cohort C = Artesunate + vitamin A|Artesunate 50mg daily for 4days. if >6 months< 1 year 4mg/kg daily for 4days + Vitamin A 5000IU daily for 4days if < 1 year and 10,000IU daily for 4days if > 1 year respectively
89338594|NCT01152931|Experimental|Artesunate, vitamin E oral administration|Artesunate 50mg daily for 4 days.if >6 months< 1 year 4mg/kg daily for 4 days + vitamin E 100mg daily administered orally to the experimental group 4 days.
89338595|NCT01152931|Experimental|cohort E will be given Artesunate and Zinc orally|cohort E will be given Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + zinc gluconate 50mg orally daily for 4 days. if < 1 year 25 mg daily for 4 days
89338596|NCT01152931|Experimental|cohort F= Artesunate and selenium will be given orally|Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + selenium 100ug daily for 4 days. if < 1 year 50ug daily for 4 days.
89338597|NCT01152931|Experimental|cohort G = Amodiaqiune and Vitamin A will be given orally|Amodiaquine 10mg/kg daily for 3 days + vitamin A 5000iu daily for 4 days if < 1 year. 10,000 IU daily for 4 days if > 1 year.
89338598|NCT01152931|Experimental|cohort H = amodiaquine and vitamin E administerd orally|Amodiaquine 10mg/kg daily for 4 days + vitamin E 100 mg daily for 4 days
89338599|NCT01152931|Experimental|cohort I = Amodiaquine and Zinc will be given orally|Amodiaquine 10mg/kg daily for 4 days + zinc 50mg daily 4 days. if < 1 year 25 mg daily for 4 days.
89338600|NCT01152931|Experimental|Cohort J = amodiaquine and selenium will be given orally|Amodiaquine 10mg/kg daily for 4 days + selenium 100ug daily for 4 days if > 1 year. 50ug daily for 4 days if < 1 year.
89338601|NCT01152931|Experimental|K= Artesunate+ vitamin A + vitamin E|Tab Artesunate 50mg orally dly x 4 days + Vitamin A, 5000IU orally, dly x 4 days if ≤ 1yr. 10,000IU orally dly x 4days if > 1 yr + vitamin E 100 mg orally dly for 4 days
89338602|NCT01152931|Experimental|L = Artesunate+ Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
89338603|NCT01152931|Experimental|M = Artesunate+ Vitamin A + selenium|Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
89338604|NCT01152931|Experimental|N = Artesunate + Vitamin E + Zinc|Artesunate 50mg daily for 4 days. vitamin E 100mg daily for 4 days. Zinc 50 mg daily for 4 days if > 1 year. 25 mg daily for 4 days if < 1 year.
89338605|NCT01152931|Experimental|O = Artesunate+ Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
89338606|NCT01155427||entecavir|Patients initiating special antiviral treatments for CHB
89338607|NCT01155427||tenofovir|Patients initiating special antiviral treatments for CHB
89338608|NCT01155427||lamivudine|Patients initiating special antiviral treatments for CHB
89338609|NCT01155427||telbivudine|Patients initiating special antiviral treatments for CHB
89338610|NCT01155427||adefovir|Patients initiating special antiviral treatments for CHB
89338611|NCT01259635|Experimental|Bio feedback for freezing|When ever freezing occures, a metronom sound will be heard
89338612|NCT01261039|Active Comparator|Solar bed UV-radiation|Solar bed UV-radiation
89338613|NCT01261039|Sham Comparator|Solar bed with UV filter|Solar bed with UV filter
89338614|NCT01261117|Active Comparator|intravenous ibuprofen|Extremely low birth weight patients receiving iv ibuprofen
89338615|NCT01261117|Active Comparator|Oral ibuprofen|Extremely low birth weight patients receiving oral ibuprofen
89338616|NCT03889717|Experimental|400 iu|neonates who will receive vitamin d dose at 400 iu per day
89338617|NCT03889717|Active Comparator|1000 iu|neonates who will receive vitamin d dose 1000 iu per day
89338618|NCT01262053|Experimental|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated.
89338619|NCT01262053|Experimental|Active Intervention|The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders.
89338620|NCT01262053|Active Comparator|Control|Parallel control with no intervention
89338621|NCT03889873|Experimental|Drinking; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
89338622|NCT03889873|Experimental|Drinking; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
89338623|NCT03889873|Experimental|Drinking; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
89338624|NCT03889873|Experimental|Drinking; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
89338625|NCT03889873|Experimental|Smartphone; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
89338626|NCT03889873|Experimental|Smartphone; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
89338627|NCT03889873|Experimental|Smartphone; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
89338628|NCT03889873|Experimental|Smartphone; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
89338629|NCT03886129||Participants with Transient Ischaemic Attack|"Inclusion Criteria:~Willing to participate~Capacity to consent~Aged >18 years~Able (in the Investigator's opinion) and willing to comply with all study requirements~A diagnosis of acute (≤7 days) TIA, made by a specialist that fulfils the 2009 American Heart Association definition of TIA~Good understanding of written and verbal English~Exclusion Criteria:~Unwilling to take part~Unable to consent~Aged <18 years~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements~Female participants who are pregnant, lactating or planning pregnancy during the course of the study~Atrial fibrillation~Severe heart failure (Ejection Fraction <30%)~Severe respiratory disease~Inadequate bilateral transcranial Doppler windows~Carotid stenosis ≥70% (unilateral or bilateral)~Participant enrolled in an interventional research study.~Poor understanding of written and verbal English"
89338630|NCT03886129||Healthy Control Participants|"Inclusion Criteria:~Willing to participate~Capacity to consent to the study~Aged >18 years~Able (in the Investigator's opinion) and willing to comply with all study requirements~Good understanding of written and verbal English~Exclusion Criteria:~Unwilling to take part~Unable to consent~Aged <18 years~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements~Female participants who are pregnant, lactating or planning pregnancy during the course of the study~Atrial fibrillation~Severe heart failure (Ejection Fraction <30%)~Severe respiratory disease~Inadequate bilateral transcranial Doppler windows~Carotid stenosis ≥70% (unilateral or bilateral)~Participant enrolled in an interventional research study.~Poor understanding of written and verbal English"
88814104|NCT04373018|Active Comparator|Sodium hypochlorite|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Sodium hypochlorite during biomechanical preparation.
89338631|NCT03886207|Experimental|Warm water with ginger powder footbath|Participants who receive a warm water with added ginger powder footbath four times a week over a six-week period.
89338632|NCT03886207|Active Comparator|Warm water only footbath|Participants who receive a warm water only footbath four times a week over a six-week period.
89338633|NCT03885895|Active Comparator|Participants with freckles (one side of the face)|one randomized side of the face will be treated by Intradermal Tranexamic acid
89338634|NCT03885895|Active Comparator|Participants with freckles (other side of the face)|other side will be treated by Q switched KTP laser
89338635|NCT01154647|Experimental|selective serotonin reuptake inhibitor|intravenous, acute, 20mg/ml
89338636|NCT01154647|Placebo Comparator|1 ml 0.9 % NaCl|
89338637|NCT03886051|Experimental|test group|Connective Tissue Graft before Orthodontic treatment
89338638|NCT03886051|Active Comparator|control group|Orthodontic treatment only
89338639|NCT01153165|Experimental|Citalopram|Participants will be commenced on Citalopram 20mgs daily
89338640|NCT01153165|Placebo Comparator|Control|Control group - will receive a matched placebo
89338641|NCT01155505|Experimental|CC-5013 in combination with Paclitaxel|"Cohorts of 3 evaluable patients will initially be entered within each dose level, sequentially. In each dose level the second and third patient will enter 2 weeks after the first one. The second and third patient may be treated simultaneously, except if a DLT is reported in the first patient, in which case the second and third patient should be treated sequentially, at least one week apart.~Dose escalation will be done when all the patients included in each DL will finish the first treatment cycle. Three additional patients will be sequentially entered (separated by one week each other) if one DLT is observed in cycle 1 among the first 3 patients entered within a dose level. If a DLT is observed in a second patient at this dose level, no further dose escalation will be allowed and the dose level will be considered the MTD.~Once the RD (one level below the MTD) has been defined, additional patients (up to 12) will be treated in order to confirm the safety profile of the combination."
89338642|NCT03890185|Experimental|A: Chemo+RT low dose|Chemo + Low dose RT: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin (CDDP) 75mg/m2 IV D1 and radiation therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for a total of 2 cycles every 21 days.
89338643|NCT03890185|Active Comparator|B: Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
89338644|NCT03885973|Experimental|Lactobacillus plantarum|1 bottle of fermented milk (100 g) containing probiotic Lactobacillus plantarum IS-10506 1.0x10^8 CFU will be given daily for three weeks.
89338645|NCT03885973|Placebo Comparator|Placebo|1 bottle of fermented milk (100 g) containing placebo will be given daily for three weeks.
89338646|NCT01154725|Other|Habitual stoma care|habitual patient education
89338647|NCT01154725|Experimental|Patient education and rehabilitation|patient education and rehabilitation
89338648|NCT01153243|Active Comparator|Ergocalciferol|The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
89338649|NCT01153243|Placebo Comparator|Placebo pill|The investigators will give intervention group 12 weeks of placebo pill (in pill every week)
89338650|NCT01259791|Experimental|Statin|Individual-specific statin causing myopathy - i.e., Patients will receive the specific statin previously associated with myopathic symptoms in them (can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously).
89338651|NCT01259791|Placebo Comparator|Placebo|Identical placebo to patient-specific statin
89338652|NCT03887065|Experimental|Starting dose|Three to five patients will receive a daily dose of 1 mg/kg JM-4 (in normal saline) delivered via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
89338653|NCT03887065|Experimental|Intermediate dose of JM-4|Three to five patients will receive a daily dose of 4 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
89338654|NCT03887065|Experimental|High dose of JM-4|Three to five patients will receive a daily dose of 9 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
89338655|NCT03886987|Experimental|Device and Control|"Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml~Negative control: Blank patch Dose: Not applicable"
89338656|NCT03433482|Experimental|GSK3536820A ACWY_Liq24 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1.
89338657|NCT03433482|Active Comparator|ACWY_1 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.
89338658|NCT03433482|Experimental|GSK3536820A ACWY_Liq30 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.
89338659|NCT03433482|Active Comparator|ACWY_2 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.
89338660|NCT03889483|Other|NeuroCatch™ Platform Assessment|All participants will undergo two NeuroCatch™ Platform Assessments.
89338661|NCT01261273||Stable angina|Patient admitted with stable angina
89338662|NCT01261273||Acute Coronary Syndrome|Patients admitted with Acute Coronary Syndrome
89338663|NCT01261273||Female|Participant female patients
89338664|NCT01261273||Bifurcation|One or more lesions treated during the baseline in bifurcation
89338665|NCT01261273||Insulin Dependent Diabetes Mellitus|Patients that were insulin-dependent diabetes mellitus at admission
89338666|NCT01261273||Non-Insulin Dependent Diabetes Mellitus|Patients that were non-insulin-dependent diabetes mellitus at admission
89338667|NCT01261273||Small Vessels|vessels smaller or equal to 2.75mm
89338668|NCT01261273||NOBORI Long Lesions|Lesions longer or equal to 20mm
89338669|NCT01261273||Renal Insufficiency|Patients that at admission had renal insufficiency (> 2.0 mg/dL - 176 µmol/mL) at admission
89338670|NCT01261273||Elderly|Patients more or equal 80 years old
89338671|NCT01261273||Restenosis|One or more lesions treated during the baseline in were restenotic lesions
89338672|NCT01261273||Multivessel Treatment|Patients who underwent the treatment of more than 1 vessel during the index procedure
89338673|NCT01261273||Complex Lesions|Patients who underwent a PCI on the Left Main Trunk, on a Chronic Total Occluded lesion or located on a Saphenous Vein Graft
89338674|NCT01261273||Overall|Total Population
89338675|NCT03432858|Active Comparator|Vancomycin|
89338676|NCT03432858|Active Comparator|Cefazolin|
89338677|NCT03432858|Placebo Comparator|Saline|
89338678|NCT01157143|Experimental|NV1FGF 500 μg|8 intramuscular injections for a total of 500 μg administered in one single administration 3 to 8 days before major amputation
89338679|NCT01157143|Experimental|NV1FGF 2000 μg|8 intramuscular injections for a total of 2000 μg administered in one single administration 3 to 8 days before major amputation
89338680|NCT01157143|Experimental|NV1FGF 4000 μg|8 intramuscular injections for a total of 4000 μg administered in one single administration 3 to 8 days before major amputation
89338681|NCT01261429|Experimental|Nilotinib|
89338682|NCT03432390|Experimental|CPAP|
89338683|NCT03432390|Active Comparator|Control|
89338684|NCT01157221|Experimental|intervention group|intervention group: end-range mobilization/scapular mobilization treatment approach group
89338685|NCT01157221|Active Comparator|control|
89338686|NCT01157221|Sham Comparator|control-criteria group|
89338687|NCT01154803|Experimental|Ready to Use Therapeutic Food (RUTF)|500 kcal /day for 2 weeks
89338688|NCT01154803|Experimental|Micronutrient Powder (MNP)|2 x 1 g sachets micronutrients /day for 2 weeks
89338689|NCT01154803|No Intervention|no supplement|no supplementation
89338690|NCT03885427|Experimental|oral ketamine|evaluate sedative,and analgesic effects
89338691|NCT03885427|Active Comparator|nebulized ketamine|evaluate sedative, and analgesic effects
89338692|NCT03881839||patient in emergency department|
89338693|NCT03881761|Experimental|experimental arm|CAR-T cell group
89338694|NCT01157299||Hemodynamic instability|Hypotension and/or evidence of end-organ hypoperfusion
89338695|NCT01157299||Hemodynamic stability|"Normotension and end-organ normoperfusion along with~Vasopressor, vasodilator or inotropic therapy~Edema and/or evidence of hypervolemia"
89338696|NCT01157299||"Hemodinamically normal"|"Normotension and end-organ normoperfusion along with~Non vasopressor, vasodilator or inotropic therapy~Normohydration state~Non Systemic Inflammatory Response Syndrome~Spontaneous breathing and PEEP, or CPAP, equal or less than 5 cm H2O"
88814105|NCT04373018|Active Comparator|Chlorhexidine|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using Chlorhexidine during biomechanical preparation.
89338697|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
89338698|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
89338699|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
89338700|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
89338701|NCT03456960|Experimental|Study 2,TAK-438ASA (Fasted + Fed condition)|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
89338702|NCT03456960|Experimental|Study 2,TAK-438ASA (Fed + Fasted condition)|One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
89338703|NCT01262209|Experimental|Low Vision Aids|"All patients will receive:~A low vision examination:~Low vision refraction~Distance best corrected visual acuity~Near best corrected visual acuity~Contrast Sensitivity~Quality of life questionnaire~Low vision therapy: to teach strategies for more effective use of remaining vision and use of low-vision devices~Prescribed low vision devices including binocular telescope (2.1x or 3.5x), monocular telescope, 6x telemicroscopes, microscopes, magnifiers, portable CCTV and absorptive filters."
89338704|NCT03881605|Experimental|MRI screening|Contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain at baseline, 4 months, 8 months and 12 months.
89338705|NCT03881605|No Intervention|Symptom-directed surveillance|Imaging of the brain will take place only if patients develop symptoms that are suggestive of brain metastases (e.g. headaches, vision changes, gait instability).
89338706|NCT01261663||NOS intake either at end of meals or as snackings.|
89338707|NCT03718572||Scoring factors|
89338708|NCT03718572||Difficulty criteria|
89338709|NCT03884959|Experimental|HepaStem Infusion|A calculated dose based on patient's body weight will be administered via Permanent mesenteric Portal Access and Catheter for four times or a Transient Percutaneous Transhepatic Catheter for three times.
89338710|NCT03716388|Experimental|FMT Vs Placebo|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus placebo granules (4g/day)
89338711|NCT03716388|Active Comparator|FMT Vs Mesalamine|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
89338712|NCT03716388|Active Comparator|Placebo Infusion Vs Mesalamine|Placebo infusion (colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
89338713|NCT03565003|Experimental|JAB-3068 (SHP2 inhibitor)|JAB-3068 will be administered orally in the morning following a fast of approximately 6 hours before on PK collection. Patients will continue to fast for approximately 2 hours after the administration of JAB-3068. On non-PK days patients will fast approximately 2 hours before JAB-3068 and continue to fast for approximately 2 hours afterwards.
89338714|NCT01311336|Active Comparator|Loratadine|Loratadine 10 mg once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
89338715|NCT01311336|Placebo Comparator|Placebo|Placebo once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
89338716|NCT03886753||Ease|Subjects using Ease as standard treatment. Registry and PK sampling
89338717|NCT03886753||Dream|Subjects using Dream as standard treatment. Registry and PK sampling
89338718|NCT03886753||Soothe|Subjects using Soothe as standard treatment. Registry and PK sampling
89338719|NCT03886753||Shine|Those subjects using Shine as standard treatment. Registry and PK sampling
89338720|NCT03886597|Experimental|60 Arbequina Table Olives|Pharmacokinetics Study
89338721|NCT03886597|Experimental|120 Arbequina Table Olives|Pharmacokinetics Study
89338722|NCT03886597|Experimental|60 Table Olives|Table Olives Nutritional Intervention
89338723|NCT03886597|No Intervention|Control|Control of Table Olives Nutritional Intervention
89338724|NCT03885271|Experimental|Group A (Experimental group) Hall Technique|Clinical examination to assess the clinical inclusion criteria. Radiographic examination.The child will be positioned upright in the dental chair . The correct size of PMC for the tooth will be selected. The tooth will be rinsed and dried, and the PMC dried. The PMC will be filled with glass ionomer luting cement. The PMC will be placed evenly over the tooth and the child instructed to bite down firmly until the crown was pushed down over the tooth;If the child was unable or unwilling to bite down on the PMC, finger pressure will be used to seat the crown Extruded cement will be removed, and the child will be asked to keep biting on the Hall PMC until the cement sets and once cement sets, excess cement is removed, floss will be used to clear the aproximal contacts, and post-fitting instructions will be given (Innes et al. 2007).
89338725|NCT03885271|Active Comparator|Group B (control group) Formecresol Pulpotomy|Clinical examination to assess the clinical inclusion criteria. Radiographic examination. The teeth anesthetized, rubber dam isolation, Complete caries removal achieved with a sterile round steel bur in a slow- speed handpiece. Access to the pulp chamber performed using a sterile slow-speed round steel bur. The pulp amputation with a sterile diamond bur in a high-speed handpiece and pulpal debris removed with a sterile saline solution on a sterile cotton pledget. After pulp amputation haemostasis achieved using a sterile cotton pledget. Formocresol (FC) applied using a sterile cotton pledget for 5 minutes. After removal of the formocresol soaked cotton pledget, the pulp chamber rinsed with water using an air-water syringe. The pulp chamber dried with a sterile cotton pledget, followed by application of Zinc Oxide & Eugenol and zinc phosphate. Tooth preparation done to receive stainless steel crown.
89338726|NCT03430986|Experimental|JUVÉDERM® VOLUMA® with Lidocaine|Participants were treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel during the 24-week Control Period. Participants were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable. Follow-up continued in the 24-week Post-Control period.
89338727|NCT03430986|Experimental|No-treatment Control|Participants received no treatment during the 24-week Control Period. After 24 weeks, participants had the option of treatment with JUVÉDERM® VOLUMA® with Lidocaine Injectable Gel in the nose area during the 24-week Post-Control period and were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable.
89338728|NCT01261741|Experimental|Memantine|
89338729|NCT01261741|Placebo Comparator|Placebo|
89338730|NCT03881527|Experimental|Resection of the aortic valve leaflets with device|Patients in which the aortic valve has been resected using the nitinol blade
89338731|NCT03881527|Other|Resection of the aortic valve leaflets in standard fashion|Patients in which the aortic valve has been resected using a conventional blade or scissor
89338732|NCT03713892|Experimental|CKD-504|investigational Drug
89338733|NCT03713892|Placebo Comparator|Placebo|investigational Drug
89338734|NCT03884881|Other|metagenomic next generation sequencing|Adjust medication for patients with severe pneumonia based on mNGS results
89338735|NCT03884881|Other|Conventional pathogen detection|Blood, bronchoalveolar lavage fluid (BALF), bronchial secretions samples will be collected and microbiologically tested prior to initial empirical antibiotic use.
89338736|NCT03716310||septic shock patients|Inclusion criteria of the study were diagnosis of septic shock and a platelet count >150*103/mcL.
89338737|NCT01263847|Placebo Comparator|No Galactooligosaccharide|0 g galactooligosaccharide added to calcium-containing yogurt beverage
89338738|NCT01263847|Active Comparator|5 g Galactooligosaccharide|5 g galactooligosaccharide provided in two calcium-containing yogurt beverage (2.5 g in each drink) per day
89338739|NCT01263847|Active Comparator|10 g Galactooligosaccharide|10 g galactooligosaccharide added to two calcium-containing yogurt beverage (5 g in each drink) per day
89338740|NCT03713814|Experimental|Experimental Group|8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.
89338741|NCT03713814|No Intervention|Control group|After the 8 weeks of intervention, the pilots will receive explanation and handbook demonstration of the same exercises.
89338742|NCT03884803|Other|HealthyMoms web-based program|An on-line self-help psychoeducational website for new moms that includes educational learning modules and tools to prevent/reduce depression. .
89338743|NCT03884803|Other|Control group|No access to the intervention but to continue with standard care. Will complete the same questionnaires as the HealthyMoms group.
89338744|NCT03713736|Other|Female patients with spondyloarthritis or rheumatoid arthritis|Female patients (18 to 65 years old) with spondyloarthritis or rheumatoid arthritis will undergo HPV screening and a have a close gynecologic follow-up.
89338745|NCT01154881|Experimental|IDeg 100U/mL 0.4U/kg|
89338746|NCT01154881|Experimental|IDeg 100U/mL 0.6U/kg|
89338747|NCT01154881|Experimental|IDeg 100U/mL 0.8U/kg|
89338748|NCT01154881|Experimental|IDeg 200U/mL 0.6U/kg|
89338749|NCT03886441|Experimental|Prevention group|Participants inhaled beclomethasone propionate aerosol daily during chest radical radiotherapy (total dose 60GY).
89338750|NCT03886441|No Intervention|Traditional therapy group|Participants were not given daily inhalation of beclomethasone propionate when undergoing radical chest radiotherapy (total dose 60GY).
89338751|NCT03713346|Other|Lactose digester|
89338752|NCT03713346|Other|Lactose maldigester|
89338753|NCT03716232|Active Comparator|Multiple plastic stents|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
89338754|NCT03716232|Experimental|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months."
89338755|NCT01154959|Experimental|Regimen 1|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 3 months (3RHZEM)
89338756|NCT01154959|Experimental|Regimen 2|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin daily for 2 months (2 RHZEM daily / 2 RHM daily)
89338757|NCT01154959|Experimental|Regimen 3|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2RHM thrice weekly)
89338758|NCT01154959|Experimental|Regimen 4|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, ethambutol and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2 RHEM thrice weekly)
89338759|NCT01154959|Active Comparator|Control Regimen|Rifampicin, isoniazid, pyrazinamide and ethambutol thrice weekly for 2 months followed by rifampicin and isoniazid thrice weekly for 4 months (2 RHZE thrice weekly / 4 RH thrice weekly)
89338760|NCT04862754|Experimental|interval training|Aerobic interval training. It consisted of a modified interval cycle ergometer training program (3 days a week for 8 weeks). AIT consisted of 8 min warm up, followed by four times of 4-min intervals with HR at 80% of submaximal predetermined HR, with active phases of 3 min of cycling at 60% of submaximal predetermined HR. The exercise session was terminated by 5 min cool down
89338761|NCT04862754|No Intervention|medical treatment|hypertensive medication
89338762|NCT03881293|Placebo Comparator|Placebo Lubricant Gel|5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion
89338763|NCT03881293|Active Comparator|Lidocaine 2% Gel|5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion
89338764|NCT01155037|Experimental|3.75 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
89338765|NCT01155037|Experimental|7.5 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 7.5µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
89338766|NCT01155037|Active Comparator|3.75 µg of the vaccine on day 0|The volunteers in the control group will receive a single application of 3.75 µg dose of the vaccine.
89338767|NCT01261897|Active Comparator|Adductor-Canal-Blockade with Ropivacaine|
89338768|NCT01261897|Placebo Comparator|Adductor-Canal-blockade with saline|
89338769|NCT03448536|Experimental|Naproxen Sodium : Acetaminophen|Subjects received one single oral dose of 440 mg naproxen sodium in treatment period 1, followed by one single oral dose of 1000 mg acetaminophen in treatment period 2
89338770|NCT03448536|Experimental|Acetaminophen : Naproxen Sodium|Subjects received one single oral dose of 1000 mg acetaminophen in treatment period 1, followed by one single oral dose of 440 mg naproxen sodium in treatment period 2
89338771|NCT01155115|Experimental|Primary Ciliary Dyskinesia (PCD) Patients|
89338772|NCT01155115|Experimental|Cystic Fibrosis (CF) Patients|
89338773|NCT03885115|Experimental|Intervention|Participants randomly assigned to the experiential group (EG) will receive a 12-week structured exercise that will consist of two group fitness sessions (i.e. kickboxing, Zumba, fitness yoga, and other aerobic exercises) every week. Certified fitness instructors will lead each session and participants will learn strategies how to be more active during the daily routines at home. Parents or other relatives in the EG will participate in one 2-hour session every four weeks (total of 3 sessions) designed to help them support their children and entire family in being active and eat healthy at home. Parents will meet with a fitness instructor who will provide specific tips on how to increase physical activity at home as well as providing community resources to be active. A basic nutrition education and cooking demonstrations, and healthy recipes will be also provided to parents at these workshops. Data/assessments are collected, pre and post the 12 weeks intervention.
89338774|NCT03885115|No Intervention|Control|Participants randomly assigned to the control group (CG) will receive once a week recreational structured group play/game sessions led by trained BOUNCE interns/staff. The control group will receive 60 minute of structured free play sessions (i.e. recreational games) once a week for 12 weeks. Every 4 weeks, parents will be given (either sent home with their child or via email or mail) basic nutrition information, healthy recipes, and tips to promote physical activity at home as well as community resources to be active. Data/assessments are collected, pre and post the 12 weeks intervention.
89338775|NCT03718338||Clinical Evaluations|Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
89338776|NCT03884725|Active Comparator|fibrinogen concentrate|patients randomized to fibrinogen group receive intravenous infusion of drug prepared based on ROTEM measurement of maximum clot firmness (MCF)
89338777|NCT03884725|Placebo Comparator|control|patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF)
89338778|NCT01264003|Active Comparator|1|Antibiotic prohylaxis / Lichtenstein repair
89338779|NCT03448224|Experimental|Group I (web-based Indoor Tanning intervention)|Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention. Participants then receive text messages twice weekly for 4 weeks.
89338780|NCT03448224|Active Comparator|Group II (wait-list)|Participants are placed on wait-list and may receive full intervention after follow-up.
89338781|NCT03713190|Active Comparator|Empagliflozin|SGLT-2 inhibitor
89338782|NCT03713190|Placebo Comparator|placebo|A substance without specific pharmacology principles.
89338783|NCT01262443|Experimental|Therapy Cool Flex catheter group|Therapy Cool Flex Catheter . No more available data
89338784|NCT03886363|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
89338785|NCT03886363|No Intervention|Wait-list control|Usual practice
89338786|NCT03718182|Active Comparator|Arm A - Cholecalciferol 400iu|Vitamin D3 (Cholecalciferol) 400 iu. Daily oral capsule. To be taken for 24 weeks (6 months)
89338787|NCT03718182|Experimental|Arm B - Cholecalciferol 3200iu/800iu|"Vitamin D3 (Cholecalciferol) supplement 3,200iu daily oral capsule. To be taken for 12 weeks (3 months).~Then switch to vitamin D3 supplement 800iu daily oral capsule. To be taken for 12 weeks (3 months)."
89338788|NCT01264159|Placebo Comparator|Control|
89338789|NCT01264159|Active Comparator|Lung impedence-guided treatment|
89338790|NCT03716154|Experimental|SRP and diode laser|In a split mouth design either left or right sites randomly treated by SRP and diode laser as an adjunct
89338791|NCT03716154|No Intervention|SRP alone|The other sites in the other side will be treated by SRP alone
89338792|NCT01155271|Active Comparator|ERGO|General endurance training on cycloergometer
89338793|NCT01155271|Active Comparator|ERGONIV/ ERGOSPIRO|General endurance training on cycloergometer using ventilatory assistance (ERGONIV) or additional respiratory muscle training (ERGOSPIRO)
89338794|NCT03881449|Experimental|ABILIFY MYCITE Group|"If patients are assigned to the ABILIFY MYCITE treatment group, the patients and physician will initiate the system at the baseline visit, and continue to use the system for 3 months. At any time after the first 3 months, a patient and his or her doctor will have the opportunity to either discontinue or continue using ABILIFY MYCITE for the remainder of the trial (9 additional months; 12 months total) as long as clinically appropriate with the goal of measuring adherence to improve clinical decision-making and care.~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
89338795|NCT03881449|No Intervention|Treatment as Usual (TAU) Group|"TAU patients will continue receiving care as recommended by their physician which will include the use of Aripiprazole according to the approved labels.~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
89338796|NCT03713112|Active Comparator|Weekly MDT deprescribing rounds|Weekly MDT deprescribing rounds for certain drugs will be performed on top of usual care.
89338797|NCT03713112|No Intervention|Control (Usual Care)|"Usual Care includes the following:~De-prescribing at the discretion of the ward doctors~Initial medication reconciliation by pharmacist on admission~Ward rounds to be conducted 3 weekdays per week for rehabilitative patients and daily on weekdays for sub-acute patients."
89338798|NCT01157611|Active Comparator|Mentoring program group|type 1 diabetes patients participating in online base mentoring program
89338799|NCT01157611|No Intervention|Control group|type 1 diabetes patients receiving regular clinic visits
89338800|NCT01265329|No Intervention|Control|No sperm selection
89338801|NCT01265329|Experimental|Annexine V negative|Sperm selection with Annexine V protein
89338802|NCT03718026||Patients with Multiple Sclerosis|"The timed 360° turn test~Berg Balance Scale~Timed Up and Go test~Functional Reach Test~One-leg stance test~Four square step test"
89338803|NCT03718026||Healthy Controls|-The timed 360° turn test
89338804|NCT03884491|Experimental|Vortioxetine|
89338805|NCT02527369|Experimental|XP1100RF group|Subjects in the XP1100RF group will be treated with the XP1100RF device.
89338806|NCT03717948|Experimental|CTL - BFR|CTL Exercise then BFR Exercise
89338807|NCT03717948|Experimental|BFR - CTL|BFR Exercise then CTL Exercise
89338808|NCT01155739||procalcitonine monitoring|PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres.
89338809|NCT01155739||control group|control group: antibiotic use and length of treatment as defined by guidelines
89338810|NCT03717870|Experimental|Surgery|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
89338811|NCT03717870|Active Comparator|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
89338812|NCT03881215|Experimental|Platelet Rich Plasma|PRP
89338813|NCT03881215|Active Comparator|intra-uterine balloon|
89338814|NCT01155817|Experimental|Nilotinib|
89338815|NCT03880981|Active Comparator|Acetaminophen|Patients will receive 650mg PO Acetaminophen every 6 hours as needed for pain
89338816|NCT03880981|Active Comparator|Ibuprofen|Patients will receive 600mg PO Ibuprofen every 6 hours as needed for pain
89338817|NCT01157689||Coartem, chloroquine, quinine|All children with a positive malaria test will included. Results will be subanalysed acording to treatment given by routine health staff.
89338818|NCT03424044|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in dual hormone mode and XeriSol glucagon to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
89338819|NCT03424044|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
89338820|NCT03424044|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in predictive low glucose suspend mode. The system will run through the closed-loop system but will utilize the patient's optimized basal rates, correction factors and carb ratios as they would normally run on their own insulin pump. But the mode will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
89338821|NCT03880903|Experimental|normal saline with bronchdilator|will recieve treatment with nebulized brochodilator(salbutamol) and normal saline every 4 to 6 hours
89338822|NCT03880903|Experimental|hypertonic saline with bronchodilator|will recieve treatment with nebulized bronchodilator(salbutamol) and hypertonic saline every 4 to 6 hours
89338823|NCT03880903|Experimental|hypertonic saline only|will recieve treatment with nebulized hypertonic saline 3% in adose of 4 ml every 4 to 6 hours
89338824|NCT03884257|Experimental|Passeo-18 Lux treatment group|These patients will be treated with the Passeo-18 Lux (Biotronik).
89338825|NCT03884257|Active Comparator|IN.PACT Admiral treatment group|These patients will be treated with the IN.PACT Admiral (Medtronic).
89338826|NCT01155895|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
89338827|NCT01155895|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
89338828|NCT01265485|Experimental|treatment|
89338829|NCT01159483|Experimental|Cohort A|"Period 1: Participants received 0.01 milligrams (mg) of PF-04958242 or matching placebo, once, orally.~Period 2: Participants received 0.03 mg of PF-04958242 or matching placebo, once, orally.~Period 3: Participants received 0.1 mg of PF-04958242 or matching placebo, once, orally."
89338830|NCT01159483|Experimental|Cohort B|"Period 1: Participants received 0.3 mg of PF-04958242 or matching placebo, once, orally (fasted).~Period 2: Participants received 0.6 mg of PF-04958242 or matching placebo, once, orally.~Period 3: Participants received 1.0 mg of PF-04958242 or matching placebo, once, orally (fed)."
89338831|NCT01157767||breast pts who have undergone surgery|This will be a feasibility study designed to evaluate the compliance of an at-home, directed exercise program and its influence on physical measures during post-operative adjuvant chemotherapy and radiation (if applicable).
89338832|NCT03422250|Experimental|Arm 1|Alzheimer's disease (AD): anodal tDCS of the default mode network (DMN)
89338833|NCT03422250|Experimental|Arm 2|Alzheimer's disease (AD): cathodal tDCS of the salience network (SN)
89338834|NCT03422250|Experimental|Arm 3|Behavioral-variant frontotemporal dementia (bvFTD): anodal tDCS of the salience network (SN)
89338835|NCT03422250|Experimental|Arm 4|Behavioral-variant frontotemporal dementia (bvFTD): cathodal tDCS of the default mode network (DMN)
89338836|NCT01159561|Experimental|Vaccinated|Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)
89338837|NCT01265641|Experimental|1|
89338838|NCT01265641|Experimental|2|
89338839|NCT01265641|Experimental|3|
89338840|NCT01265641|Placebo Comparator|4|
89338841|NCT03712800|Experimental|Rhythmical massage|Participants who receive rhythmical massage for three months.
89338842|NCT03712800|Experimental|HRV biofeedback|Participants who perform HRV biofeedback for three months.
89338843|NCT03712800|No Intervention|Control group|Participants who do not receive an intervention during the three-month intervention period but are advised to stay with their usual care during menstrual pain. For ethical and compliance reasons, these participants receive a series of rhythmical massage treatments after the initial three-month intervention/control period.
89338844|NCT01589731||Allergic group|The first group (group A) included 45 patients (17 males; mean age: 46.2 years, SD: 12.2 years) with convincing clinical histories of reproducible adverse reactions to bovine milk. All subjects presented βs-IgE that were detectable by SDS-PAGE immunoblotting.
89338845|NCT01589731||Non Allergic group|The second group (group B) was used as a control for the immunoblotting analysis performed in the first group and included 20 individuals selected based on an evident tolerance to cow's milk, an absence of βs-IgE by ImmunoCAP assay and SPT non-reactivity to β-Lg or TgPolβ-Lg (6 males; mean age: 21.9 years, SD: 17.6 years).
89338846|NCT01589731||Atopic group|The third group (group C) included 49 subjects with atopic respiratory and/or dermatological diseases (19 males; mean age: 28.7 years, SD: 20.6 years) regardless of βs-IgE status. This group was used to compare the ex vivo cell-mediated immunoreactivity between β-Lg and TgPolβ-Lg by comparing the mean ex vivo antigenic challenge results determined using the leukocyte adherence inhibition test (LAIT).
89338847|NCT01589809|Experimental|Nicotinamide|Comparison is made within-subjects to different doses and no treatment
89338848|NCT02527135|Experimental|Behavioural|Intervention arm receiving weekly HIV sensitization text messages
89338849|NCT02527135|No Intervention|Control|No weekly messages were sent to this group
89338850|NCT01264237|Experimental|Etoricoxib|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib. Patients who experience at least a 30% reduction in pain intensity will be randomized to either continued treatment with etoricoxib 90 mg qd or matching placebo (at a 1:1 ratio) for 4 weeks.
89338851|NCT01264237|Placebo Comparator|Placebo|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib, followed by a 4-week randomized, double-blind, placebo-controlled treatment phase, during which subjects will receive either etoricoxib or placebo.
89338852|NCT03884413||Breast cancer survivors|Study of spontaneous fertility outcomes following breast cancer history
89338853|NCT03884413||Control group|Study of spontaneous fertility outcomes in healthy volonteers population
89338854|NCT03880747||Vagus nerve preserving group|Patients who underwent vagus nerve-preserving distal gastrectomy for early gastric cancer
89338855|NCT03880825|Other|Metformin Only|
89338856|NCT03880825|Other|Levoketoconazole Only|
89338857|NCT03880825|Other|Levoketoconazole + Metformin|
89338858|NCT01159639|No Intervention|aspirin low responders monotherapy|patients with inappropriate response to aspirin assessed by multiple electrode aggregometry
89338859|NCT01159639|Active Comparator|aspirin low responders dual antiplatelet therapy|patients with inappropriate response to aspirin 300 mg therapy after CABG, randomized to receive clopidogrel 75 mg in addition to aspirin
89338860|NCT03880357|Experimental|Test Product|Betamethasone Scalp Suspension 0.064%;0.0005% (Taro Pharmaceuticals Inc.)
89338861|NCT03880357|Active Comparator|Reference Product|Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)
89338862|NCT03880357|Placebo Comparator|Placebo|Vehicle of the test product (Taro Pharmaceuticals Inc.)
89338863|NCT03884335|Active Comparator|epidural group|An epidural catheter was placed at L1-L2 level, and tested, prior to induction. Induction was performed intravenously with fentanyl (1.5mcg•Kg-1), propofol (1.5-2 mg•Kg-1), and rocuronium (0.6 mg•Kg-1). Orotracheal intubation was performed. Prior to skin incision 8 mL of 0.25% levo-bupivacaine were administered epidurally, and a continuous perfusion of 0.125% levo-bupivacaine at 5 mL was started.
89338864|NCT03884335|Experimental|TAP group|Bilateral Transversus abdominis plane blockade (TAP) was performed following induction of anaesthesia ( the same of epidural group) and prior to skin incision, the high-frequency lineal probe (Sonosite MicroMAXXTM) was placed midway between the costal margin and iliac crest, and transversus abdominis muscle located behind the rectus abdominis and below the IOM. 20 mL of LA (bupivacaine 0.375%) was administered via a 22 gauge Quincke spinal needle inserted in-plane on each side of the abdomen. A successful block was recorded if the plane was seen to expand with fluid under ultrasound vision.
89338865|NCT03879031||Outpatients with low back pain|"All outpatients with non-specific subacute or chronic low back pain will be submitted to a physical therapy program including:~information on pain mechanisms and the favorable nature of non-specific low back pain;~advice on positions, movements and activities recommended or advised against in people with low back pain, both at work and during leisure time;~active postural correction exercises, overactive muscles lengthening and weak musculature strengthening;~passive manual techniques, aimed at muscle relaxation and recovery of lumbar joint mobility.~A cluster of Clinical tests to measure lumbar stability will be administrated before the starting of the first session and at the ending of the last session of the physical therapy program."
89338866|NCT01262521|Experimental|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
89338867|NCT01262521|Placebo Comparator|Water|150 ml Chapelle mineral water
89338868|NCT01264393|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an internet-based weight loss program, and the option of attending face-to-face group sessions
89338869|NCT01264393|Active Comparator|Shape Up Rhode Island + Online Weight Loss Program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention in addition to an internet-based weight loss program
89338870|NCT01264393|Active Comparator|Shape Up Rhode Island + Internet Resources|Participants in this arm will receive the Standard Shape Up Rhode Island statewide intervention plus access to internet resources
89338871|NCT01157923|Experimental|intervantion group|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor.
89338872|NCT01157923|No Intervention|control group|Regular treatment, No change will be made in the insulin pump setting during the study(unless there is a medical need or any safety concern).
89338873|NCT01266031|Experimental|Bevacizumab|10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.
89338874|NCT01266031|Experimental|Vorinostat and Bevacizumab|"Vorinostat: 400 mg/day by mouth on days 1 to 7 and days 15 to 21 of a 28 day cycle.~Bevacizumab: 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle."
89338875|NCT01264471||Gulf War Syndrome patients|Gulf War veterans who have been diagnosed with Gulf War Syndrome.
89338876|NCT03880045|Active Comparator|Topical TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
89338877|NCT03880045|Active Comparator|placebo to TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus placebo to tranexamic acid
89338878|NCT01159873|Experimental|CEP-37251|
89338879|NCT01159873|Placebo Comparator|Placebo|
89338880|NCT03880201||patient undergoing upper limb orthopaedic surgery|The study will be performed on patient undergoing upper limb orthopaedic surgery which will be performed under ultrasound guided supraclavicular block.
89338881|NCT03879889|Experimental|Intervention|Intervention arm will include face-to-face counseling on smoking reduction and adherence to nicotine replacement therapy (NRT) with motivational interviews, provision of free NRT, referral to quit smoking hotline, monthly phone follow-up and two follow-up visits.
89338882|NCT03879889|No Intervention|Control|Smoking parents will be given standard advice on smoking cessation. They will be given an information leaflet showing standard information on the currently available smoking cessation service as well as a smoking cessation hotline.
89338883|NCT01159951||Hepatitis Cohort|Subjects suffering with hepatitis
89338884|NCT01158001|Experimental|Psychotherapy via telemedicine|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in a novel format - interacting with a therapist via videoconferencing.
89338885|NCT01158001|Active Comparator|Face-to-face (in person) psychotherapy|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in the traditional format - in person with a therapist.
89338886|NCT03883789||Normal pregnancies|Participants who have normal uncomplicated pregnancies
89338887|NCT03883789||Pregnancies with complications|Participants who undergo pregnancy with liver disease or develop liver disease or other conditions
89338888|NCT01155973|Experimental|EDUCORE intervention|Use of low risk SCORE table. Use of visual impact images. Handing the patient a pamphlet (advice on how to maintain cardiovascular health plus the low risk SCORE table with the patient's current score marked).
89338889|NCT01155973|Active Comparator|control group|Use of low risk SCORE table; verbally informing the patient of his/her CVR. Giving advice/verbal information on risk factors.
89338890|NCT03883555||Optiflow tm|High flow nasal therapy (HFNT)
89338891|NCT03883555||Non invasive ventilation (NIV)|Non invasive ventilation (NIV)
89338892|NCT01266109|Experimental|CM-FAM|
89338893|NCT01266109|Active Comparator|US|
89338894|NCT03879187|Experimental|High-fat diet|Participants underwent a 7 day high-fat, high-energy diet intervention with metabolic measurements before and after
89338895|NCT01266187|Experimental|Arm B|"12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery~-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab"
89338896|NCT01266187|Active Comparator|Arm A|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
89338897|NCT01264627|Experimental|Mindful Breathing (MB)|"The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn. Participants will be organized into cohorts of eight, and attend eight weekly MB sessions. Mindful breathing consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective. No other intervention is included. No FDA drug or device is involved."
89338898|NCT01264627|Other|Usual Care (UC)|Usual Care consists of the standard care made available to participants through their primary physician. No intervention is included. No FDA drug or device is involved.
89338899|NCT05666947|Experimental|Home-based resistance exercise|The experimental group participated in a home-based exercise program for eight weeks, namely elastic-band resistance exercise. Participants were forwarded to the next exercise session every two weeks and completed the exercise program within eight weeks. The program included upper and lower limb exercises. The home-based exercise program contained four sessions, namely: warm-up, start-up, vigorous, and reinforcement sessions. Participants received guidelines from a booklet and video about elastic-band resistance.
89338900|NCT05666947|Placebo Comparator|Non-resistance exercise|The control group participated in an exercise program for eight weeks, namely conventional non-resistance exercise, which contained four sessions: warm-up, start-up, vigorous, and reinforcement. Participants were forwarded to the next exercise session every two weeks and completed the exercise program within eight weeks. Participants in the control group received guidelines from a booklet and video about the conventional non-resistance exercise.
89338901|NCT01586533|Experimental|Zoenasa-1:4|
89338902|NCT01586533|Active Comparator|Mesalamine Enema|
89338903|NCT03883321||CBSM|Patients included in this group participate in the CBSM program. They attend 10 sessions of stress management according to the CBSM program, 9 take place over 3 months and the tenth session takes place 3 months after the 9th session. The session is composed of relaxation and cognitive and behavioral therapy, which is carried out in groups of 8 to 10 patients
89338904|NCT03883321||Waiting list|"The CBSM group is compared to the waiting list group that does not benefit from the CBSM program. After completing their assessment in the waiting list group, patients in this group will be integrated into the CBSM group but will not be evaluated as such."
89338905|NCT01266343||Experimental Group|
89338906|NCT01266343||Control Group|
89338907|NCT03523039|Experimental|Hemoadsorption|Hemoadsorption is performed using a CytoSorb® cartridge.
89338908|NCT03523039|No Intervention|Control|Post-cardiac arrest management will be conducted as per institutional protocols.
89338909|NCT01158235|Experimental|LTX-109 (Lytixar)|Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2%LTX-109/placebo and finally group 3: 5%LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
89338910|NCT01266421||Dienogest (DNG)|Women using DNG) for the treatment of endometriosis
89338911|NCT01266421||Other approved endometriosis drugs (OAED)|Women using hormonal medications approved for endometriosis treatment in all particiapting countries other than DNG.
89338912|NCT01266421||Non-approved endometriosis drugs (NAED)|Women using hormonal medications not approved for endometriosis treatment in all particiapting countries.
89338913|NCT03879265||Study group|No intervention. Couples who come to the study center to carry out a PGT-A cycle will be selected. Only couples that will use their own gametes will be selected and the indication of PGT-A will be advanced maternal age, failure of implantation, repeat abortion, male factor or structural chromosomal alterations. The results of chromosomal status of the embryo will be compared using the NICS and the conventional invasive method (PGT-A).
89338914|NCT01158313||Thickener|"Patients with history of swallowing difficulties associated with aging and/or neurological diseases including patients with:~neurodegenerative diseases.~non-progressive neurological diseases including stroke.~older patients including nursing home patients."
89338915|NCT03880123|Experimental|Selinexor/Ixazomib|Patients will receive combination treatment with selinexor and ixazomib. The dose of ixazomib is fixed at 4 mg, whereas several different dose levels of selinexor may be evaluated. No patients will receive a placebo.
89338916|NCT01266499|Active Comparator|Group 1: will receive PO Garamycin 80mg x 4/d|will receive PO Garamycin 80mg x 4/d
89338917|NCT01266499|Active Comparator|Group 2 : will receive PO Colistin (Polymyxin E) 100mg x 4/d|
89338918|NCT01266499|Active Comparator|Group 3: will receive both medications|
89338919|NCT01266499|Placebo Comparator|Group 4: will not receive PO treatment|
89338920|NCT00075725|Active Comparator|Arm I|Patients in arm I receive intrathecal cytarabine in week 1; infusions of vincristine and daunorubicin once a week in weeks 1-4; dexamethasone by mouth or infusion twice a day in weeks 1 and 2; intrathecal methotrexate in weeks 2 and 5 or 2-5; and an injection of pegaspargase in week 1.
89338921|NCT00075725|Active Comparator|Arm II|Patients in arm II will receive intrathecal cytarabine in week 1; infusions of vincristine and daunorubicin once a week in weeks 1-4; dexamethasone by mouth or infusion twice a day in weeks 1 and 2; intrathecal methotrexate in weeks 2 and 5 or 2-5; and an injection of pegaspargase in week 1.
89338922|NCT00075725|Experimental|Arm III|"Patients in arm III will receive cytarabine, vincristine, daunorubicin, and pegaspargase as in groups one and two. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and intrathecal methotrexate in weeks 2 and 5.~Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy by infusion, injection, intrathecally, and by mouth for up to 8 weeks."
89338923|NCT00075725|Experimental|Arm IV|"Patients in arm IV will receive cytarabine, vincristine, daunorubicin, and pegaspargase as in groups one and two. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and intrathecal methotrexate in weeks 2 and 5.~Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy by infusion, injection, intrathecally, and by mouth for up to 8 weeks."
89338924|NCT03883399||Colorectal surgeons|Survey among Spanish colorectal surgeons
89338925|NCT03879967|Experimental|Allograft block graft|For lateral alveolar ridge augmentation, all patients will be treated with allograft block with guided bone regeneration. After a minimal healing phase of six months, implants would be placed in the augmented site. After a healing phase of about 4months, the implants would be loaded and then followed until the control appointment approximately 3 years later.
89338926|NCT02953782|Experimental|Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by intravenous (IV) infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented progressive disease (PD).
89338927|NCT02953782|Experimental|Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
89338928|NCT02953782|Experimental|Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
89531671|NCT05801653|Experimental|Oat meal 2|The test portion is based on 30 gram available carbohydrates with added y amount of oat betaglucan. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning
89338929|NCT02953782|Experimental|Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both were given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
89338930|NCT02953782|Experimental|Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
89338931|NCT02953782|Experimental|Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced colorectal cancer (CRC) who are KRAS wild type (KRASwt) and are refractory to anti-EGFRmAb therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
89338932|NCT02953782|Experimental|Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRAS mutation (KRASm) who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
89338933|NCT02953782|Experimental|Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRASm who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approx. 3 hours) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approx. 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
89338934|NCT01158391|Experimental|NTrainer® Intervention|NTrainer® Intervention - Infants in the experimental group will receive the NTrainer System patterned synthetic orocutaneous stimulation during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
89338935|NCT01158391|Sham Comparator|Control Intervention|Control Intervention - Infants in the Control group will be provided orocutaneous stimulation with a 'quiet pacifier' during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
89338936|NCT01262833||Cases|Patients with erectile dysfunction by ILEF questionnaire
89338937|NCT01262833||Controls|Patients without erectile dysfunction by ILEF questionnaire
89338938|NCT01264783|Experimental|RNS60|RNS60
89338939|NCT01264783|Placebo Comparator|Placebo|Placebo
89338940|NCT03712722||rCDI|Adult patients with recurrect Clostridium difficile infection
89338941|NCT01262911|Active Comparator|1.0 g SRT2379|Single dose of 1.0g of SRT2379
89338942|NCT01262911|Placebo Comparator|1.0 g Placebo|Single dose of 1.0g of placebo
89338943|NCT03712644|No Intervention|Conservative|Patients will receive primarily optimal medical therapy alone and followed, according to protocol. Any further cardiologic investigation will be performed only in case of clinical suspicion of myocardial ischemia related symptoms.
89338944|NCT03712644|Experimental|Invasive|"In the Invasive group in addition to optimal medical therapy elective coronary angiography will be performed. Coronary catheterization is preferably scheduled within a maximum of 14 days after peripheral revascularization~All lesions of 50-90% diameter stenosis in a major coronary artery will be evaluated by fractional flow reserve (FFR) and intervened by percutaneous coronary intervention (PCI) if FFR≤0.80 or left for medical therapy if FFR>0.80. All lesions of ≥90% diameter stenosis in a major coronary artery will be intervened. This includes also efforts to recanalize chronic total occlusions (CTO) of large supplied viable myocardial territory.~For complex cases revascularization by coronary artery bypass surgery might be considered, however PCI is preferred whenever possible."
89338945|NCT01160029|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
89338946|NCT01160029|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
89338947|NCT03717714|Active Comparator|Glucosamine 1500mg|Glucosamine 1500 mg per day for 12 weeks
89338948|NCT03717714|Experimental|Polycan & Glucosamine 750mg|Polycan 50 mg + Glucosamine 750 mg per day for 12 weeks
89338949|NCT03717714|Experimental|Polycan & Glucosamine 1500mg|Polycan 50 mg + Glucosamine 1500 mg per day
89338950|NCT01264861|Experimental|Arm 1:|Arm 1: Eligible subjects will receive escalating doses of safinamide for the 6-week duration of treatment. Each dose level will be last 10-14 days. Doses 200mg and 300mg will have a 3 day intermediate step up dose, 150mg and 250mg dose.
89338951|NCT03760081|Experimental|ASP1650, Dose Level 1|Participants received ASP1650 dose level 1 as intravenous infusion, every two weeks (Q2W) starting on Cycle 1 Day 1(C1D1) for up to a maximum of 12 cycles, or until disease progression, toxicity requiring study treatment cessation, start of another anticancer treatment, or until study discontinuation criteria was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
89338952|NCT03760081|Experimental|ASP1650, Dose Level 2|Participants received ASP1650 dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criteria as met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
89338953|NCT03422172|Experimental|Subjects receiving CAB|Eligible subjects will receive oral doses of CAB 30 milligrams (mg) tablets once daily for 4 weeks followed by IM injectable suspension of CAB LA 600 mg at Week 5, Week 9, Week 17, Week 25 and Week 33. There will be an approximately 1-week washout period between the last oral dose and the first injection of CAB at Week 5.
89338954|NCT00057863|Experimental|Treatment (paclitaxel, oxaliplatin)|Patients receive paclitaxel IV over 3 hours and oxaliplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89338955|NCT03960749|Experimental|Sprotte 25G needle, stylet reinserted|
89338956|NCT03960749|Experimental|Sprotte 25G needle, stylet not reinserted|
89338957|NCT03960749|Experimental|Sprotte 22G needle, stylet reinserted|
89338958|NCT03960749|Experimental|Sprotte 22G needle, stylet not reinserted|
89338959|NCT03960749|Experimental|Spinocan 25G needle, stylet reinserted|
89338960|NCT03960749|Experimental|Spinocan 25G needle, stylet not reinserted|
89338961|NCT05451511|Active Comparator|Door-In-The-Face Technique|Using sequential request strategies, participants randomized to the Door-In-The-Face Technique group will be asked if they would like vaccination support (if not already vaccinated) and if they say no, they will be asked if they'd like to try a COVID-19 self-test at home.
89338962|NCT05451511|Active Comparator|Foot-In-The-Door Technique|Using sequential request strategies, participants randomized to the Foot-In-The-Door Technique group will be first asked if they are interested in trying an at-home COVID-19 test and then asked if they are interested in vaccination support (if not already vaccinated).
89338963|NCT01266655|Experimental|Baclofen|
89338964|NCT01266655|Placebo Comparator|Placebo|
89338965|NCT01099553|Other|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Boston Medical Center
89338966|NCT01099553|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions asking them to watch an educational video on the Center for Digestive Disorders website
89338967|NCT03878875||High Noise Exposure|One group (20, 10f:10m) with previous exposure i.e. nightclubs ++
89338968|NCT03878875||Low Noise Exposure|Group (20, 10f:10m) with less exposure measured through NESI
89338969|NCT03715920|Active Comparator|High Voltage Pulsed Galvanic Current|HVPG current is a new form of neuromuscular electrical stimulation.The total output voltage of the device ranged from 0 to 500 volts and the current intensity was increased until the sensible contraction of the applied muscle was achieved without causing too much sense of discomfort
89338970|NCT03715920|Placebo Comparator|Russian Current|"Russian currents are a high frequency current of 2500 Hz and reduce the resistance of the skin and it would penetrate deeper and reach deeper motor nerves.Russian movement, a protocol developed by Kots, also known as Russian Technique, was used in the literature. There were 10 muscle contractions per treatment session in this protocol. Each contraction lasted for 10 seconds and a resting time of 50 seconds were given for the next contraction (transition: rest ratio was 1/5)."
89338971|NCT03715920|Sham Comparator|Isometric Exercise|"Isometric or static strength training is exercises performed without joint movement and changing muscle length during muscle contraction.~The body and knee of the participants in the isometric exercise group were positioned and stabilized at 75 ° flexion and 60 ° flexion angle, respectively as in the stimulation groups. Participants were asked to do 10 repetitions as 10 seconds of maximum voluntary contractions and 10 seconds of rest."
89338972|NCT03883633||Enrolled Participants|All participants enrolled will be tracked from initial assessment to study completion.
89338973|NCT00075023|Experimental|Thalidomide gel|Thalidomide gel 20 mg applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
89338974|NCT00075023|Experimental|Placebo|Placebo gel with no Thalidomide applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
89338975|NCT03715842|Experimental|Tub shaped design|The tub-shaped preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
89338976|NCT03715842|Active Comparator|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
89338977|NCT01263067|Experimental|Lifespan Integration Therapy (LI)|
89338978|NCT01263067|Active Comparator|Waitlist Control- Lifespan Integration|
89338979|NCT03717636|Experimental|Hospital Day|Patients in the Hospital-Day group will return for medical evaluation 7-14 days in the specific unit.
89338980|NCT03717636|Other|Outpatient clinic|The patients in control group will return for medical evaluation 30 days at the outpatient clinic.
89338981|NCT01100801|Experimental|TS-1 with cisplatin|"Chemotherapy injection (60mg/m2 cisplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
89338982|NCT01100801|Experimental|TS-1 with oxaliplatin|"Chemotherapy injection (100mg/m2 oxaliplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
89338983|NCT01263145|Experimental|Treatment (Akt inhibitor MK2206 and paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and Akt inhibitor MK2206 PO QD on days 2, 9, and 16. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89338984|NCT03717558|Active Comparator|Stromectol R|Stromectol R = ivermectin 3mg (tablet)
89338985|NCT03717558|Experimental|ivermectin T1|T1= ivermectin low grade particle Size Distribution
89338986|NCT03717558|Experimental|ivermectin T2|T2= ivermectin medium grade particle Size Distribution
89338987|NCT03717558|Experimental|ivermectin T3|T= ivermectin high grade particle Size Distribution
89338988|NCT00074711|Active Comparator|Calcium Phosphate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
89338989|NCT00074711|Active Comparator|Calcium Carbonate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
89338990|NCT01156207|Experimental|Aliskiren|
89338991|NCT01156207|Placebo Comparator|placebo|
89338992|NCT05620524||Patients treated with FLOT regimen|Exposure to 5-FU in patients treated with FLOT
89338993|NCT03878641|Experimental|Children in Grade 1 to 5 with literacy and language needs|The investigators intend to identify children in Grade 1 to 5 who demonstrate language-based learning difficulties. Using the two-stage screening, the investigators will identify children who produce substantial number of reading miscues and/or self-correct more less 25% of their miscues, and/or who present weaknesses in expressive language skills with a total CUBED score lower than grade-specific cut scores.
89338994|NCT03960905||Children with the usage of anti-infective drugs|in conformity with the clinical practice
89338995|NCT05619120|Experimental|Giant T-wave electrical alternans conventional plus mexiletine therapy|It is proposed that patients presenting with giant TWA-triggered VT/VF patients to be randomized to conventional treatment and conventional plus mexiletine treatment, respectively.
89338996|NCT05619120|Active Comparator|Giant T-wave electrical alternans conventional therapy|Conventional treatment in the control group according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
89338997|NCT01158625|No Intervention|Morning dosing of antihypertensive drugs|
89338998|NCT01158625|Active Comparator|Nighttime dosing of antihypertensive drugs|
89338999|NCT01099787||FAP IBS|
89339000|NCT03712332|Experimental|Distress Tolerance Group|6 session inpatient distress tolerance group intervention twice a week for 1.5 hours for up to three weeks.
89339001|NCT01265017|Experimental|Active Treatment|"interventions include Estradiol, medroxyprogesterone, hydrocortisone, GH as follows~Estradiol 1mg every 8 hours administered orally~Medroxyprogesterone 2.5 mg every 24 hours administered orally~Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~Growth hormone 2 mg once a day administered by subcutaneous injection"
89339002|NCT01265017|Placebo Comparator|Placebo|Matching placebo
89339003|NCT01266733|Experimental|Interdisciplinary treatment|
89339004|NCT01266733|No Intervention|Usual treatment|
89339005|NCT03420300|Experimental|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination [FDC]): 1 table per os per day for 12 weeks
89339006|NCT01099943|Experimental|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
89339007|NCT01099943|No Intervention|No education, no implemented decision support tools|Clinics randomized to the control will not participate in the education intervention and implementation of decision support tools.
89339008|NCT03951155|Experimental|ADHD Group|Muscle Relaxation technique for behavioral management
89339009|NCT03951155|No Intervention|Tell Show Do Group|Tell Show Do Technique for behavioral management
89339010|NCT03419598||All study participants|All virtual participants who received a virtual opening wedge high tibial osteotomy. The baseline information was the individual CT-based geometry of tibia.
89339011|NCT01158781|Experimental|gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition
89339012|NCT01584323|Active Comparator|Pomegranate pills|treatment with pomgranate pills to women suffering preterm premature rupture of membranes
89339013|NCT01584323|Placebo Comparator|placebo pills|treatment with placebo to women with preterm premature rupture of membranes
89339014|NCT03878329|No Intervention|standard of care|standard of care treatment
89339015|NCT03878329|Experimental|remote home monitoring|use of telemedicine based remote home monitoring
89339016|NCT03951623|Active Comparator|treatment arm|Eligible subjects will be treated with planned dose of 100 mg, 200 mg and 300 mg HMPL-523 once daily for 8 weeks and 16 weeks open-label treatment.
89339017|NCT03951623|Placebo Comparator|placebo arm|Eligible subjects will be treated with HMPL-523 matching placebo once daily for 8 weeks and 16 weeks open-label treatment.
89339018|NCT03879811|Experimental|MMR-Proficient Colorectal Cancer|"The first 3 subjects will receive oral TMZ at 150mg/m2 day 1 to 5 during cycle~1, followed by nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1 (i.e. Cycle 2 day 1). Nivolumab will continue for up for 2 years maximum. If confirmed that TMB increased in at least 2 of 3 subjects following 1 cycle of TMZ, then subsequent patients will continue to receive TMZ during cycle 1 only, and the original three participants will not be replaced. If it is determined that TMB did not increase following 1 cycle of TMZ, then subsequent patients will receive TMZ up to cycle 3, those first 3 patients will discontinue further Nivolumab and be replaced and an additional 6 patients will initially be enrolled. If confirmed that TMB increased in at least 1 of 6 subjects following 3 cycles of TMZ, then 12 more patients will be allowed to enroll for a total of 18 in stage I."
89339019|NCT03951857|No Intervention|Young men|Range of age is 20-35 years, young men (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
89339020|NCT03951857|No Intervention|Young women|Range of age is 20-35 years, young women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
89339021|NCT03951857|Experimental|Elderly women (control)|Range of age is 65-80 years, Elderly women (BMI 19-23 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
89339022|NCT03951857|Experimental|Elderly obese women|Range of age is 65-80 years,Elderly obese women (BMI ≥25 Kg/m2) They did not suffer from musculoskeletal or metabolic diseases, and had not performed regular exercise within the previous 3 months.
89339023|NCT01158859|Experimental|Pregabalin|
89339024|NCT01158859|Placebo Comparator|Placebo|
89339025|NCT01100021|Experimental|tamsulosin + avanafil|
89339026|NCT01100021|Experimental|Doxazosin + avanafil|
89339027|NCT03407430|Experimental|Pregabalin, then Placebo|"Pregabalin in cycle 1; placebo in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg twice a day (BID) for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
89339028|NCT03407430|Experimental|Placebo, then Pregabalin|"Placebo in cycle 1; pregabalin in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg BID for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
89339029|NCT01266811|Experimental|001|Siltuximab Velcade and dexamethasone Given in 21-day treatment cycles Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
89339030|NCT01266811|Other|002|Placebo Velcade and dexamethasone Given in 21-day treatment cycles Placebo as 1-hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
89339031|NCT01584635|Experimental|Peroral Endoscopic Myotomy (POEM)|Peroral Endoscopic Myotomy- a less invasive treatment for patients with Achalasia
89339032|NCT01100099|Experimental|Gluten challenge.|Diagnosis of celiac disease. Before and after a gluten challenge small bowel biopsies will be taken, and blood samples will be drawn for tetramer staining of gluten specific T cells.
89339033|NCT01158937|Experimental|Extended Meropenem Infusion|Meropenem Infusion over 3 hours
89339034|NCT01158937|Experimental|Bolus Meropenem Infusion|Meropenem infusion over 30 minutes
89339035|NCT03407118|Experimental|LY900014|Single, 15 units (U)LY900014 administered subcutaneously (SC) in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus (T1DM).
89339036|NCT03407118|Active Comparator|Insulin Lispro (Humalog)|Single, 15 U insulin lispro administered SC in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus.
89339037|NCT01100177|Experimental|Sunitinib plus radiothery|"Sunitinib at doses of 37.5mg/m2/daily in a continuous dosing during 8 weeks.~After evaluation of efficacy, they will receive Sunitinib 37.5 mg/d and treatment with Radiation therapy (total dose 60 Gy).~After radiation therapy, Sunitinib al 37.5 mg/d will be continued until progression."
89339038|NCT03883243|No Intervention|Control|Patients will only receive a brochure explaining the importance of physical activity with recommendations to improve it.
89339039|NCT03883243|Experimental|Telecoaching|Patients will receive a brochure explaining the importance of physical activity with recommendations to improve it. Next to this patients will receive the telecoaching intervention in which a coaching application linked to a step counter is installed on the patients smartphone, which will weekly give a new physical activity goal to improve the amount of steps per day for 8 weeks.
89339040|NCT01327235|Active Comparator|Endostar|
89339041|NCT01327235|Active Comparator|Cisplatin|
89339042|NCT01327235|Experimental|Endostar and Cisplatin|
89339043|NCT03406962|Experimental|MGTA-456|MGTA-456 is an expanded CD34+ cell therapy investigational product used in replacement of single umbilical cord blood transplantation.
89339044|NCT03882931|Experimental|TMS to left DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the left DLPFC and complete a visuomotor rotation task.
89339045|NCT03882931|Experimental|TMS to right DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the right DLPFC and complete a visuomotor rotation task.
89339046|NCT03882931|Sham Comparator|TMS Control|A Sham Theta Burst Transcranial Magnetic Stimulation will be delivered to the right/left DLPFC and complete a visuomotor rotation task.
89339047|NCT03882931|Experimental|FUS to right/left DLPFC|Low intensity Focused Ultrasound stimulation will be delivered to either the left or right DLPFC depending on the subject's DLPFC response during their functional MRI flanker task.
89339048|NCT03951701|Experimental|observation cohort|Questionnaire to assess the supportive care needs
89339049|NCT01265095||VRE bacteremia|VRE bacteremia patients
89339050|NCT02530307|Experimental|HT-3951 (15mg)|HT-3951 capsules administered once daily
89339051|NCT02530307|Placebo Comparator|Placebo|Placebo capsules administered once daily
89339052|NCT03882853|Active Comparator|Conservative exercise group (CEG)|Conservative exercise group
89339053|NCT03882853|Experimental|Tree pose added exercise group (TPAEG)|Tree pose added exercise group
89339054|NCT03406260|Experimental|Lasmiditan 200 mg (milligrams)|Participants received 200 mg of Lasmiditan tablet orally in the fasted state with approximately 240 (milliliter) mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
89339055|NCT03406260|Experimental|Lasmiditan 100 mg|Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
89339056|NCT03406260|Placebo Comparator|Placebo|Participants received placebo tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
89339057|NCT01089179|Experimental|Torrent's Metformin tablets 500 mg|
89339058|NCT01089179|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
89339059|NCT01156285||AAU|patient with acute attack of anterior uveitis
89339060|NCT01583387|Other|1= Intervention|
89339061|NCT01583387|Other|2= Control|
89339062|NCT01160185||cisplatin|
89339063|NCT01160185||cisplatin + topotecan|
89339064|NCT01160185||cisplatin + paclitaxel|
89339065|NCT03419364|Experimental|Nicotinamide - pre-eclampsia|All participants will receive study agent
89339066|NCT03419364|Experimental|Nicotinamide - healthy pregnant|All participants will receive study agent 1000mg in single dose
89339067|NCT03419364|Experimental|Healthy Non-Pregnant|All participants will receive study agent 1000mg in single dose
89339068|NCT01089335||Papillary thyroid cancer|Patients with preoperatively diagnosed highly differentiated papillary thyroid cancer
89339069|NCT01089335||Tumour of uncertain malignant potential|Thyroid tumours with preoperative cytology indicating follicular neoplasia, or on cytology suspected but not proven malignancy
89339070|NCT01159093|Experimental|Family Decision Support|Families will receive informational vaccine reminder telephone calls.
89339071|NCT01159093|Experimental|Clinical Decision Support|In this treatment arm, clinicians receive the decision support at the point of care within an electronic health record.
89339072|NCT01159093|Experimental|Family DS+ Clinician DS|Families will receive informational vaccine reminder calls and their clinicians will receive electronic health record-based decision support for immunizations.
89339073|NCT01159093|Other|Control|This group will receive regular primary care with no decision support.
89339074|NCT01160263|Other|patients without stiffness|
89339075|NCT01160263|Other|patients with pyramidal stiffness|
89339076|NCT01160263|Other|patients with mixed stiffness|
89339077|NCT01266889||study group, control group|
89339078|NCT01265173|Active Comparator|Cefotaxime|iv 2G q 8hrs for general, dose titration if needed (eg.CKD)
89339079|NCT01265173|Experimental|Ceftriaxone|iv 2G q 24hrs
89339080|NCT01265173|Experimental|Ciprofloxacine|iv 400mg q 12hrs for general, dose titration if needed (eg.CKD)
89339081|NCT01159327|Experimental|Arm A|Sorafenib maintenance arm
89339082|NCT01159327|No Intervention|Arm B|observation arm
89339083|NCT01160341|Experimental|Testosteron, secondary hypogonadism|
89339084|NCT01265251||Test-retest|Forty-four healthy elderly 60-82 years old
89339085|NCT01265251||Validity|Twenty six patients with various diseases and various ages
89339086|NCT01265251||Feasibility|Twenty seven patients under the preoperative investigation for INPH
89339087|NCT03882619|Experimental|Calligraphy group|
89339088|NCT03882619|No Intervention|Treatment-as-usual group|
89339089|NCT03882775|Experimental|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
89339090|NCT03882775|Active Comparator|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
89339091|NCT01156441|Experimental|surgical mitral valve repair|Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree. Mitral valve repair will be performed with mitral valve annuloplasty via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia.
89339092|NCT01156441|No Intervention|control: medical management|Clinical observation will be continued without surgery. Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree.
89339093|NCT03878563||ascites with/without SBP|Cirrhosis with ascites and existing SBP or prior SBP
89339094|NCT03878563||ascites and decreased protein concentrati|Cirrhosis with ascites and decreased protein concentration <1,5 g/d
89339095|NCT03878563||ascites and normal protein concentration|Liver cirrhosis witha scites and protein concentration >1,5 g/d
89339096|NCT03878563||Liver cirrhosis without ascites|Patients with liver corrhosis without ascites
89339097|NCT03878563||Healthy controls without liver cirrhosis or other pathology|Healthy pacients (without chronic disease) undergoing screening coloscopy or gastroscopy
89339098|NCT03877705|Experimental|Dissolving xylitol chewable tablets|Listerine ready tabs 3 times/day
89339099|NCT03877705|Active Comparator|Xylitol chewing gum|Trident original 3 times/day
89339100|NCT03879421|Active Comparator|Group 1 (Epithelium-off accelerated CXL)|patients with corneal thickness > 400 µm (thinnest location) were assigned into Epi-off accelerated CXL procedure
89339101|NCT03879421|Active Comparator|Group 2 (Epithelium-on accelerated CXL)|patients with corneal thickness > 380 µm and < 400 µm thinnest location) were assigned into Epi-on Trans-epithelial accelerated CXL procedure
89339102|NCT01160419|Other|FLOT|Docetaxel, Oxaliplatin, Folinic acid, 5-FU, q 2 weeks, application of 6 cycles
89339103|NCT03878017|Experimental|skin marking of clipped axillary LN|all eligible patients underwent skin marking of their clipped axillary LN post neoadjuvant chemotherapy to determine the retrieval rate of the clipped nodes
89339104|NCT02954172|Experimental|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
89339105|NCT02954172|Active Comparator|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
89339106|NCT03879343||Clinical group|Children aged six to eleven with clinical diagnosis of attention deficit / hyperactivity disorder were recruited for interview and completion of questionnaires
89339107|NCT03879343||Control group|Normally developing children aged six to eleven studying in local mainstream primary schools were recruited for completion of questionnaires
89339108|NCT01156519|Other|Salivary cortisol|
89339109|NCT01159405|Experimental|99mTc-GP|99mTc-GP with SPECT/CT imaging & whole body scan.
89339110|NCT03877081|Experimental|Probiotics. Intervention patients|This patients will receive 2 doses of oral probiotics a day, for seven days
89339111|NCT03877081|Placebo Comparator|Placebo group|This patients will receive 2 doses of oral placebo a day, for seven days
89339112|NCT03876925|Experimental|CT053PTSA|60-100mg
89339113|NCT02953938|Active Comparator|mono therapy|ranibizumab alone
89339114|NCT02953938|Experimental|combination therapy|ranibizumab with Grid&Direct short pulse laser photocoagulation
89339115|NCT03715608|No Intervention|Control group|Patients in the control group received routine TKA surgery and perioperative management without any other interventions.
89339116|NCT03715608|Experimental|Intervention group|The patients in the intervention group received professional psychological interventions include psychological counseling and corresponding medication after the operation. Other perioperative treatments were the same as the patients in the control group. Psychotherapy was based on the clinical expertise of the psychosocial specialist, who selected the most appropriate plan for each patient.
89339117|NCT03877861||Readiband Sleep Tracking - Patient|This group is comprised of 25 participants with a diagnosis of primary Grade IV glioma. A Readiband™ Sleep Tracker device will be provided to each participant, along with necessary instructions. Participantswill return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits.
89339118|NCT03877861||Readiband Sleep Tracking - Control|Aggregate fatigue data and sleep patterns for a group of 30 healthy controls procured from FatigueScience in a de-identified manner for data analysis purposes.
89339119|NCT01161823||Nebivolol|2,5mg or maximum 5mg per day
89339120|NCT01161823||Menoflavon|2 times 1 pill at 40mg Isoflavone per day
89339121|NCT02526979|Experimental|mirabegron|single dose
89339122|NCT01267123|Experimental|Trendelenburg position|The endoscopist places the patient in 15° Trendelenberg position immediately prior to the initiation of the colonoscopy.
89339123|NCT01267123|Other|Standard care|The patient will have colonoscopy in the standard horizontal position
89339124|NCT03882541|No Intervention|Control group|headphones without music, without sedation
89339125|NCT03882541|Active Comparator|sedative group|headphones without music, with sedation
89339126|NCT03882541|Experimental|experimental group|headphones with music, without sedation
89339127|NCT01267903|Experimental|320U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 young adults aged 16-22 years old on day0,28
89339128|NCT01267903|Experimental|640U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 young adults aged 16-22 years old on day0,28
89339129|NCT01267903|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 20 children aged 5-15 years old on day0,28
89339130|NCT01267903|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 children aged 6-15 years old on day0,28
89339131|NCT01267903|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 children aged 6-15 years old on day0,28
89339132|NCT01267981|Placebo Comparator|Preparation 1|Standard diet: the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.
89339133|NCT01267981|Active Comparator|Preparation 2|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~500 ml of polyethylene glycol 30 minutes after the ingestion of video-capsule endoscopy."
89339134|NCT01267981|Active Comparator|Preparation 3|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~2 liters of polyethylene glycol between 7 pm and 9 pm.~500 ml of polyethylene glycol, 30 minutes after the ingestion of video-capsule endoscopy."
89339135|NCT01161901||blood sample|
89339136|NCT03758443|Experimental|Active Treatment TD-1473 Dose A|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
89339137|NCT03758443|Experimental|Active Treatment TD-1473 Dose B|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
89339138|NCT03758443|Experimental|Active Treatment TD-1473 Dose C|Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction.
89339139|NCT03758443|Placebo Comparator|Placebo|Participants will be randomized to receive an oral daily dose of placebo. Participants who received Placebo (and were non-responders) may move to an extended induction. Subjects who are on placebo will be assigned to active TD-1473 for the extended induction (they will be blinded to dose).
89339140|NCT03442764|Experimental|Group 1|Active Treatment for participants with base target trough concentration
89339141|NCT03442764|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
89339142|NCT03442764|Placebo Comparator|Placebo|Placebo Group
89339143|NCT03717324||First evaluation group (survey_1)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA)
89339144|NCT03717324||Co-creation group|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA) who want to participate in the co-creation workshop
89339145|NCT03717324||Second evaluation group (survey_2)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA), after improvements are made
89339146|NCT03877627|No Intervention|Negative 1|Patients in this arm will not undergo Pelvic and Peritoneal Lymphadenectomy.
89339147|NCT03877627|Experimental|Negative 2|Patients in this arm will undergo Pelvic and Peritoneal Lymphadenectomy.
89339148|NCT03442296|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
89339149|NCT03442296|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
89339150|NCT03576313|Experimental|intervention: IVM and DP|Mass Drug Administration with ivermectin (IVM) and dihydroartemisinin-piperaquine (DP) will be given to participants in the intervention villages plus the NMCP standard malaria control intervention
89339151|NCT03576313|Active Comparator|control: standard malaria control intervetions|Participants in the control clusters will receive only standard malaria control interventions such as Artemether Lumefantrine, LLINs, IRS, SMC and IPTp as implemented by the National Malaria Control Program (NMCP) of the Gambia
89339152|NCT01161979|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
89339153|NCT01161979|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
89339154|NCT01263535|Experimental|SENSIMED Triggerfish|
89339155|NCT03877783|Experimental|group of intervention|"participants receive~personalized advice of a dietician about mediterranean diet~individualized training program,~recommendation about optimized pharmacological treatment as in high risk groups for cardiovascular diseases"
89339156|NCT03877783|No Intervention|group of control|"participants receive~written information about the advantages of a healthy diet~written information about the advantages of physical activity,~medical treatment according to the latest version of the national guidelines issued by the Swedish Medical Product Agency"
89339157|NCT01160653|Experimental|1|Gait training and Cognitive Training
89339158|NCT01160653|No Intervention|2|Able Bodied
89339159|NCT01160731|Experimental|Cisplatin, Etoposide & Panobinostat|
89339160|NCT01160809|Experimental|Mosquito repellent and LLINs group vs. LLINs group only|This study is based on two population groups: 1) a group of households that use LLINs alone (control) and 2) a group of households that use both mosquito repellent and LLINs (repellent group).
89339161|NCT03882151|Experimental|Epilog Preop|patients receive Epilog preop analysis
89339162|NCT05010733|Experimental|Thick-Layer Technique|Total hip arthroplasty using the Exeter V40 cemented femoral stem [Stryker Orthopaedics, Mahwah, New Jersey].
89339163|NCT05010733|Active Comparator|Thin-Layer Technique (French Paradox)|Total hip arthroplasty using the Müller Straight Stem [Zimmer, Winterthur, Switzerland].
89339164|NCT01160887||Patients with diabetic peripheral neuropathy|
89339165|NCT01160887||Healthy matched controls|
89339166|NCT01268137|Active Comparator|stimulation on|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
89339167|NCT01268137|Placebo Comparator|Stimulation off|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
89339168|NCT03876691||Do not resuscitate|Patients who are suggested to family about a do-not-resuscitate order treatment by physicians.
89339169|NCT01162213|Experimental|100 mg of Lychee fruit extract|
89339170|NCT01162213|Experimental|200 mg of Lychee fruit extract|
89339171|NCT01162213|Experimental|600 mg of Lychee fruit extract|
89339172|NCT01162213|Experimental|2000 mg of Lychee fruit extract|
89339173|NCT01160965|Active Comparator|0.5% levobupivacaine|Participants given 15mls of 0.5% levobupivacaine as the solution for their epidural top-up
89339174|NCT01160965|Active Comparator|0.75% Rpoivacaine|Participants given 15mls of 0.75% ropivacaine as the solution for their epidural top-up.
89339175|NCT03441984|Experimental|Subjects with treatment sequence ABC|The subjects in Part 1 of the study, will receive a single dose of treatment A= adult TRIUMEQ (DTG 50 mg/ABC 600 mg/3TC 300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment B=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment C=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339176|NCT03441984|Experimental|Subjects with treatment sequence BCA|The subjects in Part 1 of the study, will receive treatment B in TP1, treatment C in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339177|NCT03441984|Experimental|Subjects with treatment sequence CAB|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment A in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339178|NCT03441984|Experimental|Subjects with treatment sequence ACB|The subjects in Part 1 of the study will receive, treatment A in TP1, treatment C in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339179|NCT03441984|Experimental|Subjects with treatment sequence BAC|The subjects in Part 1 of the study will receive a single dose each of, treatment B in TP1, treatment A in TP2 and treatment C in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339180|NCT03441984|Experimental|Subjects with treatment sequence CBA|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment B in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339181|NCT03441984|Experimental|Subjects with treatment sequence DEF|The subjects in Part 2 of the study, will receive a single dose of treatment D= Adult DTG (50 mg, 1 conventional tablet) and adult 3TC (300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment E= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment F= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339182|NCT03441984|Experimental|Subjects with treatment sequence EFD|The subjects in Part 2 of the study, will receive a single dose respectively of treatment E in TP1, treatment F in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339183|NCT03441984|Experimental|Subjects with treatment sequence FDE|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment D in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339184|NCT03441984|Experimental|Subjects with treatment sequence DFE|The subjects in Part 2 of the study, will receive a single dose of treatment D in TP1, treatment F in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339185|NCT03441984|Experimental|Subjects with treatment sequence EDF|The subjects in Part 2 of the study, will receive a single dose of treatment E in TP1, treatment D in TP2 and treatment F in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339186|NCT03441984|Experimental|Subjects with treatment sequence FED|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment E in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
89339187|NCT01162291||movement|healthy subjects, randomised to do flexion and extension movements with their left and right elbow joint after intramuscular application of NaCl 2ml in the right musculus biceps brachii, and 1ml in the left musculus biceps brachii
89339188|NCT01162291||rest|healthy subjects are randomised to rest after intramuscular application of NaCl 1ml in the left and 2ml in the right musculus biceps brachii
89339189|NCT01263613|Other|Biopsy|biopsy
89339190|NCT01162369||Group 1 - Non-Delirius Patients|
89339191|NCT01162369||Group 2 - Delirious Patients|
89339192|NCT01162447||PCO|Healthy control subjects and patients with polycystic ovarian syndrome will be recruited for the study.
89339193|NCT01156909|Experimental|Rituximab|Rituximab induction using two infusions (500mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
89339194|NCT01267357||Serous papillary endometrial ca patients|30 patients diagnosed with SP endometrial ca
89339195|NCT01267357||Endometrioid endometrial ca|32 patients diagnosed with Endometrioid endometrial ca
89339196|NCT01162525|Experimental|pTNS treatment|
89339197|NCT01162603|Experimental|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
89339198|NCT01162603|Active Comparator|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.
89339199|NCT01267435|Other|determining correct tunnel positions|
89339200|NCT03881995|Active Comparator|iGlarLixi|Subjects will receive premixed Insulin glargine + lixisenatide once daily for 12 weeks
89339201|NCT03881995|Active Comparator|Insulin glargine|Subjects will receive Insulin glargine once daily for 12 weeks
89339202|NCT01162759|No Intervention|Usual Care|The control group receiving usual care
89339203|NCT01162759|Experimental|Home Blood Pressure Monitoring Group|Intervention group
89339204|NCT02527213|Experimental|Sodium Thiosulfate|Sodium Thiosulfate at 25g in 100 ml normal sterile saline (NSS)
89339205|NCT02527213|Placebo Comparator|Placebo|similarly-formulated placebo in 100 ml NSS
89339206|NCT01161277|Active Comparator|aripiprazole|
89339207|NCT01161277|Active Comparator|haloperidol|
89339208|NCT01161277|Placebo Comparator|suger pill|
89339209|NCT01267513||normal volunteers|Normal individuals, aged 18 -75
89339210|NCT01267513||Hospitalized patients|Pulmonary and cardiac ICU, Trauma
89339211|NCT01268215|Experimental|A (two study drugs group)|The standard management + two study drugs (endotracheal instillation of a mixture containing budesonide and Infasurf)
89339212|NCT01268215|Active Comparator|B (one study drug group)|The standard management + one study drug (endotracheal instillation of Infasurf only).
89339213|NCT01268215|Sham Comparator|C (no study drug group)|The standard management only.
89339214|NCT01162837|Other|All subjects|All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control
89339215|NCT03877471|Experimental|Low dosage|The low dosage will inject 2 million MSC-like cells (in 100ul suspension) for each ovary.
89339216|NCT03877471|Experimental|Medium dosage|The medium dosage will inject 5 million MSC-like cells (in 100ul suspension) for each ovary.
89339217|NCT03877471|Experimental|High dosage|The high dosage will inject 10 million MSC-like cells (in 100ul suspension) for each ovary.
89339218|NCT01267591||control|
89339219|NCT01267591||type 1 diabetes|
89339220|NCT01267591||obesity|
89339221|NCT01269307|Active Comparator|1:1 ketamine - propofol mixture|
89339222|NCT01269307|Active Comparator|propofol|propofol
89339223|NCT03874741|Experimental|Arm - Experimental|Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
89339224|NCT03874585|Active Comparator|Standard Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange) and free nicotine replacement.
89339225|NCT03874585|Experimental|Enhanced Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange), free nicotine replacement, and the 6-week text messaging intervention.
89339226|NCT01268371|Active Comparator|Promus Element|Everolimus-eluting stent
89339227|NCT01268371|Active Comparator|Nobori|Biolimus-eluting stent with biodegradable polymer
89339228|NCT05016271|Experimental|True air purifier group|Children in this group will receive an intervention of air purifiers with high-efficiency particulate air (HEPA) filters.
89339229|NCT05016271|Sham Comparator|Sham air purifier group|Children in this group will receive an intervention of air purifiers without high-efficiency particulate air (HEPA) filters.
89339230|NCT03876613|Active Comparator|Turkish music group|Rast makam
89339231|NCT03876613|Active Comparator|classical western music|Vivaldi
89339232|NCT03876613|Active Comparator|soft rock music|Elvis presley
89339233|NCT03876613|Placebo Comparator|control group|No music
89339234|NCT01161355|Experimental|AZD9668|Tablets and intravenous (IV) dose
89339235|NCT01161433|Experimental|Intervention|Virtually delivered spirometry quality improvement program
89339236|NCT01161433|No Intervention|Standard of Care|
89339237|NCT01161511|Experimental|1|XmAb5574
89339238|NCT01162915|Experimental|Safety|Infusion of autologous bone marrow-derived mesenchymal stem cells.
89339239|NCT01267669|Experimental|EVL plus Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
89339240|NCT01267669|Placebo Comparator|EVL plus Placebo|Emergency EVL plus placebo infusion for 5 days
89339241|NCT01267747||Atrial fibrillation or flutter patients|Patients with 'lone' paroxysmal, persistent, or permanent atrial fibrillation
89339242|NCT01164943|Active Comparator|Human FSH|
89339243|NCT01164943|Active Comparator|Recombinant FSH|
89339244|NCT01269541|Active Comparator|Mupirocin|Topical treatment
89339245|NCT01269541|Active Comparator|Rifampicin+Clindamycine or Trimethoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
89339246|NCT01162993|Experimental|Spinal Cord Stimulation|Spinal cord stimulation
89339247|NCT01162993|No Intervention|Treatment as usual|Treatment as usual
89339248|NCT01269619|Experimental|Dynamic|Use of Dynamic back support
89339249|NCT01269619|Active Comparator|Static|Use of static back support
89339250|NCT01269697|Active Comparator|Nutrof|patient receive the treatment of Nutrof Total
89339251|NCT01269697|Placebo Comparator|Placebo of Nutrof|Patient receive the treatment of the placebo of Nutrof Total
89339252|NCT03877393|Experimental|PRO-GFD|Probiotic supplementation + gluten-free diet
89339253|NCT03877393|Placebo Comparator|PLA-GFD|Placebo supplementation + gluten-free diet
89339254|NCT03877393|Experimental|PRO-GD|Probiotic supplementation + gluten-containing diet
89339255|NCT03877393|Placebo Comparator|PLA-GD|Placebo supplementation + gluten-containing diet
89339256|NCT03877003|Experimental|Egg Intake|Consumption of 3 eggs per day for breakfast during 4 weeks
89339257|NCT03877003|Experimental|Choline Supplement Intake|Consumption of choline supplement 1.5 tablets (approx. 400 mg) with breakfast for 4 weeks
89339258|NCT01268449|Active Comparator|Laser group|
89339259|NCT01268449|Placebo Comparator|Placebo group|Randomly,half of the patients receive placebo.
89339260|NCT01280149|Experimental|substance P-low dose allergen|Substance P injections with 8 sequential, increasing doses of allergen
89339261|NCT01280149|Experimental|substance P-moderate dose allergen|Substance P with sequential, increasing doses of allergen
89339262|NCT01280149|Experimental|substance P-low/moderate dose allergen|substance P with 16 sequential increasing doses of allergen
89339263|NCT01280149|Active Comparator|substance P-placebo|Placebo injections of substance P and placebo
89339264|NCT01280149|Experimental|placebo-low dose allergen|Placebo injections with 8 sequential increasing low dose allergen injections
89339265|NCT01280149|Placebo Comparator|placebo-placebo|substance P placebo and allergen placebo (weekly)
89339266|NCT01268605|Active Comparator|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
89339267|NCT01268605|Active Comparator|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
89339268|NCT01165099|Experimental|manual acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were manually manipulated during this time. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
89339269|NCT01165099|Experimental|electro acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were either electronically simulated withm2 Hz pulses of 0.5 msec duration for 30 minutes sufficient to cause non-painful muscle contractions. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
89339270|NCT01165099|Sham Comparator|Sham manual or electro acupuncture|Sterile needles were inserted adjacent to the specific acupuncture sites identified for the manual and electro groups to a depth of 1-1.5mm only and insufficient to provoke an unusual sensation and left in position for a 30-60 minutes. Those randomised to 'sham-manual' received no stimulation and those randomised to 'sham-electro' were connected to the electrical stimulator but the current not activated.
89339271|NCT01165099|No Intervention|control group|Following randomisation to be control group, no specific treatment was organised at this time.
89339272|NCT01163071|Experimental|ABI-011|
89339273|NCT01165255||Infants born to women who were exposed to antidepressants|Women ages 12 through 49 (as of delivery date) who were dispensed an antidepressant between 01 January 1995 and 30 September 2004 from the original Bupropion study.
89339274|NCT01165333|Experimental|Dose escalation|In the first part of the trial, a dose-ranging study in ca. 18-21 patients will be done. A standard dose escalation strategy will be used including 3 to 6 patients at each dose level, the first cohort of patients being treated at dose level one Interventions : Cilengitide dose escalation ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
89339275|NCT01165333|Experimental|Cohort extension|An additional 20 patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations Interventions : Cilengitide ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
89339276|NCT03872323|Active Comparator|Endovascular treatment|
89339277|NCT03872323|Active Comparator|Open surgery|
89339278|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: RMS|Pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS) will receive eribulin mesylate administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 milligrams per meters squared (mg/m^2). Participants will continue study therapy until progression of disease (per Response Evaluation Criteria In Solid Tumors [RECIST] 1.1), intolerable toxicity, or withdrawal of consent.
89339279|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: NRSTS|Pediatric participants with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
89339280|NCT03441360|Experimental|Eribulin mesylate 1.4 mg/m^2: EWS|Pediatric participants with Ewing sarcoma (EWS) will receive eribulin mesylate administered as an IV infusion on Days 1 and 8 of each 21-day cycle at a dose of 1.4 mg/m^2. Participants will continue study therapy until progression of disease (per RECIST 1.1), intolerable toxicity, or withdrawal of consent.
89339281|NCT01167049|Experimental|CAPECITABINE|"Single arm:~Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; repeat three cycles (approximately 3- months);"
89339282|NCT03876145|Experimental|Minimal ovarian stimulation with rec-FSH|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 International Unit (IU) Gonal-f (Follitropin alfa, Merck Serono, Germany) after the seventh day.
89339283|NCT03876145|Experimental|Minimal ovarian stimulation with HMG|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) after the seventh day.
89339284|NCT03876145|No Intervention|Mild ovarian stimulation with rec-FSH|The group of mild ovarian stimulation that will receive 150 IU Gonal-f (Follitropin alfa, Merck Serono, Germany) daily from Day 3 of the menstrual cycle.
89339285|NCT03876145|No Intervention|Mild ovarian stimulation with HMG|The group of mild ovarian stimulation that will receive 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) daily from Day 3 of the menstrual cycle.
89339286|NCT01311180|Experimental|Sensoril®|
89339287|NCT01311180|Placebo Comparator|Placebo|
89339288|NCT03871933||AECOPD|acute exacerbation of COPD
89339289|NCT03871933||stable COPD|
89339290|NCT01311414|Experimental|cafedrine/theodrenalin|
89339291|NCT01280227|Experimental|1|Patients uses the symptom assessment tool SiSom. A summary of their reported symptoms are printed out and given to the pediatrician and nurse before the consultation. The consultation is videotaped.
89339292|NCT01280227|No Intervention|2|"The control group do not use the symptom assessment tool SiSom before the consultation. The control group receives usual care and the consultation is videoptaped."
89339293|NCT01347840||All Subjects|This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.
89339294|NCT03875989|Active Comparator|Arm A|
89339295|NCT03875989|Experimental|Arm B|
89339296|NCT03715374|Experimental|PRF+ABB treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A prf membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
89339297|NCT03715374|Active Comparator|Collagen Membrane + ABB treated patients|Periodontal surgery with collagen membrane is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A collagen membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
89339298|NCT01163305||metastatic colorectal cancer|
89339299|NCT01269775|Experimental|Face to face lecture|The lecturer allocated 1.5 hours for delivering the lecture by using provided slides about the topic and 0.5 hours for question and answer.
89339300|NCT01269775|Experimental|Internet based teaching|For providing materials for interactive internet-based group the professor's lecture was converted to an interactive electronic content. This content started with a case introduction followed with asking questions and then based on each student's answer a learning pathway would be assigned to his/her.
89339301|NCT01269775|Experimental|Computer based teaching|For providing material for computer-based group the lecture of the same professor was recorded in studio environment and was synchronized with the slides that were similar to those for lecture-based group. Then the lecture and the slides were converted to a CD as a multimedia CD.
89339302|NCT03717246|Experimental|Sleep Smart Latino|Sleep Smart Latino is a sleep hygiene intervention culturally tailored to be consistent with the beliefs, behaviors and needs of urban Latino middle school children and families. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting, and 2 60-minute long home based sessions that involve the student and their caregiver. The intervention focuses on sleep education, including effective sleep hygiene practices, use of electronics and caffeine and their impact on sleep.
89339303|NCT03717246|Active Comparator|Basic Sleep Education and Child Health|The basic sleep education and child health condition includes education regarding sleep hygiene , and the effects of sleep on child functioning integrated with additional child health topics such as nutrition, physical activity and safety. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting
89339304|NCT03717246|No Intervention|No treatment control|Students randomly assigned to this arm, will receive standard of care , which is no treatment and will not participate in any group sessions.
89339305|NCT01165411||Patients with CVCs and PICC lines placed|This group will have either Standard of Care (control) or Process Improvement infection control changes administered.
89339306|NCT01347762|Experimental|Nabilone|nabilone titrated to 2 mg daily
89339307|NCT01347762|Placebo Comparator|Placebo|Placebo
89339308|NCT03874273|Experimental|crizotinib +|Patients with unresectable, relapsed or refractory inflammatory myofibroblastic tumor, receiving crizotinib
89339309|NCT03874195|Active Comparator|Control|"Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care - www.palliativedoctors.org; getpalliativecare.org; and Wikipedia Palliative Care https://en.wikipedia.org/wiki/Palliative care)."
89339310|NCT03874195|Experimental|Intervention|Intervention Arm subjects will receive access to PCforMe.
89339311|NCT01167127|No Intervention|Tablet|OXN tablet, oral BID, flexible dose design
89339312|NCT01280305|Experimental|raloxifene|
89339313|NCT01280305|Placebo Comparator|Placebo|
89339314|NCT03872011|Experimental|Vitamin C,thiamine,hydrocortisone|"The combination of vitamin C, thiamine, hydrocortisone :~Vitamin C 2g every 6 hours x 5-days Thiamine 200mg every 12 hours x 5-days Hydrocortisone 200mg as a continuous infusion x 5-days"
89339315|NCT03872011|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
89339316|NCT01280383|Experimental|non-invasive NAVA|application of non-invasive NAVA in critically ill patients
89339317|NCT01280461||Experimental Group|
89339318|NCT01280461||Control Group|
89339319|NCT03438396|Experimental|Single arm|tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)
89339320|NCT01165489||Laryngomalacia|Patients with Laryngomalacia
89339321|NCT01165489||Control Group|Patients without Laryngomalacia
89339322|NCT01269931||Group 1 (EBUS-TBNA simulator training)|Group 1 (EBUS-TBNA simulator training): pulmonary medicine trainees with >30 bronchoscopy procedures experience, >nine months of pulmonary fellowship training and no clinical EBUS-TBNA experience (n=4).
89339323|NCT01269931||Group 2 (Clinical EBUS-TBNA training)|Group 2 (Clinical EBUS-TBNA training): pulmonary medicine trainees in the 2nd half of their final year of pulmonary training or recent graduates (within one year), with >50 bronchoscopy procedures experience who completed a one-month elective with the Interventional Pulmonary Medicine (IPM) service with ≥15 and ≤25 EBUS-TBNA procedures experience (n=4).
89339324|NCT03876067|Experimental|Ozone Group|in which Ozone will be added to cold blood cardioplegia
89339325|NCT03876067|Placebo Comparator|Control Group|: in which in which only cold blood cardioplegia
89339326|NCT03715218|Experimental|Mother Touch Program|Post natal care provided by trained carer after the birth. 6 weeks of care included massage, special diet, physical and mental relaxations.
89339327|NCT03715218|Other|Usual care Program|Usual care and supervision was provided as usual.
89339328|NCT01163929|Experimental|paclitaxel, trastuzumab and everolimus|
89339329|NCT03715140|Experimental|Patients who will recieve crucumin|patients who prescribing crucumin 80 mg daily for three months will be evaluated. A sample will be taken before taking the drug.
89339330|NCT03715140|Placebo Comparator|Patients who will receive placebo|Patients who prescribing placebo daily for three months will be evaluated. A sample will be taken before taking the placebo.
89339331|NCT01280539|Experimental|TENS|Transcutaneous electrical nerve stimulation will be applied on the impaired hand
89339332|NCT01280539|Sham Comparator|Sham TENS|Sham TENS will be applied to the impaired hand
89339333|NCT03871777|Active Comparator|Vegetarians|Healthy vegetarians (vegans and lacto-ovo vegetarians) 18 and 50 years formed this arm.
89339334|NCT03871777|Sham Comparator|Omnivores|Healthy omnivores with similar characteristics of vegetarians (age, body mass index, gender and physical activity levels) formed this arm
89339335|NCT00073307|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.
89339336|NCT00073307|Placebo Comparator|Placebo|Placebo tablets matching in appearance were to be orally administered twice a day.
89339337|NCT03715062|Experimental|Intervention group|Receives education in diagnosing urinary tract infection and use of observation, reflection and communication tool.
89339338|NCT03715062|No Intervention|Control group|No intervention
89339339|NCT01270789|Experimental|Liraglutide|
89339340|NCT01270789|Placebo Comparator|Placebo|
89339341|NCT01164085|Experimental|Ketorolac|4mg intravitreal injection of ketorolac
89339342|NCT05557656||HCC participants who received the treatment of Regorafenib|HCC participants who received the treatment of Regorafenib
89339343|NCT01271179|Active Comparator|sequential perfusion|sequential perfusion of liver grafts with low-viscosity improved Ross solution and high-viscosity UW solution.
89339344|NCT01271179|Placebo Comparator|sole perfusion|sole perfusion of liver grafts with high-viscosity UW solution only
89339345|NCT01167283|Active Comparator|Electrostimulation|Neuromuscular electrical stimulation
89339346|NCT01167283|Sham Comparator|Sham stimulation|Sham stimulation
89339347|NCT03388164|Active Comparator|Escitalopram + RT2CK17|10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
89339348|NCT03388164|Placebo Comparator|Escitalopram + Placebo|10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.
89339349|NCT03871699|Experimental|Iron Reposition|The selected patients will receive 1g of ferric carboxymaltose applied intravenously after dilution in 100ml of crystalline solution. the infusion time will be around 15 minutes realized at the moinhos the vento infusion center.
89339350|NCT01268761|Experimental|GnRH antagonist|• GnRH antagonist (Cetrorelix 0.25)
89339351|NCT01268761|Placebo Comparator|Placebo (saline solution)|• Placebo (saline solution)
89339352|NCT03714906|Experimental|Treatment|Patients randomized to the Treatment arm will be assigned to receive a stellate ganglion block. While in the hospital after surgery, patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
89339353|NCT03714906|No Intervention|Control|Patients assigned to the Control arm will receive no pre-operative intervention. While in the hospital after surgery, these patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
89339354|NCT01268839|Experimental|001|Efavirenz 600mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 28 days
89339355|NCT03403374|Experimental|Evolocumab|Evolocumab 420 mg subcutaneous (SC) once monthly (QM) or every 2 weeks (Q2W; for participants on apheresis).
89339356|NCT01165567|Experimental|sarpogrelate 300 mg per day|Patients in the sarpogrelate group receive sarpogrelate 300 mg per day for 24 hours before exposure to contrast agent.
89339357|NCT01165567|No Intervention|No sarpogrelate medication|
89339358|NCT01164163|Experimental|Treatment (Ruxolitinib)|
89339359|NCT03387462|Experimental|DOT Diary Optimization Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
89339360|NCT03756883|Experimental|Test|Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg
89339361|NCT03756883|Active Comparator|Reference|ADVAIR DISKUS® 100/50 (fluticasone propionate and salmeterol) Inhalation Powder
89339362|NCT03756883|Placebo Comparator|Placebo|Placebo
89339363|NCT01280773|No Intervention|PSV weaning|Patinens in the PSV group will be weaned using PSV mode.
89339364|NCT01280773|Experimental|NAVA weaning|Patients in NAVA group will eb weaned using NAVA mode.
89339365|NCT03386994||Idiopathic Pulmonary Fibrosis patients|all IPF patients
89339366|NCT03756571|Experimental|Ankle Foot Orthoses-Footwear Combination|The intervention is a Ankle Foot Orthoses Footwear Combination (AFO-FC). This is some form of solid ankle AFO combined with modified footwear individually designed per algorithm.
89339367|NCT03756571|Active Comparator|Traditional Solid Ankle AFO (TSAFO)|"The intervention is a solid AFO (SAFO) aligned with the ankle at 90 degrees and worn with regular footwear. We'll refer to this as the traditional SAFO (TSAFO)..."
89339368|NCT01164319|Active Comparator|Group 1 (no early recurrence)|Patients without atrial fibrillation recurrences through the implantable cardiac monitors during the 3 months post-ablation period.
89339369|NCT01164319|Active Comparator|Group 2 (early AF recurrence)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period.
89339370|NCT01164319|Active Comparator|Group 3 (early recurrence-no reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 would not receive reablation.
89339371|NCT01164319|Active Comparator|Group 4 (early recurrence-early reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 will receive early reablation based on data stored by implanted monitor.
89339372|NCT01586611|Active Comparator|Gemcitabine|Cycles to be 4 weeks in length Gemcitabine 1000 mg/m2 IV weekly for 3 weeks then one week off
89339373|NCT01586611|Experimental|FOLFOX|Cycles to be 2 weeks in length Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
89339374|NCT03386448|Placebo Comparator|control|Participants will receive placebo medication
89339375|NCT03386448|Experimental|Active|participants will receive active medications scopolamine and naltrexone
89339376|NCT01280929|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
89339377|NCT01280929|Experimental|Ranibizumab|Group 2: Intravitreous injections of ranibizumab every 4 weeks at month-0, month-1 and month-2 that can be repeated after month-3.
89339378|NCT01280929|Experimental|Ranibizumab + Panretinal Photocoagulation (PRP)|Group 3: Combination treatment of ranibizumab intravitreous injections plus PRP (2 weeks +/- 1 week after injection), at month-0, month-1 and month-2 that can be repeated after month-3.
89339379|NCT03875521||12 hours|
89339380|NCT03875521||< 12hours|
89339381|NCT03873961|Experimental|High-intensity laser therapy|The participants received stretching and exercise guidance and underwent the BTL-6000 High Intensity Laser 12 W with 10 mm pen applicator high intensity laser procedures (mode = continuous, power = 7 W, dose = 120 J/cm2, total time= 7 min. 8 sec.) 3 times per week (total of 8 procedures).
89339382|NCT03873961|Active Comparator|Low-level laser therapy|The participants received stretching and exercise guidance underwent the LAS-Expert with laser shower applicator Low-level Laser therapy procedures (785 nm wavelength, 4,0 J/cm2, 35cm2, 6:40 min) 3 times per week (total of 8 procedures).
89339383|NCT01281085||No treatment|Shoulder conditions including rotator cuff condition treated conservatively, shoulder instability treated conservatively, diaphyseal humerus fracture or subcapital humerus fracture treated surgically and frozen shoulder
89339384|NCT01164397||Dislipidemic Population|People with high levels of total cholesterol, LDL, C-HDL and triglycerides
89339385|NCT02526823|Active Comparator|R-CHOP/CHOPE or ABVD chemotherapy regimen|R-CHOP/CHOPE every 21 days or ABVD every 28 days for total 6 courses
89339386|NCT02526823|Experimental|R-CDOP/CDOPE or DBVD chemotherapy regimen|R-CDOP/CDOPE every 21 days or DBVD every 28 days for total 6 courses
89339387|NCT05397535|No Intervention|Self-directed exercise group|Participants in the self-directed exercise group will choose the type and duration of exercise by their preference.
89339388|NCT05397535|Active Comparator|Brisk walking group|Participants in Brisk Walking Group will participate in brisk walking for 52 weeks (≥5 days/week, about 30 minutes/day).
89339389|NCT05397535|Experimental|Baduanjin group|Participants in Baduanjin Group will practice Baduanjin singly for 52 weeks (≥5 days/week, about 30 minutes/day).
89339390|NCT01586923|Active Comparator|Short-storage RBC|RBC transfusion using packed RBCs stored for 10 days or less.
89339391|NCT01586923|Active Comparator|Prolonged-storage RBC|RBC transfusion using packed RBCs stored for 25 days or more.
89339392|NCT03875677|Experimental|HD-tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the defined target area
89339393|NCT03875677|Experimental|Conventional tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position
89339394|NCT03875677|Sham Comparator|Sham HD-tDCS group|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect.
89339395|NCT01587391|Experimental|BI 163538 XX|1 single dose per subject as oral solution
89339396|NCT01587391|Placebo Comparator|Placebo to BI 163538 XX|1 single dose per subject as oral solution
89339397|NCT01268917|Experimental|preoperative aspirin use|
89339398|NCT01268917|No Intervention|preoperative aspirin nonuse|
89339399|NCT01164553|Experimental|Group 2, 0.5 mL TIV|Naive cohort participants (n=180) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=40) will receive 0.5 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose.
89339400|NCT01164553|Active Comparator|Group 1, 0.25 mL TIV|Naive cohort participants (n=90) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=20) will receive 0.25 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose
89339401|NCT01281163|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD on days 1 and 15-28 of course 1 and on days 1-28 of subsequent courses. Patients also receive AKT inhibitor MK2206 PO QD on days 8, 15, and 22 of course 1 and on days 1, 8, 15, and 22 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89339402|NCT01167361||Children with upper or lower respiratory infections|Respiratory Virus infections in children who are symptomatic with either an Upper Respiratory Tract Infections and/or Lower Respiratory Tract Infections is determined by using a novel highly sensitive and rapid assay for RV detection. An aliquot from the leftover sample remaining after clinical diagnostic testing will be used for FilmArrayTM analysis. Specimens collected will include nasopharyngeal washes, nasopharyngeal swabs, tracheal aspirates and bronchoalveolar lavage as ordered by the treating physician. Diagnostic studies on this specimen will be performed as ordered and the results will be available to the treating physicians after reporting.
89339403|NCT02951988|Experimental|Rapastinel 450 mg Weekly|Rapastinel 450 milligrams (mg) intravenous (IV) once a week during OLTP followed by rapastinel 450 mg IV once a week during DBTP.
89339404|NCT02951988|Experimental|Rapastinel 450 mg Every 2 Weeks|Rapastinel 450 mg IV once a week during OLTP followed by rapastinel 450 mg IV once every 2 weeks during DBTP.
89339405|NCT02951988|Placebo Comparator|Placebo|Rapastinel 450 mg IV once a week during OLTP followed by placebo-matching rapastinel 450 mg IV once a week during DBTP.
89339406|NCT01281319||Asymptomatic normal pregnant women|
89339407|NCT01281319||Women with high risk pregnancy|Women at risk for preterm birth or recurrent abortions that are being followed at the high risk pregnancy unit (outpatients clinic, high risk day care center)
89339408|NCT01281319||Women admitted with preterm labor|Women that are admitted to the gynecology department due to pregnancy complications: preterm labor with intact membranes (PTL) or with preterm PROM.
89339409|NCT01167439|No Intervention|Mild dysphagia|
89339410|NCT01167439|Active Comparator|Severe dysphagia|
89339411|NCT01587157|Experimental|capnography|
89339412|NCT01268995|Experimental|Cyclosporine A|Patients in this arm will be switched from immunosuppressive therapy with Tacrolimus to Cyclosporine A. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
89339413|NCT01268995|Active Comparator|Tacrolimus|Patients in this arm will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
89339414|NCT00009737|Experimental|Capecitabine|Participants received capecitabine 1250 milligram per square meter (mg/m ^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).
89339415|NCT00009737|Active Comparator|5-Fluorouracil + Leucovorin|Participants received leucovorin 20 mg/m ^ 2 followed by 5-fluorouracil at 425 mg/m ^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).
89339416|NCT01164631|Experimental|Orthodontic treatment|Snoring patients enrolling for tonsil surgery with maxillary constriction, and/or jaw retrognathism
89339417|NCT01164631|No Intervention|Control Group|Patients enrolled for tonsils surgery
89339418|NCT03711240|Experimental|bevacizumab+mFOLFOXIRI|
89339419|NCT01271881|Active Comparator|Percutaneous Transluminal Angioplasty (PTA) alone|Intervention: Procedure: PTA alone without use of the GORE VIABAHN
89339420|NCT01271881|Experimental|PTA with covered stent|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
89339421|NCT05459844|Experimental|Lutetium[177Lu] Oxodotreotide Injection|"Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) Lutetium[177Lu] Oxodotreotide Injection: Four administrations of 7.4 GBq (200 mCi).~Concomitant amino acids were given with each administration for kidney protection.~Lutetium[177Lu] Oxodotreotide Injection was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
89339422|NCT05459844|Active Comparator|Octreotide LAR|"60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed."
89339423|NCT01281397||Patients undergoing elective cardiac surgery|Patients undergoing elective cardiac surgery will be enrolled in study. Data about antiplatelet therapy ingestion prior to surgery will be included.
89339424|NCT02530853|Experimental|Group A|Laser acupuncture
89339425|NCT02530853|Sham Comparator|Group B|Simulation Laser acupuncture
89339426|NCT01164709|Experimental|bortezomib + nelfinavir|escalation 3 by 3 cohorts
89339427|NCT01583465|Experimental|Aquamantys Malleable Bipolar Sealer|In 100 patients randomly assigned, primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of the Aquamantys Malleable Bipolar Sealer with Light.
89339428|NCT01583465|Active Comparator|Standard Treatment|100 patients randomly assigned will undergo primary total hip arthroplasty via the anterior supine intermuscular approach performed with the assistance of standard electrocautery.
89339429|NCT01089803||Patients Treated with Laryngectomy|Patients initially treated with laryngectomy and followed for 12 months after receiving this treatment.
89339430|NCT01089803||Patients Treated with Chemoradiation|Patients treated initially with chemoradiation and followed for 12 months after receiving treatment.
89339431|NCT03871387|Experimental|Deep Block Group|"Continuous Rocuronium infusion during surgery~Maintain TOF = 0 & PTC= 1~2~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
89339432|NCT03871387|Active Comparator|Moderate Block Group|"Continuous Rocuronium infusion during surgery~Maintain TOF 1~2~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
89339433|NCT03960671|Experimental|Anxiolytics|Pediatric patients treated with sedation using anxiolytics
89339434|NCT01281553|Experimental|001|Cisapride 0.2 mg/kg suspension q.i.d.for 8 weeks.
89339435|NCT01281553|Placebo Comparator|002|Placebo Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
89339436|NCT01089881||Group 1|patients with BPH
89339437|NCT01089881||Group 2|patients with newly diagnosed prostate cancer
89339438|NCT01089881||Group 3|patients who have received curative treatment for prostate cancer and are suspicious of recurrence/metastases because of a persistent increase in their serum PSA.
89339439|NCT03417102|Active Comparator|Bypassing Agents (BPA) On-demand|Participants received On-demand BPAs (use of these agents, as needed, for episodic bleeding episodes, and not on a regular regimen intended to prevent spontaneous bleeding) per Investigator discretion from Day 1 for treatment of breakthrough bleeding episodes, up to a total of 9 months.
89339440|NCT03417102|Experimental|Fitusiran 80 mg Prophylaxis|Participants received Fitusiran 80 mg subcutaneously (SC) as prophylaxis once monthly from Day 1, along with the on-demand BPAs (per investigator's discretion and within bleeding dosing guidelines) for treatment of breakthrough bleeding episodes, up to a total of 9 months.
89339441|NCT01164787|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
89339442|NCT01164787|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
89339443|NCT01269151|Experimental|Lucentis (Ranibizumab)|
89339444|NCT01165723|Experimental|IV Dose 1: experimental|
89339445|NCT01165723|Experimental|IV Dose 2: experimental|
89339446|NCT03417024||All Subjects|All subjects will undergo scanning with both Automated Breast Ultrasound and Digital Breast Tomosynthesis devices.
89339447|NCT00028769|Experimental|Hormone therapy, estramustine, etoposide and paclitaxel|Hormone therapy (leuprolide, bicalutamide, nilutamide, goserelin, flutamide), estramustine, etoposide and paclitaxel
89339448|NCT01165801|No Intervention|Control Group (CO)|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
89339449|NCT01281787|Active Comparator|Losartan|angiotensin II-receptor blocker
89339450|NCT01281787|No Intervention|no treatment|no preventive treatment
89339451|NCT01281787|Active Comparator|Metoprolol|beta-adrenergic antagonist
89339452|NCT01167517|Experimental|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge.
89339453|NCT01167517|Placebo Comparator|Instructions in print format|Breast milk expression instructions provided in print format at the time of hospital discharge.
89339454|NCT03951545|Active Comparator|Mechanical group|Group of patients whose tibial sections will be performed using extramedullary mechanical sighting
89339455|NCT03951545|Experimental|Gyroscopic group|Group whose tibial sections will be performed using gyroscopic and accelerometric navigation (I-Assist) will be randomized
89339456|NCT01587469||HIV-infected and -uninfected individuals|HIV-infected and -uninfected individuals with suspected TB infection
89339457|NCT02953314|Experimental|Part A|"Participants weighing <25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days.~Participants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days."
89339458|NCT02953314|Experimental|Part B|"Participants weighing <40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks.~Participants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks."
89339459|NCT01580761|Experimental|Sleep restriction|Sleep restriction
89339460|NCT01580761|No Intervention|Normal sleep|Normal sleep
89339461|NCT01100411|Active Comparator|Air Optix Aqua|Contact lens material: Lotrafilcon A
89339462|NCT01100411|Active Comparator|Biofinity|Contact lens material: Comfilcon A
89339463|NCT01100411|Active Comparator|Proclear|Contact lens material: Omafilcon A
89339464|NCT01100411|Active Comparator|Acuvue Oasys|Contact lens material: Senofilcon A
89339465|NCT01100411|Active Comparator|Acuvue 2|Contact lens material: Etafilcon A
89339466|NCT01100411|Active Comparator|Purevision|Contact lens material: Balafilcon A
89339467|NCT01585285|Experimental|LIMA to SVG Bridge|Patients will receive composite coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) and saphenous vein graft (SVG) Bridge for the anterolateral targets
89339468|NCT01585285|Active Comparator|Conventional CABG|Patients will receive conventional coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
89339469|NCT03874819|Active Comparator|Control group|Conventional Hemodialysis using a high-flux dialyzer
89339470|NCT03874819|Experimental|Experimental group|Conventional Hemodialysis using a medium cut-of dialyzer
89339471|NCT03402750|Experimental|Meds to Beds|Patients receive medication in-hand at discharge from the hospital
89339472|NCT03402750|Active Comparator|Standard Care|Electronic prescription with patient pickup at the pharmacy
89339473|NCT03869671|Experimental|PrEP uptake/adherence intervention|A trained interventionist will deliver the manualized, single session PrEP uptake/adherence intervention in private counseling rooms at a community-based setting.
89339474|NCT03869671|Active Comparator|Harm reduction standard of care|Participants will be provided harm reduction supplies and health information and counseling according to routine practice at the community-based setting.
89339475|NCT00007475|Experimental|Plasma Exchange + Cyclophosphamide|"Procedure/Surgery: Plasma exchange A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.~Drug: Cyclophosphamide For GFR > 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR < 50 ml/min/1.73 m2 but > 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months."
89339476|NCT01167673|Active Comparator|treatment with study drug|patients receiving study drug for 4 weeks. 3 capsules a day of coltect
89339477|NCT01167673|Placebo Comparator|placebo|patients receiving similar capsules but no active ingredients
89339478|NCT03714438|Experimental|Medicago sativa|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
89339479|NCT03714438|Placebo Comparator|Placebo|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
89339480|NCT01100489|Experimental|Arm I|Patients undergo breast-conserving surgery consisting of partial mastectomies followed by external beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
89339481|NCT03714360|Experimental|TXA tranexamic acid|a single dose of 10 mg/kg of TXA, with a maximum dose of 1g. Administered as IV injection and marked as 'project-drug' and amount (mL) in the medical record.
89339482|NCT03714360|Placebo Comparator|Sodium Chloride 0,9%|an equivalent volume 0.9 % Sodium Chloride.
89339483|NCT00025883|Experimental|Metreleptin|subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg per day.
89339484|NCT01169857|Experimental|Velcade Therapy|
89339485|NCT01169935|Experimental|Administration of Intra-dermal SPIO|MRI scanning before and after intra-dermal injection of SPIO.
89339486|NCT01169935|Experimental|Mantoux, Venesection, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
89339487|NCT01169935|Experimental|Mantoux, Apheresis, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
89339488|NCT01169935|Experimental|Mantoux, Administration of Endorem|Mantoux test then MRI scanning before and after administration of Endorem.
89339489|NCT01169935|Experimental|Mantoux only|Mantoux test then serial MRI scanning.
89339490|NCT01273909||Perforator Flap Breast Reconstruction|Patients who undergo perforator flap breast reconstruction with or without concomitant vascularized lymph node transfer
89339491|NCT01273909||Vascularized Lymph Node Transfer|Patients who undergo perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
89339492|NCT00072293|Active Comparator|Axillary Dissection|Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
89339493|NCT00072293|Experimental|No Axillary Dissection|Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
89339494|NCT03869827||IUGR|All birth between 24 + 0 weeks of amenorrhea and 36 + 6 weeks of amenorrhea with isolated intrauterine growth restriction at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2016.
89339495|NCT03869827||Control|To each of these children with intrauterine growth restriction is matched a control child: the child without intrauterine growth restriction of the same gestational age whose date of birth is consecutive to that of the case.
89339496|NCT01274065||Psychiatric illnesses|Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.
89339497|NCT01167751|Experimental|MNC implantation|Implantation of BM derived MNC
89339498|NCT01167751|Experimental|AC 133 implantation|Implantation of BM derived AC 133
89339499|NCT01167751|Placebo Comparator|Control|Injection of cell carrier
89339500|NCT03869983|Active Comparator|Active Comparator|Omnipaque™ (iohexol) Injection, 755 mg/mL iohexol (350 mgI/mL)
89339501|NCT03869983|Experimental|Experimental|CE-Iohexol Injection, 755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL
89339502|NCT01167985|Experimental|Root canal sealer group+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
89339503|NCT01167985|Experimental|Provisional restoration material+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
89339504|NCT01167985|Experimental|Experimental- Different root canal sealer+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
89339505|NCT03870841|Experimental|PC945|PC945 5mg once daily
89339506|NCT01274689||cohort|cohort of consecutively enrolled patients with lagophthalmos
89339507|NCT01283191|Experimental|Behavioral Incentives|Vouchers for complying with target behavior
89339508|NCT01283191|Placebo Comparator|Education Control|Education class
89339509|NCT03869359|Experimental|Group A|Gluten-free diet with placebo powder vs Gluten-free diet with gluten powder
89339510|NCT03869359|Experimental|Group B|Gluten-free diet with gluten powder vs Gluten-free diet with placebo powder
89339511|NCT01168063|Experimental|Helicobacter pilory triple treatment|Triple treatment on this arm is based on results of molecular detection of resistance to antibiotics
89339512|NCT01168063|Active Comparator|Helicobacter pilori standard recommended treatment|H.Pylori Eradication rate with empirical treatment
89339513|NCT03869593||Patients presenting E. coli and S. aureus bacteremia|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
89339514|NCT01165957||Mobile bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is designed to slide or rotate on the metal baseplate.
89339515|NCT01165957||Fixed bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is locked to the metal baseplate.
89339516|NCT01283269|Experimental|Memory Support System or Computer|
89339517|NCT01283347|Experimental|18F-DTBZ for Parkinson's Disease|"25 age-matched healthy volunteers will be enrolled. For assessing the correlation between the 18F-DTBZ binding and the severity of disease, the patients with PD will be divided into three groups according to their motor scores: mild, moderate, and advanced. We will enroll 25 patients in each group. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study, as one screening visit, one imaging visit, and one safety evaluation visit.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
89339518|NCT01275001||Intervention children|Children who are receiving a Suzuki-like violin instruction through their participation in an Early Childhood/Headstart preschool program
89339519|NCT01275001||Control Group|Preschool-age children who are not receiving Suzuki-like violin instruction
89339520|NCT01168375|Active Comparator|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
89339521|NCT01168375|Active Comparator|conventional therapy plus umbilical cord serum eye drop|
89339522|NCT03869281||PTA|patients who underwent their first deceased donor PTA, or second deceased donor PTA if their first graft was explanted within a week, at the IRCCS San Raffaele Hospital between 2 January 2005 and 31 December 2017
89339523|NCT03869281||Controls|outpatients with T1D attending the Endocrinology Unit at IRCCS San Raffaele Hospital and patients listed for a first deceased donor PTA
89339524|NCT01275235||Exposure to Type II Diabetes for two siblings|Two sibling pairs with the same parents, between the ages of 20 to 34 in the Baton Rouge Area, having mother with diabetes while pregnant with one.
89339525|NCT01168453||neutral head position|supine with neutral head position
89339526|NCT01168453||head rotation|supine with 30° head rotation
89339527|NCT03869203|Experimental|Enhanced recovery after surgery (ERAS) patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the ERAS perioperative care.
89339528|NCT03869203|No Intervention|Control patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the traditional perioperative care.
89339529|NCT01170013|Experimental|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
89339530|NCT01170013|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
89339531|NCT01275391|No Intervention|Treatment as Usual Group 1|Participants will receive treatment as usual and will complete a baseline and 1-month post-visit assessment
89339532|NCT01275391|No Intervention|Treatment as Usual Group 2|Participants will receive treatment as usual and complete only the 1-month post-visit assessment
89339533|NCT01275391|Experimental|Intervention Group 1|Computer Screening, Brief Intervention, Referral toTreatment. Participants will receive the intervention and complete a baseline and 1-month post-visit assessment
89339534|NCT01275391|Experimental|Intervention Group 2|Computer Screening, Brief Intervention, Referral toTreatment Participants will receive the intervention and complete only the 1-month post-visit assessment
89339535|NCT01283425|Experimental|Test|InsuPatch use for 3 months.
89339536|NCT01283425|No Intervention|Control|
89339537|NCT01281943|Experimental|Temsirolimus and Pegylated Liposomal Doxorubicin|Temsirolimus 25mg andPegylated liposomal doxorubicin 25mg/m2
89339538|NCT01283503|Experimental|BKM120|
89339539|NCT01276249||Fortevo Endograft|All subjects diagnosed with a qualifying AAA suitable for elective endovascular repair, who meet the inclusion/exclusion criteria for the registry, are eligible for enrollment if treated with the Fortevo Endograft.
89339540|NCT01283659|Active Comparator|Standard imaging (coronary angiography)|Subjects will undergo a coronary angiogram as planned by their attending doctor
89339541|NCT01283659|Active Comparator|Advanced imaging (CTA)|Subjects will undergo a CTA scan first. Based on the CTA results, subjects may or may not proceed to coronary angiography. CTA results will be reviewed by the attending physician.
89339542|NCT01282099||Cardiac patients|Postoperative congenital heart disease patients requiring stay in the PICU
89339543|NCT01282099||non-cardiac patients|non-cardiac patients requiring stay in the PICU
89339544|NCT03869047|Active Comparator|quadratus lumborum block(dexmedetomidine+bupivacaine)|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine ,total volume 20 ml.
89339545|NCT03869047|Active Comparator|quadratus lumborum block(bupivacaine)|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20%.
89339546|NCT01283737|Experimental|DBX|DBX Putty in glass syringe
89339547|NCT01283737|Active Comparator|Mosaicplasty|
89339548|NCT03870685|Active Comparator|TAP block with Exparel|Patients will receive immediate postoperative bilateral 2-quadrant TAP block with Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by the anesthesia team.
89339549|NCT03870685|Active Comparator|Surgical Site Infiltration of Exparel|Patients will receive surgical site infiltration of Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by surgeon.
89339550|NCT01166191|Experimental|SCLC|
89339551|NCT01276951|Placebo Comparator|Placebo|
89339552|NCT01276951|Active Comparator|6,5g Dose Group|
89339553|NCT01276951|Active Comparator|12g Dose Group|
89339554|NCT01276951|Active Comparator|25g Dose Group|
89339555|NCT01276951|Active Comparator|50g Dose Group|
89339556|NCT02526433||Pregnancy women and new mothers|The study tracks what interventions women are already registered in and compares these with their mental wellbeing.
89339557|NCT01168531|Placebo Comparator|placebo arm|
89339558|NCT01168531|Active Comparator|pregabalin arm|
89339559|NCT01168531|Experimental|dexamethasone with pregabalin arm|
89339560|NCT03753763|Experimental|Active|Safinamide methanesulfonate film-coated tablets once daily
89339561|NCT03753763|Placebo Comparator|Placebo|Safinamide Methanesulfonate matching placebo film-coated tablets once daily
89339562|NCT03870373||Test Subject|neonatal patients undergoing complex cardiac surgical procedures
89339563|NCT01168609||patients with acute myocardial infarction|Acute myocardial infarction (AMI) was defined using the European Society of Cardiology / American College of Cardiology guidelines. Myocardial infarction was detected by the presence of at least two of the following criteria: chest pain lasting more than 30 minutes, typical electrocardiographic changes, and elevated creatinine kinase-MB fraction. Consecutive patients 18 years of age or older who presented within 12 hours after the onset of symptoms were considered for enrollment. Patients who had ST-segment elevation of 1 mm or more in two or more contiguous leads were classified as ST-segment elevation MI.
89339564|NCT01170169|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's laboratories limited
89339565|NCT01170169|Active Comparator|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
89339566|NCT01166269|Experimental|Grass-Allergen x 6|This arm will receive 6 injections of allergen.
89339567|NCT01166269|Active Comparator|grass-allergen x 3 and placebo x 3|this arm will receive 3 injections of allergen, and 3 injections of placebo.
89339568|NCT01166269|Placebo Comparator|placebo x 6|this arm will receive 6 injections of placebo.
89339569|NCT01283815|Active Comparator|Conservative management|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
89339570|NCT01283815|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group
89339571|NCT01587313|Experimental|Group 1|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 am
89339572|NCT01587313|Experimental|Group 2|ISDN/HYD 2 SR caps crossover to 1 IR cap at 5 pm
89339573|NCT01587313|Experimental|Group 3|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 pm
89339574|NCT01587313|Active Comparator|Group 4|ISDN/HYD 1 IR cap and two SR caps at 8 am crossover to Day 8: BiDil Tablet tid
89339575|NCT01282333|Experimental|Treatment (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib orally every 12 hours on days 1-12, gemcitabine hydrochloride IV over 30 minutes on days 3 and 10, and cisplatin IV over 60-120 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with suspected or known germline BRCA mutations may continue to receive single-agent veliparib continuously in the absence of disease progression or unacceptable toxicity. Patients may undergo blood, tumor tissue, and hair follicle sample collection periodically for pharmacokinetic and correlative studies.
89339576|NCT01283893||Laparoscopy group|Laparoscopy group: patients who underwent laparoscopic distal gastrectomy with D2 lymphadenectomy
89339577|NCT01283893||Open group|Open group: patients who underwent open distal gastrectomy with D2 lymphadenectomy
89339578|NCT03870139|Active Comparator|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the dominant lower limb) and supraorbital cathode (ipsilateral to the dominant lower limb)."
89339579|NCT03870139|Experimental|Combined stimulation 1|"Active peripheral electrical stimulation (PES_sensorial) combined with active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
89339580|NCT03870139|Active Comparator|Peripheral stimulation|"Active peripheral electrical stimulation (PES_motor).~PES: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
89339581|NCT03870139|Experimental|Combined stimulation 2|"Active sensorial peripheral electrical stimulation (PES_sensorial) combined with active motor peripheral electrical stimulation (PES_motor)~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level~PES_motor: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
89339582|NCT03384966|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
89339583|NCT03384966|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
89339584|NCT03384966|Placebo Comparator|Placebo|Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
89339585|NCT01168765|Experimental|Intervention group|This is the promotora plus group that will receive the TSSC newsletter and exposure to the media campaign but will also receive monthly visits by promotoras/lay health workers who will review the monthly newsletter with participants, emphasize role model stories, and discuss physical activity and healthful food choices using motivational interviewing strategies.
89339586|NCT01168765|Other|Control group|TSSC Media Campaign only participants who will receive a newsletter and the same exposure to the media campaign intervention as other community members not enrolled in the behavioral intervention.
89339587|NCT01277419||Ankylosing spondylitis|Ankylosing spondylitis according to the modified New York criteria or with the clinical diagnosis of AS/r-axSpA fulfilling the ASAS Classification Criteria AND the mNY criteria plus having the indiaction for starting a bDMARD therapy according to the treating rheumatologist
89339588|NCT01277419||Non-radiographic axial spondyloarthritis|Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential or with the clinical diagnosis of nr-axSpA fulfilling the ASAS Classification Criteria not fulfilling the mNY criteria and the indiaction for starting a bDMARD therapy according to the treating rheumatologist
89339589|NCT01277419||Juvenile spondyloarthritis|Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
89339590|NCT01277419||Crohn's disease|Patients with Crohn's disease
89339591|NCT01277419||Acute anterior uveitis|Patients with acute anterior uveitis
89339592|NCT01277419||Axial psoriatic arthritis|Patients with the clinical diagnosis of psoriatic arthritis with axial involvement (sacroiliac joints and/or spine) (axPsA)
89339593|NCT01168297||Maycoba residents|Pima and non-Pima Mexicans from the village of Maycoba
89339594|NCT03869125||Obstructive sleep apnoea group|Blood pressure measurement
89339595|NCT03402126||TPD RAMWare Download|Subjects who qualify and consent to participate in the TPD study will have TPD RAMWare injected into their device to collect data.
89339596|NCT01166425|Active Comparator|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID (three times a day) at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID (two times a day) the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose.
89339597|NCT01166425|Placebo Comparator|placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
89339598|NCT03868969|Experimental|Fosfomycin|Fosomycin tromethamine, one sachet for 21 days
89339599|NCT01311570|Experimental|Buprenorphine|
89339600|NCT01168843||normal pregnant|
89339601|NCT03714282|Experimental|Noninvasive Spinal Stimulation with Gait Training|May receive up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
89339602|NCT03714282|Active Comparator|Conventional Gait Training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
89339603|NCT03714282|Other|Healthy Control Group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
89339604|NCT01170325|Experimental|Group A|
89339605|NCT01170325|Placebo Comparator|Group B|
89339606|NCT05513508|Experimental|Intervention group|In the intervention group the first mask will be randomly chosen between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask. Thereafter, NPPV mask will be changed every 6 hours, alternating the two different interfaces. Patients wearing oro-nasal masks will receive protective dressings on nasal bridge before starting NPPV.
89531672|NCT05801653|Experimental|Oat meal 3|The test portion is based on 30 gram available carbohydrates with added z amount of oat betaglucan. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning
89339607|NCT05513508|Active Comparator|Control group|In the control group, mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Patients wearing oro-nasal masks will receive protective dressings on nasal bridge before starting NPPV. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
89339608|NCT01170403||NGT/IFG/DM, MeS/no-MeS|NGT: normal glucose tolerance IFG: impaired glucose tolerance DM : diabetes mellitus MeS: metabolic syndrome no-MeS: no metabolic syndrome
89339609|NCT03355326|Experimental|Glycerin Suppository Group|
89339610|NCT03355326|No Intervention|Non-suppository Group|
89339611|NCT01170481||papilloedema without glaucoma|
89339612|NCT01170481||papilloedema with glaucoma|
89339613|NCT01170481||glaucoma without papilloedema|
89339614|NCT01169077|Experimental|Group I: 0.25 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 0.25 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
89339615|NCT01169077|Experimental|Group II: 1.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 1.0 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
89339616|NCT01169077|Experimental|Group III: 4.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 4.0 mg, Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
89339617|NCT03868813||Interview with People with Diabetes|One-on-One interview with people with diabetes
89339618|NCT03868813||Interview with Health Coaches|One-on-One interview with health coaches
89339619|NCT01169155|Active Comparator|Study 3. Adults 20-49 Years of Age|"Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in a linked study, Study 3, with adult participants 20-49 years of age to ensure that the alarms tested will also work for adults in this age group.~This arm will use the alarm signal identified in Study 2 that is significantly associated with Electroencephalography (EEG)-defined awakening and successful completion of simulated escape behaviors by children after awakening from slow wave sleep. A lower frequency tone smoke alarm will evaluate the influence of alarm signal frequency on awakening. A conventional residential tone smoke alarm will be used as a reference stimulus. Both a male and a female voice will be used as alarm stimuli. Note that these will be strangers' voices, and not a mother's voice."
89339620|NCT01169155|Active Comparator|Study 4. Older Adults 60-84 Years of Age|Study 4 of this project will take the voice alarm script in Study 2 and compare it with a low-frequency 520 Hz square wave tone smoke alarm in awakening older adults 60-84 years of age from slow wave sleep and prompting their performance of a simulated escape procedure. Note that this will necessarily be a female stranger's voice, and not a mother's voice, in this older age group. As in Studies 1 and 2, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 4. In order to maintain the same experimental design across these studies, a fourth alarm type will be introduced. This fourth alarm will be a hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm, i.e., the stimulus will begin with the 520 Hz square wave tone in a T-3 pattern followed by the voice script, with this stimulus being repeated until the subject completes the escape procedure.
89339621|NCT01169155|Active Comparator|Study 1. Maternal Voice Smoke Alarm Characteristics|"Study 1. Identification of Specific Maternal Voice Smoke Alarm Characteristics Associated With Awakening and Escaping.~Using a randomized, non-blinded, repeated measures, clinical intervention design, Study 1 will identify the critical elements (i.e., use of child's first name and/or behavior commands in message content) in the maternal voice signal that are significantly associated with EEG-defined awakening (and completion of simulated escape behaviors by children after awakening from S4). A conventional residential tone smoke alarm meeting current NFPA 72 National Fire Alarm Code will be used as a reference stimulus to allow comparison of responses to the voice alarm stimuli with responses to a conventional residential tone alarm stimulus."
89339622|NCT01169155|Active Comparator|Study 2. Mother's Versus Stranger's Voice Alarms & Alarm Freq.|"Study 2. Comparison of Mother's Versus Stranger's Voice Smoke Alarms and Alarm Frequency.~Study 2 will take the voice alarm script that was the most successful in Study 1 in awakening and prompting children to perform the simulated escape behaviors, and will compare mother's voice to a female stranger's voice using this script. This will determine whether mother's voice is a critical factor for success of the voice smoke alarm. In addition, a Temporal-Three (T-3) pattern smoke alarm with dominant tones in lower frequency ranges similar to the human voice range will be included as a stimulus in Study 2 to evaluate the influence of alarm signal frequency on EEG-defined awakening (as well as completion of simulated escape behaviors by children after awakening from S4). As in Study 1, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 2. This conventional residential tone alarm has a higher frequency signal than the other T-3 tone alarm."
89339623|NCT01169155|Active Comparator|Study 5. Male Voice and Hybrid Tone/Voice Alarm for Children|Study 5. Children 5-12 Years of Age (Testing Male Voice and Hybrid Tone/Voice Alarm) Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in Study 5 among children 5-12 years of age using the following 4 alarm stimuli: female stranger's voice, male stranger's voice, hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm (from Study 4), and conventional high frequency tone residential alarm. This study arm will allow comparison of a male versus female voice and also evaluate the hybrid low frequency tone/voice alarm among children 5-12 years of age. The same protocol will be used for children in this study arm as was used in Studies 1 and 2.
89339624|NCT01166503||Early Surgery|This group will be made up of subjects whose parents choose to have them undergo corrective surgery at or before age 11 months.
89339625|NCT01166503||Standard Surgery|This group will be made up of subjects who present after age 11 months or whose parents choose to have them undergo corrective surgery between 11-18 months.
89339626|NCT01170637|Active Comparator|Ibuprofen 200 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
89339627|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
89339628|NCT01170637|Active Comparator|Ibuprofen 200 mg BI|Oral administration as a fixed dose combination tablet (BI product)
89339629|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg BI|Oral administration as a fixed dose combination tablet (BI product)
89339630|NCT01169233|Other|Shorter Wavelength (green)|
89339631|NCT01169233|Other|Intermediate Wavelength (white w/ green filter)|
89339632|NCT01169233|Other|Longer Wavelength (red)|Placebo
89339633|NCT01170793|No Intervention|2|no educative telephone coaching (ETC)
89339634|NCT01170793|Experimental|1|with educative telephone coaching (ETC)
89339635|NCT01282567|Other|diabetic patients|
89339636|NCT03873025|Experimental|Pembrolizumab and CXD101|"Initial dose ('dose level 0'):-~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 20mg twice daily PO (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity.~Reduced dose level ('Dose level -1'; if >1 DLT observed at dose level 0):~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 given twice daily, 20mg in the morning and 10mg in the evening (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity."
89339637|NCT02526745|Experimental|high doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
89339638|NCT02526745|Experimental|low doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
89339639|NCT02526745|Experimental|high doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
89339640|NCT02526745|Experimental|middle doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with middle doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
89339641|NCT02526745|Experimental|low doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
89339642|NCT02526745|Placebo Comparator|placebo|placebo in 100 adults aged 50-80 years old on day 0
89339643|NCT03868501|Experimental|High Working memory load: n-back task|During the intervention, each participant of this group will finish the 3-back task.
89339644|NCT03868501|Experimental|Low Working memory load: n-back task|During the intervention, each participant of this group will finish the 1-back task.
89339645|NCT01278199|Other|2|Medicals measures in the treatment of non-severe acute hemoptysis
89339646|NCT01278199|Experimental|1|bronchial artery embolization (BAE)
89339647|NCT01169389|Active Comparator|Durolane|
89339648|NCT01169389|Placebo Comparator|Bupivacaine|
89339649|NCT01170871|Experimental|Experimental|Escalating doses of Ixabepilone and Pemetrexed
89339650|NCT01169545||Cancer patients over the age of 18|Cancer patients over the age of 18 who are receiving active treatment.
89339651|NCT01171027|Experimental|NOTES(R) Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery techniques
89339652|NCT01171027|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
89339653|NCT01282645||PSI in PEEK|All study subjects have received a Patient Specific Implant (PSI) made of PEEK to repair a cranial defect
89339654|NCT01278277|Placebo Comparator|placebo supplementation|patients will be assigned, in a cross-over design, to placebo or supplement administration
89339655|NCT01278277|Active Comparator|Saffron|Saffron Supplementation 20 mg/die
89339656|NCT03872869|Active Comparator|Hip School|The participants in the Hip School were required to attend three 1.5 hour classes which were conducted by specially trained physiotherapists in premise at Lund University.
89339657|NCT03872869|Active Comparator|Tai Chi for arthritis (TCA)|The treatment intervention with TCA was scheduled in a group setting. Class size for Tai Chi groups was 8- 10 individuals. The group was led by a physiotherapist, specially trained in the concept, in premise at Lund University. The participants in the Tai Chi group were required to attend classes for 12-16 one- hour sessions, twice a week for the first four weeks and then once a week.
89339658|NCT03872869|No Intervention|Control group|
89339659|NCT01171105|Experimental|1|AZD5213 (dose escalating)
89339660|NCT01171105|Placebo Comparator|2|Placebo
89339661|NCT01169623|Experimental|Educational Intervention|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
89339662|NCT01169623|Placebo Comparator|CONTROL|55 of head nurses who will not participate in educational intervention will be considered as a control arm
89339663|NCT03868111|Experimental|Sufentanil|Balanced anesthesia is maintained with 1 MAC desflurane and sufentanil during laparoscopic cholecystectomy.
89339664|NCT03868111|Experimental|Remifentanil|Balanced anesthesia is maintained with 1 MAC desflurane and remifentanil during laparoscopic cholecystectomy.
89339665|NCT01282879|Experimental|itraconazole, prophylaxis, Oral solution|For GVHD patients who are required systemic glucocorticoids therapy, itraconazole oral solution will be administered at a dose of 200mg every 12 hours.
89339666|NCT03870061|No Intervention|Control|
89339667|NCT03870061|Experimental|Treatment|This arm receives the full New Incentives' conditional cash transfer program (All Babies Are Equal Initiative).
89339668|NCT01282957|No Intervention|Active Control|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 6 months
89339669|NCT01282957|Experimental|Financial Incentive Group I|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $100 and 2 in 10 odds of winning $10. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
89339670|NCT01282957|Experimental|Financial Incentives Group II|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $50 and 2 in 10 odds of winning $5. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
89339671|NCT01172587|Experimental|Lifestyle Counseling|Couples receive behavioral couples therapy for parental drug use.
89339672|NCT03872635|Experimental|CHO Drinking Grope|receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
89339673|NCT03872635|No Intervention|Traditional fast Grope|fast on standard hospital protocol (8 hour fasting for solid and 4 hour fasting for clear liquid
89339674|NCT03872557|Active Comparator|Tyrosine (TYR) depletion, then oral TYR|"TYR supplementation: Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before oral glucose tolerance test (OGTT). On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.~Visit 2. Placement of intravenous catheter for the collection of serial blood samples and an OGTT with supplementation with oral tyrosine supplement. To supplement the OGTT with Tyrosine, the contents of four (4) L-Tyrosine 500 mg capsule are given 45 minutes before the oral glucose solution is administered. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity."
89339675|NCT03872557|No Intervention|TYR depletion, then no oral TYR|"Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before OGTT. On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.~Subsequent Visit 3. This visit will consist of placement of intravenous catheter for the collection of serial blood samples and an OGTT without supplementation with oral tyrosine supplement."
89339676|NCT03868189|Experimental|electroneuromyography|
89339677|NCT03868189|Placebo Comparator|control|
89339678|NCT01171261|Experimental|Jackie Chan Studio Fitness|The Jackie Chan Studio Fitness (J-MAT) cartridge includes four types of activities that use a four panel floor mat made of flexible material that functions as the wireless interface game controller. The celebrity actor and choreographer Jackie Chan is the avatar character in the game that demonstrates and guides users in four types of aerobic and anaerobic game modes.
89339679|NCT01171261|Experimental|XaviX Tennis|XaviX Tennis simulates tennis using a tennis racket controller and an infrared sensor to detect speed and timing of the player's swing of the racquet. The Tennis cartridge includes three playing modes. In Tournament Tour players select from eight different characters with different skills and play opponents in a bracketed tournament. In Exhibition mode players choose a computer opponent or play a tennis match with a friend. The Training Games mode includes a) Serving, b) Target Challenge, c) Serve & Finish, and d) Rally Time.
89339680|NCT01171261|Experimental|XaviX Bowling|XaviX Bowling uses a wireless bowling ball game controller to simulate bowling. The cartridge includes three modes. In Regular Game up to four people can select from 8 preset bowlers with different characteristics. In Tournament Mode up to eight people can play. Challenge Games consists of three games called Against the Clock, Moving Pins, and Panel Crusher.
89339681|NCT01171261|Experimental|XaviX Boxing|XaviX Boxing uses boxing gloves as the game controller and allows players to box against five different computer opponents in Championship and Exhibition modes and to practice boxing skills in Exercise mode. Exercise mode includes Punch Fast, Panel Toucher, Punch the Red Ball, and Combination Training.
89339682|NCT03872245|Experimental|PENS T6 + Probiotics|The patients will receive Probiotics (Adomelle 1caps/12h) associated to PENS T6 during 10 weeks.
89339683|NCT03872245|Active Comparator|PENS T6|The patients will undergo PENS T6 during 10 weeks.
89339684|NCT01172743||Diabetes|Individuals with diabetes that fit eligibility criteria.
89339685|NCT01172743||Normal Control|Individuals without history of diabetes.
89339686|NCT03868033|Experimental|Continuous Denosumab|Continuous anti-resorptive therapy by Denosumab for 2 years
89339687|NCT03868033|Experimental|Zoledronic acid to Denosumab|treat with Zoledronic acid for one year and then shift to Denosumab for another one year
89339688|NCT03868033|Experimental|Continuous Zoledronic acid|Continuous anti-resorptive therapy by Zoledronic acid for 2 years
89339689|NCT03868033|Experimental|Zoledronic acid to observation|"treat with Zoledronic acid for one year and then close follow up by bone turn over marker.~resume another dose of Zoledronic acid if elevated CTX level above normal range"
89339690|NCT01172899|Experimental|Laparoscopic adjustable gastric band|
89339691|NCT01172899|Active Comparator|Control group|
89339692|NCT01171339|No Intervention|Control|"Usual care in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
89339693|NCT01171339|Experimental|Intervention arm|"Intervention: Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
89339694|NCT01166815|Active Comparator|Zinc supplemented|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
89339695|NCT01166815|Placebo Comparator|Placebo|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
89339696|NCT03751657|Experimental|Insulin 287|Participants will receive once weekly insulin 287 and once daily placebo in combination with metformin with or without dipeptidyl peptidase-4 inhibitors (DPP4i) during 26 weeks of treatment period.
89339697|NCT03751657|Active Comparator|Insulin glargine|Participants will receive once daily insulin glargine and once weekly placebo in combination with metformin with or without DPP4i during 26 weeks of treatment period.
89339698|NCT02525809|Other|mobility insert with tripod attachment (Novae E®)|mobility insert with tripod attachment (Novae E®)
89339699|NCT02525809|Other|mobility insert with press fit pure (Sunfit®)|mobility insert with press fit pure (Sunfit®)
89339700|NCT02525809|Other|fixed insert (Quartz®).|fixed insert (Quartz®).
89339701|NCT01171417||Cohort 1|1st-line Faslodex 500 mg
89339702|NCT01171417||Cohort 2|2nd-line Faslodex 500 mg
89339703|NCT01171417||Cohort 3|3rd- line Faslodex 500 mg
89339704|NCT01171417||Cohort 4|patients on exemestane
89339705|NCT01172977||HbA1c ≤ 7|Stroke patients with mild diabetes mellitus HbA1c ≤ 7
89339706|NCT01172977||HbA1c ≥ 7,5|Stroke patients with severe diabetes mellitus HbA1c ≥ 7,5
89339707|NCT03873415|Experimental|Formulation A|Dosage formulation and area of release varies between arms
89339708|NCT03873415|Experimental|Formulation B|Dosage formulation and area of release varies between arms
89339709|NCT03873415|Experimental|Formulation C|Dosage formulation and area of release varies between arms
89339710|NCT03873415|Experimental|Formulation D|Dosage formulation and area of release varies between arms
89339711|NCT03873415|Experimental|Formulation E|Dosage formulation and area of release varies between arms
89339712|NCT03873415|Experimental|Formulation F|Dosage formulation and area of release varies between arms
89339713|NCT03873415|Experimental|Formulation G|Dosage formulation and area of release varies between arms
89339714|NCT03873415|Experimental|Formulation H|Dosage formulation and area of release varies between arms
89339715|NCT01171495|Experimental|Ensure Plus + Multivitamin/Counselling|
89339716|NCT01171495|Active Comparator|Multivitamin/Counselling|
89339717|NCT00025259|Experimental|Arm I (Patients off-therapy before callback-Induction only)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.
89339718|NCT00025259|Experimental|Arm II (RER with CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.
89339719|NCT00025259|Experimental|Arm III (RER with CR [ABVE-PC])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.
89339720|NCT00025259|Experimental|Arm IV (RER with less than CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.
89339721|NCT00025259|Experimental|Arm V (RER with PD)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.
89339722|NCT00025259|Experimental|Arm VI (SER [DECA, ABVE-PC, IFRT])|Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, and cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 and 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 and G-CSF SC beginning on day 3 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
89339723|NCT00025259|Experimental|Arm VII (SER [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
89339724|NCT01279135|Active Comparator|Conventional RT|Patients in this arm will receive conventional radiation with or without chemotherapy
89339725|NCT01279135|Experimental|Tomotherapy based IGRT|Patients in this arm will receive Tomotherapy based IGRT with or without chemotherapy
89339726|NCT03866863||HFME births.|All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2017.
89339727|NCT01171651|Experimental|JX-594 followed by sorafenib|1e9 pfu (plaque-forming units) total JX-594 dose on each of up to four (4) JX-594 treatment days. Sorafenib is initiated after 3 JX-594 treatments and briefly interrupted if an optional 4th JX-594 treatment is given.
89339728|NCT03866629||Lifitegrast 5%|Patients will receive lifitegrast 0.5% eye drops twice daily 4 weeks prior to cataract surgery.
89339729|NCT02525731||Patient Cohort|The TEACH patient cohort component will establish an observational cohort of HIV-infected patients on chronic opioid therapy.
89339730|NCT01280071|Experimental|dipyridamole, aminophylline|
89339731|NCT02526199|Active Comparator|Group BA|Bupivacaine + Adrenaline Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml
89339732|NCT02526199|Experimental|Group BAD|Bupivacine + Adrenaline + Dexamethasone Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml PLUS Dexamethsone 8 mg
89339733|NCT03866941||synthetic cannibinoids users|
89339734|NCT01100957|Active Comparator|Conventional flexible videoscope for intubation|
89339735|NCT01100957|Experimental|Single-patient flexible endoscope|Single-patient flexible video-endoscope used for tracheal intubation in this intervention-arm
89339736|NCT03351738|Placebo Comparator|Placebo|Participants will receive subcutaneous (SC) dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
89339737|NCT03351738|Experimental|MEDI5884 50 mg|Participants will receive SC dose of MEDI5884 50 mg on Days 1, 31, and 61.
89339738|NCT03351738|Experimental|MEDI5884 100 mg|Participants will receive SC dose of MEDI5884 100 mg on Days 1, 31, and 61.
89339739|NCT03351738|Experimental|MEDI5884 200 mg|Participants will receive SC dose of MEDI5884 200 mg on Days 1, 31, and 61.
89339740|NCT03351738|Experimental|MEDI5884 350 mg|Participants will receive SC dose of MEDI5884 350 mg on Days 1, 31, and 61.
89339741|NCT03351738|Experimental|MEDI5884 500 mg|Participants will receive SC dose of MEDI5884 500 mg on Days 1, 31, and 61.
89339742|NCT01284595|Experimental|AZD8931|[14C] AZD8931
89339743|NCT01284049|Active Comparator|Intralipid 20%®|reference treatment by standard lipid emulsion not enriched in n-3 EFA (Intralipid 20%®)+ vitamin E.
89339744|NCT01284049|Experimental|OMEGAVEN 10%®|Interventional treatment by a lipid emulsion enriched in n-3 EFA (OMEGAVEN 10%®).
89339745|NCT03711084|Placebo Comparator|Water|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
89339746|NCT03711084|Experimental|Natural high potency sweetener from leaf extract|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
89339747|NCT03711084|Experimental|Glucose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
89339748|NCT03711084|Experimental|Sucrose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
89339749|NCT03711084|Experimental|Maltodextrin|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
89339750|NCT03863977|Active Comparator|Dex4 group|After the surgery, the patients in this group will receive 4 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
89339751|NCT03863977|Active Comparator|Dex8 group|After the surgery, the patients in this group will receive 8 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
89339752|NCT03863977|Active Comparator|control group|After the surgery, the patients in this group will 1mg/kg of 0.5% bupivacaine in the TAP block.
89339753|NCT01171807|Active Comparator|Dexamethasone 21-phosphate encapsulated into red cells|
89339754|NCT01171807|Sham Comparator|Placebo|
89339755|NCT03866551|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
89339756|NCT05445648|Experimental|patients treated with immunotherapy-based bladder preservation therapy|Neoadjuvant immunotherapy + TURBT + postoperative adjuvant radiotherapy combined with immunotherapy.
89339757|NCT01171885|Placebo Comparator|Placebo|Bilateral superficial cervical block.
89339758|NCT01171885|Experimental|Ropivacaine 0.25%|Bilateral superficial cervical block
89339759|NCT01171885|Experimental|Ropivacaine 0.5%|Bilateral superficial cervical block.
89339760|NCT03711006|Experimental|FMT treated patients|Seven patients with active Ulcerative Colitis treated with 25 multi-donor FMT Capsules daily.
89339761|NCT03866395|No Intervention|Control Group|drug therapy according to the guidelines
89339762|NCT03866395|Experimental|Ivabradine Group|drug therapy according to the guidelines + Ivabradine 5 mg twice a day
89339763|NCT01284751||Breast cancer patients|Patients aged 30-70 years having a lumpectomy or mastectomy at the Department of Breast Surgery at Herlev Hospital, Copenhagen, Denmark.
89339764|NCT01286233||Group 1: Metformin|850 mg orally twice a day for 5 years
89339765|NCT01286233||Group 2: Placebo|One caplet orally twice a day for 5 years
89339766|NCT03351114|Experimental|Crisaborole 2% ointment|Crisaborole 2% ointment applied to affected skin twice per day.
89339767|NCT03711942|Active Comparator|Periodontally Healthy IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar.
89339768|NCT03711942|Experimental|Periodontally Healthy Base|2mm thick base was applied in periodontally health teeth.
89339769|NCT03711942|Experimental|Periodontally healthy control|coronal access was restored with composite resin without any base.
89339770|NCT03711942|Active Comparator|Periodontally diseased IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar
89339771|NCT03711942|Active Comparator|Periodontally diseased Base|2mm thick Base of GIC was applied under composite restoration
89339772|NCT03711942|Active Comparator|Periodontally diseased control|coronal access was restored with composite resin without any base
89339773|NCT03350256|Experimental|Microdosing group|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
89339774|NCT03863899|Experimental|Nerve block|ultrasound-guided ilioinguinal iliohypogastric nerve block performed by the anaesthesiologist for Transaortic valve implantation (TAVI) insertion with eventual additional intraoperative analgesia (AIA) and/or additional postoperative analgesia (APA)
89339775|NCT03863899|Active Comparator|Local infiltration|local anaesthesia infiltration performed by the operator for TAVI insertion with eventual intraoperative additional analgesia (AIA) and/or postoperative analgesia (APA)
89339776|NCT02525965|Experimental|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
89339777|NCT02525965|Active Comparator|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of narrow resection margin <1cm
89339778|NCT03867877|Experimental|Periodized Training with Motor Practice|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
89339779|NCT03867877|Experimental|Simple Periodized Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and 60-75% of subjects' maximum strength for the hypertrophy day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down
89339780|NCT01175161|Experimental|Immediate postpartum IUD insertion|Women assigned to have the IUD placed 10 minutes to 48 hours postpartum
89339781|NCT01175161|Experimental|6 week postpartum IUD insertion|Women who receive the IUD at the traditional time frame.
89339782|NCT03863743|Other|Control|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. Patient will undergo treating physician's standard of care for total hip or knee replacement. Patient will receive bladder scans in PACU, upon admission to the nursing unit, and prior to discharge (post-void).
89339783|NCT03863743|Experimental|Experimental|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. If considered high risk (determined by IPSS), then patient Patient will undergo integrated care pathway that avoids narcotics. Bladder volume will be measured in PACU, after admission to the nursing unit, and prior to discharge from the hospital (post-void).
89339784|NCT01173289|Experimental|External Beam Radiotherapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning :~Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
89339785|NCT02526121|Experimental|Phlebotomy associated with dietary and lifestyle counseling|
89339786|NCT02526121|Active Comparator|Dietary and lifestyle counseling.|
89339787|NCT01172119|Experimental|BioFreedom Standard Dose|
89339788|NCT01172119|Experimental|BioFreedom Low Dose|
89339789|NCT01172119|Active Comparator|Taxus Liberte drug eluting stents|
89339790|NCT01175239|Experimental|Single infusion of autologous CD34+ cells|
89339791|NCT01284205|Experimental|MCC|Intravesical Administration of Mycobacterial Cell-Wall DNA Complex
89339792|NCT01284205|Active Comparator|BCG|Intravesical Administration of Bacillus Calmette-Guerin
89339793|NCT03863665|Experimental|Telemetric Bluetooth home BP monitors|Telemetric Bluetooth home BP monitors will be provided to participants during their inpatient stay or clinic visit, and will commence 3- times-daily readings immediately. The BP monitoring team will assess BP readings daily and advise medication adjustments to achieve a target BP of <120/80 mm Hg
89339794|NCT03863665|No Intervention|Standard clinical care|Standard clinical care including usual BP treatment, without home monitoring, undertaken in the clinical care setting
89339795|NCT00024167|Experimental|Induction regimen A|Doxorubicin IV over 24 hours day 1; Oral ketoconazole 3 x daily on days 1-7 of weeks 1, 3, and 5; Vinblastine IV over 30 minutes Day 1, oral Estramustine 3 x daily on Days 1-7 of weeks 2, 4, and 6.
89339796|NCT00024167|Experimental|Induction regimen B|Oral Prednisone 2 x daily on days 1-21 (days 1-14 of course 5 only) and Docetaxel IV over 1 hour Day 1.
89339797|NCT00024167|Experimental|Consolidation arm I|Doxorubicin IV over 24 hours once weekly for 6 weeks + Strontium-89 IV once at beginning of chemotherapy.
89339798|NCT00024167|Experimental|Consolidation arm II|Doxorubicin as in Consolidation arm I.
89339799|NCT01173367|Active Comparator|Aggressive Fever Treatment|
89339800|NCT01173367|Active Comparator|Permissive Fever Treatment|
89339801|NCT03867565|No Intervention|No nutritional diagnosis|Patients without nutritional diagnosis get SOC
89339802|NCT03867565|Experimental|Nutritional diagnosis|Patients with nutritional diagnosis get nutritional intervention by dietitian.
89339803|NCT03867721|Experimental|Ventilator PB560 (Covidien)|The non-dedicated (NON-DED) set comprised a ventilator for MPV (PB560) using a single active tubing with an exhalation valve. A custom-made arm support and plastic mouthpiece were used.
89339804|NCT03867721|Experimental|Ventilator Trilogy (Philips Respironics)|The dedicated (DED) set comprised a ventilator for MPV (Trilogy 100, Philips Respironics; with dedicated software, with a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger, with a smart flexible tube support system and with a silicone made mouthpiece designed as a straw.
89339805|NCT03867097|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
89339806|NCT03867097|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
89339807|NCT01286389|Active Comparator|Conventional medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
89339808|NCT01286389|Experimental|caloric restriction +medical care|Nutritional counseling individually and in groups, aiming to promote weight loss (10% of body weight) through caloric restriction, +Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise)
89339809|NCT03863275|Other|No intervation|Children between the ages of 7 and 12 diagnosed with class II dental classification, who attend the Leonardo Da Vinci School after carrying out an intraoral and extraoral photography study and diagnostic impressions with study models accepting participation in the study, Children over the age of 12 who have an agreement according to the results of medical care. Patients with Pierre Robin syndrome or any form of cleft.
89339810|NCT03863275|Experimental|Myofunctional apparatus|Boys and girls between 7 and 12 years skeletal class II, for the study group the individuals will be selected from the UNICIEO postgraduate clinic of orthopedic clinic orthodontics after conducting a full clinical case study exposed to a board of specialist teachers in orthodontics, where by means of several diagnostic methods a skeletal class II is confirmed that involves a treatment with myofunctional apparatus SN1; patients presenting syndromes that generate craniofacial alterations, patients with previous orthopedic treatment, patients with signs of condyle lesions, patients with Pierre Robin syndrome or any form of slit will be excluded.
89339811|NCT01284985||METIS|Patient who has an indication of : Hallux Rigidus, Hallux Limitus with degenerative joint disease, Painful Hallux Valgus, Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis and for which surgeon has recommended that a METIS® prosthesis be implanted.
89339812|NCT03867253|Active Comparator|ORY-2001 Low dose|0.6mg ORY-2001 capsule
89339813|NCT03867253|Active Comparator|ORY-2001 High dose|1.2mg ORY-2001 capsule
89339814|NCT03867253|Placebo Comparator|Placebo|Placebo capsule
89339815|NCT03866317|Experimental|Secukinumab|Secukinumab 300 mg injection at week 0, 1, 2, 3, 4, then every 4 weeks until week 12
89339816|NCT03866005|Placebo Comparator|Placebo Arm - Standard Treatment|50 subjects with center-involved diabetic macular edema (CI-DME) and scheduled for treatment with intravitreal injection of anti-VEGF agents will receive softgel placebo containing canola oil, 2 capsules per day during the study duration
89339817|NCT03866005|Experimental|Experimental Arm - 2 DiVFuSS formula softgel capsules|50 subjects receiving two DiVFuSS softgels per day
89339818|NCT03866005|Experimental|Experimental Arm - 4 DiVFuSS formula softgel capsules|50 subjects receiving 4 DiVFuss softgels per day
89339819|NCT01285063|Experimental|physical activiy & nutrition|"25 kindergarten children in the ages of 4-6 who defined as suffering from overweigh (BMI percentage 85-95) or obesity (above BMI percentage 95).~Non-generalization criteria: children who suffer from obesity due to organic disease or children who take medicine which may influence body weight (e.g., steroids) will be excluded from the research."
89339820|NCT01285141|Experimental|Vaginal immunisation|CN54gp140 glycoprotein-hsp70 conjugate vaccine
89339821|NCT01286545||Ankylosing spondylitis, long term treatment with infliximab|Patients with ankylosing spondylitis under long term treatment with infliximab within the open label clinical trials EASIC and DIKAS are now followed up in a registration study. No intervention is planned. Patients will be followed up for clinical outcome parameters and for radiographic progression.
89339822|NCT03867331|Experimental|5 microgram VLPM01|5 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
89339823|NCT03867331|Experimental|15 microgram VLPM01|15 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
89339824|NCT03867331|Experimental|30 microgram VLPM01|30 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
89339825|NCT03867331|Experimental|Controlled Human Malaria Infection (CHMI) Phase|Infectivity Control Participants, n=6
89339826|NCT01175551||Group 1|women screened at Penn OB/GYN Associates or Helen O. Dickens Center with a documented singleton pregnancy less than 18 weeks gestational age
89339827|NCT01175551||Group 2|Nulliparous pregnant women (no previous pregnancy greater than 15 weeks) screened at Penn OB/GYN Associates or Helen O. Dickens Center less than 18 weeks gestational age
89339828|NCT01285219|Active Comparator|AOB,pegylated filgrastim to filgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
89339829|NCT01285219|Active Comparator|BOA,ﬁlgrastim to pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
89339830|NCT01173757|Experimental|PF-04995274|
89339831|NCT03867409|Experimental|Concordant virtual human|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
89339832|NCT03867409|Experimental|Dis-concordant virtual human|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
89339833|NCT03867409|Experimental|Concordant text|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
89339834|NCT03867409|Experimental|Dis-concordant text|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
89339835|NCT03867019||Subjects with BPPV|"Patients diagnosed with BPPV, who meet the following criteria:~Main complain of spinning sensation (Vertigo) when changes are made in head position relative to gravity.~Positive Dix-Hallpike / Supine Roll Test, confirmed by presence of nystagmus."
89339836|NCT03867019||Subjects without BPPV (Control group)|Patients who do not suffer from dizziness / spinning sensation (Vertigo), and do not meet the exclusion criteria in the study.
89339837|NCT01284439|Experimental|TearA|
89339838|NCT01284439|Experimental|TearB|
89339839|NCT03863431|Active Comparator|High-fat diet|"Participants will consume a diet rich in fat (approximately 65% of total energy) and low in carbohydrate for 14 days.~Measurements will be made at 0, 7 and 14 days."
89339840|NCT03863431|Active Comparator|High-carbohydrate diet|"Participants will consume a diet rich in carbohydrate (approximately 70% of total energy) and low in fat for 14 days.~Measurements will be made at 0, 7 and 14 days."
89339841|NCT01172431|Experimental|Indapamide|Indapamide SR 1.5mg qd
89339842|NCT01172431|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
89339843|NCT01285297|Experimental|TMR plus BMAC injection|Injection of bone marrow aspirate concentrate into reversibly ischemic myocardium with transmyocardial revascularization during the same open procedure.
89339844|NCT00071513|Experimental|CAST-T/HSTS|The CAST-T/HSTS condition combined the Brief Intervention and 12 school based small group sessions which taught skills to enhance personal control (to manage depression, anger, stress), self-esteem, decision making and interpersonal communications. HSTS skills groups were held in the spring of 8th grade with 4 one-on-one booster sessions delivered to the students as 9th graders by HSTP leaders; parents also participated in 4 sessions. HSTS objectives are: 1) to increase the acquisition of coping skills competencies by teaching and practicing strategies taught; 2) to increase social support resources by building a supportive network; 3) to increase the youth's engagement in positive social activities; and 4) to motivate parents to increase their support via parent educational sessions.
89339845|NCT00071513|Active Comparator|Brief Intervention|Brief Intervention: After each youth and parent completed baseline questionnaires the youth participated in a 1 on 1 standardized clinical follow-up with a trained clinician (blind to study condition) to review areas of concern, based on questionnaire responses including stressors at school, home, and with peers, level of support available and how to access support. The teen and clinician then planned a feedback call to parents, allowing teens to shape requests for support from parents as well as understand exactly what information would be shared with parents. Feedback call to parents reviewed concerns and made recommendations for services as needed. A similar procedure was followed after each assessment for all participants who indicated a risk of clinical depression or self-harm.
89339846|NCT03865849|Active Comparator|Conventional radiofrequent treatment|The patient is placed in a supine position on a fluoroscopy table with the index knee flexed 10-15°. The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 10 mm active tip
89339847|NCT03865849|Active Comparator|Cooled radiofrequent treatment|The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 100 mm long, 17 G RF cannula/introducer with an 18 G cooled probe/electrode with a 4 mm active tip (Halyard/Coolief).
89339848|NCT03866083|Experimental|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
89339849|NCT03866083|Active Comparator|Stadard Medical treatment|Stadard Medical treatment
89339850|NCT03960359||Episodic viral wheezers (EVW)|EVW: Wheezing during discrete time periods (exacerbations), absence of symptoms between exacerbations Among which SIW: EVW with ≥ 2 exacerbations over the last 6 months Clinical, microbiological and inflammatory phenotype
89339851|NCT03960359||Multiple trigger wheezers (MTW)|MTW : wheezing during exacerbations but also symptoms between episodes. Clinical, microbiological and inflammatory phenotype
89339852|NCT01172509|Placebo Comparator|sugar pill|placebo administered under double blind conditions
89339853|NCT01172509|Experimental|3 mg of R-baclofen|3 mg of R-Baclofen administered double blind
89339854|NCT01172509|Experimental|10 mg of R-baclofen|10 mg of R-baclofen administered double-blind
89339855|NCT01172509|Experimental|25 mg of R-baclofen|25 mg of R-baclofen administered double blind
89339856|NCT01172509|Placebo Comparator|second sugar pill|the second placebo administered double blind
89339857|NCT03960593||Patients with cancer and / or hematological|The population of the study will be all patients over 70 years of age with oncogeriatric HDJ cancer prior to initiation of oncologic therapy such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or hormone therapy. new generation.
89339858|NCT01173913|Experimental|ModraDoc001 10 mg capsules|The optimal dose weekly bi-daily oral docetaxel - ModraDoc001 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
89339859|NCT01173913|Experimental|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|Both new oral dosage forms, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets will be investigated to see whether these new formulations have comparable pharmacokinetic characteristics, in terms of systemic exposure to docetaxel, as ModraDoc001 10 mg capsule.
89339860|NCT01173913|Experimental|ModraDoc006 10 mg tablet|The optimal dose weekly bi-daily oral docetaxel - ModraDoc006 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
89339861|NCT01089959|Other|Esomeprazole|Effect of PPI esomeprazole on acid reflux & related arousals during sleep in patients with GERD.
89339862|NCT01175629||Group 1|The Vietnam Era Twin (VET) Registry is a closed cohort composed of 7,369 middle-aged male-male twin pairs both of whom served in the military during the time of the Vietnam conflict (1965-1975). The Registry is a United States Department of Veterans Affairs resource that was originally constructed from military records; the Registry has been in existence for more than 15 years. It is one of the largest national twin registries in the US and currently has subjects living in all 50 states. Initially formed to address questions about the long-term health effects of service in Vietnam the Registry has evolved into a resource for genetic epidemiological studies of mental and physical health conditions. Several waves of mail and telephone surveys have collected a wealth of health-related information on Registry twins. Other data collection efforts have focused on specific sets of twin pairs and conducted detailed clinical or laboratory testing.
89339863|NCT01090037|Experimental|TRK-100STP|
89339864|NCT01090037|Placebo Comparator|Placebo|
89339865|NCT01177891||Subject index|Population of familial cases of POF : 20 families with at least two subjects with POF nonsyndromic
89339866|NCT01177891||Population Index Related topics|Women, healthy women, men are potential carriers
89339867|NCT01177891||Population control|100 Caucasian women with normal cycles until at least the age of 40 years and a proven fertility
89339868|NCT01090193|Other|obstructive jaundice|
89339869|NCT01285375|Active Comparator|CDC graft perfusion|Flushing of kidney allografts prior to transplantation with UW-solution containing CDC
89339870|NCT01285375|Sham Comparator|Sham perfusion|
89339871|NCT01288105|Experimental|Optical Coherence Tomography|Patients enrolled in the study will undergo optical coherence tomography to evaluate the extent of stent strut coverage.
89339872|NCT03960281||Single implant crowns in the anterior maxilla|No drugs to be administered. Patients who have had a single implant crown placed since more than one year in the anterior maxilla (second premolar to second premolar) will be invited for a review session for dental examination and to fill the Oral Health Impact Profile (OHIP) questionnaire.
89339873|NCT01100645|Experimental|Test|Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)
89339874|NCT01100645|Placebo Comparator|Placebo|Excipient
89339875|NCT03860389|Experimental|Exercise effects on anxiety|An exercise programme will be administered 3 times a week for up to an 16 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will involve aspects of fundamental movement skills and will be fun for the students to participate in.
89339876|NCT01175863|Active Comparator|Intravascular ultrasound|
89339877|NCT01175863|Active Comparator|Fractional flow reserve|
89339878|NCT05625893|Experimental|PBT arm|
89339879|NCT01173991|Experimental|Carbohydrate counting|This group received carbohydrate counting training
89339880|NCT01173991|No Intervention|Controls|This group received standard education
89339881|NCT01102907||Liquid Meal|
89339882|NCT01102907||Solid Meal|
89339883|NCT01174069|Experimental|NOTES cholecystectomy|
89339884|NCT01102985|Experimental|aerobic resistance|12 month aerobic resistance exercise at a fitness center
89339885|NCT01102985|Active Comparator|home based physical activity|national recommendations for physical activity for adults
89339886|NCT01178047|Active Comparator|Rasagiline|
89339887|NCT01178047|Placebo Comparator|Placebo|
89339888|NCT01090271|Experimental|Eccentric training|
89339889|NCT01174147||Hospital Candida Cases|People who developed a positive blood culture for Candida while hospitalized
89339890|NCT03960203|Experimental|Comparator|The comparator arm will involve patients monitored by InSight.
89339891|NCT01101113|Experimental|Cinacalcet|stepwise dose of cinacalcet + regular medical medication including vit D
89339892|NCT01101113|Active Comparator|Control|conventional treatment for secondary HPT including vit D and phosphate binder
89339893|NCT01288183|Sham Comparator|sham tDCS|sham transcranial direct current stimulation The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region
89339894|NCT01288183|Active Comparator|active tDCS|active anodal tDCS over the right dorsolateral prefrontal cortex The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region Intensity of the stimulation: 2 mA Duration of the stimulation: 20 min 10 sessions, 2 per day
89339895|NCT03950999|Experimental|Study arm|Each subject underwent baseline assessment of pain reporting accuracy (FAST). Thereafter, the placebo response was assessed using tonic heat stimuli delivered at fixed temperature of 44, 46.5, and 48°C which evoke mild, moderate and severe pain sensations (in accordance). The stimuli were given in a pseudo-random order twice, once before receiving the placebo pill (a sugar pill) and once after, maintaining the same order as before.
89339896|NCT01288261|Experimental|Treatment|Paclitaxel, bavituximab, laboratory biomarker analysis and pharmacological study
89339897|NCT03865693|Experimental|scarmbler treatment group|Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days. The experimental participants were received scarmbler therapy 10 times for 2 weeks. The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
89339898|NCT03865693|Sham Comparator|sham treatment group|conservative management without scarmbler therapy
89339899|NCT01174303|Experimental|IDegAsp - BIAsp|
89339900|NCT01174303|Experimental|BIAsp - IDegAsp|
89339901|NCT01285453|Experimental|ASA404|
89339902|NCT01288339|Experimental|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP (MMP7+/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
89339903|NCT01288339|Experimental|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
89339904|NCT00006389|Experimental|Treatment|Patients receive bryostatin 1 IV over 72 hours on days 1-3 followed by cisplatin IV over 1 hour on day 4. Treatment repeats every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
89339905|NCT01285531|No Intervention|Lumbar puncture|The participants randomly assigned to this arm will receive a lumbar puncture using standard procedures and equipment
89339906|NCT01285531|Experimental|Lumbar puncture with the Compass device|The participants randomly assigned to this group will receive a lumbar puncture with the use of the Compass device.
89339907|NCT02525497|Experimental|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h;
89339908|NCT02525497|Active Comparator|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h;
89339909|NCT04029077||Vapor group|Bronchoscopic lung volume reduction treatment using Vapor
89339910|NCT01174381|Experimental|Lifestyle modification|Lifestyle modification for behavior change related to NCD prevention
89339911|NCT01175941|Experimental|NRL001|10 mg NRL001 in a 2 g suppository
89339912|NCT01175941|Placebo Comparator|Placebo|Matched placebo control
89339913|NCT01105481|Experimental|amisulpride add-on|
89339914|NCT01105481|Placebo Comparator|placebo add-on|
89339915|NCT01103219|Placebo Comparator|Control|Participants in this group will receive nutrition from birth and during the hospital stay until discharge according to the routines of the participating institutions.
89339916|NCT01103219|Active Comparator|Intervention|The participants in this group will receive increased supply of energy, protein, vitamin A, docosahexaenoic acid, and arachidonic acid from birth and during the hospital stay until discharge.
89339917|NCT01176019|Experimental|Interactive Video|In addition to standard care, the experimental arm will receive an interactive video designed to inform and educate patients about the choices that exist concerning prenatal screening and diagnosis.
89339918|NCT01176019|No Intervention|Control|A control arm will receive standard care, which is the opportunity to meet with a genetic counselor.
89339919|NCT01286701|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
89339920|NCT01286701|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
89339921|NCT00006305|Active Comparator|Revascularization and Insulin Providing (IP)|Prompt revascularization with intensive medical therapy and insulin providing glycemic control strategy
89339922|NCT00006305|Active Comparator|Revascularization and Insulin Sensitizing (IS)|Prompt revascularization with intensive medical therapy and insulin sensitizing glycemic control strategy
89339923|NCT00006305|Active Comparator|Medical Therapy and Insulin Providing (IP)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin providing glycemic control strategy
89339924|NCT00006305|Active Comparator|Medical Therapy and Insulin Sensitizing (IS)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin sensitizing glycemic control strategy
89339925|NCT03862573|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during the dental procedure
89339926|NCT03862573|No Intervention|Control (Standard of Care)|Participants are distracted with Standard-of-Care by dentists and/or parents.
89339927|NCT01176097|Experimental|6 - 8 cohorts|6 patients in each cohort will receive AZD5658
89339928|NCT01176097|Placebo Comparator|6 - 8 cohorts|2 patients in each cohort will receive placebo
89339929|NCT01284907|Active Comparator|Vit D|
89339930|NCT01284907|Placebo Comparator|Placebo drops|
89339931|NCT01103297|Other|Variable Angle Distal Radius Plate|
89339932|NCT03865459|Experimental|Video group|The video group watched relaxing video with a ceiling mounted television during the whole cystoscopy.
89339933|NCT03865459|No Intervention|Control group|The control group received the standard treatment from a surgical technician who works in the cystoscopy during the whole procedure.The control group didn't watch relaxing video during the procedure.
89339934|NCT01101269|Experimental|Subjects with diabetic nephropathy|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
89339935|NCT01101269|Active Comparator|Healthy volunteers|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
89339936|NCT03529773|Experimental|Sentinel Arm 1|Low dose formulation A
89339937|NCT03529773|Experimental|Sentinel Arm 2|Mid dose formulation A
89339938|NCT03529773|Experimental|Sentinel Arm 3|High dose formulation A
89339939|NCT03529773|Experimental|Sentinel Arm 4|Low dose formulation B
89339940|NCT03529773|Experimental|Sentinel Arm 5|Mid dose formulation B
89339941|NCT03529773|Experimental|Sentinel Arm 6|High dose formulation B
89339942|NCT03529773|Placebo Comparator|Sentinel Arm 7|Placebo
89339943|NCT03529773|Experimental|Expanded Arm 8|Low dose formulation A and SIIV
89339944|NCT03529773|Experimental|Expanded Arm 9|Mid dose formulation A and SIIV
89339945|NCT03529773|Experimental|Expanded Arm 10|High dose formulation A and SIIV
89339946|NCT03529773|Experimental|Expanded Arm 11|Low dose formulation B and SIIV
89339947|NCT03529773|Experimental|Expanded Arm 12|Mid dose formulation B and SIIV
89339948|NCT03529773|Experimental|Expanded Arm 13|High dose formulation B and SIIV
89339949|NCT03529773|Experimental|Expanded Arm 14|Low dose formulation A and placebo
89339950|NCT03529773|Experimental|Expanded Arm 15|Mid dose formulation A and placebo
89339951|NCT03529773|Experimental|Expanded Arm 16|High dose formulation A and placebo
89339952|NCT03529773|Experimental|Expanded Arm 17|Low dose formulation B and placebo
89339953|NCT03529773|Experimental|Expanded Arm 18|Mid dose formulation B and placebo
89339954|NCT03529773|Experimental|Expanded Arm 19|High dose formulation B and placebo
89339955|NCT03529773|Placebo Comparator|Expanded Arm 20|placebo and placebo
89339956|NCT01103375|Experimental|Treatment (enzyme inhibitor, immunotherapy)|Patients receive isotretinoin PO QD on days 1-21 and erlotinib hydrochloride PO QD on days 1-28.
89339957|NCT03865537|Experimental|Cold snare & Eleview injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Eleview
89339958|NCT03865537|Experimental|Cold Snare & Placebo injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Placebo
89339959|NCT03865537|Active Comparator|Hot snare & Eleview injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Eleview
89339960|NCT03865537|Active Comparator|Hot snare & Placebo injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Placebo
89339961|NCT02525419|Experimental|Weight Loss Phase|12 week weight loss phase consisting of High Protein - Intermittent Fast-Low Calorie diet in 43 Obese Men and Women
89339962|NCT02525419|Experimental|Weight Loss Maintenance Phase|52 week weight loss maintenance phase consisting of either High Protein - Intermittent Fast (HP-IF) or Heart Healthy (HH) diet
89339963|NCT03949049|Experimental|Citacoline|Citacoline as neuroprotector
89339964|NCT03949049|Placebo Comparator|Placebo|Placebo
89339965|NCT03865225|Sham Comparator|Control group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes sham-biofeedback over a period of three days
89339966|NCT03865225|Active Comparator|Treatment group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes biofeedback sessions over period of three days
89339967|NCT01285687|No Intervention|Standard Analgesic Treatment|
89339968|NCT01285687|Experimental|Standard Analgesic Treatment with Acupuncture|Patients will receive standard analgesic treatment and in addition acupuncture.
89339969|NCT03864991|No Intervention|Routine Care|This group will be followed up for routine care, maintaining a standard log book for documenting blood sugar and insulin dosages per advice and explanation by doctors, nurses and nutritionists.
89339970|NCT03864991|Active Comparator|e-device for step count (fit-bit)|This group will receive e-device for step count (fit-bit) in addition to routine care.
89339971|NCT03864991|Active Comparator|e-messages for log book|This group will receive daily e-messages for maintaining log book in addition to routine care.
89339972|NCT03864991|Active Comparator|e-messages for log book & fit-bit|This group will receive e-device for step count (fit-bit), daily e-messages for maintaining log book for blood sugar, insulin dosages and step count in addition to routine care.
89339973|NCT05625737|Experimental|Fruquintinib plus Sintilimab|Fruquintinib combined with sintilimab. Fruquintinib: 4 mg/d, qd, po, d1-14, q3w; Sintilimab: 200 mg/d, ivgtt, d1, q3w.
89339974|NCT01288417|Experimental|boceprevir + raltegravir|9 days of boceprevir 800mg TID; day 10 two doses of boceprevir 800mg and one dose of raltegravir 400mg
89339975|NCT01288417|Active Comparator|raltegravir alone|single dose of raltegravir 400mg
89339976|NCT03949205|Experimental|Leg Extension Isometric Training|Experimental group will perform leg extension isometric exercise.
89339977|NCT03949205|No Intervention|Control Group|Control group will be advised to maintain their work habits and not to change their routine activities, especially diet and physical activities.
89339978|NCT02529917|Experimental|Hemp powder|Hemp powder supplement
89339979|NCT02529917|Active Comparator|Soy powder|Soy powder supplement
89339980|NCT01285765|Experimental|Early-PET-result-adapted treatment|4 to 6 RCHOP21
89339981|NCT01285765|Active Comparator|standard treatment|6 RCHOP21
89339982|NCT01103453|Experimental|Intervention Group|Study group are persons diagnosed as suffering from Mild Cognitive Impairment will undergo a series of 9 sessions on a computer program of a virtual supermarket to improve their Executive and IADL functions.
89339983|NCT01103531|Experimental|Exercise Group|Participants in this group will be scheduled for 24 exercise training sessions over an 8-week period (three times weekly) and will be supervised by a certified exercise physiologist.
89339984|NCT01103531|Active Comparator|Education Group|Participants in this group will meet with a counselor who will present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
89339985|NCT03864913|Experimental|Randomized SQ vs IM|Subjects randomized to either SQ or IM testosterone injections follow study protocol.
89339986|NCT03864913|Experimental|Non-randomized SQ|Subjects choose to participate in study, but decline to randomize and select SQ injections. Follow same study protocol.
89339987|NCT03864913|Experimental|Non-randomized IM|Subjects choose to participate in study, but decline to randomize and select IM injections. Follow same study protocol.
89339988|NCT01105559||Group 1|Participants previously received 3 doses and a booster dose of the investigational vaccine DTaP IPV Hep B PRP-T.
89339989|NCT01105559||Group 2|Participants previously received 3 doses CombAct-Hib™ + Engerix™ B + OPV and a booster dose of CombAct-Hib™ + Oral poliovirus vaccine (OPV) vaccine.
89339990|NCT01105559||Group 3|Participants previously received 3 doses DTaP IPV Hep B PRP-T; a dose of Engerix™ B at birth, and a booster dose of DTaP IPV Hep B PRP-T vaccine.
89339991|NCT03865147|Experimental|Phase 1 open, pilot phase|A pilot group of 10 patients who will receive Tri-Solfen only (non-randomised) once, prior to debridement
89339992|NCT03865147|Experimental|Phase 2 - Tri-Solfen|A group of 20 patients who will receive EMLA cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by a single application of Tri-Solfen.
89339993|NCT03865147|Active Comparator|Phase 2 - Standard Care|A group of 20 patients who will receive EMLA Cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by standard of care post-operative analgesia.
89339994|NCT03865147|Experimental|Phase 3 - Tri-Solfen|A group of 20 patients who will receive two applications of Tri-Solfen (2mL/10cm2), once prior to debridement and once on completion of the procedure.
89339995|NCT03865147|Active Comparator|Phase 3 - EMLA|A group of 20 patients who will receive EMLA Cream (60-minute application) prior to surgical debridement
89339996|NCT03722823|Active Comparator|Group 1: Healthy|Match-controlled healthy subjects with normal hepatic function
89339997|NCT03722823|Experimental|Group 2: Mild Hepatic Impairment|Subjects with Mild hepatic impairment (Child-Pugh Class A, score of 5 or 6)
89339998|NCT03722823|Experimental|Group 3: Moderate Hepatic Impairment|Subjects with Moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9)
89339999|NCT03722823|Experimental|Group 4: Severe Hepatic Impairment|Subjects with Severe hepatic impairment (Child-Pugh Class C, score of 10 to 14)
89340000|NCT03862651|Experimental|Cangrelor|Cangrelor, 0.75 μg/Kg/min, a cangrelor infusion will be started in addition to SOC when the P2Y12 inhibitor has been discontinued after the need for surgery has been determined. The infusions (cangrelor or matching placebo) will continue throughout the pre-operative period
89340001|NCT03862651|No Intervention|placebo|patients will receive only standard of care, in which the P2Y12 inhibitor is discontinued after the need for surgery has been determined and a placebo infusion is administered
89340002|NCT03799211|Experimental|Motivational Interviewing|
89340003|NCT03799211|Active Comparator|Usual Care|
89340004|NCT03722745|Experimental|Study group 1|Juvenile offenders will attend 4-session Trauma Affect Regulation: Guide for Education & Treatment (TARGET) groups led by one or two juvenile staff members
89340005|NCT03722745|Active Comparator|study group 2|Juvenile offenders will receive treatment-as-usual (TAU).
89340006|NCT03349710|Experimental|Arm A|Cohort 1
89340007|NCT03349710|Experimental|Arm B|Cohort 1
89340008|NCT03349710|Experimental|Arm C|Cohort 2
89340009|NCT03349710|Experimental|Arm D|Cohort 2
89340010|NCT01286935|Experimental|Low Dose (50mg/day)|
89340011|NCT01286935|Experimental|High Dose (100mg/day)|
89340012|NCT01286935|Placebo Comparator|Placebo|
89340013|NCT01288495|Experimental|L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
89340014|NCT01288495|Placebo Comparator|Placebo|Subjects will consume the placebo prior to eating fructose-containing foods.
89340015|NCT03946943|Experimental|anlotinib + Toripalimab|Concurrent anlotinib and Toripalimab therapy, with Blood Draw and Tumor Specimen Collection for correlative studies
89340016|NCT03511053|Experimental|All participants|Epidural Lavage followed by Lumbar Epidural Steroid Injection
89340017|NCT01178515|Sham Comparator|Full fat milk|Full fat milk contain 3% fat
89340018|NCT01178515|Experimental|Partially defatted milk|Partially defatted milk contains 2% of fat
89340019|NCT01178515|Experimental|Defatted milk|Defatted milk contains 1% fat
89340020|NCT01105637|Other|Exercise|
89340021|NCT03730155|Experimental|CCT intervention|CCT intervention. 8 weeks with 2 hours session every week. Homework approx. 25 min. of meditation daily.
89340022|NCT03730155|No Intervention|Control waitlist|No treatment given. Participants only answer questionnaire packages.
89340023|NCT05666635|Experimental|Experimental：LTC004|Monotherapy, dose escalation
89340024|NCT01105715||Rheumatoid Arthritis (RA) Case Subjects|"Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA~Have currently active disease as assessed by Clinical Disease Activity Index (CDAI) score of >10~Have > or = 3 swollen joints"
89340025|NCT01105715||Control Subjects|"Age, sex, and 5-year age categories matched to cases~No historical diagnosis of RA and other primary autoimmune or inflammatory disorders"
88819870|NCT01514786|No Intervention|Control|Same information is presented in the control website as is found in the intervention website, but no interactive component: preferences and risk assessment.
89340026|NCT03711864|Experimental|IM21 CAR-T cells|IM21 CAR-T cells
89340027|NCT03865069|Active Comparator|automated oxygen control with VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) with automated pressure control (Volume Guarantee®).
89340028|NCT03865069|Active Comparator|automated oxygen control without VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) without automated pressure control (Volume Guarantee®).
89340029|NCT04934579|Experimental|R2-MTX|Experimental arm will be treated with R2-MTX regimen(Lenalidomide plus Rituximab and Methotrexate) for 6 cycles as initiate induction.If the patients achieved complete remission（CR）or partial remission（PR）with additional whole-brain radiotherapy（WBRT）, they processed to R2 maintenance(Lenalidomide plus Rituximab) for 4 cycles.
89340030|NCT03377634|Experimental|Intervention|Participants receive the MORPH intervention.
89340031|NCT03377634|No Intervention|Control|The wait list control participants receive usual care and are offered intervention materials on completion of the study.
89340032|NCT01103609|Experimental|1|twice daily on Day 1 to Day 10, with Warfarin on Day 4
89340033|NCT01103609|Placebo Comparator|2|twice daily on Day 1 to Day 10, with Warfarin on Day 4
89340034|NCT01288573|Experimental|Plerixafor 160 μg/kg|Patients will receive subcutaneous (SC) injection of 160 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
89340035|NCT01288573|Experimental|Plerixafor 240 μg/kg|Patients will receive subcutaneous (SC) injection of 240 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
89340036|NCT01288573|Experimental|Plerixafor 320 μg/kg|Patients will receive subcutaneous (SC) injection of 320 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
89340037|NCT03859531||CF patients planned to receive Orkambi|CF patients carrying the F508del mutation on both alleles planned to receive Orkambi therapy
89340038|NCT03864835|Experimental|Moderate intensity aerobic exercise|All subjects will undergo DXA and CRF measurement (relative VO2max) under the supervision of an American College of Sports Medicine (ACSM)-certified fitness professional and study physician at the Penn State PM&R Research Laboratories. Subjects selected for the interventional pilot trial will receive a FitBit Charge2 HR and be instructed on how to use a FitBit Hear Rate monitor, Fitbit application, Fitbit website, and Fitabase (secure data management platform utilized by >400 clinical trials). Participants will record their daily food and beverage intake through the Fitbit app. Individualized feedback will be provided by a registered dietician (RD). Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist.
89340039|NCT03859843|Active Comparator|PRP|
89340040|NCT03859843|Active Comparator|Chemical peeling (Salycilic acid)|
89340041|NCT03859843|Active Comparator|Chemical peeling (Jessenr's solution)|
89340042|NCT01174693|Active Comparator|Clopidogrel|Plavix® 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
89340043|NCT01174693|Experimental|Triflusal|Disgre® 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
89340044|NCT01285921|Experimental|hippocampal surgery|"Vestibular test before and after hippocampal surgery~Principal criterion:~Research for an asymmetry of the vestibular responses (Caloric test, Vestibular Evoked Myogenic potentials: VEMp, Head Impulse Test: HIT, Eye Rotational Test: ERI). Investigator performs a blind vestibular test (single blind)"
89340045|NCT01178593|No Intervention|Standard Medical Therapy (SMT)|standard medical treatment (care as usual) with supportive talks
89340046|NCT01178593|Active Comparator|Gut focused hypnotherapy|weekly sessions of gut focused hypnotherapy in groups (10 sessions within 12 weeks)
89340047|NCT00006011|Experimental|Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)|Patients receive doxorubicin IV over 30 minutes immediately followed by cisplatin IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF) SC or pegfilgrastim on days 2-11.
89340048|NCT00006011|Experimental|Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)|Patients receive doxorubicin and cisplatin as in arm I, paclitaxel IV over 3 hours on day 2, and G-CSF SC or pegfilgrastim on days 3-12. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
89340049|NCT03864679|Experimental|Exercise|Subjects will perform a cycling tests
89340050|NCT01178749||Chronic Hepatitis C Infection|patients Receiving 24-week Interferon-α with Ribavirin Treatments
89340051|NCT01105871|Active Comparator|naloxone|4 mg in 10 ml saline iv bolus
89340052|NCT01105871|Placebo Comparator|saline placebo|10 ml of normal saline iv bolus
89340053|NCT03864757|Experimental|UVFP correction surgery|Short-term implantation of VOIS and evaluation of voice quality and glottal closure.
89340054|NCT03946787|Active Comparator|EMDR Therapy + TAU|"Patients will be submitted to 20 individual sessions of Eye Movement Desensitization and Reprocessing (EMDR) Therapy of 60 minutes each, combined to the Treatment as usual (TAU).~It's an eight-step process aimed at the traumatic events, also used to address current situations that evoke emotional disturbances so they do not trigger more symptomatic reactions. In addition, it is helpful to assist the patient in developing the specific skills and behaviors required for a healthy functional life.~Our group will adapt the EMDR protocol model specific for bipolar patients with a history of trauma, developed by Ahmann et al (2017), who applies EMDR in adults with Bipolar Disorder (BD) and history of trauma."
89340055|NCT03946787|Placebo Comparator|TAU (Treatment as Usual)|"Patients will receive the Treatment as Usual. TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service. Patients are expected to be euthymic (or with subsyndromal symptoms) with the same medication for at least 3 months.~Although the medications used by patients are relevant and taken into account in future analyzes, our group will not interfere with drug treatment. Thus, patients who require any type of drug intervention will be considered losses."
89340056|NCT01174771||PSP patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., PSP
89340057|NCT01174771||CBD patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., CBD
89340058|NCT01174771||Age-matched healthy controls|People that have not been diagnosed with any kind of neurologic movement disorder.
89340059|NCT03377556|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89340060|NCT01285999|Experimental|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System (PROMUS Element)
89340061|NCT01285999|Active Comparator|TAXUS Liberté|TAXUS Liberté Paclitaxel-Eluting Coronary Stent System (TAXUS Liberté)
89340062|NCT01105949|Other|Marketed nasal strip|Marketed nasal strip
89340063|NCT01105949|Experimental|NexGen JB Organic PET/PE|NexGen JB Organic PET/PE, prototype nasal dilator strip
88819871|NCT01514786|Active Comparator|Intervention with Colorectal Website|Intervention website includes an interactive component including preferences and risk assessment.
89340064|NCT01105949|Experimental|NexGen AB 2R11|NexGen AB 2R11
89340065|NCT05625581||Glucocorticosteroids combined with Cyclophosphamide Group|"Glucocorticoid: 0.5-1.0 mg/kg/d prednisone (or other glucocorticoids of equivalent dose) for 1 month (visit V2-V3), then reduced by 5 mg every 2 weeks, and maintained at 5-10 mg/day to visit V8.~Cyclophosphamide: intravenous infusion, once a month, 0.5-1g/m2 each time, 6 times in total, until the end of visit V7."
89340066|NCT05625581||Glucocorticoids combined with tofacitinib Group|"Glucocorticoid: 0.5-1.0 mg/kg/d prednisone (or other glucocorticoids of equivalent dose) for 1 month (visit V2-V3), then reduced by 5 mg every 2 weeks, and maintained at 5-10 mg/day to visit V8.~Tofacitinib: oral, twice a day, 5mg each time, lasting for 6 months, until the end of visit V8."
89340067|NCT03750955|Experimental|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where plaque induced gingivitis results from a cessation of oral hygiene in a sextant using a stent-induced biofilm overgrowth model.
89340068|NCT03750955|Active Comparator|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene (tooth brushing with fluoride toothpaste and flossing twice daily) is maintained.
89340069|NCT03862105|Experimental|Health App with Provider Monitoring/Care|30 patients enrolled by the study team will receive notifications through a mobile health app (Twistle) before and after surgery. Patient Reported Outcome data will be collected through patient responses in this app and timely clinician feedback will be provided to patients to prevent complications and readmission.
89340070|NCT01176175|Experimental|50 mg|Progesterone microspheres injectable suspension 50 mg
89340071|NCT01176175|Experimental|100 mg|Progesterone microspheres injectable suspension 100 mg
89340072|NCT01176175|Experimental|200 mg|Progesterone microspheres injectable suspension 200 mg
89340073|NCT01176175|Experimental|300 mg|Progesterone microspheres injectable suspension 300 mg
89340074|NCT01176253||25 newly diagnosed Type 1 diabetics|25 newly diagnosed Type 1 diabetics within onset of symptoms
89340075|NCT01176253||25 healthy volunteers|25 healthy volunteers (age & sex matched)
89340076|NCT05624177|Active Comparator|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum: Chew 5 minutes|Streptococcus salivarius M18 chewing gum 1 billion cfu chewing the gum for 5 minutes duration.
89340077|NCT05624177|Active Comparator|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum: Chew 10 minutes|Streptococcus salivarius M18 chewing gum 1 billion cfu chewing the gum for 10 minutes duration.
89340078|NCT01176331||vitrectomy|
89340079|NCT05624099|Experimental|drug|"camrelizumab 200mg intravenous drip d1q3w~Paclitaxel: 150mg/m2 d1 q3w~Platinum: Cisplatin, carboplatin, nedaplatin and other platinum drugs~Radiotherapy dose: 5040cGy/28f radiotherapy efficacy evaluation after 2-3 cycles of chemotherapy PR/SD received local radiotherapy."
89340080|NCT01178905|Other|Mother CMV positive|
89340081|NCT03864601|Experimental|14C-JNJ-56136379|Participants will receive a single oral 25 milligram (mg) dose of 14C-JNJ-56136379 on Day 1 under fed conditions.
89340082|NCT03864523|Experimental|XAMNPIO|Pioglitazone 15 mg tablets 2/day during 2 years
89340083|NCT00005879|Placebo Comparator|Placebo|Placebo
89340084|NCT00005879|Experimental|Arzoxifene|LY353381, 20 mg daily
89340085|NCT01178983|Experimental|telebiofeedback|
89340086|NCT01178983|Active Comparator|biofeedback|
89340087|NCT03864367||Device|This group will use the MWeST lift device along with regular physical therapy. The lift device is the Prism Medical FGA-700 Bariatric Floor Lift including a sling to assist in walking.
89340088|NCT03864367||Control|This group will only receive regular physical therapy.
89340089|NCT05624021|Experimental|SFT group|Received Scapular functional training and cervical isometric exercises
89340090|NCT05624021|Active Comparator|Conventional group|Received only isometric cervical exercises and heating
89340091|NCT01174849|Active Comparator|Synflorix|
89340092|NCT01174849|Active Comparator|Prevenar13|
89340093|NCT01174849|Experimental|COMBO|COMBINATION SCHEDULE of comparator vaccine 1 and comparator vaccine 2 Synflorix at 1,2,4 months then Prevenar13 at 6 months.
89340094|NCT03948815|Experimental|Intervention room|An adaptable, person-centered, birthing room that is specially designed.
89340095|NCT03948815|Other|Control room|A regular standard birthing room
89340096|NCT01103687|Experimental|Ad26.ENVA.01 (rAd26)|Participants will receive the Ad26.ENVA.01 (rAd26) vaccine at baseline.
89340097|NCT01103687|Placebo Comparator|Placebo Vaccine|Participants will receive the placebo vaccine at baseline.
89340098|NCT01179061|Experimental|Apelin infusion|6 hour infusion of apelin peptide into circulation
89340099|NCT01179061|Placebo Comparator|Placebo|Infusion of saline into systemic circulation
89340100|NCT05619887|Placebo Comparator|Sea level control|Sea level exercise will be completed after the administration of 1 mL of isotonic saline into the intrathecal (spinal) space between L3-L4.
89340101|NCT05619887|Experimental|Sea level experimental (muscle reflex suppression)|Sea level exercise will be completed after the administration of 0.25 mL of fentanyl into the intrathecal (spinal) space between L3-L4.
89340102|NCT05619887|Placebo Comparator|High altitude control|High altitude exercise will be completed after the administration of 1 mL of isotonic saline into the intrathecal (spinal) space between L3-L4.
89340103|NCT05619887|Experimental|High altitude experimental (muscle reflex suppression)|High altitude exercise will be completed after the administration of 0.25 mL of fentanyl into the intrathecal (spinal) space between L3-L4.
89340104|NCT01174927|Active Comparator|Heroin-dependent patients_1|daily dose of diacetylmorphine (30 mg to 500 mg) in 5 ml
89340105|NCT01174927|Placebo Comparator|Heroin-dependent patients_2|5 ml saline
89340106|NCT05618483|Experimental|Interventional|The participants will receive Xylitol based nasal spray
89340107|NCT05618483|Placebo Comparator|Control|The participants will receive saline based placebo
89340108|NCT02525341|Experimental|Yoga Group|Participants in the yoga group received a total of eight weekly 45 minute yoga classes. A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session. Handouts were provided for participants to practice the yoga program for additional 30 minutes a day, 4 days a week at home.
89340109|NCT02525341|Active Comparator|Aerobic and Strengthening Exercise Group|Participants in the exercise group received a total of eight weekly 45 minute exercise classes. A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants. Handouts were provided for participants to practice the program at home for 30 minutes a day, 3 days a week (on non-consecutive days).
89340110|NCT02525341|Active Comparator|General education|Participants in this group received a one-time OA educational brochures from the Arthritis Foundation including topics focusing on the disease process, diet and exercise and OA management education. Participants were instructed not to begin any new exercise programs during the study period.
89340111|NCT03510663|Experimental|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
89340112|NCT03510663|Experimental|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
89340113|NCT03510663|Active Comparator|Moxifloxacin|400mg tablet will be administrated once a week.
89340114|NCT03510663|Placebo Comparator|Placebo|Placebo will be intravenously administered once a week.
89340115|NCT05616845|Experimental|Enable high qualitative estimation of bilirubin levels in the blood of new-borns|There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns with darker skin and with high melanin content such as Filipino neonates.
89340116|NCT01179139|Active Comparator|Healthy Control|
89340117|NCT01179139|Experimental|CRS|
89340118|NCT03948737|Active Comparator|Alpha-Tocopgerol|"Alpha-Tocopherol supplementation will be given orally for 4 weeks with doses adjusted by age.~5-8 years old: 200 mg daily, 9-13 years old: 400 mg daily and 14-18 years old 600 mg daily."
89340119|NCT03948737|Placebo Comparator|Control|Placebo is the drug with the same shape and color as the alpha-tocopherol supplementation.
89340120|NCT01287247||Cervical Dystonia|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.
89340121|NCT01287247||Blepharospasm|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.
89340122|NCT01101347|Experimental|Aneurysm-Embolization System|
89340123|NCT03722667|Placebo Comparator|Technology-Based Component|A Technology-based interventions comprised of three technolgy components accessible via smartphone to support self-managing hypertension.
89340124|NCT03722667|Experimental|TechSupport|A Technology-based interventions comprised of three technolgy components plus positive psychological training accessible by smartphone to support self-managing hypertension.
89340125|NCT03510273|Other|Thermocoagulation treatment|Acceptability of Liger Medical Thermocoagulator treatment
89340126|NCT01327859|Experimental|Prior Donepezil 5mg|
89340127|NCT01327859|Experimental|Prior Donepezil 10mg|
89340128|NCT01327859|Placebo Comparator|Prior Placebo|
89340129|NCT01179295|Experimental|Arm 1|
89340130|NCT01179295|Experimental|Arm 2|
89340131|NCT01179295|Experimental|Arm 3|
89340132|NCT01179295|Experimental|Arm 4|
89340133|NCT01176409|Experimental|High dose valacyclovir|Valacyclovir 1g po BID
89340134|NCT01176409|Active Comparator|Low dose valacyclovir|Valacyclovir 500mg po BID
89340135|NCT01176409|Placebo Comparator|Placebo|Inert placebo
89340136|NCT01287325|Experimental|DNK333|
89340137|NCT01287325|Placebo Comparator|Placebo|
89340138|NCT03582813|Experimental|Self-directed care|Subjects receive traditional behavioral health and non-traditional services via a self-directed care model in which they develop a person-directed plan and create a budget for the purchase of medically necessary goods and services. Program staff acting as service brokers help them secure needed goods and services from within or outside the public behavioral health provider system. A fiscal intermediary manages financial resources to pay providers and enable the purchase of approved goods..
89340139|NCT03582813|Active Comparator|Services as usual|Subjects receive traditional behavioral health services as usual via the traditional service delivery system and its network of providers.
89340140|NCT01176487|Experimental|A|A clinical trial using 3-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer
89340141|NCT03862183||dyslipidemia in hypertension|
89340142|NCT03862183||hypertension|
89340143|NCT03722433|Experimental|probiotic plus 14-day sequential therapy|D1-D56: probiotics 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
89340144|NCT03722433|Placebo Comparator|placebo plus 14-day sequential therapy|D1-D56: placebo 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
89340145|NCT03861949|No Intervention|Conventional|preoxygenation done with 100% oxygen in supine position
89340146|NCT03861949|Experimental|Positive-pressure|preoxygenation done with 5 cmH2O CPAP (continuous positive airway pressure) in supine position with 100% oxygen
89340147|NCT03861949|Experimental|Head-up|preoxygenation done in 25 degree head-up position with 5 cmH2O CPAP with 100% oxygen
89340148|NCT01286155||with gastroesophageal reflux disease(GERD)|Subjects with gastroesophageal reflux disease (GERD)
89340149|NCT01286155||Non-GERD|Subjects with no history of gastroesophageal reflux disease (GERD)
89340150|NCT01286155||Barrett's esophagus|Subjects with confirmed barrett's esophagus in Olmsted county
89340151|NCT03863821|Experimental|HHHFNC group|Practice 6 MWT with HHHFNC
89340152|NCT03863821|No Intervention|non-HHHFNC group|Practice 6 MWT without HHHFNC
89340153|NCT03480009|Experimental|Dextromethorphan, opted for narcotic prescription|Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)
89340154|NCT03480009|Placebo Comparator|Placebo, opted for narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) and patient opts for narcotics (oxycodone or other standard narcotics)
89340155|NCT03480009|Experimental|Dextromethorphan, declined narcotic prescription|Dextromethorphan hydrobromide and patient declines narcotic
88819872|NCT04088643|Experimental|tACS group|NEXALIN ADI transcranial alternating current stimulator
89340156|NCT03480009|Placebo Comparator|Placebo, declined narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic
89340157|NCT01180855|Placebo Comparator|Placebo|Placebo pills prepared by Takeda Pharmaceutical.
89340158|NCT01180855|Active Comparator|Rozerem|Rozerem 8mg
89340159|NCT01180855|Active Comparator|Rozerem + Multi Component Behavior Therapy|Rozerem 8mg in combination with 4 small group sessions and 2 phone calls of Multi Component Behavior Therapy.
89340160|NCT03721575|Active Comparator|Scarpa's preserving hernio-abdominoplasty|Hernio-abdominoplasty is performed with preservation of Scarpa's fascia.
89340161|NCT03721575|Active Comparator|Classical hernio-abdominoplasty|Hernio-abdominoplasty is performed with removalof Scarpa's fascia.
89340162|NCT03859375||2 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint two of a predefined area of the skin.
89340163|NCT03859375||3 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint three of a predefined area of the skin.
89340164|NCT01310751|Experimental|iloprost nebuliser solusion|50 ng/kg/min
89340165|NCT01310751|Placebo Comparator|distilled water|2ml
89340166|NCT01180933|Experimental|fish oil|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA and 150 eicosapentaenoic acid per day from gestational week 22 until delivery
89340167|NCT01180933|Experimental|folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 400 µg folate (methyltetrahydrofolate)per day from gestational week 22 until delivery
89340168|NCT01180933|Experimental|fish oil + folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA, 150 mg eicosapentaenoic acid and 400 µg MTHF per day from gestational week 22 until delivery
89340169|NCT01180933|Placebo Comparator|placebo|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women from gestational week 22 until delivery
89340170|NCT01310829||Virtual Reality|Board-eligible or board-certified genetic counselors and students evaluate a virtual reality-based intervention using questionnaires and physiological measurements.
89340171|NCT01287481|Experimental|Stress and Emotions|Seeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
89340172|NCT01287481|Active Comparator|Thoughts and Behaviors|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
89340173|NCT01287481|Active Comparator|Brain and Body|Seeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health. It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
89340174|NCT03721419|Experimental|High Flow High Humidity device|High Flow High Humidity device arm subjects will be placed on a High Flow Airvo device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen. This device has its own flow generator built in.
89340175|NCT03721419|Active Comparator|Low Flow High Humidity Device|Low Flow High Humidity device arm patients will be placed on a Low Flow device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen.
89340176|NCT01179373|Active Comparator|TMS, High Frequency|High Frequency TMS with H coil to prefrontal cortex
89340177|NCT01179373|Active Comparator|TMS, Low Frequency|Low Frequency TMS to Prefrontal cortex
89340178|NCT01179373|Placebo Comparator|Sham Stimulation|Sham TMS with H Coil on Prefrontal Cortex
89340179|NCT03639363|Experimental|Intervention Arm|daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
89340180|NCT03639363|Active Comparator|Control Arm|daily bathing with standard soap
89340181|NCT01287559||Subjects with NEC|Infants in which a possible diagnosis of NEC is suspected
89340182|NCT01287559||Control Infants|Age-matched and illness-severity matched to NEC subjects, controls are infants NOT suspected of having NEC.
89340183|NCT03399786|Experimental|evinacumab|
89340184|NCT03399786|Experimental|Placebo|
88819873|NCT04088643|Sham Comparator|sham stimulation group|Sham stimulator provided by NEXALIN company
89340185|NCT03505593|Experimental|EFT placement using ENVUE System|Placement of the ENvizion Medical™ Enteral Feeding Tube (EFT) in the stomach or small intestine of adult patients who require feedings via the oro/ nasoenteric route, using the ENVUE™ System.
89340186|NCT03857971|Other|Coronary OCT imaging of non flow-limiting lesion|Coronary OCT imaging will be performed of fractional flow reserve (FFR) negative lesions to assess plaque morphology.
89340187|NCT03859141|Experimental|Experimental group-phase Ⅰ|Quadrivalent influenza vaccine
89340188|NCT03859141|Experimental|Experimental group-phase Ⅲ|Quadrivalent influenza vaccine
89340189|NCT03859141|Active Comparator|Control group 1-phase Ⅲ|Trivalent influenza vaccine (contains B/Victoria strain)
89340190|NCT03859141|Active Comparator|Control group 2-phase Ⅲ|Trivalent influenza vaccine (contains B/Yamagata strain)
89340191|NCT03504189|Experimental|PregSense™|PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
89340192|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
89340193|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
89340194|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
89340195|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
89340196|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
89340197|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
89340198|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
89340199|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
89340200|NCT03859219|Placebo Comparator|Placebo in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
89340201|NCT03859219|Placebo Comparator|Placebo in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
89340202|NCT03859219|Placebo Comparator|Placebo in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
89340203|NCT03721263|Experimental|ASLAN004 Single Ascending Dose|"Up to 10 dose levels are planned.~ASLAN004 by IV route: 0.1 mg/kg (Cohort 1), 0.3 mg/kg (Cohort 2), 1 mg/kg (Cohort 3), 3 mg/kg (Cohort 4) and 10 mg/kg (Cohort 5), 20 mg/kg (Cohort 6 [optional]).~ASLAN004 SC route: 75 mg (Cohort 7), 150 mg (Cohort 8), 300 mg (Cohort 9), and 600 mg (Cohort 10 [optional])."
89340204|NCT03374358|No Intervention|No intervention arm.|Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).
89340205|NCT03374358|Experimental|Raltegravir arm.|Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).
89340206|NCT01179451||Post streptococcal reactive arthritis (PSRA)|children who were diagnosed with psra at least one year before the study
89340207|NCT05664633|Active Comparator|Sugammadex|Sugammadex dose=4 mg x kg
89340208|NCT05664633|No Intervention|Standard of Care|Standard of care= glycopyrrolate and neostigmine (0.01 mg/kg - 50mg/kg)
89340209|NCT01287637|Experimental|Early reversal group|Early reversal of temporary ileostomy
89340210|NCT01287637|Active Comparator|Control group|Standard reversal of temporary ileostomy
89340211|NCT03711708|Experimental|Zoloft Oral Solution|50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water.
89340212|NCT03711708|Active Comparator|Zoloft Tablets|Zoloft 50 mg tablet.
89340213|NCT01179529|Experimental|Omalizumab|
89340214|NCT03372096|Experimental|All patients|Patients will receive the Prostatic Artery Embolization procedure.
89340215|NCT01179607|Active Comparator|M0002|"Started at 0.3 mg/day and increased every 3 days (to 1, 3 and 6 mg/day)~for hyponatraemic subjects: dose was increased until the evening serum level was between 132 mmol/l and 145 mmol/l;~for normonatraemic subjects the dose was increased until a 500 ml increase in the 24-h urine volume compared with Day-1 was reached.~Once the required response or max dose was achieved, subjects entered a maintenance phase where they remained on the same dose of M0002 or placebo until 15 days."
89340216|NCT01179607|Placebo Comparator|Placebo|
89340217|NCT00004859|Active Comparator|Arm A (Paclitaxel + Carboplatin + RT)|"Induction chemotherapy dosing: Paclitaxel, 225 mg/m² (3 hour infusion) Day 1. Carboplatin, area under the plasma drug concentration versus time curve (AUC) =6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1~Concurrent chemotherapy / radiotherapy dosing: Paclitaxel, 45 mg/m2, administered weekly during radiotherapy over one hour. Carboplatin, AUC=2, 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy~Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV"
89340218|NCT00004859|Experimental|Arm B (Paclitaxel + Carboplatin + RT+ Thalidomide)|"paclitaxel, carboplatin, and radiotherapy are same as those in Arm A.~thalidomide: Induction chemotherapy dosing, oral daily, starting Day 1 for 24 months or until disease progression. Concurrent chemotherapy / radiotherapy dosing, oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg."
89340219|NCT01176643|Active Comparator|standard care plus yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
89340220|NCT01176643|No Intervention|Standard care|
89340221|NCT03710694|Experimental|DAV132 group|Patients randomized to the DAV132 arm will be administered DAV132 concomitantly with fluoroquinolones.
89340222|NCT03710694|No Intervention|No DAV132 group|Patients randomized to the No DAV132 arm will receive only fluoroquinolones, according to local standard of care.
89340223|NCT03861715||Single Dose antagonist Degarelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with a single dose Degarelix.
89340224|NCT03861715||Multidose antagonist Ganirelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with multidose dose Ganirelix.
88811787|NCT03008993|Experimental|Post-Intervention|The HQIS comprises three phases: 1) clinician training - to improve communication-relational skills and to instruct on the project; 2) center support - 4 on site visits by experts of the project team, aimed to introduce the project and boost motivation, instruct staff on how to implement recommendations, help with context analysis and identification of solutions; assess actual implementation in the center; 3) implementation of EBM recommendations.
88811788|NCT03008993|No Intervention|Control|
89340225|NCT03500679|Experimental|Group 1: ExPEC4V (JNJ-63871860)|Participants will receive vaccination of ExPEC4V dose as an intramuscular (IM) injection into deltoid muscle on Days 1 and 181. The ExPEC4V doses contain polysaccharide antigen (4:4:4:8 microgram [mcg]) from the ExPEC4V serotypes O1A, O2, O6A, and O25B.
89340226|NCT03500679|Placebo Comparator|Group 2: Placebo|Participants will receive placebo matching to ExPEC4V as an IM injection on Days 1 and 181.
89340227|NCT03861637|Active Comparator|drug : ESA for p correction of PTA|ESA (Aranesp or mir-CERA) injection 1 mg per kg sc every week for 1 year to correct PTA to level between 12-13g/dl.
89340228|NCT03861637|Active Comparator|ara or cera|ESA (Aranesp) 1mg/ kg (or equivalent doses) of MIR-CERA injection for 1 year to correct PTA to level between 13-15g/dl.
89340229|NCT03348930|Experimental|Tolcapone|Each subject will have a 4 week treatment phase with Tolcapone
89340230|NCT03348930|Placebo Comparator|Placebo|4 week placebo phase before or after Tolcapone phase depending on randomization.
89340231|NCT03857737|Experimental|ESD group|This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.
89340232|NCT03857737|Active Comparator|Surgery group|This group include patients who are going to undergo surgery for early gastric cancer.
89340233|NCT03500211|Experimental|Lidoderm 5% Topical Patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
89340234|NCT03500211|Sham Comparator|Sham Topical Patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
89340235|NCT01181245|Experimental|FG-3019|All subjects are treated with FG-3019
89340236|NCT03709524|Active Comparator|insertion time|1 minute Airtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
89340237|NCT03709524|Active Comparator|intubation time|2 minutesAirtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
89340238|NCT03721185|Active Comparator|LC|Lypolitic cream with hypocaloric diet and physicial activity in 51 patients
89340239|NCT03721185|Placebo Comparator|NLC|Hypocaloric diet and physicial activity alone in 51 patients
89340240|NCT03947021|Experimental|BSPM-only group|Participants will only receive body-surface potential mapping (BSPM) with an extensive electrode set (256 electrodes).
89340241|NCT03947021|Experimental|CT+BSPM group|Participants will receive body-surface potential measurements (BSPM) and a CT scan. These data will allow for non-invasive reconstruction of electrical potentials at the heart surface.
89340242|NCT01106105||control (Body Mass Index < 25)|
89340243|NCT01106105||Obese (Body Mass Index > 35)|
89340244|NCT01176721|Active Comparator|t-VNS verum|Active stimulation of the left auricle by t-VNS
89340245|NCT01176721|Placebo Comparator|Sham|Sham-simulation of the left auricle by the t-VNS device.
89340246|NCT01106183|Active Comparator|Transfer Factor|Transfer factor supplement; 2 capsules per day
89340247|NCT01106183|Placebo Comparator|Sugar pill|
89340248|NCT01289509|Experimental|Experimental 1|Drug: E5501
89340249|NCT01289509|Experimental|Experimental 2|Drug: E5501
89340250|NCT03478683|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
89340251|NCT03478683|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
89340252|NCT01289587|Experimental|Alternative frequency variant|An alternative variant of the DIAfit program (progressive increase of the number of administered PA sessions per week, namely one PA session per week during 4 weeks and then twice a week over a period of 16 weeks)
89340253|NCT01289587|Active Comparator|Standard frequency program|Standard usual program (3 times per week over a period of 12 weeks)
89340254|NCT01176799|Active Comparator|Arm A: Control Arm|"Doxorubicin - 60mg/m2 day 1~Cyclophosphamide~-600mg/m2 day1, every 3 weeks x 4 cycles"
89340255|NCT01176799|Experimental|Arm B: Experimental|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
89340256|NCT03948659||Cirrhotic patients in intensive care unit|
89340257|NCT03478371|Sham Comparator|Marketed Tampon D|Regular absorbency tampon
89340258|NCT03478371|Sham Comparator|Marketed Tampon M|Regular absorbency tampon
89340259|NCT03478371|Sham Comparator|Marketed Tampon T|Regular absorbency tampon
89340260|NCT03478371|Sham Comparator|Marketed Tampon V|Regular absorbency tampon
89340261|NCT03858673||Ligations group|VTH via the Tsuzi method with residual uterine ligament ligation (ligations group)
89340262|NCT03858673||Without ligations group|Traditional VTH without residual uterine ligament ligation (without ligations group)
89340263|NCT01103765|Placebo Comparator|classic strategy|after drug-eluting stent(DES) deployment perform of Intravascular ultrasound analysis without post-dilatation
89340264|NCT01103765|Active Comparator|post-dilatation strategy|After drug-eluting stent (DES) deployment IVUS analysis and systematic post-dilatation with noncompliant balloon 0.25mm larger than stent balloon. After post dilatation new IVUS analysis.
89340265|NCT01101503|Experimental|Intensive multifactorial group|Intensive multifactorial therapy group receive intensive blood glucose, blood pressure and blood lipids control.
89340266|NCT01101503|Experimental|conventional multifactorial therapy group|Conventional multifactorial therapy group receive conventional blood glucose, blood lipids and blood lipids control to the local targets.
89340267|NCT03477903|Experimental|Group A: TAK-954 0.1 mg|TAK-954 0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
89340268|NCT03477903|Experimental|Group B: TAK-954 0.3 mg|TAK-954 0.3 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
89340269|NCT03477903|Experimental|Group C: TAK-954 1.0 mg|TAK-954 1.0 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
89340270|NCT03477903|Active Comparator|Group D: Metoclopramide 10 mg|Metoclopramide 10 mg, injection, intravenously, three times a day along with 100 mL normal saline 60-minute infusion, intravenously, once daily for a minimum of 5 days up to a maximum of 14 days.
89340271|NCT04728425|Active Comparator|IVIG + SCIG|This group of MG patients will start with 2g/kg of IVIG on month 1, 1 g/kg of IVIG 4 and then 8 weeks later, and within 2 weeks switch to SCIG treatment
89340272|NCT04728425|Active Comparator|SCIG alone|This group of MG patients will start with SCIG alone
89340273|NCT01181401|Active Comparator|TPF standard|"TPF version 1 (standard)~Induction chemotherapy:~Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles~Antibody therapy with:~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
89340274|NCT01181401|Experimental|TPF experimental|"TPF version 2 (experimental)~Induction chemotherapy:~Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles~Antibody therapy with:~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
89340275|NCT01181401|Active Comparator|Standard RCT|"Standard RCT:~HART (72 Gy), IMRT or 3D-conformal techniques~with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5"
89340276|NCT03946865|Experimental|Hospitalized hematology/oncology cancer subjects|Hospitalized hematology/oncology cancer will participate in Reiki Therapy
89340277|NCT03858829|Experimental|fear of movement scale|
89340278|NCT03475875|Experimental|TEST/CONTROL/CONTROL|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
89340279|NCT03475875|Experimental|CONTROL/TEST/TEST|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
89340280|NCT02525107|Experimental|SCD patients on Hydroxyurea|Omega-3 capsules [750 mg], 4 capsules a day for 52 weeks. [Each capsule will contain 417.9mg Docosahexaenoic acid [DHA], 50.8 mg Eicosapentaenoic acid [EPA] and 11.9mg Arachidonic acid [AA] and 1000 IU Vitamin E]
89340281|NCT02525107|Experimental|SCD patients not on Hydroxyurea|Dietary Supplement: Placebo [730 mg], 4 capsules a day for 52 weeks.[Each capsule will contain 538.2mg Oleic Acid [OA] and 1000 IU Vitamin E]
89340282|NCT01179763||Retinal layer thickness analysis|Optical coherence tomography will be conducted to analyze retinal layer thickness (safe examination)
89340283|NCT01287715|Experimental|STOP-arm|Discontinuation of etanercept
89340284|NCT01287715|No Intervention|CONTROL-arm|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
89340285|NCT03474081|Experimental|Subjects receiving FF/UMEC/VI + Placebo to match tiotropium|Eligible subjects will receive FF/UMEC/VI at a dose of 100/62.5/25 microgram (mcg) administered once daily in the morning via ELLIPTA along with placebo to match tiotropium administered once daily in the morning via HANDIHALER. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via metered dose inhaler (MDI).
89340286|NCT03474081|Experimental|Subjects receiving Tiotropium + Placebo to match FF/UMEC/VI|Eligible subjects will receive Tiotropium at a dose of 18 mcg administered once daily in the morning via HANDIHALER along with placebo to match FF/UMEC/VI administered once daily in the morning via ELLIPTA. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via MDI.
89340287|NCT01179841|Experimental|Playgroup and Parent Training|"One to two-hour individual therapeutic sessions with parent training in the home or clinic, 1x every week over six months;~parent training/enrichment once a week in our clinic for 20 sessions at 1-2 hours;~a playgroup session for 1-2 hours 2x week for 6 months in our clinic and~Community treatment as usual."
89340288|NCT01179841|Active Comparator|Parent Training|"Parent enrichment sessions once a week for 20 sessions (for 1-2 hours)~Community treatment as usual."
89340289|NCT01177033||Best endovascular treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
89340290|NCT01177033||Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
89340291|NCT03346434|Experimental|Part A (Open label Dupilumab): Age cohorts 1 & 2|"Age cohort 1: ≥2 years old to <6 years old~Age cohort 2: ≥6 months to <2 years old"
89340292|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 1|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
89340293|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 2|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
89340294|NCT03346434|Experimental|Part B (Double-Blind): Placebo|
89340295|NCT01181557||rectal cancer with stoma|rectal cancer submitted to rectal anterior resection with stomia (RARS). Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month after stoma reconversion
89340296|NCT01181557||rectal cancer without stoma|rectal cancer submitted to rectal anterior resection (RAR) Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month later
89340297|NCT01181557||anterior resection of rectum|patients with rectal cancer submitted to RAR and patients with rectal cancer submitted to RARS
89340298|NCT03857425|Experimental|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks
89340299|NCT03857425|Experimental|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
89340300|NCT03857425|Experimental|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
89340301|NCT03857347|Experimental|Brief Psychoeducation Intervention|2 group session psychoeducation intervention feasibility study
89340302|NCT01179997|Active Comparator|Tissue Doppler Imaging (TDI) optimization|Interventricular pacing delay optimized according to Tissue-Doppler echocardiography
89340303|NCT01179997|Active Comparator|Electrocardiographic optimization|Interventricular pacing delay optimized according to QRS width observation in the 12-lead surface electrocardiogram
89340304|NCT01181635|Experimental|Psychotherapy|Short-term pychotherapy and/or psychoeduchative courses.
89340305|NCT01181713||No Antibiotic|No prophylactic antibiotic post intravitreal injection
89340306|NCT01181713||Prophylactic Antibiotic|Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
89340307|NCT03393000|Experimental|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
89340308|NCT03393000|Active Comparator|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
89340309|NCT01181791|Experimental|probiotic group|Lactobacillus reuteri will be given at a dose of 1x108 colony forming units (CFU)/day
89340310|NCT01181791|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
89340311|NCT01177111|Experimental|Sunflower seed Oil|
89340312|NCT01177111|Active Comparator|Mustard seed oil|
89340313|NCT01311804|Experimental|periarticular parecoxib sodium|patients will be given periarticular parecoxib sodium injection
89340314|NCT01311804|Active Comparator|intravenous parecoxib sodium|intravenous parecoxib sodium will be given during total knee arthroplasty
89340315|NCT03370770||patients with EGFR mutation-positive NSCLC|(Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)
89340316|NCT01180075||TDF/FTC/EFV Intensive Sampling-Group A|Patients receiving TDF/FTC/EFV who undergo intensive pharmacokinetic sampling over 24 hours
89340317|NCT01180075||TDF/FTC/ATV/r Intensive Sampling Group A|Patients receiving TDF/FTC/ATV/r who undergo intensive pharmacokinetic sampling over 24 hours
89340318|NCT01180075||TDF/FTC/EFV Sparse Sampling Group B|Patients receiving TDF/FTC/EFV who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
89340319|NCT01180075||TDF/FTC/ATV/r Sparse Sampling Group B|Patients receiving TDF/FTC/ATV/r who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
89340320|NCT01311882|Experimental|MK-4305 40 mg|Day 1 and Day 8- 4 x 10 mg MK-4305 and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305
88814106|NCT04373018|Experimental|Chlorhexidine + Hydrogen peroxide|Procedure/Surgery: Thirty mandibular molars treated with root canal treatment by using a combination of Chlorhexidine + Hydrogen peroxide during biomechanical preparation.
89340321|NCT01311882|Experimental|MK-4305 20 mg|Day 1 and Day 8- 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo
89340322|NCT01311882|Active Comparator|Zopiclone 7.5 mg|Day 1 and Day 8- 1 x 7.5 mg zopiclone and 4 x 10 mg MK-4305 matching placebo; Days 2-7- 4 x 10 mg MK-4305 matching placebo
89340323|NCT01311882|Placebo Comparator|Placebo|Day 1 and Day 8- 4 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305 matching placebo
89340324|NCT01287793|Experimental|high dose tigecycline|
89340325|NCT01287793|Experimental|regular dose tigecycline|
89340326|NCT01287793|Active Comparator|moxifloxacin|
89340327|NCT01287793|Placebo Comparator|placebo|
89340328|NCT03709290||1st group|30 patients were diagnosed with MS according to revised MacDonald's criteria 2017 & collected from Neuropsychiatry department in Assuit university hospital
89340329|NCT03709290||2nd group|30 healthy volunteers subjects matched with age, sex & education level were recruited from outpatient clinic neuropsychiatry department and included only if they had no current or previous history of any neurological illness and their neurological examination was free
89340330|NCT01177345||Terminal Disease|Terminal cervical cancer- not treatable
89340331|NCT01177345||Early Disease|Early cervical cancer = meaning treatable with hysterectomy.
89340332|NCT01177345||Advanced Disease|Advanced cervical cancer- treatable with chemotherapy and/or radiation.
89340333|NCT03391284|Experimental|Oral Acetominophen Arm|1000 mg acetominophen oral
89340334|NCT03391284|Active Comparator|Intravenous|1000 mg acetominophen intravenous
89340335|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 20 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 20 mg/m2. Drug infusions will last approximately 2 hours.
89340336|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 26 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 26 mg/m2. Drug infusions will last approximately 2 hours.
89340337|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 34 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 34 mg/m2 . Drug infusions will last approximately 2 hours.
89340338|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 44 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 44 mg/m2 . Drug infusions will last approximately 2 hours.
89340339|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 57 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 57 mg/m2. Drug infusions will last approximately 2 hours.
89340340|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 74 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 74 mg/m2 . Drug infusions will last approximately 2 hours.
89340341|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 96 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 96 mg/m2 . Drug infusions will last approximately 2 hours.
89340342|NCT03709212||Individual semi-structured interview|"20 participants will undergo individual semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.~Participants will be recruited from three ethnic backgrounds; Black African/ Caribbean, South Asian and White Caucasian."
89340343|NCT03709212||Focus Group 1|10 participants female black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
89340344|NCT03709212||Focus Group 2|10 participants male Black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
89340345|NCT03709212||Focus Group 3|10 participants female South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
89340346|NCT03709212||Focus Group 4|10 participants male black South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
89340347|NCT03709212||Focus Group 5|10 participants female White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
89340348|NCT03709212||Focus Group 6|10 participants male White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
89340349|NCT05666557|Experimental|manual erector spinae myofascial realease|Myofascial release is performed by a therapist. The patient prone and using two pillows, one on the head and the other under the abdomen, flexing the lumbar spine maximally under the abdomen with the erector spinae in extension. The therapist will then perform 3 sets of 15 reps with a 1-minute rest between sets with myofascial loosening using standard massage techniques.
89340350|NCT05666557|Experimental|self-myofascial release technique|Use a roller (roller) to release fascia. The subject stand beside the wall and roll back and forth 15 times as a group, rest for one minute in between, and do a total of 3 groups.
89340351|NCT03473301|Experimental|Allogeneic Umbilical Cord Blood|Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
89340352|NCT03473301|Experimental|Cord Tissue Mesenchymal Stromal Cells|Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
89340353|NCT03473301|Active Comparator|Natural History|Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.
89340354|NCT01180153|Experimental|SOX: advanced BTC or ampullary carcinoma|unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen
89340355|NCT03719625|Experimental|norepinephrin group|The patients of this group will recieve 0.5 micro gr/kg of norepinephin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
89340356|NCT03719625|Experimental|Ephedrin group|The patients of this group will recieve 0,3mg/kg of Ephedrin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
89340357|NCT01289743|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice weekly
89340358|NCT03390426|Experimental|Mepivacaine Block Group|Injection of local anesthetic (mepivacaine) above and beside the femoral artery.
89340359|NCT03390426|Placebo Comparator|Saline Sham Group|Injection of salt water (saline) above and beside the femoral artery.
89340360|NCT03472521|Experimental|Gabapentin|Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
89340361|NCT03472521|Placebo Comparator|Control|Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
89340362|NCT02906020|Experimental|GZ/SAR402671|Part 1: Increasing doses of GZ/SAR402671 were administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) was administered once per day.
89340363|NCT02906020|Placebo Comparator|Placebo|A matching placebo for Parts 1 and 2 was administered once per day.
89340364|NCT01181869||Oxygen therapy|Database of patients on oxygen
89340365|NCT01181869||ventilation|database of patients on ventilatory support
89340366|NCT01181869||Continuous positive airway pressure|Sleep apnoea patients on CPAP
89340367|NCT03861247|Active Comparator|Control group|
89340368|NCT03861247|Experimental|Intervention group|
89340369|NCT01177423|Active Comparator|Quicksleeper intraosseous anesthesia|Pulpal and periapical molar and premolar sedation is managed by Quicksleeper intraosseous anesthesia.
89340370|NCT01177423|Active Comparator|Inferior alveolar nerve block|Pulpal and periapical molar and premolar sedation is managed by inferior alveolar nerve block.
89340371|NCT03861169|Experimental|Viscoeleastic delivery & trabeculotomy|Patients with open angle glaucoma and cataract
89340372|NCT03861013|Experimental|Intervention group|Participation in a multidimensional stress prevention program (GeDStress).
89340373|NCT03861013|No Intervention|Wait-list control group|Participants on the wait-list control group will not receive any treatment between the baseline and last follow-up. After the study has ended, they have the option to participate in the program.
89340374|NCT01180231|Active Comparator|Moxonidine|
89340375|NCT01180231|Active Comparator|Diet|
89340376|NCT01180231|Active Comparator|Moxonidine and diet|Subjects will be asked to take moxonidine and follow dietary plan designed by a qualified nutritionist for 6 months.
89340377|NCT01180231|No Intervention|Control|Subjects will not be asked to take any interventions.
89340378|NCT03474016||Patients with early breast cancer(30)|
89340379|NCT03474016||Patients with advanced breast cancer(30)|
89340380|NCT03474016||Patients with benign breast diseases(20)|
89340381|NCT03474016||Apparently healthy females as a control group(36)|
89340382|NCT01177501|Experimental|Topotecan|
89340383|NCT02983396|Experimental|no transmural ischemia (NTI) and transmural ischemia (TI)|"Case cross-over from no transmural ischemia (NTI) to transmural ischemia at 60 s coronary occlusion during elective coronary angioplasty (TI)~Comparison of diagnostic accuracy of standard 12-lead ECG versus Mini RELF device for detection of transmural ischemia."
89340384|NCT01182025|Active Comparator|Western therapy|
89340385|NCT01182025|Experimental|Xiyanping Injection|
89340386|NCT01182025|Experimental|Xiyanping Injection with western medicine|
89340387|NCT03478150|Experimental|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol and applied in the cavity, where the ethanol evaporates, while the zinc oxide nano-particles infiltrate into the carious floor of the cavity.
89340388|NCT03478150|Experimental|laser diode|Each cavity will be irradiated in contact mode with continuous wave of radiation. The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. The fiber optic will be disinfected for each use by 70% ethyl alcohol and inserted inside the cavity to 1mm with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. This procedure improves the distribution of the laser light inside the cavity and to avoid excessive heat generation in the internal cavity surface. Irradiation time will be 15 seconds and repeated 5 times with 15 second intervals with contact, according to manufacture instructions. During this study the output power will be adjusted at 1.5W.
89340389|NCT01587547||IVF and ICSI patients|Subjects undergoing IVF or ICSI treatment with a maximum of 2 embryos transferred
89340390|NCT03499353|Experimental|TALAZOPARIB|SINGLE ARM, NON-RANDOMIZED
89340391|NCT03473158|Active Comparator|Mechanical|fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle
89340392|NCT03473158|Active Comparator|Chemical|fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle
89340393|NCT01289899|Experimental|Arm A|BR-A-657 120mg or placebo
89340394|NCT01289899|Experimental|Arm B|BR-A-657 360mg or placebo
89340395|NCT03473938||Spatz3 AIGB|Patients with implanted Spatz3 AIGB balloon.
89340396|NCT01287871||Social media intervention|Women between the ages of 18-70 who have not been diagnosed with any type of cancer and are of African descent or Latina
89340397|NCT03860545||non-AKI|patient without acute kidney injury (AKI) during perioperative observation period
89340398|NCT03860545||AKI|patient with diagnosis acute kidney injury (AKI) established during perioperative observation period
89340399|NCT02693938|Experimental|luteal phase clamp|Luteal euglycemic clamp administered during luteal phase of menstrual cycle.
89340400|NCT02693938|Active Comparator|follicular phase clamp|Follicular euglycemic clamp administered during follicular phase of menstrual cycle.
89340401|NCT01289197|No Intervention|No Feedback or services offered.|The Family Check-Up is not offered.
89340402|NCT01289197|Other|Intervention|Family Check Up is offered.
89340403|NCT03711630|Experimental|Meditation|The study cohort will participate in self-guided meditation practice over the course of eight weeks.
89340404|NCT03638934|Experimental|Videos about ACP|Subjects in experimental group get three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish watching the materials, they fill out the questionnaire.
89340405|NCT03638934|Active Comparator|Brochure for Life-Sustaining Treatment|Subjects in the group get 13-page brochure entitled, Understanding the Life-Sustaining Treatment Act. After they finish watching the materials, they fill out the questionnaire.
89340406|NCT00004259|Experimental|Radiation therapy + temozolomide (TMZ)|Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles
89340407|NCT00004259|Active Comparator|RT + BCNU/CCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles
89340408|NCT00004259|Experimental|Pilot Arm #1: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles
89340409|NCT00004259|Experimental|Pilot Arm #2: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles
89340410|NCT02819050|Experimental|Sprinting|Take off NCPAP twice daily for 3hours (day 1), Take off NCPAP twice daily for 6hours (day 2), Take off NCPAP twice daily for 9hours (day 3), Placed back on NCPAP for 24hours (day 4), Switch to nasal cannula at a flow rate of 1.5-2 L/min (day 5)
89340411|NCT02819050|Active Comparator|Non-Sprinting|"If the infant was on NCPAP 6, Infant was weaned down to CPAP 5 for 96 hours. If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC.~If the infant was on NCPAP 5, the infant was continued on CPAP 5 for 96 hours If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC."
89340412|NCT03711552||Quality of recovery|All enrolled patients will be asked to complete the ObsQoR-11 and QoR-15 questionnaires pre-surgery if feasible and at 24 and 48 hours post-surgery.
89340413|NCT01177579|No Intervention|Aim 1; Biomarkers|Blood concentrations of copper coenzymes will be monitored for 1 year
89340414|NCT01177579|Experimental|Copper supplement Arm|4 mg or 8 mg copper will be compared in a randomized controlled study
89340415|NCT01177579|No Intervention|Normal Controls|Normal subjects will be used to generate reference measures.
89340416|NCT03722355|Active Comparator|Arm 1: Conventional RT + Carmustine|Conventional RT: 60.0 Gy/30 fractions/2.0 Gy once daily + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT then every 8 weeks for 6 cycles
89340417|NCT03722355|Experimental|Arm 2: Hyperfractionated RT + Carmustine|Hyperfractionated RT: 72.0 Gy/60 fractions/6 weeks/1.2 Gy BID + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT and then every 8 weeks for 6 cycles
89340418|NCT01287949|Experimental|REPEVAX followed by REVAXIS administration|
89340419|NCT01289977||Phlebotomus group|Those in the Phlebotomus group will have exposure to P. duboscqui sand fly
89340420|NCT01289977||Lutzomyia group|Those placed in this group will receive exposure to L. longipalpis sand fly bites.
89340421|NCT03473080|Other|Internet CBT|Participants and their parents receive 16 weeks of internet-delivered cognitive behavior therapy (CBT) with psychologist support.
89340422|NCT03857815|Experimental|SBRT in combined with anti-PD-1 antibody|HCC Patients will be received stereotactic body radiation therapy (SBRT) to primary lesions or metastatic lesions, such as liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
89340423|NCT03365934|Experimental|ADHESIVE BANDAGE #1|bandage applied to wounded site.
89340424|NCT03365934|Experimental|ADHESIVE BANDAGE #2|bandage applied to wounded site.
89340425|NCT03365934|Experimental|ADHESIVE BANDAGE #3|bandage applied to wounded site
89340426|NCT03365934|Experimental|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
89340427|NCT03365934|Other|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
89340428|NCT03365934|Other|Wounded and No Bandage|This test site will be wounded and no bandage applied, serving as a positive control site.
89340429|NCT02494648|Experimental|Inspiratory muscles strengthening|"The device used is : POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK).~Class I, CE labelled. POWERbreathe fitness Plus uses the technique of training against resistance to increase the strength, the power and the endurance of the respiratory muscles (diaphragm and rib cage)."
89340430|NCT02494648|Placebo Comparator|Control|No intervention
89340431|NCT01180309||lingual frenum alterations|individuals each one with their phonological system complete
89340432|NCT03477994|Active Comparator|dexmedetomidine group|"Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4~+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur."
89340433|NCT03477994|Sham Comparator|clonidine group|In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
89340434|NCT03468855|Experimental|ATI-50002 Topical Solution|ATI-50002 topical solution, high dose active, twice-daily, 24 weeks
88814107|NCT04366154||Patients|
88814108|NCT04366154||Caregivers|
89340435|NCT04668131|Experimental|Artificial tears|Artificial tears
89340436|NCT04668131|Active Comparator|Acupuncture|Acupuncture
89340437|NCT03857581|Experimental|Clozapine Arm|
89340438|NCT03857581|Active Comparator|Olanzapine Arm|
89340439|NCT01103843|Active Comparator|Maintenance Dose Arm|Open label clopidogrel 75 mg daily or prasugrel 10 mg daily
89340440|NCT01103843|Active Comparator|Loading Dose Arm|Clopidogrel 600 mg or Prasugrel 60 mg at time of PCI.
89340441|NCT03738865|Experimental|G-Pen followed by Novo Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Novo Glucagon at the second treatment visit
89340442|NCT03738865|Active Comparator|Novo Glucagon followed by G-Pen|1 mg Novo Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
89340443|NCT02524795|Experimental|Hiomega-3 supplement|"Patients in the study group received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company). Participants were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
88814109|NCT02241122|Experimental|MRI guided prostate biopsy|prostate biopsy after MR-imaging
88814110|NCT02223065|Experimental|Treatment A|Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet
89340444|NCT02524795|No Intervention|Control group|"Patients in the control group did not receive the nutrient nor any kind of placebo. They were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
89340445|NCT03524157|Experimental|PRO-087|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: chondroitin sulfate 0.18%, sodium hyaluronate 0.1% ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
89340446|NCT03524157|Active Comparator|Xyel Ofteno|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days, Active principles: Xanthan gum 0.9 mg, sodium chondroitin sulfate 1.0 ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
89340447|NCT03524157|Active Comparator|Systane ultra|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: Polyethylene glycol 400 0.4%, propyleneglycol 0.3%, Ophthalmic solution, multi-dose dropper bottle, made by Alcon Laboratories, Inc.
89340448|NCT02750215|Experimental|Capmatinib (INC280)|"Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib.~After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles"
89340449|NCT01177657||Gastroenteritis cohort|Children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis
89340450|NCT01177657||Hospital control cohort|Children hospitalized for non gastroenteritis causes
89340451|NCT01177657||Neighbourhood control cohort|Children without any symptoms of gastroenteritis or severe gastroenteritis
89340452|NCT03719469||Green tea group|A total of 100 subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity at the division of rheumatology and clinical immunology at Mansoura University,After starting green tea supplement (4 to 6 cups/day; 60 to 125 mg catechins), patients were evaluated for therapeutic response at baseline and 12, and 24 weeks.
89340453|NCT03719469||control group|fifty healthy normal subjects were included in this study as controls.
89340454|NCT03857503||Coronary Lesion Assessment with iFR|Patients referred for cardiac catheterization for diagnostic and/or treatment purposes will undergo a screening angiogram to assess eligibility. Eligible patients will be those with at least one major epicardial vessel having a lesion of 40-90% diameter stenosis per visual assessment of angiogram.
89340455|NCT03722277|Experimental|Variable load training|"The participants will be training two times per week in 10 weeks. Training will consist of variable load training in knee flexion- and extension.~Training will be based on symptoms in isometric strength at five different angles of flexion- and extension."
89340456|NCT03722277|Active Comparator|Conventional strength training|The participants will be training two times per week in 10 weeks. Training will consist of a training programme consisting of strength training with rubber bands for hip and knee.
89340457|NCT03719391|Experimental|JUUL 5% Virginia Tobacco ENDS|Treatment with JUUL Virginia Tobacco flavored 5.0% ENDS product.
89340458|NCT03719391|Experimental|JUUL 5% Cool Mint ENDS|Treatment with JUUL Cool Mint flavored 5.0% ENDS product.
89340459|NCT03719391|Experimental|JUUL 5% Mango ENDS|Treatment with JUUL Mango flavored 5.0% ENDS product.
89340460|NCT03719391|Experimental|JUUL 5% Creme Brulee ENDS|Treatment with JUUL Creme Brulee flavored 5.0% ENDS product.
89340461|NCT03719391|Active Comparator|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine product.
89340462|NCT03719391|Active Comparator|Nicotine Gum|Treatment with nicorette white ice mint 4mg nicotine polacrilex gum product.
89340463|NCT03719391|Active Comparator|Usual Brand Combustible Cigarette|Treatment with usual brand combustible cigarette.
89340464|NCT03858595|Experimental|Intervention|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. Investigators will train our study participants (high-risk pregnant women) on how to use Salu Health Gauge to measure BP as well as how to charge them. Trained FFWs will visit the households weekly and synchronize the device with a tablet computer to collect the stored data. The FFWs will measure the weight of the participants using a digital weighing scale at enrollment and on a monthly bases thereafter. Investigators will keep monitoring up to termination of pregnancy. in any health issue arises, our health worker will ensure that an appropriate referral is made to a tertiary care facility. This intervention will be in addition to the conventional antenatal and postnatal care."
89340465|NCT03858595|No Intervention|Control group|All those women randomized to the control arm will receive conventional antenatal and postnatal care only. Investigators will collect the outcome data from the households and/or the health centers by follow-up visits or over phone. Investigators will consell participants, women both in the control group, to make at least four antenatal visits. In addition, Investigators will provide counselling about eating healty and keeping physically active during pregnancy. Investigators will provide general nutrition education on taking balanced energy and protein diet.
89340466|NCT03857269|Experimental|Acupoint Massage group|Choose Chinese medicine acupuncture points： Shenting, Baihui, Sishencong, Diwei, Chengling, Fengchi, Fengfu，Zusanli and Sanyinjiao，32 points per acupressure.32 times per acupoint.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
89340467|NCT03857269|Experimental|Aromatherapy group|Make a 5x5cm bag and put a cotton ball in the bag and the bag is clipped to the patient's collar.Dispense 10% lavender essential oil, 2-3 drops a day in cotton balls.Cotton ball replacement daily. Intervention frequency will be monday to saturday per week for 6 months.（n=30）
89340468|NCT03857269|Experimental|Acupoint Massage and Aromatherapy group|At the same time as the acupressure, the essential oil is applied to the collar and begins to sniff.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
89340469|NCT03857269|No Intervention|Blank control group|The group selects elderly people with MCI who do not receive intervention after informed.Participate in routine activities of Nursing homes.
89340470|NCT03437733|Experimental|Intervention|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
89340471|NCT03856957|Experimental|Endocuff colonoscopy|Colonoscopy performed with Endocuff
89340472|NCT03856957|Placebo Comparator|Conventional colonoscopy|Colonoscopy performed without any device
89340473|NCT01180543|Active Comparator|Active Comparator: Oplon Active Patch|
89340474|NCT01180543|Placebo Comparator|Placebo Comparator: Placebo patch|
89340475|NCT03468543|Experimental|Cohort 1|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days
89340476|NCT03468543|Experimental|Cohort 2|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days
89340477|NCT03468543|Experimental|Cohort 3|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days
89340478|NCT03857113||PSMA-radioguided surgery|Tc-99m-PSMA combined with a gamma probe, guidance of the surgical resection of recurrent PC lymph node metastases
89340479|NCT03467763|Active Comparator|Metformin Hydrochloride Extended Release|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo.
89340480|NCT03467763|Placebo Comparator|Placebo|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of placebo, followed by 500 mg placebo, 750 mg, and 1,000 mg placebo with each treatment period separated by a 2-week course of metformin XR in the same increments of dosage.
89340481|NCT02524717|Experimental|JNJ-56021927|Participants with mild and moderate hepatic impairment and with normal hepatic function will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
89340482|NCT00004031|Active Comparator|CHOP/CHOP-R x 3|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 8 cycles
89340483|NCT00004031|Experimental|CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 6 cycles followed by autologous stem cell transplant.
89340484|NCT03855397|Experimental|Microneedles|Application of microneedle patch, 30G hypodermic needle (positive control) and flat patch (negative control) in the lip, buccal, tongue, palatal and gingival mucosa for pain and safety assessment
89340485|NCT01184443|Experimental|Olanzapine|Those who choose to take olanzapine as part of their treatment (standard practice plus medication).
89340486|NCT01184443|No Intervention|Comparison|Those who choose not to take olanzapine as part of their treatment (standard practice).
89340487|NCT01184521||pulse CO-oximeter|
89340488|NCT03858127||Male infants born <32 weeks gestation|
89340489|NCT03857035|Experimental|Piezosurgery group|"One side of the patients will be randomly selected and labeled as experimental group. In experimental group, impacted third molar will be extracted using piezosurgery."
89340490|NCT03857035|Placebo Comparator|Rotary Instruments Group|"The other side will be accepted as control group. In the control group, impacted third molar will be extracted using conventional rotary instruments."
89340491|NCT01106339||A|Patients with somatoform disorders due to DSM-IV
89340492|NCT01180621|Experimental|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
89340493|NCT01106417|Experimental|NeoFuse|"Anterior Cervical Discectomy and Fusion with NeoFuse.~NeoFuseTM is constituted of STRO-3 immunological selected allogeneic MPCs, which are derived from adult bone marrow mononucleated cells that are culture-expanded and subsequently cryopreserved.~The allogeneic MPCs are formulated in concentrations of nucleated cells in a 5 mL volume and are cryopreserved in 7.5% dimethyl sulfoxide (DMSO)/50% Alpha Modified Eagle's Medium (MEM) and 42.5% ProFreeze®. The final formulation consists of 0.15mL (approximately 10 million MPCs) of thawed NeoFuse™ thawed NeoFuseTM combined with the amount of MasterGraftTM Matrix to fill the PEEK cage per ACDF level."
89340494|NCT01106417|Active Comparator|MasterGraft Granules|"Anterior Cervical Discectomy and Fusion with MasterGraft Granules~MASTERGRAFT® GRANULES are a medical-grade, polyporous resorbable ceramic hybrid composed of 15% hydroxyapatite (HA) and 85% beta-tricalcium phosphate (β-TCP). The combination of these natural bone materials provides surgeons with an osteoconductive, porous implant that improves osteointegration by allowing cells to colonize throughout the implant and optimize the bone healing process"
89340495|NCT01182571||heart transplantation|
89340496|NCT01103921|Other|Glucose|
89340497|NCT01103921|Other|Fructose|
89340498|NCT01103921|Other|High-Fructose Corn Syrup|
89340499|NCT01103921|Other|Aspartame|No sugar
89340500|NCT01290133|Experimental|Active Drug|
89340501|NCT01290133|Placebo Comparator|Placebo|
89340502|NCT03467217|Active Comparator|Losartan potassium capsule|Dose will be one 50 mg capsule of losartan per day for one week and then increased to two capsules of 50 mg of losartan per day (100 mg total) for 23 weeks patients with baseline weight ≥ 70 kg to <150 kg.
89340503|NCT03467217|Placebo Comparator|Placebo losartan capsule|Dose will be one 50 mg capsule of placebo losartan per day for one week and then increased to two capsules of 50 mg of placebo losartan per day (100 mg total) for 23 weeks for patients with baseline weight ≥ 70 kg to <150 kg.
89340504|NCT05227729||Patients undergoing abdominal surgery|Inclusion criteria: > 18 years old, American Society of Anesthesiologists physical status 1-3, abdominal surgery of > 1,5 hrs estimated duration, no contraindications to the use of oesophageal ultrasound.
89340505|NCT00003875|Experimental|Treatment (chemo, stem cell rescue, interleukin therapy)|"PREPARATIVE REGIMEN: Patients receive busulfan IV over 2 hours or PO every 6 hours on days -7 to -4 and etoposide IV on day -3.~STEM CELL INFUSION: Patients undergo autologous or syngeneic PBSC rescue on day 0.~POST-TRANSPLANT ALDESLEUKIN THERAPY: Beginning 30-100 days after transplant, patients receive low-dose aldesleukin SC daily for 12 weeks."
89340506|NCT01184677|Placebo Comparator|Group size 4|
89340507|NCT01184677|Experimental|Group size 3|ProSeal LMA size 3 is inserted to the patients of Group size 3.
89340508|NCT01180699|Experimental|influenza vaccine - intradermal|intradermal versus intramuscular
89340509|NCT01180699|Active Comparator|influenza vaccine - intramuscular|
89340510|NCT01327625|Experimental|Azithromycin|Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria
89340511|NCT03720951|Experimental|Group I(Pudendal n.)|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
89340512|NCT03720951|Experimental|Group II(Sacral n.)|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
89340513|NCT01290211|Experimental|Cohort 1|Twice daily regimen
89340514|NCT01290211|Experimental|Cohort 2|Once daily regimen
89340515|NCT03720873|Experimental|EGFR-TKIs and Anlotinib|Experimental:EGFR-TKIs and Anlotinib EGFR-TKIs:erlotinib 150mg QD or gefitinib250mgQD or icotinib 125 mg TID , Anlotinib 12mg po qd d1-14 q21d
89340516|NCT01187875|Placebo Comparator|Control|Dextrin Control
89340517|NCT01187875|Experimental|Hi-maize resistant starch 9g|Hi-maize resistant starch 9g
89340518|NCT01187875|Experimental|Novalose 330 resistant starch 9g|Novalose 330 resistant starch 9g
89340519|NCT01187875|Experimental|4.5g Hi-maize and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330
89340520|NCT01311960|Experimental|bevacizumab eye drop|
89340521|NCT01311960|Experimental|placebo normal saline eye drop|
89340522|NCT03946709|Other|Muscle strength condition|
89340523|NCT03946709|Other|Muscle weakness condition|
89340524|NCT03946709|No Intervention|Control|
89340525|NCT01587859||Cohort|Patients submitted to laparoscopic surgery for Type II-IV hiatus hernia
89340526|NCT03709056|Experimental|HSK3486 0.4/0.2mg/kg ，0.5mg/kg/0.15mg/kg|
89340527|NCT03709056|Active Comparator|Propofol 2.0/1.0mg/kg group|
89340528|NCT03946475|Other|Intervention group|4 schools in 4 subdistrict which are divided into north and south Malang District. North area (Lawang and Singosari) and South area (Kepanjen and Gondanglegi).
89340529|NCT03946475|No Intervention|Control group|4 schools in 4 subdistrict which are divided into north (Sumberpucung), south (Lawang and Singosari), and east (Tumpang) Malang District.
89340530|NCT05663307|Active Comparator|Ginkgo diterpene lactone meglumine injection|Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days ;Aspirin at a dose of 100 mg per day for 90 days.
89340531|NCT05663307|Placebo Comparator|Ginkgo diterpene lactone meglumine injection simulation|Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days ;Aspirin at a dose of 100 mg per day for 90 days.
89340532|NCT01290289|Active Comparator|Epidura, combined spinal epidura & IV|"Gp 1: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.5% lidocaine injected epidurally.~Gp 2: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.0625% bupivacaine injected epidurally.~Gp 3: received 50µg of E fentanyl analgesia, injected intrathecally & a bolus of 10 ml of 0.5% lidocaine, followed by lidocaine E top-ups.~Gp 4: received 50µg of E fentanyl injected intrathecally and a bolus dose of 10 ml of 0.125% bupivacaine, followed by E bupivacaine top-ups.~Gp 5: 50mg of IV pethidine was administered as a loading dose, followed by 0.5 mg/kg."
89340533|NCT05481294|Experimental|Intervention with Transpersonal Supportive Coaching|PLWHA is given coaching using standard operating procedures (SOP) for Transpersonal Supportive Coaching to encourage or guide patients in obtaining support. The necessary tool is a representative room for two people with two chairs.
89340534|NCT05481294|Active Comparator|Intervention with Standard Support|PLWHA is given standard support provided by peer support foundations
89340535|NCT05481294|No Intervention|No Support|PLWHA is not given any kind of support
89340536|NCT01106495|Experimental|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. Patients with subclinical atherosclerosis whose serum LDL high than 160mg/ml receive EECP 1- hour session every working day over a 7 week period. Simvastatin is used to decrease cholesterol level for 7 weeks.
89340537|NCT01106495|Active Comparator|Control|Subjects whose LDL higher than 160 mg/dl with subclinical atherosclerosis. Simvastatin is used to decrease cholesterol level for 7 weeks.
89340538|NCT01184833||Group 1|
89340539|NCT03720639|Active Comparator|Abbott, Inc Confirm Rx™|Every other consenting subject will receive the Abbott Inc. Confirm Rx™ device.
89340540|NCT03720639|Active Comparator|Medtronic, Inc Reveal LINQTM|Every other consenting subject will receive the Medtronic, Inc. Reveal LINQTM.
89340541|NCT01184911|Experimental|SP|Asymptomatic parasitemic pregnant women who receive the standard dose of sulfadoxine-pyrimethamine for prevention of placental malaria
89340542|NCT03716973|Experimental|High density programming|High density programming of spinal cord stimulator for paraesthesia-free therapy.
89340543|NCT01185067|Active Comparator|grape seed extract capsule|Grape seed extract (MegaNatural BP, Polyphenolics, Inc.) 300 milligram capsules twice daily for six weeks
89340544|NCT01185067|Placebo Comparator|maltodextrin capsule|Maltodextrin capsules (matched for appearance and taste to grape seed extract capsules) twice daily for six weeks
89340545|NCT03364686|Experimental|Biotin-Labeled Red Blood Cells Infusion|Each participant will receive 2 transfusions of biotin labeled red blood cells.
89340546|NCT05663151|Experimental|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|15 participants who meet study inclusion/exclusion criteria will be individually administered a full course of PE during 10, 60 minute-sessions, with independent multimodal assessment batteries administered at pre-treatment, mid-treatment (post session 5), post-treatment, and a 1-month follow-up.
89340547|NCT03853057|Experimental|non-invasive ventilation|Non-invasive positive pressure at different body positions: sitting - supine - prone - right lateral and left lateral.
89340548|NCT03719235|Other|column|ultra-low dose CBCT versus digital panoramic radsiography
89340549|NCT03856801|Experimental|Whole-body vibration in normoxia condition|Training session in normoxia condition
89340550|NCT03856801|Experimental|Whole-body vibration in hypoxia condition|Training session in hypoxia condition
89340551|NCT03437577|Active Comparator|immediate-release tacrolimus|This is standard of care
89340552|NCT03437577|Experimental|extended release tacrolimus|replace standard of care
89340553|NCT03853135||Behçet group|Forty two patients diagnosed to have Behçet disease fulfilling the International Study Group Criteria for Behçet disease in whom measurement of serum endocan levels will be performed.
89340554|NCT03853135||control group|including 42 age and sex matching healthy volunteers as control group in whom measurement of serum endocan levels will be performed.
89340555|NCT03336528|Experimental|Degludec inpatient|Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting aspart insulin before meals.
89340556|NCT03336528|Active Comparator|Glargine U100 inpatient|Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as basal bolus regimen with glargine once daily plus rapid-acting aspart insulin before meals.
89340557|NCT01291693|Experimental|Personal counseling|
89340558|NCT01291693|Experimental|Computer generated feedback letters|
89340559|NCT01291693|No Intervention|Control group|Treatment as usual
89340560|NCT01182649|Experimental|EES Group|Patients who received an everolimus eluting stent
89340561|NCT01182649|Active Comparator|SES Gruop|Patients who received a sirolimus eluting stent
89340562|NCT03364608|Experimental|• AS MDI 90 µg|(2 actuations of 45 µg/actuation)
89340563|NCT03364608|Experimental|• AS MDI 180 µg|(2 actuations of 90 µg/actuation)
89340564|NCT03364608|Placebo Comparator|• Placebo MDI|(2 actuations)
89340565|NCT03364608|Active Comparator|• Proventil 90 µg|(1 actuation of 90 µg/actuation)
89340566|NCT03364608|Active Comparator|• Proventil 180 µg|(2 actuations of 90 µg/actuation)
89340567|NCT03719157|Active Comparator|Unilateral ESP Block|Before general anaesthesia, Ultrasound guided unilateral ESP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
89340568|NCT03719157|Active Comparator|Unilateral OSTAP block|Under general anaesthesia, Ultrasound guided unilateral OSTAP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
89340569|NCT03719157|Active Comparator|Injection of Local Anesthetic to Trocar Insertion|After the laparoscopic surgery was completed, the trocar incision sites were closed. Following the infiltration rules, local anesthetic (15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine) was applied to the trocar sites of skin, fascia, muscle, and preperitoneal area by the surgical team after the operation. A total of 20 mL of local anesthetic was used, with 6 mL for trocar sites of 10 mm, and 4 mL for trocar sites of 5 mm .Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
88811789|NCT01383005||Kaletra (LPV/r) QD as First Kaletra Treatment|HIV-infected participants treated with lopinavir/ritonavir once daily (LPV/r QD) from ≥3 months to <2 years who had not been treated with any of the following: LPV/r twice daily (BID), a protease inhibitor, or a ritonavir-boosted protease inhibitor.
88814111|NCT02223065|Experimental|Treatment B|Single oral dose of FDC (fixed-dose combination) tablet
89340570|NCT03719157|Sham Comparator|multimodal analgesia|Perioperative and postoperative routine analgesic protocol will be performed with no additional regional anesthesia method.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
89340571|NCT01185145|Experimental|Mammosite|Accelerated Partial Breast Irradiation using Mammosite RTS
89340572|NCT01185145|Experimental|IMRT|Accelerated partial breast irradiation using IMRT planning technique of external beam radiotherapy
89340573|NCT01185223|Other|Valganciclovir|
89340574|NCT01185223|Active Comparator|Ganciclovir|
89340575|NCT03852979|Experimental|neo-adjuvant chemotherapy|The patients are given weekly paclitaxel 80 mg/m2 + carboplatin AUC=2 (or AUC=6 per three weeks) during 12 weeks/4 courses followed by conization if tumor size is reduced to <2 cm
89340576|NCT03852745|Other|Cognitive Behavioral Therapy|Online cognitive behavioral therapy intervention for 2 hours a week for 12 weeks.
89340577|NCT01188031|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
89340578|NCT01188031|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
89340579|NCT04926103|Experimental|Open label FMT therapy|FMT from a related or unrelated healthy donor screened for known communicable disease
89340580|NCT01290991|Other|Bone Graft|Single Arm.. Augment Bone Graft for Osteochondral Defects
89340581|NCT03856489||Patients|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 10 am.
89340582|NCT03856489||Nurses|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 7:30 am.
89340583|NCT01188265|Experimental|Valproate & dextromethorphan 30 mg|Valproate and dextromethorphan 30 mg per day
89340584|NCT01188265|Experimental|VPA & dextromethorphan 60 mg|VPA & dextromethorphan 60 mg per day
89340585|NCT01188265|Active Comparator|VPA & Placebo|VPA & placebo
89340586|NCT01182961|Experimental|Treadmill +virtual reality training|
89340587|NCT01182961|Active Comparator|Treadmill alone|
89340588|NCT01182961|Active Comparator|standard of care exercise group|
89340589|NCT03856333|Other|traditional treatment|30 minutes of conventional TENS, 20 minutes of hotpack, 8 minutes of therapeutic ultrasound and isotonic, isometric, stretching and relaxation exercises 2 weeks, 5 days in a week.
89340590|NCT01183039|Active Comparator|Ventilatory threshold|Training at the ventilatory threshold
89340591|NCT01183039|Active Comparator|Metabolic threshold|Training at the metabolic threshold
89340592|NCT01183117|Experimental|SM-01|
89340593|NCT01183117|Active Comparator|PTA|
89340594|NCT01291069|Experimental|Tadalafil Citrate|The study subjects will be given Tadalfil citrate, encapsulated, 0.8-1 mg/kg/day in 1 dose orally. Max dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
89340595|NCT01291069|Placebo Comparator|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a sugar pill. All patients will receive either study drug or placebo for a total of 20 days.
89340596|NCT00003869|Experimental|Arm I (CAI)|Patients receive oral carboxyamidotriazole daily.
89340597|NCT00003869|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo daily
89340598|NCT03855241|Active Comparator|Informational Sheet|Persons picking up an opioid prescription will receive an informational sheet that describes how to properly dispose of leftover opioid medications
89340599|NCT03855241|Active Comparator|Drug Disposal Kit|Persons picking up an opioid prescription will receive a drug disposal kit (DisposeRx Drug Disposal kit) and instructions on how to use it
89340600|NCT03855241|No Intervention|No intervention|Persons picking up an opioid prescription will receive no additional information or materials on disposal.
89340601|NCT01185379|Active Comparator|Efalex Active 50+|
89340602|NCT01185379|Active Comparator|DHA-rich fish oil|
89340603|NCT01185379|Placebo Comparator|Placebo|
89340604|NCT01327391|Active Comparator|On line Hemodiafiltration|Hemodialysis patients treated with on line hemodiafiltration technic
89340605|NCT01327391|Other|hemodialysis|Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers
89340606|NCT01588639||Group 1|
89340607|NCT01291771|Other|comparator|One group of patients with no myocardial ischemia on non invasive testing will be followed up for 2 years
89340608|NCT01291771|Experimental|coronary angiography group|One group of patients with myocardial ischemia on non invasive testing will undergo coronary angiography and measure of FFR + CFR to detect myocardial microvascular disease
89340609|NCT02524639|Experimental|Sirolimus|All enrolled subjects will receive Sirolimus 1 mg/m2/day twice a day for 6 weeks.
89340610|NCT03946319|Experimental|Personalized, Transdiagnostic Assessments|One or more times per day, participants in the Experimental Arm will be presented with a variable-length assessment based on the personalization algorithm. The assessment will include a dynamic number of questions based on personalized relevancy, engagement level, and assessment completion metrics. Questions are scored immediately upon submission, regardless of how many questions are answered. As questions are scored, the personalization algorithm takes the previous responses and response times into consideration when determining what and when to ask additional questions.
89340611|NCT03946319|Active Comparator|Monotopic Assessments|Once daily, participants in the Control Arm will be presented with the standard of care mental health surveillance assessments identified as relevant upon intake. The assessments will be scored in totality or not at all and have a fixed, predefined number of questions. No personalization of assessment will take place.
89340612|NCT01185457||Left interscalene block|Left shoulder surgery under left interscalene block and HRV
89340613|NCT01185457||Right interscalene block|Right shoulder surgery under right interscalene block and HRV
89340614|NCT03344640|Experimental|secukinumab|AIN457 300 mg subcutaneously (s.c.) for 12 weeks
89340615|NCT03344640|Placebo Comparator|Placebo|Placebo subcutaneously for 12 weeks
89340616|NCT01104233||The soft spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with soft spreading (using LAP Protector).
89340617|NCT01104233||The rigid spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with rigid spreading.
89340618|NCT01183273|Active Comparator|Micro-laparoscopic bypass|
89340619|NCT01183273|Active Comparator|Laparoscopic gastric bypass|
89340620|NCT01291849|Experimental|remifentanil for intranasal surgery|
89340621|NCT03950843|Experimental|Experimental Group|"Patients assigned to this group are treated with 1 capsule of CKD-825 and 2 placebo capsules(the placebo of CKD-825)~The necessity of a dose titration is adjudicated every 2 weeks.~After unblinding at the end of Administration Period, only patients in experimental group are treated with 1 capsule of CKD-825 for additional 4 weeks of Extension Period."
89340622|NCT03950843|Placebo Comparator|Placebo Group|"Patients assigned to this group are treated with 3 placebo capsules (the placebo of CKD-825)~The necessity of a dose titration is adjudicated every 2 weeks"
89340623|NCT01183351|Experimental|Psychosocial intervention|This is a single-group pilot-study
89340624|NCT03344562|Experimental|CES Active|Active cranial electrical stimulation device
89340625|NCT03344562|Sham Comparator|CES Sham|Inactive device identical to the active device.
89340626|NCT01185535|Active Comparator|2 times topical anesthesia for glottis|
89340627|NCT01185535|Active Comparator|3 times topical anesthesia for glottis|
89340628|NCT01185535|Active Comparator|4 times topical anesthesia for glottis|
89340629|NCT00003659|Experimental|intermediate or high risk chronic lymphocytic leukemia|This is a single-arm open-label pilot study designed to assess the antileukemic activity of a regimen containing sequential administration of fludarabine, high-dose cyclophosphamide, and rituximab.
89340630|NCT01185613|Experimental|Therapy™ Cool Flex Ablation Catheter|
89340631|NCT03852589|Active Comparator|C-MAC Videolaryngoscope|C-MAC Videolaryngoscope: An intubating device that is used for endotracheal intubation. Proseal laryngeal mask airway will be inserted with C-MAC Videolaryngoscope
89340632|NCT03852589|Active Comparator|Blind|Proseal laryngeal mask airway will be inserted with digital finger
89340633|NCT01101581|Experimental|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab and 90Y-Epratuzumab Tetraxetan target different b-cells. Veltuzumab will be administered in all 4 weekly study drug treatments. 90Y-Epratuzumab Tetraxetan will be administered only on days 8 & 15. The dose of veltuzumab remains the same for all patients.
89340634|NCT01101581|Experimental|90Y-epratuzumab tetraxetan|90Y-epratuzumab tetraxetan will be administered 6 mCi/m2 on days 8 and 15.
89340635|NCT01183507|Active Comparator|NIA intervention|
89340636|NCT01183507|Experimental|TSE intervention|
89340637|NCT03856021|Active Comparator|Microfracture|
89340638|NCT03856021|Active Comparator|Microfracture with Bone Marrow Aspirate Concentrate|
89340639|NCT03948425|Experimental|Stroke|Clinical suspicion of hyperacute stroke (6 hours after onset of symptoms):Intervention 'spectral CT'
89340640|NCT01183585|Experimental|1|
89340641|NCT03494985|Experimental|OralBalance moisturizing gel|All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits.
89340642|NCT03494985|Experimental|Oral rinse|All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
89340643|NCT03494985|Experimental|Moisturizing mouth spray|All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits.
89340644|NCT03494985|Sham Comparator|Water only use|All the participants in this arm used water as instructed under the supervision of trained site staff on their visits.
89340645|NCT01185769|Experimental|High fat|500 mg of tocotrienol will be administered at single dose after consumption of high fat diet
89340646|NCT01185769|Experimental|Low fat|500 mg of tocotrienol will be administered at single dose after consumption of low fat diet
89340647|NCT03852199||Case Group|Our study was performed with 30 healthy individuals at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. The FS of the knee joint was measured with a Pressure Biofeedback Device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN), a device similar to a sphygmomanometer. To correlate the outcomes of biofeedback device, simultaneously, a surface electromyography (EMG) data of M. Quadriceps femoris muscle activation levels from the individuals were recorded.
89340648|NCT01106729|Other|Cyanidin 3 glucoside|
89340649|NCT01185847|Experimental|A non-squamous|
89340650|NCT01185847|Experimental|A squamous|
89340651|NCT01185847|Active Comparator|B non-squamous|
89340652|NCT01185847|Active Comparator|B squamous|
89340653|NCT01327937|Active Comparator|Apligraf Group|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
89340654|NCT01327937|Placebo Comparator|Standard of Care Dressing Group|Standard of care dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
89340655|NCT03720483|Experimental|N-acetyl cysteine then placebo|This arm will receive NAC followed by placebo
89340656|NCT03720483|Experimental|Placebo then N-acetyl cysteine|This arm will receive placebo followed by NAC
89340657|NCT01183663|Experimental|Lenalidomide + Bevacizumab|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Bevacizumab starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
89340658|NCT01183663|Experimental|Lenalidomide + Sorafenib|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Sorafenib starting dose: 200 mg by mouth daily for 28 a day cycle.
89340659|NCT01183663|Experimental|Lenalidomide + Temsirolimus|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Temsirolimus starting dose: 15 mg by vein every week for a 28 day cycle.
89340660|NCT01183663|Experimental|Lenalidomide + Oxaliplatin + Leucovorin + 5-fluorouracil|Lenalidomide starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle. Oxaliplatin starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle. Leucovorin 400 mg/m2 by vein on day 1 of a 21 day cycle. 5-fluorouracil 400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
89340661|NCT01291927|Experimental|Pancreas-sparing duodenectomy|
89340662|NCT01291927|Active Comparator|Pancreaticoduodenectomy|
89340663|NCT00003509|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89340664|NCT05655117|Experimental|AI-based screening for early detection of diabetic retinopathy and macular Oedema|The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
89340665|NCT05655117|No Intervention|Routine screening for diabetic retinopathy and macular oedema|The Routine screening for diabetic retinopathy and macular oedema in diabetics during a routine visit to an eye care clinic at the primary care centre.
89340666|NCT03344172|Experimental|PGHA|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine and Avelumab
89340667|NCT03344172|Experimental|PGH|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
89340668|NCT03852355|Active Comparator|Radiofrequency|bilateral 3rd occipital nerve RF under fluoroscopic guidance
89340669|NCT03852355|Active Comparator|Systemic steroid|received systemic steroids oral prednisolone tablet, 10 mg/day.
89340670|NCT01106885|No Intervention|Enhanced Usual Care|"Adult patients with diabetes and depression.~Report screening results~Notify PCP of screening results (optional per patient)~PCP referrals~Educational materials regarding diabetes, physical activity, and depression"
89340671|NCT01106885|Experimental|Staged Care Management|Adult patients with diabetes and depression
89340672|NCT01188733|Experimental|Sandostatin LAR 10mg|Sandostatin LAR ( long-acting octreotide) administered every 28 days in a dose of 10mg
89340673|NCT01188733|Experimental|Sandostatin LAR 30mg|Comparison of drug doses
89340674|NCT01188733|Placebo Comparator|Saline|Saline control
89340675|NCT01101659|Experimental|001|JNJ-40411813 500 mg as 20 mL of oral suspension single dose
89340676|NCT01101659|Placebo Comparator|002|Placebo 20 mL of oral suspension single dose
89340677|NCT01101659|Other|003|ketamine Ketanest S. vials of 20 ml with 5 mg/ml diluted with saline to 0.02 mg Ketamine per mL and per kg bodyweight of the volunteer
89340678|NCT01101659|Other|004|normal saline infusion 0.5 mL /min over 90 minutes
89340679|NCT03708978||mammography group|women who receives mammography because of suspected breast lesion(s)
89340680|NCT03855865|Experimental|Rapastinel|Rapastinel (450 mg prefilled syringe, weekly intravenous IV administration).
89340681|NCT03855865|Active Comparator|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
89340682|NCT03855865|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
89340683|NCT01106963||Tibial shaft fractures|Patients had tibial shaft fractures in the last 3 years. All were treated with intramedullary (IM) reamed nails with 2 or 3 interlocking screws.
89340684|NCT05195892|Experimental|Sequence 1|Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 and a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 3.
89340685|NCT05195892|Experimental|Sequence 2|Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 3.
89340686|NCT05195892|Experimental|Sequence 3|Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 3.
89340687|NCT05195892|Experimental|Sequence 4|Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A).
89340688|NCT05195892|Experimental|Sequence 5|Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B).
89340689|NCT05195892|Experimental|Sequence 6|Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C).
89340690|NCT01290367|Experimental|High Dose MPCs|Injection of High Dose MPCs with Hyaluronic Acid
89340691|NCT01290367|Experimental|Low Dose MPCs|Injection of Low Dose MPCs with Hyaluronic Acid
89340692|NCT01290367|Sham Comparator|Saline injection|Injection of saline solution.
89340693|NCT01290367|Placebo Comparator|Hyaluronic acid injection|Injection of hyaluronic acid solution
89340694|NCT01107041|Experimental|Mobilyze!|
89340695|NCT03639207||1|Patients treated with ledipasvir/sofosbuvir in the Kaiser Permanente Northern California
89340696|NCT03946085|Experimental|Lumega-Z group|Participants assigned the study supplement Lumega-Z.
89340697|NCT03946085|Active Comparator|AREDS2 group|Participants assigned the AREDS2 supplement
89340698|NCT03946085|No Intervention|Control|Participants are determined ocular normal after clinical examination and do not have retinal drusen.
89340699|NCT03639129|Experimental|Contrast-enhanced mammography (CME)|-Patients who meet eligibility criteria and consent to participate in this study will complete a CEM examination prior to or on the day that biopsy is scheduled. CEM must occur no later than 60 days after the diagnostic mammogram. The standard of care biopsy must occur no later than 30 days after CEM.
88811790|NCT01383005||Kaletra (LPV/r) QD from Kaletra BID|HIV-infected participants treated with LPV/r from ≥3 months to <2 years who had initiated on LPV/r BID and at any time within this period (but at least 3 months before inclusion in the study) had changed dosing from BID to QD.
89340700|NCT01183819|Experimental|Space Fortress and Exercise|Participants engage in aerobic exercise 4 times week and Space Fortress sessions 3 times a week for a total of 12 weeks.
89340701|NCT01183819|Active Comparator|Control Games and Exercise|Participants engage in aerobic exercise 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
89340702|NCT01183819|Active Comparator|Control Games and Stretching|Participants engage in stretching/toning exercises 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
89340703|NCT01107119|Experimental|Integrated care pathway|"program for~communication and information flow aimed at collaboration between hospitals, general practitioners and home care services~systematic patient follow-up in home care services by using checklists"
89340704|NCT01107119|Active Comparator|usual care|usual care
88811791|NCT05236634|Active Comparator|Group A|Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks.
89340705|NCT01291147|Active Comparator|Levobupivicaine|
89340706|NCT01291147|Placebo Comparator|0.9% Saline|
89340707|NCT05413577|Experimental|Experimental Group|The experimental group was invited to listen to a 15-minute mindfulness instructional recording delivered daily through an instant messaging application and to practice accordingly for 14 consecutive days at their own choice of time and place.
89340708|NCT05413577|No Intervention|Waitlist control group|The waitlist control group was only be required to complete the demographic information, pre, post experiment and follow-up questionnaires before they receive the mindfulness training intervention.
89340709|NCT01291303|Experimental|1- optimized ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
89340710|NCT01291303|Experimental|2-standard setting of ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
89340711|NCT03465891|Experimental|atezolizumab|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
89340712|NCT03465891|Experimental|atezolizumab plus low-dose, local radiotherapy|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year). 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
89340713|NCT03948269|Experimental|Internet- and mobile-based group treatment|the therapy consists of 10 modules (15 hours in total) in groups of 8 participants each over a period of 10 weeks and one follow-up meeting (2 hours) 12 weeks after the 10th module (week 22). Each module is adapted from the previous literature on CBT rationale and will be conducted online on WeChat, a mobile social networking software with 1 billion users in 2018. First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging.
89340714|NCT03948269|Active Comparator|Face-to-face group treatment|10 modules will be conducted every weekend in the psychological counseling room of The Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University.
89340715|NCT03363906|Experimental|Dulaglutide (Reference)|Dulaglutide 4.5 mg administered subcutaneously (SC) in 3 prefilled syringes (PFS) in one of two study periods
89340716|NCT03363906|Experimental|Dulaglutide (Test)|Dulaglutide 4.5 mg administered SC in 1 single dose pen (SDP) in one of two study periods
89340717|NCT03852121|Experimental|Intervention group|Participants will receive bibliotherapy without withdrawing from the usual care. They will be asked to read the designated manual (consists of eight chapters) within a recommended period of time (over 8 weeks). Weekly telephone coaching will also be provided to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves. An orientation will be organized before the first session. Two booster sessions will be organized during the study.
89340718|NCT03852121|No Intervention|Control group|The participants in the control group will only receive usual care provided by the community health professionals.
89340719|NCT03948191|Active Comparator|Methylprednisolone(ivMP)|Methylprednisolone(ivMP) 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
89340720|NCT03948191|Experimental|99Tc-MDP|99Tc-MDP 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
89340721|NCT03855319|Experimental|SMR neurofeedback training to MCI|"A sensorimotor/theta neurofeedback training consisted of 20 individuals sessions, twice a week during 11 weeks maximum. For each subject, NF was planned and conducted by a neuropsychologist experienced in neurophysiology an neurofeedback. Each session lasted 1h10 minutes and was conducted as follows:~Preparation and installation of the electrodes, verification of the impedance, adjustement of the calibration.~NF training (tasks and video described below)(45minutes)~Feedback and debriefing about the session (15 minutes)"
89340722|NCT05353127||Patiënts who underwent a CPET prior to elective colorectal surgery investigate fitness level.|Patients considered for colorectal cancer surgery who were ≥18 years of age, had a score ≤7 metabolic equivalents of task on the veterans-specific activity questionnaire.
89340723|NCT01292083|Experimental|Treatment|See Detailed Description
89340724|NCT01104467|Experimental|Desmoteplase 70 µg/kg|
89340725|NCT01104467|Experimental|Desmoteplase 90 µg/kg|
89340726|NCT01104467|Placebo Comparator|Placebo|
89340727|NCT01184131|Experimental|Mentor Training|The group that is randomized into the intervention group to attend Mentor Training Sessions.
89340728|NCT01184131|No Intervention|No Mentor Training|
89340729|NCT01292161|Other|Silymarin|Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
89340730|NCT03947879|Experimental|L-glutamine|Treatment with L-glutamine for 3 months.
89340731|NCT03947879|Experimental|No L-glutamine|No L-glutamine for 3 months.
89340732|NCT03854851|Experimental|NALDEBAIN|In group NALDEBAIN, subjects will receive single dose of Naldebain (150 mg/2 ml) by gluteus maximus injection between 12 and 24 hours prior to surgery.
89340733|NCT03854851|Active Comparator|MORPHINE|In group MORPHINE, subjects will receive morphine as needed after surgery.
89340734|NCT01101737|No Intervention|Usual care|Patients not invited to the nurse-led clinic will continue with usual GP care
89340735|NCT01101737|Experimental|Nurse-led blood pressure clinic|Patients randomly allocated to the intervention will be invited to a specialist nurse-led blood pressure clinic.
89340736|NCT01185925|Placebo Comparator|Placebo|Control Group
89340737|NCT01185925|Active Comparator|sildenafil, pde5 inhibitor|treatment group; sildenafil 50 mg three times a day for 1 year
89340738|NCT03947801|Experimental|Greek Yogurt condition|3x 160g of 0% Plain Greek yogurt (~115 kcals, 17 g protein, ~11.5 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
89340739|NCT03947801|Placebo Comparator|Isoenergetic condition - Carbohydrate|3x 30g of isoenergetic CHO supplement (~115 kcal, 0.04 g protein, ~28.6 g carbs, 0 fat) consumed immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
89340740|NCT03947645|Experimental|Ipsilesional stimulation|Ipsilesional stimulation
89340741|NCT03947645|Experimental|Contralesional stimulation|Contralesional stimulation
89340742|NCT01107275|Experimental|2 primary ID doses|two doses of rabies vaccines given intradermally on days 0 and 28
89340743|NCT01107275|Experimental|3 primary ID doses|three doses of rabies vaccines given intradermally on days 0, 7, and 28
89340744|NCT03855553|Experimental|FBT|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
89340745|NCT03855553|Experimental|CBT-E|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
89340746|NCT03945851|Experimental|VNS + Rehabilitation|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The experimental arm for that study includes subjects whose stroke treatment via Vagal Nerve Stimulation (VNS) delivered during rehabilitation.
89340747|NCT03945851|Active Comparator|Control VNS|This study is only including subjects from the VNS-REHAB study (NCT03131960) who choose to participate in this fMRI sub-study. The active control arm for that study included subject whose stroke treatment is rehabilitation (standard-of-care) with only a minimal amount of VNS at the start of each rehabilitation session.
89340748|NCT03851809|Experimental|neurologic intensive care in acute brain injury|With the guidance of Taiwan Neurosurgical Society and Taiwan Neurological Society, patients in the control group were given the consistent treatment. (http://www.neurosurgery.org.tw/nsr/tbi/main.htm and http://www.stroke.org.tw/guideline/guideline_1.asp). The intensive treatments were established according to the traumatic brain injury treatment guidelines and spontaneously intracerebral hemorrhage general treatment principles from these two society in Taiwan.
89340749|NCT03855631||Kabuki syndrome/ unaffected parents|Intervention on primary cultured cells from 4 patients with KS and sex match parents
89340750|NCT01184287|Experimental|ranpirnase|All patients who do not progress after two cycles of pemetrexed-carboplatin will receive the study drug, ranpirnase
89340751|NCT01184365|Experimental|EnMP-1|The goal of the EnMP-1 is to enable participants, through a behavioural, psycho-educational intervention, to better manage and understand their fatigue. This program is provided in four, two-hour sessions held weekly.
89340752|NCT01184365|Active Comparator|EnMP-2|The goal of the EnMP-2 is to control for group effects
89340753|NCT03851887|Experimental|treatment group|TAI combine SBRT
89340754|NCT01291381|Active Comparator|Dermatophagoides pteronyssinus extract|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
89340755|NCT01291381|Active Comparator|Pharmacotherapy|Persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
89340756|NCT00003473|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
89340757|NCT01292317|Active Comparator|intravenous hydration|intravenous application of 0.9% saline
89340758|NCT01292317|Active Comparator|oral hydration only|
89340759|NCT01107431|Active Comparator|Sucrose with Dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
89340760|NCT01107431|Active Comparator|Sucrose without Dietary Supplement|Consumed 70 grams of sucrose without simultaneously taking the dietary supplement
89340761|NCT01186081|Experimental|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
89340762|NCT01186081|Active Comparator|Postoperative chemoradiotherapy|Postoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
89340763|NCT01186159|Experimental|Normal Saline|
89340764|NCT01104623||ADHD - Patients|Adults (18-50 years old). All eligible subjects will experience the voice recording procedure followed by the assessment of adult ADHD diagnostics. The diagnostic guidelines for ADHD in adulthood will be accomplished as outlined by expert consensus of the German Society for Psychiatry, Psychotherapy and Neurology, with a semi-structured clinical interview following the DSM-IV-TR criteria and the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002) to assess the severity of ADHD-Symptoms. Childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002). To strengthen the validity of the ADHD diagnosis the reported symptoms were corroborated by second party reports.
89340765|NCT01104623||Healthy Controls|Adults(18-50 years old). All eligible subjects will experience the voice recording procedure followed by the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002. To assess the severity of Non-ADHD, the absence of childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002).
89340766|NCT03852043|Experimental|High-intensity interval training|
89340767|NCT03852043|Active Comparator|Moderate-intensity continuous training|
89340768|NCT01104857|Experimental|Diaphragm muscle biopsy|Patients admitted to the ICU meeting severe sepsis / septic shock criteria
89340769|NCT01104857|Active Comparator|Elective laparotomy|
89340770|NCT01186237|Experimental|Early urinary catheter removal|
89340771|NCT01107509|Experimental|Neo-adjuvant everolimus|
89340772|NCT01186315|Active Comparator|Prolonged Exposure therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
89340773|NCT01186315|Experimental|Exposure therapy + VR/ER|prolonged exposure therapy plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
89340774|NCT01101815|Active Comparator|Oral Naltrexone + ART|Naltrexone (oral). 50 mg maintenance daily for 48 weeks, plus group drug counseling manual driven, N= 100
89340775|NCT01101815|Active Comparator|Naltrexone Implant + ART|Naltrexone Implant + ART. Monthly maintenance for 48 Weeks plus, group drug counseling manual driven, N=100
89340776|NCT01186393|Experimental|Control|Arm includes dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). Control diet will be prescribed for weight maintenance.
89340777|NCT01186393|Experimental|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
89340778|NCT01186393|Experimental|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on High Glycemic Index foods.
89340779|NCT01104935|Experimental|trastuzumab monotherapy|"H group (trastuzumab monotherapy group)~Trastuzumab: 1-year treatment~Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times"
89340780|NCT01104935|Active Comparator|trastuzumab and chemotherapy|"H+CT group (combination therapy of trastuzumab and chemotherapy)~Chemotherapy: 12 to 24 weeks~Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC, CMF and TCb (CBDCA)) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF. In cases of TCb (CBDCA), trastuzumab is used concomitant administration."
89340781|NCT01293643|Experimental|clindamycin/ketoconazole combination|
89340782|NCT01293643|Active Comparator|tetracycline hydrochloride/amphotericin B combination|
89340783|NCT03343626|Placebo Comparator|Flavivirus-naïve Cohort: Placebo|Placebo injection, intramuscular (IM), once on Day 1 (first dose) and Day 29 (second dose).
89340784|NCT03343626|Experimental|Flavivirus-naïve Cohort: PIZV 2 mcg (Low Dose)|PIZV 0.5 mL, 2 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
89340785|NCT03343626|Experimental|Flavivirus-naïve Cohort: PIZV 5 mcg (Medium Dose)|PIZV 0.5 mL, 5 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
89340786|NCT03343626|Experimental|Flavivirus-naïve Cohort: PIZV 10 mcg (High Dose)|PIZV 0.5 mL, 10 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
89340787|NCT03343626|Placebo Comparator|Flavivirus-primed Cohort: Placebo|Placebo injection, IM, once on Day 1 (first dose) and Day 29 (second dose).
89340788|NCT03343626|Experimental|Flavivirus-primed Cohort: PIZV 2 mcg (Low Dose)|PIZV 0.5 mL, 2 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
89340789|NCT03343626|Experimental|Flavivirus-primed Cohort: PIZV 5 mcg (Medium Dose)|PIZV 0.5 mL, 5 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
89340790|NCT03343626|Experimental|Flavivirus-primed Cohort: PIZV 10 mcg (High dose)|PIZV 0.5 mL, 10 mcg antigen, IM injection, once on Day 1 (first dose) and Day 29 (second dose).
89340791|NCT01293721|No Intervention|control|
89340792|NCT01293721|Experimental|Treatment|Receive vibration therapy
89340793|NCT01105013|Experimental|tonaftato|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
89340794|NCT01292395|Experimental|Protein level 1|
89340795|NCT01292395|Experimental|Protein level 2|
89340796|NCT01292395|Experimental|Protein level 3|
89340797|NCT03851731|Experimental|Naltrexone|Subject received a single intranasal dose of 2 mg naltrexone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
89340798|NCT03851731|Experimental|Naloxone|Subject received a single intranasal dose of 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
89340799|NCT03851731|Experimental|Naltrexol|Subject received a single intranasal dose of a combination of 2 mg naltrexone and 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
89340800|NCT03707652|Experimental|Cohort A (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
89340801|NCT03707652|Experimental|Cohort A (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
89340802|NCT03707652|Experimental|Cohort A (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
89340803|NCT03707652|Experimental|Cohort A (oral supplement A)-1 or 4 capsules|Oral supplement A (1 or 4 capsules) administered daily for 3 days
89340804|NCT03707652|Experimental|Cohort A (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
89340805|NCT03707652|Experimental|Cohort A (oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
89340806|NCT03707652|Experimental|Cohort B (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
89340807|NCT03707652|Experimental|Cohort B (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
89340808|NCT03707652|Experimental|Cohort B (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
89340809|NCT03707652|Experimental|Cohort B (oral supplement C)- 1 or 4 capsules|Oral supplement C (1 or 4 capsules) administered daily for 3 days
89340810|NCT03707652|Experimental|Cohort B (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
89340811|NCT03707652|Experimental|Cohort B(oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
89340812|NCT03849859|Active Comparator|Single plastic stent|Deployment of single plastic stent
89340813|NCT03849859|Active Comparator|Multiple plastic stents|Deployment of multiple plastic stent
89340814|NCT05671471||Allergic Children|Patients followed in the Pediatric Allergy and Pulmonology Unit, CHU Lille, aged 0-18 years with peanut and/or tree nut allergy
89531673|NCT05801653|Placebo Comparator|Reference|The test portion is based on 30 gram available carbohydrates without added oat betaglucan. Test portion consumed as a breakfast meal prior to determinations of test variables in the morning
89340815|NCT01293799|Experimental|The follow-up group|The intervention in the follow-up group consists of regular tests of the patients´ theoretical and practical skills regarding peritoneal dialysis. The test goals should be passed. If not, retraining will be given if needed til the goals are reached. The peritonitis rate in this group will be compared with that of the control group.
89340816|NCT01293799|No Intervention|Control group|Patients randomised to the control group will be treated according to the routines of the clinic.
89340817|NCT01588093|Placebo Comparator|Saline|
89340818|NCT01588093|Active Comparator|Increlex|
89340819|NCT01588249|Experimental|Novel formulation of pasteurized maple cough syrup|
89340820|NCT01588249|Placebo Comparator|Placebo|
89340821|NCT01186471|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
89340822|NCT01186471|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
89340823|NCT01186471|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
89340824|NCT03854773|Active Comparator|Erector spinae block (Group ESPB)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
89340825|NCT03854773|Active Comparator|Thoracal paravertebral block group (Group TPVB)|In group B, TPVB will be performed. US probe will be placed 2-3 cm laterally following the visualization T5 spinous process in sagittal orientation. The ribs and transverse processes will be visualized as hyperechoic structures. The costotransverse ligament will be visualized in the superior, and the pleura in the anterior region. Using in plane technique, the block needle will be inserted in the cranio-caudal direction until the costotransverse ligament will be passed. For confirmation of correct position of the needle, 5 ml saline will be injected. After the negative aspiration of cerebrospinal fluid, blood and air; 20 ml of 0.25% bupivacaine will be performed and it will be seen of moving downwards of the pleura during the injection
89340826|NCT03854773|Other|Control group (Group C)|Patients in control group will be only received fentanyl via a patient controlled analgesia (PCA) device.
89340827|NCT03854539|Experimental|Active Stimulation 0.5|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
89340828|NCT03854539|Sham Comparator|Sham Stimulation|0.5mA intermittent transdermal stimulation of the aurical vagus stimulation5 Hz 30 seconds on/30 seconds off for five cycles
89340829|NCT03854539|No Intervention|No Stimulation|0.0 mA (sham) intermittent transdermal stimulation of the aurical vagus stimulation, 0 Hz 30 seconds on/30 seconds off for five cycles
89340830|NCT03854539|Experimental|Active Stimulation 1.0|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles.
89340831|NCT03854539|Experimental|Active Stimulation 0.25|0.25 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
89340832|NCT03849781|Active Comparator|Intervention|NeoBeat will be placed on all newborns immediately after birth to assess the heartrate for at least 5 minutes, or longer if the newborn needs resuscitation. Intervention subjects will have a visible display of the heart rate on the NeoBeat, to guide healthcare providers in further management of the newborn.
89340833|NCT03849781|No Intervention|Standard Care|NeoBeat will be placed on the newborn to collect information on heart rate, but heart rate is not displayed to the healthcare providers. If the newborn is in need of resuscitation to initiate spontaneous respiration, the baby will be transferred to the resuscitation bay. According to recommendations the heart rate should be assessed and positive pressure ventilation initiated within one minute of life. Standard care is to assess heart rate by conventional ECG and/or pulse oximetry, alternatively auscultation of the heart.
89340834|NCT01292551|Active Comparator|Bosentan|
89340835|NCT01292551|Placebo Comparator|Placebo|
89340836|NCT03854383|Sham Comparator|Misoprostol alone|Enrolled women will receive 25 πg of misoprostol which will be placed intravaginally 4 hourly, maximum up to 5 doses
89340837|NCT03854383|Active Comparator|Isosorbide mononitrate with misoprostol|Enrolled women will receive 25 πg of misoprostol together with 40 mg isosorbide mononitrate which will be placed intravaginally 4 hourly, maximum up to 5 doses
89340838|NCT01189045|Experimental|Aerobic Program|The Aerobic Program will be the Experimental arm of this trial, where a structured, progressive aerobic exercise will be conducted in a class format
89340839|NCT01189045|Active Comparator|Balance and Flexibility Program|The Balance and Flexibility Program will be a non-aerobic intervention that will act as an Active Comparator. Stretching, balance exercises, yoga- or Tai Chi-style classes will be conducted.
89340840|NCT01292707|Active Comparator|Control|Prescribing staff in control facilities will receive the standard package of RDT training that is being provided by NMCP in Tanzania
89340841|NCT01292707|Active Comparator|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial.
89340842|NCT01292707|Active Comparator|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
89340843|NCT03334422|Experimental|4 Milligram (mg) Baricitinib|4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match
89340844|NCT03334422|Experimental|2mg Baricitinib|2mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
89340845|NCT03334422|Experimental|1mg Baricitinib|1mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
89340846|NCT03334422|Placebo Comparator|Placebo|Placebo administered orally once daily.
89340847|NCT03854617|Experimental|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
89340848|NCT03854617|Active Comparator|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period.
89340849|NCT01186549|Active Comparator|ephedrine 30 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
89340850|NCT01186549|Active Comparator|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
89340851|NCT01186549|Active Comparator|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
89340852|NCT01186549|Active Comparator|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
89340853|NCT01186549|Placebo Comparator|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
89340854|NCT01293877|Other|LGP|Patient underwent surgery for morbid obesity treatment between 18 to 60 years, and BMI of 40 ore more will divided in two groups, one hundred will be schedule for laparoscopic gastric plication. Our theory for this arm is that the procedure can offer the same results than the second arm with less cost and safety, reversibility included.
89340855|NCT01293877|Other|LSG|The patients in a total of one hundred will be schedule for laparoscopic sleeve gastrectomy. The is our control for development of the study.
89340856|NCT03851575|Active Comparator|Control arm|Usual guideline therapy
89340857|NCT03851575|Experimental|Accelerated arm|Accelerated treatment of endocarditis
89340858|NCT03854305|Experimental|PRV-6527|Oral administration, 2X daily for 12 weeks
89340859|NCT03854305|Placebo Comparator|Placebo|Oral administration, 2X daily for 12 weeks
89340860|NCT03849703|Experimental|Full Intervention #1|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the coparenting curriculum before the romantic relationships curriculum.
89340861|NCT03849703|Experimental|Full Intervention #2|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the romantic relationships curriculum before the coparenting curriculum.
89340862|NCT03849703|Other|Partial Intervention #1|Participants will receive the romantic relationships curriculum along with the control curriculum.
89340863|NCT03849703|Other|Partial Intervention #2|Participants will receive the coparenting curriculum along with the control curriculum.
89340864|NCT03851341|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
89340865|NCT03851341|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
89340866|NCT01293955|Experimental|JOINS 200mg|One tablet of JOINS 200mg is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with JOINS 200mg for another 1 year.
89340867|NCT01293955|Placebo Comparator|Placebo|One tablet of Placebo is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with Placebo for another 1 year.
89340868|NCT04907695||Video Laryngoscopy|Seeking all patients undergoing intubation for which the clinician chooses to use Video Laryngoscopy. The participants will undergo intubation with the investigators chosen device.
89340869|NCT03851653|Experimental|Lifestyle Intervention Group (LIG)|Participants from this group will receive a cognitive-behavioral intervention addressing weight loss and lifestyle habits such as hypocaloric diet, moderate exercise, smoking and alcohol avoidance, and sleep hygiene. This behavioral intervention will be combined with the usual treatment for OSA, i.e. CPAP.
89340870|NCT03851653|No Intervention|Control group|Participants from the control group will not receive any type of intervention apart from the usual care (CPAP).
89340871|NCT02524015|Other|Control|Standard Physical Therapy
89340872|NCT02524015|Experimental|Intervention|Novel Physical Therapy
89340873|NCT01294033|Placebo Comparator|Fractional inspired oxygen 0.21|Cardiopulmonary exercise test performed by subject on Fractional inspired oxygen 0.21
89340874|NCT01294033|Active Comparator|Fractional inspired oxygen 0.28|Cardiopulmonary exercise test performed on supplemental oxygen (Fractional inspired oxygen 0.28)
89340875|NCT03849547|Experimental|App training group|Subjects in App training group will receive App Balance training via smartphone application.
89340876|NCT03849547|Active Comparator|Home training group|Subjects in Home training group will receive Home Balance training advised by physical therapist.
89340877|NCT03849547|No Intervention|Control group|Control group will receive only education of ankle injury prevention related information.
89340878|NCT01191229|No Intervention|Tecnis One-Piece MF IOL|It is planned that about 25 people who are at least 18 years old who are scheduled to have the Tecnis One-Piece Multifocal Intraocular Lenses placed into their eyes after cataract surgery
89340879|NCT01191229|No Intervention|Crystalens AO|It is planned that about 25 people who are at least 18 years old and have been implanted with Crystalens AO
89340880|NCT01294111|Experimental|Tai Chi training|Participation in a group of 15 patients, completing a 60 minutes tai chi training programme twice-weekly for 16 weeks.
89340881|NCT01294111|No Intervention|Control|Living as usual, following ordinary care plans and personal activities. Participants will be called to hospital for data collection. Participants are asked not to start any of the activities Tai Chi, Qui Gong or Yoga during the study period.
89340882|NCT01186783|No Intervention|standard treatment|All patients receive established medical therapy according to current guidelines and therapeutic standards.
89340883|NCT01186783|Active Comparator|ivabradine (add-on)|Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
89340884|NCT05193409|Experimental|225 mg BNC210|
89340885|NCT05193409|Experimental|675 mg BNC210|
89340886|NCT05193409|Placebo Comparator|Placebo|
89340887|NCT03945929|Experimental|Distraction1 group|Distraction-1 Group (Cards containing optical illusion pictures)
89340888|NCT03945929|No Intervention|Control|Control
89340889|NCT03945929|Experimental|Distraction 2 group|Distraction-2 Group
89340890|NCT03945695|Experimental|Pneumatic Vitreolysis|All included eyes will receive one intravitreal injection of filtered sulfur hexafluoride gas (SF6).
89340891|NCT01292785||Transsexual|Female-to-Male and Male-to-Female Transsexuals receiving hormonal therapy
89340892|NCT01292785||Healthy control subjects|receiving no hormonal therapy
89340893|NCT02323126|Experimental|Nivolumab and EGF816|Group 1: EGF816 150 mg QD + Nivolumab 3 mg/kg Q2W
89340894|NCT02323126|Experimental|Nivolumab and INC280, high cMet|Group 2A: INC280 400 mg BID, High cMET + Nivolumab 3 mg/kg Q2W
89340895|NCT02323126|Experimental|Nivolumab and INC280, low cMet|Group 2B: INC280 400 mg BID, Low cMet + Nivolumab 3 mg/kg Q2W
89340896|NCT01291459|Experimental|single arm|Maraviroc/raltegravir/emtricitabine/tenofovir 24 weeks followed by Maraviroc/Raltegravir 24 weeks
89340897|NCT01107587|Experimental|HRV group|Subjects will receive GSK Biologicals' human rotavirus vaccine 444563.
89340898|NCT01107587|Placebo Comparator|Placebo Group|Subjects will receive placebo.
89340899|NCT01191307||Shunt Implant|hydropcephalus cohort
89340900|NCT01191307||Cochlear Implant|hearing impaired cohort
89340901|NCT01191307||Spinal Cord Stiumulation|spinal cord injury cohort
89340902|NCT01191307||Vagus Nerve Stimulation|epilepsy cohort
89340903|NCT01191307||Deep Brain Stimulation|dystonia cohort
89340904|NCT01294189||ICU-patients that died on the ICU|ICU-patients (post-operative and non operative patients) will be enrolled in the study. All patients are followed until their death on the ICU.
89340905|NCT01191385||Group 1|
89340906|NCT03473704|Experimental|Treatment group (TG)|The treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
89340907|NCT03473704|Placebo Comparator|Control group (CG)|The control group (CG) will be evaluated in the same phases as the TG.
89340908|NCT01189357||failed meniscal transplantation|
89340909|NCT02056054||Subjects with d-AIH|Pediatric transplant patients with de novo autoimmune hepatitis (d-AIH) will be enrolled at an outside center.
89340910|NCT02056054||Subjects with Acute Rejection|Pediatric transplant patients with acute rejection will be enrolled at an outside center.
89340911|NCT02056054||Subjects with Chronic Rejection|Pediatric transplant patients with chronic rejection will be enrolled at an outside center.
89340912|NCT02056054||Control Subjects|Healthy pediatric patients will be enrolled at the coordinating center (Yale).
89340913|NCT02056054||Subjects with Auto-immune Hepatitis|Adult non-transplant patients with auto-immune hepatitis will be enrolled at the coordinating center (Yale).
89340914|NCT02056054||Subjects with Chronic Hepatitis C Virus|Adult non-transplant patients with chronic hepatitis C will be enrolled at the coordinating center (Yale).
89340915|NCT02056054||Adult Subjects with d-AIH|Adult transplanted patients with de novo autoimmune hepatitis will be enrolled at the coordinating center (Yale).
89340916|NCT03854149||Adults with CHD & non-valvular atrial arrhythmias|Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia)
89340917|NCT05671627||patients with Rheumatoid arthritis and good response at 3/6/12 months|Patients with Rheumatoid arthritis that fulfill the inclusion/exclusion criteria and show a good response at 3/6 or 12 months upon recruitment according to EULAR guidelines with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day) Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment.
89340918|NCT05671627||patients with Rheumatoid arthritis and none at 3/6/12 months|"Patients with Rheumatoid arthritis that fulfill the inclusion/exclusion criteria and show none response at 3/6 or 12 months upon recruitment according to EULAR guidelines.~Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment."
89340919|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-positive CHB Participants|Participants with Hepatitis B e Antigen (HBeAg)-positive CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
89340920|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
89340921|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
89340922|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
89340923|NCT03491553|Experimental|Placebo: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
89340924|NCT03491553|Experimental|Placebo: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
89340925|NCT00003377|Other|Radiation therapy plus concurrent weekly chemotherapy|
89340926|NCT01189513|Experimental|SCH 900105|10 mg/kg intravenous Days 1, 8 and 15 of 30 day cycle.
89340927|NCT03950921|Experimental|Patient Safety Display Arm|Patient Safety Display in patient room
89340928|NCT03950921|No Intervention|Control Arm|Usual Care
89340929|NCT01291537|Experimental|Duodopa|
89340930|NCT01291537|Active Comparator|Best medical treatment|
89340931|NCT03947567|Experimental|Recombinant Human Coagulation FVIII|
89340932|NCT03849391|Experimental|Skate group|This group takes Skate Skin extract for 12 weeks
89340933|NCT03849391|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
89340934|NCT03950765|Experimental|Ecological Momentary Intervention|This group will receive three intervention prompts and three assessment prompts on their smartphone each day.
89340935|NCT00651742|Experimental|S-1 30 mg/m^2|Participants received 30 milligrams per meter square (mg/m^2) of S-1 orally twice daily (BID) for 2 weeks (i.e., Day 1 to 14), followed by 1 week recovery period (i.e., Day 15 to 21; one cycle equaled 21 days), treatment was repeated every 3 weeks until death, progression of disease, occurrence of intolerable side effects, withdrawal of consent, or removal by Investigator, whichever comes first.
89340936|NCT01294345||personalized genomics|genetic/genomic syndromes
89340937|NCT01189591|Experimental|Sleep deprivation|Slow-wave sleep deprivation for one night as an experimental treatment for major depressive disorder
89340938|NCT01191463|Experimental|Mung Bean Meals and Guava fruit|Subject in this group will receive, a lunch meal based on 50g of Mung beans together with a local, Vitamin C rich fruit (Guava)
89340939|NCT01191463|Active Comparator|Mung Bean|Subjects in this group will receive a lunch meal based on 50g mung beans but without any vitamin C source.
89340940|NCT01191463|No Intervention|School feeding program|Subjects in this arm, will receive the regular school feeding program as provided by the school authorities
89340941|NCT01105403|Experimental|CD34+ mobilisation for transplantation|
89340942|NCT01328015|Active Comparator|Oxybuynin, hyperhidrosis|
89340943|NCT01328015|Placebo Comparator|placebo - sugar pill|
89340944|NCT05155462||Patient treated for defined symptomatic chronic lower extremity ischemia|
89340945|NCT01294501|Experimental|Fever assessment and management|Medication administration educational module for low literacy subjects on how to administer common medications appropriately and safely.
89340946|NCT05155228|Experimental|Attachment Regulation and Competency|Weekly individual psychotherapy for 24 weeks using the Attachment Regulation and Competency intervention.
89340947|NCT05155228|Active Comparator|Treatment as usual|Weekly individual psychotherapy for 24 weeks.
89340948|NCT03950687|Active Comparator|Control group A|intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
89340949|NCT03950687|Experimental|Experimental group B|intravenous administration, 0.5μg/kg, once a week, for 32 weeks
89340950|NCT03950687|Experimental|Experimental group C|"intravenous administration,~1μg/kg, once every two weeks, for 32 weeks"
89340951|NCT01189669|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
89340952|NCT01189669|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
89340953|NCT01189669|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
89340954|NCT01101893|Experimental|Period 1|In period 1 all subjects will receive Raltegravir 400mg q12h from Day 1 to Day 5
89340955|NCT01101893|Experimental|Period 2|In period 2 all subjects will receive GSK2248761 200mg q24h from Day 1 to Day 5.
89340956|NCT01101893|Experimental|Period 3|Day 1 of Period 3 will be the day after Day 5 of Period 2. Subjects will receive GSK2248761 200mg q24h + raltegravir 400mg q12h from Day 1 to Day 5.
89340957|NCT01187251||Group 1 - mp3 users|Subjects who have been using mp3 players for at least 1 hour per day for at least 1 year
89340958|NCT01187251||Group 2 - mp3 non-users|Subjects who does not listen regularly to mp3 music
89340959|NCT05155072|Experimental|Sequence A|
89340960|NCT05155072|Experimental|Sequence B|
89340961|NCT05155072|Experimental|Sequence C|
89340962|NCT05155072|Experimental|Sequence D|
89340963|NCT05155072|Experimental|Sequence E|
89340964|NCT05155072|Experimental|Sequence F|
89340965|NCT01588327||Experimental|Patient taking FDA approved dose of dabigatran
89340966|NCT01588327||Control group|Person not taking any form of anticoagulation.
89340967|NCT01292863|Active Comparator|Conventional peritoneal dialysis solution|Subjects will be randomized to perform dialysis with the conventional peritoneal dialysis solution for 3 months. At the end of three months mesothelial cell shedding and apoptosis will be measured.
89340968|NCT01292863|Experimental|Novel biocompatible dialysis solution Delflex neutral pH|
89340969|NCT02523508|Experimental|Experimental group|Passive manual lumbar mobilization on L2-3 level
89340970|NCT02523508|Placebo Comparator|Control group|Passive limb mobilization which did not involve the spine
89340971|NCT02523430|Experimental|HepaSphere|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
89340972|NCT02523430|Placebo Comparator|control|nasopharyngeal carcinoma patients received traditional therapy
89340973|NCT01292941|Active Comparator|Active comparator/Yellow catheter|SpeediCath coated catheter
89340974|NCT01292941|Experimental|NonCE marked intermittent catheter/red|
89340975|NCT01292941|Experimental|NonCE marked intermittent catheter/green|
89340976|NCT01292941|Experimental|NonCE marked intermittent catheter/Blue|
89340977|NCT02523352|Experimental|Treatment|Volunteers with a BMI > 35 Kg/m2 and central fat distribution, without any past medical history
89340978|NCT03477682|Experimental|Early Ambulation Group|The patient will remain on bed rest for one day following surgery and will be encouraged to be out of bed and ambulating on the second day following surgery.
89340979|NCT03477682|No Intervention|Standard Group|The patient will remain on bed rest for five days following surgery and will be encouraged to be out of bed and ambulating on the sixth day following surgery.
89340980|NCT00002651|Active Comparator|Consolidation arm I|Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
89340981|NCT00002651|Experimental|Consolidation arm II|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.
89340982|NCT03853993|Experimental|Experimental group-phase I|Quadrivalent influenza vaccine
89340983|NCT03853993|Experimental|Experimental group-phase III|Quadrivalent influenza vaccine
89340984|NCT03853993|Active Comparator|Control group-1-phase III|Trivalent influenza vaccine (contains B/Victoria strain)
89340985|NCT03853993|Active Comparator|Control group-2-phase III|Trivalent influenza vaccine (contains B/Yamagata strain)
89340986|NCT03853681|Other|additional blood sampling|
89340987|NCT03473626|Experimental|Alicaforsen tablets|Regimen A - Alicaforsen tablets with food
89340988|NCT03473626|Experimental|alicaforsen tablets|Regimen B - Alicaforsen tablets without food
89340989|NCT03853603|Placebo Comparator|Placebo|Maltodextrin
89340990|NCT03853603|Active Comparator|Santa herba extract|Santa herba extract
89340991|NCT05154682|Active Comparator|Oxycodone Group (Control Group)|Patients will receive oxycodone as needed after surgery
89340992|NCT05154682|Active Comparator|Oxycodone+ Naproxen/Acetaminophen (Study Group)|each patient will receive oxycodone plus acetaminophen and naproxen for 2 weeks after surgery
89340993|NCT01107977|Experimental|Iyengar yoga|
89340994|NCT01107977|No Intervention|Waitlist control|
89340995|NCT03477526|Experimental|COPD patients (GOLD stage III-IV)|
89340996|NCT03477526|Active Comparator|IPF patients|
89340997|NCT01294657||HE Group|Health Education [HE] - Counseling, referrals to resources + self-help materials; 2 HE interventions at Baseline + 6 month visits.
89340998|NCT01294657||MAPS Group|Motivation And Problem Solving (MAPS) - HE + 12 telephone counseling sessions over 1-year period (average 1 call/month).
89340999|NCT05154604|Experimental|Treatment group: SHR-A1921|
89341000|NCT01294735|Experimental|Part A, MK-4827 + temozolomide dose escalation cohort|
89341001|NCT01294735|Experimental|Part B, MK-4827 + temozolomide melanoma cohort|
89341002|NCT01294735|Experimental|Part B, MK-4827 + temozolomide glioblastoma multiforme cohort|
89341003|NCT05154292|Experimental|eHealth Emotion Regulation Skills|The intervention aims to develop competencies for emotional regulation through exposure and acceptance strategies for coping with circumstances that produce stress or emotional discomfort. The application has a series of mini-games that the user will overcome throughout a narrative, with different challenges and rewards
89341004|NCT05154292|No Intervention|Waiting List|He or she will not be exposed to the intervention but will remain on the waiting list and will complete the pre and post-measures.
89341005|NCT03851263|Experimental|Evolocumab|All subjects are treated with evolocumab 140mg every 2 weeks (q2w) starting on day 1 and ending on day 1071 (week 153).
89341006|NCT05105243|Active Comparator|SAD Cohort 1|Each dose cohort: 8 subjects (6 active:2 placebo). 5 mg
89341007|NCT05105243|Active Comparator|SAD Cohort 2|Each dose cohort: 8 subjects (6 active:2 placebo). 15 mg.
89341008|NCT05105243|Active Comparator|SAD Cohort 3|Each dose cohort: 8 subjects (6 active:2 placebo). 45 mg.
89341009|NCT05105243|Active Comparator|SAD Cohort 4|Each dose cohort: 8 subjects (6 active:2 placebo). 125 mg
89341010|NCT05105243|Placebo Comparator|SAD Cohort 5|Each dose cohort: 8 subjects (6 active:2 placebo). 250 mg.
89341011|NCT05105243|Active Comparator|MAD Cohort 1|Each dose cohort: 8 subjects (6 active:2 placebo). 45mg
89341012|NCT05105243|Placebo Comparator|MAD Cohort 2|Each dose cohort: 8 subjects (6 active:2 placebo). 125 mg.
89341013|NCT05105243|Placebo Comparator|MAD Cohort 3|Each dose cohort: 8 subjects (6 active:2 placebo). 250 mg.
89341014|NCT05124106|Experimental|Diagnostic ability of Raman spectrometry|Endoscopic Raman spectrometry during endoscopic bladder cancer surgery
89341015|NCT02100397|Experimental|Dose|A dose of S.paratyphi will be given to up to 20 participants to determine the attack rate.
89341016|NCT01294813|Experimental|Bronchoscopy-EIT|Patients who routinely undergo bronchoscopy will be measured by EIT directly before, directly after and 10, 30, 60 minutes after bronchoscopy with a rubber belt which is placed around their chest. The EIT measurements will take 1-2 minutes; the total examination will last 1.5 hours.
89341017|NCT04562428|Experimental|XSLJZ|Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
89341018|NCT04562428|Placebo Comparator|XSLJZ Placebo|10%Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
89341019|NCT03473470|No Intervention|not warmed|Not warming system
89341020|NCT03473470|Active Comparator|warmed group 1|forced air warming and warmed intravenous fluids
89341021|NCT03473470|Active Comparator|warmed group 2|warmed intravenous fluids
89341022|NCT01189825|Experimental|Exercise|
89341023|NCT03477448|Active Comparator|PPD group|"This group will include 20 patients who will be treated with IL injection of PPD at a dose of 10 IU (0.1 ml) supplied an insulin syringe in the largest wart.~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions"
89341024|NCT03477448|Active Comparator|Bleomycin group|"This group will include 20 patients who will be treated with IL injection of bleomycin.~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions, if needed."
89341025|NCT00002597|Experimental|Neoadjuvant TAS + RT|Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
89341026|NCT00002597|Other|Radiation therapy alone|Radiation therapy alone
89341027|NCT03435081|Experimental|2 milligram (mg) Baricitinib|2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
89341028|NCT03435081|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
89341029|NCT03435081|Placebo Comparator|Placebo|Placebo administered orally every day.
89341030|NCT03851029|Experimental|Tai chi|(Yang 24 postures) Moderate intensity HRR (40%-60%)
89341031|NCT03851029|Active Comparator|Aerobic Training|Elliptical Moderate intensity HRR (40%-60%)
89341032|NCT04299100|No Intervention|Control Group|Participants randomized to the Control Group will receive usual care from their pain physician.
89341033|NCT04299100|Experimental|Sleep Health Program - Suspected No/mild sleep apnea|Participants randomized to the Sleep Health Program with no/mild sleep apnea.
89341034|NCT04299100|Experimental|Sleep Health Program - Suspected Moderate/severe sleep apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea.
89341035|NCT01294891||Control|Age matched healthy subjects
89341036|NCT01294891||Sickle Cell Patients|Patients with established SCD
89341037|NCT01294891||Paroxysmal Nocturnal Hemoglobinuria patients|Patients with PNH
89341038|NCT04458064|Active Comparator|i gel|I gel LMA was inserted for all patients
89341039|NCT04458064|Active Comparator|Air Q LMA|Air Q LMA was inserted for all patients
89341040|NCT03850873|Experimental|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m to 120mg once daily
89341041|NCT04458142|Experimental|Single buccal infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine).~Injecting by a small amount of solution in the superficial mucosa. After a few seconds, the needle was slowly advanced in the mucobuccal fold toward the apex of the molar and 1.8 ml of 4% articaine using short 30-gauge needle was slowly given.~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed by inquiring about the area of numbness from the participant, no pain during pricking the palatal mucosa. The cases in which palatal anesthesia will not be reported by the patient will be given supplemental palatal infiltration with 0.2 to 0.3 mL articaine.~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
89341042|NCT04458142|Active Comparator|Buccal and intrapapillary infiltration using 4%articaine|"Dryness the site of injection then application of topical anesthetic gel(2% benzocaine) Injecting a small amount of solution in the superficial mucosa,then needle will slowly advanced in the mucobuccal fold toward the apex of the molar and 1.5 ml of 4% articaine was slowly given. The remaining 0.3ml solution will be given equally into the distal, mesial intrapapillary and palatal sites respectively until blanching of the palate is observed extending more than halfway along the palatal gingival margin.~Subjective assessment of buccal and palatal soft tissue anesthesia will be assessed.~After achieving adequate buccal and palatal tissue anesthesia, the tooth will be extracted under aspetic technique."
89341043|NCT03853525|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with BAY207543 is investigated.
89341044|NCT03853525|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with vaseline is investigated.
89341045|NCT05133154|Other|Patients with low-grade glioma|Group 1
89341046|NCT05133154|Other|Patients with high-grade glioma|Group 2
89341047|NCT05133154|Other|Patients undergoing brain surgery for a non-tumor disease|Group 3
89341048|NCT03849157|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
89341049|NCT03849157|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
89341050|NCT01189981|Experimental|eHealth intervention|Standard lifestyle counseling. Short Message Service (SMS) encouragements for physical activity,
88811792|NCT05236634|Active Comparator|Group B|Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks.
89341051|NCT01189981|Active Comparator|Lifestyle counseling|Standard lifestyle counseling. No Short Message Service (SMS) encouragements for physical activity.
89341052|NCT03716583|Experimental|Melatonin/DMSO|25 mg melatonin in 1 g cream twice daily for the duration of the radiation therapy
89341053|NCT03716583|Placebo Comparator|Placebo|1 g of cream once daily
89341054|NCT02738008|Experimental|ARC-520 Injection|Multiple administrations of ARC-520 starting at a dose level of 2 mg/kg, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
89341055|NCT01190059|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .
89341056|NCT03720249|Experimental|supplementation of compound nutrients|Betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc are provided as a 800mg tablet. And the tablet is orally taken once a day, four tablets at a time for 12 weeks.
89341057|NCT03720249|Placebo Comparator|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc supplement.
89341058|NCT01294969|Experimental|AL-4943A|One drop per day in both eyes
89341059|NCT05017090|Sham Comparator|Group N|The patients in Group N will not receive any intervention. In the intervention and control groups, block sites will be covered with dressings, and patients and other health care workers will be blinded to treatment allocation. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
89341060|NCT05017090|Experimental|Group M-TAPA|After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
89341061|NCT03720171|Experimental|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb.
89341062|NCT01187641||colon cancer|patients undergoing treatment for colon cancer
89341063|NCT03850561|Active Comparator|Coenzyme Q10 200|Coenzyme Q10 200mg/day for 3 months
89341064|NCT03850561|Active Comparator|Coenzyme Q10 400|Coenzyme Q10 400mg/day for 3 months
89341065|NCT04971538|Experimental|HCV self-testing|the study staff will leave an HCV ST and instructions for use (IFU) with the household. The study team will also explain the HCVST process to the most senior member of the household, as well as leave a mobile number for the participant to contact for help conducting the test. The study team will follow up with the participant to inquire about if testing was completed, collect any testing results, and conduct a brief survey.
89341066|NCT04971538|No Intervention|Referral to clinic for HCV RDT|the study staff will leave information on HCV testing and direct them to the nearest clinic with screening services, the participant will not be left a HCVST. Study staff will also leave a mobile number for the participant to contact for further information on HCV testing. The study team will follow up with the participant to inquire about if testing was completed, collect any testing results, and conduct a brief survey
89341067|NCT01190137|Active Comparator|400 IU Vitamin D3|
89341068|NCT01190137|Experimental|400 IU Vitamin D2|
89341069|NCT04180228||Systemic lupus erythematosus|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire with systemic lupus erythematosus.
89341070|NCT04180228||Idiopathic juvenile arthritis|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire, with idiopathic juvenile arthritis.
89341071|NCT02529839|Experimental|Experimental|"Fludarabine 30mg/m2 for 4 days, Cyclophosphamide 50mg/kg for 2 days, Alemtuzumab administered subcutaneously 24mg total dose.~Autologous bone marrow transplantation"
89341072|NCT03850639|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
89341073|NCT03850639|No Intervention|Wait list control|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 4 weeks.
89341074|NCT04458376|Experimental|Follows the internet-based self-help program|
89341075|NCT03473314|Experimental|Nitric Oxide gas at 160ppm|Nitric Oxide 160ppm for 50-80 minutes two -three times a day for 365 days
89341076|NCT03945539|Experimental|JNJ-56136379 and Itraconazole|Participants will receive a single dose of JNJ-56136379 on Day 1 in Treatment Period 1 and itraconazole 200 mg once daily for 21 days starting on Day 34 along with a single dose of JNJ 56136379 on Day 38 in Treatment Period 2. JNJ-56136379 intake in Treatment Period 1 and the first intake of itraconazole in Treatment Period 2 will be separated by a washout period of at least 33 days. Study drug (JNJ-56136379 and itraconazole) intakes will be taken orally and under fed conditions.
89341077|NCT01293019|Experimental|Experimental|Osteopathic treatment
89341078|NCT01293019|Placebo Comparator|Placebo|Sham osteopathic treatment
89341079|NCT01293019|Active Comparator|Usual care|Classic treatment of cystic fibrosis patients
89341080|NCT03796858|Experimental|Group 1: Guselkumab|Participants will receive guselkumab 100 milligram (mg) Subcutaneous (SC) injection at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo SC at Week 24 to maintain the blind. At Week 16, Participants who meet the early escape criteria will receive placebo at Week 16 and guselkumab at Week 20, then guselkumab every 8 weeks (q8w).
89341081|NCT03796858|Experimental|Group 2: Placebo followed by Guselkumab|Participants will receive placebo SC injection at Weeks 0, 4, 12, and 20, and will crossover to receive guselkumab 100 mg SC injection at Weeks 24, 28, 36, and 44. At Week 16, Participants who meet the early escape criteria will receive guselkumab at Weeks 16 and 20, then guselkumab q8w.
89341082|NCT01190293|Experimental|All subjects|All Subjects will receive the same intervention.
89341083|NCT03950531||COPD exacerbation without Bronchiectasis|COPD patients who have been in exacerbation period and have no bronchiectasis
89341084|NCT03950531||COPD exacerbation with Bronchiectasis|COPD patients who have been in exacerbation period and have bronchiectasis
89341085|NCT03945617|Experimental|Unified treatment protocol|This intervention group receives 16 sessions of CBT-based, individual psychotherapy using to the Unified Treatment Protocol for the treatment of emotional disorders by Barlow et al. (2011).
89341086|NCT03945617|No Intervention|Waitlist Control Group|Participants in the waitlist control group gain access to the Unified Treatment after a waiting period of 16 weeks
89341087|NCT03945149|Active Comparator|Turmipure Gold™|30 subjects will be randomized under active arm and will receive Active Product at V1 and until V2 (5 weeks of treatment).
89341088|NCT03945149|Placebo Comparator|Placebo|30 subjects will be randomized under Placebo arm and will receive placebo Product at V1 and until V2 (5 weeks of treatment).
89341089|NCT03945227|Placebo Comparator|Arm A (consolidation only arm)|Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
89341090|NCT03945227|Experimental|Arm B (concurrent arm)|Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
89341091|NCT01108133|Experimental|Hydrocortisone, fMRI, Intrusions|10 mg Hydrocortisone are administered one hour before the fMRI experiment. We use the script-driven imagery paradigm to induce intrusive memories during fMRI scanning.
89341092|NCT01108133|Experimental|Dexamethasone, fMRI, Intrusions|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment. (DEX-Test). We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning.
89341093|NCT01108133|Experimental|Placebo, fMRI, Intrusions|Placebo is administered one hour before the fMRI experiment. We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning in patients with posttraumatic stress disorder.
89341094|NCT01108211|Experimental|Treatment Group|This group will receive Vibration Therapy.
89341095|NCT01108211|No Intervention|Observation Group|This group does not receive Vibration Therapy
89341096|NCT01108289|Experimental|Oxytocin in Uniject|Community Health Officers will provide 10 IU Oxytocin in Uniject device IM immediately after delivery of baby
89341097|NCT01108289|No Intervention|PPH Treatment Only|Community Health Officers will be able to treat for PPH only, not provide Oxytocin in Uniject
89341098|NCT03471286|Experimental|Sub-Protocol A|Epacadostat
89341099|NCT03489369|Experimental|Sym022|Sym022 will be administered at up to 4 planned dose levels.
89341100|NCT03947489|Experimental|Anpl-one SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
89341101|NCT03947489|Active Comparator|Sarpodipil SR Tab. 300mg|a single oral dose administration in healthy volunteers under fasting condition
89341102|NCT03947411|Experimental|Oseltamivir Phosphate+Xiyanping injection|Oseltamivir Phosphate+Xiyanping injection treatment for 7-10 days
89341103|NCT03947411|Active Comparator|Oseltamivir Phosphate treatment only|Oseltamivir Phosphate treatment for 7-10 days
89341104|NCT04035239|Experimental|BGS use|Use of BGS goggles for a 3-6 weeks period.
89341105|NCT03944759|Active Comparator|GBM:( bupivacaine/magnesium sulphate)|"serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.~GBM:( bupivacaine/magnesium sulphate): will receive bupivacaine 30 ml 0.25 and 500 mg magnesium sulphate"
89341106|NCT03944759|Active Comparator|GBN: ( bupivacaine/nalpuphin)|serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.. ( bupivacaine/nalpuphin):received bupivacaine 30 ml 0.25 % and nalpuphine 0.2mg/kg.
89341107|NCT01327469|Experimental|Albendazole 400mg|albendazole, 1 x 400mg
89341108|NCT01327469|Experimental|Albendazole 2 x 400mg|albendazole, 2 x 400mg
89341109|NCT01327469|Experimental|Mebendazole 500mg|mebendazole, 1 x 500mg
89341110|NCT01327469|Experimental|Mebendazole 2 x 500mg|mebendazole, 2x 500mg
89341111|NCT01327469|Experimental|Pyrantel-oxantel + mebendazole|pyrantel-oxantel (10mg/kg)+ mebendazole (500mg)
89341112|NCT01108679||Buprenorphine|Opioid-dependent drug users who are initiating buprenorphine treatment at the Albert Einstein College of Medicine Division of Substance Abuse (DoSA) or at Montefiore's Comprehensive Health Care Center (CHCC).
89341113|NCT03945071|Active Comparator|Puntal plug|Subjects will receive temporary punctal plug after intravitreal injection
89341114|NCT03945071|No Intervention|Non-Punctual plug|Subjects will not receive temporary punctal plug after intravitreal injection
89341115|NCT01102049|Experimental|self-administered food intake|self-administered food intake according to dietary protocol
89341116|NCT03950141|Experimental|Apatinib and S1 group|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
89341117|NCT01108601|Other|Ringer's Lactate|Each patient will act as their own control with one ear receiving treatment, and the contralateral ear acting as control.
89341118|NCT03738475|Experimental|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
89341119|NCT03738475|Placebo Comparator|Placebo|Normal saline administered intravenously on days 1 and 8.
89341120|NCT03944369|Other|Observational Control|The observational control arm is an observational control group.
89341121|NCT03944369|Other|KB109|KB109 is a novel glycan.
89341122|NCT03684629|Experimental|the response of KPI and corresponding suggestion|The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month. The multifaceted quality improvement interventions include: 1) implementation of standardized templates of medical record, evidence-based clinical pathway, and written care protocols; 2) feedback system of performance measures; 3) expert online consultation.
89341123|NCT03684629|No Intervention|a control arm|The control group indicated that the hospitals will not be provided with the multifaceted quality improvement interventions. They just provide patients with routine care.
89341124|NCT01108913|Active Comparator|Bimosiamose|
89341125|NCT01108913|Placebo Comparator|Placebo|
89341126|NCT03084718|Experimental|Treatment A|CHF 718 pMDI 100 μg Total Daily Dose (TDD), Dose 1; CHF 718 pMDI 50 μg/actuation: 1 inhalation twice daily (BID);
89341127|NCT03084718|Experimental|Treatment B|CHF 718 pMDI 400 μg Total Daily Dose (TDD) 400 μg, Dose 2; CHF 718 pMDI 100 μg/actuation: 2 inhalations BID;
89341128|NCT03084718|Experimental|Treatment C|CHF 718 pMDI Total Daily Dose (TDD) 800 μg, Dose 3; CHF 718 pMDI 100 μg/actuation: 4 inhalations BID;
89341129|NCT03084718|Placebo Comparator|Treatment D|Placebo Control, Placebo; CHF 718 pMDI matched Placebo: 4 inhalations BID;
89341130|NCT03084718|Active Comparator|Treatment E|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA), Total Daily Dose (TDD) 320 µg; QVAR® 80 μg/actuation: 2 inhalations BID;
89341131|NCT03950219||Intervention, Centre for Diabetes or local setting|Group-based course in diabetes education including 6 sessions of approximately 3 hours. Sessions are constructed around themes such as; diabetes knowledge and complication, mental health, diet, physical activity, Ramadan, medicine and include practical exercises such as blood sugar measurements, walking etc.
89341132|NCT03950219||Usual care|Usual care in 5 municipalities in the west area of Copenhagen
89341133|NCT03944993|Experimental|Pulsed Electromagnetic Field Therapy (Dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on dominant leg.
89341134|NCT03944993|Experimental|Pulsed Electromagnetic Field Therapy (Non-dominant leg)|Active Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes on non-dominant leg.
89341135|NCT03944993|Sham Comparator|Sham Therapy (Control)|Inactive Pulsed Electromagnetic Field therapy; exposed once weekly for 10 minutes.
89341136|NCT01102127||Goiter|Patients with nodular goiter
89341137|NCT01208753|Experimental|Aqueous formulations for formulation selection|50 mg once daily for 3 days of two different aqueous suspensions, with four day wash-out between formulation
89341138|NCT01208753|Experimental|GLPG0555 ascending doses|multiple ascending doses for 13 days, ranging from 100 mg once daily upto a maximum to be determined during escalation (given as once or twice daily)
89341139|NCT01208753|Placebo Comparator|3|once or twice daily for 13 days, matching the scheme of the multiple ascending dose.
89341140|NCT01102205||healthy|
89341141|NCT01102205||euthyroid hashimoto|
89341142|NCT01102205||hypothyroid hashimoto|
89341143|NCT01208831|Experimental|LDE225|
89341144|NCT01111487|Active Comparator|Group I|This group will use a pressure level of 10 cmH2O.
89341145|NCT01111487|Active Comparator|Group II|This group will use a pressure level of 15 cmH2O.
89341146|NCT03469882|Experimental|High protein and exercise (HPE) group|Begining within 48 hours of ICU admission participants will receive nutrition support with energy expenditure measured by indirect calorimetry, 2.0 to 2.2 g/kg/day of protein and in-bed cycle ergometry exercise.
89341147|NCT03469882|Other|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise
89341148|NCT02938624|Experimental|cohort1|Pembrolizumab 200 mg I.V single dose
89341149|NCT02938624|Experimental|Cohort II|Pembrolizumab 200 mg I.V Twice interval 21 days
89341150|NCT02938624|Experimental|Cohort III|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
89341151|NCT02938624|Experimental|COHORT -1|Pembrolizumab 100 mg I.V single dose
89341152|NCT03469804|Experimental|Pembrolizumab|Pembrolizumab Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
89341153|NCT03944525|Active Comparator|Intervention|Intervention consists of HFA using standard equipment at the department. A gas flow of 60L/min and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the pati ent or indication for intubation.
89341154|NCT03944525|Active Comparator|Control|Control consists of non-invasive CPAP ventilation support using a tight mask and standard respirator equipment of the Department of Emergency Medicine. A positive airway pressure of 5cm H2O and a FiO2 as clinically feasible will be used. Therapy will be continued until a pCO2-level of 50mmHg or less is reached, or therapy has to be aborted because of lack of tolerance by the patient or indication for intubation.
89341155|NCT01108991|Active Comparator|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
89341156|NCT01108991|Experimental|Physical activity self-management|Cognitive behavioral counseling to increase lifestyle physical activity delivered over five months plus six weeks of COPD self-management education and usual care
89341157|NCT01102283||Stent Group|
89341158|NCT03944291|Active Comparator|Unilateral PNB|Unilateral Pudendal Nerve Block
89341159|NCT03944291|Active Comparator|Bilateral PNB|Bilateral Pudendal Nerve Block
89341160|NCT03950297|Experimental|609A group|Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6; Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6;
89341161|NCT03265301|Other|Office hysteroscopy|
89341162|NCT03265301|Other|Conventional hysteroscopy|
89341163|NCT03165071|Experimental|ACT-132577 (50 mg)|8 healthy subjects and 8 subjects with severe renal function impairment will receive a single oral dose of 50 mg ACT-132577 administered as capsule following an overnight fast
89341164|NCT03019367|Active Comparator|Umbilical cord milking UCM|Milking the umbilical cord 4 times towards the infant at a speed of 20cm/2seconds.
89341165|NCT03019367|Active Comparator|Delayed cord clamping DCC|Delayed clamping of the umbilical cord for at least 60 seconds.
89341166|NCT05627609|Experimental|Participants with high Vitamin D genotype risk score|
89341167|NCT05627609|Experimental|PArticipants with low Vitamin D genotype risk score|
89341168|NCT03944135|Experimental|Experimental group|The sample consisted of 40 people: 20 in an experimental group. There were 5 men and 15 women.
89341169|NCT03944135|Active Comparator|Control group|The sample consisted of 40 people: 20 in a control group. There were 5 men and 15 women.
89341170|NCT01109225|Experimental|Myocardial infarction|"All patients. Patients hospitalized for a first myocardial infarction with known shift of the segment ST revascularized in acute phase by primary angioplasty and dated less than 4 days.~Intervention:~blood sample~MRI~echocardiography~urine sample~pulmonary echography~vascular check~renal echography"
89341171|NCT03950063||Patients with Cutibacterium acnes bone infections|Patients with Cutibacterium acnes orthopedic material infections
89341172|NCT03949751|No Intervention|Control group|The participants of the control group will not get the local therapy in the investigator's preoperative consultation but they will need to give written consent for taking swabs for culture samples pre- and intraoperative.
89341173|NCT03949751|Experimental|Therapy group|30 patients will get Acne Crème Plus (Benzoylperoxid and Miconazolnitrat) to apply until operation (on average 7 days) after receiving written consent. The application should be done daily in the evening on the planned operative side covering the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae.
89341174|NCT01109303|Active Comparator|TightRope System|Patients are operated on using the TightRope implant by Arthrex.
89341175|NCT01109303|Active Comparator|Screw fixation implant|Patients are operated on using the rigid four-cortices 3,5 mm screw fixation by Synthes.
89341176|NCT01102361|Experimental|Transperineal Biopsy|Biopsy of the prostate using transperineal approach
89341177|NCT03944213||MDD patients|
89341178|NCT03944213||Healthy controls|
89341179|NCT01102439|Active Comparator|Standard dose clopidogrel|300 mg Loading x 1 day, 75 mg/d x 13 days
89341180|NCT01102439|Experimental|Double dose clopidogrel|600 mg Loading x 1 day, 150 mg/d x 6 days, 75 mg/d x 7 days
89341181|NCT01102439|Active Comparator|Standard dose aspirin|Aspirin 81mg/d x 14 days
89341182|NCT01102439|Experimental|High dose aspirin|Aspirin 325 mg/d x 14 days
89341183|NCT03943979|Sham Comparator|Active Control group|This group will receive CT and sham tDCS each day, for four days.
89341184|NCT03943979|Active Comparator|Active group|This group will receive both CT and tDCS, each day, for four days.
89341185|NCT01585181|Placebo Comparator|Placebo|
89341186|NCT01585181|Experimental|PXVX0200|
89341187|NCT01102517|Experimental|VATS group|video-assisted thoracoscopic surgery
89341188|NCT01102517|Other|axillary thoracotomy|Control group
88811793|NCT05236634|Active Comparator|Group C|Forty patients with LUTS due to BPH will be given combined therapy(tamsulosin 0.4 mg and tadalafil 5 mg) for 12 weeks.
88811794|NCT05236322||study group|Removal by soft tissue laser of the tumor
88811795|NCT05236322||control group|Removal by ordinary surgical scalpel
89341189|NCT03949985||Estrogenic contraceptive users|
89341190|NCT03949985||Non-estrogenic contraceptive users|
89341191|NCT01109459|Experimental|Pediatric vision screening|intervention
89341192|NCT01109459|Active Comparator|Pediatric blood pressure screening|control
89341193|NCT01109459|No Intervention|Primary care providers observation only|Observational
89341194|NCT04321252|Experimental|Cohort A1: 10.5 mg/placebo|Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.
89341195|NCT04321252|Experimental|Cohort A2: 30 mg/placebo|Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.
89341196|NCT04321252|Experimental|Cohort A3: 75 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
89341197|NCT04321252|Experimental|Cohort A4: 120 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
89341198|NCT04321252|Experimental|Cohort A5: 210 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
89341199|NCT04321252|Experimental|Cohort B1: 60 mg/placebo, every 24 hours (q24h) × 5 days|Multiple iv bolus doses of KAE609 or placebo administered at the clinical site by the study personnel.
89341200|NCT04321252|Experimental|Cohort B2: 120 mg/placebo, every 24 hours (q24h) × 5 days|Multiple iv infusion doses of KAE609 or placebo administered at the clinical site by the study personnel.
89341201|NCT01584791|Experimental|clopidogrel napadisilate + aspirin|
89341202|NCT01584791|Active Comparator|clopidogrel bisulfate + aspirin|
89341203|NCT03471208|Experimental|Dynamic Navigation|Dental implant surgery via dynamic navigation assistance
89341204|NCT03471208|Active Comparator|Freehand|Dental implant surgery via conventional freehand
89341205|NCT04285684|Other|Ketamine, lactation|Lactating women--4 subjects, 2 dosage format: ketamine 0;5mg/kg and 1.0mg/kg IM at least 5 days apart.
89341206|NCT03473002|Placebo Comparator|Placebo|One dose of placebo (0.9% Sodium Chloride) intranasally, n=4
89341207|NCT03473002|Experimental|SeVRSV|1 x 10^7 EID50 (one dose) of SeVRSV vaccine intranasally, n=16
89341208|NCT03469726|Other|Patients with (suspected) PDAC|"Patients with (suspected) pancreatic cancer will undergo additional Contrast-enhanced Diffusion-weighted MRI (CE-DW-MRI) within two weeks from the CECT.~Suspected liver lesions on CECT and/or CE-DW-MRI will be biopsied to obtain histopathology as reference standard. For liver lesions without histopathologic proof of metastases a paired follow-up CECT and CE-DW-MRI serve as a composite reference standard. Follow up CECT and CE-DW-MRI will be performed in all patients at 3, 6, and 12 months."
89341209|NCT04836754||Case group|Pregnant women with Covid-19
89341210|NCT04836754||Control groups|Pregnant women who do not have Covid-19
89341211|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 1)|Participants (n=330) aged 18-40 years old will received OCV-S (Lot 1) according to 0-2 week schedule.
89341212|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 2)|Participants (n=330) aged 18-40 years old will received OCV-S (Lot 2) according to 0-2 week schedule.
89341213|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 3)|Participants (n=935) aged 1-40 years old will received OCV-S (Lot 3) according to 0-2 week schedule.
89341214|NCT04760236|Active Comparator|Shanchol™ group|Participants (n=935) aged 1-40 years old will received Shanchol™ according to 0-2 week schedule.
89341215|NCT04457128|Experimental|Secular Image|Secular Image
89341216|NCT04457128|Experimental|Non-secular image|non-secular images
89341217|NCT04457128|Experimental|Secular message|secular messages
89341218|NCT04457128|Experimental|Non-secular message|non-secular messages
89341219|NCT04103788|Active Comparator|95% Curcuminoid Powder|Curcumin powder standardized to >95% curcuminoids, single dose, used to determine standard absorptivity of unformulated powder.
89341220|NCT04103788|Experimental|CurQ+|Highly absorbed curcumin coconut oil emulsion, single dose, used to produce serum samples for analytical comparison of sample preparation methodologies.
89341221|NCT01598116||Hemangioma|Identify biomarkers in children with hemangiomas.
89341222|NCT01598116||Without Hemangioma|Age-matched controlled group without hemangioma.
89341223|NCT03433677|Experimental|LY900014|100 units per milliliter (U/mL) LY900014 administered by individualized, continuous, subcutaneous insulin infusion (CSII)
89341224|NCT03433677|Experimental|Insulin Lispro|100 U/mL insulin lispro (Humalog®) administered by individualized CSII
89341225|NCT02492711|Experimental|Margetuximab plus chemotherapy|Margetuximab 15 mg/kg every 21 days
89341226|NCT02492711|Active Comparator|Trastuzumab plus chemotherapy|Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 21 days
89341227|NCT02492711|Experimental|Margetuximab Infusion Sub-study|Margetuximab 15 mg/kg every 21 days (with or without chemotherapy), studying a shorter duration of infusion beginning in Cycle 2.
89341228|NCT03718689|Experimental|Group L|The second group of teeth (Group L) were etched with Er:YAG laser.
89341229|NCT03718689|Experimental|Group A+L|The third group of teeth (Group A+L) were etched with both Er:YAG laser and phosphoric acid.
89341230|NCT03718689|No Intervention|Group A|The first group of teeth (Group A) were not etched with Er:YAG laser.
89341231|NCT03716505|Active Comparator|gammaCore Sapphire active|"Treatment 3 times per day, every day for the 12-week treatment period~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
89341232|NCT03716505|Sham Comparator|gammaCore Sapphire Sham|"Treatment 3 times per day, every day for the 12-week treatment period~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
89341233|NCT03716427|Experimental|Active Treatment- CT1812 560 mg|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole)
89341234|NCT02476487|Experimental|FDG PET CT|FDG PET CT
89341235|NCT03943433|Active Comparator|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration at specific time points.
89341236|NCT03943433|Experimental|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration at specific time points.
89341237|NCT01147822|Experimental|Pazopanib|800 mg administered once daily orally continuous dosing
89341238|NCT01147822|Active Comparator|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
89341239|NCT03431337|Experimental|High dose|Amoxicillin/clavulanate 875mg/125mg & amoxicillin 875 mg twice a day x 7 days
89341240|NCT03431337|Active Comparator|Standard dose|Amoxicillin/clavulanate 875 mg/125mg & placebo (lactase) twice a day x 7 days.
89341241|NCT01428791|Active Comparator|Generations older adult member program|Rush Generations is a membership program for older adults, providing chronic disease prevention and management through educational programming, civic engagement, and individual and family consultations with social work staff.
89341242|NCT01428791|Experimental|BRIGHTEN Heart Virtual Team|BRIGHTEN Heart provides older adults with an interdisciplinary team evaluation of physical and mental health and on-going support for mental health and health behavior change for a minimum of six months. The five core components of the BRIGHTEN intervention consist of: 1) Assessment; 2) Virtual team case review; 3) Patient centered action planning; 4) Plan implementation, and; 5) When indicated, short-term evidence-based geriatric specialty psychotherapy.
89341243|NCT01364363|Other|Total Body Irradiation/VP16|Acute Leukemias, Myelodysplastic syndromes
89341244|NCT01364363|Other|Cytoxan/Total Body Irradiation|Chronic Leukemias, Bone Marrow Failure States, Lymphomas, Hodgkin's Disease
89341245|NCT01364363|Other|Busulfan/Cytoxan|Acute Leukemia, Myelodysplastic syndromes, Chronic Leukemias, Bone Marrow Failure states
89341246|NCT01364363|Other|BEAM (BCNU, etoposide, Ara-C, melphalan)|Lymphomas, Hodgkin's Disease
89341247|NCT01364363|Other|Total Lymphoid Irradiation|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
89341248|NCT01364363|Other|Cladribine/Melphalan|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
89341249|NCT01364363|Other|FLAG (fludarabine, Ara-C, G-CSF)|For patients undergoing a second allogeneic transplant
89341250|NCT03738241|Experimental|Arm 1|Participants will have prior administration of 2013 A/H7N9 IIV with MF59. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
89341251|NCT03738241|Experimental|Arm 2|Participants will have prior administration of 2013 A/H7N9 IIV with AS03. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
89341252|NCT03738241|Experimental|Arm 3|Participants will have prior administration of 2013 A/H7N9 IIV 15 mcg or 45 mcg unadjuvanted. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
89341253|NCT03738241|Experimental|Arm 4|Participants will have prior administration of 2013 A/H7N9 IIV + MF59 or AS03 (1st) then 2013 A/H7N9 IIV 15 mcg (2nd). Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
89341254|NCT03738241|Experimental|Arm 5|Participants who are A/H7 IIV-Naïve. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
89341255|NCT03746704|Experimental|89Zr˗DFO˗REGN3504|Part A: Cohorts 1-3 Part B
89341256|NCT01111643||I|
89341257|NCT03720015|Experimental|Concurrent training|Three sessions per week of concurrent training during radiotherapy period. Each session will begin with warm-up (5-min cardiovascular activity at low-moderate intensity, joint mobility and one set of resistance exercises circuit at 30-40% 1RM). Resistance training will follow the warm-up, including 9 standard exercises involving major muscle groups of the lower and upper body: vertical bench press, parallel bar dip for triceps, seated rowing, standing dumbbell curl for biceps, leg press, deadlift and shoulder press. All these exercises will be realized following circuit training with 4 sets of 8-12 repetitions, using a training load of 70-80% RM. When patient will able to complete more than 12 repetitions, load will be increased progressively 10%. Cardiovascular training will be completed 20-30 min after resistance training, and it will include High-Intensity Interval Training (HIIT) of 3 min near to the second ventilatory threshold and 2 min near to the first ventilatory threshold.
89341258|NCT03720015|Experimental|Nutritional management|Prescribed diet controlling macronutrients according to patient body weight (~4g/kg/day for carbohidrates, ~2g/kg/day for proteins, and ~1g/kg/day for fats). Patient will take one single dosage per day of probiotics (Arkoprobiotics® Defenses), 1 or 2 capsules of omega-3 fish oil concentrate (Solgar®, 600-1200mg depending on fat sources intake during the day), and a combine ingestion of 3g beta-hydroxybeta-methylbutyrate (HMB), 14g arginine, and 14g glutamine (HSN Raw Series®, all pure ingredients and making the ingestion adding each of them individually in a solution with 300-400 ml of water). During concurrent training sessions, between resistance exercise and HIIT, patient will also take 6g of BCAA's (HSN Raw Series®, 2:1:1) along with a banana. Additionally, patient could take whey isolated protein (Amix® IsoPrime CFM) to meet with some of the prescribed proteins intakes.
89341259|NCT03942809|Experimental|Effectiveness|Evaluate the Effectiveness in insertion success, insertion times, influence of respiratory, cardiac and cerebral circulation
89341260|NCT03718611|Experimental|Sequence 1|BR900A - Wash out - BR9001
89341261|NCT03718611|Experimental|Sequence 2|BR9001 - Wash out - BR900A
89341262|NCT01111721|Experimental|Project POWER Intervention Group|Intervention group participants will attend the Project POWER intervention sessions, complete a pre-intervention assessment and participate in 3, 6, and 12 month follow-up interviews when they will be asked to provide urine specimens for STI testing. The intervention consists of eight bi-weekly, 1.5 hour sessions. Intervention group participants will also attend one booster group session four weeks after the intervention before being released. Intervention participants will receive booster phone calls from a nurse-interventionist at 2, 6, and 10 weeks after release from prison. Booster phone calls will reinforce intervention content and support participant efforts to reduce risky sex behaviors and make healthy choices.
89341263|NCT01111721|Active Comparator|NC DOC Standard of Care for STIs|Control group participants will receive the North Carolina Department of Correction standard of care for Sexually Transmitted Infections, complete one interview in prison and participate in 3, 6, and 12 month follow up interviews when they will be asked to provide urine specimens for STI testing.
89341264|NCT03469570|Experimental|Assisted Fluid Management|
89341265|NCT03430245|Experimental|VelaShape III & UltraShape Power|VelaShape III treatment with radiofrequency, infrared and massage combined with UltraShape Power treatment, using pulsed, focused ultrasound treatment.
89341266|NCT05158660|Experimental|patients assessed by transcranial duplex sonography|
89341267|NCT01111799|Experimental|Clomiphene citrate + IUI + endometrial biopsy|Clomiphene citrate + IUI + endometrial biopsy
89341268|NCT01111799|No Intervention|Clomiphene citrate + IUI|
89341269|NCT01111799|Experimental|gonadotrophines + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
89341270|NCT01111799|No Intervention|gonadotrophines + IUI|
89341271|NCT01111799|Experimental|natural cycle + IUI + endometrail biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
89341272|NCT01111799|No Intervention|natural cycle + IUI|
89341273|NCT01293097|Active Comparator|Intensive statin therapy|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
89341274|NCT01293097|Other|Usual care|Usual care, but statin dose should not be higher than that described in exclusion criteria.
89341275|NCT05626517||National Heart Centre Singapore|At NHCS, patients who have undergone either CTCA or CT CAC scan within past 6 months will be identified. All the consented participants will have a one-off retinal imaging performed at the respective institution by the trained study team member, which should take approximately 15-20 minutes to complete. 3 to 4 questionnaires will also be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire), depending patient's gender and literacy. Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function questionnaire. Participants have the option to not complete sthe whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
89341276|NCT05626517||Singapore Eye Research Institute|At SERI, patients who are found to be at high risk for vision threatening diabetic retinopathy will be identified. All the consented participants will have a one-off retinal imaging performed at the respective institution by the trained study team member, which should take approximately 15-20 minutes to complete. 3 to 4 questionnaires will also be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire), depending patient's gender and literacy. Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function questionnaire. Participants have the option to not complete sthe whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
89341277|NCT03853447||Diagnostic imaging|"The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including~Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM.~Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP.~Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria."
89341278|NCT03516292||OAB-POP group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
89341279|NCT03516292||POP only group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
89341280|NCT01291615|Experimental|Gemcitabine group|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
89341281|NCT01291615|Experimental|S-1 group|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks
89341282|NCT03849079|Experimental|Hyponut|
89341283|NCT01112033||chronic HCV infection|The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.
89341284|NCT01295047|Active Comparator|ATENOLOL|ATENOLOL 75MG FOR 4 WEEKS
89341285|NCT01295047|Active Comparator|VERAPAMIL|240MG VERAPAML FOR 4 WEEKS
89341286|NCT01295047|Active Comparator|PERINDOPRIL|4MG PERINDOPRIL FOR 4 WEEKS
89341287|NCT05158504|Experimental|Motivation|Motivational notifications were sent to the nurses in the motivational group (n=30) via SMS messages to their mobile phones at 07.00, 12.00 and 16.00 for 21 days. Like a good morning message that allows you to start the day with a beautiful energy (Example: Thank you for the hard and selfless work you do every day. We love and appreciate angels like you and you. Good morning). Motivational notifications sent to the participants were prepared each day to be different from the previous day. Data were obtained with the Individual Introduction Form, Job Satisfaction, Compassion Fatigue and Communication Skills Scale.
89341288|NCT05158504|No Intervention|Control|Motivational notifications were not sent to the nurses in the control group (n=30) and they continued their routine work in the emergency room. only pretest and posttest were applied. Data were obtained with the Individual Introduction Form, Job Satisfaction, Compassion Fatigue and Communication Skills Scale.
89341289|NCT01207349||close follow-up by nurse|close follow-up by nurse : patients were visited each tree months
89341290|NCT01207349||standard follow up|stantdard follow up at one year
89341291|NCT03461289|Experimental|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
89341292|NCT03472846|Active Comparator|Group 1 - DMAB|postmenopausal women without type 2 diabetes mellitus treated with denosumab
89341293|NCT03472846|Active Comparator|Group 2 - TPTD|postmenopausal women with type 2 Diabetes mellitus treated with teriparatide
89341294|NCT03472846|Active Comparator|Group 3 - DMAB|postmenopausal women with type 2 diabetes mellitus treated with denosumab
89341295|NCT03472846|Active Comparator|Group 4 - TPTD|postmenopausal women without type 2 diabetes mellitus treated with teriparatid
89341296|NCT01190371|Other|Artesunate|Confirmation of artemisinin tolerance
89341297|NCT01109537||RLS Diagnosis|
89341298|NCT01109537||Healthy Controls|
89341299|NCT05158426||propofol susceptibility group|patients undergoing gastrointestinal endoscopy
89341300|NCT03949595||cases|women suffering from severe/massive obesity
89341301|NCT01293175|Experimental|Whole grains|Subjects will consume whole grains every day for two months
89341302|NCT01293175|No Intervention|Control|Subjects will consume their habitual diet
89341303|NCT01112111||75 PCOS Patients - step up regime|Group A will be comprised of 75 patients and these will receive a low dose step stimulation regime
89341304|NCT01112111||75 PCOS patients -step down regime|Group B will be comprised of 75 patients who will receive a step down regime of stimulation
89341305|NCT01112111||75 PCOS patients - sequential regime|Group C will be comprised of 75 patients who will be treated using a sequential stimulation regime
89341306|NCT05158348|Active Comparator|Group A|receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine.
89341307|NCT05158348|Active Comparator|Group B|receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine
89341308|NCT05158348|Active Comparator|Group C|receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.
89341309|NCT03852823|Experimental|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
89341310|NCT01112189|Experimental|Patients with stem cells|Patients that receive the stem cells treatment
89341311|NCT01112189|Active Comparator|Compressed sleeve treatment|Patients that will receive the compressed sleeve treatment
89341312|NCT05158192|Experimental|Diosmin/Hesperidin (90/10) Test Product|Participants received one tablet of the test formulation containing Diosmin/Hesperidin (90/10) 500 mg. The tablets was taken with water and in a fasting condition.
89341313|NCT05158192|Active Comparator|Diosmin/Hesperidin (90/10) Reference Product|Participants received one tablet of the marketed reference formulation containing Diosmin/Hesperidin (90/10) 500 mg. The tablets was taken with water and in a fasting condition.
89341314|NCT03716193|Experimental|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
89341315|NCT03716193|Experimental|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
89341316|NCT03716193|Experimental|Cohort 3|Patients who will receive palliative radiation (+/- concurrent systemic therapy) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
89341317|NCT03716193|Experimental|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
89341318|NCT01187719|No Intervention|Control|ARV prophylaxis for PMTCT follows national guidelines.
89341319|NCT01187719|Experimental|phenytoin interaction|ARV prophylaxis for PMTCT follows national guidelines + start phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
89341320|NCT01207505|Experimental|Enchancing Emotion Regulation|12 week group 3 week modules: 1) Mindfulness 2) Emotion Regulation 3) Distress Tolerance
89341321|NCT03472690|Experimental|Active|0.1 mL, self-administered subcutaneous injection, every second day
89341322|NCT03472690|Placebo Comparator|Placebo|0.1 mL, self-administered subcutaneous injection, every second day
89341323|NCT01102595|Experimental|1: Temozolomide plus Radiation|"Group 1:~Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy).~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
89341324|NCT01102595|Experimental|2: Temozolomide plus Radiation plus Bevacizumab|"Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles + bevacizumab 10 mg/kg every 15 days.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy) + bevacizumab 10 mg/kg every 15 days.~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
89341325|NCT01187797|Experimental|Intervention|
89341326|NCT05158036|Active Comparator|Classic massage group|Classical massage will be applied to the lumbal and abdominal region 5 days a week, from the estimated date of ovulation until the next menstrual bleeding begins. The application will take approximately 15 minutes. During the massage, the physiotherapist will apply stroking and kneading movements by using baby oil. During the treatment of the lumbal region, the patient will be in the prone position; during the treatment of the abdominal region, the patient will be in the supine position.
89341327|NCT05158036|Active Comparator|Connective tissue massage group|Connective tissue massage will be applied to the lumbosacral, lower thoracic, abdominal and anterior pelvic regions 5 days a week, from the estimated date of ovulation until the onset of the next menstrual bleeding. The application will take approximately 15 minutes. During the massage, the physiotherapist will bring the tip of the middle finger of the hand into contact with the patient's skin and apply traction to the skin. During the treatment of the lumbar region, the patient will be in the sitting position, during the treatment of the abdominal and anterior pelvic region, the patient will be in the supine position.
89341328|NCT01191619|Experimental|McIvor group|groups in which proseal laryngeal mask airway is inserted with McIvor retractor.
89341329|NCT03888742||ADT Group|Participants received continue ADT treatment for at least more than 6 months
89341330|NCT03888742||RRP Group|Participants have radical prostatectomy performed more than 6 months ago.
89341331|NCT03848611|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
89341332|NCT01584869|Experimental|capsule endoscopy|
89341333|NCT03469414||Wheelchair Mobility and Speed|This group will participate in activity-based measures employed in routine occupational and physical therapy practice to assess participants' wheelchair speed, maneuverability, and endurance. These measures include: the Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, and PART-O.
89341334|NCT03469414||GPS Tracking|A GPS tracker will be placed on the wheelchairs of 25 individuals who consent to participate in this arm of the project. Using a GPS tracker will provide a direct measure of the community locations these participants go. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
89341335|NCT05671549|Active Comparator|Chronic Closed-Lock|The participants will be enrolled in this group regarding the duration (longer than three months) of their symptoms. The allocated participants will undergo one session of the arthrocentesis procedure. The prefabricated occlusal stabilization splints will be applied. The participants' preoperative, postoperative immediate, and postoperative seventh-day pain intensities and maximum mouth-opening amounts will be recorded and analyzed.
89341336|NCT05671549|Active Comparator|Acute Closed-Lock|The participants will be enrolled in this group regarding the duration (shorter than three months) of their symptoms. The allocated participants will undergo one session of the arthrocentesis procedure. The prefabricated occlusal stabilization splints will be applied. The participants' preoperative, postoperative immediate, and postoperative seventh-day pain intensities and maximum mouth-opening amounts will be recorded and analyzed.
89341337|NCT03452943|Experimental|TEV-50717|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 12 weeks
89341338|NCT03452943|Placebo Comparator|Placebo|Placebo matched to TEV-50717 BID for a total of 12 weeks
89341339|NCT01584947|Placebo Comparator|Placebo lozenge|The patients will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards they start another two weeks treatment with the opposite type of lozenge from the first treatment period.
89341340|NCT01584947|Active Comparator|Bupivacaine lozenge|The patient will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards the patient starts another two weeks treatment with the opposite type of lozenge from the first treatment period.
89341341|NCT03848767|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
89341342|NCT04457908|Other|intelligent|receive the neurological function assessment by artificial intelligence
89341343|NCT04457908|No Intervention|manual|receive the neurological function assessment by doctor
89341344|NCT01109615|Experimental|Chemotherapy|
89341345|NCT01293253|Experimental|Stair walking|Participants of this group is encouraged to use the stairs for 10 minutes a day at the workplace
89341346|NCT01293253|Active Comparator|Control|Receives a health examination before and after the intervention period, and are advised to stay active
89341347|NCT01209065|Experimental|Part A|Approximately 12 subjects will be enrolled. In the first treatment period, all subjects will receive GSK1349572 50 mg every 24 hours for 5 days. In Period 2, subjects will receive GSK1349572 50 mg every 24 hours in combination with fosamprenavir 700 mg plus ritonavir 100 mg every 12 hours for 10 days. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
89341348|NCT01209065|Experimental|Part B|Approximately 15 subjects will be enrolled and receive three single doses of GSK1349572 approximately one week apart. One will be the current tablet formulation containing micronized drug substance and 2 will be new tablet versions, one containing unmicronized drug substance and one containing an intermediate particle size drug substance. Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
89341349|NCT01193803||Spondylodiscitis control group|Patients needing vertebral biopsy looking for tumoral etiology
89341350|NCT01193803||Prosthetic Joint Infection control group|Patients with primary prosthetic arthrosis surgery
89341351|NCT01193803||Septic arthritis control group|Arthrosic patients needing evacuating articular punction with leucocytes infiltration less than 1000 /mm3
89341352|NCT01193803||Spondylodiscitis case group|Patients suspected of Discitis and/or Vertebral Osteomyelitis is defined by the need of spinal biopsy in infectious context.
89341353|NCT01193803||Prosthetic Joint Infection case group|Patients suspected of Prosthetic Joint Infection defined by the need of surgical revision for diagnostic or therapeutic aiming in infectious context.
89341354|NCT01193803||Septic arthritis case group|Patients suspected of Septic arthritis without prosthesis were defined by the need of synovial punction and/or biopsy
89341355|NCT02782702|Experimental|Botulism Toxin treatment|Injection of 50 UI Botulism toxin for the treated zone
89341356|NCT01102673|Experimental|PF-04991532|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
89341357|NCT01102673|Placebo Comparator|Placebo|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
89341358|NCT03481725|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
89341359|NCT03481725|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
89341360|NCT01293331||Study Cohort (Case )|Participants will be examined for fever in dengue endemic regions
89341361|NCT01209221|Experimental|1|
89341362|NCT01209221|Experimental|2|
89341363|NCT01209221|Placebo Comparator|3|
89341364|NCT01209221|Placebo Comparator|4|
89341365|NCT05157334|Experimental|Deep breathing|"Sub-project 1: To compare the effect of one session of DB and one session of non-invasive auricular tVNS on vagal nerve tone measured by HRV in healthy participants and in patients with RA and SLE.~Sub-project 2: A dose-response study in healthy participants comparing the effect of 5, 15 and 30 minutes of DB on HRV.~Sub-project 3: To investigate the effect of the optimal dose found in sub-project 2 in patients with RA and SLE measured by HRV, and to investigate its reproducibility by doing it twice."
89341366|NCT03719781||Group1|patients undergoing pituitary tumor removal surgery will be tested with standardized minimental testing.
89341367|NCT03850717||Traditional Chinese Acupuncture|"Use traditional acupuncture, stronger, deeper, harder-acupuncture"
89341368|NCT03850717||Japanese Acupuncture|"Use traditional shallow, lighter acupuncture, softer-acupuncture"
89341369|NCT03472456||Articaïne|
89341370|NCT03472456||Eugénol|
89341371|NCT01209377|Experimental|standard|EMDR treatment with bilateral stimulation via eye movement
89341372|NCT01209377|Experimental|fixed|EMDR treatment with eyes fixed
89341373|NCT01209377|Experimental|no focus|trauma exposition without external stimulus
89341374|NCT01193881|Experimental|Treatment (erlotinib, RO4929097)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89341375|NCT02529605|Active Comparator|Product B® IsaGenesis®, Then IsaGenesis®|Participants will come into the clinic in a fasting state to receive the Product B® IsaGenesis®, which will be a one time dose of the liquid-gel formulation contained in 2 capsules, 1280 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the IsaGenesis®. This will be given for a comparison in a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule.
89341376|NCT02529605|Active Comparator|IsaGenesis®, Then Product B® IsaGenesis®|Participants will come into the clinic in a fasting state to receive the IsaGenesis®, which will be a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the Product B® IsaGenesis®. This will be given for a comparison in a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
89341377|NCT01194037|Experimental|Hanferon (low dose) sc weekly + RBV oral daily|
89341378|NCT01194037|Experimental|Hanferon (high dose) sc weekly + RBV oral daily|
89341379|NCT01194037|Active Comparator|Pegasys 180 ug sc weekly + RBV oral daily|
89341380|NCT01295203|No Intervention|Control group|The control group were not given access to the intervention website and received no additional information.
89341381|NCT03480243|Experimental|Padsevonil and Erythromycin|"Treatment Period 1 (Day 1 to Day 11):~Padsevonil 100 mg twice daily (bid) on Day 1 to Day 4~Padsevonil 100 mg single dose on Day 5~1 week of wash-out (from evening of Day 5 to Day 11)~Treatment Period 2 (Day 12 to 22):~Padsevonil 100 mg twice daily (bid) on Day 12 to Day 15~Padsevonil 100 mg single dose on Day 16~1 week of wash-out (from evening of Day 16 to Day 22)~Treatment Period 3 (Day 23 to Day 38):~Erythromycin 500 mg twice daily (bid) on Day 23 to Day 25~Padsevonil 100 mg bid and erythromycin 500 mg bid on Day 26 to Day 32~Padsevonil 100 mg single dose on Day 33~Erythromycin 500 mg twice daily (bid) on Day 33 to Day 36~Erythromycin 500 mg single dose on Day 37"
89341382|NCT01109693|Active Comparator|Continue sertraline|Continue sertraline at the dosage at 3 weeks
89341383|NCT01109693|Active Comparator|Augment with mirtazapine|Add mirtazapine to sertraline
89341384|NCT01109693|Active Comparator|Switch to mirtazapine|Stop sertraline and switch to mirtazapine
89341385|NCT03850405|Experimental|Chocolate|20 patients (matched per gender) undergoing a diet which includes 25g of dark chocolate (70%), i.e. ca. 145 kcal per day
89341386|NCT03850405|No Intervention|Control|20 patients (matched per gender) undergoing a low-fat dietary regimen
89341387|NCT01190683|Active Comparator|cholecalciferol|cholecalciferol 60,000IU/week for first eight weeks followed by 60,000 IU every 15 days for four months along with calcium placebo
89341388|NCT01190683|Active Comparator|Calcium carbonate|two tablets of calcium carbonate daily equivalent to 1 gm of elemental calcium for six months along with vitamin D placebo
89341389|NCT01190683|Active Comparator|oral calcium and cholecalciferol|60,000 IU of cholecalciferol every week for ist eight week and then 60,000IU every 15 days for next four months along with 1 gm of elemental calcium ever day for six months
89341390|NCT01190683|Placebo Comparator|lactose|identical placebos
89341391|NCT03949439||Non-Frail|non-frail (frailty score 1~3) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
89341392|NCT03949439||Pre-Frail|Pre-frail (frailty score 4) according to their CFS. Established diagnosis of cardiovascular disease (myocardial infarction, valve regurgitation or stenosis) determined by previous electrocardiogram and/or Doppler echocardiography, and all had surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair). Patients with prior neurological/muscular disease (previous stroke or muscular dystrophies), cognitive impairment resulting from previous injury, frailty score ≥ 5, non-elective/emergency surgery procedures or incomplete data were excluded.
89341393|NCT01293409|Placebo Comparator|Placebo|The amount of photic energy of light is considered to be non-therapeutical
89341394|NCT01293409|Experimental|Intermediate dose|"The amount of photic energy of bright light is considered to be intermediate"
89341395|NCT01293409|Experimental|High dose bright light|The amount of photic energy of bright light is considered to be fully therapeutic
89341396|NCT03943199|Active Comparator|Metamizole sodium|1 gram intravenous, will be diluted in 0.9% physiological solution of 100 ml, applied for 30 minutes
89341397|NCT03943199|Active Comparator|Ketorolac|60 milligrams intravenously, it will be added to 20 ml with 0.9% physiological solution, it will be applied for 5 minutes
89341398|NCT03943199|Active Comparator|Lysine Clonixinate|100 milligram intravenously, diluted in 5% glucose solution of 100 ml, applied for 30 minutes
89341399|NCT03943199|Placebo Comparator|Placebo|20 milliliters of 0.9% physiological solution, will be applied for 5 minutes.
89341400|NCT01190761|Experimental|A|Galantamine 4 mg Tablet, single dose
89341401|NCT01190761|Active Comparator|B|Reminyl 4 mg Tablet, single dose
89341402|NCT01209455|No Intervention|Saline|Volunteers will receive an incremental rising dose infusion of IA NAC (6 doses) together with a co-infusion of normal saline to determine a dose response curve for arterial vasodilatation in the forearm.
89341403|NCT01209455|Active Comparator|Histamine antagonists|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of histamine antagonists (H1 and H2 antagonists) to determine vasodilatation in response to NAC in the presence of histamine antagonists.
89341404|NCT01209455|Active Comparator|Low dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of low dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
89341405|NCT01209455|Active Comparator|High dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of higher dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
89341406|NCT01295359|Experimental|Trained Group|This group will receive the usual care of the hospital and a ground walking training program associated with respiratory exercises.
89341407|NCT01295359|No Intervention|Usual Care Group|This group will only receive the usual care of the hospital, including physical therapy
89341408|NCT01328483|No Intervention|No Intrapartum Oropharyngeal (IP-OP) Suction|Neonates randomized to No IP-OP group received supportive treatment as per standard unit protocols. They were also assessed as vigorous or non-vigorous and received care according to NRP 2005.
89341409|NCT01328483|Experimental|Intrapartum Oropharyngeal (IP-OP) suction|The neonates randomized to IP-OP group were provided oropharyngeal suctioning at the delivery of head before the delivery of shoulder, using suction machine at a negative pressure of 100mm of Hg or Dee Lee's suction trap in the event of electricity failure or non availability of suction machine.Subsequently, all the neonates born through MSAF were assessed by pediatrician as vigorous or non vigorous and provided care as per NRP guidelines 2005.
89341410|NCT01102751||Vitamin D deficient females|(n =18, mean age 29.1±9.9 yrs)
89341411|NCT01102751||vitamin D sufficient healthy females|(control group; n = 19, mean age 28.5±5.2 yrs)
89341412|NCT01102751||genetically-determined hypophosphatemic rahitis|(n=13, mean age 26.5±15.1 yrs)
89341413|NCT03426345|Placebo Comparator|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
89341414|NCT03426345|Experimental|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 12 weeks.
89341415|NCT01194115|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for total of 6 doses; 500 mg metronidazole per oral every 8 hours for total of 6 doses
89341416|NCT01194115|Placebo Comparator|Placebo/standard of care|Placebo pills per oral every 8 hours for total of 6 doses
89341417|NCT03942341||Adult subjects with Down syndrome and Alzheimer Disease|"Patients will be included from the 6 centers of the Horizon 21 european consortium. Horizon 21 consortium consists of DS cohorts from Spain (the Down Alzheimer Barcelona Neuroimaging Initiative -DABNI). France (the TriAl 21 at Jérôme Lejeune Institute in Paris), the UK (The LonDowns consortium and Dementia in Down's Syndrome (DiDS) in Cambridge), the Netherlands (the Rotterdam DS cohort) and Germany (AD21 in Munich), with a combined total of more than 1,000 older participants with DS to pool data and bioresources to address current gaps in knowledge about AD in DS.~All participants will be included after obtaining a written informed consent approved by the ethics committee. A total of 90 DS subjects with AD dementia of both sexes and good general condition will be included. The presence of a family member will be required as well as a sufficient visual and hearing acuity."
89341418|NCT01194193|Experimental|1|
89341419|NCT01207661|Experimental|Mesenchymal Injection|Intra Articular injection in Patients with osteoarthritis of knee joint
89341420|NCT01190917|Active Comparator|Cognitive Behavioral Therapy Group|
89341421|NCT01190917|Active Comparator|Social Play Group|
89341422|NCT05626283|Active Comparator|lumbar disc prolapse group|46 patients diagnosed as having symptomatic lumbar disc prolapse
89341423|NCT05626283|Placebo Comparator|Control|46 age and sex matched healthy controls
89341424|NCT03847363||general anesthesia|patients underwent general anesthesia
89341425|NCT03847363||general and epidural anesthesia|patients underwent general and epidural anesthesia
89341426|NCT03847363||general anesthesia combined with nerve block|patients underwent general anesthesia combined with nerve block
89341427|NCT01209611|Experimental|Autologous bone marrow mononuclear cells|Patients received autologous MNC transplantation. Bone marrow aspirates are harvested from the anterior iliac crest of the patients under general or local anesthesia. MNCs are isolated by density gradient centrifugation. The cell suspension was adjusted to a final volume of 6-20 ml with saline. The cell suspension was injected into expanded skin intradermally via a 27-gauge needle (approximately 0.5-1×10^6 cells/cm2).
89341428|NCT01209611|Placebo Comparator|Saline|Patient has intradermally and subcutaneously injection of saline.
89341429|NCT01191931||prostate cancer|Patients with histologically proven prostate cancer (positive biopsy) and who are planned to undergo radical prostatectomy.
89341430|NCT03942575|No Intervention|No negative pressure wound therapy|Historical cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage and where negative wound pressure therapy has been omitted
89341431|NCT03942575|Experimental|Negative pressure wound therapy|Prospective cohort: patients who underwent mastectomy with flap fixation using tissue glue and sutures and closed suction drainage with negative wound pressure therapy
89341432|NCT03714087|Experimental|T1 Conventional treatment before aligner|T1 before aligner: Conventional orthodontic treatment patients before the essix aligner
89341433|NCT03714087|Experimental|T2 After essix aligner|T2 after the aligner: Essix aligner appliance with setup for 3 weeks full time
89341434|NCT03714087|Active Comparator|Historic control group|Conventional orthodontic treatment without finishing protocol UdeA2
89341435|NCT03850327|Experimental|BIOMONITOR III|
89341436|NCT01207739|Active Comparator|Doxycycline|
89341437|NCT01207739|Active Comparator|Clarithromycin and hydroxychloroquine|
88811796|NCT01422161|Experimental|Botulinum Toxin commonly known as BOTOX®|Some subjects will receive BOTOX® injections. Subject will not be informed of what injection they received.
88811797|NCT01422161|Placebo Comparator|Placebo|Some subject will receive a safe Placebo injection. Subjects will not be informed of what injection they have received.
89341438|NCT01207739|Placebo Comparator|Placebo|
89341439|NCT01192009|Experimental|Immobilization and Leucine|
89341440|NCT01192009|Placebo Comparator|Immobilization and Placebo|
89341441|NCT03426267|Experimental|SDN-037|
89341442|NCT03426267|Placebo Comparator|vehicle|
89341443|NCT01296373||HIV-1-infected, off ART|HIV-1-infected, antiretroviral naive or off antiretroviral therapy for at least 12 months with CD4+ T-cell counts less than or equal to 350 cells/µL who are about to commence combination antiretroviral therapy
89341444|NCT05626127||Sun Yat-Sen Memorial Hospital of Sun Yat-sen University|The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the validation cohort.
89341445|NCT01194505|Active Comparator|ACL, sciatic, femoral, obturator|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
89341446|NCT01194505|Active Comparator|ACL, sciatic nerve block, posterior lumbar plexus block|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
89341447|NCT03412929|Experimental|Honey Impregnated Dressing|Honey Impregnated Dressing
89341448|NCT03941951|No Intervention|Pre-intervention Cohort|Cohort of patients who have received either empirical or targeted treatment with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2016 to December 2019 will be included.
89341449|NCT03941951|Other|Intervention cohort|Cohort of patients with complex infections treated with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2010 to June 2021.
89341450|NCT03941951|No Intervention|Safety cohort|Cohort of patients with bacteremia due to carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, carbapenem-resistant enterobacteria, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus occurred in participating hospitals from 2017 to 2021 will be collected.
89341451|NCT01190995|Experimental|Sucrose|The enrolled neonates will be administered a sterile solution of 24 % sucrose orally for a period of 7 days from enrollment The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure.
89341452|NCT01190995|Placebo Comparator|Placebo|The enrolled neonates will be administered double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
89341453|NCT01293487|Experimental|Arm 1|
89341454|NCT01293565||HED Affected Males|
89341455|NCT01293565||Male Controls|
89341456|NCT03847207|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 8 cohorts will be dosed. A single subcutaneous injection of HTL0030310 or placebo will be administered. In each cohort, 6 subjects will receive HTL0030310 and 2 subjects will receive placebo.
89341457|NCT03847207|Experimental|Part 2 Pasireotide PD Assessment|Sixteen subjects in 2 cohorts (8 subjects per cohort) will be dosed on 4 occasions. Within each cohort, 4 subjects will be randomised to active dosing with CRH with desmopressin, GHRH and OGTT challenge and 4 subjects will be randomised to placebo dosing with CRH with desmopressin, GHRH and OGTT challenge.
89341458|NCT03847207|Experimental|Part 3 Proof of Pharmacological Effect|Up to 80 subjects in 4 cohorts (up to 20 subjects per cohort) will be dosed in up to 3 study periods. In each period, subjects will receive active drug or placebo with GHRH, OGTT and CRH with desmopressin (optional).
89341459|NCT03942107|Active Comparator|Group 1: RCT+post+core in 1 visit|the root canal treatment will be completed with 2Shape NiTi system as well as post and core application in the same visit prior to postoperative pain evaluation.
89341460|NCT03942107|Active Comparator|Group 2: after RCT, post and core in 2nd visit|after root canal treatment conducted with 2Shape NiTi system, the postoperative pain evaluation will be completed prior applying post and core for coronal restoration.
89341461|NCT01192087|Experimental|Cetuximab arm|patients receive weekly cetuximab in combination with IMRT and carbon ion boost
89341462|NCT03942029|Experimental|Cohort 1 Part A - LY3154207 Capsule|LY3154207 capsule (reference) administered orally, once.
89341463|NCT03942029|Experimental|Cohort 1 Part A - LY3154207 Tablet|LY3154207 tablet (test) administered orally, once.
89341464|NCT03942029|Experimental|Cohort 1 Part B LY3154207 (Dose 1) + Fluconazole|LY3154207 (dose 1) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
89341465|NCT03942029|Experimental|Cohort 1 Part B - Placebo + Fluconazole|Placebo administered alone, orally, once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
89341466|NCT03942029|Experimental|Cohort 2 - LY3154207 (Dose 2) + Fluconazole|LY3154207 (dose 2) administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
89341467|NCT03942029|Experimental|Cohort 2 - Placebo + Fluconazole|Placebo administered alone, orally once. Fluconazole administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
89341468|NCT03942029|Experimental|Cohort 3 - LY3154207 + Fluconazole|LY3154207 (dose 2) administered alone, orally, on consecutive days. LY3154207 co-administered with fluconazole on consecutive days.
89341469|NCT03942029|Experimental|Cohort 3 - Placebo + Fluconazole|Placebo administered alone, orally, on consecutive days. Placebo co-administered with fluconazole on consecutive days.
89341470|NCT03846037|Placebo Comparator|Ground|Participants in this group perform protocol exercises on a stable surface.
89341471|NCT03846037|Experimental|vibrating platform|Participants in this group perform protocol exercises on a vibrating platform.
89341472|NCT03740945|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
89341473|NCT03740945|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
89341474|NCT01192165|Experimental|Treatment Group 1|Trametinib plus Docetaxel
88811798|NCT05236166|Other|Rapid withdrawal|Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).
88811799|NCT05236166|Other|Slow withdrawal|Reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).
88811800|NCT03495128|Experimental|Bed rest|Three days of bed rest at -6 degrees of head-down tilt
89341475|NCT01192165|Experimental|Treatment Group 2|Trametinib plus Erlotinib
89341476|NCT01192165|Experimental|Treatment Group 3|Trametinib plus Pemetrexed
89341477|NCT01192165|Experimental|Treatment Group 4|Trametinib plus Pemetrexed and Carboplatin
89341478|NCT01192165|Experimental|Treatment Group 5|Trametinib plus nab-Paclitaxel
89341479|NCT01192165|Experimental|Treatment Group 6|Trametinib plus Pemetrexed and Cisplatin
89341480|NCT01114295|Experimental|Overt Obscure Gastrointestinal Bleeders|The only cohort in this study are those patients identified as having overt, obscure gastrointestinal bleeding who will then undergo CE or CTE.
89341481|NCT01296451|Experimental|Arm A, group1|Intervention: MVA-NSmut. Administration schedule: 1 dose MVA-NSmut 2 x 10^8 pfu. Subjects: 4 healthy volunteers
89341482|NCT01296451|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 10 healthy volunteers"
89341483|NCT01296451|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose MVA-NSmut 2 x 10^8pfu at week 22, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
89341484|NCT01296451|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; MVA-NSmut.. Administration schedule: 1 dose AdCh3NSmut 2.5 x 1010vp at week 2 and 1 dose MVA-NSmut 2 x 108pfu at week 10, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
89341485|NCT01296451|Experimental|Arm C, group 1|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8pfu at week 8.~Subjects: 4 patients"
89341486|NCT01296451|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8pfu at week 8, 1 dose AdCh3NSmut 2.5 x 10^10vp at week 16 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 24.~Subjects: 5 healthy volunteers"
89341487|NCT01296451|Experimental|Arm A, group 4|"Intervention: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp (at least 6 months after they were initially enrolled) and 1 dose MVA-NSmut 2 x 10^8 pfu 8 weeks later.~Subjects: up to 5 healthy volunteers who were previously in group A2"
89341488|NCT01296451|Experimental|Experimental: Arm A, group5|"Intervention: AdCh3NSmut1. MVA-NSmut. Administration schedule:1 dose AdCh3NSmut1 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8 pfu at week 8 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 40.~Subjects: 5 healthy volunteers"
89341489|NCT01296451|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut1. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^7 pfu at week 8.~Subjects: 5 healthy volunteers"
89341490|NCT01296451|Experimental|Arm A, group 7|"Interventions: AdCh3NSmut1; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^6 pfu at week 8.~Subjects: 5 healthy volunteers"
89341491|NCT01209845|Experimental|Ketamine|Patients were administered a single sub-anaesthetic i.v. bolus of ketamine (0.2 mg/kg over 1-2 min) in the ED, with continuous monitoring of vital signs, adverse events and psychotomimetic side-effects for 4 h post-administration.
89341492|NCT01211717|Experimental|Branched Chained Amino Acids|
89341493|NCT01211717|Placebo Comparator|Cellulose mix|
89341494|NCT01196767|Experimental|ropivacaine|
89341495|NCT01196767|Other|normal saline|
89341496|NCT01194583||NO NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette without nicotine cartridges (NO nicotine group).
89341497|NCT03940781|Experimental|intervention group|We conducted a twice a week, 12-week-intervention of 'comprehensive rehabilitation'
89341498|NCT03940781|No Intervention|control group|We kept the patients for the waiting list until after completing baseline and 12-week measurement
89341499|NCT01192321|Experimental|Toric T3 - T9|Bilateral implantation of a Toric intraocular lens (IOL) models T3, T4, T5, T6, T7, T8 or T9
89341500|NCT01192321|Active Comparator|Monofocal|Bilateral implantation of a monofocal intraocular lens (IOL) model with no toric component.
89341501|NCT03940859||DEMAT|Patients with intramural hematoma in intracranial dissecting aneurysm treated by endovascular treatment will be recruited.
89341502|NCT03942185|Experimental|Psoriasis with Blood heat syndrome group|Participants in Psoriasis with Blood heat syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Clearing heat and Cooling blood, such as Cool blood detoxification Decoction I，Cool blood and activating blood prescription compound, Cool blood detoxification Decoction II, Cool blood activating blood Decoction, Tufu drink, Xiaoyin Decoction and etc., two times per day for 8 weeks.
89341503|NCT03942185|Experimental|Psoriasis with Blood stasis syndrome group|Participants in Psoriasis with Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of Promoting blood circulation and Removing blood stasis, such as Huoxue Sanyu Xiaoyin Decoction, Cool blood detoxification Decoction III and etc., two times per day for 8 weeks.
89341504|NCT03942185|Experimental|Psoriasis with Non-Blood heat or Blood stasis syndrome group|Participants in Psoriasis with Non-Blood heat or Blood stasis syndrome group will receive Chinese Herbal Medicine internal treatment according with the Chinese Medicine principle of syndrome differentiation therapy two times per day for 8 weeks.
89341505|NCT03942185|No Intervention|Healthy control group|No Intervention.
89341506|NCT01296529||HIV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HIV antibodies and/or HIV viral RNA, and a negative antibody test for HCV
89341507|NCT01296529||HCV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HCV antibodies and HCV viral RNA, and a negative antibody test for HIV
89341508|NCT01296529||HIV and HCV coinfection|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, and positive tests for HCV antibodies and HCV RNA.
89341509|NCT01296529||HIV/HCV coinfection with HCV clearance|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, a positive tests for HCV antibodies, and undetectable HCV RNA without hepatitis C treatment (spontaneous clearance) or >6 months after hepatitis therapy (sustained virologic response)
89341510|NCT03451773|Experimental|1/ Arm 1-Gemcitabine + de-escalating dose of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + de-escalating dose of M7824
89341511|NCT03451773|Experimental|2/ Arm 2-Gemcitabine + Recommended Phase 2 Dose (RP2D) of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + RP2D of M7824
89341512|NCT01112891|Experimental|1|
89341513|NCT01112891|Experimental|2|
89341514|NCT01112891|Experimental|3|
89341515|NCT03847441|Active Comparator|Group I|
89341516|NCT03847441|Active Comparator|Group II|
89341517|NCT03847441|Active Comparator|Group III|
89341518|NCT03847441|Placebo Comparator|Group IV|
89341519|NCT02529683|Experimental|Nuvaring (only arm)|Nuvaring use for six months, with monthly pickup of rings and returning of used rings, and other behavioral/clinical assessments conducted during the visit on day 21 of the menstrual cycle.
89341520|NCT03847129|Experimental|Biofeedback training group|The participants in the biofeedback training group attend a 30 minute biofeedback protocol per session, two times a week for six to eight weeks that is also combined with the regular diabetic care treatment in the Occupational Therapy Room.
89341521|NCT03847129|Active Comparator|Home-based training group|The participants in this group receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment.
89341522|NCT03847129|No Intervention|Control group|The participants in the control group receive only diabetes disease prevention consultation once and outcome assessments twice.
89341523|NCT01112969|Experimental|Internet-based supportive coaching OSCAR|Arm 1: Internet-based supportive coaching OSCAR
89341524|NCT01112969|Other|Waiting list control group (treatment as usual, TAU)|
89341525|NCT01296607|Other|Urocortin 2|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 2 in the presence and absence of a saline washout between incremental doses.
89341526|NCT01296607|Other|Urocortin 3|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 3 in the presence and absence of a saline washout between incremental doses.
89341527|NCT01210157||I Ischemic CMP|Patients with impaired ventricular function caused by coronary artery disease.
89341528|NCT01210157||II CMP|Patients with impaired ventricular function which is not caused by coronary artery disease. Subgroups based on etiology (familial cardiomyopathy, toxic cardiomyopathy, etc.)
89341529|NCT01210235|Experimental|FLU-FIT Arm|In this arm, eligible patients aged 50-75 will be offered a FIT kit
89341530|NCT01210235|No Intervention|FLU-Only Arm|In this arm, patients will receive flu shots as usual, without the FLU-FIT intervention.
89341531|NCT05406895|Experimental|CBCT first|This group will receive the injection technique that is guided by pre-treatment measurements made from the 3D dental scan (CBCT) during implant placement surgery and if the implant is placed as a two-stage procedure, during the second stage implant uncovery will receive the standard injection technique. If the implant is placed as a one-stage procedure, the second visit will not apply.
89341532|NCT05406895|Active Comparator|Standard technique first|This group will receive the standard injection technique first at the implant placement surgery and if the implant is placed as a two-stage procedure, during the second stage implant uncovery will receive the injection technique guided by the 3D dental scan (CBCT). If the implant is placed as a one-stage procedure, the second visit will not apply.
89341533|NCT03425253|Experimental|BELKYRA® and Juvéderm® VOLUMA™ with Lidocaine|BELKYRA® was injected into subcutaneous preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart). When the investigator and participant agreed that no further intervention was required to achieve the desired result, participants were eligible to receive VOLUMA™ treatment. VOLUMA™ was injected along the mandibular border, with an optional touch-up visit 2 weeks later if applicable.
89341534|NCT01211951|Experimental|KCT-0809 ophthalmic solution, low dose|
89341535|NCT01211951|Experimental|KCT-0809 ophthalmic solution, medium dose|
89341536|NCT01211951|Experimental|KCT-0809 ophthalmic solution, high dose|
89341537|NCT01211951|Placebo Comparator|Placebo|
89341538|NCT01296685||oxygenator with arterial filter|
89341539|NCT01296685||arterial filter|
89341540|NCT03941561|Experimental|S-1 for 9 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 9 months after D2 resection
89341541|NCT03941561|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
89341542|NCT03424239|Experimental|Drug: Zoledronic Acid, Calcium+Vitamin D|Subjects will receive a single intravenous infusion of zoledronic acid (5 mg). Supplemental calcium citrate + vitamin D (500mg+500IU) and vitamin D3 (1000 IU) will be dispensed throughout the study to fit individual needs.
89341543|NCT03941795|Experimental|JS001(Toripalimab Injection) Combined With Axitinib|
89341544|NCT03941795|Experimental|JS001 alone|
89341545|NCT03941795|Active Comparator|Axitinib alone|
89341546|NCT03845959|Experimental|TD0019.6cap|estimated dose, 2 oral capsules/time x 3 times/day
89341547|NCT03845959|Experimental|TD0019.9cap|1.5 times of estimated dose 2 oral capsules/time x 3 times/day
89341548|NCT03845959|Placebo Comparator|Placebo|Placebo 2 placebo oral capsules /time x 3 times/day
89341549|NCT01197001|Experimental|Amlodipine plus Losartan|
89341550|NCT01197001|Active Comparator|Amlodipine, Losartan|
89341551|NCT03451071|Experimental|Gardasil9|
89341552|NCT01113047|Experimental|Non responder Olmesartan/Amlodipine|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
89341553|NCT01296919||Sinus drainage|Adult patients with chronic rhinosinusitis who failed treatment with antibiotics and topical corticosteroids and underwent endoscopic sinus surgery. Preoperative evaluation included paranasal sinus CT scans. The diagnosis was confirmed by endoscopic examination showing purulent and/or mucopurulent discharge in the middle and/or superior meatus.
89341554|NCT01114451|Experimental|Early Staple Removal|Skin staple removal on post-operative day #3
89341555|NCT01114451|Experimental|Delayed Staple Removal|Skin staple removal on post-operative day 7-10
89341556|NCT01295437|Active Comparator|Vypro II mesh|A partly absorbable polypropylene-polyglactin mesh (50g/m2).
89341557|NCT01295437|Active Comparator|Premilene LP|A lightweight polypropylene mesh (55 g/m2)
89341558|NCT01295437|Placebo Comparator|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
89341559|NCT01114607|Experimental|Treatment sequence ABCDE|Eligible subjects will be randomized in sequence ABCDE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
89341560|NCT01114607|Experimental|Treatment sequence ABDEC|Eligible subjects will be randomized in sequence ABDEC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
89341561|NCT01114607|Experimental|Treatment sequence ABECD|Eligible subjects will be randomized in sequence ABECD and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
89341562|NCT01114607|Experimental|Treatment sequence ABCED|Eligible subjects will be randomized in sequence ABCED and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= a film coated tablet of GSK1605786 GSK formulation 500 mg once daily and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
89341563|NCT01114607|Experimental|Treatment sequence ABDCE|Eligible subjects will be randomized in sequence ABDCE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
89341564|NCT01114607|Experimental|Treatment sequence ABEDC|Eligible subjects will be randomized in sequence ABEDC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
89341565|NCT01114607|Experimental|Treatment sequence BACDE|Eligible subjects will be randomized in sequence BACDE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
89341566|NCT01114607|Experimental|Treatment sequence BADEC|Eligible subjects will be randomized in sequence BADEC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
89341567|NCT01114607|Experimental|Treatment sequence BAECD|Eligible subjects will be randomized in sequence BAECD and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
89341568|NCT01114607|Experimental|Treatment sequence BACED|Eligible subjects will be randomized in sequence BACED and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
89341569|NCT01114607|Experimental|Treatment sequence BADCE|Eligible subjects will be randomized in sequence BADCE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
89341570|NCT01114607|Experimental|Treatment sequence BAEDC|Eligible subjects will be randomized in sequence BAEDC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
89341571|NCT01192477|Experimental|Ozone 0.1 ppm|
89341572|NCT01192477|Experimental|Ozone 0.2 ppm|
89341573|NCT01192477|Sham Comparator|Filtered air|
89341574|NCT03449979|Experimental|alpha stimulation in participants in a depressive episode|Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
89341575|NCT03449979|Placebo Comparator|sham stimulation in participants in a depressive episode|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.
88811801|NCT03495128|Experimental|Reconditioning|Three days of one-legged knee extension contractions to recondition one leg
89341576|NCT03449979|Experimental|alpha stimulation in healthy participants|Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
89341577|NCT03449979|Placebo Comparator|sham stimulation in healthy participants|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.
89341578|NCT01197079||MSM|Young men (under 26 years of age) who have sex with men
89341579|NCT01197079||Parents|Parents of Boys aged 9 to 18 years
89341580|NCT01113125|Experimental|Fucicort|
88806875|NCT04894929|Experimental|B. Vestibular exercise|"The vestibular exercises will be performed with the instructions of a physiotherapist, in sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec All participants will have a weekly follow-up from Monday to Friday to control attendance and compliance via telephone."
89341581|NCT01113125|Placebo Comparator|Fucidin|
89341582|NCT03714009|Active Comparator|Fasting group|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. They should take adequate water and non calorie beverages intake daily (2-3 liters)"
89341583|NCT03714009|Other|Non fasting group|no fasting, patients will have usual balanced diet as 3 meals and 2 snacks all over the day. They should take adequate water and non calorie beverages intake daily (2-3 liters)
89341584|NCT03846817|Experimental|FAIS with intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
89341585|NCT03846817|Experimental|FAIS without intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
89341586|NCT01311297||Perioperative ovarian cancer patients|
89341587|NCT01311297||Pregnant patients|
89341588|NCT01311297||Female healthy volunteers|
89341589|NCT01210391|Experimental|New hydrolyzed infant formula|New, extensively hydrolyzed infant formula
89341590|NCT01210391|Active Comparator|Commercially available infant formula|Commercially available, extensively hydrolyzed infant formula.
89341591|NCT03846739|Active Comparator|Oxytocin & Placebo, 6 IU|Intranasal administration, 6 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
89341592|NCT03846739|Active Comparator|Oxytocin & Placebo, 12 IU|Intranasal administration,12 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
89341593|NCT03846739|Active Comparator|Oxytocin & Placebo, 24 IU|Intranasal administration, 24 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
89341594|NCT03716115|Experimental|Colostrum|Colostrum high protein powder (Neovite) given orally or through NG tube 1.5g daily, in addition to standard care following WHO guidelines for management of SAM.
89341595|NCT03716115|Experimental|GInNAC|N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.
89341596|NCT03716115|Experimental|Teduglutide|Teduglutide s/c. Administration by subcutaneous injection (0.5mg/kg/day) daily for 14 days, in addition to standard care following WHO guidelines for management of SAM.
89341597|NCT03716115|Experimental|Budenoside|Budesonide 3mg orally daily for 14 days, then rapidly tapered, in addition to standard care following WHO guidelines for management of SAM.
89341598|NCT03716115|No Intervention|Standard care|Standard care following WHO guidelines for management of SAM.
89341599|NCT01113203|Experimental|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
89341600|NCT01583803||Males|
89341601|NCT01583803||Females|
89341602|NCT01113281|Experimental|VPM1002 in three dosages|
89341603|NCT01113281|Active Comparator|BCG|
89341604|NCT01210469|Experimental|Strengthening Group|Performed balance training with lower limbs muscle strengthening.
89341605|NCT01210469|Experimental|Stretching Group|Performed balance training with stretching
89341606|NCT01210469|No Intervention|Control Group|
89341607|NCT01295593|Experimental|valproic acid combined with CdA|valproic acid, oral daily intake, combined with 2-chlorodeoxyadenosine administered intravenously for 4 cycles
89341608|NCT03845881|Active Comparator|Opioid|Multi-Modal Pain Protocol with Opioids Following Total Joint Arthroplasty
89341609|NCT03845881|Placebo Comparator|Non Opioid|Multi-Modal Pain Protocol without Opioids Following Total Joint Arthroplasty
89341610|NCT03849001|Experimental|Exercise Conditions|"Participants will undergo four Exercise Conditions (i.e., light intensity leg cycling, moderate intensity leg cycling, vigorous intensity leg cycling, and a seated, quiet rest) in a randomized, counterbalanced order."
89341611|NCT01210859||Ureteral stents Detrusitol treatment Lyfestyle outcome|Ureteral stents Detrusitol treatment Lyfestyle outcome
89341612|NCT01210937|Experimental|CEA and TCD monitoring|CEA involves a neck incision and physical removal of the plaque from the inside of the artery.During the surgery, the patient will be monitored by TCD.
89341613|NCT03846661|Active Comparator|Physiomesh|Patients undergoing laparoscopic incisional hernia repair reinforced with a Physiomesh.
89341614|NCT03846661|No Intervention|other mesh|Patients undergoing laparoscopic incisional hernia repair reinforced with other meshes than Physiomesh.
89341615|NCT01114685|Active Comparator|Effects of taking AlgaeCal-1|Following a bone health plan with Algae-cal-1 supplement
89341616|NCT01114685|Active Comparator|Effects of taking AlgaeCal-2|Following a bone-health plan while consuming AlgaeCal 2
89341617|NCT01211015||Control group|healthy control group
89341618|NCT01211015||Disease group|asthma, COPD, ILD, lung malignancy
89341619|NCT01197157|Placebo Comparator|placebo|"• Group A: comprises 100 chronic hepatitis patients who will receive placebo twice daily orally with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
89341620|NCT01197157|Experimental|Nitazoxanide|"• Group B: comprises 100 CHC patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
89341621|NCT01114763||Metabolic syndrome|40 men with metabolic syndrome
89341622|NCT01114763||Control|40 physically active men
89341623|NCT01194895|Experimental|protective ventilation|
89341624|NCT01194895|Active Comparator|conventional ventilation|
89341625|NCT01211093|Experimental|High frequency whole body vibration|This group will receive a single 10-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
89341626|NCT01211093|Active Comparator|low frequency whole body vibration|This group will receive a single 10-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
89341627|NCT01211093|Active Comparator|Control|This group will stand on the same vibration platform for 10 minutes, but no vibration will be given.
89341628|NCT01296997|Experimental|calcium phosphate|
89341629|NCT01296997|Placebo Comparator|placebo|
89341630|NCT01114841|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene foam 0.1%
89341631|NCT01114841|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam
89341632|NCT01113359||study group|hypertensive patients
89341633|NCT01113359||control group|healthy volunteer
89341634|NCT01192711|Experimental|insulin + DID|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections per day of insulin glulisine associated with basal insulin glargine; the DID will be used to estimate the CHO content of the food intended to eat. Insulin doses in this group will be adjusted based on DID calculations and pre-meal BG values.
89341635|NCT01192711|No Intervention|insulin + usual care|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections of insulin glulisine associated with basal insulin glargine. Insulin doses in group B will be adjusted based on SMBG values reviewed during the doctor office visit.
89341636|NCT01113437|Experimental|Omalizumab|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
89341637|NCT01113437|Placebo Comparator|Placebo|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
89341638|NCT01197235|Experimental|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
89341639|NCT01197235|Placebo Comparator|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
89341640|NCT01192789|Other|Intervention|Severe Pneumonia Treatment by LHWs with Amoxicillin at 90mg/kg/day for severe pneumonia
89341641|NCT01192789|Other|Control|LHWs refer the severe pneumonia case to local health facility or private practitioner.
89341642|NCT01211171||Group 1|
89341643|NCT01211249|Experimental|GLPG0259 (Part A)|
89341644|NCT01211249|Placebo Comparator|Placebo (Part A)|
89341645|NCT01211249|Experimental|GLPG0259 (Part B)|
89341646|NCT01211249|Placebo Comparator|Placebo (Part B)|
89341647|NCT01297075|Experimental|Outreach visits|Practices allocated to outreach visits may receive up to three outreach visits in order to motivate and support general practice clinics in implementing two chronic care programmes for chronic obstructive Pulmonary disease and Type 2 diabetes.
89341648|NCT01297075|No Intervention|Control (late intervention)|These practices are allocated to outreach visits after the initial evaluation stops at 12 months.
89341649|NCT03846973|Experimental|Tranexamic acid|group-I will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes followed by an intravenous infusion of 1 g TXA to be given and completed over 8 h in the hospital
89341650|NCT03846973|Placebo Comparator|Placebo|group-II will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes but will receive placebo (normal saline) infusion to be given and completed over 8 h in the hospital
89341651|NCT01328639|Active Comparator|Usual Care|Participants in this arm will be actively screened for depression and will receive the usual standard care for diabetes from their family physicians based on available clinical practice guidelines.
89341652|NCT01328639|Experimental|TeamCare Depression Intervention|Participants in this arm will be actively screened for depression, and will receive care for depression and diabetes based on the collaborative teamcare model for the management of diabetes and co-morbid depression.
89341653|NCT01115075|Experimental|Dietitian|Recruitment of dietitians and senior level or graduate level dietetics students who are not restrained eaters. This group is skilled in identifying and accurately recording food than individuals not trained in dietetics.
89341654|NCT01113515|Placebo Comparator|Placebo|Placebo gel
89341655|NCT01113515|Experimental|Galnobax 20% QD|Esmolol Hydrochloride (Galnobax) 20% gel once daily
89341656|NCT01113515|Experimental|Galnobax 20% BID|Esmolol Hydrochloride (Galnobax) 20% gel twice daily
89341657|NCT01113515|Experimental|Galnobax 14% BID|Esmolol Hydrochloride (Galnobax) 14% gel twice daily
89341658|NCT01195051|Experimental|Electronic medication reconciliation|Providers have access to a new, computer-based application to facilitate documentation and prescribing of outpatient medications in the inpatient setting.
89341659|NCT01195051|No Intervention|Control|
89341660|NCT01195129|Other|MicroVention Hydrogel Coils|FDA approved and in common use for cerebral aneurysm treatment.
89341661|NCT01195129|Active Comparator|Non-hydrogel coils|Cerecyte or bare platinum coils (FDA approved and in common use for treatment of cerebral aneurysm).
89341662|NCT01211327|Experimental|Cyclosporine A|Cyclosporine A (CsA) 2% eye drops
89341663|NCT01211327|Active Comparator|Dexamethasone|Dexamethasone 0,1% eye drops
89341664|NCT05601895||sorafenib group|FLT3- acute leukemia patients who receive sorafenib maintenance therapy after allo-HSCT. Sorafenib will be used from day 30 to 180 post-transplantation. The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
89341665|NCT05601895||non-sorafenib group|FLT3- acute leukemia patients who do not receive sorafenib maintenance therapy after allo-HSCT.
89341666|NCT01113671|Placebo Comparator|Placebo|
89341667|NCT01113671|Experimental|d-alpha-tocopheryl acetate|
89341668|NCT01113827|Active Comparator|150mg olive extract|
89341669|NCT01113827|Active Comparator|50mg olive extract|
89341670|NCT01113827|Placebo Comparator|Placebo control|
89341671|NCT01207817||no condition|no condition - healthy volunteers
89341672|NCT01195207|Experimental|001|CNTO 3157 or placebo 0.003 mg/kg CNTO 3157 or placebo infusion
89341673|NCT01195207|Experimental|002|CNTO 3157 or placebo 0.01 mg/kg CNTO 3157 or placebo infusion
89341674|NCT01195207|Experimental|003|CNTO 3157 or placebo 0.03 mg/kg CNTO 3157 or placebo infusion
89341675|NCT01195207|Experimental|004|CNTO 3157 or placebo 0.1 mg/kg CNTO 3157 or placebo infusion
89341676|NCT01195207|Experimental|005|CNTO 3157 or placebo 0.3 mg/kg CNTO 3157 or placebo infusion
89341677|NCT01195207|Experimental|006|CNTO 3157 or placebo 1 mg/kg CNTO 3157 or placebo infusion
89341678|NCT01195207|Experimental|007|CNTO 3157 or placebo 3 mg/kg CNTO 3157 or placebo infusion
89341679|NCT01195207|Experimental|008|CNTO 3157 or placebo 10 mg/kg CNTO 3157 or placebo infusion
89341680|NCT03943043|Experimental|gemcitabine oxaliplatin nab-paclitaxel|combination at different dose of gemcitabine, oxaliplatin and nab-paclitaxel
89341681|NCT01109927|Experimental|Insulin treatment|Insulin given as soon as possible after diagnosis
89341682|NCT01109927|No Intervention|Conventional treatment|Diet, oral hypoglycemic agents and insulin first when clinically needed
89341683|NCT01211795|Active Comparator|Topical Ketoprofen gel|
89341684|NCT01211795|Placebo Comparator|Placebo gel|
89341685|NCT01193023|Active Comparator|Pressure support|"in this arm, pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS)~with ETS +10%~with ETS -10%"
89341686|NCT01193023|Experimental|NAVA|Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.
89341687|NCT01207895|Experimental|[18F]-FLT PET scans|
89341688|NCT01193179|Experimental|OPC-262|
89341689|NCT01110083|Experimental|Arm 1|
89341690|NCT03943355||Nonoperative management protocol with angioembolization|The nonoperative management (NOM) protocol with angioembolization (AE) presents a trend in dealing with trauma patients with blunt splenic injury (BSI). This study was designed to explore the adverse events and associated risk factors before and after protocol-based NOM of BSI over a 12-year period.
89341691|NCT01193413||Non-infected necrosis group|There is no necrosis infection in severe acute pancreatitis.
89341692|NCT01193413||Single drainage group|The patients with necrosis infection in severe acue pancreatitis were cured by single drainage.
89341693|NCT01193413||Combined surgery group|If there was no clinical improvement after single drainage about 7 days, an open necrosectomy was performed in the patients with necrosis infection.
89341694|NCT01110161||Visceral fat mass|The study population will include Chinese adult men and women, over the age of 18 years. All subjects will be recruited at Fudan University. Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
89341695|NCT01193491|Experimental|IPI-493|
89341696|NCT01110317|Experimental|001|paliperidone palmitate 100 mg Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1 8 36 and 64.
89341697|NCT01193569||Standard of Care|Standard of Care for stroke except mechanical therapy
89341698|NCT01207973|Experimental|BI 113823|5 dose-groups of multiple oral doses of BI 113823
89341699|NCT01197313|Experimental|Exercise|
89341700|NCT03943121|Experimental|Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. Steroid-eluting stent were implanted in one side of ethmoid sinus and frontal sinus randomly.
89341701|NCT03943121|Sham Comparator|Without Steroid-eluting stent implant|The ESS procedure had to be successfully completed without complication on both sides. The side without the stent is defined as the control side.
89341702|NCT02529527|Experimental|MyFamilyPlan|Web-based health education tool (interactive self-assessment) provided for participant completion 7-10 days prior to a scheduled primary care visit.
89341703|NCT02529527|No Intervention|Control|Standard preconception health education document provided for participant review 7-10 days prior to a scheduled primary care visit.
89341704|NCT01197391|Experimental|Cohort 1|Dose 1 versus placebo
89341705|NCT01197391|Experimental|Cohort 2|Dose 2 versus placebo
89341706|NCT01208285|Experimental|Group A|approximately 12 male and female subjects with moderate hepatic impairment
89341707|NCT01208285|Experimental|Group B|approximately 12 healthy male and female subjects
89341708|NCT01295749|Active Comparator|ventilation by laryngeal tube|ventilation by laryngeal tube and continuous chest compression
89341709|NCT01295749|Sham Comparator|ventilation by bag valve mask|ventilation by bag valve mask and interrupted chest compression
89341710|NCT01208363|No Intervention|Unfortified Toubani|Children in the school will receive, 3 times per week 66g of raw unfortified (no added Fe) cowpea in form of Toubani (a cowpea based snack).
89341711|NCT01208363|Active Comparator|Fortified Cowpea|Study subjects will receive 3 times per week, as part of the school feeding programme 66g of raw fortified cowpea (with added 10mg Fe as NaFeEDTA)in form of Toubani (a cowpea based snack).
89341712|NCT01208441|Experimental|Arm I|"Patients receive oral letrozole once daily on days 1-21. Beginning in course 2, patients also receive oral RO4929097 on days 1-3, 8-10, and 15-18. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Beginning 1 week after completion of neoadjuvant therapy, patients undergo surgery or tumor biopsy. Patients continue to receive oral letrozole once daily during surgery and for an additional 4 weeks."
89341713|NCT03449199|Experimental|TMX-049 40 mg QD (Once Daily)|TMX-049: 40 mg of TMX-049 to be taken orally, once daily
89341714|NCT03449199|Experimental|TMX-049 200 mg QD (Once Daily)|TMX-049: 200 mg of TMX-049 to be taken orally, once daily
89341715|NCT03449199|Placebo Comparator|TMX-049 Placebo|
89341716|NCT03845569|Other|Habitual Protein phase|A trial investigating protein oxidation/metabolism that was used to model resistance trained individual's habitual dietary protein intake (2.2g/kg/d).
89341717|NCT03845569|Experimental|Moderate Protein Phase|A series of three trials over a one week period investigating protein oxidation/metabolism that was used to investigate the metabolic response of decreased protein intake (1.2g/kg/d) over a period of five days (trials on days 1, 3, 5 following reduction in protein intake from 2.2g/kg/d to 1.2g/kg/d) relative to the Habitual protein phase trial.
89341718|NCT01113905||Radiation Only|
89341719|NCT01113905||Radiation and Chemotherapy|
89341720|NCT03845647|Experimental|Tumor diameter<=2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0 differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
89341721|NCT03845647|Experimental|Tumor diameter>2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0(Clinically N0) differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
89341722|NCT03941327|Placebo Comparator|Control|Patients who provide consent for implant placement but do not receive the implant.
89341723|NCT03941327|Experimental|Interventional|Patients who provide consent for implant placement and do receive the implant.
89341724|NCT01195285|Active Comparator|Single-Incision Laparoscopic Cholecsytectomy (SILS)|
89341725|NCT01195285|Active Comparator|Traditional Laparoscopic Cholecystectomy (TLC)|
89341726|NCT01114061|Experimental|InsuPatch|The arm with the treatment: using the insupatch device to heat the insulin infusion site.
89341727|NCT03845413|Active Comparator|Intervention|The intervention arm consisted of 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
89341728|NCT03845413|Active Comparator|Control|The control arm consisted of a home visit by the Community Health Worker scheduling an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
89341729|NCT03718377|Experimental|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
89341730|NCT03718377|Active Comparator|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
89341731|NCT03941405|No Intervention|No treatment|No treatment.
89341732|NCT03941405|Experimental|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days.
89341733|NCT01197469|Placebo Comparator|Placebo|Placebo
89341734|NCT01197469|Active Comparator|Tadalafil|
89341735|NCT01211561|Experimental|Selenium, selenomethionine|
89341736|NCT01211561|Active Comparator|placebo|
89341737|NCT05595967|Active Comparator|Health education intervention|According the data collected in baseline survey, all participants will be divided into two groups: asymptomatic or mildly symptomatic and severe according the risk level of pelvic floor dysfunction. Intervention for high risk of pelvic floor women focus on emphasizing the need for medical care and access to medical resourced. The first intervention will be performed immediately after baseline survey. The second intervention will be repeated with the first one and performed three months after the first intervention. Both the two session contains modules focusing on heath related knowledge and pelvic floor muscle exercise.
89341738|NCT05595967|No Intervention|Control without intervention|No health education is provided to the participants in the control group so as to investigate the effects of health education. However, materials provided to interventional group will also be sent to the control group after the completion of the study.
89341739|NCT01213355|Experimental|Placebo|placebo, plus scopolamine 0.5 mg
89341740|NCT01213355|Experimental|PF-05212377 5 mg, plus scopolamine 0.5 mg;|
89341741|NCT01213355|Experimental|PF-05212377 20 mg, plus scopolamine 0.5 mg;|
89341742|NCT01213355|Experimental|PF-05212377 60 mg, plus scopolamine 0.5 mg;|
89341743|NCT01213355|Active Comparator|donepezil 10 mg, plus scopolamine 0.5 mg.|
89341744|NCT03938441|Experimental|Intermittent Fasting|Modified 5:2 intermittent fasting
89341745|NCT03938363|Experimental|Cervical Dystonia (CD)|Patients with cervical dystonia
88806876|NCT04888507|Experimental|Pozelimab+Cemdisiran|
89341746|NCT03938363|Placebo Comparator|Healthy Control CD|CD age- and sex-matched healthy control subjects
89341747|NCT03938363|Experimental|Blepharospasm (BS)|Patients with blepharospasm
89341748|NCT03938363|Placebo Comparator|Healthy Control BS|BS age- and sex-matched healthy control subjects
89341749|NCT01117493|Other|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
89341750|NCT01117493|Experimental|Expert Patient Programme|Receives a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
89341751|NCT05670769|Experimental|Experimental|"All forms will be filled in by the pregnant women at the beginning of the study.~The first interview will be face-to-face at the hospital.~A calendar will be created about home visits and timings for home midwifery care and counseling by meeting the pregnant woman at the hospital and obtaining their contact information.~Weekly home visits will be made to the pregnant women in the first month and training will be provided with the training booklet developed in line with the home midwifery care model based on the continuous midwifery care model during the home visits. Afterwards, two more home visits will be made to the pregnant women on a monthly basis and a total of 6 home visits will be made.~Pregnant women will be in constant communication via mobile phone.~After the sixth home visit, the Intention, Attitude and Behavior Scale in Gestational Diabetes and the Diabetes Self-Care Activities Questionnaire will be filled."
89341752|NCT05670769|No Intervention|Control|"All forms will be filled in by the pregnant women at the beginning of the study.~Pregnant women in the control group will not be subjected to any application other than the routine pregnancy follow-up and examinations recommended in the hospital.~Forms will be filled in parallel with the intervention group"
89341753|NCT03421431|Experimental|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
89341754|NCT03421431|Experimental|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
89341755|NCT03421431|Placebo Comparator|Placebo|Subjects will take 2 tablets once a day orally for 12 weeks
89341756|NCT03938285|Active Comparator|High Flux Hemodialysis|High Flux Hemodialysis with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment.
89341757|NCT03938285|Active Comparator|Extended Hemodialysis|Extended Hemodialysis with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment.
89341758|NCT03938285|Active Comparator|On Line Hemodiafiltration|On Line Hemodiafiltration with an FxCordiax 120 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
89341759|NCT03938285|Active Comparator|On Line Hemodiafiltration with an MCO membrane|On Line Hemodiafiltration with a Theranova 400 membrane, with Qb of 350, 4 hours of treatment, and post filter substitution rate of 20-21 liters.
89341760|NCT03938051|Experimental|Experimental group|Multi-component intervention
89341761|NCT03938051|Experimental|Control group|treadmill walk
89341762|NCT01115153|Experimental|Antibiotic prophylaxis|Rate of Wound infection in patients with gangrenous appendicitis with single doses of antibiotic (before surgery)
89341763|NCT01115153|Active Comparator|Antibiotic treatment, wound infection|Rate of Wound infection in patients with gangrenous appendicitis with five days antibiotic therapy (after surgery)
89341764|NCT01193725|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
89341765|NCT01193725|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
89341766|NCT01193725|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
89341767|NCT01110473|Experimental|Monotherapy, once daily|
89341768|NCT01110473|Experimental|Monotherapy, twice daily|
89341769|NCT01110473|Experimental|Combination with Azacitidine|
89341770|NCT01110473|Experimental|IV monotherapy, once daily|
89341771|NCT01208519||Case Control Study 1|To define the impact of antibiotics on new acquisition of MRSA and ESBL-producing gram negative bacteria, a matched case-control study will be done (ratio 1:4). The control group will be selected among patients not receiving antibiotics, admitted in the same ward on the day of the corresponding case, with negative cultures at hospital admission. Matching criteria will include: age (±5 years), sex, and total length of hospitalization.
89341772|NCT01208519||Case control study 2|To define individual level of risk related to specific antibiotics, patients acquiring MRSA and ESBL-producing gram negative bacteria will be compared with patients not acquiring antibiotic-resistant strains after starting antibiotic therapy (ratio 1:4). Previously known risk factors or clinically relevant significant variables from the univariate analysis will be considered for inclusion in multivariate logistic regression analysis.
89341773|NCT01296061||Failed Kidney Transplant|Adults ≥ 18 years, initiating chronic dialysis
89341774|NCT03942731||Experimental|83 adult outpatients at CHR Metz-Thionville with penicillin allergy label
89341775|NCT05547295|Other|Paper Information|Patient will have classic paper information for prevention of pressure sores
89341776|NCT05547295|Experimental|Numeric information from MEDIASCREEN|Patient will have information for prevention of pressure sores throught the digital tool MEDIASCREEN
89341777|NCT05534425|Experimental|Immediate GenX|Participants immediately commence GenX program activity (intergenerational mentoring)
89341778|NCT05534425|Active Comparator|Delayed GenX|Participants engage in parallel training/educational activities, and subsequently commence GenX program activity after 3 months
89341779|NCT03940391|Experimental|antihistamine combination|Participants in this group will get combination chlorpheniramine and midazolam injection for sedative endoscopy.
89341780|NCT03940391|Placebo Comparator|midazolam|Participants in this group will get only midazolam injection for sedative endoscopy
89341781|NCT03715881|Active Comparator|Oral prednisolone administration|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
89341782|NCT03715881|Active Comparator|Intravenous Erythropoietin injection|2. 1000 units of erythropoietin every 12 hours for three days
89341783|NCT01197781|Experimental|Period 1|
89341784|NCT01197781|Experimental|Period 2|
89341785|NCT01117649|Experimental|1|hyper-oncotic colloid
89341786|NCT01117649|Active Comparator|2|iso-oncotic colloid
89341787|NCT01117649|Active Comparator|3|crystalloid
89341788|NCT03713697|Experimental|Pap testing|Women assigned to this arm were invited to get a Pap testing at the Basic Health Unit
89341789|NCT03713697|Experimental|Self-Collection for HPV testing|Women assigned to this arm were provided with a kit to engage in self-collection for HPV testing
89341790|NCT03713697|Experimental|Choice|Women assigned to this arm were given a choice between a Pap testing at the local Basic Health Unit or self-collection for HPV testing
89341791|NCT01197859|Active Comparator|Contamac 74% silicone hydrogel contact lens|Definitive Contact Lens
89341792|NCT01197859|Placebo Comparator|Cooper Vision Biofinity|Biofinity Contact Lens
89341793|NCT01117805|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based telephone counseling intervention designed for African American women with asthma.
89341794|NCT01117805|No Intervention|usual care|Usual care at the University of Michigan Health System is based on the guidelines as recommended by the National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP-EPR3): Diagnosis and Treatment of Asthma and is coordinated so that all patients receive the same action plan, educational materials and instructions in use of devices.
89341795|NCT03713541||Patients with Anorexia nervosa (AN)|Female patients with Anorexia nervosa (AN, ICD-10: F50.0/1) of 14 years and older, receiving an initial treatment due to their AN (start of initial treatment no longer than 3 months ago, inpatient care: at least 7 days inpatient; outpatient care: at least 5 sessions with the same therapist) with sufficient language skills and no serious organic or psychiatric illnesses and no acute suicidality will be consecutively included in the study. No intervention.
89341796|NCT03713541||Carers of patients with AN|Significant caregivers in AN patients aged 14 to 15 years: parents; in AN patients aged 16 years and over: parents or other significant carer. No intervention.
89341797|NCT03713541||Physicians of patients with AN|Resident general practitioner, pediatrician, internist or gynecologist with at least one medical patient contact within the last 12 months. No intervention.
89341798|NCT01110551|Experimental|Group 2: low dose ; ID|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo intradermally on Days 0 and 90.
89341799|NCT01110551|Experimental|Group 1: low dose; SC|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo subcutaneously on Days 0 and 90.
89341800|NCT01110551|Experimental|Group 4: high dose; ID|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo intradermally on Days 0 and 90.
89341801|NCT01110551|Experimental|Group 3: high dose; SC|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo subcutaneously on Days 0 and 90.
89341802|NCT01110629|Experimental|Arm 1|
89341803|NCT01110629|Placebo Comparator|Arm 2|
89341804|NCT01296139|Experimental|A|All subjects will receive 7.5 mg/kg Fe
89341805|NCT01296217|Experimental|lymph nod detection|
89341806|NCT03940469|Placebo Comparator|Control group|received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block.
89341807|NCT03940469|Active Comparator|Dexamethasone group|received 35ml levobupivacaine+8mg dexamethasone
89341808|NCT03940469|Active Comparator|Dexmeteomidine group|received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline.
89341809|NCT03847753||Danish population|The cohort includes all those born in Denmark between 1900-2015, and who resided there in the period of 2000-2016.Whether they received a diagnosis of one of the following mental disorders will be ascertained: Organic Disorders, Substance Use Disorders, Schizophrenia Disorders, Mood Disorders, Eating Disorders, Neurotic Disorders, Personality Disorders, Intellectual Disorders, Developmental Disorders, Behavioral Disorders The risk of receiving a later diagnosis of one of the following types of general medical conditions will then be estimated: Circulatory, Endocrine, Pulmonary and Allergy, Gastrointestinal, Urogenital, Musculoskeletal, Hematological, Cancer, Neurological
89341810|NCT01296295|Experimental|Spirometry and lifestyle counseling|Intervention group: The intervention is to give brief structured smoking cessation advice combined with a detailed and structured discussion of the spirometric results.
89341811|NCT01296295|No Intervention|Lifestyle counseling|No intervention group: the patients of the control group will receive a brief structured smoking cessation advice.
89341812|NCT01110863||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
89341813|NCT03846271|Experimental|Oxytocin then placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
88806877|NCT04855266|Experimental|Iron Sucrose Group|Subjects will receive intravenous iron sucrose during a tilt table test
88806878|NCT04855266|Placebo Comparator|Placebo Group|Subjects will receive intravenous placebo during a tilt table test
88806879|NCT04827394|Experimental|Intervention group|In the intervention group, the infant will be placed on the thermal mattress, then wrapped.
89341814|NCT03846271|Experimental|Placebo then oxytocin|Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
89341815|NCT01110941|Experimental|SOL|single arm
89341816|NCT03448419|Experimental|Empagliflozin|
88806880|NCT04827394|No Intervention|Control group|In the non-intervention group, the infant will be delivered onto the sterile field as per standard of care.
89341817|NCT03448419|Placebo Comparator|Placebo|
89341818|NCT01195519||peritoneal dialysis and hemodialysis patients|peritoneal dialysis and hemodialysis patients
89341819|NCT01117961|No Intervention|control|
89341820|NCT01117961|Experimental|Intervention|Lifestyle intervention delivered during pregnancy
89341821|NCT03844711|Experimental|Transcutaneous electrical diaphragmatic stimulation (TEDS)|For transcutaneous electrical diaphragmatic stimulation, surface electrodes will be used that will be positioned at the transcutaneous motor points of the diaphragm.
89341822|NCT03844711|Experimental|Inspiratory Muscle training (IMT)|The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax.
89341823|NCT03844711|Active Comparator|Conventional physiotherapy|The protocol of physiotherapy by the physiotherapists of HCPA will be twice a day and consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
89341824|NCT01213433|Experimental|Amodiaquine+Artesunate|
89341825|NCT01199419||PCI|
89341826|NCT01199419||CABG|
89341827|NCT06108271|Experimental|ETT-T|Endotracheal tube Triglotix®
89341828|NCT06108271|Active Comparator|ETT-C|Endotracheal tube conventional
89341829|NCT06108258||Oral iron|
89341830|NCT06108258||IV iron|
89341831|NCT06108245|Experimental|Values Clarification Condition|Participants will be asked to respond to values clarification prompts twice a day over 28 days [4 weeks]. In each session, participants will receive a randomly assigned writing prompt from a pool of four categories: hierarchical, conditional, distinction, and perspective-taking prompts. In the initial session, participants will be asked to respond to a brief set of questions pertaining to their hoarding behavior in the past 12 hours and their motivation to declutter right now. From that point on, participants will respond to a brief set of questions before each writing prompt pertaining to their hoarding behaviors in the time since the previous writing prompt. After the writing prompt, they will be asked about how motivated they are to declutter right now. Each writing prompt is anticipated to take up to 10 minutes to complete and participants will receive notifications to use the app twice daily in addition email reminders twice a week to engage with the app.
89341832|NCT06108245|Placebo Comparator|Self-Reflection Condition|Participants in this condition will be asked to respond to a set of randomly selected self-reflection prompts twice a day over 28 days [4 weeks]. As with the experimental condition, participants in the initial session will be asked to respond to a brief set of questions pertaining to their hoarding behavior in the past 12 hours and their motivation to declutter right now. From that point on, participants will be asked to respond to a brief set of questions before each writing prompt pertaining to their hoarding behaviors in the time since the previous writing prompt. After the writing prompt, they will be asked about how motivated they are to declutter right now. Each writing prompt is anticipated to take up to 10 minutes to complete, and participants will receive notifications to use the app twice daily in addition to email reminders twice a week to engage with the app.
89341833|NCT06108245|No Intervention|Waitlist Condition|Participants assigned to the waitlist will not receive access to any intervention for 8 weeks. After 8 weeks, they will receive access to either the values clarification or self-reflection mobile application.
89341834|NCT06108115|Experimental|Behavioral: CueToSleep (Full Intervention Package)|Individuals will be randomly allocated to receive the full Health Rhythms package (CueToSleep) program on their smartphones. The package includes 24/7 behavioral sensing from the participant's smartphone using the global positioning system, accelerometer, and screen on/off state, as well as a series of psychoeducational learning screens about the relationship among alcohol, mood disturbance and sleep, and personalized suggestions for behavior change to improve sleep that will be sent to the participant every 3 to 4 days. These suggestions will be based on behaviors indicated by the individual participant's sensor data over the previous 3 to 4 days.
89341835|NCT06108115|No Intervention|Measure (Behavioral Sensing Only)|Individuals will only be monitored using the passive sensing capabilities of the Full Intervention Package on their smartphones. These participants will not receive psychoeducational learning screens or behavior change suggestions.
89341836|NCT06107985|Experimental|Structured exercise group|Group A (Experimental Group) will receive structured exercises protocol, will be given approximately for two days per week for twelve weeks.
89341837|NCT06107985|Active Comparator|Conventional Exercise group|Group B (control group) will receive conventional exercise program for two days per week for twelve weeks.
89341838|NCT06107959||Male|50 male subjects undergoing orthopedic surgery.
89341839|NCT06107959||Female|50 female subjects undergoing orthopedic surgery
89341840|NCT06107933||Denver Mother-Infant Pairs|Mother-infant pairs living in a Denver, Colorado zipcode
89341841|NCT06107933||Boulder Mother-Infant Pairs|Mother-infant pairs living in a Boulder, Colorado zipcode
89341842|NCT06107920|No Intervention|Arm I (Adjuvant chemotherapy) / Control arm|"Diverting stoma - colectomy - +/- adjuvant chemotherapy~The colectomy (open or laparoscopic) should be performed within 1 to 20 days after the randomization and with respect of the oncological quality criteria of resection. After completion of surgery, adjuvant chemotherapy will be discussed as follow:~Low-risk stage II: No adjuvant treatment~High-risk MSS stage II (vascular emboli, lymphatic or perinervous invasion, poor differentiation, <12 harvested lymph nodes, perforation): Investigator's discretion~pT1-T3N1: CAPOX (3 months) or FOLFOX (6 months)~pT4 and/or N2: FOLFOX (6 months)"
89341843|NCT06107920|Experimental|Arm II (Neoadjuvant Chemotherapy) / Experimental arm|"Patients receive systemic CAPOX or FOLFOX chemotherapy (3 months) within 21 days after the randomization. After completion of neoadjuvant chemotherapy and within 3 to 5 weeks, the colectomy (open or laparoscopic) will be performed with respect of the oncological quality criteria. Adjuvant chemotherapy will be discussed as follow:~Low-risk stage II: No adjuvant treatment~High-risk MSS stage II (vascular emboli, perinervous or lymphatic invasion, poor differentiation, <12 harvested lymph nodes, perforation): Investigator's discretion~Stage III: CAPOX or FOLFOX (3 months)"
89341844|NCT06107894|Experimental|Cohort 1|Autologous Tumor-infiltrating lymphocytes
89341845|NCT06107894|Experimental|Cohort 2|Autologous Tumor-infiltrating lymphocytes, Low dose IL-2
89341846|NCT06107881|Experimental|Telerehabilitation with low vision provider|Low Vision Rehabilitation for use of magnification or visual assistive devices using videoconferencing for remotely delivered follow-up care
89341847|NCT06107881|Active Comparator|Usual Care In-Office|Low Vision Rehabilitation in-office for use of magnification or visual assistive devices
89341848|NCT06107855|Experimental|Maximal-intent Resistance Training|The MI group was instructed and encouraged to deliberately commit to exerting maximal effort and force during the concentric phase of the leg press with the intention of achieving the greatest velocity possible.
89341849|NCT06107855|Experimental|Controlled-tempo Resistance Training|While the CT group followed the metronome for both eccentric and concentric phases.
89341850|NCT06107842|Active Comparator|Gerofit exercise|Participants enrolled in the Gerofit program
89341851|NCT06107842|Placebo Comparator|Health education|Participants enrolled in monthly in-person health education sessions which do not include a physical activity/exercise promotion session
89341852|NCT06107816|Placebo Comparator|Usual Care Control Group|Will receive usual care
89341853|NCT06107816|Active Comparator|F&V Rx Alone Group|Will receive 4 monthly F&V Rx vouchers regardless of their DSME/S attendance.
89341854|NCT06107816|Active Comparator|F&V Rx + DSME/S Group|Will receive monthly F&V Rx vouchers starting at the first group session and they will receive additional F&V Rx vouchers only when they attend a monthly DSME/S group (up to 4 total)
89341855|NCT06107790|Experimental|HS022+ Vinorelbine Bitartrate|
89341856|NCT06107790|Active Comparator|Trastuzumab®+ Vinorelbine Bitartrate Injection|
89341857|NCT06107699|Experimental|Patient Navigator|
89341858|NCT06107699|No Intervention|Standard of Care|
89341859|NCT06107673|Experimental|neoadjuvant endocrine group|"Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks.~AI: Take according to the instructions provided."
89341860|NCT06107673|Active Comparator|neoadjuvant chemotherapy group|"Docetaxel for injection: Administered as a 75 mg/m2 intravenous infusion Epirubicin hydrochloride for injection: Administered as a 75 mg/m2 intravenous infusion.~Cyclophosphamide for injection: Administered as a 500 mg/m2 intravenous infusion."
89341861|NCT06107660|Experimental|Study Group|"Patients in the study Group will receive 20ml 1.3% Liposomal bupivacaine (Exparel®) dose of 266mg with 40 ml of 0.25% bupivacaine.~The local anesthetic solution will be administered bilaterally in the plane between the lumber transverse process and the erector spinae muscles to block the dorsal and ventral rami of the spinal nerves under ultrasound guidance using a standard block needled. A total of 60 ml solution will be injected -30 ml on each side of the spinal column."
89341862|NCT06107660|Active Comparator|Control Group|"Patients in the control group will receive 60ml of 0.25% bupivacaine with 5 mg preservative free dexamethasone and 150 mcg Epinephrine (in a 1:400,000 dilution).~The local anesthetic solution will be administered bilaterally in the plane between the lumber transverse process and the erector spinae muscles to block the dorsal and ventral rami of the spinal nerves under ultrasound guidance using a standard block needled. A total of 60 ml solution will be injected -30 ml on each side of the spinal column."
89341863|NCT06107608|Experimental|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET/CT in patients with NSCLC with an indication for immunotherapy
89341864|NCT06107530|Experimental|Semi structured interview|
89341865|NCT06107517|Experimental|DREAMS-OT Arm (Intervention Group)|Patients will receive an early and intensive occupational therapy protocol starting within the first 15 hours after extubation.
89341866|NCT06107517|No Intervention|Standard Care Arm (Control Group)|Standard care OT as per current ICU setting
89341867|NCT06107491|Other|study group|mothers receiving routine education plus digital video disk before surgery
89341868|NCT06107491|Other|control group|mothers receiving routine education
89341869|NCT06107478||Children ALL, 2-12 years old|Children with acute lymphoblastic leukemia (ALL) and in the induction phase of its treatment (at least one month post-diagnosis and up to 50 days post-diagnosis, i.e. until the first day of consolidation).
89341870|NCT06107478||Parents of children ALL|Parents of a patient with acute lymphoblastic leukemia (ALL) being in the induction phase of his treatment (at least one month post-diagnosis and up to 50 days post-diagnosis, i.e. until the first day of consolidation), 2 to 12 years of age at diagnosis and managed by a participating centre.
89341871|NCT06107465|Active Comparator|High dose Nitroglycerin|Initial dose of >100 mic/min will be initiated
89341872|NCT06107465|Active Comparator|Low dose Nitroglycerin|Initial dose < 100 mic /min will be started
89341873|NCT06107439|Other|sampling and clinical data collection|Participant blood and urine are sampled for inflammatory signal analysis
89341874|NCT06107400|Experimental|RM-004|RM-004 (ex vivo gene-edited CD34+ autologous hematopoietic stem cells) will be administered as a single intravenous infusion
89341875|NCT06107374|Experimental|Advanced non small cell lung cancer (NSCLC) patients undergoing PD-1/PD-L1 directed therapy|
89341876|NCT06107348||Immune Disorder|
89341877|NCT06107127|Active Comparator|Researcher 1|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
89341878|NCT06107127|Active Comparator|Researcher 2|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
89341879|NCT06107101|Experimental|Treatment|20 subjects with CRSwNP and asthma that will start Mepolizumab treatment
89341880|NCT06107101|No Intervention|Disease control group|10 subjects with CRSsNP without asthma that will not start Mepolizumab and will continue their standard of care treatment.
89341881|NCT06107101|No Intervention|Control group|10 healthy subjects without any sinuses disease
89341882|NCT06107088|Experimental|Test product1|1 capsule 'lactase-bacterial strain combination' and 1 capsule placebo, once a day, one week
89341883|NCT06107088|Experimental|Test product2|1 capsule lactase and 1 capsule bacterial strain, once a day, one week
89341884|NCT06107088|Active Comparator|Comparator|1 capsule lactase and 1 capsule placebo, once a day, one week
89341885|NCT06107088|Placebo Comparator|Placebo|2 capsules placebo, once a day, one week
89531674|NCT05799833||Athletes with low QRS voltage|"Cohort (anticipated N = 60) will undergo testing with 12 lead ECG, blood test, cardiac MRI, 24 hour holter monitoring and cardiopulmonary exercise testing.~A subgroup of those identified to have low QRS voltage and myocardial scar on CMR will undergo genetic testing (anticipated number to be tested, N= 25)"
89341886|NCT06107010|Experimental|Exo group|"During the 6-week intervention period, the Exo group will complete 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy.~During sessions with the exoskeleton, the patient will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.~Conventional therapy corresponds to physiotherapy as part of post stroke standard of care of the center (tasks such as lower and upper limb practice, walking in parallel bars, etc., but this list is not exhaustive and depends on the practice of the therapists/centers)."
89341887|NCT06107010|No Intervention|Control group|During the 6-week intervention period, the Control group will complete 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).
89341888|NCT06106997|Other|sCT workflow|sCT workflow
89341889|NCT06106971|Experimental|Balloon-occluded retrograde transvenous obliteration|"Information of drug:~3% sodium tetradecyl sulfate injection Name: Fibro-vein injection Manufacturer: STD Pharmaceutical Products Ltd."
89341890|NCT06106971|Active Comparator|Endoscopic cyanoacrylate injection|"Information of drug:~N-butyl-2-cyanoacrylate Name: Histoacryl blue Manufacturer: Braun, Melsungen, Germany"
89341891|NCT06106958|Experimental|Foot Rehabilitation And Minimalist Shoes (FRAMES)|The intervention group will receive a pair of minimalist shoes along with a home exercise program and a protocol that indicates how to slowly adjust to wearing the shoes.
89341892|NCT06106958|Active Comparator|Home Exercise Program (Control)|The intervention group will receive a home exercise program.
89341893|NCT06106932|Active Comparator|GnRH-a +|Group A [GnRHa+] consisted of 30 women with a mean age of 35.5 years and a mean BMI of 27 kg/m2. Seventeen of them were stage 2 and 13 were stage 3 endometriosis. They received GnRH-a [leuprolide acetate] for a period of 3 months prior to surgery, whereas they had not received any hormonal treatment within the 12 months before the surgical procedure.
89341894|NCT06106932|No Intervention|GnRH-a -|Group B [GnRHa-] consisted of 30 patients with a mean age of 38 years and a mean BMI of 27 kg/m2. Sixteen of them had stage 2 and 14 had stage 3 endometriosis. They did not receive GnRH-a treatment before operation. In addition, no treatment with oral contraceptives or other therapy was administered within 12 months prior to surgery.
89341895|NCT06106906|Experimental|Experimental Arm|Participants will receive CD19 CAR-T cell intravenous infusion
89341896|NCT06106867|Experimental|Experimental Group|Information about applying external pressure to the palm was provided to the pregnant women in the experimental group. The researcher practically explained how, when and for how long to apply external pressure to the palm. The researcher introduced the comb to be used in the application of external pressure to the palm, and the application stage of the study was started.
89341897|NCT06106867|No Intervention|Control Group|Routine midwifery care and services applied to all pregnant women in the hospital were provided to the participants in the control group.
89341898|NCT06106854|Experimental|Intervention|
89341899|NCT06106854|Placebo Comparator|Control|
89341900|NCT06106841|Experimental|400mg of TQB3909 tablets|tablet, 28 days as a treatment cycle.
89341901|NCT06106841|Experimental|600mg of TQB3909 tablets|tablet, 28 days as a treatment cycle.
89341902|NCT06106815|Experimental|The Graded Repetitive Arm Supplementary Program|
89341903|NCT06106815|Active Comparator|Usual Care|
89341904|NCT06106802|Experimental|single arm|"Patients will be treated with Lazertinib + tepotinib based on the MET FISH results.~Lazertinib 240mg daily Tepotinib 500mg daily"
89341905|NCT06106789||Bronchiectasis|"Patients with a past medical history or a diagnosis of bronchiectasis in the current case;~Patients seen or admitted to the hospital from 1 January 2021 to 31 December 2023 (including outpatient, emergency, and inpatient);~Case record of at least 1 course of treatment (continuous administration for 28 days) with tobramycin inhalation solution or other antibiotic nebulisation;~Patients with a positive copper-green test at the first visit."
89341906|NCT06106789||Cystic fibrosis|"Patients with a past medical history or a diagnosis of cystic fibrosis in the current case;~Patients who were seen or admitted to the hospital from 1 January 2021 to 31 December 2023 (including outpatient, emergency, and inpatient);~Case record of at least 1 course of treatment (continuous administration for 28 days) with tobramycin inhalation solution or other antibiotic nebulisation;~Patients with a positive copper-green test at the first visit."
89341907|NCT06106789||Multidrug-resistant bacterial lung infections|"Patients with a diagnosis of pulmonary infection;~Patients admitted to the hospital from 1 January 2021 to 31 December 2023 (only inpatients were included);~Case records with completion of at least 3 days of treatment with tobramycin inhalation solution or other antibiotic nebulisation;~The patient tested positive for pathogens at least once during the period of medication."
89341908|NCT06106750|Experimental|Nasobiliary duct cutting|Endoscopic retrograde cholangiopancreatography and endoscopic nasobiliary duct placement and drainage are conducted first. Upon achieving a postoperative state marked by satisfactory nasobiliary duct drainage and overall patient stability, the procedure entails the employment of endoscopic scissors. The tools are applied to make an incision on the external segment of the nasobiliary duct, positioned beyond the aperture of the primary duodenal papilla. Then, extracting the severed nasobiliary duct and retaining the portion inside it.
89341909|NCT06106750|Active Comparator|Bilateral plastic stent|Standard protocol for the placement of bilateral biliary plastic stents in the management of malignant hilar biliary tract stenosis
89341910|NCT06106724|Active Comparator|group A|sphencterotomy of papilla by conventuional methodes
89341911|NCT06106724|Active Comparator|group B|precutting of the papilla by knife needle
89341912|NCT06106685|Experimental|High-dose group|The participant will receive a high dose of the washed microbiota suspension, with a bacterial quantity that is 10 times higher than the conventional clinical treatment dose, once daily for a duration of 4 days.
89341913|NCT06106685|Experimental|Low-dose group|The participant will receive a low-dose washed microbiota suspension, with a bacterial quantity equivalent to the conventional clinical treatment dose. The washed microbiota suspension will be administered once on the first day, followed by placebo of equal volume for the next 3 days.
89341914|NCT06106685|Placebo Comparator|Control group|The patient will receive a placebo of equal volume once daily for a duration of 4 days.
88806881|NCT04826939|Experimental|Device usage|All participants will complete a survey and undergo an evaluation to test the movement of their pelvic floor with the PFDx device and leva device
89341915|NCT06106607|Experimental|Intervention group|This group will undergo a 20-week individually tailored, behavioral intervention
89341916|NCT06106607|No Intervention|Control group|This group will be encouraged to maintain usual lifestyle and activities.
89341917|NCT06106542||stroke group|assessment of effect motor imagery on muscle oxygenation
89341918|NCT06106399|Active Comparator|WALLANT (group 1)|wide awake local anesthesia and no tourniquet (WALLANT)
89341919|NCT06106399|Active Comparator|CPB (group 2)|clavipectoral fascia plane block combined with superficial cervical plexus block (CPB)
89341920|NCT06106347||CVS group|positive CVS diagnosis
89341921|NCT06106347||control|participants with no-CVS diagnosis
89341922|NCT06106321|Experimental|Transalveolar crest parietal maxillary sinus floor secondary lift|In order to achieve minimally invasive surgery (RBH≤5mm) in patients with severe deficiency of residual bone height in the posterior maxillary region and obtain reliable clinical research results, a secondary sinus floor lifting technique combining the advantages of maxillary sinus lift with the low risk of maxillary sinus lift is proposed.
89341923|NCT06106321|Active Comparator|Transalveolar crest parietal maxillary sinus floor lift|Transalveolar crest parietal maxillary sinus floor lift (OSFE) requires a residual bone height of at least 5 mm and implant placement at the same time. Its advantages are simple operation, shorter surgical time, reduced trauma and reduced postoperative complications, and the concept of minimally invasive implant surgery is reflected in OSFE.
89341924|NCT06106282||Observational|Patients attend a 2-day treatment program and complete questionnaires on study. Patients also have their medical records reviewed on study.
89341925|NCT06106243|Active Comparator|The conventional heat pressing temporary flexible maxillary removable partial denture|
89341926|NCT06106243|Experimental|3D-printed and digitally designed temporary flexible maxillary removable partial denture .|
89341927|NCT06106165|Experimental|In-person delivery|Participants will attend the workshops in a mosque or community centre.
89341928|NCT06106165|Experimental|Online delivery|Participants will join the workshops via a web conferencing platform The content of the online workshops is identical to the content of in-person workshops.
89341929|NCT06106126|Other|Mild renal impairment|
89341930|NCT06106126|Other|Moderate renal impairment|
89341931|NCT06106126|Other|Severe renal impairment|
89341932|NCT06106126|Other|Normal Renal Function|
89341933|NCT06106113|Other|Mild hepatic impairment|150 mg GST-HG171
89341934|NCT06106113|Other|Moderate hepatic impairment|150 mg GST-HG171
89341935|NCT06106113|Other|healthy subjects with normal hepatic function|150 mg GST-HG171
89341936|NCT06106074|Experimental|Part 1a|3 single ascending doses of SAR442168 or placebo in fasted and fed (high-fat breakfast) conditions
89341937|NCT06106074|Experimental|Part 1b|2 single doses of SAR442168 under fed conditions (moderate-fat breakfast).
89341938|NCT06106074|Experimental|Part 1c|1 single dose of SAR442168 under fasting and fed conditions (high-fat breakfast).
89341939|NCT06106074|Experimental|Part 1d|1 single dose of SAR442168 under fasting and fed conditions (Standardized high-fat breakfast).
89341940|NCT06106074|Experimental|Part 2|3 ascending once-daily repeated single doses of SAR442168 or placebo for 14 days under fed conditions (moderate-fat breakfast)
89341941|NCT06106061|Experimental|Group one: Decompression + FFX®|
89341942|NCT06106061|Active Comparator|Group two: Decompression alone|
89341943|NCT06106048|Experimental|Group A|Group A will be treated with closed kinetic chain exercises
89341944|NCT06106048|Experimental|Group B|Group B was treated with abdominal contraction exercises for periscapular activation
89341945|NCT06105970||Community sample|Using social media to randomly inviting participants across all regions of China.
89341946|NCT06105905|Experimental|One arm pilot trial|The developed intervention will be delivered in a workshop format by facilitators, over two consecutive days for 3.5 hours each day. Feedback will be elicited on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Five groups of 10 participants each, stratified by gender and age (14-15 years old and 16-18 years old; females and males) will complete sessions, in either Spanish or English depending on participants' preference, using video conference tools. Teens will complete a 15-minute survey pre-intervention, immediately after the 2-day intervention, and three-month post-intervention. Surveys will assess acceptability and risk behaviors. As in the published Cuidate trials, previously used measures will be used to document validity and comparability.
89341947|NCT06105879||Serum|Total Serum bilirubin
89341948|NCT06105879||covered skin|Covered Skin Transcutaneous Bilirubin
89341949|NCT06105879||exposed skin|Exposed skin Transcutaneous Bilirubin
89341950|NCT06105840|Experimental|Intervention Group|Groups assigned randomly using lottery draw number 1
89341951|NCT06105840|Sham Comparator|Control Group|Groups assigned randomly using lottery draw number 2
89341952|NCT06105827|Other|Control group|Give antibiotics or diclofenac sodium suppository as needed.
89341953|NCT06105827|Experimental|Ningmitai capsule|Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day. Course of treatment: 12 weeks
89341954|NCT06105827|Experimental|Combined group (Ningmitai plus tamsulosin)|Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group. Course of treatment: 12 weeks
89341955|NCT06105814|No Intervention|Standard diagnostics|Standard microbiological diagnostics, with nasopharyngeal swab and induced sputum or endotracheal aspirate for real-time polymerase chain reaction (PCR) and culture, blood cultures and urinary antigen tests
89341956|NCT06105814|Experimental|Rapid diagnostics|In addition to standard diagnostics, induced sputum or endotracheal aspirate analyzed with multiplex PCR (FilmArray).
89341957|NCT06105762|Experimental|Ketogenic Diet Arm|During an 8-week period, individuals enrolled in the experimental group will undergo a low-carbohydrate, high-fat ketogenic diet intervention. We will implement the Modified Atkins Diet (MAD), which is a nutritionally rich and diverse variant of the ketogenic diet. It restricts net carbohydrate intake to less than 20g per day.
89341958|NCT06105762|Active Comparator|Conventional Healthy Mixed Diet Arm|The control group will be provided with a standard balanced mixed diet following the recommendations for healthy nutrition by the Schweizerische Gesellschaft für Ernährung (Société Suisse de Nutrition). This diet will consist of an average daily caloric supply from carbohydrates of approximately 45 - 60%, as per the guidelines.
89341959|NCT06105671|Experimental|Symbicort - usual care|Participants are administered Formoterol + Budesonide from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.
89341960|NCT06105671|Experimental|Formoterol - inhalation|Participants are administered Formoterol from an inhaler device testing. In addition, participants are administered a placebo capsule, which is taken orally.
89341961|NCT06105671|Experimental|Formoterol - oral|Participants are administered a Formoterol capsule, which is taken orally. In addition, participants are administered placebo from an inhaler device.
89341962|NCT06105671|Placebo Comparator|Placebo|Participants are administered placebo from an inhaler device testing and a placebo capsule.
89341963|NCT06105671|Experimental|Mannitol-test|Participants are administered Bronchitol from an inhaler device testing.
89341964|NCT06105658|Experimental|Chemotherapy+unrelated umbilical cord blood microtransplantation|"Intermittent infusion of HLA mismatched or incompletely matched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (G-PBSC) during routine chemotherapy without the use of immunosuppressants, abbreviated as microtransplantation."
89341965|NCT06105138|Experimental|200mg Cannabidiol|A single dose of 200mg commercially available (product code T-L-A-5) water-soluble solution supplied by Caliper Foods, to be consumed orally (mixed with water).
89341966|NCT06105138|Experimental|30mg Cannabidiol|A single dose of 30mg commercially available (product code T-L-A-5) water-soluble solution supplied by Caliper Foods, to be consumed orally (mixed with water).
89341967|NCT06105138|Placebo Comparator|Placebo|A single dose of water-soluble Placebo solution supplied by Caliper Foods, to be consumed orally (mixed with water).
89341968|NCT06104345|Active Comparator|Vivotif|Three oral doses of typhoid fever vaccine (Vivotif®).
89341969|NCT06104345|Active Comparator|Dukoral|Two oral doses of cholera vaccine (Dukoral®).
89341970|NCT06104345|Experimental|Dukoral+Vivotif|Oral typhoid fever and cholera vaccines (Vivotif® and Dukoral®) administered simultaneously.
89341971|NCT06103786|Experimental|1. Repeated Sprint 2. Interval Sprint 3.Long-Pass Tracking Drill 4. Chase-The-Rabbit Tracking Drill|"Make repeated sprints on the ice for a certain distance to measure its speed.~On the ice, perform 15 seconds of intermittent acceleration on the ice, with 30 seconds between each slide.~On the ice, make a long pass before taking a shot, then turn to track back.~On the ice, skate down the ice, 2 on 1, with a puck to pass and shoot."
89341972|NCT06103786|Experimental|1. Varied Pace Skating 2.Driblling and Shooting Drill 3. Passing and Catching training 4. 2-on-1|"On the ice, a 1-minute accelerated skate and skating at an even pace for 2 minutes~On the ice, dribbling the ball and shooting at the goal~On the ice, they stood facing each other at a distance of 20 meters and practiced passing and catching.~On the ice, practice 2-on-1 offensive tactics and complete shots on goal."
89341973|NCT06103357||subjects with clinical indication for coronary angioplasty|Twenty subjects with acute or chronic coronary syndrome that will be underwent to angioplasty procedure according to standard clinical practice.
89341974|NCT06103227|Experimental|Low dose of prednisone group|Low doses of an intermediate acting corticosteroids (CS) administered three weeks after two-day tocolysis and respiratory distress syndrome (RDS) prophylaxis, plus neuroprotection with magnesium sulphate.
89341975|NCT06103227|Active Comparator|Standard therapy group|Two-day tocolysis and RDS prophylaxis, plus neuroprotection with magnesium sulphate.
89341976|NCT06102811|Experimental|Low Concentration Local Anesthetic Fascia Iliaca Compartment Block|Patients will be submitted to a Suprainguinal Fascia Iliaca Block with low concentration local anesthetic (Ropivacaine 0.075%)
89341977|NCT06102811|Active Comparator|High Concentration Local Anesthetic Fascia Iliaca Compartment Block|Patients will be submitted to a Suprainguinal Fascia Iliaca Block with high concentration local anesthetic (Ropivacaine 0.25%)
89341978|NCT06102603|Experimental|the biobased polyester cast group|biobased polyester cast was applied
89341979|NCT06102603|Active Comparator|the synthetic fiberglass cast group|synthetic fiberglass cast was applied
89341980|NCT06102395|Experimental|Pembrolizumab combined with standard chemotherapy|Patients receive pembrolizumab 200mg, IV, on day1 of Q3W; plus platinum (cisplatin 75 mg/m^2, IV, day 1 of Q3W or carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W or nedaplatin 80-100 mg/m^2, IV, day 2-4 of Q3W); plus other chemotherapy（nab-paclitaxel 260 mg/m^2, IV, day 1 of Q3W or docetaxel 75 mg/m^2, IV, day 1 of Q3W or liposomal paclitaxel 135-175 mg/m^2, IV, day 1 of Q3W or fluorouracil 750 mg/m^2, IV, day 1-5 of Q3W）; total 2 cycle
89341981|NCT06102395|Active Comparator|Standard chemotherapy|Patients receive platinum (cisplatin 75 mg/m^2, IV, day 1 of Q3W or carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W or nedaplatin 80-100 mg/m^2, IV, day 2-4 of Q3W); plus other chemotherapy（nab-paclitaxel 260 mg/m^2, IV, day 1 of Q3W or docetaxel 75 mg/m^2, IV, day 1 of Q3W or liposomal paclitaxel 135-175 mg/m^2, IV, day 1 of Q3W or fluorouracil 750 mg/m^2, IV, day 1-5 of Q3W）; total 2 cycle
89341982|NCT06102382|Experimental|Norepinephrine (0.1)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.1 µg/kg/min till 5 minutes after delivery of the fetus.
89341983|NCT06102382|Active Comparator|Norepinephrine (0.075)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.075 µg/kg/min till 5 minutes after delivery of the fetus.
89341984|NCT06101927|Experimental|Experimental: Prostate cancer 50 mkg|At least five (5) evaluable subjects with prostate cancer with [99mTc]Tc-BQ0413 (50 mkg)
89341985|NCT06101927|Experimental|Experimental: Prostate cancer 100 mkg|At leaAt least five (5) evaluable subjects with prostate cancer with [99mTc]Tc-BQ0413 (100 mkg)
89341986|NCT06100484||Healthy group|Pregnant women above 20 weeks of pregnancy with no hypertensive disorders with pregnancy
89341987|NCT06100484||Diseased group|Pregnant women above 20 weeks of pregnancy with gestational hypertension or pre-eclampsia
89341988|NCT06100367|Experimental|11C-metomidate PET-CT|All patients will undergo standard-of-care investigations (CT imaging of adrenals and AVS) and the research test (11C-metomidate PET-CT) with a dose of 100 - 300 Megabecquerel (MBq) (11C-metomidate) to identify functional unilateral adrenal disease
89341989|NCT06094439||good or poor embryo quality|morphological evaluation will be performed by an expert embryologist to confirm poor and good embryo quality
89341990|NCT06094439||metabolomics profiles|metabolomics profiles will be performed by a Metabolomics core facility
89341991|NCT06092632|Experimental|Pigmented Rice|Cooked black pigmented rice will be consumed for six weeks (twice per day)
89341992|NCT06092632|Placebo Comparator|White Rice|Cooked white rice will be consumed by the control group for six weeks (twice per day)
89341993|NCT06087679|Experimental|Selfcare program|6-month intervention period with a PPS guided selfcare based intervention program
89341994|NCT06087679|No Intervention|Control group|Treatment as usual
89341995|NCT06087497|Experimental|1 hour bedrest|One hour of bedrest, elevate head of bed to 30 degrees at 30 minutes, ambulate at 60 minutes, Z stitches out at 4 hours, eligible for discharge (if appropriate) at 4.5 hours.
89341996|NCT06087497|No Intervention|4 hour bedrest|Four hours of bedrest, elevate head of bed to 30 degrees at 2 hours, Z stitches out at 4 hours, ambulate at 4 hours, eligible for discharge at 4.5 hours.
89341997|NCT06086197|Experimental|A+RGEMOX|"A-RGEMOX regimen (21 days per cycle, A total of 6 cycles) :~Allotinib: 12mg d1~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1"
89341998|NCT06080165|Experimental|Sirolimus|Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and < 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and > 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.
89341999|NCT06080165|Placebo Comparator|Placebo|matching placebo
89342000|NCT06075017|Experimental|Zirconia|Two-piece zirconia dental implant will be placed to replace a single missing tooth.
89342001|NCT06075017|Active Comparator|Titanium|Two-piece titanium dental implant will be placed to replace a single missing tooth.
89342002|NCT06071260|Experimental|Study group|Participants will receive 0.01% atropine (0.1 mg/ml)
89342003|NCT06070870|Experimental|Patient Navigation|Centralized patient navigators will be trained to help patients navigate the clinical, logistical, and financial aspects of LCS. Navigators employ case management approaches based on social work principles. The experience of patient navigation will be tailored to the individual participant
89342004|NCT06064396|Experimental|Gong's Mobilization with Stecco Fascial Therapy|Participants in this group will receive Gong's Mobilization with Stecco Fascial Therapy
89342005|NCT06064396|Active Comparator|Gong's Mobilization|Participants in this group will receive Gong's Mobilization
89342006|NCT06063005|Experimental|Translocation|
89342007|NCT06063005|Active Comparator|Peeling|
89342008|NCT06062979||Enhanced (MORE) implementation (i.e., MORE group)|Study participants in this condition will be those engaged in clinical care as part of the MORE program, receiving supportive, wrap-around, and home-based HIV care services; all participants will be offered injectable Cabenuva and studied with regard to uptake and outcomes. Participants in this group will receive quantitative health survey assessments as per standard of care at Whitman-Walker Health. Participants will be offered quantitative and qualitative assessments regarding their experiences related to Cabenuva.
89342009|NCT06062979||Standard-of-care implementation (i.e., comparison group)|Study participants in this comparison condition will be those engaged in clinical care receiving Cabenuva per standard of care at Whitman-Walker Health. Participants in this group will contribute ongoing electronic health record data under the auspices of an IRB-granted waiver of informed consent and waiver of HIPAA authorization.
89342010|NCT06032091||Participants|Persons with dementia
89342011|NCT06032026|Experimental|11C-HY-2-15 PET|Participants will undergo 11C-HY-2-15 PET scan, they may also have a brain MRI and Amyloid PET scan as well as neurological assessments
89342012|NCT06028009|Experimental|Platelet-rich plasma injection|
89342013|NCT06028009|Sham Comparator|0.9% saline injection|
89342014|NCT06027983|Experimental|Chimeric Receptor T-cells|"Eligible patients will undergo apheresis prior to cycle 1 therapy. Treatment comprises of trastuzumab followed by chimeric receptor T-cells in cycle 1.~During Cycle 2 onwards till disease progression, patients will receive IV or SC trastuzumab only, every 3 weeks."
89342015|NCT06025526|Experimental|Intervention|
89342016|NCT06025526|Other|Control|
89342017|NCT06025110|Experimental|TCD601|Administered one of three doses of TCD601 over a 12 week treatment period.
89342018|NCT06025110|Placebo Comparator|Placebo|Placebo is administered over a 12 week treatment period.
89342019|NCT06016790||the cancer group|200 cases of early breast cancer (stage I-IIa breast cancer, and breast carcinoma in situ) and 80 cases of middle and advanced breast cancer (stage IIb, IIc, III, IV)
89342020|NCT06016790||the benign control group|200 cases of control group (100 cases of breast hyperplasia, 100 cases of breast fibroma)
89342021|NCT06012019||Periodontitis Cases|Patients with stage 3 or 4 periodontitis (Chicago 2017) ; BOP ≥ 10%, PD≥ 4mm Patients requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries
89342022|NCT06012019||Gingivitis Cases|BOP ≥ 10%, PD≤ 3mm according to Chicago 2017 Patients requiring surgical care such as dental avulsion or pre-prosthetic periodontal surgeries
89342023|NCT06012019||Control|BOP < 10%, PI < 20%, PD≤ 3mm Patients with gingival health on intact or reduced periodontium without a history of periodontitis and requiring surgical care such as dental avulsion or aesthetic surgeries
89342024|NCT05999344|Experimental|Alcohol before Cannabis|Participants are randomly assigned to receive the standardized alcohol dose during the experimental session prior to going inside their residence to self-administer their preferred cannabis concentrate product.
89342025|NCT05999344|Experimental|Cannabis before alcohol|Participants are randomly assigned to go inside their residence to self-administer their preferred cannabis concentrate product and then receive the standardized alcohol dose.
89342026|NCT05995613||MABOS|Participants will have one FDA-approved pulse oximeter (Nonin PureSat) along with our novel pulse oximeter placed to acquire 90 minutes of biometric data
89531675|NCT05799833||Young healthy individuals (non-athletes) with low QRS voltage|"Cohort (anticipated N = 60) will undergo testing with 12 lead ECG, blood test, cardiac MRI, 24 hour holter monitoring and cardiopulmonary exercise testing.~A subgroup of those identified to have low QRS voltage and myocardial scar on CMR will undergo genetic testing (anticipated number to be tested, N= 25)"
89342027|NCT05989568|Experimental|BASIS-T|BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.
89342028|NCT05989568|Placebo Comparator|Attention Control|Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
89342029|NCT05965401|Experimental|Pharmacogenetic (PGx)-Guided|Participants and their physician will receive a one-time prescribing report after completing baseline for second-line selective serotonin reuptake inhibitors with dosing information based on CYP2B6, CYP2C19, and CYP2D6 genotype data.
89342030|NCT05965401|Active Comparator|Guidelines for Adolescent Depression in Primary Care (GLAD-PC)-Guided|Participants and their physician will receive a one-time prescribing report after completing baseline for second-line selective serotonin reuptake inhibitors based on GLAD-PC dosing guidelines.
89342031|NCT05965362||Infective endocarditis group|Patients diagnosed with infective endocarditis.
89342032|NCT05959057|Experimental|Enteric/Micro Order|Subjects will receive randomly two distinct formulations of ERr 731® in a 43 day trial consisting of treatment phase 1 (14-days), washout phase (14-days),treatment phase 2 (14-days): Arm 1 will receive enteric coated ERr 731® during treatment phase 1 and micro-coated ERr 731®during treatment phase 2
89342033|NCT05959057|Experimental|Micro/Enteric Order|Subjects will receive randomly two distinct formulations of ERr 731® in a 43 day trial consisting of treatment phase 1 (14-days), washout phase (14-days),treatment phase 2 (14-days): Arm 2 will receive micro-coated ERr 731® during treatment phase 1 and enteric coated ERr 731®during treatment phase 2
89342034|NCT05955456||Participants in primary care with risk factors for heart failure|
89342035|NCT05951283|No Intervention|MDI|"All participants will have:~Continuous Glucose Monitoring Neuropathy Assessments and Pain Questionnaires ACR, Blood Tests"
89342036|NCT05951283|Active Comparator|Artificial Pancreas - Closed Loop|"All participants will have:~Continuous Glucose Monitoring Neuropathy Assessments and Pain Questionnaires ACR, Blood Tests"
89342037|NCT05949567|Experimental|Lying position first - then sitting position|
89342038|NCT05949567|Experimental|Sitting position first - then lying position|
89342039|NCT05936554|Active Comparator|whole body vibration|will receive whole body Vibration training that elicits a warm up effect to improves muscle power and balance in addition to designed physical program.
89342040|NCT05936554|Active Comparator|Functional strength training|will receive Functional strength training that focuses on the movement pattern quality and treats functional movement and provides postural stability while promoting balance independence with confidence
89342041|NCT05935553|Experimental|Baclofen 30 microgram (mg) treatment|baclofen treatment (30 mg/per day)
89342042|NCT05935553|Experimental|Baclofen 60 mg|baclofen treatment (60 mg/per day)
89342043|NCT05935553|Placebo Comparator|Placebo|
89342044|NCT05932303|Experimental|BMS-986278, followed by itraconazole|
89342045|NCT05932303|Experimental|BMS-986278, followed by gemfibrozil|
89342046|NCT05932303|Experimental|BMS-986278, followed by carbamazepine|
89342047|NCT05922605|Experimental|Group E|the children are given a mixture of 0.2%ropivacaine 0.7 ml／kg and preservative-free S-ketamine 0.5 mg/kg for caudal analgesia.
89342048|NCT05922605|Active Comparator|Group C|The children are given 0.2%ropivacaine 0.7 ml／kg and saline of equal volume caudally.
89342049|NCT05919654|Experimental|Treatment|Myocare
89342050|NCT05919654|Active Comparator|Control|Clearview
89342051|NCT05917457|Experimental|treatment group|to be in the age of 7-14, Except for visual impairment (neurological and systemic diseases, hearing impairment, etc. ) not having an additional disease Having been diagnosed with low vision, To be able to establish cooperation, Volunteering to participate in the study 12 children with these criteria
89342052|NCT05917457|No Intervention|control group|to be in the age of 7-14, Except for visual impairment (neurological and systemic diseases, hearing impairment, etc. ) not having an additional disease, Having been diagnosed with low vision, To be able to establish cooperation, Volunteering to participate in the study 10 children with these criteria
89342053|NCT05887037|Experimental|Experimental group|The experimental group was sent for CSF mNGS and traditional microbiological cultures at the same time, and the mNGS results were usually earlier than the traditional microbiological cultures results. The experimental group adjusted or continued the current medication regimen according to the mNGS reporting pathogen and the expert team's opinion. Subsequently, if the CSF traditional microbiological cultures results in the experimental group are consistent with the mNGS results, the current treatment plan of the patient is continued, and if the results are inconsistent with the mNGS results, the expert team needs to discuss and adjust the treatment plan. When no causative organism is detected in mNGS, empiric treatment is continued, and treatment is adjusted pending the pathogen culture results.
89342054|NCT05887037|Active Comparator|Control group|After a clinical diagnosis of central nervous system infection, the control group was treated empirically based on only cerebrospinal fluid for traditional microbiological cultures, without mNGS detection, and the treatment plan was adjusted according to the traditional microbiological cultures results. If the patient's culture is negative and empiric therapy does not improve, cerebrospinal fluid is retained for mNGS testing. Treatment is adjusted based on mNGS results and expert team evaluation.
89342055|NCT05885412|Experimental|RP-A601|Single ascending dose of RP-A601 in 2 consecutive cohorts
89342056|NCT05880602|Placebo Comparator|Control|Subjects will take two capsule of containing starch, twice a daily for 8 weeks.
89342057|NCT05880602|Experimental|Treatment|Subjects will take two capsule of containing nettle and cranberry complex, twice a daily for 8 weeks.
89342058|NCT05877274||Patients with ACNES|Patients with ACNES who fulfill the inclusion criteria.
89342059|NCT05872854|Experimental|HyBryte (0.25 % Hypericin) with Visible Light|HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 24 (±6) hours later starting at 5 J/cm^2. Drug application/light sessions will be done twice a week (at least 2 calendar days apart) for up to 54 weeks.
89342060|NCT05860348||Device: Barostim™ System|Implantation of the Barostim™ System
89342061|NCT05855759|Active Comparator|Acellular Dermal Matrix|Enrolled patients will be randomly assigned to the suture-bridge technique with acellular dermal matrix
89342062|NCT05855759|Experimental|Acellular Dermal Matrix with autologous orthobiologics|Enrolled patients will be randomly assigned to the suture-bridge technique with acellular dermal matrix with orthobiologics autologous: humeral bone marrow concentrate and subacromial bursa
89342063|NCT05838092|Experimental|Verum|
89342064|NCT05838092|Placebo Comparator|Placebo|
89342065|NCT05831813|Experimental|Goal-Based Cognitive Behavioural Intervention|"Participants start with a 1 to 7 weeks baseline period. The duration is based on the enrolment date and therefore not random. Afterward, all participants enter the intervention, which promotes social behavioural activation aligned with personal values and teaches skills that make negative emotions and thoughts less bothersome and reduce feelings of loneliness. The intervention comprises seven weekly sessions and a follow-up, conducted in a group format to facilitate interpersonal practice and is presented as a course for enhanced acceptability.~Please note: The original design involved an RCT with a Goal-Based Cognitive Behavioral Intervention as the experimental arm and a waitlist arm. Participants in the waitlist arm would enter the intervention after a waitlist period. Due to limited enrollments, the design was modified to a single arm resembling the waitlist arm of the initial RCT design."
89342066|NCT05828667|No Intervention|Standard of Care Arm|Standard of care procedural steps per respective institution and attending physician's clinical practice.
89342067|NCT05828667|Experimental|Imaging-aided VT ablation|For subjects assigned to the imaging-aided VT ablation arm, CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This integrated mapping of VT substrates sites to be ablated will be given to the electrophysiologist prior to the ablation.
89342068|NCT05826301|Experimental|Percutaneous neuromodulation in tibial nerve|"Specifically, the procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.~2 times per week"
89342069|NCT05826301|Active Comparator|Percutaneous electrolysis|"The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per week"
89342070|NCT05807282|Experimental|Intervention group|40 farmworkers will be randomized to receive the workplace- and individual-level interventions developed in collaboration with study partners (e.g., provision of hydration packs to participants). Participants will receive the intervention at the workplace and will be monitored for five weeks after the intervention to evaluate the efficacy in reducing perceived and physiological heat stress.
89342071|NCT05807282|No Intervention|Control group|40 farmworkers will be randomized to receive no intervention, and will continue their work as normal. These farmworkers will be monitored for the same period as the intervention group to assess perceived and physiological heat stress.
89342072|NCT05756361|Experimental|20 Child-Parent Dyads|Family-Based Behavioral Treatment
89342074|NCT05732727|Experimental|Experimental group|Antihypertensive algorithm based on diuretics agents : the clinicians will adjust the drug therapy according to the antihypertensive algorithm based on diuretics agents.
89342075|NCT05732727|Active Comparator|Control group|Standard of care : the clinicians will adapt the antihypertensive strategy according to his own standard of care which can be pharmacological or non-pharmacological therapies.
89342076|NCT05721131||Temperature measurement|Each subject will have their temperature measured by both the NC° Thermometer (Gen 3) and the reference clinical thermometer.
89342077|NCT05715619|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally three times a day for 7 days (Phase 1) or 14 days (Phase 2a)
89342078|NCT05715619|Active Comparator|VRELysin™|Dose is 1mL of bacteriophage preparation given orally three times a day for 7 days (Phase 1) or 14 days (Phase 2a)
89342079|NCT05712577||MFS_PT+|MFS patients who followed psychological support/psychotherapy
89342080|NCT05712577||MFS_PT-|MFS patients who never followed psychological support/psychotherapy
89342081|NCT05696782|Experimental|Quick Start Durvalumab|Standard of care test and procedures for cancer treatments along with Durvalumab treatment at physician's discretion
89342082|NCT05691699|Experimental|Part 1, ABBV-903|Participants will receive a single ascending dose of ABBV-903 in Part 1.
89342083|NCT05691699|Experimental|Part 1, Placebo|Participants will receive a single ascending dose of placebo in Part 1.
89342084|NCT05691699|Experimental|Part 2, ABBV-903|Participants will receive multiple ascending doses of ABBV-903 in Part 2.
89342085|NCT05691699|Experimental|Part 2, Placebo|Participants will receive multiple ascending doses of placebo in Part 2.
89342086|NCT05691699|Experimental|Part 3, Sequence 1|Participants in Part 3 will follow Sequence 1.
89342087|NCT05691699|Experimental|Part 3, Sequence 2|Participants in Part 3 will follow Sequence 2.
89342088|NCT05684874|Experimental|Pre- and post- radiotherapy multiparametric quantitative MRI|"Patients with STS of the limbs and trunk will be accrued during the initial radiotherapy consultation radiotherapy (prior to receiving radiotherapy).~Two quantitative multiparametric MRI will be performed. The first one will be acquired less than 14 days before the dosimetric scan, the second one 4 to 6 weeks after the end of the radiotherapy.~A tumor resection will be performed 6 to 8 weeks post-RT and an anatomopathological observation of the surgical specimen will be performed."
89342089|NCT05662371|Placebo Comparator|Standard Clinical Care Group|Hemodynamic changes outside of the normal range i.e., hypertension (systolic blood pressure greater than 140 mm Hg), tachycardia (heart rate greater than 90 min-1) and hypotension (mean arterial pressure less than 60 mm Hg) will be first assessed using the guidance of Bispectral index and Train of four monitors. Sufentanil in doses of 2.5 to 5 mcg (maximum of 0.6-1.2 mic/kg for the entire surgery) is administered if the Bispectral index and Train of four monitor values are within normal range and if required vasopressor infusion is used. Vasoconstrictors may be given as a continuous infusion of norepinephrine, or bolus doses of ephedrine or phenylephrine. Only when blood pressure remains, low additional crystalloids will be given. Finally, in case of bradycardia (heart rate less than 30 min-1), atropine may be given
89342090|NCT05662371|Experimental|Nociception Level-guided Analgesia Group|In the nociception level-guided group, sufentanil will be administered to maintain a nociception level value between 10 and 25. In case the nociception level values rise greater than 25 for more than 60 s, additional 2.5 microgram sufentanil (if nociception level increase remained less than 45) or 5 micrograms (if nociception level increase greater than 45). Atropine will be administered when heart rate decreases less than 30 min-1. Because the nociception level may be sensitive to such medication, nociception level values will then not used for at least 5 min to guide analgesia, with the exception of norepinephrine as this drug will be given as continuous infusion
89342091|NCT05653193|Active Comparator|Antifungal|Any oral triazole antifungal as per routine care
89342092|NCT05653193|Experimental|Antifungal plus inteferon gamma|Any oral triazole antifungal as per routine care plus interferon-gamma three times weekly subcutaneously 50 micrograms/m2 for 3 months
89342093|NCT05622331||RSV cohort|Children (<5 years of age at diagnosis) with a diagnosis of RSV (ICD-10 code) in hospital care between July 1st 2006 and June 30th 2021
89342094|NCT05622331||Regional primary care RSV cohort|Children (<5 year of age) with a diagnosis of RSV (ICD-10 code) in primary care identified in regional databases (Region Skåne, Region Halland and VGR) between July 1st 2006 and June 30th 2021
89342095|NCT05622331||Regional laboratory RSV cohort|Children (<5 years of age) with a positive laboratory RSV test result (multiplex/rapid PCR, antigen, immunofluorescence or immunochromatography rapid test) in primary or hospital care, identified in regional laboratory databases (Region Skåne and Region Halland) between July 1st 2006 and June 30th 2021
89342096|NCT05622331||Acute Respiratory Infections (ARI) cohort|Children (<5 of age) with a diagnosis of ARI (ICD-10 code,) in hospital care between July 1st 2006 and June 30th 2021
89342097|NCT05622331||Regional ARI cohort|Children (<5 years of age) with a diagnosis of RSV (ICD-10 code, see Table 1) in primary care, identified in regional databases (Region Skåne, Region Halland and VGR)
89342098|NCT05622331||Rhinovirus cohort|Children (<5 of age) with a diagnosis of rhinovirus (ICD-10 code,) in hospital care between July 1st 2006 and June 30th 2021
89342099|NCT05622331||Human Metapneumovirus (HMPV) cohort|Children (<5 of age) with a diagnosis of HMPV (ICD-10 code,) in hospital care between July 1st 2006 and June 30th 2021
89342100|NCT05622331||Parainfluenza cohort|Children (<5 of age) with a diagnosis of parainfluenza (ICD-10 code,) in hospital care between July 1st 2006 and June 30th 2021
89342101|NCT05622331||Parent cohort|Parents to all children will be linked to the study population, which is possible through linkage between children and parents by their personal identifiers
89342102|NCT05622331||Non-RSV control cohort|A non-RSV control population consisting of children (<5 years of age) will be extracted to estimate the burden compared to the general population
89342103|NCT05618236||neostigmin+atropin|This will be the group of patients decurarized with neostigmine+atropine,
89342104|NCT05618236||sugammadeks|This will be the group of patients decurarized with sugammadex.
89342105|NCT05618210||erector spinae plane block group|In the ESPB group, after the patients are placed in the prone position, the linear ultrasound probe will be placed in the midline in the transverse plane to visualize the spinous processes, and the transverse process, trapezius, latissimus dorsi and erector spina muscles will be visualized on the side where VATS is planned at the T5 vertebra level. With an 'in-plane' approach, using a 22 gauge 5-8 cm block needle with extension line (Braun, Melsungen, Germany), which can be seen on ultrasound, the skin, subcutaneous and trapezius, latissimus dorsi and erector spina muscles are passed in the cranio-caudal direction and 0.5- After confirming the needle site with 1 ml of saline, the ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.
89342106|NCT05618210||Rhomboid block|In the rhomboid intercostal block group, after the patients are placed in the prone position, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and a 50-80 mm needle will be injected into the plan between them at the T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection.
89342107|NCT05598255|Active Comparator|Caudal blockade (with levobupivacaine) and dexamethasone IV|Administration of levobupivacaine 0,25% 0,5 ml/kg through the hiatus sacralis lege artis. IV administration of dexamethasone 0,5mg/kg (max. 5mg) during standard anaesthetic management.
89342108|NCT05598255|Active Comparator|Dorsal penile nerve block (with levobupivacaine) and dexamethasone IV|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia. IV administration of dexamethasone 0,5mg/kg (max. 5mg) during standard anaesthetic management.
89342109|NCT05598255|Active Comparator|Dorsal penile nerve block (with levobupivacaine)|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia.
89342110|NCT05587894|Experimental|Nirmatrelvir/r 5 days alone|
89342111|NCT05587894|Experimental|Nirmatrelvir/r 10 days alone|
89342112|NCT05587894|Experimental|Nirmatrelvir/r 5 days + remdesivir s.d|
89342113|NCT05587894|Experimental|Nirmatrelvir/r 10 days + remdesivir s.d|
89342114|NCT05572476|Experimental|Experimental Arm A: treatment by lurbinectedin and durvalumab|Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of lurbinectedin and durvalumab
89342115|NCT05572476|Other|Standard Arm B: treatment by carboplatin and etoposide|Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of carboplatin and etoposide
89342116|NCT05558813|Experimental|DMD-CMP cohort|Minor (≥ 6 years) and major patients with genetically proven Duchenne myopathy
89342117|NCT05558709|Experimental|Patients|Patients suffering from a neurodegenerative disease (Alzheimer's disease (AD), dementia with Lewy bodies (DCL) or fronto-temporal lobar degeneration (FTD))
89342118|NCT05558709|Other|Relatives|Caregivers or relatives of included patients, having regular contact with the patient (≥ 2 times per month).
89342119|NCT05545072|Experimental|Dupilumab|150 mg/mL in a pre-filled syringe to deliver 300 mg in 2 mL given subcutaneous every 2 weeks during the treatment period
89342120|NCT05545072|Placebo Comparator|Placebo|Pre-filled syringe to deliver 2 mL given subcutaneous every 2 weeks during the treatment period
89342121|NCT05533034|Experimental|Home based exercises|1 supervised session in the outpatient rehabilitation department with respiratory, aerobic and muscles strengthening exercises, followed by 3 months of self-manage personalized home exercises program. Cardiac frequency and adherence to exercise will be monitored using an activity tracker (Garmin© watch).
89342122|NCT05532904|Other|Intervention|"This 6-week program of care will include:~group education sessions including a psycho-education component (1 session / week)~a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)"
89342123|NCT05532904|No Intervention|Control|Usual care (waiting list)
89342124|NCT05523154|Active Comparator|Arm I (biospecimen collection, routine testing)|Patients undergo the collection of bile samples during standard of care surgery. Samples undergo routine laboratory testing.
89342125|NCT05523154|Experimental|Arm II (biospecimen, nanopore sequencing, routine testing)|Patients undergo the collection of bile samples during standard of care surgery. Samples undergo nanopore sequencing and routine laboratory testing.
89342126|NCT05498831||Pain relief protocol according to the recommendations of the French Emergency Medicine Society|The first phase consists in collecting, over a one-month period, data concerning the analgesic management of patients based on the recommendations of the 2010 French Emergency Medicine Society, before the effective implementation of the new pain management protocol, which should be implemented between 2 to 4 months later. Adverse events and patient's satisfaction will also be collected.
89342127|NCT05498831||Pain relief protocol with intranasal sufentanil as a starter|The second phase consists in collecting, over a one-month period, data concerning the analgesic management of patients after the implementation of the new protocol based on the use of intranasal sufentanil as a starter for pain of moderate and severe intensity. Adverse events and patient's satisfaction will also be collected during the second phase.
89342128|NCT05490667|Experimental|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
89342129|NCT05485012|Experimental|Double-blind marijuana/placebo administration|Participants will receive double-blind administration of vaporized marijuana/placebo
89342130|NCT05485012|Experimental|Double-blind opioid/placebo administration|Participants will receive double-blind administration of intranasal opioid agonist/placebo
89342131|NCT05473351||Thirst|Patients undergoing invasive mechanical ventilation for at least 24 hours in one of the participating centers
89342132|NCT05473091||Experimental group|
89342133|NCT05473091||Control group|
89342134|NCT05463900||Ulcerative Colitis (UC)|Individuals with an ICD-10 diagnosis of Ulcerative Colitis.
89342135|NCT05463900||Crohn's Disease (CD)|Individuals with an ICD-10 diagnosis of Crohn's Disease.
89342136|NCT05456568|Experimental|All participants|All participants will use IPC daily at home for 12 weeks alongside usual and standard care
89342137|NCT05450393||PillCam SB procedure and deep enteroscopy (Device-assisted enteroscopy, DAE)|Subjects with abnormal PillCam SB3 procedure followed by DAE (if performed).
89342138|NCT05428345||Participants With UC or CD|Participants diagnosed with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist and have initiated treatment with vedolizumab in a routine clinical practical setting in South Korea, will be observed prospectively for 52 weeks.
89342139|NCT05417867||Observational (survey, biospecimen collection)|Patients undergo collection of stool samples over 10 minutes and complete questionnaires over 60 minutes at baseline and 3-5 days following initiation of standard of care chemotherapy.
89342140|NCT05386901|Experimental|Conventional positive end-expiratory pressure(PEEP)|Once the patient is intubated and after initiating ventilation in a pressure control mode(PCV) using an airway pressure of 20-25mmHg with tidal volume not exceeding 6ml/kg of predicted body weight (PBW) and an inspiration: expiration ratio of 1:2;a respiratory rate of 20-30 breaths per minute to maintain the etCO2 at 35-40 mmHg.The investigators will set the PEEP value to 5 cmH2O until the end of the operation.
89342141|NCT05386901|Experimental|Lung dynamic compliance guided positive end-expiratory pressure(PEEP)|Once the patient is intubated and after initiating ventilation in a pressure control mode(PCV) using an airway pressure of 20-25mmHg with tidal volume not exceeding 6ml/kg of predicted body weight (PBW) and an inspiration: expiration ratio of 1:2;a respiratory rate of 20-30 breaths per minute to maintain the etCO2 at 35-40 mmHg.The investigators will set initial PEEP to 0cmH2O,and the PEEP is increased by 2 cmH2O every 2 minutes.Observing the PEEP value corresponding to the maximum lung dynamic compliance during the process that lung dynamic compliance=Vt/(Pplat-PEEP).After the incremental PEEP process is completed, setting the PEEP value for ventilation until the end of the operation.
89342142|NCT05378932|Experimental|Hypohidrotic ectodermal dysplasia|Patients aged 3 to 40 years old with hypohidrotic ectodermal dysplasia.
89342143|NCT05378932|Active Comparator|Healthy controls|Healthy controls aged 3 to 40 years old without hypohidrotic ectodermal dysplasia.
89342144|NCT05376813|Experimental|Experimental arm|All participants are healthy volunteers
89342145|NCT05373849|Experimental|Aromatherapy first then no intervention|The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
89342146|NCT05373849|Experimental|No intervention first then Aromatherapy|The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
89342147|NCT05366179|Experimental|Single Arm|"CAR.B7-H3 T cells:~Subjects with refractory or recurrent glioblastoma multiforme, have cells collected following their initial surgical resection to manufacture CAR.B7-H3 T cells, preferably before initiation of adjuvant chemoradiation."
89342151|NCT05337163||Lung cancer group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting sputum specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) , eligible subjects also need to undergo the chest CT or pathological examination.
89342152|NCT05337163||The normal group|Two groups of sequential enrolled subjects, eligible subjects will be included in the study according to the inclusion criteria. In addition to collecting sputum specimen for the testing kit of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) , eligible subjects also need to undergo the chest CT or pathological examination.
89342153|NCT05322070|Experimental|Fluocinolone Acetonide 0.18 mg|Fluocinolone Acetonide Intravitreal Implant 0.18 mg
89342154|NCT05319977|Experimental|Mobile incentive-based intervention|Contingent incentives on abstinence from alcohol; Text-based health promotion support
89342155|NCT05302050|Active Comparator|Intervention BT-001 + Standard of Care|Patients in this arm will receive the BT-001 treatment for up to 18 months.
89342156|NCT05302050|Other|Standard of Care|Patients will have access to a control mobile application for 6 months and then will have the option to use the treatment for the remainder of the 18 month study
89342157|NCT05283486|Experimental|Cohort 1: MYMD1 600mg|Subjects randomly assigned to the MYMD1 600mg cohort
89342158|NCT05283486|Placebo Comparator|Cohort 1: Placebo 600mg|Subjects assigned to the 600mg placebo group
89342159|NCT05283486|Experimental|Cohort 2: MYMD1 750mg|Subjects randomly assigned to the MYMD1 750 cohort
89342160|NCT05283486|Placebo Comparator|Cohort 2: Placebo 750mg|Subjects assigned to the 750mg placebo group
89342161|NCT05283486|Experimental|Cohort 3: MYMD1 900mg|Subjects randomly assigned to the MYMD1 900mg cohort
89342162|NCT05283486|Placebo Comparator|Cohort 3: Placebo 900mg|Subjects assigned to the 900mg placebo group
89342163|NCT05283486|Active Comparator|Cohort 4: MYMD1 1050mg|Subjects randomly assigned to the MYMD1 1050mg cohort
88806882|NCT04824066||Cardiothoracic Surgery Cohort|Adults patients who are scheduled to undergo cardiothoracic surgery and meet the inclusion and exclusion criteria.
89342164|NCT05283486|Placebo Comparator|Cohort 4: Placebo group 1050mg|Subjects assigned to the 1050mg placebo group
89342165|NCT05269589|Sham Comparator|Thermoneutral|Participants will immerse their feet in a foot bath with water maintained at 36°C
88806883|NCT04822584|Experimental|Phototherapy associated with active treatment|"Baricitinib 4 mg/day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.~(Phototherapy will be started 12 weeks after the beginning of baricitinib)"
88806884|NCT04822584|Placebo Comparator|Phototherapy associated with placebo|"Placebo once a day orally for 36 weeks + UVB TL01: 2 times a week during 24 weeks.~(Phototherapy will be started 12 weeks after the beginning of placebo of baricitinib)."
89342166|NCT05269589|Experimental|Heat|Participants will immerse their feet in a foot bath with water maintained at 42°C
89342167|NCT05266625|Experimental|Intervention BT-001 + Standard of Care|Patients in this arm will receive the BT-001 treatment for up to 720 days.
89342168|NCT05266625|Other|Standard of Care|Patients will have access to a control mobile application for 180 days and then will have the option to use the treatment for the remainder of the 720 day study
89342169|NCT05263349||COPD patients|Arm with patients with respiratory disease in whom we study dreams
89342170|NCT05263349||healthy subject|Arm with healthy subjects whose dream analysis will be used as a basis to compare them to the dreams of COPD patients and see if the disease (COPD) has an influence on the patients' dreams
89342171|NCT05239572|Experimental|Screening and early detection of diabetes and cardiovascular diseases|"Screening for NCDs based on questionnaire concerning vital information, lifestyle, simple measures of length, bodyweight, BMI, blood pressure, application of FinRisk score and WHO risk score.~Health promotion and lifestyle counselling and referral to PHC facilities for further diagnosis and treatment."
89342172|NCT05198960|Experimental|Experimental group|Patients randomized to receive Direct Oral Anticoagulants, at the choice of the investigator Apixaban 2.5 mg both in day or Rivaroxaban 10 mg one per day, at the choice of the investigator
89342173|NCT05198960|Active Comparator|Control group|Patients randomized to receive Low-Dose Aspirin Aspirin 100 mg one per day
89342174|NCT05151471|Experimental|MT-1186 - Group 1|Oral edaravone administered once daily for up to 48 weeks or until the drug is commercially available in that country.
89342175|NCT05151471|Experimental|MT-1186 - Group 2|Oral edaravone administered for 10 days followed by 18-day placebo (regimen denoted as on/off) for up to 48 weeks or until the drug is commercially available in that country.
89342176|NCT05126810||Observational (questionnaire)|Patients complete a questionnaire over 15-20 minutes. Patients positive for a TP53 mutation complete an additional questionnaire over 15-20 minutes within 1 month after test results.
89342177|NCT05121519|Experimental|Avoid|Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.
89342178|NCT05121519|Experimental|Consume|Patients will undergo this intervention for up to 6 months, or whenever their AF returns, whichever comes first.
89342179|NCT05054374|Experimental|Arm 1, Part 1 - mirdametinib in combination with fulvestrant|"Postmenopausal patients with estrogen receptor positive metastatic breast cancer harboring NF1 loss of function or another alteration of the MAPK pathway.~Part 1: safety run-in (confirmation of the RP2D for mirdametinib in combination with the standard recommended dose of fulvestrant). This part may include the mirdametinib dose de-escalation according to the 3+3 design if necessary"
89342180|NCT05054374|Experimental|Arm 1, Part 2 - mirdametinib in combination with fulvestrant|"Postmenopausal patients with estrogen receptor positive metastatic breast cancer harboring NF1 loss of function or another alteration of the MAPK pathway.~Part 2: dose expansion cohorts where the mirdametinib RP2D will be administered in combination with the standard recommended dose of fulvestrant"
89342181|NCT05054374|Experimental|Arm 2, Part 1 - mirdametinib as single agent|"Adult patients with advanced solid cancers driven by the alteration of the MAPK pathway~Part 1: mirdametinib dose escalation to MTD or RP2D according to the 3+3 design"
89342182|NCT05054374|Experimental|Arm 2, Part 2 - mirdametinib as single agent|"Adult patients with advanced solid cancers driven by the alteration of the MAPK pathway~Part 2: dose expansion cohorts"
89342183|NCT05051436|Experimental|Mirabegron (M)|Drug will be administered for 12 weeks after baseline procedures.
89342184|NCT05051436|Experimental|Tadalafil (T)|Drug will be administered for 12 weeks after baseline procedures.
89342185|NCT05051436|Experimental|Mirabegron and Tadalafil (MT)|Both drugs will be administered for 12 weeks after baseline procedures.
89342186|NCT05051436|Placebo Comparator|Placebo (P)|
89342187|NCT05045066|Experimental|Treatment (cholecalciferol)|Patients with low vitamin D3 levels receive cholecalciferol PO daily for 8 weeks in the absence of unacceptable toxicity.
89342188|NCT05039359|Active Comparator|FlecIH-103 (flecainide acetate inhalation solution)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1. Dosing will continue until conversion of AF to SR is observed for ≥1 minute or the full dose (120 mg eTLD) is administered, whichever occurs first.
89342189|NCT05039359|Placebo Comparator|Vehicle-matched inhalation solution (placebo)|Up to two 3.5-minute inhalations separated by a 1-minute break, for a total duration of up to 8 minutes on Day 1.
89342190|NCT05037500|Experimental|Treatment (decitabine and cedazuridine, enzalutamide)|Patients receive decitabine and cedazuridine PO QD on either days 1-3, 1-4, or 1-5 and enzalutamide PO QD on days 1-28. Treatments repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89342191|NCT05035836|Experimental|Zanidatamab|zanidatamab by vein every 2 weeks (+/- 3 days) for up to 6 doses (3 study cycles
89342192|NCT05035615||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria, are leftover from routine flow cytometry testing, and are from subjects having or suspected of having a hematological or non-hematological disorder.
89342193|NCT05032339||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for plasma cell disorders
89342194|NCT05030155|Experimental|Patients with FFS=0 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336
89342195|NCT05030155|Placebo Comparator|Patients with FFS=0 - Placebo|Placebo of Mepolizumab every 4 weeks until D336
89342196|NCT05030155|Experimental|Patients with FFS≥1 - Mepolizumab|Mepolizumab 300mg every 4 weeks until D336 and placebo of Azathioprine 1mg/kg/day from D126 until D360 and placebo of cyclophosphamide/mesna at D1, D15, D28, D56, D84 and D112
89342197|NCT05030155|Placebo Comparator|Patients with FFS≥1 - Placebo|Placebo of Mepolizumab every 4 weeks until D336, cyclophosphamide and mesna at D1, D15, D28, D56, D84 and D112 and Azathioprine 1mg/kg/day from D126 until D360
89342198|NCT05029752|Other|Vendys II Device|Your participation in this study will be over after your blood vessel health is measured 1 time with the Vendys II device
89342199|NCT05021354|Experimental|Dry needling+eccentric exercises|It is established a plan of treatment base on the evidence for dry needling, eccentric exercise in the patient with lateral epicondylalgia. This is done in two sessions, one session every 10 days and with a duration of about 45 minutes.
89342200|NCT05021354|Active Comparator|topical gel|application of topical gel to the area of pain
89342201|NCT05021354|Active Comparator|NSAIDs|oral intake of NSAIDs
89342202|NCT05020847|Active Comparator|Standard F75|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
89342203|NCT05020847|Experimental|Alternative F75 with CMV|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
89342204|NCT05020847|Experimental|Alternative F75 without CMV|"At the admission, therapeutic food is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed.~A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis."
89342205|NCT04999020|Experimental|Ravulizumab|Participants will receive ravulizumab in both Parts A and B.
89342206|NCT04999020|Placebo Comparator|Placebo|Participants will receive placebo in both Parts A and B.
89342207|NCT04990102|Experimental|CPX-351|Dose Level 1: CPX-351 administered through intravenou infusion on Day 1 and Day 3 of 28 day cycle for 6 cycles or Dose Level -1: CPX-351 administered through intravenous infusion on Day 1 of each 28 day cycle for 6 cycles.
89342208|NCT04986839|Active Comparator|Ibuprofen|Standard treatment arm which will provide the comparator arm to the proposed new treatment. This is routine standard of practice
89342209|NCT04986839|Experimental|Paracetamol|To study the efficacy of Paracetamol (proposed new treatment) in treating hsPDA in comparison to Ibuprofen (current standard treatment) in preterm infants
89342210|NCT04983407|Experimental|Phase 1b: batiraxcept+ nab-paclitaxel and gemcitabine|Up to three dose levels of bactiraxcept plus nab-paclitaxel and gemcitabine
89342211|NCT04983407|Experimental|Phase 2: batiraxcept+ nab-paclitaxel and gemcitabine|
89342212|NCT04983407|Active Comparator|Phase 2: nab-paclitaxel and gemcitabine alone|
89342213|NCT04941248||Healthy controls|All healthy subjects will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
89342214|NCT04941248||Patients with decreased cardiac function|All patients will undergo the following intervention: 13N-NH3 PET/CT scan on the total-body uEXPLORER scanner.
89342215|NCT04932603||experimental|Patients with AF, hospitalized in one of the 6 geriatrics units participating in the study, aged 75 years or over, without evaluation of their antithrombotic treatment by the multidisciplinary team. The lack of review of patient's file by the multidisciplinary team is based on physician decision.
89342216|NCT04932603||Standard of care|
89342217|NCT04927377|Experimental|AI4DM Intervention Group|
89342218|NCT04927377|Active Comparator|Attention-control Group|
89342219|NCT04923191|Other|Angiography-derived Physiology Guidance: angio-FFR (QFR and caFFR)|Quantitative Flow Ratio- QFR, Coronary angiography-derived FFR - caFFR
89342220|NCT04923191|Other|Local routine diagnostic procedure (LRDP) and usual care|
89342221|NCT04903535|Experimental|Healthy Volunteers|Study will enroll to test the assay
89342222|NCT04899089|Experimental|Video Game Training Condition|Participants complete an 8 week long computerized cognitive training intervention. Participants play the games for 45 minutes, three times per week.
89342223|NCT04899089|Active Comparator|Trivia Training Condition|Participants complete an 8 week long computerized trivia training. Participants complete the trivia training for 45 minutes, three times per week.
89342224|NCT04897841|Placebo Comparator|control arm|The control arm will receive 30 mL of bupivacaine HCl plus 50 mL of saline injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
89342225|NCT04897841|Experimental|Intervention: liposomal bupivacaine|The intervention arm will receive 30 mL of bupivacaine HCl plus 30 mL of saline plus 20 mL of liposomal bupivacaine injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
89342226|NCT04896892||Total Knee Arthroplasty|Patients in this group will be undergoing total knee arthroplasty.
89342227|NCT04896892||Total Hip Arthroplasty|Patients in this group will be undergoing total hip arthroplasty.
89342228|NCT04893356||Dacarbazine treated sarcoma patients|"Approximately 75 patients with histological diagnosis of Leiomyosarcoma (SCL) and Solitary Fibrous Tumor(SFT), previously treated with dacarbazine alone or associated with anthracyclines, will be enrolled, diagnosed from 2010 to 2020.~From formalin fixed tumor samples, DNA will be extracted and MGMT expression and MGMT promoter methylation analyzed."
89342229|NCT04893083||LRRK2 Mutant PD|Patients with a G2019S mutation
89342230|NCT04893083||LRRK2 Wild Type PD Low burden|Patients with a low burden of genetic modifiers
89342231|NCT04893083||LRRK2 Wild Type High burden|Patients with a high burden of genetic modifiers
89342232|NCT04892537|Active Comparator|CSR|Coronary Sinus Reducer implantation
89342233|NCT04892537|Placebo Comparator|Placebo|Placebo procedure
89342234|NCT04875728|Active Comparator|Arm A (cefazolin, surgical resection)|Patients receive cefazolin IV and then undergo standard of care surgical resection within 1 hour.
89342235|NCT04875728|Experimental|Arm B (surgical resection)|Patients undergo standard of care surgical resection.
89342236|NCT04851119|Experimental|Treatment (tegavivint)|Tegavivint will be administered IV over 4 hours on days 1, 8, and 15 of each cycle. Administer D5W flush after completion of each tegavivint infusion. Treatment repeats every 28 days for up to 26 cycles or 24 months in the absence of disease progression or unacceptable toxicity. Drug doses should be adjusted based on the weight (height and BSA will also be captured) measured within 7 days prior to the beginning of each cycle. The starting dose will be 5 mg/kg with dose levels for subsequent cohorts increasing to 6.5 mg/kg and 8 mg/kg if excessive toxicity does not occur. If the MTD has been exceeded at the first dose level, then the subsequent cohort of patients will be treated at a dose of 4 mg/kg. Patients undergo an x-ray at baseline, after cycle 1, and then every 3 cycles while on treatment and DEXA scan at baseline and every 6 cycles while on treatment, then at 12 months, 24 months, and annually up to 60 months following end of therapy.
89342237|NCT04843137||Individuals with cervical spinal cord injury|Cohort of individuals who have experiences a chronic spinal cord injury at the cervical level (specifically C5-C7).
89342238|NCT04837118|Experimental|Supportive care (resistance training)|SEE DETAILED DESCRIPTION.
89342239|NCT04816214|Experimental|Run-in part: Capmatinib + Osimertinib|In the run-in part, up to two dose levels of capmatinib in combination with osimertinib were planned to be investigated. The initial dose level for the combination therapy was capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation was necessary, a lower dose level was defined as capmatinib 400 mg orally b.i.d and osimertinib 40 mg orally q.d.
89342240|NCT04816214|Experimental|Randomized part: Capmatinib + Osimertinib|"In the randomized part, capmatinib in combination with osimertinib was to be administered at the recommended Phase III regimen (defined in the safety run-in part).~The study was terminated early based on Sponsor's decision unrelated to safety concerns and the randomized part of the study was not initiated."
89342241|NCT04816214|Active Comparator|Randomized Part: Platinum + Pemetrexed Based Doublet Chemotherapy|In the randomized part, platinum-pemetrexed based doublet chemotherapy was to follow local guidelines as per standard of care and products labels. Participants randomized to platinum-pemetrexed based doublet chemotherapy arm were to be allowed to crossover to receive capmatinib in combination with osimertinib. The study was terminated early based on Sponsor's decision unrelated to safety concerns and the randomized part of the study was not initiated.
89342242|NCT04814654|Experimental|CHALO! 2.0|MSM randomized to this arm will receive twice weekly digital media messages for 12 weeks about HIV, HIV-testing, prevention, and treatment and a a link to a study-specific webpage listing MSM specific testing, prevention, and care resources. Participants will also be able to interact with online outreach workers.
89342243|NCT04814654|Active Comparator|Attention-matched control (AMC)|MSM randomized to the AMC arm will receive twice weekly digital media messages for 12 weeks about general health and a link to a study-specific webpage listing testing resources and MSM-specific services. Participants will also be able to interact with online outreach workers.
89342244|NCT04814654|Active Comparator|Digital coupon only control (DCO)|MSM randomized to the DCO arm will receive, at study entry, a digital coupon for free HIV testing and a study specific webpage link listing testing and MSM specific services.
89342245|NCT04792411|Experimental|Prehabilitation group|This arm will be subject to at least 6 weeks of a tailored prehabilitation programme
89342246|NCT04785534|Experimental|Screening (survey, biomarker analysis, fibroscan)|Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.
89342247|NCT04772625||PFA|The cohort consists of all patients operated with patellofemoral arthroplasty for isolated patellofemoral osteoarthritis in Denmark from Jan 1 2008 to Dec 31 2015. The number of patients is expected to be around 500. A patellofemoral arthroplasty is defined as an arthroplasty consisting of a metal trochlear component and a polyethylene patella component. The definition of isolated patellofemoral osteoarthritis in the study is pragmatic and given by the operating surgeon.
89342248|NCT04767594||First-line Palbociclib + endocrine therapy|Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy
89342249|NCT04766684|Experimental|J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream|
89342250|NCT04766684|Active Comparator|L.M.X.4 cream with J-Tip saline injection|
89342251|NCT04738799|Experimental|Carbohydrate-Last Meal Sequence, Then Carbohydrate-First Meal Sequence|Participants will consume the carbohydrate portion of their prepared meals last during mealtimes for 6 days. They will then consume the carbohydrate portion of their prepared meals first during mealtimes for the following 6 days.
89342252|NCT04738799|Experimental|Carbohydrate-First Meal Sequence, Then Carbohydrate-Last Meal Sequence|Participants will consume the carbohydrate portion of their prepared meals first during mealtimes for 6 days. They will then consume the carbohydrate portion of their prepared meals last during mealtimes for the following 6 days.
89342253|NCT04734288|Experimental|Immune response|This is a single-arm study. All subjects will be treated equally and will receive the same type and amount of nutritional supplements.
89342254|NCT04686279|Experimental|TFV Medicated Douche|Once enrolled, participants will complete a baseline sampling session and then a single dose of study product administration. Post-dose observations and data collection will follow at 1, 6, 24, and 72 hours, using a sparse PK sampling design in which plasma and peripheral blood mononuclear cells (PBMC) are collected at each designated time. Between sampling windows, YMSM will complete a web-survey examining their perceived reactions and comfort using the study douche, factors influencing product use in the future, and comfort with the trial procedures. The survey will be administered after dosing but scheduled not to interfere with other study assessments. Sampling for safety, PK, PD, and acceptability assessments will be collected according to the schedule of events. Phase I Trial participants will complete an in-depth interview as part of their Termination visit.
89342255|NCT04671615||Patients with metastatic, HR+/HER2- breast cancer.|Patients who initiated first or subsequent lines of treatment with palbociclib
89342256|NCT04664556||Cohort of invasive pneumococcal disease in children|
89342257|NCT04643808|Experimental|taVNS once daily|taVNS paired with bottle feeding once daily for 2-3 weeks
89342258|NCT04643808|Experimental|taVNS twice daily|taVNS paired with bottle feeding twice daily for 2-3 weeks
89342259|NCT04639986|Experimental|Sacituzumab Govitecan-hziy|Participants will receive Sacituzumab Govitecan-hziy 10 mg/kg on Days 1 and 8 of a 21-day cycle.
89342260|NCT04639986|Active Comparator|Treatment of Physician's Choice (TPC)|"Participants will receive recommended doses and schedules as per package insert depending on region.~Eribulin (1.4 mg/m^2 of eribulin mesylate or 1.23 mg/m^2 of eribulin on Days 1 and 8 of a 21-day cycle)~Capecitabine (1000 to 1250 mg/m^2 twice daily on Days 1 to 14 of a 21-day cycle)~Gemcitabine (800 to 1200 mg/m^2 on Days 1, 8, and 15 of a 28-day cycle)~Vinorelbine (25 mg/m^2 on Day 1 weekly)"
89342261|NCT04635670|Placebo Comparator|Placebo|Soluble powder for oral use twice daily
89342262|NCT04635670|Active Comparator|Active|The investigational product is soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
89342263|NCT04594187|Experimental|Group I (immunotherapy, radiation therapy)|Within 12 weeks of SLNB, patients start nodal radiation therapy (30 Gy in 5 treatments over 2-2.5 weeks). Immunotherapy planned to begin at any time after SLNB.
89342264|NCT04594187|Active Comparator|Group II (immunotherapy)|Patients planned to undergo immunotherapy.
89342265|NCT04569084|Experimental|MT-1186|
89342266|NCT04569084|Experimental|MT-1186 and Placebo|
89342267|NCT04552314||patients after primary MMC-augmented trabeculectomy|
89342268|NCT04530526|Other|Regenerative Peripheral Nerve Interface (RPNI)|Using evaluative ultrasound measurements and a standard panel of patient-reported outcome measures (PROMs) to measure pain experience, anxiety and depression, patients will be evaluated at baseline (T1=0months), pre-operatively following 3 months of standard neuropathic pain management therapy (T2=3months) and at three months (T3=6months) and nine months (T4=12months) post RPNI surgery.
89342269|NCT04529395|Experimental|Aromatherapy group|
89342270|NCT04529395|Active Comparator|Control group|
89342271|NCT04520321|Placebo Comparator|Vehicle (placebo)|Placebo weekly x 4
89342272|NCT04520321|Experimental|Low dose|TTHX1114(NM141) low-dose weekly x 4
89342273|NCT04520321|Experimental|Mid-dose|TTHX1114(NM141) mid-dose weekly x 4
89342274|NCT04520321|Experimental|High-dose|TTHX1114(NM141) high-dose weekly x 4
89342275|NCT04493138|Experimental|Treatment (azacitidine, quizartinib)|Patients receive azacitidine SC or IV over about 30 minutes on days 1-5 and quizartinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89342276|NCT04471311|No Intervention|Primary closure of midline laparotomy|Primary closure of midline laparotomy
89342277|NCT04471311|Experimental|Sub-lay mesh supported closure|Sub-lay permanent mesh supported the closure
89342278|NCT04413331||Vasculitis|Those with systemic vasculitis
89342279|NCT04413331||EGPA vasculitis|
89342280|NCT04400214|Experimental|Food Allergy Superheroes Training (FAST) Program|Participants enrolled in this arm of the study will receive 5, 20 minutes skills training sessions designed to promote adherence to food allergy safety guidelines. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
89342281|NCT04400214|Active Comparator|Food Allergy Knowledge (FAK) Intervention|Participants enrolled in this arm of the study will receive 5, 20 minutes educational training sessions designed to increase knowledge pertaining to food allergies. These sessions will occur over the period of <2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
89342282|NCT04395677|Experimental|AB-106 （DS-6051b）|Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106
89342283|NCT04372095||group 1: Exposed to CPA + Meningioma|"Meningioma diagnosed in women by medical imaging examination and confirmed histologically if surgery is performed.~Cyproterone acetate taken for at least 6 months."
89342284|NCT04372095||group 2: Exposed to CPA without Meningioma|Women exposed to Cyproterone acetate without developing any meningioma Absence of meningioma assessed by a normal cerebral MRI . Cyproterone acetate taken for at least 5 years.
89342285|NCT04372095||group 3: Not exposed to CPA, Meningioma diagnosed|"Meningioma in women not exposed to cyproterone acetate. Meningioma diagnosed by medical imaging examination and confirmed histologically if surgery was necessary.~Never exposed to cyproterone acetate."
89342286|NCT04372095||group 4: General population|Subjects (women) never diagnosed with meningioma and not exposed to cyproterone acetate.
89531676|NCT05799833||Age and sex matched control group of athletes with normal QRS voltage|Cohort (anticipated N = 60) will undergo testing with 12 lead ECG, blood test, cardiac MRI, 24 hour holter monitoring and cardiopulmonary exercise testing.
89531677|NCT05799833||Age and sex matched young healthy controls (non-athletes) with normal QRS voltage|Cohort (anticipated N = 60) will undergo testing with 12 lead ECG, blood test, cardiac MRI, 24 hour holter monitoring and cardiopulmonary exercise testing.
89342287|NCT04350827|Active Comparator|Platelet Rich Plasma|Procedure will be carried out with excellent sterile technique. 54ml of whole blood will be drawn. 54ml will be processed by centrifugation using the GPS III system (Zimmer Biomet, Warsaw, IN) and 1 ml will undergo a complete blood count (for a baseline comparison to determine the fold increase in platelets). The resultant PRP (5ml) will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) into the patellar tendon using ultrasound guidance to accurately direct the injection to the site of the tendon abnormality. The patient will rest after the injection for 15 minutes and then be dismissed.
89342288|NCT04350827|Active Comparator|Platelet Rich Plasma plus IGF|The PRP preparation and blood draw will be identical to the above. 55ml of whole blood will be drawn (1ml will undergo a CBC and the remaining 54ml will be used to make PRP). In addition to preparing the PRP, the resultant PPP (instead of discarding it) will be placed into the Plasmax device (Zimmer Biomet, Warsaw, IN) and concentrated via a second centrifugation cycle. The plasmax concentrate (concentrated IGF) will be added to the PRP (3ml of PRP + 2ml of plasmax concentrate for a total of 5ml) and then will be injected (after 5ml 1% lidocaine has been injected into the skin for comfort) under ultrasound guidance followed by the same rest period.
89342289|NCT04327791|Experimental|baloxavir|Baloxavir: 40 mg po once for wt < 80 kg OR 80 mg po once for wt >/= 80 kg
89342290|NCT04327791|Placebo Comparator|placebo|placebo po once
89342291|NCT04323956|Experimental|Arm I (parsaclisib, R-CHOP)|Patients receive parsaclisib PO QD on days 1-10 or 1-14, rituximab IV or biosimilar substitute, cyclophosphamide IV over 30 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC or biosimilar substitute on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89342292|NCT04323956|Active Comparator|Arm II (parsaclisib, R-CHOP, polatuzumab vedotin)|Patients receive parsaclisib PO once daily QD on days 1-10 or 1-14, polatuzumab vedotin IV over 90 minutes, rituximab IV or biosimilar substitute, cyclophosphamide IV over 30 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV over 15 minutes on day 1. Patients also receive prednisone PO on days 1-5 and pegfilgrastim SC or biosimilar substitute on day 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89342296|NCT04303000|Experimental|Opioid Overdose Education and Naloxone Distribution|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will be provided with a naloxone nasal spray kit (4mg).
89342297|NCT04303000|Active Comparator|Opioid Overdose Education|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will receive information about pharmacies in their area where they can purchase a naloxone kit.
89342300|NCT04300140|Experimental|Phase 1b: Batiraxcept + cabozantinib|Two dose levels of batiraxcept administered Q2W (once every two weeks) in combination with QD (once a day) cabozantinib will be evaluated.
89342301|NCT04300140|Experimental|Phase 2 Part A: batiraxcept + cabozantinib|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib will be evaluated.
89342302|NCT04300140|Experimental|Phase 2 Part B: batiraxcept + cabozantinib + nivolumab|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib and nivolumab.
89342303|NCT04300140|Experimental|Phase 2 Part C: batiraxcept alone|One dose level of batiraxcept administered Q2W will be evaluated.
89342304|NCT04279613|Experimental|NNC0361-0041|Dosage form: 9 mg/ml Solution for injection Route of administration: Subcutaneous Initial dose/Unit dose strength(s)/Dosage level(s) in cohort 1: 1mg Additional doses in cohorts 2, 3, and 4: 5mg, 12.5mg and 25mg Dosing instructions: Once weekly on site
89342305|NCT04279613|Placebo Comparator|Placebo|Dosage form: Solution for injection Route of administration: Subcutaneous Dosing instructions: Once weekly on site
89342306|NCT04271709|Active Comparator|Enhanced Intervention|Consented subjects living in buildings randomized to the Enhanced Intervention arm who fail the screening and need vision correction will receive free eyeglasses, which will be fitted by an optician at the housing building. If they are referred to an ophthalmologist for a follow-up eye exam, they will receive enhanced support with patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
89342307|NCT04271709|Placebo Comparator|Usual Care|Consented subjects living in buildings randomized to Usual Care arm who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
88814112|NCT04366232|Experimental|Anakinra +/- Ruxolitinib|"According to clinical stage (gradual strategy):~Stage 2b or 3 : Anakinra 300 mg IV~Overcome stage 3 : Anakinra 300 mg IV and Ruxolitinib 5 mg x 2"
89342308|NCT04259749|Active Comparator|Status Quo|The StoreLab power wall will display all tobacco products.
89342309|NCT04259749|Experimental|Flavors Banned|The StoreLab will display tobacco products without characterizing flavors, but will allow mint and menthol products to be displayed.
89342310|NCT04259749|Experimental|Flavors and Menthol Banned|The StoreLab will display only tobacco products without characterizing flavors; mint and menthol will not be displayed.
89342311|NCT04253418|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of target lesion.
89342312|NCT04252235|Sham Comparator|Sham air purifier|Participants will receive a sham air purifier that will be installed in the bedroom and living room. These purifiers will make a noise, but will not filter the air.
89342313|NCT04252235|Experimental|True air purifier|Participants will receive a HEPA air purifier in the bedroom and living room.
89342314|NCT04251780|Experimental|Hyperaldosteronism treatment|Patients with Hyperaldosteronism will either be treated by adrenalectomy (adrenal adenoma) or receive medical treatment (Spironolactone/Eplerenone; bilateral hyperplasia) as indicated by the Endocrinological Guideline (J Clin Endocrinology & Metabolism, May 2016). Before and after intervention tissue sodium and tissue potassium amount will be assessed by MRI.
89342315|NCT04249115|Experimental|Nano-Pulse Stimulation (NPS) Treated Lesion|Nano-Pulse Stimulation of targeted lesion.
89342316|NCT04245280|Active Comparator|PENG and LFCN blocks with ropivacaine|For the PENG block, and after negative aspiration, 20 ml of a solution of ropivacaine 0.5% with epinephrine 2.5 mcg/ml will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same solution will be injected with the same needle.
89342317|NCT04245280|Placebo Comparator|PENG and LFCN blocks with saline solution|For the PENG block, and after negative aspiration, 20 ml of a saline solution will be injected in 5 ml aliquots. Then, for the LFCN block, the lateral femoral cutaneous nerve will be localized, infero-medially to the antero-superior iliac spine, superficially to the sartorius muscle and 5 ml of the same saline solution will be injected with the same needle.
89342318|NCT04234035|Experimental|Shared Decision-Making (via Decision Aid)|The intervention is a decision aid, which both encourages and facilitates a shared decision-making conversation between the clinician and the patient. The decision aid educates patients regarding evidence-based approaches to the management of suspected kidney stones in the ED. Clinicians will receive training specific to this decision aid, though the decision aid is designed to be used with no additional training.
89342319|NCT04234035|Active Comparator|standardized educational intervention (pamphlet +usual care)|The control arm will receive Usual Care and a standardized educational intervention (pamphlet). This intervention (pamphlet) contains information about kidney stones. Usual care for this clinical scenario generally involves the clinician choosing the management plan. Clinicians of subjects assigned to the usual care group will be asked to practice usual, evidence-based medical care, without shared decision-making.
89342320|NCT04221295|Experimental|Exercise Group|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
89342321|NCT04221295|No Intervention|Control Group|The control group will receive the World Health Organization recommendations for physical activity for people greater or equal to the age of 65 years old pamphlet, as well as a guide to healthy eating for older adults.
89342322|NCT04212650|Experimental|Losartan|12.5mg Losartan capsules, oral administration, twice daily (25mg total per day), taken for 30 consecutive days starting on the evening of the second post-surgery day.
89342323|NCT04212650|Placebo Comparator|Placebo|Appearance-matched placebo capsules, oral administration, twice daily, taken for 30 consecutive days starting on the evening of the second post-surgery day.
89342324|NCT04196101|Experimental|EDP-938|Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days
89342325|NCT04196101|Placebo Comparator|Placebo|Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days
89342326|NCT04191785|Experimental|plasmatic NGAL and MRI|
89342327|NCT04188067|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic, the non-fluent variant or the semantic variant. All participants will receive the same study interventions in a within-subject crossover design.
89342328|NCT04179799||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
89342329|NCT04172220|Experimental|PECS + Opioid-free GA|Loco-regional anesthesia with PEC I and serratus plane block with an echoguided technique and opioid-free general anesthesia
89342330|NCT04172220|Active Comparator|GA|General anesthesia
89342331|NCT04166058|Active Comparator|72 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
89342332|NCT04166058|Active Comparator|145 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
89342333|NCT04166058|Active Comparator|290 μg linaclotide|An oral capsule that is taken once daily. It may be taken whole or sprinkled into 1 teaspoonful of applesauce or 30mL of bottled water.
89342334|NCT04161534|Active Comparator|Arm Sling Group|
89342335|NCT04161534|Experimental|KT Tape Group|
89342336|NCT04153955|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after undergoing thrombectomy per usual care
89342337|NCT04153955|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after undergoing thrombectomy per usual care
89342338|NCT04153942|Experimental|12-Hour Bed Rest|Subjects will be mobilized 12 hours after receiving IV thrombolysis therapy per usual care
89342339|NCT04153942|Active Comparator|24-Hour Bed Rest|Subjects will be mobilized 24 hours after receiving IV thrombolysis therapy per usual care
89342340|NCT04148989|No Intervention|Pre-implementation usual care (intervention site)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the intervention hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
89342341|NCT04148989|Experimental|Code Sepsis post-implementation (intervention site)|Adult patients age ≥18 years presenting to the ED of the intervention hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation). The primary analysis will focus on the subset of patients with sepsis.
89342342|NCT04148989|No Intervention|Pre-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department before implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
89342343|NCT04148989|No Intervention|Post-implementation usual care (control sites)|Adult patients age ≥18 years who receive usual care after presenting to the ED of the control hospital emergency department after implementation of sepsis care reorganization (Code Sepsis implementation) at the intervention hospital. The primary analysis will focus on the subset of patients with sepsis.
89342344|NCT04145752|Experimental|Nurse-led femoral nerve block|"Trained nurses in ED provide ultrasound guided single-shot femoral nerve block shortly after (at arrival emergency department) the patient is diagnosed with a hip fracture.~Drug: Ropivacaine 3 mg/kg, single-shot"
89342345|NCT04145752|Active Comparator|Standard of care|Nurses do not provide ultrasound guided single-shot FNB and the patient follows the standard of care course.
89342346|NCT04129515|Experimental|PHASE 1: NovoTTF-200A + PEMBROLIZUMAB|"The Phase I portion of the study will have a 3 + 3 design and consist of one cohort treated~NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.~Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
89342347|NCT04129515|Experimental|PHASE 2: NovoTTF-200A + PEMBROLIZUMAB|"NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle.~Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle"
89342348|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pancreatic|SMART will be administered per each individual disease site standards
89342349|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Renal|SMART will be administered per each individual disease site standards
89342350|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Central Lung|SMART will be administered per each individual disease site standards
89342351|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Adrenal Metastases|SMART will be administered per each individual disease site standards
89342352|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Liver Metastases|SMART will be administered per each individual disease site standards
89342353|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Metachronous Oligometastatic Nodes|SMART will be administered per each individual disease site standards
89342354|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Oligoprogressive Oligometastatic Nodes/Soft Tissue|SMART will be administered per each individual disease site standards
89342355|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Synchronous Oligometastatic Nodes/Soft Tissue|SMART will be administered per each individual disease site standards
89342356|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate|SMART will be administered per each individual disease site standards
89342357|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Borderline Resectable Pancreas|SMART will be administered per each individual disease site standards
89342358|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Brain Metastases|SMART will be administered per each individual disease site standards
88814113|NCT04366232|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
89342359|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mesothelioma|SMART will be administered per each individual disease site standards
89342360|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate Boost|SMART will be administered per each individual disease site standards
89342361|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pelvic Re-Irradiation|SMART will be administered per each individual disease site standards
89342362|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Spine|SMART will be administered per each individual disease site standards
89342363|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Single-Fraction Kidney Tumors|SMART will be administered per each individual disease site standards
89342364|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--1/3 Fraction for Oligometastatases in the Abdomen/Pelvis|SMART will be administered per each individual disease site standards
89342365|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Post-Operative Radiation Therapy in Lung Cancer|SMART will be administered per each individual disease site standards
89342366|NCT04115254|Experimental|PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mediastinal and Hilar Lymph Nodes|SMART will be administered per each individual disease site standards
89342367|NCT04095715||Children and adults with unexplained hemorrhagic syndrome|Patients with spontaneous or induced hemorrhagic manifestations who are present for a consultation to investigate a thrombopathy or during follow-up consultations as part of their usual care.
89342368|NCT04080778|Experimental|magnetic seizure therapy (MST)|
89342369|NCT04080778|Active Comparator|electroconvulsive therapy (ECT)|
89342370|NCT04049474|Experimental|Bronchoscopic Cryo-Immunotherapy (BCI)|BCI is performed by advancing a flexible cryoprobe through a bronchoscope to reach a peripheral tumor. The cryoprobe is activated to freeze a portion of the tumor. The cryoprobe is allowed to thaw to prevent removal of lung or airway tissue. The tumor must be located by radial EBUS and a guide sheath placed prior to cryoablation.
89342371|NCT04037735|Experimental|ATTUNE|Total Knee Replacement with the ATTUNE S+ Knee Prosthesis by DePuy
89342372|NCT04037735|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
89342373|NCT04016090|Placebo Comparator|Placebo treatment|Participant will be asked to ingest a placebo capsule.
89342374|NCT04016090|Experimental|Folic Acid|Participant will be asked to ingest a capsule containing 5 mg of folic acid.
89342375|NCT04007939||Employee population|Subject comprised of employees of Metagenics but later will be expanded to those recruited from practitioner practices
89342376|NCT04005456|Other|N of 1 Tent|Personalized dietary supplements, food plans, and behavioral change support program for a broad group (both an employee population and those recruited from practitioner practices) inclusive of all study Participants and specifically generally healthy individuals, those with established disease/conditions requiring a personalized approach, those with diseases/conditions currently with low prevalence in our study population and those women currently pregnant or breastfeeding.
89342377|NCT04005456|Other|Wellness Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals characterized by minimal physical complaints and laboratory biomarkers of modest clinical significance.
89342378|NCT04005456|Other|Elevated Homocysteine Bucket|Personalized dietary supplements, food plans, and behavioral change support program for individuals from the Wellness Umbrella with elevated homocysteine level ≥ 10.4 µmol/L.
89342379|NCT04005456|Other|Dental Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with established dental disease.
89342380|NCT04005456|Other|Immune Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of individuals with autoimmune/inflammatory conditions (excluding metabolic disorders/atherosclerosis)
89342381|NCT04005456|Other|Elevated Anti-Nuclear Antibodies (ANA) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with elevated levels of antinuclear antibodies (preclinical symptomatology only).
89342382|NCT04005456|Other|Autoimmune Conditions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with an established diagnosis of an autoimmune conditions (Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Bowel Disease and Hashimoto's Thyroiditis) with ANA level >1:80 titer, rheumatoid factor (RF) ≥ 14 IU/ml, fecal calprotectin ≥ 50 mcg/g and thyroid autoantibody levels specifically thyroglobulin antibodies ≥ 115 IU/ml and/or thyroid peroxidase antibodies ≥ 35 IU/ml.
89342383|NCT04005456|Other|Symptomatic Fatigue/Myalgias Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a broad employee health group with symptoms of persistent fatigue and myalgias.
89342384|NCT04005456|Other|Gastrointestinal Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health and of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
89342385|NCT04005456|Other|Irritable Bowel Syndrome (IBS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of gastrointestinal health.
89342386|NCT04005456|Other|Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals with conditions associated with issues of environmental toxicity or dysfunction related to detoxification of external toxins and internal metabolites.
89342387|NCT04005456|Other|Wellness Detoxification Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of individuals characterized by minimal physical complaints and normal biomarkers.
89342388|NCT04005456|Other|Metabolic Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia).
89342389|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket C/S Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). C/S = crossover
89342390|NCT04005456|Other|Consequences of Metabolic (Dys)function Bucket R/I Design|Personalized dietary supplements, food plans, and behavioral change support program for a broad group of participants classified as desirable weight with markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia). R/I = randomization/inclusion
89342391|NCT04005456|Other|Ketogenic Product Development Exploratory Group|Subgroup investigation in participants (classified as desirable weight with and without markers of dysglycemia/dyslipidemia or overweight/obese with and without markers of dysglycemia/dyslipidemia) during their 8- or 12-week ketogenic program intervention phase
89342392|NCT04005456|Other|Reproductive Health Umbrella|Personalized dietary supplements, food plans, and behavioral change support program for a group of participants with conditions associated with reproductive and hormonal health (including polycystic ovary syndrome, premenstrual syndrome, endometriosis, peri-menopause and menopausal conditions, women currently pregnant or breastfeeding, testosterone deficiency and andropause/late onset hypogonadism, and prostate health).
89342393|NCT04005456|Other|Perimenopausal and Menopausal Transitions Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically peri-menopause and menopausal conditions.
89342394|NCT04005456|Other|Premenstrual Syndrome Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with conditions associated with reproductive and hormonal health specifically premenstrual syndrome.
89342395|NCT04005456|Other|Polycystic Ovary Syndrome (PCOS) Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of women with PCOS with signs/symptoms/biomarkers of both metabolic dysfunction and hormonal derangements.
89342396|NCT04005456|Other|Andropause/Late Onset Hypogonadism Bucket|Personalized dietary supplements, food plans, and behavioral change support program for a group of men with conditions associated with reproductive and hormonal health specifically testosterone deficiency and andropause/late onset hypogonadism.
88806885|NCT04822194|Experimental|Distancing|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the distancing strategy is explained (i.e. appraising an emotional stimulus as an objective, impartial observer).
89342397|NCT03999151|Active Comparator|Arm A: Reference Group|Arm A will receive print educational materials about the benefits of exercise and diet for men with prostate cancer, with recommendations geared at men living with prostate cancer, mailed around the date of surgery. They also receive a 10-week text messaging program focused on recovery after radical prostatectomy surgery.
89342398|NCT03999151|Experimental|Arm B (Arm A + Exercise)|Arm B receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise habits and various tools, such as the ability to track exercise; additional educational print materials on exercise; additional text messages over 2 years that supports healthy exercise habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years.
89342399|NCT03999151|Experimental|Arm C (Arm A + Diet)|Arm C receives the following: Arm A material plus access to an online portal with additional educational materials to help improve diet habits and various tools, such as the ability to track diet; additional educational print materials on diet; additional text messages over 2 years that supports healthy diet habits; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
89342400|NCT03999151|Experimental|Arm D (Arm A + Exercise + Diet)|Arm D receives the following: Arm A material plus access to an online portal with additional educational materials to help improve exercise and diet habits and various tools, such as the ability to track exercise and diet; additional educational print materials on exercise and diet; additional text messages over 2 years that supports healthy exercise and diet habits; a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with an exercise coach over 2 years; and a 1-hour phone session at the start of the study followed by eight 30-minute quarterly phone sessions with a diet coach over 2 years.
89342401|NCT03998319|Experimental|Tenecteplase (1/3 systemic weight based dose)|Tenecteplase will be reconstituted in 20mL sterile water for injection at 1/3 of the weight based dose, and administered by intracoronary infusion over 3 minutes.
89342402|NCT03998319|Placebo Comparator|Sterile Water for injection (WFI)|Water for injection will be prepared to 20mL over an equivalent time period to the reconstitution time of the experimental arm, in order to maintain the blind, and administered by intracoronary infusion over 3 minutes.
89342403|NCT03995667|Experimental|Prevention (TTFields therapy, questionnaire)|Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
89342404|NCT03992196|Experimental|Rotigotine|Subjects will be initiated on 1 mg/24 h rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, with the aim of achieving the individually optimized dosage. Dose adjustment of rotigotine is allowed at any time during the following Maintenance Period up to a maximum dose of 3 mg/24 h. At the end of the Maintenance Period, subjects will be down-titrated.
89342405|NCT03970200|Active Comparator|No investigational product|Participants who receive the antibiotics usually prescribed for C diff infection.
89342406|NCT03970200|Experimental|Upper gastrointestinal Fecal Microbiota Transplantation|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given by mouth in capsules or through a tube that goes into your stomach/intestines if you already have one (upper delivery). You will not be assigned to this group if you cannot take any medications either by mouth or through a tube safely, as determined by your doctor
89342407|NCT03970200|Experimental|Lower gastrointestinal Fecal Microbiota Transplantation|Participants who receive the antibiotics usually prescribed for C diff infection, along with PMT that is given through the rectum by an enema (lower delivery).
89342408|NCT03913728|Experimental|Outcome of blood test provided|These patients are given the results of their drug level blood tests and treatment can be altered/ further advice can be provided as a result of this.
89342409|NCT03913728|No Intervention|Outcome of blood test not provided|The blood results for these people are not fed back to the patient or the clinical site.
89342410|NCT03913728|Experimental|Patients have a telephone interview|All patients are randomised for a second time; 20% (10) of them will have a semi-structured phone interview
89342411|NCT03913728|No Intervention|No telephone interview|All patients are randomised for a second time; 80% won't have a phone call and this will be as per standard care.
89342412|NCT03866772|Active Comparator|MISOPROSTOL|"oral misoprostol, 50 microgram, every 4 hours~Repeat treatment every 4 hours until active labour begins: regular painful contractions (≥ 3 in 10 min), cervical dilatation ≥ 3 cm~maximal number of doses: 6~Oxytocin infusion can be initiated 4 hours after the last dose of Misoprostol.~Failure of induction will be considered if no cervical change nor uterine contractions have begun during 24 hours of treatment.~Electronic fetal monitoring should be performed for 30 min after administration of misoprostol and 60 min after any tachysystole."
89342413|NCT03866772|Active Comparator|DOUBLE BALLOON|"Insertion of the DBD as instructed by the manufacturer, removal after 6 hours.~Artificial rupture of membranes (AROM) if suitable + IV oxytocin administration~If AROM cannot be performed- oxytocin infusion will be initiated at first.~If Bishop <3 after DBD removal, clinical evaluation and lag time before considering other methods for ripening is suitable and is up to the physician on call."
89342414|NCT03866772|Active Comparator|MISOPROSTOL+DOUBLE BALLOON|
89342415|NCT03840200|Experimental|Dose escalation-Cohort 1|Participants with advanced breast cancer, ovarian cancer, or prostate cancer will receive ipatasertib, 300 milligrams (mg), orally, once daily (QD) for 7 days in the run-in period. Participants will then receive ipatasertib, 300 mg, orally QD, and rucaparib, 400 mg, orally twice daily (BID) in each 28-day cycle until disease progression, unacceptable toxicity, death, or participant or investigator's decision to withdraw, whichever occurs first.
89342416|NCT03840200|Experimental|Dose escalation-Cohort 2a|Participants with advanced breast cancer, ovarian cancer, or prostate cancer will receive ipatasertib, 300 mg, orally, QD for 7 days in the run-in period. Participants will then receive ipatasertib, 300 mg, orally QD, and rucaparib, 600 mg, orally BID in each 28-day cycle until disease progression, unacceptable toxicity, death, or participant or investigator's decision to withdraw, whichever occurs first.
88814114|NCT02241200|Experimental|IV Administration|The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
89531678|NCT05789576|Experimental|VTAMA (tapinarof) cream, 1%|VTAMA (tapinarof) cream, 1% applied topically once daily
89342417|NCT03840200|Experimental|Dose escalation-Cohort 2b|Participants with advanced breast cancer, ovarian cancer, or prostate cancer will receive ipatasertib, 400 mg, orally, QD for 7 days in the run-in period. Participants will then receive ipatasertib, 400 mg, orally QD, and rucaparib, 400 mg, orally BID in each 28-day cycle until disease progression, unacceptable toxicity, death, or participant or investigator's decision to withdraw, whichever occurs first.
89342418|NCT03840200|Experimental|Dose escalation-Cohort 3|Participants with advanced breast cancer, ovarian cancer, or prostate cancer are planned to receive ipatasertib 400 mg orally QD for 7 days (run-in period prior to Cycle 1). Participants will then receive ipatasertib 400 mg orally QD and rucaparib 600 mg, orally BID in 28 days cycle until disease progression, unacceptable toxicity, death, or participant or investigator's decision to withdraw, whichever occurs first.
89342419|NCT03840200|Experimental|Dose Expansion|The recommended dose (ipatasertib and rucaparib) identified in Part 1 will be evaluated in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).
89342420|NCT03837314|Experimental|Deep Brain Stimulation|"Deep Brain stimulation using a novel device. Bioinduction Picostim Deep Brain Stimulation system"
89342421|NCT03836105||Group 1|This group will enroll patients with advanced (defined as locally advanced or metastatic [nodal or distant]) CSCC.
89342422|NCT03836105||Group 2|This group will enroll patients with advanced (defined as locally advanced or metastatic [nodal or distant]) BCC.
89342423|NCT03833674|Experimental|Adults with incomplete SCI|Adults with chronic, incomplete SCI who have >20% impairment in respiratory function, who will complete a battery of clinical assessments and 4 randomly ordered intervention and testing blocks (Daily AIH Block, Sham dAIH Block, Respiratory Strength Training Block and AIH + Strength Training Block).
89342424|NCT03818711|Experimental|Communication & Coping Intervention|A cognitive behavioral intervention for mothers of adolescents with type 1 diabetes to improve coping and the quality of parental involvement.
89342425|NCT03818711|Active Comparator|Education & Check Ins|The comparison group receives educational materials on diabetes management and phone calls, as well as access to a secret Facebook group with daily posts on diabetes management.
89342426|NCT03801486||Experimental (SCF40)|At the experimental data collection visits participants consumed 255g of pasta made with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
89342427|NCT03801486||Control (SEM100)|At the control data collection visits participants consumed 255g of pasta made with 100% semolina flour (SEM100) with butter.
89342428|NCT03780517|Experimental|BOS172738|In Part A (dose escalation), participants with advanced solid tumors with rearranged during transfection (RET) gene alterations will receive oral BOS172738 at a starting dose of 10 milligrams (mg) once daily in each 28-day cycle. In Part B (dose expansion), participants with RET gene-fusion non-small cell lung cancer (NSCLC), with RET gene-mutant medullary thyroid cancer (MTC), and with RET gene-altered advanced tumors or NSCLC/MTC with prior specific RET gene-targeted therapy will be enrolled in Cohorts 1, 2, and 3, respectively, and will receive oral BOS172738 once daily in each 28-day cycle at the recommended Phase 2 dose (RP2D) established in Part A.
89342429|NCT03595059|Experimental|Escalation 1a: ABBV-155|Participants will be administered ABBV-155 (various doses).
89342430|NCT03595059|Experimental|Escalation 1b: ABBV-155 + paclitaxel or docetaxel|Participants will be administered ABBV-155 (various doses) in combination with paclitaxel or docetaxel .
89342431|NCT03595059|Experimental|Expansion 2a: ABBV-155 in SCLC|Description: Participants with small cell lung cancer (SCLC) will administer ABBV-155 (at the recommended Phase 2 dose).
89342432|NCT03595059|Experimental|Expansion 2b: ABBV-155 + paclitaxel in Breast Cancer|Participants with breast cancer will be administered ABBV-155 (at the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with paclitaxel.
89342433|NCT03595059|Experimental|Expansion 2b: ABBV-155 + docetaxel in NSCLC|Participants with non-small cell lung cancer (NSCLC) will be administered ABBV-155 (at or near the recommended Phase 2 dose identified for combination with paclitaxel in part 1b) in combination with docetaxel.
89342434|NCT03564678|Experimental|Treatment (levocarnitine, vitamin B complex)|Patients receive levocarnitine IV over 2-3 minutes every 6 hours up to 4 times a day (inpatient) or PO TID (outpatient). Patients also receive vitamin B complex PO BID. Treatment continues for up to 30 days after the last dose of either PEG-asparaginase or inotuzumab, or until Tbili of ≤ 1.5 x ULN or at least a 50% reduction in peak Tbili is achieved.
89342435|NCT03532373|No Intervention|Control|None- normal care
89342436|NCT03532373|Experimental|Intervention|Patients will use a preference elicitation tool to determine their preferences for diagnosis and treatment of CTS
89342437|NCT03490383||patients without CBD calculi|patients without CBD calculi
89342438|NCT03490383||CBD calculi without ERCP history|patients with CBD calculi without ERCP history
89342439|NCT03490383||CBD calculi with ERCP history|patients with CBD calculi and ERCP history
89342440|NCT03425786|Experimental|Early BPPV Management|Diagnostic and treatment training for BPPV.
89342441|NCT03425786|Active Comparator|Late BPPV Management|Diagnostic training for BPPV. Sports Medicine providers will refer patients positive for BPPV to an Otolaryngologist at our institution for treatment.
89342442|NCT03416153|Active Comparator|Standard Treatment|Patients will receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy)
89342443|NCT03416153|Experimental|De-escalation Treatment|Patients will initially receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). If certain parameters are met radiation therapy will be reduced to 54Gy to high risk Planned Target Volume (PTV) and 43.2Gy to low risk PTV all in 27 fractions.
89342444|NCT03364647|Experimental|Arm A - Blood flow restriction training|Group will use blood flow restriction training and standard of care
89342445|NCT03364647|Sham Comparator|Arm B - standard of care plus sham|Group will receive standard of care plus a sham version of blood flow restriction training
89342446|NCT03345654||New Hearing Aid Users fit with standard-of-care|Adults (18+) with hearing loss and newly fit with hearing aids
89342447|NCT03334851|Experimental|Part A, Cohort 1|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration
89342448|NCT03334851|Experimental|Part A, Cohort 2|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
89342449|NCT03334851|Experimental|Part A, Cohort 3|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
89342450|NCT03334851|Experimental|Part A, Cohort 4|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
89342451|NCT03334851|Experimental|Part A, Cohort 5|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
89342452|NCT03334851|Experimental|Part A, Cohort 6|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
89342453|NCT03334851|Experimental|Part A, Cohort 7|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
89342454|NCT03334851|Experimental|Part A, Cohort 8|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
89342455|NCT03334851|Experimental|Part B, Cohort 1|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous administration.
89342456|NCT03334851|Experimental|Part B, Cohort 2|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
89342457|NCT03334851|Experimental|Part B, Cohort 3|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
89342458|NCT03334851|Experimental|Part B, Cohort 4|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
89342459|NCT03334851|Experimental|Part B, Cohort 5|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
89342460|NCT03334851|Experimental|Part B, cohort 6|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
89342461|NCT03263650|Experimental|Cabazitaxel + Carboplatin|Cabazitaxel, Cabazitaxel and Carboplatin intravenously on day 1 of cycles 1-6. Prednisone by mouth twice daily on days 1-21 of cycles 1-6.
89342462|NCT03263650|Experimental|Olaparib Maintenance|Participants randomized to receive Olaparib by mouth twice daily on Day 1 of cycle 7.
89342463|NCT03263650|No Intervention|Observation Only|Participants randomized to observation only beginning cycle 7.
89342464|NCT03172299|Active Comparator|Injection of anti-VEGF|
89342465|NCT03172299|Placebo Comparator|false injection of anti-VEGF|
89342466|NCT03150914|Placebo Comparator|Placebo|Overencapsulated matrix
89342467|NCT03150914|Active Comparator|Treatment|Over-encapsulated 1 mg sirolimus tablet
89342468|NCT03120299|Experimental|Group A Drug|"Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks~Other Names:~Omega-3 Fatty Acid fish oil Omega 3 Treasure"
89342469|NCT03120299|Placebo Comparator|Group B Drug|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
89342470|NCT03093493||EDS patients|Medical records from other institutions and clinical notes for visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints Hypermobility Syndrome (JHS), and other metabolic or genetic disorders and laboratory results, radiology reports and images, and genetic testing that supports EDS diagnoses. Genotyping will be done.
89342471|NCT03093493||EDS family members with or without EDS|Family members of EDS patients with or without EDS. Genotyping will be done.
89342472|NCT03059992|Experimental|Ibrexafungerp (SCY-078)|Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.
89342473|NCT03057626||Observational (specimen collection)|Patients undergo collection of blood and urine samples on day 1. Patients also undergo clinical assessments, laboratory, radiographic, and other ancillary studies on day 1.
89342474|NCT02987387||TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV
89342475|NCT02979119||Cohort I|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2000 until December 31st 2009 who have been or are to be treated with coagulation proteins in one of the participating centres
89342476|NCT02979119||Cohort II|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2010 until December 31st 2019 who have been or are to be treated with coagulation proteins in one of the participating centres
89342477|NCT02979119||Cohort III|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2020 until December 31st 2029 who have been or are to be treated with coagulation proteins in one of the participating centres
89342478|NCT02956499|Experimental|Cohort 1|single intravenous dose
89342479|NCT02956499|Experimental|Cohort 2|single intravenous dose
89342480|NCT02956499|Experimental|Cohort 3|single intravenous dose
89342481|NCT02956499|Experimental|Cohort 4|single intravenous dose
89342482|NCT02956499|Experimental|Cohort 5|single intravenous dose
89342483|NCT02956499|Experimental|Cohort 6|single intravenous dose
89342484|NCT02956499|Experimental|Cohort 7|multiple intravenous doses
89342485|NCT02956499|Experimental|Cohort 8|multiple intravenous doses
89342486|NCT02956499|Experimental|Cohort 9|multiple intravenous doses
89342487|NCT02956499|Experimental|Cohort 10|multiple intravenous doses
89342488|NCT02924857|Experimental|Test Group (Chocolate Touch)|"The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1.~The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome.~If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation."
89531679|NCT05787600|Experimental|Perhyal rinse|Participants will be given the test interventions,Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing.
89342489|NCT02924857|Active Comparator|Control Group (Lutonix Drug Coated Balloon)|"Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion.~The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of >1:1).~If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit.~Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome."
89342490|NCT02885311|Other|At-Risk Drinkers (AR)|AR will receive feedback about their drinking and brief advice along with follow up assessments.
89342491|NCT02885311|Other|Problem Drinkers (PD)|PD will be offered a choice of either an evidence-based behavioral intervention(Motivational Enhancement Therapy) or medication (Naltrexone) plus medication management. These participants will also receive follow up assessments.
89342492|NCT02885311|Other|AD with physiological withdrawal (AD-W)|AD-W will referred to outpatient detoxification as part of standard care, unless medically contraindicated, and will be offered medication (naltrexone) plus medication management as or an evidence-based behavioral intervention (Modified Behavioral Self-Control Therapy [MBSCT]) adapted from our two prior protocols. These participants will also receive follow up assessments.
89342493|NCT02885311|Other|AD with complex presentation (AD-CMPLX)|AD-CMPLX will receive a referral to specialty substance use disorder treatment and also receive follow up assessments.
89342494|NCT02872441|Experimental|diagnosis of disease associated with IgG4|patients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4
89342495|NCT02742454|Active Comparator|Standard 30-60 Seconds Cord Clamping|Standard treatment for extremely preterm infants which is delayed cord clamping 30-60 seconds after birth, and assisted ventilation after cord clamping.
89342496|NCT02742454|Experimental|VentFirst 120 Seconds Cord Clamping|Assisted ventilation (face mask continuous positive airway pressure, CPAP, or positive pressure ventilation, PPV) is provided prior to cord clamping at 120 seconds.
89342497|NCT02740192|Experimental|Adductor Canal Block|Patients in this group received local infiltration of bupivacaine in the adductor canal after surgery, in addition to the periarticular injection intra-op.
89342498|NCT02740192|Sham Comparator|Periarticular Injection|Patients in this group received a bandaid at the presumed adductor canal injection site, in addition to the periarticular injection intra-op.
89342499|NCT02727868|Other|exclusive breast irradiation group|to assess the impact of irradiation areas
89342500|NCT02727868|Other|breast and sternal irradiation group|to assess the impact of irradiation areas
89342501|NCT02717507|Experimental|Arm I (carvedilol)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
89342502|NCT02717507|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
89342503|NCT02699437||Pregnant women with preeclampsia|Testing for antiphospholipid antibodies (anticardiolipin antibodies and lupus anticoagulant) will be performed in pregnant women with preeclampsia.
89342504|NCT02596906|Experimental|tDCS+Training|This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
89342505|NCT02596906|Sham Comparator|Sham tDCS+training|"This group will receive 20 minutes of sham tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks."
89342506|NCT02588209|Experimental|SMART Training|This group will receive the Strategic Memory Advanced Reasoning Training (SMART) program, twice a week for four weeks.
89342507|NCT02588209|Active Comparator|Health|This group will receive the Brain Health Workshop educational program, twice a week for four weeks.
89342508|NCT02547662|Experimental|Treatment (ixazomib citrate, pomalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88806886|NCT04822194|Active Comparator|Reinterpretation|Participants will receive structured cognitive emotion regulation training from an experimenter during an approximately 10-minute interaction in which detailed instructions for implementation of the reinterpretation strategy is explained (i.e. imagining a better outcome than what initially seemed apparent).
88806887|NCT04772209|Active Comparator|Sodium bicarbonate Arm|In this arm, the catheter lock solution is sodium bicarbonate
89342509|NCT02515383||Part 1 (MDASI questionnaire, interview)|Patients complete the MDASI questionnaire and then complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
89342510|NCT02515383||Part 2 (MDASI questionnaires, interview)|Patients complete the MDASI questionnaire twice (1-7 days apart). Approximately 1 week after beginning standard of care treatment, patients complete the MDASI questionnaire at 4 additional time points, each 1 week apart. Patients may also complete a cognitive debriefing interview regarding its comprehensibility, the acceptability of each item, and whether any important symptoms are missing from the questionnaire.
89342511|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging - Neoadjuvant Chemo (NAC) Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 6 time points.
89342512|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging - Non-NAC Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 1 time point.
89342513|NCT02470585|Active Comparator|Placebo + Carboplatin + Paclitaxel -> Placebo|Participants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
89342514|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Placebo|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
89342515|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Veliparib|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles.
89342516|NCT02425306|Experimental|Arm A:6MHP + Montanide ISA-51|Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
88806888|NCT04772209|Active Comparator|Heparin arm|In this arm, classic heparin will be used as a reference catheter lock solution (standard lock solution)
89342517|NCT02425306|Experimental|Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide|"Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
89342518|NCT02425306|Experimental|Arm C:6MHP + polyICLC + Montanide ISA-51|Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
89342519|NCT02425306|Experimental|Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide|"Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
89342520|NCT02330770|Active Comparator|Dual trigger group|Trigger with concomitant GnRHa and HCG (single low-dose) administration
89342521|NCT02330770|Active Comparator|Single low-dose HCG group|Trigger with GnRHa then HCG (single low-dose) administration in luteal phase
89342522|NCT02330770|Active Comparator|Multiple low-doses HCG group|Trigger with GnRHa then HCG (multiple low-doses) administration in luteal phase
89342523|NCT02330757|Active Comparator|HRT group|Women will be subjected to HRT using Estradiol valerate before FET
89342524|NCT02330757|Active Comparator|MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
89342525|NCT02312089|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
89342526|NCT02312089|No Intervention|Control group|No GnRHa administration in luteal phase
89342527|NCT02312076|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
89342528|NCT02312076|No Intervention|Control group|No GnRHa administration in luteal phase
89342529|NCT02199080|Other|Atrial fibrillation|D-dimer assay before ablation of atrial fibrillation
89342530|NCT02173379|Experimental|Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
89342531|NCT02173379|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
89342532|NCT02134925|Experimental|Arm I (MUC1 peptide-poly-ILCLC adjuvant vaccine)|Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine SC in weeks 0, 2 and 10 and a booster injection in week 53.
89342533|NCT02134925|Placebo Comparator|Arm II (saline)|Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.
89342534|NCT02016430|Experimental|MeLT Dietary intervention|Mediterranean Low-TMAO (MeLT) diet. Used in cohorts 1, 2 and 3.
89342535|NCT02016430|Experimental|TLC Dietary intervention|Therapeutic Lifestyle Changes (TLC) diet. Used in cohorts 1, 2 and 3.
89342536|NCT02016430|Experimental|MeLT dietary intervention with TMAO|Mediterranean Low TMAO diet with TMAO levels reported. Used in cohort 1 only.
89342537|NCT01949077||Sustained virological response|Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
89342538|NCT01949077||Non-responders|Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
89342539|NCT01849874|Experimental|MEK162|
89342540|NCT01849874|Active Comparator|Physician's choice chemotherapy|
89342541|NCT01849263|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.
89342542|NCT01841723|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89342543|NCT01829204||Non pregnant asymptomatic|Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
89342544|NCT01829204||Non pregnant symptomatic|Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
89342545|NCT01829204||Pregnant asymptomatic|Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
89342546|NCT01829204||Pregnant symptomatic|Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
89342547|NCT01771107|Experimental|Treatment (brentuximab and combination chemotherapy)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
89342548|NCT01665326||Infantile Pompe disease|Individuals with a confirmed diagnosis of Infantile Pompe disease
89342549|NCT01411345|Other|Phase 3 - Arm I: Standard Salvage Radiation Treatment (SSRT)|"Phase 3 total dose of 68 Gy will be delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.~this arm is closed"
89342550|NCT01411345|Experimental|Phase 3 - Arm II: Mapped Tumor Salvage RT (MTSRT)|"Phase 3 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).~this arm was continues as single arm phase 2"
89342551|NCT01411345|Experimental|Phase 2: Mapped Tumor Salvage RT (MTSRT)|Phase 2 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).
88814115|NCT02241200|Experimental|SC Administration|The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
89342552|NCT01375114|Experimental|Panax Ginseng|Panax ginseng 400 mg by mouth twice a day from Day 1-29 for first 30 participants in Part 1. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
89342553|NCT01375114|Experimental|Ginseng (Part 2)|Panax ginseng 400 mg by mouth twice a day from Day 1-29. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
89342554|NCT01375114|Placebo Comparator|Placebo (Part 2)|Oral placebo twice daily for 4 weeks. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
89342555|NCT01189799|Experimental|Motivational Therapy Aftercare|Twelve, 60 minute weekly structured manualized therapy sessions.
89342556|NCT01189799|Active Comparator|Dual Recovery Anonymous/Tx as usual|Aftercare Treatment as Usual,which is twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
89342557|NCT01009645|Experimental|Fact Only|The educational message used will contain facts only.
89342558|NCT01009645|Experimental|Fact and Myth|The educational material seen by this arm will contain facts and myths only.
89342559|NCT01009645|Experimental|Fact, Myth, Why|The educational material seen by this arm will contain myths, facts, and refutations of the myths.
89342560|NCT01009645|Placebo Comparator|Control|This arm will receive fact/myth educational materials originally developed and used by the CDC.
89342561|NCT01008501||Experimental|Individuals with recurrent or sporadic hydatidiform moles and their first-degree family members. Sometimes additional family members are also enrolled.
89342562|NCT00950846|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion
89342563|NCT00290381|Experimental|Placebo followed by Drug (OC000459)|Placebo and Drug are followed by Nasal Allergen Challenge
89342564|NCT00290381|Experimental|Drug (OC000459) followed by Placebo|Drug and Placebo are followed by Nasal Allergen Challenge
89342565|NCT03940079|Experimental|gross-motor group (GMG)|"The participants of GMG received motor-cognitive dual-task training. The sensors used by the participants were four different colored buttons. The participants wear a suit with two buttons on the shoulders and the other two fasten on the knees by velcros. To accomplish the tasks, the participants had to slap the correct colored buttons. The stretching of upper or lower limbs was demanding while slapping, so the participants of GMG received a training which required cognitive and motor functions at the same time.~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
89342566|NCT03940079|Active Comparator|fine-motor group (FMG)|"The participants of FMG received cognitive training only. Four colored sensors used by the participants were the keys on the keyboard of the laptop. The participants simply pressed correct colored keys by fingers to complete the tasks.~The participants attended 2 sessions per week and lasted for 4 weeks. Each session lasted 75 minutes, mainly including 30 minutes for game introduction and warm-up, 30 minutes for game training, and 15 minutes for rest during the training. Each task lasted 10 minutes, and each session contained 3 tasks. The game difficulty could be adjusted automatically according to the performance of participants."
89342567|NCT01198015||Rett syndrome girls|The study population (identical to the population in the preliminary research project) consists of a well-defined group of thirteen Dutch RTT girls with complete clinical, molecular, neurophysiological and metabolic work-up.
89342568|NCT01213511|Active Comparator|MECC Group|Patients operated for elective coronary artery bypass grafting with the use of minimal extracorporeal circulation.
89342569|NCT01213511|Active Comparator|CECC Group|Group of patients undergoing elective coronary bypass grafting with the use of conventional extracorporeal circulation.
89342570|NCT01195753|Experimental|Liver Cell Infusion|
89342571|NCT01111097|Active Comparator|Cohort 1|Subjects are given a dose of Dichloroacetate 4mg/kg twice a day for 30 days
89342572|NCT01111097|Active Comparator|Cohort 2|Subjects are given a dose of Dichloroacetate 12.5mg/kg twice a day for 30 days
89342573|NCT05299879||Symptomatic patients with HFrEF corresponding to NYHA II-III|
89342574|NCT03848533|Experimental|melatonin plus metformin|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before bedtime) per 90 days."
89342575|NCT03848533|Active Comparator|metformin plus placebo|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.~Will administrate homologated placebo once a day in the night (before bedtime) per 90 days."
89342576|NCT03848533|Experimental|melatonin plus placebo|"It will be indicate homologated placebo once a day in the morning (before breakfast) per 90 days.~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before sleep) per 90 days."
89342577|NCT05129215||Development|A primary cohort of eligible patients from the Sixth Affiliated Hospital of Sun Yat-sen University is used for model derivation.
89342578|NCT05129215||Internal cross-validation|A cohort of consecutive patients from the Sixth Affiliated Hospital of Sun Yat-sen University is used for internal cross-validation.
89342579|NCT05129215||External validation|An independent cohort of eligible patients from other hospitals is used for external validation.
89342580|NCT01115465|Other|Macroplastique|Macroplastique will be used for the treatment in an open-label, five year, post-market study
89342581|NCT01199497|Experimental|Group 1|Fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
89342582|NCT01199497|Placebo Comparator|Group 2|Placebo
89342583|NCT05289817|Experimental|Transcutaneous Vagus Electrical Nerve Stimulation (t-VNS)|Transcutaneous electrical stimulation will be delivered by trains for twenty minutes to the right cymba conchae at the ear.
89342584|NCT05289817|Active Comparator|Transcutaneous Sympathetic Ganglion Electrical Nerve Stimulation (t-SNS)|Transcutaneous electrical stimulation will be delivered continuously for twenty minutes to the cervicothoracic region.
89342585|NCT05289817|Sham Comparator|Sham Transcutaneous Vagus Electrical Nerve stimulation (sham t-VNS)|Transcutaneous electrical stimulation will be delivered by trains for twenty minutes to the right scapha at the ear.
89342586|NCT01111253|Active Comparator|Conservative strategy with antibiotics|"Hospital admission~Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration~Adequate pain relief~Oral intake as tolerated~Daily monitoring"
89342587|NCT01111253|No Intervention|Liberal strategy without antibiotics|"Admission only if discharge criteria are not met~No initial antibiotics~Intravenous fluids only for those not tolerating oral liquids~Adequate pain relief~Oral intake as tolerated~Daily monitoring when admitted to the hospital~Self-monitoring at home (Patient diary with temperature and VAS pain score until full recovery)"
89342588|NCT01213667|Other|ranibizumab as needed|
89342589|NCT01195987||Hepatitis C with Arthritis|
89342590|NCT01195987||Hepatitis C without Arthritis|
89342591|NCT01212263|Experimental|Clomiphene Citrate plus HP uFSH|Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
89342592|NCT01212263|Active Comparator|Step-up HP uFSH|HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter
89342593|NCT01196065|Experimental|Single Arm|
89342594|NCT01213745|Experimental|Intervention|
89342595|NCT01213745|Experimental|Attention|
89342596|NCT01213745|Active Comparator|Control|
89342597|NCT01118195||TBI and Suicidal Behavior|
89342598|NCT01118195||TBI and No Suicidal Behavior|
89342599|NCT01111409|Experimental|VFIX|
89342600|NCT03845179|Placebo Comparator|Placebo|Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
89342601|NCT03845179|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
89342602|NCT03936179|Experimental|high dose radiochemotherapy|A total dose of 86 Gy to residual metabolic disease with concurrent chemotherapy
89342603|NCT01196221||Patients with 30 to 70% carotid artery stenosis|
89342604|NCT05235295|Experimental|Fluoroscopic-guided sacroiliac joint injection|
89342605|NCT05235295|Active Comparator|Ultrasound-guided sacroiliac joint injection|
89342606|NCT01121627|Experimental|Computerized cognitive training|A 12 week computerized cognitive training
89342607|NCT04806139|Experimental|Intervention Group - Remote Enhance Fitness|Participants assigned to the intervention group will participated in a 16-week remote exercise intervention. Following a home/space environment and technology needs assessment, participants will attend a one-on-one orientation and practice class with a research assistant. Participants will join a live-streamed, instructor-led group Enhance Fitness exercise session for 1-hour, 3 days/week for 4 months (16-weeks).
89342608|NCT04806139|No Intervention|Waitlist Control|Participants randomized to the waitlist control group will be offered the opportunity to participate in the Remote Enhance Fitness class after study measures are completed. Cuff weights will be provided along with technical orientation, support, and equipment as needed.
89342609|NCT01212341|Experimental|Singe-dose infusion|Cohort 1: 1x10^6 cells/kg Cohort 2: 1x10^7 cells/kg
89342610|NCT01212341|Experimental|Repeated dose infusion|Cohort 3: 1x10^6 cells/kg Cohort 4: 3x10^6 cells/kg Cohort 5: 1x10^7 cells/kg Cohort 6: 3x10^7 cells/kg
89342611|NCT01199653|Active Comparator|Non-operative treatment|Non-operative (conservative) treatment of the clavicle fracture
89342612|NCT01199653|Active Comparator|Operative treatment|Operative stabilization (i.e. ORIF) of the fracture with a plate and screws.
89342613|NCT01121705|No Intervention|A1. standard duration|Patients were randomly assigned in a 1:1 ratio to two treatment arms. In the standard treatment group (A1), patients were treated for 24 weeks irrespective of the HCV RNA status at week 4 with Peg-interferon alfa-2b at a dose of 1.5 mcg per kilogram of body weight weekly in combination with oral ribavirin administered at a dose of 1000 mg/day for patients with a weight <75 kg or 1200 mg/day for those with a weight of ≥75 kg. Patients enrolled in Arm A1 will be treated for standard 24 weeks duration of treatment with standard dosages of PegInterferon alpha 2b and weight-based dosages of ribavirin.
89342614|NCT01121705|Experimental|B 1 I or II|In the variable treatment group, patients with a virologic response at week 4 will receive treatment for 12 weeks and those without a virologic response at 4 weeks treatment for 36 weeks. Patients without RVR will be treated for 24 or 36 weeks and labelled (B1I) or (B1II, respectively Intervention: different durations of treatment for patients without RVR
89342615|NCT03937427||CRS with Asthma|
89342616|NCT03937427||CRS without Asthma|
89342617|NCT01198171||Basic science (DNA analysis)|DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
89342618|NCT03937739||Group 1: Case group,|The patients who admitted to the general surgery for operation with inguinal hernia were the case group of this study.
89342619|NCT03937739||Group 2: Control group,|The patients who were admitted to the same hospital with such as eye, ear/nose/throat, dermatologic diseases or elective surgeries and did not have any inguinal hernia complaints, constipation and other chronic disease which could increase the intra abdominal pressure selected as control group.
89342620|NCT01215773|Experimental|BI 671800 HEA medium dose|Tablet, oral administration with 240 mL of water for each treatment
89342621|NCT01215773|Experimental|BI 671800 HEA high dose|2 Tablets, oral administration with 240 mL of water for each treatment
89342622|NCT01215773|Placebo Comparator|Placebo|Matching to HEA 200 mg tablets, oral administration
89342623|NCT03846583|Experimental|Dose Escalation|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
89342624|NCT03846583|Experimental|Arm A: Active Brain Metastases|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
89342625|NCT03846583|Experimental|Arm B: Surgical Resection Needed|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
89342626|NCT03846583|Experimental|Arm C: Progressive Extracranial Disease|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
89342627|NCT01115543|Active Comparator|calcitriol|The subjects were randomized to receive calcitriol in a dose-escalating fashion for up to 24 weeks.
89342628|NCT01115543|Experimental|alfacalcidol|
89342629|NCT01115621|Active Comparator|Glutenfree diet|Glutenfree diet during the first year of life
89342630|NCT01115621|No Intervention|Control - normal diet|
89342631|NCT05670613|Other|Dispense Ready to Use PN Solutions|Dispensed to patient commercial solution.
89342632|NCT05670613|Other|Dispense the most effective commercial Solution calculated with the use of the CDSS|Dispensed to patient the most effective commercial solution after the CDSS calculations.
89342633|NCT03937505|Experimental|Dose-escalation|Dose-cohort escalation of single intravenous injection of IS-001 starting with 20 mg (n=8), escalating in 20 mg increments until optimal dose is determined.
89342634|NCT03937505|Experimental|Optimal dose-characterization|Single intravenous injection of IS-001 at the optimal dose will be administered to subjects assigned to the treatment group. Safety control subjects will not receive any study drug but will undergo robotic surgery and all associated safety assessment clinical trial procedures.
89342635|NCT01118507||TRISOMY|mothers of a trisomic fetus 21
89342636|NCT01118507||NORMAL KARYOTYPE|mothers of DISOMIQUE foetus 21
89342637|NCT03846349|Experimental|Study Group|Participants from the study group will follow an upper airway reinforcement regimen using the IOPI device over 6 weeks. The reinforcement protocol will be adapted each week to improve Percentage of initial strength Exercises will be adapted each week
89342638|NCT03846349|Sham Comparator|Control group|"Participants from the control group will perform a sham reeducation protocol using an EMT threshold at minimal resistance. The expiratory pressure will remain unchanged over the weeks."
89342639|NCT01118585|Other|TIF Procedure|Intervention: Transoral incisionless fundoplication procedure using the EsophyX device. During general anesthesia the EsophyX device is introduced trans orally into the stomach and used to created a 270 degree, 3cm in length, wrap at the distal end of the esophagus to treat GERD.. .
89342640|NCT03844867|Experimental|Filippo Cea and Carmel|Subjects <65 years.
89342641|NCT01216007|Active Comparator|TIVA|TIVA
89342642|NCT01216007|Active Comparator|Inhalational|Inhalational/volatile general anesthetic
89342643|NCT05493553|No Intervention|Baseline|A baseline period (no supplements or intermittent fasting).
89342644|NCT05493553|Experimental|Phase 1|A four-day period during which subjects will take a yerba mate supplement once per day in the morning and a fiber-based supplement twice per day prior to two meals.
89342645|NCT05493553|Experimental|Phase 2|A four-day period during which subjects will take a yerba mate supplement once per day in the morning and a fiber-based supplement twice per day prior to two meals, while also practicing daily intermittent fasting (16 hours fasting, 8 hours eating window).
89342646|NCT01198249|Experimental|amlodipine monotherapy|
89342647|NCT01198249|Experimental|losartan monotherapy|
89342648|NCT01198249|Experimental|HCTZ|
89342649|NCT01198249|Experimental|mlodipine and Losartan and HCTZ|
89342650|NCT01212497|Experimental|Mindfulness meditation coaching|Assess effectiveness of using a virtual computer coach to train mindfulness meditation
89342651|NCT04734301|Active Comparator|Group 1: IVES (2 times in a week)|This group included the IVES in addition to all components of the BT. IVES was performed in lithotomy position via electrical stimulation device with a vaginal probe.
89342652|NCT04734301|Experimental|Group 2: IVES (5 times in a week)|This group also included the IVES in addition to all components of the BT as in Group 1. IVES performed in the same way as Group 1, except for frequency of treatment.
89342653|NCT01121783|Active Comparator|Lactisole-Glucose|
89342654|NCT01121783|Active Comparator|Lactisole-water|
89342655|NCT01121783|Placebo Comparator|Water-Glcuose|
89342656|NCT01121783|Placebo Comparator|Water-Water|
89342657|NCT03844009|Experimental|Debriefing|Participant's of the debriefing group had a computer integrated debriefing at the end of each scenario of the computer-based simulator
89342658|NCT03844009|No Intervention|No debriefing|Participant's of the debriefing group had no computer integrated debriefing at the end of each scenario of the computer-based simulator
89342659|NCT02529761|Experimental|Sorafenib combined with TACE|220 subjects in this study group will receive the treatment of sorafenib combined with conventional TACE.
89342660|NCT02529761|Active Comparator|TACE monotherapy|110 subjects in this study group will receive the treatment of conventional TACE monotherapy.
89342661|NCT01118819|Experimental|Clostridium novyi-NT spores|
89342662|NCT01115777||Pediatric patients treated with radiotherapy|
89342663|NCT03844243|Experimental|NGF condition + Control condition|"All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.~After 4 weeks:~All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
89342664|NCT03844243|Experimental|Control condition + NGF condition|"All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.~After 4 weeks:~All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
89342665|NCT01118897|Experimental|Neoadjuvant chemoradiation|All patients will receive concurrent chemoradiation. Chemotherapy will consist of Inj. Gemcitabine 300mg/mt2 weekly throughout the course of Radiotherapy. Radiotherapy will be delivered using Tomotherapy to a dose of 57Gy/25# over 5 weeks
89342666|NCT01116011|Experimental|AZD7268|
89342667|NCT01116011|Placebo Comparator|Placebo|
89342668|NCT01196611|Experimental|Function Voice Exercises|Behavioral: Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
89342669|NCT01196611|Experimental|Voice amplification|Behavioral: Voice amplification Patients will use VA over a course of 6 weeks.
89342670|NCT03937271||Sjögren's syndrome|Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
89342671|NCT03937271||Systemic lupus erythematosus|Systemic lupus erythematosus patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1982 revised Systemic lupus erythematosus criteria
89342672|NCT03937271||Rheumatoid Arthritis|Rheumatoid Arthritis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 2010 ACR/EULAR Rheumatoid Arthritis classification criteria
89342673|NCT03937271||Systemic Sclerosis|Systemic Sclerosis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1980 ACR eSystemic Sclerosis criteria
89342674|NCT03937271||Ankylosing spondylitis|Ankylosing spondylitis patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) fulfilled the 1984 Ankylosing spondylitis Modified New York criteria
89342675|NCT03937271||Dry eye syndrome|Dry eye syndrome patients were screened in the ophthalmology outpatient departments, rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 20 and 75 years; (2) Schirmer's test less than 10 mm/5 min
89342676|NCT05479591||Participants with type 2 diabetes (T2D)|Participants with T2D previously treated with premix insulin for at least 12 weeks (3 months) based on local clinical guidelines will initiate treatment with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia.
89342677|NCT01119209|Active Comparator|Ropivacaine|
89342678|NCT01119209|Placebo Comparator|Saline|
89342679|NCT05670535||pSS group (Study group)|"Women with the diagnosis of pSS for at least 3 years.~At reproductive age (without menopause).~Receiving only hydroxychloroquine sulfate treatment.~Presence of the symptoms of vaginitis."
89342680|NCT05670535||Women without pSS (Control group)|"Women without any known disease.~At reproductive age (without menopause).~Presence of the symptoms of vaginitis."
89342681|NCT01116089|Active Comparator|PARI LC® PLUS nebulizer|
89342682|NCT01116089|Active Comparator|PARI eFlow® rapid electronic nebulizer|
89342683|NCT01213901|Experimental|1|"Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.~Injections will be given in a random order and the technician will be blinded to the injection.~Each patient will evaluate the comfort of the injection by completing a visual analog scale."
89342684|NCT01116167|Experimental|Letrozole -Berberine|
89342685|NCT01116167|Active Comparator|Letrozole|
89342686|NCT01116167|Active Comparator|Berberine|
89342687|NCT03844165|Experimental|Diet change (red rice) with yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. Food for the diet (red rice and lentils) will be provided for those randomised to the diet arm. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
89342688|NCT03844165|Active Comparator|Yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
89342689|NCT03843931|Active Comparator|GLA:D|8 weeks of education (1 session/week for 2 weeks) and exercise therapy (2 sessions/week for 6 week)
89342690|NCT03843931|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injection (5 ml of 0.9% sodium chloride) every 2 weeks over an 8-week period
89342691|NCT01119521|Experimental|Group A: INH; BCG|6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI) (completed within no more than 7 months) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination.
89342692|NCT01119521|Experimental|Group B: observation; BCG; observation; INH|7 months of observation (run in period) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination followed after 6 months of observation by 6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI).
89342693|NCT05670457|No Intervention|Control group|this group will include 22 patients who will receive anti peptic ulcer only for 2 months.
89342694|NCT05670457|Active Comparator|Diosmin group|this group will include 22 patients who will receive anti peptic ulcer and diosmin 500 mg twice daily for 2 months.
89342695|NCT01199809|Experimental|1|
89342696|NCT01199809|Placebo Comparator|2|
89342697|NCT01119599|Experimental|Treatment (RO4929097, surgery, radiation therapy)|See Detailed Description.
89342698|NCT03419403|Experimental|Standard Steroids|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days
89342699|NCT03419403|Experimental|Standard Steroids + Vasoconstrictor + Cold Compress|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. The cold compress was to be applied in increments no longer than 30 min (could be shorter if the participant was uncomfortable).
89342700|NCT03419403|Experimental|Enhanced Steroids + Vasoconstrictor + Cold Compress|Enhanced steroid eye drops: 1 drop each eye, 6 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Ophthalmic Steroid Ointment; applied to each eye once daily before sleep, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. Cold compress was to be applied in increments no longer than 30 min (could be shorter if the patient is uncomfortable).
89342701|NCT01116245|Experimental|Low Dose|5x10^7 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
89342702|NCT01116245|Experimental|Middle Dose|3.3x10^8 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
89342703|NCT01116245|Experimental|High Dose|1x10^9 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
89342704|NCT01116245|Placebo Comparator|Placebo|normal saline x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
89342705|NCT05156437|Experimental|Group I (Experimental)|Two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of oral therapy with outpatient follow-up.
89342706|NCT05156437|Active Comparator|Group II (Control Group)|Conventional two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of IV antibiotic therapy (inpatient or facility supervised if indwelling catheter utilized).
89342707|NCT01119677|Experimental|Group 1|No dose titration
89342708|NCT01119677|Experimental|Group 2|Fast dose titration
89342709|NCT01119677|Experimental|Group 3|Slow dose titration
89342710|NCT01212575||300 patients|Female or male aged 18-65 years with a diagnosis of schizophrenia having received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
89342711|NCT03713385||Aged group (n =49)|Determined the optimal endotracheal tube size according to age of the child (internal diameter [ID] in mm = [age in years + 16] /4) suggested by Cole
89342712|NCT03713385||Subglottic diameter group (n =49)|The subglottic transverse diameter was estimated with ultrasonography on the middle of the anterior region of the neck at the level of cricoid cartilage
89342713|NCT03713385||Epiphyseal diameter group (n =49)|The epiphyseal transverse diameter of the distal radius was estimated with ultrasonography.
89342714|NCT01196689|Experimental|1|AZD1981 100 mg twice daily for 6 ½ days
89342715|NCT03715725||Registry cohort|Registries in Norway are nation-wide and provision of the information is mandatory, which eliminates the risk of both selection and re-call bias. The large and detailed dataset also makes it possible to adjust for other risk factors on which information is available.
89342716|NCT03715725||Electronic Medical Records (EMR) cohort|Patients with NVAF diagnosis will be identified through extraction of patient-level data from EMRs from a number of hospitals in Norway, in order to describe these patients more closely regarding their clinical characteristics that are not available in nation-wide registers (e.g., in-patient treatments, anthropometric data and laboratory test results).
89342717|NCT01212653|Active Comparator|Golimumab|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
89342718|NCT01212653|Placebo Comparator|Pacebo-controlled|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either Golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
89342719|NCT03843697|Experimental|Patients with IBD who develop resistance to anti TNF|Patients with inflammatory bowel disease who developed partial or complete resistance to anti TNF based drugs
89342720|NCT01119989|No Intervention|weight maintenance diet|
89342721|NCT01119989|Placebo Comparator|weight maintenance + fructose|
89342722|NCT01119989|Experimental|weight maintenance diet + fructose and amino-acid|
89342723|NCT01199887|Experimental|IW001|Three dose cohorts, 0.1 mg, 0.5 mg, 1.0 mg
89342724|NCT01213979|Active Comparator|1000 mg iron isomaltoside 1000 as intravenous infusion|
89342725|NCT01213979|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
89342726|NCT03937115|Experimental|Group S1|High level jump practice : more 4000 hours of practice during the last five years
89342727|NCT03937115|Experimental|Group S2|Amateur jump practice : less 4000 hours of practice during the last five years
89342728|NCT03937115|Experimental|Group C1|High level cycling practice: more 4000 hours of practice during the last five years
89342729|NCT03937115|Experimental|Group C2|Amateur cycling practice: less 4000 hours of practice during the last five years
89342730|NCT03937115|Experimental|Group T|Sedentary : less two hours of recreationally practice of sport by week
89342731|NCT03844555|Experimental|End Stage Renal Disease|Single oral dose of elafibranor 120mg
89342732|NCT03844555|Experimental|Healthy|Single oral dose of elafibranor 120mg
89342733|NCT05282719|Experimental|Treatment regime|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
89342734|NCT01118429|Experimental|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
89342735|NCT01118429|Placebo Comparator|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
89342736|NCT01214135||1|Patients with a diagnosis of schizophrenia who have been hospitalized and received at least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010).
89342737|NCT01200043|Experimental|fructose restriction|Isocaloric fructose restricted diet for 10 days
89342738|NCT01116479|Active Comparator|Haemoglobin (<6.0 mmol/l)|Blood transfusion thresholds:Haemoglobin < 6.0 mmol/l (9.9 g/dL)
89342739|NCT01116479|Experimental|Haemoglobin (< normal range)|Blood transfusion threshold: Haemoglobin < 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l (13.4 g/dL) for males
89342740|NCT01120145||Therapeutic efficacy study|Asymptomatic parasitemic pregnant women at 16-26 weeks of gestation will be enrolled into the study and followed weekly for 42 days after the receipt of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy to assess the clearance of parasitemia.
89342741|NCT01120145||Birth outcomes study|Women presenting for delivery will be enrolled and assessed for a history of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy and evidence of malaria infection by placental histology, maternal peripheral parasitemia, maternal anemia and infant cord blood parasitemia.
89342742|NCT01120145||Characterizing molecular markers of SP resistance|Parasitemic outpatients attending the health facility will be tested for parasite molecular markers of sulphadoxine-pyrimethamine resistance.
89342743|NCT05121259|Experimental|Exercise Guide|Single group feasibility group. Single group (intervention group) will be given access to the intervention (Exercise Guide UK) for eight-weeks.
89342744|NCT03447249|Placebo Comparator|Placebo|Participants who received placebo matched to VX-659/TEZ/IVA for 24 weeks in the TC treatment period.
89342745|NCT03447249|Experimental|VX-659/TEZ/IVA TC|Participants who received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
89342746|NCT01120301|Experimental|Transcranial Laser Therapy|
89342747|NCT01120301|Sham Comparator|Sham control procedure|
89342748|NCT04156555|Experimental|Study drug|
89342749|NCT01200121|Experimental|Arm A Bevacizumab|48 patients randomized into arm A will receive repeated intra¬peritoneal application of Bevacizumab
89342750|NCT01200121|Placebo Comparator|Arm B Placebo|26 patients randomized into arm B will receive repeated intra¬peritoneal application of Placebo
89342751|NCT01116557|Other|THERMOCOOL® group|Radiofrequency ablation to achieve PVI using the CARTO® 3 System, the THERMOCOOL® Catheter and the LASSO® Circular Mapping Catheter.
89342752|NCT01116557|Active Comparator|PVAC® group|Radiofrequency ablation to achieve PVI using fluoroscopy and the PVAC®
89342753|NCT01198405|Experimental|Enhanced External Counterpulsation|Treatment of Enhanced External Counterpulsation (EECP) with a prespecified protocol on top of guideline-driven standard medical therapy.
89342754|NCT01198405|Active Comparator|Control|Guideline-driven standard medical therapy.
89342755|NCT03715647||Sepsis|"The puerperal / postpartum women who evolved with sepsis, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
89531680|NCT05787600|Active Comparator|Chlorhexidine 0.12%|Participants will be given the positive-control, Chlorhexidine 0.12%, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing.
89342756|NCT03715647||HELLP Syndrome|"The puerperal / postpartum women who evolved with HELLP syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
89342757|NCT03715647||Respiratory Distress Syndrome, Adult|"The puerperal / postpartum women who evolved with Adult Respiratory Distress Syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
89342758|NCT01214369|Active Comparator|X-tip intraosseous injection|
89342759|NCT01214369|Active Comparator|PDL injection|
89342760|NCT03713151|Experimental|Dividat FIT: Computer based exercise|One arm with 10-15 Haemophilia patients and 10-15 Myositis patients.
89342761|NCT01116635|Experimental|50mg dose loading per vial of doxorubicin|
89342762|NCT01116635|Experimental|75mg dose loading per vial of doxorubicin|
89342763|NCT01200199||Varicose veins|
89342764|NCT01214447||Low - OSND less than 22|
89342765|NCT01214447||Moderate - OSND score 23-27|
89342766|NCT01214447||Normal - OSND score 28-32|
89342767|NCT03936803|Active Comparator|exercise group|Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD) and taking their standard medications in addition to aerobic interval training exercise .Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with heart rate (HR) at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum heart rate HR. The exercise session was terminated by 5 minutes cool-down
89342768|NCT03936803|Active Comparator|electro-acupuncture group|"Twenty-five patients suffering from Nonalcoholic fatty liver disease (NAFLD), and taking their standard medications In addition to electro acupuncture (EA) of (2 Hz, 4 mA) was applied at points of: liver 3 (LR3) ,liver 14 (LR14), gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
89342769|NCT01566799|Experimental|Metformin|Patients will be receive 12 weeks of paclitaxel followed by 4 cycles of FAC combined with 500 mg/day of metformin p.o.
89342770|NCT03418545|Experimental|JUVÉDERM VOLBELLA® XC|JUVÉDERM® VOLBELLA™ XC injectable gel was injected into the infraorbital and adjacent area at Randomization as determined by the investigator. Participants were eligible to receive an optional touch-up treatment 1 month later and an optional repeat treatment 12 months after last treatment, if applicable. A maximum of 2.2 milliliter (mL) per side was injected for initial and touch-up treatments combined.
89342771|NCT03418545|No Intervention|No-treatment Control|Participants randomized to the No-treatment Control group completed a 3-month No-treatment Period. Participants were then eligible to receive optional treatment with JUVÉDERM® VOLBELLA™ XC injectable gel injected into the infraorbital and adjacent area followed by an optional touch-up treatment 1 month later.
89342772|NCT03936959|Experimental|LY3434172|LY3434172 administered IV
89342773|NCT01198483|Active Comparator|Micro|Microincision cataract surgery
89342774|NCT01198483|Active Comparator|Small|Smallincision cataract surgery
89342775|NCT01120457|Experimental|Arm 1: Dose Escalation and Expansion cohort (AML Patients)|"Dose Escalation: BMS-936564 0.3-10 mg/kg solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)~Dose Expansion: BMS-936564 maximum tolerated dose (MTD) based on dose escalation, solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)"
89342776|NCT01120457|Experimental|Arm 2: Dose Expansion cohort (DLBCL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
89342777|NCT01120457|Experimental|Arm 3: Dose Expansion cohort (CLL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
89342778|NCT01120457|Experimental|Arm 4: Dose Expansion cohort (FL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
89342779|NCT03842371||Sepsis with type 2 diabetes|Sepsis patients with type 2 diabetes
88814116|NCT02223455|Placebo Comparator|Single Hand Hygiene Sign|Wards/units in this arm of the study will have the same hand hygiene sign posted by the hand sanitizer dispensers outside each patient room. The sign will not change.
89342780|NCT03842371||Sepsis without type 2 diabetes|Sepsis patients without type 2 diabetes
89342781|NCT03842371||Volunteers|Healthy volunteers
89342782|NCT01214525||Meatotomy|Toilet trained children scheduled for urethral meatotomy for the treatment of urethral meatal stenosis.
89342783|NCT04642807|Active Comparator|"Group 1 Long-arm full cast and routine follow-up"|Patients assigned to Group 1 will be placed in a long arm cast, at 90-100 degrees in neutral rotation. A referral will then be made to the orthopedic department and the patient reviewed at week 3 with cast removal, clinical assessment and radiographic assessment as determined by the normal practice at the local center.
89531681|NCT05787600|Placebo Comparator|Placebo Product|Participants will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing.
89342784|NCT04642807|Experimental|"Group 2 Long-arm soft cast and no clinical or radiographic follow-up"|"Patients assigned to group 2 will be placed in a long arm cast at 90-100 degrees in neutral rotation. They will be given verbal and written information on the injury, when and how to remove the cast and contact details if there are any concerns.~Since they will not be attending clinical follow-up, an email or telephone survey will be undertaken at 3 weeks and after 6 months. The survey will inquire initially about pain, unplanned returns to the Family Physician and hospital, complications, parent/patient satisfaction and a standardized patient reported outcome score will be taken. Please see attached documentation for the itemized survey questions. The 6 month follow-up will include photographs and an illustrated guide will be given to the families on how to obtain pictures of maximal flexion, extension and the child's carrying angle (attached). Measurements of range of motion from photographs are considered comparable to clinical assessment of range of motion"
89342785|NCT03939845|Active Comparator|TACE|
89342786|NCT03939845|Experimental|TACE+RT|
89342787|NCT01216085|Experimental|imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
89342788|NCT01198561||repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS
89342789|NCT01122017|Experimental|Medial Opening-Wedge Osteotomy|Medial Opening-Wedge Osteotomy (MOWO) is an approach for the correction of malalignment of the knee
89342790|NCT01198639|Active Comparator|manual administration of iv anesthetics|
89342791|NCT01198639|Experimental|closed-loop administration of iv anesthetics|
89342792|NCT03936725||Chronic and non specific low back pain patients|Chronic and non specific low back pain patients
89342793|NCT01200277|Experimental|vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
89342794|NCT01200277|Sham Comparator|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
89342795|NCT01214681|Placebo Comparator|Placebo|
89342796|NCT01214681|Experimental|Hi-maize 260|
89342797|NCT01214681|Experimental|Polydextrose|
89342798|NCT01214681|Active Comparator|Hi-maize 260 and polydextrose|
89342799|NCT03842059|Experimental|Computer-aided detection|
89342800|NCT03842059|Placebo Comparator|Standard colonoscopy|
89342801|NCT01116713|Active Comparator|Dexamethasone group|This group of patients received intravenous dexamethasone (8 mg) 60 minutes before skin incision.
89342802|NCT01116713|Placebo Comparator|Placebo group|Patients of these group received homologated placebo 60 minutes before skin incision.
89342803|NCT01202149|Active Comparator|Elidel Right Side, Hylatopic Plus Left Side|Elidel applied topically on Right Side of body twice a day and Hylatopic plus emollient foam applied topically on Left Side of body three times a day
89342804|NCT01202149|Active Comparator|Elidel Left Side Hylatopic Plus Right Side|Elidel applied topically on Left Side of body twice a day and Hylatopic plus emollient foam applied topically on Right Side of body three times a day
89342805|NCT03446781|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
89342806|NCT03446781|Placebo Comparator|Placebo|Placebo
89342807|NCT01116791|Experimental|CRS+HIPC|Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment
89342808|NCT03841903||relapsing-remitting MS undergoing spinal cord MRI|
89342809|NCT03841903||secondary progressive MS undergoing spinal cord MRI|
89342810|NCT03841903||primary progressive MS undergoing spinal cord MRI|
89342811|NCT03841903||healthy control (HC) undergoing spinal cord MRI|
89342812|NCT01120535|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
89342813|NCT01585259|Active Comparator|Anfibatide|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
89342814|NCT01585259|Placebo Comparator|Placebo|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
89342815|NCT03940001|Experimental|arm|"Biological: Sintilimab For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1~Drug: Paclitaxel 50 mg/m^2 IV Q3W day 1, day 8 and day 15~Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15~Radiotherapy:~1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy"
89342816|NCT04131907|Experimental|Optilume™ BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
89342817|NCT04131907|Sham Comparator|Sham Device|The Sham Device is a 21 Fr Optilume BPH, Prostatic Pre-dilation Catheter within the sheath.
89342818|NCT04131907|Experimental|Pharmacokinetics Optilume Arm|A single arm of 15 non-randomized subjects will be treated in the pharmacokinetics (PK) arm. These subjects will be treated with the Optilume BPH Catheter System
89342819|NCT01120613|Experimental|chronotherapy|Patients identified with Nocturnal Hypertension, will have one of the blood pressure medications switched from daytime dosing to nighttime dosing
89342820|NCT03715569||Cohort with CNS infections|"Otoacoustic emissions (OAE), Wide Band Tympanometry (WBT), Vestibular function tests. Audiometry. MOCA, eGOS are cognitive tests.~Biomarker is a protein found in the inner ear examined in the cerebral fluid."
89342821|NCT03715569||OAE/WBT control: Healthy individuals|Otoacoustic emissions in normal position with head. Otoacoustic emission in different head positions.
89342822|NCT03715569||OAE/WBT control: Systemic infection|Otoacoustic emission during admission
89342823|NCT03715569||OAE/WBT control: ICP changes|Otoacoustic emission on patients without an CNS infection before and after elective lumbare puncture with measurement of intracranial pressure (ICP).
89342824|NCT03715569||Biomarker control|Inner ear biomarkers in patients without CNS infection. Inner ear fluid examination from patients that underwent elective cochlea implantation.
89342825|NCT01120769|Active Comparator|Acetaminophen|
89342826|NCT01120769|Placebo Comparator|Placebo|
89342827|NCT03715413|Other|Tamoxifen group|they was received Tamoxifen 10 mg daily.
89342828|NCT03715413|Active Comparator|Tamoxifen and pulsed radiofrequency group|they was received Tamoxifen 10 mg daily and pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.
89342829|NCT01120847||Veterans with PTSD|No intervention; this is an observational study.
89342830|NCT01120847||Control group w/out PTSD|No intervention; this is an observational study.
89342831|NCT01120925|Experimental|MNC|Bone marrow derived MNC
89342832|NCT01120925|Experimental|CD133|CD133 derived from Bone marrow
89342833|NCT01120925|Placebo Comparator|Control|Normal saline with 5% Human Serum Albumin
89342834|NCT04631419|Experimental|Maxillary flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 maxillary arches (experimental side) before canine retraction.
89342835|NCT04631419|Active Comparator|Maxillary control group|Canine retraction will be done on the other side without Laser corticotomy .
89342836|NCT04631419|Experimental|Mandibular flapless laser corticotomy group|Flapless laser corticotomy will randomly be assigned to one side of the 14 mandibular arches (experimental side) before canine retraction.
89342837|NCT04631419|Active Comparator|Mandibular control group|Canine retraction will be done on the other side without Laser corticotomy .
89342838|NCT03935945|Experimental|Personalized Feedback Intervention (PFI)|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes.
89342839|NCT03935945|No Intervention|Attention-Control|Attention control information will be comparable in focus on health-related behaviors (e.g., nutrition, exercise). We will use behaviors in the attention control feedback that are not associated with study outcomes. Attention control feedback will have text and graphs that are similar in appearance and length (i.e., 20-30 minutes) to intervention feedback.
89342840|NCT01122095||Psoriasis|Children with psoriasis Age matched controls without psoriasis or other significant inflammatory disease
89342841|NCT01122095||Control patient|Age matched, without psoriasis or significant inflammatory disease
89342842|NCT01122251|Experimental|Lercanidpine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
89342843|NCT01122251|Active Comparator|Lercanidipine or Valsartan|L10, L20, V80, V160
89342844|NCT01122251|Placebo Comparator|Placebo|Placebo comparators of Lercanidipine and Valsartan
89342845|NCT01585337||patients with lumbar fusion|
89342846|NCT04600999|Experimental|Group Avigan|Favipiravir from Day1 + Supportive care (symptomatic therapy) a regimen of 3600 mg (1800 mg twice a day orally) loading dose on Day1 followed by 1600 mg maintenance dose (800 mg twice a day orally) on Day2 to Day14.
89342847|NCT04600999|No Intervention|Group Control|Supportive care (symptomatic therapy)
89342848|NCT01122329|Placebo Comparator|inactive food packet|
89342849|NCT01122329|Active Comparator|Axona®|
89342850|NCT01216475|Active Comparator|Femtosecond LASIK|2 lasers refractive procedure
89342851|NCT01216475|Experimental|SMILE|Small incision lenticule extraction (SMILE)
89342852|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (8hrs)|
89342853|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (12hrs)|
89342854|NCT01199029|Active Comparator|(Part 1) 5 mg Prednisone|
89342855|NCT01199029|Experimental|(Part 2) X mg PF-04308515|
89342856|NCT01199029|Experimental|(Part 2) Y mg PF-04308515|
89342857|NCT01199029|Active Comparator|(Part 2) 5 mg Prednisone|
89342858|NCT01199029|Active Comparator|(Part 2) 20 mg Prednisone|
89342859|NCT01121003|Other|Low fructose diet/no exercise|
89342860|NCT01121003|Experimental|high fructose diet/no exercise|
89342861|NCT01121003|Experimental|high fructose diet+exercise|
89342862|NCT01200745|Active Comparator|capsaicin patch|
89342863|NCT01200745|Placebo Comparator|Hydrogel patch|
89342864|NCT01121081|Placebo Comparator|Placebo|sugar pills
89342865|NCT01121081|Experimental|Dunaliella|drug
89342866|NCT01585415|Experimental|Single Arm|Two weeks prior to the start of the preparative regimen, patients will begin taking vemurafenib. Patients will then receive lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine, followed by young TIL and high dose aldesleukin
89342867|NCT03841825|No Intervention|Control|No messages or oral hygiene instructions
89342868|NCT03841825|Experimental|Text message reminders|Standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays
89342869|NCT03841825|Active Comparator|In-person oral hygiene instructions|Oral hygiene instructions and motivation during visit
89342870|NCT03841825|Experimental|Text messages and in-person instructions|standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays and oral hygiene instructions and motivation during visit
89342871|NCT01212731||Cohort 1|Subjects with a histological diagnosis of malignancy of the base of skull necessitating irradiation to a minimum of 60 Gy, ECOG PS 0-1 with no evidence of metastatic disease and an estimate life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
89342872|NCT01212731||Cohort 2|Subjects with a histological diagnosis of low grade glioma requiring radiotherapy. ECOG PS 0-1 with no evidence of metastatic disease and an estimated life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
89342873|NCT01566643|Experimental|Hybrid-10|RA3-RACM7: rabeprazole + amoxicillin x 3 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days.
89342874|NCT01566643|Experimental|Hybrid-12|RA5-RACM7: rabeprazole + amoxicillin x 5 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
89342875|NCT01566643|Experimental|Hybrid-14|RA7-RACM7: rabeprazole + amoxicillin x 7 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
89342876|NCT01121159||Preoperatively preformed orbital plates|Reconstruction with MatrixMIDFACE Preformed Orbital Plate (Synthes) or Custom-made orbital implant
89342877|NCT01121159||Non-preformed orbital plates|Reconstruction with Orbital Floor Mesh Plate or SynPOR Titanium Reinforced Fan Sheet (both Synthes)
89342878|NCT01121237||CKD5, renal anaemia, haemodialysis|CKD5, renal anaemia, haemodialysis receiving recombinant human erythropoietin alfa (biosimilar)
89342879|NCT03445065|Experimental|Cohort 1, Enabled - Eversense XL CGM System|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c >8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
89342880|NCT03445065|Active Comparator|Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c >8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]), and the implanted Eversense XL CGM System remained in blinded mode.
89342881|NCT03445065|Experimental|Cohort 2, Enabled - Eversense XL CGM System|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending >1.5 hours per day with a sensor mean glucose of <70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
89342882|NCT03445065|Active Comparator|Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending >1.5 hours per day with a sensor mean glucose of <70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]), and the implanted Eversense XL CGM System remained in blinded mode.
89342883|NCT03841591|Active Comparator|Insulin Group|This includes women with GDM allocated to receive insulin treatment. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
89342884|NCT03841591|Active Comparator|Metformin Group|This includes women with GDM allocated to receive metformin treatment. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
89342885|NCT01216553|Active Comparator|hypertonic inhalation + O2|oxygen for 30 minuets after inhalation of 3% saline 4 times daily
89342886|NCT01216553|Active Comparator|Epinephrine & bromhexine nebulized + O2|oxygen for 30 minuets after inhalation of racemic epinephrine with bromhexine 4 times daily
89342887|NCT03939611|Experimental|Foot Reflexology Group|Foot reflexology was performed to the reflexology group infants. Foot reflexology application (FRA) involved relaxation for the first 3-5 minutes and the last 2 minutes; the remaining 12-15 minutes included stimulation of the brain and digestive system organs. To ensure relaxation, rotation was performed by using the thumbs of the hand under the feet, cephalocaudally. The session of FRA included stimulating the brain and medulla spinalis (2 min), the solar plexus (1min), the stomach (2min), the liver (2min), the pancreas (2min), the gallbladder (1min), and the ileocecal valve and intestine (5min) reflex points. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
89342888|NCT03939611|Placebo Comparator|Placebo Foot Reflexology Group|Placebo foot reflexology was performed to the placebo group infants. Placebo foot reflexology application (PFRA) was constrained to ineffective touch without any stimulation and pressure. The aim of the PFRA was to create only a touch effect. It was applied by patted the foot by using the thumbs of the hand, for 20 minutes with the same rotation and to the same points as FRA. Application was performed on all infants twice a week, for a total of four times during two consecutive weeks. Between two consecutive applications, a minimum of 48 hours and a maximum of 5 days was allotted (Stone, 2011). A total of 6 follow-ups were performed during the study period.
89342889|NCT01200901|Experimental|Melancolic depression patients|Patients with major depression will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing).
89342890|NCT01212809|Active Comparator|Juvéderm Ultra|Juvéderm Ultra injection
89342891|NCT01212809|Active Comparator|Cosmoderm 1|Cosmoderm 1 injection
89342892|NCT01214993|Experimental|Treatment A|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
88818403|NCT01819415|Experimental|Anti-VEGF plus AREDS-2|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).
89342893|NCT01214993|Experimental|Treatment B|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q12h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
89342894|NCT01214993|Placebo Comparator|Treatment C|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive placebo q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
89342895|NCT03843229|Experimental|treatment group|The treatment group receives Cinobufacini injection 20ml via hepatic artery during Transarterial Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
89342896|NCT03843229|Other|control group|The control group only receives Transarterial Chemoembolization (TACE).
89342897|NCT03717831||Healthy|Healthy subjects will be enrolled as age and activity matched controls for muscle power assessment at one time-point to establish normative values.
89342898|NCT03717831||ICU|Observational, subjects enrolled initially in the ICU and followed for six months after hospital discharge. ICU subdivided based on diagnosis
89342899|NCT01200979||pregnant flu vaccinated|pregnant women that choose to receive the seasonal flu vaccine
89342900|NCT01200979||pregnant non-flu vaccinated|pregnant women that do not receive the flu vaccine
89342901|NCT03939221|Experimental|intervention of infrared lamp and acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6(neiguan) and ST36(zusanli) for one minutes) for our patient for the cold limbs, pain control and constipation problems.
89342902|NCT03712995|Experimental|Cutler-Beard modified with graft|Reconstruction of Upper Eyelid With a Newly Modified Cutler-Beard Technique With Tarsoconjunctival Graf
89342903|NCT01121315||1|Diabetes type II patients, according to medical records, prescriptions or lab results, followed for >6 months after diagnosis.
89342904|NCT03841435|Experimental|Hypofractionated Radiotherapy|15 Gy given in 3 fractions over 2 weeks
89342905|NCT03935477||High risk surgery|those undergoing elective and emergency, high-risk surgery receiving arterial cannulation and urethral catheterisation as standard
89342906|NCT03935477||Critical Care|Emergency admissions to UCLH critical care unit receiving arterial cannulation and urethral catheterisation as standard
89342907|NCT01199107|Experimental|Prolonged Exposure + Exercise|
89342908|NCT01199107|Active Comparator|Prolonged Exposure + Wellness Intervention|
89342909|NCT03939299|Experimental|OCT group|Patients, whose coronary chronic total occlusion lesion was successfully implanted stent, received optical coherence tomography imaging immediately and at 9-12 months after index procedure.
89342910|NCT01199185|Active Comparator|Tobacco Quitline Group|
89342911|NCT01199185|Experimental|Tobacco Quitline plus Interactive Technology Group|
89342912|NCT01215071|Experimental|limited lymphadenectomy|Fields 5, 7, 9, 11, 13, 14 are removed
89342913|NCT01215071|Experimental|extended lymphadenectomy|Fields 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are removed
89342914|NCT04522531|Experimental|Exercise performed on stabil ground|Open cinetic chain shoulder exercise will performed on stabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
89342915|NCT01215149|Experimental|Group A|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3
89342916|NCT01215149|Experimental|Group B|Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3
89342917|NCT01215149|Experimental|Group C|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3
89342918|NCT01215149|Experimental|Group D|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3
89342919|NCT01215149|Experimental|Group E|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
89342920|NCT01215149|Experimental|Group F|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
89342921|NCT01215149|Experimental|Group G|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
89342922|NCT01215149|Experimental|Group H|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
89342923|NCT01215149|Experimental|Group I|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
89342924|NCT01215149|Experimental|Group J|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
89342925|NCT01215149|Experimental|Group K|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
89342926|NCT01215149|Experimental|Group L|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
89342927|NCT03843307|Experimental|Electrical stimulation|
89342928|NCT04961281|Active Comparator|Dexmeditomidine group|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
89342929|NCT04961281|Active Comparator|triamcinolone group|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
89342930|NCT01116869||MBC patients|300 MBC patients, each of whom will provide a series of at least 3 blood draws (baseline, 3-4 weeks and 6-8 weeks after the initiation of the systemic therapy) for CTC analysis, will be enrolled. All MBC patients will be followed for a maximum of 36 months for disease progression and survival.
89342931|NCT01116869||Benign disease volunteers|100 Benign disease volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
89342932|NCT01116869||Healthy volunteers|100 Healthy volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
89342933|NCT03935789|Experimental|BLAST|All participants in this study will be assigned to this group to participate in the BLAST intervention. The intervention will be a self-guided web-based platform using a self-management model to help support better engagement in everyday life activity
89342934|NCT03844477|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
89342935|NCT03844477|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
89342936|NCT03960697|Experimental|walk out from operating room|patients will return to the ward after surgery by walking
89342937|NCT03960697|No Intervention|leave operating room by transporting bed|patients will return to the ward after surgery by lying on the transporting bed
89342938|NCT02529449|Placebo Comparator|Placebo|once daily
89342939|NCT02529449|Experimental|ASP1941 Low dose group|once daily
89342940|NCT02529449|Experimental|ASP1941 Middle dose group|once daily
89342941|NCT02529449|Experimental|ASP1941 High dose group|once daily
89342942|NCT05667961||the function remitted off-medicine group|"Off-medicine definition: Continuous antipsychotic maintenance therapy for at least two years before drug discontinuation and drug discontinuation of all reasons (treatment benefits, adverse events, socioeconomic difficulties, migration, stigma, etc.) for at least one year;~Function remitted definition: Meet the criteria of functional remission in both WHOQoL-BREF (overall points ≥ 60) and FROGS (social functioning dimension points ≥ 33, daily life dimension points ≥ 12, and treatment dimension points ≥ 12)"
89342943|NCT05667961||the function not-remitted off-medicine group|"Off-medicine definition: Continuous antipsychotic maintenance therapy for at least two years before drug discontinuation and drug discontinuation of all reasons (treatment benefits, adverse events, socioeconomic difficulties, migration, stigma, etc.) for at least one year;~Function not-remitted definition: Fail to meet the criteria of functional remission in both WHOQoL-BREF and FROGS"
89342944|NCT05667961||the function remitted on-medicine group|"On-medicine definition: Continuous antipsychotic maintenance therapy during the time this study is conducted~Function remitted definition: Meet the criteria of functional remission in both WHOQoL-BREF and FROGS"
89342945|NCT05667961||the function not-remitted on-medicine group|"On-medicine definition: Continuous antipsychotic maintenance therapy during the time this study is conducted~Function not-remitted definition: Fail to meet the criteria of functional remission in both WHOQoL-BREF and FROGS"
89342946|NCT03939377|Experimental|Osteopathy|Management will be centered on the skull, the sacrum, the cranio-sacral axis, the entire visceral abdominal and thoracic system.
89342947|NCT03939377|Placebo Comparator|Simulate|The simulated treatment will be characterized by placing the practitioner's hands on the patient in the areas tested without any intention of treatment.
89342948|NCT01216709|Experimental|iron drops|
89342949|NCT01216709|Experimental|iron-fortified formula (2.3 mg iron/L)|
89342950|NCT01216709|Experimental|iron-fortified formula (12.4 mg iron /L)|
89342951|NCT03841045||ulcerative colitis patient|people that have UC diagnosis can participate in the study. the disease can be at any level and the patients can handle any medications.
89342952|NCT03841045||CD patient|people that have CD diagnosis can participate in the study. the disease can be at any label and the patients can handle any medications.
89342953|NCT03841045||Health people|control group. no IBD patients can be included. patients with other diseases can be included.
89342954|NCT01216787|Experimental|Treatment (gamma-secretase inhibitor RO4929097, surgery)|Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Within 35-56 days after completion of therapy, patients with stable or responsive disease undergo surgery. Patients may continue RO4929097 for 28 days after surgery in the absence of disease progression or unacceptable toxicity.
89342955|NCT05282251|Experimental|Pain managment after VATS|
89342956|NCT01215305||Visiting outpatient departments, if symtoms|patients with upper GI symptoms, visiting the outpatient departments of peripheral hospitals in Greece
89342957|NCT01202383|Active Comparator|NADCC tablets|
89342958|NCT01202383|Placebo Comparator|Placebo tablets|
89342959|NCT01116947|Active Comparator|Intervention Arm|1. Treatment Arm (CASES) will receive high protein meals during thrice weekly hemodialysis in-center (each meal includes ~50 g of protein, ~850 Cal, and phos/protein ratio <10 mg/g) PLUS dietary counseling to continue similar high protein intake with low phosphorus to protein ratio and to avoid foods with high preservative content. Fosrenol 1.0 to 1.5 g per meal will be prescribed (use of pill crusher will be recommended) and will be titrated based on bi-weekly phosphorus levels.
89342960|NCT01116947|Active Comparator|Control Arm (CONTROLS)|2. Control Arm (CONTROLS) will receive salad boxes in-center (no protein, low calorie) and routine dietary counseling and will continue pre-existing phosphorus binder regimen.
89342961|NCT01224106|Placebo Comparator|Placebo (Parts 1 and 2)|Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
89342962|NCT01224106|Experimental|Gantenerumab 105 mg (Parts 1 and 2)|Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
89342963|NCT01224106|Experimental|Gantenerumab 225 mg (Parts 1 and 2)|Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
89342964|NCT01224106|Placebo Comparator|Placebo (Parts 1 and 2) switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])|Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.
89342965|NCT01224106|Experimental|Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])|Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.
89342966|NCT01215383||psychiatric patients|20 in patients and outpatients with schizophrenia, schizoaffective and bipolar disorder based on psychiatrist diagnostic evaluation using DSM-IV criteria, before and at least two months after antipsychotic therapy will be enrolled.
89342967|NCT01215383||healthy volunteers|"Ten healthy volunteers will be checked as controls:~Employee from the hospital staff with no metabolic disease (Diabetes mellitus, hypertension or dyslipidemia) and non-smokers."
89342968|NCT05282563|Other|The safety of esophagojejunostomy in total gastrectomy for gastric cancer|The safety of esophagojejunostomy depends on the integrity of the anastomosis, sufficient blood supply and satisfactory tension. Early tight mucosal anastomosis and the proliferation of mucosal epithelial cells can reduce the stimulation of digestive fluid to the anastomotic wound.Professor Zhao Yuzhou surgical team proposed double and a half layered esophagojejunal anastomosis to improve the safety of anastomosis. This method is simple and has no special requirements for the selection of instruments and sutures. It can be carried out in all levels of hospitals. In order to verify the value of this method in gastrointestinal reconstruction of gastric cancer, Professor Zhao Yuzhou surgical team plans to carry out a multicenter, randomized controlled study throughout the province.
89342969|NCT01117025|Active Comparator|Circumferential PVI|
89342970|NCT01117025|Active Comparator|Circumferential PVI+renal denervation|
89342971|NCT03842761|Experimental|Dose group 1|Low Dose
89342972|NCT03842761|Experimental|Dose group 2|Medium Dose
89342973|NCT03842761|Experimental|Dose group 3|High Dose
89342974|NCT03842761|Experimental|Dose Group 4|Dose for healthy volunteers dependent on results from prior dose groups with patients
89342975|NCT03939455|Experimental|Experimental|Participants will complete a brief tablet-based intervention, which includes watching a 5 minute educational video on the importance of HIV testing, and respond via tablet computer to the offer of an HIV test.
89342976|NCT03939455|No Intervention|Treatment as usual|Participants will be offered an HIV test by hospital staff, and will respond face-to-face.
89342977|NCT01199341|Experimental|Treatment A|AZD1981, low dose, + Warfarin
89342978|NCT01199341|Experimental|Treatment B|AZD1981, high dose, + Warfarin
89342979|NCT01215539|Experimental|Panitumumab,capecitabine,oxaliplatin|"Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg.~Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 Capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14"
89342980|NCT01203709|Experimental|Combination treatment|treatment arm
89342981|NCT01201135||Sickle cell disease|
89342982|NCT01201135||hereditary spherocytosis.|
89342983|NCT01122407|Experimental|trimethaphan|Trimethaphan infusion doses of 4 mg/min
89342984|NCT01122407|Experimental|Trimethaphan plus L-NMMA|Trimethaphan infusion 4 mg/min L-NMMA (L-NG-monomethyl Arginine citrate) infusion 250 mpg/kg/min A small group of arm 1 will receive both drugs.
89342985|NCT03469180|Active Comparator|Control Group|Childrens in this group will receive treadmill training, three times a week for 8 weeks. Each season will be supervised and last 45 minutes.
89342986|NCT03469180|Experimental|Training Group|İn addition to treadmill training, childrens in this group (after a rest for 5 minutes) will also receive whole body vibration training for 15 minutes.
88814117|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Monthly|Intervention: Hand Hygiene Signs Changed Monthly Hand hygiene signs will be changed monthly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
89342987|NCT04411927||control group|this group included 25 typically developed children
89342988|NCT04411927||on-heamodialysis group|this group included children with CKD on-heamodialysis treatment
89342989|NCT04411927||non-dialysis group|this group included children with CKD who don't require dialysis
89342990|NCT01213121|Experimental|bipolar depression|unmedicated patients with bipolar depression receiving quetiapine treatment
89342991|NCT01213121|No Intervention|Control|healthy controls matched for age, gender, and body mass index
89342992|NCT05156086||Kidney transplant recipients with booster|Patients who received kidney-only transplant or multi-organ transplant including kidney and fully vaccinated with standard dose(s) of messenger RNA (mRNA) or vector vaccine
89342993|NCT01122485|Experimental|Low dose group|two tablets per dose (one tablet of investigational drug and one tablet of placebo)
89342994|NCT01122485|Experimental|High dose group|two tablets per dose (two tablets of investigational drug)
89342995|NCT01122485|Placebo Comparator|Control group|two tablets per dose (two tablets of placebo)
89342996|NCT03409107|Experimental|Daprodustat receivers|Participants will receive oral daprodustat once daily
89342997|NCT03409107|Placebo Comparator|Placebo receivers|Participants will receive oral placebo once daily
89342998|NCT01216865|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
89342999|NCT01216865|Active Comparator|Standard Therapy|Any therapy for diabetic foot which is routinely practiced and accepted in China
89343000|NCT01121471|Placebo Comparator|Safflower Oil|8.0 g/day safflower oil
89343001|NCT01121471|Experimental|CLA 6.4g/day|Conjugated linoleic acid at a dose of 6.4g/day in a supplement with a total of 8.0g oil
89343002|NCT03921073|Experimental|Intralesional injection of T-VEC|Participants will undergo intralesional injections of up to 4 cc of 10^6 plaque-forming units (PFU)/mL of T-VEC. Dose is dependent on the diameter of the lesions to be injected (volume injected is related to diameter of lesion(s) at time point 0). Three weeks later and every other week thereafter, the participants will be injected with up to 4 cc of 10^8 PFU/mL, with dose dependent on the diameter of the lesion(s) to be injected. Participants may be treated for up to 12 months.
89343003|NCT01215617|Experimental|Aerobic Interval Training|Patients randomized to training will meet for supervised aerobic interval training three times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
89343004|NCT01215617|Other|Control|Patients will receive standard medical treatment at the University Hospital lung department.
89343005|NCT02529371|Experimental|UriCap-RM|The device is comprised of a reusable part and a single use adhesive tape. The device is removed once daily and the reusable part is rinsed, dried and reapplied with a new adhesive tape.
89343006|NCT03920683||Diabete type 1 and 2|Data collection from patients treated in the diabetes department, in Pitié-Salpêtrière hospital, and adressed for a one-day hospitalization to assess cardiovascular comorbidities.
89343007|NCT03939143|Experimental|Test drug, Reference drug group|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
89343008|NCT03939143|Active Comparator|Reference drug,Test drug group|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
89343009|NCT03938753|Experimental|Phonak Audéo M90-T|The Phonak Audéo M90-T is a Receiver-in-the-canal Hearing aid with direct connectivity functionality and a T-Coil from Phonak which will be fitted to the participants individual Hearing loss.
89343010|NCT03860623||Overweight|Otherwise healthy overweight and obese men (BMI 30-40kg/m2) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
89343011|NCT03860623||Normal Weight|Healthy normal weight men (BMI 18-25kg/m2, but including those with BMI up to 28kg/m2 if waist circumference <96cm) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
89343012|NCT03840655||palmar hyperhidrosis|VATS R4 Sympathicotomy performed on all patients. Fluorescent thoracoscopy was used to identify the shifting mode of sympathetic ganglions.
89343013|NCT01219049|Experimental|Tyrosine 1000 mg / day|Patients receive 1000 mg tyrosine per day.
89343014|NCT01219049|Experimental|Tyrosine 2000 mg / day|Patients receive 2000 mg tyrosine per day.
89343015|NCT01219049|Placebo Comparator|Placebo|Patients receive placebo daily.
89343016|NCT03294304|Experimental|Nivolumab, Cisplatin, & Gemcitabine|
89343017|NCT03712761||Supplementation with Enriched Protein®|Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
89343018|NCT03712761||Low protein breakfast|No supplementation
89343019|NCT03712761||High protein breakfast|No supplementation
89343020|NCT01204021|Experimental|Tai Chi Chih|12 weeks of physical exercise in the form of Tai Chi Chih
89343021|NCT01204021|Active Comparator|Stress Education Control|Stress management education
89343022|NCT01201213|Active Comparator|Extradural bupivacaine|Local anesthetic
89343023|NCT01201213|Active Comparator|Extradural levobupivacaine|local anaesthetic
89343024|NCT01201213|Active Comparator|Extradural ropivacaine|local anaesthetic
89343025|NCT01201213|Active Comparator|Intrathecal bupivacaine|local anaesthetic
89343026|NCT01201213|Active Comparator|Intrathecal levobupivacaine|local anaesthetic
89343027|NCT01201213|Active Comparator|Intrathecal ropivacaine|local anesthetic
89343028|NCT03715257|Active Comparator|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
89343029|NCT03715257|Active Comparator|Tube changing catheter|"Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
89343030|NCT01124513|Active Comparator|Digital Camera|Digital camera images will be taken of a a 2cm^2 area of sun protected skin.
89343031|NCT01124513|Active Comparator|Spectrophotometer|The probe of the protable reflectance spectrophotometer is lightly applied to the sufance of the skin and a reading is taken.
89343032|NCT01124513|Active Comparator|Videodermoscopy|The instrument is put in contact with sun protected skin and an image is taken of a 2 cm^2 area.
89343033|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.4|Fraction of inspired normobaric oxygen of 0.4 (low oxygen group)
89343034|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.7|Fraction of inspired normobaric oxygen of 0.7 (high oxygen group)
89343035|NCT03195322|Experimental|Pre-pectoral Tissue Expander|Pre-pectoral immediate tissue expander breast reconstruction with complete AlloDerm® coverage to reinforce breast tissues.
89343036|NCT03712683|Experimental|Sub clinical hypothyroid women|"Levothyroxine sodium(Euthyrox 50µg and 25 µg MerckSerono) treatment was initiated and the women were followed in a combined clinic of endocrinologist and Gynecologist.~2.5 µg of Thyroxine daily was prescribed to women with TSH more than 2.5 mIU/L. Women with TSH more than 4mIU/L were given 50 µg daily . When pregnancy was confirmed Thyroxine was continued till 13 weeks gestation ."
89343037|NCT03933839|Experimental|PainCOACH|This group will take part in an 8-week pain coping skills training (PCST) intervention.
89343038|NCT03933839|No Intervention|Wait List Control|The other group will be the wait list group and will receive the pain CST program after completing all study measures.
89343039|NCT03839173|No Intervention|Retrospective Chart Review|Retrospective Chart Review for historical controls. Historic controls fed cow's milk fortifier
89343040|NCT03839173|Experimental|Prospective|"All neonates with birth weights ranging from 750-1500 grams and gestational ages 23-33 weeks admitted to the NICU at Augusta University within 24 hours of life will be eligible for screening within 72 hours of admission and upon parent's or legal guardian's consent.~Infants will be fed a human milk fortifier made with donor human milk. Data will be compared with historic control data."
89343041|NCT03472378|Experimental|Active Treatment Group|DFN-15
89343042|NCT03472378|Placebo Comparator|Placebo Group|
89531682|NCT05763420|Experimental|SBO with AH Plus Bioceramic Sealer|The teeth will be obturated using a single cone technique with AH Plus Bioceramic Sealer.
89343043|NCT01219127|Experimental|Derma-PACE|Pre-treatment evaluations include complete history and physical examination, chemistry and coagulation profiles, detailed past surgical and medical treatments. The local findings of the ulcer are quantitatively assessed using the S(AD) SAD classification (6) including photo-documentation for the size, shape and configuration of the ulcer
89343044|NCT03842605|Experimental|Strength training|
89343045|NCT03408873|Experimental|Patient Noncompliance|Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention
89343046|NCT01124591|Experimental|Treatment|Assessment and brief intervention
89343047|NCT01201369|Active Comparator|Cypher™ Stent|Participants in the Cypher arm will be randomised to receive a Cypher™ (Cordis, Miami Lake, USA) coronary stent
89343048|NCT01201369|Active Comparator|Xience™ Stent|Patients in the Xience™ arm will receive a Xience™ Stent(Abbott Vascular, Santa Clara, USA.
89343049|NCT03471052|Experimental|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)
89343050|NCT03471052|No Intervention|Sham procedure|Endoscopy will be performed under conscious sedation and all BarrX RFA equipment will be set up in room. A sound recording of the BarrxTM RFA device will be played (a distinct bell sound that is emitted from the generator) during the procedure.
89343051|NCT02937142|Experimental|Cognitive behavior group therapy|Cognitive behavior group therapy in weekly 1,5 hour sessions during 12 weeks, 8 participants and 2 therapists per group, in addition to education on ADHD, and ADHD medication if indicated.
89343052|NCT02937142|Other|Controls|Treatment as usual: Education on ADHD, and ADHD medication if indicated.
89343053|NCT03715101|Experimental|Rosuvastatin 20 mg PO|Rosuvastatin 20 mg daily for 21 days
89343054|NCT04457830|Experimental|Single arm|
89343055|NCT01202617||Schizophrenic outpatients between 18 & 70 years of age|
89343056|NCT03780959|Placebo Comparator|Etanercept/Placebo|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to receive placebo subcutaneous injection twice weekly for up to 4 months.
89343057|NCT03780959|Experimental|Etanercept/Etanercept|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to continue receiving etanercept twice weekly for up to 4 additional months.
89343058|NCT03838783|No Intervention|Usual CSII|Continue to use the established CSII insulin therapy
89343059|NCT03838783|Experimental|Untethered CSII|Basal dosing - total CSII basal dose will be delivered by 50% through continuing CSII therapy used prior to study enrollment and 50% through the addition of once daily insulin degludec injected in the morning; Bolus dosing - continue the established bolus insulin dose
89343060|NCT03935165|Experimental|Indocyanine Green arm|"All the patients to be enrolled have to meet the inclusion criteria. All enrolled patient is subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions are described.~Subsequently, 0.25 mg /(kg BW) Indocyanine Green is administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision is made, in order to identify the fluorescent lesions. All the lesions are described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged."
89343061|NCT03408639|Experimental|CinnaPoietin®|"The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.~In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients."
89343062|NCT03408639|Active Comparator|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
89343063|NCT03838237||Fabry Disease patients|Patients with genetic diagnosis of Fabry Disease, clinical indication to Migalastat and signs of cardiac involvement (early or advanced) will undergo cardiological evaluation before and 18 months after therapy with Migalastat (123 mg every other day)
89343064|NCT01217021|Experimental|Assess [18F] MNI-558 and PET imaging|
89343065|NCT01219205|Active Comparator|major branched retinal venous occlusion|
89343066|NCT01219205|Active Comparator|macular branched retinal venous occlusion|
89343067|NCT03810235|Active Comparator|Transdermal Lidocaine Patch|Drug: Including placebo The intervention is the post-operative application of a 5% lidocaine transdermal patch for women who have undergone Cesarean delivery.
89343068|NCT03810235|Placebo Comparator|Transdermal Hydrocolloid Placebo Patch|Drug: Including placebo The intervention is the post-operative application of a hydrocolloid transdermal patch for women who have undergone Cesarean delivery.
89343069|NCT01213277|Active Comparator|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
89343070|NCT01213277|Active Comparator|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
89343071|NCT03408483|Experimental|quadratus lumborum block (QLB)|"Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to anterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.~After QLB is placed, patients will have THA under spinal anesthesia."
89343072|NCT03408483|Active Comparator|Standard of Care|"Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected."
89343073|NCT04830423|Active Comparator|medikal ozone group|medical ozone group patients diagnosed with knee ostheoarthritis
89343074|NCT04830423|Other|steroid group|steroid group patients diagnosed with knee ostheoarthritis
89343075|NCT03717675|Experimental|Interventional|Interventional arm, where the NovaCross™ CTO micro-catheter will be placed in study subjects during the Total Occlusion opening procedure.
89343076|NCT03840889||Women with a severe late PPH|Women with a severe late PPH will be recruited prospectively after verification of the inclusion criteria by a gynecologist-obstetrician or the investigating midwives, who will provide the patients information about the study and include them unless they object
89343077|NCT03715023|Experimental|Active + SoC|Daily doses of PC786 for 3 days + SoC
89343078|NCT03715023|Placebo Comparator|Placebo + SoC|Daily doses of Placebo for 3 days + SoC
89343079|NCT03842527|Active Comparator|Standard Fasting Group|Ultrasound scan of gastric antrum 1 hour prior to procedure. Patients assigned to this group will follow standard fasting procedures of no eating or drinking 8 hours prior to C-section.
89343080|NCT03842527|Experimental|Carbohydrate Loading Group|"Ultrasound scan of gastric antrum 1 hour prior to procedure.~Patients assigned to this group must stop eating 8 hours prior to their scheduled C-section time.~The night before their C-section they must drink 800mL of 100% apple juice (not from concentrate) OR 800mL of cranberry juice cocktail, not both~The day of their C-section, starting 3 hours before surgery and to be finished 2 hours before surgery time, patients must drink 400mL of 100% apple juice OR 400mL of cranberry juice cocktail, not both~Please note:~The apple juice must be 100% juice, not from concentrate~The cranberry juice cocktail must not be plain cranberry juice"
89343081|NCT01311375|Experimental|w3 supplement + capsule CA-D|Mor DHA :w3 supp will be given to this group + capsule Ca(500 mg)-D(200 micro gram)
89343082|NCT01311375|Placebo Comparator|placebo+ CA-D|placebo in the same color,shape,size
89343083|NCT03777059|Placebo Comparator|Placebo|Placebo-matching atogepant tablets orally once daily for 12 weeks.
89343084|NCT03777059|Experimental|Atogepant 10 mg|Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
89343085|NCT03777059|Experimental|Atogepant 30 mg|Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
89343086|NCT03777059|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
89343087|NCT01201447||Questionable occlusal lesions|
89343088|NCT03638973|Experimental|Biopsy with Er: YAG|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser under previous local anesthesia
89343089|NCT03638973|Active Comparator|Biopsy with Scalpel|Biopsies taken with Er: YAG are compared with biopsies taken with a scalpel in patients with lichenoid or leukoplakic changes of the oral mucosa.
89343090|NCT01201525|Experimental|Surgical scar - part 1|Surgical scar - part 1
89343091|NCT01201525|Placebo Comparator|Surgical scar - part 2|Surgical scar - part 2
89343092|NCT03714945||Case Group with Allergic Rhinitis|"- Inclusion Criteria~Both genders of 11-14 years, diagnosed with allergic rhinitis on basis of screening instruments, medical history, clinical assessment (by general ORL examination including nasal endoscopy)~Chinese in ethnicity~Positive skin prick test with wheal diameter >= 3mm~Ability to understand the nature, scope, and possible consequences of the study~Capability and willingness to comply with the requirements of the protocol"
89343093|NCT03714945||Control Group without Allergic Rhinitis|"- Inclusion Criteria~Both genders of 11-14 years~Chinese in ethnicity~Subjects who have not been diagnosed with a long term medical or psychiatric problem~Subjects who are not currently undergoing any long term medical treatment."
89343094|NCT02913001|Experimental|Low Glycemic Load Diet|Participants received a diet education to follow a low glycemic load diet and received some low glycemic load staple foods.
89343095|NCT02913001|Active Comparator|Usual Eating Plan|Participants received a diet education to continue with their usual diet.
89343096|NCT03842449|Experimental|Smoking pregnant woman withCO measurement|
89343097|NCT03842449|Other|Smoking pregnant woman without CO measurement|
89343098|NCT03842449|Other|Non Smoking pregnant woman|
89343099|NCT03714867|Experimental|Treatment|Treatment arm intervention consists of patients who will be administered a single enteral dose of concealed over-encapsulated Pregabalin 150mg in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
89343100|NCT03714867|Placebo Comparator|Control|Treatment arm consists of patients who will be administered a single enteral dose of concealed over-encapsulated placebo capsules in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
89343101|NCT01204177|Experimental|Arm 1|
89343102|NCT01219283||Control (no PGD)|Receive their planned IVF treatment without PGD. 2 morphologically best embryos are transferred.
89343103|NCT01219283||Case (PGD)|Receive PGD in addition to their planned IVF Cycle. 2 morphologically best PGD normal embryos are transferred.
89343104|NCT01217099|No Intervention|methylprednisolone|methylprednisolone pulse azithromycin
89343105|NCT01217099|No Intervention|azithromycin|azithromycin
89343106|NCT04305457|Experimental|Nitric Oxide inhalation|Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system.
89343107|NCT04305457|No Intervention|Control|Patients assigned to the control group will not receive any gas therapy.
89343108|NCT04305457|Experimental|Nitric Oxide Inhalation (Non-Randomized)|All subjects part of this arm will receive nitric oxide gas either as an inpatient or outpatient. Nitric Oxide will be delivered through a non invasive CPAP system (with minimal pressure support to decrease discomfort due to the facial mask) or through a non-rebreathing mask system. Patients in this arm will not be randomized, so that all patients receive the study medication.
89343109|NCT02881099||Recent diagnosis (P3)|Primary cohort; participants recruited if diagnosed within the last three years
89343110|NCT02881099||Early diagnosis (P50)|Participants recruited if diagnosed before the age of 50 years old
89343111|NCT02881099||Relatives (R)|Siblings of existing participants
89531683|NCT05763420|Active Comparator|WVC with resin-based AH Plus Sealer|The teeth will be obturated using warm vertical compaction with resin-based AH Plus Sealer.
89343112|NCT01217177|Experimental|2.5 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (2.5mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
89343113|NCT01217177|Experimental|5.0 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (5.0mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
89343114|NCT01217177|Experimental|10 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (10mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
89343115|NCT03933527|No Intervention|control group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).
89343116|NCT03933527|Experimental|coffee group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make coffee rinses for 30 seconds, four times daily.
89343117|NCT03933527|Experimental|tea group|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval).During the tooth bleaching procedure and 3 weeks after the procedure,the participants will be instructed to make tea rinses for 30 seconds, four times daily.
89343118|NCT01117415||Gall Bladder Surgery|Who have symptomatic cholelithiasis and wish to undergo laparoscopic cholecystectomy for treatment.
89343119|NCT01204333|Experimental|Endovascular thrombolysis|
89343120|NCT01204333|Active Comparator|Standard treatment|
89343121|NCT02529059|Experimental|Switch from Atripla to Eviplera|
89343122|NCT01217255||Brazilian Subject's|Subject's will be recruited from the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paolo (HCFMUSP); Universidade Estadual de Campinas (UNICAMP); Universidade Federal de São Paulo (UNIFESP)
89343123|NCT01217255||Canadian Subject's|Recruited from The Hospital for Sick Children
89343124|NCT03932669|Experimental|Nilotinib group|Patients with SCA and taking nilotinib treatment
89343125|NCT01217333|Active Comparator|In-person|Participants in this arm have been randomized to receive Consultation Planning in-person
89343126|NCT01217333|Active Comparator|Telephone|Participants in this arm have been randomized to receive Consultation Planning by telephone.
89343127|NCT01567189|Experimental|Hospital cardiac rehabilitation|The patients will perform physical training sessions in the hospital
89343128|NCT01567189|Active Comparator|Home cardiac rehabilitation|The patients will perform physical training sessions at home
89343129|NCT03100058|Experimental|LIK066 2.5mg qd (Epoch 3)|LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks.
89343130|NCT03100058|Placebo Comparator|Placebo (Epoch 3)|Matching placebo tablets for 24 weeks
89343131|NCT03100058|Experimental|LIK066 10mg qd (Epoch 3)|LIK066 10mg qd (once daily) dosing frequency for 24 weeks
89343132|NCT03100058|Experimental|LIK066 50mg qd (Epoch 3)|LIK066 50mg qd (once daily) dosing frequency for 24 weeks
89343133|NCT03100058|Experimental|LIK066 150mg qd (Epoch 3)|LIK066 150mg qd (once daily) dosing frequency for 24 weeks
89343134|NCT03100058|Experimental|LIK066 2.5mg bid (Epoch 3)|LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks
89343135|NCT03100058|Experimental|LIK066 5mg bid (Epoch 3)|LIK066 5mg bid (once daily) dosing frequency for 24 weeks
89343136|NCT03100058|Experimental|LIK066 25mg bid (Epoch 3)|LIK066 25mg bid (once daily) dosing frequency for 24 weeks
89343137|NCT03100058|Experimental|LIK066 50mg bid (Epoch 3)|LIK066 50mg bid dosing frequency for 24 weeks
89343138|NCT03100058|Experimental|LIK066 qd/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
89343139|NCT03100058|Experimental|LIK066 bid/LIK066 35mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
89343140|NCT03100058|Experimental|Placebo/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
89343141|NCT03100058|Placebo Comparator|Placebo/Placebo (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
89343142|NCT01201603|Experimental|Orange Juice|Orange Juice reconstituted from frozen concerntrate
89343143|NCT01201603|Placebo Comparator|Orange drink|Sugars matched orange drink
89343144|NCT03933683||Pathologic Group|Patients affected by Fecal Incontinence
89343145|NCT03933683||Control Group|Healty volunteers cohort
89343146|NCT03933761|Experimental|Pamiparib (BGB-290)|Drug: Pamiparib Oral capsules 60mg twice daily continuously Although treatment is continuous, a cycle is defined as 4 weeks or 28 days.
89343147|NCT01202929||Type I achalasia|classic achalasia: complete esophageal motor failure
89343148|NCT01202929||Type II achalasia|compression achalasia: simultaneous panesophageal pressurization with aperistalsis
89343149|NCT01202929||Type III achalasia|spastic achalasia with aperistalsis: 100% spasm
89343150|NCT01124747|Experimental|ASP1585 and 14C-Labeled ASP1585|
89343151|NCT02866279|Experimental|Postplacental|contraceptive implant placed within 30 minutes of placental delivery
89343152|NCT02866279|Experimental|Immediate Postpartum|Contraceptive Implant placed 1-3 days postpartum
89343153|NCT02866279|Active Comparator|Delayed|Contraceptive Implant placed 6 or more weeks postpartum
89343154|NCT01222169|Experimental|larynx assessment under stimulation|
89343155|NCT01222169|Placebo Comparator|Larynx assessment under stimulation|
89531684|NCT05753995|Other|single arm|for diagnostic
89343156|NCT02871778|Experimental|Part A: VX-371 in Hypertonic Saline (HS), Then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS twice daily through oral nebulized inhalation from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
89343157|NCT02871778|Experimental|Part A: HS, Then VX-371 in HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
89343158|NCT02871778|Experimental|Part A: VX-371, Then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
89343159|NCT02871778|Experimental|Part A: Placebo, Then VX-371|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
89343160|NCT02871778|Experimental|Part B: VX-371 in HS + Ivacaftor|Participants who were on 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
89343161|NCT02871778|Experimental|Part B: HS + Ivacaftor|Participants who were on 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
89343162|NCT02871778|Experimental|Part B: VX-371 + Ivacaftor|Participants who were on 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
89343163|NCT02871778|Placebo Comparator|Part B: Placebo + Ivacaftor|Participants who were on 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
89343164|NCT01217489||Attendees to symptomatic breast clinic|
89343165|NCT01203007|Experimental|Tailored diet|Tailored diet according to demonstrated food sensitivity
89343166|NCT01203007|Experimental|Low-antigen content (LAC) diet|Low-antigen content diet
89343167|NCT01222325|Active Comparator|swl 3000 impulses- 60 imp/min|patients in this group were submitted to extracorporeal shockwave lithotripsy (SWL) 3000 impulses at 60 impulses per minute under general anesthesia. Unique session
89343168|NCT01222325|Active Comparator|swl- 4000 impulses - 90 impulses /min|patients in this group were submitted extracorporeal shockwave lithotripsy (swl) to 4000 impulses at 90 impulses per minute under general anesthesia- unique session
89343169|NCT04226911|Experimental|Sweeteners and sweetness enhancers (S&SEs)|Healthy diet < 10 energy % (E%) sugar, foods and drinks with S&SEs allowed.
89343170|NCT04226911|Active Comparator|Sugar group|Healthy diet, < 10 E% sugar, foods and drinks with S&SEs not allowed.
89343171|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery - s.l.|
89343172|NCT01217567|Experimental|Woman with previous ceasarean section - staples left|
89343173|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery|
89343174|NCT01217567|Experimental|Woman with previous ceasarean section|
89343175|NCT02860975|Experimental|Inhaled Nitrogen|A humidified mixture of gas will be delivered by mask, nasal cannulae, and small room-sized tent. Inspiratory oxygen fraction (FiO2) will be gradually decreased to 11% over a period or five days to obtain a peripheral capillary O2 saturation (SpO2) between 80%-85% (corresponding to 40-55 mmHg of arterial partial oxygen pressure (PaO2)). Healthy volunteers will be monitored and blood and urine will be obtained at 24h and 48 hours after returning to normoxia.
89343176|NCT02855242|Other|Intervention Program Group|Lifestyle Counseling
89343177|NCT02855242|Active Comparator|Controls Group|No lifestyle counseling
89343178|NCT01124825|Active Comparator|IGel|Subjects will receive an IGel(TM) airway induction and maintenance of positive pressure ventilation
89343179|NCT01124825|Active Comparator|King Airway|Subject will receive a KING-LTS-D(TM) for induction and maintenance of positive pressure ventilation
89343180|NCT03130972||developmental delay|Children who visited tertiary rehabilitation clinic for delayed motor development were all included.
89343181|NCT01124903|Experimental|Dehydration|Multiple measures of hydration status were made when subjects were normally hydrated (euhydrated) and when dehydrated. The diagnostic usefulness of the measures was determined.
89343182|NCT02735473|Experimental|Choline bitartrate|Powdered drink mix containing choline bitartrate 19 mg. per kg.
89343183|NCT02735473|Placebo Comparator|Placebo|Powdered drink mix containing matching placebo
89343184|NCT01124981|Placebo Comparator|Albumin|
88814118|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Weekly|Intervention: Hand Hygiene Signs Changed Weekly Hand hygiene signs will be changed weekly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
89343185|NCT01124981|Experimental|Haemocomplettan® P|
89343186|NCT01201681||Post-operativeTooth Pain|
89343187|NCT03931733|Active Comparator|Music Therapy Intervention|Receiving one thirty minute music therapy intervention.
89343188|NCT03931733|No Intervention|Usual Care|Receiving usual care for a patient in the ICU during a 30 minute intervention.
89343189|NCT04457986|Experimental|Erector spina plane block (ESP)|Patients will receive Erector spina plane block (ESP) with bupivacaine for postoperative analgesia
89343190|NCT04457986|Experimental|Modified thoracolumbar interfacial plane block (MTI)|Patients will receive Modified thoracolumbar interfacial plane block (MTI) with bupivacaine for postoperative analgesia
89343191|NCT04457986|Active Comparator|Intravenous patient controlled analgesia (IV-PCA)|Patients will receive Intravenous patient controlled analgesia (IV-PCA) with tramadol for postoperative analgesia
89343192|NCT01219517|Experimental|Study Group|All patients in the study receive the same treatment. All will have 2 polar body biopsies and all embryos biopsied prior to transfer.
89343193|NCT01222481||Newly-diagnosed Head and Neck Cancer|
89343194|NCT03740633|Experimental|Study group|Patients in the study group accept functional training and regular care.
89343195|NCT03740633|Active Comparator|Control group|Patients in the control group only accept regular care.
89343196|NCT01566877|Active Comparator|AVI-7288|AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges (PMOplus™) that targets Marburg virus nucleoprotein (NP). AVI-7288 is supplied in 5 mL vials containing 5 mL AVI-7288 at a concentration of 50 mg/mL. The dose levels of AVI-7288 will vary in four cohort's.
89343197|NCT01566877|Placebo Comparator|Placebo|Placebo control consists of approximately 150 mL normal saline solution administered by IV infusion over 30 minutes once a day for 14 days.
89343198|NCT01125059|Active Comparator|Methadone Group|0.2 mg/kg IV methadone
89343199|NCT01125059|Placebo Comparator|Placebo Group|5 mL saline bolus
89343200|NCT01566955|Experimental|transgastric adnexectomy|patients are operated transgastric
89343201|NCT01125137|Experimental|Biopsy|
89343202|NCT01471444|Experimental|Flu + Bu|Fludarabine 40 mg/m2 intravenous (IV) over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours. Both delivered for 4 consecutive days (days -6 to -3). Stem cell transplant Day 0.
89343203|NCT01471444|Experimental|Flu +Clo + Bu|Fludarabine 10 mg/m2 over 1 hour. Clofarabine 40 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, infused over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours, immediately after Clofarabine. All delivered on 4 consecutive days (days -6 through -3). Stem cell transplant Day 0.
89343204|NCT05282407|Experimental|Experimental group|Tenolid Tab
89343205|NCT05282407|Active Comparator|Control group|Viread Tab
89343206|NCT01222559|Experimental|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
89343207|NCT01222559|Active Comparator|Micofracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
89343208|NCT01125215|Placebo Comparator|Placebo|Matched gel base of capsaicin nanoparticle
89343209|NCT01125215|Experimental|Capsaicin|0.075% capsaicin nanoparticle gel
89343210|NCT01141816|Experimental|Contrast-Enhanced Ultrasound|
89343211|NCT04943614|Experimental|BIODEX training group|These individuals will receive conventional along with postural stability training with biodex balance system which stimulates specific movement patterns or strategies by placing markers on a specific location on-screen grid subject attempted to touch targets nine times using an onscreen cursor manoeuvred by the subject leg on the device platform
89343212|NCT04943614|Active Comparator|Conventional therapy group|These individuals will perform balance exercises including proprioception exercises, balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program (advices).
89343213|NCT02644135|Experimental|Halo Oral Spray|Based upon the preliminary studies that assessed the duration of the antimicrobial effects of Halo as reported in the preliminary studies and feasibility, subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
89343214|NCT02644135|Placebo Comparator|Halo Placebo|The placebo will consist of purified sterile water without CPC - the active antiseptic. Subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
89343215|NCT01217723|Experimental|Thymoglobulin|Thymoglobulin will be administered on Days -2, -1 prior to the transplant and on the day of transplant.
89343216|NCT01217723|Other|No Thymoglobulin|Patients will receive a standard preparative regimen. (i.e. one that does not normally contain Thymoglobulin.)
89343217|NCT05162872|Experimental|PD-(L)1 naive patients, ≥1L of platinum-based chemotherapy|"Histologically confirmed recurrent or metastatic nasopharyngeal carcinoma (including recurrence and metastasis after radiotherapy, or a condition not suitable for surgery and radiotherapy judged by investigator)~≥ 1L of platinum-based chemotherapy at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, PD-(L)1 naive patients, Niraparib 200 mg QD D1-21,Sintilimab 200 mg IV q3W, first step enroll N1=23 participants, if CR+PR≥3,then go to the second step, continue to enroll N2=39 participants, if CR+PR<3，then do not go to the second step."
89343218|NCT05162872|Experimental|PD-(L)1 previously treated patients，≥1L of platinum-based chemotherapy|"Histologically confirmed recurrent or metastatic nasopharyngeal carcinoma (including recurrence and metastasis after radiotherapy, or a condition not suitable for surgery and radiotherapy judged by investigator)~≥ 1L of platinum-based chemotherapy at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, PD-(L)1 previously treated patients, Niraparib 200 mg QD D1-21,Sintilimab 200 mg IV q3W, first step enroll N1=20 participants, if CR+PR≥1,then go to the second step, continue to enroll N2=17 participants, if CR+PR<1，then do not go to the second step."
89343219|NCT01222637|Experimental|CetuGEX™, weekly|application weekly
89343220|NCT01222637|Experimental|CetuGEX™ 2-weekly|application biweekly
89343221|NCT03842215||silver hair people|Exam subject's physical function by a smart physical exam
89343222|NCT05156554|Experimental|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day+1 after transplantation.
89343223|NCT05156554|Active Comparator|rhG-CSF|Patients in rhG-CSF group received rhG-CSF day+1 after transplantation.
89343224|NCT03931967||MR-proADM|
89343225|NCT01567111|Experimental|Subjects with PA|All study subjects have biochemically confirmed PA and undergo adrenal CT, AVS and MTO-PET to diagnose lateralization of aldosterone production.
89343226|NCT03443427|Experimental|Schedule 0-2-6 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).
89343227|NCT03443427|Experimental|Schedule 0-2-12 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).
89343228|NCT04744636|Other|Healthy volunteers aged of 18-30 years|
89343229|NCT04744636|Other|Healthy volunteers aged of 50-59 years|
89343230|NCT04744636|Other|Healthy volunteers aged of 60-70 years|
89343231|NCT04744636|Other|Type 2 diabetic patients aged of 50-70 years|
89343232|NCT03955211|Experimental|Treatment Group 1|A single dose of HTX-011 administered via instillation into the surgical site.
89343233|NCT03955211|Experimental|Treatment Group 2|A single dose of HTX-011 administered via instillation into the surgical site and a scheduled non-opioid multimodal analgesic (MMA) regimen.
89343234|NCT02632669|Experimental|Hemigland focal LDR brachytherapy|Hemigland focal LDR brachytherapy using permanent iodine 125 seed implantation
89343235|NCT03472222|Experimental|Arsha Vidya Program|Arsha Vidya outreach community program was conducted with children. An unique well-planned teaching program developed to educate Indian cultural values & heritage to young children and adults with yoga, chants, religious and spiritual practices through stories, group activities and plays.
89343236|NCT03933605|Active Comparator|midazolam and palonosetron|0.05 mg/kg of midazolam i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
89343237|NCT03933605|Active Comparator|palonosetron|the same volume (0.05 mg/kg) of normal saline i.v. with 0.075 mg of palonosetron i.v. was administered after anesthetic induction
89343238|NCT03931811|Experimental|Short wave diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.~SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device). Both groups took injections in the beginning of the therapy, 3rd week and 6th week, a total of 3 times. SWD or sham SWD therapy was given right after the injections, also for a total of 3 times."
89343239|NCT03931811|Sham Comparator|Sham diathermy group|"Patients were randomized into 2 groups depending on their patient number, with odd numbers being recruited to SWD group, and even numbers to sham SWD group.~Prolotherapy solutions were injected using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular.~Sham SWD group took 20 minutes of SWD therapy with device not working(Enraf-Nonius, Curapuls 970 Short wave diathermy device)."
89343240|NCT03714789||Meropenem|Patients requiring dialysis and receiving meropenem for infection or suspended infection.
89343241|NCT03714789||Vancomycin|Patients requiring dialysis and receiving vancomycin for infection or suspended infection.
88811802|NCT01502813|Experimental|Citicoline, Creatine, and Omega-3 Arm|Each participant will be given a supplement log at the end of visit 1. They will be asked to complete the log during the 28 days to indicate that the daily dose of supplements were taken according to instructions. The study coordinator will check the log on the second and third visits as well as count the remaining supplement pills. If participants do not comply with the daily supplement schedule, then the PI will determine if the participant should be withdrawn from the study.
89343242|NCT03714789||Ceftriaxone|Patients requiring dialysis and receiving ceftriaxone for infection or suspended infection.
89343243|NCT01217645|Experimental|150 mg [14C] AZD6765|
89343244|NCT01127477|Experimental|1|
89343245|NCT00701974|Experimental|1|patients treated with collagenase (IRUXOL)
89343246|NCT00701974|Experimental|2|patients treated with collagenase (Kollagenase)
89343247|NCT03717363|Active Comparator|Control group|Educational talk: an educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
89343248|NCT03717363|Experimental|Interventional group|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
89343249|NCT05162716||LBBAP|Patients with permanent atrial arrhythmia with an indication of cardiac pacing and atrioventricular junction ablation will undergo the implantation of a single-chamber pacemaker with left bundle branch area pacing, and then atrioventricular junction ablation.
89343250|NCT03935243|Experimental|equine assisted therapy|In the active intervention phase, patients participate twice a week in a equine assisted group therapy, while during the control phase they participate twice a week in a group that includes a non-specific and general activity program. After 15 therapy units in a study phase, the subjects will complete the 15 units of the other study phase (within-subject-design). All participants complete both study phases, with the order being randomized.
89343251|NCT03935243|Active Comparator|activating control phase|"In the present study, the interventions in the control phase are based on the sub-program Social Skills of the Integrated Psychological Treatment Program (IPT) for schizophrenic patients (Brenner et al., 1994, Roder et al., 1988, 2002)."
89343252|NCT03837223||"patients underwent rescue protocols and fresh embryotransfer"|they were patients with good prognosis with a mean age of 34.13 ± 4.42 years, with a good ovarian reserve
89343253|NCT05624541||preterm Infant|30 premature infants with a gestational age of 37 weeks and below and a history of stay in the neonatal intensive care unit will be evaluated.
89343254|NCT03535831|Experimental|18F-DCFPyL PET/ MR or PET/CT imaging|"Will use a newer technology called PET-MR that combines a Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. This new combined imaging test, where PET and MRI data is gathered at one time, will be performed on an integrated PET-MR scanner located at Toronto General Hospital.~Or technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.~Choice of imaging method (PET/CT or PET/MR) will be made by one of the study PIs, based on clinical judgement taking into account the specific exam indication, prior recent imaging, and suitability for MR imaging."
89343255|NCT04456738|Experimental|Parent Training|16 weeks of parent training in a group context with 5 to 10 relative and non-relative foster caregivers
89343256|NCT04456738|No Intervention|Services as Usual|Foster care services as usual
89343257|NCT01311141|Experimental|Doripenem i.v.|no comparator, PK study
89343258|NCT01204489|Experimental|Intensified dietary counseling|The dietary intervention consists of tailored dietary counseling, information leaflets and self-evaluation cards given to the families.
89343259|NCT01204489|Active Comparator|Normal dietary counseling|Public health nurses continue their usual dietary counseling.
89343260|NCT01122641|Placebo Comparator|Placebo|
89343261|NCT01122641|Experimental|Vildagliptin|Vildagliptin 50mg bid
89343262|NCT03417219|Experimental|Mobile Media Education and Skill-Building Rehabilitation Int|The investigators' ESBR-m intervention consists of four, 90-minute group (= 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
89343263|NCT03417219|Active Comparator|Usual Care|"Usual Care (plus supplemental educational materials). Participants randomized to the Usual Care (UC) group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
89343264|NCT03520855|Experimental|ETP + Serious game|patients receiving the serious game additionally to the classic therapeutic education
89343265|NCT03520855|Active Comparator|ETP|patients under classic therapeutic education
89343266|NCT01219595|Active Comparator|Part 1|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
89343267|NCT01219595|Other|No treatment|20 non-UTI susceptible women will be enrolled to collect data on the types of E. coli flora present in non-UTI women.
89343268|NCT01219595|Active Comparator|Part 2A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
89343269|NCT01219595|Placebo Comparator|Part 2B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
89343270|NCT01219595|Active Comparator|Part 3A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
89343271|NCT01219595|Placebo Comparator|Part 3B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
89343272|NCT05162248||Microsatellite instability|Immunohistochemical analysis was performed for Microsatellite Instability (MSI) status of colorectal tumors tissue.
89343273|NCT01125449|Other|Intravenous IVC Intervention|Intravenous ascorbic acid, 1.5g/kg at an infusion rate not to exceed 250mg/min.
89343274|NCT04741126|Experimental|Intervention Protocol|Hospital-based manually assisted cough technique for 4 weeks.
89343275|NCT03714477|Active Comparator|Treatment Arm|immediate extracorporeal shock wave lithotripsy - subject will have SWL arranged in the next available list
89343276|NCT03714477|No Intervention|Control Arm|delayed extracorporeal shock wave lithotripsy - subject will have SWL done 6 months later
89343277|NCT01206049|Experimental|Combination chemotherapy + panitumumab|
89343278|NCT01206049|Experimental|Combination chemotherapy + bevacizumab|
89343279|NCT05162092|Experimental|Group A|training duration for each session is 30 mints with 5 mints rest and it includes passive soft tissue elogation of tight muscles,lower limb resistance exercises,movement transition,balance board standing ,walking and stair climbing
89343280|NCT05162092|Experimental|Group B|It included passive soft tissue elongation of tight muscles,lower limb resistance exercises,movement transition,balance board standing ,walking and stair climbing and Vestibular Stimulation exercises such as Swinging in standing in all directions, trampoline jumps, rocking movement in rocking chair, gaze stabilization exercises and visual pursuit exercises under supervision.
89343281|NCT03931889|Active Comparator|Vitamin D3|Cholecalciferol 80,000 IU (2 capsules of 40,000 IU) per oral per week for consecutive 26 weeks.
89343282|NCT03931889|Placebo Comparator|Vitamin D3 placebo|Placebo (2 capsules) per oral per week for consecutive 26 weeks.
89343283|NCT05417672||Lung cancer scheduled lobectomy|
89343284|NCT03931421|Experimental|experiment group|In this arm, patients are treated with B Cell Maturation Antigen (BMCA)-targeted CAR-T cells and the safety and efficacy will be observed.
89343285|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group must be lying down facing up 2 hours postoperatively
89343286|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperatively
89343287|NCT04739020|Active Comparator|PCR SARS-CoV-2 Negative Adults|Healthy adults with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of parents of participating children and other healthy volunteers.
89343288|NCT04739020|Active Comparator|PCR SARS-CoV-2 Positive Adults|Adults with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic parents that are in the hospital with their children and symptomatic adults that are admitted to the infectious disease ward.
89343289|NCT04739020|Active Comparator|PCR SARS-CoV-2 Negative Children|Children with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of children admitted to the Children's Hospital or presenting for planned diagnostic testing or follow up.
89343290|NCT04739020|Active Comparator|PCR SARS-CoV-2 Positive Children|Children with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic children that are admitted to the Children's Hospital for reasons other than COVID-19 and symptomatic children.
89343291|NCT02953821|Experimental|Acthar Gel|Participants receive Acthar Gel every other day for 4 weeks, and then twice per week for 20 weeks
89343292|NCT02953821|Placebo Comparator|Placebo Gel|Participants receive Placebo Gel every other day for 4 weeks, and then twice per week for 20 weeks
89343293|NCT01206205|Experimental|Lenalidomide, Bortezomib|"3 induction cycles of bortezomib, lenalidomide and dexamethasone (VRD) followed by high dose melphalan and autologous stem cell transplantation.~Two months after haematological recovery, patients will receive 2 consolidation cycles of VRD and maintenance therapy for 1 year with lenalidomide."
89343294|NCT05155930|Experimental|IFS|Internal Family Systems (IFS)
89343295|NCT03783923|Experimental|Deflazacort|Participants will receive deflazacort 0.6 milligrams per kilograms per day (mg/kg/day) orally. The dose could be reduced in case of tolerability issues. Any participant assigned to placebo prior to the Version 4.0 amendment (prior to or after 01 February 2020) will have the option to be consented under Version 4.0 and will be switched to deflazacort for 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (prior to 01 February 2020) will have the option to re-consent under Protocol Version 4.0 and continue for an additional 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (after 01 February 2020) will have the option to re-consent under Protocol Version 4.0 at their Week 13 Visit and continue treatment until Week 26. Any new participant enrolled until 31 May 2020 will receive deflazacort for 26 weeks.
89343296|NCT03470974|Experimental|Intervention Group|The intervention group receives self-titration strategy training and lifestyle education.
89343297|NCT03470974|No Intervention|Control Group|The control group receives usual care and lifestyle education.
89343298|NCT01298245||Case: diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those with known positive results of diabetic retinopathy
89343299|NCT01298245||Control: no diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those without known positive results of diabetic retinopathy
89343300|NCT05588271||Group with PIs|stage 1pressure injury: non-blanchable erythema of intact skin; stage 2 pressure injury: partial-thickness skin loss with exposed dermis; stage 3 pressure injury: full-thickness skin loss; stage 4 pressure injury: full-thickness skin and tissue loss; unstageable pressure injury: obscured full-thickness skin and tissue loss; deep tissue pressure injury: persistent non-blanchable deep red, maroon or purple discoloration
89343301|NCT05588271||Group without PIs|Skin in good condition
89343302|NCT03472144|Experimental|CRSwNP - Subgrp 1(Momentasone - Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
89343303|NCT03472144|Experimental|CRSwNP-Subgrp 2(Levofloxacin - Right)|Patients undergoing balloon sinuplasty with receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
89343304|NCT03472144|Experimental|CRSwNP-Subgrp 3(Steroid/Antibotic Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
89343305|NCT03472144|Experimental|CRSsNP - Subgrp 1 (Momentasone Right)|Patients undergoing ballon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
89343306|NCT03472144|Experimental|CRSsNP - Subgrp 2 (Levofloxacin Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
89343307|NCT03472144|Experimental|CRSsNP-Subgrp 3(Steroid/Antibiotic Right|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
89343308|NCT03472144|Active Comparator|CRSwNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on left side and placebo on right side
89343309|NCT03472144|Active Comparator|CRSwNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
89343310|NCT03472144|Active Comparator|CRSwNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
89343311|NCT03472144|Active Comparator|CRSsNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only left side and placebo on right side
89343312|NCT03472144|Active Comparator|CRSsNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
89343313|NCT03472144|Active Comparator|CRSsNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
89343314|NCT03840499||Willing to participate in clinical study|
89343315|NCT03840499||Not-willing to participate in clinical study|
89343316|NCT03417141|Experimental|Valchor treatment of Lichen Planopilaris|Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
89343317|NCT03840265|Other|Carotid endarterectomy|All patients in this study will undergo carotid endarterectomy procedure
89343318|NCT01222949|Experimental|Asian Healthy Volunteers|Asian males with a body weight ≤ 65 kg (12 subjects) Asian females with a body weight ≤ 65 kg (12 subjects)
89343319|NCT01222949|Experimental|Caucasian Healthy Volunteers|Caucasian males with a body weight ≤ 65 kg (12 subjects) Caucasian females with a body weight ≤ 65 kg (12 subjects) Caucasian males with a body weight > 65 kg (24 subjects)
89343320|NCT04536688|Experimental|RGLS4326 1 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 1 mg/kg of RGLS4326 every other week for 4 doses
89343321|NCT04536688|Experimental|RGLS4326 0.3 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.3 mg/kg of RGLS4326 every other week for 4 doses
89343322|NCT04536688|Experimental|RGLS4326 0.1 or 0.5 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.1 or 0.5 mg/kg of RGLS4326 every other week for 4 doses
89343323|NCT01219751|Experimental|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
89343324|NCT01203163||PDT with porfimer sodium|
89343325|NCT03714321|Experimental|Mechanical insufflation-exsufflation arm|MIE will be given as prescribed by physician responsible at the intermediate care unit, typically every 4 hours. MIE will be administered with standard settings of insufflation 20 cm H2O and exsufflation 20 cm H2O, with possible individual changes from 10/-10 H2O up to 40/-40 H2O, and oxygen flow up to 15 l/min. The standard settings will be set to five cycles of 2 seconds insufflation, 3 seconds exsufflation with a three second pause between each cycle. Every treatment session consists of five rounds of five cycles, in all 25 insufflation/exsufflation, with time between each cycle of 30 seconds, meant used for suction.
89343326|NCT03714321|No Intervention|CPAP arm|CPAP will be given as prescribed by the physician responsible at the intermediate care unit, typically every 4 hours. CPAP will be administered with standard settings of H2O and an oxygen flow of 15L/min.
89343327|NCT01223105|Experimental|Slow Freezing|oocytes will be frozen by slow freeze/ rapid thaw
89343328|NCT01223105|Experimental|Vitrification|oocytes will be frozen using rapid freezing/rapid thaw
89343329|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
89343330|NCT05161624||Path planning model|
89343331|NCT05161624||Junior ablation specialists|
89343332|NCT05161624||Senior ablation specialists|
89343333|NCT05584917|Experimental|surgery patient|phone call after surgery to answer the tegner activity scale
89343334|NCT01219829||Family History patients|Patients with a strong family history of pancreatic cancer or with a genetic syndrome that puts them at risk for pancreas cancer.
89343335|NCT01219829||Recurrence patients|Patients who underwent surgery for pancreatic cancer and developed tumor recurrence after surgery
89343336|NCT03470896|Active Comparator|Preanesthesia teleconsultation|Preanesthesia teleconsultation through video-conference, between an anesthesiologist of the surgical center Emile Galle, in a medical consulting room in the surgical center Emile Galle, and a patient at home or at work. The patient must be in a quiet area, which allows the confidential medical contact.
89343337|NCT03470896|Active Comparator|Preanesthesia traditional consultation|Preanesthesia traditional consultation between an anesthesiologist of the surgical center Emile Galle, and a patient, in a medical consulting room in the surgical center Emile Galle.
89343338|NCT03470896|Other|Bis traditional consultation|"If a patient, in the group  preanesthesia teleconsultation  cannot realized his teleconsultation because of technical problem, he will be assigned on the sub group  bis traditional preanesthesia consultation ."
89343339|NCT01203241|Active Comparator|Conventional ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
89343340|NCT01203241|Active Comparator|Conventional ablation plus left atrial roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
89343341|NCT04823091|Experimental|Fludarabine + Cyclophosphamide + anti-CD7 CAR-T Cells|Patients will received lymphodepletion with fludarabine (30 mg/kg) and cyclophosphamide (250 mg/kg) on day -5, -4, and -3, followed by the infusion of CAR7-T cells with the dose of 1×10^6/kg and 2×10^6/kg (with an allowance of ±20%). If no dose-limited toxicity (DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.
89343342|NCT01125527|Active Comparator|Arm 1|
89343343|NCT01125527|Active Comparator|Arm 2|
89343344|NCT03934853|Other|No arm|There is no arm for this study.
89343345|NCT01206283|Active Comparator|Cerebral perfusion pressure-targeted|15 comatose operated patients after aneurysmal subarachnoid haemorrhage and severe traumatic brain injury respectively were managed postoperatively using cerebral perfusion pressure-targeted therapy according to the American Associations of Neurological Surgeons. Results were categorised into different Glasgow Outcome Scores.
89343346|NCT01206283|Active Comparator|Intracranial pressure-targeted therapy|
89343347|NCT05577195|Experimental|Impella + VA-ECMO|
89343348|NCT05577195|Active Comparator|VA-ECMO only|
89343349|NCT01122797||Alcoholic liver disease|Alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
89343350|NCT01122797||Controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination.
89343351|NCT01298401|Experimental|Arm A|Dose level -1A (Ganitumab 6 mg/kg, Capecitabine 825mg/m2)
88814119|NCT02241278|Placebo Comparator|Control|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision.
89343352|NCT01298401|Experimental|Arm B|Dose level 1A (Ganitumab 12 mg/kg, Capecitabine 825mg/m2)
89343353|NCT01298401|Experimental|Arm C|Dose level 2A (Ganitumab 20 mg/kg, Capecitabine 825mg/m2)
89343354|NCT01298401|Experimental|Arm D|Dose level -1B (Ganitumab 6 mg/kg, Capecitabine 625mg/m2)
89343355|NCT01298401|Experimental|Arm E|Dose level 1B (Ganitumab 12 mg/kg, Capecitabine 625mg/m2)
89343356|NCT01298401|Experimental|Arm F|Dose level 2B (Ganitumab 20 mg/kg, Capecitabine 625mg/m2)
89343357|NCT03931343|Experimental|Thoracolumbar interfascial plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
89343358|NCT03931343|Active Comparator|Erectro spinae plane block|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
89343359|NCT03840109||All Participants|All participants will take an online questionnaire which includes their evaluation of one of 18 different emotional support messages randomly assigned through the Qualtrics survey system. The participants answer a series of closed ended scales regarding quality of the support message, supporter's competence, amount of emotional improvement they experienced after reading the message, and likelihood to seek support from the person writing the message.
89343360|NCT03472066||a group of women who have been conized|Previous conization
89343361|NCT03472066||control group with asymptomatic patients|on routine second trim no previous conization
89343362|NCT01122875|Experimental|A|
89343363|NCT01298479||Group 1|All subjects
89343364|NCT02146885||Weight Control|Weight Control
89343365|NCT01298557||Traumatic brain injured patients|This group consists of participants who suffered a traumatic brain injury an average of 4 months to 4 years prior to testing. Patients must not have history of prior head injury, substance abuse, psychiatric illness, or contraindications to MRI.
89343366|NCT01298557||Controls (no traumatic brain injury)|This group consists of participants who do not have a history of brain trauma. Furthermore, controls must not suffer from substance abuse, psychiatric illness, or have contraindications to the MRI.
89343367|NCT03931499||Study cohort|Patients undergoing surgery under cardiopulmonary bypass
89343368|NCT01206361||fixed dose prostaglandin combination|
89343369|NCT01122953|Experimental|Phenytoin|
89343370|NCT01122953|Active Comparator|Epamin|
89343371|NCT01298635|Active Comparator|trab|
89343372|NCT01298635|Active Comparator|phacotrab|
89343373|NCT01125683|Experimental|1|2,5 mg once daily
89343374|NCT01125683|Active Comparator|2|single dose of 5 mg
89343375|NCT01125683|Placebo Comparator|3|
89343376|NCT01125683|Experimental|4|60 mg once daily
89343377|NCT01125683|Experimental|5|60 mg three times daily
89343378|NCT03840031|Experimental|Orange Fleshed Sweet Potato High Iron|Meal sequence B, OFSP High Fe
89343379|NCT03840031|Active Comparator|Orange Fleshed Sweet Potato Control|Meal sequence A, OFSP control
89343380|NCT03470662|Experimental|experimental group|Care bundle
89343381|NCT03470662|No Intervention|control group|routine care
89343382|NCT01219907|Experimental|Arm I|"VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.~CHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.~IMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20."
89343383|NCT01203397|Active Comparator|GROUP 2|
89343384|NCT01203397|Experimental|GROUP 1|
89343385|NCT04672876|Experimental|Telotristat Ethyl (Xermelo®)|After the surgery is performed, study participants will stop taking telotristat ethyl (Xermelo®) as part of this study and there will be no follow-up visits or calls required outside of the usual postoperative care. The research team will collect clinical data on the participants' outcomes up to 30 days after surgery by accessing medical records.
89343386|NCT03935009|Active Comparator|Manual toothbrush with electric toothbrush N°1|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and will be instructed to use them for six weeks.
89343387|NCT03935009|Active Comparator|Manual toothbrush with electric toothbrush N°2|Participants will receive manual toothbrush (Curaprox 5460 ultra soft, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chums) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
89343388|NCT03935009|Active Comparator|Electric toothbrush N°1 with electric toothbrush N°2|Participants will receive an electric toothbrush N°1 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App) and an electric toothbrush N°2 (Playbrush Smart Sonic, Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia) and will be instructed to use them for six weeks.
89343389|NCT03471988|Experimental|AK1820|Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
89343390|NCT03471988|Active Comparator|Voriconazole|Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.
89343391|NCT03724981|Experimental|Dulaglutide Pen|Injection of commercial dulaglutide pen on a practice pad.
89343392|NCT03724981|Experimental|Semaglutide Pen|Injection of commercial semaglutide pen on a practice pad.
89343393|NCT04648306||Impella cohort|Single arm study of patients who underwent non-emergent percutaneous coronary intervention with prophylactic Impella support
89343394|NCT03931577|Experimental|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the use of C-reactive protein rapid testing.
89343395|NCT03931577|Experimental|Enhancement of communication skills|Continuous (on-site and monthly online training) illness-focused intervention with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
89343396|NCT03931577|Experimental|C-reactive protein + communication skills|Continuous (workshop and monthly web-based training) disease-focused intervention with C-reactive protein rapid testing and on-site and continuous (monthly online training illness-focused intervention) with enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets.
89343397|NCT03931577|No Intervention|Usual care|Usual care.
89343398|NCT03834181|Experimental|Monitoring evaluation|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"
89343399|NCT01123031|Active Comparator|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
89343400|NCT01123031|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
89343401|NCT04637932|Active Comparator|Use of endotracheal tube During Percutaneous Dilatation Tracheostomy|Group 1 was determined as endotracheal tube
89343402|NCT04637932|Active Comparator|Use of Pro-seal LMA and Bronchoscopy During Percutaneous Dilatation Tracheostomy|group 2 as pro-seal laryngeal mask group.
89343403|NCT04354454|Active Comparator|Fitbit|"After the screening procedures confirm participation in the research study. Participants randomized into Fitbit only group.~-- Participants will track their daily steps for 4.5 months with use of a Fitbit~The study interventions involved in this research are:~Fitbit (also known as a wearable accelerometer or fitness tracker)~Way to Health platform~Surveys/Interviews"
89343404|NCT04354454|Experimental|Fitbit + Game + Support from a Teammate|"After the screening procedures confirm participation in the research study. Participants randomized into Fitbit + Game + Support from a Teammate.~Participants will select a step goal, use a Fitbit to track daily activity, and select a teammate (e.g. family member or friend) who they think will help them achieve their goals.~Participants will participate a 3-month game designed to increase activity and then followed for another 1.5 months to see if their increased activity can be maintained without the game.~The study interventions involved in this research are:~Fitbit (also known as a wearable accelerometer or fitness tracker)~Help from a Teammate (i.e. friend or family member chosen to help reach goals, if applicable~Way to Health Platform~Surveys/Interviews"
89343405|NCT03714243|Experimental|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
89343406|NCT01204567|Active Comparator|Training follow-up after discharge|Aerobic training Home-program
89343407|NCT04353050|No Intervention|Cohort 1 (retrospective)|Only data from medical records and formalin-fixed paraffin-embedded tissue blocks will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
89343408|NCT04353050|No Intervention|Cohort 2 (retrospective)|Only data from medical records, formalin-fixed paraffin-embedded tissue blocks and cytologic slides will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio
89343409|NCT04353050|Other|Cohort 3 (prospective)|Patients with pigmented lesions on the skin or mucosa who are referred for excisional biopsy will be offered to apply investigated non-invasive adhesive system on their lesion just before the excisional biopsy. After biopsy cytological slides and FFPE tissue blocks will be prepared. All three types of obtained samples will be investigated separately (adhesive patches, cytologic slides and FFPE tissue blocks) for genetic markers whereas cytologic slides and FFPE tissue blocks will be processed also routinely and regular cytologic and histopathologic report will be generated.
89343410|NCT05575557|Active Comparator|His bundle pacing group|HBP was performed on the patient, and the detection of the His bundle potential during the procedure is the sign of the success of the procedure. The HB capture threshold was accepted if lower than 3.0 V at 0.42ms.
89343411|NCT05575557|Active Comparator|Left branch bundle pacing group|HBP was performed on the patient, and the detection of the His bundle potential during the procedure is the sign of the success of the procedure. During the procedure, the duration from the pacing signal to the peak of R wave (on V4-V6 lead) is measured as pacing to left ventricular activation time (p-LVAT). An eligible site of left bundle capture was confirmed if selective LBBP was demonstrated by ECG, if p-LVAT shortened abruptly >10 ms through increasing pacing output, or if p-LVAT stayed shortest and stable at the site.
89343412|NCT05575557|Active Comparator|Right ventricular pacing group|If we could not achieve an acceptable HB or LBB capture after five attempts of lead positioning or a fluoroscopy exposure time over 30min, the lead was then placed in the RV with traditional approach.
89343413|NCT02051101|Other|Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
89343414|NCT01220063|Other|Radiation + Irinotecan|"Irinotecan will be administered :~- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy~Radiotherapy (RSHF) will be administered :~at D1, D3, D8 and D10~48 Gy, 12 Gy by fractions twice a week"
89343415|NCT03109366|Other|Online self-management support|Access to online self-management support tool for six months
89343416|NCT04834622|Experimental|Melodies for Mums|Mothers will start a block of 10-week classes and continue with their group for the duration of the course. Classes will take place in Children's Centres (or online). Mothers will attend with their babies and will sit in a socially-distanced circle on the floor surrounded by soft play cushions and mats. Classes will start with welcome songs, introducing everyone to one another, and involve a range of singing and music activities. Mothers will be required to respect social distancing guidelines. Music activities will include learning songs from around the world and will be accompanied by instruments that the mothers and babies can play together. Instruments will not be shared and will be disinfected before and after the singing sessions. Mothers will also work to write some of their own songs over the weeks. Recordings of the group singing the songs together will be made for the mothers to listen to at home. Classes will be led by professional workshop leaders trained by Breathe.
89343417|NCT04834622|Active Comparator|Control (mother-baby community sessions)|Our control group will be a 'active' control. During the first 10 weeks (during the study period), mothers in the control group will receive details of other non-music classes available to them in the community (or online if necessary, depending on the programs available at the time and government guidelines) and will receive the same schedule of texts and phone calls to encourage them to join these activities. They will still be seen by the researchers to collect clinical measures and biological samples (including the pre-post saliva samples) and to monitor engagement in other activities. Following the first 10 weeks, the mothers in the control group will be offered a place on the singing programme, but these data will not be part of the study, and they will not join groups with women who are in the study
88818404|NCT01819415|No Intervention|Control|Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.
89343418|NCT01223339|Experimental|Single Dose Japanese Cohort|This will be a single dose Cohort in which Japanese healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin or placebo through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
89343419|NCT01223339|Experimental|Single dose Western cohort|This will be a single dose Cohort in which Western healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
89343420|NCT01223339|Experimental|Multiple Dose Japanese Cohort|This will be a multiple dose Cohort in which Japanese healthy participants will receive once-daily 25 mg ertugliflozin or placebo for 7 days.
89343421|NCT03585478|Active Comparator|Latiglutenase|IMGX003
89343422|NCT03585478|Placebo Comparator|Placebo|Placebo
89343423|NCT01298791|Experimental|Provider sitting|Providers seated during communication through hospitalization
89343424|NCT01298791|Experimental|Provider standing (control)|Providers standing during communication through hospitalization
89343425|NCT01220141||A|
89343426|NCT01347879|Experimental|Visonac cream with PDT|active treatment with light dose of 37 Joule/cm2
89343427|NCT01347879|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 Joule/cm2
89343428|NCT04127006||Vision Cohort 1|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter 10 degrees or more in every meridian of the central field
89343429|NCT04127006||Vision Cohort 2|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 [approximate Snellen equivalent 20/100 - 20/400] or (visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter less than 10 degrees in any meridian of the central field)
89343430|NCT04127006||Vision Cohort 3|Participants with the better eye Screening Visit visual acuity ETDRS letter score of 18 or less [approximate Snellen equivalent 20/500 or worse]
89343431|NCT01217879||Group 1|
89343432|NCT03470584||Tzu Chi Vegetarian Study|12062 Tzu Chi volunteers of the Buddhist Tzu Chi Foundation recruited throughout communities in Taiwan in the year 2005. All participants filled out a self-administered questionnaire on basic information, medical history, lifestyle, and diet. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
89343433|NCT03470584||Tzu Chi Health Study|6002 participants who came for health examination at the Dalin Tzu Chi Hospital between the years 2007 to 2009. 77% were Tzu Chi volunteers. All participants were interviewed on a structured questionnaire including basic information, medical history, lifestyle, and diet, and received a comprehensive health examination. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
89343434|NCT01204645||Acute Coronary Syndrome (ACS)|Continuous inclusion at emergency hospitals of patients with acute coronary syndrome (according to ESC/AHA definitions)
89343435|NCT01204645||Follow up|Patients included at 6 or 12 months follow-up visit after an acute coronary event.
89343436|NCT01204645||Coronary|Patients included when undergoing an coronary angiography for suspected or confirmed coronary heart disease
89343437|NCT04249310||Tiotropium/Olodaterol|Combination of Tiotropium and Olodaterol
89343438|NCT04249310||Tiotropium|
89343439|NCT05665075|Experimental|QN-023a|QN-023a in adult subjects with r/r AML
89343440|NCT04294420|Experimental|Patient education program|Patient education program
89343441|NCT01123109|Other|nulliparous females|nulliparous women over the age of 18
89343442|NCT04117646||Patients|Patients of 2 and 12 years of age with chronic rhinosinusitis.
89343443|NCT04117646||Controls|Subjects of 2 and 12 years of age without chronic rhinosinusitis.
89343444|NCT04230928|Placebo Comparator|Standard GLB Control|Individuals will receive the standard Diabetes Prevention Program-Group Lifestyle Balance (GLB) program as outlined by the American Diabetes Association. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.
89343445|NCT04230928|Experimental|VLC-GLB Intervention|Individuals will receive a version of the DPP-GLB program in which 4 of the 12 modules will teach a very low carbohydrate diet instead of the standard. All other components of the DPP-GLB will follow the standard. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.
89343446|NCT03828955|Experimental|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage.
89343447|NCT03828955|Placebo Comparator|Placebo|Subjects receive two bags starch placebo of similar appearance per day for 8 weeks of a stage.
89343448|NCT01123187|Experimental|islet transplantation|Islet transplantation
89343449|NCT03932825|Placebo Comparator|Air oxygen mixture|participants in this arm inhale mixed oxygen-air gas (inspired oxygen concentration ~50%).
89343450|NCT03932825|Experimental|Nitrous oxide|Participants in this group inhale mixed 50% nitrous oxide and 50% oxygen.
89343451|NCT01298869||Chronic kidney disease|Chronic kidney disease stage IV and V
89343452|NCT03471910|Experimental|Diosmin|Diosmin 600mg, one tablet once daily
89343453|NCT03471910|Active Comparator|Diosmin + Hesperidin|Diosmin 900mg + Hesperidin 100mg, one tablet once daily
89343454|NCT03932981|Experimental|Temozolomide|Chemotherapy by temozolomide
89343455|NCT03470506||Ischemic stroke|Diagnosed with an ischemic stroke by a Neurologist
89343456|NCT01220219|Experimental|Pregabalin controlled release, 82.5 mg|
89343457|NCT01220219|Experimental|Pregabalin controlled release, 165 mg|
89343458|NCT01220219|Other|Pregabalin immediate release, 75mg|Reference Treatment
89343459|NCT03441789|Experimental|Otezla plus Enstilar foam|Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily
89343460|NCT03441789|Placebo Comparator|Otezla plus vehicle foam|Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily
89343461|NCT01125839||Spondylitis|Patients who checked spine MRI for back pain
89343462|NCT03359005|Experimental|5d VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 50mg/m2/d IV over 60 minutes on days 1-5.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
89343463|NCT03359005|Active Comparator|5d x 2 VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 20mg/m2/d IV over 60 minutes on days 1-5 and 8-12.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
89343464|NCT01223651|Active Comparator|CGMS at sea level.|To assess reliability of continuous glucose monitoring system at sea level whilst subject undergo's a hyperinsulinaemic glucose clamp study.
89343465|NCT01223651|Active Comparator|CGMS reliability at simulated 8000 feet.|To assess reliability of continuous glucose monitoring system at a simulated altitude of 8,000 feet whilst the participant undergo's a hyperinsulinaemic glucose clamp study.
89343466|NCT04321174|Experimental|Lopinavir/ritonavir|This arm will receive oral lopinavir/ritonavir 400/100 mg (or equivalent weight-based dosing) twice daily for 14 days.
89343467|NCT04321174|No Intervention|Control|This arm will receive no intervention.
89343468|NCT03711513|Experimental|Exposure only|Psycho-education (PE) (plus homework) + 4 x Exposure (EX) (plus homework): 20 participants will receive four exposure group sessions after the psycho-education session. In the four sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
89343469|NCT03711513|Experimental|Cognitive restructuring plus exposure|PE (plus homework) + Cognitive Restructuring (CR) (plus homework) + CR (plus homework) + EX (plus homework) + EX: 20 participants will receive two cognitive restructuring group sessions after the psycho-education session. In these two session they will practice identifying dysfunctional cognitions and formulating more functional (alternative/helping) cognitions. After the cognitive sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
89343470|NCT03711513|Experimental|Relaxation plus exposure|PE (plus homework) + Relaxation (RE) (plus homework) + RE (plus homework) + EX (plus homework) + EX: 20 participants will receive two relaxation exercises group sessions after the psycho-education session. In these two session they will practice muscle relaxation and breathing exercises. After the relaxation sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
89343471|NCT05281783|Experimental|Percutaneous Radiofrequency Ablation|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
89343472|NCT01123265||Anti-TNF|
89343473|NCT01123265||Methotrexate|
89343474|NCT04231162|Experimental|probiotic powder, Bifidobacterium lactis|
89343475|NCT04231162|Placebo Comparator|Placebo|
89343476|NCT01204723|Experimental|Behavioral Condition 1|Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
89343477|NCT01204723|Experimental|Behavioral Condition 2|Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
89343478|NCT01204723|Experimental|Behavioral Condition 3|Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
89343479|NCT03717285|Experimental|Group 1:Under direct vision|Patients in Group 1 insert the UAS under direct vision.In this procedure,the investigators will insert the ureteroscope into urinary bladder beside the guidewire to observe the process of uas insertion into the ureter.
89343480|NCT03717285|Active Comparator|Group 2:Under non direct vision|Patients in Group 2 insert the UAS under non direct vision.In this procedure,the investigators will insert the UAS under fluoroscopy control.
89343481|NCT01127789|Experimental|non-invasive brain stimulation|
89343482|NCT03130816|Experimental|allogeneic cord blood transplantation|"Intravenous(IV) infusion will be done by the following method A. After 4 hours of fasting, subjects will be sedated with chloral hydrate (Pocral®) syrup B. Intravenous infusion will be conducted in stem cell center, CHA Bundang Medical Center and the therapy will be performed by the Principal Investigator or a physician delegated from the Principal Investigator. The physician conducting the infusion will not participate in the efficacy and result analysis of this study.~C. Oxygen saturation will be monitored during therapy."
89343483|NCT01204801|Experimental|Thermochemotherapy|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy.
89343484|NCT01204801|Active Comparator|Chemotherapy (control)|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs
89343485|NCT01218191||Subarachnoid hemorrhage|Patients presenting a SAH
89343486|NCT04194814|Other|crisaborole and topical Corticosteroid|"crisaborole (2%) ointment on the other forearm, twice daily application for 4 weeks (randomised site allocation)~betamethasone valerate (0.1%) cream on one forearm, twice daily application for 4 weeks (randomised site allocation)"
89343487|NCT03832621|Experimental|temozolomide + nivolumab + ipilimumab|Temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks, for two cycles followed by TC scan assessment: if SD/PR/CR second treatment phase with nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide at the previously adopted schedule
89343488|NCT01220375|Experimental|1|Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell release from bone marrow and HSC movement into the peripheral circulation.
89343489|NCT03998878|Experimental|Low-Carbohydrate Diet|Participants will be instructed to consume less than 30 grams of carbohydrates per day.
89343490|NCT03998878|Experimental|Intermittent Energy Restriction|Participants choose 2 non-consecutive days per week in which they will consume 500-650 calories.
89343491|NCT03998878|Experimental|Hunger Training|Participants monitor their hunger symptoms and blood glucose, and eat only when blood glucose is below a certain threshold level.
89343492|NCT01125995|Active Comparator|late CCRT|radiotherapy start on day one of the third cycle of chemotherapy
89343493|NCT01125995|Experimental|Early CCRT|Radiotherapy start on day 1 of 1st cycle of chemotherapy
89343494|NCT04456582|Experimental|Amyloidosis transthyretin with cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
89343495|NCT04456582|Experimental|Amyloidosis transthyretin without cardiac commitment|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
89343496|NCT04456582|Placebo Comparator|Healthy subjects|Shear wave elastography (SWE) will be used to evaluate to assess miocardial elasticity.
89343497|NCT01203553||Control Group|The main operation will be performed as planned. For the closure of the abdominal wall, a standard technique will be applied using a running suture of PDS 1 loop. The distance of the sutures to the fascial border is 1cm and the distance between two stitches is not more than 1cm. The total length of suture is at least 4 times the total length of the abdominal incision
89343498|NCT01203553||Treatment Group|The main operation will be performed as planned. Prior to the closure of the abdominal wall a mesh will be implanted in a standardized fashion: A Dynamesh IPOM mesh will be used for the present study. The mesh has a width of 15cm and is tailored to overlap lateral and cranial boarders at least 5cm. The mesh will be placed intra-abdominally and fixed using intra-abdominal stitches using Prolene 2/0 in all four corners. After the initial fixation of the mesh in all quadrants, the boarders of the mesh will be adapted using Prolene 2/0 running sutures. The fixation aims to prevent any intestinal structures to herniate onto the mesh. Afterwards, the abdominal wall is closed as described in the control group.
89343499|NCT01223729|Experimental|Acetyl-L-Carnitine|
89343500|NCT01223729|Placebo Comparator|placebo|
89343501|NCT04456348||positive|Subjects have gait disorder according to intelligent gait assessment at baseline.
89343502|NCT04456348||negative|Subjects don't have gait disorder according to intelligent gait assessment at baseline.
89343503|NCT01223807|No Intervention|Control Group|The control group will receive only usual care.
89343504|NCT01223807|Experimental|Diaphragmatic breathing training|The training group will be submitted to a diaphragmatic breathing training program of 4 weeks.
89343505|NCT03712293|Experimental|BBB Disruption with Chemotherapy Arm|All subjects in this arm will undergo ExAblate Type 2.0 BBBD procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).
89343506|NCT01126073|Placebo Comparator|placebo|
89343507|NCT01126073|Active Comparator|Niacin/Laropiprant 2000mg/40 mg|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will be randomized in the ratio 1:1 to either receive ER niacin/laropiprant or placebo in addition to the statin therapy. Patients in the ER niacin/laropiprant group will receive 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
89343508|NCT03827707|Experimental|Noise|
89343509|NCT03827707|Sham Comparator|Silence|
89343510|NCT01298947|Active Comparator|Laser atherectomy and drug-coated balloon|Laser atherectomy and Paclitaxel-coated balloon angioplasty in treatment of instent lesions of femoropopliteal arteries
89343511|NCT01298947|Active Comparator|Drug eluting Ballon PTA|Paclitaxel-coated balloon angioplasty
89343512|NCT01567748||Hemodynamics Measured|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
89343513|NCT03287050|Experimental|Pembrolizumab + SBRT|
89343514|NCT01204879|Active Comparator|CM for general activities|Standard care plus individual contingency management session for general activities
89343515|NCT01204879|Experimental|CM for exercise-related activities|Standard care plus individual contingency management session for physical activities
89343516|NCT03712215|Experimental|Experimental Group 1|synchronized FES mode, according to the parameters based on the Gueddes et al., (1991): current frequency (F) 30 Hz; pulse width (T) 0,4 ms; upload time (Rise) 1s; time of muscle contraction (On time) 1 s; down time (Decay) 2s e muscle relaxation time (Off time) 1 s.
89343517|NCT03712215|Experimental|Experimental Group 2|the same apparatus will be used, differing in the parameters that will be based on the studies of Cancelliero et al., (2012) for the EDET procedure, being used in synchronized FES mode, with frequency of 30 Hz; pulse width (T) 0,4 ms, climb (ramp) of 0,7 s (maximum value). The support was of 0.4 s, already standardized and fixed in the apparatus
89343518|NCT03712215|No Intervention|Control Group|The control group (CG) with the same characteristics of the experimental groups will perform conventional physiotherapy
89343519|NCT03130504|Active Comparator|17α hydroxy progesterone caproate group|
89343520|NCT03130504|No Intervention|No intervention group|
89343521|NCT01206829|Active Comparator|Audiological rehabilitation|16 hours of psychosocial rehabilitation course
89343522|NCT01126151|Experimental|parent handbook|parent handbook to increase the quantity and quality of communications about alcohol
89343523|NCT01126151|Experimental|parent handbook with boosters|boosters are given to parents at three times (move in, visit weekend; student visits home)
89343524|NCT01126151|Experimental|parent handbook delay|parent handbook is delayed and given after semester has begun
89343525|NCT01993082|Experimental|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
89343526|NCT01993082|No Intervention|Activity Maintenance Group|Participants randomized into the waitlist control group receive no aerobic training. Wait-list control participants will receive monthly check-in phone calls to establish that they have not significantly increased activity engagement. Participants in this group will receive a free gym membership at the end of the study, monthly phone calls with a fitness coach support provider for 6 months, and 2 coaching text messages per week.
89343527|NCT04106986|Experimental|PEMF and PRE|The PEMF and PRE group received 24 sessions (3 sessions/week for 8 weeks) of combined treatment group (pulsed electromagnetic field with PRE training)
89343528|NCT04106986|Experimental|PRE|The PRE group received 24 sessions (3 sessions/week for 8 weeks) of only progressive resistance exercise
89343529|NCT03819127|Active Comparator|Metformin|metformin 1 g twice a day for 24 weeks
89343530|NCT03819127|Experimental|Metformin plus vildagliptin|metformin 1 g plus vildagliptin 50 mg twice a day for 24 weeks
89343531|NCT01218269|Other|no arms|all patients will receive the treatment - there is only one arms
89343532|NCT03387735|Placebo Comparator|Treatment as usual (TAU) + Internet|Patients will be given access to helpful websites such as National Institute on Aging.
89343533|NCT03387735|Experimental|Treatment as usual (TAU) + ElderTree|Patients will be given access to the ElderTree website for 12 months which provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.
89343534|NCT03931031||Cardiac Surgery Patients|Patients taking antiplatelet medication who are scheduled for elective cardiac surgery.
89343535|NCT04177394||MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system
89343536|NCT02908789|Experimental|Antimicrobial photodynamic therapy (aPDT)|1)Selective caries removal: caries dentin was partially removed with hand excavators (Fava, Pirituba, Brazil). 2)The laser technique: 0.01% methylene blue solution was applied, and a pre-irradiation period of 5 minutes was done with an Indium Gallium Aluminum Phosphorus diode laser (InGaAlP) with a wavelength of 660 nm (visible red), a spot area of 3mm2, and fixed output power of 100 mW (energy of 9 J with 90 seconds). 3) The restorative technique was done as described in comparator group.
89343537|NCT02908789|Sham Comparator|Group without Antimicrobial photodynamic therapy (aPDT)|1) Selective caries removal 2) The restorative technique was done by etching with 37% CondacTM phosphoric acid conditioner (FGM) for 15 s in enamel and 7 s in dentin was performed followed by washing for 30 s until the conditioner was completely removed. The excess of dentin moisture was removed with sterile cotton balls, and the enamel was air-dried until it had an opaque appearance. Subsequently, two consecutive layers of Adper Single Bond 2TM (3M ESPE) were applied with a KG Brush (KG Sorensen) on the enamel and dentin for 15 s and subjected to light air blast to promote solvent evaporation. The adhesive was photoactivated for 10 s with a light-emitting diode (LED) unit (BioLuz Plus; BioArt) with an intensity of 460 mW/mm2. The cavity was restored with a Filtek Z250TM composite resin (3M Dental Products) according to the incremental technique. Each increment was photo-activated for 40 s.
89343538|NCT01498393|Other|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
89343539|NCT01123343|Active Comparator|LRI Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for LRI.
89343540|NCT01123343|Active Comparator|Capsulorhexis Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for Capsulorhexis.
89343541|NCT03632174|Experimental|Topical Ointment with L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
89343542|NCT03632174|Experimental|Topical Ointment without L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
89343543|NCT01204957|Experimental|Arm 1 Seaweed and Soy Protein|Arm 1 5 g/d Seaweed for 6 wk, then 5 g/d Seaweed and Soy Protein for 1 wk
89343544|NCT01204957|Experimental|Arm 2 Placebo and soy protein|Arm 2 5 g/d Placebo for 6 wk, then 5 g/d Placebo and Soy Protein for 1 wk
89343545|NCT01123421||With osteoporotic fracture|Approximately 100 postmenopausal women that have been enrolled in a population-based case-control study that have experienced a clinically-diagnosed fracture of thoracolumbar spine or distal forearm due to minimal or moderate trauma based on review on their inpatient and outpatient medical records will be enrolled.
89343546|NCT01123421||Without osteoporotic fracture|Approximately 100 control women will have no history of a prior spine, hip, or wrist fracture.
89343547|NCT01223885|Experimental|Camel's milk, Cow's milk allergy|
89343548|NCT01299181|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
89343549|NCT01299181|Placebo Comparator|Placebo|Placebo
89343550|NCT01123577|Experimental|Intervention|
89343551|NCT01123577|No Intervention|Control|Participants receive usual care by providers.
89343552|NCT03960892|Experimental|E-CAU with Group Problem Management Plus (PM+)|"190 participants will be randomly assigned to E-CAU with Group PM+. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.~The participants in the experimental arm will receive Group PM+ by trained, non-specialist peer-refugees in addition to E-CAU."
89343553|NCT03960892|No Intervention|Enhanced care as usual (E-CAU) only|190 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a leaflet which will include information on the services that they can get from RASASA and other public services. ), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
89343554|NCT01483495||Diagnostic tool|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
89343555|NCT03930875||Control - No Obstructive Sleep Apnea with Aspirin|"The control group consist of patients with a negative diagnosis of OSA (based on a negative home sleep apnea test (REI) < 5 and attended sleep study, AHI < 5; or attended NPSG with an AHI < 5) and the patient is taking aspirin at a dose of 81 mg/day for at least a week prior to inclusion.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
89343556|NCT03930875||Arm 1- Obstructive Sleep Apnea with CPAP therapy and Aspirin|"Arm 1 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI > 15 with or without symptoms or REI/AHI > 5 with symptoms of sleep apnea in a patient 18-85 years old, CPAP has been started within the last 2 years, and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
89343557|NCT03930875||Arm 2 -Obstructive Sleep Apnea with no CPAP & Aspirin|"Arm 2 consist of patients with a diagnosis of OSA (based on home or attended sleep study) with an REI/AHI > 15 with or without symptoms or REI/AHI > 5 with symptoms of sleep apnea in a patient 18-85 years old and patient is taking aspirin at a dose of 81mg/day for at least a week, last dose taken within 24 hours prior to enrollment.~After obtaining written informed consent, approximately 6 ml of blood was collected via venipuncture."
89343558|NCT03932968||Symptomatic pain|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry during 24 hours will be performed.
89343559|NCT03932968||Control|patients after a sleeve gastrectomy without symptomatic pain
89343560|NCT03831997||Historical Controls|The retrospective arm will consist of our control group, it will be derived from a retrospective medical chart review of all patients with CSDH at the facility.
89343561|NCT03831997||Prospective Arm|The prospective arm of the study will be looking at the effects of Dextrose 5% W/ Sodium Chloride 0.225% on the recurrence rate defined by the need for secondary surgical intervention for residual/recurrent CSDH) of CSDH in a 3-month post-operative window.
89343562|NCT03925246|Experimental|Nivolumab|Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 weeks for 8 doses (4 months), followed by a 60 minutes intravenous infusion at dose of 480 mg every 4 weeks for 8 doses (8 months) or until progression, death , unacceptable toxicity or end of the research.
89343563|NCT01218347|Experimental|Rosuvastatin|rosuvastatin treatment
89343564|NCT01220765|No Intervention|Standard care|Patients randomized to the standard care group receive standard of care using pulse oximetry
89343565|NCT01220765|Experimental|Capnography|In the intervention group capnography is measured using a cannula under the nose connected to the capnograph. The capnographic device displays respiratory rate, end-tidal carbon dioxide (ETCO2) levels, and continuous waveforms.
89343566|NCT01126229|Placebo Comparator|Placebo|Dietary Supplement: placebo
89343567|NCT01126229|Experimental|300 mg/d Resveratrol|Dietary Supplement: 300 mg/d Resveratrol
89343568|NCT01126229|Experimental|1000 mg/d Resveratrol|Dietary Supplement: 1000 mg/d Resveratrol
89343569|NCT03831841|Experimental|Intervention|Multicomponent exercise programe involving all physical fitness paramenters and consisting on sesions of 1 hour, 3 days a week.
89343570|NCT03831841|No Intervention|Control|Control group with no intervention programe
89343571|NCT03471754|Experimental|Treatment Arm A|TESA-HB Device, Mode 3 (15mA). Treatment arm involves two 5-day treatment cycles over a 2-week period, with 2 days off between each of the 5-day cycles. The treatment period will as for two full weeks.
89343572|NCT01127945|Experimental|atorvastatin 80mg|
89343573|NCT01127945|Active Comparator|conventional therapy (for heart failure)|
89343574|NCT03827005|Placebo Comparator|placebo|3 grams cornstarch once per day for one day.
89343575|NCT03827005|Experimental|L-arginine|3 g L-arginine once per day for one day.
89343576|NCT03474640|Experimental|Toripalimab 80 mg repeat dose every 14 days|3-6 subjects (Part A)
89343577|NCT03474640|Experimental|Toripalimab 240 mg repeat dose every 14 days|3-6 subjects (Part A)
89343578|NCT03474640|Experimental|Toripalimab 480 mg repeat dose every 14 days|3-6 subjects (Part A)
89343579|NCT03474640|Experimental|Toripalimab 240 mg repeat dose every 21 days|240 subjects (Part B)
89343580|NCT03973996|Experimental|Green Tea|Participants consuming gummy confections with catechin-rich green tea extract daily for 4 weeks
89343581|NCT03973996|Placebo Comparator|Placebo|Participants consuming matched gummy confections formulated without green tea extract daily for 4 weeks
89343582|NCT01126307|Active Comparator|verapamil|verapamil 80mg tid
89343583|NCT01126307|Placebo Comparator|placebo sugar pill|placebo tid
89343584|NCT03831061|Experimental|Cognitive stimulation|"10 sessions of 45 minutes/week during 10 weeks. Each session included : (a) temporo-spatial orientation , (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.~There are 54 participants subdivided into two groups of 27 participants that perform the same intervention in different days of the week."
89343585|NCT03831061|No Intervention|Control group (No intervention)|There are 68 participants in total. These participants did not receive intervention.
89343586|NCT01128023||PET Rb-82 perfusion imaging|Patients diagnosed with or suspected coronary artery disease requiring evaluation and/or risk stratification will undergo PET Rb-82 perfusion imaging.
89343587|NCT01128023||SPECT perfusion imaging|Patients diagnosed with or suspected coronary artery disease who have undergone SPECT myocardial perfusion imaging.
89343588|NCT04055090|Experimental|Subjects who received Engensis (VM202)|VM202, Engensis
89343589|NCT04055090|Placebo Comparator|Subjects who received Placebo|Placebo, vehicle
89523599|NCT03384511|Experimental|Apatinib & RGD PET/CT|All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.
89343590|NCT03818893|Experimental|New Combination Immunotherapy|"Patients will receive Pembrolizumab once every 3 weeks and a maximum of 35 doses over 105 weeks .~The patients should be inpatient during treatment with GEN0101 in each treatment cycle and may be outpatient during off-treatment period with GEN0101, observation period, follow-up period with Pembrolizumab.~GEN0101 in a vial will be reconstituted with 1 mL of sterile distilled water and then will be injected intracutaneously (including skin tumor site). Nonetheless, it will not be deemed as deviation if an injection has been given subcutaneously unintentionally, e.g., leakage around the peri-injection sites.~A dose will be 60,000 mNAU in total, and 1 mL per injection site should be administered to 6 injection sites in total. For a patient, the total dose in a treatment cycle will be 360,000 mNAU (360 NAU), and the total dose over 2 treatment cycles will be 720,000 mNAU (720 NAU)."
89343591|NCT01126385||Transpedicular stabilization|Patients undergoing transpedicular stabilization of the spine
89343592|NCT03666754|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
89343593|NCT03666754|Experimental|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
89343594|NCT04173338|Experimental|Cabozantinib + Pemetrexed|Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.
89343595|NCT03933137||Not prolonged length of stay|Living donor patients who had ≤ 6 days length of stay after laparoscopic nephrectomy procedure
89343596|NCT03933137||Prolonged length of stay|Living donor patients who had > 6 days length of stay after laparoscopic nephrectomy procedure
89343597|NCT01311531|Active Comparator|TriMed fragment-specific fixation|
89343598|NCT01311531|Active Comparator|TriMed volar locking plate|
89343599|NCT01207063|Experimental|Radiotherapy|
89343600|NCT03531112|Experimental|Appetite Awareness Treatment (AAT) + Lifestyle Modification (LM)|Participants will receive an 8-week Appetite Awareness Training (AAT) program using a group format, will be provided a smart scale (with bluetooth connection) and instructions to weigh themselves daily. Participants will also be provided with weekly tailored feedback on self-weighing frequency and weight change. Assessment will be conducted at 0, 2, and 6 months.
89343601|NCT03531112|No Intervention|Control|Control group participants will receive no intervention in months 1-6, but will be offered the chance to receive an abbreviated form of AAT (4 weeks) following the 6-month assessment.
89343602|NCT04796168|Active Comparator|post operative Ankle fractures with splint|All patient who meet the inclusion criteria of having ankle fracture that rigidly fixed and randomized to receive splint post operative
89343603|NCT04796168|No Intervention|post operative Ankle fractures without splint|All patient who meet the inclusion criteria of having ankle fracture that rigidly fixed and randomized to receive NO splint post operative
89343604|NCT03936491|Experimental|Methylphenidate|The subjects will receive methylphenidate according to their clinical symptoms
89343605|NCT03936491|Active Comparator|Atomoxetine|The subjects will receive atomoxetine according to their clinical symptoms
89343606|NCT05555511|Active Comparator|N-acetylcysteine group|(23 Patients) Patients will recieve N-acetylcysteine 600 mg intravenous(IV) every 12 hours 24 hours before surgery and will be continued for 48 hours after surgery
89343607|NCT05555511|No Intervention|Standard group|Patients will not receive N-Acetylcysteine and will receive standard care according to our institutional protocol
89343608|NCT00890617|Experimental|Prednisone & Cryotherapy|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
89343609|NCT05101382||Cohort of CRC patients|Stage-mixed cohort of at least 500 CRC patients that cannot be reached for informed consent (death or lost-to-follow-up)
89343610|NCT03514498||Autism Spectrum Disorder|Children aged 4-12 years with a clinical diagnosis of mild-to-moderate Autism Spectrum Disorder undergoing dental surgery
89343611|NCT03514498||Typically Developed Controls|Children with no neurodevelopmental delays matched to Autism Spectrum Disorder participants according to age (within 6 months), gender, and ASA physical status level, scheduled to undergo dental surgery
89343612|NCT03934385|Experimental|Mental Rehearsal|Between-session rehearsal/retrieval exercises focused upon consolidating non-fear learning gained from exposures by prompting reflection of expectancy violation and rehearsal of the inhibitory association between the conditioned stimulus (i.e., spider) and unconditioned stimulus (e.g., bite/attack).
89343613|NCT03934385|Active Comparator|Control Rehearsal|Between-session rehearsal/retrieval exercises focused upon an unrelated, recent academic experience.
89343614|NCT03711357|Active Comparator|laser|980 nm diode laser (maximum output of 3 watts and coupled with a fiber optic tip of 200 µm diameter) will be used for four irradiations, of 5 seconds each, after chemo-mechanical preparation procedures.
89343615|NCT03711357|Placebo Comparator|Placebo|After chemo-mechanical preparation procedures, the diode laser fiber optic tip will be inserted inside the root canals but not activated.
89343616|NCT03468946|Other|high caries risk|children with high caries -identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
89343617|NCT03468946|Other|medium caries risk|children with medium caries- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
89343618|NCT03468946|Other|low risk|no caries or low risk- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
89343619|NCT03403413|Experimental|Muscle Vibration|Test feasibility of muscle vibration of tibialis anterior, rectus femoris, short head of biceps and tensor fasciae latae bilaterally during walking for 1 hour 3 times per week for 12 weeks to improve walking speed through improved coordination of hip, knee and ankle flexion.
89343620|NCT01299259|Experimental|Text Message Reminders|Subjects randomized to the the intervention group will receive a total of 4 text messages on days 2 through 5 to remind them to schedule and attend a PCP follow-up appointment
89343621|NCT01299259|No Intervention|Control Group|The control group will not receive any additional reminders to follow-up with PCP.
89343622|NCT01218425|Experimental|Medication|In this study, a crossover design is applied. All participants receive all three treatments in randomized order on separate days.
89343623|NCT03443908||CPAP therapy|CPAP therapy (minimum of 3-4 weeks)
89343624|NCT05621005|Experimental|treatment group or Rifaximin group|they received Rifaximin 550 milligram every 12 hour
89343625|NCT05621005|Active Comparator|control group or Norfloxacin group|they received Norfloxacin 400 milligram per day
89343626|NCT05657535|Other|Treatment group|Single treatment group for evaluation pain relief before and after LICUS treatment
89343627|NCT04770038||Patient Group|56 BPD patients
89343628|NCT04770038||Control Group|31 Healthy participants
89343629|NCT01224041|Experimental|Tacrolimus group|
89343630|NCT03181828|Experimental|Acetohydroxamic Acid Oral Tablet then No Intervention|Participants receive a single oral dose of 60 mg/kg acetohydroxamic acid (rounded to the nearest 250 mg) in the fasted state on the morning of the study. After completion of the 4-h study, participants then enter a wash-out period of 3 days. Participants then completed an identical 4-h study in the fasted state without acetohydroxamic acid.
89343631|NCT03181828|Experimental|No Intervention then Acetohydroxamic Acid Oral Tablet|Participants completed a 4-h study in the fasted state without acetohydroxamic acid. 3 days later, participants then completed an identical 4-h study in the fasted state, after having received a single oral dose of 60 mg/kg acetohydroxamic acid (rounded to the nearest 250 mg).
89343632|NCT01297153|Active Comparator|Aphakia|"The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. If it is aphakia,IOL will not be implanted.Aphakia will be corrected with aphakic glasses / contact lenses. Bilateral aphakes are given both contact lenses and glasses. So when they do not wear contact lenses they can put on aphakic glasses. Unilateral aphakes are given only contact lenses. Contact lenses should be fitted in the eye in OT immediately after the operation.~Aphakic glasses :~Prescribed within 2 weeks of surgery for both eyes."
89343633|NCT01297153|Active Comparator|Pseudophakia|The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. Hydrophobic Acrysof IOL is implanted.All pseudophakic children will be refracted and given the residual correction within a month of surgery.
89343634|NCT05449743|Experimental|patient treated with a phlebology-oriented spa therapy|Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
89343635|NCT01123811|Experimental|Cetuximab IF|Treatment with combination of Cetuximab and Irinotecan 5-FU
89343636|NCT05068687|Experimental|intraoperative high-resolution PET-CT imaging of resected malignancy|
89343637|NCT03165526||First Cohort|All available Emergency and Compassionate PIVSD Occluder subject data from 2011 until the end of 2016 will be utilized to determine technical success and acute survival. All subjects belonging to this cohort must have undergone an attempt to close a post-infarct VSD using the AMPLATZER™ PIVSD Occluder.
89343638|NCT03165526||Second Cohort|"This cohort will consist of subjects over the age of 18 years who have previously been successfully implanted with the PIVSD Occluder and~For living subjects, the subject or subject's legally authorized representative has provided consent to participate in this study.~Subject's post-procedure echocardiogram is evaluable and can be sent to the echocardiography core laboratory for residual shunt assessment.~Therefore, this cohort will be composed of retrospectively enrolled subjects. This cohort will be utilized to determine acute and chronic closure and chronic survival."
89343639|NCT01128101|Experimental|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
89343640|NCT01299337||placebo|Subjects will be randomized either receiving T3 or placebo.
89343641|NCT01299415|Experimental|ASA404 + Fluvoxamine|ASA404 + Fluvoxamine (Core Phase), ASA404 + either paclitaxel or docetaxel or paclitaxel plus carboplain chemotherapy combination (Extension Phase)
89343642|NCT01123967|Experimental|PRO+NRT+TC|Proactive outreach (mailed invitation letter followed by telephone outreach) combined with free nicotine replacement therapy (NRT) and telephone counseling (PRO+NRT+TC)to usual care (UC)
89343643|NCT01123967|Active Comparator|Usual Care (UC)|Usual (standard) care - Smoking cessation products: patch, gum, lozenge, inhaler and nasal spray
89343644|NCT01126463|Experimental|Rhenium Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
89343645|NCT01299493|Experimental|Interventional|Access to systems-level interventions to increase colorectal cancer screening.
89343646|NCT01299493|No Intervention|Usual Care|Practices will receive access to intervention components after outcomes data collection is complete.
89343647|NCT03201640|Other|slideshow|Participant receives traditional slideshow presentation for preoperative preparation
89343648|NCT03201640|Other|virtual|Participant receives virtual reality presentation for preoperative preparation
89343649|NCT01224119|Experimental|Amplex (synthetic bone graft)|
89343650|NCT01224119|Active Comparator|Autograft bone|
89343651|NCT01126697|No Intervention|Enhanced standard of care|
89343652|NCT01126697|Active Comparator|Lisinopril|
89343653|NCT01126697|Active Comparator|Coenzyme Q10|
89343654|NCT01126697|Active Comparator|Coenzyme Q10 and Lisinopril|
89343655|NCT04456114|Experimental|Acid etched brackets|Stainless steel bracket base etched with 10% Hydrofluoric acid for 1 minute
89343656|NCT04456114|Active Comparator|Sandblasted brackets|Stainless steel bracket sandblasted base
89343657|NCT05620147|Experimental|Root canal instrumentation EdgeFile X7 to size #35/0.06|The mechanical preparation will be continued using EdgeFile X7 #35 .04 and #35 .06
89343658|NCT05620147|Experimental|Root canal instrumentation EdgeFile X7 to size #45/0.04|The mechanical preparation will be continued using EdgeFile X7 #35 .04, #40 .04 and #45 .04
89343659|NCT05620147|Experimental|Root canal instrumentation EdgeFile X7 to size #45/0.06|The mechanical preparation will be continued using EdgeFile X7 #35 .04, #40 .04, #45 .04 and #45 .06
89343660|NCT05620147|Active Comparator|Root canal instrumentation EdgeFile X7 to size #35/0.04|The mechanical preparation will be continued using EdgeFile X7 #35 .04
89343661|NCT01220843|Placebo Comparator|Placebo|DOuble blinded, same labels than the active drug same dosage (2 tablets 3 times per day) during the meal
89343662|NCT01220843|Experimental|Sevelamer carbonate|DOuble blinded, dosage 2 tablets 3 times per day corresponding to 4.8/d to taken during meals
89343663|NCT02918890|Experimental|CIMT|Procedure: Constraint-Induced Movement Therapy 90 hours Other Name: CIT, CI Therapy, restraint therapy, PT, OT, rehab
89343664|NCT02918890|Experimental|HABIT|Procedure: Hand-Arm Bimanual Intensive Therapy (HABIT) 90 hours Other Name: HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
89343665|NCT02856646||Population with Condition|Community Sample
89343666|NCT03933995||Mesenchymal stem cell|Long-term follow up of Mesenchymal stem cell group
89343667|NCT02804932|Experimental|Beetroot crystals (nitrate)|Participants will receive a nitrate rich beetroot powder (10g/day) for 8 weeks.
89343668|NCT02804932|Placebo Comparator|Placebo (beetroot powder, no nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 8 weeks.
89343669|NCT02529215|Experimental|Just-in-time training (JITT) group|Receive a 20min just-in-time simulation-based teaching session targeting: (1) CPR quality and (2) medication administration within 3 hours of the scheduled in situ simulation.
89343670|NCT02529215|No Intervention|No additional training (control) group|Control group who receives no additional training.
89343671|NCT01205191|Experimental|CBT-ubiquitous|
89343672|NCT01205191|Placebo Comparator|CBT-placebo|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management
89343673|NCT01205191|Active Comparator|CBT-TAU|Cognitive behavioural Therapy provided 'As Usual'
89343674|NCT03468790|Experimental|CMAB007 + Seretide/Symbicort + Ventolin|CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection ) will be at a fixed dose determined by the subjects' total IgE and weight at V0. All the subjects will be treated subcutaneously for 24 weeks. The 4-week total dose is 0.016mg/kg/IgE(IU/ml), administered every 2 or 4 weeks, for the subjects with total IgE level 60-700IU/ml. If the total IgE level is 700-1500IU/ml, they will be administered 375mg every 2 weeks. Symbicort(Budesonide and formoterol fumarate powder for inhalation) or Seretide (salmeterol xinafoate and fluticasone propionate powder for inhalation) will be used 1/2 inhalations bid as asthma-controlled drug during the whole study. Ventolin (Salbutamol sulphate aerosol) will be used as asthma rescue drug.
89343675|NCT03468790|Placebo Comparator|Placebo + Seretide/Symbicort + Ventolin|Placebo is without active components of the study drug and used as same as the study drug.
89343676|NCT01224197|Experimental|001|TMC435 100 or 200 mg capsule one single dose
89343677|NCT01224197|Experimental|002|TMC435 100 or 200 mg capsule once daily for 5 days
89343678|NCT01844362|Experimental|Uterine transplantation|Patients undergo transplantation of the uterus from live donor.
89343679|NCT01218503|Experimental|CHOICES - obese|behavioral weight loss treatment - overweight/obese females
89343680|NCT01126775||group non-high-risk|
89343681|NCT01126775||group high risk|
89343682|NCT03064750|Experimental|Pre-surgery exercise|pelvic floor exercises individually and in groups
89343683|NCT03064750|Other|Waiting list|wait as usual until surgery
89343684|NCT03740555|Experimental|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose,
89343685|NCT03740555|Placebo Comparator|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose
89343686|NCT03740555|Experimental|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route
89343687|NCT03740555|Placebo Comparator|Placebo, multiple ascending doses|Placebo, multiple ascending doses, Intravenous route,
89343688|NCT01124123|Experimental|Bilastine 20 mg|Single dose 20 mg bilastine oral tablet. Test drug
89343689|NCT01124123|Active Comparator|Bilastine 10 mg|Single dose 10 mg Bilastine endovenous. Control drug
89343690|NCT03721705|Experimental|Treatment Arm|The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.
89343691|NCT03721705|Sham Comparator|Sham Arm|The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.
89343692|NCT01224353|Placebo Comparator|Thioctacid Oral Placebo Tablet|
89343693|NCT01224353|Active Comparator|Thioctacid Oral Tablet|
89343694|NCT05663047|Experimental|Prevent It 2.0|
89343695|NCT05663047|Active Comparator|Waitlist|
89343696|NCT01207297|Active Comparator|TAC group|Oral tacrolimus (0.04-0.08 mg/kg/d) and prednisone for 12 months.
89343697|NCT01207297|Active Comparator|CYC group|Pulse cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day）for 6 months.
89343698|NCT03934151||intracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with intracorporeal technique
89343699|NCT03934151||extracorporeal anastomosis|patients who underwent elective right hemicolectomy whose ileocolic anastomosis was performed with extracorporeal technique
89343700|NCT01300897||Healthy Volunteer|healthy volunteers will serve as controls. In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potentials will be measured.
89343701|NCT01300897||Constipated patients|Patients with chronic constipation and rectal hypersensitivity or hyposensitivity and/or dyssynergic defecation.In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potential will be measured
89343702|NCT03818347|Experimental|oxyhydrogen generator (AMS-H-03)|Model: AMS-H-03 Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively In this group, the patients will inhale hydrogen and oxygen with oxyhydrogen generator. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89343703|NCT03818347|Placebo Comparator|Control|In this group, the patients will inhale normal air with analogue machine. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88806889|NCT04757662|Experimental|Tadalafil|"Tadalafil will be given orally once daily for a total of 60 days at a weight-normalized dose as follows:~10 mg/day if weight ≤63.5 kg~15 mg/day if weight >63.5 kg and ≤104.3 kg~20 mg/day for weight >104.3 kg~Standard of care fractionated radiation therapy (RT) to 60 Gy in 30 daily fractions will be administered in this study.~Concurrent temozolomide (TMZ) will be administered as per standard of care, i.e., continuously (Monday through Sunday) from Day 1 of RT to the last day of RT at a daily oral dose of 75 mg/m^2 at the discretion of treating medical oncologist.~Adjuvant therapy will administered as per standard of care. Typically, this consists of adjuvant TMZ initiated 4 to 6 weeks after completion of RT for 6 cycles at 150-200 mg/m^2 PO per day on Days 1-5 of every 28-day cycle. Tumor-treating fields or Optune device (Novocure) as per routine clinical care during adjuvant TMZ is permitted at the discretion of the treating physician."
88806890|NCT04756050|Experimental|corner pocket|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
88806891|NCT04756050|Experimental|corner+intracluster|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) 10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
88806892|NCT04756050|Experimental|multi|The block will be performed by an experienced anesthesiologist in block applications under USG guidance. After the antisepsis of the area to be blocked, a 22G 50 mm stimulator needle will be used for the block . Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture. 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml) Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
88806893|NCT04748107|No Intervention|Provider preference: Control group|Provider will prescribe blood pressure medication based on his professional expertise.
88806894|NCT04748107|Experimental|ICG directed therapy group|ICG directed therapy will be used to determine which blood pressure medication is received.
88806895|NCT04732143|Experimental|Incentive Spirometry|Participants will undergo inspiratory muscle training using an incentive spirometer daily for 14 days prior to surgery.
88806896|NCT04732143|No Intervention|Standard Care|Participants will not undergo any inspiratory muscle training prior to surgery.
88806897|NCT04731103|Active Comparator|Abacavir (ABC)|Participants receive Abacavir (ABC) for 6 weeks and 4 weeks of washout.
88806898|NCT04731103|Active Comparator|Lamivudine (3TC)|Participants receive Lamivudine (3TC) for 6 weeks and 4 weeks of washout.
88806899|NCT04731103|Active Comparator|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Participants receive Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) for 6 weeks and 4 weeks of washout.
88806900|NCT04716712|Active Comparator|Biannual mass oral azithromycin + child health days|Bi-annual Mass Azithromycin distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform
88806901|NCT04716712|Placebo Comparator|Biannual mass placebo + child health days|Bi-annual Mass placebo distribution to all children 1-11 months old in participating communities paired with the Child Health Days Vitamin A distribution platform
88806902|NCT04716712|Active Comparator|Resistance Sub Study: Azithromycin + Child Health Days|Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion
88806903|NCT04716712|Placebo Comparator|Resistance Sub Study: Placebo + Child Health Days|Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion
88806904|NCT04709562|Experimental|High Velocity Nasal Insufflation (HVNI)|Patients randomly assigned to this arm will be placed on HVNI therapy with an appropriately fitted Vapotherm Prosoft HVNI nasal cannula. Physiologic and ventilation parameters will be recorded.
88806905|NCT04709562|Active Comparator|Noninvasive Positive Pressure Ventilation (NIPPV)|Patients randomly assigned to this arm will be placed on NIPPV therapy with an appropriately fitted full face mask using a pressure support mechanical ventilator system. Physiologic and ventilation parameters will be recorded.
88806906|NCT04700553|Experimental|Conventional physical therapy intervention plus localized muscle vibration|physical therapy intervention plus localized muscle vibration
88806907|NCT04700553|Sham Comparator|Conventional physical therapy intervention|physical therapy intervention
88806908|NCT04699539|Experimental|Arm A|GTV uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel or S-1.
88806909|NCT04699539|Experimental|Arm B|GTV non-uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel or S-1.
88806910|NCT04697849|Experimental|CREST|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
88811803|NCT00865202|Experimental|L-Tryptophan|L-tryptophan supplementation (1 gram enterally three times per day) starting post-operatively and continuing for a maximum of 9 doses or the time of discharge from ICU (whichever occurs first)
89343704|NCT01220921|Experimental|Lumbar Microdiscectomy|Patients aged 18-80 with symptomatic lumbar disc herniation resulting in single nerve root compression recalcitrant to non-invasive therapies for at least 6 weeks
89343705|NCT01220921|Experimental|Single-Level Lumbar Fusion|Patients aged 18-80 with symptomatic grade I degenerative or isthmic spondylolisthesis with mechanical back pain with or without radiculopathy recalcitrant to non-invasive therapies for at least 3 months
89343706|NCT03932435|Experimental|TWLO_C → TWLO|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
89343707|NCT03932435|Experimental|TWLO → TWLO_C|"TWLO_C: Dong-a Bepotastine Besilate Tab (Bepotastine Besilate 10mg), TWLO: Twolion Tab (Bepotastine Besilate 10mg)"
89343708|NCT03720847|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
89343709|NCT03720847|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
89343710|NCT01128257||1|
89343711|NCT01128257||2|
89343712|NCT01205347|Experimental|Simvastatin 80mg|Simvastatin 80mg once a day
89343713|NCT01205347|Active Comparator|Simvastatin 10mg|Simvastatin 10mg once a day
89343714|NCT01218737|Experimental|Association|0.3% gatifloxacin and 1.0% prednisolone acetate association in eye drops plus placebo
89343715|NCT01218737|Active Comparator|Isolated ingredients|0.3% gatifloxacin and 1.0% prednisolone acetate isolated eye drops formulations
89343716|NCT03818113||HTK-Bretschneider cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with HTK-Bretschneider cardioplegic solution
89343717|NCT03818113||St. Thomas cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with St. Thomas cardioplegic solution
89343718|NCT03933917|Experimental|Large Volume Acute Normovolemic Hemodilution|All the participants will undergo Large Volume Acute Normovolemic Hemodilution.
89343719|NCT03818269|Other|Septic shock|
89343720|NCT03818269|Other|Control|
89343721|NCT01224509|Experimental|Mifepristone|
89343722|NCT01224509|Active Comparator|Non-treatment|
89343723|NCT01329107|No Intervention|No intervention|Standard Care
89343724|NCT01329107|Experimental|Multimodal intervention|Intervention group will be assigned to specific decribed multimodal intervention
89343725|NCT01297231||Breast cancer|This prospective study will recruit patients with stage 0-3 breast cancer who have had or are scheduled for a breast MRI prior to treatment.
89343726|NCT03932513|Experimental|Treatment A: inarigivir soproxil|Inarigivir 400 mg once per day for 6 weeks (2800mg/week).
89343727|NCT03932513|Experimental|Treatment B: inarigivir soproxil|Inarigivir 400 mg three times per week for 6 weeks (1200mg/week).
89343728|NCT01300975|Experimental|Intralesional antimony|3 intralesional injections of antimony at D1, D3 and D7
89343729|NCT01300975|Active Comparator|Cryotherapy|Liquid nitrogen until freezing at DF1 and D14
89343730|NCT01300975|Placebo Comparator|Topical cream|topical treatment 3 times a day during 21 days with an emollient cream
89343731|NCT05623813||Individual-based education|Participants in the individual-based education would receive tailored education on sternal precautions to facilitate engagement in daily activities.
89343732|NCT05623813||Group-based education|"Participants in the group-based education would receive the same education on sternal precautions to facilitate engagement in daily activities.The group-based education included between two and five participants.~They were invited to ask questions about their recovery and voice any concerns they had about being discharged home specific to their needs, covering a tailored portion of the education. Participants in group-based education had a chance to share their experiences and concerns with the group members."
89343733|NCT01221467|Active Comparator|Overnight closed-loop combined with real-time CGM|
89343734|NCT01221467|Active Comparator|Real-time CGM alone|
89343735|NCT01297387||Revascularization of limb ischemia|Procedure/Surgery
89343736|NCT01124201|Experimental|Stabilization group|In the Segmental Stabilization group exercises focused on the transversus abdominis and lumbar multifidus muscles.
89343737|NCT01124201|Experimental|Strengthening group|In the Superficial Strengthening group, exercises focused on the rectus abdominis, abdominus obliquus internus, abdominus obliquus externus and erector spinae muscles.
89343738|NCT01124201|Experimental|Stretching group|Stretching group: erector spinae, posterior connective tissues and ischiotibials muscles
89343739|NCT01301053|Other|Current UVA intensive care insulin protocol without brakes|Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days and uses the current UVA intensive care insulin for insulin management for 12 hours.
89343740|NCT01301053|Active Comparator|Current UVA intensive care insulin protocol with brakes|"Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days. Uses the current UVA intensive care insulin protocol for insulin management for 12 hours with the addition of brakes that reduce insulin administration based on continuous glucose monitoring data between hourly reference glucose data."
89343741|NCT01299649||Non-contrast echocardiography|Non-contrast echocardiography
89343742|NCT01299649||Contrast Echocardiography|Contrast Echocardiography
88811804|NCT00865202|Placebo Comparator|Placebo|Similar appearing placebo administered post-operatively (1 enterally three times per day) for a total of nine doses or discharge from ICU (whichever occurs first)
89343743|NCT03932747|Placebo Comparator|Placebo Creams|Measuring the skin before the application of the cream without urea (placebo), wait 3 hours and re-measure the hydration
89343744|NCT03932747|Active Comparator|Urea 5%|Measuring the skin before the application of the cream with urea (5%), wait 3 hours and re-measure the hydration
89343745|NCT03932747|Active Comparator|Urea 20%|Measuring the skin before the application of the cream with urea (20%), wait 3 hours and re-measure the hydration
89343746|NCT01297621|Experimental|Breast reduction|Breast hypertrophy women allocated to this arm will undergo reduction mammaplasty
89343747|NCT01297621|Other|Control|Patients in this arm will be assessed twice, without surgical intervention
89343748|NCT01224587|Experimental|1|D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition
89343749|NCT01224587|Experimental|2|D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition
89343750|NCT01224587|Experimental|3|D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition
89343751|NCT01224587|Experimental|4|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition
89343752|NCT01224587|Experimental|5|D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition
89343753|NCT01224587|Experimental|6|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition
89343754|NCT01301131|Experimental|Probiotic|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
89343755|NCT01301131|No Intervention|control|
89343756|NCT01221545|Experimental|A - AZD1656|AZD1656
89343757|NCT01221545|Placebo Comparator|B - Placebo|Placebo
89343758|NCT01218581|Active Comparator|group A|Group A received oral letrozole (2.5 mg/day, Femara, Novartis PharmaServices, Basel, Switzerland)
89343759|NCT01218581|Active Comparator|group B|group B received goserelin subcutaneosly (3.6 mg/month, Zoladex@, Zeneka Pharma International, UK)
89343760|NCT01124279|Experimental|AMG 853|
89343761|NCT01205425|Experimental|CT|Procedure of stent implantation will be planed on the basis of both angiography and computed tomography results.
89343762|NCT01205425|Active Comparator|Angio|Procedure of stent implantation will be planned only on the basis of diagnostic coronary angiography.
89343763|NCT03930719||PSD|Patients fulfilling DSM-5 criteria of PSD within 7 days of admission.
89343764|NCT03930719||No PSD|Patients NOT fulfilling DSM-5 criteria of PSD within 7 days of admission.
89343765|NCT01126853|Experimental|Vaccination|Receipt of up to 3 series of double dose combination hepatitis A/B vaccine (Twinrix)
89343766|NCT03824821||IBS|
89343767|NCT03825133|Experimental|Bone Marrow Aspirate Concentrate|Patients treated with single injection of BMAC in the knee
89343768|NCT03825133|Experimental|Leukocyte Rich Platelet Rich Plasma|Patients treated with single injection of LR-PRP in the knee
89343769|NCT03825133|Experimental|Hyaluronic Acid|Patients treated with 3 single injection of high molecular HA in the knee ( one injection weekly)
89343770|NCT01224743|Placebo Comparator|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
89343771|NCT01224743|Experimental|Blend 2|Blend 2 - combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
89343772|NCT01224743|Experimental|Blend 1|Blend 1 - combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
89343773|NCT03817567|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|6.0mg/kg QW for 6 weeks, then 8.0mg/kg Q2W
89343774|NCT03932591|Experimental|intervention|Inhibitory kinesio taping method will be used for intervention group. Y shaped, 34-40 cm length, 5 cm width, skin color kinesio tape will be applied on spastic gastrocsoleus muscle. The base of Y shaped tape will be strapped on calcaneus ( no stretch for first 5 cm) and the both legs of Y shaped tape will be strapped on gastrocnemius muscle medial and lateral head with 15% stretch.
89343775|NCT03932591|Sham Comparator|Control|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be applied on achilles tendon without stretch.
89343776|NCT01301209||treatment|patients undergoing treatment
89343777|NCT01127009|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11; and mitoxantrone IV, etoposide IV over 1 hour, and intermediate-dose cytarabine IV over 6 hours on days 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.
89343778|NCT03817411|Active Comparator|Telatinib+Capecitabine+Oxaliplatin|Patients receive Telatinib orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
89343779|NCT03817411|Placebo Comparator|Placebos+Capecitabine+Oxaliplatin|Patients receive placebo orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
89343780|NCT03817645|Experimental|Panaceo MED|Zeolite, Medicinal product, class IIa for oral intake, daily intake of 2 sachets (3 g), for 3 months.
89343781|NCT03817645|Placebo Comparator|Control|Micro crystalline cellulose daily intake of 2 sachets (3 g), for 3 months.
89343782|NCT01218815|Experimental|Culprit lesion IRA Revascularization|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
89343783|NCT01218815|Active Comparator|Complete IRA revascularization|Primary PCI of culprit lesion in IRA with DES stent
89343784|NCT01205737|Experimental|TL011|
89343785|NCT01205737|Active Comparator|MabThera®|
89343786|NCT01124357|Active Comparator|novasure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
89343787|NCT01124357|Other|thermachoice|ThermachoiceTM III thermal balloon ablation
89343788|NCT03934073|Experimental|DEXTRAIN|The DexTrain group sessions will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting dexterity components.
89343789|NCT03934073|Active Comparator|CONVENTIONNELLE|Conventional training involving stretching of the spastic muscles as well as a set of exercises conventionally used in the protocols of post-stroke rehabilitation (repeated movements, manipulation of objects).
89343790|NCT03934073|Other|CONTROLE|To compare the results of SMT and functional MRI.
89343791|NCT03817723||Specialist surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy. C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
89343792|NCT03817723||Resident surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy.C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
89343793|NCT01218893|Active Comparator|15-15-15|This group will receive three times 15 infected mosquito bites under chloroquine prophylaxis, as we know that this dose is protective.
89343794|NCT01218893|Experimental|10-10-10|This group will receive three times 10 infected and 5 uninfected mosquito bites under chloroquine prophylaxis.
89343795|NCT01218893|Experimental|5-5-5|This group will receive three times 5 infected and 10 uninfected mosquitobites under chloroquine prophylaxis.
89343796|NCT01218893|Placebo Comparator|0-0-0|This group will receive three times 15 uninfected mosquitobites under prophylaxis.
89343797|NCT01297699|Experimental|Tocilizumab|
89343798|NCT01297699|Placebo Comparator|Sterile 0.9% Sodium Chloride|
88806911|NCT04697849|Active Comparator|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
88811805|NCT01424033|Experimental|N-Acetylcysteine|This is an open label trial, all patient will be entered into one treatment arm.
88811806|NCT01503749|No Intervention|Control|Three patients with liver cirrhosis of this arm will not receive any intervention regarding to peripheral blood mononucleated cells.
89343799|NCT03930407||Hayman group|Who had undergone cesarean section within the last 6 months and received a The Hayman uterine compression suture for uterine atony.
89343800|NCT03930407||Control|Who had undergone cesarean section within the last 6 months and did not experience neither any complication nor any additional intervention
89343801|NCT01301287|Experimental|Chlorella|
89343802|NCT01224899|Experimental|Surgery|
89343803|NCT01224899|No Intervention|Control|
89343804|NCT03824119|Active Comparator|Standard Postpartum Care|Subjects will receive NSAIDs (e.g. ibuprofen, ketorolac) for routine postpartum pain management.
89343805|NCT03824119|Active Comparator|Standard Postpartum Care without NSAIDs|Subjects will receive standard postpartum care without NSAID administration for pain management. Acetaminophen or narcotics will be substituted for ibuprofen as indicated by provider.
89343806|NCT01221701|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus one booster session scheduled 1 month later.
89343807|NCT01221701|No Intervention|typical home visitation|Standard of care in home visitation in which mothers can receive treatment in the community if they choose.
89343808|NCT03824509||Patients with an echocardiagram who suffered a stroke or TIA|"Medical record number~Sex~Age~BMI~Body surface area~Smoking status~Congestive heart failure~Hypertension~Diabetes,~Previous history of heart attack or vascular disease~Previous history of stroke~Date of stroke~Type of stroke~CHA2DS2-VASc scores~On an anticoagulant yes/no at time of stroke~Date of atrial fibrillation diagnosis~Date of echocardiogram~Echocardiographic features:~a. Left atrial volume, indexed to body surface area (BSA) b. Left ventricular hypertrophy 4. Stroke outcome:~Mortality~NIH Stroke Scale~Modified Rankin Scale~Discharge placement:~i. Home ii. Long term care iii. Skilled nursing facility e. 6-month survival"
89343809|NCT03824509||Control Group - matched CHA2DS2-VASc score, age, and gender|"Controls from both PBMC and MMC will be obtained. Controls are patients from 2014-2017 with matched age (+/- 5 years), gender, and CHA2DS2-VASc score who had atrial fibrillation and had not had a documented stroke or TIA in EPIC or the Get with the Guidelines registry maintained at PBMC. Controls must have an echocardiogram on record and have a diagnosis of atrial fibrillation at the time of the echocardiogram."
89343810|NCT03930563|Experimental|Beetroot Juice Low|Subjects will consume beetroot juice containing 250mg inorganic nitrate and 20mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
89343811|NCT03930563|Experimental|Beetroot Juice High|Subjects will consume beetroot juice containing 500mg inorganic nitrate and 40mg nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
89343812|NCT03930563|Active Comparator|Beetroot Juice Placebo|Subjects will consume beetroot juice devoid of inorganic nitrate and nitrite dissolved in 120ml bottled water. Peripheral chemoreflex sensitivity as well as common carotid artery blood flow will be assessed before and after supplementation.
89343813|NCT03823417|Placebo Comparator|Normal saline placebo|the participant will get saline 0.9% intravenous infusion for the duration of the surgery
89343814|NCT03823417|Experimental|Intravenous Tranexamic acid|Intravenous TXA will be given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
89343815|NCT01129037|Other|Goal directed fluid management|
89343816|NCT01297777|Experimental|Imatinib mesylate|Imatinib mesylate 300 or 400 mg daily for 12 months.
89343817|NCT03817489|Experimental|Intervention: Baduanjin qigong|This arm of participants will be receiving the Baduajin qigong intervention.
89343818|NCT03817489|Experimental|Intervention: Mindfulness meditation|This arm of participants will be receiving the Mindfulness meditation intervention.
89343819|NCT03817489|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a Wait-list Control group.
89343820|NCT01224977|Other|azithromycin|
89343821|NCT03830437||Case group|The group will be subjected to double weighing, before and after the next 6 breastfeeding. Breastfeeding will be carried out each 4 hr.
89343822|NCT03830437||Control group|The group will be subjected to monitoring of body weight only at 24, 36 hr and 48 hr of life.
89343823|NCT03930329|Experimental|MBRP group|The mindfulness-based relapse prevention program consists of eight weekly 2-hour sessions. It combines mindfulness with evidence-based cognitive behavioural techniques that help participants to recognize internal and external triggers of their substance abuse, including smoking. Each session consists of mindful practices with cognitive exercises. The standardized treatment manual was published
89343824|NCT03930329|No Intervention|usual care|All participants in this trial will receive usual care, which consists of 8-12 weeks of counselling and drug treatment to help smokers quit. Data from the centre shows that approximately 50% of smokers are successfully abstinent from smoking at end of the program, as confirmed by the carbon monoxide breath test. This trial will only recruit those who successfully quitted smoking. During this 8-12 week program, written information about relapse prevention is given, including information for maintaining healthy lifestyles (e.g. diet/sleep/exercise/emotional control). Participants will receive follow-up phone interviews by trained smoking cessation counsellors at end of the program (week 8-12)
89343825|NCT01205893|Experimental|Reducer|Implant Reducer
89343826|NCT01205893|Sham Comparator|Control|No treatment
89343827|NCT01226069|Active Comparator|Glycerine Magnesium Sulphate paste|
89343828|NCT01226069|Active Comparator|Hirudoid cream|Topical Mucopolysaccharide polysulphate
89343829|NCT01226069|Experimental|No application|Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms.
89343830|NCT01205971|Experimental|Motivational Interviewing|Motivational Interviewing to reduce caregiver risk factors for early childhood caries in their children is delivered by Dental Health Advocates (trained public housing residents) in combination with fluoride varnish applications, oral health assessments and referrals for children.
89343831|NCT01205971|Active Comparator|Dental Preventive Services|Fluoride varnish applications, written oral health educational materials regarding early childhood caries prevention, oral health assessments and referrals.
89343832|NCT03928691||Study group|pregnant women admitted to Women's Health Hospital , Assiut university during 2019-2020 will be counseled to participate in the study
89343833|NCT01299883|Active Comparator|Cancer and CVD Education|Participants receive education about both cancer and CVD risk factors and their relationship to dietary and physical activity health behaviors.
89343834|NCT01299883|Active Comparator|CVD Education|Participants receive education about CVD risk factors and their relationship to dietary and physical activity health behaviors.
89343835|NCT03823027|Experimental|Single-arm|The device will be taken before three daily main meals togteher with water. The dose will be escalated from 1g per main meal to the full dose of 3g per main meal. The device is provided in foil stick-packs packed in boxes with weekly supply. The treatment is for 12 weeks.
89343836|NCT01127243|Active Comparator|inpatient LSH|LSH means laparoscopic supracervical hysterectomy
89343837|NCT01127243|Experimental|Day-case LSH|LSH means laparoscopic supracervical hysterectomy
89343838|NCT01297855|Active Comparator|Colistin|Colistate
89343839|NCT01297855|Experimental|Colistin plus Rifampicin|Colistate Rifampin
89343840|NCT01221779|Placebo Comparator|sham tDCS|
89343841|NCT01221779|Experimental|anodal tDCS|
89343842|NCT03817099|Experimental|My Dia-RNP|In the My Dia-RNP group, participants will undergo the pre-RNP assessment 2 weeks before Ramadan. They will be given a nutrition education based on the Ramadan Nutrition Plan Guide published by IDF-DAR Practical Guidelines. They will also be asked to incorporate diabetes-specific nutrition formula (Nutren untuk Diabetik®) within the prescribed calories before Ramadan period to help them familiarise with a dietary change.
89343843|NCT03817099|Active Comparator|Usual Care|Participant in this group will continue in a usual care (UC) group. They will receive dietary advice based on the Practical Guide to Diabetes Management in Ramadan produced by Ministry of Health (2015).
89343844|NCT03740477|Experimental|Intrevention|Eligible participants will receive a 30-second smartphone-based ECG
89343845|NCT03930173|Experimental|18F-fluciclovine PET/CT of the brain|"Arm includes participants with a known diagnosis of brain metastases who have undergone prior intracranial SRS and whose MRI brain scan is equivocal for radiation necrosis versus tumor progression.~Participants will undergo 18F-fluciclovine PET/CT of the brain. Qualitative and quantitative metrics will be documented at the time of image acquisition. Qualitative image assessment will be performed independently by 3 separate physicians."
89343846|NCT02631070|Experimental|Experimental Arm - Luspatercept (ACE-536)|Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks
89343847|NCT02631070|Placebo Comparator|Control Arm: Placebo|Subcutaneous injection every 3 weeks
89343848|NCT03817177|Placebo Comparator|nasal prong|conventional nasal prong application after the surgery in postanesthetic care unit (PACU)
89343849|NCT03817177|Experimental|high flow nasal cannula oxygenation|high flow nasal cannula application after the surgery in postanesthetic care unit (PACU)
89343850|NCT01225133|Active Comparator|Complex Ayurvedic Treatment|In the Āyurveda arm treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
88806912|NCT04690777|Experimental|VESTIBULAR EXERCISE at home telerehabilitation|"1. The vestibular exercises were performed with the indications of a physical therapist, in sessions of about 20 minutes with 5 times per week (Monday to Friday) consisting of 5 repetitions ensuring the following were not overworked:~Head and eye movements while sitting.~Head and body movements while sitting.~Paused exercises.~Combined exercises of modifications on rungs, unstable surfaces and walking exercises."
88806913|NCT04690777|Experimental|MULTICOMPONENT EXERCISE at home telerehabilitaion|"1. A 6-week multi-component therapeutic physical exercise program was carried out. The ministerial guide and the Vivifrail consensus was followed (25, 26). There were 5 daily sessions per week (Monday to Friday), each lasting approximately 45 minutes. These sessions were conducted following the instructions of a physical therapist. VIVIFRAIL exercises are intended to be used over a progression period of up to 12 weeks, with combined exercises by days in cardiovascular aerobic balance strength and flexibility."
88806914|NCT04690777|Experimental|VESTIBULAR EXERCISE in clinic|"1. The vestibular exercises were performed with the indications of a physical therapist, in sessions of about 20 minutes with 5 times per week (Monday to Friday) consisting of 5 repetitions ensuring the following were not overworked:~Head and eye movements while sitting.~Head and body movements while sitting.~Paused exercises.~Combined exercises of modifications on rungs, unstable surfaces and walking exercises."
88806915|NCT04690777|Experimental|multi component exercise in clinic|"1. A 6-week multi-component therapeutic physical exercise program was carried out. The ministerial guide and the Vivifrail consensus was followed (25, 26). There were 5 daily sessions per week (Monday to Friday), each lasting approximately 45 minutes. These sessions were conducted following the instructions of a physical therapist. VIVIFRAIL exercises are intended to be used over a progression period of up to 12 weeks, with combined exercises by days in cardiovascular aerobic balance strength and flexibility."
88806916|NCT04683640|Experimental|Daily Oral GABA|You will take, by mouth, 2 pills of GABA (500 mg) (Capsule 250mg) daily at home for 4 weeks
88806917|NCT04683640|Placebo Comparator|Daily Placebo|You will take, by mouth, 2 pills of Placebo daily at home for 4 weeks
88806918|NCT04680221|Active Comparator|Treatment|The transversus abdominis plane block is a procedure involving injection of a local anesthetic solution into the abdominal plane between the internal oblique muscle and the transversus abdominis muscle. In our institution, this is done under ultrasound guidance which is the current standard to improve efficacy and limit complications. Liposomal bupivacaine uses an innovative technology consisting of lipid-based particles containing active pharmaceutical agent (bupivacaine) which extends the duration of the medication through a process of gradual release for metabolism.This drug delivery technology extends the duration of action to up to 96 hours when given at a dose of 266 mg liposomal bupivacaine admixed with 30 ml of bupivacaine 0.25% and 30 ml of saline. Forty ml of solution is deposited on the left side of the abdomen and 40 ml on the right.
88806919|NCT04680221|Placebo Comparator|Control|The transversus abdominis plane block will be performed under ultrasound guidance with deposition of 80 ml of saline (40 ml on either side).
88806920|NCT04676607|Experimental|treatment group|SHR7390
88806921|NCT04662060|Experimental|Acebilustat|Participants are randomized to receive acebilustat for 28 days.
88806922|NCT04662060|Placebo Comparator|Matching Placebo|Participants are randomized to receive placebo to match acebilustat for 28 days.
88806923|NCT04649190||TAVI|
88806924|NCT04644796|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
88806925|NCT04644796|Active Comparator|Liposomal bupivacaine|Patients in this group will be given the study drug (liposomal bupivacaine).
88806926|NCT04643340||active group 1|This group will train the insular cortex by real-time fMRI
88806927|NCT04643340||active group 2|This group will train the visual cortex by real-time fMRI
88806928|NCT04643340||sham|This group will only train the insula by a particular strategy
88806929|NCT04621929|Experimental|Allocated to intervention/treatment|Daily phentermine/topiramate x 18 months
88806930|NCT04621929|Active Comparator|Allocated to pragmatic control|Remain on their current regimen
88806931|NCT04618432||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed head and neck or communication disorder.
88806932|NCT04612491||Pre-operative Consultation|
88806933|NCT04612491||No consultation|
88806934|NCT04596553|Active Comparator|Essential Amino Acid|Participants will consume 1 dose of: 15 g crystalline essential amino acid supplement (Pure Encapsulation Essential Aminos 180) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
88806935|NCT04596553|Active Comparator|Collagen Peptide|Participants will consume 1 dose of: 15g collagen peptide (Gelita TENDOFORTE) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
88806936|NCT04596553|Placebo Comparator|Maltodextrin Placebo|Participants will consume 1 dose of:15 g maltodextrin (Canadian Protein Maltodextrin) + 80 ml (48 mg) Vitamin C (Ribena Blackcurrant) + 250 ml water
88806937|NCT04582279|Experimental|Receiving Ultrasound|Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.
88806938|NCT04572763|Experimental|Dose Escalation Copanlisib + Venetoclax|"Phase 1~Dose escalation will occur using a 3+3 design~Copanlisib will be administered IV on days 1, 8 and 15 in 28 day cycle~Venetoclax will be administered orally daily for each 28-day cycle. During cycle 1, a venetoclax dose ramp-up is performed in the outpatient setting"
88806939|NCT04572763|Experimental|Recommended phase II dose (RP2D) Copanlisib + Venetoclax|Patients will be treated with copanlisib in combination with venetoclax, administered at the Recommended phase II dose (RP2D).
88806940|NCT04556981|Experimental|M72/AS01E vaccine|
88806941|NCT04556981|Placebo Comparator|Placebo|
88806942|NCT04556370|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
88806943|NCT04556370|Experimental|0.025 μg/kg/min group|A maintenance dose of norepinephrine (0.025 μg/kg/min) infusion simultaneous with subarachnoid block
88806944|NCT04556370|Experimental|0.050 μg/kg/min group|A maintenance dose of norepinephrine (0.050 μg/kg/min) infusion simultaneous with subarachnoid block
88806945|NCT04556370|Experimental|0.075 μg/kg/min group|A maintenance dose of norepinephrine (0.075 μg/kg/min) infusion simultaneous with subarachnoid block
88806946|NCT04535687|Experimental|Treatment group|Fluzoparib alone
88806947|NCT04527887|Active Comparator|Dextenza (IDI) (Sustained Release Dexamethasone, (0.4 mg)|intracanalicular dexamethasone insert
89343851|NCT01225133|Active Comparator|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
89343852|NCT01127399||Bariatric, nonasthma|Participants that will have had a bariatric surgery but do not have asthma.
89343853|NCT01127399||Bariatric, asthma|Participants that will have had a bariatric surgery and have been physician diagnosed with asthma prior to the surgery.
89343854|NCT01127399||Control, nonasthma|Healthy participants that who will not be getting a bariatric surgery and who do not have asthma.
89343855|NCT01127399||Control, asthma|Healthy participants that will not be having a bariatric surgery but do have asthma.
89343856|NCT03930095|Experimental|Acceptance-Based Behavior Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
89343857|NCT03930095|Active Comparator|Non-directive Supportive Therapy|10 sessions of a two-hour group therapy with 12 participants during 14 weeks
89343858|NCT01298011|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|
89343859|NCT03816943|No Intervention|Control|control group with no intervention
89343860|NCT03816943|Experimental|Whatsapp|intervention group receiving a Whatsapp instant text message with encouraging words after bond up of fixed appliances
89343861|NCT03816943|Experimental|Call|intervention group receiving a phone cal with encouraging words after bond up of fixed appliances
89343862|NCT01300039||Antibiotics for H. pylori|Patients who underwent upper endoscopy and were found to have H. pylori, and were then to be treated with antibiotics for eradication of H. pylori
89343863|NCT01300039||Control group, no H. pylori|Patients who underwent upper endoscopy and found to not have H. pylori, and then would not receive antibiotics
89343864|NCT01221935||Patients initiated on Pristiq as a first line treatment|
89343865|NCT01221935||Patients initiated on Pristiq as a 2nd-line treatment|
89343866|NCT01221935||Patients initiated on a SNRI or SSRI as a first-line treatment|
89343867|NCT01221935||Patients initiated on a SNRI or SSRI as a 2nd-line treatment|
89343868|NCT05143918||Hypothyroid patients as a cases|"Inclusion criteria:~age ranges will be 18 - 60 years~both genders~previously confirmed diagnosed~Exclusion criteria:~pregnancy~other comorbidities (hypertension, diabetes, malignancy,,,etc)"
89343869|NCT05143918||Control group|Healthy people without chronic disease
89343870|NCT01300117||with extracorporeal circulation|Patients undergoing cardiac surgery with the use of an extracorporeal circulation
89343871|NCT01300117||without extracorporeal circulation|Patients undergoing cardiac surgery without the use of extracorporeal circulation (OPCAB)
89343872|NCT01226225|Experimental|Aerobic interval training|
89343873|NCT01226225|Active Comparator|Moderate endurance training|
89343874|NCT05137678|Experimental|Experimental group|Glibenclamide was given orally or through nasogastric tube, 1.25 mg every 8 hours for 7 days
89343875|NCT05137678|No Intervention|Control group|No glibenclamide treatment
89343876|NCT01226303|Experimental|standard risk|are defined as those patients with a WBC less than 10x10 9 /L at presentation
89343877|NCT01226303|Active Comparator|high risk|are defined as those patients whose highest treatment WBC is equal to or greater than 10x10 9 /L at presentation
89343878|NCT03814759|Experimental|SP+CCRT|S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5) radiation 45Gy per 5 weeks
89343879|NCT03929861|Experimental|Fluconazole, period 1|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 1 after an overnight fast of at least 10 hours
89343880|NCT03929861|Experimental|Fluconazole, period 2|Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 2 after an overnight fast of at least 10 hours
89343881|NCT03821623|Experimental|Nicotinamide riboside|Subjects will take 500 mg of the vitamin B3-precursor, nicotinamide riboside (NIAGEN) twice per day (1,000 mg per day total) for 3 months.
89343882|NCT03821623|Placebo Comparator|Placebo|Subjects will take placebo pills twice a day for 3 months.
89343883|NCT05010694|Experimental|Monotherapy Dose Escalation.|Treatment with GH35 alone, conducted until disease progression, intolerance or end of study.
89343884|NCT01225367||pulmonary doppler|
89343885|NCT04878640|Active Comparator|Group A|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
89343886|NCT04878640|Active Comparator|Group B|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
89343887|NCT03820999|Experimental|Teaching arm|The Primary Health Care physicians getting oral and written information on tick-bites and Lyme disease with focus on Lyme neuroborreliosis.
89343888|NCT03820999|No Intervention|Passive arm|The Primary Health Care physicians that does not get contacted with an offer to receive oral and written information.
89343889|NCT03928145|Experimental|Chlorthalidone 25 mg + amiloride 20 mg|Chlorthalidone 25 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
89343890|NCT03928145|Active Comparator|Chlorthalidone 25 mg + amiloride 10 mg|Chlorthalidone 25 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
88806948|NCT04527887|Placebo Comparator|ProLong™ collagen plugs|collagen plug
89343891|NCT03928145|Active Comparator|Hydrochlorothiazide 50 mg + amiloride 20 mg|Hydrochlorothiazide 50 mg plus amiloride 20 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
89343892|NCT03928145|Active Comparator|Hydrochlorothiazide 50 mg + amiloride 10 mg|Hydrochlorothiazide 50 mg plus amiloride 10 mg combined in a single capsule, taken orally in the morning, for 12 weeks.
89343893|NCT01300195||lung cancer surgery|Patients undergoing video-assisted thoracic surgery
89343894|NCT03928535|Other|High-Flow Nasal Cannula|High-flow oxygen was applied immediately after extubation through specific nasal cannula.
89343895|NCT03928535|Other|Noninvasive Ventilation|Noninvasive Ventilation was applied immediately after extubation.
89523600|NCT03385603|Experimental|Fear-based Dilator Progression group|Participants in this group will complete a home dilator program using levels of pain-related fear to progress through the program.
89343896|NCT03819907|No Intervention|Control|"15 participants will be randomly assigned to the control group. They will receive no intervention other than the injection (which is not a part of the trial).~Pre-injection they will receive all baseline measures and questionnaires. Post injection they will receive the primary outcome measures: 1) Numeric Pain Rating Scale and 2) Anxiety thermometer"
89343897|NCT03819907|Active Comparator|Audiovisual (AV) Guided Relaxation|Combination Product: Audiovisual Guided Relaxation Five-minute guided relaxation delivered via a computer screen and speakers
89343898|NCT03819907|Experimental|Virtual Reality (VR) Guided Relaxation|"Combination Product: Virtual Reality Guided Relaxation Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.~Other Names:~• Samsung Galaxy 7s/Samsung adaptable VR headset"
89343899|NCT01129193|Experimental|Arm I (Hematologic Malignancies)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
89343900|NCT01129193|Experimental|Arm II (Solid Tumors)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
89343901|NCT03817255|Experimental|Substance use|In this screening intervention, participants complete a substance use questionnaire (=intervention).
89343902|NCT03817255|Active Comparator|Physical activity|In this screening control condition, participants complete a physical activity questionnaire (=control).
89343903|NCT01129271|Experimental|Group clopidogrel fed - fasting|"Period 1:~Day 1: clopidogrel 300 mg loading dose with high fat breakfast~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily"
88811807|NCT01503749|Active Comparator|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm.
89343904|NCT01129271|Placebo Comparator|Group placebo fed - fasting|"Period 1:~Day 1: placebo loading dose with high fat breakfast~Day 2 to Day 5: placebo with standard breakfast, once daily~Period 2:~Day 1: placebo loading dose under fasted conditions~Day 2 to Day 5: placebo under fasted conditions, once daily"
89343905|NCT01129271|Experimental|Group clopidogrel fasting - fed|"Period 1:~Day 1: clopidogrel 300 mg loading dose under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose with high fat breakfast~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily"
89343906|NCT01129271|Placebo Comparator|group placebo fasting -fed|"Period 1:~Day 1: placebo loading dose under fasted conditions~Day 2 to Day 5: placebo in fasted conditions, once daily~Period 2:~Day 1: placebo loading dose with high fat breakfast~Day 2 to Day 5: placebo with standard breakfast, once daily"
89343907|NCT03816631|Experimental|Part A: Group 1: Severe hepatic function|Participants with severe hepatic function will receive single oral dose of pimodivir 600 milligram (mg) (2*300 mg tablet) under fasted condition on Day 1.
89343908|NCT03816631|Experimental|Part A and B: Group 2: Normal hepatic function|Participants with normal hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
89343909|NCT03816631|Experimental|Part B: Group 3: Moderate hepatic function|Participants with moderate hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
89343910|NCT03816631|Experimental|Part B: Group 4: Mild hepatic function|Participants with mild hepatic function will receive single oral dose of Pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
89343911|NCT01129349|Experimental|Oprozomib|Phase I, Dose Escalation, Single Arm, Open Label
89343912|NCT01222013|Experimental|Imatinib Mesylate|
89343913|NCT01131143|Experimental|Treatment Group 1|Patients will receive a pre-visit, post-referral and post-contact phone call using providers voice
89343914|NCT01131143|Experimental|Treatment Group 2|Patients will receive a previsit, post-referral and post-contact call using a generic voice
89343915|NCT01131143|No Intervention|Treatment Group 3|Patients will be provided usual care with no additional phone calls.
89343916|NCT03816475|Experimental|Hypofractionated radiotherapy|5x5 Gy radiotherapy and delayed surgery (after 6-8 weeks)
89343917|NCT05362045|Experimental|Mavacamten- Dose A|
89343918|NCT05362045|Experimental|Mavacamten- Dose B|
89343919|NCT00741988|Experimental|Cohort A|ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
89343920|NCT00741988|Experimental|Cohort B|ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
89343921|NCT01228253|No Intervention|1|Safe voluntary.
89343922|NCT01228253|No Intervention|2|patient with psychotrauma but without PSTD and without any psychiatric trouble at the time of inclusion
89343923|NCT01228253|No Intervention|3|patient with psychotrauma and PTSD (post-traumatic stress disorder) and in full remission at the time of inclusion
89343924|NCT01228253|No Intervention|4.3|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
89343925|NCT01228253|Sham Comparator|4.2|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
89343926|NCT01228253|Experimental|4.1|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
89343927|NCT01567267|Experimental|Experimental educational intervention|Experimental educational intervention
89343928|NCT01567267|Active Comparator|Standard educational intervention|Standard educational intervention
89343929|NCT03924713||Community Health Worker|"initial comprehensive health, behavioral, and social needs assessment;~development of an individualized 'action plan' to address identified needs;~linkage to necessary services and work with neighborhood-based health care and social services organization to address each individual's unique needs; and 4) provide follow-up support as needed."
88806949|NCT04526145|Experimental|Stress and emotion Management for Black/African Americ|Four weekly sessions delivered in a group format via Zoom teleconference. The following topics are listed in the workbook: Planning Your Information Diet; My Spheres of Influence Worksheet; Practical Wisdom for Tolerating Uncertainty; Reducing Anxiety With Thought Challenging; Reducing Anxiety Through Distraction Activities; Starting a Planning Practice; Starting a Daily Gratitude Practice; Starting a Daily Breathing Practice; Improving the Quality of Your Social Connections; Developing a Regular Exercise Routine; and Creating Your Stress-Resilience Action Plan. Each session will begin with a 15-30 minute check in on what went well, challenges, and Coronavirus Anxiety workbook. The Coronavirus Anxiety Workbook topics are complementary and the sessions will tie together the themes of comprehensive stress and emotional management through blood pressure knowledge/self-monitoring, diet, interpersonal communication skills building, and sleep hygiene.
88806950|NCT04484285|Active Comparator|Younger Cohort|Healthy individuals aged 18 - 55
88806951|NCT04484285|Active Comparator|Older Cohort|Healthy individuals aged 56 - 85
88806952|NCT04480099|Active Comparator|CHOP|Patients in this arm will receive conventional CHOP regimen for 6 cycles
88806953|NCT04480099|Experimental|CHOP+X|Patients in this arm will receive targeted drug in combination with conventional CHOP regimen for 6 cycles, based on NGS results
88806954|NCT04438460|Experimental|Patient group|150 children aged 1 month to 12 years with multi-visceral failure syndrome within 48 hours of hospitalization in pediatric resuscitation will be included in this study
88806955|NCT04438460|Other|Control group|60 children aged 1 month to 12 years hospitalized for simple elective surgery will be included in this study
88806956|NCT04436926|Experimental|opioid approach bias training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of opioid approach bias modification taking place over two weeks.
88806957|NCT04436926|Sham Comparator|sham training|Immediately following screening, patients will be randomly assigned to receive 6 sessions of sham training taking place over two weeks.
88806958|NCT04423757|Experimental|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
88806959|NCT04423757|Placebo Comparator|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
88806960|NCT04423055|Experimental|COC users or new starts|Subjects will have an etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women using COC for less than 1 month will be considered new starts.
88806961|NCT04418401|Experimental|Experimental group|Treatment with Donafenib 100mg PO BID，and anti-PD-1 antibody 3mg/kg ivgtt Q2W. Treatment will last 6 months, unless the tumor recurrence.
88806962|NCT04404400|Experimental|Active|For CIRCI patients: hydrocortisone + fludrocortisone therapy.
88806963|NCT04404400|Placebo Comparator|Placebo|For CIRCI patients: hydrocortisone placebo + fludrocortisone placebo
88806964|NCT04385602|Placebo Comparator|CON group|placebo
88806965|NCT04385602|Active Comparator|DT group|Intratracheal dexmedetomidine
88806966|NCT04379713|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
88806967|NCT04379713|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
88806968|NCT04359108|Experimental|Navigation system for users of a visual prosthesis|This intervention will assess the feasibility of using a navigation system to aid blind users of a visual prosthesis with navigation tasks, by using the navigation system to provide navigational cues through multiple sensory modalities including vision and audition. The navigation system will be designed and developed as part of the proposed research and will interface with the Argus II retinal prosthesis system, which is an FDA approved visual prosthesis. Existing blind users of the Argus II device will be recruited for this study, and the navigation system will interface with these subjects' existing Argus II systems. Sighted subjects will also be recruited for this study, in which case the navigation system will interface with a head-mounted display (such as the Oculus Rift) worn by the sighted subjects that simulates the visual sensory information experienced by blind users of the Argus II retinal implant.
88806969|NCT04346615|Experimental|Zavegepant|Zavegepant (BHV-3500) 10 mg intranasal (IN) dosed every 8 hours (3 times/day) (Q8h) for 14 days
88806970|NCT04346615|Placebo Comparator|Placebo|"Placebo Q8h for 14 days~Subjects dosed every 8 hours; 3 times/day (Q8h)"
88806971|NCT04323397|Experimental|nasal high frequency oscillatory ventilation|"nHFO: flow 8-10 L/minute, frequency 10 Hz, MAP = MAP (before extubation) + 2 or 8 (preterm), 10 (term) cmH2O, dP = 2-3 times of MAP with visible chest oscillations or 25-35 cmH2O, I:E = 1:1, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%"
88806972|NCT04323397|Experimental|nasal synchronized intermittent positive pressure ventilation|"nSIPPV: flow 8-10 L/minute, rate 60/minute, PIP = PIP (before extubation) + 2-5 or 20 (preterm), 25 (term) cmH2O, PEEP = 5 cmH2O, IT = 0.5 s, FiO2 = FiO2 (before extubation) + 0.1-0.2 keep targeted SpO2 90-94%. The highest trigger sensitivity avoiding auto triggering was selected."
88806973|NCT04317937|Experimental|Jaw Movement Group|"A: Jaw opening-closing movements~Active jaw movements~Active neck exercises~B: Isometric strengthening exercises (Same as control group) C: Postural Advice and Home Exercise Program with Dairy (Same as control group)"
88806974|NCT04317937|Active Comparator|Exercise therapy|"A: Active neck exercises Active neck exercises Active jaw movements (Active Jaw movement will not be perform in this group) B: Isometric strengthening exercises C: Postural Advice and Home Exercise Program with Dairy i: Postural Advise ii: Home Exercise Program (unsupervised) iii: Home Dairy~Frequency and Duration of Treatment Non-specific Chronic Neck Pain (more than 3 months history of pain)~Initial Assessment (week 1) 60 minutes First treatment session (week1) 40 minutes~3 treatment sessions per week (week- 2) 40 minutes~3 treatment sessions per week (week- 3) 40 minutes~3 treatment sessions per week (week- 4) 40 minutes~3 treatment sessions per week (week- 5) 40 minutes~Last treatment session (week 6) 40 minutes~Final Assessment (week 6) 60 minutes"
88806975|NCT04300998||older lymphoma patients|This is a prospective observational cohort where 18 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory high-grade B-cell lymphoma will undergo serial comprehensive geriatric assessment, neurocognitive testing, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
89343930|NCT03924713||Usual Health Plan Services|1) receipt of other plan services besides the CHW program for which they are eligible.
89343931|NCT02135302|Experimental|Impaired hepatic function|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each hepatically impaired subject.
89343932|NCT02135302|Experimental|Healthy subjects|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each healthy subject.
89343933|NCT01131377|Experimental|Acetazolamide|"If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
89343934|NCT01131377|Placebo Comparator|Placebo|This group will be managed with general metabolic alkalosis treatment such as electrolyte correction, hydration except acetazolamide.
89343935|NCT01300273|Experimental|Ketosteril|
89343936|NCT04457050|Experimental|Non-Diabetic Hepatitis C infected patients|"clinical examination,~measurement of weight (Kg), height (meter), and waist circumference (cm).~Calculation of the body mass index.~Ultrasound abdominal examination.~Laboratory Investigations including Complete blood count, Serum aspartate and alanine aminotransferases, serum albumin, serum bilirubin, serum gamma-glutamyl transpeptidase, and international normalization ratio. HCV-RNA quantification before treatment and 12 weeks after the end of therapy.. Serum lipid profile, fasting and post-prandial blood sugar, glycated hemoglobin A1c also included.~Treatment of all patients with the available generic direct antivirals in Egypt (sofosbuvir/ledipasvir ± ribavirin or sofosbuvir plus daclatasvir ± ribavirin).~Evaluation of insulin resistance using the homeostasis model assessment of insulin resistance before and 12 weeks after end of treatment.~measurement of serum levels of resistin before and at 12 weeks after treatment."
89343937|NCT01228409|Other|Low dose Acitretin (17.5 mg)|
89343938|NCT01301911|Experimental|Cipatinib|Each subject will receive a single dose of cipatinib on treatment day 1, followed by 4-day observation period, and then will receive cipatinib once daily in cycles consisting of 21 days.
89343939|NCT03470350|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer treated with galunisertib and capecitabine
89343940|NCT01301443|Experimental|Subretinally Injected RetinoStat|Subretinally injected RetinoStat
89343941|NCT01228487||Acute knee pain|Patients with a history of knee pain < 6 months. The radiologic and arthroscopic OA stadium is less or equal II°. n=20.
89343942|NCT01228487||Chronic knee pain|Clinical manifestation of knee joint OA, radiological and arthroscopic III° or more. n=20
89343943|NCT01228487||Control group|Patients coming for post- primary repair of the cruciate ligament, having no inflammation and no sign of OA. n=10
89343944|NCT03468712|Experimental|Experimental group|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
89343945|NCT03928613|Experimental|Mild Cognitive Impairment|"Clinical dementia rating 0 or 0.5~Diagnosed by physicians as mild cognitive impairment according to the criteria of International Working Group on Mild Cognitive Impairment"
89343946|NCT01301521|Experimental|Cinnulin PF|Will take (by mouth) 2 gelatin capsules that contains 1 gram (2-500 mg capsules) water-soluble cinnamon extract (Cinnulin PF) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
89343947|NCT01301521|Placebo Comparator|Placebo|Will take (by mouth) 2 placebo capsules (gelatin capsule filled with wheat bran) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
89343948|NCT03928301|Active Comparator|Wholetones Intervention|"Wholetones music to help participants sleep. Data collected after listening to the Wholetones music was compared to that collected both at Baseline, and after listening to the other music condition (i.e. Classical music).~Wholetones® 2Sleep is music that is designed to lull the listener into a deep, delta sleep, using frequency-enhanced music and precise tempos. Wholetones® differs from other musical genres in that it employs a proprietary method of tuning and layering the music with a unique frequency underlayment."
89343949|NCT03928301|Active Comparator|Classical Intervention|"Classical music was the additional music condition used to compare to both Baseline data and Wholetones data.~The classical music was selected based on the Mayo Clinic and NIH music recommendations for better sleep. More specifically, the classical music consisted of the following six pieces: Beethoven (i.e., Moonlight Sonata, first movement), Marconi Union (i.e., Weightless), Chopin (i.e., Nocturne No.2, Op.9), Ravel (i.e., Piano Concerto in G major, 2nd movement), and J.S. Bach (i.e., Prelude No.1)."
89343950|NCT03814525|Active Comparator|Photobiomodulation group|PBM will be applied after the surgeries with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
89343951|NCT03814525|Placebo Comparator|Control group|Participants will be attended in the same way as the PBM group. The person who is responsible for the application of the PMB will simulate the irradiations by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off.
89343952|NCT04565392|Experimental|famotidine|A 20-milligram tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
89343953|NCT04565392|Placebo Comparator|Placebo|A placebo tablet to match a 20-milligram (mg) tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
89343954|NCT03816787|Experimental|dry cupping for patients of low back pain|Patients will receive four consecutive dry cupping therapy application in one month.
89343955|NCT03816787|Active Comparator|dry cupping for health people|Health people will receive four consecutive dry cupping therapy application in one month.
89343956|NCT03928379|Experimental|LY3305677|LY3305677 administered SC
89343957|NCT03928379|Placebo Comparator|Placebo|Placebo administered SC
89343958|NCT01226537|Active Comparator|Diabetes Mellitus type 1 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
89343959|NCT01226537|Placebo Comparator|Diabetes mellitus type 1 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
89343960|NCT01226537|Active Comparator|Diabetes type 2 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
89343961|NCT01226537|Placebo Comparator|Diabetes type 2 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
89343962|NCT01226615|Experimental|1|Chondroitin sulphate
89343963|NCT01226615|Placebo Comparator|2|Placebo
89343964|NCT03470272|Experimental|Active Device|"Active Device: The FB Professional LED red light therapy system~FB Professional is a treatment regime using the FB Professional device for fat removal using red light therapy.~Intervention device: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs."
89343965|NCT01301989|Placebo Comparator|Sleep Education Control|"The control group receives a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers (in English and Spanish)."
89343966|NCT01301989|Experimental|Sleep Counselor Intervention|"The sleep counselor visits are to assess the family's understanding of their child's sleep problems; help parents recognize the child's sleep deficiency; discuss how sleep problems affect behavior, learning, and health; and reassure parents that the sleep counselor can help them with these problems.~Additionally, sleep counselors: review parent's sleep goals to monitor changes to the child's bedtime routine and sleep environment; help them solve problems with implementation; provide positive feedback to help the parent recognize success; and help parents set additional goals for improving sleep."
89343967|NCT01226693|Experimental|Sequence 1|
89343968|NCT01226693|Experimental|Sequence 2|
89343969|NCT01226693|Experimental|Sequence 3|
89343970|NCT01226693|Experimental|Sequence 4|
89343971|NCT01226693|Experimental|Sequence 5|oral, 6mg, single dose
89343972|NCT01226693|Experimental|Sequence 6|oral, 6mg, single dose
89343973|NCT04240210|No Intervention|To assess degree of adherence to ART in a real world seeting.|Part I of the study is a Cohort Survey of HIV+ outpatient clinic patients currently receiving ART to assess medication adherence and tolerability by determining a change in adherence and tolerability from baseline to 4 months, measured by standardized patient reported outcome and adherence surveys
89343974|NCT04240210|Experimental|Potential changes in ART adherence when switced to Symtuza.|Part 2 of the study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
89343975|NCT05654233|Experimental|Taking sulodexide|Sixty patients with varicose veins who received radiofrequency ablation combined with sclerotherapy were given Sulodexide softgels 250LSU twice a day for two months after surgery。
89343976|NCT05654233|No Intervention|Not taking drug|Sixty patients with varicose veins of the lower extremities who received radiofrequency ablation combined with sclerotherapy were selected and did not take sulodexide after surgery.
89343977|NCT01226771|Experimental|"Group A (Loading)"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
89343978|NCT01226771|Experimental|"Group B (Priming)"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
89343979|NCT01226771|Active Comparator|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
89343980|NCT03814447|Experimental|anti- MESO CAR-T cells|The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d d-4~-2. Then anti- MESO CAR-T cells will be injected by a dose of 5×106/kg once at d1(rang from d1-3).
89343981|NCT04456192|Experimental|Women with Obesity|23 healthy, obese (BMI ≥ 30 kg/m2; waist circumference > 80) women, aged 34-62, screened at the outpatient clinic of the Department of Internal Medicine, Metabolic Disorders, and Hypertension, University of Medical Sciences, Poznań, Poland were enrolled based on the inclusion criteria and the willingness to participate in the research.
89343982|NCT04456192|Active Comparator|Normal-weight Women|"8 healthy, normal-weight (≤ 24.9 and ≥ 18.5 kg/m2) women, aged 34-62 were enrolled to intervention from the announcement.~Random selection for groups was not applicable due to the planned body mass difference in the studied groups."
89343983|NCT01129427|Experimental|Group clopidogrel - clopidogrel + pantoprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
89343984|NCT01129427|Placebo Comparator|Group placebo - placebo + pantoprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
89523601|NCT03385603|Active Comparator|Standard Dilator Progression Group|Participants in this group will complete a standard home program based on dilator manufacturer instructions for use.
88814120|NCT02241278|Experimental|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision. (a single dose).
89343985|NCT01129427|Experimental|Group clopidogrel + pantoprazole - clopidogrel|"Period 1:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions."
89343986|NCT01129427|Placebo Comparator|Group placebo + pantoprazole placebo|"Period 1:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions."
89343987|NCT03816241|No Intervention|Control|Vignette contains no extra information.
89343988|NCT03816241|Experimental|Frame|Vignette is framed in a particular manner
89343989|NCT03816241|Experimental|Norms|Vignette contains extra information about norms
89343990|NCT03816241|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
89343991|NCT05164510|Experimental|ct-DNA test in MPC|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
89343992|NCT03928067|Experimental|TREK Study Abroad Program|On-screen personalized normative feedback (PNF) will contain information on the drinking behavior and attitudes about gender- and country-specific study abroad peers. Participants will view text-based tips and strategies and watch clips of prior student abroad students discussing how they met their cultural engagement goals while abroad (Sojourner Adjustment Feedback or SAF). Content focuses around the four aspects of positive sojourner adjustment (social interaction with host nationals, cultural understanding and participation, language development and use, host culture identification) and the two negative sojourner adjustment factors while abroad (i.e., social interaction with co-nationals, homesickness/feeling out of place). The intervention will also contain text- and video-based tips and strategies for protective strategies used abroad to limit experience of risk sex and sexual violence victimization.
89343993|NCT03928067|No Intervention|Control|"Control participants will receive a link to a general website offering study abroad advice (www.studyabroad.com) and will be asked to spend at least 20 to 30 minutes reviewing their institution's study abroad website content, including policies for drinking abroad. This control condition was selected as a form of treatment as usual as our conversations with study abroad personnel indicate this is the extent of typical information students receive about alcohol use abroad."
89343994|NCT03814291|Experimental|cohort 1 IBI302 treated with first dose level of IBI302|
89343995|NCT03814291|Experimental|cohort 2 IBI302 treated with second dose level of IBI302|
89343996|NCT03814291|Experimental|cohort 3 IBI302 treated with third dose level of IBI302|
89343997|NCT03814291|Experimental|cohort 4 IBI302 treated with fourth dose level of IBI302|
89343998|NCT03814291|Experimental|cohort 5 IBI302 treated with fifth dose level of IBI302|
89343999|NCT03814291|Experimental|cohort 6 IBI302 treated with sixth dose level of IBI302|
89344000|NCT05160454|Active Comparator|patient|child with moyamoya
89344001|NCT05160454|Active Comparator|control|unaffected control
89344002|NCT03354429|Experimental|TICAGRELOR|
89344003|NCT03354429|Placebo Comparator|TICAGRELOR PLACEBO|
89344004|NCT03816085|Experimental|Shoe with 4 cm heel|Shoes with 4 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
89344005|NCT03816085|Experimental|Shoe with 10 cm heel|Shoes with 10 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
89344006|NCT03816085|No Intervention|Without shoes|Women will be included in the tests to measure balance, muscular endurance and function without shoes.
89344007|NCT03927755||Sub-xyphoid|Ultrasound views of the heart obtained using the sub-typhoid approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
89344008|NCT03927755||Para-sternal Long|Ultrasound views of the heart obtained using the parasternal long approach. Individuals with a mix of co-morbidities but are clinically stable will be viewed. Physicians with experience in bedside ultrasound are being studied.
89344009|NCT05164198|Experimental|Open-label reduced-dose TNFi|"Participants in the experimental arm will receive one of the intervention below according to the TNFi agent used at baseline:~Adalimumab 40mg subcutaneous every 3 weeks (Q3W) from week 0 to week 48.~Etanercept 50mg subcutaneous every 10 days (Q10D) from week 0 to week 48.~Golimumab 50mg (100mg if a participant's body weight ≥ 100kg) subcutaneous every 5 weeks (Q5W) from week 0 to week 48.~Remsima SC 120mg subcutaneous every 3 weeks (Q3W) from week 0 to week 48."
89344010|NCT05164198|Active Comparator|Open-label full-dose TNFi|"Participants in the comparator arm will receive one of the intervention below according to the TNFi agent used at baseline:~Adalimumab 40mg subcutaneous every 2 weeks (Q2W) from week 0 to week 48.~Etanercept 50mg subcutaneous every week (QW) from week 0 to week 48.~Golimumab 50mg (100mg if a participant's body weight ≥ 100kg) subcutaneous every 4 weeks (Q4W) from week 0 to week 48.~Remsima SC 120mg subcutaneous every 2 weeks (Q2W) from week 0 to week 48."
89344011|NCT03819751|Other|MRI-targeted prostate biopsy|Participants receive both type of MRI-targeted biopsy. Patients are randomized with one half having visual registration first and the other half having software registration first.
89344012|NCT03814369|Experimental|AmplifEYE colonoscopy|Colonoscopy performed with AmplifEYE equipped
89344013|NCT03814369|No Intervention|Standard colonoscopy|Standard colonoscopy performed
89344014|NCT03740399|Active Comparator|Group sitting|we are performing spinal anesthesia in sitting position pregnant patients
89344015|NCT03740399|Active Comparator|Group lateral decubitus position|we are performing spinal anesthesia in lateral decubitus position pregnant patients
89344016|NCT03740399|Active Comparator|Group Modified 45-degree head-up tilt|we are performing spinal anesthesia in Modified 45-degree head-up tilt position pregnant patients
89344017|NCT05160220|Active Comparator|Psilocybe cubensis|0.5 g dried and powdered P. cubensis in gel capsules, dosing on two separate days, separated by one week from the placebo, randomized order.
89344018|NCT05160220|Placebo Comparator|Inactive placebo|Same weight of inactive placebo in gel capsules, dosing on two separate days, separated by one week from the placebo, randomized order.
89344019|NCT03924245|Experimental|Treatment (entinostat, olaparib)|Patients receive entinostat PO 1 week before starting combination therapy (day -7). Patients then receive entinostat PO on days 1, 8, 15, and 22, olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity
89344020|NCT05164042|Experimental|Treatment group|Subjects who meet the enrollment conditions will receive intravenous infusion of allogeneic CD19 CAR-T cells after pretreatment.
89344021|NCT01225445|Experimental|Treatment|ramipril 2.5 mg daily
89344022|NCT01225445|No Intervention|Control|
89344023|NCT03814213||No-CGA|Patients were not initially offered CGA due to no booking for CGA
89344024|NCT03814213||CGA alone|Patients had CGA, but no tailored follow-up upon identified problems
89344025|NCT03814213||CGA with tailored care|CGA and a tailored follow-up and care for 90 days following the CGA
89344026|NCT03924011|Sham Comparator|Control group|Receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
89344027|NCT03924011|Experimental|Treatment group|Receives PBMT (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
89344028|NCT05204212|Experimental|Experimental intervention|Percutaneous closure of the LAA by use of the CE-mark approved LAA exclusion device Amplatzer Cardiac Plug or Amulet followed by dual antiplatelet therapy with aspirin 100mg od and clopidogrel 75 mg od for 3 months. In patients with excessive bleeding risk DAPT duration can be shortened according to the physicians' discretion to a minimum of 6 weeks. Oral anticoagulants are not prescribed in this group.
89344029|NCT05204212|No Intervention|Control intervention|No catheter-based LAA closure. Treatment with best medical care (warfarin or NOAC therapy or other best medical care if (N)OAC therapy is contraindicated).
89344030|NCT03924089|Experimental|Oral nutritional supplement with probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), with probiotics.~Physical activity recommendations."
89344031|NCT03924089|Experimental|Oral nutritional supplement without probiotics|"Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), without probiotics.~Physical activity recommendations."
89344032|NCT03924089|Active Comparator|Individualized dietary recommendations|Individualized dietary recommendations. Physical activity recommendations.
89344033|NCT05555329|Experimental|Group A; Pomalidomide 4 mg every other day in cycle 2|Group A (6 patients): Cycle 1: Pomalidomide 4 mg every day on day 1-21; Cycle 2: 4 mg every other day on day 1-21; Cycle 3: 2 mg every day on day 1-28. In Cycles of 28 days.
89344034|NCT05555329|Experimental|Group B; Pomalidomide 4 mg every other day in cycle 3|Group B (6 patients): Cycle 1: Pomalidomide 4 mg every day on day 1-21; Cycle 2: 2 mg every day on day 1-28; Cycle 3: 4 mg every other day on day 1-21. In Cycles of 28 days.
89344035|NCT01228565|Placebo Comparator|Placebo|Radiotherapy+Erbitux+Placebo
89344036|NCT01228565|Experimental|OTD70DERM|Radiotherapy+Erbitux+OTD70DERM®
89344037|NCT03927677|Experimental|Cohort|Period 1: LC350189 200mg Day 1~ Day 4 qd, Period 2: Colchicine 0.6 mg Day 8 ~ Day 15 bid, Period 3 : LC350189 200mg (qd) + Colchicine 0.6 mg (bid) Day 16~ 19
89344038|NCT05159986|Experimental|Group Diadynamic and Exercises|Group Diadynamic and Exercises received Diadynamic currents associated to Exercise three times a week for 8 weeks following initial assessment (n=30, 60 knees) Diadynamic currents was performed with the following parameters: application of the two-phase current and then the long-term one. Each current was applied for 4 minutes on the medial and lateral sides of the knee.
89344039|NCT05159986|Experimental|Group Exercises|Group Exercises received only exercises three times a week for 8 weeks following initial assessment (n=30, 60 knees).
89344040|NCT01226849|Experimental|Single Arm|"bortezomib, rituximab, ifosphamide, etoposide, carboplatin~Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended"
89344041|NCT03813901|Experimental|Samalochana Counselling group|Arsha Vidya advaita vedanta based counselling were given to the women
89344042|NCT03813901|Other|Wait-list control group|Wait list group were not given any supportive care during the period. After that, they were offered the similar program as Counselling group.
89344043|NCT01300429||patients with Non Small Cell Lung cancer|This is a protocol to obtain and/or analyze tissue specimens of patients with NSCLC harboring an activating ALK inversion or translocation that have had a previous clinical response to tyrosine kinase inhibitor therapy and subsequently experience progressive disease. The tissue will be used to identify changes in the ALK gene that are acquired during treatment with an ALK TKI and may account for acquired resistance.
89344044|NCT03927365|Active Comparator|Salt particle inhaler with content|Participants inhaling from a salt particle inhaler with content
89344045|NCT03927365|Placebo Comparator|Salt particle inhaler without content|Participants inhaling from a salt particle inhaler without content
89344046|NCT03352713|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
89344047|NCT05159674|Experimental|Dexmedetomidine+electroacupuncture compound anesthesia|EA was given every day three days before surgery, 30 minutes before induction of anesthesia + the whole course of surgery, and every 12 hours from the first day after surgery, each treatment was performed for 30 minutes until 48 hours after surgery. During the operation, only dexmedetomidine was used to make BIS<80.
89344048|NCT05159674|No Intervention|Dexmedetomidine anesthesia|There was no EA treatment before, during or after operation. During the operation, only dexmedetomidine was used to make BIS<80.
89344049|NCT03813979|Experimental|Hepatic impairment group|Dolutegravir in HIV-seronegative subjects with severe hepatic impairment (child-Pugh score 10 or greater)
89344050|NCT03813979|Active Comparator|Matched controls|Dolutegravir in control group matched for gender, age and BMI with subjects in hepatic impairment group
89344051|NCT01226927|Active Comparator|Continuous infusion rate|Patients received a continuous infusion of 0.2% ropivacaine at 10.1 mL/hr via their femoral nerve catheter.
89344052|NCT05554887|Experimental|Thrust manipulation Group|Participants undergoing thrust manipulation
89344053|NCT05554887|Sham Comparator|Sham thrust manipulation group|Participants undergoing sham thrust manipulation
89344054|NCT03814135|Experimental|HIPNOS 3|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Hipnos 3 and 1 placebo tablet, oral, once a day."
89344055|NCT03814135|Experimental|HIPNOS 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Hipnos 5 and 1 placebo tablet, oral, once a day."
89344056|NCT03814135|Placebo Comparator|HIPNOS Placebo|The study is double-dummy. Thus, the patient will take 2 tablet of placebo, oral, once a day.
89344057|NCT03927599||Advanced refractory tumor solid tumors patients|Patients with advanced refractory solid tumors carrying TP53 mutations and receive PARP-inhibitors in combination with the VEGFR-inhibitors therapy
89344058|NCT03711201|Active Comparator|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
89344059|NCT03711201|No Intervention|Group NoIORE|The patient's hemodynamic data will be measured in the evening service before surgery. The patient will be brought to the operating room by the anesthesiologist on the day of surgery and hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured in the preop unit. The hemodynamic data and the ST-STAI scale will measure the anxiety level in the operating room.
89344060|NCT03819673|Experimental|Intervention Group (IG)|Care based on the computerised decision-support tool
89344061|NCT03819673|No Intervention|Control Group (CG)|Usual care advice by primary care provider or dietitian of participating hospital
89344062|NCT01129661|Placebo Comparator|normal saline (0.9%)|
89344063|NCT01129661|Experimental|CSL112|
89344064|NCT03901144|Experimental|Test cream (2% urea/20% glycerol)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
89344065|NCT03901144|Active Comparator|Reference cream 1: Miniderm® 20% cream (20% glycerol)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
89344066|NCT03901144|Active Comparator|Reference cream 2: Diprobase® cream (cream without humectants)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
89344067|NCT03901144|No Intervention|Untreated|Untreated skin area on the volar forearm
89344068|NCT01129739|Experimental|Human umbilical cord-derived MSCs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle
89344069|NCT01129739|Active Comparator|cyclosporine A (CsA)|CsA at a dose of 5 mg CsA/kg
89344070|NCT01129817|Experimental|Cognitive Functional Therapy|
89344071|NCT01129817|Active Comparator|Manual Therapy and Exercise|
89344072|NCT02952261|Other|CT-guided localization|This group of participants received conventional CT-guided lung nodule localization.
89344073|NCT02952261|Experimental|template-guided localization|Three-dimensional printed template was customized based on participant's computed tomography information. Participants received template-guided lung nodule localization.
89344074|NCT01129895|Experimental|Health promotion|5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
89344075|NCT01129895|No Intervention|Promoting Health|No intervention follow-up only
89344076|NCT03859336|Experimental|Transdermal Neuromodulation Stimulation|"Day 1 of Transdermal Neuromodulation Stimulation (TENS) is a one-day sham stimulation, consisting of: 30 seconds of sensation in which amplitude is increased up to the threshold of salient sensation, followed by 19 minutes of no stimulation (device is turned off), followed by 30 more seconds of salient stimulation. Day 1 is used to exclude those who cannot tolerate study procedures and placebo responders; it will also serve as baseline for anxiety measures. TENS treatment begins one day after sham, and lasts 3 days with 20 minutes of stimulation per day. One day following open label treatment all participants will once again receive sham stimulation following the same procedures utilized at Day 1.~Treatment amplitude is adjusted for each participant, in which the stimulation will be administered just below the participant's sensation threshold. Amplitude from the TENS device does not exceed 20mA. Frequency will be at 300hz."
89344077|NCT01311999||IGRA-positive group|The subjects who have positive results of interferon-gamma release assay
89344078|NCT01311999||IGRA-negative group|The subjects who have negative results of interferon-gamma release assay
89344079|NCT01301599|Experimental|combination group|combination therapy of alpha blocker and 5-alpha-reductase inhibitor medication
89344080|NCT01301599|Active Comparator|alpha blocker group|alpha blocker monotherapy
89344081|NCT01301599|Active Comparator|5 ARI group|5 alpha-reductase inhibitor group
89344082|NCT05390554|Experimental|Buteyko Breathing Technique|single group pre-post test
89344083|NCT01227083||1|Asthma control test check AQLQ(Asthma Quality of Life Questionnaire)after being cAQOL(Computerized Asthma specific quality of life)
89344084|NCT01227083||2|Asthma control test check cAQOL(Computerized Asthma specific quality of life)after being AQLQ(Asthma Quality of Life Questionnaire)
89344085|NCT03384693|Experimental|Prophylactic Defibrotide|6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.
89523602|NCT03385525|Experimental|BIIB074 150 mg and Valproic Acid 500 mg|Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.
89344086|NCT03815617|Active Comparator|Probiotic|The study design is a crossover randomized double-blind two-block placebo-controlled single center trial with an allocation ratio of 1:1 conducted between February 2017 and May 2018. Subjects are randomized at baseline visit to receive Block 1 (Zircombi 3 g, containing Bifidobacterium longum BB536 four billion CFU, Lactobacillus rhamnosus HN001 one billion CFU with B6 vitamin 1.4 mg) and Block 2 (placebo: maltodextrins, corn starch, silicon dioxide) depending on the randomization sequence. Subjects received one sachet pack daily containing placebo or probiotic. The active treatment was undistinguishable from placebo by physical and organoleptic characteristics. Participants in the study followed a free diet.
89344087|NCT03815617|Placebo Comparator|Placebo|Same appearance of probiotic.
89344088|NCT01227161||ultrasonography children|American Society of Anesthesiologists (ASA) I-II children between the age 0-7, undergoing elective urological surgery, such as inguinal hernia repair, orchiopexy, ureteroneocystostomy
89344089|NCT03923855|Experimental|BTL-899 Therapy Arm|
89344090|NCT05348967|No Intervention|Control|Ketogenic diet
89344091|NCT05348967|Experimental|TECADRIOL|Ketogenic diet plus a food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
89344092|NCT03923621|Experimental|Experimental - EPSiT|Endoscopic Pilonidal Sinus Treatment
89344093|NCT03923621|Active Comparator|Control - excision|Excision treatment
89344094|NCT03923777|Other|Active Surveillance|Active surveillance is a way of either delaying or avoiding treatment and its possible side effects through carefully watching for changes in the tumor. Patients continue on this regimen, watching for tumor growth, up to 2 years on study or until rate or extent of growth leads to a shared decision to initiate treatment, whichever comes first.
89344095|NCT03712059||Screening group|All patients receive FIT test and colonoscopy, whose age, sex, family history, smoking history, body mass index (BMI), diabetes and other risk factors are collected by researchers through pad, equipped with a specially designed database and app. Using colonoscopy results as the gold standard, the diagnostic value of risk prediction model for the Chinese population is explored, and the optimal strategy of colonoscopy practice for the Chinese established initially.
89344096|NCT03712059||Adenoma resection group|During the polypectomy of 2000 patients, for all pathologically confirmed or NBI-predicted adenomas with size<10mm, 1-2 biopsies were randomly performed on the edge after resection to determine the completion rate of the polypectomy.
89344097|NCT03712059||Identification and classification group|For 12000 patients regardless of cancer diagnosis or polypectomy, if there is polyp, NBI (magnification) observation is required, with 4 white light and NBI images collected and reserved, respectively. If there is magnifying endoscopy, another 4 endoscopic images of magnification are also required. Endoscopists are invited to predict the pathology of polyps according to the NICE classification principle and endoscopic images, and upload the pathological results and endoscopic images within 2-4 week after colonoscopy.
89344098|NCT05390320|Experimental|Periodontally accelerated osteogenic orthodontics|The patients in this group will be treated by periodontally accelerated osteogenic orthodontics using fixed appliances.
89344099|NCT05390320|Active Comparator|Conventional treatment|The patients in this group will be treated using fixed appliances and conventional treatment without any surgical intervention to accelerate tooth movement.
89344100|NCT03814057||Elderly Medical Patients at hospital admission|
89344101|NCT05533281|Experimental|tropisetron|Troisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
89344102|NCT05533281|Experimental|metoclopramide|Metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
89344103|NCT05533281|Experimental|dexamethasone|Dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
89344104|NCT05533281|Placebo Comparator|normal saline|Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was given intravenously to ensure constant speed.
89344105|NCT01128725|Other|Group Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
89344106|NCT04802109|Placebo Comparator|CPR with level D PPE|The participant doing CPR for 5 minutes with wearing level D personal protective equipment with surgical face mask
89344107|NCT04802109|Experimental|CPR with level C PPE|The participant doing CPR for 5 minutes with Level C personal protective equipment with N-95 face mask
89344108|NCT04802109|Experimental|CPR with Level C PPE + PAPR|The participant doing CPR for 5 minutes with Level C personal protective equipment with Powered Air-Purifying Respiratory.
89344109|NCT03525808|Experimental|AXIOS|Patients will receive the AXIOS stent for the treatment of walled-off pancreatic necrosis.
89344110|NCT01228799|Active Comparator|Trabeculectomy|Trabeculectomy with Mitomycin C
89344111|NCT01228799|Active Comparator|Canaloplasty|Canaloplasty with implant of suture
89344112|NCT03813823||Phobic|Adults aged 18-40 exhibiting high levels of self-reported phobic symptoms to spiders
89344113|NCT03813823||Nonphobic|Adults aged 18-40 exhibiting low levels of self-reported phobic symptoms to spiders
89344114|NCT03709875|Experimental|TR Treatment|TR will be delivered by means of an advanced video-conferencing system, and patients will be provided with low-cost monitoring devices, able to collect data about the health status and QoL. All treatments from remote are based on scheduled videoconferences between the patient's home and the Clinical Units, and therapists can control and modify the exercises. A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech and cognitive exercises will be delivered from the two Research Institutes to the patient's home.
89344115|NCT03709875|Other|Conventional Treatment|"In this group patients will be treated with conventional physiotherapy and speech training, adjusted in reason of the clinical needs, as usually. Treatments for motor limbs activity will be focused on functional active-assistive and active exercises. Conventional paper and pencil training will be used to improve cognitive function."
89344116|NCT03821311|Experimental|Computed tomography examination|Each patient will undergo a low-dose supine position chest CT scan including end-inspiratory and expiratory acquisitions, corresponding to the routine protocol for COPD patients, except that this end-inspiratory/end-expiratory CT is repeated 3 times for total of 6 CT acquisitions.
89344117|NCT03923153|Active Comparator|Inspiratory muscle training group|Inspiratory muscle training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
89344118|NCT03923153|Sham Comparator|Sham group|Sham group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
89344119|NCT03813667|No Intervention|Control|The control patients have standard care given through the WVU hospital and outpatient clinics, prescribed by the patient's pulmonologist and recorded in the medical record
89344120|NCT03813667|Experimental|Intervention|The FamPALcare intervention group receives all standard care plus 2 weeks of home EOLPC coaching by community nurses experienced in end-of-life palliative care.
89344121|NCT05390242||Smoking Patients with Dental Implantes|Smoking Patients rehabilitated with dental implants at the Dentistry Hospital of the University of Barcelona (Campus of Bellvitge).
89344122|NCT05390242||Non-Smoking Patients with Dental Implantes|Non-Smoking Patients rehabilitated with dental implants at the Dentistry Hospital of the University of Barcelona (Campus of Bellvitge).
89344123|NCT03923075|Active Comparator|Dexmedetomidine|"Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution [that corresponds to the volume (ml) calculated by the type body weight (Kg)/4 or body weight (Kg) X 0.25.~THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
89344124|NCT03923075|Placebo Comparator|0.9 % saline|"Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: body weight (Kg)/4 or body weight (Kg) X 0.25 THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY"
89344125|NCT03923231||Children <5 years|Children under the age of 5 years who are receiving atazanavir as part of clinical care
89344126|NCT03923231||Children 6-11|Children aged 6-11 years who are receiving atazanavir as part of clinical care
89344127|NCT03923231||Adolescents 12-17|Adolescents aged 12-17 years who are receiving atazanavir as part of clinical care
89344128|NCT03923231||Pregnant women|Women who are at least 20 weeks gestation, who are receiving atazanavir as part of clinical care
89344129|NCT03923231||BMI < 18.5|Adults with a BMI of <18.5 kg/m2 who are receiving atazanavir as part of clinical care
89344130|NCT03923231||BMI >30|Adults with a BMI of >30 kg/m2 who are receiving atazanavir as part of clinical care
89344131|NCT01227239|Experimental|1|
89344132|NCT01300585|Other|MRI|All patients on study will undergo an MRI of the breast(s).
89344133|NCT05390164||Active vitiligo|
89344134|NCT05390164||Stable vitiligo|
89344135|NCT01301677|Active Comparator|Hydrocortisone|
89344136|NCT01301677|Experimental|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
89344137|NCT01301677|Experimental|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
89344138|NCT01227317||Acute dyspnea in ED|Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)
89344139|NCT01301755||1|
89344140|NCT01128881|Experimental|IMMUNINE|
89344141|NCT02618980|Experimental|early endoscopy|endoscopic hemostasis
89344142|NCT02618980|No Intervention|without early endoscopy|Patients assigned to non-endoscopic treatment group receive high dose infusional PPI therapy. If UGI bleeding subsided after medical treatment alone, diagnostic EGD will be done under stable hemodynamic and 2 weeks after ACS to confirm UGI SRH. If the SRH is not located at UGI tract, the patients will be excluded. Troponin I or T and complete ECG will be checked every 8 hours within 24 hours of interventions. APACHE II score at intervention will be calculated for each patient.
89344143|NCT03927287||Radical prostatectomy (RP cohort)|Our institutional prostate cancer database was queried for all patients between 2000-2017 who had a biochemical recurrence (BCR) after radical prostatectomy (RP) (Total PSA>=0.2 ng/ml) and had at least one post-BCR free PSA ratio (FPSAR) blood test (RP cohort). FPSAR ascertainments were performed incidentally or reflexively (e.g. PSA in the range of 4-10 ng/ml, as per Institutional policy). If multiple FPSAR tests were performed, only the first FPSAR test was analyzed. otal PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
89344144|NCT03927287||Radiotherapy cohort|Our institutional database was queried or all patients between 2000-2017 who had a rising PSA after radiotherapy (RT) for intermediate- and high-risk prostate cancer, and at least one post-treatment free PSA ratio (FPSAR) blood test (RT cohort). As in the RP cohort, FPSAR was performed either incidentally or reflexively, and the first FPSAR test was used for the analyses. Total PSA and Free PSA data was performed with the Abbott Architect analytical platform, according to the instructions of the manufacturer.
89344145|NCT03927287||Biobank surgical cohort|To validate our findings in the two retrospective cohorts (RP and RT), we analyzed a third cohort of prospectively collected biobank specimens of patients who underwent RP and developed biochemical recurrence(Biobank cohort). The retrieved samples were batched and tested for FPSAR levels to determine the results in lower PSA ranges and also to account for intrinsic analyte measurements variability in the retrospective cohorts. For his cohort we used the Roche Elecsys analytical platform, according to the instructions of the manufacturer.
89344146|NCT02613598|Experimental|Bortezomib and Ruxolitinib|Bortezomib on days 1, 4, 8, and 11 of a 21 day cycle in combination with Ruxolitinib (5, 10, 15, 20, or 25 mg) twice daily.
89344147|NCT03718429|Experimental|aspirin|Patients on aspirin 81 mg daily will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
89344148|NCT03718429|Experimental|aspirin and clopidogrel|Patients on aspirin (81 mg daily) plus clopidogrel (75 mg daily) will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
89344149|NCT03718429|Experimental|aspirin and ticagrelor|Patients on aspirin (81 mg daily) and ticagrelor (90 mg bid) will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
89344150|NCT03718429|No Intervention|rivaroxaban|A control cohort of subjects with atrial fibrillation on full dose rivaroxaban (20 mg daily) as per standard of care will be recruited and will undergo a single PD assessment.
89344151|NCT01225523|Active Comparator|Preoperative chemotherapy followed by surgery|
89344152|NCT01225523|Active Comparator|Perioperative chemotherapy with surgery|
89344153|NCT05390008|Experimental|Group 1: Pelvic Floor Muscle Training|volunteer elderly women with SUI
89344154|NCT05390008|Experimental|Group 2: Modified Pilates Exercises|volunteer elderly women with SUI
89344155|NCT01130129|Experimental|Ex-vivo treatment of platelets|Ex-vivo treatment of platelets
89344156|NCT03813745||early denudation|Cumulus-oocyte complexes will be denudated in 30 min after oocyte retrieval
89344157|NCT03813745||late denudation|Denudation will be done 2 hr after oocyte retrieval
89344158|NCT03922685|Active Comparator|Morning sedentary arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 11:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
89344159|NCT03922685|Active Comparator|Morning exercise arm|"After arriving at MCRU at 7 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 7:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 7:20 and 11:20, 3-ml blood samples were collected at 10-min intervals.After the 11:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
89344160|NCT03922685|Active Comparator|Evening sedentary arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. Over the next 4 hours, subjects reclined on a bed and had 3-ml blood samples collected at 10-min intervals. After the 23:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
89344161|NCT03922685|Active Comparator|Evening exercise arm|"After arriving at MCRU at 19 h, and having eaten three 25%-carbohydrate meals over the previous 24 h, subjects had an antecubital-vein catheter inserted and consumed their fourth 25%-carbohydrate meal at 19:20 h. At 8 h, subjects walked on the treadmill at 50% maximal effort. Between 19:20 and 23:20, 3-ml blood samples were collected at 10-min intervals.After the 23:20 blood sample, subjects were released from MCRU.~This arm is compared to the other three arms."
89344162|NCT03815539|Experimental|dry eye group|Part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
89344163|NCT01225601||Histocytosis|Adult with isolated pulmonary Langerhans cell histiocytosis (pulmonary LCH)
89344164|NCT01300663||post-surgery symptom experience|women with vulvar intraephitelial neoplasia or vulvar cancer
89344165|NCT03922919|Active Comparator|Cefotaxime or ceftriaxone group|free use of cefotaxime or ceftriaxone by the investigator
89344166|NCT03922919|Experimental|Cefotaxim group|Systematic use of cefotaxime
89344167|NCT04455880|Active Comparator|GDM with insulin therapy|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
89344168|NCT04455880|Active Comparator|GDM treated with only diet (without any medical therapy)|Singleton pregnancies above 36 gestational weeks diagnosed Gestational Diabetes Mellitus and treated with insulin therapy.
89344169|NCT04455880|Active Comparator|Non-diabetic Controls|Singleton non diabetic healthy pregnancies above 36 gestational weeks
89344170|NCT03819205|Experimental|kinesiotaping group(before/after)|"Hemiplegic CP:Kinesiotaping on the affected side~Diplegic, tetraplegic CP: side of upper extremity which children have been used to but have obstacles in daily life~intervention Duration: For 1 week at least 2-3 hours a day, renewing if it's necessary.~Note:Patients will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day.~Evaluation: In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion"
89344171|NCT03922607|Experimental|Substudy 2: Group 2|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose D or matching placebo on Day 1 through Day 28
89344172|NCT03922607|Experimental|Substudy 2: Group 1|Participants with chronic plaque psoriasis will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 28
89344173|NCT03922607|Experimental|Substudy 1: Group 3|Participants, who are healthy volunteers, will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 14
89344174|NCT03922607|Experimental|Substudy 1: Group 2|Participants, who are healthy volunteers, will be administered with ABBV-157 dose B or matching placebo on Day 1 through Day 14
89344175|NCT03922607|Experimental|Substudy 1: Group 1|Participants, who are healthy volunteers, will be administered with ABBV-157 dose A or matching placebo on Day 1 through Day 14
89344176|NCT03813277|Experimental|Dexmedetomidine|Dexmedetomidine 100microg/ml
89344177|NCT03922763|Active Comparator|Anatomically-matched cut|
89344178|NCT03922763|Active Comparator|Cutting guide|
89344179|NCT02522962|Experimental|GroupCoreSIT|Before the group training starts, the physiotherapist in charge of the group does a clinical assessment of each participant in order to individualise the training. Each training group will consist of three participants. The training sessions will last for 60 minutes, performed three days per week, for six weeks, between 10 am and 5 pm.
89344180|NCT02522962|Active Comparator|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
89344181|NCT03815461|Experimental|experiment group|Nab-paclitaxel+S-1
89344182|NCT01285102|Experimental|Arm I|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for up to 3 (unilobar disease) or 4 (bi-lobar disease) courses in the absence of disease progression or unacceptable toxicity.
89344183|NCT03740243|Active Comparator|buprenorphine|"Buprenorphine 2 mg to 8 mg daily: Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24~Buprenorphine 8 mg to 16 mg daily: Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
89344184|NCT03740243|Experimental|buprenorphine/naloxone|"Buprenorphine/naloxone 4 mg/1 mg daily once daily or twice daily (BID): Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24~Buprenorphine/naloxone 8 mg/2 mg daily once daily or twice daily (BID): Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
89344185|NCT03813043|Other|Midazolam|Midazolam 2 mg as started dosage will be used for first patients and for the other patients will receive an predetermined dosage accordingly
89344186|NCT01225679||polysomnography|Overnight supervised polysomnography (Embla System®) was performed in a sleep laboratory, which included capnometry. Arterial blood gas analysis was performed by radial arterial puncture. Ventilatory response to progressive hypercapnia was measured using the Read breathing technique. Briefly, subjects rebreathed into an air tight 5-L bag containing a mixture of 8% carbon dioxide (CO2) and 40% oxygen (O2). The spirometer technology used to monitor ventilation was based on a bi-directional rotating vane principle (flow sensitive). A continuous record of CO2 concentration in the expired gas was obtained by a CO2 analyzer within the circuit. The ventilatory hypercapnic drive was calculated from the slope produced by changes in ventilation (L. min-1) and changes in end-tidal PCO2.
89344187|NCT03740087|Experimental|Omnivorous diet|This group was assigned a meal containing beef (test meal) that consisted of 200 g roast beef with salad (lettuce, tomato, lentils) and a cup of rice.
89344188|NCT03740087|Active Comparator|Vegan diet|This group was assigned a control meal consisted of salad (lettuce, tomato, lentils) and a cup of rice.
89344189|NCT01560325|Experimental|CKD-516 inj.|CKD-516 Inj, 3.3~13mg/m2/day, D1, 4, 8, 11 every 3 weeks
89344190|NCT01227473|Experimental|mindfulness prediabetes education group|The mindfulness-based diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with instruction in mindfulness.
89344191|NCT01227473|Active Comparator|conventional prediabetes education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
89344192|NCT00677560||3|"Mild-moderate asthma.~Within the asthma group, there were two sub-groups; mild-moderate asthma and severe asthma distinguished using the Global Initiative for Asthma (GINA) guidelines (GINA, 2009)."
89344193|NCT00677560||4|"Severe Asthma~Within the asthma group, there were two sub-groups; mild-moderate asthma and severe asthma distinguished using the Global Initiative for Asthma (GINA) guidelines (GINA, 2009)."
89344194|NCT00677560||1|"Normal subjects~Normal subjects were a group made up of healthy subjects, with normal lung function, non-smokers at the time of the screening."
89344195|NCT00677560||2|"Healthy smokers~Healthy smokers were comprised of people who were current smokers and had normal lung function at the time of screening."
89344196|NCT00677560||5|"COPD (Gold stage I - III)~The COPD group included stage I to III patients, classified according to severity of airflow limitation (post bronchodilator FEV1), from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD, 2011)."
89344197|NCT03928925|Active Comparator|BOUGIE|"For patients randomized to use of a bougie, the operator will use a bougie on the first attempt at intubation. If successful, an assistant will load an endotracheal tube over the bougie, and the operator (without removing the laryngoscope from the mouth) will guide the tube through the vocal cords to the desired depth in the trachea.~If the bougie is not successfully placed in the trachea or the endotracheal tube cannot be successfully advanced over the bougie on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
89344198|NCT03928925|Active Comparator|Endotracheal Tube with Stylet|"For patients randomized to use of an endotracheal tube with stylet, the operator will use an endotracheal tube containing a removeable, malleable stylet, on the first attempt at intubation.~Manipulation of the shape/curve of the endotracheal tube with stylet is at the discretion of the operator, however a straight-to-cuff shape and a bend angle of 25° to 35° is encouraged. The stylet will be left in place until the tube is advanced to the trachea.~If the endotracheal tube with stylet is not successfully placed in the trachea on the first attempt at intubation, the operator may use any approach during subsequent attempts at tracheal intubation."
89344199|NCT03382899|Experimental|Pegilodecakin + Pembrolizumab|"Participants received pegilodecakin subcutaneously (SQ) at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Pembrolizumab administered as an intravenous (IV) infusion at 200 mg on Day 1 of a 21-day cycle."
89344200|NCT03382899|Active Comparator|Pembrolizumab|Participants received pembrolizumab as an IV infusion at 200 mg on Day 1 of a 21-day cycle.
89344201|NCT03808753|Experimental|Treatment - hemodynamic tests: EEOT and mFC|Interventions: all the enrolled patients will be tested using the EEOT and the mFC.
89344202|NCT03740321|Experimental|Embospheres 500-700 microns|Intervention.Embolization with 500-700 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
89344203|NCT03740321|Experimental|Embospheres 700-900 microns|Intervention.Embolization with 700-900 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
89344204|NCT03815305|Active Comparator|Topical CA and Placebo Oral Drug|Patient given 10gr 1% CA ointment and 56 pcs of placebo drug
89344205|NCT03815305|Placebo Comparator|Petroleum Jelly and placebo oral drug|Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug
89344206|NCT03815305|Experimental|Centella asiatica extract and Topical CA|Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA
89344207|NCT03929003|Experimental|Contingent|Participants in this arm will be required to meet CO goals in order to earn game-based rewards.
89344208|NCT03929003|Active Comparator|Non-contingent|Participants in this arm will submit CO verifications but will earn game-based rewards independent of meeting CO goals.
89344209|NCT01560013|Experimental|Naltrexone|Treatment with naltrexone for two months together with psycho-social support
89344210|NCT03709797|Experimental|Experimental group|Experimental group will receive dry needling treatment.
89344211|NCT03709797|Sham Comparator|Control group|Control group will receive sham dry needling treatment.
89344212|NCT01302145|Experimental|ASP1941 + metformin|Oral
89344213|NCT01302145|Placebo Comparator|Placebo + metformin|Oral
89344214|NCT00709852|Experimental|Gadobutrol then Gadoteridol|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) in Period 1 and a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 2.
89344215|NCT00709852|Experimental|Gadoteridol then Gadobutrol|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 1 and a single dose of gadobutrol 0.1 mmol/kg bw via i.v. in Period 2.
89344216|NCT05348811|Experimental|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, Day 1, every 3 weeks (Q3W). The maximum of 6 times.~Sintilimab will be given on Day 1, 200 mg i.v. Q3W.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment."
89344217|NCT01560091|Placebo Comparator|Group A|Patients will receive ESWL and no medication
89344218|NCT01560091|Active Comparator|Group B|Patients will receive Flomax after ESWL
89344219|NCT01560091|Active Comparator|Group C|Patients will receive silodosin after ESWL
89344220|NCT01311609|Experimental|Systane|Systane Lubricant Eye Drops
89344221|NCT03926975|Experimental|Experimental: Scleral Lens|One eye will be randomly selected to wear a scleral lens for a 6-hour testing period.
89344222|NCT03926975|Active Comparator|Control: no lens|The contralateral eye will not wear a lens.
89344223|NCT03807427|Experimental|READY-Nepal|Skills groups based on dialectical behavior therapy principles delivered over 10-12 weeks in a classroom format.
89344224|NCT03807427|No Intervention|Waitlist Control|Adolescent participants assigned to the control condition will be placed on a waitlist for future enrollment in READY-Nepal. After primary data collection has ceased, those assigned to the control arm will receive the identical READY-Nepal intervention delivered in the experimental condition.
89344225|NCT03382041|Experimental|Carbon Fiber Implant|There is an alternative to the standard treatment, which is carbon fiber implants (tibial nails), especially in the prophylactic reinforcement of bones susceptible to pathological fractures following metastatic tumors. The new carbon fiber has also been used in the treatment of tibial non-union (non- healing bone); which has shown satisfactory outcomes.
89344226|NCT03382041|Active Comparator|Titanium Implant|The standard of practice in the treatment of fractures of the tibial shaft and other long bones has been the intramedullary nailing using titanium or stainless steel implants.
89344227|NCT01585571||Control|50 individuals of typical development with no known neuromuscular issues.
89344228|NCT01585571||Adults with CP|50 Individuals with a pediatric diagnosis of spastic, hemiplegic, diplegic or quadriplegic cerebral palsy.
89344229|NCT03807271|Experimental|Smart Pilot(R) View|Anesthesia provided by standard procedure, additionally guided by Smart Pilot(R) View, a device with calculated and graphically produced depth of anesthesia.
89344230|NCT03807271|No Intervention|Standard|Anesthesia provided by standard procedure.
89344231|NCT01131533|Experimental|Erythropoietin|patients with chronic macular edema associated with diabetic retinopathy
89344232|NCT03812731|Active Comparator|Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2 mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.~Children in will then receive CEB with 0.2 % ropivacaine 1-ml/kg for maintaining analgesia"
89344233|NCT03812731|Active Comparator|Non- Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2-mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.~Children in will then receive fentanyl citrate 1-mcg/kg/hr for maintaining analgesia"
89344234|NCT03922841||Subjects with pleural disease|"The subject must meet all of the following inclusion criteria to participate in this study.~Evidence of pleural disease on chest radiograph or bedside ultrasound or Computed Tomography regardless of underlying aetiology~No age or gender restrictions~Ability to provide informed consent"
89344235|NCT03806959|Other|Pan Capsule and colonoscopy|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only
89344236|NCT03351231|Experimental|Dose Escalation|BMS-986242 administered in combination with Nivolumab
89344237|NCT03351231|Experimental|Dose Expansion|BMS-986242 administered in combination with Nivolumab
89344238|NCT01228877|Experimental|Exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
89344239|NCT03807115|Other|Intervention|Arm: Intervention: Implementation of stroke mobility guidelines
89344240|NCT03807115|No Intervention|Control|Arm: Control: Usual care
89344241|NCT03920033|Experimental|Hypofractionated|65 Gy/ 26 fractions (fraction size 2.5 Gy)
89344242|NCT03920033|Active Comparator|Standard|66 Gy/ 33 fractions (fraction size 2 Gy)
89344243|NCT03381339|Experimental|Powered toothbrush intervention|Subjects will be provided an oscillating rotating powered toothbrush as the experimental intervention, and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
89344244|NCT03381339|No Intervention|Manual toothbrush|Subjects will be provided a manual toothbrush as the control group and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
89344245|NCT04493671|Active Comparator|SAD (Part 1): Cohort 1, TBAJ-876 10mg|In cohort 1 with 8 subjects, n= 6 will receive TBAJ-876 10mg under fasting conditions.
89344246|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 1, placebo for TBAJ-876 10mg|In cohort 1 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 10mg under fasting conditions.
89344247|NCT04493671|Active Comparator|SAD (Part 1): Cohort 2, TBAJ-876 25mg|In cohort 2 with 8 subjects, n= 6 will receive TBAJ-876 25mg under fasting conditions.
89344248|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 2, Placebo for TBAJ-876 25mg|In cohort 2 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 25mg under fasting conditions.
89344249|NCT04493671|Active Comparator|SAD (Part 1): Cohort 3, TBAJ-876 50mg|In cohort 3 with 8 subjects, n= 6 will receive TBAJ-876 50mg under fasting conditions.
89344250|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 3, Placebo for TBAJ-876 50mg|In cohort 3 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 50mg under fasting conditions.
89344251|NCT04493671|Active Comparator|SAD (Part 1): Cohort 4, TBAJ-876 100mg|In cohort 4 with 8 subjects, n= 6 will receive TBAJ-876 100mg under fasting conditions.
89344252|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 4, Placebo for TBAJ-876 100mg|In cohort 4 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 100mg under fasting conditions.
89344253|NCT04493671|Active Comparator|SAD (Part 1): Cohort 5, TBAJ-876 200mg|In cohort 5 with 8 subjects, n= 6 will receive TBAJ-876 200mg under fasting conditions.
89344254|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 5, Placebo for TBAJ-876 200mg|In cohort 5 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 200mg under fasting conditions.
89344255|NCT04493671|Active Comparator|SAD (Part 1): Cohort 6, TBAJ-876 400mg|In cohort 6 with 8 subjects, n= 6 will receive TBAJ-876 400mg under fasting conditions.
89344256|NCT04493671|Placebo Comparator|SAD (Part 1): Cohort 6, Placebo TBAJ-876 400mg|In cohort 6 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 400mg under fasting conditions.
89344257|NCT04493671|Active Comparator|SAD (Part 1): Food effect Cohort, TBAJ-876|In food-effect cohort with 10 subjects, n=8 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive the chosen dose of TBAJ-876 under fed conditions.
89344258|NCT04493671|Placebo Comparator|SAD (Part 1): Food effect Cohort, Placebo|In food-effect cohort with 10 subjects, n=2 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive matching placebo for the chosen dose of TBAJ-876 under fed conditions.
89344259|NCT04493671|Active Comparator|MAD (Part 2): Cohort 1, TBAJ-876 Dose 1|In cohort 1 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.
89344260|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 1, Placebo|In cohort 1 with 12 subjects, n=3 is expected to receive the matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
89344261|NCT04493671|Active Comparator|MAD (Part 2): Cohort 2, TBAJ-876 Dose 2|In cohort 2 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.
89344262|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 2, Placebo|In cohort 2 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
89344263|NCT04493671|Active Comparator|MAD (Part 2): Cohort 3, TBAJ-876 Dose 3|In cohort 3 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements
89344264|NCT04493671|Placebo Comparator|MAD (Part 2): Cohort 3, Placebo|In cohort 3 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.
89344265|NCT03919721|Experimental|Learners receiving Applied Behavior Analysis therapy|All children enrolled in the study will already receiving therapy. Each BT-child pair will have worked together regularly for at least 3 months prior to the study.
89344266|NCT01131611|Experimental|CBPT intervention|Standard PT treatment + CBPT
89344267|NCT01131611|Placebo Comparator|Control-Attention|Standard PT treatment + weekly phone calls
89344268|NCT03815383|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
89344269|NCT03711123|Experimental|Group metacognitive therapy (GMCT)|10 weekly sessions of GMCT With 90 minutes duration
89344270|NCT03711123|Active Comparator|Clinical Management|10 weekly individual sessions with up to 60 minutes duration
89344271|NCT03922373|Experimental|Benzonatate|
89344272|NCT03812497|Experimental|Obese Children Group|To reduce the weight, every obese children will receive individualized education program about a way of dietary control and exercise in their usual life. This individualized education program, developed by investigators, specialized dietitian and exercise teacher, is scheduled once a month.
89344273|NCT03812497|No Intervention|Normal Weight Children Group|Normal weight children
89344274|NCT03922295|Active Comparator|endoscopic double flap group|
89344275|NCT03922295|Active Comparator|endoscopic single flap group|
89344276|NCT03711045||Suicide Risk Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) also have a history of suicide attempt in the past 6 months.
89344277|NCT03711045||Disorder Control Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) and without suicide ideation or behavior.
89344278|NCT03711045||Healthy Control Group|
89344279|NCT01302223||Minor Burns|Total burn surface area less than 5% of second and third degree.
89344280|NCT01302223||Major Burns.|Total Burn Surface Area more than 25% of second and third degree, and less than 50%.
89344281|NCT03709719|Experimental|blinatumomab|
89344282|NCT03921983|Experimental|LTOT +|COPD patients with long term oxygenotherapy
89344283|NCT03921983|Active Comparator|LTOT -|COPD patients without chronic hypoxemia (no LTOT)
89344284|NCT03709641|Experimental|Restylane Defyne receiver|Participants will receive Restyane Defyne injected into punctum of one eye.
89344285|NCT05166070|Experimental|Administration of RD133|"Three dose groups of 1.0×10^6 CAR-T/kg, 3.0×10^6 CAR-T/kg, and 6.0×10^6 CAR-T/kg RD133 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.~RD133 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of RD133 will be infused in a single infusion within 30 minutes on day 0."
89344286|NCT03926663|Experimental|group Bupivacaine|Group B; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) as preincisional local infiltration of the nasal mucosa of the nasal septum ,injected once before surgical intervention
89344287|NCT03926663|Active Comparator|group Bupivacaine +Dexmedetomidine|group B+D; will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa of the nasal septum,injected once before surgical intervention.
89344288|NCT05481775|Experimental|Experiment group|Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy
89344289|NCT05481775|Active Comparator|Control group|Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy
89344290|NCT03711981|Active Comparator|TAP block of 10cc Liposomal bupivacaine|Patients in this arm of the study would receive a bilateral Laparoscopic Assisted TAP block with 10cc Liposomal bupivacaine, 10cc 0.25% bupivacaine and 10cc normal saline each bilaterally at the beginning of their surgery.
89344291|NCT03711981|No Intervention|Routine pre-incisional injections at trocar incision sites|The patients in the control arm of the study would receive routine pre-incisional injections at the trocar incision sites using a total of 20cc 0.25% bupivacaine.
89344292|NCT05389384|Experimental|Peripheral fatigue - No support|peripheral fatigue induced and overhead work performed without exoskeleton support
89344293|NCT05389384|Experimental|Peripheral fatigue - Exoskeleton support|peripheral fatigue induced and overhead work performed with exoskeleton support
89344294|NCT05389384|Experimental|No fatigue - No support|peripheral fatigue induced and overhead work performed without exoskeleton support
88806976|NCT04300998||older patients with lymphoma and other lymphoid malignancies|This is a prospective observational cohort where 80 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory lymphoma and lymphoid malignancies will undergo comprehensive geriatric assessment, aging biomarker analysis, and quality of life evaluation prior to and following CAR T therapy. The standard follow-up period is one year.
89344295|NCT05389384|Experimental|No fatigue - Exoskeleton support|peripheral fatigue induced and overhead work performed with exoskeleton support
89344296|NCT01130285||Non-Lung Cancer, Heavy Smoker|Subjects will be ≥ 50 years of age and have a ≥ 20 pack year smoking history and will be either healthy volunteers or individuals undergoing diagnostic bronchoscopy, with absence of lung cancer documented at the time of enrollment.
89344297|NCT03710967|Experimental|Bilateral TMS|
89344298|NCT03710967|Active Comparator|Unilateral TMS|
89344299|NCT01132079|Experimental|Pimecrolimus cream treatment|
89344300|NCT01132079|Active Comparator|Betamethasone valerate cream treatment|
89344301|NCT05165914|Active Comparator|Midazolam group|In the midazolam group, patients double blindly received 0.03 mg.kg-1 midazolam intravenously just before emergence from general anesthesia.
89344302|NCT05165914|Placebo Comparator|Placebo group|In the placebo group, patients double blindly received normal saline of similar volume to midazolam just before emergence from general anesthesia.
89344303|NCT01132157|Experimental|Propofol group|
89344304|NCT01132157|Active Comparator|Desflurane group|
89344305|NCT05389150|Experimental|Group A: Pregabalin/ Tramadol Fixed dose|Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral
89344306|NCT05389150|Active Comparator|Group B: Pregabalin (Lyrica®)|Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral
89344307|NCT05389150|Active Comparator|Group C: Tramadol (Tradol®)|Pharmaceutical Form: Tablet Dosage: 50 mg Administration way: oral
89344308|NCT03926351|Placebo Comparator|Arm 1a; Placebo|Valid for the first 24 weeks of the study. Arm 1a: placebo, soft gelatine capsule containing 1000 mg olive oil, refined.
89344309|NCT03926351|Experimental|Arm 2a; Omega-3 capsules|Valid for the first 24 weeks of the study. Arm 2a; Omega-3, (1000 mg fill weight per capsule) containing omega-3 ethyl ester concentrate with a high proportion of DHA.
89344310|NCT03806101|Experimental|Arm 1|Single dose of rosuvastatin on Day 1 of Period 1 and Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 2.
89344311|NCT03806101|Experimental|Arm 2|Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 1 and single dose of rosuvastatin on Day 1 of Period 2.
89344312|NCT01228955||Yoga Group|Group will enter a 10 week yoga class
89344313|NCT03812419|Active Comparator|group I|Esomeprazole 40 mg capsules once daily for 6 months
89344314|NCT03812419|Active Comparator|group II|Pantoprazole 40 mg tablets once daily for 6 months
89344315|NCT05373550|No Intervention|Comparison group: usual care|It is made up of women between 35 and 65 years old who are on the waiting list for surgical treatment (hysterectomy) of the gynecology service of the HGOLEA and receive routine care.
89344316|NCT05373550|Experimental|Experimentation group: nursing education intervention with technological support.|It is made up of women between 35 and 65 years of age who are on the waiting list for surgical treatment (hysterectomy) in the gynecology service of the HGOIA. Women seen at this facility receive care similar to that previously described for the HGOLEA. This group will additionally receive the educational intervention of face-to-face nursing with technological support.
89344317|NCT03922061|Experimental|fIPV-dmLT|fractional-dose inactivated polio vaccine (fIPV) given intradermally with double mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant
89344318|NCT03922061|Active Comparator|fIPV|fractional-dose inactivated polio vaccine (fIPV) given intradermally
89344319|NCT05165680|Experimental|experimental group, group A|Thirty patients in this group will perform aerobic exercise in the form of walking on electric treadmill three times/ week day after day and low caloric diet rich in iron, vitamin C and folate and iron supplement for 12 weeks.
89344320|NCT05165680|Active Comparator|healthy diet|ow caloric diet rich in iron, vitamin C and folate and iron supplement for 12 weeks.
89344321|NCT04415515|Experimental|Treatment 1|RN Standard care coordination and disease management + RN Case Management
89344322|NCT04415515|Experimental|Control|RN Standard care coordination and disease management
89344323|NCT04415515|Experimental|Treatment 2|RN Standard care coordination and disease management + Community Health Worker Case Management
89344324|NCT02528981|Experimental|Probiotic|L. rhamnosus GR-1 and L. reuteri RC-14 will be supplied to 100 randomized pregnant people in gelatin capsules containing 2.5 billion viable cells of each strain (CFU). These organisms have been previously shown to colonize the vagina after being taken orally (11) and displace the pathogens causing bacterial vaginosis (12) and vaginal yeast infections (13), and have been shown to be an effective treatment, or accessory to treatment of these conditions. (7- 9, 13)
89344325|NCT02528981|Placebo Comparator|Placebo|Placebo capsules will be supplied to 100 randomized pregnant people in gelatin capsules that are identical to the probiotics that the experimental group will receive.
89344326|NCT01229033|Active Comparator|Ablation|Ablation of atrial tachycardia
89344327|NCT01229033|Active Comparator|Cardioversion|Cardioversion of atrial tachycardia
89344328|NCT04455568||experimental group|Non-invasive Wearable Device, use ECG Wisdom bracelet
89344329|NCT04455490||Delayed wound healing|Patients with delayed wound healing after Achilles tendon suture who were treated at Peking University Third Hospital
89344330|NCT01560169||Gluten challenge|Gluten containing or gluten-free study food in established celiac disease patients
89344331|NCT01560169||Observation|Observation in newly diagnosed celiac disease patients
89344332|NCT01130363||Fundic Gland Polyps on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have also been prescribed and regularly take a proton pump inhibitor.
89344333|NCT01130363||Fundic Gland Polyp not on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have not been prescribed a proton pump inhibitor.
89344334|NCT01130363||Group 3 (Control Group)|Individuals who are prescribed proton pump inhibitor but are not found to have fundic gland polyps on endoscopic evaluation.
89344335|NCT03401229|Experimental|Benralizumab 30mg SC + MF|SC - subcutaneously MF - Mometasone Furoate
89344336|NCT03401229|Placebo Comparator|Placebo SC + MF|
89344337|NCT03926429||Patient with reactive arthritis|
89344338|NCT05339230|Experimental|Active|Salovum egg powder high in antisecretory factor, 4 g/sachet. Four sachets, ie 16 g q 8 h for 6 days starting 6 days before 1st cycle of chemotherapy. SPC-flakes flat dose of 75 g/d divided in 2 - 4 doses started in parallel with Salovum to be continued during the first 8 weeks of chemotherapy.
89344339|NCT05339230|Placebo Comparator|Control|Salovum placebo powder without antisecretory factor, 4 g/sachet. Four sachets, ie 16 g q 8 h for 6 days starting 6 days before 1st cycle of chemotherapy. SPC placebo flakes flat dose of 75 g/d divided in 2 - 4 doses started in parallel with Salovum placebo to be continued during the first 8 weeks of chemotherapy.
89344340|NCT01302457||Healthy Same Subjects|The control group will be 19 years or older and be randomly picked from from volunteer staff at Saint Elizabeth Regional Medical Center. This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects
89344341|NCT01302457||Health Volunteers|"The control group will be 19 years or older and be randomly picked from volunteer staff at Saint Elizabeth Regional Medical Center.~DESIGN This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects"
89344342|NCT05332132|Experimental|Intrauterine Morcellation of Uteri Post-Surgery|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
89344343|NCT01132391|Experimental|1|Endoanal application
89344344|NCT01132391|Experimental|2|Perianal application
89344345|NCT05165134|Experimental|Experimental kinesiotape group A|Kinesiotape group
89344346|NCT05165134|Placebo Comparator|Placebo kinesiotape group B|Control group
89344347|NCT01130441||self-harming group|
89344348|NCT01130441||non-self-harming group -control group|
89344349|NCT05296642|Experimental|Cycling at a Moderate Intensity Aerobic Exercise (AE) group|All participants will be asked to cycle during the first phase at a moderate intensity for 20 minutes.
89344350|NCT05296642|Experimental|Blood Flow restriction training with cycling at a moderate intensity (BFR+AE) group|All participants will be asked to wear an automated personalize tourniquet system to restrict blood flow. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Then, participants will be asked to cycle at a moderate intensity for 20 minutes during the second phase.
89344351|NCT05281081|Active Comparator|levobupivacaine with morphine|30 patients will have intraperitoneal instillation of levobupivacaine with added morphine at the end of laparoscopic cholecystectomy operation
89344352|NCT05281081|Experimental|levobupivacaine with magnesium sulfate|30 patients will have intraperitoneal instillation of levobupivacaine with added magnesium sulfate at the end of laparoscopic cholecystectomy operation
89344353|NCT05164900|Experimental|patients with nasal pterygium.|
89344354|NCT03812965|Experimental|Group 1 - Botulinum Toxin type A (4 points of application)|4 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle and Levators labii superioris muscle (n=10 Patients)
89344355|NCT03812965|Experimental|Group 2 - - Botulinum Toxin type A (2 points of application)|2 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle (n=10 Patients)
89344356|NCT01132469|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
89344357|NCT05085184|Experimental|UI018|
89344358|NCT05085184|Active Comparator|UIC201806 and UIC201602|
89344359|NCT03921749|Experimental|Focused shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be focused shock wave therapy (0.20 mJ/mm 2 )
89344360|NCT03921749|Experimental|Raidal shock wave|The extracorporeal shock wave will be applied to the patellofemoral and tibiofemoral borders and the subchondral bone of the medial tibia condyle of the affected knee joint. The intensities used will be radial shock wave therapy (3 bar)
89344361|NCT05260762|Active Comparator|Arabinoxylan|Arabinoxylan (15 g AX/d) wheat buns
89344362|NCT05260762|Placebo Comparator|Control|Non-fiber, carbohydrate control (15 g /d) wheat buns
89344363|NCT01302535|Active Comparator|Yoga group with supervision/trainer|
89344364|NCT01302535|Active Comparator|Yoga at home|
89344365|NCT01302535|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention groups.
89344366|NCT01227863|Experimental|Test|Dexamethasone + neomycyn + polimixyn B
89344367|NCT01227863|Active Comparator|Comparator|Dexamethasone + neomycyn + polimixy B
89344368|NCT03349515|Active Comparator|Group A - povidone-iodine ophthalmic solution.|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first.
89344369|NCT03349515|Active Comparator|Group B - ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution, with the right eye to receive the drops first.
89344370|NCT05496010|Experimental|Dry Needling|Dry needling will be performed on the patients of group A after the diagnosis of trigger points in particular muscles.The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved.
89344371|NCT05496010|Active Comparator|Ischemic Compression Technique|Ischemic Compression technique will be performed on the patients of group B after the diagnosis of trigger points in particular muscles by diagnostic ultrasound. The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved.
89344372|NCT01303315|Other|GLP-1 receptor agonist therapy|Group A: Subjects on GLP-1 receptor agonist therapy only. After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c < 7.5 are moved to Group A, continue GLP-1 receptor agonist therapy, and then start the Evaluation Period These patients will not be implanted with the TANTALUS system.
89344373|NCT01303315|Experimental|GLP-1 receptor agonist and TANTALUS|Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c > 7.5 are moved to Group B, continue GLP-1 receptor agonist therapy, implanted with TANTALUS within 4 weeks, and then start the Evaluation Period
89344374|NCT01303315|Active Comparator|Subjects on TANTALUS therapy only|Group C: subjects on TANTALUS therapy only After run in of 12 weeks on GLP-1 receptor agonist therapy, patients intolerant to low dosage of GLP-1 receptor agonist therapy will be implanted with the TANTALUS system
89344375|NCT01132625|Experimental|AUY922|
89344376|NCT03349437|Experimental|Vitabreath Device|The Philips Respironics investigational device VitaBreath is a handheld, battery powered, intermittent positive airway pressure device that is non-invasive, and provides positive airway pressure (PAP) of 18 cm water (H2O) during inspiration and 8 cm H2O on expiration, thus creating 10 cm H2O of pressure support. Pressure support is defined as the difference between inhalation pressure and exhalation pressure. The study device is intended as an adjunct therapy to relieve shortness of breath in COPD patients who experience exertion-related dyspnea to allow them to be more active. The air is delivered to the patient via a mouthpiece on the device.
89344377|NCT03349437|Active Comparator|Pursed Lip Breathing|Pursed lip breathing is a commonly used technique by COPD patients. That involves exhaling through tightly pressed lips and inhaling through the nose with the mouth closed.
89344378|NCT01227941|Experimental|Part A: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination. Dose escalation/confirmation in participants with advanced solid tumors
89344379|NCT01227941|Experimental|Part B: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination at 1 or 2 dose levels of MK-4827 to be determined from the results of Part A. Ovarian Cancer Cohort
89344380|NCT03919565|Active Comparator|TDF group|80 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to 144 weeks.
89344381|NCT03919565|Experimental|Peginterferon alfa group|40 patients would receive treatment of subcutaneous injection of peginterferon alfa 2a 180 μg or peginterferon alfa 2b 80μg once per week from baseline to 48 weeks. Then they would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from 49 to 144 weeks.
89344382|NCT03380091|Experimental|Metformin|Metformin 1000 mg PO bid
89344383|NCT03380091|Experimental|Vitamin D (Cholecalciferol)|Cholecalciferol 5,000 IU PO daily
89344384|NCT02529293|Active Comparator|BioChaperone Lispro U-100|injection of 2 doses of 0.2 U/kg on separate visits
89344385|NCT02529293|Experimental|BioChaperone Lispro U-200|injection of 2 doses of 0.2 U/kg on separate visits
89344386|NCT03919253|Experimental|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously; nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
89344387|NCT05458648||Persistent AF Arm|Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation
89344388|NCT01130675|Active Comparator|eight ounces of caffeinated coffee for breakfast and lunch|
89344389|NCT01130675|No Intervention|standard care|
89344390|NCT05165290|Active Comparator|LAT, 0.005%|Commercially available FDA-approved generic latanoprost ophthalmic solution, 0.005%
89344391|NCT05165290|Experimental|TC-002|TC-002, TearClear latanoprost ophthalmic solution, 0.005%
89344392|NCT03379233|Active Comparator|Usual Care|Concept2 inhaler
89344393|NCT03379233|Experimental|Telehealth|Concept2 inhaler with patient application
89344394|NCT03815071|Experimental|ips-nsc treatment group|
89344395|NCT01132703|Placebo Comparator|Matching Placebo|Matching placebo (glyburide excipients without active) is administered as a bolus followed by continuous infusion for 72 hours.
89344396|NCT01132703|Experimental|Glyburide for Injection: Dose 1|Glyburide is administered as a bolus followed by a infusion for 72 hours
89344397|NCT01132703|Experimental|Glyburide for Injection: Dose 2|Glyburide is administered as a bolus followed by a infusion for 72 hours
89344398|NCT01132703|Experimental|Glyburide for Injection: Dose 3|Glyburide is administered as a bolus followed by a infusion for 72 hours.
89344399|NCT03815149||patients with intracranial aneurysm(s)|Standard of care elective, unscheduled or emergency procedures for the treatment of an unruptured or ruptured intracranial aneurysm(s) using a Pipeline™ Flex Embolization Device(s) with Shield Technology™
89344400|NCT03919487||Back-to-back colonoscopy group|As I described the study method in the protocol, the experimental group will be a screening colonoscopy cohort with back to back method. In fact, this study is to evaluate the correlation between quality indicators of colonoscopy and adenoma miss rate (AMR), and intervention is a single arm for back-to-back colonoscopy.
89344401|NCT03711825|Experimental|Sentinel/Main|Sentinel dosing of two subjects in clinic of LYN-057 (50 mg), followed by Main, i.e. remaining 6 subjects, for total of 8 subjects doses; followed by imaging assessment (MRI/abdominal U/S)
89344402|NCT03607162|No Intervention|Usual care|Local usual management of FWS (pragmatic approach)
89344403|NCT03607162|Experimental|DIAFEVER algorithm|New DIAFEVER sequential algorithm PCT rapid test-based will be applied
89344404|NCT01228097||Gastric Bypass|Participants who receive gastric bypass surgery.
89344405|NCT01228097||Principally Restrictive Surgery|Participants who receive gastric banding or sleeve gastrectomy surgery.
89344406|NCT01228097||Weight Stable|Participants who remain weight stable.
89344407|NCT03919331|Experimental|Experimental|Every adult patient admitted to the medical intensive care unit for de novo acute hypoxemic respiratory failure, and placed under hign flow nasal canula (HFNC). Inclusion and exclusion criterion are listed elsewhere.
89344408|NCT01303393||Surgery for colorectal cancer|Patients that had surgery for colorectal cancer without receiving a stoma, and their next of kin.
89344409|NCT01585649|Experimental|XM22, 100 μg/kg BW|
89344410|NCT01377922|Placebo Comparator|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
89344411|NCT01377922|Experimental|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
89344412|NCT02528903|Experimental|Cohort A|
88806977|NCT04300998||older patients with myeloma and other plasma cell disorders|This is a prospective observational cohort where 40 older patients (≥60yo) undergoing CAR T therapy for relapsed refractory plasma cell disorders will undergo
88806978|NCT04293146|Active Comparator|pre-pectoral IBBR|
89344413|NCT02528903|Experimental|Cohort B|
89344414|NCT02528903|Experimental|Cohort C|
89344415|NCT02528903|Experimental|Cohort D|
89344416|NCT02528903|Experimental|Cohort E|
89344417|NCT03811795|Other|Arm 1-Repeat Cryoballoon Ablation|Subjects will be randomized to repeat cryoballoon ablation.
89344418|NCT03811795|Other|Arm 2-Radiofrequency Ablation|Participants will have radiofrequency ablation guided by high-fidelity mapping (Rhythmia) following an initial cryoballoon ablation.
89344419|NCT03919175|Experimental|Umbralisib+Rituximab|"A treatment cycle is defined as 28 consecutive days.~Umbralisib will be administered at 800 mg by mouth once daily on days 1-28 of cycles 1-24.~Rituximab will be administered at 375 mg/m2 by intravenous infusion on Cycle 1 Day 1 and may be administered at 375 mg/m2 by intravenous infusion or at 1400 mg by subcutaneous injection on days 8, 15, 22 of cycle 1, day 1 of cycles 2 to 6, then every 8 weeks starting on day 1 of cycle 7 until completion of 24 cycles of umbralisib (i.e. every other cycle for 18 cycles or 9 doses, for a total of 15 doses of rituximab), or until progression or intolerance."
89344420|NCT01303471|Experimental|opioïd|Different levels of remifentanyl of each group during nociceptive stimulation
89344421|NCT03372603|Experimental|Treatment Sequence AB|Subjects will receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days).
89344422|NCT03372603|Experimental|Treatment Sequence BA|Subjects will receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days).
89344423|NCT01560247||Treatment Group|Subjects in whom a MindFrame Device was employed for restoration of flow and clot removal
89344424|NCT03919019|Experimental|Macuprev Group|patients taking oral supplementation (Macuprev) 2 capsules per day for 6 months
89344425|NCT03919019|Placebo Comparator|Placebo Group|patients taking oral placebo 2 capsules per day for 6 months
89344426|NCT03811717|Experimental|FAST+EX - FAST|FAST+EX then FAST alone
89344427|NCT03811717|Experimental|FAST - FAST+EX|FAST alone then FAST+EX
89344428|NCT03919409|Experimental|Part A: Cohort 1: TS-161 15 mg|Single dose of TS-161 15 mg or placebo in a fasted condition.
89344429|NCT03919409|Experimental|Part A: Cohort 2: TS-161 50 mg|Single dose of TS-161 50 mg or placebo which will be dosed first in a fasted condition, and then in a fed condition, with a washout period in between 2 dosing. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
89344430|NCT03919409|Experimental|Part A: Cohort 3: TS-161 100 mg|Single dose of TS-161 100 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
89344431|NCT03919409|Experimental|Part A: Cohort 4: TS-161 200 mg|Single dose of TS-161 200 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
88806979|NCT04293146|Active Comparator|sub-pectoral IBBR|
89344432|NCT03919409|Experimental|Part A: Cohort 5: TS-161 400 mg|Single dose of TS-161 400 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.
89344433|NCT03919409|Experimental|Part B: Cohort 6: TS-161 TBD|Single dose of TS-161 in a fasted condition. The dose level will be determined based on the results from the preceding cohorts.
89344434|NCT03919409|Experimental|Part C: Cohort 7: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
89344435|NCT03919409|Experimental|Part C: Cohort 8: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
89344436|NCT03919409|Experimental|Part C: Cohort 9: TS-161 TBD|Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.
89344437|NCT03804541|Experimental|[14C]Ensartinib|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]Ensartinib to healthy Chinese male subjects。
89344438|NCT01377844|Experimental|EGT0001442|EGT0001442 capsule, 20 mg, daily, 96 weeks
89344439|NCT01377844|Placebo Comparator|Placebo|Placebo
89344440|NCT03709485|Experimental|prostate biopsy patients|a cohort o consecutive patients referred to prostate biopsies. In all patients, a rectal swab will be taken prior to biopsy and antimicrobial treatment. The swab will be cultured and analyzed in the lab for characterization of the microbiome.
89344441|NCT01329497|Experimental|interventional group|
89344442|NCT05065489||Schizophrenia patients|patients who diagnosed with schizophrenia in accordance with DSM-5 criteria
89344443|NCT05065489||Bipolar disorder patients|patients who diagnosed with bipolar disorder in accordance with DSM-5 criteria
89344444|NCT05065489||Depression patients|patients who diagnosed with major depression disorder in accordance with DSM-5 criteria
89344445|NCT05065489||Health control|health participants who have not diagnosed with any psychological or psychiatric disease.
89344446|NCT03710811||Type 2 Diabetes|drug naive Type 2 Diabetes received insulin therapy
89344447|NCT03710811||normal control|healthy volunteers as normal control
89344448|NCT01229969|Experimental|NeuroCom EquiTest® System|Measure balance assessment (test for Sensory Organization Test (SOT) and Limit of Stability (LOS).
89344449|NCT01229969|Experimental|Wii Fit|Determine if the Wii Fit is valid and feasible in detecting balance problems in older adults
89344450|NCT01303549|Experimental|Anidulafungin|Anidulafungin IV once a day: initial dose 200 mg/day, following doses 100 mg/day.
89344451|NCT01303549|Active Comparator|Liposomal Amphotericin B|Liposomal amphotericin B once a day: 3 mg/kg/day
89344452|NCT03710733|Active Comparator|Sequential boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus sequential boost 10 Gy/4 fx (2.5 Gy/fx) to lumpectomy cavity
89344453|NCT03710733|Experimental|Concomitant boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus concomitant boost 8 Gy/15 fx (0.53 Gy/fx) to lumpectomy cavity
89344454|NCT03925571|Experimental|music-listening group|patient will listen to music during the dental surgery (1 to 1h30 hours).
89344455|NCT03925571|No Intervention|non music-listening group|patient will receive their dental intervention without music-listening.
89344456|NCT03709407|Experimental|cervical stimuli|Godoy´s maneuver with traction-sliding in supraclavicular fossa
89344457|NCT03709407|Experimental|terminus|Vodder´s maneuver with medial and anterior traction in supraclavicular fossa
89344458|NCT03709407|Sham Comparator|placebo|maneuver with sliding ON clavicular
89344459|NCT03709407|No Intervention|Control group|only lying down
89344460|NCT03811639|Active Comparator|RF ablation|Patients treated with point-by-point radio-frequency ablation
89344461|NCT03811639|Experimental|Cryoballoon ablation|Patients treated with cryoballoon ablation
89344462|NCT03925337|Experimental|Arm-1 Standard Colonoscopy/AI-Assisted Combined Colonoscopy|Normal scope insertion and withdrawal first, followed by a second withdrawal with the research software running on a separate screen to catch any additional polyps missed during the first withdrawal.
89344463|NCT03925337|Experimental|Arm-2 AI-Assisted Combined Colonoscopy/Standard Colonoscopy|Normal scope insertion but first withdrawal with the research software running on a separate screen, followed by a second withdrawal without the research software running.
89344464|NCT05400460|Other|ASBR group|Anterior cruciate ligament reconstruction using STG, absorbable interface nails and ASBR procedures.
89344465|NCT05400460|Other|CASBR group|Anterior cruciate ligament reconstruction using STG, absorbable interface nails and CASBR procedures.
89344466|NCT05400460|Other|DB group|Anterior cruciate ligament reconstruction using STG, absorbable interface nails and DBR procedures.
89344467|NCT05061979|Experimental|Mild renal impairment|Participants with mild renal impairment will receive a single dose of BAY1747846.
89344468|NCT05061979|Experimental|Moderate renal impairment|Participants with moderate renal impairment will receive a single dose of BAY1747846.
89344469|NCT05061979|Experimental|Normal renal function|Participants with normal renal function will receive a single dose of BAY1747846.
89344470|NCT03918707||Prospective|The prospective group will consist of approximately 15 evaluable patients who will undergo rWGS sequencing in addition to standard of care genetic testing. Subjects in this study will be drawn from children admitted to the NICU at OSF HealthCare Children's Hospital of Illinois who meet inclusion criteria.
89344471|NCT03918707||Historical Control|The historical control group will consist of patients admitted to the NICU between January 1, 2016 and December 31, 2018 who received genetic testing at less than 4 months of age and fulfil eligibility criteria.
89344472|NCT03372369|Active Comparator|CDC Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view CDC poster for contraceptive effectiveness.
89344473|NCT03372369|Experimental|Patient-Centered Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view Patient-Centered poster for contraceptive effectiveness.
89344474|NCT05400382|Experimental|Mindfulness|Receiving mobile, self-guided mindfulness intervention
89344475|NCT05400382|No Intervention|Treatment as usual with monitoring|Receiving treatment as usual with monitoring by study PI and investigators.
89344476|NCT03796975|Experimental|Combination of Pioglitazone and Metformin Tablets|dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
89344477|NCT03796975|Active Comparator|Metformin Hydrochloride Tablets|dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
89344478|NCT03925493|No Intervention|Control Group Procedures (RPE based exercise)|Patients in the control group will follow standard exercise prescription protocols in CR. Exercise intensity will be guided by the patient's reported rating of perceived exertion (RPE). The modified Borg scale will be used by the patients to determine their RPE. Therefore, a scale of 1-10 will be used. The general goal will be to exercise between intensity level 3 or 4 (i.e. moderate intensity), per current program standards. Based on exercise levels achieved on the first day, patients will be given exercise recommendations for their 2nd session of CR and so forth. As the patients progress in CR, patients will increase their time, intensity, and mode of exercise as appropriate. Exercise progression will be guided by RPE and clinical assessment.
89344479|NCT03925493|Experimental|Exercise Test and Heart Rate Range|Patients randomly assigned to this group will complete a graded exercise test (GXT) per standard protocols. The researchers will obtain the patients peak heart rate from this stress test. Obtaining an accurate peak heart rate will allow for the calculation of a target heart rate range (THRR) using the Karvonen formula. Based upon the Karvonen formula, the THRR will be between 60-80% of the patient's heart rate reserve. The Karvonen formula can be calculated as follows ((peak heart rate - resting heart rate) X % intensity (0.6 or 0.8) + resting heart rate)). An example would be: (155 -75) X (.6) + 75) = 123; ((155 - 75) X (.8) + 75 = 139) THRR: 123 - 139. Patients will then adjust their exercise intensity to match this target heart rate range for the duration of their time in cardiac rehabilitation. Cardiac rehabilitation staff will provide feedback about heart rate when they are able.
89344480|NCT03925493|Experimental|Exercise Test, Heart Rate Range, and Heart Rate Monitor|"Patients randomly assigned to this group will also undergo a stress test (GXT) and exercise within a target heart rate range (THRR) during cardiac rehabilitation comparable to second arm of the trial. Additionally, they will receive a personal heart rate monitor (HRM). This monitor will consist of a polar heart rate chest strap and polar watch. Patients will be asked to wear this during cardiac rehabilitation and adjust their own exercise intensity. This will provide continuous feedback to the patient about their heart rate. Cardiac rehabilitation staff will also provide feedback when available.~The investigators are using the heart rate monitors because cardiac rehab staff are not always able to adjust exercise intensity for all patients, and telemetry is not always used."
89344481|NCT01302613|Other|arm one|RT + Chemo + surgery
89344482|NCT05399914||Preterm infants with a gestational age (GA) between 26 ≥ and < 32 weeks|
89344483|NCT03796897|Experimental|Leucine-enriched protein + exercise|whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein), vitamin D, and free leucine
89344484|NCT03796897|Sham Comparator|Habitual diet + exercise|habitual diet only
89344485|NCT03918785|Experimental|Rice Germ|"The Rice Germ was supplied in vacuum jars of a weight of 130 grams. These jars once opened, were stored in the refrigerator (-3-4°C). Together with cans, small containers were provided to act as dosers and served to determine the correct dose to be taken (25 grams, twice a day). The rice germ or placebo were continually taken every day twice a day (25 grams in the morning with breakfast and 25 grams in the afternoon as snacks) for 5 weeks. The rice germ was supplied by the company Acquerello (TenutaColombara, Livorno Ferraris, Vercelli, Italy)."
89344486|NCT03918785|Active Comparator|Control group|Active comparator, which consisted of an isocaloric wheat germ-based supplement. Characteristics of supplementation are the same of experimental group.
89344487|NCT03709329|Experimental|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
89344488|NCT03709329|Active Comparator|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
89344489|NCT05399524|Experimental|Additional pre- and intra-operative imaging|Surgery to resect the GB using Diffusion Tensor Imaging (DTI) and intraoperative Ultrasound (iUS) (navigated iUS where available) in addition to standard care (i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-aminolevulinic acid (5-ALA))
89344490|NCT05399524|Active Comparator|Standard of Care|The comparator is standard care as per current NICE guidelines (i.e. neuronavigation based on preoperative MRI and intraoperative use of 5-ALA).
89344491|NCT03918863|Experimental|Neuromuscular electrical stimulation|8-week exercise program, twice a week, with neuromuscular eletrical stimulation on vastus medialis and gluteus medius.
89344492|NCT03918863|Active Comparator|Exercise|8-week exercise program, twice a week.
89344493|NCT03796585|Experimental|Intervention|Pharmacists assigned to this group will receive an immunization registry training program and informational flyer.
89344494|NCT03796585|Active Comparator|Control|Pharmacists assigned to this group will receive an informational flyer. They will not receive training.
89344495|NCT01230047|Experimental|Psychoeducational Course|In this arm, clients receive the psychoeducational course.
89344496|NCT01230047|No Intervention|Treatment-as-usual/Waiting list|Clients assigned to this condition will receive treatment-as-usual (TAU) and be placed on a waiting list.
89344497|NCT05399212|Experimental|FPT-20|FPT-20 should be used regularly (>6 to 12 months) until the therapeutic purpose is achieved.
89344498|NCT03803371|Experimental|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets by mouth on Day 1 of period 1 or 2
89344499|NCT03803371|Active Comparator|Ultracet tablet|Ultracet tablet (Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg) by mouth on Day 1 of period 1 or 2
89344500|NCT03918941|Experimental|Carey|
89344501|NCT03918941|Active Comparator|conventional information|
89344502|NCT05399134|Experimental|Modified Functional Foods (Treatment)|Anthocyanin black rice extract powder (ABREP)-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice for breakfast, lunch, and dinner respectively served in a mixed meal.
89344503|NCT05399134|Placebo Comparator|Control Functional Foods (Control)|White bread, beehoon noodles, and jasmine white rice for breakfast, lunch, and dinner respectively served in a mixed meal.
89344504|NCT01130909|Experimental|AZD6765 75 mg|
89344505|NCT01130909|Experimental|AZD6765 150 mg|
89344506|NCT01130909|Active Comparator|Ketamine 0.5 mg/kg|
89344507|NCT01130909|Placebo Comparator|125 mL sterile NaCl 0.9%|
89344508|NCT04963231|Experimental|Setmelanotide|Patients with specific gene variants in the MC4R pathway on setmelanotide
89344509|NCT04963231|Placebo Comparator|Placebo|Patients with specific gene variants in the MC4R pathway on placebo
89344510|NCT05398978|Experimental|Intervention|The intervention arm will be registered in th e-Register database and recieve voice calls and text messages
89344511|NCT05398978|No Intervention|Control|The control group will be enrolled and followed until their delivery. They will not get the intervention.
89344512|NCT03918551|Other|Sequence AB|25 subjects assigned to the sequence AB will receive a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in Period 1 and a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89344513|NCT03918551|Other|Sequence BA|25 subjects assigned to the sequence BA will receive a single 120 mg dose of the reference product Adenuric (1 x 120 mg film-coated tablet), marked as B in the sequence, in Period 1 and a single 120 mg dose of the test product Febuxostat (1 x 120 mg film-coated tablet), marked as A in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89344514|NCT03918473|Experimental|Mobilization with Movement|A weight- bearing mobilization directed to the talocrural joint in a standing position.
89344515|NCT03918473|Experimental|Thrust Mobilization|A high velocity, low amplitude thrust mobilization directed to the talocrural joint with the participant in a non-weight bearing position.
89344516|NCT04453930|Experimental|Camrelizumab+Irinotecan+Platinum→Camrelizumab+apatinib|Participants received intravenous infusions of Camrelizumab 200 mg in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) or Cisplatin 30 milligrams per square meter (mg/m^2) followed by Irinotecan 65 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4/5/6). On Days 8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6), Cisplatin 30 mg/m^2 and Irinotecan 65 mg/m^2 was administered. Thereafter, participants received maintenance (Cycle onward) Camrelizumab 200 mg on Day 1 of every 21-day cycle with Apatinib 250mg until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
89344517|NCT03796507|Experimental|Temozolomide Arm|This study will only include one treatment group who will receive oral temozolomide at 75 mg per square meter of body surface area daily for 21 days before progressing to standard chemoradiation treatment.
89344518|NCT01130987|Experimental|Comprehensive Handoff Program|Introduction of Computerized tool plus team training
89344519|NCT04454008|Experimental|Intervention|The intervention group will receive 12 sessions of executive function family training, including executive function training for children and parenting guidance for parents.
89344520|NCT04454008|Active Comparator|waiting|The waiting group will receive routine clinical intervention, including health education, family support and guidance from outpatient clinic.
89344521|NCT03796351|Experimental|MT10107(botulinum toxin type A)|Subjects will be administered a single equivalent dose of MT10107 by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
89344522|NCT03796351|Active Comparator|BOTOX® 50U(botulinum toxin type A)|Subjects will be administered a single equivalent dose of BOTOX® 50U by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
89344523|NCT03925259|Active Comparator|Full-ACT|Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of eight modules in the Full-ACT arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all eight mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; self-as-context; values; and committed action.
89344524|NCT03925259|Experimental|ACT-SAC|"Participants received eight 50-minute sessions of ACT. A treatment protocol comprising of seven modules in the ACT-SAC arm was developed by the research team. Each module comprised a series of exercises and metaphors, as well as guidance on how to discuss specific components. There was some degree of flexibility by which therapists introduced modules (Strosahl et al., 2004). However, by the final session, all mandatory subjects, exercises, and metaphors had to be covered. Modules were as follows: creative hopelessness; acceptance; defusion; present-momentness; values; and committed action.~The ACT-SAC condition removed the self-as-context module; therapists were instructed to avoid any reference to self-as-context or to support discussions regarding this process."
89344525|NCT03796429|Experimental|GS+Toripalimab|
89344526|NCT03918395|Placebo Comparator|Placebo|Placebo beverage
89344527|NCT03918395|Active Comparator|Protein-Polyphenol supplement|Protein-polyphenol beverage
89344528|NCT03796117|Experimental|Experimental Group 1: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
89523603|NCT03384433|Experimental|exosome or vesicle|CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal
89344529|NCT03796117|Experimental|Experimental Group 2: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
89344530|NCT05398432|Experimental|control|The control group did not intervene
89344531|NCT05398432|Experimental|experiment|"Initial data were collected after meeting the patients. Then, a total of 6 seans, 1 seans per week, were performed on the patients. Self-care training was given in the 1st, 2nd and 3rd seans. Motivational interviews were conducted in the 4th, 5th and 6th seans. After the first seans of the self-care supported motivational interview, the Self Care and Adaptation Training Guide prepared by the researcher in line with the literature was given to the experimental group. Second data were collected from patients after 6 weeks. Follow-up data were collected for 4 weeks without any intervention."
89344532|NCT01132781|Placebo Comparator|Placebo|200mg twice daily of placebo drug
89344533|NCT01132781|Active Comparator|200mg theophylline|200mg twice daily of slow release theophylline
89344534|NCT03795961|Experimental|Active tDCS group|This group will include 42 patients with CTS Intervention (active transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
89344535|NCT03795961|Sham Comparator|Sham tDCS group|This group will include 42 patients with CTS Intervention (sham or inactive transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
89344536|NCT03925103|Experimental|3D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a three-dimensional display system
89344537|NCT03925103|Active Comparator|2D VATS lobectomy|Patients undergo thoracoscopic lobectomy by a two-dimensional display system
89344538|NCT03497767|Experimental|Osimertinib|80mg Osimerinib taken once daily
89344539|NCT03497767|Experimental|Stereotactic Radiosurgery + Osimertinib|Upfront Stereotactic Radiosurgery (SRS) followed by 80mg Osimerinib taken once daily
89344540|NCT01230203|Other|Computed tomography scan versus color duplex ultrasound|
89344541|NCT05398042|Placebo Comparator|Placebo|Ketone placebo will be provided
89344542|NCT05398042|Experimental|Ketone|Ketone esters will be provided
89344543|NCT01231763||Healthy volunteers|
89344544|NCT03802045|Experimental|Low frequency EA|"25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 2Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm)."
89344545|NCT03802045|Experimental|High frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
89344546|NCT03802045|Experimental|Alternating frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz and 2Hz for 3 seconds each; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
89344547|NCT03802045|Active Comparator|Control Group|"25 participants will follow exactly the same protocol as the experimental groups, however they will not undergo electrical stimulation, as the acupuncturist will activate channels that are not connected to the patient.~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
89344548|NCT03802045|Placebo Comparator|Placebo Group|"25 participants will will follow exactly the same protocol as the experimental groups, however an adhesive moxa (Dong Yang®) will be placed on each acupoint and the needle will be inserted over it, so that the participant only feels the needle prick, but without perforation of the skin and the deQi sensation. In addition, as in the control group, the electrodes will be connected to the needles, however, no electrical current will be applied.~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
89344549|NCT03918317|Experimental|AirXpanders AeroFormtissue expander + Radiation therapy|AirXpanders AeroFormtissue expander in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate.
89344550|NCT01230281|Experimental|Black bean seed coat extract|Daily 1000 mg oral Black bean seed coat extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
89344551|NCT01303705|Experimental|Cyclophosphamide - Cohort 1|Cyclophosphamide 300 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
89344552|NCT01303705|Experimental|Cyclophosphamide - Cohort 2|Cyclophosphamide 600 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
89344553|NCT01303705|Experimental|Cyclophosphamide - Cohort 3|Cyclophosphamide 900 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
89344554|NCT01134341|Experimental|Bexarotene (Targretin) & Pralatrexate (Folotyn)|"Bexarotene (Targretin): administered po qd. The initial daily dose of bexarotene will depend on the cohort to which each patient is assigned. Bexarotene will be self-administered except in patients who underwent plasma PK sampling on cycle 1, dose 1 and cycle 1, dose 3, at which time bexarotene was to be administered at the investigational site 1 hour (± 5 minutes) prior to pralatrexate administration.~Pralatrexate (Folotyn): administered weekly via IV push over a minimum of 30 seconds up to a maximum of 5 minutes. One cycle is 4 weeks in duration consisting of weekly dosing of pralatrexate for 3 weeks followed by 1 week of rest. The initial dose of pralatrexate will depend on the cohort to which each patient is assigned."
89344555|NCT03811483||Female gender|
89344556|NCT03811483||Male gender|
89344557|NCT04308304|Experimental|MK-1942|Dose Level 1: 8-mg MK-1942 twice daily (BID) x 7 days (7D), Day 1 to Day 7; Dose Level 2: 15-mg MK-1942 BID x 7D, Day 8 to Day 14; Dose Level 3: 30-mg MK-1942 BID x 7D, Day 15 to Day 21; Dose Level 4: ≤50-mg MK-1942 BID x 7D (Provisional Dose Level), Day 22 to Day 28 All participants to receive Donepezil once daily.
89344558|NCT04308304|Placebo Comparator|Placebo|Placebo to MK-1942 BID x 21 [28] D All participants to receive Donepezil once daily.
89344559|NCT05402501||Patients with multiple sclerosis (MS)|Patients will participate in an online lifestyle program organized by Voeding Leeft, which consists of four main topics: diet, physical activity, relaxation and sleep.
89344560|NCT05397262|Other|Standard Arm|"1 Arm: combination Treatment: Deep regional hyperthermia: 1-2/week up to 10 sessions Radiotherapy: 50.4Gy + Boost 5.4Gy (R0) or 9.0Gy (R1/2)~Chemotherapy:~5-Fluorouracil 600mg/m^2, civ 120h; d1-5, 29-3~Chemotherapy:~Cisplatin 20mg/m^2; d1-5, 29-33"
89344561|NCT03800719|Experimental|Intervention Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, regular messages through Instant Messaging (IM), psychosocial support and referral to SC services through IM
89344562|NCT03800719|Active Comparator|Control Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, SMS message on general health
89344563|NCT01230359|Experimental|Vitamin B6 and magnesium|
89344564|NCT01230359|Placebo Comparator|Tang powder group|
89344565|NCT01133015|Experimental|Intermediate lesion|Intermediate lesion will be evaluated by both IVUS and FFR
89344566|NCT05396716|Experimental|transcutaneous electrical acupoint stimulation|
89344567|NCT05396716|No Intervention|Control|
89344568|NCT01230437||asthmatic patients taking montelukast|asthma with or without rhinitis
89344569|NCT04286542|Experimental|Provocation with cold air|Participants will be exposed to cold dry air for 15 minutes
89344570|NCT01304485|Experimental|Sodium Acetate C11 PET Imaging|
89344571|NCT03371355|Placebo Comparator|Pooled Placebo|Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).
89344572|NCT03371355|Experimental|Cohort B: ISIS 703802, 40 mg Q4W|Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.
88806981|NCT04222231|Experimental|Blood-flow restriction resistance training|Resistance training with low loads (15-30% RM) in combination with a brief occlusion of venous blood flow using a tourniquet while exercising.
88806982|NCT04222231|Experimental|Classical resistance training|Resistance training with high loads (60-80% RM).
88814121|NCT04347512|Experimental|Hydroxychloroquine|"Hydroxychloroquine is given for 5 days, with a loading dose of 400 mg qd at D1, and 200 mg qd for the next 4 days (D2-D5).~Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc)"
89344573|NCT03371355|Experimental|Cohort C: ISIS 703802, 80 mg Q4W|Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.
89344574|NCT03371355|Experimental|Cohort A: ISIS 703802, 20 mg QW|Participants received ISIS 703802, 20 mg once every week for 26 doses.
89344575|NCT03918005|Experimental|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
89344576|NCT03918005|Active Comparator|High glycemic load diet|Foods with high glycemic index or glycemic load (white rice, white bread, corn flakes, mashed potatoes, orange juice, banana, persimmon, grape, raisins, honey, sugar)
89344577|NCT05396482||Patients with vestibular migraine and their relative|
89344578|NCT03811327|Experimental|Treatment group|Zero-time Exercise group
89344579|NCT03811327|No Intervention|Waitlist group|
89344580|NCT05396326|Experimental|SOX-TACiE|Preoperative transcatheter arterial chemoinfusion and embolism (TACiE) alternated with systemic chemotherapy.
89344581|NCT03795571|Experimental|R2-GOD|
89344582|NCT01231919|Experimental|Treatment (Akt inhibitor)|Patients receive oral Akt inhibitor MK2206 every other day (schedule 1) OR once weekly (schedule 2) on days 1-28. Treatment repeats every 28 days for up 12 courses (1 year) in the absence of disease progression or unacceptable toxicity.
89344583|NCT03795649|No Intervention|The control group (Group K)|The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.
89344584|NCT03795649|Active Comparator|Group A, Tranexamic acid|The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later
89344585|NCT03795649|Other|Group B, autologous transfusion|The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.
88806983|NCT04218773|Experimental|Induced hypertension|The scientists will investigate the potential consequences of increasing baseline systolic blood pressure with intravenous fluids and phenylephrine by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The maximum allowed SBP is 220 mmHg or 180 mmHg, if intravenous TPA was administered.
88806984|NCT04175340|Experimental|BL-300-PFM04|
88806985|NCT04175340|Active Comparator|Lubricating and rewetting drops|
88806986|NCT04138823|Experimental|Part A: BI 891065 followed by Part B: BI 891065 + BI 754091|
89344586|NCT03795649|Other|Group C, alogenous transfusion|The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability.
89344587|NCT05396092|Experimental|Integrated mindfulness-based Tai Chi Chuan|MBTCC
88806989|NCT04100824|Experimental|Bupivacaine 0.5%|patient will take stellate ganglion block 10 ml bupivacaine 0.5% and nimodipine
88806990|NCT04100824|Active Comparator|Nimodipine|patient will take nimodipine 60 mg every 4 h.
88806991|NCT04088851|Experimental|Metformin - T2D|Participants with type-2 diabetes will intake metformin 1 g daily for 2 weeks
88806992|NCT04088851|Placebo Comparator|No Metformin - T2D|Participants with type-2 diabetes will pause metformin 1 g daily for 2 weeks
88806993|NCT04085328|Experimental|LID015385|LID015385 soft contact lenses worn in both eyes for up to 6 nights/7 days continuously (awake and asleep). Must sleep 1 night per week without lenses. Lenses will be replaced as specified in the study protocol.
88806994|NCT04085328|Active Comparator|Biofinity|Comfilcon A soft contact lenses worn in both eyes for up to 6 nights/7 days continuously (awake and asleep). Must sleep 1 night per week without lenses. Lenses will be replaced as specified in the study protocol.
88806995|NCT04082611|Active Comparator|Group 1 - Data-driven clinical recommendations (CR)|Data-driven clinical recommendations (CR)
88806996|NCT04082611|Experimental|Group 2 - Data-driven coached multi-modal intervention (MMIC)|Data-driven coached multi-modal intervention (MMIC)
88806997|NCT04074265|Active Comparator|Pain injection|This group will be injected with a cocktail totaling 40mL (20mL on each side) that will be composed of ropivicaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), ketorolac 30mg/mL (0.5mg/kg).
88806998|NCT04074265|Placebo Comparator|Normal saline|The control group will receive an injection of 40mL of 0.9% sodium chloride solution.
88806999|NCT04070144|Experimental|IQ-Tip|At most four lumbar punctures with Injeq IQ-Tip(tm) system per participant
88807000|NCT04058067|Experimental|Brolucizumab 6 mg|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
88807001|NCT04058067|Active Comparator|Aflibercept 2 mg|5 x every 4 weeks loading then every 8 weeks maintenance
88807002|NCT03983057|No Intervention|Chemotherapy group|Treatment with modified-FOLFIRINOX Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
88807003|NCT03983057|Experimental|Combination group|Treatment with modified-FOLFIRINOX and Anti-PD-1 antibody Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2, Anti-PD-1 antibody 3mg/kg
88807004|NCT03960619|Experimental|in-person & mHealth coping skills training|hybrid in-person and mHealth coping skills training and activity coaching intervention is to reduce physical disability and decrease pain, fatigue and stress while enhancing patients' abilities to cope with symptoms that interfere with activity.
88807005|NCT03947437|Experimental|Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
88807006|NCT03947437|Experimental|High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.
88807007|NCT03947437|Experimental|TBD dose in patients|TBD μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in paucibacillary leprosy patients. Dose will be determined by safety and immunogenicity data from healthy participants.
88807008|NCT03947437|Placebo Comparator|Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
88807009|NCT03898310|Experimental|Cranberry Extract Capsules|36mg of proanthocyanidins in cranberry capsules
88807010|NCT03898310|Placebo Comparator|Placebo Capsules|
88807011|NCT03852030|Experimental|Mindfulness text/email message|"Weekly MBSR specific text or email messages related to course teachings were sent.~TYPES OF MESSAGES INCLUDED: Non-reaction; Non-Judgment; Awareness; Loving Kindness; Acceptance."
88807012|NCT03852030|Placebo Comparator|Health promotion text/email message|Weekly general/informational texts or emails about healthy living and lifestyle were sent. TYPES OF MESSAGES INCLUDED: Diet; Exercise; Sleep; Illness; Stress.
88807013|NCT03852030|No Intervention|No text/email message|No texts or emails were sent. There are no examples or descriptions for these messages, because no messages were sent to this group.
88807014|NCT03775915|Experimental|Real Neurofeedback|3 sessions of Real Neurofeedback over 1 week
88807015|NCT03775915|Sham Comparator|Sham Neurofeedback|3 sessions of Sham Neurofeedback over 1 week
88807016|NCT03775759|Experimental|Study arm|Tricuspid valve ring annuloplasty or replacement at the time of LVAD implantation plus medical therapy
88807017|NCT03775759|Active Comparator|Control arm|LVAD implantation plus medical therapy
88807018|NCT03759028|Experimental|Ibuprofen|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed ibuprofen for breakthrough pain (liquid oral medication, 10mg/kg/dose every 8 hours as needed, max dose 40mg/kg/day).
88807019|NCT03759028|Active Comparator|Oxycodone|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed oxycodone for breakthrough pain (liquid oral medication, 0.1mg/kg/dose every 6 hours as needed).
88807020|NCT03716921|Experimental|Short antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 3 weeks
88807021|NCT03716921|No Intervention|Long antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 6 weeks according to standard care
88807022|NCT03693560|Experimental|vildagliptin / metformin|Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
88807023|NCT03693560|Experimental|glimepiride / metformin.|Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
88807024|NCT03675893|Experimental|Cohort 1|"Abemaciclib is administered by mouth twice daily~LY3023414 is administered by mouth twice daily~Letrozole is administered by mouth once daily"
88807025|NCT03675893|Experimental|Cohort 2|"Abemaciclib is administered by mouth twice daily~LY3023414 is administered by mouth twice daily"
88807026|NCT03675893|Experimental|Cohort 1A|"Abemaciclib is administered by mouth twice daily~Letrozole is administered by mouth once daily"
88807027|NCT03675893|Experimental|Cohort 3|"Abemaciclib is administered by mouth twice daily~Letrozole is administered by mouth once daily~Metformin is administered by mouth once daily"
88807028|NCT03664791||Vanguard Rocc knee implant|Patient in need for a total knee arthroplasty and who met the inclusion/ exclusion criteria and received the Vanguard Rocc implant
88807029|NCT03627988|Experimental|Patients with breast cancer|
88807030|NCT03594760|Experimental|Main arm|PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi
88807031|NCT03574090|Experimental|amoxicillin clavulanate|1000 mg amoxicillin and potassium clavulanate equivalent to 200mg of clavulanic acid. administered topically and dissolved in 500 ml 0.9% Physiological Serum.
88807032|NCT03574090|Active Comparator|Physiological Saline|500 milliliters of 0.9% Physiological Serum.
88807033|NCT03510117|Other|Mindfulness|Mindfulness
88807034|NCT03427047|Active Comparator|MyKnee with single use Efficiency Instrument|Patients randomized in this group will undergo Total Knee Arthroplasty utilizing patient matched cutting blocks and single use instruments. Customization will be by a CT scan of patients knee.
88807035|NCT03427047|Active Comparator|Stryker Navigational with conventional metal instruments|Patients randomized in this group will undergo Total Knee Arthroplasty with conventional metal instruments. CT scan are not utilized with this arm.
88807036|NCT03417544|Experimental|ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB|"Patients will receive the following treatment:~Atezolizumab (IV) every 3 weeks (q3w)]~Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV)~High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w)."
88807037|NCT03363464||patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus
88807038|NCT03363464||patients with T2DM initiating a DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor treated patients
88807039|NCT03363464||patients with T2DM initiating a GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist treated patients
88807040|NCT03314714|Experimental|Acute bout of endurance exercise|Intramyocellular lipid metabolism will be assessed in insulin resistant and healthy, sedentary individuals after an acute bout of endurance exercise.
88807041|NCT03314454|Active Comparator|Elevated Mental Status|Elevated score on Patient Health Questionnaire
88807042|NCT03314454|Active Comparator|Non-elevated depressed mood|Lower score on Patient Health Questionnaire
88807043|NCT03314454|Active Comparator|Social Drinking status|The social drinker group will be those who consume alcohol regularly but with infrequent heavy drinking days.
88807044|NCT03314454|Active Comparator|Heavy drinker status|The heavy drinker group will be those who consume alcohol regularly with frequent heavy drinking days.
88807045|NCT03294863|Experimental|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive will be applied to 1/2 of the cutaneous wound
88807046|NCT03294863|Placebo Comparator|Standard of Care|Another 1/2 of cutaneous wound will be treated per standard of care
88807047|NCT03275584|Experimental|Main arm|N-13 ammonia intravenous injection; 2 injections, 3-7 MBq/kg per injection
88807048|NCT03241459|Experimental|Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.
88807049|NCT03241459|Active Comparator|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
88807050|NCT03229863|Experimental|Sweet Potatos|Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
88807051|NCT03229863|Experimental|Pears|Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
88807052|NCT03177642||Data Repository Group|All adults presenting to the hand and upper extremity service at Massachusetts General Hospital.
88807053|NCT03113851|Experimental|Radiotherapy and rhGM-CSF|Patients with metastatic non-small cell lung cancer received 3.5 Gy per fraction to a total dose of 35 Gy/ 10 fractions over 2 weeks, combined with rhGM-CSF (125 μg/m2).
88807054|NCT03074474|Other|OviTex Permanent 1S|All subjects included in this post-market study had a ventral hernia repaired with OviTex 1S Permanent reinforced tissue matrix.
88807055|NCT03064503|Experimental|Healthy volunteers|Sedentary healthy subjects will be recruited in this study. MRI, skin auto-fluorescence measures and blood sampling will be performed
88807056|NCT03017118|Experimental|Turmeric|Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
88807057|NCT03017118|Placebo Comparator|Control|Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.
88807058|NCT02990299|No Intervention|Usual Care|Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will change to the mDAS intervention arm for one year.
88807059|NCT02990299|Experimental|mHealth for Diabetes Adherence Support|Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.
88807060|NCT02968732|Experimental|Surgical|
89344588|NCT05396092|Active Comparator|Mindfulness-based intervention|MBI
89344589|NCT05396092|Active Comparator|Tai Chi Chuan|TCC
89344590|NCT05396092|Active Comparator|Sleep Hygiene Education|SHE
89344591|NCT01230515||Caregiver|Family members will be asked to complete a demographic survey, an assessment of the patient's current pain, and a series of questionnaires including: Caregiver Pain Medicine Questionnaire, the Stressful Caregiving Adult Reactions To Experiences of Dying Scale, and the Caregivers' Self Efficacy in Pain Management Questionnaire. Upon completion of the questionnaires, patients and caregivers will be interviewed separately.
89344592|NCT01230515||Hospice staff|Hospice staff will be asked to complete the Pain Knowledge and Attitudes survey. They will also complete the Technology Acceptance Model (TAM) questionnaire to assess the perceived utility of an opioid titration order sheet to help manage pain control. A demographic survey will also be completed.
89344593|NCT01230515||Referring physician|Referring physicians will be asked to complete the Pain Knowledge and Attitudes survey as well as the TAM questionnaire and Demographic Survey.
88807061|NCT02963558|Experimental|Intervention|The intervention group will receive in-bed cycle ergometry within 48 hours of randomization if safety criteria are met. The intervention arm will receive early physical therapy (PT). This PT will be performed according to a protocol of additional ICU and hospital-administered rehabilitation strategies that have been previously developed. Patients will receive 30 minutes of PT at least 5 times per week while conscious. If unconscious, subjects will only receive passive range of motion (PROM) for 10 repetitions per body part daily. Once conscious, subjects will progress through PT with an emphasis on ambulation. Therapy for the intervention arm patients will continue while on the floor. Outpatient therapy will be provided at the discretion of the patient's treating physicians.
88807062|NCT02963558|No Intervention|Usual Care|The control group will receive usual care physical therapy as ordered by the treating team both in the ICU and on the floor through hospital discharge. These subjects will also receive therapy as outpatients only as ordered by their regular physicians.
88807063|NCT02903381|Experimental|Nivolumab, Lenalidomide, Dexamethasone|"A treatment cycle is defined as 28 consecutive days.~Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months."
88807064|NCT02850991|Experimental|High-dose|"concurrent chemoradiotherapy High-dose RT:59.4 Gy in 33 fractions, 1.8 Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
88807065|NCT02850991|Active Comparator|Standard-dose|"concurrent chemoradiotherapy Standard-dose RT:50.4 Gy in 28 fractions, 1.8Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
88807066|NCT02744391|Experimental|L-DOPA|Patients will receive titration of L-DOPA from 150 mg to 450 mg.
88807067|NCT02634645||Patients with Barrett's Esophagus|Patients with non-dysplastic Barrett's esophagus, patients with Barrett's related dysplasia which includes low-grade dysplasia, high-grade dysplasia and intramucosal cancer who will be evaluated and treated with endoscopic eradication therapies (EET).
88807068|NCT02634645||Patients with invasive esophageal cancer|Patients with invasive esophageal cancer who will be treated with surgery (esophagectomy), chemotherapy, radiation, and palliative treatment modalities.
88807069|NCT02555072|Other|naive children and adults for yellow fever vaccine|both sexes; ages between 9 months and 4 years, 11 months and 29 days old; 18 years to 50 years old
88807070|NCT02462837|Experimental|Treatment Arm|after stent placement, patient will be given Mirabegron 50 mg, PO, once daily, for 2 weeks
88807071|NCT02462837|Placebo Comparator|Placebo Arm|after stent placement, patient will be given placebo PO, once daily, for 2 weeks
88807072|NCT02366221||All subjects|Subjects with a history of complex arm trauma
88807073|NCT02346201|Active Comparator|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), in 5 mg over-capsulated tablets, and psychosocial intervention
88807074|NCT02346201|Placebo Comparator|Placebo|Matching over-encapsulated placebo and psychosocial intervention
88807075|NCT02326207|Experimental|Weekly ventilator circuit change|Ventilator circuit change every 7 days until extubation
88807076|NCT02326207|Active Comparator|No routine ventilator circuit change|No routine ventilator circuit change until soiling or malfunction or extubation
88807077|NCT02318732|Experimental|Group 1|APPS intervention will be implemented in Group 1 communities prior to implementation in Group 2 communities.
88807078|NCT02318732|Active Comparator|Group 2|APPS intervention will be implemented in Group 2 communities following implementation in Group 1 communities.
88807079|NCT02042378|Experimental|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
88807080|NCT01981538||Adult informal caregivers|Subjects will be eligible for this protocol if they are adult informal caregivers that are family members or friends of a patient enrolled in a cancer treatment study at the NIH Clinical Center
88807081|NCT01956942|Experimental|Micropulse Laser Trabeculoplasty|Patient's randomized to MLT would be treated with the following settings: 300 micron spot size, 0.3 second duration, 15% duty cycle, and 1000 milliWatt power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative intraocular pressure (IOP) spikes as per standard pre-laser trabeculoplasty protocol.
88807082|NCT01956942|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Patient's randomized to SLT would be treated with the following settings: 400 micron spot size, 0.3 second duration, and 1.00 milliWatt (mW) power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative IOP spikes as per standard pre-laser trabeculoplasty protocol.
88807083|NCT01866930|Experimental|Cohort A: GT-2 or -3 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 weeks~Ribasphere 200 mg tablets (800 mg per day: two 200 mg tablets in the morning and two 200 mg tablets in the evening) by mouth twice daily for 24 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
88807084|NCT01866930|Experimental|Cohort B: GT-1 or -4 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 or 48 weeks~Ribasphere 200 mg tablets, (1000 mg per day: two 200 mg tablets in the morning and three 200 mg tablets in the evening for subjects weighing <75 kg and 1200 mg per day: three 200 mg tablets in morning and three 200 mg tablets in evening for subjects weighing ≥75 kg) by mouth twice daily for 24 or 48 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
88807085|NCT01807819||Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
88807086|NCT01693094|No Intervention|No decision aid|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
88807087|NCT01693094|Active Comparator|Decision Aid|One cohort will receive a decision aid.
88807088|NCT01682187|Experimental|LY2157299 (Part A)|Administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part A dose escalation will have starting dose of 40 mg/day and may increase up to 360 mg/day.
88807089|NCT01682187|Experimental|LY2157299 + Lomustine (Part B)|"LY21547299 will be administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part B dose expansion will have starting dose of 80 mg twice daily and may increase up to 150 mg twice daily.~Lomustine will be administered orally by capsule once on Day 7 of Cycle 1 after receiving LY2157299, and once after receiving LY2157299 on Day 21 of Cycles 2, 5, 8, 11, and every 4th cycle thereafter."
88807090|NCT01621568|Experimental|Group 1 (Thymoma and thymic carcinoma)|Group 1 (Thymoma and thymic carcinoma) treated with sunitinib 50 mg/day, 4 weeks on, 2-weeks off (6 week cycle).
88807091|NCT01621568|Experimental|Group 2 (Thymic carcinoma only)|Group 2 (Thymic carcinoma only) treated with sunitinib 50 mg/day, 2 weeks on, 1 week off (3 week cycle).
88807092|NCT01511393||Questionnaire|None. Non-interventional study.
88807093|NCT01472328|Experimental|Hyperbaric oxygen therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
88807094|NCT01472328|Sham Comparator|Hyperbaric room air|Effect of 2 hrs hyperbaric room air herapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
88807095|NCT01366612|Active Comparator|Group 1|FLUDARABINE AND BUSULFAN
88807096|NCT01366612|Experimental|Group 2|FLUDARABINE, BUSULFAN AND LOW DOSE TOTAL BODY IRRADIATION
88807097|NCT00813293|Experimental|Sorafenib|Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
88807098|NCT00813293|Placebo Comparator|Placebo|Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
88807099|NCT00481091|Experimental|Navitoclax 14/21 Day Cycle: 10 mg|Navitoclax 10 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
88807100|NCT00481091|Experimental|Navitoclax 14/21 Day Cycle: 110 mg|Navitoclax 110 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
88807101|NCT00481091|Experimental|Navitoclax 14/21 Day Cycle: 200 mg|Navitoclax 200 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
88807102|NCT00481091|Experimental|Navitoclax 14/21 Day Cycle: 250 mg|Navitoclax 250 mg administered for 14 consecutive days followed by 7 days off drug to complete a 21-day cycle.
88807103|NCT00481091|Experimental|Navitoclax 21/21 Day Cycle: 125 mg|Navitoclax 125 mg administered for 21 consecutive days to complete a 21-day cycle.
88807104|NCT00481091|Experimental|Navitoclax 21/21 Day Cycle: 200 mg|Navitoclax 200 mg administered for 21 consecutive days to complete a 21-day cycle.
88807105|NCT00481091|Experimental|Navitoclax 21/21 Day Cycle: 250 mg|Navitoclax 250 mg administered for 21 consecutive days to complete a 21-day cycle.
88807106|NCT00481091|Experimental|Navitoclax 21/21 Day Cycle: 300 mg|Navitoclax 300 mg administered for 21 consecutive days to complete a 21-day cycle.
88807107|NCT00481091|Experimental|Phase 2: Navitoclax 100 mg|Navitoclax 100 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).
88807108|NCT00481091|Experimental|Phase 2: Navitoclax 250 mg|Navitoclax 250 mg in participants with CLL who had relapsed following any (but no more than 5) prior myelosuppressive/chemotherapy treatment regimen(s).
88807109|NCT00085982|Experimental|Leptin Treatment|300 mg of study drug administered via subcutaneous (SC) injections.
88807110|NCT00067821||1/Patients|Must have a brain tumor, or residual abnormality that is measurable or evaluable on standard MRI or CT
88807111|NCT00003641|Other|Observation|Patients undergo observation for 4 weeks.
88807112|NCT00003641|Experimental|Interferon Alfa-2b|Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
88807113|NCT05327400||pancreatic cancer patients|pathologically confirmed pancreatic cancer patients
88807114|NCT05327400||healthy people|people without no neoplastic lesions and other organic diseases
88807115|NCT05326542|Experimental|ESWL and ERCP|The patients will receive intravenous analgesia (flurbiprofen and remifentanil) before the ESWL (Compact Delta II; Dornier Med Tech, Wessling, Germany). The time scale between the last ESWL session and following ERCP will be greater than 48h. ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
88807116|NCT05326542|Active Comparator|LL and ERCP|ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, laser lithotripsy will be performed. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
89344594|NCT01230515||Patient|Demographic information includes education, marital status, number in household, and employment status will be obtained from patient. Clinical data will be obtained from the patient's medical records. Information to be obtained will include information about the type of cancer, stage of disease, time since diagnosis, current treatment for cancer, type of pain, time since onset of pain, and time of first opioid prescription. The patient will also take a pain assessment survey.
89344595|NCT05402267||OA: OME-Adenoid group|Patients who meet the follow inclusion criteria will be considered eligible as the OME-Adenoid (OA) group
89344596|NCT05402267||CA: Control-Adenoid group|Patients who meet the follow inclusion criteria will be considered eligible as the Control-Adenoid (CA) group
89344597|NCT05402267||CO: Control-OME group|Patients who meet the follow inclusion criteria will be considered eligible as the Control-OME (CO) group
89344598|NCT05402267||control group|Patients without OME and adenoid hypertrophy will be considered eligible as the control group
89344599|NCT04211272|Experimental|Part A: Macitentan + Substrate Drug (Sildenafil/Riociguat)|Participants will receive a single dose of film-coated tablet of sildenafil under fasted condition (Treatment A1), then riociguat under fasted condition (Treatment A2) followed by macitentan under fed condition (Treatment B1), then riociguat along with macitentan under fasted conditions followed by macitentan under fed conditions (Treatment B2) and then sildenafil along with macitentan under fasted condition (Treatment B3). Macitentan will be administered in an up-titration regimen.
89344600|NCT04211272|Experimental|Part B: Macitentan + Substrate Drug (Rosuvastatin)|Participants will receive a single dose of film-coated tablet of rosuvastatin under fasted condition (Treatment A1), then macitentan under fed condition (Treatment B1) followed by rosuvastatin along with macitentan under fasted condition followed by macitentan under fed condition (Treatment B2). Macitentan will be administered in an up-titration regimen. Part B of the study will be conducted depending on the results of Part A and feedback from Health Authorities.
89344601|NCT01302925|Experimental|PEP005 Gel 0.05%/2 days|Subjects will be exposed to investigational product for 2 consecutive days.
89344602|NCT01302925|Experimental|PEP005 Gel 0.015%/3 days|Subjects will be exposed to investigational product for 3 consecutive days.
88807117|NCT00392834|Experimental|Regimen A (R-CODOX-M chemotherapy)|Patients receive rituximab IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim SC on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until level is adequate. Patients receive CNS prophylaxis of methotrexate IT, cytarabine IT, and hydrocortisone IT on day 1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive G-CSF SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.
88807118|NCT00392834|Experimental|Regimen B (rituximab and IVAC chemotherapy)|Patients receive rituximab IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover. Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.
88807119|NCT02982980|Experimental|Physiotherapy Guidance Mastectomy|Patients who underwent radical breast surgery, received pre and postoperative assessment and orientation.
88807120|NCT02982980|Experimental|Phys Muscle strengthening Mastectomy|Patients who underwent radical breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
88807121|NCT02982980|Experimental|Physiotherapy Guidance Quadrantectomy|Patients who underwent partial breast surgery, received pre and postoperative assessment and orientation.
88807122|NCT02982980|Experimental|Phys Muscle strengthening Quadrantectomy|Patients who underwent partial breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
88807123|NCT00393380|Experimental|Parathyroid Hormone (teriparatide)|Parathyroid hormone after double umbilical cord blood transplant.
88807124|NCT05362422|Experimental|PAS|
88807125|NCT05362422|Sham Comparator|SHAM|
88807126|NCT05361642|Active Comparator|regional nasal block|sphenopalatine ganglion block with general anesthesia
88807127|NCT05361642|Active Comparator|dexmedetomidine|use the drug with general anesthesia
88807128|NCT05359770|Experimental|Experimental|Experimental: Experimental Group/ Active HD-tDCS Patients randomly enrolled in this group will receive 10 sessions of anodal HD-tDCS stimulation on cortical representation zone of left diaphragmatic motor cortex associated to respiratory training; for 20 minutes (each session) with a 2mA intensity. The electrical current will be delivered with a ramp-up time of 30 s, held at 3mA for 20 min, and then ramped down over 30 s.
88807129|NCT05359770|Sham Comparator|Sham Comparator|Sham Comparator: Control Group / Sham Group In the sham condition, the device will provide a 30-second ramp-up followed immediately by a 30-second ramp down in HD-tDCS associated with inspiratory muscle training for 20 minutes
88807130|NCT04422834|Experimental|Health Professional Students|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
88807131|NCT00395876|Placebo Comparator|Placebo + Tenecteplase + Tenecteplase (PTT)|
88807132|NCT00395876|Experimental|Tenecteplase + Tenecteplase + Placebo (TTP)|
88807133|NCT05324514|Active Comparator|Standard of Care|STSG grafting application.
88807134|NCT05324514|Experimental|High Density|MSTC high density application.
88807135|NCT05324514|Experimental|Low Density|MSTC low density application.
89344603|NCT03810937|Active Comparator|Group sniffing (S)|intervention: Head position changes : we will start by performing first videolaryngoscopy to find best view in flat position then the anesthesiologist will remove the Glidescope and the patient will be positioned in sniffing position using the pillow and another videolaryngoscopy will be attempted in sniffing position to find best view in this position and the patient will be intubated in this position.
89344604|NCT03810937|Active Comparator|Group Flat (F)|intervention: Head position changes same procedure will be done but starting from sniffing position and the patient will be intubated in flat position.
89344605|NCT05402189|Active Comparator|Ketodex group : Group (KD)|
89344606|NCT05402189|Active Comparator|Opioid group: Group (OP)|
89344607|NCT01134419|Experimental|Computerized Handoff Tool plus training|Computerized handoff tool implemented together with team training for residents
89344608|NCT01134419|Active Comparator|Team training only|No computerized tool
89344609|NCT01304563|Active Comparator|IM15|15 mcg TIV 2010/2011 influenza vaccine delivered via intramuscular injection (control)
89344610|NCT01304563|Active Comparator|ID1|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
89344611|NCT01304563|Active Comparator|ID2|Higher low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
89344612|NCT01304563|Active Comparator|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device
89344613|NCT01231997|Experimental|Healthy Volunteers|
89344614|NCT01231997|Experimental|Patients with mild renal impairment|
89344615|NCT01231997|Experimental|Patients with moderate renal impairment|
89344616|NCT01231997|Experimental|Patients with severe renal impairment|
89344617|NCT03795805|Other|TKA and Tourniquet|Total knee arthroplasty and use of tourniquet limb cuff at 270 mmHg
89344618|NCT03795805|Experimental|Intraarticular lidocain|Total knee arthroplasty with Intaarticular lidocain
89344619|NCT01133249||Total hip|all consented patients receiving total hip arthroplasty
89344620|NCT03799237|Experimental|GOS trap and dengue NS1 antigen kit|Gravid Oviposition Sticky (GOS) traps will be placed to trap adult Aedes mosquitoes and changed weekly. NS1 will be used to detect dengue in trapped Aedes mosquitoes. When dengue NS1 positive mosquitoes are found, community will be alerted via flyers, banners and other means. Routine Aedes/dengue control and surveillance will be carried out as usual as per the current Ministry of Health guidelines.
89344621|NCT03799237|No Intervention|Control|The GOS traps will be placed randomly in the control arm once per month for entomological survey. Routine Aedes control and surveillance will be carried out as per the current Ministry of Health guidelines. Dengue control measure will be initiated by the health authorities when human cases are reported from this arm.
89344622|NCT04072042|Experimental|Apatinib monotherapy|patient will receive Apatinib 250mg tablet by mouth, bid.
89344623|NCT01133327|Experimental|Adapt Carotid Stent System|Intervention with Adapt Carotid Stent System with the FilterWire EZ System
89344624|NCT03799315|Experimental|Jail-Based Use of Smoking Cessation Treatment (JUST)|Participants will receive guidline-based smoking cessation counseling while in jail and phone-based smoking cessation counseling sessions and nicotine lozenges after release from jail.
89344625|NCT03799315|No Intervention|Enhanced Treatment As Usual (TAU)|Participants will receive the usual, limited smoking cessation treatment while in jail, plus an additional health and wellness education session in jail. Nicotine lozenges will be offered at the end of the study to those who did not quit smoking.
89344626|NCT05387200|Experimental|Masibone S|Masibone S (alendronate sodium trihydrate 70mg, oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily for 48 weeks
89344627|NCT05387200|Active Comparator|Fosamax|Fosamax (aledronate sodium 70mg, oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily for 48 weeks
89344628|NCT05401955|Experimental|Graft versus host disease Group|
89344629|NCT05401877||short term rehabilitation|breast cancer survivors that recieved post-OP rehabilitation for equal or less than 300 minutes totally.
89344630|NCT05401877||long term rehabilitation|breast cancer survivors that recieved post-OP rehabilitation for more than 300 minutes totally.
89344631|NCT01585727|Experimental|TME with neuromonitoring|Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.
89344632|NCT01585727|Active Comparator|TME without neuromontoring|Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.
89344633|NCT05380336||Patients with the Nivolumab weight-dependent dosage|Patients treated for their metastatic cancer with Nivolumab, with a dosage calculated upon their weight (3mg/kg every two weeks).
89344634|NCT05380336||Patients with the Nivolumab fixed dosage|Patients treated for their metastatic cancer with Nivolumab, with a fixed-dose regimen of 240 mg every 2 weeks or 480 mg every 4 weeks
89344635|NCT03442972|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
89344636|NCT03442972|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
89344637|NCT01134497|Active Comparator|Arm A (control): carboplatin + placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle.
89344638|NCT01134497|Experimental|Arm B: carboplatin + ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
89344639|NCT03370419|Experimental|The Pick Two to Stick To|Participants are asked to participate in five health-coaching sessions and to return in Week 20 for follow-up data collection. The initial face-to-face coaching session lasts approximately 90 minutes with subsequent telephone sessions lasting approximately 20 minutes. Coaching sessions will include education about MetS, weight loss, dietary and physical activity recommendations, and the principles of habit development, guidance in forming implementation intentions for each self-selected habit, and identifying routines and contextual cues that could be modified to support habit development Coaching sessions are augmented with a participant workbook. Participants' also receive individually tailored study text messages to maintain their motivation.
89344640|NCT03370419|Other|Usual Care|Participants receive usual care only.
89344641|NCT03918161|Experimental|MRE exam|Magnetic Resonance Elastography (MRE) exam associated with standard T1-weighted and T2-weighted sequences
89344642|NCT05375656|Active Comparator|Traditional Inuit Diet|"The traditional Inuit diet will consist of local foods, being primarily of animal origin, e.g. fish, marine mammals, caribou, and lamb. The diet will be supplemented with eggs, potatoes, and berries, and/or other foods low in starch and with no sucrose content. The diet will therefore have a high content of fat and protein, a low content of carbohydrate and no content of sucrose.~The participants will receive foods that will cover at least 100% of their energy requitement. Each participant will throw a dice in order to randomize the order of which the participants receive the two intervention diets."
89344643|NCT05375656|Experimental|Western Carbohydrate-Rich Diet|"The Western diet will have high amounts of grain products, e.g. bread, pasta, rice, as well as fruits and vegetables and some foods with a high sucrose content, e.g. cake and sweet snacks and/or drinks, and cereal products with added sucrose. The diet will have a low amount of meat. Hence, the diet will be high in carbohydrates, starch, and some sucrose and have a lower content of protein and fat.~The participants will receive foods that will cover at least 100% of their energy requitement. Each participant will throw a dice in order to randomize the order of which the participants receive the two intervention diets."
89344644|NCT03799081|Other|Fetoscopy in missed abortion|Women who have decided to undergo fetoscopy in missed abortion
89344645|NCT03921671|Experimental|Ramucirumab +carboplatin+ paclitaxel|All patient will receive the combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with recurrent and / or metastatic thymic carcinoma or thymoma B3 with area of carcinoma, in the first line.
89344646|NCT03709251|Experimental|High Intensity Walking|HIW (70-80% Heart Rate max)
89344647|NCT03709251|Experimental|Casual Speed Walking|Self selected pace
89344648|NCT03795727|Experimental|Sectional matrix|precontoured sectional matrix band
89344649|NCT03795727|Active Comparator|Circumferential matrix|Circumferential matrix band applied by tofflemire retainer
89344650|NCT03921593||Simultaneous Pancreas Kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Simultaneous Pancreas Kidney Transplant (SPK)
89344651|NCT03921593||Pancreas after kidney Transplant Recipients|Patient affected by Insulin Dependent Diabetes Mellitus and renal failure undergoing Pancreas after kidney Transplant (PAK)
89344652|NCT03921593||Pancreas Transplant Alone Recipients|Patient affected by Insulin Dependent Diabetes Mellitus with hypoglycemia unawareness undergoing Pancreas Transplant Alone (PTA)
89344653|NCT03918083|Other|5-pronged wellness approach|30-day assessment of daily exercise, mindfulness, sleep, social connectedness, and nutrition
89344654|NCT03373006|Experimental|Men with Gleason Score 7 prostate cancer|Men seeking focal therapy for Gleason Score 7 prostate cancer will receive Axumin PET/CT imaging to detect metastasis which will result in exclusion from laser focal therapy.
89344655|NCT03917849|Experimental|Heavy slow resistance training|"The program is performed 3 times per week using resistance equipment in a fitness center. Each session consists of three 2-legged loaded quadriceps and lower limb kinetic chain exercises. The patients complete 3 or 4 sets in each exercise with a 2- to 3-minute rest between sets and a 5-minute rest period between the 3 exercises.~The number of repetitions decreases, and load gradually increases, every week. The repetitions and loads are as follows: 3 times, 15-repetition maximum (15RM ), in week 1; 3 times, 12RM , in weeks 2 to 3; 4 times, 10RM , in weeks 4 to 5; 4 times, 8RM , in weeks 6 to 8; and 4 times, 6RM , in weeks 9 to 12."
89344656|NCT03917849|Experimental|Inertial flywheel resistance training|The program is performed 3 times per week using resistance equipment in a fitness center. Inertial flywheel resistance is a type of strength training; which is based on the increasing demands on eccentric action (breaking) after a concentric action (acceleration), due to the inertial load caused during the return movement. The patients complete 12 repetition máximum (RM) with moment inertia 0.05 m² from week 1-6 and 8 repetition máximum (RM) with moment inertia = 0.10 m² from week 6-12.
89344657|NCT03369951|Experimental|Minocin® IV|200 mg minocycline hydrochloride IV infusion over approximately 60 minutes, n=50
89344658|NCT04842955|Experimental|real tACS|Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)
89344659|NCT04842955|Sham Comparator|sham tACS|Single session of sham tACS over the superior parietal cortex (Precuneus)
89344660|NCT04040192|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied once daily (QD)
89344661|NCT04040192|Placebo Comparator|Vehicle|Vehicle ointment applied once daily (QD)
89344662|NCT01131767|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
89344663|NCT01131767|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
89344664|NCT03795259|Active Comparator|Sevoflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 2% sevoflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
89344665|NCT03795259|Active Comparator|Desflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 6% desflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
89344666|NCT03354052|Experimental|Real-rTMS + Gloreha device|
89344667|NCT03354052|Active Comparator|Sham-rTMS + Gloreha device|
89344668|NCT01229189|Experimental|Maternal and Neonatal Intervention Arm|Pregnant women will be individually randomized; a daily dose of vitamin D in 4000 IU will be given to Intervention group, started at 20-22 weeks of pregnancy till the time of delivery. The infants of this group will further stratify into two groups, one group will receive 400 IU of Vitamin D for 6 months as Intervention.
89344669|NCT01229189|Placebo Comparator|Maternal and Neonatal Control Arm|
89344670|NCT03795415||Immediate Arm (G1)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G1 will receive the intervention Gundo-So immediately. (From month 3 to month 6).~112 women will be in immediate arm in 14 groups of 8 women."
88807136|NCT02662634|Experimental|Sequential, no radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
88807137|NCT02662634|Experimental|Concurrent, no radiation|"AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
88807138|NCT02662634|Experimental|Sequential, radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).~Radiation therapy per PI"
88807139|NCT02662634|Experimental|Concurrent, radiation|"AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy choice of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).~Radiation therapy per PI."
88807140|NCT02524158|Experimental|Yoga|The yoga intervention will consist of 2x weekly, 60-minute Hatha Yoga classes for 12 weeks, geared toward a CLBP population. Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
88807141|NCT02524158|No Intervention|Delayed Treatment Control - Usual Care|Participants randomly assigned to this arm are allowed to continue all existing treatments. Participants and their primary care physician are asked to not change treatments unless medically necessary. participants are asked to not do yoga for 6 months. They are given free yoga and a yoga mat after 6 months.
88807142|NCT05323500|Experimental|Senobi breathing group|The study participants will be screened first, then trained to perform SBE (1-minute maneuver). The participants will also guided to repeat this procedure 3 times in one minute with resting period of 10 seconds. They will perform it 3 times a day for 3 months. Assessments will be taken at Baseline & after 3 months.
88807143|NCT00396032|Experimental|1|
88807144|NCT00396032|Placebo Comparator|2|
88807145|NCT02277782|Active Comparator|No Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 0.05 ml of 0.9% normal saline.
88807146|NCT02277782|Experimental|Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 50 mcg preservative-free hydromorphone (0.05 ml)
88807147|NCT02525094|Experimental|MEDI9929 280 mg|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
88807148|NCT02525094|Placebo Comparator|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
88807149|NCT04255914|Experimental|Root coverage procedure along with orthodontic treatment|subepithelial connective tissue graft and orthodontic levelling and alignment
88807150|NCT04255914|Active Comparator|Root coverage procedure only|sub epithelial connective tissue graft procedure for recession coverage
88807151|NCT02271230|Experimental|Vitamin D and fish oil|2000 IU per day and 1 g per day of fish oil
88807152|NCT02271230|Placebo Comparator|Vitamin D alone|2000 IU Vitamin D and fish oil placebo
88807153|NCT02271230|Experimental|Fish oil (EPA/DHA) alone|1 g per day of fish oil and vitamin D placebo
88807154|NCT02271230|Placebo Comparator|Fish oil and vitamin D placebo|Placebo for both vitamin D and fish oil
88814122|NCT04347512|Active Comparator|Control|The patient is given antibiotics only. Standard of care is also prescribed (oxygen therapy, analgesics, antipyretics, anticoagulant drug, etc).
89344671|NCT03795415||Delayed Arm (G2)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G2 will receive the intervention Gundo-So 3 months after. (From month 6 to month 9).~112 women will be in delayed arm in 14 groups of 8 women."
89344672|NCT05341180|Active Comparator|Study group 1(Polyethylene Glycol)|Polyethylene glycol syrup will be used at a dose of 15-30 ml per day for 2 weeks maximum.
89344673|NCT05341180|Active Comparator|Study group 2 (Isabgol and Lactulose)|Isabgol 2 teaspoons in 200ml of warm water to consume immediately after soaking before bedtime and syrup Lactulose 30 ml at bedtime for 2 weeks.
89344674|NCT01134653|Experimental|Jump stretch|Distraction with early mobilization
89344675|NCT01134653|Active Comparator|RICE|Subject receive standard ankle sprain treatment of Rest Ice compression and elevation for one week. This is followed by traditional strength and range of motion therapy. The subject does not receive distraction treatments.
89344676|NCT03798613|Active Comparator|Apple Watch 4 Series Device|Apple watch 4 series heart rate monitoring device
89344677|NCT03798613|Active Comparator|Continuous Telemetry|Standard continuous telemetry monitoring device
89344678|NCT01133483|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
89344679|NCT01133483|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
89344680|NCT03369249|Experimental|Link2CARE|This arm is comprised of participants randomized to the 4-session Link2CARE intervention.
89344681|NCT03369249|No Intervention|Standard of Care|This arm is comprised of participants who will not receive the 4-session Link2CARE intervention.
89344682|NCT05401721||Ascites without SBP|Cirrhotic ascitic patients not diagnosed with SBP
89344683|NCT05401721||Ascites with SBP|Cirrhotic ascitic patients diagnosed with SBP
89344684|NCT01560481|Experimental|Step A: metformin glycinate 620 mg|620mg single dose by mouth
89344685|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg|1240mg single dose by mouth
89344686|NCT01560481|Experimental|Step A: metformin glycinate 2480 mg|2480mg single dose by mouth
89344687|NCT01560481|Active Comparator|Step A: metformin hydrochloride 1000 mg|1000mg single dose by mouth
89344688|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg, food intake|1240mg single dose by mouth after food intake
89344689|NCT01560481|Experimental|Step B: metformin glycinate 620 mg BID|620mg BID for 8 days
89344690|NCT01560481|Active Comparator|Step B: metformin hydrochloride 500 mg BID|500mg tablets BID for 8 days
89344691|NCT03336034||IBS-C|Constipation-predominant irritable bowel syndrome
89344692|NCT03921437|Experimental|decision support intervention|The intervention measures in this study were discussed with the nephrologist and CKD health teachers. Based on theoretical considerations, the experimental group provides decision support. Measures, including CKD Guardian as a decision-maker, and the use of e-book software to develop medical decision-assist tools, and the application and decision-making mode complemented by introduction and selection, including team discussions, option discussions, and decision-making conversations. The control group is introduced with traditional care instructions for routine care. The experimental group and the control group were referred to the CKD health teacher for the introduction of renal replacement therapy by the physician. The experimental group was guided by CKD Health Education to guide the patients to participate in the discussion, discuss the advantages and disadvantages of each treatment and guide patients to explore preferences. And value, supplemented by discussion and final decision.
89344693|NCT03921437|No Intervention|routine care|According to the nursing routine provide paper education.
89344694|NCT03921359|Experimental|Conventional physical training|Participants assigned to this arm will receive the conventional physical training.
89344695|NCT03921359|Experimental|SMARTfit training|Participants assigned to this arm will receive the SMARTfit training.
89344696|NCT05292898|Experimental|LCAR-AIO Cells|Each subject will be treated with LCAR-AIO Cells
89344697|NCT03917771|Experimental|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery. Lower Limb measurement and care education
89344698|NCT03917771|Active Comparator|Usual follow-up|The usual follow-up will be carried out in GO consultation (0,1,6,12 months)
89344699|NCT01134809||Major abdominal surgery|Patients having major abdominal surgery
89344700|NCT05261776|Experimental|Group-A|Group-A will receive pilates exercise and standard care
89344701|NCT05261776|Active Comparator|Group-B|Group-B will receive brisk walk and standard care
89344702|NCT02528747||Study population|Breast cancer patients with metastatic bone disease
89344703|NCT05238844|Experimental|ATI-2173 25mg, Vebicorvir 300mg and Tenofovir 300mg|Subjects randomized to active arm will receive active 25mg ATI-2173 + active Vebicorvir 300mg + active Tenofovir 300mg
89344704|NCT05238844|Active Comparator|Tenofovir Disoproxil Fumarate|Subjects randomized to placebo arm will receive placebo 25mg ATI-2173 + placebo Vebicorvir 300mg + active Tenofovir 300mg
89344705|NCT03921125||Responders|
89344706|NCT03921125||Non responders|
89344707|NCT05228080||acute ischemic stroke|
89344708|NCT04785625|Experimental|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
89344709|NCT04785625|Placebo Comparator|Placebo implant|Placebo collagen-matrix implant
89344710|NCT01229345|Experimental|Breakfast & exercise|
89344711|NCT01229345|Experimental|Breakfast & no exercise|
89344712|NCT01229345|Experimental|No breakfast & exercise|
89344713|NCT01229345|No Intervention|No breakfast & no exercise|
89344714|NCT05227768|Experimental|VV116|Subjects will receive VV116 orally for single dose.
89344715|NCT05227768|Experimental|Placebo|Subjects will receive placebo orally for single dose.
89344716|NCT01230671|Experimental|Yoga|Patients in this arm will receive yoga therapy
89344717|NCT01230671|Placebo Comparator|No yoga|Patients will not have yoga in this arm
89344718|NCT03795025|Experimental|3x10RM + no training|
89344719|NCT03795025|Experimental|6x10RM + no training|
89344720|NCT03795025|Experimental|3x10RM + 6x10RM|
89344721|NCT03795025|No Intervention|Control|This arm includes 3 weeks of testing and 7 weeks of no intervention and post tests, followed by 7 weeks of progressive unilateral strength training 3 times per week for 7 weeks. Both legs exercises individually with 3 sets of 10 maximal repetitions.
89344722|NCT03917615|Experimental|"after women health course"|The participants will be instructed to contract the pelvic floor muscle
89344723|NCT03917615|Active Comparator|"before women health course"|The participants will be instructed to contract the pelvic floor muscle
89344724|NCT04453696||Communication before operation|Communication was established before the operation.
89344725|NCT04453696||Communication after operation|Communication was established after the operation.
89344726|NCT04453696||Communication before and after operation|Communication took place both before and after the operation.
89344727|NCT04453696||No communication|No communication.
89344728|NCT03794947|Experimental|Remote Ischaemic Conditioning|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg (arm) and 220 mmHg (leg). RIC will be completed 3 times weekly for 4 weeks.
89344729|NCT03794947|Sham Comparator|Sham Intervention|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The arm and leg blood pressure cuffs in the sham intervention will inflate to 20mmHg. Sham will be completed 3 times weekly for 4 weeks.
89344730|NCT04453618|Experimental|Food effect|Healthy subjects receive a single dose of SYHA1402 (100mg) in either a fasted state or with a meal.
89344731|NCT04453618|Experimental|Multiple doses 25mg|Healthy subjects receive multiple doses of SYHA1402 (25mg) or Placebo(25mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
89344732|NCT04453618|Experimental|Multiple doses 50mg|Healthy subjects receive multiple doses of SYHA1402 (50mg) or Placebo (50mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
89344733|NCT04453618|Experimental|Multiple doses 150mg|Healthy subjects receive multiple doses of SYHA1402 (150mg) or Placebo (150mg) for a total of 7 days (QD on Day1 and Day7, Q8h on Day2 to Day6）.
89344734|NCT03920579|Experimental|Sequence 1|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: D326, D337, D013(3 tabs, once)
89344735|NCT03920579|Experimental|Sequence 2|Period 1: CKD-386 formulation 1(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 2(1 tab, once)
89344736|NCT03920579|Experimental|Sequence 3|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: D326, D337, D013(3 tabs, once) / Period 3: CKD-386 formulation 1(1 tab, once)
89344737|NCT03920579|Experimental|Sequence 4|Period 1: CKD-386 formulation 2(1 tab, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: D326, D337, D013
89344738|NCT03920579|Experimental|Sequence 5|Period 1: D326, D337, D013(3 tabs, once) / Period 2: CKD-386 formulation 1(1 tab, once) / Period 3: CKD-386 formulation 2(1 tab, once)
89344739|NCT03920579|Experimental|Sequence 6|Period 1: D326, D337, D013 (3 tabs, once)/ Period 2: CKD-386 formulation 2(1 tab, once) / Period 3: CKD-386 formulation 1(1 tab, once)
89344740|NCT03798457||Patients with CAP hospitalized in IM|Data of Patients with Community-acquired pneumonia (CAP) hospitalized in Internal Medicine Units will be collected for this study; no intervention is planned for this study
89344741|NCT03368859|Experimental|ABT-165 plus FOLFIRI|ABT-165 plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
89344742|NCT03368859|Active Comparator|Bevacizumab plus FOLFIRI|Bevacizumab plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
89344743|NCT03798379|Active Comparator|Exercise group|Eligible patients who were planned to receive neurotoxic chemotherapy
89344744|NCT03798379|No Intervention|Control group|Patients eligible for the study and received the 3rd cycle of chemotherapy
89344745|NCT04100590|Experimental|Active Cannabis|In this session, the participant will smoke two-thirds of one active cannabis cigarette (7% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
89344746|NCT04100590|Placebo Comparator|Placebo Cannabis|In this session, the participant will smoke two-thirds of one inactive placebo cannabis cigarette (0% THC) according to our paced-puff procedure (Foltin et al. 1987). They will complete an eye task battery (5 minutes per battery) 15 minutes prior to smoking as a baseline measure in each session, and again at the following timepoints: 0, 15, 30, 45, 60, 75, 90, 105, 120, and 165 minutes post-cannabis. Baseline assessments will be compared to those at post-cannabis timepoints.
89344747|NCT01134965|Experimental|Digoxin plus Flibanserin|Flibanserin 100 mg tablets once daily for 7 days plus Digoxin 0.5 mg (2 tables of 0.25 mg) as single dose
89344748|NCT01134965|Experimental|Digoxin|Digoxin 0.5 mg as single dose
89344749|NCT03810625|Experimental|Sequence AB|D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.
89344750|NCT03810625|Experimental|Sequence BA|D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.
89344751|NCT01135043|Experimental|education|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
89344752|NCT01135043|Placebo Comparator|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure.
89344753|NCT03794791||education|Education will be used to see whether or not improve the HCV screening and diagnosis in HBsAg(+) patients. Blood test ,HCV-RNA quantification test and HCV genotyping will be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
89344754|NCT03794791||no education|There is no education at all.Screening and diagnosis of HCV infection in HBsAg(+) patients are based on voluntary. Blood test ,HCV-RNA quantification test and HCV genotyping will still be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
89344755|NCT03917693|Active Comparator|Phytin capsules|2.4 g phytin to be consumed daily for a period of 2 weeks. Participants will consume 2 test capsules containing phytin, 3 times a day with a meal for a period of 2 weeks.
89344756|NCT03917693|Placebo Comparator|Microcrystalline cellulose (MCC) capsules|2.4 g MCC to be consumed daily for a period of 2 weeks. Participants will consume 2 placebo capsules, each containing microcrystalline cellulose, 3 times a day with a meal for a period of 2 weeks.
89344757|NCT03462160|Placebo Comparator|Placebo supply for 90 days|Patients will receive placebo (in blinded sachets)
89344758|NCT03462160|Experimental|Probiotic supply for 90 days|Patients will receive probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 (in blinded sachets).
89344759|NCT05428917|Experimental|Near infrared spectroscopy|This method allows (like fMRI) to study cerebral neurovascular coupling. It is based on the fact that an activated brain region increases its local blood flow. Oxygenated (HbO) and deoxygenated (HbR) hemoglobin absorb infrared light and it is then possible to identify the cerebral cortical regions involved in a given task. This technique therefore makes it possible to study cerebral activation under more ecological conditions than fMRI and is thus particularly suitable for exploring rehabilitation techniques.
89344760|NCT03810547|Active Comparator|Spinal anesthesia|Patients undergoing abdominoplasty under spinal anesthesia may need to drug administration like propofol or ketamine or change anesthesia to general anesthesia.
89344761|NCT03810547|No Intervention|General anesthesia|General anesthesia for abdominoplasty
89344762|NCT03096314|Active Comparator|High dose vitamin D formulation|A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
89344763|NCT03096314|Placebo Comparator|Placebo|A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
89344764|NCT03461926|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
89344765|NCT03461926|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
89344766|NCT05424861|Active Comparator|Acupressure group|Postpartum 6-24 days in the acupressure group. Acupressure will be applied 1 time just before breastfeeding between hours. The visual analog scale, in which the introductory information form is filled by the researcher and the pain score is evaluated, will be marked by the participant once before breastfeeding, once at the 10th minute of breastfeeding, and once at the 20th minute, in total 3 times.
89344767|NCT05424861|Active Comparator|Control group|Postpartum 6-24 days in the control group. Introductory information form will be filled by the researcher between hours. The visual analog scale, in which the pain score is evaluated, will be marked by the participant for a total of 3 times, once just before breastfeeding, once at the 10th minute of breastfeeding, and once at the 20th minute.
89344768|NCT03794713|Experimental|Patient support tool group|Subjects were managed the HR by using the Patient Support Tool through a smart phone application and a wristband and be guided by physicians
89344769|NCT03794713|No Intervention|Control group|Subjects were received a usual patient care at baseline, which left to the discretion of physicians, without any specific intervention at follow-up period
89344770|NCT03461770|No Intervention|Control group|Patients will receive anesthesia induction with Sevoflurane using a circular circuit without CPAP. Protective ventilation with 5 cmH20 of positive end-expiratory pressure (PEEP) will be initiated after induction. At the end of surgery, mechanical ventilation will stop allowing spontaneous ventilation. Patients will be extubated without CPAP. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
89344771|NCT03461770|Experimental|CPAP group|Patients will receive anesthesia induction using 5 cmH20 of CPAP until the moment of intubation. After induction patients will receive the same protective ventilation than the control group. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery. At the end of surgery, patients will be extubated under the modality of CPAP with 5 cmH20. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
89344772|NCT01303081|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
89344773|NCT01303081|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
89344774|NCT01303081|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
89344775|NCT01303081|Experimental|Chosen Deposits|Same as USUAL CARE, plus financial incentive as follows: participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine or anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
89344776|NCT01303081|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
89344777|NCT03920891|Experimental|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm second or third cryoballoon catheter will be used.~Esophageal temperature will be monitored to prevent esophageal injury.~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and cryoablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
89344778|NCT03920891|Active Comparator|Radiofrequency Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
89344779|NCT03710655|Experimental|treatment group|skin test, dose escalation, final dose of 1.5mg weekly over 16 weeks of Apitox pure honeybee toxin
89344780|NCT03710655|Placebo Comparator|placebo group|histamine placebo administered intradermally in dose escalation, final dose of 1.5mg weekly over 16 weeks
89344781|NCT01135121||Weaning failure|
89344782|NCT01135121||Weaning succes|
89344783|NCT04775797|Experimental|Part 1 (Healthy Subjects): Single Ascending Dose (SAD)|Two cohorts (Cohorts A and B) of healthy subjects will receive single doses of AB-836/placebo in an alternating cohort design under fasted conditions. One additional treatment will be administered under fed conditions.
89344784|NCT04775797|Experimental|Part 2a (Healthy Subjects): Multiple Ascending Dose (MAD)|Participants in Cohorts C, D and E will receive a once daily dose of AB-836/placebo for 10 days
89344785|NCT04775797|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohorts F-H|Participants in Cohorts F, G, and H will receive multiple doses of AB-836/placebo once daily for 28 days.
89344786|NCT04775797|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD Cohort I|Participants in Cohort I will receive multiple doses of AB-836/placebo once daily for 28 days in combination with ongoing nucleos(t)ide analog (NA) therapy.
89344787|NCT04775797|Experimental|Part 2b (Healthy Subjects): MAD|Participants in Cohorts J will receive a once daily dose of AB-836/placebo for 35 days
89344788|NCT03461614|Experimental|Exercise Group|In addition to the service routine rehabilitation program, in this group all participant receive as group training with instructor supervising 5-6 participants. The specific days of the week and time of day in which the participants trained remained constant throughout each training protocol. Training programs lasted 6 weeks and comprised 2 training sessions per week with a total of 12 training sessions. A 45-60 min training sessions per week with a 2 day gap between each session.
89344789|NCT03461614|Other|Control Group|In addition to the service routine rehabilitation program, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
89344790|NCT03707613|Experimental|DWT learning curve|Initial cannulation is performed with a wire-guided sphincterotome by a trainee. If the cannulation proves difficult (cannulation time >10min, cannulation attemtps >5 or inadvertent PD cannulation >1) and PD is inadvertently entered, DWT will be performed by one of the two trainees. If DWT fails within 5min or 5 attempts, a trainer will take over and continue the cannulation. To prevent PEP, all patients receive prophylactic PD stent and post-ERCP rectal indomethacin. Aggressive hydartion will be administrated at the discretion of endoscopists.
89344791|NCT03794869|Experimental|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of the core: awareness of breathing, front and side plate abdominal, glute bridge/hip elevations, lift extended leg, pelvic tilt, hamstring stretch, strengthening lower abdominals, cat-camel posture, trunk rotations with flexed knees, rolling in sitting and lumbar extension with hip extensión in prone
89344792|NCT03794869|Active Comparator|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
89344793|NCT03461380|Experimental|Menopause Relief EP-40|Fixed combination of black cohosh EP-40 and Rhodiola rosea EPR-7 206.5 mg orally twice daily; daily dose 413 mg of active ingredients
89344794|NCT03461380|Active Comparator|High Dose Black Cohosh|Black cohosh 500 mg orally twice daily; daily dose 1000 mg of active ingredient
89344795|NCT03461380|Placebo Comparator|Placebo|Placebo capsule 600 mg excipients orally twice daily
89344796|NCT03461380|Active Comparator|Low Dose Black Cohosh|Black cohosh 6.5 mg orally twice daily; daily dose 13 mg of active ingredient
89344797|NCT03917537||HNSCC patients have used Nivolumab|Retrospectively analyze WGS information from cancer tissues from HNSCC patients have used Nivolumab
89344798|NCT03335163|Experimental|ENG Implant Users|Healthy women using an ENG implant for at least 12 months and no greater than 36 months will be administered a 6 week titration schedule of topiramate to a max dose of 200mg bid by the final week.
89344799|NCT01133561|Active Comparator|actozone A|Pioglitazone 30 mg tablets daily
89344800|NCT01133561|Placebo Comparator|actozone B|placebo
89344801|NCT04749602|Experimental|Cohort 1: Intrapleural Nivolumab in patients with renal cell carcinoma|Drainage followed by nivolumab (40 mg, single intrapleural instillation) will be performed.
89344802|NCT04749602|Experimental|Cohort 2: Intrapleural Nivolumab in patients with non-small cell lung cancer|Drainage followed by nivolumab (40 mg, single intrapleural instillation) will be performed.
89344803|NCT01230905|Other|MPI nuclear scan|Nuclear MPI for CAD for prostate cancer subjects undergoing treatment and development of normal comparison.
89344804|NCT03461302|Experimental|Topical Coal Tar treatment|
89344805|NCT03461302|Active Comparator|Topical Corticosteroids treatment|
89344806|NCT01232075|Experimental|Extended letrozole regimen|
89344807|NCT01232075|Active Comparator|Clomiphene citrate regimen|
89344808|NCT03461224||MARA-1: accelerated hypofractionated RT|A forward planned IMRT technique was used and the prescribed dose to the breast was 40 Gy in 16 fx with a concomitant boost of 4 Gy.
88807155|NCT00396266|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
88807156|NCT00396266|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
88807157|NCT05381142|Experimental|Elinzanetant (BAY3427080)|Healthy female participants who meet all of the inclusion criteria and do not meet any of the exclusion criteria will be randomized to treatment with elinzanetant.
88807158|NCT05381142|Placebo Comparator|Placebo|Healthy female participants who meet all of the inclusion criteria and do not meet any of the exclusion criteria will be randomized and assigned to treatment with placebo.
88807159|NCT05610384|Active Comparator|Ketorolac group|ketorolac 30 mg
88807160|NCT05610384|Active Comparator|Ibuprofen group|ibuprofen 800 mg
88807161|NCT05286944|Experimental|Mobile daily alarm|A mobile smartphone with functioning alarm system and solely owned by the patient. The alarm will be set by the second investigator to alert the participant between 6am - 10am (based on participant's preference) in the morning daily. A recorded dual-language (English and Malay version) tone for alarm mobile phone will be used. Apart from that participants are also counseled and educated about allergic rhinitis and are also asked to fill up self monitored adherence card to document their nasal steroid intake.
88807162|NCT05286944|No Intervention|Control|This group of participant will receive counseling and education regarding allergic rhinitis and the importance of compliance. Patients are also given a self monitored adherence card to document their nasal steroid intake.
88807163|NCT00397904|Experimental|Cetuximab, Cisplatin, and Irinotecan|Cetuximab will be combined with weekly irinotecan and cisplatin. Patients will receive cetuximab 400 mg/m2 on day 1, week 1. Following this loading dose, patients will receive weekly cetuximab 250 mg/m2 (day 8, 15, 22, etc.) until disease progression or unacceptable toxicity. Patients will continue to receive irinotecan and cisplatin weekly on day 1 and day 8, on an every 21 day cycle. The standard maximum doses are irinotecan 65 mg/m2 and cisplatin 30 mg/m2.
88807164|NCT05610228||LLC|
88807165|NCT00398918|Experimental|Zonisamide|
88807166|NCT00398918|Placebo Comparator|Placebo|
88807167|NCT00399308|Active Comparator|Control|Multi-layer compression bandaging (Profore)
88807168|NCT00399308|Experimental|Celaderm, Bi-Weekly|Celaderm, bi-weekly applications, up to a maximum of four applications
88807169|NCT00399308|Experimental|Celaderm, Weekly|Celaderm, applied weekly, up to a maximum of four applications
88807170|NCT05599776|No Intervention|Control group|The control group of this trial will receive standard postoperative care which includes physiotherapy appointments 4 weeks and 3 months after the surgery. The 4-week physiotherapy appointment will be at local health center, occupational health clinic or in private physiotherapy clinic and patients are instructed to book the appointments independently according to the standard of care in Coxa Hospital. The 3-month physiotherapy appointment in Coxa Hospital will be carried out by physiotherapists who are dedicated to research projects at Coxa outpatient clinic.
88807171|NCT05599776|Experimental|Intervention group|The patients in the intervention group will receive standard physiotherapy care but patients also use smart rings (Oura ring) 3 months postoperatively. Patients will be remotely monitored to follow their recovery from TKR surgery: the study group physiotherapists will follow the patients' activity and sleep and if necessary, make a contact with patient if there seems to low activity indicating difficulties with recovering from the surgery. If there is a constantly decreasing trends in these parameters or patient improvement plateaus, patient is contacted and their status is evaluated by telephone. Based on the information from this contact, the patients may be asked to visit the physiotherapist at the outpatient clinic to assess the situation, and also anesthetist may be consulted on the pain medication. Data collected with the Oura ring will also be used in physiotherapy appointments as a part of therapeutic treatment and guidance.
88807172|NCT05286476|Experimental|group A|received Whole-body Vibration, pelvic floor exercise and static abdominal exercises interventions In addition to diet instructions
88807173|NCT05286476|Other|group B|received pelvic floor exercises and static abdominal exercises in addition to diet instructions only
88807174|NCT05599074|Experimental|AOB adults|adult patients over 18 years having an anterior open bite of more than 2 mm, requiring incisors extrusion
88807175|NCT00401102|Other|Interpersonal psychotherapy|All participants received interpersonal psychotherapy adapted for self-injury
88807176|NCT01793402||Preterm infants born at or less than 32 weeks gestation|
88807177|NCT05350722|Experimental|Pre-operative single dose partial breast irradiation|
88807178|NCT04750694|Experimental|RT + BFRE|High intensity Resistance training combined with Blood Flow
88807179|NCT04750694|Active Comparator|RT|Resistance training alone
88807180|NCT05317104|Experimental|Aerobic Exercise Group|"Intervention group will be included in a program consisting of warm-up, loading and cool-down periods. Maximum Heart Rate (MHR) method will be used to determine the intensity of aerobic exercise training. Since moderate aerobic exercise training was aimed, exercise training will be given in 55-74% of MHRs. Exercise training will be started at mild-moderate intensity. Afterwards, within the limits that the person can tolerate and does not cause complications, with 5-10 minute increments every 1-2 weeks, the person will progress without muscle pain, injury, respiratory distress or fatigue due to overload. Polar H9 Heart Rate Sensor, which will be worn on the chest, will be used to monitor heart rate during exercise training.~Aerobic exercise training will be given in accordance with the procedures determined on the treadmill in the laboratory environment, with a program consisting of 6-week."
88807181|NCT05317104|No Intervention|Control Group|No intervention will be made other than evaluations. However, in order for the participants in this group to achieve the same health gains, they will remain under follow-up and control to apply the same aerobic exercise training program after the study is completed.
88807182|NCT01794884|Experimental|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg)(volume ratio=1:5).Intravenous injection twice (24 hours、1 hour before operation).
89344809|NCT03461224||CG: conventional fractionated RT|In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) delivered with 3D-RT, followed by a sequential boost on the tumour bed of 10 Gy in 4 fx delivered with electrons
89344810|NCT03940300|Experimental|Adults with or risk for Type 2 Diabetes|All adult individuals with (non-insulin treated) or at risk for type 2 diabetes are in the treatment group and will receive prescriptions of fresh organic vegetables on a weekly basis for 10 weeks.
89344811|NCT01135277||Sepsis|Patients who have been diagnosed with Sepsis within 24 hours of admission
89344812|NCT01135277||Non-Septic|Patients who have not been diagnosed with sepsis within 24 hours of admission
89344813|NCT01131845|Experimental|Treprostinil diethanolamine|
89344814|NCT03926260|Experimental|ctDNA analysis|additional blood sample of 20 ml
89344815|NCT03711500|Experimental|D-serine 80 mg/kg|
89344816|NCT03711500|Placebo Comparator|Placebo|
89344817|NCT03711500|Experimental|D-serine 100 mg/kg|
89344818|NCT03711500|Experimental|D-serine 120 mg/g|
89344819|NCT03810157|Experimental|Laser-assisted hatching system|Embryos were exposed to a dose of laser energy focused outside the zona pellucida by aser-assisted hatching system.
89344820|NCT03810157|No Intervention|Control group|Nothing is done.
89344821|NCT03920735||Opportunistic infection|Immunocompromised or frail patients with an opportunistic infection
89344822|NCT03920735||Control group|Immunocompromised or frail patients with no opportunistic infection
89344823|NCT03461068|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
89344824|NCT03461068|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
89344825|NCT01304719|Experimental|Computer Assisted home visitation|Home visitation with computer modules added
89344826|NCT01304719|Experimental|Home Visitation TAU|Home Visitation Treatment as Usual
89344827|NCT01304719|No Intervention|Community Referral|Community Referral
89344828|NCT03460912||All participants|
89344829|NCT03920501|Experimental|Tele-Critical Care|Tele-Critical Care + Audit & Feedback.
89344830|NCT03920501|No Intervention|Usual Care|Usual Care.
89344831|NCT03711422|Experimental|Part A|Standard dose oral afatinib. If patients in Part A do not benefit from the regimen, they can be enrolled into Part B
89344832|NCT03711422|Experimental|Part B|Intermittent high dose oral afatinib
89344833|NCT04132843|Experimental|Diagnostic (MRI, gadobutrol, gadobenate dimeglumine)|Within 21 days before standard of care chemotherapy and/or radiation therapy, patients undergo an MRI scan for the first set of images. Patients then receive either gadobutrol or gadobenate dimeglumine IV and undergo an MRI for the second set of images. All MRI scans take a total of 60 minutes to complete. Patients then repeat the MRI scans 120 days after standard of care chemotherapy and/or radiation therapy.
89344834|NCT03460834||Obese asthmatic patients|Observational Cohort
89344835|NCT03364335|Placebo Comparator|Placebo|Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.
89344836|NCT03364335|Experimental|Leu Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
89344837|NCT03364335|Experimental|Leu Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
89344838|NCT03364335|Experimental|Leu Met Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
89344839|NCT03364335|Experimental|Leu Met Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
89344840|NCT03460678|Other|Pemetrexed Arm|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium)
89344841|NCT03460678|Other|Erlotinib Arm|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride)
89344842|NCT03810391|Experimental|preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group A were >11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
89344843|NCT03810391|Placebo Comparator|preoperative anxiety and saline|preoperative anxiety scores of patients in Group B were >11 and received an infusion of the same volume of physiological saline
89344844|NCT03810391|Experimental|non-preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group C were ≤ 11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
89344845|NCT03810391|Placebo Comparator|non-preoperative anxiety and saline|preoperative anxiety scores of patients in Group D were ≤11 and received an infusion of the same volume of physiological saline
89344846|NCT02528591|Experimental|renal transplant patient|
89344847|NCT03898024|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
89344848|NCT03898024|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
89344849|NCT03898024|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
89344850|NCT03898024|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
89344851|NCT03898024|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
89344852|NCT03630770|No Intervention|Control|This group receives no feeding supplement.
89344853|NCT03630770|Experimental|MCT Oil|This group is supplemented with MCT oil
89344854|NCT03917069|Experimental|nab-paclitaxel + endostatin+ carboplatin|nab-paclitaxel + endostatin+ carboplatin nab-paclitaxel 260mg/m2, d1 +Carboplatin AUC=5, d1 +endostatin 15mg, d1-14 q28d
89344855|NCT03917069|Active Comparator|paclitaxel+carboplatin|paclitaxel+carboplatin paclitaxel 175 mg/m2, d1+ Carboplatin AUC=5, d1 q21d
88807183|NCT01794884|Placebo Comparator|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation).
88807184|NCT05315934|Experimental|Upper Body Aerobic Exercise|Participants will perform 30 minutes of arm-crank cycling at a moderate exercise intensity based off the participants perceived RPE13
88807185|NCT05315934|Experimental|Lower Body Aerobic Exercise|Participants will perform 30 minutes of static cycling at a moderate exercise intensity based off the participants perceived RPE13
88807186|NCT00401414|Experimental|Warfarin|We will develop a nomogram for warfarin dosing that uses rapid turnaround genetic testing and monthly nomogram modification (if necessary) to achieve effective and safe warfarin induction and maintenance. More than 70% of the time, we will maintain warfarin naïve patients within the target therapeutic range. The percent of time in the therapeutic range will be analyzed beginning 2 weeks after initiation of warfarin. Analyses will be stratified by the indication for anticoagulation.
88807187|NCT05513196||ESPB Group|Erector spinae plane block performed group.
88807188|NCT05513196||Control Group|Control group.
88807189|NCT00370838|Experimental|Levetiracetam|"Levetiracetam (Keppra) is used in one phase of this cross-over study.~The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
88807190|NCT00370838|Active Comparator|Clonidine|"Clonidine is used in one phase of this cross-over study.~The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
88807191|NCT00370994|Active Comparator|Caudal epidural injection|Caudal epidural with placement of catheter in sacral canal with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 0.9% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
88807192|NCT00370994|Active Comparator|Percutaneous adhesiolysis|Pecutaneous adhesiolysis and targeted placement of Racz catheter with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 10% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
88807193|NCT01795430|Experimental|Treatment (radiation therapy/chemotherapy, stem cell infusion)|"BLOCK I: Patients receive etoposide IV over 1-2 hours and ifosfamide IV over 1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation therapy BID, 5 days a week, for approximately 4 weeks. Patients may also undergo 4 fractions of SRT QOD, 3-8 fractions of SBRT QOD, or 10 fractions of 3D RT daily to sites of metastatic disease.~BLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous peripheral blood or bone marrow stem cell infusion on day 0."
88807194|NCT04750382|Experimental|HX008+Cisplatin+Gemcitabine|
88807195|NCT04271150|Experimental|Self-etch|Self-etch mode of the universal adhesive will be used
88807196|NCT04271150|Active Comparator|Total-etch|Total etch mode of the universal adhesive will be used
88807197|NCT00401882|Active Comparator|Standard Of Care Drug Epinephrine|Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
88807198|NCT00401882|Active Comparator|IV Metoprolol instead Epinephrine|IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses
88807199|NCT01794962|Experimental|Manual therapy and exercises|Manual therapy treatment: spinal manipulation, Soft tissue treatment, muscle energy techniques. Exercises: stabilisation exercises, Mckenzie exercises and general muscle exercises.
88807200|NCT01794962|Experimental|Cognitive Functional Therapy|An in depth interview, including investigating the patients beliefs on back pain, fear towards movement, anxiety and distress, using reflecting questions. The physical part consists of specific and functional exercises related to the patients functional complaints.And general physical activity for 30 mins 3-4 times weekly.
88807201|NCT00371540|No Intervention|I|Routine care in the clinic
88807202|NCT00371540|Experimental|II|Follow-up in clinic every 3 months, home visits monthly
88807203|NCT04248738|Experimental|SocNSuppR|Inpatient teams systematically provided with information about patients' social needs and supportive resources.
88807204|NCT05345886|Experimental|Hippotherapy|The experimental group will receive 30 minutes of hippotherapy once a week for 12 weeks.
88807205|NCT05345886|No Intervention|Control|The control group will receive its rehabilitation care
88807206|NCT05555394|Experimental|Basic Body Awareness Therapy|the Basic Body Awareness Therapy is usual therapy of physiotherapy in mental health in nord europe. BBAT is based in twelve movements and massage that improve the movements quality of patient, also improves other movement qualities like biomechanical, physiologic, socio-cultural and existential
88807207|NCT05555394|Active Comparator|Stretching group|"Stretching exercise will be developed in control group in order to blind the intervention of interest. It will consist in analytic stretching of trunk, upper and lower limb.~It will last around 45 min twice a week during 12 weeks."
88807208|NCT00373334|Experimental|1|
88807209|NCT00373334|Experimental|2|
88807210|NCT00373334|Sham Comparator|3|
88807211|NCT05553288||active group|Every study participant will actively receive daily text messages asking about their change in health and concomitant medication.
88807212|NCT05286086|Sham Comparator|PREHAB-PREOP|PREHABILITATION BEFORE SURGERY
88807213|NCT05286086|Experimental|PREHAB-NEOADJ|PREHABILITATION DURING NEOADJUVANCY AND BEFORE SURGERY
88807214|NCT05305404|Active Comparator|Guanfacine|single dose of dexamethasone (1.5mg) administered orally
88807215|NCT05305404|Placebo Comparator|Placebo|single dose of placebo administered orally
88807216|NCT00402896|Experimental|ZD6474|300 mg/day orally for 10 weeks.
88807217|NCT05303610||Experimental group|This group will consist of 28 patients with diagnosed Patellofemoral pain syndrome, aged between 25-50 years.
88807218|NCT05303610||Control group|Healthy individuals between the ages of 25-50 and without any orthopedic (Anterior cruciate ligament rupture, Meniscal tears etc.), neurological (Multipl sclerosis, Stroke etc) and rheumatological disorders (Rheumatoid arthritis, Ankylosing spondylitis etc.).
88807219|NCT00405704|Active Comparator|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
88807220|NCT00405704|Placebo Comparator|Placebo|Cherry-flavored liquid suspension matched to active comparator.
88807221|NCT01657266|Experimental|PRO-155|"Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
88807222|NCT01657266|Active Comparator|Nevanac|"Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension~Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
88807223|NCT05302440||single-group|All care staff who manage the system will complete a very brief survey (1-minute) after each work shift for 14 days. Detection of abnormal vital signs will be recorded by the system. Hospital admission and further medical assistance due to the use of the system will be documented by the care team. The staff will be interviewed about their perceived benefits and acceptability of the system.
88807224|NCT05286008|Placebo Comparator|Normal Saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side.
88807225|NCT05286008|Experimental|Ropivacaine at high concentration|Before the induction of anesthesia, 0.375% Ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
88807226|NCT05286008|Experimental|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
88807227|NCT05302284|Experimental|RC48-ADC + JS001|Participants will receive RC48-ADC + JS001 every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
88807228|NCT05302284|Active Comparator|Gemcitabine + cisplatin/carboplatin|Participants will receive Gemcitabine + cisplatin or carboplatin every 3 weeks (Q3W) for maximum 6 weeks or until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
88807229|NCT05265078||Participants Diagnosed With VWD|Participants who have been diagnosed with VWD and prescribed VEYVONDI for the approved indications for the index infusion (first eligible VEYVONDI infusion) will be assessed using secondary data obtained from medical records to evaluate the safety of VEYVONDI in real-world clinical practice. All study data will be retrospectively abstracted from medical records by dedicated clinical research staff in partnership with the treating physician. The data window for this study will begin on 01 January 2019 and end one day before site activation at each site.
88807230|NCT05300802|Placebo Comparator|Group A|Ringer acetate
88807231|NCT05300802|Experimental|Group B|Priming Dexmedetomidine 1 mcg/kg, Intravenous Ringer acetate
88807232|NCT05300802|Experimental|Group C|Priming Dexmedetomidine 0.5 mcg/kg, Intravenous Dexmedetomidine 0.25 mcg/kg/hour
88807233|NCT05262114||Pre-cursor text|A pre-notification text message (SMS) will be sent to eligible people informing them of their imminent invitation to participate in The Who, two days later a brief text message (SMS) will be sent from the general practice to eligible people, inviting them to participate in The Who.
88807234|NCT05262114||Invitation only|A brief text message (SMS) will be sent from the general practice to eligible people, inviting them to participate in The Who.
88807235|NCT05299476|Experimental|CAPOX combined with bevacizumab and Tislelizumab|
88807236|NCT00405938|Experimental|Bevacizumab/anastrozole|Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.
88807237|NCT00405938|Experimental|Bevacizumab/fulvestrant|Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant). Treatment will be given in 4-week cycles.
88807238|NCT04239534|Other|Single Arm|In this Single Arm Study, Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access. Followed by the sue of an endocardial ablation catheter that will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter.
88807239|NCT05299398|Experimental|Trazodone|Trazodone once daily for 24 weeks.
88807240|NCT05299398|Placebo Comparator|Placebo|Placebo once daily for 24 weeks
88807241|NCT01793480|Experimental|patient-controlled dose of methadone|The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.
88807242|NCT01793480|Experimental|fixed-dose of methadone|The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.
88807243|NCT05285930|Experimental|group A|received phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
88807244|NCT05285930|Experimental|group B|received phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
89344856|NCT01567345|Active Comparator|Intrathecal pump with continuous flow|After placement of the implantable pump, continuous flow is scheduled by physician and the patient can't modify it.
89344857|NCT01567345|Experimental|Intrathecal pump with programmable flow.|After placement of the implantable pump, programmable flow is scheduled by physician and patient can do himself morphine bolus injections for a better control of acute episodes of pain.
89344858|NCT02522026||Healthy volunteers|
89344859|NCT02522026||Healthy smokers|
89344860|NCT02522026||COPD GOLD1|
89344861|NCT02522026||COPD GOLD2|
89344862|NCT02522026||COPD GOLD3/4|
89344863|NCT01229579|Experimental|Zinc Supplement|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc
89344864|NCT01229579|Placebo Comparator|Placebo|2.5 ml supplement syrup daily without elemental zinc
89344865|NCT03460444|Experimental|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days while consuming a diet similar to the recommended health guidelines (40-50% carbohydrate; 30-40% fat; 20-25% protein).
89344866|NCT03916991|Experimental|Neuromuscular Exercise|Neuromuscular Exercise
89344867|NCT03916991|No Intervention|Control|No intervention
89344868|NCT03916991|Sham Comparator|Sham Exercise|Sham Exercise
89344869|NCT03460288|Experimental|Intervention Group|The training-program includes ten pictures related to slot-machine gambling and 10 neutral pictures that need to be either pushed (i.e., avoidance) or pulled (i.e., approach) with the computer mouse or finger (when a tablet is used) according to a non-affective dimension (color of the frame). Pictures are presented in random order.
89344870|NCT03460288|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive the retraining intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including pharmacological treatment. Participants in the wait-list control condition receive full access to the training program after completion of the post-assessment.
89344871|NCT01131923|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
89344872|NCT01131923|Active Comparator|Norvasc Tablets, 10 mg|
89344873|NCT03794557|Experimental|PUL-042|PUL-042 Inhalation Solution
89344874|NCT03794557|Placebo Comparator|Placebo|Sterile Water for injection
89344875|NCT03460132|Experimental|Extraction cases|patients receive Tomas orthodontic miniscrew implant as a mean of anchorage augmentation
89344876|NCT03460054||IgA Nephropathy (IgAN)|Biopsy-Proven IgAN
89344877|NCT03460054||Focal Segmental Glomerulosclerosis (FSGS)|Biopsy-Proven FSGS
89344878|NCT03460054||Membranous Nephropathy (MGN)|Biopsy-Proven MGN
89344879|NCT03460054||Mesangioproliferative Glomerulonephritis (MPGN)|Biopsy-Proven MPGN
89344880|NCT03460054||Minimal Change Disease (MCD)|Biopsy-Proven MCD
89344881|NCT01133717||Control without Sleep Apnea|
89344882|NCT01133717||Subjects with Sleep Apnea|
89344883|NCT03459976||2 groups|control group case group
89344884|NCT03459742|Experimental|Intervention|Gamification strategy. In 2018, the intervention group are 15 schools from Municipality of Santiago. In 2019, the intervention will cover all eligible schools in the Municipality of Santiago.
89344885|NCT03459742|No Intervention|Control|In 2018, the control group will be 5 randomly selected schools from Municipality of Santiago and 4 schools from Municipality of Estación Central. In 2019, the control group will be 4000 participants chosen from neighboring municipalities
89344886|NCT01230983|Experimental|Treatment 1: (No HD MTX / No Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, IT methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
89344887|NCT01230983|Active Comparator|Treatment 2: (No HD MTX / Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, dexrazoxane hydrochloride (Zinecard or DZR), IT methotrexate /cytarabine, radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
89344888|NCT01230983|Active Comparator|Treatment 3: (HD MTX / No Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, leucovorin calcium (LCV), HD methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
89344889|NCT01230983|Active Comparator|Treatment 4: (HD MTX / Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, HD methotrexate /cytarabine, dexrazoxane hydrochloride (Zinecard or DZR), radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
89344890|NCT03810001|No Intervention|standard ICSI procedure|a single spermatozoon was injected into the ooplasm
89344891|NCT03810001|Experimental|modified ICSI procedure|slight mechanical stimulation before standard ICSI procedure
89344892|NCT03334695|Experimental|Group 1: Ad26.RSV.preF|Participants will receive single intramuscular injection of 1*10^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.
89344893|NCT03334695|Placebo Comparator|Group 2: Placebo|Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.
89344894|NCT01304797|Experimental|MM-302|
89344895|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab|
89344896|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab q3w|
89344897|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab and Cyclophosphamide|
89344898|NCT03459664|Experimental|RECOVER|The intervention in the RECOVER stepped-care model includes specific evidence-based treatment options for severity grade 1 to 4.
89344899|NCT03459664|Active Comparator|Treatment As Usual|The active comparator is treatment as usual (TAU) and provides all common care options within the German health care system, depending on the severity grade 1 to 4.
89344900|NCT03458806||Control|Subjects with echocardiographically confirmed valvular disease of less than moderate-to-severe grading with regards to aortic stenosis (AS) and mitral regurgitation (MR). Note that within this cohort will be a sub cohort consisting of subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
89344901|NCT03458806||AS Case|Subjects with echocardiographically confirmed aortic stenosis (AS) of moderate-to-severe or greater grading.
89344902|NCT03458806||MR Case|Subjects with echocardiographically confirmed mitral regurgitation (MR) of moderate-to-severe or greater grading.
89344903|NCT03458806||Control Subgroup|Subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
89344904|NCT03920345|Experimental|Treatment: Endoscopic ET on SI joint|New techniques have been developed and tested to expand the usefulness of minimally invasive spine surgery beyond disk herniation. This includes endoscopic electrothermic ablation which can be used to target SIJ-associated CLBP. A small retrospective study demonstrated significant improvements in Visual Analog Scale and Oswestry Disability Index from pre-operative levels in patients with CLBP associated with the SIJ for up to 21 months following the procedure. However, there has not yet been a prospective study to assess the efficacy of this procedure, and therefore, this is the aim of this study.
89344905|NCT03707535|Experimental|CT-P13|
89344906|NCT03707535|Active Comparator|China-approved Remicade|
89344907|NCT03793153|No Intervention|Control|Standard Lower Segment Cesarean Section (LSCS) will be done.
89344908|NCT03793153|Active Comparator|Study|Uterine Cooling Technique: Standard LSCS will be done except immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. The skin of the abdomen will be draped to prevent contact with the cold towels. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
89344909|NCT03920423|No Intervention|shallow depth|Radial arterial deth is shallow than the cutoff point that relative to results.
89344910|NCT03920423|Experimental|improved depth|Radial arterial deth is shallow than the cutoff point that relative to results, and increased by injection of saline to more than deep cutoff point.
89344911|NCT03458182|Experimental|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
89344912|NCT03458182|No Intervention|No intervention|No added exercise period (normal exercise test).
89344913|NCT01133795|Experimental|Midodrine, Albumin|Midodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
89344914|NCT03364023||Acute Ischemic Stroke Patients|Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device
89344915|NCT01133873|Experimental|1|
89344916|NCT01133873|Placebo Comparator|2|
89344917|NCT03458026|Experimental|connected object + SMS of physical activity reminders|"The patients will be included during their visit of follow-up and will receive a watch connected. They will have an information meeting for their to explain how step shows it. They will also receive advice to practise an adapted physical activity. During 12 weeks of SMS (text messages) every week to motivate them to realize these exercises.~At the end of 12 weeks the connected watch will be deprived of them as well as SMS (text messages). They will have to realize an activity in autonomy during 12 weeks.~At the end of the twenty-fourth week, they will get back their watch. They will have in more 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.~In 36 week, they return the watch and finish the study."
89344918|NCT03458026|Other|Without connected object|"The patients will be included during their visit of follow-up.They will have an information to practice suitable activity during 12 weeks At the end of 12 weeks, they realised follow-up. They will have to realize an activity in autonomy during 12 weeks.~At the end of the twenty-fourth week, they will have 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.~In 36 week, the study will be finished."
89344919|NCT01304017|Experimental|Virtual Reality Therapy|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing.
89344920|NCT01304017|Active Comparator|Traditional Therapy|The traditional therapy will include exercises for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
89344921|NCT01229813|Active Comparator|bevacizumab and erlotinib (KRAS WT)|
89344922|NCT01229813|Active Comparator|bevacizumab (KRAS WT)|
89344923|NCT01229813|Active Comparator|bevacizumab (KRAS mutated)|
89344924|NCT01229813|Active Comparator|low dose capecitabine (KRAS mutated)|
89344925|NCT03792997|Active Comparator|control|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid
89344926|NCT03792997|Experimental|study|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid but the investigators add in this arm lipid emulsion & prednisolone & LMWH
89344927|NCT03457012||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
89344928|NCT04744532|Experimental|Drug: Bosutinib (Phase 1 part)|"Phase 1 part:~3 to 6 ALS patients will be enrolled in each of the 4 bosutinib dose lelvels [100 mg/day (dose level 1), 200 mg/day (dose level 2), 300 mg/day (dose level 3), or 400mg/day (dose level 4)] to evaluate the safety and tolerability of the investigational drug (bosutinib) under a 3+3 dose escalation study design. The dose will be escalated by 1 dose level at a time; no skipping will be allowed.~Dose escalation and MTD will be determined by the safety assessment committee comprising oncologist, hematologist, ALS Expert based on the incidence of DLT in 4 weeks of treatment among 3 subjects enrolled (6 subjects if additionaly enrolled) in each dose level."
89344929|NCT04744532|Experimental|Drug: Bosutinib (Phase 2 part)|"Phase 2 part:~25 ALS patients will be enrolled; patients will be randomly assigned to the following groups: 13 patients in 300mg/day group and 12 patients in 200mg/day group of the investigational drug (bosutinib). The efficacy and the safety of bosutinib in ALS patients for 24 weeks will be assessed."
89344930|NCT03455920|Experimental|Multidisciplinary arm|Patients randomized in this group will have their first sleep clinic evaluation with the clinical nurse. She will then discuss each case with the pulmonologist and validate the diagnostic and therapeutic avenue.
89344931|NCT03455920|Active Comparator|Pulmonologist arm|Patients randomized in this group will have their first sleep clinic evaluation with the pulmonologist.
89344932|NCT01231061|Experimental|Arm A: SBRT|
89344933|NCT01231061|Experimental|Arm B: Radiosurgery|
89344934|NCT03920813|Experimental|Antitumor drugs|Mercaptopurine administered at standard dose for children with hematological neoplasms.
89344935|NCT01649947|Experimental|Cohort 2: Bevacizumab ineligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Hydroxychloroquine 200 mg PO BID
89344936|NCT01649947|Experimental|Cohort 1: Bevacizumab eligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for Hydroxychloroquine 200 mg PO BID
89344937|NCT01137461|Other|abdominal ultrasound|traditional technique
89344938|NCT01137461|Other|transvaginal ultrasound|new technique
89344939|NCT03709173||Premanifest HDGEC participants|
89344940|NCT03709173||Early-manifest HDGEC participants|
89344941|NCT03709173||Companions of Premanifest HDGEC|
89344942|NCT03709173||Companions of Early-manifest|
89344943|NCT03454750|Experimental|177Lu-PSMA|177Lu PSMA
89344944|NCT03793075|Placebo Comparator|Propofol group (P)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of propofol 17 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
89344945|NCT03793075|Active Comparator|Ketamine group ((K)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of ketamine 5 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
89344946|NCT01233167|Experimental|clopidogrel|
89344947|NCT01233167|Placebo Comparator|placebo|
89344948|NCT01233167|Experimental|steply discontinued clopidogrel|
89344949|NCT05044208||No atrial fibrillation detected|In this cohort, AF is not detected in 7-day ECG monitoring or 2-years follow-up period
89344950|NCT05044208||Atrial fibrillation detected|In this cohort, AF is detected in 7-day ECG monitoring or 2-years follow-up period
89344951|NCT03710499|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 8 consecutive weeks.
89344952|NCT01304095|Active Comparator|Ranolazine|Ranolazine in addition to standard of care medical therapy
89344953|NCT01304095|No Intervention|Standard of Care|
89344954|NCT03454282|Experimental|FMD Arm|The intervention consists in 5-day FMD (Fasting Mimicking Diet) to be followed for one cycle (Cohorts A and B) or for 4 consecutive every-four week cycles postoperatively.
89344955|NCT03707457|Experimental|Arm A: Nivolumab + anti-GITR|Patients receive nivolumab intravenously (IV) over 30 minutes and anti-GITR intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89344956|NCT03707457|Experimental|Arm B: Nivolumab + IDO1 inhibitor|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1 and IDO1 inhibitor daily by mouth. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89344957|NCT03707457|Experimental|Arm C: Nivolumab + Ipilimumab|Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab intravenously (IV) over 90 minutes on Day 1. Courses repeat every 21 days for up to 4 doses. After ipilimumab is discontinued, courses of nivolumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89344958|NCT03797755||Palliative Cancer Patients|Stage IV cancer patients evaluated for palliative radiotherapy.
89344959|NCT01134029|No Intervention|Enhanced Usual Care|Control Group
89344960|NCT01134029|Experimental|Stepped Care|Intervention
89344961|NCT03453814|Experimental|Interventional|Music therapy.
89344962|NCT03453814|No Intervention|Comparison|No music therapy.
89344963|NCT03739697|Active Comparator|spontaneous breathing|spontaneous breathing after adminitration of anesthetics
89344964|NCT03739697|No Intervention|mechanical ventilation|mechanical ventilation after adminitration of anesthetics and neuromuscula blockade
89344965|NCT01568294|Experimental|pomalidomide|Patients will receive pomalidomide orally on Days 1-21 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, development of an unacceptable toxicity, voluntary withdrawal, or pomalidomide is in market for the target indication.
89344966|NCT03916913|Experimental|Local therapy|Consolidation local radiotherapy
89344967|NCT01304953|Placebo Comparator|P+P|
89344968|NCT01304953|Experimental|P+T|
89344969|NCT01304953|Placebo Comparator|S+P|
89344970|NCT01304953|Experimental|S+T|
89344971|NCT03422666|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
89344972|NCT03422666|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
89344973|NCT03794245|Experimental|Men-Centered HIV Testing|Mobile HIV testing is conducted at sites in the community where men gather.
89344974|NCT03794245|Active Comparator|Clinic-based HIV Testing|Men are referred to the nearest clinic for HIV counseling and testing
89344975|NCT03794245|Experimental|Linkage to Care for HIV+ Men|The patient coordinator arranges an appointment time at the clinic and accompanies the patient to the initial visit
89344976|NCT03794245|Active Comparator|Clinic Referral for HIV+ Men|Men diagnosed with HIV are referred to the nearest clinic for treatment of HIV
89344977|NCT03410810||Infant Control Group|The control arm (term born Infants) will receive an MRI at neonatal age and neurodevelopmental follow-up assessments, investigators will then compare significant morphological and diffusion properties within the brain to those of a Preterm brain.
89344978|NCT03410810||Infant Preterm Group|The experimental group will consist of preterm infants, who will receive an MRI at neonatal age and neurodevelopmental assessments. This groups scans will then be compared to those of the control arm. Significant biomarkers will then be identified.
89344979|NCT03410810||Childhood Control Group|The experimental group will consist of preterm born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children control arm. Significant biomarkers will then be identified.
89344980|NCT03410810||Childhood Preterm Group|The experimental group will consist of term born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children preterm group. Significant biomarkers will then be identified.
89344981|NCT03453190|Other|Psoriasis Patients on Comb. Treatment|Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.
89344982|NCT02528669|Experimental|RX Navigait|Individuals in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals. In addition, they will be given additional education about the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
89344983|NCT02528669|No Intervention|Control Group|Participants in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals but will not receive additional education regarding the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
89344984|NCT03452254|Active Comparator|Experimental Group|Active bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
89344985|NCT03452254|Sham Comparator|Control Group|Sham bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
89344986|NCT01231139|Experimental|Paracetamol|Paracetamol dissolved in 0.9% Sodium Chloride
89344987|NCT01231139|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride
89344988|NCT03382574|Experimental|Arm I (denosumab, risk-reducing salpingo-oophorectomy)|Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.
89344989|NCT03382574|Active Comparator|Arm II (risk-reducing salpingo-oophorectomy)|Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.
89344990|NCT01137695|Active Comparator|Symlin Naive, Usual Dose|Symlin 120 mcg three times daily in patients not previously treated with pramlintide before the study.
89344991|NCT01137695|Experimental|Symlin Naive, Dose Escalation|Escalation of pramlintide dose to 360 mcg three times daily in patients not taking pramlintide prior to study.
89344992|NCT01137695|Active Comparator|Symlin treated, Usual Dose|pramlintide 120 mcg three times daily in patients who have been treated with pramlintide 120 mcg prior to the trial.
89344993|NCT01137695|Experimental|Symlin Treated, Dose Escalation|pramlintide 360 mcg three times daily in patients previously treated with 120 mcg prior to the study.
89344994|NCT03451396|Active Comparator|Mild Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >308 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
89344995|NCT03451396|Active Comparator|Moderate to Severe Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >320 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
89344996|NCT01231217|Other|green (or white) tea|Patients are recommended to drink green (or white) tea but are not allowed to consume any coffee
89344997|NCT01231217|Other|coffee|Patients are recommended to drink coffee but are not allowed to consume any tea
89344998|NCT03632096|Active Comparator|Photobiomodulation group|Patients will receive 3 applications of low intensity light directly in the region of the three pairs of salivary glands already described. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The first application will be after the stimulated collection of saliva and the following applications will be given once a week for another 2 weeks.
89344999|NCT03632096|Sham Comparator|Sham group|The placebo group will have a simulation of application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
89345000|NCT05322460|Experimental|Intervention group|The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
89345001|NCT05322460|No Intervention|Control group|Usual care in the nursing consultation in primary care
89345002|NCT05024864|Active Comparator|Helicobacter pylori screening|At centers randomized to screening, all patients with confirmed MI will be tested H. pylori infection with a bedside UBT incorporated into MI routine care during the hospitalization period. In patients tested H. pylori positive, standard triple eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.
89345003|NCT05024864|No Intervention|Usual care without Helicobacter pylori screening|At centers randomized to no screening, all MI patients will receive usual care and will be followed in national registries. Concerning the use of eradication therapy and other relevant medication), follow-up is performed in the National Drug Prescription Registry.
89345004|NCT05321836|Active Comparator|control group|chondritin sulfate 1500/1200mg
89345005|NCT05321836|Experimental|experimental group|chondritin sulfate plus physiotherapy
89345006|NCT05617573||Patients undergone TKA due to advanced knee osteoarthritis|
89345007|NCT02528825|Experimental|smooth emergence|ASA I-II, aged 19-65 years undergoing general anesthesia with DLT for lung wedge resection were enrolled in this study.After completing the surgery, the propofol infusion was stopped, and effect-site concentration of remifentanil was titrated to predetermined concentration ( initial concentration being 1.5ng/ml for the first patient).The predetermined concentration was maintained at least 10 min throughout emergence for the effect site concentration and plasma concentration can be expected stable. The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
89345008|NCT03363321|Experimental|PF-06741086 (Cohort 1)|
89345009|NCT03363321|Experimental|PF-06741086 (Cohort 2)|
89345010|NCT03363321|Experimental|PF-06741086 (Cohort 3)|
89345011|NCT03363321|Experimental|PF-06741086 (Cohort 4)|
89345012|NCT03363321|Experimental|PF-06741086 (Cohort 5)|
89345013|NCT03363321|Experimental|PF-06741086 (Cohort 6)|
89345014|NCT05321680|Experimental|Treatment withdrawal|discontinuation of treatment (anti-cholinesterase inhibitors including donepezil, rivastigmine and galantamine; and/or memantine)
89345015|NCT05321680|No Intervention|Treatment continuation|treatment continuation (anti-cholinesterase inhibitors including donepezil, rivastigmine and galantamine; and/or memantine)
89345016|NCT01233245||Group 1|
89345017|NCT01231295||Memory problems|Group with clinically validated memory problems
89345018|NCT01231295||Reference group|Group without memory problems
89345019|NCT03776812|Experimental|Continuous Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
89345020|NCT03776812|Experimental|Intermittent Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
89345021|NCT03776812|Active Comparator|Nab-paclitaxel Comparator|Patients will receive nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
89345022|NCT01233323||All study patients (single arm study)|All eligible patients will be included in the only study arm and will undergo study testing.
89345023|NCT03361605|Experimental|Propofol Administration|
89345024|NCT03916757|Experimental|V-Boost recipients|In this open label study all eligible participants will receive daily tablet of V-Boost
89345025|NCT03792685|Experimental|Normal weight|Normal weight men. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
89345026|NCT03792685|Experimental|Overweight/obesity|Men with overweight or obesity. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
89345027|NCT03792685|Experimental|Diabetes|Men with prediabetes or type 2 diabetes mellitus. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
89345028|NCT05193903|Experimental|Intervention: Simulation|Interactive information tools
89345029|NCT05193903|Other|Control: Text|Standard text-based information
89345030|NCT05416970||non-alcoholic fatty liver disease affected patients|Patients affected by NAFLD based on clinical, biochemical, imaging and histology, in accordance to CPG diagnostic criteria, continuously followed by the Hepato-gastroenterology Division of the University of Campania Luigi Vanvitelli, between January 2018 and January 2022 were enrolled, after signing an informed consent, in the present study.
89345031|NCT05321446|Experimental|GoHand Feedback Group|"Both groups will receive a standardized home practice program, the GRASP (Graded Repetitive Arm Supplementary Program). This is a program that has a standard set of arm and hand movements to be practiced 45 minutes per day over a one month period. The person manipulates objects to practice different hand movements. These are everyday objects and each person will be given a set of these to take home and to keep.~For the Experimental Group, the person will be taught the GRASP program and how to move the wrist and hand optimally to activate the GoHand sensor to hear the sound."
89345032|NCT05321446|Sham Comparator|GoHand Measurement Group|For Group 2, the person will be taught GRASP program and how to wear the sensor so it measures movement but does not emit a sound.
89345033|NCT03794167|Experimental|busulfan cyclophosphamide etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
89345034|NCT03794167|Active Comparator|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
89345035|NCT05332821||Study group: TACE+PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|TACE was performed up to 3 months after the first PD-1/PD-L1 inhibitor/anti-angiogenic drug treatment or within 1 month before treatment. The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
89345036|NCT05332821||Control group: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|The interval between first use PD-1/PD-L1 inhibitors and anti-angiogenesis drugs ≤1 week；
89345037|NCT01305031|Experimental|Room air|Initiation of resuscitation with 21% Oxygen, adjustments to the inspired oxygen concentration (increased 10%) will be made every 60 seconds for infants to achieve a target SpO2 range of 85-92%
89345038|NCT01305031|Active Comparator|100% Oxygen|Initiation of resuscitation with 100% Oxygen and achieve oxygen saturation in the preset limits 85-92%
89345039|NCT01231451|Experimental|All Subjects|All Subjects will receive the same intervention
89345040|NCT05320900||Severance hospital|Cardiovascular disease patients
89345041|NCT05320900||Yongin Severance hospital|Cardiovascular disease patients
89345042|NCT05320900||Soon Chun Hyang University Hospital Bucheon|Cardiovascular disease patients
89345043|NCT05401149||IV rt-PA cohort|Intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) cohort: AIS patients aged > 80 years who received IV rt-PA within 4.5 hours of symptom onset
88814342|NCT04367948|Experimental|68Ga-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
89345044|NCT05401149||Non-reperfusion cohort|Non-reperfusion cohort: AIS patients aged > 80 years who arrived or admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatments
89345045|NCT01233401||Mothers|
89345046|NCT01233401||Other Infant Caregivers|Includes fathers, grandparents, and other adults who are infant caregivers
89345047|NCT01304251|Active Comparator|Short-term fasting|short term fasting (i.e. 24 hours before and 24 hours after administration of chemotherapy) in 20 breast cancer patients
89345048|NCT01304251|Placebo Comparator|Healthy nutrition|20 breast cancer patients eat according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy.
89345049|NCT01134185|Active Comparator|Group I|Moderate hepatic impairment (grade B)
89345050|NCT01134185|Active Comparator|Group II|Severe hepatic impairment (grade C)
89345051|NCT01134185|Active Comparator|Group III|healthy subjects
89345052|NCT03797677|Experimental|Home based airway clearance with Metaneb|"Patients with CF and MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.~The MN4000 is an airway clearance and lung expansion therapy device that has been cleared to market by the FDA as The MetaNeb® System for Homecare environment, for clearance of pulmonary secretions and for treatment or prevention of pulmonary atelectasis. It is a Class II device, cleared to market on March 17, 2016 under premarket notification 510(k) K151689 as The MetaNeb® 4 System with application for homecare environment."
89345053|NCT03829046|Placebo Comparator|Placebo|Placebo SC QM
89345054|NCT03829046|Active Comparator|Evolocumab|Evolocumab SC 420mg/dL QM
89345055|NCT05320588|Experimental|Single agent BIO-106|Escalating doses followed by expansion targeting advanced cancers
89345056|NCT05320588|Experimental|Combination BIO-106 plus pembrolizumab|Escalating doses followed by expansion targeting advanced cancers
89345057|NCT03797599|Experimental|20 minutes of mindfulness practice|Two sessions a week for two weeks of: 5 minutes listening to audio book excerpts followed by 20 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
89345058|NCT03797599|Active Comparator|5 minutes of mindfulness practice|Two sessions a week for two weeks of: 20 minutes listening to audio book excerpts followed by 5 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
89345059|NCT03797599|Placebo Comparator|Audio book control|Two sessions a week for two weeks of: 25 minutes listening to audio book excerpts (with non mindfulness practice). Participants will be asked not to engage in formal mindfulness practice during the study.
89345060|NCT01137851||New to bDMARD|New to bDMARD RA patients with high and low cost share who continue or discontinue treatment
89345061|NCT03361293|Active Comparator|Cognitive Training and Active tDCS|5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus active tDCS (also 5 sessions).
89345062|NCT03361293|Sham Comparator|Cognitive Training and Sham tDCS|"5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus sham tDCS (also 5 sessions) which consists of placebo stimulation with tDCS (ramp-up, but no actual stimulation)."
89345063|NCT01231529|Experimental|Part 1 Cohort 1|8 subjects with moderate hepatic impairment defined by a Child-Pugh score of 7 to 9 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
89345064|NCT01231529|Experimental|Part 1 Cohort 2|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 1 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
89345065|NCT01231529|Experimental|Part 2 Cohort 3|8 subjects with mild hepatic impairment defined by a Child-Pugh score of 5 to 6 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
89345066|NCT01231529|Experimental|Part 2 Cohort 4|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 3 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
89345067|NCT05306704|Placebo Comparator|Control Arm: Olive oil|In control arm participants will receive Placebo (Olive Oil) orally in all visits i.e from visit 1 to visit 4. Allocation of arms will be as per the pre-created random list.
89345068|NCT05306704|Active Comparator|Vitamin-D|In the Vitamin-D arm, participants will receive Vitamin-D (100000 IU) orally in all visits i.e from visit 1 to visit 4. Allocation of arms will be as per the pre-created random list.
88807245|NCT05285930|Sham Comparator|group C|received a noncontact low-frequency pulsed ultrasound delivered through only plain gel without BV gel at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
88807246|NCT00407420|Experimental|Mandometer|Active intervention - one meal eaten per day off Mandometer
88807247|NCT00407420|Active Comparator|Control|Nutritional and activity advice alone
88807248|NCT05258526|Experimental|Home-based exercise program|This is a single study arm consisting of a home-based exercise program for individuals with breast or prostate cancer during active treatment.
89345069|NCT01137929||With APN, With VUR, With Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and a renal scar on follow-up DMSA renal scan.
89345070|NCT01137929||With APN, With VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and NO renal scar on follow-up DMSA renal scan.
89345071|NCT01137929||With APN, without VUR, with Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan but who will NOT have VUR by VCUG; however they will have a renal scar on follow-up DMSA renal scan.
89345072|NCT01137929||With APN, Without VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will NOT have VUR by VCUG, NOR will they have a renal scar on follow-up DMSA renal scan.
89345073|NCT01137929||Without APN, With VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also have VUR by VCUG. They will not undergo a second DMSA scan since the first one is normal.
89345074|NCT01137929||Without APN, Without VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also NOT have VUR by VCUG, NOR a renal scar on follow-up DMSA renal scan.
89345075|NCT03707379||common care group|diabetic patients under common care group
89345076|NCT03792529||breast cancer with HER2 overexpression|
89345077|NCT03792529||hormone receptor-positive breast cancer|
89345078|NCT03792529||triple negative breast cancer|
89345079|NCT03709095|Active Comparator|Moderate Intensity Continuous Training|Training was performed three times a week for five weeks. Each session began with a 2 minute warm up, and concluded with a 3 minute cool down. Following the warm-up, participants performed 20 minutes of arm cycling at a self-selected cadence at 45-65% of their peak power output. Total training duration was 25 mins.
89345080|NCT03709095|Experimental|Sprint Interval Training|"The SIT protocol was adopted from Gillen and colleagues (See Ref), and consisted of 3 x 20 second all-out efforts at ≥ 100% of an individuals peak power output. Each sprint was interspersed by 120 seconds of active recovery at 10% of an individuals peak power output. Total training duration was 10 mins."
89345081|NCT01231685|Active Comparator|ritonavir-boosted protease inhibitor|
89345082|NCT01231685|Experimental|Raltegravir|
89345083|NCT03632486||Suspected Dengue|Children with fever and two of the following criteria: anorexia and nausea, rash, aches and pains, warning signs, leukopenia, positive tourniquet test will all receive a diagnostic bedside ultrasound.
89345084|NCT01233557||Bone Metastases|
89345085|NCT03797287|Experimental|Tensor Tunnler|The Tensor Tunneler (Chattanooga, TN) will be used to create the bone tunnels during the arthroscopic procedure. This is an FDA approved device and is used currently in routine clinical practice.
89345086|NCT03797287|Active Comparator|Smith and Nephew PEEK Helicoil Anchor|The anchors used in this trial are FDA approved and are used currently in routine clinical practice (Anchor Rotator Cuff Repair).
89345087|NCT01305109|Experimental|Oral Rotavirus Vaccine 116E (ORV 116E)|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5 mL at 4 week intervals
89345088|NCT01305109|Placebo Comparator|Placebo|3 doses of 0.5 mL at 4 week intervals
89345089|NCT04819295||Latinx Adolescents|
89345090|NCT04819295||Parents of Latinx Adolescents|
89345091|NCT04819295||Healthproviders|
89345092|NCT05280808|Experimental|Experimental phone app|Experimental phone app for self-fitting of hearing aids
88807249|NCT05258292||Women with type 1 diabetes|
89345093|NCT01138085|Experimental|Dose Escalation|Dose escalation will proceed until unacceptable toxicity is observed. Dose escalation decisions will take into account all available data, including PK data and the safety profile of prior cohorts and will occur following review of these data by the investigator(s), GSK medical monitor, pharmacokineticist, and statistician.
89531685|NCT05742269||PD-L1 positive disease (on PET and/or IHC)|"Nab-paclitaxel at a dose of 100 mg per square meter of body-surface area, administered intravenously, on days 1, 8, and 15, and carboplatin at a dose of Area Under the Curve (AUC) 5 on day 1 of every 28-day cycle.~The patients with a PD-L1+ tumour, according to IHC with the SP142 antibody (≥ 1% on immune cells) and/or 89Zr-atezolizumab tracer uptake on PET-imaging, will receive atezolizumab at a dose of 840 mg, administered intravenously, on days 1 and 15."
89345094|NCT01138085|Experimental|Expansion Cohorts|"Enrollment into expansion cohort(s) in Part 2A may begin once a recommended dosing regimen(s) is identified in Part 1A utilizing a once daily continuous dosing schedule for both GSK1120212 and GSK2141795. Enrolment to cohorts utilizing this daily dosing schedule may proceed in parallel with enrolment in Part 1B. Expansion cohort(s) will preferentially enroll subjects with treatment-refractory, measurable and biopsiable triple negative breast cancer or BRAF- wild type melanoma. Subjects selected for enrollment into Part 2A or Part 2B will be tested for PTEN deficiency and must agree to provide paired tumor biopsies (at baseline and once while on- treatment). An additional tumor biopsy at the time of disease progression should also be collected if feasible.~In Part 2A and Part 2B, up to 35 additional subjects per tumor type and schedule (i.e., a total of up to 70 subjects per schedule tested) may be enrolled in a two-stage design to better characterize safety, PK and PD."
89345095|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: Surgery Not Performed Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled but did not have surgery. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
89345096|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
89345097|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
89345098|NCT03361137|Experimental|PwHA Without Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
89345099|NCT03361137|Experimental|PwHA Without Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
89345100|NCT03792217|Experimental|1.3% NaOCl|Root canal irrigation done using 1.3% NaOCl.
89345101|NCT03792217|Active Comparator|5.25% NaOCl|Root canal irrigation done using 5.25% NaOCl.
89345102|NCT04800731||Group 1|Group 1 will consist of 100 patients COVID-19 positive patients older than 70 years old hospitalized in UZ Brussel from February 2020 until September 2020 with a positive RT-PCR test for SARS-CoV-2.
89345103|NCT04800731||Group 2|Group 2 will consist of 100 patients older than 70 years old hospitalized in UZ Brussel for acute infections other than COVID-19.
89345104|NCT04800731||Group 3|Group 3 will consist of healthy aged people defined as in the modified SENIEUR protocol (12, 13). This group is recruited from a previously conducted study. These are community dwelling individuals above the age of 70 and considered as almost healthy with some conditions that are present in the majority of old people such as osteoporosis, osteoarthritis or atherosclerosis.
89345105|NCT05624983|Experimental|Case group (children with language disorder)|Hearing diagnostic test
89345106|NCT05624983|Other|controle group (children without language disorder)|Hearing diagnostic test
89345107|NCT03360747|Experimental|AKCEA-ANGPTL3-LRx 20 mg|Participants received a subcutaneous (SC) injection of AKCEA-ANGPTL3-LRx, 20 milligrams (mg), weekly (QW) for 13-weeks of treatment period. Participants were followed up to Week 26.
89345108|NCT03797365|Active Comparator|Classical rehabilitation|Twenty women will benefit from two-phases perineal rehabilitation: first phase pelvic floor muscles (PFM)'s analytic rehabilitation, then a functional rehabilitation.
89345109|NCT03797365|Experimental|Classical and cognitive associated rehabilitation|Twenty women will receive, added to the classic perineal rehabilitation, the cognitive rehabilitation and will have to execute twice a day the rehabilitation protocol.
89345110|NCT05256784||Probiotic 1|Four members of an extended family: 1 white man of 71 years, 1 white woman of 75 years, 1 white man of 44 years, and 1 white woman of 44 years.
89345111|NCT01138241||1|ARV experience (TDF based HAART)
89345112|NCT01138241||2|ARV experience (non TDF based ART)
89345113|NCT01138241||3|ARV Naive
88807250|NCT05256264||Control group|Sevoflurane
88807251|NCT05256264||Low dose ketamine group|Sevoflurane + 3µg/kg/min ketamine infusion
88807252|NCT05256264||High dose ketamine group|Sevoflurane + 6µg/kg/min ketamine infusion
88807253|NCT00379574|Experimental|Bortezomib + CHOP every 2 weeks|Bortezomib + CHOP(Cycloophosphamide, vincristine, doxorubicin,and predinisolone) every 2 weeks
89345114|NCT03751670|Experimental|PR+conventional treatment|Patients will be treated with daily medication prescribed by the physician. Additionally, patients will receive 6 sessions (2 times a week during 3 weeks) of Pulmonary Rehabilitation (PR). PR will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training, education and psychosocial support.
89345115|NCT03751670|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician.
89345116|NCT03797053||Cohort 1 : metastatic cohort|Cohort1: Cohort of patients with stage III inoperable or IV metastatic melanoma This cohort will enable the achievement of objectives 1 (proof of concept) and 2 (establishment of prognostic and predictive value).
89345117|NCT03797053||Cohort 2 : adjuvant cohort|"Cohort 2: Cohort of patients with melanoma who are candidates for sentinel lymph node analysis.~This group includes patients with melanoma in whom sentinel lymph node testing is performed. According to current French recommendations, these are patients whose primary melanoma has a Breslow index (thickness) of more than 1 mm or ulcerated primary melanoma (loss of the epidermis)."
89345118|NCT03359811|Experimental|Standard-of-Care Thoracic Epidural Analgesia (TEA)|An epidural catheter placed before induction of anesthesia by an anesthesiologist. A bolus or infusion of the local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
89345119|NCT03359811|Active Comparator|4Q-TAP Blocks|Participants have an ultrasound guided 4Q-TAP block. A maximum of 80 cc of a solution consisting of 30 mg of bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) and 65 mg of liposomal bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
89345120|NCT05624905||PCI group|All consecutive patients with coronary artery disease who underwent percutaneous coronary intervention
89345121|NCT05127772|Experimental|single dose of HEC93077（pilot trial arm）|Healthy subjects receive single dose of HEC93077
89345122|NCT05127772|Experimental|single dose of HEC93077（Cohort 1）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
89345123|NCT05127772|Experimental|single dose of HEC93077（Cohort 2）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
89345124|NCT05127772|Experimental|single dose of HEC93077（Cohort 3,Fed/Fasting）|Following an overnight fast of at least 10 hours, a single dose of HEC93077 or placebo will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
89345125|NCT05127772|Experimental|single dose of HEC93077（Cohort 4）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
89345126|NCT05127772|Experimental|single dose of HEC93077（Cohort 5）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
89345127|NCT05127772|Experimental|single dose of HEC93077（Cohort 6）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
89345128|NCT05127772|Experimental|single dose of HEC93077（Cohort 7）|Healthy subjects receive sinele dose of HEC93077 or matching placebo
89345129|NCT05127772|Experimental|multiple doses of HEC93077（ Cohort 8）|Healthy subjects receive multiple doses of HEC93077 or matching placebo
89345130|NCT05127772|Experimental|multiple doses of HEC93077（ Cohort 9, Group 1)|Healthy subjects receive multiple doses of HEC93077 or matching placebo
89345131|NCT05127772|Experimental|multiple doses of HEC93077（ Cohort 9, Gruop 2)|Hyperuricemia subjects receive multiple doses of HEC93077 or matching placebo
89345132|NCT05127772|Experimental|multiple doses of HEC93077（ Cohort 10)|Healthy subjects receive multiple doses of HEC93077 or matching placebo
89345133|NCT03728426|Experimental|Letermovir|Open label letermovir will be administered daily for up to 12 weeks. The study allows an optional additional 12 weeks of treatment for secondary prophylaxis if clinically indicated.
89345134|NCT01140581|Experimental|Group A|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks followed by dronedarone 400 mg twice daily for 8 weeks
89345135|NCT01140581|Experimental|Group B|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Two weeks wash-out followed by dronedarone 400 mg twice daily for 6 weeks
89345136|NCT01140581|Experimental|Group C|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Four weeks wash-out followed by dronedarone 400 mg twice daily for 4 weeks
89345137|NCT03793699||case group : realized a suicide attempt|adults having realized a suicide attempt and without histories of suicide attempt.
89345138|NCT03793699||control group : only suicidal ideas|adults having suicidal ideas without suicidal acting out and without histories of suicide attempt.
89345139|NCT03707223|Experimental|experimental|"The interfaces Program"
89345140|NCT03707223|Active Comparator|control group|supported employment using the individual placement and support (IPS) model
89345141|NCT03449368||Cohort 1|Includes age group 5-10 with a cap at 50 subjects. This is a retrospective, observational study.
89345142|NCT03449368||Cohort 2|Includes age group 11-15 with a cap of 50 subjects. This is a retrospective, observational study.
89345143|NCT03449368||Cohort 3|Includes age group 16-20 with a cap of 40 subjects. This is a retrospective, observational study.
89345144|NCT03449368||Cohort 4|Includes age group 21-30 with a cap of 40 subjects. This is a retrospective, observational study.
89345145|NCT03449368||Cohort 5|Includes age group 31-40 with a cap at 40 subjects. This is a retrospective, observational study.
89345146|NCT03449368||Cohort 6|Includes age group 41-50 with a cap at 40 subjects. This is a retrospective, observational study.
89345147|NCT03449368||Cohort 7|Includes age group 51-70 with a cap at 40 subjects. This is a retrospective, observational study.
89345148|NCT03792139|Experimental|LY3200882|LY3200882 administered orally.
89345149|NCT03792139|Experimental|Itraconazole + LY3200882|Itraconazole + LY3200882 administered orally.
89345150|NCT03449290|Experimental|Kinesio taping group|Kinesio taping was applied on trunk muscles
89345151|NCT03449290|Sham Comparator|Control group|Sham Kinesio taping was applied on trunk muscles
89345152|NCT03792295|Experimental|Multimodal Therapy|Patients will receive scheduled ibuprofen 400mg po q 4 hours and acetominophen 1gram po q 8 hours during the post operative phase and oxycodone 5mg po q 4 to 6 hours as needed for pain control.
89345153|NCT03792295|Active Comparator|Classic/standard opiod Therapy|Patients will receive oxycodone 5mg po q 4 to 6 hours as needed during their post operative phase for pain control.
89345154|NCT03797131|Experimental|KB195 Arm|
89345155|NCT05390879|Experimental|Meditation Post-OSCE|One half of the students will watch a 6 minutes auto-guided video of meditation, just after the OSCE.
89345156|NCT05390879|Sham Comparator|Control|One half of the students will watch a 6 minutes control video, just after the OSCE
89345157|NCT05624827|Experimental|Women with CIN 2 and under 36 years old|We will analyze patients under 36 years old (≤ 35) with histological confirmed CIN 2 lesions and without any additional risk factors.
89345158|NCT03449056|Experimental|TREATMENT|salbutamol nebulization
89345159|NCT05600569||All the target population|Patients who will undergo any surgical procedure in a Spanish Thoracic Surgery Department
89345160|NCT03448900|Experimental|Multicomponent intervention|The intervention group consisted in face-to-face 50-minute meeting [motivational interviewing (MI)]; online self-help material focused on: (1) decisions; (2) moods; (3) social life; (4) smoking health effects; and (5) quitting; e-mail 15 days before the MI, group therapy 2 months after the MI (60 minutes), a second follow-up visit 4 months after the MI (20 minutes).
89345161|NCT03448900|Active Comparator|Brief advice|The control group received a brief advice (5-10minutes) and a self-help pamphlet called 'Stop smoking'. Before giving brief advice, the nurse assessed smokers' habits and their willingness to quit. As is usually in this type of studies there were no follow-up sessions for this group.
89345162|NCT01135433|Experimental|ASP group|ASP1941 and metformin
89345163|NCT01135433|Placebo Comparator|Placebo group|placebo and metformin
89345164|NCT02095678|Experimental|HCC or metastatic Liver Lesions|Patients with HCC or metastatic liver lesions who are refered to the abdominal imaging and biopsy clinic will have a liver biopsy performed. 3-5 days after a clinical MRI indicating a cancerous lesion, patients will return for the free-breathing MRI and a liver biopsy. These images will be compared to the clinical MRI and to images of the benign lesions.
89345165|NCT02095678|Active Comparator|Benign Liver Lesion|Patients with benign liver lesions will be referred to the study team. 3-5 days after a clinical MRI an experimental, free-breathing MRI will be performed on these patients. The results will be compared to their clinical MRI images and to images of HCC or metastatic lesions
89345166|NCT04745273|Active Comparator|Ondansetron|Participants will receive Kemoset 4 mg iv intraoperatively
89345167|NCT04745273|Placebo Comparator|Salin solution|Participants will receive Salin solution 2ml (iv) intraoperatively
89345168|NCT01305187|Experimental|Hyaluronic Acid Filler - Medical Device|
89345169|NCT01138397|Experimental|Group 1|Participants at 18 to 59 years of age
89345170|NCT01138397|Experimental|Group 2|Participants at 60 years of age or older
89345171|NCT03448822||sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure.
89345172|NCT03793777|Placebo Comparator|placebo|microcrystalline cellulose supplementation
89345173|NCT03793777|Experimental|Aronia|aronia melanocarpa supplementation
89345174|NCT01140659|Other|Objective measurement of sweat|"We selected 40 patients from February 2007 to May 2009. All participants were randomized into two groups of 20 patients (G3 and G4) and underwent the sympathectomy, being followed for 12 months. We used an objective method for measuring sweat, checking the TEWL (transepidermal water loss) measured by the VapoMeter, and evaluated the quality of life before and after the operation. Also studied were: incidence and intensity of the compensatory hyperhidrosis."
89345175|NCT03448744|Experimental|combiantion therapy group|thymosin alpha 1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
89345176|NCT03448744|Placebo Comparator|entecavir group|ETV (0.5 mg orally, daily) at least for 72 weeks
89345177|NCT03448588||group with normal T4 level or T4/T3|participants with T4 within 4.3-12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) ≤7.52, which are considered to be normal T4 level and T4/T3.
89345178|NCT03448588||group with elevated T4 level or T4/T3|participants with T4 more than 12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) > 7.52, which are considered to be elevated T4 level and T4/T3.
89345179|NCT03797443|Experimental|AA NABPLAGEM|Ascorbic Acid Paclitaxel protein-bound cisplatin gemcitabine
89345180|NCT01135589|Experimental|HSCT|
89345181|NCT03792373||frailty|
89345182|NCT03792373||nonfrailty|
89345183|NCT01140737|Experimental|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily.
89345184|NCT03448510|Experimental|Irreversible electroporation treatment|Subjects will receive irreversible electroporation of the prostate
89345185|NCT03448510|Active Comparator|standard medication group|Subjects will receive either α-blocker or 5α reductase monotherapy or combination therapy.
89345186|NCT01233713|Active Comparator|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering ileostomy, followed by a stoma reversal operation.
89345187|NCT01233713|Active Comparator|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
89345188|NCT01560559|Experimental|Single Arm|Peroral endoscopic myotomy
89345189|NCT01305343||Surgical treatment|This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity.
89345190|NCT03448354|Experimental|NAC-IDS-HIPEC|Under the clinicians' decision, HIPEC procedures will be performed at the time of IDS.
89345191|NCT03448354|No Intervention|NAC-IDS|Under the clinicians' decision, HIPEC procedures will not be performed at the time of IDS.
89345192|NCT03448276|Experimental|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
89345193|NCT03448276|Active Comparator|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
89345194|NCT03448198|Other|Knee arthritis|Total knee replacement
89531686|NCT05742269||PD-L1 negative disease (on PET and IHC)|Nab-paclitaxel at a dose of 100 mg per square meter of body-surface area, administered intravenously, on days 1, 8, and 15, and carboplatin at a dose of Area Under the Curve (AUC) 5 on day 1 of every 28-day cycle.
89531687|NCT05742074|Experimental|FMT (faecal microbiota transplantation)|25-30 capsules of faecal material.
89345195|NCT05624671|Other|IS THERE ANY ROLE OF OVERACTIVE BLADDER IN POSTSPINAL HYPOTENSION IN ELECTIVE CAESAREAN SECTIONS?|According to our institution protocol, intravenous (iv) hydration will not be given as preload and afterload and vasopressor infusion will not be initiated before spinal anesthesia. After the skin is prepared sterile and local infiltration with 2% lidocaine is done, from L3-L4 OR L4-L5 range on midline with the 16 gauge Tuohy needle and the loss of resistance technique epidural space is identified and then 26 gauge pencil point needle is passed trough the Touhy and the dura will be drilled. After the cerebrospinal fluid (CSF) is seen the fluid containing 5mg isobaric bupivacaine and 15µg fentanyl will be given in 30 seconds to patients. After the spinal needle is removed, the epidural catheter is placed 3-5 cm in the epidural space through Tuohy, and after the catheter is fixated, the patients will be placed in the supine position by placing a height under their right hip with a 15 ° angle.
89345196|NCT03447964||Type 1 diabetes|dosing of sphingolipids
89345197|NCT03447964||Type 2 diabetes|Dosing of sphingolipids
89345198|NCT03447886||Quality Of Life|"This study uses qualitative research methods, specifically semi-structured interviews.~This will include moderator guide development,~Phone interviews with breast cancer survivors will be conducted~Qualitative data analysis of the phone interviews will be conducted"
89345199|NCT03763877|Experimental|Group 1|PXL770 Dose 1
89345200|NCT03763877|Experimental|Group 2|PXL770 Dose 2
89345201|NCT03763877|Experimental|Group 3|PXL770 Dose 3
89345202|NCT03763877|Placebo Comparator|Group 4|Placebo oral capsule
88807254|NCT05256108|Experimental|Cebranopadol 600 µg|Single oral dose of 6 capsules containing 3 cebranopadol 200 µg tablets and placebo
88807255|NCT05256108|Experimental|Cebranopadol 1000 µg|Single oral dose of 6 capsules containing 5 cebranopadol 200 µg tablets and placebo
88807256|NCT05256108|Active Comparator|Oxycodone 40 mg|Single oral dose of 6 capsules containing 2 oxycodone 20 mg and placebo
88807257|NCT05256108|Active Comparator|Tramadol 600 mg|Single oral dose of 6 capsules containing 6 tramadol 100 mg tablets
89345203|NCT00850954|Experimental|Group I (smoking cessation)|Participants receive smoking cessation intervention materials based on TTM.
89345204|NCT00850954|Experimental|Group II (informational)|Participants receive fotonovelas and other materials on secondhand smoking and how to assist the smoker in quitting.
89345205|NCT03578965|No Intervention|Arm A: No antibiotic prophylaxis prior to skin incision|-Women randomized to no antibiotic prophylaxis will not receive any antibiotics prior to skin incision.
89345206|NCT03578965|Experimental|Arm B: Antibiotic prophylaxis prior to skin incision|-Women randomized to prophylactic antibiotics will receive a cefazolin as per ACOG guidelines.
89345207|NCT05178004||Non-IgE-mediated CMPA|Infants with mild, moderate and severe non-IgE-mediated cow's milk protein allergy
89345208|NCT05178004||IgE-mediated CMPA|Infants with IgE-mediated CMPA
89345209|NCT05178004||Healthy|Healthy infants who have never shown signs of cow's milk protein allergy
89345210|NCT05178004||Non allergic gastrointestinal conditions|Infants with suspected cow's milk allergic at enrolment and ruled out following Oral Food Challenge
89345211|NCT03791905|Experimental|TP Arm|Patients with baseline PET scan assigned to this Arm will receive two cycles of 3-weekly schedule of induction chemotherapy with paclitaxel/cisplatin (TP), consisting of paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to FOLFOX regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
89345212|NCT03791905|Experimental|FOLFOX Arm|Patients with baseline PET scan assigned to this Arm will receive three cycles of 2-weekly schedule of induction chemotherapy with FOLFOX (oxaliplatin, leucovorin, 5-FU), consisting of oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2, and 5-FU 2 g/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to TP regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
89345213|NCT03447652|No Intervention|Control Group|Each patient in the control group did not perform any rehabilitation exercises. Over the intervention time frame, the patient was required to check in with a member of the research team each week to discuss any changes in their ankle or report any injury incidence.
89345214|NCT03447652|Experimental|Resistance Band Group|Each session, patients completed resistance training using a resistance band in 4 directions of ankle motion (plantarflexion, dorsiflexion, inversion and eversion). Patients would complete 3 sets of 10 repetitions during each session. Every 3 sessions, the band resistance would increase.
89345215|NCT03447652|Experimental|Biomechanical Ankle Platform System|The Biomechanical Ankle Platform System board is an oval shaped board that utilizes a half-sphere on the bottom of the board to allow the patient to train on an unstable surface. A one legged stance on their involved limb was performed on the Biomechanical Ankle Platform System board while clockwise and counterclockwise circles were completed. The initial rotation of direction was selected by the patient and changed every 10 seconds of the 40-second trial. Five 40-second trials were completed with 1-minute rest intervals in between the trials. Progression was determined by the supervising clinician and was based on the patient's ability to make smooth transitions between direction changes and completion of smooth circular rotations in both directions.
89531688|NCT05742074|Placebo Comparator|Placebo|25-30 placebo capsules.
88807258|NCT05256108|Placebo Comparator|Placebo|Single oral dose of 6 capsules containing placebo
88807259|NCT05209776|Experimental|Patients|Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle
88807260|NCT05209776|Experimental|Control case|Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).
88814343|NCT04367948|Experimental|18F-NOTA-FAPI04|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
89345216|NCT03447652|Experimental|Combination Group|Patients completing the combination protocol completed both the resistance band and Biomechanical Ankle Platform System board protocols during each session. The order of exercise completion was counterbalanced for each session.
88807261|NCT05484492|Experimental|demineralized and mineralized combination putty bone allograft|Fifteen test patients will receive an intrasocket demineralized and mineralized combination putty allograft (MinerOss Putty, BioHorizons) with a regenerative tissue matrix membrane (AlloDerm GBR, BioHorizons) following tooth extraction.
88807262|NCT05484492|Active Comparator|calcium phosphosilicate putty alloplast graft|The positive control group of fifteen patients will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft (NovaBone, Osteogenics) covered with a regenerative tissue matrix membrane (AlloDerm GBR, BioHorizons) following tooth extraction.
89345217|NCT03789409|Experimental|Intermittent Fasting|Over rehabilitation treatment during and admission (at least 1 week), intermittent fasting (IF) for more than 12 hours (water can be allowed). For subgroup assignment, participants can choose IF1 (eat early in the evening and late in the morning) or Post-IF2 (eat the remaining two meals without breakfast), depending on own their faver.
89345218|NCT03789409|No Intervention|Ad libitium|Participants will be allowed to have hospital meals and all the desired intake without time limit.
89345219|NCT01232153|Active Comparator|NIV preoxygenation|
89345220|NCT01232153|No Intervention|Classical preoxygenation|
89345221|NCT03447496||Closed reduction|The children were treated with closed reduction.
89345222|NCT03447496||Open reduction|The children were treated with open reduction.
89345223|NCT01138553|Experimental|Mifepristone|
89345224|NCT05624593|Other|Optical Coherence Tomography (OCT)|
89345225|NCT05171374||Adjuvant cohort|Patients with resectable stage III melanoma, reciveng dabrafenib and trametinib in adjuvant settings
89345226|NCT05171374||Metastatic cohort|Patients with unresectable stage IIIC/D or stage IV melanoma, reciveng dabrafenib and trametinib in metastatic settings
89345227|NCT03447418|Other|no treatment, open label|
89345228|NCT01138631|Active Comparator|Embryoscope|
89345229|NCT01138631|No Intervention|Conventional incubator|
89345230|NCT03358407|Experimental|Part A: Cohort 1|Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.
89345231|NCT03358407|Experimental|Part A: Cohort 2 fasting|Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions
89345232|NCT03358407|Experimental|Part A: Cohort 2 fed|In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.
89345233|NCT03358407|Experimental|Part B|Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.
89345234|NCT03447184||Androgen priming|Eight weeks prior to stimulation for IVF - at the onset of menses, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor will commence, concomitantly with GnRHa down-regulation with a depot GnRHa (28days). After 8 weeks, a standard rFSH stimulation with either 300 IU rFSH or 300 IU rFSH+rLH will start. The androgen priming (hCG and aromatase inhibitor) will stop on the first day of stimulation.
89345235|NCT03739541|Experimental|[14C]-Benznidazole|A single dose of 100 mg [14C]-BNZ, orally administered on Day 1 following an overnight fast.
89345236|NCT02014051|Experimental|SyB C-1101|
89345237|NCT03447106|Experimental|Open|
89345238|NCT03447106|Experimental|Laparoscopic|
89345239|NCT03447106|Experimental|Robotic|
89345240|NCT01138787|Active Comparator|Reference spread|"2250 mg PS (as PSE) in spread (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
89345241|NCT01138787|Placebo Comparator|Placebo spread|"regular light margarine (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
89345242|NCT01138787|Experimental|Test spread|"2250 mg PS in innovatively processed spread (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
89345243|NCT01135667|Active Comparator|clopidogrel|clopidogrel 150 mg once daily for 30 days (and then 75 mg for additional 11 months - not study related)
88814344|NCT04368026||Group 1|"Responders currently working in a COVID-19-dedicated hospital, which was transformed by Polish Ministry of Health during SARS-CoV-2 pandemic into institution designated only for SARS-CoV-2 patients, including those developing symptoms and quarantined."
89345244|NCT01135667|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 30 days (and then clopidogrel 75 mg once daily for additional 11 months - not study related)
89345245|NCT03446950|Active Comparator|Candy Cane|Participants in this arm will be positioned with their legs in candy cane stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
89345246|NCT03446950|Active Comparator|Boot Stirrups|Participants in this arm will have their feet placed in boot stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
89345247|NCT01135745|Experimental|Deep Brain Stimulation Therapy for OCD|Reclaim® DBS Therapy uses thin wires to deliver electric current (stimulation) to a very specific target in the brain. These wires are implanted surgically. They are attached to internal neurostimulators implanted under the skin of the chest below the collarbone, similar to cardiac pacemakers, or in the abdominal wall. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
89345248|NCT03793387|Experimental|Pre-op|
89345249|NCT03793387|Active Comparator|Intra-op|
89345250|NCT03446872||All Study Participants|Patients in South Korea with a diagnosis of metastatic pancreatic cancer who have been prescribed ONIVYDE
89345251|NCT01232231|Active Comparator|decolonization treatment|topical antiseptic, intranasal antimicrobial, and oral antimicrobial that have activity against MRSA in addition to education regarding personal hygiene and environmental cleaning
89345252|NCT01232231|Other|education|No decolonization treatment in addition to education regarding personal hygiene and environmental cleaning
89345253|NCT05624203|Experimental|Extracorporeal cardiac shock wave therapy was performed（ECSW）|Patients with acute ST-segment elevation myocardial infarction who underwent Percutaneous coronary intervention (PCI) were treated with extracorporeal cardiac shock wave therapy 2-3 days after operation. The duration of treatment was 3 months, and 9 treatments were completed within 3 months as a course. One week of treatment was followed by a 3-week rest in each month. CSWT was performed three times in each treatment week, respectively on the 1st, 3rd, and 5th day of the treatment week, for a total of 3 months.
89345254|NCT05624203|No Intervention|Extracorporeal cardiac shock wave therapy was not performed（NO ECSW）|Patients with acute ST-segment elevation myocardial infarction undergoing Percutaneous coronary intervention (PCI) are not treated with extracorporeal cardiac shock wave
89345255|NCT03446716|Experimental|EXTENSION|During the extension condition, caregivers were instructed to put their child to bed 90 minutes earlier than their habitual bedtime for five consecutive nights. Caregivers were provided a list of tips to aid in implementing the earlier bedtime.
88814345|NCT04368026||Group 2|"Responders currently working in non-COVID-19-dedicated hospital."
89345256|NCT03446716|No Intervention|CONTROL|Children followed their normal bedtime routine for five consecutive nights.
89345257|NCT03739385|Experimental|Intergenerational Group|Pre-school children and residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
89345258|NCT03739385|Active Comparator|Peer Group Children|Pre-school children will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
89345259|NCT03739385|Active Comparator|Peer Group Seniors|Residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
89345260|NCT03739385|No Intervention|Control Group Children|Pre-School children will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
89345261|NCT03739385|No Intervention|Control Group Seniors|Residential seniors will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
89345262|NCT03707145|Active Comparator|Professional led with online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
89345263|NCT03707145|Active Comparator|Professional led without online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
89345264|NCT03707145|Experimental|Patient empowered with online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
89345265|NCT03707145|Active Comparator|Patient empowered without online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
89345266|NCT03793231||Fungal Cases|Patients with confirmed invasive fungal infections according to internationally accepted criteria identified by active manual surveillance. Clinical data will be sent to fungalAi platform technology for disease classification.
89345267|NCT03793231||Control patients|Patients without invasive fungal infections.Clinical data will be sent to fungalAi platform technology for disease classification.
89345268|NCT03446638|Experimental|Computational Biology-Informed Treatment|Patients randomized to this arm will receive an FDA-approved drug or combination of drugs predicted to have a therapeutic effect based on their individual MDS disease genetic profile by a computational biology simulation software program. The specific drug or combination of drugs that a patient on this arm will receive will be decided jointly by a molecular oncology board comprised of physicians, pharmacists, and nurse coordinators and the treating physician. Patients will receive a minimum of 2 months and a maximum of 4 months of treatment with the selected drug or combination of drugs.
89345269|NCT03446638|Active Comparator|Standard of Care Treatment|Patients randomized to this arm will receive either one of three standard of care treatment regimens of the treating physician's choice (low-dose cytarabine, 7 + 3 induction, or FLAG induction) or supportive care alone. Patients will receive a minimum of 2 months and a maximum of 4 months of the selected treatment regimen or of supportive care alone.
89345270|NCT05401019|Experimental|Experimental arm|Treatment with pramipexol, once a day, tablet of 0.088, 0.18, 0.35, 0.53 mg per day during 16 weeks
89345271|NCT05401019|Active Comparator|Control arm|Treatment with Risperidone, once a day, tablet of 0.5, 1, 1.5, 2 mg per day during 16 weeks + 8 weeks follow-up.
89345272|NCT03446560|Active Comparator|CPAP, conventional follow up|Follow up of patients after initiation of treatment according to clinical routine at the study site.
89345273|NCT03446560|Active Comparator|CPAP, telemedicine based follow up|Follow up of patients after initiation of treatment according to a telemedicine based routine.
89345274|NCT03707067|Experimental|Custom fitted compression garments|Made-to-measure compression garments providing high pressures (> 30 mmHg at the ankle and >20 mmHg at the thigh - equivalent to European class-2 stockings)
88814346|NCT04368182|Experimental|Treatment group|Autologous C-TCR055 administered by intravenous (IV) infusion
89345275|NCT03707067|Sham Comparator|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
89345276|NCT03788863||Pregnant women exposed to glucocorticoids|Pregnant women exposed to any glucocorticoid or corticosteroid or steroids in early pregnancy or first trimester of pregnancy
89345277|NCT03788863||Non-exposed pregnant women|Women not using any glucocorticoid or corticosteroid or steroids during pregnancy
89345278|NCT05135572|Active Comparator|control group|Fibromiyalgia patients with foot pain.
89345279|NCT05135572|Experimental|study group|Patients with foot pain
89345280|NCT03708939|Experimental|glucose|
89345281|NCT03708939|Experimental|aspartame|
89345282|NCT03708939|Experimental|sucralose|
89345283|NCT03708939|Experimental|saccharin|
89345284|NCT03708939|Experimental|Stevia|
89345285|NCT03708939|Experimental|No supplement control|
89345286|NCT05622019||Gingival health|Healthy participants had no sites with inter-proximal attachment loss, probing pocket depth (PPD) of ≤3 mm in all sites, bleeding on probing (BOP) ≤ 10%, and had <10% of sites with modified gingival index (mGI) ≥ 2
89345287|NCT05622019||periodontitis|Participants were diagnosed with periodontitis if interdental clinical attachment loss (AL) was detected at ≥2 non-adjacent teeth, or buccal or oral AL was ≥3 mm with probing depth ≥3 mm was detected at ≥2 teeth.The participants in this group were divided into subgroups according to their periodontitis stage grade.
89345288|NCT03129256|Experimental|Apatinib & S-1|Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg~60mg twice daily by mouth, d1-14, repeated every 3 weeks.
89345289|NCT02950545|Experimental|Placebo, Spherical, then Toric Lenses|Crossover order 1
89345290|NCT02950545|Experimental|Placebo, Toric, then Spherical Lenses|Crossover order 2
89345291|NCT02950545|Experimental|Spherical, Placebo, then Toric Lenses|Crossover order 3
89345292|NCT02950545|Experimental|Spherical, Toric, then Placebo Lenses|Crossover order 4
89345293|NCT02950545|Experimental|Toric, Placebo, then Spherical Lenses|Crossover order 5
89345294|NCT02950545|Experimental|Toric, Spherical, then Placebo Lenses|Crossover order 6
88809702|NCT00745940|Experimental|MBCT Intervention Group|The curriculum of our mindfulness intervention draws upon elements from the mindfulness-based stress reduction program, and Segal and colleagues manual for mindfulness-based cognitive therapy. It was modified by one of the investigators to address issues associated with traumatic brain injury (e.g., problems with attention, concentration, memory, fatigue). The intervention was increased to ten weeks with one and a half hour weekly sessions, along with a 20-30 minute daily meditation home practice. Further adaptations included simplified language, the use of repetition to reinforce concepts, and visual aids. More attention was paid to fostering learning conditions to encourage an environment of trust and non-judgement. Connections between learning activities was also made more explicit.
89345295|NCT01138865|Other|1|Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
89345296|NCT01138865|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
89345297|NCT03129334|Experimental|LST Middle School Online|Students will participate in a series of e-learning modules plus classroom sessions related to drug abuse prevention, including prescription drug abuse
89345298|NCT03129334|No Intervention|Treatment as Usual (Control)|Students will not participate in the e-learning modules. They will receive any standard classroom instruction on drug abuse/health education.
89345299|NCT05682807|No Intervention|control group (group I)|will include 30 preterm neonates with BPD who will receive traditional therapy of BPD including minimizing exposure to oxygen, ventilation strategies, adequate nutrition and prudent administration of fluids
89345300|NCT05682807|Active Comparator|caffeine group (group II)|will include 30 preterm neonates with BPD who will receive traditional therapy of BPD in association with caffeine by intravenous route at a dose of 20 mg/kg loading dose with a 5-10 mg/kg/day maintenance dose given after 24 h ( Yuan et al., 2022) until discharge from the unit after clinical and laboratory improvement after two months.
89345301|NCT05682807|Active Comparator|probiotic group (group III)|will include 30 preterm neonates with BPD who will receive traditional therapy of BPD in association with probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months
89345302|NCT01138943|Active Comparator|Chlorhexidine alcohol-base mouthrinse|
89345303|NCT01138943|Experimental|non alcohol chlorhexidine mouthrinse|
89345304|NCT03446404||MOST Cohort|"One portion of the cohort will be age 62-92 years, average age approximately 71 years, at the start of this study. This cohort will consist of participants who already have symptomatic knee OA, in many cases advanced disease, or who had risk factors at the start of the Multicenter Osteoarthritis Study but have not developed symptomatic knee OA. All of the existing cohort who have 1 or 2 native knees will be approached providing native knees are not considered to be Kellgren-Lawrence grade 4 (bone on bone). The other portion of the cohort will consist of subjects with knee pain, aching or stiffness at baseline and participants without any knee symptoms in the previous 30 days. Both knees with Kellgren-Lawrence grades of radiographic OA of 0, 1, or 2 in the tibiofemoral (TF) and patellofemoral (PF) compartments."
89345305|NCT01135901|Experimental|group programme|Group based behaviour change programme
89345306|NCT03446248|Active Comparator|Fetal Acoustic Stimulator|Participants in this group will receive fetal vibroacoustic stimulation with the Corometrics-146 device first, followed by the mobile phone application second.
89345307|NCT03446248|Experimental|Mobile Phone Application|Participants in this group will receive fetal vibroacoustic stimulation with the mobile phone application first, followed by the Corometrics-146 device second.
89345308|NCT01234727||Diabetes|Patients with Type 1 or Type 2 diabetes requiring insulin.
89531689|NCT05734417|Experimental|Probiotic|Intervention consists of daily administration of excipient plus Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day administered daily for 4-weeks
89345309|NCT03446014||Control Group for Fitbit Sub-Study|Patient will be given Fitbit device, but will have no access to Fitbit website or interface. The coordinator will set up the patient's Fitbit on the office computer and will have access to the fitbit's associated username and password (this will be generated by the coordinator). The patient will be instructed to walk as much as they can each day, and to check the Fitbit wrist band periodically throughout the day to view their walking progress. At the end of the three month intervention, the patient will complete questionnaires and undergo a repeat 6 minute walk test.
89345310|NCT03446014||Intervention Group for Fitbit Sub-Study|Patient will be given the Fitbit device and instructed on how to use it. They will be given their username and password to the Fitbit device, and instructed on how to interact with other patients in the study as well as the coordinator on the Fitbit website. The coordinator will also show the patient how to install the application on a smart phone device and use the device via smartphone. The patient will then be instructed to walk as far as they can each day for a period of 12 weeks. Patients will check their steps daily and interact with other patients who participate in the study. Patients will return for a 3 month follow-up appointment where they will undergo a redo 6 minute walk test and questionnaires.
89345311|NCT03358329|Experimental|S8 Sinus Implant|corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)
89345312|NCT01234805|Experimental|Supportive care (yoga therapy)|Patients participate in yoga classes comprising postures, deep relaxation, breathing practices, and meditation twice weekly for 75 minutes during weeks 1-6. Patients then practice yoga at home twice weekly for 45 minutes during weeks 7-12.
89345313|NCT01135979||Arterio-venous fistulae creation|
89345314|NCT03445780|Experimental|First Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection
89345315|NCT03445780|Experimental|Second Group|The skin between the distal palmar crease and the palmo-digital crease and the palmo-digital crease will be pinched for 5 seconds prior to injection
89345316|NCT03445780|Experimental|Third Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection as well as a second pinch to the skin between the distal palmar crease and the palmo digital crease
89345317|NCT03445780|Experimental|Fourth Group|Subjects will sit behind a screen with a small opening large enough to introduce the injection hand. They will not see any of the procedure.
89345318|NCT03445702|Experimental|Metformin intolerant & metformin|Metformin 1000mg once
89345319|NCT03445702|Placebo Comparator|Metformin intolerant & placebo|Placebo 1000mg once
89345320|NCT03445702|Active Comparator|Metformin tolerant & metformin|Metformin 1000mg once
89345321|NCT03445702|Placebo Comparator|Metformin tolerant and placebo|Placebo 1000mg once
89345322|NCT01136057||Influenza A Exposure|Participants will include people who have recovered from influenza, received a seasonal influenza vaccine, or have both recovered from influenza and received a seasonal influenza vaccine.
89345323|NCT05302635|Experimental|Simulated group|"Students will be given training on nasogastic tube insertion and practice will be demonstrated in the laboratory based on the demonstration method and checklists, and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will implement the scenario in the simulation laboratory and will wear uniforms. The student will be given 5 minutes for preparation, the application will be taken one by one and 15 minutes will be given for practice. Researchers will only observe during this time. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance. Each session will last 20-30 minutes. Students will be given a post-test."
89345324|NCT05302635|No Intervention|Control group|"Students will be given training on nasogastric tube insertion and nasogastric tube application will be demonstrated with the demonstration method in the laboratory and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will apply the scenario on the model in the skill laboratory and will wear uniforms. The student will be given 5 minutes for preparation. Students will be taken to the application one by one and 15 minutes of practice time will be given. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance in the debriefing session. Each session will last 20-30 minutes. Students will be given a post-test."
89345325|NCT01700335|Experimental|SyB L-1101|"In Cohort 1, SyB L-1101 1200 mg/day group, Participants were administered 1200 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~In Cohort 2, SyB L-1101 1800 mg/day group, Participants were administered 1800 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~For both Cohorts, the treatment period of 14 days constitutes 1 cycle, and the treatment was allowed for up to 8 cycles."
88809703|NCT00745940|No Intervention|MBCT Control Group|Control group waited.
88809704|NCT03830606|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
89345326|NCT03445624||patient on traditional therapy|Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)
89345327|NCT03445624||patient on infliximab|drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months
89345328|NCT01312077|Experimental|Levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine, and will receive peri- and intraarticular surgical site infiltration during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure and this will be left in situ in the wound. The catheter will be sited under the fascia lata exiting antero-superior to the incision. A bacterial filter will be attached and it will be connected to an elastomeric pump which will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
89345329|NCT01312077|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.2 mg).
89345330|NCT05090098||Breast cancer|Sixty patients with grade I-II-III breast cancer, whose primary treatment (surgery, radiotherapy and/or chemotherapy) is continuing, who applied to the Hospital Breast Unit clinic, will be included in the study. Patients with problems in reading and writing in Turkish, poor cognitive functions and a serious chronic disease, musculoskeletal pain or disease, severe psychiatric illness, current cancer attack or metastasis will be excluded from the study
89345331|NCT05090098||Breast cancer survivors|Sixty patients with grade I-II-III breast cancer, whose primary treatment (surgery, radiotherapy and/or chemotherapy) was completed at least three months ago, who applied to the Hospital Breast Unit clinic, will be included in the study. Patients with problems in reading and writing in Turkish, poor cognitive functions and a serious chronic disease, musculoskeletal pain or disease, severe psychiatric illness, current cancer attack or metastasis will be excluded from the study
89345332|NCT05090098||Healthy people|healthy individuals matched for age and gender will also be included in the study.
89345333|NCT01139099|Other|Arm|There is no arm in this study.
89345334|NCT03791983|Experimental|Therapy Group|
89345335|NCT03791983|Other|Control Group|
89345336|NCT03710031||HSCT Survivors|PNS tracking will occur through blood and stool samples to track the interplay among psychoneurologic symptoms (PNS) as they relate to diminished QOL among survivors of HSCT.
89345337|NCT03445546||oral P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with oral P2Y12 Inhibitor (from the historic cohort of NCT02914795)
89345338|NCT03445546||intravenous P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with intravenous P2Y12 Inhibitor (cangrelor)
89345339|NCT03793309|Experimental|Low dose|Subjects in this group receive 400 IU vitamin D daily for 4 weeks.
89345340|NCT03793309|Experimental|High dose|Subjects in this group receive 800 IU vitamin D daily for 4 weeks.
89345341|NCT01140893|Experimental|exenatide|55 subjects
89345342|NCT01140893|Placebo Comparator|Placebo|55 subjects
89345343|NCT01312155||Patients undergoing general anesthesia|
89345344|NCT03788785|Experimental|Experimental arm|The specific tobacco cessation intervention of the treatment group will begin during the diagnostic phase of the HNSCC by three ½ hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days top. The most important point is that this intervention will be provided by trained nurses of the health care team within the ENT department, rather than in an external smoking cessation center.
88809705|NCT04385342|Active Comparator|FSH then HP-hMG|Women will receive 225 IU FSH alone from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm, the 150 IU HP-hMG will substitute FSH and continued to the day of triggering
89345345|NCT03788785|Other|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
89345346|NCT03445468|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The vaccine contains both B strain (Yamagata, Victoria)
89345347|NCT03445468|Active Comparator|IL-YANG Flu Vaccine Pre-filled Syringe|The vaccine contains the B/Yamagata strain and it was approved for commercial sale by Ministry of Food and Drug Safety.
89345348|NCT05682729|Experimental|Size to Number|
89345349|NCT05682729|Experimental|Mixed|
88809706|NCT04385342|Active Comparator|FSH + HP-hMG|Women will receive 150 IU FSH plus 75IU HP-hMG from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm 150 IU HP-HMG till day of triggering
89345350|NCT05682729|Active Comparator|Traditional Counting|
89345351|NCT05682729|Placebo Comparator|Non-Numerical Control|
89345352|NCT03791827||Corticosteroid|Pediatric lupus nephritis treated with hydroxychloroquine and corticosteroid
89345353|NCT03791827||Corticosteroid and cyclophosphamide|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclophosphamide
89345354|NCT03791827||Corticosteroid and mycophenolate mofetil|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and mycophenolate mofetil
89345355|NCT03791827||Corticosteroid and azathioprine|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and azathioprine
89345356|NCT03791827||Corticosteroid and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and tacrolimus
89345357|NCT03791827||Corticosteroid and cyclosporine A|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclosporine A
89345358|NCT03791827||Corticosteroid, mycophenolate mofetil and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid, mycophenolate mofetil and tacrolimus
89345359|NCT03791827||Retuximab|An option for refractory lupus nephritis
89345360|NCT01139177|Experimental|Stent placement|
89345361|NCT01232309|Active Comparator|High Dose Chitin-Glucan|Daily oral dose of 4.5 g of chitin-glucan
89345362|NCT01232309|Active Comparator|Low Dose Chitin-Glucan|Daily oral dose of 1.5 g chitin-glucan
89345363|NCT01232309|Experimental|Low Dose Chitin-Glucan + Olive Extract|Daily oral dose of 1.5 g chitin-glucan + 135 mg olive extract
89345364|NCT01232309|Placebo Comparator|Placebo|Placebo (Rice Flour)
89345365|NCT03708861|Experimental|MVC + ATV/r|maraviroc (300 mg tablet, 300 mg per day every 24 hours) + atazanavir/ritonavir (300 and 200 mg capsule, 300 and 200 mg per day every 24 hours / 100 mg capsule, 100 mg per day every 24 hours)
89345366|NCT03789019|Experimental|BP-C1|"Dose-response part: patients who have completed the first 32-day treatment period with BP-C1 under Protocol BMC2011-1/Protocol MBC-BPC1/IIB or Protocol BMC2012-4, and having a maximum of moderate toxicity at the end of treatment are offered to continue in the second 32-day treatment period with BP-C1 under the protocol BMC2011-02. Patients completing 64-day treatment period with BP-C1 will be followed up for 28 days.~Follow-up study: the patients will be given BP-C1 as long as they obtain benefit from the treatment (i.e. until disease progression or increase in toxicity not above moderate grade)."
89345367|NCT03445312||study cohort|All non-ICU medicine and surgery patients at Sinai Health System who have a mid-stream urine culture ordered
89345368|NCT01306279||Cystic Fibrosis, infection|Cystic Fibrosis patients with an infective exacerbation
89345369|NCT01234961|Experimental|Redesigning Daily Occupations|The ReDO intervention focuses on how people compose their everyday lives. Supporting people in how to change and modify their patterns of daily occupations is a new intervention method for people with stress-related disorders, but it has been shown to be effective in improving quality of life and self-rated health in other target groups. The basic idea is that re-structuring of an individual's lifestyle and pattern of daily occupations will lead to a healthier balance between the occupations of everyday life, and that this balance will promote wellness and improved work capacity. The program is group based and comprises 16 weeks, with sessions 2 x 2 hours per week, followed by 3-4 booster sessions.
89345370|NCT01234961|Active Comparator|Care as usual|Standard rehabilitation provided by the Social Insurance Office, such as stress management, physical therapy, mindfulness training.
89345371|NCT03445234|Experimental|Blueberry|Freeze-dried blueberry powder
89345372|NCT03445234|Placebo Comparator|Placebo|Placebo powder
89345373|NCT03445234|Experimental|Banana|Acute banana ingestion
89345374|NCT03445234|Experimental|No banana|No banana ingestion
89345375|NCT01308229|Experimental|Nile PAX®|
89345376|NCT01232387||Fetomaternal hemorrhage - Mothers|Mothers in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
89345377|NCT01232387||Fetomaternal hemorrhage - Babies|Babies in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
89345378|NCT03445078|Active Comparator|A|Participants will be administered firstly selenium-rich corn powder 20g/d for 1 month and ordinary corn powder 20g/d for another month subsequently with a month washout period.
89345379|NCT03445078|Placebo Comparator|B|Participants will be administered firstly ordinary corn powder 20g/d for 1 month and selenium-rich corn powder 20g/d for another month subsequently with a month washout period.
89345380|NCT03357471|Experimental|Certolizumab Pegol Q2W injection by e-Device|Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.
89345381|NCT03357471|Experimental|Certolizumab Pegol Q4W injection by e-Device|Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.
89345382|NCT03444922|Placebo Comparator|Placebo|Participants consume Vanilla Wafer cookie
89345383|NCT03444922|Experimental|BPA 4 ug/kg BW|Participants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie
89345384|NCT03444922|Experimental|BPA 50 ug/kg BW|Participants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie
89345385|NCT03791671|Experimental|individual balance training|"After the initial assessments, the three week intervention time begins, which is completed with the reassessments.~The patients receive 2x weekly individual balance training for 25 minutes each. This runs in addition to the normal, prescribed rehabilitation program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period."
89345386|NCT03791671|Active Comparator|group balance training|"The patients receive 2x weekly group balance training for 25 minutes each. This runs in addition to the normal, prescribed rehab program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period.~In group therapy are 3 to 6 patients with different neurological diagnoses. As it is usual in rehabilitation everyday life."
89345387|NCT01233791|Experimental|Vaginal Diazepam Suppository|Patients in this arm will be asked to use one vaginal suppository every night for 28 days
89345388|NCT01233791|Placebo Comparator|Vaginal Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
88809707|NCT01272752|Experimental|Study Group|Subjects will take 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
89345389|NCT03444688|Active Comparator|CT, Control Group|Conventional Gait Training
89345390|NCT03444688|Experimental|WT, Experimental Group|Gait rehabilitation with walker
89345391|NCT01308307|Experimental|one arm|
89345392|NCT01139255|Experimental|Podcasting + mobile media|
89345393|NCT01139255|Active Comparator|Podcasting|
89345394|NCT03788707|Experimental|Passive leg raising|Passive leg raising for 3 minutes after 20 seconds of lying flat
89345395|NCT03444610|Other|Arm (blood transfusion escalation rate)|The intervention for the arm (blood transfusion escalation rate) will be about giving blood transfusion with escalating rate as described in intervention part to Any condition that expected to receive more than one blood transfusion, like thalassemia major or intermedia, sickle cell anemia, aplastic anemia, malignant diseases.
89345396|NCT01140971|Active Comparator|Misoprostol|Use 25 micrograms vaginal every 6 hours (max dosis 200 micrograms in 48 hours)
89345397|NCT01140971|Active Comparator|Foley|Foley catheter number 14 or 16 was installed intracervical for no more than 48 hours.
89345398|NCT03444532|Experimental|12-week aerobic exercise and cognitive-behavioral therapy|12-week aerobic exercise, two times per week, and cognitive-behavioral therapy for insomnia in total four sessions
89345399|NCT03444532|No Intervention|Control group|Patients assigned to the control group will receive usual care
89345400|NCT01136135||CARDIAC MRI|
89345401|NCT03129022|Active Comparator|Successful epidural anaesthesia|It is defined as VAS score <5, 30 min after a loading dose, given after the last attempt.
89345402|NCT03129022|Active Comparator|Failed epidural anaesthesia|It is defined as VAS score ≥5, 30 min after a loading dose, given after the last attempt.
89345403|NCT05623033||infection group|
89345404|NCT05623033||non-infection group|
89345405|NCT05608889|Experimental|Mindfulness Enhanced Web App-enabled Total Worker Health Program|The Total Worker Health Mindful Program will include 12, 45-minute sessions completed each week at participant's workplace. Sessions will be guided by written curriculum and focus on healthy eating, exercise, sleep and stress reducing behaviors enhanced by mindfulness activities. Participants will be provided with free enrollment codes to use the Headspace® application (app).
89345406|NCT03788629|Experimental|Study Group 1|Bobath Concept+ Talocrural joint Mulligan MWM techniques were applied to this group.
89345407|NCT03788629|Active Comparator|Study Group 2|Subtalar joint Mulligan MWM techniques were applied to this group in addition to Bobath Concept+ Talocrural joint Mulligan MWM techniques
89345408|NCT03444454|Experimental|VRRS Khymeia|"The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program).~The exercise program will be remotely charged by therapist on the patient's computer.~Each patient's performed session will be reviewed remotely by the therapist."
89345409|NCT03444454|Active Comparator|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
89345410|NCT03444454|Experimental|VRRS Khymeia plus active tDCS|The group will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
89345411|NCT03444454|Active Comparator|VRRS Khymeia plus placebo tDCS|The group will receive 5 sessions of an individualized home-based VRRS training combined with placebo tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
89345412|NCT03342963|Experimental|ASC-01 in period 1, Aripiprazole and sertraline in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting."
89345413|NCT03342963|Experimental|Aripiprazole and sertraline in period 1, ASC-01 in period 2|"At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
89345414|NCT03342963|Experimental|Fasting in period 1, After breakfast in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast."
89345415|NCT03342963|Experimental|After breakfast in period 1, Fasting in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
89345416|NCT04611581||PD patients with apathy|PD patients with apathy according to the diagnostic criteria by Robert et al. 2018
89345417|NCT04611581||PD patients with impulse control disorder|PD patients with a) at least one item >2 or b) at least two items >1 on the hyperdopaminergic subscale of the Ardouin Scale of Behaviour in Parkinson's Disease
89345418|NCT04611581||PD patients without any relevant neuropsychiatric symptoms|PD patients with a score <2 on each item of the Ardouin Scale of Behaviour in Parkinson's Disease
89345419|NCT03786055|Experimental|Somatic Yoga and Meditation (SYM)|Participants will engage in 16 sessions of somatic yoga and meditation with appropriate props as needed over 8 weeks and continue with a home practice. Application of SYM throughout activities of daily living is reinforced. All sessions are facilitated by trained yoga therapists.
89345420|NCT05608733|Experimental|Epidural catheter|Epidural catheter infusion of bupivacaine 0.1% (4-6 cc/h) at level L3-L4
89345421|NCT05608733|Active Comparator|Continuous sciatic nerve block|Continuous sciatic catheter infusion of bupivacaine 0.1% (6-10 cc/h)
89345422|NCT03706755|Active Comparator|A|group A: will receive 1 mcg/Kg of Norepinephrine intravenously
89345423|NCT03706755|Active Comparator|B|group B: will receive 0.5 mcg/Kg of Norepinephrine intravenously
89345424|NCT03791515|Active Comparator|Calcitonin Gene-Related Peptide (CGRP)|"30 patients with PPTH will be allocated to receive intravenous infusion of 1.5 µg/min calcitonin-gene related peptide over 20 minutes~Other Name: CGRP"
89345425|NCT03791515|Placebo Comparator|Placebo|"30 patients with PPTH wil be allocated to receive 40 mL Placebo (isotonic saline) over 20 minutes.~Other Name: Isotonic Saline"
89345426|NCT05235035||health care professionals|Staff from the department of anesthesia and general resuscitation and thoracic cardiac pediatric with patient contact that regularly works in shifts including night shifts
89345427|NCT05693623|Experimental|Cold Application to the Sacral Area|
89345428|NCT05693623|No Intervention|control group|
89345429|NCT05682573||covid-19 Inpatients|Participant is diagnosed with symptomatic COVID-19 by a positive polymerase chain reaction(PCR) or rapid antigen detection for SARS-CoV-2 and with treatment in hospital
89345430|NCT03361956|Experimental|Part A: Arm 1 (JNJ-56136379 or NA) (open label)|Participants with hepatitis B virus (HBV) currently not being treated and receiving JNJ-56136379 tablet (at a lower dose) orally for 24 weeks, will stop further dosing with JNJ-56136379 and start treatment with nucleos(t)ide analog (NA) (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]), and enter the 24 week post treatment follow-up phase.
89345431|NCT03361956|Placebo Comparator|Part A: Arm 2 (Placebo+NA [ETV] or [TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
89345432|NCT03361956|Experimental|Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
89345433|NCT03361956|Placebo Comparator|Part A: Arm 4 (Placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
89345434|NCT03361956|Experimental|Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
89345435|NCT03361956|Experimental|Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.
89531690|NCT05734417|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
89345436|NCT03361956|Placebo Comparator|Part B: Arm 7 (placebo + NA [ETV or TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
89345437|NCT03361956|Experimental|Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
89345438|NCT03361956|Placebo Comparator|Part B: Arm 9 (placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
89345439|NCT03361956|Experimental|Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
89345440|NCT05371639|Experimental|Tian Ma Bian Chun Zhi Gan group|Tian Ma Bian Chun Zhi Gan tablets
89345441|NCT05371639|Placebo Comparator|Placebo group|placebo identified to Tian Ma Bian Chun Zhi Gan tablets
89345442|NCT04595591|Active Comparator|Group Ⅰ|titration dosing speeds of propofol at 2mg/kg/min
89345443|NCT04595591|Active Comparator|Group Ⅱ|titration dosing speeds of propofol at 1mg/kg/min
89345444|NCT04595591|Active Comparator|Group III|titration dosing speeds of propofol at 0.5mg/kg/min
89345445|NCT03709953|Experimental|apatinib|apatinib, 500 mg, po, QD; 28 days every cycle
89345446|NCT03444220|Active Comparator|ACHIM|Anaerobically Cultivated Human Intestinal Microbiota
89345447|NCT03444220|Placebo Comparator|Placebo|Anaerobically Cultivated medium
89345448|NCT05176275|Experimental|68Ga-NOTA-RP25|Intravenous injection
89345449|NCT05608187|Experimental|ILP100Lo|During the Treatment Phase, subjects will continue on standard of care according to the protocol and ILP100Lo (ILP100-Topical, 5x10^7 colony forming units (CFU)/cm^2) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.
89345450|NCT05608187|Experimental|ILP100Hi|During the Treatment Phase, subjects will continue on standard of care according to the protocol and ILP100Hi (ILP100-Topical, 1x10^9 CFU/cm^2) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.
89345451|NCT05608187|Placebo Comparator|Placebo|During the Treatment Phase, subjects will continue on standard of care according to the protocol and Placebo (ILP100 dilution buffer mixed with the activation peptide SppIP) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.
89345452|NCT03444142|Active Comparator|Drug: Exenatide LAR|Exenatide LAR 2 mg, once weekly subcutaneously before breakfast during 4 weeks.
89345453|NCT03444142|Active Comparator|Drug: Dulaglutide|Dulaglutide .75 mg, once weekly subcutaneously Before breakfast during 4 weeks.
89345454|NCT03706599|Experimental|Fever therapeutic education session|Therapeutic education session on fever
88809708|NCT01272752|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
89345455|NCT03706599|Placebo Comparator|Control therapeutic education session|Control therapeutic education session (on household accidents)
89345456|NCT04586075||Undiagnosed Disease Group|Blood or other relevant biological samples obtained from consenting research subjects will be banked and extracted for DNA and RNA.
89345457|NCT01306435|Experimental|Laser Group|
89345458|NCT01306435|Placebo Comparator|Placebo Group|
89345459|NCT03443986|Experimental|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes.
89345460|NCT03443986|Sham Comparator|Resistance training associated with sham|"The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown. The vibration sham; will be held with the disconnected platform. A device will be connected producing a noise similar to the sound of the connected platform for a time equivalent to the treatment protocol, since it will not be possible to distinguishing noticeably stimulate vibrator. Participants that will undergo false vibration will not have contact with those who carry out the real treatment."
89345461|NCT03443986|No Intervention|Control group|Will not be submitted to any physical intervention. It continues in your daily life with only monitoring via phone callings. Guidelines about foot care.
89345462|NCT05682417|Experimental|Patients with anorexia nervosa according to DSM-5|Patients over 15 years old, suffering from anorexia nervosa according to DSM-V with a BMI<18.5 and without psychiatric comorbidities
89345463|NCT01305733|Active Comparator|local infiltration analgesia|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
89345464|NCT01305733|Placebo Comparator|saline injection|The normal saline injection are used in the control group in the same manner than in the RKA group.
89345465|NCT05210153||Standard dose|Patients are allocated to this group at visit V1 if 100 mg/day sertraline dose resulted in optimal sertraline exposure (20-40 ng/ml) as measured at VK. These patients continue to be treated with 100 mg/day during the V1-V2 period.
89345466|NCT05210153||Adjusted dose|Patients are allocated to this group at visit V1 if 100 mg/day sertraline dose resulted in high (>40 ng/ml) or low (<20 ng/ml) sertraline exposure, as measured at VK. These patients continue to be treated with the adjusted sertraline dose, different from 100 mg/day, during the V1-V2 period.
89345467|NCT03443830|Experimental|0.2 mg/kg|Subject will be administered with 0.2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
89345468|NCT03443830|Experimental|0.5 mg/kg|Subject will be administered with 0.5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
89345469|NCT03443830|Experimental|1 mg/kg|Subject will be administered with 1 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
89345470|NCT03443830|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
89345471|NCT03443830|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
89345472|NCT03443830|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
89345473|NCT03785899|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
89345474|NCT03785899|Experimental|SPOCnew and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 2s."
89345475|NCT03785899|Experimental|SPOCnew and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 8s."
89345476|NCT03785899|Active Comparator|SPOCold and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 2s."
89345477|NCT03785899|Active Comparator|SPOCold and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 8s."
89345478|NCT04749459|Experimental|ChapStick Moisturizer, Classic Flavor|This arm will include all the test sites on the participants back where ChapStick Classic Moisturizer (ANZ) will be applied.
89345479|NCT04749459|Experimental|ChapStick Moisturizer, Strawberry Flavor|This arm will include all the test sites on the participants back where ChapStick Strawberry Moisturizer (ANZ) will be applied.
89345480|NCT04749459|Active Comparator|ISO 24444:2010 P2 Standard Sunscreen|This arm will include all the test sites on the participants back where ISO 24444:2010 P2 Standard Sunscreen will be applied.
89345481|NCT03438370|No Intervention|Three monthly ART supply at facilities|Sites at which patients will be provided three monthly ART supply at health facilities.
89345482|NCT03438370|Experimental|Three monthly ART supply at CAGs|Sites at which patients will be provided three monthly ART supply at Community ART Groups (CAGs).
89345483|NCT03438370|Experimental|Six monthly ART supply at outreaches|Sites at which patients will be provided six monthly ART supply at Community distribution points or outreaches.
89345484|NCT03708783|Experimental|No. 10 Lymph Node Dissection group|Patients with locally advanced upper or middle third gastric cancer will receive laparoscopic total gastrectomy and D2 lymphadenectomy with spleen-preserving No.10 lymph node dissections
89345485|NCT03785821|Experimental|BMSO|Bitter melon seed oil supplementation
89345486|NCT03785821|Placebo Comparator|OO|Olive oil supplementation
89345487|NCT03710382|Experimental|Walking epidural|Parturients will receive a lower concentration of bupivacaine in their epidural infusion and will be encouraged to walk during labor.
89345488|NCT03708705||Relapse|Relapse of tumor within two years after liver transplantation
89345489|NCT03708705||Non-relapse|Non-relapse of tumor within two years after liver transplantation
89345490|NCT03707496||DeWinterCohort|Patients with de Winter syndrome pattern ECG
89345491|NCT03438292|Experimental|Group A - TPGS emulsified with berberine|After an 8-10 hour overnight fast, Group A will receive two soft capsules of TPGS (400mg) emulsified berberine. Following a 7 day wash out period, Group A participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Following another 7 day wash out period, Group A participants will then receive two hard shell capsules of the berberine reference powder 400mg. Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
89345492|NCT03438292|Experimental|Group B - Quillaja extract emulsified with Berberine|After an 8-10 hour overnight fast, Group B will receive four soft capsules of Quillaja extract emulsified berberine (400mg). Following a 7 day wash out period, Group B participants will then receive two hard shell capsules of the berberine reference powder (400mg). Following another 7 day wash out period, Group B participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
89345493|NCT03438292|Experimental|Group C - Berberine reference powder|After an 8-10 hour overnight fast, Group C will receive two hard shell capsules of the berberine reference powder (400mg). Following a 7 day wash out period, Group C participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Following another 7 day wash out period, Group C participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
89345494|NCT04782999|Active Comparator|Oral glucose tolerance test|"Oral glucose tolerance test with ingestion of 75 g glucose and blood sampling.~This test will be performed before and 3 months after RYGB."
89345495|NCT04782999|Active Comparator|Hyperglycemic clamp with saline infusion combined with arginine test|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 120 min with co-infusion of saline.~After 120 min an arginine test with infusion of 50 g Arginine is performed.~This test will be performed before, 1 week and 3 months after RYGB."
89345496|NCT04782999|Active Comparator|Hyperglycemic clamp with GLP-1 infusion|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusion of intraveneous glucose for 90 min with co-infusion of GLP-1.~This test will be performed before, 1 week and 3 months after RYGB."
89345497|NCT04782999|Active Comparator|Hyperglycemic clamp with GIP infusion|"Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 90 minutes with co-infusion of GIP.~This test will be performed before, 1 week and 3 months after RYGB."
89345498|NCT01136213||Multiple system atrophy|
89345499|NCT01136213||Idiopathic Parkinson Disease|
89345500|NCT01136213||Volunteers without neuropsychiatric disorder (Control)|
89345501|NCT03361176|Active Comparator|Control|Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
89345502|NCT03361176|Experimental|w/ Triamcinolone|Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
89345503|NCT03438214|Active Comparator|Vancomycin continuous infusion|Continuous infusion of vancomycin
89345504|NCT03438214|Active Comparator|Vancomycin intermittent infusion|Intermittent infusion of vancomycin
89345505|NCT05620693|Experimental|Treatment group|TCR-T treatment group
89345506|NCT01141127|Active Comparator|INTERMITENT ADMINISTRATION|Administration of 10 mg/kg of Tranexamic Acid at the beginning ,the middle and at the end of the intervention
89345507|NCT01141127|Experimental|continuous administration of Tranexamic Acid|Administration of 10 mg /Kg of Tranexamic Acid at the beginning in the priming pump and continuous infusion of 1 mg/KG of Tranexamic Acid until the end of the intervention
89345508|NCT05679999||Control group|31 male volunteers who did not have erectile dysfunction
89345509|NCT05679999||Patient group|150 patients with erectile dysfunction
89345510|NCT01232621|Experimental|Physician introduction|Physicians will introduce Research Coordinators (RCs) by name to SDMs and acknowledge patient eligibility to participate in a study using a standardized script.
89345511|NCT01232621|Active Comparator|Non-physician introduction (usual approach)|RCs will either introduce themselves or be introduced by a non-physician member of the health care team.
89345512|NCT01308385||Patients with pectus excavatum|
89345513|NCT05280444|Experimental|Lipiodol-TACE with Idarubicin|The initial dose of idarubicin is 10 mg and the maximum tolerated dose is 20 mg. Idarubicin is first dissolved in water for injection to make a solvent of 2mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents.
89345514|NCT01308541|Active Comparator|LUSEDRA (arm 1)|
89345515|NCT01308541|Active Comparator|LUSEDRA (arm 2)|
89345516|NCT01308541|Active Comparator|Propofol (arm 3)|
89345517|NCT05679765|Experimental|Group G|Greater occipital nerve block (GONB) under ultrasound guidance with lidocaine and dexamethasone on the side of headache
88809709|NCT00751634|Experimental|A|Application of the Gaymar Rapr-Round device per approved use
89345518|NCT05679765|Active Comparator|Group S|Greater occipital nerve block (GONB) under ultrasound guidance on the side of headache with 0.9% Saline (Placebo)
89345519|NCT05271708|Experimental|Fespixon cream|Fespixon cream contains 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%) with appearance in yellow-green to light green color. Fespixon cream will be applied twice daily for up to 12 weeks to the linear wound.
89345520|NCT05271708|Placebo Comparator|Placebo Cream|Placebo cream with appearance in yellow-green to light green color, same appearance as Fespixon cream, will be applied twice daily for up to 12 weeks to the linear wound.
89345521|NCT03785431|Experimental|Intervention|Patient diagnosed with ST elevation myocardial infarction will undergo bioresorbable stent deployment in culprit lesion.
89345522|NCT03706443|Active Comparator|Systane® Complete|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Complete, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
89345523|NCT03706443|Active Comparator|Systane® Ultra|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Ultra, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
89345524|NCT01136369||OSNA Breast Cancer System|
89345525|NCT03438136|Experimental|Intervention arm|This arm will be enrolled in the intervention.
89345526|NCT03438136|No Intervention|No intervention arm|This arm will be enrolled in a no contact control group.
89345527|NCT03785353|Experimental|PNE Group|A group of Spanish-speaking individuals will listen to a translated lecture related to PNE (PNE lecture). They will fill out the R-NPQ pre and post the lecture.
89345528|NCT05255055|Experimental|Manual Therapy Group|Manipulation of the high dorsal region in extension. Cervical mobilizations. Massage therapy. Suboccipital inhibition. Once a week.
89345529|NCT05255055|Experimental|Therapeutic Exercise Group|Recruitment and strengthening of the cervical flexors. Isometric cervical exercises with self-resistance. Shoulder girdle strengthening exercise. Alternating days.
89345530|NCT03438058||With complement-activating anti-HLA DSAs|Patients with complement-activating anti-HLA DSAs either C1q, C3d, C4d and IgG subclass
89345531|NCT03438058||Without complement-activating anti-HLA DSAs|Patients with anti-HLA DSAs but without the ability to activate the complement (either C1q, C3d, C4d and IgG subclass)
89345532|NCT03438058||Without DSAs and without complement-activating DSAs|Matching group of patients without DSAs and without complement-activating DSAs
89345533|NCT01136447|Placebo Comparator|Neurostimulation|Block catheter will be introduced using neurostimulation
89345534|NCT01136447|Active Comparator|Ultrasound|Block catheter will be introduced using ultrasound
89345535|NCT01306513|Experimental|cells|
89345536|NCT03437980|Experimental|propofol spinal acceptance|"The surgeon and the anesthetist will discuss the exclusion criteria. Then they will discuss the information's about spinal and general anesthesia with the illegible patients, also reply the patient's questions in a preoperative visit. The primary decision for the patient; either spinal or general anesthesia will be recorded.~The patients refusing spinal anesthesia will be discussed again to detect the rate of acceptance of spinal anesthesia if propofol sedation is ensured during the procedure to provide a painless spinal injection. The final decision will be applied; either spinal with procedural sedation, or general anesthesia."
89345537|NCT05176119|Active Comparator|Nalbuphine arm|0.1 mg /kg nalbuphine was given to 30 patients
89345538|NCT05176119|Active Comparator|Ketamine arm|0.25 mg /kg ketamine was given to 30 patients
88809710|NCT01278134|Experimental|Arm B Extension|All patients in treatment arm B were offered to receive Pegasys/Cogepus therapy for an additional 24 weeks.
88809711|NCT01278134|Experimental|RO5024048 & ritonavir-boosted danoprevir without Ribavirin (B)|
89345539|NCT05176119|Placebo Comparator|Saline arm|an equivalent volume of normal saline was given to 30 patients
89345540|NCT01139489|Active Comparator|procalcitonin-guidance|A daily advise to continue or stop antibiotics based on the measurement of the biomarker procalcitonin
89345541|NCT01139489|No Intervention|standard-of-care|standard-of-care treatment of ICU infections based upon consensus guidelines and expert opinion
89345542|NCT05679531|No Intervention|Control group|Children in the control group, who met the research criteria, were not applied any procedure other than clinical routine protocol and nursing care. After being brought to the pediatric surgery service, patients with nausea and vomiting were filled out with a questionnaire. The severity of nausea was evaluated with the BARF Scale during nausea and vomiting and 30, 60 and 120 minutes after nausea and vomiting in patients with nausea and vomiting.
89345543|NCT05679531|Experimental|Chewing gum group|Starting from the second hour after the child was brought to the clinic after appendectomy, menthol sugar free gum was given to children with nausea and vomiting outside the clinical routine nursing care, as soon as they could chew gum and follow the instructions, and were asked to chew for an average of 15 minutes. The product of a single brand of gum was used. In the first stage, the patient's nausea was evaluated with the BARF nausea scale before the intervention. After filling out the patient information form, the patients who met the research criteria were chewed gum for an average of 15 minutes. During the intervention (between 5-10 minutes), the patient was re-evaluated for nausea with the BARF nausea scale at 30.,60. and 120 minutes after the intervention. Episodes of vomiting were recorded in patients with vomiting.After the quantitative stages of the study were completed, the patient's level of relief was evaluated using a verbal descriptive scale.
89345544|NCT03437902|Experimental|Rutin C group|patients will receive Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks..
89345545|NCT03437902|Experimental|Vitamin C group|patients will receive vitamin C 500 mg once daily in addition to usual antidiabetic treatment for 8 weeks.
89345546|NCT03437902|No Intervention|Control group|patients will receive their usual antidiabetic treatment only for 8 weeks.
89345547|NCT05194085|No Intervention|Female SOC/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and laboratory HIV testing at enrollment and every 6 months until 6 months postpartum
89345548|NCT05194085|Active Comparator|Female intervention/Male SOC arm|Women will be provided the standard of care invitation letter for male partners for fast-track visit for HIV testing and POC VL tests for women at enrollment, delivery, and 6 months post-partum
89345549|NCT05194085|Active Comparator|Female SOC/Male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and laboratory-based HIV VL testing for women at enrollment, delivery, and 6 months post-partum
89345550|NCT05194085|Active Comparator|Female intervention/male intervention arm|Women will be provided an invitation letter for male partners for wellness visits and POC viral load testing for women at enrollment, delivery, and 6 months post-partum
89345551|NCT05283499|Active Comparator|Opioid|Combination analgesic of hydrocodone 5mg/acetaminophen350 mg
89345552|NCT05283499|Active Comparator|Non-Opioid|Combination analgesic of ibuprofen 400mgacademinophen 350mg
89345553|NCT05682105||Development dataset|Slit-lamp images collected from the Department of Hepatobiliary Surgery of the Third Affiliated Hospital of Sun Yat-sen University(HTH)， Affiliated Huadu Hospital of Southern Medical University(HDH)， and Nantian Medical Centre of Aikang Health Care (NMC).
89345554|NCT05682105||Testing dataset|Slit-lamp and smartphone images collected from the Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University（ITH）， Huanshidong Medical Centre of Aikang Health Care， the Medical Centre of the Third Affiliated Hospital of Sun Yat-sen University(MCH).
89345555|NCT03437824|Experimental|Cyanocobalamin|Vitamin B12, 1,000 mg, Once
88809712|NCT01278134|Experimental|RO5024048 and ritonavir-boosted danoprevir with Ribavirin (A)|
89345556|NCT03437824|Placebo Comparator|Placebo|Normal Saline Solution (0.9% Sodium Chloride), Once
89345557|NCT05187767||Malignant GGOs|Patients with histologically proven malignant pulmonary ground glass opacities (GGOs)
89345558|NCT05187767||Benign GGOs|Patients with histologically or radiologically proven benign pulmonary ground glass opacities (GGOs)
89345559|NCT01139567||Standard Care Group|Subjects who will undergo only standard wound care management.
89345560|NCT01139567||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
89345561|NCT05272891|Experimental|Experimental|audio book will be played
89345562|NCT05272891|No Intervention|Control Group|No application will be made
89345563|NCT05175963||High Risk|"Nurses (auxiliary nurses, enrolled nurses and professional nurses), medical doctors (interns, medical officers, registrars and consultants) and auxiliary/para-medical staff involved in the care of patients admitted for respiratory illnesses at Chris Hani Baragwanath Academic Hospital (CHBAH). This will include staff that have been assigned to work in:~Internal Medicine: Staff working in the Ambulatory and Emergency Department, staff in the pneumonia-admission ward (ward 24), and staff in the COVID-19 confirmed case wards.~Paediatrics: Staff involved in-hospital care of patients admitted to the dedicated pneumonia ward and COVID-19 cases wards.~Intensive Care Unit: All medical staff working in the intensive care unit."
89345564|NCT05175963||Low Risk|Nursing and medical-doctor staff that are working in the neonatal high-care and intensive care unit; who are likely to be at lower risk from SARS-CoV-2 acquisition in the health-care facility compared to their peers listed in Group 1.
88809713|NCT01273844|Experimental|Bortezomib|Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.
88809714|NCT01270568|Experimental|Positive Psychology|8 weekly positive psychology exercises
88809715|NCT01270568|Active Comparator|Relaxation Response|Meditation-based treatment
88809716|NCT01270568|Sham Comparator|Recollection|Recollection of daily events, recorded weekly
88809717|NCT01271348|Active Comparator|Etoricoxib|
88809718|NCT01271348|Placebo Comparator|Placebo tablet|
88809719|NCT04385264|Placebo Comparator|Placebo|Placebo (Mannitol), oral capsules Day 0: 4 capsules PO OD Days 1-5: 2 capsules PO OD
89345565|NCT05175963||Intermediate Risk|"A third group, with a likely intermediate risk for hospital-facility based SARS-CoV-2 infection, are:~VIDA staff involved in sample collection related to COVID-19, and laboratory personnel that will be involved in sample collection at VIDA.~Nurses and medical doctors from the Obstetrics & Gynaecology."
89345566|NCT05175963||Mixed Risk|In 2021 with an eminent 3rd wave spreading across the country an additional group will be included comprising of any person working at CHBAH even if not in direct contact with patients.
89345567|NCT05175963||TND group|Any person working at CHBAH or Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH) even if not in direct contact with patients.
89345568|NCT03437590|Experimental|Part 1: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline positron emission tomography (PET)/ magnetic resonance (MR) scan with [18F]-JNJ-64413739 on Day 1. In Period 1 (on Day 2) and Period 2 (on Day 1), participants will receive oral dose of JNJ-55308942 (maximum dose 120 milligram [mg]). After approximately 4 hours of JNJ-55308942 dosing, participants will receive an intravenous (IV) injection of [18F]-JNJ-64413739, followed by a PET/MR scan. Doses will be selected based on the principal investigator's discretion. A wash-out period of at least 7 days will be maintained between the 2 doses of JNJ-55308942.
89345569|NCT03437590|Experimental|Part 2: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline PET/MR scan with [18F]-JNJ-64413739 on Day 1. Participants will receive oral dose of JNJ-55308942 (maximum dose 120 mg) on Day 2, followed by two post-treatment scans, one obtained at Tmax (4 hours postdose) and one at 24 hours postdose. Doses will be selected based on the principal investigator's discretion.
89345570|NCT05253963|No Intervention|Control|During the first and second study nights, subjects will undergo baseline polysomnography.
89345571|NCT05253963|Experimental|Continuous Positive Airway Pressure|Baseline polysomnography will be perfomed during the first study night and CPAP titration polysomnography will be performed during the second study night.
89345572|NCT01136525|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
89345573|NCT01136525|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
89345574|NCT03437434||BunnyLens and Gore-Tex suture|All patients Underwent 4 point PC-IOL scleral fixation with Gore-Tex sutures
89345575|NCT05678829|Experimental|Virtual Reality|Using a virtual reality application based on individuals in Virtual Reality creatures, it will be explained for an average of 20 minutes in a time period where they are appropriate, through extensive trainings according to what is given.
89345576|NCT05678829|Experimental|Face to face|By using the training room of the family health center specified for the individuals in the Face to face group, training content covering the subjects of reproductive and health and family planning methods will be prepared, and the days when women are suitable will be determined, and each training will be given for 40 minutes with face-to-face classical training method. Educational subjects will be continued in parallel with Virtual Reality group by using Ministry of Health hand brochures and training materials for Face to face group.
89345577|NCT05678829|No Intervention|Control|No intervention will be made to the control group during the training.
89345578|NCT05632445|Other|Apixaban|Apixaban 5mg bid oral.Duration: 3 months Aspirin 80 / 100 mg bid oral. Duration: 9 months
89345579|NCT05632445|Other|DAPT|Aspirin 80/100 mg + Clopidogrel 75 mg bid oral. Duration: 3 months Aspirin 80 / 100 mg bid oral. Durtaion: 9 months
89345580|NCT03437122|Experimental|All|
89345581|NCT05271175|Experimental|Active TMS & Neutral videos|Received active iTBS stimulation while watching neutral videos
89345582|NCT05271175|Experimental|Active TMS & Smoking videos|Received active iTBS stimulation while watching smoking-related videos
89345583|NCT05271175|Sham Comparator|Sham TMS & Smoking videos|Received sham stimulation while watching smoking-related videos
89345584|NCT05131217|Experimental|Acute bout of Continuous Moderate Intensity Exercise|
89345585|NCT05131217|Experimental|Acute bout of High Intensity Interval Training (HIIT)|
89345586|NCT05131217|Experimental|Control|
89345587|NCT05127785||Medical Management|Patients deemed not candidates for advanced heart failure interventions.
89345588|NCT05127785||Left Ventricular Assist Device (LVAD)|Recipients of a left ventricular assist device
89345589|NCT05127785||Heart Transplant|Recipients of a heart transplant.
89345590|NCT04398550|Experimental|Specific Carbohydrate Diet|Exclusive consumption of the specific carbohydrate diet for 6 weeks
89345591|NCT04398550|Experimental|Mediterranean Diet|Exclusive consumption of the Mediterranean diet for 6 weeks
88809720|NCT04385264|Experimental|Hydroxychloroquine|Hydroxychloroquine 200mg (HCQ, Plaquenil), oral capsules Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
88814347|NCT01632215|Experimental|preoperative gabapentine,|Gabapentine
89345592|NCT05175807|Experimental|Mindfulness Group_1|The intervention will be characterized by be based on Mindfulness exercises (e.g. body scan, gentle yoga, sitting, grounding and walking meditation), relaxation techniques and cognitive rehabilitation exercises. walking), relaxation techniques and cognitive rehabilitation exercises. The objective is to provide specific practical skills to learn how to deal with difficult and/or stressful situations managing emotions and intercurrent thoughts. The intervention is proposed to last for a total of 5-6 sessions lasting 45 minutes each, two sessions per week, for a three-week commitment. In addition, between sessions, reflection materials, readings or exercises will be offered. The intervention will be conducted in telemedicine by a Psychologist, who has experience in conducting these interventions and who receives regular supervision. The sessions will be conducted through special platform and audio-recorded to ensure the reliability of the data collected, prior consent.
89345593|NCT05175807|No Intervention|Waiting List Group_2|"In both groups the usual care or usual treatment, will consist of the usual daily medical examinations of the department, respiratory and motor physiotherapy sessions. The Group 2, therefore, will not be submitted to other type of treatment outside of that previewed near O.U. for the course of the first three weeks, during which they will be placed on the waiting list. Once the Once the assessment is carried out after 3 weeks, we will proceed to implement the intervention proposed to the Group 1. If the participant has already been discharged from the structure, it will still be possible to proceed with the intervention, since it is online. If the participant has already been discharged from the structure, you can still proceed with the intervention, since this is in telemedicine, in order to promote the continuity hospital-territory."
89345594|NCT01306591|Active Comparator|Bevacizumab 1|
89345595|NCT01306591|Active Comparator|Bevacizumab 2|
88814348|NCT01632215|Placebo Comparator|sugar pill|Placebo group
89345596|NCT03708471|Experimental|Two-stage hybrid abltaion|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will receive percutaneous catheter ablation and recommendations about cardiovascular risk control.
89345597|NCT03708471|Active Comparator|Thoracosopic surgical ablation|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will only receive recommendations about cardiovascular risk control.
89345598|NCT03098030|Experimental|Part 1: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
89345599|NCT03098030|Active Comparator|Part 2: Irinotecan|Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle.
89345600|NCT03098030|Experimental|Part 2: Dinutuximab + Irinotecan|Dinutuximab (16 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
89345601|NCT03098030|Active Comparator|Part 2: Topotecan|Topotecan (1.5 mg/m^2 IV) on Days 1 to 5 of each q21d cycle.
89345602|NCT04376632|No Intervention|Control|Participants in this group avoid all nuts for 8 weeks.
89345603|NCT04376632|Experimental|Pecan ADD|Participants in this group consume 68 g of pecans/d with no additional dietary instructions and avoid all other nuts.
89345604|NCT04376632|Experimental|Pecan SUB|Participants in this group consume 68 g of pecans/d with instructions to substitute pecans with isocaloric foods in the habitual diet. They are also instructed to avoid all other nuts.
89345605|NCT01233947|Experimental|AFP464|74 mg/m2 AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycle.
89345606|NCT01233947|Experimental|AFP464 + Faslodex|AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycles and Faslodex administered per package label.
89345607|NCT01306669|Active Comparator|Trivalent influenza vaccine|Single dose administration of trivalent influenza vaccine prior to onset of influenza season
89345608|NCT01306669|Placebo Comparator|Normal saline|
89345609|NCT01139645|Experimental|Proton Pump Inhibitors|patients were started on Proton Pump inhibitors for 3 months (the whole duration of the study)
89345610|NCT01139645|No Intervention|No Proton Pump Inhibitors|patients are not taking any Proton Pump Inhibitor, and they are matched by age to patients in the experimental group.
89345611|NCT03436576|Active Comparator|Autologous Serum 20%|Treatment with Autologous Serum 20% for 2 months
89345612|NCT03436576|Active Comparator|Autologous Serum 50%|Treatment with Autologous Serum 50% for 2 months
89345613|NCT03706287|Experimental|Anlotinib + AP/PC|
89345614|NCT05693389|Active Comparator|patients with bipolar disorder who will partaicpmg in acceptance and commitment therapy|patients with bipolar disorder who will participate in acceptance and commitment therapy
89345615|NCT05693389|Placebo Comparator|patients with bipolar disorder who will be under routine hospital care|patients with bipolar disorder who will be under routine hospital care
89345616|NCT03436342|Experimental|68Ga-Pentixafor, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
89345617|NCT05115201|Experimental|Test group (TG)|Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
89345618|NCT05115201|Active Comparator|Control group (CG)|Patients will be treated with scaling and root planing only
89345619|NCT03791047|Experimental|Experimental Group: Balance analysis|Sixty older subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
89345620|NCT03791047|Active Comparator|Control Group:Balance Analysis|Sixty young subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
89345621|NCT02522806|Experimental|Group A|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle.
89345622|NCT02522806|No Intervention|Group B|none endometrial biopsy
89345623|NCT03791203|Experimental|Calorie restriction (MACR)|Participants restricted 70% of their energy needs over 24 hours on a calorie restriction day alternate with a feeding day for the next 24 hours, where they were allowed eating (ad libitum). The calorie restriction and feeding days begun at 9 am each day, and on the calorie restriction day, meals were consumed between 2 pm and 8 pm to ensure that they underwent the same duration of calorie restriction. On each calorie restriction day, they were allowed energy-free beverages and sugar-free gum and encouraged to drink plenty of water. Diet plans were self-selected using detailed individualized food portion lists, meal plans, and recipes. Participants received phone calls from the investigator and four 2-weekly appointments with a dietitian. Adverse experiences were assessed every 2 weeks.
89345624|NCT03791203|No Intervention|Control group|Participants in the control group continued their usual habitual diet for 8 weeks. No specific dietary advice or educations were provided throughout the entire trial.
89345625|NCT05569187||Ribociclib in combination with non-steroidal aromatase inhibitors|Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
89345626|NCT05404672|Experimental|Aerobic Training|Progressive breathing training exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control. In addition to this Aerobic Training (cycling, treadmill) will also be practiced for 30 minutes constituting 5 days/ week. Initial training would avoid upright position. Mild-to-moderate-intensity endurance training, progressing from semi-recumbent to upright position plus strength training will be practiced.
89345627|NCT05404672|Active Comparator|Conventional Treatment|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control.
89345628|NCT03788395|Experimental|Symbicort Turbohaler plus Turbo+|10 asthmatic children
89345629|NCT03788395|Active Comparator|Symbicort Turbohaler without Turbo+|10 asthmatic children
89345630|NCT05174013|Experimental|Participants receiving GSK3858279|
89345631|NCT05174013|Placebo Comparator|Participants receiving placebo|
89345632|NCT02522650|Experimental|Amiloride Phase|Subject receives 5mg of Amiloride twice daily for 8 weeks.
89345633|NCT02522650|Active Comparator|Triamterene Phase|Subject receives 50mg of Triamterene twice daily for 8 weeks.
89345634|NCT02522650|No Intervention|Washout Phase|Subject does not take any study medication for 4 weeks
89345635|NCT01306747|Experimental|Chronic Pain Self-Management|
89345636|NCT01306747|No Intervention|Control group|
89345637|NCT05681871|Experimental|Iron-deficiency anaemia|Participants will receive oral iron supplementation for a minimum of 6 weeks prior to surgery
89345638|NCT03791281|Experimental|BASIS|Received a 3-hour BASIS implementation strategy.
89345639|NCT03791281|Active Comparator|Attention Control|Received a 3-hour session designed to control for dose, information provided, and presenter effects.
89345640|NCT05416892||Patients of Geriatric Wards SU06 and SU13 of the CHU Brugmann Hospital|
89345641|NCT04455256||recurrent pregnancy loss group|Women between the ages of 18 and 45 who had a history of miscarriage under 3 weeks and above 22 weeks were included in this group.
89345642|NCT04455256||women who had healthy birth|Women between the ages of 18-45 who have not had a history of pregnancy loss and who have had at least one healthy birth and no known chronic diseases are included in this group.
89345643|NCT04455958|Experimental|Group I (lopinavir/ritonavir)|Patients receive lopinavir/ritonavir PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
89345644|NCT04455958|Placebo Comparator|Group II (placebo)|Patients receive placebo PO BID for 14 days in the absence of disease progression or unacceptable toxicity.
89345645|NCT01308697|Active Comparator|Operative|Operative intervention
89345646|NCT01308697|Active Comparator|Non Operative Treatment|Non Operative management
89345647|NCT03791125|Experimental|Experimental|
89345648|NCT03791125|Placebo Comparator|Placebo|
89345649|NCT03341637|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose)
89345650|NCT03341637|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
89345651|NCT05327140||patients with axial spondyloarthritis|ASAS classification criteria which relies either on sacroiliitis on imaging plus one SpA feature (imaging arm) or HLA-B27 antigen plus two SpA features (clinical arm), in a patient with chronic back pain and age at onset of less than 45 years
89345652|NCT05327140||patients with mechanical back pain|Patients diagnosed as chronic (more than 3 months) mechanical back pain, the diagnosis has been made prior to the study by the treating specialist, these patients are herein as a control group
89345653|NCT03788239|Experimental|Arm 1|Right knee wound closure by staples and Left Knee wound closure by sutures
89345654|NCT03788239|Experimental|Arm 2|Right knee wound closure by sutures and Left Knee wound closure by staples
89345655|NCT01378858|Experimental|Varenicline treatment as usual (TAU)|Subjects in the TAU arm will self administer varenicline for 12 weeks.
89345656|NCT01378858|Experimental|Varenicline directly observed therapy|Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
89345657|NCT03790969|Experimental|26 gauge needle|intervention group
89345658|NCT03790969|Active Comparator|23 gauge needle|control group
89345659|NCT03706209|Experimental|150 mg MP1032 bid|3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
89345660|NCT03706209|Experimental|300 mg MP1032 bid|6 × 50 mg (300 mg) MP1032 hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
88809721|NCT00746954|Other|Arm 1 BUS to PLA to ACET|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
88809722|NCT00746954|Other|ARM 2 ACET to BUS to PLA|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
88809723|NCT00746954|Other|ARM 3 PLA to ACET to BUS|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=2
89345661|NCT03706209|Placebo Comparator|Placebo bid|6 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
89345662|NCT03790735||Diagnostic test|Targeted chromosomal aberrations detection by FISH (MDA TEST).
89345663|NCT05272774|Experimental|Intervention group|The intervention group will get a 6-week online stress recovery intervention with the support from therapist.
89345664|NCT05272774|Experimental|Control group|The control group will use the intervention with on-demand support. The control group will participate in the program at the same time as the intervention group.
89345665|NCT03706131|Experimental|experimental group|one session 15 minutes cervical mobilisation and home exercise
89345666|NCT03706131|No Intervention|control grup|no intervention
89345667|NCT03790891|Experimental|CD19-TriCAR-T/SILK|CD19-TriCAR-T/SILK cells will be administered intravenously
89345668|NCT02891850|Experimental|Riociguat|PDE5i treatment will be stopped and riociguat treatment initiated following a defined washout period with a starting dose of 1 mg riociguat TID followed by an 8 weeks dose adjustment phase according to the approved riociguat dose adjustment scheme.
89345669|NCT02891850|Active Comparator|PDE-5i|Patients will continue to receive PDE5i treatment as well as other standard of care treatments at the discretion of the investigator up to Week 24. Patients in the experimental and active comparator treatment arms follow the same visit schedule.
89345670|NCT03790813|Experimental|Eligible patients|
89345671|NCT05145556|Experimental|Videolaryngoscopy (McGrath Macintosh)|First pass success rate using the videolaryngoscopy
89345672|NCT05145556|Experimental|conventional direct laryngoscopy|First pass success rate using the conventional direct laryngoscopy
89345673|NCT01308775|Active Comparator|SIS.NET, Routine Follow up|
89345674|NCT05175027|Active Comparator|Hypochlorosis|Hypochlorosis was used as an antiseptic for the patients
89345675|NCT05175027|Active Comparator|Povidone iodine|Povidone iodine was used as an antiseptic for the patients
89345676|NCT03785119||Standard strategy|According to embryo quality (morphologic criteria)
89345677|NCT03785119||Experimental strategy|Association of embryo quality and sCD146 rate
88809724|NCT00752102|Active Comparator|Calcitriol|"Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Calcitriol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and as an oral solution containing 1 mcg/ml of calcitriol. All dosage forms contain butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) as antioxidants.~Subjects taking calcitriol started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels."
89345678|NCT03705975|Active Comparator|edit arms|classical physiotherapy and manual treatment. Classical physiotherapy consisting of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Manual treatment is consist of scapular mobilization, glenohumeral joint inferior and posterior mobilization. Treatment modality is implemented by physical therapist three times a week for 8 weeks.
89345679|NCT03705975|Active Comparator|edit arm/intervention cross|classical physiotherapy and proprioceptive neuromusculer fasilitation. Classical physiotherapy consist of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Scapular PNF and upper extremity PNF (flexion-abduction-external rotation) pattern. Treatment programme was implemented by physical therapist three times a week for 8 weeks.
89345680|NCT03790501||People living with HIV (PLHIV).|We will recruit and enroll 850 people living with HIV (PLHIV) to participate in this longitudinal observational study.
89345681|NCT03707418|Active Comparator|Bivalirudin Injection (Angiomax)|This arm will receive intravenous Bivalirudin for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
89345682|NCT03707418|Active Comparator|Heparin Sodium|This arm will receive intravenous Heparin Sodium for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
89345683|NCT03785041|Active Comparator|Levobupivacaine and tramadol Preemptive|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular preemptive.
89345684|NCT03785041|Active Comparator|Tramadol and levobupivacaine postoperative|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular postoperative.
89345685|NCT03785041|Active Comparator|Tramadol and levobupivacaine preemptive and postoperative|20 ml 0.25% Levobupivacaine + 50 mg tramadol injected intraarticular preemptive and postoperative.
89345686|NCT03785041|Active Comparator|Levobupivacaine|20 ml 0.5% Levobupivacaine only injected intraarticular preemptive.
89345687|NCT03708666|Other|Telemonitoring of blood pressure|Patients measure their blood pressure and register their results on the app or website.
89345688|NCT05087056|Experimental|ABCWY-24 Group|Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 721, 1 dose of Placebo at Day 1441.
89345689|NCT05087056|Experimental|ABCWY-48 Group|Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 1441, 1 dose of Placebo at Day 721.
89345690|NCT03708510|Experimental|Filtek Silorane-Er,Cr:YSGG Laser|
89345691|NCT03708510|Experimental|Filtek Silorane- Diamond Bur|
89345692|NCT03708510|Experimental|Kalore- Er,Cr:YSGG Laser|
89345693|NCT03708510|Experimental|Kalore- Diamond Bur|
89345694|NCT05537623|Experimental|Safe Alternatives for Teens and Youths (SAFETY)|SAFETY is a transdiagnostic cognitive-behavioral family treatment informed by Dialectical Behavior Therapy (DBT) and Multisystemic Therapy (MST). The twelve week long treatment is principle based, structured in phases, and individually tailored based on a cognitive-behavioral fit analysis that specifies key risk and protective processes. Each session contains one individual component for youth and parents respectively, and one family component where youth and parents work together with therapists to practice skills identified as critical for preventing future suicidal behavior. Treatment targets are arranged in a SAFETY Pyramid, consisting of (a) safe settings; (b) safe people; (c) safe activities and actions; (d) safe thought; and (e) safe stress reactions, emphasizing strengthening protective support and validation within the family and/or social environment surrounding the youth.
89345695|NCT05537623|Active Comparator|Supportive Therapy|Supportive Therapy is a manualized client-centered therapy. The Supportive Therapy will be adapted to match SAFETY to control for nonspecific treatment factors such as therapist characteristics, time, and treatment exposure. The Supportive Therapy program consists of twelve weekly individual sessions with the youth, focusing on the therapeutic supporting relationship between the therapist and the youth, and follow-ups with parents. Therapeutic strategies include acceptance and validation, to increase feelings of connectedness and belonging and counteract thwarted belongingness, helplessness, and hopelessness. Cognitive-behavioral techniques (e.g., active modeling, problem-solving training, cognitive restructuring) are not allowed.
89345696|NCT03710304|Active Comparator|oxytocin|20 IU oxytocin ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal(ranitidine) plus 110 ml saline iv
89345697|NCT03710304|Active Comparator|Tranexamic acid plus misoprostol|400 μg misoprostol (2 tablets of 200 μg) or two placebo tablets were given buccally after spinal anesthesia and few minutes before skin incision; then 1 gm TA will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision, plus 500 ml normal saline intravenous solution infusion over 15 min after delivery of the baby
89345698|NCT04454710|Active Comparator|Real Pulsed Radiofrequency|The participant will receive real pulsed radiofrequency for 2 minutes at a frequency of 2 pulses per second (2Hz) while lie in the supine position with their leg of interest partially flexed about 45 degrees and externally rotated. The full procedure will take eight minutes, composed of four sessions of 2 minutes in which the temperature was maintained below 42°C.
89345699|NCT04454710|Sham Comparator|Sham Pulsed Radiofrequency|Identical to the real pulsed radiofrequency, except the participants will only receive the initial 2 seconds of ramp-up, after which the device will switch-off for the rest of the session and will turn-on again at the end of the session.
89345700|NCT05416268|Other|Diopsys NOVA and Diopsys Electrodes|Subjects will receive the PhNR test three times using the Diopsys device and Diopsys Electrodes. Next, subjects will receive the FL Flicker test three times using the Diopsys device and Diopsys Electrodes.
88814349|NCT02994095|Experimental|Single intervention arm|Trained CHAs in Motivational Interviewing in pilot study
88814350|NCT02244242|Experimental|Tamsulosin hydrochloride|modified release capsules
88814351|NCT02244320||functional BPH|patients with functional BPH who switched from phytotherapy to ALNA®
89345701|NCT05416268|Other|Diopsys device with LKC Electrode Arrays|Subjects will receive the PhNR test three times using the Diopsys device with LKC Electrode Arrays, followed by the FL Flicker test three times using the Diopsys device with the LKC electrode arrays.
89345702|NCT05416268|Other|LKC device with the LKC electrode arrays|Subjects will receive the PhNR test three times using the LKC device with the LKC electrode arrays, followed by the FL Flicker test three times using the LKC device with the LKC electrode arrays.
89345703|NCT04454866|Placebo Comparator|Control group|For patients in the control group, a dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron 10 mg, diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
89345704|NCT04454866|Experimental|Single injection group|For patients in this group, a dose of penehyclidine (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
89345705|NCT04454866|Experimental|Continuous infusion group|For patients in this group, a dose of penehyclidine (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
89345706|NCT03790345|Experimental|Experimental group 1|15 subjects will be randomly assigned to adjuvant treatment with 200mg of vitamin B6 (pyridoxine).
89345707|NCT03790345|Experimental|Experimental group 2|15 subjects will be randomly assigned to adjuvant treatment with 2mg of vitamin B12 (cobalamin).
89345708|NCT03790345|Sham Comparator|Placebo oral tablet|15 subjects will be randomly assigned to adjuvant treatment with placebo.
89345709|NCT04901728||Target Population|People living with HIV and following a DTG/3TC drug regimen
89345710|NCT04901728||Control Group on Dual Regimens|The first control population will include a group on dual regimens other than DTG/3TC and a group on triple therapy. In the control group of patients receiving dual therapies, we will include patients (i) on Juluca (DTG/rilpivirine[RPV]), (ii) on boosted darunavir plus lamivudine (DRV/r or DRV/c + 3TC), and (iii) on boosted darunavir plus raltegravir (DRV/r or DRV/c + RAL).
89345711|NCT04901728||Control Group on Triple Regimens|The second control population will include a group on triple regimens including: 2 NRTIs + 1 NNRTI; 2 NRTIs + 1 INSTI, and 2 NRTIs + 1 PI/b.
89345712|NCT05416190|Other|Group/Cohort 1 :|Notion of the presence of lupus anticoagulant (according to ISTH criteria) and whose last test was positive
89345713|NCT05416190|Other|Group/Cohort 2:|Without a previous thrombosis and considered healthy on the basis of the interview and clinical examination. Without coagulation disease.
89345714|NCT05415566|No Intervention|Routine Treatment Group|Inhaler treatment was applied according to the routine procedure in the emergency department.
89345715|NCT05415566|Experimental|Therapeutic Play Group|"Inhaler treatment was applied according to the Therapeutic Play Guide prepared by the researcher."
89345716|NCT03788005|Active Comparator|Intervention group|"Early mobilization as soon as possible, within a maximum of 12 hours post-surgery.~Subdural drains will be closed when the patient is allowed to mobilize and will be open during a nocturnal period of 8 hours. Subdural drains will be removed past 48 hours of surgery."
89345717|NCT03788005|No Intervention|Control Group|Bed rest with head of bed at 0 degrees for 48h. Subdural drains will be removed past 48 hours of surgery.
89345718|NCT04454788|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
89345719|NCT04454788|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
89345720|NCT03339999|Placebo Comparator|Placebo|Placebo-matching AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
89345721|NCT03339999|Experimental|AGN-242428 Higher Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
89345722|NCT03339999|Experimental|AGN-242428 Medium Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
89345723|NCT03339999|Experimental|AGN-242428 Lower Dose|AGN-242428 capsule and placebo-matching AGN-242428 capsule, oral administration, once-daily for up to 12 weeks.
89345724|NCT03784729|Experimental|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted."
89345725|NCT03784729|Sham Comparator|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm.
89345726|NCT03790189|Experimental|Bone Marrow Concentrate|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
89345727|NCT03788161|Experimental|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
89345728|NCT03788161|Placebo Comparator|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
89345729|NCT05174793|Experimental|dehydration to rehydration|subjects were rehydrated following 2% dehydration
88814352|NCT04376450|Experimental|Nonincised Papillae Surgical Approach|Nonincised papillae surgical approach is a papillae preservation technique, where an apical approach is carried out, without incisions or disinsertion of tissues at the level of the papillae or marginal tissues.
89345730|NCT05174793|Experimental|euhydration to dehydration|subjects were dehydrated by 2% with exercise in the heat
89345731|NCT01308931||Tubal ligation|Patients who elect to have tubal ligation
89345732|NCT01308931||Essure|Group that elects to have Essure placement
89345733|NCT01308931||Levonorgestrel IUD|Patients that elect to have a levonorgestrel intra-uterine device placement
88807263|NCT05261048|Experimental|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week.~The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal.~These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between.~Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300.~Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
88807264|NCT05261048|Placebo Comparator|Conventional Physical Therapy|"Patient will perform conventional physiotherapy in form of truncal exercises, which consist of upper and lower part of trunk in spine and sitting position for total 30 minutes and then participants will be asked to take some rest. In supine position, pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
89345734|NCT04510948|Experimental|Intervention (Implementing Patient Priorities Care)|Patient Priorities Care requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences (collectively referred to as health priorities). Participants will be contacted by a trained priorities facilitator in-person or over the phone to elicit their health priorities. This information will be documented in the PPC- GOALS AND PREFERENCES form in the EHR and shared with the clinicians who will then use the Patient Priorities Care approach with patients to inform and guide treatment decisions.
89345735|NCT04510948|No Intervention|Usual Care (Not implementing PPC)|Patients will receive routine clinical care.
89345736|NCT05681403|Experimental|Improved BEAM regimen|The enrolled subjects will received mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine as conditioning regimen for ASCT.
89345737|NCT03784885|Experimental|30 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 30 μg of AD07010
89345738|NCT03784885|Experimental|45 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 45 μg of AD07010
89345739|NCT03784885|Active Comparator|AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine
89345740|NCT04454632|Experimental|Mirror therapy group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the mirror therapy group bilateral exercised with the affected arm behind the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation.
89345741|NCT04454632|Experimental|Visual feedback group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the visual feedback group bilateral exercised by seeing both arms in the mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
89345742|NCT04454632|No Intervention|Control group|The number of participants in this group is anticipated to be 12. In addition to basic treatment, the control group bilateral exercised without a mirror for 10 minutes after every session. Participants in this group perform three exercises as glenohumeral flexion, abduction, and rotation while seeing both arms in the mirror.
89345743|NCT01309009|Experimental|Nepadutant High Dose|
89345744|NCT01309009|Experimental|Nepadutant Low Dose|
89345745|NCT01309009|Placebo Comparator|Placebo|
89345746|NCT04454398|Experimental|COVI-GUARD|COVI-GUARD (STI-1499) administered via a single IV push injection at a dose of 10 mg, 30 mg, 100 mg, or 200 mg, in addition to standard of care
89345747|NCT04454398|Placebo Comparator|Placebo|Placebo administered via a single IV push injection, in addition to standard of care
89345748|NCT04584086|Experimental|MRI 3 Tesla|Patients will be followed by 3 Tesla MRIs during the study
89345749|NCT03339453|Experimental|Nasal Glucagon|Single dose of Nasal Glucagon.
89345750|NCT03339453|Active Comparator|Intramuscular Glucagon|Single intramuscular (IM) dose of Glucagon.
89345751|NCT01306903|Experimental|MECC|Minimal extracorporeal circuit
89345752|NCT01306903|Placebo Comparator|MOPS|
89345753|NCT01306903|Placebo Comparator|Super MOPS|
89345754|NCT04454164|Experimental|PRP group|Intraarticular 5 ml single PRP injection
89345755|NCT04454164|Placebo Comparator|Saline group|Intraarticular 5 ml single saline injection
89345756|NCT04454164|Experimental|Multiple PRP group|Intraarticular 3 dose of 5 ml PRP injection (0, 1, 3 month injection)
89345757|NCT04454164|Placebo Comparator|Multiple saline group|Intraarticular 3 dose of 5 ml saline injection (0, 1, 3 month injection)
89345758|NCT05418686|Experimental|Colchicine-resistant Familial Mediterranean Fever patients|
89345759|NCT01306981|Experimental|Ranibizumab|
89345760|NCT01306981|Placebo Comparator|Saline|
89345761|NCT05418530|Active Comparator|with pause- without pause|Start with an expiratory pause during aspiration and after 6hours the aspiration is performed without an expiratory pause
89345762|NCT05418530|Active Comparator|without pause - with pause|Start without an expiratory pause during aspiration and after 6hours the aspiration is performed with an expiratory pause
89345763|NCT05552157|Experimental|Part 1: Gantenerumab|Active gantenerumab- blinded
89345764|NCT05552157|Placebo Comparator|Part 1: Matching placebo (Gantenerumab)|Matching placebo
89345765|NCT05552157|Active Comparator|Part 2: Gantenerumab Open Label|Open label will start after last dose of Part 1
89345766|NCT05076799|Active Comparator|3 L Polyethylene glycol solution group|The participants were instructed to consume 3000 mL of PEG solution
89345767|NCT05076799|Experimental|100 ml lactulose combined with 1 L PEG group|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
89345768|NCT05076799|Experimental|100 ml lactulose combined with 2 L PEG group|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
89345769|NCT05076799|Experimental|200 ml lactulose group|the participants were instructed to consume 200 ml lactulose
89345770|NCT03784495|Placebo Comparator|Placebo (P)|Placebo.
89345771|NCT03784495|Experimental|Melatonin (M)|1 mg/day of melatonin.
89345772|NCT03784495|Experimental|Essential Aminoacids (eAA)|4 g/day of essential aminoacids
89345773|NCT03784495|Experimental|Essential Aminoacids + Melatonin (eAAM)|4 g/day of essential aminoacids and 1 mg/day of melatonin
89345774|NCT03045068|Experimental|Study Group|"Platelet Transfusion Management~Pre-Termination of CPB- Platelet Transfusion 10ml/kg to be administered to the patient via central venous access when the patient has been rewarmed to 35*C, (the Sano or BT shunt clip is still on in children with SV physiology)~Post CPB- Platelet transfusion 10ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
89345775|NCT03045068|Active Comparator|Control Group|"Platelet Transfusion Management~Pre-Termination of CPB- No intervention~Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
89345776|NCT05581537|Experimental|Study group (GA)|receive systematic desensitization in addition to goal directed paradigm for eight weeks, Three sessions per week (1hour and half)
89345777|NCT05581537|Experimental|Control group (GB)|receive goal directed paradigm for eight weeks, Three sessions per week (45 minutes)
89345778|NCT02525510|Active Comparator|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.
89345779|NCT02525510|Active Comparator|Pump Eligible - Hypothermia and Pump Right Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.
89345780|NCT02525510|Active Comparator|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
89345781|NCT02525510|Active Comparator|Not Pump Eligible - Normothermia|Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.
89345782|NCT02525510|Active Comparator|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
89345783|NCT03905746||acute decompensation group|patients admitted within 48 hours for acute decompensation of cirrhosis, with or without evidence of sepsis
89345784|NCT03905746||Pathological control group|patients with Chronic Liver Disease (CLD), also named stable cirrhotic patients, without any admission in the last 6 months for an acute event
89345785|NCT02318264|Experimental|Distal to Proximal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting distal by knee and ending proximal by hip.
89345786|NCT02318264|Experimental|Proximal to Distal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting proximal by hip and ending distal by knee.
89345787|NCT01568372|Experimental|Nurse telephone follow-up|This group received a telephone follow-up by a nurse following discharge from the hospital and up until the 10th postoperative day, which is considered as the usual period of healing for a tonsillectomy
89345788|NCT01568372|No Intervention|Standard care group|This group received the standard care which consisted of an informative session before discharge and no follow-up once discharged home.
89345789|NCT03784573|Active Comparator|Dog + handler|
89345790|NCT03784573|Placebo Comparator|No dog|
89345791|NCT03632018|Active Comparator|Standard Cardiac Rehabilitation|Participants in the STANDARD condition will receive the standard of care cardiac rehabilitation, consisting of 36 sessions across 12 weeks of prescribed, supervised exercise sessions.
89345792|NCT03632018|Experimental|HEART-PLAY|Participants in the HEART-PLAY will receive standard CR and additionally receive pedometers, resistance bands, and the National Institute of Aging (NIA) exercise guide. They will further receive counseling from peer health coaches, social support from group education sessions, and supplemental educational materials. After the 12 weeks of prescribed, supervised exercise sessions, HEART-PLAY group participants will continue to receive support from peers and clinic staff with check-in calls, feedback on pedometer goals, and twice weekly group events including walks and/or resistance band group exercise classes.
89345793|NCT01307137|Experimental|Telehealth (TAP)|
89345794|NCT01307137|Experimental|Peer-led care (PC)|
89345795|NCT03575156|Experimental|Systemic lupus erythematosus (SLE)|
89345796|NCT03575156|Experimental|systemic scleroderma (SSc)|
89345797|NCT03790423|Experimental|18F-ASIS PET|One injection of 18F-ASIS (app. 200 MBq) followed by 3 PET/CT scans 1 hour, 2 hours and 4hours post-injection
89345798|NCT02226536|Placebo Comparator|control|Usual diet without any orientation
89345799|NCT02226536|Active Comparator|fractioned diet without glucose|Fractioned diet without glucose
89345800|NCT05234697||Morning group|Surgery performed during 08:00 to 12:00
89345801|NCT05234697||Afternoon group|Surgery performed during 14:00 to 18:00
89345802|NCT03784807||Infected|Patients with prosthetic joint or osteoarticular infection
89345803|NCT03784807||Not infected|Patients with implant failure not due to infection
89345804|NCT03790033|Experimental|UCHA group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Shinhwa Pharmaceutical company
89345805|NCT03790033|Placebo Comparator|Placebo group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Tsumura Co., Tokyo, Japan
89345806|NCT02133404|Experimental|ASP7991 group|receiving ASP7991 and Cinacalcet-placebo
89345807|NCT02133404|Active Comparator|Cinacalcet group|receiving Cinacalcet and ASP7991-placebo
89345808|NCT05167305||liver disease without COVID-19 infection-April-May 2019|
89345809|NCT05167305||liver disease without COVID-19 infection -April- May 2021|
89345810|NCT01307215|Experimental|20mLs of 0.5% ropivacaine per side|
89345811|NCT01307215|Experimental|30mLs of 0.33% ropivacaine per side|
89345812|NCT01307215|Experimental|40mLs of 0.25% ropivacaine per side|
89345813|NCT02015936|Experimental|Prescriped Physical Activity|Physical fitness evaluation followed by prescribed physical activity and progress reporting.
89345814|NCT05574751|Active Comparator|Titanium tacker group (n=30)|Group A
89345815|NCT05574751|Active Comparator|Polypropylene group (n=30)|Group B
89345816|NCT05227365|Other|Single Treatment Arm Study|The Lenire device is a CE marked medical device intended to reduce the symptoms of tinnitus. It comprises a handheld controller, an intra-oral device called a Tonguetip that delivers gentle electrical stimulation to the tongue, and a set of wireless headphones that deliver audio stimulation to the ears. The sound and tongue stimulation are configured and calibrated to individual participant hearing and sensation characteristics during the initial fitting procedure completed by a trained clinician. The participants will receive 12 weeks of treatment, in which the first 6-weeks will consist of sound-only stimulation (PS6-No ETS) and the second 6-weeks will consist of bimodal stimulation (PS6, includes sound and tongue stimulation).
89345817|NCT01307293|Experimental|Cognitive Behavior Therapy|6-12 sessions of Cognitive Behavior Therapy to address PTSD symptoms and parenting issues related to premature infants.
89345818|NCT01307293|No Intervention|Placebo comparison|Education regarding NICU parenting issues.
89345819|NCT03420794|Active Comparator|Control Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once just prior to surgery.
89345820|NCT03420794|Experimental|Study Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once 3-4 hours prior to surgery.
89345821|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, fasted)|
89345822|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, after high fat meal)|
89345823|NCT01568450|Active Comparator|Oxycontin CR 10mg (Oxycodone 10mg, fasted)|
89345824|NCT05144139|Experimental|Low dose group with mRNA vaccine|25μg with COVID-19 mRNA vaccine
89345825|NCT05144139|Placebo Comparator|Low dose group with placebo|Low dose group with placebo
89345826|NCT05144139|Experimental|High dose group with mRNA vaccine|45μg with COVID-19 mRNA vaccine
89345827|NCT05144139|Placebo Comparator|High dose group with placebo|High dose group with placebo
89345828|NCT05279222|Experimental|gait training|
88807265|NCT05260580|Experimental|Two-hour sessions per week for 18 weeks|The classroom learning of study subjects and clinical care experience of in-service students are both very important in this intervention course. The teaching method will primarily focus on empowerment strategies, with support from the school's digital action learning platform for teaching-related activities.
88811808|NCT01503749|Experimental|Infusion of the mobilized monocyte cells|"G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells~. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance."
89345829|NCT05546073|No Intervention|Control - Usual Care|Participants in the control-arm will undergo usual care. This covers clinical inspection, vital parameters (respiratory rate(breaths/min), saturation (%), blood pressure (mmHg), heart rate (beats/min), body temperature (celsius), and Glasgow Coma Scale) , and point-of-care blood-test for CRP and haemoglobin
89345830|NCT05546073|Experimental|Intervention - Advanced point-of-care technology|Participants in the intervention-arm will undergo usual care as well as advanced point-of-care technology.
89345831|NCT03784339|Placebo Comparator|Physiotherapy|Participants will receive standard physiotherapy care, which will involve strength exercises and taping.
89345832|NCT03784339|Experimental|Physiotherapy + education|Physiotherapy + education Standard physiotherapy care plus 30 minute education session addressing fear of movement and catastrophizing thoughts.
89345833|NCT05141409||CAD-A|
89345834|NCT05141409||CAD-B|
89345835|NCT03700606|Active Comparator|Nasal CPAP - Period 1|"Eligible infants stable on high flow nasal cannula (nCPAP) therapy of 5-7 cm H20 achieved with a ventilator, an underwater bubble system, or a variable-flow device will be enrolled. A data acquisition cart will be placed at the subject's bedside to collect hemodynamic and respiratory parameters measured including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices. A neonatal chest belt, sized to the infant's chest circumference (nipple level) using warmed ultrasound gel applied to the belt beforehand, will collect regional lung volume measurements using electrical impedance tomography (EIT). Subject video recording will capture apnea events and the interventions used to resolve them such as positive pressure ventilation, repositioning, or stimulation. Data will be collected for 15 minutes on nCPAP."
89345836|NCT03700606|Active Comparator|High Flow Nasal Cannula (HFNC) - Period 2 & 3|Respiratory support will be crossed over to a HFNC Optiflow Jr 2 (Fisher & Paykel Healthcare, Auckland, New Zealand) at a flow rate of 8 LPM. The size of the nasal cannula will be determined according to the manufacturer's instructions in order to maintain a leak at the nares. Identical data collection will occur for two 15 minute periods on HFNC, at the beginning and end of the six hour Study period.
89345837|NCT03700606|Active Comparator|Nasal CPAP - Period 4|After 6 hours of HFNC of 8 LPM, or sooner if the infant meets failure criteria, the infant will then be crossed back to the nCPAP device and at the settings previously utilized in Study Period 1. The infant will remain on the nCPAP device with identical data collection for 15 minutes. The total duration of the study and data collection will be 8 hours. The infant's body position will be similar for each lung volume measurement during the study periods.
89345838|NCT03784105|Experimental|Codeine|
89345839|NCT03784105|Placebo Comparator|Siripus simplex|
89345840|NCT05044689||Colorectal Cancer (Cases)|Based on the existing ARGO (African Colorectal Cancer Group) platform where a current colorectal cancer study is going on, 400 patients with a prior diagnosis and a new diagnosis will be recruited into this study.
89345841|NCT05044689||Controls|We will select our 400 controls from two groups of participants who are free of cancer and gastrointestinal diseases. First, we will leverage community mobilization groups to identify and recruit a target group of 200 community-based population controls. Second, we will identify and recruit the remaining 200 controls from those seeking care in the Outpatient Health Center at OAU, which sees ~50-60 patients per day as part of routine care.
89345842|NCT03784183|Experimental|moderate AD-experimental|Experimental Intervention: The CS shall be carried out in groups (5-7 participants), twice a week. Each session lasts 90 minutes. CS sessions begin with a training for temporal and spatial orientation in which participants are asked to recognize and recall the date and the place with the help of some environmental aids (calendars, clocks, pictures and maps). Then the participants complete an array of cognitive tasks for memory, attention, language, visuo-spatial functions and executive functions. These tasks range from individual paper-and-pencil exercises to verbal-learning exercises that have to be solved by the group.
89345843|NCT03784183|Experimental|mild AD-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
89345844|NCT03784183|Experimental|MCI-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
89345845|NCT03784183|No Intervention|moderate AD-placebo|
89345846|NCT03784183|No Intervention|mild AD-placebo|
89345847|NCT03784183|No Intervention|MCI-placebo|
89345848|NCT05177445|Experimental|Intervention group with phototherapy|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction ) positive for coronavirus-19 will receive the phototherapy intervention. It consists of the introduction of the nasal probe of the phototherapy device in the nasal cavity of the patient. A mixture of ultraviolet light A, ultraviolet light B and red light will be applied between 2 and 3 minutes. The patient will receive a maximum of 10 interventions. Furthermore both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
89345849|NCT05177445|Active Comparator|Intervention group (corticosteroids + OT) without Phototherapy|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
89345850|NCT04563884||Patients with deafness|Patients aged 12 months to 17 years with deafness
89345851|NCT04563884||Controls|Normal-hearing patients aged 12 months to 17 years
89345852|NCT03784261|Active Comparator|SAR, usually subucutaneous injection every 2 weeks|
89345853|NCT03784261|Active Comparator|TCZ, usually subucutaneous injection every 2 weeks|
89345854|NCT03784261|Active Comparator|ABT, usually subucutaneous injection every week|
89345855|NCT02989402|Experimental|Rivastigmine patch|15 cm2 patch sizes loaded with 27 mg of rivastigmine
89345856|NCT01309321|Experimental|Perinatal Handwashing Intervention Arm|
89345857|NCT01309321|Active Comparator|Neonatal Health Promotion|
89345858|NCT02861950|Active Comparator|Caudal block|Patients will receive a caudal block with 0.75-1ml/kg of 0.2% ropivacaine.
89345859|NCT02861950|Active Comparator|Penile Nerve Block|Patients will receive a dorsal penile nerve block with up to 0.75ml/kg of 0.25% bupivacaine.
89345860|NCT05681247|Experimental|ezetimibe tablet|ezetimibe tablet test formulation at a single dose of 10 mg
89345861|NCT05681247|Active Comparator|ezetimibe tablet(Ezetrol ®)|ezetimibe tablet reference formulation at a single dose of 10 mg
89345862|NCT03787927|Other|5 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 5 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~The first 20 participants who complete the study will be randomized to this arm or '5 day RTP, then 5 day CSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
89345863|NCT03787927|Other|5 day RTP, then 5 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 5 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~The first 20 participants who complete the study will be randomized to this arm or '5 day CSP, then 5 day RTP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
89345864|NCT03787927|Other|5 day RTP, then 10 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 10 day autologous CSP (cold-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
89345865|NCT03787927|Other|5 day RTP, then 15 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 15 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
89345866|NCT03787927|Other|10 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 10 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
89345867|NCT03787927|Other|15 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 15 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
89345868|NCT05681169|Experimental|School-based HPV-counselling and HPV-vaccination|640 pupils
89345869|NCT05681169|No Intervention|Control group|The control population will be approximately 2560 children comparable in age and regions in Denmark with similar high concentration of ethnic minority populations.
89345870|NCT02374450||Active surveillance group and enhanced hospitalisation group|Children <18 months of age at time of enrolment and living in the HDSS area (active surveillance group) and children <5 years of age and hospitalised at any time during the study, living in the HDSS area (enhanced hospitalisation surveillance group).
89345871|NCT01307371||Diabetes|Patients with diabetes.
89345872|NCT01307371||non-diabetes|Patients without diabetes.
89345873|NCT00602576|Experimental|Arm A|Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
89345874|NCT00602576|Experimental|Arm B|Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33.
89345875|NCT00602576|Experimental|Arm C|Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
89345876|NCT00602576|Experimental|Arm D|Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33.
89345877|NCT04500171|Active Comparator|English Original Assessment Tools|Short-Test of Functional Health Literacy in Adults ColoCARE Instruction Sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
89345878|NCT04500171|Active Comparator|Samoan Original Assessment Tools|Samoan Short-Test of Functional Health Literacy in Adults ColoCARE Instruction sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
89345879|NCT04500171|Experimental|English Modified Assessment Tools|Short-Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
89345880|NCT04500171|Experimental|Samoan Modified Assessment Tools|Samoan Short Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
89345881|NCT03359850|Experimental|Normal hepatic function (Group 1):|To evaluate the pharmocokinetics and safety of niraparib
89345882|NCT03359850|Experimental|Moderate hepatic impairment (Group 2):|To evaluate the pharmocokinetics and safety of niraparib
89345883|NCT01306123|Experimental|Nascobal nasal spray (cyanocobalamin USP)|One single administration of intranasal cyanocobalamin (initially)
89345884|NCT01306123|Active Comparator|Vitamin B12-ratiopharm N, injection solution|One single injection of IM cyanocobalamin (initially)
89345885|NCT03787459|Active Comparator|oseltamivir plus placebo|
89345886|NCT03787459|Experimental|oseltamivir plus arbidol|
89345887|NCT04930432|Experimental|MCLA-129|In the dose escalation phase 1 part, MCLA-129 will be administered every two weeks with increasing doses to patients with advanced solid tumors. In Part 2, patients with NSCLC and other advanced solid tumors in each corhort will be dosed with MCLA-129 every two weeks at the RP2D.
89345888|NCT05405504||ICU part|Acute heart failure patients with Swan-Ganz catheter and an arterial catheter.
89345889|NCT05405504||Out-patient part|Chronic heart failure patients with CardioMEMS.
89345890|NCT03710226||cases|women with recurrent miscarriage (two or more consecutive miscarriages)
89345891|NCT03710226||controls|women without recurrent miscarriage and delivered at least once before
89345892|NCT05683080||Achilles Tendon Rupture|Individuals who have experienced an Achilles tendon rupture and presented to the Achilles tendon rupture clinic.
89345893|NCT03620994||Irritable Bowel Syndrome|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an JiaoTong University, Xijing Hospital ,Tangdu Hospital or affiliated hospital of Northwest University received investigation. Patients who participate in the study are determined on their own initiative, with full understanding and informedness.
89345894|NCT04644328|Experimental|High-Intensity Treatment Arm|"Treatment: Individuals received approximately 3 Facebook ads over a 2-week period. Each ad contained a short video recorded by a physician using a script that discusses staying safe during the holidays by considering not traveling and using a mask when appropriate.~Randomization to treatment: The 13 states which centrally report COVID-19 cases at the ZCTA level contained 829 counties. At Thanksgiving, 9 counties were excluded due to data limitations. At Christmas, 62 counties were excluded due to data limitations and potential negative impacts in rural, conservative areas resulting from polarization in the wake of the 2020 presidential election. Approximately half of the counties were randomized to high-intensity treatment with the remaining randomized to low-intensity treatment. In high-intensity counties, 3/4 of ZCTAs were treated (i.e., Facebook users in those ZCTAs received ads) and 1/4 were not. In low-intensity counties, 1/4 of ZCTAs were treated and 3/4 were not."
89345895|NCT04644328|No Intervention|Low-Intensity Control Arm|"Control: Individuals did not receive ads containing short physician-recorded videos.~Randomization to treatment: The 13 states which centrally report COVID-19 cases at the ZCTA level contained 829 counties. At Thanksgiving, 9 counties were excluded due to data limitations. At Christmas, 62 counties were excluded due to data limitations and potential negative impacts in rural, conservative areas resulting from polarization in the wake of the 2020 presidential election. Approximately half of the counties were randomized to high-intensity treatment with the remaining randomized to low-intensity treatment. In high-intensity counties, 3/4 of ZCTAs were treated (i.e., Facebook users in those ZCTAs received ads) and 1/4 were not. In low-intensity counties, 1/4 of ZCTAs were treated and 3/4 were not."
89345896|NCT03130660|Experimental|Short Axis Ultrasonography|one person does both ultrasound and line insertion
89345897|NCT03130660|Experimental|Long Axis Ultrasonography|one person does ultrasound and another inserts the central line
89345898|NCT03130426|Experimental|Intervention|Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise
89345899|NCT03130426|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
89345900|NCT00114140|Experimental|Temozolomide + Radiation Therapy (RT)|Daily temozolomide plus concurrent radiotherapy followed by temozolomide
89345901|NCT03130582||Disease status at mobilization PR|
89345902|NCT03130582||Disease status at mobilization PD|
89345903|NCT03605524|Other|Sensory training|"Sensory (Olfactory or visual) training will be done at home for 12 weeks.~The effect of the training will be evaluated using an experimental protocol includes (i) clinical and psychometric evaluations, (ii) the study of olfactory perception using Sniffin' Sticks Test and (iii) the study of the emotional perception using the subjective Sense'n Feel method and the objective measurement of the spontaneous pupillary dilatation."
89345904|NCT04752540|Experimental|Mild hepatic impairment|120 mg olorofim
89345905|NCT04752540|Experimental|Moderate hepatic impairment|60 to 120 mg olorofim
89345906|NCT04752540|Active Comparator|Normal hepatic function|120 mg olorofim
89345907|NCT03371030|Experimental|Pronator quadratus reparation|Surgical Intervention: Radius fracture teated with plate and pronator quadratus muscle repair.
89345908|NCT03371030|Active Comparator|No pronator quadratus reparation|Surgical Intervention: Radius fracture with plate without pronator quadratus muscle repair.
89345909|NCT04341454|Experimental|DWP14012 X mg QD|"Morning: 1 tablet of DWP14012 X mg + 1 tablet of DWP14012 Y mg placebo~Evening: 1 tablet of DWP14012 Y mg placebo"
89345910|NCT04341454|Experimental|DWP14012 Y mg BID|"Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg~Evening: 1 tablet of DWP14012 Y mg"
89345911|NCT04341454|Placebo Comparator|placebo|"Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg placebo~Evening: 1 tablet of DWP14012 Y mg placebo"
89345912|NCT01567982|Experimental|smokers and nonsmokers|both smokers and nonsmokers will receive same tDCS
89345913|NCT03712345|Experimental|IFX-1 low dose|Will receive IFX-1 low dose regimen diluted in sodium chloride solution
89345914|NCT03712345|Experimental|IFX-1 high dose|Will receive IFX-1 high dose regimen diluted in sodium chloride solution
89345915|NCT03712345|Placebo Comparator|Placebo|Will receive placebo
89345916|NCT04659538|Experimental|CAPTIS Embolic Protection|TAVR will be performed according to standard institutional practice under local or general anesthesia by the transfemoral approach. The investigational device will be advanced and deployed across the aortic arch covering the ostia of the 3 great vessels (innominate, left carotid, and left-subclavian arteries) at the initiation of the procedure and withdrawn at the completion of the TAVR procedure.
89345917|NCT05420870|Experimental|Exercise group|
89345918|NCT05420870|No Intervention|Usual care group|
89345919|NCT05222230|Experimental|FFP3 Respirator|Participants will wear FFP3 respirators during the study.
89345920|NCT05420792|Active Comparator|intervention group|Peplau Interpersonal Relations based IPSRT will be applied to the intervention group
89345921|NCT05420792|No Intervention|control group|the control group will be given a Community Mental Health Center and will also continue the treatment
89345922|NCT03130348|Experimental|Treatment (ibrutinib, bortezomib, dexamethasone)|Patients receive ibrutinib PO QD on days 1-28. After 3 courses, patients who achieve partial response repeat treatment every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who do not achieve partial response after 3 courses continue receiving ibrutinib PO QD on days 1-28. Beginning at course 4, patients who do not achieve partial response also receive bortezomib SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
89345923|NCT03789955|Experimental|Fluoroscopic-guided TEB|After assessment of the epidural space using the loss of resistance technique with air under fluoroscopic guidance, six fluoroscopic views will be obtained: true anteroposterior, contralateral oblique (CLO) at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral for comparison CLO view with lateral view.
89345924|NCT03358290|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
89345925|NCT03358290|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
89345926|NCT03358290|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
89345927|NCT03358290|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
89345928|NCT03358290|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
89345929|NCT05091710|Experimental|Follow up care program for HF patients|Discharged HF patients in rural Haiti will be receive a follow-up care program delivered by trained community health workers (CHWs).
89345930|NCT05091710|Other|Standard of care|Historical reference group who received standard of care for HF identified prior to CHW training.
89345931|NCT05069701|Experimental|Healthy volunteers|SVV test will be done.
89345932|NCT05439928|Experimental|DEXCOM G6 CGM|Continuous glucose monitoring by DEXCOM G6 (glucose monitoring device) in a step-down unit in participants with DKA
89345933|NCT05439928|No Intervention|Hourly Finger Stick Point of Care (Historical Control)|Retrospective chart review of DKA patients that received hourly glucose monitoring by finger stick while in the ICU
89345934|NCT03789799|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
89345935|NCT03789799|Placebo Comparator|Placebo|From the first postoperative day for ten days, single vaginal capsule per day of sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
89345936|NCT01309399|Active Comparator|teriparatide|six weeks of teriparatide
89345937|NCT01309399|Placebo Comparator|placebo|placebo identical in appearance to teriparatide
89345938|NCT03187444|Experimental|Patients with chronic inflammatory rheumatism|All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included.
89345939|NCT05682924||Study group|35 patients with ph-positive chronic myeloid leukemia in the chronic phase, aged 40 to 60 years, receiving bosutinib at a dose of 500 mg / day
89345940|NCT05682924||Comparison group|35 patients with ph-positive chronic myeloid leukemia in the chronic phase, aged 40 to 60 years, receiving nilotinib at a dose of 800 mg / day
89345941|NCT05682924||Control group|35 patients with ph-positive chronic myeloid leukemia in the chronic phase, aged 40 to 60 years, receiving imatinib at a dose of 600 mg / day
89345942|NCT03789643|Experimental|JTT-251 Dose 1|One dose of study drug by mouth daily for 24 weeks
89345943|NCT03789643|Experimental|JTT-251 Dose 2|One dose of study drug by mouth daily for 24 weeks
89345944|NCT03789643|Experimental|JTT-251 Dose 3|One dose of study drug by mouth daily for 24 weeks
89345945|NCT03789643|Placebo Comparator|Placebo|One dose of study drug by mouth daily for 24 weeks
89345946|NCT03710070|Experimental|Intervention|In the presence of a significant coronary artery stenosis and randomization to the intervention group: Catheter-based permanent occlusion of the ipsilateral (to the culprit coronary lesion) IMA will be performed at the projected height of inferior vena cava confluence and right atrium using a dedicated occlusion device (Amplatzer vascular plug 4, CE0086).
89345947|NCT03710070|Sham Comparator|Sham-Control|In the presence of a significant coronary artery stenosis, and randomization to the sham-procedure: IMA will be selectively intubated using an appropriate catheter. Angiography of the IMA and the pericardiacophrenic branch will be performed.
89345948|NCT01309477|Experimental|ADVAGRAF|All subjects in the study will take the Tacrolimus Sustained-release Capsules (ADVAGRAF) orally at the basis of low dose prednisone treatment
89345949|NCT05598554|Experimental|Study Group|chair-based yoga program with tele-rehabilitation was applied to elderly people.
89345950|NCT05598554|Active Comparator|Control Group|1 session of training was given on the effect of physical activity and exercise on function and quality of life.
89345951|NCT05439304||Care staff|
89345952|NCT05439304||Residents|
89345953|NCT05439304||Family members|
89345954|NCT01568762|Experimental|VAK694|VAK694 was administered as a 1 hour intravenous infusion
89345955|NCT01568762|Placebo Comparator|VAK694 Placebo|VAK694 placebo was administered as a one hour intravenous infusion
89345956|NCT01568762|Experimental|QAX576|QAX576 was administered intravenously as a 2 hour infusion
89345957|NCT01568762|Placebo Comparator|QAX576 placebo|QAX576 placebo was administered as a 2 hour intravenous infusion
89345958|NCT03789565||Group 1. Healthy individuals from periodontal perspective:|GI < 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
89345959|NCT03789565||Group 2. Individuals diagnosed with Gingivitis|GI > 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
89345960|NCT03789565||Group 3. Individuals diagnosed with CP|GI > 1, PD ≥ 5 mm, CAL ≥ 3 mm, with apparent bone loss on radiography.
89345961|NCT03789487|Experimental|Non-responders to CRT|Non-responders to CRT who will undergo an electrical optimization of the settings of their device
89345962|NCT05191212|Experimental|Experimental injection|Cervical indocyanine green injections until real-time visualization of the afferent lymphatic channels bilaterally.
89345963|NCT05191212|Active Comparator|Standart injection|Cervical indocyanine green injections group
89345964|NCT05066126|Experimental|High-Mixed Presentation / Current Smoker|Current smokers receive a social media feed with a high-mixed presentation of content.
89345965|NCT05066126|Experimental|Low-Mixed Presentation / Current Smoker|Current smokers receive a social media feed with a low-mixed presentation of content.
89345966|NCT05066126|Experimental|High-Mixed Presentation / Former Smoker|Former smokers receive a social media feed with a high-mixed presentation of content.
89345967|NCT05066126|Experimental|Low-Mixed Presentation / Former Smoker|Former smokers receive a social media feed with a low-mixed presentation of content.
89345968|NCT03783637|Other|Whole Grain Oat|Volunteers will consume a breakfast meal containing whole grain oats after 7 days of a whole grain free diet.
89345969|NCT03783637|Other|Whole Grain Wheat|Volunteers will consume a breakfast meal containing whole grain wheat after 7 days of a whole grain free diet.
89345970|NCT03089216|Experimental|Combined Bleaching(2x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
89345971|NCT03089216|Experimental|Combined Bleaching(2x20) with arginine|Combined Bleaching(2x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
89345972|NCT03089216|Experimental|Combined Bleaching(1x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
89345973|NCT03089216|Experimental|Combined Bleaching(1x20) with arginine|Combined Bleaching(1x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
89345974|NCT03783793|Experimental|Mindfulness Training App|
89345975|NCT03783793|Active Comparator|Cognitive Training With 2048|
89345976|NCT03783481|Experimental|Mobile community group|join the mobile community via the smartphone application
89345977|NCT03783481|Active Comparator|No community group|
89345978|NCT03339726|Experimental|New Formulation Phenylephrine HCl|
89345979|NCT03339726|Active Comparator|Marketed Phenylephrine HCl|
89345980|NCT03339726|Placebo Comparator|Placebo|
89345981|NCT05438368|Experimental|bi-4SCAR-GD2/CD70 T Cell Therapy for GD2 and/or CD70 positive tumor|
89345982|NCT05669131|Experimental|Motor Imagery Training|Participants will do motor imagery training in 5 minute blocks for a total of 20 minutes.
89345983|NCT05669131|No Intervention|Control|Participants will watch a documentary in 5 minute blocks for a total of 20 minutes.
89345984|NCT02951494|Active Comparator|AlterG Anti-gravity treadmill|cont. aerobic exercise training with lower body weight support
89345985|NCT02951494|No Intervention|Exercise without body weight support|cont. aerobic exercise training without lower body weight support
89345986|NCT03787225|Experimental|NNC0174-0833 (0.3 mg)|Participants will receive single dose of NNC0174-0833
89345987|NCT03787225|Experimental|NNC0174-0833 (0.9 mg)|Participants will receive single dose of NNC0174-0833
89345988|NCT03787225|Experimental|NNC0174-0833 (1.8 mg)|Participants will receive single dose of NNC0174-0833
89345989|NCT03787225|Placebo Comparator|Placebo (NNC0174-0833)|Participants will receive placebo (NNC0174-0833)
89345990|NCT02900326|Placebo Comparator|Control patients with no intervention|group without intervention
89345991|NCT02900326|Experimental|Endurance training program (8 weeks) group|only physical training group
89345992|NCT02900326|Experimental|MBSR group (mindfulness-based-stress-reduction)|only mental training group (8 weeks)
89345993|NCT02900326|Experimental|Endurance training program combined with MBSR sessions|Endurance training program combined with MBSR sessions, during 8 weeks (mindfulness-based-stress-reduction)
89345994|NCT03339297|Experimental|Defibrotide Prophylaxis|Standard of Care Immunoprophylaxis + Defibrotide
89345995|NCT03339297|Active Comparator|Standard of Care|Standard of Care Immunoprophylaxis Alone
89345996|NCT03789331||Transgender Male individuals|"Group Description: This group consists of transgender male individuals who come to the gynecology clinic for medico-legal evaluation before the sex reassignment surgery.~Intervention: Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
89345997|NCT03789331||Normal healthy female individuals|"Group Description: Healthy women with normal sexual orientation.~Intervention: (The same) Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
89345998|NCT05434624|Experimental|Group M|Bronchoscopy group in which only midazolam will be used
89345999|NCT05434624|Experimental|Group P|Bronchoscopy group in which midazolam and propofol will be used
89346000|NCT01309633|Experimental|Arm A|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
89346001|NCT01309633|Experimental|Arm B|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
89346002|NCT01309633|Experimental|Arm C|Arm C Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
89346003|NCT01309633|Experimental|Arm D|Arm D Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
89346004|NCT03001310|Experimental|Biological-Low dose AAV - CNGB3|Subretinal administration of a single low dose of AAV - CNGB3
89346005|NCT03001310|Experimental|Biological-Medium dose AAV - CNGB3|Subretinal administration of a single intermediate dose of AAV - CNGB3
89346006|NCT03001310|Experimental|Biological-High dose AAV - CNGB3|Subretinal administration of a single high dose of AAV - CNGB3
89346007|NCT04686487|Other|Stereotactic Ablative Radiotherapy|Stereotactic body radiation therapy delivered to the thick heart muscle at the point of obstruction
89346008|NCT04974788|Active Comparator|Low Intensity Respiratory Muscle Training Group|Low intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
89346009|NCT04974788|Active Comparator|Medium Intensity Respiratory Muscle Training Group|Medium intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
89346010|NCT04974788|Active Comparator|High Intensity Respiratory Muscle Training Group|High intensity respiratory muscle training will be applied to those with chronic obstructive pulmonary disease. Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength.
89346011|NCT03783559|Experimental|Arm A|TACE plus chemotherapy ± target therapy
89346012|NCT03783559|Active Comparator|Arm B|chemotherapy ± target therapy
89346013|NCT03783247|Experimental|FIB|hip fracture with fascia Iliaca block
89346014|NCT03783247|Experimental|PENG|Hip fracture with Pericapsular nerve group block
89346015|NCT05225571||cervical myofascial pain syndrome|The participants who diagnosed as cervical myofascial pain syndrome aged 18-64 years. The pain must last at least 3 months.
89346016|NCT05580757||Pharmacists and pharmaceutical technical assistants (FTA)|Dutch-speaking Belgian public pharmacists or pharmaceutical technical assistants (FTA)
89346017|NCT05215431||systemic sclerosis group|Patients with established diagnoses of systemic sclerosis and periodontitis
89346018|NCT05215431||periodontitis group|Systemically healthy periodontitis patients
89346019|NCT05228028|Experimental|fascia iliaca compartement block [FICB] group|
89346020|NCT05228028|Experimental|quadratus lumborum block [QLB] group|
89346021|NCT03713281|Experimental|Test Lens|Subjects between the ages 40 to 70 years of age and who are adapted contact lens wearers with astigmatism in both eyes will be assigned to the same Test Lens according to the lens wear schedule.
89346022|NCT05176782|Active Comparator|Group A (HTK cardioplegia)|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
89346023|NCT05176782|Active Comparator|Group B ( Cold Cardioplegia)|will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
89346024|NCT03706950||Elpida® + 2 NRTIs|Elpida® 20mg qd in the first line of therapy for HIV-1 infected patients with a background standard ART.
89346025|NCT03339219|Experimental|Cabozantinib 60 mg|Cabozantinib 60 mg, tablet, orally, once daily (QD) in the fasted state until unacceptable toxicity or need for subsequent systemic anticancer treatment up to 2.5 years.
89346026|NCT03706872|Experimental|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care.
89346027|NCT03706872|No Intervention|Control Group|Provision of usual prenatal care
89346028|NCT01310647|Experimental|Testosterone|Transdermal testosterone (20µg/day) from day 24 of the previous cycle until day 2 of the ICSI cycle
89346029|NCT01310647|Experimental|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
89346030|NCT01310647|Experimental|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI~Estradiol valerate 4 mg/day during 10 days, starting the second day of the cycle prior to the ICSI cycle."
89346031|NCT05682768||Patients|Patients with cancer pancreas with soft pancreas and non-dilated pancreatic duct
89346032|NCT01560715|Experimental|Experimental: Test group|Retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200 or visual field less than 20 degrees
89346033|NCT05176236|Experimental|Pictographic group|Participants received the pictographic handouts on tracheostomy care
89346034|NCT05128968|Experimental|Simple extension|After induction of anesthesia, endotracheal intubation was performed in simple extension without a pillow using a McGrath MAC videolaryngoscope.
89346035|NCT05128968|Experimental|Head elevated position|After induction of anesthesia, endotracheal intubation was performed in a head elevated position with a pillow using a McGrath MAC videolaryngoscope.
89346036|NCT05128968|Experimental|Sniffing position|After induction of anesthesia, endotracheal intubation was performed in a sniffing position using a McGrath MAC videolaryngoscope.
89346037|NCT03338673|Experimental|Dual Therapy First|Participants receive 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises (BrainHQ), followed by 10 hours of computerized cognitive exercises alone
89346038|NCT03338673|Experimental|Mono Therapy First|Participants complete 10 hours of computerized cognitive exercises (BrainHQ) alone, followed by 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises
89346039|NCT01310881|Experimental|Dose 1|
89346040|NCT01310881|Experimental|Dose 2|
89346041|NCT01310881|Experimental|Dose 3|
89346042|NCT01310881|Experimental|Dose 4|
89346043|NCT01310881|Experimental|Dose 5|
89346044|NCT01310881|Experimental|Dose 6|
89346045|NCT01310881|Experimental|Dose 7|
89346046|NCT03782389||Elite football players aged 16-40 years|
89346047|NCT03708081||Group 1|Root canal treatments will be completed by ProTaper Next instruments with rotational motion
89346048|NCT03708081||Group 2|Root canal treatments will be completed TF Adaptive instruments with adaptive motion.
89346049|NCT04477161|Experimental|Ketone Intervention|Subjects will take the Ketone Ester Elite Endurance Nutrition Drink. They will drink 1 bottle 4 times daily for 4 weeks
89346050|NCT03783169||Symptomatic patients|All pregnant women (under the care of the Maternal-Fetal Medicine physicians or Faculty Medical Center physicians with MFM involvement) experiencing a hypertensive emergency (sustained systolic blood pressure > 160 mmHg or sustained diastolic blood pressure > 110 mmHg {or both} on at least two consecutive occasions 15 minutes apart). All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
89346051|NCT03783169||Asymptomatic patients|All asymptomatic pregnant women who are undergoing routine obstetric ultrasound evaluations at any gestational age who elect to undergo cardiovascular sonographic assessment for research purposes at no cost. All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
89346052|NCT02949024|Experimental|TX Naïve Arm|Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.
89346053|NCT02949024|Experimental|Previous TX Arm|Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.
89346054|NCT05694481||Circadian rhythm disorders|Observational, no intervention administered.
89346055|NCT05694481||Healthy controls|Observational, no intervention administered.
89346056|NCT05236257||Larotrectinib|Pediatric patients with IFS harboring an NTRK gene fusion who have been enrolled in the SCOUT study.
89346057|NCT05236257||Standard care|Pediatric patients with IFS harboring an NTRK gene fusion in the eligible external cohort(s).
89346058|NCT05679960|Active Comparator|Patients low gastrointestinal tract bleeding|Patients presenting in the surgical outpatients or emergency department with low gastrointestinal tract bleeding
89346059|NCT05679960|Active Comparator|Participants who are high risk due to a family history of CRC|First degree relatives of patients diagnosed with colorectal cancer
89346060|NCT05679960|Active Comparator|Patients with a diagnosis of stage I-III CRC who have no evidence of disease|Patients previously diagnosed of stage I-III CRC and managed in the hospital but are now having no evidence of disease
89346061|NCT01312116|Experimental|Internet-delivered CBT|Active treatment: Internet-delivered Cognitive Behavior Therapy, 8 weeks treatment, guided self-help
89346062|NCT01312116|Experimental|Internet-delivered PDT|Active treatment: Internet-delivered Psychodynamic Therapy Active treatment: Internet-delivered Psychodynamic Therapy, 8 weeks treatment, guided self-help
88814353|NCT04376450|Active Comparator|Entire Papilla Preservation Technique|Entire Papilla preservation technique is a tunnel-like procedure to preserve the defect associated papilla
89346063|NCT01312116|No Intervention|Control condition|Wait-list condition, received treatment 3 months after initial treatment period
89346064|NCT03782311||2 groups: OHSE-high and OHSE-low|"OHSE-high: Group with ≥ 50 OHSE scores received motivation and oral hygiene instructions .~OHSE-low: Group with < 30 OHSE scores received motivation and oral hygiene instructions ."
89346065|NCT05176002|Experimental|Neoadjuvant Camrelizumab combined with radiotherapy group|
89346066|NCT04394481|Experimental|DMD|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection Dexmedetomidine: IV injection (1µg/kg)
89346067|NCT04394481|Active Comparator|Control|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection
89346068|NCT03781999|Experimental|Actiful|a supplement containing 500 mg orange extract and 200 mg pomegranate actives
89346069|NCT03781999|Placebo Comparator|Placebo|Maltodextrin
89346070|NCT03782935|Experimental|prenatal multivitamin mineral supplement|received prenatal multivitamin mineral supplement at time of enrollment TheraVit multivitamin/mineral prenatal supplement with instructions to take 1 per day through the remainder of pregnancy
89346071|NCT03782935|Experimental|prenatal multivitamin mineral supplement plus choline|received prenatal multivitamin mineral supplement plus additional choline supplemental vitamin TheraVit multivitamin mineral supplement plus 750 mg. choline with instructions to take1 multivitamin mineral supplement and 750 mg. per day of choline through the remainder of pregnancy
89346072|NCT03782935|No Intervention|Comparison|Advised to follow obstetrics standard of care which is to take a prenatal vitamin/mineral supplement
89346073|NCT04370847||Lung Ultrasound (LUS) Examination|Ultrasonographic assessment of fluid status through scanning the lungs would be performed in all included patients
89346074|NCT03708120|Experimental|Consumer Dose and Tick Repellency|Consumer dose: Dosimetry test of insect repellent application to forearms. Tick repellency: Treatment of forearm with insect repellent and exposure to ticks every 15 minutes for 10 hours.
89346075|NCT03093428|Experimental|Pembrolizumab Plus Radium-223|"Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose~Pembrolizumab will be administered intravenously every 3 weeks at a pre-determined dose~Radium-223 will be halted after 3 doses. Once radiographic progressive disease occurs, the last 3 doses of radium will be given."
89346076|NCT03093428|Experimental|Radium-223|- Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
89346077|NCT03706716|Other|Intervention with use of decision aid in the consultation|With use of developed decision aid for pelvic organ prolapse / At the beginning of the consultation the IF will be opened within the patients electronic journal. The conversation will take its starting point from the generated IF which should define the area of interest rather for the patient.
89346078|NCT03706716|No Intervention|Control with no use of decision aid in the consultation|Without decision aid / The conversation during the consultation will follow the general standard for consultation conversations in the department.
89346079|NCT03782155|Experimental|HMB and glutamine supplementation|Patients with type 2 diabetes with supplementation HMB 3g, powder once a day and glutamine powder 14g once a day supplementation during 15 days.
89346080|NCT03782155|Placebo Comparator|placebo patients|Patients with type 2 diabetes with placebo( calcium caseinate) supplementation during 15 days 17g of powder once a day
89346081|NCT05675826||Donor infected with covid19|This includes donors who have been infected or are infected with COVID19 at the time of hematopoietic stem cell collection.
89346082|NCT05675826||Donor not infected with covid|Including donors not yet infected with COVID19 at the time of hematopoietic stem cell collection.
89346083|NCT04780035|Experimental|"Group Vaccine"|2,250 volunteers who will be vaccinated with the EpiVacCorona vaccine, twice intramuscularly at a dose of 0.5 ml.
89346084|NCT04780035|Placebo Comparator|"Control Group"|750 volunteers who will be vaccinated with a placebo, twice intramuscularly at a dose of 0.5 ml.
89346085|NCT03782857|Experimental|Intervention group|Initiation/stepwise escalation of antihypertensive medication in case of blood pressure above individual target Initiation/stepwise escalation of cholesterol lowering medication in case of LDL-cholesterol above individual target Advice on healthy lifestyle and life long adherence to preventive medication
89346086|NCT03782857|No Intervention|Control group|Participants had the usual treatment: all patients were invited to one visit in the outpatient clinic three months after discharge with a diagnosis of stroke/TIA
89346087|NCT02735980|Experimental|Prexasertib (Platinum Sensitive Disease)|105 mg/m^2 Intravenous (IV) prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had platinum-sensitive disease (has prior platinum based therapy with subsequent progression greater or less than 90 days after last dose of platinum based therapy).
89346088|NCT02735980|Experimental|Prexasertib (Platinum Resistant Disease)|105 mg/m^2 IV prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had resistant/refractory disease (did not have an objective response to platinum-based therapy or had progression greater than 90 days after the last dose of platinum).
89346089|NCT02735980|Experimental|Prexasertib Exploratory Addendum (Platinum Sensitive Disease)|40 mg/m^2 IV prexasertib Day 1, 2, and Day 3 of a 14 day cycle in participants with ED-SCLC platinum sensitive disease.
89346090|NCT01309789|Experimental|1|Sequential
89346091|NCT01309789|Experimental|2|Combination
89346092|NCT01309789|Experimental|3 Brentuximab vedotin/CH-P|Combination
89346093|NCT03707847|Experimental|Crizotinib + etoposide capsule+Auto-HSCT|"Crizotinib and etoposide capsule followed by autologous hematopoietic stem cell transplantation.~Crizotinib: 250mg, bis in die （BID）, PO.~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle.~Patients will receive the treatment of crizotinib and etoposide capsule, and those who have achieved CR（complete response）or VGPR（very good partial response）will undergo the Auto-HSCT."
89346094|NCT03338400|Active Comparator|Dexamethasone|Patients in the Dexamethasone arm will be administered the drug at the time of induction.
89346095|NCT03338400|Placebo Comparator|Normal Saline|The placebo arm patients will receive normal saline at the time of induction.
89346096|NCT03787147|Other|Spinal Injection|Adults receiving Spinal Injection(SI) without Virtual Reality(VR).
89346097|NCT03787147|Active Comparator|Google Cardboard|Adults receiving SI while using Google Cardboard Virtual reality head mounted display powered by a iPod touch
89346098|NCT03787147|Active Comparator|Oculus|Adults receiving SI while using VR with Oculus Rift.
89346099|NCT02620306|Experimental|Fimasartan(A)|
89346100|NCT02620306|Experimental|Fimasartan(B)|
89346101|NCT02620306|Active Comparator|Losartan(A)|
89346102|NCT02620306|Active Comparator|Losartan(B)|
89346103|NCT03337113|Experimental|WMT + rTMS|WMT + rTMS is the Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. Both conditions are active.
89346104|NCT03337113|Active Comparator|Sham WMT + rTMS|Sham WMT + rTMS is the sham Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of rTMS. WMT is inactive.
88807266|NCT00407888|Experimental|Arm I|Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.
89346105|NCT03337113|Active Comparator|WMT + sham rTMS|WMT + sham rTMS is the Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of WMT. rTMS is inactive.
89346106|NCT03337113|Sham Comparator|Sham WMT + sham rTMS|sham WMT + sham rTMS is the sham Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. Both are inactive in this arm.
89346107|NCT01307683|Active Comparator|Mindful Moms|Based on the Mindful Motherhood Training (developed by Cassandra Vieten, PhD), Mindfulness-Based-Eating and Awareness Training (MB-EAT) (developed by Jean Kristeller, PhD), and other mindfulness- and acceptance-based interventions
89346108|NCT01307683|No Intervention|Comparison Group|Usual prenatal care
89346109|NCT03706638|Other|Daily|Patients randomized to this arm will take ferrous sulfate 325 mg every day.
89346110|NCT03706638|Other|Intermittent (Every other day)|Patient's randomized to this arm will take ferrous sulfate 325 mg every other day.
89346111|NCT03781843|Active Comparator|Genicular nerve block with lidocaine|The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 6 mL of a solution containing 6 mL of 2% lidocaine or 6 mL dextrose or 6 mL saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves Interventions: Drug: 6 mL 2% lidocaine Procedure: Genicular nerve block
89346112|NCT03781843|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.~Interventions:Drug: Saline Procedure: Genicular nerve block"
89346113|NCT03781843|Placebo Comparator|Genicular nerve block with dextrose|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a dextrose was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.~Interventions:Drug: Dextrose Procedure: Genicular nerve block"
89346114|NCT05205447|Experimental|Part 1 Period 1 (LY3410738 Alone)|Single dose of LY3410738 administered orally.
89346115|NCT05205447|Experimental|Part 1 Period 2 (LY3410738 + Itraconazole)|Single dose of LY3410738 administered orally with multiple doses of itraconazole orally.
89346116|NCT05205447|Experimental|Part 2 Period 1 (LY3410738 Alone)|Single dose of LY3410738 administered orally.
89346117|NCT05205447|Experimental|Part 2 Period 2 (LY3410738 + Carbamazepine)|Single dose of LY3410738 administered orally with multiple doses of carbamazepine orally.
89346118|NCT05347576|Experimental|sequence 1|Period 1- A single dose of 4 tablets(CKD-501 1T, D759 1T, D150 1T, D029 1T) under fed condition Period 2- A single dose of 2 tablets(CKD-393(2) 2T) under fed condition
89346119|NCT05347576|Experimental|sequence 2|Period 1- A single dose of 2 tablets(CKD-393(2) 2T) under fed condition Period 2- A single dose of 4 tablets(CKD-501 1T, D759 1T, D150 1T, D029 1T) under fed condition
89346120|NCT03786913||children with muscle disease|fifty children diagnosed to have inflammatory myositis or Duchenne muscular dystrophy in whom Quantitative muscle ultrasound measurements will be performed .The captured images will be analyzed for echo intensity by means of computer-assisted grayscale histogram analysis at baseline and after 24 months.
89346121|NCT03786913||control group|20 healthy children matching age and sex as control group in whom Quantitative muscle ultrasound measurement will be performed at baseline
89346122|NCT03782779|Experimental|Breathing program and regular exercise|Diaphragmatic Breathing Program plus regular upper and lower limb exercises
89346123|NCT03782779|Active Comparator|Regular Exercise|Regular upper and lower limb exercises
89346124|NCT05335564|Experimental|General information about depression|Exposure to general information about depression
89346125|NCT01560793|Experimental|VAX161B|Dose escalating study where subjects are treated with VAX161B at one of six dose levels. Subjects will be injected with VAX161B twice during the study at Day 0 and Day 21. The dosages are: 1 mcg; 2.5 mcg; 4 mcg; 6 mcg; 8 mcg; and 12 mcg.
89346126|NCT03707769|Experimental|Fistula treatment|Treatment of fistula with TIPS microspheres
89346127|NCT03781687|Active Comparator|Bilateral|Bilateral ESP block will be performed
89346128|NCT03781687|Active Comparator|Unilateral|Unilateral ESP block will be performed
89346129|NCT03092726|Experimental|ASP8062|Participants received 30 mg of ASP8062 orally once daily for 8 weeks.
88807267|NCT05208684|Experimental|Breast stimulation|A 30-minute stimulation with moderate intensity by an electric milk pump (Elvie Pump) will be performed.
89346130|NCT03092726|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 8 weeks.
89346131|NCT05330416|Active Comparator|Group Reference Strategy|Detailed examination of the suppuration and drainage with a seton
89346132|NCT05330416|Experimental|Group test strategy|Detailed examination of the suppuration without drainage via a seton
89346133|NCT01307761||Patients with thyroid nodule received US-FNA exam|Patients with thyroid nodules which underwent head and neck ultrasound(US) examination and US-FNA cytology at Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan. No patient included in this series had a previous diagnosis of thyroid malignancy before US exam.
89346134|NCT05329168|Experimental|Sequential ascending-dose cohort|Sequential ascending-dose cohort
89346135|NCT05460429|Experimental|Immunogenicity and safety group|360 subjects including 120 subjects aged 1-3 years with no history of varicella vaccination,240 subjects aged 4-6 years with a history of 1 dose of varicella vaccine will be enrolled to evaluate the immunogenicity and safety of varicella vaccine.All subjects will receive one dose of varicella vaccine.
89346136|NCT05460429|Experimental|Antibody level investigation study group|Immunization levels will be monitored among 2530 subjects aged 0-59 years old and will be collected venous blood to detect varicella antibody.
89346137|NCT05460429|Experimental|Safety group|30000 subjects aged 1-12 years old will be enrolled to conduct safety observation of mass vaccination of varicella vaccine.All subjects will receive one dose of varicella vaccine and all adverse events of all subjects will be collected.
89346138|NCT05460429|Experimental|Protective effect group|5000 subjects aged 1-12 years old will be enrolled to conduct protective effect study of varicella vaccine after exposure.
89346139|NCT05460429|Experimental|Etiology Group|30 varicella cases aged 1-12 years old from study 4 will be enrolled. Herpes fluid or pharyngeal swab samples of subjects will be collected to study the pathogenicity of varicella.
89346140|NCT03786757|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy.
89346141|NCT03786757|No Intervention|dual antiplatelet therapy (DAPT)|Conventional dual antiplatelet therapy will be adopted.
89346142|NCT05126511|Active Comparator|Post-Covid patients, anxious, functional device|Applitation of 100µA CES for one hour per day to anxious patients
89346143|NCT05126511|Placebo Comparator|Post-Covid patients, anxious, Sham|Use of Sham CES for one hour per day by anxious patients
89346144|NCT05126511|Active Comparator|Post-Covid patients, non anxious, functional device|Application of 100µA CES for one hour per day to non anxious patients
89346145|NCT05126511|Placebo Comparator|Post-Covid patients, non anxious, Sham|Use of Sham CES for one hour per day by non anxious patients
89346146|NCT04501562||Subject|
89346147|NCT03786835|No Intervention|Control (No intervention)|Participants will not undergo any treatment. Continue with usual daily activities and diet for 6 months.
89346148|NCT03786835|Experimental|Nutrition group|Participants will receive protein enriched food to supplement the diet for 6 months.
89346149|NCT03786835|Experimental|Exercise group|Participants will exercise 3 times a week for 60 minutes each time over 6 months.
89346150|NCT03786835|Experimental|Nutrition + Exercise group|Participants will receive protein enriched food to supplement the diet and exercise 3 times a week for 60 minutes each time over 6 months.
89346151|NCT05598242|Experimental|Amniotic membrane extract|patients receive amniotic membrane eye drops (AMEED) as 1 drop in each eye 6 times daily, 30 days
89346152|NCT05598242|Active Comparator|autologous serum eye drops|patients receive autologous serum eye drops (ASED) as 1 drop in each eye 6 times daily, 30 days
89346153|NCT03781531||Venous thromboembolism|Patients presenting with venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
89346154|NCT04461938|Other|Fasting|All study participants follow the same dietary intervention; thus, no randomization will take place.
89346155|NCT01879774|Other|Patients with hyponatremia|Neuropsychological and motoric tests are conducted in patients with hyponatremia.
89346156|NCT01879774|Other|Patients with normal serum sodium|Neuropsychological and motoric tests are conducted in patients with normal serum sodium.
89346157|NCT03786601||Group A,|High-risk HPV infection in postmenopausal women
89346158|NCT03786601||Group B|High-risk HPV negative in postmenopausal women
89346159|NCT03786601||Group C|High-risk HPV infection in gestational women
89346160|NCT03786601||Group D|High-risk HPV negative in gestational women
89346161|NCT05598164|Experimental|main group|Patients of main group are treated with injection in internal sphincter Botulinum toxin type A.
89346162|NCT05598164|Experimental|control group|In the control group, the fissure is excised in combination with a injection in internal sphincter Botulinum toxin type A.
89346163|NCT03787069|Experimental|Lignocaine group|This group will be given 1.5 mg/kg I/V lignocaine before intubation
89346164|NCT03787069|Placebo Comparator|Placebo|This group will be given 6 ml normal saline before intubation
89346165|NCT05278390|Experimental|Thoracic CT Scan|
89346166|NCT05455203|Experimental|ADAPT-ITT guided implementation and adaptation|ADAPT-ITT is an implementation science framework that guides the adaptation of evidence-based interventions (EBI) for specific settings or populations. ADAPT-ITT will be used to adapt the target interventions in partnership with a Family and Community Advisory Board, consisting of parents, caregivers, and leaders of family-based organizations in New Jersey.
89346167|NCT01561027|Experimental|CNV1014802|CNV1014802 350mg on prescription (BID) for 21 days
89346168|NCT01561027|Placebo Comparator|Placebo|Placebo 350mg BID for 21 days
89346169|NCT05260060|Active Comparator|Usual Treatment (Control)|Participants allocated to the control group will receive treatment as usual under the child and adolescent mental health service.
89346170|NCT05260060|Experimental|Group MCT (Intervention)|Participants allocated to the intervention group will receive group metacognitive therapy sessions.
89346171|NCT04913961|Experimental|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study.
89346172|NCT04913961|Active Comparator|Control|The control group will get the western medicine conventional therapy with some additional tests for the study.
89346173|NCT05694325|Other|Biological evaluation|characterization of biological features of enrolled ITP patients
89346174|NCT04447118|Experimental|Study treatment Arm|Pyrotinib maleate tablet, 400 mg, once daily (QD)
89346175|NCT04447118|Active Comparator|Control Arm|Docetaxel injection, 75 mg/m2, once every 3 weeks (Q3W)
89346176|NCT05225350|No Intervention|Controls|In the first arm the patients received care consistent with regional guidelines. Treatment as usual.
89346177|NCT05225350|Experimental|Dietary Intervention|In the second arm the patients received care consistent with regional guidelines in combination with the intensive dietary intervention for three months
89346178|NCT01553032|Active Comparator|Erbitux®|
89346179|NCT01553032|Active Comparator|Fractionated Radiotherapy|
89346180|NCT05472649||Participants exposed to Gene-Modified Cell Therapy|
89346181|NCT05309811|Experimental|Group A|RLRL therapy with routine IOP-lowering medications in the 1st-12th weeks then crossing to only routine IOP-lowering medications in the 13th-24th weeks
89346182|NCT05309811|Experimental|Group B|Only routine IOP-lowering medications in the 1st-12th weeks then crossing to RLRL therapy with routine IOP-lowering medications in the 13th-24th weeks
89346183|NCT01561105|Experimental|IMPACT|
89346184|NCT01561105|No Intervention|Care as Usual|Patients received all depression care available to them as part of care as usual in the participating primary care clinics.
89346185|NCT05181124|Experimental|JP-1366 and aceclofenac|
89346186|NCT05181124|Experimental|JP-1366 and meloxicam|
89346187|NCT05181124|Experimental|JP-1366 and naproxen|
89346188|NCT05181124|Experimental|JP-1366|
89346189|NCT05088759|Experimental|Alert|"an on-screen electronic alert will prompt the responsible inpatient provider (inpatient cohort) or the cardiologist of record for the clinic visit (outpatient cohort) as follows:~All patients whose LDL-C is not less than 70 mg/dL and not taking a maximally tolerated statin dose will prompt a recommendation for statin intensification~All patients whose LDL-C is within 20% of 70 mg/dL and who are on a maximally tolerated statin dose but not on ezetimibe or PCSK9 inhibitor will receive a prompt for adding ezetimibe~All patients whose LDL-C is greater than 20% of goal, and on a maximally tolerated statin (±ezetimibe) but not on PCSK9 inhibitor will receive a prompt for initiating PCSK9 inhibitor"
89346190|NCT05088759|No Intervention|No Alert|No notification will be issues
89346191|NCT03781609|Active Comparator|Roller system group (RG)|A group performing motor learning manual wheelchair propulsion repetitions on a roller system.
89346192|NCT03781609|Active Comparator|Overground group (OG)|A group performing motor learning manual wheelchair propulsion repetitions overground.
89346193|NCT03781609|Placebo Comparator|Placebo - Wheelchair skills group (WSG)|A group receiving conventional manual wheelchair skills training.
89346194|NCT04834635|Experimental|FundoRingOAGB group|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part (and suture cruroplasty if present hiatal hernia).
89346195|NCT04834635|Active Comparator|OAGB group|laparoscopic one anastomosis gastric bypass (and suture cruroplasty if present hiatal hernia).
89346196|NCT03338010|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre [mmol/L]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).
89346197|NCT03338010|Active Comparator|Lantus®|Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.
89346198|NCT04750148||Cancer|Individuals with an oncology disease will be included in the study.
89346199|NCT05103202||10 weeks or less|Patients receiving botulinum toxin injections at a frequency of 10 weeks or less
89346200|NCT05103202||12 weeks or more|Patients receiving botulinum toxin injections at a frequency of 12 weeks or more
89346201|NCT05309499|Active Comparator|FCM group|The ferric carboxymaltose doses were determined using the patient's screening visit body weight measurement and haemoglobin value. Patients receives all doses during hospitalization accordance with the drug local labels.
89346202|NCT05309499|Active Comparator|Ferrous sulphate group|100 mg of ferrous sulphate is administrated 2 times per day during hospitalization and continue within next 2 month.
89346203|NCT05309499|No Intervention|Group with normal iron status|Patiants with normal iron status
89346204|NCT05090254|Active Comparator|Cardiac output maximization group|"Patients will be treated according to a goal-directed therapy protocol aiming at a cardiac output maximization.~Detailed protocol adapted from Edwards, M.R., et al., Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery. BMJ Open, 2019. 9(1): p. e023455."
89346205|NCT05090254|Active Comparator|Cardiac output personalization group|"Patients will be treated according to a goal-directed therapy protocol aiming at a personalized cardiac output goal determined with preoperative cardiac output assessment.~Detailed protocol adapted from Nicklas, J.Y., et al., Personalised haemodynamic management targeting baseline cardiac index in high-risk patients undergoing major abdominal surgery: a randomised single-centre clinical trial. Br J Anaesth, 2020. 125(2): p. 122-132."
89346206|NCT05090254|No Intervention|Routine management group|Patients will be treated according to routine hemodynamic management.
89346207|NCT04959591|Experimental|Experimental (Pre): Acetaminophen|Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg after anesthetic induction/before surgical incision and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given at the end of surgery before skin closure.
89346208|NCT04959591|Experimental|Experimental(post): Acetaminophen|Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg at the end of surgery before skin closure and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given after anesthetic induction/before surgical incision.
89346209|NCT04959591|Placebo Comparator|Placebo comparator : placebo|Participants will receive 1.5ml/kg placebo (0.9% saline) before and after surgery and the same dose will be given postoperatively at 8hour intervals for 24hours.
89346210|NCT05598086|Experimental|TXA group|Postoperative 1g TXA was infiltrated locally around the incision immediately for patients in TXA group.
89346211|NCT05598086|Placebo Comparator|Normal saline group|1 g 0.9% saline was infiltrated locally around the incision immediately after surgery for patients in normal saline group.
89346212|NCT00753532|Placebo Comparator|MRI(+ve),|121 volunteers in MRI(+ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 62 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 59 received placebo. They were followed up every 3 months for a period of 2 years for their blood biochemistry profile and MRI of the brain was conducted at baseline, 12 months and 24 months..
89346213|NCT00753532|Placebo Comparator|MRI(-ve)|120 volunteers in MRI(-ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 63 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 57 received placebo. They were followed up every 3 months for a period of 1 year for their blood biochemistry profile and MRI of the brain was conducted at baseline and 12 months.
89346214|NCT02864888|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
89346215|NCT02864888|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 24 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
89346216|NCT03777553|Experimental|VETNET|Narrative Exposure Therapy for Justice-Involved Veterans
89346217|NCT03777475|Experimental|low dose|low oxaliplatin (85mg/m2)
89346218|NCT03777475|Active Comparator|high dose|high oxaliplatin (135mg/m2)
89346219|NCT03337542|Other|Treatment arm description|Subjects will receive maintenance dosing with AR101. Maintenance doses are provided in sachets, where each sachet contains 300 mg of peanut protein. Subjects are to ingest 300 mg orally once a day during maintenance.
89346220|NCT01307839|Active Comparator|5% lidocaine patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
89346221|NCT01307839|Placebo Comparator|placebo patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
89346222|NCT01316809|Experimental|A|Surgical arm
89346223|NCT01316809|Experimental|B|Non-surgical arm
89346224|NCT03708042|Experimental|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day.
89346225|NCT03708042|Active Comparator|Neoadjuvant Radiochemotherapy|Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
89346226|NCT03777085|Experimental|TQB2303|
89346227|NCT03777085|Active Comparator|Rituximab|
89346228|NCT01328548||Nursing Home Elderly Cases|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs (single nucleotide polymorphisms). A case will be considered failure to mount a high response.
89346229|NCT01328548||Nursing Home Elderly Controls|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.
89346230|NCT01328548||Community dwelling seniors|Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.
89346231|NCT04415463|Experimental|FC-SEMS|Placement of multisegmented fully covered self-expandable metal stent
89346232|NCT03777241|Active Comparator|Behavioral Intervention Team|The participants in this arm will receive the Behavioral Intervention Team.
89346233|NCT03777241|Active Comparator|Standard of Care|The participants in this arm will receive the standard of care.
89346234|NCT05675202|Experimental|TQ-B3525 tablet|100 µ Ci [14C] TQ-B3525, 20mg, once in total
89346235|NCT04453306|Placebo Comparator|placebo|"Patients with the same characteristics as the intervention group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
89346236|NCT04453306|Experimental|intervention|"Patients with the same characteristics as the placebo group. Bottles containing 30 white and green tablets are provided to the participants. The number of bottles is anticipated according to the day of the next appointment. Patients should take 2 tablets bedtime with a full glass of water.~Bottles are labeled as TPMT100 or TPMT200. The dosage of each tablet is 25 mg, totaling 50 mg / day. The dosage is doubled at 3 months if the patient does not lose at least 3% of the initial weight."
89346237|NCT05682456|Experimental|High-fat shake|
89346238|NCT05682456|Active Comparator|Reference shake|
89346239|NCT04411082|Experimental|Lower Dose IMR-687|Oral administration of once daily IMR-687
89346240|NCT04411082|Experimental|Higher dose IMR-687|Oral administration of once daily IMR-687
89346241|NCT04411082|Placebo Comparator|Placebo|Oral administration of once daily placebo
89346242|NCT05667714|Experimental|Experimental Group A（ non-continuous exposure to COVID-19）|1725 participants who were non-continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.
89346243|NCT05667714|Placebo Comparator|Control Group A（ non-continuous exposure to COVID-19）|575 participants who were non-continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day .
89346244|NCT05667714|Experimental|Experimental Group B (continuous exposure to COVID-19)|400 participants who were continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.
89346245|NCT05667714|Placebo Comparator|Control Group B(continuous exposure to COVID-19)|200 participants who were continuous exposure to COVID-19 received nasal spray every 3 hours,about 5-6 times/day.
89346246|NCT01307917|Experimental|healthy controls high flavonoid|20 healthy adolescents (12-21 years old) receiving the flavonoid-rich capsule/supplement
89346247|NCT01307917|Active Comparator|healthy controls low flavonoid|20 healthy adolescents (12-21 years old) receiving the placebo
89346248|NCT01307917|Experimental|T1DM or T2DM high flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the capsule/supplement
89346249|NCT01307917|Active Comparator|T1DM or T2DM low flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the placebo
89346250|NCT05060679||Non-sepsis|Non-septic patients receive supportive treatment at the ICU.
89346251|NCT05060679||Sepsis|Patients receive sepsis therapy.
89346252|NCT05060679||Sepsis-related organ dysfunction|Patients receive sepsis therapy and advanced supportive treatment based on the occurrence of specific sepsis-related organ dysfunctions.
89346253|NCT03786289|Experimental|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection
89346254|NCT03786289|Active Comparator|Recombinant human erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection
89346255|NCT05059509|Experimental|FB825|One dose FB825, 5mg/kg, by 1 hour IV infusion on Day 1
89346256|NCT05309343||Exposed group|Western medicine treatment with Chinese medicine treatmen
89346257|NCT05309343||Non-exposed group|Western medicine treatment
89346258|NCT01307995||GDM|Patients with Gestational Diabetes Mellitus found during pregnancy by means of 75g OGTT
89346259|NCT01307995||NGT|Pregnant patients with normal glucose tolerance as observed in 75g OGTT
89346260|NCT03638661|Experimental|n-3 fatty acid enriched formula|"Those assigned to the n3EN group received vegetable n-3 fatty acid enriched formula by tube feeding (product; Yonsei Dairy Co., Seoul, South Korea).~vegetable (canola, flaxseed) derived n-3 fatty acid"
89346261|NCT03638661|Placebo Comparator|soybean oil used formula|"Patients assigned to the control group received a soybean used formula by tube feeding.~soybean used formula"
89346262|NCT03780985|Active Comparator|intrauterine device insertion with a suture fixation|Intruterine device through hysterotomy incision during cesarean section with a suture fixation
89346263|NCT03780985|Active Comparator|intrauterine device insertion without a suture fixation|IUD through hysterotomy incision during cesarean section without a suture fixation
89346264|NCT04989231||Experimental Group|Subjects who have received 4 doses of the experimental vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
89346265|NCT04989231||Control Group|Subjects who have received 4 doses of control vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
89346266|NCT05597852|Experimental|Study Arm|All patients with local recurrence of prostate cancer post irradiation will undergo placement of a hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life prior to SABR.
88807268|NCT00407966|Experimental|Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)|"Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63 days after completion of course 1, patients achieving complete or partial remission may receive a second course of treatment as above.~Patients age 50 and over with core binding factor acute myeloid leukemia (AML) (e.g., t[8;21], inv[16], or t[16;16]) achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator."
88807269|NCT00408200|Other|AAD:YES|Subjects receive membrane-active anti-arrhythmic medication after ablation. See intervention list below.
89346267|NCT01561183|Experimental|Indirect pulp capping (IPC)|Indirect pulp capping
89346268|NCT01561183|Experimental|Direct pulp capping (DPC)|Direct pulp capping
89346269|NCT01561183|Experimental|Miniature pulpotomy (MP)|Miniature pulpotomy
89346270|NCT01561183|Experimental|Full pulpotomy (FP)|Full pulpotomy
89346271|NCT01312545|Experimental|local made implant (3DP)|Enucleation and local made implant (3DP) insertion
88807270|NCT00408200|Other|AAD:NO|Subjects do not receive membrane-active anti-arrhythmic medications after ablation.
89346272|NCT01312545|Experimental|imported implant (Medpor)|Enucleation and imported implant (Medpor) insertion
89346273|NCT01308073||EMIC 2 dialysis|Patients on ICU requiring dialysis for acute renal insufficiency
89346274|NCT03620955||Risk stratification|Risk stratification based on cytogenetic and molecular and MRD level after three courses of chemo therapy.
89346275|NCT03776851|Experimental|Erythropoietin|Erythropoietin plus standard of care (RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability)
89346276|NCT03776851|No Intervention|No Intervention|Standard of care: RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability
89346277|NCT03468322|Experimental|AC-203 1% ointment|AC-203 1% ointment, QD
89346278|NCT03468322|Placebo Comparator|Vehicle ointment|Vehicle ointment, QD
89346279|NCT03337308|Experimental|BA 180 mg + EZE 10 mg FDC|Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
89346280|NCT03337308|Experimental|BA 180 mg|Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
89346281|NCT03337308|Active Comparator|EZE 10 mg|Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
89346282|NCT03337308|Placebo Comparator|Placebos|Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks
89346283|NCT03631862|Experimental|Apatinib combined with CHOP regimen|Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
89346284|NCT03631862|Experimental|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
89346285|NCT04352673||Healthy individuals|Healthy students 18 years and older
89346286|NCT03468244|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma
89346287|NCT03468088|Experimental|Hand grip strengthening|This group will receive handgrip strengthening exercises.
89346288|NCT03468088|Active Comparator|Conventional treatment|This group will receive conventional exercises.
89346289|NCT03468010|Active Comparator|The control group (Group A)|In Group A, observation is given after chemoradiation
89346290|NCT03468010|Experimental|The experiment group (Group B)|in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.
89346291|NCT04403984||Patients with Luminal A breast cancer|Patients confirmed with Luminal A breast cancer sub type
89346292|NCT04403984||Patients with Luminal B breast cancer|Patients confirmed with Luminal B breast cancer sub type
89346293|NCT03776617|Experimental|Group Ropivacaine|general anesthesia + scalp block with 20 ml xylocaine 1% and 20ml ropivacaine 0.5%
89346294|NCT03776617|Experimental|Group Ropivacaine-Dexmedetomidine|general anesthesia + scalp block with 20 ml xylocaine 1%, 20ml ropivacaine 0.5% and 1mcg/kg dexmedetomidine
89346295|NCT03776617|No Intervention|Group control|general anesthesia
89346296|NCT03776617|Sham Comparator|Group sham|general anesthesia + Scalp block with 40ml Normal Saline
89346297|NCT04795726|Experimental|Treatment group|Patients received treatment in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).
89346298|NCT04795726|Placebo Comparator|Placebo group|Patients received placebo in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).
89346299|NCT05175378|Active Comparator|Intervention arm|In the intervention group, MS women received a personalized daily eating plan (specific meals, recipes, food portions) together with nutritional consultation on the Meditteranean dietary pattern, as well as physical activity guidelines. All essential aspects of the dietary plan e.g. daily energy expenditure, classification of physical activity based on the concept of metabolic equivalent (MET), caloric adjustment according to nutritional status, and macronutrient distribution were calculated by a Clinical Decision Support System (CDSS). Body mass index (BMI) was also calculated, as the ratio of reported weight (kg) to the square of height (m2). Co-existed health issues, such as constipation or esophageal reflux, were taken into consideration. All MS patients acquired personal login passwords that allowed them to get access to their personal CDSS account and track their progress in regards to body weight, physical activity, and healthy food choices consumption.
89346300|NCT05175378|Sham Comparator|Control arm|"Patients of the control group received general dietary advice and physical activity recommendation that was in accordance with the National Dietary Guidelines for Greek adults"
89346301|NCT04453228||2017-2018 snow season|Injured skiers in the 2017-2018 snow season
89346302|NCT04453228||2018-2019 snow season|Injured skiers in the 2018-2019 snow season
89346303|NCT03780907|Experimental|E2007 1 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
89346304|NCT03780907|Experimental|E2007 2 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
89346305|NCT03780907|Placebo Comparator|Placebo|Tablet, once daily to be taken in the morning, one hour before breakfast, with a glass of water.
89346306|NCT03467776||healthy|healthy control, 5 months to 3 years
89346307|NCT03467776||wheezing with atopy|suspected asthma with wheezing (>3 episodes per year) and atopy
89346308|NCT03467776||wheezing without atopy|wheezing without atopy
89346309|NCT03786211|Active Comparator|IANB without panoramic|They will get Ianb without using panoramic
89346310|NCT03786211|Experimental|IANB with panoramic|They will get IANB by the guide of panoramic
88807271|NCT05255406|Experimental|Furmonertinib|Furmonertinib (160mg)
89346311|NCT01312623|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
89346312|NCT01312623|No Intervention|Control|No ischemic preconditioning
89346313|NCT03776773|Active Comparator|patients AR (+) and sleep apnea (+)|Patients with AR and obstructive sleep apnea (OSA) will have sleep and pollution exposure recordings
89346314|NCT03776773|Active Comparator|AR (-) and sleep apnea (+)|Patients without allergic rhinitis (+ sleep apnea) will have sleep and pollution exposure recordings
89346315|NCT03776773|Active Comparator|AR (+) and sleep apnea (-)|Patients with allergic rhinitis but no sleep apnea will have sleep and pollution exposure recordings
89346316|NCT03776773|Sham Comparator|AR (-) and sleep apnea (-)|Volunteers without allergic rhinitis and no sleep apnea will have sleep and pollution exposure recordings
89346317|NCT03337152|Other|1A: primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1A. Participants in arm 1A will receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
89346318|NCT03337152|Other|1B: chloroquine + primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1B. Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
89346319|NCT03467620|Experimental|Cannabidiol oral capsule|25-mg capsule of Cannabidiol (CBD) per day taken daily for a duration of 12 weeks.
89346320|NCT03467620|Placebo Comparator|Placebo oral capsule|One placebo capsule per day for a duration of 12 weeks
89346321|NCT03780205||Bilateral Group|Patients have bilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 each eye.
89346322|NCT03780205||Unilateral Group|Patients have unilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 in the amblyopic eye; and interocular difference of best-corrected visual acuity at least two logMAR lines.
89346323|NCT02725580|Experimental|Open Label|Participants with diagnosis of vLINCL6 Batten disease will receive a single intrathecal injection of AT-GTX-501 into the lumbar spinal cord region.
89346324|NCT04305249|Experimental|Module A (ATG-017 Monotherapy)|Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
89346325|NCT04305249|Experimental|Module B (ATG-017+Nivolumab Combination Therapy in Solid Tumors)|With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be given at fixed dosing, 480 mg Q4W, on D1 of each cycle.
89346326|NCT03467464|Experimental|Intervention|EMDR treatment
89346327|NCT03707964|Placebo Comparator|Control|Subjects allocated to the control arm will receive standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles, as part of their regular teaching schedule.
89346328|NCT03707964|Experimental|Intervention|Subjects allocated to the intervention arm will receive education on crisis resource management (CRM) and teaching targeting the cognitive skills required to monitor and challenge a superior's decision, and conflict resolution tools, in addition to standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
89346329|NCT03467308||Colorectal cancer patients|50 Patients confirmed histopathologically to have early stages of colorectal cancer.
89346330|NCT03467308||Risky group|20 risky patients (those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
89346331|NCT03707886|Experimental|Pain SMART (Intervention Arm)|The Intervention Arm will be invited to participate in a one-time group intervention, Pain SMART
89346332|NCT03707886|Placebo Comparator|Minimally Enhanced Usual Care|The Minimally Enhanced Usual Care group will receive educational information via mail.
89346333|NCT03467230||NoL Index|All patients will be monitored by PMD-200 device
89346334|NCT03091400|Experimental|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
89346335|NCT03091400|Placebo Comparator|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
89346336|NCT02946333||Patient with MM who are not candidates for ASCT|Patients with newly diagnosed MM who are not candidates for ASCT and who are going to start drug treatment for the study disease and patient who is capable of understanding and filling in the study questionnaires At least 450 patients will be enrolled in a 2-year period. Patients must meet all of the inclusion criteria and none of the exclusion criteria and must have previously granted their informed consent in writing.
89346337|NCT05197452|Experimental|COVID-19 Testing|COVID-19 antigen and PCR Testing
89346338|NCT05595668|Experimental|Prism adaptation treatment|Prism Goggles with 15-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
89346339|NCT05595668|Placebo Comparator|Placebo control prism adaptation treatment|Prism goggles with 5-degree rightward deviating prism lenses will be used to maintain the double-blind methodology.
89346340|NCT01318993|Experimental|GSK1605786A|500 milligrams twice daily
89346341|NCT02761070|Active Comparator|Bevacizumab (BEV) alone|Bevacizumab 10 mg/kg, day 1 div, every 2 weeks
89346342|NCT02761070|Experimental|Dose Dense Temozolomide Followed by BEV|Temozolomide (120 mg/m2, po, 7 days on/7 days off, every 2 weeks per cycle) up to 48 cycles. The dose will be escalated to 150 mg/m2 at 3rd cycle if the defined conditions are met throughout the first 2 cycles. At recurrence or progression, bevacizumab alone(10 mg/kg, day 1 div, every 2 weeks)
89346343|NCT03466840|Experimental|The Coronally Advanced Lingual Flap|"On the lingual side of mandible, a full-thickness muco-periosteal flap is elevated until reaching mylohyoid line. Using a blunt instrument, a connective tissue band is localized continuing with the epimysium of the mylohyoid muscle and is inserted into the inner part of the lingual flap . The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe the amount of advancement is measured."
89346344|NCT03466840|Active Comparator|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured"
89346345|NCT05587868||Patients who have not received vaccination for COVID-19|This group includes patients who refused or contraindicated to receive vaccination for COVID-19.
89346346|NCT05587868||Patients who had received first dose of vaccination for COVID-19|Regardless of the type of COVID-19 vaccine used (received before or after laboratory-confirmed SARS-CoV-2 infection).
89346347|NCT05587868||Patients who had received second dose vaccination for COVID-19|Regardless of the type of COVID-19 vaccine used, using same type of vaccine as the first dose (received before and/or after laboratory-confirmed SARS-CoV-2 infection).
89346348|NCT05587868||Patients who had received third dose/booster vaccination for COVID-19|Complete cycle of vaccination using same type of vaccine for the first and second dose and a same/different type for the third dose/booster (received before and/or after laboratory-confirmed SARS-CoV-2 infection).
89346349|NCT05175300|Experimental|Group 1|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
89346350|NCT05175300|Active Comparator|Group 2|Prosthesis with ceramic-on-ceramic (CoC) torque.
89346351|NCT04714671|Experimental|Euthymics patients with history of suicide attempt (suicide attempters)|Euthymics patients with a lifetime history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
89346352|NCT04714671|Experimental|Euthymics patients without any history of suicide attempt (affective controls)|Euthymics patients without history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
89346353|NCT03466684|Experimental|BIA-directed fluid resuscitation|After the achievement of CVP, MAP and ScvO2 goals, if hyperhydration (HL > 74.3%) was found, then the following fluid management was applied with each passing 6h. If HL was above 87% (severe level), fluid infusion was restricted, a furosemide drip was used, and CRRT was initiated with an ultrafiltration rate when patients were failure or inadequate response to above diuretic therapy that gave a net negative fluid balance of at least 1500 ml during the next 6h. If HL was 81%-87% (moderate level), above methods were used to trigger a net negative fluid balance (about 1000 ml) for the next 6h. Similarly, If HL was 74.3%-81% (mild level), a net negative fluid balance of about 500 ml would be achieved during the next 6h of ICU hospitalization. If HL was blow 71%, a state of dehydration, CVP, MAP, and ScvO2 was maintained as above during ICU resuscitation.
89346354|NCT03466684|Active Comparator|Traditional fluid resuscitation|A timely restricted intravenous fluid regimen or dehydration therapy was implemented by two senior clinicians according to cumulative fluid balance recording and hemodynamic condition such as heart rate, blood pressure, central venous pressure, mean arterial pressure, urine output and body weight change.
89346355|NCT05175222|Experimental|Laser|Patients receive low-level laser therapy with LightWalker laser from the first day of conditioning chemotherapy till +2 day post hematopoietic stem cell transplantation. Additionally, standard supportive care is introduced.
89346356|NCT05175222|No Intervention|Control|Patients are observed and receive standard supportive care.
89346357|NCT03466606|Experimental|Prehabilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
89346358|NCT03466606|No Intervention|Control|Conventional treatment
89346359|NCT04686903|Experimental|Epiduroscopy|Epiduroscopy in patients with FBSS
89346360|NCT04686903|Experimental|Racz catheter epidural procedure|Racz catheter epidural procedure in patients with FBSS
89346361|NCT04686903|Experimental|Caudal epidural block|Caudal epidural block treatment of FBSS
89346362|NCT03090152|Active Comparator|Periarticular Injection (PAI)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~Peri-articular injection in the operating room~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~A pain regimen while in the hospital that includes EPCA (saline) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
89346363|NCT03090152|Active Comparator|Epidural Patient-Controlled Analg (EPCA)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
89346364|NCT03090152|Experimental|PAI + EPCA|"Aspirin and nerve pain medications including duloxetine and clonidine~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~Anesthetic, Antiemetic and peri-articular injection in the operating room~A pain regimen while in the hospital that consists of EPCA (with 0.06% bupivacaine) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
89346365|NCT03706404|Experimental|Point-of-care Testing and Ultrasound pathway|
89346366|NCT03706404|No Intervention|Classical pathway|
89346367|NCT03466528|Active Comparator|Standard treatment - Pabrinex alone|Pabrinex alone
89346368|NCT03466528|Active Comparator|Pabrinex + magnesium sulphate|standard treatment and magnesium sulphate
89346369|NCT03466528|Experimental|Magnesium sulphate alone|This group receives the study intervention and delayed Pabrinex
89346370|NCT04664985|Active Comparator|Mucogyne®|The dosage during the study will be 1 Mucogyne® ovule per day at bedtime for 10 days and then 1 ovule every 2 days until the end of the 3-month follow-up.
89346371|NCT04664985|No Intervention|Control|No treatment for this arm.
89346372|NCT03776929|No Intervention|Standard Care|No intervention - Standard care only. Group of 32 subjects
89346373|NCT03776929|Experimental|Dialectical Behavioral Therapy|Dialectical Behavioral Therapy in addition to standard care. Four hour and a half group sessions (or one-on-one sessions, if not enough for a group session) commencing after surgery while still inpatient. Each session is designed to stand-alone, allowing for enrolling patients on a rolling basis.
89346374|NCT03466372|Experimental|biofeedback 1|biofeedback training with progression of targets
89346375|NCT03466372|Active Comparator|biofeedback 2|biofeedback training with progression of targets and speeds
89346376|NCT03466216|Experimental|AlphaMedix|There is only a single treatment arm.
89346377|NCT03098654|Experimental|Enhanced Intervention|"Members will have DM and HTN managed at the CTC together with their HIV care. Interventions include:~Community mobilization activities to inform community members of available services~Support at the local health center to aid clinicians in managing uncontrolled cases of DM and HTN, including training for clinical staff, glucometers/test strips, and BP monitors.~HIV counseling and serial rapid HIV testing~Blood glucose and blood pressure testing~DM/HTN medications as needed~Personalized diet and lifestyle counseling for all participants with elevated glucose or BP that includes education, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose/BP."
89346378|NCT03098654|No Intervention|Control|Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care. HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing. Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
89346379|NCT05175066|Experimental|Bisoprolol|40 patients who were given bisoprolol at a dose of 1.25 mg daily, and in the absence of clinical symptoms and heart rate above 60 and systolic blood pressure above 100, 1.25 mg was added to the therapeutic dose every 2 weeks to reach 5 mg daily.
89346380|NCT05175066|Placebo Comparator|Placebo|Two placebo tablets in similar shape and color to bisoprolol were given on a daily basis to each of the 40patients as the control group.
89346381|NCT03786133||type 2 diabetics|Analysis of microbiological tests in chronic periodontitis patients with type 2 diabetes mellitus
89346382|NCT03786133||non-diabetics|Analysis of microbiological tests in chronic periodontitis patients without type 2 diabetes mellitus
89346383|NCT03466138||General Anesthesia|subjects requiring a surgical procedure under general anesthesia. monitored by PMD-200
89346384|NCT04571658||NEPTUNE Match Participants|"Approximately 375 participants will be consented from the NEPTUNE observational study with age and demographic groups representing the patient population in the NEPTUNE study site geographical areas.~NEPTUNE observational cohort eligibility includes: participants in NEPTUNE observational cohort A are of any age and have a biopsy-confirmed diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Participants in NEPTUNE observational cohort B have documented NS based on proteinuria, serum albumin, and/or edema with age of onset less than 19 years."
89346385|NCT01308151|Experimental|Experimental Arm|Culturally Adapted Manualised Cognitive Behavioral Therapy (CBT) Sessions will be offered weekly in the first month and then fortnightly.
89346386|NCT01308151|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
89346387|NCT03465826|Experimental|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
89346388|NCT03465826|Active Comparator|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
89346389|NCT05513521|Experimental|High-velocity interval training|Subjects will be provided high-speed, low-load training to target improvements in velocity.
89346390|NCT05513521|Experimental|Resistance training|Subjects will be provided low-speed, high-load training to target improvements in velocity
89346391|NCT03130114|Placebo Comparator|Control|Placebo mixture, 0.25 ml / kg / day
89346392|NCT03130114|Experimental|Azithromycin|Azithromycin mixture (40 mg / ml), 0.25 ml / kg / day
89346393|NCT03638739|Experimental|Exercise|Participants will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS for 12 weeks at McMaster University. Following this, they will return to their normal daily activities for a further 12 weeks.
89346394|NCT03638739|Experimental|Wait-list Control|Participants will engage in their usual daily activities for the first 12 weeks of the study, then will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS at McMaster University for the 2nd 12 weeks.
89346395|NCT03130270|Experimental|Apatinib group|Apatinib mesylate tablet：the starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd).
89346396|NCT03780361|Experimental|Aflibercept injection group|"drug: Eylea (aflibercept) (11.12mg/0.278ml) dose: 2mg (0.05ml) usage: With topical anesthesia and intravitreal injection of aflibercpt in aseptic condition.~frequency and duration: monthly intravitreal aflibercept injections."
89346397|NCT02522572|Experimental|Group A|4 doses of plerixafor and plasmapheresis
89346398|NCT02522572|Experimental|Group B|4 doses of plerixafor, 1 dose of bortezomib, and plasmapheresis
89346399|NCT02522572|Experimental|Group C|6 doses of plerixafor, 2 doses of bortezomib, and plasmapheresis
89346400|NCT05074225|Experimental|ED&C|The ED&C arm will receive the standard ED&C care.
89346401|NCT05074225|Experimental|Excision|The excision arm will undergo standard excision with repair by complex linear closure.
89346402|NCT04602507|Experimental|Intervention|50 patients with the routine care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
89346403|NCT04602507|Placebo Comparator|Control|50 patients with routine care offered in the hospital plus placebo orally (2 drops per kg) in a single dose.
89346404|NCT02522338|Other|iohexol plasma clearance|patients had received iohexol for measuring GFR
89346405|NCT03780595|Experimental|Passiflora|
89346406|NCT03780595|Placebo Comparator|Control|
89346407|NCT03706326|Experimental|Treatment with Anti-MUC1 CAR-T cells|Anti-MUC1 CAR-T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
89346408|NCT03706326|Experimental|Combination Therapy: CAR-T combining PD-1 knockout T Cells|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
89346409|NCT03706326|Experimental|Treatment with PD-1 knockout Engineered T cells|PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
89346410|NCT05278507|Experimental|Arrow PICC With Arrowga+rd Blue Advanced Protection|"The Arrow PICC with Arrowga+rd Blue Advanced protection (Teleflex Medical Incorporated, Morrisville, NC, USA; hereafter referred to as AGBA) is an FDA-cleared pressure injectable device that offers both antimicrobial and anti-thrombogenic protection for at least 30 days. The application of Arrowga+rd Blue Advanced protection uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body. The device is cleared for marketing in the United States of America by the Food and Drug Administration, and has obtained the CE mark for marketing in the European Union. The French size and length selected for use will be documented."
89346411|NCT05278507|Sham Comparator|Standard of Care PICC|The standard, unprotected PICC currently in use at the institution will be used in this study (here after referred to as Standard). The details of the PICC selected will be recorded including brand, French size, and length.
89346412|NCT05174676|Experimental|Intervention|The participant will receive 6 therapy sessions of approximately 25 minutes each WITH the application of error enhancement.
89346413|NCT05174676|Sham Comparator|Control|The participant will receive 6 therapy sessions of approximately 25 minutes each WITHOUT the application of error enhancement.
89346414|NCT03773809|Placebo Comparator|Group A0|Vitamin D3 deficient ACO patients with placebo at day 0.
89346415|NCT03773809|Placebo Comparator|Group A90|Vitamin D3 deficient ACO patients with placebo at day 90.
89346416|NCT03773809|Active Comparator|Group B0|Vitamin D3 deficient ACO patients with vitamin D3 at day 0.
89346417|NCT03773809|Active Comparator|Group B90|Vitamin D3 deficient ACO patients with vitamin D3 at day 90.
89346418|NCT04840095|Experimental|Metabolic Manipulation via Diet fMRI|All subjects are tested three times, each in a different diet-induced metabolic state: glycolytic (glucose burning), fasting (8 hours no food), and ketotic (fat burning). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink up to 75g glucose. Our data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
89346419|NCT04840095|Experimental|Metabolic Manipulation via Ketone Supplement fMRI|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). While having their brains scanned with MRI, subjects are initially tested at rest, and then perform a task. Midway through the session, subjects are removed from the scanner and drink either of two fuel sources. In the ketotic (ketone burning) session they will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones. Our data analyses quantify network reorganization in response to changing energy constraints (i.e., cognitive demand, fuel).
89346420|NCT04840095|Experimental|Metabolic Manipulation via Ketone Supplement MR/PET|All subjects are tested twice, both times in a fasting condition (8 hours no food, unrestricted water). For both sessions, we will intravenously administer the FDG radioisotope continuously throughout the scan. Thus, PET will map glucose uptake across the brain, while we simultaneously use MRS to measure production of the neurotransmitters glutamine and GABA. While having their brains scanned with MR/PET, subjects are initially tested at rest, and then perform a task. Subjects will drink a ketone sports drink dosed at 395mg/kg. During the glycolytic (glucose burning) session the same subjects will drink a bolus of glucose, calorie-matched to the ketones.
89346421|NCT05172492|Experimental|Endocare|
89346422|NCT05172492|Active Comparator|Digital control|
89346423|NCT05041231|Sham Comparator|Sham (group A)|Treatment procedure performed with the device that will not provide the bioactive light (laser)
89346424|NCT05041231|Experimental|PBT (group B)|Treatment procedure performed with the device that will provide the bioactive light (laser)
89346425|NCT05170386|Experimental|study group|receive cognitive training combined with instructive conventional treatment for sleeping disorder
89346426|NCT05170386|Experimental|control group|receive instructive conventional treatment for sleeping disorder
89346427|NCT01313611|Experimental|Rituximab + bendamustine|
89346428|NCT03706248||No recurrence|"CT scan has confirmed that subjects are without recurrence. Blood can be drawn up to 4 weeks after scan.~Effective Feb 28, 2019, this group is closed to accrual as it has reached the goal."
89346429|NCT03706248||Recurrence|CT scan has confirmed that subjects are have recurrence of their colorectal cancer. Blood can be drawn prior to any treatment for the recurrent disease.
89346430|NCT04608838|Experimental|JTR-161|
89346431|NCT04608838|Placebo Comparator|Placebo|
89346432|NCT03779815|Experimental|[18F]Florbetaben PET/CT imaging|"Maximally 18 subjects with multiple myeloma (up to 6 subjects in whom amyloidosis in suspected and up to 12 subjects in whom amyloidosis is not suspected)~Intravenous injection of [18F]Florbetaben and PET/CT scanning~Intervention: Drug ([18F]Florbetaben)"
89346433|NCT03465670|Active Comparator|CHX|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse (10 ml for 1 minute, t.i.d. for 21 days)
89346434|NCT03465670|Experimental|CHX+HA+ADS|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) (10 ml for 1 minute, t.i.d. for 21 days)
89346435|NCT03776383|Active Comparator|Antibiotic use feedback letter 1|Antibiotic use feedback letter 1 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic prescribing for acute respiratory conditions
89346436|NCT03776383|Active Comparator|Antibiotic use feedback letter 2|Antibiotic use feedback letter 2 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic durations for common infections
89346437|NCT03776383|No Intervention|Control|Controls will not receive a letter
89346438|NCT03779893|Active Comparator|conventional group|Conventional resin based Pits & fissures sealant 3M™ Clinpro™ Sealant is administrated
89346439|NCT03779893|Experimental|bioactive group|Bioactive Pits & fissures sealant BioCoat® by Premier®.
89346440|NCT05166252|Experimental|Experimental group|"Installation of the study app.~At the beginning of the meal, participants press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and participants need to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the participants are instructed to take a picture with their smartphone from the meal table.~A time out from the smartphone starts, meaning that all functions of the phone are locked. The time-out is over as soon as the participant presses the stop button.~A short questionnaire about the meal is sent via App to the participating family member when the smartphone is used again.~During the whole period of the study the App tracks the smartphone behavior (i.e., frequency and duration of smartphone use and the specific applications used). Active comparator: control group"
89346441|NCT05166252|Active Comparator|Control group|Control points in time include all parts as in the experimental group except for number 3.
89531691|NCT05708742|Sham Comparator|Control group|The control group underwent US-guided sham block at L4 vertebrae level with 20 ml of saline 0.9%. At the level of L4 and after skin sterilization, sham block was administered in a sitting position. Hydro dissection of the interfascial plane between the erector spinae muscle and TP was confirmed by visualizing the local anesthetic spreading in a linear pattern between the muscle and the bony acoustic shadows of the TP. Then, up to 20 ml Saline 0.9% was injected.
89346442|NCT03773731|Experimental|High intensity interval training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test~30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test.~10 minutes with 30% of maximal power output."
89346443|NCT03773731|Active Comparator|Moderate intensity continuous training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test~30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output~10 minutes with 30% of maximal power output."
89346444|NCT03780049|Experimental|HAIC plus H101|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and recombinant human type-5 adenovirus 0.5ml via hepatic artery
89346445|NCT03780049|Active Comparator|HAIC|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and normal saline via hepatic artery
89346446|NCT05154864||SBUF-SMUF|All patients underwent standard of care cardiac surgery, cardiopulmonary bypass and SBUF-SMUF with effluent removal of 30 ml/kg/hr and physiologic solution replacement of 25ml/kg/hr.
89346447|NCT04452760|Active Comparator|Control group|Only testing sessions
89346448|NCT04452760|Experimental|Progressive resistance training group|10-weeks of progressive resistance training group. Leg press, leg extension, calf raises, hip extension exercises.
89346449|NCT04252287|Experimental|Canagliflozin 100 mg|Participants will be administered 100 milligram (mg) immediate-release, over-encapsulated tablets (as a capsule) orally once daily for 12 weeks.
89346450|NCT04252287|Placebo Comparator|Placebo|Participants will be administered matching placebo capsules orally once daily for 12 weeks.
89346451|NCT05681754|Experimental|RCT using hydraulic calcium silicate sealer and L-PRF + GTR|Endodontic-periodontal disease patients undergoing root canal treatment using hydraulic calcium silicate sealer and L-PRF + GTR (bone substitute + collagen membrane)
89346452|NCT05681754|Experimental|RCT using conventional sealer and L-PRF + GTR|Endodontic-periodontal disease patients undergoing root canal treatment using conventional sealer and L-PRF + GTR (bone substitute + collagen membrane)
89346453|NCT05681754|Experimental|RCT using hydraulic calcium silicate sealer and GTR|Endodontic-periodontal disease patients undergoing root canal treatment using hydraulic calcium silicate sealer and GTR (bone substitute + collagen membrane)
89346454|NCT05681754|Active Comparator|RCT using conventional sealer and GTR (bone substitute + collagen membrane)|"Endodontic-periodontal disease patients undergoing root canal treatment using conventional sealer and GTR (bone substitute + collagen membrane)~This is our control group Both the endodontic and periodontal lesions are managed using gold standard of care biomaterials and techniques"
89346455|NCT02577536||1 All Subjects|No interventions
89346456|NCT03465202|Experimental|Capecitabine|
89346457|NCT05153850||Cases|Patients diagnosed with inflammatory bowel disease with the complete vaccination regimen.
89346458|NCT03465124|Active Comparator|Femtosecond Laser assisted Cataract Surgery|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order.
89346459|NCT03465124|Active Comparator|Manual Cataract Surgery|Manual Cataract Surgery will be performed in contralateral (to LCS) eye of patient with bilateral age-related cataract.
89346460|NCT04247139|Experimental|Commercial Kefir|Commercially produced kefir
89346461|NCT04247139|Experimental|Traditional Kefir|Traditionally grown kefir
89346462|NCT04195958|Experimental|Omalizumab|
89346463|NCT02735200|Experimental|Topical Vitamin D3 application|Intervention is Application of topical Vitamin D3 Frequency: Daily Dosage: 1 gram (5000 IU) Duration: 120 days
89346464|NCT02735200|Active Comparator|Aloe vera gel Application|Application of Aloe vera gel will be carried out Dosage: 1 gram Frequency: Daily Duration: 120 days
89346465|NCT01312311|Experimental|weekly docetaxel and cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
89346466|NCT03465046|Experimental|low performance group 1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
89346467|NCT03465046|Experimental|low performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
89346468|NCT03465046|Experimental|moderate-high performance group1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
89346469|NCT03465046|Experimental|moderate-high performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
89346470|NCT01568840|Experimental|Global Postural Reeducation Group|Global Postural Reeducation
89346471|NCT01568840|Active Comparator|Segmental Exercises Group|Segmental Exercises
89346472|NCT04592445|Active Comparator|Axon Treatment Arm|Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
89346473|NCT04592445|Sham Comparator|Sham Control Arm|Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.
89346474|NCT02946918|Experimental|Tablets|Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)
89346475|NCT02946918|Experimental|Gelcaps|Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)
89346476|NCT03464968|Experimental|mFOLFOX|D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
89346477|NCT03464968|Experimental|mFOLFIRI|D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
89346478|NCT03464890|Experimental|LICHTENA DermAD|"Comparison within subjects of P926 - LICHTENA DermAD CREMA VISO and P927 - LICHTENA DermAD CREMA CORPO versus placebo and versus untreated control area. Study products were applied once, on experimentally induced erythema by repeated tape stripping on 4 different adjacent skin areas of the forearms (volar surface - 2 areas on each side)"
89346479|NCT05073744|Experimental|Tumor ablation using nalbuphine for pain control and anaesthesia|Nalbuphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
89346480|NCT05073744|Active Comparator|Tumor ablation using morphine for pain control and anaesthesia|Morphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
89346481|NCT05146596|Experimental|LLLT group|use low level light therapy,The Dr.Tai's energy cap
89346482|NCT05146596|No Intervention|control group|routine care.
89346483|NCT05308251|Active Comparator|high ligation|High ligation of the indirect hernia sac is traditional in inguinal hernia repairs. In this arm, patients with indirect inguinal hernia undergoing open mesh herniorrhaphy will have their hernia sac was opened and high ligated.
89346484|NCT05308251|Experimental|non-ligation|In this arm, the patients' hernia sac will be dissected high but not opened or ligated. The sac will be invaginated to the abdomen.
89346485|NCT05681598|Experimental|Hydroxyurea treatment|participants were treated with hydroxyurea
89346486|NCT05515302|Experimental|Experimental Group|The experimental group consists of 50 Participants as per the inclusion criteria. The Audio clips will be administered to the experimental group.
89346487|NCT05515302|No Intervention|Control Group|The control group will not receive the intervention but will receive treatment as usual.
89346488|NCT04348708||Dose Level Cohort 1|Dose Level 1 of HMI-102 delivered intravenously one time
89346489|NCT04348708||Dose Level Cohort 2|Dose Level 2 of HMI-102 delivered intravenously one time
89346490|NCT04348708||Dose Level Cohort 3|Dose Level 3 of HMI-102 delivered intravenously one time
89346491|NCT01312350|Active Comparator|CCRT only arm|no neoadjuvant chemotherapy before definitive CCRT
89346492|NCT01312350|Experimental|neoadjuvant chemotherapy arm|2 cycles of TPF chemotherapy before definitive CCRT
89346493|NCT03464812|Other|DSMES Group|Patients with type 2 diabetes will undergo a diabetes education program (DSMES) and evaluated for outcomes before and after completing the program.
89346494|NCT03464656|Experimental|Patients|"Patients presenting with male infertility, who are found to have abnormal semen analysis shall be recruited to this study.~Interventions:~Patients will be given Fairhaven Pro for Men as antioxidant in a dose of 3 tablets twice daily for 3 months.~Full assessment of fertility will be done."
89346495|NCT05129982|Experimental|Intervention|The reflex response will be recorded during whole-body vibration.
89346496|NCT05512494|Experimental|Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 1|420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 1.
89346497|NCT05512494|Experimental|Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 2|420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 2.
89346498|NCT05512494|Experimental|Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 3|420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 3.
89346499|NCT04343248|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks
89346500|NCT04343248|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 6 weeks
89346501|NCT03464188|No Intervention|Usual Care|Usual care family caregiver participants will be informed of the UAB Comprehensive Cancer Center Patient and Family Resources webpage.
89346502|NCT03464188|Experimental|Project Cornerstone|The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician. Regular caregiver distress thermometer screening and problem support and self-care coaching. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions.
89346503|NCT03464032|Experimental|BCD-135|Dose-escalation Arm (0.4, 1, 3, 10, 20 mg/kg)
89346504|NCT05310162|Experimental|Food, fun and family|This intervention aims to change eating and screen time habits in children to decrease the amount of added sugar consumed and the time spent using recreational screens, this with guides and precise instructions given to the parents to have a healthier lifestyle.
89346505|NCT05310162|Active Comparator|Counseling|The parents will receive simple verbal instructions to reduce the consumption of added sugar and recreational screen time, giving advice on which foods to avoid and the amount of time permitted for the use of screens.
89346506|NCT03705936|Sham Comparator|Sham 1Hz rTMS--5Hz rTMS|Participants will receive sham 1Hz rTMS, then immediately followed by 5Hz rTMS.
89346507|NCT03705936|Experimental|1Hz rTMS--5Hz rTMS|Participants will receive 1Hz rTMS, then immediately followed by 5Hz rTMS.
89346508|NCT03705936|Experimental|1Hz rTMS--30-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 30 minutes break, then followed by 5Hz rTMS.
89346509|NCT03705936|Experimental|1Hz rTMS--60-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 60 minutes break, then followed by 5Hz rTMS.
89346510|NCT03705936|Sham Comparator|Sham 5Hz rTMS--1Hz rTMS|Participants will receive sham 5Hz rTMS, then immediately followed by 1Hz rTMS.
89346511|NCT03705936|Experimental|5Hz rTMS--1Hz rTMS|Participants will receive 5Hz rTMS, then immediately followed by 1Hz rTMS.
89346512|NCT03705936|Experimental|5Hz rTMS--45-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 45 minutes break, then followed by 1Hz rTMS.
89346513|NCT03705936|Experimental|5Hz rTMS--90-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 90 minutes break, then followed by 1Hz rTMS.
89346514|NCT03705858|Experimental|Ac-lintuzumab|Subjects with AML will receive Ac-lintuzumab.
89346515|NCT03463720||Extremity wound|Patients with extremity wounds. Infected and not infected patients will be compared.
89346516|NCT03463642|Experimental|Vitamin D3 pill|100 pills = 100,000IU + Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
89346517|NCT03463642|Placebo Comparator|Pill placebo|100 pills = Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
89346518|NCT03463642|Experimental|Vitamin D3 oral liquid|100 drops = 100,000IU in orange syrup
89346519|NCT03463642|Placebo Comparator|Oral liquid placebo|100 drops orange syrup
89346520|NCT03463642|Experimental|Skin oil + Vitamin D3 + penetrator|100,000IU + mineral oil+ Tangerine essential oil (10ml)
89346521|NCT03463642|Experimental|Skin oil + Vitamin D3|100,000IU + mineral oil
89346522|NCT03463642|Placebo Comparator|Skin oil placebo|Skin application: 100ml of mineral oil coloured with food colourant to match active oil sample
89346523|NCT05140824|Placebo Comparator|Placebo|0.9% sodium chloride solution
89346524|NCT05140824|Experimental|TJ202|TJ202 injection
89346525|NCT03463564|Active Comparator|Insulin pump|Insulin Pump with rapid acting insulin analog lispro
89346526|NCT03463564|Active Comparator|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection at bed-time of basal insulin glargine or degludec
89346527|NCT05092386|Experimental|Experimental Group of One Dose|110 Participants (including 20 subjects aged 18~49 years, 20 subjects aged 6~17 years , 30 subjects aged2-5 years) will receive one dose of experimental vaccine
89346528|NCT05092386|Experimental|Experimental Group of Two Doses|30 Participants aged 12~23 months will receive two doses of experimental vaccine on the schedule of month 0,2.
89346529|NCT05092386|Experimental|Experimental Group of Three Doses|30 Participants aged 7~11 months will receive two doses of experimental vaccine on the primary immunization schedule of month 0,2 and one dose of booster immunization during the participants aged 12~15 months .
89346530|NCT05092386|Experimental|Experimental Group of Four Doses|30 Participants aged 3 months will receive three doses of experimental vaccine on the primary immunization schedule of month 0,1,2 and one dose of booster immunization during the participants aged 12~15 months ; 30 Participants aged 2 months will receive three doses of experimental vaccine on the primary immunization schedule of month 0,2,4 and one dose of booster immunization during the participants aged 12~15 months
89346531|NCT05092386|Active Comparator|Control Group of One Dose With WALVAX PCV13|30 Participants aged 2-5 years will receive one dose of control vaccine (WALVAX PCV13)
89346532|NCT05092386|Active Comparator|Control Group of Two Doses With WALVAX PCV13|30 Participants aged 12~23 months will receive two doses of control vaccine(WALVAX PCV13) on the schedule of month 0,2.
89346533|NCT05092386|Active Comparator|Control Group of Three Doses With WALVAX PCV13|30 Participants aged 7~11 months will receive two doses of control vaccine(WALVAX PCV13) on the primary immunization schedule of month 0,2 and one dose of booster immunization during the participants aged 12~15 months .
89346534|NCT05092386|Active Comparator|Control Group of Three Doses With Pfizer PCV13|30 Participants aged 2 months will receive three doses of control vaccine(Pfizer PCV13 on the primary immunization schedule of month 0,2,4 and one dose of booster immunization during the participants aged 12~15 months
89346535|NCT03463252|Active Comparator|MPA for EC without progesterone contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
89346536|NCT03463252|Experimental|MPA+Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
89346537|NCT03463252|Experimental|Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
89346538|NCT03463252|Active Comparator|GnRH agonist+Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
89346539|NCT03463252|Experimental|Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
89346540|NCT03463252|Active Comparator|Mirena® for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
89346541|NCT03463252|Experimental|MPA for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
89346542|NCT03463252|Active Comparator|Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
89346543|NCT03463252|Experimental|GnRH-a+Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
89346544|NCT05080452||ACNES patients|Patients referred to ultrasound-guided treatment for abdominal wall pain caused by ACNES
89346545|NCT05080452||LUCNES patients|Patients referred to ultrasound-guided treatment for lower back pain caused by LUCNES
89346546|NCT05309538|Active Comparator|Group A|Control group
89346547|NCT05309538|Experimental|group B|experimental group
89346548|NCT04241614||The First Hospital of Ji Lin University|CT data and corresponding CT raw data of patients with lung nodule will be collected.
89346549|NCT05098912|Active Comparator|Manual acupuncture|"The subjects/population of this study is woman at age 30-50 who meet the inclusion criteria. Subjects group with manual acupuncture treatment will be treated with 6 session of manual acupuncture at:~From the superior of zygomatic arch through ST 2 to LI 20 bilaterally using a needle size of 0.25 x 60 mm From the inferior of zygomatic arch through SI 18 to ST 4 bilaterally using a needle size of 0.25 x 60 mm From ST 7 to ST 4 bilaterally using a needle size of 0.25 x 60 mm Along the nasolabial crease through ST 4 to the bilateral EXHN-8 using a needle size of 0.25 x 40 mm"
89346550|NCT05098912|Active Comparator|Thread embedding acupuncture|"The subjects/population of this study is woman at age 30-50 who meet the inclusion criteria. Subjects group with thread embedding acupuncture group treatment will be treated with 1 session of thread embedding acupuncture at:~From the superior of zygomatic arch through ST 2 to LI 20 bilaterally using a gauge and length of the needle of 31G x 50 mm From the inferior of zygomatic arch through SI 18 to ST 4 bilaterally using a gauge and length of the needle of 31G x 50 mm From ST 7 to ST 4 bilaterally using a gauge and length of the needle of 31G x 50 mm Along the nasolabial crease through ST 4 to the bilateral EXHN-8 using a gauge and length of the needle of 31G x 30 mm"
89346551|NCT03463174|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have a dental implant placed in the mandibular midline followed by the immediately insertion of a ball attachment and the incorporation of a retention matrix to the mandibular denture.
89346552|NCT03463174|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment besides the new set of conventional complete dentures. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
89346553|NCT03463096|Experimental|Centrifuge study|High G acceleration on a long-arm human centrifuge
89346554|NCT05041530|Experimental|REBUILD|Subjects who meet the inclusion criteria and agree to participate in the study will be enrolled and undergo oncologic laparotomy per the standard of care. The abdominal wall will be closed with REBUILD Bioabsorbable and suture of the surgeon's choice.
89346555|NCT03462940|Experimental|TUDCA Group|All subjects will receive 500 mg/day in a one week run-in period and then 1750 mg/day in one week treatment period of of the nutritional supplement Tauroursodeoxycholic acid (TUDCA).
89346556|NCT03011450|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator for 12 weeks
89346557|NCT03011450|Active Comparator|40 week extension|K-877 or fenofibrate comparator for 40 weeks
89346558|NCT05078736|Experimental|moderate intensity intermittent training|baseline physical therapy treatment along with moderate intensity intermittent training
89346559|NCT05078736|Experimental|moderate intensity continuous training|baseline physical therapy treatment along with moderate intensity continuous training
89346560|NCT03462862|Experimental|Group 1|patients will receive partial denture constructed from PEEK material
89346561|NCT03462862|Active Comparator|Group 2|patients will receive partial denture constructed from breflex material
89346562|NCT05072028|Experimental|[14C]DBPR108|Subjects will receive a single oral 100 mg (radioactivity of 150 µCi) dose of [14C]DBPR108 on Day 1.
89346563|NCT03462784||Cases|
89346564|NCT03638856|Experimental|Misoprostal group|Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy
89346565|NCT03638856|No Intervention|Placebo group|Patients were take placebo 2 tab per oral 3 hour before hysteroscopy
89346566|NCT01312194|Experimental|One vist group|All patients included in this treatment group will receive the complete endodontic treatment in a single visit.
89346567|NCT01312194|Active Comparator|Two-vist group|All patients included in this treatment group will receive treatment in two visits. The first will be done chemo mechanical root canal preparation, the placement of the intracanal medication the basis of calcium hydroxide and coronal sealing. Ten to twelve days later, this medication is removed and the root canal will be permanently filled.
89346568|NCT03462472|Experimental|15 minute lower leg heating|
89346569|NCT03462472|Experimental|45 minute lower leg heating|
89346570|NCT03462472|No Intervention|Control|
89346571|NCT03462472|Experimental|15 minute lower leg TENS|
89346572|NCT03462472|Experimental|45 minute lower leg TENS|
89346573|NCT05026944|Experimental|Group A|Percussive massage and static stretching exercises
89346574|NCT05026944|Other|Group B|Static stretching exercises
89346575|NCT03462394||Current Script Version|This arm will receive the version of the call script currently used as part of regular care at NYU Langone Health.
89346576|NCT03462394||Script Iterations|This arm will receive an iterated version of the script that might contain changes in wording or structure that are different from the current version of the script.
89346577|NCT03705780|Other|the short OSAS scale|In preoperative interview，distributing the short OSAS screening scales to children's parents，and the scale was completed preoperative，calculate the score of the scale
89346578|NCT03705780|Experimental|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
89346579|NCT02734810|Experimental|Part A|Liprotamase Powder for Oral Solution in Subjects aged ≥7 years of age
89346580|NCT02734810|Experimental|Part B|Liprotamase Powder for Oral Solution in Subjects aged 28 days to <7 years
89346581|NCT03705702|Active Comparator|Intervention Group (IG)|The intervention of active comparator will be education program plus behavioral intervention through physical activity counseling program combined with a monitoring-and-feedback tool.
89346582|NCT03705702|Sham Comparator|Control Group (CG)|The intervention of sham comparator will be an education program in asthma and physical activity recommendations.
89346583|NCT04980846|Experimental|Intervention group|Intervention: Other: Driving under the influence of alcohol with a driving simulator
89346584|NCT04976790|Experimental|Chinese Tuina group (CTG)|The participants in Chinese Tuina group will receive the traditional Chinese Tuina therapy on the basis of health education and home-exercise. All the treatment will cost 20-25 minutes. Patients in this group received 4 treatments over 14 days.
89346585|NCT04976790|Active Comparator|Flurbiprofen Cataplasms group (FCG)|The FCG group received flurbiprofen gel on the basis of the health education and home-exercise, twice daily, for 14 days.
89346586|NCT04858594||Arm A: with Periodontitis|Patients with periodontitis
89346587|NCT04858594||Arm B: without Periodontitis|Patients without periodontitis
89346588|NCT05535920|Other|Rate Atrial fibrillation - 2.0K+ dialysate bath wo/ Lokelma to crossover|"Sequence A: standard 2.0 K+/2.5 Ca++ dialysate with no Lokelma supplementation for two (2) months, followed by a cross-over to experimental 3.0 K+/2.5 Ca++ dialysate with 5 grams powder oral suspension Lokelma supplementation (on off-dialysis days) for two (2) months.~Each two-month treatment period (both 2.0 K+/2.5 Ca++ dialysate and 3.0 K+/2.5 Ca++ dialysate with Lokelma sequences) will be preceded by a two-week run-in period, to allow the patient to adapt to the new dialysate bath. While receiving the higher K+ dialysate, patient will be treated on off-dialysis days (4 days/week) with Lokelma, titrated to maintain K+ between 4.0 and 5.5 mEq/L. Refer to section 7.2 for the initial dose and frequency details."
89346589|NCT05535920|Other|Rate Atrial fibrillation - 3.0K+ dialysate bath w/ 5 grams Lokelma to crossover|"• Sequence B: experimental 3.0 K+/2.5 Ca++ dialysate with 5 grams Lokelma supplementation (on off-dialysis days) for two (2) months, followed by standard 2.0 K+/2.5 Ca++ dialysate with no Lokelma supplementation for two (2) months.~Each two-month treatment period (both 2.0 K+/2.5 Ca++ dialysate and 3.0 K+/2.5 Ca++ dialysate with Lokelma sequences) will be preceded by a two-week run-in period, to allow the patient to adapt to the new dialysate bath. While receiving the higher K+ dialysate, patient will be treated on off-dialysis days (4 days/week) with Lokelma, titrated to maintain K+ between 4.0 and 5.5 mEq/L. Refer to section 7.2 for the initial dose and frequency details."
89346590|NCT04452838|Other|Cohort 1 Sequence 1 (Part A)|Treatment Sequence A,B,C and D
89346591|NCT04452838|Other|Cohort 1 Sequence 2 (Part A)|Treatment Sequence B, A,C and D
89346592|NCT04452838|Other|Cohort 2 Sequence 1 (Part B)|Treatment Sequence E, F, G, and H
89346593|NCT04452838|Other|Cohort 2 Sequence 2 (Part B)|Treatment Sequence E, F, H and G
89346594|NCT04452838|Other|Cohort 2 Sequence 3 (Part B)|Treatment Sequence F, E, G, and H
89346595|NCT04452838|Other|Cohort 2 Sequence 4 (Part B)|Treatment sequence F, E, H, and G
89346596|NCT05534594|Experimental|Patients with Medullary Thyroid Cancer undergoing 18F-PSMA PET/CT|"Only 1 arm exists in this study.~Patients with Medullary Thyroid Cancer undergo a PET/CT after receiving the Fluorine-18 labeled prostate specific membrane antigen (18F-PSMA-1007) tracer intravenously. Each patient will undergo this process one time. Patients will receive 3 MBq/kg (+- 10%) in 8,3 ml (maximum 400 MBq). Waiting time after injection is 60 minutes. Scanning time is approximately 45 minutes."
89346597|NCT04452682||Era of COVID 19|Total number of cases admitted during first six months of 2020
89346598|NCT04452682||Era of Non COVID 19|Total number of cases admitted the first six months of 2019
89346599|NCT01383746|Experimental|1|Yttrium microsphere injection
89346600|NCT04743388||Cohort 1|Approximately 300 volunteers, healthy or with chronic diseases (diabetes mellitus, hypertension, heart disease, CRF, etc.) with no autoimmune disorders.
89346601|NCT04743388||Cohort 2|People with hematological malignancies or solid tumors in various phases of their treatment (under treatment or in remission/ follow-up). This cohort may include patients with smoldering multiple myeloma (n=50), multiple myeloma (n=140), chronic lymphocytic leukemia (with or without hypoglobulinemia) (n=50), lymphoma (n=80), AL amyloidosis (n=30), patients who receive PARP (n=30), CDK4/6 (n=30), or immune checkpoint inhibitors (n=40), and patients under therapy with Androgen Receptor Targeted Agents (n=50).
89346602|NCT04188860|Experimental|Study group|The patients in the study group would accept the treatment of a combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel.
89346603|NCT02251106|No Intervention|-LBP/-Brace|Subjects in this arm did not have back pain nor did they wear brace (asymptomatic controls). Subjects had their spine function measured before and after a two week period.
89346604|NCT02251106|Active Comparator|-LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm did not have back pain but wore a brace for a two week period (asymptomatic intervention). Subjects had their spine function measured before and after a two week period.
89346605|NCT02251106|Experimental|+LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm had back pain and wore a brace for a two week period (symptomatic intervention). Subjects had their spine function measured before and after a two week period.
89346606|NCT03631238||Apparently normal participants|Participants are not complaining from any cognitive decline are subjected to cognitive and cholesterol and homocysteine levels assessment.
89346607|NCT01383668|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD on days 1-28 and gold sodium thiomalate IM on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89346608|NCT03656068|Experimental|Open label NTZ|Open label. All patients will receive study drug
89346609|NCT01382030|Experimental|Treatment Arm|All patients receive 4 cycles of EIA chemotherapy pre- and postoperatively. There is no further observation arm. The study is non-randomized.
89346610|NCT01383590|Experimental|Cat-PAD|
89346611|NCT04460222|Experimental|Rotational Thromboelastometry (ROTEM)|To prevent bleeding during invasive procedure, cirrhotic children in the ROTEM group will receive prophylactic transfusion based on the following protocol:- EXTEM CT > 80 sec - FFP will be transfused at 15 ml/kg MCF < 35 mm- Platelet will be transfused at 10 ml/kg FIBTEM MCF < 7 mm- Cryoprecipitate will be transfused at 5 ml/kg
89346612|NCT04460222|Active Comparator|Conventional Transfusion|"To prevent bleeding during the procedure, cirrhotic children in the conventional group will receive prophylactic transfusion if either FFP, Platelet or Cryoprecipitate is deranged based on the following protocol~If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg~If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg~If Fibrinogen < 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
89346613|NCT01381796|Active Comparator|Treatment A - NP101|
89346614|NCT01381796|Active Comparator|Treatment C - oral sumatriptan succinate|
89346615|NCT01381796|Experimental|Treatment B - NP101B|
89346616|NCT01381796|Experimental|Treatment D - NP101D|
89346617|NCT04390282|Experimental|Application-based support system Lifepod®PAD|Patients in the experimental group will be introduced to and use Lifepod®PAD, a web-based application designed to support adherence to lifestyle advice and medication for three months. Lifepod®PAD is built as a two-side system. One side is the patient interface, the web-based application, accessible through a smartphone or tablet. The patients can log information about their lifestyle, symptoms and medication and review their data in relation to recommended targets. They get positive feedback, recommendations about healthy behaviours and receive notifications as short messages depending on their individual health status. The other side is the medical interface managed by the health care professionals. All information the patient is reporting into the app can be accessed by the treating nurse and the system ranks the patients, thus gives high priority to patients who have the greatest needs.
89346618|NCT04390282|No Intervention|Life style advice according to usual practice|Patients in the control group will receive usual care meaning advice about lifestyle changes and medication from the physician at the visit in the vascular open clinic.
89346619|NCT04375228|Experimental|Rituximab|Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors that have documented irAEs will receive Rituximab.
89346620|NCT04375228|Experimental|Tocilizumab|Patients with histologically confirmed advanced (metastatic or unresectable) solid tumors that have documented irAEs will receive Tocilizumab.
89346621|NCT02521714|Experimental|Treatment A: 25mg capsule -under fasted condition|Single oral dose of 25mg lenalidomide (reference formulation, 1 x 25mg capsule) under fasted condition.
89346622|NCT02521714|Experimental|Treatment B: 25mg oral suspension - under fasted condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fasted condition.
89346623|NCT02521714|Experimental|Treatment C: 25mg oral suspension -under fed condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fed condition.
89346624|NCT02944383|Experimental|Gemcabene 300 mg|Participants received 300 mg Gemcabene orally, once daily for 12 weeks.
89346625|NCT02944383|Experimental|Gemcabene 600 mg|Participants received 600 mg Gemcabene orally, once daily for 12 weeks.
89346626|NCT02944383|Placebo Comparator|Placebo|Participants received matching placebo orally, once daily for 12 weeks.
89346627|NCT03768089|Placebo Comparator|Part A: Pooled Placebo (Cohorts A1-5; Except A3)|Participants received single dose of placebo matched to VX-121.
89346628|NCT03768089|Experimental|Part A: VX-121 (Cohort A1)|Participants received single dose of VX-121 10 milligrams (mg).
89346629|NCT03768089|Experimental|Part A: VX-121 (Cohort A2)|Participants received single dose of VX-121 20 mg.
89346630|NCT03768089|Experimental|Part A: VX-121 (Cohort A3)|Participants received single dose of VX-121 5 mg or matched placebo without milk, followed by open label VX-121 5 mg with milk.
88814354|NCT04376294|Experimental|Study group|This group received Extracorporeal Shockwave Therapy(ESWT) + conservative Physical Therapy Treatment (eccentric training + stretching exercise)
89346631|NCT03768089|Experimental|Part A: VX-121 (Cohort A4)|Participants received single dose of VX-121 40 mg.
89346632|NCT03768089|Experimental|Part A: VX-121 (Cohort A5)|Participants received single dose of VX-121 60 mg.
89346633|NCT03768089|Experimental|Part A: VX-121 (Cohort A9)|Participants received single dose of VX-121 10 mg suspension on Day 1, VX-121 10 mg tablet on Day 9, followed by VX-121 10 mg tablet with milk on Day 17.
89346634|NCT03768089|Placebo Comparator|Part B: Pooled Placebo (Cohorts B1-4)|Participants received placebo matched to VX-121 for 10 days.
89346635|NCT03768089|Experimental|Part B: VX-121 (Cohort B1)|Participants received VX-121 10 mg once daily (qd) for 10 days.
89346636|NCT03768089|Experimental|Part B: VX-121 (Cohort B2)|Participants received VX-121 20 mg qd for 10 days.
89346637|NCT03768089|Experimental|Part B: VX-121 (Cohort B3)|Participants received VX-121 40 mg qd for 10 days.
89346638|NCT03768089|Experimental|Part B: VX-121 (Cohort B4)|Participants received VX-121 60 mg qd for 10 days.
89346639|NCT03768089|Placebo Comparator|Part C: Pooled Placebo (Cohorts C1-3)|Participants received placebo matched to VX-121/TEZ/IVA for 14 days.
89346640|NCT03768089|Experimental|Part C: VX-121 (Cohort C1)|Participants received VX-121 10 mg qd/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) for 14 days.
89346641|NCT03768089|Experimental|Part C: VX-121 (Cohort C2)|Participants received VX-121 20 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 14 days.
89346642|NCT03768089|Experimental|Part C: VX-121 (Cohort C3)|Participants received VX-121 5 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 14 days.
89346643|NCT03768089|Placebo Comparator|Part D: Placebo|Participants received placebo matched to VX-121/TEZ/IVA for 4 weeks.
89346644|NCT03768089|Experimental|Part D: VX-121/TEZ/IVA|Participants received VX-121 5 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks.
89346645|NCT02501018|Experimental|CLI Due to ASO with CLBS12 + SOC|This group of subjects with CLI due to ASO will be administered with CLBS12 + SOC for collecting efficacy and safety data.
89346646|NCT02501018|Active Comparator|CLI Due to ASO with SOC|This group of subjects with CLI due to ASO will be administered with SOC only.
89346647|NCT02501018|Experimental|CLI Due to BD with CLBS12|CLBS12 will be administered to patients with CLI due to BD for collecting safety and efficacy data.
89346648|NCT03548584|Experimental|Brexpiprazole 2 mg|Participants followed a titration schedule, to gradually increase their dose from 0.5 milligrams per day (mg/day) in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 milligrams (mg), once daily until Week 12.
89346649|NCT03548584|Experimental|Brexpiprazole 3 mg|Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.
89346650|NCT03548584|Placebo Comparator|Placebo|Participants received matching placebo, once daily for 12 weeks.
89346651|NCT04327804||Odd numbered birth year|The collection of patient samples will be different as defined by odd/even birth year. Patients born in an odd numbered year will first have their left nostril swabbed by the foam swab followed by their right nostril being swabbed by the two polyester swabs.
89346652|NCT04327804||Even numbered birth year|The collection of patient samples will be different as defined by odd/even birth year. Patients born in an even numbered year will first have their left nostril swabbed by the two polyester swabs followed by their right nostril being swabbed by a foam swab.
89346653|NCT01381640|Active Comparator|Marketed paracetamol|Marketed formulation
89346654|NCT01381640|Experimental|Experimental paracetamol formulation|Experimental formulation
89346655|NCT04483973|Experimental|SPI-1005 400 mg BID|Oral administration of SPI-1005 400 mg BID for 14 days, with 30-day follow-up
89346656|NCT04483973|Experimental|SPI-1005 800 mg BID|Oral administration of SPI-1005 800 mg BID for 14 days, with 30-day follow-up
89346657|NCT04483973|Placebo Comparator|Placebo|Oral administration of matching placebo BID for 14 days, with 30-day follow-up
89346658|NCT04283890|Experimental|Phase Ib|
89346659|NCT04283890|Active Comparator|Phase II - Combination treatment|
89346660|NCT04283890|Active Comparator|Phase II - PHP|
89346661|NCT03706092||Before|Elderly patients > = 70 in ICU without any intervention of the pharmacists and of the geriatricians
89346662|NCT03706092||After|Elderly patients > = 70 in ICU with individualized intervention of the pharmacists and of the geriatricians
89346663|NCT01491620|Experimental|532 nm KTP laser treatment|
89346664|NCT01136603|Experimental|TIGR Mesh|Experimental - TIGR Mesh
89346665|NCT01136603|Active Comparator|Control|Control group - Non absorbable Polypropylene mesh
89346666|NCT04314206|Experimental|VNRX-5024|Capsule formulation
89346667|NCT04314206|Placebo Comparator|Placebo|Placebo for VNRX-5024
89346668|NCT01139723|Experimental|A|
89346669|NCT01139723|Experimental|B|
89346670|NCT03508258||Participants with NVAF starting Apixaban|
89346671|NCT03508258||Participants with NVAF starting Warfarin|
89346672|NCT05068037|Active Comparator|STANDARD|"TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Patients will receive an antiemetic (ondansetron 4 mg). The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g.~PACU:~Analgesia in VAS> 3: piritramide 3 mg p.p. Antiemetic for POSB: metoclopramide 10 mg"
89346673|NCT05068037|Active Comparator|CONTROL|"TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Group does not receive neither acupuncture nor antiemetics. The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g.~PACU:~Analgesia in VAS> 3: piritramide 3 mg p.p. Antiemetic for POSB: ondansetron 4 mg."
89346674|NCT05068037|Active Comparator|STUDY|"Before surgery, one of the team members will talk to the patient and perform brief medical hypnosis to gain the patient's confidence in the method and teach him the method of relaxing and building an imaginary safe place where he feels comfortable and safe. Therapeutic communication through hypnosis will be used as an additional method in order to improve the well-being and comfort of the patient, reduce stress and use sedatives.~TCI anaesthesia with remifentanil (4-6 µg / ml) and propofol (4-6 µg / ml) Patients will receive acupuncture (PC6 and LI4 bilaterally) and no antiemetic The depth of anesthesia will be adjusted to maintain BIS values of 40-55. The remifentanil infusion will be adjusted according to the pain monitor values.~Analgesia: piritramide 0.1 mg / kg and metamizole 2.5 g. Removal of acupuncture needles at the end of operation~PACU:~Analgesia in VAS> 3: piritramide 3 mg p.p. Antiemetic for POSB: ondansetron 4 mg"
89346675|NCT01383512|Experimental|Rehabilitation robotics|Subjects will be practicing an Armeo Spring rehabilitation program in addition to their usual care (1.5h/day,5d/week) 1h/day 5d/week 4 weeks.
89346676|NCT01383512|Active Comparator|Self-rehabilitation|Subject will associated to there classical care 1 hours, 5 days per week during 4 weeks, of self rehabilitation.
89346677|NCT01383512|Other|Healthy volunteer|20 healthy volunteer will be recruiting and using ARMEO Spring. All volunteer will repeat 5 times the same program on the medical device.
89346678|NCT01141361||Peripheral arterial disease patients|Patients with a peripheral arterial disease, defined by an ankle to brachial index below 0.90
89346679|NCT03440476|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
89346680|NCT03440476|Active Comparator|Intervention plus feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-only booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The content is clearly automatically generated.
89346681|NCT03440476|Active Comparator|Intervention plus feedback and personal contact booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-plus-personal-contact booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The email is sent from a member of the research staff.
89346682|NCT01136759|Placebo Comparator|Pregnancy cohort, placebo|Pregnant women will receive placebo gel.
89346683|NCT01136759|Experimental|Lactation cohort, tenofovir gel|Lactating mothers will receive tenofovir gel.
89346684|NCT01136759|Experimental|Pregnancy cohort, tenofovir gel|Pregnant women will receive tenofovir gel.
89346685|NCT01136837||fragmented QRS positive|fQRS at 48 hours after Primary PCI
89346686|NCT01141439||IPDI HFA-BDP MDI|Patients who commenced inhaled corticosteroid therapy as HFA-BDP via MDI
89346687|NCT01141439||IPDI FP MDI|Patients who commenced inhaled corticosteroid therapy as FP via MDI
89346688|NCT01141439||IPDA FP MDI|Patients who had a step up in inhaled corticosteroid therapy as FP via MDI
89346689|NCT01141439||IPDA HFA-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as HFA-BDP via MDI
89346690|NCT01141439||IPDI CFC-BDP MDI|Patients who commenced inhaled corticosteroid therapy as CFC-BDP via MDI
89346691|NCT01141439||IPDA CFC-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as CFC-BDP via MDI
89346692|NCT03303040|Experimental|Stimulation|Electrical stimulation of hemidiaphragm
89346693|NCT03303040|No Intervention|Control|No stimulation of hemidiaphragm
89346694|NCT05549531|Experimental|Investigational and interaction treatment|"ACT-1004-1239 (10 mg) will be administered on Day 1 (in Treatment A) and Day 9 (in Treatment B2).~Itraconazole (200 mg, o.d.) will be administered from Day 6 until Day 13. On Day 9, itraconazole will be administered concomitantly with ACT-1004-1239."
89346695|NCT03739463|Experimental|MAG-DHA|1500 MG of MAG-DHA per day until childbirth or for up to 2 weeks
89346696|NCT03739463|Placebo Comparator|Placebo|1500 MG of oleic acid per day until childbirth or for up to 2 weeks
89346697|NCT01232699|Active Comparator|Internet Obesity Treatment|Participants will attend weekly class sessions on line and track food and exercise in an on-line journal.
89346698|NCT01232699|Experimental|Internet Obesity Treatment with MI|Participants will attend weekly classes on line, record food and exercise in an on-line journal, and will have no more than 6 individual motivational interviewing sessions.
89346699|NCT01232699|Experimental|Contingent MI|Intervention is the same as for the MI arm, however participants will only receive MI if meeting certain treatment participation conditions.
89346700|NCT04452370|Experimental|oral Etoposide+Anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
89346701|NCT03865030|Active Comparator|psoriatic patients|psoriatic patients that are recruited from the dermatology clinic. This arm will undergo audiovestibular evaluation.
89346702|NCT03865030|Active Comparator|healthy volunteers|Healthy volunteers that are members of the hospital staff and will be recruited from the hospital. This arm will undergo audiovestibular evaluation.
89346703|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.75mg/0.03cc|1/3 of study participants will be randomized to this treatment in one eye (study eye) and the other eye will receive laser (fellow eye)
89346704|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.625mg/0.025cc|1/3 of patients will be randomized to this treatment in 1 eye (study eye) and the other eye will receive laser (fellow eye).
89346705|NCT01232777|Active Comparator|Laser ablation|1/3 of study participants will be randomized to this treatment in both eyes (study eye and fellow eye)
89346706|NCT03129412|Experimental|Arm 1|4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.
89346707|NCT01136993||All bi-directional telestroke consultations|
89346708|NCT03248271||Type 2 Diabetes, Insulin Naive|Study participants will be tested prior to and 3 and 6 months after starting insulin to manage their diabetes
89346709|NCT01139957||Ancillary-correlative|Patients complete the Health Update Questionnaire annually for up to 5 years. The questionnaire focuses specifically on cancer risk, incidence, and mortality. Patients also receive ongoing communication (e.g., periodic newsletters, copies of study-related publications, etc.) to keep them informed regarding study-related research results, new research findings, new research opportunities for which patients may be eligible, and evolving clinical recommendations regarding hereditary breast/ovarian cancer.
89346710|NCT03443206|Experimental|Intervention|This condition will include access to a website that includes a social component, in addition to psychoeducation and access to resources.
89346711|NCT03443206|Active Comparator|Control|This condition will include access to a website that includes psychoeducation and access to resources.
89346712|NCT04213677|Experimental|Dapagliflozin|Dapagliflozin (Participants will receive dapagliflozin 10mg po qd).
89346713|NCT04213677|Placebo Comparator|Placebo|Placebo (Participants will receive placebo po qd)
89346714|NCT04921995|Experimental|Experimental|"Main group: Patients will be given first line tislelizumab plus investigator's choice chemotherapy, with re-irradiation postponed or omitted.~Subgroup: For patients that progressed after exposure to another PD-1 antibody, tislelizumab rechallenge combined with either low dose SBRT or low dose gemcitabine and metronomic capecitabine is accepted as a second subgroup."
89346715|NCT05038943|Experimental|SherpaPak|cardiac allografts recovered from donors after circulatory determined death using thoracoabdominal normothermic regional perfusion will be transported to the recipient center in Paragonix SherpaPak Cardiac Transport System
89346716|NCT04452448|Experimental|Laser in situ keratomileusis|A prospective clinical study including 20 eyes of 10 cases undergoing laser in situ keratomileusis (LASIK)
89346717|NCT04917549||Patients diagnosed with COVID-19|
89346718|NCT05152108|Experimental|Stroke patients|Experimental group of stroke survivors for testing the feasibility of a BCI system
89346719|NCT01235273|Experimental|GH replacement therapy|
89346720|NCT01235273|Placebo Comparator|Placebo|
89346721|NCT05147896|Active Comparator|Interventional Arm|Beside metformin and sulphonyl urea treatment, the active, interventional arm, will be receiving Semaglutide Oral Tablets as per protocol, 3 mg for the first month, 7 mg in the second month and 14 mg form the third month onwards.
89346722|NCT05147896|No Intervention|Comparative Arm|This group will not be receiving the additional therapy besides metformin and sulphonyl urea treatment. After 6 months a revaluation of glycemic control will be performed, if needed, rescue therapy with basal insulin will be implemented.
89346723|NCT01140035|Experimental|Intensive insulin therapy|"Intensive insulin therapy with goal of glucose < 150 mg/dl~Control group with standard insulin therapy with goal of glucose 180 mg/dl"
89346724|NCT04886583||Gabi Baby Band|GSC 1
89346725|NCT01137149|Active Comparator|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
89346726|NCT01137149|Experimental|Behavioral Acitivation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
89346727|NCT04401917|Other|HIV positive (HIV+) subjects with Opioid Use Disorder (OUD)|HIV positive (HIV+) subjects with Opioid Use Disorder (OUD): HIV+/OUD+
89346728|NCT04401917|Other|HIV negative (HIV-) subjects with OUD|HIV negative (HIV-) subjects with OUD: HIV-/OUD+
89346729|NCT04401917|Other|HIV Positive (HIV+) subjects with OUD negative|HIV+ subjects who may have been opioid-exposed but do not have current or past OUD
89346730|NCT04401917|Other|Healthy volunteer|HIV-, OUD- healthy controls who have been opioid-exposed but do not have current or past OUD
89346731|NCT04728711|Experimental|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week|
89346732|NCT04728711|Placebo Comparator|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week|
89346733|NCT05530967|Experimental|Triaging Tool|
89346734|NCT05530967|Experimental|Video Education|
89346735|NCT01137227||Description|"2137 studies retrieved in 8 databases (Biomed Central, CINAHL, EMBASE, ERIC, PsycInfo, PUBMED, SCOPUS, SPORTDiscus and uploaded in EndNote Web®.~332 studies were excluded as duplicates by EndNote Web®.~1805 titles and abstracts were assessed independently by two researchers (PG/AM): 1541 studies excluded.~264 studies referred for full-text assessment by two independent investigators (PG/AM)~225 studies were excluded according to the eligibility criteria (in case of discrepancies in the assessment of the researchers, studies were reviewed in duplicate)~39 Studies assessed for quality using STROBE~13 Studies were included in the descriptive synthesis"
89346736|NCT01140113|No Intervention|Placebo|this group had undergone to routine coronary artery bypass graft surgery
89346737|NCT01140113|Experimental|Modified Ultrafiltration|patients after weaning from bypass were submitted to ultrafiltration
89346738|NCT03086330|Experimental|Semaglutide|
89346739|NCT03086330|Placebo Comparator|Placebo|
89346740|NCT05522699|Experimental|Cough suppressive therapy|"The cough suppressive therapy consists of four one-to-one treatment sessions, 45 minutes per session, over a 2 months period. The sessions include patient education about chronic cough; negative effects of repeated cough as well as patient education of voluntary control of cough; identification of cough triggers and learning cough suppression techniques, and psychoeducational counselling including patient self-motivation, repetition of aims and techniques, behavior modification regarding over-awareness of the need to cough.~The sessions will be conducted by a specially trained physiotherapist or speech and language therapist. All components of the cough suppressive therapy will be delivered to each participant but the focus and emphasis on individual techniques will be individually tailored for each participant, determined by the physio- or speech and language therapist together with the participant."
89346741|NCT05522699|Active Comparator|Healthy lifestyle instructions|The Healthy lifestyle instructions consists of four one-to-one treatment sessions, 30 minutes per session, over a 2 months period. The sessions will be conducted by a specially trained physiotherapist or speech and language therapist. The sessions include patient education and motivational conversation about healthy eating habits, physical activity, stress and relaxation.
89346742|NCT04830345|Experimental|ATGC-100 100U|ATGC-100 will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
89346743|NCT04830345|Active Comparator|Botox 100U|Botox inj. will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
89346744|NCT01232933|Experimental|VPS System|Use of navigational VPS system to place catheter
89346745|NCT02686372|Experimental|HBV/TCR-T cell infusion|Subjects enrolled in the experimental (treatment) group will receive escalating doses of HBV/ TCR expressing autologous T cells. The interval between the first two doses is 14 days, followed by one month of safety monitoring, before subsequent two doses of 1 month interval in between. Thereafter, subjects would enter into observation period of the safety and tolerability of the treatment and will be followed up until disease relapse.
89346746|NCT02686372|Other|No intervention and TCR-T (at crossover)|No intervention and to be crossover to experimental arm upon confirmation of disease recurrence.
89346747|NCT03631394|Experimental|beetroot and anthocyanin|A compound pharmacy will formulate capsules with nitrates extracted from beetroot and anthocyanins from tart cherries. A daily dose of the capsules will be taken for 7 days after the washout period. Each dose will comprise 500 mg of nitrates and 450 mg of anthocyanins. In a meta-review by Dominguez and colleagues, 6-8 mmol of nitrates from beetroot was associated with increased exercise performance. Another review by Kelley et al., showed that marathon runners and resistance trainers ingesting between 450-480 mg of anthocyanins had reduced muscle soreness and decreased oxidative stress. Subject will consume each supplement orally with only water 2 hours pre-prandial.
89346748|NCT03631394|Placebo Comparator|beetroot and placebo|The same compound pharmacy will formulate capsules with nitrate extracted from beetroot and a placebo element made of starch. This product will taste the same as the nitrate and anthocyanin supplementation. A daily dose of the capsules will be taken for 7 days after the washout period. Each supplementation will have 500 mg of nitrate and 450 mg of placebo. Subjects will consume each supplement orally with only water 2 hours pre-prandial.
89346749|NCT01329653|Experimental|aerobic training|12 weeks of aerobic training, 4X/week
89346750|NCT01329653|Placebo Comparator|wait list control|wait list control condition, 12 weeks to parallel the active intervention group
89346751|NCT03233217|Experimental|Cohort 1: QIV-HD by IM|Participants were randomized to receive a single 0.7-milliliter (mL) injection of QIV-HD by IM route on Day 0.
89346752|NCT03233217|Experimental|Cohort 1: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
89346753|NCT03233217|Experimental|Cohort 2: QIV-HD by IM|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by IM route on Day 0.
89346754|NCT03233217|Experimental|Cohort 2: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
89346755|NCT03233217|Active Comparator|Cohort 2: QIV-SD by SC|Participants were randomized to receive a single 0.5 mL injection of QIV-SD by SC route on Day 0.
89346756|NCT01568996|Experimental|Low dose BSE-SFN|BSE-SFN will be orally administered at 50 µmol SFN for 28 days.
89346757|NCT01568996|Experimental|Mid dose BSE-SFN|BSE-SFN will be orally administered at 100 µmol SFN for 28 days.
89346758|NCT01568996|Experimental|High dose BSE-SFN|BSE-SFN will be orally administered at 200 µmol SFN for 28 days.
89346759|NCT01141985|Other|Treated|This is a single arm study.
89346760|NCT02681614|Experimental|Uronav|"Participants will undergo a Uronav guided biopsy with Magnetic Resonance Imaging confirmation.~All biopsies will be completed in the outpatient setting in the ambulatory OR prior to routine prostate brachytherapy under general anesthesia."
89346761|NCT03064269|Experimental|Arm 1|CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
89346762|NCT04220840||Study Group|All consecutive patients who underwent damage control surgery (DCS) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers
89346763|NCT04220840||Control group|All consecutive patients who underwent other than DCS surgery (resection with primary anastomosis, Hartmann´s procedure, laparoscopic lavage) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers which do not apply DCS routinely.
89346764|NCT01381484|No Intervention|Placebo|This group received placebo gel and requested to apply periorbital area and over the face for 3 months.
89346765|NCT01381484|Experimental|Study group|This group received La Jolie Gel and requested to apply periorbital area and over the face for 3 months.
89346766|NCT02943993||Patients treated with Edoxaban|Patients with established initial or recurrent acute symptomatic VTE treated with edoxaban according to the Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
89346767|NCT02620150|Experimental|Experimental|CCBT plus Escitalopram, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
89346768|NCT02620150|Placebo Comparator|Placebo|CCBT plus Placebo, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
89346769|NCT05198219|Experimental|Rhinolaryngoscope Ambu® aScope™ 4 Rhinolaryngo|All approved procedures performed during the study period.
89346770|NCT05198219|Active Comparator|Conventional reusable rhinolaryngoscope|All procedures performed during the study period.
89346771|NCT04098302|Active Comparator|dutasteride|two 0.5 mg capsules of dutasteride daily
89346772|NCT04098302|Placebo Comparator|placebo capsule|inactive placebo matched in appearance with dutasteride capsules
89346773|NCT02596126|Active Comparator|Treatment Prevention for Secondary CV|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
89346774|NCT02596126|Experimental|Cardiovascular Polypill|Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.
89346775|NCT01381328||RAL Group|HIV-1 infected patients failing to a RALTEGRAVIR-containing regimen
89346776|NCT05288517|No Intervention|Control Arm|Control patients received three invitations for a survey only and were blind to the L2L intervention.
89346777|NCT05288517|Active Comparator|Lock to Live Intervention Arm|Patients in the Intervention Arm received the invitation to Lock to Live, including up to 3 EHR invitation messages plus three messages to complete a follow-up survey evaluating study outcomes.
89346778|NCT05420246||These cases were given the treatment regimen including Ainuovirine|These cases were given the regimen including Ainuovirine (150mg, oral,qd)
89346779|NCT05494541||Overall cohort|All the patients who met the base inclusion criteria were included in the cohort.
89346780|NCT05494541||Three-month cohort (3m cohort)|Patients with stability and eligibility in IQVIA Patient Centric Medical Claims Database (Dx) and stability and eligibility in IQVIA Longitudinal Prescription Database (LRx) during the 3 months following the index date were included in the cohort.
89346781|NCT05494541||Six-month cohort (6m cohort)|A subset of patients from the 3m cohort with stability and eligibility in Dx and stability and eligibility in LRx during the 6 months following the index date were included in this cohort.
89346782|NCT01381250|Experimental|Treatment|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
89346783|NCT05488613||Midostaurin|Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
89346784|NCT04281316|Active Comparator|Non Invasive Ventilation device group|The patients in the NIV arm will receive treatment as in their usual care with an additional educational session of one hour for improving compliance.
89346785|NCT04281316|Experimental|Nasal High Flow (MyAirvo) device group|The patients in the NHF arm will receive NHF treatment and two hours training adaptation session will be conducted in the hospital.
89346786|NCT04047290|Experimental|AK112|AK112 IV every 2 weeks (q2w) or every 3 weeks (q3w)
89346787|NCT01233089|Experimental|CARE|Investigational single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
89346788|NCT01233089|Active Comparator|AIR OPTIX AQUA|Commercially available single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
89346789|NCT01233089|Active Comparator|AIR OPTIX AQUA MULTIFOCAL|Commercially available multifocal contact lenses worn bilaterally on a daily wear basis and replaced monthly
89346790|NCT04240366|Other|Group 1|Balloon-based ablation of atrial fibrillation by pulmonary vein isolation alone
89346791|NCT04240366|Experimental|Group 2|Balloon-based ablation of atrial fibrillation by pulmonary vein and left atrial appendage isolation
89346792|NCT05278611|Experimental|EP-9001A|Dose-escalation trial
89346793|NCT05278611|Placebo Comparator|Placebo|Dose-escalation trial
89346794|NCT05420168||Patient who received antibiotic prophylaxis|Patient who received antibiotic prophylaxis to assess appropriateness and consumption of treatment.
89346795|NCT03449992|Experimental|Intervention group|Participants in this group ingested nitrate-rich beetroot juice for 15 days
89346796|NCT03449992|Placebo Comparator|Placebo group|Participants in this group ingested a placebo drink for 15 days
89346797|NCT01137383|Experimental|Treatment group|
89346798|NCT03449836|Experimental|Streptococcus salivarius 24SMBc + Strept.oralis 89a|spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a
89346799|NCT03449836|Active Comparator|fluticasone + mometasone|spray with fluticasone and mometasone
89346800|NCT03449836|Placebo Comparator|placebo|spray with isotonic solution
89346801|NCT01142765|Experimental|Group 1|1 dose of AdCh63 MSP1 and 1 dose MVA MSP1 followed by sporozoite challenge
89346802|NCT01142765|Experimental|Group 2|1 dose of AdCh63 AMA1 and 1 dose MVA AMA1 followed by sporozoite challenge
89346803|NCT01142765|Experimental|Group 3|1 dose of AdCh63 AMA1 and 1 dose AdCh63 MSP1 co-administered into separate arms followed by 1 dose of MVA AMA1 and 1 dose MVA MSP1 co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
89346804|NCT01142765|Experimental|Group 4|1 dose of AdCh63 MSP1 and 1 dose AdCh63 ME-TRAP co-administered into separate arms followed by 1 dose of MVA MSP1 and 1 dose MVA ME-TRAP co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
89346805|NCT01142765|Other|Group 5|Non-vaccinated controls for sporozoite challenge
89346806|NCT05419544|Experimental|The intervention group/ Holy Quran Recital|The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital.
89346807|NCT05419544|No Intervention|The control group/ Usual care by the nurse|The control group received usual care by their nurses.
89346808|NCT03449524|Active Comparator|75mg CXA-10|Once daily dosing of 75mg CXA-10 in the morning
89346809|NCT03449524|Active Comparator|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
89346810|NCT03449524|Placebo Comparator|Placebo|Once daily dosing in the morning
89346811|NCT01384370||AHPV positive and negative subjects|
89346812|NCT01234181|Experimental|BMSCs transplantation|
89346813|NCT01234181|Sham Comparator|No BMSCs transplantation|
89346814|NCT03443752|Experimental|Shotokan-Karate|The protocol for Shotokan-karate training will involve a one hour training session which will be broken down into 3 major components. The training program will consist of warm-up exercises, katas (choreographed karate movements), and cool-down exercise.
89346815|NCT03443752|Experimental|Tai-Chi|The protocol for Tai Chi will involve a one-hour training session which will be conducted by an instructor at the Sun Life Financial Movement Disorders and Rehabilitation Centre.The following program will be held three times per week.
89346816|NCT03961256|Experimental|Exenatide SR Intervention Group|Subjects will receive, in addition to standard care, Exenatide SR 2 mg subcutaneous (SQ) weekly for 24 months.
89346817|NCT03961256|No Intervention|Standard of Care|Subjects will receive standard post-transplant care as per Mayo Clinic usual practice.
89346818|NCT04929197|Experimental|Wear Personalized breast holder system (PERSBRA) to receiving radiotherapy|Wear PERSBRA to the end of radiotherapy.
89346819|NCT03443596|Active Comparator|Early intensive BP control|BP in participants in this arm is treated aggressively, lowered and maintained at systolic blood pressure between 140-160mmHg, within 6 hours of stroke onset and maintained in this range for first 72 hours.
89346820|NCT03443596|No Intervention|Guidelined based BP control|Participants are treated according to the current international guidelines in thrombolysed acute ischemic stroke patients, i.e., less than 180/105mmHg
89346821|NCT03443518|Experimental|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical land mark for psoas plexus, also normal saline 0.9% IV infusion will be in the same rate of the Remifentanil infusion for the other group.
89346822|NCT03443518|Experimental|L.A infiltration /Remifentanil infusion|L.A infiltration (lidocaine) 5 ml of 2% will be injected subcutaneous as L.A infiltration then Remifentanil infusion with rate 0.03-0.1 μg / kg / min to achieve Visual Analog Scale 3 or less.
89346823|NCT03443362||Chronic urticaria|50 consecutive chronic urticaria patients receiving medical care within the CHU Brugmann Hospital. Diagnose according to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines.
89346824|NCT03443362||Control|20 healthy control patients, without chronic urticaria. Patients coming to the CHU Brugmann hospital for the excision of atypical naevi.
89346825|NCT01234259|Experimental|Study group|Device: Venus Freeze (MP)2 V2 system
89346826|NCT01234259|Sham Comparator|control group:|Sham comparator
89346827|NCT01142063||Treatment A (Reference fasted)|Treatment A (Reference fasted): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fasted condition.
89346828|NCT01142063||Treatment B (Test fasted)|Treatment B (Test fasted): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fasted condition.
89346829|NCT01142063||Treatment C (Reference fed)|Treatment C (Reference fed): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fed condition.
89346830|NCT01142063||Treatment D (Test fed)|Treatment D (Test fed): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fed condition.
89346831|NCT03443284|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of an iPhone or iPod Touch Operating System (iOS) mobile application (app) and a health care provider (HCP) portal.
89346832|NCT03443284|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health & Services.
89346833|NCT04330625|Experimental|REMD-477|REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for four weekly doses
89346834|NCT04959604|Experimental|ICG-marked Colon Carcinoma|The participants will receive an endoscopic marking via ICG preoperatively
89346835|NCT03747497|Experimental|contezolid acefosamil|contezolid acefosamil 1500 mg IV x 1 dose, followed by 1000 mg IV q12h for at least 3 total IV doses, followed by 1300 mg PO q12h for 10 to 14 days
89346836|NCT03747497|Active Comparator|linezolid|linezolid 600 mg IV q12h for at least 3 total IV doses, followed by 600 mg PO q12h for 10 to 14 days
89346837|NCT02521558|Experimental|Intervention Group|In the Intervention Group, patients will receive an iPad with the Constant Therapy cognitive rehabilitation application. Patients in the Intervention Group will practice the memory tasks developed for the Constant Therapy application for a total of six months. On a weekly basis, a clinician and/or research assistant will check in with the patient to answer any questions or address any concerns the patient has with using the Constant Therapy application, or how to perform any of the memory tasks. At the end of six months, each individual in the Intervention Group is assessed with standard cognitive testing to determine if there was any change on overall cognition.
89346838|NCT02521558|Active Comparator|Control Group|The Control Group will not receive any intervention. The Control Group will be given simple sets of puzzle booklets to practice over the 6 month period (e.g., word search puzzles, number and/or math puzzles). The Control Group will also receive standardized cognitive testing at the end of 6 months. Weekly check-ins by a clinician and/or research assistant will also occur in the Control Group. Every 4th patient recruited for the study will be assigned to the Control Group.
89346839|NCT03745703|Experimental|MOCHA|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
89346840|NCT03745703|Experimental|"MOCHA+, Stories Matter"|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
89346841|NCT03745703|No Intervention|Wait-list control|There is no intervention to be administered during the 12-week wait-list control period
89346842|NCT04451824|Experimental|Intervention with Routine Use of Red Light|Routine Use of red light (635nm) for 30 minutes on patients is to be observed in relation to its effect(s) in achieving circumferential reduction of the thighs, hips and waist of the patient, and a contour reduction of any protrusion of fat.
89346843|NCT05179031|Other|Arm 1|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346844|NCT05179031|Other|Arm 2|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346845|NCT05179031|Other|Arm 3|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346846|NCT05179031|Other|Arm 4|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346847|NCT05179031|Other|Arm 5|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346848|NCT05179031|Other|Arm 6|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346849|NCT05179031|Other|Arm 7|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346850|NCT05179031|Other|Arm 8|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346851|NCT05179031|Other|Arm 9|All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
89346852|NCT04452058||Internal cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to December 31,2019. Patients with single pulmonary lesion underwent preoperative chest CT scan and histologically confirmed precancerous lesions or early stage lung adenocarcinoma after thoracic surgery was included.
89346853|NCT04452058||External cohort 1|The same inclusion/exclusion criteria were applied for another independent centers, Sun Yat-sen Memorial Hospital ,Guangdong Province, China, forming an external validation cohort of 73 patients
89346854|NCT04452058||External cohort 2|The same inclusion/exclusion criteria were applied for another independent centers, Zhoushan Lung Cancer Institution, Zhejiang Province, China, forming second external validation cohort of 30 patients
89346855|NCT04452058||Immune Cohort|The internal cohort was retrospective enrolled in Guangdong Provincial People's hospital from March 1, 2015 to May 31,2020. Patients with advanced lung cancer underwent preoperative chest CT scan and histologically confirmed NSCLC before receiving immunotherapy was included.
89346856|NCT03443050|Experimental|Experimental|Balance training on unstable surfaces
89346857|NCT03443050|Active Comparator|Control|Balance training on stable surface
89346858|NCT01142141|Other|Manual therapy, kinesiotherapy|
89346859|NCT01235429|Experimental|Educational|Participants will receive 12 diabetes self-management educational lessons in a small group setting located within the participating communities and delivered by trained community health workers.
89346860|NCT01235429|Active Comparator|Delayed education|The delayed education group will receive the same intervention after the intervention group has completed the educational lessons and all participants have completed the follow-up assessments.
89346861|NCT03740867|Experimental|Group1|"Those with poor cognition (MOCA score<23)~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
89346862|NCT03740867|Experimental|Group2|"Those with good cognition (MOCA score≥23)~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
89346863|NCT03442660|Other|Data collection|An electronic data capture (EDC) system will be used to collect data in electronic format. Data will be collected at the enrolment visit, at the follow-up visit (8 weeks +/-2 weeks) and 1 to 4 days after the follow-up visit.
89346864|NCT04226807|Experimental|Early Postpartum Contact|Patient receive a phone call from research staff 2-3 weeks after giving birth in addition to routine postpartum visit
89346865|NCT04226807|No Intervention|Routine Postpartum Care|Patient receives routine postpartum visit only
89346866|NCT03109600|Experimental|Vi-DT (Bio Farma)|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
89346867|NCT03109600|Active Comparator|Vi polysaccharide vaccine|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Influenzae Vaccine
89346868|NCT03109600|Experimental|Vi-DT (Bio Farma) ~ Children|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
89346869|NCT03109600|Active Comparator|Vi polysaccharide vaccine ~ Children|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Pneumococcal Conjugate Vaccine
89346870|NCT01142921|Active Comparator|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
89346871|NCT01142921|Experimental|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
89346872|NCT03442348|Experimental|Omega 3 fatty acid supplements|Participants in this arm (N>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
89346873|NCT03442348|Active Comparator|Inulin fibre|The participants in the control arm (N>32) will be asked to take 20 g of fibre (inulin fibre) per day for a period of 6 weeks.
89346874|NCT01142219|Experimental|L-arginine|0.1g/kg/day for 6 months
89346875|NCT01142999|Active Comparator|Intervention (moisturizer group)|One group will be instructed to use a choice of 3 FDA-approved moisturizers and soap substitutes on their newborn infants.
89346876|NCT01142999|Active Comparator|Control group (no moisturizers)|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
89346877|NCT03441802|Active Comparator|Cases|
89346878|NCT03441802|Other|Controls|
89346879|NCT02943447|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
89346880|NCT02943447|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for 12 weeks.
89346881|NCT02943447|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
89346882|NCT02943447|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive open-label cilofexor 100 mg for an additional 96 weeks.
89346883|NCT03679013|Other|Opioid based standard of care regimen.|Inova Heart and Vascular Institute (IHVI) opioid based standard of care regimen given for post operative cardiac surgery pain.
89346884|NCT03679013|Experimental|Opioid sparing pain regimen.|Multimodal pain regimen consisting of PO Gabapentin paired with intravenous Acetaminophen given for post operative cardiac surgery pain.
89346885|NCT01140425|Experimental|PF-00232798 supratherapeutic dose|PF-00232798 supratherapeutic dose
89346886|NCT01140425|Experimental|PF-00232798 therapeutic dose|PF-00232798 therapeutic dose
89346887|NCT01140425|Placebo Comparator|Placebo for PF-00232798|Placebo for PF-00232798
89346888|NCT01140425|Active Comparator|Moxifloxacin|Moxifloxacin
89346889|NCT04890275|Experimental|BFR|Participants will participate in a supervised low load lower body blood flow restriction resistance exercise program twice a week for 12 weeks
89346890|NCT04890275|Active Comparator|NON-BFR|Participants will participate in a supervised low load lower resistance exercise program twice a week for 12 weeks (matched training volume as experimental arm but without BFR)
89346891|NCT03441724||STEMI before PCI|ST-segment elevation, recording acquired before coronary intervention
89346892|NCT03441724||STEMI after PCI|ST-segment elevation, recording acquired from the same patients after coronary intervention
89346893|NCT01235663|Experimental|advisory support|advisory support for six months to prolong the breast-feeding period
89346894|NCT02844777|Placebo Comparator|Placebo|Excipeint alone
89346895|NCT02844777|Experimental|5% VDA-1102|Active study medication
89346896|NCT02844777|Experimental|10% VDA-1102|Active study medication
89346897|NCT01236443|Experimental|HPPH|3 mg/m2
89346898|NCT03441568|Experimental|BAY987534|Infants and children with quiescent atopic dermatitis
89346899|NCT03991013|Active Comparator|Supplementary dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later for the first 14 days.
89346900|NCT03991013|Placebo Comparator|Placebo dose|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet daily with a matching placebo taken 12 hours later for the first 14 days.
89346901|NCT03441490|Active Comparator|ICBT standard|Internet-based cognitive behavioural therapy with therapeutic guidance through mail
89346902|NCT03441490|Experimental|ICBT chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat
89346903|NCT03441490|Experimental|ICBT learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail
89346904|NCT03441490|Experimental|ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat
89346905|NCT03620877|Experimental|personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
89346906|NCT03966833|Experimental|group-based interpersonal therapy (IPT-G)|14 weeks of group-based interpersonal therapy (IPT-G): StrongMinds is focused on treating depression in Uganda by training community members (in this case ELA club mentors) to act as mentors in IPT-G techniques. This intervention will be offered to 13-19 year old young women who score a 10 or higher on the PHQ-8. These adolescents who take up the offer will then be enrolled in the 14 weeks of therapy. Group therapy sessions build bonds between young women and encourage them to actively engage in the healing process and to support each other in the exploration of their depression triggers. With new healthier patterns and skills, women can learn to manage their current depression and ensure future depressive episodes can be quickly identified and resolved before the onset of any long-term consequences.
89346907|NCT03966833|Experimental|IPT-G + Unconditional Cash Transfer:|A one time lump sum of 200,000 UGX (~$54) be provided to all study participants in a random sub-set of intervention (IPT-G) clusters near or at the conclusion of the 14-week therapy. This treatment variation will allow for determination of whether complimentary income support enhances the effects of IPT-G on psychological wellbeing and other outcomes of interest.
89346908|NCT03966833|No Intervention|control|ELA clubs function as normal
89346909|NCT02521402|Other|Keloid Revision Surgery with Biovance|All enrolled patients will have Biovance applied during Keloid Revision Surgery
89346910|NCT01236599|No Intervention|traditional care|Preterm Infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off and wrapped up in a sterile preheated field
89346911|NCT01236599|Experimental|Polyethylene bag with previous drying|infants were placed under the radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off, and wrapped up in a polyethylene bag, leaving their faces discovered as well as the access at umbilical catheters or veined access.
89346912|NCT01236599|Experimental|Polyethylene bag without previous drying|Preterm infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel) and without previous body drying (only the head was dried), were wrapped up with the polyethylene bag, leaving their faces discovered as well as the access to umbilical catheters or veined access
89346913|NCT03441412|Experimental|Ticagrelor/Epinephrine/Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
89346914|NCT01235819|Active Comparator|Insulin alone|Type 1 DM only on Insulin
89346915|NCT01235819|Active Comparator|Insulin and Exenatide|Newly detected Type 1 DM on Insulin and exenatide
89346916|NCT01235819|Active Comparator|Insulin and Sitagliptin|Newly detected Type 1 DM using Insulin and Sitagliptin
89346917|NCT05275569|Experimental|True acupuncture + standard antiemetic treatment|
89346918|NCT05275569|Placebo Comparator|Sham acupuncture + standard antiemetic treatment|
89346919|NCT05272527|Experimental|Intervention Group|After the pre-tests were completed, the pregnant women were divided into experimental and control groups. Within the scope of the Transition to Motherhood Program, 5-session training and phone follow-ups were made in the first week and the fourth week postpartum to the experimental group. Post-tests were applied to the experimental group at the postpartum 1st month and 4th month.
89346920|NCT05272527|No Intervention|Control Group|After the pre-tests were completed, the pregnant women were divided into experimental and control groups. Pretest and postpartum 1st month and 4th month posttests were applied to the control group.
89346921|NCT04867096|Experimental|Physical activity intervention|"Arm A : standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months."
89346922|NCT04867096|No Intervention|Control|"Arm B : standard oncologic care."
89346923|NCT04848844||Patient transplanted due to ACHD and heart failure|Patients successfully transplanted due to congenital heart failure.
89346924|NCT04848844||ACHD listed due to heart failure for heart or heart and combined organ transplantation|Patients on the actual waiting list for heart or heart and combined organ transplantation. They can have either outcome transplantation or the primary outcome death on the waiting list or delisting due to clinical worsening. The secondary outcome is as well delisting due to clinical improvement.
89346925|NCT04848844||ACHD evaluated for heart transplantation|All patients evaluated for heart or heart and combined organ transplantation at the hospital level
89346926|NCT01234415|Experimental|Patient|
89346927|NCT04743609||Bronchiolitis|"- Children under 24 months of age (≤) with First episode of bronchiolitis.~Aims :~- For city physicians: Enrrollment of 1000 children with Bronchiolitis not associated with otitis~- In the hospital (at pediatric emergencies): Enrrollment of 900 children with bronchiolitis"
89346928|NCT04743609||Acute otitis media|"Define with Paradise Criteria) or otorrhea~Enrrollment only for city physicians :~500 children with Otitis not associated with Bronchiolitis~500 children with Otitis associated with Bronchiolitis"
89346929|NCT04743609||Pneumonia|"Defined by the presence of opacity of parenchymal condensation and/or pleural effusion on chest X-ray associated with fever.~Aims:~- For city physicians: Enrrollment of 100 children with pneumonia~- In the hospital (pediatric emergencies): Enrollment of 500 children with pneumonia"
89346930|NCT03441256|Experimental|Intervention|All participant in the intervention group will undergo the LION procedure and subsequent neurostimulation.
89346931|NCT03441256|Active Comparator|Control|All participants in the control group will be issued with a device for neuromuscular electrical stimulation.
89346932|NCT01234493|Active Comparator|fixation|Syndesmosis fixation with one 3.5mm fully threaded screw
89346933|NCT01234493|Active Comparator|no fixation|No syndesmosis fixation
89346934|NCT03441022|Experimental|Cardioversion|Amiigo watch during atrial fibrillation cardioversion. Optional sub-study: additional 30 days wearing Amiigo watch as well as BodyGuardian device.
89346935|NCT03638115|Experimental|VaSecure™ Drug Coated PTA Balloon Catheter|
89346936|NCT03620799|Experimental|Intervention group|10 participants will be assigned to the intervention group in order to the inclusion criteria for the study. Experimental group. Manual therapy intervention
89346937|NCT03620799|No Intervention|Control group|10 participants will be assigned to the control group in order to the inclusion criteria for the study. Control group
89346938|NCT03440710|Experimental|with BET|with BET and Tympanoplast
89346939|NCT03440710|Other|without BET|with Tympanoplast only
89346940|NCT03942536||MNH Emergency Cohort|Participants will be either patients who have experienced a critical pregnancy-related, obstetric, or neonatal health emergency.
89346941|NCT03942536||Birth Planning cohort|Pregnant women who complete an initial Birth Plan through the HN program within Mfangano Island East and South Sub-locations.
89346942|NCT03128788|Active Comparator|Active Comparator: supine position|Active Comparator: supine position thoracic epidural catheterization with supine position
89346943|NCT03128788|Active Comparator|Active Comparator: flexed lateral position|Active Comparator: flexed lateral position thoracic epidural catheterization with flexed lateral position
89346944|NCT01380860|Experimental|Mesh|The patients allocated to this arm of the study will have mesh (Covidien France: mono filament polyester bidimensional knit) implanted in association with their colostomy.
89346945|NCT01380860|Active Comparator|No mesh|The patients allocated to this arm of the protocol will not receive mesh implantation with their colostomy.
89346946|NCT03440632|Other|FES start|"Start: 4 weeks 'adaptation phase' and 8 weeks 'FES phase'. Adaption phase: the stimulus (in Volt) will gradually be increased up to an effective level and the wear time has to be increased from 30 minutes to 6 hours a day. FES phase: the participants have to wear the FES device for minimal 6 hours a day during walking. Usual physiotherapy can be continued during the FES phase.~Second: after the FES phase, this group will enter the 'wash-out' period of 6 weeks for fading of the therapeutic effects, in which they return to their conventional therapy. Afterwards, 12 weeks of conventional therapy (orthoses/shoes and usual physiotherapy) with measurements at start and end will follow."
89346947|NCT03440632|Other|Conventional start|"Start: wearing usual orthoses/shoes on a daily basis for the first 12 weeks of the study. Usual physiotherapy can be continued.~Second: after 12 weeks this group will enter a 6 week watch out phase, and next be switched to FES treatment for 12 weeks, consisting of: 4 weeks 'adaptation phase' with gradual increase of the treatment and 8 weeks 'FES phase'."
89346948|NCT02612337|Experimental|OTO-104|12 mg dexamethasone
89346949|NCT02612337|Placebo Comparator|Placebo|
89346950|NCT03440554|Experimental|Whole Body Non-Contrast MRI|
89346951|NCT03128710||Survey Group|Approximately 300 patients with prostate cancer will be provided a survey investigating their treatment preferences and side effects faced during and after receiving radiation treatment.
89346952|NCT03128710||Focus Group|Approximately 75 participants will participate in a focus group. All participants will have completed radiation treatment and will discuss side effects after having received radiation, as well as their quality of life while receiving radiation.
89346953|NCT02824575|Experimental|Arm A1-2: Paclitaxel plus Rebastinib.|"Arm A1 (Dose Escalation Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~Arm A2 (Expansion Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
89346954|NCT02824575|Experimental|Arm B1-2: Eribulin plus Rebastinib.|"Arm B1 (Dose Escalation Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~Arm B2 (Expansion Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
89346955|NCT05101330|No Intervention|Pilot Trial A, Usual Care arm|At recruitment, participants will be dispensed with new medication provided together with PMLs in English. After 2 weeks, data will be collected during a home visit and no changes will be made to the PMLs. After another 2 weeks, data will be collected and Rx Cap pill bottles will be retrieved.
89346956|NCT05101330|Experimental|Pilot Trial A, Intervention arm|At recruitment, participants will be dispensed new medication in Rx Cap pill bottles provided with PMLs in English. After 2 weeks, a home visit will be conducted, where the English PMLs will be switched out with bilingual PMLs. A final home visit will be done after another 2 weeks, and the labels will be switched back to the standard-issue PMLs issued by SGH, and the Rx Cap pill bottles will be retrieved.
89346957|NCT05101330|No Intervention|Pilot Trial B, Usual Care arm|At recruitment, participants will be dispensed new medication in Rx Cap pill bottles provided with PMLs in English. After 2 weeks, data will be collected and Rx Cap bottles will be retrieved.
89346958|NCT05101330|Experimental|Pilot Trial B, Intervention arm|At recruitment, participants will be dispensed new medication in Rx Cap pill bottles, provided with bilingual PMLs. After 2 weeks, data will be collected accordingly during the home visit and Rx Cap bottles will be retrieved. Bilingual labels will be removed and participants will resume usage of standard-issue SGH PMLs.
89346959|NCT01380704|Experimental|Active|
89346960|NCT01380704|Placebo Comparator|Placebo|
89346961|NCT04759300|Active Comparator|Group C-MAC VS|patients undergoing tracheal intubation using the C-MAC VS.
89346962|NCT04759300|Placebo Comparator|Group C-MAC VL D -blade|patients undergoing intubation using the C-MAC VL D-blade.
89346963|NCT03641937|Experimental|INVSENSOR00011 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00011 investigational sensor.
89346964|NCT01380626|Experimental|exercise training|
89346965|NCT04754464|Active Comparator|synbiotic|synbiotic consisting of three different strains of Lactobacillus fermentum + acacia gum (gum arabic)
89346966|NCT04754464|Placebo Comparator|microcrystalline cellulose|microcrystalline cellulose
89346967|NCT03780608|Experimental|GC|Patients with refractory gastric cancer who have failed secondary chemotherapy treatments for advanced disease will be enrolled. Patients must have imaging confirmed progression on previous chemotherapy for gastric cancer treatment with at least one measurable lesion per modified RECIST 1.1. GC patients must not have received previous therapy with immune checkpoint inhibitors. Prior exposure to AZD6738 is not allowed.
89346968|NCT03780608|Experimental|Melanoma|Patients with metastatic melanoma patients who have failed prior anti-PD(L)1 will be enrolled. Anti-PD(L)1 therapy should be the immediate prior regimen before study entry.
89346969|NCT03691298||Arthroscopic hip repair|
89346970|NCT03440242||JJVC Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
89346971|NCT03440242||JJVC Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
89346972|NCT03440242||Marketed Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
89346973|NCT03440242||Marketed Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
89346974|NCT03631316|Experimental|Generic valganciclovir|Participants will receive generic formulation (Pisa) of valganciclovir, 450 mg tablets, total dosage 900 mg daily for 4 days.
89346975|NCT03631316|Active Comparator|Innovative valganciclovir|The same participant will receive innovative drug valcyte (roche), 450 mg tablets, total dosage 900 mg daily during 4 days.
89346976|NCT03608865|Experimental|experimental group|Drug:Durvalumab + tremelimumab Dose/Potency:Durvalumab 1500mg(up to 4cycle) / tremelimumab 75mg(up to 13 cycle) Dose Frequency:Q4W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 4 week cycle Use:Experimental
89346977|NCT04751578|Experimental|Intervention|
89346978|NCT03532451|Experimental|Cohort 1: Nivolumab|Nivolumab 480 mg IV on week 0 and week 4
89346979|NCT03532451|Experimental|Cohort 2: Nivolumab/Lirilumab|Nivolumab 480 mg IV and Lirilumab 240 mg on week 0 and week 4
89346980|NCT04704531|Experimental|Group 1|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) BID in OU during 30 days.
89346981|NCT04704531|Experimental|Group 2|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
89346982|NCT04704531|Experimental|Group 3|Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) 6 times per day in OU during 30 days.
89346983|NCT01569230|Experimental|Individualized acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
89346984|NCT01569230|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
89346985|NCT01569230|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
89346986|NCT01569230|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
89346987|NCT02637531|Experimental|Part A/B: IPI-549 Dose Escalation|Participants receive IPI-549 orally (PO) once a day (QD) for Part A and twice a day (BID) in Part B until disease progression.
89346988|NCT02637531|Experimental|Part C: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346989|NCT02637531|Experimental|Part D: IPI-549 Monotherapy|Participants receive IPI-549 (dose determined from Part A/B) orally until disease progression.
89346990|NCT02637531|Experimental|Part D Annex: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346991|NCT02637531|Experimental|Part E: NSCLC: IPI-549 and nivolumab|Participants with NSCLC receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346992|NCT02637531|Experimental|Part E: Melanoma: IPI-549 and nivolumab|Participants with melanoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346993|NCT02637531|Experimental|Part E: SCCHN: IPI-549 and nivolumab|Participants with squamous cell cancer of the head and neck receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346994|NCT02637531|Experimental|Part F: TNBC: IPI-549 and nivolumab|Participants with triple negative breast cancer receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346995|NCT02637531|Experimental|Part G: ACC: IPI-549 and nivolumab|Participants with adrenocortical carcinoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346996|NCT02637531|Experimental|Part G: Mesothelioma: IPI-549 and nivolumab|Participants with mesothelioma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346997|NCT02637531|Experimental|Part H: High-circulating MDSCs: IPI-549 and nivolumab|Participants with high-circulating MDSCs receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
89346998|NCT01237925|Experimental|Dexchlorpheniramine 1% gel|
89346999|NCT01237925|Active Comparator|Dexchlorpheniramine 1% cream|
89347000|NCT01380548|Placebo Comparator|Placebo|
89347001|NCT01380548|Placebo Comparator|Iron alone|
89347002|NCT01380548|Experimental|Low-dose 5-aminolevulinic acid|
89347003|NCT01380548|Experimental|Medium-dose 5-aminolevulinic acid|
89347004|NCT01380548|Experimental|High-dose 5-aminolevulinic acid|
89347005|NCT01313247|Placebo Comparator|Placebo pills|Placebo tablets resembling paracetamol 500 mg are given as alternative 2 tablets 4 times daily
89347006|NCT01313247|Active Comparator|oral paracetamol 4 g daily|Patients are given 2 tablets of 500 mg paracetamol on a regular basis 4 times daily
89347007|NCT03109678|Experimental|Aura-i / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with Rüsch Super Safety Silk™ tracheal tube
89347008|NCT03109678|Experimental|Aura-i / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with LMA ETT™ tracheal tube
89347009|NCT03109678|Experimental|Fastrach / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with Rüsch Super Safety Silk™ tracheal tube
89347010|NCT03109678|Experimental|Fastrach / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with LMA ETT™ tracheal tube
89347011|NCT01144871||Male Parent/Guardians|Male Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
89347012|NCT01144871||Female Parent/Guardian|Female Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
89347013|NCT01313325|Experimental|Treatment group|Children between 5-17 years who have balance deficits related to any movement disorder (preferably neuromuscular)
89347014|NCT03439696|Experimental|Needlescopic-assisted|Thoracoscopic surgery performed with the fashion of single 2.5-3.5 cm intercostal incision and 1-2 additional 2-3 mmm needlescopic ports.
89347015|NCT03439696|Active Comparator|Uniportal|Conventional uniportal VATS with single 2.5-3.5 cm intercostal incision
89347016|NCT03439618|Other|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
89347017|NCT03439618|Other|time-restricted feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 6h (7:00-9:00,11:00-13:00,17:00-19:00).
89347018|NCT01238003||Hospitalized patients|
89347019|NCT04701424|Experimental|Closed loop insulin delivery|"Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 8 weeks~The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data"
89347020|NCT04701424|Active Comparator|Standard therapy|Participants in the control arm will continue to follow their current diabetes management plan for the 8 week study period. Participants will be wear a masked continuous glucose monitoring (CGM) system during the 8 week study period
89347021|NCT03560193|Experimental|Chlorhexidine Group|
89347022|NCT03560193|Active Comparator|Povidone Iodine Group|
89347023|NCT04451434|Experimental|Danicopan 200 mg Fasted|Fasting participants will receive a single dose of 200 mg danicopan.
89347024|NCT04451434|Experimental|Danicopan 200 mg Fed|Fed participants will receive a single dose of 200 mg danicopan.
89347025|NCT04451434|Experimental|Danicopan 400 mg Fed|Fed participants will receive a single dose of 400 mg danicopan.
89347026|NCT04679181|Experimental|Active arm|use of telemedicine
89347027|NCT04451200|Experimental|busulfan treatment|Personalized BU administration
89347028|NCT01143233|Active Comparator|control formula group|infants are fed a commercial, hydrolysed formula during the first 4 month of life, according to protocol
89347029|NCT01143233|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula with different protein content during the first 4 month of life, according to protocol
89347030|NCT01143233|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula with different protein content with pro- and prebiotics during the first 4 month of life, according to protocol
89347031|NCT01143233|Experimental|intervention formula 3 group|infants are fed hydrolyzed instant formula with different protein content with pro- and prebiotics during the first 4 months of life, according to protocol
89347032|NCT01143233|No Intervention|Reference group|infants are breast fed
89347033|NCT02359929|Experimental|Dose Level 1: Infusion of MSCs|First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight
89347034|NCT02359929|Experimental|Dose Level 2: Infusion of MSCs|Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight
89347035|NCT02359929|Experimental|Dose Level 3: Infusion of MSCs|Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight
89347036|NCT01585883|Experimental|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session.
89347037|NCT01585883|Active Comparator|Standard of care|Patients in this condition will receive usual care as decided by their oncology clinic team or physician.
89347038|NCT03085238|Experimental|M-Trap|
89347039|NCT01142531||COPD|COPD patients aged 40 or more, with a smoking history of > 10 PY and a post-bronchodilator FEV1/VC < 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5y.
89347040|NCT04668118|Experimental|Diquafosol group|The treatment period is 12 weeks. The day after subjects who meet the inclusion criteria undergo baseline examination is the day starting the medication. Dosing frequency was six times daily for 3% Diquafosol Ophthalmic Solution. The follow-up time points are 2, 4, 8, 12 weeks, and no other medication is required on the follow-up day.
89347041|NCT02251821|Experimental|Treatment (ruxolitinib, transplant)|Patients receive a ruxolitinib and undergo myeloablative or reduced-intensity conditioning followed by transplant and GVHD prophylaxis; see detailed description.
89347042|NCT03439540|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 12 weeks.
89347043|NCT03439540|Experimental|Plantago major|Individuals receive Plantago major daily, for 12 weeks.
89347044|NCT03439384|Experimental|Experimental: Home Telemonitoring|Patients will receive home telemonitoring equipment and monitor their health for 60 days post-enrollment. A monitoring nurse will receive and review the patients health data on a daily basis for the 60 day duration and provide remote care, counseling and education.
89347045|NCT03439384|No Intervention|Control: No Home Telemonitoring|The patient will not receive any home telemonitoring once enrolled and will continue to receive the usual care he/she can expect as part of his/her care plan.
89347046|NCT05394701|Experimental|RxOmega-3 soft gels (Enteric)|"Each participant receives their treatment of RxOmega-3 soft gel (Enteric) capsules at a total dose of 1260 mg Omega-3 Fatty Acids. Treatments are consumed with a glass of water (approx. 200 mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 14 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
89347047|NCT05394701|Experimental|Omega-3 Complete soft gels (Non-Enteric)|"Each participant receives their treatment of Omega-3 Complete soft gel (Non-Enteric) capsules at a total dose of 1260 mg Omega-3 Fatty Acids. Treatments are consumed with a glass of water (approx. 200 mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 14 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
89347048|NCT05394701|Experimental|Omega-3 LipoMicel® soft gels|"Each participant receives their treatment of Omega-3 LipoMicel® soft gel capsules at a total dose of 1260 mg Omega-3 Fatty Acids. Treatments are consumed with a glass of water (approx. 200 mL), followed by a standardized breakfast (diet-controlled condition). Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.~Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 14 days between each treatment will be used.~Adverse events are recorded throughout the study by direct questioning."
89347049|NCT03439306||healthy adult volunteer|"Subject is 18 to 50 years of age.~Subject is a non-smoker or who has not smoked within 2 days prior to the study."
89347050|NCT03784781||Asthmatic children|Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene
89347051|NCT03784781||Controls|Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.
89347052|NCT03439150|Other|Study arm|The study arm will undergo absolute flow and resistance measurements immediately after PPCI of the culprit artery
89347053|NCT05383703|Experimental|Treatment of MNC-168 enteric-coated capsules as a single oral drug|Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. The dosage increased in different stages. Each phase was administered once a day for three weeks.
89347054|NCT03538821|Experimental|Intact cod protein from fillet|Dietary supplement: intact cod protein from fillet, 8 g protein daily for 8 weeks
89347055|NCT03538821|Experimental|Intact cod protein from residual material|Dietary supplement: intact cod protein from residual material, 8 g protein daily for 8 weeks
89347056|NCT03538821|Experimental|Control|Control group receive tablet containing fillers and no proteins
89347057|NCT03438994|Active Comparator|Participants diagnosed with ASD|
89347058|NCT03438994|Experimental|Participants diagnosed with OND|
89347059|NCT03438994|Active Comparator|Typically developing participants|
89347060|NCT02215551||Study Group|"Younger than 90 years old. no communication barriers (e.g., English speaking, household telephone) Affirmative response to each of the three following questions: a) Do patients have pain, weakness, numbness, or tingling in their legs when walking standing? b) Does this pain, weakness, numbness or tingling in their legs interfere with their daily activities? c) Have patients tried at least one non-surgical treatment for their leg symptoms (e.g., physical therapy, pain medications, spinal injection)? Have been scheduled for surgery on lower back for a condition called lumbar spinal stenosis.~Whom have non degenerative causes of LSS such as tumor, infection, trauma, hemorrhage, or epidural lipomatosis, Prior lumbar spinal surgery, spondylolisthesis with spinal instability, significant cognitive impairment."
89347061|NCT05414162||CAR T-cell Therapy Group|Hematooncological patients undergoing CAR T-cell therapy with Tisagenlecleucel, Axicabtagen-ciloleucel, Idecabtagen-vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel or Ciltacabtagene Autoleucel (dosages, frequency and duration to be determined by the treating oncologist).
89347062|NCT03438760|Placebo Comparator|Science + Phonological Awareness|In all conditions, science is taught via the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) Journal/Reflection, and 4) dialogic reading centered around a given theme such as plant life. In the control condition, a minimum of six phoneme identifications and five rhymes will be incorporated into each lesson of this curriculum. While these activities are likely to improve the children's awareness of the sounds of the language (a foundational skill for learning to read), they are not likely to improve their access to the science being taught. Therefore, this intervention constitutes a placebo.
89347063|NCT03438760|Experimental|Science + Grammar Intervention|In the science + grammar condition, focused stimulation, an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities. The approach is incidental, rather than explicit. The active ingredients are models and recasts of the target structure. Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Recasts and/or models will be provided at an average rate of one per minute, an accepted therapeutic dose.
89347064|NCT03438760|Experimental|Science + Vocabulary Intervention|This arm involves Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 20 words that pertain to scientific practices applicable to the FOSS lessons. The children receive a cumulative exposure of at least 20 times per word (a minimum of 5 times per each of four lessons) and at least 4 chances to produce the word (a minimum of 1 chance per each of four lessons).
89347065|NCT02509689|Experimental|Single Arm|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
89347066|NCT03438604|Other|Donepezil TDS with Heat Applied|Corplex Donepezil TDS 5 mg/day with heat applied
89347067|NCT03438604|Other|Donepezil TDS without Heat|Corplex Donepezil TDS 5 mg/day with no heat applied
89347068|NCT03438604|Other|Donepezil TDS Extension Study with Heat|Corplex Donepezil TDS 5 mg/day with heat. Two skin sensors will be placed underneath the TDS and adjacent to the TDS.
89347069|NCT05413538|Experimental|Experimental Group|The experimental group will be invited to listen to a 15-minute mindfulness instructional recording delivered daily through an instant messaging application and to practice accordingly for 14 consecutive days at their own choice of time and place.
89347070|NCT05413538|No Intervention|Waitlist control group|The waitlist control group will only be required to complete the demographic information, pre, post experiment and follow-up questionnaires before they receive the mindfulness training intervention.
89347071|NCT03631160|Experimental|TAES treatment|"Patients in the treatment group receive Transcutaneous Acupoint Electrical Stimulation (TAES) at Zhongji ( CV3),Guanyuan ( CV4), bilaterally Sanyinjiao ( SP6) and bilaterally Ciliao ( BL32) points by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained until the end of treatment."
89347072|NCT03631160|Sham Comparator|Sham TAES treatment|"Participants in the control group receive shallow TAES at SP6, BL32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the acuponit is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output."
89347073|NCT03433378|Active Comparator|Tretinoin cream, 0.05%|Apply once a day application, under at-home use conditions.
89347074|NCT03433378|Active Comparator|RETIN-A® (tretinoin) cream, 0.05%|Apply once a day application, under at-home use conditions.
89347075|NCT03433378|Placebo Comparator|Vehicle of the test product|Apply once a day application, under at-home use conditions.
89347076|NCT01236677||Community acquired pneumonia,age≥14 ys|Patients with community acquired pneumonia,age≥14 ys and less than one week after the onset of symptoms, without pregnancy,breast-feeding,HIV infection,recent 90-day hospitalized history and in nursing homes or rehabilitation hospitals
89347077|NCT03433300|Experimental|Microprocessor Knee|Ottobock Kenevo/Ottobock C-Leg
89347078|NCT03433300|Active Comparator|Nonmicroprocessor knee|Ottobock 3R60 for K3 participants, Ottobock 3R62 for K2 participants.
89347079|NCT01143311|Other|ARM A|"4 distinct biopsies will be taken~in a non UV-exposed area (inner arm)~in a UV-exposed area (external surface of the forearm)~in a pretumoral region (actinic keratosis)~inside the tumor"
89347080|NCT03433222|Experimental|HF-LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
89347081|NCT03433222|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
89347082|NCT03383666|Experimental|Treatment Group|PulseRider® Aneurysm Neck Reconstruction in conjunction with coil embolization for unruptured wide-neck intracranial aneurysms.
89347083|NCT01236131||Endometrial biospy samples|The Endometrial Biopsy samples will be provided by women enrolled in the University of Pittsburgh IRB PRO10010112 and PRO10010159
89347084|NCT05016076|Active Comparator|Dexamethasone|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia. Anesthesia will be maintained with 2-3 vol% sevoflurane and 60% oxygen in nitrogen, whereas the fraction of inspired oxygen (FiO2) 0.8-1.0 will be used during pneumoperitoneum to ensure oxygen saturation higher than 92%.
88814355|NCT04376294|Active Comparator|Control group|This group received conservative physical therapy treatment(eccentric training + stretching exercise) only.
89347085|NCT05016076|Placebo Comparator|Placebo (0.9% sodium chloride)|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia. Anesthesia will be maintained with 2-3 vol% sevoflurane and 60% oxygen in nitrogen, whereas the fraction of inspired oxygen (FiO2) 0.8-1.0 will be used during pneumoperitoneum to ensure oxygen saturation higher than 92%.
89347086|NCT05016076|Active Comparator|Inspiratory pressure (10 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
89347087|NCT05016076|Active Comparator|Inspiratory pressure (15 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
89347088|NCT05016076|Active Comparator|Inspiratory pressure (20 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
89347089|NCT05016076|Active Comparator|Inspiratory pressure (25 cmH2O)|After the loss of eyelash reflex, a Guedel oropharyngeal airway (Biçakcilar, Istanbul, Turkey) will be placed into the oral cavity to assure adequate mouth opening. A facemask will be applied firmly to the patient's face to ensure an adequate seal. A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea is determined by end-tidal capnography occurs, mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure, at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator.
89347090|NCT05016076|Active Comparator|Video intubating stylet|A tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved.
89347091|NCT05016076|Active Comparator|Video laryngoscopy|A tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients.
89347092|NCT05016076|Active Comparator|Direct laryngoscopy|Tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
89347093|NCT05016076|Active Comparator|Goal-directed hemodynamic therapy|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2.61 In brief, if cardiac index < 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is < 10%. If cardiac index < 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is < 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
89347094|NCT05016076|No Intervention|Usual care (control)|Subjects allocated to the control group are hemodynamically managed as per anesthesiologist preference. Typically, isolated hypotension (20% decrease in mean arterial pressure below baseline or < 60 mmHg) is treated by single or consecutive boluses of norepinephrine 5 or 10 μg. If hypotension persists, repeat boluses of ephedrine 4 mg will be administered until mean arterial pressure is above 60 mmHg. If hypotension is accompanied by signs of hypovolemia (urine output < 0.5 ml·kg-1·hr-1 and/or an increase in heart rate > 20% above baseline), crystalloid or colloid fluids will be given until urine output and/or heart rate are normalized. If hypotension persists despite volume challenge, norepinephrine will be used.
89347095|NCT01145027|No Intervention|Control group|
89347096|NCT01145027|Experimental|Sensorial Stimulus|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste, in order to trigger the cephalic phase of insulin secretion
89347097|NCT01380470||Chronic Obstructive Pulmonary Disease|Group of patients seen in consultation not previously diagnosed with COPD, both sexes, aged between 40 and 70 years.
89347098|NCT03707405|Active Comparator|ROC-sit|Ride-On Cars with Sitting Posture (ROC-sit) The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary. The natural play session can be divided into two 20-to-25 sessions depending on the participant's condition. Training will concentrate on building the concept of casual-effect on the switch and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person) in public spaces (e.g., hallways, convenient stores, garden, museum) and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying motor skills for mobility and socialization in natural play session. All the programs will be discussed by the family, the treating therapist and the research team.
89347099|NCT03707405|Active Comparator|ROC-sit45 and stand25|Ride-On Cars with 45-min Sitting and 25-min Standing Postures (ROC-sit45 and stand25) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 45-minute driving with sitting posture and then transfers to the standing posture for driving 25 minutes.
89347100|NCT03707405|Active Comparator|ROC-sit25 and stand45|Ride-On Cars with 25-min Sitting and 45-min Standing Postures (ROC-sit25 and stand45) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 25-minute driving with sitting posture and then transfers to the standing posture for driving 45 minutes.
89347101|NCT03707405|Active Comparator|ROC-stand|Ride-On Cars with Standing Postures (ROC-stand) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute standing session can be divided into two 30-minute sessions with 10-minute break, depending on the child's condition with the standing posture.
89347102|NCT03086018|Experimental|Successor hearing aid to Juna|The intervention is the new device which is the successor to the Juna device. The participants will use their current device as a control. The will wear the intervention device for approximately two weeks.
89347103|NCT03319953|Experimental|Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics|TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
89347104|NCT03319953|Experimental|Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
89347105|NCT03319953|Experimental|Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics|TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
89347106|NCT03319953|Experimental|Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
89347107|NCT03433144|Experimental|Intervention TXA|patients receiving TXA10mg/kg IV pre-operatively
89347108|NCT03433144|Placebo Comparator|Placebo|patients will receive an equivalent amount of normal saline 0.9% IV pre-operatively
89347109|NCT03433066|Experimental|group I (Test)|Advanced platelet-rich fibrin mixed with biphasic alloplast
89347110|NCT03433066|Active Comparator|Group II (control)|Biphasic alloplast mixed with saline
89347111|NCT01142609|Experimental|Internet (eGetgoing)|Subjects will assigned to use an accredited web-based platform (eGetgoingTM, CRC Health Group, Inc.) to deliver routine substance abuse counseling.
89347112|NCT01142609|No Intervention|Routine on-site|Subjects will attend routine face-to-face individual counseling sessions.
89347113|NCT01384214|Experimental|1|botulinum toxin Type A
89347114|NCT03432988|Experimental|nurses in the hemodialysis service|Nursing Solution-Focused: Two two-hour training modules were designed by two recognized solution-focused therapy experts. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays.
89347115|NCT02927834|Active Comparator|Antibiotic only|1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.
89347116|NCT02927834|Active Comparator|Augmentin with 6 day steroid|Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)
89347117|NCT02927834|Active Comparator|Augmentin with 21 day steroid|Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )
89347118|NCT01236209|Active Comparator|web page|"Control group:~Information web page with some mindfulness exercises"
89347119|NCT01236209|Experimental|Webpage and situational feedback|"Intervention group:~have access to the same web-page with information about coping with pain and relaxation and are completing 3 diaries and receiving personalized feedback for 4 weeks at home through a smartphone."
89347120|NCT03432910|Other|treatment group|Participants of the study undergo the standard stages of the clinical routine within a PAP therapy setting: a diagnostic night followed by one or two treatment nights.
89347121|NCT03757637|No Intervention|General module|"Control group will be case manager care only group. Eligible patients will also invite and receive their first time assessment as baseline during hospitalization. The usual cancer care group will receive routine cancer care in the inpatient wards through OPD visits."
89347122|NCT03757637|Experimental|NLSCP|NLSCP group will receive 5 section of NLSCP. Contents of scheduled intervention will be developed baed on the literature mentioned above. Ex 1 group, patients will receive at least 3 times face-to-face NLSCP, and two times by telephone calls for following up.
89347123|NCT03757637|Experimental|ICT supported HAP|The ICT supported HAP group will receive information or counseling through mobile phone App as the schedule intervention time. For this group, patients will receive two face to face interventions in the first two sections (pre-discharge from hospital and 5th week post-op). It will be delivered by research nurse to intervene patients and help them to build up the App system. Research nurse will also help patients to be familiar with the operation system. The rest parts of the intervention will all through Apps in the scheduled time. Patients can raise their questions and concerns through APPs. Patients in the HAP can raise their concerns or questions through APP and receive interventions or answers through App interactively.
89347124|NCT04000594|Experimental|Dose level 1 of RO7234292 (RG6042)|Participants will receive dose level 1 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
89347125|NCT04000594|Experimental|Dose level 2 of RO7234292 (RG6042)|Participants will receive dose level 2 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
89347126|NCT04000594|Experimental|Dose level 3 of RO7234292 (RG6042)|Participants will receive dose level 3 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
89347127|NCT03170180|Experimental|sunitinib|
89347128|NCT03170180|Experimental|gefitinib|
89347129|NCT03170180|Experimental|imatinib|
89347130|NCT03319667|Experimental|Isatuximab/Bortezomib/Lenalidomide/Dexamethasone = IVRd arm|"Induction treatment with 4x6-week cycles with intravenous (IV) isatuximab + subcutaneous (SC) bortezomib + oral lenalidomide + IV or oral dexamethasone~Continuous treatment with 4-week cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone"
89347131|NCT03319667|Active Comparator|Bortezomib/Lenalidomide/Dexamethasone = VRd arm|"Induction treatment with 4x6-week cycles with SC bortezomib + oral lenalidomide + IV or oral dexamethasone~Continuous treatment with 4-week cycles with oral lenalidomide + IV or oral dexamethasone"
89347132|NCT03319667|Other|Isatuximab/Lenalidomide/Dexamethasone = IRd crossover arm|4-weeks cycles with IV isatuximab + oral lenalidomide + IV or oral dexamethasone
89347133|NCT02521480|Active Comparator|Active Transcranial Magnetic Stimulation|During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression.
89347134|NCT02521480|Sham Comparator|Sham Transcranial Magnetic Stimulation|During sham TMS, a coil will be placed on the left prefrontal area of the head. Sham TMS will simulate active treatment as described in active arm.
89347135|NCT04698590|Active Comparator|WFG Scleral Lenses|Scleral lenses with customized wavefront guided optics
89347136|NCT04698590|Placebo Comparator|Traditional Scleral Lenses|Scleral lenses with traditional optics
89347137|NCT03432754|Experimental|Mindfulness-Based Attention Training|Four weekly group mindfulness attention training sessions of a 1.5-hour duration. Participants provided with audio recordings, readings, and homework assignments consisting of various mindfulness practices.
89347138|NCT03432754|Active Comparator|Lifestyle Education Group|Four weekly group lifestyle education sessions of a 1.5-hour duration. Homework consisting of reading, diet monitoring, stretching/toning exercises, and brainstorming new healthy living techniques/ideas.
89347139|NCT03432676|Experimental|Treatment (pembrolizumab, epacadostat)|Participants receive pembrolizumab IV over 30 minutes on day 1 and epacadostat PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unaccepted toxicity.
89347140|NCT03432598|Experimental|Non-squamous NSCLC|"Day 1 of each 21-day (3 weeks) cycle: Tislelizumab + pemetrexed + cisplatin 75 mg/m²/day IV (or carboplatin AUC 5).~Pemetrexed plus cisplatin (or carboplatin) should be given for up to 4 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate. Pemetrexed maintenance after completion of doublet chemotherapy is permitted."
89347141|NCT03432598|Experimental|Squamous NSCLC Cohort A|"Tislelizumab every 3 weeks (Q3W) + paclitaxel + cisplatin (or carboplatin), Q3W.~Paclitaxel plus cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
89347142|NCT03432598|Experimental|Squamous NSCLC Cohort B|"Tislelizumab Q3W on Day 1 + gemcitabine on Day 1 and Day 8 + cisplatin IV (or carboplatin) on Day 1.~Gemcitabine plus cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
89347143|NCT03432598|Experimental|SCLC|"Tislelizumab Q3W on Day 1, etoposide on Days 1, 2, and 3 + cisplatin (or carboplatin) on Day 1.~Etoposide and cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
89347144|NCT03318497|Experimental|Diagnostic (Interim FLT PET/CT)|"The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.~Procedure: Computed Tomography~Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
89347145|NCT03432442|Experimental|Group 1 (6 dengue patients)|Volunteers weighed > 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
89347146|NCT03432442|Experimental|Group 2 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
89347147|NCT03432442|Experimental|Group 3 (6 dengue patients)|Volunteers weighed > 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
89347148|NCT03432442|Experimental|Group 4 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
89347149|NCT01238159|Experimental|CCRT+MIDLE|Patients who are planned to be treated with CCRT plus MIDLE chemotherapy. CCRT means concurrent chemoradiation, and MIDLE represent systemic chemotherapy.
89347150|NCT01384136||High risk pregnancy|
89347151|NCT01384136||"|Control - Normal low risk pregnancies"|
89347152|NCT01964547|Active Comparator|Sativex|"Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.~Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability."
89347153|NCT01964547|Placebo Comparator|Placebo|Oromucosal spray, containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability.
89347154|NCT03432208|Active Comparator|ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)|GI consult Procedure performed is EGD
89347155|NCT03432208|Experimental|ENDOSCOPIC ULTRASOUND (EUS)|GI consult Procedure performed is EUS
89347156|NCT01380314|Experimental|1|Miltefosine 150 mg x day + Imiquimod 5%
89347157|NCT01380314|Placebo Comparator|2|Miltefosine 150 mg x day + Placebo
89347158|NCT03432130|Experimental|Experimental group|Performing a structural training program twice a week, 30 minutes each.
89347159|NCT03432130|No Intervention|Control group|
89347160|NCT03110510|Experimental|FOLFIRI|D1 Irinotecan 180 mg/m2 IV D1-2 5-FU 400mg/m2 bolus and then 2400mg/m2 continuous infusion D1 Leucovorin 200 mg/m2 Until disease progression, patient's refusal or unacceptable toxicities
89347161|NCT01238237|Experimental|Cetuximab|
89347162|NCT05179967|Experimental|WeFlow-JAAA Stent Graft System|
89347163|NCT03319719|Experimental|Belotero® Balance with integral lidocaine|Belotero® Balance with integral lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
89347164|NCT03319719|Active Comparator|Belotero Balance without lidocaine|Belotero Balance without lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
89347165|NCT01142687|Active Comparator|dihydrocapsiate 3 mg|• Group 1: 1 Dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner
89347166|NCT01142687|Active Comparator|dihydrocapsiate 9 mg|• Group 2: 3 Dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
89347167|NCT01142687|Placebo Comparator|Placebo capsule|• Group 3: 3 placebo capsules three times per day within 30 minutes before breakfast, lunch and dinner
89347168|NCT03128554|Experimental|Intervention with Training and Materials|Clinics randomized to the intervention group will receive a one time, 2-hour Continuing Medical Education/Group Learning training session on the smoking reduction intervention model, along with provider and patient handouts.
89347169|NCT03128554|No Intervention|Usual Care|Clinics randomized to the control group will not be exposed to the intervention program.
89347170|NCT01145261||Anxiety|Children with anxiety disorders
89347171|NCT01145261||healthy controls|children without anxiety disorders
89347172|NCT03128320|Experimental|BAY1193397/Placebo (sequence A-B-C)|Subjects with type II diabetes who follow treatment sequence A-B-C. Single oral dose of a placebo tablet in the first intervention period (Treatment A); followed by single oral dose of 1 mg BAY1193397 (Treatment B); then single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
89347173|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-C-A)|Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
89347174|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-A-C)|Subjects with type II diabetes who follow treatment sequence B-A-C. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of a placebo tablet in the second intervention period (Treatment A), then 5 mg BAY1193397 IR tablet under fasted conditions in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
89347175|NCT04567667|Experimental|Group 1|
89347176|NCT04567667|Experimental|Group 2|
89347177|NCT03128476|Active Comparator|1 bottle|
89347178|NCT03128476|Active Comparator|2 bottles|
89347179|NCT03128476|Placebo Comparator|Placebo|
89347180|NCT02528435||JIA patients|observationational study including children diagnosed with JIA. Patients aged 9 years and above, whom are treated with low-dose MTX may be included.
89347181|NCT02528435||ALL patients|observationational study including children diagnosed with ALL. Patients aged 9 years and above, whom are in maintenance treatment with low-dose MTX may be included.
89347182|NCT03318783|Active Comparator|GSK2256294|10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
89347183|NCT03318783|Placebo Comparator|Placebo|10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
89347184|NCT03128242|Experimental|oxytocin group|oxytocin treatment
89347185|NCT03128242|Placebo Comparator|placebo group|placebo treatment
89347186|NCT01313689|Experimental|Ofatumumab|Biological
89347187|NCT01313689|Active Comparator|Physicians' Choice|Physicians' choice of treatment
89347188|NCT01145339|Experimental|Lactase EUF|1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g).
89347189|NCT01145339|Active Comparator|Lactase Ref|1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g).
89347190|NCT03903094||Subjects With Overactive Bladder Treatment|Subjects who have dispensing records for treatment of overactive bladder will be included
89347191|NCT03903094||Subjects Without Overactive Bladder Treatment|Subjects who do not have dispensing records for treatment of overactive bladder will be included
89347192|NCT04825821||Low transverse hysterotomy closed by double-layer unidirectional barbed suture|Patients who had undergone cesarean section during which the low transverse hysterotomy was closed by double-layer unidirectional barbed suture
89347193|NCT04825821||Low transverse hysterotomy closed by conventional double-layer smooth suture|Patients who had undergone cesarean section during which the low transverse hysterotomy was closed by conventional double-layer smooth suture
89347194|NCT03431662|Experimental|Ellipse IM HTO Nail|In this arm, the subjects varus malalignment is corrected with Ellipse Intramedullary High Tibial Osteotomy Intramedullary Nail, which is a CE device. The device achieves the correction via progressive distraction osteogenesis.
89347195|NCT03431662|Active Comparator|TomoFix|In this arm, the subjects varus malalignment is corrected with Synthes TomoFix system, which is a CE device. The device achieves the correction via fixating an accute intraoperative correction of the varus malalignment.
89347196|NCT03431506|Active Comparator|non-training group|
89347197|NCT03431506|Experimental|training group|
89347198|NCT03431428|Experimental|transanal surgery|"To ensure the complete cutting edge with no residual tumor, the tumor with corresponding mesorectal excision was removed by the distance edge of 1cm.~The intestinal wall was sutured to ensure the integrity of the bowel."
89347199|NCT03431428|Placebo Comparator|Miles surgery|According to the total mesorectal excision(TME) principle, complete mesorectum, lymph node and the anus was excised. A sigmoid colostomy was finally performed.
89347200|NCT04501055|Experimental|Perineal nerve block|Man receive the perineal nerve block before under the transperineal prostate biopsy
89347201|NCT04501055|Active Comparator|Periprostatic block|Man receive the periprostatic block before under the transperineal prostate biopsy
89347202|NCT03431272|Experimental|Treatment|lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day
89347203|NCT03773497|Other|Common snack combination|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of a combination of common snack foods (pretzels, potato chips, and popcorn).
89347204|NCT03773497|Other|Cheese broccoli|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli.
89347205|NCT03773497|Other|Cheese broccoli with Daikon radish powder|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder.
89347206|NCT03773497|Other|Uncooked broccoli with ranch-type dip|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of uncooked, freeze-dried broccoli with ranch-type dip.
89347207|NCT02528513|Experimental|midazolam|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation."
89347208|NCT02528513|Experimental|midazolam/propofol|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation."
89347209|NCT02528513|Experimental|midazolam/dexmedetomidine|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation."
89347210|NCT03431116||Low implanted placenta group|
89347211|NCT01320007|Experimental|Group 1: Optivol Group|
89347212|NCT01320007|Active Comparator|Group 2: Optivol alarm muted|
89347213|NCT03430960|Other|Group A - Standard of Care|
89347214|NCT03430960|Experimental|Group B - mCare group|
89347215|NCT04980157||All Participants|Patients born between 1945-1965 who have clinic visits at a partnering federally qualified health center.
89347216|NCT03436264||high sensitivity to pain|
89347217|NCT03436264||low sensitivity to pain|
89347218|NCT03318315|Experimental|Group 1|3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant and 0.5 ml dose of IIV4 vaccine, both administered intramuscularly within 15 minutes on day 1, and 3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22, n=60
89347219|NCT03318315|Experimental|Group 2|0.5 ml dose of IIV4 vaccine intramuscularly on day 1 and 3.75 mcg HA per 0.5 ml dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22 and day 43, n=60
89347220|NCT03318315|Active Comparator|Group 3|0.5 ml dose of IIV4 vaccine intramuscularly on day 1, n=30
89347221|NCT03779971|Placebo Comparator|Control|The placebo comparator will be a fully controlled diet made from typical American foods and containing no beans or pulses.
89347222|NCT03779971|Experimental|Lentil|The lentil arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain lentils.
89347223|NCT03779971|Experimental|Chickpeas|The chickpea arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain chickpeas.
89347224|NCT03436186||no arm|no arm
89347225|NCT04460183|Experimental|Investigational arm|Participants will receive inhaled RESP301 administered using a nebulizer three times a day for up to 10 days in addition to the standard of care.
89347226|NCT04460183|Active Comparator|Control arm|Participants will receive institutional SOC for the treatment of COVID-19
89347227|NCT03710083|Experimental|Study arm|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-5, or 7).
89347228|NCT01243697|Experimental|desogestrel|Tablets of 75 µg, once daily during 112 days
89347229|NCT03638271|Other|nonischemic cardiomyopathic patient|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging.
89347230|NCT01244165|Other|Cytrix|Observational Study
89347231|NCT01244165|Other|Control Group|Patients with similar indications who were treated at the same centers using other products
89347232|NCT03318003|Experimental|Auto-PAP Therapy|
89347233|NCT03318003|No Intervention|No Therapy|
89347234|NCT01145573|Placebo Comparator|Placebo|Inactive pill taken daily
89347235|NCT01145573|Active Comparator|Calcium|1000mg of calcium taken daily
89347236|NCT04687813|Experimental|Single Ascending Doses 100mg|Drug: FTP-198, single dose 100mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet
89347237|NCT04687813|Experimental|Single Ascending Doses 300mg(food-impact)|Drug: FTP-198, single dose 300mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet 2-X: fasting (Period 1) ; 2-Y:Postprandial (Period 1) 2-X:Postprandial (Period 2); 2-Y:fasting (Period 2)
89347238|NCT04687813|Experimental|Single Ascending Doses 400mg|Drug: FTP-198, single dose 400mg Drug: Placebo, single dose Placebo matched to FTP-198, tablet
89347239|NCT01320709|Experimental|Arm 1|
89347240|NCT01320709|Experimental|Arm 2|
89347241|NCT01320709|Placebo Comparator|Arm 3|
89347242|NCT01320709|Experimental|Arm 4|
89347243|NCT01238315|Other|HuCNS-SC|
89347244|NCT03317379|Experimental|Peer mentorship|Participants meet weekly with an adult peer mentor who has recovered from an eating disorder. The focus of meetings is on eating disorder symptoms and how to overcome them. The goal of this program is to reduce eating disorder symptoms directly by receiving support and guidance from someone who has been through it.
89347245|NCT03317379|Active Comparator|Social support mentorship|Participants meet weekly with an adult mentor who has not personally struggled with an eating disorder but who is dedicated to offering support. During weekly meetings, participants and mentors (and possibly 1-2 other mentees) engage in activities unrelated to the eating disorder. The goal of this program is to reduce eating disorder symptoms indirectly by exploring aspects of self outside the eating disorder.
89347246|NCT03317379|No Intervention|Wait list|Participants are on a wait list and then get matched with either type of mentor (of their choice) 6 months later
89347247|NCT03780283|Experimental|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
89347248|NCT03780283|No Intervention|placebo|observation
89347249|NCT04299581|Experimental|Cryoablation in combination with Camrelizumab|Cryoablation treatment starts at day 1. Camrelizumab will be initiated on day 14 after Cryoablation. Camrelizumab will be administered every three weeks (3mg/Kg, IV) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89347250|NCT03779737|Active Comparator|Habitual training|The control group will be monitored passively for the detection of adverse or secondary events.
89347251|NCT03779737|Experimental|Muscular resistance training|This phase includes the execution of the study with three arms, one group will be assigned to strength training and the other to aerobic capacity training, taking into account the plan of sessions per week.
89347252|NCT03779737|Experimental|Cardiorespiratory training|In stage, a combined program of strength and aerobic capacity will be implemented, which will last six months more than will be compared with the previously defined control group.
89347253|NCT03316911|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
89347254|NCT03316911|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
89347255|NCT01238393|Experimental|Ranibizumab|('intravitreal ranibizumab' )
89347256|NCT03776305|Experimental|Imipenem ECMO|1-h infusion of 0.5 g of imipenem, q6h
89347257|NCT04491331||Non-anesthetized volunteers|Hemodynamic parameters will be measured in supine position. Volunteers will be turned into prone position. After a five-minute stabilization phase will be monitored CI, MAP, heart rate (HR), stroke volume variation SVV, systemic vascular resistance index (SVRI) by non-invasive measurements using a ClearSight (Edwards) in two prone positions (lying on support system allowing a free abdomen and then lying flat without any device). Furthermore, the width of the inferior vena cava and vena jugularis interna, vena saphena and vena cephalica will be measured by ultrasound. The measurement will be performed in inspiration and in expiration phase.
89347258|NCT04938193|Experimental|68Ga-citrate PET/CT|
89347259|NCT01106391|Experimental|AAA stent graft system|"Cordis AAA stent graft system INCRAFT TM"
89347260|NCT01146509|Experimental|1|
89347261|NCT03775993|Active Comparator|GHD|
89347262|NCT03775993|Placebo Comparator|Placebo|
89347263|NCT01145729|Active Comparator|Biomarker feedback|Biomarkers of tobacco exposure (laboratory values) delivered to health care provider
89347264|NCT01145729|Placebo Comparator|Usual care (general counseling)|Brochure about pesticides, lead, SHS
89347265|NCT01320787|Experimental|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
89347266|NCT01244945|Experimental|L. reuteri DSM 17938|
89347267|NCT01244945|Placebo Comparator|Placebo|
89347268|NCT05273203|Experimental|Control|No intervention. Participated only in measurements at baseline and at 6 months.
89347269|NCT05273203|Experimental|FIM-1|Participated in a supervised 6 months football training program once per week and in measurements at baseline and at 6 months.
89347270|NCT05273203|Experimental|FIM-2|Participated in a supervised 6 months football training program twice per week and in measurements at baseline and at 6 months.
89347271|NCT05273203|Experimental|FIM-3|Participated in a supervised 6 months football training program thrice per week and in measurements at baseline and at 6 months.
89347272|NCT03316131|Experimental|Treatment A|"Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin;"
89347273|NCT03316131|Experimental|Treatment B|"Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin matched placebo"
89531928|NCT04758975|Experimental|Venetoclax + Rituximab +/- Ibrutinib|"VENETOCLAX: Cycle 1 Day 1-Cycle 1 Day 28 Ramp-up with weekly dose escalation; Cycles 2-12: 400 mg QD RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2~At the end of Cycle 12 the MRD status is checked:~3 consecutive uMRD in PB + 1 uMRD in BM at last assessment treatment discontinuation and follow-up At least 1 MRD+ sample in the last 3 assessments venetoclax 400 mg QD until uMRD or up to 24 months or unacceptable toxicity (whichever occurs first) in combination with IBRUTINIB 420 mg QD until uMRD or PD or unacceptable toxicity"
89347274|NCT03944447|Experimental|Cannabis users|"Most patients will have used cannabis before their initial physician visit, and many current patients will be returning for an in-person follow-up. Patients will be given the survey shortly after the physician encounter to assess baseline parameters with current cannabis use. Any patient who is cannabis-naïve, defined as no use within the past year or longer, will be placed into a separate data analysis arm. The investigators will follow up with patients again at 3, 6, 9, and 12 months with the online survey. Patients returning for their annual physician encounter will continue on the 3-month survey schedule until the end of the study, or if lost to follow-up. There may be slight variations in the interval based on state law, for example in Florida the in-person follow-up with the physician is required every 210 days, and some states allow for 2 year in-person visits. Every attempt will be made to adhere to a 3-month interval survey distribution."
89347275|NCT03944447|Experimental|Cancer prevention|Non-cancer patient medical cannabis users with extensive or life-long cannabis use will be compared to the general population for incidence and prevalence of development of cancer. The hypothesis is that cannabis use acts as a cancer preventive substance.
89347276|NCT03944447|Experimental|Life-Threatening Conditions|"Opioids are a class of drugs naturally found in the opium poppy plant. Opioids are often used as medicines because they contain chemicals that relax the body and can relieve pain. Prescription opioids are used mostly to treat moderate to severe pain. Opioids can also make people feel very relaxed and high - which is why they are sometimes used for non-medical reasons. This can be dangerous because opioids can be highly addictive, and overdoses and death are common.~From 1999 to 2017, more than 700,000 people have died from a drug overdose. Around 68% of the more than 70,200 drug overdose deaths in 2017 involved an opioid.~In 2017, the number of overdose deaths involving opioids was 6 times higher than in 1999.~On average, 130 Americans die every day from an opioid overdose.~This study will focus on examining outcomes of patients that have been treated with cannabis as a replacement or alternative to life-threatening opioids or other prescription drugs."
89347277|NCT03944447|Experimental|COVID-19 / SARS-CoV-2|Inhibition of viral entry and thereby spread constitute plausible therapeutic avenues. Similar to other respiratory pathogens, SARS-CoV2 is transmitted through respiratory droplets, with potential for aerosol and contact spread. It uses receptor-mediated entry into the human host via angiotensin-converting enzyme II (ACE2) that is expressed in lung tissue, as well as oral and nasal mucosa. Modulation of ACE2 levels in these gateway tissues may prove a plausible strategy for decreasing disease susceptibility. Cannabis sativa, especially one high in the anti-inflammatory cannabinoid cannabidiol (CBD), has been proposed to modulate gene expression and inflammation and possess anti-cancer and anti-inflammatory properties. Covid-19 infection rates in cannabis users will be compared to rates in the general population. Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population.
89347278|NCT03779659|Experimental|Synapse TENS device|SYnapse TENS device will be used for alleviating pain through electrical stimulation. This is a battery powered device where an electrical current is applied intra-orally on the buccal and lingual sides using an intra-oral pad applicator. This device has been cleared for marketing by the Food and Drug Administration (FDA) and the prescribed electrical field falls almost a 10 factor level lower than routine pulp testing devices used in dentistry. The TENS device was previously tested in a pilot study with promising results. Chair side application and at-home use of the device by the patient was shown to drastically reduce pain and discomfort associated with orthodontic tooth movement.
89347279|NCT03779659|Active Comparator|Topical anesthetic gel|Topical anesthetic Gel is the active comparator in this study. The topical anesthesia (anesthetic gel) Centrix LolliCaine with 20% benzocaine in single package of 0.3 ml will be used. The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure. This will be done based American Association of Pediatric Dentistry guidelines for the use of local anesthesia.
89347280|NCT01320865||Subjects with PAH treated with nilotinib|
89347281|NCT01145807|Placebo Comparator|Placebo|non Transfersome® placebo
89347282|NCT01145807|Sham Comparator|Transfersome® vehicle|Transfersome® vehicle
89347283|NCT01145807|Experimental|TDT 067|TDT 067
89347284|NCT03898895|Experimental|Radiotherapy+anti-PD-1 antibody|The total radiation dose is over 45Gy without damaging organic function. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
89347285|NCT01245569|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
89347286|NCT01245569|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
89347287|NCT01314859|Experimental|Nifedipine|"Oral Treatment with Nifedipine capsules (10 mg)~Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~Maximum Duration of the treatment: 48 hours."
89347288|NCT01314859|Active Comparator|Atosiban|"Intravenously Treatment with Atosiban (7.5mg/ml)~Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~Maximum Duration of the treatment: 48 hours."
89347289|NCT03765125|Experimental|collagen peptide test|1 x daily consumption of 1 blister package of the collagen-peptide test powder dissolved in water over a period of 90 days
89347290|NCT03765125|Placebo Comparator|collagen peptide placebo|1y daily consumption of 1 blister package of the placebo powder dissolved in water over a period of 90 days
89347291|NCT03779425|Experimental|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
88814356|NCT02244632|Experimental|Modufolin / Nordic FLV|Modufolin in combination with 5-Fluorouracil only.
89347292|NCT02528279|Other|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
89347293|NCT01315015|Experimental|Contrast enhanced breast MRI|The additional MRI will take place biennially after the regular screening mammogram for a study period of 6 years.
89347294|NCT01315015|No Intervention|Regular breast cancer screening|No further follow-up until next scheduled screening examination two years later (according to the current Dutch guideline).
89347295|NCT01238627|Experimental|Nicotine Sublingual Tablet Mint (NSTM)-2|Experimental 2 mg NSTM
89347296|NCT01238627|Active Comparator|Microtab-2|2 mg Nicotine tablet
89347297|NCT01238627|Experimental|NSTM-4|Experimental 4 mg Nicotine Sublingual Tablet Mint
89347298|NCT01238627|Active Comparator|Microtab-4|2 x 2 mg Nicotine tablet
89347299|NCT04904029|Experimental|1. Digital Assessment Routing Tool (DART) 2. Physiotherapy-led remote triage|Participants complete the Digital Assessment Routing Tool (DART), which is followed by physiotherapy-led remote triage with the usual care clinician.
89347300|NCT04904029|Experimental|1. Physiotherapy-led remote triage 2. Digital Assessment Routing Tool (DART)|Participants complete their physiotherapy-led remote triage with the usual care clinician, which is followed by the Digital Assessment Routing Tool.
89347301|NCT01321021|Experimental|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan, Diphenhydramine
89347302|NCT01238705|Active Comparator|Felodipine,Irbesartan,Sexual Dysfunction|
89347303|NCT01238705|Active Comparator|Felodipine,Metoprolol,Sexual Dysfunction|
89347304|NCT03779347|Experimental|Schistosomiasis treated during pregnancy|Praziquantel 40mg/kg once will be given during pregnancy at second to third trimester
89347305|NCT03779347|Active Comparator|Schistosomiasis treated after pregnancy|Praziquantel 40mg/kg once will be given to parturient after delivery during lactation
89347306|NCT03779347|Experimental|All study participants|UCP-LF CAA and composite diagnostic reference test based on extensive egg microscopy, plus serology, plus qPCR on egg DNA, and plus POC-CC will be used to detect schistosomiasis infection in pregnant women
89347307|NCT01146587|Experimental|GangTrainer GT1|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Gangtrainer GT1 for 30 minutes of gross therapy time every workday for a 8 weeks period
89347308|NCT01146587|Experimental|Lokomat|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Lokomat for 30 minutes of gross therapy time every workday for a 8 weeks period
89347309|NCT01146587|Active Comparator|Conventional Physiotherapy|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo a conventional physiokinetherapeutic treatment session for 30 minutes of gross therapy time every workday for a 8 weeks period
89347310|NCT01321099|Experimental|NaFeEDTA|
89347311|NCT01321099|Experimental|Phatase|
89347312|NCT01321099|Experimental|Vitamin C|
89347313|NCT05213897||30 subjects testing positive for Covid-19|30 subjects testing positive for Covid-19 using the proprietary SARS-CoV-2 Antigen Assay
89347314|NCT05213897||30 subjects testing negative for Covid-19|30 subjects testing negative for Covid-19 using the proprietary SARS-CoV-2 Antigen Assay
89347315|NCT03773263|Experimental|sequential oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. COCs were removed from aspirated follicular fluid and transferred into HEPES-buffered collection medium. The immature oocytes will be cultured in sequential IVM medium 1 for 6 hours (37℃, 5% CO2), and removed into sequential IVM medium 2 for further cultivation. After 24 and 40 hours cultivation, the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle.
89347316|NCT03773263|Active Comparator|traditional oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. On the day of ovulation, COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed and the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle. If biochemical pregnancy is not achieved, thawed blastocysts transfer will be performed.
89347317|NCT01245725|Experimental|Tirofiban (Aggrastat)|
89347318|NCT01245725|Placebo Comparator|Placebo|
89347319|NCT01143545|Experimental|1|Allogeneic tumor cell vaccine + chemotherapy
89347320|NCT03779035|Experimental|Gemcitabine plus Capecitabine|Gemcitabine (1000 mg per square meter) on days 1 and 8 Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
89347321|NCT03779035|Active Comparator|Capecitabine|Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
89347322|NCT01586117|Experimental|Amifostine|intrarectal Amifostine assign to the Amifostine arm
89347323|NCT01238783|Experimental|AL-15469A 0.5% and AL-65150.3% Ophthalmic Suspension|
89347324|NCT01238783|Experimental|AL-15469A 0.5%|
89347325|NCT01238783|Experimental|AL-6515 0.3%|
89347326|NCT01238783|Placebo Comparator|Vehicle|
89347327|NCT05461963||breastfeeding pregnants( n:76)|pregnants in early weeks of pregnancy who practice breastfeeding
88814357|NCT02244632|Experimental|Modufolin / Nordic FLOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime
89347328|NCT05461963||control group ( n:76)|pregnants in early weeks of pregnancy who not practice breastfeeding
89347329|NCT03633149|Experimental|Computer tablet-delivered C4H|Two session CHOICES4Health intervention delivered by a computer tablet to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
89347330|NCT03633149|Experimental|Person-delivered C4H|Two session CHOICES4Health intervention delivered by a counselor to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
89347331|NCT03633149|Active Comparator|Brief Advice|Women will receive advice and educational material from a research assistant about risk drinking, smoking, marijuana, and contraception, depending on their specific risk behaviors, as well as information about women's health. In addition, the women will receive referrals to the Harris Health System's SBIRT clinic if needed.
89347332|NCT05451667|Experimental|Cohort 1 (6 active, 2 placebo)|148 mg
89347333|NCT05451667|Experimental|Cohort 2 (6 active, 2 placebo)|296 mg
89347334|NCT05451667|Experimental|Cohort 3 (6 active, 2 placebo)|552 mg
89347335|NCT05451667|Experimental|Cohort 4 (6 active, 2 placebo)|828 mg
89347336|NCT03301415|Experimental|Confirmed congenital CMV without baseline SNHL|Valganciclovir 16 mg/kg/dose orally twice daily for four months, n=229
89347337|NCT03778801||fibromyalgia syndrome|Thirty patients with a diagnosis of fibromyalgia syndrome according to the 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria and a disease duration of longer than three months
89347338|NCT03778801||chronic neck pain|30 patients with chronic neck pain lasting for more than three months and didn't meet 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria.
89347339|NCT03778801||healthy controls|30 healthy controls without pain or additional disease
89347340|NCT01145963|Experimental|experimental pasta B|Past B
89347341|NCT01145963|Experimental|experimental pasta C|Pasta C
89347342|NCT01145963|Placebo Comparator|Control pasta|Control
89347343|NCT05449015|Experimental|1% atropine|1% atropine eye drops, in the conjunctival sac, once a night, for 7 days
89347344|NCT05449015|Placebo Comparator|tropicamide|tropicamide eye drops, in the conjunctival sac, once every 5 minutes, after 3 consecutive doses, close eyes for 20 minutes
89347345|NCT03510689||Group 1|Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
89347346|NCT03510689||Group 2|Subjects with genetic testing confirming deleterious mutations in BRCA1 or BRCA2 whose prior treatment for breast cancer does not include anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
89347347|NCT03510689||Group 3|Subjects with genetic testing confirming no mutation in BRCA1 or BRCA2 whose prior treatment for breast cancer includes anthracycline exposure. All groups have same schedule of study procedures, including echocardiography, cardiopulmonary exercise testing, and blood collection.
89347348|NCT01238939|Experimental|Treatment|
89347349|NCT01146743|Active Comparator|EUS-guided|EUS-guided gallbladder drainage in acute cholecystitis with high risk patients
89347350|NCT01146743|Active Comparator|percutaneous transhepatic|percutaneous transhepatic gallbladder drainage in acute cholecystitis with high risk patients
89347351|NCT03778879|Experimental|Group 1:With CCX872-B|Concurrent SBRT 25 Gy in 5 fractions over 5-7 days, and 21 days of CCX872-B therapy. CCX872-B 150 mg by mouth twice daily approximately 12 hours apart.
89347352|NCT03778879|No Intervention|Group 2:Without CCX872-B|SBRT Alone: 25 Gy in 5 fractions over 5-7 days
89347353|NCT01239017|Experimental|Dose 1|SC REGN475 Dose 1 and IV Placebo
89347354|NCT01239017|Experimental|Dose 2|SC REGN475 Dose 2 and IV Placebo
89347355|NCT01239017|Experimental|Dose 3|SC REGN475 Dose 3 and IV Placebo
89347356|NCT01239017|Experimental|Dose 4|SC Placebo and IV REGN475 Dose 4
89347357|NCT01239017|Placebo Comparator|Dose 5|SC Placebo and IV Placebo
89347358|NCT02732938|Experimental|PF-04136309 + Nab-p + Gem|"PF-04136309 oral dosing~Nab-paclitaxel IV dosing Gemcitabine IV dosing"
89347359|NCT03775447||Parkinson's Disease Patients|"A diagnosis of Parkinson's disease in the opinion of the enrolling investigator~Disease duration: any~Male or female age 18 years or older at time of PD diagnosis."
89347360|NCT03775447||Healthy Control (HC) Subjects|• Male or female age 18 years or older at Screening.
89347361|NCT03773029|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 capsules)
89347362|NCT03773029|Placebo Comparator|control|2 capsules of placebo
89347363|NCT03775135||Children with neuromuscular diseases|Questionnaires will be administered by children with neuromuscular disease between 12 and 25 years and their parents
89347364|NCT01146821|No Intervention|Standard care|Standard care
89347365|NCT01146821|Active Comparator|standard care + 0.20gm/kg fish oil|standard care + 0.20gm/kg fish oil
89347366|NCT01146821|Active Comparator|standard care + 0.50 gm/kg fish oil|standard care + 0.50 gm/kg fish oil
89347367|NCT03778723|Experimental|Total intravenous anesthesia (TIVA)|Patients will receive total intravenous anesthesia using Propofol and Midazolam
88814358|NCT02244632|Experimental|Modufolin / Nordic FLIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan.
89347368|NCT03778723|Active Comparator|Inhalation Anesthesia|Patients will receive Inhalation anesthesia using Sevoflurane
89347369|NCT03436030|Experimental|Single arm, breathing manuevers|All subjects perform/undergo Valsalva, Muller, CPAP, hand grip, and passive leg raise, with ultrasound examination of heart recorded before and during the manoeuvre.
89347370|NCT01245959|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
89347371|NCT01245959|Active Comparator|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
89347372|NCT01561573|Other|Ultrasound colles fracture|This is a single arm study
89347373|NCT01143623|Active Comparator|Probiotic|
89347374|NCT01143623|Active Comparator|Probiotic-2|
89347375|NCT01143623|Placebo Comparator|Placebo|
89347376|NCT04326478|Experimental|Azithromycin Group|Enrolled children in a household randomized to the experimental group will receive a single weight-based dose of azithromycin administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera. They will then complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
88814359|NCT02244632|Experimental|MOFOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime
89347377|NCT04326478|Placebo Comparator|Non-antibiotic Placebo Group|Enrolled children in a household randomized to the placebo arm will receive a single dose of non-antibiotic placebo during their first study visit, which will occur within 12 hours of a member of their household testing positive for cholera. Like the participants in the intervention arm, they will complete 9 follow-up study visits in their home, during which rectal swabs and/or stool samples will be collected.
89347378|NCT01316497|Experimental|Remote ischemic preconditioning (RIPC)|See intervention description
89347379|NCT01316497|Placebo Comparator|Control|
89347380|NCT01320241|Active Comparator|novel radiation stent|"Patients undergo placement of a novel biliary stent loaded with 125I seeds on day 1.~Intervention: Device: self-expandable 125I radioactive seeds-loaded-stent"
89347381|NCT01320241|Experimental|conventional stent|"Patients undergo placement of a conventional nitinol SEMS on day1.~Intervention: Device: self-expandable biliary nitinol alloys stent"
89347382|NCT04316884||COVID-19|Patients with suspected or verified COVID-19 admitted to intensive care at Uppsala University Hospital
89347383|NCT01246427|Experimental|BRN01|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~Experimental: BRN01~Placebo Comparator: Placebo"
89347384|NCT01246427|Placebo Comparator|Placebo|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~Experimental: BRN01~Placebo Comparator: Placebo"
89347385|NCT04308616||Psoriasis|Patients with psoriasis
89347386|NCT04674163|Experimental|Patients with clinical signs that suggest Multiple Sclerosis (MS) or Guillain Barré Syndrome (GBS)|
89347387|NCT03435874|Experimental|Group 1 Active|n=6. Age 18-35 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 at D56.
89347388|NCT03435874|Placebo Comparator|Group 1 Comparator|n=3. Age 18-35 years. Rabies vaccine at D0 and D56.
89347389|NCT03435874|Experimental|Group 2a Active|n=6. Age 1-6 years. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
89347390|NCT03435874|Placebo Comparator|Group 2a Comparator|n=3. Age 1-6 years. Rabies vaccine at D0 and D56.
89347391|NCT03435874|Experimental|Group 2b Active|n=12. Age 1-6 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
89347392|NCT03435874|Placebo Comparator|Group 2b Comparator|n=6. Age 1-6 years. Rabies vaccine at D0 and D56.
89347393|NCT03435874|Experimental|Group 3a Active|n=6. Age 6-11 months. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
89347394|NCT03435874|Placebo Comparator|Group 3a Comparator|n=3. Age 6-11 months. Rabies vaccine at D0 and D56.
89347395|NCT03435874|Experimental|Group 3b Active|n=12. Age 6-11 months. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
89347396|NCT03435874|Placebo Comparator|Group 3b Comparator|n=6. Age 6-11 months. Rabies vaccine at D0 and D56.
89347397|NCT05119751|Active Comparator|Birch allergy|"randomised (1:1) to receive vestibular or sublingual birch pollen~once daily tree 12 SQ-Bet AIT tablet"
89347398|NCT05119751|Active Comparator|Grass allergy|"randomised (1:1) to receive vestibular or sublingual grass pollen~grass 2800 BAU AIT tablet"
89347399|NCT05119751|Active Comparator|ragweed allergy|randomised (1:1) to receive vestibular or sublingual ragweed pollen ragweed 12 Amb a 1-U AIT Tablet
89347400|NCT05119751|Active Comparator|House dust mite allergy|"randomised (1:1) to receive vestibular or sublingual HDM~HDM 12 SQ-HDM"
89347401|NCT03430804||Single gruop320 parturients|Measurement of cervical length and digital examination of Bishop score in 320 women undergoing induction of labour will be carried out in ain shams university maternity hospital.
89347402|NCT03470116|Experimental|MacGrath MAC video laryngoscopy|Patients will benefit MacGrath MAC video laryngoscopy for intubation after curarization
89347403|NCT03470116|Active Comparator|direct laryngoscopy|Patients will benefit direct laryngoscopy for intubation after curarization
89347404|NCT04647721|Experimental|Left side Radiesse® / Right side Restylane®|
89347405|NCT04647721|Experimental|Left side Restylane® / Right side Radiesse®|
89347406|NCT01239251||breast cancer patients taking endocrine therapy|Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
89347407|NCT03430726|Experimental|Healthy Kids Probiotic Yogurt Drink Group|Healthy children will be given a commercially available yogurt drink containing a multi-strain probiotic, Bio-Kidz® (12.5 billion CFU/98g; Lactobacillus acidophilus CL1285®, Lactobacillus casei LBC80R® and Lactobacillus rhamnosus CLR2®), daily for 14 days.
89347408|NCT03772795|Active Comparator|Group 1- Alignment with fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Uniteks, 0.022 Roth prescription brackets.Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
89347409|NCT03772795|Experimental|Group 2- Alignment with clear aligners|Clear aligner orthodontic appliance (EON, Eon Dental NV, Belgium). Teeth alignment with clear aligners.
89347410|NCT01236833|No Intervention|Fasting|
89347411|NCT01236833|Active Comparator|Lactated Ringer's Solution|
89347412|NCT03775057|Experimental|MyDose Coach app intervention|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
89347413|NCT03470038|Experimental|NGF condition + Control condition|"All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg~After 4 weeks:~All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
89347414|NCT03470038|Experimental|Control condition + NGF condition|"All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg~After 4 weeks:~All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
89347415|NCT03778333|Experimental|Open label single arm study|All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks.
89347416|NCT03816748|Experimental|intervention|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept HFNC treatment
89347417|NCT03816748|No Intervention|control|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept usual care
89347418|NCT03778567|Other|lamivudine + nucleotide analogue|At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued
89347419|NCT03784066|Active Comparator|A|Durvalumab
89347420|NCT03784066|Active Comparator|B|Durvalumab + Tremelimumab
89347421|NCT01239329||Complex multiple disabilities|People with complex multiple disabilities, living in a care institution participating in the Governor Kremers Centre (GKC.)
89347422|NCT03435406||cirrhosis with HPS|Diagnosed as HPS
89347423|NCT03435406||cirrhosis without HPS|Not Diagnosed as HPS
89347424|NCT05168683|Experimental|Part One|Four Study Treatments will be dosed during Part One of the study with radiolabelled ALLN-346 tablets (in 12 subjects): Treatment A ALLN-346 enteric coated (EC) fast release tablet; Treatment B ALLN-346 fast release capsule; Treatment C ALLN-346 EC slow release tablet; Treatment D ALLN-346 slow release capsule. Subjects will be dosed in a lightly fed state.
89347425|NCT05168683|Experimental|Part Two|Following completion of Part One of the study, study treatment (one or both of those administered in Part One) and dosing requirements will be confirmed for dosing in Part Two, to be administered in fasted and/or fed states (in 12 subjects).
89347426|NCT03435328|Experimental|TENS intervention|"one group receiving TENS:~- The electrode of TENS unit will be placed vertically, externally on skin overlying the parotid gland, in the preauricular area bilaterally, 1 cm in front of the tragus area."
89347427|NCT01320319|Placebo Comparator|Placebo|
89347428|NCT01320319|Experimental|Nutritional Supplementation with EPA|This arm will receive the nutritional supplementation of EPA 960mg Three times a day.
89347429|NCT03113123|Other|PrEP with Truvada®|"On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later~Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours."
89347430|NCT04267276|Experimental|Part 1: BI 1265162 - intravenous|
89347431|NCT04267276|Experimental|Part 2: BI 1265162 - oral|
89347432|NCT03772639|Experimental|Experimental group|The experimental group received a standard medical and pharmacological care in a daily format and shared decision making (SDM). The general framework of SDM was developed focusing on self-management goals which include education that addresses continuous use of medication, behavioral change, breathing training, learning to interpret changes in the disease and its consequences, and use of medical and community resources.
89347433|NCT03772639|No Intervention|Control Group|The control group received standard care and pharmacological care including systemic steroids, antibiotics, inhaled bronchodilators, and oxygen therapy.
89347434|NCT01239407|No Intervention|Treatment as usual|"The treatment as usual arm consists of two phone or in-person interviews:~Patients are asked questions about their mental health, their views of mental health, and how they cope with their mental health (including any treatment they might be receiving).~Patients are asked the same questions 6 months after the initial interview."
89347435|NCT01239407|Experimental|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
89347436|NCT04451122|Other|Treatment of ocular demodicosis|
89347437|NCT01247129|Experimental|SIEA,delay procedure,widening of diameter|
89347438|NCT05030285|Experimental|Intervention|People who are randomised into the intervention arm will undergo 6 weekly psychotherapy sessions
89347439|NCT05030285|No Intervention|Control|People who are randomised into the control arm will undergo usual care
89347440|NCT01143857|Active Comparator|Varenicline|
89347441|NCT01143857|Placebo Comparator|Placebo|
89347442|NCT03750292|Experimental|HEPAirX air filter|
89347443|NCT03750292|Placebo Comparator|Control air filter|
89347444|NCT02934659|Experimental|Investigational|Intervention - Atlas Knee System device for medial knee osteoarthritis
89347445|NCT03778255|Experimental|Undergoing sentinel lymph node biopsy|
89347446|NCT03718000|No Intervention|Control|Participants in this group received no intervention during t he holiday season
89347447|NCT03718000|Experimental|Daily Self-Weighing (DSW)|Participants in this group performed daily self-weighing using digital WiFi scales during the holiday season
89347448|NCT01316653|Active Comparator|GROW Smarter|Library based program to promote early literacy
89347449|NCT01316653|Experimental|GROW Healthier|Healthy lifestyle intervention focused on building healthy lifestyle skills for preschool children and participating parents and building new social networks between the intervention group members.
89347450|NCT03435172|Experimental|Treatment Group|Device-ADRCs intravenously infusion 20 million ADRCs generated by Celution device will be intraveously infused through peripheral vein. Standard care of split thickness meshed skin graft (STSG) will be used.
89347451|NCT03435172|No Intervention|Usual Care|Standard care of split thickness meshed skin graft (STSG) will be used.
89347452|NCT01239173|Active Comparator|1|Post-traumatic stress disorder patient receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
89347453|NCT01239173|Placebo Comparator|2|Post-traumatic stress disorder receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
89347454|NCT01239173|Active Comparator|3|Controls receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
89347455|NCT01239173|Placebo Comparator|4|Controls receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
89347456|NCT03778099|Experimental|Cinnamon Group|Two capsules of cinnamon 500mg twice per day after meals (2g/day). All capsules will be given simultaneously with the clomiphene citrate medication (standard treatment for infertility in women with PCOS). Participants will be asked to keep their normal lifestyle including daily food and physical activity level.
89347457|NCT03778099|Placebo Comparator|Placebo Group|"Placebo capsules will contain 450 mg of starch and 50 mg of cinnamon powder (to improve blindness regarding taste and odor). Color, shape, and size of placebo capsules will be exactly the same as the cinnamon capsules.~2g/day along with clomiphene citrate"
89347458|NCT03774667||Placenta Previa|Pregnant women is diagnosed with placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
89347459|NCT03774667||None-Placenta Previa|Pregnant women is diagnosed without placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
89347460|NCT03063203|Experimental|Decitabine|"Cycle 1: All patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle~Cycle 2: Patients with bone marrow blast counts < 5% may receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. All other patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle.~Cycle 3 and subsequent cycles: All patients will receive 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of the 28-day cycle"
89347461|NCT04484155|Experimental|Minimally invasive micro sclerostomy (MIMS)|create a drainage channel at the sclera-corneal junction
89347462|NCT03435094||Fosamax®|1 group will be treated with alendronate 70 mg tablets (Fosamax®)
89347463|NCT03435094||Binosto®|1 group will be treated with alendronate 70 mg effervescent tablets for buffered solution (Binosto®)
89347464|NCT03772483|Active Comparator|Control group|Local anesthesia with conventional syringe
89347465|NCT03772483|Active Comparator|Virtual reality group|Local anesthesia with conventional syringe + VR device
89347466|NCT03434938|Experimental|MI Intervention|Standard geriatric rehabilitation combined with 4 MI sessions (within 72 hours from admission, within 6 days, at 1 week from the second session and pre-discharge, respectively). MI will be delivered by nurses trained through a certified MI course and additional group coaching sessions will be offered them throughout the study. Quality control of the MI sessions will be carried out using Motivational Interviewing Treatment Integrity (MITI) Code 3.1.1 through random video recording.
89347467|NCT03434938|No Intervention|Standard rehabilitation|Routine geriatric rehabilitation will include a multidisciplinary and individualized treatment plan based on comprehensive geriatric and specific rehabilitation assessments. As a specific control intervention, within 72 hours from admission a nurse without training in MI will handle the patient written information about generic benefits of exercising.
89347468|NCT01236911||Calcium after moderate-severe TBI|Patients with moderate -severe TBI with less as 24 hrs , admitted in emergency. We will measure seric calcium to compare the differences between both groups
89347469|NCT03772561|Experimental|AZD5363+Olaparib+Durvalumab|"A traditional 3+3 design will be used during the dose escalation part of the study.~Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities."
89347470|NCT03430570|Experimental|Tablet TRAC Emotion Regulation Intervention|
89347471|NCT03430570|No Intervention|Waitlist Control|Control participants are assessed on the same schedule as the treatment condition and offered the intervention after the 3-month follow-up
89347472|NCT03772405|Experimental|Nascum Plus and ACC|In a cross-over design, patients are exposed to pollen in the ACC twice for 4 hours each 3 weeks apart. Subjects will receive treatment with Nascum Plus either 5 minutes before the first or the second 4 hour pollen challenge.
89347473|NCT01143935||Live patients|All patients undergoing CT scans of the abdomen for non hepatobiliary conditions
89347474|NCT01143935||Autopsy cases|All autopsy cases with no liver disease or trauma.
89347475|NCT03430414||Therapy Responders|
89347476|NCT03430414||Non-Responders|
89347477|NCT05497297|Experimental|Mild Renal Impairment|A1 group subjects will receive a single dose of 10 mg HSK7653
88811809|NCT00867932|Experimental|Eculizumab|Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.
89347478|NCT05497297|Experimental|Moderate Renal Impairment|B1 group subjects will receive a single dose of 10 mg HSK7653
89347479|NCT05497297|Experimental|Severe Renal Impairment|C1 group subjects will receive a single dose of 10 mg HSK7653
89347480|NCT05497297|Experimental|Kidney failure|D1 group subjects will receive a single dose of 10 mg HSK7653
89347481|NCT05497297|Experimental|Normal Renal function|A2, B2, C2 and D2 group subjects will receive a single dose of 10 mg HSK7653, If the age, sex and weight of the subjects in group A2 can be matched with the subjects in groups A1 and B1 at the same time, the subjects in group B2 will not be enrolled, and so on.
89347482|NCT01239485|Experimental|Irinotecan|
89347483|NCT03430336|Experimental|Computer-assisted medication management|"Family physician adds, modifies and optimizes medication in patient's with polypharmacy assisted by an user-initiated computerized decision support system (CDSS) which provides drug-therapy relevant information about patients (e.g. diagnoses and treatments) and alerts in case of drug-drug, drug-disease, drug-age interactions to systematically assess the appropriateness of medication:~CDSS provides drug-therapy relevant information~modification of medication~assessment of medication appropriateness~medication plan~Guidance in medication process"
89347484|NCT03430336|No Intervention|Control arm|Patients will receive the usual clinical care based on current clinical practice guidelines during intervention period. After completion of trial, the patients in the control group will be invited to participate after written informed consent to receive the intervention.
89347485|NCT03434860|Active Comparator|probiotic|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
89347486|NCT03434860|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
89347487|NCT01146041|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
89347488|NCT01146041|Active Comparator|exelon|Exelon 1.5 mg capsules of Novartis
89347489|NCT03411148|Experimental|Exercise Group A|Weekly exercise sessions with physical therapist and psychologist
89347490|NCT03411148|Placebo Comparator|Exercise Group B|Home-based exercises
89347491|NCT01146899|Experimental|Provider Alert|Provider receives alert for patient visit
89347492|NCT01146899|No Intervention|No Alert|No alert provided
89347493|NCT04450810||Control|Evaluation of serum and salivary NLRP3
89347494|NCT04450810||Periodontitis|Evaluation of serum and salivary NLRP3
89347495|NCT04450810||Diabetes|Evaluation of serum and salivary NLRP3
89347496|NCT04450810||Periodontitis + diabetes|Evaluation of serum and salivary NLRP3
89347497|NCT03430258|Placebo Comparator|conventional oxygen therapy|oxygen was delivered by a nasal cannula or nonrebreather mask
89347498|NCT03430258|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
89347499|NCT05155735||Replantation|This group will include subjects who suffered a single digit non-thumb amputation, and whose finger was replanted.
89347500|NCT05155735||Revision Amputation|This group will include subjects who suffered a single digit non-thumb amputation, and whose finger was not replanted.
89347501|NCT03430180|Placebo Comparator|placebo nasal spray|Drug: placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
89347502|NCT03430180|Active Comparator|Naloxone hydrochloride 40mg/ml nasal spray|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
89347503|NCT03777787|Experimental|Bitter|A single intragastric administration of denatonium benzoate (1 µmol/kg)
89347504|NCT03777787|Placebo Comparator|Placebo|A single intragastric administration of placebo (water)
89347505|NCT03774589|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
89347506|NCT03774589|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
89347507|NCT03428776|Sham Comparator|Controls|Self returns
89347508|NCT03428776|Active Comparator|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives
89347509|NCT03428776|Active Comparator|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives
89347510|NCT04854031||Cochlear Implant Recipients|30 participants who lost their hearing and received one or two cochlear implants as adults will participate in this study. We will include unilaterally and bilaterally implanted individuals listening with their everyday hearing configuration. Individuals with residual acoustic hearing better than 60 A-weighted decibels at any audiometric frequency will be excluded. Participants will range in age between 19 and 80 years old, although most are expected to be within 50 - 75 years of age.
89347511|NCT04807387|Experimental|Healthy participants: acute|Healthy participants will wear one of two vaginal stents for 24 hours, followed by a 24 hour wash out period. They will then wear the second vaginal stent for 24 hours. After both stents have been worn, the participants will choose the most comfortable stent.
89347512|NCT04807387|Experimental|Healthy participants: chronic|Healthy participants will wear the stent chosen to be the more comfortable for 2 weeks without removal.
89347513|NCT04807387|Experimental|Pediatric participants: post vaginal surgery|Pediatric participants will wear the vaginal stent for 2 weeks after undergoing vaginal surgery.
89347514|NCT04807387|Experimental|Adult participants: post vaginal brachytherapy|Adult participants undergoing vaginal brachytherapy for cancer treatment will wear the stent for 2 weeks, be evaluated by a physician, and wear the stent for an additional 2 weeks.
89347515|NCT03430102||LeftHeartCath|Patients scheduled for LV catheterization for direct measurement of LVEDP
89347516|NCT03774511|Active Comparator|Study group 1|High Intensity Interval Excercise
89347517|NCT03774511|Active Comparator|Study group 2|Moderate Intensity Interval Exercise
89347518|NCT03774511|No Intervention|Control group|No Intervention
89347519|NCT03430024||Cases|"We will enrol 100 women who have been newly diagnosed with T2 (>2cm) palpable invasive breast cancer having primary surgical treatment at Maidstone Hospital. We will exclude all patients with a metabolic disorder, significant co-morbidities and locally advanced or metastatic disease as well as those with a previous history of cancer treatment. We will collect data on tumour size, grade and phenotype as well as ER, progesterone receptor (PR) and Her-2 expression status and patient demographic information.~We will investigate the Association of Myosin VI with oestrogen receptor."
89347520|NCT03430024||Controls|A cohort of control breast tissue will be obtained from 20 patients undergoing benign surgical breast procedures. For those control patients having reduction mammoplasties the excised tissue will be core biopsied but patients having other types of benign surgery will have an extra core biopsy taken from breast tissue surrounding the lesion being excised.
89347521|NCT05482555||Intervention/treatment Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
89347522|NCT05482555||Percutaneous arteriotomy closed with closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
89347523|NCT03769597|Experimental|Iohexol administration|After injecting a loading dose of 5ml of Iohexol Inj 300 MG/ML bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
89347524|NCT03434782|Experimental|G1- Negative Control|Group with no desensitizing treatment. Prior to bleaching therapy, a water-soluble placebo gel, with non-active agent will be applied to dental vestibular surfaces. After bleaching therapy, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
89347525|NCT03434782|Experimental|G2- LASER (Positive Control)|Group treated with placebo gel before bleaching and with LLLT after in-office bleaching.
89347526|NCT03434782|Experimental|G3- KNO3 (Positive Control)|Group treated with desensitizing gel before bleaching and after in-office bleaching, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
89347527|NCT03434782|Experimental|G4- KNO3 + LASER|Group treated with desensitizing gel before bleaching and with LLLT after in-office bleaching.
89347528|NCT01320397|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
89347529|NCT01320397|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
89347530|NCT01320397|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
89347531|NCT01320397|Experimental|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
89347532|NCT03428698|Experimental|experimental device|The extraction was completed, the socket was filled with a topical amino acid + sodium hyaluronate gel (Aminogam®, sterile syringe 2 ml).
89347533|NCT03428698|Placebo Comparator|control no device|The extraction was completed, socket was flushed, using a 2ml sterile syringe similar to one utilized to apply the gel, with sterile physiological solution.
89347534|NCT03434704|Experimental|Single Arm Treatment|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis."
89347535|NCT03768973||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
89347536|NCT03768973||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
89347537|NCT02521636|Placebo Comparator|Anibiotic therapy guided with actual french recommandations|Guided by the antibiotic 2006 recommendations of the French consensus conference on anti-infective therapy of respiratory tract infections in low immuno-competent adult.
89347538|NCT02521636|Experimental|Anibiotic therapy guided with serum PCT value|"Guided antibiotic therapy serum PCT at admission, revalued at day 1, day 3 and day 6 as long as PCT is not less than 0.1 ng / mL:~PCT <0.1 ng / mL: no antibiotics~0.1 <PCT <0.25 ng / mL: antibiotic advised~PCT> 0.25 ng / mL: highly recommended antibiotics"
89347539|NCT03774277|Experimental|Intervention Communities|Packed Promise for a Healthy Heart intervention, free Tribal Wellness Center membership, a Fitbit, and the AYA culturally based mobile walking app.
89347540|NCT03774277|No Intervention|Control Communities|Free Tribal Wellness Center membership, Fitbit, and the AYA culturally based mobile walking app
89347541|NCT03325504|Experimental|hBM-MSCs-Low Dose|Autologous Cultured Mesenchymal Stem Cells +Biomaterial (Low Dose): 100x106 cells
89347542|NCT03325504|Experimental|hBM-MSCs-High Dose|Autologous Cultured Mesenchymal Stem Cells+Biomaterial (High Dose): 200x106 cells
89347543|NCT03325504|Active Comparator|Autologous iliac crest graft|Autologous Iliac Crest Grafting
89347544|NCT04449640||Uterine rupture|Women who had uterine rupture during pregnancy.
89347545|NCT04760587||study group|smart devices in adolescent
89347546|NCT02891226|Experimental|Mirikizumab|"Period 1 (Weeks 0 -12): 200 Milligram (mg), 600 mg, and 1000 mg mirikizumab administered intravenously (IV) every 4 Weeks (Q4W).~Period 2 (Weeks 12 - 52): 200 mg, 600 mg, and 1000 mg mirikizumab administered IV Q4W; 300 mg mirikizumab administered subcutaneously (SC) Q4W; 1000 mg mirikizumab administered IV Q4W for non-improvers in period 1; and 1000 mg mirikizumab administered IV Q4W for participants on placebo during period 1.~Period 3 (Weeks 52 - 208): 300 mg mirikizumab administered SC Q4W."
89347547|NCT02891226|Placebo Comparator|Placebo|Period 1 (Weeks 0 -12): Participants received placebo administered intravenously (IV) Q4W.
89347548|NCT01561417|Active Comparator|CP-rFVIIa|
89347549|NCT01561417|Experimental|VII25|
89347550|NCT03772015||Study|"Patients who had the operation of laparoscopic lateral mesh suspension for apical prolapse will have magnetic resonance imaging preoperatively and at postoperative 6th month"
89347551|NCT03772015||Control|Multiparous, sexually active participants who have grade 0 or 1 (asymptomatic if exists) prolapse will have magnetic resonance imaging as a control group
89347552|NCT03771781|Other|Empagliflozin Tablets|The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.
89347553|NCT03771781|Other|Empagliflozin Tab 25 MG|The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.
89347554|NCT03772093|Active Comparator|Patients with manual massage therapy|30 patients were randomly assigned to massage therapy. The procedures were performed for ten days, with weekend break. Manual massage of lumbar area was performed by certified massage therapist with the typical course of the procedure. The technique was consisted of stroking, kneading, grinding, patting and shaking. The procedure lasted twenty minutes.
89347555|NCT03772093|Active Comparator|Patients with Trabert current therapy|30 patients were randomly assigned to Trabert current therapy. The Trabert current was administered by 143 frequency, time of 2 ms impulse, time of break 5 ms. The current was generated by Pulsotronic ST-6D device (ZAMED©). The electric pads were placed on the lumbar area, in the middle part of spine. The anode in the lower part, near to buttocks. The intensity of current was regulated between 15-25 mA. The time of procedure lasted fifteen minutes.
89347556|NCT03774199|Other|Pulse oximeter calibration population|
89347557|NCT03434626|Experimental|ACP Education|Eligible patients in the experimental group will receive an educational intervention from an advance care planning navigator consisting of a 4-item values tool, a Goals of Care Designation form and, if applicable, watch a cardiopulmonary resuscitation video.
89347558|NCT03434626|Active Comparator|Usual care|Patients in the usual care group will complete a Goals of Care Designation form with the family physician.
89347559|NCT03768895||MRI group|The criteria for patient inclusion were: Age > 18 years old, who had realised a pelvis MRI for any cause at MRI Center. Exclusion criteria included age < 18 years old, inadequate imaging quality, medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.
89347560|NCT03705624|No Intervention|Standard of Care|Standard of care with passively monitored malaria incidence at health centers that receive appropriate diagnostic and clinical supplies and Seasonal Malaria Chemoprevention (SMC) for children less than 5 years of age
89347561|NCT03705624|Experimental|CCM|Standard of care supplemented with enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with artemether-lumefantrine (AL) according to national guidelines
89347562|NCT03705624|Experimental|CCM+MSAT|Standard of Care supplemented with CCM and Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
89347563|NCT03774043|Experimental|Single session of Acute Intermittent Hypoxia (AIH)|
89347564|NCT03774043|Placebo Comparator|Single session of Sham Acute Intermittent Hypoxia (Sham AIH)|
89347565|NCT03774043|Experimental|Two successive sessions of AIH|
89347566|NCT03774043|Placebo Comparator|Two successive sessions of Sham AIH|
89347567|NCT03434314|Experimental|MISACE arm|"Minimally-Invasive Segmental Artery Coil-Embolization~MISACE procedure prior to aneurysm repair~segmental arteries are occluded with coils or plugs in one to three MISACE sessions (staged procedure)"
89347568|NCT03434314|No Intervention|control arm|receives treatment of aneurysm as usual: open surgical repair or endovascular repair without MISACE
89347569|NCT04937088|Placebo Comparator|Placebo|Soy Bean Oil identical packaging as the active arm, taken once daily by mouth for 30 days.
89347570|NCT04937088|Active Comparator|Liquid ASA|Aspirin 150 mg liquid formulation (2.5%w/w) taken once daily by mouth for 30 days
89347571|NCT03774355|Experimental|CG1801|Dosing 'CG1801' followed by dosing 'CGL1802'
89347572|NCT03774355|Experimental|CGL 1802|Dosing 'CGL1802' followed by dosing 'CG1801'
89347573|NCT04924842||Children|Hospitalized children, 0 to 17 years of age, 30 subjects, consecutive sample survey, recruitment in quotas of five age ranges.
89347574|NCT04924842||Adults|Hospitalized adults, 18 years and above, 60 matched subjects
89347575|NCT03434236|Placebo Comparator|Placebo|Patients will be taking placebo twice daily for 5 days prior to surgery. The placebo has a similar taste and smell as the active supplement.
89347576|NCT03434236|Experimental|low dose Lipinova (30mL)|Patients will take 15 mL Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
89347577|NCT03434236|Experimental|high dose Lipinova (60mL)|Patients will take 30mL of Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
89347578|NCT03771547||More 80|The first group included ERCP patients aged 80 and above.
89347579|NCT03771547||Less 80|The second group included those ERCP patients younger than 80.
89347580|NCT03429790|Experimental|group intra-operative cell salvage|"The theoretical amount of blood transfusion should be based on the following formula:~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether the experimental group or the no intervention group."
89347581|NCT03429790|Active Comparator|group allogeneic blood transfusion|"The theoretical amount of blood transfusion should be based on the following formula:~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether group intra-operative cell salvage or group allogeneic blood transfusion."
89347582|NCT01312506||Subjects undergoing a craniotomy|This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
89347583|NCT01312506||Metastases, no craniotomy|These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
89347584|NCT01312506||Healthy Volunteers|Subjects who do not have known melanoma or metastases.
89347585|NCT03768817||Patients treated with triheptanoin|Patients with LC-FAOD treated with triheptanoin before 01 September 2018 under eIND
89347586|NCT05681364||COPD and bronchiectasis patients with some metabolic profiling|The patients with stable COPD and bronchiectasis who meet the screening criteria and with some metabolic profiling according to the previous studies.
89347587|NCT05681364||COPD and bronchiectasis patients without the metabolic profiling|The patients with stable COPD and bronchiectasis who meet the screening criteria and without the metabolic profiling according to the previous studies.
89347588|NCT03224104|Experimental|Group A - TG02 + RT|Elderly patients with IDH1R132H-non mutant and MGMT promoter-unmethylated anaplastic astrocytoma or glioblastoma who will receive TG02 and radiation therapy.
89347589|NCT03224104|Experimental|Group B - TG02 + TMZ|Elderly patients with IDH1R132H-non mutant and MGMT promoter-methylated anaplastic astrocytoma or glioblastoma who will receive TG02 and temozolomide.
89347590|NCT03224104|Experimental|Group C - TG02|Patients initially diagnosed with anaplastic astrocytoma or glioblastoma at first relapse post TMZ/RT --> TMZ therapy who will receive TG02.
89347591|NCT05177562||PCOS|No intervention.
89347592|NCT05177562||PCOS surgery|No intervention
89347593|NCT05177562||Surgery control|No intervention
89347594|NCT05177562||IVF PCOS|No intervention
89347595|NCT05177562||IVF control|No intervention
89347596|NCT05177562||Investigations, fertility PCOS|No intervention
89347597|NCT05177562||Investigations, fertility control|No intervention
89347598|NCT05177562||Pregnancy - gestational diabetes mellitus|No intervention
89347599|NCT05177562||Pregnancy - Intrahepatic cholestasis of pregnancy|No intervention
89347600|NCT05177562||Pregnancy - control|No intervention
89347601|NCT01320475|Experimental|iv Ketamine|Epidural infusion of levobupivacaine and saline (placebo for sufentanil)and iv infusion of ketamine Up to the third postoperative day (6 PM)
89347602|NCT01320475|Active Comparator|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
89347603|NCT03428620|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints that will be manipulated include proximal tibiofibular, the distal tibiofibular, and talocrural joints and will be mobilized the first three sessions prior to the participants performing the exercise protocol.
89347604|NCT03428620|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
89347605|NCT05309148|Experimental|Training on eye tracker based device|Patients will undergo a primary diagnostics of cognitive functions (memory, thinking skills, language, visual-spatial and communicative functions) and an diagnostics of the visual attention index on an eye tracker-based device. Based on the results of the diagnosis, participants will be offered a scheme of correctional training and secondary diagnostics at the end of training. Correctional training on an eye tracker-based device consists, firstly, of a 10-minute exercise at the beginning of each lesson aimed at improving visual functions and attention. Patients had to follow a spontaneously moving object. Secondly, correctional training includes a block of neurorehabilitation (simple cognitive exercises similar to the tasks presented in the assessment).
89347606|NCT05309148|Active Comparator|Training with a neuropsychologist|Patients will undergo primary and secondary diagnostics on an eye tracker-based device, then participants will have a conventional correctional training with a neuropsychologist according to an individual correction plan.
89347607|NCT05309148|Active Comparator|Training on eye tracker based device and with a neuropsychologist|Patients will undergo primary and secondary diagnostics and correctional training on an eye tracker-based device, in the same time participants will have a conventional correctional training with a neuropsychologist according to an individual correction plan.
89347608|NCT03768739||CICU extubated patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
89347609|NCT03429634|Experimental|Balloon-Stent Kissing technique|randomly, patients with bifurcation lesion treated by Balloon-Stent Kissing intervention technique in this group.For procedure,stent in main vessel and balloon protect of side branch,final kiss-balloon was performed.
89347610|NCT03429634|Sham Comparator|Jailed Wire technique|randomly,patients with bifurcation lesion treated by Jailed Wire intervention technique in this group.For procedure,stent in main vessel and only wire protect of side branch.If need,post-stent rewire of branch,and balloon dilation of side branch was performed.
89347611|NCT03773887|Other|acute alcoholic hepatitis|collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)
89347612|NCT03773887|Other|Alcoholic cirrhosis|collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)
89347613|NCT03773887|Other|Without chronic liver disease|collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)
89347614|NCT04858542|Experimental|Mask-wearing healthcare workers|All participants in this arm will view the educational health modules and their subjective/objective outcomes will be measure pre/post module viewing.
89347615|NCT03434002|Experimental|Arm-A|Randomized 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation
89347616|NCT03434002|Experimental|Arm-B|Randomized other 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation
89347617|NCT05177406||Full cohort|patients newly initiating Aimovig therapy
89347618|NCT03768661||SILC Group|patients with symptomatic cholelithiasis submitted to a single-incision laparoscopic cholecystectomy
89347619|NCT03768661||Laparoscopy Group|patients with symptomatic cholelithiasis submitted to a standard three trocar laparoscopic cholecystectomy
89347620|NCT02521246|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 12,5 mg) a day, in the morning.
89347621|NCT02521246|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 25 mg) a day, in the morning.
89347622|NCT02521246|Active Comparator|Comparator: Losartan+hydrochlorothiazide (Hyzaar®)|The patients will take 1 tablet (Losartan 100 mg + Hydrochlorothiazide 25 mg) a day, in the morning.
89347623|NCT05309070|Active Comparator|Study group|female patients with primary burning mouth syndrome
89347624|NCT05309070|Placebo Comparator|Control group|female patients with primary burning mouth syndrome
89347625|NCT04243876||paraoxanase|Enzyme level
89347626|NCT04243876||Myocardial infarction|RESULTS OF ANGIOGRAPHY
89347627|NCT05308992|Other|Couples who use condom|The investigator will recruit heterosexual couples who have experience using silicone-lubricated latex condoms. All couples are required to have a backup birth control option and must be monogamous to participate in the study.
89347628|NCT04239820||RRMS patients initiating cladribine|Patients will be imaged using PET and MRI at baseline prior the cladribine treatment initiation and 18 months after baseline
89347629|NCT05176938|Experimental|Ultrasound guided Thoracic Interfascial plane Block (TIFB)|Patients will receive (20ml) (plain bupivacaine 0.25% injected in the serratus intercostal space at 6 ribs midaxillary line and (20ml) in pecto-intercostal space at 2 ribs parasternal.
89347630|NCT05176938|Experimental|Ultrasound guided Erector Spinae plane Block (ESPB)|Patients will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the fourth thoracic segment (T4).
89347631|NCT05176938|No Intervention|General anesthesia|Patients will receive general anesthesia only without blocks.
89347632|NCT03627208||1|Retrospective chart review of children and young adults with ALL/LBL enrolled on treatment protocols in the POB
89347633|NCT03771235|Experimental|Mindfulness-based Intervention for Tics|8-week group-based mindfulness-based program
89347634|NCT03771235|Active Comparator|Tic Information and Coping Strategies|8-week group-based educational and supportive therapy program
89347635|NCT05308836|Experimental|Adipose-derived messenchymal stem cell (AD-MSC)|Intervention: Intravenousling (IV) AD-MSC in 10 patients with type 1 diabetes mellitus.
89347636|NCT03768583|Experimental|Group TSM ICT sneakers|"ICT with sneaker~five weeks~twice a week~half hour."
89347637|NCT03768583|Experimental|Group TSM ICT barefoot|"ICT barefoot~five weeks~twice a week~half hour."
89347638|NCT03768583|Experimental|Group TSM health barefoot|"Health with sneaker~five weeks~twice a week~half hour."
89347639|NCT03768583|Experimental|Group TSM health sneakers|"Health barefoot~five weeks~twice a week~half hour."
89347640|NCT04763928|Experimental|VenDec|Patients will receive a combination of VENETOCLAX (400 mg per day orally on days 1 to 28 of 28-days courses) and DECITABINE (20 mg/sqm intravenously on days 1 to 5 of 28-days courses)
89347641|NCT01567501|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
89347642|NCT01567501|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
89347643|NCT05385978|Active Comparator|APHD-012|Participants will receive a single dose of APHD-012 12 g daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.
89347644|NCT05385978|Placebo Comparator|APHD-012P|Participants will receive a single dose of APHD-012P daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.
89347645|NCT04374721|Experimental|Patients with Adrenal Insufficiency|Patients with Adrenal Insufficiency established or newly diagnosed, under glucocorticoid replacement therapy.
89347646|NCT04374721|Experimental|Patients with Cushing's Syndrome|patients with adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent Cushing's Syndrome diagnosis during active disease (new diagnosis or recidivating) at enrollment.
89347647|NCT04374721|Experimental|Healthy Controls|Age-, sex- and BMI- matched patients referring to our center for diagnostic procedures not affected by Adrenal Insufficiency or Cushing's Syndrome.
89347648|NCT03428542|No Intervention|Control arm|Instructed not to practice any yoga or mindfulness during the five-week study period.
89347649|NCT03428542|Active Comparator|Yin yoga intervention arm|"The Yin yoga intervention arm will receive Yin yoga, a calm-paced practice that uses seated and lying down positions.~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
89347650|NCT03428542|Active Comparator|YOMI program intervention arm|"The YOMI intervention arm will receive stress education + yoga, and bring together education about stress, mindfulness and yoga practice. It will involve weekly group meetings, homework, and yoga postures. Stress education and mindfulness will make up one portion of the intervention. This will take place in a group lecture format and shall be conducted by a mental health professional(s). Yoga practice in a group format will make up the second portion of the intervention.~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
89347651|NCT03602404||St. Petersburg: School aged children|Generally healthy 9 to 12 years old children
89347652|NCT03602404||St. Petersburg: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
89347653|NCT03602404||Papua New Guinea: School aged children|Generally healthy 9 to 12 years old children
89347654|NCT05384340|Experimental|Beet protocol|Acute intervention: 1st day [140 ml - Beet It Juice, 800mg nitrate/day] Continued intervention: 2nd to 7th day [70 ml - Beet It Juice, 400mg nitrate/day] Exercise intervention [Treadmill - 40 minutes duration, 65% - 70% VO2 Peak]: Acute [Just on day] / Continued [First and latest day] Washout: 7 days
89347655|NCT05384340|Placebo Comparator|Placebo protocol|Acute intervention (1st day): [140 ml - Beet It Juice, 0mg nitrate/day] Continued intervention (2nd to 7th day): [70 ml - Beet It Juice, 0mg nitrate/day] Exercise intervention [Treadmill - 40 minutes duration, 65% - 70% VO2 Peak]: Acute [Just on day] / Continued [First and latest day] Washout: 7 days
89347656|NCT01321957|Active Comparator|FOLFOX+Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
89347657|NCT01321957|Experimental|FOLFOX+Bevacizumab+Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
89347658|NCT04450030||Intravenous methyl prednisolone|Patients receiving an additional course of intravenous methyl prednisolone for treatment of a steroid-refractory MS relapse
89347659|NCT04450030||Immunoadsorption|Patients receiving 6 courses of immunadsorption treatment for treatment of a steroid-refractory MS relapse
89347660|NCT05308758|Experimental|GameHIIT intervention group|In the GameHIIT group, a specially designed game-based training program with HIIT in nature will be delivered to the participants for 8 weeks.
89347661|NCT05308758|Active Comparator|GameSE intervention group|In the GameSAE group, participants will attend a tailor-made game-based exercise training program. Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week.
89347662|NCT05308758|No Intervention|Control group|No intervention.
89347663|NCT04450420|Experimental|Simulation based curriculum|"Three phases:~Self-study of an eBook - Participating trainees will be required to learn material pertaining to tunnel construction and general surgical principles during SICS from an eBook that has been developed by HelpMeSee.~Instructor led teaching - didactic training, lab activities to gain familiarity with instruments, simulator based training through deliberate practice, and debriefing with instructor.~Instructor supervised performance of surgery on patients in the operating room."
89347664|NCT04450420|Active Comparator|Standard training|Current standard curriculum for resident training.
89347665|NCT03763435||Antenatal Classes Received|Women who are involved into at least 3 comprehensive session of Antenatal pregnancy classes (educational) during the prenatal period.
89347666|NCT03763435||Without education|Groups are not randomized for not to give rise to ethical problems in order to maximize the community health care. Only women who are not involved into the educational classes due to their inaccessibility related to their own conditions or wishes.
89347667|NCT03428464|Experimental|Sodium bicarbonate|During the treatment period, participants will receive 0.5 mEq/kg-lean body weight (LBW)/day of oral sodium bicarbonate for 8 weeks.
89347668|NCT03428464|Placebo Comparator|Placebo|During the control period, participants will take the same number of placebo capsules as if they were assigned 0.5 mEq/kg-LBW/day of sodium bicarbonate.
89347669|NCT05681208|Experimental|Intervention group|The training, which is prepared based on the motivational interview method, will be given individually, starting when baby is 4 months old, will be interviewed once a week for nine weeks. In first meeting; before starting motivational interview, mothers were interviewed face-to-face with the Baby, Mother Introductory Information Form, Mothers', Babies' Food Consumption Frequency Registration Form, Microbiota Awareness Scale (MFI), Infant Nutrition Attitude Scale (LOWA), Behavior Change Stage Diagnostic Form, Motivational Interview rating the schedule will be applied. At the end of this meeting, which lasts for 45-50 minutes, next meeting date will be determined, the meeting will be terminated. Second interview is planned to last 60-90 minutes. After the second meeting, Motivational interviews will provide information on nutritional posters, brochures of the Ministry of Health, complementary nutrition, nutrition for microbiota. The scales to be used will be re-administered.
89347670|NCT05681208|No Intervention|Control group|Within the scope of the research, no intervention will be made to the mothers in the control group other than routine family health center practices. In Turkey, 4-month-old baby follow-up continues at the Family Health Center, followed by midwives, nurses and doctors. Scales will be applied to mothers by face-to-face interview method when they come for routine baby follow-up. The training content given in the Family Health Center will be presented to the control group.
89347671|NCT04953078|Experimental|10 μg Baiya SARS-CoV-2 Vax 1, Adult Participants|2 doses of Baiya SARS-CoV-2 Vax 1 (10 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
89347672|NCT04953078|Experimental|50 μg Baiya SARS-CoV-2 Vax 1, Adult Participants|2 doses of Baiya SARS-CoV-2 Vax 1 (50 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
89347673|NCT04953078|Experimental|100 μg Baiya SARS-CoV-2 VAX1, Adult Participants|2 doses of Baiya SARS-CoV-2 VAX1 (100 μg), each on Day 1 and Day 22 for adult participants (18 - 60 years old)
89347674|NCT04953078|Experimental|10 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (10 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
89347675|NCT04953078|Experimental|50 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (50 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
89347676|NCT04953078|Experimental|100 μg Baiya SARS-CoV-2 VAX1, Elderly Participants|2 doses of Baiya SARS-CoV-2 VAX1 (100 μg), each on Day 1 and Day 22 for elderly participants (61 - 75 years old)
89347677|NCT03428386|Experimental|Gastric plication ileal bypass|single-anastomosis plication ileal bypass
89347678|NCT03433768||poor responders|
89347679|NCT03433768||normal responders|
89347680|NCT05363592|Experimental|CT-L01 12.5/500 mg FDC Tablet|Alogliptin Benzoate 12.5 mg/Metformin HCl XR 500 mg, FDC Tablet
89347681|NCT05363592|Active Comparator|Alogliptin Benzoate 12.5 mg, Metformin HCl XR 500 mg|"Alogliptin Benzoate 12.5 mg~Metformin HCl XR 500 mg"
89347682|NCT03428308|Experimental|Individualized treatment of detected somatic disease(s)|
89347683|NCT03433690|Experimental|High Intensity Interval Training|Twelve weeks of High Intensity Interval Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
89347684|NCT03433690|Active Comparator|Moderate training|Twelve weeks of Moderate Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
89347685|NCT05264298|Experimental|VIRTUAL Intervention (Treatment)|Participants assigned to intervention arm will have scheduled video telehealth appointments with a multidisciplinary team (Stroke provider, social worker, pharmacist) and remote telemonitoring of blood pressure with blood pressure medication adjustments biweekly as needed by pharmacists.
89347686|NCT05264298|Active Comparator|Standard Care|Participants assigned to standard care will follow-up with a stroke provider within 2 weeks of discharge and primary care as per usual recommendations. Participants will monitor their blood pressure on their own and pharmacists will contact participants monthly to review blood pressure. Pharmacists will make recommendations for blood pressure medication adjustment to participant primary care provider.
89347687|NCT03428074||Patients with the surgery of Ivor-Lewis|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Ivor-Lewis
89347688|NCT03428074||Patients with the surgery of Mckeown|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Mckeown
89347689|NCT04209088|Experimental|Pulmonary ultrasounds|All patients will be included in the experimental arm
89347690|NCT03333837|Active Comparator|Dance Group|The Dance Group will participate in 1-hour group improvisational dance lessons 2x/week for 12 weeks. Improvisational dance classes are grounded in 4 principles that shape the tone of the class and result in a sense of social belonging: non-judgment, non-competitiveness, curiosity, and playfulness. The following training strategies are used to maintain: active imagination, variability, and pacing.
89347691|NCT03333837|Active Comparator|Non-group Dance|The Non-group dance intervention is designed to capture the same dance movement and auditory stimuli as the group class without social interaction. Recordings of the dance instructor teaching a dance class will be played. This will ensure participants hear comparable music and receive comparable verbal auditory cues to prompt dance movements that students in the group class will hear, without interacting with other people. Improvisational dance is particularly suited for this means of delivery because the primary method of instruction is verbal auditory cueing. Participants will be asked to follow the same schedule as participants in the Dance Group arm and complete 2 one-hour dance sessions each week.
89347692|NCT03333837|Active Comparator|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
89347693|NCT03333837|Sham Comparator|No Contact|A No Contact condition captures the condition of no added social contact and no added dance movement. Participants randomized to the No Contact condition will be asked to continue their current disease management and lifestyle for 12 weeks
89347694|NCT03708211|Experimental|Part1: TAK-931 80 mg PIC + TAK-931 80 mg Tablet|TAK-931 80 milligram (mg), PIC, orally, once on Day 1 Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, tablet, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until progressive disease (PD), or unacceptable toxicity or any treatment discontinuation is determined.
89347695|NCT03708211|Experimental|Part1: TAK-931 80 mg Tablet + TAK-931 80 mg PIC|TAK-931 80 mg, tablet, orally, once on Day 1 of Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, PIC, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until PD, or unacceptable toxicity or any treatment discontinuation is determined.
89347696|NCT03708211|Experimental|Part 2: TAK-931 Fed + TAK-931 Fasted + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fed state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fasted state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
89347697|NCT03708211|Experimental|Part 2: TAK-931 Fasted + TAK-931 Fed + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fasted state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fed state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
89347698|NCT02948634|Sham Comparator|Sham Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy.
89347699|NCT02948634|Active Comparator|Active Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
89347700|NCT04186390||Medical doctors|Medical doctors with no prior experience in the evaluation of small bowel capsule endoscopy.
89347701|NCT03433612|Other|All Patients|"Estimates of the location of the L4-L5 intervertebral space will be done by the classic intercristal line technique and novel SAIL technique. Each technique will be performed by different randomly assigned investigators.~* Both techiques will be assessed on all patients"
89347702|NCT03768193|Experimental|Deep serratus anterior plane block|Ultrasound-guided deposition of 40mls of 2mg/ kg levobupivacaine into the deep serratus anterior plane space, in the mid axillary line, at the level of the 4th/5th rib. Insertion of a continuous local anaesthetic infusion catheter(Portex™) and continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
89347703|NCT03768193|Active Comparator|Surgically-placed paravertebral block|Surgical placement of paravertebral local anaesthetic infusion catheters (Portex™) prior to closure. Bolus of levobupivacaine as per protocol. Continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
89347704|NCT03770923|No Intervention|No intervention|No intervention
89347705|NCT03770923|Active Comparator|Rupatadine|Rupatadine 10 mg once daily.
89347706|NCT03770923|Active Comparator|Montelukast|Montelukast 10 mg daily
89347707|NCT03433534||Pharmacokinetic of Nivolumab|Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.
89347708|NCT04690218||Mastalgia|"Mastalgia group will consist of women with confirmed mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
89347709|NCT04690218||Controls|"Controls group will consist of women attending to general surgery clinic for reasons other than mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
89347710|NCT04080934|Experimental|Experimental Group|In the experimental group, patients allocated to the swimming/experimental group will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum. They will be asked to undergo a range of motion (ROM) assessment by a registered kinesiologist, as well as a few short questionnaires administered over the phone by a research assistant, once at the onset of the intervention and once a month for 3 months during the intervention.
89347711|NCT04080934|No Intervention|Control Group|The control group will include patients who receive standard of care. This includes the recommendation to undertake exercise and physiotherapy; however, no formal exercise program will be provided. In the control group, participants will be asked to answer a few short questionnaires administered over the phone by a research assistant once per month for 4 months.
89347712|NCT05445895|Experimental|Renexin CR 200/160mg|Renexin CR 200/160mg will be added to Aspirin 100mg
89347713|NCT05445895|Active Comparator|Clopidogrel 75mg|Plavix 75mg will be added to Aspirin 100mg
89347714|NCT03367299|Experimental|Chemotherapy + Blinatumomab|Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
89347715|NCT04450186|Experimental|EEG/fMRI neurofeedback|Healthy volunteers
89347716|NCT02945046|Placebo Comparator|Placebo|Participants will receive placebo administered via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injection at Weeks 4 and 8, respectively.
89347717|NCT02945046|Experimental|Fremanezumab 675 mg/Placebo/Placebo|Participants will receive placebo as an approximately 1-hour intravenous infusion followed by fremanezumab at 675 milligrams (mg) administered as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 and placebo administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
89347718|NCT02945046|Experimental|Fremanezumab 900/225/225 mg|Participants will receive fremanezumab at 900 mg administered via an approximately 1-hour intravenous infusion followed by 3 placebo subcutaneous injections at Week 0 and fremanezumab at 225 mg administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
89347719|NCT03705793|Experimental|Mometasone Furoate Nasal Irrigation|The study intervention will be mometasone furoate powder (1.2 mg/capsule) and placebo nasal spray. The placebo nasal spray will contain the same inert ingredients found in MF nasal spray: glycerin, microcrystalline cellulose and carboxymethylcellulose, sodium citrate, citric acid, benzalkonium chloride, and polysorbate 80. The placebo nasal spray will be packaged identically to the mometasone nasal spray. Participants will be required to dissolve the contents of two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
89347720|NCT03705793|Active Comparator|Mometasone Nasal Spray|The study intervention will be mometasone nasal spray (50 mcg/spray) and placebo nasal irrigation. The placebo will contain lactose monohydrate and will be supplied in capsules identical to the budesonide capsules. Participants will be required to dissolve the contents of the two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
89347721|NCT03333057|Experimental|NOV03 4 times daily (QID)|Perfluorohexyloctance solution 4 times daily (QID)
89347722|NCT03333057|Experimental|NOV03 2 times daily (BID)|Perfluorohexyloctance solution 2 times daily (BID)
89347723|NCT03333057|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
89347724|NCT03333057|Placebo Comparator|Placebo 2 times daily (BID)|Saline solution (0.9% sodium chloride solution) 2 times daily (BID)
89347725|NCT04449718|Experimental|Experimental|Patients will receive 200,000 IU of vitamin D3 on admission + conventional care
89347726|NCT04449718|Placebo Comparator|Placebo|Patients will receive an equivalent amount of a placebo solution on admission + conventional care
89347727|NCT03763279|Experimental|Triclosan-coated barbed suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone barbed suture
89347728|NCT03763279|Experimental|Triclosan-coated monofilament suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone monofilament suture
89347729|NCT03763279|Sham Comparator|Monofilament suture|Abdominal wall closure will be performed using a monofilament suture
89347730|NCT03429478|Experimental|Music|Preoperative application of a Bluetooth enabled headphones with standard music played for atleast 2 hours preoperatively.
89347731|NCT03429478|Active Comparator|No Music|Preoperative application of a Bluetooth enabled headphones with no music played and headphones will just mask the surrounding noise.
89347732|NCT03638037||Study|69 women, delivered preterm babies (less than 37weeks).
89347733|NCT03638037||Control|69 women, delivered at term (38-42 weeks) of full tem babies.
89347734|NCT03763201||rheumatoid arthritis|recently diagnosed rheumatoid arthritis patients in whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum and synovial fluid (if clinically determined knee effusion)
88814360|NCT02244632|Experimental|MOFOX / Bevacizumab|Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab
89347735|NCT03763201||control group|age and sex matched healthy volunteers whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum.
89347736|NCT03763123|Experimental|Sevacizumab +Chemotherapy Combined chemotherapy drug including|Investigators selected single-agent chemotherapy on an individual patient basis from the following options, with appropriate premedication according to local standards: paclitaxel 80mg/m2 intravenously (IV)on days 1, 8, 15, and 22 every 4 weeks; or topotecan 4 mg/m2 IV on days 1, 8, and 15 every 4 weeks.
89347737|NCT03429400|Other|Morphine Sulfate|oral morphine sulfate tablets oral morphine sulfate oral solution
89347738|NCT04805307|Experimental|Part A, Dose escalation|CMG901 will be administered in treatment cycles once every 3 weeks (Q3W). Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 2 dose levels (0.3mg/kg and 0.6mg/kg), and then traditional 3+3 dose escalation design will be used for the following levels (1.2mg/kg, 1.8mg/kg, 2.2mg/kg, 2.6mg/kg and 3.0mg/kg).
89347739|NCT04805307|Experimental|Part B, Dose expansion _GC_ MTD level|"This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation."
89347740|NCT04805307|Experimental|Part B, Dose expansion _PC_ MTD level|"This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation."
89347741|NCT04805307|Experimental|Part B, Dose expansion _GC_ MTD-1 level|"This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation."
89347742|NCT04805307|Experimental|Part B, Dose expansion _PC_ MTD-1 level|"This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation."
89347743|NCT03429088|Experimental|Telephone counseling|Participants were provided with approximately 7 telephone-based motivational interviewing over a 24-week period to increase their physical activity.
89347744|NCT03429088|No Intervention|Usual care|Participants in the usual care arm received a packet of places near their home in which they could engage in physical activity if they chose.
89347745|NCT02944968|Experimental|Treatment group|Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF-5D catheter in Paroxysmal AF population.
89347746|NCT03429010|Experimental|"New guideline"|"New guideline anesthesia strategy team (Group A)"
89347747|NCT03429010|No Intervention|Current strategy|Current anesthesia strategy team (Group B)
89347748|NCT03761797||Subjects with type 2 Diabetes Mellitus|
89347749|NCT03127930|Experimental|Intervention|Intervention: Participants receive both usual care including a standard brochure on patient management provided by the Alzheimer's Association plus a tailored problem-solving intervention to improve caregiver's management of medications for their family or friend care recipient who has memory deficit.
89347750|NCT03127930|No Intervention|Usual Care|No Intervention: Participants do not receive the problem solving intervention and are followed as a Usual Care condition including receiving a standard brochure on patient management provided by the Alzheimer's Association. .
89347751|NCT02944656|Experimental|Gabapentin group|This group will receive local anesthesia per clinic protocol plus Gabapentin 600mg 1-2 hours preoperatively.
89347752|NCT02944656|Placebo Comparator|Placebo group|This group will receive local anesthesia per clinic protocol plus placebo 1-2 hours preoperatively.
89347753|NCT02713529|Experimental|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
89347754|NCT03763045|Experimental|Sildenafil 25|Twenty hemodialysis patients will receive a dose of 25mg sildenafil daily for 3 months.
89347755|NCT03763045|Experimental|Sildenafil 50|Twenty hemodialysis patients will receive a dose of 50mg sildenafil daily for 3 months.
89347756|NCT03763045|Placebo Comparator|Placebo|Twenty hemodialysis patients will receive a placebo tablet daily for 3 months.
89347757|NCT01321489|Experimental|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
89347758|NCT01321489|Active Comparator|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
89347759|NCT03427840||Hypo|The participants with a superior hypogastric block
89347760|NCT03427840||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retroperitone is opened intraoperatively by the surgeon)
89347761|NCT04800627|Experimental|Treatment (pevonedistat, pembrolizumab)|Patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
89347762|NCT03771625||single-group studies|All the patients received chemotherapy and radiotherapy.
89347763|NCT03768037|Experimental|Anlotinib plus Pemetrexed|Anlotinib plus Pemetrexed
89347764|NCT03768037|Other|Pemetrexed|Pemetrexed
89347765|NCT01146977|Experimental|Autologous HCT|"5.1.3. After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~5.1.3.1. If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
89347766|NCT01146977|Active Comparator|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
89347767|NCT03762967|Experimental|Lipoaspiration and SVF introduction I.|Patients with azoospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
89347768|NCT03762967|Active Comparator|Standard therapy I.|Patients with azoospermia that introduce with Standard therapy only.
89347769|NCT03762967|Experimental|Lipoaspiration and SVF introduction II|Patients with oligospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
89347770|NCT03762967|Active Comparator|Standard therapy II.|Patients with oligospermia that introduce with Standard therapy only.
89347771|NCT05055856|Active Comparator|Frailty or more|patients with the geriatric syndrome who will be recruited at the geriatric out patient clinic
89347772|NCT05055856|Placebo Comparator|healthy|healthy aged people defined as in the modified SENIEUR protocol who will be recruited by an extern call thanks UZ Brussel website of thanks to staff's knowledge
89347773|NCT03762889|Experimental|Eyeprotx™ Group|This group of participants will use the Eyeprotx™ General Anesthesia Protective Goggles when intubated perioperatively under general anesthesia.
89347774|NCT03762889|Active Comparator|Eyelid Tape Group|This group of participants will be receiving the eyelid tape as the preventative measure when intubated perioperatively under general anesthesia.
89347775|NCT03762889|Active Comparator|Eye Ointment Group|This group of participants will be receiving the ointment application when intubated perioperatively under general anesthesia.
89347776|NCT04555239|Active Comparator|Standard of Care, Upper Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
89347777|NCT04555239|Active Comparator|Standard of Care, Lower Extremity Pain|Patients will receive standard emergency department care as determined by their treating physician for their extremity pain.
89347778|NCT04555239|Experimental|FDM, Upper Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
89347779|NCT04555239|Experimental|FDM, Lower Extremity Pain|Patients will receive the FDM intervention for their extremity pain. They may also receive standard emergency department care as determined by their treating physician for their extremity pain.
89347780|NCT03427762|Experimental|Healthy cycling group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then there is a bicycle every 1 hour.
89347781|NCT03427762|Experimental|Healthy xbox group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then they will train 1 hour every day on an xbox program.
89347782|NCT03427762|No Intervention|Healthy controll group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Thereafter, the group does not move only in everyday life.
89347783|NCT03427762|Experimental|PD groupe|"Patients with PD have already been evaluated and compared to the results of a healthy group within a separate experiment.~The study and the results have been completed. Clinical trial number:NCT03193268"
89347784|NCT03746041|Experimental|abaloparatide and bevacizumab treatment|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days. In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
89347785|NCT01236989|Experimental|Anatomical resection|
89347786|NCT01236989|Active Comparator|Non-anatomical resection|
89347787|NCT03423472|Experimental|Full intervention|Healthy Baby Toolkit (HBT) in addition to Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
89347788|NCT03423472|Active Comparator|Partial intervention|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
89347789|NCT03423472|Other|Control|Government standard of care for nutrition education through the Health Development Army
89347790|NCT03767959|Experimental|Chen's U-Suture|Patients in this group will treated by Chen's U-suture technique in pancreaticojejunostomy.
89347791|NCT03767959|Active Comparator|Classic pancreatic duct to mucosa|Patients in this group will treated by classic pancreatic duct to mucosa technique in pancreaticojejunostomy.
89347792|NCT01239563|Experimental|Thymoglobulin|Thymoglobulin induction group
89347793|NCT01239563|Active Comparator|Basiliximab|Basiliximab induction - 20 mg, day 0 and day 4
89347794|NCT03423394|Experimental|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment.
89347795|NCT03423394|Active Comparator|Treatment as Usual|The treatment as usual (TAU) condition was selected to mirror the existing process in the military for identifying and encouraging treatment for personnel who screen positive for PTSD.
89347796|NCT03767803||Positive Preeclampsia group|A group with diagnosis of preeclampsia within 24 hours of testing and pre-term delivery
89347797|NCT03767803||Study Cohort|A group without diagnosis of preeclampsia. Also includes a group without diagnosis of preeclampsia within 24 hours of testing, but who have subsequent worsening or re-emergence of signs and symptoms of preeclampsia, and are later diagnosed with preeclampsia and have pre-term delivery.
89347798|NCT04982159||Invasive Fusariosis|Patients hospitalized with an invasive fusariosis diagnostic in the stablished period of study.
89347799|NCT05308368|Experimental|Tremor Group|Individuals with either parkinson's disease or essential tremor will be recruited in this group
89347800|NCT05308368|Experimental|Able Body Group|Individuals with no disorders will be recruited in this group
89347801|NCT03427684|Experimental|Hypo-fractionated radiotherapy|Hypo-fractionated neoadjuvant radiotherapy concurrent with S1 chemotherapy for local advanced gastric cancer
89347802|NCT03762811|Other|NanoFUSE® PMCF|NanoFUSE® Bioactive Matrix will be implanted according to labeling and the intended surgical treatment plan of the surgeon.
89347803|NCT01321255|Experimental|FDC Fixed Dose Combination|
89347804|NCT01321255|Active Comparator|Conventional treatment|
89347805|NCT04958837|Experimental|FIFA 11+ with dynamic core stability training|Participants in this group will undergo FIFA 11+ protocol along with additional Core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge will be given. Each exercise plan will be progressively increased.
89347806|NCT04958837|Active Comparator|FIFA 11+ protocol|Participants in this group will undergo traditional FIFA 11+ protocol which consists of slow paced running exercises, strength, plyometric & Balance exercises and high speed running with planting/cutting
89347807|NCT03417310|Experimental|"H joystick"|"Patients are treated with the H joystick on a traction table"
89347808|NCT03417310|Active Comparator|Common reduction methods|Patients are treated with common reduction methods on a traction table
89347809|NCT03427606|Experimental|Continuous Suture|
89347810|NCT03427606|Active Comparator|Single 5-points Suture|
89347811|NCT03762577|Experimental|Training Group|Training group will attend ground-based walking training under the supervision of a physiotherapist for 2 days and 30 minutes a week. Patients will walk for 1-2 days in a week without supervision.
89347812|NCT03762577|No Intervention|Control Group|Patient education will be given and no intervention will be made.
89347813|NCT03638778|Active Comparator|Oral semaglutide (reference)|Participants will receive oral semaglutide (reference) for 10 days.
89347814|NCT03638778|Experimental|Oral semaglutide formulation B|Participants will receive oral semaglutide formulation B for 10 days.
89347815|NCT03638778|Experimental|Oral semaglutide formulation C|Participants will receive oral semaglutide formulation C for 10 days.
89347816|NCT03638778|Experimental|Oral semaglutide formulation D|Participants will receive oral semaglutide formulation D for 10 days.
89347817|NCT01146119|Experimental|Multimeric-001, Adjuvanted|64 subjects received 2 injections of Adjuvanted Multimeric-001, 500 mcg with an interval of 21 days and then 60 days later were further immunized with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
89347818|NCT01146119|Active Comparator|PBS and TIV 15%|32 subjects received 2 injections of PBS (Phosphate Buffered Saline) with an interval of 21 days and then were further immunized 60 days later with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
89347819|NCT01146119|Placebo Comparator|Placebo, Adjuvanted|32 subjects received Adjuvanted PBS (Placebo) with an interval of 21 days.
89347820|NCT01146119|Experimental|Co-administration M-001 and TIV 15%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 15%.
89347821|NCT01146119|Experimental|Co administration of M-001 and TIV 50%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 50%.
89347822|NCT01146119|Active Comparator|Co administration of PBS and TIV 50%|24 subjects received 2 injections on the same day, one injection containing PBS and the other containing TIV 50%.
89347823|NCT03417232|Experimental|Split Full Split Elevation of CAF|The central portion of the flap apical to the recession was elevated full thickness by the use of a small periostium elevator inserted into the probable sulcus
89347824|NCT03417232|Sham Comparator|Split Elevation of CAF|The flap was fully elevated with a split thickness approach: the blade of the knife was inserted into the sulcus
89347825|NCT03707821|Experimental|senofilcon A TEST Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.
89347826|NCT03707821|Active Comparator|senofilcon A CONTROL Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.
89347827|NCT03423316|No Intervention|Healthy Controls|
89347828|NCT03423316|No Intervention|Age-Matched Controls|Subjects without PAD who have the same average age as the PAD patients
89347829|NCT03423316|Experimental|PAD Patients|Patients with PAD. Approximately 75% of PAD patients will be enrolled in the 12-week exercise therapy program.
89347830|NCT04546581|Experimental|Intervention Group|Participants in this group will receive the investigational product and standard of care (SOC).
89347831|NCT04546581|Placebo Comparator|Control Group|Participants in this group will receive a placebo and standard of care (SOC).
89347832|NCT02204254|Experimental|Radiofrequence|3 sessions of radiofrequency at 3 weeks intervals V1, V2 (W3 or W4) and V3 (between W6 and W8), with clinical examination, evaluation of tolerance, adverse events report, photos, surface biopsy (SSSB), and confocal microscopy (V1 and V3). Follow up visit V4 (M6) with clinical evaluation, photos, SSSB, confocal microscopy, adverse events report and treatment satisfaction.
89347833|NCT02204254|Placebo Comparator|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
89347834|NCT05302128|Experimental|Cold vapor group|Cold vapor will be applied to the experimental group patients for 15 minutes in the recovery room. For the study, Nebtime UN600A Ultrasonic Nebulizer Device will be used to apply cold steam to the patients which used in the hospital and calibrated (https://elmaslarmedikal.com.tr/urunler/nebtime-un600aultrasonik-nebulizator/). The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5 (1-10), air blowing intensity 5 (1-10), heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
89347835|NCT05302128|No Intervention|Control group|Patients in the control group will receive standard care that includes all medical and non-medical treatments in the hospital. Nursing care, which is routinely applied to patients in the postoperative period, both in the recovery room and in the service, will be continued within the standard care. The patients will be evaluated by the researchers in terms of nausea and vomiting when they come to the recovery room and at the 2nd, 6th,12th, and 24th hours after the surgery in the postoperative service.
89347836|NCT01312935|Experimental|Heparin and PMX-60056|
89347837|NCT03707587|Experimental|1200 mg intravenous (IV) of M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
89531929|NCT04722731|Experimental|Confident Parents - Brave Children|"The Confident Parents - Brave Children (CPBT) is a group parent training targeted to anxious parents, delivered by a psychologist via video conference (the Zoom software solution).~The CPBT will comprise six 120-minutes digital sessions. One month after the last group session, all parents will be offered to have an individual booster session with a psychologist over Zoom."
89347838|NCT03925077|Active Comparator|Movement to Music (M2M)|All M2M sessions are delivered using videos uploaded to a secure study website (the SCIPE website). Participants in M2M will have access to the website and attend three 60-minute M2M sessions per week for a total of 8 weeks. Each session provides rhythmic-based exercises that are choreographed to music to target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
89347839|NCT03925077|Active Comparator|Standardised Exercise Training (SET)|All M2M sessions are delivered using videos uploaded to the SCIPE website. Participants in SET will have access to the website and attend three 60-minute SET sessions per week for a total of 8 weeks. Each session provides traditional exercises that target range of motion, muscular strength, cardiorespiratory fitness, and balance. In addition, participants in M2M will receive and read weekly educational articles on health and fitness through the SCIPE website.
89347840|NCT03925077|No Intervention|Attention Control (AC)|Participants in AC will not have access to any exercise videos. They will have access to the weekly educational articles on health and fitness, same as the ones received by the M2M and SET groups, through the SCIPE website.
89347841|NCT03423004|Experimental|Patient with lesional skin|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
89347842|NCT03423004|No Intervention|Patients with healthy skin|the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed
89347843|NCT05299632||Patients with biochemical and clinical evidence of primary hyperparathyroidism|Patients who have biochemical and clinical evidence of primary hyperparathyroidism and who are scheduled for routine surgery and preoperative imaging including 99mTc-MIBI planar imaging and SPECT/CT. Subjects who enroll in the study will receive one additional F-18PSMA PET/CT imaging study. F-18 PSMA imaging study will be scheduled on the same day as of the Tc-99m MIBI scan. Since F-18 PSMA PET/CT employs 511kEv annihilation photon, the lower energy if (140 KeV) of Tc-99m MIBI will not interfere.
89347844|NCT04289025|Active Comparator|Exercise|Personalised exercise programme is provided to the exercise group.
89347845|NCT04289025|No Intervention|No Intervention|This group of patients will receive no intervention.
89347846|NCT03417076|Experimental|Bexagliflozin|Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of < 30 ug 14C-bexagliflozin in 0.9% saline solution).
89347847|NCT03416920|Experimental|Wellframe|Subjects in this arm will use the Wellframe application for 90 days
89347848|NCT03638544|Active Comparator|Reduced Gluten-Normal Gluten|
89347849|NCT03638544|Active Comparator|Normal Gluten-Reduced Gluten|
89347850|NCT02192008|Active Comparator|Part A|Cohort naive to typhoidal Salmonella challenged with either S. Typhi or S. Paratyphi
89347851|NCT02192008|Active Comparator|Part B|Cohort previously challenged with S. Typhi or Paratyphi re-challenged with either S. Typhi or S. Paratyphi.
89347852|NCT03427372||group 1: patients with headache|the patients who have post spinal puncture headache after spinal anesthesia
89347853|NCT03427372||group 2: patients without headache|the patients who do not have post spinal puncture headache after spinal anesthesia
89347854|NCT03427372||group 3: patients with backache|the patients who have post spinal puncture backache after spinal anesthesia
89347855|NCT03427372||group 4: patients without backache|the patients who do not have post spinal puncture backache after spinal anesthesia
89347856|NCT03416842|Experimental|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
89347857|NCT03312933||Duration of boot >2 weeks|All patients who were placed into a CAM walker boot for >2 weeks were prospectively enrolled. Patients were placed by an orthopedic cast technician into either a tall or short CAM walker boot, based upon the appropriate boot type needed for treatment. Inclusion criteria included anticipated boot wear for at least two weeks, and weightbearing as tolerated weightbearing restrictions. Exclusion criteria included transitioning into a CAM walker boot as part of a postoperative protocol, injury requiring restricted weightbearing, or an additional acute injury to the lower back or lower extremity. Those who subsequently reported wearing the boot for less than two weeks or had a treatment plan change were removed from the study.
89347858|NCT03164655|Experimental|HAI oxaliplatin combined with I.V. FOLFIRI + target therapy|"HAI oxaliplatin 100 mg/m² on D1~I.V. cetuximab 500 mg/m² or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT~modified FOLFIRI regimen without fluorouracil bolus~I.V. irinotecan 180 mg/m² D1~I.V. bolus 5-Fluorouracil (5-FU): 0~I.V. leucovorin 400 mg/m² in 2 hours D1~I.V. continuous infusion 5-FU 2400 mg/m² in 46 hours"
89347859|NCT03164655|Active Comparator|conventional systemic CT|"Response to systemic induction CT~Toxicity and duration of the systemic induction CT~RAS status~Current guidelines/standard of care"
89347860|NCT04373694|Active Comparator|Standard hysteroscopy|morcellation hysteroscopy with intravenous sedation and paracervical bloc
89347861|NCT04373694|Experimental|Vaginoscopy|morcellation hysteroscopy with only intravenous sedation
89347862|NCT03422926|Experimental|Intervention|Social marketing messaging campaign
89347863|NCT03422926|No Intervention|Control|No messaging campaign
89347864|NCT03312543|Experimental|Active Cell: Active Mask|Cleanser, Moisturizer, Active Mask
89347865|NCT03312543|Sham Comparator|Sham Cell: Sham Mask|Cleanser, Moisturizer, Sham Mask
89347866|NCT02521012|Active Comparator|Vitamin D 10 micrograms|"Vitamin D supplementation 10 micrograms/day given to depressed individuals, defined as reference"
89347867|NCT02521012|Experimental|Vitamin D 100 micrograms|Vitamin D supplementation 100 micrograms/day given to depressed individuals
89347868|NCT03416764|Experimental|EFP-NF (participants without steady menstrual cycle).|EFP-NF training, twice a week for a total of 10 sessions .
89347869|NCT03416764|No Intervention|TAU|Participant will receive no EFP-NF training, and continue their treatment as usual (TAU).
89347870|NCT03416764|Experimental|EFP-NF during HIGH estrogen phase|EFP-NF training, twice a week, during high-estrogen phases only (days 7-21 of a 28-day cycle), for a total of 10 sessions.
88814361|NCT02244632|Experimental|MOFIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan
89347871|NCT03416764|Experimental|EFP-NF during LOW estrogen phase|EFP-NF training, twice a week, during low-estrogen phases only (days 21-28 of a cycle and days 1-7 of the following cycle,based on a 28-day cycle), for a total of 10 sessions.
89347872|NCT04756128|Experimental|Colchicine-Only Arm|"Patients randomized to a colchicine-containing treatment arm will receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided the first dose can be given prior to 16:00 that day, patients are eligible to receive two doses; the second dose will be scheduled for 22:00. Patients experiencing gastrointestinal side effects (nausea, vomiting, and diarrhea) on twice daily dosing may have the dose decreased to 0.6 mg daily. Dosing will continue twice daily unless there is a change that requires a dose adjustment or an exclusion criterion is met. Dosing deviations above the study protocol will be allowed if medically necessary for the treatment of an additional indication (e.g. colchicine for viral pericarditis).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
89347873|NCT04756128|Experimental|"Colchicine and Naltrexone (Combined) Arm"|"Patients randomized to a colchicine-containing treatment arm (including the combined arm) will receive colchicine 0.6 mg twice daily for up to 28 days. On the day of enrollment, provided the first dose can be given prior to 16:00 that day, patients are eligible to receive two doses; the second dose will be scheduled for 22:00.~Patients in the combined arm will also receive naltrexone. Patients randomized to an LDN-containing treatment arm (including the combined arm) will receive naltrexone 4.5 mg once daily. The first dose can be given at any time during the day of enrollment/randomization, and will be timed at 08:00 daily thereafter (with AM colchicine dose, if in combined colchicine/LDN arm) for up to 28 days (unless new contraindication or exclusion criteria met).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
89347874|NCT04756128|Experimental|Naltrexone-Only Arm|"Patients randomized to an LDN-containing treatment arm (including the combined arm) will receive naltrexone 4.5 mg once daily. The first dose can be given at any time during the day of enrollment/randomization, and will be timed at 08:00 daily thereafter (with AM colchicine dose, if in combined colchicine/LDN arm) for up to 28 days (unless new contraindication or exclusion criteria met).~Patients in this arm will also receive the investigating institution's current standard of care (described in detail in the standard of care arm) for patients with COVID-19."
89347875|NCT04756128|No Intervention|Standard of Care Arm|Patients in this arm will receive the investigating institution's current standard of care for patients with COVID-19. For example, all patients requiring supplemental oxygen (assuming no contraindications) would be candidates for both remdesivir 200 mg x 1 IV dose followed the next day by 100 mg q24h IV x up to 4 doses, as well as dexamethasone 6 mg q24h x 10 up to 10 doses.
89347876|NCT03427216|Active Comparator|Vaginal Baclofen/diazepam supp|Insert vaginal suppository once daily
89347877|NCT03427216|Placebo Comparator|Vaginal Placebo supp|Insert vaginal suppository once daily
89347878|NCT01144091|Experimental|pentoxyphylline cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
89347879|NCT01144091|Placebo Comparator|placebo cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
89347880|NCT01144091|Experimental|radiology pentoxyphylline|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
89347881|NCT01144091|Placebo Comparator|radiology placebo|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
89347882|NCT01321333|Experimental|HuCNS-SC cells|Single dose intramedullary administration of HuCNS-SC cells
89347883|NCT03416686|Experimental|Radiofrequency|
89347884|NCT01313013|Experimental|intervention|question prompt sheet
89347885|NCT01313013|No Intervention|control|no question prompt sheet
89347886|NCT05060328||Health services research (Google Translate Conversation Mode)|"Patients use Google Translate Conversation Mode translation application before and after surgery. Patients also complete survey over 10 minutes."
89347887|NCT02008552|Other|Mediagene|Sampling blood
89347888|NCT03762499|Active Comparator|Prospective participants|250 participants will be recruited prospectively during the hypertension clinic, where a full set of data will be collected from each participant as part of their standard hypertension clinical service. An additional echocardiography scan will be performed for this cohort by the study team, if the scan has not been performed as a part of the clinical care service
88807272|NCT05250050|Experimental|Genotypic resistance guided therapy|After Helicobacter pylori drug resistance mutation gene detection, according to genotypic antibiotic resistance pattern of each one, give esomeprazole 20mg bid and bismuth potassium citrate 0.6 g bid, combined two sensitive antibiotics of Amoxicillin, tetracycline,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
89347889|NCT03762499|No Intervention|Retrospective participants|500 participants will be recruited retrospectively, and no additional echocardiography scan will be required for them.
89347890|NCT03767725|Experimental|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART19 cells.
89347891|NCT02392559|Placebo Comparator|Placebo|Matching subcutaneous injection every 4 weeks (QM)
89347892|NCT02392559|Experimental|EvoMab 420 mg QM|Evolocumab subcutaneous injection QM
89347893|NCT03422692|Experimental|BioXlude memebrane|Subjects in this arm will receive demineralized freeze dried bone allograft covered with BioXclude amnion-chorion membrane following tooth extraction
89347894|NCT03422692|Active Comparator|Mem-Lok|subjects in this arm will receive demineralized freeze dried bone allograft covered with Mem-Lok collagenous membrane following tooth extraction
89347895|NCT03767647|Experimental|Intervention group|Receives 6 lessons in 6 different weeks on Emotional Intelligence
89347896|NCT03767647|No Intervention|Control group|Receives no intervention.
89347897|NCT03422614||Patient|Patients with Primary Immunodeficiency
89347898|NCT03422614||Control|Healthy Controls
89347899|NCT01561729|Experimental|Study group|This is the only arm of the study. All patients enrolled will have a nasogastric or orogastric tube placed. All will be assessed by both the RightSpot pH Indicator and chest radiograph.
89347900|NCT04919070|Experimental|Connect for Caregivers|Connect for Caregivers is a single session behavioral intervention with three components: 1) psychoeducation on the importance of connectedness for health and well-being; a card sort-based discussion prioritization tool that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; 3) personalized resources to address the identified barriers and targets.
89347901|NCT03332589|Experimental|Monotherapy Safety Run-in: E6201|"E6201 320 mg/m^2 administered IV over 2 hours twice weekly on Days 1, 4, 8, 11, 15 and 18, repeated every 28 days (=1 cycle).~Dose reductions for toxicity are 240 mg/m^2 (Dose Level -1) and 160 mg/m^2 (Dose Level -2) twice weekly."
89347902|NCT03332589|Experimental|Combination Safety Run-in: E6201 Plus Dabrafenib|Dose Level 1: E6201 320 mg/m^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -1: E6201 240 mg/m^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -2: E6201 240 mg/m^2 twice weekly plus dabrafenib 100 mg BID. Dose Level -3: E6201 160 mg/m^2 twice weekly plus dabrafenib 100 mg BID Dose Level -4: E6201 160 mg/m^2 twice weekly plus dabrafenib 75 mg BID. Dose Level -5: E6201 160 mg/m^2 twice weekly plus dabrafenib 50 mg BID.
89347903|NCT03332589|Experimental|Expansion: E6201 Plus Dabrafenib|A total of up to N=18 will be treated at the E6201 plus dabrafenib combined MTD.
89347904|NCT03427138|Experimental|Jasper|JASPER (Joint Attention Symbolic Play Engagement Regulation) is a targeted intervention that focusses on early communication skills.
89347905|NCT03427138|Experimental|Parent Education|Parent education intervention focusses on parenting a child with autism.
89347906|NCT03767569|Experimental|Myo-inositol|Pretreatment with Gynositol (Myo-Inositol 4mg + Folic Acid 0.4mg) daily during 12 weeks before start of ART (Assisted Reproductive Technology)
89347907|NCT03767569|Other|Folic acid|Folic acid 0.4 mg daily during 12 weeks before start of ART
89347908|NCT03416452|Experimental|PD patients no|PD patients without freezing of gait
89347909|NCT03416452|Placebo Comparator|Healthy|HV using Mobile Gait Trainer
89347910|NCT03416452|Experimental|PD patients|pd patients using vibratory cueing device
89347911|NCT03416452|Experimental|PD patients 1|PD patients with freezing of gait
89347912|NCT03416452|Experimental|Healthy Volunteers|Age and gender matched healthy volunteers.
89347913|NCT03620916|Experimental|Intrathecal morphine|Intrathecal morphine (0,4 mg) immediately before operation
89347914|NCT03620916|Active Comparator|Intravenous morphine|Intravenous morphine (0,15 mg/kg body mass) immediately after the operation
89347915|NCT03767413|Active Comparator|PNF group|It will be consisted of 15 -25 healthy subjects receiving only proprioceptive nueromuscular facilitation training for 5 weeks with 17 days follow up after completion of program.
89347916|NCT03767413|Experimental|PNFMP|It will be consisted of 15 -25 healthy subjects receiving proprioceptive nueromuscular facilitation training and mental practice technique for 5 weeks with 17 days follow up after completion of program.
89347917|NCT01237067|Experimental|Group 1|Dose esc: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis
89347918|NCT01237067|Experimental|Group 2A|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
88811810|NCT05236088|Experimental|NMES group|Neuromuscular electrical stimulation (NMES) will be applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device for 30 minutes 3 days a week during 4 weeks
89347919|NCT01237067|Experimental|Group 2B|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
89347920|NCT03762187|Experimental|Self-affirmation|Participants completed a written self-affirmation manipulation before completing the standard counseling provided by the clinic.
89347921|NCT03762187|Active Comparator|Positive living counseling|Participants completed the standard counseling provided by the clinic (treatment as usual control condition).
89347922|NCT03422458|No Intervention|natural healing|no treatment and the coagulum within the socket is left open for spontaneous healing
89347923|NCT03422458|Experimental|Alveolar Ridge Preservation|A bone substitute material (BioOss Collagen) is placed within the bony envelope at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mucograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
89347924|NCT03422458|Experimental|Immediate Implant + Alveolar Ridge Preservation|An immediate implant (Winsix) placement is performed. After implant insertion, a bone substitute material (BioOss Collagen) is placed in the gap occurred between the implant surface and the hard tissue walls of the extraction socket at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mugograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
89347925|NCT05279352|Experimental|Treatment Arm|FBR-002 at 4.3 EU/kg on D1 and D3 or FBR-002 at 5.7 EU/kg on D1 and D3
89347926|NCT05279352|Placebo Comparator|Placebo Arm|Two administrations of placebo at D1 and D3
89347927|NCT03426982|Experimental|Anti-Xa group|- Heparin was monitored by Anti-Xa activity, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 0.30 and 0.70 IU/mL
89347928|NCT03426982|Experimental|APTT group|- Heparin was monitored by APTT, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 1.5 and 2.5 time the basiline.
89347929|NCT03762031|Experimental|GC4711 30mg|
89347930|NCT03762031|Experimental|GC4711 60mg|
89347931|NCT03762031|Experimental|GC4711 90mg|
89347932|NCT03762031|Experimental|GC4711 120mg|
89347933|NCT03762031|Placebo Comparator|Placebo|
89347934|NCT03762031|Experimental|GC4711 75mg|
89347935|NCT03762031|Experimental|GC4711 105mg|
89347936|NCT03422380||Weight Loss Maintainers (WLM)|Individuals maintaining ≥13.6 kg (30 lb) weight loss for ≥1 year
89347937|NCT03422380||Normal Weight Controls (NC)|Individuals with normal weight whose BMI was matched to the current BMI of the WLM. NC had to be weight stable and not maintaining a weight loss of ≥13.6kg
89347938|NCT03422380||Controls with Overweight/Obesity (OC)|Individuals with overweight/obesity whose BMI was matched to the pre-weight loss maximum BMI of WLM. OC had to be weight stable and not maintaining a weight loss of ≥13.6kg
89347939|NCT03770533|Other|MR-proADM guided|
89347940|NCT03770533|No Intervention|Standard Care|
89347941|NCT03416296||normal placenta|TA , TV ,TP us
89347942|NCT03416296||placenta previa and MAP|TA,TV.TP us
89347943|NCT01312584|Placebo Comparator|Non alkalised High Flavanol|Non-alkalised high flavanol cocoa drink containing 1745 mg of total flavanols
89347944|NCT01312584|Active Comparator|Alkalised high Flavanol|Alkalised high flavanol cocoa drink (medium alkalisation) containing 410 mg of total flavanols
89347945|NCT01312584|Active Comparator|Alkalised Low Flavanol|Alkalised low flavanol cocoa drink (heavily alkalised) containing 1.26 mg of total flavanols
89347946|NCT03416218|Experimental|Intervention|All participants enrolled in the study will play Prognosis, the intervention being assessed in this study.
89347947|NCT01561885|Active Comparator|Patients on Pathway Care|
89347948|NCT01561885|No Intervention|Patients on Usual Care|
89347949|NCT03684343|Other|Atopic Dermatitis patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
89347950|NCT03684343|Other|Healthy patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
89347951|NCT03767179||Study Group|The study group consisted of 30 fertile, under 35 years old women who were included in the study for the first time missed abortus diagnosis.
89347952|NCT03767179||Control Group|30 cases with the same trimester, fertile, and under 35 years old who were referred to Obstetrics clinic, who had no systemic disease, were included in the study.
89347953|NCT01546948|Experimental|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
89347954|NCT01546948|Active Comparator|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
89347955|NCT00458003|Experimental|Phenylephrine|Subject will receive a phenylephrine infusion to prevent and to treat hypotension associated with spinal anesthesia
89347956|NCT00458003|Active Comparator|Ephedrine|Subject will receive an ephedrine infusion to prevent and to treat hypotension associated with spinal anesthesia
89347957|NCT03416140|Experimental|Therapeutic exercise|
89347958|NCT03416140|No Intervention|Control|
89347959|NCT03770611|Active Comparator|Probiotic|Subjects receiving probiotic supplementation: 2x108 CFU probiotic bacteria + prebiotic placebo per day during 3 months
89347960|NCT03770611|Active Comparator|Prebiotic|Subjects receiving prebiotic supplementation: 20 g of prebiotic fiber + probiotic placebo per day during 3 months
89347961|NCT03770611|Experimental|Symbiotic|Subjects receiving probiotic and prebiotic supplementation: 2x108 CFU probiotic bacteria + 20 g of prebiotic fiber per day during 3 months
89347962|NCT03770611|Placebo Comparator|Placebo|Subjects receiving placebo of probiotic and prebiotic per day during 3 months
89347963|NCT03008616|Active Comparator|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
89347964|NCT03008616|Placebo Comparator|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
89347965|NCT03422146|Experimental|Cliradex® eyelid hygiene|Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.
89347966|NCT03422146|Other|I-Lid 'n Lash® Hygiene|Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,
89347967|NCT03770377|Experimental|Stroke without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
89347968|NCT03770377|Experimental|Stroke with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
89347969|NCT03770377|Experimental|SCA6 without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
89347970|NCT03770377|Experimental|SCA6 with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
89347971|NCT03770377|Active Comparator|Age-Matched Controls|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
89347972|NCT03422068|Experimental|BI 1015550|
89347973|NCT03422068|Placebo Comparator|Placebo|
89347974|NCT03623659|Active Comparator|AH group|Subjects whose vitrified/warmed blastocysts will be subjected to the treatment of laser assisted hatching
89347975|NCT03623659|No Intervention|Control group|Subjects whose vitrified/warmed blastocysts will be subjected to the same procedures except for the treatment of laser assisted hatching
89347976|NCT03767023||Stable AAA|"= patients with a small abdominal aortic aneursym diameter < 55 mm "
89347977|NCT03767023||instable AAA|"=patients with a large abdominal aortic aneursym diameter > 55 mm and/or AAA with rapid growth who needs open surgery or EndoVascular Aneurysm Repair EVAR"
89347978|NCT03426670|Active Comparator|OraQuick HIV Self-Test|Sex workers in the intervention arm will be instructed to self-test before starting each monthly course of PrEP. HIV Self-testing will be performed during the months between scheduled quarterly visits.
89347979|NCT03426670|No Intervention|In-clinic testing|All study participants will receive quarterly in-clinic HIV testing as standard-of-care.
89347980|NCT03127462|Experimental|Individualized Education|
89347981|NCT03127462|No Intervention|Control group|
89347982|NCT03770143||Group 1|Infants feeding predominantly with palm olein free formula if presence in addition to breast milk for 8 weeks of life
89347983|NCT03770143||Group 2|Infants feeding with other formulas including palm olein if presence in addition to breast milk for 8 weeks of life
89347984|NCT03770143||Group 3|Having similar demographical properties with infants feeding with breast milk (gender, age, weight, height)
89347985|NCT04506736|Active Comparator|SPV spontanous ventilation|The patients will be ventilated using volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
89347986|NCT04506736|Active Comparator|OLA open lung ventilation|The patients will undergo ARM followed by personalized PEEP.
89347987|NCT03426592|Active Comparator|Vitamin D3, 10000 Intl Units Oral Capsule|Vitamin D3, 10000 Intl Units Oral Capsule, daily for 6 months
89347988|NCT03426592|Placebo Comparator|Placebo oral capsule|Oleic acid capsule by mouth, daily for 6 months
89347989|NCT01567657|Active Comparator|Pethidin plus midazolam|Initial dose of 25 mg Pethidin iv. plus 1-2 mg Midazolam iv. Additional Bolus of Midazolam (1 mg wise iv.) if needed, until a maximal dose of 7 mg Midazolam iv.
89347990|NCT01567657|Active Comparator|Propofol|Initial dose of Propofol of 50-60 mg iv. for patients 50 years or younger. Initial dose of Propofol of 30-40 mg iv. for patients over 50 years. If needed additional Bolus of 20-30 mg Propofol iv. as usual until sedation is achieved.
89347991|NCT03770065||Group A|
89347992|NCT03770065||Group B|
89347993|NCT03416062|Experimental|Remaxol® 400 ml + Placebo 400 ml|Treatment with Remaxol® 400 ml IV + Ringer solution 400 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
89347994|NCT03416062|Experimental|Remaxol® 800 ml|Treatment with Remaxol® 800 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
89347995|NCT03416062|Placebo Comparator|Control|Treatment with Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
89347996|NCT03761485|Experimental|Dentifrice 750 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
89347997|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF neutral|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
89347998|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
89347999|NCT03426514|Experimental|Three-port Laparoscopic Surgery|Patients with colorectal cancer undergo three-port laparoscopic surgery.
89348000|NCT03426514|Experimental|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（4 or more ports）.
89348001|NCT03766867|Experimental|Vortioxetine|
89348002|NCT03766867|Placebo Comparator|Placebo|
89348003|NCT03415984||Exposed patients|Patients with Parkinson's disease treated with L-DOPA
89348004|NCT03415984||Non exposed patients|Patients with Parkinson's disease not treated with L-DOPA
89348005|NCT03761407|Experimental|Group 1 (100 mg GRT0151Y)|"The dose of 100 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 100 mg. On Day 5 the last dose of 100 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group."
89348006|NCT03761407|Experimental|Group 2 (125 mg GRT0151Y)|"The dose of 125 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 125 mg. On Day 5 the last dose of 125 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
89348007|NCT03761407|Experimental|Group 3 (150 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 150 mg. On Day 5 the last dose of 150 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
89348008|NCT03761407|Experimental|Group 4 (225 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the dose of 225 mg will be administered twice (b.i.d.). On Day 5 the last dose of 225 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
89348009|NCT02061293|Experimental|Psilocybin|Psilocybin 25 mg/70 kg PO administered at week 4, 25-40 mg/70 kg PO administered at week 8.
89348010|NCT02061293|Active Comparator|Diphenhydramine|Diphenhydramine 50 mg PO administered at week 4, 50-100 mg PO administered at week 8.
89348011|NCT03426280|Experimental|Apple Watch|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
89348012|NCT03426280|No Intervention|Usual Care|Usual care.
89348013|NCT03761329|Active Comparator|Bier's block|Upperarm intravenous regional anesthesia (Bier's block) with lidocaine 0.5% 40ml
89348014|NCT03761329|Experimental|Mini-Bier's block|Forearm intravenous regional anesthesia (mini-Bier's block) with lidocaine 0.5% 25ml
89348015|NCT03415906|Experimental|sacubitril+valsartan|Combined angiotensin receptor and neprilysin inhibition
89348016|NCT03415906|Active Comparator|valsartan|Angiotensin receptor inhibition alone
89348017|NCT03766789|Active Comparator|Intervention|They will receive the cell phone application, as reminder of medications time and dose.
89348018|NCT03766789|No Intervention|Control|Patients will receive standard of care recommendations.
89348019|NCT03415750|Experimental|Everolimus arm|Patients will be converted from Tacrolimus + Mycophenolate mofetil to Everolimus + Tacrolimus 'Conversion from Mycophenolate mofetil to Everolimus'
89348020|NCT03415750|Active Comparator|Mycophenolate arm|Patients will remain in Tacrolimus + Mycophenolate mofetil combination
89348021|NCT01239719|Experimental|Dexamethasone + Clemastine|Dexamethasone + clemastine fumarate cream
89348022|NCT01239719|Active Comparator|Dexamethasone|Dexamethasone 0.5 mg
89348023|NCT03761251|Experimental|Pet Fish|Participants will be instructed to partner thrice daily and once weekly fish care activities with diabetes care activities for 3 months
89348024|NCT03916679|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
89348025|NCT03421990||Group A|General anesthesia technique
89348026|NCT03421990||Group B|Regional anesthesia technique
89348027|NCT01248143|Experimental|Green tea|
89348028|NCT01248143|Experimental|FPP|
89348029|NCT03421912|Experimental|Arm A : Cicaplast balm B5|Use of Cicaplast balm B5, 2 to 3 applications per day, since the first day of iEGFR treatment initiation for 30 days to avoid or limit appearance of cutaneous toxicities related to iEGFR treatment.
89348030|NCT03421912|Active Comparator|Arm B : Dexeryl|Use of Dexeryl, 2 to 3 applications per day, since de first day of iEGFR treatment initiation for 30 days to avoid or limit appearence of cutaneous toxicities related to iEGFR treatment.
89348031|NCT03766711|Experimental|Actual - Augmented|Reaching task as a physical therapy intervention. First with 1:1 visual feedback, then with augmented forward symmetry.
89348032|NCT03766711|Experimental|Augmented - Actual|Reaching task as a physical therapy intervention. First with augmented forward symmetry, then with 1:1 visual feedback.
89348033|NCT03426202|Experimental|modafinil group|a single dose of p.o. modafinil (200mg)
89348034|NCT03426202|Experimental|placebo group|a single dose of p.o. placebo (200mg)
89348035|NCT04449016|Experimental|Caucasian|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
89348036|NCT04449016|Experimental|Hispanic|Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
89348037|NCT03916523|Experimental|Group A|Infants in the group receive CPAP for respiratory support in the delivery room. In addition, they receive a total of 15 sustained lung inflations in the first 96 hours of life; 6 in the first day, 3 in the second day, 3 in the third day and 3 in the forth day of life.
89348038|NCT03916523|Experimental|Group B|Infants in the group receive CPAP for respiratory support in the delivery room. No sustained lung inflation will be applied.
89348039|NCT03916523|Active Comparator|Group C|Infants in this group are intubated in the delivery room and supported with mechanical ventilation.
89348040|NCT03421678||Japanese American|Two parents of Japanese descent
89348041|NCT03421678||Non-Hispanic Whites|Two parents of non-Hispanic white descent
89348042|NCT03421678||Native Hawaiians|At least one parent of Hawaiian descent
89348043|NCT01237145||non-EAA, pigeon|subject with BAL because of diseases not suspected to be EAA
89348044|NCT01237145||EAA, pigeon|Bird fanciers with a typical clinical presentation suspected for pigeon induced EAA
89348045|NCT03421600|Active Comparator|Blue laser imaging|Blue laser imaging
89348046|NCT03421600|Experimental|White light imaging|White light imaging
89348047|NCT01248299|Experimental|Chemotherapy plus best supportive care|Chemotherapy plus best supportive care with follow up at each cycle of the treatment with FU-CDDP; LV5FU2-CDDP; FOLFOX; TPF
89348048|NCT01248299|Active Comparator|Best supportive care|Best supportive care with follow up every 6 weeks
89348049|NCT03766633||Living liver donors|This is a group of living liver donors that underwent a CT prior to donating their partial liver to a recipient.
89348050|NCT03638154|Placebo Comparator|GroupI|safety with received beta-tricalcium phosphate (β TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)
89348051|NCT03638154|Active Comparator|GroupII|"safety with surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane.~(Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA)."
89348052|NCT03415672|Active Comparator|Group 1|Subjects included in Group 1 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine. They will receive three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
89348053|NCT03415672|Experimental|Group 2|"Subjects included in Group 2 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine). They will receive three doses of HBAI20 at 0, 1, and 2 months.~The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly."
89348054|NCT03766399|Experimental|Part 1a (SAD) Cohort 1|6 participants will receive inhaled dose 1 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
89348055|NCT03766399|Experimental|Part 1a (SAD) Cohort 2|6 participants will receive inhaled dose 2 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
89348056|NCT03766399|Experimental|Part 1a (SAD) Cohort 3|6 participants will receive inhaled dose 3 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
89348057|NCT03766399|Experimental|Part 1a (SAD) Cohort 4|6 participants will receive inhaled dose 4 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
89348058|NCT03766399|Placebo Comparator|Part 1a (SAD) Cohort 5|6 participants will receive inhaled dose 5 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
89348059|NCT03766399|Experimental|Part 1a (SAD) Cohort 6|6 participants will receive inhaled dose 6 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
89348060|NCT03766399|Experimental|Part 1b (IV cohort 1)|All 6 participants will receive single IV dose of AZD0449 solution.
89348061|NCT03766399|Experimental|Part 2a (MAD) Cohort 1|6 participants will receive inhaled dose 7 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
89348062|NCT03766399|Experimental|Part 2a (MAD) Cohort 2|6 participants will receive inhaled dose 8 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
89348063|NCT03766399|Experimental|Part 2b (MAD/healthy volunteers) Cohort 3|18 healthy volunteers will receive inhaled dose 9 of AZD0449 nebulized suspension and 12 healthy volunteers will receive inhaled placebo.
89348064|NCT03766399|Experimental|Part 3a (DPI/PoM)|18 participants will receive inhaled dose 10 of AZD0449 DPI and 6 participants will receive inhaled placebo.
89348065|NCT03766399|Experimental|Part 1b (IV cohort 2)|6 healthy volunteers will receive single IV dose of AZD0449 solution.
89348066|NCT03766399|Experimental|Part 3b (DPI/healthy volunteers)|Part 3b is optional. 8 healthy volunteers; 6 volunteers will receive AZD0449 DPI and 2 volunteers will recieve placebo.
89348067|NCT01239875|Experimental|Arm A|Patients receive pneumococcal polyvalent vaccine intramuscularly in weeks -4, 2, and 10. Patients undergo cryoablation followed by dendritic cell vaccine (CA-DC) intratumorally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
89348068|NCT01239875|Experimental|Arm B|Patients receive pneumococcal polyvalent vaccine as in arm A. Patients also receive autologous dendritic cell-tumor fusion vaccine (TL-DC) intradermally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
89348069|NCT03415594|Experimental|FE203799 5 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
89348070|NCT03415594|Placebo Comparator|Placebo|Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration
89348071|NCT03415594|Other|FE203799 10 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
89348072|NCT01321411||1. ARDS/COPD|Critically ill patients with either ARDS or COPD weaning from mechanical ventilation.
89348073|NCT01321411||2. Healthy Volunteers|
89348074|NCT04448860|Experimental|Retinitis Pigmentosa patients|Patients with Retinitis Pigmentosa (RP) at different stages of impairment of the visual field, acuity and sensitivity to contrasts 15 patients will be included in phase 1 versus 36 in phase 2 (15 in step 1 and 21 in step 2).
89348075|NCT04448860|Other|healthy volunteers patients|36 patients will be included just in phase 2 (15 in step 1 and 21 in step 2).
89348076|NCT01144169|Experimental|Hydroxychloroquine (HC)|HC orally for 14 days prior to nephrectomy
89348077|NCT03415516|Experimental|Gluma Universal, self-etch mode (GSE)|
89348078|NCT03415516|Experimental|Gluma Universal, selective etching (GSL)|
89348079|NCT03415516|Experimental|Gluma Universal, etch&rinse (GER)|
89348080|NCT03415516|Experimental|All Bond Universal, self-etch (ASE)|
89348081|NCT03415516|Experimental|All Bond Universal, selective etching (ASL)|
89348082|NCT03415516|Experimental|All Bond Universal, etch&rinse (AER)|
89348083|NCT03415516|Experimental|Single Bond2, etch&rinse (SBU)|
89348084|NCT05152979|Experimental|Telepractice treatment (TP-T)|"Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy through an online platform."
89348085|NCT05152979|Active Comparator|In-clinic treatment (IC-T)|"Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy in person at a clinic."
89348086|NCT01322113||Na+, K+-ATPase/DLC system in BD|Bipolar patients in the various phases of the disease.
89348087|NCT01248689|Active Comparator|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
89348088|NCT01248689|Active Comparator|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
89348089|NCT01248689|Active Comparator|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
89348090|NCT02920866|Experimental|Functional Strength Integration (FSI)|Progressive strength training exercise, specific functional activity to improve pelvic stability and core muscle strength
89348091|NCT02920866|Active Comparator|Control Group (CON)|Usual care, continuing education on postsurgical precautions
89348092|NCT03415438||Group 1|Assessments will be done for 30 patients diagnosed as subacromial impingement syndrome in physical medicine and rehabilitation department of Baskent University.
89348093|NCT03415438||Group 2|Assessments will be done for 30 healthy volunteers
89348094|NCT01144247|Experimental|alloreactive CTL arm|
89348095|NCT03874767|Active Comparator|10th floor south|"The unit in this arm will be assigned physical therapists plus mobility technicians in the first month and only physical therapists in the following month.~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:~On evaluation, a PT will assign a JH-HLM scale rating to the patient~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list~The mobility technician will then see that patient daily, unless the score is <4~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
89523604|NCT05172739|Active Comparator|Opioid-Based Anaesthesia Analgesia|Premedication: IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Propofol 2-3mg/kg, Fentanyl 1-2mcg/kg and Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/ kg. Anesthesia maintenance: Desflurane set at approximately 1 MAC, Morphine 0.1-0.12mg/kg, Fentanyl 1-2mcg/kg during induction and 50-100mcg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, along with Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. Surgical ward: PCA pump with Morphine for the first 3 postoperative days. Additional postoperative analgesia: Paracetamol 1g 1x3 +/- Dexketoprofen trometamol 50mg 1x2. Rescue therapy only: Tramadol 50-100mg.
89348096|NCT03874767|Active Comparator|6th floor Round Wing|"The unit in this arm will be assigned only physical therapists in the first month and physical therapists plus mobility technicians in the following month.~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:~On evaluation, a PT will assign a JH-HLM scale rating to the patient~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list~The mobility technician will then see that patient daily, unless the score is <4~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
89348097|NCT03620838||Group 1|Patients with endometrioma who had at least one endometrioma >3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed
89348098|NCT03620838||Group 2|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with OCP during the study period
89348099|NCT03620838||Group 3|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with oral progesterone during the study period
89348100|NCT03620838||Group 4|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with surgery short after recruitment
89348101|NCT03620838||Group 5|The control group, who do not have endometrioma and any gynecological disorder
89348102|NCT03916367||Early Stage Lung Cancer|The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018.
89348103|NCT03415360|Other|cryoablation|peripheral nerve cryoablation
89348104|NCT03845751|Experimental|ADT protocol|ADT protocol is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone [LHRH] agonist). ADT protocol starts one month prior to the scheduled HIFU session. The intervention of the study is HIFU hemi-ablation combined with ADT.
89348105|NCT03760861|Experimental|Prototype Microcapsule Treatment Arm|Intervention by placement of prototype weight-loss microcapsule in the stomach. Subjects will have a weight-loss microcapsule deployed endoscpically in the stomach. The intragastric balloon in the capsule will be inflated using an external magnet..
89348106|NCT04890743|Experimental|Conventional TENS group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
89348107|NCT04890743|Experimental|Pseudo-acupuncture TENS group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
89348108|NCT04890743|Experimental|Trabert ultrastimulation group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
89348109|NCT04890743|Placebo Comparator|Placebo group|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
89348110|NCT03415282|Experimental|Open-label treatment arm|Open-label treatment arm - patients will receive RVT-501 0.5% twice daily (BID) for 4 weeks.
89348111|NCT05276661|Experimental|"A gel (TAC/Collagen gel)"|"The A gel (TAC/Collagen gel) was applied on subjects' right face"
89348112|NCT05276661|Placebo Comparator|"B gel (placebo lotion)"|"the B gel (placebo lotion) on their left face"
89348113|NCT03766243|Experimental|Brochure and DVD plus nursing training|"In addition to the control intervention, see below, the experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. The nurse provided theoretical explanations on the exercises, watched the explanatory DVD with the patients, answering questions and commenting relevant points, and then had the patients repeat the exercises in front of a mirror under direct observation, so that any errors could be pointed out and corrected."
89348114|NCT03766243|Active Comparator|Brochure and DVD only|"After recruitment, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use. At the same time, she contacted the research nurse to obtain the random allocation to one of the study groups for that patient.~These exercises had to be done every day for the entire duration of the program (12 months) and registered in the diary with any comments."
89348115|NCT01239953|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
89348116|NCT01239953|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
89348117|NCT03421522|Experimental|Intervention - ICBN preservation|For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved.
89348118|NCT03421522|No Intervention|Control - Usual Care|For participants allocated to the usual surgical care arm, attending surgeons will perform a standard Level 1 and 2 axillary node dissection (sacrifice of the ICBN), either alone or with mastectomy or breast conserving surgery.
89348119|NCT01322191|Experimental|1|Random assignment to a single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
89348120|NCT03760705||Coronary Artery Disease|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
89348121|NCT03760705||Heart Failure|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
89348122|NCT03760705||Atrial Fibrillation|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
89348123|NCT02776306|Experimental|Mirror box therapy|The participants in the mirror box therapy arm will receive mirror box therapy for 3 weeks for upper limb rehabilitation post stroke.
89348124|NCT02776306|No Intervention|Standard treatment group|The participants will receive the standard treatment arm for 3 weeks for upper limb rehabilitation post stroke.
89348125|NCT03323736|Other|Pivotal Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office.
89348126|NCT03323736|Other|Office Lead-In Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office. Physician initial in-office iontophoresis and tube insertion procedures (minimum of 2 subjects per investigator).
89348127|NCT03323736|Other|OR Lead-In Cohort|Tubes insertion using the Tube Delivery System in the operating room (OR). Physician initial tube insertion procedures in the OR (minimum of 2 subjects per investigator).
89348128|NCT03760549||Extension of NasoVAX high dose|A serum sample will be collected from each eligible subject who received NasoVAX at the 1×10(11th) vp dose in Study ALT-103-201 for evaluation of influenza hemagglutination assay against influenza A/California/07/2009(H1N1), a strain homologous to the one used for NasoVAX (monovalent AdcoCA09.HA). Ad5 antibody neutralization assay may also be performed.
89348129|NCT03426046|Experimental|Biodentine|Partial pulpotomy treatment with Biodentine
89348130|NCT03426046|Active Comparator|Calcium Hydroxide|Partial pulpotomy treatment with Calcium Hydroxide
89348131|NCT03426046|Experimental|Mineral Trioxide Aggregate|Partial pulpotomy treatment with Mineral Trioxide Aggregate
89348132|NCT03769831|Experimental|SHR2285|Up to 7 cohorts of healthy subjects will receive a single dose of oral SHR2285 tablet.
89348133|NCT03769831|Experimental|Placebo|Up to 7 cohorts of healthy subjects will receive a single dose of oral placebo.
89348134|NCT01310530|Experimental|Partial Breast Proton Therapy|Two weeks of daily proton therapy delivered to the lumpectomy site.
89348135|NCT03620760|Experimental|Lower dose ticagrelor|Subjects will be treated with ticagrelor 45 mg twice daily in combination with aspirin 100mg once daily.
89348136|NCT03620760|Active Comparator|Standard dose ticagrelor|Subjects will be treated with ticagrelor 90 mg twice daily in combination with aspirin 100mg once daily.
89348137|NCT03765931|Active Comparator|subjects treated with doxycycline|The participants treated by doxycycline 100 mg will have one dose but followed 5 days
89348138|NCT03765931|Placebo Comparator|subjects treated with amoxycilline|The participants treated with amoxycilline 500 mg will have 2 doses per days during 5 days treatement and follwed during these 5 days
89348139|NCT00817726||1- RBD|polysomnographically diagnosed RBD patients. RBD is a sleep disorder diagnosed by a sleep lab in which the individual has muscle movements during the phase of deep sleep during which the muscles should be relaxed. Suspicion of RBD by history will be confirmed during screening.
89348140|NCT00817726||2 - control|"control:~must not have any neurological degenerative diagnosis.~must NOT have RBD.~must be able to age and/or gender-match to RBD and PD subjects already enrolled."
89348141|NCT03916445||gynecological cancer|all patients having a consultation doctor during the recruiting time
88811811|NCT05236088|Sham Comparator|Sham group|Sham group will be applied from the same device (INNOVO brand (Atlantic Therapeutics, Galway, Ireland)), for 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
89348142|NCT03916445||chronic gynecological disease|all patients having a consultation doctor during the recruiting time
89348143|NCT02365363|Experimental|Bagel control|100% wheat flour
89348144|NCT02365363|Experimental|Bagel with pea flour|Pea flour (30%)
89348145|NCT02365363|Experimental|Bagel with pea fibre|Pea fibre (11g)
89348146|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre|Pea flour (30%) + pea fibre (11g)
89348147|NCT02365363|Experimental|Bagel w/ pea flour + pea protein|Pea flour (30%) + pea protein (24g)
89348148|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre + pea protein|Pea flour (30%) + pea fibre (11g) + pea protein (24g)
89348149|NCT03415204|Experimental|acupuncture|
89348150|NCT03415204|No Intervention|no acupuncture|
89348151|NCT01240265|Experimental|Vitamin D 150,000 units once|Single dose of vitamin D3 150,000 IU given orally once
89348152|NCT01240265|Experimental|Vitamin D 5000 units daily|Vitamin D3 5000 IU daily given orally for 28 days
89348153|NCT03415126|Experimental|ASN007 ascending doses|Patients will receive escalating doses of ASN007 to identify the best dose.
89348154|NCT03415126|Experimental|ASN007 RD: KRAS mutant Melanoma|Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.
89348155|NCT03415126|Experimental|ASN007 RD: NRAS mutant Melanoma|Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.
89348156|NCT03415126|Experimental|ASN007 RD: KRAS mutant metastatic CRC|Patients with KRAS mutant CRC will receive the recommended dose from Part A
89348157|NCT03415126|Experimental|ASN007 RD: KRAS mutant NSCLC|Patients with KRAS mutant NSCLC will receive the recommended dose from Part A
89348158|NCT03415126|Experimental|ASN007 RD: Metastatic Pancreatic Cancer|Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A
89348159|NCT03415126|Experimental|ASN007 RD: MEK, All BRAF, BRAF-fusion cancers|Patients with solid tumors will receive the recommended dose from Part A
89348160|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，bid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg twice daily for 48 weeks.
89348161|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，tid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg three times daily for 48 weeks .
89348162|NCT03916211|No Intervention|routine treatment|Diabetic foot routine treatment without intervention
89348163|NCT03916211|Experimental|MSCs treatment|On the basis of routine treatment of diabetic foot, adipose stem cells will be added to treat diabetic foot
89348164|NCT03614364|Experimental|nanoxel and herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
89348165|NCT03760393|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
89348166|NCT03760393|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
89348167|NCT01146197|Experimental|Amiloride, Indometacin, Eplerenone|Amiloride, indometacin(+Omeprazole), Eplerenone
89348168|NCT01146197|Experimental|Amiloride, Eplerenone, indometacin|Amiloride, Eplerenone, indometacin (+Omeprazole)
89348169|NCT01146197|Experimental|Eplerenone, Amiloride, indometacin|Eplerenone, Amiloride, indometacin (+Omeprazole)
89348170|NCT01146197|Experimental|Eplerenone, Indometacin, Amiloride|Eplerenone, Indometacin, Amiloride
89348171|NCT01146197|Experimental|Indometacin, Eplerenone, Amiloride|Indometacin, Eplerenone, Amiloride
89348172|NCT01146197|Experimental|Indometacin, Amiloride, Eplerenone|Indometacin, Amiloride, Eplerenone
89348173|NCT03765775|Experimental|Anlotinib Hydrochloride+Sintilimab|Participants receive Sintilimab (IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle , Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
89348174|NCT01240499|Experimental|Health-At-Every-Size (HAES)|
89348175|NCT01240499|Active Comparator|Social Support (SS)|
89348176|NCT01240499|No Intervention|Control|
89348177|NCT02255929|Experimental|Gamma Knife Radiosurgery|Gamma Knife treatment is conducted in one day and takes approximately 70 to 90 minutes.
89348178|NCT01329731|Active Comparator|Test|1.25% fluoride (elmex® gelée)
89348179|NCT01329731|Placebo Comparator|Control|0% fluoride (negative control)
89348180|NCT03765697|Experimental|Lidocaine 5% medicated plaster|Up to 3 plasters were applied per day.
89348181|NCT01144481||breast cancer with metastasis|female breast cancer patients with metastases to any site
89348182|NCT03765385|Experimental|High-intensity training|Each high-intensity training (HIT) session will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load set to reach a supramaximal exercise intensity (i.e. power output is higher than power output at maximum oxygen uptake). Session duration for HIT is 20 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
89348183|NCT03765385|Active Comparator|Moderate-intensity continuous training|Each moderate-intensity continuous training (MICT) session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is 40 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
89348184|NCT01144559|Active Comparator|Continuous Infusion|Each subject will have one lower extremity (Right or Left) randomized to receive a perineural catheter with a continuous infusion of local anesthetic and then the outcomes will be measured.
89348185|NCT01144559|Active Comparator|Bolus Administration|The opposite lower extremity (right or left) will be randomized to receive a perineural catheter with the local anesthetic being delivered via a bolus as opposed to continuous as is the case with their other extremity. The outcome measures will then be assessed as described.
89348186|NCT01322503|Experimental|Norovirus Challenge|
89348187|NCT01322503|Experimental|Norovirus challenge|
89348188|NCT03311841|Experimental|End Stage Renal Disease|Participants requiring hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). A washout period of at least 14 days will separate dosings.
89348189|NCT03311841|Experimental|Severe Impairment|Participants with <30 mL/min/1.73m^2 estimated glomerular filtration rate (eGFR) not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
89348190|NCT03311841|Experimental|Moderate Impairment|Participants with 30 to <60 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
89348191|NCT03311841|Experimental|Mild Impairment|Participants with 60 to <90 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
89348192|NCT03311841|Active Comparator|Healthy Control|Participants with ≥90 mL/min creatinine clearance. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
89348193|NCT01249469|Placebo Comparator|Vehicle|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
89348194|NCT01249469|Experimental|Skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
89348195|NCT01237379||Health Controls|
89348196|NCT01237379||Bipolar Patients with High-Risk of Mania|
89348197|NCT01237379||Bipolar Patients with Ultra-High Risk|
89348198|NCT01237379||First Manic Episode Bipolar Youth|
89348199|NCT03915743|Experimental|Palliative care|Specialized palliative care arm in a newly formed COPD outpatient clinic
89348200|NCT03915743|No Intervention|Usual care|Usual care in a standard pulmonary out-patient clinic. Treatment as described in national standards.
89348201|NCT03760159||Group RESPIRATORY SIMUL (Study A)|In 46 healthy subjects, a computer program will generate random instructions of periods of normal breathing, voluntary end-expiratory breathing cessation periods (as surrogate of central apnoea) and Muller's manœuvre (as surrogate of obstructive apnoea). Meanwhile, the KCG will record the parameters of biological interest. ECG, heart rate, beat to beat non-invasive blood pressure (Finometer), ventilation, end-tidal CO2 (AD instruments), O2 saturation (Nellcor), cardiac output (CO) (Philips) will also be recorded.
89348202|NCT03760159||Group SDB (Study B)|In patients suspected of sleep apnoea and admitted to the sleep unit of the Erasme hospital to perform sleep test as required by their medical condition, the investigators will simultaneously record KCG and PSG and qualitatively compare the data (Bland-Altman plots).
89348203|NCT03760159||Group nCPAP (Study C)|In patients with a diagnosis of sleep apnea, the investigators will determine if KCG is capable to reliably assess the efficacy of the nCPAP therapy in comparison to simultaneous PSG recording. Ongoing adjustment in the CPAP therapy pressure during the night, and its effect on cardiovascular haemodynamic assessed by the KCG, will be taken into account as well.
89348204|NCT03760159||Group UNSELECTED (Study D)|After validation of the three previous steps, the investigators plan to extend the recordings on 100 unselected consecutive patients, without recruitment restrictions, which will undergo PSG recordings because of complains of sleep apnoea.
89348205|NCT03687047|Experimental|New complete dentures|"Steps: 1) Preliminary impressions will be done using stock trays and impression compound; 2) primary casts will be fabricated to make custom trays for definitive impressions; 3) definitive impressions will be made using zinc oxide eugenol impression paste;4) definitive impressions will be poured with type III dental stone to obtain mastercasts; 5)jaw relations will be recorded, and the casts will be mounted on the articulator; 6) the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up. After denture insertion, post-denture insertion instructions such as oral hygiene will be explained to the patients.~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and at 3, 6, 9, 12 months after treatment."
89348206|NCT03760003|Experimental|ABX464|ABX464 will be administrated orally (Capsules) and daily for 16 weeks
89348207|NCT03760003|Placebo Comparator|Matching Placebo|Matching placebo will be adminstrated orally (Capsules) and daily for 16 weeks
89348208|NCT04822493|Experimental|Counseling Aid|"A. Complete the demographic questionnaire, the survey questions, and then complete the counseling aid. Receive standard counseling as part of routine prenatal care.~B. Prior to discharge after delivery, study personnel will administer the postpartum questionnaire via a mobile tablet. The questionnaire is programmed into the study application."
89348209|NCT04822493|No Intervention|Standard Care|"A. Complete the demographic questionnaire and survey questions without watching the educational video. Receive standard counseling as part of routine prenatal care.~B. Prior to discharge after delivery, study personnel will administer the postpartum questionnaire via a mobile tablet. The questionnaire is programmed into the study application."
89348210|NCT01249937|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
89348211|NCT01249937|Active Comparator|Ranibizumab and Triamcinolone acetonide|"Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections.~Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and Triamcinolone Acetonide will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration."
89348212|NCT05138783|Other|PRECISION1, then Biotrue|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for 8 -0/+3 days. A fresh pair of lenses will be worn each day.
89348213|NCT05138783|Other|Biotrue, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for 8 -0/+3 days. A fresh pair of lenses will be worn each day.
89348214|NCT03915353||Experiment|No interventions
89348215|NCT03915353||Control|No interventions
89348216|NCT03765151|Experimental|LLLT group|Low-level laser therapy and orthodontic retention
89348217|NCT03765151|Placebo Comparator|control group|orthodontic retention and no laser treatment.
89348218|NCT02528201|Active Comparator|Celecoxib 200 milligrams mg QD|celecoxib 200 milligrams (mg) once a day (QD)
88807273|NCT05250050|Experimental|Phenotypic resistance guided therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to phenotypic antibiotic resistance pattern of each one, give esomeprazole 20mg bid and bismuth potassium citrate 0.6 g bid, combined two sensitive antibiotics of Amoxicillin, tetracycline,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
89348219|NCT02528201|Active Comparator|Celexocib 400 mg QD|celecoxib 400 milligrams (mg) once a day (QD)
89348220|NCT02528201|Active Comparator|Diclofenac 50 mg TID|diclofenac 50 milligrams (mg) three times a day (TID)
89348221|NCT03764839|No Intervention|Active Control Group (Digital Health Education)|"Demographics survey~Baseline surveys~Participants receive a digital information sheet on nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery~Post-surgery:~Pain check-ins (2 times per week) (detailed above)~Patients receive 30 second booster videos at 7, 14, and 21 days after surgery~Follow-up surveys (4, 8, and 12 weeks after surgery)"
89348222|NCT03764839|Experimental|"My Surgical Success Treatment Group"|"Demographics survey~Baseline surveys~Intervention:~45-minute digital behavioral pain medicine intervention My Surgical Success that emphasized cognitive and emotional regulation of pain and downregulation of physiologic arousal.~downloadable app with an audio file~personalized plan that allows learners to incorporate the treatment information~Post-video survey (detailed above)~Post-surgery:~Pain check-ins (2 times per week) (detailed above)~Follow-up surveys (4, 8, and 12 weeks after surgery) Intervention: Behavioral: Perioperative Digital Behavioral Pain Medicine My Surgical Success"
89348223|NCT05276583||Patients with depression like symptoms|Participants in this condition must indicate that they are currently suffering from a mental health illness and score at least 20 on the Becks Depression Inventory. These participants will undergo the motivate learning task and will study images associated with high and low rewards. After 24-hours participants will be tested on their memory for those images.
89348224|NCT05276583||Healthy controls without depression like symptoms|Participants in this condition must indicate that they do not currently suffer from a mental health condition and score less than 20 on the Becks depression inventory. These participants will also undergo the motivate learning task and will study images associated with high and low rewards. After 24-hours participants will be tested on their memory for those images.
89348225|NCT03759769|Experimental|simulator|Practice at home all activities of the wheelchair simulator, at least 20 minute per session, at least one session every second day
89348226|NCT03759769|Active Comparator|control|Practice on a computer video game, at least 20 minute per session, at least one session every second day
89348227|NCT01241747|Experimental|Supervised Exercise|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes at an exercise intensity of 40% of exercise capacity.
89348228|NCT01241747|Active Comparator|Control|Light resistance training without any walking
89348229|NCT05276427||Non clinical procedure|Completion of consent form and interview session
89348230|NCT03638193|Experimental|CART-meso cells|A single dose of CART-meso T cells will be administered intravenously.The dose is 1-3×10^7/m^2 CART positive cells(chort 1)or 1-3×10^8/m^2 CART positive cells(chort 2).
89348231|NCT03758677|Experimental|Patients who progressed after EGFR-TKI without T790M mutation|Single arm; Plan to enroll 30 cases; Patients who progressed after EGFR-TKI treatment without T790M mutation
89348232|NCT03915509|Experimental|Bioactive group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
89348233|NCT03915509|Active Comparator|Sandblasted group|In this study different surfaced implants applied patients who has bilateral edentulous mandibular molar region In one hemiarch, an alkali-modified surfaced implants were applied (bioactive group); in the other hemiarch, sand-blasted surfaced implants were applied (sand-blasted group). The implants were randomly selected.
89348234|NCT05276271||epileptic children|epileptic children who had been diagnosed with epilepsy with at least two focal seizures within a year, and treated with levetiracetam monotherapy for at least 12 months
89348235|NCT05276271||healthy controls|healthy controls who was without an exposure to levetiracetam
89348236|NCT03758599|Experimental|Climbing Exercise Group|At the beginning of each session, a standardized body-centered, mind-setting warmup of ten minutes will take place. The general warm-up will be followed by climbing specific warm-up, which will consist of bouldering (20-30 minutes). Afterwards the rope climbing session will start. Climbing sessions also contain several sport-specific skill-development training sessions to familiarize the participants with gear and rope management, to acquire footwork and route finding, and to locate good belay spots and resting positions while climbing. At the end of the climbing session a short cool-down of five minutes will be executed.
89348237|NCT03758599|Experimental|Aerobic Exercise Group|As the climbing exercise group, the aerobic exercise group will start with a ten minutes body-centered, mind-setting warm-up, followed by 60 minutes of Nordic walking and five minutes cool down. A physiotherapist or sport scientist will instruct and guide the group. Nordic walking will be performed at a moderate pace at varying paths.
89348238|NCT03758599|Active Comparator|Social Contact Control Group|Patients allocated to the social contact control group will receive the same amount of social interaction as the exercise groups. A physiotherapist or sport scientist will be present while participants watch movies with relevant content to disease followed by interactive group discussions. This group is required to control for the impact of social contact/support on AD/PTSD and secondary outcomes.
89348239|NCT01146353||CRRT Patients receiving Peramivir|"Eligible patients are male or female patients ≥18 years of age who are hospitalized, undergoing CVVH or CVVHD, and receiving peramivir.~Eligible patients will additionally have the following: blood flow rate will be required to be ≥100 mL/ min with an ultrafiltrate +/- dialysis flow rate greater than or equal to 3000mL/hr, and the continuous renal replacement therapy must be scheduled to run for the full duration of the dosing interval (full 24 hours).~Written informed consent in a form approved by the Northwestern University and the Midwestern University Institutional Review Boards will be granted by the patient."
89348240|NCT03425968||Knee hyperextension group|athletes who has knee hyperextension
89348241|NCT03425968||Control group|athletes who doesn't have knee hyperextension
89348242|NCT03764683|Experimental|Drug-Drug|This arm will receive the active drug in the first and second phase of the study.
89348243|NCT03764683|Other|Placebo-Drug|This arm will receive placebo in the first phase of the study and the active drug in the second phase.
89348244|NCT03764683|Placebo Comparator|Placebo-Placebo|This arm will receive placebo in the first phase and second phase of the study.
89348245|NCT03414892|Experimental|Globalagliatin Hydrochloride (SY-004)|If subjects tolerate 20mg of Globalagliatin Hydrochloride (SY-004) for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
89348246|NCT03414892|Placebo Comparator|Placebo|If subjects tolerate 20mg of Placebo for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
89348247|NCT03311373|Experimental|Treatment Period 1|Test Formulation (Regimen B or D) or Reference Formulation (Regimen A or C)
89348248|NCT03311373|Experimental|Treatment Period 2|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
89348249|NCT03311373|Experimental|Treatment Period 3|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
89348250|NCT03311373|Experimental|Treatment Period 4|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
89348251|NCT03759691||Stroke patients|Structured interviews of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
89348252|NCT03759691||Bystander|Structured interviews of bystanders of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
89348253|NCT01242605|Experimental|single armed|This is not a randomised trial, there is only one study group. All patients will receive cisplatin/gemcitabine chemotherapy in addition to oral daily dosing of selumetinib
89348254|NCT04448470||patients with a clinical suspicion of sleep apnea (n=150)|patients with a clinical suspicion of sleep apnea
89348255|NCT04448470||healthy subjects (n=10)|healthy subjects
89348256|NCT03759613|Experimental|Experimental Group|Thirty subjects with unilateral upper burn injury will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. Their evaluations will be made within 5 days following burn injury.
89348257|NCT03759613|Active Comparator|Control Group|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, they will be asked to walk their natural walking.
89348258|NCT03759613|Sham Comparator|Control Grup (Restricted arm swing)|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, their arms will be fixed with a bandage on their bodies. Their arm swing will be restricted.
89348259|NCT03414814|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
89348260|NCT03840525|Experimental|Qigong Intervention|The qigong intervention consists of 1 hour/week qigong classes for 12 weeks to be delivered virtually. The first 2 weeks will include 2 hours/week classes. In addition, each participant will be instructed to practice qigong at home for 90 minutes.
89348261|NCT03840525|Sham Comparator|Sham Qigong|This group will also have 1 hour/weekly class delivered virtually that includes movements that are similar to qigong but will not include the meditation or breathwork that will be included in the actual qigong intervention arm.
89348262|NCT03840525|No Intervention|Treatment-as-usual|This group will receive no classes.
89348263|NCT03759535||Control group and Case group|"Control group:~The allograft kidneys function normally. The rejection of allograft kidneys are excluded. The patients have no infectious complications.~Case group:~There is obvious evidence for acute rejection of the allograft kidneys. The patients have no infectious complications."
89348264|NCT03759457|Experimental|High Flow Nasal Cannula|High Flow Nasal Cannula is a relatively new technique able to deliver both oxygen and high flow in order to improve oxygenation and waking out CO2 from the upper airways
89348265|NCT03660657|Experimental|Ozone Group:|Standard treatment + Ozone therapy (O3/O2)
89348266|NCT03660657|Placebo Comparator|Control Group:|Standard treatment + Oxygen (O2)
89348267|NCT03421366||Cystic Fibrosis on Posaconazole|"Able to provide written informed consent~Greater than 18 years of age or older~Have a diagnosis of cystic fibrosis~No known azole hypersensitivity~To commence as part of their standard of care the newer modified release oral formulation of posaconazole to treat Aspergillus~Able to provide a pre-treatment sputum collected for fungal culture as part of standard of care~Have been prescribed a loading dose of 300mg bd for 1 day of the modified release posaconazole tablet followed by 300mg daily."
89348268|NCT03764605|Experimental|Metformin|"Patients will take metformin starting from 500 mg a day. They will up-titrate every week, if tolerating IMP, adding one 500 mg dose 8 hours after the former, till reaching 500 mg thrice a day.~The minimum tolerated dose requested in order to be admitted to the study is 500 mg twice a day.~Those reaching eGFR<45 ml/min will reduce the dose by one third. Those reaching eGFR<30 will drop out the study."
89348269|NCT03764605|Active Comparator|Tolvaptan|Patient will start Tolvaptan in a split dose regimen 45 mg as first dose, followed by 15 mg 8 hours later. Those tolerating this dose will uptitrate to 60/30 mg and then to 90/30 mg a day. Those not tolerating 45/15 mg a day will drop out.
89348270|NCT03425890|Experimental|SURE Program Group|The intervention group will receive a SURE program booklet and will perform individualized daily self-exercise and functional use of the arm and hand on their own outside of therapy for 60 minutes/day, 6 days/week for 4 weeks. These self-exercises and upper limb functional use will be performed in addition to usual care. Three SURE program booklets have been developed which relate to the affected upper limb motor capability using individual Fugl Meyer (ULFM) score. Each SURE program booklet consists of warm-up exercises, strengthening exercises and motor tasks. The SURE program booklet also includes selected functional motor tasks to be performed by the participants using their affected upper limb. The performance of the exercises and functional motor tasks will be reviewed three times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.
89348271|NCT03425890|Experimental|Education Group|The control group will receive an education booklet with 10 modules. The education booklet will contain information on stroke, recovery and management strategies after stroke. Participants are to complete 2-3 modules per week and answer 1-2 simple questions after each module. Each module including answering questions takes approximately 5-10 minutes to complete. CPI will review the information with the participants 3 times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.The participants in the control group will continue with their usual care in the hospital.
89348272|NCT03764527|Active Comparator|Artemether-lumefantrine (AL)|One tablet of artemether-lumefantrine (Coartem®) was administered twice daily for 3 days to children with a body weight of 9 to <15 kg, and 2 tablets were administered twice daily for 3 days to children with a body weight of >15 to 25 kg. All doses were taken under direct observation.
89348273|NCT03764527|Active Comparator|Artesunate + Amodiaquine (AA)|Artesunate + amodiaquine (ASAQ) was administered as follows: 4 mg/kg body weight of artesunate plus 10 mg/kg body weight of amodiaquine once daily for 3 days under direct observation.
89348274|NCT04662489|Active Comparator|Control arm. Pulmonary vein isolation|Pulmonary vein isolation with ablation.
89348275|NCT04662489|Experimental|Treatment arm. Radial ablation|Pulmonary vein isolation plus radial ablation of rotational activity sites.
89348276|NCT02669602||No intervention|No Intervention
89348277|NCT05668975|Experimental|Training Group|Individuals with sarcopenia in this group will perform three sets of 10 repetitions, with 1-minute of rest allocated between sets, twice daily, 5 days per week for eight weeks. The first session will be performed supervised in a clinic, other sessions will be performed at home. Telephone contact will be held twice a week to ensure the completion of training and clarify any doubts. Training intensity will be set at 60% of the maximum inspiratory pressure for the first week then will be set at %70 of the maximum inspiratory pressure for the second week. After the second week, training intensity will be increased as much as participants tolerated at the start of each week.
89348278|NCT05668975|Sham Comparator|Sham Group|Individuals with sarcopenia in this group will perform two sets of 10 repetitions, with 1-minute of rest allocated between sets, one time a day, 2 days per week for eight weeks. The first session will be performed supervised in a clinic, other sessions will be performed at home. Training intensity will be set at 10 cm H₂O for all training sessions.
89348279|NCT03421054|Other|nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
89348280|NCT01321801|Active Comparator|Pregabalin|Preoperative administration of pregabalin 600mg to patients undergo laparoscopic cholecystectomy.Patients receive oral Pregabalin 300 mg the night before the surgery, and another one dose of 300 mg 1 hour prior to surgery
89348281|NCT01321801|Placebo Comparator|Placebo|Preoperative administration of placebo to patients undergo laparoscopic cholecystectomy.Patients receive oral Placebo the night before the surgery, and another one dose 1 hour prior to surgery.
89348282|NCT03420976|Experimental|Novel Supplement-based Therapy|"Low FODMAP diet + supplements outlined below:~Product Name: Liver-G.I. Detox Active Ingredients: Alpha lipoic acid, n-acetyl-l-cystine, turmeric root extract, milk thistle seed extract, broccoli sprout concentrate, artichoke leaf extract, taurine, glycine, l-glutamine, l-methionine, and chlorella.~Product Name: l-Glutamine Active Ingredients: l-glutamine~Product Name: MicroDefense Active Ingredients: berberine sulfate, olive leaf extract, sweet wormwood, clove bud powder, and grapefruit seed and fruit extract.~Product Name: A.C. Formulla II Active Ingredients: calcium and magnesium undecylenate, calcium and magnesium caprylate, bromelain, grapefruit seed and fruit extract, and berberine sulfate~Product Name: Probiotic-5 (Pure Encapsulations) Active Ingredients: Probiotic blend~Product Name: Digestive Enzymes Ultra with Betaine HCl Active Ingredients: Digestive enzyme blend and betaine HCl"
89348283|NCT03054727||Villalta phone score > or = to 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call AND a random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call
89348284|NCT03054727||Villalta phone score < 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call AND random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call
89348285|NCT03414580||Ulcerative colitis|Patients with ulcerative colitis whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
89348286|NCT03414580||Crohn's disease|Patients with crohn's disease whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
89348287|NCT03414580||Healthy control|Subject with no intestinal symptoms or no known gastrointestinal disorders. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
89348288|NCT01155375|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
89348289|NCT01155375|Active Comparator|Oral Iron|Participants will receive oral iron 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
89348290|NCT03759301|Active Comparator|Growth Hormones Somatropin Recombinant|Growth hormone (Somatropin) 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup for the treatment group which consists of 70 women.
89348291|NCT03759301|Placebo Comparator|Placebo saline solution|Control group consisting of 70 women who will receive subcutaneous placebo injection in the same dosing as the treatment group
89348292|NCT03109132|Active Comparator|Model 1|Device - O2/CO2 Oral/Nasal cannula sample line - Oridion smart CapnoLine® H Plus with Wedge cannula
89348293|NCT03109132|Active Comparator|Model 2|Device -O2/CO2 Oral/Nasal cannula sample line- Oridion smart CapnoLine® Plus with Non-Wedge cannula
89348294|NCT03109132|Active Comparator|Model 3|Device - Experimental sample line Model 3
89348295|NCT03109132|Active Comparator|Model 4|Device - Experimental sample line Model 4
89348296|NCT03109132|Active Comparator|Model 5|Device - Experimental sample line Model 5
89348297|NCT03109132|Active Comparator|Model 6|Device - O2/CO2 cannula w/female luer (Westmed comfort plus #0504)
89348298|NCT03759145|Experimental|Intervention arm, usual rehabilitation + Jintronix exergame|On top of the usual out-patient rehabilitation sessions planned for the participant, participants attend sessions to use the Jintronix system for up 30 minutes up to 3 times per week
89348299|NCT03759145|Other|Control group|Participants continue their prescribed rehabilitation sessions
88807274|NCT05250050|Active Comparator|Empiric therapy|Esomeprazole 20 mg bid, bismuth potassium citrate 0.6 g bid, metronidazole 0.4 g qid, and Amoxicillin 1.0 g bid (no penicillin allergy) OR tetracycline 0.5g qid (penicillin allergy) for 14 days
89348300|NCT03764215|Experimental|Group 1|Ten (10) participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If Nilotinib 150 mg per mouth daily dose is tolerated by the 1st group of 10 participants for 3 months, another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
89348301|NCT03414346|Experimental|Exclusively ice pack:|Ice pack application: 500 grams of crushed ice.
89348302|NCT03414346|Experimental|Ice pack added 10% of water:|Wetted ice pack application: 500 grams of crushed ice added to 50 mL of water at room temperature.
89348303|NCT03414346|Experimental|Ice pack added 100% of water:|Wetted ice pack application: 500 grams of crushed ice added to 500 mL of water at room temperature.
89348304|NCT03420898||1|General Medicine in Hospital Unit 70 Bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
89348305|NCT03420898||2|General Medicine in Hospital 38 Bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
89348306|NCT03420898||3|Cardiovascular Surgery in Hospital Unit 36 bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
89348307|NCT03420898||4|General Surgery in Hospital 24 bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
89348308|NCT03420898||5|Cardiac 36-bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
89348309|NCT03420898||6|General Medicine 26 Bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
89348310|NCT03420820|Experimental|5% Betadine, Ocular Surface only|Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
89348311|NCT03420820|Experimental|10% Betadine, Ocular Surface only|Use of 10% P-I swabstick to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
89348312|NCT03420820|Experimental|10% Betadine, Ocular Surface and Adnexa|Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.
89348313|NCT03764059|Experimental|Investigational device/experimental group: Filtek™ Bulk Fill Posterior Restorative|"The investigational device, Filtek™ Bulk Fill Posterior Restorative, was used for class 1 or 2 restorative in experimental group. The clinical assessments were performed immediately after restoration and included restoration retention/fracture, marginal fracture, anatomic form/marginal integrity, proximal contact, color match, surface texture/roughness, staining, marginal discoloration/secondary caries and pulp vitality.~Subjects returned to the site for follow up visits at 1 week and 1 year postoperative for the same clinical assessments."
89348314|NCT03764059|Active Comparator|Control device/control group: Filtek™ Z350XT Universal Restorative|"The control device, Filtek™ Z350XT Universal Restorative, which was approved by CFDA in 2010 and has been in the market for 5 years with some validated clinical data, was used for class 1 or 2 restorative in control group. The clinical assessments were performed immediately after restoration and included restoration retention/fracture, marginal fracture, anatomic form/marginal integrity, proximal contact, color match, surface texture/roughness, staining, marginal discoloration/secondary caries and pulp vitality.~Subjects returned to the site for follow up visits at 1 week and 1 year postoperative for the same clinical assessments."
89348315|NCT02294968|Experimental|Family Startup|Family Startup plus usual pre- and postnatal care
89348316|NCT02294968|No Intervention|Control|Usual pre- and postnatal care
89348317|NCT03414190|Experimental|Experimental|Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
89348318|NCT03414190|No Intervention|No Intervention|Usual Care
89348319|NCT02260102|Active Comparator|urinary tract infections|Children requiring antibiotic treatment for urinary tract infections. Intervention: blood sampling for assay of temocillin
89348320|NCT02260102|Active Comparator|cholangitis|"Cirrhotic children requiring antibiotic treatment due to suspicion of cholangitis.~Intervention: blood sampling for assay of temocillin"
89348321|NCT02260102|Active Comparator|hepatic transplant|Children requiring antibiotic prophylaxis following a hepatic transplant. Intervention: blood sampling for assay of temocillin
89348322|NCT03425734|Experimental|D group|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
89348323|NCT03425734|Experimental|S group|50 ml saline
89348324|NCT03127072|Experimental|Arm A|RFA plus chemotherapy ± target therapy
89348325|NCT03127072|Active Comparator|Arm B|chemotherapy ± target therapy
89348326|NCT03420586|Active Comparator|Nitrous oxide Group|The nitrous oxide group (GN2O) will receive air in 30% O2 during general anesthesia until the last 30 min of surgery, when 70% N2O in 30% O2 will be administered.
89348327|NCT03420586|No Intervention|Oxygen Group|The Oxygen group will receive gas carrier mixture consisting of air in 30% O2 during general anesthesia.
89348328|NCT03763981|Active Comparator|prolene seton|Prolene thread will be used as seton treatment for perianal fistulas
89348329|NCT03763981|Active Comparator|silk seton|Silk thread will be used as seton treatment for perianal fistulas
89348330|NCT00677482||1|Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.
89348331|NCT03759067|Active Comparator|LD group|clopidogrel 600 mg once loading, usually 2-24 h before the procedure
89348332|NCT03759067|Experimental|MD group|After randomization, the routine therapy using daily clopidogrel 75mg
89348333|NCT03759067|Active Comparator|RL group|After randomization, additional clopidogrel 300 mg reloading for patients who were taking a maintenance dose.
89348334|NCT03425656|Experimental|Trastuzumab (AryoTrust)|Trastuzumab (AryoTrust) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
89348335|NCT03425656|Active Comparator|Trastuzumab (Herceptin)|Trastuzumab (Herceptin) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
89348336|NCT00628095|Experimental|Active|
89348337|NCT00628095|Placebo Comparator|Placebo|
89348338|NCT03420352|Other|butterfly needle with valve|thromboelastography
89348339|NCT03420352|Other|Standard hypodermic needle|thromboelastography
89348340|NCT03413956||NSCLC patients with lymph metastases|Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
89348341|NCT03413878|Experimental|Wet snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a small air pocket
89348342|NCT03413878|Experimental|Dry snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a small air pocket
89348343|NCT03413878|Experimental|Wet snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a large air pocket
89348344|NCT03413878|Experimental|Dry snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a large air pocket
89348345|NCT03745677|Experimental|Phase I|Each study site has selected 1-2 units ideally suited for initial implementation of the Advanced and Integrated MicroSystems (AIMS) interventions (Phase I Implementation) and 1-2 units for later implementation of AIMS interventions (Phase II Implementation). During Implementation Phase I, AIMS interventions were implemented on the initial, phase I Implementation units. The phase II units serve as control units during phase I.
89348346|NCT03745677|Experimental|Phase II|During Implementation Phase II, Advanced and Integrated MicroSystems (AIMS) interventions are being implemented on additional, phase II implementation units, leveraging lessons learned during phase I.
89348347|NCT03425578|Experimental|MSG + CHO|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.
89348348|NCT03425578|Active Comparator|MSG + placebo B|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.
89348349|NCT03425578|Active Comparator|Placebo A + CHO|Participants will ingest placebo capsules followed by 75 g dextrose.
89348350|NCT03425344|Other|Diagnostic|All participants will be exposed to shoulder- MRI, ultrasound and sonoelastography.
89348351|NCT03413722||Conversion Group|Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made.
89348352|NCT03413722||Control Group|Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression.
89348353|NCT04787757||Percutaneous cardiac procedures|Patients undergoing percutaneous cardiac procedures
89348354|NCT03420196|Experimental|Supervised Rehabilitation program|It will be consist in a supervised exercise program by physical therapist, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility
89348355|NCT03420196|Active Comparator|Nonsupervised rehabilitation program|It will consist in an exercise program for home, nonsupervised, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility. The patients will perform an exercise program at home.
89348356|NCT02889861|Experimental|Regimen 1|IMCgp100 (77 kDa bi-specific protein) weekly dosing regimen (QW)
89348357|NCT00454948|Experimental|Home based Nutrition and Physical Activity|Home-based nutrition sessions and park play activity sessions
88807275|NCT05294328|Experimental|Combination ophthalmic solution (LNZ101) dosed bilaterally|Aceclidine/Brimonidine combination ophthalmic solution
89348358|NCT00454948|Active Comparator|Group Nutrtion|Group based nutrition classes and activity booklets
89348359|NCT04843462|Experimental|edupression.com® + treatment-as-usual|Patients are receiving treatment with edupression.com® in addition to TAU (treatment-as-usual) with esketamine nasal spray
89348360|NCT04843462|Active Comparator|treatment-as-usual|Patients are receiving TAU (treatment-as-usual) with esketamine nasal spray
89348361|NCT05275257|Experimental|Uricap group|the new incontinence device
89348362|NCT05275257|No Intervention|Control group|the usual incontinence care
89348363|NCT03420040|Experimental|QS-M Needle Free Injector group|To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.
89348364|NCT03420040|Active Comparator|Glargine pen group|To observe the amount of insulin used by the Glargine pen group under good blood glucose control.
89348365|NCT01313169|Experimental|EMR reminder|EMR reminder
89348366|NCT01313169|Experimental|EMR reminder + Panel management|EMR reminder + Panel manager
89348367|NCT01313169|No Intervention|Control|Control
89348368|NCT03413566||Children with clinical diagnosis of CP|All children residing in Norway with a validated diagnosis of cerebral palsy.
89348369|NCT03413566||Children without CP|All children residing in Norway without a diagnosis of cerebral palsy.
89348370|NCT05274945|Experimental|total neoadjuvant therapy|patients will be treated by total neoadjuvant therapy, including concurrent chemoradiotherapy in the form of radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil + Calcium leucoverin for first 4 days and last 3 days of radiotherapy or capecitabine at 825 mg\m2 twice daily. Then, after 2-3 weeks preoperative chemotherapy will be started in the form of 6 cycles of FOLFOX or CAPOX. Then, after 3-4 weeks surgery will be done.
89531930|NCT04722731|Active Comparator|Self-help book|"In the control group, participants will receive a parenting book, titled What all parents ought to know. This is a self-help book for parents, partly based on the scientifically evaluated parent program All Children in Focus."
89531931|NCT04708457|Active Comparator|Early ECMO|Early ECMO therapy for patients who have SARI and have been mechanically ventilated for 5-7 days.
89348371|NCT05274945|Active Comparator|standard neoadjuvant therapy|patients will be treated by standard neoadjuvant therapy , including concurrent chemoradiotherapy in the form of radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil + Calcium leucoverin for first 4 days and last 3 days of radiotherapy or capecitabine at 825 mg\m2 twice daily . Then, after 6-8 weeks surgery will be performed followed by adjuvant chemotherapy.
89348372|NCT03413488|Experimental|Kinesio taping|subject with shoulder impingement syndrome
89348373|NCT03413488|Active Comparator|Exercise|subject with shoulder impingement syndrome
89348374|NCT02520856||Hypertrophic cardiomyopathy|"All patients with newly diagnosed unexplained HCM will be prospectively included.~All patients will undergo both classical genetic analysis and WES technology."
89348375|NCT04728958|Experimental|Gratitude Journal|Participants will be given instructions and asked to write a gratitude journal about their week, focusing upon what they are grateful for. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times).
89348376|NCT04728958|Placebo Comparator|Weekly Diary|Participants will be given instructions and asked to write a diary about their week, focusing upon both the good and the bad they have experienced that week. Over the course of the 4-week intervention they will be asked to do this weekly (a total of four times).
89348377|NCT03413410|Experimental|Metoprolol interventional group|"This is a multi-center, prospective, open label, single-arm interventional study.~Patients hospitalized for ACS, fulfilling all of the inclusion criteria and none of the exclusion criteria can be enrolled in this study."
89348378|NCT03413332|Experimental|E-Talkcare Group|use the web-based patient education tool
89348379|NCT03413332|Placebo Comparator|Usual Care Group|receive usual care
89348380|NCT03548961|Experimental|Neoadjuvant chemotherapy|
89348381|NCT03419806|Experimental|Infudopa i.v.|"Infudopa i.v. in 75% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion.~From patient 6 and onwards:~Infudopa i.v. in 81% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion."
89348382|NCT03419806|Experimental|Infudopa s.c.|"Infudopa s.c. in the same dosage as the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion.~From patient 6 and onwards:~Infudopa s.c. in 86% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion."
89348383|NCT03419806|Active Comparator|LCIG (Duodopa)|Individually optimized dosing of LCIG (Duodopa) (delivered directly to the proximal small intestine via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube connected to a portable infusion pump) will be delivered over a 16-h period, administered as a morning rapid constant rate administration followed by continuous infusion.
89348384|NCT04179591|Experimental|Exercise|Exercises will be performed three times per week for six weeks.
89348385|NCT04179591|Experimental|Insole|Customized arch support insoles will be worn for six weeks.
89348386|NCT04179591|Experimental|Exercise plus Insole|Exercises will be performed three times per week, and customized arch support will be worn for six weeks.
89348387|NCT03419728|Experimental|Healthy Families, Healthy Futures|Family coaches meet with participating pregnant and parenting females, the woman's partner, and the child. Visit frequency varies from once per week to once per month, depending on the length of time in the program, the client's needs, and the accomplishment of program milestones. In the short term, the program seeks to increase the use of Long-Acting Reversible Contraception (LARC), enhance family functioning including improving father involvement, and to meet the baby's child development needs. In the long term, the program aims to delay subsequent pregnancies, ensure positive child development, and increase parents' self-sufficiency.
89348388|NCT03419728|No Intervention|Control group|"No active treatment for control group. Control group has access to business as usual services in community."
89348389|NCT03424954|Experimental|EpxOstomy|Post-operative ileostomy patients will receive the study intervention for 30 days following discharge from the hospital.
89348390|NCT03424876||Arm A|Imatinib 400 mg/day or 600mg/day, and within 6 weeks after surgery, continuous treatment was not tolerated until tumor progression, recurrence or adverse reactions were not tolerated.
89348391|NCT03424876||Arm B|Sunitinib 37.5 mg/day, continuous taking, or 50 mg/day (4/2), began within 6 weeks after surgery, and was continuously administered until tumor progression, recurrence or adverse reactions were not tolerated
89348392|NCT04448236|Experimental|BFR-RE intervention group|"The participants will have the standardised 2 week resistance training with BFR-device with details as follows:~Cuff size: medium~Restriction time: 5- 10 mins (stop after finishing 4 sets of training or terminating by Physiotherapists)~Applied location: alternate quadriceps in consecutive day~Applied pressure: 80% limb occlusion pressure (LOP)"
89348393|NCT04448236|No Intervention|Control group|"Same standardized 2-week in-patient rehabilitation and same amount of the above-mentioned resistance training without the BFR device."
89348394|NCT03325881|Experimental|SHP465|Participants will be randomized to receive SHP465 capsule 6.25 milligram (mg) orally once daily for 4 weeks.
89348395|NCT03325881|Placebo Comparator|Placebo|Participant will receive placebo matching to SHP465 capsule orally once daily for 4 weeks.
89348396|NCT04687852|Experimental|Focused Pelvic Floor Exercise with Motor ImageryTechnique Group|5 minute-Meditation Therapy 10 minute-Progressive Relaxation training ( Bernstein-Borkovec Method) 5 min - Breathing Exercises (Diaphragmatic Breathing Exercise, Pursed lip breathing Exercise) 35 min -Motor Imagery Technique Focused Pelvic Floor Exercises-MOPEXE 5 min - Meditation Therapy Twice a week for 60 minutes 12 weeks Participants will be evaluated online at the beginning of the research and at the end of the 12-week program.
89348397|NCT04687852|Active Comparator|Nonsteroidal Anti-Inflammatory Drug(NSAID) Group|Naproxen Sodium 550 mg film-coated tablet prescribed by the physician will be given to patients. During the menstrual period, 1 or 2 times a day will be used depending on the pain of the patient. Treatment time; 12 weeks.
89348398|NCT04687852|Other|Diosmin Group|Diosmin (90%) 500 mg film-coated tablets prescribed by the physician will be given to patients. During the menstrual period, 1 or 2 times a day will be used depending on the patient's pain. Treatment time; 12 weeks.
89348399|NCT04687852|Experimental|Acupressure Group|"4 acupuncture points will be applied twice a day for 12 weeks. These points are; LI4, CV4, CV6, SP6~."
89348400|NCT04687852|No Intervention|Control Group|Participants will not be treated.
89348401|NCT04678180|Experimental|Virtual tic training|A combination of treatment using virtual tic training and training at the hospital. In total nine sessions using a combined training of HRT and ERP. In four of the nine sessions (session 3, 5, 6, 7) training is performed as a virtual training. All sessions last 60 minutes
89348402|NCT04678180|Experimental|Video tic training|A combination of treatment using self-instructive videos and training at the hospital. In total nine sessions using a combined training of HRT and ERP. Four of the nine sessions are completed at the hospital (session 1 and 2 are combined 120 minutes, session 4: 60 minutes, session 8: 60 minutes and session 9: 60 minutes). For all sessions, self-instructive videos have been recorded instructing the child and their families how they should perform the training
89348403|NCT03957213|Experimental|Active IH + CT|Acute intermittent hypoxia will be provided to the subject by delivering 15 brief exposures (~60 seconds) of hypoxic air alternated with 15 brief exposures (~60 seconds) of room air. The amount of oxygen delivered during hypoxic exposures may range from 15%-9% fraction of inspired oxygen, compared to 21% oxygen in normal atmospheric air. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training.
89348404|NCT03957213|Sham Comparator|Sham IH + CT|A sham protocol will be administered in which 21% fraction of inspired oxygen will be delivered by the hypoxicator during hypoxic intervals, and room air will be delivered through the four-way valve during room air intervals. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training (Posit; Brain HQ).
89348405|NCT03424720|Experimental|Comparison of PLE and BIS|Investigators assess PLE and BIS values as indicators of the depth of anesthesia during induction and emergence of anesthesia and facial nerve integrity monitoring
89348406|NCT03413098|Experimental|Trial nasal Continuous Positive Airway Pressure (CPAP) mask|Trial nasal CPAP mask
89348407|NCT03720561||Group: Ibrutinib Treatment|Participants will not receive any intervention as a part of this study. This study will collect retrospective and prospective real-world data to describe retention rates for participants of chronic lymphocytic leukemia (CLL) receiving ibrutinib in routine Italian clinical practice over a 2-year follow-up period. Participants with CLL who have started ibrutinib treatment within 3 months before enrollment visit or in case ibrutinib was prescribed before or on the enrollment day as per routine clinical practice within the 30 days after enrollment visit will be included in the study. The primary data source for this observational study will be the medical records of each enrolled participant, as well as questionnaires concerning quality of life and treatment adherence. Data will be collected every 3 months for the first year and every 6 months for the second year during prospective period.
89348408|NCT03419650|Other|Treatment arm|treatment arm for 12 weeks followed by observation period of 12 weeks, and a bone density at week 52.
89348409|NCT03424642|Experimental|Interactive 4D-ultrasound examination|Pregnant women who are randomized to 4D-ultrasound intervention group will receive additional 4D-ultrasound examinations 2-3 times between gestational weeks 25-32. Patients in this group will also receive psychologist's interview twice and fill out questionaries.
89348410|NCT03424642|No Intervention|Control group|Pregnant women who are randomized to control group will receive psychologist's interview twice twice and fill out questionaires.
89348411|NCT04893915|Experimental|Lead In Cohort Recipient: Cytokine-induced memory-like NK cells|"Fludarabine and cyclophosphamide beginning on Day -6.~NK cell product will be infused on Day 0.~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.~NK cell product will be infused into the recipient on Day +14.~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.~In the Lead-in Cohort, three patients will receive NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.~Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0."
89348412|NCT04893915|Experimental|Phase II Recipient: Cytokine-induced memory-like NK cells|"Fludarabine and cyclophosphamide beginning on Day -6.~NK cell product will be infused on Day 0.~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.~NK cell product will be infused into the recipient on Day +14.~IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.~Will receive the NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.~Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0."
89348413|NCT04893915|Experimental|Donor|"The allogeneic donor will undergo non-mobilized large volume (20-L) leukapheresis on Day -1.~On Day +13 the allogeneic donor will again undergo non-mobilized large volume (20-L) leukapheresis"
89348414|NCT03419494||VDCLD regimen containing PLD|PLD 36mg/㎡.d d1、d15，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
89348415|NCT03419494||VDCLD regimen containing DNR|DNR 45mg/㎡.d d1～3，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
89348416|NCT04986189|Other|Invitation to have a low dose CT thorax|All participants are invited to undergo a low dose CT thorax
89531932|NCT04708457|No Intervention|Standard Care|Patients with SARI who are already mechanically ventilated will continue to receive the standard intensive care therapies, including ECMO if required.
89348417|NCT04985409|Experimental|Feedback|Participants in the intervention arm will receive a Fitbit upon admission and will receive feedback from the activity tracker and the in-room TV screen as demonstrated by the Study Navigator. Study participants in this arm will be engaging with their physicians around achievement of daily step goals by viewing the in-room TV display of their daily step counts on rounds.
89348418|NCT04985409|No Intervention|Control|Subjects in the control arm will receive a Fitbit upon admission for their transplant but neither the physician, nurse, nor patient will receive any feedback from the device. They will be blinded to any data capture by their activity monitor. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods to encourage ambulation.
89348419|NCT03413020|Experimental|Tailored Therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.
89348420|NCT03424564|Experimental|Perampanel single-dose Part: 2 mg group|Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
89348421|NCT03424564|Experimental|Perampanel single-dose Part: 4 mg group|Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
89348422|NCT03424564|Experimental|Perampanel single-dose Part: 8 mg group|Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
89348423|NCT03424564|Experimental|Perampanel multiple-dose Part|Participants will receive multiple oral dose of perampanel (2 milligrams per day [mg/day] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.
89348424|NCT03412942|Other|Treatment with FISH device|Vascular closure to be performed with FISH device.
89348425|NCT02887989|Experimental|Virtual Reality|Patients will be allowed to use commercially-available VR equipment in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
89348426|NCT02887989|Sham Comparator|'Health and Wellness Channel'|Patients will be allowed to watch relaxing television content in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
89348427|NCT03419338|Experimental|Test group|Surgical alveolus + maxillary sinus lift with inorganic bovine bone + newly forming bone + collagen membrane
89348428|NCT03419338|Active Comparator|Control group|Maxillary sinus lift with inorganic bovine bone + collagen membrane
89348429|NCT03424486||Adolescents (14 to 17 years old)|Patients with CF
89348430|NCT03424486||Parents|Parents of adolescents (14 to 17 years old with CF (father, mother and other)
89348431|NCT01313481|Experimental|Group exercise|Otago exercise performed in groups
89348432|NCT01313481|Active Comparator|Home exercise|Otago exercise performed as home exercise
89348433|NCT03424408|Other|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
89348434|NCT03412708|Active Comparator|Vestibular Rehabilitation|"Vestibular Rehabilitation Program Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
89348435|NCT03412708|Experimental|Vestibular Rehabilitation supported with Virtual Reality|"Patients will perform the exercises in a virtual reality environment using a virtual reality goggle and a smartphone.The virtual environments consist of 2 media provided by the videos taken with a 360 camera . 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full. Exercises conducted while sitting and standing on a soft ground will happen in the 1st environment, and the ones on the treadmill will happen in the 2nd environment.~Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
89348436|NCT02887521|Experimental|Pulmonary Rehabilitation (PR)|Patients will receive 10 in-clinic sessions of preoperative Pulmonary Rehabilitation (PR) two weeks prior to surgery. Patients will receive a Participant Manual demonstrating and explaining the rehabilitation process. Patients will also receive a log for recording their efforts and notes for every day until the day of surgery. A video recording of the intervention from start to finish will be provided to all patients. The video recording should be played in all 10 sessions at the registering site. The PR sessions will include breathing awareness, upper and lower extremity exercise, instructions for inspiratory muscle training using the PFlex valve, practice at home and goal setting. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
89348437|NCT02887521|Active Comparator|Standard of Care|Patients will receive a pedometer to monitor their daily steps and a pamphlet with exercises plus the standard course of care for patients undergoing lung resection surgery. The patients will not be asked to return the pedometer. The local institutional coordinator will go over the use of the pedometer and the exercise materials with the patient. The patients will be asked to keep a log of their pre-operative steps and mail the log to the registering site. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
89348438|NCT03419182|Active Comparator|RCT - ORIF|A patient in this study arm consents to randomization and receives RCT - ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation.
89348439|NCT03419182|Active Comparator|RCT - (THA) + ORIF|A patient in this study arm consents to randomization and receives RCT - (THA) + ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
89531933|NCT04700878|Experimental|Internet-based compassion course|Therapist guided Internet-compassion course for workrelated stress.
89348440|NCT03419182|No Intervention|OBS - ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation.
89348441|NCT03419182|No Intervention|OBS (THA) + ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
89348442|NCT03419104|Experimental|Preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
89348443|NCT03305055|Experimental|Fentanyl Plus Ketamine|"Study drug group~Ketamine Loading Dose (Low Dose, Slow Infusion) =~• 0.3 mg/kg; Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, … Then,~Fentanyl Loading Dose (UC, injection) =~• 1 mcg / kg. This is given to participants in both Group 1 and Group 2 initiated < 1 minute prior to wound care.~Ketamine (Study Drug, Infusion) = • 2.5 mcg/kg/min, Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~Fentanyl PRN dose* = 1 mcg / kg. Provided when participant requires additional pain medication."
89348444|NCT03305055|Active Comparator|Fentanyl Plus Saline|"Usual care group~Saline Loading Dose (Low Dose, Slow Infusion) =~• An identical volume of saline as that in 0.3 mg/kg of ketamine. Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, (i.e., same time/rate as STUDY DRUG GROUP receives ketamine loading dose), … Then, ...~Fentanyl Loading Dose (UC, injection) =~• 1 mcg / kg: This is given to participants in both Group 1 and Group 2 initiated <1 minute prior to wound care.~Saline (Placebo, Infusion) = • Identical volume of fluid as that in 2.5 mcg/kg/min of ketamine; Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~FENTANYL PRN DOSE = 1 mcg / kg. Provided when participant requires additional pain medication."
89348445|NCT03424252|Experimental|FDL169 Dose Level 1,sublingual to oral|Dose level 1 sublingual first and oral second.
89348446|NCT03424252|Experimental|FDL169 Dose Level 1 dosing,oral to sublingual|Dose level 1 oral first and sublingual second.
89348447|NCT03424252|Experimental|FDL169 Dose Level 2 sublingual to oral,Optional|Dose level 2 sublingual first and oral second.
89348448|NCT03424252|Experimental|FDL169 Dose Level 2 oral to sublingual,Optional|Dose level 2 oral first and sublingual second.
89348449|NCT03419026||breast cancer|
89348450|NCT03419026||control|
89348451|NCT05121675|Experimental|App with behavioral economics + financial incentives|NeuroFlow uses behavioral economics reminders, gamification, and fun, motivating messages to encourage use. It also includes financial incentives so users can earn redeemable points accrued for activity completion for gift cards at popular outlets (e.g., 1000 points which is the maximum per month = $10 gift card).
89348452|NCT05121675|Active Comparator|App with behavioral economics incentives only|NeuroFlow uses behavioral economics reminders, gamification, and fun, motivating messages to encourage use. including points accrued for activity completion. This version of the app does not have financial incentives.
89348453|NCT03412552||severe preeclampsia without HELLP syndrome|severe preeclampsia if they met one or more of the following criteria of The American College of Obstetricians and Gynecologists (10): systolic blood pressure >160 mm/ Hg or diastolic blood pressure >110 mm/Hg, headache, epigastric or right-upper-quadrant pain, visual disturbances,pulmonary edema, and proteinuria (urinary protein level >5 g/24 h).Women with severe preeclampsia selected for analysis also met all of the following laboratory criteria: platelet count ≥150,000/ mm3, serum lactate dehydrogenase <600 IU /dL, serum total bilirubin <1.2 mg/dL and serum aspartate aminotransferase <70IU/L
89348454|NCT03412552||eclampsia without HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded
89348455|NCT03412552||eclampsia with HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded.HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
89348456|NCT03412552||HELLP syndrome without eclampsia|HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
89348457|NCT02763189|Active Comparator|Control|Control group will study the learning material independently. 'Self-study'.
89348458|NCT02763189|Experimental|Mentored|Mentored group will study the learning materials and then receive expert mentoring
89348459|NCT02521168|Experimental|Oral triiodothyronine|Oral T3 (triiodothyronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
89348460|NCT02521168|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
89348461|NCT03412474|Active Comparator|Bupivacaine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%).
89348462|NCT03412474|Active Comparator|Dexmedetomidine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
89348463|NCT03273387|Placebo Comparator|Sugar pill|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
89348464|NCT03273387|Experimental|trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
89348465|NCT03418948|Active Comparator|2 x CC|2 x conventional colonoscopy (CC), back-to-back design
89348466|NCT03418948|Active Comparator|CC followed by EC|Conventional colonoscopy followed by Endocuff Vision- assisted colonoscopy, back-to-back design
89348467|NCT03418948|Active Comparator|EC followed by CC|Endocuff Vision-assisted colonoscopy followed by conventional colonoscopy, back-to-back design
89348468|NCT03418948|Active Comparator|2 x EC|2 x Endocuff Vision-assisted colonoscopy
89348469|NCT03423784|Experimental|HA BPX V3.3|A HMWHA gel available in a formulation specificaly designed for use in infants
88807276|NCT05294328|Experimental|Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally|Aceclidine ophthalmic solution
89348470|NCT03423784|Active Comparator|Dentinox-Gel N|Gold standard for teething symptoms
89348471|NCT03412318|Experimental|Twisted file|Use of twisted file during cleaning and shaping of root canals
89348472|NCT03412318|Active Comparator|Mpro|Use of Mpro file during cleaning and shaping of root canals
89348473|NCT03423706|Experimental|new model of haplo-HSCT|use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion
89348474|NCT04447612|Experimental|Durvalumab arm|"Induction phase: Durvalumab 1500mg via intravenous infusion every 4 weeks, with chemotherapy gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.~Concurrent phase: Durvalumab 1500mg via intravenous infusion every 4 weeks for 2 cycles, with cisplatin 100mg/m2 via intravenous infusion every 3 weeks for 3 cycles.~Maintenance phase: Durvalumab 1500mg daily via intravenous infusion every 4 weeks for 8 cycles."
89348475|NCT04447612|Active Comparator|Standard of care arm|"Induction phase: Chemotherapy with gemcitabine 1000mg/m2 on day 1 and day 8 and cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles.~Concurrent phase: Cisplatin 100mg/m2 on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles."
89348476|NCT03412240|Experimental|Anti tachycardia pacing|
89348477|NCT01328080|Experimental|Targeted UV-B (Left)|Targeted UV-B on left side of the scalp.
89348478|NCT01328080|Experimental|Targeted UV-B (Right)|Targeted UV-B on right side of the scalp.
89348479|NCT05171140|Experimental|Hollow nails are arranged in a triangle|Hollow nails are arranged in a triangle
89348480|NCT05171140|Experimental|Hollow nail inverted triangle arrangement|Hollow nail inverted triangle arrangement
89348481|NCT03418870|Experimental|Family Integrated Care (mFI-Care)|Parents of infants assigned to the Family Integrated Care (mFI-Care) intervention will be treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches. Parent training on the Canadian FI-Care Parent Curriculum will be provided during small group sessions facilitated by the study team. Parents will receive peer support from mFI-Care-trained alumni parents and can interact with other mFI-Care parents through the We3Health App secure online parent forum. mFI-Care parents will be expected to track time spent with their infant; record infant activity, feeds and output; track learning and skills acquisition; and keep a journal of the NICU experience using the We3Health app.
89348482|NCT03418870|No Intervention|Family-Centered Care (FCC)|Infants assigned to usual FCC will have NICU nurses as primary caregivers per standard NICU protocol. FCC provides parents with orientation to the NICU; individualized teaching and support; and encouragement to participate in infant care under nursing supervision. Individualized support from social workers, lactation consultants and other specialists will be offered. As part of the study, parents will be asked to use the We3Health mobile app track their time in the NICU, time learning and time spent in infant caregiving activities and to keep of a journal of their NICU experience.
89348483|NCT03418636|Experimental|Staying Safe (Ssafe)|"Ssafe is delivered in a small group format (consisting of approximately 10-12 participants) by a trained facilitator over 4 2.5-hour sessions (10 hours total). To help promote the maintenance of risk reduction over the trial's 12-month follow-up period, Ssafe participants will be provided with a novel interactive, smartphone-delivered booster application based on core Ssafe principles and risk reduction strategies."
89348484|NCT03418636|Active Comparator|Healthy Living|Healthy Living is a time- and attention-matched control intervention of equivalent session structure and duration as Ssafe (4 2.5-hour sessions; 10 hours total), also delivered in a small group format (10-12 participants). Healthy Living participants will be provided with a publicly available, sleep hygiene-focused smartphone app to promote healthy sleep habits over the trial's follow-up period.
89348485|NCT02790034|Experimental|Sarizotan low dose|2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg 5 mg bid (≥13 years of age and weighing ≥25 kg)
89348486|NCT02790034|Experimental|Sarizotan high dose|5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to <13 years; ≥13 years of age and weighing <25 kg 10 mg bid (≥13 years of age and weighing ≥25 kg)
89348487|NCT02790034|Placebo Comparator|Placebo|Placebo bid for 24 wks DB age 4 and above
89348488|NCT05170360||patient group|Patients who are recently diagnosed with CRC based on clinical and pathological examinations
89348489|NCT05170360||control group|Control subjects will be CRC-free, based on the clinical history and physical examination.
89348490|NCT03418558|Experimental|HERACLES RESCUE|Patients will receive trastuzumab-emtansine, iv 3,6 mg/kg every 21 days. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first
89348491|NCT05170750|Experimental|Mechanical foot stimulation evaluation|"We have a 2 factors' interaction (vision and foot) with several levels.~foot: 4 levels =3 foams and a Control (CT) condition)~vision: 2 levels (open/close) A test will consist of maintaining a standing position on a stabilometric platform for 30s in a given condition. 3 trials are performed for each condition (combination of different levels) Between each trial: the subject is asked to self evaluate his stability. We evaluate the plantar discrimination with a discrimination disk. 5 foot zones are tested.~3/5 subjects from PIMOUSS1 are asked to be in PIMOUSS2. We have the interaction of 2 factors. foot: 2 levels (insole/CT) vision : 2 levels (open/close) A trial is the combination of the different levels while walking. It is repeated 5 times per condition.~The participant will perform this task under several experimental conditions presented in a randomized order:~Trajectory: (straight ahead/90° turns)~Visual: (close/open)~Mechanical stimuli (CT/insole)"
89348492|NCT05170282||Retrospective cohort|The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
89348493|NCT05170282||Prospective cohort|The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
89348494|NCT05169892||Aquablation|
89348495|NCT03412006|Experimental|Fulacimstat (BAY1142524)|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
89348496|NCT03412006|Placebo Comparator|Placebo|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
89348497|NCT02734108|Experimental|Transcranial direct current stimulation|10 patients will be stimulated twice a day for two weeks or 20 sessions. 2 milli ampere stimulation will be applied for 25 min respecting a period of four hours between sessions.
89348498|NCT02649946|Experimental|Covera Vascular Covered Stent following PTA|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
89348499|NCT02649946|Active Comparator|PTA only using uncoated PTA Balloon|Percutaneous Transluminal Angioplasty (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
89348500|NCT03418246|Sham Comparator|GIC filling|"Intervention/treatment One group will be treated with a tooth colored filling that will be placed near the gum line (Glass Ionomer).~Placebo Comparator: GIC~Participants will have a restoration placed with GIC in the lesion near the gum line. Device: GIC Application of a tooth colored filling in the cavitated dental lesion. Other Name: Resin modified glass ionomer"
89348501|NCT03418246|Experimental|Biodentine filling|"Intervention/treatment The second group will be treated with Biodentine that will be placed near the gum line.Experimental: Biodentine~Participants will have a restoration placed with Biodentine in the lesion near the gum line. Device: Biodentine Application of a white colored filling in dental lesion."
89348502|NCT03411928|Experimental|Tracheolator|Tracheal dilatation using the study device as per the protocol.
89348503|NCT03411850|Active Comparator|Orencia (Abatacept)|Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
89348504|NCT03411850|Placebo Comparator|Placebo|Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)
89348505|NCT05170594|Experimental|Bevacizumab combined with Fluzoparib|Bevacizumab combined with Fluzoparib will be administered in patients with platinum-resistant recurrent ovarian cancer.
89348506|NCT05170594|Experimental|Bevacizumab combined with chemotherapy|Bevacizumab combined with non-platinum chemotherapy will be administered in patients with platinum-resistant recurrent ovarian cancer.
89348507|NCT05170594|Experimental|Fluzoparib|Fluzoparib monotherapy will be administered in patients with platinum-resistant recurrent ovarian cancer.
89348508|NCT03411772|Active Comparator|TAP block|Patients undergoing bariatric surgery having TAP block upon completion of the procedure
89348509|NCT03411772|Sham Comparator|Non TAP block|Patients undergoing bariatric surgery without having TAP block
89348510|NCT03411538||Hospital-acquired bacterial infection|
89348511|NCT03411460|Experimental|Interstitial glucose|Glucose level tested by continuous monitoring device
89348512|NCT03411460|Active Comparator|Blood glucose|Glucose level tested on glucose monitor using standard finger prick
89348513|NCT03418168|Experimental|Molidustat (BAY85-3934)|Molidustat group
89348514|NCT03127306||CAM-ICU (+) Delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
89348515|NCT03127306||CAM-ICU (-) Non-delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
89348516|NCT02521090|Experimental|Treatment (EGFRBi-armed autologous T cells)|"PHASE I: Patients receive EGFRBi-armed autologous T cells IT twice weekly for 4 weeks.~PHASE II: Patients receive EGFRBi-armed autologous T cells* IT twice weekly for 4 weeks and then IV over 15-30 minutes twice weekly for 2 weeks.~*NOTE: Six selected patients receive EGFRBi-armed autologous T cells IV on day -3, -2, or -1 prior to first IT infusion."
89348517|NCT03273153|Experimental|Cobimetinib and Atezolizumab|Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle.
89348518|NCT03273153|Active Comparator|Pembrolizumab|Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.
89348519|NCT03418090|Active Comparator|Arm 1|Subjects will first undergo hyperpolarized 129Xe MRI followed by 133Xe scintigraphy
89348520|NCT03418090|Active Comparator|Arm 2|Subjects will first undergo 133Xe scintigraphy followed by hyperpolarized 129Xe MRI
89348521|NCT03410680|No Intervention|Control arm|Patients will receive the standard of care at the clinic. Questionnaires will be applied 4 times in a period of 10 months
88807277|NCT05294328|Experimental|Vehicle Ophthalmic Solution dosed bilaterally|Proprietary Vehicle ophthalmic solution
89348522|NCT03410680|Experimental|Intervention arm|"Each participant will receive FUERTES for a period of 4 months. It consists of receiving a habit-formation kit, which include an information and habit-formation tool that can be accessed through a web platform, a mobile app and a booklet; b) pill cases; c) a fidget cube; and f) a notebook. Patients will have the option of contacting a MD though WhatsApp regarding questions related to their treatment.~After completing baseline a questionnaire, patients with a score of 2 for barriers that might affect their ART adherence will be assigned a coach. The coach will have 7 one-on-one sessions with the patient in a period of 4 months in order to catalyze ART adherence. MSM living with HIV who have been taking ART for >3 years will provide a one-time one-on-one peer support session"
89348523|NCT03418012|Experimental|Cervical Pessary-Group|Cervical Pessary Group: placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37
89348524|NCT03418012|Other|Control-Group|Control-Group women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
89348525|NCT04410783|Other|Before group|Mechanically ventilated emergency department patients receiving standard post-intubation sedation prior to an educational initiative on the importance of ED-based targeted sedation
89348526|NCT04410783|Other|After group|Mechanically ventilated emergency department patients receiving post-intubation sedation after an educational initiative aimed at improving sedation practices in the ED
89348527|NCT02520934|Experimental|Case_Miglustat|Besides regular ERT, patients in this group also need to take Miglustat for 24 months.
89348528|NCT02520934|No Intervention|Control|Patients will be tested for their pupil cycle time.
89348529|NCT02749968|Active Comparator|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
89348530|NCT02749968|Placebo Comparator|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
89348531|NCT03270657|Other|Intraoperative Recording During DBS Implant Surgery|Participants will be recruited and enrolled from individuals who have Parkinson's disease (PD) and who already are scheduled to undergo the planned deep brain electrode placement for treatment of their movement disorder. Intraoperative recordings of participants' neural signals will be made through the implanted deep brain electrode(s).
89348532|NCT03410602|Placebo Comparator|Supragingival and subgingival scaling|Supragingival and subgingival scaling group comprised of 15 orthodontic patients treated with routine full-mouth supragingival scaling and subgingival scaling only around all banded first molars. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
89348533|NCT03410602|Active Comparator|Subgingival irrigation|Subgingival irrigation group comprised of 15 orthodontic patients treated with full-mouth supragingival scaling and subgingival scaling only around all banded first molars followed by irrigation with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
89348534|NCT04787250|Experimental|Arm 1, Phage Therapy with Antibiotic Treatment|Phage therapy will be administered in conjunction with antibiotic treatment.
89348535|NCT04787250|Active Comparator|Arm 2, Standard of Care|Two-stage exchange arthroplasty entails resection arthroplasty and placement of an antibiotic-loaded spacer, antibiotic therapy, an antibiotic-free observation period, and re-implantation of a new prosthesis.
89348536|NCT03303417|Experimental|Kiwifruit|Participants asked to consume 2 kiwifruit twice a day for 3 days before undergoing MRI Scan
89348537|NCT03303417|Placebo Comparator|Control|Participants asked to consume a calorie-matched sugar drink twice a day for 3 days before undergoing MRI Scan
89348538|NCT03127150||CL group|Subjects who had CL after pancreatic operation will be observed.
89348539|NCT03127150||Observation group|Subjects without CL after pancreatic operation will be observed.
89348540|NCT03411226||re-TREPP|Patients who presented with a recurrent inguinal hernia after previous TREPP repair.
89348541|NCT04908748|Experimental|Active Arm|Esflurbiprofen Hydrogel Patch containing 165 mg Esflurbiprofen
89348542|NCT04908748|Placebo Comparator|Control Drug|Placebo patch that does not contain the active ingredient but is otherwise indistinguishable from the investigational drug Esflurbiprofen Hydrogel Patch
89348543|NCT02943564|Experimental|Rapastinel 225 mg|Rapastinel 225 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
89348544|NCT02943564|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
89348545|NCT02943564|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
89348546|NCT04900402||Individuals with physical disabilities continuing rehabilitation after COVID-19|International Physical Activity Questionnaire Short Form (IPAQ) and Child Quality of Life Scale (PedsQL) questionnaires will be applied to individuals who continue their rehabilitation after the COVID-19 pandemic is declared.
89348547|NCT04900402||Individuals with physical disabilities not continuing rehabilitation after COVID-19|International Physical Activity Questionnaire Short Form (IPAQ) and Child Quality of Life Scale (PedsQL) questionnaires will be applied to individuals who do not continue rehabilitation after the COVID-19 pandemic is declared.
89348548|NCT03417700|Experimental|Training NW|exercise and supplementation
89348549|NCT03417700|Experimental|Training HICT and vitamin D|Training HICT plus vitamin D
89348550|NCT03417700|Experimental|Placebo|placebo Vitamin D
89348551|NCT03410524|Active Comparator|Simethicone with PEG-3350 bisacodyl preparation|"Treatment arm:~200 mg Simethicone in 3 mL of liquid formulation mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
89348552|NCT03410524|Placebo Comparator|Placebo with PEG-3350 bisacodyl preparation|"Placebo arm:~3 mL of water mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
89531934|NCT04700878|Active Comparator|General internet-based CBT stress management course|Therapist guided Internet-cognitive behavioral (CBT) course for workrelated stress.
89531935|NCT04700878|Other|Waitlist|Waitlist for 10 weeks, and thereafter the general internet-based CBT management course.
89348553|NCT04756440|Experimental|Experimental: Intervention Group|Firstly, Pre-tests were applied to the women in the experimental group. The 4-week training program created by taking into account the cultural characteristics of the Roma; It includes the Anatomy of Female Reproductive Organs, Anatomy of the Cervix, Cancer, Cervical Cancer, Early diagnosis and its importance, Pap smear test, HPV-DNA test, Cancer Early Diagnosis, Screening and Education Center. Afterwards, music therapy will be applied to the women in the experimental group with the song written and composed by the researchers who emphasized the importance of early diagnosis. At the end of the program, a focus group discussion will be held with the participants in the experimental group regarding their educational experiences, learning experiences for cervical cancer and screening, and program outcomes. Final tests will be made 3 months after the training ends.
89348554|NCT04756440|No Intervention|No Intervention: Control Group|First, pre-tests will be applied to the women in the control group. Women in this group will not be intervened and post-tests will be made 3 months after the pre-test.
89348555|NCT03417622|Experimental|Post-treatment volume-resection margin|Lumpectomy is performed with resection margin of the clinically / radiologically identifiable post-treatment tumor.
89348556|NCT03417622|Active Comparator|Pre-treatment volume-resection margin|Lumpectomy is performed with resection margin of the bracketed tissue.
89348557|NCT02713776|Experimental|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
89348558|NCT02713776|Placebo Comparator|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
89348559|NCT04813510|Experimental|electroacupuncture treatment|"Participants in the treatment group underwent 30 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi,electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment."
89348560|NCT04813510|Sham Comparator|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
89348561|NCT02677818||experimental group|The risk of bleeding adverse reactions when FVIII below the normal level.
89348562|NCT02677818||control group|The risk of bleeding adverse reactions when FVIII in normal level.
89348563|NCT05168878|No Intervention|Patient > 9 yo, no video|Caregivers of patients greater than or equal to 10 years old will not be shown a video in the PED.
89348564|NCT05168878|Active Comparator|Patient > 9 yo, 3 minute video|Caregivers of patients greater than or equal to 10 years old will be shown a 3-minute BeSMART video in the PED.
89348565|NCT05168878|Experimental|Any age, 30-second video|Caregivers of patients of any age will be shown a 30 second BeSMART video in the PED.
89348566|NCT05168878|Experimental|Any age, 3 minute video|Caregivers of patients of any age will be shown a 3-minute BeSMART video in the PED.
89348567|NCT03397810|Experimental|Singe arm|Subjects will receive a low dose radiotherapy focused to the heart
89348568|NCT03397732||Aorto-bifemoral bypass|Patients scheduled for elective aorto-bifemoral bypass surgery by vascular surgeons and consented to participate in the study.
89348569|NCT03397732||Aorta stentgraft|Patients scheduled for elective aorta stentgraft implantation by vascular surgeons and consented to participate in the study.
89348570|NCT05215990|Active Comparator|Patient receive metformin with pulmonary tuberculosis standard treatment.|Patient receive pulmonary tuberculosis standard treatment: isoniazid, rifampicin, pyrazinamide, and ethambutol in first and second month(weight adjusted dose), then in third to sixth month switch tuberculosis standard treatment to isoniazid and rifampicin(weight adjusted dose). In all 6 months, patient receive metformin (500 mg) 1 tablet simultaneously.
89348571|NCT05215990|Placebo Comparator|Patient receive placebo drug with pulmonary tuberculosis standard treatment.|Patient receive pulmonary tuberculosis standard treatment: isoniazid, rifampicin, pyrazinamide, and ethambutol in first and second month(weight adjusted dose), then in third to sixth month switch tuberculosis standard treatment to isoniazid and rifampicin(weight adjusted dose). In all 6 months, patient receive placebo drug 1 tablet simultaneously.
89348572|NCT03126058|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally. B: Remove catheter early.~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation for right hemicolectomy, Miles rectectomy and Hartman rectectomy, simple cleansing enema for left hemicolectomy,sigmoidectomy and Dixon rectectomy; C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
89348573|NCT03268941|Placebo Comparator|Part 1: Placebo|TAK-906 placebo-matching (4x0 mg), capsule, orally, twice daily (BID) on Days 1-8 and once on Day 9 under fasted conditions.
89348574|NCT03268941|Experimental|Part 1: TAK 906 Maleate 5 mg|TAK-906 maleate 1x5 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8, followed by TAK-906 maleate 1x5 mg, capsule, orally once on Day 9 under fasted conditions.
89348575|NCT03268941|Experimental|Part 1: TAK 906 Maleate 25 mg|TAK-906 maleate 1x25 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8 followed by TAK-906 maleate 1x25 mg, capsule, orally, once on Day 9 under fasted conditions.
89348576|NCT03268941|Experimental|Part 1: TAK 906 Maleate 100 mg|TAK-906 maleate 100 mg (4x25 mg), capsules, orally, BID on Days 1-8 and once a day on Day 9 under fasted conditions.
89348577|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fed Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (high fat breakfast), followed by a minimum 7- day washout.
89348578|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fasted Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions.
89348579|NCT03268941|Active Comparator|Part 2: Metoclopramide 10 mg|Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1 in Part 2.
89348580|NCT05215834|Active Comparator|PR group|Propofol and Remifentanil group
89348581|NCT05215834|Experimental|RR group|Remimazolam and Remifentanil group
89348582|NCT03410368|Experimental|autologous natural killer cells|Infusion of 1-2×10^9 NK cells every 14 days in the absence of progression or unacceptable toxicity until the 6 courses of treatment.
89348583|NCT03410368|No Intervention|routine follow-up|According to present guideline, no special treatment is advised for patients with SCLC after first-line therapy.They will be followed-up regularly.
89348584|NCT03394144|Experimental|C1:AZD9150, C2:AZD9150+Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open
89348585|NCT02346825|Experimental|Intensive Plus Cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
89348586|NCT02346825|Experimental|Intensive Plus Splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
89348587|NCT02346825|Experimental|Intensive no Constraint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks but will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
89348588|NCT05011149|Experimental|Selective early medical treatment (SMART) strategy|"Infants who are randomized to experimental group will follow the SMART treatment protocol, which includes echocardiographic screening every 72 hours to categorize PDA disease severity by combining clinical and echocardiographic features. At any evaluation if patients are found to have a severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness, they will receive pharmacotherapy aimed at PDA closure (The PDA severity has been divided into mild, moderate or severe based on pre-defined clinical and echocardiographic criteria)."
89348589|NCT05011149|No Intervention|Early conservative management strategy|Infants randomized to this arm will not undergo any further echocardiographic assessment or pharmacological treatment of the PDA regardless of the clinical signs. If the infant gets an echocardiographic assessment for a reason different than PDA assessment (such as hypotension or oxygenation failure) and a PDA is incidentally noted that fits the treatment criteria, the infant will not be initiated on pharmacotherapy. After 7 days of age, decision on PDA assessment and treatment will be at the discretion of the treating physician.
89348590|NCT03397498|Experimental|Computerized cognitive training|Received the Computerized cognitive training program, CogniFit™
89348591|NCT03397498|Active Comparator|Control-games|Received the Computerized games program
89348592|NCT03126994|Experimental|PhysioWave Cardiovascular Analyzer|The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.
89348593|NCT03410290||Group 1|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
89348594|NCT03397420|Experimental|FAM-CARE|"Two facility clusters (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program (where all HIV-positive family members are seen together as a unit and receive care together) with viral load monitoring"
89348595|NCT03397420|Active Comparator|Control Standard of Care|"Two clusters (one hospital and one health center, with their filter clinics) will be control standard-of care (usual practice) sites. Standard HIV care and treatment services, (drug resupply, clinical assessments etc.), including viral load monitoring, will be provided to adults and children in separate adult and pediatric clinics, even though they many be from the same family."
89348596|NCT03393988|Active Comparator|Group F|Fentanyl infusion (0.5 µg/kg/hr)
89348597|NCT03393988|Active Comparator|Group (TAP-Dex)|"Ultrasound guided TAP block and Dexmedetomidine~Ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine~Dexmedetomidine infusion(200 µg in 2 ml diluted in 48 ml of saline)~Fentanyl infusion (0.5 µg/kg/hr)."
89348598|NCT04447300|Active Comparator|Standard power application|
89348599|NCT04447300|Active Comparator|High power application|
89348600|NCT03410212|Active Comparator|Ketorolac Tromethanine|In the experimental group, 30mg/mL, ketorolac tromethamine will be injected as same as the first IANB and 5 minutes following it.
89348601|NCT03410212|Sham Comparator|No injection|In the control group, 5 minutes following the IANB, the sham injection will be provided at the same place of the first injection.
89348602|NCT04447924|Placebo Comparator|Placebo arm|Placebo arm. Similar trial product, but without Bif195 bacteria
89348603|NCT04447924|Experimental|Bif195 arm|Active trial product with minimum 15 billion CFU daily dose
89348604|NCT03393910|No Intervention|Observational|Normal pelvic exam exposures: External exam followed by speculum exam, followed by bimanual exam
89348605|NCT03393910|Active Comparator|Experimental Pelvic Exam|Changing the order of the pelvic exam Intervention: External exam, bimanual exam,speculum exam
89348606|NCT03410134|Experimental|NeoMTA|Vital pulp therapy with NeoMTA
89348607|NCT02520700|Experimental|Study participants|This was split scalp design - so each patient had one half of scalp treated with daylight PDT and one side treated with the artificial white light PDT - a surgical light (Maquet Power 500 LED surgery light)
89348608|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 0.3 mg OPT-302 intravitreal injection (0.05 mL)
89348609|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 1.0 mg OPT-302 intravitreal injection (0.05 mL)
89348610|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)
89348611|NCT03397264|Experimental|Ph 2a: 2.0 mg aflibercept with 2.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)
89348612|NCT03397264|Sham Comparator|Ph 2a: 2.0 mg aflibercept with sham|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by sham intravitreal injection
89348613|NCT03397186|Other|Basic science (trabectedin, biopsy)|Patients undergo a biopsy at baseline and then receive trabectedin for up to 4 cycles. Beginning 1 week after completion of cycle 2 and prior to cycle 3, patients undergo a second biopsy. Patients who achieve clinical benefit (CR, PR, SD) after the first post-treatment scan and who continue trabectedin for 4 cycles undergo a third biopsy after cycle 4.
89348614|NCT02520466|Active Comparator|flavanol-containing drink|flavanol-containing drink
89348615|NCT02520466|Placebo Comparator|flavanol-free drink|flavanol-free drink matched for taste and calories
89348616|NCT03397030|Experimental|Home-Based Exercise Program|Participants will complete a prescribed home-based exercise program and will follow up with research staff at the UT Health San Antonio School of Nursing.
89348617|NCT03397030|No Intervention|Waitlist-Control Group|Participants assigned to this group will be asked to maintain normal activity and visit the UT Health San Antonio School of Nursing for research appointments.
89348618|NCT03393442|Experimental|1. Gd-exposed subjects|Diagnostic Test: Brain MRI scan Female subjects at high risk for breast cancer that previously underwent more than 6 Gd-based contrast enhanced MRI exams of the breast.
89348619|NCT03393442|Active Comparator|2. Healthy subjects|Diagnostic Test: Brain MRI scan Age-matched female control subjects that never received Gd-based contrast agents.
89348620|NCT03393364|Experimental|Opioid arm|Patients receive opioid medication, oxycodone, after outpatient urologic surgery.
89348621|NCT03393364|Experimental|Non-opioid arm|Patients receive a non-opioid medication, ketorolac, after outpatient urologic surgery.
89348622|NCT03405922|Placebo Comparator|Placebo|Placebo 40 mL Saline 0.9%
89348623|NCT03405922|Active Comparator|Ropivacain|40 mL Ropivacain 0.5%
89348624|NCT04632706|Experimental|50mcg/kg (oral)|Ivermectin loading dose of 200 mcg/kg followed by daily doses of 50mcg/kg from D2 to D28
89348625|NCT04632706|Experimental|75mcg/kg (oral)|Ivermectin loading dose of 200 mcg/kg followed by daily doses of 75mcg/kg from D2 to D28
89348626|NCT04632706|Experimental|100mcg/kg (oral)|Ivermectin loading dose of 200 mcg/kg followed by daily doses of 100mcg/kg from D2 to D28
89348627|NCT04632706|Placebo Comparator|Matching Placebo (oral)|Placebo using tablets identical to the Active IMP
89348628|NCT03396796|Experimental|Vagus nerve-preserving group|Every patient of vagus nerve-preserving group will receive the modified vagus nerve-preserving laparoscopic azygoportal disconnection procedure.
89348629|NCT03396796|No Intervention|Conventional group|Every patient of conventional group will receive the conventional laparoscopic azygoportal disconnection procedure.
89348630|NCT03405454|Active Comparator|standard chemotherapy|Patients on physician's choice of chemotherapy are allowed to receive any systemic chemotherapy either as a single agent or in combination. However, biologics( including bevacizumab) and oral tyrosine kinase inhibitors will not be allowed for patients on this arm
89348631|NCT03405454|Experimental|durvalumab|Patients on durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months
89348632|NCT02520622|Experimental|Control|Patients use digital photographs loaded onto a mobile device
89348633|NCT02520622|Experimental|Reminders|Patients use digital photographs loaded onto a mobile device and receive skin exam reminders
89348634|NCT02520622|Experimental|Social Support|Patients use digital photographs loaded onto a mobile device and a social support network
89348635|NCT02520622|Experimental|Combined|Patients use digital photographs loaded onto a mobile device and a social support network and receive skin exam reminders
89348636|NCT05035264|Active Comparator|Neutral head position|Laryngeal mask will be inserted after anaesthesia induction in neutral head position
89348637|NCT05035264|Active Comparator|Sniffing position|Laryngeal mask will be inserted after anaesthesia induction in sniffing head position
89348638|NCT05035264|Experimental|Beyond sniffing position|Laryngeal mask will be inserted after anaesthesia induction in sniffing head position
89348639|NCT04609930||The study population|Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1
89348640|NCT04569604||Postsurgical hypoparathyroidism|Patients with hypoparathyroidism for 3 or more years after neck surgery
89348641|NCT04569604||Non-surgical hypoparathyroidism|Patients with hypoparathyroidism for 3 or more years without neck surgery
89348642|NCT04569604||Pseudohypoparathyroidism|Patients with the diagnosis of Pseudohypoparathyroidism
89348643|NCT04569604||Healthy controls|25 controls from the background population matched on age (±3 years), gender and level of education with the 25 patients with postsurgical hypoparathyroidism
89348644|NCT04446520|Experimental|autogenic drainage and traditional physiotherapy|autogenic drainage technique plus traditional physiotherapy (localized breathing exercise, diaphragmatic breathing and splinted coughing)
89348645|NCT04446520|Active Comparator|traditional physiotherapy|traditional physiotherapy (localized breathing exercise, diaphragmatic breathing, and splinted coughing)
89348646|NCT05168176|Experimental|Dotilavir sodium tablet|
89348647|NCT05168176|Active Comparator|Dotilavir sodium tablet(Tivicay@)|
89348648|NCT04872088|No Intervention|Control|The control group will receive preventive (BCC on child health and nutrition) and screening services from existing unsupervised Nutrition Activity Support Groups (NASGs) without additional support from the IRAM project. Children with wasting are eligible to be enrolled in the existing national Community Management of Acute Malnutrition (CMAM) program.
89531936|NCT04691284|Experimental|Observational arm|Patients will be asked to provide a sample of blood, urine and stool. This blood will be used for plasma and serum banking for further analysis, including miR and chemokine detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S rRNA gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic sequencing and subsequent taxonomic and functional classification of microbial genes will be used. Moreover, we might be able to characterized potentially clinically relevant features of the microbiome such as antibiotic resistance and microbial virulence factors.
89348649|NCT04872088|Experimental|Intervention|"The intervention group will receive the integrated package of interventions that will be delivered by the NASGs.~The NASG platform will be strengthened by the IRAM project by increasing their number proportional to the size of the population of the catchment area they serve and by regular formative supervision by NGO and health center staff.~The package of interventions includes:~Social and Behavioral Change Communication by NASGs during home visits and group sessions~Monthly delivery of preventive SQ-LNS to children 6-17 months of age~Screening and referral of children 6-59 months of age through the introduction of the MUAC family approach (distribution MUAC tapes to families and offering formative supervision by NASGs to enhance measurement quality)~Cooking demonstrations for complementary foods using nutrientdense foods in the community."
89348650|NCT03393130||Participants possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who possess at least one copy of the APOE-ε4 allele.
89348651|NCT03393130||Participants not possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who do not possess a copy of the APOE-ε4 allele.
89348652|NCT04565080||FMD Patients|adult FMD patients who participated in protocol 07-N-0190
89348653|NCT04565080||PD Patients|adult PD patients who participated in protocol 01-N-0206
89348654|NCT04539730|Active Comparator|Ropivacaine Standard of Care Group|Participants undergoing elective Total Knee Arthoplasty (TKA) surgery that are randomized to the control group will undergo an ultrasound-guided Adductor Canal Block (ACB) with standard of care (SoC) Ropivacaine post TKA surgery.
89348655|NCT04539730|Experimental|Liposomal Bupivacaine Intervention Group|Participants undergoing elective TKA surgery that are randomized to the intervention group will undergo an ultrasound-guided ACB with Liposomal Bupivacaine post TKA surgery.
89348656|NCT05168098|Experimental|olfactory intervention group|
89348657|NCT05168098|Active Comparator|game comparison group|
89348658|NCT05168098|No Intervention|control group|
89348659|NCT03396484|Experimental|Methyldopa|"Adults: methyldopa 500mg twice daily for one week and then increased to 500mg three times a day~Children: methyldopa dose based on weight twice daily for one week then increased to three times a day"
89348660|NCT03396484|Placebo Comparator|Placebo|Inactive agent to match active drug in appearance and dose frequency.
89348661|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohorts 1 to 8. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065.
89348662|NCT03245619|Experimental|Subjects receiving Placebo (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.
89348663|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.
89348664|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.
89348665|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Six subjects will be randomized to receive a single IV dose of GSK3335065.
89348666|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.
89348667|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.
89348668|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Two subjects will be randomized to receive placebo.
89348669|NCT05167942|Sham Comparator|Sham dTMS|29 patients will be randomly allocated into this group,they will receive sham stimulation.
89348670|NCT05167942|Active Comparator|dTMS 20Hz|29 patients will be randomly allocated into this group,they will receive real stimulation.
89348671|NCT05167942|Active Comparator|dTMS iTBS|29 patients will be randomly allocated into this group,they will receive real stimulation.
89348672|NCT04483882|Sham Comparator|Phase I- Visually Obscured Healthy Subjects|Tactile label to be evaluated by healthy subjects without visual defect. Subjects in visually obscuring lenses but without peripheral neuropathies or other tactile deficits will evaluate the tactile labeling product for efficacy in drug identity and dosing definition. .
89348673|NCT04483882|Active Comparator|Phase II- Low Vision Over 50 years of age|Subjects with documented Low Vision of 20/70 or less or visual field less than 20 degrees will be asked to evaluate tactile labeling product for efficacy in drug identity and dosing definition.
89348674|NCT03396406|Experimental|PCRF group|received Pulsed radiofrequency (PRF) at 42°C for 8 minutes followed by CRF at 60°C for 270s
89348675|NCT03396406|Experimental|CRF group|received sole thermocoagulation at 70°C for 270 s
89348676|NCT05000463|Active Comparator|ozone group|Ozone injection under ultrasound guidance in addition to the medical treatment
89348677|NCT05000463|Other|control group|receive the medical treatment only. The medical treatment includes optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin
89348678|NCT04472650|Experimental|Dosing Sequence 1: Sitravatinib Free Base then Malate Salt|Sitravatinib free base capsule 120 mg on Day 1 in Period 1 then sitravatinib malate salt capsule 100 mg on Day 1 in Period 2, with a minimum washout period between dose administrations of 14 days
89348679|NCT04472650|Experimental|Dosing Sequence 2: Sitravatinib Malate Salt then Free Base|Sitravatinib malate salt capsule 100 mg on Day 1 in Period 1 then sitravatinib free base capsule 120 mg on Day 1 in Period 2, with a minimum washout period between dose administrations of 14 days
89348680|NCT03620565||Laparoscopic sacrocolpopexy(LSC)|Patients who prefer to accept laparoscopic sacrocolpopexy after hysterectomy. For patients who has desire of uterine-preservation,laparoscopic sacrocervicopexy or sacrohysteropexy is carried.
89348681|NCT03620565||Reconstruction with transvaginal mesh(TVM)|Patients who undertake pelvic reconstruction with tran-vaginal mesh(commercial mesh kits or self-cut synthesized mesh).
89531937|NCT04680637|Placebo Comparator|Placebo + Standard of Care|
89348682|NCT03620565||Reconstruction with native tissue(NT)|Patients who prefer to accept reconstruction with native tissue,mainly including high uterosacral ligament suspension, sacrospinous ligament fixation,ischial spinous fascia fixation,the Lefort operation.
89348683|NCT03620565||Tension-free vaginal tape surgery(TVT)|Patients who undertake anti-incontinence surgeries(tension-free vaginal tape procedure).
89348684|NCT02606461|Experimental|Phase 2 Double-blinded: Selinexor|Participants received a fixed blinding dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until progressive disease (PD).
89348685|NCT02606461|Experimental|Phase 3 Double-blinded: Selinexor|Participants received a fixed blinding dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD.
89348686|NCT02606461|Placebo Comparator|Phase 2 Double-blinded: Placebo Followed by Open Label- Selinexor|Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD in double-blinded treatment period. Participants in the placebo group who had PD during the Phase 2 double-blinded treatment, will be elected to cross over to open-label selinexor.
89348687|NCT02606461|Placebo Comparator|Phase 3 Double-blinded: Placebo Followed by Open Label- Selinexor|Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD or development of unacceptable toxicity. Participants in the placebo group who had PD during the Phase 3 double-blinded treatment, will be elected to cross over to open-label selinexor.
89348688|NCT03321396|Experimental|Endoscopic submucosal dissection|All participants in the study received Endoscopic submucosal dissection with Sodium Alginate mixed with Calcium Lactate prior to endoscopic resection.
89348689|NCT03244917|Experimental|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education.
89348690|NCT03244917|No Intervention|CONTROL|Facility randomized to the control arm will employ usual care for the management for suspected infections in advanced dementia,
89348691|NCT04809376|Experimental|PPS Twice Weekly|Pentosan Polysulfate Sodium (PPS) twice weekly for 6 weeks
89348692|NCT04809376|Experimental|PPS Once Weekly|Pentosan Polysulfate Sodium (PPS) + placebo once weekly for 6 weeks
89348693|NCT04809376|Experimental|PPS Fixed Dose Once Weekly|Pentosan Polysulfate Sodium (PPS) Fixed dose (100mg,150mg, or 180mg) once weekly + placebo once weekly for 6 weeks
89348694|NCT04809376|Placebo Comparator|Placebo|Placebo twice weekly for 6 weeks
89348695|NCT03321006|Active Comparator|Antidepressant (AD) + full amplification hearing aids|Participant will be randomized to active comparator and will receive escitalopram or duloxetine + active hearing aid for 12 weeks.
89348696|NCT03321006|Sham Comparator|Antidepressant (AD) + Low amplification (sham) hearing aids|Participant will be randomized to sham comparator and will receive escitalopram or duloxetine + sham hearing aid for 12 weeks.
89348697|NCT04507347|Experimental|Test product|Eligible participants will be randomized to receive test product, TRC041266 1500 mg twice daily for 48 weeks.
89348698|NCT04507347|Placebo Comparator|Placebo product|Eligible participants will be randomized to receive matching placebo twice daily for 48 weeks.
89348699|NCT03572244|Experimental|Laser-Lok|A Laser-Lok microgrooved implant will be placed.
89348700|NCT03572244|Active Comparator|Machine|A machined implant will be placed.
89348701|NCT04238247|No Intervention|Enhanced Usual Care|"Participants will be randomized after completion of the baseline survey and receive a basic information sheet (print or electronic).~Months 1-12: Participants receive monthly, unscheduled requests to submit photographs as their child usually travels. Feedback is provided for critical errors and misuse. Follow-up occurs at 6 months. Outcomes are assessed at 12 months."
89348702|NCT04238247|Experimental|Basic Intervention|"Participants will be randomized after completion of the baseline survey and receive a basic information sheet (print or electronic). Participants receive a counseling session, access to the study's tailored, educational website, and tailored informational and motivational text messages.~Months 1-6: Participants receive monthly, unscheduled requests to submit photographs as their child usually travels. Feedback is provided. Follow-up occurs at 6 months.~After completion of their 6 month follow-up, participants in the Basic Intervention group will be eligible for re-randomization if they continue to not adhere to guidelines or plan a premature transition.~Months 7-12: Participants continue to receive monthly, unscheduled requests to submit photographs as their child usually travels. Feedback is provided. Outcomes are assessed at 12 months."
89348703|NCT04238247|Experimental|Enhanced Intervention|"After completion of their 6 month follow-up, participants re-randomized to Enhanced Intervention receive Basic Intervention components plus an additional counseling session (Months 7/8) and additional tailored text messages (Months 7-12).~Months 7-12: Participants continue to receive monthly, unscheduled requests to submit photographs as their child usually travels. Feedback is provided. Outcomes are assessed at 12 months."
89348704|NCT01974609|Experimental|Narcotic|Hydrocodone + acetaminophen 4 times per day 1 week after surgery
89348705|NCT01974609|Active Comparator|non-narcotic|ibuprofen + acetaminophen 4 times per day 1 week after surgery
89348706|NCT04741386||Cohort A|Patients with CKD stages 4 and 5
89348707|NCT04741386||Cohort B|Patients on hemodialysis and peritoneal dialysis
89348708|NCT04741386||Cohort C|Kidney Transplant Recipients
89348709|NCT04741386||Cohort D|Controls
89348710|NCT05167708|No Intervention|control|the group underwent distalization, with no Micro-osteoperforation
89348711|NCT05167708|Experimental|Single MOP|the group underwent one time Micro-osteoperforation procedure
89348712|NCT05167708|Experimental|repeated MOP|the group underwent monthly Micro-osteoperforation procedure
89348713|NCT03396328|Active Comparator|Conventional education|
89348714|NCT03396328|Experimental|Low salt dietary education by smartphone application|
89348715|NCT01868373|Other|microbiota transplantation|Two hundred mL of the bacterial suspension (microbiota transplantation) will be instilled into the small intestine via a catheter introduced through the biopsy channel of the endoscope and the flushed with 25 mL of sterile pre-reduced 0.9% saline. After removal of the endoscope, after recovery, patients will be allowed to resume a normal diet and physical activities.
89348716|NCT02593123|Experimental|Arm I (MMF-15, sargramostim)|Patients receive mycophenolate mofetil (MMF) PO or IV twice daily (BID) on days 0-15 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.
89348717|NCT02593123|Active Comparator|Arm II (MMF-30, filgrastim)|Patients receive mycophenolate mofetil PO or IV (twice daily) BID on days 0-30 and filgrastim G-CSF from post-transplant day 4 until neutrophil engraftment.
89348718|NCT03396250|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
89348719|NCT03396250|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
89348720|NCT04697290|Experimental|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion.
89348721|NCT03302559|Experimental|Retinol Complex 0.5|During a 2-week washout period the participant used a basic skin care regimen (SkinMedica facial cleanser in the morning and in the evening, Cetaphil Fragrance Free Moisturizing Lotion in the morning and in the evening and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen in the morning and as needed), followed by the same basic skin care regimen plus SkinMedica Retinol Complex 0.5 applied topically to the face in the evening for 12 Weeks. Assessments of the participant's facial skin were made utilizing investigator clinical grading, digital photography, a spectrophotometer and in vivo skin imaging.
89348722|NCT03396172|Other|Control|The intervention is an hospitalization with usual care. The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
89348723|NCT03396172|Active Comparator|FreeDom|"FreeDom strategy (early discharge, automated weaning at home, telemedicine, telereadaptation):~-initial conventional hospitalization before discharge home, O2 flow rate automatically titrated by FreeO2 (based on a SpO2 target). The hospital discharge will be possible if the definite criteria are met.~After hospital discharge, patient will have home hospitalisation. Automated oxygen flow titration, patient education will be conducted for using the telemedicine system, for questionnaires and for the tele-rehabilitation program will be initiated for home hospitalization,"
89348724|NCT03763903|Other|3D training|Basic laparoscopic skills (FLS tasks) training using 3D visualization
89348725|NCT03763903|Other|2D training|Basic laparoscopic skills (FLS tasks) training using 2D visualization
89348726|NCT05167474|Active Comparator|breast milk smell|The application of maternal education for the phototherapy method for newborns is to place the cotton unloaded by the mother in a container and place it close to the shape.
89348727|NCT05167474|No Intervention|control group|No intervention was performed during phototherapy treatment in newborns.
89348728|NCT03763825|Experimental|Intervention group|Patient will receive the Mini-AFTERc intervention after completion of primary breast cancer treatment.
89348729|NCT03763825|No Intervention|Control group|Patients will receive usual care after completion of primary breast cancer treatment.
89348730|NCT03393052|Active Comparator|Left Radial access|Left Radial approach for coronary angiography in patients with prior history of CABG surgery
89348731|NCT03393052|Active Comparator|Femoral access|Femoral approach for coronary angiography in patients with prior history of CABG surgery
89348732|NCT03763669|Experimental|Intervention|Pregnant women randomly assigned to receive (n. 40) diet and folic acid (400 mcg per day) and myo-inositol supplementation
89348733|NCT03763669|Placebo Comparator|Control|Pregnant women randomly assigned to receive (n. 40) only diet and folic acid (400 mcg per day)
89348734|NCT05167240||Group 1|Group 1 - will constitute of participants with two repeated ABPM recordings (visits): the second visit performed between 01.04.2020 - 31.03.2021 (i.e., during the COVID-19 pandemic announced by the WHO in 11.03.2020) and the first visit 9-15 months before the second ABPM recording, but not later than 31.12.2019.
89348735|NCT05167240||Group 2|Group 2 - will constitute of participants with two repeated ABPM recordings (visits) - both visits performed before the pandemic: the second visit in 01.01.2019 - 31.12.2019 and the first visit 9-15 months before the second.
89348736|NCT03302247|Experimental|Nivolumab+Gemcitabine|Nivolumab infusion on day 1 and 15 with the addition of gencitabine on day 1, 8 and 15 of 28 day cycle
89348737|NCT04993339|No Intervention|Standard Surgery|Participants in this group undergoing standard of care reparative surgery will not receive additional intervention
89348738|NCT04993339|Experimental|Standard Surgery with OOC|Participants in this group undergoing standard of care reparative surgery will receive OOC as an additional intervention
89348739|NCT03404830|Experimental|HIIT group|This group receives physical training based on HIIT
89348740|NCT03404830|Experimental|MICT group|This group receives physical training based on MICT
89348741|NCT03404830|No Intervention|No intervention group|This group does not receive any treatment.
89348742|NCT03392896|Experimental|Group A Active (DCR-PHXC)|HVs, single ascending doses of DCR-PHXC.
89348743|NCT03392896|Placebo Comparator|Group A Placebo|HVs, normal saline 0.9% injection to match active doses.
89348744|NCT03392896|Experimental|Group B Active (DCR-PHXC)|PH1 and PH2 patients, open label, single ascending doses of DCR-PHXC.
89348745|NCT03758209|Experimental|Prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:~Physical status (walking, respiratory training)~Nutrition (nutritional supplements)~Mental status (weekly groups led by clinical psychologist on anxiety and depression management).~Each patient will be treated in an ERAS program preoperatively."
89348746|NCT03758209|Active Comparator|ERAS|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
89348747|NCT01665573|Active Comparator|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
89348748|NCT01665573|Placebo Comparator|Placebo|Placebo
89348749|NCT04363840|No Intervention|Observation|
89348750|NCT04363840|Experimental|Aspirin 81 mg|
89348751|NCT04363840|Experimental|Aspirin + vitamin D|Offered to COVID-19 patients who are vitamin D deficient AND randomized to aspirin
89348752|NCT03758131|Experimental|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. Mi is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
89348753|NCT03758131|Active Comparator|Motivational Interviewing|In the Motivational Interviewing (MI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
89348754|NCT03758131|Placebo Comparator|Waitlist Control|Those dyads randomized to the Waitlist Control (WC) condition willl be offered teh PMI intervention at month 2 post-intervention for the PMI arm.
89348755|NCT04985331|Experimental|W-GenZD|W-GenZD is powered by natural language processing and machine learning techniques, the brief, self-guided intervention draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT-A) and some elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile medical application is designed to be targeted, relevant, tailored, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.
89348756|NCT04985331|No Intervention|Psychoeducation Control|The control for this study is the scheduled delivery of digital psychoeducational files (PDFs). The PDFs were selected to provide information on depression, anxiety and stress, as well as outline common coping skills.
89348757|NCT03403270|Experimental|ENCOURAGE App Intervention|Users will download the ENCOURAGE mobile app. The App uses a time management technique (i.e. Pomodoro technique) as a strategy to provide prompts for users to engage in an activity. The App can be customized by the users to set prompts at intervals that fit into their schedule. For example, these activities can range from a stretching activity (e.g., a neck stretch), a standing activity (e.g., stand and read), or a physical activity (e.g., fill up the printer with paper, do a squat). Additionally, the App will use Behaviour Change Techniques as a strategy to support participants as they reduce their sedentary behaviour and improve their physical activity levels. The App uses a series of Behavior Change Techniques shown to be effective in promoting a more active lifestyle.
89348758|NCT04974697|Experimental|JJVC Investigational Multifocal Toric Contact Lens|Eligible subjects that are adapted contact lens wearers with presbyopia, ametropia (hyperopia or myopia) and astigmatism will be dispensed the study lens in a bilateral fashion.
89348759|NCT03265119|Experimental|AEVI-001|
89348760|NCT03265119|Placebo Comparator|Placebo|
89348761|NCT03396094|Experimental|Intervention|High-flow nasal cannula oxygenation at 60L/min for pre-oxygenation and apnoeic oxygenation
89348762|NCT03396094|Active Comparator|Control|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
89348763|NCT03758053||Individuals with alcohol use disorder + ACE|Individuals with AUD and varying levels of adverse childhood experiences (ACE)
89348764|NCT03758053||Healthy controls|Healthy individuals without AUD
89348765|NCT03758053||Individuals with alcohol use disorder, no ACE|Individuals with AUD and no adverse childhood experiences (ACE)
89348766|NCT04981665|Experimental|Postoperative TACE + Tislelizumab 200mg IV Q3W|TACE will be performed after curative resection (4±1w) once and then Tislelizumab Injection will be initiated after TACE (5±2d). Tislelizumab will be administered every three weeks, until the disease recurrence, intolerable toxicity, death, withdrawal of consent or completion of 17 cycles of Tislelizumab.
89348767|NCT03392818|Experimental|formula|Calculate the depth of intubation according to the formula of 0.1977* patient's height - 4.2423
89348768|NCT03392818|Experimental|Fiberoptic bronchoscope|intubation of Uniblocker under the Under the guidance of Fiberoptic bronchoscope
89348769|NCT03392818|Experimental|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of FOB.
89348770|NCT04952701|Active Comparator|Control Lens|All subjects will wear control lenses for two weeks and then will wear Test lenses for two weeks.
89348771|NCT04952701|Experimental|Test Lens|After wearing control lenses for two weeks, all subjects will wear test lenses for two weeks.
89348772|NCT05166928|Active Comparator|group 1: control group|will be treated using carriere motion appliance for distalization of upper buccal segment in the presence of upper third molar
89348773|NCT05166928|Active Comparator|group2: teste group|will be treated with using carriere motion appliance for distalization of upper buccal segment with upper third molar extraction or have congenital missing upper third molar
89348774|NCT03392740|Experimental|Lisinopril treatment|These patients will be initiated at 5mg lisinopril daily by the research nurse at the time of enrollment. The drug will then be titrated up by the research nurse in a stepwise fashion from 5mg, to 10mg, and then to 20mg once a day every 1 to 3 weeks according to their regular/scheduled next office visits. Blood pressure will be monitored at every visit by the research nurse if it is less than or equal to 90 mmHg
89348775|NCT03392740|Placebo Comparator|Placebo Oral Tablet|These patients will be started on the placebo medication at the time of enrollment. According to their regular scheduled visits every 1 to 3 weeks, they will meet with the research nurse and be given a new placebo medication to take once a day.
89531938|NCT04680637|Experimental|Efavaleukin Alfa Dose Level One + Standard of Care|
89531939|NCT04680637|Experimental|Efavaleukin Alfa Dose Level Two + Standard of Care|
89531940|NCT04680637|Experimental|Efavaleukin Alfa Dose Level Three + Standard of Care|
89348776|NCT04723173|Experimental|Experimental device: Noise reduction on|The noise reduction is activated. The feature shall support the hearing aid user in noisy situation and shall reduce the listening effort in these special situations.
89348777|NCT04723173|Active Comparator|Experimental device: Noise reduction off|To compare the advantage of the special noise reduction feature the tests will be done additionally with the deactivated feature.
89348778|NCT03126838||diaphragmatic dysfunction|diaphragmatic displacement < 10 ml, and / OR diaphragmatic thickening fraction < 36 %.
89348779|NCT03126838||non diaphragmatic dysfunction|diaphragmatic displacement > 10 ml, and / OR diaphragmatic thickening fraction > 36 %.
89348780|NCT02938689|Experimental|Lumbar extension exercise|Exercise education based on Mckenzie lumbar extension exercise for 4 weeks
89348781|NCT02938689|Active Comparator|Lumbar flextion exercise|Exercise education based on Wilillams lumbar flexion exercise for 4 weeks
89348782|NCT03126526|Experimental|Food specific inhibitory control training|The stimuli in this task will involve pictures of food.
89348783|NCT03126526|Active Comparator|General inhibitory control training|The stimuli in this task will not involve pictures of food, but pictures of stationary and household items.
89348784|NCT03126526|No Intervention|Baseline brain activation assessment (healthy controls)|This arm is included to assess brain activation using EEG among healthy controls at baseline in order to compare responses to participants with eating disorders.
89348785|NCT02839551|Experimental|Simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
89348786|NCT03392506|Experimental|EBUS-TBNA-RTE|Patients do CT、 PETCT examination and EBUS-TBNA-RTE
89348787|NCT05166772|Experimental|Donafenib combined with Sintilimab and HAIC|Donafenib：200mg bid； Sintilimab：200mg Q3D； HAIC：Q3W；
89348788|NCT02818023|Experimental|Pembrolizumab plus vemurafenib and Cobimetinib|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
89348789|NCT04919161|Active Comparator|Body weight support system control group|In this arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system.
89348790|NCT04919161|Experimental|Body weight support system with balance perturbations|Similar to the control group arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system, with the inclusion of 8 total balance perturbations each session, including 2 in the posterior, anterior, left lateral, and right lateral directions.
89348791|NCT04919161|No Intervention|Historical Standard of Care control|Retrospective anonymized Berg Balance Score data of stroke inpatients was collected from an institutional report for fiscal year 2018. 2018 was chosen as it preceded the implementation of the ZeroG body weight support system and reflects a no-intervention control baseline. This data was then filtered to show only patients with a Berg score of 21 or greater to match the study's inclusion criteria.
89348792|NCT03402256|Experimental|Text Message (TM)|"Participants will receive daily text messages and all elements of standard care. They received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Key domains of message topics were chosen based on the content of evidence-based, relapse prevention treatment. Daily messages determined current level of functioning and provide intervention messages in response. Text messages will be sent via Google Voice on a research computer. Participants will respond to the text messages either with a specified response (e.g. YES/NO) or a generic response (e.g. 1). Some messages will ask for a specific reply in response to a question. Based on the participant's response (e.g. high, med, low), the research assistant will respond with a text message tailored to the participant's message. All text messages will be sent to the HIC in an amendment to this protocol for approval."
89348793|NCT03402256|No Intervention|Standard Care (SC)|"Participants will receive only standard care provided by the liver transplantation team. No additional behavioral or psychosocial interventions will be provided. All aspects of care received by SC participants will also provided to the TM condition participants. Medical care will be managed by medical specialty providers. SC condition participants will receive behavioral treatment within the liver transplantation clinic by psychology fellows and/or psychologists/psychiatrists. Treatment schedules and session topics will be determined by individual providers, per usual practice.~These participants will receive only study-specific assessments. Participants in this condition will complete assessments at baseline, 4-weeks and 8-weeks that measure self- reported substance use, stress, and coping skills. At each in-person assessment, participants will provide urine for EtG analysis and will be compensated."
89348794|NCT03262389|Experimental|Multiple Myeloma Patients|Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.
89348795|NCT03400930||OptiDiag-Cohort, Liberia|A respresentative population of 275 Liberian children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
89348796|NCT03400930||OptiDiag/MANGO-Cohort, Burkina Faso|A respresentative population of 275 Burkinabé children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
89348797|NCT03400930||OptiDiag-cohort, Bangladesh|A respresentative population of 275 Bangladeshi children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
89348798|NCT04460313|Other|prospective cohort|Nasopharyngeal sample for each enrolled children
89348799|NCT04460313|Other|ESBL cohort|Stool or anorectal swab samples for a subgroup of children
89531941|NCT04677257|Experimental|STEMI acute myocardial infarction treated with effective primary PCI|STEMI patients treated with effective primary PCI to assess the ability of coronary physiology parameters (CFR and IMR) measured soon after recanalization to predict myocardial tissue characterization assessed with cardiac magnetic resonance (CMR) within a week of the acute event.
89348800|NCT04631536|Experimental|Endothelial Dysfunction Protocol|"Our study will evaluate the impact of the endothelial treatment protocol (atorvastatin, nicorandil, l-arginine, folic acid and nebivolol) in patients already on optimal medical therapy for the treatment of COVID0-19 virus.~Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc).~Atorvastatin or continue home statin Atorvastatin will be provided as a 40 mg tablet to be given PO once daily. This dose was suggested because high intensity statin has been associated with a better endothelial profile (Int J Cardiol 2017 Oct 1;244:112-118.-- Eur J Clin Pharmacol 2014 Oct;70(10):1181-93)~Nicorandil Nicorandil 10 mg PO BID as the recommended dose for coronary vasodilatation by the manufacturer~Nebivolol Nebivolol 2.5-5 mg PO ONCE daily while keeping Heart Rate (HR) between 50-90 bpm~Folic Acid Folic Acid 5 mg po once daily~L-Arginine L-Arginine 1 g po TID"
89348801|NCT04631536|Placebo Comparator|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
89348802|NCT03758911||bone marrow/blood stem cell donors|Participants underwent a one time semi-structured telephone interview to understand the perspectives of bone marrow/stem cell donors experience, including how family dynamics impacted participants' decision to donate and identifying unique supportive care needs of bone marrow/stem cell donors.
89348803|NCT03262233|Experimental|Active Deprived|"21 mg nicotine patches and 2 mg nicotine lozenges~+ First NPU task takes place 24 hours after start of quit attempt"
89348804|NCT03262233|Experimental|Active Non-deprived|"21 mg nicotine patches and 2 mg nicotine lozenges~+ First NPU task takes place during normal smoking prior to quit attempt"
89348805|NCT03262233|Active Comparator|Placebo Deprived|"Placebo patches and placebo lozenges~+ First NPU task takes place 24 hours after start of quit attempt"
89348806|NCT03262233|Active Comparator|Placebo Non-deprived|"Placebo patches and placebo lozenges~+ First NPU task takes place during normal smoking prior to quit attempt"
89348807|NCT03261531|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)
89348808|NCT04151290|Experimental|Cognoa Assessment|Cognoa diagnostic ASD device.
89348809|NCT03400540|Experimental|Group A|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles~squeeze and lift the pelvic floor muscles as if stopping the flow of urine~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~contract all of the above together"
89348810|NCT03400540|Experimental|Group B|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles~squeeze the anus~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~contract all of the above together"
89348811|NCT04389333|Experimental|Non-contact MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination. In order to simplify the examination procedure, the data recorder was put on the examination bed. The patient lay down after swallowing the capsule under the remote guidance of the endoscopist.
89348812|NCT04389333|Active Comparator|MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of an endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient was instructed to assume the supine or left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist face to face, the subject turned over on the bed to complete the examination.
89348813|NCT04099498|No Intervention|Standard Control group|This group will not partake in the intervention but will be assessed with the same protocol at the same moments.
89348814|NCT04099498|Experimental|Online-Intervention group|This group will take part of the 20-week long online intervention to promote healthy eating. The program will be developed to promote self-regulation skills and strategies about healthy eating among elementary school-aged children and each week will include: i) a narrative embedded with self-regulation skills and strategies; ii) a weekly parental involvement activity; and iii) a weekly group synchronous videoconference session with a trained educational psychologist serving as a mediator.
89348815|NCT04099498|Experimental|Enhanced-online-Intervention Group|This group will take part of the 20-week long online intervention to promote healthy eating. The program will be developed to promote self-regulation skills and strategies about healthy eating among elementary school-aged children and each week will include: i) a narrative embedded with self-regulation skills and strategies; ii) a weekly parental involvement activity; and iii) a weekly group synchronous videoconference session with a trained educational psychologist serving as a mediator. In addition, gamification strategies (e.g., points for each complete activity, feedback) will be implemented in order to promote engagement with the program and activities.
89348816|NCT05166538|Experimental|Ticagrelor|
89348817|NCT05166538|Active Comparator|Clopidogrel|
89348818|NCT03399916|Experimental|Prompt|"An email based prompt was sent- containing either a stand or move message. Exploratory variations of the prompt were designed to include the addition of a goal e.g., stand for the next 5-minutes, and/or employer support e.g., PTS says stand for the next 5 minutes."
89348819|NCT03399916|No Intervention|No Prompt|Prompt delivery was sequentially randomized to be sent (ST) or not sent (NST) to all participants (probability of 0.5), at eight decision points per day (between 9am and 5pm), to achieve a total of 3200 randomizations across participants (160 per participant). Therefore 50% of the time, no prompt was sent.
89348820|NCT04055740|Experimental|IVUS imaging|IVUS imaging will be used each patient undergoing transvenous lead extraction to visualize ILA
89348821|NCT04459546|Experimental|Study group|Study group intervention consists patient education, training booklet and 3 month follow-up.
89348822|NCT04459546|No Intervention|Control group|Control group received only general care
89531942|NCT04647422|Experimental|AUD patients|Alcohol Use Disorder patients
89531943|NCT04647422|Experimental|AUD controls|Healthy control participants matched to group 1
89348823|NCT03399760|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
89348824|NCT03399760|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
89348825|NCT03392350|Active Comparator|Behavioral Intervention arm|"A behavioral intervention consisting of a physician body scan consultation with a radiologist which included viewing self imagery followed by an 18 month behavioral intervention which included educational modules covering:~Responding to Stress More Effectively Enhancing the effects of Relaxation Nourishing your immune system Energizing your Body Welcoming Others and Strengthening Relationships"
89348826|NCT03392350|Active Comparator|Control Group|No Intervention
89348827|NCT03395938|Placebo Comparator|Current practice|"Intervention A depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation."
89348828|NCT03395938|Active Comparator|Proactive engagement|"Intervention B involves a series of proactive engagements in hope to spur patients into contacting their siblings and improve their receptiveness towards colorectal cancer screening."
89348829|NCT03260205|Placebo Comparator|Placebo|Participant will receive placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
89348830|NCT03260205|Experimental|SPD489 (Lisdexamfetamine dimesylate)|Participants will be randomized to receive SPD489 capsule in a 5:5:5:5:6 ratio to SPD489 5, 10, 20, 30 milligram (mg) orally once daily for 6 weeks. Dosing will begin with the lowest strength of SPD489 (5 mg), and will be titrated until the randomly assigned fixed-dose is reached.
89348831|NCT03395860|Experimental|group A|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
89348832|NCT03395860|Experimental|group B|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
89348833|NCT03399682||Incidence of Post Cystography Urinary Tract Infections|all children less than 16 years having cystography
89348834|NCT04666441|Experimental|IV Dose 1|Combination therapy intravenous (IV) single dose
89348835|NCT04666441|Experimental|IV Dose 2|Combination therapy IV single dose
89348836|NCT04666441|Experimental|IV Dose 3|Combination therapy IV single dose
89348837|NCT04666441|Experimental|IV Dose 4|Combination therapy IV single dose
89348838|NCT04666441|Experimental|Placebo IV Dose|Matching placebo IV single dose
89348839|NCT04666441|Experimental|SC Dose 1|Combination therapy subcutaneous (SC) single dose
89348840|NCT04666441|Experimental|SC Dose 2|Combination therapy SC single dose
89348841|NCT04666441|Experimental|Placebo SC Dose|Matching placebo SC single dose
89348842|NCT03320850|Experimental|100U cohort - BOTOX® plus Hydrogel admixture|100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
89348843|NCT03320850|Placebo Comparator|100U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
89348844|NCT03320850|Experimental|300U cohort - BOTOX® plus Hydrogel admixture|300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
89348845|NCT03320850|Placebo Comparator|300U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
89348846|NCT03320850|Experimental|400U cohort - BOTOX® plus Hydrogel admixture|400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
89348847|NCT03320850|Placebo Comparator|400U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
89348848|NCT03320850|Experimental|500U cohort - BOTOX® plus Hydrogel admixture|500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
89348849|NCT03320850|Placebo Comparator|500U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
89348850|NCT03923920||Spinal Stenosis Biopsy|Biopsy of ligamentum flavum tissue during spinal stenosis surgery sent to pathology for amyloid-specific analysis
89348851|NCT04447378|Experimental|Fondaparinux|Subcutaneous injection of fondaparinux 2.5 mg once daily would be given over 10 days for post partum thromboprophylaxis
89348852|NCT03125980|Experimental|Perioperative chemotherapy with CapOX regimen|
89348853|NCT03125980|Active Comparator|Postoperative chemotherapy with CapOX regimen|
89348854|NCT03529344|Active Comparator|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
89348855|NCT03529344|Placebo Comparator|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
89348856|NCT03399604|Experimental|LIQ861 Inhaled Treprostinil|"LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg.~LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg to 150 μg treprostinil QID in individual patients."
89348857|NCT04447066||Patients hospitalized at the rehabilitation department|
89348858|NCT03301623|Experimental|Clinical Decision Support|Patients within the physicians randomized to the IDM arm will receive the Clinical Decision Support alerts via the EHR when certain order criteria are triggered appropriately.
89348859|NCT03301623|Experimental|Patient Education and Activation Tools|Patients within the physicians randomized to SDM will receive the PEAT materials via REDCap two days prior to their PCP office visit. They will receive these materials every time they have an office visit with their PCP.
89348860|NCT03399526|Experimental|Mapracorat|10 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
89348861|NCT03399526|Active Comparator|Prednicarbate|10 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
89348862|NCT03399526|Active Comparator|Clobetasol|10 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
89348863|NCT03399526|Active Comparator|Calcipotriene|10 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
89348864|NCT03399526|Active Comparator|Calcipotriene/Betamethasone dipropionate|10 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
89348865|NCT03392272|Experimental|Tisseel|Müller's Muscle-Conjunctival Resection (MMCR) using glue instead of sutures
89348866|NCT03392272|Active Comparator|Sutures|Müller's Muscle-Conjunctival Resection (MMCR) using the usual procedure
89348867|NCT03756493|Experimental|OFD+ABG+L-PRF treated patients|Periodontal surgery with Leukocyte and Platelet Rich Fibrin (L-PRF) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous bone graft mixed with cutted L-PRF will be applied to the furcation defects; then, a L-PRF membrane is positioned above the filling material. Finally the flap will be coronally positionated and sutured by interrupted sutures.
89348868|NCT03756493|Active Comparator|OFD+ABG treated patients|Periodontal surgery with Autogenous Bone Graft (ABG) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. ABG will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
89348869|NCT03756493|Active Comparator|OFD treated patients|Periodontal surgery with Open Flap Debridement is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. No grafts will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
89348870|NCT03319212|Other|Active Comparator|Subjects that are between the ages 18-55 and are current spherical soft contact lens wearers will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.
89348871|NCT03392116|Experimental|Part A: NGM120|Single Dose
89348872|NCT03392116|Placebo Comparator|Part A: Placebo|Single Dose
89348873|NCT03392116|Experimental|Part B: NGM120|Multiple Dose
89348874|NCT03392116|Placebo Comparator|Part B: Placebo|Multiple Dose
89348875|NCT03756415|Experimental|mask plus CO2 removal device|"a traditional mask with inserted a new CO2 removal device that is called DiMax Zero Total face mask R,"
89348876|NCT03756415|Active Comparator|traditional face mask|Traditional mask without a CO2 clearance device inserted
89348877|NCT03905902|Experimental|DCVAC/OvCa with standard of care|"Induction period: DCVAC/OvCa with carboplatin and gemcitabine, or carboplatin and paclitaxel, or carboplatin and pegylated liposomal doxorubicin, with or without bevacizumab~Maintenance period: DCVAC/OvCa with bevacizumab, best supportive care or a PARPi"
89348878|NCT03905902|Placebo Comparator|Placebo with standard of care|"Induction period: DCVAC Placebo with carboplatin and gemcitabine, or carboplatin and paclitaxel, or carboplatin and doxorubicin, with or without bevacizumab~Maintenance Period:DCVAC placebo with bevacizumab, best supportive care or a PARPi carboplatin and gemcitabine or carboplatin and paclitaxel with or without bevacizumab, best supportive care or a PARPi"
89348879|NCT03638310|Experimental|ITG (intratympanic gentamicin) group|Patients who underwent prehabituation by gentamicin prior to surgery for vestibular schwannoma. They underwent intratympanic application of gentamicin and microsurgical removal of vest. schwannoma.
89348880|NCT03638310|Active Comparator|control group|patients without prehabituation before surgery. They underwent microsurgical removal of vest. schwannoma.
89348881|NCT03395782||Age group 40-49|30 patients will be stratified to this age group.
89348882|NCT03395782||Age group 50-59|30 patients will be stratified to this age group.
89348883|NCT03395782||Age group 60-69|30 patients will be stratified to this age group.
89348884|NCT03395782||Age group 70-79|30 patients will be stratified to this age group.
89348885|NCT04656691|Experimental|Participants with COVID-19|Participants testing positive for COVID-19 may be eligible to receive a one-time dose of bamlanivimab 700 mg, delivered via infusion through the vein, lasting around 60 minutes. This infusion will be done in-home and administered by a registered nurse.
89348886|NCT04016532|Other|Patient malnourished or at risk of undernutrition|Dietary follow-up at home: 4 visits (D15, D30, D60, D90)
89348887|NCT04016532|Other|Not undernourished patients|Dietary follow-up at home: 3 visits ( D30,D60, D90)
89348888|NCT02520232|Experimental|Physical activity program (A)|Physical exercises
89348889|NCT02520232|Experimental|Physical activity program (B)|Physical exercises
89348890|NCT02520232|No Intervention|Control|No physical exercices assigned by the protocol
89531944|NCT04647422|Experimental|First-degree relatives|Healthy first-degree relatives of AUD patients
89531945|NCT04647422|Experimental|First-degree controls|Healthy control participants matched to group 3
89348891|NCT03756181|Experimental|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of compassion: self-kindness, mindfulness, and common humanity, and will work on soothing the processes of self-criticism, self-neglect and perfectionism that are believed to withhold upon experiencing psychological distress. There will also be sessions dedicated to incorporating self-compassion in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
89348892|NCT03756181|Active Comparator|Five-week Mindfulness-based Stress Reduction program (MBSR5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator will perform a brief check-in and may discuss the student's experience within the course of the session. These discussions will reinforce the guiding principles of meditation: awareness, non-judgment and acceptance and will work on automatic mental processes that are believed to be at the root of experiencing psychological distress. There will also be sessions dedicated to incorporating mindfulness into daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
89348893|NCT03301155|Experimental|Anaferon for children|"Tablet for oral use. One tablet per intake, once daily (approximately at the same time).~The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature."
89348894|NCT03301155|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Anaferon for children scheme.
89348895|NCT03763513|Active Comparator|ESWT|the first group:The group that will receive Extra corporeal shock wave therapy
89348896|NCT03763513|Experimental|ESWT+KT|the second group:The group that will receive Extra corporeal shock wave therapy + Kinesiotaping application
89348897|NCT03392038|Experimental|Thin ADM|Periodontal root coverage surgery using a coronally positioned tunnel and thin acellular dermal matrix (ADM GBR)
89348898|NCT03392038|Active Comparator|Thick ADM|Periodontal root coverage surgery using coronally positioned tunnel surgery and thick acellular dermal matrix graft (ADM)
89348899|NCT01952730|Experimental|Experimental Treatment Arm|GVAX, up to 6 vaccinations, administered via injection
89348900|NCT03753529|Experimental|deep friction massage group|
89348901|NCT03753529|Experimental|pressure release group|
89348902|NCT03753529|Experimental|control group|
89348903|NCT03638232||Patients with multiple myeloma|"Data to be collected are :~Drug exposition data~Administrative data~Medical data"
89348904|NCT03395626|Experimental|ID-JPL934|probiotics 20%, corn starch 80%
89348905|NCT03395626|Placebo Comparator|placebo|corn starch 100%
89348906|NCT03757975||TAH|patients before and after total abdominal hysterectomy (TAH)
89348907|NCT03757975||TLH|patients before and after total laparoscopic hysterectomy (TLH)
89348908|NCT03757975||TVH|patients before and after total vaginal hysterectomy (TVH)
89348909|NCT03757975||SAH|patients before and after abdominal supracervical hysterectomy (SAH)
89348910|NCT03757975||SLH|patients before and after supracervical laparoscopic hysterectomy (SLH)
89348911|NCT03399448|Experimental|Multiple Myeloma (MM)|
89348912|NCT03399448|Experimental|Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL)|
89348913|NCT03399448|Experimental|Melanoma|Not Recruiting at the UPenn Site
89348914|NCT03883282||study group|Patients who have been participated in RCT in the period from 2011 to 2018 (study group)
89348915|NCT03883282||control group|- Patients who have never participated in RCT
89348916|NCT03756025|Experimental|Vitro Molar® (DFL, Rio de Janeiro, Brazil)|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Vitro Molar® (DFL, Rio de Janeiro, Brazil).
89348917|NCT03756025|Active Comparator|Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).
89348918|NCT04202757|Active Comparator|Young Fresh Frozen Plasma (yFFP)|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors
89348919|NCT04202757|Placebo Comparator|Saline|0.1% riboflavin in normal saline
89348920|NCT03316170|Experimental|Social Support + NRT Sampling|"The treatment group will receive:~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~a written directory of a range of social support resources delivered via mail,~a brief phone consult (10-15 minutes via phone) germane to smoking cessation,~a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and~a free, 2-week supply of nicotine patches and lozenges delivered via mail."
89348921|NCT03316170|Active Comparator|Social Support|"The control group will receive:~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~a written directory of a range of social support resources delivered via mail,"
89348922|NCT03395548|Active Comparator|Inflammatory bowel disease|"The aim is to recruit 20 persons suffering from Crohn's disease or ulcerative colitis with stable medication and stable control of the disease.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
89348923|NCT03395548|Active Comparator|Irritable bowel syndrome|"The aim is to recruit 20 persons suffering from irritable bowel syndrome (IBS) fulfilling rome criteria.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
89348924|NCT03395548|Active Comparator|Healthy|"The aim is to recruit 20 persons without known illnesses with a comparable age to the other two groups.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
89348925|NCT03753451|No Intervention|Group 1|20 patients without periodontal disease and coronary artery disease
89348926|NCT03753451|No Intervention|Group 2|20 patients without periodontal disease and with coronary artery disease
89348927|NCT03753451|Active Comparator|Group 3|20 patients with periodontal disease and with coronary artery disease received treatment of periodontal disease
89348928|NCT03753451|Active Comparator|Group 4|20 patients with periodontal disease and without coronary artery disease received treatment of periodontal disease
89348929|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 1|IV injection, 0.27 mg/kg
89348930|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 2|IV injection, 0.54 mg/kg
89348931|NCT03638388|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
89348932|NCT03638388|Active Comparator|Dry Needling with Intramuscular electrical stimulation (DNES)|"Subjects will receive dry needling treatment with electrical stimulation, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
89348933|NCT03755947|Experimental|IGV|"Cytoreduction 3 cycles (I) Ibrutinib, [Imbruvica, Janssen]~Induction 6 cycles (G) Obinutuzumab, [Gazyva, Roche]~Consolidation 12 cycles (V) Venetoclax, [Venclexta, Abbvie]."
89348934|NCT03395470|Experimental|Group A1|Dose 1 or placebo
89348935|NCT03395470|Experimental|Group A2|Dose 2 or placebo
89348936|NCT03395470|Experimental|Group A3|Dose 3 or placebo
89348937|NCT03395470|Experimental|Group A4|Dose 4 or placebo
89348938|NCT03395470|Experimental|Group A5|Dose 5 or placebo
89348939|NCT03395470|Experimental|Group B|Dose + Rosuvastatin
89348940|NCT03257865|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
89348941|NCT03257865|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind
89348942|NCT04620330|Experimental|Arm 1: avutometinib (VS-6766) monotherapy|in patients with NSCLC KRAS-G12V tumor
89348943|NCT04620330|Experimental|Arm 2: avutometinib (VS-6766) in combination with defactinib|in patients with a NSCLC KRAS-G12V tumor
89348944|NCT04620330|Experimental|Arm 3: avutometinib (VS-6766) in combination with defactinib|in patients with a NSCLC KRAS-other (non-G12V) tumor
89348945|NCT04620330|Experimental|Arm 4: avutometinib (VS-6766) in combination with defactinib|in patients with a NSCLC BRAF-V600E tumor
89348946|NCT04620330|Experimental|Arm 5:avutometinib (VS-6766) in combination with defactinib|in patients with a NSCLC BRAF-non-V600E tumor
89348947|NCT04104412|Experimental|treatment group A （with mesenchymal stem cell intervention）|observe the effectiveness and safety of patients by injecting human umbilical cord mesenchymal stem cells(2*10^7/ml normal saline) and Low temperature plasma vaporization ablation
89348948|NCT04104412|No Intervention|control group B|observe the effectiveness and safety of patients by injecting normal saline and Low temperature plasma vaporization ablation
89348949|NCT03399058|Other|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
89348950|NCT03399058|Other|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2). The Hearth messages are contextualized messages on child feeding practices that women in the community have found helpful to successfully prevent child malnutrition. This program will be delivered through in person community meetings.
89348951|NCT03399058|Other|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a similar program as group 2 with contextualized child feeding messages (PDH lite program) and receive follow-up through mobile support phone calls (Group 3).
89348952|NCT03395158||Prior alert criteria|Patients who activated full, limited or no alert criteria according to the prior alert criteria
89348953|NCT03395158||Present alert criteria|Patients who activated full, limited or no alert criteria according to the present alert criteria
89348954|NCT04848727||Atelectasis or Pneumothorax|Infants with asymmetric lung disease (i.e. atelectasis or pneumothorax) confirmed by chest radiograph
89348955|NCT01686906|Experimental|Bowman layer graft implantation|
89348956|NCT04617847|Experimental|WVE-120101 (Dose A)|
89348957|NCT04615507|Experimental|Test/Control/Control|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Test/Control/Control)
89348958|NCT04615507|Experimental|Control/Test/Test|Eligible subjects that are habitual soft contact lens wearers will be randomized to lens wear sequence, (Control/Test/Test)
89348959|NCT03753295||Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
89348960|NCT03753295||Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
89348961|NCT03753295||Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
89348962|NCT04120233|Placebo Comparator|Placebo|Participants will receive placebo.
89348963|NCT04120233|Experimental|Dose 1|Participants will receive 10 mg of MW151.
89348964|NCT04120233|Experimental|Dose 2|Participants will receive 20mg of MW151.
89348965|NCT04120233|Experimental|Dose 3|Participants will receive 40mg of MW151.
89348966|NCT04120233|Experimental|Dose 4|Participants will receive 80mg of MW151.
89348967|NCT04120233|Experimental|Dose 5|Participants will receive 160mg of MW151.
89348968|NCT01610700|Experimental|GW-1000-02|Active treatment
89348969|NCT01610700|Placebo Comparator|Placebo|Control
89348970|NCT03753217|Experimental|qCON Monitor|Simultaneous measurement of BIS and qCON
89348971|NCT03755869|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
89348972|NCT04595851|Other|Pharmacist Coordinated care Oncology Model (PCOM)|The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and primary care pharmacists.
89348973|NCT04632459|Experimental|pembrolizumab plus ramucirumab|"Ramucirumab 8mg/kg on q2W~Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles"
89348974|NCT04663932|Placebo Comparator|immediate stenting group|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
89348975|NCT04663932|Experimental|deferred stenting group|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
89348976|NCT03256851|Active Comparator|In-Person Delivered Exercise|"Participants in the in-person training group will:~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~complete one of their prescribed training sessions (lasting 1 hour total) each week with a physical therapist or trained member of the research team. Training sessions will focus on progression of aerobic and strength training exercises."
89348977|NCT03256851|Experimental|Telephone-Delivered Exercise|"Participants in the telephone-delivered training group will:~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~receive a 60-minute, 1x/week telephone call from a trained research team member. Participants will report their progress from the prior week, discuss/troubleshoot any issues or problems, and receive progressions of both aerobic and strength training exercises for the upcoming week."
89348978|NCT03757663|Experimental|UV Dosimeter|UV Dosimeter will measure participants' UV exposure for two separate 3-week periods.
89348979|NCT03393078|Active Comparator|Real Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
89348980|NCT03393078|Sham Comparator|Sham Stimulation|The procedure of this protocol was performed by a placebo coil, lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT). No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
89348981|NCT04837807|Experimental|Unit Dose First, Then Multi-Dose|Subjects randomized to this group will apply the unit-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
88807278|NCT01657032|Experimental|Lactobacillus GG and Smectite|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~smectite, dose 3 g, once daily orally until diarrhea stopped"
89348982|NCT04837807|Experimental|Multi Dose, Then Unit Dose|Subjects randomized to this group will apply multi-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
89348983|NCT04103931|No Intervention|Usual Care|Participants will receive usual care and will not get the decision aid to review.
89348984|NCT04103931|Experimental|Patient Decision Aid|"Participants in this arm will receive the patient decision aid, titled Treatment Choices for Aortic Stenosis to review."
89348985|NCT03974022|Experimental|Part A Dose escalation|
89348986|NCT03974022|Experimental|Part A Dose expansion cohort 1|
89348987|NCT03974022|Experimental|Part A Dose expansion cohort 2|
89348988|NCT03974022|Experimental|Part A Dose expansion cohort 3|Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
89348989|NCT03974022|Experimental|Part A Dose expansion cohort 4 (Ongoing)|Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy
89348990|NCT03974022|Experimental|Part A Dose expansion cohort 5 (Ongoing)|Patients with EGFR Exon20ins, treatment naïve
89348991|NCT03974022|Experimental|Part A Dose expansion cohort 6|
89348992|NCT03974022|Experimental|Part B Dose extension (Ongoing)|Patients with EGFR Exon20ins should have received at least 1 line, but no more than 3 lines of systemic therapy for metastatic/locally advanced disease.
89348993|NCT03985371|Experimental|Drops Used|
89348994|NCT03753139||Atrial fibrillation|Patients with atrial fibrillation as recorded by Holter
89348995|NCT03753139||Sinus rhythm|Patients with sinus rhythm as recorded by Holter
89348996|NCT04111965|Experimental|Nanodrop® (PRO-176)|- Nanodrop®. 0.6% propylene glycol. Ophthalmic emulsion Laboratorios Sophia, S.A. from C.V. Route of administration: Ophthalmic.
89348997|NCT04111965|Active Comparator|Systane® Balance|"Systane® Balance. 0.6% propylene glycol. Ophthalmic emulsion Alcon Laboratories, Inc.~Route of administration: Ophthalmic."
89348998|NCT03753061|Experimental|Aspiration Catheter|Mechanical thrombectomy with Aspiration Catheter.
89348999|NCT03753061|Active Comparator|Stent Retriever (Solitaire FR)|Mechanical thrombectomy with Solitaire FR.
89349000|NCT03316872|Experimental|Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)|"Pembrolizumab, intravenously, at a dose of 200 mg, once every 3 weeks~SBRT starting Day 2 of Cycle 1 of pembrolizumab treatment, given in 5 fractions over 10-15 days."
89349001|NCT03256695|Experimental|ABS eMDPI|Participants will receive 90 micrograms (mcg) of albuterol sulfate (ABS) via eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks. ABS eMDPI is a rescue/reliever agent that includes an eModule on top of the approved PROAIR RESPICLICK® inhaler. Participants will be allowed to continue use of other COPD and non-COPD medications as advised by their physician without changes unless deemed necessary by their physician.
89349002|NCT03752983||cases|patients with SLE
89349003|NCT03752983||controls|Healthy people
89349004|NCT04623684|Experimental|Study Group|Mydriasis with microdrops
89349005|NCT04623684|Active Comparator|Control Group|Mydriasis with standard drops
89349006|NCT03757507|Experimental|Optoacoustic imaging|Optoacoustic Imaging before and after tracer administration
89349007|NCT03305016|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
89349008|NCT03808311|Experimental|Intensive BP treatment arm|Participants in the intensive BP treatment arm will be treated to a systolic BP target of <120 mmHg.
89349009|NCT03808311|Other|Standard BP treatment arm|Participants in the standard BP treatment arm will be treated to a systolic BP target of <140 mmHg.
89349010|NCT03752905|Experimental|PTR-01 0.1 mg/kg|Three intravenous infusions of PTR-01 at 0.1 mg/kg with doses 2 weeks apart.
89349011|NCT03752905|Experimental|PTR-01 0.3 mg/kg|Three intravenous infusions of PTR-01 at 0.3 mg/kg with doses 2 weeks apart.
89349012|NCT03752905|Experimental|PTR-01 1.0 mg/kg|Three intravenous infusions of PTR-01 at 1.0 mg/kg with doses 2 weeks apart.
89349013|NCT03752905|Placebo Comparator|Normal Saline|Saline control to mimic PTR-01.
89349014|NCT03752905|Experimental|PTR-01 3.0 mg/kg|Three intravenous infusions of PTR-01 at 3.0 mg/kg with doses 2 weeks apart.
89349015|NCT03297021|Placebo Comparator|Ondansetron 4mg Pre-emergence|
89349016|NCT03297021|Experimental|Ondansetron 8mg Pre-emergence|
89349017|NCT03297021|Experimental|Ondansetron Pre-Incision and Pre-emergence|4mg Ondansetron Pre-Incision and 4mg Ondansetron Pre-emergence
89349018|NCT03755635|No Intervention|Standard of care|Continuously monitoring of neonatal sepsis under standard of care at one site
89349019|NCT03755635|Experimental|Hand hygiene|The WHO multimodal hand hygiene strategy is implemented at one site
89349020|NCT02312193||Case|Hypertensive subjects
89349021|NCT02312193||Control|Normotensive subjects
89349022|NCT04820491|Active Comparator|X-Ray|
89349023|NCT04820491|Active Comparator|Ultrasound|
89349024|NCT03752749|Experimental|Prednisolone + Acute Intermittent Hypoxia|
89349025|NCT03752749|Placebo Comparator|Placebo + Acute Intermittent Hypoxia|
89349026|NCT01988571|Active Comparator|Arm 1 - Atorvastatin|One 40 mg Atorvastatin tablet each morning by mouth for 24 months
89349027|NCT01988571|Placebo Comparator|Arm 2 - Placebo|One placebo tablet each morning by mouth for 24 months.
89349028|NCT04794751|Experimental|senofilcon A C3/delefilcon A/delefilcon A|Subjects randomized to this arm will wear the senofilcon A C3 lens during period 1 and the delefilcon A lens during period 2 and period 3
89349029|NCT04794751|Experimental|delefilcon A /senofilcon A C3/senofilcon A C3|Subjects randomized to this arm will wear the delefilcon A lens during period 1 and the senofilcon A C3 lens during period 2 and period 3
89349030|NCT04578457|Active Comparator|Hearing Aid without NR(0) enabled|Hearing Aid without Noise Reduction (NR 0) enabled serves as reference condition.
89349031|NCT04578457|Experimental|Hearing Aid with NR (1)|Hearing Aid with Noise Reduction I (NR) enabled.
89349032|NCT04578457|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
89349033|NCT04578457|Experimental|Hearing Aid with NR(3)|Hearing Aid with Noise Reduction III (NR) enabled.
89349034|NCT04673331||Cystic fibrosis|"Inclusion Criteria:~Having been diagnosed with cystic fibrosis Being over 18 years old The clinical condition is stable Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis~Exclusion Criteria:~Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy"
89349035|NCT04673331||Healthy individuals|"Inclusion Criteria:~Being over 18 years old Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis~Exclusion Criteria:~Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy"
89349036|NCT03334188|Other|Control|Patients will receive care-as-usual. The only study procedures patients will be exposed to will be a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment.This arm will include 'No Intervention--Usual Care'.
89349037|NCT03334188|Active Comparator|Intervention|Patients will receive the patient engagement video and HFrEF medication checklist by email one week prior to their next clinic appointment after enrollment. Patients in the intervention arm will also receive a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment. This arm will include the 'Intervention :Behavioral: Patient engagement materials.'
89349038|NCT04374669||patients with lumbar spinal stenosis|Patients with lumbar spinal stenosis will be scheduled for neuroplasty.
89349039|NCT05460403||Surgery alone|patients without adjuvant radiotherapy after R0 resection.
89349040|NCT05460403||Adjuvant Radiotherapy|patients treated with adjuvant radiotherapy after R0 resection.
89349041|NCT01325805|Experimental|Structured Weight Loss|Women randomized to this arm will meet with a registered dietician regularly for review of calorie recommendations and food diary. As well as regular clinic visits to measure patients weight.
89349042|NCT01325805|Active Comparator|Routine Weight Loss Counseling|Patients are counseled by a physicians about the impact of maternal weight on fertility and pregnancy outcomes.
89349043|NCT03752671|Experimental|the IntraSPINE® device associated with discectomy|
89349044|NCT03752671|Active Comparator|discectomy alone|
89349045|NCT03333876|Active Comparator|Nasal Dilator|Nasal dilators have been used to treat snoring and sleep apnea. Many studies focus on external nasal dilators like Breathe Right Strips. These interventions largely were not effective in treating OSA. However, there is some evidence to suggest internal to the nose dilators (like Mute) may work to reduce snoring
89349046|NCT03333876|Active Comparator|Mandibular Advancement|Mandibular advancement devices have shown to be effective, but not necessarily acceptable to primary snorers.
89349047|NCT03333876|Active Comparator|Positional Therapy|Studies have shown mixed results for positional therapy as a whole. Braver and Block reported that foam wedges used to keep patients in a lateral position were not effective in reducing snoring in 20 individuals.
89349048|NCT03755557|Placebo Comparator|Placebo|Application of a placebo nasal spray once daily for 8 days Nasal Sprays
89349049|NCT03755557|Active Comparator|Rhinocort|"Nasal Sprays Application of Rhinocort Aqua 64 micrograms, nasal spray once daily for 8 days. Daily dosage 256 µg/d"
89349050|NCT03755557|Experimental|Budesolv|Application of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays
89349051|NCT03511599|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
89349052|NCT03511599|Active Comparator|Placebo|Participants will ingest a capsule identical to the study medication, however this capsule will contain a placebo.Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
89349053|NCT03294681||Cochlear Implant Recipients|
89349054|NCT04822818|Experimental|Bevacizumab + SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
89349055|NCT04822818|Active Comparator|SOC|SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
89349056|NCT01140867|Experimental|1|
89349057|NCT04572997|Experimental|Full analysis set (FAS)|The full analysis set (FAS) consisted of all patients who received at least one dose of study drug.
89349058|NCT02943096|Active Comparator|Flavanol|Blinded treatment with either CocoaVia 500mg or placebo.
89349059|NCT02943096|Placebo Comparator|Placebo|Blinded treatment with either CocoaVia 500mg or placebo.
89349060|NCT04571515|Experimental|MR-107A-01 15 mg once in a 24-hour period|Oral tablet one day of dosing
89349061|NCT04571515|Experimental|MR-107A-01 10 mg once in a 24-hour period|Oral tablet one day of dosing
89349062|NCT04571515|Experimental|MR-107A-01 15 mg twice in a 24-hour period|Oral tablet one day of dosing
89349063|NCT04571515|Experimental|MR-107A-01 10 mg twice in a 24-hour period|Oral tablet one day of dosing
89349064|NCT04571515|Placebo Comparator|Placebo twice in a 24-hour period|Placebo tablet one day of dosing
89349065|NCT03292653|Placebo Comparator|Placebo|Participants were randomized to matching placebo to sotagliflozin administered as two tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
89349066|NCT03292653|Experimental|Sotagliflozin 200 mg|Participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
89349067|NCT03292653|Experimental|Sotagliflozin 400 mg|Participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
89349068|NCT03858634|Experimental|KPL-716|Weekly for 8 weeks
89349069|NCT03858634|Placebo Comparator|Placebo|Weekly for 8 weeks
89349070|NCT03752593||Obese|Patients with a BMI of greater than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
89349071|NCT03752593||Non-Obese|Patients with a BMI of less than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
89349072|NCT02891070|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative
89349073|NCT02891070|Active Comparator|DuraSeal Dural Sealant|DuraSeal Dural Sealant, single use treatment, intraoperative
89349074|NCT05399953|Active Comparator|Control Group|Participants in the control group will receive usual care ( standard physical therapy program)
89349075|NCT05399953|Experimental|Intervention Group|Particiapnts in intervevention group will receive both usual care and myofascial release techniques
89349076|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
89349077|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
89349078|NCT03255291|Experimental|Risk Display Format:Table:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
89349079|NCT03255291|Experimental|Risk Display Format:Table: Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
89349080|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
89349081|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
89349082|NCT00381381|Experimental|1|
89349083|NCT03637335|Experimental|irradiation + carboplatin|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
89349084|NCT03637335|Placebo Comparator|irradiation + placebo|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation
89349085|NCT03637257|Experimental|Nasal cannula / Guedel|Record of capnography using a standard nasal cannula followed by use of a modified Guedel airway
89349086|NCT03637257|Experimental|Guedel / nasal cannula|Record of capnography using a modified Guedel airway followed by use of a standard nasal cannula
89349087|NCT04670991|Other|EXATRAC imaging|For each radiotherapy session, patient will first have an Exatrac imaging and then a CBCT imaging. Patient's repositionning will be performed accoding to CBCT data
89349088|NCT02939937|Experimental|phenytoin|patients received phenytoin 100mg three time daily up to 3 months
89349089|NCT02939937|Experimental|placebo|patients received placebo 100 mg three time daily for 3 months
89349090|NCT02939079|Experimental|Fingolimod and Fish Oil|Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year.
89349091|NCT02939079|Active Comparator|Fingolimod and Placebo|Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year.
89349092|NCT04562155|Experimental|BAY1817080 dose A BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
89349093|NCT04562155|Experimental|BAY1817080 dose B BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
89349094|NCT04562155|Experimental|BAY1817080 dose C BID|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
89349095|NCT04562155|Placebo Comparator|Placebo|Each participant will be randomized to receive one of three oral doses of BAY 1817080 or placebo, administered twice daily over the course of 12 weeks.
88807279|NCT01657032|Placebo Comparator|Lactobacillus GG and Placebo|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~placebo (glucose), dose 3 g, once daily orally until diarrhea stopped"
88807280|NCT05202912|Other|Cohort A(Food effect)|
89349096|NCT03313050|Experimental|Stage 1 multivalent (ages 50-64 years)|multivalent
89349097|NCT03313050|Active Comparator|Stage 1 Tdap (ages 50-64 years)|Tdap
89349098|NCT03313050|Experimental|Stage 2 multivalent (ages 65-85 years)|multivalent
89349099|NCT03313050|Active Comparator|Stage 2 polysaccharide (ages 65-85 years)|polysaccharide
89349100|NCT02774265|Active Comparator|VTE prophylaxis with Enoxaparin 30mg BID|The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
89349101|NCT02774265|Active Comparator|VTE prophylaxis with Aspirin 81mg BID|The group receiving VTE prophylaxis with ASA 81mg PO BID
89349102|NCT04595058|Active Comparator|EUSDB-LAMS|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stent . Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.~EUSDB-LAMS (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent)"
89349103|NCT04595058|Experimental|EUSDB-LAMS-Pigtail|"Endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stents without coaxial plastic stent. Formal indication on biliopancreatic drainage according to the instruction forms of the manufacturer.~In this arm, a double pigtail through the lumen apposing metal stent will be inserted as an axis-orienting stent.~EUSDB-LAMS-Pigtial (Endoscopic ultrasound guided biliary drainage with lumen-apposing metal stent (LAMS) and axis-orienting double-pigtail plastic stent through LAMS)"
89349104|NCT04755595|Experimental|Facial aesthetic treatment|Study participants will receive all three injectables: Botox Cosmetic (onabotulinumtoxinA), Juvéderm Voluma XC (hyaluronic acid gel filler), and Juvéderm Volbella XC (hyaluronic acid gel filler) during a single procedure, with an optional touch-up treatment at 2 weeks.
89349105|NCT02697279|Active Comparator|Traditional Incision and Drainage|Treatment of a simple cutaneous abscess with traditional incision and drainage with or without packing, decision made at the discretion of the provider.
89349106|NCT02697279|Experimental|Loop drainage|Treatment of a simple cutaneous abscess with incision and drainage using the loop drainage technique.
89349107|NCT03755479||Single Arm Group|Patient on multiple daily injections will start Hybrid Closed Loop System Insulin Pump Minimed 670G
89349108|NCT05179473||Acute stroke patients|12 weekly evaluations starting within the first week post-stroke. Follow-up assessment at week 16. MRI at week 6.
89349109|NCT04447144||COVID-19 mild severity|"Definition of mild cases according to MOH:~Age < 60~Temperature <38.5~arterial oxygen saturation (SaO2) >92%~Heart Rate <110~Respiratory Rate <25 /min.~Neutrophil / lymphocyte ratio on complete blood count (CBC) < 3.1~No co-morbidities that necessitates hospital admission: Pregnancy, severe uncontrolled Diabetes, Chronic lung disease, Chronic kidney disease, Chronic liver disease, Serious heart diseases (arrythmia, Ischemic heart disease, uncontrolled hypertension), immunocompromised: prolonged use of corticosteroids and other immunosuppressive drugs/ organ transplantation/ HIV/ Immunodeficiency, Obesity (BMI > 40)"
89349110|NCT04447144||COVID-19 moderate severity|Any patient not fulfilling the above mild criteria is considered having moderate disease as well as any positive pulmonary imaging findings
89349111|NCT02616705||IgG4-related sclerosing cholangitis|Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)
88807281|NCT05202912|Other|Cohort B(Single dose)|
88807282|NCT05292456||RA, SLE, and vasculitis patients who have just started glucocorticoid treatment|
88807283|NCT05292456||RA, SLE and vasculitis patients receiving glucocorticoid treatment for the last 2 years|
88807284|NCT05250648|Active Comparator|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|
88807285|NCT05250648|Experimental|complete cytoreductive surgery without HIPEC|
88807286|NCT00382148|Experimental|1|
88807287|NCT02111252|Experimental|TAK-850 0.5 mL|A single dose of 0.5 mL TAK-850 (15 µg of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle.
88807288|NCT05292066|Other|Duloxetine Group|Oral intake Duloxetine tablets, 30mg/day for 12 weeks.
88807289|NCT05292066|Other|Pregabalin Group|Oral intake of Pregabalin tablets, 75 mg/day for 12 weeks.
88807290|NCT04270994|Experimental|Misoprostol|
89349112|NCT02616705||Controls|cholangiocarcinoma, PSC, and other patients with biliary strictures
89349113|NCT01322659|Active Comparator|Helmet NPPV|Weaning from mechanical ventilation with noninvasive positive pressure ventilation (NPPV)delivered by means of the helmet
89349114|NCT01322659|Sham Comparator|ETT IMV|Weaning from mechanical ventilation with standard invasive mechanical ventilation (IMV) delivered by means of the endotracheal tube (ETT)
89349115|NCT05239390|Experimental|SCI -110|SCI -110 (Previously known as THX-110): a combination of THC (Doses: 2.5 mg - 12.5 mg per daily dose) and PEA (Dose: 800 mg per daily dose), administered together as separate pills, orally, twice daily (morning and evening - except for the initial titration dose, of 2.5 mg THC+800 mg PEA given once a day, in the morning.
89349116|NCT03752437|Experimental|Real Weight|Injection of 300 IU of heparin based on REAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
89349117|NCT03752437|Experimental|Ideal Weight|Injection of 300 IU of heparin based on IDEAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
89349118|NCT05239312||Patients with prosthetic joint infection|
89349119|NCT03757273|Experimental|FFF with CAD/CAM customized cutting guide|Mandibular reconstruction using free fibular flap with CAD/CAM customized osteotomy guide.
89349120|NCT03757273|Active Comparator|FFF without customized cutting guide|Mandibular reconstruction using free fibular flap without customized osteotomy guide. CAD/CAM 3D model for mandible will be used.
89349121|NCT04749745|Active Comparator|L-Theanine|Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
89349122|NCT04749745|Placebo Comparator|Placebo|Subject will receive 400mg single dose of matching Placebo, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
89349123|NCT03257436|Other|Single Arm|General population who receive a Boston Scientific Resonate family of CRT-D device in accordance with its labeled indication for use.
88807291|NCT05495490|Experimental|Osseodensification Internal Sinus Lift / Sticky Bone graft material|Osseodensification Internal Sinus Lift will be performed using sticky bone as a graft material.
89349124|NCT04748341|Active Comparator|Traditional Group|Group A will be taught through the two steps traditional method (2 lectures/week + 1 skill lab/week). First, learn through didactic Lectures and then practice skills on the Mannequins. The educational lecture content will be the same for both groups.
89349125|NCT04748341|Experimental|Pedagogical Group|Group B will learn through the 5-step method [ 2 lectures/week + video + 2skill lab/week (1 session under instructor + 1 session for skill maintenance)], learn skill, see the video on resuscitation, practice on simulator, prove through practice, observe skill on clinical rotation and lastly maintain it through clinical supplemented with simulation.
89349126|NCT01328002|Experimental|Milnacipran|oral administration, twice daily dosing
89349127|NCT01328002|Placebo Comparator|Placebo|oral administration, twice daily dosing
89349128|NCT02086578|Experimental|Group 1|Physical examination by MD, optional Breast MRI, Breast-Q© at baseline (after permanent implant exchange, physical exam and Breast-Q© may be done after the initiation of IMRT), 12 ± 2 months and 24 ± 2 months post- IMRT. Total length of the follow-up time will be 24 ± 2 months post-IMRT. A subset of 10 left-sided patients will receive 13N-NH3 PET scans within the radiation simulation session. A CT for coronary calcium scoring and a low-dose CT for attenuation correction will also be obtained at this time. Myocardial blood flow will be measured during rest and at peak stress with 13N-NH3 as a perfusion tracer. A follow-up 13N-NH3 PET study with low-dose CT for attenuation correction will be obtained 12-18 months (± 6 months) post-IMRT.
89349129|NCT02086578|Experimental|Group 2|Physical examination by MD, optional Breast MRI, Breast-Q © at baseline (after permanent implant exchange and after IMRT), 18 ± 2 months and 30 ± 2 months post-IMRT, as these patients will undergo exchange of the temporary expander for the permanent implant approximately 4-8 months following the completion of radiation (at the discretion of the treating plastic surgeon). Total length of the follow-up time will be 30 ± 2 months post-IMRT
89349130|NCT05239078|Active Comparator|Inferior Alveolar nerve block with 2% lidocaine with epinephrine|An inferior alveolar nerve block was given with 2% lidocaine with epinephrine
89349131|NCT05239078|Experimental|Inferior Alveolar nerve block with 4% articaine with epinephrine|An inferior alveolar nerve block was given with 4% articaine with epinephrine
89349132|NCT05239078|Experimental|Inferior Alveolar nerve block with 3% plain mepivacaine|An inferior alveolar nerve block was given with 3% plain mepivacaine
89349133|NCT05238610||Experimental: intervention group|"This group will receive PFO-closure and standard antiplatelet treatment PFO-closure will be performed after 3-6 months of observation and monitoring for paroxysmal atrial fibrillation Standard antiplatelet treatment will be prescribed - aspirin 100mg and clopidogrel 75mg, once daily, principally. However, the final decision of antiplatelet treatment will be made by the physician. If paroxysmal atrial fibrillation is detected, anticoagulation will be considered.~Intervention : PFO closure Drug: aspirin 100mg/day Drug: clopidogrel 75mg/day"
89349134|NCT05238610||Active comparator: control group|"This group will receive standard antiplatelet treatment only Dual antiplatelet treatment with Aspirin 100mg and Clopidogrel 75mg, once daily, or single antiplatelet treatment with those agents can be considered. If paroxysmal atrial fibrillation is detected, anticoagulation will be considered.~Drug: aspirin 100mg/day Drug: clopidogrel 75mg/day"
88807292|NCT05495490|Active Comparator|Osteotome Internal Sinus Lift /Sticky Bone graft material|Osteotome Internal Sinus Lift will be performed using sticky bone as a graft material.
88807293|NCT05291832|Experimental|Brain.fm Music|Music with rhythmic amplitude modulation designed to drive neural oscillations.
88807294|NCT05291832|Active Comparator|Spectrally-matched Noise|Noise shaped to have the same frequency spectrum (i.e., input level across the cochlea) as the Music condition.
89349135|NCT02579265|Experimental|Smoflipid 20%|"Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
89349136|NCT02579265|Active Comparator|Intralipid® 20%|"Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
89349137|NCT03752359|Experimental|whey protein group|Participants received a dose of 35 grams of whey protein after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
89349138|NCT03752359|Placebo Comparator|placebo group|Participants received a dose of 35 grams of maltodextrin after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
89349139|NCT05238220||continue valganciclovir prophylaxis|continue valganciclovir prophylaxis for up to 12 months total when anti-CMV immunity absent
89349140|NCT05238220||discontinue valganciclovir prophylaxis|discontinue valganciclovir prophylaxis when anti-CMV immunity present after routine care prophylaxis
89349141|NCT04446598|Experimental|Laser group|In the laser group, the patients received two sessions of Er:YAG intraurethral laser in non-ablative SMOOTH™ mode, with 1 month interval between sessions.
89349142|NCT04446598|Active Comparator|Tadalafil group|The tadalafil group was treated with daily oral administration of tadalafil, at a dose of 5 mg/day, which lasted consecutively for two months.
89349143|NCT01322737|Experimental|SUMO Tissue Access and Resection System|
89349144|NCT03391804|Experimental|ALLN-177|ALLN-177 7,500 units (2 capsules)
89349145|NCT05572593|Experimental|Guided Group|Subjects treating physician will receive PGx results to facilitate clinical decisions
89349146|NCT05572593|Active Comparator|Unguided Group|Subjects treating physician will be blinded to PGx results and will receive standard medical care
89349147|NCT03757195|Experimental|augmentation by xenograft|xenograft mixed with plasma extracted from blood
89349148|NCT03391726|Experimental|Arm 1|CART-19 cells treat
89349149|NCT04469907|Experimental|Treatment - AZD9977|There are 4 cohorts in this arm based on renal function (mild, moderate, severe, and normal). Each cohort will have 8 participants.
89349150|NCT03391648||Cesarean|
89349151|NCT03391570|Active Comparator|COX-2 inhibitor (Celecoxib)|Celebrex; COX-2 inhibitor
89349152|NCT03391570|Placebo Comparator|Placebo drug (Ramnos)|Ramnos; Lactobacillus casei variety rhamnosus
89349153|NCT03752281||Health and activity|The cohort consists of long-term social assistance recipients where there is need to investigate the health status and working ability.
89349154|NCT03755089|Active Comparator|Oral Phenazopyridine|Patients randomized to the oral phenzopyridine arm will receive 200mg phenazopyridine to take by mouth 1-2 hours before their scheduled procedure.
89349155|NCT03755089|Active Comparator|Intravesical Lidocaine|Patients randomized to the intravesical lidocaine arm will have the bladder back-filled with 30mL 2% lidocaine for the 20 minutes immediately preceding their procedure.
89349156|NCT03391492||influenza group|All consecutive patients older than 18 years ,admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
89349157|NCT03391492||control group|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza,
89349158|NCT03391414|Experimental|hypertonic bicarbonate|subjects will be administered a solution of 8.4% hypertonic bicarbonate by nebulizer
89349159|NCT03391414|Active Comparator|hypertonic saline|subjects will be administered a solution of 7% sodium chloride by nebulizer
89349160|NCT03757117|Experimental|Intervention|Feminizing hormone therapy and peer navigation
89349161|NCT03752125|Experimental|Flavonoid, caffeine|Flavonoid, caffeine capsules
89349162|NCT03752125|Placebo Comparator|Placebo|Placebo capsules
89349163|NCT03398980||survivors treated with CRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with convention radiotherapy (CRT).
89349164|NCT03398980||survivors treated with IMRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with intensity-modulated radiotherapy (IMRT).
89349165|NCT03289533|Experimental|Experimental 1|Avelumab (MSB0010718C) in combination with axitinib (AG-013736)
89349166|NCT04727749|Experimental|Therapy Dog Team Visit|Patient interacts with the therapy dog and handler.
89349167|NCT04727749|No Intervention|No Therapy Dog Team Visit|No patient interaction with the therapy dog or handler.
89349168|NCT03391258|Experimental|Bone Regeneration with GLAM technique|At the beginning of each surgery, a venipuncture will be performed, to obtain the L-PRF membranes. Also, two white topped tubes will be centrifuged for 3 minutes to obtain PRP. After implant placement, achieving a primary stability of at least 45 Ncm, the stiff bone-block (L-PRF membranes and PRP combined with bovine xenograft) will be used in the buccal plate of the pre-maxilla, to enhance bone volume in the esthetic area.
89349169|NCT03391180|Experimental|ICON Remineralization|Firstly, Conditioning of the WSL surface by 15% HCL gel (Icon-Etch, DNG) and subsequent application of the drying solution (Icon-Dry, DMG), Numbers of additional etching intervals have been determined by visual assessment after each of the etch/dry intervals to achieve individual, customized intensities of WSL surface conditioning.
89349170|NCT03391180|Active Comparator|CPP-ACPF|Participants in group 2 (CPP-ACPF) were treated with applying a pea sized amount of ACC-ACPF plus on a gloved finger of the examiner and rubbed the surface of the labial tooth for 4 minutes with advising the patient to avoid drinking and eating for the next 30 minutes of application.
89349171|NCT04553107|Experimental|Deprescribing Intervention|
89349172|NCT04553107|Active Comparator|Usual Care|
89349173|NCT03395002|Experimental|Tiotropium/Salmeterol/Fluticasone|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Discair®
89349174|NCT03395002|Active Comparator|Tiotropium + Salmeterol/Fluticasone|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® + Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus®
89349175|NCT05460091|Sham Comparator|Control Group|Control group - sham Ptech device(does not vibrate)
89349176|NCT05460091|Active Comparator|Test group|Test group - active Ptech device (High-Frequency Vibrational device)
89349177|NCT05238064|Experimental|PI3Kδ inhibitor Parsaclisib plus CHOP|"Phase Ib (Explored the appropriate dose of Parsaclisib in combination with CHOP)~Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day.~CHOP was given at the standard dose, 21 days per cycle~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib day 1-14 of each cycle, as well as CHOP at standard dose for 6 cycles.~Maintain treatment: Parsaclisib maintenance (2.5mg po, qd) will be performed on CR or PR patients after 6 cycles of induction therapy until disease progression, death, unacceptable toxicity, withdrawal of informed consent, or the investigator's decision or initiation of new antitumor therapy. The maximum maintenance period of parsaclisib is 24 months."
89349178|NCT05009368|Experimental|Arm A - Sequence AC|Treatment A in Period 1 and Treatment C in Period 2
89349179|NCT05009368|Experimental|Arm B - Sequence BC|Treatment B in Period 1 and Treatment C in Period 2
89349180|NCT03751891|Experimental|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
89349181|NCT03751891|Active Comparator|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_A which will be fitted to the participants individual Hearing loss.
89349182|NCT03751891|Active Comparator|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_B which will be fitted to the participants individual Hearing loss.
89349183|NCT03755011|Experimental|patients exposed to white noise|Six patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined; pausing will be at nurse, provider, and patient discretion during routine care and conversations with the patients.
89349184|NCT03755011|Placebo Comparator|usual care|Six patients exposed to normal ICU activity noise.
89349185|NCT03391024|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
89349186|NCT04547023|Experimental|Fasting before gestational diabetes screen|Fasting for at least 6 hours prior to the 1-hour gestational diabetes screen.
89349187|NCT04547023|Active Comparator|Fed before gestational diabetes screen|Liberal per oral intake within 2 hours of the 1-hour gestational diabetes screen.
89349188|NCT03398746|Experimental|LOOP Technique|Placement of subcutaneous loop drain
89349189|NCT03398746|Active Comparator|Incision and Drainage|Standard Incision and Drainage Technique
89349190|NCT03390946|Experimental|four-drug interval-compressed regimen|"Interventions for 'four-drug interval-compressed regimen': Drug: methotrexate, cisplatin, doxorubicin, ifosfamide.~Newly diagnosed oseteosarcoma patients under 40 years are eligible. Neoadjuvant chemotherapy with four drugs in an interval-compressed schedule will be done as a single arm.~Duration of neoadjuvant chemotherapy will be 10 weeks like that of conventional three-drug regimen, although four-drugs are employed in the current protocol.~After tumor resection operation, participants will be divided to poor responder group and good responder group based on 90% necrosis rate of a tumor specimen.~Poor responder group and will be assigned to 'Poor responder group adjuvant chemotherapy' and good responder will be assigned to 'Good responder group adjuvant chemotherapy'."
89349191|NCT03390868|Experimental|Intervention arm|Phase 1, participants in the intervention group will take part in an web-based training for staff working with people with intellectual disabilities and challenging behaviour aiming to in a more effective way communicate to prevent challenging behaviour. The participants (staff) will by their own, go through the web-based training program during working hours. Measurement are conducted before intervention, at intervention completion an average of 12 weeks, and for a 3 month follow up after completed intervention
89349192|NCT03390868|Other|control arm|Control arm: participants in the control-group will maintain regular care and have the opportunity to receive the web-based training for staff working with people with intellectual disabilities and challenging behaviour in phase 2.
89349193|NCT03390790|Experimental|Lidocaine gel|If assigned to this arm, participants have lidocaine gel 2% applied to their external urethra and vagina one time prior to the urodynamics procedure.
89349194|NCT03390790|Placebo Comparator|Lubricant gel|If assigned to this arm, participants will have a standard lubricant gel applied to their external urethra and vagina prior to the urodynamics procedure.
89349195|NCT03697993|Experimental|Strategy 1|Fosfomycin 3 g orally once daily for 5-7 days as initial or step-down oral therapy for complicated urinary tract infections (cUTI) without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy. N=317
89349196|NCT03697993|Experimental|Strategy 2|Levofloxacin 750 mg orally once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therap, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.y. N=317
89349197|NCT04446988|Experimental|Ultrasound(US)|Sacroiliac joint injection using ultrasound
89349198|NCT04446988|Experimental|Fluoroscopy(FL)|Sacroiliac joint injection using fluoroscopy
89349199|NCT05393245||COPD patients treated with tiotropium and olodaterol (Tio+Olo)|
89349200|NCT05393245||COPD patients using other Long-acting muscarinic antagonists/Long-acting β2-agonists (LAMA/LABAs)|
89349201|NCT03394690|Active Comparator|green coffe|green coffe 2 capsuls of green coffe
89349202|NCT03394690|Placebo Comparator|control|2 capsuls of placebo
89349203|NCT03754855||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria
89349204|NCT05237830||Use|Patients in whom the cell saver was effectively used
89349205|NCT05237830||Not Use|Patients in whom the cell saver wasn't effectively used
89349206|NCT03398668|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
89349207|NCT03398668|Sham Comparator|Sham Comparator: Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
89349208|NCT03289455|Experimental|AUTO3|Paediatric patients with relapse or refractory B-cell ALL
89349209|NCT03390712||Paliperidone Palmitate|Patients who have received a minimum of 3 months of treatment with an injection of paliperidone palmitate.
89349210|NCT03390712||Risperidone Long-acting injection.|Patients who have received a minimum of 3 months of treatment with Risperidone long-acting injection.
89349211|NCT03754777|Experimental|Modified ERAS protocol group|"Laparoscopic appendectomy with modified ERAS protocol group Preadmission. Not available due to the emergency setting. Preoperative care.~1) Patient brochure with a detailed description of the type of pathology, surgery procedure, rehabilitation process, possible complications, and other.~Surgery.~Low pressure (8-9 mmHg) pneumoperitoneum.~Routinely remove of appendix mesentery in presence of any signs of its inflammation.~Additional local anesthesia with 0.25% ropivacaine.~Abdominal cavity draining only in patients with perforated appendicitis and diffuse peritonitis (Gomes 5).~Postoperative care.~Early mobilization (2 h after surgery)~Early fluid intake (2 h after surgery)~Early liquid food (6 h after surgery)"
89349212|NCT03754777|Placebo Comparator|Standard care group|"Standard care laparoscopic appendectomy. Preadmission. Not available due to emergency setting. Preoperative care. 1) Patient oral informing about the type of pathology, surgery procedure and possible complications. No brochure.~Surgery.~Standard pressure (12-14 mmHg) pneumoperitoneum~Abdominal draining for patients with perforated and not perforated appendicitis complicated by abscess, local or diffuse peritonitis (Gomez ≥ 3A).~Appendix mesentery removing in the appearance of its necrotic changes.~No intraabdominal anesthesia. Postoperative care.~1) Mobilization in 4-6 h after surgery 2) Fluid intake in 6 hours 3) Liquid food intake in 12 hours"
89349213|NCT03756805|Active Comparator|Group 1 (CPAP)|Patient, who are receiving a CPAP
89349214|NCT03756805|Experimental|Group 2 (UAS)|Patient, who are receiving a device for upper airway stimulation
89349215|NCT03126604||vaginal delivery|Women underwent non complicated non instumental normal vaginal delivery
89349216|NCT03126604||Cesarean section|Women underwent elective Cesarean section
89349217|NCT03756727|Experimental|Ascorbic acid group|the patients received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery.
89349218|NCT03756727|Placebo Comparator|Control comparator group|the patients received 10ml saline at the night before surgery, during the surgery and five days after surgery.
89349219|NCT04962724|Experimental|Radiolabeled Xevinapant Oral Solution|"Participants will receive:~• single oral dose of [14C]-xevinapant, as an oral solution"
89349220|NCT04962724|Experimental|Radiolabeled Xevinapant Intravenous Solution + Xevinapant Oral Solution|"Participants will receive:~• single oral dose of xevinapant, as an oral solution followed by an IV bolus of [14C]-xevinapant, solution for infusion"
89349221|NCT03398590|Experimental|mHealth Intervention for Older Adults|"Pilot study to test the feasibility and acceptability of a self-regulation theory-based mHealth behavior intervention for overweight or obese older adults with T2DM.~This is a one Group Pretest-Posttest Designed study. Ten participants will be recruited from Joslin Diabetes Center, Boston, MA. They will receive a 2-month, self-regulation theory-based weight loss intervention (five 60-minute, biweekly group sessions) and will be provided with a technology toolkit for self-monitoring including an (1) iPhone Plus, (2) the Lose It! app for self-monitoring of dietary intake, (3) Fitbit for self-monitoring of physical activity, (4) Bluetooth-enabled scale for daily weight, and (5) Bluetooth-enabled blood glucose monitor for testing blood glucose levels."
89349222|NCT03390556|Experimental|Asthma education|
89349223|NCT03390478|No Intervention|Control Group|The participants that will be assign to the control group will receive institutional usual care.
89349224|NCT03390478|Experimental|Combined Intervention Group|The participants that will be assigned to the experimental group will receive the Combined Intervention Program
89349225|NCT03398512|Experimental|Experimental|HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
89349226|NCT03390400|Active Comparator|Anterior Capsulotomy before Lens Fragmentation|Anterior capsulotomy will be performed by femtosecond laser before lens fragmentation
89349227|NCT03390400|Active Comparator|Lens Fragmentation before Anterior Capsulotomy|Lens fragmentation will be performed by femtosecond laser before anterior capsulotomy
89349228|NCT04484857|Experimental|Roxadustat|Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 24 weeks. If a participant require roxadustat <60 milligrams (mg)/week to maintain hemoglobin (Hb) levels, the dose frequency will be reduced in a stepwise manner, for example, to twice weekly (BIW), and then once weekly (QW). For participants converted from an ESA, the initial roxadustat dose will be based on the average prescribed ESA dose in the last 4 weeks (for epoetin alfa and darbepoetin alfa) or 8 weeks (for methoxy polyethylene glycol-epoetin beta [Mircera®]). For participants with <6 weeks of prior ESA use, the initial roxadustat dose will be based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations will be made every 4 weeks and doses will be titrated based on Hb level and rate of Hb change. The prescribed dose will not exceed the maximum allowable dose of 3.0 mg/kilogram (kg)/dose or 400 mg per dose, whichever is lower.
89349229|NCT03398434|Experimental|MAA868 low dose regimen|patients receive dose monthly.
89349230|NCT03398434|Experimental|MAA868 middle dose regimen|patients receive dose monthly.
89349231|NCT03398434|Experimental|MAA868 high dose regimen|patients receive dose monthly.
89349232|NCT03398434|Active Comparator|Apixaban|Apixaban 5 mg b.i.d
89349233|NCT03398122|Experimental|Apatinib combined with TACE|patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
89349234|NCT03398122|Placebo Comparator|chemoemtranscatherer arterial bolization|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
89349235|NCT03750799|Experimental|Experimental group|Whole body vibration was applied on the right lower extremity.
89349236|NCT03750799|Sham Comparator|Sham group|Unlike the experimental group, sham vibration was applied to the control group.
89349237|NCT03754621||Pregnants|400 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment and are TPOAb negative. Serum thyroid functions tests will be obtained on the first visit.
89349238|NCT05459857|Experimental|Product sequence ABCD|Subjects use Product A on Day 1, Product B on Day 2, Product C on Day 3 and Product D on Day 4
89349239|NCT05459857|Experimental|Product sequence BDAC|Subjects use Product B on Day 1, Product D on Day 2, Product A on Day 3 and Product C on Day 4
89349240|NCT05459857|Experimental|Product sequence CADB|Subjects use Product C on Day 1, Product A on Day 2, Product D on Day 3 and Product B on Day 4
89349241|NCT05459857|Experimental|Product sequence DCBA|Subjects use Product D on Day 1, Product C on Day 2, Product B on Day 3 and Product A on Day 4
89349242|NCT03394222|Experimental|Budesonide inhalation group|This group of participants were to receive 2mg/4ml of preoperative budesonide inhalation (Khartoum Road NORTH RYDE NSW 2113 Australia. AstraZeneca Pty Ltd) for 10 to 15min.
89349243|NCT03394222|Placebo Comparator|Normal saline inhalation group|This group of participants were to receive4ml of preoperative normal saline inhalation for 10 to 15min.
89349244|NCT03398044|Experimental|Dexamethasone|Patients randomised into the Dexamethasone arm will be administered active studied drug during anaesthesia induction.
89349245|NCT03398044|Placebo Comparator|Placebo|Patients randomised into the control Placeboarm will be administered placebo during anaesthesia induction.
89349246|NCT04095793|Experimental|ampreloxetine|Participants will receive a single, oral, daily dose of active drug (TD-9855) for 182 weeks.
89349247|NCT03848260|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device prototype. Test the device one time (duration: 30-120 mins/each time) and 3 times within 3 months.~Intervention: using the magnetic device prototype"
89349248|NCT04914520|Experimental|Step 1: VN-0200 low dose|Healthy adults subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.
89349249|NCT04914520|Experimental|Step 1: VN-0200 medium dose|Healthy adults subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.
89349250|NCT04914520|Experimental|Step 1: VN-0200 high dose|Healthy adults subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
89349251|NCT04914520|Placebo Comparator|Step 1: Placebo|Healthy adults and elderly subjects will be randomized to receive intramuscular injection of placebo.
89349252|NCT04914520|Experimental|Step 2: VN-0200 low dose|Healthy elderly subjects will be randomized to receive intramuscular injection of low dose of VAGA-9001a adjuvanted with low dose of MABH-9002b.
89349253|NCT04914520|Experimental|Step 2: VN-0200 dose medium dose|Healthy elderly subjects will be randomized to receive intramuscular injection of medium dose of VAGA-9001a adjuvanted with medium dose of MABH-9002b.
89349254|NCT04914520|Experimental|Step 2: VN-0200 high dose|Healthy elderly subjects will be randomized to receive intramuscular injection of high dose of VAGA-9001a adjuvanted with high dose of MABH-9002b.
89349255|NCT04914520|Placebo Comparator|Step 2: Placebo|Healthy adults and elderly subjects will be randomized to receive intramuscular injection of placebo.
89349256|NCT04482439|Experimental|Vivity mini-monovision|Subjects will have bilateral Vivity IOL implanted, with a target of slight myopia in the non-dominant eye.
89349257|NCT03785236||Tx-group|T1D patients that received islet of Langerhans transplantation (Tx) at least 3 months earlier
89349258|NCT03785236||Control group|T1D patients that await islet of Langerhans transplantation
89349259|NCT03750682|Active Comparator|Physical Activity Intervention (PA)|The PA intervention will consist of a twice per week group-based moderate-intensity program that includes aerobic, strength, flexibility, and balance training.
89349260|NCT03750682|Placebo Comparator|Health Education Intervention (HE)|The HE intervention will consist of bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics including relevance to older adults, including nutrition, understanding the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services, information on resources, etc.
89349261|NCT03751813|Placebo Comparator|Placebo|placebo supplement
89349262|NCT03751813|Experimental|Supplement|actual supplement
89349263|NCT02813200|Experimental|Group 1|
89349264|NCT02813200|Experimental|Group 2|
89349265|NCT02813200|Experimental|Group 3|
89349266|NCT04535947|Placebo Comparator|Vehicle|Vehicle
89349267|NCT04535947|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Active
89349268|NCT03389542|Experimental|Early mitral valve repair|Surgery will be performed within 3 months after randomization. Clinical interview will be performed at discharge, at 6 months and afterwards yearly until the end of follow-up. Echocardiography will be performed at discharge, at 6 months and at the end of follow-up.
89349269|NCT03389542|Active Comparator|Conservative management|Patients will be followed up by clinical interview and echocardiography every 6 months.
89349270|NCT03750721||Role of rifampin in staphylococcal PJI|retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (< 1 month) PJI treated with DAIR in 2011-2016 period
89349271|NCT01481272|Experimental|O-IVAC|Ofatumumab Etoposide Ifosfamide Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Colony Stimulating Factor
89349272|NCT03751735|Experimental|Dose 1|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up
89349273|NCT03389464|Experimental|confrontation group|computer-based confrontation with dysfunctional beliefs
89349274|NCT03389464|No Intervention|control group|no computer-based confrontation with dysfunctional beliefs
89349275|NCT03389386||Congestive Heart Failure (NYHA II-IV)|"N=90~Patients with a clinically documented diagnosis of congestive heart failure (CHF), as assessed per New York Heart Association (NYHA) functional classification will be prospectively and consecutively enrolled in this group. Patients will be of both sexes, enrolled in 1:1 ratio.~All subjects in this group will undergo blood withdrawal for laboratory analysis, transthoracic echocardiography (TTE) examination and will be treated with the Standard-of-care treatment according to their current clinical condition at admission."
89349276|NCT03389386||Healthy Control Group|"N=30~Healthy volunteers (both sexes, enrolled in 1:1 ratio) with a negative history of cardiovascular diseases will be enrolled in this group that will serve as a study control.~All subjects in this group will undergo blood withdrawal for laboratory analysis and transthoracic echocardiography (TTE) examination."
89349277|NCT04474405|Experimental|Brain flortaucipir PET scan|Subjects receiving a brain PET scan after flortaucipir administration
89349278|NCT04474405|Experimental|Whole body flortaucipir PET scan|Subjects receiving a whole body PET scan after flortaucipir administration
89349279|NCT04474405|Other|MRI and Amyloid Extension Cohort|Magnetic resonance imaging (MRI) scans and amyloid scans for subjects previously participating in Study T807000 (NCT01733355)
89349280|NCT02687386|Experimental|Mitoxantrone packaged EDV|Mitoxantrone packaged EDV (EnGeneIC Dream Vector)
89349281|NCT04531813|Experimental|Cumulative Irritation Test|Participants received butenafine HCl 1% cream on the skin test site, 0.3% solution of sodium lauryl sulfate on the skin Positive Control test site, and a blank patch on the skin Negative Control test site daily (excluding weekends) for 21 days, or 15 applications.
89349282|NCT03750643|Experimental|LY3454738 - Part A|Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants
89349283|NCT03750643|Placebo Comparator|Placebo - Part A|Placebo administered IV to healthy participants
89349284|NCT03750643|Experimental|LY3454738 - Part B|LY3454738 administered IV to healthy participants
89349285|NCT03750643|Placebo Comparator|Placebo - Part B|Placebo administered IV to healthy participants
89349286|NCT03750643|Experimental|LY3454738 - Part C|LY3454738 administered IV to participants with atopic dermatitis (AD)
89349287|NCT03750643|Placebo Comparator|Placebo - Part C|Placebo administered IV to participants with AD
89349288|NCT03538444|Experimental|Active rTMS|Participants will receive 18 sessions of active repetitive Transcranial Magnetic Stimulation over a period of three days. TMS consists of 3000 pulses of 10Hz stimulation applied to the left DLPFC using the beam F3 method
89349289|NCT03538444|Placebo Comparator|Sham rTMS|Participants will receive 18 sessions of sham rTMS over a period of three days.
89349290|NCT03125824|Other|Tattoos previously treated in Soliton 2016-001 trial|Identical tattoos treated by Laser + AWD in Soliton's previous trial
89349291|NCT01380028|Placebo Comparator|placebo|The aim of this prospective multicenter randomized, double blind, is to evaluate in patients with chronic subdural hematoma, compared with placebo, the efficacy of postoperative corticosteroid treatment orally for approximately 2 months on the rate of clinical recurrence
89349292|NCT01380028|Active Comparator|oral corticosteroids|The aim of this prospective multicenter randomized, double blind, is to evaluate in patients with chronic subdural hematoma, compared with placebo, the efficacy of postoperative corticosteroid treatment orally for approximately 2 months on the rate of clinical recurrence
89349293|NCT03750565|Experimental|Cohort 1|Japanese subjects will receive oral doses of either TD-1473 - Dose A or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
89349294|NCT03750565|Experimental|Cohort 2|Japanese subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
89349295|NCT03750565|Experimental|Cohort 3|Caucasian subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Caucasian subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
89349296|NCT03750565|Experimental|Cohort 4|Japanese subjects will receive oral doses of either TD-1473 - Dose C or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
89349297|NCT01305460|Experimental|Azacitidine intensified dose|
89349298|NCT03754543|Active Comparator|Testmeal A|A new, whole-grain infant cereal fortified with ferrous fumarate
89349299|NCT03754543|Active Comparator|Testmeal B|An alternative new whole-grain infant cereal recipe fortified with ferrous fumarate
89349300|NCT03754543|Placebo Comparator|Testmeal C|An existing, refined grain infant cereal fortified with ferrous fumarate
89349301|NCT03754543|Active Comparator|Testmeal D|An existing, whole-grain infant cereal fortified with ferrous fumarate
89349302|NCT03754543|Active Comparator|Testmeal E|An existing, whole-grain infant cereal fortified with ferrous bisglycinate
89349303|NCT05177809||RFC1|Participants with genetically confirmed RFC1 repeat expansion disease (ORPHA: 504476; OMIM 102579) will be recruited. Target sample size for the RFC1 cohort is 100 participants.
89349304|NCT05177809||Unrelated healthy controls|Unrelated healthy controls Healthy controls may undergo the same study procedures as the RFC1 cohort. Target sample size for the control cohort is 50.
89349305|NCT01199302|Experimental|Brodalumab 350 mg|Participants received brodalumab 350 mg intravenously (IV) on day 1, week 4 and every 4 weeks thereafter for up to 132 weeks.
89349306|NCT05459623|Active Comparator|Manual myofascial release|Manual myofascial release as conventional treatment
89349307|NCT05459623|Experimental|Emmett intervention|Emmett intervention and myofascial release
89349308|NCT03754387|Active Comparator|Antibiotic therapy group|Ceftazidime will chosen as the antibiotic for this study because of its efficacy as a monotherapy for serious intraabdominal infections, requiring only a single, daily dose. Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) is administered for 3 days to patients in the AT group, with the first dose given in the emergency department. The clinical status of patients in the AT group is reevaluated within 12 to 24 hours after admission by the surgeon on call. If the surgeon suspected progressive infection, perforated appendicitis, or peritonitis, the patient will underwent appendectomy. Intravenous antibiotic treatment will followed by 7 days of oral cefuroxime (250mg twice daily).
89349309|NCT03754387|Experimental|Laparoscopic Appendectomy group|Laparoscopic appendectomy will performed using. Prophylactic antibiotics (ceftazidime sodium 50mg/kg/dose ) will administered approximately 30 minutes before the incision was made. No further antibiotics will given to patients in the surgical group unless a wound infection was suspected postoperatively.
89349310|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 1)|TAK-925, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
89349311|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 2)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 2). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
89349312|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 3)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 3). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
89349313|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 4)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 4). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
89349314|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
89349315|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 6)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 6). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
89349316|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 1-2)|TAK-925 Placebo, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
89349317|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 3; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy elderly participants will be enrolled in double blind manner.
89349318|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 3)|TAK-925 Placebo, Intravenous single administration. Healthy elderly participants will be enrolled in double blind manner.
89349319|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 4; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy adults will be enrolled in non-blinded manner.
89349320|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 5)|TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
89349321|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 6)|TAK-925, Intravenous single administration. Dose in Cohort 6 TBD based on safety, tolerability, PK data, and results of the Maintenance Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
89349322|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 7)|TAK-925, Intravenous single administration. Dose in Cohort 7 TBD based on safety, tolerability, PK data, and results of the Maintenance of Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
89349323|NCT03332784|Placebo Comparator|Part 2: Placebo (Cohort 5-7)|TAK-925 Placebo, Intravenous single administration. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
89349324|NCT05317741|Experimental|A mg IA-14069 or Placebo|
89349325|NCT05317741|Experimental|B mg IA-14069 or Placebo|
89349326|NCT05317741|Experimental|C mg IA-14069 or Placebo|Period 1: Fasted condition → Period 2: Fed condition
89349327|NCT05317741|Experimental|D mg IA-14069 or Placebo|
89349328|NCT05317741|Experimental|E mg IA-14069 or Placebo|
89349329|NCT03751501|Experimental|Experimental Group|Indocyanine green-Guided Targeted Laser photocoagulation combines routine procedures, that are, the detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT. Indocyanine green-Guided Targeted Laser photocoagulation is administered in combination with anti VEGF treatment
89349330|NCT03751501|Sham Comparator|Control Group|Sham laser is administered at randomization visit and repeated if needed 3 month later in combination with anti VEGF treatment
89349331|NCT03248154|No Intervention|Immunocompetent with 2-14% TBSA|Immunocompetent with 2-14% TBSA thermal burn subjects. Does biofilm infection result in conversion of partial-thickness burn wounds to full-thickness?
89349332|NCT03248154|Experimental|Immunocompromised with >=20% TBSA|Immunocompromised patients with large thermal burn >=20% TBSA. Higher bacterial burden with biofilm infection will result in higher rates of graft loss. Does application of a wireless electroceutical dressing (Procellera) lower biofilm burden compared to burn subjects receiving standard of care therapy?
89349333|NCT03248154|No Intervention|Peripheral blood - all subjects|All subjects enrolled in arms 1 and 2. Do children have a more robust innate immune response to prevent biofilm infection?
89349334|NCT03171480|Experimental|Monoket pill|Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris[1] and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur,
89349335|NCT03171480|Placebo Comparator|Placebo pill|The pharmacy has compounded an identical appearing placebo
89349336|NCT04465357|Experimental|Erenumab-Aooe 140 MG/ML [Aimovig]|Participants received 140 mg/mL administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for three months (12 weeks).
89349337|NCT03912324|Experimental|Unipolar voltage subtraction map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury~Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure and Ablation time, and perfusion saline dose~Rhythm follow-up after the procedure in accordance with the study design."
89349338|NCT03912324|Experimental|CT myocardial thickness map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure time, Ablation time, and perfusion saline dose~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
89349339|NCT03912324|Active Comparator|Empirical PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure time, Ablation time, and perfusion saline dose~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
89349340|NCT03750409|Active Comparator|Helmet Active Device|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
89349341|NCT03750409|Sham Comparator|Helmet Sham|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
89349342|NCT01313052|Experimental|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
89349343|NCT01313052|Active Comparator|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
89349344|NCT03750253|Other|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy to relieve pain after arthroscopy for osteochondral lesions of talus
89349345|NCT04901221|Experimental|Extrusion arch|"Hand made stainless steel extrusion arch wire (0.016x0.22)"
89349346|NCT03332628|Other|Microneedle application|This is the only study arm, which all participants complete. Nine sites on the upper arm will be identified. Baseline measurements of transepidermal water loss, electrical resistance, hydration, and color will be made at each site. The 9 sites will be divided into clusters of 3 sites each. The first cluster will have small microneedle patches applied to at each site. This will only occur on the first study day. Transepidermal water loss and electrical resistance are re-measured immediately after microneedle application. The sites will be covered with a small patch secured with medical tape. The second cluster of sites will not receive microneedle application but will just be covered with patches. The last cluster of sites will not have microneedle application or patches. Electrical resistance will be re-measured at all sites for 4 days after microneedle application. Measurements from the 2nd and 3rd cluster of sites allow each subject to serve as their own control in data analysis.
89349347|NCT05459467|Experimental|Exercise|"Participants began exercising at 70% of their heart rate reserve (HRR). The Borg scale was used to monitor exertion during the programme. Participants were provided with watches to monitor their HR and also wore ECG monitors to assess for arrhythmias during exercise classes.~Sessions consisted of a circuit of set exercises alternating between aerobic/cardiovascular and resistance exercises. Participants were progressed in a graded fashion (up to a maximum of 85% HRR). Participants were also expected to participate in a predefined exercise session remotely.~Educational session took place in the half an hour following the exercise session. Examples of topics covered included: living with HCM, medications, diet, stress/anxiety management and mindfulness, ICD therapy- what to expect?."
89349348|NCT05459467|No Intervention|Usual care|Patients exercised as per usual.
89349349|NCT03754075||CME group|The CME group consisted of patients, who underwent elective CME for right-sided colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2013.
89349350|NCT03754075||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for right-sided adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
89349351|NCT05397860|Experimental|Patients with clinically diagnosed hepatocellular carcinoma (HCC) (equal or less than 4 cm )|Patients with chronic hepatitis B or liver cirrhosis have hepatocellular carcinoma (HCC) (equal or less than 4 cm) which is diagnosed on contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI).
89349352|NCT04516759|Experimental|AZD1656 (plus Usual Hospital Care)|50mg film-coated tablets at a dose of 100mg BID
89349353|NCT04516759|Placebo Comparator|Matched Placebo (plus Usual Hospital Care)|Matched placebo tablets
89349354|NCT03332160|Active Comparator|Standard of Care|Standard home lymphedema care
89349355|NCT03332160|Experimental|Flexitouch head and neck lymphedema treatment system|Daily treatment with Flexitouch® pneumatic compression device for treatment of head and neck lymphedema and standard home lymphedema care
89349356|NCT02680106|Experimental|SPINNER|All patients in this arm will be treated with the SPINNER .
89349357|NCT02680106|Active Comparator|JELONET or IBU-Biatain|All patients in this arm will be treated with JELONET/IBU Biatain dressing, regarded as the standard of current care for split-skin donor-site wounds.
89349358|NCT05396690|Experimental|remimazolam group|"In the Remimazolam group as an induction dose 6 mg/kg/h of remimazolam with 0.5-1.0 mcg/kg of sufentanil was injected together. If consciousness was lost, rocumerone 1 mg/kg was given intravenously, and endotracheal intubation was performed when sufficient muscle relaxation was achieved 2 minutes later.~Maintenance of anesthesia is achieved by using a programmed infusion pump with remimazolam 1 mg/kg/h (up to 2 mg/kg/h) and sufentanil effect site concentration of 0.4 to 0.5 to reach the appropriate depth of anesthesia. The optimal level of anesthesia is based on maintaining a bispectral index (BIS) of 35-65."
89349359|NCT05396690|Other|sevoflurane group|After injection of 2-5 mg of midazolam and 0.5-1.0 mcg/kg of sufentanil as an induction dose, 1 mg/kg of rocumerone is given intravenously when consciousness is lost, and endotracheal intubation is performed when sufficient muscle relaxation is achieved 2 minutes later. For maintenance of anesthesia, the concentration of sevoflurane and sufentanil effect site concentration is 0.4 to 0.5 to reach the appropriate depth of anesthesia, and the optimal degree of anesthesia is based on maintaining the BIS 35 to 65.
89349360|NCT01384058|Active Comparator|Ezetimibe 10mg/d|intake of ezetimibe 10mg per day for six weeks after wash-out
89349361|NCT01384058|Active Comparator|Simvastatin 20 mg per day|intake of simvastatin 20 mg per day for six weeks after wash-out
89349362|NCT01384058|Active Comparator|Ezetimibe 10 mg/d and Simvastatin 20mg/d|intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out
89349363|NCT04401384|Other|Diclectin plus active acupuncture|Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) , 2-4 tablets/day) + active acupuncture (30 min /every day).
89349364|NCT04401384|Other|Diclectin plus sham acupuncture|Diclectin (combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg), 2-4 tablets/day) + sham acupuncture (30 min /every day).
89349365|NCT04401384|Other|Placebo plus active acupuncture|Diclectin placebo (2-4 tablets/day) + active acupuncture (30 min / every day)
89349366|NCT04401384|Other|Placebo plus sham acupuncture|Diclectin placebo (2-4 tablets/day) + sham acupuncture (30 min /every day)
89349367|NCT04835701|Experimental|Music Intervention group|Subjects randomized to the music group will choose 10 songs, which will be played during the procedure, from the time of positioning through completion of IUD insertion and speculum removal. Participants will otherwise undergo standard protocol for IUD insertion in an outpatient clinic setting. Total participation is predicted to last approximately 30 minutes.
89349368|NCT04835701|No Intervention|Control group|Participants to undergo same standard protocol for IUD insertion in an outpatient clinic setting. No music will be played during the procedure.
89349369|NCT03631082|Experimental|Slump stretching group|"Slump stretching will be performed with the patient in the long sitting position. The position will be held for 30 seconds. A total of 5 repetitions will be completed.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, and quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
89349370|NCT03631082|Active Comparator|Lumbar mobilization group|"Maitland Grade 1 - 2 Posterior to anterior lumbar spine mobilization will be applied for 30 - 45 seconds for all segments through L1 to L5 at rate of 1 oscillation per 2 seconds.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
89349371|NCT03312114|Experimental|Single arm|Avelumab and SABR
89349372|NCT03694327|Experimental|Treatment A Mobile Application|Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.
89349373|NCT03694327|Active Comparator|Treatment B Mobile Application|Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.
89349374|NCT01380158|Experimental|Pessary use during pregnancy|Device: Cup pessary
89349375|NCT01380158|No Intervention|Expectant management|Expectant Management + weekly intramuscular progesterone injections
89349376|NCT04239222|Experimental|Revo-M to Proflex XC|Transtibial amputees randomized to start with Revo-M and cross over to Proflex XC
89349377|NCT04239222|Experimental|Proflex XC to Revo-M|Transtibial amputees randomized to start with Proflex XC and cross over to Revo-M
89349378|NCT04239222|Experimental|Revo-M to Taleo|Transfemoral amputees randomized to start with Revo-M and cross over to Taleo
89349379|NCT04239222|Experimental|Taleo to Revo-M|Transfemoral amputees randomized to start with Taleo and cross over to Revo-M
89349380|NCT03750097|Experimental|Walking protocol|Walking for 250 steps with comfortable walking velocity (CWV), slow walking velocity (SWV: CWV - 20%) and fast walking velocity (FWV: CWV + 20%) with sufficient rest between conditions.
89349381|NCT04732260|Experimental|letermovir|Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP
89349382|NCT02517398|Experimental|MSB0011359C (M7824)|
89349383|NCT03330288||Participants with Stage I-III Knee osteoarthritis (KOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
89349384|NCT03330288||Participants with Stage I-III Hip osteoarthritis (HOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
89349385|NCT01383278|Experimental|Computer-directed 5 A's intervention for smoking|
89349386|NCT01383278|Active Comparator|Screening and resource provision|
89349387|NCT04680156||EN3835|Previously treated with EN3835 in EN3835-210 or the pivotal phase 3 studies
89349388|NCT04680156||Placebo|Previously treated Placebo in EN3835-210 or the pivotal phase 3 studies
89349389|NCT01383980|No Intervention|Control|Tube feeds are held night prior to elective surgery (standard of care)
89349390|NCT01383980|Experimental|Continuous Feeding|Tube feeds are continued up until surgery. Subjects with a nasogastric tube will have their stomach contents emptied prior to surgery.
89349391|NCT03178370||Diabetic Gastroparesis|
89349392|NCT03178370||Idiopathic Gastroparesis|
89349393|NCT01383902|Other|dessert / chocolate|
89349394|NCT01383824|Other|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
89349395|NCT03084536|Active Comparator|Preoperative PECS blocks|"PECS I & II block will be administered preoperatively~For unilateral surgeries, a PECS I block will be performed with 0.15mL/kg of 0.375% bupivacaine (maximum 10mL). The PECS II block will be performed with 0.3 mL/kg of the same solution (maximum 20mL). If there is a contralateral surgery (simple mastectomy) a PECS II block will also be performed on the other side with 0.2mL/kg of 0.375% bupivacaine (maximum 20mL)~To ensure blind integrity, study drug syringes will be marked only study drug and subject number~Perioperative analgesic will be encouraged.. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative area. All patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist"
89349396|NCT03084536|Placebo Comparator|Placebo PECS blocks|"A sham block (normal saline) will be placed preoperatively~To ensure blind integrity, study drug syringes will be marked only study drug and subject number.~Perioperative analgesic regimen will be encouraged. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative holding area. On the day of surgery all patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist."
89349397|NCT05291936|Experimental|TEST/CONTROL|Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
89349398|NCT05291936|Experimental|CONTROL/TEST|Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period.
89349399|NCT03289143|Experimental|Dose 1 Semorinemab|
89349400|NCT03289143|Experimental|Dose 2 Semorinemab|
89349401|NCT03289143|Experimental|Dose 3 Semorinemab|
89349402|NCT03289143|Placebo Comparator|Placebo|
89349403|NCT03311724|Experimental|4,8,12mg Tirzepatide|Participants received Tirzepatide by subcutaneous (SC) injection in three dose escalations starting with 4 milligrams (mg) for four weeks followed by 8mg for four weeks followed by 12mg for four weeks.
89349404|NCT03311724|Experimental|2.5,5,10,15mg Tirzepatide|Participants received Tirzepatide by SC injection in four dose escalations starting with 2.5mg for two weeks followed by 5mg for two weeks followed by 10mg for four weeks followed by 15mg for four weeks.
89349405|NCT03311724|Experimental|2.5,7.5,15mg Tirzepatide|Participants received Tirzepatide by SC injection in three dose escalations starting with 2.5mg for four weeks followed by 7.5mg for four weeks followed by 15mg for four weeks.
89349406|NCT03311724|Placebo Comparator|Placebo|Placebo administered by SC injection.
89349407|NCT05213312|Experimental|NIT+NCT Group (Arm A)|"Neoadjuvant immunotherapy : Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;~Neoadjuvant chemotherapy (investigator's choice) : Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cisplatin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.~MIE : Esophagectomy plus two/three field lymphadenectomy, 4-6 weeks after neoadjuvant therapy.~Adjuvant immunotherapy : 4-6 weeks after operation, (for subjects with non-pCR) Nivolumab injection, 240mg intravenous infusion, Q2W for 16 weeks, followed by 480mg intravenous infusion, Q4W. The maximum duration of adjuvant Nivolumab therapy is one year."
89349408|NCT05213312|Placebo Comparator|NCT Group (Arm B)|"Placebo: NS ivgtt (dose, frequency and duration same as the Nivolumab);~Neoadjuvant chemotherapy (investigator's choice) : Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cisplatin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.~MIE : Esophagectomy plus two/three field lymphadenectomy, 4-6 weeks after neoadjuvant therapy.~Adjuvant immunotherapy : 4-6 weeks after operation, (for subjects with non-pCR) Nivolumab injection, 240mg intravenous infusion, Q2W for 16 weeks, followed by 480mg intravenous infusion, Q4W. The maximum duration of adjuvant Nivolumab therapy is one year."
89349409|NCT03846024|Experimental|RibFx belt arm|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
89349410|NCT03846024|No Intervention|Control|"Patients in the control arm receive normal standard of care for rib fractures at the participating institution.~The current standard of care for rib fractures at the University of Vermont (participating institution) is as follows: includes oral and IV analgesia and other multimodal pain control as appropriate, including muscle relaxants such as methocarbamol (robaxin) unless there is a contraindication, pulmonary hygiene/toilet and respiratory care (including frequent evaluations by physicians, respiratory therapists, and nursing staff, early mobilization, and monitoring for pulmonary complication (via vital signs, pulse oximetry, oxygen requirement, chest imaging if appropriate)."
89349411|NCT03311646|Experimental|Nicotine Content Manipulation|All participants receive normal nicotine content (NNC) cigarettes during Baseline and all participants receive very low nicotine content (VLNC) cigarettes during the very low nicotine content condition.
89349412|NCT05276232|Experimental|Baseline followed by 5-10% THC Validation|
89349413|NCT05276232|Experimental|Baseline followed by 5-10% THC Verification|
89349414|NCT01672892|Experimental|Intensity-Modulated Radiation Therapy|intensity-modulated radiation therapy (IMRT) to the pelvis of either 45 Gy or 50.4 Gy
89349415|NCT01672892|Active Comparator|Standard Radiation Therapy|Standard radiation therapy (4-field) to the pelvis of either 45 Gy or 50.4 Gy
89349416|NCT03680274|Experimental|Vitamin C|Vitamin C: 50 mg/kg every 6 hours for 96 hours.
89349417|NCT03680274|Placebo Comparator|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
89349418|NCT05276076|Experimental|Part 1 Single Ascending Dose, Cohort 1|Cohort 1 : 1X10^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the two subjects: Begin enrollment for Cohort 2.
89349419|NCT05276076|Experimental|Part 1 Single Ascending Dose, Cohort 2|Cohort 2 : 3X10^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the two subjects: Begin enrollment for Cohort 3.
89349420|NCT05276076|Experimental|Part 1 Single Ascending Dose, Cohort 3|Cohort 3 : 5X10^6 cells/kg The safety of 2 subjects is evaluated for 1 week after single dose of IP.
89349421|NCT05276076|Experimental|Part 2 Multiple Ascending Dose, Cohort 1|Cohort 1 : two doses in total, 1X10^6 cells/kg per dose, weekly The safety of 3 subjects is evaluated for 4 week after two dose of IP. If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the three subjects: Begin enrollment for Cohort 2.
89349422|NCT05276076|Experimental|Part 2 Multiple Ascending Dose, Cohort 2|Cohort 2 : four doses in total, 1X10^6 cells/kg per dose, weekly The safety of 3 subjects is evaluated for 8 week after two dose of IP.
89349423|NCT03288987|Experimental|Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (AryoGen) 5 mg/kg will be administered every 2 weeks.
89349424|NCT03288987|Active Comparator|Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (Avastin®) 5 mg/kg will be administered every 2 weeks.
89349425|NCT01379846|Experimental|TAK-816|
89349426|NCT01379846|Active Comparator|ActHIB|
89349427|NCT02939781||Febrile critically ill children|Children above 10kg admitted to the paediatric intensive care unit at Great Ormond Street Hospital who are mechanically ventilated and have a high likelihood of developing a fever. Energy expenditure will be measured using indirect calorimetry at baseline, and continuously during fever, until fever subsides.
89349428|NCT05275764||optic capture group|IOL optic was captured through the posterior continuous curvilinear capsulorhexis
89349429|NCT05275764||endocapsular group|IOL was placed in the bag
89349430|NCT05179161|Experimental|Prone crawl position|Patients are placed in the prone crawl position for whole breast irradiation and are treated with 15 x 2,67 Gy (± boost treatment if required as per international guidelines)
89349431|NCT01379690||Control|Controls were selected from patients with diabetes on consultation during the year 2005-2010 in specialist clinic, without a previous hip fracture. There was no followup period for these patients. Instead the A1C value upon the point of consultation was used to reflect glycaemic control at the point of consultation
89349432|NCT01379690||Case|All patients with treated diabetes admitted with primary diagnosis hip fractures from 2005-2010 to Changi General Hospital was included in the study. The A1C at the point of admission was used to reflect the glycaemic control at that point in time. This was a retrospective study and there was no subsequent follow up on patients after the point of admission
89349433|NCT03728166|Experimental|Alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
89349434|NCT03728166|No Intervention|No Alert|No notification to the provider.
89349435|NCT03995199||Furlow group|All cleft palate patients surgically treated with a modified Furlow technique since January 2012
89349436|NCT03995199||Furlow + Sommerlad group|All cleft palate patients surgically treated with a modified Furlow technique in combination with an intravelar veloplasty by Sommerlad
89349437|NCT01379612||Rectal cancer patients in chemoradiation|
89349438|NCT05275452||School age children aged 9-13 years|
89349439|NCT05275452||Women of reproductive age aged 18-44 years|
89349440|NCT03637881||Other|Daily or non-daily Consumers
89349441|NCT04339920||Chinese patients with clinical suspicious of prostate cancer|Chinese patients with clinical suspicious of prostate cancer, due to elevated serum PSA or abnormal digital rectal examination, will be recruited for the study from the Prince of Wales Hospital and North District Hospital.
89349442|NCT01379456|Experimental|physiotherapy|exercises
89349443|NCT01379456|No Intervention|conventional treatment|care as usual
89349444|NCT01379300|Experimental|Dabigatran|Single 150-mg dose of dabigatran etexilate
89349445|NCT01379300|Experimental|Rivaroxaban|Single 20-mg dose of rivaroxaban
89349446|NCT01379300|No Intervention|No intervention|No study drug will be administered
89349447|NCT04316130|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
89349448|NCT04316130|Active Comparator|Exercise using brochure|brochure
89349449|NCT01383122|Active Comparator|Active device|Functional pulsed electromagnetic field device
89349450|NCT01383122|Placebo Comparator|Placebo - inactive device|Inactive pulsed electromagnetic field device
89349451|NCT05422196|No Intervention|Control group|No platelet-rich fibrin was added to the cleft site during grafting.
89349452|NCT05422196|Experimental|Study group|Platelet-rich fibrin was added to the cleft site during grafting.
89349453|NCT03682224|Active Comparator|Exparel|
89349454|NCT03682224|Active Comparator|Marcaine|
89349455|NCT04061733|Experimental|Experimental|Subjects who will receive an injection of the hydrogel
89349456|NCT01377818|Experimental|ventilation|Group program of positive pressure ventilation noninvasive
89349457|NCT01377818|Experimental|exercise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~d. 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~e. Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
89349458|NCT01377818|Experimental|exercise training and ventilation|Group of exercise training program and noninvasive positive pressure ventilation
89349459|NCT04345965||Active endovascular treatment|Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
89349460|NCT04018508|Experimental|Massages|During routine clinic visits, subjects will receive a total of six 30-minute massages (one massage per week for 4 weeks, then one massage every two weeks for 4 weeks).
89349461|NCT04018508|No Intervention|Control|Subjects randomized to the control arm will also attend routine clinic visits at the same pre-prescribed intervals (one clinic visit per for 4 weeks, then one visit every two weeks for 4 weeks).
89349462|NCT05421884|Experimental|Cancer Patient and their significant other|The intervention will implemented in all cancer patients and their significant others
89349463|NCT05178615|Experimental|Education group|Preoperative education
89349464|NCT05178615|No Intervention|control|Traditionally care
89349465|NCT01383044|Experimental|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
89349466|NCT01383044|Active Comparator|carvedilol|carvedilol 6.25-12.5 mg per day
89349467|NCT05421572||Single Group Assignment|Adults with health check-ups at multiple health examination centers across China
89349468|NCT01377506|Experimental|Lifestyle counseling|Diabetes Prevention Program Lifestyle Balance Intervention delivered by lay health educator
89349469|NCT01377506|Active Comparator|Cognitive Training|Adaptation of SeniorWise Memory Training program for delivery by lay health educator, matched in duration and contact to the other study arm
89349470|NCT01382966||Single group|Maintenance hemodialysis patients of minimal 6 months of hemodialysis duration; free of malignancy, infection and autoimmune disease; age over 18 years
89349471|NCT03710486||Cohort 1: Vedolizumab|Participants diagnosed with UC or CD, who have initiated vedolizumab treatment between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index vedolizumab treatment initiation during the eligibility period, and then from date of index vedolizumab treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when vedolizumab treatment was initiated.
89349472|NCT03710486||Cohort 2: Other Biologic|Participants diagnosed with UC or CD, who have initiated other biologic treatment (infliximab, adalimumab, or golimumab [UC only]) between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index other biologic treatment initiation during the eligibility period, and then from date of index other biologic treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when other biologic treatment was initiated.
89349473|NCT01377428|Experimental|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
89349474|NCT01377428|Active Comparator|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
89349475|NCT03508622|Experimental|Telehealth|This group will receive weight management treatment via 12 online group sessions, over 6 months. They will have Bluetooth-enabled scales that will allow them to transmit their weight data to the PI in between research visits. They will answer questionnaires and have research visits at baseline, 3 months, and 6 months.
89349476|NCT03508622|Other|Empower|This retrospective control group received standard in-clinic individualized weight management with a multi-disciplinary group of providers, via 6 monthly clinic visits, over 6 months.
89349477|NCT03083990|Experimental|Group A|IBI 305 ,3mg/kg, infusion in 90 minutes
89349478|NCT03083990|Active Comparator|Group B|Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes
89349479|NCT04950998|Other|Target Users - Moving Up-A app|In this single-arm trial, target users (participants) will use a physical activity smartphone app for a two-month period. The app includes motivational messages, tips to increase the intensity level of everyday activities, and strategies to reduce sedentary behaviors. Users can also track their physical activity levels and sedentary activity.
89349480|NCT04950998|Other|Study Partners - Moving Up-A app|In this single-arm trial, study partners were invited to support target users (participants) in using a physical activity smartphone app for a two-month period. The app includes motivational messages, tips to increase the intensity level of everyday activities, and strategies to reduce sedentary behaviors. Users can also track their physical activity levels and sedentary activity.
89349481|NCT03252015|Experimental|Probe Drug Cocktail (Cohort 1a)|Probe Drug Cocktail administered orally on Day -3.
89349482|NCT03252015|Experimental|200 milligrams (mg) Lasmiditan+Probe Drug Cocktail (Cohort 1)|200 mg lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
89349483|NCT03252015|Placebo Comparator|Placebo+Probe Drug Cocktail (Cohort 1b)|Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
89349484|NCT03252015|Experimental|400 mg Lasmiditan (Cohort 2a)|400 mg lasmiditan administered orally for 7 days.
89349485|NCT03252015|Experimental|Placebo (Cohort 2b)|Placebo administered orally for 7 days.
89349486|NCT01314027|Experimental|neoadjuvant + adjuvant chemotherapy|neoadjuvant chemotherapy is based on gemcitabine/oxaliplatin adjuvant therapy is based on gemcitabine
89349487|NCT01314027|Active Comparator|adjuvant chemotherapy|adjuvant therapy is based on gemcitabine
89349488|NCT03708003|Experimental|venetoclax + ibrutinib|Ibrutinib lead-in followed by venetoclax plus ibrutinib administered until cycle 31. The combination treatment will be continued as maintenance treatment or stopped depending on MRD-neg CR/CRi status.
89349489|NCT05178303|Experimental|Cirrhosis|Experimental benefits in resistance to cirrhosis were observed in all patients who had previously received certain components of the treatment for cirrhosis SB-1121(1) for various therapeutic purposes.
89349490|NCT05178303|Experimental|"Cirrhosis/Hcc stable"|Experimental benefits in resistance to cirrhosis/Hcc were observed in all patients who had previously received certain components of the treatment for cirrhosis SB-1121(2) for various therapeutic purposes.
89349491|NCT05178147|Experimental|Volunteers|Volunteers having compression bandages applied to their legs.
89349492|NCT03083132|Active Comparator|Early-start|24 weeks of modafinil 50 mg oral daily
89349493|NCT03083132|Placebo Comparator|Delayed-start|12 weeks of oral placebo followed by 12 weeks of modafinil 50 mg oral daily
89349494|NCT03683823|Experimental|Attention guidance|In addition to the components included in the control intervention the experimental attention guidance condition consists of three unique components: (1) the rationale will include information about the importance of visually attending to the faces of the audience; (2) in addition to being given a speech topic, participants will be given target audience members to focus their gaze on during the speech. They will be told that they should look at and focus on the target audience member for the whole speech; (3) between speeches, the researcher will tell participants the percentage of time they were focused on the target face.
89349495|NCT03683823|Active Comparator|Control intervention|"Participants will complete two intervention sessions within one week. The intervention will use a manualized protocol.~On the first session, participants will receive a brief standardized psychoeducation module, presented via a 15-minute video recording. This video will explain the intervention, its rationale, and the procedure.~Participants will then have 5 minutes to plan and outline a speech based on a topic given to them. All participants will receive the same topic. Participants will not be allowed to use the outline during the public speaking exposure trials.~Participants will then give six speeches that are each 3 minutes long on the same topic. Participants will give all the speeches in the immersive 360º-video environment.~Between speeches participants will have a 1-minute break."
89349496|NCT03476018|Placebo Comparator|Placebo|
89349497|NCT03476018|Experimental|0.2 microgram Z-100|
89349498|NCT03476018|Experimental|2 microgram Z-100|
89349499|NCT03476018|Experimental|20 microgram Z-100|
89349500|NCT03466814||JIA participants|
89349501|NCT04121468|Other|Group A|"Placebo for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
89349502|NCT04121468|Other|Group B|"Placebo for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 6 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
89349503|NCT04121468|Other|Group C|"Placebo for 9 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day.~Metformin for 3 months at dose of 500 mg/m2/day po (to be rounded) given in 1 or 2 divided doses for one week and if there are no side effects increased to 1000 mg/m2/day po given in 2 divided doses up to a maximum dose of 2000 mg/day."
89349504|NCT01377350|Experimental|"Pneumedicares monitoring system"|"Single arm study - Pneumedicares monitoring system is used for monitoring heart failure patients"
89349505|NCT03285711|Experimental|Lanraplenib 30 mg|"Participants receive lanraplenib 30 mg tablet + filgotinib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
89349506|NCT03285711|Experimental|Filgotinib 200 mg|"Participants receive filgotinib 200 mg tablet + lanraplenib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
89349507|NCT03285711|Experimental|Lanraplenib 30 mg to Filgotinib 200 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive filgotinib 200 mg + lanraplenib placebo for additional 16 weeks.~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
89349508|NCT03285711|Experimental|Filgotinib 200 mg to Lanraplenib 30 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive lanraplenib 30 mg + filgotinib placebo for additional 16 weeks.~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
89349509|NCT01313871||All Participants|Adults with a confirmed diagnosis of rheumatoid arthritis
89349510|NCT03648489|Active Comparator|Arm 1: Weekly paclitaxel alone|Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
89349511|NCT03648489|Experimental|Arm 2: Weekly paclitaxel plus TAK228|"Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria~TAK228, oral capsule 4mg on days 2-4, 9-11, 16-18 and 23-25 of a 28 day cycle i.e. in concurrence with paclitaxel. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria"
89349512|NCT03284606|Experimental|TAPING|taping in conjunction with common rehabilitation for hemiplegic patients
89349513|NCT03284606|Placebo Comparator|NO TAPING|Common rehabilitation for hemiplegic patients without taping
89349514|NCT01382888|Active Comparator|Heparin 2,400 IU /ml Cutaneous Spray|Patients are randomized to receive the active comparator heparin 2,400 IU/ml cutaneous spray for 24 weeks
89349515|NCT01382888|Placebo Comparator|Placebo Cutaneous Spray|Patients are randomized to receive placebo cutaneous spray for 24 weeks
89349516|NCT01313949|No Intervention|Usual Care|A total of 90 patients with diabetes will be recruited. Thirty will be selected for the training course and the other 60 will be compared as controls. These controls will receive their usual diabetes care.
89349517|NCT01313949|Experimental|Peer leader training|"Peer leaders are people with diabetes who had volunteered to undertake an extensive program of training. The purpose of this training is to make them effective in the provision of support and advice to their peers on a one-to-one basis via telecommunication.~These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors."
89349518|NCT04045041|Experimental|Treatment group|10 week internet-based acceptance and commitment therapy
89349519|NCT04045041|No Intervention|Control group|Waiting-list control.
89349520|NCT02927366|Experimental|QCC374|Adult patients with pulmonary arterial hypertension (PAH) on QCC374. All patients were initiated at 0.03 mg BID (Day 1-3), and were up-titrated to next higher dose 0.06 mg BID (Day 4) and increased to 0.12 mg BID (Day 7-14).
89349521|NCT02927366|Placebo Comparator|Placebo|Adult patients with pulmonary arterial hypertension (PAH) on placebo matching to QCC374 doses (0.03 mg BID (Day 1-3), 0.06 mg BID (Day 4) and 0.12 mg BID (Day 7-14)).
89349522|NCT03249909|Other|Exufiber Ag +|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
89349523|NCT03249909|Other|Exufiber|Gelling fibre dressing without silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
89349524|NCT03249909|Other|Aquacel® Ag Extra|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
89349525|NCT01382810|Active Comparator|Altaire Gel forming solution|
89349526|NCT01382810|Placebo Comparator|Refresh Tears|
89349527|NCT05421260||Adult onset SCI|Spinal cord injury accident when the patient is over the age of 18 years old.
89349528|NCT05421260||Paediatric onset SCI|Spinal cord injury accident when the patient is under the age of 18 years old.
89349529|NCT04809116|Experimental|open-label pimavanserin 34mg at bedtime for 6 weeks|Subjects enrolled into treatment with open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
89349530|NCT03081884|Experimental|FACBC PET-CT Imaging|Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.
89349531|NCT01377038|Active Comparator|Duloxetine|Phenotype assessment prior to and after treatement with duloxetine 20-30 mg oral daily for eight weeks.
89349532|NCT01377038|Active Comparator|Diclofenac|Phenotype assessment prior to and after treatment with topical diclofenac four times daily
89349533|NCT03077438|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MenACYW Conjugate vaccine on Day 0.
89349534|NCT03077438|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MENVEO® Conjugate vaccine on Day 0.
89349535|NCT01382732|Experimental|Carbetocin|"Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.~Ringer's Lactate 4mL applied to a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr"
89349536|NCT01382732|Active Comparator|Oxytocin|Protocol B (oxytocin + placebo) Ringer's Lactate 11mL directly into the vein in no less than two minutes. Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
89349537|NCT02183870|Experimental|Crizotinib|Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated.
89349538|NCT03076970|Experimental|Lasmiditan 200 mg|single oral tablet
89349539|NCT03076970|Active Comparator|Sumatriptan 100 mg|single oral tablet
89349540|NCT03076970|Experimental|Combination of lasmiditan and sumatriptan|single oral tablet of each
89349541|NCT05416346|Experimental|dCBT-i|The dCBT-i group received the whole intervention
89349542|NCT05416346|Active Comparator|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
89349543|NCT04801394|Experimental|Mesh Group|Patient with large incisional hernia treated with FLaPp® mesh as neoperineium
89349544|NCT04784312|Experimental|9MW1411 injection|
89349545|NCT04784312|Experimental|9MW1411 injection placebo|
89349546|NCT00726596|Experimental|Hydroxychloroquine|Hydroxychloroquine - 400 mg (cohort A) Hydroxychloroquine - 600 mg (cohort B)
89349547|NCT01376960|Active Comparator|single shot popliteal fossa block|
89349548|NCT01376960|Active Comparator|ankle blocks|
89349549|NCT01382576||PCOS patients|
89349550|NCT01382576||PCOS patients and healthy controls|There are two groups in this study. One group is PCOS patients and other group is healthy controls.
89349551|NCT04897880|Experimental|Osteosarcoma [arm closed]|
89349552|NCT04897880|Experimental|Malignant Rhabdoid Tumor/Atypical Teratoid Rhabdoid Tumor|
89349553|NCT04897880|Experimental|Neuroblastoma [arm closed]|
89349554|NCT03630458|Experimental|Pearl millet couscous - made in Senegal|Steamed pearl millet couscous - commercially produced in Senegal
89349555|NCT03630458|Experimental|Pearl millet couscous - made in USA|Steamed pearl millet couscous - pearl millet obtained from Senegal but processed and prepared in USA
89349556|NCT03630458|Experimental|Pearl millet thick porridge|Thick porridge prepared according to traditional West African methods with pearl millet obtained from Senegal but processed and prepared in USA
89349557|NCT03630458|Experimental|Wheat couscous|Steamed wheat couscous - wheat flour processed and prepared in USA
89349558|NCT03630458|Active Comparator|White rice|White rice - medium-grain prepared using a rice cooker
89349559|NCT04460690|Experimental|Rapid Onsite COVID-29 Testing|Community participants provide a saliva sample for a simple test to detect high concentrations of SARS-CoV-2 in saliva with assays that require no specialized equipment and can be completed in one hour.
89349560|NCT04456244||Group 1:Transtibial Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
89349561|NCT04456244||Group 2:Transfemoral Amputation|Photographs will be taken with posturography device during free posture and equal weighting on both extremities. Static postural adaptations will be determined by photo analysis.
89349562|NCT02890992|Experimental|Cohort 1 - Alirocumab 30 mg Q2W: <50 kg|"Period 1: Participants with body weight less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 30 milligram(mg) administered every 2 weeks (Q2W) up to 8 weeks added to lipid modifying therapy (LMT).~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 30 mg administered Q2W from Week 16 until they started receiving dose matching to Cohort 2 dosage including dose adjustment to body weight as required. Cohort 2 dosage was: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
89349563|NCT02890992|Experimental|Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg|"Period 1: Participants with body weight greater than or equal to (>=) 50 kg received SC injection of alirocumab 50 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 50 mg administered Q2W from Week 16 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
89349564|NCT02890992|Experimental|Cohort 2 - Alirocumab 40 mg Q2W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W from Week 16 until switch of dosage in Cohorts 1 and 3. If body weight was still < 50 kg, participants continued to receive SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
89349565|NCT02890992|Experimental|Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W from Week 16 until Week 130."
89349566|NCT02890992|Experimental|Cohort 3 - Alirocumab 75 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered every 4 weeks (Q4W) up to 8 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered Q4W from Week 14 until switch to Cohort 2 dosage including dose adjustment to body weight as required, then Cohort 2 dosage: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
89349567|NCT02890992|Experimental|Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W up to Week 8 added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W from Week 14 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
89349568|NCT02890992|Experimental|Cohort 4 - Alirocumab 150 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 150 mg administered Q4W up to 12 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of Alirocumab 150 mg administered Q4W from Week 12 until Week 48."
89349569|NCT02890992|Experimental|Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W up to 12 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W from Week 12 until Week 48."
89349570|NCT04268628||Participants with mCRPC|Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen [PSA] response).
89349571|NCT05275296|Experimental|experimental group|Microport NeuroTech Intracranial Visualized Stent
89349572|NCT05275296|Active Comparator|control group|LVIS™ and LVIS™ Jr
89349573|NCT05275062|Experimental|IM92 CAR-T cells|
89349574|NCT01313364|Experimental|All subjects to self-administer 4 IM injections|Subjects will be recruited and stratified into BMI groups: <18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and >30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.
89349575|NCT04357730|No Intervention|Control|Patients randomized to Control arm will receive no study medication; the treatment will be standard of care according to the institution's protocol for ARDS.
89349576|NCT04357730|Experimental|Alteplase-50 bolus|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Re-bolusing of Alteplase, at the same dose, is permitted in those patients who show an initial transient response. The repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
89349577|NCT04357730|Experimental|Alteplase-50 bolus plus drip|Patients randomized to Alteplase-50 plus drip group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours. Immediately following this initial Alteplase infusion, a drip of 2 mg/hr of Alteplase will be initiated over the ensuing 24 hours (total 48 mg infusion).
89349578|NCT05274984|Placebo Comparator|Group Placebo|the control group will be given the same volume of saline as the experimental group
89349579|NCT05274984|Active Comparator|Group Lidocaine|the experimental group will be given l-1.5mg lidocaine and then 2mg/kg/h
89349580|NCT05274672|Experimental|Patients not receiving postoperative antibiotics|Patients who will not receive prophylactic postoperative antibiotics after HoLEP.
89349581|NCT05274672|Active Comparator|Patients receiving postoperative antibiotics|Patients who will receive3 days prophylactic postoperative antibiotics after HoLEP.
89349582|NCT04308434|Experimental|CSD190601-11|Subjects will self-assign to flavor variant CSD190601-11 of 1.5% ENDS products based on their preferred flavor.
89349583|NCT04308434|Experimental|CSD190601-12|Subjects will self-assign to flavor variant CSD190601-12 of 1.5% ENDS products based on their preferred flavor.
89349584|NCT04308434|Experimental|CSD190601-13|Subjects will self-assign to flavor variant CSD190601-13 of 1.5% ENDS products based on their preferred flavor.
89349585|NCT04308434|Experimental|CSD190601-14|Subjects will self-assign to flavor variant CSD190601-14 of 1.5% ENDS products based on their preferred flavor.
89349586|NCT04308434|Experimental|CSD190601-15|Subjects will self-assign to flavor variant CSD190601-15 of 1.5% ENDS products based on their preferred flavor.
89349587|NCT04308434|Experimental|CSD190601-16|Subjects will self-assign to flavor variant CSD190601-16 of 1.5% ENDS products based on their preferred flavor.
89349588|NCT04308434|Experimental|CSD190601-17|Subjects will self-assign to flavor variant CSD190601-17 of 1.5% ENDS products based on their preferred flavor.
89349589|NCT04308434|Experimental|CSD190601-21|Subjects will self-assign to flavor variant CSD190601-21 of 3.0% ENDS products based on their preferred flavor.
89349590|NCT04308434|Experimental|CSD190601-22|Subjects will self-assign to flavor variant CSD190601-22 of 3.0% ENDS products based on their preferred flavor.
89349591|NCT04308434|Experimental|CSD190601-23|Subjects will self-assign to flavor variant CSD190601-23 of 3.0% ENDS products based on their preferred flavor.
89349592|NCT04308434|Experimental|CSD190601-24|Subjects will self-assign to flavor variant CSD190601-24 of 3.0% ENDS products based on their preferred flavor.,
89349593|NCT04308434|Experimental|CSD190601-25|Subjects will self-assign to flavor variant CSD190601-25 of 3.0% ENDS products based on their preferred flavor.
89349594|NCT04308434|Experimental|CSD190601-26|Subjects will self-assign to flavor variant CSD190601-26 of 3.0% ENDS products based on their preferred flavor.
89349595|NCT04308434|Experimental|CSD190601-27|Subjects will self-assign to flavor variant CSD190601-27 of 3.0% ENDS products based on their preferred flavor.
89349596|NCT03630848|Experimental|10 mg/ml protein concentration in Embryo Culture Media|
89349597|NCT03630848|No Intervention|5 mg/ml protein concentration in Embryo Culture Media|
89349598|NCT03630692||observance of oral drug treatment|Study of observant or nonobservant patient behavior for their oral drug treatment
89349599|NCT01379144|Experimental|latanoprost 75 ug|
89349600|NCT01379144|Experimental|latanoprost 100 ug|
89349601|NCT01379144|Experimental|latanoprost 125 ug|
89349602|NCT01379144|Active Comparator|latanoprost 50 ug|
89349603|NCT05341466|Experimental|Repetitive Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
89349604|NCT05341466|Sham Comparator|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
89349605|NCT03076190|No Intervention|Active Control Group (Health Education)|"Prior to surgery:~Demographics survey~Baseline surveys~Participants receive online information regarding nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery.~Follow-up questions about the handouts (detailed above)~Post-surgery:~Daily surveys (detailed above)~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
89349606|NCT03076190|Experimental|My Surgical Success Treatment Group|"Prior to surgery:~Demographics survey~Baseline surveys~Intervention:~90-minute psychoeducational My Surgical Success video that emphasizes catastrophizing treatment.~audio file~personalized plan that incorporates the information learned in the video.~Follow-up questions about the video (detailed above)~Post-surgery:~Daily surveys (detailed above)~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
89349607|NCT01376882|Experimental|Acute withdrawal|Chronic intervention 100 mg caffeine capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
89349608|NCT01376882|Experimental|Acute caffeine-independent of withdrawal|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
89349609|NCT01376882|Experimental|Chronic abstinence|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
89349610|NCT01376882|Experimental|Acute caffeine-in state of withdrawal|Chronic intervention of 100 mg caffeine capsule 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
89349611|NCT03630380||Single Arm|All children under five years of age with clinical suspicion of pneumonia (fever or respiratory complaints) who have a chest radiograph ordered will be consented. Clinical history, physical exam findings (temperature, respiratory rate, oxygen saturation, and lung auscultation findings), laboratory findings (white blood cell count, differential, and CRP) will be recorded. Lung ultrasound will be performed on all patients.
89349612|NCT04656002|Experimental|Paclitaxel, Ramucirumab + TEW-7197|"Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours~-Paclitaxel, Ramucirumab Intravenous (IV) Ramucirumab injection, provided as a single-use 500-mg/50-mL vial containing 10 mg/mL of product in histidine buffer, with disease progression, toxicity requiring discontinuation, or without interruption for any reason. After diluting to 8 mg/kg every 2 weeks, IV It is administered by infusion.~Paclitaxel is administered at a dose of 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle, with disease progression, toxicity requiring discontinuation, or without interruption for any reason."
89349613|NCT03328182|Experimental|New oral endotracheal tube holder|Single Study Product Arm
89349614|NCT01382498|Placebo Comparator|Placebo|Placebo tablets will be administered to the patients in Placebo arms daily for three months.
88818405|NCT01819883||Active Acromegaly|All study subjects with acromegaly will be studied twice - once during the active stage of their disease (pre-treatment) and a second time: 3 months after treatment of acromegaly. Controls will be studied at one time point.
89349615|NCT01382498|Experimental|Calcium dobesilate|Calcium dobesilate as 500 mg tablets will be administered once to the patients daily.
89349616|NCT05297942|Experimental|Intervention (Expansion) Arm|Expansion of abbreviations and acronyms
89349617|NCT05297942|No Intervention|Control (Abbreviation) Arm|No expansion of abbreviations and acronyms
89349618|NCT03539796|Experimental|Dural puncture epidurals (DPE)|Dural puncture epidurals for cesarean section.
89349619|NCT03539796|Active Comparator|Traditional epidurals (EPI)|Traditional epidurals (EPI) for cesarean section.
89349620|NCT03539796|Active Comparator|Combined-spinal epidural technique (CSE)|Combined-spinal epidural technique (CSE) for cesarean section.
89349621|NCT04139798|Experimental|NOV03 4 times daily (QID)|100% Perfluorohexyloctance solution 4 times daily (QID)
89349622|NCT04139798|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.6% sodium chloride solution) 4 times daily (QID)
89349623|NCT01312662||normal ophthalmological status|
89349624|NCT01312662||opacity of the refractive media|
89349625|NCT01312662||maculopathy|
89349626|NCT01312662||optic neuropathy|
89349627|NCT01312662||chiasmal and postchiasmal visual pathway pathologies|
89349628|NCT01312662||amblyopia (deprivation)|
89349629|NCT01312662||amblyopia (strabism)|
89349630|NCT04615052|Experimental|Exercise group|
89349631|NCT04615052|No Intervention|Control group|The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
89349632|NCT03327402|Experimental|SHP465|Participants will receive SHP465 capsule at a dose of 6.25 mg, orally once daily for 4 weeks.
89349633|NCT03075878|Experimental|Cohort 1: ALXN1830|SYNT001 Dose 1
89349634|NCT03075878|Experimental|Cohort 2: ALXN1830|SYNT001 Dose 2
89349635|NCT03326856|Placebo Comparator|Vehicle|Vehicle
89349636|NCT03326856|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
89349637|NCT03326856|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
89349638|NCT03326856|Experimental|Dose 3|botulinum toxin, Type A, Dose 3
89349639|NCT03326856|Experimental|Dose 4|botulinum toxin, Type A, Dose 4
89349640|NCT01382420|Active Comparator|Adrenalectomy group|patients who undergo adrenalectomy
89349641|NCT01382420|No Intervention|Control group|patients who receive conservative treatment
89349642|NCT04095078|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
89349643|NCT04095078|No Intervention|Control|Usual care
89349644|NCT03819842|No Intervention|Aphakic Measure only|Eye measured in aphakic state only
89349645|NCT03819842|Active Comparator|Pseudophakic measure|Eye measured in aphakic state then again in pseudophakic state with toric IOL using the ORA System. Pseudophakic measurement obtained will provide data about placement of toric iol and the surgeon will use that data to rotate the iol if necessary.
89349646|NCT04088136|Experimental|Everyday Metacognitive Memory|Training in techniques for managing memory demands in everyday life
89349647|NCT04088136|Active Comparator|Memory Strategy Control|Trains the use of memory strategies for learning new associations and concepts
89349648|NCT00000116|Experimental|Docosahexaenoic acid + Vitamin A|Participants randomized to this arm received 1200 mg/d docosahexaenoic acid and 15000 IU/d Vitamin A as retinyl palmitate
89349649|NCT00000116|Placebo Comparator|Control fatty acid + Vitamin A|Patients randomized to this arm received 500 mg/d of fatty acid with no docosahexaenoic acid and 15000 IU/ Vitamin A as retinyl palmitate
89349650|NCT05232396|Experimental|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg, single dose usage
89349651|NCT05232396|Experimental|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg, single dose usage
89349652|NCT05232396|Experimental|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg, single dose usage
89349653|NCT05232396|Active Comparator|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg，as active comparator, single dose usage.
89349654|NCT01379066||Tuberculosis Patients|Suspected Tuberculosis patients
89349655|NCT01379066||Control|Healthy volunteers
89349656|NCT05222724|Experimental|Tachifene|paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
89349657|NCT05222724|Active Comparator|Brufen|ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
89349658|NCT04581356|Experimental|voxelotor|Voxelotor 1500mg daily orally
89349659|NCT01382342|Experimental|rasagiline|Participants in this arm will receive 1 mg of rasagiline daily for the six month duration of the study.
89349660|NCT01382342|Placebo Comparator|Placebo|Participants in this group will receive 1 mg of placebo daily for the six month duration of the study.
89349661|NCT03471728||Irritable Bowel Syndrome|Patients with Irritable Bowel Syndrome with Constipation (IBS-C) who have used linaclotide for the first time
89349662|NCT03471728||Chronic Constipation|Patients with Chronic Constipation (CC) (excluding constipation due to organic diseases) who have used linaclotide for the first time
89349663|NCT03309696|Experimental|tDCS and 1 Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC. .
89349664|NCT03309696|Experimental|tDCS and 10Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
89349665|NCT03309696|Experimental|tDCS over DLFC and 1 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
89349666|NCT03309696|Experimental|tDCS over DLFC and 10 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
89349667|NCT01382264|Experimental|CADS|
89349668|NCT03294330|Experimental|Patients with Melanoma or Breast Cancer|The SPY machine used in conjunction with the IC-green kit will be used exclusively to identify sentinel nodes in patients diagnosed with Melanoma or Breast Cancer who are undergoing sentinel lymph node biopsy.
89349669|NCT03463148||1|Men/Women who meet the inclusion/exclusion criteria of this protocol.
88811812|NCT02209259|Experimental|Intervention Group 1|The first intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing the standard PCS.
89349670|NCT03630614|Experimental|Electronic cigarette condition|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
89349671|NCT03630614|Active Comparator|Varenicline condition|Reference group: Electronic cigarette without nicotine (ECwoN) plus active varenicline tablets
89349672|NCT03630614|Placebo Comparator|Placebo condition|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
89349673|NCT05192694|Other|FAPI PET|Prospective single arm cohort
89349674|NCT03630926||Prostate Cancer (PCa)|Comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy.
89349675|NCT03630926||Benign Prostatic Hypertrophy (BPH)|comprosed of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP).
89349676|NCT03630926||Bladder/kidney stone|Comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
89349677|NCT05190042|Experimental|Continuous suture group|"Surgical sutures were used to completely close the post-EMR/ESD mucosal/submucosal defects.~This group was set as a experimental group."
89349678|NCT05190042|Active Comparator|Clips group|Clips were used to completely close the post-EMR/ESD mucosal/submucosal defects. This group was set as a control group.
89349679|NCT01378910|Experimental|Change of 3rd drug to maraviroc|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
89349680|NCT03946098|Experimental|iCBT for Gambling Disorder|Treatment will consist of a 1+10 module internet delivered CBT program targeting problem gambling, newly developed. A bottom-up procedure was used to develop the treatment protocol, inspired by Clark's (2004) method for developing novel CBT treatments. We developed a clinical model delineating what factors contribute to the persistence of problem gambling behavior, and aligned these with targeted treatment interventions; based on behavioral upon research on the learning and maintenance processes of gambling behavior (Ramnerö et al, in press), theoretical models of gambling and comorbidity (Blaszczynski & Nower, 2002); as well as qualitative interviews with treatment seeking gamblers with or without comorbidity.
89349681|NCT03922698||Case Group|Patients who undergo surgical intervention of carotid trombo-endo-arterectomy at the Department of Vascular Surgery of the IRCCS Neuromed, with specific inclusion/exclusion criteria
89349682|NCT03902028|Experimental|Reinforced multidisciplinary follow-up|"Entrance medication reconciliation performed by a pharmacist~Patient compliance evaluation~Patient quality of life evaluation~Pharmaceutical analysis with focus on medication optimization with a specific check-list (according to ESC 2016 recommendations)~Hospitalisation discharge medication reconciliation~Patient pharmaceutic interview at the hospitalisation discharge~Transmission of informations to the general practitioner and the pharmacist's patient~Multidisciplinary consult at 1 month after hospitalisation discharge"
89349683|NCT03902028|No Intervention|Standard care|"Drug review by a paramedic or a pharmacist~Pharmaceutical analysis~Therapeutic optimisation based on the usual practices care of the cardiologic department~Writing of the prescription given on leaving hospital based on the usual care of the department~Treatments explanations and support to the patient on the usual care~Transmission of the hospitalisation report to the patient general practitioner as the usual practice~Medical consult in usual time frames (an average of 1 month after hospitalisation discharge) at the patient location of choice"
89349684|NCT04847778|Active Comparator|Masked arm|"Participants will be instructed on the correct installation and use of the Insulclock device and app on masked mode for recording insulin bolus information.~Participants do not receive any other information and will not have access to the Insulclock 360 application from the Internet.~Participants will keep administering insulin treatment as usual."
89349685|NCT04847778|Active Comparator|Active arm|"Participants will receive detailed instructions on using the Insuclock 360 app and Insulclock device~Participants will be instructed and motivated for full use of all system functions: alarms, messages to the caregivers and investigation team."
89349686|NCT04570488||Quality improvement - Display|Display of risk score/ colored flag in Epic patient list column; will be viewable to all frontline workers
89349687|NCT04570488||No Display|"No display (hidden) of risk score/ colored flag in Epic patient list column; not viewable to all frontline workers"
89349688|NCT03075644|Experimental|Somapacitan|
89349689|NCT03075644|Active Comparator|Norditropin|
89349690|NCT04521296|Experimental|DWJ1248|Camostat mesylate
89349691|NCT04521296|Placebo Comparator|Placebo|Placebo
89349692|NCT05764538|Experimental|DAOIB|
89349693|NCT03689478|Experimental|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
89349694|NCT01378754|Experimental|6.5 milligram per kilogram of Fospropofol (Lusedra®)|
88807295|NCT02111798|Placebo Comparator|Placebo/Abstinence Initiation|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did not provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
88818406|NCT01819883||Healthy controls|
89349695|NCT01378754|Experimental|10 milligram per kilogram of Fospropofol (Lusedra®)|
89349696|NCT01378754|Experimental|12 milligram per kilogram of Fospropofol (Lusedra®)|
89349697|NCT05764382|Experimental|T'ai Chi and Qigong Rehabilitation|
89349698|NCT05764382|Active Comparator|Usual care|
89349699|NCT05462678|Experimental|Cognitive Rehabilitation|the first group carried out a training of CR by three memory modules of the Rehacom program (http://www.emsmedical.net).
89349700|NCT05462678|Experimental|Combined Training|the second group followed a mixed training program with the use of the version of the verbal memory module of the Rehacom program combined with the MR training.
89349701|NCT05462678|Experimental|Motor Rehabilitation|the third group carried out a traditional MR training.
89349702|NCT05462366||Mother|healthy mothers
89349703|NCT05462366||Infant|healthy infants
89349704|NCT05764304|Experimental|Sinomenine|
89349705|NCT05764304|Active Comparator|Glucocorticoid|
89349706|NCT03075410|Experimental|Cohort 1- GSK3036656 in Part A|During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
89349707|NCT03075410|Placebo Comparator|Cohort 1- Placebo in Part A|During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
89349708|NCT03075410|Experimental|Cohort 2- GSK3036656 in Part A|During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
89349709|NCT03075410|Placebo Comparator|Cohort 2- Placebo in Part A|During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
89349710|NCT03075410|Experimental|Cohort 3- GSK3036656 in Part B|During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.
89349711|NCT03075410|Placebo Comparator|Cohort 3- Placebo in Part B|During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
89349712|NCT03075410|Experimental|Cohort 4- GSK3036656 in Part B|During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
89349713|NCT03075410|Placebo Comparator|Cohort 4- Placebo in Part B|During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
89349714|NCT03075410|Experimental|Cohort 5- GSK3036656 in Part B|During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
89349715|NCT03075410|Placebo Comparator|Cohort 5- Placebo in Part B|During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
88818407|NCT04350749|Experimental|Test group (PRF group)|PRF membrane is added to the bone block to evaluate if any effect on bone healing, soft healing, post-operativ pain
88807296|NCT02111798|Active Comparator|Bupropion XL/Abstinence Initiation|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did not provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
89349716|NCT03075410|Experimental|Cohort 6- GSK3036656 in Part B|During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
89349717|NCT03075410|Placebo Comparator|Cohort 6- Placebo in Part B|During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
89349718|NCT04084964|Experimental|Study group|These patients receive the home-hospitalisation platform
89349719|NCT03630068||Patients with hepatocellular carcinoma treated with microwave|
89349720|NCT03246698|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position. Additionally they will receive standard physiotherapy.
89349721|NCT03246698|Experimental|Static stretching group|"The participants in this group will receive static stretching in modified cross body position.~Additionally they will receive standard physiotherapy."
89349722|NCT03246698|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
89349723|NCT04731818|Experimental|ZB-06|All participants will receive a single ZB-06 film for intravaginal administration prior to intercourse.
89349724|NCT05764226|Experimental|35 kDa HA fragment HA35 injection|100 mg of the freshly made 35 kDa low molecular weight hyaluronan fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds
89349725|NCT02826512|Experimental|Niraparib|niraparib 300 mg QD continuously
89349726|NCT05763134||weaning failure|Unstable patient without mechanical ventilator support within 48 hours
89349727|NCT05763134||weaning success|Stable patient for more than 48 hours without mechanical ventilator support
89349728|NCT01569386|Experimental|low intensity physical activity|Daily low intensity physical activity by the half squat
89349729|NCT01569386|Active Comparator|stretch exercise and usual activity|They do whole body stretch exercise for 20 minute in a day
89349730|NCT01663844|Experimental|(Study 1) ICBT for insomnia and depression|
89349731|NCT01663844|Active Comparator|(Study 1) ICBT for depr. plus placebo insomnia intervention|
89349732|NCT01663844|Experimental|(Study 2) ICBT for insomnia with added support|
89349733|NCT01663844|Active Comparator|(Study 2) ICBT for insomnia with regular level of support|
89349734|NCT05762978|Experimental|Asthmatic Children|NIF will be measured using an In-Check Dial
89349735|NCT05762900|Experimental|Ultra-hypofractionated arm|The patients will be treated by Ultra-hypofractionated irradiation.
89349736|NCT05764148|Experimental|Behavioral activation|Behavioral activation
89349737|NCT05764148|Placebo Comparator|Traatment as usual|
89349738|NCT00614432||1|Women who are anticoagulated.
89349739|NCT00614432||2|Matched case controls.
89349740|NCT02815124|Active Comparator|Standard of Care|Cochlear Implant programming using standard of care
89349741|NCT02815124|Experimental|Image-Guided Cochlear Implant Programming|Cochlear Implant programming using Image-Guided Cochlear Implant Programming
89349742|NCT01378442|Experimental|high level training group|receive high frequency fitness training program(Frequency: three times a week, Duration: 40 minutes).
89349743|NCT01378442|Experimental|low level training group|will receive low frequency fitness training program(Frequency: 1-2 times a week, Duration: 40 minutes).
89349744|NCT01378442|No Intervention|control|No intervention, but maintain usual physical activities
89349745|NCT01378364|Experimental|AbGn-168H very low dose i.v.|subject to receive a single very low dose of AbGn-168H intravenously (i.v.) or placebo
89349746|NCT01378364|Experimental|AbGn-168H low dose i.v.|subject to receive a single low dose of AbGn-168H intravenously (i.v.) or placebo
89349747|NCT01378364|Experimental|AbGn-168H medium dose i.v.|subject to receive a single medium dose of AbGn-168H intravenously (i.v.) or placebo
89349748|NCT01378364|Experimental|AbGn-168H high dose i.v.|subject to receive a single high dose of AbGn-168H intravenously (i.v.) or placebo
89349749|NCT01378364|Experimental|AbGn-168H very low dose s.c.|subject to receive a single very low dose of AbGn-168H subcutaneously (s.c.) or placebo
89349750|NCT01378364|Experimental|AbGn-168H medium dose s.c.|subject to receive a single medium dose dose of AbGn-168H subcutaneously (s.c.) or placebo
89349751|NCT02731352|Experimental|iodine-131 Refractory/Resistant Differentiated Thyroid Cancer|iodine-131 (131I) -Refractory/Resistant Differentiated Thyroid Cancer
89349752|NCT05132660|Experimental|Sinemet|25 mg carbidopa/100 mg levodopa
89349753|NCT05132660|Placebo Comparator|Placebo|Placebo pill of similar size/shape
89349754|NCT05132660|No Intervention|follow-up|Follow-up testing on participants previously prescribed levodopa
89349755|NCT05762744|Other|Homozygous for major alleles of GCGR and GIPR|"Based on data in a genotype database, these individuals were homozygous for the wild type major alleles of both GCGR and GIPR."
89349756|NCT05762744|Other|Homozygous for missense variant in GIPR|Based on data in a genotype database, these individuals were homozygous for rs1800437 a missense variant (p.E354Q) in the GIP receptor gene (GIPR).
89349757|NCT05762744|Other|Homozygous for missense variant in GCGR|Based on data in a genotype database, these individuals were homozygous for rs1801483a missense variant (p.G40S) in the glucagon receptor gene (GCGR).
89349758|NCT02257424|Other|Phase 1/2|
89349759|NCT02121158|Other|1|ICD implantation in addition to Optimal Medical Therapy
89349760|NCT02121158|Active Comparator|2|Optimal Medical Therapy
89349761|NCT02111642|Experimental|Online risk calculator used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence used during preoperative counseling session.
89349762|NCT02111642|Placebo Comparator|Online risk calculator not used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence not used during preoperative counseling session.
89349763|NCT01569776|Experimental|New Amino Acid formula|
89349764|NCT01569776|Active Comparator|Control formula|Commercially available Amino Acid infant formula
89349765|NCT01858922|Experimental|Rapid Early Responders|All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients with rapid early response (RER) determined by FDG-PET/CT scan after two cycles of ABVE-PC will receive two more cycles of ABVE-PC. If subsequent PET/CT scan indicates a complete response (CR), therapy will stop and regular follow-up will begin. If the subsequent PET/CT for RER patients indicates a partial response, those patients will undergo IFRT.
89349766|NCT01858922|Experimental|Slow Early Responders|"All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients determined to have a slow early response (SER) determined by PET/CT scan after two cycles of ABVE-PC will receive 2 courses of DECA. If after PET/CT, the patient has a partial or complete response, then 2 additional courses of ABVE-PC will be given. If subsequent PET/CT scan indicates PR or CR, those patients will then undergo IFRT.~If stable or progressive disease is found at either PET/CT scan, the patient will be taken off-study and follow up will begin."
89349767|NCT01378286|Experimental|artesunate/amodiaquine|"artesunate (AS) / amodiaquine (AQ) as fixed dose combination~1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment"
89349768|NCT01378286|Active Comparator|chloroquine|150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment
89349769|NCT04151420||Adult IBD patients|
89349770|NCT01378208|Experimental|Normal weight|Body Mass Index between 18-25 kg/m2 Age between 18-35 years male
89349771|NCT05762588||Patients requiring soft tissue fixation of the shoulder, knee, foot/ankle, elbow, or hip|
89349772|NCT01378052||urothelial carcinoma pateints|
89349773|NCT01378052||healthy controls|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
89349774|NCT01377974|Active Comparator|Standard Treatment|Meglumine antimoniate as recommended by the Brazilian Ministry of Health
89349775|NCT01377974|Experimental|Tested Intervention|Miltefosine as the tested intervention
89349776|NCT04838990|Active Comparator|conventional visit|Regular outpatient visit
89349777|NCT04838990|Experimental|phone visit|Remote visit via phone
89349778|NCT04838990|Experimental|video visit|Remote visit via videochat
89349779|NCT05202548||Lymphadenitis TB|The group study was blocked paraffin from lymphadenitis tuberculosis patient that already confirmed diagnosis histopathological anatomy (PA histopathology)
89349780|NCT05762510|Experimental|LentiRed|LentiRed Drug Product
89349781|NCT05202236|Experimental|selective FGFR1-3 inhibitor|
89349782|NCT03071276|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
89349783|NCT03629600|Experimental|Aggressive Hydration|Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) [COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
89349784|NCT03629600|Active Comparator|Rectal Indomethacin|Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin [Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA] just after the completion of ERCP procedure.
89349785|NCT04804904|Experimental|TQ-B3101: Fed + Fast|In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fed condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fasted condition on Day 1 of treatment period 2.
89349786|NCT04804904|Experimental|TQ-B3101: Fast+Fed|In each of the two study periods (separated by a washout period),a single dose of TQ-B3101 will be administered.Participants will receive TQ-B3101 in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of TQ-B3101 in fed condition on Day 1 of treatment period 2.
89349787|NCT04801550|Active Comparator|Millimeter wave emitter status 1|Somatosensory stimulus during Magnetoencephalography (MEG) records
89349788|NCT04801550|Sham Comparator|Millimeter wave emitter status 2|Somatosensory stimulus during Magnetoencephalography (MEG) records
89349789|NCT04606628|Experimental|Intervention|Participants will consume 2 capsules containing eggshell membrane(ESM) with breakfast every day in 4 weeks.
89349790|NCT04606628|Experimental|Placebo|Participants will consume 2 capsules with no bioactive substance (placebo) with breakfast every day in 4 weeks.
89349791|NCT05200910||Patient|Patients whose ventricular septal defect closed percutaneously.
89349792|NCT05200910||Control|Healthy children
89349793|NCT03074162|Experimental|Diclofenac Sodium (A)|
89349794|NCT03074162|Experimental|Diclofenac & Capsaicin (B)|
89349795|NCT03074162|Active Comparator|Diclofenac Sodium Topical Gel|
89349796|NCT04045496|Experimental|JAB-3312|JAB-3312 will be administered orally once daily in 21 days treatment cycles.
89349797|NCT03070964|Experimental|Plitidepsin|
89349798|NCT05763992|Placebo Comparator|Arm A|12 consecutive cycles of weekly paclitaxel plus carboplatin (PCb) combined with 4 triweekly cycles of Pembrolizumab, followed by 4 consecutive cycles of triweekly anthracycline (doxorubicin or epirubicin)-cyclophosphamide (AC or EC) chemotherapy combined with 4 triweekly cycles of Pembrolizumab.
89349799|NCT05763992|Experimental|Arm B|Standard treatment (12 consecutive cycles of weekly paclitaxel plus carboplatin (PCb) combined with 4 triweekly cycles of Pembrolizumab, followed by 4 consecutive cycles of triweekly anthracycline (doxorubicin or epirubicin)-cyclophosphamide (AC or EC) chemotherapy combined with 4 triweekly cycles of Pembrolizumab) in combination with up to a maximum of 8 consecutive triweekly cycles of 5-day Fasting-Like Approach
89349800|NCT04352036||patient|
89349801|NCT01569620|Active Comparator|Culturally targeted print materials|Best clinical practices plus culturally print materials
89349802|NCT01569620|Active Comparator|Standard print materials|Best clinical practices plus standard print materials
89349803|NCT01569620|Active Comparator|Best clinical practices alone|Best clinical practices alone: This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
89349804|NCT04268654|Experimental|Ischemic Conditioning|"Preoperative artery embolization prior to esophagectomy~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
89349805|NCT04268654|No Intervention|Control|"Surgery without previous ischemic conditioning of the gastric conduit~Tissue pressure of oxygen measurement in both arms by Licox system. The probe is inserted directly through the skin as a cervical drainage and it is fixed by Witzel technique in the gastric conduit. It is removed after the three measurements (intraoperatively, 24h and 48h after surgery) of the PtiO2 as a normal drainage."
89349806|NCT05069012|Active Comparator|50 micrograms|Patients in this arm will receive 50 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
89349807|NCT05069012|Active Comparator|150 micrograms|Patients in this arm will receive 150 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
89349808|NCT05069012|Active Comparator|250 micrograms|Patients in this arm will receive 250 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
89349809|NCT04670588||Locally advanced rectal cancer patients|Patients with LARC undergoing TNT.
89349810|NCT05762042|Experimental|Femal|Patients in this arm will receive FEMAL (2 cp/die) for three months long
89349811|NCT05762042|Placebo Comparator|Placebo|Patients in this arm will receive PLACEBO (2 cp/die) for three months long
89349812|NCT03920306|Experimental|Intervention|"Drug administration for the experimental arm includes:~AgNO3 applied to the fistula tract.~A topical adhesive of either 2-Octylcyanoacrylate glue (Dermabond), or Fibrin glue, or Histoacryl glue (Tissue Seal), will be applied over the fistula's aperture.~Oral anti-reflux therapy of either Pantoprazole 20-40mg PO OD, or Ranitidine 5-10mg/kg/day PO divided twice daily or 150mg PO BID, for either 4 weeks or until gastrocutaneous fistula tract closure, whichever comes first."
89349813|NCT02888106|Active Comparator|Arm A|PEG IFN alfa-2a 180 µg for 48 weeks
89349814|NCT02888106|Experimental|Arm B|Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks
89349815|NCT02888106|Experimental|Arm C|Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks
89349816|NCT02888106|Experimental|Arm D|Myrcludex B 2 mg for 48 weeks
89349817|NCT02888106|Experimental|Arm E|Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks
89349818|NCT02888106|Experimental|Arm F|Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks
89349819|NCT04018196|Experimental|Experimental group|Patient aged over 80 years old will be included. They will have motor imagery training of manual task and motor imagery training of motor task.
89349820|NCT04018196|Active Comparator|Control group|Patient aged over 80 years old will be included. They will have emotionally neutral film as training of manual task and emotionally neutral film as training of motor task.
89349821|NCT05761340|Experimental|Helfer Skin Tap Group|Pregnant women were vaccinated against tetanus with the Helfer skin tap technique.The pain was evaluated with Number rating scale immediately after the procedure and also hemodynamic parameters were measured before and after the vaccination. A total of 33 pregnant women completed the study in the Helfer skin tap group
89349822|NCT05761340|Experimental|Standard Application Group|Pregnant women were vaccinated against tetanus with thestandard application technique.The pain was evaluated with Number rating scale. The pain was evaluated immediately after vaccination and hemodynamic parameters were examined before and after the vaccination. A total of 32 pregnant women completed the study in the standard application group.
89349823|NCT04798716|Experimental|Escalating Dose First Cohort|"First Cohort:~Five patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 2 x 10^9 exosomes"
89349824|NCT04798716|Experimental|Escalating Dose Second Cohort|"Second Cohort:~Five patients will receive an escalating dose every other day for a period of 5 days, with a minimum of 24 hours between doses recorded. Dose escalation will begin at 4 x 10^9 exosomes."
89349825|NCT04798716|Experimental|Escalating Dose Third Cohort|Five patients will receive a treatment dose of 8 X 10^9 exosomes every other day for a period of 5 days, with a minimum of 24 hours between doses recorded.
89349826|NCT04798716|Placebo Comparator|Treatment Dose Fourth Cohort Randomized control ratio 1:3|"Fourth Cohort:~Randomized Cohort Up to 40 patients may be enrolled in this phase of the trial. For those receiving the placebo (~25%), 3 doses will be given over the 5 day period, dispensed from identical vials with physician and patient blinded. The full dose of 8 X 10^9 exosomes will be given to 75% of the patients in 3 doses over the course of 5 days, with one dose occurring every other day."
89349827|NCT04767906|Other|Cabozantinib|Enrolled patients start with 60mg of Cabozantinib. The maximum duration of treatment is 336 days. The dose can be adjusted by the physician to 40mg or 20mg.
89349828|NCT05203016||caesarean sections|
89349829|NCT05203016||Plastic surgery|
89349830|NCT05203016||Maxillofacial surgery|
89349831|NCT03135990|Experimental|CBT + VR|Cognitive Behavioral Therapy with Virtual Reality technology.
89349832|NCT03055026|Experimental|Rivaroxaban|Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
89349833|NCT03055026|Placebo Comparator|Placebo|Orally administered, OD for 3 weeks (extended prophylaxis)
89349834|NCT01313754|Other|Vicryl|These patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive the vicryl material on the left.
89349835|NCT01313754|Experimental|Dermabond|The patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive dermabond skin glue on the left
89349836|NCT04561284|Experimental|Indigestible fiber supplementation|Participants will receive an indigestible fiber supplementation (classified) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals.
89349837|NCT04561284|Placebo Comparator|Placebo supplementation|Participants will receive placebo supplementation (Maltodextrin) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals. The amount of maltodextrin taken will be isocaloric with the amount of indigestible fiber.
89349838|NCT03304626|Experimental|Study Group|"Budesonide EC 3 mg capsule. The dose will be as follows~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1"
89349839|NCT03304626|Active Comparator|Control Group|"Standard of Care~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Prednisone 15-60 mg Days 31-45 SIS + Prednisone 10 mg Days 46-90 SIS + Prednisone 2.5 to 7.5 mg Days 90 onwards SIS"
89349840|NCT03620682|Experimental|Mobile mental health intervention|Participants will receive emotional support and problem-solving / stress-management skills via over-the-phone coaching sessions and mobile applications.
89349841|NCT05121714|Other|Evaluation of CYP1A2 inhibition and induction potential by ABX464|Using a fixed-sequence crossover study design, the Pharmacokinetics (PK) of caffeine (50 milligrams (mg) single oral dose) will be evaluated in the absence and presence of ABX464 (50 mg once daily for 14 days) in 24 healthy subjects. Caffeine will be administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.
89349842|NCT05121714|Other|Evaluation of ABX464 as a substrate for CYP1A2|Using a fixed-sequence crossover study design, the PK of ABX464 (50 mg single oral dose) will be evaluated in the absence and presence of fluvoxamine (100 mg once daily for 10 days) in 36 healthy subjects. ABX464 will be administered on Day 1 in the absence of fluvoxamine and on Day 11 simultaneously with fluvoxamine following 10 days of once daily dosing of fluvoxamine to evaluate whether ABX464 is a substrate for CYP1A2
89349843|NCT02958150|Experimental|Dexmedetomidine|Dexmedetomidine according to the stablished protocol
89349844|NCT02958150|Active Comparator|Standard Clinical Practice|The physician in charge will decide the treatment to be administered (if deemed necessary) in accordance with the protocol established at the department
89349845|NCT03274986|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
89349846|NCT03274986|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
89349847|NCT02919306|Experimental|Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) 0.5 milliliter (mL) injection intramuscularly (containing 5 * 10^10 viral particles [vp]) at Weeks 0 and 12 followed by modified Vaccinia Ankara-Mosaic (MVA mosaic) 0.5 mL injection (containing 10^8 Plaque-forming unit [pfu]) at Week 24 and 48.
89349848|NCT02919306|Placebo Comparator|Placebo|0.5 mL Sodium Chloride Injection United States Pharmacopeia (USP) 0.9% will be administered by intramuscular (IM) injection.
89349849|NCT03274440|Experimental|High THC/Low CBD Marijuana|This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (<1%) content.
89349850|NCT03274440|Experimental|Low THC/High CBD Marijuana|This condition involves the ingestion of marijuana with a low THC (<1%) and high CBD (>10%) content.
89349851|NCT03274440|Placebo Comparator|No THC/No CBD|This condition involves the ingestion of a placebo control with no THC and no CBD content.
89349852|NCT03637530|Experimental|intervention group|in this group of patients, inverse ratio ventilation is provided during general anaesthesia
89349853|NCT03637530|No Intervention|control group|in this group of patients, conventional ventilation is provided during general anaesthesia
89349854|NCT04250142|Active Comparator|Conventional Glass Ionomer|Selective removal of carious tissue to soft dentin. Deep carious dentin will be lined by a conventional glass ionomer, followed by a composite resin restoration.
89349855|NCT04250142|Experimental|Self-etching Adhesive|Selective removal of carious tissue to soft dentin. Deep carious dentin will not be lined and a self-etching adhesive will cover the tissue, followed by a composite resin restoration.
89349856|NCT02740608|Other|Liver transplantation|All Participants will receive liver transplantation using the OrganOx metra device
89349857|NCT02714322|Experimental|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
89349858|NCT02714322|Active Comparator|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
89349859|NCT03268746|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag following cataract removal. Both eyes will be implanted.
89349860|NCT03268590|Experimental|All Study Participants|Breathing 21% oxygen via non-rebreather face mask followed by breathing 100% oxygen via non-rebreather face mask
89349861|NCT03267576|Experimental|Treatment Sequence AB|Participants will receive metformin monotherapy at stable doses (greater than or equal to [>=] 1500 milligram per day [mg/day]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin >=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from Days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
89349862|NCT03267576|Experimental|Treatment Sequence BA|Participants will receive treatment B from Day 0 to 27 (treatment Period 1), followed by treatment A from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
89349863|NCT04236726||Non-invasive ventilation|Users of non-invasive ventilation
89349864|NCT04236726||Long term tracheostomy ventilation|Long term tracheostomy ventilated patients
89349865|NCT02472912|Experimental|Treatment A|Single Injection of 40mg / 0.8 mL BMO-2
89349866|NCT02472912|Active Comparator|Treatment B|Single Injection of 40mg / 0.8 mL EU-Humira
89349867|NCT02472912|Active Comparator|Treatment C|Single Injection of 40mg / 0.8 mL US-Humira
89349868|NCT04489368||Study Group|Patients undergoing NA-CCRT followed by Surgery
89349869|NCT02356458|Experimental|Ibrutinib & Bortezomib|Combination therapy (trial treatment of ibrutinib in combination with bortezomib) followed by ibrutinib maintenance therapy
89349870|NCT03267264|Experimental|Group 1|
89349871|NCT03267264|Experimental|Group 2|
89349872|NCT03267264|Experimental|Group 3|
89349873|NCT03267264|Experimental|Group 4|
89349874|NCT03244800|Placebo Comparator|Placebo Cohort 1|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
89349875|NCT03244800|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 7 days, followed by Dose 2 for 7 days, Dose 3 for 7 days, and Dose 4 for 28 days
89349876|NCT03244800|Placebo Comparator|PLacebo Cohort 2|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
89349877|NCT03244800|Experimental|MEDI0382 Cohort 2|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 14 days, followed by Dose 2 for 14 days, Dose 3 for 14 days, and Dose 4 for 7 days.
89349878|NCT03637452||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
89349879|NCT03637452||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
89349880|NCT04516291|Placebo Comparator|Placebo|No drug
89349881|NCT04516291|Experimental|Vupanorsen 80 mg every 4 weeks|80 milligrams (mg) given subcutaneously every 4 weeks.
89349882|NCT04516291|Experimental|Vupanorsen 60 mg every 2 weeks|60 mg given subcutaneously every 2 weeks.
89349883|NCT04516291|Experimental|Vupanorsen 120 mg every 4 weeks|120 mg given subcutaneously every 4 weeks.
89349884|NCT04516291|Experimental|Vupanorsen 80 mg every 2 weeks|80 mg given subcutaneously every 2 weeks.
89349885|NCT04516291|Experimental|Vupanorsen 160 mg every 4 weeks|160 mg given subcutaneously every 4 weeks.
89349886|NCT04516291|Experimental|Vupanorsen 120 mg every 2 weeks|120 mg given subcutaneously every 2 weeks.
89349887|NCT04516291|Experimental|Vupanorsen 160 mg every 2 weeks|160 mg given subcutaneously every 2 weeks.
89349888|NCT03243630|Placebo Comparator|Menthol e-liquid|Menthol Flavor + IV saline Menthol Flavor + IV nicotine (0.25mg/70kg) Menthol Flavor + IV nicotine (0.5mg/70kg)
89349889|NCT03243630|Active Comparator|green apple e-liquid|Green apple + IV saline Green apple + IV nicotine (0.25mg/70kg) Green apple + IV nicotine (0.5mg/70kg)
89349890|NCT03243630|Active Comparator|green apple and menthol e-liquid|Green apple and menthol + IV saline Green apple and menthol + IV nicotine (0.25mg/70kg) Green apple and menthol + IV nicotine (0.5mg/70kg)
89349891|NCT03753841|Active Comparator|Adjustment of oral diet|Patients who need a change in their diet regime, in whom FEES shows that they have not the adequat diet.
89349892|NCT03753841|No Intervention|No adjustment of oral diet|Patients who have the adequat diet based on FEES findings.
89349893|NCT03750019|Experimental|Satisfying rehearsal|Participants completed the satisfying rehearsal task where they rehearsed the satisfying aspects of the lunchtime meal.
89349894|NCT03750019|Experimental|Dissatisfying rehearsal|Participants completed the dissatisfying rehearsal task where they rehearsed the dissatisfying aspects of the lunchtime meal.
89349895|NCT03750019|Active Comparator|Neutral rehearsal|Participants completed the neutral rehearsal task where they rehearsed their journey to campus that day.
89349896|NCT03751345|No Intervention|Treatment As Usual (TAU)|The TAU condition consists of the standard treatment elements offered to all Gateway (study site) patients, and will be received by patients in both the PW and the TAU-only condition. TAU services during the adolescent's treatment are typically eclectic and mainly entail meeting with the adolescent alone to provide support and psychoeducation, with occasional family therapy sessions. Medication management is offered as needed.
89349897|NCT03751345|Experimental|Parenting Wisely (PW)|In addition to TAU services, the PW arm includes in-person sessions where parents complete computer-administered PW sessions, in-person session including therapist coaching to reinforce PW material and personalize treatment by applying PW skills to individual issues, and access to PW material remotely so parents can access information and skills from home as needed.
89349898|NCT04761289|Active Comparator|Control group. Health education program|The participants in this group will undergo the usual clinical practice: compliance and adherence to the prescribed drug treatment will be explained, as well as the established guidelines for individualized health care. A Health Education Program will also be added at discharge, mainly aimed at reinforcing and promoting an active and healthy life.
89349899|NCT04761289|Experimental|Experimental Group. Multimodal Exercise and Functional Rehabilitation Program|"Prescription of multimodal physical exercise. A supervised and structured home program will be carried out for one month. It will be carried out daily in two short sessions of 15-20 minutes, one in the morning and one in the afternoon. Each session will be structured in a warm-up, a main part and a cool-down and relaxation (14).~Reeducation of Activities of Daily Living (ADL). Specific training will be carried out after the evaluation and before the discharge of the patients from the university healthcare complex. It is intended to identify the factors that are interfering with the performance of activities of daily living. The intervention will consist of three parts: Direct intervention on Activities of Daily Living (ADL), carried out in situ in the hospitalization and generalizable to their daily environment; teaching in Energy Saving Techniques (APR).~Prescription of support products and adaptations of the environment."
89349900|NCT05457595|Experimental|carbon ion radiotherapy|All enrolled subjects will undergo carbon ion radiation therapy. Patients affected by pelvic recurrence of gynecological neoplasia, already undergone to radiotherapy on pelvis, will be enrolled in the study.
89349901|NCT03753685|Experimental|X-396(Ensartinib) Capsule|
89349902|NCT03751267|Experimental|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
89349903|NCT03751267|No Intervention|Wait-list control|This group of patients will receive Tuina (massage) 4 weeks after baseline assessments.
89349904|NCT04450381|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
89349905|NCT03068468|Experimental|BIIB092|Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
89349906|NCT03068468|Placebo Comparator|Placebo|Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
89349907|NCT04512001|Experimental|MSB11456|
89349908|NCT04512001|Active Comparator|RoActemra®|
89349909|NCT01569698||extrarenal replacement therapy|Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
89349910|NCT01569854||statin|
89349911|NCT05181176|Experimental|Coffee|The coffee group was instructed to consume 2 cups of coffee a day, the amount that was previously described as beneficial in epidemiological studies and safe for children and adolescence. Each cup of coffee contains 250 ml of coffee, which contains approximately 80 mg of caffeine. The children were allowed to add milk to the coffee and sweeten it with artificial sweetener
89349912|NCT05181176|Experimental|Green Tea|The green tea group will be instructed to drink 3 cups (230CC) of Chinese green tea (Wissotzky Tea Israel Ltd). Each tea bag contains 500 g of fine dried herb parts. Each cup contains 84 mg total catechin and 32 mg caffeine. The participants were instructed to leave the tea bag for 2 minutes before drinking.
89349913|NCT05181176|Placebo Comparator|Herbal tea|The control group consumed 3 cups a day of Wissotzky- kid drink (Wissotzky Tea Israel Ltd), which is a drink that is marketed for children containing an infusion of fruits and plants. Each tea bag contains 2.7 gr plants parts with no evidence of polyphenols or caffeine.
89349914|NCT04528160|Experimental|Pain neuroscience education and exercise|"This group will receive an 8-week intervention (1 session per week) of pain neuroscience education and exercise.~PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will include mobility, balance and strength exercises."
89349915|NCT04528160|Active Comparator|Usual care|This group will receive usual care administered by general practitioners at primary care.
89349916|NCT04447417|No Intervention|Healthy Volunteer|Healthy volunteers with age, gender, location of targeted skin lesion area and study site matched to a selected atopic dermatitis (AD) participants, received no treatment, but were monitored in similar way as like enrolled AD participants.
89349917|NCT04447417|Experimental|Atopic Dermatitis Patients|"Participants with moderate to severe AD and aged 18 years and older received dupilumab 600 milligrams (mg) (loading dose) subcutaneous (SC) injection on Day 1, followed by dupilumab 300 mg SC injection every 2 weeks (Q2W) through Week 14 (i.e., at Day 15, 29, 43, 57 and 85).~Participants aged greater than or equal to (>=) 12 to less than (<) 18 years received treatment based on their body weight: <60 kilograms (kg) and >=60 kg - received dupilumab 400 mg and 600 mg (loading dose) SC injection on Day 1, respectively, followed by dupilumab 200 mg and 300 mg SC injection Q2W through Week 14 (i.e., at Day 15, 29, 43, 57 and 85)."
89349918|NCT02787044|Experimental|High Dose Influenza Vaccine|High Dose Influenza Vaccine
89349919|NCT02787044|Active Comparator|Standard Dose Influenza Vaccine|Standard Dose Influenza Vaccine
89349920|NCT01345019|Active Comparator|Zoledronic acid|Zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaniously (SC) once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
89349921|NCT01345019|Experimental|Denosumab|Denosumab 120 mg subcutaniously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
89349922|NCT04507867|Sham Comparator|control group|Patients who received the standard diet
89349923|NCT04507867|Experimental|Intervention group|Patients who received the nutritional support system (NSS) and the standard diet
89349924|NCT04487522||Retromuscular ventral hernia repair|These subjects will undergo an open, a laparoscopic, or a robotic-assisted retromuscular ventral hernia repair.
89349925|NCT04487522||Retromuscular TAR ventral hernia repair|These subjects will undergo an open or a robotic-assisted retromuscular transversus abdominis release (TAR) ventral hernia repair.
89349926|NCT02610374|Other|Cohort A|HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
89349927|NCT02610374|Other|Cohort B|HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
89349928|NCT02610374|Other|Cohort C|HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
89349929|NCT03069716|Experimental|Smartphone Text Messaging|"Group receives personalized, health coaching via smart text messages."
89349930|NCT03069716|Other|No Smartphone Text Messaging|"Group does not receive personalized, health coaching via smart text messages."
89349931|NCT03749785|Active Comparator|Regular carbohydrate feeding|Ingestion of 75 g sucrose, given in regular doses for the first 75 minutes of exercise during a time to exhaustion run
89349932|NCT03749785|Active Comparator|Single carbohydrate bolus|Ingestion of 75 g sucrose, given in a single bolus after 75 minutes of exercise, during a time to exhaustion run
89349933|NCT03749707|Other|SLNs from early-stage cervical cancer patients|Tissue from SLNs removed from early-stage cervical cancer patients are analyzed for HPV.
89349934|NCT02535884|Experimental|Stimulation group|Patients in the stimulation group will be stimulated immediately after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
89349935|NCT02535884|Sham Comparator|Non-stimulation group|Patients in the non-stimulation group will not be stimulated for the first three months after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
89349936|NCT03629522|Active Comparator|ondansetron group|Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
89349937|NCT03629522|Placebo Comparator|control group|administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
89349938|NCT04742543|Experimental|Virtual reality glasses|Patients referred for conization due to cervical dysplasia under local anesthesia. In this arm , patients will be allocated to undergo the conization procedure with Virtual reality glasses on
89349939|NCT04742543|No Intervention|No intervention. standard treatment|Patients referred for conization due to cervical dysplasia under local anesthesia. In this arm , patients will be allocated to undergo the conization procedure without virtual reality glasses (no intervention)
89349940|NCT03751111|Experimental|Naloxone|Naloxone at an sublingual dose of 40 mg daily will be given to each subject.
89349941|NCT03751111|Placebo Comparator|Placebo|Sublingual placebo will be given to each subject.
89349942|NCT01250015||control|given standard nhs advice leaflet
89349943|NCT01250015||interventional|given standard nhs advice leaflet with numerical information and pictograms
89349944|NCT05167370|Experimental|Amifostine|
89349945|NCT03693625|Experimental|Parent Study: GDC-0853|Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
89349946|NCT03693625|Placebo Comparator|Parent Study: Placebo|Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
89349947|NCT03629366|Experimental|Supported Employment (SE)|Follow-up with Supported Employment (SE), provided by a job specialist trained in the eight evidence-based principles of Individual Placement and Support (IPS). The SE intervention is provided in addition to the mandatory introduction program for refugees in Norway (treatment as usual).
89349948|NCT03629366|Active Comparator|Treatment as usual (TAU)|Follow-up with treatment as usual, which involves participation in the mandatory introduction program provided for all refugees in Norway. The program includes training in Norwegian language and culture, as well as the various traditional employment schemes offered by the Norwegian labor and welfare Administration.
89349949|NCT01265537|Experimental|Low target tacrolimus (Advagraf)|"This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and low-target Advagraf."
89349950|NCT01265537|Active Comparator|Standard target tacrolimus (Advagraf)|"This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and standard target Advagraf."
89349951|NCT05330767||Wound on either the upper or lower extremity with DermaClose and/or DermaClose XL|Non-fasciotomy
89349952|NCT05330767||Wound undergoing fasciotomy with DermaClose and/or DermaClose XL|
89349953|NCT05330767||Wound undergoing fasciotomy with conventional wound dressings|
89349954|NCT05763836|Active Comparator|Group Block|Scalp nerve block applied group
89349955|NCT05763836|Experimental|Group Ibuprofen|Intravenous ibuprofen applied group
89349956|NCT05763836|Experimental|Grup Ibuprofen&Block|Both intravenous ibuprofen and scalp nerve block applied group
89349957|NCT04435249|Experimental|Treatment Arm|Patients will have a patch of expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold surgically implanted to repair bronchial fistula.
89349958|NCT01237535|Experimental|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel)Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.
89349959|NCT01237535|Experimental|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].
89349960|NCT01237535|No Intervention|No luteal support|
89349961|NCT03747913|Experimental|Antioxidative Supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
89349962|NCT04396639|Experimental|Treatment Arm|Fifty eligible male subjects will be enrolled in the treatment arm to receive Moroctocog alfa (AF-CC) until 24 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
89349963|NCT01146431||Hemodynamic parameters|Hemodynamic parameters will be used as a guide for anesthesia.
89349964|NCT01146431||BIS|Bispectral Index (BIS) will be used as a guide for anesthesia.
89349965|NCT02226458|Experimental|EPI-743|15 mg/kg oral solution three times per day, maximum of 200 mg per dose
88818408|NCT04350749|Active Comparator|Control group (Standard operation)|A standard bone augmentation procedure, which is weel-described is performed to compare the outcome of the test group
89349966|NCT01250249|Active Comparator|BCG Vaccine - Intradermal injection|"Subjects must be in the age group of 0 - 14 years of age.~2. Subject's parent should be able to understand and have to sign the informed consent form after being explained by the investigator. They must be aware of the experimental nature of the therapy, its potential benefits, side effects and risks.~3. Ability to comply with the schedule of treatment and follow-up.~4. Absence of BCG scar~5. Tuberculin negative~6. No evidence of any other infection~7. No evidence of skin disease~Skin testing with tuberculin is not generally carried out before giving BCG but when performed, those who are found to be positive reactors need not to be immunized"
89349967|NCT03747679|Experimental|A- Bosutinib in water|200 Mg of bosutinib (50 mg capsule x4) in Water solution
89349968|NCT03747679|Experimental|B- bosutinib in sorbitol|200 Mg of bosutinib sorbitol base in water solution
89349969|NCT03747679|Experimental|C- - bosutinib mannitol|200 Mg of bosutinib powder mannitol base in water solution
89349970|NCT03747679|Experimental|D - bosutinib in mannitol low sweet|200 Mg of bosutinib mannitol low sweet solution
89349971|NCT03747679|Experimental|E- - bosutinib in mannitol high sweet|200 Mg of bosutinib High % sweet mannitol solution
89349972|NCT03747679|Experimental|F- - bosutinib low flavour|Taste assessment of 200 Mg of bosutinib low % Flavour
89349973|NCT03747679|Experimental|G- bosutinib high flavour|Taste assessment of 200 Mg of bosutinib high percentage of flavor in water
89349974|NCT03747679|Experimental|H- - bosutinib capsules in low sweet|Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet
89349975|NCT03747679|Experimental|I - bosutinib capsules high sweet|200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener
89349976|NCT03747679|Experimental|J- - bosutinib capsules low flavour|Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution
89349977|NCT03747679|Experimental|K - bosutinib capsules high flavour|Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour
89349978|NCT03747679|Experimental|L - bosutinib capsules applesauce|200 Mg of bosutinib (50 mg x 4 capsules) in applesauce
89349979|NCT03747679|Experimental|M - bosutinib capsules full fat yougurt|200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt
89349980|NCT03747679|Experimental|N - bosutinib capsules in water (retest)|200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)
89349981|NCT01243385|Other|Metformin|Metformin at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
89349982|NCT03751033|Experimental|BSS and DisCoVisc|Following lens removal and removal of all OVD from the anterior chamber during cataract surgery, the chamber will be filled with BSS and the main incision hydrated with BSS. Intraoperative aberrometry, using the Optiwave® Refractive Analysis with VerifEye+ (ORA), will be performed, and the results of aphakic refraction and suggested IOL power will be recorded in triplicate. Immediately following, the BSS will be replaced with DisCoVisc; and, triplicate readings will be measured under the same conditions.
89349983|NCT01147133|Experimental|Original|Treatment phase with the original formulation of clopidogrel
89349984|NCT01147133|Active Comparator|Generic|Treatment phase with the generic clopidogrel
89349985|NCT04633499|Active Comparator|dmPFC tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the dmPFC while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
89349986|NCT04633499|Experimental|rTPJ tDCS + Social Cognition tasks in older participants|Participants will receive either active or sham stimulation over the rTPJ while conducting two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking.
89349987|NCT04633499|Active Comparator|Social cognition tasks in younger participants|Participants will conduct two different social cognition paradigms: one regarding emotion recognition, one on visual perspective taking but without tDCS stimulation.
89349988|NCT04432298|Experimental|Pamrevlumab|Pamrevlumab: 35 milligrams/kilogram (mg/kg) on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks
89349989|NCT04432298|Experimental|Placebo|Pamrevlumab-matching placebo on Days 1, 7, 14 and 28 for a total of 4 infusions over 4 weeks
89349990|NCT01250795|Experimental|15 ug HAI-05 plus Alhydrogel|vaccine
89349991|NCT01250795|Experimental|45 ug HAI-05 plus Alhydrogel|vaccine
89349992|NCT01250795|Experimental|90 ug HAI-05 plus Alhydrogel|vaccine
89349993|NCT01250795|Experimental|90 ug HAI-05 in saline|vaccine
89349994|NCT01250795|Placebo Comparator|Saline|placebo
89349995|NCT03913793|Active Comparator|Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction with peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
89349996|NCT03913793|Active Comparator|Non-Neuropathy group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction without peripheral neuropathy , enrolled into exercise program From those referred for cardiac rehabilitation in the cardiac rehabilitation unit, Alexandria Teaching Hospital
89349997|NCT03913793|No Intervention|Control group|post-myocardial infarction patients with type-II diabetes mellitus enrolled in the study within 1-6 months of myocardial infarction, not enrolled into exercise program.
89349998|NCT01237691|Experimental|HOPE supervision|Parolee supervised under California's new HOPE parole model.
89349999|NCT01237691|Active Comparator|Parole-as-usual|Parolees supervised under California parole-as-usual.
89350000|NCT04167085|Experimental|Doxycycline, then Placebo|Doxycycline for a period of 2 months followed by a 1-month washout period, and then placebo for a further 2 months period followed by a 1-month washout period.
89350001|NCT04167085|Experimental|Placebo, then Doxycycline|Placebo for a period of 2 months followed by a 1-month washout period, and then Doxycycline for a further 2 months period followed by a 1-month washout period.
89350002|NCT03913403||Intervention|Participants will receive 2 ECHO's and 2 Blood Draws
89350003|NCT01562509|Active Comparator|Standard implementation strategy|Standard intervention
89350004|NCT01562509|Experimental|Innovative implementation strategy|Implementation tools
89350005|NCT01250327|Experimental|Melody|insertion of a pulmonic valved stent
89350006|NCT01250327|Active Comparator|Bare stent|insertion of a bare metal stent
89350007|NCT01250327|Active Comparator|Surgery|conventional surgery methode.
89350008|NCT01147289|Experimental|dexalgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose for 3 days, at least
89350009|NCT01147289|Active Comparator|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose for at least 3 days.
89350010|NCT03749473|Active Comparator|Control|Participants receive a daily message with their step count on the prior day to serve as an active control for 24 weeks (daily performance feedback). No other interventions during the 24-week study
89350011|NCT03749473|Experimental|Choice + Immediate|Participants choose a step goal between 1000-3000 steps greater than their baseline (choice). They are asked to reach their full step goal upon intervention start (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
89350012|NCT03749473|Experimental|Choice + Gradual|Participants are asked to choose a step goal between 1000-3000 steps greater than their baseline (choice). They will be asked to increase their step goal by even increments of 12.5% each week for the 8 weeks of the ramp-up period (gradual). After the 8-week ramp-up period, they will be asked to maintain the step goal for the study. They may change their goal within the range at anytime. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
89350013|NCT03749473|Experimental|Assigned + Immediate|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to reach their full step goal as soon as the intervention begins (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
89350014|NCT03749473|Experimental|Assigned + Gradual|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to achieve their step goal of 2000 steps incrementally over the 8 weeks of the ramp-up period (gradual). After the first 8 weeks, they will be asked to maintain their full step goal of 2000 for the the study. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
89350015|NCT01237769|Active Comparator|Vitamin D|All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.
89350016|NCT01237769|Active Comparator|Lifestyle measures|
89350017|NCT01562665||All Population|
89350018|NCT01562665||Sample of patients will be invited to complete Quality of Life|
89350019|NCT03914963|Experimental|Fibrin sealant treatment hemipelvis|•Drug: Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis).
89350020|NCT03914963|Placebo Comparator|Control hemipelvis|Other hemipelvis
89350021|NCT03915119|Experimental|VR Obstacle group|"Initial Visit: navigates a cluttered array of fixed and moving virtual obstacles to reach a way-point (goal) as fast and efficiently (avoiding obstacles) as possible. In each block, task difficulty (i.e., complexity) will increase linearly, regardless of success or failure (≥ 1 collision before reaching the goal).~Second (Training) Visit (randomized into two groups):"
89350022|NCT03915119|Experimental|Agility Group|"Initial Visit: Completes a soccer ball dribbling agility task in which they must dribble a soccer ball toward an artificial way-point, while avoiding artificial obstacles overlaid onto the real world via a Microsoft Hololens augmented reality display.~Second (Training) Visit"
89350023|NCT04162795|Experimental|Loratadine chewable tablet|Participants received one dose of loratadine chewable tablet to chew completely before swallowing.
89350024|NCT01237847|Other|Wait List|
89350025|NCT01237847|Experimental|2 phone sessions|
89350026|NCT01237847|Experimental|4 phone sessions|
89350027|NCT04541953|Active Comparator|Telerehabilitation|
89350028|NCT04541953|Active Comparator|In-Person Rehabilitation|
89350029|NCT01250951|Experimental|Deferasirox|
89350030|NCT03069482|Experimental|Learn to Quit|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
89350031|NCT03069482|Active Comparator|NCI QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
89350032|NCT01250405|Active Comparator|Cinacalcet|
89350033|NCT01250405|Placebo Comparator|Placebo|
89350034|NCT01147367|No Intervention|Control|no physical activity intervention
89350035|NCT01147367|Experimental|Exercise intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
89350036|NCT03915197|Experimental|group 1|cohorts of infants with acute bronchiolitis
89350037|NCT05083910|Experimental|Oxytocin Group|The oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord
89350038|NCT05083910|Experimental|Oxytocin+Intrauterine Misoprostol|The oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity
89350039|NCT05083910|Experimental|Carbetocin|100-mg carbetocin was intravenously administered immediately after birth of the baby
89350040|NCT01250483||BPH|men aged more than 40 years who presented with BPH/LUTS and showed negative results of transrectal prostate biopsy before the period of AB medication
89350041|NCT01250483||prostate cancer|men aged more than 40 years who presented with BPH/LUTS and showed positive results of transrectal prostate biopsy before the period of AB medication
89350042|NCT01147445|Experimental|Cohort 1: 5 mcg dmLT|6 subjects to receive 5 micrograms (mcg) of dmLT vaccine.
89350043|NCT01147445|Experimental|Cohort 4: 100 mcg dmLT|6 subjects to receive 100 mcg of dmLT vaccine.
89350044|NCT01147445|Experimental|Cohort 2: 25 mcg dmLT|6 subjects to receive 25 mcg of dmLT vaccine.
89350045|NCT01147445|Experimental|Cohort 3: 50 mcg dmLT|6 subjects to receive 50 mcg of dmLT vaccine.
89350046|NCT01147445|Experimental|Cohort 5: 50 mcg or 100 mcg dmLT|12 subjects randomized, double-blinded, to receive either 50 mcg or 100 mcg of dmLT vaccine.
89350047|NCT03266172|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)
89350048|NCT03266172|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR
89350049|NCT03266172|Experimental|Subjects in Part C|Subjects in Part C will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2)
89350050|NCT04356937|Experimental|Tocilizumab|"Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.~Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab.Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures."
89350051|NCT04356937|Placebo Comparator|Standard of care plus placebo|Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.
89350052|NCT01147523|Experimental|Vitamin E|Vitamin E, capsules 400 mg daily, for 52 weeks
89350053|NCT05761808|Active Comparator|Exercise Group|Lumbar stabilization exercises constitute the first step of treatment in chronic low back pain.
89350054|NCT05761808|Active Comparator|NMES Group|NMES will be applied in addition to lumbar stabilization exercises.
89350055|NCT01251029|Experimental|sugar pil and saline|
89350056|NCT03915041|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
89350057|NCT03915041|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
89350058|NCT03914729|Active Comparator|Primary Closure|After pilonidal sinus is excised, subcutaneous fat and skin are closed in midline with a running suture
89350059|NCT03914729|Active Comparator|Gluteus Maximus Plasty Flap|After pilonidal sinus is excised, gluteus maximus fascia flaps will be mobilised, approximated in the midline and fixed with a running suture. Subcutaneous fat and skin are closed in midline with a running suture.
89350060|NCT01251107|Experimental|Arm B|BEACOPP (Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for 4 escalated cycles followed by 4 standard cycles
89350061|NCT01251107|Active Comparator|Arm A|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 6 to 8 cycles
89350062|NCT01125176|Experimental|All subjects|In Cycle -1, even numbered patients will receive oral lenalidomide daily on days 1-14 and then no treatment on days 15-28. In Cycle -1, odd numbered patients will receive oral thalidomide daily days 1-14 followed by no treatment on days 15-28. Starting with cycle 1, all patients will alternate daily thalidomide (every odd day) with daily lenalidomide (every even day) for days 1-28. Rituximab will be given on days 1, 8, 15, and 22 starting with Cycle 1, and then again every 6th cycle thereafter (cycles 7, 13, 19, etc.)
89350063|NCT03914339|Experimental|Test group|Eighteen periodontally compromised patients who will be given both orthodontic and periodontal treatment .
89350064|NCT03914339|Active Comparator|control group|Eighteen periodontally compromised patients will receive periodontal treatment alone .
89350065|NCT03301740|Experimental|UF Profiling Phase First|"First treatment phase begins with linear UF profiling during HD.~Participants randomized to starting with the experimental UF profiling phase will receive 9 HD treatments with UF profiling (1st experimental phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 conventional HD treatments (1st control phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase)."
89350066|NCT03301740|Experimental|Conventional HD Phase First|"First treatment phase begins with conventional HD.~Participants randomized to starting with the control conventional HD phase will receive 9 conventional HD treatments (1st control phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 HD treatments with UF profiling (1st experimental phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase)."
89350067|NCT03914183|Other|Control|Standard of care arm - using insulin pen needles as previously prescribed
89350068|NCT03914183|Active Comparator|mCPN intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened The current research study has accordingly been designed to determine if a pharmacist-dispensed montméd Coloured Pen Needle (mCPN) intervention will improve injection site rotation relative to the standard dispensing of non-mCPN insulin pen needles."
89350069|NCT01147679||bvFTD|This group will include 33 patients who have been diagnosed with behavioral variant frontotemporal dementia by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
89350070|NCT01147679||Alzheimer's disease|This group will include 33 patients who have been diagnosed with clinically probable Alzheimer's disease by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
89350071|NCT01147679||Controls|33 health individuals without clinically significant cognitive impairments will be enrolled in this study.
89350072|NCT04355767|Experimental|Convalescent Plasma|Participants receive 1 unit of convalescent plasma.
89350073|NCT04355767|Placebo Comparator|Placebo|Participants receive 1 unit of saline with multivitamin.
89350074|NCT00882050|Experimental|Exentatide 0.27 ng/kg/min|"Exenatide to be infused by intravenous method at 0.27 ng/kg/min (0.066 pmol/kg/min) over 3-6 hours.~Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
89350075|NCT00882050|Experimental|Exentatide 0.41 ng/kg/min|"Experimental: IV Exenatide to be infused by intravenous method at 0.41 ng/kg/min (0.099 pmol/kg/min) over 3 to 6 hours.~Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin,Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
89350076|NCT00882050|Placebo Comparator|Placebo IV NSS|"Placebo of IV normal saline solution as comparator.~Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
89350077|NCT01251185|Experimental|CHF|Single-arm, open label, subjects with Congestive Heart Failure, with ischemic etiology.
89350078|NCT03912857|Experimental|test group|"Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
89350079|NCT04932590|Experimental|Patients|Patients less than 2 years old admitted in the pediatric intensive care unit of the Armand-Trousseau hospital, under invasive mechanical ventilation and in whom a volume expansion is planned by the attending physicians.
89350080|NCT04917614|Active Comparator|group teas|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at Hegu (LI4), Neiguan (PC6), and Zusanli (St 36) with an electronic acupuncture device.
89350081|NCT04917614|Sham Comparator|Control Group|In the sham group, the patients were connected to the electronic acupuncture, but electronic stimulation was not applied.
89350082|NCT03912935|No Intervention|Sniffing position|Subject will be maintained in standard intubation position which is supine position with head elevation with head rest (foam donut).
89350083|NCT03912935|Experimental|Bed up head elevation position|Subject will be maintained at bed up 20-30 degree aiming alignment between the external auditory meatus with sternal notch
89350084|NCT03266094|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs Radio frequency (RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
89350085|NCT05206916|Other|evaluation of cryotherapy as treatment for obstructive sleep apnea patients|
89350086|NCT04441879|Experimental|Blended intervention|Women will receive a blended intervention (integrating face-to-face and online sessions) for the treatment of postpartum depression.
89350087|NCT04441879|Active Comparator|Control (online intervention)|Women will receive an online intervention (Be a Mom program).
89350088|NCT01147211|Experimental|MK2206 in combination with Gefitinib|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
89350089|NCT04161079||MAR population|Subjects, who underwent MV repair operation with successful MAR implantation in clinical investigation 2010-040
89350090|NCT04892420|Active Comparator|Group DX|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia
89350091|NCT04892420|Active Comparator|Group DM|The patients receive 20 ml plain bupivacaine(0.5%)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
89350092|NCT04892420|Active Comparator|Group M|The patients receive 20 ml plain bupivacaine(0.5%)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
88818409|NCT01822301|Experimental|Repeat Facial fat grafting|
89350093|NCT04892420|Placebo Comparator|Group C|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
89350094|NCT01251263|Other|Group 1|Cyclic OC users prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
89350095|NCT01251263|Other|Group 2|Spontaneous ovulation group prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
89350098|NCT04887896|Experimental|GS500 flexible dose|3, 2, or 4 GS500 capsules 2 times per day
89350099|NCT04887896|Placebo Comparator|Placebo flexible dose|3, 2, or 4 placebo capsules 2 times per day
89350100|NCT05667467|Experimental|CONTROL GROUP|
89350101|NCT05667467|Experimental|NURSE GROUP|
89350102|NCT05667467|Experimental|STUDY GROUP|
89350103|NCT05761730|No Intervention|Control group|Patients suffering from acute pain due to symptomatic irreversible pulpitis on a lower mandibular molar . Conventional emergency treatment is performed . Pulpotomy is performed after inferior alveolar nerve block injection ( IANB )
89350104|NCT05761730|Experimental|Intervention Group|Patients suffering from acute pain due to symptomatic irreversible pulpitis on a lower mandibular molar . Short course orally administered dexamethasone after inferior alveolar nerve block injection without performing conventional pulpotomy
89350105|NCT04904718|Experimental|DreaMed Advisor Pro tool used for insulin optimization|
89350106|NCT03913871|Experimental|Telephone (text messages) support for healthy eating|Participants will receive average of 1-2 text messages per day for 4 weeks focused on health eating with the aim increasing consumption of fruits, vegetables and water; and a reduce intake of sugar sweetened beverages.
89350107|NCT03913871|Active Comparator|Telephone (text messages) support for physical activity|Participants will receive an average of 1-2 text messages per day for 4 weeks that offer physical activity and general health/wellbeing advice.
89350108|NCT03914027|No Intervention|Control|Patients allocated to the control group will follow the same procedure except for not using tele-rehabilitation.
89350109|NCT03914027|Experimental|Intervention|The intervention is the use of a tele-rehabilitation program during 12 weeks. The patient's training time will be registered automatically. The control group will receive standard treatment only.
89350110|NCT03243084|Sham Comparator|Sham tACS|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
89350111|NCT03243084|Active Comparator|Active 10 Hz tACS|Participants will receive 2mA of alternating current stimulation at a frequency of 10Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
89350112|NCT04353817|Placebo Comparator|Placebo|Participants received placebo matched to ELX/TEZ/IVA and placebo matched to IVA in the treatment period for 24 weeks.
89350113|NCT04353817|Experimental|ELX/TEZ/IVA|Participants weighing less than (<) 30 kilograms (kg) at screening received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) and participants weighing greater than equals to (>=) 30 kg at screening received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
89350114|NCT05206760||Trial participants|Patients with severe traumatic brain injury requiring craniotomy or ICP bolt insertion
89350115|NCT01254695|Active Comparator|Standard settings|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 210 μsec
89350116|NCT01254695|Experimental|Experimental Setting 1|Amplitude: Sensory threshold Frequency:6.9 Hz Pulse width 210 μsec
89350117|NCT01254695|Experimental|Experimental setting 2|Amplitude: Sensory threshold Frequency:31 Hz Pulse width 210 μsec
89350118|NCT01254695|Experimental|Experimental setting 3|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 330 μsec
89350119|NCT01254695|Experimental|Experimental setting 4|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 90 μsec
89350120|NCT03903575|Experimental|En Masse Retraction|Group treated by retracting the six anterior teeth simultaneously.
89350121|NCT03903575|Active Comparator|Two-Step Retraction|Group treated by retracting the canines incisors in two different steps.
89350122|NCT00159588|Active Comparator|Prophylaxis from the start|Use of preventive drugs from the start without abrupt withdrawal
89350123|NCT00159588|Other|Abrupt withdrawal|Device: Abrupt withdrawal. Standard out-patients detoxication program including telephone call after 2 weeks and rescue medicine up to 2 days/week
89350124|NCT00159588|Other|Controls|Active control: No instruction for abrupt withdrawal or prophylactic treatment. The controls finished the study period after 5 months observation, and were then offered the optimal type of treatment
89350125|NCT04166942|Experimental|Normal Hepatic Function (Group 1--Control)|Matched healthy subjects with normal hepatic function
89350126|NCT04166942|Experimental|Mild Hepatic Impairment (Group 2)|Subjects with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6
89350127|NCT04166942|Experimental|Moderate Hepatic Impairment (Group 3)|Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9
89350128|NCT04166942|Experimental|Severe Hepatic Impairment (Group 4)|Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10 to 14
89350129|NCT02527967||Group 1 (≤4 days)|Group 1 consisted of patients whose hospital stay was shorter or equal to the target LOS (≤ 4 days).
89350130|NCT02527967||Group 1 (>4 days)|In group 2 were patients whose hospital stay was longer than 4 days.
89350131|NCT03265938||Indirect laryngoscopy|Head and neck pathology patients undergoing indirect laryngoscopy. Patients with a past medical history of active or previously treated head and neck pathology.
89350132|NCT04353037|Experimental|Sub Study 1 Patients|Patients tested for COVID-19 who meet symptomology and age requirements for eligibility
89350133|NCT04353037|Experimental|Sub Study 2 Health Care Workers|Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months
89350134|NCT05206214|Experimental|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver
89350135|NCT05206214|Experimental|mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver
89350136|NCT01149161|Active Comparator|C group|Routine central neck dissection
89350137|NCT01149161|No Intervention|N group|No central neck node dissection
89350138|NCT04704804||Prostate cancer|Man with cancer and localized (non-metastatic) prostate cancer
89350139|NCT04704804||Brain cancer|Male or Female with a brain tumor (primitive)
89350140|NCT05205902|Other|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
89350141|NCT05205902|Other|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
89350142|NCT05558423|Experimental|Self-controlled|n-of-1 design. Participants complete a baseline habitual eating phase following by an intervention TRE phase.
89350143|NCT04893954|Other|Obese patients|
89350144|NCT04349917|Placebo Comparator|Placebo, then Methylphenidate|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
89350145|NCT04349917|Experimental|Methylphenidate, then Placebo|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
89350146|NCT03903029||Low-dose (10mg) rosuvastatin|Four statin benefit groups per 2013 ACC/AHA guideline in Korea
88807297|NCT02111798|Placebo Comparator|Placebo/Relapse Prevention|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
89350147|NCT02986620||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
89350148|NCT04775654|Experimental|Supplement|Participants consume 455mg of blackcurrant extract standardized to contain 50mg anthocyanins in a 2-capsule dose for 70 days.
89350149|NCT04775654|Placebo Comparator|Placebo|Participants consume 2 capsules of microcrystalline cellulose for 70 days.
89350150|NCT02527889|Experimental|Exercise Group|The exercise group will receive a supervised resistive exercise training. Subjects in the exercise group will attend small group-based exercise sessions twice a week for 8 weeks supervised by physiotherapists.
89350151|NCT02527889|No Intervention|Control Group|The control group will receive no exercise training and continue to receive standard medical care.
89350152|NCT04747730|Experimental|Transcendental Meditation training|The intervention of the project is the teaching and learning of Transcendental Meditation technique. The technique involves the use of a sound (mantra) to effortlessly allow the mind to settle down to a state of inner calm. It is a simple, natural and effortless practise, and unlike other meditation strategies, it does not involve concentration or control of the mind. The practice does not require any religion, philosophy, or change in lifestyle. Once learned the technique, participants will practice it twice a day, 20 minutes every morning and 20 minutes in the afternoon.
89350153|NCT04747730|No Intervention|control|no intervention
89350154|NCT04691856|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
89350155|NCT04691856|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
89350156|NCT04691856|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml/h, lockout period: 7 min.
89350157|NCT04156399|Experimental|Acupuncture|All subjects will receive active acupuncture.
89350158|NCT01254929||F-18 PET bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo an F-18 PET bone scan for diagnostic imaging.
89350159|NCT01254929||Tc-99m MDP bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo a Tc-99m MDP bone scan for diagnostic imaging.
89350160|NCT03749395|Active Comparator|Erector Spinae Plane Block group|"The Erector Spinae Plane block will be done as follow,the patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.~All patients will receive general anesthesia as described in conventional group"
89350161|NCT03749395|No Intervention|Conventional group|"Nothing will be injected~All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCo2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC), 0.5μg/kg fentanyl will be given intraoperative when either heart rate or Non Invasive Blood Pressure report an increase by more than 20% of the basal records. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria."
89350162|NCT03902795||Group of 62 eyes|Group of 62 eyes with rhegmatogenous retinal detachment who underwent successful vitrectomy with SF6 tamponade
89350163|NCT03300570|Experimental|Arm A (dolcanatide)|Participants receive dolcanatide PO QD for 7 days.
89350164|NCT03300570|Placebo Comparator|Arm B (placebo)|Participants receive placebo PO QD for 7 days.
89350165|NCT04154605|Active Comparator|ClariFix|Cryotherapy of the nasal passages with the ClariFix device.
89350166|NCT04154605|Sham Comparator|Sham|Sham cryotherapy of the nasal passages with the ClariFix device
89350167|NCT03264456|Experimental|[18F] Fluciclovine PET/MRI|[18F] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer
89350168|NCT03902327|Experimental|NAC group|NAC for 12 weeks, 1.6 mg/day, 4x400 mg; a diet based on general recommendations for people with carbohydrate metabolism disorder
89350169|NCT03902327|Active Comparator|Control group|Placebo for 12 weeks and a diet based on general recommendations for people with carbohydrate metabolism disorder
89350170|NCT03853694|Active Comparator|Group 1 (Standard of Care Group)|150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
89350171|NCT03853694|Experimental|Group 2 (Duramorph + EXPAREL TAP)|50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
89350172|NCT03853694|Experimental|Group 3 (EXPAREL TAP)|EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.
89350173|NCT01255007|Experimental|Post chemotherapy group|The first group consists of patients with colorectal liver metastases who have had treatment with chemotherapy and are now awaiting surgery. This group would have had Multidetector Liver CT (MDCT) imaging prior to the chemotherapy, and will now undergo post chemotherapy MDCT as part of standard clinical care in addition to Gd-EOB-DTPA enhanced liver MRI and Diffusion Weighted MRI (DW-MRI). The MRI will be performed as an additional imaging investigation after obtaining informed consent.
89350174|NCT01255007|Experimental|Pre and Post Chemotherapy Group|The second group consists of patients with colorectal liver metastases who are due to receive neoadjuvant chemotherapy. This group will be imaged prior to receiving and after receiving chemotherapy. This will all be done prior to surgical resection of their colorectal liver metastases.
89350175|NCT03902405|Active Comparator|Active CEASAR Intervention|"Participants will be given the active CEASAR intervention where they will be trained to avoid cues associated with stimulant use and approach healthy cues based on the orientation of the images presented. Individuals will be asked to approach (pull in) portrait images and avoid (push away) landscape images. In the active condition, pushed pictures (landscape orientation) will exclusively be stimulant-use related pictures. Conversely, healthy images will be in the portrait orientation which will be pulled in."
89350176|NCT03902405|Placebo Comparator|Placebo CEASAR|In the control condition, stimulant use-related pictures will be randomized and equally divided into push (landscape) and pull (portrait) conditions.
89350177|NCT04154293|Placebo Comparator|Vehicle Ointment (Control)|Topical, BID (Twice daily)
89350178|NCT04154293|Experimental|TMB-001 Ointment, 0.05%|Topical, BID ( twice daily)
89350179|NCT04154293|Experimental|TMB-001 Ointment, 0.1%|Topical, BID (Twice daily)
89350180|NCT01148147|Placebo Comparator|Placebo|Intracoronary Placebo administration
89350181|NCT01148147|Active Comparator|Adenosine|Intracoronary adenosine administration
89350182|NCT05205824|Other|Algorithm validation|all subjects will be measured with inertial measurement units while performing tasks like walking, standing and sitting.
89350183|NCT03902249|Active Comparator|Dexamethasone group|Patients who received 0.15mg/kg of Dexamethasone in 8ml of saline
89350184|NCT03902249|Placebo Comparator|Placebo group|Patients who received the same volume of saline as the study group (8ml)
89350185|NCT05761652||Modeling group|
89350186|NCT05761652||Validation group|
89350187|NCT03908489|Experimental|intervention we want to test vital pulpotomy using garlic oil|interventional group as garlic oil pulpotomy dressed in zinc oxide powder
89350188|NCT03908489|Active Comparator|control or comparator as mta vital pulpotomy in primary molars|mta vital pulpotomy in primary molars
89350189|NCT01149317|Experimental|Acupuncture|Weekly acupuncture treatment for up to 14 weeks
89350190|NCT03901937|Placebo Comparator|Placebo|parenteral nutrition without ω-3 polyunsaturated fatty acid
89350191|NCT03901937|Experimental|ω-3 fatty acid|parenteral nutrition with ω-3 polyunsaturated fatty acid
89350192|NCT04342897|Experimental|LY3127804|Participants received 20 milligrams (mg) per kilogram (kg) of LY3127804 as an intravenous (IV) infusion on Days 1 and 15.
89350193|NCT04342897|Placebo Comparator|Placebo|Participants received 20 mg/kg of Placebo as an IV infusion on Days 1 and 15.
89350194|NCT03902171||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
89350195|NCT03902171||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in In-Home Addiction Treatment Program.
89350196|NCT03908723|Experimental|all patients in the study|
89350197|NCT03263767|Experimental|LYMPHOID HEMOPATHY without ATG|patients with lymphoid hemopathy
89350198|NCT03263767|Experimental|MYELOID HEMOPATHY without ATG|patients with myeloid hemopathy
89350199|NCT03263767|Experimental|LYMPHOID HEMOPATHY witH ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
89350200|NCT03263767|Experimental|MYELOID HEMOPATHY with ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
89350201|NCT01569932||chemotherapy|Patients will be assessed both before and after they undergo treatment with chemotherapy.
89350202|NCT03908411|Active Comparator|Paratracheal pressure|Left Paratracheal pressure is applied by ultrasound transducer after confirmation of the location of the esophagus.
89350203|NCT03908411|Active Comparator|Sellick's maneuver|Conventional Sellick's maneuver is applied.
89350204|NCT04603742|Experimental|Anakinra IV|Patients in the intervention arm will receive anakinra IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
89350205|NCT04603742|Placebo Comparator|Normal Saline IV|Patients in the placebo arm will receive normal saline IV (N=85) 4 times a day for 7 days. The investigator will follow up with patients for up to 60 days.
89350206|NCT03902015|Experimental|Nuance Phone case|"Nuance Hearing has developed a technology enabling focused hearing. The Selective Noise Cancellation (SNC) technology consists of an advanced beam-forming algorithm that tones down the ambient sound by up to 15 decibels (dB) in order to focus on a primary audio source. The device consists of a special phone case(for iPhone) containing microphone array. Controlling the direction of focus is enabled through the use of a designated app. The user can place the phone case on his/hers table and can choose the direction of preferred listening, without having to ask the talker to hold the device."
89350207|NCT03908333|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
89350208|NCT04340557|Experimental|Group A (Study drug+SOC)|Standard of Care plus an ARB to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 2 - 10 if confident the subject will tolerate.
89350209|NCT04340557|No Intervention|Group B (SOC)|Standard of Care
89350210|NCT01255085|Experimental|10 g of yellow pea fiber|
89350211|NCT01255085|Experimental|20 g of yellow pea fiber|
89350212|NCT01255085|Experimental|10 g of yellow pea protein|
89350213|NCT01255085|Experimental|20 g of yellow pea protein|
89350214|NCT01255085|Experimental|Control Tomato Soup|
89350215|NCT03901859||Patients with ADHD|drug-naive patients with ADHD, aged 7-18 year old
89350216|NCT03901859||Healthy Controls|drug-naive healthy controls, aged 7-18 year old
89350217|NCT04549376|Experimental|PVP-I 0.4% NI|Arm-1 will receive Povidone iodine (PVP-I) nasal irrigation (NI) at concentration of 0.4% single time
89350218|NCT04549376|Experimental|PVP-I 0.5% NI|Arm-2 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5% single time
89350219|NCT04549376|Experimental|PVP-I 0.6% NI|Arm-3 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6% single time
89350220|NCT04549376|Experimental|PVP-I NS 0.5% NS|Arm-4 will receive will receive PVP-I nasal spray (NS) at concentration of 0.5% single time
89350221|NCT04549376|Experimental|PVP-I 0.6% NS|Arm-5 will receive will receive PVP-I nasal spray at concentration of 0.6% single time
89350222|NCT04549376|Placebo Comparator|DW NI|Arm-6 will receive distilled water through nasal irrigation
89350223|NCT04549376|Placebo Comparator|DW NS|Arm-7 will receive distilled water through nasal spray
89350224|NCT03746197|Experimental|Project EVO Multi- Treatment|Treatment group receives video game device treatment. Participant plays the game for 30 minutes a day, at least five days a week for four weeks.
89350225|NCT03746197|No Intervention|Control|No contact control
89350226|NCT03901703|Active Comparator|Dorsiflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their dorsiflexor muscles alongside standard functional progressive strengthening exercises.
89350227|NCT03901703|Active Comparator|Plantarflexor Muscle Strengthening Group|The children in this group will receive functional exercises aiming to strengthen their plantarflexor muscles alongside standard functional progressive strengthening exercises.
89350228|NCT03901703|Active Comparator|Dorsiflexor and Plantarflexor Muscle strengthening Group|The children in this group will receive functional exercises aiming to strengthen both their dorsiflexor and plantarflexor muscles alongside standard functional progressive strengthening exercises.
89350229|NCT03713060|Other|Women with RYGB and fetus/ child|20 pregnant women with previous gastric bypass surgery. During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
89350230|NCT03713060|Other|Matched controls and fetus/ child|20 pregnant women matched on age, prepregnancy-BMI and parity (n = 20). During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
89350231|NCT03901625|Active Comparator|ManualTB+Floss|Cleaning teeth with a manual toothbrush and a dental floss three times a day.
89350232|NCT03901625|Experimental|ManualTB+Waterjet|Cleaning teeth with a manual toothbrush and a waterjet three times a day.
89350233|NCT03901625|Experimental|Electric TB+Floss|Cleaning teeth with an electric toothbrush and dental floss three times a day .
89350234|NCT03901625|Experimental|Electric TB +Waterjet|Cleaning teeth with an electric toothbrush and a waterjet three times a day .
89350235|NCT01149395|Experimental|Dexlansoprazole|
89350236|NCT04001192|Experimental|exercise|exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
89350237|NCT02527733|Active Comparator|Ranibizumab|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
89350238|NCT02527733|Active Comparator|Ranibizumab and laser|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
89350239|NCT04382053|Experimental|DFV890 + SoC|DFV890 50 mg was administered orally or nasogastrically twice per day (b.i.d) approximately 12 hours apart (morning and evening) for 14 days in addition to SoC.
89350240|NCT04382053|Active Comparator|Standard of Care (SoC)|SoC was used as an active comparator arm.
89350241|NCT03907865|Experimental|intense|Patients have been randomized to receive Softacort eye drops for 12 days 4 times daily followed by 2 days twice daily treatment resulting in a total time of 14 days
89350242|NCT03907865|Experimental|standard|Patients have been randomized to receive Softacort eye drops for 8 days 3 times daily followed by 3 days twice daily treatment resulting in a treatment time of 11 days total
89350243|NCT04135495|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
89350244|NCT01148303|Experimental|Etoricoxib First|This arm will receive etoricoxib for six days, followed by placebo for eight days.
89350245|NCT01148303|Experimental|Etoricoxib Second|This arm will get placebo for eight days before beginning their fast, followed by etoricoxib for six days.
88807298|NCT02111798|Active Comparator|Bupropion XL/Relapse Prevention|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
89350246|NCT03901157|Experimental|Active yogurt|Contains 120 g yogurt + 60 g oil-gel particles (containing 6 g oil) + 24 g water
89350247|NCT03901157|Active Comparator|Control yogurt|Contains 120 g yogurt + 54 g empty gel particles + 6 g oil in 24 g water
89350248|NCT03907709||First Responders in In-Home Addiction Treatment Program|- First responders (individual who does or has worked as a police officer, fire fighter, corrections officer, military police, emergency medical technician, paramedic, parole or probation officer)
89350249|NCT03907787|Other|One-group pretest-posttest quasi-experimental design|50 subjects with moderate knee osteoarthritis were supplied for four weeks with two tablets/day, each containing 350 mg of standardized extracts of Zingiber officinale and Acmella oleracea.
89350250|NCT01149551||Group 1|
89350251|NCT03900611|Experimental|Active stimulation|
89350252|NCT03900611|Sham Comparator|Sham stimulation|
89350253|NCT03900611|No Intervention|healthy control|
89350254|NCT03066830|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received two Sotagliflozin tablets of 200 mg, orally once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
89350255|NCT03066830|Placebo Comparator|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo administered as 2 tablets, once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
89350256|NCT03907553||Health and Anemia|"individuals belonging to the Health and Anemia'' prospective population-based observational study (2003-2013) of all elderly residents (>65 years) in the municipality of Biella"
89350257|NCT03907553||Monzino|"individuals belonging to the Monzino Over 80 trial"
89350258|NCT03900455|Experimental|Hydrocellular polyurethane foam multilayer dressing|
89350259|NCT03900455|Active Comparator|standard preventive care|
89350260|NCT05205278|Experimental|training group|Group 1 (n=21) was the training group and, in addition to the routine volleyball training programmes, an 8-week (3 days/week) progressive core stability training programme was applied.
89350261|NCT05205278|No Intervention|control group|Group 2 (n=21) was the control group, and they only engaged in routine volleyball training: no core stability training was given.
89350262|NCT01255241||othopaedic surgical intervention|children with lower limbs deformities
89350263|NCT01149629|Active Comparator|Fed Dosing|Subjects fed a high calorie, high fat meal prior to receiving 3 x 100mg capsules
89350264|NCT01149629|Active Comparator|Fasted Dosing|Subjects fasted prior to receiving 3 x 100mg capsules
89350265|NCT01149629|Active Comparator|Bioequivalence|Subjects fasted prior to receiving 1x 300mg capsule
89350266|NCT01149629|Active Comparator|TID Dosing|Droxidopa 300 mg given TID
89350267|NCT03900143|Experimental|Treatment - Tightra|Treatment group with the Tightra device
89350268|NCT05205122|Experimental|Infants with primary congenital glaucoma|
89350269|NCT03907085|Active Comparator|High intensity laser therapy (HILT) + exercise|Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist.
89350270|NCT03907085|Placebo Comparator|Placebo HILT + exercise|Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist.
89350271|NCT04379336|Experimental|Bacille Calmette-Guérin (BCG)|Participants will receive an intradermal injection of 0.1ml of the suspended BCG vaccine which accounts for 0.075mg of attenuated Mycobacterium bovis. BCG-Vaccin SSI [Statens Serum Institut], Danish strain 1331.
89350272|NCT04379336|Placebo Comparator|Placebo|The placebo used for this study is 0.9% Sodium Chloride (NaCl). Participants that are randomized to the control arm will receive a placebo injection of 0.1ml 0.9% NaCl, which is the same volume and has the same colour as the suspended BCG vaccine.
89350273|NCT03900065|No Intervention|Control group|No preconditioning of the flap.
89350274|NCT03900065|Experimental|Preconditioned group|Preconditioning of the flap prior to surgery.
89350275|NCT05208632||BLOCK SİDE|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
89350276|NCT05208632||UNBLOCK SİDE|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
89350277|NCT03907007|No Intervention|Sole Medication|Monitoring under current prescribed medication
89350278|NCT03907007|Active Comparator|Combined stimulation & medication|Concurrent usage of stimulation with the prescribed medication
89350279|NCT03907007|Active Comparator|Sole Stimulation|Alternating usage of stimulation to the prescribed medication
89350280|NCT04360616||MG+|the lesion could detected by mammography
89350281|NCT04360616||US+|the lesion could detected by breast ulrtasound
89350282|NCT03907163|Experimental|healthy subjects|
89350283|NCT03907163|Placebo Comparator|healthy volunteers|
89350284|NCT04330274||Group 1|Unilateral transtibial amputee
89350285|NCT04330274||Group 2|Unilateral transfemoral amputee
89350286|NCT01149707|Experimental|PUR 0110 Rectal Enema 250 mg|Active treatment
89350287|NCT01149707|Experimental|PUR 0110 Rectal Enema 500 mg|Active treatment
89350288|NCT01149707|Experimental|PUR 0110 Rectal Enema 1000 mg|Active treatment
89350289|NCT01149707|Placebo Comparator|Placebo Enema|Placebo comparator
89350290|NCT04320680|Other|lupus cohort follow up|it is a descrption lupus patients study
89350291|NCT01253681|Experimental|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
89350292|NCT05204966|Other|Infant with suspected dysphagia|For newborns and infants who satisfy the inclusion and exclusion criteria, after taking a video of a bottle feeding, we try to develop an evaluation of swallowing disorder through artificial intelligence-based analysis. The developed evaluation will be verified for validity by comparing it with NOMAS (and VFSS if possible), and the correlation with future development will be analyzed through the relationship with the 1st and 2nd year correctional Bailey Developmental Evaluation.
89350293|NCT01149941|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
89350294|NCT01149941|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
89350295|NCT01253759||1|Combined treatment of Transpupillary Thermotherapy and ICG-based photodynamic therapy (PDT)
89350296|NCT01589549|Experimental|Mesenchymal stromal cell therapy|Mesenchymal stromal cell therapy in addition to corticosteroid therapy
89350297|NCT01589549|Active Comparator|Corticosteroid therapy|
89350298|NCT03906773||Intervention|The investigators seek to conduct a pragmatic trial including 2 sister clinical sites to test an innovation using a patient portal framework for Advance Care Planning. The intervention site implemented the intervention (secure patient portal delivered pre-visit planning framework for Advance Care Planning communication). The presence of ACP and the quality of documentation will be assessed through post-intervention chart review. Practice level enrollment was sought for the trial, and the framework will be delivered to all patients during a period of roll out. About 250 patients will receive the intervention.
89350299|NCT03906773||control|The control site delivered usual care during the same period of roll out.
89350300|NCT03899675|Experimental|Caffeine|Volunteers will ingest 300mg caffeine one hour before strength training.
89350301|NCT03899675|Placebo Comparator|Placebo|Volunteers will ingest 300mg placebo one hour before strength training.
89350302|NCT03899909|Experimental|GLPG3121 SAD|Single doses of GLPG3121 at up to 6 dose levels in ascending order
89350303|NCT03899909|Placebo Comparator|Placebo SAD|Single doses of placebo
89350304|NCT03899909|Experimental|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 4 dose levels in ascending order
89350305|NCT03899909|Placebo Comparator|Placebo MAD|Multiple doses of placebo
89350306|NCT03906383|Experimental|Remote Ischemic Conditioning|
89350307|NCT01150019||Obese Group|
89350308|NCT01150019||Non Obese Group|
89350309|NCT04380961|Experimental|Sirukumab|Participants will receive single intravenously (IV) dose infusion of sirukumab on Day 1 along with standard of care treatment.
89350310|NCT04380961|Placebo Comparator|Placebo|Participants will receive IV single dose infusion of placebo on Day 1 along with standard of care treatment.
89350311|NCT01253837|Experimental|L19TNFa|"Phase I: Prospective, open-label, dose escalation study.~Phase II: Prospective, single-arm, open-label study, equivalent to the stage 1 of the Simon two-stage phase II design."
89350312|NCT03906305|Experimental|Dry needling in a myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into trigger point spastic muscle of the shoulder.
89350313|NCT03906305|Active Comparator|Dry needling in a non myofascial trigger points area|The intervention will consist of a sixty minutes physical therapy session based on the modulating Bobath technique focused on the upper limb. Besides, during the intervention patients will receive deep dry needling that will be inserted into a non trigger point spastic muscle of the shoulder.
89350314|NCT03899441|No Intervention|Control|Patients in the control arm will have pre-operative teaching from their physician and sign consent for surgery, as is the current standard of care at the investigators' institution.
89350315|NCT03899441|Experimental|Video arm|Patients in the intervention arm will watch two short animated video about minimally-invasive endometrial cancer surgery followed by focused pre-operative teaching from their physician. They will then sign consent for surgery.
89350316|NCT01562197|Experimental|Axitinib|axitinib treatment arm
89350317|NCT01562197|Experimental|Axitinib plus Lomustine|Axitinib plus Lomustine
89350318|NCT01253915|Experimental|Carbon Dioxide|
89350319|NCT01253915|Placebo Comparator|Placebo|
89350320|NCT03749239|Experimental|Effects of collagen protein.|Non-hydrolized collagen protein
89350321|NCT01255397|Experimental|Male Infertility Protocol|
89350322|NCT03899363|Experimental|surgery|
89350323|NCT03899363|Active Comparator|custom thermoplastic orthosis|
89350324|NCT04331899|Experimental|Study drug Peginterferon Lambda-1a|Study participants assigned to study drug will receive a single subcutaneous dose of Peginterferon Lambda-1a in addition to standard of care treatment.
89350325|NCT04331899|Placebo Comparator|Placebo injection|Study participants will receive a placebo along with the standard of care treatment.
89350326|NCT03905915|Other|Preoperative virtual reality session|Amsterdam Anxiety score recorded before VR session is followed by a 15 min VR session and finally Amsterdam Anxiety score is recorded after VR session
89350327|NCT03905837|Experimental|Lidocaine IV|Group 1: intravenous lidocaine and paravertebral saline (SF). In this group during intraoperative anesthetic maintenance, a continuous intravenous infusion of lidocaine at 1.5mg/kg/h until the end of surgery and perfusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1ml/kg/h will be administered.
89350328|NCT03905837|Experimental|Lidocaine PV|Group 2: intravenous SF and paravertebral lidocaine. During anesthesia maintenance, a continuous intravenous infusion of 0.9% SF and an infusion of 2% lidocaine will be administered through the intraoperative paravertebral catheter at a rate of 0.1 ml/kg/h.
89350329|NCT03905837|Active Comparator|no lidocaine|Group 3: intravenous remifentanil and paravertebral SF. During the maintenance of anesthesia, a continuous intravenous infusion of remifentanil at a rate of 0.1 mg/kg/min until the end of surgery and an infusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1 ml / kg / h.
89350330|NCT03899129|Experimental|simultaneous working length control|• Using simultaneous working length control during root canal preparation using E-CONNECT S endomotor with integrated apex locator.
89350331|NCT03899129|Active Comparator|Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
89350332|NCT04328467|Experimental|Intervention Once Weekly|400 mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg weekly for the duration of follow up, up to 12 weeks
89350333|NCT04328467|Experimental|Intervention Twice Weekly|400mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg twice weekly for the duration of follow up, up to 12 weeks
89350334|NCT04328467|Placebo Comparator|Control Group|Placebo 2 tabs once, followed by 2 tabs 6 to 8 hours later, thereafter two tabs weekly or twice weekly for the duration of follow up, up to 12 weeks
89350335|NCT04254770|Active Comparator|ADA (American Dental Association) approved Manual Toothbrush|
89350336|NCT04254770|Experimental|Marketed Power Toothbrush|
89350337|NCT03899207|Experimental|training +acupressure|In the training+acupressure group, 10 women were excluded from the study since they could not participate in acupressure application at different times, 2 women were excluded since they had menstrual irregularities and 4 women were excluded since they could not be contacted.
89350338|NCT03899207|Experimental|training|In the training group, 4 women were excluded since they did not participate in the reminder training, 1 woman was excluded since she had menstrual irregularities, 3 women were excluded since they wanted to withdraw from the study and 3 women were excluded from the study since they could not be contacted.
89350339|NCT03899207|No Intervention|control|In the control group, 4 women were excluded from the study since they could not be reached and 5 women were excluded since they did not agree to participate in the posttest.
89350340|NCT04232618||FIND cohort|Evaluation of biomarkers in serum samples from 500 people with suspected TB from non-African countries provided by FIND diagnostic biorepository.
89350341|NCT04232618||Phase 1|Evaluate the basic 3-marker multi-biomarker test (MBT) signature in 150 participants across three African sites. This will be used to lock down the final MBT signature to be used in the next phase of testing.
89350342|NCT04232618||Phase 2|Enrolment of 750 participants across three African sites using the locked down MBT signature from phase 1.
89350343|NCT01148615|Experimental|Aflibercept/ docetaxel|"Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel.~Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks"
89350344|NCT04227470|Experimental|Experimental: HBM9161, 340mg|HBM 9161 injection, 340mg, weekly administered by subcutaneous for a period of 4 weeks.
89350345|NCT04227470|Experimental|Experimental: HBM9161, 680mg|HBM 9161 injection, 680mg, weekly administered by subcutaneous for a period of 4 weeks.
89350346|NCT01150175|Experimental|Autologous bone marrow cells|
89350347|NCT01150175|Placebo Comparator|Plasma|
89350348|NCT03905447|Experimental|PC945|
89350349|NCT03905447|Other|Standard of Care|Standard of care anti-fungal medication
89350350|NCT03905681|Active Comparator|"Active TENS Group Group A"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. While the device is off, it will be set at the following settings: The selector switch will be set to 'Milli' or milliamperes, and the frequency dial will be rotated to 100 Hertz. The participant will be instructed to rotate both dials in a clockwise direction if more intensity is desired, or counter-clockwise if less intensity is desired. The participant will wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
89350351|NCT03905681|Placebo Comparator|"Placebo TENS Group Group B"|After all necessary data collection forms are obtained, a pre-VAS score will be obtained. The participant will point to the area of maximum subjective pain, and then four TENS pads will be applied directly around the point of maximal pain that was determined by the patient, located at least 3 centimeters but no more than 6 centimeters from the area in a square or frame-like placement. However, no electrical stimulation will be provided. The participant will also wear the device and pads for a 30-minute duration; upon completion, post-VAS scores and a patient satisfaction survey will be obtained.
89350352|NCT03905759|Active Comparator|colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
89350353|NCT03905759|Active Comparator|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
89350354|NCT03905759|Active Comparator|amiodarone|amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
89350355|NCT05204498|Experimental|Education plan|"Education plan and adherence to exercise Educational talk about the importance of exercise as an important strategy to change dyspnea at the start of the study.~Twice a week, corresponding to the days that do not attend the sessions of pulmonary rehabilitation, calls will be made with a duration of 15 minutes each, in the calls will encourage and guide the practice of physical activity and breathing exercises"
89350356|NCT05204498|No Intervention|control|"A survey will be conducted at week 8 of monitoring where adherence to exercise is measured during the 8-week study.~At the end of week 8, patients will be referred to the pulmonary rehabilitation unit in order to evaluate the anthropometric parameters, assess dyspnea with the modified Medical Research Council scale, the hospital anxiety and depression scale, the Saint George respiratory questionnaire, the pulmonary information needs questionnaire and the 6-minute walk test again."
89350357|NCT01255475|Experimental|Intervention|
89350358|NCT01255475|Placebo Comparator|Control|
89350359|NCT05208398|Experimental|Apixaban|Apixaban, 5 mg oral tablets, on top of updated guidelines of acute coronary syndrome management recommendations
89350360|NCT05208398|Active Comparator|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acute coronary syndrome management recommendations
89350361|NCT05593991|Experimental|Healthy adults|Subjects with elevated heels
89350362|NCT04117802|Experimental|Maple|
89350363|NCT04117802|Placebo Comparator|Placebo|
89350364|NCT05593601|Active Comparator|Neomycin|Patients enrolled in this arm will receive Neomycin.
89350365|NCT05593601|No Intervention|Non neomycin|Patients enrolled in this arm will not receive any interventions.
89350366|NCT05207930|Experimental|Intervention Group|This arm will undertake a centre-based health education on nutrition and cognitive frailty for 4 weeks, followed by an 8-week homed based gamified cognitive-nutrition training (GAHOCON).
89350367|NCT05207930|Placebo Comparator|Control Group|This arm will undertake the same centre-based health education on nutrition and cognitive frailty for 4 weeks but will be opened to undertake a remotely supervised online open-source cognitive games, with which the contents are unrelated to nutrition, at the elderly community centre.
89350368|NCT04109690|Experimental|CPX-351|Phase I will evaluate the safety and tolerability of CPX-351 (44mg/m2 of daunorubicin and 100mg/m2 of cytarabine) administered on 2 days (day 1 and day 5) to determine the Phase II dose. Phase II will evaluate the efficacy of the RP2D.
89350369|NCT03899051|Experimental|Test group|Papilla reconstruction would be done with platelet rich fibrin
89350370|NCT03899051|Active Comparator|Control group|Papilla reconstruction would be done with subepithelial connective tissue graft
89350371|NCT03629210|Experimental|Combination Treatment|Combination treatment: Participants will receive intravitreal Eylea (AFL, 2.0 mg) injection and OZURDEX implant (0.7 mg) injection within 0 to 8 days of each other.
89350372|NCT03629210|Active Comparator|Monotherapy|Monotherapy treatment: Participants will receive OZURDEX implant (0.7 mg) injection.
89350373|NCT05560061|Experimental|Uneven terrain walking training|Participants will complete walking practice on an uneven terrain surface.
89350374|NCT05560061|Active Comparator|Flat terrain walking|Participants will complete walking practice on a level surface.
89350375|NCT04007198|Experimental|EQ001|EQ001 administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
89350376|NCT04007198|Placebo Comparator|EQ001 Placebo|Placebo administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses.
89350377|NCT03899285|Experimental|Citalopram increase (group A)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of citalopram 20 mg for a length of 14 days. The total dose of citalopram will be 40 mg once daily.~Follow up will last 8 weeks in total."
89350378|NCT03899285|Placebo Comparator|Placebo (group B)|"At the end of the preparation phase, non-responders will be randomized to receive a pill of citalopram 20 mg and a capsule of placebo (a capsule without medication) for a length of 14 days. The total dose of citalopram will be 20 mg once daily.~Follow up will last 8 weeks in total."
89350379|NCT03899285|No Intervention|Observational arm (group c)|"Eligible patients to this arm are responders to citalopram. A diminution of at least 30% of the symptoms from baseline with the MADRS is required to enter this arm. At the end of the first phase, these patients will pursue their citalopram 20 mg for the rest of the study (=6 weeks). It's possible that in this group, the treatment approach may vary depending the physician.~Follow up will last 8 weeks in total."
89350380|NCT04328077|Experimental|TERN-101 dose level 1|Orally administered.
89350381|NCT04328077|Experimental|TERN-101 dose level 2|Orally administered.
89350382|NCT04328077|Experimental|TERN-101 dose level 3|Orally administered.
89350383|NCT04328077|Placebo Comparator|Placebo|Orally administered.
89350384|NCT05204108||Contrast-enhanced Ultrasonography|To evaluate the diagnostic accuracy of CEUS for the preoperative staging of bladder cancer, which would benefit the implementation of efficient therapeutic strategies.
89350385|NCT01254071|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
89350386|NCT05207852||0.5 h group|Blood samples were taken 0.5 h after dexamethasone administration
89350387|NCT05207852||2 h group|Blood samples were taken 2 h after dexamethasone administration
89350388|NCT05207852||4 h group|Blood samples were taken 4 h after dexamethasone administration
89350389|NCT05207852||6 h group|Blood samples were taken 6 h after dexamethasone administration
89350390|NCT05207852||12 h group|Blood samples were taken 12 h after dexamethasone administration
89350391|NCT05207852||24 h group|Blood samples were taken 24 h after dexamethasone administration
89350392|NCT05207852||36 h group|Blood samples were taken 36 h after dexamethasone administration
89350393|NCT05207852||48 h group|Blood samples were taken 48 h after dexamethasone administration
89350394|NCT03898739|Active Comparator|traction therapy from neutral position|Patients in this group will receive traction decompression from neutral neck position with rope angle (0°)
89350395|NCT03898739|Active Comparator|traction therapy from lateral bending|patients will undergo traction decompression from (30°) lateral bending of the neck toward the non-affected side
89350396|NCT03898739|Active Comparator|traction from flexion with lateral bending and rotation|patients will be treated with traction decompression from (15°) neck flexion, (30°) lateral bending toward non- affected side and (15°) rotation to the affected side.
89350397|NCT05761418|Experimental|Dinoprostone|Will receive 20 mg of Dinoprostone vaginally 2 hrs. preoperatively.
89350398|NCT05761418|Experimental|Misoprostol|will receive 400 μg of Misoprostol vaginally 2 hrs. preoperatively.
89350399|NCT05761418|No Intervention|control|received a placebo vaginally 2 hrs. preoperatively.
89350400|NCT05207774|Experimental|oxytocin|8 U/oxytocin three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks
89350401|NCT05207774|Placebo Comparator|placebo|intranasal spray containing placebo three-times daily, 30 min before breakfast, lunch and dinner, using a nasal atomizer for 8 weeks
89350402|NCT03905291|Experimental|MT921 60mg Group|MT921 60 mg
89350403|NCT03905291|Experimental|MT921 120mg Group|MT921 120 mg
89350404|NCT03905291|Experimental|MT921 150mg Group|MT921 150 mg
89350405|NCT03905291|Placebo Comparator|Placebo Group|Placebo
89350406|NCT03905213|Active Comparator|conventional gauze|Device is a conventional gauze and the change will be to the day 2 and 4 of surgery
89350407|NCT03905213|Experimental|polyurethane dressing|Device is a polyurethane dressing and the change will be to the day 7 of surgery
89350408|NCT03905213|Experimental|vacuum therapy dressing|Device is a vacuum therapy dressing and the change will be to the day 7 of surgery
89350409|NCT05742932||Study group|Male and female, major or minor patients. The patients have maxillary, mandibular, maxillomandibular fracture with/without annex face or skull fracture, and will be treated by trauma surgery.
89350410|NCT03905057|Sham Comparator|Sham ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), using a sham applicator which is highly similar to the active applicator except that the sham applicator does not emit shockwaves, twice a week (total of 6 weeks) without treatment interval. Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
89350411|NCT03905057|Active Comparator|Active ESWT + 5mg Tadalafil|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks). Patients will receive Tadalafil 5mg for 24 weeks daily beginning the day of removal of the urinary catheter.
89350412|NCT03629132|Experimental|PRP|Platelet-rich plasma
89350413|NCT03629132|Sham Comparator|Gel|Self-crosslinking sodium hyaluronate gel
89350414|NCT03904901|Active Comparator|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, drink with water and drink before bed. Probiotics contain a dose of 10 9 CFU per capsule.
89350415|NCT03904901|Placebo Comparator|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
89350416|NCT02528123|Experimental|Small incision lenticule extraction|Patients with high myopia will undergo a SMILE procedure to correct their refraction. Proxymetacaine 0.5% and Oxybuprocaine 0.4% will be used as anaesthetic during the procedure. Tobramycin and dexamethasone, and ofloxacin will be used four times a day for one week after the procedure.
89350417|NCT05214248|Experimental|multimedia admission orientation|Multimedia admission orientation for the parents of infants admitted to NICU is provided to the experimental group of the parents. The multimedia orientation based on animation and graphic figures to explain the basic information about the NICU environment and precautions and the essential tests and examination taken for their infant during the initial stage of NICU admission.
89350418|NCT03992612|Other|control group|The patients received usual medical care.
89350419|NCT03992612|Experimental|MBPM- Minfulness- Based Pain Management|"Psychological intervention with 8 group sessions ( 8 -10 subjects) with a duration of 2 and a half hours per session and a weekly periodicity (total hours 1080).~It is centered on training on the awareness of physical, cognitive and emotional sensations, and the attentional processes to become an observer of one's own thoughts and emotions. With the aim to provide greater flexibility to manage pain"
89350420|NCT02527811|Experimental|ulinastatin group|the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.
89350421|NCT02527811|No Intervention|control group|patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.
89350422|NCT03691831|Active Comparator|Active|A-101 45% (Topical solution, hydrogen peroxide 45%)
89350423|NCT03691831|Placebo Comparator|Vehicle|Topical solution, isopropyl alcohol and water
89350424|NCT01254383|Active Comparator|Treatment A|Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions
89350425|NCT01254383|Experimental|Treatment B|Sildenafil ODT tablet 50 mg, administered without water under fasted conditions
89350426|NCT01254383|Experimental|Treatment C|Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.
89350427|NCT03700970|Experimental|TAP block with liposomal bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
89350428|NCT03700970|Active Comparator|TAP block with regular bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of 0.25% bupivacaine injected on each side.
89350429|NCT01256021|Experimental|Treatment Group 1|Meditoxin
89350430|NCT01256099|Experimental|Guided Internet-CBT for insomnia|
89350431|NCT01256099|Placebo Comparator|Control treatment|
89350432|NCT01256099|Experimental|Guided Internet-CBT for insomnia (9)|(9 weeks instead of 8)
89350433|NCT01256099|Active Comparator|Guided Internet-CBT for depression|
88807299|NCT05145140|Active Comparator|Standardized Western Medicine Treatment Group|All participants undergo a similar treatment protocol for the diabetic foot, based on the Infectious Diseases Society of America (IDSA).
88818623|NCT05114213|Active Comparator|Arm B: SOC|Continuing SoC-CT (according to clinical routine appr. 2 weeks after the previous cycle) without SBRT.
89350434|NCT04320745|Experimental|Androderm® 4 mg|Participants received Androderm® 4 mg, transdermal dose, once daily (QD) for up to 16 weeks. At Day 14, if serum concentration was less than 400 nanograms per deciliter (ng/dL), the dose was increased to 6 mg, transdermal dose, QD for up to 16 weeks and if the serum concentration was more than 930 ng/dL, the dose was decreased to 2 mg, transdermal dose, QD for up to 16 weeks. The dose was not adjusted if serum concentrations were within the normal range.
89350435|NCT01254461|Experimental|A|
89350436|NCT01254461|Experimental|B|
89350437|NCT03904511|Experimental|Low Dose Souroubea-Platanus|190 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
89350438|NCT03904511|Experimental|High Dose Souroubea-Platanus|380 mg souroubea-platanus preparation in vegicap. Administered once daily for 14 days.
89350439|NCT03904511|Placebo Comparator|Placebo|Inert placebo in an identical vegicap to the experimental treatment groups. Administered once daily for 14 days.
89350440|NCT03747523|Experimental|Healthy Group|40 Healthy individuals will receive a single dose of ergocalciferol (200,000 units)
89350441|NCT03747523|Experimental|ADTKD-MUC1 Group|40 individuals with ADTKD-MUC1 (Autosomal Dominant Tubulo-Interstitial Kidney Disease- a rare disease caused by mutation in MUC1) will receive a single dose of ergocalciferol (200,000 units)
89350442|NCT03898505|Placebo Comparator|Placebo|Placebo powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour. Participants in the placebo group will ingest 1 scoop of the placebo material per day (30-35g). Placebo powder is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Placebo will be consumed once per day for 60 days.
89350443|NCT03898505|Experimental|Low Dose|All Participants randomized to the low dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 50 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the low dose group will ingest 1 scoop of this test product per day (30-35g). Low dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Low dose test product will be consumed once per day for 60 days.
89350444|NCT03898505|Experimental|High Dose|All Participants randomized to the high dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 200 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the high dose group will ingest 1 scoop of this test product per day (30-35g). High dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. High dose test product will be consumed once per day for 60 days.
89350445|NCT05207072||Mobile Cardiac Rehabilitation (mCR) group|The mCR programme involves a home-based programme for 12 months in which patients are supplied with a smartphone/application with a data subscription from LIVA. Through this application patients are able to measure and register physical activity, heart frequency and intensity (BORG scale) and can monitor progress. A healthcare professional (coach) also has access to a portal to monitor progress of different patients, advice on rehabilitation approach and stimulate compliance. Together with their coaches every patient makes their own rehabilitation programme. Patients will be coached for 12 months starting intensively with decreasing amounts of contacts over time.
89350446|NCT05207072||Traditional Cardiac Rehabilitation (CR) group|The traditional CR programme involves standard a standard CR programme over a 6-8 weeks period. Subjects receive no advice or coaching after the end of the traditional CR program.
89350447|NCT03904667||Watson on oncology recommends surgery|
89350448|NCT03904667||Watson on oncology does not recommend surgery|
89350449|NCT03747445||Roux-en-Y gastric bypass patients|severely obese non-diabetic adult female patients scheduled for RYGB
89350450|NCT03747445||Normal weight controls|normal weight healthy non-diabetic adult females
89350451|NCT03747445||Obese controls|Severely obese non-diabetic adult female patients not scheduled for RYGB
89350452|NCT01150253|Experimental|probiotic fermented milk|
89350453|NCT01150253|Placebo Comparator|placebo|
89350454|NCT05293171|Experimental|1.25 mg/kg BL-8040 + BL-8040-matching placebo administered via SC injection (Therapeutic)|1.25 mg/kg BL-8040 + BL-8040-matching placebo administered via SC injection (Therapeutic)
89350455|NCT05293171|Experimental|2 mg/kg BL-8040 administered via SC injection (Supratherapeutic)|2 mg/kg BL-8040 administered via SC injection (Supratherapeutic)
89350456|NCT05293171|Placebo Comparator|BL-8040-matching placebo administered via SC injection|BL-8040-matching placebo administered via SC injection
89350457|NCT05293171|Active Comparator|400 mg moxifloxacin (1 x 400 mg tablet) administered orally|400 mg moxifloxacin (1 x 400 mg tablet) administered orally
89350458|NCT03904433|Experimental|1. Sunflower oil|Sunflower oil (30 g)
89350459|NCT03904433|Experimental|2. Caprylic acid|Caprylic acid (20 g) + Sunflower oil (10 g)
89350460|NCT03904433|Experimental|3. Caprylic acid + Glucose|Caprylic acid (20 g) + Sunflower oil (10 g) + Glucose (50 g)
89350461|NCT03904433|Experimental|4. Coconut oil|Coconut oil (30 g)
89350462|NCT03904433|Experimental|5. Coconut oil + Glucose|Coconut oil (30 g) + Glucose (50 g)
89350463|NCT03904433|Experimental|6. Coconut oil + Caprylic acid|Coconut oil (30 g) + Caprylic acid (20 g)
89350464|NCT03063086|Active Comparator|Sequence 1|A-B-C
89350465|NCT03063086|Active Comparator|Sequence 2|A-C-B
89350466|NCT03063086|Active Comparator|Sequence 3|B-C-A
89350467|NCT03063086|Active Comparator|Sequence 4|B-A-C
89350468|NCT03063086|Active Comparator|Sequence 5|C-A-B
89350469|NCT03063086|Active Comparator|Sequence 6|C-B-A
89350470|NCT03749161|Experimental|Lentis comfort|Patient will receive the low-add multifocal IOL during cataract surgery
89350471|NCT03749161|Experimental|Lentis L-313|Patient will receive the monofocal IOL Lentis L-313 during cataract surgery
89350472|NCT03904745|Experimental|Atosiban used before embryo transfer|the patients in this group will be administered 6,75mg atosiban intravenously.
89350473|NCT03904745|No Intervention|Control group|the patients in this group will not be administered atosiban before embryo transfer.
89350474|NCT03749083||Tumor Sequencing|"Quality of life assessments will be collected using The Functional Assessment of Cancer Therapy- Colorectal~Blood for circulating tumor DNA will be collected"
89350475|NCT05191160|Active Comparator|2% Soy Milk|Participants will be asked to substitute their regular sugar sweetened beverage with the 2% soy milk (up to a maximum of 6 servings/day)
89350476|NCT05191160|Active Comparator|2% Cow's Milk|Participants will be asked to substitute their regular sugar sweetened beverage with the 2% cow's milk (up to a maximum of 6 servings/day)
89350477|NCT05191160|Active Comparator|Usual Sugar Sweetened Beverage|Participants will be asked to continue drinking their regular sugar sweetened beverage
89350478|NCT01148927||Adult acute lymphoblastic leukemia patients|
89350479|NCT05213702|Active Comparator|Traditional free hand puncture for renal calyx access|For human PCNL, we target 60 cases of PCNL, 30 ANT-X puncture and 30 traditional free hand puncture performed by 4 urologic trainees(15 cases per urologic trainee).
89350480|NCT05213702|Active Comparator|RObotic ANT-X device puncture for renal calyx access|For human PCNL, we target 60 cases of PCNL, 30 ANT-X puncture and 30 traditional free hand puncture performed by 4 urologic trainees(15 cases per urologic trainee).
89350481|NCT04128007|Experimental|ARQ-154 foam 0.3%|active
89350482|NCT04128007|Placebo Comparator|ARQ foam VehicleRQ-154 foam Vehicle|placebo
89350483|NCT05187338|Experimental|3 drugs|Three antibodies combination against PD1, PDL1, and CTLA4.
89350484|NCT03898583|Experimental|Microarray patch A|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use
89350485|NCT03898583|Experimental|Microarray patch B|21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use
89350486|NCT03898583|Placebo Comparator|Vehicle|21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance
89350487|NCT03898583|Active Comparator|Daivobet|21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use
89350488|NCT05213546|Active Comparator|High intensity aerobic training group(HIT)|15 patients who received High Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months.
89350489|NCT05213546|Active Comparator|Moderate intensity aerobic training group(MIT)|15 patients who received moderate Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months.
89350490|NCT05213546|Active Comparator|Low intensity aerobic training group(LIT)|15 patients who received low Intensity aerobic Training in the form of bicycle ergometer exercise for the lower limbs three times /week for three months
89350491|NCT03898193|Other|Sequence Test-Reference (TR)|17 participants (total number of enrolled volunteers - 34) assigned to sequence TR will receive a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 1 and a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89350492|NCT03898193|Other|Sequence Reference-Test (RT)|17 participants (total number of enrolled volunteers - 34) assigned to sequence RT will receive a single 5 mg dose of the reference product Singulair (1 x 5 mg tablet) marked as R in period 1 and a single 5 mg dose of the test product Montelukast (1 x 5 mg tablet) marked as T in period 2. These treatments will be administered orally with 200 ml of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
89350493|NCT03321188|Experimental|HIPEC + adjuvant IV chemotherapy|"HIPEC~HIPEC will be administered intraoperatively one time only.~*HIPEC cisplatin will be administered at rate of 100 milligram per meter squared (mg/m2)~Administration of HIPEC will have a duration of 90 minutes.~Adjuvant IV chemotherapy~IV Paclitaxel~Dose: 80mg/m2 IV over 1 hour~Schedule: Days 1, 8 and 15~Cycle Length: 3 weeks (21 days)~IV Carboplatin~Dose: Area under the curve (AUC) 6 IV~Schedule: Day 1~Cycle Length: 3 weeks (21 days)"
89350494|NCT03904355|Active Comparator|Fiboroid group|Women with intramural myoma no reaching the cavity
89350495|NCT03904355|Active Comparator|Non fibroid group|Women without myomas
89350496|NCT03748849||Low back pain group|Males and females who have had low back pain lasting between 12 weeks - 5 years without any other health problems (physical or psychological). Following baseline measurements, all subjects are offered individualized physiotherapy. The interventions mainly consist of exercises targeting their functional limitations. These are supplemented by a thorough explanation of their pain condition. This is done within the boundaries of the current understanding of musculoskeletal pain. This is supplemented with encouragement to do regular exercise and with manual therapy if needed/indicated.
89350497|NCT03748849||Control group|"Healthy males and females who have no current musculoskeletal pain problem (specific to the low back and/or in general). Likewise, they cannot have a previous history of on-going musculoskeletal pain. On-going pain is defined as a condition that limited their function for 3 months or more.~Participants in the control group take part in the baseline measurement and then another measurement after 6-8 weeks"
89350498|NCT03747367|No Intervention|Baseline|8 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab. Repeated for visit 1 and visit 2.
89350499|NCT03747367|Experimental|Insufficient Sleep|3 days with 3 hour sleep opportunities in lab, immediately following baseline on both visit 1 and visit 2.
89350500|NCT03898427||Individuals with atopic dermatitis|Sensor technology and digital measures will be used to evaluate scratch and sleep in individuals with atopic dermatitis receiving standard of care treatments (SOC) who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
89350501|NCT05187260||5q SMA type I|
89350502|NCT05187260||5q SMA type II|
89350503|NCT05187260||5q SMA type III|
89350504|NCT05187260||Non-5q SMA|
89350505|NCT05187260||Non-SMA subjects|Including asymptomatic carriers of SMA, relatives of SMA patients and carriers, and patients undergoing clinical standard lumbar puncture
89350506|NCT01254539|Experimental|Autologous bone marrow stem cells intraspinal transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
89350507|NCT01254539|Experimental|Intrathecal infusion of autologous bone marrow stem cells|Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.
89350508|NCT01254539|Placebo Comparator|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
89350509|NCT03628664|Active Comparator|CT planned total knee arthroplasty|Surgeon will follow the CT plan
89350510|NCT03628664|No Intervention|Non CT planned total knee arthroplasty|Surgeon will not follow the CT plan
89350511|NCT04318093|Experimental|BMS-986259|
89350512|NCT04318093|Placebo Comparator|Placebo|
89350513|NCT01254617|Experimental|Treatment (lenalidomide and cetuximab)|Patients receive lenalidomide PO QD on days 1-21 and cetuximab IV over 1-2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89350514|NCT05187026||EPIC-26 follow-up|All men will receive EPIC-26 in paper and also an electronic version.
89350515|NCT01150331|Experimental|Clonazepam + levetiracetam|Clonazepam IV 1 mg+ levetiracetam IV 2500 mg
89350516|NCT01150331|Active Comparator|Clonazepam + placebo|Clonazepam IV 1 mg + placebo levetiracetam IV
89350517|NCT03747289|Experimental|weight bearing group|performing exercises in a weight bearing posture
89350518|NCT03747289|Active Comparator|non-weight bearing group|performing exercises in a non- weight bearing posture
89350519|NCT01256489|Other|Infliximab|Every patient enrolled in the study will receive monthly infusions of Infliximab throughout the term of the study. Infliximab will be administered intravenously.
89350520|NCT03746119|Active Comparator|Nicotine-free e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine-free vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
89350521|NCT03746119|Active Comparator|Nicotine e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine containing vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
89350522|NCT03160118|Other|Seasonal,quadrivalent,influenza vaccine|1 vaccine will be administered to all participants, namely Alfa-Rix Tetra 2016-2017
89350523|NCT01150565|Experimental|LiRIS low dose|The first dose group of approximately 10 patients receive low dose LiRIS on Day 1 to Day 14.
89350524|NCT01150565|Experimental|LiRIS high dose|The second dose group of approximately 10 patients receive high dose LiRIS on Day 1 to Day 14.
89350525|NCT01149005|Experimental|insulin|patients who will get insulin with main meals during Intravenous (IV) antibiotic therapy due to pulmonary exacerbation
89350526|NCT01256645|No Intervention|restrictive transfusion|No transfusion given to correct anemia unless vital indication is given
89350527|NCT01256645|Experimental|liberal transfusion|transfusions are given in single units until Hb is > 12 mg/dl
89350528|NCT03903887|Experimental|PD1-TIL combined with chemotherapy|Participants would receive anti-PD1 antibody-activated TILs after the final cycle of adjuvant chemotherapy.
89350529|NCT03903419|Experimental|68Ga-PSMA PET-CT and 18F-FDOPA PET-CT|Functional imaging: 68Ga-PSMA and 18F-FDOPA PET-CT Immunohistochemistry of initial chirurgical sample with determination of PSMA expression
89350530|NCT05122130|Experimental|Melatonin group|Melatonin loaded Carbopol hydrogel will be synthesized as follows: 1 gm of Carbopol will be dissolved in 100 ml deionized water while stirring at 600 rpm for 25°C. Melatonin (3gm) will be dissolved in 1 ml ethanol and added to the formed gel while stirring at 600 rpm at 25 °C. The pH will be adjusted to 7.4 using triethanolamine until a gel is formed and it will be loaded on gelatin sponge and will be applied to the donor site.
89350531|NCT05122130|Placebo Comparator|Placebo group|•Topical placebo carbopol gel will be prepared as follows: 1 gm of Carbopol will be dissolved in 100ml deionized water while stirring at 600 rpm for 25°C. The pH will be adjusted to 7.4 using triethanolamine until a gel is formed
89350532|NCT03898271|Experimental|Virtual World Training|Synchronous PTSD training in a virtual world environment
88818624|NCT05747729|Experimental|Surufatinib/Serplulimab/Platinum/Etoposide|
89350533|NCT03898271|Active Comparator|Web-based Video Training|Asynchronous web-based PTSD training
89350534|NCT03897803||Group (I):juvenile dermatomyositis (JDM)|"Group (I): twenty children diagnosed to have juvenile dermatomyositis (JDM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.~."
89350535|NCT03897803||Group (II):idiopathic inflammatory myopathies(IIM)|"Group (II): twenty adults diagnosed to have idiopathic inflammatory myopathies(IIM) Who will be evaluated using using strain elastography to assess muscle stiffness at baseline and after 4 months.~•"
89350536|NCT03897803||Group (III): juvenile control group|"20 healthy children matching age and sex as first control group to children with JDM .Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .~."
89350537|NCT03897803||Group (VI):adult control group|20 healthy adults matching age and sex as second control group to adults with IIM. Who will be evaluated at baseline using using strain elastography to assess muscle stiffness .
89350538|NCT01256723||J-LESSON Central committee|
89350539|NCT05212532|Experimental|non-ICU hospitalized|Patients who are hospitalized at study enrollment but are not being treated in the ICU
89350540|NCT05212532|Experimental|ICU hospitalized|Patients who, at study enrollment, are being treated in the hospital ICU
89350541|NCT01258205|Experimental|Part B|One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.
89350542|NCT01258205|Experimental|Part A|Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.
89350543|NCT03893981|Experimental|Proprioception and Balance Training|Proprioception and Balance Program
89350544|NCT03893981|Experimental|Strengthening Training|Strengthening Program
89350545|NCT02898506|Active Comparator|Liraglutide|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with Victoza®
89350546|NCT02898506|Placebo Comparator|Placebo|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with placebo
89350547|NCT03897959|Other|Kohli vs Foley Study|Compare various performance characteristics of two urinary catheters.
89350548|NCT03897647|Experimental|POCUS Patients|A bedside echocardiogram will be taken using a point-of-care pocket ultrasound (General Electric (GE) Vscan). Central venous pressure (right atrial pressure) and pulmonary capillary wedge pressure (left atrial pressure) will be collected from pulmonary artery catheters.
89350549|NCT04123405|Experimental|Group A: 600 mg acetylcysteine|one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
89350550|NCT04123405|Experimental|Group B: 1200 mg acetylcysteine|two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
89350551|NCT04123405|Experimental|Group C: 2400 mg acetylcysteine|four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)
89350552|NCT04123405|Placebo Comparator|Group D: Placebo|four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
89350553|NCT02611232|Active Comparator|Victoza®|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)
89350554|NCT02611232|Placebo Comparator|Placebo|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo
89350555|NCT01258283||The study population|See inclusion and exclusion criteria.
89350556|NCT05076734|Other|Analysis of blood samples from healthy pregnant women|A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.
89350557|NCT01150877|Experimental|Experimental Dietary Supplement (e.g., vitamins, minerals)|Experimental arm is supplemented with high-dose of vitamin D.
89350558|NCT01150877|No Intervention|No Intervention|
89350559|NCT03893591||Body mass index below 35|
89350560|NCT03893591||Body mass index 35 and above|
89350561|NCT01256801||cytokine|The patients are randomized to receive the cytokine infusion in the pleural cavity
89350562|NCT02519738|Active Comparator|Silver Nitrate|Silver Nitrate is supplied in the form of pre-packaged applicator sticks to parents and patients. The concentration is 75% Silver Nitrate and 25% Potassium Nitrate. Application will be done 3 times a week for a period of 3 weeks.
89350563|NCT02519738|Active Comparator|Kenalog (Triamcinolone)|Kenalog is a topical corticosteroid that shares anti-inflammatory, anti-pruritic, and vasoconstrictive actions.The dosage of Kenalog used in the study is 0.5%. Application is topical, and the frequency is 3 times a day for the 3 week trial period. FDA approved use of Kenalog in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It has not been studied whether Kenalog has any proven advantage over Silver nitrate in the treatment of granulation tissue, but it has been used for the treatment of granulation tissue at the gastrostomy site with good effect.
89350564|NCT02519738|Active Comparator|Washcloth Abrasion|Washcloth abrasion will be done with regular soap and water applied to a washcloth. The granulation tissue will be gently washed and abraded once daily for three weeks.
89350565|NCT03747211|Experimental|Aerobic exercise intervention|Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
89350566|NCT03747211|No Intervention|Control group|No intervention for 12 weeks
89350567|NCT01256957|Active Comparator|Indoor air HEPA filtration|HEPA filters operating in the participant's bedroom and living room.
89350568|NCT01256957|No Intervention|Control|Control
89350569|NCT03893669|Experimental|Group 1|NBP607 0.5ml
89350570|NCT03893669|Active Comparator|Group 2|Agrippal 0.5ml
89350571|NCT03893747|Experimental|the first batch vaccine producted by 40 L reactor|500 subjects will be randomly received the first batch vaccine producted by 40 L reactor
89350572|NCT03893747|Experimental|the second batch vaccine producted by 40 L reactor|500 subjects will be randomly received the second batch vaccine producted by 40 L reactor
89350573|NCT03893747|Experimental|the third batch vaccine producted by 40 L reactor|500 subjects will be randomly received the third batch vaccine producted by 40 L reactor
89350574|NCT03893747|Experimental|the first batch vaccine producted by 150 L reactor|500 subjects will be randomly received the first batch vaccine producted by 150 L reactor
89350575|NCT03893747|Experimental|the second batch vaccine producted by 150 L reactor|500 subjects will be randomly received the second batch vaccine producted by 150 L reactor
89350576|NCT03893747|Experimental|the third batch vaccine proudected by 150 L reactor|500 subjects will be randomly received the third batch vaccine producted by 150 L reactor
89350577|NCT02343224|Experimental|Pegylated interferon alpha-2b|Subjects will receive PEG-Intron based on their weight (1 mcg/kg/dose) once a week
89350578|NCT01257035||18F-FAZA-PET/CT|
89350579|NCT01151891||Diabetics|Diabetics in the parish of St. James, Jamaica
89350580|NCT04314037|Experimental|Sequence 1 (T1-R1-T2-R2)|Participants will receive first dose of Cesol on Day 1 in treatment period 1 followed by first dose of Biltricide on Day 8 in treatment period 2 followed by second dose of Cesol on Day 15 in treatment period 3 followed by second dose of Biltricide on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
89350581|NCT04314037|Experimental|Sequence 2 (R1-T1-R2-T2)|Participants will receive first dose of Biltricide on Day 1 in treatment period 1 followed by first dose of Cesol on Day 8 in treatment period 2 followed by second dose of Biltricide on Day 15 in treatment period 3 followed by second dose of Cesol on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
89350582|NCT03893357||Positive for antiphospholipid antibodies|Patients tested positive for antiphospholipid antibodies
89350583|NCT03893357||Negative for antiphospholipid antibodies|Patients tested negative for antiphospholipid antibodies
89350584|NCT02248688|Other|Embolic Agent - BeadBlock|Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.
89350585|NCT03897569||patellofemoral pain syndrome|twenty subjects with anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
89350586|NCT03897569||control|twenty-six asymptomatic subject will be recruited for this study and should have no pain or other relevant clinical symptoms in the lower quadrant
89350587|NCT01589705||polycystic kidney ,no hypertension|The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function
89350588|NCT03745963|Experimental|Skin-to-skin contact|"Infants will be placed in full ventral skin-to-skin with their mother at least fifteen minutes prior to heel lance to allow time to settle and recover following transfer. Positioning will be determined based on individual maternal preference in order to optimize comfort as well as facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Skin to skin contact will continue until the procedure is completed.~In addition, infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) during SSC. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
89350589|NCT03745963|Active Comparator|24% Oral sucrose|"Infants will be placed in a cot or in an incubator, depending on their gestational age, for the duration of the blood collection. Administration of 0.12mls (0.04mls per drop) of 24 percent oral sucrose will occur two minutes prior to the heel lance.~The infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
89350590|NCT01257113|Experimental|supervised exercise|The group gets 10 supervised exerciseclasses at the physiotherapy clinic in addition to homebased exercises
89350591|NCT01257113|Experimental|homebased exercises|The group gets 1 supervised exerciseclass before they do all their exercises at home
89350592|NCT05737862|Experimental|Moringa oleifera leaf capsule|Subjects in this arm receive experimental capsules containing powdered Moringa oleifera leaf capsules along with IFA tablets
89350593|NCT05737862|Active Comparator|Iron and folic acid capsule|Subjects in this arm only receive iron and folic acid (IFA) tablets
89350594|NCT03745885|Experimental|0.15mg Supaglutide or placebo|0.15 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
89350595|NCT03745885|Experimental|0.375mg Supaglutide or placebo|0.375 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
89350596|NCT03745885|Experimental|0.75mg Supaglutide or placebo|0.75 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
89350597|NCT03745885|Experimental|1.5mg Supaglutide or placebo|1.5 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
89350598|NCT03745885|Experimental|3.0mg Supaglutide or placebo|3.0 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
89350599|NCT02101970|Experimental|Weight Loss + Omega-3 FA|Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
89350600|NCT02101970|Active Comparator|Weight Loss + Placebo|Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
89350601|NCT01258361||The study population|Patients will be recruited during anesthesia consultations carried out before programmed pelvic or visceral surgeries.
89350602|NCT05211830|Experimental|SXR1096 cream|The active treatment will be the specific small molecule inhibitor of KLK5, 7 and 14 in a proprietary skin cream formulation.
89350603|NCT05211830|Placebo Comparator|Placebo cream|The placebo control will be the proprietary skin cream formulation without the active substance.
89350604|NCT03893201||Venaseal|Patients that have undergone venaseal
89350605|NCT02097680|Experimental|Letrozole|
89350606|NCT02097680|Placebo Comparator|Placebo comparator|
89350607|NCT01150955|Active Comparator|Resveratrol|Dietary supplement of resveratrol 500 mg three times a day over five weeks.
89350608|NCT01150955|Placebo Comparator|Placebo|
89350609|NCT03897413|Experimental|Sequence 1|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fed state in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
89350610|NCT03897413|Experimental|Sequence 2|Participants received a single oral dose of 0.75 mg S-888711 in the fed state in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in period 2, and a single oral dose of 0.75 mg S-888711 in the fasted state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
89350611|NCT03897413|Experimental|Sequence 3|Participants received a single oral dose of 0.75 mg S-888711 in the fasted state with 4000 mg of calcium carbonate in treatment period 1, a single oral dose of 0.75 mg S-888711 in the fasted state in period 2, and a single oral dose of 0.75 mg S-888711 in the fed state in period 3. Each period consisted of 6 days, separated by a 5-day washout period.
89350612|NCT03986372|Experimental|PRP injection, once|PRP injection, once
89350613|NCT03986372|Experimental|PRP injection, twice|PRP injection, twice, 2 weeks apart
89350614|NCT03986372|Experimental|PRP injection, 3 times|PRP injection, 3 times, 2 weeks apart
89350615|NCT01258439|Active Comparator|1.Raltegravir plus truvada|Raltegravir 400mg twice daily plus truvada 300mg/200mg once daily for 24 weeks
89350616|NCT01258439|Active Comparator|2. ritonavir boosted darunavir plus truvada|Darunavir 800mg with ritonavir 100mg plus truvada 300mg/200mg once daily for 24 weeks
89350617|NCT05011448|Other|Single arm study with two interventions|Single arm where each participant will undergo two interventions in the following order: Verbal Interaction and Music Therapeutic Interaction. Both interactions will be conducted by the same music therapist.
89350618|NCT01258517||group 1, group 2, group 3, group 4|administration of beractant with single lumen ET tube administration of poractant with single lumen ET tube administration of beractant with double lumen ET tube administration of poractant with double lumen ET tube
89350619|NCT03628820|Experimental|Therapy Dog|"This group is exposed to the therapy dog and handler. On a convenience sample of shifts, a dog will be available. Participants will not know when dogs will be present and will not be informed of whether or not they will see a dog on any given shift. The dog and handler will be kept out of site of other providers. Participants who agree to participate will be approached by study personnel between 3 and 7 hours into his or her shift and asked would now be a good time to see a therapy dog? If the physician answers yes, then the physician will be escorted to a separate private, quiet room away from the usual work area to interact with a therapy dog and handler. We will ask the physician to spend approximately 5 minutes with the therapy dog, but will not specify or mandate any time. Study personnel will record the time spent. Only the handler and dog will be present in the room."
89350620|NCT03628820|Experimental|Mandala Coloring|This group is not exposed to the therapy dog or handler. At 3-7 hours into the shift, study personnel will encourage providers to take a 5 min period of mindfulness, achieved by coloring mandalas. Participants will be escorted out of the work area to the same private, quiet room where the interaction occurs with the dog and handler in the therapy dog group. Participants will have their choice of one of three mandalas to color and will be provided a full palette of colored pencils. When the provider's time is up, study personnel will notify them of the five minute period. Study personnel will not be present in the room but will photograph the work when the participant is done with the session and record the image in REDcap. The original art work will be returned to the provider.
89350621|NCT03628820|No Intervention|No Intervention|This group is not exposed to the therapy dog or handler.
89350622|NCT01257191|Experimental|Carbon Black|
89350623|NCT01257191|Experimental|Diesel Exhaust Particles|
89350624|NCT01257191|Experimental|Fine Concentrated Ambient Particles|
89350625|NCT01257191|Experimental|Ultrafine Concentrated Ambient Particles|
89350626|NCT01257191|Placebo Comparator|Placebo|
89350627|NCT05507021|Experimental|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Subjects will take 1 sachet of Lactobacillus plantarum DSM 33464 (2 g) per day for 8 weeks
89350628|NCT05507021|Placebo Comparator|placebo group|Subjects will take 1 sachet of Placebo (2 g) per day for 8 weeks
89350629|NCT05211674||COPD patients|
89350630|NCT05211674||Healthy controls|
89350631|NCT05751824|Experimental|With automatic surveillance system|Patients were reminded of the surveillance time by an automatic surveillance system before the surveillance time.
89350632|NCT05751824|Active Comparator|With manual reminder|Patients were reminded of the surveillance time manually before the surveillance time.
89350633|NCT05751824|No Intervention|Normal group|The patients in the control group were observed in the clinical natural state of surveillance without automatic surveillance system or manual reminder.
89350634|NCT01151033|Experimental|stent implantation|ProNOVA XR Polymer Free Drug Eluting Stent implantation - single arm
89350635|NCT01151969|Experimental|New multicomponent intervention|
89350636|NCT01151969|No Intervention|Usual Care|
89350637|NCT00647036|Active Comparator|1|Dipeptiven (L-glutamine- Lalanine)
89350638|NCT00647036|Placebo Comparator|2|Isonitrogenous Vaminolact
89350639|NCT03893123||Firefighters|
89350640|NCT00394550|No Intervention|control|If laryngomalacia is found, then in the control group, no supraglottoplasty will be performed. Only the tonsils and adenoids will be removed.
89350641|NCT00394550|Experimental|Treatment|"If laryngomalacia is found, then in the Treatment group, a supraglottoplasty with laser will be performed, as well as removal of the tonsils and adenoids.~Intervention: supraglottoplasty with laser"
89350642|NCT01560572|Active Comparator|standard immunosuupression|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg
89350643|NCT01560572|Experimental|steroidfree|maintenance immunosuppression with tacrolimus OD (target range 6-10 ng/ml), mycophenolic acid (2 dd 540 mg)
89350644|NCT01560572|Experimental|low dose tacrolimus|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg. After 6 months lowering of tacrolimus OD maintenance 3-5 ng/ml
89350645|NCT03897023||Stable patient|Stable patients who admitted to ICU for observation.
89350646|NCT01258673|Experimental|Fimasartan/HCTZ combination group|
89350647|NCT01258673|Active Comparator|Fimasartan group|
89350648|NCT05209256|Experimental|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve [AUC] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
89350649|NCT05209256|Sham Comparator|chemotherapy|arboplatin (area under the curve [AUC] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
89350650|NCT03897101||MILD NE|"gestational age > 35 weeks and weight > 1800 gr~Apgar score < 5 at 10 minutes o need for cardiopulmonary resuscitation at 10 minutes or evidence of base excess > 12 mmol/L or pH < 7,0 at initial blood gas analyses~evidence of mild encephalopathy graded according to Sarnat&Sarnat neurological evaluation~normal amplitude integrated electroencephalography~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
89350651|NCT03897101||ISOLATED METABOLIC ACIDOSIS|"gestational age > 35 weeks and weight > 1800 gr~evidence of base excess > 12 mmol/L or pH < 7,0 at initial blood gas analyses~Normal Sarnat&Sarnat neurological evaluation~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokines will be evaluated"
89350652|NCT03897101||HEALTY CONTROLS|"gestational age > 35 weeks and weight > 1800 gr Normal blood pH or base excess~Plasma levels of melatonin, Atg5, Parkin, Pink1, inflammatory cytokiness will be evaluated"
89350653|NCT01258751|Experimental|PF-05212377|
89350654|NCT01258829|Experimental|Non-invasive haemodynamic optimisation|Optimization of pressure production by the heart, as measured by systolic blood pressure in the systemic circulation
89350655|NCT01258829|Active Comparator|ECHO optimisation|Optimization of AV/VV delay using the guideline recommendations
89350656|NCT05211128||Radical prostatectomies|
89350657|NCT05211128||Total hysterectomies|
89350658|NCT05211128||Thoracic lobectomies|
89350659|NCT05211128||Partial nephrectomies|
89350660|NCT05211050|Active Comparator|Levcromakalim-Sumatriptan|20 participants with migraine without aura will receive a 20 min infusion of levcromakalim followed by a 10 min infusion of sumatriptan.
89350661|NCT05211050|Placebo Comparator|Levcromakalim-Placebo|20 participants with migraine without aura will receive a 20 min infusion of levcromakalim followed by a 10 min infusion of saline.
89350662|NCT03892733|Experimental|Intervention|CHEKS (calorie health, education, knowledge and skills) intervention will educate participants about calories in fast-food and teach skills to select lower calorie fast-food items.
89350663|NCT03892733|No Intervention|Control|Participants will receive a brochure about healthier choices in fast-food restaurants.
89350664|NCT04883138|Experimental|5 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 5 mg GIGA-2050 per kg BW
89350665|NCT04883138|Experimental|15 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 15 mg GIGA-2050 per kg BW, or as determined by SRC review
89350666|NCT04883138|Experimental|50 mg GIGA-2050 per kg BW|Participants will receive a single IV infusion of 50 mg GIGA-2050 per kg BW, or as determined by SRC review
89350667|NCT03892811||Infants referred for swallow study|"This is a within-subjects intervention study where each infant in the study will receive all three conditions.~The three study conditions are bottle-feeding with 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple."
89350668|NCT05210738||Single incision sling group|The patient will receive Altis mini-incision sling for treatment of occult SUI
89350669|NCT05210738||Urethral bulking group|The patient will receive Bulkamid urethral bulking agent for treatment of SUI
89350670|NCT02527655|Experimental|Choice-Based Physical Activity and Active Transportation|Participants will meet one-on-one with an activity coach to develop a choice-based physical activity and active transportation plan based on their interest, abilities, and resources; attend group-based motivational meetings; and receive ongoing support and encouragement for physical activity and active transportation (e.g., telephone-assisted support, community centre and transit passes).
89350671|NCT02527655|No Intervention|Wait-List Control|Participants will be offered the Choice-Based Physical Activity and Active Transportation intervention after the experimental arm has completed the study.
89350672|NCT05209022|Experimental|Beetroot supplementation|One serving 140 mL of beetroot juice (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
89350673|NCT05209022|Placebo Comparator|Placebo supplementation|One serving of beetroot juice depleted in NO3- (0.08 mmol of NO3-) as placebo (Beet It; James White Drinks Ltd, Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
89350674|NCT03892499|Experimental|Healthy Volunteers|Period 1: Single dose of olinciguat. Period 2: ITZ is dosed once daily (QD) for 10 days; a single dose of olinciguat is administered 1 hour after the fourth ITZ QD dose.
89350675|NCT05732558|Experimental|prospective|8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system
89350676|NCT05732558|No Intervention|retrospective|8 Patients with a bone lesion for which a percutaneous biopsy has been performed from January 2011 to May 2022
89350677|NCT03896243||Uterine artery ligation (UAL)|"We would like toinvite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They would be evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
89350678|NCT03896243||Control Group:|"We would like to invite the patients to the hospital at least 6 months after C-section who delivered baby without any complication.~They would be also evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
89350679|NCT04358900||Mood disorder group|Participants must meet criteria for one of the following disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 criteria (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, cyclothymia. Multiple mood disorders are employed, in line with the Research Domain Criteria (RDoC; (53)) framework and the relative imprecision of current symptom diagnostic clusters for tracking treatment responses and course of disease. To ensure adequate representation across diagnostic categories (including controls), the investigators will cap enrollment of major mood disorders (MDD, BD type I/II) to 50%, PDD and cyclothymia to 25% and recruit a healthy comparison group to comprise the remaining 25% of the sample.
89350680|NCT04358900||Control group|Participants who do not meet the Diagnostic and Statistical Manual of Mental Disorders-5 criteria for (52): major depressive disorder (MDD), persistent depressive disorder (PDD), bipolar disorder (BD) type I/type II, or cyclothymia.
89350681|NCT01152047|Experimental|oxytocin, satiety|Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
89350682|NCT04356404||Prospective group|Patients will be followed up until development of hepatitis flare or at 2 years after study recruitment. We plan to recruit 150 patients for the prospective cohort.
89350683|NCT01257659|Experimental|STARR arm|In this group of patients, the STARR transanal stapling system is used to treat the rectocele.
89350684|NCT01257659|Active Comparator|Elevate arm|In this group of patients, a posterior Elevate mesh is placed transvaginally to treat the rectocele.
89350685|NCT01151267|Other|Control Arm|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
89350686|NCT01151267|Active Comparator|HSH Group|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
89350687|NCT03056300|Experimental|Powered vascular stapler|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
89350688|NCT01152125|Experimental|Autologous bone marrow stem cells|
89350689|NCT05210426|Experimental|Pilates|The Pilates Group completed a 10-week. The intervention was performed in 20 sessions. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week .
89350690|NCT05210426|No Intervention|Control|The Control Group did not perform any Pilates. The children in the CG continued their routine physical activities at school.
89350691|NCT01259141|Experimental|Moxifloxacin|
89350692|NCT01259141|Experimental|Cephalosporins and azithromycin|
89350693|NCT05210348||HPV positive group|
89350694|NCT05210348||HPV negative group|
89350695|NCT05210348||Disease group (clinical diagnosis positive)|CIN2 and above disease cases, including HSIL or (CIN2, CIN2-3, CIN3) cervical cancer.
89350696|NCT05210348||Control group (clinical diagnosis is negative)|includes other benign lesions such as inflammation, polyps, and HPV-negative cases without pathological diagnosis and no abnormalities in TCT.
89350697|NCT03896087|Experimental|clinical performance of the HCV DBS assay|The study will be conducted in different geographical regions and populations and is designed to meet requirements of the for assays (medical devices) used for the qualitative and quantitative detection of Hepatitis C RNA.
89350698|NCT03896087|Active Comparator|comparison PQ marked reference assay arm|Plasma specimens from the participants will be tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities.
89350699|NCT05210192|Placebo Comparator|placebo arm|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. Placebo group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
89350700|NCT05210192|Active Comparator|lidocaine arm|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. Lidocaine group will be injected with 4ml of 0.1%Lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
89350701|NCT01152203|Experimental|Bendamustine + Bevacizumab|Bendamustine starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle. Bevacizumab 10 mg/kg by vein on Days 1 & 15 of every 28 day cycle.
89350702|NCT05210036|Active Comparator|Ultrasound Therapy|"The patients in group 1 received therapeutic US with BTL-4710 ultrasound device.~The therapeutic US was administered at the frequency of 3 megahertz, intensity of 1.5 w/cm2 and an area of 25 cm2 for 5 minutes in the continue mode.~The procedure of therapeutic US was performed by a physiotherapist experienced in using the device for 15 sessions in total 5 times a week for 3 weeks."
89350703|NCT05210036|Active Comparator|High-Intensity Laser Therapy|"The patients in group 2 received HILT with BTL-6000 high-intensity laser device.~The therapy consisted of 2 stages in each session.~The first stage was performed in analgesic mode for analgesic effect at the frequency of 25 Hz, in the wavelength of 1064 nm, the power of 8 watt, the dose of 12 j/cm2, the area of 25 cm2, and 300 j in total for 2 minutes and 30 seconds.~The second stage was performed in bio-stimulating mode for biostimulation effect in the wavelength of 1064 nm, the power of 7 watt, the dose of 100 j/cm2, the area of 25 cm2, and 2500 j in total for 5 minutes and 57 seconds.~The total length of administration was approximately 8.5 minutes for each stage.~The procedure of the therapy was performed by a physiotherapist experienced in using the device for 9 sessions in total 3 times a week for 3 weeks."
89350704|NCT01257815|Experimental|Ranibizumab 0.5mg|
89350705|NCT04638920||Exacerbators|Patients with COPD exacerbation
89350706|NCT03892421|Experimental|Modified DHAP|Rituximab 375 mg/m² day 1, i.v. Carboplatin AUC(Area Under Curve) 5 day 1, i.v. Cytarabine 2000 mg/m², on day 2 and 3, i.v. Dexamethasone 40 mg, days 1-4, i.v. Filgrastim 300 mcg, days 10-15, s.c.
89350707|NCT03892109|Active Comparator|Gingitrac|The gingitrac cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the selected abutment. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
89350708|NCT03892109|Active Comparator|traxodent|The traxodent cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the tooth. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
89350709|NCT03892109|Experimental|Ultrapk cord|the cord packed into the gingival sulcus around the tooth
89350710|NCT03892109|Placebo Comparator|nocord|used directly in the tray
89350711|NCT01152281|Active Comparator|Maximal Control|Basic awareness messages with stories of people living with AIDS
89350712|NCT01152281|Experimental|Instrumental|Instrumental messages with stories of people living with HIV
89350713|NCT01152281|Experimental|Empowering|Empowering messages with stories of people living with HIV
89350714|NCT01152281|Experimental|Instrumental and Empowering|Instrumental and empowering messages with stories of people living with HIV
89350715|NCT01152281|Active Comparator|Minimal Control|Basic awareness messages with stories of people who are not infected with HIV
89350716|NCT03895619|Experimental|Men living with HIV|Uptake of safer conception strategies among men living with HIV and/or their female partners
89350717|NCT05546567|Experimental|Nicotinamide Riboside|Open Label. Nicotinamide Riboside 1200mg x1 daily
89350718|NCT03895229|Experimental|Experimental Arm|Subjects will receive a single oral dose of Empagliflozin 10 MG Oral Tablet [Jardiance]
89350719|NCT03892343||Transplant recipients|Patients undergoing live donor kidney transplant.
89350720|NCT03892343||Non-transplanted|Patients on the deceased donor waiting list without prospect of a live donor transplant.
89350721|NCT03895073||healthy|healthy volunteers' replies to questionnaire
89350722|NCT03895073||heart failure|heart failure patients' replies the questionnaire
89350723|NCT01257893|Experimental|Aspirin 81 mg|Subjects will take 81 mg aspirin per day for 10-14 consecutive days
89350724|NCT01257893|Placebo Comparator|Placebo|Subjects will take matching placebo capsule (excipient: methylcellulose) for 10-14 consecutive days.
89350725|NCT01152593|Experimental|Intranasal Mupirocin|
89350726|NCT01257971||1|Patients with hypercholesterolaemia
89350727|NCT01259219|Experimental|Rifabutin (Mycobutin)|Rifabutin is a red-violet powder souble in chloroform and methanol, sparingly souluble in ethanol, and very slightly soluble in water. Mycobutin capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. Mycobutin capsules for oral administered contain 150mg of rifabutin, USP, per capsule, along with the inactive ingredients microcrystalline cellulose magenesium stearate, red iron oxide3, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink.
89350728|NCT01258127||Pemetrexed and Carboplatin|For patients in arm pemetrexed/carboplatin, folic acid (350-1000 μg) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. Vitamin B12 (1000 μg) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day before, the day of, and the day after each dose of pemetrexed, for rash prophylaxis unless medically contraindicated. Patients must receive pemetrexed at day 1 at the dose of 500 mg/m2 as an IV infusion over approximately 10 minutes, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
89350729|NCT01258127||Vinorelbine and Carboplatin|Patients in arm vinorelbine and carboplatin follow the regimen: The scheduled infusion time is 6-10 minutes for IV vinorelbine at the dose of 25 mg/m2 d1,8, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
89350730|NCT03895151|Experimental|Milk supplementation|"Children will receive 130 ml fresh milk, 6 days/week for 20 weeks (January-June 2019).~Milk will be provided and delivered by appointed supplier directly to school. Milk will be distributed with name of the student on the bottle - during break time.~Subjects must be consumed with supervision of the teacher at school during the break.~If they can not finish the milk at once, they can store it in the provided cool box. Student then can consume it again before they go home. Teacher have to record the remaining milk in each bottle that corresponds to every child name and record it in the provided form.~Prior to holiday, student will be given the milk according to school leave days.~Enumerators should collect the form every 3 days and make a recap in the provided form."
89350731|NCT03895151|Experimental|Food Based Recommendation (FBR) nutrition education|FBR group will received nutrition education delivered by trained teacher under the supervision of researcher/research assistant once a week. Those who received nutrition education is not only the recruited subjects but also includes their classmates.
89350732|NCT03895151|No Intervention|Control|Control group will receive standard nutrition education
89350733|NCT03891407|Experimental|HIV Self-testing Group|Camp members will receive information about HIV self-testing from peer educators who will be nominated by you and other camp members in your camp. Camp members in the STEP project will receive pretest counseling and a 10 minute demonstration. They will receive 1 oral fluid HIV self-test kit to conduct the self-test at home or in a private location during the next 1 month and a phone number to call in case you need assistance when performing the self-test at home. They will also receive information about the nearest HIV Care and Treatment Center where they can seek a confirmatory HIV test and start HIV treatment in the event of a positive self-test result.
89350734|NCT03891407|No Intervention|Non-intervention Group|Camp members will be encouraged to seek HIV testing at the clinics.
89350735|NCT03895385|Experimental|Bimekizumab|Subjects randomized to this arm will receive a single dose bimekizumab followed by inactivated influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
89350736|NCT03895385|No Intervention|No Treatment|Subjects randomized to this arm will receive the influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.
89350737|NCT03891719|Experimental|Changes in nose symmetry|- Direct anthropometric assessment (frontal, oblique, lateral and basal views) and three- dimensional observations of the nose preoperatively and postoperatively in order to evaluate the nostril symmetry, the angles, ratios of the nose and its relation to the face.
89350738|NCT01151501|Experimental|noninvasive positive pressure ventilation|
89350739|NCT03891095|Experimental|Intranasal oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)
89350740|NCT03891095|Experimental|L-DOPA|L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)
89350741|NCT03891095|Placebo Comparator|Placebo|Participants in the Placebo group received spray and oral placebos. 24 IU saline (spray placebo) 187.5 mg calcium carbonate (oral placebo)
89350742|NCT05667077|Experimental|amantadine|The group that was treated with amantadine
89350743|NCT05667077|No Intervention|control|The group that was not treated
89350744|NCT03891017|Experimental|vacuum casting|Vacuum casting will be performed using the Ottobock vacuum casting system. For our vacuum casting procedures, we will be following the protocols outlined in the Harmony Fabrication Quick Guide
89350745|NCT03891017|Active Comparator|hydrostatic casting|For the aqua casting system, we will be using an in-house manufactured device. This device will be created following guidelines from the PCAST Technical Manual
89350746|NCT03890939|Experimental|BiPAP AutoSV Advanced System One|
89350747|NCT03890939|Experimental|Dreamstation BiPAP AutoSV|
89350748|NCT03890939|Active Comparator|ResMed S7 VPAP Adapt device|
89350749|NCT01589627|Experimental|experimental|Patients will be treated with the Standard of Care physical therapy, NSAIDs as well as a Wrist Extension Dynasplint
89350750|NCT01589627|No Intervention|Control|Patients will receive standard of care physical therapy and NSAIDS
89350751|NCT01152671|Experimental|Arm 1|
89350752|NCT01152671|Placebo Comparator|Arm 2|
89350753|NCT03894839|Active Comparator|glutaraldehyde disinfection and microwave application|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
89350754|NCT03894839|Active Comparator|Chlorhexidine gluconate disinfection and microwave application|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
89350755|NCT03894839|Active Comparator|Sodium hypochlorite disinfection and microwave application|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 3 minutes 650 watt microwave energy application by dentists at each control session
89350756|NCT03894839|Active Comparator|glutaraldehyde disinfection and ozone therapy|%2 glutaraldehyde, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
89350757|NCT03894839|Active Comparator|Chlorhexidine gluconate disinfection and ozone therapy|%2 chlorhexidine gluconate, solution form, duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
89350758|NCT03894839|Active Comparator|Sodium hypochlorite disinfection and ozone therapy|%5 sodium hypochlorite, solution form,duration time 1 minute and 1 time in a day by patients and 15 minutes ozone therapy at each control session by dentists
89350759|NCT03894761|Other|Patients with Rotator Cuff Syndrome|The patients diagnosed with rotator cuff syndrome by clinical and magnetic resonance imaging.
89350760|NCT01152749|Experimental|UNG-GC-2|2 mg experimental NRT product
89350761|NCT01152749|Experimental|UNG-GC-4|4 mg experimental NRT product
89350762|NCT01152749|Active Comparator|Nicorette® Gum-2|2 mg Nicorette® Gum
89350763|NCT01152749|Active Comparator|Nicorette® Gum-4|4 mg Nicorette® Gum
89350764|NCT03894683|Experimental|Melatonin|Melatonin (10 mg tablets) by oral root, ingested at bedtime for 6 months
89350765|NCT03894683|Placebo Comparator|Placebo|Placebo tablets in the same shape as melatonin tablets, ingested the same as the melatonin tablets.
89350766|NCT01259453|Active Comparator|Standard vaccination schedule|Standard dosing at 0, 1, and 6 months
89350767|NCT01259453|Active Comparator|Accelerated Schedule|Accelerated dosing at 0, 1, and 2 months
89350768|NCT01151657|Placebo Comparator|Placebo|Capsules containing maltodextrin.
89350769|NCT01151657|Experimental|Probiotics|Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.
89350770|NCT03894527|Active Comparator|Control|"Subjects with simple obesity will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
89350771|NCT03894527|Active Comparator|Metabolic Syndrome|"Subjects with metabolic syndrome will complete 2 different testing conditions in a counterbalanced order with at least one week between conditions.~10-12 hrs post test condition the subject will report for a Euglycemic-Hyperinsulinemic clamp study, where Flow Mediated Dilation (FMD) and Contrast Enhanced Ultrasound (CEU) will be performed."
89350772|NCT03890783||Patients after surgery of oropharyngeal cancers|Patients after surgery of oropharyngeal cancers with soft palate with free flap reconstruction and adjuvant radiotherapy
89350773|NCT03894293||ventilator group|It's a observational study. Participants entry the Respiratory Care Center and are evaluated. If the participant meet the inclusion criteria, the first assessments will be collected. After the weaning training, the second assessment will be collected before the the endotracheal tube is removed.
89350774|NCT01259531|Experimental|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
89350775|NCT03894137|Experimental|Grains of Paradise|
89350776|NCT03894137|Placebo Comparator|Placebo|
89350777|NCT01586351||Patch and ACP Treatment|Patents who get an patch augmentation and ACP injection following an arthroscopic repair of the rotator cuff.
89350778|NCT03894371|Other|Thermage|Subjects will undergo treatment with the Thermage FLX system using a 900 pulse, 4cm2 Total Tip to treat the face and neck and a 450 pulse, 0.25cm2 tip to treat the upper and lower eyelids.
89350779|NCT01151735|Active Comparator|C-1-esterase inhibitor 1000 units|1000 units of C-1-esterase inhibitor given at time of prodromal symptoms
89350780|NCT01151735|Active Comparator|1500 units of C-1-esterase inhibitor|treatment with 1500 units of C-1-esterase inhibitor IV at the time of prodromal symptoms to decrease risk of exacerbation of HAE
89350781|NCT01151735|Placebo Comparator|placebo injection|placebo injection given for prodromal symptoms as double blinded therapy
89350782|NCT01259843||Acute Aortic Syndrome|Patients admitted to cardiology, radiology or surgery for a clinical picture suggestive of acute aortic syndrome whose diagnosis was subsequently confirmed in due course of hospitalization by further investigations.
89350783|NCT03890393||patients with episodic headache|
89350784|NCT03890393||patients with chronic headache|
89350785|NCT03890393||healthy controls|
89350786|NCT03061214|Experimental|Semaglutide 0.5 mg OW + sitagliptin placebo OD|
89350787|NCT03061214|Experimental|Semaglutide 1 mg OW + sitagliptin placebo OD|
89350788|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 0.5 mg OW|
89350789|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 1 mg OW|
89350790|NCT01152827|Experimental|RAD001|RAD001 10 mg daily po medication
89350791|NCT03890471|Experimental|Preoperative telephone call|Patients will receive routine preoperative counseling in the clinic plus a provider initiated telephone call 3 days before surgery.
89350792|NCT03890471|No Intervention|No preoperative telephone call|Patients will receive routine preoperative counseling in the clinic.
89350793|NCT03890549||obstructive sleep apnea group|The patients were diagnosed by thoracic and ENT (Eye-Nose-Throat) specialist through polysomnography.
89350794|NCT01259921|Experimental|Neurofeedback T4-P4|40 sessions of SMR neurofeedback training using T4-P4 placement administered twice weekly
89350795|NCT01259921|Active Comparator|Neurofeedback T3-T4|40 sessions of SMR neurofeedback using T3-T4 placement training administered twice weekly
89350796|NCT01153373|Placebo Comparator|Minimal Intervention Control|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only. The reports will not be printed or dynamic referrals generated, and all patients will receive treatment-as-usual by their ED providers."
89350797|NCT01153373|Active Comparator|DARSSA Intervention|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
89350798|NCT03889301|Experimental|E-E Video|Watch E-E video that incorporates health and educational messages
89350799|NCT03889301|Active Comparator|Discussion|Structured discussion about depression and anxiety
89350800|NCT01259999|Experimental|Energy dense formula|
89350801|NCT05209958||Group A|Patients with NLR level below 2
89350802|NCT05209958||Group B|Patients with NLR level equal to or above 2
89350803|NCT01260077||Experimental group|The sample was composed of 78 individuals (156 ears), 40 females (80 ears) and 38 males (76 ears).
89350804|NCT03889145|Active Comparator|Telmisartan, Amlodipine|
89350805|NCT03889145|Active Comparator|Hydrochlorothiazide|
89350806|NCT03889145|Experimental|Telmisartan, Amlodipine, Hydrochlorothiazide|
89350807|NCT05209724|Experimental|Provider Supervised|Digital monitoring system with provider supervision
89350808|NCT05209724|No Intervention|Self Supervised|Digital monitoring system without provider supervision
89350809|NCT04299776|Experimental|IPR therapy|Intrathoracic pressure regulation (IPR) therapy level of -10 cmH2O (-7 cmH2O for run-in) provided by the CirQPOD device during shoulder surgery in the sitting position
89350810|NCT04299776|Active Comparator|Standard airway|Standard airway pressure (PEEP of +5 cmH2O) during shoulder surgery in the sitting position
89350811|NCT01153451|No Intervention|Usual Care|Responsible inpatient and ambulatory physicians assigned to usual care will not receive any email(s) of patients' test results generated from the notification system.
89350812|NCT01153451|Other|Email Notification|Responsible inpatient and ambulatory physicians will receive automated email(s) of patients' tests results finalized post-discharge generated from the notification system. Finalized results will be batched such that no provider will receive more than one email per day.
89350813|NCT03889223|Active Comparator|The LDF neuraxial positioning technique|In the LDF neuraxial positioning technique, fifty participants were planned to lay down the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist. Volunteers jaw touch to chest and legs in abdominal flexion with hands are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
89350814|NCT03889223|Experimental|The SCF neuraxial positioning technique|In the SCF neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
89350815|NCT01153529||Group 1|OEF/OIF Veterans
89350816|NCT03888677|Active Comparator|Standard|Standard FEC (F600, E60, C600) every 3rd week.
89350817|NCT03888677|Experimental|Tailored|Tailored FEC (F600, E75-90, C900-1200) every 3rd week.
89350818|NCT03888677|Active Comparator|Registered|Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.
89350819|NCT01153607|Experimental|Arm 1|
89350820|NCT01153607|Experimental|Arm 2|
89350821|NCT01153607|Experimental|Arm 3|
89350822|NCT04208126|Active Comparator|Early ECMO|ECMO is placed immediately after admission to the intensive care unit
89350823|NCT04208126|No Intervention|Control|Conservative therapy unless failure of therapy.
89350824|NCT01260155|Experimental|Treatment A Fasted|
89350825|NCT01260155|Experimental|Treatment B Fasted|
89350826|NCT01260155|Experimental|Treatment C Food Effect|
89350827|NCT04655690|Experimental|NNC0471-0119|Participants randomised to NNC0471-0119
89350828|NCT04655690|Active Comparator|Faster aspart|Participants randomised to faster aspart.
89350829|NCT03912545||Trauma patients|Subjects experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
89350830|NCT03912545||Obstetric hemorrhage patients|Subjects experiencing obstetric hemorrhage such that viscoelastic testing is performed as standard of care is performed to assess coagulopathy.
89350831|NCT04107662||Traumatic Brain Injury|
89350832|NCT01251341|Experimental|Compassion Meditation Group|
89350833|NCT01251341|Active Comparator|Health Education and Wellness Group|
89350834|NCT01251341|Experimental|Mindful Attention Training|
89350835|NCT03628196||Quality Improvement Program Basic and Enhanced Phase|Patients that meet the eligibility criteria and participate in the QIP.
89350836|NCT03628196||Retrospective Group|Patients seen a year prior to the QIP period at the clinic but that did not participate in the QIP.
89350837|NCT03628196||Concurrent Group|Patients seen during the QIP period at the clinic but that did not participate in the QIP.
89350838|NCT01260233|No Intervention|Control|No intervention. Patients will receive standard of care.
89350839|NCT01260233|Experimental|Smoking cessation program|Receives smoking cessation program
89350840|NCT03628118||open radical hysterectomy|"The patients who would undergo open radical hysterectomy procedure."
89350841|NCT03888521|Experimental|Resound Relief|All participants are in the same group, and receive the same intervention - use of the Resound Relief smartphone app for 6 months
89350842|NCT03888833||Veno arterial extracorporeal membrane oxygenation|
89350843|NCT01251419|Experimental|Testimonial and Union Arm|The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
89350844|NCT01251419|Experimental|Control|The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication.
89350845|NCT01251419|Experimental|Testimonial Treatment Arm|The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial.
89350846|NCT03912623|Active Comparator|3 weeks SPA Treatment|"3-week thermal cure:~Spa treatment harmonized in the different stations~Therapeutic education workshops and conferences common to all stations in the form of practical workshops during supervised lunches~Adapted physical activity, workshops are common to all spas and use an electric bike suitable for health (VELIS) with briefing and debriefing. An APA (Adapted Physical Activity) coaching consultation at the end of the cure for personalized post-cure programs and objectives is planned as well as a telephone or internet coaching during the 5 months post-cure (objectives and adaptation, motivation)~Maintenance of the usual treatment within 6 months post randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by the software Diascope and / or HAS~Information booklet for inclusion (French Association of Diabetics)"
89350847|NCT03912623|Sham Comparator|Discovery week end|"Maintenance of usual treatment within 6 months post-randomization with optimization of the therapeutic target in HbA1c and therapeutic strategies by Diascope and HAS software In addition, a discovery access to the baths of 2-3 days will be offered to patients. Finally, the information booklet on diabetes will be given at the inclusion (French Federation of Diabetics)."
89350848|NCT04435964||Overall series|Patients treated with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule. No limitations to previous lines of treatment. ICI therapy may be either as single agent or in combination. Concomitant chemotherapy (CT) and radiotherapy (RT) is allowed.
89350849|NCT03912779|Experimental|C2Hear RLOs|C2Hear RLOs (https://www.youtube.com/C2HearOnline): nine (custom earmould) or eight (open fit hearing aid) multi-media learning clips covering practical and psychosocial components of owning a hearing aid, alongside user testimonials (n= 7). Participants asked to watch all relevant to their prospective hearing aid coupling (custom earmould or open fit), with no limit on number of views. A paper diary documented usage during the study duration.
89350850|NCT03912779|Placebo Comparator|Printed hearing aid booklet|A 32-page printed A5 colour booklet, designed and written by local Audiology staff, supplied to all prospective hearing aid owners at the study centre as standard care. Same booklet supplied irrespective of hearing aid style (custom/open fit). All content conveyed via text and supporting pictures only. Participants assigned to the placebo comparator were asked to read the booklet once. A paper diary documented usage during the study duration.
89350851|NCT04040426|Experimental|Human split thickness skin allograft (Theraskin™)|Theraskin™ is an all-human split thickness skin allograft with a native extracellular matrix that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing. Theraskin™ is an allograft tissue and will be used in compliance with homologous use by the FDA under section 361 of the PHS Act and 21 CFR Part 1271
89350852|NCT04040426|Active Comparator|Fibracol wound dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
89350853|NCT01153919|Active Comparator|Arm I|Patients receive romiplostim subcutaneously once weekly for 8 weeks in the absence of disease progression or unacceptable toxicity.
89350854|NCT01153919|Placebo Comparator|Arm II|Patients receive placebo subcutaneously once weekly for 8 weeks. Patients failing to achieve a platelet count of &gt; 100,000/L cross over to arm I.
89350855|NCT01260389|No Intervention|control group|Usual pharmacist care in patients with Chronic Obstructive Pulmonary Disease (COPD).
89350856|NCT01260389|Experimental|pharmaceutical care intervention|A pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
89350857|NCT03888443||uCP children|15 Children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol twice separated from 2 to 4 weeks
89350858|NCT03888443||uCP children with botulinum toxin injections|5 children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol three times
89350859|NCT03888443||healthy volunteers (TDC children)|20 children aged from 6 to 17 (healthy volunteers) will realize the bimanual protocol once
89350860|NCT03941444|Experimental|Active arm|ANAVEX2-73 liquid oral solution
89350861|NCT03941444|Placebo Comparator|Placebo arm|Placebo liquid oral solution
89350862|NCT03912389|Experimental|BCD-100|BCD-100 3 mg/kg Q3W
89350863|NCT03912389|Placebo Comparator|Placebo|
89350864|NCT05703464|Experimental|Elobixibat|10mg Elobixibat administration for 4 weeks
89350865|NCT03934658|Experimental|Active Treatment Arm|Intervention with the NightWare Therapeutic System every night.
89350866|NCT03934658|Sham Comparator|Sham Arm|NightWare Therapeutic System every night with interventions not-enabled.
89350867|NCT01147757|Placebo Comparator|saline|Group S (n = 15): saline
89350868|NCT01147757|Experimental|remifentanil 0.3 mcg/kg/min|Group 0.3 (n = 15): remifentanil 0.3 mcg/kg/min
89350869|NCT01147757|Experimental|remifentanil 0.6 mcg/kg/min|Group 0.6 (n = 15): remifentanil 0.6 mcg/kg/min
89350870|NCT01147757|Experimental|remifentanil 0.9 mcg/kg/min|Group 0.9 (n = 15): remifentanil 0.9 mcg/kg/min
89350871|NCT01153997|Experimental|A|
89350872|NCT01153997|Experimental|B|
89350873|NCT01153997|Placebo Comparator|C|
89350874|NCT01153997|Placebo Comparator|D|
89350875|NCT03619928|Experimental|Dry needling|Procedure in which a thin needle is used to penetrate the skin, subcutaneous tissues and muscle with the intention of mechanically stimulating the tissue without the use of an anesthetic. The physiological mechanism supporting the effects of dry needling remains to be clarified. It has been suggested that the needle works according to the pain gate control theory, indicating that one type of sensory input could be inhibited in the Central nervous system by another input
89350876|NCT03619928|Active Comparator|Massotherapy|Among the therapeutic approaches for DOMS is massage therapy. Several authors have examined the effects of DOMS massage and indirect markers of muscle damage, such as impaired muscle function, edema and muscle changes in blood proteins.
89350877|NCT04184726|Experimental|MBCT-vision|8 x once weekly group sessions, and home practice between sessions
89350878|NCT01154309|Experimental|1|Clients are invited to attend 18 group CBT sessions
89350879|NCT01154309|No Intervention|2|Clients receive usual care
89350880|NCT01586429||Epidural|
89350881|NCT01586429||Femoral catheter|
89350882|NCT01251731|Experimental|Treatment Group 1|
89350883|NCT01251731|Experimental|Treatment Group 2|
89350884|NCT01251731|Experimental|Treatment Group 3|
89350885|NCT01251731|Experimental|Treatment Group 4|
89350886|NCT01260545|Experimental|Infusion|A standard 3+3 design will be employed to determine maximum tolerated dose
89350887|NCT01147913|Experimental|Positive Interpretation Training|Four sessions of positive information-processing training for interpretation of ambiguous scenarios relevant to themes of depression.
89350888|NCT01147913|Sham Comparator|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
89350889|NCT03888209|Experimental|Anodal tDCS|Patients will receive 20min anodal tDCS
89350890|NCT03888209|Sham Comparator|Sham tDCS|Patients will receive 20 minutes of Sham anodal tDCS
89350891|NCT01251809|Experimental|PEG-rASNase 500|500 U/m2 BSA at day 0
89350892|NCT01251809|Experimental|PEG-rASNase 1000|1000 U/m2 BSA at day 0
89350893|NCT01251809|Experimental|PEG-rASNase 1500|1500 U/m2 at day 0
89350894|NCT01251809|Active Comparator|Oncaspar|2000 U/m2 at day 0
89350895|NCT03912077|Experimental|Culturally Adapted Cognitive Behavioural Therapy|"Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) is an evidence-based psychological intervention manual developed by Devon Hinton, MD from Harvard University and Baland Jalal from University of Cambridge. It is a group therapy protocol that consists of 7 sessions.~It is a brief, feasible and culturally sensitive intervention that has a transdiagnostical approach. Detailed information about Syrian culture, idioms of stress, cultural differences, and psychological problems that Syrian refugee women have been facing and their needs, expectations and sensitivities are considered in the adaptation process. Examples, cultural metaphors and imageries that take part in the manual are adapted according to Syrian culture."
89350896|NCT03912077|No Intervention|Treatment as Usual|Control arm participants will receive routine social support and/or care according to ordinary practice of the non-governmental organization (treatment as usual). Also, they will receive baseline and post assessments according to the study schedule.
89350897|NCT01154387|Active Comparator|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
89350898|NCT01154387|Experimental|TOL101 (Dose A)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
89350899|NCT01154387|Experimental|TOL101 (Dose B)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
89350900|NCT03911765|Experimental|Executive Function cognitive training|20 hours of digital cognitive training targeting executive function.
89350901|NCT03911765|Active Comparator|Games|10 hours of computer games c available online which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc), followed by 10 hours of of digital cognitive training targeting executive function.
89350902|NCT01154465|Active Comparator|Anatomical guidance puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The preparation of the CVC installation will follow the procedures for disinfection, for skin preparation of the operator, for installation of sterile fields and for local anaesthesia.~The veins will be tracked by simple palpation of the carotid pulse.~The puncture will be made following:~The anterior Boulanger's incision for the internal jugular vein;~When venous aspiration is obtained, the catheter is assembled according to the Seldinger method."
89350903|NCT01154465|Experimental|US-guided puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed. A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein pathway;"
89350904|NCT03887975|Active Comparator|Percentage of force in monoplane occlusion|Different occlusal scheme evaluation using tscan
89350905|NCT03887975|Active Comparator|Percentage of force in lingualized occlusion|Different occlusal scheme evaluation using tscan
89350906|NCT03911921|Experimental|RSYYT decoction|RSYYT decoction Compound granules of traditional Chinese medicine
89350907|NCT03911921|Experimental|Astragalus membranaceus|one herb decoction Compound granules of one herb (Astragalus membranaceus)
89350908|NCT03887897|Active Comparator|Airtraq|Airtraq laryngoscope
89350909|NCT03887897|Active Comparator|Macintosh|Macintosh laryngoscope
89350910|NCT03890315||Neuropathic pain|Adult patients with upper extremity neuropathic pain due to radiculopathy Duration of >1 month Unilateral extremity pain will be recruited
89350911|NCT03890315||Control|Age and gender matched control patients will also be recruited to show whether differences exist in outcome measures.
89350912|NCT01152905||Air/TIVA group|The patients received during the anesthesia a mixture of air with 30% oxygen All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
89350913|NCT01152905||Nitrous oxide/TIVA group|The patients received nitrous oxide with 30% oxygen.All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
89350914|NCT01259609|Experimental|Diabetic Macular Edema Group|
89350915|NCT01259609|Active Comparator|Epiretinal Membrane Group|
89350916|NCT01259609|No Intervention|Healthy Control|
89350917|NCT03887585|Experimental|Achilles tendon lengthening|Surgery of percutaneous Achilles tendon lengthening by triple hemisection
89350918|NCT01252043||cohort|cholestatic children without esophageal variceal bleeding
89350919|NCT01252043||study|cholestatic children with esophageal variceal bleeding
89350920|NCT01252043||cholestatic children without EV|cholestatic children without esophageal variceal bleeding
89350921|NCT04115839|Experimental|Filgotinib 200 mg (Main Study)|Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.
89350922|NCT04115839|Experimental|Filgotinib 100 mg (Main Study)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 16 weeks.
89350923|NCT04115839|Placebo Comparator|Placebo (Main Study)|Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.
89350924|NCT04115839|Experimental|Filgotinib 200 mg (LTE)|Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 44 weeks.
89350925|NCT04115839|Experimental|Filgotinib 100 mg (LTE)|Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 44 weeks.
89350926|NCT01154543||HIV positive, gential HSV,Famvir™ 500mg bd, suppressive|
89350927|NCT01252121|Other|Systane, Hialid, Unisol|1 drop Systane in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
89350928|NCT01252121|Other|Systane, Unisol, Hialid|1 drop Systane in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
89350929|NCT01252121|Other|Hialid, Systane, Unisol|1 drop Hialid in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
89350930|NCT01252121|Other|Hialid, Unisol, Systane|1 drop Hialid in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
89350931|NCT01252121|Other|Unisol, Systane, Hialid|1 drop Unisol in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
89350932|NCT01252121|Other|Unisol, Hialid, Systane|1 drop Unisol in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
89350933|NCT03911609|Experimental|Isometric (Static) Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
89350934|NCT03911609|Experimental|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
89350935|NCT01148069|Experimental|Surgery combined with IMRT-IGRT|
89350936|NCT01153061|Experimental|Fistula closure with occluder|Patients with benign tracheoesophageal fistulas will be submitted to the correction with the occluder.
89350937|NCT03890159|Experimental|Computer Assisted Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours, and patients will progress to the difficulty level automatically. Their performance during this process (response time etc.) will be recorded.
89350938|NCT03890159|Experimental|Conventional Cognitive Rehabilitation|The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests.
89350939|NCT03890159|No Intervention|Waiting list controls|These patients will get no intervention as means of cognitive rehabilitation, but will get their usual treatments.
89350940|NCT03889847|Experimental|silicone DLT|Fibreoptic intubation with silicone double lumen tube
89350941|NCT03889847|Experimental|PVC DLT|Fibreoptic intubation with PVC double lumen tube
89350942|NCT03890003|Experimental|AID System Containing Insulin Lispro|The automated insulin delivery (AID) system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a PLGS algorithm, and a continuous glucose monitor (CGM) component.
89350943|NCT01252199|Experimental|cαStx1/cαStx2|
89350944|NCT01252199|Placebo Comparator|Control|
89350945|NCT05484245|Experimental|Surgery|Ultrasound-guided resection of brain tumors, vascular malformations and hematomas
89350946|NCT01259687||Study group|
89350947|NCT01154621|Experimental|1|Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers
89350948|NCT01154621|Placebo Comparator|2|Sterile 5% dextrose solution
89350949|NCT03889691||Control group|The control group consisted of patients who verbal explanation of the surgical procedure and the potential postoperative complications was given with a written informed consent document
89350950|NCT03889691||Study group|Participants in the study group asked to watch impacted lower third molar extraction video which was previously uploaded to the internet with their own device. This video includes only visual components of the surgery such as anesthesia, incision, extraction and suturing. Patients in the second group were also informed verbally about the surgical procedure-possible postoperative complications and was given with a written informed consent document.
89350951|NCT01260935|Active Comparator|Arm A|Laparoscopic Hill
89350952|NCT01260935|Active Comparator|Arm B|Laparoscopic Nissen
89350953|NCT01153139|Experimental|bilateral theta burst stimulation to the DLPFC|intermittent TBS (iTBS) to the left DLPFC continuous TBS (cTBS) to the right DLPFC
89350954|NCT01153139|Placebo Comparator|Sham stimulation|Sham stimulation with a 45° tilted coil
89350955|NCT01261013||keratoconus stage I in whom KeraRing ICRS were implanted|
89350956|NCT01261013||keratoconus stage II in whom KeraRing ICRS were implanted|
89350957|NCT01261013||keratoconus stage III in whom KeraRing ICRS were implanted|
89350958|NCT01261091|Experimental|Early Tracheostomy|Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 3 days from intubation.
89350959|NCT01261091|Active Comparator|Prolonged Intubation|Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy between days 7 to 14 from intubation.
89350960|NCT03889457||Patients with venous thromboembolic disease|Patients with deep vein thrombosis, superficial or muscular vein thrombosis, pulmonary embolism, over 18 years of age.
89350961|NCT01153217|Experimental|Abacavir|Switch from tenofovir to abacavir
89350962|NCT01153217|No Intervention|tenofovir|Follow same ART regimen
89350963|NCT01561430|Experimental|15 mg LY2886721|LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks.
89350964|NCT01561430|Experimental|35 mg LY2886721|LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks.
89350965|NCT01561430|Experimental|70 mg LY2886721|LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks.
89350966|NCT01561430|Placebo Comparator|Placebo|Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.
89350967|NCT03887507|Experimental|Experimental|There will be 3 Vojta therapy sessions conducted on 2 consecutive weeks with an interval of 7 dayssessions, on 1st, 7th and 14th days. Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling Réflex, and 1st phase and 2nd phase Rolling reflex. The relative or close person will be instructed to carry out an exercise protocol to do at home every day for 20 minutes during the 2-week study. All interventions will be made by the principal investigator.
89350968|NCT03887507|Active Comparator|Standard Therapy|The standard group shall perform 4 sessions of physiotherapy in the same period for two consecutive weeks, with one hour per session in its specialized MS association, on 1st, 3rd, 8th, 10th and 15th days. This will be applied by experienced physiotherapists during the treatment of people with MS. The program will consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept. Patients in this group will walk at least for 20 minutes per day during the study period.
89350969|NCT03887195||students|The clinical sample is made up of 501 students (male and female) in the 4th year of medicine at Paris Descartes University, participating at the obligatory training module during the 2018-2019 academic year : this constitutes the entire population concerned by the intervention.
89350970|NCT03931070|Experimental|Ramelteon|Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
89350971|NCT03931070|Placebo Comparator|Placebo|Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
89350972|NCT01153295|Experimental|Positive diagnosis|The diagnosis of IBS is based on the international ROME III criteria, few blod tests, and abscence of danger signals
89350973|NCT01153295|Active Comparator|Diagnosis of exclusion|The diagnosis of IBS is based on normal extended blood tests, screening for celiac sprue and lactose intolerance, stool for ova and parasites and endoscopy with biopsy
89350974|NCT03773120|Experimental|Using Neuromonitoring to find EBSLN|With Neuromonitoring of the EBSLN using nerve monitoring system
89350975|NCT03773120|No Intervention|No Using Neuromonitoring to find EBSLN|Without Neuromonitoring of the EBSLN using nerve monitoring system
89350976|NCT01259765|Active Comparator|VHH|"The active substance is VHH batch 203027."
89350977|NCT01259765|Placebo Comparator|Placebo|Placebo product
89350978|NCT05683886|Experimental|KC1036|60mg QD
89350979|NCT01261169||Myfortic|
89350980|NCT03747848|Experimental|CBT group|Subjects will participate in group treatment sessions (once a week for six weeks).
89350981|NCT03911063|Experimental|Cognitive behavioral therapy (CBT)|
89350982|NCT03911063|Active Comparator|Placebo Talking Sessions|
89350983|NCT03939962|Experimental|treatment group|"Neoadjuvant therapy:SHR1210 combined with FOLFOX repeat every 14 days for a total of 4 cycles.~Adjuvant therapy:SHR1210 combined with chemotherapy (the specific regimen will be chosen at the discretion of the investigator), every 14 days for a total of 4 cycles. After that, the patients will receive camrelizumab monotherapy for up to 1 year (from the first SHR1210 treatment)."
89350984|NCT02527499|Experimental|ROCBT group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Ride-On Cars with Bimanual Training Program (ROCBT) group.
89350985|NCT02527499|Active Comparator|Early Mobility Training group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Early Mobility Training Program group.
89350986|NCT02527499|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Regular Therapy Program group.
89350987|NCT03889379|Experimental|Effects of Albuterol on Immune Cell Composition|This is a single subject repeated measure experimental design with each participant acting as his/her own control.
89350988|NCT03911219||CANKADO (Arm A)|CANKADO application as eHealth support system: Patients use CANKADO for regular symptom self-reporting in addition to standard of care symptom management.
89350989|NCT03911219||Control (Arm B)|Control arm without eHealth support: Patients recieve standard of care symptom management.
89350990|NCT03887039||ADHD group|clinical examination
89350991|NCT03887039||normal group|clinical examination
89350992|NCT03910829|Experimental|Action Observation|This group receives an action observation training through the visualization of a video of cervical movements.
89350993|NCT03910829|Experimental|Motor Imagery|This group receives an motor imagery through the imagery process of cervical movements.
89350994|NCT03910829|Placebo Comparator|Placebo Group|This group receives a placebo action observation training through the visualization of a video of a documentary video
89350995|NCT05159102|Experimental|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)-[Parents and Children-Workshop Group]. These workshops will be offered in person. In addition to the workshops, this group and the home-based group will receive information (activity booklets via the Fit Families App) and physical education (physical activity)-related equipment.
89350996|NCT05159102|Experimental|Home-based group|Participants in the home-based group will not participate in the four half-day workshops (face to face), but they will receive the same information remotely (workshop content) and will have access to the activity booklets (via the App) and physical activity equipment as the workshop group (during intervention)-[Parents and Children-Home Group].
89350997|NCT05159102|Other|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-[Parents and Children-Control Group]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks after the completion of the 12-week period. Immediately following the follow-up test, participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
89350998|NCT01252433|Experimental|Entree energy density 100%|100% energy density
89350999|NCT01252433|Experimental|Entree energy density 85%|85% energy density
89351000|NCT01252433|Experimental|Entree energy density 75%|75% energy density
89351001|NCT03361982|No Intervention|Fresh surgical testicular sperm|Fresh, surgically obtained testicular sperm
89351002|NCT03361982|Experimental|Frozen surgical testicular sperm|Surgically obtained testicular sperm that will undergo slow freezing and thawing
89351003|NCT03886337|No Intervention|Control|The control arm will be surgical care according to usual practice with usual ambient lighting
89351004|NCT03886337|Experimental|Treatment Arm|The treatment arm will include surgical care according to usual practice with germicidal ambient lighting
89351005|NCT01586507|Experimental|Group 1|
89351006|NCT01586507|Experimental|Group 2|
89351007|NCT01155401||1|Patients with acute upper gastrointestinal bleeding
89351008|NCT05152394|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
89351009|NCT03910595|Experimental|Mepitel Film Arm|This is a single arm trial where all patients will receive the intervention of Mepitel Film.
89351010|NCT01252511|Active Comparator|long biliopancreatic limb, 75 cm|
89351011|NCT01252511|Active Comparator|long Roux limb, 150 cm|
89351012|NCT03910517||E-sport athletes|People aged 15-35 who engage in structured E-sport (e.g. community-based, pro team or educational setting).
89351013|NCT03910361|Experimental|Evogliptin|evogliptin 5mg
89351014|NCT03910361|Active Comparator|Pioglitazone|pioglitazone 15mg
89351015|NCT03910205||Type 1 diabetes with gingivitis|Children with type 1 diabetes mellitus and gingivitis
89351016|NCT03910205||Type 1 diabetes with healthy gingiva|Children with type 1 diabetes mellitus and healthy gingiva
89351017|NCT03910205||Healthy patients with gingivitis|Systemically healthy patients with gingivitis
89351018|NCT03910205||Healthy patients with healthy gingiva|Systemically healthy patients with healthy gingiva
89351019|NCT03700658|Experimental|TV-46046 Undiluted|Participants will receive TV-46046 undiluted (120 mg/0.3 mL of 400 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
89351020|NCT03700658|Experimental|TV-46046 Diluted|Participants will receive TV-46046 saline-diluted (60 mg/0.3 mL of 200 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
89351021|NCT03700658|Placebo Comparator|TV-46046 Placebo|Participants will receive TV-46046 placebo (0.3 mL) SC injection in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
89351022|NCT03700658|Active Comparator|Depo-subQ 104|Participants will receive Depo-subQ 104 (medroxyprogesterone acetate injectable suspension; 104 mg/0.65 mL) SC injection as a reference formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
89351023|NCT03910127|Experimental|TQB2450 + Anlotinib (10 mg)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Anlotinib capsules 10 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89351024|NCT03910127|Experimental|TQB2450 + Anlotinib (12 mg)|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89351025|NCT03910127|Placebo Comparator|TQB2450 + Placebo|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle plus Placebo for Anlotinib capsules given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
89351026|NCT03886103|Experimental|Healthy volunteer|Single of 14C-PXL770
89351027|NCT03031964||revision multihole acetabular cup|Revision total hip arthroplasty using multihole revision acetabular cup
89351028|NCT03885947|Experimental|VPA expanded cord blood stem cells|"CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood for patients with hematological malignancies undergoing allogeneic stem cell transplantation.~VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation"
89351029|NCT04653272||Experimental|"Patients aged 16 to 40 years with ACL anterior cruciate ligament rupture, meniscal injury, patella instability or dislocation (Young Adult group),~Patients over 55 years of age with gonarthrosis (Senior adults group)."
89351030|NCT04653272||Control|"a group of young (16 to 40 years old)~senior (over 55 years old) adult controls~Everybody free of knee pathology."
89351031|NCT01155557|Active Comparator|Specific Strength Training|10 weeks of specific strength training of neck and shoulder muscles using elastic resistance.
89351032|NCT01155557|Active Comparator|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
89351033|NCT03885869||Type 2 Diabetics|Type 2 diabetic individuals aged 30-65 years
89351034|NCT03886883|Experimental|Exercise-induced hypoalgesia (EIH)|Exercise-induced hypoalgesia - isometric muscle contractions of the hand flexors
89351035|NCT03886883|Active Comparator|Static stretch (SS)|A static stretch of the knee flexors
89351036|NCT03886883|Sham Comparator|Rest|No intervention
89351037|NCT03886883|Experimental|Conditioning painful stimulus (CPM)|Conditioned pain modulation - cold pressure test
89351038|NCT03885791|Experimental|Vaginal cryotherapy - intervention|"The intervention group will be provided with one vaginal cryotherapy tube, filled with a mixture of isopropyl alcohol (2ml) and water (8ml) that has been kept in the freezer. This mixture results in a slushy consistency and prevents the solution from freezing solid thus decreases the risk of discomfort or injury due to the temperature of the tube. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home freezer."
89351039|NCT03885791|Placebo Comparator|Vaginal cryotherapy - control|The control group will be provided with an identical tube that is empty. An empty tube was chosen as the control because a tube with room-temperature liquid may still be perceived as cold. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home at room temperature.
89351040|NCT01252589||Adults with CML|Adult patients (18 years of age or older) with confirmed diagnosis of CML
89351041|NCT01261481|Experimental|Tolvaptan Intact Tablet Orally|
89351042|NCT01261481|Experimental|Tolvaptan via Nasogastric Tube|
89351043|NCT01261637|Experimental|0.25% Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
89351044|NCT01261637|Placebo Comparator|Placebo|20ml saline
89351045|NCT03910049||Study group|The group will include all adult patients that will sign ICF and will be operated for total thyroidectomy regardless of the undelying disease
89351046|NCT03885635|Active Comparator|Hemiarch repair|Standard hemiarch repair with open distal anastomosis in the proximal arch without replacement of the head vessels.
89351047|NCT03885635|Active Comparator|Extended arch repair|Ascending aortic and arch replacement with or without head vessel re-implantation and single TEVAR device placement within 1 week.
89351048|NCT01262183|Experimental|Concurrent chemoradiation therapy with panitumumab|
89351049|NCT01262183|Active Comparator|Concurrent chemoradiation therapy without panitumumab|
89351050|NCT03885479||IBD patients|"Full history taking and examination~Colonoscopy, biopsy and histopathology to determine the extent of the lesion~An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)~Patients will be categorized into 3 groups (UC patients, Crohn disease patients and controls)~All of the following factors will be taken into consideration; type and duration of the treatment, age of diagnosis, BMI, smoking status and activity of the disease at the time of the study"
89351051|NCT03885479||Controls|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
89351052|NCT03885557|Experimental|Group I Experimental Dynamic oscillatory stretch(DOS)|Dynamic oscillatory stretch technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group.
89351053|NCT03885557|Active Comparator|Group II Static Stretching(SS) Group|Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group.
89351054|NCT03886805|Experimental|Dual task with variable- and fixed-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks. From the 1st to 12th week the participants were trained under variable-priority instructions (half the session was focused on balance motor task and half the session focused on cognitive task performance). From the 13th to 24th week) the participants performed dual tasks under fixed-priority instructions (simultaneous focus attention on balance and cognitive tasks). The motor tasks were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks will include activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, working memory, among other cognitive tasks.
89351055|NCT03886805|Active Comparator|Dual-task with variable-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks (48 sessions). From the 1st to 24th week, the participants were trained under variable-priority instructions, in which they were asked to spend half the session focused on balance (motor task) and half the session focused on cognitive task performance. The motor tasks (gait and postural balance) of this protocol were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks included activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, rescue working memory, among other cognitive tasks.
89351056|NCT01154855||Periodontitis|"Patients with severe periodontal disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning~1 per patient at 2nd visit lasting approximately 1 hour."
89351057|NCT01154855||Healthy patients|"Patients without periodontal (gum) disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning"
89351058|NCT03884933|Experimental|Mobile team community mental health services|
89351059|NCT03884933|No Intervention|Current clinical services|
89351060|NCT03885323|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with RF-utilizing powered toothbrush
89351061|NCT03885323|Placebo Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
89351062|NCT01261871||Robotic laparoscopic prostatectomy|Patients who are undergoing primary surgical treatment for a diagnosis of prostate operatively will be enrolled. IOP will be measured throughout the case to assess for change. The various techniques employed for a radical prostatectomy will be compared. Patients undergoing RRP (open surgery) will act as controls. Those undergoing LRP (minimally invasive surgery) will be compared with the control group to assess for differences in IOP that may result from the different approaches. three arms will be used for the comparison: open, laparoscopic intraperitoneal approach), and laparoscopic (extraperitoneal approach).
89351063|NCT01154933|Experimental|exenatide 5 mcg|exenatide 5 mcg
89351064|NCT01154933|Experimental|exenatide 10 mcg|exenatide 10 mcg
89351065|NCT01154933|Placebo Comparator|placebo|placebo
89351066|NCT01155635|Active Comparator|Beta-blocker|Use of Carvedilol with any dose
89351067|NCT01155635|Active Comparator|Non Beta-blocker|No use of Carvedilol
89351068|NCT03886727|Active Comparator|Rubber Dam|Isolation of single tooth using rubber dam
89351069|NCT03886727|Active Comparator|Cotton Roll|Isolation of quadrant using cotton rolls
89351070|NCT01261949|Experimental|Combined frontal and temporal rTMS|Combined low frequency frontal and temporal transcranial magnetic stimulation of auditory cortex and right DLPFC
89351071|NCT01261949|Experimental|Temporal low frequency rTMS|temporal low frequency rTMS of auditory cortex
89351072|NCT01155245||Forteo (teriparatide)|postmenopausal women with osteoporosis
89351073|NCT01155245||Forteo (teriparatide) with AFF|Women with atypical femur fractures
89351074|NCT03884699|Other|Segmental maxillary lefort I re-positioning|Accuracy of the planned virtually re-positioned segmental Lefort I maxilla using a specifically designed patient implant, comparing the virtual plan to the actual postoperative position.
89351075|NCT01155713|Experimental|Arm 1 - TKI258 - bioavailability|
89351076|NCT01155713|Experimental|TKI258 - food effect|
89351077|NCT01157039|Experimental|Dietary Supplement|Arm A: At cycle 2, patients will be randomized to receive for 6 days- Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3
89351078|NCT01157039|Experimental|Dietary supplement|Arm B: At cycle 2, patients will be randomized to receive for 6 days: Glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3.
89351079|NCT03881735|Experimental|Cohort A (enasidenib, hematopoietic cell transplantation)|Patients receive enasidenib PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo a HCT 7-14 days after treatment. Within 30-100 days following the transplant, patients receive enasidenib QD. Treatment repeats every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity.
89351080|NCT03881735|Active Comparator|Cohort B (enasidenib)|Patients receive enasidenib PO QD. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
89351081|NCT01262417|Experimental|- Seprafilm group|patients receiving resorbable barrier membrane during the first surgery
89351082|NCT01262417|Other|- No-treatment control group|patients without seprafilm barrier during the first surgery
89351083|NCT01157195|Active Comparator|CI therapy|
89351084|NCT01157195|Experimental|Tele-AutoCITE|AutoCITE stands for Automated Constraint Induced Therapy Extender.
89351085|NCT01157273||High Anxiety (HA) group|13 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores above 41 in STAI-Trait
89351086|NCT01157273||Low Anxiety (LA) group|11 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores below 41 in STAI-Trait
89351087|NCT03884621|Experimental|EHP Group|The Enhanced post-discharge home-based care program (EHP) offers one coaching session upon hospital discharge and 12-week home follow-up (including 6 home visits, 6 telephone calls and 24-hour hotline) post hospital discharge to participants by an especially trained nurse case manager with the support of a clinical team. The five intervention protocols integrate with an individualized home-based rehabilitation training and self-care plan.
89351088|NCT03884621|No Intervention|Control Group|Usual discharge care and post-discharge care provided to all stroke patients discharged home.
89351089|NCT01155791|Experimental|combination sodium selenite and docetaxel|
89351090|NCT01263743|Experimental|This is a single arm study|Relaxation Response training will be given to all participants
89351091|NCT03881657|Experimental|Intervention Group|The intervention group received a reverse colocated integrated behavioral health intervention or usual care
89351092|NCT03881657|Active Comparator|Control Group|The control group received behavioral health services only (usual care)
89351093|NCT03881813|Experimental|Fiber reinforced composite retainers|Fiber reinforced composite retainers were inserted in group 1 and were evaluated after every 3 months for a follow up period of 3 months.
89351094|NCT03881813|Experimental|Multistranded stainless steel retainers|Multistranded stainless steel retainers were inserted in group 2 and were evaluated after every 3 months for a follow up period of 3 months.
89351095|NCT01589783||Pregnant or newly post partum women|
89351096|NCT01589783||family practice physicians and obstetricians|
89351097|NCT03881969|Experimental|Financial incentive offered|Patient offered £100 incentive payment in initial trial invitation letter.
89351098|NCT03881969|Experimental|No incentive. Payment not offered|Patient sent standard trial invitation letter with no offer of incentive payment.
89351099|NCT01157507|Active Comparator|Botulinum A toxin|Botulinum A toxin intravesical injection.
89351100|NCT01157507|Sham Comparator|Bladder overdistension|Standard treatment: bladder overdistension
89351101|NCT01157507|Placebo Comparator|Placebo|
89351102|NCT03881267|Experimental|Human Autologous Homologous Skin Construct (SkinTE)|SkinTE, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a venous leg wound in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing and compression
89351103|NCT03881267|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on venous leg wounds in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing and compression
89351104|NCT01263821|Experimental|Arm I|Patients undergo magnetic resonance spectroscopic imaging, functional magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks.
89351105|NCT01262495|Other|orchidectomy|as specified in the summary
88811813|NCT02209259|Experimental|Intervention Group 2|The second intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing a positively-adjusted version of the PCS.
89351106|NCT01263899|Experimental|SB1518|
89351107|NCT03881423|Active Comparator|Deep block|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
89351108|NCT03881423|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
89351109|NCT03884465|Experimental|Inhaled dry powder treprostinil (LIQ861)|Full study population receives inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg or 100μg capsule strengths.
89351110|NCT01263977|Experimental|Thermodilution controlled volume management|Volume management based on parameters: GEDI, ELWI, CI
89351111|NCT01263977|Active Comparator|Volume management based on surviving sepsis campaign|volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2
89351112|NCT01155947|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
89351113|NCT01155947|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
89351114|NCT03881189|Experimental|SUNEKOS ® 200|"The 1st intradermal treatment (T1i) with Sunekos ® 200 was carried out during the basal visit (T0), after basal evaluations planned by the study procedure, and then repeated 2 more times with an interval of 15 days (T2i and T3i)"
89351115|NCT03884309|Experimental|Experimental Hydrolyzed Protein Infant Formula|hydrolyzed protein infant formula powder in cans
89351116|NCT01157585|Other|drug|
89351117|NCT02527577|Experimental|ropivacaïne chlorhydrate monohydrate|
89351118|NCT02527577|Placebo Comparator|placebo|
89351119|NCT03883841||Study group|patients with iron deficiency anemia
89351120|NCT03883841||control group|normal pregnant patients
89351121|NCT03881111|Experimental|Pembrolizumab + Cisplatin + 5-FU|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
89351122|NCT03881111|Placebo Comparator|Placebo + Cisplatin + 5-FU|Participants receive placebo to pembrolizumab (saline) IV Q3W, cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
89351123|NCT01157663|Experimental|Adapted Balance Training group|
89351124|NCT01157663|Active Comparator|Standard Balance training group|Balance training with unipedal standing during 8 weeks
89351125|NCT03884387|Experimental|Use of a Patient Decision Aid|A Patient Decision Aid is used in this arm in the clinical encounter. A tool designed to facilitate shared decision making when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
89351126|NCT03884387|No Intervention|Usual counceling|Usual counseling in the clinical encounter, when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
89351127|NCT03883997||Participants|Professional male soccer players from the second professional Mexican division.
89351128|NCT01264211|Experimental|Diacerein|
89351129|NCT01264211|Placebo Comparator|Placebo|
89351130|NCT03881033|Placebo Comparator|P12|
89351131|NCT03881033|Active Comparator|P7+5|
89351132|NCT03880877|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followed by Leucovorin (400 mg/m2 IV infusion over 2 hours), and fluorouracil (5-FU) (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).~Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle."
89351133|NCT03880877|Active Comparator|Regorafenib|Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle.
89351134|NCT01157741|No Intervention|Standard Practice (H-C)|1) Hospital control group (Group H-C): children assigned to this group received the standard hospital-based, outpatient treatment package, which consisted of fortnightly follow-up for growth monitoring, health and nutrition education, and micronutrient supplementation.
89351135|NCT01157741|Experimental|C-C|Community-based follow-up (Group C-C): the standard community-based follow-up package was identical to the one provided to the hospital-based control group, except that the follow-up visits took place at the nearest CNFU rather than the HNFU.
89351136|NCT01157741|Experimental|C-SF|Community-based follow-up plus supplementary food (Group C-SF): children assigned to this group received the same treatment package as those in Group C-C, except that supplementary food (SF) packets and preparation instructions were also provided at the time of each follow-up clinic visit for consumption at home in addition to the children's usual meals.
89351137|NCT01157741|Experimental|C-PS|Community-based follow-up plus psychosocial stimulation (Group C-PS): children assigned to this group received the same treatment package as those in Group C-C, except that they were also provided with psychosocial stimulation (PS).
89351138|NCT01157741|Experimental|C-SF+PS|Community-based follow-up plus SF and PS (Group C-SF+PS): children assigned to this group received the same treatment package as those in the Group C-C, except that they were also provided with both SF and PS, as described above.
89351139|NCT05666999|Other|FibDex|IMD
89351140|NCT05666999|Active Comparator|Suprathel|Primary Comparator.
89351141|NCT05666999|Active Comparator|Aquacel Foam|Secondary Comparator.
89351142|NCT03880799|Experimental|Mindfulness Intervention|Newly diagnosed breast cancer patients who undergo a mindfulness session before their surgical appointment.
89351143|NCT01262729|Experimental|Xenon-Arm|Patients in Xenon-Arm will be inhalated with xenon within 2 hours additionally to therapeutical hypothermia after successful cardiopulmonary resuscitation.
89351144|NCT01262729|Active Comparator|MTH|Patients after successful cardiopulmonary resuscitation will be treated only with therapeutical hypothermia
89351145|NCT01156025|Experimental|GV550|(Ganciclovir 1.5 mg/g ophtalmic gel)
89351146|NCT01156025|Placebo Comparator|Placebo|Placebo ophtalmic gel
89351147|NCT03880721||Good prognosis|
89351148|NCT03880721||Poor prognosis|
89351149|NCT03880721||Recurrence|
89351150|NCT03880721||Not Recurrence|
89351151|NCT03880721||Survival|
89351152|NCT03880721||Death|
89351153|NCT01264289|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
89351154|NCT01264289|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
88807300|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL tablet+TNTL cream Group|Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day. Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
89351155|NCT03883451|Experimental|Helmet type|football player helmet model
89351156|NCT01156103|Experimental|SCORES|America SCORES, Bay Area, after-school program
89351157|NCT01156103|No Intervention|Usual care|Standard after-school programming
89351158|NCT03880487|Experimental|KP-1199|
89351159|NCT03880487|Placebo Comparator|Placebo oral capsules|
89351160|NCT03880487|Active Comparator|Oxycodone oral capsules|
89351161|NCT03880409|Active Comparator|2% lidocaine with 1:000,000 epinephrine|supplemental intraseptal injections using 0.8 mL 2% lidocaine with 1:000,000 epinephrine
89351162|NCT03880409|Active Comparator|4% articaine with 1:000,000 epinephrine|buccal infiltration of 1.8 ml 4% articaine with 1:000,000 epinephrine
89351163|NCT01262807|Experimental|Exercise|This group will receive instructions on specific exercises to perform after randomization.
89351164|NCT01262807|No Intervention|Standard Care|This group will receive standard care
89351165|NCT01157819|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
89351166|NCT01157819|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
89351167|NCT03883373||Cortical group|Group of patient who had an alveolar bone graft with cancellous bone and a cortical block
89351168|NCT03883373||Cancellous group|Group of patient who had an alveolar bone graft with cancellous bone only
89351169|NCT01264367|Experimental|1|Clevudine 30mg
89351170|NCT01264367|Active Comparator|2|Clevudine 30mg + peg-interferon 180mcg
89351171|NCT01262885|Experimental|Part A Cohort 1|GSK2251052 500 mg (6 subjects), Placebo (1 subject)
89351172|NCT01262885|Experimental|Part A Cohort 2|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
89351173|NCT01262885|Experimental|Part A Cohort 3|GSK2251052 2000 mg (6 subjects), Placebo (1 subject)
89351174|NCT01262885|Experimental|Part A Cohort 2 - fed|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
89351175|NCT01262885|Experimental|Part B Cohort 1|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
89351176|NCT01262885|Experimental|Part B Cohort 2|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
89351177|NCT01262885|Experimental|Part B Cohort 3|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
89351178|NCT01262885|Experimental|Part A Cohort 4|Placebo (1 subject), GSK2251052 (6 subjects) dose to be determined
89351179|NCT01262963|Experimental|Study Medication|GSK2118436 suspension
89351180|NCT01264445|Experimental|Group A|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
89351181|NCT01264445|Experimental|Group B|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
89351182|NCT01264445|Experimental|Group C|Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.
89351183|NCT01264445|Experimental|Group D|Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.
89351184|NCT01263041|Experimental|glutamine, PT, sepsis|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
89351185|NCT01263041|No Intervention|Control|after been allocated, will receive nothing and observed for the same outcomes
89351186|NCT01263041|Experimental|L-arginine,NEC, PT|enteral or via NG tube dose of 260 mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
89351187|NCT03883685|Experimental|experimental group|40 subjects will be randomly allocated to receive probiotics pills for consecutive 8 weeks.
89351188|NCT03883685|Placebo Comparator|Control group|40 subjects will be randomly allocated to receive placebo pills for consecutive 8 weeks.
89351189|NCT03883295|Experimental|Control|root canal treatment will be initiated
89351190|NCT03883295|Experimental|NeoMTA Plus|vital pulp treatment using neomta plus will be used.
89351191|NCT03880331|Active Comparator|Aggressive Debridement|Aggressive and frequent debridement of fibrin and crust from the wound base down to pinpoint bleeding, both by the patient as part of daily wound care at home, and also by the clinician (either physician or experienced dermatologic surgery nurse) during follow-up visits. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return weekly until healed. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
89351192|NCT03880331|Active Comparator|Minimal Debridement|No debridement of fibrin by the patient or the clinician. Exceptions include debridement of dried crust or eschar. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return every two weeks until healed. In between visits at weekly intervals, the patient will be contacted by phone to determine if healing has occurred in between clinic visits11. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
89351193|NCT01261715|Active Comparator|Woman with previous ceasarean section - staples|
89351194|NCT01156181|Experimental|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
89351195|NCT01156181|Active Comparator|Control|Embryo transfer without any intervention
89351196|NCT03880253|Experimental|CTP-692 Low Dose or Matching Placebo|Once daily dosing
89351197|NCT03880253|Experimental|CTP-692 Mid Dose or Matching Placebo|Once daily dosing
89351198|NCT03880253|Experimental|CTP-692 High Dose or Matching Placebo|Once daily dosing
89351199|NCT03880097||Research Biopsy|"The research biopsy is the same procedure as a standard of care percutaneous biopsy. A core (hollow) needle is inserted into the tumour tissue in order to collect tissue samples. The procedure is called a research biopsy as it is an additional procedure to the standard of care, used purely to collect tissue samples for research purposes."
89351200|NCT01157975|Experimental|Pioglitazone|
89351201|NCT01157975|Experimental|Prednisone|
89351202|NCT03060512|Active Comparator|Crossover Group 1|"Crossover Group Movantik to Polyethylene Glycol 3350~2-period, 2-treatment cross-over model: Subjects will be randomized to Movantik during Treatment period 1 (2 weeks), then crossed over to receive Polyethylene Glycol 3350 for Treatment period 2 (2 weeks) after 1 week washout."
89351203|NCT03060512|Active Comparator|Crossover Group 2|"Crossover group Polyethylene Glycol 3350 to Movantik~2-period, 2-treatment cross-over model: Subjects will be randomized to Polyethylene Glycol 3350 during Treatment period 1 (2 weeks), then crossed over to receive Movantik for Treatment period 2 (2 weeks) after 1 week washout."
89351204|NCT01263275|Experimental|Active tDCS|
89351205|NCT01263353|Experimental|Functional tumors, pre-treated|
89351206|NCT01263353|Experimental|Functional tumors, treatment naïve|
89351207|NCT01263353|Experimental|Nonfunctional tumors, pretreated 1|
89351208|NCT01263353|Experimental|Nonfunctional tumors, pretreated 2|
89351209|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 1|
89351210|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 2|
89351211|NCT01156259|Experimental|30 Gy|
89351212|NCT01156259|Active Comparator|40 Gy|
89351213|NCT01158131|Experimental|Lifestyle Intervention group|Participants in this group will take part in the lifestyle intervention.
89351214|NCT01158131|No Intervention|Post-gestational diabetes mellitus (GDM) Follow-up Group|Participants in this group will not take part in the intervention.
89351215|NCT02622542|Active Comparator|BMT Alone|Patients in this group will be managed with the best medical therapy (BMT) alone
89351216|NCT02622542|Experimental|BMT+TEVAR|Patients in this group will be managed with thoracic endovascular aortic repair (TEVAR) in addition to the best medical therapy (BMT)
89351217|NCT01158209||Assessed cohort|Subjects attending out-patient health services for gynaecological examination.
89351218|NCT03882983|Experimental|Antria Cell Preparation Process|Safety will be evaluated by collection of vital signs, EKG, patient surveys, and assessments
89351219|NCT03883061||mortality of sepsis|the study sample would be extracted from electronic health records in emergence departments. risk factor analysis and mathematical modeling would be performed to evaluate the significant and independent risk factors and predictive models.
89351220|NCT03882593||Analysis of arterial filters during CPB|This is a clinical and observational study to investigate of blood cells addesion to surfaces of arterial filters during CPB and the impact in coagulations laboratory exams
89351221|NCT01158287|Experimental|Sorafenib 400mg bd, p.o, continuously|
89351222|NCT01156337||low sodium diet 80 mmol/day|
89351223|NCT01156337||moderate sodium intake 120 mmol/day|
89351224|NCT01158365|Experimental|Dermacyd (different fragrances)|Day 1 until 30: Investigational Product (Dermacyd) Day 31 until 37: wash-out Day 38 until 67: Glycerine Vegetal Soap Granado Traditional
89351225|NCT01158365|Active Comparator|Glycerine Vegetal Soap Granado Traditional|Day 1 until 30: Glycerine Vegetal Soap Granado Traditional Day 31 until 37: wash-out Day 38 until 67: Investigational Product (Dermacyd)
89351226|NCT01158443|Experimental|Behavioral activation therapy|The Behavioral Activation Program for Energy and Productivity (BA-PEP) is a manualized, 8-session intervention, scheduled to coincide with maintenance armodafinil treatment. It is a structured counseling program with homework, short-term activities and goals, and includes problem-solving, identification of barriers and strategies for their resolution, with an ongoing focus on achieving employment or training.
89351227|NCT01158443|Placebo Comparator|supportive counseling (SC)|Supportive counseling is designed to create an empathic, accepting environment, to direct attention to the patient's feelings and to facilitate acceptance of affective experience using supportive statements, reflective listening and empathic communications.
89351228|NCT03882515|Experimental|Experimental group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after myofascial release
89351229|NCT03882515|Sham Comparator|Sham group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after continuous surface slip technique
89351230|NCT03882515|Active Comparator|Control group|Evaluation and reassessment of asymptomatic individuals
89351231|NCT01156493|Experimental|Protein Hydrolyzed Formula|Infants assigned to this group will receive HP formula when breast milk not available or indicated to receive formula by the attending physician
89351232|NCT01156493|No Intervention|Control|Infants in this group will receive standard prematrue formula when no breast milk available or indicated by the attending physician
89351233|NCT01264757|Active Comparator|Education|Educational brochure about physical activity provided.
89351234|NCT01264757|Experimental|Pedometer|A pedometer was provided in addition to educational materials.
89351235|NCT01263431|Active Comparator|Hemorrhoidectomy|Excision of hemorrhoid cushions
89351236|NCT01263431|Experimental|Hemorrhoidal dearterialization|Ligation of therminbal branches oh hemorrhoid arteries
89351237|NCT05064683|Experimental|white noise|The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
89351238|NCT05064683|Experimental|facilitated tucking|The newborns in the facilitated tucking were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.
89351239|NCT05064683|No Intervention|control|Newborns in the control group did not receive any treatment other than routine applications while receiving Nasal CPAP support in the neonatal intensive care unit.
89351240|NCT03880175|Experimental|FCC DEB and Anti-stigma|
89351241|NCT03880175|Experimental|FCC DEB and HIV info|
89351242|NCT03880175|Experimental|FCC DEB and ART info|
89351243|NCT03880175|Experimental|FCC DEB and HIV-ART info|
89351244|NCT03880175|Experimental|FCC DEB and high coupon value|
89351245|NCT03880175|Experimental|FCC DEB and no info|
89351246|NCT03880175|Experimental|FCC non-DEB and Anti-stigma|
89351247|NCT03880175|Experimental|FCC non-DEB and HIV info|
89351248|NCT03880175|Experimental|FCC non-DEB and ART info|
89351249|NCT03880175|Experimental|FCC non-DEB and HIV-ART info|
89351250|NCT03880175|Experimental|FCC non-DEB and high coupon value|
89351251|NCT03880175|Experimental|FCC non-DEB and no info|
89351252|NCT03880175|Experimental|FCC control and Anti-stigma|
89351253|NCT03880175|Experimental|FCC control and HIV info|
89351254|NCT03880175|Experimental|FCC control and ART info|
89351255|NCT03880175|Experimental|FCC control and HIV-ART info|
89351256|NCT03880175|Experimental|FCC control and High coupon value|
89351257|NCT03880175|No Intervention|FCC control and no info|
89351258|NCT01264913||Shift Workers|
89351259|NCT01264913||Day Workers|
89351260|NCT01264991|Experimental|APM group|
89351261|NCT01264991|Placebo Comparator|Sham group|
89351262|NCT01158599|Other|IXIARO 0,5 ml|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
89351263|NCT01156649|Sham Comparator|Sham PAP therapy|Sham PAP will be used with 30 children, and consists of continuous sub-therapeutic levels of air pressure (approximately 1 cm of water) that are delivered through the nasal interface device.
89351264|NCT01156649|Active Comparator|Treatment group|30 children will receive active treatment PAP, which consists of automatically adjusted air pressures that are delivered through the nasal interface device at levels which effectively treats the obstructive events.
89351265|NCT01158755|Active Comparator|Standard dose rifampisin|"Subjects in this arm receive 450 mg rifampicin orally.~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
89351266|NCT01158755|Experimental|High dose rifampisin|"Subjects in this arm receive 600 mg Rifampisin i.v. for 14 days, and the dosage will be switched to 450 mg Rifampisin p.o afterwards until completion of TB medication (in accordance with National TB Program)~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
89351267|NCT01156727||SURVEY: 6 months post-deployment|Michigan Army National Guard soldiers 6 months post deployment between August 2011 and December 2013
89351268|NCT01156727||SURVEY: 12 months post-deployment|Michigan Army National Guard soldiers 12 months post deployment between August 2011 and December 2013.
89351269|NCT01156727||INTERVIEWS|Michigan Army National Guard soldiers 12-24 months post deployment between October 2011-April 2014. Also key stakeholders from the B2B program.
89351270|NCT01158833||spastic diplegia due to Cerebral Palsy|
89351271|NCT03879785|Active Comparator|Self-Administration followed by Interviewer-Administered|
89351272|NCT03879785|Active Comparator|Interviewer-Administered followed by Self-Administration|
89351273|NCT03879707|Experimental|Experimental|Melatonin and magnesium for 14 days
89351274|NCT03879707|Placebo Comparator|Control|Placebo for 14 days
89351275|NCT01265069|Active Comparator|high dose dual therapy|Group A - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
89351276|NCT01265069|Experimental|concomitant therapy|Group B - concomitant therapy (rabeprazole 20 mg, amoxicillin 1000 mg, metronidazole 500 mg, clarithromycin 500 mg, bid for 10 days).
89351277|NCT01158911||non-diabetic Chronic Kidney disease|
89351278|NCT01158989||Critically ill|Critically ill subjects were intubated, mechanically ventilated and sedated
89351279|NCT01158989||Ambulatory Group|Subjects were scheduled for an outpatient procedure but were otherwise healthy
89351280|NCT01265147|Active Comparator|Cisplatin|cisplatin combine with IMRT
89351281|NCT01265147|Experimental|Nedaplatin|Nedaplatin combine with IMRT
89351282|NCT03882281|Experimental|A group|Subjects in the group A will be given HQP1351 after fasting meal on Day 1. Then after a seven-day of cleaning time, subjects in the group A will be given HQP1351 after 30 minutes of high-fat meal on Day 8.
89351283|NCT03882281|Experimental|B group|Subjects in the group B will be given HQP1351 after 30 minutes of high-fat meal on Day 1. Then after a seven-day of cleaning time, subjects in the group B will be given HQP1351 after fasting meal on Day 8.
89351284|NCT01159145|Experimental|D961H 10 mg capsule|2 way crossover
89351285|NCT01159145|Experimental|Omeprazole 10 mg tablet|2 way crossover
89351286|NCT03882125|Experimental|Mindfulness|Assigned to a 6-week mindfulness-based relapse prevention course
89351287|NCT01156961|Experimental|Single Arm|
89351288|NCT01265303|Other|Catheter ablation|
89351289|NCT01265303|Other|Pacemaker implantation|
89351290|NCT01265303|Other|Pharmacotherapy|
89351291|NCT01265381||Cohort of Chernobyl Cleanup Workers in Ukraine|Thyroid cancer cases and matched controls in the cohort
89351292|NCT01159457|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Sci-B-Vac vaccination series
89351293|NCT01159457|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Engerix 3-dose vaccination series
89351294|NCT01159223|Experimental|1|ATV/r 200 mg/100 mg OD
89351295|NCT01159223|Experimental|2|ATV/r 300 mg/100 mg OD
89351296|NCT01159301|Experimental|Treatment (entinostat, sorafenib tosylate)|Patients receive oral entinostat once daily on days 1 and 15 and oral sorafenib tosylate twice daily on days 1-28 (days 15-28 only of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89351297|NCT03610334|Experimental|SAD IFB-088 2.5mg|Cohort 1: A single daily dose of 2.5mg IFB-088 in oral capsule, is administered with 250 ml of water at room temperature, in the morning around 8:00am, in one intake
89351298|NCT03610334|Placebo Comparator|SAD Placebo 2.5mg|Cohort 1: A single daily dose of 2.5mg placebo in oral capsule, is administered with 250 ml of water at room temperature, in the morning around 8:00am, in one intake
89351299|NCT03610334|Experimental|SAD IFB-088 5.0mg|Cohort 2: A single daily dose of 5.0mg IFB-088 in oral capsule, divided in two doses of 2.5mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351300|NCT03610334|Placebo Comparator|SAD Placebo 5.0mg|Cohort 2: A single daily dose of 5.0mg placebo in oral capsule, divided in two doses of 2.5mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351301|NCT03610334|Experimental|SAD IFB-088 10.0mg|Cohort 3: A single daily dose of 10.0mg IFB-088 in oral capsule, divided in two doses of 5.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351302|NCT03610334|Placebo Comparator|SAD Placebo 10.0mg|Cohort 3: A single daily dose of 10.0mg Placebo in oral capsule, divided in two doses of 5.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351303|NCT03610334|Experimental|SAD IFB-088 20.0mg|Cohort 4: A single daily dose of 20.0mg IFB-088 in oral capsule, divided in two doses of 10.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351304|NCT03610334|Placebo Comparator|SAD Placebo 20.0mg|Cohort 4: A single daily dose of 20.0mg Placebo in oral capsule, divided in two doses of 10.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351305|NCT03610334|Experimental|SAD IFB-088 40.0mg|Cohort 5: A single daily dose of 40.0mg IFB-088 in oral capsule, divided in two doses of 20.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
88807301|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL tablet Group|Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day.
89351306|NCT03610334|Placebo Comparator|SAD Placebo 40.0mg|Cohort 5: A single daily dose of 40.0mg Placebo in oral capsule, divided in two doses of 20.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351307|NCT03610334|Experimental|SAD IFB-088 60.0mg|Cohort 6: A single daily dose of 60.0mg IFB-088 in oral capsule, divided in two doses of 30.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351308|NCT03610334|Experimental|SAD Placebo 60.0mg|Cohort 6: A single daily dose of 60.0mg Placebo in oral capsule, divided in two doses of 30.0mg are administered with 250 ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, and in the evening around 8:00pm
89351309|NCT03610334|Experimental|MAD IFB-088 15 mg|Cohort 7: subject taking 15.0mg of IFB-088 in oral capsule divided into 2 doses of 7.5mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
89351310|NCT03610334|Placebo Comparator|MAD Placebo 15 mg|Cohort 7: subject taking 15.0mg of placebo in oral capsule divided into 2 doses of 7.5mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
89351311|NCT03610334|Experimental|MAD IFB-088 30 mg|Cohort 8: subject taking 30.0mg of IFB-088 in oral capsule divided into 2 doses of 15.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
89351312|NCT03610334|Placebo Comparator|MAD Placebo 30 mg|Cohort 8: subject taking 30.0mg of Placebo in oral capsule divided into 2 doses of 15.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
89351313|NCT03610334|Experimental|MAD IFB-088 50 mg|Cohort 9: subject taking 50.0mg of IFB-088 in oral capsule divided into 2 doses of 25.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
89351314|NCT03610334|Placebo Comparator|MAD Placebo 50 mg|Cohort 9: subject taking 50.0mg of Placebo in oral capsule divided into 2 doses of 25.0mg administered with 250ml of water at room temperature, seperated by an interval of 12h, in the morning around 8:00am, an in the evening around 8:00pm, for 14 days.
89351315|NCT01265771|Experimental|Telemetry ordered by a Cardiologist|
89351316|NCT01265771|Experimental|24 hours standard Holter monitoring|
89351317|NCT01265771|Experimental|Telemetry ordered by a Pediatrician|
89351318|NCT01159613||Non Responders|Non Responders
89351319|NCT01159613||RESPONDERS|
89351320|NCT01159379|Experimental|ertapenem, tolerance tests|Patients with IgE-mediated allergy to beta-lactams
89351321|NCT01159847|Experimental|Sitagliptin|Patients will receive insulin therapy with sitagliptin.
89351322|NCT01159847|Active Comparator|Insulin|Patients will receive insulin therapy without sitagliptin.
89351323|NCT02539160|Active Comparator|CKD - Ticagrelor 90|Patients with chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
89351324|NCT02539160|Experimental|CKD - Ticagrelor 60|Patients with chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
89351325|NCT02539160|Active Comparator|Non-CKD - Ticagrelor 90|Patients without chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
89351326|NCT02539160|Experimental|Non-CKD - Ticagrelor 60|Patients without chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
89351327|NCT04988906|No Intervention|Before Arm|The before arm of the study prehospital providers will provide resuscitation as per standard practice. The providers will utilize the Zoll Accuvent device without activation of the real-time dashboard. This will allow us to collect baseline ventilation data.
89351328|NCT04988906|Active Comparator|After Arm|The after arm of the study the prehospital providers will provide resuscitation as per standard practice. The real-time ventilation dashboard will be activated and the providers will use real-time feedback to monitor ventilation quality during the resuscitation.
89351329|NCT01267799||photocopier exposure|
89351330|NCT01267799||control|
89351331|NCT01265927|Experimental|GRN163L + Trastuzumab|
89351332|NCT01266005|Experimental|1|Clevudine 30mg
89351333|NCT01266005|Active Comparator|2|Entecavir 0.5mg
89351334|NCT04292899|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
89351335|NCT04292899|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
89351336|NCT04292899|Experimental|Part B: Remdesivir, 10 Days (Extension)|Part B (Extension) will enroll participants after enrollment to Part A is complete. Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10.
89351337|NCT04292899|Experimental|Part B: Remdesivir 10 days (Mechanically Ventilated)|Participants on mechanical ventilation will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10
89351338|NCT02530112||Phase 1|First round of survey respondents.
89351339|NCT02530112||Phase 2|Second round of survey respondents.
89351340|NCT02530112||Phase 3|Third round of survey respondents.
89351341|NCT03876899|Active Comparator|Evening Primrose Oil|
89351342|NCT03876899|Placebo Comparator|Placebo|
89351343|NCT03241173|Experimental|Phase 1, Dose Escalation: INCAGN01949 + Nivolumab|INCAGN01949 (70, 200, 350, or 700 milligrams [mg]) combined with nivolumab 240 mg in participants with advanced or metastatic select solid tumors
89351344|NCT03241173|Experimental|Phase 1, Dose Escalation: INCAGN01949 + Ipilimumab|INCAGN01949 (70, 200, 350, or 700 mg) combined with ipilimumab 1 mg/kilogram (kg) in participants with advanced or metastatic select solid tumors
89351345|NCT03241173|Experimental|Phase 1, Dose Escalation: INCAGN01949 + Nivolumab + Ipilimumab|INCAGN01949 combined with nivolumab 3 mg/kg and ipilimumab 1 mg/kg in participants with advanced or metastatic select solid tumors
89351346|NCT03241173|Experimental|Phase 1, Safety Expansion: INCAGN01949 + Nivolumab|Run-in with INCAGN01949 (70, 200, or 350 mg) x 2 doses, followed by INCAGN01949 (70, 200, or 350 mg) combined with nivolumab 240 mg in participants with advanced or metastatic select solid tumors
89351347|NCT03241173|Experimental|Phase 1, Safety Expansion: INCAGN01949 + Nivolumab + Ipilimumab|Run-in with INCAGN01949 x 2 doses, followed by INCAGN01949 combined with nivolumab 3 mg/kg and ipilimumab 1 mg/kg in participants with advanced or metastatic select solid tumors
89351348|NCT03241173|Experimental|Phase 2, Part A: INCAGN01949 + nivolumab|INCAGN01949 combined with nivolumab in programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) refractory participants with gastric cancer, squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), or renal cell carcinoma (RCC)
89351349|NCT03241173|Experimental|Phase 2, Part B: INCAGN01949; INCAGN01949 + nivolumab; INCAGN01949 + nivolumab + ipilimumab|INCAGN01949 alone, combined with nivolumab, and combined with nivolumab and ipilimumab in PD-1/L1 refractory participants with advanced or metastatic gastric cancer, SCCHN, NSCLC, or RCC
89351350|NCT01159925||Possible hepatitis A Cohort|Children with an acute disease characterized by discrete onset of symptoms and jaundice
89351351|NCT01159925||Probable hepatitis A Cohort|Children with an increase in serum levels of transaminase 2.5 times higher than the maximum limit of the normal interval
89351352|NCT01159925||Confirmed hepatitis A Cohort|Children presenting a positive result for Immunoglobulin M for hepatitis A virus
89351353|NCT01267877|Active Comparator|Guideline unfavorable article|
89351354|NCT01267877|Active Comparator|Guideline favorable article|
89351355|NCT01161719|Experimental|Videoconference|Parent training through videoconference
89351356|NCT01161719|Active Comparator|Control|Parent training through face to face conference
89351357|NCT01266083|Experimental|WT1 peptide vaccine|This is a Phase II study evaluating the safety and efficacy of the WT1 peptide vaccine in patients who are in CR from Acute Myeloid Leukemia (AML).
89351358|NCT05571501|Active Comparator|Typically developing children|"500 children aged 1-18 male and female will be recruited from local schools, after school clubs and playgroups.~Each child will complete a screening form following appropriate information and consent process. Each child will then complete the walking assessment which takes 15 minutes in total"
89351359|NCT05571501|Active Comparator|Clinical groups|"Children will be recruited through their patient journey. Families who consent to participation will complete the screening form and the GAITRite walking assessment as part of their pre-planned clinical followup in outpatient clinics.~One group of children will be assessed at one time point, whilst a second group of children with progressive orthopaedic conditions or treatment will be assessed at intervals to give longitudinal data"
89351360|NCT01266239|Active Comparator|SES-KB|Sirolimus-eluting stent (SES) is deployed in the main vessel (MV)and subsequent kissing balloon inflation is performed in the bifurcation.
89351361|NCT01266239|Active Comparator|SES-NK|SES is deployed in the MV without kissing balloon inflation.
89351362|NCT01266239|Active Comparator|EES-KB|Everolimus-eluting stent (EES) is deployed in the MV and subsequent kissing balloon inflation is performed in the bifurcation.
89351363|NCT01266239|Active Comparator|EES-NK|EES is deployed in the MV without kissing balloon inflation.
89351364|NCT01562353||Case|Subject has a diagnosis of current prescription opioid dependence (confirmed by the MINI). Subject had no history of dependence on alcohol or illicit or prescription drugs, including opioids, prior to prescription opioid exposure for the treatment of chronic pain.
89351365|NCT01562353||Control|Subject's prescribing physician has reported absence of significant problematic behavior with respect to prescription opioids or other substances while under the physician's care. Subject has a negative urine drug screen for alcohol, illicit drugs, and nonprescribed controlled substances at screening. Subject has no current or past substance abuse or dependence (confirmed by the MINI and medical history).
89351366|NCT01562431|Other|Control|Participants complete the Signal-checklist BUT counselors do not obtain the results of the checklist
89351367|NCT01562431|Other|Intervention|Participants complete the Signal-checklist AND the counselor will get the results of the questionnaire
89351368|NCT03264066|Experimental|Cohort 1 - SCCHN - Treatment Naive|In participants with recurrent or advanced / metastatic SSCHN who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
89351369|NCT03264066|Experimental|Cohort 2 - UC - Treatment Naive|In participants with advanced / metastatic UC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
89351370|NCT03264066|Experimental|Cohort 3 - RCC - Treatment Naive|In participants with metastatic RCC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 milligrams (mg) once daily (QD) for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
89351371|NCT03264066|Experimental|Cohort 4 - SCCHN - Previous Treatment Exposure|In participants with SCCHN whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
89351372|NCT03264066|Experimental|Cohort 5 - UC - Previous Treatment Exposure|In participants with UC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
89351373|NCT03264066|Experimental|Cohort 6 - RCC - Previous Treatment Exposure|In participants with RCC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
89351374|NCT03264066|Experimental|Cohort 7 - Biopsy Cohort|In participants with solid non-melanoma, non- hematologic tumors who previously developed primary or secondary resistance to an anti-PD-1 or anti-PD-L1 agent, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle. The first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1. Thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
89351375|NCT03759041|Placebo Comparator|Placebo (after placebo pre-treatment)|Once-daily dosing of Placebo (after placebo pre-treatment)
89351376|NCT03759041|Experimental|SER-287 Induction Dosing (after vancomycin pre-treatment)|Once-daily dosing of SER-287 (Induction Dose, after vancomycin pre-treatment)
89351377|NCT03759041|Experimental|SER-287 Step-Down Induction Dosing (after vancomycin pre-treatment)|Once-daily dosing of SER-287 (Step-Down Induction Dose, after vancomycin pre-treatment)
89351378|NCT04110145|Experimental|Cohort 1 (Linaclotide 18 μg)|Linaclotide 18 microgram (μg), capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
89351379|NCT04110145|Experimental|Cohort 2 (Linaclotide 36 μg)|Linaclotide 36 μg, capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
89351380|NCT04110145|Experimental|Cohort 3 (Linaclotide 72 μg)|Linaclotide 72 μg, capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
89351381|NCT04110145|Experimental|Final Cohort (Linaclotide 72 μg)|Linaclotide at the highest dose tested/determined to be safe (72 μg), capsules, mixed with water and administered orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period.
89351382|NCT04110145|Placebo Comparator|Placebo Pooled|Matching placebo, orally, once daily in fasted state (30 minutes before any meal) for the 4-week Study Intervention Period pooled from Cohorts 1, 2, 3, and Final Cohort.
89351383|NCT02477618|Active Comparator|SAGE-547|Intravenous
89351384|NCT02477618|Placebo Comparator|Placebo|Intravenous
89351385|NCT04102501|Experimental|RT001|"9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.~Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
89351386|NCT04102501|Placebo Comparator|Placebo|"9 capsules daily (8.64 g total dose) given as 3 capsules three times a day (TID) with meals for the first month of treatment.~Six capsules daily (5.76 g total dose) given as 3 capsules (BID) with breakfast, and 3 capsules with dinner after the first month of treatment"
89351387|NCT03879083|Experimental|With reproduction of palatal rugae|Participants will receive maxillary complete dentures with a reproduction of the patients's own palatal rugae to the palatal surface.
89351388|NCT03879083|Active Comparator|Without reproduction of palatal rugae (smooth surface)|Participants will receive maxillary complete dentures with smooth palatal surfaces without a reproduction of the patients's own palatal rugae to the palatal surface.
89351389|NCT01266473|Experimental|Physiotherapy techniques|Cough Technique vs Forced Expiration Technique
89351390|NCT01268033|Experimental|Rituximab|two infusions of Rituximab - at the dose of 375 mg/m²
89351391|NCT01268033|Placebo Comparator|placebo|two infusions of placebo
89351392|NCT02879162|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg IV 60 min Day 1 every 4 weeks Tremelimumab 75 mg IV 60 min Day 1, cycles 1-4
89351393|NCT01266551|No Intervention|lifestyle counseling|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring. In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
89351394|NCT03285477|Placebo Comparator|Placebo|Vehicle Ointment was applied topically once daily for 5 consecutive days on face or scalp
89351395|NCT03285477|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment 1% was applied topically once daily for 5 consecutive days on face or scalp
89351396|NCT01160003|Experimental|Treatment Period 1|5mg of GW870086X or placebo will be given once daily for 14 days.
89351397|NCT01160003|Experimental|Treatment Period 2|GW870086X (5mg or 8.75mg) or placebo will be given once daily for 14 days. In a randomised dose escalating manor following on from treatment period 1.
89351398|NCT01160003|Experimental|Treatment Period 3|8.75mg of GW870086X or placebo will be given once daily for 14 days.
89351399|NCT03748693||POP Group|Women with POP undergoing surgery in our OB/GYN department.
89351400|NCT03748693||Non-POP Group|Women undergoing hysterectomy for other indications.
89351401|NCT02285504|Experimental|SAGE-547|Participants received SAGE-547 intravenous injection over 60 hours (including 12-hour titration infusion of 21.5 micrograms per kilogram per hour [mcg/kg/hr] [4 hrs], 43 mcg/kg/hr [4 hrs] and 64.5 mcg/kg/hr [4 hrs] on Day 1, followed by 13 to 48 hrs [36 hrs] maintenance infusion of 86 mcg/kg/hr from Day 1 to 3, followed by a 12-hr taper infusion of 64.5 mcg/kg/hr [49 - 52 hrs], 43 mcg/kg/hr [53 - 56 hrs] and 21.5 mcg/kg/hr [57 - 60 hrs] on Day 3).
89351402|NCT01160081||National Health and Nutrition Survey 2006 (ENSANUT 2006)|
89351403|NCT01586585||post cardiac surgery patients|
89351404|NCT04289623||Standard email|This email mentions the cost-saving benefits of enrollment by participants who met their 2018 goals. It also includes the message that registration can be completed quickly (in less than five minutes). Finally, it also includes reward incentive information, wherein registering by a March deadline provides qualified recipients with the potential to win prizes. This information is contained in all other emails.
88818778|NCT04340037||proximal ureteral stone patient|Patients underwent percutaneous nephrolithotomy treating unilateral, solitary and proximal ureteral stones.
89351405|NCT04289623||Loss frame email|"In addition to the content of the generic email, the subject line and content of the loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action. This email further frames the reward as something recipients will miss out on if they do not sign up.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
89351406|NCT04289623||Testimonial (medical expert) email|"In addition to the content of the generic email, the testimonial (medical expert) email includes a testimonial from a doctor, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a presumed authority figure. Recipients may be more likely to enroll for this program if they see a physician - who would be seen as an authority on health and wellness - talking about the medical benefits of the program. It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
89351407|NCT04289623||Testimonial (rank-and-file) email|"In addition to the content of the generic email, the testimonial (rank-and-file) email includes a testimonial from a customer care specialist, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a peer (relative to most Geisinger employees). Recipients may be more likely to enroll for this program if they see a rank-and-file employee talking about the program as this person would be more relatable (relative to a doctor). It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
89351408|NCT04289623||Social norms (percentage) email|"In addition to the content of the generic email, the social norms (percentage) email will include communication about the percentage of benefit-eligible employees who had already registered for myHealth Rewards.~This message sets up a descriptive norm, showing that a majority of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. The use of percentages makes it clear that this behavior is indeed being done by most people in the group. It is unclear in the current context and population if a message using percentages or numbers would be more effective."
89351409|NCT04289623||Social norms (number) email|"In addition to the content of the generic email, the social norms (number) email will include communication about the number of benefit-eligible employees who had already registered for myHealth Rewards.~This message sets up a descriptive norm, showing that a large number of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. While the use of numbers does not indicate that this behavior is being done by a majority, using a large number can be more convincing just in showing sheer quantity."
89351410|NCT03248037|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months
89351411|NCT03248037|Placebo Comparator|Placebo|Placebo eye drop, dosed topically once a day for 9 months
89351412|NCT02227394|Experimental|Z7200 - Symbicort® Turbohaler|"The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the test product (Z7200) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the second dosing day (Period 2, Visit 3).~Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.~Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.~Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided."
89351413|NCT02227394|Experimental|Symbicort® Turbohaler - Z7200|"The patients randomized to this sequence were to receive a single dose consisting of 2 inhalations of the reference treatment (Symbicort® Turbohaler) on the first dosing day (Period 1, Visit 2), then, after a wash out period of at least 3 days but no more of 31 days, a single dose consisting of 2 inhalations of the test product (Z7200) on the second dosing day (Period 2, Visit 3).~Patients were also to receive 2 inhalations with matching placebo to the alternate treatment as a dummy inhaler to achieve double-blinding.~Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg)."
89351414|NCT04287517|Active Comparator|Capacitive-Resistive Therapy Group|This group was treated with capacitive resistive diathermy and exercise
89351415|NCT04287517|Sham Comparator|Sham Group|This group was treated with sham capacitive-resistive diathermy and exercise
89351416|NCT03284229|Experimental|Excimer Laser Coronary Atherectomy|ELCA® in patients with single or multivessel CAD either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA). The entire procedure will be carried out as per the site routine practice and the device will be used as per the 'Instruction for Use'. Treating physicians/study investigators will be trained by the study Sponsor on the study protocol and procedures prior to clinical investigation procedure. Subject preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted.
89351417|NCT01162265||Contacts|Contacts of active cases of tuberculosis
89351418|NCT01162265||new entrants|new entrants from high incidence (>40/100000) countries.
89351419|NCT03242928|Placebo Comparator|Placebo|Matching tablet of placebo taken orally BID
89351420|NCT03242928|Experimental|AFQ056|Mavoglurant was up titrated on a bid regimen followed by fixed-dose bid regimen: 50 mg bid from Day 1 to Day 7, 100 mg bid from Day 8 to Day 14, and then fixed-dose 200 mg bid for 84 days
89351421|NCT03876353|Other|Left Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
89351422|NCT03876353|Other|Right Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
89351423|NCT03747055|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
89351424|NCT03747055|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
89351425|NCT05158491|Active Comparator|180 mg/mm2|Subjects will be dosed at 180 mg/mm2 level.
89351426|NCT05158491|Active Comparator|220 mg/mm2|Subjects will be dosed at 220 mg/mm2 level.
89351427|NCT05158491|Active Comparator|260 mg/mm2|Subjects will be dosed at 260 mg/mm2 level.
89351428|NCT05158491|Active Comparator|300 mg/mm2|Subjects will be dosed at 300 mg/mm2 level.
89351429|NCT03876665||Focus Group|"Active Duty Air Force, Army and Navy women diagnosed with PCOS.~Up to three focus groups per service branch will be conducted. Considering attrition for those who may volunteer and not show up for the FG session, the investigators will recruit up to 20 participants per site, with the goal of including a maximum of six participants per FG to maximize individual participation."
89351430|NCT03300024|Active Comparator|Expanded polytetrafluoroethylene (ePTFE)|The ePTFE grafts used are the Flixene (Maquet-Atrium Medical, Hudson, NH), Advanta VXT (Maquet-Atrium), GORE-TEXStretch Vascular Graft For Vascular Access (W. L. Gore and Associates, Flagstaff, Ariz), or Venaflo (Bard Peripheral Vascular, Tempe, Ariz). The choice of graft used is at the surgeons' discretion. The graft it is offered in both large and small diameters, as well as thin-wall and rapidly-tapering designs for cases where arterial steal syndrome is a potential complication. A 6 mm graft featuring external supporting rings in 5 cm centered or 7 cm offset sections enables tight loop configurations and crossing the cubitus. A 4-7 mm tapered graft with 10 or 15 cm of removable rings allows for tailoring or exact placement of the ringed section.
89351431|NCT03300024|Experimental|Bovine carotid Artery Graft|The bovine carotid artery biological grafts (Artegraft®; Artegraft, Inc., North Brunswick, NJ) consist of a biological fibrous matrix processed to enhance long-term patency and provide a tightly woven, cross-linked conduit that is flexible and compliant.
89351432|NCT01162577|Experimental|Intervetion|The intervention group received the 5 standard tobacco calls plus 3 weight calls with a weight coach to address weight concerns related to quitting smoking
89351433|NCT01162577|No Intervention|Control|Participants in this arm received only the 5 standard tobacco calls
89351434|NCT04276207|Experimental|100 U/mL LY900014|100 units per milliliter (U/mL) LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.
89351435|NCT04276207|Active Comparator|100 U/mL Insulin Lispro (Humalog)|100 U/mL Insulin Lispro (Humalog) administered by CSII in one of two study periods.
89351436|NCT01162655|Experimental|Telehealth|Complete CBT group via telehealth
89351437|NCT01162655|Experimental|Internet|Complete Internet-based CBT program
89351438|NCT03748615|Experimental|Computer Guided ridge splitting in posterior mandible|fabrication of a computer aided surgical guide and performing ridge splitting in posterior mandible using piezosurgery
89351439|NCT03876587|Experimental|Pyrotinib Maleate combine with Docetaxel|"Pyrotinib Maleate combine with Docetaxel should be administrate to all subjects.~Initial dose: Pyrotinib Maleate 400mg oral administration everyday plus Docetaxel 75mg per square of BSA every three weeks intravenous injection."
89351440|NCT01268345|Experimental|Andon|Andon blood glucose test strips with test meter
89351441|NCT01268345|Active Comparator|Lifescan|
89351442|NCT01162811|No Intervention|Control group|The control group receives conventional care and treatment
89351443|NCT01162811|Experimental|Intervention group|the intervention group receives visualization and relaxation exercises together with structured behavioural attention
89351444|NCT04646343||group for cross cultural adaptation of questionnaire|Pre final French version of the CISS and PWES will be administered to French native speaking patients suffering from various hand injuries. 30 patients are sufficient. They will be asked to write commentaries on difficulties of questionnaire's items, especially comprehension of the different items (clear or unclear).If the item is considered unclear, the patient is asked to provide suggestions for making the item clearer .The distribution of the responses will be examined for searching missing responses. An item considered unclear by 20 % or more of the patients must be re-evaluated . The definitive version of French-CISS and French PWES (F-CISS and F- PWES) and the verification of the different stages of the cross-cultural adaptation will be validated during a new consensus meeting.
89351445|NCT04646343||group for validation of questionnaire|For the second part (validation study) we will administered F-CISS, F-PWES, F-DASH, F-HFS, F-SF 36 questionnaires and a pain VAS to a population of in and outpatients with hand injuries. We aim to include patients during one year for a total expected of 100 patients.
89351446|NCT01162889|Placebo Comparator|Placebo - SC injection|
89351447|NCT01162889|Experimental|Drug dose level 1 - SC injection|
89351448|NCT01162889|Experimental|Drug dose level 2 - SC injection|
89351449|NCT01162889|Experimental|Drug dose level 3- SC injection|
89351450|NCT01162889|Experimental|Drug dose level 4 - SC injection|
89351451|NCT01162889|Experimental|Drug dose level 5 - SC injection|
89351452|NCT01162889|Experimental|Drug dose level 6 - IV Infusion|
89351453|NCT01162889|Experimental|Drug dose level 7 - IV Infusion|
89351454|NCT01162889|Experimental|Drug dose level 8 - IV infusion|
89351455|NCT01162889|Placebo Comparator|Placebo - IV infusion|
89351456|NCT01162889|Experimental|Drug dose level 9 - IV infusion|
89351457|NCT05666843|Experimental|Intervention group|Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care. The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
89351458|NCT05666843|No Intervention|Usual care group|Participants in the control group receive usual health care as provided by general practitioners and nurse practitioners or other health care professionals involved in diabetes care.
89351459|NCT03876431|Active Comparator|Traditional Exercise Group|Only traditional exercises will be performed in the early post-op period.
89351460|NCT03876431|Experimental|Easy-Flex Group|Easy-Flex group will be treated with the Easy-Flex device in addition to the traditional exercise program.
89351461|NCT03282357|Experimental|Radiesse|Subjects are randomized as to which of the two nasolabial folds is treated with Radiesse.
89351462|NCT03282357|Active Comparator|Restylane|Subjects are randomized as to which of the two nasolabial folds is treated with Restylane.
89351463|NCT03876509||Impedance Cardiography|Impedance Cardiography
89351464|NCT01162967|Active Comparator|Benznidazole|
89351465|NCT01162967|Experimental|Posaconazole, low dose|
89351466|NCT01162967|Experimental|Posaconazole, high dose|
89351467|NCT01268423|Experimental|Early percutaneous tracheostomy|
89351468|NCT01268423|Active Comparator|Prolonged translaryngeal intubation|
89351469|NCT01163045|Experimental|neuromonitoring and neurostimulation|
89351470|NCT01163045|Experimental|neurostimulation of recurrent laryngeal nerve|
89351471|NCT01268657|Experimental|Cognitive Behavioral Exposure Therapy|
89351472|NCT01268735|Experimental|Lubricating eyedrops containing HP-guar|
89351473|NCT04272775|Experimental|Cohort 1: Ixazomib 4.0 mg|Ixazomib 4.0 milligram (mg), capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
89351474|NCT04272775|Experimental|Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone|Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 milligram per day (mg/day), capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 62.
89351475|NCT04272775|Experimental|Cohort 3: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
89351476|NCT04272775|Experimental|Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 87.
89351477|NCT03876197|Experimental|Autologous Adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia
89351478|NCT03876197|Placebo Comparator|Placebo|2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%
89351479|NCT03232983|Experimental|LY900014 (SC Abdomen)|Single dose of 15-U of LY900014 administered subcutaneously (SC) into the abdomen in one period
88807302|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL cream Group|Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
89351480|NCT03232983|Experimental|LY900014 (SC Thigh)|Single dose of 15-U of LY900014 administered SC into the thigh in one period
89351481|NCT03232983|Experimental|LY900014 (SC Arm)|Single dose of 15-U of LY900014 administered SC into the arm (deltoid) in one period
89351482|NCT03232983|Active Comparator|LY900014 (IV)|Single dose of 15-U of LY900014 administered intravenously (IV) in one period
89351483|NCT01163201|Experimental|Treg Plus CD3+Teff Treatment|Includes dose adjustment of T regulatory (Treg) and CD3+ T effector (CD3+ Teff) cells in recipients of double UCB transplantation
89351484|NCT03876041|Active Comparator|dexamethasone group|this group will receive Dexamethasone: 0.1 to 0.3 mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
89351485|NCT03876041|Active Comparator|methylprednisolone group|this group will receive Methylprednisolone: 5-10mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
89351486|NCT04102345|Experimental|Lavender|1-2 drops of Lavender (essential oil) in approximately 120 ml of distilled water is added to a diffuser 10 minutes before light out. The diffuser runs for approximately 2 hours before automatically being shut off. A low mist option is used on the diffuser.
89351487|NCT04102345|Active Comparator|Zolpidem|Pre-prescribed, physician directed use of zolpidem. There is no dose exclusionary criteria for the zolpidem. This study does not have any dose specifications, anyone on zolpidem may be eligible.
89351488|NCT01163435|Experimental|high dose dual therapy|group A1 and A2 - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
89351489|NCT01163435|Experimental|sequential therapy|group B1 and B2 - sequential therapy (rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days)
89351490|NCT01163435|Active Comparator|clarithromycin-based triple therapy|group C1 - clarithromycin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days)
89351491|NCT01163435|Active Comparator|levofloxacin-based triple therapy|group C2 - levofloxacin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days)
89351492|NCT04271605|Experimental|behavior intervention and pharmacological therapy|"For participants with abnormal biochemical markers, pharmacological therapy and diet modification are applied.~Dietary education on phosphorus additives is applied specifically for retention of phosphorus or high serum phosphorus level.~Exercise for bone and cardiovascular health.~Osteoporosis medications are initiated according to the reimbursed criteria of National Health Insurance, otherwise medications are used with non-insurance payment."
89351493|NCT01163513||White population|
89351494|NCT01163513||Indian|
89351495|NCT01163513||Pakistani|
89351496|NCT01163513||Bangladeshi|
89351497|NCT01163513||Other|other South Asian
89351498|NCT01163591||Case|Patients with overt diabetic nephropathy as evidenced by ACR greater than or equal to 30mg/mmol on urinalysis and eGFR greater than or equal to 15ml/min/1.73m2 and less than 60ml/min/1.73m2
89351499|NCT01163591||Control|Patients without diabetic nephropathy as defined by the absence of albuminuria (defined by a random spot urinary ACR <2.5 mg/mmol in women or ACR<3.5 mg/mmol in men)and eGFR greater or equal to 90 ml/min/1.73m2
89351500|NCT01163669||kidney transplant recipients|
89351501|NCT03299244|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous (IV) bolus injection at the end of each hemodialysis session three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum parathyroid hormone (PTH) ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
89351502|NCT03299244|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
89351503|NCT03757715|Experimental|Treatment Group|20 mL of 1.3% bupivacaine with 2 mg dexamethasone injected locally in the location for sensory nerves of the sinus cavities and face during the functional endoscopic sinus surgery (FESS) procedure
89351504|NCT03757715|No Intervention|Control Group|No regional anesthetic of any kind during the functional endoscopic sinus surgery (FESS) procedure
89351505|NCT01163825|Experimental|Nerve Growth Factor|Dose 1
89351506|NCT01163825|Experimental|Nerve Growth Factor 2|Dose 2
89351507|NCT01163903|Experimental|Pantoprazole and doxorubicin|
89351508|NCT01163981|No Intervention|Blind cannulation|Cannulation without guidance
89351509|NCT01163981|Experimental|Ultrasound guided cannulation|Ultrasound guided cannulation
89351510|NCT03281577|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
89351511|NCT03281577|Experimental|TAK-954 0.1 mg|TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
89351512|NCT03281577|Experimental|TAK-954 0.3 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
89351513|NCT03281577|Experimental|TAK-954 1 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
89351514|NCT04098367|Experimental|VIVITY|VIVITY IOL implanted in the eye during cataract surgery
89351515|NCT04098367|Active Comparator|SYMFONY|SYMFONY IOL implanted in the eye during cataract surgery
89351516|NCT04098367|Active Comparator|AT LARA|AT LARA implanted in the eye during cataract surgery
89351517|NCT03745807|Experimental|Combination|NKTR-214 + nivolumab
89351518|NCT01164059|Experimental|atypical antipsychotics|Olanzapine, Quetiapine, or Aripiprazole
89351519|NCT01164059|Active Comparator|typical antipsychotics|Haloperidol or Flupentixol
89351520|NCT04091659|Active Comparator|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
89351521|NCT04091659|Experimental|Virtual Reality|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
89351522|NCT02814708|Experimental|Dose Group 1|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 1
89351523|NCT02814708|Experimental|Dose Group 2|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 2
89351524|NCT02814708|Experimental|Dose Group 3|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 3
89351525|NCT02814708|Experimental|Dose Group 4|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 1
89351526|NCT02814708|Experimental|Dose Group 5|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 2
89351527|NCT02814708|Experimental|Dose Group 6|rTSST-1 Variant Candidate Vaccine 100 µg Number of Immunizations: 3
89351528|NCT02814708|Placebo Comparator|Dose Group 7|Al(OH)3 Adjuvant, 1mg Number of Immunizations: 3
89351529|NCT01266629||capsule patients|All patients that will undergo endoscopic capsule
89351530|NCT01268813|Experimental|Exhaled breath uptake blood test|Diabetic patients receiving oral hypoglycemic drug will be tested for biomarkers in their breath and blood samples
89351531|NCT01268813|No Intervention|Exhaled breath and blood test|Breath and blood samples will be collected from healthy volunteers and analyzed using Gas Chromatography-Mass Spectroscopy. The results will be compared to the experimental arm.
89351532|NCT03879005|Other|Renal scintigraphy|5 mci of 99mTc-DTPA or 99mTc-DMSA is injected once IV. Dose is adjusted according to age and weight.
89351533|NCT04256785|Experimental|VSL#3|probiotic VSL#3, 2 sachets b.i.d for 3 months
89351534|NCT04256785|Placebo Comparator|placebo|matched placebo, 2 sachets b.i.d for 3 months
89351535|NCT03878771|Experimental|autologous Platelet rich fibrin in Orabase (PRF)|applied to oral ulcer and/or mucositis 3 times per day
89351536|NCT03878771|Active Comparator|Clobetasol propionate 0.05%(Dermovate cream) in orabase|applied to oral ulcer and/or mucositis 3 times per day
89351537|NCT02959918|Experimental|SEL-037 Pegadricase LD (low dose) alone|Pegadricase 0.2 mg/kg intravenous (IV) every 28 days for 5 treatments
89351538|NCT02959918|Experimental|SEL-037 Pegadricase HD (high dose) alone|Pegadricase 0.4 mg/kg intravenous (IV) every 28 days for 5 treatments
89351539|NCT02959918|Experimental|SEL-212, Pegadricase LD & SEL-110 (1a)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.05 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
89351540|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (1b)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.05 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
89351541|NCT02959918|Experimental|SEL-212, Pegadricase LD & SEL-110 (2a)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.08 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
89351542|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (2b)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.08 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
89351543|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (3a)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
89351544|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (3b)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
89351545|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (4a)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.125 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
89351546|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (4b)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
89351547|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (5a)|Pegadricase 0.4 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
89351548|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (5b)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 5 treatments
89351549|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (6a)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.10 mg/kg IV every 28 days for 1 treatment followed by pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 4 treatments
89351550|NCT02959918|Experimental|SEL-212, Pegadricase HD & SEL-110 (6b)|Pegadricase 0.2 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 5 treatments
89351551|NCT01160159||Thrombophilia|
89351552|NCT01160159||Healthy volunteers|
89351553|NCT01266707|Experimental|Vaccine|VEGRF1, VEGFR2
89351554|NCT03263442|Experimental|Intervention|Thiamine 200 mg IV
89351555|NCT03263442|Placebo Comparator|Control|Normal saline IV
89351556|NCT01164215|Experimental|mFOLFOX6|"Patients will receive cycle 1 of standard dose mFOLFOX6, with the same dose of mFOLFOX6 continued in subsequent cycles, once patient achieves the target AUC.~mFOLFOX 6 is a regimen comprised of Oxaliplatin + Leucovorin +5-Fluorouracil (FU)"
89351557|NCT04245709|Experimental|Open label Arm|This is an open label pilot trial in which 25 people with ALS will take clenbuterol orally at 40-80 micrograms twice daily for 24 weeks.
89351558|NCT03878693|Experimental|A|Oral APAP and IV Fomepizole.
89351559|NCT03878693|Active Comparator|B|Oral APAP.
89351560|NCT05305495|Experimental|Patients with diuretic resistance|
89351561|NCT01164293|Experimental|Atopy patch test|Atopy patches were applied on food allergy patient's back for 48 hrs then the patches were removed. Reaction was evaluated at 48 and 72 hrs after applying atopy patch test
89351562|NCT03748537|Experimental|Hydrocortisone|Hydrocortisone will be administered intravenously at 200 mg every 24 hours for 5 days, then tapered to a 50 mg intravenous bolus every 12 hours for days 6 to 8 and 50 mg every 24 hours for days 9 to 11, and then stopped.
89351563|NCT03748537|No Intervention|No Hydrocortisone|In control group, patient will not receive any corticosteroids for seven day after inclusion.
89351564|NCT01164371||Initial presentation of coronary disease - Stable angina|Patients whose initial symptomatic presentation of coronary disease is stable angina (either diagnosis or symptoms)
89351565|NCT01164371||Initial presentation of coronary disease - ACS|Patients whose initial symptomatic presentation of coronary disease is acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-STEMI [nSTEMI] or unstable angina) without prior stable angina or symptoms of stable angina
89351566|NCT01164371||Initial presentation of coronary disease - Coronary death|Patients whose initial symptomatic manifestation of coronary disease is coronary death with no prior diagnosis of stable angina (or symptoms of stable angina) or diagnosis of acute coronary syndrome
89351567|NCT01164371||Initial presentation of coronary disease - None|Patients without symptomatic presentation of coronary disease, either alive or dead from non-coronary cause
89351568|NCT04091581|Experimental|Non-Dry Eye|Instill eye drop and perform followup assessments on people with a Ocular Surface Disease Index score <13 and a non-invasive Keratograph break-up time of >/= 10 seconds in the worst eye
89351569|NCT04091581|Experimental|Dry Eye|Instill eye drop and perform followup assessments on people with an Ocular Surface Disease Index score >/= 13 and a non-invasive Keratograph break-up time </= 5 seconds in the worst eye
89351570|NCT02527109|Placebo Comparator|Placebo|Intra-anal placebo administered BID.
89351571|NCT02527109|Experimental|Nifedipine 12 mg/day|Intra-anal Nifedipine 12 mg administered OD.
89351572|NCT02527109|Experimental|Nifedipine 24 mg/day|Intra-anal Nifedipine 12 mg administered BID.
89351573|NCT02940522|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector
89351574|NCT02940522|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle
89351575|NCT03878615||Elective Hepatic Surgery|Patientes undergoing elective hepatic resection, managed according to departement routine.
89351576|NCT03875807|Active Comparator|0 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 0 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
89351577|NCT03875807|Active Comparator|30 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 30 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
89351578|NCT02526719|No Intervention|Standard Nipple-Sparing Mastectomy|Patients in the control group will receive usual care. The surgical oncologist will perform the NSM and sentinel lymph node biopsy if indicated (active breast cancer or DCIS). We will submit a nipple core biopsy and a 1cm thick biopsy of immediately retro-areolar ductal tissue for permanent section pathology for control patients, and all patients will have the mastectomy specimen submitted for permanent section pathology. Under the same general anaesthesia, the plastic surgeon will perform the IBR (2-stage tissue expander to implant or 1-stage direct to implant). Patients who later have a positive nipple core and retro-areolar biopsy will have a discussion with the surgical oncologist regarding the need for revision breast surgery to excise the NAC, as is current practice.
89351579|NCT02526719|Experimental|Nipple Delay Intervention|Patients in the experimental group will have a nipple-delay intervention in addition to usual care. The nipple delay procedure will be performed by the plastic surgeon in the minor clinic procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
89351580|NCT03746977|Active Comparator|energy restriction and protein supplementation|Energy restriction of 500 kcal/d and total Protein Uptake (including Supplementation) of 1.2 g/kg body mass/d
89351581|NCT03746977|Active Comparator|Energy restriction, walking and protein|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d) and total protein uptake (including supplementation) of 1.5 g/kg body mass/d
89351582|NCT03746977|Active Comparator|Energy restriction, walking, protein and WB-EMS|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d), total protein uptake (including supplementation) of 1.5 g/kg body mass/d and WB-EMS application 1,5x 20 min/week
89351583|NCT03262038|Experimental|Ondansetron IV|Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
89351584|NCT03262038|Placebo Comparator|Placebo|Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)
89351585|NCT01268969|Active Comparator|excision and krydakis reconstruction|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
89351586|NCT01268969|Active Comparator|surgical excision and limberg closure|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia . The fasciocutaneous flap was transposed medially so that the defect would be covered without any tension.
89351587|NCT03745573|Experimental|Empateach Intervention|All teachers in intervention schools will be invited to participate. Participants in the intervention condition will receive Empateach, a 10-week group intervention. Groups meet 14 times for 1-1.5 hour length sessions, which are led by peers. The aim of the Empateach intervention is to improve 'student and teacher well-being; self-regulation; teacher classroom management and teacher's use of positive discipline techniques. The intervention uses cognitive behavioural therapy techniques to change negative thought and behaviour patterns related to corporal punishment. The teachers receive information on alternatives to corporal punishment, planning exercises and reinforcement SMS, and because the intervention is in a group setting, social support to change their behaviours. They discuss their experiences and challenges in group sessions.
89351588|NCT03745573|No Intervention|Wait-list control|Teachers in wait-list control schools will receive no specific interventions related to violence prevention during the study, but will receive the intervention after the study is over if it is shown to be effective (pending donor funding).
89351589|NCT01266863|Experimental|E test method|
89351590|NCT03746821|Other|Biotin|Volunteers to take biotin suppliment
89351591|NCT01266941|Experimental|Mild Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
89351592|NCT01266941|Experimental|Moderate Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
89351593|NCT01266941|Experimental|Matched healthy volunteers|Once a moderate subject has been recruited, a healthy control subject should be recruited (matched to the moderate subject on gender, ethnicity, body mass index +/-15%, age +/-5 years). In total there will be 9 matched healthy volunteers 1 for each subject with moderate hepatic impairment.
89351594|NCT01266941|Experimental|Severe Hepatic Impairment|Severe subjects will not be enrolled into the study until 9 moderate subjects and their matched control subjects have completed the study and the safety and PK data have been reviewed.
89351595|NCT02472964|Active Comparator|Herceptin© + Taxane|"Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal ."
89351596|NCT02472964|Experimental|MYL- 1401O + Taxane|"Part 1:MYL-1401O Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to MYL-1401O alone once every 3 weeks until DP or subject withdrawal."
89351597|NCT01160315|Experimental|Arm A (GnRha arm)|IM injection of Triptorelin -Decapeptyl PR 11.25mg- (every 3 months) and Norethisterone acetate- Primolut-Nor 5 mg- per os continuously until the end of the chemotherapy
89351598|NCT01160315|Active Comparator|Arm B (control Arm)|Norethisterone acetate alone, 5mg par day, (ARM B) until the end of the chemotherapy.
89351599|NCT03875417||Group A|Patients who developed HCC recurrences after surgery and treated with re-resection, or microinvasive non-surgical means.
89351600|NCT03875417||Group B|Patients who did not develop recurrences after surgery.
88811814|NCT02209259|Experimental|Control|The third group (the control arm) will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS).
89351601|NCT01160393|Other|Miniaturized bypass system|Miniaturized bypass system and the incidence of atrial fibrillation after cardiac surgery
89351602|NCT03385252|Experimental|Egg Group|Egg Intervention: Provision of eggs to caregivers of enrolled infants, with instructions to prepare and feed one egg to the infant each day for 6 months time. Households will be visited twice weekly to provide eggs and monitor intake.
89351603|NCT03385252|Active Comparator|Control Group|Control Group: Caregivers will receive a food basket at the end of the study. Throughout the trial, households will be visited twice weekly and asked about food intake.
89351604|NCT01164449|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
89351605|NCT03878225|Active Comparator|Ketone Mono Ester|"The ketone mono ester is commercially available dietary supplement beverage named H.V.M.N. Ketone Ester, marketed by HVMN Inc®. The KME beverage consists of water, D-β-hydroxybutyrate ester, stevia leaf extract, natural flavors, malic acid, potassium sorbate and potassium benzoate. The active ingredient is the D-β-hydroxybutyrate ester, with each dose containing 25g. Participants will be asked to ingest this 5 times daily for 3 days (72 hours), to a total of 15 doses during the study."
89351606|NCT03878225|Placebo Comparator|Placebo|The placebo beverage will consist of water added with a colorless, bitter flavor enhancer and a sweetening agent (Stevia) to approximate the taste of the KME beverage as closely as possible. The bitter flavor enhancer used is denatonium benzoate (Bitrex®). The placebo beverage will be delivered to patients in bottles identical to those used in the active arm. Patients, investigators and other caregivers will be blinded to treatment allocation until time of database unlock.
89351607|NCT03385174|Other|Carbon monoxide|Each participant receives CO inhalation
89351608|NCT03878303|Experimental|AC0058TA|AC0058TA will be administered in 25 mg capsules orally at the following doses: 50 mg QD, 100 mg QD, 200 mg QD and 100 mg BID
89351609|NCT03878303|Placebo Comparator|Placebo AC0058TA|Placebo AC0058TA will be administered orally at the equivalent dose of investigational product
89351610|NCT03380806|Active Comparator|Arm 1|Conventional Radiotherapy (CRT) Prostate Boost Pelvic Radiation LHRH agonist
89351611|NCT03380806|Experimental|Arm 2|Stereotactic Body Radiotherapy (SBRT) Prostate Boost Pelvic Radiation LHRH agonist
89351612|NCT03746743||Preterm neonates|Neonates born between 32 and 37 weeks gestation
89351613|NCT03746743||Fullterm neonates|Neonates born at or after 37 weeks gestation
89351614|NCT03875261|Experimental|Study arm|Participants are treated with the investigational medical product
89351615|NCT03748459||Permanent suture|Subjects will have skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
89351616|NCT03748459||Resorbable suture|Subjects will have skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty
89351617|NCT01160471||Healthy Volunteers|Adult men and women without a clinical diagnosis of heart failure
89351618|NCT01160471||Patients|Adult men and women with a clinical diagnosis of heart failure
89351619|NCT03380728|Experimental|Group 1|Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7
89351620|NCT03380728|Experimental|Group 2|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, placebo on day 7
89351621|NCT03380728|Experimental|Group 3|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, Ibogaine Hydrochloride 400 mg on day 7
89351622|NCT03874949|Active Comparator|SEALITE Regular|zinc oxide eugenol sealer
89351623|NCT03874949|Experimental|SEALITE Ultra|zinc oxide eugenol sealer containing 1% Enoxolone (NSAID)
89351624|NCT03877835|Other|Ropivacaine|SSNB will be performed with 4 ml ropivacaine 5 mg/ml LSIB will be performed With 15 ml ropivacaine 7.5 mg/ml
89351625|NCT01104922|Experimental|Cetuximab and stereotactic radiosurgery|
89351626|NCT01164683|Experimental|Arm 1|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
89351627|NCT01164683|Active Comparator|Arm 2|Usual care
89351628|NCT04079803|Placebo Comparator|Placebo Cohort|Subjects administered placebo oral tablets twice daily (BID)
89351629|NCT04079803|Experimental|Simufilam (PTI-125) 100 mg tablets Cohort|Subjects administered simufilam (PTI-125) 100 mg oral tablets twice daily (BID)
89351630|NCT04079803|Experimental|Simufilam (PTI-125) 50 mg tablets Cohort|Subjects administered simufilam (PTI-125) 50 mg oral tablets twice daily (BID)
89351631|NCT01160549||Cases|Women living in rural environments
89351632|NCT01160549||Controls|Women living in more urban environments
89351633|NCT00894244|Experimental|Treatment|Treatment using a non-invasive skin tightening radiofrequency device to observe skin shrinkage in the arms
89351634|NCT03278613|Experimental|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS treatment entails insertion of a 36 gauge needle electrode at a 60 degree angle 3-4 cm deep towards the tibial nerve, approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. The PTNS grounding electrode, placed near the calcaneus and the needle electrode will be connected to the ES-130 device pulse generator.
89351635|NCT03278613|Sham Comparator|Validated Sham|Sham treatment will use the Streitberger acupuncture placebo needle in the same location as the needle electrode for PTNS. The sham uses an active gel surface electrode pad placed on the bottom of the foot just below the fifth (smallest) toe. This location is not part of the acupuncture nerve pathway connected to the bladder, pelvis or any major organs. Electrical current is delivered to this pad via a TENS unit resulting in sensory stimulation.
89351636|NCT03761147|Experimental|Paula Method|
89351637|NCT03761147|No Intervention|Standard of Care|
89351638|NCT00560716|Experimental|CYC116|CYC116 dose escalation first-in-human evaluation
89351639|NCT03909659|No Intervention|Control|Normal salt
89351640|NCT03909659|Experimental|Reduced-sodium added-potassium salt substitute|salt substitute
89351641|NCT03380650|Other|durg-coated balloon dilation|The drug-coated balloon will be used to treat the femoropopliteal occlusion.
89351642|NCT03380650|Other|directional atherectomy and LDD|The directional atherectomy and local drug delivery will be used to treat the femoropopliteal occlusion.
89351643|NCT01164761|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
89351644|NCT01164761|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
89351645|NCT03748381|Experimental|Trifocal IOL|The patients will receive two different diffractive trifocal IOLs in each eye (AT Lisa tri vs. Rayner trifocal) during cataract surgery
89351646|NCT03385096|Experimental|BUCY+VP-16|For MM patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -8 and -6；CY 60 mg/kg/day on days -5 and -4; VP-16 10mg/kg/day on days -3 and -2.
89351647|NCT03385096|Active Comparator|Melphalan|For MM patients undergoing auto-HSCT，Melphalan conditioning regimen was Melphalan 200mg/m2 on day -2.
89351648|NCT01252823|Experimental|Implantable loop recorder (ILR) in hemodialysis patients|implantation of loop recorder in hemodialysis patients
89351649|NCT03746665|Experimental|meningococcal serogroup A conjugate|mothers will be vaccinated with meningococcal serogroup A conjugate vaccine between 28 - 34 weeks gestation
89351650|NCT03746665|No Intervention|control|serological samples from 100 control mother-infant pairs already recruited as part of the PROPEL trial, (SCC1433), NCT02628886
89351651|NCT04445974|Active Comparator|Expand Your Horizons: More than my skin|Participants allocated to the intervention condition will be asked to follow the adapted instructions for 'Expand Your Horizon'. Participants will be asked to complete three 15 min writing exercises over approximately six days. Participants who complete the first exercise on Qualtrics will be sent links to and asked to complete the second and third writing exercises.
89351652|NCT04445974|Experimental|Control writing activity|Participants in the control condition will be asked to complete three 15 minute creative writing exercises online via Qualtucs over approximately six days. Participants completing the first writing exercise will be sent links to the second and third writing exercises.
89351653|NCT02526875|Experimental|night|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 pm to 10 pm, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
88807303|NCT05290662||Participants having received oNKord® as part of the WiNK clinical trial|WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in adults with acute myeloid leukemia (AML) who are in morphologic complete remission with residual measurable disease and not currently proceeding to hematopoietic stem cell transplantation
88807304|NCT05143502|Experimental|Montelukast Group|Patients in group A (interventional group) will be treated with fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 monthes and oral Prednisolone 40 mg/day for two weeks.
88807305|NCT05143502|Active Comparator|Control Group|Subjects in treatment group B will receive topical and systemic steroids in an identical regimen only.
89351654|NCT02526875|Active Comparator|morning|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 am to 10 am, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
89351655|NCT05570877|Experimental|Active group|Active group will apply ChitoCare medical Wound Healing Gel to the wound in addition to standard of care.
89351656|NCT05570877|No Intervention|Control group|Control group will only administer standard of care to treat their wounds.
89351657|NCT03380494|Experimental|Overhead perturbation training technique|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied with a weight and resistance band- such that the glenohumeral joint is exposed to a perturbed stimulus and has to utilise proprioception and motor control to correct arm position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
89351658|NCT03380494|Active Comparator|Non-perturbed exercise|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied via a weight held in the hand- such that the glenohumeral joint is exposed to a load but without a perturbation of joint position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
89351659|NCT01267097|Experimental|Cognitive Behavioural Therapy (CBT)|Group-based lifestyle counseling for parents
89351660|NCT01267097|Experimental|Psycho-Education Program (PEP)|Group-based lifestyle counseling for parents
89351661|NCT04222699|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
89351662|NCT03637179|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
89351663|NCT03637179|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
89351664|NCT01269203|Active Comparator|Curcumin|1000 mg/day Curcumin + 5 -15 mg/day Lenalidomide
89351665|NCT01269203|Placebo Comparator|Placebo|Placebo daily + 5 -15 mg/day Lenalidomide
89351666|NCT05569083||Patients with Subjective Cognitive Decline|Patients complaining about cognitive decline with normal functioning on the activities of daily living and unsatisfied criteria for MCI or dementia at baseline.
89351667|NCT05569083||Patients with Mild Cognitive Impairment|Patients diagnosed with MCI
89351668|NCT05569083||Healthy controls|
89351669|NCT01160627|Active Comparator|Standard treatment|Hydration
89351670|NCT01160627|Active Comparator|Combined Acetylcystein and Sodium Bicarbonat|
89351671|NCT01160627|Active Comparator|Sodium Bicarbonate|
89351672|NCT01160627|Active Comparator|Acetylcystein for 2 days|Standard treatment + acetylcystein for 2 days
89351673|NCT03985813|Experimental|Screening Wizard|Youth and parents receiving Screening Wizard will be screened for depression and suicidal risk within their pediatric primary care provider's office. Screening will be analyzed in real-time to produce a decision support tool meant to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
89351674|NCT02731690|Experimental|Open Label UX001, 6g/day|
89351675|NCT03909581|Active Comparator|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization
89351676|NCT03909581|Active Comparator|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator
89351677|NCT05568849|Experimental|OCTA measurement arm|There is only one arm in the study and patient care will not be changed. Additional measurements will be obtained over and above usual patient care in the OCTA measurement arm as detailed in the protocol.
89351678|NCT05567211|No Intervention|Control group|Will receive basic recommendations from the World Health Organization on healthy eating and physical activity.
89351679|NCT05567211|Placebo Comparator|Control group with free use of the virtual platform|The athletes, in addition to the recommendations indicated in the previous point, will have access to the virtual platform designed to voluntarily record the parameters they consider appropriate.
89351680|NCT05567211|Active Comparator|Intervention group with Mediterranean diet and physical exercise planning|They will receive nutritional plans adapted to their energy expenditure and based on Mediterranean diet. The physical exercise intervention will be based on 3 weekly sessions of 50 minutes of combined resistance and strength, deferred.
89351681|NCT05567211|Active Comparator|Intervention group with red berries and physical exercise planning|They will also receive personalized nutritional plans with a diet rich in antioxidants obtained from red berries and the same physical exercise intervention as in the Mediterranean diet intervention group.
89351682|NCT01252979|Experimental|Medium Chain Triglyceride|
89351683|NCT04075513|Experimental|Toujeo|Toujeo (Insulin Glargine, 300 U/ml) subcutaneous (SC) injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
89351684|NCT04075513|Active Comparator|Tresiba|Tresiba (Insulin Degludec, 100U/ml) SC injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
89351685|NCT03874871||Function preserving gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients indicated for function preserving gastrectomy (including pylorus preserving gastrectomy, proximal gastrectomy, partial gastrectomy), they will receive the function preserving gastrectomy. After the surgery, a close follow up is performed.
89351686|NCT03874871||Standard gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients not indicated for function preserving gastrectomy, they will receive standard gastrectomy. After the surgery, a close follow up is performed.
89351687|NCT04619823|Other|Patient infected by arboviruses|
89351688|NCT03388996||Benign ovarian disease|The group consists of patients of benign ovarian diseases and health conditions (eg infertility), who would accept the tests of pelvic microbiomes.
89351689|NCT03388996||Malignant ovarian disease|The group consists of patients of high grade serous carcinoma, who would accept the tests of pelvic microbiomes.
89351690|NCT03877523|Experimental|Cocarnit|disodium adenosine triphosphate trihydrate 10mg, cocarboxylase 50mg, cyanocobalamin 500mg and nicotinamide 20mg
89351691|NCT01313715|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 children aged 13-60 months old on day0,28
89351692|NCT01313715|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 children aged 13-60 months old on day0,28
89351693|NCT01313715|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 children aged 13-60 months old on day0,28
89351694|NCT01313715|Experimental|160U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 infants aged 6-12 months old on day0,28
89351695|NCT01313715|Experimental|320U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 infants aged 6-12 months old on day0,28
89351696|NCT01313715|Experimental|640U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 infants aged 6-12 months old on day0,28
89351697|NCT01313715|Placebo Comparator|0/0.5ml placebo in children|0/0.5ml placebo in 45 children aged 13-60 months old on day0,28
89351698|NCT01313715|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 45 infants aged 6-12 months old on day0,28
89351699|NCT03388918|Experimental|Intervention group|"The intervention group has three steps:~Step I: Titration of medicine ( 0-3 months)~Step II: Telerehabilitation program at healthcare center or by call center ( 3 months)~Step III: Rehabilitation in everyday life ( 6 months)~The patients is monitoring vital signs such as blood pressure, pulse, weight, steps, respiration, and sleep. Have access to a Heart Portal that is an information cite on heart failure. Via the portal patients can see measured values & communicate with staff. Every other week the patients fill in an online questionnaires on symptoms, sleep and well being."
89351700|NCT03388918|No Intervention|Traditional rehabilitation group|"This group follows the International Cardiac Guidelines. There are three steps in this arm:~Step I: Titration of medicine (3 months).~Step II: Traditional rehabilitation at the healthcare center ( 3 months).~Step III: Everyday life with HF ( 6 months)~The participants do not have access to the Heart Portal and is not monitoring any vital signs."
88811815|NCT00825266|Active Comparator|bosentan|Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
88811816|NCT00825266|Active Comparator|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
89351701|NCT03877679|Experimental|turmeric paste|Topical curcumin gel (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University traumeric extracted from Curcuma plant, it has anti-inflammatory, antioxidative and antineoplastic properties ((Nosratzehi et al., 2018), The curcumin is safe even in high doses, Since oxidative stress may play a role in pathophysiology of OLP, and by noting that OLP is a chronic inflammatory disease, the herbs which have both anti-inflammatory and antioxidant properties may efficiently control OLP (Kia et al., 2015).
89351702|NCT03877679|Active Comparator|Triamcenolone in orabase|Triamcenolone + na ploycarboxylate
89351703|NCT03330249|Experimental|Split Cisplatin and radiotherapy|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy
89351704|NCT03330249|Active Comparator|Cisplatin and radiotherapy|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy
89351705|NCT04652206|Experimental|SCO-101 in combination with gemcitabine and nab-paclitaxel|"Patients receive escalating doses of SCO-101 in combination with the standard recommended dose of gemcitabine and nab-paclitaxel according to local clinical practice. Gemcintabine and nab-paclitaxel is the recommended treatment for the patient group.~Starting dose of SCO-101 is 150 mg. Maximum dose tested is 350 mg. The dose is increased with 50 mg increments between each cohort."
89351706|NCT01269281|Experimental|Sumatriptan Succinate tablets 100 mg|Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited
89351707|NCT01269281|Active Comparator|Imitrex 100 mg Tablets|Imitrex 100 mg Tablets of Glaxosmithkline
89351708|NCT03385018|Experimental|Laparoscopic group|Arm Description: Laparoscopic radical total gastrectomy with D2 (or D2-#10) lymph node dissection
89351709|NCT03385018|Active Comparator|Open group|Open radical total gastrectomy with D2 (or D2-#10) lymph node dissection
89351710|NCT04073407|Active Comparator|AXA1957|AXA1957 20.4g
89351711|NCT04073407|Placebo Comparator|Placebo|Placebo 24g
89351712|NCT02778204|Experimental|Cohort 1 Stratum 1A|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; without in utero exposure to maternal efavirenz.
89351713|NCT02778204|Experimental|Cohort 1 Stratum 1B|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; with in utero exposure to maternal efavirenz.
89351714|NCT02778204|Experimental|Cohort 2 Stratum 2A|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; without in utero or breast milk exposure to maternal efavirenz.
89351715|NCT02778204|Experimental|Cohort 2 Stratum 2B|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; with in utero and breast milk exposure to maternal efavirenz
89351716|NCT03874403|Experimental|NIVATS|Patients receiving Non-intubated VATS with DSA changes
89351717|NCT03874403|Other|Intubated VATS|Patients receiving intubated VATS with DSA changes
89351718|NCT04578028|Experimental|ONO-2808 Part A - Fasted|Single ascending doses of ONO-2808 or placebo orally under fasted conditions. Additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.
89351719|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part A- Fasted|Single ascending doses of ONO-2808 or placebo orally under fasted conditions
89351720|NCT04578028|Experimental|ONO-2808 Part A - Fed|Single ascending doses of ONO-2808 or placebo orally under fed conditions
89351721|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part A - Fed|Single ascending doses of ONO-2808 or placebo orally under fed conditions
89351722|NCT04578028|Experimental|ONO-2808 Part B|Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers .
89351723|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part B|Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers
89351724|NCT04578028|Experimental|ONO-2808 Part C|Multiple ascending doses of ONO-2808 or placebo orally
89351725|NCT04578028|Placebo Comparator|ONO-2808 Placebo Part C|Multiple ascending doses of ONO-2808 or placebo orally
89351726|NCT04072159|Experimental|Pharmacist-Administered HPV Vaccine Series Completion group|For the Pharmacist-Administered HPV Vaccine Series Completion group (intervention group), primary care providers will refer patients who have received the initial HPV vaccine to receive the additional doses at patients' community retail pharmacies. Patients between ages 9-14 will need to receive one additional HPV vaccine dose with their community pharmacist 6-12 months after receiving Dose 1. Patients aged 15 and older will need to receive the 2nd dose 1-2 months after receiving the first HPV vaccine dose and the 3rd dose 6-months after receiving the initial dose.
89351727|NCT04072159|No Intervention|Primary Care Provider HPV Vaccine Series Completion|Participant in the Primary Care Provider HPV Vaccine Series Completion (control group) will receive standard care and will be scheduled to return to the clinic for the remaining HPV vaccine doses.
89351728|NCT03232281|Experimental|Triptorelin pamoate PR 3-month|Subjects received 15 mg triptorelin pamoate per injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections, at baseline and Week 12).
89351729|NCT03232281|Active Comparator|Triptorelin acetate PR 1-month|Subjects received 3.75 mg triptorelin acetate per injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections, at baseline and Weeks 4, 8, 12, 16 and 20).
89351730|NCT04572126|Experimental|Mindfulness Group|Participants in the mindfulness group will receive mindfulness based instructions.
89351731|NCT04572126|Active Comparator|Control Group|Participants in the control group will receive instructions to cope with cravings how they normally would.
89351732|NCT01253057||Experimental Group|
89351733|NCT01253057||Control Group|
89351734|NCT04071301|Experimental|Investigational Device|TENA SmartCare Change Indicator
89351735|NCT03261336|Experimental|Calcitriol, Ketoconazole, Hydrocortisone|Patients receive calcitriol (10mcg QD X3 weekly) in addition to ketoconazole (400mg QD) and hydrocortisone (20mg AM, 10 mg PM).
89351736|NCT03388840|Experimental|Adipose derived stem cells suspention|suspension rich in adipose derived stem cells plus platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
89351737|NCT03388840|Active Comparator|Platelet rich plasma|platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
89351738|NCT03745417|Experimental|UCMSCs group|Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks.
89351739|NCT01269359||radiation|
89351740|NCT03960255||Normal adiposity group|Body fat < 25% and <32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
89351741|NCT03960255||High adiposity group|Body fat ≥ 25% and ≥32% in men and women respectively, will be categorized as high adiposity. This is according to the The American Council on Exercise criteria.
89351742|NCT03384862|Experimental|Nutritional Intervention Arm|5 μg vitamin B12 plus 400 μg folic acid
89351743|NCT03384862|Placebo Comparator|Control Arm|Placebo
89351744|NCT03909191||treatment-naïve|treatment-naïve patients with chronic HBV infection
89351745|NCT03909191||NAs treated CHB patients|CHB patients undergoing long-term NAs treatment
89351746|NCT05513235|Experimental|Intervention|Parents of eligible children and youth with special healthcare needs will use a digital personal record mobile application to coordinate care for six months.
89351747|NCT01269437|Experimental|Budesonide, Novolizer|Budesonide Dry Powder Inhaler
89351748|NCT01269437|Active Comparator|BudesonideTurbuhaler|Budesonide Dry Powder Inhaler
89351749|NCT03636867||data and specimen collection|consecutive diabetic patients admitted to Maria Cecilia Hospital for critical limb ischemia
89351750|NCT03909269||Haemodialysis and type 2 diabetes|On chronic haemodialysis and type 2 diabetes
89351751|NCT03909269||Control group|Type 2 diabetes and with eGFR above 60ml/min
89351752|NCT00462748|Experimental|1|Arm 1: Drug
89351753|NCT00462748|Active Comparator|2|Arm 2: Active comparator
89351754|NCT00462748|Active Comparator|3|Arm 3: Active comparator
89351755|NCT04206085|Experimental|Active treatment|Radiofrequency and Cryogen
89351756|NCT04206085|Active Comparator|Cryogen-Only|Crygen-Only
89351757|NCT04206085|Sham Comparator|Sham|Sham comparator
89351758|NCT01161017|Active Comparator|1 Amitriptyline.|Amitriptyline
89351759|NCT01161017|Active Comparator|2 Topiramate|Topiramate
89351760|NCT03874559||Arm A|All patients enrolled will be placed in Arm A. Serum blood draw samples will be collected as well as additional data from medical records will be collected. This data includes demographic data, clinical information from notes, radiology images and reports, diagnostic test results, and procedure and pathology reports.
89351761|NCT04202497|Experimental|TAK-418 1.5 mg|TAK-418 1.5 milligram (mg), orally, once on Day 1. Participants will also receive 10 millicurie (mCi) of [18F]MNI-1054 injection intravenously, prior to each PET scans on Day -1, Day 1, and either on Day 2 or 3. Dose levels for subsequent participants may vary based on available review of imaging and pharmacokinetics (PK) data.
89351762|NCT03935685|Experimental|mirtazapine in glioma patients treated with Temozolomide|Using the well-known Beck Depression Inventory, we will assess the changes in depression scores from baseline to after four and eight weeks of treatment with mirtazapine. We will also assess the change in nausea, vomiting, and weight at the same time points, and collect information on tolerability of mirtazapine throughout the course of the study.
89351763|NCT01164917|Active Comparator|AMG811|All will receive AMG 811, either on Day 1 or Day 85
89351764|NCT01164917|Placebo Comparator|AMG811 Placebo|All will receive placebo, either on Day 1 or Day 85
89351765|NCT03297294|Experimental|EMA401|During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.
89351766|NCT03297294|Placebo Comparator|Placebo|Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.
89351767|NCT03874637|Experimental|Treatment|Active therapy
89351768|NCT03874637|Sham Comparator|Sham Control|Sham Control
89351769|NCT01161095|Experimental|Immediate|LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
89351770|NCT01161095|Active Comparator|Interval|LNG-IUS insertion after 6 weeks postpartum
89351771|NCT03238911|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
89351772|NCT03238911|Active Comparator|Ferric carboxymaltose|Administered IV
89351773|NCT03909113|Experimental|amino acid based formula|amino acid based formula
89351774|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART-|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
89351775|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART-|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
89351776|NCT01269515|No Intervention|Control ART-|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
89351777|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART+|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
89351778|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART+|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
89351779|NCT01269515|No Intervention|Control ART+|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
89351780|NCT00418834|Active Comparator|1|
89351781|NCT00418834|Active Comparator|2|
89351782|NCT03908957|Experimental|Ga68-Dolacga Injection|The healthy volunteer was injected with Ga68-Dolacga Injection iv and performed PET imaging for liver reserve evaluation.
89351783|NCT03908801|Experimental|Intervention|Specialized water dance intervention
89351784|NCT03908801|No Intervention|Control|No intervention
89351785|NCT01267331|Experimental|stem cells injection|Direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG
89351786|NCT01267331|Placebo Comparator|palcebo intramyocardial injection|Direct intramyocardial injection of placebo containing saline and 5% human serum albumin during CABG.
89351787|NCT01269671|Experimental|Melatonin, Peppermint Oil, Simethicone|
89351788|NCT01269671|Placebo Comparator|Sugar pill|
89351789|NCT04407286|Experimental|Treatment Group|"This group will receive vitamin D.~The dosage for the first two weeks will be 10,000 IU/day b.i.d. (age 18-69 years) or 15,000 IU/day t.i.d. (age 70+)~After two weeks of taking vitamin D, if vitamin D levels are still below 30 ng/ml, continue the dosage for 3 more weeks. If vitamin D levels are 30-49 ng/ml, continue at a dosage of 5000 IU/day. If vitamin D levels are 50+ ng/ml, stop supplementation."
89351790|NCT03276975|Active Comparator|Patching of CSF Leaks with Autologous Blood and Fibrin|CT fluoroscopy-guided blood and fibrin glue patching targeted to the site of CSF leak.
89351791|NCT03276975|Placebo Comparator|Simulated Patching Procedure|Instead of injection of blood and fibrin glue patching material through the needles, an equivalent volume of preservative free sterile Elliots B solution will be injected.
89351792|NCT03380416|Experimental|Portfolio Diet|The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)
89351793|NCT03380416|Active Comparator|MUFA Diet|The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)
89351794|NCT03125746|Experimental|LXI-15029|
89351795|NCT03125746|Experimental|LXI-15029+Exemestane|
89351796|NCT03877601|Experimental|Topical administration of bevacizumab-800CW|The tracer will be topically administered 5 minutes prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform).
89351797|NCT03380338|Experimental|Exercise program|Twice weekly exercise program, combined aerobic and strenght training
89351798|NCT01161251||Atrial fibrillation patients|Non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
89351799|NCT03297216|Active Comparator|250 mg 17P|weekly intramuscular injection of 250mg 17P
89351800|NCT03297216|Placebo Comparator|Placebo|weekly intramuscular injection of indistinguishable placebo
89351801|NCT03908645|Experimental|Artificial Intelligence assisted Scoring Group|Patients in this group go through colonoscopy under the AI monitoring device.
89351802|NCT03908645|Active Comparator|Conventional Human Scoring Group|Patients in this group go through conventional colonoscopy without AI monitoring device.
89351803|NCT03125668|Experimental|Intervention Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive a telephone follow-up (five calls) and two Face to face counseling.
89351804|NCT03125668|Active Comparator|Control Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive two face to face counseling.
89351805|NCT01165073|Experimental|Naso-gastric tube feeding|
89351806|NCT01165073|Active Comparator|Oral feeding|
89351807|NCT03872219|Placebo Comparator|Placebo|The children will receive and they are exposed daily to harmless materials that look and feel like the biodiversity intervention materials.
89351808|NCT03872219|Experimental|intervention arm|The children will receive and they are exposed daily to materials of high microbiological biodiversity.
89351809|NCT05174104|Experimental|Early Vestibular Rehabilitation|This group will undergo a 4 weeks of vestibular rehabilitation in the first month and then it will be only followed up in the second month
89351810|NCT05174104|Experimental|Delayed Vestibular Rehabilitation|This group will be followed-up for the first month and the it will undergo 4 weeks of vestibular rehabilitation in the second month
89351811|NCT01165151|Experimental|Small group|10-member groups
89351812|NCT01165151|Active Comparator|Large group|30-member groups
89351813|NCT03388528|Experimental|Treatment Group|This is a single arm study where forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial CRESTA clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle. All forty patients will be assessed prior to and following a 12 week low residue diet study intervention.
88811817|NCT05235932|Experimental|Robotic radical total gastrectomy with D2 lymphadenectomy|After exploration and randomization, patients received robotic radical total gastrectomy with D2 lymphadenectomy
89351814|NCT03260868|Experimental|Virtual|Participants included in this virtual trial approach group did not visit the study sites during the study course. All study assessments, including vital signs, weight, laboratory variables, etc., were completed via the Bluetooth devices that instantly transfer the digital data.
89351815|NCT03260868|Active Comparator|Traditional|Participants included in this traditional trial approach group visited the study site, followed the study visit schedules for all study assessments that was performed either in-person or phone visits.
89351816|NCT01165385|Experimental|Pazopanib and Cisplatin|"Steady state period:Pazopanib will be given 8 days prior to cisplatin~Then pazopanib will be given 400 mg, 600 mg or 800 mg/day, daily and cisplatin 60, 75 or 100 mg/m2 , day 1 - 3 weekly, depending of the dose level"
89351817|NCT03380260|Experimental|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
89351818|NCT03380260|No Intervention|Control Condition|No manipulation of paranoid ideation
89351819|NCT03380182|Experimental|Acupuncture/Acupressure Group|Bilateral P6 point acupuncture will be performed intra-operatively by the PI, who has UC Davis Medical Center privilege for this specific acupuncture, while the patient is under anesthesia. Patient will be sent home with an acupressure band, which is to remain on for 24 hours post operatively.
89351820|NCT03380182|Sham Comparator|Control Group|Bilateral sham point acupuncture will be performed intra-operatively. Patient will be sent home with a wrist sham band matching in appearance of acupressure bands without the acupressure function, which is to remain on for 24 hours post operatively.
89351821|NCT03872141||patients with stage I-III breast cancer|Patients with Stage I-III breast cancer who will receive paclitaxel or docetaxel treatments as part of their standard of care adjuvant or neoadjuvant therapy are eligible for this study.
89351822|NCT03384628|Active Comparator|First Pair Senofilcon A contact lens|The first pair of Senofilcon A contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the first pair Senofilcon A contact lens and subsequent removal.
89351823|NCT03384628|Active Comparator|Second pair Senofilcon A contact lens|The second pair of contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the second pair Senofilcon A contact lens and subsequent removal.
89351824|NCT03384628|Active Comparator|Third pair Senofilcon A contact lens|The third pair of Senofilcon A contact lens is applied (according to the fitting schedule), allowed to settle before assessment of the third pair Senofilcon A contact lens and subsequent removal.
89351825|NCT03293394|Experimental|Real tDCS|10 days anodal bilateral motor cortex and cathodal spinal tDCS
89351826|NCT03293394|Placebo Comparator|Sham tDCS|10 days sham bilateral motor cortex and sham spinal tDCS
89351827|NCT01267487|Active Comparator|Fixed doses plus PO protamine|"Intraoperative fixed dose schemes (as in fixed doses plus placebo group) plus continuous infusion of 25mg/hour of protamine during first 6 PO hours"
89351828|NCT01267487|Active Comparator|Titrated doses plus PO protamine|"Same as titrated doses arm, plus continuous infusion of 25mg/ hour of protamine during first 6 PO hours"
89351829|NCT01267487|No Intervention|Fixed doses plus placebo|"Before CPB, fixed heparin dose of 400 Units per kg of body weight to achieve an Activated Coagulation Time (ACT) > 480 seconds.~Reversal of heparin after CPB using 1 : 1 ratio (1 mg of protamine for each 100 units (1mg) of heparin), plus 0.8 mg/kg of protamine at the end of the surgery.~Continuous infusion of placebo (saline 0.9%) during the first 6 PO hours."
89351830|NCT01267487|Active Comparator|Titrated doses plus placebo|"Titrated doses of heparin before and during CPB and reversal with protamine after CPB calculated by the construction of individualized Bull's dose-response curve.~Continuous infusion of placebo (saline 0.9%) during first 6 PO hours."
89351831|NCT05173948|Experimental|Kinesio taping and Conventional Physical therapy|Kinesio taping with Transcutaneous Electrical Nerve Stimulation and Supervised Exercise therapy
89351832|NCT05173948|Experimental|Conventional Physical therapy|Transcutaneous Electrical Nerve Stimulation and Supervised Exercise therapy
89351833|NCT01267565|Other|intubated and ventilated patients|patients undergoing mechanical ventilation for an anticipated length of more than 48h
89351834|NCT01267565|Other|non intubated patients|non intubated patients with an independant indication of bronchoscopy including an endotracheal aspiration during the procedure
89351835|NCT03380104|Experimental|Single Arm|Intradural Spinal Cord Stimulation; Administration of Questionnaires
89351836|NCT01267643|Experimental|Alefacept|
89351837|NCT03620604||Stress urinary incontinence surgery|This is a single observational study were all patients had stress urinary incontinence. All of them underwent surgery performing a single incision sling type ALTIS
89351838|NCT03388450|Active Comparator|Omega 3|Patients received enteral nutrition supplemented with 1000 mg omega-3.
89351839|NCT03388450|Placebo Comparator|Placebo|Patients received enteral nutrition supplemented without 1000 mg omega-3.
89351840|NCT03874481||PCI|Patients who had stent
89351841|NCT05173402||The experimental group|The experimental group included 26 patients - orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw.
89351842|NCT05173402||The comparison group|The comparison group included 20 patients - orthopedic treatment was performed using a face mask.
89351843|NCT01269827|Experimental|pentoxifylline|
89351844|NCT01269827|Placebo Comparator|placebo|
89351845|NCT03388372|Experimental|Nimotuzumab plus RT and temozolomide.|Nimotuzumab, administered once a week intravenously in addition to radiotherapy with concomitant and adjuvant temozolomide (TMZ) after surgery.
89351846|NCT01161485|Active Comparator|HIV Testing and Counseling|HIV Testing and Counseling
89351847|NCT01161485|Active Comparator|Contingency Management (CM)|Contingency management is based on Skinner's principles of operant conditioning in behavioral psychology, dating back to the 1930s (Skinner 1938). The basis of this model is that behavior is learned and reinforced by environmental contingencies that reward or punish.
89351848|NCT01161485|Experimental|CM with Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community.
89351849|NCT03379948||Group 1 with central venous line|lab investigation Complete blood count blood culture
89351850|NCT03379948||Group 2 with only peripheral line|lab investigation Complete blood count blood culture
89351851|NCT03259308|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
89351852|NCT03259308|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using PFS on Week 0, Week 4 and Week 8.
89351853|NCT03259308|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab SC injection using PFS on Week 0, Week 4, and Week 8.
89351854|NCT01280279||group with nocturnal polyuria and nocturia|Patients were enrolled when they had the urine volume at nighttime more than one third of total daily urine volume (NPU) and voided more than two times at nighttime (nocturia)
89351855|NCT05173246|Experimental|JS001 Combined With TP|recombinant humanized anti-PD-1 monoclonal antibody for injection (JS001) in combination with nab-paclitaxel and cisplatin or carboplatin for injection
89351856|NCT01167101|Other|Pantoprazole|controls Pantoprazole 40mg qd for 28days
88811818|NCT05235932|Active Comparator|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|After exploration and randomization, patients received laparoscopic radical total gastrectomy with D2 lymphadenectomy
89351857|NCT01167101|Active Comparator|Pantoprazole + Rebamipde|Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days
89351858|NCT01165463|Experimental|Clinic-based SOPT basic training|Clinic-based SOPT basic training for 10 hours.
89351859|NCT01165463|Experimental|Home-based SOPT basic training|Home-based SOPT basic training for 10 hours.
89351860|NCT01165463|Active Comparator|Crossword Puzzles Training|Crossword puzzles training for 10 hours in our lab.
89351861|NCT01165463|Experimental|SOPT basic and SOPT booster-training|Clinic-based SOPT basic training and SOPT booster training.
89351862|NCT03388216|Experimental|Stage I - Drug: INM004 Dose 1|
89351863|NCT03388216|Placebo Comparator|Stage I - Placebo Dose 1|
89351864|NCT03388216|Experimental|Stage I- Drug: INM004 Dose 2|
89351865|NCT03388216|Placebo Comparator|Stage I- Placebo Dose 2|
89351866|NCT03388216|Experimental|Stage II- Drug: INM004 Repeated Dose|
89351867|NCT03388216|Placebo Comparator|Stage II- Placebo Repeated Dose|
89351868|NCT01269905||Group A|Group A patients received mechanical heart valve replacement MHVR (and were educated in INR self-management using the Coagu-Check monitor.
89351869|NCT01269905||Group B|Group B patients received MHVR and their anticoagulation was managed by their general practitioners.
89351870|NCT01269905||Group C|Group C patients received stentless bioprosthesis, with initial 6 weeks on oral anticoagulation managed by their general practitioners.
89351871|NCT01267721||Study Group|A single group of 100 consecutive patients will undergo additional blood sampling at different time points
89351872|NCT05173090|Active Comparator|Ropivacaïne 0,5%|3 mg/kg of ropivacaine 0.5% sprayed into the abdominal cavity
89351873|NCT05173090|Placebo Comparator|NaCl 0,9%|NaCl 0,9% sprayed into the abdominal cavity
89351874|NCT03384550|Active Comparator|Control|"Participants in this arm receive no incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
89351875|NCT03384550|Experimental|Financial Incentives|"Participants in this arm receive financial incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
89351876|NCT03384550|Experimental|Charity Incentives|"Participants in this receive charity incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
89351877|NCT03877367|Experimental|Upper Extremity Group, Day 1|"Day 1: This group will receive a pre-test, upper extremity intervention, and post-test.~Day 2: This group will receive a pre-test, lower extremity intervention, and post-test."
89351878|NCT03877367|Experimental|Lower Extremity Group, Day 2|"Day 1: This group will receive a pre-test, lower extremity intervention, and post-test.~Day 2: This group will receive a pre-test, upper extremity intervention, and post-test."
89351879|NCT03877445|Other|Melasma Group exposed left half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
89351880|NCT03877445|Other|Melasma Group exposed right half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
89351881|NCT03388060|Active Comparator|Ultrasound guided SWL|ultrasound guided SWL for Radiolucent stone
89351882|NCT03388060|Active Comparator|Dissolution therapy|Dissolution therapy for Radiolucent stone
89351883|NCT03388060|Active Comparator|Combined ultrasound guided SWL and dissolution therapy|Combined treatment for Radiolucent stone.
89351884|NCT02526953|Experimental|Paclitaxel|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of paclitaxel 45 mg/m2 on days 3,10,17,24,31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1.
89351885|NCT02526953|Active Comparator|Standard|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of capecitabine 825 mg/m2 bid on treatment days and mitomycin C 12 g/m2 on day 1.
89351886|NCT04343638|Active Comparator|conventional nociception control arm|Intraoperative opioid will be administered by conventional clinical practice. ANI monitor readings will not be visible to the anesthesiologist.
89351887|NCT04343638|Experimental|ANI-monitor guided nociception control arm|Intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50.
89351888|NCT03874247|Experimental|Pelubiprofen|
89351889|NCT03874247|Placebo Comparator|Pelubiprofen placebo|
88811819|NCT01385189|Experimental|Cohort 1|10 μg Na-GST-1/Alhydrogel vs. 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
88811820|NCT01385189|Experimental|Cohort 2|30 μg Na-GST-1/Alhydrogel vs. 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
89351890|NCT01269983|Experimental|fascial manipolation|8 treatment sessions: 4 of fascial manipulation treatment, and 4 of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
89351891|NCT01269983|Active Comparator|physiotherapy|8 treatment sessions of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
89351892|NCT03258762|Experimental|Healthy Japanese male subjects|Healthy Japanese male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
89351893|NCT03258762|Experimental|Healthy Caucasian male subjects|Healthy Caucasian male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
89351894|NCT03871985|Experimental|Lavage combined with aspiration|Intermittent subglottic secretions lavage combined with aspiration
89351895|NCT03871985|Active Comparator|Pure aspiration|Intermittent subglottic secretions aspiration
89351896|NCT03379714||Patients with ruptured or unruptured intracranial aneurysms|
89351897|NCT05427669|Experimental|mFOLFOXIRI|Patients will receive mFOLFOXIRI chemotherapy once every two weeks for at the most 12 cycles as adjuvant therapy
89351898|NCT05427669|Active Comparator|mFOLFOX6|Patients will receive mFOLFOX6 chemotherapy once every two weeks for at the most 12 cycles as adjuvant therapy
89351899|NCT01280513|Experimental|High Protein intake|
89351900|NCT01280513|Experimental|Low Protein intake|
89351901|NCT03379636|No Intervention|no tape|tests are realised without any shoulder tape
89351902|NCT03379636|Experimental|kinesiotape|tests are realised with a kinesiotape applied according to Dr Kase model, over the deltoid muscle and over the acromioclavicular joint
89351903|NCT03379636|Sham Comparator|sham tape|tests are realised with a sham tape, applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area
89351904|NCT01270373|Active Comparator|FAC x 3 followed by Docetaxel x 3|
89351905|NCT01270373|Experimental|Docetaxel x 3 followed by FAC x 3|
89351906|NCT03669237|Experimental|end-to-side anastomosis|All surgeries during the study were performed by the same experienced surgical team and were performed following TME principles. End-to-side anastomosis was used to perform colorectal anastomosis after primary tumor resection.
89351907|NCT03669237|No Intervention|end-to-end anastomosis|All surgeries during the study were performed by the same experienced surgical team and were performed following TME principles. After resection of the primary tumor, end-to-end anastomosis was used for colorectal anastomosis.
88811821|NCT01385189|Experimental|Cohort 3|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
89351908|NCT03713086|Active Comparator|Rabipur®|
89351909|NCT03713086|Experimental|CV7202 Dose level 1|
89351910|NCT03713086|Experimental|CV7202 Dose level 2|
89351911|NCT03713086|Experimental|CV7202 Dose level 3|
89351912|NCT05172856|Experimental|IBI321 in advanced solid tumors|
89351913|NCT01271231|Placebo Comparator|Group IP1|
89351914|NCT01271231|Experimental|Group IP2|
89351915|NCT01271231|Active Comparator|Group IP3|
89351916|NCT04575285||Electroencephalogram (EEG)|All participants will undergo EEG recording at baseline and end of treatment for a duration of 10-20 minutes per session.
89351917|NCT04132596|Experimental|Motor Complete Tetraplegia|C4-T1 American Spinal Injuries Association (ASIA) Impairment Scale Classification A or B spinal cord injury tscs with activity based therapy intervention
89351918|NCT04132596|Experimental|Motor Complete Paraplegia|T2-12 ASIA Impairment Scale A or B spinal cord injury tscs with activity based therapy intervention
89351919|NCT04132596|Experimental|Motor incomplete SCI|C4-T12 ASIA Impairment Scale C or D spinal cord injury tscs with activity based therapy intervention
89351920|NCT01271309||Acute Myocardial Infarction patients|Patients with thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
89351921|NCT03384394|Placebo Comparator|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
89351922|NCT03384394|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
89351923|NCT01271699||Observation|Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria for MS
89351924|NCT03379558||Cohort 1 : alirocumab exposed|Pregnant women diagnosed with primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and exposed to alirocumab during the current pregnancy.
89351925|NCT03379558||Cohort 2 : disease matched comparison|Pregnant women diagnosed of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and unexposed to alirocumab during the current pregnancy.
89351926|NCT03379558||Cohort 3 : non disease comparison|Healthy pregnant women who do not have a known diagnosis of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and have no known exposure to a known human teratogen.
89351927|NCT01169909|Experimental|Ranibizumab treatment|Patients will receive a sub-tenons injection of Ranibizumab 0.5mg, to be repeated twice with 30 day intervals between each dose.
89351928|NCT03379480|Active Comparator|Yoga arm|Patients with Schizophrenia will undergo 12 sessions of yoga. According to randomization one group of patients will start yoga immediately after recruitment ,whereas another group will go into wait list for 12 weeks after which they will also undergo Yoga treatment.
89351929|NCT03379480|No Intervention|Control arm|Healthy volunteers who will not receive yoga.
89351930|NCT04502589|Active Comparator|perampanel by itself|
88811822|NCT01385189|Experimental|Cohort 4|100 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
89351931|NCT04502589|Active Comparator|Perapanel with Disulfiram|
89351932|NCT01586663|Experimental|Experimental Group|Splint group
89351933|NCT01586663|Active Comparator|Control Group|Drug treatment
89351934|NCT05172622|Experimental|JP-2266|Drug: JP-2266
89351935|NCT05172622|Placebo Comparator|JP-2266 Placebo|Drug: JP-2266 Placebo
89351936|NCT03387904|Experimental|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt. Both should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89351937|NCT03387904|Active Comparator|Irinotecan|Irinotecan Day 1,8 ivgtt and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
89351938|NCT01283165||health education|This was an intervention follow up Knowledge Attitude and Practice study that investigated the distribution of polyparasitism with schistosomiasis, STHs and P. falciparum among primary schoolchildren.
89351939|NCT03291288|Experimental|Pexidartinib|"Part 1 (Drug-drug Interaction Phase):~On Day 1, all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg). On Day 3, pexidartinib (800 mg/d) in twice daily (400 mg BID) dosing will be initiated and continue throughout the remainder of Part 1 and into Part 2. On the first day of pexidartinib treatment (Day 3), a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning pexidartinib dose (400 mg). On Day 13, a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning dose of pexidartinib (400 mg).~Part 2 (Efficacy and Safety Phase):~All participants will continue to receive pexidartinib 400 mg BID."
89351940|NCT05172310|Experimental|Cancer patients|"Adults with suspected cancer of either pancreas, bile ducts or stomach~Adults with primary and recurrent epithelial ovarian cancer (EOC)"
89351941|NCT05172310|Active Comparator|Non cancer patients|Non cancer patients operated for non-malignant diseases in pancreas during the same period of time will be investigated with the same procedure.
89351942|NCT03636711||experimental group|• Patient admitted to emergency for infectious syndrome Description of antibiotic protocol, according to a syndromic approach will be performed
89351943|NCT03869801|Active Comparator|ESP Block|
89351944|NCT03869801|Active Comparator|QLB block|
89351945|NCT03869723||Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
89351946|NCT03869723||Virtual planning|Fibula free flap in mandibular reconstruction using preoperative virtual planning, cutting guides and osteosynthesis plates. Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
89351947|NCT04084626|Experimental|PD-1 antibody|PD-1 antibody and lenalidomide administered in 2 week cycles for 6 cycles.
89351948|NCT03387826|Experimental|Ticagrelor|Ticagrelor 60mg twice daily followed by Prasugrel 5mg once daily
89351949|NCT03387826|Active Comparator|Prasugrel|Prasugrel 5m once daily followed by Ticagrelor 60mg twice daily
89351950|NCT03869411|Experimental|aerobic exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness. The aerobic exercise group will arranged to the supervised aerobic dance program, it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
89351951|NCT03869411|Experimental|home exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness.The home exercise group will give the exercise recommendation based on ACSM's guideline, and it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
89351952|NCT03869411|Active Comparator|health control group|This study will recruit subjects without type 2 diabetes and the age matched to the diabetes groups.
89351953|NCT04016454|Experimental|Intervention group|No handover of anesthesia care
89351954|NCT04016454|No Intervention|Control group|Complete handover of anesthesia care
89351955|NCT03387748|Experimental|Gesture elicitation|Observation: hand gesture elicitation task
89351956|NCT01280747||1|Eligible fibromyalgia patients receive usual care with pregabalin prior authorization requirements in place
89351957|NCT01280747||2|Eligible fibromyalgia patients receive usual care without pregabalin prior authorization requirements in place
89351958|NCT01280747||3|Eligible painful diabetic peripheral neuropathy patients receive usual care with pregabalin prior authorization requirements in place
89351959|NCT01280747||4|Eligible painful diabetic peripheral neuropathy patients receive usual care without pregabalin prior authorization requirements in place
89351960|NCT03379324|Active Comparator|Superiority of augmented repairs|Assess pain, function, and structural integrity of the rotator cuff at 3 months, 6 months, 1 year, and 2 years post-operation
89351961|NCT03379324|Active Comparator|Fat degeneration of supraspinatus muscle|MRI assessment the quantity and disposition of fat within the supraspinatus muscle body compared to pre-operation MRI, at 1 year and 2 years post-operation
89351962|NCT03953742|Experimental|CPI-200|"Dose Escalation Group: CPI-200 will be administered via intravenous infusion once every 3 weeks for up to 7 dose levels using an accelerated titration method followed by a conventional 3 + 3 study design~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
89351963|NCT01167335|Experimental|BGG492|
89351964|NCT01167335|Placebo Comparator|Placebo|
89351965|NCT03943914|Experimental|"An early NIV strategy associated with HFNC-O2"|
89351966|NCT03943914|Active Comparator|"A late NIV strategy associated with COT"|
89351967|NCT03872063|Experimental|Myofascial|Each session will last 17 minutes, taking place for 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the technique of myofascial induction and eccentric exercises will be performed.
89351968|NCT03872063|Active Comparator|Eccentric|Each session will have a duration of 9 minutes, taking place during 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the eccentric exercises will be performed.
89351969|NCT03930966|Experimental|PDEQ, PCL-5 and demographic survey|State of the patient evaluated with questionnaires to make the connection between peri-traumatic dissociation and the occurrence of post-traumatic stress disorder
89351970|NCT03871517|Experimental|Indobufen|Drug: Indobufen and aspirin mimetic Day 1 to 90±7: The first time : Indobufen 100mg + aspirin mimetic The second time: indobufen 100mg
89351971|NCT03871517|Active Comparator|Aspirin|Drug: Aspirin and Indobufen mimetic Day 1 to 90±7: The first time : aspirin 100mg+ Indobufen mimetic, The second time: indobufen mimetic.
89351972|NCT03387592|Active Comparator|FOLFIRI regimen|CPT-11 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by Calcio levofolinate 200 mg/m2, given as a 2h i.v. infusion on days 1 every 2 weeks followed by 5-Fluorouracil 400 mg/m2 given as bolus, and then 5-Fluorouracil 2400 mg/m2 given as a 48 h continuous infusion on day 1, every 2 weeks, until progression or for a maximum of 12 cycles
89351973|NCT03387592|Experimental|CAPTEM regimen|Capecitabine 750 mg/m2 twice a day on days 1-14 in combination with Temozolomide 200 mg/m2 daily on days 10-14, every 4 weeks, until progression or for a maximum of 6 cycles
89351974|NCT02501226|Other|Control group|Treatment as usual
89351975|NCT02501226|Experimental|Interventional group|ENVIE psychoeducational program
89351976|NCT01587053||AVK|patient with AVK treatment
89351977|NCT03384160|Active Comparator|Group 1-Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction
89351978|NCT03384160|Active Comparator|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction
89351979|NCT01587131|Experimental|Group 1- DNA prime DNA boost|0.9 mg of FVH1 vaccine delivered ID followed by electroporation on Day 0, Week 15 and Week 27
89351980|NCT01587131|Experimental|Group 2 - DNA prime Seasonal Vaccine boost|0.9 mg FVH1 vaccine delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
89351981|NCT01587131|Placebo Comparator|Group 3 - sWFI prime Seasonal Vaccine boost|100 microliters of sterile water for injection delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
89351982|NCT01165619||Hypothalamic Amenorrhea|This group is for pre-menopausal women between the aged 18-40 who have been previously diagnosed with Hypothalamic Amenorrhea. They can be currently diagnosed or may have recovered.
89351983|NCT01165619||Healthy Adult Men|This group is men over the age of 18 who do not have any history of reproductive disorders or chronic disease.
89351984|NCT01165619||Healthy Adult Women|This group is pre-menopausal, regularly menstruating women ages 18-40 who do not have a history of reproductive disorders or chronic disease.
89351985|NCT01165619||Idiopathic Hypogonadotropic Hypogonadism|This group is for adult men and women over the age of 18 who have been diagnosed with Idiopathic Hypogonadotropic Hypogonadism with or without anosmia.
89351986|NCT03387436|No Intervention|1.) Treatment as usual (TAU)|Patients assigned to this arm will receive palliative treatment as usual.
89351987|NCT03387436|Sham Comparator|2.) Sham-Intervention|Patients assigned to this arm will receive an sham intervention with unspecific supportive therapy (i.e. listening, empathy etc., but no specific intervention rationale) and palliative treatment as usual.
89351988|NCT03387436|Experimental|3.) Study-Intervention|Patients assigned to this arm will receive the study-intervention and palliative treatment as usual.
89351989|NCT04445818|Experimental|More Appreciation|"A 6-minute engaging video will be shown, illustrating examples where a mother initially withholds her appreciation for her son's effort in school and later express it. The video will also capture the effect on the child and the family. Attributional discussion questions will follow to elicit positive outcomes of expressing appreciation and the negative outcomes of withholding appreciation (e.g., What may be the long-term effects of showing appreciation on your child, family, or on yourself?). Key points will be summarised and reinforced to enhance behavioural intention (Schwarzer & Luszczynska, 2008). Then the participants will be asked to plan by indicating when (e.g., Saturday afternoon), what (e.g., child helping a younger sibling prepare for a dictation test), and how (e.g., I can see that you gave up your leisure time to help your sister with the spelling. Thank you!) they would express appreciation to their children."
89351990|NCT04445818|Experimental|Less Criticism|"Participants will watch a 6-minute video showing examples of a father criticising his son, which will be replaced by positive communication later, and the different reactions evoked in the child and the family. Then, participants will have an attributional discussion on the negative effects of criticism (e.g., negative effect on self-worth and motivation) and positive outcomes of using constructive feedback (e.g., promptly identifying undesirable behaviours without relating to personal traits or abilities). In small groups, they will work out alternatives (i.e., constructive feedback; termed positive reminder in the intervention) to criticism, and each plan and write down when (e.g., after school), what (e.g., low test marks), and how (e.g., How do you prepare for the tests?)"
89351991|NCT04445818|Experimental|Fruit and Vegetable|This workshop will emphasise the importance of consuming at least 5 portions of fruit and vegetable daily for a healthy diet, and aim to boost participants' self-efficacy in achieving this. Participants will be presented with examples of one portion of fruit or vegetable, and then create their own recipes. They will also consider how to overcome obstacles of consuming more portions. Each participant will set goals and write down plans on when, where, what, and how they would increase their fruit and vegetable intake of their children and family as a whole.
89351992|NCT03384082|Experimental|Hysteroscopic treatment|Hysteroscopic surgery
89351993|NCT03384082|No Intervention|Control group|No treatment
89351994|NCT04445506||SARS-CoV2 patients that received dexamethasone|
89351995|NCT01283243||HIV patients with normal liver status|HIV patients without abnormal liver function and chronic liver disease
89351996|NCT03387358||Historical Comparison Group|This group includes patients who were admitted to St. Paul's Hospital ICU (Vancouver BC, Canada) from September 2014 to September 2015, and had a small bore feeding tube in place at some point during their ICU admission, and were matched to key variables to the prospective observational treated group.
89351997|NCT03387358||Prospective Observational Treated Group|This group includes all patients who were admitted to St. Paul's Hospital ICU from Nov. 2017 to Dec. 2018, and nasal bridle securement device for small bore feeding tubes at some point during their ICU admission. The clinical indicators for a nasal bridle securement device outlined in our nursing practice standards include one or more of the following: recurrent nasoenteric tube dislodgement; confused and/or agitated patients; fluoroscopically or endoscopically placed nasoenteric tube; history of difficult tube placement; facial burn victims with nasoenteric tube; and/or oily skin causing decreased adhesion of traditional securement.
89351998|NCT03869489|Experimental|Anodal left dorsolateral prefrontal cortex tDCS stimulation|
89351999|NCT03869489|Experimental|Anodal right dorsolateral prefrontal cortex tDCS stimulation|
89352000|NCT03869489|Sham Comparator|Sham tDCS stimulation|
89352001|NCT03384004|Experimental|Irrigation Technique 1|Patients randomized into this group will be treated using EndoVac Pure followed by Ultrasonic Irrigation.
89352002|NCT03384004|Experimental|Irrigation Technique 2|Patients randomized into this group will be treated using EndoVac Pure only.
89352003|NCT01587365|Experimental|Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo|BMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
89352004|NCT01587365|Experimental|Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo|BMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
89352005|NCT01587365|Experimental|Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
89352006|NCT01587365|Experimental|Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
89352007|NCT01587365|Experimental|Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
89352008|NCT01587365|Experimental|Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo|BMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
89352009|NCT01587365|Experimental|Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
89352010|NCT01587365|Experimental|Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
89352011|NCT04445272|Experimental|Tocilizumab|"Patients will receive IV tocilizumab as per clinical practice and at the discretion of treating investigator, following the posology indicated in the SmPC, or the recommendations proposed by the Spanish Ministry of Health:~The recommended posology by the SmPC is 8 mg per kg in patients weighing greater than or equal to 30 kg or 12 mg per kg in patients weighing less than 30 kg. If no clinical improvement in the signs and symptoms up to 3 additional doses of tocilizumab may be administered. The interval between consecutive doses should be at least 8 hours.~The recommendations of the Spanish Ministry of Health:~Patients more than 80 kg: first dose 600 mg; second dose 600 mg. Patients less than 80 kg: first dose 600 mg; second dose 400 mg.~A third dose might be considered 16 to 24 hours after if: fever persists or a worsening of the laboratory parameters~Given the exceptionality of the situation modification of doses according to the physician experience will be allowed."
89352012|NCT01587209||Divers with decompression sickness|The sole group under study is SCUBA divers who have sustained decompression sickness
89352013|NCT01587443||Hemodialysis|
89352014|NCT01587443||Peritoneal dialysis|
89352015|NCT03383926|Experimental|Group 1|Suture confection of theTobacco-pouch of 4.5cm from the anal margin.
89352016|NCT03383926|Experimental|Group 2|Suture confection of theTobacco-pouch of 6cm from the anal margin.
89352017|NCT01587287||Corneal power measurement|All recruited volunteers in present study, that underwent corneal power measurement with 8 different instruments
89352018|NCT03379012|Experimental|Testosterone and Targeted therapy|Testosterone undecanoate (Nebido®) and Targeted therapy (sunitinib or pazopanib)
89352019|NCT03379012|Active Comparator|Control|Targeted therapy (sunitinib or pazopanib) only
89352020|NCT03869255||Hospitalized patients|Within 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
89352021|NCT03869255||Community patients|"People coming to donate blood in Etablissement Français du Sang will be included and a nasal swab will be performed"
89352022|NCT03839667|Experimental|intensive diet intervention group|The participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
89352023|NCT03839667|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
89352024|NCT03839667|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
89352025|NCT01271777|Experimental|GFT505 80mg|
89352026|NCT01271777|Placebo Comparator|Matching placebo|
89352027|NCT03387280||proximal RCA stenosis|The stenosis site is before the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
89352028|NCT03387280||distal RCA stenosis|The stenosis site is after the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
89352029|NCT03387280||left circumflex coronary artery stenosis|The stenosis site is located at the left circumflex coronary artery according to the coronary angiograms.
89352030|NCT01283399||Rituximab + Methotrexate|All participants with active refractory RA who were eligible to receive treatment with methotrexate and rituximab in the Investigators' opinion as per the routine clinical practice following inadequate response to a single cycle of anti-TNF therapy.
89352031|NCT03387202||pelvic organ prolapse|"Participants received Laparoscopic lateral suspension with mesh as part of routine medical care in apical prolapse, thus, the investigator does not assign a intervention but studies the effects.Vaginal length, bladder neck mobility and pelvic floor biometry with AP hiatal diameter and pelvic organ descent measurements are measured by Transperineal ultrasound to assess anatomic success in the preoperative and at postoperative 18th months. POP-Q assessment and translabial usg for objective success; Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS) are used to assess subjective success."
89352032|NCT01281215|Experimental|Pharmaceutical Education|The patients will receive pharmaceutical education.
89352033|NCT01281215|No Intervention|Control|
89352034|NCT05181501|Experimental|CT103A in Newly Diagnosed Subjects With High-risk Multiple Myeloma|Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection（CT103A）will be infused at 1.0 x 10^6 CAR+ T cells/kg in newly diagnosed subjects with high-risk multiple myeloma
89352035|NCT03573154|Other|e-liquid 1|
89352036|NCT03573154|Other|e-liquid 2|
89352037|NCT01283477|Experimental|ACUPUNCTURE|
89352038|NCT01283477|Sham Comparator|SHAM ACUPUNCTURE|
89352039|NCT03873779|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental/submandibular area.
89352040|NCT03383848|Experimental|Experimental Software Group|Subjects in the experimental group will be provided with free access to the medication management software online, which will be able to be accessed on the SmartPhone/SmartDevice and home tablet(s) or computer(s) of their choice, through any browser. They will also be provided with links to the surveys to be filled out in the REDCap secure web application throughout the study.
89352041|NCT03383848|No Intervention|Control Group|Subjects in the control group will receive standard of care, and will receive emails with links to the surveys to be filled out in the REDCap secure web application throughout the study.
89352042|NCT01167413||FIbromyalgia Patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR criteria
89352043|NCT03383302|Experimental|Arm 1 Tolerabilty|This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status < 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.
89352044|NCT01165697||Fabry disease biomarker|Neuro-retinal fluorescein angiography (NRFA) exam will be administered once every 6 months for up to 3 years.
89352045|NCT03493126|Experimental|Estradiol|Estrace: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
89352046|NCT03493126|Placebo Comparator|Placebo|Placebo: pea sized amount 2 times per week from week 1 postpartum to 3 months postpartum.
89352047|NCT01167491|Other|Disease group|Physiopathology
89352048|NCT03488758|Active Comparator|CMF|infant formula based on cow milk protein fractions
89352049|NCT03488758|Experimental|GMF|infant formula based on whole goat milk
89352050|NCT01283633|Experimental|programming with non-experienced nurse|Programming done by an experienced neuromodulation clinician will be compared to the patient satisfaction of a programming session with an inexperienced nurse via remote presence robotics, which will be directed by the experienced clinician
89352051|NCT01272479||HCV (+)|Hemodialysis patients with chronic hepatitis C
89352052|NCT01272479||HCV (-)|Hemodialysis patients without chronic hepatitis C
89352053|NCT01272479||Control|Healthy volunteers
89352054|NCT01283711|Experimental|apollo|
89352055|NCT03257358|Other|Cohort 1|RMS patients who were newly prescribed commercially available fingolimod 0.5mg per day
89352056|NCT03257358|Other|Cohort 2|RMS patients who had been on commercially available fingolimod 0.5mg per day continuously for ≥ 2 years
89352057|NCT03386656|Experimental|Amchafibrin|Estimated total blood loss, measured using the formula described by Nadler. A difference in estimated blood loss greater than or equal to 245 ml will be considered clinically relevant.
89352058|NCT03386656|Placebo Comparator|Saline Solution 0,9%.|Comparator of tranexamic acid
89352059|NCT03871439|Experimental|PF-05221304 Formulation A|
89352060|NCT03871439|Experimental|PF-05221304 Formulation B|
89352061|NCT03125278||Medication indication on the label|Patients discharged from Regions Hospital (St. Paul, MN) where we have implemented a standard process of printing the indication for all new medications on the prescription bottle.
89352062|NCT03125278||No medication indication given|Patients discharged from Brigham and Women's Hospital (Boston, MA) where there is no requirement for providing information on medication indications to patients at discharge.
89352063|NCT01165853|Other|Glucose|
89352064|NCT01165853|Other|Fructose|
89352065|NCT03378778||Less than 33% Tooth Structure remaining|Root canal treatment followed by CAD CAM restoration
89352066|NCT03378778||33%-50% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
89352067|NCT03378778||50% -66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
89352068|NCT03378778||More than 66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
89352069|NCT01281527|Experimental|Paliperidone Palmitate|Paliperidone Palmitate 50 - 150 mg eq. every 30 days for 6 months during the core phase and for 12 months during an optional extension phase after the last patient has completed the 6-month core treatment phase or until product will be available on market (whichever comes first)
89352070|NCT03378700|Experimental|Brief Hope Intervention Group|In addition to the pre-dialysis educational programme on self-care and treatment options for ESRF patients as per the control group, brief hope intervention will be offered: a four-weeks individual intervention. Two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between. A booklet modified from the goal worksheet in Lopez et al. (2000) will be prepared for the participants for reviewing their planned goals, recording achieved targets and successful experiences.
89352071|NCT03378700|Active Comparator|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
89352072|NCT03378622|Experimental|Anchor|Anchor used for mesh attachment
89352073|NCT03378622|Active Comparator|Suture|Suture used for mesh attachment
89352074|NCT03871127||Left main coronary disease|
89352075|NCT03378544|Experimental|Experimental arm|Patients with suicidal ideation and depression will receive psychosocial interventions adapted from the WHO mental health Global Action Programme Intervention Guide (mhGAP-IG). The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity.
89352076|NCT03378544|No Intervention|Control group|Patients with suicidal ideation and depression will be trained on how to refer patients suffering from depression, using a referral note to the nearest health centre for further treatment
89352077|NCT01313832|Experimental|remote ischemic preconditioning|
89352078|NCT03385876|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
89352079|NCT01281605|Active Comparator|Active titration algorithm|titrate insulin dose by contacting with investigator by telephone weekly.
89352080|NCT01281605|Experimental|Usual titration algorithm|contact with investigator only at routine study visit.
89352081|NCT03386422|Experimental|Mindfulness Self-Compassion Intervention MSC|"Mindfulness Self-Compassion (MSC) is a standardized program to increase self-compassion. It has been developed by Neff and Germer. The structure of the program is similar to de Mindfulness-Based Stress Reduction program (MBSR), with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with practical and experiential exercices in sessions and between sessions.~The MSC program focuses primary on helping patients to develop self-compassion, and it includes Mindfulness just as a secondary component.~The MSC program will be conducted by a clinician trained in this specific program."
89352082|NCT03386422|Active Comparator|Cognitive-Behavioural Intervention CBT|"It has been adapted a Cognitive-Behavioural Intervention for Chronic Pain by Moix and Kovacs. Our program will have 8 sessions, with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with homework between sessions.~During these 8 sessions we will train the following techniques: psychoeducation about pain, relaxation training, cognitive restructuring training, solving problem training, psychoeducation about emotions, interpersonal skills and time organization."
89352083|NCT03871205|Experimental|Vaccinated group|Neoantigen loaded-DC vaccination will be performed with 6 doses in total, once per week, adjacent lymph-node injection.
89352084|NCT01281683||TACE|
89352085|NCT01281683||RFA|
89352086|NCT01170143|Active Comparator|Trastuzumab QW|Arm A: Trastuzumab 2mg/kg, d1; qw (loading dose 4mg/kg wk1) Paclitaxel 80mg/m2,. d1; qw Carboplatin AUC 2 d1, qw
89352087|NCT01170143|Active Comparator|Trastuzumab Q3W|Arm B: Trastuzumab 6mg/kg, d1(loading dose 8mg/kg wk1) Paclitaxel 175mg/m2,. d1, q3w; Carboplatin AUC 6 ,. d1,q3w
89352088|NCT05171530|Experimental|Lenvatinib with taxane drugs treatment for advanced gastric cancer|"Experimental: Lenvatinib plus taxane drugs The subjects in this arm will receive a Lenvatinib combined with single-agent taxanes therapy. A standard dose of chemotherapy: paclitaxel 135mg/m2 every 3 weeks or docetaxel 75mg/m2 every 3 weeks will be administrated. Lenvatinib is exploring four doses of 4mg, 8mg, 12mg, and 16mg, orally once a day every 3 weeks. In the first cycle, lenvatinib was administered 5 days before chemotherapy，once a day. Chemotherapy lasts up to 6 cycles, and lenvatinib continues to be administered until the disease progresses, intolerable side effects, or death.~Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and there is no obvious DLT within 21 days before the next subject can be treated.~Interventions:~Drug: Paclitaxel or Docetaxel~Drug: Lenvatinib"
89352089|NCT02936037|Placebo Comparator|GROUP 1|Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
89352090|NCT02936037|Experimental|GROUP 2|MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
89352091|NCT03288714|Experimental|Active sTMS|Synchronized Transcranial Magnetic Stimulation (sTMS) treatments to be administered using an active device 5 times per week for six treatment weeks.
89352092|NCT03288714|Sham Comparator|Sham Stimulation|Sham treatments to be administered using a sham device 5 times per week for six treatment weeks.
89352093|NCT03869099||Sindh|
89352094|NCT03869099||KPK|
89352095|NCT03869099||Punjab|
89352096|NCT03869099||Balochistan|
89352097|NCT05171452||Group A: Adult IBD with active inflammation|
88811823|NCT01385189|Experimental|Cohort 5|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
89352098|NCT05171452||Group B: Adult IBD in remission|
89352099|NCT03386188|Experimental|Healthy arm|posterior parietal cortex (PPC) transitory inactivation
89352100|NCT03868865|Experimental|Integrative mind-body-medicine group program|The 66 hour program encompasses mindfulness training, yoga, moderate exercise, nutrition, naturopathic self-help strategies, cognitive restructuring and acupuncture for the management of side effects caused by chemotherapy.
89352101|NCT03256578|Experimental|RFM visible|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.
89352102|NCT03256578|No Intervention|RFM masked|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.
89352103|NCT04933071|Experimental|Podcast Education|Residents will be given access to podcasts during their rotation They will complete a survey after each obstetrics rotation
89352104|NCT04933071|No Intervention|Usual Teaching|Residents will have usual teaching They will complete a survey after each obstetrics rotation
89352105|NCT01283789|Experimental|Lapatinib and RAD-001|"RAD-001 will be administered orally as a once-daily dose of 5 mg (one 5 mg tablet) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD-001 in the morning, at the same time each day.~Lapatinib will be administered orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take lapatinib at bedtime, at the same time each day. Lapatinib should be taken by the patient in a fasting state."
89352106|NCT03383068|Other|control|metformin(1000-1500mg/d) treated for 6 months, reverse to normal glucose tolerance
89352107|NCT03383068|Experimental|acarbose|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with acarbose (100mg tid ) for 3 months
89352108|NCT03383068|Experimental|Exenatide|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Exenatide 10μg/bid ) for 3 months
89352109|NCT03383068|Experimental|Orlistat|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Orlistat(0.12mg/tid ) for 3 months
89352110|NCT03378388||Vedolizumab|Participants diagnosed with UC or CD, who fail or are intolerant to a previous biologic treatment or with contra-indication to anti-tumor necrosis factor alpha (TNF alpha) after failure of conventional treatments without exclusion except participant refusal, and were potentially eligible for a treatment with vedolizumab will be observed from the first prescription during consultation over a period of 24 months.
89352111|NCT03227445|Experimental|Treatment sequence A|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
89352112|NCT03227445|Experimental|Treatment sequence B|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
89352113|NCT03227445|Experimental|Treatment sequence C|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
89352114|NCT03227445|Experimental|Treatment sequence D|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
89352115|NCT03869021|Active Comparator|Computer guided surgery|A surgical guide is 3d printed to guide through the surgery, the patients of this group will have the distraction surgery by a guide designed by Mimics 19.0, Materialise NV,Belgium
89352116|NCT03869021|Other|No surgical guide (free hand surgery)|control group added to investigate the effect of surgical guide
89352117|NCT04067401|Experimental|Wingman Connect|Wingman-Connect total training time is 5 hours, typically spread over three consecutive training 'blocks'(or days), plus 1-hour of booster training (one month later).
89352118|NCT04067401|Active Comparator|Stress Management|The control training condition will consist of a 2 hr. informational training that provides an overview of the human stress response system and strategies to manage stress. The training will be delivered through lecture format using PowerPoint, supplemented by brief videos and interactive discussion.
89352119|NCT03378310|Experimental|Reference tablet followed by BMS-986205 tablet with free base|BMS-986205 reference tablet (treatment period 1) followed by BMS-986205 tablet with free base (treatment period 2).
89352120|NCT03378310|Experimental|BMS-986205 tablet with free base followed by reference tablet|BMS-986205 tablet with free base (treatment period 1) followed by BMS-986205 reference tablet (treatment period 2).
89352121|NCT01283867|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
89352122|NCT01283867|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
89352123|NCT03382990||STEMI|Patients with STEMI treated with PCI and stent placement (DES or BMS)
89352124|NCT03382990||NSTEMI|Patients with NSTEMI treated with PCI and stent placement (DES or BMS)
89352125|NCT03378232|Placebo Comparator|Placebo Olive Oil|Placebo supplement with olive oil
89352126|NCT03378232|Experimental|High EPA Supplement|Supplements providing up to 3g per day of Omega-3, with increased EPA
89352127|NCT03378232|Experimental|High DHA Supplement|Supplements providing up to 3g per day of Omega-3, with increased DHA
89352128|NCT03378154|Experimental|Tracheal Intubation in infants using Macintosh laryngoscopes|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the Macintosh laryngoscope
89352129|NCT03378154|Experimental|Tracheal Intubation in infants using King vision|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the King vision videolaryngoscope
89352130|NCT04194151|Active Comparator|2 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 2 mg/kg of propofol
89352131|NCT04194151|Active Comparator|2 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1,5 mg/kg of propofol
89352132|NCT04194151|Active Comparator|2 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1 mg/kg of propofol
89352133|NCT04194151|Active Comparator|1 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 2 mg/kg of propofol
89352134|NCT04194151|Active Comparator|1 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1,5 mg/kg of propofol
89352135|NCT04194151|Active Comparator|1 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1 mg/kg of propofol
89352136|NCT01281761|Experimental|cetuximab/irinotecan/simvastatin|"D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily)~every 2weeks"
89352137|NCT04280328|Experimental|Ciforadenant in combination with daratumumab|Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg.
89352138|NCT03385954|Experimental|Intervention|distance education curse with 8 hours to be accomplished in 2 weeks,
89352139|NCT03385954|Experimental|Control|Wiil receive a lecture of 30 minutes
89352140|NCT03820323|Other|Standard of Care|Participants in the Standard-of-Care control arm will receive laboratory based VL testing based on the existing Kenyan national guidelines by routine clinical staff (not study staff). DRM testing is usually done if there is a failing 2nd line ART regimen based on the current Kenyan guideline.
89352141|NCT03820323|Experimental|Intervention|POC VL and targeted DRM testing.
89352142|NCT03748147|Active Comparator|Control|Standard of care, misoprostol 25 mcg po every four hours
89352143|NCT03748147|Experimental|Intervention|Misoprostol 50 mcg po every four hours
89352144|NCT01580813|Experimental|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visi
89352145|NCT01580813|Placebo Comparator|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit
89352146|NCT03637920||transmen|Biological women, who identify as men and are seeking gender reassignment.
89352147|NCT05002504|Experimental|Patients receiving craniosacral therapy|30 children without previous pathology receiving craniosacral therapy
89352148|NCT05002504|Active Comparator|Patients receiving balance and coordination therapy|31 patients without previous pathology receiving balance and coordination therapy
89352149|NCT05002504|Placebo Comparator|Patients receiving placebo|25 patients without previous pathology receiving placebo
89352150|NCT01314183|Active Comparator|exercise|Subjects in this arm receive 12 exercise sessions in 9 weeks.
89352151|NCT01314183|Active Comparator|exercise + manual therapy|Subjects in this group receive exercise combined with manual therapy techniques for 12 sessions in 9 weeks.
89352152|NCT01314183|Experimental|exercise + booster|subjects in this arm will receive exercise sessions delivered with booster sessions (8 sessions in the first 9 weeks, 2 sessions at 5 months, 1 session at 8 months, and 1 session at 11 months).
89352153|NCT01314183|Experimental|exercise + manual therapy + booster|Subjects in this arm will receive exercise combined with manual therapy techniques and booster sessions.
89352154|NCT04446364|Experimental|Aloe vera group|Gel cavity disinfection
89352155|NCT04446364|Active Comparator|Chlorohexidine group|2% cavity disinfection
89352156|NCT01588535|Active Comparator|benzocaine solution|ear drops
89352157|NCT01588535|Placebo Comparator|Placebo|ear drops
89352158|NCT03287622|Experimental|Education Intervention + Nudge|This group will receive BOTH the scenario-tailored STOMP educational feedback AND the behavioral Nudge intervention
89352159|NCT03287622|Experimental|Standard of Care + Nudge|This group will receive routine, standard of care information AND the behavioral Nudge intervention
89352160|NCT03287622|Experimental|Educational Intervention no Nudge|This group will receive scenario-tailored opioid message (STOMP) feedback and NO behavioral nudge intervention.
89352161|NCT03287622|No Intervention|Standard of Care no Nudge|This group will receive only standard of care information and NO behavioral nudge intervention.
89352162|NCT04063657|Active Comparator|External fixation|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in external fixator until the patient is deemed clinically appropriate for definitive surgical fixation.
89352163|NCT04063657|Active Comparator|Splinting|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in a short leg splint until the patient is deemed clinically appropriate for definitive surgical fixation.
89352164|NCT01165931|Experimental|Arm 1|
89352165|NCT03636945|Experimental|Medullary thyroid carcinoma|Patients with MTC who have serum calcitonin> 150 pg / ml at initial diagnosis and have performed baseline imaging examinations within the last 3 months will be included in the study A PET at 18F-FDOPA will be performed according to a very powerful acquisition protocol
89352166|NCT02970136|Experimental|Home Based Screening|The participant will be receiving home-based screening tests (OraQuick Swab, OraQuick Fingerstick, Human Papillomavirus (HPV) Self-Sampling Test, Fecal Immunochemical Test) delivered by the community health worker
89352167|NCT02970136|Active Comparator|Clinic Based Screening|The participant will meet the Community Health Worker and will be navigated to a clinic appointment for standard screening tests
89352168|NCT01170377||Mental Retardation|Patients receiving valproate or not
89352169|NCT05181111|Experimental|Monitoring Group|wearable sensor, besides usual care monitoring
89352170|NCT05181111|Other|Usual Care group|usual care monitoring
89352171|NCT03377998|Experimental|vitiligo patients|lesional skin biopsy to measure ERDR1 level
89352172|NCT03377998|Experimental|controls|normal skin biopsy to measure ERDR1 level
89352173|NCT01274273|Experimental|Interleukin-2, interferon, bevacizumab|
89352174|NCT01274273|Active Comparator|Interleukin-2 and interferon-alfa|
89352175|NCT03377920|Experimental|Severe asthma patients; COPD patients|Cross sectional study Lung function measurement
89352176|NCT04058353|Active Comparator|Control: IVA or TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants either received IVA 150 milligrams (mg) every 12 hours (q12h) or TEZ 100 mg once daily (qd)/IVA 150 mg q12h in the treatment period for 8 weeks.
89352177|NCT04058353|Experimental|TC: ELX/TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 8 weeks.
89352178|NCT01170455|Experimental|Blind Intubation Device|
89352179|NCT01170455|Active Comparator|Direct laryngoscope|
89352180|NCT01167647||bronchoscopy patients|
89352181|NCT03226353|Experimental|somofilcon A 1-day soft contact lenses|Habitual and refitted wearers of omafilcon A were refit into somofilcon A for a week
89352182|NCT01274507|Other|All participants|
89352183|NCT02730598|Experimental|Hybrid Training System (HTS)|HTS stimulation while walking at a comfortable pace for 30 minutes.
89352184|NCT02730598|Active Comparator|Transcutaneous Electrical Nerve Stimulation (TENS)|Sensory TENS while walking at a comfortable pace for 30 minutes.
89352185|NCT04874415|Experimental|Condition 1|1RLD=One text per day, ramped goal, loss incentive, daily goal time period.
89352186|NCT04874415|Experimental|Condition 2|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
89352187|NCT04874415|Experimental|Condition 3|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
89352188|NCT04874415|Experimental|Condition 4|1RGW=One text per day, ramped goal, gain incentive, weekly goal time period.
89352189|NCT04874415|Experimental|Condition 5|2RLD=Two texts per day, ramped goal, loss incentive, daily goal time period.
89352190|NCT04874415|Experimental|Condition 6|2RLW=Two texts per day, ramped goal, loss incentive, weekly goal time period.
89352191|NCT04874415|Experimental|Condition 7|2RGD=Two texts per day, ramped goal, gain incentive, daily goal time period.
89352192|NCT04874415|Experimental|Condition 8|2RGW=Two texts per day, ramped goal, gain incentive, weekly goal time period.
89352193|NCT04874415|Experimental|Condition 9|1FLD=One text per day, fixed goal, loss incentive, daily goal time period.
89352194|NCT04874415|Experimental|Condition 10|1FLW=One text per day, fixed goal, loss incentive, weekly goal time period.
89352195|NCT04874415|Experimental|Condition 11|1FGD=One text per day, fixed goal, gain incentive, daily goal time period.
89352196|NCT04874415|Experimental|Condition 12|1FGW=One text per day, fixed goal, gain incentive, weekly goal time period.
89352197|NCT04874415|Experimental|Condition 13|2FLD=Two texts per day, fixed goal, loss incentive, daily goal time period.
89352198|NCT04874415|Experimental|Condition 14|2FLW=Two texts per day, fixed goal, loss incentive, weekly goal time period.
89352199|NCT04874415|Experimental|Condition 15|2FGD=Two texts per day, fixed goal, gain incentive, daily goal time period.
89352200|NCT04874415|Experimental|Condition 16|2FGW=Two texts per day, fixed goal, gain incentive, weekly goal time period.
89352201|NCT01167725|Active Comparator|Arm I|Patients receive standard systemic therapy, at the discretion of patients' oncologist, comprising combinations of fluorouracil, leucovorin calcium, irinotecan hydrochloride, oxaliplatin, and/or capecitabine (including FOLFOX4, mFOLFOX6, CapeOx, or FOLFIRI), bevacizumab, or cetuximab. Treatment repeats in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm II.
89352202|NCT01167725|Experimental|Arm II|Patients undergo cytoreduction surgery and hyperthermic intraperitoneal mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6 courses in the absence of disease progression or unacceptable toxicity.
89352203|NCT03815695|Experimental|Single ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of FT-4202 or placebo. The first cohort will receive 200 mg of FT-4202 or placebo. Dose escalation will occur if FT-4202 or placebo is tolerated. The maximum dose of FT-4202 or placebo will be 1500 mg.
89352204|NCT03815695|Experimental|Multiple ascending dose cohorts in healthy subjects|Healthy volunteer subject cohorts randomized 9:3 to receive FT-4202 or placebo for 14 days continuous dosing. The first cohort will receive 100 mg of FT-4202 or placebo daily X 14 days. The maximum dose of FT-4202/placebo will be 600 mg FT-4202/placebo daily for 14 days.
89352205|NCT03815695|Experimental|Food Effect Cohort in healthy subjects|Health Volunteer subject cohort of 10 subjects who will receive a single dose of FT-4202 with food and without food. Dose will be administered per the protocol defined dose.
89352206|NCT03815695|Experimental|Single ascending dose cohorts in SCD subjects|Sickle cell disease subject cohort randomized 6:2 receiving a single dose of FT-4202 or placebo. The dose of FT-4202/placebo administered will be a dose that was found to be safe in healthy subjects.
89352207|NCT03815695|Experimental|Multiple ascending dose cohorts in SCD subjects|Sickle cell disease subject cohorts randomized 9:3 to receive FT-4202 or placebo for 14 days continuous dosing. The dose of FT-4202/placebo administered will be a dose less than the maximum tolerable dose evaluated in MAD healthy volunteers.
89352208|NCT03815695|Experimental|12-week dosing cohort in SCD subjects|Sickle cell disease subjects cohort to receive up to 84 consecutive daily doses of open-label FT-4202. The dose of FT-4202 administered will not exceed the highest dose evaluated in the MAD SCD subject cohorts
89352209|NCT04446130|Experimental|Decitabine combined with HAAG Regimen|This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in the newly diagnosed T-ALL/LBL and T/M-MPAL patients.
89352210|NCT01274663|Experimental|10 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
89352211|NCT01274663|Experimental|30 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
89352212|NCT01274663|Experimental|100 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
89352213|NCT01274663|Experimental|300 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
89352214|NCT01274663|Experimental|600 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
89352215|NCT01274663|Experimental|800 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
89352216|NCT01274663|Experimental|xxx mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
89352217|NCT03226275|Experimental|Fasting: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
89352218|NCT03226275|Experimental|Fasting: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
89352219|NCT03226275|Experimental|Fed: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
89352220|NCT03226275|Experimental|Fed: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
89352221|NCT04189081|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
89352222|NCT04189081|Sham Comparator|Water Control|Water will be used as a mouth rinse and can be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using water, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
89352223|NCT04189081|Active Comparator|Positive Control|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
89352224|NCT03382756|Experimental|Group A|"Period 1: 1 capsule of test drug(CKD-337) administered under fasting condition~Period 2: 1 capsule of test drug(CKD-337) under high fat diet condition"
89352225|NCT03382756|Experimental|Group B|"Period 1: 1 capsule of test drug(CKD-337) under high fat diet fed condition~Period 2: 1 capsule of test drug (CKD-337) administered under fasting condition"
89352226|NCT01274819|Experimental|Dynamic light|ICU patients exposed to dynamic light during ICU stay
89352227|NCT01274819|No Intervention|Normal Light|control group is exposed to normal light during ICU stay
89352228|NCT04187989|Experimental|Social Media Intervention|Facebook page that will deliver health information focused on increasing well-being and reducing risky behaviors.
89352229|NCT04187989|No Intervention|Control|An Attention-Control E-News (control) condition
89352230|NCT03868553||Under-10|
89352231|NCT03868553||Under-12|
89352232|NCT03868553||Under-16 female|
89352233|NCT03868553||Under-16 male|
89352234|NCT01170611|Experimental|AAISAFER alone - AAISAFER+PREVENTIVE ALGORITHM - DDD|
89352235|NCT01166087|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
89352236|NCT01166087|Active Comparator|Prozac ® weekly|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
88807306|NCT05247840||diabetic children|Children aged 5-18 years (boys, girls) with type 1, type 2 and monogenic diabetes mellitus who are treated at the Endocrinology Department and Outpatient Clinic of Heim Pál National Pediatric Institute (HOGYI, Budapest, Hungary) will be enrolled. Definition of diabetes is based on the American Diabetes Association (ADA) criteria. All patients who meet the inclusion criteria will be informed of the possibility of taking part in the INTACT Trial.
88811824|NCT01385579|No Intervention|usual care|Patients assigned to the usual care arm may be referred for colorectal cancer screening by their providers per usual health center protocol and practice. They receive no additional outreach by the preventive care care manager.
89352237|NCT01170689||Inpatient schizophrenia or schizoaffective disorder|
89352238|NCT01170767|Experimental|Avastin|intravitreal injection of bevacizumab
89352239|NCT01170767|Active Comparator|Lucentis|intravitreal injection of ranibizumab
89352240|NCT01170845|Placebo Comparator|Control group|Patients in the control group received saline for 7 days starting at the beginning of surgery
89352241|NCT01170845|Active Comparator|S group|Patients in the S group received sivelestat sodium hydrate at a dosage 4.8mg/kg/day for 7 days starting at the beginning of surgery
89352242|NCT01150890|Placebo Comparator|Placebo|Participants received placebo intravenously at baseline and week 4.
89352243|NCT01150890|Experimental|Brodalumab 210 mg|Participants received 210 mg brodalumab intravenously at baseline and week 4.
89352244|NCT01150890|Experimental|Brodalumab 350 mg|Participants received 350 mg brodalumab intravenously at baseline and week 4.
89352245|NCT01150890|Experimental|Brodalumab 700 mg|Participants received 700 mg brodalumab intravenously at baseline and week 4.
89352246|NCT04057573|Experimental|Double-Blind Period: Ruxolitinib cream 1.5% BID|Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.
89352247|NCT04057573|Placebo Comparator|Double-Blind Period: Vehicle cream BID|Participants applied matching vehicle cream BID for 24 weeks.
89352248|NCT04057573|Experimental|Treatment-Extension Period: Ruxolitinib cream 1.5% BID|Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.
89352249|NCT04057573|Experimental|Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID|Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.
89352250|NCT01167803|Active Comparator|Reference - desflurane|The patients in this group will undergo anesthesia using remifentanil associated with desflurane.
89352251|NCT01167803|Experimental|Experimental - xenon|The patients in this group will undergo anesthesia using remifentanil associated with xenon
89352252|NCT01167959||obesity diabetes, surgical and dietary|
89352253|NCT01168037||Open repair|Open Surgical Repair (aortic replacement with revascularization of visceral arteries)
89352254|NCT01168037||Endovascular (Windows 1)|Endovascular therapy branched or fenestrated stent-graft
89352255|NCT01168037||Endovascular (Windows 3)|Endovascular therapy branched or fenestrated stent-graft (vascutek anaconda)
89352256|NCT01275521|Experimental|BONT-A intra-prostatic injection|
89352257|NCT01275521|Active Comparator|optimized medical BPH treatment|
89352258|NCT01275911|Experimental|Esmolol|
89352259|NCT01275911|Active Comparator|Remifentanil|
89352260|NCT01170923|Experimental|FDG-PET guided|Chemotherapy regimen will be changed depending on metabolic response.
89352261|NCT01170923|Active Comparator|CT guided|Chemotherapy regimen will be changed depending on CT findings (RECIST).
89352262|NCT04054765|Experimental|Teens in the Invite Only VR videogame|155 adolescents playing the Invite Only VR intervention
89352263|NCT04054765|Other|Teens receive treatment as usual|132 adolescents receive treatment as usual, which includes regular instruction in health class regarding the dangers of e-cigarettes
89352264|NCT01166165|Active Comparator|Cholecalciferol|
89352265|NCT01166165|Placebo Comparator|Placebo|
89352266|NCT01168193|Other|Patients that underwent surgery|Single arm
89352267|NCT03873155|Experimental|Mindfulness-based cognitive therapy|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in an MBCT intervention whilst the same variables are measured. Following the intervention,there will be a 4-week follow-up period, and MBCT groups will not run during this time.
89352268|NCT04179721|Experimental|The PES-4-BPSD Model|The intervention arm consists of PES and NAs who work on the intervention unit which consists of: I. Cohorting of patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES staff. III. Staff Support: The PI will hold monthly 20 minute group sessions to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of hospital caregivers towards patients. IV. Staff Training
89352269|NCT04179721|Active Comparator|The attention control condition|The control group consists of NAs that work on a 40-bed medicine unit, staffed with 39 nurses (1:6 ratio) and 26 NA (1:8 ratio), that primarily cohorts older patients with geriatric syndromes. All components of the intervention arm are the same with the exception of the PES staff. The control arm (NAs) will receive the same training as the intervention arm.
89352270|NCT01171079|Experimental|Interceed|
89352271|NCT03286218|Placebo Comparator|Placebo|Placebo was administered orally in one of five treatment periods
89352272|NCT03286218|Active Comparator|Alprazolam 2 milligram (mg)|2 mg of alprazolam was administered orally in one of five treatment periods
89352273|NCT03286218|Experimental|Lasmiditan 100 mg|100 mg of lasmiditan was administered orally in one of five treatment periods
89352274|NCT03286218|Experimental|Lasmiditan 200 mg|200 mg of lasmiditan was administered orally in one of five treatment periods
89352275|NCT03286218|Experimental|Lasmiditan 400 mg|400 mg of lasmiditan was administered orally in one of five treatment periods
89352276|NCT01171157||Group 1|Subjects with influenza like illness
89352277|NCT03745261|Experimental|YCC capsule+conventional medicine|Patients in this group will be given Yong Chong Cao (YCC) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD,which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
89352278|NCT03745261|Experimental|BL capsule + conventional medicine|Patients in this group will be given Bailing (BL) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD, which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
89352279|NCT01166243|Experimental|Fibrin Pad|Biologic
89352280|NCT01166243|Other|Standard of Care|Procedure
89352281|NCT03744949|Experimental|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
89352282|NCT03744949|Experimental|Remifentnil dose 1 ug/kg|Remifentanil will be given (dosage of 1.0 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
89352283|NCT03744949|Experimental|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
89352284|NCT03744949|Experimental|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
89352285|NCT03870581|Experimental|AI-SMART group|Participants' warfarin therapy were guided by an AI-based miniprogram embedded in the Wechat social software.
89352286|NCT03870581|Active Comparator|Human-SMART group|Participants' warfarin therapy were guided by an human-based miniprogram embedded in the Wechat social software.
89352287|NCT03224325|Other|Placebo (Pooled)|TAK-831 placebo-matching suspension, orally, once daily (QD) for up to Day 16.
89352288|NCT03224325|Experimental|TAK-831 100 mg|TAK-831 100 mg, tablets, orally, QD on Days 1 and 3 to 16.
89352289|NCT03224325|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, QD on Days 1 and 3 to 16.
89352290|NCT03224325|Experimental|TAK-831 600 mg|TAK-831 600 mg, tablets, orally, QD on Days 1 and 3 to 16.
89352291|NCT03224325|Experimental|TAK-831 15 mg|TAK-831 15 mg, suspension, orally, multiple doses (MD) daily, on Days 1 and 3 to 16.
89352292|NCT03224325|Experimental|TAK-831 800 mg|TAK-831 800 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
89352293|NCT03224325|Experimental|TAK-831 1200 mg|TAK-831 1200 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
89352294|NCT01166399||Primiparous women with an obstetric anal sphincter tear|Subjects in this trial will be primiparous women who underwent anal sphincter repair at the time of a singleton vaginal delivery. Sphincter tears will be clinically characterized at the time of delivery as <50% tear through the anal sphincter (modified WHO 3a), >50% (modified WHO 3b), or complete tear through the anal sphincter (4th degree). Subjects in this study will not have receive study interventions.
89352295|NCT04016779|Placebo Comparator|Placebo|Placebo, qd, oral capsule
89352296|NCT04016779|Experimental|SPN-812|SPN-812, qd, oral capsule
89352297|NCT03870503|Active Comparator|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
89352298|NCT03870503|Active Comparator|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mc sublingual misoprostol
89352299|NCT03870503|Active Comparator|Carbetocin|The patient will be received Carbetocin 100 mic gm IV
89352300|NCT02857426|Experimental|Nivolumab for population with PCNSL|Specified dose on specified days
89352301|NCT02857426|Experimental|Nivolumab for population with PTL|Specified dose on specified days
89352302|NCT05181033|Active Comparator|Control arm|intramuscular (IM) fulvestrant 500mg on day 1 and day 15 during cycle 1, then day 1 only from cycle 2 onwards of every 4-weekly cycle
89352303|NCT05181033|Experimental|Experimental arm|oral (PO) letrozole 2.5mg daily plus lenvatinib 14mg daily
89352304|NCT05666765|Experimental|acne vulgaris patients group 1|acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
89352305|NCT05666765|Experimental|acne vulgaris patients group 2|acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
89352306|NCT05666765|Experimental|acne vulgaris patients group 3|acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
89352307|NCT01127256|Experimental|1|
89352308|NCT01127256|Active Comparator|2|
89352309|NCT01277471|Experimental|Arm A: 6 and 2 meals/day|6 meals/day for the first 12 weeks followed by 2 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
89352310|NCT01277471|Active Comparator|Arm B: 2 and 6 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
89352311|NCT03059472|Experimental|Group 1 (Intervention)|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
89352312|NCT03059472|Experimental|Group 2 (Delayed intervention)|Delayed intervention participants will participate in the same activities as Group 1 but 6 months after Group 1.
89352313|NCT03873233|Active Comparator|Volume Controlled Ventilation|Volume Controlled Ventilation with Aisys Carestation ventilator and normal endotracheal tube'
89352314|NCT03873233|Active Comparator|Flow Controlled Ventilation|Flow Controlled Ventilation with Evone ventilator and Tritube
89352315|NCT03377842|Active Comparator|FOLFOX regimen|FOLFOX regime alone.
89352316|NCT03377842|Experimental|Apatinib and FOLFOX regimen|Apatinib combine with FOLFOX regimen.
89352317|NCT03377764||Landmark Technique|Control group
89352318|NCT03377764||Ultrasound guided technique|Neuroaxial block using Ultrasound guidance
89352319|NCT04016311|Experimental|Mindful Drinking/Eating Group|Behavioral: Mindful Drinking/Eating Intervention Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
89352320|NCT04016311|No Intervention|Wait list control|Usual care. Offered intervention after post-test data collected.
89352321|NCT01277705|Experimental|Group A|
89352322|NCT01277705|Experimental|Group B|
89352323|NCT01277705|Active Comparator|Group C|
89352324|NCT03377686||Asthma|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with doctor's diagnosed asthma
89352325|NCT03377686||Cystic fibrosis|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with CF
89352326|NCT03377686||Healthy|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years old without respiratory diseases
89352327|NCT04757337|Active Comparator|Doxorubicin|Intravenous Doxorubicin 60 mg/m² Cycle 1 then 75 mg/m² Cycle 2 to Cycle 6 D1-D21 with granulocyte-colony stimulating factor (G-CSF) and dexrazoxane.
89352328|NCT04757337|Experimental|Cyclophosphamide|Cyclophosphamide per os 100 mg twice a day, 1 week on, 1 week off until 2 years, or unacceptable toxicity, disease progression, withdrawn of consent or death.
89352329|NCT03868241|Experimental|Bactiguard-coated Devices|Patients will receive endotracheal tube, central venous catheter and urinary cather coated with gold, silver and palladium (Bactiguard coating)
89352330|NCT03868241|Placebo Comparator|Control|Shelf endotracheal tube, central venous catheter and urinary cather available at each intensive care unit without any type of coating designed to prevent infection
89531946|NCT04631029|Experimental|Treatment (carboplatin, etoposide, atezolizumab, entinostat)|"INDUCTION THERAPY: Patients receive carboplatin IV over 30-60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, atezolizumab IV over 30-60 minutes on day 1, and entinostat PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive atezolizumab IV over 30 minutes on day 1 and entinostat PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity."
89352331|NCT03921970|Active Comparator|Group ESP = ESP group|ESP block (Group ESP) will be performed in the preoperative block room. US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. From superior to inferior; trapezius (upper), rhomboideus major (middle), erector spinae (lower) muscles will be visualized on the hyperechoic transverse process. The 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be inserted in a cranio caudal direction and then for correction of the needle 5 ml normal saline solution will be enjected into the erector spina muscle fascia (figure). Following confirmation of the correct position of the needle, a dose of 20 ml %0.25 bupivacaine was administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine).
89352332|NCT03921970|No Intervention|Group C = Control group|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
89352333|NCT03946527|Experimental|lanreotide arm|Patients with a histopathologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability who meet the inclusion/exclusion criteria. Approximately 40 patients will be enrolled.
89352334|NCT03377608||Depo-Provera|
89352335|NCT03377608||Non-hormonal contraception|
89352336|NCT01282073|Experimental|Mycophenolate mofetil, low dose steroid|
89352337|NCT01282073|Active Comparator|Cyclosporin, low dose steroid|
89352338|NCT04052425|Experimental|Double-Blind Period: Ruxolitinib cream 1.5% BID|Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.
89352339|NCT04052425|Placebo Comparator|Double-Blind Period: Vehicle cream BID|Participants applied matching vehicle cream BID for 24 weeks.
89352340|NCT04052425|Experimental|Treatment-Extension Period: Ruxolitinib cream 1.5% BID|Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.
89352341|NCT04052425|Experimental|Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID|Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.
89352342|NCT03235089|Active Comparator|Test lens|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
89352343|NCT03235089|Active Comparator|nelfilcon A lens (control)|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
89352344|NCT03377530||Premature neonates infected with bacillus Species|The investigators studied retrospectively eleven cases of these infections in our NICU and reviewed series and report cases in literature.
89352345|NCT03873077|No Intervention|intravenous analgesia|Patient receives intravenous analgesia: paracetamol 30 mg/kg, diclofenac 75 mg, clonidine 1 µg/kg and morfine 0,05 mg/kg
89352346|NCT03873077|Other|intravenous analgesia + LIA|Patient receives intravenous analgesia and a local infiltration analgesia in the knee
89352347|NCT03377374|Experimental|Probiotic|L. reuteri ATCC PTA 5289 + L. reuteri DSM 17938 at a dose of 2x10^8 Colony Forming Units (CFU)
89352348|NCT03377374|Placebo Comparator|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
89352349|NCT03870347||Biliary Dilation Cohort|Patients referred for endoscopic evaluation of biliary dilation
89352350|NCT02736526|Experimental|Surgical treatment|The recession or resection of the horizontal extraocular muscles will be processed in the beginning of the trial.
89352351|NCT02736526|No Intervention|Observation only|
89352352|NCT02526173|Experimental|dHACM|This group will receive RALP using full nerve sparing technique plus dHACM application.
89352353|NCT02526173|Other|Control|This group will receive RALP using full nerve sparing technique only.
89352354|NCT03125512|Experimental|Night Shift positional device|Randomized to Night shift positional therapy first for 8 weeks, followed by CPAP for 8 weeks, with a 1 week washout period.
89352355|NCT03125512|Active Comparator|Continuous positive airway pressure|Randomized to CPAP first for 8 weeks, followed by positional therapy for 8 weeks, with a 1 week washout period.
89352356|NCT01166477|Active Comparator|Triple therapy|The patients who would be allocated to this arm will continue with their triple therapy treatment, based on any protease inhibitor boosted with ritonavir
89352357|NCT01166477|Experimental|Monotherapy|Those patients allocated to this arm will start to take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
89352358|NCT02714920|Other|DNA Repair enzyme signature|Tumor biopsies and blood samples performed specifically to determine DNA Repair enzyme signature biomarkers profiles (CHEMRAD assay)
89352359|NCT02526641||AbbVie|
89352360|NCT01282151|Experimental|Taxotere|Docetaxel plus Cisplatin
89352361|NCT01282151|Active Comparator|Pemetrexed|Pemetrexed plus Cisplatin
89352362|NCT03377218|No Intervention|Control|Without additional iodine supplementation.
89352363|NCT03377218|Experimental|Iodine|Receiving iodine.
89352364|NCT03377218|Experimental|Iodine + Selenium|Receiving iodine and selenium.
89352365|NCT01168505|No Intervention|no iron supplentation|
89352366|NCT01168505|Experimental|iron supplement|
89352367|NCT01282307|Experimental|Method Guided Self-Determination|The Method Guided Self-Determination consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
89352368|NCT01282307|No Intervention|Treatment as usual|
89352369|NCT03377140|Active Comparator|Hesperidin|2 capsuls of Hesperidin
89352370|NCT03377140|Placebo Comparator|control|2 capsuls of placebo
89352371|NCT03868319|Experimental|control group|nonprotective ventilation with a tidal volume of 9 ml kg-1 PBW with ZEEP
89352372|NCT03868319|Experimental|LPV group|a tidal volume of 6 ml kg-1 PBW with a 7 cmH2O level PEEP
89352373|NCT04013191|Experimental|Adult study participants|Participants will receive assigned single and multiple doses of padsevonil.
89352374|NCT04013191|Experimental|Elderly study participants|Participants will receive assigned single and multiple doses of padsevonil.
89352375|NCT03872765|Other|Patients with chronic anal fissure|Use of laser in surgery of chronic anal fissure instead of the conventional surgical techniques.
89352376|NCT01171391|Experimental|VA106483 1mg|
89352377|NCT01171391|Experimental|VA106483 2mg|
89352378|NCT01171391|Experimental|VA106483 4mg|
89352379|NCT01171391|Placebo Comparator|Sugar pill|
89352380|NCT03898726|Active Comparator|laparoscopical l cuff closure|needle holder laparoscopic vaginal cuff closure
89352381|NCT03898726|Active Comparator|transvaginal cuff closure|transvaginal cuff closure
89352382|NCT03867929||STUDY|Patient with serum 25-Hydroxy vitamin D level <27.32
89352383|NCT03867929||CONTROL|Patient with serum 25-Hydroxy vitamin D level >27.32
89352384|NCT03285594|Placebo Comparator|Placebo|Following a 4-week run-in period, participants were randomized to matching placebo to sotagliflozin 200 milligrams (mg) administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
89352385|NCT03285594|Experimental|Sotagliflozin 200 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 200 mg administered as 1 tablet and matching placebo as 1 tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
89352386|NCT03285594|Experimental|Sotagliflozin 400 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 400 mg administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
89352387|NCT01171469|Experimental|Dose Level 3|15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
89352388|NCT01171469|Experimental|Dose Level 2|10 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
89352389|NCT01171469|Experimental|Dose Level 1|5 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
89352390|NCT01168583||Positive Fluid Balance of 2000ml|
89352391|NCT01168583||Negative Fluid Balance of 2000ml|
89352392|NCT03872921|Experimental|norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg capsules, 6 capsules/day for 2 years
89352393|NCT03872921|Placebo Comparator|Placebo to norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg Placebo-capsules, 6 capsules/day for 2 years
89352394|NCT03234465|Experimental|AG013: three mouth rinses/day|Subjects will rinse three times per day with AG013 mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
89352395|NCT03234465|Placebo Comparator|Placebo: three mouth rinses/day|Subjects will rinse three times per day with placebo mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
89352396|NCT03290131|Active Comparator|AERT 40 mg|40 mg Arbaclofen Extended-Release Tablets
89352397|NCT03290131|Active Comparator|AERT 80 mg|80 mg Arbaclofen Extended-Release Tablets
89352398|NCT03290131|Placebo Comparator|Placebo|Placebo
89352399|NCT01278719||Antrochaonal polyp; non recurrent type|
89352400|NCT01278719||Antrochoanal polyp; recurrent type|
89352401|NCT01278719||Ethmoidal polyp - non recurrent type|
89352402|NCT01278719||Ethmoidal polyp - recurrent type|
89352403|NCT03870191|Active Comparator|Twin Block Group|This group will receive twin block injections.
89352404|NCT03870191|Active Comparator|Trigger Point Injection Group|This group will receive trigger point injections.
89352405|NCT05180877||Intermittent& mild persistent asthma|According to asthma severity assessment, this group included asthmatic pregnant females patients with intermittent asthma and mild persistent asthma
89352406|NCT05180877||Moderate& severe persistent asthma|According to asthma severity assessment, this group included asthmatic pregnant females patients with Moderate& severe persistent asthma
89352407|NCT03746353|Experimental|Early closure of ileostomy|Early clousure of ileostomy before 30 days
89352408|NCT03746353|Active Comparator|Conventional closure of ileostomy|Conventional closure of ileostomy after 30 days
89352409|NCT02526485||Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
89352410|NCT02695992|Active Comparator|Metoprolol|Metoprolol, extended release tablets. 100 mg daily
89352411|NCT02695992|Active Comparator|Diltiazem|Diltiazem, extended release tablets. 360 mg daily
89352412|NCT05180643|Experimental|non-fluctuating patients or with minor fluctuations (Group A)|Patient without fluctuation or with minor motor fluctuations (rated 0 or 1 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)
89352413|NCT05180643|Experimental|patients with mild to moderate fluctuations (Group B).|Patient without fluctuation or with minor to moderate motor fluctuations (rated 2 or 3 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)
89352414|NCT04050865|Experimental|OTX-DP|
89352415|NCT04050865|Placebo Comparator|Placebo|
89352416|NCT01168661|No Intervention|Control arm|Participants in this arm will be recruited from the group who applied to participate in the study and fulfilled the inclusion criteria but for various reasons (such as time constraints) could not participate.
89352417|NCT01168661|Active Comparator|Cognitive psychotherapy arm|In this arm, participants will attend a group meeting to practice cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
89352418|NCT01168661|Active Comparator|Mindfulness based cog psychotherapy arm|In this arm, participants will attend a group meeting to practice mindfulness based cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
89352419|NCT01168661|Active Comparator|Yoga treatment group|Persons in this arm will practice yoga >= 5 time each week (2 times in a supervised group and the other times on their own).
89352420|NCT03283566|Active Comparator|Hydroxychloroquine|Administered pre-transplant through 3 months after surgery.
89352421|NCT03283566|Placebo Comparator|Placebo|Placebo treatment following the same schedule as Arm 1 (i.e. Hydroxychloroquine).
89352422|NCT03210519|Experimental|Eleutherococcus senticosus|Acanthopanax senticosus-mono formula (30mg/vial) and Fructus Ziziphi Jujube concentrated juice15ml/vial
89352423|NCT03210519|Placebo Comparator|Placebo|Fructus Ziziphi Jujube concentrated juice15ml/vial
89352424|NCT03745183|Experimental|Senna alata leaf decoction|The participants were instructed to take a bath once a day using a syndet bar and to towel dry their skin before applying the akapulko decoction. Fresh decoction was prepared by the patients every day. After a bath, the patient applied the fresh cooled decoction by hand on the whole body especially on the affected areas and left it to dry. Approximately one glassful (350ml) of akapulko decoction should be consumed for one whole body application. The total duration of daily application should be 4 weeks (28 days +3) until the next outcome assessment.The patients were given illustrated, laminated instructional materials and a tabulated checklist of instructions on how to prepare and apply the decoction which served as a monitoring sheet of each patient.
89352425|NCT03872687|Experimental|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size for 6 months.
89352426|NCT03872687|Active Comparator|interdental brushes|Subjects in this group will only receive interdental brushes 6 months.
89352427|NCT01166555|Experimental|1|
89352428|NCT03737305|Active Comparator|Control Group|Control group of conventional therapy with manual distraction performed by the physiotherapist in the office (active comparator)
89352429|NCT03737305|Experimental|Distractor Test Group|Test group with manual distraction performed by the physiotherapist in the office and the condylar distraction performed by the patient with the condylar distraction device in an ambulatory basis.
89352430|NCT01283945|Experimental|Lucitanib|
89352431|NCT04048681|Experimental|Diet Soda|12oz can of Diet Coke
89352432|NCT04048681|Active Comparator|Soda|12oz can of Coke
89352433|NCT04048681|Placebo Comparator|Carbonated Water|12oz can of carbonated (unflavored) water
89352434|NCT01171703|Experimental|bypass|femoral-popliteal bypass
89352435|NCT01171703|Experimental|stent|
89352436|NCT03737227|Other|Cinematographic recording|Cinematographic recordings of the asymptomatic participants during flexion and extension of the lumbar spine.Cinematographic recordings will be performed twice with an interval of two weeks.
89352437|NCT03870113|Experimental|Vaccinated group|Patients will be vaccinated with autologous mature dendritic cells-loaded with HPV 16/18 E6/E7, DC vaccine will be injected into the adjacent lymph-node 6 times, once a week.
89352438|NCT01282385|Experimental|simvasatin|"a) patients responding to treatment with beta-blockers, in which she was treated with nadolol Subsequently randomized into two treatment arms, double-blind:~a.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~a.2: placebo capsules with external characteristics similar to simvastatin.~b) non-responders to treatment with beta blockers, receive treatment with carvedilol.Subsequently randomized into two treatment arms, double-blind~b.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~b.2: placebo capsules with external characteristics similar to simvastatin."
89352439|NCT01282385|Placebo Comparator|placebo|
89352440|NCT04007107|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
89352441|NCT04007107|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
89352442|NCT01166711|Experimental|Bare Metal Stent (BMS) followed by Drug Eluting Balloon (DEB)|
89352443|NCT01166711|Active Comparator|Drug Eluting Stent (DES)|
89352444|NCT04046341|Experimental|Behavioral Sleep Intervention|Parents attend 1-3 one-hour sessions at their primary care office or via telemedicine, where they receive sleep education and work with interventionists to develop strategies to help their child at bedtime.
89352445|NCT03869879|Active Comparator|Feedback-assisted physical therapy|During a visual feedback session, therapists will spend 30min per session using the Mobility Rehab system for gait training with patients. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
89352446|NCT03869879|Placebo Comparator|Traditional physical therapy|During a regular session, patients with gait impairment will work on gait with the following tasks for 30min: weights on ankles, dual tasks, UE support, partial body weight support, speed challenges, obstacles, and head turning. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
89352447|NCT01171781|Active Comparator|3 weekly CDDP based CCRT|radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin
89352448|NCT01171781|Experimental|weekly cisplatin based CCRT|radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy
89352449|NCT01284023||Controls|Uninjured volunteers
89352450|NCT03233529|Experimental|Crisaborole ointment|
89352451|NCT03233529|Placebo Comparator|Placebo ointment (vehicle)|
89352452|NCT04006171|Active Comparator|women with polycystic ovary syndrome|36 patients with PCOS
89352453|NCT04006171|Active Comparator|Healthy women of reproductive age|30 patients with regular normal menstrual cycle
89352454|NCT01171859|Experimental|Doxycycline + Tauroursodeoxycholic acid|
89352455|NCT01284101|Active Comparator|Forceps delivery of donor graft|Using the forceps to insert the donor graft.
89352456|NCT01284101|Experimental|Tan Endoglide for insertion of the donor graft|Use of the Tan Endoglide for insertion of the donor graft.
89352457|NCT02652468|Experimental|Peripheral Blood Stem Cell Transplant|"PREPARATIVE REGIMEN: Participants receive fludarabine phosphate IV over approximately 30 minutes on days -5 to -2, and mesna IV over 24 hours and cyclophosphamide IV over approximately 2 hours on days -5 and -4. Participants also undergo total nodal irradiation on day -1.~TRANSPLANT: Participants undergo T-Cell Receptor (TCR) alpha-beta/CD19 depleted hematopoietic stem cell transplant on day 0. If the graft contains less than 4 x 10^6 CD34+ cells/kg participant body weight (BW), patients may receive a second graft on day 1.~GVHD PROPHYLAXIS: Participants receive mycophenolate mofetil orally twice a day (PO BID) on days -1 to 30, tacrolimus PO or IV on days 2-180 with a taper beginning on day 90 (given only if graft TCR alpha-beta+ cell content is over 1 x 10^5 cells/kg ideal BW of the patient), and rituximab IV on day 2 (given only if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the participant)."
89352458|NCT03737071|Experimental|Low Carbohydrate Diet|Low Carbohydrate Diet
89352459|NCT04673877|Experimental|Bier Block Group|Subjects will receive antibiotic Vancomycin from a Bier Block (injected into an arm vein with a tourniquet up to keep antibiotics in the arm). Samples will be collected from bone and tissue that is normally removed during surgery.
89352460|NCT04673877|Active Comparator|Systemic Intravenous IV Group|Subjects will receive antibiotic Vancomycin through intravenous administration. Samples will be collected from bone and tissue that is normally removed during during surgery.
89352461|NCT01284179|Experimental|Hypnotherapy|Participants will be randomized to either the home hypnotherapy or educational group. The HHT protocol will consist of sequences of two different types of sessions, longer biweekly sessions (LS), each approximately 30-40 minutes in length, and shorter daily sessions (SS), approximately 12 minutes in length. On the first day of each sequence, the patient will listen to the appropriate LS. The patients will listen to the SS on a daily basis in between each LS. Every 2 weeks a new sequence will begin, for a total of 12 weeks of treatment.
89352462|NCT01284179|Other|Educational|Participants will be randomized to receive either home hypnotherapy or an educational program. The control group will receive an educational digital audio program on MP3 players. These digital audio files will contain general information about FCP and FGIDs. These audio files will be similar to the intervention audio files in length. Patients will be instructed to begin listening on the day of randomization. Patients will be instructed to continue their other medical treatment for chest pain during the study. The control group will be assessed at the same times as the HHT group.
89352463|NCT05179590||General anesthesia Group|
89352464|NCT01166789|Active Comparator|Lubiprostone|Lubiprostone 48ug taken daily for 14 days.
89352465|NCT01166789|Placebo Comparator|Placebo|2 capsules containing a substance with no active ingredient taken daily for 14 days.
89352466|NCT01314339|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
89352467|NCT01314339|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
89352468|NCT03736915|Active Comparator|1 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
89352469|NCT03736915|Active Comparator|3 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
89352470|NCT03736915|Active Comparator|5 cc needle with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
89352471|NCT01168817|Experimental|Arm 1|
89352472|NCT01168817|Active Comparator|Arm 2|
89352473|NCT01168817|Placebo Comparator|Arm 3|
89352474|NCT04523649|Experimental|Home-based atrial fibrillation screening group|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
89352475|NCT04523649|No Intervention|Control group|Conventional medical care
89352476|NCT03639961|Experimental|Staff of facilities for intervention|Intervention: Participants have been trained two times in six months period with integrated leading, managing and governing for results model.
89352477|NCT03639961|Active Comparator|Staff of facilities for control|Intervention: Participants have been trained two times in six months period with traditional model.
89352478|NCT01279811|Other|Single Arm|Vasopressor Crossover - Dopamine & NORepinephrine
89352479|NCT04043143|Placebo Comparator|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
89352480|NCT04043143|Experimental|Arm 2 Prescription Tool Intervention|At the time of writing the discharge prescription for a patient the provider will be informed by the best practice alert (BPA) Prescription Tool that a patient may be considered for a lower post-discharge opioid dose (no opioids for patients who did not take any opioids in the last 24 hours, and 10 oxycodone 5mg tablets, for patients having taken less than 22.5 MME, e.g. 1-3 oxycodone 5mg tablets in the last 24 hours). Final dosing decisions and drug choices will remain at the discretion of the treating provider and decisions will be tracked.
89352481|NCT01168895|Experimental|Arm 1|
89352482|NCT01168895|Experimental|Arm 2|
89352483|NCT01169051||Thoracic sugery statins|
89352484|NCT01169051||Thoracic surgery non-statins|
89352485|NCT01169129|Active Comparator|surgery+whole-brain irradiation|brain metastases is resected and the patient is submitted to whole-brain irradiation
89352486|NCT01169129|Active Comparator|whole-brain irradiation+radiosurgery|patients will be submitted to whole-brain irradiation and after, they will be submitted to radiosurgery.
89352487|NCT03736837|Experimental|Anlotinib Plus Icotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Icotinib 125mg p.o, tid. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
89352488|NCT02526407|No Intervention|Control|Participants continue with usual care. No planned intervention.
89352489|NCT02526407|Active Comparator|Group play|Participants take part in 10 weeks of group play activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
89352490|NCT02526407|Experimental|Singing|Participants take part in 10 weeks of group singing activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
89352491|NCT04041895||Alzheimer's Disease|Those individuals who possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
89352492|NCT04041895||Control|Those individuals who do not possess a significant amyloid burden per results of a previous amyloid PET scan radiology report.
89352493|NCT03523806|Experimental|Solution-Focused Coaching Group|Half of the participants (n=15) will be assigned a coach and receive coaching 8 times for up to 1 hour over 6 months. The first session will take place in the home and subsequent session will take place online using an online meeting tool.
89352494|NCT03523806|No Intervention|Control Group|Half of the participants (n=15) will not be receiving coaching
89352495|NCT03745105|Experimental|dexamethasone|Pretreatment intraligamentary injection of 0.4 mL of 8 mg/2 mL dexamethasone (Dexamethasone, AMRIYA pharmaceutical, Egypt)
89352496|NCT03745105|Experimental|piroxicam|Pretreatment intraligamentary injection of 0.4 mL of 20 mg mL-1 piroxicam (Feldene, Pfizer, Egypt)
89352497|NCT03745105|Active Comparator|Mepivacaine HCL|Pretreatment Intraligamentary injection of 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml (Mepecaine - L, Alexandria Co.-Egypt)
89352498|NCT01282541|Active Comparator|Transconjunctival|
89352499|NCT01282541|Active Comparator|Transcutaneous|
89352500|NCT03744325|Active Comparator|Hen's egg OIT|Daily intake of gradually increasing doses of egg white protein under a 32 weeks period, continued by regular, daily intake of 1000 mg egg white protein.
89352501|NCT03744325|No Intervention|Hen's egg avoidance|Hen's egg is avoidance diet is continued.
89352502|NCT03745027|Experimental|In vitro fertilization|Paients undergoing in vitro fertilization with Gonadotropin-releasing Hormone agonist. Follicular fluid sialic acid levels will be measured.
89352503|NCT03744247|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89352504|NCT03744247|Active Comparator|Lenvatinib alone|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received placebo intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
89352505|NCT01282619|Experimental|Huperzine A Sustained-Release Tablet|
89352506|NCT01282619|Active Comparator|Huperzine A Tablet|
89352507|NCT01282619|Placebo Comparator|Placebo|
89352508|NCT01282697|Experimental|rapamycin+irinotecan at a given dose|
89352509|NCT03283098|Placebo Comparator|Placebo|Intravenous (IV) administration of placebo three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
89352510|NCT03283098|Experimental|Etelcalcetide|5 mg intravenous (IV) dose of etelcalcetide three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
89352511|NCT03655951|Experimental|Resource 1|Web-based resource on adolescent sexual health
89352512|NCT03655951|Active Comparator|Resource 2|Alternate web-based resource on adolescent sexual health
89352513|NCT02527798|Experimental|Furosemide Cohort 1|Within cohort 1, infants will be randomized using a 3:1 scheme to receive furosemide or placebo. Those randomized to receive furosemide will receive (1mg/kg daily intravenously or 2 mg/kg daily enterally for 28 days.
89352514|NCT02527798|Placebo Comparator|Placebo Cohort 1|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
89352515|NCT02527798|Experimental|Furosemide Cohort 2|Cohort 2 Infants will receive furosemide (1mg/kg every 6 hours intravenously or 2 mg/kg every 6 hours daily enterally) for 28 days.
89352516|NCT02527798|Experimental|Furosemide Cohort 3|Cohort 3 Infants will receive furosemide (2mg/kg every 6 hours intravenously or 4 mg/kg every 6 hours daily enterally) for 28 days.
89352517|NCT02527798|Placebo Comparator|Placebo Cohort 2|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
89352518|NCT02527798|Placebo Comparator|Placebo Cohort 3|Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
89352519|NCT01282775|No Intervention|Environment / Usual Care|
89352520|NCT01282775|Other|WEB+ Environment|Web-based weight loss program (WEB) + Environment - Participants have access to a proven Web-based weight loss program with weekly lessons focused on lifestyle behavior changes
89352521|NCT01282775|Other|WEB + Cash Incentive for Weight Loss|Web-based Weight Loss Program + Cash Incentive for Weight Loss - participants have access to a proven web-based weight loss program plus they are paid cash based on the percent weight lost at 12 months compared to baseline.
89352522|NCT01282853|Active Comparator|A1|one biopsy specimen taken from gastric antrum was put into RUT kit
89352523|NCT01282853|Experimental|A4|4 biopsy specimens taken from gastric antrum were put into RUT kit
89352524|NCT01282853|Experimental|B1|one biopsy specimen taken from gastric body was put into RUT kit
89352525|NCT05331911|Experimental|Propofol Group|The propofol group was maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
89352526|NCT05331911|Experimental|Sevoflurane group|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
89352527|NCT03188991|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
89352528|NCT03188991|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
89352529|NCT03188991|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
89352530|NCT03188991|Experimental|Second Phase: NanoPac® at Best Dose|Intracystic injection of NanoPac®. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® injections, with the second injection administered 12 weeks after the first injection.
89352531|NCT03857542|Placebo Comparator|Vehicle|Participants received one drop of vehicle in each eye, once daily, for up to 30 days.
89352532|NCT03857542|Experimental|Pilocarpine HCl Ophthalmic Solution|Participants received one drop of pilocarpine HCl ophthalmic solution 1.25% in each eye, once daily, for up to 30 days.
89352533|NCT01172717|Experimental|Panitumumab|Single arm study
89352534|NCT01172795||healthy controls|
89352535|NCT01172795||chronic whiplash patients|
89352536|NCT01172795||Fibromyalgia patients|
89352537|NCT03382366|Other|Sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as sarcopenic by the DXA.~This group will undergo the same evaluations/intervention of the second group."
89352538|NCT03382366|Other|Non-sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as non-sarcopenic by the DXA.~This group will undergo the same evaluations/intervention of the first group."
89352539|NCT03209973|Experimental|Tislelizumab|Tislelizumab 200 mg administered intravenously (IV) every-3-weeks (Q3W)
89352540|NCT03751631|Other|1-TR/PE, 2-TR, 3-PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
89352541|NCT03751631|Other|1-TR/PE, 2-PE, 3-TR|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
89352542|NCT03751631|Other|1-TR, 2-TR/PE, 3-PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
89352543|NCT03751631|Other|1-TR, 2-PE, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
89352544|NCT03751631|Other|1-PE, 2-TR/PE, 3-TR|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
89352545|NCT03751631|Other|1-PE, 2-TR, 3-TR/PE|Participants were dosed once at 3 separate clinic visits in accordance with this sequence. Each participant received 2 sprays of the study drug in each eye.
89352546|NCT03736525|Experimental|Design For Wellness (DWELL)|Intervention participants will: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
89352547|NCT03736525|Other|Wait list control group|After the close of the study, we will open the Facebook group to all, and wait list control group participants can receive a delayed form of the intervention, which includes: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
89352548|NCT01172951|Active Comparator|OGTT-OGTT-Physical tests|2 successive Oral Glucose Tolerance Tests followed by a physical tests session
89352549|NCT01172951|Active Comparator|OLTT-OLTT-Physical tests|2 successive Oral Lipid Tolerance Tests followed by a physical test session
89352550|NCT01172951|Active Comparator|OGTT-OLTT-Physical tests|Oral glucose tolerance test followed by an oral lipid tolerance test (or vice-versa) followed by a physical tests session
89352551|NCT03688711|Experimental|Dasiglucagon|single fixed dose (subcutaneous injection) of dasiglucagon
89352552|NCT03688711|Placebo Comparator|Placebo|single fixed dose (subcutaneous injection) of placebo
89352553|NCT03866681|Experimental|Patients cohort|A total of 40 patients with refractory classic PNH will be included and will be intervened by a combined therapy including sirolimus and low-dose warfarin
89352554|NCT03188055|Experimental|Best Case/Worst Case communication tool|The patient's enrolled surgeon will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the patient.
89352555|NCT03188055|No Intervention|Usual Care|Usual care typically includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.Usual care also consists of daily updates with patient and family, describing each new problem as it arises and what will be done to treat it, regardless of how this fits into the patient's overall prognosis or health trajectory.
89352556|NCT03866915||Patients undergoing elective surgery|All patients older than 18 years undergoing elective surgery that receive a preoperative visit by anesthesiologists in which Aortic pulse wave velocity measurement and the 6 minutes walking test (6MWT) is carried out
89352557|NCT04035577|Experimental|Extended usability of a mobile self-help intervention|Participants will have open access to the Intellicare Hub app for 8-weeks and be surveyed at Baseline, 4-weeks, and 8-weeks
89352558|NCT02416492|Experimental|SB623 Cells|SB623 Cells: 2.5, 5 or 10 million cells
89352559|NCT02416492|Sham Comparator|Sham Surgery|Control Sham Surgery
89352560|NCT01284569|Experimental|ALX-0061|
89352561|NCT01284569|Placebo Comparator|Placebo|
89352562|NCT01172015|Experimental|PTI patients|Study NK cells functions, phenotypic changes and transcripts from ITP patients
89352563|NCT01172015|Other|healthy volunteers|Study NK cells functions, phenotypic changes and transcripts from healthy volunteers
89352564|NCT03736369|Experimental|DWP14012 40mg|Orally, once daily
89352565|NCT03736369|Active Comparator|Esomeprazole 40mg|Orally, once daily
89352566|NCT03867695|Experimental|Serratus Block|"At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.~Under ultrasonography assistance, block will be performed at the fifth rib in the midaxillary line. Local anesthetic will be injected either superficial to the serratus anterior muscle or deep underneath the muscle.~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of ropivacaine will be prepared identically by the central pharmacy, without any possible identification of the product."
89352567|NCT03867695|Placebo Comparator|Placebo Block - Control Group|"Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution. Under ultrasonography assistance, placebo will be injected at the fifth rib in the midaxillary line, either superficial to the serratus anterior muscle or deep underneath the muscle.~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of sterile saline will be prepared identically by the central pharmacy, without any possible identification of the product."
89352568|NCT02412046|Active Comparator|Time of the first biopsy: H0|For the patients in arm H0, the first biopsy is done as soon as the patient is lying on the air mattress.
89352569|NCT02412046|Active Comparator|Time of the first biopsy: H1|For a patient in arm H1, it is done after 1 hour lying on the air mattress.
89352570|NCT02412046|Active Comparator|Time of the first biopsy: H2|For a patient in arm H2, it is done after 2 hour lying on the air mattress.
89352571|NCT02412046|Active Comparator|Time of the first biopsy: H3|For a patient in arm H3, it is done after 3 hour lying on the air mattress.
89352572|NCT03124654||Education|
89352573|NCT01172171|Active Comparator|Melatonin|The randomized patients will receive 10 ml 0,1 mg/ml melatonin intracoronarily and 49 mg intravenously.
89352574|NCT01172171|Placebo Comparator|Isotonic saline|The randomized patients will receive 10 ml isotonic saline (NaCl)and 490 ml intravenously.
89352575|NCT03655717|Experimental|Phase 2A|In a double-blind placebo-controlled, random order cross-over study of single dose dronabinol, participants received dronabinol or identical placebo on two separate study visits in randomized order.
89352576|NCT03655717|Experimental|Phase 2B|In a randomized, double-blind, 4-treatment, 4-period, crossover study with THC or placebo administration and ethanol or placebo administration, participants were randomly assigned to 1 of 4 sequences and received each of the following treatments: placebo dronabinol + placebo ethanol, placebo dronabinol + ethanol, dronabinol + placebo ethanol, & dronabinol + ethanol.
89352577|NCT03382288|Experimental|Examination of participants|Examination of participants by means of the investigational device, Eyestar 900 as well as the comparative devices.
89352578|NCT01284257||Enteric coated mycophenolate sodium (EC-MPS) arm|Patients to whom EC-MPS is prescribed by their practitioner.
89352579|NCT01284257||MMF arm|Patients to whom MMF is prescribed by their practitioner.
89352580|NCT03382210||ERP group|A prospective series of patients (N=100) undergoing elective colorectal resection and completing a standardized enhanced recovery protocol in 2013-2015 (ERP group) at the S. Anna University Hospital in Ferrara (Italy).
89352581|NCT03382210||Pre-ERP group|A retrospective series of patients (N=100) operated on at the the S. Anna University Hospital in Ferrara (Italy) in 2009-2011 (Pre-ERP group), before the introduction of ERP methodology.
89352582|NCT03124498|Experimental|CIK Cell|"Phase I - Three dose levels escalated according to 3+3 rule~Phase II - The recommended dose level according to the results from Phase I"
89352583|NCT01172249|Experimental|Glucosamine-Chondroitin Mantecorp|1 capsule three times daily before meals (drug test - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Mantecorp)
89352584|NCT01172249|Active Comparator|Condroflex|1 capsule three times daily before meals (reference medication - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Condroflex ®).
89352585|NCT03744169||Children with acute respiratory failure|Point-of-care lung ultrasound on admission to the PICU to determine the cause of respiratory failure.
89352586|NCT03867461|Active Comparator|Group A|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group A: Initial Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-80 mmHg, End tidal CO2 38-40 mmHg."
89352587|NCT03867461|Active Comparator|Group B|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group B: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg,"
89352588|NCT03867461|Active Comparator|Group C|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group C: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 24-26 mmHg, Subsequent Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg,"
89352589|NCT03867461|Active Comparator|Group D|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group D: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-100 mmHg, End tidal CO2 24-24 mmHg,"
89352590|NCT05153733|Experimental|RIFRAM implant|RIFRAM implant
89352591|NCT03385642||Chondromimetic|Treatment of osteochondral defect in the knee with Chondromimetic device(s) in previous study 0MCM0107
89352592|NCT03621813|Other|Control|Participants maintain their current activity level.
89352593|NCT03621813|Active Comparator|Exercise Rehabilitation|Participants will exercise 2x/week at training facilities and at home one day a week.
89352594|NCT03867071|Experimental|erythropoietin (EPO) group|
89352595|NCT03867071|Placebo Comparator|Placebo (PLA) group|
89352596|NCT03382132|Experimental|momHealth|Participants will receive support and information via the momHealth program.
89352597|NCT03382132|Active Comparator|Control|Participants will receive the normal support they would normally receive if they were not in a study.
89352598|NCT04032613|Experimental|Vascular access quality improvement program participants|All participants enrolled in the study who are involved in the Vascular Access Navigation and Education Quality Improvement Program.
89352599|NCT01172327|Experimental|Multicomponent exercise|This arm is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks.
89352600|NCT01172327|Active Comparator|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks.
89352601|NCT03375502|Experimental|MG1111(Varicella vaccine)|A single injection of 0.5ml MG1111 will be administered subcutaneously at Visit 1
89352602|NCT03375502|Active Comparator|Comparator(Varicella vaccine)|A single injection of 0.5ml comparator will be administered subcutaneously at Visit 1
89352603|NCT01284413|Experimental|S-1, Gemcitabine, Cisplatin|
89352604|NCT03867149|Other|patient with first thalamic infarct|Patient with first thalamic infarct, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
89352605|NCT03867149|Other|healthy subject matched with control|Healthy subject matched with control, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
89352606|NCT05152017|Experimental|Flu-M Quadro with preservative|25 volunteers were vaccinated with the Flu-M Quadro inactivated split influenza vaccine with a preservative
89352607|NCT05152017|Experimental|Flu-M Quadro without preservative|25 volunteers were vaccinated with the Flu-M Quadro inactivated split influenza vaccine without a preservative
89352608|NCT05152017|Placebo Comparator|Placebo|25 volunteers were vaccinated with a Placebo
89352609|NCT03866993|Experimental|AK105 plus Carboplatin and Paclitaxel|Subjects receive AK105 200 mg intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
89352610|NCT03866993|Placebo Comparator|placebo plus Carboplatin and Paclitaxel|Subjects receive placebo intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
89352611|NCT03376906|Experimental|Obese Subjetcs|The subjects were welcomed for a visit to the Laboratory of Studies of Physical Training Applied to Health, where they performed an evaluation of body composition, maximal ergospirometric exercise test, and three experimental sessions (HIIE 1, HIIE 3 and Control) in a random order, which were performed with a 96 h interval between them.
89352612|NCT01172405|Experimental|Ibuprofen + Caffeine|72 patients treated with one or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
89352613|NCT01172405|Active Comparator|Ibuprofen|72 patients treated with one or two tablets of ibuprofen 400 mg when presenting headache.
88807307|NCT05247840||healthy children|Healthy children aged 5-18 years (boys, girls) without any acute or chronical disease will be will enrolled and the same tests will be performed on them as in diabetic children. Children with voided volume <20 mL, postvoid residual volume >15%, and signs of an overstretched bladder [voided volume more than: 30 x age (years) + 30 mL] will be excluded.
89352614|NCT03381976|Active Comparator|Intervention 2X/week (G2X)|This group performed resistance training twice a week (Tuesdays and Thursdays)
89352615|NCT03381976|Active Comparator|Intervention 3X/week (G3X)|This group performed resistance training three sessions a week (Mondays, Wednesdays, and Fridays).
89352616|NCT03381976|No Intervention|Control group (GC)|This group did not perform any type of organized physical exercise during the study period.
89352617|NCT02966691|Active Comparator|Patients 'sick'|"The patients of this arm have a clinical signs of bladder cancer with :~a positive result of bladder endoscopy~or an negative endoscopy and a positive result of the conventional cytology~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice .This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized"
89352618|NCT02966691|Active Comparator|Patients 'healthy'|"The patients of this arm have no suspicion of bladder cancer with negative results of their bladder endoscopy and conventional cytology.~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
89352619|NCT02966691|Active Comparator|Patients 'monitoring'|"The patients of this arm have a history of bladder cancer, but the results of their follow up examinations (cytologic and endoscopic) are negative (no tumor).~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
89352620|NCT01166867||Infant Development|Photo-plethysmography monitoring
89352621|NCT04000165|Experimental|AG-348 in participants with Sickle Cell Disease|Intra-patient dose escalating study, starting with 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
89352622|NCT03376828|Active Comparator|Hypertensive T group|Hypertensive T group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) Macintosh laryngoscopy using intubated
89352623|NCT03376828|Active Comparator|Hypertensive VL group|Hypertensive VL group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) C-Mac Videolaryngoscope using intubated
89352624|NCT03376828|Sham Comparator|Non-hypertensive T group|Non-hypertensive T group: (Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg) Macintosh laryngoscopy using intubated
89352625|NCT03376828|Sham Comparator|Non-hypertensive VL group|Non-hypertensive VL group: Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg C-Mac Videolaryngoscope using intubated
89352626|NCT02526563||Iliac crest wound catheter group|These patients will receive an iliac crest wound catheter after an iliac crest bone harvest to repair a palatal defect. This catheter is part of standard of care. This study will collect blood to measure unbound ropivicaine levels.
89352627|NCT03375424||1st subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced Vedolizumab (VDZ) therapy (n=1.800). A former therapy with other biologics is allowed. More than 30% of these Vedolizumab patients will be biologics-naiv.
89352628|NCT03375424||2nd subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced anti-TNF-alpha therapy other than VDZ (n=350) in biologics-naiv patients.
89352629|NCT03375424||3rd subpopulation|IBD patients (age at enrollment: 18-80 years) with an early disease (n=350), who were first diagnosed <2 years before the start of documentation in the Investigator initiated non-interventional study (NIS) but have not yet received and are not planned to receive biologics in the near future.
89352630|NCT01172483|Experimental|multimodal community program|multimodal community program of exercise and education
89352631|NCT01172483|Active Comparator|active control|general practice in primary care and education of chronic disorders
89352632|NCT03187197||Cohort A|consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
89352633|NCT03187197||Cohort B|patients being newly diagnosed with NVAF and initiated on Pradaxa®
89352634|NCT03375346|Experimental|Whole body vibration group|Whole body vibration group performed a single session of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
89352635|NCT03375346|Active Comparator|Exercise only group|The control group performed the same session without vibration.
89352636|NCT01284647|Experimental|Teprenone capsule|
89352637|NCT01284647|Active Comparator|sucralfate|
89352638|NCT04000009|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
89352639|NCT03381898|Experimental|Telehealth Coordinated Allied Health|rural persons with Parkinson's disease will receive telehealth exercise, speech therapy, medication management for 8 weeks. Exercise, speech therapy, and medication management are usual care for persons with Parkinson's disease. Having the 3 areas coordinated in delivery via telehealth is the new delivery that our aims address
89352640|NCT01280045|Experimental|AROMATASE INHIBITOR|this would be compared before and after VAGINAL HYSTERECTOMY
89352641|NCT01280045|Active Comparator|GNRH ANALOG|this would be compared before and after VAGINAL HYSTERECTOMY
89352642|NCT03282240|Experimental|QIV-HD|Participants randomized to receive a single injection of 0.7 mL QIV-HD by intramuscular (IM) route at Day 0.
89352643|NCT03282240|Active Comparator|TIV-HD1 (Licensed TIV-HD1)|Participants randomized to receive a single injection of 0.5 mL licensed TIV-HD1 by IM route at Day 0.
89352644|NCT03282240|Active Comparator|TIV-HD2 (Investigational TIV-HD2)|Participants randomized to receive a single injection of 0.5 mL investigational TIV-HD2 by IM route at Day 0.
89352645|NCT03185949|Sham Comparator|Sedation and subcutaneous lidocaine|Lidocaine injected at the femoral artery site. This patients will undergo behavioral therapy for 6 months and will crossover and will receive bariatric embolization.
89352646|NCT03185949|Experimental|interventional: bariatric embolization|• In patients randomized to intervention bariatric embolization will be performed using Endobar Infusion Catheter System. After procedure patients will undergo behavioral therapy
89352647|NCT01284725|Experimental|immunosuppressive treatment discontinuation,|
89352648|NCT01284725|Active Comparator|Continuation of immunosuppressive therapy|with MMF or AZA, with a background therapy with hydroxychloroquine, and possibly low-dose corticosteroids
89352649|NCT03655405|Experimental|Individual Deprescribing Intervention|Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).
89352650|NCT03655405|No Intervention|Control|Participants allocated to the control group will receive usual care.
89352651|NCT03510598|Experimental|Treatment for Submental Fat Reduction withCoolSculpting System followed by Kybella|CoolSculpting followed by Kybella treatments. Kybella supplied in 2mL vials.
89352652|NCT01173107|Experimental|MDRD eGFR 10~50 ml/min/1.73m2|
89352653|NCT01175057||Group A|10 patients who undergo home monitoring with the MeDiNa Homebox for 4 weeks and then 4 weeks without the MeDina Homebox
89352654|NCT01175057||Group B|Group B starts without the MeDiNa Homebox for 4 weeks and then undergo Homemonitoring with the MeDiNa Homebox for 4 weeks.
89352655|NCT03376750|Experimental|CO - OP via telerehabilitation + standard care|10 CO-OP videoconferencing sessions from an occupational therapist . Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
89352656|NCT03376750|Experimental|CO - OP via face to face + standard care|10 CO - OP face to face sessions from an occupational therapist. Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
89352657|NCT03376750|No Intervention|control group - standard care|standard care as given from public health service
89352658|NCT03860441|Experimental|Intervention group|Participants in the intervention group received 24 sessions of computerized cognitive training, with a total time of 960 min.
89352659|NCT03860441|Active Comparator|Active control group|Participants in the control group attended activities separate activities, such as learning about healthy lifestyle, had cooking and other social lessons for the same amount as the intervention group performed cognitive training.
89352660|NCT04656210||Group 1: MD type 1 normal|patients with type 1 myotonic dystrophy with normal carbohydrate tolerance
89352661|NCT04656210||Group 2: MD type 1 Diabetes|"patients with type 1 myotonic dystrophy with diabetes. Patients with carbohydrate intolerance (pre-diabetes) who became diabetic at 3 years of age will be divided into Group 2."
89352662|NCT03736291|Active Comparator|active rTMS|"The Active rTMS: The magnetic head uses the Magro X100's 8-shaped coil, and the intervention site is the cerebellar vermis (1 cm below the occipital carina). The stimulation intensity is gradually increased by the 80%-100% exercise threshold according to the patient's tolerance. The total number of stimulation pulses per day is 600, the basic frequency is 5 Hz, and one short burst stimulus is given every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and every 10 short bursts are stimulated for 8 s. A total of 200 short bursts of stimulation. Intervention once a day, 5 times a week, intervention for 2 weeks, a total of 10 times."
89352663|NCT03736291|Sham Comparator|sham rTMS|"The sham rTMS: The sham stimulation method was to invert the 8 shaped coil, which was 180° to the scalp, and other intervention parameters were consistent with the study group."
89352664|NCT03381820|Experimental|music listening|Participants who were randomized into intervention group were assigned to listen to the music everyday (day 1st to day 30th), at anytime of day that was suitable with their lifestyles but not at the time of BP measurement. During day 31st -120th, participants did not listen to the music. Other treatment was the same as the control arm.
89352665|NCT03381820|No Intervention|control|control arm received conventional hypertension treatment.
89352666|NCT03222141|Experimental|SAPIEN 3™ valve|
89352667|NCT01313598|Experimental|GLPG0187|GLPG0187 for infusion
89352668|NCT03744091|Active Comparator|10 mg P1|10 mg of P1 will be administered and compared with an active dose of 20 mg P1 on crossover
89352669|NCT03744091|Active Comparator|20 mg P1|20 mg of P1 will be administered and compared with an active dose of 10 mg P1 on crossover
89352670|NCT03376594|Active Comparator|Benjakul Extract|Benjakul Extract 100 mg capsule by mouth 3 times a day for 42 days
89352671|NCT03376594|Placebo Comparator|Loratadine|Loratadine 10 mg capsule by mouth 3 times a day for 42 days
89352672|NCT03863873|Active Comparator|PRP Injection Group|PRP Preparation: 16 ml of blood was obtained from each patient using special PRP kits (GD medical pharma, Dutch company). The blood was collected on citrated tubes with a mixing ratio of 9:1 by volume. Tubes underwent 1st centrifugation at speed of 3000 rpm (704g) for 3 minutes (to separate red blood cells from plasma). Plasma was then removed by syringe and then placed into another sterile tube with no anticoagulant and then underwent 2nd centrifugation at speed of at 4000 rpm (1252g) for 15 min. The supernatant platelet-poor plasma was then removed leaving 2 ml of PRP pellets in the sediment, and suspend the PRP pellets by gentle shaking of the tube. PRP is activated by adding 200 μl of 0.025 calcium chloride(Dhurat and Sukesh, 2014).
89352673|NCT03863873|Active Comparator|Steroid injection Group|A single injection of methylprednisolone acetate 40 mg/ml using a technique similar to that described for the PRP injection
89352674|NCT05572164|Active Comparator|TRADITIONAL EPIDURAL|standard epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia
89352675|NCT05572164|Active Comparator|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
89352676|NCT03381664|Experimental|AVP-923-20/10 capsule|Participants will receive a single AVP-923-20/10 (dextromethorphan hydrobromide [DM] 20 milligram [mg]/quinidine sulfate [Q] 10 mg) capsule administered orally.
89352677|NCT03381664|Experimental|AVP-923-20/10 via applesauce|Participants will receive the contents from a single AVP-923-20/10 capsule mixed and consumed in 1 tablespoon of applesauce.
89352678|NCT03381664|Experimental|AVP-923-20/10 via nasogastric feeding tube|Participants will receive the contents from a single AVP-923-20/10 capsule solubilized in feeding solution and administered through a nasogastric feeding tube.
89352679|NCT04029961|Active Comparator|Video Education|Participants will receive video education on radiation therapy.
89352680|NCT04029961|Experimental|VR-based Education|Participants will receive VR-based education on radiation therapy.
89352681|NCT03863561||Waiting room sample|Patients with type 1 or type 2 diabetes attending an LMC Diabetes & Endocrinology specialist clinic in Ontario completed the SCPI in the waiting room while attending their usual appointment with their healthcare provider.
89352682|NCT03863561||DSME Intervention|Patients with poor glycemic control (A1C >8.0%) were enrolled into a diabetes self-management education (DSME) program. The SCPI was completed at their first and last visit and and their individual results were incorporated into the care paths that were then customized for that participant. The patient met with a diabetes educator five to seven times over the course of three to four months.
89352683|NCT05126979|Experimental|Flu-M (without a preservative)|15 volunteers were treated with the Flu-M inactivated split influenza vaccine without a preservative
89352684|NCT05126979|Experimental|Flu-M (with a preservative)|15 volunteers were treated with the Flu-M inactivated split influenza vaccine with a preservative
89352685|NCT05126979|Placebo Comparator|Placebo|15 volunteers were treated with a placebo
89352686|NCT04060758|Experimental|14.7 mcg (single dose)|PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.
89352687|NCT04060758|Experimental|26.6 mcg (single dose)|PA5108 Latanoprost FA SR Ocular Implant which releases 26.6 mcg.
89352688|NCT04060758|Experimental|35.5 mcg (single dose)|PA5108 Latanoprost FA SR Ocular Implant which releases 35.5 mcg.
89352689|NCT04060758|Experimental|14.7 mcg (repeat dose)|Repeat dose of PA5108 Latanoprost FA SR Ocular Implant which releases 14.7 mcg.
89352690|NCT03484455|Experimental|Hypothermic Machine Perfusion|Hypothermic Machine Perfusion with Organ Recovery Systems LLT system
89352691|NCT03484455|Active Comparator|Static Cold Storage|Standard of Care - Static Cold Storage
89352692|NCT03863405|Experimental|Metformin Group|850 mg metformin twice daily for six months in addition to standard therapy
89352693|NCT03863405|Active Comparator|Control Group|placebo in addition to standard therapy for rheumatoid arthritis
89352694|NCT03637218|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
89352695|NCT03637218|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
89352696|NCT03866369|Experimental|Experimental|IMP Under investigation
89352697|NCT03866369|Placebo Comparator|Placebo to Match|
89352698|NCT01284803|Experimental|experimental arm|
89352699|NCT05177952|Experimental|Blood Flow Restriction|The BFR group will complete 1 set of 30 (1 x 30) at 30% of their 1 repetition maximum for leg press, leg extension, leg curl, chest press, seated row, and shoulder press completed on exercise machines with 2 minutes between exercises.
89352700|NCT05177952|Active Comparator|Standard of Care|The standard of care group will complete 1 set of 8-12 repetitions at 60-80% of their 1 repetition maximum for leg press, leg extension, leg curl, chest press, seated row, and shoulder press completed on exercise machines with 2 minutes between exercises.
89352701|NCT03124576||control group|Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
89352702|NCT03124576||group B|Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
89352703|NCT03124576||group C|Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
89352704|NCT03124576||group D|Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
89352705|NCT03860675|Active Comparator|persons with Multiple Sclerosis (MS)|
89352706|NCT03860675|Placebo Comparator|Healthy controls|
89352707|NCT04024891|Experimental|Phentolamine Mesylate Ophthalmic Solution 1%|1 drop in each eye, 1 hour post medically-induced mydriasis
89352708|NCT04024891|Placebo Comparator|Phentolamine Mesylate Ophthalmic Solution Vehicle|1 drop in each eye, 1 hour post medically-induced mydriasis
89352709|NCT03381586|Experimental|Group A|1.0 mg/ml ALT-803
89352710|NCT03381586|Experimental|Group B|2.0 mg/ml ALT-803
89352711|NCT01178021|Active Comparator|Chloroquine|Standard arm
89352712|NCT01178021|Experimental|Chloroquine/Primaquine|Chloroquine combined with primaquine
89352713|NCT03250182|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol per protocol. Administered as 2 inhalations per use as instructed in the protocol.
89352714|NCT03381508||The study population|"The study population corresponds to patients with obstructive sleep apnea syndrome treated via continuous positive pressure and monitored according to usual practice with the latest Brizzy device.~Intervention: Brizzy continuous positive pressure device"
89352715|NCT01173263|Active Comparator|BIS 70|BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);
89352716|NCT01173263|Active Comparator|BIS 50|BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity)
89352717|NCT01173263|Active Comparator|BIS 35|BIS levels of 35 will be targeted (low frequency EEG activity)
89352718|NCT05177874|Experimental|Traumacel FAM Trium|Randomized application haemostatic agent Traumacel FAM Trium in the bleeding site.
89352719|NCT05177874|Active Comparator|Surgicel Fibrillar|Randomized application of haemostatic agent Surgicel Fibrillar in the bleeding site.
89352720|NCT03381430|Experimental|Gefitinib + Radiotherapy|Experimental: Gefitinib Gefitinib 250 mg/day oral daily Radiotherapy Total dose 50-54Gy, divided dose 1.8-2Gy
89352721|NCT01288157|Experimental|001|Golimumab Single dose of 50 mg subcutaneously
89352722|NCT01288157|Experimental|002|Golimumab Single dose of 100 mg subcutaneously
89352723|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-front line|histologically or cytologically confirmed solid tumor who have received no prior treatment
89352724|NCT03993379|Experimental|CX-072 in combination with ipilimumab|histologically or cytologically confirmed Stage III (unresectable) or Stage IV melanoma who have experienced progressive disease or relapse following treatment with a PD-1/PD-L1 immune checkpoint inhibitor
89352725|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-Progressed|histologically or cytologically confirmed, advanced/unresectable or metastatic solid tumor that have experienced disease progression during or following treatment with platinum based therapy
89352726|NCT03993379|Experimental|CX-072 in combination with anti-cancer therapy-Neoadjuvant|neo-adjuvant study in subjects with histologically confirmed solid tumor
89352727|NCT01284881||OSAHS|
89352728|NCT03376282|Other|HBOT treatment|HBOT treatment: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
89352729|NCT03376282|No Intervention|Standard treatment|follow up with the standard recommended treatment
89352730|NCT03866291||ESBL carrier|"This cohort is followed for a year with additional selective ESBL cultures after 1, 3, 6 and 12 months. In the end of the year a questionnaire is handed in to the study group.~Sera is donated after 4-6 weeks and in year."
89352731|NCT03866291||Non ESBL-carrier|No further rectal cultures. In the end of the year a questionnaire is handed in to the study group. Sera is donated after 4-6 weeks and in year.
89352732|NCT01173419|Active Comparator|VenaCure EVLT NeverTouch|
89352733|NCT01173419|Active Comparator|RF ClosureFAST|
89352734|NCT03866447|Active Comparator|vitamin D versus placebo|This group will be treated by topical Vitamin D analogue (Calcipotriol) versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
89352735|NCT03866447|Active Comparator|Adapalene versus placebo|this group will be treated by topical Adapalene (0.1%) versus versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
89352736|NCT03370120|Experimental|Padsevonil|"Padsevonil will be administered in an open-label manner. The individual starting dose of each subject will be the one at the end of the parent study.~Once subjects enter EP0093 further individual dose adjustments are allowed after 1 week to the extent possible with the combination of tablet strengths available."
89352737|NCT03247686|Placebo Comparator|Placebo|Placebo
89352738|NCT03247686|Active Comparator|RSLV-132|Experimental drug
89352739|NCT01173575||Bacterial Infection|All Patients with bacterial infection receiving fosfomycin may be included
89352740|NCT01286363||Brachyfacial|Subjects with a horizontal facial growth pattern
89352741|NCT01286363||Mesofacial|Subjects with a balanced facial growth pattern
89352742|NCT01286363||Dolichofacial|Subjects with a vertical facial growth pattern
89352743|NCT05160324|Active Comparator|Axillary dissection (standard treatment)|"Axillary dissection in women with sentinel lymph node metastases.~(removal of at least 10 lymph nodes recommended)"
89352744|NCT05160324|Experimental|Preservation of axillary lymph nodes|Omission of Axillary dissection in women with sentinel lymph node metastases.
89352745|NCT03990649|Placebo Comparator|Double-Blind Treatment Period - Part A: Placebo|Soticlestat matching placebo tablets, orally, twice daily (BID) for Weeks 1, 2 and 3 in Double blind Titration Period. Soticlestat matching placebo tablets, orally BID for 12 weeks in Double blind Maintenance Period. Taper period (if participant did not continue to Part B): Dose of soticlestat matching placebo tablets was reduced to next lower dose every 3 days (maximum 6 days) until discontinuation.
89352746|NCT03990649|Experimental|Double-Blind Treatment Period - Part A: Soticlestat|Soticlestat, tablet, orally, 100 mg BID for Week 1, followed by 2×100 mg tablets, soticlestat, orally BID for Week 2, further followed by 3×100 mg tablets, soticlestat, orally BID for Week 3. Dose was uptitrated every week based on safety and tolerability. Part A (Double blind Maintenance Period): 3×100 mg tablets, soticlestat, orally BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period (if participant did not continue to Part B): Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
89352747|NCT03990649|Experimental|Open-Label Extension Period - Part B: Soticlestat|Soticlestat, 2×100 mg tablets, orally, BID for Week 1, followed by 3×100 mg tablets, soticlestat, orally, BID for Week 2. Dose was uptitrated every week based on safety and tolerability. Part B (Open label extension: Maintenance Period): 3×100 mg tablets, soticlestat, orally, BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period: Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
89352748|NCT01175291|Active Comparator|Arm A - FOLFOX 7 + MK-0646|
89352749|NCT01175291|Placebo Comparator|Arm B - FOLFOX 7 + Placebo|
89352750|NCT03863717|Experimental|Arm Endurance Exercise Training Group|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
89352751|NCT03863717|Active Comparator|Control Group|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
89352752|NCT05572008|Experimental|paediatric Crohn's disease|CD young population (ages 12-17 years) - N=20
89352753|NCT05572008|Active Comparator|Healthy volunteers|Age-, BMI- and gender-matched healthy volunteers (HV) - N=20
89352754|NCT03230266|Other|collection|collection of biological and device samples
89352755|NCT03732469|Experimental|Fentanyl/propofol + acetaminophen|In addition to the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol, one dose of 1300 mg of solid base rectal acetaminophen suppository (2 suppositories) will be administered at the end of oocyte retrieval.
89352756|NCT03732469|Active Comparator|Fentanyl/propofol only|Participants in this arm will receive the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol.
89352757|NCT01175447|Experimental|Chemoradiotherapy with S-1|radiation 54Gy over 30 fractions,and concurrent with s-1 on days 1-14 and 29-42
89352758|NCT02519998||Concussed patients|The clinical focus of this study will be on concussed athletes, both children and adults, and we will also include non-sports patients who have mild traumatic brain injury due to other situations including slip and fall, occupational, motor vehicle accidents, assault, and blast exposure.
89352759|NCT02519998||Non-concussed patients|Cohort control. Primarily athletes who undergo routine pre-season baseline assessment
89352760|NCT01313988|Active Comparator|Dose 1|Spread that contains plant sterols and fish oil
89352761|NCT01313988|Active Comparator|Dose 2|Spread that contains plant sterols and fish oil
89352762|NCT01313988|Active Comparator|Dose 3|Spread that contains plant sterols and fish oil
89352763|NCT01313988|Placebo Comparator|Placebo|Placebo spread
89352764|NCT01313988|Active Comparator|Control|Spread that contains plant sterols
89352765|NCT03743857|Experimental|Manual Therapy|6 sessions of ankle manual therapy
89352766|NCT03743857|No Intervention|Control|No intervention
89352767|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-1)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-1 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
89352768|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-2)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-2 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
89352769|NCT03863327||Acute severe 3-vessel disease or critical left main stenosis|"Severe 3-vessel disease: >/=75% stenosis in all three major coronary vessels (or equivalents in the case of anatomic variants or preexisting bypass) with an acute culprit lesion (TIMI<3) or~Left main stenosis > 50% (see Smith review paper for reference): acute left main culprit of any TIMI score, or any lesion of the left main with TIMI<3 or~Any other cardiac catheterization findings prompting initiation of emergent coronary artery bypass grafting within the next 120 hours"
89352770|NCT03863327||No evidence of acute coronary occlusion|"At least three sequential negative cardiac biomarkers within 24 hours of presentation~cardiac catheterization showing no culprit lesion.~Angiogram showing an acute culprit lesion but both no occlusion (TIMI 2 or greater) and troponins not exceeding the cutoff above~If positive troponin values present but no angiography, then the patient must have echocardiography showing no wall motion abnormality and troponin values less than the above cutoff~If the patient has insufficient data to classify into one of these categories, the patient must be excluded from the study as they cannot be classified as ACO or non-ACO. For example, patients with extremely high troponin but no culprit seen on cath may have acute occlusion with complete autolysis of thrombus, myocarditis, spasm, etc. Thus the investigators cannot classify them as NO ACO when the possibility of ACO remains and cannot be disproven."
89352771|NCT03381352|Experimental|Chemo-radiotherapy with IMRT technique|Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
89352772|NCT01175525|Placebo Comparator|sugar pill|sugar pill dissolved in water to be given 4 times a day 30 minutes prior to meals
89352773|NCT01175525|Active Comparator|Cromolyn|Cromolyn dose of 200mg(dissolved in water) will be given 4 times a day(30 minutes before a meal)
89352774|NCT05571852|Experimental|Computerized Cognitive Training|Participants will be asked to complete short sessions of around 10 minutes each consisting of a variety of games designed to train the five cognitive skills (attention, memory, coordination, reasoning and perception). Each training session include two games selected among a pool of 12 different games. Participants will be asked to complete a training lasting for 8 weeks in which they could access the training platform as frequently as they wanted.
89352775|NCT03375190|Experimental|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
89352776|NCT03375190|Experimental|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM, Devon, UK) at insertion site
89352777|NCT03375190|Experimental|Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
89352778|NCT03375190|Experimental|Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
89352779|NCT03375190|Experimental|Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
89352780|NCT03375190|Experimental|Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
89352781|NCT03735355|Experimental|Balloon dilation|TTS balloon dilation
89352782|NCT03735355|Active Comparator|Surgery|Resection of the fibrostenotic area
89352783|NCT01175603|Experimental|Cognitive behavioral intervention|Women in the intervention condition will receive 6 two-hour intervention sessions delivered weekly in a group format by the Study Clinician. Each session contains didactic instruction on core content, as well as activities and group discussion. One of the strengths of embedding the MB Course within home visiting is our ability to have home visitors reinforce the material presented by the Study Clinician. The 6-week curriculum is divided into three modules: (a) pleasant activities, (b) thoughts, and (c) relationships with others. Each module has two sessions. These sessions map onto core cognitive-behavioral concepts.
89352784|NCT01175603|No Intervention|Usual home visiting|Women in the control group will receive usual home visiting services and information on postpartum depression.
89352785|NCT04818424|Experimental|REAL training|Robotic Exosuit Augmented Locomotion (REAL) refers to gait training with soft robotic exosuits, performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by the physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. REAL includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
89352786|NCT04818424|Active Comparator|Control training|Control training refers to similarly structured gait training as with REAL, with the only exception of using soft robotic exosuits. Control training is performed under a speed-based approach where participants are asked to walk at faster speeds in treadmill and overground environments. Cues and summary feedback emphasizing walking speed and forward propulsion are provided by physical therapist to facilitate goal-directed walking practice. Training is progressively challenging based on environmental complexity and practice variability. Control training includes 12 training sessions, administered 2-3x/week. Each session includes 30 minutes of total walking time.
89352787|NCT03185481|Experimental|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
89352788|NCT03185481|Experimental|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
89352789|NCT03185481|Experimental|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
89352790|NCT03185481|Experimental|15 mg QD PF-06649751|15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
89352791|NCT03185481|Experimental|1 mg to 7 mg QD PF-06649751|Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
89352792|NCT03185481|Experimental|3 mg QD to 7 mg QD PF-06649751|Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
89352793|NCT03185481|Experimental|7 mg QD to 7 mg QD PF-06649751|7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
89352794|NCT03185481|Experimental|15 mg to 7 mg QD PF-06649751|15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751
89352795|NCT03863249|Active Comparator|The exCELLigence system|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics selected by 'the exCELLingence' system will be started at the second SRP visit."
89352796|NCT03863249|Active Comparator|Origen|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics agents selected by 'Origen' laboratories analysis will be started at the second SRP visit."
89352797|NCT03863249|Active Comparator|Echevarne|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit."
89352798|NCT03652675|Experimental|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|
89352799|NCT03652675|No Intervention|Educational control condition|Participant will spend 20 minutes at the clinic, observed by the counselor, reviewing an educational pamphlet on drinking, HIV, and HCV.
89352800|NCT03381118|Experimental|Ara-C+HaploLymphocyte+Nivo|"Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:~[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0~+ Nivolumab 40 mg D+5] х 2-3 cycles"
89352801|NCT03381118|Experimental|Ara-C+ Nivo|"Patients treated with nivolumab and intermediate dose cytarabine:~[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1] х 2-3 cycles"
89352802|NCT03863171||Ocular ischemia syndrome|Patients with ocular ischemia syndrome
89352803|NCT03863171||Control|Patients with age-related macular degeneration
89352804|NCT03241368|Other|MRE, Patency Capsule (if needed), CE, and IC|Single-arm study, which includes MRE procedure, Patency Capsule Procedure (if needed), PillCam Crohn's Capsule Endoscopy Procedure and Ileocolonoscopy procedure.
89352805|NCT01286597|Experimental|dietary|
89352806|NCT03220581|Active Comparator|Referral for care|Referral for mental health issues and family support services
89352807|NCT03220581|Experimental|Behavioral therapy|8-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors
89352808|NCT02954575|Experimental|All patients|All patients will receive Wilate for prophylactic treatment
89352809|NCT02997358|Active Comparator|Doxorubicin|6 cycles - 1 cycle every 3 weeks (day 1 to day 21) On day 1: Doxorubicin 75 mg/m² IV
89352810|NCT02997358|Experimental|doxorubicin + trabectedin followed by maintenance trabectedin|"Doxorubicin + trabectedin 6 cycles - 1 cycle every 3 weeks (day 1 to day 21) Doxorubicin 60 mg/m² IV D1, then Trabectedin 1.1 mg/m² per CIV 3 hours D1. Surgery for residual disease is possible after 6 cycles (in case of non evolutive disease)~In case of response or stable disease after 6 cycles 3-weeks cycle until disease progression or for a maximum of 12 months of treatment (maximum 17 cycles in maintenance therapy), whichever occurs first Trabectedin 1.1 mg/m² per CIV 3 hours"
89352811|NCT01175681|Experimental|treatment|remote ischaemic preconditioning
89352812|NCT01175681|No Intervention|untreated|control
89352813|NCT03375034|Experimental|NDMC 20mg|oral single dose
89352814|NCT03375034|Experimental|NDMC 60mg|oral single dose
89352815|NCT03375034|Active Comparator|Clonazepam 1.5mg|oral single dose
89352816|NCT03375034|Placebo Comparator|Placebo|oral single dose
89352817|NCT03184701|Experimental|Experimental|Patients assigned to this arm receive the intervention in addition to routine standard of care. Telehealth based remote monitoring of symptoms and brain tests is the intervention in this study. A device with preloaded questionaires will be given to patients randomized to this group. The patients will respond on a daily basis for the 3 months of intervention phase.
89352818|NCT01175759|Experimental|Healthy control group|
89352819|NCT01175759|Experimental|UPRL|
89352820|NCT03376204||Adult subjets|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase, matched by by sex and age with healthy subjects.
89352821|NCT03247530|Placebo Comparator|Placebo|Placebo, qd, oral capsule
89352822|NCT03247530|Experimental|100mg SPN-812|100mg SPN-812, qd, oral capsule
89352823|NCT03247530|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
89352824|NCT03735277|Experimental|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters.
89352825|NCT01175837|Experimental|Short-term fasting prior to systemic chemotherapy|"COHORT I: Patients fast 24 hours before day 1 of course 2 of chemotherapy. If fast is well tolerated, patients may escalate fasting by 12 hours for each subsequent course of chemotherapy for up to 3 courses in the absence of unacceptable toxicity.~COHORT II: Patients fast at the longest fasting regimen found to be safe and tolerable in cohort I before day 1 of each course of course of chemotherapy for up to 4 courses in the absence of unacceptable toxicity."
89352826|NCT03381040|Active Comparator|Group A|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with adequate skin envelope (normal or thick skin). Treated with Restylane Lyft.
89352827|NCT03381040|Active Comparator|Group B|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with poor skin envelope (thin skin). Treated with Restylane Volyme.
89352828|NCT01175915|Active Comparator|Western therapy|
89352829|NCT01175915|Experimental|Reduning Injection|
89352830|NCT01175915|Experimental|Reduning Injection plus western therapy|
89352831|NCT03376048|Experimental|Wound infiltration plus TAP|Wound infiltration placed by surgeon + TAP-LAP placed laparoscopically guided by surgeon
89352832|NCT03376048|Active Comparator|Wound infiltration|Wound infiltration placed by surgeon
89352833|NCT03743779||Intervention|Participants enrolled in Mastering Diabetes.
89352834|NCT03374878|Experimental|oral contraceptive and training|Users of oral contraceptive training for 10 weeks
89352835|NCT03374878|Placebo Comparator|no oral contraceptive and training|Non-users of oral contraceptive training for 10 weeks
89352836|NCT01285037|Experimental|LY2801653|"This study consists of a dose escalation of LY2801653 (Part A) followed by dose confirmation cohorts in four tumor types (adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma, uveal melanoma with liver metastasis, and cholangiocarcinoma) (Part B).~Part C consists of dose determination for LY2801653 in combination with cetuximab in participants with head and neck squamous cell carcinoma followed by an expansion cohort.~Part D consists of dose determination for LY2801653 in combination with cisplatin in participants with cholangiocarcinoma followed by an expansion cohort.~Part E consists of dose determination for LY2801653 in combination with gemcitabine and cisplatin.~Part F consists of dose determination for LY2801653 in combination with ramicirumab."
89352837|NCT03743701|Active Comparator|Transrectal ultrasound in В-mode|
89352838|NCT03743701|Experimental|Transrectal ultrasound examination using three-di|
89352839|NCT03380884|No Intervention|Control|Control group will remain in their habitual life style and no vibration used
89352840|NCT03380884|Experimental|Vibration Group|The intervention group will undergo Low-magnitude high-frequency vibration (LMHFV) at 35Hz, 0.3g (peak to peak magnitude), displacement of <0.1mm, 20 min/day, at least 3 times per week, for 6 months in community centres
89352841|NCT03441126||Multicenter Quality Improvement program|Locally developed and reliably implemented ICU Quality Improvement program to reduce blood culture use.
89352842|NCT01287767|No Intervention|Control group, ordinary support|Home care as usual.
89352843|NCT01287767|Experimental|A multidimensjonalt support program|•Behavioral (e.g., Psychotherapy, Lifestyle Counseling) The family will receive individual consulting, teaching and problem solving in support groups.
89352844|NCT03732391|Experimental|single arm|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will come continued with the same schedule until unacceptable toxicity or disease progression
89352845|NCT01178177||SOT recipients|solid organ transplant recipients with invasive pulmonary aspergillosis
89352846|NCT01178177||Hematologic disease|Hematologic disease patients with invasive pulmonary aspergillosis
89352847|NCT03374722||Mechanically ventilated critically ill patients|Mechanically ventilated critically ill patients who receive opioid as continuous infusion for more than 24 hours
89352848|NCT03246672|Experimental|maintenance|behavioral intervention to increase adherence to lifestyle recommendations
89352849|NCT01285115|Placebo Comparator|Placebo; corn flour,|"raw material total contents(500㎎) cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, content: adults;three times a day each sack taken before or between meals~dose, standard: for each sack 7.67g~storage : airtight container, stored in room temperature~expiration date : after manufacture 36 month~macufacturing company: KyungBangnShinYak inc."
89352850|NCT01285115|Active Comparator|Gamisoyosan extract|"name of product: KyungBangn-Gamisoyosan-x-gwarip~standard code for item : 200005799~shape, type: extract(grayish brown)~usage, content : adults;three times a day , each sack taken before or between meals~dose, standard: 7.67g for each sack~storage : airtight container, stored in room temperature expiration date : after manufacture 36 month macufacturing company: KyungBangnShinYak inc."
89352851|NCT01285115|Active Comparator|Gamisoyosan extract powder|"name of product: KyungBangn Gamisoyosan~standard code for item: 200005591~shape, type: powder(brown)~usage, content: adults;three times a day each sack taken before or between meals~dose, standard: 7.67g for each sack~storage : airtight container, stored in room temperature~expiration date : after manufacture 36 month~macufacturing company: KyungBangnShinYak inc."
89352852|NCT03983317|No Intervention|Baseline|For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.
89352853|NCT03983317|Experimental|Active treatment|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
88807308|NCT00382928|No Intervention|Standard of Care Group|Patients will receive standard of care measures in case of cardiac arrest. They will not receive AECD monitoring or intervention
89352854|NCT01285193|Experimental|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
89352855|NCT03374644|Experimental|ETCO2 monitoring with nasal cannula|SentriTM ETCO2 adult nasal cannula (Intersurgical ® code 1144002) will be placed into patient's nostril following radial artery catheter insertion. A baseline (without oxygen flow) ETCO2, PaO2, SPO2, RR and PaCO2 will be recorded. Oxygen will then be administered at 2,4, and 6 liters per minute for a period of five minutes.ETCO2, PaCO2 and PaO2 will be recorded for each level of oxygen administration.Sedation will be given during intra-operative period with the target of Observer Assessment of alertness/sedation scale (OAA/S) score of 3. During intraoperative period, oxygen will be administered at 2 and 4 liters per minute for a period of five minutes. ETCO2, PaCO2 and PaO2 level will be recorded during each level of oxygen administration.
89352856|NCT03207243|Experimental|Subjects receiving GSK3772847|Eligible subjects will receive GSK3772847 once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
89352857|NCT03207243|Placebo Comparator|Subjects receiving placebo drug|Eligible subjects will receive placebo once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
89352858|NCT01285271|Experimental|Xenon|Xenon will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
89352859|NCT01285271|Active Comparator|Sevoflurane|Sevoflurane will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
89352860|NCT03982069|Active Comparator|FluMist live attenuated influenza vaccine|Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally
89352861|NCT03982069|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
89352862|NCT04434586|Sham Comparator|angiography 2D|Control group: an arteriography will be performed on the entire treated segment to assess the quality of the result, the application or not an active balloon will be left to the discretion of the operator. In case of application of the active balloon, a new arteriography before decision or not the use of stenting will be practiced. In case of stenting, an arteriographic final is performed.
89352863|NCT04434586|Experimental|angiography 2D with OCT|Experimental group: an arteriography and OCT acquisition on the entire treated segment to ensure the quality of the result, the application or not of an active ball will be left. In case of application of the active balloon, a new arteriography and OCT acquisition before decision or not the use of stenting will be practiced. In case of stenting, a final arteriography and then OCT acquisition are performed.
89352864|NCT03863015|Active Comparator|Tocilizumab|A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.
89352865|NCT03863015|Placebo Comparator|Isotonic saline|A one hour infusion of isotonic saline
89352866|NCT02937870|Experimental|Test Product 1|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
89352867|NCT02937870|Experimental|Test Product 2|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
89352868|NCT02937870|Active Comparator|Reference Product|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
89352869|NCT02937870|Other|Negative Control|
89352870|NCT03125434|Experimental|healthy volunteers|EOS full-spine, MRI, gait analysis
89352871|NCT03375970|Experimental|Collaborative Care of TCM and Western Medicine|
89352872|NCT03375970|Active Comparator|Western Medicine|
89352873|NCT03862937|Experimental|Experimental|The experimental group will perform 12 weeks of strength training twice a week associated with whey protein supplementation.
89352874|NCT03862937|Placebo Comparator|Placebo|The placebo group will perform 12 weeks of strength training twice a week associated with maltodextrin supplementation.
89352875|NCT03743623|Experimental|Treatment Group|Study treatment with Neurocytotron, which is a device is designed to generate a controlled beam of electromagnetic waves of certain frequencies in the presence of a magnetic field with pre-determined strength.
89352876|NCT03743623|Placebo Comparator|Placebo Group|The placebo control is a mock treatment in which a subject will go through the same procedures as subjects assigned to the treatment group, only without being actually exposed to electromagnetic waves and magnetic fields.
89352877|NCT03862703|Experimental|Experimental group|PTSD Help intervention combined with care as usual.
89352878|NCT03862703|No Intervention|Control group|Care as usual.
89352879|NCT02519920|Experimental|group 1|This group patients were given dosages of fluorescein sodium 0.01ml/kg intravenous administration.
89352880|NCT02519920|Experimental|group 2|This group patients were given dosages of fluorescein sodium 0.02ml/kg intravenous administration.
89352881|NCT02519920|Experimental|group 3|This group patients were given dosages of fluorescein sodium 0.05ml/kg intravenous administration.
89352882|NCT02519920|Active Comparator|group 4|This group patients were given dosages of fluorescein sodium 0.1ml/kg intravenous administration.
89352883|NCT05666479||Patients with Type 2 Diabetes Undergoing Orthopaedic Hip or Knee Replacement Surgery|
89352884|NCT01286675|Experimental|Eltrombopag|0 mg Eltrombopag
89352885|NCT04525690|Experimental|HCV Screening Default-1 Hospital Crossed Over|Upon entering the admission order set in the EHR clinicians will receive a default order for HCV screening for eligible patients. Clinicians will have the opportunity to opt-out and not order screening
89352886|NCT04525690|Experimental|HCV Screening Default-2 Hospitals Crossed Over|Upon entering the admission order set in the EHR clinicians will receive a default order for HCV screening for eligible patients. Clinicians will have the opportunity to opt-out and not order screening.
89352887|NCT04176952|Experimental|FOLFOX-A|"FOLFOX A arm (14-day cycle)~nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)~Patients will also receive daily G-CSF as primary prophylaxis against neutropenic events for all cycles. This should be given as per local policy for chemotherapy regimens given every 14 days e.g. it may be started on day 4 for 7 days (preparation and dose should be given as per local policy)."
89352888|NCT04176952|Active Comparator|Abraxane and Gemcitabine|"Nab-Paclitaxel + Gemcitabine (AG) arm (28-day cycle)~nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
89352889|NCT05571774||TTP|TTP patients
89352890|NCT03629041|Experimental|Treatment A - Microneedle patch|The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
89352891|NCT03629041|Sham Comparator|Treatment B - Patch with no microneedles|The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
89352892|NCT01288313|Experimental|rapeseed oil|
89352893|NCT01288313|Experimental|n-3 margarine and rapeseed oil|
89352894|NCT01288313|Experimental|n-3 margarine|
89352895|NCT01288313|Active Comparator|Olive oil|
89352896|NCT04171570|Other|Distal Transradial Access|Distal Transradial Access
89352897|NCT04171570|Other|Conventional Transradial Access|Conventional Transradial Access
89352898|NCT03735043|Experimental|ccNexfin ©|
89352899|NCT03860363||Treatment Group|Patients selected to participate.
89352900|NCT03219723||Vonoprazan 20 mg|For adults, the following three-drug regimen will be administered orally at the same time twice daily for 7 days: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 200 mg (potency) dose of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg (potency)/dose twice daily. If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful, as an alternative treatment, the following three drugs will be administered orally twice daily for 7 days to adults: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 250 mg dose of metronidazole. Participants will receive interventions as part of routine medical care.
89352901|NCT03375814|Experimental|Experimental group|The group that takes the main drug. They received the conventional treatment group and crocin.
89352902|NCT03375814|Placebo Comparator|Placebo group|The group that takes the Placebo.
89352903|NCT03866213||Quantitative Measurement of Bilirubin|Bilirubin content of the neonate will be measured by the following: BiliSpec, laboratory spectophotometric bilirubinometer (Reichert UNISTAT), and transcutaneous bilirubinometer. The infant may or may not be receiving phototherapy treatment at the time of sample measurement.
89352904|NCT03628417|Experimental|Calcium Electroporation|"Calcium~Calcium chloride 220 mmol/L (9 mg/ml):~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)"
89352905|NCT03628417|Experimental|Bleomycin based electrochemotherapy|"Bleomycin~Bleomycin 1000 IU/ml:~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)~Maximum of injected bleomycin per tumor will be 1500 IU and total dose per treatment 7500 IU. Normal maximum limit for bleomycin is 15.000 IU/m² body surface area."
89352906|NCT03375736|Experimental|Intervention arm|Whole body vibration will be provided by an equipment, GalileoTM Med L Plus (Novotech Medical GmbH). The study participant will stand still on the vibration platform with both knees slightly flexed.
89352907|NCT04948905||Patients diagnosed as having Borderline Personality Disorder|These patients have been diagnosed as having Borderline Personality Disorder according to the Diagnostic and Statistical Manual IV classification after taking the Structured Clinical Interview for DSM-IV Axis I Disorders test.
89352908|NCT04948905||Healthy Controls (Patients not diagnosed as having Borderline Personality Disorder )|These patients have NOT been diagnosed as having Borderline Personality Disorder according to the Diagnostic and Statistical Manual IV classification after taking the Structured Clinical Interview for DSM-IV Axis I Disorders test.
89352909|NCT03866057||1 study group|All patients hospitalized in 4 intensive rehabilitation Structures of Don Gnocchi Foundation during the enrollment period, suffering from acute (within 30 days) ischemic or emorragic stroke
89352910|NCT03369964|Experimental|Atezolizumab + Emactuzumab|Participants will receive Atezolizumab and Emactuzumab on Day 1 of each 21- day cycle
89352911|NCT03369964|Active Comparator|Atezolizumab + Emactuzumab + Obinutuzumab|"Participants will receive Atezolizumab, Emactuzumab, and Obinutuzumab on Day 1 of each- 21 day cycle (starting in cycle 2)~(Atezolizumab starting in cycle 2); and Obinutuzumab on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2-8."
89352912|NCT01288391|Experimental|100 mcg/kg|
89352913|NCT01288391|Experimental|200 mcg/kg|
89352914|NCT03375658|Experimental|Intervention arm|All vital signs registered as part of usual care are used for modelling patients state and trajectories and made available to clinicans via the Patient Deterioration Warning System in nursing and physician offices.
89352915|NCT03375658|No Intervention|Control arm|Usual care
89352916|NCT02525705|Experimental|Every EA patients|This is a one group interventional study. Every patient is included in the same arm.
89352917|NCT03184077|Active Comparator|Polyglactin 910|
89352918|NCT03184077|Active Comparator|poliglecaprone 25|
89352919|NCT03245736|Experimental|Tisotumab Vedotin|All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.
89352920|NCT03369886|Other|Early glaucoma group|Patients whose visual field mean deviation is > -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
89352921|NCT03369886|Other|Advanced glaucoma group|Patients whose visual field mean deviation is < -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
89352922|NCT03375411|Experimental|INC1-Bare metal stent|Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement
89352923|NCT01173809|Active Comparator|Control|Patient will continue taking Amiodarone before, during and after catheter ablation (8 weeks post-ablation).
89352924|NCT01173809|Active Comparator|Study|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
89352925|NCT03375580|Placebo Comparator|TLC group|transform life custom (TLC) group
89352926|NCT03375580|Active Comparator|TLC + metformin group|transform life custom (TLC) combined with 0.5g metformin, PO tid
89352927|NCT03375580|Experimental|TLC + CZT capsules group|transform life custom (TLC) combined with 2.52 Compound Zhenzhu Tiaozhi capsules (four tablets), PO tid
89352928|NCT03375580|Active Comparator|TLC + simvastatin group|transform life custom (TLC) combined with 20mg simvastatin, PO qn
89352929|NCT01286831|Experimental|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
89352930|NCT02855710|Other|No training|Parkinsonian Patients with no Rhythm Workers training perceptive timing and senrorimotor timing
89352931|NCT02855710|Other|Perceptive timing training|Parkinsonian Patients with Rhythm Workers training perceptive timing
89352932|NCT02855710|Other|Sensorimotor timing training|Parkinsonian Patients with Rhythm Workers training sensorimotor timing
89352933|NCT02855710|Other|Healthy volunteers|Healthy people with Rhythm Workers training perceptive timing
89352934|NCT01286909|Experimental|LaFlavon|
89352935|NCT01286909|No Intervention|Placebo|
89352936|NCT02954887|Experimental|GWP42003-P|"Administered orally, up to the target dose recommended by the data safety monitoring committee.~Participants continue at the target dose, or the highest tolerated dose up to the target dose, for a total of 12 months' treatment."
89352937|NCT03183063|Experimental|4DCT and SPECT/CT|Anticipated 15 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. Both 4DCT scans will be obtained with normal breathing. Data will be analyzed for objectives 1, 4 and 5.
89352938|NCT03183063|Experimental|4DCT with BiPAP and SPECT/CT|Anticipated 5 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. The second of the two 4DCT scans will be obtained with positive airway breathing via BiPAP. Results in these patients will be analyzed for objective 6 only.
89352939|NCT03183063|Experimental|4DCT with CTA in suspected PE|Anticipated 124 participants with CTA ordered/performed for suspected PE will be enrolled to have 4DCT. Goal for analysis is 62 with positive CTA results for PE and 62 with negative CTA results for PE. Data will be analyzed for objectives 2 and 3.
89352940|NCT05155722|Experimental|Single group|First Phase: dose escalation study. It was divided into three dose groups: 100mg, 300mg and 600mg. The safety, tolerance and pharmacokinetics of BAT1308 injection were explored according to the 3+3 dose increasing mode. It is expected that 12-18 cases will be included in the group. Second Phase: dose expansion study. After the completion of dose increment, 300mg tolerated doses were selected for extended research on advanced non-small cell lung cancer, advanced hepatocellular carcinoma and cervical cancer (80-130 cases), so as to provide recommended doses for subsequent clinical trials.
89352941|NCT03860129|Other|ISO|Drug name: Isoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (0.5 Vol%)
89352942|NCT03860129|Other|SEVO|Drug name: Sevoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (1.0 Vol%)
89352943|NCT03860129|Other|DES|Drug name: Desflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (3.0 Vol%)
88807309|NCT00382928|Experimental|AECD Monitoring + Standard of Care Group|Patients will receive AECD monitoring and intervention in addition to standard of care in case of cardiac arrest during admission to the hospital. Defibrillation of pulseless VT/VF by AECD.
89352944|NCT03374098|Experimental|Education|Attend an hour-long classes once per week for three weeks
89352945|NCT03374098|Experimental|Home Visitation|Receive home visits that focus on the social determinants of health and attend hour-long classes once per week for three weeks
89352946|NCT05240703|Experimental|Stabilization splint group|The patients in the splint group were treated with a stabilization splint and received counseling and instructions for masticatory muscle exercises
89352947|NCT05240703|No Intervention|Control group|The controls received only counseling and instructions for masticatory muscles exercises.
89352948|NCT03865901||Non-diabetic pregnant women|Non-diabetic women with singleton pregnancy undergoing screening for gestational diabetes who provide plasma samples for testing with the Mellitus GCD59 Test
89352949|NCT03369808|Experimental|7.5μg H7N9 Vaccine|Participants will receive 2 doses of 7.5μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
89352950|NCT03369808|Experimental|15μg H7N9 Vaccine|Participants will receive 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
89352951|NCT03369808|Experimental|30μg H7N9 vaccine|Participants will receive 2 doses of 30μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
89352952|NCT03369808|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will receive 2 doses of aluminum hydroxide adjuvant at 21-day intervals.
89352953|NCT03369808|Placebo Comparator|Phosphate buffer solution|Participants will receive 2 doses of phosphate buffer solution at 21-day intervals.
89352954|NCT03734575|Experimental|ClariCore System|Biopsy tissue, correlative spectral data, T2-weighted MR scans and ultrasound images acquired with the ClariCore System will be collected and recorded during standard practice transperineal biopsy.
89352955|NCT04630626||Simplify Disc|Extended follow-up of IDE Subjects treated with the Simplify Cervical Artificial Disc during IDE G140154
89352956|NCT01178255|Experimental|Group 1|
89352957|NCT01178255|Experimental|Group 2|
89352958|NCT01178255|Experimental|Group 3|
89352959|NCT01178255|Experimental|Group 4|
89352960|NCT03374020||Intermediate AMD|
89352961|NCT03374020||Advanced AMD|
89352962|NCT03374020||DR without macular edema|
89352963|NCT03374020||DR with macular edema|
89352964|NCT03182829||Factor Xa inhibitor|"Patients on treatment with Apixaban, Edoxaban or Rivaroxaban are included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Factor Xa inhibitor in urine.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
89352965|NCT03182829||Thrombin inhibitor|"Patients on treatment with Dabigatran are included included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Thrombin inhibitor in urine.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
89352966|NCT03363724||HaGuide version 1.0 software module|Patients diagnosed with Parkinson's Disease who underwent implantation of DBS electrode in the STN for the treatment of Parkinson's Disease, using the Neuro-Omega device for navigation and procedure's MER digital recorded data is available.
89352967|NCT02525237|Experimental|Apatinib plus S-1|Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)
89352968|NCT03369652|Experimental|Intervention|Medication history by pharmaconomist. Medication review by pharmacist, patient interview, and conference with physician in hospital, telephone contact to general practitioner after discharge, medication report sent to primary care.
89352969|NCT03369652|No Intervention|Control|Medication history by pharmaconomist. Usual care by physicians.
89352970|NCT01173887|Active Comparator|mLSG15|
89352971|NCT01173887|Experimental|mLSG15 + KW-0761|
89352972|NCT04524052|Experimental|cohort 1 (144 mg)|Arms (both) 0.1 mL/site*2 sites Hips (both) 0.2 mL/site*2 sites
89352973|NCT04524052|Experimental|cohort 2 (432 mg)|Arms (both) 0.3 mL/site *2 sites Hips (both) 0.6 mL/site*2 sites
89352974|NCT04524052|Experimental|cohort 3 (960 mg)|Arms (both) 0.8 mL/site*2 sites Hips (both) 1.2 mL/site*2 sites
89352975|NCT04524052|Experimental|cohort 4 (1200 mg)|Arms (both) 1.0 mL/site *2 sites Hips (both) 1.5 mL/site*2 sites
89352976|NCT02525159|Active Comparator|DIM pills|75 mg of 3,3´-diindolylmethane (DIM) once a day for 30 days
89352977|NCT02525159|Placebo Comparator|Placebo pills|2 pills once a day for 30 days
89352978|NCT03373942||Primary Open Angle Glaucoma (POAG)|The study included 30 eyes of 30 patients diagnosed with POAG who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
89352979|NCT03373942||Pseudoexfoliation Syndrome (PEX)|The study included 30 eyes of 30 patients diagnosed with PEX glaucoma who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
89352980|NCT03373942||Control|The control group included 30 eyes of 30 healthy individuals with similar age distribution with POAG and PEX group
88807310|NCT05290116|Experimental|HAIC Combined with Tislelizumab and Apatinib|
89352981|NCT01178489||Patients undergoing arthroplasty|Patients undergoing primary, unilateral, total hip or knee arthroplasty under spinal anaesthesia
89352982|NCT03865823||anal Fistula|patient with anal fistula with indication to surgical treatment
89352983|NCT03369574||chronic rhinosinusitis and eosinophilic asthma|Adults over the age of 18, diagnosed with poorly controlled moderate to severe asthma with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment) who are initiating/undergoing reslizumab therapy and also carry a physician diagnosis of chronic rhinosinusitis with nasal polyposis
89352984|NCT03278028|Experimental|Active|A-101 Topical Solutions
89352985|NCT03278028|Placebo Comparator|Vehicle|Vehicle
89352986|NCT01176149|Experimental|SMBG + intensive education|Patients will receive specific educational interventions to teach them how to perform Self monitoring Blood Glucose (SMBG), how to modify diet and level of physical activity according to blood glucose levels, and the actions to be undertaken in case of abnormal values (hypoglycemia, particularly elevated glucose levels). Patients will be instructed to modify their lifestyle habits (diet, physical activity) in order to reach specific goals (weight reduction, reduction in fat consumption intake, reduction in saturated fat intake, increase in fiber intake, regular physical activity.
89352987|NCT01176149|No Intervention|Usual Care|Usual Care
89352988|NCT02651740|Experimental|Combining therapy|taking rifaximin for 3 days and then receiving fecal microbiota transplantation with donor stool through enteral nutrition tube
89352989|NCT03862547|Experimental|Men with ED and diabetes|"A peripheral blood sample from the cubital vein~A collection of peripheral blood from the routinary cubital vein for hormone dosage and metabolic evaluation~An introverted cavernous infiltration of Prostaglandin E1 to achieve erection (Aprostadil);~A blood sample from both the corpus cavernosum and the cubital vein, once the erection is achieved Baseline interaction of prostaglandin E1 on the concentration of NGF released in the medium and on the expression of its receptors Evaluation of NGF and Cytokine levels Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs"
89352990|NCT03181503|Placebo Comparator|Placebo|Participants received 3 subcutaneous injections of placebo (matched to nemolizumab) every 4 weeks (Q4W) up to Week 8.
89352991|NCT03181503|Experimental|Nemolizumab 0.5 mg/kg|Participants received 3 subcutaneous injections of nemolizumab 0.5 milligram per kilogram (mg/kg) Q4W up to Week 8.
89352992|NCT03363568|Experimental|Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition involved real-time adaptive gameplay that increased in difficulty as performance increased.
89352993|NCT03363568|Active Comparator|Non-Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition had no change in difficulty (non-adaptive gameplay).
89352994|NCT03277794|Active Comparator|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
89352995|NCT03277794|Experimental|Full HOP-C Service|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
89352996|NCT03862391|Active Comparator|Postsurgical Pain|pain is defined as unpleasant sensation that can range from mild, localized discomfort to agony.
89352997|NCT03862391|Active Comparator|Postanesthesia nausea and vomiting|nausea defined as feeling of sickness or discomfort in the stomach that may come with an urge to vomit.
89352998|NCT03369496||MoNNET-HA Panel|Adults 25 years and older residing in the Montreal Metropolitan Area
89352999|NCT03862313|Experimental|active-rtACS arm|Active rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
89353000|NCT03862313|Sham Comparator|sham-rtACS arm|Sham rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
89353001|NCT03363490|Other|Control|The patients in this group will only receive health education intervention.
89353002|NCT03363490|Other|Neuromuscular exercise therapy|The patients in this group will receive exercise therapy intervention.Besides, health education will be performed for every group.
89353003|NCT03363490|Other|Self-management program|The patients in this group will receive self-management intervention.Besides, health education will be performed for every group.
89353004|NCT03363490|Other|Exercise therapy+self-management|The patients in this group will receive exercise therapy and self-management intervention.Besides, health education will be performed for every group.
89353005|NCT02509702|Experimental|Connected to Care|The SMS intervention will consist of 15 text messages that will be sent to the intervention group over a period of 10 months. There will be two types of text messages: (1) educational text messages; and (2) SMS reminders for the follow-up appointment.
89353006|NCT02509702|No Intervention|Control|The control group will receive standard care, which is a follow-up appointment at 14 months written on an appointment card.
89353007|NCT03859583|Experimental|Capsaicin|4 tsp of cayenne pepper in a 60g omelette
89353008|NCT03859583|Placebo Comparator|Control|60 g omelette
89353009|NCT03369262|Experimental|Active|"OBE022 plus atosiban:~OBE022 will be given orally from Day 1 to Day 7. OBE022 treatment will be initiated ideally simultaneously or at a maximum within 24 h after atosiban start.~Loading dose: 1 000 mg on Day 1.~Maintenance dose on Day 1: 500 mg in the evening if loading dose was administered in the morning. If loading dose was administered in the afternoon, then the next dose will take place on the morning of Day 2.~Maintenance dose from Day 2 to Day 7: 500 mg twice a day (only morning dose on Day 7)~Atosiban will be administered over 48h as per label."
89353010|NCT03369262|Active Comparator|Placebo|"OBE022 matching placebo plus atosiban:~OBE022 matching placebo administration will follow the same regimen as the active group.~Atosiban will be administered over 48h as per label."
89353011|NCT03862235||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
89353012|NCT03862235||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
89353013|NCT03862235||Sedentary control|"This group were sedentary men without cardiovascular disease.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
89353014|NCT03276078|Experimental|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/Formoterol Fumarate 400/12μg inhalation powder twice-daily. Oral inhalation via Genuair® dry powder inhaler (DPI).
89353015|NCT01288547|Active Comparator|theobromine|theobromine (700 mg) in capsule
89353016|NCT01288547|Active Comparator|caffeine|caffeine (120 mg) in capsule
89353017|NCT01288547|Placebo Comparator|Placebo capsule|no theobromine or caffeine
89353018|NCT01288547|Active Comparator|theobromine + caffeine|Combined theobromine and caffeine treatment, consisting of 700 mg theobromine and 120 mg caffeine
89353019|NCT03180801|Placebo Comparator|Group 1 adjuvanted placebo|0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0
88807311|NCT00409292|Experimental|RAD001|"RAD001 was administered continuously at a dose of 10 mg daily by mouth until disease progression, unacceptable toxicity, or withdrawal of consent.~Four weeks of study drug was considered to be one cycle of treatment."
89353020|NCT03180801|Experimental|Group 2 adjuvanted FLU-v one dose|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0
89353021|NCT03180801|Experimental|Group 3 adjuvanted FLU-v two doses|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0
89353022|NCT03373864|Experimental|Unilateral spinal anesthesia|In this arm, the patients will have a hypobaric lateral spinal anesthesia. Sedation can be added for the patients comfort.
89353023|NCT03373864|Active Comparator|General anesthesia|In this arm, the patients will have a general anesthesia.
89353024|NCT03373786|Experimental|RG-012 Single Dose|1.5 mg/kg RG012 subcutaneous injection
89353025|NCT03373786|Experimental|RG012 Every Other Week|1.5 mg/kg RG012 subcutaneous injections every other week
89353026|NCT01176227|Placebo Comparator|Kyodophilus matching placebo capsules|
89353027|NCT01176227|Active Comparator|Kyodophilus multi strain probiotic capsules|
89353028|NCT04597320|Active Comparator|Fentanyl group|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
89353029|NCT04597320|Experimental|Esketamine group|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer. Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
89353030|NCT03373708|Experimental|EC follow T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
89353031|NCT03373708|Experimental|TC follow endocrine|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for four cycles followed by goserelin acetate+tamoxifen for young patients/ letrozole for postmenopausal patients
89353032|NCT01176305||Danish Women 15 to 49 years old.|Free of previous VTE and current use of oral contraceptives.
89353033|NCT01173965|Active Comparator|Endometrial ablation with microwaves|Endometrial ablation with the use of MEA(microwaves endometrial ablation device)
89353034|NCT01173965|Active Comparator|Endometrial ablation with bipolar diathermy|Endometrial ablation with Novasure(bipolar impedence control system)
89353035|NCT03363412|Experimental|Underdilated TIPS|Patients will be treated with PTFE-covered stent grafts balloon-dilated to less than 8 mm.
89353036|NCT03742271|Experimental|senofilcon A|Subjects that are habitual spectacle wearers that have never worn contact lenses and have had an eye exam and an updated spectacle prescription in the last 6 months will be enrolled and fitted into the senofilcon A TEST Lens for a total period of 4 weeks.
89353037|NCT03214224|Experimental|remote PFT (rPFT) validation|Subjects in this arm perform both standard and remote PFT assessments in order to validate the procedure.
89353038|NCT03123562|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
89353039|NCT05280353|Experimental|lymphadenectomy without drainage and with Glubran|Application of Glubran 2 in axillary dissection with the objective of seroma reduction. No drain
89353040|NCT05280353|No Intervention|Lymphadenectomy without drainage|No intervention required, only axillary dissection without drain
89353041|NCT03369184|Experimental|Supplemental oxygen|Inhalation of oxygen 6 L/min through an open face mask
89353042|NCT03369184|Sham Comparator|Ambient air|Breathing ambient air through an open face mask
89353043|NCT01174277||Collection of blood sample|Blood draw
89353044|NCT03865745|Experimental|Korean Red Ginseng|Product: Red ginseng Everytime 1 pack(3g/day)
89353045|NCT03373630|Experimental|Midline catheter|
89353046|NCT03180645|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
89353047|NCT03180645|Other|Test product/ Positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
89353048|NCT03180645|Other|Positive control /No treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
89353049|NCT03124030||Direct Oral Anticoagulants|assuming Pradaxa or Apixaban or Eliquis; undergo simple dental extraction
89353050|NCT03124030||Oral Anticoagulant therapy|assuming Coumadin or Sintrom; undergo simple dental extraction
89353051|NCT03750695|Experimental|Acute Resistance Exercise|One acute exercise session of 40 minutes of resistance exercise
89353052|NCT03750695|Experimental|Acute Aerobic Exercise|One acute session of 40 minutes of aerobic exercise
89353053|NCT03750695|Placebo Comparator|Acute Resting Session|One session of 40 minutes of quiet rest
89353054|NCT02519530|Experimental|Intervention|Behavioral: Teen Outreach Program
89353055|NCT02519530|No Intervention|Comparison|This group did not receive TOP, they received business as usual health curriculum offered through the public school system
89353056|NCT05010213|No Intervention|Control group|There will be no intervention to the control group.
89353057|NCT05010213|Experimental|Experimental group|The experimental group will be given training based on the roy adaptation model.
89353058|NCT03373474|Experimental|local distribution points association|Participants will receive warm acupuncture with the local distribution acupoints association on the affected arm only.
89353059|NCT03373474|Experimental|local-distal points association|Participants will receive warm acupuncture with the local-distal acupoints association on the affected arm, unaffected arm, abdomen, and legs.
89353060|NCT03373474|No Intervention|waiting-list|Patients in the waiting-list group will not receive any acupuncture treatment during the study. However, for ethical consideration, 20 free acupuncture treatments will be offered after the study is completed.
89353061|NCT02518906|Experimental|Adolescent Identity Treatment|Psychotherapeutic treatment performed routinely at the centres in Basel and Santiago de Chile
89353062|NCT02518906|Experimental|DBT-A|Psychotherapeutic treatment performed routinely at the centre in Heidelberg
89353063|NCT02519608|Active Comparator|Aspirin 100 mg + Clopidogrel 75 mg|dual antiplatelet therapy as suggested by guidelines with aspirin 100 mg and clopidogrel 75 mg daily
89353064|NCT02519608|Experimental|Aspirin 100 mg + Ticagrelor 90 mg x2|dual antiplatelet therapy with aspirin 100 mg and ticagrelor 90 mg x 2 daily
89353065|NCT03699930|Active Comparator|tDCS + speech therapy|Participants will receive 20 minutes of anodal tDCS paired with speech and language therapy over five consecutive days.
89353066|NCT03699930|Sham Comparator|sham + speech therapy|Participants will receive 20 minutes of sham tDCS paired with speech and language therapy over five consecutive days.
89353067|NCT03363178|Experimental|GC3107|BCG Vaccine, 0.1mL
89353068|NCT05181852|Experimental|IP2015_dose 1|Active
89353069|NCT05181852|Experimental|IP2015_dose 2|Active
89353070|NCT05181852|Placebo Comparator|Placebo|Placebo
89353071|NCT05181852|Active Comparator|Pregabalin|Comparator
89353072|NCT03373396|Other|Case group with Metavir score between F1 and F4|Patient with Metavir score between F1 and F4 will be assigned to the case group. Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
89353073|NCT03373396|Other|Control group with Metavir score of between F0|Patient with Metavir score of F0 will be assigned to the control group. Collected data will contain epidemiological and biological data. Blood samples with chlordecone dosage will be performed.
89353074|NCT03369106||Multiple Sclerosis siblings|Group of siblings having multiple sclerosis, n=120 Composite severity score calculation for all subjects
89353075|NCT03369028||2d and 3D image|A 2D and 3D image of the participants' face will be taken. It will at least last 2-3 sec.
89353076|NCT03373318|Experimental|Experimental|Human Albumin
89353077|NCT03373318|Active Comparator|Control|Plasmalyte
89353078|NCT03124420|Active Comparator|Group A (Drug: 7-day triple therapy)|Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
89353079|NCT03124420|Sham Comparator|Group B (Drug: 14-day triple therapy)|Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).
89353080|NCT03231228|Active Comparator|Cefazolin 1 g Infusion|Pediatric surgical subjects weighing at least 25 kg to less than 60 kg will receive a single 30-minute infusion of 1 g cefazolin.
89353081|NCT03231228|Active Comparator|Cefazolin 2 g Infusion|Pediatric surgical subjects weighing at least 60 kg will receive a single 30-minute infusion of 2 g cefazolin.
89353082|NCT01176383|No Intervention|Control group|The control group will have a standard NHS cessation clinic experience
89353083|NCT01176383|Experimental|Respiragene test and risk score|Subjects will have a buccal swab taken at first attendance for a 12 gene test of SNP variants associated with risk of lung cancer. From the genetic data and clinical data (any history of COPD, family history of lung cancer in a first degree relative and age) a risk score is calculated from which a lifetime risk of lung cancer if the subject continues to smoke can be calculated. This is expected to be a powerful motivator to encourage smoking cessation.
89353084|NCT03363100|Experimental|Intervention|
89353085|NCT03363100|No Intervention|Control|
89353086|NCT03363022|Experimental|Standard Medical Treatment+Fecal Microbiota Transplant|
89353087|NCT03363022|Active Comparator|Standard Medical Treatment+Placebo|
89353088|NCT01178645|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
89353089|NCT02525315|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
89353090|NCT05181774||Bleeding|After one-year follow-up, AF patients with anticoagulation-related bleeding complications were enrolled in this group.
89353091|NCT05181774||Non-bleeding|After one-year follow-up, AF patients without anticoagulation-related bleeding complications were enrolled in this group.
89353092|NCT03368872|Experimental|Astaxanthin and exercise|Astaxanthin formulation intake for one month followed by a 3-month exercise training program with astaxanthin formulation intake.
89353093|NCT03368872|Placebo Comparator|Placebo and exercise|Placebo intake for one month followed by 3-month exercise training with placebo intake.
89353094|NCT04525768||JAK2 mutation Group|Patients with portal caver cavernoma and gastroesophageal varices and JAK2 Mutation.
89353095|NCT04525768||Portal caver cavernoma Group|Patients with portal caver cavernoma and gastroesophageal varices without JAK2 Mutation.
89353096|NCT01178801||liver cancer|Clinical data of patients with liver cancer
89353097|NCT01174355|Experimental|ND0801|
89353098|NCT03213366|Experimental|E-PrEP- Peer-Led Intervention about PrEP|8 Peer Leaders (PLs) will be randomly assigned to the E-PrEP arm. Each of the PLs will recruit at least 15 participants into a private social media group on one of several social media platforms. PLs will then deliver a behavioral intervention over a 6 week period, posting information and engaging participants in a discussion about PrEP, PrEP access, and other related health issues. All contents will be formatted to be both mobile device accessible.
89353099|NCT03213366|Active Comparator|BxNow - General Health Campaign|BxNow is an attention-matched control. Eight of the 16 PLs will be randomly assigned to the BxNow arm. The BxNow campaign will be a 6-week long social media intervention about general health wellness topics chosen and administered by the PLs assigned into this arm. Similarly to the intervention group, PLs in the BxNow arm will create private social media groups and recruit participants into these private groups. General health information in the BxNow arm will be posted with the same frequency as in the intervention arm.
89353100|NCT04525924|Experimental|Bright light therapy|Bright light therapy (BLT) will be given via a lightbox device in the morning for 30 minutes after waking up. Duration of therapy will be 7 consecutive days.
89353101|NCT01285505|Active Comparator|Alprazolam commercial sublingual tablet|
89353102|NCT01285505|Experimental|Alprazolam test sublingual tablet|
89353103|NCT01285583|Other|Olesoxime|All patients will receive the IMP as add-on to riluzole 50 mg bid orally, 50 mg morning and evening on an empty stomach ie at least 20 min before the meal.
89353104|NCT04525612|Experimental|68Ga-BNU-PSMA|Each subject receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT imaging within the specificed time.
89353105|NCT04523896|Experimental|HDR brachytherapy + SABR|"High-Dose-Rate prostate brachytherapy: a single fraction of 15 Gy to the whole prostate.~Between 2-4 weeks after the brachytherapy session, SABR treatment will be delivered:~5 sessions of 5 Gy in consecutive days (i.e monday to friday) to a total dose of 25 Gy to the whole prostate."
89353106|NCT01287299|Experimental|Low Glycemic Load Diet|Counseled to consume a diet with a low or higher intake of carbohydrate sources that cause rapid or significant intakes in blood glucose. The average glycemic load of the diet should be less than 55 per 1000 calories or greater than 55 per 1000 calories.
89353107|NCT01287299|Experimental|Low Fat Diet|Pregnant women were counseled to consume a diet providing less that 25% of the energy as fat.
89353108|NCT03637140|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
89353109|NCT03637140|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
89353110|NCT03372850|Experimental|Sequence Group 1|Period 1: Reference Drug(HGP1705) Period 2: Test Drug(HIP1601)
89353111|NCT03372850|Experimental|Sequence Group 2|Period 1: Test Drug(HIP1601) Period 2: Reference Drug(HGP1705)
89353112|NCT01178879|Experimental|Telehealth consultation|Telehealth nurse consultation plus treatment as usual
89353113|NCT01178879|No Intervention|Conventional|Treatment as usual
89353114|NCT04525066|Experimental|Treatment Group - Receiving Hyaluronic Acid Injection|Randomized group of patients receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
89353115|NCT04525066|Placebo Comparator|Control Group - Not Receiving Hyaluronic Acid Injection|Randomized group of patients not receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
89353116|NCT01178957||Type 1 diabetes|
89353117|NCT03362788||VKA|"Patients receiving VKA as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
89353118|NCT03362788||NOAC|"Patients receiving a NOAC as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
89353119|NCT03859505|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
89353120|NCT03859505|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) active.
89353121|NCT03368794|Experimental|Intervention|Telephone alert signal from ambulance staff to out-patient substance use disorder treatment facility, for active outreach aiming to locate and include the patient in long-term evidence-based treatment for the substance use disorder.
89353122|NCT03368794|Active Comparator|Control|Information-only. Ambulance staff hand over written information to the individual about how to seek treatment for the substance use disorder.
89353123|NCT03862001|Experimental|LungCARE Group|The intervention group will receive the LungCARE intervention
89353124|NCT03862001|No Intervention|Comparison Group|The comparison group will receive usual care.
89353125|NCT02518828|Active Comparator|High SpO2|In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%
89353126|NCT02518828|Active Comparator|Low SpO2|In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%
89353127|NCT03862079|Experimental|Arm I (TGD + FMT)|Patients receive piperacillin-tazobactam PO TID and nystatin QID. Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
89353128|NCT03862079|Experimental|Arm II (FMT)|Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
89353129|NCT03862079|Active Comparator|Arm III (standard therapy)|Patients receive standard of care.
88807312|NCT05246046|Experimental|Tiotropium Easyhaler 10 microg/dose, Product variant J|Each subject will receive a single dose of 2 inhaled doses from Tiotropium Easyhaler Product variant J in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
88814462|NCT01640171|Other|Top Anesthesia 1 Eye SC Lidocaine 1 Eye|"One eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Acuvail Intra-vitreal Anti-VEGF Drug~Fellow Eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Xylocaine 2% Injectable Anesthetic Acuvail Intra-vitreal Anti-VEGF Drug"
89353130|NCT03362632||Infection Group|Patients with end stage liver disease with SBP
89353131|NCT03362632||Non-infection Group|Patients with end stage liver disease without SBP
89353132|NCT03213210|Other|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
89353133|NCT01179035|Active Comparator|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
89353134|NCT01179035|Experimental|Transitions Clinic - Parolee Targeted Care|Following randomization, subjects in this arm receive ongoing primary care in a parolee-targeted clinic. Parolee-targeted care includes care from clinicians with a knowledge of the impacts of incarceration on health and experience caring for formerly incarcerated patients, a community health worker that works in medical and social services coordination and chronic disease education, and linkages with community-based organizations serving formerly incarcerated individuals.
89353135|NCT03372772|No Intervention|Control group|Control group - patients with only levothyroxine therapy
89353136|NCT03372772|Experimental|Intervention group|Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy
89353137|NCT01235494|Experimental|polarised 3 helium|inhaled gas
89353138|NCT01174433|Experimental|Tryton bifurcation stent system|
89353139|NCT02932878|Experimental|DSXS topical|administered twice daily for 28 days
89353140|NCT01093066|Experimental|surgical resection and chemotherapy|"Maximal and optimal TURB using a standardized procedure. The TURB will always try to be optically complete.~Neoadjuvant chemotherapy for 3 months with the intensified MVAC (6 cycles administered every 2 weeks): METHOREXATE: 30 mg/m2 D1 - VINBLASTINE: 3 mg/m2 D2 - ADRIAMYCINE 30 mg/m2 D2 - CISPLATINE 70 mg/m2 D2. + G-CSF: 5 µg/kg from D4 to D10 New maximal standardized TURB at the end of the chemotherapy. In case of a lesion localized at the bladder dome, and if a maximal TURB appears to be unsafe, a partial cystectomy without lymph node dissection will be performed."
89353141|NCT03859271|Experimental|brief motivational interviewing|Participants will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
89353142|NCT03859271|Placebo Comparator|Placebo Control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
89353143|NCT03368638|Experimental|Intervention|
89353144|NCT01179269|Experimental|Pazopanib plus Paclitaxel|Pazopanib daily and weekly Paclitaxel IV.
89353145|NCT03230292|Experimental|Cohort 1|Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is >=50% to <75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.
89353146|NCT01174511|Experimental|A-1 COOL cream|"A research product - A-1 COOL cream contain herbal medicine plants basically :~WATER PETROLATUM~WILD YAM (DIOSCOREA VILLOSA) EXTRACT~SORBITAN SESQUIOLEATE~CALENDULA OFFICINALIS EXTRACT~MINERAL OIL~ARNICA MONTANA EXTRACT~MICROCRYSTALLINE WAX~LICORICE (GLYCYRRHIZA GLABRA) EXTRACT~DECYL OLEATE~DICOCOYL PENTAERYTHRITYL DISTEARYL CITRATE~BEESWAX~ALUMINUM STEARATES"
89353147|NCT01174511|Placebo Comparator|Vaselin ointment|Using the study as placebo.
89353148|NCT01287455|Active Comparator|vitamin D|vitamin D deficient asthmatic patients receiving vitamin D supplement
89353149|NCT01287455|Placebo Comparator|placebo|vitamin D deficient asthmatic patients receiving placebo
89353150|NCT04527172||systemic lupus patients|Nerve conduction study and neuromuscular ultrasound for median , ulnar, tibial, peroneal and sural nerves
89353151|NCT04527172||Healthy subjects|Nerve conduction study and neuromuscular ultrasound for median , ulnar, tibial, peroneal and sural nerves
89353152|NCT03865433|Experimental|Exercise Group|Intervention: aerobic exercise Subjects in the exercise group will be prescribed exercise at a target heart rate (THR) of approximately 80% of the achieved heart rate during the Buffalo Concussion Treadmill Test (BCTT). They will be given this prescription in writing to provide to their athletic trainer. Subjects will complete 30 minutes of daily exercise (including 5 minutes of warm up and 5 minutes of cool down) on an exercise bike or walking and supervised by an athletic trainer. This program may be modified by increasing heart rate threshold 5-10 beats per minute per week by the athletic trainer as the heart rate for symptom exacerbation increases.
89353153|NCT03865433|Placebo Comparator|Placebo/Stretching|Intrvention: stretching program Subjects assigned to the Stretching/Placebo group will be given a stretching protocol and instructions to report to their athletic trainer on a daily basis as soon as possible. . Subjects will then complete a 15-25 minute stretching program under supervision by the athletic trainer or other designated research personnel. The stretching protocol will be progressive and will change weekly as subjects continue their recovery.
89353154|NCT03368560|Active Comparator|Sudarshan Kriya Yoga|Thirty participants with treatment-resistant late life depression (TR-LLD) will attend 5 instructional days of Sudarshan Kriya Yoga (SKY), followed by 3 weekly follow-ups, and 8 weeks of bimonthly follow-ups. Participants will also practice SKY for 25 minutes per day at home. These participants will attend 4 mental health assessments at weeks 0, 4, 8, and 12. Thirteen of the recruited TR-LLD will attend an MRI at baseline and post-intervention.
89353155|NCT03368560|No Intervention|Control|The seven recruited age-matched controls will complete a screening appointment and an MRI only for comparison. Demographic information will also be collected from the control participants. These individuals will not undergo the study intervention.
89353156|NCT03859817||Patients with albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
89353157|NCT03859817||patients with normo albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
89353158|NCT03865511|Experimental|TAGRISSO® 80mg (Osimertinib)|"Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.~Tumor biopsies performed at baseline and clinical progression. ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial."
89353159|NCT03368482|Experimental|Brain Gym Exercises|Brain Gym® (BG) is a movement-based program originally designed to improve learning capabilities through the performance of mind-body exercises. BG can be considered as an interesting field of research due to the need of identifying novel therapies which might be more pleasant for older adults who tend not to be prone to participating in conventional exercise programs and might have a positive effect on their cognitive function. In spite of this, scientific evidence regarding the effects of BG on people with cognitive impairment is scarce.
89353160|NCT03368482|Active Comparator|Standard Exercises|A traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
89353161|NCT03865355||Cohort 1 / High grade Glioma|"Cohort 1:~Histologically confirmed high-grade glioma (grade III and grade IV (glioblastoma (GBM)))~Planned treatment (surgery followed by radiation therapy (RT) alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
89353162|NCT03865355||Cohort 2 / Low grade Glioma|"Cohort 2:~Histologically confirmed low-grade (grade I/II) glioma~Planned treatment either expectant monitoring or surgery followed by RT alone or Chemotherapy alone or a combination of RT/Chemotherapy"
89353163|NCT03865355||Cohort 3 / Conditionally healthy volunteers|"Cohort 3:~No oncological disease was diagnosed~Planned treatment (reconstructive surgery after craniofacial trauma)"
89353164|NCT03362398|Active Comparator|Omarigliptin|Drug: Omarigliptin 25 mg
89353165|NCT03362398|Active Comparator|Trelagliptin|Drug: Trelagliptin 100 mg
89353166|NCT03865199|Experimental|Intervention Group|The intervention arm will view a digital story on a tablet created by the research team, then respond to a writing prompt. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
89353167|NCT03865199|No Intervention|Control Group|The control group will receive care as usual at the abortion clinic. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
89353168|NCT01287533|Experimental|Ibandronate treatment|Ibandronate 150mg PO once every 4 weeks
89353169|NCT01287533|Placebo Comparator|Placebo arm|Placebo PO once every 4 weeks
89353170|NCT03859349|Active Comparator|Systematic Sampling|Patients will undergo systematic sampling of lymph node stations in the mediastinum with a minimum sampling of 3 stations: 4R, 4L and 7, as is the standard of care. Other stations may be included at the endoscopist's discretion. CLNS is not used for this arm.
89353171|NCT03859349|Experimental|Selective Targeted Sampling|"Patients will first undergo endosonographic assessment of 3 mediastinal lymph node stations (i.e. 4R, 4L, and 7) using the four criteria of the CLNS. Lymph node stations that exhibit a CLNS >1/4 will be biopsied as is standard of care. Lymph node stations with CLNS ≤ 1/4 will be marked as not requiring biopsy but will be biopsied nevertheless, so that there is no deviation from the standard of care. Other stations may be included at the endoscopist's discretion."
89353172|NCT03372616||All participants|Aortic blood pressure, LV filling pressrue, and LV volume will be measured in all participants. Meanwhile, echocardiography and non-invasive aortic blood presure measurement will be performed. Three devices will be used in non-invasive aortic blood presure measurement, including Sphygmocor (AtCor Medical, Australia), PulsePen (DiaTecne SRL, Italy), and Mobil-O-Graph (IEM, Germany). In conclusion, all participants will receive invasive and non-invasive left ventricular diastolic function assessment, together with invasive and non-invasive aortic blood pressure assessment.
89353173|NCT01179425|Active Comparator|non-marijuana dependent controls|
89353174|NCT01179425|Experimental|Marijuana-dependent subjects|
89353175|NCT03372538||multidisciplinary team group|500 patients of placenta accreta managed by obstetricans and urologists
89353176|NCT03372538||obstetricians only group|500 patients of placenta accreta managed by obstetricans only
89353177|NCT01176539||Sleep Clinic|
89353178|NCT03368404|Experimental|CBL-102 eye drops|CE marked medical device, tear substitute containing 0.24% hyaluronic acid salt, carbomer and medium chain triglycerides
89353179|NCT03368404|Active Comparator|Vismed Multi eye drops|CE marked medical device, tear substitute containing 0.18% sodium hyaluronate
89353180|NCT03859037|Experimental|Umbilical cord milking|One group will have umbilical cord milking and will ba assessed for blood pressure,oxygen saturation and heart rate by monitor
89353181|NCT03859037|Placebo Comparator|Immediate cord clamping|One group will have immediate cord clamping and will be assessed for bloob pressure,heart rate,oxygen saturation by monitor
89353182|NCT03362320|Experimental|double layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with double layer fixation
89353183|NCT03362320|Experimental|single layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with single layer fixation
89353184|NCT01287689||Patient treated with any IgG|Any marketed SC or IV IgG can be documented
89353185|NCT03228420|Active Comparator|HF10 therapy plus CMM|The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
89353186|NCT03228420|Other|CMM Alone|Conventional Medical Management
88807313|NCT05246046|Experimental|Tiotropium Easyhaler 10 microg/dose, Product variant K|Each subject will receive a single dose of 2 inhaled doses from Tiotropium Easyhaler Product variant K in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
88818779|NCT05731505|Experimental|THE EFFECT OF A SUPPORTIVE APPROACH STRUCTURED ACCORDING TO KOLCABA'S COMFORT THEORY|The study group consisted of parents who were given a supportive approach structured according to Kolcaba's Comfort Theory by the researcher.
89353187|NCT03859115|Active Comparator|preanesthesia-TENS|Patients in preanesthesia-TENS group receive TENS for 30 minutes at one arm before anesthesia.
89353188|NCT03859115|Sham Comparator|preanesthesia-sham|Patients in preanesthesia-sham group receive sham stimulation for 30 minutes at one arm before anesthesia.
89353189|NCT03859115|Experimental|sevoflurane-TENS|Patients in sevoflurane-TENS group receive TENS for 30 minutes at one arm under sevoflurane anesthesia.
89353190|NCT03859115|Active Comparator|sevoflurane-sham|Patients in sevoflurane-sham group receive sham stimulation for 30 minutes at one arm under sevoflurane anesthesia.
89353191|NCT03859115|Experimental|propofol-TENS|Patients in propofol-TENS group receive TENS for 30 minutes at one arm under propofol anesthesia.
89353192|NCT03859115|Active Comparator|propofol-sham|Patients in propofol-sham group receive sham stimulation for 30 minutes at one arm under propofol anesthesia.
89353193|NCT03362242|Active Comparator|ARO-AAT|
89353194|NCT03362242|Placebo Comparator|Placebo|
89353195|NCT05181306||Robotic surgery|
89353196|NCT05181306||Laparoscopic surgery|
89353197|NCT03372694|Experimental|Chemotherapy+Training+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Rehabilitation training is mainly composed of gymnastic qigong, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
89353198|NCT03372694|Experimental|Chemotherapy+Education+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
89353199|NCT03372694|Placebo Comparator|Chemotherapy+Education+Placebo|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.~Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages. The patient will take placebo granules for 3 months."
89353200|NCT01179503|Active Comparator|Calcium only|1200 mg Calcium per day
89353201|NCT01179503|Experimental|Vitamin D plus calcium|2000 IU vitamin D plus 1200 mg calcium per day
89353202|NCT03368248||All neonatal resuscitation services.|All professionals in contact with children were interviewed: doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical.
89353203|NCT03372304|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 10 mL, every 8th hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
89353204|NCT03372304|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
89353205|NCT03372304|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
89353206|NCT02525081|Experimental|ACE-inhibitor|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.~Patients taking a dose of~2,5 mg will take a half tablet a day~5 mg will take one whole tablet a day~10 mg will take two tablets a day"
89353207|NCT02525081|Placebo Comparator|Placebo|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.~Patients taking a dose of~2,5 mg will take a half tablet a day~5 mg will take one whole tablet a day~10 mg will take two tablets a day"
89353208|NCT05566548||Group of patients with liver cirrhosis and ACLF|"This group will include patients with diagnosed liver cirrhosis regardless of the cause hospitalized and/or presenting to the emergency department for possible ACLF.~With any etiology of liver cirrhosis including alcoholic liver disease (ALD), chronic hepatitis C virus (HCV), metabolism associated fatty liver disease (MAFLD) and autoimmune liver diseases."
89353209|NCT05566548||Group of patients with liver cirrhosis compensated|"This group will include patients with diagnosed liver cirrhosis, any etiology of liver cirrhosis including alcoholic liver disease (ALD), chronic hepatitis C virus (HCV), metabolism associated fatty liver disease (MAFLD) and autoimmune liver diseases.~No previous episodes of ACLF and at the time of admission."
89353210|NCT05566548||Group of healthy people|People who do not have any acute or chronic degenerative disease. Participation on a voluntary basis.
89353211|NCT05566548||Group of patients with liver cirrhosis and hepatic encephalopathy|This group will include patients with diagnosed liver cirrhosis who develop hepatic encephalopathy graded according to West Haven.
89353212|NCT02519686||Trendelenburg position maneuver|Trendelenburg (TD) positioning (supine with head tilt-down) is used in abdominal and gynecological surgery as well as during colonoscopy to allow better access to the pelvic organs, as gravity pulls the bowel out of the pelvic cavity and the rectosigmoid angle straightens.
89353213|NCT02519686||Left lateral position maneuver|Left Lateral (LL) position (patient laying on their side, traditionally used for colonoscopies)
89353214|NCT02525003|Placebo Comparator|Group 1: placebo|Group 1: daily dose of regular bread (87 g/d) and placebo pill (0 µg of vitamin D/d) for 8 weeks
89353215|NCT02525003|Experimental|Group 2: Vitamin D2 supplement|Group 2: daily dose of regular bread (87 g/d) and D2 supplement (25 µg of vitamin D2/d.) for 8 weeks
89353216|NCT02525003|Experimental|Group 3: Vitamin D3 supplement|Group 3: daily dose of regular bread (87 g/d) and D3 supplement (25 µg of vitamin D3/d.) for 8 weeks
89353217|NCT02525003|Experimental|Group 4: Vitamin D2-fortified bread|Group 4: D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
89353218|NCT03367936|Active Comparator|Self-monitoring group|All subjects will use a smartphone to self-monitor diet and monitor physical activity (Fitbit Charge 2), and a Withings or Fitibit digital scale for weight. Following randomization, participants will be oriented to Self-monitoring and provided a tutorial with images shown on the laptop and devices as well as printed materials showing the screen shots. At baseline, each participant will have a one-on-one session with the project interventionist, which covers the core principles of behavioral weight loss. The participant also will be given personalized fat, calorie, and PA goals for weight loss and information about how to access the intervention materials from the Diabetes Prevention Program (DPP) online which is publicly available (https://www.diabetesprevention.pitt.edu/).
89353219|NCT03367936|Experimental|Self-monitoring+Feedback group|All subjects will be asked to do everything the self-monitoring group is asked to do. Subjects will receive up to 4 Feedback messages per day (messages will be delivered between the hours set by the participants on the participant's phone, e.g., 8 AM and 9:30 PM). Messages will be delivered automatically, remotely and in real-time. Messages will be tailored to each participant's progress based on standardized algorithms. The Feedback program will be explained to them and how this is responsive to information entered on the self-monitoring diaries.
89353220|NCT03464448||1|Patients with RRMS who have been newly prescribed Teriflunomide.
89353221|NCT03464448||2|Healthy Controls
89353222|NCT01179581|Experimental|1|single ascending doses
89353223|NCT01179581|Placebo Comparator|2|single dose placebo
89353224|NCT01179581|Experimental|3|multiple dose, 10 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
89353225|NCT01179581|Placebo Comparator|4|multiple dose, capsules, 10 days; scheme to match that of Study Arm 3.
89353226|NCT03362008|Experimental|Group I|Period I: administration of Zeropix Period II: administration of Champix®
89353227|NCT03362008|Experimental|Group II|Period I: administration of Champix® Period II: administration of Zeropix
89353228|NCT03858959|Experimental|HYBENX® Oral Tissue decontaminantTM (HBX)|HYBENX® Oral Tissue decontaminantTM is a concentrated aqueous solution of sulfonated aromatics and free sulphates. Once placed onto susceptible organic material, the product instantly absorbs free and electrostatically bonded water, denaturing the molecular structure of the organic matter. Biofilm is expected to be especially sensitive to the disruptive action of HBX solution by virtue of its porous structure and high water content.
89353229|NCT03858959|Active Comparator|Chlorhexidine Digluconate CorsodylTM (CHX)|Chlorhexidine Digluconate CorsodylTM Dental Gel 1% is an antiseptic gel with cationic nature, effective against a wide range of Gram positive and negative bacteria, favourable to the plaque control and oral inflammation prevention.
89353230|NCT03123406|Experimental|Severe SHPT|Administer Cinacalcet HCL to subjects whose iPTH>900 pg/ml from 1st to 32nd week.
89353231|NCT03123406|Experimental|Moderate SHPT|Administer Cinacalcet HCL to subjects whose 600≤iPTH<900 pg/ml from 1st to 32nd week.
89353232|NCT03123406|Experimental|Mild SHPT|Administer Cinacalcet HCL to subjects whose 300≤iPTH<600 pg/ml from 1st to 32nd week.
89353233|NCT03361930|Experimental|CP participants|Single-day data collection for walking conditions; barefoot, with plain ankle-foot orthosis (flat foot plate) on involved side, with tone-reducing ankle-foot orthosis on involved side.
89353234|NCT01179659|Active Comparator|Protonix|Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)
89353235|NCT01179659|Experimental|Pantoprazole 40 mg DR Tablet|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
89353236|NCT03858725|Experimental|D569/CKD-374 5mg|"Period 1: D569 Tab. 1T~Period 2: CKD-374 5mg Tab. 1T"
89353237|NCT03858725|Experimental|CKD-374 5mg/D569|"Period 1: CKD-374 5mg Tab. 1T~Period 2: D569 Tab. 1T"
89353238|NCT03361774|Experimental|Test dentifrice|Participants in this arm will receive experimental dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 parts per million [ppm] fluoride).
89353239|NCT03361774|Active Comparator|Control dentifrice|Participants in this arm will receive comparator dentifrice containing 0.454% SnF2 (1100ppm fluoride).
89353240|NCT03746483|Experimental|MS1819 2240 mg/day (3 weeks) then PERT pre-study dose (3 weeks)|Patients in arm will further be randomized to receive either the sequence consisting of MS1819 2240 mg/day for 3 weeks followed by PERT for another 3 weeks. During the PERT treatment period the patients will take their stable pre-study PERT dose.
89353241|NCT03746483|Experimental|PERT pre-study dose(3 weeks) then MS1819 2240 mg/day (3 weeks)|Patients in arm will be randomized to receive PERT for 3 weeks followed by MS1819 2240 mg/day for another 3 weeks. During the PERT treatment period the patients will take their stable pre-study PERT dose.
89353242|NCT04523740|Experimental|Placebo replacement|Participants will discontinue the paracetamol treatment, and be administered 6 to 8 tablets of placebo per day
89353243|NCT04523740|Active Comparator|Usual care with paracetamol|Participants will continue the paracetamol treatment, and be administered 6 to 8 tablets of 500mg paracetamol per day
89353244|NCT03410706||Rivaroxaban|Anticoagulation with rivaroxaban
89353245|NCT04523662|Experimental|Carrelizumab treatment group started during radiotherapy|
89353246|NCT04523662|Experimental|Start the carrelizumab treatment group within 3 days after the|
89353247|NCT04266522|Active Comparator|Arm I (printed materials)|Patients receive printed materials describing the technical aspects of their treatment.
89353248|NCT04266522|Experimental|Arm II (printed materials, physicist interaction)|Patients receive printed materials as in Arm I. Patients also receive a minimum of 2 direct physicist interactions to describe the technical aspects of their treatment either immediately prior to or immediately after treatment simulation.
89353249|NCT03746405|Active Comparator|Repetitive TMS (rTMS)|excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)
89353250|NCT03746405|Sham Comparator|Sham repetitive TMS (rTMS)|electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)
89353251|NCT02518672|Active Comparator|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
89353252|NCT02518672|Placebo Comparator|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
89353253|NCT03372226|Experimental|Online self-help program|"The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 10 modules with many interactional exercises and homework-sheets.~Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse."
89353254|NCT03372226|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
89353255|NCT03226392|Active Comparator|QAW039|QAW039 once daily
89353256|NCT03226392|Placebo Comparator|Placebo|Placebo once daily
89353257|NCT03372070|Experimental|cNEP|silicone collar applied to anterior neck
89353258|NCT03371992|Other|Lung Cancer Patients|Lung cancer patients receiving one of three standard of care immunotherapy drugs including nivolumab, pembrolizumab or atezolizumab. 3D-EX will be performed on biopsies from patients enrolled in the study to correlate with the patient's evaluation of response by RECIST.
89353259|NCT03371914|Experimental|Treatment: Management + data training|"The treatment group in the study will receive a 5-day training. The first two days of the training will consist of introducing the data collection tools and collecting baseline data. Days three through five of the training will consist of a variety of management topics.~On a monthly basis, the treatment group will receive data visualizations that will compare their site's performance that month to pervious performance and to other sites in the study. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis."
89353260|NCT03371914|No Intervention|Control: data training only|The control group will receive only a 2-day training which will focus on data collection alone. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis.
89353261|NCT03371758|Experimental|vitiligo patients|
89353262|NCT03371758|Experimental|healthy controls|
89353263|NCT03205371|Experimental|South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
89353264|NCT03205371|Experimental|South Korea (Group 2): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
89353265|NCT03205371|Active Comparator|South Korea (Group 3): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
89353266|NCT03205371|Experimental|Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
89353267|NCT03205371|Experimental|Thailand (Group 11):MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
89353268|NCT03205371|Active Comparator|Thailand (Group 12): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
89353269|NCT03205371|Experimental|Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.
89353270|NCT03205371|Experimental|Mexico (Group 5): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
89353271|NCT03205371|Active Comparator|Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.
89353272|NCT03205371|Experimental|Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.
89353273|NCT03205371|Experimental|Russian Federation (Group 8): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
89353274|NCT03205371|Active Comparator|Russian Federation (Group 9): PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.
89353275|NCT03371680|Experimental|Injection of stable isotopes|Injection of 1-13 Carbon Leucine and deuterated water: all patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
89353276|NCT03371524||Native valves_30 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop during routine cardiac echography.
89353277|NCT03371524||Native valves_30 and 60 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop and a 60 second loop during routine cardiac echography.
89353278|NCT03371524||Bioprosthesis_30 seconds loops|Patient with calcified aortic stenosis on bioprosthesis: record of a 30 second loop during routine cardiac echography.
89353279|NCT03371446||Smokers/Non-smokers|It was an experimental study with parallel controls, comparing two groups, a group with patients who smoked for more than 10 years, consuming 10 more cigarettes per day and diagnosing chronic periodontitis (case) and another group (control) were non-smokers with chronic periodontitis, according to the standard of World Health Organization (WHO) definition of the smoking population
89353280|NCT03371290|Experimental|Mirror Therapy Intervention|
89353281|NCT03371290|Active Comparator|Control Intervention|
89353282|NCT03367858|Experimental|Motivational Interviewing (MI)|This randomly assigned group receives two 60-minute 1:1 sessions of motivational interviewing.
89353283|NCT03367858|Active Comparator|Brief Adolescent Mindfulness (BAM)|This randomly assigned group receives two 60-minute 1:1 sessions of Brief Adolescent Mindfulness.
89353284|NCT03682705|Placebo Comparator|ELS placebo/UPA placebo|Placebo capsule for elsubrutinib once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
89353285|NCT03682705|Experimental|UPA 15 mg/ELS 60 mg|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; 60 mg elsubrutinib capsule once a day by mouth for 12 weeks
89353286|NCT03682705|Experimental|ELS 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
89353287|NCT03682705|Experimental|ELS 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
89353288|NCT03682705|Experimental|ELS 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
89353289|NCT03682705|Experimental|UPA 15 mg/ELS placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; placebo capsule for elsubrutinib once a day by mouth for 12 weeks
89353290|NCT03361618|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
89353291|NCT03361618|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
89353292|NCT01314495|Active Comparator|Abatacept|Abatacept administered as a 30 minute intravenous infusion
89353293|NCT01314495|Placebo Comparator|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
89353294|NCT03367780||RT with curative intent for HNSCC|several schemes for radical (chemo)radiotherapy, administered in 30-35 fractions over 6-7 weeks
89353295|NCT03361540|Experimental|Single dose of ASP8302 dose-1|Subjects will receive a single dose of ASP8302.
89353296|NCT03361540|Experimental|Single dose of ASP8302 dose-2|Subjects will receive a single dose of ASP8302.
89353297|NCT03361540|Experimental|Single dose of ASP8302 dose-3|Subjects will receive a single dose of ASP8302.
89353298|NCT03361540|Experimental|Single dose of ASP8302 dose-4|Subjects will receive a single dose of ASP8302.
89353299|NCT03361540|Placebo Comparator|Single dose of Placebo|Subjects will receive a single dose of Placebo.
89353300|NCT03361540|Experimental|Multiple dose of ASP8302 dose-5|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
89353301|NCT03361540|Experimental|Multiple dose of ASP8302 dose-6|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
89353302|NCT03361540|Placebo Comparator|Multiple dose of Placebo|Subjects will receive once daily dosing of Placebo for 14 consecutive days.
89353303|NCT04943367|Active Comparator|GROUP TEAS|Patients will receive TEAS bilaterally at two acupoints: Hegu (L14) and Neiguan (PC6).
89353304|NCT04943367|Placebo Comparator|Control Sham Group|Patients in the sham group will be undergoing electrode attachment on the target acupoints without electronic stimulation.
89353305|NCT04539561|Experimental|Pigmentation|Treatment of Hand Pigmentation Using PiQo4 Laser System
88807314|NCT05246046|Active Comparator|Spiriva HandiHaler 18 microg/capsule|Each subject will receive a single dose of 2 inhaled Spiriva capsules via HandiHaler device in one of the three periods (cross-over). The total dose is 20 micrograms of tiotropium (delivered dose) as Tiotropium Bromide Monohydrate.
88807315|NCT00383942|Active Comparator|Misoprostol|Patients randomized to this arm will receive 25 micrograms of misoprostol every four hours.
88807316|NCT00383942|Experimental|EASI Catheter|Patients randomized to this arm will receive extra amniotic saline infusion (EASI) administered via catheter
88807317|NCT05482308|Experimental|Test tablet followed by Reference tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.
89353306|NCT03123484|Experimental|β-elemene+EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene
89353307|NCT03123484|Active Comparator|EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
89353308|NCT02519764|Experimental|Hydration when thirsty|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
89353309|NCT02519764|Experimental|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
89353310|NCT03367468|Active Comparator|Physiotherapy group|Strengthening and stretching exercises,cross friction massage (supervised by physiotherapist) Mobilization techniques Daily usage of prescribed orthotic insole
89353311|NCT03367468|Active Comparator|Home exercise group|Strenthening and stretching exercises Daily usage of prescribed orthotic insole
89353312|NCT03367468|No Intervention|Control group|Follow ups Daily usage of prescribed orthotic insole
89353313|NCT03745937|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous (SC) dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week treatment extension period (TEP).
89353314|NCT03745937|Placebo Comparator|Placebo Cohort 1|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the uptitration period and thereafter once daily through 3 week TEP.
89353315|NCT03745937|Experimental|MEDI0382 Cohort 2|Participants will receive SC dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week TEP.
89353316|NCT03745937|Placebo Comparator|Placebo Cohort 2|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
89353317|NCT02956057|Active Comparator|PEG1D|Polyethylene glycols single dose a day before colonoscopy
89353318|NCT02956057|Active Comparator|PEG2D|Polyethylene glycols split dose
89353319|NCT02956057|Active Comparator|SPMC1D|Natrium picosulfate/ Magnesium citrate single dose day before colonoscopy
89353320|NCT02956057|Active Comparator|SPMC2D|Natrium picosulfate/ Magnesium citrate split dose
89353321|NCT02956057|Active Comparator|PEGA1D|Polyethylene glycol / Ascorbic acid single dose day before colonoscopy
89353322|NCT02956057|Active Comparator|PEGA2D|Polyethylene glycol / Ascorbic acid split dose
89353323|NCT03179319|Experimental|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
89353324|NCT03179319|No Intervention|Standard of Care|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
89353325|NCT04526392||Questionnaire|Patients will choose how they wish to complete the Pubertal Course Questionnaire: electronically (web link), on paper, by telephone, or face-to-face at a follow-up consultation.
89353326|NCT04526470|Experimental|Alpelisib + Paclitaxel|"Phase IB is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D of alpelisib will be determined based on the MTD and toxicity profiles.~In phase II part, RP2D from the phase IB part will be applied as follows: alpelisib ( ) mg PO bid daily + paclitaxel ( ) mg/m² IV on D1, 8, and 15 every 4 weeks."
89353327|NCT01314651|Experimental|Sleep Management|Instructions in stimulus control and sleep restriction.
89353328|NCT01314651|Sham Comparator|Lifestyle Modification|Instructions to change general lifestyle habits (maintain consistent liquid consumption, range of motion exercises, etc.)
89353329|NCT03361384|Experimental|Alcohol condition|The amount of alcohol received in the alcohol condition will be determined by an algorithm developed by Curtin (Curtin, 2000). Participants in the alcohol condition will receive a dose of alcohol (target BAC = .08%), administered in a chilled beverage of 80-proof vodka mixed with tonic water and lime juice in a 1:4 ratio.
89353330|NCT03361384|Placebo Comparator|Placebo condition|Placebo participants will receive tonic water and lime juice served to enhance alcohol cues in an amount comparable to the amount that they would have received if assigned to the alcohol condition.
89353331|NCT03361384|No Intervention|Control (water)|Participants in the water control condition will receive a glass of chilled water in volume of liquid comparable to the amount that they would have received if assigned to the alcohol or placebo condition.
89353332|NCT02519374|Placebo Comparator|Placebo|Placebo
89353333|NCT02519374|Active Comparator|PROMITOR® dose 1|Investigational product dose 1
89353334|NCT02519374|Active Comparator|PROMITOR® dose 2|Investigational product dose 2
89353335|NCT02519374|Active Comparator|PROMITOR® dose 3|Investigational product dose 3
89353336|NCT01176695|Experimental|1|fish oil containing lipid emulsion
89353337|NCT01176695|Active Comparator|2|MCT/LCT containing lipid emulsion
89353338|NCT03361150|Experimental|HIT|Preoperative nutrition, relaxation strategies + high intensity interval training (HIT). HIT alternates a series of high-intensity bouts with relief period. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
89353339|NCT03361150|Active Comparator|MCT|Preoperative nutrition, relaxation strategies + high intensity interval training (MCT). MCT is continuous exercise with a constant intensity below anaerobic threshold. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
89353340|NCT04526626|Experimental|High ligation and stripping|High ligation and stripping of long saphenous vein is the traditional standard procedure for the treatment of varicose veins
89353341|NCT01289093||laparoscopic ingunal herniotomy|
89353342|NCT01289093||laparoscopic incisional herniotomy|
89353343|NCT01289093||Lichtenstein inguinal herniotomy|
89353344|NCT01289093||laparoscopic umbilical hernia repair|
89353345|NCT03367390|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
89353346|NCT01179893|Active Comparator|IVIG|Intravenous Immunoglobulin, 2G/Kg, infused over 2 days in the Medical Day Unit of the University Health Network
89353347|NCT01179893|Experimental|PLEX|Patients received one plasma volume plasma exchanges with 5% albumin replacement fluid. Five plasma exchange procedures occurred every second day with breaks over the weekend allowed. Patients treated in the apheresis units at the University Health Network.
89353348|NCT04526080|Experimental|TheraBionic Arm|Self-administered from the device that delivers low levels of radiofrequency electromagnetic fields into the body with a spoon-shaped antenna placed in the mouth.
89353349|NCT04526080|Placebo Comparator|Placebo Arm|Placebo device that looks and sounds like the active device.
89353350|NCT01176851|Experimental|Glyco pMDI|Glyco pMDI 100 µg
89353351|NCT01176851|Experimental|Glyco pMDI Charcoal|Glyco pMDI 100 µg + charcoal block
89353352|NCT01176851|Active Comparator|Glyco IV injection|Glyco solution for injection 100 µg
89353353|NCT01176929|Experimental|Interventional group|Usual treatment + prevention program of recurrent suicidal acts
89353354|NCT01176929|Active Comparator|Control group|Usual treatment
89353355|NCT03627091|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous (SC) injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
89353356|NCT03627091|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using a prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
89353357|NCT03627091|Placebo Comparator|Placebo|Participants will receive placebo matched with ontamalimab SC injection using prefilled syringe once every 4 weeks for 52 weeks; starting at Day/Week 1 Baseline Visit (Week 16 of the SHP647-305 [NCT03559517] or SHP647-306 [NCT03566823]).
89353358|NCT01179971|Experimental|Fish oil|3g/d
89353359|NCT01179971|Experimental|Gamma-linolenic Acid|3g/d gamma-linolenic acid
89353360|NCT01179971|Experimental|Fish oil plus GLA|1.5 g/d DHA + EPA plus 1.5g/d gamma-linolenic acid
89353361|NCT01179971|Sham Comparator|Olive oil|3 g/d olive oil
89353362|NCT04526314||Stage 3 with adjuvant chemotherapy|
89353363|NCT04526314||Stage 3 without adjuvant chemotherapy|
89353364|NCT04237584|Other|Enzalutamide during Lead-in Period|Randomized, open-label lead-in ARB (enzalutamide tablets, 160 mg PO QD) for 12 weeks.
89353365|NCT04237584|Active Comparator|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|Randomized, open-label lead-in ARB (enzalutamide) for 12 weeks followed by randomized, double-blind Radium-223 IV at 55 kBq/kg IV up to 6 cycles (at 4 week intervals) with continued randomized open-label enzalutamide.
89353366|NCT04237584|Placebo Comparator|Lead-in Enzalutamide followed by Placebo/Enzalutamide|Randomized, open-label lead-in ARB (enzalutamide) for 12 weeks followed by randomized, double-blind normal saline placebo IV up to 6 cycles (at 4 week intervals) with continued randomized open-label enzalutamide.
89353367|NCT04237584|Other|Darolutamide during Lead-in Period|Randomized, open-label lead-in ARB (darolutamide tablets, 300 mg PO BID) for 12 weeks.
89353368|NCT04237584|Active Comparator|Lead-in Darolutamide followed by Radium-223/Darolutamide|Randomized, open-label lead-in ARB (darolutamide) for 12 weeks followed by randomized, double-blind Radium-223 IV at 55 kBq/kg IV up to 6 cycles (at 4 week intervals) with continued randomized open-label darolutamide.
89353369|NCT04237584|Placebo Comparator|Lead-in Darolutamide followed by Placebo/Darolutamide|Randomized, open-label lead-in ARB (darolutamide) for 12 weeks followed by randomized, double-blind normal saline placebo IV up to 6 cycles (at 4 week intervals) with continued randomized open-label darolutamide.
89353370|NCT02893787||Patients treated with anthracyclines in childhood|
89353371|NCT02893787||Healthy volunteers|
89353372|NCT02519296|Active Comparator|Prolonged Exposure Therapy|"In total 30 Danish veterans will be recruited, who meet the ICD-10 diagnostic criteria for PTSD, and treated with PE.~Intervention with eight sessions of PE, psychometrics, blood analyses and fMRI."
89353373|NCT02519296|Active Comparator|30 Danish veterans without PTSD|"A group of controls will be recruited consisting of age-appropriate same sex veterans who have participated in international missions similar to the patient group.~Observation with psychometrics, blood analyses and fMRI."
89353374|NCT01177085|Experimental|Mushroom|Mushroom enriched weight loss diet. Participants will be given a personalized diet plan, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
89353375|NCT01177085|Active Comparator|No mushroom diet|Participants will be given a personalized diet plan, without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
89353376|NCT04525378|No Intervention|Control|Patients will receive standard care.
89353377|NCT04525378|Experimental|MSC - low dose (2.5x10ˆ7)|Patients will receive standard care plus cell therapy.
89353378|NCT04525378|Experimental|MSC - intermediate dose (5x10ˆ7)|Patients will receive standard care plus cell therapy.
89353379|NCT04525378|Experimental|MSC - high dose (10x10ˆ7)|Patients will receive standard care plus cell therapy.
89353380|NCT03858803|Active Comparator|FM2 first, LAST delayed|Parent intervention, Families Matter 2 (FM2), immediate, adolescent intervention, Living as a Safer Teen (LAST), delayed six months
89353381|NCT03858803|Active Comparator|FM2 and LAST simultaneous|Parents participate in Families Matter 2 (FM2) and adolescents in Living as a Safer Teen (LAST) intervention immediately following the baseline assessment.
89353382|NCT03858803|Active Comparator|Comparison arm|Comparison arm in which both parents and adolescents will be offered their respective interventions following the final assessment. Following the final assessment parents will be offered the Families Matter (FM2) intervention and youth the Living as a Safer Teen (LAST) intervention as an ethically justified service.
89353383|NCT03371134||Sarcopenic group|Harvesting of muscular biopsies Muscular biopsies will be harvested from old sarcopenic patients undergoing hip replacement surgery
89353384|NCT03371134||Control group|Harvesting of muscular biopsies Muscular biopsies will be harvested from young patients undergoing Anterior Cruciate Ligament (ACL) reconstruction surgery
89353385|NCT05180916|Active Comparator|Brivaracetam + Transcutaneous vagal nerve stimulation|Start of Brivaracetam (treatment as usual), combined with tVNS in the first 3 months of treatment
89353386|NCT05180916|No Intervention|Brivaracetam|Start of Brivaracetam (treatment as usual)
89353387|NCT03360994|Experimental|WATChmAN|Patients randomized to the WATChmAN Active Surveillance arm will receive their active surveillance testicular cancer care via an online virtual clinic. Importantly, patients will follow the same surveillance schedule as patients in the standard of care arm. However, patients in the WATChmAN arm will be able to see their upcoming tests and virtual appointments online, request requisitions to perform their required testing at outside institutions, and indicate any concerns for physicians to review during the virtual visit.
89353388|NCT03360994|Active Comparator|Standard of Care|Patients randomized to the standard of care arm (in-person active surveillance) will follow the current active surveillance protocol in place at Princess Margaret Cancer Centre's Multidisciplinary Testicular Cancer Clinic. This protocol involves the same schedule of testing as the WATChmAN arm, but will require patients to come into the clinic to receive their test results (as in current practice).
89353389|NCT01177163|Other|001|Placebo one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
89353390|NCT01177163|Experimental|002|JNJ 28431754 100 mg/placebo one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
89353391|NCT01177163|Experimental|003|JNJ 28431754 300 mg/placebo one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
89353392|NCT05180604|Experimental|experience learning programs of eHealth care|Patients in the experimental group received 6 sections of activities.
89353393|NCT05180604|No Intervention|Usual care|Patients in control group received usual care
89353394|NCT03367234|Experimental|Personalized Addiction-to-Health (PATH)|Cognitive Behavioral Therapy (CBT) sessions with a behavioral health consultant twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed weeks 27-52; Contingency management rewards for specified recovery behaviors which could include medication adherence, attendance at CB/RP sessions and/or CB/RP exercise participation; Medication-assisted treatment, either extended-release naltrexone once monthly or buprenorphine once daily; Peer recovery specialist support twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed for weeks 27-52; Psychiatric consultation as needed.
89353395|NCT03367234|Active Comparator|Standard Care|Treatment may differ slightly by treatment program, but addiction specialty Intensive Outpatient Treatment (ASAM Level 2.1) will generally include individual therapy sessions with a counselor 1 hour per week for week; Medication-assisted treatment, either extended-release naltrexone once monthly or suboxone once daily; Group therapy sessions 9 hours per week then decreasing to 3 hours per week; Psychiatric consultation as needed.
89353396|NCT02524925|Active Comparator|fast track protocol|Oral fluids intake (0.5 lt) 6 hours after operation Mobilization 4 hours after operation Check discharge criteria the 4th-6th postoperative day
89353397|NCT02524925|No Intervention|conventional protocol|Oral intake after bowel mobilization Mobilization after the 1st postoperative day Check discharge criteria the 7th-15th postoperative day
89353398|NCT03370978|Experimental|Text Messaging|Receives text messages to remind of upcoming follow-up appointment with primary care doctor. Also provides opportunity for subjects to text ED staff for follow-up care concerns or to reschedule primary care appointment.
89353399|NCT03370978|No Intervention|Usual Care|Received usual care including follow-up phone calls if clinically indicated.
89353400|NCT03858881|Active Comparator|PROJECT PERSONALITY|
89353401|NCT03858881|Experimental|VR PERSONALITY PROJECT|
89353402|NCT03858881|Placebo Comparator|SHARING FEELINGS PROGRAM|
89353403|NCT04524988|Active Comparator|Fundamentals of Laparoscopic Surgery (FLS)|This group will undergo 2.5h of training on the current standard laparoscopic simulation trainer (FLS), including the following tasks: peg transfer, intracorporeal knot tying and ligating loop.
89353404|NCT04524988|Experimental|Essentials in Minimally Invasive Gynecology (EMIG)|This group will undergo 2.5h of training on a new gynecology-specific laparoscopic simulation trainer (EMIG), including the following tasks: peg transfer, intracorporeal knot tying and running suture.
89353405|NCT03224598|Experimental|No medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
89353406|NCT03224598|Experimental|Medically abrading|A-101 40% with the identified DPN lesions medically abraded prior to treatment
89353407|NCT03224598|Experimental|Initial cohort - no medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
89353408|NCT01177241||CLBP|
89353409|NCT01177241||CLBP OU|
89353410|NCT03681691|Experimental|Post menopausal women with diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women with type 2 diabetes
89353411|NCT03681691|Experimental|Post menopausal women without diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women without type 2 diabetes.
89353412|NCT03370822||Study Participants|Women who have continuous fetal monitoring using the MONICA AN24 device. The MONICA AN24 is a wearable monitor with five adhesive electrodes placed on the mother's abdomen. This records the fetal heart rate, maternal heart rate and uterine contractions.
89353413|NCT03360760|Experimental|Pre surgical Chemotherapy|Immediate pre surgical chemotherapy treated with four drugs including doxorubicin, cisplatin, high-dose methotrexate (MTX) and ifosfamide in eleven weeks, and then definitive surgery followed by adjuvant chemotherapy according to chemotherapy regimen in Peking University People's Hospital(PKUPH).
89353414|NCT03360760|Other|Immediate Surgery|Immediate definitive surgery, and then post operative chemotherapy based on doxorubicin, cisplatin, high-dose MTX and ifosfamide according to chemotherapy regimen in PKUPH.
89353415|NCT01285661|Experimental|Proximal DVT|Patients whose veins have recanalized (either at the recruitment or later on during the follow-up) will receive the D-dimer determination before discontinuing sodium warfarin. Veins are defined as recanalized when the vein diameter under maximum compressibility is lower than 4 mm both at the common femoral and at the popliteal vein. In those with negative D-dimer sodium warfarin will be discontinued. These patients will have two further determinations of D-dimer (after 1 and 3 months, respectively). While patients with persistently negative D-dimer will no longer receive sodium warfarin, those in whom D-dimer is positive or reverts to positive values in the following determinations will have their sodium warfarin resumed and no longer discontinued.
89353416|NCT02935842|Experimental|Specific SL-therapy for PD (with and without DBS)|Rhythmic specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
89353417|NCT02935842|Active Comparator|rBMT for PD (with and without DBS)|Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
89353418|NCT02935842|No Intervention|PD (with and without DBS); no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
89353419|NCT02935842|No Intervention|Healthy Controls; no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
89353420|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 1|"The patient or donor is not a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is not a carrier of the hepatitis B virus.~treatment 48 weeks"
89353421|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 2|"The patient or donor is a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is a carrier of the hepatitis B virus.~treatment 48 weeks"
89353422|NCT01180205|Active Comparator|T/A|Telmisartan + Amlopidpine
89353423|NCT01180205|Active Comparator|O/HCT|Olmesartan + Hydrochlorothiazide
89531969|NCT04464798|Experimental|Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects|"Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles.~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC administration at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
89353424|NCT04523506|Experimental|the temporomandibular joint (TMJ) group|This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The TMJ group will be injected with two units of Botox into four different injection points to each masseter (16 units of Botox total) at the initial visit. No additional Botox will be injected in subsequent visits. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1
89353425|NCT04523506|Experimental|the perioral group|Biological/Vaccine: Botulinum toxin(Botox) This study will evaluate the use of botulinum toxin for microstomia (reduced oral aperture) in scleroderma patients. The perioral group will be injected with two units of Botox into eight different injection points (16 units of Botox total) around the lips (in the orbicularis oris). Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1-3.
89353426|NCT01174589|Other|6 weeks of physical training|The 6 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
89353427|NCT01174589|Other|12 weeks of physical exercise|The 12 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
89353428|NCT03370744||Subjective cognitive decline, SCD|The inclusion criteria for SCD are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) failure to meet the following criteria for MCI.
89353429|NCT03370744||Normal control, NC|NC are individuals who have no self-report persistent decline in cognitive capacity, and with neither worry nor concern about their cognition. Without measurable cognitive impairment according to results of standard assessments.
89353430|NCT03370744||Mild cognitive impairment, MCI|MCI are defined by an actuarial neuropsychological method proposed by Jak and Bondi. Participants are considered to have MCI if any one of the following three criteria are met with a total Clinical Dementia Rating (CDR) score of 0.5 as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as >1 SD below the age-corrected normative mean) on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled; (3) the Functional Activities Questionnaire (FAQ) ≥9.
89353431|NCT03370744||Alzheimer's disease, AD|The diagnosis of AD syndrome is based on the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA) with a total CDR score of 1.
89353432|NCT03370744||Subjective Cognitive Decline plus, SCD-plus|The inclusion criteria for SCD-plus are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) concerns (worries) associated with memory complaint; and (3) failure to meet the following criteria for MCI.
89353433|NCT01180283|Experimental|lodenafil carbonate (Helleva®)|
89353434|NCT01285739||NIMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged with tracheostomy but in domiciliary non invasive ventilation
89353435|NCT01285739||IMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged in domiciliary invasive mechanical ventilation (IMV)
89353436|NCT01177475|Active Comparator|natural milk|
89353437|NCT01177475|Experimental|pasteurized milk|
89353438|NCT04525846|Experimental|PFMT group|Researcher was trained and test pelvic floor muscle strength by urogynecologist with Brink scores, participants PFMT group were educated by VDO and recieved program of PFMT after consented form 4 weeks reassess Brink score for check compliance of PFMT and followed up by telephone weekly about compliance of PFMT, general symptom, notice self recording book total 12 weeks and evaluate urinary incontinence by UDI-6 questionaires at third trimester
89353439|NCT04525846|Experimental|non PFMT|Randomized to non PFMT group watchful waiting until 36-38 week gestation follow up and evaluate UI by UDI6 questionaires at third trimester sames as intervention group
89353440|NCT01287845|Experimental|Arm 1|
89353441|NCT01287845|Experimental|Arm 2|
89353442|NCT03360604|Experimental|Low GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a low glycaemic index. This is the Low Glycaemic Diet intervention.
89353443|NCT03360604|Experimental|High GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a high glycaemic index. This is the High Glycaemic Diet intervention.
89353444|NCT03867084|Experimental|Pembrolizumab|Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle for up to 17 cycles.
89353445|NCT03867084|Placebo Comparator|Placebo|Participants receive IV placebo on Day 1 of each 21-day cycle for up to 17 cycles.
89353446|NCT03860831|Experimental|intranasal (IN)|"Group IN will receive nasal ketamine+midazolam mixture by mucosal atomisation device: midazolam (0.2 mg/kg) +ketamine (5mg/kg).~the calculated dose will be equally divided into the two nostrils by the parents"
89353447|NCT03860831|Active Comparator|intramuscular (IM)|"Group IM will receive intramuscular administration of liquid ketamine +midazolam mixture:midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.~Mild to moderate restraint was done with the help of the parents during drug administration."
89353448|NCT03360526|Active Comparator|PICSI|Physiological ICSI
89353449|NCT03360526|Experimental|TESA|Testicular sperm aspiration
89353450|NCT01289249||Children receiving meropenem|Children aged from 3 months to 18 years that receive treatment with meropenem.
89353451|NCT01287923||DLBCL|DLBCL patients included 075-GOELAMS trial or 075-like patient.
89353452|NCT01287923||Healthy controls|Blood donors from the EFS (French Blood Bank) of Rennes.
89353453|NCT01287923||Septic patients|septic patients included at the Rennes University Hospital.
89353454|NCT01287923||DLBCL in completed remission|DLBCL patients from the 075 GOELAMS study in completed remission.
89353455|NCT03123796||Only PPI|Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists.
89353456|NCT03123796||Only H2RA|Kidney transplant recipients who used only histamine H2 receptor antagonists and did not use proton pump inhibitors.
89353457|NCT03123796||PPI and H2RA|Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists.
89353458|NCT03123796||No Acid Suppressive Treatment|Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists.
89353459|NCT03639883|Placebo Comparator|0.033% versus Vehicle|One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.
89353460|NCT03639883|Placebo Comparator|0.1% versus Vehicle|One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.
89353461|NCT03639883|Placebo Comparator|0.3% versus Vehicle|One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.
89353462|NCT03639883|Placebo Comparator|1% versus Vehicle|One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.
89353463|NCT03360448|Experimental|Experimental|Ad5.hAC6: Intracoronary delivery of adenovirus encoding human adenylyl cyclase type 6
89353464|NCT03360448|Placebo Comparator|Placebo Comparator|Placebo: Intracoronary delivery of formulation buffer ( 3% sucrose)
89353465|NCT01288001|Experimental|Ostenil plus|Patient will get Ostenil plus injection and standard treatment of Osteoarthritis
89353466|NCT03732313|Active Comparator|Central toenail resection|Under local ring anaesthesua using xylocaine injection in base of big toe ,Surgical resection of the central part of toenail with underlying germinal matrix.the defect is sutures by prolene.
89353467|NCT03732313|Active Comparator|wedge toenail resection|Under local ring anaesthesiausing xylocaine injection around the base of big toe. Resect lateral wedge of toenail with removal of ingrown toenail and periungual skin. The wound is then sutured.
89353468|NCT03360370||6 to 66 months children with significant CHD|"Children with significant congenital heart disease (CHD) aged from 6 to 66 months at the time of the study and fulfilling inclusion criteria for whom an age-appropriate questionnaire completed by parents (Ages & Stages Questionnaires, Third Edition in French (ASQ-3™) will be used to screen developmental delays."
89353469|NCT03667326|Active Comparator|Low-Dose Aspirin (LDA) Intervention Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take 81mg of aspirin daily for up to 3 weeks postpartum, starting within 4 days after delivery.
89353470|NCT03667326|Placebo Comparator|Placebo Control Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take placebo oral capsule daily for up to 3 weeks postpartum, starting within 4 days after delivery.
89353471|NCT03667326|No Intervention|Healthy Controls Group|Subjects who are healthy volunteers (n = 10) without severe preeclampsia prior to delivery.
89353472|NCT03860519|Experimental|Intervention Group|"The components of the intervention unique to the treatment group include: 1) access to the Propeller Health Asthma App on his/her phone, which includes tracking of ICS and SABA usage; 2) receipt of NorthShore Connect physician alerts (these will be sent by the asthma nurse on behalf of the NS physician) if he/she has poor adherence ie missed 4 consecutive days of all of his/her controller medication dosages and their sensor has sent heartbeat to application OR at risk alerts if a patient transitions to a not well controlled or poorly controlled status (defined by the NHLBI guidelines); and 3) monthly phone calls with a nurse from his/her asthma doctor's office to review ICS and SABA usage reports (provided by Propeller Health on their Propeller Health dashboard)."
89353473|NCT03860519|Experimental|Control Group|The control group will not receive access to view the contents of the Propeller Health Asthma App on his/her phone, NorthShore Connect alerts for missing ICS or overuse of SABA, or for his/her asthma doctor (the asthma nurse will be viewing this information on behalf of the asthma doctor) to view his/her ICS and SABA use on the Propeller Health dashboard until after the 3-month study has been completed.
89353474|NCT03370666|Experimental|HFNT|HFNT performed with any available device. The flow will be initially set at 60 liters per minute and temperature at 37° C. The target will be an oxygen saturation (SpO2) of 88-92%. In case of patient not tolerating these settings, flow and temperature will be titrated to the maximum tolerated level.
89353475|NCT03370666|Active Comparator|NIV|NIV must be delivered by full or oronasal mask with any available ventilator. The ventilator settings will be decided according to the usual practice: maximal tolerated inspiratory pressure to obtain a measured or estimated expired tidal volume of 6-8 mL·kg-1 of body weight and a positive end expiratory pressure (PEEP) between 3 and 5 cmH2O. An interface rotational strategy will be allowed among only different types of masks.
89353476|NCT03734341|Experimental|EZ START Titration|"CPAP titration test performed with an auto CPAP device preset on incremental fixed pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with EZ START pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.~Afterwards, the device will be remotely preset on the next modality: auto-adjusting pressure (no wash-out period)."
89353477|NCT03734341|Active Comparator|APAP Titration|"CPAP titration test performed with an auto CPAP device preset on auto-adjusting pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with APAP pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.~Afterwards, the device will be remotely preset on the next modality: incremental fixed pressure (no wash-out period)."
89353478|NCT03261323|Active Comparator|Immediate breast reconstruction|The surgical schedule will follow unaltered standard protocol for immediate reconstruction right after the patient's mastectomy. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and at different time points during the follow up. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
89531970|NCT04464798|Experimental|Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects|"Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6."
88807318|NCT05482308|Experimental|Reference tablet followed by Test tablet|On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug
89353479|NCT03261323|Experimental|Delayed breast reconstruction|Patients will start the reconstruction process after cancer therapy has been completed. Patients will be directed to smoking cessation and weight loss resources such as the Bariatric Institute to most directly facilitate risk reduction goals. Risk scores will be assessed at a plastic surgery appointment every 3 months. Reconstruction will proceed after the cancer treatment has been completed, according to individual patient evaluation. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and after the final reconstruction surgery. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
89353480|NCT04525300|Experimental|Liraglutide|Subject receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
89353481|NCT04525300|Placebo Comparator|placebo|Subject receiving placebo 3.0 mg subcutaneous (under the skin) injection once daily for 28 weeks.
89353482|NCT03865121|Experimental|Nicotine Nasal Spray 10 MG/ML|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
89353483|NCT03680911|Experimental|NAC Group|NAC group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
89353484|NCT03680911|Placebo Comparator|Placebo Group|Placebo group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
89353485|NCT03370588|Experimental|dexmedetomidine infusion group|
89353486|NCT03370588|Active Comparator|normal saline infusion group|
89353487|NCT05156814|Experimental|Fixed-dose Combination (FDC) estradiol / dydrogesterone|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
89353488|NCT05156814|Active Comparator|Combination therapy with estradiol and dydrogesterone|Duphaston®, 10 mg and Divigel, 0.1%
89353489|NCT05156814|Active Comparator|non-hormonal therapy|Cimicifuga racemosa rhizomatum extract (Klimadynon®)
89353490|NCT03250013|Experimental|Children and adolescents with ADHD|Children and adolescents medicating for ADHD of any subtype (presentation) with comorbidities
89353491|NCT03367078||tDCS cohort|DOC patients treated according to usual care, plus anodal tDCS (prospective cohort)
89353492|NCT03367078||Historical control cohort|DOC patients treated according to usual care only (retrospective cohort of patients matched for demographic and clinical characteristics, admitted at the Montecatone Rehabilitation Institute no more than 3 years before the introduction of tDCS)
89353493|NCT03370432||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
89353494|NCT03370432||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
89353495|NCT01174667|Experimental|Fascial massage|A specific type of fascial massage to release restricted lumbodorsal fascia.
89353496|NCT01174667|No Intervention|No treatment control|Patient will rest quietly without receiving any instruction.
89353497|NCT03224130|Experimental|Nurse Phone Call|Families in this arm will receive a phone call within 96 hours of discharge
89353498|NCT03224130|Active Comparator|Standard of Care|This arm will receive standard of care.
89353499|NCT03858413||Chronic kidney disease stage V|No intervention
89353500|NCT03858413||Chronic kidney disease stage III|No intervention
89353501|NCT03864887||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
89353502|NCT03864887||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
89353503|NCT03864887||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
89353504|NCT03864887||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
89353505|NCT03370354||Control group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is > 18, the patient will be in the control group.
89353506|NCT03370354||troubled sleeping patterns group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is < 18, the patient will be in the troubled patterns group.
89353507|NCT03367000|Experimental|Ceprolac|Received supplementation which added 27.6g protein and 114kcal to daily nutritional intake as well as standard diet counselling for 6 months
89353508|NCT03367000|Placebo Comparator|Dietary counseling (DC)|Received standard diet counselling only for 6 months.
89353509|NCT01180907||patients with cancer|
89353510|NCT01180907||patients with autoimmune diseases|
89353511|NCT01180907||healthy subjects|
89353512|NCT03366922|Active Comparator|Control Arm|Participants will be on routine HAART only. No Artemisia Annua, Moringa oleifera will be given.
89353513|NCT03366922|Experimental|Intervention Arm 1|Participants will be given HAART and Artemisia annua leaf powder 4 g per day. They will only receive Artemisia Annua, Moringa oleifera will not be given.
89353514|NCT03366922|Experimental|Intervention Arm 2|Participants will be given HAART with Artemisia annua leaf powder of 4 grams per day and Moringa oleifera leaf powder of 10 grams per day. Both Artemisia Annua, Moringa oleifera will be given.
89353515|NCT03370198|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
89353516|NCT03370198|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
89353517|NCT03370198|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
89353518|NCT01289405|Placebo Comparator|placebo exercices|relaxation exercises and stretching neck, without therapeutic purpose.
89353519|NCT01289405|Active Comparator|phonoaudiologic therapy|isometric and isotonic exercises to improve posture, mobility and muscle tone of the soft palate, pharyngeal constrictor muscles, tip and base of tongue, cheeks and lips.
89353520|NCT03366688|Active Comparator|IBI306|Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design
89353521|NCT03366688|Placebo Comparator|placebo|Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design
89353522|NCT01289483|Active Comparator|fospropofol 6.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 6.5 mg/kg.
89353523|NCT01289483|Active Comparator|fospropofol 5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 5 mg/kg.
89353524|NCT01289483|Active Comparator|fospropofol 3.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 3 mg/kg.
89353525|NCT01289483|Active Comparator|fospropofol 2 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 2 mg/kg.
89353526|NCT01180517|Active Comparator|Drug Eluting Balloon|
89353527|NCT01180517|Active Comparator|Plain Old Balloon Angioplasty (POBA)|
89353528|NCT03864809||psoriasis patients|sleep disturbance
89353529|NCT03864809||atopic dermatites patients|sleep disturbance
89353530|NCT03864809||control|sleep disturbance
89353531|NCT03358342||ED Patients treated using ePneumonia CDS|ED patients with community-acquired pneumonia treated in ED's after roll out of ePneumonia
89353532|NCT03358342||Usual care|ED patients with pneumonia receiving usual care without electronic CDS
89353533|NCT03858257|Experimental|High flow nasal oxygen|The gas temperature will commence at the 'High' setting (ranges 30-32º Celsius) and titrated downwards if the patient complains of irritation. The gas flow rate will commence at 30 liters per minute prior to sedation administration and be titrated up to 70 liters per minute as tolerated by the patient after sedation has been administered. The fraction of oxygen in the gas will be commenced at 50% (same as that delivered from 6 liters per minute via facemask) and can be titrated upward according to patient requirements (i.e. increased if there is evidence of hypoventilation, airway obstruction or inadequate oxygenation, decreased during use of diathermy). Anesthesia Assistants at the site will be provided with training in the use of this mode of oxygen delivery prior to study commencement.
89353534|NCT03858257|Other|Standard oxygenation|Supplemental oxygen through a facemask with the flow rate chosen by the clinician responsible for sedation as per their standard practice. The oxygen flow rate is typically commenced at 6 liters per minute and can be titrated up to 15 liters per minute.
89353535|NCT03679741|Experimental|TEST/CONTROL/CONTROL|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
89353536|NCT03679741|Experimental|CONTROL/TEST/TEST|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
89353537|NCT03360058|Experimental|Immediate access to STBD training|Immediate access to training materials and print pieces to support implementation
89353538|NCT03360058|Placebo Comparator|Delayed access to STBD training|Delayed access to training materials and print pieces
89353539|NCT01289327|Active Comparator|propofol|
89353540|NCT01289327|Active Comparator|midazolam+alfentanil|
89353541|NCT03359980|Experimental|treated patients|Treated with Fecal Microbiota Transfer (FMT)
89353542|NCT03857789|Other|Regular care|Participant will be received by Healthcare professional (HCP). The HCP will administer a questionnaire. The HCP will discuss the results.
89353543|NCT03857789|Experimental|New care|Participant will be received by Healthcare professional (HCP). The social robot will administer a questionnaire. The HCP will discuss the results.
89353544|NCT02446405|Experimental|Enzalutamide|"Enzalutamide is 160 mg daily, by mouth, until clinical disease progression or prohibitive toxicity.~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
89353545|NCT02446405|Active Comparator|Conventional NSAA|"Conventional NSAA, by mouth until clinical disease progression or prohibitive toxicity.~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
89353546|NCT03858023|Experimental|Hippotherapy|Children in hippotherapy arm will participate in hippotherapy (30 min/sessions, twice a week, 15 weeks)
89353547|NCT03858023|No Intervention|Control|Children in control group will not receive hippotherapy
89353548|NCT03366610||Patients Previously Treated with Daclatasvir-Based Regimens|Patients in China Previously Treated with Daclatasvir-Based Regimens
89353549|NCT01181063|Experimental|400/12 μg D94-2BF (60/40) inhaler|
89353550|NCT01181063|Experimental|320/9 μg D94-2BF (20/80) inhaler|
89353551|NCT01181063|Active Comparator|Symbicort 320/9 μg inhaler|
89353552|NCT01181063|Experimental|320/9 μg D94-2F (60/40) inhaler|
89353553|NCT01181063|Experimental|320/9 μg D94-2BF (60/40) inhaler|
89353554|NCT03359824|Other|Exercise|Arm: Exercise: Combination of moderate intensity continuous training, high intensity interval training and endurance training 5 times per week for a total of 6 weeks. Out of 5 sessions three were supervised by trainer and two sessions were performed by subjects on their own.The duration of the exercise was increased progressively. The first two weeks was 30 minutes that increased to 45 minutes in the third and fourth week. It was 60 minutes for the last two weeks.
89353555|NCT03678103|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
89353556|NCT03358264|Experimental|Type 2 diabetic patients|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to type 2 diabetic patients with HbA1c>6
89353557|NCT03358264|Experimental|Healthy volunteers|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to non-diabetic healthy volunteers
89353558|NCT03858179|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
89353559|NCT03858179|Experimental|PBMT + training/ placebo + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
89353560|NCT03858179|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
89353561|NCT03858179|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
89353562|NCT03366532||Nurses' Health Study|The NHS began in 1976 when 121,700 female nurses aged 33-55 years and residing in the United States responded to a baseline questionnaire.
89353563|NCT03366532||Nurses' Health Study II|The NHSII was initiated in 1989 with the recruitment of 116,671 younger female registered nurses, 24 to 44 years of age, from 14 states
89353564|NCT03366532||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was established in 1986 and was comprised of 51,529 US male health professionals ranging in age from 40 to 75 years at enrollment from 50 states
89353565|NCT03639805|Active Comparator|non interventional arm|Standard Of Care
89353566|NCT03639805|Experimental|interventional arm|Standard of Care + music therapy program MUSIC CARE®
89353567|NCT01180595|Other|Modular|Trabecular Metal Modular Tibial Total Knee Component
89353568|NCT01180595|Other|Monoblock|Trabecular Metal Monoblock Tibial Total Knee Component
89353569|NCT03358186||revision of periprosthetic fracture|patients with surgically treated periprosthetic femur fracture
89353570|NCT04522258|Placebo Comparator|Placebo|Refined cereal flour
89353571|NCT04522258|Active Comparator|Dietary fiber|Fermentable cereal bran
89353572|NCT03649477|Placebo Comparator|Placebo|matched placebo during first 8-weeks; prospectively randomized 1:1 to either one of the two doses of carbetocin during 56-week follow-up and optional extension periods
89353573|NCT03649477|Experimental|3.2 mg of LV-101|3.2 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
89353574|NCT03649477|Experimental|9.6 mg of LV-101|9.6 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
89353575|NCT01181219|Experimental|CXL without epithelial removal|Application of Riboflavin and the consequent UV-irradiation with intact corneal epithelium
89353576|NCT01181219|Active Comparator|CXL with epithelial removal|Corneal epithelial removal prior to Riboflavin and the consequent UV-irradiation
89353577|NCT03359746|Experimental|Treatment Group|This is a prospective, interventional, case-control study at King Faisal Specialist Hospital & Research Centre in post-renal transplant patients who are receiving Grazoprevir/Elbasvir combination. Data will be compared with matched historical controls, which will be selected according to the following matching criteria: age, time from transplant to initiation of therapy. Only patients who completed at least 48 weeks of pegylated Interferon + Ribavirin therapy in the control group and 12 weeks of therapy on the case group will be enrolled. Any patient who received at least one dose of Grazoprevir/Elbasvir combination will be included in the safety analysis.
89353578|NCT03359668|Experimental|Non-contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
89353579|NCT03359668|Active Comparator|Contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
89353580|NCT01180673|Experimental|MINT-TLC|
89353581|NCT01180673|Active Comparator|Control Condition|
89353582|NCT01310101|Experimental|Ofatumumab plus dexamethasone|
89353583|NCT03864497||Orthotopic liver transplantation candidates|No intervention, imaging test and risk stratification as part of routine clinical care.
89353584|NCT03359512|Experimental|qCON monitor|Simultaneous measurement of BIS and qCON
89353585|NCT03639727|Active Comparator|Citric acid aerosol bronchial challenge|Inhaled citric acid aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is citric acid aerosol challenge.
89353586|NCT03639727|Active Comparator|Mannitol aerosol bronchial challenge|Inhaled mannitol aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is mannitol aerosol challenge.
89353587|NCT01180751|Other|[18F]-Fluorodeoxyglucose|Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.
89353588|NCT03358108||Group A: interferon group|formerly interferon group (including interferon alone or interferon combined with other drugs)
89353589|NCT03358108||Group B:nucleoside analogue group|formerly nucleoside analogue treatment group. Each group was followed for five years
89353590|NCT01181297|Experimental|Extensively Hydrolyzed Formula with a Probiotic|Extensively Hydrolyzed Formula with a Probiotic
89353591|NCT01181297|Placebo Comparator|Extensively Hydrolyzed Formula without a Probiotic|
89353592|NCT01180829|No Intervention|Control condition|No interventions text messages sent
89353593|NCT01180829|Experimental|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking
89353594|NCT01180829|Experimental|Consciousness raising text message|A series of 12 text messages, each of which contains text designed to get the person to think about his or her drinking
89353595|NCT03677869|Experimental|Pneumatic vitreolysis (PVL)|Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.
89353596|NCT04523272|Experimental|TQB2450 + Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89353597|NCT04523272|Active Comparator|Sunitinib Malate Capsules|Sunitinib malate capsule 50mg administered orally, once daily in 28-day cycle(14 days on treatment from Day 1-14, 14 days off treatment from day 15-28).
89353598|NCT01587677||Confirmed tuberculosis|
89353599|NCT01587677||Confirmed non-tuberculous mycobacterial infection|
89353600|NCT01587677||Confirmed bronchial carcinoma|
89353601|NCT01587677||Suspected tuberculosis but confirmed alternative diagnosis|
89353602|NCT01289561|Experimental|Alcohol self-administration|All participants will participate in seven sessions. In three sessions, each participant will consume a beverage containing alcohol and caffeine. In three separate sessions, participants will consume a beverage containing alcohol and caffeine-placebo. In the final session, all participants may choose which beverage they consume. Participants and research assistants will be blinded to inclusion of caffeine/caffeine-placebo in beverage, but each beverage will be labeled for identification (e.g., A or B).
89353603|NCT03366376|Experimental|Experimental|WBRT with hippocampus-sparing and SIB
89353604|NCT03855527|Experimental|Silver Diamine Fluoride (SDF) group|Atraumatic restorative technique will be performed. Then the cavities will be dried with a gentle flow of compressed air. One drop of silver diamine fluoride (Advantage Arrest Silver Diamine Fluoride 38% - Bottle) will be dispensed into a dappen dish. A micro brush will be bent, dipped into SDF and dabbed on the side of the dappen dish to remove excess liquid before application. SDF will be applied directly to affected tooth surface and dried with gentle flow of compressed air for 1 minute. Excess SDF will be removed with cotton roll. Teeth will be restored with glass ionomer cement (GC Fuji IX).
89353605|NCT03855527|Active Comparator|Chlorhexidine group|Atraumatic restorative treatment will be performed. Then, the cavities will be disinfected by placing a cotton pellet soaked in chlorhexidine solution (Consepsis®2% Chlorhexidine Antibacterial Solution) for 1 minute, air dried and restored using glass ionomer cement.
89353606|NCT03855527|Sham Comparator|Atraumatic Restorative Treatment without Disinfection|Cavities will be cleaned according to the ART approach.The cavity will be enlarged if needed using sterile hatchet.The carious dentin will be removed with excavators starting at the enamel-dentine junction. The unsupported thin enamel will be fractured off with the hatchet. The caries will be removed carefully until firm dentin is reached (physically resistant to hand excavation). The cavity will be cleaned with wet cotton pellets. Cavities will be restored immediately using conventional glass ionomer cement. All the cavities in the 3 groups will be temporary restored with glass ionomer cement handled according to manufacturer's instructions, however acid etching will not be carried out in order to make sample collection easier following the experimental period.
89353607|NCT03864263||Children with HBsAg-positive patients|Children from a father or mother who are infected with HBV
89353608|NCT03864263||Children without a family history of HBV|Children without a family history of HBV infection
89353609|NCT03366064|Experimental|Pemetrexed and donor NK cell infusion|Eligible patients with stage 4 non-small cell lung cancer receive NK cells derived from HLA-haploidentical family donors. One week prior to NK cell infusion, patients receive pemetrexed (500 mg/m2) intravenous infusion
89353610|NCT03677401|Experimental|5 mg Serlopitant Tablets|
89353611|NCT03677401|Placebo Comparator|Matching Placebo Tablets|
89353612|NCT02525393|Experimental|tDCS+rTMS|Stroke patients were treated with an initial two weeks of transcranial direct current stimulation and after six months with two weeks of repetitive transcranial magnetic stimulation.
89353613|NCT02525393|Experimental|rTMS+tDCS|Stroke patients were treated with an initial two weeks of repetitive transcranial magnetic stimulation and after six months with two weeks of transcranial direct current stimulation.
89353614|NCT02525393|Sham Comparator|Sham stimulation|Stroke patients were treated with two weeks of sham transcranial direct current stimulation.
89353615|NCT03359278||open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
89353616|NCT01290809||Prophylactic Cranial Irradiation|NSCLC patients treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
89353617|NCT01290809||no Prophylactic Cranial Irradiation|NSCLC patients not treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
89353618|NCT03357874|Experimental|Clopidogrel group|
89353619|NCT03357874|Experimental|Ticagrelor group|
89353620|NCT03855293|Other|Study group|rhexis protection shield
89353621|NCT03855293|No Intervention|Control group|regular surgery
89353622|NCT01286051|Active Comparator|Follistim|standard treatment
89353623|NCT01286051|Experimental|Follistim plus single ganirelix injection|
89353624|NCT03357796|Experimental|Group A: LY03005 cross-over to Pristiq®|Subjects in Group A will receive an 80 mg oral dose of LY03005 and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator followed by a 4-day stay in the CRU (Period 2).
89353625|NCT03357796|Experimental|Group B: Pristiq® cross-over to LY03005|Subjects in Group B will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005 followed by a 4-day stay in the CRU (Period 2).
89353626|NCT02359513|Experimental|boulimic|Analyse of serotoninergic brain activity (determined by positron emission tomography using [18F]MPPF) from bulimic patients treated with serotoninergic antidepressants during 3 months. The serotoninergic brain activity is measured before adnd after the serotoninergic antidepressant treatment.
89353627|NCT01184495|Experimental|Epoetin Bio-Manguinhos|
89353628|NCT01184495|Active Comparator|EPO-BioSimilar|Subcutaneous administration of EPO-BioSimilar
89353629|NCT04522024|Active Comparator|Mei Mini Maze|Mei Mini Maze procedure (Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side)
89353630|NCT04522024|Experimental|Mei Mini Maze plus epicardial cryoablation|Epicardial focal cryoablation during Mei Mini Maze procedure
89353631|NCT03218787|Experimental|XIENCE|Subjects will receive XIENCE family stents and if a subject was DAPT compliant and event free, then took 3 month DAPT, following with aspirin mono-therapy until 12 month
89353632|NCT03639649|Experimental|STHLM3|
89353633|NCT03639649|Active Comparator|PSA|
89353634|NCT01184573||Mild to Moderate CP|Subjects must have a history compatible with chronic pancreatitis.
89353635|NCT01184573||Healthy Controls|Subjects must be in good health of greater than 18 years of age.
89353636|NCT03640039|Experimental|study group: 3d strut plate fixation without post op IMMF.|Open reduction and internal fixation with 3d strut plate without post operative IMMF.
89353637|NCT03640039|Active Comparator|control group: 3d srut plate fixation with post op IMMF.|Open reduction and internal fixation with 3d strut plate with post operative IMMF for 15 days.
89353638|NCT03864575|Experimental|Combination Group|Celecoxib 400 mg/d Nivolumab 240 mg q2w
89353639|NCT03357718|Experimental|Dexmedetomidine|2 µg/kg Precedex
89353640|NCT03357718|Active Comparator|Midazolam|0.5 mg/kg dormicum
89353641|NCT01184651||Girls|Girls with 21-hydroxylase deficiency (21-OHD) congenital adrenal hyperplasia (CAH) ages 10-13
89353642|NCT01184651||Parents|Parent, guardian, or significant caretaker of girls with CAH
89353643|NCT04521790||Arrhythmic (A)|"Arrhythmic Group. To oversimplify, specific subgroups of patients will be considered.~Group 1: major ventricular arrhythmias (haemodynamically unstable VT, hu-VT; ventricular fibrillation, VF).~Group 2: other ventricular arrhythmias (high-burden premature ventricular complexes = hb-PVC; nonsustained VT = NSVT; haemodynamically stable VT = hs-VT).~Group 3: bradyarrhythmias (2nd type II or 3rd degree atrioventricular block = advanced AVB; critical sinus pauses = SND).~Group 4: supraventricular arrhythmias (atrial fibrillation = AF; atrial flutter = AFlu; atrial tachycardia = AT)."
89353644|NCT04521790||Nonarrhythmic (NA)|"Nonarrhythmic Group. To oversimplify, specific subgroups of patients will be considered.~Heart failure presentation (and subtypes)~Chest pain presentation (and subtypes)~Asymptomatic presentation/screening (and subtypes)"
89353645|NCT04521790||Subgroups|"For specific study aims, different patient subgroups will be compared. The main groups are hereby reported:~A. Arrhythmic myocarditis subgroups (1-4). B. Non-arrhythmic myocarditis subgroups (i.e.: fulminant, acute coronary syndrome-like, pericarditis-like, heart failure, nonischaemic dilated /hypokinetic cardiomyopathies of unknown aetiology…).~C. Infectious vs. autoimmune vs. toxic myocarditis. D. Myocarditis treated by aetiology-based treatment vs. isolated cardiac medical treatment.~E. Myocarditis at different disease stages: acute, hyperacute, fulminant, chronic active, post-inflammatory, or active vs. previous vs. non-myocarditis.~F. Myocarditis presenting as organ-specific diseases vs. in the context of a genetic disorder or systemic disease.~G. Myocarditis vs. peri-myocarditis/myo-pericarditis. H. Other subgroups."
89353646|NCT01184729||Spinal Cord Injury|
89353647|NCT05239923|Experimental|generation of neutralizing antibody for unvaccinated participants|participants received vaccine 1 capsule of 1×10^10 CFU of B. subtilis spore at day 0, 14, and 28 respectively.
89353648|NCT04521400|Experimental|Arm1|Lopinavir /Ritonavir +high dose Interferon-β 1a
89353649|NCT04521400|Experimental|Arm2|Lopinavir /Ritonavir + Low dose Interferon-β 1a
89353650|NCT01184807|Other|OPB-51602|
89353651|NCT01184963|Other|Controls|Women in reproductive age regular ovulatory cycles
89353652|NCT01184963|Other|PCOS patients|Patients with anovulatory cycles, hyperandrogenism with or without polycystic ovarian appearance
89353653|NCT01348087|Experimental|AFQ056 100 mg (Bid)|All patients initiated treatment with AFQ056 at a starting dose of 25 milligram (mg) twice daily. The dose was titrated from 25mg bid to 50mg bid, 75mg bid and 100mg bid at weekly intervals. Dose adjustments (up- and down titrations) were permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose not to exceed 100mg bid.
89353654|NCT01185041|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
89353655|NCT01185041|Experimental|Watermelon|(6g per day)containing L-citrulline/L-arginine (4/2 g)
89353656|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody positive)|
89353657|NCT03864185|Placebo Comparator|Placebo group (IgG4 autoantibody positive)|
89353658|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody negative)|
89353659|NCT01347931|Experimental|NIOV System|Noninvasive ventilation and oxygen delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
89353660|NCT01347931|Active Comparator|Standard Oxygen Therapy|Supplemental oxygen using standard oxygen cannula connected to a portable oxygen cylinder.
89353661|NCT01174979|Experimental|Caroverin|
89353662|NCT01174979|Placebo Comparator|Placebo|
89353663|NCT03359044||Sedation + topical anesthesia|midazolam 0.1～0.2 mg/kg for sedation, 2%lidocaine for topical anesthesia
89353664|NCT03359044||General anesthesia+ topical anesthesia|propofol 4～5mg/kg、Remifentanil2～3μg/kg for induction ,insert Laryngeal Mask Airway(LMA) , 2%lidocaine for topical anesthesia
89353665|NCT01185119|Active Comparator|GLP-1|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
89353666|NCT01185119|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
89353667|NCT03357640|Placebo Comparator|no intervention|The women will receive one package of placebo. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
89531971|NCT04464798|Experimental|Cohort D -CC-220 monotherapy in participants with aggressive B-cell lymphoma and follicular lymphoma|
89531972|NCT04464798|Experimental|Cohort E - CC-220 and rituximab in participants with aggressive B-cell lymphoma|
89353668|NCT03357640|Active Comparator|combined oral contraception pills|The women will receive intervention of one package of combined oral contraception pills and will be counseled about how to take oral contraception and informed of possible side effects. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
89353669|NCT01185197|Experimental|Myfortic plus low-dose steroid|Not necessary
89353670|NCT01185197|Active Comparator|Standard-dose steroid|Not necessary
89353671|NCT03733873|Experimental|desmopressin plus Suoquan|Drug1. name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months Drug2 name:Suoquan mixture form:liquid dosage:10ml/time frequence:bid duration:3 months
89353672|NCT03733873|Active Comparator|desmopressin|name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months
89353673|NCT03365674|Experimental|Vibration group|Vibrator head was applied (100Hz) on the popliteal fossa, during the trigger point injection
89353674|NCT03365674|Placebo Comparator|Placebo group|In placebo group, vibrator head was applied with switch-off sate, during the trigger point injection
89353675|NCT03733795||Control|'Healthy babies' to establish 'normal' blood flow in neonates.
89353676|NCT03733795||ECMO|Children undergoing extracorporeal membrane oxygenation for acute respiratory failure.
89353677|NCT03733795||Conventional|Neonates undergoing conventional treatment for acute respiratory failure.
89353678|NCT03357484|Experimental|L-PRF|Third molar extraction sockets were filled with two leukocyte- and platelet rich fibrin (L-PRF) clots
89353679|NCT03357484|Active Comparator|Blood clot|Third molar extraction sockets allowed to form a natural blood clot and undergo natural healing
89353680|NCT01290965|Placebo Comparator|Placebo comparator|
89353681|NCT01290965|Active Comparator|SCY-635 30 mg once daily|
89353682|NCT01290965|Active Comparator|SCY-635 100 mg once daily|
89353683|NCT01290965|Active Comparator|SCY-635 300 mg once daily|
89353684|NCT01290965|Active Comparator|SCY-635 100 mg three times daily|
89353685|NCT01290965|Active Comparator|SCY-635 200 mg three times daily|
89353686|NCT01290965|Active Comparator|SCY-635 300 mg three times daily|
89353687|NCT03733639|Active Comparator|Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm Tisseel® surgeon dispenses the product all over the anastomosis. The rest of the surgical procedure is as usual."
89353688|NCT03733639|Other|no Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm  noTisseel® surgeon performs the surgical procedure as usual."
89353689|NCT03357406|Experimental|edentulism side 1|ultrasound implant site preparation
89353690|NCT03357406|Active Comparator|edentulism side 2|conventional implant site preparation
89353691|NCT01291043|Experimental|Shiatsu Group|
89353692|NCT01291043|No Intervention|Control Group|
89353693|NCT03358966||Early to moderate CKD (stage 1-3)|40 patients with CKD stage 1-3. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
89353694|NCT03358966||Advanced CKD (stage 4-5)|40 patients with CKD stage 4-5. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
89353695|NCT03863951||Patients with poststroke depression|No intervention
89353696|NCT03863951||Patients without poststroke depression|No intervention
89353697|NCT03733561|Experimental|LY03003|LY03003
89353698|NCT03733561|Active Comparator|Neupro transdermal patch|Neupro transdermal 4 mg patch
89353699|NCT03358888|Active Comparator|Standard of Care|
89353700|NCT03358888|Active Comparator|Multi-modal with as needed opioids|
89353701|NCT03358888|Active Comparator|Multi-modal with one week of opioids offered|
89353702|NCT03733405|Experimental|Postpartum Visit 6 Weeks|Participants will have a postpartum visit scheduled 6 weeks after birth
89353703|NCT03733405|Experimental|Postpartum Visit 2 and 6 Weeks|Participants will have postpartum visits scheduled 2 and 6 weeks after birth
89353704|NCT03365518|Experimental|Cognitive Behavioural Therapy (CBT)|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
89353705|NCT03365518|Experimental|Mindfulness-Based Therapy|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
89353706|NCT03365518|No Intervention|Control - Usual Care|"Participants who are randomized to the control group will not receive mindfulness or CBT treatment. They will proceed with the course of treatment they were receiving prior to enrollment in the study. As resources for couples dealing with changes to their sexual lives after prostate cancer are limited, it is anticipated that the majority of these patients will have no treatment targeting sexual intimacy during the 6-week period between completing the first and second questionnaire.~Those randomized to the control group will have the opportunity to be randomized to one of the treatment groups following their third and final questionnaire if they wish. In this case, they will be issued an additional participant ID within one of the treatment groups."
89353707|NCT01291121|Active Comparator|group 1|Intravitreal ranibizumab 0.5mg only group
89531973|NCT04464798|Experimental|Cohort F - CC-220 and rituximab with follicular lymphoma grade 1-3a|
89531974|NCT04464798|Experimental|Cohort G - CC-220 plus obinutuzumab in participants with follicular lymphoma grade 1-3a|
89531975|NCT04440228|Experimental|Schools implementing TeamSTEPPS|Select schools will take a participatory approach to collaboratively identify solutions to challenges in collocated school-based mental health services based upon the feedback of stakeholders and use TeamSTEPPS to support mental health team-school collaboration.
89353708|NCT03357328|Active Comparator|Therapy light room|This group (4 NH units, about 35 patients) will receive light therapy administered via LED technology. The light will vary in intensity and colour temperature throughout the day. Ceiling-mounted LED-lights are installed in the living rooms of participating nursing home units. Between 07:00 and 10:00 light of 400 lux at eye level, with 4000 K, will be provided. Between 10:00 and 15:00 the light will comprise 1000 lux at eye level, with 6000 K. From 15:00 to 18:00 the light will comprise 400 lux at eye level and 4000 K. When light is on from 18:00 to 07:00, standard light (about 100 lux at eye level, 3000K) will be administered.
89353709|NCT03357328|Placebo Comparator|Standard light|"This group (4 NH units, about 35 patients) will receive standard light (100 lux at eye level, 3000K). The light will be administered between 07:00 and 18:00; and the same when light is on between 18:00 to 07:00. This represents the placebo light intervention, which at the same time ensures a constant standard light condition in all control units."
89353710|NCT01185275||Severe Asthma Patients|Severe asthma patients symptomatic despite high dose inhaled corticosteroid and long acting beta-agonist
89353711|NCT03365440||EP study with transseptal passage|"15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure~Focal pacing maneuvers"
89353712|NCT03365440||EP study without transseptal passage|- 15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure
89353713|NCT03365440||Healthy participants|- 60 minute esophageal ECG (using esoECG-3D catheter) & respiration recording
89353714|NCT01185431|Experimental|Ficus carica (Fig paste)|
89353715|NCT01185431|Placebo Comparator|Control (Placebo paste)|
89353716|NCT01187849|Active Comparator|Metformin|
89353717|NCT01187849|Placebo Comparator|Placebo|
89353718|NCT03358810|Active Comparator|Active group|patients randomized to receive active PES
89353719|NCT03358810|Sham Comparator|Sham treatmment|Patients randomized to sham will not receive any PES.
89353720|NCT02524535|Other|Therapetic alliance|
89353721|NCT03358732|Experimental|Mock embryo transfer|The patients underwent a mock embryo transfer one day before the scheduled actual transfer
89353722|NCT03358732|No Intervention|No mock embryo transfer|The patients did not undergo mock embryo transfer one day before the scheduled actual transfer
89353723|NCT01185587||healthy patients with a normal heart|
89353724|NCT01185587||patients with HF without an lCD|
89353725|NCT01185587||patients with HF and an ICD without shock|
89353726|NCT01185587||patients with HF and an ICD with shock|
89353727|NCT03358654|Experimental|mesenchymal stem cells|Inject mesenchymal stem cells from umbilical cord. The patients will be followed up at 1, 2, 3, and 6 months after the injection
89353728|NCT04927871|Experimental|Hybridized Lyfestile Intervention|The participants will receive three interventions including Total Diet Replacement, Medical Nutrition Therapy, and the Diabetes Prevention Program
89353729|NCT04927871|Active Comparator|Only Diabetes Prevention Program|The comparison group will receive only the Diabetes Prevention Program
89353730|NCT03365284|Experimental|Smart Kneebrace|Smart Kneebrace with a smart phone app will be used during the rehabilitation after surgery for three months
89353731|NCT03365284|Placebo Comparator|without Smart Kneebrace|regular rehabilitation procedure will be applied after surgery
89353732|NCT01187927||Female subjects|Subjects received Cervarix® as per routine practice
89353733|NCT04522882|Experimental|At home clinical data collection|Clinical data will be collected during 7 days: physical activity, sleep duration, chronotype, food and medication intake, glucose level and insulin administration.
89353734|NCT01185665|Active Comparator|TENS|FBSS patients treated with TENS
89353735|NCT01185665|Placebo Comparator|Sham-TENS|patients treated with Sham-Tens
89353736|NCT03123718|Other|Intrathecal Methotrexate|
89353737|NCT03123718|Active Comparator|High-dose Intravenous Methotrexate|
89353738|NCT01185743|Active Comparator|olanzapine|olanzapine
89353739|NCT01185743|Active Comparator|ziprasidone|ziprasidone
89353740|NCT01185743|Placebo Comparator|Sugar pill|Sugar pill
89353741|NCT04445038|Experimental|610 group|Participants will be administered with 0.03mg/kg, 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg of 610 by subcutaneous injection. Subjects will be followed for 84 days.
89353742|NCT04445038|Placebo Comparator|controll group|Participants will be administered with 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg placebo once by subcutaneous injection. Subjects will be followed for 84 days.
89353743|NCT01188005|Experimental|OSAS patients|This arm includes the OSAS diagnosed cohort that has been planned to undergo four polysomnographic studies. One standard, one with oxygen supplementation, one with n-CPAP device and one post antioxidants administration
89353744|NCT01188005|No Intervention|Control Group|This group is scheduled to undergo a plain polysomnographic study, whilst plasma cytokine levels will be measured. It will comprise of healthy, non-OSAS volunteers.
89353745|NCT03645421|Placebo Comparator|placebo|Placebo per day,SC injection on 48 days.
89353746|NCT03645421|Experimental|MEDI0382 100μg|50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days
89353747|NCT03645421|Experimental|MEDI0382 200μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
89353748|NCT03645421|Experimental|MEDI0382 300μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days
89353749|NCT04445194|Experimental|Population I|Population I has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population I is intramuscular injection of deltoid muscle of upper arm with low dose of vaccine.
89353750|NCT04445194|Experimental|Population II|Population II has 20 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population II is a high-dose vaccine intramuscular injection of deltoid muscle of the upper arm.
89353751|NCT04445194|Placebo Comparator|Population Ⅲ|Population Ⅲ has 10 subjects and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. Population Ⅲ is a placebo intramuscular injection of deltoid muscle of the upper arm.
89353752|NCT04445350|Experimental|External focus of attention training program|The intervention group receives a strength and neuromuscular training program. The training instructions have an external focus of attention.
89353753|NCT04445350|Active Comparator|Internal focus of attention training program|The control group receives a strength and neuromuscular training program. The training instructions have an internal focus of attention.
89353754|NCT01291199|Experimental|Vardenafil 10 mg bid|
89353755|NCT01291199|Placebo Comparator|Placebo|
89353756|NCT04521010||Staff absenteeism|A retrospective analysis of above-mentioned data, covering the period January-April 2019 and January-April 2020, was carried out. The evaluation of the staff's absence included all workers employed under an employment contract: 713 workers in 2019 and 747 workers in 2020.
89353757|NCT04521010||healthcare services|The variable number of employees was a result of the employment dynamics in the subsequent 2 years, due to variable quantity of healthcare services that were contracted with the national payer and changes in the form of employment of some hospital workers
89353758|NCT04444726|Experimental|"Phototherapy PUVA +traditional medical treatmentn"|"patient sock his hands in a bath containing water with the constitution of psoralen meladinine  capsule for 20 minutes then irradiated at the UVA device for 3 sessions per week for 8 weeks Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
89353759|NCT04444726|Experimental|Tap Water Iontophoresis + Traditional medical treatment|"Tap-water iontophoresis was given 3 times weekly for 10 min The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30mA. Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
89353760|NCT04444726|Active Comparator|traditional medical treatment|"Traditional medical treatment. which is the betamethasone dipropionate 0.05%  diprolene for 2 times a day for 8 weeks."
89353761|NCT03733327|Experimental|BUCYE|For PCNSL patients undergoing auto-HSCT，BUCYE conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/ day on days -3 and -2.
89353762|NCT01188083|Experimental|Fructose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
89353763|NCT01188083|Experimental|Glucose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
89353764|NCT01185899||Suspected ACS patients|Patients presenting with chest pain to the Emergency Department, who are suspected of having ACS, will be asked to participate in the study.
89353765|NCT03733171|Active Comparator|Platelet rich plasma|endoscopic injection of PRP
89353766|NCT03733171|Placebo Comparator|CONTROL GROUP|diluted epinephrine
89353767|NCT03207750|Experimental|HRV PCV-free Liq Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in PCV-free liquid formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4). PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
89353768|NCT03207750|Active Comparator|HRV Lyo Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4).
89353769|NCT04444570||Control group|14 days before the date of the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom)
89353770|NCT04444570||Study group|Right after the surgery every participant will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
89353771|NCT03854981|Placebo Comparator|Standard Care|If subjects are assigned to this group they will not be provided materials to increase exercise participation. Subjects will however be asked to participate in the standard education sessions that are provided to all bariatric surgery patients. This standard care includes meetings with a nutritionist, psychologist, and bariatric surgeon.
89353772|NCT03854981|Active Comparator|Exercise + Standard Care|Subjects will be asked to exercise 5 days/week for 30 min/day at an intensity of 65-85% of their measured HRmax. Walking will be the main type of exercise. In addition to this training program, subject's will participate in the standard education sessions that are provided to all bariatric surgery patients.
89353773|NCT04521322|Placebo Comparator|Control|Participants in this arm will receive a nasal spray with placebo
89353774|NCT04521322|Experimental|Experimental|Participants in this arm will receive a nasal spray with Iota-Carrageenan
89353775|NCT03674281|Experimental|Sensor Augmented Pump (SAP)-Closed-Loop Control (CLC)|"SAP: Subjects will be utilizing their own insulin pumps (without automated insulin delivery) plus Dexcom G6 CGM to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period.~CLC with Control-IQ plus CGM: Following SAP, subjects will be utilizing the Tandem t:slim X2 with Control-IQ along with a Dexcom G6 continuous glucose monitor to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period."
89353776|NCT04523038||Low albumin|Patients presenting with low albumin levels preoperatively (<3,5 mg/l)
89353777|NCT04523038||Normal albumin|Patients presenting with normal or high albumin levels preoperatively (>3,5 mg/l)
89353778|NCT01188161||Normal subjects|Volunteers without a history of dizzyness or vertigo
89353779|NCT01185977|Active Comparator|Fluoxetine|1 week single-blinded placebo lead-in and double-blinded FLX treatment for 8 weeks
89353780|NCT01185977|Placebo Comparator|Placebo (PBO)|Placebo treatment for 9 weeks of study
89353781|NCT03673345|Experimental|Cohort 1A|0.25 mL dose of IIV-4 administered intramuscularly on days 0 and 28 of study year 1 and on day 0 of study year 2 in children 6-12 months of age who have not previously had an influenza infection or vaccination, n=20
89353782|NCT03673345|Experimental|Cohort 1B|0.25 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 after primary influenza infection in study year 1 in children 3-12 months of age, who have not previously had an influenza vaccination, n=20
89353783|NCT03673345|Experimental|Cohort 2A|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=60
89353784|NCT03673345|Experimental|Cohort 2B|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
89353785|NCT03673345|Experimental|Cohort 3A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2006 and 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=30
89353786|NCT03673345|Experimental|Cohort 3B|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2006 and 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
89353787|NCT03673345|Experimental|Cohort 4A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2003 and 2006, who have previously received 2 doses of influenza vaccine prior to the study, n=30
89353788|NCT03673345|Experimental|Cohort 4B|0.5 mL does of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2003 and 2006, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
89353789|NCT01588067||Medical|Patients treated for PAD medically or with exercise therapy
89353790|NCT01588067||Endovascular|Patients with PAD treated with endovascular therapy
89353791|NCT01588067||Surgery|Patients with PAD treated with surgery
89353792|NCT04521244|Experimental|Thrust joint lumbar manipulation|Thrust joint lumbar manipulation (Lumbar rotation manipulation) ,Moist Hot pack
89353793|NCT04521244|Active Comparator|Lumbar mobilization|Lumbar mobilization (Stretch rotation mobilization), Moist Hot pack
89353794|NCT03854825||AKI|patients with postoperative AKI defined by KDIGO
89353795|NCT03854825||no AKI|patients without postoperative AKI defined by KDIGO
89353796|NCT03223662|Other|Neoadjuvant Chemoradiotherapy and esophagectomy|Standard of care neoadjuvant chemoradiotherapy (nCRT) and esophagectomy
89353797|NCT03364972|Experimental|Experimental intraocular lens implant|'Alcon Clareon' : New monofocal, hydrophobic acrylic intraocular lens implant
89353798|NCT03364972|Active Comparator|Standard intraocular lens implant|Abbott Tecnis PCB00- Standard monofocal,hydrophobic acrylic intraocular lens implant
89353799|NCT03852641|Experimental|Bolus gavage feeds|Bolus gavage feeds over 15-30 minutes
89353800|NCT03852641|Experimental|Continuous feeds|Continuous feeds over 2.0 hrs
89353801|NCT01188239||HIGH 6wks LOW 6wks NICOTINE|"Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with ORIGINAL 7.4 mg nicotine cartridges for 6 weeks followed by CATEGORIA 5.2 mg nicotine cartridges for a further 6 weeks (high and low nicotine group)."
89353802|NCT03357172|Experimental|Recipient|
89353803|NCT03357172|Experimental|Donor|
89353804|NCT01181453|Experimental|Dermagraft(R)|Weekly application of Dermagraft(R) with standard care
89353805|NCT01181453|Other|Standard care only|Weekly application of standard care
89353806|NCT01291355|Experimental|Specific maternal position|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts. According to Dr de Gasquet, author of the description of this posture, the effect on the variety of presentation would be almost immediate."
89353807|NCT01291355|No Intervention|Control|Not specific intervention for this group- Only usual care
89353808|NCT03358498||β-thalassemia group|"SICT It is a questionnaire to assess patient satisfaction with ICT regimens. It comprises 19 items assessing four domains: perceived effectiveness of ICT (PE), burden of ICT (BD), acceptance of ICT (AC), and side effects of ICT (SE). Patients rate all items on scale from 1 very dissatisfied to 5 very satisfied.~Lab methods :~full history and thorough clinical evaluation.~. Complete blood count. .3- Serum ferritin .~4-Renal function tests. 5-liver function tests."
89353809|NCT01186055||Smoking Cessation Counseling|Individuals will receive individual and group counseling for 8 weeks (6 visits) while they quit smoking.
89353810|NCT01186211||Patients presenting for elective TKA|Patients will be advised preoperatively about an accelerated path while in hospital that will share many attributes of the standard TOH care map but with several additions, chosen to help reduce pain and hemarthrosis, both felt to be the major impediments to faster recuperation.
89353811|NCT03857399|Experimental|Arm-1|Patients will be assigned to receive intravenous local caspofungin (70 mg on day 1 and 50 mg once daily),If the study therapy was well tolerated but fever persisted for four or more days and the patient's clinical condition deteriorated, the dosage could be increased to 70 mg once daily.For patients who have no evidence of baseline or breakthrough fungal infection, study therapy was administered until the absolute neutrophil count was at least 500 per cubic millimeter and for up to 72 hours thereafter. The onsite investigator determined the duration of therapy for patients with baseline or breakthrough fungal infections; however,it was recommended that treatment be given for at least 14 days and for at least 7 days after neutropenia and symptoms resolved.
89353812|NCT03857399|Active Comparator|Arm-2|Patients will be assigned to receive intravenous original caspofungin (70 mg on day 1 and 50 mg once daily),the therapeutical duration is 4 Days.
89353813|NCT04520620|Experimental|enoxaparin treatment|"Patients infected by SARS-CoV-2 in intensive care unit with enoxaparin treatment will be included.~They will have enoxaparin pharmacokinetic and ultrasound of the lower limbs at 7, 14 and 21 days after inclusion."
89353814|NCT03857633||Pre Dialysis (CKD Stage 4/5)|Patients recruited from low clearance clinic with advanced CKD (stage 4/5). Patients will undergo Cardiac MRI 1 - With Gadolinium Contrast at the time of recruitment and Cardiac MRI 2 - With Gadolinium Contrast at time of commencement on renal replacement therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
89353815|NCT03857633||Haemodialysis Dialysis (CDK Stage 5d)|Patients started on Haemodialysis will have Cardiac MRI 3 - With Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
89353816|NCT03857633||Peritoneal Dialysis (CDK Stage 5d)|Patients started on Peritoneal Dialysis will have Cardiac MRI 3 - Without Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
89353817|NCT03357016|Experimental|High Intensity Interval Training program (HIIT)|Subjects perform three sessions of training during 12 weeks: 35 min at 50% maximal aerobic power on bicycle.
89353818|NCT03357016|Experimental|Moderate Intensity Continuous Training program (MICT)|Subjects perform three sessions of training during 12 weeks: repeated cycles of sprinting for 8s and pedaling slowly for 12s (between 20 and 30 rpm) for a maximum of 60 repeats per session.
89353819|NCT03357016|Experimental|HIIT + Resistance Training program (RT)|Subjects perform three sessions of training during 12 weeks: Each subject performed HIIT protocol and then a single set of 8 exercises with 1 ou 2min resting period between exercises. Each set consisted of 8-12 repetitions at about 80% maximum repetition.
89353820|NCT03857711|Active Comparator|Conventional CABG|Coronary artery bypass grafting (CABG) treatment (CABG group,n=70)
89353821|NCT03857711|Active Comparator|CABG+ PVI|CABG + prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation (CABG +PVI group, n=70)
89353822|NCT03857711|Active Comparator|CABG+ PVI+amiodarone|CABG+ prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation + amiodarone (CABG +PVI+ class III antiarrhythmic drug- amiodarone, group, n=70)
89353823|NCT03857711|Active Comparator|CABG+amiodarone|CABG+class III antiarrhythmic drug- amiodarone, group, n=70
89353824|NCT04524676|Experimental|Individualized Treatment Group|
89353825|NCT03364816||TDR with Prodisc-C|participant underwent total disc replacement with Prodisc-C artificial disc
89353826|NCT03364816||TDR with Mobi-C|participant underwent total disc replacement with Mobi-C artificial disc
89353827|NCT03364816||TDR with Prestige-LP|participant underwent total disc replacement with Prestige-LP artificial disc
89353828|NCT01291745||Patients with MYELODYSPLASTIC SYNDROMES|Patients diagnosed with MDS according to FAB, WHO and IPSS classifications. Patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine).
89353829|NCT03672097|Experimental|Prasugrel|Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)
89353830|NCT04520542|Experimental|acupressure|The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention. Each acupressure point was massaged for 30 seconds to provide circulation before the pressure. After the massage, consecutive pressures were applied for 90 seconds. In each intervention, a total of 8-minute sessions were applied to 4 points as 2 minutes for each point. Consecutive pressures were applied on a frequency that did not disturb the women, did not cause pain, and had a soothing effect. Until the end of the intervention it was continued 2 times a week, 16 times in total in 8 weeks.
89353831|NCT04520542|No Intervention|Control Group|no intervation
89353832|NCT04444960||Intracoronary physiology and imaging-guided group|
89353833|NCT04444960||Angiography-guided group|
89353834|NCT03847896|Experimental|BDA MDI (PT027) 160/180 μg|Budesonide/Albuterol sulfate BDA MDI (PT027) high dose
89353835|NCT03847896|Experimental|BDA MDI (PT027) 80/180 μg|Budesonide/Albuterol sulfate BDA MDI (PT027) low dose
89353836|NCT03847896|Active Comparator|BD MDI (PT008) 160 µg|Budesonide BD MDI (PT008)
89353837|NCT03847896|Active Comparator|AS MDI (PT007) 180 µg|Albuterol sulfate AS MDI (PT007)
89353838|NCT03847896|Placebo Comparator|Placebo MDI|Placebo MDI
89353839|NCT01186289|Experimental|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
89353840|NCT01186289|Placebo Comparator|placebo|
89353841|NCT04444648||One groupe without distinction of age, sexe, and pathology.|"Patients with strok in coma, with or without wake up, and with disorder of consciousness. No limit in age (maybe give the younger age).~We obtain this data from medical record. Every assessment was made of clinical purposes.~We use the Glasgow coma recovery scale for assessment of behavior to check the variation of wakefulness. The scale was performed by the nursing staff every 2 to 8 hours depending on the severity of the medical condition.~The continuous analysis of neurophysiologic data was based on EEG with a bipolar montage composed of the less noisy electrodes per recording period.~The EEG features will include: spectral analysis (relative and absolute power in 4 canonical bands: Delta/Theta/Alpha/Beta) and complexity analysis (DFA, determinism, SVD entropy and permutation entropy).~The patient outcome at the ICU and hospital discharges were collected from the medical files."
89353842|NCT03670537||First trimester pregnant women|
89353843|NCT03364504|Experimental|PXE patients|urine collection and culture of renal cells
89353844|NCT04509388|Placebo Comparator|Commercially Available Sports Drink A|A commercially available sports water, with small amounts of flavouring, sweetener and electrolytes
89353845|NCT04509388|Experimental|Commercially Available Sports Drink B|A commercially available sports water, with small amounts of flavouring, sweetener and electrolytes.
89353846|NCT04509388|Experimental|Commercially Available Sports Drink A with added Amino Acids|The same as sports drink A above (a commercially available sports water, with small amounts of flavouring, sweetener and electrolytes), but with the addition of a small amount of amino acids (~0.7 g/100 ml).
89353847|NCT01291823|Experimental|Concomitant Gefitinib and radiotherapy|Patients received Gefitinib and radiation therapy
89353848|NCT03354676||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
89353849|NCT03354676||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
89353850|NCT01181765|Experimental|Infliximab infusions (5 mg/kg) at weeks 0, 2, 6, 14 and 22|
89353851|NCT04509310|Experimental|Active Bodysuits|The potential materials that can provide support are 3D printable rigid materials, semirigid foam padding, Velcro tape and stretchable wide waistbands. The 3D printable materials can be very versatile in terms of properties and can be further finished with an epoxy resin or thermoplastics. Different compositions and structures of knitted fabrics will be used in different areas of the proposed bodysuits to provide a close fit, high breathability and effective pain management due to extra support. The fastening system includes a magnetic zipper and pulley system that can be adjusted by pulling on knobs. The pulley system contains a microadjustable dial, super-strong lightweight lacing, and low friction lacing guides.
89353852|NCT00893035||Intermediate prognosis prostate cancer|Intermediate prognosis prostate cancer
89353853|NCT00893035||Breast cancer|conservative treatment and age<60 Boost irradiation and age>60
89353854|NCT01186445|Experimental|Morphine chlorhydrate|Intracoronary injection of morphine chlorhydrate during reperfusion
89353855|NCT01186445|Placebo Comparator|Saline solution|Intracoronary injection of saline solution during reperfusion
89353856|NCT03356938|No Intervention|Baseline recording|
89353857|NCT03356938|Experimental|Sleep restriction|
89353858|NCT03356938|Experimental|Sleep deprivation|
89353859|NCT03739333|Experimental|patients with glioblastoma|implementation of 11C-Methionine PET-MRI
89353860|NCT05183100|Experimental|Experimental Condition (Neurodynamics Treatment)|Neurodynamic treatment for about 13 minutes in supine position. It will be comprised of three stages, and the tensioner technique of the tibial nerve will be used.
89353861|NCT05183100|Active Comparator|Control Condition|Lying in supine.
89353862|NCT04520464|Active Comparator|Self-test for cervical sample|First sequence will start with self-test. Second sequence will start with traditional method.
89353863|NCT04520464|Active Comparator|Traditional provider for cervical sample|First sequence will start with traditional method. Second sequence will start with self-test method.
89353864|NCT05666531||Healthy people|The physical examination ruled out the disease
89353865|NCT05666531||Chronic gastritis|The endoscopic diagnosis is consistent with chronic gastritis or self-reported stomachache
89353866|NCT05666531||Insomnia|The Pittsburgh Sleep Quality Index Scale was measured and assessed as meeting a diagnosis of insomnia disorder or self-reported insomnia for more than three months
88818896|NCT05445531|Experimental|Long Covid|Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline fulfilled.
89353867|NCT04520230|Experimental|Group 1|Group 1: 15 patients with COPD who will receive inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination (160/4.5mcg) 2 inhalations bid).
89353868|NCT04520230|Experimental|Group 2|Group 2: 15 patients with COPD who will receive inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg inhaled capsule once daily+ Budesonide inhalation 200 mcg twice daily).
89353869|NCT04520230|Experimental|Group 3|Group 3: 15 patients with COPD who will receive long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC). (Tiotropium 18 mcg inhaled capsule once daily+ Formoterol 12 mcg inhaled capsule twice daily)
89353870|NCT05155410|Experimental|Experimental|"Participants will consume 15 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.~All meals will be provided throughout the supplementation period Participants will wear a continuous glucose monitor for the first 10 consecutive days during the supplementation period."
89353871|NCT05155410|Placebo Comparator|Placebo|Participants will consume a flavor-matched placebo drink and undergo the same procedures described in the Experimental Arm
89353872|NCT03619837|Experimental|Treatment Arm|"Single Arm: Sofosbuvir/Velpatasvir~Dosage: 400mg/100mg. Once daily for 12 weeks."
89353873|NCT03852485||Normal|no glaucoma or retinal pathology or corneal conditions
89353874|NCT03852485||Glaucoma|diagnosis of glaucoma
89353875|NCT03852485||Retina|diagnosis of AMD, DR or other retinal pathology
89353876|NCT03852485||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
89353877|NCT03852563|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
89353878|NCT03852563|Active Comparator|Women_Hemiface Vaseline|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
89353879|NCT03356782|Experimental|Sarcoma-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have CD133, GD2, Muc1, CD117 or other marker positive sarcoma will be obtained through apheresis, and T cells will be activated and modified to sarcoma-specific CAR-T cells.
89353880|NCT03739255|Experimental|Cacicol20|One drop of Cacicol20 will be applied 4-6 hours after the surgery, in one of the randomly chosen eye, and thereafter one drop daily until the reepithelialization is completed.
89353881|NCT03739255|Placebo Comparator|Placebo|One drop of conservative free artificial tear (Oculac, Thea Laboratories) will be applied to one eye at the same time when Cacicol20 is instilled to the other eye.
89353882|NCT01188317|Experimental|1|
89353883|NCT01188317|Placebo Comparator|2|
89353884|NCT03356704||General anaesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had general anesthesia
89353885|NCT03356704||continued spinal anesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had continued spinal anesthesia
89353886|NCT03356704||peripheral nerve blocks|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had peripheral nerve blocks
89353887|NCT03206970|Experimental|Zanubrutinib|Zanubrutinib (160 milligrams) administered orally twice daily
89353888|NCT01181843||Cesearean sections receiving duramorph|
89353889|NCT04520386|Experimental|Open label single arm|1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval
89353890|NCT03739021|Experimental|Group 1 (30 participants)|
89353891|NCT03739021|Experimental|Group 2 (30 participants)|
89353892|NCT01588145|Experimental|HM61713|
89353893|NCT03363958|Experimental|RIC Group|Three cycles of remote ischemic conditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation); First three cycles the patient will receive 24 hours preoperatively, second three cycles the patient will receive after the induction of general anesthesia but before skin incision shortly before CABG. Remote ischemic postconditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation) will be administered to the patient within 60 minutes after the completion of all coronary artery bypass grafts and the restoration of coronary blood flow.
89353894|NCT03363958|Sham Comparator|Control Group|Control group will receive sham procedure near identical to intervention. That will be afforded by inflation of pressure cuff on artificial leg hidden under the draping by an assistant who is not included in the research team and does not have any connection to study design and data analysis.
89353895|NCT03738943|Experimental|ATP, Ach, SNP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Acetylcholine: 1, 4, 8, and 16 μg/dl forearm volume/min for 3 minutes each.~Sodium Nitroprusside: 0.25, 0.5, 1, and 2 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
89353896|NCT03738943|Experimental|ATP, ADP, AMP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Adenosine Diphosphate: 20, 40, 80, and 160 μg/dl forearm volume/min for 3 minutes each.~Adenosine Monophosphate: 25, 50, 100, and 200 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
89353897|NCT03738943|Experimental|ATP, UTP, Adenosine|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Uridine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Adenosine: 3.125, 6.25, 12.5, and 25 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
89353898|NCT01588223|Experimental|Lipids|
89353899|NCT01588301|Experimental|Group 1 : Further invitation by mail|Further invitation to attend for cervical cytology
89353900|NCT01588301|Experimental|Group 2 : Kit for Self-collected vaginal sample|Kit for Self-collected vaginal sample sent at home and then test for Human Papillomavirus (HPV)
89353901|NCT01588301|No Intervention|Group 3: Control|
89353902|NCT04520308|Experimental|dupilumab|
89353903|NCT01289795||first-ever ischemic stroke|first-ever ischemic stroke according to the WHO definition
89353904|NCT03644173|Experimental|Study arm - PREP Intervention|Participants receiving the coaching intervention
89353905|NCT01188395||subtypes of bipolar disorders|Bipolar I Disorder with alcoholism Bipolar I Disorder without alcoholism Bipolar II Disorder with alcoholism Bipolar II Disorder without alcoholism
89353906|NCT04509154|Experimental|Multimodal pain therapy|"The treatment will last 6 weeks maximum 8 weeks. The three questionnaires will be completed by all study subjects in a maximum time of 10 minutes. Immediately after receiving the two face-to-face sessions; 6 weeks after (8 weeks maximum after treatment) and three months just after having completed treatment.~The pain management application includes automatic monitoring, skills training, social support, education, goal setting and achievement of 4 components: exercises, psychological well-being, pharmacological and health assets interventions. Every week participants have a look at digital presentations about every component, doing then 3 activities related to each of them.This program will be."
89353907|NCT04509154|Experimental|Standardized treatment.|Both groups (control and intervention) received two face-to-face health education sessions led by nurses and physicians, and had access to a non-interactive web page with material for pain management from a self-help approach.
89353908|NCT03854669|Experimental|Assessing pain reporting accuracy|Subjects will undergo pre-operative evaluation of their pain reporting accuracy ability in order to assess its relation to post-operative acute pain and analgesic consumption
89353909|NCT03178851|Experimental|Cohort A|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles.
89353910|NCT03178851|Experimental|Cohort B|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants will initiate both atezolizumab and cobimetinib on Day 1 of each cycle. Participants in this cohort will undergo tumor biopsies before and during treatment.
89353911|NCT03178851|Experimental|Cohort C|Participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.
89353912|NCT03733015|Active Comparator|cTBS group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. TBS refers to a rTMS protocol where pulses are applied in bursts of three, delivered at a frequency of 50 Hz and an inter-burst interval of 200 ms (5 Hz)."
89353913|NCT03733015|Active Comparator|High frequenct rTMS group|High frequency refers to a rTMS protocol where pulses are applied in at 10Hz frequency
89353914|NCT01291979|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
89353915|NCT01291979|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
89353916|NCT04443634|Experimental|Adductor 20|Ultrasound guided adductor canal block will be performed with injection of 20 ml bupivacaine
89353917|NCT04443634|Experimental|Adductor 30|Ultrasound guided adductor canal block will be performed with injection of 30ml bupivacaine
89353918|NCT04443634|Experimental|Adductor /Saphenous|Ultrasound guided adductor canal block will be performed by injection of 20 ml bupivacaine , combined with ultrasound guided saphenous nerve block at the distal third of the thigh in the intermuscular plane between Vastus Medialis and Sartorius muscle with injection of 10ml bupivacaine 0.5%.
89353919|NCT03643159|Experimental|Abilify MyCite|Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
89353920|NCT03643159|Active Comparator|Virtual Matched Controls|Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.
89353921|NCT03205566|Active Comparator|Arm A Raltegravir, then Raltegravir/Lamivudine|7 days Raltegravir 400mg bd followed by minimum 4 weeks wash out and then 7 days Raltegravir 400mg/lamivudine 150mg (oral tablets) bd.
89353922|NCT03205566|Active Comparator|Arm B Raltegravir/Lamivudine, then Raltegravir|Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days followed by a minimum of 4 weeks wash out and then 7 days Raltegravir 400mg bd.
89353923|NCT01181999|Experimental|rituximab|
89353924|NCT03363880|Experimental|experimental group|The trauma treatment team will be established in the experimental group
89353925|NCT03363880|Active Comparator|control group|The trauma treatment team will not be established in this group，just establish the basic experimental settings
89353926|NCT03732937||Control group|Pregnant ladies with no medical disorders from 16 weeks till term
89353927|NCT03732937||case group|Pregnant ladies with medical disorders from 16 weeks till term
89353928|NCT04523974||Preemptive and Precise Intervention|Preemptive surgical intervention will be performed on enrolled CKD-SHPT patients. Safety and efficacy of this intervention will be evaluated during peri-operative period, and long-term outcomes will be analyzed during 1-year follow-up.
89353929|NCT03854435|Experimental|Heart rate assessed by using a stethoscope (auscultation)|Heart rate will be assessed by using a stethoscope (auscultation) in newborn infants immediately after birth
89353930|NCT03854435|Active Comparator|Heart rate assessed by palpation of the umbilical cord|Heart rate will be assessed by palpation of the umbilical in newborn infants immediately after birth
89353931|NCT04509232|Experimental|group A|- 38% Silver diamine fluoride will be applied to carious lesions by microbrush on the affected surface application time should be 1 min, Application time will be shorter in very young patients.
89353932|NCT04509232|Experimental|group B|"-38% Silver diamine fluoride will be applied by the same protocol as in group A~Then Glass Ionomer restoration is applied as follows~Self cure glass ionomer restoration is applied not light cured as light causes oxidation of silver and the filling appears darker.~Glass ionomer won't be applied immediately after SDF placement it will be applied at time ranging from 2 hours to two days.~Conditioning of the base of the cavity is done by 3M ESPE conditioner for 10 seconds then rinsing the cavity for 10 to 20 secs.~Applying High strength hand mix chemical self cure glass ionomer."
89353933|NCT02935452|Active Comparator|Genie|This group will have the Genie social tool delivered on a one to one basis at discharge points in the study.
89353934|NCT02935452|No Intervention|Normal Care|This group will have the same questionaires at discharge, but will be offered normal care
89353935|NCT03732235||TACE+ systemic Bevacizumab|"TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.~Bevacizumab (5 mg/kg) therapy was initiated 15 days after first round of TACE and was repeated every two weeks, for a total of 8 cycles."
89353936|NCT03732235||FOLFIRI+Bevacizumab|FOLFIRI consists of 5-FU administered as a 48-hour continuous infusion to a total dose of 3,200 mg/m2 without a bolus, leucovorin 200 mg/m2, irinotecan 165 mg/m2 Bevacizumab (5 mg/kg) therapy was repeated every two weeks, for a total of 8 cycles.
89353937|NCT03732235||TACE|TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
89353938|NCT01289951|Experimental|Patients with Child-Pugh C hepatic-cirrhosis.|VIH/VHC coinfected patients with advanced (Child-Pugh C) hepatic cirrhosis.
89353939|NCT01289951|Active Comparator|VIH/VHC coinfected patients without liver damage.|
89353940|NCT03178773|Active Comparator|TExT-MED only|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
89353941|NCT03178773|Experimental|TExT-MED+FANS|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
89353942|NCT04508920||Basal|"All adults (age >18 years), both gender, Heart failure patients (european society of cardiology ) criteria, sign consent.~A survey to access information about symptomatology, treatment, and medical care in period may 15 to june 15, 2019 ( without covid-19 )"
89353943|NCT04508920||Ourbreak|"All adults (age >18 years), both gender, Heart failure patients (european society of cardiology ) criteria, sign consent.~A survey to access information about symptomatology, treatment, and medical care in period may 15 to june 15, 2020 ( ongoing covid-19 )"
89353944|NCT01188473|Experimental|NPPV plus standard of care|NPPV initiated early and for a prolonged period of time in addition to standard of care in the management of children admitted to the hospital with status asthmaticus
89353945|NCT01188473|No Intervention|Control: standard of care alone|standard of care in the management of children admitted to the hospital with status asthmaticus
89353946|NCT03738787|Experimental|Pancreatic duct occlusion|Patients considered at high risk for pancreatic fistula or oncological relapse due to introperative evaluation submitted to pancreatic duct occlusion with Neoprene-based glue.
89353947|NCT03738787|Active Comparator|Pancreato-Jejunal anastomosi|Patients considered at low risk for pancreatic fistula submitted to pancreato-jejunal anastomosis.
89353948|NCT01186523|Experimental|400 kcal of exercise/session|400 kcal of exercise/session
89353949|NCT01186523|Experimental|600 Kcal of exercise/session|600 Kcal of exercise/session
89353950|NCT01186523|Experimental|Control, no exercise|No exercise control group
89353951|NCT04508608||Ischemic cardiomyopathy group - 1 (ICM-1)|"Inclusion criteria:~History of myocardial infarction (MI) or revascularization (CABG or PCI);~> 75% stenosis of left main or proximal left anterior descending artery (LAD) and/ or stenosis of > 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);~LV ejection fraction (EF) <40% and increase in LV volumes according to echocardiography (ECHO)~Exclusion criteria:~Presence of contraindications to the stress test with inotropic stimulation;~inflammatory myocardial diseases;~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
89353952|NCT04508608||Ischemic cardiomyopathy group - 2 (ICM-2)|"Inclusion criteria:~History of myocardial infarction (MI) or revascularization (CABG or PCI);~> 75% stenosis of left main or proximal LAD and/ or stenosis of > 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);~LV EF <40% and increase in LV volumes according to echocardiography (ECHO)~Exclusion criteria:~Presence of contraindications to the stress test with inotropic stimulation;~inflammatory myocardial diseases;~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
89353953|NCT04508608||Control group for GBPS.|"Inclusion criteria:~Absence of obstructive coronary artery lesion;~Absence of history of MI and revascularization.~Exclusion criteria:~Presence of contraindications to the stress test with inotropic stimulation;~inflammatory myocardial diseases;~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
89353954|NCT04508608||Control group for CFR.|"Presence of obstructive coronary artery lesion;~Indications for coronary artery bypass grafting~Exclusion criteria:~Presence of contraindications to the adenosine stress test;~inflammatory myocardial diseases;~the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;~life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury)."
89353955|NCT03732157||outpatient management of parathyroidectomy|
89353956|NCT03732157||conventional management of parathyroidectomy|
89353957|NCT01182077|Experimental|Group 1|ASP015K low dose and midazolam followed by ASP015K high dose and midazolam
89353958|NCT01182077|Experimental|Group 2|ASP015K high dose and midazolam followed by ASP015K low dose and midazolam
89353959|NCT03854513||-Group 1 (anuric)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output less than 100ml / day
89353960|NCT03854513||Group 2 (good UOP)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output 400ml / day or more
89353961|NCT03218397|Active Comparator|Standard blood culture and AST|Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.
89353962|NCT03218397|Active Comparator|Rapid organism identification and AST|Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.
89353963|NCT03618823|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary.
89353964|NCT03618823|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary.
89353965|NCT01188629|Placebo Comparator|Safety Training|
89353966|NCT01188629|Experimental|Personal Health Partner and Counseling (PHP+C)|
89353967|NCT04504786|Experimental|Vitality acupunch (VA)|The VA program took 40 minutes to complete and included three phases: 1) activating qi and blood (5 movements, 10 minutes): warm-up exercises that allowed the body to accumulate heat and promote flexibility of the joints to loosen up the body, 2) punching meridians (14 movements, 20 minutes): both hands were used to exert a vibrating effect according to the rhythms that stimulate the 14 meridians in the entire body to improve aerobic endurance, and 3) relaxing body and mind (5 movements, 10 minutes): muscle relaxing exercises to rest the body and cease the qi. Participants in the experimental group received the VA program led by the instructors, who were trained and certified by the PI, 3 times per week and 40 minutes per session for 6 months.
89353968|NCT04504786|Active Comparator|Control|Participants in the control group continued with their daily activities as usual.
89353969|NCT01188707|Experimental|Belinostat, Erlotinib, NSCLC|
89353970|NCT03356158|Experimental|CPGJ 602 low dose|Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
89353971|NCT03356158|Experimental|CPGJ 602 normal dose|Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
89353972|NCT03356158|Active Comparator|Cetuximab normal dose|Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.
89353973|NCT05048706|Experimental|Super Pulse Thulium fiber Laser|
89353974|NCT05048706|Active Comparator|Holmium: Yttrium-Aluminium-Garnet Laser|
89353975|NCT03738709|Experimental|Occupational therapy group sessions|In the collective experimental group, the care includes 6 group sessions of one hour each, programmed over 2 weeks and progressive courses.
89353976|NCT03738709|Active Comparator|Individual Occupational therapy sessions|In the individual control group, care consists of 6 individual sessions of 45 minutes each, not programmed over 2 weeks and progressive courses.
89353977|NCT03854591||Gunshot related injury|Patients admitted to orthopaedic trauma service with gunshot related injury
89353978|NCT05239689|Experimental|Treatment of CD38-positive Hematological Malignancies|Administration of CD38 CAR T-cells A dose levels of 2-8*10E6/kg are administrated for each subject.
89353979|NCT03356080|Experimental|DLAAG|"All patients receive 1-2 cycles of induction chemotherapy,that is DLAAG,which is expected to be 6 weeks/cycle,including decitabine,cytarabine, all-transretinoic acid,and Granulocyte Colony-Stimulating Factor(G-CSF).~patients with CR after the first course of induction therapy (DLAAG) will continue to receive 1 cycle of consolidation therapy, while those with therapy failure will continue the second course of induction therapy. If CR is not achieved, quit the study.~Patients who achieve CR after induction therapy will be in accordance with the guidelines, such as the proposed active treatment of allogeneic hematopoietic stem cell transplantation"
89353980|NCT03640507|Active Comparator|Chlorhexidine-alcohol|Subjects will receive vaginal preparation with chlorhexidine-alcohol.
89353981|NCT03640507|Active Comparator|Povidine-iodine|Subjects will receive vaginal preparation with povidine-iodine.
89353982|NCT03640507|Placebo Comparator|Saline|Subjects will receive vaginal preparation with sterile saline.
89353983|NCT02467413|Active Comparator|BAC treatment group|BAC, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
89353984|NCT02467413|Placebo Comparator|BAC Matched vehicle|BAC Matched vehicle, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
89353985|NCT02937636|Experimental|Test Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
89353986|NCT02937636|Active Comparator|Reference Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
89353987|NCT03356002|Active Comparator|High risk subjects|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following:~c. Surveillance - Significant findings in previous optical colonoscopy d. Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy e. Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy f. Diagnostic - Positive FIT test g. Diagnostic - one or more of the typical symptoms:"
89353988|NCT03356002|Experimental|Average risk|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~Average risk based on their age and demographics referred for screening for polyps."
89353989|NCT05212259|Experimental|Collagen type II (40 mg/day)|4 capsules per day for 180 days
89353990|NCT05212259|Experimental|Collagen type II (80 mg/day)|4 capsules per day for 180 days
89353991|NCT05212259|Experimental|Collagen type II (120 mg/day)|4 capsules per day for 180 days
89353992|NCT05212259|Active Comparator|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day for 180 days
89353993|NCT05212259|Placebo Comparator|Placebo|4 capsules per day for 180 days
89353994|NCT05239611|No Intervention|Usual care|Participants will receive usual standard of care
89353995|NCT05239611|Active Comparator|exercise coaching|Participants will receive weekly coaching intervention
89353996|NCT02518360|Experimental|OSTEOPATHIC PROTOCOL|"Physiotherapist applies an osteopathic treatment in non-specific low back pain patients.~The experimental group is treated with osteopathy, three sessions (20 minutes/session) and a frequency one session/week. Osteopathic treatment osteopathic is a body adjustment protocol. This protocol adjusts the musculoskeletal disorders since neck to lower limbs in the experimental group. Before treatment, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry."
89353997|NCT02518360|Active Comparator|Auto Stretching|The patients realizes stretching protocol: two stretching global postures once a week (10 minutes for each posture) for three weeks: the first is for the anterior muscular chain and the second posture to stretch the posterior muscle chain. Before three stretching, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry.
89353998|NCT03732079||Research group|Women with early postpartum hemorrhage.
89353999|NCT03732079||Control group|Postpartum women without abnormal bleeding.
89354000|NCT03354442|Experimental|Modified Fixed Mandibular Retractor|All patients in this group will be treated using Modified Fixed Mandibular Retractor Appliance. This appliance will be used full-time.
89354001|NCT03354442|No Intervention|Untreated control group|All patients in this group will be observed during the period of treating the patients in the other group to assess the growth changes.
89354002|NCT03638635|Active Comparator|Standard Bupivacaine|Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
89354003|NCT03638635|Experimental|Bupivacaine Liposome|Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
89354004|NCT03854279|Experimental|Bizact|Tonsillectomy will be done With the Bizact device
89354005|NCT03854279|Active Comparator|Electro-scissor|Tonsillectomy will be done With electro-scissors
89354006|NCT03204981|Experimental|Intramural Needle Ablation|
89354007|NCT03354364|Active Comparator|Group 1|Receives pea hull fiber snack for the first 4 weeks and then control snack for the last 4 weeks of the study with 4-week washout between them.
89354008|NCT03354364|Active Comparator|Group 2|Receives control snack for the first 4 weeks and then pea hull fiber snack for the last 4 weeks of the study with 4-week washout between them
89354009|NCT03857009||Symptomatic|No intervention.
89354010|NCT03857009||Asymptomatic|No intervention.
89354011|NCT03354286|Experimental|Developmental & Technological Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving. Identify and troubleshoot barriers to keeping young children in Auto Mode.
89354012|NCT03354286|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
89354013|NCT03354286|Experimental|Nutrition, Set Point, & C:I Ratio|Provide education on a variety of properties of food and how they affect blood glucose levels. Optimize the use of carbohydrate to Insulin ratios, insulin duration of action, and use of temporary target glucose set point in the 670G pump and the Quick bolus feature to gain better glycemic control.
89354014|NCT03354286|Experimental|Hypoglycemia management|Focus on hypoglycemia management to avoid hyperglycemia, review fear of hypoglycemia
89354015|NCT03354286|Placebo Comparator|Minimal Intervention|A short communication detailing the percentage of time spent in range and in Auto Mode and if the goals have been met.
89354016|NCT03205488|Active Comparator|Cohort 1|Moderate to Advanced PD Population Randomized 1:1:1
89354017|NCT03205488|Active Comparator|Cohort 2|Early/de novo Randomized 2:1
89354018|NCT01662609||Endoscopic Ultrasound (EUS) Participants|High-risk for Pancreatic Cancer: Patients with 2 or more relatives with pancreatic cancer and a first degree relationship with at least one of the relatives with pancreatic cancer.
89354019|NCT01587755|Other|Topical Treatment Optimizing Program|Optimized care
89354020|NCT01587755|Other|non-Topical Treatment Optimizing Program|Standard care
89354021|NCT02518516||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (rosuvastatin, high doses of atorvastatin, and high doses of simvastatin between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
89354022|NCT02518516||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
89354023|NCT04508686|Experimental|Experimental|Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w
89354024|NCT03852095||minor trauma|Child from 1 to 18 years old suffering an isolated minor trauma presenting at the hospital emergency services.
89354025|NCT03852173|Experimental|"Intervention group Wasserschulen"|Schools receive refillable drinking bottles for all school children and drying racks for each classroom. Schools receive special project educational material and informational material and one training session for teachers. The intervention will be implemented during one school year (2018/2019), but schools can use the material and bottles also after ending of the intervention period.
89354026|NCT03852173|No Intervention|Control group|No intervention (usual education). Schools do not receive any project material. Schools got the information that they are part of a study on drinking and eating habits of third grade elementary school children.
89354027|NCT02518438|Active Comparator|the tramadol group|A preprepared 20 ml solution (tramadol 2 mgkg-1 within a 0.9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
89354028|NCT02518438|Placebo Comparator|the placebo group|A preprepared 20 ml solution (0,9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
89354029|NCT04521556|Active Comparator|Epidural anesthesia and analgesia|"Epidural catheter insertion: Th 9 - Th 10 or Th 10 - Th 11 using the midline approach.~Safety of the epidural catheter was confirmed with lidocaine 60 mg. Epidural loading dose was given according to our classification (3,4,5 or 6 ml).~Postoperative period in urology high care unit. Epidural analgesia ropivacaine/morphine was administered by a urologist according to our classification (2x2 ml, 2x3 ml and 3x3 ml)."
89354030|NCT04521556|Active Comparator|Balanced general anesthesia and tramadol analgesia|Postoperative period in urology high care unit.
89354031|NCT03204279|Experimental|Netupitant 1.33 mg/kg plus Palonosetron|Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients < 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.
89354032|NCT03204279|Experimental|Netupitant 4 mg/kg plus Palonosetron|Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients < 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.
89354033|NCT02524301|Experimental|anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
89354034|NCT02524301|Experimental|Recovered anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
89354035|NCT02524301|Experimental|Healthy Volonteers|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
89354036|NCT03122782|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
89354037|NCT03122782|Placebo Comparator|Normal Saline (control group)|Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
89354038|NCT04938414||subarachnoid hemorrhage|Patients with subarachnoid hemorrhage
89354039|NCT04938414||Control|patients with non-neurological diseases
89354040|NCT01291433|Experimental|PENTOCLO|Association pentoxifylline, tocopherol and clodronate
89354041|NCT01291433|Placebo Comparator|Placebo|Triple placebo
89354042|NCT04517422|Experimental|Probiotics|Active test product contains four lactic acid bacteria strains with Qualified Presumption of Safety (QPS)status by European Food Safety Authority (EFSA): Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, with maltodextrin (E1400, qs) as excipient, formulated in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0. Active test product is a food supplement and not an investigational medicinal product
89354043|NCT04517422|Placebo Comparator|Placebo|The control study product is identical in packaging and formulation except that Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483 (probiotic bacteria) are not present. The Control product only contains maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0.
89354044|NCT01314144|Experimental|Bupivacaine|Patients will receive intraoperative wound soakage with 20ml of 0.5% bupivacaine with adrenaline by the surgeon before closure and receive a continuous infusion of 4ml/hr of 0.2% bupivacaine delivered by an elastomeric pump the catheter of which will be placed by the surgeon in the wound before closure. Postoperative anlagesia will be provided with oxycodone, paracetamol and diclofenac.
89354045|NCT01314144|No Intervention|Control|Patients will receive morphine up to 0.1mg/kg intraoperatively. Postoperative analgesia will be provided with oxycodone, paracetamol and diclofenac.
89354046|NCT04516798|Experimental|Experiment|Local and whole body vibration were applied
89354047|NCT01186601|Experimental|Arm 1|
88807319|NCT05196672|Experimental|Virtual reality|Participants will receive virtual reality for 30 minutes before bedtime and then will be placed on an eye mask for a whole night's sleep for consecutive two days or until discharge from ICU. A total treatment dosage of 60 minutes is required.
88807320|NCT05196672|Experimental|Eye masks|Participants will receive eye masks during their sleep for consecutive two days or until discharge from ICU.
88807321|NCT05196672|No Intervention|Control group|The control group only receive routine care.
89354048|NCT03354208||Group 1|patients with hypoxic-ischemic encephalopathy (HIE) receiving hypothermia therapy
89354049|NCT03354208||Group 2|patients with suspected HIE, non-confirmed
89354050|NCT03354208||Group 3|healthy, retrospectively classified as such
89354051|NCT03173547|Active Comparator|146-9251 cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
89354052|NCT03173547|Placebo Comparator|Vehicle cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
89354053|NCT01314378|Active Comparator|Cognitive-Behavioral Therapy|
89354054|NCT01314378|Experimental|Mindfulness Training|
89354055|NCT01182233|Experimental|Total Skeletal Irradiation|Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.
89354056|NCT03350308||Patients with chronic end-stage renal failure|
88807322|NCT05288400|Experimental|Group A|single-capsule of fixed dosed combination (FDC) of amlodipine 5 mg / bisoprolol fumarate 5 mg / perindopril arginine 5 mg
88807323|NCT05288400|Active Comparator|Group B|Free triple therapy of amlodipine 5 mg + bisoprolol fumarate 5 mg + perindopril arginine 5 mg, given concomitantly
88807324|NCT05193864||Ambulatory CHF patients|Patients visiting an outpatient CHF clinic
88807325|NCT05193630|Experimental|Treatment|The subjects in the treatment arm will be given Milnutri Sure TM product with dietary counselling
89354057|NCT01182311||Controls|Never received HBV vaccine and never had HBV
89354058|NCT01182311||HIV vaccinated >= 10 years|Well compensated HIV disease, vaccinated HBV >= 10 years ago
89354059|NCT01182311||Spontaneously recovered >= 10 years|Spintaneously recovered from acute HBV >= 10 years ago
89354060|NCT01182311||Vaccinated >= 20 years|Vaccinated against HBV >= 20 years ago
89354061|NCT01182311||Vaccinated 10 < 15 years|Vaccinated against HBV 10 < 15 years ago
89354062|NCT01182311||Vaccinated 15 < 20 years|Vaccinated against HBV 15 < 20 years ago
89354063|NCT02954653|Experimental|Dose Escalation|Single agent PF-06747143 dose escalation
89354064|NCT02954653|Active Comparator|Cohort 1|PF-06747143 with standard dose cytarabine and daunorubicin.
89354065|NCT02954653|Active Comparator|Cohort 2|PF-06747143 in combination with Azacitidine or Decitabine.
89354066|NCT02954653|Experimental|Cohort 3|PF-06747143 dose expansion as a single agent.
89354067|NCT04504084|Experimental|Decision aid group|Shared decision making using decision aid
89354068|NCT04504084|No Intervention|Controlled group|Standard oral explanation the details of treament options
89354069|NCT01186679|Experimental|Intralesional|"Surgical transplantation into the lesion site in chronic patients~Direct intrathecal implantation in acute and subacute patients"
89354070|NCT01186679|Experimental|intrathecal|direct into the CSF through lumbar puncture
89354071|NCT03173313|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
89354072|NCT03173313|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
89354073|NCT04508374|Experimental|1470 nm diode laser treatment of right HS-fistula|This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the right side, while the HS tunnel on the left side will be left as an untreated control.
89354074|NCT04508374|Experimental|1470 nm diode laser treatment of left HS-fistula|This is an intra-person study, comparing outcomes within participants. All participants will receive active 1470 nm intra-lesional diode laser treatment on one HS tunnel. Half of the enroled patients will receive active treatment of the left side, while the HS tunnel on the right side will be left as an untreated control.
89354075|NCT01182389|Active Comparator|robotic VT Ablation|Robotic VT ablation by substrate elimination
89354076|NCT01182389|Active Comparator|Conventional therapy|review of ICD programming to ensure that detection and therapy will occur appropriately.
89354077|NCT05218473|Experimental|Prolonged ECG monitoring group|Patients receive 14-day continuous electrocardiography patch monitoring
89354078|NCT05218473|Active Comparator|Conventional procedure group|Patients received serial 12-lead electrocardiograms once daily for five days or 24-hour Holter monitoring
89354079|NCT01182467||Crohn's disease|Patients will receieve Radiation: PET-CT scan
89354080|NCT04508452|Experimental|mXELOXIRI+Bev reintroduction|"Patients will receive mXELOXIRI+BEV as first-line therapy (to be repeated every 2 weeks for a maximum of 12 cycles), followed to initiate a MDT to determine whether to perform a surgery or receive maintenance therapy. Maintenance treatment: CAP+BEV. The following CAP+BEV therapy will be repeated in 2-week cycles.~At the time of disease progression, patients will be re-introduced XELOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 12 cycles. If no progression occurs during XELOXIRI plus bev, patients will receive maintenance CAP+BEV at the same dose used in the last cycle of the induction treatment."
89354081|NCT02524223|Other|Population of couples candidate for MAP program|MAP = medically assisted procreation
89354082|NCT03355846|Experimental|AAF treated with Centella® Complex|Centella® Complex 1 cps 60 mg per os
89354083|NCT03355846|Experimental|AAF treated with Proctocella® cream|Proctocella® Complex cream to be applied in anal area and anal canal
89354084|NCT03355846|Experimental|AAF treated with Flavonil® cps|Flavonil® 1 cps 300 mg per os
89354085|NCT03355846|Experimental|AAF treated with Flavonil® Cream|Flavonil® Cream Cream to be applied in anal region and anal canal
89354086|NCT03355846|Experimental|AAF treated with Rectalgan Mousse|Rectalgan Mousse cleansing cleanser for anal and perineal region
89354087|NCT03215667|Experimental|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
89354088|NCT03856853|Experimental|treatment group|pirfenidone group
89354089|NCT03856853|Placebo Comparator|placebo group|placebo group
89354090|NCT03732703|Experimental|Sub-Protocol A1|Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
89354091|NCT03732703|Experimental|Sub-Protocol B1|Patients with IDH2 activating mutation receive Enasidenib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
89354092|NCT03732703|Experimental|Sub-Protocol C1|Patients with the presence of RAF/RAS mutation receive Cobimetinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
89354093|NCT03732703|Experimental|Sub-Protocol D1|Patients with presence of FGFR3 activating mutations receive Erdafitinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
89354094|NCT03732703|Experimental|Sub-Protocol E1|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
89354095|NCT03732703|Experimental|Sub-Protocol Y1|Patients with Non-Actionable Genetic Abnormality receive Daratumumab in combination with ixazomib, pomalidomide and dexamethasone (IPd)
89354096|NCT03732703|Experimental|Sub-Protocol Y2|Patients with Non-Actionable Genetic Abnormality receive Belantamab mafodotin in combination with ixazomib, pomalidomide and dexamethasone (IPd)
89354097|NCT03732703|Experimental|Sub-Protocol Y3|Patients with Non-Actionable Genetic Abnormality receive Selinexor in combination with ixazomib, pomalidomide and dexamethasone (IPd)
89354098|NCT03350152||LAM group|Have a diagnosis of AML according to World Health Organization (WHO) classification Are at least 70 years of age
88818897|NCT03478007|No Intervention|Usual Treatment|Usual standard of care (exercises)
89354099|NCT03636555|Active Comparator|Oxytocin|Syntocinon Spray (intranasal oxytocin spray). Each dose is 10 intranasal insufflations totaling 1.0 mL of Syntocinon Spray containing 40 IU of oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
89354100|NCT03636555|Placebo Comparator|Placebo|Each dose is 10 intranasal insufflations totaling 1.0 mL of a solution containing all ingredients in Syntocinon Spray except oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
89354101|NCT03636984||rheumatoid arthritis patients|subjects with rheumatoid arthritis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
89354102|NCT03636984||ankylosing spondylitis patients|subjects with ankylosing spondylitis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
89354103|NCT01186757|Active Comparator|PF-03715455 1.6mg BID|
89354104|NCT01186757|Active Comparator|PF-03715455 4 mg BID|
89354105|NCT01186757|Active Comparator|PF-03715455 10 mg BID|
89354106|NCT01186757|Placebo Comparator|Placebo|
89354107|NCT03123016|Experimental|Vitiligo with Apremilast and NB-UVB phototherapy|Each participant will be compared with one side of the body to the other side
89354108|NCT01182545|Placebo Comparator|The normoventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a tidal volume (TV) of about 8 mL.kg-1 and respiratory rate (R.R) owas adjusted to maintain an end-tidal CO2 (ETCO2) of 4.6-6 kPa throughout the procedure.
89354109|NCT01182545|Active Comparator|The hyperventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a TV of 8 mL.kg-1 with the adjustment of the R.R to maintain an ETCO2 of 4-4.6 kPa, until the end of anaesthesia.
89354110|NCT03636477|Experimental|Ad-RTS-hIL-12 + veledimex in combination with nivolumab|Intratumoral Ad-RTS-hIL-12 and varying doses of oral veledimex (activator ligand) given in combination with nivolumab via infusion.
89354111|NCT03732001|Experimental|Anlotinib combined Docetaxel|patients treated with Anlotinib and Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
89354112|NCT03732001|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
89354113|NCT01186835|Experimental|Combination Botulinum Toxin A and Hyaluronic Acid|One side of face treated with the combination of Botulinum Toxin A and Hyaluronic Acid injections.
89354114|NCT01186835|Active Comparator|Botulinum Toxin A alone|Other side of face treated with =Botulinum Toxin A injection alone.
89354115|NCT03649464|Experimental|OKN-007|Oral OKN-007
89354116|NCT04812951|No Intervention|young control|25 patients < 65 years old without any prophylactic anti-inflammatory preoperative treatment
89354117|NCT04812951|No Intervention|control|25 patients > 75 years old without any prophylactic anti-inflammatory preoperative treatment
89354118|NCT04812951|Experimental|Study group|25 patients > 75 years old with prophylactic anti-inflammatory preoperative treatment
89354119|NCT04812951|Active Comparator|Vehicle group|25 patients > 75 years old with vehicle preoperative treatment
89354120|NCT01290185|Experimental|Coiled Catheter|Placement of the coiled catheter for continuous infusion of local anesthetics close to the femoral nerve: To place coiled catheters ab 18-gauge Tuohy needle (Sonoline Curl Catheter Set, Pajunk® Medizintechnologie GmbH, Geisingen, Germany) of 8 cm length is placed adjacent to the nerve by ultrasound guidance and nerve stimulator control. At this position and after injection of 5 ml dextrose 5% in water to dilate the space the coiled catheter is blindly advanced 2 cm through the needle and the final position verified with ultrasound.
89354121|NCT01290185|Active Comparator|Conventional stimulating Catheter|For the control group a conventional stimulating catheter is placed adjacent to the femoral nerve as follows: To place the simulating catheter an 18-gauge Tuhoy needle s placed adjacenit to the nerve by ultrasound guidance. At this position a stimulation catheter is introduced through the needle and stimulated with a decreasing current from 1 mA to 0.4 mA, with a pulse width 0.1ms to verify the appropriate motor response of the quadriceps muscle. The catheter is slowly advanced 3 cm beyond the needle tip under continuous electric stimulation using a current that is subsequently adapted according to the motor response achieved. If muscles twitches disappear during catheter placement at a current above 1 mA, either the catheter or the needle are manipulated until muscle twitches reappear.
89354122|NCT05666089|Experimental|N-acetylcysteine|intracanal medication of NAC paste
89354123|NCT05666089|Active Comparator|Calcium hydroxide|intracanal medication of Ca(OH)2 paste
89354124|NCT04508218|Experimental|Protein+ Exercise group|Received oral protein supplementation, exercise program and traditional burn care
89354125|NCT04508218|Experimental|Protein group|Received oral protein supplementation and traditional burn care
89354126|NCT04508218|Experimental|Exercise group|Received exercise program and traditional burn care
89354127|NCT04508218|Other|Control group|Received traditional burn care
89354128|NCT01188785|Experimental|1 arm|SOC + siG12D LODER
89354129|NCT03732625|Experimental|Raltegravir|Raltegravir (RAL) x 2 600mg QD (Total 1200mg QD)
89354130|NCT03555006|Other|Local vs remote group|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation
89354131|NCT03555006|Other|Local vs local group|The examination will be interpreted by two department's radiologists
89354132|NCT03123172|Other|co2 gap|arterial and central venous blood gases to measure Co2 gap
89354133|NCT04694157||Treatment group|The treatment group will receive cardiac shock wave therapy. The CSWT entire treatment will period last 3 months with 9 sessions. CSWT will administered in the first week, followed by a 3-week non-treatment interval.
89354134|NCT01186913||Stratum A: Typical SCID +HCT|"Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.~Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
89354135|NCT01186913||Stratum B: Atypical SCID +HCT|"Stratum B: Atypical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.~Participants with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
89354136|NCT01186913||Stratum C:SCID +Non-HCT|"Stratum C: Severe Combined Immunodeficiency (SCID) who receive alternative therapy per standard of care, non-standard care and/or investigational. This stratum includes:~Adenosine Deaminase-Deficient SCID (ADA Deficient SCID) with intention to treat with Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT)~ADA Deficient SCID with intention to treat with gene therapy~X-linked SCID (XSCID) with intention to treat with gene therapy~Any individual with SCID previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)"
89354137|NCT03738319||HGSOC group|This group includes patients of high grade serous ovarian cancer (HGSOC).
89354138|NCT03738319||Control group|This group includes patients of benign gynecologic diseases as control.
89354139|NCT04503928|Experimental|Experimental: Kansui 1g per day x 7 days|Study participants will be given 1 g of Euphorbia kansui Pill for a total of 7 consecutive daily doses.
88807326|NCT05193630|Active Comparator|Control|The subjects in the control arm, no Milnutri Sure TM product will be given, nevertheless, dietary counselling will be provided by the investigator.
88818898|NCT03478007|Experimental|Intervention Technology Only|Exercises with technology alone
89354140|NCT04684875||Long-Term Study Subjects|All subjects who were treated with the Aerin Medical InSeca/RhinAer Stylus in the 50-subject TP668 interventional study, who consent to continue to provide quality of life data.
89354141|NCT04597476|Experimental|Fucoidan Group|Fucoidan powder at 4.4 g per sachet (dose) for oral administration. Fucoidan 4.4 g, PO, bid for 24 weeks
89354142|NCT04597476|Placebo Comparator|Potato starch|Potato starch at 4.4 g per sachet (dose) for oral administration. Potato starch 4.4 g, PO, bid for 24 weeks
89354143|NCT01188863|Experimental|Solid Oral Dose - 150 mg tablets|
89354144|NCT01188863|Experimental|Solid Oral Dose - 50 mg tablets|
89354145|NCT01188863|Experimental|Liquid Oral Dose|
89354146|NCT03634579|Experimental|MRI-guided focal laser ablation|Subjects will undergo MRI Guided Focal Laser Interstitial Thermal Ablation of localized low and intermediate risk prostate cancer.
89354147|NCT01188941|No Intervention|Standard of Care|
89354148|NCT01188941|Experimental|Assigned a Health System Navigator|
89354149|NCT02730208|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 72 weeks.
89354150|NCT02730208|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed dose combination tablet orally once daily in the morning and placebo matched to IVA tablet orally once daily in the evening for 72 weeks.
89354151|NCT01291511|Experimental|Iloperidone|After meeting all entry criteria, completing a 1-week open-label iloperidone titation period (up to 12 mg/day), followed by a 14-24 week open-label iloperidone flexible dose-stabilization period (up to 24 mg/day), approximately 260 patients will be randomized to one of two arms in a 1:1 ratio of iloperidone (flexible dosing 8-24 mg/day) to placebo. Post-randomization double-blind study medication will be administered orally twice daily for up to 26 weeks to evaluate relapse prevention. Subsequently, during the extension period, after a 1-week mock double-blind titration, open-label iloperidone (8-24 mg/day) is administered for up to 51 weeks to evaluate long-term safety.
89354152|NCT01291511|Placebo Comparator|Placebo|Post-randomization matching placebo is administered orally bid during the double-blind period.
89354153|NCT03354130|Active Comparator|Tofu control|Volunteers will consume a vegetarian diet containing tofu during 3 days for 5 meals in total
89354154|NCT03354130|Experimental|Non-processed pork diet|Volunteers will consume a diet containing non-processed pork during 3 days for 5 meals in total
89354155|NCT03354130|Experimental|Bacon diet|Volunteers will consume a diet containing bacon during 3 days for 5 meals in total
89354156|NCT03354130|Experimental|Sausage diet|Volunteers will consume a diet containing sausage during 3 days for 5 meals in total
89354157|NCT03354130|Experimental|Dry-cured sausage diet|Volunteers will consume a diet containing dry-cured sausage during 3 days for 5 meals in total
89354158|NCT01292213||Cases|Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.
89354159|NCT01292213||Controls|Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.
89354160|NCT03349918|Experimental|Mobile Health Monitoring|Participants will monitor their blood pressure using a wireless-enabled blood pressure cuff or mood using a mobile health application once per week at baseline. The investigators will monitor their medical records to determine if a medication change has occurred. After this, the investigators will increase the frequency of notifications to monitor the participant's specific health condition to once daily for 1 month. This monitoring will continue for a study duration of 6 months.
89354161|NCT04507984||Children with hypercholesterolemia (Slovenia)|Children (aged 5 years) with total cholesterol measurement at primary care pediatricians at the programed visit prior to school entry.
89354162|NCT04507984||Children with hypercholesterolemia (Lower Saxony, Germany)|Children (aged 2-6 years) with LDL-cholesterol measurement during the compulsory routine check-ups and at any voluntary visits to the primary care pediatricians.
89354163|NCT04507984||Children referred for FH genetic analysis (Slovenia and LS)|Children referred for familial hypercholesterolemia genetic analysis to the tertiary center, according to the screening algorithm.
89354164|NCT04507984||Parents and siblings of children with confirmed FH (Slovenia)|Parents or siblings of index cases with completed familial hypercholesterolemia genetic analysis, according to the screening algorithm.
89354165|NCT03201900|Experimental|E2007|The Treatment Phase consists of the 4 milligrams (mg) Treatment Phase (the Titration Period [6 weeks] and the Maintenance Period [26 weeks]) and the 8 mg Treatment Phase (the Titration Period [4 weeks] and the Maintenance Period [26 weeks]) if participants require a higher dose. In the 4 mg Titration Period (6 weeks), participants will initiate 2 mg perampanel once daily (QD) for 2 weeks and then will be up-titrated to 4 mg QD and will continue this dose for 4 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 4 mg Maintenance Period for 26 weeks. Participants will only need the higher dose if they are having seizures. In the 8 mg Titration Period (4 weeks), participants will be administered 6 mg perampanel QD for 2 weeks and then will be up-titrated to 8 mg QD and will continue this dose for 2 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 8 mg Maintenance Period for 26 weeks.
89354166|NCT01314729|Active Comparator|Fiber-reinforced-composite retainer|
89354167|NCT01314729|Active Comparator|composite-wire retainer|
89354168|NCT03122938|Experimental|Lactoferrin Group|lactoferrin-supplemented formula
89354169|NCT03122938|Placebo Comparator|Control Group|formula without lactoferrin supplementation
89354170|NCT01587833||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
89354171|NCT01587833||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
89354172|NCT05208723|Experimental|Stress and emotion management|A locally adapted self-help guidebook originally developed by the World Health Organization (WHO), 'Doing what matters in times of stress' for managing disruptive emotions and psychological distress, will be delivered to female entrepreneurs at their residence, followed by 5-6 phone calls from a trained mental health helper to reinforce the materials over a 6-week period. The intervention is intended to help people manage their psychological distress associated with a range of adversities but is not intended for participants with severe mental health problems such as psychosis or imminent risk of suicide.
89354173|NCT05208723|No Intervention|Control group|No intervention. May receive intervention post study if findings are indicative of any benefit.
89354174|NCT01587911|Active Comparator|Whey protein|Complete whey protein.
89354175|NCT01587911|Active Comparator|Whey-CMP|Complete whey protein missing the CMP (aka GMP) portion of the peptide.
89354176|NCT01587911|Placebo Comparator|Control|Placebo preload control, matched for energy.
89354177|NCT01587911|Active Comparator|CMP (casinomacropeptide)|Small peptide cleaved from complete whey protein.
89354178|NCT01587911|Active Comparator|MPI|Complete milk protein.
89354179|NCT01587911|Active Comparator|CPI (casein)|Preload containing casein.
89354180|NCT03800862||CTP and CT-FFR|"This will be a prospective, observational study designed to include a convenience sample of all qualifying patients undergoing myocardial CTP and CT-FFR.~The study will enroll patients who have chest discomfort and will require further evaluation for the presence of coronary artery disease. Patients in the study will include those who have had a clinically indicated CCTA for suspicion of coronary artery disease and are determined to have a coronary stenosis ≥50% and ≤99%. However, patients with Left main disease greater than 50% and occluded vessels Coronary Artery Disease Reporting and Data System (CAD RADS 5) will be excluded from the study. CCTA is a clinically indicated and standard of care procedure at Lancaster General Hospital.~."
89354181|NCT01572207|Experimental|Immediate Exercise|Subjects assigned to the immediate group will be prescribed a home exercise program during the first meeting. During the 12 week training period, the subject will read pamphlets (sent by mail) once to twice a month about developing skills to manage MS symptoms and motivational pamphlets about physical activity. In addition, the subject will have a phone conversation every two to three weeks with research staff to discuss the progress of the exercise program and to complete a short survey about his/her physical activity level.
89354182|NCT01572207|Experimental|Delayed exercise|Subjects assigned to the delayed group will be asked to begin the same home exercise program 12 weeks following the first meeting. During the 12 week training period, the subject will receive pamphlets, have phone conversations with research staff, and complete physical activity surveys as described above.
89354183|NCT04444258|Experimental|Experimental I Group|After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
89354184|NCT04444258|No Intervention|Control Group|FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
89354185|NCT04971005|Experimental|Intervention (aHSCT)|Autologous Hematopoietic Stem Cell Transplantation. Mobilisation will be performed with 2 g/m2 cyclophosphamide and 10 μg/kg G-CSF from day 5 until apheresis is completed. Conditioning will be 200 mg/kg cyclo-phosphamide and Anti-T-lymphocyteglobuline (Grafalon®, Neovii) with cu-mulative doses of 20 mg/kg given on day +1 (10 mg/kg) and day +2 (10 mg/kg).
89354186|NCT04971005|Active Comparator|Control|In the control arm patient and physician will decide which treatment to choose. Patients will be either treated with ocrelizumab according to the SmPC (600 mg every 6 months continuously) or with alemtuzumab according to the SmPC (12 mg/day for 5 consecutive days and again after 365 days for 3 days).
89354187|NCT03782532|Experimental|Dupilumab|For patients without oral corticosteroids (OCS) maintenance therapy, dose 1 of dupilumab administered once in 2 weeks (q2w) with loading dose of dupilumab, two times dose 1; for patients on OCS maintenance therapy, the dose will be dupilumab dose 2 q2w with loading dose 2 times dose 2
89354188|NCT03782532|Placebo Comparator|Placebo for dupilumab|For patients without OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 1 q2w with loading dose; for patients on OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 2 q2w with loading dose
89354189|NCT01187069|Experimental|Training course for practice nurses in autonomy support|
89354190|NCT01187069|No Intervention|Control|Control practices were randomly drawn from among intervention practice applicants and were informed by mail about their status as control practice.
89354191|NCT03854201|Experimental|Personalized Exercise Counseling (PEC)|The Personalized Exercise Counselling intervention includes 3 face-face counseling sessions and 4-6 phone calls during six months. In addition, the participants are provided with the ExSed® interactive accelerometer to record their physical activity 24/7 from which they will receive personal daily feedback on their smart phone, which is provided to each person not having a suitable one of their own to be used during the 6-month intervention period.
89354192|NCT03854201|No Intervention|Control-arm|The participants only take part in the study measurements at baseline and the three follow-up time points. They will be provided personal written information by the UKK Institute on their blood sugar and lipid profiles, objectively measured physical activity (light, moderate, vigorous), standing, sedentary behaviour and sleep, and the three fitness tests measuring flexibility, muscular strength and cardiorespiratory fitness.
89354193|NCT03355768|Experimental|Romidepsin Arm|Control Arm: Subjects will receive Romidepsin 14 mg/m2 on Days 1, 8, 15.
89354194|NCT03355768|Experimental|Romidepsin + Pralatrexate Combination Arm|Combination Arm: Subjects will receive Romidepsin 12 mg/m2 and Pralatrexate 25 mg/m2.
89354195|NCT04804800|No Intervention|Control group|The patients benefit from the care recommended by the HAS. They benefit from psychological interviews, psychiatric follow-up, dietetic follow-up, family interviews and therapy. Body therapies (physiotherapy, massage, fascia therapy, psychomotor skills, dance therapy, etc.) may also take place. Patients will also benefit from relaxation and body scan.
89354196|NCT04804800|Experimental|Experimental group 1 : Virtual Reality|The patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan (1 hour).
89354197|NCT04804800|Experimental|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|The patients benefit from the care recommended by the HAS, the virtual reality and the multisensory remediation programs, and also the body scan.
89354198|NCT01182701|Active Comparator|Behavioral intervention|
89354199|NCT01182701|No Intervention|Education support|
89354200|NCT03349840|Active Comparator|Insulin glargine U100|Intervention: half of the subjects will be randomised to insulin glargine U100 basal insulin treatment (or continued on glargine if already treated) that will be administered daily in the evening
89354201|NCT03349840|Active Comparator|insulin degludec U100|Intervention: half of the subjects will be randomised to insulin degludec U100 basal insulin treatment that will be administered daily in the evening
89354202|NCT01187147|Experimental|Green Tea|Recruited subjects will be asked to take green tea capsules for 3 months and then stopped for another 3 months.
89354203|NCT01182779|Experimental|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
89354204|NCT01182779|Active Comparator|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
89354205|NCT03353896|Experimental|Treatment (medical device)|Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over 18 hours QD. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity.
89354206|NCT01292369||Breast cancer|Women diagnosed with breast cancer by a positive biopsy test after mammography.
89354207|NCT01292369||Breast control|Women with negative biopsy result done due to a suspicious mammography exam.
89354208|NCT01292369||Colon cancer|Men and women diagnosed with colon cancer by a positive colonoscopy and biopsy.
89354209|NCT01292369||Colon control|Men and women with negative colonoscopy and biopsy tested due to complaints indicating the possibility of colon cancer.
89354210|NCT03170271|Experimental|Benralizumab (Medi-563)|Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
89354211|NCT03170271|Placebo Comparator|Placebo|Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
89354212|NCT03613129|Active Comparator|D0.20|Subcutaneous infusion of CT38 at 0.20 μg/kg/hour, for 3 hours on each of 2 days
89354213|NCT03613129|Active Comparator|D0.03|Subcutaneous infusion of CT38 at 0.03 μg/kg/hour, for 3.5 hours on each of 3 days
89354214|NCT03613129|Active Comparator|D0.06|Subcutaneous infusion of CT38 at 0.06 μg/kg/hour, for 3.5 hours on each of 3 days
89354215|NCT03613129|Active Comparator|D0.01|Subcutaneous infusion of CT38 at 0.01 μg/kg/hour, for 3.5 hours on each of 3 days
89354216|NCT04504006||Cohort A|PMMR + TCL, followed by systematic lymphadenectomy in node positive patients.
89354217|NCT04504006||Cohort B|Therapy according to actual guidelines
89354218|NCT01187225|Active Comparator|Fibrinogen concentrate|
89354219|NCT01187225|Active Comparator|Cryoprecipitate|
89354220|NCT03353818|Active Comparator|Golf|In three different golf clubs patients will be introduced how to play golf. They will be taught techniques and recieve basic golf equipment. A total of 1 year membership free membership in the golf clubs will be given.
89354221|NCT03353818|Placebo Comparator|Placebo|No intervention given. No restrictions on physical activity.
89354222|NCT03851939|Experimental|treatment group|Transarterial Chemoinfusion (TAI) Combine Toripalimab
89354223|NCT03355612|Experimental|experimental group|Drug:Apatinib with XELOX(Capecitabine and Oxaliplatin)
89354224|NCT03355612|Active Comparator|active comparator|Drug:XELOX(Capecitabine and Oxaliplatin)
89354225|NCT03235284|Active Comparator|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
89354226|NCT03235284|Active Comparator|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
89354227|NCT03235284|Experimental|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
89354228|NCT03732547|Experimental|'PolyIC plus PD-1 mAb' and 'PD-1 mAb'|"'PolyIC plus PD-1 mAb' group: PolyIC, 2mg, i.m., every other day, for three weeks. PD-1 mAb, 200mg, i.v., every three weeks.~'PD-1 mAb' group: PD-1 mAb, 200mg, i.v., every three weeks."
89354229|NCT04503850||Group A Mirabegron|50 patients receiving Mirabegron 50 mg once daily & alpha blocker
89354230|NCT04503850||Group B alpha blocker only|50 patients receiving alpha blocker only
89354231|NCT03349684|Experimental|Acarbose plus metformin arm|Participants received loose combination of acarbose and metformin 3 times daily.
88807327|NCT01796600|Experimental|Conventional and a cone-beam scanner 5G|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner
89354232|NCT03349684|Active Comparator|Metformin plus placebo arm|Participants received loose combination of placebo and metformin 3 times daily.
89354233|NCT03856385|Experimental|Mindful Walking|Four weekly 60 minute sessions of mindful walking.
89354234|NCT03856385|No Intervention|Control|Weekly email messages encouraging physical activity.
89354235|NCT03856697|Experimental|Abivertinib Maleate Capsules+ Placebo Gefitinib Tablets|Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Placebo Gefitinib Tablets (250 mg orally, once daily), in accordance with the randomization schedule.
89354236|NCT03856697|Active Comparator|Gefitinib Tablets+ Placebo Abivertinib Maleate Capsules|Placebo Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Gefitinib Tablets(250 mg orally, once daily), in accordance with the randomization schedule.
89354237|NCT03355378|Experimental|study group|gum chewing during spinal anesthesia and early ambulation
89354238|NCT03355378|No Intervention|Control group|no gum chewing
89354239|NCT03856541|Experimental|SHR-A1403 Dose Escalation|SHR-A1403 given intravenously (IV).
89354240|NCT03353662||Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years
89354241|NCT03353662||Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6 - 59 months
89354242|NCT03353662||Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years
89354243|NCT03353662||Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between 6 - 59 months
89354244|NCT03353662||Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years
89354245|NCT03353662||Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6 - 59 months
89354246|NCT05195229|Experimental|Arm 1|Aim: To estimate the viral load in aerosols generated from children with COVID-19 infection, and to compare the viral load contained in aerosols from children with aerosols from adults
89354247|NCT03349606|Experimental|Cocaine dependence|[C-11]FLB 457 PET at baseline and post d-amphetamine
89354248|NCT03349606|Experimental|Controls|[C-11]FLB 457 PET at baseline and post d-amphetamine
89354249|NCT02843451|Experimental|Silymarin (Milk Thistle)|Each subject will have a 4 week treatment phase with milk thistle.
89354250|NCT02843451|Placebo Comparator|Placebo|4 week placebo phase before or after milk thistle phase depending on randomization.
89354251|NCT01182935||participants in the 4th Tromsø study|
89354252|NCT03353506|Active Comparator|LFMT|Lyophilized fecal microbiota transplant capsules
89354253|NCT03353506|Experimental|LSFF|Lyophilized sterile fecal filtrate capsules
89354254|NCT03854045|Experimental|Home-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the home with 2 clinicians present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR but are not eligible for Medicaid reimbursement.
89354255|NCT03854045|Active Comparator|Clinic-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the clinic with 1 clinican present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR and eligible for Medicaid reimbursement.
89354256|NCT01183091||First AF ablation|Description of the patients experiencing an AF ablation
89354257|NCT01292525|Active Comparator|Tacrolimus|
89354258|NCT01292525|Experimental|Withdrawal of Tacrolimus|
89354259|NCT03355222|No Intervention|No Intervention|No intervention: The community receives no chickens and no special education is provided.
89354260|NCT03355222|Experimental|Experimental: providing chickens and egg shell|"Experimental: Two chickens are given to each family so that eggs are available for children and of eggshell powder for mothers.~The community receives these chickens so each designated family has an egg to give to young child. In a subgroup the mother will receive ESP (1000 mg calcium). The community receives information on using egg and has help on caring for chickens."
89354261|NCT03851861|Experimental|Mediterranean Diet|Participants will be given individualized diet education on the Mediterranean diet and instructed to follow the diet for the 5-week intervention period. Individualized diet education will be administered by a licensed, registered dietitian nutritionist (RDN) followed by weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
89354262|NCT01189019|Experimental|Group 1 - 2mg ranibizumab monthly|2mg ranibizumab monthly
89354263|NCT01189019|Active Comparator|Group 2 - 2mg x 3 then PRN|
89354264|NCT04515862|Experimental|intervention|Intervention group: Mothers in the intervention group were included in the breastfeeding training program with the group training method. The training program was developed by the researchers, and the content of the program was evaluated with the expert opinion of academicians, obstetricians, nurses and breastfeeding counselor midwives working on breastfeeding.
89354265|NCT04515862|No Intervention|control|Control Group:Routine obstetric care and treatment procedures were applied to the mothers in the control group. In the hospital where the study was conducted, all mothers are routinely evaluated for breastfeeding by an infant nurse.
89354266|NCT01183247|Active Comparator|Rapamycin|Rapamycin-MMF-tacrolimus
89354267|NCT01183247|Active Comparator|Everolimus|Everolimus - tacrolimus - MMF
89354268|NCT01183247|Active Comparator|Prednisone|tacrolimus - MMF -prednisone
89354269|NCT03853967|Experimental|screening|participants performed lung cancer screening by Low Dose CT scan
89354270|NCT04514146||Water-only Fasting Group|Overweight and obese, non-diabetic participants undergoing elective water-only fasting treatment
89354271|NCT03853889|Active Comparator|preepidural ONSD|The diameter of the optic nerve sheath to be measured(ONSD) with the help of ultrasonography before epidural anesthesia(pre epidural ONSD). The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
89531976|NCT04391023|Sham Comparator|Sham tDCS|The tDCS device will perform a 30 second ramp up to 2 mA and then an immediate 30 second ramp down to 0 mA. Until the 19:30 minute time point, the tDCS will remain at 0 mA. At this time point, the tDCS will ramp up to 2 mA and then will immediately ramp back down to 0 mA.
89354272|NCT03853889|Experimental|post epidural ONSD|The diameter of the optic nerve sheath to be measured with the help of ultrasonography Immediately after epidural anesthesia(post epidural ONSD) (T1), 15 minutes (T2), 30 min (T3), 60. min (T4) epidural anesthesia. The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
89354273|NCT03353428|Experimental|LC-CTLs|Autologous lung cancer specific cytotoxic lymphocytes
89354274|NCT01183325|Experimental|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
89354275|NCT03170193|Experimental|AMG 529|Participants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection.
89354276|NCT03170193|Placebo Comparator|Placebo|Participants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection.
89354277|NCT03349216|Experimental|Intravenous regional Analgesia|in this arm patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes will be deflated (hence named Rapid MiniBier's block).
89354278|NCT03349216|Experimental|Systemic Analgesia|In this arm patients will receive ketamine 1-2 mg/kg IV slow as a systemic analgesia. ketamine as a PCP derivative has both hypnotic and analgesic effects.
89354279|NCT04507750|Experimental|camrelizumab+apatinib mesylate|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
88807328|NCT05474040|Active Comparator|opioid|2.5mg/iv morphine every 6hr postoperative
89354280|NCT03355144|Experimental|Internal Medicine residents at NYU|effect of supplying Internal Medicine residents at NYU with free coffee on self reported features of psychological health, energy and burnout
89354281|NCT05173077||Colorectal cancer patients|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
89354282|NCT05173077||Control group patients without colorectal cancer|Patients without colorectal malignant disease according to data obtained in colonoscopy
89354283|NCT05173077||Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer
89354284|NCT05173077||Colorectal cancer patients undergoing surgery|Patients with histologically confirmed colorectal cancer (adenocarcinoma) planned for surgical management
89354285|NCT05173077||Patients with polyps undergoing polypectomy|Patients with colon polyps that will perform polypectomy
89354286|NCT03633331|Experimental|Treatment (palbociclib, letrozole or fulvestrant)|Patients receive palbociclib PO QD on days 1-21. Patients also receive letrozole PO QD on days 1-28 or fulvestrant IM on days 1 and 15 of course 1 and on day 1 of subsequent courses per MD discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89354287|NCT01292681|Other|Multi-modality imaging|
89354288|NCT01189097|Experimental|dextromethorphan|
89354289|NCT02524457||Premenopausal|Premenopausal women going through gynecological surgery
89354290|NCT02524457||Postmenopausal|Postemnopausal women going through gynecological surgery
89354291|NCT02524457||Postmenopausal + HT|Postmenopausal women going through gynecological surgery who has been taking hormone treatment through the past year (as a minimum)
89354292|NCT02518204|Experimental|BPT, NP|Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments
89354293|NCT02518204|Experimental|NP, BPT|Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery
89354294|NCT03856151|Active Comparator|Group 1|"For Group 1, each subject will receive Treatment 1# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 2#.~Treatment 1# will be regular dialysis 3 times per week for 4 weeks. Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks."
89354295|NCT03856151|Active Comparator|Group 2|"For Group 2, each subject will receive Treatment 2# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 1#.~Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks.~Treatment 1# will be regular dialysis 3 times per week for 4 weeks."
89354296|NCT01187459|Experimental|10 ug/day|
89354297|NCT01187459|Experimental|50 ug/day|
89354298|NCT03354988|Active Comparator|physical exercise group|For the exercise group, Intervention by doing physical exercise. systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital.
89354299|NCT03354988|Other|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
89354300|NCT01189175|Experimental|BI 113823|single oral dose per subject
89354301|NCT01189175|Experimental|BI 113823 + Ketokonazole|after wash-out 5 days ketokonazole with BI 113823 on day 3
89354302|NCT03201003|Active Comparator|AR101|AR101 powder provided in capsules & sachets
89354303|NCT03201003|Placebo Comparator|Placebo|Placebo powder provided in capsules & sachets
89354304|NCT04503538|Other|CAR-T cell therapy and Telemedicine|All outpatient CAR-T patients will require assessments for cytokine release syndrome and neurotoxicity three times daily (every 8 hours)
89354305|NCT01187537|Experimental|Continuous Femoral Nerve Block|
89354306|NCT01187537|Active Comparator|Single-Inj Nerve Block with IV PCA|
89354307|NCT01187537|Active Comparator|IV PCA|
89354308|NCT03349138|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different standard motor training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
89354309|NCT03349138|Experimental|Robotic Glove|Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
89354310|NCT03349138|Experimental|Electrical Stimulation|Electrical Stimulation & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
89354311|NCT03349138|Experimental|Electrical Stimulation and Robotic Glove|Electrical Stimulation & Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy or 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. Half of the sessions are allocated to the electrical stimulation system, and half are allocated to the robotic glove system. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
89354312|NCT03851315||LBBAP group|patients received left bundle branch area pacing
89354313|NCT03851315||traditional RVP group|Age and sex-matched patients received traditional right ventricular pacing
89354314|NCT03348982|Experimental|Intervention group|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session) in a hall/gymnasium of each participating school.Each intervention session will be conducted in the morning by a trained research assistant assisted by student helpers. Each intervention session will be conducted in an identical format, comprising three activities: warm-up (5 min), jogging (20 min), and cool-down (5 min). In the jogging activity, participants will be asked to jog side-by-side with the research staff around an activity circuit (57m x 50m) marked with 4 red cones.
89354315|NCT03348982|No Intervention|Control group|Participants in the control group will receive no physical intervention and will be required to follow their daily routine without participating in any additional physical activity/exercise program throughout the whole study period (T1-T3).
89354316|NCT03856073|Experimental|Novice|Anesthesiologists without experiment of manufacturing bronchoscopy.
89354317|NCT03354832||Foetal death|In-utero dead foetus weighting at least 500 g or 22-amenorrhea weeks old. In utero death means that death occurs during delivery or per partum
89354318|NCT03354832||New-born death|New-born dead during post-birth hospital stay and at least 23-amenorrhea weeks old.
89354319|NCT03354832||Birth control for foetal death|Same gender child born, and alive, in the same hospital, and born on time (37-41 amenorrhea weeks old).
89354320|NCT03354832||Birth control for new-born death|"Same gender infant born, and alive, in the same hospital, and:~for 23-amenorrhea weeks old new-born death: control new-born are born on time (37-41 amenorrhea weeks old).~for 24 to 31-amenorrhea weeks old new-born death: control new-born are premature infant (24-31 amenorrhea weeks old), and are included when their hospital stay ends.~for 32 and more-amenorrhea weeks old new-born death: control new-born are 32 and more-amenorrhea weeks old infant"
89354321|NCT05115357|No Intervention|Intravenous analgesia group|Patients will receive systemic intravenous analgesia only.
89354322|NCT05115357|Experimental|Pecto-Intercostal Fascial Block (PIFB) group|Patients will receive PIFB on each side with an injection of 19 mL of 0.25% bupivacaine plus 1 ml of 4 mg dexamethasone.
89354323|NCT05115357|Experimental|Transversus Thoracis Muscle Plane Block (TTP) group|Patients will receive TTP on each side with an injection of 19 mL of 0.25% bupivacaine plus 1 ml of 4 mg dexamethasone.
89354324|NCT01183715|Experimental|Cohort 1|Subjects in Cohort 1 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-05161704 will be administered in Period 4 in the fasted state.
89354325|NCT01183715|Experimental|Cohort 2|Subjects in Cohort 2 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3
89354326|NCT04507672|Placebo Comparator|saline group|Use saline for fluid resuscitation during the first 72 hours after enrollment
89354327|NCT04507672|Experimental|Acetated Ringer's solution group|Use acetated Ringer's solution for fluid resuscitation during the first 72 hours after enrollment
89354328|NCT01291589|Experimental|Cognitive-behavioral counseling|
89354329|NCT01183793|Other|Bras pair|MR-enterography then barium follow through
89354330|NCT01183793|Other|Bras impair|Barium follow-through then MR-enterography
89354331|NCT04507516||Water-only Fasting Cohort|Obese/overweight, non-diabetic patients undergoing elective water-only fasting treatment.
89354332|NCT03738007|Experimental|HA IDF II|
89354333|NCT03738007|Active Comparator|Perlane|
89354334|NCT03855839||Healthy participants|Participants will be ask to perform a repetitive upper limb task while posture is being monitored.This will be done while wearing a posture shirt, compression shirt or no shirt.
89354335|NCT03353038|Active Comparator|Off-The-Shelf Pillbox vs 3D Printed Pillbox|Participants in the study were pillbox users at baseline. Participants described their experiences and preferences with their own pillbox. Then participants will be given a 3D printed pillbox. Researchers will compare participants' experiences and preferences between their off-the-shelf pillbox used at baseline and the customized 3D printed pillbox delivered to participants as part of the study.
89354336|NCT03855761|Experimental|Intervention group|Experimental Occupational Therapy services
89354337|NCT03855761|Active Comparator|Comparison group|Treatment as usual
89354338|NCT03348826|Experimental|Alteplase then Sodium Bicarbonate|Alteplase will first be administered to restore flow. If flow is not restored, then sodium bicarbonate will be administered.
89354339|NCT03348826|Experimental|Sodium Bicarbonate then Alteplase|Sodium bicarbonate will first be administered to restore flow. If flow is not restored, then alteplase will be administered.
89354340|NCT01290419|Experimental|A: Dose 1 + adjuvant|
88818899|NCT03478007|Experimental|Intervention Technology Plus Coaching|Exercises with technology plus coaching
89354341|NCT01290419|Experimental|B: Dose 2 + adjuvant|
89354342|NCT01290419|Experimental|C: Dose 3 + adjuvant|
89354343|NCT01290419|Experimental|D: Dose 3 alone|
89354344|NCT01290419|Placebo Comparator|E: Placebo control|
89354345|NCT01290419|Experimental|F: Dose 4 alone|
89354346|NCT01290419|Experimental|G: Dose 4 +adjuvant|
89354347|NCT04507282||COVID 19 positive patients|
89354348|NCT03737773|Active Comparator|group prisms|Patients that receive active prismatic lenses
89354349|NCT03737773|Placebo Comparator|group placebo lenses|Patients that receive non-active prismatic lenses
89354350|NCT04507048|Active Comparator|Passive intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
89354351|NCT04507048|Experimental|Active intervention|"A standardized oral explanation will be given to the patient by a dermatologist, together with the administration of a booklet containing written information of 2 clinical rules for detection of melanoma, as the ABCDE and the ugly duckling rules."
89354352|NCT01183871|Active Comparator|good pulmonary functions (group 1)|FVC and/or FEV1 of 80% of predicted or more
89354353|NCT01183871|Active Comparator|mild pulmonary dysfunction (group 2)|FVC and/or FEV1 of 70%-79% of predicted
89354354|NCT01183871|Active Comparator|moderate pulmonary dysfunction (group 3)|FVC and/or FEV1 of 60%-69% of predicted
89354355|NCT01183871|Active Comparator|severe pulmonary dysfunction (group 4)|FVC and/or FEV1 of 50%-59% of predicted
89354356|NCT01060579|Experimental|AR-12286 0.5% ophthalmic solution|
89354357|NCT01060579|Experimental|AR-12286 0.25% Ophthalmic Solution|
89354358|NCT01060579|Experimental|Latanoprost 0.005% ophthalmic solution|
89354359|NCT04443946|Active Comparator|Group-P|Group-P: (Propofol group): 5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
89354360|NCT04443946|Experimental|Group-PAS|Group-PAS: (Propofol and after 20 min adding Sevoflurane group): 2.5 mg kg-1 h-1 propofol were pumped continuously and add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
89354361|NCT04443946|Experimental|Group-PS|Group-PS: (Propofol and Sevoflurane group): 2.5 mg kg-1 h-1 propofol were continuously pumped after endotracheal intubation, and 1% sevoflurane was inhaled continuously at the same time.
89354362|NCT04443946|Experimental|Group-S|Group-S: (Sevoflurane group): 2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
89354363|NCT04443946|Experimental|Group-PSu|Group-PSu: (Propofol and Sufentanil group): 5 mg kg-1 h-1 propofol, 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
89354364|NCT01184027||G-tube/swallowing intervention|patients will receive G-tube/nutritional and swallowing intervention. As per patient needs
89354365|NCT01184027||G-tube/swallowing counseling|G-tube/ad lib dietary and swallowing counseling. Current standard of care.
89354366|NCT01184027||nutrition/swallowing intervention|Patients will receive active nutrition and swallowing intervention based on patients caloric and swallowing needs.
88807329|NCT05474040|Active Comparator|multimodal|combination of Gabapentin Orally (600 mg) the night before surgery and 2 hours before anesthesia induction plus dexmedetomidineIV bolus 1 μg/kg/10min + infusion pump 0.5 μg /kg/hrs intraoperative. Bupivacaine(scalp block) R/A 20ml 0.5% Postoperative. Acetaminophen IV 10-15 mg/kg 8hr postoperative. NSAIDs(ketorolac IV15-30mg every 6 postoperative
88807330|NCT05245422|Active Comparator|Cow's milk intact protein infant formula|Control
88807331|NCT05245422|Experimental|Partially hydrolyzed cow's milk protein infant formula|Investigational
89354367|NCT01184027||nutrition/swallowing counseling|Patients will have ad lib dietary intake with general nutrition and swallowing counseling.
89354368|NCT03730129|Experimental|Ig replacement|Subjects will receive Hizentra 0.4 mg/kg subq once weekly.
89354369|NCT03348592|Experimental|Oligofructose-enriched inulin (p-inulin)|Participants are on no treatment for 8 weeks, then the pre-biotic p-inulin for 12 weeks, then no treatment for 8 weeks. Inulin is derived from chicory root fiber. The dose is 16 grams of p-inulin powder per day.
89354370|NCT03729973|Active Comparator|Group (K)|"Group (K) (n=25): patients nebulized ketamine 50 mg(milgram) (1ml) plus 4ml normal saline.So total volume (5ml).~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized 1ml ketamine (Ketalar 50mg/VI Solution for Injection) by compressor nebulizing for 15 minutes."
89354371|NCT03729973|Active Comparator|Group (M)|"Group M(n=25) : patients nebulized isotonic magnesium sulfate 250mg (3ml)( 50% Magnesium Sulfate Injection)plus 1ml normal saline.~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
89354372|NCT03729973|Active Comparator|Group (L)|"Group (L) (n=25): patients nebulized lidocaine 2% 100mg .So total volume (5ml). In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
89354373|NCT03729973|Active Comparator|Group (C)|"Group (C) (n=25): patients nebulized normal saline(0.9%). 5ml .In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
89354374|NCT01189253|Active Comparator|Doxorubicin 75 mg/m² every 3 weeks|Doxorubicin administered on day 1 every 3 weeks for a maximum of 6 cycles
89354375|NCT01189253|Experimental|Trabectedin IV 3 hours|Trabectedin administered on day 1 every 3 weeks at the dose of 1.3 mg/m² until progression
89354376|NCT01189253|Experimental|Trabectedin IV 24 hours every 3 weeks|Trabectedin administered on day 1 every 3 weeks at the dose of 1.5 mg/m² over 24 hours until progression
89354377|NCT04443790|Active Comparator|Obesecure Capsules (Test Group)|A dose of 500mg capsule twice daily of Polyherbal formulation Obesecure was given in the test group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
89354378|NCT04443790|Placebo Comparator|Plasicure (Control Group)|A dose of 500mg capsule twice daily of Placebo as Plasicure was given in the control group for three months. Short term effectiveness was assessed by BMI calculation on follow up visit after two weeks and long term follow up was assessed by BMI and Leptin Level at three months.
89354379|NCT03166215|Placebo Comparator|Part 1: Placebo|TAK-935 matching-placebo tablets, orally or through gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) from Days 1 to 30 in dose titration period.
89354380|NCT03166215|Experimental|Part 1: TAK-935|TAK-935 100 mg, tablet, orally or through G-tube/PEG tube, BID from Days 1 to 10 followed by TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 11 to 20 followed by TAK-935 100 mg tablets x3, orally or through G-tube/PEG tube, BID from Days 21 to 30 in dose titration period. The dose of TAK-935 was escalated or de-escalated during Part 1 as per investigator's discretion.
89354381|NCT03166215|Experimental|Part 2: TAK-935|TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 31 to 40 followed by TAK-935 100 mg tablets x1, x2 or x3, orally or through G-tube/PEG tube, BID from Days 31 to Day 85 as per investigator's discretion in the maintenance period. At the end of Part 2, the dose of TAK-935 was de-escalated until discontinuation.
89354382|NCT03851549|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring Systems (BGMS): Results obtained from the new BGMS for UP are compared to a reference instrument (YSI 2300)
89354383|NCT04443868|Experimental|Nitric Oxide Releasing Solution|Daily nasal irrigation (240mL) 14.4ppm
89354384|NCT04443868|Placebo Comparator|Placebo Isotonic Saline|Daily nasal irrigation (240mL) 0.9% saline
89354385|NCT03851393|Experimental|Peptest™ analysis of saliva pepsin|Induction of cough with inhaled citric acid and measurement of saliva pepsin following citric acid cough challenge using the peptest lateral device
89354386|NCT04444024||NTC/-HTN group|Patients with TC < 5.18 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to normal TC/ none hypertension(NTC/-HTN) group.
89354387|NCT04444024||NTC/+HTN group|Patients with TC < 5.18 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to normal TC/ hypertension(NTC/+HTN) group.
89354388|NCT04444024||BHTC/-HTN group|Patients whose TC is 5.18 ≤ TC < 6.19 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to borderline-high TC/ none hypertension (BHTC/-HTN) group.
89354389|NCT04444024||BHTC/+HTN group|Patients whose TC is 5.18 ≤ TC < 6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg belong to borderline-high TC/ hypertension (BHTC/+HTN) group.
89354390|NCT04444024||HTC/-HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg belong to high TC/ none hypertension(HTC/-HTN) group.
89354391|NCT04444024||HTC/+HTN group|Patients with TC ≥6.19 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 80 mmHg belong to high TC/ hypertension(HTC/+HTN) group.
89354392|NCT04443556|Active Comparator|Group Rhomboid Intercostal and Subserratus Plane Block|Standart postoperative analgesia + Continue Rhomboid Intercostal and Subserratus Plane Block
89354393|NCT04443556|Other|Control Group|Standart postoperative analgesia
89354394|NCT05054985|Experimental|Intervention arm|Patients with thoracoabdominal aortic aneurysms, and passed the screening and signed the informed consent form.
89354395|NCT01187615|Experimental|Arm 1|
89354396|NCT01187615|Experimental|Arm 2|
89354397|NCT05375097||Erenumab responder patients|Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
89354398|NCT05375097||Migraine controls|Age and gender matched migraine patients on triptan medication, excluding those on botulinum toxin, erenumab and fremanezumab to benchmark the level of HCRU, sick leaves, and medication patterns
89354399|NCT04509934|Active Comparator|Group 1|Connective Tissue Manipulation was performed to participants in Group 1, starting at the end of the menstrual cycle, 5 days a week and for 1 cycle (approximately 3 weeks) until the beginning of the next period.
89354400|NCT04509934|Active Comparator|Group 2|In Group 2, Connective Tissue Manipulation was started with the completion of menstrual cycle performed to participants for 5 days a week and until the other menstrual cycles. At the end of the menstrual cycle, it was restarted and a total of 2 cycles were applied until the second menstrual cycle started (approximately 6 weeks).
89354401|NCT01189331|No Intervention|CT and FFR|
89354402|NCT01184105|Experimental|Cohort 1 (pre)|Active treatment or placebo
89354403|NCT01184105|Experimental|Cohort 2 (post)|Active treatment or placebo
89354404|NCT02752191|Active Comparator|Ferumoxytol|Ferumoxytol, 4mg/kg of body weight, one time infusion of several minutes
89354405|NCT02752191|Active Comparator|gadofosveset|gadofosveset, 0.03mmol/kg, one time bolus injection
89354406|NCT03853577|Active Comparator|Psilocybin|
89354407|NCT03853577|Placebo Comparator|Placebo|
89354408|NCT01290497|Active Comparator|Hyaluronic acid 5 x 2.5 ml|
89354409|NCT01290497|Experimental|Hyaluronic acid 1 X 5 ml|
89354410|NCT01290497|Experimental|Hyaluronic acid 2 x 5 ml|
89354411|NCT03352804||Patients hospitalized in internal medicine ward|Patients included are patients hospitalized in internal medicine ward.
89354412|NCT03853265|No Intervention|Control|
89354413|NCT03853265|Experimental|Virtual Reality|Simulated dental office visit
89354414|NCT04509778||SHARP|ShangHai At Risk for Psychosis
89354415|NCT01184183||Accuseal patch|
89354416|NCT01184183||Bovine Pericardial patch|
89354417|NCT03352726|Experimental|DBV712 Solution for Skin Prick Test|DBV712 In-House Reference Skin Prick Test preparation
89354418|NCT03122626|Experimental|Experimental Group|The intervention is a group, task-oriented exercise program involving two 1-hour exercise classes per week for 12 weeks. The class involves a seated warm-up, repetitive, progressive practice of functional balance and mobility tasks, and a seated cool down. The warm-up consists of active range-of-motion exercises, aerobic exercise, leg loading, stretching, and sit-to-stand training. The cool-down involves exercises with an emphasis on stretching and relaxation. Tasks are organized in a 3-station circuit completed by participants grouped by overall ability: Superstation 1: walking, aerobic training, and wall work (standing and reaching, wall push-ups); Superstation 2: standing weight shifts, coordinated with stepping and lunging; and Superstation 3: tap-ups, step-ups, and heel/toe raises, hamstring curls, marching-on-the-spot, and mini-squats. Participants are instructed to be physically active by walking in their neighbourhood, practicing the program exercises, or using the stairs.
89354419|NCT03122626|No Intervention|Wait-listed Control Group|The control group will receive usual care which will be monitored and is expected to consist of provision of a home exercise program and information on community resources according to current best practices. At the end of the study period, participants in the control group will be offered to participate in the 3-month exercise program.
89354420|NCT03168711|Experimental|Inosine|Subjects will be administered oral inosine daily. The dose of inosine will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
89354421|NCT03168711|Placebo Comparator|Placebo|Subjects will be administered oral placebo daily. The dose of placebo will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
89354422|NCT04509856|No Intervention|Control Group|Routine diabetes education will given to the patients included in the Control Group by a diabetes education nurse. The diabetes education nurse has been working for 10 years in the same center.
89354423|NCT04509856|Experimental|Intervention Group|Intervention Group will take their diabetes education by teach-back educational strategy.
89354424|NCT03738215|Experimental|Cariprazine 1.5 mg/Day + ADT|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
89354425|NCT03738215|Experimental|Cariprazine 3 mg/Day + ADT|During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2).
89354426|NCT03738215|Placebo Comparator|Placebo + ADT|During the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
89354427|NCT03122704|Experimental|Group B Streptococcus (GBS) screening|Vaginal and anal swab of patients will be screened for GBS screening
89354428|NCT04506580|Experimental|Dermabond group|close capsule using 1-0 vicryl suture material close subq layer using 1-0 and 2-0 bicryl suture material and close skin layer using DERMABOND™ PRINEO™
89354429|NCT04506580|No Intervention|Subcuticular group|close capsule using 1-0 vicryl suture material close subq layer using 1-0 and 2-0 bicryl suture material and close skin layer using 3-0 Dermalon with subcuticular suture method
89354430|NCT05352321|Experimental|Surgery Plus Target-reduction Chemoradiotherapy|"Surgery:~Endoscopic nasopharyngectomy: Radical resection of primary lesion using nasal endoscopy.~Retropharyngeal lymphadenectomy: Radical retropharyngeal LNs resection using nasal endoscopy or da Vinci robotics.~Neck lymph node dissection: Selective neck dissection of the region where the positive lymph nodes are located.~Induction Chemotherapy for stage III-IVa:~Gemcitabine, 1000 mg/m2, Day 1 and Day 8, Q3W, 3 cycles Cisplatin, 80 mg/m2, Day 1, Q3W, 3 cycles~Intensity-modulated Radiotherapy with GTV and CTV1 reduction:~CTV2 : 54.12Gy/33Fr/1.64Gy~Concurrent Chemotherapy:~Cisplatin, 100 mg/m2, intravenously, Day 1, Q3W during radiotherapy"
89354431|NCT05352321|Active Comparator|Regular Chemoradiotherapy|"Induction Chemotherapy for stage III-IVa:~Gemcitabine, 1000 mg/m2, intravenously within 30min, Day 1 and Day 8, Q3W, 3 cycles Cisplatin, 80 mg/m2, intravenously, Day 1, Q3W, 3 cycles~Intensity-modulated Radiotherapy:~GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy GTVrnd (retropharyngeal lymph nodes): 69.96Gy/33Fr/2.12Gy GTVnd: 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy~Concurrent Chemotherapy:~Cisplatin, 100 mg/m2, intravenously, Day 1, Q3W during radiotherapy"
89354432|NCT01290575|Active Comparator|Arm 1 BMS-820132 or placebo|
89354433|NCT01290575|Active Comparator|Arm 2 BMS-820132 or placebo|
89354434|NCT01290575|Active Comparator|Arm 3 BMS-820132 or placebo|
89354435|NCT01290575|Active Comparator|Arm 4 BMS-820132 or placebo|
89354436|NCT01290575|Active Comparator|Arm 5 BMS-820132 or placebo|
89354437|NCT01290575|Active Comparator|Arm 6 BMS-820132 or placebo|
89354438|NCT01290575|Active Comparator|Arm 7 BMS-820132 or placebo|
89354439|NCT01290575|Active Comparator|Arm 8 BMS-820132 or placebo|
89354440|NCT01290575|Active Comparator|Arm 9 BMS-820132 or placebo|
89354441|NCT03352570|Experimental|COLOVAC device|colorectal surgery performed per standard of care with deployment of the Colovac device to protect the anastomosis site
89354442|NCT01290653|Experimental|Dry Needling of trigger point|Deep dry needling will be applied on the upper trapezius myofascial trigger point
89354443|NCT01290653|Experimental|Strain-counterstraing technique|This manual technique will be applied at the upper trapezius.
89354444|NCT01290653|Placebo Comparator|Placebo manual technique|A technique simulating strain-counterstrain, but without any therapeutic manoeuvre will be applied at the upper trapezius site.
89354445|NCT03348436|Experimental|patients with atrioventricular nodal reentrant tachycardia|radiofrequency catheter ablation therapy
89354446|NCT03348436|Experimental|patients with atrioventricular tachycardia|radiofrequency catheter ablation therapy
89354447|NCT05031741|Experimental|Telemedicine|Teens who are randomly assigned a telemedicine card will have exposure to a pretend telemedicine visit equipped with an iPad and telehealth provider on the other end. The study team will demonstrate how a teen can acquire sexual and reproductive health as well as mental health care through telemedicine from their own home or private space.
89354448|NCT05031741|Experimental|In-person Mobile Unit|Teens who are randomly assigned a in-person mobile unit card will have exposure to a pretend mobile unit visit equipped with a healthcare provider. The study team will demonstrate how a teen can acquire sexual and reproductive health as well as mental health care on the mobile unit.
89354449|NCT01189565||Joint Replacement Patients|
89354450|NCT03199911|Experimental|Topical Antibiotic Ointment|Intervention: 200 patients in the antibiotic arm will receive either erythromycin or bacitracin, based on allergies, surgeon preference, and antibiotic availability. If neither antibiotic is obtainable by the patient, bacitracin polymyxin will be prescribed instead. Antibiotic ointment is to be applied to the surgical incision(s) 4 times daily for 1 week.
89354451|NCT03199911|Placebo Comparator|Topical Non-Antibiotic Ointment|Intervention: 200 patients in the placebo group will receive mineral oil/petrolatum-based artificial tear ointment to be applied to the surgical incision(s) 4 times daily for 1 week.
88807332|NCT00410150|Experimental|Group 1 (Heliox-powered albuterol)|Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.
89354452|NCT05511532|Experimental|Foot orthoses|Hallux limitus
89354453|NCT03853421|Experimental|Dose cohort 3 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
89354454|NCT03853421|Experimental|Dose cohort 6 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
89354455|NCT03853421|Experimental|Dose cohort 9 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
89354456|NCT03352492|Experimental|Bilateral iridotomy: Superior|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
89354457|NCT03352492|Experimental|Bilateral iridotomy: Temporal|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
89354458|NCT02517814|Experimental|Patients with cardiomyopathy|Patients with vitamin D deficiency and cardiomyopathy will receive supplementation with vitamin D 400 units per day for 6 months.
89354459|NCT05349201||Adult R/R DLBCL cohort: KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma [R/R DLBCL])
89354460|NCT05349201||Adult R/R DLBCL cohort: YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma [R/R DLBCL])
89354461|NCT05349201||ALL pediatric and young adult cohort: KYMRIAH|Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) ( refractory, in relapse post transplant or in second or later relapse
89354462|NCT05303727|Experimental|Conditioning regimen for different sources of donors|There are 3 groups according to different sources of donor: (1) Cord blood HSCT: Flu+Bu+CTX+Topotecan (without ATG); (2) Peripheral blood HSCT or haploid bone marrow combined with peripheral stem cell transplantation: Flu+Bu+Melphalan+Antithymocyte globulin (ATG)+ Thiotepa (TT) or (3) Flu+Bu+Melphalan+ATG (applicable to peripheral stem cells or haploid bone marrow combined with peripheral stem cell transplantation for which TT cannot be used).
89354463|NCT04506658|Experimental|Intervention group|
89354464|NCT04506658|Sham Comparator|Control group|
89354465|NCT04503525||COVID 19 hospitalized patients|COVID 19 infected patients admitted in conventional hospitalization for less than 72 hours
89354466|NCT05011929|Experimental|online CBT-I with support (individualized feedback and reminders)|The mobile-APP based CBT-I consists of 6 weekly session. The treatment is structured and based on the well-established CBT elements for treating insomnia. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention. reminders and individualized feedback regarding the behavioral strategies will be sent to the participant every week.
89354467|NCT05011929|Active Comparator|online CBT-I without support|same as the experimental arm but without reminders and individualized feedback
89354468|NCT03348358|Placebo Comparator|control|No music during labor
89354469|NCT03348358|Experimental|Quiet music|Women hearing quiet music during labor
89354470|NCT03348358|Experimental|Rhythmic music|Women hearing rhythmic music during labor
89354471|NCT04984083|Experimental|Group I|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
89354472|NCT04984083|No Intervention|Group II|patients will not take vitamin k before cesarean section
89354473|NCT03736967|Experimental|REGN3500|
89354474|NCT03736967|Experimental|Dupilumab|
89354475|NCT03736967|Experimental|Combo|
89354476|NCT03736967|Experimental|Placebo|
89354477|NCT04506502|Experimental|Muscle Toning|The treatments are designed to evaluate muscle toning, firming and strengthening in the abdomen and buttocks.
89354478|NCT04938219|Experimental|Shivering Treatment Group|Participants will be observed, and intervention will begin when a shivering score of 2 or higher is reached. The participants in the treatment group will receive one glove filled with warm water into each hand.
89354479|NCT04938219|No Intervention|Control Group|Participants in the control group will only be observed, and not given additional treatment for the shivering.
89354480|NCT04506346||OSAHS|patients with OSAHS, undergoing UPPP
89354481|NCT03348202||Focus Group Participants|Approximately 24 groups (6 per country; Finland, Norway, Spain, Italy) consisting participants aged 80+ recruited from: senior community centres, adult day care centres, nursing homes. Each focus group will comprise from 4 to 8 people. Attempts would be made to create gender-balanced groups.
89354482|NCT03352258|No Intervention|Observation|Subjects in this arm will only be followed and not treated (observational arm)
89354483|NCT03352258|Experimental|Treatment arm|Subjects will receive a low dose brain radiotherapy
89354484|NCT01581203|Experimental|Arm 1: Null or Partial Responder to P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
89354485|NCT01581203|Experimental|Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
89354486|NCT01581203|Experimental|Arm 3: Treatment naive (ASV + DCV)|"[Subjects will receive ASV + DCV for 24 weeks] followed by ASV + DCV for 24 weeks in protocol AI444026]~Subjects meeting prespecified rescue criteria in the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg/1200 mg (total daily dose) tablet by mouth for 24 or 48 weeks"
89354487|NCT01581203|Experimental|Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week|"Subjects meeting prespecified rescue criteria in the null or partial responder cohort or active arm of the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg / 1200 mg (total daily dose) Tablet by mouth, for 24 or 48 weeks"
89354488|NCT04506268|Experimental|Opt-in Recruitment Email|Participants will receive a recruitment email that describes the objectives of a new COVID-19 voluntary screening program, and invites them to enroll.
89354489|NCT04506268|Experimental|Opt-out Recruitment Email|Participants will receive a recruitment email that describes the objectives of a new COVID-19 voluntary screening program, and informs them that they have been conditionally enrolled.
89354490|NCT03168555|Experimental|Intervention|chenodeoxycholic acid 1250mg po.
89354491|NCT03352180|Active Comparator|subscapularis tendon repair|arthroscopic reapir of subscapularis tendon
89354492|NCT03352180|Active Comparator|subscapularis tendon debridement|arthroscopic debredement of subscapularis tendon
89354493|NCT03235050|Experimental|MEDI0382 low dose + Metformin|Drug: MEDI0382 low dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
89354494|NCT03235050|Experimental|MEDI0382 mid dose + Metformin|Drug: MEDI0382 mid dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
89354495|NCT03235050|Experimental|MEDI0382 high dose + Metformin|Drug: MEDI0382 high dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
89354496|NCT03235050|Placebo Comparator|Placebo + Metformin|Drug: Placebo Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
89354497|NCT03235050|Active Comparator|Liraglutide + Metformin|Drug: Liraglutide Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
89354498|NCT01184339||Standard of Care|Current practice methods for the determination of bacteremia, specific to site practice.
89354499|NCT01184339||Gold Standard ID/AST|"Identification of S. aureus: coagulase positive, catalase positive, Staphaurex positive, and PYR negative, if performed).~Determination of MRSA:S. aureus gold standard and </=11mm OXA DD or </=21mm CFX DD.~Determination of MSSA: S. aureus gold standard and >/=13mm OXA DD or >/=22mm CFX DD."
89354500|NCT03636399|Experimental|Standard GIST|Standard Group Interactive Structured Treatment.
89354501|NCT03636399|Other|Waitlist control/Intensive GIST|After a wait list control period of nine months the participants receive Intensive Group Interactive Structured Treatment.
89354502|NCT03348124|Experimental|Intervention|"Educational lessons based on the conversational material Toolkit Children - what does it involve?, will be delivered in the classroom at school and caring for the RCB simulator during three days and nights."
89354503|NCT03348124|No Intervention|Control|Education as usual.
89354504|NCT01187693|Other|Shoe lift|
89354505|NCT04933149|Experimental|Ketamine Infusion Group|Subjects will receive ketamine infusion during their planned surgery and postoperatively.
89354506|NCT04933149|No Intervention|Standard of Care Group|Subjects will receive general anesthesia as standard of care during their planned surgery
89354507|NCT03855683|Experimental|Group therapy (Unified Protocol)|Participants experiencing stress, anxious, and/or depressive symptoms will receive 8 sessions of Unified Protocol for Emotional Disorders lasting for 90 minutes each. Includes psycho-education about (mal)adaptive emotion regulation, cognitive and behavioral tools to reduce symptoms of stress, anxiety, and/or depression.
89354508|NCT03853499||Successful vacuum extraction|Patients for whom vacuum extraction was successful
89354509|NCT03853499||Failed vacuum extraction|Patients who had an emergency caesarean section after failed vacuum extraction
89354510|NCT03004365|Active Comparator|Arm 1A: 27.2 mg C16G2|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
89354511|NCT03004365|Placebo Comparator|Arm 1B: 27.2 mg Placebo|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
89354512|NCT03004365|Active Comparator|Arm 2A: 13.6 mg C16G2|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
89354513|NCT03004365|Placebo Comparator|Arm 2B: 13.6 mg Placebo|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
89354514|NCT03004365|Active Comparator|Arm 3A: 54.4 mg C16G2|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
89354515|NCT03004365|Placebo Comparator|Arm 3B: 54.4 mg Placebo|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
89354516|NCT04502212|Experimental|Insonification|All subjects enrolled will receive a 3-day, 15 minute per day ultrasound insonification targeting the portis hepatis (liver).
89354517|NCT01293617|Placebo Comparator|Gelatin|
89354518|NCT01293617|Experimental|Blackberries|
89354519|NCT01292915||1|
89354520|NCT03851471|Experimental|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
89354521|NCT03352102|Experimental|Diaphragm Group (DG)|"subjects who received conventional physical therapy once a day, plus a daily session of electrical stimulation in the diaphragm.~Intervention: Electrical stimulation of the diaphragm."
89354522|NCT03352102|Active Comparator|Quadriceps Group (QG)|"subjects who also received conventional physical therapy once a day, plus a daily session of electrical stimulation in the quadriceps.~Intervention: Electrical stimulation of the quadriceps."
89354523|NCT03352102|No Intervention|Control Group (CG)|subjects who received regular treatment, i.e., conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day, including weekend, during their stay in the ICU.
89354524|NCT01189721|Active Comparator|sevoflurane|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients who are in this group will be infused propofol intraoperatively.
89354525|NCT01189721|Experimental|propofol|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients included this group will be inhaled sevoflurane intraoperatively.
89354526|NCT04503070||Baseball Batters|Participants must be healthy volunteers who accept all provisions of the study and agree to complete the program in its entirety. Participants should have their own bat and relative experience of at least 2 years of hitting a baseball. Ages accepted will be 16-40.
89354527|NCT03847883|Active Comparator|0.6 mg/kg Ateplase|Low dose 0.6 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke (n = 26 in cohort A)
89354528|NCT03847883|Active Comparator|0.75 mg/kg Ateplase|Low dose 0.75 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A)
89354529|NCT03847883|Active Comparator|0.9 mg/kg Ateplase|Low dose 0.9 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A and n= 330 in Cohort B)
89354530|NCT03492216|No Intervention|Control|All participants will receive brief alcohol and adherence counseling according to Uganda Ministry of Health guidelines.
89354531|NCT03492216|Experimental|Escalating incentives (EtG tests)|Escalating incentives for EtG negative urine test (Intervention: Incentives for negative EtG test).
89354532|NCT03492216|Experimental|Escalating incentives (IsoScreen tests)|Escalating incentives for IsoScreen positive urine tests (Intervention: Incentives for positive IsoScreen test).
89354533|NCT03492216|Experimental|Escalating incentives (EtG + IsoScreen)|Escalating incentives for EtG negative tests and for IsoScreen positive urine tests with the incentives rewarded separately (Interventions: Incentives for negative EtG test and Incentives for positive IsoScreen test).
89354534|NCT03167619|Experimental|A - olaparib alone|Twice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
89354535|NCT03167619|Experimental|B - olaparib plus durvalumab|Twice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
89354536|NCT03578809|Placebo Comparator|Cohort A: Placebo|Participants will receive placebo matched to MEDI6012 on Day 1 prior to pPCI followed by a second inpatient dose on Day 3 by IV push.
89354537|NCT03578809|Experimental|Cohort A: MEDI6012|Participants will receive loading dose of MEDI6012 300 mg on Day 1 prior to pPCI followed by a second inpatient dose of MEDI6012 150 mg on Day 3 by IV push.
89354538|NCT03578809|Placebo Comparator|Cohort B: Placebo|Participants will receive placebo matched to MEDI6012 on Day 1 prior to pPCI followed by a second inpatient dose on Day 3, and outpatient maintenance doses on Days 10, 17, 24, and 31 by IV push.
89354539|NCT03578809|Experimental|Cohort B: MEDI6012|Participants will receive loading dose of MEDI6012 300 mg on Day 1 prior to pPCI followed by a second inpatient dose of MEDI6012 150 mg on Day 3, and outpatient maintenance doses of MEDI6012 100 mg on Days 10, 17, 24, and 31 by IV push.
89354540|NCT01189877|Experimental|pO2 measurements|In patients meeting eligibility requirements outlined below, comparisons will be made between direct pO2 measurements using a tissue hypoximeter and IHC-assessed expression of hypoxia related proteins (HIF-1α, VEGF, CA IX and GLUT-1) in both normal and tumor tissue.
89354541|NCT03850925|Experimental|Picosecond laser|Intervention: four consecutive sessions of 1,064-nm picosecond laser at 3-week intervals
89354542|NCT03850925|Active Comparator|Fractional laser|Intervention: four consecutive sessions of nonablative fractional laser at 3-week intervals
89354543|NCT03198507|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin
89354544|NCT03198507|Active Comparator|Active Comparator|Active comparator is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin and Omeprazole; as well as separate Riboflavin
89354545|NCT01184261|Experimental|Arm I|Patients attend behavioral sessions for smoking and binge drinking cessation over 30 minutes once weekly in weeks 1-6.
89354546|NCT01184261|Experimental|Arm II|Patients attend behavioral sessions for smoking cessation over 30 minutes once weekly in weeks 1-6.
89354547|NCT01189955|Active Comparator|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
89354548|NCT01189955|Active Comparator|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
89354549|NCT04738344|Experimental|Percutaneous coronary intervention and stent implantation using one long stent|Long coronary lesions will be treated percutaneously with a single long stent (more than 40 mm in length) and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture
89354550|NCT04738344|Experimental|Percutaneous coronary intervention and stent implantation using more than one overlapping stents|Long coronary lesions will be treated with more than one overlapping stents and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture
89354551|NCT03610165|Placebo Comparator|Arterial line - Control|Arterial line waveform and pressure
89354552|NCT03610165|Experimental|Acumen HPI-enabled EV1000 screen|Arterial line waveform and pressure + HPI alert from EV1000 monitor
89354553|NCT03850769|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 4 cycles.
89354554|NCT04663464|Experimental|abaloparatide-SC (Period 1) followed by abaloparatide-sMTS (Period 2)|Abaloparatide-SC injection (Period 1) followed by abaloparatide-sMTS application (Period 2). Abaloparatide-SC is a drug-device combination product consisting of abaloparatide, an active synthetic peptide analog of parathyroid hormone related peptide (PTHrP), administered to the periumbilical region via an injection pen. Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide.
89354555|NCT04663464|Experimental|Abaloparatide-sMTS (Period 1) followed by abaloparatide-SC (Period 2)|Abaloparatide-sMTS (Period 1) application followed by Abaloparatide-SC injection (Period 2).
89354556|NCT05671601||TLI+AI Assessment Group|
89354557|NCT05671601||Morphological Assessment Group|
89354558|NCT03729895|Experimental|patients with OSAS in different degrees|OSAS patients will be treated with an adjustable oral appliance and evaluated with cone-beam computed tomography and polysomnography.
89354559|NCT01190033|Active Comparator|Neurolysis|In this intervention the neurotome will be connected
89354560|NCT01190033|Placebo Comparator|Neurotome OFF|neurotome not raised
89354561|NCT01190111|Experimental|CYT107 (r-hIL-7)|
89354562|NCT03609619|Experimental|AEVI-001|
89354563|NCT03609619|Placebo Comparator|Placebo|
89354564|NCT01292993|Experimental|Treatment A|400 mg LX4211
89354565|NCT01292993|Experimental|Treatment B|1000 mg metformin
89354566|NCT01292993|Experimental|Treatment C|400 mg LX4211 + 1000 mg metformin
89354567|NCT04892355|Experimental|Conventional Syringe Irrigation Group|During the final irrigation procedure, a 30 - G side vented needle was placed 2 mm shorter than the working length and was applied without agitation. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
88807333|NCT00410150|Active Comparator|Group 2 (Oxygen-powered albuterol)|Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.
89354568|NCT04892355|Experimental|Xp Endo Finisher Group|Xp Endo Finisher file was used with VDW Silver (VDW) endomotor at 800 rpm speed and 1 Ncm torque according to the manufacturer's instructions. The Xp Endo Finisher file was placed in the canal, 2 mm shorter than the working length, and was used with slow movements of 7-8 mm amplitude in the canal during activation. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
89354569|NCT04892355|Experimental|EDDY Group|An EDDY tip of size 25/04 was used for sonic activation. The EDDY was placed in the duct 2 mm shorter than the working length and the activation process was performed with slow movements with an amplitude of 2-4 mm. In the irrigation process, 5 mL of 2.5% NaOCI was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
89354570|NCT04892355|Experimental|Endoactivator Group|Medium Endoactivator tip of 25 / .04 size was used for irrigation activation. Medium type was placed in the canal 2 mm shorter than the working length and activation was performed by making short strokes of 2-3 mm. 5 mL of 2.5% NaOCl was applied for 1 minute for each channel. Each canal was then washed with 2 mL of 17% EDTA for 1 minute.
89354571|NCT03737617|Experimental|Active arm|Weekly subcutaneous immunoglobulin therapy (0.1g/Kg) Cuvitru 20% Injectable Solution for 1 Year
89354572|NCT03737617|No Intervention|Control|Standard Care arm without immunoglobulin replacement therapy
89354573|NCT01293773|Active Comparator|Taxus Element|Patients treated with paclitaxel-eluting stent (Taxus Element, Boston Scientific, MN)
89354574|NCT01293773|Active Comparator|Xience Prime|Patients treated with Everolimus-eluting stent (Xience Prime, Abbott, IL)
89354575|NCT01293773|Active Comparator|Integrity Resolute|Patients treated with ABT 578-eluting stent (Integrity Resolute, Medtronic, MA)
89354576|NCT05196477||Olokizumab treatment group|Subjects with the infection caused by SARS-CoV-2 who received olokizumab injection in addition to the standard therapy.
89354577|NCT05196477||Standard treatment group|Subjects with the infection caused by SARS-CoV-2 who received the standard therapy without monoclonal antibodies (mAbs).
89354578|NCT03849833|Other|Vitamin D3 supplementation|All participants will be selected for treatment with cholecalciferol, vitamin D3 supplementation and included in this single arm
89354579|NCT03849521||Asymptomatic group|Group with asymptomatic patients with carotid atherosclerosis.
89354580|NCT03849521||Symptomatic group|Group with symptomatic patients with carotid atherosclerosis.
89354581|NCT03167151|Experimental|Arm A Intravesical|"Intravesical Pembrolizumab (solution for infusion) 50-200 mg, given on D1, D8, D15, D22, D29, D36 & D64.~Dose to be decided after safety run-in."
89354582|NCT03167151|Active Comparator|Arm B Intravenous|Intravenous Pembrolizumab (solution for infusion), 200mg, given on D1, D22, D43, D64
89354583|NCT01191125|Experimental|medical food with AN777|
89354584|NCT01191125|Active Comparator|oral nutritional formula|
89354585|NCT03660943|Placebo Comparator|Placebo|Matching placebo of 2.0 mL for IA injection
89354586|NCT03660943|Experimental|CNTX-4975-05|Pre-filled glass syringes administered as a single 2.0 mL IA injection
89354587|NCT03167073|Experimental|BreastFeeding Friend (BFF)|BFF is a novel android app initially created in Microsoft PowerPoint with the results of a well-validated questionnaire administered to the target patient population, in which participants identified barriers preventing them from starting or continuing breastfeeding. The app was then modified by a multidisciplinary team of neonatologists, perinatologists, and certified lactation consultants. The finalized prototype was presented to three focus groups of test users sociodemographically similar to the target population. This approach allowed BFF to be adjusted to maximize the users' experience per their opinions. Once the focus groups' feedback was consistent, the app prototype was provided to a freelance coding team at Washington University of St. Louis, which built a native android app.
88807334|NCT01796678|Experimental|Arginine|100 mg/kg T.I.D 3x a day IV or PO
88807335|NCT01796678|Placebo Comparator|Placebo|Saline or sugar pill
89354588|NCT03167073|Placebo Comparator|dummy app|The dummy app looks identical to BFF but is limited to a few pages of information on breastfeeding that is provided in hand-out form during routine prenatal care.
89354589|NCT03731767|Other|Subject group|Distraction thrust manipulation of the talocural joint in supine position
89354590|NCT01191203|Active Comparator|Depo Medroxyprogesterone Acetate|
89354591|NCT01191203|Active Comparator|Copper IUD (CuT360)|
89354592|NCT03657277|Other|Micropatch Application|This is the only study arm, which all participants complete. Five sites each on each the upper arm, forearm, and abdomen will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, hydration, and skin color will be made. Micropatches will be applied at three sites (at each body location). This only occurs on the first study day. Trans-epidermal water loss and electrical resistance are re-measured immediately after micropatch application. The sites will be covered with a small patch secured with medical tape. One site at each location will just be covered with a patch. The last site will not have micropatch application or patches. Electrical resistance will be re-measured at all sites for 3 days. Measurements from the 4th and 5th sites allow each subject to serve as their own control in data analysis.
89354593|NCT03197883|Experimental|Group 1|Participants will apply a pea-sized quantity of test product (approximately 0.6-1 grams (g)) topically onto the fingertips and will apply twice daily (morning and evening) to the full face after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
89354594|NCT03197883|Other|Group 2|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
89354595|NCT01293929||Non- obese group|
89354596|NCT01293929||Obese group|
89354597|NCT03849677||Omnivore|
89354598|NCT03849677||Vegan|
89354599|NCT03729661|Experimental|Breath hold|Patients who receive a breathhold CT- and treatment
89354600|NCT03849599|Experimental|PRV-300|Subjects in this arm will receive the study drug, PRV-300, via IV infusion, followed by an 8-week follow-up period.
89354601|NCT03849599|Placebo Comparator|Placebo|Subjects in this arm will receive placebo via IV infusion, followed by an 8-week follow-up period.
89354602|NCT03731689|No Intervention|Control group|Control group( Intrauterine patients) do not apply intrauterine lavage therapy or intrauterine gel-injection therapy after surgery.
89354603|NCT03731689|Experimental|Intrauterine lavage therapy group|Intrauterine lavage therapy group apply intrauterine lavage therapy after surgery.
89354604|NCT03731689|Experimental|Intrauterine gel-injection therapy group|Intrauterine gel-injection therapy group apply intrauterine gel-injection therapy after surgery.
89354605|NCT03731689|No Intervention|Healthy control group|Healthy control group 1)have regular menstrual cycles,diagnostic hysteroscopy with endometrial biopsy and laparoscopy as part of their infertility diagnostic work-up prior to IVF, hysteroscopy and subsequent pathological results having shown no abnormality in the uterine cavities and abdominal cavity.2) had male partners who were infertile and diagnosed with defective sperm function,such as asthenozoospermia, oligoasthenozoospermia, severe oligoasthenozoospermia and azoospermia, defined according to guidelines published by the World Health Organization.
89354606|NCT03729583|Active Comparator|Control group|The control group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme without breathing retraining All patients were medically stable and referred by their caring respiratory consultant
89354607|NCT03729583|Experimental|Active group|The active group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme with breathing retraining exercises. All patients were medically stable and referred by their caring respiratory consultant
89354608|NCT01191281|Experimental|Diet/nutrition counsel+food aid|Intervention. Patients enrolled in the intervention group will receive a multi-component intervention that includes dietary and nutritional counseling and food assistance (food aid basket)
89354609|NCT01191281|Active Comparator|dietary/nutritional counseling|Patients enrolled in the comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
89354610|NCT03729505|Active Comparator|Pyloric injection of magnesium sulfate and lidocaine mixture|After sleeve gastrectomy, the pylorus is injected with a mixture of magnesium sulfate and lidocaine
89354611|NCT03729505|Active Comparator|Pyloric injection of saline|After sleeve gastrectomy, the pylorus is injected with normal saline
89354612|NCT03234036|Experimental|Treatment sequence ABC: Part 1|"A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.~Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
89354613|NCT03234036|Experimental|Treatment sequence BAC: Part 1|"A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
89354614|NCT03234036|Experimental|GSK2838232 tablet without RTV: Part 2|In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
89354615|NCT03234036|Placebo Comparator|Placebo without RTV: Part 2|In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.
89354616|NCT03849365|Experimental|TOOKAD VTP|TOOKAD is administered as part of focal VTP under general anaesthetic. TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
89354617|NCT03847805|Experimental|Experimental|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
89354618|NCT03847805|Active Comparator|Control|The control group followed a program of glenohumeral stabilization exercises,
89354619|NCT03606109|Active Comparator|High Tibial Osteotomy (HTO)|
89354620|NCT03606109|Active Comparator|Tibial Tubercle Ostetomy (TTO)|
89354621|NCT01191359|Active Comparator|sublingual administration|oral immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
89354622|NCT01191359|Active Comparator|vestibular administration|oral immunotherapy with drops applied by single dose containers (200 STU per dose)
89354623|NCT01293071|Active Comparator|Mixing arm|Antibiotic rotation, each consecutive initiated antibiotic treatment a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems)
89354624|NCT01293071|Active Comparator|Cycling|Antibiotic rotation, every 1.5 month a different preferred antibiotic treatment from a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems) is used for empiric treatment.
89354625|NCT03771144|Experimental|Experimental|
89354626|NCT03849755|Other|PEPPER/Control|Group with intervention applied (PEPPER system) during the first three months and then, after wash -out period, swap to control group (using standard bolus calculator) for the next 3 months.
89354627|NCT03849755|Other|Control/PEPPER|Group without intervention applied (using standard bolus calculator) during the first three months and then, after wash -out period, swap to intervention group (using PEPPER system) for the next 3 months.
89354628|NCT01294475|Experimental|Cell Phone Enhanced Parent Training|Cell phones will be provided to mothers participating in Planned Activities Training.
89354629|NCT01190345|Experimental|WITH bevacizumab|"bevacizumab 15 mg/kg on day 1 of each cycle : 4 cycles of 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
89354630|NCT01190345|Active Comparator|without bevacizumab|"4 cycles 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV of (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
89354631|NCT02729896|Experimental|Dose-Escalation Phase|During the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months, during maintenance treatment for FL participants.
89354632|NCT02729896|Experimental|Expansion Phase|For FL during the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola at identified RP2D (decided from dose-escalation phase) on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1 and Pola at RP2D on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months (during maintenance treatment for FL participants).
89354633|NCT02729896|Experimental|Safety Run-In Phase|For DLBCL, during the induction treatment Cycles 1-6 (21-day cycles): participants will receive rituximab on Day 1 and Pola on Day 1.
89354634|NCT04698174|Experimental|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|
89354635|NCT04698174|Experimental|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|
89354636|NCT04698174|Active Comparator|Standard Photorefractive keratectomy (PRK)|
89354637|NCT03847727||Experimental: 6 cycles BR -> 4 x BR|Induction plus BR as maintenance (N=56)
89354638|NCT03847727||Proper historical control: 6 cycles BR|Induction only (N=56)
89354639|NCT01190423|Experimental|Family Based therapy for young adults|
89354640|NCT01190501|Experimental|complier device|
89354641|NCT04506034|Experimental|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
89354642|NCT04506034|Active Comparator|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
89354643|NCT04506034|Placebo Comparator|IV saline infusion|received i.v. saline infusion.
89354644|NCT01294631|Experimental|001|"Canagliflozin 300 mg once daily and HCTZ 25 mg once daily Period 1: canagliflozin tablets oral 300 mg once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets oral 25 mg once daily for Days 1 to 28 followed by canagliflozin tablets oral 300 mg once daily taken with HCTZ tablets oral 25 mg once daily on Days 29 to 35.."
89354645|NCT03849209|Experimental|Stylet Slow-Pull Technique group|In patients randomized to the stylet slow-pull techniques an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
89354646|NCT03849209|Active Comparator|Standard Suction Technique group|In patients randomized to the standard suction technique an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed with the use of a 10-mL suction syringe.
89354647|NCT05342662|Experimental|Blue light-blocking glasses|Participants will wear blue light-blocking glasses to evaluate whether sleep behaviors improve.
89354648|NCT05342662|Placebo Comparator|Glasses with clear lenses|Participants will wear glasses with clear lenses to serve as the control condition.
89354649|NCT03847571||Acetazolamide|Oral administration of acetazolamide 5 mg/kg/day for 4 weeks
89354650|NCT03433846||Preterm Infants|Blood samples will be obtained from preterm and former preterm infants at birth and then monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
89354651|NCT03433846||Term Infants|Blood samples will be obtained from term control infants admitted to the NICU monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
89354652|NCT01293149|Experimental|Ropivacaine plus clonidine|Ropivacaine plus clonidine for femoral block
89354653|NCT01293149|Active Comparator|Ropivacaine|Ropivacaine alone for femoral block
89354654|NCT03575065|Experimental|Cohort 1: Triple-negative breast cancer (TNBC)|Locally advanced or metastatic TNBC
89354655|NCT03575065|Experimental|Cohort 2: HR(+)/HER2(-) breast cancer|Locally advanced or metastatic Hormone receptor-positive(HR+) human epidermal growth factor receptor2 Negative(HER2-) breast cancer
89354656|NCT03636672|Experimental|experimental|Perturbation training during stationary bicycle riding
89354657|NCT03636672|Active Comparator|control|stationary bicycle riding training
89354658|NCT03847961|No Intervention|Control Group|The control group receive routine treatment of sepsis only. All sites agree, when feasible, to follow the tenets of the Surviving Sepsis Campaign clinical practice guidelines for management of sepsis.
89354659|NCT03847961|Experimental|Experimental Group|The experimental group receive routine treatment of sepsis combined with hemoperfusion with cytokine adsorption column (CA330).
89354660|NCT04454424|Experimental|Arm A: Child-Pugh A|Participants with mildly impaired hepatic function (Child-Pugh A)
89354661|NCT04454424|Experimental|Arm B: Child-Pugh B|Participants with moderately impaired hepatic function (Child-Pugh B)
89354662|NCT04454424|Experimental|Arm C: Child-Pugh C|Participants with severely impaired hepatic function (Child-Pugh C)
89354663|NCT04454424|Experimental|Arm D: Normal hepatic (Matched A and B)|Participants with normal hepatic function matched to Arm A and B
89354664|NCT04454424|Experimental|Arm E: Normal hepatic (Matched to C)|Participants with normal hepatic function matched to Arm C
89354665|NCT02518126||control|Women with IUGR embryos so that their fetal weight estimate puts them in a percentile bellow 10th percentile
89354666|NCT02518126||IUGR|Women with AGA embryos so that their fetal weight estimate puts them in a percentile between 20th and 80th percentiles
89354667|NCT01194167|Experimental|Eltrombopag|Eltrombopag 75 mg per day. Possible escalation to 150 mg per day after day 15 lab results. Possible escalation to 300 mg per day after day 29 lab results.
89354668|NCT05313802|Experimental|LY3502970 (Dose Level 1)|LY3502970 administered orally.
89354669|NCT05313802|Experimental|LY3502970 (Dose Level 2)|LY3502970 administered orally.
89354670|NCT05313802|Experimental|LY3502970 (Dose Level 3)|LY3502970 administered orally.
89354671|NCT03521310|Experimental|Skin-to-skin Contact group|Neonates in gestational age between 28+0 - 32+6 will get continuous Skin-to-skin contact with one parent/caregiver the first 6 hours after birth and as much as possible the first 72 hours after birth.
89354672|NCT03521310|Active Comparator|Conventional care group|Neonates in gestational age between 28+0 - 32+6 will get Conventional care - incubators, warmers etc - the first 72 hours after birth.
89354673|NCT03514134|Experimental|Services as usual + Virtual Reality Job Interview Training|In addition to the services as usual comparator, participants will participate in Virtual Reality Job Interview Training.
89354674|NCT03514134|Active Comparator|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
89354675|NCT03849287|Experimental|Group 1|"Period 1: CKD-333, formula I~Period 2: CKD-333, formula II~Period 3: CKD-330, D090"
89354676|NCT03849287|Experimental|Group 2|"Period 1: CKD-333, formula I~Period 2: CKD-330, D090~Period 3: CKD-333, formula II"
89354677|NCT03849287|Experimental|Group 3|"Period 1: CKD-333, formula II~Period 2: CKD-330, D090~Period 3: CKD-333, formula I"
89354678|NCT03849287|Experimental|Group 4|"Period 1: CKD-333, formula II~Period 2: CKD-333, formula I~Period 3: CKD-330, D090"
89354679|NCT03849287|Experimental|Group 5|"Period 1: CKD-330, D090~Period 2: CKD-333, formula I~Period 3: CKD-333, formula II"
89354680|NCT03849287|Experimental|Group 6|"Period 1: CKD-330, D090~Period 2: CKD-333, formula II~Period 3: CKD-333, formula I"
89354681|NCT03352024|Other|Standard Care|Relational care used to help the patient by reducing the fear and anxiety
89354682|NCT03352024|Other|Hypnosis|Hypno-analgesia is used to help the patient by reducing the fear and anxiety
89354683|NCT03188718|Other|WatchPAT Intervention|Wearing the WatchPAT device simultaneously while receiving a clinically indicated sleep study (polysomnogram).
89354684|NCT01294865||septic|Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.
89354685|NCT01294865||non-septic|Infants without any clinical or hematological septic signs. Blood samples will be taken only once.
89354686|NCT01194323||Controls|No complaints or history of heartburn or acid regurgitation; no erosion at EGD; and normal pH monitoring
89354687|NCT01194323||GERD Cases|Patients with esophageal erosion at EGD and abnormal pH monitoring.
89354688|NCT05584930|Other|Cancer patient|Collection of blood sample
89354689|NCT01294943||Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
89354690|NCT04505644|Experimental|lidocaine patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
89354691|NCT04505644|Active Comparator|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight >70 kg or 1 mg/min if body weight <70 kg.
89354692|NCT04505644|Placebo Comparator|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
89354693|NCT03574753|Experimental|ABBV-399|"C-MET overexpression is seen in 30% of patients with lung squamous cell carcinoma (SCCA). ABBV-399 (Process II) is a first-in-class antibody-drug conjugate (ADC) comprised of ABT-700, an anti-c-Met monoclonal antibody linked to monomethyl auristatin E (MMAE), which is a potent microtubule inhibitor. This delivers a direct anti-mitotic effect without relying on MET pathway inhibition.~ABBV-399 will be administered intravenously on day 1 of each 21-day cycle. Treatment will continue in consenting patients until disease progression or intolerable toxicity."
89354694|NCT03850613|Experimental|Intervention arm|Participants in the intervention arm download the E-painting mobile app and use this app to make their own painting.
89354695|NCT04505800|Experimental|Tryptophan supplement|"Pure L-tryptophan in capsules (500mg/capsule)~3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
89354696|NCT04505800|Placebo Comparator|Maltose|"Placebo is maltose powder capsule (500mg/capsule)~3g maltose powder per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
89354697|NCT01194401||Cohort|
89354698|NCT03725839|Experimental|Arm|F&P Interface will be used by OSA participants in-home for 2 weeks.
89354699|NCT05200156|Experimental|Choline supplement group|Phosphatidyl choline tablets at a dose of 1200 mg twice per day plus conventional management for 12 weeks
89354700|NCT05200156|No Intervention|Control group|conventional management only for 12 weeks
89354701|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine sulfate|Pharmaceutical form capsule.
89354702|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine Sulfate|Oral powder.
89354703|NCT01293305|Active Comparator|Condroflex®|Pharmaceutical form capsule.
89354704|NCT01293305|Active Comparator|CONDROFLEX®|Oral powder
89354705|NCT01310257||Knee osteoarthritis|Patients will have osteoarthritis (OA) of the knee defined and scored radiologically in Study 1. Patients in Study 2 will also have OA of the knee, but a clinical diagnosis will suffice. All patients will report knee pain.
89354706|NCT03347968|Experimental|MEDI0382|All participants will receive MEDI0382.
89354707|NCT03347968|Active Comparator|Warfarin|All participants will receive Warfarin
89354708|NCT03347968|Active Comparator|Esmolol|All participants will receive Esmolol
89354709|NCT03848975|Experimental|Simulation training for ECV|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the Control group for VE : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
89354710|NCT03848975|Experimental|Simulation training for VE|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the the control group for for ECV : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
89354711|NCT03731533|Experimental|WellStart|WellStart is a 12-week virtual intensive therapeutic lifestyle program utilizing web-based encounters with physicians, dietitians, health coaches and additional resources.
89354712|NCT03731533|No Intervention|Usual Care|The control group will continue with usual care.
89354713|NCT05179720|Experimental|puncture stent-assisted transperineal prostate biopsy|This group of patients underwent puncture stent-assisted transperineal prostate biopsy.
89354714|NCT05179720|Active Comparator|transperineal free-hand biopsy|This group of patients underwent perineal free-hand biopsy
89354715|NCT01191515||Near visual outcomes with Monofocal IOL|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
89354716|NCT01191515||Intermediate Visual outcomes|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
89354717|NCT03346954|Experimental|Patients with Cushing's disease|Implementation of [11C]-Methionine PET/MRI
89354718|NCT01194557|Active Comparator|rapid diagnostic test|Treatment and diagnosis of malaria in drugs hops using rapid diagnostic tests
89354719|NCT01194557|No Intervention|Presumptive malaria treatment|Presumptive treatment for malaria in drug shops
89354720|NCT03729193||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 soccer players.
89354721|NCT03729193||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 basketball players.
89354722|NCT03729193||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 volleyball players.
89354723|NCT03729193||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 archers.
89354724|NCT03729193||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 kickboxers.
89354725|NCT03729193||table tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 table tennis athletes.
89354726|NCT03729193||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 runners.
89354727|NCT03729193||field tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 field tennis athletes.
89354728|NCT03346876||Study group|patients with pectus excavatum
89354729|NCT03346876||Control group|healthy subjects without pectus excavatum
89354730|NCT03848897|Experimental|Non falling elderly|
89354731|NCT03848897|Experimental|Falling elderly|
89354732|NCT03848897|Experimental|Non falling patients with Parkinson's disease|
89354733|NCT03731455|Experimental|Investigational and Comparator devices|Investigational (WISE Cortical Strip, WCS) and comparator (Subdural Strip Electrode, Ad-Tech Medical Instruments Corporation) devices will be used together.
89354734|NCT03351946|Active Comparator|ZEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) until start of emergence preoxygenation.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.~First CT scan after completion of surgery, before emergence. After the first CT scan and immediately before start of emergence preoxygenation, this group will have the PEEP exchanged for zero PEEP (ZEEP). ZEEP will remain until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
89354735|NCT03351946|Active Comparator|PEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) even after start of emergence preoxygenation.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.~First CT scan after completion of surgery, before emergence. After the first CT scan, this group will have PEEP remained until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
89354736|NCT03847259||A(public school)|"it will be consists of 200 adolescent female from public schools, their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire.~pain will be evaluated by VISUAL ANALOG SCALE(VAS) .stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21)."
89354737|NCT03847259||B(international school)|it will be consists of 200 adolescent female from international schools their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire .pain will be evaluated by VISUAL ANALOG SCALE (VAS).stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21).
89354738|NCT03351868|Experimental|Gene-modified autologous stem cells|Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo
89354739|NCT01191593|Experimental|Adductor-Canal-Blockade with ropivacaine|
89354740|NCT01191593|Placebo Comparator|Adductor-Canal-blockade with saline|
89354741|NCT03347890|Experimental|Liraglutide 3.0 mg|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg).
89354742|NCT03347890|Placebo Comparator|Placebo|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Placebo by pen injector.
89354743|NCT03848819|Other|Control pursed lip breathing|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe adopting the pursed lip breathing technique. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
89354744|NCT03848819|Experimental|pNIV|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe via the VitaBreath device. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
89354745|NCT03347812||Endovascular Aortic Repair|Patients with aortic arch lesions who only received endovascular treatment, including chimney / fenestration / branch stent-grafts technique and combination of these techniques, would be assigned to this group.
89354746|NCT03347812||Total Arch Replacement|Patients with aortic arch lesions who only received traditional open surgery for total aortic arch replacement, would be assigned to this group.
89354747|NCT01190657|Experimental|Selbex 50mg (14 days)|
89354748|NCT01190657|Experimental|Selbex 50mg (56 days)|
89354749|NCT04505488|Experimental|Intervention Group|The intervention group will receive a parent manual, a resource packet, and 12 weekly sessions delivered by the clinician and peer leader.
89354750|NCT04505488|No Intervention|Control Group|The control group will receive a parent manual and a resource packet. Four phone check-ins will be conducted across 12-14 weeks to address questions by the research team.
89354751|NCT03351790||All included participants|Patients that complete study questionnaire and have endoscopy recorded.
89354752|NCT04505332|Other|orthopedists|orthopedists working actively and performing arthroplasty every day
89354753|NCT03573505|Experimental|BG00011|Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks.
89354754|NCT03573505|Placebo Comparator|Placebo|Participants will receive placebo once weekly by (SC) injection for 52 weeks.
89354755|NCT01293383|Other|LEO 90105|
89354756|NCT01293383|Other|Vehicle|
89354757|NCT01296503|Active Comparator|Dexamethasone (Arm A)|Sixty days (D+60) after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days)
89354758|NCT01296503|Experimental|Thalidomide and Dexamethasone (Arm B)|"D+60 after ASCT: dexamethasone plus thalidomide 200 mg by mouth daily for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
89354759|NCT01376908|Experimental|Kuvan® + Phe-restricted diet|Subjects will be treated with Kuvan® tablets once daily along with Phe-restricted diet therapy.
89354760|NCT01376908|Other|Phe-restricted diet alone|Subjects will follow a Phe-restricted diet alone.
89354761|NCT03729037|Experimental|Serious game|Intervention: CPR self-training with serious game.
89354762|NCT03729037|Active Comparator|Training video|Intervention: CPR self-training with Keynote presentation with the addition of voice-over narration.
89354763|NCT01295099|Active Comparator|5-Fluorouracil|Patients with small keloidal scars to have intralesional 5FU injected
89354764|NCT01295099|Active Comparator|Radiotherapy|Large keloid scars undergo extralesional excision and radiotherapy
89354765|NCT01295099|Active Comparator|TAC|
89354766|NCT01310335|Experimental|Training|The whole-body vibration (WBV) training
89354767|NCT01426529|Experimental|major allele homozygous|we will compare this arm with the minor allele carrier arm
89354768|NCT01426529|Experimental|minor allele carriers|we will compare this arm with the major allele homozygous arm
89354769|NCT03346798|Experimental|Food Photography|On the first visit, participants will engage in food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
89354770|NCT03346798|Experimental|Non-Food Photography|On the first visit, participants will engage in non-food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
89354771|NCT03728959|Experimental|Liquid meal (Nutridrink)|Liquid meal (Nutridrink)
89354772|NCT03728959|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
89354773|NCT03728959|Experimental|GLP-2|Glucagon-like peptide-2
89354774|NCT03728959|Experimental|Placebo (saline)|Placebo (saline)
89354775|NCT03849053|Experimental|Mézières method|
89354776|NCT03849053|Active Comparator|Control Group|
89354777|NCT03728803|Sham Comparator|Sham inspiratory muscle training|"Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. For sham IMT the valve will be removed, creating a low resistance.~The participants will perform the sham IMT twice a day during 15 minutes for a period of 8 weeks."
89354778|NCT03728803|Active Comparator|Active inspiratory muscle training|Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. After the sham IMT, the participants will perform an active inspiratory muscle training during 8 weeks with the same training schedule. The resistance will gradually be increased in the first couple of weeks until the intended resistance (30% of MIP) is reached.
89354779|NCT03122392|Experimental|AMS 800 Artificial Urinary Sphincter|"The AMS 800™ Urinary Control System is an implantable, fluid-filled, solid silicone elastomer prosthesis used to treat urinary incontinence due to reduced outlet resistance (intrinsic sphincter deficiency) following prostate surgery. The AMS 800 Urinary Control System simulates normal sphincter function by opening and closing the urethra, under patient control. When the cuff is closed, urine stays in the bladder.~When the patient wishes to void, he simply squeezes and releases the pump several times. This causes the fluid in the cuff to move into the pressure-regulating balloon . The cuff opens and urine passes through the urethra. The balloon then automatically re-pressurizes the cuff through the pump, within several minutes, the cuff again closes the urethra.~The control pump, which in implanted in the scrotum, is also designed to allow the clinician or patient to deactivate and activate the system without additional surgery."
89354780|NCT03728725||TB case detection Group|Patients with pulmonary TB symptoms and at least one DR-TB risk factor will be screened by Xpert MTB/RIF or Ultra. Patients with a clear TB-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Ultra and who consent to study procedures will be tested by Xpert MTB/XDR.
89354781|NCT03728725||RIF-resistance MTB Group|"An anticipated 316 additional RIF-resistant patients, as detected by Xpert MTB.~/RIF, will be enrolled in this study to evaluate sensitivity and specificity of the Xpert MTB/XDR test against strains with other potential drug-resistance mutations."
89354782|NCT03122158|Active Comparator|Major depressive disorder|In this group, adolescents with major depressive disorder will be recruited. It was planned to include 30 participants.Escitalopram treatment will be given to those with Major Depressive Disorder with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
89354783|NCT03122158|Active Comparator|Anxiety disorders|In this group, adolescents with anxiety disorders will be recruited. It was planned to include 30 participants. Additionally, the specification of which anxiety disorders are assigned to the participants will also be provided. Escitalopram treatment will be given to participants with anxiety disorders with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
89354784|NCT03728647|Experimental|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
89354785|NCT03728647|Active Comparator|regular health education|The regular (traditional) education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
89354786|NCT03122236|Active Comparator|Standard walking with tDCS dosage A|Neurorehabilitation of Standard Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
89354787|NCT03122236|Active Comparator|Complex walking with tDCS dosage A|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
89354788|NCT03122236|Active Comparator|Complex walking with tDCS dosage B|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage B
89354789|NCT03728569|Other|Subjects over the age of 70 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
89354790|NCT03728569|Other|Subjects between 18 and 30 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
89354791|NCT03736031|Experimental|Intervention (Promotora)|The intervention group will have three face-to-face meetings with the promotora. Participant will continue to receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
89354792|NCT03736031|No Intervention|Self-Education (Control)|Participant will receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
89354793|NCT04503304|Experimental|HAS group|"hip abductors strengthening group~Hip abduction -standing[Ferber et al.,2015].~Sidelying hip abduction(clamshell)[Schache et al.,2016].~lateral leg raise: in brief, the patients lie down on bed on the unaffected side, with the resistance band positioned around the distal thigh of the affected limb.;later, they raise the above lower limbs upwards for about 30 degrees, stay for 5- 10 s and slowly lay down[Xie et al.,2018].~pelvic lift training, specifically, patients stand single-leg off the side at a 10-cm step. Later, they begin with the other limb that is lower than the step level, and contract the stance-limb hip abductor to raise the free leg to the step level while keeping the stance knee extended[Xie et al.,2018].~Stretching Hamstrings [Fukuda et al.,2012]. Number of sets = 3, Repetitions =10 repetitions for each set"
89354794|NCT04503304|Active Comparator|KES group|"knee extensors strengthening group~Isometric quadriceps setting~Knee extensions from sitting with knee bend to 90~Terminal knee extension from sitting.~Stretching Hamstrings Number of sets = 3, Repetitions =10 repetitions for each set"
89354795|NCT01296659|Experimental|AIM Arm|Ridaforolimus combined with doxorubicin/ifosfamide/mesma (AIM)
89354796|NCT01296659|Experimental|TG Arm|Ridaforolimus combined with docetaxel and gemcitabine (TG)
89354797|NCT03122080|Active Comparator|Electroacupuncture group|electroacupuncture+standard care
89354798|NCT03122080|Placebo Comparator|Control A group|placebo acupuncture+standard care
89354799|NCT03122080|Other|Control B group|standard care
89354800|NCT03725683|Experimental|Incrementing groups|Each of the Increased caliber balloon capsules was predilated one by one, and the order of the increased balloon capsules was as follows: Balloon 2 diameter = target lesion reference vessel diameter minus 1; Balloon 3 diameter = target lesion reference vessel diameter;
89354801|NCT03725683|Experimental|matching groups|Pre-dilatation of the matched caliber balloon, whose diameter = the target lesion's diameter as a reference vessel, was applied.
89354802|NCT04502992|Other|Single Arm (pre-post, quasi-experimental)|Pre-post intervention, single arm. (Intervention was 4 weeks of Acceptance and Committment therapy, 2 times per week, 90 min per session, in a group setting).
89354803|NCT04313361||Smokers or Recent Smoking Quitters who Have lung Surgery|The enrolled eligible participants, that is smokers or recent smoking quitters, will be assessed for the current smoking status and smoking cessation attempts during the perioperative period, to describe postoperative complications (PCs) including postoperative pulmonary complications (PPCs) following a lung surgery, and to describe the smoking cessation methods and services participants received from their health care professionals (HCPs) and participant's satisfaction among participants with lung cancer, chronic obstructive pulmonary disorder (COPD), a pulmonary lesion (example nodule, ground glass opacity) or other pulmonary conditions who are admitted to the thoracic surgical unit of the participating hospitals in China.
89354804|NCT01190735|Experimental|Caffeine|Each patient will take pills twice per day containing 100-200 mg of caffeine (as synthetic caffeine alkaloid). Patients will be instructed to take whatever caffeine-containing beverages they are accustomed to taking, without changing their habitual schedule (note that all will be taking <200 mg per day). Caffeine intake will be assessed at each visit. Patients will continue their usual PD medications, without change in dose or timing for the entire duration of the study. Medication will be provided in pre-packaged dosettes.
89354805|NCT01296893|No Intervention|Delayed exercise control|Participants asked to maintain usual lifestyle and provided with abbreviated version of intervention upon completion of end of study testing.
89354806|NCT01296893|Experimental|Exercise|Aerobic exercise Intervention as per below
89354807|NCT05097118|Experimental|Group of Ketamine injection|Ketamine infiltration for post operative analgesia
89354808|NCT05097118|Experimental|Group of Bupivacaine injection|Bupivacaine infiltration for post operative analgesia
89354809|NCT03847103|Experimental|Robotic-aided rehabilitation with bilateral practice|In addition to a 10-minutes sensorimotor stimulation programs, the experimental group received 40-minutes Robotic-assisted Therapy with Bilateral Practice programs.
89354810|NCT03847103|Active Comparator|Unilateral task-specific training|In addition to a 10-minutes sensorimotor stimulation programs, the control subjects received 40-minute unilateral task-specific training.
89354811|NCT03602053|Experimental|ROTAVAC 5D|Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5D is in liquid form.
89354812|NCT03602053|Experimental|ROTAVAC®|Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.
89354813|NCT03602053|Active Comparator|Rotarix®|GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P[8] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.
89354814|NCT03351634|Experimental|Children with neurogenic incontinence with spinal dysraphism|
89354815|NCT01194713|Active Comparator|Sleep deprivation|"13 subjects will undergo full sleep deprivation~these subjects are blind to allocation ntil they enter the study center"
89354816|NCT01194713|No Intervention|Control night|control night of unrestricted sleep in 13 other subjects
89354817|NCT05584306|Experimental|610 30mg group|610 30 mg administered subcutaneously every 4 weeks
89354818|NCT05584306|Experimental|610 100mg group|610 100 mg administered subcutaneously every 4 weeks
89354819|NCT05584306|Experimental|610 300mg group|610 300mg administered subcutaneously every 4 weeks
89354820|NCT05584306|Placebo Comparator|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
89354821|NCT05584306|Placebo Comparator|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
89354822|NCT05584306|Placebo Comparator|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
89354823|NCT03351400|Experimental|Treatment group|Stem cells administered to participants
89354824|NCT01194791|Experimental|Lenalidomide, Cyclophosphamide and Dexamenthasone|
89354825|NCT04831515|Experimental|Lens A|"daily disposable soft contact lens - test lens~Subjects will be randomized to wear test lenses for one week and then cross-over to control lenses for one week."
89354826|NCT04831515|Active Comparator|Lens B|"daily disposable soft contact lens - control lens~Subjects will be randomized to wear control lenses for one week and then cross-over to test lenses for one week."
89354827|NCT03351322|Experimental|ENERGI-F701|ENERGI-F701, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
89354828|NCT03351322|Active Comparator|Regaine|Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
89354829|NCT01296971|Experimental|A|genotype 1, treatment-naive
89354830|NCT01296971|Experimental|B|genotype 2 and 3, treatment-naive
89354831|NCT01296971|Experimental|C|all genotypes, non-responders or relapses
89354832|NCT04697667|Experimental|Group I|Each subject in this group will receive a combined treatment protocol consisting of three PRP injections to knee joint and supervised exercise program.
89354833|NCT04697667|Active Comparator|Group II|Each subject in this group will receive a treatment of supervised exercise program.
89354834|NCT04697667|Active Comparator|Group III|Each subject in this group will receive a treatment of three PRP injections to knee joint.
89354835|NCT03554629|Other|Capnography CO2 Sampling Filterline Performance|Adult volunteer exhaled gas was sampled by 8 different CO2 cannula sampling filterline (CCSF) designs connected to a Capnostream 35 for measurement of CO2 during patient simulated scripted activities in order to assess patient interface design performance to provide a quality gas sample for CO2 partial pressure measurement.
89354836|NCT04691661|Placebo Comparator|Placebo: Dose escalation|Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.
89354837|NCT04691661|Experimental|Radotinib HCl: Dose escalation|"Forty (40) subject will be recruited and randomized into 4 dosing groups. In each dosing group, ten (10) will be randomized and 8 of 10 will receive the active product (Radotinib) and 2 subjects will receive the matching placebo orally once daily for 6 months at each escalating dose level.~The inclusion of subjects in the next dose level will be decided by the sponsor in consultation with a Data Monitoring Committee (DMC)."
89354838|NCT01194947||Study participants|patients 18 or older presenting to the Sheba Medical Center pigmented lesion clinic for skin cancer surveillance. Patients routinely undergo total skin examination that includes clinical and dermoscopic evaluation of skin lesions. Patients also routinely undergo annual total body digital photography that allows identification of new or changing lesions.
89354839|NCT01297049|Experimental|Lifestyle counseling|
89354840|NCT01314807||patients with COPD|patients who were defined as COPD, based on post-bronchodilator spirometry (GOLD criteria). Patients will have at least 10 pack years
89354841|NCT01314807||smoking controls|patients with at least 10 pack years who have no COPD (based on post-bronchodilator spirometry)
89354842|NCT01314807||non-smoking controls|patients with < 1 pack year who have no COPD (based on post-bronchodilator spirometry)
89354843|NCT03846869|Experimental|major cations|bood sample
89354844|NCT03196791|Experimental|Deep neuromuscular block group|Sugammadex sodium 4mg/kg/IV after operation
89354845|NCT03196791|Experimental|Moderate neuromuscular group|Sugammadex sodium 2mg/kg/IV after operation
89354846|NCT03347734|Experimental|Eye Exercises Group (EEG)|For the individuals in the group of eye exercises (GEG), 10 repetitive eye exercises protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
89354847|NCT03347734|Experimental|Convergence Exercise Group (CEG)|For the individuals in the group of convergence exercise, 5 minutes convergence exercise protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
89354848|NCT03347734|Experimental|Oculomotor Exercise Group (OMEG)|For the individuals in the group of oculomotor exercise, 10 repetitive, four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
89354849|NCT03846011||Experiment group|All eligible patients administered for active stone removal.
89354850|NCT05670899|Experimental|CAD PEEK frame-work|Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
89354851|NCT05670899|Active Comparator|CAD metallic frame-work|A metallic framework will be obtained using the conventional lost wax technique and casting. After de-investing, finishing and polishing, the framework will be fitted on the master cast. Intraoral try in of the framework will be done followed by bite registration record. The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally. The finished removable partial denture will then be checked intraorally for any needed modifications and finally delivered.
89354852|NCT05023174|Experimental|PRP|Patients in this treatment arm will have PRP injected into the crura of the diaphragm and coating the mesh placed during the hiatal hernia repair.
89354853|NCT05023174|Active Comparator|No PRP|Patients in this arm will undergo an identical surgical procedure, however will not have the addition of PRP injected into the cura of the diaphragm or onto the mesh placed during the hiatal hernia repair.
89354854|NCT03196635|Experimental|All Study Participants|All subjects will undergo their regularly scheduled full-field digital mammogram, consisting of bilateral, 2-view (craniocaudal [CC] and mediolateral oblique [MLO]) image acquisition. In addition, a study-specific, unilateral 2-view image set will obtained, utilizing the PA breast compression mode.
89354855|NCT01297127||Cohort|
89354856|NCT01195181|Active Comparator|peginterferon alfa-2a plus ribavirin|patients will receive a fixed dose of 180ug/week of peginterferon alfa-2a plus ribavirin at 15mg/kg/daily.
89354857|NCT01195181|Active Comparator|peginterferon alfa-2b plus ribavirin|patients will receive a weight adjusted dose (1,5ug/kg) from 50 to 150ug/week of peginterferon alfa-2b (standard dose) or a lower dose (1,0ug/kg) at physician discretion (randomization list available only for 100 cases) plus ribavirin at 15mg/kg/daily.
89354858|NCT05065437|Experimental|Virtual reality and spinal stimulation|Safety and feasibility of a virtual reality and spinal stimulation intervention will be tested.
89354859|NCT05441943|Experimental|Lymphovenous anastomosis surgery|Lymphovenous anastomosis surgery with pre-operative planning using ICG lymphography and ultra high frequency ultrasound.
89354860|NCT05600699||left bundle branch potential group|the left bundle branch potential was recorded at implantation
89354861|NCT05600699||Purkinje potential group|the purkinje potential was recorded at implantation
89354862|NCT05600699||no-potential group|no potential was recorded at implantation
89354863|NCT05047341|Experimental|Single arm|
89354864|NCT03845855|Experimental|Virtual reality with robotic gait|virtual reality treatment with robotic gait therapy 2 times for week by 6 weeks.
89354865|NCT03845855|Active Comparator|Robotic gait therapy only|only robotic gait therapy 2 times for week by 6 weeks
89354866|NCT01196897|Experimental|Implantable device|WATCHMAN LAA Closure Technology (Gen 4.0)
89354867|NCT01197053|Experimental|100 mcg DBV712 (active)|100 mcg DBV712 administered epicutaneously every 24 hours.
89354868|NCT01197053|Placebo Comparator|Placebo|Placebo will be administered epicutaneously every 24 hours
89354869|NCT05671133|Experimental|Experimental|Patient's clinician is given Clinician Decision Support Tool
89354870|NCT05671133|No Intervention|Control|Patient's clinician is not given Clinician Decision Support Tool (care as usual)
89354871|NCT03845777||Surgical Staff|The surgical staff group is the only group of the study. Blood samples of the surgical staff before and after the using antiseptics solution that include iodine were analyzed.
89354872|NCT03846713|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
89354873|NCT03846713|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
89354874|NCT03194217|Experimental|BEN-2001, 0.5mg|Experimental treatment
89354875|NCT03194217|Placebo Comparator|Placebo|Placebo comparator
89354876|NCT03194217|Experimental|BEN-2001, 1.0mg|Experimental treatment
89354877|NCT03194217|Experimental|BEN-2001, 3.0mg|Experimental treatment
89354878|NCT01197131||autistic boys|Boys with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician
89354879|NCT01197131||autistic girls|Girls with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician.
89354880|NCT01197131||control boys|"Healthy boys, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger-Syndrome (MBAS)."
89354881|NCT01197131||control girls|"Healthy girls, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger Syndrome (MBAS)."
89354882|NCT01195259||metformin|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
89354883|NCT01195259||rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
89354884|NCT05584228|Experimental|Medical treatment|Combination therapy with subcutaneous infliximab and azathioprine
89354885|NCT05584228|Active Comparator|Surgery|Intestinal resection
89354886|NCT03193047|Experimental|bempedoic acid|Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
89354887|NCT03193047|Placebo Comparator|placebo|Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
89354888|NCT01197209|Experimental|Ad-REIC/Dkk-3 Arm|Active arm on Ad-REIC/Dkk-3
89354889|NCT03346720||Participants recruited into biomedical research|Participants recruited into biomedical research where data collected may be shared with the wider research community.
89354890|NCT03346720||Frontline research staff|Frontline research staff directly involved in obtaining consent from participants in the above studies e.g. study nurses, investigators
89354891|NCT03346720||Research related staff and other stakeholders|Research related staff and other stakeholders involved in the implementation of the data sharing policy e.g. study managers, data access committee members, ethics committee members, study nurses, investigators, research collaborators, data managers and other clinical trials support staff.
89354892|NCT03346720||Community advisory board members|Community advisory board members and other community members
89354893|NCT04970212||Study Arm|Subjects will receive your standard liver ablation procedure, including ultrasound images. Data will be collected from the standard liver ablation procedure, including imaging. Subjects will receive a CT scan within 24 hours after the liver ablation procedure. There will then be an analysis of ultrasound images and research CT scan.
89354894|NCT01195337||Study Group|Newsletters, Physical Activity (PA) Prescription Plan, Pedometer
89354895|NCT04504552|Experimental|Single Arm Avelumab|Avelumab monotherapy on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
89354896|NCT01197287|Experimental|QAK423A Arm A|
89354897|NCT01197287|Experimental|QAK423A Arm B|
89354898|NCT01197287|Experimental|QAK423A Arm C|
89354899|NCT03351166|Experimental|Molidustat (BAY85-3934)|Molidustat group
89354900|NCT01197365|Experimental|STUDY GROUP|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
89354901|NCT01197365|Other|CONTROL GROUP|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
89354902|NCT03351088|Other|Preventive ligation|Preventive ligation of DVC is done after the opening of endopelvic fascia and before bladder neck dissection. DVC is ligated at the level of the apex with a 8-fashion single stich (1-0 Monocryl® CT-1 stich) trying to preserve puboprostatic ligaments and the muscle fibres of the rabdosphincter. DVC is then dissected at the end of prostatectomy before the section of the urethra.
89354903|NCT03351088|Other|Delayed ligation|Delayed ligation is done after the section of the urethra and once the prostatectomy is completed with a single stich (3-0 Monocryl® UR-6).
89354904|NCT03845387|Experimental|KDT-3594|
89354905|NCT03845387|Other|Pramipexole|Reference drug
89354906|NCT05584072||Active pedal plantarflexion (APP) test|
89354907|NCT01197443|Experimental|Parent-only Group|Treatment will be administered to parents of the overweight child. Parent-only group treatment will include all of the same skills and techniques to promote weight loss, but the information will be delivered only to the parent. Participation of the children assigned to the parent-only treatment arm will be limited to the baseline and follow-up assessments.
89354908|NCT01197443|Active Comparator|Parent + child Group|The treatment for participants in the parent + child arm will be administered in two separate groups, one for the parents and one for the child.
89354909|NCT01197599||Spinal Cord Injury|
89354910|NCT01197599||Able-Bodied Control|
89354911|NCT03351010|Experimental|Mindfulness|Receiving education program and mindfulness training
89354912|NCT03351010|Active Comparator|Control|Receiving education program
89354913|NCT01295177|Placebo Comparator|vehicle cream|Intervention: Placebo cream vehicle. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream (cream with the same constitution but without insulin). The placebo cream vehicle was used for 8 weeks.
89354914|NCT01295177|Placebo Comparator|cream insulin|Intervention: insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with insulin cream (cream with the same constitution but with insulin). The insulin cream was used for 8 weeks.
89354915|NCT02918019|Experimental|MSTT1041A 210 mg|Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
89354916|NCT02918019|Experimental|MSTT1041A 490 mg|Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
89354917|NCT02918019|Experimental|MSTT1041A 70 mg|Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
89354918|NCT02918019|Placebo Comparator|Placebo|Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.
89354919|NCT03350932|No Intervention|Control|This group of children, will have to perform a sensory imagination task about neutral facts before choosing the portion size of a food.
89354920|NCT03350932|Experimental|Food sensory imagination|"This group, the food sensory imagination group, will have to perform a sensory imagination task foods (being the intervention) before choosing the portion size of a food."
89354921|NCT01295333|Other|conventional approach|conventional traitment
89354922|NCT01295333|Experimental|experimental approach|early and systematic traitment
89354923|NCT04848454|Experimental|Experimental group|"Drug:~Vinorelbine i.v. 25 mg/m2, d1, d8 or p.o. 60-80 mg/m2 d1, d8; q3w; for 6 cycles.~Cisplatin i.v. 75 mg/m2，d1, d2; q3w; for 6 cycles. Camrelizumab i.v. 200mg, q3w; for 17cycles (1 year)."
89354924|NCT04842292|Experimental|Nebulized heparin|Nebulized heparin 25,000 units in 3 mL inhalation every 6 hours
89354925|NCT04842292|Placebo Comparator|Nebulized placebo|Sodium chloride 0.9% 5 mL inhalation every 6 hours
89354926|NCT01191905|Experimental|High dose CRRT|Clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
89354927|NCT01191905|Active Comparator|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
89354928|NCT01191983|Experimental|Methoxy polyethylene glycol-epoetin beta|Participants will receive 1.2 mcg/kg methoxy polyethylene glycol-epoetin beta given in monthly doses at each visit. Dose will be measured on the basis of the participants Hb level during the study period. The dose administration will be the nearest possible dose using the prefilled syringes containing 50, 75 and 100 mcg/kg Q4W.
89354929|NCT03350854|No Intervention|The non-intervention control group|In the non-intervention control group, providers are blind to the patient's preferred decision making role.
89354930|NCT03350854|Experimental|The intervention group|The provider will be informed of the patient preference in treatment decision making (preferred role) and have a discussion about this with the patient in the intervention group.
89354931|NCT01192061||Normal tension glaucoma group|
89354932|NCT01192061||Control group|
89354933|NCT03055988|Experimental|Tiotropium/Olodaterol Fixed Dose Combination|
89354934|NCT03055988|Active Comparator|Fluticasone Propionate + Salmeterol Fixed Dose Combination|
89354935|NCT03346642|Experimental|GVD and SHR-1210 with or without Decitabine|This is a two stage study. For the first stage, the participants will receive the combination of GVD chemotherapy and PD-1 antibody SHR-1210. The patients enrolled into the second stage will received the combination of GVD and SHR-1210 with low-dose decitabine primed.
89354936|NCT03636321|Experimental|intraductal stent|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis with internal biliary stent
89354937|NCT03636321|Active Comparator|stentless|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis will done without internal biliary
89354938|NCT01192217|Active Comparator|VATS group|
89354939|NCT01192217|Active Comparator|Mini-thoracotomy group|
89354940|NCT02473107|Other|Control Caries Detection Strategy|Detection and treatment based on more advanced lesions, despite activity status - Advanced caries lesions detection (no activity assessment)
89354941|NCT02473107|Other|Test Caries Detection Strategy|Detection and treatment based on all detected caries lesions, considering their activity status as a differential in clinical decision-making - All caries lesions detection (+activity assessment)
89354942|NCT05583916|Other|Lung Cancer Patients|Patients with stage I or II primary lung cancer or pulmonary metastasis scheduled to undergo surgery.
89354943|NCT05668325|Experimental|Mini trampoline exercise group|"Structured Patient Information Form and Foot care behavior scale, 5.07/10 g Semmes-Weinstein Monofilament, 128 Hz Manual Electronic Tunnel and Goniometer were applied to the patients as a pre-test and recorded in the patient registry. related forms. Afterwards, diabetic foot care information was given to the patients and Diabetic Foot Care Information Brochure was given. Afterwards, the patients were visited for a total of 24 times a week, three days a week for eight weeks. At the first visit, the patients were informed about the exercise program and then the Home-based Mini Trampoline Exercise Information Brochure was given to the patients. The patients were given an exercise program three times a week, a total of 24 times for eight weeks. In addition, the Foot Monitoring Form was applied to the patients once a week. Apart from the Structured Patient Information Form, other data collection tools were applied to this patient group as a post-test."
89354944|NCT05668325|Experimental|Control group|"Data collection tools were applied to this group of patients before the study. Diabetic foot care information was given and Diabetic Foot Care Information Brochure was given. A total of eight home visits were made for eight weeks, once a week, and the Foot Monitoring Form was applied. At the end of eight weeks, all data collection tools except the Structured Patient Information Form were applied again."
89354945|NCT02912949|Experimental|Part 2 Pancreatic adenocarcinoma harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
89354946|NCT02912949|Experimental|Part 2 NSCLC cancer harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
89354947|NCT02912949|Experimental|Part 2 Solid tumour (basket) harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
89354948|NCT03496636|Experimental|Ovarian tissue transplant|Transplantation of ovarian tissue into the abdomen. Only for patients who have previously frozen ovarian tissue
89354949|NCT01250912|Experimental|Imaging Tracer|No arms, the Radio tracer will be used in all subjects imaging tests.
89354950|NCT05583682|Experimental|Nano-filled resin-modified glass ionomer restoration|One of the carious mandibular first molar teeth will be restored according to randomisation with nano-filled resin-modified glass ionomer restorative material (Ketac N 100/3M ESPE, USA)
89354951|NCT05583682|Experimental|Sub-micron hybrid resin composite|One of the carious mandibular first molar teeth will be restored according to randomisation with sub-micron hybrid resin composite restorative material (Spectrum TPH3, Dentsply Caulk, USA)
89354952|NCT04780724|Experimental|Hypoxic|Participants inhale ambient air, the hypoxic gas mixture, and ambient air.
89354953|NCT04780724|Experimental|Hypercapnic|Participants inhale ambient air, the hypercapnic and hypoxic gas mixture, and the ambient air.
89354954|NCT05216276|Active Comparator|TEP|Patient with uni- or bilateral inguinal hernia receiving a laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair.
89354955|NCT05216276|Experimental|rTAPP|Patient with uni- or bilateral inguinal hernia receiving a robotic transabdominal preperitoneal (TAPP) inguinal hernia repair.
89354956|NCT03636087|Active Comparator|Conventional|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
89354957|NCT03636087|Experimental|Enhanced sterile protocol|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Changing gloves before obturation Disinfecting rubber dam The use of new instruments at time of obturation Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
89354958|NCT03733301|Experimental|4 Milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.
89354959|NCT03733301|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.
89354960|NCT03733301|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with TCS.
89354961|NCT04767334|Experimental|Gait training on Lower body positive pressure|"All participants will have gait training for 40 minutes a day, for three days a week, for six weeks. On session one, the lower body positive pressure chamber will be set to unload 50% of patient's body weight.On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
89354962|NCT05583214|Experimental|Ondansetron|Patients given Ondansetron (8mg)
89354963|NCT05583214|Experimental|Dexamethasone|Patients given Dexamethasone (8mg)
89354964|NCT05583214|Placebo Comparator|Placebo|
89354965|NCT02895711||Patients with urolithiasis|To record the effective radiation dose to the patient during endourologic procedures to treat urolithiasis
89354966|NCT04502680|Experimental|Eribulin Mesylate|Patients receive eribulin mesylate following standard adjuvant chemotherapy.
89354967|NCT04502680|No Intervention|Observation|Observation. No intervention.
89354968|NCT04768478|Active Comparator|Cannabidiol (CBD)|
89354969|NCT04768478|Placebo Comparator|Control|
89354970|NCT02871297|Experimental|Vortioxetine|Vortioxetine tablets for 26 weeks. Single dose of vortioxetine oral drops (only a subset of participants).
89354971|NCT04758104|Experimental|Yttrium90|Intracystic application of yttrium90
89354972|NCT03121924|Experimental|Immediately oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~The first arm is the immediately denudation and immediately ICSI of the oocytes, and in the second arm the oocyte are denuded and injected after 4 hours from the pick up ."
89354973|NCT03121924|Experimental|Delayed oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~In this arm, the oocyte are denuded and injected after 4 hours from the pick up ."
89354974|NCT03628430|Placebo Comparator|Group C|"For patients of this group, the intervention was a Local Anesthesia with:~10 mL of 2% lidocaine with epinephrine 0.005mg/ml~and 5 mL of 0.9% NaCl"
89354975|NCT03628430|Active Comparator|Group A|"For patients of this group, the intervention was a Local Anesthesia with:~10 mL of 2% lidocaine with epinephrine 0.005mg/ml~and 5 mL of 4.2 % sodium bicarbonate"
89354976|NCT03121846|Experimental|apatinib group|apatinib 500mg po qd, 28 days for a cycle.
89354977|NCT03628352|Experimental|Tricaprilin|Approximately 5 mL liquid of tricaprilin using various flavoring agents (swish and expectorate) up to 20 times. Dose will not be ingested.
89354978|NCT03122314|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
89354979|NCT03122314|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
89354980|NCT03554005|Experimental|PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)|Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
89354981|NCT03554005|Experimental|PEG Interferon Alfa-2b 1.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 1.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
89354982|NCT03554005|Experimental|PEG Interferon Alfa-2b 3 mcg/kg OW|Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
89354983|NCT03554005|Experimental|PEG Interferon Alfa-2b 4.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
89354984|NCT03554005|Experimental|PEG Interferon Alfa-2b 6 mcg/kg OW|Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
89354985|NCT03554005|Experimental|PEG Interferon Alfa-2b 7.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
89354986|NCT01314573|Experimental|Interval maximal exercise|Interval exercise involving repeated Wingate tests (30s durations of maximal exercise on a cycle ergometer).
89354987|NCT01314573|Experimental|Continuous maximal exercise|Continuous exercise of maximal exertion that has been work matched to an initial bout of interval exercise of 4 x 30s of maximal exercise. This exercise is performed on a cycle ergometer.
89354988|NCT00709228||PegIntron plus Rebetol|Those with chronic Hepatitis C infected with HCV LVL G1
89354989|NCT01584557|Active Comparator|Tolvaptan, Samsca|Tolvaptan, Samsca, uncoated tablet, 30 mg, once per day, up to 7 days.
89354990|NCT01584557|Placebo Comparator|sugar pill|placebo, sugar pill
89354991|NCT03728491|Experimental|Healthy Figurant|Hands-on training on healthy figurants for gaining competence in TUS
89354992|NCT03728491|Experimental|Simulator|Hands-on training on US Mentor simulator for gaining competence in TUS
89354993|NCT03728491|No Intervention|Controls|Controls with no hands-on training
89354994|NCT01587599|Active Comparator|Pharmaceutical care|
89354995|NCT01587599|Placebo Comparator|Standard care|
89354996|NCT05215964||TAE arm|Patients will receive TAE
89354997|NCT03728413|Other|Elderly Non-smoking|RSV A Memphis 37 will be given as intra-nasal drops.
89354998|NCT03728413|Other|Elderly ex and current smokers|RSV A Memphis 37 will be given as intra-nasal drops.
89354999|NCT03728413|Other|Young non-smokers|RSV A Memphis 37 will be given as intra-nasal drops.
89355000|NCT01192373|Experimental|High circulating free fatty acids|using Heparin af intralipid infusion for 8 hours
89355001|NCT01192373|Active Comparator|Low circulation free fatty acids|using hyperinsulinaemic euglycemic clamp for 8 hours
89355002|NCT01310491|No Intervention|Usual Care|
89355003|NCT03847025||Lead extraction|Patients undergoing clinically indicated lead extraction procedures.
89355004|NCT05215028||users|users of the web-application MALO
89355005|NCT03725527|Active Comparator|Rectus sheath catheter block|Patients will receive ultrasound-guided rectus sheath block with catheter insertion performed after induction of general anesthesia and before surgery.
89355006|NCT03725527|Active Comparator|Epidural Catheter block|Patients will receive thoracic epidural at the level of T7 performed before anesthesia induction.
89355007|NCT05283317|Active Comparator|Patients received MSCs|10 patients with sepsis and septic shock and received MSCs&standart therapy
89355008|NCT05283317|No Intervention|Patients not received MSCs|20 patients with sepsis and septic shock and not received MSCs, only received standart therapy
89355009|NCT05670665||Non-exposed|Low-risk, singleton pregnancies.
89355010|NCT05670665||Exposed|Singleton pregnancies that are admitted to hospital due to threatened preterm labor or preterm premature rupture of membranes.
89355011|NCT02606799|No Intervention|Standard Care|intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required
89355012|NCT02606799|Experimental|CytoSorb|all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination
89355013|NCT05214872||PREDIALYSIS GROUP|(n = 48) - patients in the pre-dialysis period (stages G3b-G4 of chronic kidey disease (CKD)) with moderate or severe decrease in estimated glomerular filtration rate (eGFR) (eGFR 44-29 ml/min/1.73 m^2)
89355014|NCT05214872||END-STAGE RENAL DISEASE (ESRD) GROUP|"Patients with ESRD (n=106) - (eGFR <15 ml/min /1.73 m^2) undergoing renal replacement therapy have formed this group.~Depending on the method of renal replacement therapy used, two subgroups have been distinguished: (1) peritoneal dialysis (PD) subgroup (n=35) including patients treated by peritoneal dialysis. In this subgroup, due to the treatment technique, two groups have been distinguished, a group (n=15) treated with the automatic peritoneal dialysis (APD) technique and a group (n = 20) using the technique of continuous cycling peritoneal dialysis (CCPD), (2) hemodialysis (HD) subgroup (n = 71) including patients treated with repeated hemodialysis. The duration of hemodialysis was at least 10 hours/week using standard bicarbonate dialysis fluids and polysulfone low-flux dialyzers. The blood flow during hemodialysis was 200-350 ml/min, with an average dialysis fluid flow of 500 ml/min."
89355015|NCT05214872||CARDIOLOGY (CARD) GROUP|"CARD group (n = 37) - patients with at least one history of a cardiovascular event, admitted to hospital for elective angiography, without any signs of impaired kidney function.~The studies in this group were conducted to check the changes that occur as a result of cardiovascular disease (CVD) but without kidney disease."
89355016|NCT05214872||Chronic kidney disease (CKD) 1-2 GROUP|"CKD1-2 (n=29) (stage G1-G2 CKD) with mild decrease in eGFR (eGFR >90-60 ml/min/1.73 m^2)~The studies in this group were performed to disclose the changes that occur as a consequence of the beginning of kidney function deterioration."
89355017|NCT05214872||Healthy volunteers (HV)|HV (n = 32) - this group was composed of healthy people, with no evidence of impairment in renal function and cardiovascular disorders in the history and at the time of enrollment in the study.
89355018|NCT01195571|No Intervention|vaccine administration|Each subject will receive on of four chimera CMV vaccines
89355019|NCT01330095|Active Comparator|Eearly administration|Administration of Bifidobacterium within 48h after birth
89355020|NCT01330095|Active Comparator|Late administration|Administration of Bifidobacterium more than 48h after birth
89355021|NCT01197989|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
89355022|NCT01197989|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
89355023|NCT03219372|Experimental|Pravastatin Pill|Daily pravastatin (40mg)
89355024|NCT03219372|Placebo Comparator|Placebo Oral Tablet|Placebo
89355025|NCT02427867|Experimental|remote ischemic preconditioning|Three cycles of 5 minutes ischemia will be applied to the upper left arm (or right arm or legs if the left arm will not be deemed suitable by the attending physician), achieved by inflation of a blood-pressure cuff to 200 mm Hg, followed by 5 minutes reperfusion while the cuff will be deflated.
89355026|NCT02427867|Placebo Comparator|no ischemic preconditioning|The cuff will be placed around the arm but not inflated.
89355027|NCT05668247|Experimental|Intervention|foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group. The bucket has a five-level water heating system (35-48 °C). It has a magnetic field and operates at 390 Watt. It has a splash shield. There are non-slip rubber legs on its bottom. it has heat protection feature for thermal insulation as it has a two-walled structure
89355028|NCT05668247|No Intervention|Control|"On the first day (the first follow-up), Patient Information Form, PSQI (ANNEX-II) and Piper Fatigue Scale were applied to the patients in the control group whose consent was obtained in the first follow-up, through face-to-face interview. At the end of the 30th day (the second follow-up), PSQI and Piper Fatigue Scale were applied again to the patients who came for the outpatient clinic control.~The routine treatment of the control group was not interfered and no intervention was performed."
89355029|NCT05214638||Assessed with the paper version of Longshi Scale first and then with electronic version|
89355030|NCT05214638||Assessed with the electronic version of Longshi Scale first and then with the paper version|
89355031|NCT03628040|Sham Comparator|Sham Block|Patient will receive a single shot of normal saline 20 mL injected at the erector spinae plane
89355032|NCT03628040|Active Comparator|Erector Spinae Block|Patient will receive a single shot of Ropivacaine Injection [Naropin] 0.5% 20 mL injected at the erector spinae plane
89355033|NCT04715763|Active Comparator|Telmisartan (80 mg)|Telmisartan 80 mg (given as two 40 mg encapsulated tablets) given orally each day x 21 days
89355034|NCT04715763|Placebo Comparator|Placebo|Two placebo capsules given orally each day x 21 days
89355035|NCT04487210|Experimental|Phase 1a (Low Dose)|15 subjects will be enrolled to receive Low-dose S-protein with adjuvant MVC-COV1901.
89355036|NCT04487210|Experimental|Phase 1b (Medium Dose)|15 subjects will be enrolled to receive Medium-dose S-protein with adjuvant MVC-COV1901.
89355037|NCT04487210|Experimental|Phase 1c (High Dose)|15 subjects will be enrolled to receive High-dose S-protein with adjuvant MVC-COV1901.
89355038|NCT01295411|Other|schizophrenia PATIENTS|
89355039|NCT01330173|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
89355040|NCT03848741|Placebo Comparator|Non-exercise control with placebo|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the β-hydroxy β-methylbutyrate (HMB) Plus Vitamin D (VitD) capsules.
89355041|NCT03848741|Experimental|Non-exercise control with HMB+VitD|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
89355042|NCT03848741|Active Comparator|Resistance exercise training with placebo|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the HMB + VitD capsules.
89355043|NCT03848741|Experimental|Resistance exercise training with HMB+VitD|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
89355044|NCT03356626|Experimental|ULTRACISION Harmonic Scalpel|Patients group randomized to use ULTRACISION Harmonic Scalpel when receives laparoscopic gastrectomy
89355045|NCT03356626|Experimental|Ligasure Maryland|Patients group randomized to use Ligasure Maryland when receives laparoscopic gastrectomy
89355046|NCT03356626|Experimental|Thunderbeat|Patients group randomized to use Thunderbeat when receives laparoscopic gastrectomy
89355047|NCT04540458|Other|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
89355048|NCT04540458|Other|Placebo|Mother or Mother/Father is given printed picture of 3D ultrasound of fetus
89355049|NCT01295489||Group A (IP catheter removed)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and blood (for cell, plasma, and serum isolations) is collected before courses two and three for translational research.
89355050|NCT01295489||Group B (IP catheter in place)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolations) before courses two and three for translational research.
89355051|NCT04361266|Experimental|Rotium patch recipient|Subjects with Rotium nano scaffold patch included in rotator cuff repair construct
89355052|NCT04361266|Active Comparator|Control|Subjects undergoing non-patch augmented rotator cuff repair
89355053|NCT04659746|No Intervention|Control|Participants allocated to the control group will receive the routine care and follow-up for chronic patients in Pandemic situation at Hospital Regional de Encarnación (Encarnación, Paraguay), according to epidemiological surveillance and preventive isolation management protocol released by the Ministry of Health of Paraguay (URL: https://www.mspbs.gov.py/dependencias/portal/adjunto/c1c79a-ProtocoloVigilanciaEpidemiolgica.pdf)
89355054|NCT04659746|Experimental|Intervention|"Participants allocated to the intervention group will follow the same routine care as the control group. Additionally, they will receive access to the MejoraCare app.~The MejoraCare app delivers the following functionalities:~Remote symptoms monitoring through an electronic Patient Reported Outcome (ePRO)~Patient empowerment through personalized educational resources promoting healthy lifestyles"
89355055|NCT04338828|Experimental|Treatment Group|Inhaled nitric oxide
89355056|NCT04338828|Placebo Comparator|Control Group|Inhaled supplemental oxygen
89355057|NCT01295567|Placebo Comparator|placebo|
89355058|NCT01295567|Experimental|dipyridamole|
89355059|NCT04656080||transplant recipients <1year without AMR|20 recent transplant recipients (<1 year) without antibody-mediated rejection (AMR);
89355060|NCT04656080||3 months post-heart transplant with AMR|• 7 transplant recipients, at least 3 months post-transplant, with antibody-mediated rejection
89355061|NCT03848585|Experimental|Pilloxa Pillbox|
89355062|NCT03848585|Sham Comparator|Non active Pilloxa Pillbox|
89355063|NCT01192529|Experimental|Experimental Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of Supressi nutritional supplement"
89355064|NCT01192529|Active Comparator|Control Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of T-Diet plus High Protein product"
89355065|NCT01195649||Group 1|
89355066|NCT02226796|Active Comparator|Prime Condition|The primed (PRIME) condition is an intervention that will consist of presentation of a-tDCS for 20 minutes to the dorsolateral prefrontal cortex prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
89355067|NCT02226796|Active Comparator|Non-Prime Condition/Control|The non-primed (NON-PRIME) condition, or sham controlled, is an intervention that will consist of presentation of sham tDCS to the dorsolateral prefrontal cortex for 20 minutes prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
89355068|NCT03056690|Experimental|ASP0819|Participants received ASP019 15 mg capsules, orally, once daily in the morning, with or without food for 8 weeks.
89355069|NCT03056690|Placebo Comparator|Placebo|Participants received ASP019 matching placebo capsules, orally, once daily in the morning, with or without food for 8 weeks.
89355070|NCT04895267|Experimental|Real Low-field thoracic magnetic stimulation (LF-ThMS)|Crossover, single-blind session of low field thoracic magnetic stimulation (real LF-ThMS)
89355071|NCT04895267|Sham Comparator|Sham Low-field thoracic magnetic stimulation (LF-ThMS)|In the same patients the coils are positioned in the same coordinates for sham exposure, but the pulse generator is not turned on. Subjects are blinded for the real LF-ThMS or sham stimulation conditions.
89355072|NCT03846557||Treatment|Transcatheter Aortic Valve Implantation (TAVI)
89355073|NCT03191799|Experimental|1.5 mg/kg Emicizumab QW|Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period
89355074|NCT03845309|Experimental|Nutritional intervention for CHF|
89355075|NCT01195727|Experimental|Group 5A - Apixaban (Low Dose)|"Group 5: 12 years to <18 years;~0.66 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
89355076|NCT01195727|Experimental|Group 5B - Apixaban (High Dose)|"Group 5: 12 years to <18 years;~1.32 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
89355077|NCT03848507|Experimental|20% Albumin|Administration of 3ml per kg bodyweight of 20% albumin within 30 min during cystectomy.
89355078|NCT04958876|Experimental|SP-104 crossover to naltrexone immediate release|SP-104 administration followed by a crossover to naltrexone immediate release oral capsule administration
89355079|NCT04958876|Experimental|Naltrexone immediate release crossover to SP-104|Naltrexone immediate release oral capsule administration with a crossover to SP-104 administration
89355080|NCT01195805|Active Comparator|Amiloride|
89355081|NCT01195805|Active Comparator|Spironolactone|
89355082|NCT01195805|Placebo Comparator|Placebo|1 tablet twice a day for 28 days
89355083|NCT03627962|Experimental|gaze-directed oculomotor training|device: Tobii PCEye Treatment group went through the oculomotor training with a gaze-pointer interface (Tobii PC Eye) in reading in Chinese.
89355084|NCT03627962|No Intervention|control|No intervention: participants in control read ordinary Chinese textbooks.
89355085|NCT04899986|Experimental|Trial Group|Patients from this group will use chlorhexidine Biorepair gel and toothpaste for home oral care.
89355086|NCT04899986|Active Comparator|Control Group|Patients from this group will not use chlorhexidine and Biorepair gels and toothpastes, but will perform home oral care with standard toothpastes.
89355087|NCT01192685|Other|Depressed outpatients treated with TMS|This a 12- week study (1-4 week screening, 6 weeks treatment, 2 weeks follow-up) outpatient open label clinical trial. Twenty-five subjects diagnosed with depression with a Montgomery Asberg Depression Rating Scale (MADRAS) score of 26 or higher, will be enrolled into this trial, up to fifty subjects will be consented. Transcranial Magnetic Stimulation (TMS) will be administered to subjects 5 days a week for 6 weeks. Near infrared spectroscopy (NIRS), a spectroscopic method that uses the near infrared region of the electromagnetic spectrum (from about 700 nm to 2500 nm), will be used to assess blood flow in the brain.
89355088|NCT04709679|Experimental|Constant dwell time but varying power and duration|The laser dwell time will be constant but the laser power and duration will be varied for patients
89355089|NCT04709679|Experimental|Constant power but varying dwell time and duration|The laser power will be constant but the laser dwell time and duration will be varied for patients
89355090|NCT04709679|Experimental|Constant duration but varying dwell time and power|The laser duration will be constant but the laser dwell time and power will be varied for patients
89355091|NCT03845231|Other|unvaccinated|will receive no Flucelvax vaccination and will receive human challenge virus
89355092|NCT03845231|Experimental|Vaccinated|will receive Flucelvax vaccination and human challenge virus
89355093|NCT05126537||Health volunteers|Health volunteers as control group
89355094|NCT05126537||ICU non-sepsis patients|ICU non-sepsis patients as control group
89355095|NCT05126537||Sepsis patients|Sepsis patients as study group
89355096|NCT03845153|Active Comparator|Metformin|20 post-menopausal women with a bone fracture treated with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily for three months.
89355097|NCT03845153|Placebo Comparator|Placebo|20 post-menopausal women with a bone fracture treated with placebo once daily for two weeks then twice daily for three months.
89355098|NCT00198718|Experimental|Infant vitamin A Mother vitamin A|Infant received 50,000 IU vitamin A, mother received 400,000 IU vitamin A
89355099|NCT00198718|Experimental|Infant vitamin A Mother placebo|Infant received 50,000 IU vitamin A, mother received placebo
89355100|NCT00198718|Experimental|Infant placebo, mother vitamin A|Infant received placebo, mother received 400,000 IU vitamin A
89355101|NCT00198718|Experimental|Infant received placebo, mother received placebo|Infant and mother received placebo
89355102|NCT03951116|Experimental|Dose escalation cohort of FCN-437c|"The dose-escalation cohort:~Participants will receive FCN-437c monotherapy once daily (QD) for 21 days followed by a 7 day rest period (28-day cycle).~FCN-437c will be administered orally.~Participants with histologically or cytologically confirmed advanced unresectable/metastatic solid tumor will participate in this cohort."
89355103|NCT04500808|Experimental|Part 1: Double Blind Phase|Participants will receive macitentan or matching placebo from Day 1 up to Day 13 under fed conditions and will be up-titrated starting with 2 once daily (QD) dosing of Dose 1 from Days 1 to 2 followed by 3 qd doses of Dose 2 of macitentan from Days 3 to 5, followed by qd doses of Dose 3 macitentan from Days 6 to 13.
89355104|NCT04500808|Experimental|Part 2: Open Label Phase: Treatment Sequence AB|Participants will receive Dose 3 of macitentan under fasted conditions (Treatment A) in period 1 followed by Dose 3 of macitentan under fed condition (Treatment B) in period 2 on Day 1 with a washout phase of at least 14 days between the two treatment periods.
89355105|NCT04500808|Experimental|Part 2: Open Label Phase: Treatment Sequence BA|Participants will receive Treatment B in period 1 followed by Treatment A in period 2 on Day 1 with a washout phase of at least 14 days between the two treatment periods.
89355106|NCT03628274|Experimental|Magnetic Resonance Imaging (RMI) 7 Tesla|
89355107|NCT01192763|Experimental|Arm I|Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Beginning 7 days after completion of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the anatomic location of the cancer. Tumor tissue from biopsy and surgery and blood samples are collected periodically for pharmacodynamic studies.
89355108|NCT02517970|Experimental|Classical Music versus Television show|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
89355109|NCT01192841|No Intervention|White coat group|Participants continued their regular practice of wearing their physician white coat.
89355110|NCT01192841|Experimental|Uniform group|Participants were given a clean uniform (scrubs) at the beginning of the day.
89355111|NCT01192919||Patients with lung cancer|Patients with lung cancer requiring therapy
89355112|NCT00708916|Experimental|Apremilast|CC-10004 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
89355113|NCT01196039|Experimental|A|
89355114|NCT01196039|Placebo Comparator|B|
89355115|NCT02352753|Experimental|Denosumab|"Participants received denosumab 1 mg/kg (up to a maximum of 60 mg) subcutaneously every 6 months (Q6M) for up to 36 months.~Early efficacy and PK data from Q6M dosing supported adjustment of the dosing regimen from Q6M to every 3 months (Q3M). Participants enrolled and still receiving denosumab were transitioned from Q6M to Q3M dosing schedule. Participants could transition to Q3M dosing schedule up to and including the date they attended for their month 36 visit under the Q6M dosing regimen. Those participants received denosumab during the Q3M dosing regimen for 12 months. Participants who transition to Q3M at month 18 of the Q6M dosing regimen received denosumab Q3M for up to 18 months."
89355116|NCT01192997|Active Comparator|Menveo-Meningitec|Subjects who were primed with Meningitec who will receive Novartis Menveo
89355117|NCT01192997|Active Comparator|MenACWY-TT-Meningitec|Subjects who were primed with Meningitec who will receive GSK MenACWY-TT
89355118|NCT01192997|Active Comparator|Menveo-Menjugate|Subjects who were primed with Menjugate who will receive Novartis Menveo
89355119|NCT01192997|Active Comparator|MenACWY-TT-Menjugate|Subjects who were primed with Menjugate who will receive GSK MenACWY-TT vaccine.
89355120|NCT01192997|Active Comparator|Menveo-NeisVac-C|Subjects who were primed with NeisVac-C who will receive Novartis Menveo
89355121|NCT01192997|Active Comparator|MenACWY-TT-NeisVac-C|Subjects who were primed with NeisVac-C who will receive GSK MenACWY-TT vaccine
89355122|NCT04532294|Experimental|BGB-DXP593: Dose Level A|Participants will receive BGB-DXP593 10 mg/kg on Day 1
89355123|NCT04532294|Experimental|BGB-DXP593: Dose Level B|Participants will receive BGB-DXP593 30 mg/kg on Day 1
89355124|NCT04532294|Experimental|Placebo|Placebo to match (PTM) BGB-DXP593 on Day 1
89355125|NCT02517736|Experimental|sorafenib at a dose of 800 mg / day|
89355126|NCT03347578||Lung cancer surgery|All patients undergoing thoracic surgery for lung cancer either with thoracoscopy or thoracotomy will receive diaphragmatic Ultrasonography 2 and 24 hours after surgery
89355127|NCT03844841|Active Comparator|Propofol|Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous
89355128|NCT03844841|Active Comparator|Dexmedetomidine|Active agent: Dexmedetomidinum ut Dexmedetomidini hydrochloridum. Route of administration: intravenous
89355129|NCT03197766|Experimental|Active BMN 111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111
89355130|NCT03197766|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
89355131|NCT03704025|Active Comparator|Current guidelines rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by diary.
89355132|NCT03704025|Experimental|Mobile device guided rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by virtual augmented reality glasses or by mobile device.
89355133|NCT04501900|Active Comparator|prolonged DAPT group|
89355134|NCT04501900|No Intervention|standard DAPT group|
89355135|NCT03738332|Other|Low-level laser therapy|Single arm
89355136|NCT01330251||Patients with diabetes having Roux-en-Y gastric bypass|
89355137|NCT01330251||Patients without diabetes having Roux-en-Y gastric bypass|
89355138|NCT01330251||Control subjects (patients having gastroscopy, no surgery)|
89355139|NCT04501744|Experimental|M701|Patients will undergo a 2-week screening period and a 4-week core treatment period, and eligible patients who complete the core treatment period will receive a cycle of extended treatment (once weekly for 4 weeks) until disease progression or toxicity intolerance.
89355140|NCT01196195|Experimental|QD kaletra|Once daily kaletra
89355141|NCT01196195|Active Comparator|BID kaletra|twice daily dose of kaletra
89355142|NCT01330329|Experimental|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention.
89355143|NCT01330329|Experimental|Standard behavioral treatment (SBT)|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program.
89355144|NCT03637556|Experimental|DST-0509|DST-0509 (deferasirox) will be supplied in 360 mg, 180 mg and 90 mg tablets. DST-0509 is taken once daily with food; the first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
89355145|NCT03637556|Active Comparator|Jadenu|Jadenu is commercially available as tablets and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. Jadenu is taken once daily with or without a light meal. However, Jadenu can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
89355146|NCT03637556|Active Comparator|Exjade|Exjade is commercially available as tablets and Exjade as tablets for oral suspension and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. If converting from Exjade, the dose will be scaled for each treatment by 28 mg/40 mg (treatment/Exjade). Jadenu and Exjade are taken once daily, Jadenu is taken with or without a light meal, and Exjade is recommended to be taken without food. However, either Jadenu or Exjade can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
89355147|NCT04501510||HumerusFracture|Patients with humerus fracture
89355148|NCT04501510||RadiusFracture|Patients with radial bone fracture
89355149|NCT01193231||Acuvail 0.45%|Each subject will be randomized to the eye that they will use Acuvail in for 3 days after PRK
89355150|NCT01193231||Systane Ultra Preservative Free Tears|Each subject's contralateral eye (other eye) will use Sytane for 3 days after PRK surgery.
89355151|NCT01330407|Experimental|gp2|Cultured Epidermal Autografts
89355152|NCT01330407|Active Comparator|gp1|cryopreserved skin allografts.
89355153|NCT04069910|Experimental|Arm A (SRS/SRT, surgery)|Patients undergo 1, 5, or 10 fraction of SRS/SRT radiation. Surgery is performed within 72 hours of radiation therapy.
89355154|NCT04069910|Active Comparator|Arm B (surgery, SRS/SRT)|Within 2-5 weeks after standard of care surgery, patients undergo 1, 5, or 10 fraction of SRS/SRT.
89355155|NCT03347500||obese OA patients|"Use of patient-derived biological samples~Inclusion Criteria:~Subscription of informed consent~BMI ≥ 30~age between 60-80 years included~Kelgrenn-Lawrence equal or superior to grade III~presence of synovitis~patients undergoing knee replacement~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice~Exclusion criteria:~- HCV, HIV, HBV, TPHA infection"
89355156|NCT03347500||Non-obese OA patients|"Use of patient-derived biological samples~Inclusion criteria:~Subscription of informed consent~BMI ≤ 28~age between 60-80 years included~Kelgrenn-Lawrence equal or superior to grade III~presence of synovitis~patients undergoing knee replacement~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice~Exclusion criteria:~- HCV, HIV, HBV, TPHA infection"
89355157|NCT04500730|Experimental|Shaoyao Gancao Decoction Jiawei|"Shaoyao Gancao Decoction Jiawei by adding Pueraria montana, Salvia Miltiorrhiza, into Shaoyao Gancao.~The medication will be taken twice daily for 28 consecutive days. Each prescription will consist of 4 herbal granules."
89355158|NCT03346330|Experimental|TRK-750, single and multiple doses|
89355159|NCT03346330|Placebo Comparator|Placebo, single and multiple doses|
89355160|NCT01193387|Experimental|IDeg (M) IM1|
89355161|NCT01193387|Experimental|IDeg (M) IM2|
89355162|NCT05560594|Other|Intermittent catheter|Coloplast SpeediCath CH12 male intermittent catheter
89355163|NCT04479332|Experimental|Resuscitation Area|Critical patient is assigned to the resuscitation area for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1-2 licensed physicians, 2-3 nurses (1 for preparing intubation materials and acts as the assist, 1-2 for administering medications and documentation); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside resuscitation area, 1 at nurses' station), 4 nurses (2 inside resuscitation area, 2 at the sterile area)
89355164|NCT04479332|Experimental|Negative Pressure Isolation Room|Critical patient is assigned to the negative pressure isolation room for treatment under medical staff on personal protective equipment; Manpower distribution during tracheal intubation: 1 licensed physician, 2 nurses (1 for preparing intubation materials, acts as the assist, and for administering medications; 1 for documentation at the anteroom); Manpower distribution during cardiopulmonary resuscitation: 2 licensed physicians (1 inside negative pressure isolation room, 1 at nurses' station), 5 nurses (2 inside negative pressure isolation room, 1 at the anteroom, 2 at the sterile area)
89355165|NCT01196273||Regional Ruhrgebiets Cohort|
89355166|NCT03346174|Experimental|AAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage. By modulating manually the functional breathing level within the vital capacity, optimal airflow will be obtained at the targeted airway generations, where secretions have been identified. A gentle increase of manual pressure on the chest during each inspiration is performed to guide the breathing of the patient towards the desired lung volume level. During expiration the breathing movement of the patient is followed gently.
89355167|NCT03346174|Experimental|BAAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage .AAD sometimes leads to crying or resistance against therapy.Bouncing (at low amplitude:6-8 cm) in a stable upright position is a gentle up-and-down movement on a physio ball. It is not an ACT, but used to maximize the relaxation of the infant, avoiding resistance against or crying during treatment. Due to the relaxing effect of bouncing, infants appear to tolerate better AAD, increasing the effectiveness of the treatment.
89355168|NCT04467554|Experimental|Measurements and T-chair training|This group will receive three measurements sessions and training with a new developed device (15 therapy sessions in total).
89355169|NCT04467554|No Intervention|Measurements|This group will receive three measurements sessions.
89355170|NCT01198223|Other|drug: garlic extract, nystatin|Drug: garlic extract 40mg/dl or nystatin suspension 100000 iu/ml tid for one month Patients had been clinically with denture stomatitis and confirmed by oral medicine specialist were selected for the study. Gender, age, medical history, erythema types, size, and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received garlic extract and second group used nystatin suspension for 1 month. Each patients was examined at the beginning of the therapy ,and then every 1 weeks up to 1 months .
89355171|NCT03346564|Experimental|Ritual training program|ritual training program for 8 weeks, biweekly
89355172|NCT03346564|Placebo Comparator|Routine care|Routine care following hospital
89355173|NCT03346486|Placebo Comparator|Control diet|Regular diet
89355174|NCT03346486|Active Comparator|Intervention diet|Brainfood diet
89355175|NCT01196351|Experimental|Sedentary activity, noncaloric beverage|
89355176|NCT01196351|Experimental|Sedentary activity, glucose beverage|
89355177|NCT01196351|Experimental|Exercise activity, noncaloric beverage|
89355178|NCT01196351|Experimental|Exercise activity, glucose beverage|
89355179|NCT05559424|Active Comparator|POT/KISSING/POT (PKP)|"SB rewiring is performed with the objective to cross distal stent struts (distal rewiring) through pullback technique.~KBI is performed using short non-compliant balloons (balloon of MV sized in a 1:1 ratio with distal MV reference diameter and SB balloon sized in a 1:1 ratio with SB reference diameter), with sequential followed by simultaneous inflation.~Final POT is performed at the same way as initial POT"
89355180|NCT05559424|Active Comparator|POT/SIDE/POT (PSP)|"SB rewiring is performed with the objective to cross distal stent struts (distal rewiring) through pullback technique.~SB dilatation is performed with a balloon sized 1:1 according to SB reference diameter.~Final POT is performed at the same way as initial POT."
89355181|NCT05005988|Experimental|Empowerment educational intervention|Three 30-minute sessions will be conducted with each mother in the intervention group, the first during the first week after admission, the second session within 7 days after the second session, and the third 3 to 2 days before discharge. An induction to the out-of-hospital kangaroo program will also take place on the day of admission to the program. Mothers will receive a booklet with general care contents and empowerment information.
89355182|NCT05005988|No Intervention|Usual intervention|Mothers receive information for home infant care, no theoretical perspective and no empowerment approach is considered
89355183|NCT01193465|Experimental|humidity|
89355184|NCT03347344|Experimental|RILUZOLE|Riluzole PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet. The tablets will be held under a blister of 20 tablets.
89355185|NCT03347344|Placebo Comparator|PLACEBO|The placebo PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet matching the appearance of the Riluzole used in this study
89355186|NCT01193543|Experimental|calanus oil|calanus oil 1 gram twice daily
89355187|NCT01193543|Placebo Comparator|olive oil|olive oil 1 gram twice daily
89355188|NCT03173456|Active Comparator|oxycodone/acetaminophen (APAP)|5 mg oxycodone + 325 mg acetaminophen
89355189|NCT03173456|Active Comparator|hydrocodone/APAP|5 mg hydrocodone + 300 mg acetaminophen
89355190|NCT03173456|Active Comparator|codeine/APAP|30 mg codeine + 300 mg acetaminophen
89355191|NCT03173456|Active Comparator|400 ibuprofen/APAP|400 mg ibuprofen + 1000 mg acetaminophen
89355192|NCT03173456|Active Comparator|800 ibuprofen/APAP|800 mg ibuprofen + 1000 mg acetaminophen
89355193|NCT03846245||Young adults group|Cognitively unimpaired 18-25 years old
89355194|NCT03846245||Old adults group|Cognitively unimpaired >= 70 years old
89355195|NCT01193621|Active Comparator|haloperidol|"0.5, 1, 3 mg of haloperidol will be administered orally every 24 hours for 7 days to 4 healthy subjects in each dose level (a total of 12 subjects).~Dose groups are as follows; D2-receptor occupancy study Group Single Oral Dose No. of subjects~0.5 mg 4~1 mg 4~5 mg 4"
89355196|NCT04501198|Experimental|Moxibustion with characteristic lifestyle intervention of TCM|Participants will receive moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine.In this study, xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. Participants will receive the treatment of moxibustion 6 times a week to fulfill a 8-session treatment course, and the intervention of Xiusheng Decoction and Traditional exercises will last for 8 weeks.While the intervention of modern lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
89355197|NCT04501198|Experimental|moxibustion with lifestyle intervention|Participants will receive moxibustion combined with lifestyle intervention. Participants will receive the treatment of moxibustion 6 times a week to fulfill a 8-session treatment course,while the intervention of modern lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
89355198|NCT04501198|Other|lifestyle intervention|Participants will receive lifestyle intervention which includes modern dietary exercise modifications. Participants will receive this treatment for a 8-session treatment course and 4-session follow-up course.
89355199|NCT02668874|Other|Isolite System|The Isolite technique utilizes a flexible plastic dental adapter to separate the cheek and tongue prior to sealant placement.
89355200|NCT02668874|Other|Cotton Roll technique|A cotton roll is placed between the cheek and tongue prior to sealant placement.
89355201|NCT05211479|Experimental|intervention group|Tele-nursing will be applied to adolescents in this group for 24 weeks. Weekly meeting and blood glucose monitoring will be done. The HbA1c value will be checked and the scales will be filled by meeting 3 times in total with 3 months intervals.
89355202|NCT05211479|No Intervention|Control Group|This group will be given face-to-face training only in the first encounter. During the research, no interviews will be provided through tele nursing. Only at the 3rd and 6th months will be interviewed to measure the HbA1c value and to fill the scales.
89355203|NCT02517424|Experimental|High THC/Low CBD Cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
89355204|NCT02517424|Experimental|High THC/High CBD cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
89355205|NCT02517424|Placebo Comparator|Low THC/Low CBD cannabis|Product will be administered via vaporization up to 2 grams per day as needed.
89355206|NCT03846323|Experimental|Visiting policies: open 24h/24|Visiting policies: 24 hours a day, 7 days a week
89355207|NCT03846323|Other|Restriction of visiting policies|Restriction of visiting policies < 6 hours
89355208|NCT01567904|Experimental|Age group from 12 to 18 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
89355209|NCT01567904|Experimental|Age group from 6 to 12 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
89355210|NCT01567904|Experimental|Age group from 2 to 6 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
89355211|NCT01567904|Experimental|Age group from 3 months to 2 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
89355212|NCT01567904|Experimental|Age group from birth to 3 (<) months|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
89355213|NCT02517346|Active Comparator|Standard follow up-Sleep Unit|Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit
89355214|NCT02517346|Experimental|Telemonitoring|Patients diagnosed as OSA and treated with CPAP in sleep unit, followed up by telemonitoring system
89355215|NCT01196507|Experimental|Carvedilol|Tablet Carvedilol 12.5 mg BD or maximum tolerated dose
89355216|NCT01196507|Placebo Comparator|Placebo|Placebo tablets 2 to 4 BD
89355217|NCT02340884|Experimental|PRISM|Promoting Resilience In Stress Management Intervention (skills-based intervention designed to teach stress-management, goal-setting, cognitive reframing, and meaning-making skills)
89355218|NCT02340884|No Intervention|Control|Standard psychosocial supportive care
89355219|NCT03347266|Experimental|VVZ-149 injections|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a 1000mg for 10 hours.
89355220|NCT03347266|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
89355221|NCT04987970|Experimental|Sequence 1|Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 3: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 4: CKD-386(2)- A single oral dose of 1 tablet under fasting condition
89355222|NCT04987970|Experimental|Sequence 2|Period 1: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-386(2)- A single oral dose of 1 tablet under fasting condition Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition
89355223|NCT02517190|Other|Stress response measurements|
89355224|NCT05180201|Experimental|LP7+FOS|Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) with 150mg fructooligosaccharide (FOS) and 100mg maltodextrin, for 7 days.
89355225|NCT05180201|Experimental|LP7|Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) plus 250mg maltodextrin, for 7 days.
89355226|NCT05180201|Experimental|LP1+FOS|Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) with 150mg FOS and 100mg maltodextrin, for one day, followed by 6 days of placebo (250mg maltodextrin).
89355227|NCT05180201|Experimental|LP1|Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) plus 250mg maltodextrin for one day, followed by 6 days of placebo (250 mg maltodextrin).
89355228|NCT05180201|Placebo Comparator|Placebo|Once daily oral administration of placebo (250 mg maltodextrin), for 7 days.
89355229|NCT03627650|Experimental|1 group of 15 patients|procedure/surgery: fat grafting injection of scar
89355230|NCT03627650|Experimental|Same group of 15 patients|procedure/surgery: placebo injection of scar
89355231|NCT03143660|Active Comparator|Coaching|A parent support component consisting of eight weekly telephone counseling calls by centrally located nutritionists to provide parents coaching tailored to their family's unique needs to help them set goals and make targeted lifestyle changes recommended by the American Academy of Pediatrics (AAP) for Stage 1, Prevention Plus, accompanied by a parent booklet
89355232|NCT03143660|Active Comparator|Materials|Parents will receive the same educational materials provided in the Fitline family workbook mailed over 8 weeks to control for weekly contact and educational curriculum, but no Fitline counseling.
89355233|NCT02517112|Other|Cardiovascular parameters measurements|
89355234|NCT01295801||Linezolid+vitamin B6|
89355235|NCT01295801||Linezolid|
89355236|NCT03964246|Experimental|Compassion Meditation (CM) intervention group|"Thee CBCT-Vet includes 10 90-minute sessions that will be led by certified CBCT therapist with significant experience in administering CBCT-Vet. Sessions 1 - 4 assist participants in basic mindfulness breathing practices; sessions 4 - 8 focus on personal analysis of factors underlying difficulties with compassion for self or others; the final two sessions (9 and 10) review content and assist with relapse prevention. Session by session topics are: (1) Introduction and learning breathing meditation, (2) Focused attention, (3) Creating space, (4) Mindful awareness, (5) Re-engaging with heroic spirit, (6) Seeing ourselves in others, (7) Appreciation and gratitude, (8) Empathy and engaged compassion, (9) Putting it all together, and (10) Putting it all together 2."
89355237|NCT03964246|Active Comparator|Psychoeducational healthy aging group|The investigators will develop and test a 10-week psychoeducational group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent VA Merit-supported randomized controlled trial. This will include multiple resources for community education regarding healthy aging, including a library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity. These resources will be incorporated into 90-minute sessions wherein the key information from talks is shown to participants, with a follow-up discussion and review period led by the group facilitator. In the context of the present feasibility study, the investigators anticipate modifying and refining the content and format of the group in response to participant feedback.
89355238|NCT05282771|Experimental|Halobetasol Propionate and Tazarotene Topical lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
89355239|NCT05282771|Active Comparator|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
89355240|NCT05282771|Placebo Comparator|Placebo Control|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks
89355241|NCT03954652|Other|Cohort 1: Intellectual disability|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
89355242|NCT03954652|Other|Cohort 2 Retinal diseases|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
89355243|NCT03954652|Other|Cohort 3: Rare tumors in childhood|Genetic: WGS Diagnostic Blood take for genetic diagnostic.
89355244|NCT03848117|Active Comparator|(DTF massage & Mill's manipulation)(Group 1)|For any given subject in group 1, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in 1st group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
89355245|NCT03848117|Active Comparator|( Taping & MWM) (Group 2).|For any given subject in group 2, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
89355246|NCT02512978|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
89355247|NCT02512978|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
89355248|NCT03848273||Ischemic|questionnaire, physical-neurological examination, labor investigations, EEG
89355249|NCT03848273||Hemorrhagic|questionnaire, physical-neurological examination, labor investigations, EEG
89355250|NCT03848273||Control|questionnaire, physical-neurological examination, labor investigations, EEG
89355251|NCT05487833|Experimental|insulin|
89355252|NCT05487833|Placebo Comparator|standard management|
89355253|NCT03197376|Experimental|Pneumosil Lot 1|Pneumosil Lot 1
89355254|NCT03197376|Experimental|Pneumosil Lot 2|Pneumosil Lot 2
89355255|NCT03197376|Experimental|Pneumosil Lot 3|Pneumosil Lot 3
89355256|NCT03197376|Active Comparator|Synflorix|Synflorix
89355257|NCT01295957|Active Comparator|reminiscence therapy, story telling|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. Refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography. Three main variables contributed to successful reminiscing: individuality, evaluation and structure.
89355258|NCT01295957|Placebo Comparator|comparison|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, but they didn't participate in reminiscence sessions to rule out the possibility that improvement in quality of life was due only to attention received and social stimulation.
89355259|NCT01295957|No Intervention|control|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour,
89355260|NCT01196585|Experimental|Patients under CT- guided pleural biopsy|Arm A: Patients who go under CT-guided pleural needle biopsy for pleural diseases
89355261|NCT01196585|Experimental|Patients under ultrasonography guided needle biopsy|Arm B: Patients who go under ultrasonography guided cutting needle pleural biopsy for pleural diseases
89355262|NCT01193699|Experimental|P1101|
89355263|NCT03600805|Experimental|Placebo+52 Week Taper|Participants received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.
89355264|NCT03600805|Experimental|Placebo+26 Week Taper|Participants received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
89355265|NCT03600805|Placebo Comparator|Sarilumab 150mg q2w+26 Week Taper|Participants received sarilumab 150 milligrams (mg) as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
89355266|NCT03600805|Placebo Comparator|Sarilumab 200mg q2w+26 Week Taper|Participants received sarilumab 200 mg as SC injection q2w up to 52 weeks along with prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Participants received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.
89355267|NCT05473247|Experimental|Ring-Fit Adventure Group|"In Phase 1, participants will be asked to play Ring-Fit Adventure for 60 minutes per week for 4 weeks. Participants will also be asked to attend a weekly, 90 minute health education session with a health educator on zoom.~In Phase 2, participants will be asked to play Ring-Fit Adventure for 60 (wk 1), 90 (wk 2), 120 (wk 3), and 150 (wk 4-12) minutes per week. Participants will also be asked to attend a weekly, 90 minute health education session with a health educator on zoom."
89355268|NCT01198379|Experimental|Aspirin|
89355269|NCT01198379|Placebo Comparator|Sugar pills|Hemodialysis (HD) patients receive placebo not containing aspirin in this study.
89355270|NCT02729740|Other|Penumbra Smart System|
89355271|NCT05283005|Active Comparator|alveolar cleft patients will be treated by conventional technique|Reconstruction of alveolar cleft by autogenous cancellous bone from the anterior iliac crest (gold standard technique).
89355272|NCT05283005|Experimental|alveolar cleft patients will be treated by double cortex technique|Reconstruction of alveolar cleft by autogenous double iliac cortico-cancellous bone blocks from the anterior iliac crest.
89355273|NCT05433857|No Intervention|Control group|20 patients will receive the standard therapy for 12 weeks
89355274|NCT05433857|Experimental|Interventional group|20 patients will receive the standard therapy in addition to two capsules once daily of probiotic Lacteol Forte® Capsules for 12 weeks
89355275|NCT03848039|Experimental|Gardasil-9|Intramuscular Gardasil-9 vaccination at 0, 2 and 6 months.
89355276|NCT03848039|Placebo Comparator|Placebo|Placebo injection at 0, 2 and 6 months
89355277|NCT01296269|Experimental|Vasopressin|vasopressin condition
89355278|NCT01296269|Experimental|oxytocin|oxytocin condition (syntocinon)
89355279|NCT01296269|Placebo Comparator|placebo|
89355280|NCT05595772|Active Comparator|group A (Concentrated Growth Factor) CGF|ten patients indicated for immediate implant in the maxillary anterior region (class II socket)
89355281|NCT05595772|Active Comparator|group B (Plasma Rich in Growth Factor) PRGF|Ten patients who indicated immediate implant in the maxillary anterior region (class I or class II socket),
89355282|NCT03844451|Experimental|Liposomal bupivicaine with nerve block|The treatment group will receive an intraoperative V2 trigeminal nerve block using liposomal bupivacaine in addition to a standard bupivacaine nerve block.
89355283|NCT03844451|Placebo Comparator|Nerve block only|The control group will undergo conventional perioperative management without an ERAS protocol and standard bupivacaine intraoperative nerve block.
89355284|NCT01198457||Group 1|
89355285|NCT02516956|Experimental|Breakfast meal 1|"Breakfast meal 1 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 2 and health-related cognitive perception as Breakfast meal 3.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
89355286|NCT02516956|Experimental|Breakfast meal 2|"Breakfast meal 2 is isocaloric (330 kcal) and balanced for protein and fiber contents with regard to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 1 but a higher health-related cognitive perception than the other two experimental breakfasts.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
89355287|NCT02516956|Experimental|Breakfast meal 3|"Breakfast meal 3 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same health-related cognitive perception as Breakfast meal 1 but lower lipid and higher sugar amounts than the other two experimental breakfasts.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
89355288|NCT02516956|Placebo Comparator|Breakfast meal 4|"Breakfast meal 4 is a non-caloric meal representing fasting condition (control arm).~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
89355289|NCT03386214|Experimental|Arm 1: Starting Dose - 5 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
89355290|NCT03386214|Experimental|Arm 2: Dose Level 2 - 10 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
89355291|NCT03386214|Experimental|Arm 3: Dose Level 3 - 20 mg/m^2 pevonedistat + ruxolitinib|"Pevonedistat will be given as an IV infusion at the assigned dose over the course of 60 minutes on Days 1, 3, and 5 of each 28-day cycle.~Ruxolitinib will be continued at the same dose as prior to enrollment and will be administered as standard of care outside the study protocol."
89355292|NCT01198535|Experimental|Arm A (RO4929097, cetuximab)|Patients in Arm A will receive cetuximab at the standard dose: 400 mg/m2 IV loading dose on Day 1 followed by cetuximab 250 mg/m2 IV weekly. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
89355293|NCT01198535|Experimental|Arm B (RO4929097, cetuximab)|Patients in Arm B will receive cetuximab 200 mg/m2 IV weekly without a loading dose. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
89355294|NCT02516878|Experimental|Acupuncture group|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
89355295|NCT02516878|Sham Comparator|Control group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion.~The Semen Vaccariae embedded tape used in treatment group will be applied on 4 non-acupoints at the helix unilaterally, retained until the next visit and then the alternate ear will be used."
89355296|NCT01198613|Placebo Comparator|Placebo|
89355297|NCT01198613|Experimental|ToleroMune Ragweed Regimen 1|
89355298|NCT01198613|Experimental|ToleroMune Ragweed Regimen 2|
89355299|NCT01198613|Experimental|ToleroMune Ragweed Regimen 3|
89355300|NCT01198613|Experimental|ToleroMune Ragweed Regimen 4|
89355301|NCT02516800||Aortic valve calcification|Patients with calcific aortic valve disease, age = 65 years or below
89355302|NCT02516800||Control group|Matched control group
89355303|NCT02516644|Experimental|Virtual reality|Xbox Kinect + treadmill training
89355304|NCT02516644|Active Comparator|Conventional Therapy|Specific conventional training for Parkinson's Disease
89355305|NCT05670977|Active Comparator|Study product plus collagen supplement|"5g/bag, containing the following ingredients per 5g serving:~Collagen tripeptide 1500 mg~Elastin peptide 150 mg"
89355306|NCT05670977|Placebo Comparator|Study product without collagen supplement|"5g/bag, containing the following ingredients per 5g serving:~Peach juice 8 mg~Erythritol 10 mg"
89355307|NCT03896620||Stage II-III Sarcomas undergoing preoperative radiation therapy (RT)|This group will have preoperative chemotherapy (if administered), preoperative radiation and surgery.
89355308|NCT03896620||Stage II-III Sarcomas undergoing postoperative RT|This group will have surgery, postoperative radiation, post operative chemotherapy (if administered).
89355309|NCT03896620||Stage IV Sarcomas|This group will only have chemotherapy.
89355310|NCT04499404|Experimental|Intervention group|Participants receive breastfeeding-related information from WeChat
89355311|NCT04499404|Active Comparator|Control group|Participants receive non-breastfeeding information from WeChat
89355312|NCT03844685|Experimental|Treatment group|1 tablet /day of MCE-11 (Promensil) taken orally for 24 months
89355313|NCT03844685|Placebo Comparator|Placebo group|Placebo tablet (without active principle) given once a day for 24 months
89355314|NCT02942966|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections below the knee.
89355315|NCT04151069||At home group|Participants with allergy to tree nuts who follow the introduction procedure A (at home)
89355316|NCT04151069||At the hospital group|Participants with allergy to tree nuts who follow the introduction procedure B (at the hospital)
89355317|NCT04151069||Control group|Participants with allergy to tree nuts who follow strict avoidance of the offending nuts.
89355318|NCT03844763|Experimental|Phase I - II trial of CTX, RT, Avelumab|CTX: 50 mg Daily untill PD or major toxicity; Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity; RT: 8 Gy single shot day 8.
89355319|NCT02516566|Experimental|PEEP group|Mechanical ventilation with PEEP 8 cmH2O
89355320|NCT02516566|No Intervention|No PEEP group|Mechanical ventilation with no PEEP
89355321|NCT05018039|Experimental|Collaborative care model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider (psychologist or psychiatrist) and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments with the physiotherapist and/or occupational therapist (usual care)."
89355322|NCT05018039|No Intervention|Usal Care|"Current usual care within musculoskeletal outpatients involves an initial patient assessment by a physiotherapist or occupational therapist (or both) to determine the needs and goals of the patient in relation to their musculoskeletal condition. Clinicians also help to inform, educate, and empower patients to self-manage their rehabilitation where possible.~Following this initial assessment, patients are provided with a plan of their therapy treatment. The therapist(s) progress patients exercise, as appropriate. Therapy is most often a 1:1 session but can also include group classes. Physical therapy involves exercise and education, while occupational therapy focuses on practical strategies to perform daily tasks.~If the therapists feel that patients require additional support for their mental health problems, they can request this support via the General Practitioner or the hospital mental health services."
89355323|NCT03121300||High Risk Lung Cancer Patients|
89355324|NCT02512822|Experimental|Participants|Noninvasive Radiofrequency
89355325|NCT01202045||systemic sclerosis patients|Every patient will have a rest echocardiography, a stress echocardiography, a right heart catheterization, a blood specimen, and a pulmonary function test.
89355326|NCT02516722|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
89355327|NCT03606616||ACOSOG Z0011 no further ALND arm|patients meeting the criteria for ACOSOG Z0011 trial inclusion：histologically confirmed invasive breast cancer;clinical T1/T2;breast conserving surgery；1 or 2 positive sentinel lymph nodes; Whole-breast RT planned; no preoperative chemotherapy
89355328|NCT01198847|Active Comparator|Low intensity arm|Written information about a healthy lifestyle
89355329|NCT01198847|Experimental|High intensity arm|Lifestyle support (PA, sleep, food intake) using MI
89355330|NCT02512666|Experimental|Non-Invasive Imaging|"Commercial portable optical microscope (AM4113-N5UT Dino-Lite ) which will be employed during the study for a pre determined time of non-invasive imaging of the nailfold capillaries in ASCT patients.~For Autologous Stem Cell Transplant (ASCT) participants, the imaging will be performed once prior to ASCT upon admission to the hospital, and then daily after ASCT (starting on day +7) until count recovery"
89355331|NCT01198925|Active Comparator|extended infusion|
89355332|NCT01198925|Experimental|continuous infusion|
89523605|NCT05172739|Active Comparator|Opioid-Free Anesthesia Analgesia|Premedication: Pregabalin 150mg 1x2, IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Dexmedetomidine 0.5-1mcg/kg, Lidocaine 1mg/kg, Propofol 2-3mg/kg, Ketamine 1-1.5mg/kg, Hyoscine 10mg, Cisatracurium 0.2mg/ kg or alternatively Rocuronium 0.6-1.2mg/kg, Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg. Anesthesia maintenance: Desflurane set at ~1 MAC, Dexmedetomidine 0.5-1.2mcg/kg/h, Lidocaine 0.5-1mg/kg/h, Ketamine 0.3-0.5mg/kg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, and Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. Surgical ward: PCA pump with Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam for the first 3 postoperative days. Additionally, Pregabalin 50mg per os 1x1 and 25mg 1x1, Paracetamol 1g 1x3 +/- Dexketoprofen trometamol 50mg 1x2. Rescue therapy only: Tramadol 50-100mg.
89523606|NCT04445623|Active Comparator|prasugrel hydrochloride|film-coated tablets of prasugrel hydrochloride (10 mg daily dose after loading dose of 60 mg)
89523607|NCT04445623|Placebo Comparator|placebo|film-coated tablets of placebo (10 mg daily dose after loading dose of 60 mg)
89523608|NCT04445311|Experimental|Ivermectin group|group that will receive ivermectin plus standard of care ttt
89523609|NCT04445311|No Intervention|Control group|group that will receive standard of care ttt
89523610|NCT05172583|Active Comparator|Control|The control groups will receive the nursing interventions that are performed daily in the adult ICU
89523611|NCT05172583|Experimental|Experimental|Interventions for this group are based on the Dynamic Symptom Model and scientific evidence
89523612|NCT05172427|Active Comparator|CLUE intervention (EMA + EMI)|"Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, they will have a meeting with a clinician and be given the CLUE intervention targeting intolerance of uncertainty. Following this intervention, participants will be given 14 days of EMA, which will include EMI prompts that they come up with at the end of the CLUE intervention (framed as key takeaways). After the two week period of EMA/EMI, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline, acceptability and feasibility of the intervention will be assessed at post-intervention. One month after post-intervention, participants will complete a one-month follow up questionnaire battery, that will again ask about acceptability and feasibility of the intervention, as well as parallel questions from baseline and post-intervention."
89523613|NCT05172427|Active Comparator|CLUE intervention (EMA only)|Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, they will have a meeting with a clinician and be given the CLUE intervention targeting intolerance of uncertainty. Following this intervention, participants will be given 14 days of EMA. After the two week period of EMA, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline, acceptability and feasibility of the intervention will be assessed at post-intervention. One month after post-intervention, participants will complete a one-month follow up questionnaire battery, that will again ask about acceptability and feasibility of the intervention, as well as parallel questions from baseline and post-intervention.
89523614|NCT05172427|No Intervention|Waitlist control|Participants will complete baseline questionnaires, followed by seven days of baseline EMA. After seven days of baseline EMA, participants will be assigned 14 days of EMA. After the two week period of EMA, participants will complete a post-intervention questionnaires. In addition to similar questionnaires to those administered at baseline. One month after the post-intervention questionnaires, participants will complete a one-month follow up questionnaire battery, that will include parallel questions from baseline and post-intervention. As these participants did not receive the intervention following their baseline EMA, they will be given the opportunity to schedule an appointment for the intervention after they have completed their one-month follow up questionnaire.
89523615|NCT03384355||Class 0|no visible or palpable varicose veins
89523616|NCT03384355||Class 1|telengiectasia ( thread veins, spider veins, broken veins)
89523617|NCT03384355||Class 2|varicose veins
89523618|NCT03384355||Class 3|edema
89523619|NCT03384355||Class 4|skin changes (pigmentation, eczema, lipodermatosclerosis, atrophie blanche)
89523620|NCT03384355||Class 5|healed venous ulcer
89523621|NCT03384355||Class 6|active venous ulcer
89523622|NCT03384199|Experimental|Dose escaltion|insertion of 3 fiducial markers, prostate will receive 78 Gy with dose escalation to prostate focal lesion up to 87 Gy
89523623|NCT03384823|Experimental|EDP-938 SAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
89523624|NCT03384823|Experimental|EDP-938 MAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days
89523625|NCT03384823|Placebo Comparator|EDP-938 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
89523626|NCT03384823|Placebo Comparator|EDP-938 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 7 days
89523627|NCT03375229|Active Comparator|Group On|This group was composed of 15 subjects. The application of dry needling and Low-Level Laser Therapy (LLLT) turned on will be directly on the trigger point. The intervention will be administered one time.
89523628|NCT03375229|Active Comparator|Group Off|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be directly on the trigger point. The intervention will be administered one time.
89523629|NCT03375229|Placebo Comparator|Placebo group|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be 1.5 cm medially from the trigger point. The intervention will be administered one time.
89523630|NCT03378895|Experimental|adults aged 35 to 55 years|
89523631|NCT03384121|Experimental|Rifampin|All subjects
89523632|NCT03378817|Active Comparator|Conventional cold storage|Conventional static cold storage (CCS) on temperature 0-4 °C from organ procurement (historical case matched group)
89523633|NCT03378817|Experimental|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
89523634|NCT03124225||Ultrasound|Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic
89523635|NCT03124225||Non-Ultrasound|Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic
89523636|NCT03384043|Experimental|Smartphone Personal Assistant|"Participants will use the personal assistant feature of the smartphone (Cortana) to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state Cortana, I need to remember to... for time--based tasks (...take my medicine at 7pm) and event--based tasks (pick-up milk at the grocery store)."
89523637|NCT03384043|Active Comparator|Implementation Intention|"The implementation intention is a memory strategy, in which individuals verbally state when/where they will perform a prospective memory intention. In the current study, participants will verbally specify an external cue in a When…then format and record doing so using the smartphone's voice recorder app. They will use the implementation intention strategy for time--based tasks (When it is 7pm, then I will remember to take my medicine), and event--based tasks (When I am at the grocery store, then I will remember to pick--up milk)."
89523638|NCT03383965|Experimental|ICAR30 T cells|anti-CD30 CAR-T cells. Patients receive ICAR30 T cells infusion.
89523639|NCT03367429|Experimental|Exp 2 & 3 - Arm 1|"If within-subject design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM and one standard BT injection of of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic MGM.~If between-subjects design is adopted, subjects will receive one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic LGM."
89523640|NCT03367429|Experimental|Exp 2 & 3 - Arm 2|"If within-subject study design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM and one experimental BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.50 cc of saline to their spastic MGM.~If between-subjects design is adopted, subjects will receive one standard BT injection of 25 units onobotulinumtoxinA (Botox®) diluted in 0.25 cc of saline to their spastic LGM."
89523641|NCT03378661|Experimental|BZN STD Regimen|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
89523642|NCT03378661|Experimental|BZN 300 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
89523643|NCT03378661|Experimental|BZN 300 mg - 2 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 2 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 6 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
89523644|NCT03378661|Experimental|BZN 150 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
89523645|NCT03378661|Experimental|BZN 150 mg - 4 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
89523646|NCT03378661|Experimental|BZN 300 mg (weekly) 8 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets by mouth, once weekly for 8 weeks (total 8 days of intermittent treatment) and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in the other 6 days of the week for 8 weeks~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
89523647|NCT03378661|Placebo Comparator|Placebo|"Benznidazole Placebo (100 mg and 50mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
89523648|NCT03378583||control,|control normal ventilation
89523649|NCT03378583||sellick,|ventilation while sellick manoeuvre is applied
89523650|NCT03378583||low paratracheal esophagus compression|ventilation while low paratracheal esophagus compression is applied
89523651|NCT03383809|Experimental|Strawberry juice with inulin|One dose of 300 g of strawberry with 10 g of inulin will be given to subjects in the form of juice
89523652|NCT03383809|Experimental|Strawberry juice|One dose of 300 g of strawberry juice will be given to subjects in the form of juice
89523653|NCT03383809|Experimental|Inulin|One dose of 10 g of inulin will be given to subjects in the form of a drink
89523654|NCT03375151|Experimental|EEG based feedback|The therapist will give feedback to the participants during the exercise based on their performance.and use the feedback from the EEG analyzed data to direct cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
89523655|NCT03375151|Other|Standard practice based feedback|The therapist will give feedback to the participants during the exercise based on their performance.
89523656|NCT03375151|Other|No feedback|The participants will perform the exercise without feedback during practice.
89523657|NCT03383731|Active Comparator|Group 1|Group 1: The patients in Group 1 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
89523658|NCT03383731|Experimental|Group 2|Group 2: The patients in Group 2 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
89523659|NCT03383497||Idiopathic Parkinson Disease|
89523660|NCT03383497||Other Parkinsonian syndromes|
89523661|NCT03375073|Experimental|Positive communication|Positive communication during medical transmission
89523662|NCT03375073|No Intervention|Non-optimized communication|Medical transmission with non-optimized communication.
89523663|NCT03378505|Experimental|Mobile App|Half of the students randomly assigned
89523664|NCT03378505|Experimental|Reflection|Half of the students randomly assigned
89523665|NCT03378427|Experimental|Tedizolid Phosphate 200 MG [Sivextro]|All included patients will receive prolonged (>= 6 weeks) tedizolid treatment given orally.
89523666|NCT05172115|Experimental|Conventional catheter-directed thrombolysis (CDT)|Conventional catheter-directed thrombolysis (CDT) will be the interventional arm. CDT will be administered using fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours (0.5 mg/h per catheter if bilateral or 1 mg/h per unilateral catheter) with 500 unit per hour of infusion of unfractionated heparin during the thrombolytic therapy. The therapeutic dose of heparin will immediately be substituted the CDT after termination, and twice-daily subcutaneous enoxaparin (1mg/kg) for the first 48 hours after the thrombolytic therapy will be administered. Direct oral anticoagulation will be in ones with no clinical deterioration.
89523667|NCT05172115|Active Comparator|Anticoagulation-only therapy|The anticoagulation-only therapy will be the assigned treatment in the control arm. Control patients will receive subcutaneous enoxaparin (twice-daily, 1mg/kg) in the first 48hours of enrollment. Direct oral anticoagulation will be in ones with no clinical deterioration.
89523668|NCT03378349|Experimental|Internet-delivered CBT over 10 weeks|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
89523669|NCT03378349|Placebo Comparator|Treatment as usual wait list|Patients randomized to the treatment as usual wait list arm will receive standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health. Thus, the treatment as usual arm will control for the provision of basic patient information, but without the guidance of a psychologist or any CBT interventions.
89523670|NCT03374917|Experimental|ABBV-951|ABBV-951 administered by continuous subcutaneous infusion (CSCI) for 4 weeks.
89523671|NCT03383341|Experimental|Cricket powder protein|Participants were provided with frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. The amount of intervention food consumed daily contained 25 grams of cricket protein powder.
89523672|NCT03383341|Placebo Comparator|Placebo Control|Participants were provided with a placebo comparator that included frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. These foods were formulated to taste and appear similar to the cricket intervention foods but did not consume any cricket powder.
89523673|NCT03374761|Experimental|Families First Home Visiting Program|10 group sessions conducted weekly and 4 home visits for the duration of the program. Sessions and visits of the Families First Home Visiting Program cover child development, parenting skills, parent-child communications, and positive discipline practices. The intervention is delivered by para-professional community facilitators, trained in the program.
89523674|NCT03374761|No Intervention|Control Group|The control group receives the standard, government run, services provided by community health workers in West Java. Once the evaluation of the intervention arm is completed, participants in the control arm will be offered the intervention.
89523675|NCT03378037|Experimental|Acupuncture group|Disposable acupuncture needles will be inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
89523676|NCT03378037|Sham Comparator|Control group|Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
89523677|NCT03374605|Experimental|Active tDCS|
89523678|NCT03374605|Sham Comparator|Sham tDCS|
89523679|NCT03374527||Psoriasis|Patients with psoriasis vulgarism without clinical signs of PsA
89523680|NCT03374527||Psoriatic Arthritis (PsA)|Patients with a diagnosis of psoriatic arthritis and cutaneous psoriasis
89523681|NCT03374527||Control group|Healthy subjects
89523682|NCT03383263||Children with juvenile arthritis|Children with diagnosed polyarticular juvenile arthritis according to International League of Associations for Rheumatology (ILAR) criteria treated with HUMIRA (adalimumab) in the routine clinical settings in the Russian Federation
89523683|NCT03980743|Active Comparator|iOTA text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly meetings with a study health coach to develop reasonable health goals and interactive text messaging to provide daily support and self-monitoring of behavior change goals between in-person visits. Participants may receive phone calls between visits from their health coach for additional support if needed. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
89523684|NCT03980743|Placebo Comparator|Health Education text messaging intervention|"There will be a 6 month active treatment phase consisting of monthly in-person visits with a health coach to learn about healthy eating and activity behaviors, including developing readiness for health behavior change. Participants will not set specific health goals, but will receive weekly text messages about general health tips related to their in-person visits. Following the active treatment phase, participants will receive daily health-related text messages for another 3 months."
89523685|NCT03377959|Experimental|Pilates Group|Pilates Method Mat classes and Ballet Classes three times a week, totaling 24 session of each.
89523686|NCT03377959|Other|Ballet Group|Ballet Classes three times a week, totaling 24 sessions.
89523687|NCT03383185||Non-hormonal contraceptive|Users of non- hormonal intrauterine device during the 5 years follow-up
89523688|NCT03383185||Hormonal contraceptives|Users of combined oral contraceptive, progestin-only pills, depot-medroxyprogestereone acetate during 5 years follow-up
89523689|NCT03383029|Experimental|iEAT|Children with food refusal will participate in the iEAT program.
89523690|NCT03374293|Experimental|Experimental Group|Radiation to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
89523691|NCT02730871|Experimental|Simbrinza + Duotrav|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
89523692|NCT02730871|Placebo Comparator|Vehicle + Duotrav|Brinzolamide/brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
89523693|NCT03377335|Experimental|Dapagliflozin|"Dapagliflozin (10mg daily) as add-on to metformin (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
89523694|NCT03377335|Placebo Comparator|Metformin alone|"Metformin alone (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
89523695|NCT03377257|Active Comparator|Active group|The treatment with oral zolmitriptan is 2.5mg when headache attack.
89523696|NCT03377257|Experimental|Experimental group|The treatment with zolmitriptan by sublingual administration is 2.5mg when headache attack.
89523697|NCT03374059|Experimental|Exercise|Exercise group received a home exercise program treatment for 4 weeks including isometric exercises for neck muscles and postural correction exercises for neck region.
89523698|NCT03374059|Experimental|Exercise and Life modification|This group received life modification suggestions additional to home exercise treatment program for 4 weeks.
89523699|NCT03374059|No Intervention|Control Group|Control group did not receive any treatments
89523700|NCT03373903|Placebo Comparator|Placebo once daily for 16 weeks|
89523701|NCT03373903|Experimental|BEZ235 once daily for 16 weeks|
89523702|NCT03373903|Experimental|BEZ235 twice daily for 16 weeks|
89523703|NCT03373903|Experimental|BEZ235 plus RAD001 once daily for 16 weeks|
89523704|NCT05089279|Experimental|Sequence 1|Period 1: D113/ Period 2: CKD-349
89523705|NCT05089279|Experimental|Sequence2|Period 1: CKD-349/ Period 2: D113
89523706|NCT02775409|Active Comparator|Subcutaneous|Subcutaneous placement of tissue expander
89523707|NCT02775409|Active Comparator|Submuscular|Submuscular placement of tissue expander
89523708|NCT05048329|Experimental|Soft Launch|The study will include ten eligible patients into the soft launch to test and reconfigure workflow, protocol, alerting structure and other operation related factors.
89523709|NCT05048329|Experimental|Pilot|After the soft launch, the study will include 45 eligible patients into the pilot to conduct the rest of the study
89523710|NCT05019547||Axial Spondyloarthritis|Participants with Axial Spondyloarthritis
89523711|NCT02440945|Experimental|collection of blood|160 old people for the collection of blood
89523712|NCT03872089|Experimental|Study participants|Measurements of the temperature of the plantar arch by thermal imaging. Result analysis regarding podologic grade ( 0-1-2-3)
89523713|NCT04445857|Active Comparator|Group 1|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 100 IU salmon calcitonin(1ml) intrathecally and injection of 10 ml normal saline (NS) slowly intravenously (IV) over 5 min.
89523714|NCT04445857|Active Comparator|Group 2|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 100 IU salmon calcitonin (1ml) diluted in 9 ml NS slowly IV over 5 min.
89523715|NCT04445857|Placebo Comparator|Group 3 (control group)|injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 10 ml NS slowly IV over 5 min.
89523716|NCT03373825|Experimental|Arm 1|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask participants to use the take-home rapid drug test to test their urine for presence or absence of fentanyl.
89523717|NCT03373825|Experimental|Arm 2|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask the participants to use the take-home rapid drug test to test the residue of their drug (ie. instruct them to test bags, cookers, spoons, etc.) for the presence or absence of fentanyl.
89523718|NCT03382873|Active Comparator|Group Lifestyle Balance (GLB)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who achieve >2.5% weight loss at week 5 will remain in the GLB arm.
89523719|NCT03382873|Experimental|Group Lifestyle Balance Plus (GLB+)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who fail to achieve >2.5% weight loss at week 5 will transfer to the GLB+ arm.
89523720|NCT04445779|Experimental|CoQ10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in the form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before the surgical procedure.
89523721|NCT04445779|Placebo Comparator|Placebo|Patients will receive per-orally placebo in three divided doses.
89523722|NCT03377101|Active Comparator|Arm I (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
89523723|NCT03377101|Experimental|Arm I (fulvestrant, palbociclib, copanlisib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib PO on days 1-21, and copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
89523724|NCT03373747|Experimental|Reliability of IET|In phase 1, the first of familiarization is to the participants understand the test and familiarize with the equipment after 24 to 48 hours, the participants will do the test applied twice at the same day with 10 minutes of rest. For realization of the IET the participants will be instructe to make the maximum effort as possible and mantain until they can't resiste. After one week the retest session will be doing. The order between the evaluators will be changed in the test and retest sessions.
89523725|NCT03373747|Experimental|Physiological analysis of IET|In phase 2, the participants will be submitted two sessions, familiarization session and test session. In the test session there is be two teste applied in the same day with approximately 20 minutes of rest. In the first test, thers is gas analysis during all the test until seven minutes after the test and blood lactat concentrate will be colected before the test with 10 minutes of rest, immediately after the teste and in the first, in the third, fifth and seventh minutes after the test. In the second test will be assess the muscular activation porcentage of lateral vastus muscle by means of twitch interpolation technique there is be performe before and after the test.
89523726|NCT04445467|Experimental|Favipiravir|1800 mg Favipiravir twice daily on Day 1 followed by 800 mg Favipiravir twice daily for the next 13 days.
89523727|NCT04445467|Placebo Comparator|Placebo|Matched Placebo
89523728|NCT03382795|Experimental|EGFR retreat group|
89523729|NCT03373669|Active Comparator|Shanchol Dose-interval Group 1|Participants in Dose-Interval Group 1 (DIG-1) will receive the oral cholera vaccine, Shanchol, according to the manufacturer instructions: in 2 doses at Day 0 and two weeks later (Day 14).
89523730|NCT03373669|Experimental|Shanchol Dose-Interval Group 2|Participants in Dose-Interval Group 2 (DIG-2) will receive the Adjusted Dose oral cholera vaccine, Shanchol, with a delayed second dose. The vaccine will be given at Day 0 and six months later.
89523731|NCT03124615|Experimental|Enzalutamide|Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
89523732|NCT03373513|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
89523733|NCT03373513|Active Comparator|Multiport Laparoscopy|Multiport Laparoscopic hysterectomy is performed in this other arm
89523734|NCT03125473|Experimental|Dose Group 1|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 8
89523735|NCT03125473|Experimental|Dose Group 2|Multiple doses of low doseVXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1, 3, and 5
89523736|NCT03125473|Experimental|Dose Group 3|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 29.
89523737|NCT03125473|Experimental|Dose Group 4|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 6 tablets of VXA-G1.1-NN on Days 1 and 29
89523738|NCT03373357|Other|Patient not SAHOS|The medical follow-up of patients no SAHOS will be assured by the investigators of the unity of cardiovascular explorations: phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.
89523739|NCT03373357|Other|Patient SAHOS sailed by the ventilation in PPC and not sailed|The patients who have a SAHOS sailed by the ventilation in PPC will be estimated and followed in 3 months then every 6 months by the investigators of the service of pneumology and the unity of cardiovascular explorations. The control of the material and its tolerance, the data supplied by the service providers (bodies of ventilation at home) will be estimated by the investigator of the service of pneumology. IDE the unity of cardiovascular explorations will plan and will realize a 2nd one MAPA after 3 months of ventilation in PPC.
89523740|NCT03376945||trail cohort|n-3 FAs
89523741|NCT03376945||control cohort|Structolipid
89523742|NCT03376789|Active Comparator|MYL-1501D (Process V Product)|MYL-1501D (Process V Product)
89523743|NCT03376789|Active Comparator|MYL-1501D (Process VI Product)|MYL-1501D (Process VI Product)
89523744|NCT03376711|No Intervention|Standard Care Group|Participants in this arm of the study will not have access to the online peer support program until the end of the 12-week trial.
89523745|NCT03376711|Experimental|Online Peer Support Program|Participants in the online peer support program arm of the intervention will have access to the website for 12 weeks.
89523746|NCT03125239|Experimental|Merestinib and LY2874455|"Patients who fulfill eligibility criteria will be entered into the trial to receive Merestinib and LY2874455.~After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Merestinib~LY2874455"
89523747|NCT03382483||EXOGEN Treated|Patients prescribed EXOGEN and treatment initiated
89523748|NCT03382483||Non-EXOGEN Treated|Patients in insurance claims database who have not been treated with a bone growth stimulator; derived via propensity score subclassification
89523749|NCT03376555|Active Comparator|Baseline|Subjects on normal personal diet Acetylcholine (ACh) Dose Response, Local heating (LH), and Flow Mediated Dilation with nitroglycerin experiments
89523750|NCT03376555|Experimental|Low Sodium, No Cheese|"Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
89523751|NCT03376555|Experimental|Low Sodium, Cheese|"Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
89523752|NCT03376555|Experimental|High Sodium, No Cheese|"Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
89523753|NCT03376555|Experimental|High Sodium, Cheese|"Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
89523754|NCT03382405|Experimental|mRNA-1647|
89523755|NCT03382405|Experimental|mRNA-1443|
89523756|NCT03382405|Placebo Comparator|Placebo|
89523757|NCT03373123|Experimental|Single arm study|Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy
89523758|NCT03372967||Comprehensive Vaccination History Review|Patients who receive a comprehensive vaccination history review at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
89523759|NCT02519881|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of ankle
89523760|NCT02519881|Active Comparator|microfracture|simple microfracture for cartilage defect of ankle
89523761|NCT03382327|Experimental|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review.
89523762|NCT03372889|Active Comparator|Patient educaiton materials Print based|Patients are randomly assigned to view print based educational material.
89523763|NCT03372889|Active Comparator|Patient educaiton materials Media Based|Patients are randomly assigned to view media based educational material.
89523764|NCT03372811|Active Comparator|TC cream (10%)|
89523765|NCT03372811|Placebo Comparator|Vehicle|
89523766|NCT03382171|Experimental|FoodforCare group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of five to six small protein and energy enriched meals that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
89523767|NCT03382171|No Intervention|Usual care group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
89523768|NCT03382093|Active Comparator|Personalized Feedback Intervention|A brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills.
89523769|NCT03382093|Active Comparator|Smoking Information Control|Standard, computer-delivered smoking cessation treatment/information.
89523770|NCT03382015|Active Comparator|Group 1|Receives 28 days of active test product (BKR-013) in Part 1 of the study and receives 28 days of placebo in Part 2 of the study, following a washout period.
89523771|NCT03382015|Placebo Comparator|Group 2|Receives 28 days of placebo in Part 1 of the study and receives 28 days of active test product (BKR-013) in Part 2 of the study, following a washout period.
89523772|NCT03715231|Experimental|Glaucoma & Glaucoma Suspect Patients|Patients with Glaucomatous optic neuropathy
89523773|NCT03376243|Experimental|Emollient (LIPIKAR BAUME AP+)|Daily application of Lipikar Baume AP+ emollient AND Structured parent education
89523774|NCT03376243|No Intervention|Control|Only structured parent education
89523775|NCT03381937|No Intervention|Spontaneous breathing|Spontaneous breathing without mechanical ventilation
89523776|NCT03381937|Experimental|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
89523777|NCT03381937|Experimental|Speech specific mechanical ventilation|Mechanical ventilation with specific parameters to improve speech
89523778|NCT03381859|Experimental|Treatment Arm|Patients to receive 12 weeks of Elbasvir (50mg) / Grazoprevir (100mg)
89523779|NCT03372499|Experimental|nutritional management group|diet management strategy for encephalopathy
89523780|NCT03372499|No Intervention|control group|Current ordinary guidance for patients after TIPS placement performed by trained nurse in the inpatient department
89523781|NCT03381781|Experimental|Experimental group|Patients with p53 mutations will be treated with Decitabine,Arsenic Trioxide and Cytarabine.
89523782|NCT03372421|Experimental|Social Story|Participants will read information about what to expect from the assessment in the format of a Social Story
89523783|NCT03372421|Active Comparator|Standard Information|Participants will read standard information about what to expect from the assessment.
89523784|NCT03381703|Experimental|Part 1|Investigate the absorption, metabolism, and excretion of YH12852
89523785|NCT03381703|Experimental|Part 2|Investigate the absolute bioavailability of YH12852
89523786|NCT03372265|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 15 mL, every 10th hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
89523787|NCT03372265|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
89523788|NCT03372265|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
89523789|NCT03376009||Liver transplant assessment patients|"Adult patients admitted to the Scottish Liver Transplant Unit for liver transplant assessment, over a 6 month study period will be considered for recruitment.~Interventions:~Blood sample for serum and plasma biomarkers:~Urine sample for biomarkers Cardiac bio-impedance (Cardioscreen Medis) Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor) Optical Coherence Tomography (Spectralis OCT) Arterial Spin Labelling Magnetic Resonance Imaging"
89523790|NCT03381625|Experimental|BMX-010 0.03%|200 subjects will receive BMX-010 0.03% twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
89523791|NCT03381625|Placebo Comparator|Placebo|100 subjects will receive placebo twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
89523792|NCT03372187|Experimental|DIET-MS|This group will follow a low glycemic load diet plan prescribed to them by a health coach and will receive information on exercise as well. This group will have weekly calls with the telehealth coach and will be provided access to the eHealth platform.
89523793|NCT03381547|Active Comparator|A|Pegilodecakin: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.
89523794|NCT03381547|Active Comparator|B|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.
89523795|NCT03381547|Active Comparator|C|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.
89523796|NCT03372109|Active Comparator|Modified Fasting Arm|Dietary Supplements administered daily for 52 days with a meal replacement shake administered two days per week for the study duration
89523797|NCT03372109|Placebo Comparator|Placebo|Multivitamin tablet administered daily for 52 days
89523798|NCT03372031|Experimental|Active-Passive|Active Piano training (8 sessions in two weeks) followed by listening to piano training (8 sessions in 2 weeks) (Passive condition)
89523799|NCT03372031|Experimental|Passive-Active|Passive piano training listening (8 sessions in two weeks) followed by active piano training (8 sessions in two weeks)
89523800|NCT03381469|Experimental|Periodontitis patients undergoing NSPT|Case group participants will receive comprehensive periodontal treatment also known as non-surgical periodontal therapy (NSPT) that will be completed by the end of week 20-21 of gestation.
89523801|NCT03381469|Active Comparator|Periodontitis Patients undergoing supragingival scaling|The control group participants with periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
89523802|NCT03381469|Active Comparator|Without Periodontitis undergoing supragingival scaling|Placebo group participants without periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
89523803|NCT03371953|Active Comparator|Vecuronium group|Vecuronium 0.08 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
89523804|NCT03371953|Active Comparator|Atracurium group|Atracurium 0.6 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
89523805|NCT03371953|Active Comparator|Vecuronium-Atracurium group|Vecuronium 0.04 mg/kg + atracurium 0.3 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
89523806|NCT03381391|Experimental|Feedback intervention condition|
89523807|NCT03381391|No Intervention|Assessment-only control condition|
89523808|NCT03375931|Experimental|prayer group|
89523809|NCT03375931|Active Comparator|non-prayer group|
89523810|NCT03550183|Experimental|mesenchymal stem cells|Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks.
89523811|NCT03381313|Experimental|Anomic Patients|Pure Anomic Patients underwent to conditioned word repetition training or traditional one.
89523812|NCT03371797||Treatment group|Valsartan, Amlodipine single pill combination.The recommended dosage of AVSAR (Valsartan/Amlodipine) is one tablet per day.
89523813|NCT02520115|Experimental|Arm I (induction)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum and tissue samples for analysis via PCR and IHC at baseline, time of surgery, and 7-14 days after surgery.
89523814|NCT02520115|Experimental|Arm II (surveillance and recurrence)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum samples for analysis via PCR and IHC at the time of clinically suspected recurrence, 2 days after completion of induction, and 7-14 days after induction.
89523815|NCT03375775|Experimental|Treatment group|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
89523816|NCT03375775|Active Comparator|Control group|No immunotherapy, symptomatic treatment These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
89523817|NCT03381235|Experimental|Moderate exercise|Subjects in the moderate exercise group will participate in Spin exercise designed by Dr. Nocera.
89523818|NCT03381235|No Intervention|Mild exercise|Sessions will be focused on balance and stretching.
89523819|NCT03371641|Other|Alcoholic exposure group|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
89523820|NCT03371641|Other|Control|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
89523821|NCT03381157||Cystic Fibrosis Group|
89523822|NCT03381157||Control Group|
89523823|NCT04527133|Experimental|Stage 1/Group 1|Intravenous Aprotinin in addition to standard care: 1 000 000 KIU IV daily during 3 days
89523824|NCT04527133|Experimental|Stage 2/Group 2|Inhaled Aprotinin in addition to standard care: 625 KIU 4 times per day during 5 days
89523825|NCT04527133|Experimental|Stage 2/Group 3|Intravenous Aprotinin in addition to standard care that includes Favipiravir: 1 000 000 KIU IV daily during 5 days
89523826|NCT03371563||elderly patients|
89523827|NCT03371563||middle-aged patients|
89523828|NCT03371563||controls|
89523829|NCT03371563||young patients|
89523830|NCT03381079|Experimental|Surgical group|In this arm, the adults with high myopia will be given posterior scleral reinforcement.
89523831|NCT03381079|No Intervention|Control group|In this arm, the adults with high myopia will not be given any surgical treatment.
89523832|NCT03375541|No Intervention|Control|Natural discussion of disease modifier selection conducted without augmentation by risk aversion calculator
89523833|NCT03375541|Experimental|Calculator|Natural discussion of disease modifier selection conducted with augmentation by risk aversion calculator
89523834|NCT03371329|Experimental|Group 1 MSC dose .5 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for 3 participants.
89523835|NCT03371329|Experimental|Group 2 MSC dose 1 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10^6/kg for next 3 participants.
89523836|NCT03371329|Experimental|Group 3 MSC dose 2 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10^6/kg for next 3 participants.
89523837|NCT03371329|Experimental|Group 4 MSC dose 0.5 x 10^6/kg I|Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for final 3 participants.
89523838|NCT03381001|Active Comparator|embryo transfer after embryo thaw|Embryos will be transferred at the same day of the thawing procedure
89523839|NCT03381001|Experimental|embryo transfer after thaw and culture|Embryos will be transferred one day after thawing procedure
89523840|NCT03380923|Experimental|Moderate Intensity (MOD)|"Endurance Training (ET): 3 d/wk x 30 minutes (min) of steady-state, moderate-intensity exercise on a treadmill or stationary cycle ergometer at target heart rate (HR) = 65-75% of maximum oxygen consumption rate (VO2max). The two modes (treadmill, bicycle) are offered for variety, and each subject is required to use each mode at least 1 d/wk to prevent bias.~Resistance training (RT): 2 d/wk consisting of a prescription engaging all major muscle groups in 10 movements. Excluding abdominal crunches, target intensity is 12 repetitions/set to volitional fatigue. Subjects complete 3 sets of each movement, with ~60 seconds (s) rest between sets. For each movement, resistance increases when 14 repetitions are achieved for 2 of 3 sets.~HR is monitored throughout each session and stored for analysis."
89523841|NCT03380923|Experimental|High Intensity (HI)|"RT: The 2 d/wk RT prescription differs from the MOD arm only in intensity and rest intervals. The same approach to progression applies, but HI RT intensity targets 8-10 repetitions per set; thus, resistance loads increase when 10 repetitions are achieved for 2 of 3 sets. The HI arm performs superset training, pairing movements stressing different muscle groups, with only 30-45 s between.~ET: In lieu of steady-state endurance exercise, the HI arm performs high-intensity interval training (HIIT) 3 d/wk using a mix of challenging, explosive movements at maximal intensity. 10 x 30 s maximal intensity intervals are separated by 30 s rest intervals.~HR is monitored throughout each session and stored for analysis."
89523842|NCT03125161|Experimental|Arm A|HAI plus chemotherapy ± target therapy
89523843|NCT03125161|Active Comparator|Arm B|chemotherapy ± target therapy
89523844|NCT03370081|Experimental|CAPNO+|END TIDAL CO2(EtCO2) is monitoring and PACU nurses can see the values delivered by the capnography device
89523845|NCT03370081|No Intervention|CAPNO-|END TIDAL CO2(EtCO2) is monitoring but PACU nurses cannot see the values delivered by the capnography device
89523846|NCT03125317||The music group|Participant will allow to listen any kind of music which they wish
89523847|NCT03125317||valsalva maneuver|participants will be asked to take a deep breath and exhale the air out in 15 seconds
89523848|NCT03125317||The control group|no intervention
89523849|NCT03363685||Low risk|For NSCLC spinal metastasis patients with 0-3 of novel survival prediction algorithm.
89523850|NCT03363685||Intermediate risk|For NSCLC spinal metastasis patients with 4-6 of novel survival prediction algorithm.
89523851|NCT03363685||High risk|For NSCLC spinal metastasis patients with 7-10 of novel survival prediction algorithm.
89523852|NCT03369925|Placebo Comparator|Placebo|
89523853|NCT03369925|Experimental|Cognizin|
89523854|NCT03369847|Experimental|Inhaled Corticosteroids|"Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer x 28 days.~Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer x 28 days"
89523855|NCT03369847|No Intervention|Standard Care|Patients allocated to this group will not receive an asthma controller medication from the emergency department. The intervention group will receive prescriptions for inhaled albuterol and oral corticosteroids as per standard treatment.
89523856|NCT04526743||BS patients|Candidates to primary BS undergoing laparoscopic gastric bypass (LGBP) or laparoscopic sleeve gastrectomy (LSG) from September 2020 to September 2021. Patients will be evaluated prior to BS and at 4 months, 1, 3 and 5 years after BS.
89523857|NCT04526743||no BS patient|A control group of subjects with obesity not candidates to BS matched with the intervention group for age, sex and BMI prior to BS. Patients will be evaluated once.
89523858|NCT04526431||Tacrolimus once-daily|Patients receiving tacrolimus as a once-daily formulation (Envarsus)
89523859|NCT04526431||Tacrolimus bid|Patients receiving tacrolimus as a twice-a-day formulation.
89523860|NCT04526353|Experimental|Oxybutynin during 9 months.|0.1mg / kg 2x / day from inclusion and for 9 months.
89523861|NCT04526353|No Intervention|No oxybutynin|No treatment affecting bladder function
89523862|NCT03363607|Experimental|3D printed transfer tray group|Indirect bonding using digital 3D printed transfer tray
89523863|NCT03363607|Active Comparator|Thermoformed transfer tray group|Indirect bonding using Thermoformed transfer tray
89523864|NCT03369769|Experimental|Canine & Adult Handler Activity|Unstructured 10-minute small group interaction with canine & handler
89523865|NCT03369769|Active Comparator|Toy and Adult Handler Activity|Unstructured 10-minute small group interaction with toy & handler
89523866|NCT03371173|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
89523867|NCT03371095|Experimental|Infliximab|Infliximab 5mg/kg intravenously at week 0, 2, 6, 12, and 18
89523868|NCT03371095|Active Comparator|Cyclophosphamide|Cyclophosphamide 0.7g/m2 up to 1.2g/m2 intravenously at week 0, 4, 8, 12, 16 and 20
89523869|NCT03363451||Infection Group|Patients with end stage liver disease with infection
89523870|NCT03363451||Non-infection Group|Patients with end stage liver disease without infection
89523871|NCT04525963|Experimental|Experimental: Intervention Arm|":In the experimental group,the operating room nurse, who is given intervention training , will be provided to visit the patient before surgery. After the verbal training of the operating room nurse, a printed booklet will be left for the patient to read.~Assigned Interventions The level of anxiety experienced by the patients increases the postoperative perception and analgesic need, increasing the sequence and anesthetic substance. For these reasons, there is a need for studies to reduce pain distribution and severity by directly dealing with pre- and postoperative anxiety and anxiety levels. Similarly, the role of the operating room nurse in reducing patient anxiety is increasingly recognized. It is observed that the pre-operative visit and education reduce the pre-operative anxiety level in patients undergoing surgical intervention, and the pre-operative visit of the operating room nurse is on the agenda."
89523872|NCT04525963|No Intervention|No Intervention|There will be no intervention in the control group. The procedures of the institution will be applied before and after the operation.
89523873|NCT03369535|Placebo Comparator|Baseline|Baseline corresponds to typical American diet
89523874|NCT03369535|Active Comparator|PROT rich diet|Protein rich diet for 6 weeks
89523875|NCT03369535|Active Comparator|MUFA rich diet|MUFA rich diet for 6 weeks
89523876|NCT03369535|Active Comparator|CARB rich diet|CARB rich diet for 6 weeks
89523877|NCT03363295|Experimental|Intracameral moxifloxacin|Injection of 0,03ml of moxifloxacin in the anterior chamber following phacoemulsification surgery
89523878|NCT03363295|No Intervention|No - Intracameral moxifloxacin|This group won't receive any prophylaxis after phacoemulsification surgery
89523879|NCT03370705|Active Comparator|CT group|78 patients will be treated by conventional treatment : antiplatelet therapy + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l
89523880|NCT03370705|Experimental|Sulodexide + CT group|"78 patients will be treated by :~Sulodexide (250ULS, twice daily , oral administration)~Conventional treatment : antiplatelet agents + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l"
89523881|NCT03363139||Patients with T790M mutation|Patient who has progressed to Tyrosin Kinase inhibitors and has the mutation of the gen T790M
89523882|NCT04525807||Multiomics arm|Guide therapy based on multi-omics
89523883|NCT04445077|Experimental|Intervention group|The education will be delivered weekly with 60-90 minutes per lecture for eight lectures. Multiple teaching methods will be used, including lectures, structured handouts, video, role play, case study and discussion. During the study period, the research team will provide ongoing support and consultation through electronic communication and bimonthly field visits.
89523884|NCT04445077|Other|Control group|Printed materials will be given to the participants in the control group for their self-study.
89523885|NCT03370549|Experimental|AWARE intervention|Group psychotherapy intervention for Asian-American women
89523886|NCT03370549|Other|Waitlist control|Delayed AWARE intervention for Asian-American women
89523887|NCT03369379|Active Comparator|D3 Vitamin|In this group subjects will receive 1 vitamin D3 capsule of 50,000 units, each week, for 12 weeks.
89523888|NCT03369379|Placebo Comparator|Placebo|In this group the subjects will receive 1 placebo capsule each week for 12 weeks.
89523889|NCT03123991|Experimental|Experimental Group|UP-A adapted as a preventive intervention. Specifically, the Spanish version of The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a 9 sessions school-based preventive intervention. The intervention is delivered in nine weekly sessions (each session lasting around 55 minutes).
89523890|NCT03123991|Other|Wait-list Control Group|Same than experimental group (EG), after EG finishes. Specifically, classes in waitlist condition will be offered the same intervention than experimental group after EG finishes the three months follow-up.Before that, waitlist means that the classess work as usual with issues of mental health.
89523891|NCT03369145|Experimental|High-fat diet|Participants will consume a hypercaloric, high-fat diet. Participants will be provided with all the food during the week and will be instructed to consume all of the foods provided and no extra calorie containing food or drink. In the event of leftover food, participants will be asked to return the food for measurement and subsequent subtraction from their total energy intake.
89523892|NCT03369145|No Intervention|Control diet|Participants will consume their normal 'habitual' diet for seven days which will be compared to their habitual diet recorded by a three day food diary before commencing the two diets. Participants will be instructed to carry on as normal and eat their usual diet and this period will be used as a comparator to the high-fat diet. They will also be told to record their food intake for 3 days during the diet to quantify their control diet.
89523893|NCT03362983|Experimental|Care HND Intervention|Integrated, multidisciplinary, person centered care at HND-centrum.
89523894|NCT03362983|No Intervention|Standard care|Standard care at separate specialty clinics and primary care as needed.
89523895|NCT02519569|Experimental|Intervention group|Internet-based cognitive-behavioral therapy for complicated grief
89523896|NCT03372577|Experimental|patient and partner|
89523897|NCT03372577|Experimental|patient ,partner and cardiac rehabilitation team|
89523898|NCT03372577|Active Comparator|Treatment as usual|
89523899|NCT03362905|Experimental|Lidocaine spray Arm|This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.
89523900|NCT03362905|Active Comparator|Lidocaine cream Arm|This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.
89523901|NCT03362905|Active Comparator|Lidocaine injection Arm|This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight o'clock of the cervico-vaginal junction, and 2 ml to the area to be grasped with the tenaculum for paracervical block.
89523902|NCT02519647|Active Comparator|tracheal intubation with Gliderite|Gliderite will be used for intubation
89523903|NCT02519647|Experimental|Tracheal intubation with S-Guide|S-Guide will be used for intubation
89523904|NCT04525651|Experimental|Digital Acupuncture Instrument Group|The needles will be stimulated manually to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness) and then paired electrodes from the digital acupuncture instrument will be attached to the needle handles and another two adjunct acupoints by the research assistant. The electric current will be increased until the needles begin to vibrate slightly.
89523905|NCT04525651|Active Comparator|Manual Acupuncture Group|Patients in the MA group will undergo similar procedures as the EA group except that no current will be output from the instrument.
89523906|NCT04525651|Sham Comparator|Sham Acupuncture Group|Patients in the SA group will receive non-invasive acupuncture to avoid de qi.
89523907|NCT03370315|Experimental|Dance Group|"This group will be undergo dance classes two times a week, for 12 weeks. 24 sessions.~Intervention administered: Dance classes inspired by the rhythm of Forró and Samba."
89523908|NCT03370315|Experimental|Walking Group|"This group will be undergo walking training two times a week, for 12 weeks. 24 sessions.~Intervention administered: Walking program with 3 different moments."
89523909|NCT03362827||Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
89523910|NCT03362827||Subjects without chronic low back pain|Participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
89523911|NCT03370159|Experimental|Treatment (CPI-613, docetaxel)|Patients receive CPI-613 IV over 2 hours on days 1 and 3, and docetaxel IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
89523912|NCT02519725|Active Comparator|With diary|a ICU diary is open by staff for the patient and his relatives during the ICU stay
89523913|NCT02519725|No Intervention|Without diary|No diary is open during the ICU stay
89523914|NCT03362593|Experimental|MEDI7219|Experimental Drug
89523915|NCT03362593|Placebo Comparator|Placebo|Placebo
89523916|NCT03362593|Placebo Comparator|Formulation without Active Drug|Formulation without Active Drug
89523917|NCT03358459||EP|For diagnosis non-acquired epilepsy;
89523918|NCT03358381|Experimental|gap balance group|The type of total knee arthroplasty will be the balance gap.The gap balance type of total knee arthroplasty will be performed.
89523919|NCT03358381|Active Comparator|measured resection group|The type of total knee arthroplasty will be the measured resection.The measured resection type of total knee arthroplasty will be performed.
89523920|NCT04522297|Experimental|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
89523921|NCT04522297|Active Comparator|Nor-epinephrine|Intravenous infusion norepinephrine
89523922|NCT03358225||Anterior Cervical Discectomy and Fusion|The patients undergoing anterior cervical discectomy and fusion surgery
89523923|NCT03358225||Cervical Artificial Disc Replacement|The patients undergoing cervical artificial disc replacement surgery
89523924|NCT03358225||Hybrid surgery|The patients undergoing hybrid surgery(1-level ADR plus 1-level ACDF) surgery
89523925|NCT04521907||Group 1|Group 1 includes patients who underwent cataract surgery with primary IOL implantation
89523926|NCT04521907||Group 2|Group 2 includes patients who underwent cataract surgery with secondly IOL implantation
89523927|NCT04521907||Group 3|Group 3 includes patients who underwent cataract surgery without IOL implantation.
89523928|NCT03369067|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
89523929|NCT03369067|Placebo Comparator|Sensor Augmented Pump Therapy|Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
89523930|NCT03368989||treatment with radium-223 Dichloride (Xofigo)|
89523931|NCT03368911|Experimental|Reinforced tube group|use an reinforced endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
89523932|NCT03368911|Active Comparator|Conventional tube group|use an conventional endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
89523933|NCT04525729|Experimental|Rituximab+RASi(ACEI and/or ARB)|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject, combined with rituximab 1g(D1, D31 respectively, intravenous infusion). Add 1 g rituximab at 6 months.
89523934|NCT04525729|Other|RASi(ACEI and/or ARB）|The maximum tolerable dose of RASi will be using everyday depending on the individual factors of the subject.
89523935|NCT03362437|Experimental|Treatment A|Receive 200 mg BMS-986177 Form A without food
89523936|NCT03362437|Experimental|Treatment B|Receive 200 mg BMS-986177 Form B without food
89523937|NCT03362437|Experimental|Treatment C|Receive 200 mg BMS-986177 Form B with food
89523938|NCT04525495|Experimental|Dopamine treatment|
89523939|NCT03362359|Experimental|Ga-68-PSMA-11|
89523940|NCT04525417|Other|hospital healthcare workers|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
89523941|NCT04525417|Other|private health professionals|Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test
89523942|NCT03358069||deep anesthetic state|technique of Anesthesia at the time of airway device removal
89523943|NCT03358069||awake|technique of Anesthesia at the time of airway device removal
89523944|NCT03358069||emergence time (clinical): min|The duration from the time of anesthestic medications stop and the time that patient spontaneously open their eyes
89523945|NCT03358069||Emergence time (entropy): min|time from Entropy value above 60 to 90
89523946|NCT03362281|Experimental|Ilaprazole|
89523947|NCT03362281|Active Comparator|omeprazole|
89523948|NCT04521985||thoracolumbar kyphosis|patients undergoing thoracolumbar kyphosis surgery
89523949|NCT03362203||Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
89523950|NCT03362203||Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
89523951|NCT04032093|Experimental|RSV dose with aluminum hydroxide|RSV vaccine with aluminum hydroxide
89523952|NCT04032093|Experimental|RSV dose without aluminum hydroxide|RSV vaccine without aluminum hydroxide
89523953|NCT04032093|Experimental|Higher RSV dose with aluminum hydroxide|Higher dose level RSV vaccine with aluminum hydroxide
89523954|NCT04032093|Experimental|Higher RSV dose without aluminum hydroxide|Higher dose level RSV vaccine without aluminum hydroxide
89523955|NCT04032093|Placebo Comparator|Placebo dose|Normal saline solution for injection (0.9% sodium chloride injection)
89523956|NCT03357913||Co morbidities after lung transplantation in cystic fibrosis|The population studied is the cohort of cystic fibrosis patients who received a bipulmonary transplant between 2004 and 2014 in one of the two transplantation centers in the Rhône-Alpes region.
89523957|NCT03357835||Normal Triage|Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (att), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded.
89523958|NCT03357835||Software Triage|"triage maintenance / evaluation will be done with computer software called Trauma Decision System (TraumaDS) developed by us. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes. According to this scoring, patients who need urgent care and who should not wait will be considered red code, patients who should wait less than 15 minutes will be considered orange coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded."
89523959|NCT03368755|Experimental|Cases (IUGR)|50 school-aged children (7-10 years old) exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with controls Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance
89523960|NCT03368755|Active Comparator|Controls|"100 school-aged children (7-10 years old) not exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with cases.~Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance"
89523961|NCT03368599|Experimental|Bronchoscope guide group|DLT is advanced into the main bronchus through the guide of fiberoptic bronchoscope (Bronchoscope guided advancement).
89523962|NCT03368599|Active Comparator|Conventional group|DLT is advanced blindly to the main bronchus level (Conventional advancement).
89523963|NCT02518789|Experimental|Low-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.
89523964|NCT02518789|Experimental|High-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.
89523965|NCT02518789|Placebo Comparator|normal saline Control group|-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.
89523966|NCT03361969|Active Comparator|estetrol|
89523967|NCT03361969|Placebo Comparator|placebo|
89523968|NCT03368521|Other|Back pain screening group|Includes the Group of patients where the care giver has used the back pain screening tests studied in order to judge how to proceed with rehabilitation, which level of rehabilitation is appropriate.
89523969|NCT03368521|No Intervention|treatment as usual|The Group get treatment as usual, where the care giver base the rehabilitation plan without taking the scorings from the screening tool into consideration.
89523970|NCT02994225|Experimental|Study arm|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
89523971|NCT03361891|No Intervention|Control|Patients receive no intervention
89523972|NCT03361891|Experimental|WalkMORE group|WalkMORE Ambulation program. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge.
89523973|NCT03357679|Active Comparator|Bed up head elevated intubation|Patients positioned in the bed up head elevated position, followed by tracheal intubation
89523974|NCT03357679|Active Comparator|Glidescope assisted intubation|Glidescope is used for laryngoscopy, followed by intubation
89523975|NCT02983695|Experimental|treatment|all participants will be in this arm and will receive study drug 'Cannabidiol-Rich whole Plant Extract (TIL-TC150) to assess dosing and tolerability according to study protocol.TIL-TC150 Oil is the study product The active ingredients in TIL-TC150 Oil are THC and CBD, present in a 1:50 ratio. These active ingredients are derived from Cannabis sativa L. strains produced by Tilray, and suspended in a grape seed oil. This suspension is administered at a dose of 2mg/kg/day CBD divided BID and titrated up to a maximal dose of 16mg/kg/day CBD (or maximal tolerated).
89523976|NCT02549781|Experimental|Gambler performing Go-Nogo|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
89523977|NCT02549781|Active Comparator|Social layer performing Go-Nogo|"In this study, social player performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
89523978|NCT02549781|Placebo Comparator|non-gamer witnesses performing Go-Nogo|"In this study, non-gamer witnesses performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
89523979|NCT03361813|Active Comparator|trans-cutaneous ultrasound guided peritonsillar infiltration|
89523980|NCT03361813|Placebo Comparator|trans-oral ultrasound guided peritonsillar infiltration|
89523981|NCT03357601|Experimental|High Intensity Interval Training|six 20 second bouts of high intensity interval exercise (HIIT) separated by 2 minutes of active recovery with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
89523982|NCT03357601|Experimental|MCEET|14 minutes of Moderate Endurance Training with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
89523983|NCT02929485|Experimental|Experimental: Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
89523984|NCT02929485|Placebo Comparator|Comparator: Placebo|Drug: Placebo for tolcapone administered at study visit
89523985|NCT02929485|Experimental|Experimental: Bromocriptine|Drug: Bromocriptine 1.25mg (single dose) administered at study visit
89523986|NCT03368443|Active Comparator|Single-room group|The participants assigned to the Single-room group will receive treadmill training and overground gait training in one room (Room A) throughout the training sessions.
89523987|NCT03368443|Experimental|Two-room group|The participants in the Two-room group will receive treadmill training and overground gait training in 2 rooms (Room A and B) in an alternating order.
89523988|NCT04523623|Experimental|Ibuprofen Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
89523989|NCT04523623|Experimental|Oxycodone Group|To compare analgesia from ibuprofen to oxycodone in the initial treatment of acute pain in suspected isolated forearm fractures in children.
89523990|NCT03368365|Other|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®.
89523991|NCT04521595|Experimental|weigh smart intervention|open treatment arm to receive group based lifestyle intervention via telehealth.
89523992|NCT03361657||One sample|Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 10-12mmHg
89523993|NCT03357289|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89523994|NCT03357289|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89523995|NCT03368287|Experimental|activity tracker|In this study, Fitbit One, the activity tracker, will be used for every participants to evaluate the daily steps before and after surgery for one year
89523996|NCT03368209|Experimental|OUH protocol|"The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:~Optical Coherence Tomography (OCT)~Optical screening on measuring site with WM3.4.~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2."
89523997|NCT03368209|Experimental|Home 1 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference."
89523998|NCT03368209|Experimental|Home 2 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference."
89523999|NCT02518867|Experimental|high intensity iTBS|high intensity iTBS: 100% of active motor threshold for 3 days.
89524000|NCT02518867|Experimental|low intensity iTBS|low intensity iTBS: 80% of active motor threshold for 3 days.
89524001|NCT02518867|Sham Comparator|sham iTBS|sham iTBS for 3 days.
89524002|NCT03368131|Experimental|Trastuzumab XELOX and radiotherapy|Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. XELOX：Capecitabine 825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45 Gray (unit)Gy/25f （1.8Gy/f/d，5 f/w）
89524003|NCT03368131|Active Comparator|XELOX and radiotherapy|Capecitabine：825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
89524004|NCT04521751|Experimental|EMP16-02 120 mg orlistat/40 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.~Dosage: 120 mg O/40 mg A (given as 2 capsules EMP16-02-60/20). Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
89524005|NCT04521751|Experimental|EMP16-02 150 mg orlistat/50 mg acarbose|"Dosage form: Oral, modified-release (MR) fixed dose combination (FDC) of orlistat and acarbose formulated in capsules.~Dosage: 150 mg O/50 mg A (given as 1 capsule EMP16-02-90/30 and 1 capsule EMP16-02-60/20).~Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
89524006|NCT04521751|Placebo Comparator|Placebo|"Dosage form: Matching, oral capsule. Identical in appearance but contain only cellulose.~Dosage: Placebo (given as 2 placebo capsules) Frequency: Three times daily (TID) together with the three main daily meals .Taken halfway through each meal, together with approximately 100-200 mL water (or other drink).~Duration: 26 weeks."
89524007|NCT02518711|Experimental|Behavioral teacher program|The behavioral teacher program was used by the participant's teacher in the classroom during 18 weeks.
89524008|NCT02518711|No Intervention|Control group|Children within the control group did not receive the behavioral teacher program but were allowed to receive regular care
89524009|NCT04521517|Experimental|Pamphlet with timing of family planning|"Pamphlet with timing of family planning and Routine service"
89524010|NCT04521517|No Intervention|Only routine service|Receive only routine service
89524011|NCT04521673||infectious uveitis|Patients suffering from suspected infectious uveitis, who have vitrectomy performed for diagnostic purpose or anterior chamber tap
89524012|NCT04521673||Control group|Patients suffering from either cataract surgery or vitrectomy who has been ruled out for infectious ocular diseases
89524013|NCT03361579|Other|Placebo education group|Prior to the intervention during the Placebo is given, the volunteer receives a detailed information about the effect and the strength of an open-label placebo. This education is performed via a slide show and a news report video. The important terms for Placebo analgesia: positive expectations, conditioning, communication are discussed
89524014|NCT03361579|Other|Placebo non education group|No detailed Information about open-label placebo prior to the intervention. The volunteer is told about the possible strength of the Placebo effect on pain directly before the application.
89524015|NCT03367897||Bleeding ulcer/erosions|Patients with hematemesis and/or melena, anemia or positiv FOBT that during gastroscopy are diagnosed with ulcer and/or erosions of the ventricle and/or duodenum. Gastroscopy must be performed within 72 hours of the findings above.
89524016|NCT03367897||Peptic ulcer without bleeding|Control group for H. pylori will be patients with peptic ulcer without bleeding. These patients are systematically registered at SØ from August 2013 through the ongoing European registration study - HpEuReg study. SØ participate in this study, together with 9 other Norwegian hospitals, which is approved by REK.
89524017|NCT03361501|Experimental|CaPre|
89524018|NCT03361501|Placebo Comparator|Placebo|
89524019|NCT03123523||Patients group|35 patients
88811825|NCT01385579|Experimental|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit
89524020|NCT03123523||Healthy volunteers|20 healthy volunteers
89524021|NCT01675167|Placebo Comparator|Placebo Buccal Film|Twice Daily Dosing
89524022|NCT01675167|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
89524023|NCT03370627|Experimental|Patient|
89524024|NCT03367663|Experimental|low dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
89531977|NCT04391023|Experimental|2 mA tDCS|The participants in this group will receive tDCS at 2 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (2 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
89531978|NCT04391023|Experimental|4 mA tDCS|The participants in this group will receive tDCS at 4 mA while seated comfortably. The intensity will start at 0 mA and will be incrementally increased to the target intensity (4 mA) over the initial 30 seconds. Then, the tDCS will deliver stimulation at the target intensity until the 19:30 minute time point. At this point, the current will gradually decrease back to 0 mA.
89524025|NCT03367663|Experimental|high dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
89524026|NCT03123601|Experimental|Risk sign displays|At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.
89524027|NCT02265939|Placebo Comparator|0% NPO-13|Placebo
89524028|NCT02265939|Active Comparator|0.2% NPO-13|Low dose
89524029|NCT02265939|Active Comparator|0.4% NPO-13|Medium dose
89524030|NCT02265939|Active Comparator|0.8% NPO-13|High dose
89524031|NCT03123289|Experimental|68Gallium-citrate|"This arm, undergoing the 68-Gallium citrate PET/CT scan intervention, includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms."
89524032|NCT03123289|Experimental|18F-FDG|"This arm, undergoing the 18F FDG PET/CT scan intervention, includes the PET/CT scans performed with 18F-FDG tracer.~Note that same patients scanned with different radiotracers serve in both arms."
89524033|NCT02459847|Experimental|Mindfulness|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant listening to a 19-minute audio-recorded body scan (i.e., mindfulness training), followed by standard care.
89524034|NCT02459847|Experimental|Biofeedback|Two sessions, each lasting 60-minutes total. The first session involves standard hand therapy care for the entire session. The second session begins with the participant receiving 20 minutes of visual biofeedback training using sonographic imaging (i.e., sonographic biofeedback), followed by standard care.
89524035|NCT04521049|Active Comparator|saxagliptin|patients received 5 mg daily ( 2.5 mg daily dose was given to patients with an eGFR of <50 mL/min/1.73 m2
89524036|NCT04521049|No Intervention|control|patients received the antihyperglycemic medication(s) such as metformin and/or sulphonyl ureas or insulin with no added gliptins,
89524037|NCT02267343|Experimental|ONO-4538 Arm|ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89524038|NCT02267343|Placebo Comparator|Placebo Arm|Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
89524039|NCT03123445|Experimental|Endostar + Gemcitabine and Cisplatin|Patients in this group will be given endostar combined with gemcitabine and cisplatine.
89524040|NCT03123445|Active Comparator|Gemcitabine and Cisplatin|Patients in this group will be given gemcitabine and cisplatine.
89524041|NCT04520581|No Intervention|Control|Use in the shape of an endotracheal tube.
89524042|NCT04520581|Experimental|"Group O"|"Just before the induction of medicine is injected, the assistant makes endotracheal tube into O shape."
89524043|NCT03361267|Active Comparator|Bismuth containing quadruple therapy|If CLO test is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days If CLO test is negative, no intervention is needed
89524044|NCT03361267|Experimental|tailored therapy|If H. pylori PCR is negative, no intervention is needed If H. pylori PCR is positive and mutation is negative, triple regimen (rabeprazole 20 mg bid, amoxacillin 1000 mg bid, clarithromycin 500mg bid) are prescribed for 7 days is given If H. pylori PCR is positive and mutation is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days is given
89524045|NCT03357133|Experimental|Tirofiban and alteplase|
89524046|NCT03357133|Placebo Comparator|Alteplase|
89524047|NCT05128305|Experimental|group 1|traditional chinese medicine 1 and traditional chinese medicine 2 simulant
89524048|NCT05128305|Experimental|group 2|traditional chinese medicine 1 simulant and traditional chinese medicine 2
89524049|NCT05128305|Experimental|group 3|traditional chinese medicine 1 and traditional chinese medicine 2
89524050|NCT05128305|Placebo Comparator|group 4|traditional chinese medicine 1 simulant and traditional chinese medicine 2 simulant
89524051|NCT03357055|Experimental|Ketamine arm|Ketamine group will receive an IV infusion of 0.25mg/kg of ketamine in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure patients will receive 0.25mg/kg of ketamine infusion at 10ml/hour until the end of operation.
89524052|NCT03357055|Placebo Comparator|Control arm|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation.
89524053|NCT03367585|Experimental|Experimental|The experimental group, which will supplement vitamin D3 50,000 IU / week, being in two capsules (25,000 IU / week each),
89524054|NCT03367585|Placebo Comparator|Placebo|The placebo group will inject two capsules of equal size, volume and coloration, composed of lactose, without the vitamin D3 supplement.
89531979|NCT04360785|Experimental|Methotrexate + Adalimumab|Experimental group : patients will receive 2 subcutaneous injections of methotrexate in addition of the usual adalimumab
89531980|NCT04360785|No Intervention|Adalimumab|Reference group : patient will receive adalimumab as usual to treat spondyloarthritis
89531981|NCT04338022|Experimental|Evobrutinib + Teriflunomide matched Placebo: DB Period|
89531982|NCT04338022|Active Comparator|Teriflunomide + Evobrutinib matched Placebo: DB Period|
89524055|NCT03367507|Experimental|80% Sub-symptom threshold aerobic exercise|The moderate intensity intervention group will exercise at 80% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The participants will be instructed to follow a program of moderate intensity activity in the form of their choice, we will recommend the following: stationary cycling, brisk walking, light jogging or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate wearing both the Actigraph and Polar HR monitor provided.
89524056|NCT03367507|Active Comparator|60% Sub-symptom aerobic exercise|The light (conservative) intensity intervention group will exercise at 60% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The low intensity group will perform their exercise program at their own discrepancy however we will advise either of the following activities: light walking, stationary cycling or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate while simultaneously wearing both the Actigraph and polar HR monitor.
89524057|NCT04796259|No Intervention|Negative control|Water
89524058|NCT04796259|Active Comparator|Positive control|Non-alcoholic beer solids
89524059|NCT04796259|Experimental|Intervention 1|Malt ingredient I
89524060|NCT04796259|Experimental|Intervention 2|Malt ingredient II
89524061|NCT03360955||Total Intravenous Anesthesia|Patients with total intravenous anesthesia during the cardiac surgery
89524062|NCT03360955||Spinal Anesthesia|Patients with spinal anesthesia with minimal opioid dose.
89524063|NCT00584025|Experimental|1|Keppra IV
89524064|NCT00584025|Placebo Comparator|2|Placebo
89524065|NCT02519179|Experimental|Conventional vs. Opaque, Weighted Bottle|This is a within-subject experiment; mothers will be asked to feed their infants from a clear, conventional bottle during one visit and an opaque, weighted bottle during the other visit. Order of conditions will be counterbalanced.
89524066|NCT05124015||Patients with pulmonary arterial hypertension|Exercise capacity using six minute walk test, respiratory muscle strength using mouth pressure device, pulmonary function using spirometry, dyspnea using Modified Borg scale physical activity using multi-sensor activity monitor.
89524067|NCT05124015||Healthy controls|Exercise capacity using six minute walk test, respiratory muscle strength using mouth pressure device, pulmonary function using spirometry, dyspnea using Modified Borg scale physical activity using multi-sensor activity monitor.
89524068|NCT04520893|Experimental|VCV pause|volume controlled ventilation with pause time 30%
89524069|NCT04520893|Active Comparator|VCV|volume controlled ventilation (without pause)
89524070|NCT04520893|Active Comparator|PCV-VG|pressure controlled ventilation - volume guaranteed
89524071|NCT01735461|Experimental|Dietary supplement|Calcium Carbonate
89524072|NCT04520737|Active Comparator|16W group|Multimodal prehabilitation program (MPP) will be implemented during 16 weeks, 12 weeks during chemotherapy (CT) and 4 weeks while waiting for surgery.
89524073|NCT04520737|Active Comparator|4W group|Multimodal prehabilitation program (MPP) will start at the end of preoperative chemotherapy (CT) until surgery (4 weeks in total).
89524074|NCT01595841|Experimental|Sirolimus|Participants will take sirolimus for 3 days prior to procedure and 30 days post procedure.
89524075|NCT01595841|No Intervention|Not taking Sirolimus|Participants will not change the standard of care.
89524076|NCT03360877|Other|Health-care associated infection|
89524077|NCT05405049|Active Comparator|Group intraperitoneal instillation of local anesthetic + local anesthetic infiltration (IPLA+ LWI)|local anesthetic infiltration into all layers of the anterior abdominal wall and peritoneal instillation
89524078|NCT05405049|Active Comparator|Group morphine ( M )|intrathecal injection of morphine with local anesthesic
89524079|NCT04698369|Experimental|low frequency low amplitude|The vibration frequency is 60 Hz and amplitude is 0.2 mm
89524080|NCT04698369|Experimental|low frequency high amplitude|The vibration frequency is 60 Hz and amplitude is 2 mm
89524081|NCT04698369|Experimental|high frequency low amplitude|The vibration frequency is 120 Hz and amplitude is 0.2 mm
89524082|NCT04698369|Experimental|high frequency high amplitude|The vibration frequency is 120 Hz and amplitude is 2 mm
89524083|NCT03360799||Observational (questionnaire)|Participants complete 5 questionnaires.
89524084|NCT02871843|Experimental|Escalation of RRx-001 with TMZ + RT|Dose escalation of RRx-001 with fixed doses of Temozolomide and radiation followed by Temozolomide maintenance therapy
89524085|NCT03356899|Active Comparator|Low dose bupivacaine 0.5% (8mg)|Bupivacaine 0.5% for spinal anesthesia
89524086|NCT03356899|Active Comparator|High dose bupivacaine 0.5% (10mg)|Bupivacaine 0.5% for spinal anesthesia
89524087|NCT03356821|Experimental|Mesenchymal Stem Cells|All (near-)term newborns ≥36 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study.
89524088|NCT04525105||Study group|wıth URGE INCONTINANCE
89524089|NCT04525105||Control group|not urge incontinance
89524090|NCT04523467|Experimental|Combined group|Anti-angiogenic targeted drug + Rg3 + TACE
89524091|NCT04523467|Active Comparator|Single group|TACE alone
89524092|NCT02837757|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.~Available tumor tissues samples will be collected."
89524093|NCT03367351|Experimental|Web-Based Educational Intervention|Participants receiving the Web-Based Educational Intervention will be enrolled to the research protocol for six weeks of module-based learning and online discussion sessions and followed for a total of 3-months post CGM implementation to collect study measures.
89524094|NCT03367351|Placebo Comparator|Standard of Care|Participants will receive standard clinical care. Similar study measures will be collected to compare between groups.
89524095|NCT02801097|Experimental|RRx-001 + Irinotecan|Cohorts of participants with an advanced, malignant, solid tumor(s) will receive weekly doses of RRx-001 for 3 weeks, switching at week 4 to every-other-week treatments of RRx-001 with irinotecan.
89524096|NCT04636983|Experimental|BV100|BV100 intravenous infusion
89524097|NCT04636983|Placebo Comparator|Placebo|Saline intravenous infusion
89524098|NCT03367273|Experimental|vitiligo patients|
89524099|NCT03367273|Experimental|controls|
89524100|NCT04520269|Experimental|Patient with (cfDNA) 1q21.3 copy number amplification|The phase Ib segment will be carried out in a standard 3+3 design. In the phase II portion, 2 parallel cohorts will be enrolled (Cohort A: 1q21.3 amplified breast cancers, Cohort B: 1q21.3 amplified other solid tumors).
89524101|NCT04589091||Group(1): Patient who underwent PRK|
89524102|NCT04589091||Group(2): Patient underwent LASIK|
89524103|NCT03356743|Experimental|Ex-Vivo|
89524104|NCT05404659|Active Comparator|Oscillatory Mobilizations|
89524105|NCT05404659|Experimental|Mckenzie Retraction Exercises|
89524106|NCT03367195|Active Comparator|Treatment 1|1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily
89524107|NCT03367195|Experimental|Treatment II|1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily
89524108|NCT03360487|Sham Comparator|Sham photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the laser will be placed for 10 minutes, without being turned on.
89524109|NCT03360487|Active Comparator|Photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the region will be irradiated for 10 minutes.
89524110|NCT03360487|Sham Comparator|Sham photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be pretended on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be wakely irradiated for 30 seconds (total treatment time: 10 minutes).
89524111|NCT03360487|Active Comparator|Photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
89524112|NCT03360487|Sham Comparator|Sham Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific turned-off bracelet of the DMC laser Therapy EC model.
89524113|NCT03360487|Active Comparator|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
89524114|NCT04213911||Morbid obese|BMI>40 kg/m2
89524115|NCT04213911||Non-obese|BMI<30 kg/m2
89524116|NCT03356665|Experimental|Clinical suspect|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
89524117|NCT04523389||colorectal cancer|
89524118|NCT05123781|Experimental|Treatment A|Test Product Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
89524119|NCT05123781|Active Comparator|Treatment B|Reference Product Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
89524120|NCT04523233||Neural tube defects (NTDs)|NTDs are a group of birth defects in which an opening in the spine or cranium remains from early in human development. Neural tube defects may be diagnosed during the ultrasound scan that is carried out around week 12 of the pregnancy or, more likely, during the anomaly scan that is carried out at around weeks 19 to 20.
89524121|NCT04523233||Control group|The control group will be included pregnant women with healthy fetuses (n = 70), who were matched for gestational weeks and maternal age and underwent amniocentesis because of age-related risk or increased risk in the triple test.
89524122|NCT05127447|Experimental|ES group|External neuromuscular electrical stimulation was applied to the patients in supine position. It was applied for 30 minutes 3 days a week for 8 weeks. This stimulation consists of a total of eight external electrodes, including 2 sheaths wrapped around the thigh area and 4 electrodes for each leg. Electrodes were placed on the anterior and posterior proximal thighs, buttocks, and outside of the hips. The treatment protocol was applied with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 seconds of contraction and 5 seconds of rest.
89524123|NCT05127447|Sham Comparator|Sham group|In the Sham group, for 45 minutes, 2 days a week, a vacuum electrode was connected from combined vacuum electrotherapy device over the pelvis and thigh, and only vacuum was applied while the patient was in the supine position, and no current was given from the applied device.
89524124|NCT03356587|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class) Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
89524125|NCT05123625|No Intervention|RC combined with lymph node dissection|When radical cystectomy was performed, pelvic lymph node dissection was also performed.
89524126|NCT05123625|Experimental|Only RC|In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
89524127|NCT04444375||obese, non-obese|obese and non-obese diabetic patients
89524128|NCT05127369|Experimental|Test group|Dental pulp mesenchymal cell injection (dose: 0.1u/kg) + fluoxetine hydrochloride
89524129|NCT05127369|Active Comparator|control group|Dental pulp mesenchymal cell injection vehicle + fluoxetine hydrochloride capsule
89524130|NCT05127213|Experimental|Intragastric balloon system group|"Operation way: intragastric balloon system~Using the intragastric balloon system to treat obesity."
89524131|NCT05127213|Experimental|Sleeve gastrectomy group|"Operation way: sleeve gastrectomy~Using the sleeve gastrectomy to treat obesity."
89524132|NCT03360409|Experimental|grade 1|ACD
89524133|NCT03360409|Active Comparator|grade 2|ACDF
89524134|NCT03360409|Active Comparator|grade 3|ACDA
89524135|NCT04096963||The WATCHMAN FLX Delivery System|Patients who are eligible for a WATCHMAN FLX device according to current international and local guidelines (and future revisions) and per physician discretion;
89524136|NCT05127135|Experimental|ThisCART7 cells injections|In this study, allogeneic anti-CD7 CAR T Cells(ThisCART7 cells) is used to treat patients with refractory or relapsed CD7 positive T cell malignancies.
89524137|NCT03356509|Experimental|Exercise|They will do a 26-min bout of high intensity interval exercise.
89524138|NCT03356509|No Intervention|No exercise|They will sit quietly for 26 minutes without access to electronic devices or reading materials.
89524139|NCT03360253|Experimental|HMilkProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
89524140|NCT03360253|Placebo Comparator|HMilkPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
89524141|NCT03360253|Experimental|IFormProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
89524142|NCT03360253|Placebo Comparator|IFormPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
89524143|NCT03356353|Experimental|sildenafil citrate|Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.
89524144|NCT04520035|Experimental|neoadjuvant chemotherapy with camrelizumab|"paclitaxel and cisplatin~Carilizumab 200 mg, every 3 weeks, 2 cycles.~Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles~Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles"
89524145|NCT05404269||Group AGC|The FLOW-i anesthesia machine (Maquet, Solna, Sweden) can be equipped with automated gas control (AGC), an automated low flow tool with target control of the inspired oxygen concentration (FIO2) and end-expired concentration (FA) of a potent inhaled anesthetic. İnitially before induction, we set the minimal fresh gas flow to 0.5 L min-1 and target end-expired agent concentration for 1 MAC (minimal alveolar concentration). Shortly after intubation of the patient, we switched to AGC mode.
89524146|NCT05404269||Group Minimal Flow|İn this group; following intubation, we set the fresh gas flow to 4 L min-1 and than we readjusted fresh gas flow manually to 0.5 L min-1 after sevoflurane concentration reaching to 1 MAC.
89524147|NCT05404269||Group Medium Flow|İn this group; following intubation, we set the fresh gas flow to 4 L min-1 and than we readjusted fresh gas flow manually to 2 L min-1 after sevoflurane concentration reaching to 1 MAC.
89524148|NCT04519567|Experimental|CTI-1601|
89524149|NCT04519567|Placebo Comparator|Placebo|
89524150|NCT01675011|Experimental|Embozene® Microspheres|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
89524151|NCT01675011|Active Comparator|Embosphere®|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
89524152|NCT03356275|Experimental|Mobile application|Psychosocial support for parents, including: brief audio mindfulness recordings, videos, and psychoeducational materials.
89524153|NCT03356119|Experimental|RemovAid arm|New IMD Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
89524154|NCT03356041|Active Comparator|Intervention Group|The intervention group will receive the three months' lifestyle modification program by a clinical pharmacist.
89524155|NCT03356041|No Intervention|Usual care Group|The usual care group will be provided the standard medical services
89524156|NCT04208997|Experimental|Continuation of antiarrhythmic drugs|Patients will continue the class III antiarrhythmic drug they were receiving prior the VT catheter ablation for 3 months after the ablation.
89524157|NCT04208997|No Intervention|Discontinuation of antiarrhythmic drugs|Patients will stop class III antiarrhythmic drug they were receiving prior to the VT catheter ablation.
89524158|NCT03124147|Active Comparator|Anodal tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
89524159|NCT03124147|Active Comparator|Cathodal tDCS with motor training|20 minutes of cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
89524160|NCT03124147|Active Comparator|Dual tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere and cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
89524161|NCT03124147|Sham Comparator|Sham tDCS with motor training|20 minutes of sham transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
89524162|NCT05126667||Breast-conserving surgery|Patients who underwent breast-conserving surgery plus whole-breast irradiation
89524163|NCT05126667||Mastectomy|Patients who underwent mastectomy
89524164|NCT03355963|Placebo Comparator|Group A|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
89524165|NCT03355963|Active Comparator|Group B|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
89524166|NCT03355963|Active Comparator|Group C|"The treatment group C:~intervention: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test."
89524167|NCT05122923|Experimental|Patients with Serious Game|
89524168|NCT05122923|No Intervention|Patients without Serious Game|
89524169|NCT03360175||Thoracic Surgery Patients|"Inclusion criteria include: Patients scheduled to undergo thoracic surgery at Brigham and Women's Hospital, between the ages 18-85 years old. Exclusion criteria are: pre-existing chronic pain or opioid use; current treatment with corticosteroids; evidence of active infection; chronic liver disease; end-stage renal disease (CKD-5); chronic inflammatory disorders; recent major surgery or illness within 30 days; use of immunosuppressive medication; history of organ transplantation.~Pro-inflammatory eicosanoid and pro resolving lipid mediator temporal profiles will be determined pre-operatively, on post-operative day 1 and on post-operative day 14. In addition, daily pain scores will be recorded for 60 days after surgery and at 3, 6 and 12 months."
89524170|NCT05122845|Experimental|Healthy volunteers comparators to dialysis subjects|Creation of a biological collection for biological analysis
89524171|NCT02518633||men with obstructive sleep apnoea|Continuous positive airway pressure devices
89524172|NCT02518633||control subjects|subjects with no obstructive sleep apnoea
89524173|NCT04519489|Experimental|PAP therapy with telemonitoring|This arm will consist of 86 subjects.
89524174|NCT04519489|Other|Control group|This arm will consist of 43 subjects.
89524175|NCT03360097|No Intervention|Fresh ET|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.
89524176|NCT03360097|Experimental|Frozen Embryo Transfer|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.
89524177|NCT04518475|Experimental|efficacy of eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
89524178|NCT04518475|Active Comparator|efficacy of eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10^9/L, the eltrombopag will stop until the platelet count <30×10^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
89524179|NCT05114811|Experimental|Physiotherapist massage|Perineal massage was applied by a physiotherapist expert in urogynecology and obstetrics during a total of 6 to 10 sessions (from 34th gestation week until delivery) of 30 minutes each on a weekly basis.
89524180|NCT05114811|Experimental|Self-massage intervention|Self-massage group received permanent instructions on perineal massage during pregnancy: it should be applied at least twice a week (on alternate days) during 10 minutes using a water-based lubricant from the 34th gestation week until delivery.
89524181|NCT05114811|No Intervention|Control|Group receiving standard obstetric care (consultation and check-ups with the gynaecologist and midwife). No contact with the research physiotherapists.
89524182|NCT02518399|Experimental|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
89524183|NCT02518399|Sham Comparator|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
89524184|NCT05109663|Experimental|Dose Escalation Cohort 1: single oral dose of SKLB1028|Eligible subjects received a single dose of SKLB1028 50 mg on Day 1.
89524185|NCT05109663|Experimental|Dose Escalation Cohort 2: single oral dose of SKLB1028|Eligible subjects received a single dose of SKLB1028 100 mg on Day 1.
89524186|NCT05109663|Experimental|Food Effect Cohort A: SKLB1028, fasted dosing followed by fed dosing|Eligible subjects received a single dose of SKLB1028 150 mg on Day 1 in a fasting state, and a single dose of SKLB1028 150 mg on Day 11 in a fed state, with a 10-day washout period between the 2 doses.
89524187|NCT05109663|Experimental|Food Effect Cohort B: SKLB1028, fed dosing followed by fasted dosing|Eligible subjects received a single dose of SKLB1028 150 mg on Day 4 in a fed state, and a single dose of SKLB1028 150 mg on Day 14 in a fasting state, with a 10-day washout period between the 2 doses.
89524188|NCT04517539|Experimental|SBRT+GM-CSF+INF-αb|Metastasis lesion will be treated with a SBRT of 30Gy/5F from day 1 to day 5 . Injection of Immunological Agenthuman recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.Subcutaneous injection of Peginterferon alfa-b2(90ug) will be executed in day8. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Injection of Peginterferon alfa-b2(90ug) will be executed in day8 of this cycle.
89524189|NCT05101863||Normal-weight, NON-food addicted|
88811826|NCT01386983||Early 5ARI Initiation|Patients with EP receiving either 5ARI monotherapy or combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
89524190|NCT05101863||obese food addicted|
89524191|NCT05101863||obese NON-food addicted|
89524192|NCT03359941|Experimental|Integrative Treatments|This study's arm is single, so all participants will receive acupuncture treatments.
89524193|NCT04444219|Other|Breakfast meal_1|100 g white bread, 40 g yellow cheese and Κing Oyster mushrooms (test meal)
89524194|NCT04444219|Other|Breakfast meal_2|100 g white bread, 40 g yellow cheese and 6-7 cherry tomatoes (control meal)
89524195|NCT03367039|Experimental|ProDisc-C vivo|This group of patients will be treated with ProDisc-C vivo disc replacement (single segment).
89524196|NCT03367039|Active Comparator|Anterior cervical discectomy fusion|This group of patients will be treated with anterior cervical discectomy fusion (ACDF) procedure (single segment).
89524197|NCT04278651|Active Comparator|Oral Iron|325mg oral iron (ferrous sulfate) twice daily
89524198|NCT04278651|Experimental|Intravenous Iron|510mg ferumoxytol intravenous infusion for two doses total; second dose 3-8 days after first dose.
89524199|NCT03366961|Other|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
89524200|NCT05125965|Experimental|Patient undergoing immunotherapy with an indication for cardiac MRI|Patient undergoing immunotherapy with an indication for cardiac MRI for suspected myocarditis or myocarditis or other cardiovascular complications
89524201|NCT04523155|Experimental|Treatment Sequence AB|Participants randomized to sequence AB will receive 3 months of meals, followed by a 3 month washout period and a 3 month intervention period with no meals.
89524202|NCT04523155|Experimental|Treatment Sequence BA|Participants randomized to sequence BA will receive 3 months of no meals followed by a 3 month washout period and a 3 month intervention period with meals.
89524203|NCT03975465|Experimental|Expiratory Muscle Strength Training|Patients randomized to the EMST arm will use the EMST150 device as packaged, i.e. following package instructions
89524204|NCT03975465|Active Comparator|Pharyngeal Muscle Strengthening Exercises|Patients randomized to Standard Care will receive swallowing exercises designed to strengthen muscles that contribute to pharyngeal phase motor events and increase structural range of motion
89524205|NCT05125575|Experimental|Treatment A|Test Product Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
89524206|NCT05125575|Active Comparator|Treatment B|Reference Product Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
89524207|NCT03366883|Experimental|"Paclitaxel, Cisplatin Plus 5-FU (TCF)"|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks
89524208|NCT03366883|Experimental|Preoperative radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week
89524209|NCT03971799|Experimental|CD33CART autologous|Patients who receive an autologous CD33CART cell infusion
89524210|NCT03971799|Experimental|CD33 CART allogeneic|Patients who receive an allogeneic CD33CART cell infusion
89524211|NCT03123367|Active Comparator|Group 1: Nella VuSleeve|Sleeve
89524212|NCT03123367|Active Comparator|Group 2: Nella NuSpec|Speculum
89524213|NCT03123367|Active Comparator|Group 3: NellaSpec|Speculum
89524214|NCT03123367|Active Comparator|Group 4: Nella Insert|Sleeve
89524215|NCT04444297|Active Comparator|2D telemedicine|2D telemedicine first, followed by crossover to 3D telemedicine with no washout period
89524216|NCT04444297|Experimental|3D Telemedicine|3D telemedicine first, followed by crossover to 2D telemedicine with no washout period
89524217|NCT02550093|Experimental|Oxytocin, then Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing on intervention 1 (day 1). Following a wash-out period of 13 days the same subject will then receive a nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing on intervention 2 (day 14).
89524218|NCT02550093|Experimental|Normal Saline, then Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing on intervention 1 (day 1). Following a wash-out period of 14 to 15 days the same subject will then receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing on intervention 2 (day 14).
89524219|NCT04444063|Experimental|NIPSA technique with Allograft plus PRF|Non-incised papilla preservation technique to treat intraosseous bony defects with the addition of Allograft plus PRF
89524220|NCT04444063|Active Comparator|NIPSA technique|Non-incised papilla preservation technique to treat intraosseous bony defects without the addition of Allograft plus PRF
89524221|NCT03366805|Active Comparator|Wound Care Video|Wound Care Patient Education Video
89524222|NCT03366805|Experimental|Pain Management Video Group|Pain Management Patient Education Video
89524223|NCT03355807|Experimental|Group MgSO4|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4 (30 mg/kg by bolus and 10 mg/kg/h by infusion for 24 hours)
89524224|NCT03355807|No Intervention|Group Control|the control group (group C, n _ 40) received the same amount of IV saline
89524225|NCT02512107|Active Comparator|Juice Plus+|Subject will be taking supplement.
89524226|NCT02512107|Placebo Comparator|Placebo|Subjects will be taking the placebo.
89524227|NCT03359317|Experimental|jogging|At least 5 times/week
89524228|NCT02494791|Other|Endometrial and Ovarian Cancer Participants|All study subjects will be offered the same options for screening and follow-up.
89524229|NCT03355651|Active Comparator|PROGEN Group|PROGEN + Standard Rehabilitation + ACL reconstruction
89524230|NCT03355651|No Intervention|Control Group|Standard Rehabilitation + ACL reconstruction
89524231|NCT04186455|Active Comparator|insertion time|lma pro seal and basks-mask in patients undergoing ups
89524232|NCT04186455|Active Comparator|oropharyngeal leak pressure|lma baska-mask undergoing urs
89524233|NCT03366571||Anti-viral therapy group|"Subjects who have completed the 3 years research Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis"
89524234|NCT03366571||Non anti-viral therapy group|History study from literature
89524235|NCT05125107||Group 1|Predominant focal residual disease without major gradient
89524236|NCT05125107||Group 2|Predominant focal residual disease with major gradient
89524237|NCT05125107||Group 3|Predominant diffuse residual disease without major gradient
89524238|NCT05125107||Group 4|Predominant diffuse residual disease with major gradient
89524239|NCT04523311|Experimental|Hypnosis + usual care|An online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis. Participants will continue with whatever usual care they receive/undertake.
89524240|NCT04523311|Other|Waitlist control + usual care|The control group will receive no intervention beyond whatever usual care they receive/undertake. After the study is complete, they will be offered the option of participating in the hypnosis intervention.
89524241|NCT05055765|Experimental|TEST GROUP I|Thin periodontal phenotype will be treated with microneedling. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
89524242|NCT05055765|Active Comparator|TEST GROUP II|Thin periodontal phenotype will be treated with i-PRF procedure. A total of 4 sessions will be done with an interval of 10 days each. And all the parameters will be measured.
89524243|NCT03366493|Experimental|FRD, Cyctology, HPV testing|Subjects will be asked to have the FRD, Cytology, and HPV test performed on them by the study doctor or staff.
89524244|NCT03366493|Experimental|Colposcopy Examination (and ECC if necessary)|Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
89524245|NCT03366493|Experimental|Biospy|According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken. Finally, a histopathological examination will be done and used as the gold standard. Subjects with a histopathological examination result of < CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion.
89524246|NCT03355495|No Intervention|Left Lateral Decubitus Position|Gold standard positioning for colonoscopy
89524247|NCT03355495|Active Comparator|Right Lateral Decubitus Position|Comparing positioning in Right Lateral Decubitus (intervention) for visualization in colonoscopy to the gold standard of Left Lateral Decubitus.
89524248|NCT05124951|Experimental|iGCTS|"Stratum I (Germinoma) Patients who achieved complete response after induction chemotherapy will receive WVI 2400cGy/15f plus primary boost 640cGy/4f.~Stratum II (NGGCTs) At the time of response evaluation before radiotherapy, those with complete response or residue disease <1.5cm will receive WVI 3060cGy/17f plus primary boost 2340cGy/13f."
89524249|NCT03355417|Experimental|OT-SI|Occupational therapy using a sensory integration approach
89524250|NCT04375449|Active Comparator|Pep2dia- dosage 1|700mg of whey protein hydrolysates single dose
89524251|NCT04375449|Active Comparator|Pep2Dia - dosage 2|1400mg of whey protein hydrolysates single dose
89524252|NCT04375449|Placebo Comparator|Placebo|maltodextrin single dose
89524253|NCT04523077||Oral lichen planus|Female patients of the Department of Oral Medicine with oral lichen planus
89524254|NCT04523077||Control|Female patients of the Department of Oral Medicine without oral lichen planus or other immune disorders
89524255|NCT05124717|Experimental|Treatment A|Test Product Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)
89524256|NCT05124717|Active Comparator|Treatment B|Reference Product Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
89524257|NCT03355339|Experimental|Binasal occlusion|Participants will be fitted with glasses covered with occlusive tape from the inner canthi to the nasal border on each lens.
89524258|NCT03355339|Active Comparator|No binasal occlusion|Participants will be fitted with non-occluded glasses.
89524259|NCT05116839|Placebo Comparator|the first 15 minutes with PSV|"All patients will breath at the first 15 minutes with PSV:triggered by minute volume <3 Liter,with with no frequency .~Monitoring: (basal&every 3minutes)~Tidal volume (inspiratory & expiratory).~End tidal co2.~Mean air way pressure.~Leakage %.~Respiratory rate .~Spo2.~Heart rate.~Blood pressure (mean arterial pressure"
89524260|NCT05116839|Active Comparator|the following 15 minutes ventilation will be changed to CPAP mode|"then the following 15 minutes ventilation will be changed to CPAP mode at 10 cm H2o .~Monitoring: (basal&every 3minutes)~Tidal volume (inspiratory & expiratory).~End tidal co2.~Mean air way pressure.~Leakage %.~Respiratory rate .~Spo2.~Heart rate.~Blood pressure (mean arterial pressure)."
89524261|NCT03358927|Active Comparator|Standard Group|Deferred fast-track care
89524262|NCT03358927|Experimental|Immediate Fast-Track Group|Immediate fast-track care
89524263|NCT04139655|Experimental|Colchicine Group|Administration of oral colchicine at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
89524264|NCT04139655|Placebo Comparator|Placebo Group|Participants allocated to the control group will receive a placebo pill at the same dosing regimen as with treatment group. Perioperative and surgical care will not be different from standard clinical practice.
89524265|NCT03355261|Experimental|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
89524266|NCT03355261|Experimental|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
89524267|NCT03355261|Experimental|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
89524268|NCT03355261|Experimental|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
89524269|NCT04113057|Experimental|Remote Coaching|All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The remote coaching arm will receive regular provider feedback based on LIVMOR data.
89524270|NCT04113057|No Intervention|Remote health monitoring without provider feedback|"All subjects enrolled in the study will be enrolled in supervised exercise therapy. They will also receive directions for supplemental home-based exercise and a LIVMOR remote health monitoring system. The no intervention arm will have access to LIVMOR data, but without provider feedback on the LIVMOR data."
89524271|NCT04515511|Experimental|standard care|ICU septic shock patients with refractory hypotension with indwelling pulmonary artery catheter received five sequential intravenous boluses of 100 mL 4% gelatin. Cardiac output measured by thermodilution of PAC before fluid challenge (baseline) and three minutes after each bolus. Fluid responsiveness (FR) was defined as an increase in CO greater than 10% after 500 mL fluid infusion. The smallest volume which can perform an effective fluid challenge was analyzed.
89524272|NCT04109547|Experimental|Oral semaglutide 3mg|Subjects will remain on 3 mg for the entire treatment period (26 weeks)
89524273|NCT04109547|Experimental|Oral semaglutide 7mg|Subjects will receive 3 mg for for the first 4 weeks, 7 mg for the remainder of the treatment period
89524274|NCT04109547|Experimental|Oral semaglutide 14mg|Subjects will receive 3 mg for the first 4 weeks, 7 mg for the next 4 weeks and 14 mg for the remainder of the treatment period
89524275|NCT04109547|Placebo Comparator|Placebo (oral semaglutide)|Subjects will receive placebo tablets for the entire treatment period
89524276|NCT03366259|Active Comparator|Group A (Misoprostol group)|200 mcg rectal Misoprostol administration before cesarean section
89524277|NCT03366259|Placebo Comparator|Group B (control group)|No prostaglandins administration before cesarean section
89524278|NCT03366181||heart failure patients|
89524279|NCT03358849|Experimental|experimental group|
89524280|NCT05403411|Experimental|Intervention group|Distance education for nursing students on critical thinking
89524281|NCT05403411|No Intervention|Control group|The control group was given a booklet for critical thinking.
89524282|NCT03366025||Oocyte donors|Healthy oocyte donors undergoing ovarian stimulation with recombinant Follicular stimulating hormone
89524283|NCT05403333|Experimental|Utidelone|Drug: utidelone Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
89524284|NCT04514887|Experimental|Mild Hyperventilation|In this study arm, patients were mildly hyperventilated intraoperatively so their end-tidal CO2 levels are brought down to 30-32 mmHg.
89524285|NCT04514887|No Intervention|Control|In this study arm patients' ventilation is managed according to guidelines with end-tidal CO2 levels kept in the normal range of 35-40 mm Hg
89524286|NCT03358771|No Intervention|Usual Care|"During the initial stepped wedge phase, all sites will receive usual care. There is currently no standardized discharge care bundle for COPD in Alberta. Some electronic patient information sheets do exist; however, their content is general and use is limited. It is expected that a vast majority of patients will transition to the community on a sub-optimal medication regimen, with limited referral to additional outpatient programs and no formal follow-up organized with a primary care provider (e.g., F/U prn or F/U with Fam MD)."
89524287|NCT03358771|Active Comparator|COPD discharge care bundle|"COPD discharge care bundle:~Ensure patient has demonstrated adequate inhaler technique~Send discharge summary to family physician office and arrange follow-up~Optimize and reconcile prescription of respiratory medications~Provide a written discharge management plan, and assess patient's and care giver's comprehension of discharge instructions~Refer to pulmonary rehabilitation~Screen for frailty and comorbid condition(s)~Assess smoking status, provide counseling and refer to smoking cessation program, where appropriate"
89524288|NCT03358771|Experimental|COPD discharge care bundle & coordinator|COPD discharge care bundle as listed for active comparator arm enhanced with care coordinator support.
89524289|NCT05403255||Multiple or isolated pituitary hormone deficiency group|Patient with multiple pituitary deficiency or isolated pituitary deficiency diagnosed for at least 6 months.
89524290|NCT04513405|Other|subjects with skin tears (Group A)|"A sample of peripheral venous blood will be taken to measure the levels of estrone and estradiol.~A skin biopsy on the intact skin area near the skin tear will be performed."
89524291|NCT04513405|Other|subjects without skin tears (Group B)|"A sample of peripheral venous blood will be taken to measure the levels of estrogen.~A skin biopsy (thin layer) on the intact skin area of the arm will be performed in order to evaluate skin estrogen receptors."
89524292|NCT05403099|Active Comparator|control|Each implant was placed into the prepared implant site.
89524293|NCT05403099|Experimental|Hyaluronic acid|Each implant was placed after topical application of HA on its surface
89524294|NCT03355183|Experimental|Healthy athletes|Muscular strength of healthy athletes who are not physically disabled and doing sports for 3 years as a professional will be measured by isokinetic dynamometer.
89524295|NCT05404035|Experimental|Family Connections for relatives of people with eating disorders and personality disorders|The intervention lasts 3 months and includes 14 two-hour sessions with a group format on a weekly basis. The FC program is divided into 7 modules: 2 of Psychoeducation (ED and PD criteria, explanatory theories, available treatments, comorbidity with PD, etc.) and 5 modules of Dialectical Behavioral Therapy skills training (Relationship mindfulness, effective communication, aceptation, validation, problem management and meaning of life).
89524296|NCT05404035|Active Comparator|Optimized Treatment As Usual|Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, with 3 two-hour psychoeducation sessions in group format each week (ED and PD, explanatory theories, available treatments, comorbidity with PD).
89524297|NCT05403957|Experimental|TID video|
89524298|NCT05403957|Active Comparator|TID worksheet|
89524299|NCT05403957|Placebo Comparator|SSB worksheet|
89524300|NCT04512469|No Intervention|Control Group|The control group will undergo standard running fascial closure with PDS .
89524301|NCT04512469|Experimental|Treatment Group - Mesh|The treatment group will undergo standard running fascial closure with PDS plus a low molecular weight mesh extending 3 cm from the fascial incision.
89524302|NCT04512157|Experimental|PATHS, Intervention preschools|These preschools implement PATHS for one school year
89524303|NCT04512157|No Intervention|Waitlist control preschools|Preschool as usual, which does have some social emotional learning but not PATHS specifically
89524304|NCT03707301||Cancer patients performing sophrology sessions|Cancer patients performing sophrology sessions will be recruited in this study, and will complete questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
89524305|NCT03365869|Active Comparator|Sirolimus|Add sirolimus according to the protocol. Sirolimus active: 2mg po. QD
89524306|NCT03365869|Placebo Comparator|placebo|sirolimus placebo: 2mg po. QD
89524307|NCT04932213|Active Comparator|Tropicamide 0.5%|This group receives tropicamide 0.5% (one drop every 5 minutes for 2 times) drops.
89524308|NCT04932213|Active Comparator|Tropicamide 1%|This group receives tropicamide 1% (one drop every 5 minutes for 2 times) drops.
89524309|NCT03365557|Experimental|Intracuff pressure set by airway peak pressure|
89524310|NCT03365557|Other|Intracuff pressure set at 60 mmHg|
89524311|NCT03365479|Experimental|Study cohort|The study comprises a 1-day Screening period, followed by a right heart catheterization with a single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
89524312|NCT04032795|Experimental|Lycium barbarum polysaccharide (LBP)|Experimental group takes LBP tablet (300mg/day) for 6 weeks
89524313|NCT04032795|Placebo Comparator|Placebo|Placebo control group takes placebo 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
89524314|NCT03365401|Experimental|grade 1|Decompression surgery
89524315|NCT03365401|Active Comparator|grade 2|nonsurgical treatment
89524316|NCT04925271|Experimental|X-Tack|The gastrointestinal tract mucosal or submucosal defect is closed using the X-Tack device.
89524317|NCT04925271|Active Comparator|Overstitch|The gastrointestinal tract mucosal or submucosal defect is closed using the Overstitch device.
89524318|NCT03355027|Experimental|Alirocumab Treatment Arm|30 patients with stable cardiovascular disease to receive Alirocumab 150mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
89524319|NCT03355027|Active Comparator|Comparator Treatment Arm|30 patients with stable cardiovascular disease to receive Ezetimibe 10mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
89524320|NCT03354949||Positioning hemiplegic.|"Positioning all hemiplegic by stroke requiring a single wheelchair even at the exit of the SSR and hemiplegic patient with sequelae.~Measurement of sitting postural control of the adult (MCPAA). Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~Propulsion speed of a wheelchair."
89524321|NCT04182867|Experimental|UK dietary guideline diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). The experimental diet will meet UK dietary guidelines for fiber, salt, sugar, saturated fat, fruit and vegetable intake. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant. The diet will be consumed across 3 consecutive night shifts.
89524322|NCT04182867|Other|Shift worker diet|A 4-day diet (food and beverage provision for 3 meals and 2 snacks) will be provided along with an eating plan (time of each meal / snack). Typical 'shift diet' based on previous research investigating what UK night workers eat. The 'shift diet' will contain ~15% energy from added sugar, 15g fiber, 2.5 portions fruit/vegetable, no whole grains. Required energy intake (calories) for each day to maintain their current body weight. Energy (calorie) requirements for each participant will be calculated from age, sex and weight of the participant.The diet will be consumed across 3 consecutive night shifts.
89524323|NCT03828045||Psoriatic Arthritis patients on Apremilast|Patients diagnosed with PsA (according to the CASPAR diagnosis criteria), naïve to biological treatments, who have - following the routine practice in their centers - initiated treatment with apremilast 6 months (±1 months) before their inclusion in the study, irrespective of treatment duration.
89524324|NCT03354793||endometriosis|Survey on first pregnancy after endometriosis diagnosis
89524325|NCT03354793||non endometriosis|Survey on first pregnancy
89524326|NCT03365323||infectious group|Patients who met the criteria according of Periprosthetic Joint Infection were identified as the infectious group.
89524327|NCT03365323||non-infectious group|Patients who didn't meet the criteria according of Periprosthetic Joint Infection were identified as the non-periprosthetic joint infection group.
89524328|NCT04522609|No Intervention|Control group|Guideline recommended pharmacologic therapy
89524329|NCT04522609|Experimental|NMES group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
89524330|NCT03358537|Active Comparator|Clear Liquid Diet|110 subjects received clear liquid diet 24 hours before colonoscopy
89524331|NCT03358537|Active Comparator|Low-residue Diet|105 subjects received a prespecified low-residue diet 24 hours before colonoscopy
89524332|NCT03123757|Other|Intervention|Patients performed the 6-minute walk test and completed the EQ-5D quality of life questionnaire.
89524333|NCT02519335|Other|Dexrazoxane|"Trial subjects will be assigned preoperatively to receive Dexrazoxane at one of three doses: low (200mg/m2/dose), medium (300mg/m2/dose), or high (400mg/m2/dose). Four patients will be assigned to each dosing regimen for a total of 12 patients.~The medication will be administered in the operating room 15-30 minutes prior to starting cardiopulmonary bypass (dose #1), after finishing cardiopulmonary bypass (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3)."
89524334|NCT03354715|Sham Comparator|Rapid prototyping Denture base|Complete Denture Using Rapid Prototyping method for fabrication of the complete denture depending on
89524335|NCT03354715|Sham Comparator|Heat Cured Conventional Complete Denture|Complete Denture using heat cured Denture base using flasking and deflasking method
89524336|NCT03365245|Other|study arm|Microperimetry and automated visual field are performed at three different days
89524337|NCT03365167|Active Comparator|LANAP|LANAP (Laser Assisted New Attachment Procedure)
88811827|NCT01386983||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (within 31 to 180 days after initiation of AB)
88811828|NCT00868712||1|Warfarin use < 6 months
89524338|NCT03365167|Placebo Comparator|LANAP off|laser therapy in off mode
89524339|NCT03365089|Experimental|Collateral vein ligation|Ligation of collateral veins under sonographic guidance
89524340|NCT03365089|No Intervention|Control|No collateral vein ligation.
89524341|NCT03364933|Experimental|Primary intensivist and nurses|Patients randomized to the experimental arm will have a primary intensivist and a team of primary nurses assigned to them.
89524342|NCT03364933|No Intervention|Control|Patients who are randomized to the control group will receive usual care and not be assigned a primary intensivist or nurses.
89524343|NCT04509895|Experimental|lateral extensile approach in calcaneal fractures fixation|Lateral extensile approach is the standard approach for intra-articular calcaneal fractures .
89524344|NCT04509895|Experimental|minimally invasive sinus tarsi approach in calc.fixation|Sinus tarsi approach become one of the most frequently applied minimally invasive approaches.
89524345|NCT04509817|Experimental|Acupuncture+Usual care|Subjects in experimental group will receive a standardized acupuncture treatment, 10 times per 4 weeks for 16 weeks with a total of 40 sessions in addition to usual care.
89524346|NCT04509817|Active Comparator|Usual care|Subjects in control group will receive usual care only.
89524347|NCT04509583|Experimental|PROFortil group|"Men with increased sperm DNA fragmentation (>=30%) will be indicated for multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months then checked again post-treatment for DF).~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
89524348|NCT04509583|Other|Vitamin E group|"Any case with high DNA fragmentation index (DFI >=30%) will be randomized indicated only Vitamin E (Enat 400 once per day) in 3 months then checked again post-treatment for (DFI).~The IVF/ICSI cycles will then be analyzed for embryo quality, pregnancy outcomes including biochemical pregnancy rate, clinical pregnancy rate, on-going pregnancy, miscarriage."
89524349|NCT04509661|Experimental|Experimental group|Indacaterol-Glycopyrronium (110ug/50ug QD inhalation) for one year.
89524350|NCT04509661|Placebo Comparator|Control group|Placebo treatment for the airway limitation.
89524351|NCT03122977|Experimental|Full mouth scaling and root planing|FM-SRP Non surgical periodontal treatment will be performed in all dentition within 24 hours
89524352|NCT03122977|Active Comparator|Quadrant scaling and root planing|"Q-SRP Non surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
89524353|NCT04509271||Normal aged|
89524354|NCT04509271||MCI due to AD|
89524355|NCT04509271||Mild AD|
89524356|NCT04509271||Moderate AD|
89524357|NCT04509271||Severe AD|
89524358|NCT04509271||Dementia with Lewy body|
89524359|NCT04509271||Frontotemporal dementia|
89524360|NCT03350737|Experimental|Heparin-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise
89524361|NCT03350737|Placebo Comparator|Placebo-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise
89524362|NCT03350659|Experimental|Atomoxetine|Atomoxetine 18mg once a day.
89524363|NCT03350659|Active Comparator|Midodrine|midodrine 2.5mg twice a day (increase to 5mg three times a day if necessary)
89524364|NCT03350581|Active Comparator|FAM-CT 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM with CT or MRI.
89524365|NCT03350581|Experimental|FAM 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM alone.
89524366|NCT04524793|Other|Endovenous Microwave Ablations|Patients that have undergone Endovenous Microwave Ablation from ECO (Nanjing ECO Microwave System Co., Ltd) to treat primary great and short saphenous vein reflux
89524367|NCT03364855|Active Comparator|SEBT exercise group|Star Excursion Balance Test will be used
89524368|NCT03364855|Active Comparator|KAT 2000 exercise group|Kinesthetic ability trainer will be used
89524369|NCT03364855|Active Comparator|combined exercise group|Both star Excursion Balance Test exercise and Kinesthetic ability trainer will be used.
89524370|NCT03364777||lumbar surgery patients|patients undergoing lumbar surgery with or without anxiety or depression emotional state
89524371|NCT04443517|Experimental|Maintenance-Alpha Optimization / Wake from Propofol|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive individualized titration of anesthetic gas and opioid. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
89524372|NCT04443517|Active Comparator|Maintenance-Alpha Optimization / Wake from Volatile|During the first randomization, participants randomized to intraoperative oscillatory EEG alpha optimization will receive real-time monitoring of alpha recordings and individualized titration of desflurane and opioid. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
89524373|NCT04443517|Active Comparator|Maintenance-Routine Care / Wake from Propofol|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to conversion to a propofol infusion for emergence from anesthesia will received an infusion of propofol 400mg/h and simultaneous reduction of desflurane concentration during the final 10-20 minutes of surgery.
89524374|NCT04443517|No Intervention|Maintenance-Routine Care / Wake from Volatile|During the first randomization, participants randomized to standard of care will receive anesthesia per usual care with quantitative processed EEG index values and EEG wave forms. During the second randomization, participants randomized to standard emergence from volatile anesthesia will be woken up per standard practice.
89524375|NCT04524559|Placebo Comparator|conventional physical therapy training|received 90 minutes conventional physical therapy training focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms.
89524376|NCT04524559|Experimental|oral stimulation|received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time. The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol
89524377|NCT03364699|Active Comparator|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
88811829|NCT00868712||2|Warfarin use 6-24 months
89524378|NCT03364699|Experimental|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, participants were supplemented. Blood samples were collected before and after both half-marathon race.
89524379|NCT03364543||Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs. This group will also have access to access to a social worker and a community worker.
89524380|NCT03364543||Usual Care|Access to a social worker and a community worker, but no systematic process for addressing health-harming legal needs.
89524381|NCT02519257|Experimental|CAD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
89524382|NCT02519257|Experimental|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
89524383|NCT03350425||Recently vaccinated patients|Patients who recently received pneumococcal vaccination.
89524384|NCT03350425||Patients vaccinated >2 years ago|Patients who received pneumococcal vaccination more than two years ago.
89524385|NCT04443595|Experimental|Experimental|Treatment of Acute Severe Pancreatitis with DPN
89524386|NCT04509349|Active Comparator|Real tACS|For transcranial stimulation, a stimulation method called high-definition tACS (HD-tACS) will be applied to target the primary motor cortex (M1), an area of the brain that is involved in controlling movement, using gel electrodes placed on the scalp. Participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage, to create focused stimulation over the M1 region. A stimulator will be connected to the electrodes to deliver a low-intensity stimulating current to the scalp.
89524387|NCT04509349|Placebo Comparator|Sham tACS|For the transcutaneous ACS, the procedure for real and sham stimulation will be identical to HD-tDCS, but ACS will be delivered to the upper arm contralateral to hand attached to the accelerometer.
89524388|NCT03350347|Experimental|Molidustat (BAY85-3934)|Molidustat group
89524389|NCT03350347|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
89524390|NCT03350191|Experimental|SAR425899 high dose|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 20 days
89524391|NCT03350191|Experimental|SAR425899 low dose|Repeated once daily SC doses of SAR425899 administered over 20 days
89524392|NCT03364465|No Intervention|GruopFix|one-lung ventilation with constant tidal volume
89524393|NCT03364465|Active Comparator|GroupVariable|one-lung ventilation with variable tidal volume Intervention: change of ventilatory settings
89524394|NCT04508959||Screened patients|All individuals screened using the hospital's microbiology laboratory.
89524395|NCT04508959||Outpatient (Emergency Department) cases|All individuals seen in the emergency department who test positive for COVID-19.
89524396|NCT04508959||Inpatient (General Medical or Intensive Care) cases|All individuals admitted to a general or intensive care bed who test positive for COVID-19.
89524397|NCT04508569|Experimental|Big Decisions|
89524398|NCT04508569|Active Comparator|Youth Voices|
89524399|NCT02519101|Experimental|Continunous blood pressure monitoring|Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring
89524400|NCT02519101|No Intervention|Intermittent blood pressure monitoring|Control group with intermittent blood pressure monitoring
89524401|NCT03354559||pre-ECS group|Data collection from 01-01-2011 to 31-12-2012. Patients were treated according to a massive transfusion protocol with the following targets: fresh frozen plasma(FFP)/packed red blood cells(PRBCs) ratio ≥ 1:1.5, target platelet count > 100.000 x 10 9/L
89524402|NCT03354559||ECS group|Data collection from 01-01-2013 to 31-12-2014. Patients were treated according to the ECS protocol.
89524403|NCT02649231|Experimental|Ketamine+Psychological Therapy|Ketamine with psychological therapy
89524404|NCT02649231|Active Comparator|Ketamine+Education|ketamine with alcohol education
89524405|NCT02649231|Active Comparator|Placebo+Psychological Therapy|placebo with psychological therapy
89524406|NCT02649231|Placebo Comparator|Placebo+Education|placebo with simple alcohol education
89524407|NCT03364075|Active Comparator|Duloxetine Treatment|patients treated with Duloxetine
89524408|NCT03364075|Active Comparator|Propranolol Treatment|patients treated with Propranolol
89524409|NCT03364075|Placebo Comparator|Placebo Treatment|patients treated with placebo
89524410|NCT03363997|Experimental|Test 1 vaginal ring|Single vaginal application of 1 vaginal ring containing 100 mg estriol, with delivery rate of 0.125 mg/day over 21 days
89524411|NCT03363997|Experimental|Test 2 vaginal ring|Single vaginal application of 1 vaginal ring containing 300 mg estriol, with delivery rate of 0.250 mg/day over 21 days
89524412|NCT03363997|Experimental|Test 3 vaginal ring|Single vaginal application of 1 vaginal ring containing 600 mg estriol, with delivery rate of 0.500 mg/day over 21 days
89524413|NCT05378295|Active Comparator|isocaloric fermentable oligosaccaride|isocaloric fermentable oligosaccaride
89524414|NCT05378295|Experimental|Personalized fiber mixture|12 g for 2 weeks, followed by 24 g for 10 weeks
89524415|NCT03350113|Experimental|HemoSpec|Blood Sampling for analysis in the HemoSpec device
89524416|NCT02518477|Experimental|exercise group|"The first 20 weeks, twice-weekly 60 minute session of physical exercise supervised by the research assistant and once weekly home exercise programme is offered. The exercise intervention will consist of stretching, scar tissue mobilization and resistance exercises.~For the following 32 weeks a home-training manual specifying three times weekly training is provided. At week 26 an individual booster session will be offered. In the case of lymphedema, referral to trained lymphedema physiotherapist for evaluation of appropriate intervention is made."
89524417|NCT02518477|No Intervention|usual care control group|Receives all standard care offered from the operating hospital and rehabilitation in the municipality.
89524418|NCT03547869|Experimental|Active tDCS|Active tDCS
89524419|NCT03547869|Sham Comparator|Sham tDCS|Sham tDCS
89524420|NCT04504279|Experimental|FB-401|FB-401 applied topically for 16 weeks.
88811830|NCT00868712||3|Warfarin use >24 months
89524421|NCT04504279|Placebo Comparator|Placebo|Placebo applied topically for 16 weeks.
89524422|NCT03354481|Experimental|Behavioral recording of arithmetic and associated information|The experiment will contain several behavioral tasks in which solving time and correct answer will be recorded. The main one will be a computerized task on arithmetic facts. There will also be three additional tasks as described below.
89524423|NCT03354403||Patients|Up to 50 mothers of sons of all ages diagnosed with XLRS are eligible to participate in this study. Up to 50 fathers of sons of all ages with XLRS are also eligible to participate and will serve as a comparison group.
89524424|NCT04174989|Experimental|Plasminogen-Depleted Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of PDP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
89524425|NCT04174989|Other|Fresh-Frozen Plasma Infusion|Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and due to undergo a plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of FFP. In case of transfusions needing more than two units, the third unit and above will consist in regular plasma regardless of treatment group. Patients will be continuously monitored for 8 hours following the transfusion, and will be assessed between 8-12 hours after plasma transfusion or the following morning (the earlier of the two options), between 24-48 hours after plasma transfusion or at discharge (the earlier of the two options) and after 30±3 days after transfusion.
89524426|NCT03349879||Vitamin D deficiency|serum 25(OH)D < 30 nmol/L
89524427|NCT03349879||Vitamin D insufficiency|serum 25(OH)D between 30 and 49 nmol/L
89524428|NCT03349879||Vitamin D sufficiency|serum 25(OH)D ≥ 50 nmol/L
89524429|NCT04524169|Experimental|Thymosin Alpha 1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
89524430|NCT04524169|No Intervention|Standard Care|Participants under the regularly treatment
89524431|NCT03568929||Idelalisib|Participants who have been or are currently being treated with 100 or 150 mg of idelalisib
89524432|NCT03354247|No Intervention|Healthy Control|Participants in this group will attend small group sessions providing basic education about NAFLD/NASH, and about principles of healthy eating, physical activity and weight control. These sessions occur every 12 weeks and are conducted by a Master's level nutritionist or health educator. Providing basic education about diet and exercise has produced minimal weight loss in other clinical trials. The educational sessions will be included in this study in order to provide standard care to these patients and to maximize subject retention.
89524433|NCT03354247|Experimental|NAFLD Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants who are able to lose more than 10% of their body weight will be encouraged to do so. Participants will be seen weekly for the first 6 months and then biweekly for months 7-12. The lifestyle intervention focused on diet, exercise, and behavior modification.
89524434|NCT04503967|Experimental|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line treatment of Gastric and Esophageal Cancer patients
89524435|NCT04841499|Experimental|Treatment Arm|7 days of BASIS™ orally
89524436|NCT04503889|Experimental|Real taVNS intervention|taVNS will be administered to cymba conchae of both ears using ECO2-TENS device
89524437|NCT04503889|Sham Comparator|Sham|aVNS will be administered to lobes of both ears using ECO2-TENS device
89524438|NCT04822935|No Intervention|Posterior Spinal Instrumentation|
89524439|NCT04822935|Experimental|Vertebral Body Tethering|
89524440|NCT04808817|Experimental|patients|
89524441|NCT04522999|Experimental|Photobiomodulation|Valeda™ Light Delivery System
89524442|NCT05028465|Experimental|EP combined with RFA|Endoscopic Papillectomy Combined with Endobiliary Radiofrequency Ablation
89524443|NCT04773405|Other|Selective Trunk Block|Selective trunk block will be done under ultrasound guidance to patients scheduled for upper extremities surgeries. Local anaesthetic agents (a 1:1 mixture of 2% lidocaine with 5ug/ml of epinephrine and 0.5% levobupivacaine) will be injected at the superior, middle, and inferior trunks of the brachial plexus in order to anaesthetize the whole upper limb.
89524444|NCT04991571|Experimental|Part 1|Participants will be administered with zibotentan once daily for 5 days.
89524445|NCT04991571|Experimental|Part 2: Treatment Sequence ABC|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment A; Treatment B; Treatment C) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
89524446|NCT04991571|Experimental|Part 2: Treatment Sequence BCA|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment B; Treatment C; Treatment A) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
89524447|NCT04991571|Experimental|Part 2: Treatment Sequence CAB|Each participant will receive 3 single-dose treatments of zibotentan and dapagliflozin (Treatment C; Treatment A; Treatment B) in 3 treatment periods, separated by a washout period of at least 7 days between treatment periods.
89524448|NCT03191019|Experimental|Mobile-phone app for smoking cessation|"The intervention arm will receive a smoking cessation program based on a mobile-phone app. The program contains strategies to support smoking cessation, including motivational messages, tips on stress management, on how to ask support from friends and family, how to use distraction techniques and how to deal with cravings, lapses and early relapse. It also includes a saving calculator, a help button which provides extra messages in case of cravings and a lapse button, which provides advice about what to do if the participant presents lapses or relapse after being abstinent at least 24 hours."
89524449|NCT03191019|Placebo Comparator|Control mobile-phone app|The control arm will receive a mobile-phone app which will send 1 message every two weeks thanking participants for taking part in the study, and encouraging them to stay in the study for the 6 month follow-up period.
89524450|NCT03176979|Experimental|Diagnostic (CESM with DBT)|Patients undergo a clinical breast examination and a diagnostic mammogram with or without targeted breast ultrasound to the index cancer as part of their standard of care preoperative work-up. As part of the research study, patients receive contrast agent IV and then undergo a CESM with DBT over 30 minutes. Patients also receive a contrast agent, gadolinium, IV and undergo bilateral breast CE-MRI over 10 minutes.
89524451|NCT01376245|Experimental|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
89524452|NCT01376245|Placebo Comparator|placebo|matching placebo
89524453|NCT04508881|Active Comparator|External ligation|External ligation of the valve tube by vicryl sutures
89524454|NCT04508881|Active Comparator|intraluminal stenting|stenting of the valve tube by prolene suture
89524455|NCT05403645|Experimental|Movement With Mobilization among patients with knee osteoarthritis in household females|using the techniques of Movement With Mobilization among patients with knee osteoarthritis in household females
89524456|NCT05403645|Experimental|Exercise Therapy among patients with knee osteoarthritis in household females|using the techniques of Exercise Therapy among patients with knee osteoarthritis in household females
89524457|NCT04508491|Experimental|Rhythm control|Rhythm control with medication or any procedure
89524458|NCT04508491|Active Comparator|Rate control|Rate control with medication or any procedure
89524459|NCT03349489|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
89524460|NCT03349489|Active Comparator|Reduction of insulin basal rate 90 minutes prior to exercise|
89524461|NCT03349411||Acute Ischemic Stroke Sample|45 acute patients with first ever ischemic stroke on the right side of the brain will be recruited at NYC Health + Hospitals/Bellevue . They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS)
89524462|NCT03349411||Subacute Ischemic Stroke Sample|30 patients with first ever ischemic stroke on the right side of the brain who are within 3 months of their stroke will be recruited at Kessler Institute for Rehabilitation. They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Florida Mental Status Examination (FMSE); Kessler Foundation Neglect Assessment Process (KF-NAP); and Geriatric Depression Scale (GDS). These participants will also complete a research Magnetic Resonance Imaging (MRI) scan.
89524463|NCT04724577|Experimental|Carbon ion treatment|dose escalation study with five dose levels [54GGyE(Gray equivalent)/12Fx,55.2GyE/12Fx,56.4GyE/12Fx,57.6GyE/12Fx and 58.8GyE/12Fx ].
89524464|NCT03349255|Experimental|intravenous (i.v.) arm|autologous ET1402L1-CART cells administered by intravenous (IV) infusion
89524465|NCT03349255|Experimental|intra-hepatic artery (i.a.) arm|autologous ET1402L1-CART cells administered by intra-hepatic artery (IA) infusion
89524466|NCT04861155|Experimental|Intervention Arm|The experimental intervention uses the SIVA-P3 system, the prototype of a digital solution aiming to support the diagnostic process in cases of chronic cough. The SIVA-P3 system primarily consists of a wearable audio and movement recorder and a smartphone app for the patient.
89524467|NCT05477719|Experimental|Compression stockings - No Compression|The patient will wear specific compression stockings in the first phase, and no compression in the second phase of the study
89524468|NCT05477719|Experimental|No Compression - Compression stockings|The patient won't wear anything in the first phase, and specific compression stockings in the second phase of the study
89524469|NCT05452525|Experimental|Sequence 1|Period 1: Test drug(CKD-379 I) Period 2: Test drug(CKD-379 II) Period 3: Reference drug(D759+D745+D150)
89524470|NCT05452525|Experimental|Sequence 2|Period 1: Test drug(CKD-379 I) Period 2: Reference drug(D759+D745+D150) Period 3: Test drug(CKD-379 II)
89524471|NCT05452525|Experimental|Sequence 3|Period 1: Test drug(CKD-379 II) Period 2: Reference drug(D759+D745+D150) Period 3: Test drug(CKD-379 I)
89524472|NCT05452525|Experimental|Sequence 4|Period 1: Test drug(CKD-379 II) Period 2: Test drug(CKD-379 I) Period 3: Reference drug(D759+D745+D150)
89524473|NCT05452525|Experimental|Sequence 5|Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379 I) Period 3: Test drug(CKD-379 II)
89524474|NCT05452525|Experimental|Sequence 6|Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379 II) Period 3: Test drug(CKD-379 I)
89524475|NCT04584567|Experimental|DOXY ZINC|Doxycycline daily dosing (100mg) Zinc daily dosing (15mg)
89524476|NCT04584567|Placebo Comparator|DOXY PLACEBO|Doxycycline daily dosing (100mg) placebo of Zinc
89524477|NCT04584567|Placebo Comparator|PLACEBO|placebo of Doxycycline daily dosing placebo of Zinc
89524478|NCT04508257|Experimental|Investigational Formula (Stage 1&2)|Investigational formula contains DHA，ARA and enriched whey protein (source of milk fat globule membrane) to support the healthy growth and Cognitive development of infants.
89524479|NCT04508257|Active Comparator|Control formula (Stage 1&2)|Control formula have comparable macronutrients and micronutrients, but does not contain DHA，ARA and MFGM.
89524480|NCT04508257|Other|Breast feeding|Breast fed of human milk
89524481|NCT04814901|Experimental|Study group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae using FAMM and assessment of success regarding patient satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection.
89524482|NCT04814901|Active Comparator|Comparator group|Surgical closure of patients with recurrent small to medium sized oronasal fistulae and its effect on patient's satisfaction and healing and absence of complications such as venous congestion, dehiscence, facial nerve injury and infection
89524483|NCT03354091|Experimental|Intervention|Patient education program and the use of an Fitbit where the users can monitore their activity and receive minor feedback regarding physical activity.
89524484|NCT03354091|No Intervention|Control|Patient education program only.
89524485|NCT04777461|Experimental|Group 1|Pilot the structured education in women with PCOS
89524486|NCT03349177|Experimental|FEC group|Fluorouracil 500mg/m2 on day 1, epirubicin 100mg/m2 on day 1 and cyclophosphamide 500mg/m2 on day 1 every 3 weeks for six cycles
89524487|NCT03349177|Experimental|EC-T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
89524488|NCT03349177|Experimental|TC group|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for six cycles
89524489|NCT02518321|Experimental|Standard Toileting First|This group will complete the standard toileting trial before the TAT toileting trial.
89524490|NCT02518321|Experimental|TAT Toileting First|This group will complete the TAT toileting trial before the standard toileting trial.
89524491|NCT04691505||Methotrexate|Reference group
89524492|NCT04691505||Hydroxychloroquine|Exposure group
89524493|NCT04507945|Experimental|living quality|
89524494|NCT04507945|Experimental|complication|
89524495|NCT04653363||1|study1 is the patients who will be assessed by first rater.
89524496|NCT04653363||2|study2 is the patients who will be assessed by second rater.
89524497|NCT04653363||3|Theh are healty peers control patients who will be assessed by first rater.
89524498|NCT05364619|Experimental|QHD group|Qingre Huashi Granules 1 package twice daily, Rabeprazole 20mg triple daily, Amoxycillin 1g triple daily. The duration is 14 days.
89524499|NCT05364619|Active Comparator|Control group|Rabeprazole 20mg twice daily, bismuth potassium citrate 220mg twice daily, Amoxycillin 1g twice daily, clarithromycin 500mg twice daily. The duration is 14 days.
89524500|NCT03349021|Experimental|Bougiecap|Treatment with Bougiecap instead of Savary Bougie
89524501|NCT04433013|Experimental|Treatment group|
89524502|NCT04433013|Placebo Comparator|Control group|
89524503|NCT03353935||NERVE SPARING|Patients who underwent surgery for deep endometriosis were submitted to surgical procedures aiming at sparing the pelvic ortho- and parasympathetic nerves. The subjects were then followed with interviews using validated questionnaires, to assess the possible changes in post-operative urinary sexual and fecal function.
89524504|NCT03353857|Experimental|levonorgestrel|levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
89524505|NCT03353857|Experimental|norethindrone|norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
89524506|NCT03353857|Experimental|desogestrel|desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
89524507|NCT03353857|Experimental|dienogest|dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
89524508|NCT03353857|Experimental|Drospirenone/ ethinylestradiol|"drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26.~rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29."
89524509|NCT04499859|Experimental|ezetimibe 10 mg plus rosuvastatin 5 mg|Rosuzet 5/10 mg , once a day for 24 months
89524510|NCT04499859|Active Comparator|rosuvastatin 20 mg only|Any brand drugs of rosuvastatin 20mg, once a day for 24 months
89524511|NCT03348943|Active Comparator|Right hemiparesis, right upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
89524512|NCT03348943|Experimental|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
89524513|NCT03348943|Active Comparator|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
89524514|NCT03348943|Experimental|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
89524515|NCT03348865|Experimental|Fertility Life Counselling Aid (FeLiCiA)|"Patients to undergo weekly Felicia counselling interventions for 6 weeks; making a total of 6 sessions.~Each session is expected lasts 30 mins to 1 hour."
89524516|NCT03348865|No Intervention|Control|Patients are to undergo treatment as usual.
89524517|NCT05306899|Active Comparator|Ketamine infusion|Intravenous Ketamine
89524518|NCT05306899|Placebo Comparator|Placebo infusion|
89524519|NCT03348787|Experimental|Behavioral and Cognitive Therapies|Chronic psychotic patients will have Behavioral and Cognitive Therapies
89524520|NCT00807651|Active Comparator|insulin therapy|The participants not accepted written informed consent will receive insulin therapy
89524521|NCT00807651|Experimental|AHSCT|The participants accepted written informed consent will receive the therapy of autologous hematopoietic stem cell transplantation(AHSCT)
89524522|NCT03353623|Experimental|ISG-Group (Immediate Serious Game)|Children in the ISG-Group first participated in the VR-assisted rehabilitation, which consisted in 8 sessions with immersive virtual environment and wearable haptic devices, and were then crossed over and followed during an intended duration of 6 hours of conventional therapy.
89524523|NCT03353623|Experimental|DSG-Group (Delayed Serious Game)|Children from DSG-Group were followed during an intended duration of 6 hours of conventional therapy before receiving VR-assisted rehabilitation with immersive virtual environment and wearable haptic devices.
89524524|NCT00752193|Experimental|1|Probiotic lactobacilli
89524525|NCT00752193|Placebo Comparator|2|Placebo
89524526|NCT00700791|Placebo Comparator|Group I Single Site Randomization|Patients with 1 surgical scar will be given both oral placebo and topical cream placebo
89524527|NCT00700791|Active Comparator|Group II Single Site Randomization|Single surgical site will be given oral placebo and topical TCT
89524528|NCT00700791|Active Comparator|Group III Single Site Randomization|Patients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream
89524529|NCT00700791|Active Comparator|Group IV Single Site Randomization|Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT).
89524530|NCT00700791|Placebo Comparator|Group I: Bilateral Site Randomization|Patients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site.
89524531|NCT00700791|Active Comparator|Group II: Bilateral Site Randomization|Patients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites.
89524532|NCT00700791|Active Comparator|Group III: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site.
89524533|NCT00700791|Active Comparator|Group IV: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site.
89524534|NCT00700791|No Intervention|Normal Skin and Adipost Tissue Group|Normal human skin and adipose tissue will be collected
89524535|NCT04502329|Experimental|IER|Intermittent Energy Restriction
89524536|NCT04502329|No Intervention|CER|Continous Energy Restriction
89524537|NCT03348709|Experimental|Isoosmolar|Iso-osmolar oral supplement (276 mOsm/kg)
89524538|NCT03348709|Active Comparator|Hyperosmolar|Hyper-osmolar oral supplement (681 mOsm/kg)
89524539|NCT05129553|Experimental|Single Use|The participants will then be given the Béa Applicator and Béa Cervical Cap with accompanying instructions for single-use in a home use environment.
89524540|NCT03348553|Sham Comparator|control group|20 subjects do not receive any supplementation
89524541|NCT03348553|Active Comparator|Omega2|20 subjects receive an Omega-Fatty-acid Nutratceutical
89524542|NCT03348553|Active Comparator|Omega4|20 subjects receive an Omega-Fatty-acid Nutraceutical
89524543|NCT03348553|Active Comparator|Omega2+OGV|20 subjects receive an Omega-Fatty-acid Nutraceutical + encapsulated fruit, vegetable and berry-juice concentrate
89524544|NCT05343273||Healthy|
89524545|NCT05343273||Periodontitis|
89524546|NCT05129007||Study group|All patients
89524547|NCT05128851|Active Comparator|High Tibial Osteotomy and arthroscopy|High Tibial Osteotomy with arthroscopically treatment of intraarticular lesions.
89524548|NCT05128851|Sham Comparator|High Tibial Osteotomy|Descending High Tibial Osteotomy with arthroscopy without treatment of intraarticular lesions.
89524549|NCT05128851|Active Comparator|High Tibial Osteotomy, arthroscopy and microfractures|High Tibial Osteotomy with arthroscopically treatment of intraarticular lesions and microfracture.
89524550|NCT05128695||Covid-19 positive|Adults who tested Covid-19 positive
89524551|NCT05128695||Covid-19 negative|Adults who tested Covid-19 negative
89524552|NCT04457115|Experimental|TPV Block|Thoracic paravertebral block performed at thoracic level T2-T3 and T4-T5 with administration of Ropivacaine 0.7% 8 ml for each level.
89524553|NCT04457115|Experimental|ESP Block|Erector spinae plane block performed at thoracic level T2 and T5 with administration of Ropivacaine 0.5% 12 ml for each level.
89524554|NCT05120583|Experimental|study group|Patients in the study group received Pilates exercises (25 minutes/ session). There are different types of equipment to be used in Pilates exercises to achieve different purposes; mat, Pilates band or elastic bands, and Pilate's ball were used.
89524555|NCT05120583|Experimental|control group|Participants in control group received the traditional physical therapy program program (60 minutes/session, three sessions /week for three months).
89524556|NCT04400877||SARS-CoV-2 pos|Patients who have been tested positive for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
89524557|NCT04400877||SARS-CoV-2 neg|Patients without symptoms for SARS-CoV-2 infection who haven't been tested for the virus or patients with symptoms who have been tested negative for SARS-CoV-2 virus by either nasopharyngeal swab PCR or antibody testing.
89524558|NCT04373733|Experimental|Favipiravir & Standard of Care|Favipiravir: Day 1 1800mg twice per day, Days 2-10 800mg twice per day
89524559|NCT04373733|Other|Standard of care|No trial intervention
89524560|NCT05403489||Group B (bronchoalveolar lavage)|"Patients who underwent BAL* were named Group B~* BAL: bronchoalveolar lavage"
89524561|NCT05403489||Group E (endotracheal aspirate)|"Patients who received ETA** were named Group E.~** ETA: Endotracheal aspirate"
89524562|NCT05039385|Experimental|ESATRAL Group|They will perform the supervised physical exercise program. The supervised exercise program (ESATRAL) will last 24 weeks with 2-3 non-consecutive weekly sessions. The duration of each session will be 30 minutes and will progressively increase depending on the phase in which we are until reaching 60 minutes.
89524563|NCT05039385|No Intervention|Control Group|They will follow their daily treatment without added exercise
89524564|NCT04987515||Fenestration decompression combined with secondary curettage (FDSC)|Design of the opening window reasonably；Making cyst plug；secondary curettage
89524565|NCT04987515||local curettage (LC)|The tumor was removed by local curettage only
89524566|NCT04969731|Experimental|Immuncell-LC/Gemcitabine|Patients will receive 6 cycles Gemcitabine (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle) and Immuncell-LC 16 times during 60 weeks (4 treatments once a week, followed by 4 treatments every other week, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks)
89524567|NCT04969731|Active Comparator|Gemcitabine|Patients will receive 6 cycles Gemcitabine alone (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle)
89524568|NCT04921761|Placebo Comparator|Group A|Women who received the conventional epidural technique (group A). Intervention: Procedure: Conventional epidural
89524569|NCT04921761|Active Comparator|Group B|Women who received the dural puncture epidural technique (group B). Intervention: Procedure: Dural puncture epidural
89524570|NCT03058653|Experimental|Study patients|Small fluid boluses - The first 250ml of fluid will be given in 50ml boluses using a 50ml syringe
89524571|NCT04807647|Experimental|music band|"The starting person will first talk about white noise and explain how he can direct breastfeeding, and fill the Informed Volunteer Form, Patient Identification Form and Application Registration Form. The mother and baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. During the second breastfeeding, 30 newborn group Orhan OSMAN's Kolik album will be played on the music player Your Baby Don't Cry. After the process is completed, a written response will be received for the data Premature Baby Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form."
89524572|NCT04807647|No Intervention|control|First, the mother will be informed about the study. Then the appropriate position will be given. The informed volunteer form, the Patient Identification Form and the Application Registration Form will be filled. The mother and the baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. No intervention will be applied during the second breastfeeding. After the procedure is completed, a written response will be received with the data Premature Infant Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form.
89524573|NCT04839315|Other|mRNA COVID19 vaccines|mRNA-based COVID19 vaccines
89524574|NCT04489251||PH subjects|"Pediatric subjects ages 2-17 years~Subjects undergoing a clinically indicated cardiac catheterization.~Subjects with proven or being evaluated for pulmonary hypertension in WHO classification group 1 or 3†~Subjects will be categorized as PAH subjects if they meet the hemodynamic criteria: pulmonary artery pressure >20mmHg, pulmonary vascular resistance index >3 Woods units*m2, and wedge pressures <15mmHg."
89524575|NCT04489251||Control subjects|"Pediatric subjects ages 2-17 years~Subjects undergoing a clinically indicated cardiac catheterization.~Subjects can be categorized as control subjects if they do not have PH on catheterization and do not meet any exclusion criteria."
89524576|NCT05301231||NAFLD group without fibrosis|Group diagnosed to have NAFLD without fibrosis according to the recommendation of EASL; AASLD (13) and ESPGHAN Hepatology Committee (14), (75 adults aged 30-60 years, 75 children aged 12-18 years) ,
89524577|NCT05301231||NAFLD group with fibrosis (potential NASH)|Group diagnosed to have NAFLD with fibrosis according to the recommendation of EASL; AASLD (13) and ESPGHAN Hepatology Committee (14), (75 adults aged 30-60 years, 75 children aged 12-18 years),
89524578|NCT05301231||Healthy group|Healthy control group age and sex-matched with the previous group (75 adults aged 30-60 years, 75 children aged 12-18 years),
89524579|NCT02045901|Active Comparator|Diclegis|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
89524580|NCT02045901|Placebo Comparator|Placebo|Participants will be randomized to receive Diclegis or placebo. On Day 1, all participants will take 2 tablets of study drug at bedtime. On Days 2 to 14, participants will take 2 tablets of study drug at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
89524581|NCT04899219|Experimental|Group A (subjects with severe renal impairment)|
89524582|NCT04899219|Experimental|Group B (control subjects)|
89524583|NCT04478409||Children or adult with Familial Mediterranean fever|"Considering 5 clearly pathogenic (homozygous) genotypes, 15 possibly pathogenic genotypes (5 pathogenic mutations in the heterozygous state, 10 possibly pathogenic mutations in the homozygous or heterozygous state), a number of 80 patients will be necessary to cover the correlation analysis genotype / phenotype.~The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients."
89524584|NCT04478409||Healthy blood donor|Healthy blood donor
89524585|NCT04473885|Experimental|Perturbation-based balance training group|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
89524586|NCT04473885|No Intervention|Control group|Participants in the control group will remain their regular activity without additional training.
89524587|NCT04458363|Experimental|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria) convalescent plasma will be administered
89524588|NCT04662411|Placebo Comparator|Placebo|
89524589|NCT04662411|Experimental|butyrate and hexanoate amount 1|1325 mg of butyrate and hexanoate
89524590|NCT04662411|Experimental|butyrate and hexanoate amount 2|
89524591|NCT04662411|Experimental|butyrate and hexanoate amount 3|
89524592|NCT01674621|Experimental|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Patch - 50 microgram (mcg) daily applications for up to 6 months
89524593|NCT01674621|Experimental|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Patch - 100 mcg daily applications for up to 6 months
89524594|NCT01674621|Experimental|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Patch - 150 mcg daily applications for up to 6 months
89524595|NCT01674621|Active Comparator|Abaloparatide Injection (80 mcg)|Abaloparatide-SC Subcutaneous Injection - 80 mcg daily injections for up to 6 months
89524596|NCT01674621|Placebo Comparator|Abaloparatide Transdermal Placebo (0 mcg)|Abaloparatide Transdermal Microneedle Patch - 0 mcg daily applications for up to 6 months
89524597|NCT04644705|Active Comparator|Part A: verum niclosamide|"The SAD cohorts are planned as follows:~Cohort A1: 200 mg (fasted conditions) Cohort A2: 600 mg (fasted conditions) Cohort A3: 1600 mg (fasted and fed conditions)"
89524598|NCT04644705|Placebo Comparator|Part A: placebo to niclosamide|"The SAD cohorts are planned as follows:~Cohort A1: placebo to niclosamide 200 mg (fasted conditions) Cohort A2: placebo to niclosamide 600 mg (fasted conditions) Cohort A3: placebo to niclosamide 1600 mg (fasted and fed conditions)"
89524599|NCT04644705|Active Comparator|Part B: verum as solution (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
89524600|NCT04644705|Active Comparator|Part B: verum as chewing tablet (niclosamide)|Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
89524601|NCT04644705|Active Comparator|Part C: verum (niclosamide and camostat)|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
89524602|NCT04644705|Placebo Comparator|Part C: placebo to niclosamide and camostat|Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
89524603|NCT04412733|Experimental|Pulsed Ultrasound Group|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2 ) 5-min daily session, 5 days per weeks, for a total of 15 sessions.
89524604|NCT04412733|Sham Comparator|Sham Group|Control group received sham ultrasound with the same protocol.
89524605|NCT04095975|Active Comparator|Baking Soda|Subjects randomized to baking soda will be provided instructions for using baking soda to provide 40 mEq alkali, to be accomplished by dissolving ¼ teaspoon baking soda in water or other beverage (any amount) in the morning on an empty stomach and ½ teaspoon baking soda in water or other beverage again at bedtime, also on an empty stomach.
89524606|NCT04095975|Active Comparator|LithoLyte|Subjects randomized to LithoLyte® will be provided 40 mEq of alkali in the form of LithoLyte® and advised to take 20 mEq twice daily according to package instructions, once in morning and once at bedtime; no requirements about proximity to meals are necessary.
89524607|NCT04038489|Experimental|Tamoxifen and Aspirin with AC-T Chemotherapy|AC-T chemotherapy includes 4 cycles of doxorubicin and cyclophosphamide given every 2 or 3 weeks followed by either 12 weekly cycles of lower dose paclitaxel or 4 cycles of higher dose paclitaxel every 2 or 3 weeks. During this time, all participants would receive daily aspirin and daily tamoxifen. After the AC-T chemotherapy, participants will undergo standard of care surgery to remove any remaining tumor.
89524608|NCT05134077|Experimental|kidneys with simple cysts|Patients involve from Citi Clinical Hospital with simple renal accidentally discovered cyst.
89524609|NCT05134077|Active Comparator|contralateral kidneys without cyst|Рatients involve from Citi Clinical Hospital with simple renal accidentally discovered cyst.
89524610|NCT04468425|Experimental|Pharmacokinetic Study|"Period 1 (Day 1) and 2 (Day 8 - Day 21) separated by 7-day washout period. Period 1: A single 5 mg tofacitinib tablet will be administered orally on Day 1.~Period 2: Repeat dosing of Tofacitinib Citrate Topical Gel 3.2% to approximately 10% BSA in the morning of Day 8 and twice daily from Day 9 to Day 20 with the last dose in the morning of Day 21."
89524611|NCT05133843|Other|Coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
89524612|NCT03891771|No Intervention|Usual Care|Patients allocated to usual care will receive standard follow-up procedures at their primary care facility.
89524613|NCT03891771|Experimental|Telemonitoring sensors|Patients allocated to this arm will receive a complex sensor platform aimed at detecting falls at home, nocturia and several environmental variables, including carbon monoxide concentrations, humidity and temperature. The system also includes a panic button that can be used to request assistance in emergencies.
89524614|NCT03830619||lung cancer patients|
89524615|NCT03830619||normol volunteers|
89524616|NCT04287855|Experimental|Intervention|Isatuximab, Carfilzomib, Pomalidomide and Dexamethasone
89524617|NCT03710265|Experimental|SHR-1701|
89524618|NCT03640455|Placebo Comparator|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; dummy stimulation will be given.
89524619|NCT03640455|Experimental|Anodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in anodal polarity.
89524620|NCT03640455|Experimental|Cathodal tDCS|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; Current Transcranial Stimulation (intensity 2 mA) will be given in cathodal polarity.
89524621|NCT05133609|Experimental|Group 1|Health professionals who will receive vaccine in the vaccination campaign against SARS-CoV-2.
89524622|NCT05133609|Experimental|Group 2|Patients with immune-mediated inflammatory diseases who will receive vaccine in the vaccination campaign against SARS-CoV-2.
89524623|NCT05133375|Experimental|GROUP A|Macintosh laryngoscope was used for endotracheal intubation.
89524624|NCT05133375|Experimental|GROUP B|McCoy laryngoscope was used for endotracheal intubation.
89524625|NCT02952885|Experimental|Pegvisomant|Open-label, non-randomized single arm variable dose study of pegvisomant conducted in a real world setting.
89524626|NCT02183727|Experimental|L-C Ligament|Soft Tissue Regeneration's L-C Ligament is an investigation, interventional device intended for ACL reconstruction surgery within 18 weeks of acute rupture of the ACL and no previous surgical treatment. The L-C Ligament temporarily replaces the human anterior cruciate ligament (ACL) and provides a bioresorbable scaffold within and around which the native ACL will regenerate over time.
89524627|NCT02183727|Active Comparator|Hamstring Autograft|Hamstring autograft is the active comparator for this study. Autograft tissue is the gold-standard treatment for primary ACL reconstruction.
89524628|NCT02113917||hemophagocytic syndrome|patient with hemophagocytic syndrome
89524629|NCT01959087|Experimental|1: Single port surgery|Surgery with single port
89524630|NCT01959087|Active Comparator|2: Multiport surgery|Surgery with multiport
89524631|NCT04082481|Experimental|TAK-988: Part A|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1 to healthy non-Japanese participants. Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]). Dose escalation in Cohorts A2 to A6 will be based on emerging safety/tolerability, PK, and PD data from previous cohorts.
89524632|NCT04082481|Experimental|TAK-988: Part B|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 14 to healthy non-Japanese participants. Dose escalation will be based on review of the emerging safety/tolerability, PK, and PD data from previous cohorts and Part A.
89524633|NCT04082481|Experimental|TAK-988: Part C|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 7 to healthy non-Japanese participants. Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
89524634|NCT04082481|Experimental|TAK-988: Part D|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, twice daily (6-hour interval) from Day 1 to Day 14 to HE non-Japanese participants. Dose will be determined based on previous MRD cohorts.
89524635|NCT04082481|Experimental|TAK-988: Part E|TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1, followed by a washout period of 2 days and twice daily (6- hour interval) on Day 3 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts.
89524636|NCT04435587|Experimental|ivermectin|"Combination of~oral ivermectin 600 mcg/kg/day once daily for 3 days~Zinc sulfate (100mg/tab) 2 tab every 12 hours for 3 days"
89524637|NCT04435587|Active Comparator|ART/hydroxychloroquine|"Combination of~Day1 hydroxychloroquine 400mg bid, then 200mg bid on Day 2-5~Darunavir/ritonavir (400/100mg) every 12 hours for 5 days~Zinc sulfate (100/tab) 2 tab every 12 hours for 5 days"
89524638|NCT03849105|Experimental|Single administration of 131I-IPA (1f group)|Study participants with GBM receive a single administration of 4-L-[131I]iodo-phenylalanine (131I-IPA), followed by 18 cycles of external radiotherapy, each cycle being of 2 Gy.
89524639|NCT03849105|Experimental|Three administrations of 131I-IPA (3f-parallel group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above, 1- 3 days prior to 1st XRT. The 2nd and 3rd 131I-IPA fractions will be administered after 5-9 XRT fractions (subject to investigator's discretion and day of IMP administration) following the previous 131I-IPA fraction. The remainder of XRT fractions will be given following the 3rd 131I-IPA fraction.
89524640|NCT03849105|Experimental|Three administrations of 131I-IPA (3f-sequential group)|Study participants will be administered in 2GBq in 3 fractions corresponding to ⅓ full dose activity (0.67 GBq for the 2.0 GBq dose level). The 1st fraction of 131I-IPA will be administered as above 1- 3 days prior to 1st XRT. The 2nd 131I-IPA fraction will be administered after all 18 XRT fractions have been completed, and the 3rd 131I-IPA fraction will be administered 1 week after the 2nd 131I-IPA fraction.
89524641|NCT03849105|Experimental|Dose escalation of fractionated dosing|Dose escalation will be made in steps of 2.0 GBq, i.e. 4.0 (3*1.33 GBq), 6.0 GBq (3*2.0 GBq), up to 8.0 GBq (3*2.67 GBq) until the maximum tolerated dose (MTD) is reached, using cohorts of N=3 patients.
89524642|NCT04499391|Experimental|ECHO plus|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Participants in this arm will receive a 2 month (8 sessions total) refresher course in Fall 2021. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
89524643|NCT04499391|Active Comparator|ECHO|Nursing homes in this arm will receive the intervention via real-time, interactive videoconferencing using Zoom at no cost to participants. Sessions will be 90 minutes in duration and held weekly for 6 months (25 sessions total) at regularly scheduled times. Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation
89524644|NCT04498065||A|COVID positive and Troponin positive
89524645|NCT04498065||B|COVID positive and Troponin negative
89524646|NCT04497363|Experimental|Focused Ultrasound|On the day of the ultrasound appointment, patients will undergo ten minutes of ultrasound targeting the anterior cingulate. The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
89524647|NCT05132751|Experimental|Group A|Machine Learning Ventilator Decision System Ventilation
89524648|NCT05132751|Active Comparator|Group B|Standard Controlled Ventilation
89524649|NCT03685929||Pressure ulcers|Patients with pressure ulcers category II/III at sacrum or trochanter
89524650|NCT03685929||Incontinence-associated dermatitis|Patients with incontinence-associated dermatitis category IIA at sacrum (or trochanter)
89524651|NCT03685929||Combined lesion|Patients with pressure ulcer category II/III and incontinence-associated dermatitis category IIA at sacrum or trochanter
89524652|NCT05131893||LuminalA|"tamoxifen (+ LHRH analogue for premenopausal participant)~non-steroidal aromatase inhibitor (+ LHRH analogue for premenopausal participant)~Non-steroidal aromatase inhibitor in non-resectable tumor (+ LHRH analogue in premenopausal participant) + CDK4 / 6 inhibitor"
89524653|NCT05131893||LuminalB (Her2 negative)|"12 times weekly paclitaxel (80 mg / m˄2) followed by 4 times every 3 weeks epirubicin (E) (90-100 mg / m˄2) + cyclophosphamide (C) (600) (preferred)~4x 3 weekly E (90-100mg / m˄2) + C (600mg / m˄2), then~docetaxel (90-100 mg / m˄2) 4 times in every 3 weeks or~12x weekly paclitaxel (80mg / m˄2)~4x every 2 weeks Epirubicin (E) (90-100mg / m˄2) + Cyclophosphamid (C) (600mg / m˄2), then~4 times every 2 weeks with paclitaxel (175 mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2)~TC: docetaxel (75 mg / m˄2) + cyclophosphamide (600 mg / m˄2) every 21 days with GCSF prevention (6 cycles)"
89524654|NCT05131893||Her2 positive|"4x 3 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~12 times weekly paclitaxel + trastuzumab (every week or 3 weekly) +/- pertuzumab (3 weekly) or~4x 3 weekly docetaxel (100mg / m˄2) + trastuzumab +/- pertuzumab~Docetaxel (75 mg / m˄2) + carboplatin (AUC6) + trastuzumab +/- pertuzumab 6 times every 3 weeks c) E (90-100mg / m˄2) + C (600mg / m˄2) 4x every 2 weeks, then 12 times weekly paclitaxel + trastuzumab (every week or 3 weekly) +/- pertuzumab (3 weekly)"
89524655|NCT05131893||Triple-negative breast cancer|"Paclitaxel (80 mg / m˄2) +/- carboplatin (AUC2) 12 times weekly, then E (90-100 mg / m˄2) + C (600 mg / m˄2) 4 times three weekly (preferred)~4x every 3 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~4x docetaxel (90-100mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2) +/- carboplatin (AUC2 )~4x every 2 weeks E (90-100mg / m˄2) + C (600mg / m˄2), then~4 times every 2 weeks paclitaxel (175 mg / m˄2) or~12x weekly paclitaxel (80mg / m˄2) +/- carboplatin (AUC2)"
89524656|NCT03522519||Assessment of real world performance|
89524657|NCT03343041|Active Comparator|low carbohydrate nutrition|"We will use a low-carbohydrate nutrition (LCN) formulated by the MICU registered dietitian and pharmacy staff, who routinely prepare enteral and parenteral nutrition which will provide:~5% carb, 41% protein, 54% lipid."
89524658|NCT03343041|Active Comparator|standard enteral nutrition|"The standard enteral nutrition (SEN) and per cent contribution of carbohydrates used in the Yale MICU is as follows:~Jevity 1.2 56% carb, 29.5% lipid, 18.5% protein Diabetisource 33% carb, 44% lipid, 20% protein Promote 55% carb, 25% lipid, 25% protein Vital AF 37% carb, 40% lipid, 25% protein Peptamin Intense 29% carb, 34% lipid, 37% protein Osmolite 1.5 54% carb, 29.5% lipid, 16.5% protein"
89524659|NCT05130879|Experimental|BRAW intervention group|BRAW is designed as an online intervention comprising of six sessions over six weeks. The six sessions are: (1) happiness and positivity, (2) cognitive restructuring, (3) behavioural activation, (4) emotion regulation, (5) positive work climate and (6) problem solving.
89524660|NCT05130879|No Intervention|Waitlist control group|Participants will receive the intervention after the follow-up assessment.
89524661|NCT05122065||Asymptomatic/non-HRT|Samples derived from women in menopause who do not self-reportedly experience GSM (Genitourinary Syndrome of Menopause) and who do not take HRT (Hormone Replacement Therapy).
89524662|NCT05122065||Asymptomatic/HRT|Samples derived from women in menopause who do not self-reportedly experience GSM and who take HRT
89524663|NCT05122065||GSM/non-HRT|Samples derived from women in menopause who self-reportedly experience GSM and who do not take HRT
89524664|NCT05122065||GSM/HRT|Samples derived from women in menopause who self-reportedly experience GSM and who take HRT
89524665|NCT03239067||ticagrelor group|patients prescribed with ticagrelor
89524666|NCT03239067||clopidogrel group|patients prescribed with clopidogrel
89524667|NCT03069807|Experimental|Intervention|Participants with LTBI will be treated in the Community/Primary Care.
89524668|NCT03069807|Active Comparator|Control|Participants with LTBI will be treated in the Hospital/TB Clinic
89524669|NCT03014583|Experimental|HF/TCS/BURST|HF/TCS/BURST
89524670|NCT03014583|Experimental|HF/BURST/TCS|HF/BURST/TCS
89524671|NCT03014583|Experimental|BURST/HF/TCS|BURST/HF/TCS
89524672|NCT03014583|Experimental|BURST/TCS/HF|BURST/TCS/HF
89524673|NCT03014583|Experimental|TCS/BURST/HF|TCS/BURST/HF
89524674|NCT03014583|Experimental|TCS/HF/BURST|TCS/HF/BURST
89524675|NCT02901405|Experimental|Negative Pressure Wound Therapy|120 hours of negative pressure wound therapy (ActiVAC, KCI) applied to a primarily closed ('acute') wound.
89524676|NCT02901405|Active Comparator|Standard dressings|Absorbant dressings applied in a standard fashion, i.e. only changed as necessary
89524677|NCT02889237|No Intervention|Standard care|Start of calcium and vitamin D3 supplementation according to standard care, i.e. 12 weeks after fracture.
89524678|NCT02889237|Active Comparator|Calcium|Immediate administration of daily calcium supplementation (1000 mg calcium)
89524679|NCT02889237|Active Comparator|Calcium and low dose vitamin D|Immediate administration of daily calcium + low dose vitamin D supplementation (1000 mg calcium + 880 IU vitamin D).
89524680|NCT02889237|Active Comparator|Calcium and high dose vitamin D|Immediate administration of daily calcium + high dose vitamin D supplementation (1000 mg calcium + 1760 IU vitamin D)
89524681|NCT02889237|No Intervention|Already on treatment with Calcium or vitamin D|Patients who are already treated with Calcium or Vitamin D.
89524682|NCT02689167|Active Comparator|Arm A 4/6|"Sunitinib 37.5 mg/day; regimen 4/6 (Marketing Authorisation Indication) 4 weeks on  alternating with 2 weeks off "
89524683|NCT02689167|Experimental|Arm B 2/3|"Sunitinib 50 mg/day; regimen 2/3 (experimental arm) 2 weeks on  alternating with 1 week off "
89524684|NCT02582697|Active Comparator|Standard Arm - Standard BEP|"Participants 16 years or older will receive 4 cycles of Standard BEP as follows:~Bleomycin 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients < 16 years old and weighs ≥ 45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16 years old and weighs < 45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Filgrastim 10mcg/kg/day on day 6, until post-nadir Absolute Neutrophil Count ≥1 x10^9/ L~The dose of bleomycin is decided by the treating physician and based on the patient's Body Surface Area.~Each cycle is 3 weeks (21 days).~The planned total duration of treatment is 12 weeks."
89524685|NCT02582697|Experimental|Experimental Arm - Accelerated BEP|"Participants 16years or older will receive 4 cycles of Accelerated BEP as follows:~Bleomycin 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1- 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16years and weighs ≥45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Pegylated G-CSF 6 mg SCI on day 6~Patients <16years and weighs <45 kg will receive:~Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses~Etoposide 100 mg/m2 IV on day 1 - 5~Cisplatin 20 mg/m2 IV on day 1 - 5~Filgrastim 10mcg/kg/day on day 6, until ANC ≥1 x10^9/ L~Each cycle is 2 weeks (14days)~Following 4xBEP cycles, patients will receive additional bleomycin as follows:~- Bleomycin *15,000 - 30,000 IU IV wkly for 4 doses~* The dose of bleomycin is decided by the treating physician and based on the patient's BSA.~The planned total duration is 12 weeks."
89524686|NCT05292417|Experimental|Experimental Group|hypofractionation radiotherapy combined with sintilimab,GM-CSF and Fruquintinib in the third-line or above treatment of MSS Metastatic Colorectal Carcinoma(mCRC)
89524687|NCT05285241|Experimental|Multidirectional exercise group|Multidirectional stepping exercises along with conventional physiotherapy were provided to the patients. Conventional physiotherapy included one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min).
89524688|NCT05285241|Active Comparator|Conventional Physiotherapy Group|One-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min) were provided to the patients.
89524689|NCT02137473|Active Comparator|Bovine protein-based fortifier|
89524690|NCT02137473|Experimental|Human milk-based fortifier|
89524691|NCT01503489||Bipolar depressed patients|Bipolar I or II outpatients, current major depressive episode (HDRS-17 over 20).
89524692|NCT04492683|Experimental|Disease group|One active patch and one control patch applied to subjects with clinical symptoms suggestive of non-IgE mediated CMA
89524693|NCT04492683|Experimental|Control group|One active patch and one control patch applied to subjects without any history of allergic disease
89524694|NCT05137977||SIR|All adult intensive care patients. Data from the The Swedish intensive care registry
89524695|NCT05059587|Experimental|MBA-P01|MBA-P01 will be injected into the GL: initial double-blind treatment on Day 1.
89524696|NCT05059587|Active Comparator|BOTOX®|BOTOX® will be injected into the GL: initial double-blind treatment on Day 1.
89524697|NCT05137509||Patients Infected by severe acute respiratory syndrome coronavirus 2 (SARS-cov-2)|Patients Infected by COVID -19 diagnosed by Reverse transcriptase polymerase chain reaction and computerized tomography
89524698|NCT05137509||patients suffering from chronic lung disease|Diagnosed by clinical manifestation and Computerized tomogarphy
89524699|NCT05137509||Healthy Individuals|They must be without prior history of chronic inflammation in the lung
89524700|NCT05137197|No Intervention|TAU|Treatment as Usual: The treating clinician will decide on what antidepressant to prescribe based on the clinical evaluation.
89524701|NCT05137197|Active Comparator|PGT|Predictix Guided Treatment: The treating clinician will decide on what antidepressant to prescribe based on clinical evaluation and the Predictix report
89524702|NCT05200221||Donafenib|Patients with uHCC taking donafenib in clinical treatment
89524703|NCT05054907||Wearable devices + Smartphone|The only arm in the study.
89524704|NCT05185167|Experimental|Desflurane Group|Desflurane 1,0 minimum alveolar concentration will be administered during anesthesia maintenance
89524705|NCT05185167|Experimental|Propofol Group|Propofol 6 mg//kg/hour will be administered during anesthesia maintenance
89524706|NCT04474119|Experimental|Experimental arm|KN046 plus Carboplatin and Paclitaxel
89524707|NCT04474119|Placebo Comparator|Control arm|Placebo plus Carboplatin and Paclitaxel
89524708|NCT05134389||Israel|OAGB patients from Israel
89524709|NCT05134389||Spain|OAGB patients from Spain
89524710|NCT05134389||Portugal|OAGB patients from Portugal
89524711|NCT05133453|Active Comparator|Pirfinedone group|asbestosis patients given pirfenidone drug
89524712|NCT05133453|No Intervention|Conventional group|Asbestosis patients on conventional treatment
89524713|NCT05008341|Experimental|Solriamfetol|Participants will receive a single oral dose of solriamfetol 150 mg with 240 mL water at 0 hour on the morning of Day 1, 2 hours after completion of a light breakfast.
89524714|NCT05121363|Experimental|TQB2858 injection + Anlotinib Hydrochloride capsules|"TQB2858 injection: once every 3 weeks, 1800mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.~Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur."
89524715|NCT04244877|Experimental|Rifaximin|Rifaximin 550 mg by mouth twice daily for eight weeks.
89524716|NCT05305833|Experimental|umbilical cord derived mesenchymal stem cells transplantation group|taking umbilical cord derived mesenchymal stem cells
89524717|NCT05305833|Experimental|stromal vascular fraction cells application group|taking stromal vascular fraction cells
89524718|NCT05118945||SWITCH group: Change from Basal IQ to Control IQ|"The patients of the SWITCH group used the X:s insulin pump with the Basal IQ algorithm until the start of the study and switched to the Control IQ algorithm at study start."
89524719|NCT05118945||START group: Change from conservative therapy to Control IQ|"The patients of the START group have a conservative Insulin therapy (MDI = multiple daily injections or CSII = Continuous subcutaneous insulin infusion) until the start of the study, but will switched to the Control IQ algorithm at study start."
89524720|NCT05114655|Experimental|Intervention 1|Participants apply an herbaceous, earthy based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
89524721|NCT05114655|Experimental|Intervention 2|Participants apply a light, citrus-based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
89524722|NCT05114655|Placebo Comparator|Placebo|Participants apply an inert blend including fractionated coconut oil to the jawline three times each day for 7 days.
89524723|NCT02730169|Experimental|BGS649 0.1 mg|BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
89524724|NCT02730169|Experimental|BGS649 0.3 mg|BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
89524725|NCT02730169|Experimental|BGS649 1.0 mg|BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
89524726|NCT02730169|Placebo Comparator|Placebo|Placebo weekly (3 indistinguishable placebo capsules)
89524727|NCT05105763|Other|feedback training on single joint first|Participants in Subgroup 1 will first undergo Condition B in the first visit and then Condition A in the second visit.
89524728|NCT05105763|Other|sequential feedback training on multi-joint first|Participants in Subgroup 2 will start with Condition A in the first visit and then undergo Condition B in the second visit.
89524729|NCT05305131|Experimental|Induction cisplatin and gemcitabine|Each treatment cycle is 3 weeks. All patients would receive 3 cycles of induction chemotherapy as part of the study, and would then be considered for subsequent concurrent chemoradiotherapy at the investigator's discretion. Cross over is not allowed.
89524730|NCT05305131|Experimental|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab|Each treatment cycle is 3 weeks. All patients would receive 3 cycles of induction chemotherapy as part of the study, and would then be considered for subsequent concurrent chemoradiotherapy at the investigator's discretion. Cross over is not allowed.
89524731|NCT03353467|Experimental|Group in endoscopic surgery|Stage I patients were only treated with endoscopic surgery without additional chemotherapy. Endoscopic nasopharyngectomy included endoscopic resection , with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
89524732|NCT03353467|Active Comparator|Group in IMRT|Stage I patients were only treated with radical intensity-modulated radiotherapy without additional chemotherapy. IMRT was delivered with a dynamic multileaf intensity-modulating collimator (NOMOS, Sewickley, PA) by a slice-by-slice arc rotation approach.
89524733|NCT03122665|Active Comparator|Nefopam low dose|Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
89524734|NCT03122665|Active Comparator|Nefopam high dose|Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
89524735|NCT05099913|Experimental|2-week group|Patients were treated with antidepressants for 10-14 days combined with first-class medication(anti-acid drugs, prokinetics), followed by on demand.
89524736|NCT05099913|Experimental|4-week group|Patients were treated with antidepressants for 4 weeks combined with first-class medication(anti-acid drugs, prokinetics).
89524737|NCT03346993|Experimental|24C° 0,5% bupivacaine group|24C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 24C° 20 ml 0,5% bupivacaine
89524738|NCT03346993|Experimental|37C° 0,5% bupivacaine group|37C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 37C° 20 ml 0,5% bupivacaine
89524739|NCT03346915|Experimental|Subjects receiving WoW and BNI|The behavioral intervention (WoW and BNI) will supplement the subject's standard of care by incorporating interactive messaging, reminders, patient education, and enhanced provider communication.
89524740|NCT03346837|Experimental|Inhibition (Cohort 1)|Single oral dose BMS-986205
89524741|NCT03346837|Experimental|Inhibition (Cohort 2)|Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4
89524742|NCT03346837|Experimental|Induction (Cohort 3)|Single oral dose BMS-986205
89524743|NCT03346837|Experimental|Induction (Cohort 4)|Daily oral rifampin doses for21 days; single oral dose BMS-986205 on day 8
89524744|NCT04987905|Experimental|Experimental Group|"In the study, for 60 minutes once a week for 8 weeks the MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice). In addition to these, nurses will be required to keep a diary of the program. This app contains basic mindfulness exercises and does not pose any health risks to practitioners. While the MIND-BE program is carried out in the online environment, the cameras of the nurses in the experimental group will be turned on and the researcher who made the application will be able to see each nurse."
89524745|NCT04987905|No Intervention|Control Group|No intervention will be made to the control group, only the data will be collected at the same time as the study group. After all data are collected (after the 12th week), the training content will be explained to the nurses in the control group and the MIND-BE program will be started for them as well. In this way, both groups will benefit from this program.
89524746|NCT03353311||Enhanced Recovery After Surgery|"Patients undergoing elective colorectal surgical resection for benign/malignant disease.~A multidisciplinary validated approach based on 24 items including Preadmission information, education and counselling Preoperative optimization (increasing exercise, stop smoking and alcohol consumption should 4 weeks before surgery) No preoperative bowel preparation Use of preoperative carbohydrate drinks Pre-anesthetic medication Prophylaxis against thromboembolism Antimicrobial prophylaxis and skin preparation Standard anesthetic protocol for rapid awakening PONV Mini-invasive surgery No nasogastric dreinage Prevention of intraoperative hypothermia Perioperative fluid management No drains in the peritoneal cavity after colonic anastomosis Early remouval of urinary drainage (24-48 hrs) Prevention of postoperative ileus (including use of postoperative laxatives) Postoperative analgesia Perioperative nutritional care Postoperative control of glucose Early mobilization Auditing"
89524747|NCT05158621||Advanced/Metastatic Colorectal Cancer|Eligible patients include those with newly-diagnosed or recurrent advanced/metastatic CRC who are initiating fluoropyrimidine and oxaliplatin (FOLFOX or CAPEOX) in combination with bevacizumab. Patients will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE(TM), to warrant manufacturing of an individualized vaccine. Patients with sufficient neoantigens will have vaccine manufactured while receiving FOLFOX or CAPEOX/bevacizumab.
89524748|NCT05158621||Localized Colon Cancer|Eligible patients include those with high-risk Stage II or Stage III colon cancer who have MRD based on the presence of ctDNA following surgical resection. Patients with MRD will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE(TM), to warrant manufacturing of an individualized vaccine.
89524749|NCT05035797|Active Comparator|CaRe-ECMO group|Patients in the CaRe-ECMO group will be treated with usual care, ECMO therapy, and cardiopulmonary rehabilitation program.
89524750|NCT05035797|Placebo Comparator|Control group|Usual care and ECMO therapy
89524751|NCT05304429|Experimental|nutritional counseling group|This group will have nutrition education sessions every fifteen days and will keep track of 10 healthy behaviors through goal setting and self-monitoring.
89524752|NCT05304429|No Intervention|group without nutritional counseling|This group will have sessions every fifteen days of reading, knitting and other activities unrelated to health.
89524753|NCT03348891|Other|Subgroup 1|Patients treated with anti-PD-1 alone (nivolumab or pembrolizumab)
89524754|NCT03348891|Other|Subgroup 2|Patients treated with the combined treatment anti-PD-1+anti-CTLA-4 (nivolumab + ipilimumab)
89524755|NCT03348475|Experimental|Experimental Group|Binge Focused Therapy (BFT) Intervention
89524756|NCT03348397||Contegra patients|
89524757|NCT03348397||Pulmonary homograft patients|
89524758|NCT02956317|Active Comparator|STP705|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.
89524759|NCT02956317|Placebo Comparator|Placebo|Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar
89524760|NCT03353155|Active Comparator|Usual Care|Telephone and/or home visits at 1 week, and thereafter, monthly for 6 months, to check on medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges by the relevant service departments as recommended by the discharging physician.
89524761|NCT03353155|Active Comparator|CareHub|Telephone follow-up by a nurse care coordinator acting as single point of contact for medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges based on automatic enrollment using ACE score cut-off at admission.
88811831|NCT01387139|Active Comparator|Ketamine Alone|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
89524762|NCT02517931|Active Comparator|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
89524763|NCT02517931|Placebo Comparator|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
89524764|NCT05303961|Experimental|SA001|"Part 1: 24 subjects are assigned to single dose groups(240mg, 480mg, 720mg, 1080mg of SA001) in a ratio of 1:1:1:1 and receiving each dose of SA001 in the period 1.~Part2: 18 subjects are assinged to multiple dose groups(360mg, 720mg, 1080mg of SA001) in a ratio of 1:1:1 and receiving each dose of SA001."
89524765|NCT05303961|Active Comparator|Rebamipide|Part 1: 12 subjects are assigned to single dose groups(200mg, 600mg of Rebamipide) in a ratio of 1:1 and receiving each dose of Rebamipide in the period 2.
89524766|NCT05303961|Placebo Comparator|Placebo|"Part 1: 8 subjects receiving a single dose of Placebo in the period 1.~Part2: 6 subjects receiving multiple dose of Placebo."
89524767|NCT03353077|Experimental|Alpha DaRT|Alpha DaRT Seeds, Diffusing alpha-emitters Radiation Therapy.
89524768|NCT04974333|Experimental|Mobile health application|"Participants assigned to the intervention group will use a mobile application on their smart phones that will assist the patients with their diabetes control, provide and update information on their clinical history, offer a monitoring their nutritional and physical activity habits as well as anthropometric measurements, provide recommendations how to improve on nutritional habits and physical activity behavior, assist in planning and reminding on clinical appointments.~The duration of the intervention will be 12 months. Each patient will be invited to follow-up visits and measurements each three months (month 3, month 6, month 9 and month 12)."
89524769|NCT04974333|No Intervention|Standard care|Participants assigned to the control arm will continue their regular standard diabetes care without mobile health technology assistance.
89524770|NCT03122353|Experimental|Calcipotriene Hydrate and Betamethasone|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
89524771|NCT03122353|Active Comparator|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
89524772|NCT03122353|Placebo Comparator|Placebo|Topical suspension without active ingredient
89524773|NCT04970433|Experimental|Electroacupuncture (EA)|Acupoint regimen: Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation using an EA apparatus, with a pair of electrodes connecting acupoints LI4 with PC6, and another pair of electrodes connecting ST36 with SP6. EA stimulation will last for 15 min with a continuous wave of 2 Hz and a current intensity of 0.1-1 mA.
89524774|NCT04970433|Active Comparator|Laser acupuncture (LA)|Participants allocated to the LA group will receive LA therapy at the same acupoints used in EA group. The laser will be applied to each point for 40 seconds, which delivered 3 J of energy at each of the acupoints.
89524775|NCT04970433|Sham Comparator|Sham laser acupuncture (SLA)|Participants in the control group will receive sham LA treatment without any laser output. The acupuncture points, application duration, and total number of treatments are the same as those in the LA group.
89524776|NCT03122275|Experimental|Stepwise intervention|"Stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening, implemented through three steps:~step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professional phone call and face-to-face appointment.~Intervention stops whenever the participant adheres to organized screening or after undergoing the complete stepwise intervention."
89524777|NCT03122275|Active Comparator|Written Letter|Comparator will be the standard of care of invitation to cervical cancer screening: written letter
89524778|NCT05303259|Experimental|HNC patients with radiation-induced brain injury.|Bevacizumab 2.5mg/kg， q2w，4 cycles.
89524779|NCT05303259|No Intervention|HNC patients without brain injury after radiotherapy.|No treatment.
89524780|NCT03121963|Experimental|Treatment Group|A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.
89524781|NCT03121963|Active Comparator|Control Group|A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.
89524782|NCT04507789|Experimental|exercise intervention group|This group will be taken an exercise intervention during their radiotherapy programme.
89524783|NCT04507789|Active Comparator|routine radiotherapy protocol|This group will not be taken into an exercise intervention during their radiotherapy programme.
89524784|NCT04502251|Active Comparator|LDN + tDCS|Low Dose Naltrexone and Transcranial Direct Current Stimulation
89524785|NCT04502251|Sham Comparator|LDN + Sham tDCS|Low Dose Naltrexone and Sham Transcranial Direct Current Stimulation
89524786|NCT04502251|Placebo Comparator|Placebo + tDCS|Placebo and Transcranial Direct Current Stimulation
89524787|NCT04502251|Other|Placebo + Sham tDCS|Placebo and Sham Transcranial Direct Current Stimulation
89524788|NCT03348319||Cadaver organs|
89524789|NCT03348241|Experimental|Gum Arabic group|Patients of study group was received a dose of 30 grams Gum Arabic per day as oral solution (dissolved in 250 ml purified water) for six weeks along with the chemotherapy prescribed addition to verbal instructions pertaining to the optimal nutrition and daily routine for oral hygiene.
89524790|NCT03348241|Other|Control group|Patients of control group was received only chemotherapy regimen and verbal counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
89524791|NCT02648217|Experimental|IDegAsp U100 BID|
89524792|NCT02648217|Active Comparator|BIAsp U100 BID|
89524793|NCT04507399|Experimental|Protein Beverage|Whey Protein Beverage
89524794|NCT04507399|Experimental|Control Beverage|Whey Permeate Beverage
89524795|NCT03122041|Experimental|SITA|Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
89524796|NCT03122041|Experimental|CON|Controls (CON) Lifestyle intervention
89524797|NCT04943679||Anti-PD-1/PD-L1 antibodies and Pegylated Interferon Alfa-2b|Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years; Anti-PD-1/PD-L1 Antibodies: given by intravenous injection at indicated dose for up to 2 years
89524798|NCT04507165|Experimental|opioid-free general anesthesia|under opioid-free general anesthesia
89524799|NCT04507165|Active Comparator|opioid based general anesthesia|under opioid based general anesthesia
89524800|NCT02315469||Observational (geriatric assessment)|At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
89524801|NCT05585437||gastric cancer specialist training program|
89524802|NCT04507087|Experimental|Intervention|See detailed preregistration: https://osf.io/xrckh/registrations
89524803|NCT04507087|Sham Comparator|Control|See detailed preregistration: https://osf.io/xrckh/registrations
89524804|NCT05585359|Experimental|injectable platelet rich fibrin with Vitamin C|Injectable platelet rich fibrin: 10-mL sample of whole venous blood will be drawn from the patient's forearm and transferred into two plain plastic test tubes without an anticoagulant and will centrifuge immediately at 700 rpm for 3 minutes (60×g) . After centrifugation, the upper yellow fluid liquid (i-PRF) will be collected as close as possible to the layer of red cells the will be mixed with 250 micromole of Vitamin C.
89524805|NCT05585359|Active Comparator|Injectable platelet rich fibrin alone|injectable platelet rich fibrin: 10-mL sample of whole venous blood will be drawn from the patient's forearm and transferred into two plain plastic test tubes without an anticoagulant and will centrifuge immediately at 700 rpm for 3 minutes (60×g) . After centrifugation, the upper yellow fluid liquid (i-PRF) will be collected as close as possible to the layer of red cells
89524806|NCT05060575|Experimental|EDUTC|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
89524807|NCT05060575|Active Comparator|Control Group|Routine hospital care.
89524808|NCT04503421|Experimental|BFR|"Patient will use the following rehabilitation protocol while incorporating blood flow restriction therapy:~Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only~Sling immobilization with active wrist and shoulder ROM~Active extension of biceps to 30 degrees, No active flexion~6-9 weeks full active extension in brace~Maintain wrist and shoulder flexibility~Begin rotator cuff/deltoid isometrics, progress active extension in brace~Weeks 9-12: Gently advance ROM to tolerance~Discontinue sling~Begin active flexion and extension against gravity.~Advance strength to light resistance, maintain flexibility/ROM~Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
89524809|NCT04503421|No Intervention|Control (no BFR)|"patients will use following rehabilitation protocol without the use of blood flow restriction therapy:~Post-op weeks 0-6: Passive shoulder and wrist Range of Motion (ROM) only~Sling immobilization with active wrist and shoulder ROM~Active extension of biceps to 30 degrees, No active flexion~6-9 weeks full active extension in brace~Maintain wrist and shoulder flexibility~Begin rotator cuff/deltoid isometrics, progress active extension in brace~Weeks 9-12: Gently advance ROM to tolerance~Discontinue sling~Begin active flexion and extension against gravity.~Advance strength to light resistance, maintain flexibility/ROM~Weeks 12-6 months: Gradual return to full ROM and pain free o Begin gradual flexion strengthening and advance as tolerated"
89524810|NCT03352999|Other|ROHCA rescued by vaECMO|Patients experiencing a ROHCA despite advanced CPR and finally rescued with a va ECMO device.
89524811|NCT02164695|Active Comparator|PPCI plus RIPC|The patients randomized to PPCI plus RIPC group will receive RIPC during PPCI.
89524812|NCT02164695|Sham Comparator|PPCI only|The patients randomized to PPCI only group will receive PPCI only but the sham procedure of RIPC.
89524813|NCT04506697|Experimental|Patients with LUTS|Patients who are indicated for uroflowmetry
89524814|NCT03352921|Experimental|clinical pilates exercises|The experimental group will receive clinical pilates exercise training in group form for 3 weeks a week for 8 weeks. The training will be done 40-50 minutes per one day. The exercise session will be started with a 10 minute warming program, 30 minutes with the core stabilization training and the clinical pilates exercises with the postural alignment exercises will be applied and the exercise session will be ended with the 10 minutes cooling period.
89524815|NCT03352921|Active Comparator|Home exercises program|For 8 weeks the member in comparison group will be ask to do the exercise program 3 days a week at home. This group will receive a program of stretching, strengthening, and posture exercises. All the exercises in the program will be illustrated on a descriptive form with images. In terms of the follow-up during 8-week duration, the individuals will be called frequently and in the interview by the end of the study.
89524816|NCT05303181|Experimental|Group1|training used Russian Current carrier frequency at 2500-Hz alternating current.
89524817|NCT05303181|Experimental|Group2|training used Russian Current carrier frequency at 3750-Hz alternating current.
89524818|NCT05303181|Experimental|Group3|training used Russian Current carrier frequency at 5000-Hz alternating current.
89524819|NCT05303181|Experimental|Group4|training used Russian Current at different mode.
89531983|NCT04334525|No Intervention|Generic placemats and frequent diner cards|Participants will receive generic placemats listing all of the restaurant's kids' meals. Families will also receive a generic frequent diner card, which after purchasing (any) kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
89524820|NCT04506541|Experimental|Kangaroo Care Group|"The pregnant women who were in the kangaroo care group of the study and who were 36-38 weeks of gestation were given 20 minutes of kangaroo care and breastfeeding training by the researcher. A video about kangaroo care and breastfeeding was sent to pregnant women to remind them two weeks after the training. Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room. In the first, third, sixth, and ninth months after the discharge of the mothers who started applying kangaroo care, kangaroo care application status, breastfeeding status, baby's growth, and development status were evaluated. In each follow-up, the baby's height, weight, and head circumference were measured with a standard measuring tool."
89524821|NCT04506541|No Intervention|Control Group|The pregnant women in the control group were not trained other than breastfeeding training given in the hospital. In the maternity room, routine care practices were performed after delivery of the pregnant women. As in mothers in the kangaroo care group, in the first, third, sixth, and ninth months after the discharge of mothers, kangaroo care application situations, breastfeeding conditions, growth, and development of the baby were evaluated.
89524822|NCT04475991|Active Comparator|Currently used therapy (CT) only|"Treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present."
89524823|NCT04475991|Experimental|Maraviroc+CT|"Maraviroc AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
89524824|NCT04475991|Experimental|Favipiravir+CT|"Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients."
89524825|NCT04475991|Experimental|Maraviroc+Favipiravir+CT|"Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients"
89524826|NCT03387475|Experimental|Deferasirox|efficacy of 3.5mg/kg/day
89524827|NCT04502017|Active Comparator|Standard Antithrombotic Therapy|OAC for 6 weeks followed by DAPT until 6 month-follow-up, then aspirin alone
89524828|NCT04502017|Active Comparator|Genetic-Tailored AntiThrombotic Strategy|OAC for 6 weeks followed by DAPT (clopidogrel responders) or aspirin plus half-dose OAC (clopidogrel non-responders) until 6 month-follow-up, then aspirin alone
89524829|NCT04502017|Active Comparator|Half-Dose NOAC|Half Dose of Novel OAC
89524830|NCT05302713|Experimental|Ionic Calcium|Ionic calcium (IC) is a calcium in a free ionic state. Participants will be instructed to take 8mg of IC/60kg body weight dissolved into approximately 500ml of purified water. Participants will titrate their dose at the start of the study as follows: days 1-3: 1 dose per day 30 min prior to a meal; Days 4-6: twice per day, 30 minutes before meals; from day seven onward, the full dosage of three times per day, 30 minutes before meals.
89524831|NCT05302713|Active Comparator|Calcium Carbonate|Participants will be instructed to take 8mg of calcium carbonate/60kg body weight dissolved into approximately 500ml of purified water. Participants will titrate their dose at the start of the study as follows: days 1-3: 1 dose per day 30 min prior to a meal; Days 4-6: twice per day, 30 minutes before meals; from day seven onward, the full dosage of three times per day, 30 minutes before meals.
89524832|NCT04992949|Experimental|CPX351|Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of CONSOLIDATION therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.
89524833|NCT05584969|Experimental|Moms-only treatment arm|In this treatment arm, 10 Care Groups comprised of only mothers (10 - 20 participants per group) engaged in the peer-led intervention that consisted of infant feeding guidelines [16], cooking demonstrations, and backyard farming demonstrations conducted over 10 months. The peer-led trainings lasted 60 - 90 minutes and were conducted every two weeks and supervised by a selected VHT.
89524834|NCT05584969|Experimental|Moms and Dads treatment arm|This treatment arm received a similar peer-led intervention to the Moms-only treatment arm, however, this arm comprised both moms and dads (a couple)
89524835|NCT05584969|No Intervention|Control arm|This was the comparison arm of the study. No intervention was provided to the participants of this arm. However, all study arm participants accessed the standard of care which was the routine health services delivered through the government health centers.
89524836|NCT05584891||group 1|radical mastoidectomy
89524837|NCT05584891||group2|mastoid obliteration operation.
89524838|NCT05302557|Experimental|Interventional|"During the two weeks prior to the ileostomy closure procedure, daily stimulation of the efferent loop will be performed by irrigation with 500 ml of physiological saline or 500 ml of warm water, preferably bottled, associated with a nutritional thickener. The patient will be instructed by a stomatotherapy nurse. Stimulation will be performed up to the day before the intervention. Kegel exercises will be suggested.~Every surgeon will use his or her usual technique for all patients included in the study, regardless of the group assigned in the randomization.~All patients in both groups will receive the same antibiotic and antithrombotic prophylaxis. No antibiotic administration is expected during the postoperative period, following a Zero Surgical Infection (ZSI) protocol."
89524839|NCT05302557|No Intervention|Control|"Direct standard surgery. Every surgeon will use his or her usual technique for all patients included in the study, regardless of the group assigned in the randomization.~All patients in both groups will receive the same antibiotic and antithrombotic prophylaxis. No antibiotic administration is expected during the postoperative period, following a Zero Surgical Infection (ZSI) protocol."
89524840|NCT05584813|No Intervention|ground control binocular|Intervention: pressure chamber environment Procedures: Colour vision tests were performed under normoxia with both eyes three times in a row for appropriate comparability to the simulated flight stages pre-peri-post hypoxia in the intervention groups
89524841|NCT05584813|No Intervention|ground control monocular|Intervention: pressure chamber environment Procedures: Colour vision tests were performed under normoxia with one eye at a time three times in a row for appropriate comparability to the simulated flight stages pre-peri-post hypoxia in the intervention groups
89524842|NCT05584813|Experimental|10,000 ft, 60 min, monocular pre-peri-post|"Intervention: Hypoxia equivalent to an altitude of 10.000 ft. for 60 minutes~Procedures: Colour vision tests were performed with one eye at a time, thereby:~pre intervention with no hypoxia administered~during intervention with hypoxia equivalent to an altitude of 10.000 ft. for 60 minutes~post intervention with no hypoxia administered"
89524843|NCT05584813|Experimental|15,000 ft, 15 min, binocular|"Intervention: Hypoxia equivalent to an altitude of 15.000 ft. for 15 minutes~Procedures: Colour vision tests were performed with both eyes, thereby:~pre intervention with no hypoxia administered~during intervention with hypoxia equivalent to an altitude of 15000 ft. for 15 minutes~post intervention with no hypoxia administered"
89524844|NCT05584813|Experimental|15,000 ft, 60 min, monocular|"Intervention: Hypoxia equivalent to an altitude of 15.000 ft. for 60 minutes~Procedures: Colour vision tests were performed with one eye at a time, thereby:~pre intervention with no hypoxia administered~during intervention with hypoxia equivalent to an altitude of 15.000 ft. for 60 minutes~post intervention with no hypoxia administered"
89524845|NCT03352687|Experimental|Anterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by anterior route
89524846|NCT03352687|Experimental|Posterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by posterior route
89524847|NCT04922853|Experimental|2 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have TME operation after reevaluation and randomization.
89524848|NCT04922853|Other|4 cycles group|patients which recruited have 2 cycles Capox regimen (oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals), then those patients with no sever chemotheraputic AE, have two more cycles chemotherapy and TME operation after reevaluation and randomization.
89524849|NCT03348007|Experimental|HEPAR|1L of Hépar + 0.5L of low-mineral water (Hépar group).
89524850|NCT03348007|Active Comparator|VITTEL Bonne Source|1.5L of low-mineral water (Vittel Bonne Source, control group)
89524851|NCT05302401|Experimental|Women receiving uninterrupted midwife support during the intrapartum period|28. - Visual Analog Scale will be applied to determine the Wijma Birth Expectation/Experience (W-DEQ A) Scale and birth fear in order to determine the birth fears of pregnant women in the 36th week. During outpatient checks, the first saliva cortisol samples will be taken by researcher Meserret Aslan between 8:30 and 09:00 in the morning. Researcher Meserret Aslan will provide six hours of online pregnancy training to pregnant women in the experimental group and provide uninterrupted midwife support during the intrapartum period.Within the first half hour of postpartum after birth, saliva cortisol samples of women will be repeated by researcher Meserret Aslan. Between the 24th and 72nd hours before postpartum discharge procedures take place, saliva cortisol samples of women will be taken for the last time by researcher Meserret Aslan from the experimental group.
89524852|NCT05302401|No Intervention|Women who do not receive uninterrupted midwife support during the intrapartum period|Between the 28th and 36th weeks, the pregnancy diagnosis form will be applied by the researcher to the pregnant women in the control group. 28. - Visual Analog Scale will be applied to determine the Wijma Birth Expectation/Experience (W-DEQ A) Scale and birth fear in order to determine the birth fears of pregnant women in the 36th week. During outpatient checks, the first saliva cortisol samples will be taken by researcher Meserret Aslan between 8:30 and 09:00 in the morning. After birth, postpartum from control groups will be repeated by researcher Meserret Aslan in the first half hour. Between the 24th and 72nd hours before postpartum discharge procedures take place, saliva cortisol samples of women will be taken for the last time by researcher Meserret Aslan from the control groups.
89524853|NCT04921033|Experimental|Exclusive Enteral Nutrition|35kcal/kg/day EEN (Nestle Modulen®) - Subjects will take medicine and EEN solution orally themselves.
89524854|NCT04921033|Active Comparator|Standard of care|"Budesonide 9mg/day for mild disease~Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~Patients with moderate-to-severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
89524855|NCT03352375|Active Comparator|Orotracheally Intubation|Intervention:orotracheally intubation
89524856|NCT03352375|Active Comparator|Laryngeal Mask Airway|Intervention: Laryngeal Mask Airway
89524857|NCT04915833|Experimental|Patients for CRC screening and diagnostic colonoscopy|Consecutive patients >45 years of age submitted for diagnostic colonoscopy
89524858|NCT03346681|Experimental|NAC and albuterol|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
89524859|NCT03346681|No Intervention|Albuterol|Albuterol will be administered via nebulization every six hours.
89524860|NCT05136573|Experimental|Combined Exercises on Symptoms of CIPN, Fatigue, and Quality of Life in Colon Cancer Patients|The control group received routine care and maintenance of general daily activities; the experimental group received routine care and maintenance of general daily activities, and also received combined exercises
89524861|NCT03347851||On-X AAP|Patients with prior AVR surgery with the CryoLife On-X Ascending Aortic Prosthesis (AAP).
89524862|NCT03347851||SJM Masters or Carbomedics Carbo-seal|Patients with St. Jude Medical Masters HP Valved Graft with Gelweave Valsalva™ Technology or Carbomedics Carbo-seal (including Carbo-seal Valsalva) mechanical aortic valve prostheses patients
89524863|NCT03347773|Experimental|Intervention|The subjects will be assigned to receive nutritional supplement consisting of one can of ReGen 18% (19.1 g protein, 425 Kcal) daily and standard care.
89524864|NCT03347773|No Intervention|Control|The subjects will be assigned to receive standard care alone.
89524865|NCT04853121|Active Comparator|tapered implant|
89524866|NCT04853121|Placebo Comparator|straight implant|
89524867|NCT05136261|Active Comparator|Treatment|Ceradan Advanced Moisturising Skin Barrier cream - applied twice a day
89524868|NCT05136261|Placebo Comparator|Control|Aqueous Cream - applied twice a day
89524869|NCT04503187||Chronic Stroke|Participants who suffered a single event of cerebral vascular accident at least six months ago before study enrollment.
89524870|NCT04503187||Multiple Sclerosis|Participants who has been diagnosed with multiple sclerosis
89524871|NCT04503187||Healthy control|Age-matched healthy adults who are self-reported healthy and has no known musculoskeletal, neuromuscular, and cardiovascular diseases.
89524872|NCT04506307|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the torso area with a new applicator design.
89524873|NCT05136183|No Intervention|Standard of care|"Patients randomized to this arm are treated with standard of care for patients with septic shock, including~Fluid resuscitation and vasoactive agents~Hemodynamic monitoring in intensive care units~Antibiotics and infection source control, when applicable~Supportive therapies and devices, including mechanical ventilation and renal replacement therapy~Immunoregulatory medications, including systemic corticosteroids~All treatment provided are according to treating physicians"
89524874|NCT05136183|Experimental|Standard of care, with hemoperfusion with HA-330|Patients randomized to this arm are treated with standard of care for patients with septic shock as described for 'Standard of care' arm, along with hemoperfusion with HA-330 Disposable Hemoperfusion Cartridge, as detailed under 'Interventions'
89524875|NCT05135793|Experimental|A test|Test drug (Topoprazan) 1 tablet contains 20 mg vonoprazan
89524876|NCT05135793|Active Comparator|B reference|Reference drug (Takecab) 1 tablets contains 20 mg vonoprazan
89524877|NCT04841889|Other|Associated factors with decannulation|Collection of demographic, biological, ventilatory, respiratory and extra-respiratory parameters at the admission and the end of stay in the respiratory weaning center. Lung and diaphragm ultrasound, swallowing and muscles assessment will be performed.
89524878|NCT00709735|Experimental|Reactivation Propranolol (RP)|"0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
89524879|NCT00709735|Active Comparator|Non-Reactivation Propranolol (NRP)|"0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
89524880|NCT04568811|Experimental|Adenovirus Type-5 Vectored COVID-19 Vaccine|
89524881|NCT04503031|Active Comparator|cylindrical tube group|The patient in cylindrical tube group (n=26) were intubated with cylindrical shaped endotracheal tube.
89524882|NCT04503031|Experimental|tapergaurd tube group|The patient in taperguard tube group (n=26) was intubated with TaperGuard endotracheal tube.
89524883|NCT04806555|Experimental|Compression ultrasound|All recruited patients
89524884|NCT05135637||Kharotabad 1 - Intervention Union Council (UC)|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
89524885|NCT05135637||Ward 11 - Control UC|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
89524886|NCT05135637||Bhana Mari - Intervention UC|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
89524887|NCT05135637||Sheikh Junaidabad - Control UC|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
89524888|NCT05135637||Bakhmal Ahmedzai - Intervention UC|UC where all interventions (mobile health services, community mobilization, private practitioner engagement and test of Sehat Nishani app) will take place, and the UC will undergo a baseline, midline and endline survey.
89524889|NCT05135637||Pahar Khel Thal|UC where no interventions will be done but the UC will undergo a baseline, midline and endline survey.
89524890|NCT03352219|Experimental|Reality Check|Received streamed 13-episode HIV risk reduction serial drama, Reality Check, developed based on Social Cognitive Theory integrated with findings from focus groups and community advisory boards. Each character has a behavioral trajectory related to HIV. For example, one character modeled negotiating condom use with his partner when she was against it. Messages in the serial drama showed that the characters had normative support for HIV testing and condom use. One character modeled a mastery experience when she overcame her fear and got tested for HIV. Homophobia is addressed when a mother discovers that her son is gay. Over the course of the episodes, the interweaving storylines play out, with all the characters eventually achieving their positive goals.
89524891|NCT03352219|Placebo Comparator|Physical Activity Attention Control|Received streamed physical activity promotion videos designed to control for Hawthorne effects, including special attention, consisting of a series of 13 videos from YouTube on physical activity and exercise. The videos, selected to be appropriate for African Americans 18 to 24 years of age, were tailored to be gender specific and hence varied between men and women. The videos focused on the importance of physical activity, coping strategies for lack of motivation to engage in physical activity, and other challenges faced in becoming more physically active, provided specific knowledge and skills regarding how to engage in aerobic and muscle-strengthening exercises, and model aerobic and muscle-strengthening exercises in a variety of settings.
89524892|NCT04561713|Experimental|Attention Deficit Hyperactivity Disorder (ADHD)|Children aged 8 to 12 diagnosed with ADHD
89524893|NCT04561713|Sham Comparator|Control|Control group of healthy ADHD children matched in age, gender and laterality to children in ADHD group
89524894|NCT04664257|Experimental|e-CBT|All e-CBT sessions will be administered through OPTT and will consist of approximately 30 slides per week. The content and format of each weekly online session will be designed to mirror in-person CBT for the treatment of BAD-II. Participants will complete the module and submit the assigned homework to their clinician through OPTT where the clinician will be able to provide personalized feedback. These pre-designed engaging and multimedia modules will be able to streamline the therapy process, helping care providers save time on repeating similar materials to all patients and focusing on delivering personalized feedback to each patient. The slides will highlight a different topic each week and include general information, an overview of skills, and homework that is to be completed within that week. All weekly sessions have an estimated completion time of 50 minutes. During the 12 weeks, both groups will continue with their TAU.
89524895|NCT04664257|No Intervention|Treatment as Usual|Participants will continue with treatment as usual and any lifestyle activities (diet, exercise, medication, etc.)
89524896|NCT05584501|Placebo Comparator|Dental Team|ETE activity implementation with existing Dental Team only (i.e. practitioners, dental assistants, hygienists)
89524897|NCT05584501|Active Comparator|Care Navigator|ETE activity implementation with additional Care Navigator resource
89524898|NCT04502953|Active Comparator|Vertical plication|Vertical plication of the rectovaginal septum was done
89524899|NCT04502953|Active Comparator|Horizontal plication|Horizontal plication of the rectovaginal septum was done
89524900|NCT02647905|Experimental|Accuracy assessment, CGMS|To determine accuracy of the Senseonics Continuous Glucose Monitoring System measurements through approximately 90 days post-insertion. Manipulation of glucose levels during multiple clinic days
89524901|NCT04502875|Experimental|Treatment Arm|Intracavernosal infusion of Platelet Rich Plasma
89524902|NCT04502875|Active Comparator|Control Arm|Intracavernosal infusion of Platelet Poor Plasma
89524903|NCT03352141|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced along the jawline with Cryolipolysis.
89524904|NCT04546971|Active Comparator|Brief intervention|A brief alcohol intervention lasting about 10 minutes, delivered after the baseline assessments.
89524905|NCT04546971|Experimental|Brief Intervention plus Telehealth Counseling|A brief alcohol intervention followed by referral to a telehealth counseling protocol including 5 sessions of counseling based on Motivational Interviewing and delivered by videoconferencing. Telehealth counseling extends for up to two years and also includes a text messaging intervention to encourage reductions in drinking.
89524906|NCT04502797|Experimental|Interventional: Electronic Patient Visit Assessment (ePVA)|Participants diagnosed with head and neck cancer randomized to Electronic Patient Visit Assessment intervention
89524907|NCT04502797|No Intervention|Usual care|Participants diagnosed with head and neck cancer randomized to usual care.
89524908|NCT04541121|Experimental|3D printed model|Mother is given 3D printed model of fetus' face
89524909|NCT04541121|Placebo Comparator|Placebo|Mother is given printed picture of 3D ultrasound of fetus
89524910|NCT04316481|Other|AngelMed Guardian System|All eligible subjects will have the AngelMed Guardian System implanted with alerting features turned ON; receive an external device which provides additional alerting; and receive training on system use.
89524911|NCT04506229||COVID-19 positive|
89524912|NCT04506229||COVID-19 negative|
89524913|NCT04582357|Experimental|Exercise arm|This arm is the only arm of the study, every patient is included in this arm, the patients will follow the physical activity program
89524914|NCT05584189|Experimental|At least 30 persons 14-65+ years of age who test themselves|Participants between the ages of 14-65+ years will perform candidate Ag self-test kit anterior nasal specimen collection and testing under the supervision of qualified site personnel in person.
89524915|NCT05584189|Experimental|At least 30 persons 18-65+ years of age who test another participant|Participants between the ages of 18-65+ years will perform candidate Ag self-test kit anterior nasal specimen collection on another participant aged 2-65+ years and testing of the candidate Ag self-test kit under the supervision of qualified site personnel in person.
89524916|NCT04536519|Active Comparator|Lateral Heel Wedged Insole Alone with physical therapy|"the lateral heel wedged insole (19) comprised non-custom, high density based on insoles of ethyl-vinyl acetate distributed bilaterally, preferably, covered in leather, were used in the study. The insole were equipped with a lateral wedge of 50 to 60.~In the case of unilateral knee osteoarthritis, the non-wedge insole were used to compensate for possible leg length discrepancy in the contra-lateral leg. Shoes used was based on gymnast type to keep wedge insole in place. This further finalized individual to individual with unanimous decisions of Cordwainers, orthotics, and principal researcher, physiotherapist."
89524917|NCT04536519|Active Comparator|Lateral aand medial Heel Wedged Insole with physiotherapy|medial arch support part were combine with aforementioned lateral heel wedged support, full length support. There is a debate, however, 4 to 6 mm of full length support is considered to be effective for required alteration in mechanics
89524918|NCT04505995|Experimental|Intervention group|
89524919|NCT04486911|Experimental|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
89524920|NCT05135247|Experimental|continuous aerobic training (CA)|The CA group was trained with 70% of maximum heart rate (MHR) for 30 minutes.
88807336|NCT05288322|Experimental|Mostafa Maged maneuver to prevent and control post-partum haemorrhage|"all pregnant females ( primigravida and multi-gravida ) . this study includes forty pregnant females with normal vaginal delivery .this study includes pregnant females Inclusion criteria :-~All pregnant patients~Age is between (18) to (40) years old~The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery ."
88807337|NCT01796756|Experimental|Handover program|Standardized handover program Dedicated place and time Template Face-to-face communication Evidence-based education session Feedback and audit
88807338|NCT01796756|No Intervention|Usual handover practice|
89524921|NCT05135247|Experimental|resistance training (R)|The R sessions consisted of a set of each proposed exercise: sitting bench press, legpress, back row, leg extension, shoulders high pull, seated leg curl, biceps curls, standing calf, triceps in the pulley, and abdominal crunches, with 8 - 10 repetitions with 75% 1MR.
89524922|NCT05135247|Experimental|interval aerobic training (IA)|The IA group was submitted to exercise intensities of 60% for 2 minutes and 80% for 2 minutes, alternately, with a total of 30 minutes.
89524923|NCT05135247|No Intervention|control (C)|Individuals in the control group maintained their usual activities.
89524924|NCT04526977||Cases|HIV-1 infected individuals with previous or current diagnosis of SARS-CoV-2 infection, defined as the presence of suggestive symptoms and a positive PCR from the nasopharyngeal swab.
89524925|NCT04526977||Controls|HIV-1-infected individuals of the same age (range, 5 years) and sex, who not have been diagnosed of clinical (asymptomatic) or confirmed SARS CoV-2 infection, but were positive for IgG antibodies (controls group 1) or with no evidence of SARS-CoV-2 infection (no previous neither current symptoms, negative for IgM/IgG antibodies, controls group 2)
89524926|NCT03352063|Active Comparator|Sitting with Exercise|Subjects will complete a short term training protocol while sitting >11 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
89524927|NCT03352063|Active Comparator|Walking with exercise|Subjects will complete a short term training protocol while sitting <5 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
89524928|NCT02518165|Active Comparator|Proprietary spearmint extract|Subjects randomized into the active treatment group will be asked to consume 900 mg/day of the proprietary spearmint extract.
89524929|NCT02518165|Placebo Comparator|Microcrystalline cellulose|Subjects randomized into the placebo group will be asked to consume 900 mg/day of the excipient, microcrystalline cellulose.
89524930|NCT05135013||Cases|1.Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020).
89524931|NCT05135013||Matched Controls|2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening.
89524932|NCT04522713|Experimental|Large-group transdiagnostic course|6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing
89524933|NCT04516161||Radium-223 dichloride (Xofigo, BAY88-8223)|Patients with mCRPC who received treatment of Ra-223.
89524934|NCT03351985||Delirium Group|The cardiac surgery patients with delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
89524935|NCT03351985||Non-delirium Group|The cardiac surgery patients without delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
89524936|NCT04509609||LGMD 2E with a genetic diagnosis|Any patient affected by LGMD 2E with a genetic diagnosis
89524937|NCT04505917|Experimental|dinoprostone|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
89524938|NCT04505917|Active Comparator|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
89524939|NCT04505917|Placebo Comparator|placebo|Placebo Comparator: placebo 2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
89524940|NCT04412967|Active Comparator|Standard Technique PVC placement|Standard PVC placement technique
89524941|NCT04412967|Experimental|DUST|Dynamic ultrasound-guided short-axis needle tip navigation (DUST)
89524942|NCT04505761|Experimental|Intervention group|Participants will receive Virtual Reality as an add-on to standard physiotherapy after COVID-19.
89524943|NCT04185909|Experimental|All Subjects|Subjects will be treated with the Renuvion Dermal System.
89524944|NCT04505683|Experimental|test drug arm|Benapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
89524945|NCT04505683|Active Comparator|active control arm|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 14 days.
89524946|NCT03351829|Experimental|Gene-modified autologous stem cells|Autologous stem cells transduced with lentiviral vector carrying the related gene ex vivo
89524947|NCT05580055||Capillary Sample|This group donates finger prick blood samples to Entia for the purpose of development.
89524948|NCT05580055||Venous Sample|This group donates venous blood samples to Enta, taken by a registered nurse.
89524949|NCT05576155|Experimental|Local losartan perfusion|~1 hour of losartan is perfused through an intradermal microdialysis fiber
89524950|NCT05576155|Other|Local lactated Ringer's (control) perfusion|~1 hour of lactated Ringer's is perfused through an intradermal microdialysis fiber
89524951|NCT04505215|Experimental|Mulligan Technique|In addition to the exercises applied to the participants in the control group, the participants in this group used Mobilization with movement, which was performed with the principle of painless movement 3 times a week for a total of 12 times a week for 4 weeks. Mobilization with movement has been performed by a certified physiotherapist who has been practicing this technique for 10 years.
89524952|NCT04505215|Experimental|Muscle Energy Technique|In addition to the exercises applied to the participants in the control group, the Janda method (Post Isometric Relaxation Technique) from Muscle Energy Technique (3 times a week) was used 3 times a week for 4 weeks.
89524953|NCT04505215|Active Comparator|Only Exercise (Control)|Stretching and strengthening exercises for the forearm extensors were shown to the participants in the control group for 4 weeks every day of the week.
89524954|NCT04443855|Active Comparator|Water quality|90 clusters, approx. 720 newborns
89524955|NCT04443855|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
89524956|NCT04443855|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
89524957|NCT04443855|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
89524958|NCT04443855|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
89524959|NCT04443855|Active Comparator|Nutrition+ Combined WASH|90 clusters, approx. 720 newborns
89524960|NCT04443855|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
89524961|NCT04443127|Experimental|Game-Based Rehabilitation|
89524962|NCT04443127|Placebo Comparator|Conventional Rehabilitation|
89524963|NCT04501783|Experimental|TL-FVP-t (favipiravir) Treatment Arm|Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC); Days 2-10: 800 mg BID plus SOC.
89524964|NCT04501783|Active Comparator|Standard of Care Arm|Standard of Care including etiotropic therapy according to MoH of Russian Federation Recomendations for COVID-19 (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine, or mefloquine in recomended regimen) up to10 days
89524965|NCT04501471|Experimental|SAAF-T|Participants received a 5 session, 10-hour family centered prevention program designed to prevent substance use, conduct problems, and risky sexual behavior
89524966|NCT04501471|Placebo Comparator|Fuel for Families|Participants received a 5 session, 10 hour family centered program that focused on healthy nutrition and exercise.
89524967|NCT04505137|Experimental|GMA301 1500mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 1500 mg single Intravenous dose of GMA301 Injection.
89524968|NCT04505137|Experimental|GMA301 2000mg Or Placebo Injection|Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 2000 mg single intravenous dose of GMA301 Injection.
89524969|NCT04424745|Active Comparator|Attention Bias Modification Training with real tDCS|
89524970|NCT04424745|Placebo Comparator|Attention Bias Modification Training with sham tDCS|
89524971|NCT03351751|Placebo Comparator|Placebo|Subjects receiving placebo
89524972|NCT03351751|Experimental|PF-06372865|Subjects receiving PF-06372865
89524973|NCT04501315||ICU TBI|Patients treated on the ICU with brain injury
89524974|NCT04501315||ICU tumor|Patients treated on the ICU because of intracranial tumor
89524975|NCT04501315||ICU surgery|Patients treated on the ICU following surgery without brain injury
89524976|NCT04501315||ICU control|Patients treated on the ICU without TBI, tumor or surgery
89524977|NCT04407585||Covid-19 Symptom Study app-user|UK-based Covid-19 Symptom Study primary app-user completing self-reports in the app
89524978|NCT04381533|Experimental|I-A-CRA|Internet-delivered Adolescent Community Reinforcement Approach: The treatment program consists of 8 extensive treatment modules delivered over 10 weeks with continuous therapist support and guidance. There are two separate treatments for the young adult and the caregiver/significant other.
89524979|NCT04381533|Active Comparator|Psychoeducation alcohol use|Psychoeducation focusing on alcohol use: This support program provides 8 brief modules of psychoeducation (alcohol information) over 10 weeks. Participants receive no therapist guidance/support but have the possibility of asking questions to a therapist. There are two separate programs for the young adult and the caregiver/significant other.
89524980|NCT03347461|Experimental|Otiprio by surgeon|Otiprio will be administered through the tympanic membrane by the otolaryngologist immediately after tympanostomy placement.
89524981|NCT03347461|Active Comparator|Ciprodex by surgeon|Ciprodex drops will be instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery.
89524982|NCT03347461|Active Comparator|Ciprodex by surgeon and parent|Ciprodex drops will be instilled by the otolaryngologist into the ear immediately after tympanostomy tube surgery. The parent or guardian will administer Ciprodex drops into the ears twice daily for five days after surgery.
89524983|NCT03351673|Experimental|endometrial volume 2D TVS|perimenopausal women who bleed are examined by 2D TVS and the calculated endometrial volume using a specific formula and followed by endometrial biopsy for correlation with the pathological findings
89524984|NCT05118555||Type 1|"Patients scheduled to undergo a routine clinical MR examination of the relevant anatomical regions and/or disease type will be identified from MRI department schedules.~The new MR technique will be used to acquire additional data in patients undergoing a routine MR examination. The routine MR examination will be conducted according to the standard protocol."
89524985|NCT05118555||Type 2|"Patients with the relevant disease type and no contraindications to MRI will be identified by delegated radiologists in clinics.~An additional MR examination will be scheduled; this examination is in addition to any examinations that the patient may undergo as part of their clinical care. The MR examination will be conducted using the new MR technique; standard MR techniques may also be used for comparison."
89524986|NCT05118555||Type 3|"Normal volunteers who are members of staff or students at RMH/ICR will be invited to participate using a mailing list. Exceptionally employees of other NHS Trusts and Academic Institutions will be allowed to participate if they are in collaboration with RMH/ICR.~An MR examination will be conducted using the new MR technique; standard MR techniques may also be used for comparison."
89524987|NCT03351517|Experimental|Tapentadol arm|Single dose of 100 mg of extended release oral tapentadol will be administered 1 hour before surgery.
89524988|NCT03351517|Placebo Comparator|Placebo arm|A comparable placebo will be administered 1 hour before surgery.
89524989|NCT04351659||Blood donors|Donors who had tested positive for SARS-CoV-2 in the past and have recovered from COVID-19 and are now suitable for blood donation.
88807339|NCT00385268|Experimental|Active medication Acamprosate|1998mg/day for 8 weeks
88807340|NCT00385268|Placebo Comparator|Placebo|placebo pills for 8 weeks
89524990|NCT03346525|Experimental|BPG Arm|Intramuscular BPG prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days
89524991|NCT03346525|No Intervention|Control Arm|No prophylaxis
89524992|NCT05070273|Experimental|Hypoglossal nerve conduction study.|
89524993|NCT05060523|Experimental|Tolvaptan with Midodrine|
89524994|NCT05060523|Active Comparator|Tolvaptan with Placebo|
89524995|NCT04502641|Experimental|Arm I|Patients receive induction chemotherapy with docetaxel-based, with or without cisplatin or fluorouracil. Treatment repeats every 21 days for 3 courses. Then, patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
89524996|NCT04502641|Active Comparator|Arm II|Patients receive cisplatin on day 1 day 21, 3 weeks as one cycle and undergo concurrent radiotherapy once daily, 5 days a week, for 6 to 7 weeks.
89524997|NCT05555797|Experimental|group of patients with psoriasis vulgaris|"in each patient lesions will be divided into 3 groups; Group 1: treated with Excimer laser alone(1-2 sessions/ week for 12 sessions according to induration protocol*).~Group 2: treated with Excimer laser combined with topical tazarotene gel 0.1% Group3: treated with Excimer laser combined with topical betamethasone valerate ointment 0.1%"
89524998|NCT04502485|Experimental|Gastric water exchange|Air will be minimally insufflated to partially open the lumen and any residual fluid will be suctioned when the scope passes through the esophagus. Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further. Air will be opened when the scope enter the prepylorus area where there is usually an air pocket. The scope will enter the duodenal bulb and 2nd portion of duodenum where withdrawal inspection will start.
89524999|NCT04502485|Active Comparator|Traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
89525000|NCT03347305|Experimental|Patients Group DPA|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
89525001|NCT03347305|Experimental|Healthy Volunteers|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
89525002|NCT04076943|Experimental|Roxadustat|Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 16 weeks.
89525003|NCT04219033||with postoperative cognitive dysfunction|
89525004|NCT04219033||without postoperative dysfunction|
89525005|NCT04325763|Experimental|TQB2450+Anlotinib|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89525006|NCT04325763|Experimental|TQB2450+Anlotinib(blank)|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89525007|NCT04325763|Placebo Comparator|TQB2450(blank)+Anlotinib(blank)|TQB2450 0 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
89525008|NCT00708643|Active Comparator|Habitual silicone hydrogel|Habitual contact lens wear.
89525009|NCT00708643|Experimental|narafilcon A|Silicone hydrogel daily disposable contact lens
89525010|NCT03955575|Active Comparator|Liraglutide/placebo-colesevelam|Liraglutide as active and colesevelam as placebo
89525011|NCT03955575|Active Comparator|Placebo-Liraglutide/colesevelam|Liraglutide as placebo and colesevelam as placebo
89525012|NCT04204759|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the ventromedial prefrontal cortex and one cathodal electrode (35cm2) will be placed over the occipital cortex. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 30 seconds at the beginning and end of the stimulation period.
89525013|NCT04204759|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
89525014|NCT03762603|Experimental|robotic exoskeleton device|Patients who are scheduled to be discharged to a ECF will be asked if they would want to use the exoskeleton device ( for which safety and comfort has been established) instead of going for ECF.
89525015|NCT03347149||Pre-Phase (Control)|no Alarm Advisor Software installed
89525016|NCT03347149||Post-Phase (Observation)|Alarm Advisor Software implemented
89525017|NCT03351205|Experimental|Uterine cavity barrier only|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
89525018|NCT03351205|Experimental|hormone|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
89525019|NCT04698057|Active Comparator|Amoxicillin clavulanate + ciprofloxacin|Treatment with amoxicillin-clavulanate 1g tib and ciprofloxacine 750mg bid for 5 days
89525020|NCT04698057|Experimental|Amoxicillin clavulanate + Placebo|Treatment with amoxicillin-clavulanate 1g tib for 5 days
89525021|NCT03351127||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
89525022|NCT03351127||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
89525023|NCT03351127||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
89525024|NCT03351127||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
89525025|NCT03351127||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
89525026|NCT03351127||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
89525027|NCT02449005|Experimental|Group A|Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue
89525028|NCT02449005|Experimental|Group B|in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect
89525029|NCT02449005|Active Comparator|Group C|Group C will receive open flap debridement retaining the soft tissue wall of the pocket
89525030|NCT03049111|Experimental|Inhaled Allergen Challenge|Der f sensitive, mild asthmatic subjects will undergo inhaled allergen challenge
89525031|NCT04485507|Experimental|Nature-VR|Viewing 3D pictures of natural environments
89525032|NCT04485507|Active Comparator|Urban-VR|Viewing 3D pictures of urban environments
89525033|NCT04274049|Experimental|investigational produc|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
89525034|NCT04274049|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
89525035|NCT02929069|Experimental|ESTEEM|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive ESTEEM. ESTEEM is a 10-session intervention based on the Unified Protocol,an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
89525036|NCT02929069|Active Comparator|Community Mental Health Treatment (CMHT)|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive Community Mental Health Treatment (CMHT). CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
89525037|NCT02929069|Active Comparator|Voluntary Counselling and Testing (VCT)|Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
89525038|NCT04132791|Other|aspirin after awakening + placebo before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. Intake in de morning after awakening. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken before bedtime, orally. The placebo is given throughout the study."
89525039|NCT04132791|Experimental|placebo after awakening +aspirin before bedtime|"Acetylsalicylic acid 80 mg once daily, orally. The time will be changed form morning to bedtime. Participants already use acetylsalicylic acid 80 mg once daily due to secondary prevention of cardiovascular disease.~Placebo tablet once daily will be added to their medication. The placebo tablet will be taken after awakening, orally. The placebo is given throughout the study."
89525040|NCT04263987|Active Comparator|Holmium Laser Enucleation of Prostate|Traditional holmium laser enucleation of the prostate as currently performed
89525041|NCT04263987|Experimental|Moses Holmium Laser Enucleation of Prostate|holmium laser enucleation of the prostate as currently performed but with Moses laser settings activated.
89525042|NCT03350971|Experimental|Virtual reality training|Training with ergometer associated with training on wii videogame during 4 days
89525043|NCT03350971|Active Comparator|Control|chest physical therapy
89525044|NCT04250493|Experimental|MSA patient|Patients will be recruited at the French Reference Center for MSA.
89525045|NCT04250493|Other|Control|Healthy volunteer matched for age (+/- 5years) and sex with MSA patient.
89525046|NCT04501003|Other|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm.
89525047|NCT04064229|Experimental|Infiltrated Tissue|The ivWatch Model 400 sensors monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
89525048|NCT04501159||End-stage renal disease (ESRD)|Patients with end-stage renal disease undergoing regular haemodialysis 3 times weekly.The investigation will measure cardiac output (CO), oxygen saturation (SaO2), arterial blood gases (ABG) and white blood cell (WBC) count during HD to assess changes in haemodynamics, pH, leukostasis and hypoxia. Patients undergoing regular HD will be recruited with arterial blood samples for gas analysis drawn over three consecutive HD treatments. Arterial samples will be taken at the start, 15 minutes and end of HD treatment for ABG and WBC analysis. Dialysis membrane, ultrafiltration volume, serum and dialysate bicarbonate levels will also be recorded. Regression analysis will be performed with pH, ABG and SaO2. A subset of patients will be used to assess an if cardiac output, WBC or pH better predicts PaO2 during HD.
89525049|NCT03350893|Placebo Comparator|Control Group|Emulsion base without probiotics
89525050|NCT03350893|Experimental|Active Group|Emulsion base with probiotics
89525051|NCT04501237|No Intervention|Bruxers without sleep hygiene instructions|
89525052|NCT04501237|Experimental|Bruxers with sleep hygiene instructions|
89525053|NCT01591707|Experimental|ISC+PRT Intervention|For the duration of at least one school year children will receive 45-90 minutes of intervention in the classroom in an attempt to increase social and communication skills.
89525054|NCT01591707|No Intervention|Instruction As Usual|For the duration of at least one year children will receive the typical classroom instruction
89525055|NCT04500925||UPSCALED|
89525056|NCT04500925||NOT UPSCALED|
89525057|NCT04645329|Experimental|group I (no immobilization)|patients will be allowed to freely use their arm without any immobilization after surgery
89525058|NCT04645329|Active Comparator|group II (3-week immobilization)|patients will be kept in an immobilization device for three weeks after surgery
89525059|NCT02513017|Experimental|Stimulus Control Instructions (SCI)|"SCI is a behavioral treatment that aims to assist persons with insomnia to re-associate the bed and the bedroom with falling asleep or back to sleep, and to acquire a consistent sleep pattern. SCI entails specific instructions that focus on developing new sleep habits, such as avoiding activities other than sleep (e.g., reading, watching TV) in bed, and getting out of bed if unable to fall asleep and engaging in quiet activities until sleepy.~A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SCI. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt."
89525060|NCT02513017|Experimental|Sleep Restriction Therapy (SRT)|SRT aims at consolidating sleep by limiting sleep to a specified time and restricting the amount of time spent in bed. Sleep time is individualized based on the persons' sleep needs, and the sleep-wake schedule is planned to fit the persons' lifestyle. The sleep-wake schedule is changed to accommodate improvements in the persons' sleep, over time.. A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SRT. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt.
89525061|NCT02513017|No Intervention|No therapy|No behavioral therapy for the management of insomnia is provided. However, a list of general recommendations and suggestions are provided to participants.
89525062|NCT04623177||Anticoagulation|Patients receiving an anticoagulant dose (equal or higher than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
89525063|NCT04623177||Thromboprophylaxis|Patients receiving a prophylactic dose (lower than 150 IU/kg/24 h) of LMWH within the first 48 hours after the ICU admission
89525064|NCT04623177||No heparin|Patients receiving no anticoagulant drug within the first 48 hours after the ICU admission
89525065|NCT04619355||TVC K-Registry|
89525066|NCT01210365|Experimental|furosemide (40 mg) +amiloride (10 mg)|One group of patients will receive furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow the tablet in whole form on an empty stomach with some liquid.
89525067|NCT01210365|Active Comparator|Lasix ®|One group of patients will receive Lasix® (furosemide 40 mg). For treatment, the patient will swallow the tablet in whole form on an empty stomach with some liquid.
89525068|NCT01119807|Experimental|Intra Venous Access|Patient initially receives IV access during resuscitation
89525069|NCT01119807|Experimental|Humeral IO|Patient receives humeral IO access during resuscitation
89525070|NCT01119807|Active Comparator|Tibial IO|Patient receives tibial IO access during resuscitation
89525071|NCT05583331|Active Comparator|Cataract surgery then Vitrectomy|Patients will undergo first the cataract surgery then the vitrectomy, as a combined surgery performed on the same day.
89525072|NCT05583331|Experimental|Vitrectomy then cataract surgery|Patients will undergo first the vitrectomy then the cataract surgery, as a combined surgery performed on the same day.
89525073|NCT04615689||Infants with febrile urinary tract infection|The investigators will recruit infants hospitalized for acute febrile urinary tract infection. Before starting antibiotics treatment, The investigators will collect feces with the informed consents from infants' parents.
89525074|NCT04615689||Healthy infants|The investigators will recruit healthy controls from the clinics for routine check up with the informed consents from infants' parents.
89525075|NCT02517853|Experimental|Tibial nerve stimulation|Tibial nerve stimulation during 16 sessions
89525076|NCT02517853|Sham Comparator|Sham comparator|Sham tibial nerve stimulation during 16 sessions
89525077|NCT04147221|Experimental|Imipenem-Relebactam|Participants will receive a single dose of intravenous imipenem-relebactam (500mg-250mg) as a 30 minute infusion.
89525078|NCT04499365|Experimental|Experimental: 68Ga-DOTA/NOTA-FAPI-04|Each subject receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT imaging within the specificed time.
89525079|NCT04435509|Experimental|Greek Mountain Tea|50 patients Greek Mountain Tea 50 grams one per 30 days. Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams Intervention:Greek Mountain Tea in a plastic bag.
89525080|NCT04435509|Placebo Comparator|Mediterranean Diet|50 patients same dietary habits and a Mediterranean dietary protocol Intervention: Mediterranean diet.
89525081|NCT01037907|Experimental|BGC20-0134 (Pleneva TM)|Structured lipid
89525082|NCT01037907|Placebo Comparator|Placebo control|Placebo - dummy pill
89525083|NCT02517775|Active Comparator|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
89525084|NCT02517775|Active Comparator|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
89525085|NCT02517775|Active Comparator|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
89525086|NCT02517775|Active Comparator|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
89525087|NCT02517775|Active Comparator|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
89525088|NCT02517775|Placebo Comparator|Cranberry deprived supplement|Placebo comparator: Cranberry deprived supplement Acute intake of 500 mL (1x daily)
89525089|NCT02517697|Experimental|Active drug|14 Nitrogen (N) Sodium Nitrite 40mg three times daily (TID)
89525090|NCT02517697|Placebo Comparator|Placebo|placebo capsules three time daily (TID)
89525091|NCT02517619|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate ophthalmic solution (40 mg/mL)
89525092|NCT02517619|Active Comparator|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate Ophthalmic (1%)
89525093|NCT03504943|Active Comparator|Early Intradialytic Exercise|Intradialytic cycling will occur in the first half of hemodialysis treatment
89525094|NCT03504943|Experimental|Late Intradialytic Exercise|Intradialytic cycling will occur in the second half of hemodialysis treatment
89525095|NCT03892395|Active Comparator|Treatment group|"Supplementation for 2 years with one of the following treatments in capsule form:~Treatment group will receive: B vitamins + vitamin D, a daily capsule containing 200 µg/day folic acid, 10 µg/day vitamin B12, 10 mg/day vitamin B6 and 5 mg/day riboflavin, and 10 µg/day vitamin D combined"
89525096|NCT03892395|Placebo Comparator|Control group|"Supplementation for 2 years with one of the following treatments in capsule form:~Control group will receive: Vitamin D, a daily capsule containing 10 µg/day vitamin D"
89525097|NCT03335553|Experimental|Single ascending dose (SAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
89525098|NCT03335553|Experimental|Multiple ascending dose (MAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
89525099|NCT04120467|Experimental|Dance|Dance Standard rehabilitation post-stroke
89525100|NCT04120467|Active Comparator|Control|Standard rehabilitation post-stroke
89525101|NCT03300921|Experimental|Arm A|Arm A: 50mcg IV weekly
89525102|NCT03300921|Experimental|Arm B|Arm B: 12mcg PO daily
89525103|NCT03888339|Active Comparator|Control group - Commercially available high abutments|Commercially available 2.5mm high abutments
89525104|NCT03888339|Experimental|Test group - Modified shape abutments|Modified shape 2.5mm high abutments (imitating the shape of 0.5mm short abutments)
89525105|NCT04116099||Conservative care alone|Conservative care alone which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
89525106|NCT04116099||Flexitouch Plus and conservative care|Flexitouch Plus and conservative care which includes Flexitouch Plus treatment as well as conservative care measures which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
89525107|NCT03882021|Other|Mapping protocol with GRID catheter|All patient will undergo a protocol required mapping protocol using the GRID catheter.
89525108|NCT03852615|Experimental|Ovarian torsion|Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion, that went through laparoscopic ovarian de-torsion surgery
89525109|NCT03852615|Other|No ovarian torsion|Control group - Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion and went through laparoscopic surgery, however no ovarian torsion has been demonstrated
89525110|NCT03259815|Experimental|PIOS Intervention Group|"Operator-blinded pre and post-PCI coronary physiology measurements will be recorded. If FFR is <0.90, the result will be disclosed to the operator and a hyperaemic pressure wire pullback will be performed during a standard peripheral intravenous adenosine infusion (140mcg/kg/min).~The operator will then follow the PIOS protocol to attempt to obtain the target optimal post-PCI FFR result."
89525111|NCT03259815|Active Comparator|Control Group|Operator-blinded pre and post-PCI coronary physiology measurements will be recorded and the angiographically defined result will be accepted.
89525112|NCT04114695||Non-CKD (eGFR >60 ml/min/1.73 m2)|Patients with renal function considered normal for age (eGFR >60 ml/min/1.73 m2) without proteinuria or structural kidney disease.
89525113|NCT04114695||CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)|Patients with CKD stage 3a (eGFR 45-59 ml/min/1,73 m2)
89525114|NCT04114695||CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)|Patients with CKD stage 3b (eGFR 30-44 ml/min/1,73 m2)
89525115|NCT04114695||CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)|Patients with CKD stage 4 (eGFR 15-29 ml/min/1,73 m2)
89525116|NCT04114695||CKD stage 5 (eGFR <15 ml/min/1,73 m2)|Patients with CKD stage 5 (eGFR <15 ml/min/1,73 m2). 50% of these patients will be in dialysis, while the other 50% will be pre-dialysis patients.
89525117|NCT04094103|Experimental|Active strawberry powder|Participants will consume a 39g freeze-dried active strawberry powder beverage once per day for 4-weeks.
89525118|NCT04094103|Placebo Comparator|Placebo strawberry powder|Participants will consume a 39g freeze-dried strawberry powder placebo beverage once per day for 4-weeks.
89525119|NCT04094103|Active Comparator|Mixed active/placebo strawberry powder|Participants will consume a 39g mixed active/placebo strawberry powder beverage once per day for 4-weeks.
89525120|NCT04086147|Experimental|Low dose tenecteplase|
89525121|NCT04086147|Experimental|High dose tenecteplase|
89525122|NCT03179397|Experimental|Model SC9|Investigational IOL
89525123|NCT03179397|Active Comparator|Model LI61SE|FDA Approved IOL
89525124|NCT03161223|Other|A: Oral 5-azacitidine, durvalumab, romidepsin|Arm A: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase), durvalumab will be administered intravenously on day 8 and romidepsin intravenously on days 8 and 15 of a 28-day treatment cycle
89525125|NCT03161223|Other|B: durvalumab, pralatrexate, romidepsin|Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
89525126|NCT03161223|Other|C: durvalumab, romidepsin|Arm C: Durvalumab will be administered intravenously on day 1 and romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle
89525127|NCT03161223|Other|D: durvalumab, 5-azacitidine|Arm D: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase) and durvalumab will be administered intravenously on day 8 of a 28-day treatment cycle
89525128|NCT03105921|Experimental|Electrodes|Electrodes
89525129|NCT03735927|No Intervention|Control phase|no intervention, i.e. care as usual
89525130|NCT03735927|Experimental|Intervention phase|experimental intervention: spot monitoring device (excl. sham), i.e. use of DeltaScan
89525131|NCT03660813|Experimental|HCG triggering|Ovitrelle ( hCG 250 mcg)
89525132|NCT03660813|Experimental|Dual triggering|Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg*2 )
89525133|NCT06152614|Active Comparator|Enhanced Usual Care (EUC)|"Participants randomized to EUC will have access to existing usual primary care services. They will also be enrolled in Hypertension Self-Management Education and Support (SMES) class (Hypertension group), which is an existing CDC-endorsed program offered at Eskenazi Health to provide information and skills for managing hypertension (HTN). Classes are led by registered dietitians via Webex."
89525134|NCT06152614|Experimental|Food Delivery and Cooking PLUS Aerobic Training (FoRKS+)|"Participants randomized to FoRKS+ will attend weekly HTN SMES classes separately from EUC participants. SMES classes will include the EUC curriculum stated above and an introduction to the upcoming FoRKS+ intervention.~Following HTN SMES completion, FoRKS+ continues with home-delivered Mediterranean-style ingredient kits, food management lessons, and hands-on cooking classes in one's own kitchen. Classes are led by registered dietitians via Webex. Classes are held twice per week thru Week 12, then only once per week through Week 16. Intervention continues with aerobic exercise led by health coaches via Webex. Classes start in Week 13 with one session per week, increasing to two sessions per week in Weeks 17-28."
89525135|NCT06152562||Individualized ASA therapy group using platelet inhibition monitoring|The first VerifyNow ARU measurement will be done minimum 2 hours and at latest 24 hours after the first four doses of ASA. If the ARU is ≤ 549, the current daily ASA dose will be continued and the patient will be discharged with this dose. If the ARU is ≥ 550, the dose will be increased by 50 mg and the test is repeated after two doses. We will increase the dose step by step until the ARU decreased below 550 or a maximum ASA dose of 300 mg per day is reached. If there is no sufficient drug effect at the maximum dose assessed by VerifyNow, the patient will be count as non-responder and a change to a P2Y12-inhibitor (e.g. Clopidogrel 75 mg) is indicated. A resistance against Clopidogrel will not be examined. The other tests will be held at the first follow-up visit and six months after implantation.
89525136|NCT06152562||Standard ASA therapy|Initiation of standard dose ASA therapy as per center guidelines with HeartMate 3: 100mg/day; HVAD: 200mg/day
89525137|NCT06152536|Experimental|Meal 2|Meal with a vegetarian protein
89525138|NCT06152536|Active Comparator|Meal 1|Meal with animal protein
89525139|NCT06152523|Experimental|MSI/dMMR tumors across all solid tumor types in adult patients|
89525140|NCT06152510||Children with autism spectrum condition|Thirty children with autism spectrum condition and with medium-high functioning, aged 4 to 13 years, IQ > 75, in the absence of motor deficits due to another clinical condition.
89525141|NCT06152510||Children with typical development|Thirty children with typical development aged 4 to 13 years, IQ > 75, in the absence of motor deficits due to clinical condition.
89525142|NCT06152484||Normal control group|
89525143|NCT06152484||Subclinical keratoconus|
89525144|NCT06152484||Keratoconus|
89525145|NCT06152471|Experimental|Experimental|"Salovum egg powder high in antisecretory factor, 4 g/sachet. Four sachets, ie 16 gr q 8 hours for 6 days before start of abemaciclib~SPC-flakes flat dose 75gr/day in parallel and during first 12 weeks of treatment with abemaciclib"
89525146|NCT06152471|Placebo Comparator|Placebo Comparator|Placebo, identical to investigational product but without antisecretory factor.
89525147|NCT06152458|Experimental|intervention group|Patients in the intervention group (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
89525148|NCT06152458|No Intervention|control group|As a control group, we selected 20 age- and sex-matched patients with septic shock who did not receive vitamin treatment.They received the standard of care for septic shock.
89525149|NCT06152445|Placebo Comparator|Gluten free bread|Bread will be eaten by the participants for 7 consecutive days
89525150|NCT06152445|Active Comparator|Gluten free bread with added wheat flour|Bread will be eaten by the participants for 7 consecutive days
89525151|NCT06152445|Experimental|Wheat bread with Yeast, short fermentation + bread improver|Bread will be eaten by the participants for 7 consecutive days
89525152|NCT06152445|Experimental|Wheat bread with Yeast, long fermentation|Bread will be eaten by the participants for 7 consecutive days
89525153|NCT06152445|Experimental|Wheat bread with Sourdough, long fermentation|Bread will be eaten by the participants for 7 consecutive days
89525154|NCT06152432|Active Comparator|Maxilillary implant overdenture retained by bars|Patients treated with 4 dental implants in the edentulous maxilla and an overdenture retained by bars
89525155|NCT06152432|Active Comparator|Maxilillary implant overdenture retained by Locators|Patients treated with 4 dental implants in the edentulous maxilla and an overdenture retained by solitary abutments (Locators)
89525156|NCT06152393||Control patients|Controls were patients diagnosed with TPHA/TPPA serology ≥80 and neurological symptoms requiring a lumbar puncture.
89525157|NCT06152393||NS1 patients|NS1 includes: 1) neurological symptoms suggestive of central nervous system (CNS) involvement or acute ophthalmological or acute auditory signs consistent with neurosyhilis (NS), or syphilis with treatment serological failure (< fourfold decrease in the antibody titer of RPR/VDRL 12 months after treatment), and 2) a TPHA/TPPA serology ≥ 80 and a CSF-TPHA/TPPA test ≥ 320, and 3) either CSF-WBC > 5 cells/mm3, and/or CSF-protein > 0,45g/l in the absence of other known causes of these abnormalities, and/or a reactive CSF-VDRL/RPR test, and 4) no differential diagnosis.
89525158|NCT06152393||NS2 patients|NS2 includes:1) acute ocular symptoms (recent and sudden decrease in visual acuity) and/or acute otologic dysfunctions (sudden hearing loss, acute tinnitus or vertigo) without other known diagnosis for these clinical abnormalities, 2) and a TPHA/TPPA serology ≥ 80, 3) and a response to NS treatment assessed by ophthalmologic or hearing tests and at least a fourfold reduction of RPR/VDRL titer in blood after 12 months following treatment.
89525159|NCT06152380||Clinic-based Rehabilitation|Individualised clinic-based face-to-face sessions with a physiotherapist in public or private rehabilitation facility
89525160|NCT06152380||Knee Care @Home|Individualised synchronous internet-based remote sessions at home via conferencing software under the supervision of a certified exercise and health coach as a complement to conventional clinic-based rehabilitation sessions.
89525161|NCT06152367|Experimental|TAPCells|Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
89525162|NCT06152354|Active Comparator|Control group|20 mandibular primary molars in which pulpectomy were performed by hand instrumentation system using K- File from size 15 to size 35.
89525163|NCT06152354|Experimental|Experimental group|20 mandibular primary molars in which pulpectomy were performed by rotary system using Kedo-SG rotary file system according to manufacturer's instructions .
89525164|NCT06152315||mitral splay sign|Patients with at least mild mitral regurgitation and splay sign on color doppler echocardiography
89525165|NCT06152315||no mitral splay sign|Patients with at least mild mitral regurgitation and no splay sign on color doppler echocardiography
89525166|NCT06152198|Experimental|Hip arthroplasty|Operative treatment with hip arthroplasty i.e cemented total- or hemiarthroplasty.
89525167|NCT06152198|Active Comparator|Internal fixation|Operative treatment with internal fixation i.e screws, pins, hook pins, sliding hip device.
89525168|NCT06152159||The second parent of a child|The second parent of a child born since minimum 3 months and maximum 6 months.
89525169|NCT06152107|Experimental|subsegmental BTVA treatment plus optimal medical therapy (GOLD guidelines)|Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments per single procedure.
89525170|NCT06152107|Active Comparator|segmental BTVA treatment plus optimal medical therapy (GOLD guidelines)|Patients in control group will be treated with the InterVapor System in at least 1 segment per single procedure.
89525171|NCT06152068||Obesity|Subjects with obesity were assessed with body mass index or BMI (calculated with body weight in kg divided by body height square in m). The subjects were determined to be obese if BMI value z-score > +2 SD of WHO child growth standard (assessed with WHO Anthroplus).
89525172|NCT06152068||non-obesity|Subjects non-obesity were assessed with body mass index or BMI (calculated with body weight in kg divided by body height square in m). The subjects were determined to be non-obesity if BMI value z-score < +2 SD of WHO child growth standard (assessed with WHO Anthroplus).
89525173|NCT06152029||Patients treated with a temporary PNS system|These patients will receive a temporary PNS system for their knee pain secondary to osteoarthritis
89525174|NCT06152016|Other|BE-FAST|
89525175|NCT06152016|Other|FAST|
89525176|NCT06152003|No Intervention|Enhanced Treatment as Usual (ETAU)|We anticipate the control condition will contain the following: the enhanced treatment as usual (ETAU; n=30) will consist of PWH receiving treatment at their HIV primary care clinic as usual, enhanced by supplemental food parcels and referrals for mental health care and food service organizations. Treatment as usual for mental health care is evaluation by a nurse and referral to a medical officer or to a traveling psychologist available 1 day per week. Because there is no standard of care for food insecurity, we propose that all participants will receive food parcels, but ETAU participants will not receive case management or psychosocial intervention.
89525177|NCT06152003|Experimental|Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)|We anticipate the intervention condition (CBT-SA) will contain the following: cognitive behavioral therapy for syndemics and adherence (CBT-SA; n=30) likely will be comprised of both psychosocial and structural intervention components, based on the results of Aim 1 and refinement in Aim 2. In addition to food parcels, we expect the CBT-SA condition will also receive nutritional counseling, linkage to care, and case management. Only the CBT-SA condition will receive the psychological intervention for depression and PTSD and adherence counseling. Specific intervention components will be informed by prior aims.
89525178|NCT06151990||newly diagnosed juvenile systemic lupus erythematosus|
89525179|NCT06151990||old cases of juvenile systemic lupus in activity|
89525180|NCT06151990||old cases of juvenile systemic lupus not in activity(controlled)|
89525181|NCT06151964|Experimental|Part A: AZD9550|Multiple repeat doses of AZD9550 given as 4 once weekly SC doses for 4 weeks to 2 sequential cohorts in overweight/obese participants with T2DM, evaluating 2 low dose levels of AZD9550
89525182|NCT06151964|Experimental|Part B: AZD9550|Once weekly up-titration over 5 doses of AZD9550 in overweight/obese participants with T2DM
89525183|NCT06151964|Experimental|Part C: AZD9550|Bi-weekly/monthly up-titration of AZD9550 for 24 weeks in overweight/obese participants with T2DM.
89525184|NCT06151964|Experimental|Part D: AZD9550|Bi-weekly/monthly up-titration of AZD9550 for 24 weeks in overweight/obese with T2DM Japanese participants (Part D).
89525185|NCT06151964|Experimental|Part A: placebo|Multiple repeat doses of placebo given as 4 once weekly SC doses for 4 weeks to 2 sequential cohorts in overweight/obese participants with T2DM, evaluating 2 low dose levels of AZD9550
89525186|NCT06151964|Experimental|Part B: placebo|Once weekly up-titration over 5 doses of placebo in overweight/obese participants with T2DM
89525187|NCT06151964|Experimental|Part C: placebo|Bi-weekly/monthly up-titration of placebo for 24 weeks in overweight/obese participants with T2DM.
89525188|NCT06151964|Experimental|Part D: placebo|Bi-weekly/monthly up-titration of placebo for 24 weeks in overweight/obese with T2DM Japanese participants (Part D).
89525189|NCT06151951|Experimental|Group A|Movement control training of Neck flexor muscles with Pressure Biofeedback along with baseline treatment
88811832|NCT01387139|Experimental|Ketamine Co-Administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
89525190|NCT06151951|Experimental|Group B|Movement control training of Neck flexor muscles with Visual Biofeedback along with baseline treatment
89525191|NCT06151925|Active Comparator|Laminaria tents group|Laminaria tent used to be inserted in cervix and left for 6-12 hours
89525192|NCT06151925|Placebo Comparator|vaginal prostaglandin group|Misoprostol 25 mcg inserted for one or multiple doses
89525193|NCT06151912|Experimental|Fibrin Glue Group|Sleeve gastrectomy will be performed on morbidly obese patients, starting 3 cm cranial to the pylorus, under the guidance of a 36 F bougie. Then, Fibrin Glue (TisseelTM-Baxter, USA) will be applied to the staple line.
89525194|NCT06151912|Active Comparator|Suture Group|Sleeve gastrectomy will be performed on morbidly obese patients, starting 3 cm cranial to the pylorus, under the guidance of a 36 F bougie. Then, the stapler line will be sutured with continuous sutures with 3/0 prolene suture, with the stapler line inverted.
89525195|NCT06151899|Experimental|Kinesio tape applying group|To the mothers in the experimental group; Kinesio tape application will be performed by two experienced physiotherapists, one of whom is an expert and the other has a doctorate degree, with a kinesio tape certificate.
89525196|NCT06151899|No Intervention|Control group|The control group will receive placebo kinesio taping.
89525197|NCT06151886||Patients|
89525198|NCT06151886||Relatives|
89525199|NCT06151886||Trained respiratory patient caregiver|
89525200|NCT06151860|Experimental|Static stretching|A equipment (Ladder Barrel), used in Pilates sessions, will help with the movement. To stretch the knee flexor muscles, the participant, standing, will place the dominant lower limb on the equipment and keep the other on the ground, remaining with both knees extended. The trunk will be flexed forward within the maximum range of movement achieved by the participant, until discomfort occurs in the posterior region of the thigh, but not pain. To stretch the knee extensor muscles, the participant, standing, will position the back of the foot of the dominant lower limb on the equipment and keep the other limb with the foot flat on the ground. The glute of the dominant lower limb will meet the heel of the same limb, until there is discomfort, but not pain. In both stretches, the position will be maintained for 30 seconds, followed by an equal rest time. Three series of stretching will be performed for the knee flexor muscles and then another three series for the extensor muscles.
89525201|NCT06151860|Experimental|Pilates stretching|The protocol will be the same as the Static stretching Group, with the exception of maintaining the static position during the exercise. To do this, when stretching the knee flexor muscles, the trunk will perform continuous flexion movements until the point of muscular discomfort, followed by the extension movement, until an upright posture, continuously. On the other hand, when stretching the knee extensor muscles, the gluteal muscle of the dominant lower limb will meet the heel of the same limb, until there is discomfort, followed by the movement away, continuously.
89525202|NCT06151860|No Intervention|Control|
89525203|NCT06151821|Experimental|Group MTG|The intervention arm received Guided Meditation sessions
89525204|NCT06151821|No Intervention|Group STG|The control arm received standard care without any Guided meditation sessions
89525205|NCT06151808|Sham Comparator|non-cognitive impairment|30 subjects with non-cognitive impairment
89525206|NCT06151808|Experimental|AD-derived MCI|30 subjects with AD-derived MCI
89525207|NCT06151808|Experimental|mild to moderate AD.|30 subjects with mild to moderate AD.
89525208|NCT06151795|Experimental|XTR006|Single dose 8.0-10.0 mCi intravenous injection of XTR006
89525209|NCT06151756|Other|Video mobile application supported education|In order to ensure standardization in the expression of all skills, a video flow plan was prepared and recordings were conducted in accordance with this plan. The videos were organized in a way that the practitioner narrates all the steps of the procedure, with being visible and audible. Before the application, each video was watched repeatedly by the research team and necessary arrangements were performed. Then, the videos created about the applications were uploaded to the mobile application-based web system. After the systematic preparations were completed, trainings on the system and usage were provided to the instructors in charge of the skill practices. In addition, all students were trained on research, the system, and usage, and were provided with the opportunity to download the mobile application to their phones.
89525210|NCT06151756|No Intervention|Control|"The students in the control group, on the other hand, were subjected to standardized training in the skills laboratory without watching any videos after the theoretical information provided in the course. While the students were practicing, they were evaluated by the relevant instructors according to the process steps in the Basic Nursing Skills Learning Guide. In both groups, students were informed about the research and evaluated in terms of inclusion criteria. Prior to the start of the intervention, all students were asked to fill the student introduction form, the Problem Solving Inventory and the California Critical Thinking Disposition Scale."
89525211|NCT06151743|Experimental|Neoadjuvant therapy+Surgery+Adjuvant therapy|Participants receive three cycles of neoadjuvant therapy (toripalimab+cetuximab+platinum), followed by radical surgery. After surgery, participants receive radiotherapy or chemoradiotherapy according to the pathological results of the operation.
89525212|NCT06151704|Experimental|True high intensity laser therapy on lumbar region, sciatic, tibial, and peroneal nerves|The laser scanner, 50 cm from the skin, will target the area from the 12th ribs to the upper iliac crest, 4.2 cm lateral to the spine. The sciatic, tibial, and peroneal nerves will also be irradiated.
89525213|NCT06151704|Sham Comparator|Deactivated high intensity laser therapy, an audio device will mimic the laser's operational sound|the laser will remain deactivated, and an audio device will generate a simulation of the operational sound of the device. The subject will also participate in the same foundational treatment regimen involving motor control exercises as the intervention group.
89525214|NCT06151691||Case-Cancer arm|Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
89525215|NCT06151678||UK population survey|The UK population who accessed the electronic survey link disseminated via social media and via a gatekeeper at a Scottish council
89525216|NCT06151678||Participants attending online webinars|Individuals who signed up for an online webinar related to persistent pain. This group offered quantitative feedback via online surveys and qualitative data via interview.
89525217|NCT06151678||Participants who attended in person seminars during a community outreach tour|Individuals who attended six different venues across the English county of Lincolnshire. This group offered quantitative feedback via paper and online surveys and qualitative data via interview.
89525218|NCT06151678||Brain bus cohort|Participants who attended a pop up interactive tent with practical demonstrations to improve pain related knowledge. This group offered quantitative feedback via paper postcards and qualitative data via interview.
89525219|NCT06151678||Community outreach tour volunteers|Focus groups were arranged for those who volunteered to lead and deliver the community outreach tour
89525220|NCT06151665|Experimental|Single Rotary file|single rotary file will be used in primary molars to preform pulpectomy then restored with zinc oxide eugenol and stainless steel crown.
89525221|NCT06151665|Active Comparator|Conventional Manual Files|Conventional Manual Stainless steel K files will be used in primary molars to preform pulpectomy then restored with zinc oxide eugenol and stainless steel crown.
89525222|NCT06151639||Surgery under general anesthesia|13 patients were anesthetized intravenous with routine general anesthesia.
89525223|NCT06151639||Surgery with Pecs block|13 patients underwent surgery with PECS block
89525224|NCT06151587|Experimental|QLM3004 Concentration 1|Solution low dose
89525225|NCT06151587|Experimental|QLM3004 Concentration 2|Solution medium dose
89525226|NCT06151587|Experimental|QLM3004 Concentration 3|Solution high dose
89525227|NCT06151587|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
89525228|NCT06151522|Other|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525229|NCT06151522|Other|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525230|NCT06151509|Other|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525231|NCT06151509|Other|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525232|NCT06151496|Active Comparator|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525233|NCT06151496|Experimental|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525234|NCT06151470|Other|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525235|NCT06151470|Other|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525236|NCT06151457|Other|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525237|NCT06151457|Other|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525238|NCT06151444|Active Comparator|Standard group|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525239|NCT06151444|Experimental|Intensive group|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
89525240|NCT06151392|Active Comparator|Probiotic group|probiotic will be administered to this group of pediatric patients with ventriculitis
89525241|NCT06151392|Active Comparator|Zinc group|Zinc will be administered to this group of pediatric patients with ventriculitis
89525242|NCT06151392|Active Comparator|Probiotic and Zinc group|probiotic and Zinc will be administered to this group of pediatric patients with ventriculitis
89525243|NCT06151392|No Intervention|Control group|interventional drug will not be administered to this group of pediatric patients with ventriculitis
89525244|NCT06151379||Pathologic complete response (pCR)|Patient with complete pathological response
89525245|NCT06151379||Pathologic incomplete response (non-pCR)|Patient with partial pathological response
89525246|NCT06151301||control group|20 subjects of apparently healthy persons for estimating the standard levels of the tested biomarkers.
89525247|NCT06151301||case group|60 patients divided into mild, moderate and severe toxicity according to the poisoning severity score.
89525248|NCT06151262|Experimental|Trilaciclib+mFOLFIRINOX|"The treatment regimen was as follows:~Trilaciclib 240mg/m2 IV infusion, D1, D2，Q2W； Oxaliplatin 68mg/m2 IV infusion, D1; Irinotecan 135mg/m2 IV infusion D1; leucovorin 400mg/m2 IV infusion D1; 5-FU 2.4g/m2 IV infusion for 46h, D1; A total of 12 cycles of treatment were performed every 14 days as a cycle."
89525249|NCT06151249|Experimental|Chemotherapy+Meritup|Chemotherapy+Meritup 20ml TID
89525250|NCT06151249|Placebo Comparator|Chemotherapy+Placebo|Chemotherapy+Placebo 20ml TID
89525251|NCT06151223||Tier 1|"Participants with Peutz-Jeghers syndrome and/or carriers of a germline CDKN2A mutation and/or hereditary pancreatitis with PRSS1 mutation and clinical history of pancreatitis(age ≥40 or 10 years younger than youngest affected blood relative)~Carriers of a germline BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation with at least one affected first-degree blood relative (age ≥45 or 10 years younger than youngest affected blood relative)~At least one first-degree relative (FDR) with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer and/or at least two affected blood relatives on the same side of the family, of whom at least one is an FDR to the individual and/or at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual(age ≥50 or 10 years younger than youngest affected blood relative)"
89525252|NCT06151223||Tier 2|"Individual with family history of PDAC in only one first degree relative (FDR); age ≥50 or 10 years younger than the affected first degree relative~OR known BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation; age > 45 who do not meet tier 1 criteria."
89525253|NCT06151210|Experimental|DA-5219|administered for 2weeks(DA-5219 + Stillen® Tab placebo)
89525254|NCT06151210|Active Comparator|Stillen® Tab|administered for 2weeks(Stillen® Tab + DA-5219 placebo)
89525255|NCT06151132||Patients with atrial fibrillation|Direct current cardioversion
89525256|NCT06151093|Experimental|Video-based balance games group|
89525257|NCT06151093|Experimental|Balance exercises group|
89525258|NCT06151015|Experimental|Dietary nitrate plus caloric restriction|Participants will drink beetroot juice with a calorie-restricted diet for 28 days.
89525259|NCT06151015|Active Comparator|Dietary nitrate alone|Participants will drink beetroot juice with a weight-maintenance diet for 28 days.
89525260|NCT06150963|Active Comparator|Thyroid Biopsy (Control)|Patients within this arm received standard procedure thyroid biopsies without virtual reality.
89525261|NCT06150963|Experimental|Thyroid Biopsy (Virtual Reality)|Patients within this arm received standard procedure thyroid biopsies with virtual reality for the length of the procedure.
89525262|NCT06150963|Active Comparator|PICC (Control)|Patients within this arm received standard procedure PICC placements without virtual reality.
89525263|NCT06150963|Experimental|PICC (Virtual Reality)|Patients within this arm received standard procedure PICC placements with virtual reality for the length of the procedure.
89525264|NCT06150950|Experimental|Cardiac rehabilitation|For patient randomized to cardiac rehabilitation, the ACHD clinician will place the referral after they and the patient have seen the group assignment. All participants will be referred to Heart Fit for Life community-based cardiac rehabilitation program in Palo Alto, CA. Cardiac rehabilitation will be offered as an in-person, hybrid, or completely virtual program for Stanford participants and will be entirely virtual for Vanderbilt participants. Participants will attend 3 sessions per week for 12 weeks. Participants will receive weekly email reminders via the electronic medical record to encourage participation. The study protocol pertains only to referral to cardiac rehabilitation. All other aspects of the cardiac care will be at the discretion of clinicians. All study participants will receive a Fitbit for daily activity tracking.
89525265|NCT06150950|Active Comparator|Usual care|For patients randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians. All study participants will receive a Fitbit for daily activity tracking.
89525266|NCT06148428||Normal group|"Based on the Hospital Anxiety and Depression scale anxiety sub-score (HADS anxiety sub-score, the seven-item anxiety sub-score for scaling a patient's anxiety levels before LASIK)~Patients who had a sub-score of ≤7 denotes no anxiety scale (normal)."
89525267|NCT06148428||Borderline anxiety group|"Based on the Hospital Anxiety and Depression scale anxiety sub-score (HADS anxiety sub-score, the seven-item anxiety sub-score for scaling a patient's anxiety levels before LASIK)~Patients who had a sub-score of 8-10 denotes doubtful anxiety scale (borderline)."
89525268|NCT06148428||Anxious group|"Based on the Hospital Anxiety and Depression scale anxiety sub-score (HADS anxiety sub-score, the seven-item anxiety sub-score for scaling a patient's anxiety levels before LASIK)~Patients who had a sub-score of 11-21 is abnormal and denotes a definite anxiety scale (case)."
89525269|NCT06147999|Experimental|Treatment Group|The 14 active Biophoton Generators packed with the same 32-Oz metal can will be labeled with a code and placed under a hotel bed. Each participant will rest on the bed during the entire study period for 4 weeks. Participants will receive biophotons inside of the biophoton field generated by 14 active Biophoton Generators
89525270|NCT06147999|Placebo Comparator|Control Group|The 14 inactive Biophoton Generators packed with the same 32-Oz metal can will be labeled with a code and placed under a hotel bed. Each participant will rest on the bed during the entire study period for the first 2 weeks. Then will be switched to the active treatment group for being treated for 4 weeks. Participants will receive placebo effect from the 14 inactive comparators.
89525271|NCT06147622|Experimental|KT110|Subjects will be randomized to receive KT110 on period 1 or period 2
89525272|NCT06147622|Experimental|Prazosin + cyproheptadine|Subjects will be randomized to receive prazosin + cyproheptadine on period 1 or period 2
89525273|NCT06147479|Experimental|CS-ADL|CS-ADL is a multi-component cognitive stimulation program that aims to enhance performance of activities of daily living (ADL) for people living with mild-to-moderate dementia.
89525274|NCT06147479|No Intervention|Treatment as Usual (TAU)|The control group continue to receive their usual care. This may differ between individuals, but may include physiotherapy, occupational therapy, nursing, medication or attendance at a day-care centre/day hospital. This treatment is decided by their healthcare provider who is external to the research team. It is possible that 'TAU' for some individuals dictates no treatment.
89525275|NCT06147245|Experimental|Person-centred culturally sensitive course of treatment|The intervention consists of a 12-month person-centred and culturally sensitive course of treatment.
89525276|NCT06147245|No Intervention|Control|The control group will follow the standard care with regular visits at the T2D outpatient clinic at SDCC 3-4 times/year.
89525277|NCT06147154||Pancreatic head cancer (PHC) tumor tissues|
89525278|NCT06147154||Pancreatic head cancer (PHC) matched non-tumor tissues|
89525279|NCT06147154||Pancreatic body/tail cancer (PBTC) tumor tissues|
89525280|NCT06147154||Pancreatic body/tail cancer (PBTC) matched non-tumor tissues|
89525281|NCT06146946|Experimental|Omitting dissection of the No.253 lymph node|Perform surgery based on the principle of Total Mesorectal Excision (TME), without denuding the root of the Inferior Mesenteric Artery (IMA) and without dissection of the No.253 lymph node. Ligation of the IMA is performed at a low position distal to the origin of the left colonic artery.
89525282|NCT06146946|Active Comparator|Dissection of the No.253 lymph node|Perform surgery based on the principle of Total Mesorectal Excision (TME). During the procedure, fully expose the root of the Inferior Mesenteric Artery (IMA), thoroughly dissect the No.253 lymph node, and perform a high ligation along the artery at the root of the IMA; or expose the bifurcation of the left colonic artery, ligating the IMA at a low position distal to the origin of the left colonic artery, ensuring the dissection of the No. 253 lymph node while preserving the left colonic artery.
89525283|NCT06144515||Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome|
89525284|NCT06144008||Medical experts in departments at risk|Expert healthcare workers at the Munich University Hospital within departments potentially affected by a major medical incident that could benefit from student surge capacity workforce. The following departments are included: Emergency Department, Intensive Care Units, Intermediate Care Units, Medical and Surgical wards, Department for Microbiology, Department for Infectious Diseases, Department for Laboratory Medicine, Antibiotic Stewardship Team, Department for Tropical Medicine, Max-von-Pettenkofer Institute, Institute for Emergency Medicine, Faculty Dean's office.
89525285|NCT06144008||Students|Medical students from all medical faculties in Germany to be questioned on their willingness to partake in clinical work as surge capacity work force in the context of a potential major medical incident.
89525286|NCT06138600|Active Comparator|Cabotegravir Long Acting Injectable|Investigational Product: Cabotegravir Dosage Formulation: 600 mg suspension for injection Route of Administration: Intra-muscular injection Dosing Instructions: 1 vial (600 mg) injected monthly for the initial visit (Month 1 and 2), then every 2 months thereafter (from Month 2 onwards)
88812184|NCT05945446||Normal Pregnancies (control group)|Healthy pregnancies with similar gestational age and body mass index with study group.
89525287|NCT06138600|Active Comparator|Tenofovir disoproxil fumarate + Emtricitabine/Lamivudine (TDF/FTC[3TC])|Investigational Product: Tenofovir disoproxil fumarate / emtricitabine (or lamivudine) Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily
89525288|NCT06138145|Sham Comparator|Group A|No Video w/ monetary incentive
89525289|NCT06138145|Experimental|Group B|Generic video w/ monetary incentive
89525290|NCT06138145|Experimental|Group C|Appeal video w/ monetary incentive
89525291|NCT06138145|Sham Comparator|Group D|Non-Incentive and no video
89525292|NCT06128460|Experimental|Concurrent themoradiotherapy Followed by Zimberelimab|"Radiotherapy: Intensity modulated conformal radiation therapy (IMRT) is used for external irradiation, and the pelvic target volume dose (PTV) is: 45-50 Gy/1.8Gy/25-28f; the stump margin is positive, and after the external irradiation is completed, Additional CT-guided three-dimensional conformal brachytherapy, HR-CTV: 24--30Gy/4-5f.~Concurrent chemotherapy: performed during external radiotherapy. Starting from the first week of radiochemotherapy, cisplatin 40 mg/m2 was given. Chemotherapy is given every 7 days, up to 5-6 times;~Zimberelimab injection: 240 mg/time, intravenous infusion, administered every 21 days, starting within four weeks after completing concurrent chemoradiotherapy, and maintained for 8 cycles"
89525293|NCT06124391||HA-PCOS|Patients were classified into each PCOS subtype based on our machine-learning classification model. The feature of the HA-PCOS group is hyperandrogenism.
89525294|NCT06124391||OB-PCOS|Patients were classified into each PCOS subtype based on our machine-learning classification model. The feature of the OB-PCOS group is overweight/obesity.
89525295|NCT06124391||SHBG-PCOS|Patients were classified into each PCOS subtype based on our machine-learning classification model. The feature of the SHBG-PCOS group is the high level of serum SHBG.
89525296|NCT06124391||LH-PCOS|Patients were classified into each PCOS subtype based on our machine-learning classification model. The feature of the LH-PCOS group is the high level of LH and AMH.
89525297|NCT06117618|No Intervention|No alert|Participants will receive no physician alert or registered nurse (RN) alert.
89525298|NCT06117618|Experimental|Nurse alert|Participants will receive RN alert.
89525299|NCT06117618|Experimental|Prescribing clinician alert|Participants will receive physician alert.
89525300|NCT06117618|Experimental|Nurse alert and prescribing clinician alert|Participants will receive physician alert and RN alert.
89525301|NCT06117605|No Intervention|No alert|Participants will receive no physician alert or registered nurse (RN) alert.
89525302|NCT06117605|Experimental|Nurse alert|Participants will receive RN alert.
89525303|NCT06117605|Experimental|Prescribing clinician alert|Participants will receive physician alert.
89525304|NCT06117605|Experimental|Nurse alert and prescribing clinician alert|Participants will receive physician alert and RN alert.
89525305|NCT06114615|Active Comparator|Discharged with LiveCare and Text Message Intervention|Patients receive blood pressure monitoring and text messages reminders for enrollment in cardiac rehab, follow up appointment, diet and exercise counseling.
89525306|NCT06114615|Sham Comparator|Discharged with Conventional Care|Patients do not receive blood pressure monitoring and text messages reminders for enrollment in cardiac rehab, follow up appointment, diet and exercise counseling.
89525307|NCT06108596|Experimental|Experimental group|Sintilimab with Interleukin-2+CAPOX
89525308|NCT06091423|Experimental|Experimental|XELOX combined with Fruquintinib and Sintilimab
89525309|NCT06091358|No Intervention|Control|"Participants will arrive at the Laboratory and complete a series of questionnaires: general physical activity, BDI, TDI, PSQI, General health questionnaire, Post COVID fatigue scale, EQ 5D-5L. They will undergo spirometry testing FEV1, MIP and PEF. Participants will undergo a 6 minute walk test and a Sub-maximal exercise test (CPET) using a cycle ergometer (15W/min) until an RPE of 17.~Participants continue usual life between baseline and follow up testing. Participants will have 1 call per week where MIP is measured using a Care fusion hand held spirometer device.~After 4 weeks, participants will return to the Laboratory and repeat baseline testing."
89525310|NCT06091358|Experimental|Inspiratory Muscle training intervention|"Participants will arrive at the Laboratory and complete a series of questionnaires: general physical activity, BDI, TDI, PSQI, General health questionnaire, Post COVID fatigue scale, EQ 5D-5L. They will undergo spirometry testing FEV1, MIP and PEF. Participants will undergo a 6 minute walk test and a Sub-maximal exercise test (CPET) using a cycle ergometer (15W/min) until an RPE of 17.~Participants undergo inspiratory muscle training for 4 weeks between baseline and follow up testing. They will be given a PrO2 device where the intervention will be 3 times per week for 4 weeks. Each session will be 6x6 breaths at 80% MIP. Participants will have 1 call per week where MIP is measured using a Care fusion hand held spirometer device.~After 4 weeks, participants will return to the Laboratory and repeat baseline testing."
89525311|NCT06085144||Galcanezumab|Postpartum women both nursing and receiving treatment for migraine with galcanezumab.
89525312|NCT06082804|Experimental|A: IPA group|Patients in arm A are followed by the advanced practice nurse and the hematologist.
89525313|NCT06082804|Active Comparator|B: Control group|Patients in arm B are followed by the hematologist only (standard of care).
89525314|NCT06080737||standard oxygen group|telephone interview comprising a quality of life questionnaire
89525315|NCT06080737||awake prone group|telephone interview comprising a quality of life questionnaire
89525316|NCT06061900|Experimental|Participants who receive group exercise intervention|Intervention will include a warm-up, restive exercises with dumbbells, interval training, game or dancing, and cool down. Intervention sessions will run for 30-45 minutes, 2-3 times a week, for 8 weeks. Participants will also participate in pre and post-testing.
89525317|NCT06061900|No Intervention|Participants who do not receive group exercise intervention|Participants will participate in pre and post-testing.
89525318|NCT06061354|Experimental|Teriparatide|"Access to the maxillary sinus will be done through osteotomy, using a piezosurgery . Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material Bio-Oss® mixed with Forteo® will be delivered for placement on the sinus floor maxilla below Schneider's membrane.~Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed"
89525319|NCT06061354|Placebo Comparator|Placebo|"Access to the maxillary sinus will be done through osteotomy, using a piezosurgery . Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material, Bio-Oss® mixed with saline solution, will be delivered for placement on the sinus floor maxilla below Schneider's membrane.~Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed"
89525320|NCT06054594|Experimental|Metabolically healthy obesity (MHO)|Healthy/normal metabolic profile
89525321|NCT06054594|Experimental|Metabolically unhealthy obesity (MUHO)|Abnormal metabolic profile
89525322|NCT06051604|Experimental|Group I (active treatment 1)|4 LPM of dehumidified air administered via Mi-Helper for 15 minutes
89525323|NCT06051604|Experimental|Group II (active treatment 2)|6 LPM of dehumidified air administered via Mi-Helper for 15 minutes
89525324|NCT06051604|Experimental|Group III (active treatment 3)|10 LPM of dehumidified air administered via Mi-Helper for 15 minutes
89525325|NCT06051604|Sham Comparator|Group IV (sham treatment)|2 LPM of ambient air administered intermittently via Mi-Helper for 15 minutes
89525326|NCT06038604|Experimental|Psychosocial Support Intervention|The psychosocial support intervention includes components such as logistical and practical support and self-care, strategies to manage cognitive changes, as well as strategies for effective communication when coping with glioblastoma.
89525327|NCT06037564|Experimental|Intervention|Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
89525328|NCT06037564|No Intervention|Control|"Participants randomized to the control arm will continue to take their fully suppressive ART at baseline. The following selection of treatment combinations could be encountered in the control group (among others):~Once-daily co-formulated elvitegravir 150 mg, cobicistat 150 mg, tenofovir alafenamide 10 mg, emtricitabine 200 mg (Genvoya®) and darunavir 800 mg (e.g. Darunavir Mylan®)~Once-daily co-formulated darunavir 800 mg, cobicistat 150 mg, tenofovir alafenamide 10 mg, emtricitabine 200 mg (Symtuza ®) and DTG 50 mg (Tivicay ®)~Once-daily DTG 50 mg (Tivicay®), darunavir 800 mg (e.g. Darunavir Mylan®), and ritonavir 100 mg (Norvir®)~Etravirine 200 mg twice daily (Intelence®), raltegravir 400 mg twice daily (Isentress®),darunavir 800 mg once daily (e.g. Darunvair Mylan®) and ritonavir 100 mg once daily (Norvir®)"
89525329|NCT06033352|Experimental|Laser and cream|
89525330|NCT06033352|Active Comparator|Laser alone|
89525331|NCT06032130||Parkinson Disease Group (PD)|"Anamnesis~Measurement of best visual acuity with an EDTRS (Early Treatment Diabetic Retinopathy Study) test~Measurement of refraction with trial frame refraction~Measurement of pupillary diameter under photopic and mesopic illumination conditions using a specific millimetric ruler~Measurement of ocular sensory dominance with the red filter test~Measurement of binocular vision status with the Cover Test, prism bar and Maddox wing~Photopic and mesopic achromatic contrast sensitivity using the Functional Test Analyzer device~Stereopsis using the Titmus Test~Colour vision using the Farnsworth-Munsell 100 Hue sorting test~Measurement of eye movements with aDEMd (adult Developmental Eye Movement) test and NSUCO (Northeastern State University College of Optometry)~Measurement of reading speed with Radner-Vissum test~National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25)"
89525332|NCT06032130||Control Group (GP)|"Anamnesis: name, sex, date of birth, contact, family contact, medical report, Hoehn & Yahr classification, medication, systemic, ocular and family history, consumption of tobacco, alcohol, drugs, coffee, physical activity, eye colour, other observations~Measurement of best visual acuity with an EDTRS test~Measurement of refraction with trial frame refraction~Measurement of pupillary diameter under photopic and mesopic illumination conditions using a specific millimetric ruler~Measurement of ocular sensory dominance with the red filter test~Measurement of binocular vision status with the Cover Test, prism bar and Maddox wing~Photopic and mesopic achromatic contrast sensitivity using the Functional Test Analyzer device~Stereopsis using the Titmus Test~Colour vision using the Farnsworth-Munsell 100 Hue sorting test~Measurement of eye movements with aDEMd test and NSUCO~Measurement of reading speed with Radner-Vissum test~NEI VFQ-25"
89525333|NCT06032130||Therapy Parkinson Disease Group (TPD)|Oculomotor exercises such as tracking eye movements, saccadic eye movements and fixations will be performed. These exercises will be performed in a non-invasive manner using simple and easy-to-use instruments. An application on an electronic device, namely the virtual reality software Visionary, could also be used. If financial resources allow, the intention is to use tablets or computers for this purpose. Perceptual learning exercises will also be carried out on an electronic device. The following variables will be collected from these exercises: time taken to carry out the tests, errors made, speed of completion, latency, etc. These will be compared before and after the exercises in the third phase. In addition, the patients will be given indications for working on these exercises at home.
89525334|NCT06032130||Control Parkinson Disease Group (CPD)|These patients will not receive oculomotor or perceptual therapy. They will be evaluated in the same manner as patients who will receive therapy, both at the beginning and at the end of therapy in the other group.
89525335|NCT06025643|Experimental|Cervical stimulation group|TENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
89525336|NCT06025643|Experimental|Plus cervical stimulation group|TENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
89525337|NCT06025643|Experimental|Renal stimulation group|TENS will be applied for 30 minutes with a frequency of 5 Hz, pulse width of 200 µs and sufficient intensity to reach the sensory threshold. Ten sessions will be performed over four weeks.
89525338|NCT06025643|No Intervention|Control group|This group will not receive any treatment with electrical stimulation.
89525339|NCT06023680|Active Comparator|Continuous sedentary reduction intervention|Structured intervention to progressively replace sedentary time with one daily 30-minute light-intensity walking bout
89525340|NCT06023680|Active Comparator|Bouted sedentary reduction intervention|Structured intervention to progressively replace sedentary time with three daily 10-minute light-intensity walking bouts
89525341|NCT06022081|Other|Diagnostic modalities comparison|All participants belong to a single arm. A chest X-ray (CXR) and lung ultrasound (LUS) in a predetermined order (CXR followed by LUS), will be performed sequentially for pneumothorax (PNX) detection after chest/mediastinal tube removal. There is no control group or randomization.
89525342|NCT06020209|Experimental|STEMI patients|Patients with reperfused ST-segment Elevation Myocardial Infarction
89525343|NCT06017934|No Intervention|Control|Usual care
89525344|NCT06017934|Experimental|Volunteer-led physical activity|Trained volunteers will deliver walking, or bedside exercises with hospitalised older adults twice per day.
89525345|NCT06008275|Experimental|neratinib + ruxolitinib|There is only one arm
89525346|NCT06002919|Active Comparator|MindWalk Intervention|12 week intervention: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit Charge HR) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability.
89525347|NCT06002919|No Intervention|Control group|For the participants assigned to control group, there is no intervention. At the end of study, the control group participants will be given access to the recorded virtual mindful walking training only (this includes the 30 minutes introductory training and the weekly 10-minute mindfulness topics/modules).
89525348|NCT06002165|Placebo Comparator|Usual Care Arm|The Usual Care Arm is comprised of the clinics that are not yet receiving the intervention. All 20 clinics participating in the study are in the Usual Care Arm until they begin the Active Implementation phase.
89525349|NCT06002165|Active Comparator|Active Implementation Arm|The Active Implementation Arm is comprised of the clinics that have started to receive the intervention, which is the ACHIEVE multi-component implementation strategy delivered by the Nurse Coordinators. All 20 clinics (divided into 3 Cohorts) move from the Usual Care Arm into the Active Implementation Arm in sequential order (six months apart).
89525350|NCT06000423|Experimental|Treatment|After three consecutive days of bleeding, five days of 1300mg TXA three times per day (TID).
89525351|NCT06000423|Placebo Comparator|Placebo|After three consecutive days of bleeding, five days of placebo three times per day.
89525352|NCT05996718|Experimental|Informal Caregivers of Persons Living with Dementia|"Participants will receive the training program, Improving Care through Improv. This involves four weekly 2-hour in-person training sessions."
89525353|NCT05986630|Experimental|TEOSYAL® TPVM|n=116 subjects
89525354|NCT05986630|Active Comparator|COMPARATOR|n= 39 subjects
89525355|NCT05981508|Active Comparator|In-person Family Skills Training|The index partner will participate in intervention as a dyad with a family member with an in-person skills training.
89525356|NCT05981508|Experimental|Online Family Skills Training|The index partner will participate in intervention as a dyad with a family member with an online skills training.
89525357|NCT05978648|Experimental|Cohort A: Triple-negative Breast Cancer|Cohort A Administered Trilaciclib in Combination with Chemotherapy(EC-wP)
89525358|NCT05978648|Experimental|Cohort B: ER-negative PR-negative Her2-positive Breast Cancer|Cohort B Administered Trilaciclib in Combination with Chemotherapy(TCbH±P)
89525359|NCT05977543|No Intervention|Control wheat crackers|Volunteers consumed 80g of white bread, 30g of full fat butter and 55g of wheat flour crackers.
89525360|NCT05977543|Other|Grape seed flour crackers|Volunteers consumed 80g of white bread, 30g of full fat butter and 55g of wheat flour crackers, enriched with 10% grape seed flour crackers.
89525361|NCT05977543|Other|Barley flour and β-glucan crackers|Volunteers consumed 80g of white bread, 30g of full fat butter and 55g of 60% wheat flour and 40% barley flour crackers, enriched with β-glucan
89525362|NCT05972525|Experimental|Shared decision-making (SDM)|Patients will be informed by a nurse before being consulted by the surgeon randomized to SDM and use the in-consultation PtDA during the consultation on patients with severe hip or knee osteoarthritis
89525363|NCT05972525|No Intervention|Usual practice|Patients will be informed by a nurse before being consulted by the surgeon randomized to usual practice during the consultation on patients with severe hip or knee osteoarthritis
89525364|NCT05961371|Experimental|Exercise|In-person, supervised resistance training program
89525365|NCT05961371|No Intervention|Control|Waitlist control group. Will be offered the exercise program following a 9-month wait.
89525366|NCT05945888|Experimental|SRD part: Treatment group|
89525367|NCT05945888|Placebo Comparator|SRD part: Placebo group|
89525368|NCT05945888|Experimental|FE part: Treatment sequence reference (R) - test (T)|
89525369|NCT05945888|Experimental|FE part: Treatment sequence test (T) - reference (R)|
89525370|NCT05938114|Experimental|Group A (Bonalive®)|The test bone substitute is Bonalive®, bioactive glass S53P4, which contains SiO2, Na2O, CaO, and P2O5 (granule size 0.5-0.8mm). Bonalive® is osteoconductive, meaning that it has the ability of promoting bone growth across the granules and the grafting area and slowly replace it with new bone over time. Bonalive® is osteostimulative and has antibacterial properties
89525371|NCT05938114|Active Comparator|Group B ( Bio-Oss®)|The comparator is Bio-Oss®, deproteinized bovine bone granules (granule size 0.25- 1mm). Bio-Oss® is osteoconductive, which means it acts as a scaffold only for new bone to grow.
89525372|NCT05927376|Experimental|Mediterranean-style dietary pattern|A Mediterranean-style diet (as a whole diet, no supplements)
89525373|NCT05927376|Active Comparator|Western-style dietary pattern|A Western-style diet (as a whole diet, no supplements)
89525374|NCT05926401||Planned elective cardioversion for atrial fibrillation|
89525375|NCT05917171|Experimental|painTRAINER intervention|40 Spanish speaking Hispanic and Latine participants will participate in an 8 week online pain coping skills training program designed to address cancer-related pain.
89525376|NCT05914883|Experimental|ECG screening|
89525377|NCT05914883|No Intervention|No ECG screening|
89525378|NCT05910944||Group 1 - prodromal iNPH|Individuals with typical imaging findings consistent with iNPH but none or too mild symptoms to motivate shunt surgery.
89525379|NCT05910944||Group 2 - Healthy controls|Age matched healthy controls
89525380|NCT05910944||Group 3 - symptomatic iNPH|Patients with symptomatic iNPH
89525381|NCT05903573|Experimental|Intervention Group: Cognitive Training|Participants will complete computerized cognitive training via Posit Science Brain HQ. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
89525382|NCT05903573|Active Comparator|Active Control Group: Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
89525383|NCT05899647|Experimental|Enrolled Patients|Consented patients who have had an additional Pap sample taken at their visit.
89525384|NCT05899257|Experimental|Immersive Training using EYME-Explore Your Meanings|Immersive training based on the RGT and EYME to improve the metacognitive abilities and self-knowledge of young people.
89525385|NCT05898633|Experimental|Recombinant fragment of human surfactant protein D (rfhSP-D) administration|"This is a single arm trial with administration of rfhSP-D.~All participants will be administered rfhSP-D via an endotracheal tube in 1-3 doses in the first 24-48hrs after birth whilst the infant is still intubated and ventilated.~A dose escalation design from 1mg/kg to 4mg/kg will be used. Infants are enrolled in cohorts of three, with the first cohort receiving the lowest dose 1mg/kg.~Participants are followed up until they are discharged from hospital."
89525386|NCT05897125|Experimental|TELE-TOC plus Usual Care|Patients randomized to this arm will receive the TELE-TOC intervention as well as the standard COPD care via the institution's COPD readmission reduction program.
89525387|NCT05897125|Active Comparator|Usual Care|Patients randomized to this arm will receive standard COPD care via the institution's COPD readmission reduction program.
89525388|NCT05895279|Experimental|MiCaP Research Digest Video Group|Participants watch MiCaP Research Digest video on study. Participants complete a survey throughout the trial.
89525389|NCT05895279|Active Comparator|Alternate Video Group|Participants watch an alternative video on study. Participants complete a survey throughout the trial.
89525390|NCT05885672||Young Adults|Adults between the ages of 18 and 39 years
89525391|NCT05880953|Experimental|Parent Coaching|"Participants will be involved for about 6 months or until they feel that they no longer need the parent-to-parent support.~Parents will participate in the following contact attempts:~Introductions and rapport building which will include a demographic survey with a needs assessment, and the Family Empowerment Scale (FES)~A series of coaching points which may include some or all of the following topics~Interviewing and selecting a home health agency~Expectation setting for home based nursing care~Tips for finding home health professionals from inpatient nursing~Tips for using personal and professional care networks to find and recruit home health team members~An exit interview assessment including the FES and components of the demographic survey that may have changed"
89525392|NCT05878873|Sham Comparator|Split-belt Treadmill Training without TENS|During this arm, participants will perform split-belt treadmill training with sensory stimulation equipment outfitted but not active during all adaptation sessions.
89525393|NCT05878873|Experimental|Split-belt Treadmill Training with TENS|During this arm, participants will perform split-belt treadmill training with active sensory stimulation occuring simultaneously during all adaptation sessions.
89525394|NCT05877846|Experimental|Participants with Weakness|Participants will take beta-hydroxymethyl butyrate (HMB) with vitamin D3 for 12 weeks. Those participants with vitamin D3 levels > 80 ng/dL will be provided intervention capsules without vitamin D3.
89525395|NCT05876806|Experimental|Dabrafenib + Trametinib|Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
89525396|NCT05868109|Sham Comparator|Participants with Sham (no nitric oxide)|The mechanical ventilator circuit of the study participants are attached to the inhaled nitric oxide delivery device but nitric oxide is not delivered.
89525397|NCT05868109|Experimental|Participants with Nitric Oxide|The mechanical ventilator circuit of the study participants are attached to the inhaled nitric oxide delivery device and nitric oxide is delivered.
89525398|NCT05864326|Experimental|Warm group|The Balloon Catheter will be filled with heated saline water up to 40° C
89525399|NCT05864326|Active Comparator|Room temperature group|the Balloon Catheter will be filled with saline water at room temperature.
89525400|NCT05863910||Epilepsy Cohort|"For children with epilepsy, the following tools will be added for data collection at each time point:~Side effects: Pediatric Epilepsy Side Effects Questionnaire [PESQ]~Seizure frequency/severity: Seizure Diary Data Questionnaire"
89525401|NCT05863910||Cancer Cohort|"For children with cancer, the following tools will be added for data collection at each time point:~Cancer symptom burden: Symptom Screening in Pediatrics Tool [SSPedi]~Cachexia: Pediatric Functional Assessment of Anorexia/ Cachexia Treatment [peds-FAACT]"
89525402|NCT05863910||General Pediatrics Cohort|There are no specific outcome scales added for this cohort.
89525403|NCT05859464|Experimental|ZL-1218|
89525404|NCT05859464|Experimental|ZL-1218 in combination with Pembrolizumab|
89525405|NCT05856838|Experimental|NovaSure ablation|
89525406|NCT05846295|No Intervention|Control|No video tutorial, no feedback
89525407|NCT05846295|Active Comparator|Feedback|Feedback only
89525408|NCT05846295|Active Comparator|Video|Video tutorial only
89525409|NCT05846295|Experimental|Video + Feedback|VIdeo tutorial and feedback
89525410|NCT05843435||Alcohol Use Disorder/AUD|A group of 30 detoxified patients who are part of the specialized residential treatment program at the Clinic Suedhang in Kirchlindach in Switzerland.
89525411|NCT05843435||Healthy Controls/HC|A group of 30 age- and gender-matched healthy control subjects who are recruited via advertisement in social media or local newspaper.
89525412|NCT05834920|Active Comparator|Neurofeedback|
89525413|NCT05834920|Experimental|Transcranial pulse stimulation|
89525414|NCT05834920|No Intervention|Waitlist|
89525415|NCT05829408|Other|Intervention (KOPPeling)|In this arm participants directly receive the KOPPeling intervention.
89525416|NCT05829408|Other|Waiting list|In this arm participants are placed on a waiting list (ten to twelve weeks) before receiving the KOPPeling intervention.
89525417|NCT05821686|Experimental|Intervention Arm|Intralesional IL-2 therapy x 4 weeks between initial consultation and planned surgery
89525418|NCT05814211|Experimental|Investigational device - newly developed intermittent catheter|"Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (CH12 and CH14) for urinary drainage. The investigational device is for single use.~Randomization will decide the order of investigational device/comparator device and which of the two comparator devices the subject will receive in the comparator study period."
89525419|NCT05814211|Active Comparator|Comparator device (#1 OR #2)|"SpeediCath Eve or SpeediCath Compact Plus Female (CH12 and CH14). Both comparators are CE marked Coloplast products.~Randomization will decide the order of investigational device/comparator device and which of the two comparator devices the subject will receive in the comparator study period."
89525420|NCT05812950|Experimental|Group Schema Therapy for eating disorders (GST)|"GST starts with 5 individual sessions for introducing the ST model, placing the ED symptoms and behaviors in the context of coping modes, and organizing these in a mode map conceptualization. Thereafter there are 26 weekly group sessions of ST for EDs, supplemented with 8 optional individual ST sessions, and a psycho-education webinar for relatives. The sessions focus on recognizing and changing personal coping modes and underlying early maladaptive schemas, and developing and strengthening the healthy adult mode. GST combines interpersonal, experiential, cognitive and behavioral elements in a unified ST approach (Farrell et al., 2014). Although not at the core of GST, addressing the physiological aspects of the ED (weight care and (restrictive) eating) is necessary and therefore also incorporated in the protocol.~Note that the participants in this condition have followed phase 1 and 2 of CBT-E before starting the GST, as following these phases is required to be included in the RCT."
89525421|NCT05812950|Active Comparator|Cognitive Behavioral Therapy-Enhanced (CBT-E) (TAU)|This transdiagnostic ED treatment (current standard of care/treatment of choice) consists of 20-40 individual therapy sessions, based on the transdiagnostic CBT model of EDs. CBT-E consists of four phases. In phase one, the patient creates a personal case formulation, and the focus is on psycho-education on maintaining factors and at starting well with monitoring eating behaviours and establishing a regular eating pattern. In phase two, the first phase is evaluated and a treatment plan is made. In phase three, the main mechanisms that are thought to maintain the patient's ED (over-evaluation of shape, weight, and eating, dietary restraint or restriction, being underweight, and event- or mood-triggered changes in eating behaviour), are targeted, and a relapse plan is created. Phase four focuses on evaluating the progress so far and maintaining the changes that have been obtained (Fairburn et al., 2009).
89525422|NCT05812885|Experimental|Active TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
89525423|NCT05812885|Placebo Comparator|Placebo TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramps off.
89525424|NCT05812885|No Intervention|No TENS|Participants will wear a TENS unit that will be turned off to blind the outcome assessor
89525425|NCT05807620|Experimental|Eye Cream|"Eye Cream composed of botanical extracts, bioavailable peptides, THD Ascorbate and Caffeine.~Subjects to apply a dime size amount onto the under-eye area and crow's feet area while avoiding direct eye contact twice daily for the duration of the 12-week clinical study."
89525426|NCT05797974|Experimental|Virtual coach|Participants will utilize the MyChart enabled virtual coach to aid preoperative weight loss.
89525427|NCT05797974|Active Comparator|Standard weight loss tools|Participants will not utilize the MyChart enabled virtual coach to aid preoperative weight loss, but instead use standard weight loss tools.
89525428|NCT05796609|Experimental|Treatment Group|"Driving under the influence of alcohol~Aware of the possible induction of alcohol (purpose of the study), but blinded to the actual amount and target blood alcohol concentration"
89525429|NCT05796609|No Intervention|Reference Group|"Driving without the influence of alcohol or placebo~Fully informed"
89525430|NCT05796609|Placebo Comparator|Placebo Group|"Driving under the influence of a placebo~Not informed (blinded)"
89525431|NCT05794035|Active Comparator|Surgery alone|After inclusion of patient aged ≥ 70 years with performance status OMS 0-3 who had completed surgery (R0) for SCC and BCC with at least one unfavorable prognostic factor, patient will have surgery alone with no hypo fractionation treatment
89525432|NCT05794035|Experimental|Surgery + Moderate hypo fractionation (HF)|Surgery + Moderate hypo fractionation (HF) 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed.
89525433|NCT05794035|Experimental|Surgery + Extreme hypo fractionation (HF)|Surgery + Extreme hypo fractionation (HF): 30Gy in 5 fractions of 6Gy, 1 fraction per week, over 5 weeks to the operative bed.
89525434|NCT05793151|Experimental|ENDURE|ENDURE is a theoretically-informed, navigation-based, multilevel intervention targeting barriers to timely, equitable guideline-adherent PORT.
89525435|NCT05793151|No Intervention|Treatment As Usual|Treatment as usual at each site consists of standard of care clinical practices
89525436|NCT05791864|Experimental|Cohort 1: Main Treatment Arm|2×10^10 GC/eye
89525437|NCT05791864|Experimental|Cohort 2: Main Treatment Arm|6×10^10 GC/eye
89525438|NCT05791864|Experimental|Expansion Cohort: Early Treatment Arm|Dose level to be determined based on Independent Data Monitoring Committee review.
89525439|NCT05791864|Experimental|Expansion Cohort: Main Treatment Arm|Dose level to be determined based on Independent Data Monitoring Committee review.
89525440|NCT05791864|Experimental|Expansion Cohort: Late Treatment Arm|Dose level to be determined based on Independent Data Monitoring Committee review.
89525441|NCT05781607||PE|Patient education combined with drug therapy group
89525442|NCT05781607||PT|Individualized comprehensive physical therapy group
89525443|NCT05778747|Experimental|Intervention|A total of 20 patients with HF and 20 caregivers (n= 40) who have at least mild depressive symptoms (Patient Health Questionnaire 9 [PHQ-9] score = 5) will be randomly assigned to the intervention or usual care group stratified by patient and caregiver groups (Figure 1). Only participants in the intervention will be asked to attend the 12-week sessions (two sessions per week; a total of 24 sessions in 12 weeks) via video conferencing (i.e., ZOOM). The short-term intervention efficacy will be assessed at the following week of the completion of 12-weeks sessions. Primary psychological outcomes include depressive symptoms, anxiety, stress, and quality of life. Primary physical outcomes include physical activity level, sleep quality, and perceived symptoms.
89525444|NCT05778747|No Intervention|Usual Care|Participants in the usual care group will also receive the printed information and links to the AHA's Life's Simple 7 program without explicit skills and training, including education and stress management. We will encourage stress management by watching and practicing yoga programs by providing a yoga mat.
88814463|NCT04361474|Experimental|Experimental group|Nasal irrigation with budesonide and physiological saline (Budesonide 1mg/2mL diluted in 250mL of physiological saline 9°/00): 3 syringes of 20mL in each nasal cavity, morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
89525445|NCT05775549||Retrospective Cohort|Patients with newly diagnosed AOC BRCAwt with known HRD status who have been prescribed 1L olaparib maintenance treatment.
89525446|NCT05772897|Experimental|Circle of Security Parenting (COSP) group|This group of mothers will be assigned to begin the parenting skills intervention (COSP) group soon after enrollment, and data collection (developmental testing, buccal swabs, play-based assessment, questionnaires) will proceed as planned. COSP groups will be conducted remotely via Zoom.
89525447|NCT05772897|No Intervention|Waitlist Control Group|This group of mothers will be assigned to a waitlist control group and will be scheduled to begin the parenting skills group at a later time. In order to serve as a no-intervention control, they will be administered assessments while on the waiting list. These assessments will be given concurrently with mid-point assessment of the intervention group.
89525448|NCT05765058|Placebo Comparator|SDF solution|Subjects will receive one of the available non-operative treatment methods for root caries, namely silver diamine fluoride solution (SDF [38% F-, 38,000 ppm F]) twice yearly applied professionally by a dentist, Placebo Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, [0.32% F-, 1,450 ppm F]) twice daily.
89525449|NCT05765058|Placebo Comparator|NaF Varnish|Subjects will receive one of the available non-operative treatment methods for root caries, namely sodium fluoride varnish (NaF, [5% F-, 22,600 ppm F]) twice yearly applied professionally by a dentist, Placebo Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, [0.32% F-, 1,450 ppm F]) toothpaste twice daily.
89525450|NCT05765058|Experimental|Tooth mousse|Subjects will receive placebo varnish (water-based) twice yearly applied professionally by a dentist, Biosmalto Tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, [0.32% F-, 1,450 ppm F]) toothpaste twice daily.
89525451|NCT05765058|Sham Comparator|Placebo varnish|Subjects will receive placebo varnish (water-based) twice yearly applied professionally by a dentist, Placebo tooth mousse twice daily applied at home by the subject and will perform tooth brushing with regular fluoridated toothpaste (NaF, [0.32% F-, 1,450 ppm F]) toothpaste twice daily.
89525452|NCT05763823|Experimental|Letermovir|Chinese HSCT recipients will receive 240 mg [for participants on Cyclosporin A (CsA)] or 480 mg (for participants not on CsA) Letermovir orally or IV once daily through week 14 (~100 days) post-transplant.
89525453|NCT05761275|Active Comparator|Conventional Abdominal Laparoscopy|Use of conventional transabdominal laparoscopy as the surgical approach to perform the indicated procedure in the included patient with benign adnexal pathology (elective cystectomy/oophorectomy elective salpingectomy or tubal sterilization).
89525454|NCT05761275|Experimental|vNOTES|Use of vNOTES (Transvaginal Natural Orifice Transluminal Endoscopic Surgery) as the surgical approach to perform the indicated procedure in the included patient with benign adnexal pathology (elective cystectomy/oophorectomy elective salpingectomy or tubal sterilization).
89525455|NCT05754840|Experimental|Arm 1. High-CBD arm (MPL-001)|High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD.
89525456|NCT05754840|Experimental|Arm 2. Medium-CBD arm (MPL-005)|Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD.
89525457|NCT05754840|Experimental|Arm 3. Balanced arm (MPL-009)|Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD.
89525458|NCT05754333|Experimental|White Light/near-infrared fluorescence - Adults with normal renal function or mild renal impairment|Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354.
89525459|NCT05754333|Experimental|White Light - Adults with normal renal function or mild renal impairment|Adult participants with normal renal function or mild renal impairment will receive a single dose of ASP5354.
89525460|NCT05754333|Experimental|White Light/near-infrared fluorescence - Adolescents|Adolescent participants will receive a single dose of ASP5354.
89525461|NCT05754333|Experimental|White Light/near-infrared fluorescence - Adults with moderate or severe renal impairment|Adult participants with moderate or severe renal impairment will receive a single dose of ASP5354.
89525462|NCT05750043||Population of selected villages in Maridi county|A total of 2,511 households containing 17,652 individuals were visited in 2018, and 2,254 households containing 14,402 individuals in 2022.
89525463|NCT05748808|Experimental|Tweens and teens|Kids between 10 and 16. ADHD, Asperger or ODD, with lack of aggressiveness control.
89525464|NCT05745194|Experimental|Interventional Group|Interventional group with six nutritional counselling consultations promoting the adherence to the MedDiet and TAU for MDD
89525465|NCT05745194|No Intervention|Control Group|Individuals with TAU for MDD
89525466|NCT05743283|Experimental|SynEx|The experimental arm will receive SynEx Wound Cleanser to cleanse the wound as directed by their healthcare provider.
89525467|NCT05743283|Active Comparator|Saline|The comparator arm will receive Saline Solution to cleanse the wound as directed by their healthcare provider.
89525468|NCT05742009|Experimental|iCare ST500 vs GAT and iCare IC200|Measurement of intraocular pressure (IOP) with iCare ST500 compared to GAT and iCare IC200. Measurements will be performed in three categories: Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (≥23 mmHg).
89525469|NCT05741658|Other|Dapagliflozin|4-week, Daily Oral Use of Dapagliflozin 10mg Tablet in Adults with Fontan Circulation
89525470|NCT05739357|Active Comparator|Cerebral perfusion monitoring|Multimodal monitoring includes cerebral oxygenation (with NIRS) and EEG (with SEDLINE). During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
89525471|NCT05739357|No Intervention|Control|The control arm does not have any monitor of cerebral perfusion and oxygenation, during the carotic clamp only intervention is regulating arterial blood pressure values.
89525472|NCT05738148|Active Comparator|Epinephrine|"Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed[2,3]. Chest compressions and epinephrine will be continued until ROSC."
89525473|NCT05738148|Experimental|Vasopressin|"Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC [2,3] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing."
89525474|NCT05736575||Chronic Pain Patient|A blood draw is to be performed to analyze peripheral BDNF.
89525475|NCT05736575||Asymptomatic subject|A blood draw is to be performed to analyze peripheral BDNF.
89525476|NCT05736172|Experimental|Pain group education|In this group, the education session will be provided in a face-to-face group setting.
89525477|NCT05736172|Active Comparator|Pain material education|In this group the same education session will be provided in written form by means of a leaflet.
89525478|NCT05732649|Experimental|Experiment 1|Participants will take part in three different sessions. In each session, network communication at visual areas will be coupled with the intensity of a sound, of a tactile stimulation, or both.
89525479|NCT05732649|Experimental|Experiment 2 (Group A)|Participants undergo neurofeedback training of network communication between the target brain area (i.e., the left superior parietal area) and the rest of the brain during about 20 minutes (the precise duration will be defined with the experience of Experiment 1), using the sensory feedback modality defined in Experiment 1. Then, they perform the mirror-drawing task.
89525480|NCT05732649|Active Comparator|Experiment 2 (Group B)|Participants will use neurofeedback to train network communication of a control brain area in the other (right) hemisphere which is not directly linked to visuo-motor processing or learning, using otherwise the same duration and feedback setup. This control condition allows to obtain a similar feedback experience and hence a true blinding. Moreover, it enables an evaluation of the spatial specificity of the feedback training. After neurofeedback, they perform the mirror-drawing task.
89525481|NCT05732649|No Intervention|Experiment 2 (Group C)|Participants will not receive neurofeedback, but directly train the mirror-drawing task.
89525482|NCT05730868|Experimental|group 1 myofascial release|soft tissue release technique to release tension from muscles which relieves pain and increase range of motion
89525483|NCT05730868|Experimental|group 2 muscle energy technique|soft tissue release technique to release tension from muscles which relieves pain and increase range of motion
89525484|NCT05730868|Experimental|group 3 MFR & MET|combination of two soft tissue release techniques to release tension from muscles which relieves pain and increase range of motion
89525485|NCT05730868|Experimental|group 4 conventional therapy|combination of traditional techniques to relieve pain and spasm
89525486|NCT05730348||Patients with eating disorders|
89525487|NCT05727592|Experimental|Intervention Group|Intervention: Diabetic Brazilian spinach supplementation group Subjects in this group will be receiving Brazilian spinach for 12 weeks in which they must consume 15g of Brazilian spinach daily with lunch or dinner.
89525488|NCT05727592|Experimental|Control Group|No intervention: Diabetic control group Subjects in this group will not receive Brazilian spinach. However, they will be receiving standard dietary counselling and educated for the same lifestyle intervention as in the intervention group.
89525489|NCT05720793|Experimental|FMT capsule + SIMBA Capsule|adults with OCD who are being treated with an approved first line treatment for OCD medication will be assigned to receive FMT capsules as an adjunct treatment.
89525490|NCT05716204|Experimental|High force lateral distraction group|High force lateral distraction of the hip in maximun adjusted position.
89525491|NCT05716204|Sham Comparator|Placebo distraction group|Placebo lateral distraction of the affected hip in maximun adjusted position.
89525492|NCT05715216|Experimental|Etigilimab plus Nivolumab|Participants will receive the study drugs on Days 1 and 15 of each study cycle,Cycle 1, Participants will receive the drugs on separate days (etigilimab on Day 1 and nivolumab on Day 2). Starting with Cycle 2, you will receive both drugs on Day 1 (separated by 2 hours).
89525493|NCT05712486|Experimental|Lateral distraction group|High force lateral distraction of affected hip.
89525494|NCT05712486|Sham Comparator|Placebo distraction group|Placebo lateral traction of affected hip.
89525495|NCT05710614|Active Comparator|animal protein|Whey protein will be used as the active comparator for animal protein arm
89525496|NCT05710614|Experimental|plant protein|A combination of pea and soy protein will be used as the experimental arm
89525497|NCT05707663||JoHD|Children adolescents and young adults ages 6-30 who have been clinically diagnosed with Juvenile-onset Huntington's Disease
89525498|NCT05703919|Experimental|Titrated Oxygen|"If the treating EMT or paramedic finds indications for inhaled bronchodilators, this will be done with compressed air 6-8 l/min. as the driver for the nebulizer. The patient will have a Bi-nasal EtCO2 (end-tidal carbon dioxide) meter placed under the nebulizer. This will measure the EtCO2 during the treatment and at the same time oxygen can be titrated through this to a target SpO2 of 88-92%. Repeated treatment will be at the discretion of the treating EMT or paramedic according to SOP (standard operating procedures).~Following scenarios regarding SpO2 can occur during treatment:~SpO2 <88%: Supplemental oxygen via the EtCO2-meter up to 10 l/min, if higher oxygen levels are needed oxygen will be used as driver for the nebulizer. If the SpO2 remains under 88% additional oxygen can be added via the EtCO2-meter.~SpO2 88-92%: No intervention.~SpO2 >92%: No intervention.~If repeated treatment is not indicated the patient receives oxygen to SpO2 88-92% according SOP."
89525499|NCT05703919|Active Comparator|Standard Oxygen|"If the treating EMT or paramedic finds indication for inhaled bronchodilators, this will be done with oxygen 6-8 l/min. as the driver for the nebulizer. The patient will have a Bi-nasal EtCO2 meter placed under the nebulizer. This will measure the EtCO2 during the treatment and at the same time mask the patient for group allocation. Repeated treatment will be at the discretion of the treating EMT or paramedic according to SOP.~Following scenarios regarding SpO2 can occur during treatment:~SpO2 <88%: Supplemental oxygen via the EtCO2 -meter up to 10 l/min.~SpO2 88-92%: No intervention.~SpO2 >92%: No intervention.~If repeated treatment is not indicated the patient receives oxygen to SpO2 88-92% according SOP."
89525500|NCT05698277||Cases|Singleton pregnancies affected by congenital heart disease
89525501|NCT05698277||Controls|Singleton healthy pregnancies
89525502|NCT05698095|Experimental|Cohort 1 - 0.5 mg single-dose|A single 0.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
89525503|NCT05698095|Experimental|Cohort 2 - 2.5 mg single-dose|A single 2.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
89525504|NCT05698095|Experimental|Cohort 3 - 4.5 mg single-dose|A single 4.5 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
89525505|NCT05698095|Experimental|Cohort 4 - 7 mg single-dose|A single 7 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
89525506|NCT05698095|Experimental|Cohort 5 - 10 mg single-dose|A single 10 mg 5-MeO-DMT or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
89525507|NCT05698095|Experimental|Cohort 6 - 13 mg single-dose|A single 5-MeO-DMT 13 mg or placebo dose administered intramuscularly (randomized as 5 active and 1 placebo subject).
89525508|NCT05698095|Experimental|Cohort 7 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (2.5 mg followed by 4.5 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
89525509|NCT05698095|Experimental|Cohort 8 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (2.5 mg followed by 7 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
89525510|NCT05698095|Experimental|Cohort 9 - multiple-dose, 3 hour interval|Administration of up to two 5-MeO-DMT (2.5 mg followed by 10.5 mg) or placebo doses administered intramuscularly within a single day with a 3 hour dose interval (randomized as 5 active and 1 placebo subject).
89525511|NCT05691972|Experimental|Treatment|
89525512|NCT05691972|No Intervention|Control|
89525513|NCT05686356|Experimental|Arm 1 (S1200BP)|Sutezolid 1200mg QD plus bedaquiline and pretomanid for 4 months
89525514|NCT05686356|Experimental|Arm 2 (S1600BP)|Sutezolid 1600mg QD plus bedaquiline and pretomanid for 4 months
89525515|NCT05686356|Experimental|Arm 3 (S1600BPN)|Sutezolid 1600mg QD plus bedaquiline pretomanid and N-acetyl cysteine for 4 months
89525516|NCT05686356|Active Comparator|Arm 4 (HRZE)|Rifafour (2HRZE/4HR)
89525517|NCT05678023|Active Comparator|Contrast media 2 hours|Patients will receive contrast media after 2 hours of nasogastric decompression
89525518|NCT05678023|Active Comparator|Contrast media 24 hours|Patients will receive contrast media after 24 hours of nasogastric decompression
89525519|NCT05675722|Experimental|autologous vaginal construct for patients with vaginal aplasia|Biologic vaginal construct, surgically implanted into native vaginal site
89525520|NCT05672875||Healthy and Symptomatic Subjects|Blood sample testing on the Anthrax LF Dx System
89525521|NCT05670379|Experimental|NPM-119|One NPM-119 implant that delivers approximately 52 microgram/day of exenatide for a duration of 12 weeks will be inserted subdermally just under the skin of the upper outer arm.
89525522|NCT05670379|Active Comparator|Bydureon BCise (exenatide extended release)|2 mg subcutaneous injection every week for a duration of 12 weeks
89525523|NCT05668039|Experimental|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP/ECPT) is a non-invasive technique used to improve cardiac and cerebral perfusion. It aims to achieve 'diastolic augmentation' by increasing arterial blood pressure and retrograde aortic blood flow during diastole. This technique is currently used to treat refractory angina and heart failure, and was demonstrated to be well tolerated without limiting side effect. Practially, blood pressure cuffs are put along the lower limbs and are inflated to 300 mmHg pressure intermittently during one hour session. 15 sessions will be performed over 15 weeks.
89525524|NCT05668039|Sham Comparator|Sham procedure|The procedure will be identical to the experimental procedure, excluding the pressure that will reach only 80 mmHg.
89525525|NCT05664880|Experimental|Paricalcitol|Participants receive Paricalcitol 2mcg capsule once daily for 12 months.
89525526|NCT05664880|Placebo Comparator|Placebo|Participants receive Paricalcitol Placebo capsule matching Paricalcitol once daily for 12 months.
89525527|NCT05658510|Experimental|Part 1: 60 mcg of BXCL501|Sublingual film containing 60 Micrograms Dexmedetomidine
89525528|NCT05658510|Placebo Comparator|Part 1: Matching Placebo|Sublingual Placebo film
89525529|NCT05658510|Experimental|Part 2: 80 mcg of BXCL501|Sublingual film containing 80 Micrograms Dexmedetomidine
89525530|NCT05658510|Placebo Comparator|Part 2: Matching Placebo|Sublingual Placebo film
89525531|NCT05655702|Other|community-based TB intervention|
89525532|NCT05633979|Experimental|Group 1|Participants will receive the same drugs at the same schedule, and the same dose of trastuzumab deruxtecan
89525533|NCT05633979|Experimental|Group 2|Participants will only receive 1 dose level of valemetostat.
89525534|NCT05628857|Experimental|Cohort 1|gastric cancer patients
89525535|NCT05628857|Experimental|cohort 2|colorectal cancer patients
89525536|NCT05628857|Experimental|cohort 3|liver cancer patients
89525537|NCT05628857|Experimental|cohort 4|other digestive system malignancies, including esophageal cancer, pancreatic cancer, gallbladder cancer, etc.
89525538|NCT05626920|Placebo Comparator|Placebo|Placebo medication
89525539|NCT05626920|Active Comparator|Disulfiram|Disulfiram medication
89525540|NCT05626595|Experimental|Control|Outdoor play is an essential component of childhood development, including supporting children's cognitive, physical, emotional, and social growth. Currently, the early learning and childcare centres (ELCCs) host children within childcare settings, with outdoor playtime governed by institutional regulations.
89525541|NCT05626595|Sham Comparator|Project|"The PRO-ECO project to increase the quality of outdoor play involves four primary components:~Modifying ELCC's outdoor play policies: the ELCC policy on outdoor play requirements and procedures will be modified in conjunction with ELCC management.~ECE training and mentorship:~ECEs will undergo the Learning Outside Together (LOT) program, which incorporates traditional wisdom into training on Indigenous ways of knowing, learning and experiencing the land as teacher.~ELCC outdoor space modification:~This includes designing and implementing tailored modifications for each centre's outdoor play space developed by landscape architecture students.~Parent engagement:~ELCCs will host parent-engagement events and opportunities to increase knowledge of the importance of outdoor play."
89525542|NCT05622812|Experimental|Treatment group|Initial Restylane Lyft Lidocaine injection and one optional touch-up treatment at 1 month after treatment
89525543|NCT05622812|No Intervention|No-treatment control group|Optional treatment will be administered at 12 months
89525544|NCT05620108|Experimental|Intubation at TOFC=1|Subjects scheduled for an elective surgical procedure will have endotracheal intubation performed when muscles are almost relaxed and monitoring shows only a single count of muscle twitch (in response to a monitor that assesses muscle relaxation)
89525545|NCT05620108|Active Comparator|Intubation 2 minutes after rocuronium administration|Subjects scheduled for an elective surgical procedure will have endotracheal intubation performed 2 minutes after the anesthesia provider gives muscle relaxing medication
89525546|NCT05615779|Placebo Comparator|Randomized pectin diet|
89525547|NCT05615779|Placebo Comparator|Randomized B-fructan diet|
89525548|NCT05615779|Experimental|Personalized pectin diet|
89525549|NCT05615779|Experimental|Personalized B-fructan diet|
89525550|NCT05612659|Experimental|Transcranial Electrical stimulation|Subjects will receive transcranial electrical stimulation.
89525551|NCT05612659|Experimental|Transcutaneous direct current stimulation|Subjects will receive Transcutaneous direct current stimulation
89525552|NCT05608746|Experimental|Intervention Group|
89525553|NCT05608746|Other|Control Group|
89525554|NCT05604326|Experimental|Pathways Intervention|Twenty-four weeks of a manualized Naturalistic Developmental Behavioral Intervention (NDBI) parent-mediated early autism intervention that uses a coaching model.
89525555|NCT05604326|Active Comparator|Parent Education Intervention (PEI)|Twenty-four weeks of individual caregiver training without the child being present.
89525556|NCT05603741|Other|Receiving Local Anesthetic Injection|"Patients meeting the diagnostic criteria (2017) for Ehlers-Danlos Syndrome~Healthy control volunteers who do not meet the criteria for Ehlers-Danlos Syndrome"
89525557|NCT05600829|Experimental|Intervention|Patients participate in a traditional 12-week outpatient CR program with added weekly behavioural weight loss classes.
89525558|NCT05600829|Other|Control|Patients participate in a traditional 12-week outpatient CR program.
89525559|NCT05598814|Experimental|Intervention group - FESS|Biologic treatment with Mepolizumab and functional endoscopic sinus surgery (FESS).
89525560|NCT05598814|Active Comparator|Control group - No-FESS|Biologic treatment with Mepolizumab
89525561|NCT05595811||Inuit|Inuit living in Greenland
89525562|NCT05595811||Danish|Danish patients living in Denmark
89525563|NCT05588440|Experimental|Phase 1: Dose Escalation|Patients will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by ONCT-808 IV infusion escalated sequentially with a target dose consistent with the dose required by cohort being enrolled to determine Phase 2 dose (RP2d) regimen(s). Participants may receive bridging therapy that is appropriate to the subject's disease and treatment history if clinically indicated to maintain disease stability.
89525564|NCT05588440|Experimental|Phase 2: Dose Expansion|Patients with LBCL or MCL will receive ONCT-808 for each RP2D regimen determined in Phase 1.
89525565|NCT05581069|Experimental|STEPS|All participants receive the STEPS intervention
89525566|NCT05580978|Experimental|GEM + CGM + Activity Monitor|GEM plus CGM and Activity Monitor (FitBit)
89525567|NCT05580978|Active Comparator|Routine Care|Usual care already being received for prediabetes as treated by their care team.
89525568|NCT05580588|Experimental|SPH4336|400 mg (2 - 200 mg tablets) PO QD
89525569|NCT05576259|Experimental|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for social anxiety, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
89525570|NCT05576259|No Intervention|Waitlist|Participants in the waitlist condition will be offered the intervention directly after post-test.
89525571|NCT05575089|Active Comparator|Incentive Spirometer - The Control Group|The control group will receive an aerobic exercise in the cycle ergometer that will be conducted on a cycle ergometer divided into three steps: heat 5 minutes; 20 minutes with a confortable speed ( individuallyprescribed) and 5 minutes recovery. They will also perform active respiratory exercises, and incentive spirometer during 10 face-to-face physical therapy sessions. They will be instructed to do exercises with incentive spirometer at home, 3 times a day with 30 to 40 repetitions, during all preoperative period. The patients will receive a diary to note the exercises frequency.
89525572|NCT05575089|Experimental|Inspiratory muscle training - Powerbreath - The intervention group|This intervention group will receive the same control group protocol: aerobic exercise in cycle ergometer, divided into three steps: heat 5 minutes; 20 minutes with a confortable speed ( individually prescribed) and 5 minutes recovery and active respiratory exercises ( deep inspirations associated to raise upper limbs ( 3 times of 10 repetitions each), and, in addition, inspiratory muscle training with Powerbreath during 10 face-to-face physical therapy sessions. They will be instructed to do exercises with Powerbreath at home, 3 times a day with 30 to 40 repetitions, inspiratory load: 60% of MIP ( first evaluation - protocol admission) during all preoperative period. The patients will receive a diary to note the exercises frequency.
89525573|NCT05570578|Active Comparator|HD-tDCS|high-density transcranial direct current stimulation (HD-tDCS) over Broca's area
89525574|NCT05570578|Sham Comparator|sham-tDCS|sham transcranial direct current stimulation. The same setup will be used as in the HD-tDCS arm, except that the current will be ramped up for 30 seconds and then switched off. This does not lead to neural effects, but the patients have a similar sensation.
89525575|NCT05558800|Active Comparator|Xpeed|Implant with Xpeed surface
89525576|NCT05558800|Active Comparator|SLA surface|Implant with SLA surface
89525577|NCT05558800|Placebo Comparator|Machined|Implant with machined surface
89525578|NCT05558800|Active Comparator|XPEEDActive|Implant with plasma treatment reactivated XPEED implant surface
89525579|NCT05557539|Other|all patients|The intervention consists of taking blood samples, urine sample and naso-pharyngeal sample at two different time points (at inclusion and at week8-12).
89525580|NCT05537883|Active Comparator|Bupivacaine only|Active control group patients receive Transversus Abdominis Plane (TAP) block with a Bupivacaine only mixture, containing 50 mL 0.5% Bupivacaine, and 100 mL normal saline solution.
89525581|NCT05537883|Experimental|Liposomal Bupivacaine|Study group patients will receive Transversus Abdominis Plane (TAP) block with a Liposomal Bupivacaine mixture, containing 20 mL Liposomal Bupivacaine, 30 mL 0.5% Bupivacaine, and 100 mL normal saline solution.
89525582|NCT05524181|Experimental|Intervention|Individuals in the intervention group will undergo a series of two telehealth video visits and a series of survey assessments at baseline, 3, 6, 9, and 12 months.
89525583|NCT05524181|No Intervention|Control|Individuals in the control group will continue with their usual standard of care and undergo a series of survey assessments at baseline, 3, 6, 9 and 12 months.
89525584|NCT05521360|Experimental|Experimental|Participants randomized to the experimental group will complete baseline assessments, the 6 week AMT treatment online and then complete the follow up assessment (8 weeks total)
89525585|NCT05521360|No Intervention|Control|Participants randomized to the control group will be matched to the experimental group on demographic and outcome measures. Control participants will take the baseline assessments, will wait 7 weeks and take the follow-up assessment (8 weeks total). Control group participants are able to enrol in the AMT intervention at the end of their wait-list control period.
89525586|NCT05520905|Experimental|Telemedicine for pre-exposure prophylaxis of HIV|"We will identify youth potentially eligibile for PrEP using tenfovir alefenamide/emtricitabine (TAF/FTC).~Eligible youth will be contacted for rapid (same day) consenting and enrollment.~Participants who consent to the study will undergo a PrEP initiation visit either the same day or within two weeks with a provider. The initial visit may be in-person or via Telemedicine.~TelePrEP visits may be carried out in the setting of the participant's choosing and may include home or at a community organization.~Recommended laboratory testing will be arranged as part of the PrEP initiation visit. HIV testing will be carried out as well as Centers for Disease Control and Prevention (CDC)-recommended laboratory testing will be obtained.~TelePrEP(or in-person visits as needed) will be conducted by a skilled multidisciplinary team one month after initiation and then every three months."
89525587|NCT05509517|Experimental|Rhythm monitoring group|Patients randomized to the rhythm monitoring arm will assess their heart rhythm with a photoplethismography (PPG) based smartphone application (FibriCheck™). Measurements are performed three times daily and while experiencing symptoms. The patients start measuring immediately after discharge and continues until the scheduled postoperative consultation with the cardiologist or cardiac surgeon at 21-91days after discharge.
89525588|NCT05509517|No Intervention|Usual care|Patients randomized to the rhythm monitoring arm will be discharged without protocol mandated rhythm monitoring. A postoperative consultation is scheduled with the cardiologist or cardiac surgeon at 21-91days after discharge.
89525589|NCT05505552|Experimental|Vitamin K|Participants receive 1 mg/d phylloquinone orally for 24 weeks
89525590|NCT05505552|Placebo Comparator|Placebo|Participants receive daily placebo matching phylloquinone for 24 weeks
89525591|NCT05495841||Face Mask Alone|40 patients receiving the pre-oxygenation face mask alone method during clinical routine will be studied. As per clinical standard, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes. In case of suspected full stomach, it is recommended to perform a rapid sequence induction and the patient does not receive bag-mask ventilation during the apnea period (45-60s). In the other case, a standard pre-oxygenation will be performed (see figure 1: experimental design of the study).
89525592|NCT05495841||Face Mask and Nasal Cannula|40 patients using the pre-oxygenation combined facemask + HFNO technique as part of routine clinical care will be studied. As to clinical standards, the standard oxygen facemask will be tightly applied on the face of the patient at 100% FiO2 for 3 to 4 minutes and HFNO at 100% with a flow at 40 L/minutes during the pre-oxygenation (the flow can be decreased to less than 40 L/minutes if no tolerance by the patient). Then, after a general anesthesia induction and/or a rapid sequence induction is performed, the patient receives HFNO at 100% FiO2 and the flow of HFNO is increased to up to 80 L/minutes (which corresponds to a close delivered FiO2 at 80%) during the apnea period (1 to 2 min) until correct position of the endotracheal tube is confirmed with capnography.
89525593|NCT05486572|Active Comparator|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
89525594|NCT05486572|Other|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
89525595|NCT05482399|Experimental|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
89525596|NCT05482399|No Intervention|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
89525597|NCT05482386|Experimental|Statin discontinuation|Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
89525598|NCT05482386|No Intervention|Statin continuation|Continuation of statin therapy - no change in the prescribed statin therapy (control arm).
89525599|NCT05471076|Experimental|Bolus Delivery, Group 1: First injection - Medium dose, Final injection - Lower dose|The Bolus Delivery Arm Group 1 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
89525600|NCT05471076|Experimental|Bolus Delivery, Group 2: First injection - Medium dose, Final injection - Higher dose|The Bolus Delivery Arm Group 2 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
89525601|NCT05471076|Placebo Comparator|Bolus Delivery, Group 3: First injection - Placebo, Final injection - Placebo|The Bolus Delivery Arm Group 2 will receive injections at 2 visits scheduled 3 months apart. At each injection visit the patient will get one dose divided into 2 injections - one in the deltoid muscle of each arm.
89525602|NCT05471076|Experimental|Fractionated Delivery, Group 1: First injection - Medium dose, Final injection - Lower dose|The first dose for the Fractionated Delivery Arm Group 1 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
89525603|NCT05471076|Experimental|Fractionated Delivery, Group 2: First injection - Medium dose, Final injection - Higher dose|The first dose for the Fractionated Delivery Arm Group 2 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
89525604|NCT05471076|Placebo Comparator|Fractionated Delivery, Group 3: First injection - Placebo, Final injection - Placebo|The first dose for the Fractionated Delivery Arm Group 2 will be divided into 6 smaller amounts (2 visits per week for 3 weeks). The second dose will be given about 3 months later and will be given all at once. At each injection visit for the first dose, the patient will get one amount divided into 2 injections - one in the deltoid muscle of each arm.
89525605|NCT05470842|Experimental|Continuous glucose monitoring|Continuous Glucose Monitoring Device for up to 10 days
89525606|NCT05458167|Experimental|Device: Hedia Diabetes Assistant with physical activity module.|The participants will take part in a 45-minute moderate-intensity exercise bout on a stationary ergometer bike. Participants will use the Hedia Diabetes Assistant bolus calculator with the physical activity module (intervention) during a 24-hour period starting one hour before the bout of exercise.
89525607|NCT05458167|Active Comparator|Usual treatment|The participants will take part in a 45-minute moderate-intensity exercise bout on a stationary ergometer bike. Participants will use their habitual diabetes management approach during a 24-hour period starting one hour before the bout of exercise (control).
89525608|NCT05457127|Experimental|Automatic Positive Airway Pressure (APAP) device|
89525609|NCT05456594|Placebo Comparator|Conventional bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing their own conventional bra.
89525610|NCT05456594|Active Comparator|Bounceless bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing provided Bounceless bra.
89525611|NCT05456594|Active Comparator|Shefit bra|Measurement of kinematic and kinetic data during physical activities while participant is wearing provided Shefit bra.
89525612|NCT05454280|Active Comparator|Control Arm: Standard Perioperative Management|Patients in the Control Arm will receive standard post-discharge surveillance (i.e., usual care).
89525613|NCT05454280|Experimental|Intervention Arm: Intensified Post-Discharge Surveillance|"Patients in the Intervention and Control Arms will be monitored~Through PDD 30 for postoperative deaths and complications (as defined by ACS NSQIP) and/or adverse events (as defined by CTCAE)~Through the end of the index hospitalization for ICU admission, postoperative LOS, return to operating room, and discharge to home.~Through PDD 90 for hospital readmission, QOL, and receipt of anti-neoplastic therapy"
89525614|NCT05453773|Experimental|Tobacco flavor preparation; High Sweetness, High Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
89525615|NCT05453773|Experimental|Tobacco flavor preparation; High Sweetness, Medium Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
89525616|NCT05453773|Experimental|Tobacco flavor preparation; Medium Sweetness, High Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
89525617|NCT05453773|Experimental|Tobacco flavor preparation; Medium Sweetness, Medium Humectant (tobacco smoking)|Participants smoke 1 of 4 waterpipe tobacco preparations over 45-60 minutes over 4 sessions, separated by at least 1 week. Questionnaires administered.
89525618|NCT05452057|Experimental|Prehabilitation|"This will include an individualized, light to moderate intensity resistance training and aerobic exercise components. Each prescribed session will include: a minute warm-up, aerobic exercise, resistance training, and a cool-down, but may be modified to accommodate the participants exercise ability.~A registered dietitian will provide an individualized nutrition assessment and counselling session within the first week of prehabilitation and again in the week prior to surgery.~A staff psychologist or psychology resident will deliver a ~60-minute psychoeducation session that focuses on stress management via relaxation, mindfulness, goal setting, and strategies to overcoming barriers to practice. In the week prior to surgery, participants will be offered a second consultation with the psychology team member to review their stress management experiences and provide further support for the acute perioperative period."
89525619|NCT05452057|No Intervention|Usual care|Usual care group will be asked to resume your typical lifestyle behaviours until the date of the surgery and will be provided with publicly available resources on physical activity, diet, and stress management.
89525620|NCT05451927|Experimental|Phaseolus Vulgaris|Three oral doses of 1000 mg Phaseolus Vulgaris daily for 3 months
89525621|NCT05451927|Placebo Comparator|Placebo|Three oral doses of Placebo daily for 3 months
89525622|NCT05441215|Experimental|nirmatrelvir/ritonavir|nirmatrelvir/ritonavir will be given by mouth two times a day as a tablet
88807341|NCT05287932|Experimental|Intervention|Brief physical activity intervention including an initial 45-minute physical activity consultation, telephone support after 2 weeks (approx. 15-minute call), and provision of a pedometer, written information, and a physical activity diary. Embedded behaviour change techniques will include goal setting, self-monitoring, building self-efficacy and social support, and overcoming barriers.
89525623|NCT05432648|Experimental|Short Bowel Syndrome Arm|Patients with SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
89525624|NCT05432648|Active Comparator|Control Arm -|Patients without SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
89525625|NCT05425563|Experimental|Cue-established expectations|"Prior to experiencing the stimuli from three tasks (somatic pain/cognitive effort/vicarious pain), the participant is presented with an expectancy cue. The cue depicts 10 data points on a semi-circular scale (0-180 degrees) with categorical labels ranging from no effort to strongest effort of any kind. Subsequently, participants report expectation ratings and outcome ratings."
89525626|NCT05424744|Experimental|Telemedicine Management of Hypertension|using home blood pressure monitoring
89525627|NCT05423652|Experimental|POCUS-PRESUNA|Daily home hospital care will be enhanced by lung POCUS acquired remotely by community paramedics or in-person by physicians, and interpreted by physicians. They will then document their findings on PRESUNA to obtain a longitudinal record that enables monitoring of trends to support clinical decision-making.
89525628|NCT05423652|No Intervention|Standard Care|Standard home hospital care
89525629|NCT05422924|No Intervention|Control Arm|No use of My Viva Plan
89525630|NCT05422924|Experimental|Intervention Arm|Use of My Viva Plan
89525631|NCT05422872||Croatia|Twenty to twenty-five professionals assigned to Croatian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525632|NCT05422872||Estonia|Twenty to twenty-five professionals assigned to Estonian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525633|NCT05422872||Finland|Twenty to twenty-five professionals assigned to Finnish healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525634|NCT05422872||Germany|Twenty to twenty-five professionals assigned to German healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525635|NCT05422872||Israel|Twenty to twenty-five professionals assigned to Israeli healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525636|NCT05422872||Lithuania|Twenty to twenty-five professionals assigned to Lithuanian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525637|NCT05422872||Malta|Twenty to twenty-five professionals assigned to Maltese healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525638|NCT05422872||Portugal|Twenty to twenty-five professionals assigned to Portuguese healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525639|NCT05422872||Slovakia|Twenty to twenty-five professionals assigned to Slovakian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525640|NCT05422872||Spain|Twenty to twenty-five professionals assigned to Spanish healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525641|NCT05422872||Serbia|Twenty to twenty-five professionals assigned to Serbian healthcare institutions (inpatient and outpatient settings, and community, and social care centers) who are responsible for mentoring and supervising residents and students during their clinical internships in the fields of family medicine, obstetrics, midwifery, pharmacy, surgery, and department of medicine.
89525642|NCT05417620|No Intervention|Standard of Care|"Full-time peer educators employed by the TB HIV Care programme to engage women, layer PrEP promotion across prevention programs, and implement refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to increase young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
89525643|NCT05417620|Experimental|Enhanced social media campaign|Social media campaign which will be disseminated on Facebook, Instagram, and WhatsApp with targeted ads/promotion of materials in intervention districts.
89525644|NCT05417620|Experimental|Enhanced social media campaign + PrEP champions|Venue-based peers who will provide PrEP information, share personal experiences with PrEP, and refer young women to TB HIV Care to receive PrEP if interested in addition to the enhanced social media campaign.
89525645|NCT05417620|Experimental|Enhanced social media campaign + Community mobilization|Peers will work within wards to organize and attend community meetings to share PrEP information and facilitate discussions with young women, male partners, family members, and other community members in addition to the enhanced social media campaign.
89525646|NCT05417620|Experimental|Enhanced social media campaign + PrEP champions + Community mobilization|Clusters in this arm will receive both the PrEP champion and community mobilization interventions in addition to the enhanced social media campaign.
89525647|NCT05413122|Experimental|Intensive Behavioral Counselling|Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice. ].
89525648|NCT05413122|Experimental|Peer Support|Participants randomized to receive Peer Support will be engaged by participants' own peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
89525649|NCT05413122|Experimental|c-NRT|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package. Participants will be provided with education on its use, including where and how to place a patch, strength of patches to use and how to taper, not smoking while using the patch, and using gum ad hoc; the investigators will also discuss possible side effects. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and monitor adherence; calls will taper to every other week after four weeks.
89525650|NCT05413122|Experimental|Varenicline|At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician according to randomization into the varenicline condition and participants will be provided with education on its use. Participants will be instructed to begin taking varenicline one week prior to participants' quit date and for 11 weeks following quit date. Participants will be given a number to call should the participants require assistance, and weekly calls will be made to participants to screen for adverse events and to monitor adherence; calls will taper to every other week after four weeks.
89525651|NCT05413122|No Intervention|Control|No intervention
89525652|NCT05413122|Experimental|Varenicline & c-NRT|Varenicline & c-NRT
89525653|NCT05413122|Experimental|Peer Support & Varenicline|Peer Support & Varenicline
89525654|NCT05413122|Experimental|c-NRT & Peer Support|c-NRT & Peer Support
89525655|NCT05413122|Experimental|c-NRT & Peer Support & Varenicline|c-NRT & Peer Support & Varenicline
89525656|NCT05413122|Experimental|Intensive Behavioral Counseling & Varenicline|Intensive Behavioral Counseling & Varenicline
89525657|NCT05413122|Experimental|Intensive Behavioral Counseling & c-NRT|Intensive Behavioral Counseling & c-NRT
89525658|NCT05413122|Experimental|Intensive Behavioral Counseling & Varenicline & c-NRT|Intensive Behavioral Counseling & Varenicline & c-NRT
89525659|NCT05413122|Experimental|Intensive Behavioral Counseling & Peer Support|Intensive Behavioral Counseling & Peer Support
89525660|NCT05413122|Experimental|Intensive Behavioral Counseling & Peer Support & Varenicline|Intensive Behavioral Counseling & Peer Support & Varenicline
89525661|NCT05413122|Experimental|Intensive Behavioral Counseling & Peer Support & c-NRT|Intensive Behavioral Counseling & Peer Support & c-NRT
89525662|NCT05413122|Experimental|Intensive Behavioral Counseling & Peer Support & c-NRT & Varenicline|Intensive Behavioral Counseling & Peer Support & c-NRT & Varenicline
89525663|NCT05412420|Experimental|Patient Self-Reporting of Symptoms|
89525664|NCT05399680|Experimental|Interventional|Treatment with SMART RADIANZ, BRITE TIP RADIANZ and SABERX RADIANZ devices
89525665|NCT05398120|Experimental|Skills Group|There will be one condition which is the group and participants will complete feasibility and outcome measures at baseline (within 1 month), at midpoint (3-4 months after baseline), and at the end of the group (6-7 months after baseline).
89525666|NCT05396924|Active Comparator|Room Group|Room temperature irrigation fluids will be used routinely for Group 1. Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer, whose batteries will be changed every two operations.
89525667|NCT05396924|Active Comparator|Warmed Group|Irrigation fluids heated up to 36-38 degrees will be used for Group 2.Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer, whose batteries will be changed every two operations.
89525668|NCT05379205|Active Comparator|Usual Care/Control Group|Usual care group will follow the usual institutional pre-surgery care..
89525669|NCT05379205|Experimental|Prehabilitation + Postoperative Programs (PPP) Group|PPP group will include 3 complementary modules: (i) supervised physical exercise, (ii) dietary behavior change, and (iii) psychological support.
89525670|NCT05378607|Experimental|Externally assigned sub-goals|"Participants will be eligible for prize drawings every three months based on meeting externally chosen subgoals in year 1 and maintaining 90% or more adherence in Year 2 as measured using a Wisepill device. In addition, there will be a larger prize drawing conditional on showing 90% adherence at the end of year 1 and viral suppression at the end of Year 2.~This arm will receive the intervention 'Incentivization based on gradually increasing externally chosen adherence goals ', 'Annual adherence prize drawing', 'SMS motivational messages + reminder of prize drawing', 'Year 2 re-allocation based on year 1 performance' and the intervention 'End of Year 2 viral suppression prize drawing.'"
89531984|NCT04334525|Experimental|Placemats and frequent diner cards promoting healthier meals|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
89525671|NCT05378607|Experimental|Participatory sub-goals|"Participants will be eligible for prize drawings every three months based on meeting self-chosen subgoals in year 1 and maintaining 90% or more adherence in Year 2 as measured using a Wisepill device. In addition, there will be a larger prize drawing at the end of Years 1 and 2 that is conditional on showing 90% adherence and viral suppression, respectively.~This arm will receive the intervention ' Incentivization based on gradually increasing self-chosen adherence goals ', 'Annual adherence prize drawing', 'SMS motivational messages + reminder of prize drawing', 'Year 2 re-allocation based on year 1 performance' and the intervention 'End of Year 2 viral suppression prize drawing.'"
89525672|NCT05378607|Experimental|Fixed goal|"Participants will be eligible for prize drawings every three months based on meeting a fixed adherence goal of 90% in year 1 and maintaining this adherence level in Year 2 as measured using a Wisepill device. In addition, there will be a larger prize drawing at the end of Years 1 and 2 that is conditional on showing 90% adherence and viral suppression, respectively.~This arm will receive the intervention ' Incentivization based on a fixed adherence goal', 'Annual adherence prize drawing', 'SMS motivational messages + reminder of prize drawing', 'Year 2 re-allocation based on year 1 performance' and the intervention 'End of Year 2 viral suppression prize drawing.'"
89525673|NCT05378607|Placebo Comparator|Control|"This arm will be provided with Mildmay's usual standard of care. Participants will not receive a prize drawing incentive based on adherence, but they will also be asked to use the Wisepill device and receive weekly motivational messages.~This arm will receive the intervention ' SMS motivational messages '"
89525674|NCT05373966||Delphi Panel|A team of experts in the field of robotic RNU will be invited to participate in the current survey. These experts are identified according to surgical experience, research and academic interest, expertise in running training courses, and participation in live-surgery cases.
89525675|NCT05371002|Experimental|Online group nonviolent communication (NVC) interventions|"Rosenberg's Nonviolent Communication: A Language of Life: Life-changing Tools for Healthy Relationships and Raising Children Compassionately: Parenting the Nonviolent Communication Way will be used as reference guides. Six 1.5-hour weekly online group sessions (10-14 participants in each group) will be delivered by NVC professionals to the intervention group, including (1) introduction to four key principles of NVC, communication that blocks compassion, and distinguishing observations from evaluations, (2) identifying and expressing feelings, providing a list of words to express feelings and four steps to express anger, (3) taking responsibility for feelings (needs), distinguishing between an outside event and the met or unmet needs behind the feelings, (4) using positive action language to make requests, (5) review and summary, and (6) experience sharing and suggestions for further practice. Group discussion will be used to sustain the participants' engagement."
89525676|NCT05371002|Active Comparator|Waitlist control group|The participants in WL group will not be provided any materials or training content between baseline (T1) and immediate post assessment (T2). Once the participants completed the T2 assessments, they will be delivered one 1.5-hour online session about physical activity (completely different from NVC training content). In the session, the participants will be introduced the concept of Zero-time exercise and provided video demonstrations of exercise. Six 1.5-hour weekly NVC training sessions (the same as those in intervention group) will be delivered to participants as soon as they have completed the final assessment at T3 (three months after T2).
89525677|NCT05357794|Experimental|Brentuximab vedotin|Participant will receive radiation therapy to the entire skin surface over the course of 2 days. Each dose will take about 60 to 90 minutes and will vary from one patient to another
89525678|NCT05356910|Experimental|OPPEN Intervention|OPPEN consists of three small-group and two one-on-one sessions to train YMSM of color engaged in HIV or PrEP care to be peer PrEP educators within their social networks.
89525679|NCT05356910|Other|Control Condition|The time- and attention-matched control condition consists of three small-group and two one-on-one sessions to support diet and nutrition behavior change.
89525680|NCT05350514||T1D|Young adults with youth-onset type 1 diabetes (n=5) from the SEARCH for Diabetes in Youth study cohort
89525681|NCT05350514||T2D|Young adults with youth-onset type 2 diabetes (n=5) from the SEARCH for Diabetes in Youth study cohort
89525682|NCT05350514||NDM|Age-similar group of young adults without diabetes (n=5)
89525683|NCT05349630|Placebo Comparator|Healthy individuals - pre-iron|"Five healthy participants will be enrolled. Baseline echocardiography and exercise data prior to oral iron supplementation will be obtained as part of the parent study to this study (NCT05272514)."
89525684|NCT05349630|Active Comparator|Healthy individuals - post-iron|The same five healthy participants will complete echocardiography and exercise testing after taking 30 days of oral iron supplementation.
89525685|NCT05345002|Experimental|Arm A (failed prior TMZ + one other alkylating chemotherapy)|Subjects in Arm A are alkylator-refractory and at high risk for progression of disease, have failed temozolmide and another alkylating agent. Subjects in Arm A will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1 through 14 and retifanlimab 500mg IV on day 1.
89525686|NCT05345002|Experimental|Arm B (failed only one prior alkylating chemotherapy)|Subject in Arm B are patients who have failed only one prior alkylating chemotherapy regimen and have gone at least 12 months since the last treatment. Subjects in Arm B will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1 through 14 and retifanlimab 500mg IV on day 1.
89525687|NCT05345002|Experimental|Arm C (surgical arm, ATRA alone pre-operatively)|Subject in Arm C will receive ATRA 45mg/m2/day orally in two equally divided doses for 14 days pre-surgery, then undergo surgery. Following surgery all patients will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1-14 and retifanlimab 500mg IV on day 1.
89525688|NCT05345002|Experimental|Arm D (surgical arm, ATRA + retifanlimab pre-operatively)|Subject in Arm D will receive the combination of ATRA 45mg/m2/day orally in two equally divided doses for 14 days pre-surgery plus a 500mg IV dose of retifanlimab 14 days prior to the date of surgery. Following surgery all patients will receive 28-day cycles of treatment, with ATRA 45mg/m2/day given orally in two equally divided doses on days 1-14 and retifanlimab 500mg IV on day 1.
89525689|NCT05340322|Experimental|HPV+ Pap smear|Visualization of cervix and if abnormalities are present treat with SOC thermocoagulation.
89525690|NCT05337033|Experimental|Cannabidiol-enriched Cannabis Herbal Extract|CBD50 plus
89525691|NCT05335850|Experimental|Intervention Group|Breathing and Wellness Webinar: a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga).
89525692|NCT05335850|Active Comparator|Waitlisted Control Group|This group will be asked to wait for 6 weeks before being introduced to the Breathing and Wellness Webinar intervention which includes a Yogic Breathing practice (Nadi Shuddhi) and two guided meditations (Isha Kriya and Nada Yoga).
89525693|NCT05333029|Experimental|MSCs + ECP|"The treatment period consists of a single, 28-day cycle. Participants will be treated with ECP 2 to 3 times per week per the discretion of the treating physician. Participants will receive IV infusions of MSCs on days 1 (+ 2 days) and 8 (+/- 2 days). A third dose may be given on day 15 (+/- 2 days) if the principal investigator (PI) and treating physician determine the MSC infusions have benefited the participant.~Participants will be followed for up to 1 year for assessment of endpoints."
89525694|NCT05330572||Oral lichen planus|No interventions were administered to this group of patients as a part of the study.
89525695|NCT05330572||Oro-vulvovaginal lichen planus|No interventions were administered to this group of patients as a part of the study.
89525696|NCT05330481||<70 kg body mass|Cyclists or triathletes with a body mass of less than 70 kg
89525697|NCT05330481||>70 kg body mass|Cyclists or triathletes with a body mass of less than 70 kg
89525698|NCT05329077|Other|Home Ultrasound users|Single Arm home ultrasound in pregnant women users
89525699|NCT05326347|Experimental|Rollover subjects|For rollover subjects, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation at 24 mg. From Week 1 onward, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 51 weeks.
89525700|NCT05326347|Experimental|New subjects|In medication switching period, treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation 24 mg, and the dose of the other antipsychotics will be gradually reduced, finally switching to monotherapy with 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) by Week 4. In treatment period, 2 tablets of brexpiprazole QW formulation 24 mg (48 mg/week) will be orally administered for 52 weeks.
89525701|NCT05325645|Experimental|Brexpiprazole QW 48mg|Brexpiprazole QW 48mg, tablet, once weekly, for seven weeks(Initial dose Brexpiprazole QW 24mg)
89525702|NCT05325645|Placebo Comparator|Placebo|
89525703|NCT05316766|Experimental|Intervention|Will receive intervention through the multi-user touch surface
89525704|NCT05316766|Active Comparator|Treatment as usual|This will receive conventional therapy
89525705|NCT05315960||Qualitative study|Consenting participants will complete a form asking about basic characteristics including age, sex, ethnicity, marital status etc. People living in long-term care and family carers will participate in an individual interview and professional staff will participate in an individual interview or focus group (between 5 and 10 participants) depending on their preference. The interview or focus group is expected to last 30-60 minutes. Sessions will be conducted in-person or online (using MS Teams), depending on preference and COVID-19-related restrictions. All sessions will be audio-recorded and transcribed.
89525706|NCT05315960||Cross-sectional study|"Procedures:~Consent will be obtained from residents, for those who have mental capacity to give informed consent, or from a nearest relative or caregiver as consultee, for those who lack capacity. Once consent is obtained, the LTC resident will be asked to complete a form asking about their characteristics and a questionnaire about their social connections which is expected to take approximately 15 minutes. The proxy will be asked to complete a sociodemographic form about themselves along with a number of questionnaires regarding the LTC resident's dementia severity, neuropsychiatric symptoms, activities of daily living and quality of life for comparison. Data collection for the proxy is expected to take approximately 30-60 minutes. Anticipated sample size 150 between Canada and the UK."
89525707|NCT05314647|Experimental|Lutein|5 mg lutein gummy taken daily for 180 days
89525708|NCT05314647|Placebo Comparator|Placebo|0 mg lutein gummy taken daily for 180 days
89525709|NCT05310812||Control group (Sepsis - no acute kindey injury)|"Septic patients diagnosed by sepsis criteria but no have an acute kidney injury. (According ot KDIGO classification - creatinin values).~Blood plasma will be taken for biochemical evaluation."
89525710|NCT05310812||Study group (Sepsis induced acute kidney injury)|"Septic patients diagnosed by sepsis criteria, and have an acute kidney injury. (According ot KDIGO classification - creatinin values).~Blood plasma will be taken for biochemical evaluation."
89525711|NCT05308719|No Intervention|Standard Oxygen Therapy|Standard oxygen therapy arm patients will be given 30-40% inspired O2 and flow 2-6 l/min via nasal prongs or non-rebreathing mask (not humidified and not heated) post extubation. Monitoring of saturations, respiratory rate and arterial gases will happen 15 minutes post extubation and then as per local policy thereafter. If saturations < 93% then FiO2 will be increased as per respiratory escalation protocol. Standard oxygen therapy will be given for a minimum of 16 hours post extubation.
89525712|NCT05308719|Other|High-Flow Nasal Therapy|High-flow nasal therapy arm patients will be given AIVRO 2 high flow oxygen therapy machines post extubation, start at 30-40% inspired O2 and flow 30 l/min then up to 50 l/min over 5-10 min. Monitoring of saturations, respiratory rate and arterial gases will happen after 15 minutes post extubation and then as per local policy thereafter. If saturations < 93% then increase FiO2 as per respiratory escalation protocol. High flow nasal therapy will be given for a minimum of 16 hours post extubation.
89525713|NCT05294679|Placebo Comparator|Propofol group|"The initial dose of propofol was 2mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score =0), the colonoscopy will commence. If subjects' MOAA/S score ≥ 1 point, additional administration of cyclopofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was 0 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after colonoscopy: In order to maintain a certain degree of sedation after colonoscopy (MOAA/S score ≤1 point), the evaluator decides when to administer additional drugs.~Additional administration of propofol: The additional dose was 0.5mg/kg/ time, and intravenous bolus was administered."
89531985|NCT04309006|Experimental|CTG and customized healing abutment|Customized healing abutment used with connective tissue graft
89531986|NCT04309006|Experimental|CTG and conventional healing abutment|Conventional healing abutment (same diameter of the implant) used with connective tissue graft
89531987|NCT04309006|Active Comparator|customized healing abutment|Customized healing abutment used without connective tissue graft
89525714|NCT05294679|Experimental|Ciprofol ground|"The initial dose of ciprofol was 0.4mg/kg, and the intravenous infusion time was 30s. Within 1 minute (inclusive) of the end of the initial dose: if the subject has achieved sufficient sedation (MOAA/S score =0), the colonoscopy will begin; If subjects' MOAA/S score ≥ 1 point, additional administration of ciprofol will be allowed 1 minute after the end of the initial dose. If the MOAA/S score was 0 after 3 consecutive times of addition, sedation failure was determined, and the study was recorded and quit. The drug was given according to clinical needs and the examination was completed. Maintenance of sedation after colonoscopy: In order to maintain a certain degree of sedation after colonoscopy (MOAA/S score ≤1 point), the evaluator decides when to administer additional drugs.~Ciprofol supplemental administration: the supplemental dose was 0.1mg/kg/ time, and intravenous bolus was administered."
89525715|NCT05293340|Experimental|Hispanic/Latino adults with or at risk of T2D- Active Group|Eligible participants receive vouchers for free avocados.
89525716|NCT05293340|No Intervention|Hispanic/Latino adults with or at risk of T2D- Control Group|Eligible participants will not receive vouchers for free avocados.
89525717|NCT05291143|Experimental|Intervention arm|This arm will get the educational video intervention
89525718|NCT05290389||Physicians|All Emergency Medicine physicians and Interventional Cardiologists involved in STEMI care in the Hamilton Niagara Haldimand Brant Local Health area will be eligible for participation in this study.
89525719|NCT05284513|Other|Phase 1|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
89525720|NCT05284513|Other|Phase 2|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
89525721|NCT05284513|Other|Phase 3|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
89525722|NCT05284513|Other|Phase 4|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
89525723|NCT05284513|Other|Phase 5|Phased rollout to clinic sites across the the Geisinger system using stepped wedge design
89525724|NCT05269615|Active Comparator|Valsartan tablets|
89525725|NCT05269615|Placebo Comparator|Placebo tablets|
89525726|NCT05269134|Experimental|DAIR + Phage Treatment + Antibiotics|Phage therapy will be administered in conjunction with antibiotic treatment.
89525727|NCT05269134|Placebo Comparator|DAIR + Placebo + Antibiotics|Placebo will be administered in conjunction with antibiotic treatment.
89525728|NCT05247229|Experimental|Middle school education program|"The education intervention centers around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices, including those for shellfish.~The education program is divided into three units, following other tribal education programs. Primary data collection will be conducted by unit to assess student learning for each unit. The first unit will cover an introduction to shellfish, harmful algal blooms (HAB), and paralytic shellfish poisoning (PSP). The second unit will cover herring and how herring relates to Tlingit culture. The third unit will focus on intertidal zones as zones relate to Tlingit culture."
89525729|NCT05243875|Experimental|Navigation|COVID education for people with lupus and tailored guidance in vaccination and testing for COVID and making appointments.
89525730|NCT05243875|Active Comparator|Education|COVID education for people with lupus.
89525731|NCT05242263|Experimental|Training group - ACT with feedback|At the beginning of each session participants will complete 45 standard dot-probe trials. During these trials, participants' ABV will be measured and set as their baseline. In the following trials, participants will receive feedback: a green screen background when their ABV will reach below their baseline or a red screen background when their baseline ABV score is surpassed.
89525732|NCT05242263|Sham Comparator|Control group - ABV with yoked sham feedback|Participants in this group will receive sham feedback that is unrelated to their ABV during the task, this is by presenting a feedback given to another participant in the training group (i.e., yoked sham feedback).
89525733|NCT05237973||Neuromuscular disorders|Diagnosed with a neuromuscular disorder such as motor neuron disorder, myopathy or have findings consistent with a peripheral neuropathy.
89525734|NCT05237973||Normal volunteers|No known abnormal muscle or nerve disorders
89525735|NCT05221905|Active Comparator|Acute High-Intensity Exercise|Subjects will exercise at an intensity of 75% of the difference between the lactate threshold and VO2peak until 200 kcal are expended. Pre- and post-testing measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, with exercise taking place during time points 0-60 min.
89525736|NCT05221905|Active Comparator|Acute Moderate-Intensity Exercise|Subjects will exercise at an intensity at the lactate threshold until 200 kcal are expended. Pre- and post-testing measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, with exercise taking place during time points 0-60 min.
89525737|NCT05221905|Placebo Comparator|Non-Exercise Control|Measures of vascular health will be completed at baseline (0 min) and again 60, 90, 120, 150, 180 min post-baseline testing, without exercise taking place during time points 0-60 min.
89525738|NCT05212792||Case with COVID-19 vaccine adverse event|Patients with GBS, VITT/TTS, or myocarditis/pericarditis after COVID-19 vaccination
89525739|NCT05212792||Control without COVID-19 vaccine adverse event|Participants without experiencing GBS, VITT/TTS, or myocarditis/pericarditis after COVID-19 vaccination
89525740|NCT05210075|Experimental|A wait list controlled|A wait list controlled
89525741|NCT05200728|Experimental|SIM1910-09|"This trial includes of 2 parts, Part A-single ascending doses and Part B- multiple ascending doses.~Part A, there are 4 dose cohorts and each cohort will enroll 6 subjects to receive SIM1910-09.~Part B, there are 4 dose cohorts and each cohort will enroll 6 subjects to receive SIM1910-09.~The dose ascending will be determined by independent third party clinical physician. The next higher dose cohort could be initiated only if the stopping rules is not met."
89525742|NCT05200728|Placebo Comparator|Placebo|"This trial Includes of 2 parts, Part A-single ascending dose and Part B- multiple ascending dose.~Part A, there are 4 dose cohorts and each cohort will enroll 2 subjects to receive placebo.~Part B, there are 4 dose cohorts and each cohort will enroll 2 subjects to receive placebo.~The dose ascending will be determined by independent third party clinical physician. The next higher dose cohort could be initiated only if the stopping rules is not met."
89531988|NCT04309006|Active Comparator|conventional healing abutment|Conventional healing abutment (same diameter of the implant) without connective tissue graft
89525743|NCT05180968|Experimental|Nabilone 0.5mg|Subjects will receive nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks (over-encapsulated). Drug will be dispensed from a central site to other sites and pharmacy personnel will dispense the study medications directly to research personnel or participants. Drug dispensation will coincide with study visits at randomization and crossover and will allow research personnel to reinforced adherence. The study oral medications may be taken at any time of day with food or water, but we will request that participants take it at the same time each day, preferably at night when uremic pruritus symptoms are usually at the worst. If participants have any side effects or intolerability to study drugs, they may decrease the frequency of nabilone or placebo to 1 capsule by mouth once daily, preferably taken at night.
89525744|NCT05180968|Placebo Comparator|Oral placebo|Subjects will receive placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks (over-encapsulated). Drug will be dispensed from a central site to other sites and pharmacy personnel will dispense the study medications directly to research personnel or participants. Drug dispensation will coincide with study visits at randomization and crossover and will allow research personnel to reinforced adherence. The study oral medications may be taken at any time of day with food or water, but we will request that participants take it at the same time each day, preferably at night when uremic pruritus symptoms are usually at the worst. If participants have any side effects or intolerability to study drugs, they may decrease the frequency of nabilone or placebo to 1 capsule by mouth once daily, preferably taken at night.
89525745|NCT05180760|Active Comparator|Smartphone app arm|Use the dedicated smartphone app for NAFLD patients
89525746|NCT05180760|Other|Standard of care|Standard of care
89525747|NCT05176756|Active Comparator|Attention Control|In addition to using a wearable device, participants in this arm will receive a daily notification of their step count from the previous day. This notification serves as an 'attention control' and allows us to better isolate the impact of the gamification with social support. It may also help to reduce differential attrition across arms.
89525748|NCT05176756|Experimental|Gamification and Social Support|Participants in this arm will receive the same devices and daily messaging as control. They will also be entered into a game designed using behavioral economic principles for 6 months. This intervention has been adapted from our prior successful pilot studies. The game runs automatically and does not require any effort on the part of the participant to 'play' the game other than to strive for physical activity goals. Participants in this arm will also select a family member or friend who will serve as a support partner to encourage the participant to meet their step goals. The gamification and social support interventions will end after 6 months at which point participants will receive the same treatment as the attention control arm for the 3-month follow-up period.
89525749|NCT05161676|Experimental|Ketone monoester (3-OHB)|
89525750|NCT05161676|Experimental|Placebo Treatment|
89525751|NCT05161650|Experimental|Ketone monoester (3-OHB)|
89525752|NCT05161650|Experimental|Isocaloric placebo|
89525753|NCT05145062||BIVV003 Cohort|All participants treated in parent and future studies with BIVV003
89525754|NCT05145062||ST-400 Cohort|All participants treated in parent studies with ST-400
89525755|NCT05135494|Experimental|Experimental Group|Experimental Group: Inspiratory Muscle Training + rehabilitation program
89525756|NCT05135494|Other|Control Group|Control Group: rehabilitation program
89525757|NCT05130619|Experimental|Treatment order A-.B-C-D|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
89525758|NCT05130619|Experimental|Treatment order B-D-A-C|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
89525759|NCT05130619|Experimental|Treatment order C-A-D-B|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
89525760|NCT05130619|Experimental|Treatment order D-C-B-A|A: 5g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice B:10g ethanol-2-D3 mixed into 250ml water with added aromas of gin and lime juice C: 8g Triacetin mixed into 250ml water with added aromas of gin and lime juice D: 250ml water with added aromas of gin and lime juice
89525761|NCT05130268|Experimental|Dronedarone|In most patients, the investigators anticipate usual care to include an atrioventricular nodal blocking agent (beta-blocker, non-dihydropyridine calcium channel blocker, or digoxin) without an antiarrhythmic. As dronedarone has anti-adrenergic rate controlling properties, a low dose of beta-blocker or calcium-channel blocker is recommended in the United States Prescribing Information (USPI) when starting dronedarone. In the dronedarone arm concomitant digoxin use will be contraindicated due to P-gp interaction based upon data from the PALLAS trial. All patients will receive oral anticoagulation for stroke prevention according to current guideline recommendations.
89525762|NCT05130268|No Intervention|Usual care|In most patients, the investigators anticipate usual care to include an atrioventricular nodal blocking agent (beta-blocker, non-dihydropyridine calcium channel blocker, or digoxin) without an antiarrhythmic. All patients will receive oral anticoagulation for stroke prevention according to current guideline recommendations.
89525763|NCT05129540|Experimental|Custom-made foot orthoses group|Custom-made foot orthoses will be applied to participants in this arm. The orthoses will consist on a 3-mm thick polypropylene layer from heel to just proximal to the metatarsal heads, and a cover layer of polyethylene foam from heel to toe tips. Both materials will be adapted to the foot positive casts that will be obtained from all participants.
89525764|NCT05129540|Placebo Comparator|Placebo group|The placebo orthoses will consist on a 3-mm thick polyethylene foam layer from heel to toe tips and a 0.8-mm thick resin layer from heel to just proximal to the metatarsal heads. None of the materials will be adapted to the foot positive casts.
89525765|NCT05119335|Experimental|Phase 1 dose escalation|Phase 1 is designed to determine the maximum tolerated dose and/or identify the recommended Phase 2 dose of NKT2152 as a single agent administered orally once daily in ccRCC patients
89525766|NCT05119335|Experimental|Phase 2 dose expansion|Phase 2 dose expansion will evaluate the safety, pharmacokinetics and antitumor efficacy of NKT2152 as a single agent administered orally once daily in ccRCC patients. Patients will be randomized to one of two dosage levels being evaluated.
89525767|NCT05102747|Experimental|Hypofractionated SRT (stereotactic radiotherapy)|
89525768|NCT05102747|Active Comparator|Historical single-dose SRS (stereotactic radiosurgery)|
89525769|NCT05097963|Experimental|Subjects undergoing EUS shear wave elastography|Subject who are eligible will undergo EUS for clinical indications. EUS shear wave measurements will be gathered and studied to determine diagnostic accuracy when compared to MR Elastography.
89525770|NCT05094570|Experimental|Dupilumab treatment|Treatment with dupilumab to demonstrate decreased staph prevalence and improve microbial diversity
89525771|NCT05093348|Active Comparator|Click2Print digital Artificial Eye|Supply and fit a digitally designed and manufactured ocular prosthesis for four months in comparison to the current hand-made ocular prosthesis in a cross over trial
89525772|NCT05093348|Active Comparator|Current hand made artificial eye|Wear the hand-made artificial eye for four months and compare to the digitally design ed and manufactured artificial eye
89525773|NCT05086055||Stroke patients|Stroke patients admitted to the stroke unit, St Olav´s hospital, Trondheim, Norway, without previous stroke, neurological disease or central nervous system (CNS) trauma, will be eligible for inclusion into the study. The planned cohort size is 135 patients.
89525774|NCT05086055||healthy volunteers|Age and gender matched controls without previous CNS disease or trauma are eligible for inclusion into the study. Estimated cohort size is 45 individuals. Volunteers will be recruited through announcement in local newspaper.
89525775|NCT05082883||Cognitively Normal|No cognitive impairment, medically stable
89525776|NCT05082883||Mild Cognitive Impairment|Meets NIA-AA criteria for MCI
89525777|NCT05082883||Mild Dementia|Meets NIA-AA criteria for dementia
89525778|NCT05082285|Experimental|ABCWY-2Gen low dose Group|Participants receive 3 doses of the MenABCWY-2Gen low dose vaccine.
89525779|NCT05082285|Active Comparator|MenB+MenACWY-TT Group|Participants receive 3 doses of both the meningococcal group B (MenB) vaccine and the meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine.
89525780|NCT05082285|Experimental|ABCWY-2Gen high dose Group|Participants receive 3 doses of the MenABCWY-2Gen high dose vaccine in.
89525781|NCT05082285|Experimental|ABCWY-1Gen Group|Participants receive 3 doses of the MenABCWY-1Gen vaccine.
89525782|NCT05078021||Normal control|Healthy, non-asthmatic control subjects
89525783|NCT05078021||Mild asthma|Requiring low dose inhaled corticosteroid (ICS) plus as needed short acting beta-agonist (SABA) or as needed ICS-Formoterol.
89525784|NCT05078021||Moderate asthma|Low dose ICS-Long acting beta-agonist (LABA) maintenance + ICS-LABA reliever or SABA reliever
89525785|NCT05078021||Severe asthma|Medium to high dose ICS-LABA maintenance + as needed SABA or ICS-formoterol
89525786|NCT05075135|Experimental|3D-splint group|Patients wear the Swibrace 3D splint for 6 weeks of immobilization of the wrist for distal radius fractures, including the basis of the thumb for scaphoid fractures. X-rays after week 1, 3 and 6 are planned to document bone healing, together with weekly visits at the hand therapy unit to measure patient satisfaction and hand function. This results in 2-3 surgeon and 6 hand therapy visits at the Inselspital Bern, where regular check-ups on the patient's comfort in the splint are made.
89525787|NCT05075135|Active Comparator|Plaster cast group|"The control intervention is the same as the study intervention, but the participants wear the gold-standard plaster cast instead of the newly designed Swibrace 3D-splint."
89525788|NCT05061446|Experimental|Etrasimod Dose 1|
89525789|NCT05061446|Experimental|Etrasimod Dose 2|
89525790|NCT05061446|Placebo Comparator|Placebo|
89525791|NCT05055323|Experimental|Treatment (pyrvinium pamoate)|Patients receive pyrvinium pamoate PO QD for 3 days in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
89525792|NCT05055115|Experimental|Balloon Eustachian Tuboplasty|Patients with long-lasting symptoms of ETD, who benefits from tympanostomy tube insertion, will be offered Balloon Eustachian Tuboplasty (BET) of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
89525793|NCT05051098||TherVacB Subgroup|"No interventions. The participating study centers of the EU funded project TherVacB recruit patients with stricter inclusion- and exclusion criteria, hence forming a sub-cohort."
88814464|NCT04361474|Placebo Comparator|Control group|Nasal irrigation with physiological saline 9°/00 only: 3 syringes of 20cc in each nasal cavity, morning and evening, for 30 days, in addition to olfactory re-education twice a day.
89525794|NCT05049655||Cohort 1|Babies who were fed commercial formula, study formula, or were fed with human milk in the SS-101-18 study that consented to the BH-10118-02 study
89525795|NCT05049655||Cohort 2|Babies fed with commercial formula (including ByHeart formula) or fed with human milk
89525796|NCT05037175|Experimental|CPT-Text + Incentive|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.~Retention Incentive (RI). Participants will be told at baseline that they can earn discounts for other users with PTSD if they message with their therapist regularly."
89525797|NCT05037175|Experimental|CPT-Text + Reminder As Usual|"CPT-Text. CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma.~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
89525798|NCT05037175|Active Comparator|Culturally Informed Trauma Treatment (CITT) + Incentive|"CITT will be conducted by Talkspace therapists with a specialty in PTSD culturally informed PTSD treatment.~Retention Incentivefor other users with PTSD in subsequent months if they message with their therapist regularly."
89525799|NCT05037175|Active Comparator|CITT+ Reminder as Usual|"CITT will be conducted by Talkspace therapists with a specialty in culturally informed PTSD treatment.~Reminder as Usual (RAU). As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage."
89525800|NCT05036681|Experimental|futibatini|
89525801|NCT05036681|Experimental|pembrolizumab|
89525802|NCT05036239|Experimental|Exercised|One bout of 50 eccentric biceps curls
89525803|NCT05036239|No Intervention|Control|No eccentric biceps curls
89525804|NCT05028179|No Intervention|Standard Care (comparator)|Patients will receive standard care
89525805|NCT05028179|Experimental|Standard Care plus AI platform (EchoGo)|Patients will receive standard care plus their Echocardiogram will be sent to Ultromics for AI assessment. The report from the assessment will be sent to the clinician, and utilised to inform the patients further care.
89525806|NCT05019495|No Intervention|Treatment as Usual|Treatment as Usual (TAU) participants will follow traditional clinic pathways for receiving tobacco treatment in the Medical University of South Carolina Health Infectious Disease outpatient clinic. All patients randomized to TAU will have the opportunity to access smoking cessation pharmacotherapy from the Infectious Disease clinical pharmacist.
89525807|NCT05019495|Experimental|ProMOTE|In the PrOMOTE group, the participants will be contacted by the clinical pharmacist on the tobacco treatment staff three times for medication prescriptions and refills. They will also receive brief counseling and motivational interviewing by the clinical pharmacist.
89525808|NCT05008705|Experimental|Intervention|Patients allocated to this arm will be submitted to intervention (protein supplementation plus neuromuscular electrostimulation).
89525809|NCT05008705|Placebo Comparator|Placebo|Patients allocated to this arm will be submitted to a placebo intervention (isocaloric supplement plus sham for neuromuscular electrostimulation).
89525810|NCT05008211|Experimental|Intervention|"There will be a respiratory team, same as the usual care, responsible for patients requiring domiciliary NIV in the intervention group.~The IMB model-based intervention of this study is a six-week program consisted of a one-hour face-to-face home visit in the first week, two 20-minute telephone follow-ups in the second and fourth weeks, and a half-hour face-to-face follow-up at hospital in the sixth week, and a telephone consultation hotline during office hours.~There are three major components including information, motivation and behavioral skill interventions as proposed by the IMB model and will be deliberately arranged in the different sessions."
89525811|NCT05008211|Placebo Comparator|Control - usual care|There is a respiratory team of health care professionals responsible for patients requiring domiciliary NIV. The team is led by a Medical Consultant and with respiratory nurse(s) as team members who are responsible for assisting patients or their family to initiate domiciliary NIV and teaching the relevant technical skills. The nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems such as leakage and pressure sore in hospital before discharge. Commercial leaflet or booklet according to the choice of ventilator with information of the ventilator, interface, accessories and the ventilator company will be provided to the patient.
89525812|NCT05004519|Experimental|Opioid free anesthesia|"Dexmedetomidine 0,5 microgrammes/kg of ideal body weight (IBW) + magnesium 40 mg/kg of total body weight (TBW) in 10 minutes~Dexmedetomidine 0,4- 0,8 microgrammes/kg of IBW/h;Lidocaine 2% 49ml+ Ketamine 50mg: 1ml/10kg of IBW/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if >120 kg, 3g if >120Kg;Paracetamol 15 mg/ KgTBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;dexmedetomidine: 0,4-0,8 microgramme/kg/h;Rocuronium 0,1 mg/kg of IBW if posttetanic count>1/10;Atropine 0,5 mg if heart rate < 40/min;Ephedrine 5mg in Arterial mean pressure < 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure > 20% of basal value Emergence~Stop dexmedetomidine;Stop sevorane;1 ml of NaCL 0,9%;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Lidocaïne 2% 49ml + Ketamine 50 mg: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
89525813|NCT05004519|Experimental|Multimodal anesthesia|"magnesium 40 mg/kg of total body weight (TBW) in 10 minutes~Remifentanil 0,2-0,4 microgrammes/kg/min of ideal body weight; Saline 0,9%: Infusion at 1ml/10kg of ideal body weight/ hour;Ketamine 25 mg;lidocaïne 1,5 mg/kg IBW;Propofol 2mg/kgTBW;Rocuronium 1,2 mg/kg IBW;Cefazoline 2g if >120 kg, 3g if >120Kg;Paracetamol 15 mg/ Kg TBW;Diclofenac 75 mg;Dexamethasone 10 mg;Ondansetron 4 mg;Sevorane;remifentanil 0,2-0,4 microgrammes/kg/min;Rocuronium 0,1 mg/kg of IBW if posttetanic count>1/10;Atropine 0,5 mg if heart rate < 40/min;Ephedrine 5mg in Arterial mean pressure < 20% of basal value;Nicardipine 0,5 mg if Arterial mean pressure > 20% of basal value Emergence~Stop remifentanil;Stop sevorane;1 ml of morphine 10mg/ml;Suggamadex 4 mg/ kg of IBW+ 4mg/kg of 40% ABW Post-anesthesia:Salne 50ml: 0,5 ml/ 10 kg IBW;Paracetamol 1g/6h;Diclofenac 75mg/12h;Morphine patient controlled analgesia: 1 mg/5 min, maximum 20mg/ 4 hours"
89525814|NCT05004493||Plasma arm|Patients receiving plasma as one of the main replacement fluids
89525815|NCT05004493||No Plasma|Patients receiving saline and/or 5% albumin as the replacement fluid.
89525816|NCT05000983|Active Comparator|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
89525817|NCT05000983|Experimental|Test dressing|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
89525818|NCT04991857|Experimental|The technology-based family-centered empowerment program for heart failure (T-FAME-HF)|The T-FAME-HF is a 16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits. The Program includes 3 four-week phases, which followed by 2 bi-weekly telephone visits. Each phase is designated with a specified goal of care to guide the disease management activities. Commenced with the home visit by the team nurse for each phase, patients' condition and self-care will be assessed. A goal-setting approach will be used to enhance disease monitoring, symptom recognition and response, and treatment compliance. A mobile apps (T-FAME) will be installed in participants' smart-phone and supports the prescribed actions for goal attainment.
89525819|NCT04991857|Active Comparator|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by another team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
89525820|NCT04991103|Experimental|Induction - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DaraVRD)|Quadruplet therapy with DaraVRD in the treatment of newly diagnosed myeloma
89525821|NCT04988256|Active Comparator|Cyclosporine|"All Patients start with 5 mg/kg/day (3 mg/kg/day if renal impairment) PO divided bid for 7 days (or IV if patient is NPO)~If complete resolution, stop cyclosporine and monitor closely for relapse~a. If patient relapses, give 5 (3 if renal impairment) mg/kg/day PO divided bid PO for 7 days~i. If down-trending, start oral taper regimen~ii. If not down-trending, switch to steroid arm~If >25% improvement and labs are down-trending, start the oral taper regimen.~If 0-25% improvement, give 5 (3 if renal impairment) mg/kg/day PO divided bid for 3 days~If down-trending, start oral taper regimen~If not down-trending, switch to steroid arm~If no improvement or up-trending labs at 7 days, switch to steroid arm~Oral Taper Regimen set as 3 mg/kg PO divided bid for 14 days, then 2 mg/kg PO divided bid for 20 days. If renal impairment, oral taper regimen set as 2 mg/kg PO divided bid for 14 days, then 1 mg/kg PO divided bid for 20 days"
89525822|NCT04988256|Experimental|Corticosteroids|"All Patients start with 500 mg IV Methylprednisolone for 3 days~1. If >25% improvement (must be >25% in all involved organs), start the taper regimen 2. If 0-25% improvement (in ≥1 involved internal organ), give 500 mg IV Methylprednisolone for 4 days~If no improvement, switch to cyclosporine arm of treatment~If 0-25% improvement, give 500 mg IV Methylprednisolone for 3 days~i. If labs are down-trending, start the taper regimen~ii. If labs are not down-trending, switch to cyclosporine arm of the study~c. If >25% improvement, start the taper regimen~Taper Regimen set as:~125 mg IV Methylprednisolone x3 days~1.2 mg/kg PO prednisone x1 week~1 mg/kg PO prednisone x1 week~0.8 mg/kg PO prednisone x1 week~0.6 mg/kg PO prednisone x1 week~0.4 mg/kg PO prednisone x1 week~0.2 mg/kg PO prednisone x1 week~0.1 mg/kg PO prednisone x1 week~0.05 mg/kg PO prednisone x1 week"
89525823|NCT04978077|Experimental|High fat test meal first, high carbohydrate test meal second|Consumption of a high fat challenge first, consumption of a high carbohydrate challenge after two weeks wash out
89525824|NCT04978077|Experimental|High carbohydrate test meal first, high fat test meal second|Consumption of a high carbohydrate challenge first, consumption of a high fit challenge after two weeks wash out
89525825|NCT04977297|Experimental|Move to Music Video Intervention|Participants in this arm will receive the Move to Music with Video (M2M-V) intervention. The participant will be asked to exercise twice daily for 5 consecutive days.
89525826|NCT04977297|Active Comparator|Move to Music Intervention|Participants in this arm will receive the Move to Music (M2M) only intervention without video. The participant will be asked to exercise twice daily for 5 consecutive days.
89525827|NCT04976686|Experimental|All study participants|All participants will undergo sample collection during their regular diet and after modification of their diet to a low carbohydrate diet
89525828|NCT04967118|Experimental|Skin-to-skin contact|Neonates will be placed ventral skin-to-skin position with their mother at least thirty minutes prior the heel lance to give time to calm down following transfer. Skin-to-skin positioning will be taken account comfortable position as possible for mother and the baby, easy to access heel for blood sample and interference minimizing during video recording and continuous NIRS, ECG and oxygen saturation measurement. Skin-to-skin contact will be continued for approximately fifteen minutes after completion of blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
89525829|NCT04967118|Experimental|Mother's heartbeats as sound and vibration|Neonates will be placed in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The platform on which the mother's heartbeat will be played will be placed under mattress of the incubator or crib. The playing of the mother's recorded heartbeats will be started thirty minutes prior the heel lance and will be continued during and fifteen minutes after the blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
89525830|NCT04967118|Active Comparator|30% oral glucose|Neonates will be placed on in an incubator or a cot, depending on their gestational age, and will be supported on side position by nest-shaped rolls according to department's normal practice. The neonates will be given a 30% oral glucose solution two minutes prior the heel lance
89525831|NCT04961814||gastric ultrasound|Patients will be asked to fast not less than 6 hours and preoperative bedside gastric ultrasound will be done
89525832|NCT04958382|Experimental|Ciprofol|
89525833|NCT04958382|Placebo Comparator|placebo|
89525834|NCT04948203|Active Comparator|Sirolimus 0.5mg|Subject will take Sirolimus 0.5mg orally daily for 14 days.
89525835|NCT04948203|Active Comparator|Sirolimus 1mg|Subject will take Sirolimus 1mg orally daily for 14 days.
89525836|NCT04948203|Active Comparator|Sirolimus 2mg|Subject will take Sirolimus 2mg orally daily for 14 days.
89525837|NCT04939623|Active Comparator|Probenecid 500 mg PO BID|Probenecid 500 mg X 1 PO BID and Placebo X 1 PO BID
89525838|NCT04939623|Active Comparator|Probenecid 1000 mg PO BID|Probenecid 500mg X 2 PO BID
89525839|NCT04939623|Placebo Comparator|Placebo PO BID|Placebo X 2 PO BID
89525840|NCT04937829|Experimental|BI 1569912 treatment group|
89525841|NCT04937829|Placebo Comparator|Placebo group|
89525842|NCT04925882|Experimental|Block|"The Block group will be made up of patients who will benefit from an injection of levopubivacaïne for the realization of the erector spinae plane block."
89525843|NCT04925882|Placebo Comparator|Placebo|"The Placebo group corresponds to the reference group, that is to say that it will consist of patients who benefit from an injection of physiological serum for the realization of the erector spinae plane block."
89525844|NCT04915040|Experimental|Behavioral Activation for Depression|
89525845|NCT04913818|Experimental|BUDPA Program|The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40 minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements in order to achieve a feeling of 'somewhat hard' at the Borg RPE rating of 12-14. The training session will end with a 10-minute cool down exercise session.
89525846|NCT04913818|Active Comparator|Usual Care|Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
89525847|NCT04913727|Experimental|Treatment Arm|Patients undergoing transcatheter mitral edge-to-edge repair in this single-arm study.
89525848|NCT04909385||Bronchoalveolar lavage (BAL) samples for pulmonary TB|
89525849|NCT04909385||(EBUS-TBNA) samples for mediastinal TB|
89525850|NCT04908943|Experimental|Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW)|RENEW was created by researchers, doctors, and patients with scleroderma. It is a web-based peer-led program to help manage energy and symptoms in people who have scleroderma.
89525851|NCT04908943|No Intervention|Waitlist|Participants will be asked about changes in health status, and use of any new treatments or services at 6 and 12 weeks.
89525852|NCT04897516|Experimental|Short regimen of benznidazole 2 weeks|"Experimental: Short regimen of benznidazole Participants will receive an investigational treatment of benznidazole for 2 weeks.~Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks."
89525853|NCT04897516|Experimental|Short regimen of benznidazole 4 weeks|"Experimental: Short regimen of benznidazole Participants will receive an investigational treatment of benznidazole for 4 weeks.~Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks."
89525854|NCT04897516|Active Comparator|Standard treatment with benznidazole|Active Comparator: Standard treatment with benznidazole Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks
89525855|NCT04893577|Experimental|Study Drug (EDTA Eye Drops)|Patients will treat herpes simplex eruption with EDTA eye drops.
89525856|NCT04893577|Active Comparator|Active Comparator (Abreva)|Patients will treat herpes simplex eruption with Abreva.
89525857|NCT04876404||Parkinson's Disease|Individuals with early stage Parkinson's Disease (diagnosed within the last 5 years)
89525858|NCT04876404||Healthy Controls|Healthy control individuals with no neurological or mood disorders.
89525859|NCT04876183|Active Comparator|Intervention Group|Web-based intervention (Selfapy for Binge Eating Disorder)
89525860|NCT04876183|No Intervention|Waitlist Control Group|12-week waiting period
89525861|NCT04869761|Experimental|Dose Arm 1|Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10^6 cells at day 0 and month 3.
89525862|NCT04869761|Experimental|Dose Arm 2|Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10^6 cells at day 0.
89525863|NCT04869657|Active Comparator|Sustainment 1: Coaches with CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by Children's Hospital of Philadelphia (CHOP) research consultants. In Year 2, schools in Sustainment 1 will receive reduced support for Tier 2 interventions provided by school district coaches. The coaches will in turn receive diminished support from research consultants. In Year 3, schools in both conditions will implement Tier 2 interventions with support from school district coaches; coaches will not receive direct assistance from research consultants.
89525864|NCT04869657|Active Comparator|Sustainment 2: Coaches without CHOP Support|In Year 1 of participation, schools in both arms will receive support for Tier 2 interventions provided by CHOP research consultants. In Years 2 and 3, schools in Sustainment 2 will receive support from school district coaches but coaches will not receive help from research consultants.
89525865|NCT04868188||Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support|Adult (>18 years) patients with severe influenza / Covid-19 supported on ECMO and with confirmed or suspected aspergillosis infection.
89525866|NCT04853238||Cohort 1: Participants with newly and previously diagnosed stable disease|
89525867|NCT04853238||Cohort 2: Participants with moderate acute exacerbation not requiring hospitalization|
89525868|NCT04853238||Cohort 3: Participants requiring hospitalization for an acute exacerbation|
89525869|NCT04834388|Experimental|Anakinra High dose|500mg i.v. loading dose, followed by continuous iv infusion with 2mg/kg/h over 3 days
89525870|NCT04834388|Experimental|Anakinra Low dose|100mg s.c. loading dose, followed by subcuteanous administration of 100mg twice daily for 3 days.
89525871|NCT04834388|No Intervention|Standard care|Standard care group
89525872|NCT04834167|Experimental|Treatment|Eligible patients will receive ten picopulse treatments for bi-monthly.
89525873|NCT04828226|Experimental|Intervention|"The study drug (clonidine 2 mcg/kg) is diluted in 100 ml sodium chloride 0.9 % by trained post-anaesthesia care staff not involved in the study.~At admission, electrocardiogram, non-invasive blood pressure and pulse oximetry is installed, a peripheral venous line established and supplemental oxygen applied.~The study drug will be given intravenously over 10 minutes at least 10 minutes before induction of anaesthesia.~Electroconvulsive therapy will be conducted according to hospital standard (Etomidate 0.2 mg/kg, Suxamethonium 1.0 mg/kg, isolated limb technique, THYMATRON® SYSTEM IV, Somatics Inc., Lake Bluf, Illinois, USA) adjusted to the patient's condition. Seizure quality will be assessed, prolonged seizure activity terminated with propofol 0.2 - 0.3 mg/kg. Severe agitation (Richmond Agitation and Sedation Score (RASS) > 1) needing intervention will be treated with propofol or lorazepam. Patients will be assessed for delirium using CAM-ICU at 20 minutes after induction."
89525874|NCT04828226|Placebo Comparator|Control|The placebo will be created by diluting 1ml of sodium chloride 0.9% in 100ml of sodium chloride in a sterile manner prior to application. The container will be identically labelled as the verum. The placebo will be applied by the same team members named above via the same route (intravenously), with the same speed and the same timing. All other parts of the procedure are identical as to the procedure described above.
89525875|NCT04819555||adult patients with ALS|incident population of ALS patients followed in the FILSLAN centres.
89525876|NCT04815486|Experimental|Bilateral rTMS combined with MI through a BCI training platform in VR with NeuRow|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks, and Motor Imagery (MI) treatment through the BCI training paradigm in VR (NeuRow) for 12 sessions in four weeks (3 sessions a week).The first 6 MI-neurofeedback sessions will carry out after bilateral stimulation with rTMS (i.e., rTMS as a priming method during the first two weeks), and the last 6 sessions, without rTMS as prior priming during the last two weeks
89525877|NCT04815486|Active Comparator|Repetitive TMS in bilateral cortical primary motor area|Sequential active rTMS at low frequency (healthy hemisphere) and high-frequency (injured hemisphere) application during 10 sessions in two weeks.
89525878|NCT04809350|Active Comparator|Adjustable Human Milk Fortification|Human milk fortification based on blood urea levels
89525879|NCT04809350|Experimental|Targeted Human Milk Fortification|Human milk fortification based on milk analysis
89525880|NCT04791267|Experimental|Intervention|Community health navigator program for six months
89525881|NCT04791267|Other|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program
89525882|NCT04790604|Experimental|Intervention|Community health navigator program for six months.
89525883|NCT04790604|Other|Control|Waitlist control: six-month waiting period followed by six months of community health navigator program.
89525884|NCT04783467|Experimental|Time Restricted Eating (TRE) Schedule|For 6-weeks out of the 16-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. The meal plans will be individualized to meet weight maintenance energy requirements.
89525885|NCT04783467|No Intervention|Control Schedule|For 4 weeks out of the 16-week randomized dietary crossover study, women will receive frozen lunch and dinner meals, and a standardized breakfast and snacks menu. The meal plans will be individualized to meet weight maintenance energy requirements. There are no restrictions on timing of eating.
89525886|NCT04783246|Experimental|Group A- Intervention/Non-Intervention|Participants in this arm will initially be randomized to the intervention period and will receive the interventions for 11 weeks followed by no interventions for 11 weeks.
89525887|NCT04783246|Active Comparator|Group B- Non-Intervention/Intervention|Participants in this arm will initially be randomized to the non-intervention period for 11 weeks followed by the intervention period for 11 weeks.
89525888|NCT04781855|Experimental|Part A (ipilimumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 1 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks for up to a total of 2 years.
89525889|NCT04781855|Experimental|Part B (ipilimumab, nivolumab, ibrutinib)|Patients receive ipilimumab IV over 90 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning day 7 of cycle 1, patients also receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity. Patients who complete 4 doses of ipilimumab and nivolumab, and are deriving benefit from it, without severe toxicities, may continue to receive ipilimumab every 12 weeks and nivolumab every 4 weeks for up to a total of 2 years.
89525890|NCT04777786|Experimental|Physical Therapy Intervention|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning ~4 weeks after surgery (x̄=10 visits).
89525891|NCT04777786|No Intervention|Usual Care|The usual care group will be instructed to continue with their typical daily activities.
89525892|NCT04765553|Active Comparator|emapalumab|emapalumab i.v infusion
89525893|NCT04765553|Placebo Comparator|Placebo|Saline i.v. infusion
89525894|NCT04763902|Experimental|Time Restricted Eating (TRE) Schedule|For 8 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calories-containing beverages within an 8 to 10-hour period that fits their schedule. The fasting period will ramp up during the first week (Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day).
89525895|NCT04763902|No Intervention|Control Schedule|For 4 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals, and a standardized breakfast and snacks menu. All meals and snacks will be culturally competent, and meal plans will be individualized to meet weight maintenance energy requirements.
89525896|NCT04760899|Active Comparator|Active Group|This group will receive the active form of tDCS. The tDCS will be administered with the anode over the right lobule of the cerebellum, and the cathode over the left lobule of the cerebellum. Stimulation will be administered for a twenty minute period that does not include the 30 second ramp up at the beginning and end of the stimulation.
89531989|NCT04287907|Experimental|Monitor|Qualitative End Tidal Co2 detector will be attached to the face mask used to provide mask ventilation to the preterm baby before connected to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
89525897|NCT04760899|Sham Comparator|Sham Group|This group will receive the sham form of tDCS. The electrodes will be placed in the same montage as in the Active group, however the stimulation parameters are different. For this group, the stimulation will be ramped up to the target intensity over thirty seconds at the beginning, then immediately ramp down over thirty seconds. The stimulation will then remain off for the next twenty minutes. After twenty minutes the stimulation will ramp up to the target intensity and then back down over thirty seconds.
89525898|NCT04760899|No Intervention|Healthy Controls|These will be age and sex-matched healthy controls who only come in for the baseline visit in order to provide comparative values with which to confirm adequate impairment in our diseased population.
89525899|NCT04754399|Experimental|Cannabidiol (CBD)|Oral solution given 2x daily.
89525900|NCT04734990|Experimental|Treatment (azacitidine, seclidemstat)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7. Patients also receive seclidemstat PO QD on day 1 of cycle 1 and PO BID on days 2-28 of cycle 1 and on days 1-28 of all subsequent cycles. There are 6 planned dose levels for seclidemstat: 300 mg, 450 mg, 600 mg, 900 mg, 1200 mg and 1500 mg. Successive cohorts of eligible patients will be treated with azacitidine. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
89525901|NCT04714762|Experimental|Intervention (eMOM GDM application)|Participants in the intervention group will use the eMOM GDM -application one week/month. The participants will also receive regular antenatal care in maternity clinics and hospitals. In addition they will meet a study nurse three times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum).
89525902|NCT04714762|No Intervention|Control|Participants in the control group will meet a study nurse 3 times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum). They also receive regular antenatal care in maternity clinics and hospitals.
89525903|NCT04691739|Active Comparator|In-person occupational therapy|occupational therapy delivered in-person
89525904|NCT04691739|Active Comparator|Teletherapy|Video-conferencing occupational therapy
89525905|NCT04685824|Active Comparator|Biofeedback Training|"Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total).~30 min daily reading at home for 4 weeks."
89525906|NCT04685824|Experimental|Biofeedback Training + Immersive VR|"Biofeedback training (BFT) [1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks], 1 session per week for 4 weeks (4 sessions total).~30 min daily reading at home for 4 weeks~Immersive virtual-reality stimulation (IVR) [1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks], 1 session every 2 days for 4 weeks (14 sessions total)."
89525907|NCT04685746||Typically developing school-aged children|Study group to achieve objective 1 and 2; control group to achieve objective 3 and 4 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
89525908|NCT04685746||Vestibular-impaired school-aged children|Study group to achieve objective 3 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
89525909|NCT04685746||Neurodevelopmental group (ADHD, ASD and/or DCD)|Study group to achieve objective 4 - Behavioural protocol: balanced growth protocol, consisting of audiovestibular, cognitive and motor assessments
89525910|NCT04675281||Critically-ill adult patients who died in the Intensive Care Unit from a documented COVID-19|
89525911|NCT04673539||Single group|Instrument validation in stroke patients
89525912|NCT04669886||endotoxin study group|Patients scheduled for Percutaneous Nephrolithotomy (PCNL) as surgical treatment for their kidney stones will be evaluated for postoperative endotoxin levels as a risk marker for sepsis.
89525913|NCT04669223|Other|Seldinger chest drain 14F|Patients with seldinger chest drain 14F inserted
89525914|NCT04669223|Active Comparator|Seldinger chest drain 8F|Patients with seldinger chest drain 8F inserted
89525915|NCT04661280|No Intervention|Cognitive remediation|Non-drug treatment, cognitive remediation, cognitive stimulation
89525916|NCT04661280|Experimental|Cognitive remediation + Donepezil|Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil
89525917|NCT04653285|Experimental|motor skill practice + aerobic exercise|bout of aerobic exercise following motor skill practice
89525918|NCT04653285|Active Comparator|motor skill practice + rest|seated rest following motor skill practice
89525919|NCT04646187|Experimental|Intervention group|In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.
89525920|NCT04646187|No Intervention|Control group|Unchanged dosing interval. Consists of two groups: Patients randomised to the control group and patients allocated to the control group based on preference.
89525921|NCT04635046||Patients with tears to their peroneal tendons|Patients with pain over their peroneal tendons clinically, with a verified injury to either of the two tendons on MRI, where we might expect a tendon transfer of the peroneus longus, or extirpation of the peroneus longus, during surgery.
89525922|NCT04633018|Experimental|Patient-centered asthma intervention feasibility|Investigate the effect of the patient-centered asthma intervention using the AsthmaMD app on school days missed and medication adherence.
89525923|NCT04633018|Experimental|Wait list control|Control group with usual care (not using app).
89525924|NCT04617522|Experimental|Advanced or Metastatic Solid Tumor and Moderate Liver Impairment|Participants with advanced solid tumor and moderate hepatic impairment will receive an escalating dose of sacituzumab govitecan-hziy on Days 1 and 8. The dose-escalation plan will start at 5 mg/kg and escalate to 7.5 mg/kg, and finally 10 mg/kg, if deemed to be safe. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
89525925|NCT04617522|Experimental|Advanced or Metastatic Solid Tumor and Normal Liver function|Participants with advanced or metastatic solid tumor and normal hepatic function will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8. At the completion of study treatment, participants who are deriving benefit from sacituzumab govitecan-hziy may continue to receive treatment in a Gilead sponsored rollover study (IMMU-132-14; NCT04319198).
89525926|NCT04606914|Experimental|neoadjuvant chemotherapy regimen|"IV Carboplatin AUC 5 (Q21 days) 7 cycles (first cycle is Carbo alone, dosing for C1D1 will be provider's choice)~IV Mirvetuximab 6 mg/kg (adjusted ideal body weight) day 1 (Q21 days) 6 cycles (starting with cycle #2)"
89525927|NCT04573530|Experimental|We Walk Plus Intervention|The intervention group will receive a Fitbit, SMS and will be assigned to a private Fitbit community (4-5 participants per group) for 12 weeks. During the intervention, participants will receive weekly personalized SMS on their mobile phones including encouraging messages, reminders, and tips to increase steps, and weekly step goals. The investigators will use a secure, web-based platform, iCardia, to support continuous real-time remote monitoring of activity data from Fitbit devices and personalized communication via SMS based on incoming data. The investigators will set up the Fitbit networking settings on participants' phones to give notifications when there are posts to this group. Individual goals and a weekly team goal of steps will be set up by the research team. Each member will be awarded a badge upon reaching each individual's weekly goal. Teams will also be awarded badges when all team members reach their individual weekly goals.
89525928|NCT04573530|No Intervention|Attention control group|The attention control group will also receive a Fitbit and will be asked to continue with normal daily activities. During the initial in-person session, they will receive the same PA recommendations as the intervention group to walk at least 30 minutes for 5 days or more a week or 10,000 steps a day. However, a plan for improving PA will not be discussed.
89525929|NCT04572178|Experimental|Cash payment and brief behavioral counseling|The intervention consists of in person counseling and cash payment. The participants receive 25 Euro per week if they have succeeded in quitting smoking. Quitting smoking is evaluated by carbon monoxide measurements twice a week.
89525930|NCT04568161|Experimental|pre and post chemotherapy assessments|The patients will be assessed before and after chemotherapy treatment.
89525931|NCT04558398|Experimental|Resistance exercise training group|Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
89525932|NCT04558398|Experimental|High-intensity interval training group|Participants randomized to this arm will engage in a 4-week home-based training program with anticipated 12 sessions (3 per week) with participants required to attend a minimum of 9 sessions.
89525933|NCT04552223|Experimental|Nivolumab Plus Relatlimab Group|Participants in this group will receive Nivolumab and Relatlimab administered together on Day 1 of every 4 week cycle. Both drugs will be administered until disease progression or intolerable toxicity for up to 24 months.
89525934|NCT04549129|Experimental|Intervention group|Participants randomized to the intervention group will receive breastfeeding education and teaching of hand expression using a breastfeeding education video and associated breastfeeding website, as well as hands-on teaching of hand expression techniques during their 36 week visit.
89525935|NCT04549129|Active Comparator|Control group|Participants randomized to the control group will receive usual breastfeeding education during their 36-week visit.
89525936|NCT04529096|Experimental|750 Mg-500 mg LY3016859|Participants received LY3016859 every 2 weeks with 750 milligram (mg) as starting dose followed by 500 mg intravenous (IV) infusion for a total of 4 doses
89525937|NCT04529096|Placebo Comparator|Placebo|Participants received placebo every 2 weeks by IV infusion for a total of 4 doses.
89525938|NCT04525534||Placenta accreta spectrum|Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum
89525939|NCT04525534||Phenotypically-matched controlled group|Mother-infant dyads admitted for delivery without placenta accreta spectrum
89525940|NCT04513626|Other|Delayed switch|the maintaining of their current ART followed by a switch to doravirine/raltegravir at W48 (delayed switch group).
89525941|NCT04513626|Experimental|Immediate switch|Immediate switch to doravirine/raltegravir
89525942|NCT04504825|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. The study is divided into 2 parts, the Primary Evaluation Treatment period part and the Open-Label Extension period of Study.
89525943|NCT04504825|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment.
89525944|NCT04487249|Experimental|Vision Therapy|Participants will receive 20 consecutive weeks of office-based vision therapy with home therapy.
89525945|NCT04487249|No Intervention|Observation|Participants will receive no treatment for IXT is received during the study unless one of the deterioration criteria is met.
89525946|NCT04484974|Experimental|Pecan snack condition|In this crossover condition, a mid morning snack consisting of 250 kcal of lightly salted roasted pecan nuts will be administered.
89525947|NCT04484974|Active Comparator|Tortilla chip snack condition|In this crossover condition, a mid morning snack consisting of 250 kcal of lightly salted pretzels will be administered.
89525948|NCT04473963|Experimental|EGF-Guided Ablation Therapy|"Subjects randomized to therapy will be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software)."
89525949|NCT04473963|No Intervention|Control - No Ablation Therapy|"Subjects randomized to control will not be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software). The subjects will be cardioverted (as applicable) and the procedure will end."
89531990|NCT04287907|No Intervention|Control|face mask used to provide mask ventilation to the preterm baby will be connected directly to the T piece resuscitator. Respiratory function monitor sensor will be placed within circuit to measure parameters e.g. PIP, PEEP, FiO2, tidal volume.
89531991|NCT04277741|Experimental|Resistant starch bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW.
89531992|NCT04277741|Active Comparator|Native wheat bar|The control group will consume one native wheat starch bar per day.
89531993|NCT04268823|Experimental|QBW251|Oral use, one capsule twice daily.
89525950|NCT04472091|Experimental|Genicular artery embolization|"Participants will undergo the genicular artery embolization (GAE) procedure for the treatment of moderate to severe knee osteoarthritis. A total of 30 patients will be enrolled in the single treatment arm of the study.~The study will involve a screening period in which patient eligibility is determined. Once eligibility is confirmed, patients will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ). Following treatment, patients will undergo follow-up at 1, 6, 12, and 24 months post GAE."
89525951|NCT04442503|Placebo Comparator|Placebo|Participants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days.
89525952|NCT04442503|Experimental|SAGE-217 50 mg|Participants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days.
89525953|NCT04427072|Experimental|Capmatinib|400mg of capmatinib tablets, administered orally twice daily
89525954|NCT04427072|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 solution administered by intravenous infusion on Day 1 of every 21-day cycle
89525955|NCT04415372||Cognitive Impairment|Adults diagnosed with MS that have evidence of cognitive decline.
89525956|NCT04415372||No Cognitive Impairment|Adults diagnosed with MS that have no evidence of cognitive decline.
89525957|NCT04415372||Healthy Controls|Healthy adult volunteers will form a control group matched for age, gender, education, handedness
89525958|NCT04401774|Experimental|Nivolumab Maintenance|All patients will undergo cerebrospinal fluid (CSF) and blood collection as well as MRI imaging as standard of care prior to (- 21 days) first-line treatment initiation, during first-line therapy (before initiation of the 5th methotrexate dose (+/- 7 days)), at completion of first-line chemotherapy therapy (+/- 7 days) as well as 60, 180, and 360 days after enrollment into maintenance or observation (+/- 7 days). Those patients with persistent cfDNA in the CSF after completion of first-line chemotherapy and either complete or partial response on imaging will be enrolled into the nivolumab maintenance treatment arm. All other patients (no persistent cfDNA in the CSF and either complete or partial response on imaging) are followed with observation. Patients who do not respond to first-line therapy are not eligible for nivolumab maintenance and will no longer be followed in the biospecimen and clinical data collection cohort.
89525959|NCT04384822|Experimental|Tai Chi Group|Subjects will participate in a tai chi program conducted in small groups (10 subjects per group) delivered by qualified instructors, who have experience in teaching tai chi to older adults. The tai chi intervention will be prescribed as a 3-month program with two 1-hour sessions weekly. Tai chi forms will be taught for 2 months followed by 1 month of consolidation. The 24-form simplified Yang-style tai chi will be adopted, as it is the most popular form of tai chi and older adults can manage to learn this simplified form of tai chi within 2-3 months. The instructors will introduce the safety issues, proper training principles, and skills to the subjects in their first class to minimize any avoidable adverse events due to improper skill/practice. The appropriate intensity will be individually determined for each subject by the attending instructors to achieve the training principle of progressive adaptation regarding the exercise intensity.
89525960|NCT04384822|Active Comparator|CBT-I Group|Subjects will participate in a conventional CBT-I program conducted in small groups (10 subjects per group) delivered by trained personnel. The CBT-I will be prescribed as a 3-month program with two 1-hour sessions weekly. The CBT-I components will be delivered for 2 months, which is consistent with the duration of the majority of CBT-I treatments, followed by 1 month of consolidation.
89525961|NCT04382274|Experimental|Quadratus Lumborum Block|the transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized, leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial then placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
89525962|NCT04382274|Experimental|Dual block|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
89525963|NCT04379778|Experimental|Aerobic exercise|Moderate to high intensity aerobic exercise for 24 weeks.
89525964|NCT04379778|No Intervention|Standard care|Habitual lifestyle including standard care.
89525965|NCT04374773|Experimental|Estradiol|1 week treatment with 0.3 mg/24 hr transdermal estradiol
89525966|NCT04374773|Experimental|Cortisol|1 week treatment with 30 mg hydrocortisone daily, administered in 2 divided doses
89525967|NCT04369794|Active Comparator|BCG vaccine|BCG Group (n = 200): 0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
89525968|NCT04369794|Placebo Comparator|Placebo|Placebo group (n = 200): 0.9% saline solution in the same volume as BCG vaccine in a single dose.
89525969|NCT04360538||COVID19 positive|ICU patients coronavirus positive
89525970|NCT04360538||non-COVID19|ICU patients without coronavirus
89525971|NCT04359238|Active Comparator|Intervention group with motivation messages|There are 100 patients in the intervention group with automated or observer initiated motivation messages. They receive an individualized training program with regular notifications about their training status via their SmartWatch.
89531994|NCT04268823|Placebo Comparator|Placebo|Oral use, one capsule twice daily.
88814465|NCT04357808|Experimental|Sarilumab plus standard of care|Sarilumab 200 mg, 2 sc injections in pre-filled syringe or pen, single dose. Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed
89525972|NCT04359238|Active Comparator|Intervention group without motivation messages|There are 100 patients in the intervention group without automated or observer initiated motivation messages. They receive an individualized training program without regular notifications about their training status via their SmartWatch.
89525973|NCT04359238|No Intervention|Control group|100 patients are in the control group without an individualized training program.
89525974|NCT04346511|Experimental|Acupuncture|In a supine position with a cardboard blocking view of their legs, patients will have six, 0.25*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal. After which the needles will be removed.
89525975|NCT04346511|Sham Comparator|Sham Acupuncture|Specially designed Sham acupuncture needles that are not actually penetrate the skin and activate the acupoint will be used in an identical procedure to RA. The patient would be able to feel light pressure at the site.
89525976|NCT04333862||Healthcare workers providing healthcare|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
89525977|NCT04333862||Healthcare workers staying at home|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
89525978|NCT04333862||Hospitalized patients|To compare the infection rate of hospitalized patients versus healthcare workers
89525979|NCT04331704|Experimental|Personalized Information|Participants randomized to this condition will complete a web-based questionnaire and then receive personalized information regarding their alcohol use and sexual health behavior. They will complete daily, phone-based IVR monitoring for assessment purposes and receive further personalized information based on their responses.
89525980|NCT04331704|Active Comparator|Educational Information|Participants randomized to this condition will complete a web-based questionnaire and then receive educational material regarding their alcohol use and sexual health behavior. They will complete daily phone-based IVR monitoring for assessment purposes.
89525981|NCT04322097|Other|Lingual Muscle Stimulation Patients|DISE
89525982|NCT04319939||Participants receiving mechanical ventilation|
89525983|NCT04318769|Experimental|AFFIRM|AFFIRM is an 8-session psychoeducational weekly group intervention
89525984|NCT04318769|No Intervention|Waitlisted control|Waitlisted control
89525985|NCT04317989|Experimental|Practice Facilitation|All enrolled practices will receive practice facilitation for the duration of the intervention period.
89525986|NCT04304144|Experimental|Part A: CAEL-101 combined with SoC CyBorD|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The initial cohort dose assignments of CAEL-101 will be: Cohort 1 - 500 mg/m^2 Cohort 2 - 750 mg/m^2 Cohort 3 - 1000 mg/m^2. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study. Patients from Part A who are in the Continued Treatment Period and who, in the Investigator's judgment, should have their SoC treatment complemented with daratumumab may do so (Part B).
89525987|NCT04304144|Experimental|Part B: CAEL-101 combined with SoC CyBorD and daratumumab|CAEL-101 is administered as an intravenous (IV) infusion at the RP3D dose level. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy and daratumumab. After completing approximately 50 weeks of treatment, participants may switch to an alternative maintenance dosing regimen of every four weeks (q4wk), if agreed upon by the Investigator and the Sponsor Medical Monitor. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study.
89525988|NCT04300751|Experimental|Alcohol|Participants will receive experimental doses of active or placebo alcohol, p.o. Alcohol/placebo will be administered once per session.
89525989|NCT04300751|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered orally
89525990|NCT04300751|Experimental|Opioid Agonist/Alcohol Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with experimental doses of active alcohol placebo. Opioid/placebo and alcohol/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Both opioid and alcohol doses will be administered orally.
89525991|NCT04299412||Melioidosis cases|serum samples collected from patients with B. pseudomallei positive cultures
89525992|NCT04299412||Non-melioidosis cases|serum samples collected from patients with B. pseudomallei negative cultures
89525993|NCT04294927|Experimental|Risk-reducing salpingectomy with delayed oophorectomy|Risk-reducing salpingectomy after the completion of childbearing with delayed oophorectomy.
89525994|NCT04294927|Active Comparator|Risk-reducing salpingo-oophorectomy|Risk-reducing salpingo-oophorectomy.
89525995|NCT04285086|Experimental|Ropeginterferon alfa-2b (P1101)|Pre-filled Syringe, Q2W, SC injection
89525996|NCT04285086|Active Comparator|Anagrelide|Capsules, Daily, p.o.
89525997|NCT04265872|Experimental|Bortezomib followed by pembro/cis|There is only one arm.
89525998|NCT04255953|Active Comparator|Treatment as Usual|Following baseline assessment, patients randomized to the TAU arm will receive monthly dietary pamphlets and web-based obesity prevention educational materials from the U.S. Office of Disease Prevention and Health Promotion (https://healthfinder.gov/HealthTopics/). After the 6-month assessment, TAU patients will begin the weight loss intervention arm.
89525999|NCT04255953|Experimental|Group Telehealth Obesity|Participants will receive 24 weekly group phone counseling sessions and monthly individual sessions that encourage healthy eating and exercise. The planned intervention is guided by a social-cognitive framework and includes self-monitoring, goal setting, stimulus control, social support, cognitive reframing of unrealistic and negative thoughts, and developing positive expectancies for long-term weight control. The primary objective is to decrease caloric intake and increase physical activity to produce weight loss of approximately .4 to.9 kg per week, with the study goal of 10% reduction from baseline.
89526000|NCT04249037|Active Comparator|Arm A: Rapid Start Group|Same day antiretroviral therapy (ART) with bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + new diagnosis package with laboratory evaluations and social work referral.
89526001|NCT04249037|Placebo Comparator|Arm B: Standard Group|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
89526002|NCT04245865|Experimental|Arm A, standard treatment + tocotrienol|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + tocotrienol OR capecitabine + bevacizumab + tocotrienol
89526003|NCT04245865|Placebo Comparator|Arm B, standard treatment + placebo|Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + placebo OR capecitabine + bevacizumab + placebo
89526004|NCT04245839|Experimental|Administration of JCAR017|"Subjects will be treated with fludarabine IV (30 mg/m2/day for 3 days) and cyclophosphamide IV (300 mg/m2/day for 3 days) prior to JCAR017 infusion. Refer to the most recent package inserts for further details on administration of these agents.~JCAR017 will be infused on Day 1 at a target dose of 100 × 10^6 CAR-positive viable T cells (CAR+ T cells), 2 to 7 days after completion of LD chemotherapy. Each JCAR017 dose includes CD4+ CAR+ T cells and CD8+ CAR+ T cells."
89526005|NCT04244032|Experimental|Working Memory Training (WM)|Participants complete training in a working memory task designed to utilize individually-adapted difficulty levels.
89526006|NCT04244032|Experimental|Inhibitory Control Training (IC)|Participants complete training in an inhibitory control task designed to utilize individually-adapted difficulty levels.
89526007|NCT04244032|Active Comparator|Bias Modification Training (BM)|Participants complete training in an active comparator task designed to weaken approach responses to alcohol-associated cues.
89526008|NCT04244032|No Intervention|Non-Trained control (NTC)|No active intervention is delivered beyond typical care.
89526009|NCT04239716|Experimental|regional anesthesia|combination of erector spinae plane block (ESPB) and interscalene block(IB).the ESPB will be performed using linear ultrasound transducer (Philips® cx 50 extreme edition, USA) and we will inject 20 ml solution(10 ml 0.5% bupivacaine, 5 ml 2% lidocaine, and 5 ml normal saline). the IB will be performed using the same ultrasound machine and injecting the same solution
89526010|NCT04237441||MDT conference|participants evaluated at MDT conference
89526011|NCT04237441||no MDT conference|participants not evaluated at MDT conference
89526012|NCT04227951|Sham Comparator|Drain|Participants enrolled in this arm have an abdominal drain positioned at the end of the operation (any type, inserted from right flank with the tip close to the esophago-jejunal or Gastro-jejunal anastomosis and the duodenal stump). Drain will stay in place until postoperative day (POD) 4th (drain output and quality will be registered). If normal drain debt and patient have no abdominal complications that need reoperation and/or percutaneous drain placement until POD 4, a methylene-blue test is be performed (200 ml water + 5 ml blue orally, check drain after 60 minutes: negative test if no blu was seen in the drain). If negative-blue test drain can be removed according to centre preference (no strict POD defined); if positive-blue test complication will be treated according to centre preference. Only in this arm drain related complications are registered. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
89526013|NCT04227951|Experimental|No Drain|Participants enrolled in this arm do not have any abdominal drain placed at the end of the operation. Postoperative management (e.g. resume of oral intake, anastomosis integrity tests) is left to centre preference. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.
89526014|NCT04226820|Experimental|participant|Participants are divided into 3 groups based on their diagnosis: diabetes mellitus type 1, diabetes mellitus type 2, and healthy persons. Each participant (independent of group) will have the same examinations. There is no retesting of the same participant in other conditions.
89526015|NCT04214366|Experimental|Carbon Ion irradiation|22 x 3 Gy(RBE) Carbon Ions
89526016|NCT04214366|Active Comparator|Bimodal Arm|25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost
89526017|NCT04211935|Experimental|Patient Controlled Analgesia|This technique involves connecting a patient controlled analgesia pump to the intravenous line. The patient has the ability to push a button to obtain a predetermined dose of an intravenous opioid with a set lockout time period to minimize the potential for over sedation. PCA pumps will be connected to the intravenous line of the patient at the end of the MIRPE operation. anesthesiologists with experience in regional anesthesia.
89526018|NCT04211935|Experimental|Erector Spinae Block|This method consists of the anesthesiologist placing two catheters on each side of the vertebrae which then delivers pain medicine continuously via pumps for 2-3 days post-surgery.
89526019|NCT04211935|Experimental|Intercostal Nerve Cryoablation|The INC technique relies on multilevel freezing of the intercostal neurovascular bundle intraoperatively to block sensation and pain for approximately 2 months postoperatively. Trained pediatric surgeons will perform the INC at the time of a MIRPE procedure.
89526020|NCT04208256|Sham Comparator|Energy Neutral|Bottled water (300 ml) with added fruit punch-flavored non-nutritive sweetener (aspartame) will be used as the energy neutral stimulus.
89526021|NCT04208256|Active Comparator|Energy Surplus|300ml fruit punch-flavored Glucola (75-gram[g], Azer Scientific) will be used as the energy surplus stimulus.
89526022|NCT04180449||Dysphagia screening positive|
89526023|NCT04180449||Dysphagia screening negative|
89526024|NCT04170725|Experimental|Patients and Healthy volunteers|Patients and Healthy volunteers will undergo a 14-day training protocol. No study drugs will be administered. Patients and Healthy volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Participants will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
89526025|NCT04140396|Placebo Comparator|Placebo Comparator|Participants will receive placebo infusion consisting of normal saline
89526026|NCT04140396|Active Comparator|Active Comparator|Participants will receive a lidocaine infusion
89526027|NCT04135456|Experimental|Low dose group|0.5g/kg of 20% mannitol administered at skin incision.
89526028|NCT04135456|Experimental|Medium dose group|1.0g/kg of 20% mannitol administered at skin incision.
89526029|NCT04135456|Experimental|High dose group|1.5g/kg of 20% mannitol administered at skin incision.
89526030|NCT04129411|Experimental|RFA Group|
89526031|NCT04128748|Experimental|Treatment (CPX-351, quizartinib)|"INDUCTION: Patients receive CPX-351 IV over 90 minutes on days 1, 3 and 5 and quizartinib PO on days 6-19. Patients who do not respond to treatment during cycle 1 receive CPX-351 IV on days 1 and 3 and quixartinib PO on days 6-19 during cycle 2. Treatment repeats every 28 days for up 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive CPX-351 over 90 minutes on days 1 and 3 and quizartinib PO on days 4-28 of cycle 1. Treatment with CPX-351 repeats every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive quizartinib PO on days 1-28 in the absence of disease progression or unacceptable toxicity."
89526032|NCT04111588||Glioma|"20 low-grade (LGG) and 40 high-grade glioma (HGG) patients will be included from the Department of Neurosurgery at St. Olavs Hospital and the Department of Neurosurgery at the University hospital of North Norway and examined with 18F-FACBC PET/MRI at baseline and 4-6 months after surgery. Furthermore, 10 of the LGG patients and 10 of the HGG patients will be examined with an additional 18F-FET PET/MRI at baseline for comparison with 18F-FACBC.~30 recurrent HGG patients will be recruited from the Department of Neurosurgery and the Department of Oncology at the Haukeland University Hospital. These patients will be examined with 11C-MET PET/MRI at treatment/baseline and 1 month after radiosurgery."
89526033|NCT04111588||Brain Metastases|Patients with brain metastases (18F-FACBC: n=20, 18F-FET: n=20 and 11C-MET: n=30) will be included from the Department of Neurosurgery at St. Olavs Hospital, the Department of Neurosurgery at Haukeland University Hospital and the Department of Neurosurgery at the University hospital of North Norway, and examined with amino acid PET/MRI at baseline, 1 month after surgery/stereotactic radiosurgery (St. Olavs Hospital/UNN: Linac, Haukeland University Hospital: Gamma Knife® radiosurgery) and at suspicion of recurrence.
89526034|NCT04109976|Experimental|Bimekizumab-SS|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
89526035|NCT04109976|Experimental|Bimekizumab-AI|Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).
89526036|NCT04100044|Experimental|Health Services Research (physical therapist, exercise)|Patients meet with a physical therapist on day 0 and at 3 and 6 months and receive a personalized home exercise intervention consisting of aerobic and resistance training for 6 months. Patients also receive face-to-face sessions, video chats, or text message check-ins with physical therapist weekly for 6 weeks and then every other week for up to 24 weeks.
89526037|NCT04081259|Experimental|Arm B: Dose Escalation LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients with inhibitors for fungal prophylaxis/treatment
89526038|NCT04081259|Experimental|Arm A: Dose Expansion LY3214996|-LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle for patients without inhibitors for fungal prophylaxis/treatment
89526039|NCT04076020|Experimental|Intervention arm|Receive the relational agent and the AliveCor Kardia for use for 120 days. Participants are directed to use these interventions daily.
89526040|NCT04076020|Active Comparator|Usual care arm|"Receive a brochure on atrial fibrillation that is published by the American Heart Association and a smartphone with the WebMD application.~Participants are directed to use the WebMD application as often as they would like."
89526041|NCT04075994|Experimental|Intervention arm|Receive the relational agent coupled with the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
89526042|NCT04075994|Active Comparator|Usual care arm|Receive a brochure on atrial fibrillation, the WebMD app and the AliveCor Kardia heart rate and rhythm monitor for 120-day use.
89526043|NCT04068519|Experimental|Tislelizumab|Tislelizumab 200 mg intravenously (IV) once every 3 weeks (21 days per cycle) until no evidence of continued clinical benefits, unacceptable toxicity, or withdrawal of informed consent at the discretion of the investigator. There were 3 parts in this study: dose verification, pharmacokinetic (PK) sub-study, and indication expansion.
89526044|NCT04063098|Other|All participants|Participants scheduled for endoscopic sleeve gastroplasty
89526045|NCT04059705|Experimental|Dual-Task Intervention|This study arm will receive the dual-task training program.
89526046|NCT04059458|Experimental|Regenerative therapy w/BCP and collagen membrane|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and collagen membrane.
89526047|NCT04059458|Active Comparator|Regenerative therapy w/BCP and enamel matrix proteins|In this arm, treatment of furcation grade II defects includes open flap debridement and regenerative therapy with biphasic calcium phosphate (BCP) and enamel matrix proteins.
89526048|NCT04059172|Active Comparator|Ibuprofen|one 200 mg tablet of ibuprofen and 2 placebo tablets
89526049|NCT04059172|Experimental|Ibuprofen and acetaminophen|one 200 mg table of ibuprofen and two 325 mg tablets of acetaminophen
89526050|NCT04059172|Placebo Comparator|Placebo|3 tablets of tableting compounds with no active ingredients
89526051|NCT04057209|Active Comparator|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|Transoral CO2-Laser Microsurgical Cordectomy defined by European Laryngological Society (Remacle M, Eckel HE, Antonelli A, et al. Endoscopic cordectomy. A proposal for a classification by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol. 2000;257(4):227-231.)
89526052|NCT04057209|Experimental|Arm B: Single Vocal Cord Irradiation (SVCI)|Single Vocal Cord Irradiation defined by Kwa et al. and Al-Mamgani et al. (Kwa SLS, Al-Mamgani A, Osman SOS, Gangsaas A, Levendag PC, Heijmen BJM. Inter- and Intrafraction Target Motion in Highly Focused Single Vocal Cord Irradiation of T1a Larynx Cancer Patients. Int J Radiat Oncol Biol Phys. 2015;93(1):190-195. Al-Mamgani A, Kwa SLS, Tans L, et al. Single Vocal Cord Irradiation: Image Guided Intensity Modulated Hypofractionated Radiation Therapy for T1a Glottic Cancer: Early Clinical Results. Int J Radiat Oncol Biol Phys. 2015;93(2):337-343.)
89526053|NCT04047641|Experimental|Treatment (idarubicin, cladribine, cytarabine, quizartinib)|"INDUCTION: Patients receive idarubicin Intravenous over 1 hours on days 1-3, cladribine intravenous over 1-2 hours on days 1-5, cytarabine Intravenous over 3 hours on days 1-5 (or days 1-3 for patients over age 60), and quizartinib by mouth daily on days 6-19. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR or CRp after Induction receive idarubicin Intravenous over 1 hours on days 1-2, cladribine Intravenous over 1-2 hours on days 1-3, cytarabine Intravenous over 3 hours on days 1-3, and quizartinib by mouth daily on days 4-28. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients who achieve CR or CRi/CRh after Consolidation receive quizartinib by mouth daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
89526054|NCT04046003|Experimental|Tai Chi intervention|24-form Yang style Tai Chi
89526055|NCT04044040|Experimental|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
89526056|NCT04038008|Other|Sequence AB|13 subjects assigned to the sequence AB will receive a single 200 mg dose of test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 1 and a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
89526057|NCT04038008|Other|Sequence BA|13 subjects assigned to the sequence BA will receive a single 200 mg dose of reference product Diflucan® (1 x 200 mg hard capsule), marked as B in the sequence, in Period 1 and test product Fluconazole (1 x 200 mg tablet), marked as A in the sequence, in Period 2. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a minimum of 10-hour overnight fast. The tablet or hard capsule must be swallowed whole and must not be chewed or broken.
89526058|NCT04036799||Hypertrophic Cardiomyopathy|
89526059|NCT04019821|Active Comparator|Normal Bolus|Pre-breakfast insulin will be given as a Normal Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Normal Bolus will be calculated based on individual insulin-to-carbohydrate ratio (ICR).
89526060|NCT04019821|Experimental|Super Bolus|Pre-breakfast insulin will be given as a Super Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Super Bolus will be calculated based on individual ICR increased to 150% and basal insulin will be suspended for 2 hours at the same time.
89526061|NCT04017039|No Intervention|Phase 1|Phase I is a cross-sectional study to compare endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep more than 7 hours/night (normal sleep) and those who habitually sleep less than 6.5 hr/night (short sleep)
89526062|NCT04017039|Experimental|Phase 2|Phase II is an intervention study to determine the effects of individualized targeted sleep interventions that increase sleep duration and improve sleep quality on endothelial vasodilator and fibrinolytic function in adults with elevated blood pressure who habitually sleep less than 6.5 hr/night (Specific Aims 3).
89526063|NCT04009343|Active Comparator|Artemether-lumefantrine|Standard 6-dose regimen
89526064|NCT04009343|Experimental|Dihydroartemisinin-piperaquine|Standard 3-dose regimen
89526065|NCT04008199|No Intervention|Control|Control group will not receive any intervention. Households in this group will only be surveyed.
89526066|NCT04008199|Experimental|Treatment|Treatment group will receive an invitation to join Super Abbu in addition to identical surveys to those in the control group.
89526067|NCT04001842|Experimental|Axially vascularized constructs|Reconstructing a mandibular defect using an axially vascularized bone substitute using the arteriovenous loop (AVL)
89526068|NCT03991923|Experimental|Non-ischemic heart preservation (NIHP)|Continous cold cardioplegic perfusion of hearts
89526069|NCT03991923|Active Comparator|Ischemic cold static storage (ICSS)|Standard preservation technique
89526070|NCT03984708|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
89526071|NCT03984708|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
89526072|NCT03980977|Other|skin and/or tumor Biopsy and blood sample|
89526073|NCT03940703|Experimental|Tepotinib and Osimertinib|Participants will receive a combination of tepotinib and osimertinib. The combination will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
89526074|NCT03940703|Experimental|Tepotinib Mono-therapy|Participants will receive once daily dose of tepotinib. The mono therapy will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
89526075|NCT03918798|Experimental|Chloroprocaine 1%|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
89526076|NCT03918798|Experimental|Chloroprocaine 2%|All the eligible patients will be administrated by Chloroprocaine 2 % according to the randomization criteria.
89526077|NCT03909815|Experimental|Intervention|Insertion of dual mobility cup
89526078|NCT03909815|Active Comparator|Control|Insertion of standard cup
89526079|NCT03909737|Experimental|Azithromycin to pregnant women and azithromycin to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week Expanded Programme on Immunization (EPI) visits
89526080|NCT03909737|Experimental|Azithromycin to pregnant women and placebo to infants|2 gram oral dose of Azithromycin to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
89526081|NCT03909737|Experimental|Placebo to pregnant women and azithromycin to infants|Oral placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
89526082|NCT03909737|Placebo Comparator|Placebo to pregnant women and placebo to infants|Placebo to pregnant women at their 2nd and 3rd trimester antenatal care visits and during delivery, plus oral placebo to infants at 6 and 14 week EPI visits
89526083|NCT03909737|Experimental|No intervention to pregnant women and azithromycin to infants|No intervention to pregnant women and 20 mg/kg to 1 gram oral dose of azithromycin to infants at 6 and 14 week EPI visits
89526084|NCT03909737|Placebo Comparator|No intervention to pregnant women and Placebo to infants|No intervention to pregnant women and placebo to infants at 6 and 14 week EPI visits
89526085|NCT03882645|Experimental|CHH-diet arm|"During the 4-week intervention period, free meals conformed to CHH-diet will be provided 3 times per daily (breakfast, lunch, dinner). Different center offers different meals of different cuisines but all conformed to CHH-diet. The main nutrientional healthy goal of different cuisines will be achieved through specific nutrient targets, including fat, carbohydrate, protein, dietary fiber, sodium, potassium, magnesium and calcium."
89526086|NCT03882645|Other|local usual diet arm|During the 4-week intervention period, three meals per day (breakfast, lunch, dinner) will be provided free of charge in line with local dietary characteristics. The energy,protein, carbohydrate, as week as dietary fiber, sodium, calcium, magnesium and potassium will be kept the same as that in the run-in phase.
89526087|NCT03864133|Other|Omidria|Phenylephrine/Ketorolac (1%/0.3%) will be administered to all participants enrolled into the study.
89526088|NCT03861403|Experimental|All Solid Tumors|"Phase 1b, Part 1 Dose Escalation: TRX518 + CTX Combination (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Assigned dose of cyclophosphamide administered intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle~Phase 1b, Part 2 Dose Escalation: TRX518 + CTX + avelumab in (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide administered at the MTD from Part 1 intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle"
89526089|NCT03861403|Experimental|Advanced Triple Negative Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
89526090|NCT03861403|Experimental|Advanced Hormone Receptor+/Endocrine Refractory Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
89526091|NCT03861403|Experimental|Advanced Metastatic Castration-Resistant Prostate Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
89526092|NCT03861403|Experimental|Advanced Platinum-Resistant Ovarian Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
89526093|NCT03857594||Individuals at risk of hereditary cancer syndrome|All individuals at risk of a hereditary cancer syndrome with or without a known germline mutation from clinical genetic testing.
89526094|NCT03853395|Active Comparator|Control Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will not receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant.
89526095|NCT03853395|Experimental|Experimental Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant. They will be able to act accordingly.
89526096|NCT03842995|Placebo Comparator|Genetic Counselor|Standard of Care. Parents/caregivers of neonates enrolled in SouthSeq will receive counseling on their child's Whole Genome Sequencing (WGS) results from Genetic Counselors
89526097|NCT03842995|Experimental|Trained Healthcare Provider|Healthcare providers (e.g., neonatologists and neonatology nurse practitioners) will receive training to competently deliver Whole Genome Sequencing results to parents/caregivers of neonates enrolled in SouthSeq
89526098|NCT03837158|Experimental|Control-group|Two Tissue Level TiZr Sand blasted long grit acid-etched (SLA) implants placed in positions 33 and 43 (diameter 3.3mm, length ≥10mm), early loading
89526099|NCT03837158|Experimental|Experimental-group|Four narrow-diameter implants (NDI) TiZr SLA implants in positions 34, 32, 42, and 44 (diameter 2.4mm, length ≥10mm), immediate loading
89526100|NCT03833024|Active Comparator|Venixxa|Micronized Purified Flavonoid Fraction (MPFF) for 6 months MPFF 500 mg, BID (morning and evening) for 6 months
89526101|NCT03833024|Placebo Comparator|Placebo|"Placebo for 6 months~1 Tablet, BID (morning and evening) for 6 months"
89526102|NCT03832257|Experimental|ECHO CT Intervention|Weekly video conference between hospitalist at Beth Israel and skilled nursing facilities.
89526103|NCT03832257|Other|Matched Non- Participating Facilities|Matched non-participating facilities
89526104|NCT03830151|Experimental|Diagnostic (carbon C 13 pyruvate, MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and then undergo an MRSI scan.
89526105|NCT03823157|Experimental|Tai Chi|Tai Chi exercise
89526106|NCT03819660|Experimental|amifampridine phosphate|The dose of amifampridine was based on optimal neuromuscular benefit determined from the Run-in Period from SMA-001 or could be modified as the discretion of the Investigator. The maximum single dose was 20 mg. The dose range for patients 6 to 16 years of age was 15 to 60 mg, and for those 17 years and older the range was from 30 to 80 mg daily.
89526107|NCT03818672|Experimental|Rifaximin|Rifaximin 550 mg BID
89526108|NCT03815604|Experimental|RCT-IHS|Behavioral: At the Zurich site, the experimental intervention is called Independent Housing and Support
89526109|NCT03815604|Active Comparator|RCT-RCS/TAU|Behavioral: At the Zurich site, the comparator is usual residential care
89526110|NCT03815604|Experimental|OSD-IHS|Behavioral: At the Berne site, the experimental intervention is called Independent Housing and Support
89526111|NCT03815604|Active Comparator|OSD-RCS/TAU|Behavioral: At the Berne site, the comparator is usual residential care
89526112|NCT03810365|Experimental|Behavioral: Brief behavioral treatment for insomnia|Brief behavioral treatment for insomnia includes 45 minute individual intervention with two follow up phone calls.
89526113|NCT03810365|Active Comparator|Behavioral: Healthy eating control|Healthy eating control involves a 45 minute individual session with two follow up phone calls.
89526114|NCT03805516|Experimental|Intervention|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.~12 weekly SCOPP-CW educational modules delivered via WeChat.~6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences"
89526115|NCT03805516|Active Comparator|Control|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.~12 weekly non-tailored educational modules on general health topics delivered via WeChat."
89526116|NCT03792490|Experimental|Fasudil 30 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 30 mg/ day Frequency: 2 x 15 mg Duration of treatment: 20 days
89526117|NCT03792490|Experimental|Fasudil 60 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 60 mg/ day Frequency: 2 x 30 mg Duration of treatment: 20 days
89526118|NCT03792490|Placebo Comparator|Placebo|Sodium chloride (NaCl) 0.9% Dosage form: intravenous, application over 45 minutes Dosage: 100 ml Frequency: 2 x Duration of treatment: 20 days Do2 x 1 ml, NaCl 0.9%
89526119|NCT03772366||Antivitamin K|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Fluindione
89526120|NCT03772366||Rivaroxaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Rivaroxaban
89526121|NCT03772366||Apixaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Apixaban
89526122|NCT03772366||Control|Women in childbearing age with superficial venous insufficiency without treatment oral anticoagulant or antiplatelet.
89526123|NCT03772119||Surgical treatment of hemivertebra|cohort of children with a vertebral malformation treated by surgical resection
89526124|NCT03771612|Active Comparator|Naproxen|
89526125|NCT03771612|Placebo Comparator|Placebo|
89526126|NCT03769259|Experimental|Brief Cognitive Behavioral Therapy|
89526127|NCT03769259|Active Comparator|Present-Centered Therapy|
89526128|NCT03752216|Experimental|NIRAPARIB|Oral Niraparib Daily
89526129|NCT03752034|Experimental|Muscle Fiber Fragments (MFF)|Participants undergoing rotator cuff repair will have autologous muscle tissue harvested. The tissue will be processed to obtain Muscle Fiber Fragments (MFFs) and administered via direct injection into the supraspinatus muscle belly.
89526130|NCT03742960|Experimental|Behavioral Sleep Restriction|Participants will be required to go to sleep half an hour later than their usual bedtime. Wake up time will be determined via their usual wake time.
89526131|NCT03730753|Active Comparator|Control group|Continuous infusion + patient controlled epidural analgesia
89526132|NCT03730753|Experimental|Study group|Programmed intermittent epidural bolus + patient controlled analgesia
89526133|NCT03729687|Experimental|LARCT-US|Short Course Radiation Therapy (5 x 5 Gy in 1 week, scRT) followed by 4 cycles of Pre-operative Chemotherapy using capecitabine and oxaliplatin (CAPOX) and Surgery in High-risk Rectal Cancer
89526134|NCT03713424|Active Comparator|Clav|4-day 125 bid oral capsule administration
89526135|NCT03713424|Placebo Comparator|Placebo|4-day, twice-daily oral capsule administration
89526136|NCT03711773|Experimental|Group Physical Therapy Class|Group Physical Therapy Classes. Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
89526137|NCT03710421|Experimental|Treatment (leukapheresis, chemotherapy, CS-1 CAR T therapy)|Patients undergo leukapheresis over 2-4 hours. Beginning 3-4 weeks, patients receive cyclophosphamide IV on days -4 and/or -3 or fludarabine IV and cyclophosphamide IV on days -5 to -3. Patients then undergo CS1-CAR T therapy over 10-15 minutes on day 0.
89526138|NCT03705598|Placebo Comparator|Light physical exercise|Normal walking, light intensity resistance exercise and stretching, and health education discussions.
89526139|NCT03705598|Active Comparator|Tai Chi|Joint rotations and balance games, Tai Chi walking drills and the 8 forms.
89526140|NCT03682146|Other|RARP|robot-assisted laparoscopic prostatectomy
89526141|NCT03682146|Other|LRP|conventional laparoscopic radical prostatectomy
89526142|NCT03673709|No Intervention|Individual Antenatal Care (usual care)|Women are provided antenatal care services on a first come, first serve basis and listen to a health lecture. They meet individually with a midwife for a physical assessment. Women complete laboratory tests (including HIV testing) at their first visit. Congruent with the new WHO recommendations, individual antenatal care consists of 8 antenatal care visits and 2 postnatal visits at 1 week and 6 weeks.
89526143|NCT03673709|Experimental|Group Antenatal Care (intervention)|Women have the same number of visits as those in individual care. Their first antenatal care (intake) and first postnatal visit is done individually (identical to individual care). Women in group care bypass the waiting area and have a 2-hour visit with the same provider in a group of 8-12 women at a similar stage of pregnancy. Women assess their blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
89526144|NCT03671954|Experimental|TKA Intervention Group|The TKA intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy.
89526145|NCT03671954|Active Comparator|TKA Control Group|The TKA control group will receive standard physical therapy alone.
89526146|NCT03671954|Active Comparator|Healthy Control Group|The Healthy Control Group, aged 49-85 years without any signs of degenerative joint, disease will undergo the preoperative assessments only.
89526147|NCT03661827|Experimental|Patients with heart failure|Patients with heart failure
89526148|NCT03655236|Experimental|K0706, low dose|
89526149|NCT03655236|Experimental|K0706, high dose|
89526150|NCT03655236|Placebo Comparator|Placebo|
89526151|NCT03618537|Experimental|ixazomib|"Enrolled patients will receive ixazomib at a fixed dose of 4mg on days~1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. Treatment cycles will be repeated until disease progression for up to 24 cycles or until development of significant treatment-related toxicities."
89526152|NCT03612960|Experimental|Very low nicotine content cigarettes|Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
89526153|NCT03612960|Placebo Comparator|Normal nicotine content cigarettes|Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.
89526154|NCT03608475|Active Comparator|Comprehensive Ultrasound Group|Children in the comprehensive ultrasound protocol group will follow the current standardized treatment protocol used at the Hospital for Sick Children in Toronto, Canada. For children presenting with stable hip dysplasia, Pavlik harness (PH) treatment is initiated at the initial visit (week 0) and runs for a total of 12 weeks. Children return to clinic at weeks 2, 5, 8 and 12 for clinical and ultrasound examinations to ensure that the harness is fitting correctly, to screen for PH complications and to monitor acetabular development.
89526155|NCT03608475|Experimental|Limited Ultrasound Group|Children in the limited ultrasound protocol group will receive the same treatment as described for the comprehensive ultrasound group above, except the ultrasound imaging conducted at weeks 2, 5 and 8 will be omitted. Children will still return to clinic at 2, 5, and 8 weeks for clinical examination, which includes the assessment of the Pavlik harness fit and screening for complications.
89526156|NCT03605758|Active Comparator|Ivermectin on Days 1 and 2|Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.
89526157|NCT03605758|Active Comparator|Ivermectin on Days 1 and 14|Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.
89526158|NCT03586414|Experimental|A: 'MITOQUINOL MESYLATE then placebo|'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
89526159|NCT03586414|Experimental|B: Placebo then 'MITOQUINOL MESYLATE'|Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'
88807342|NCT05287932|No Intervention|Wait-list control|The control group will not receive any active or placebo intervention during the 4-week study period. They will also not receive any trial contacts during this period. They will however continue to be able to access their usual care from primary, secondary, community, and social services. After the final (4-week) follow-up assessment, this group will receive the full physical activity intervention.
89526160|NCT03567889|Experimental|Daromun plus Surgery and Adjuvant therapy (Arm 1)|Two-weeks screening period and a 4-weeks open-label treatment period, followed by surgery within a maximum of another 4 weeks and adjuvant therapy (Arm 1).
89526161|NCT03567889|Active Comparator|Surgery and adjuvant therapy (Arm 2)|Patients in the control arm (Arm 2) will receive direct surgery within 4 weeks from randomization, followed by adjuvant therapy.
89526162|NCT03546894||Brigatinib|The dosage and regimen of brigatinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
88807343|NCT01657500|Active Comparator|Life 4°C media for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
89526163|NCT03546894||Any FDA Approved ALK Inhibitor Other Than Crizotinib|The dosage, regimen of any Food and Drug Administration (FDA) approved ALK inhibitor (at any point in therapy) other than crizotinib will be decided by participant's prescribing physician and will not be determined by participation in the study.
89526164|NCT03531736|Experimental|Patients with Myeloid Malignancies & Aplastic Anemia|Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
89526165|NCT03522610|Experimental|ADAPT|Parents participate in a 14-week in person group based version of ADAPT with web-enhanced online ADAPT materials.
89526166|NCT03522610|No Intervention|Comparison Group|Parents receive services as usual (pamphlets, brochures, etc) on parenting typically found at a VA or Dr.'s office.
89526167|NCT03511209|Experimental|CBTI plus Taper method A|Participants in this arm will receive CBTI plus the novel hypnotic tapering method.
89526168|NCT03511209|Active Comparator|CBTI plus Taper method B|Participants in this arm will receive CBTI plus the usual tapering method used by the VA.
89526169|NCT03504501|Experimental|Exp. I: Noonan Syndrome - Lovastatin|200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance
89526170|NCT03504501|Experimental|Exp. II: Noonan Syndrome - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
89526171|NCT03504501|Experimental|Exp. III: Neurofibromatosis Type 1 - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
89526172|NCT03493971|Active Comparator|Carotid artery stenting (CAS)|Carotid revascularization performed using CAS
89526173|NCT03493971|Active Comparator|Carotid endarterectomy (CEA)|Carotid revascularization performed using CEA
89526174|NCT03451513|Experimental|Pride Body Project (PBP)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
89526175|NCT03451513|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
89526176|NCT03437681|Experimental|Insufficient sleep|Each participant will receive 4 nights of insufficient sleep.
89526177|NCT03404258||Study Patients|Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
89526178|NCT03404258||Control Patients|Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
89526179|NCT03371017|Experimental|Atezolizumab|Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle
89526180|NCT03371017|Placebo Comparator|Placebo|Participants will receive Placebo on day 1 of each 3-week treatment cycle
89526181|NCT03342976|Active Comparator|Cases|"Pre-frail subjects will use an ICT platform (my-AHA platform) embedded in a mobile phone and a fit-band that will continuously monitor physical and cognitive activities.~Interventions regarding physical, cognitive, psychological and social domains will be prescribed and monitored through the my-AHA platform. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
89526182|NCT03342976|Placebo Comparator|Controls|"Pre-frail subjects will be followed according to best standard of care protocols. Interventions regarding physical, cognitive, psychological and social domains will be prescribed. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
89526183|NCT03342534|Active Comparator|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
89526184|NCT03342534|Active Comparator|High definition (HD) anodal tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
89526185|NCT03342534|Active Comparator|Bihemispheric tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the primary motor cortex of the contralesional hemisphere.
89526186|NCT03342534|Sham Comparator|Sham tDCS|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
89526187|NCT03341143|Experimental|Fecal Microbiota Transplant (FMT) with Pembrolizumab|"The FMT along with an intestinal biopsy will be performed as outpatient by a gastroenterologist. The FMT is infused into the colon by performing a colonoscopy. FMT will be performed on Cycle 1 Day 1 and will take 15 to 30 minutes.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT), and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
89526188|NCT03305627|Experimental|Short PAP|Perioperative antibiotic prophylaxis will be stopped after 24h
89526189|NCT03305627|Active Comparator|Extended PAP|Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)
89526190|NCT03258658|Experimental|Autologous Engineered Urethral Construct|All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure. Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct. Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct. All subjects will be followed for 3 years for safety and efficacy.
89526191|NCT03248622||Anti-HBc positive|Anti-HBc positive
89526192|NCT03248622||HCV positive Cohort|HCV positive Cohort
89526193|NCT03222128|Experimental|PIIS3i - SAPIEN 3|PIIS3i - SAPIEN 3 is Operable Group
89526194|NCT03077386|Experimental|ENCOMPASS program|Clinics assigned to the intervention will receive the ENCOMPASS intervention and a CHN will be matched to their clinic and be available to patients that meet the eligibility criteria.
89526195|NCT03077386|No Intervention|Usual care|Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention.
89526196|NCT03076021|Other|Adolescents|dextromethorphan pre- and post isotretinoin
89526197|NCT03049189|Experimental|177Lu-edotreotide PRRT|"177Lu-edotreotide (177Lu-DOTATOC)~A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each.~Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)"
89526198|NCT03049189|Active Comparator|Everolimus|"Everolimus (Afinitor ®)~Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)"
89526199|NCT03016975|Experimental|Randomized - Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
89526200|NCT03016975|Active Comparator|Randomized - Control|Guideline directed medical therapy (GDMT)
89526201|NCT03016975|Experimental|Roll-In - Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
89526202|NCT03005782|Experimental|Monotherapy (REGN3767)|Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
89526203|NCT03005782|Experimental|Combination Therapy (REGN3767+cemiplimab)|Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion
89526204|NCT02994355|Experimental|Intervention Clinics|Clinics randomized to the intervention will be introduced to the Systems Analysis and Improvement Approach (SAIA) to understand barriers to HIV testing in family planning clinics. Sequential process flow mapping will be used to highlight areas for improvement and then specific interventions will be implemented for the clinics with the goal of increasing HIV testing rates.
89526205|NCT02994355|No Intervention|Control Clinics|Clinics randomized to the control arm of the study will continue HIV testing as per usual procedures.
89526206|NCT02935946|No Intervention|Room Temperature Swallows|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled RTS for room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study."
89526207|NCT02935946|Experimental|Cold Liquid Swallows- 5|"Immediately following the RTS condition, a total of 5 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS5 for cold swallows-5."
89526208|NCT02935946|Experimental|Cold Liquid Swallows- 10|"After 10 minutes of feeding a cold liquid, a total of 10 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS10 for cold swallows-10."
89526209|NCT02933892|Active Comparator|Transradial Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the arm access site (transradial access).
89526210|NCT02933892|Active Comparator|Transfemoral Access|Patients scheduled for cardiac catheterization will be randomly assigned to have the doctor insert the catheter via the inner thigh access site (transfemoral access).
89526211|NCT02931084||ACL injury|Patients with an acute (not more than 6 weeks old) anterior cruciate ligament (ACL) injury
89526212|NCT02931084||ACL reconstruction|Some of the patients with ACL injury will have reconstruction of the ACL. These will be followed as a new group.
89526213|NCT02911792|Experimental|Dapagliflozin/Hyperfiltration|Subjects with eGFR above 125 ml/min per 1.73 m2 will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day, Subjects who are taking Metformin at time of randomization will have Dapagliflozin added to current metformin.
89526214|NCT02911792|Active Comparator|Metformin/Hyperfiltration|Subjects who Drug naïve we will give Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).Subject who are on metformin at time of randomization we will add Glipizide 5 mg( to be increased to 10 mg at Visit 5), Subject who are on Glipizide at time of randomization will have Metformin- XR, 1000 mg/day added. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
89526215|NCT02911792|Experimental|Dapagliflozin/Normofiltration|Subjects with eGFR below 124 ml/min per 1.73 m2 will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day, Subjects who are taking Metformin at time of randomization will have add Dapagliflozin added to current metformin.
89526216|NCT02911792|Active Comparator|Metformin/Normofiltration|Subjects with eGFR below 124 ml/min per 1.73m2 drug naïve will receive Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).Subject who are on metformin at time of randomization we will add Glipizide 5 mg( to be increased to 10 mg at Visit 5), Subject who are on Glipizide at time of randomization we will add Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
89526217|NCT02906943||Advanced cancer|Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.
89526218|NCT02804815|Active Comparator|Aspirin 100mg|Aspirin 100mg
89526219|NCT02804815|Placebo Comparator|Placebo 100mg|100mg Placebo
89526220|NCT02804815|Active Comparator|Aspirin 300mg|Aspirin 300mg
89526221|NCT02804815|Placebo Comparator|Placebo 300mg|300mg Placebo
89526222|NCT02747914|Experimental|Transcranial magnetic stimulation therapy|Group of patients treated with rTMS low than 5Hz
89526223|NCT02747914|Active Comparator|Conventional exercise treatment|Group of patients treated with conventional exercise
89526224|NCT02729649|Experimental|ArmAssist therapy|The group will be treated with ArmAssist robot therapy.
89526225|NCT02729649|Active Comparator|Conventional therapy|The group will be treated with conventional therapy.
89526226|NCT02729649|Active Comparator|Extended Conventional therapy|The group will be treated with extended conventional therapy.
89526227|NCT02728154||Normal control|The subjects in the normal heart function group will provide a blood sample and stool sample.
89526228|NCT02728154||heart failure|The subjects in history of heart failure group will provide a blood sample and stool sample.
89526229|NCT02728154||pre-HFpEF|The subjects in history of diastolic dysfunction but not had heart failure clinical presentations group will provide a blood sample and stool sample.
89526230|NCT02718001|Experimental|Treatment|Treatment with the Edwards EVOQUE Eos mitral valve replacement system
89526231|NCT02704000|No Intervention|Control|No interventions - only baseline and endline assessments to be conducted at children's home.
89526232|NCT02704000|Experimental|Home visits by CDAs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained child development agents (CDAs). CDAs will implement the Jamaica curriculum intervention during the home visits..
89526233|NCT02704000|Experimental|Home visits by CHWs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained community health workers (CHWs) trained on delivering the intervention. CHWs will implement the Jamaica curriculum intervention during the home visits..
89526234|NCT02675114|Active Comparator|Surgical aortic valve replacement (SAVR)|
89526235|NCT02675114|Experimental|Transcatheter aortic valve replacement (TAVR)|
89526236|NCT02622854|Experimental|plasma exchange|plasma exchange, with 1.5 estimated plasma volume exchanged with albumin solution, using citrate anticoagulation, performed daily until triglycerides <=10 mmol/l
89526237|NCT02622854|Active Comparator|conservative treatment|infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l
89526238|NCT02615210|No Intervention|Standard|Standard of care biopsies with optional SOC-directed biopsy afterwards
89526239|NCT02615210|Experimental|Study|SOC-directed biopsies using the SpyGlass System plus standard of care biopsies
89526240|NCT02546128|Experimental|intervention|"rehabilitation + active-dose ESWT (extra-corporeal shockwave therapy)"
89526241|NCT02546128|Placebo Comparator|control|"rehabilitation + placebo-dose ESWT (extra-corporeal shockwave therapy)"
89526242|NCT02496624|Other|Lung cancer|
89526243|NCT02460887|Experimental|Experimental|Induction chemotherapy+IMRT gemcitabine and cisplatin regimen Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT).
89526244|NCT02460887|Active Comparator|Active Comparator|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with weekly cisplatin 40 mg/m² up to 7cycles.
89526245|NCT02388685|Experimental|Home exercise|Patients will undergo home exercise therapy under the supervision of the exercise laboratory
89526246|NCT02388685|No Intervention|No exercise|Patients will continue with usual care
89526247|NCT02321228|Experimental|Salpingectomy with delayed oophorectomy|Female BRCA mutation carriers can opt for early salpingectomy upon completion of childbearing, followed by second stage oophorectomy delayed for five years beyond current guideline ages for risk-reducing salpingo-oophorectomy (i.e. age 40-45 for BRCA1 mutation carriers and 45-50 for BRCA mutation carriers).
89526248|NCT02321228|Active Comparator|Risk-reducing salpingo-oophorectomy|Female BRCA mutation carriers can opt for standard risk-reducing salpingo-oophorectomy at current guideline ages (age 35-40 for BRCA1 mutation carriers and age 40-45 for BRCA2 mutation carriers).
89526249|NCT02203643|Experimental|CCyd|"Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
89526250|NCT02203643|Experimental|CRd|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
89526251|NCT02203643|Experimental|CRd long treatment|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. Stem cells collection will be performed. Carfilzomib Lenalidomide and Dexamethasone administered for 8 28-day cycles.~After that all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
89526252|NCT02173080||Polycystic liver disease patients|will receive PLD-Q, EORTC QLQ-30 symptoms subscale, EQ5D-VAS score and SF36
89526253|NCT02173080||ADPKD group without PLD|will receive PLD-Q
89526254|NCT02173080||Healthy controls|receive PLD-Q
89526255|NCT02173080||PLD patient focus group|to discuss and improve PLD-Q
89526256|NCT02173080||PLD clinical expert focus group|to discuss and improve PLD-Q
89526257|NCT02155946|Experimental|active tDCS + mnemonic strategy training|Group receives active brain stimulation plus memory rehabilitation
89526258|NCT02155946|Active Comparator|sham tDCS + mnemonic strategy training|Group receives sham brain stimulation plus memory rehabilitation
89526259|NCT02155946|Active Comparator|active tDCS + autobiographical memory recall|Group receives active brain stimulation plus reminiscence training
89526260|NCT02155946|Active Comparator|sham tDCS + autobiographical memory recall|Group receives sham brain stimulation plus reminiscence training
89526261|NCT02146924|Experimental|Arm I (cellular immunotherapy closed to accrual January 2019)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells after 28 days.
89526262|NCT02146924|Active Comparator|Arm II (cellular immunotherapy)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells after 28 days.
89526263|NCT02026908|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
89526264|NCT02006134||PEDIATRIC VASCULITIS/PROSPECTIVE|Pediatric patients in this cohort are those diagnosed with vasculitis within 12 months from study entry. Clinical data, blood (RNA, plasma, serum), urine, and saliva (DNA) will be collected at 3 to 5 timepoints: time-of-diagnosis, post-induction, 12-month post diagnosis, disease flare, and remission/post-flare.
89526265|NCT02006134||PEDIATRIC VASCULITIS/RETROSPECTIVE|Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA & serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.
89526266|NCT01994824|Experimental|Intervention arm|"Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8)."
89526267|NCT01882023||Eating disorder|Patients currently in treatment for eating disorders.
89526268|NCT01882023||Healthy Controls|Age- and gender matched healthy controls.
89526269|NCT01867606|Experimental|Arm I (serum-derived bovine immunoglobulin protein isolate)|"Patients receive SBI PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
89526270|NCT01867606|Placebo Comparator|Arm II (placebo)|"Patients receive placebo PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
89526271|NCT01828112|Experimental|Ceritinib|Patients in this arm received 750 mg of ceritinib.
89526272|NCT01828112|Active Comparator|Chemotherapy|Patients in this arm received chemotherapy of either pemetrexed or docetaxel as determined by BIRC.
89526273|NCT01786590|Experimental|EBUS-TBNA|
89526274|NCT01740427|Experimental|PD-0332991 + Letrozole|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
89526275|NCT01740427|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
89526276|NCT01657682|Experimental|Cohort A - No prior FLT3 TKI exposure|Will enroll relapsed/refractory AML patients with FLT3 activating mutations who progressed on one or more prior chemotherapy regimens excluding any FLT3 TKI.
89526277|NCT01657682|Experimental|Cohort B - Prior therapy with FLT3 TKI|Will enroll relapsed/refractory AML patients with FLT3 activating mutations whose leukemia has progressed and have history of prior therapy with one or more FLT3 TKIs.
89526278|NCT01644292|Experimental|EPIC Wheels Training Intervention|EPIC Wheels skills training program
89526279|NCT01556243|Experimental|Breast conservation surgery and radiation therapy|Patients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy.
89526280|NCT01516125||Screening only - no intervention|
89526281|NCT01477957||Surgery|bariatric surgery
89526282|NCT01421771|Active Comparator|Treatment to an intensive BP goal|Treatment to a pre-dialysis standardized dialysis unit systolic blood pressure of 110-140 mm Hg
89526283|NCT01421771|Placebo Comparator|Treatment to standard BP goal|Treatment to a pre-dialysis Standardized dialysis unit systolic BP of 155-165 mm Hg
89526284|NCT01352858|Experimental|TolDC|Experimental arm - TolDC administered arthroscopically
89526285|NCT01352858|Placebo Comparator|Control|Arthroscopy & saline irrigation alone
88807344|NCT01657500|Active Comparator|Optisol GS|Donor cornea is stored in the Optisol GS media prior to implantation.
88807345|NCT00411086|Experimental|Rituximab + GM-CSF|Rituximab 375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22. Sargramostim (GM-CSF) 250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
89526286|NCT01238432||Inpatient population|Children with asthma who are admitted to the hospital with an exacerbation.
89526287|NCT01238432||Outpatient population|Children with asthma who have not been admitted to the hospital with an exacerbation.
89526288|NCT01238432||Healthy controls|Children without asthma or any other chronic condition.
89526289|NCT01135199|Other|Treatment|Open label
89526290|NCT01128218|Experimental|Phase 1 Dose Level 1 (10mg/kg)|Dose Level 1: Participants were given a one-time, single-dose administration of oral 10mg/kg Aminolevulinic Acid (5-ALA)
89526291|NCT01128218|Experimental|Phase 1 Dose Level 2 (20mg/kg)|Dose Level 2: Participants were given a one-time, single-dose administration of oral 20mg/kg Aminolevulinic Acid (5-ALA)
89526292|NCT01128218|Experimental|Phase 1 Dose level 3 (30mg/kg)|Dose Level 3: Participants were given a one-time, single-dose administration of oral 30mg/kg Aminolevulinic Acid (5-ALA)
89526293|NCT01128218|Experimental|Phase 1 Dose level 4 (40mg/kg)|Dose Level 4: Participants were given a one-time, single-dose administration of oral 40mg/kg Aminolevulinic Acid (5-ALA)
89526294|NCT01128218|Experimental|Phase 1 Dose level 5 (50mg/kg)|Dose Level 5: Participants were given a one-time, single-dose administration of 50mg/kg Aminolevulinic Acid (5-ALA)
89526295|NCT01128218|Experimental|Phase 2 (40mg/kg)|Phase 2: Participants were given a one-time, single-dose administration of 40mg/kg Aminolevulinic Acid (5-ALA)
89526296|NCT01067157|Other|A|"Other = Lifestyle intervention~A: Medical examination before and after inpatient therapy (clinic staff), questionnaires.~Further medical examination and questionnaires after 6 months, 1, 2, 5 and 10 years at home by pediatrics or general practitioner.~The lifestyle intervention includes an age-specific diet (1200-1800 kcal/d), 11 h/wk physical activity (walking, swimming, sports) and behavioural therapy."
89526297|NCT00943423|Active Comparator|Arm I|Within 6 weeks after completion of course 3 of chemotherapy, patients undergo involved field radiotherapy to disease areas.
89526298|NCT00943423|Experimental|Arm II|Patients receive no further treatment.
89526299|NCT00882193|Experimental|Safety & Efficacy of Betaine Combined with Standard Anti-viral Therapy|"The primary objective is to examine safety & efficacy of betaine when combined with standard anti-viral therapy in previously treated adult subjects with chronic hepatitis C infected with genotype 1. Efficacy will be determined through comparison of the sustained viral response (SVR) to our protocol three-drug regimen (Betaine, Peginterferon plus Ribavirin) to that historically seen in relapsers and non-responders when retreated with standard therapy (Peginterferon and Ribavirin alone).~Betaine (trimethylglycine) dose is 10 gm twice a day for 48 weeks. Pegasys (peginterferon alpha 2a) dose is 180mcg/0.5 ml subcutaneous injection for 48 weeks. Coegus (ribavirin) dose is 200mg - weight based, 1000 - 1200 mg/day for body weight or 75mg in 2 divided doses."
89526300|NCT00819156|Experimental|Degarelix 200/80|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
89526301|NCT00819156|Experimental|Degarelix 200/120|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
89526302|NCT00819156|Experimental|Degarelix 200/160|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
89526303|NCT00819156|Experimental|Degarelix 240/80|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
89526304|NCT00819156|Experimental|Degarelix 240/120|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
89526305|NCT00819156|Experimental|Degarelix 240/160|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
89526306|NCT00818623|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
89526307|NCT00818623|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
89526308|NCT00818623|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
89526309|NCT00818623|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
89526310|NCT00818623|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
89526311|NCT00818623|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
89526312|NCT00818623|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
89526313|NCT00818623|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
89526314|NCT00774371|Experimental|1|The intervention program consists of group sessions provided according to the following schedule: weekly for 4 months, every other week for two months, and follow-up monthly sessions through 18 months of active subject participation. The time points for data collection from all subjects are baseline, 6 months, and 18 months. The group sessions offered to the treatment study arm are closed-group contingents with an average of 12-15 women assigned to each group.
89526315|NCT00756639|Experimental|Radiation|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks. On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
89526316|NCT00755898|Active Comparator|1|Patients with a medical diagnosis of cancer appearing at outpatient clinics for treatment and/or monitoring of their disease status
89526317|NCT00755898|Active Comparator|2|Healthy adult volunteers
89526318|NCT00582478||1|women with breast cancer
89526319|NCT00567606|Experimental|Strength/Weight Training|Subjects in the G1 group receive drug/supplement combination and strength/weight training exercises for upper and lower extremities and the spine.
89526320|NCT00567606|Experimental|Drug Supplement only|Subjects in the G2 group receive drug/supplement combination, but do not participate in strength/weight training exercises.
89526321|NCT00540995|Experimental|Arm I: 1200cGy|"1200cGy = 150cGy x 8 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.~GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive GVHD prophylaxis that excludes methotrexate."
89526322|NCT00540995|Experimental|Arm II: 1350cGy|1350cGy = 150cGy x 9 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.
89526323|NCT05431959|Experimental|Self-controlled|"The skin microbiome was collected by swabbing method from the crook of the arm (normal skin) and the nearest plaque's surface.~Balneotherapy in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l."
89526324|NCT01285557|Experimental|S-1+Cisplatin|Participants received S-1 25 milligrams per meter square (mg/m^2) orally twice daily (BID) every 12 hours from Day 1 through Day 21, 1 hour before or after meal with a glass of water; followed by a 7-day rest period from Day 22 to Day 28 in a 28-day cycle. Participants received a single dose of cisplatin 75 mg/m^2 as a 1- to 3-hour intravenous (IV) infusion on Day 1 following the morning dose of S-1 for a maximum of 8 cycles (each cycle of 28 days). Participants received study medication until progression of disease (PD), adverse event (AE), withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
89526325|NCT01285557|Active Comparator|5FU+Cisplatin|Participants received 5-Fluorouracil (5-FU) 800 mg/m^2 per 24 hours as continuous IV infusion over 120 hours from Day 1 through Day 5 followed by a 16-day rest period on Days 6 through 21 in a 21-day cycle. Participants received a single dose of cisplatin 80 mg/m^2 as a 1- to 3-hour IV infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles (each cycle of 21 days). Participants received study medication until PD, AE, withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
89526326|NCT03351283|Experimental|Severe sodium restriction|"Patients will be assigned to a diet with two grams of sodium. The nutritionist will be responsible for calculating diets appropriate to the needs of each patient. The diet will not have the intention to modify the weight of the patient but only to indicate the menus that the patients will follow. All the patients will be explained the diet. Patients will be allowed a maximum intake of 1.5 liters of water per day, including the liquid of soups, juices and drinks; This will be explained in detail to the patients.~The diets will be identical in calories according to the weight of the patient. The only difference in diets will be the sodium content, which will be 2 grams of sodium vs. 3 grams of sodium."
89526327|NCT03351283|Active Comparator|Moderate sodium restriction.|Patients will be assigned to a diet with three grams of sodium.
89526328|NCT03083067|Experimental|Salvational intervention(SI) group|Budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug on the foundation of original treatment.
89526329|NCT03083067|Active Comparator|Control(CT) group|CT group maintain the original treatment
89526330|NCT03406975|Active Comparator|Control Group: Lifestyle Modification|Participants randomized to the control group (lifestyle modification only) in Year 1 will undergo a standard moderate intensity life-style intervention during the first 12 months of participation.
89526331|NCT03406975|Experimental|Treatment Group: Overstitch ESG Procedure|Participants randomized to the treatment group will proceed to have the Overstitch Endoscopic Sleeve Gastroplasty (ESG) at the start of Year 1 and will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. All patients undergoing ESG will go on a 6 weeks transitional diet.ESG patients will undergo a standard moderate intensity life-style intervention administered over 15 12 visits in the first year after ESG. ESG patients who have not achieved >25% EWL at the end of Year 1 will undergo a repeat upper endoscopy at 52 to 60 weeks to assess the durability of the plications. Patients will continue follow-up with a modified lifestyle intervention program administered over 6 visits in the second year
89526332|NCT03406975|Experimental|Crossover Group: Lifestyle Intervention to ESG Procedure|Control group participants (lifestyle modification only) who were compliant with at least 75% of visits in Year 1, have not achieved ≥25% EWL or have a BMI >30 measured at the week 52 visit, and have no new psychosocial contraindications as deemed by the treatment team to the procedure will cross over to receive the Overstitch ESG in Year 2, in addition to the standard moderate intensity lifestyle intervention program of 12 months.
89526333|NCT03023241|Experimental|all study patients|Same intervention for all subjects: anamnesis, questionnaires and biological samples (bladder biopsy, bladder washing, blood and urine) are collected at one single visit.
89526334|NCT05431569|Experimental|6MW3211|6MW3211injection,30mg/kg,Q2W
89526335|NCT02994771|Active Comparator|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
89526336|NCT02994771|Active Comparator|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
89526337|NCT02512549|Active Comparator|Rehabilitation|Patients with diagnosed Chronic Obstructive Pulmonary Disease with severe airflow obstruction (spirometric forced expiratory volume in one second (FEV1) below 50% of the normal) and modified medical research council (mMRC) dyspnea grading 1 to 3 will undergo pulmonary rehabilitation program thrice a week for 2 months.
89526338|NCT02512549|No Intervention|Usual Care|Patients with COPD as described in rehabilitation arm, will be provided usual care from the hospital outpatient clinic.
89526339|NCT02512627|Active Comparator|Cognitive training group (Cog)|The BrainHQ program will be used to train different cognitive functions of the participants. The participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions. The tasks will become more difficult as the participants progress in their abilities.
89526340|NCT02512627|Active Comparator|Physical exercise group (PE)|The participants in this group participate in multimodal exercise programs including aerobic exercise, balance, and strength training. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The 70 minutes of exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period.
89531995|NCT04246593|Experimental|Intervention - Market|"Partner sites that are randomized to the Intervention - Market will plan and start (or expand) a Mobile Market and run the Market weekly for at least 10 months (non necessarily nonconsecutive). The Mobile Market will follow the Veggie Van Model which includes a share model, price reductions (incentives), and an educational component."
89526341|NCT02512627|Experimental|Sequential training group (Seq)|The participants in this group will first perform 45 minutes of physical exercise followed by 45 minutes of cognitive training. The physical exercise training will be similar to the programs used in the PE group. The entire exercise program for the PE group will contain 5 minutes of warm-up, 35 minutes of physical exercise, and 5 minutes of cool-down. The cognitive training will be implemented with BrainHQ similar to what has been described in the COG group.
89526342|NCT02512627|Experimental|Dual-task training group (Dual)|In this group, the participants will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance.
89526343|NCT02992431|Active Comparator|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
89526344|NCT02992431|Experimental|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
89526345|NCT03346291|Experimental|Persistence Targeted Smoking Cessation|8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
89526346|NCT03346213||Major surgery|"Adult patients undergoing elective surgery~Having a CPET as part of routine care~Patients with a Hb value of < 130 g/L who are iron deficient, iron restricted/deplete or have functional iron deficiency.~Able to provide written informed consent."
89526347|NCT03345043|Experimental|VAL-339851|
89526348|NCT03345043|Placebo Comparator|Placebo|
89526349|NCT05638399|Experimental|Denosumab|denosumab (60 mg subcutaneously, per 6 month)
89526350|NCT05638399|Active Comparator|zoledronate|zoledronate (5mg, intravenous infusion once a year)
89526351|NCT03346369|Experimental|Experimental single arm|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period.
88807346|NCT05191524|Experimental|Constrained induced movement therapy|"In this group of patients, they will use the CIMT technique for treatment. Patient will perform following tasks, while unaffected limb in constrains for 3 hours/day~Sit-to-Stand~Forward and Backward stepping~Stair Climbing and Descending (only the first stair will be used)~Side-to-Side stepping with the affected limb"
88814466|NCT04357808|Active Comparator|Standard of care|Treatment with drugs or procedures in routine clinical practice
88814467|NCT04366622|Experimental|Riociguat, Child Pugh A|Participants with liver cirrhosis and mild hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
89526352|NCT02512471|Experimental|middle aged group|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB
89526353|NCT02512471|Active Comparator|young group|brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB
89526354|NCT02517385|Experimental|Phosphatidylcholine paste|One dose of phosphatidylcholine paste 600 mg given orally 3 times a day at Days 0, 28, 56, and 84
89526355|NCT04499443|Experimental|Single-dose experimental group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo. Each group was administered once, under the fasting condition of Day1, and the tolerance was evaluated on Day2，Day4 and Day6. Subjects in different dose groups were enrolled in turn, and the next set of trials was conducted on the premise that the previous set of tolerability assessments were tolerated. The actual completion of the final dose, depending on the test results.
89526356|NCT04499443|Placebo Comparator|Single-dose control group|10mg, 30mg, 60mg, 100mg, 150mg, 200mg, 250mg and 300mg need to complete a single-dose clinical study, each group of 10 subjects, of which 8 received test drugs, 2 received placebo.
89526357|NCT04499443|Experimental|Multi-dose experimental group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo. It is necessary to decide the multiple administration method and dosage according to the result of single administration, which is initially determined to be once a day. After the first dose, Day3, Day6, Day8 and Day12 were evaluated for tolerance, and the next group of tests was conducted under the premise that the previous group of Day12 tolerance evaluation was tolerated.
89526358|NCT04499443|Placebo Comparator|Multi-dose control group|According to the results of the single-dose study, it is planned to carry out multiple-dose studies in 1 to 3 dose groups. A total of 12 subjects in each dose group, of which 10 received the test drug, 2 received placebo.
89526359|NCT04499443|Experimental|Food Impact Study Group A|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
89526360|NCT04499443|Experimental|Food Impact Study Group B|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 ~ Day15 in the second cycle. Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 ~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days. In group A, the tolerance evaluation was conducted on Day2, Day4 and Day6 after the first administration. After the first dose of group A is completed and the tolerability evaluation result is considered tolerable, the second cycle of this group and the first cycle of group B can be carried out.
89526361|NCT02992119|Experimental|Group 1|RTS,S/AS01B Fractional dose
89526362|NCT02992119|Experimental|Group 2|Double RTS,S/AS01E Fractional dose
89526363|NCT02992119|Experimental|Group 3|RTS,S/AS01E Standard dose
89526364|NCT02992119|Experimental|Group 4|RTS,S/AS01E + DHA-PIP+PQ Standard dose
89526365|NCT02992119|Experimental|Group 5|RTS,S/AS01E Fractional dose
89526366|NCT02992119|Experimental|Group 6|RTS,S/AS01E + DHA-PIP+PQ Fractional dose
89526367|NCT02992119|Experimental|Group 7|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose
89526368|NCT04500691||FBSS patients|FBSS patients who are treated with high frequency Spinal Cord Stimulation
89526369|NCT02507479|Experimental|thiotepa|Thiotepa 5-10 mg/kg/d x 2 days
89526370|NCT02512705|Other|Seclusion Room|The current practice is followed as a control group A.
89526371|NCT02512705|Experimental|Physical Restraint|Patient is placed in physical restraints to enable delivery of chemical restraints and medical monitoring and is monitored 1:1.
89526372|NCT03394365|Experimental|SOT cohort -Subgroup A|Participants who have failed rituximab will receive IV tabelecleucel.
89526373|NCT03394365|Experimental|SOT cohort -Subgroup B|Participants who have failed both rituximab and chemotherapy will receive IV tabelecleucel.
89526374|NCT03394365|Experimental|HCT cohort|Participants who have failed rituximab will receive IV tabelecleucel.
89526375|NCT02512315|Active Comparator|CCRT group (Group A)|Patients who are allocated into in this group will be treated with concurrent chemoradiation (CCRT).
89526376|NCT02512315|Experimental|NACT-CCRT group (Group B)|Patients who are allocated into in this group will be treated with 4 cycles of neoadjuvant chemotherapy (NACT, docetaxel plus cisplatin) followed by CCRT.
89526377|NCT02507401||Total laryngectomy patients|Users of voice prostheses
89526378|NCT02507323|Active Comparator|ticagrelor or matching placebo|ticagrelor (180 mg loading followed by 90 mg twice daily) or matching placebo
89526379|NCT02507323|Active Comparator|prasugrel or matching placebo|prasugrel (60 mg loading followed by 5-10 mg/d) or matching placebo
89526380|NCT02507245||GHD Children|Treatment with Growth Hormone-Releasing Hormone in children affected by idiopathic growth hormone deficiency (GHD)
89526381|NCT02517229|Other|in balance control in response to microgravity|to evaluate changes in balance control in response to microgravity during reactive balance tasks compared to normal gravity.
89526382|NCT02516917|Experimental|Attention Training Technique (ATT)|Participants will receive 3-5 sessions of the ATT over a period of 3-5 weeks. A set of standardised instructions will be read to each participant and then they will engage in the procedure for a period of 12 minutes. Participants will listen to a set of auditory stimuli and follow the directions of the recording. This will ask them to focus their attention on selected sounds or spatial locations, switch attention between different sounds and locations, before allocating their attention to all sounds simultaneously. Participants will be given a recording of the ATT on a C.D and asked to practice this at least once before the second session.
89526383|NCT05431257|Experimental|Elderly/unfit AML patients or sec. and R/R AML patients|
88814468|NCT04366622|Experimental|Riociguat, Child Pugh B|Participants with liver cirrhosis and moderate hepatic impairment received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
89526384|NCT02516995|Experimental|Patients with prostate cancer|
89526385|NCT05431023|Experimental|Patients with pneumonia who receive only treatment for pneumonia|They receive only treatment for pneumonia
89526386|NCT05431023|Experimental|pneumonia patients receive treatment for pneumonia and lactoferrin|They receive treatment for pneumonia and lactoferrin
89526387|NCT05430945|Experimental|Administration of BCMA Targeted CAR T-cells|Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.
89526388|NCT02517151|Experimental|Ferric carboxymaltose|200 mg in normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
89526389|NCT02517151|Placebo Comparator|Placebo|normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
89526390|NCT02507089|Experimental|Intervention|In this arm, the participants will receive access to a password protected website that features tailored information and educational materials on sleep health and the signs of sleep disorders such as obstructive sleep apnea (OSA). There will be both text-based information on sleep health and OSA, and also videos depicting narrative stories about patients who have been diagnosed with OSA and sought treatment.
89526391|NCT02507089|Active Comparator|Control|In this arm, participants will receive access to generic sleep educational materials that do not feature linguistic or cultural tailoring to the target population. This arm will include access to the same general information (materials on sleep health, sleep disorder signs and symptoms) but be intended for a general audience.
89526392|NCT04484727||ICU-patients in ventilator treatment|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each is performed and data on airway pressure and tidal volume changes collected. The data is transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes, suctioning, inhalation, CO2 insufflation etc. is performed, and repeated during the whole period of ventilator treatment."
89526393|NCT04484727||Surgery-patients during general anaesthesia|"Directly after intubation and start of mechanical ventilation, a two-PEEP-step up and down procedure with steps of 5-7 cmH2O each, is performed in the same way as described for ICU patients. Data of airway pressure and volumes are transferred into a dedicated software for calculation of ΔEELV by cumulative difference in expiratory tidal volume before and during PEEP inflation. Consequently, the lung P/V curve from baseline clinical PEEP to end-inspiration of the highest PEEP level. The PEEP level where clinically used tidal volume has the lowest transpulmonary driving pressure is calculated.~A one-PEEP-step procedure with a step of 5-7 cmH2O is performed when clinical events such as disconnection of the breathing circuit, posture changes or suctioning is performed, and before and after implementation of pneumoperitoneum."
89526394|NCT02507167|Placebo Comparator|mixed meal|
89526395|NCT02507167|Active Comparator|mixed meal 2 h after single dose rifampin (600 mg)|
89526396|NCT02512159|Experimental|drenovac handcrafted|Patients treatment with the handicraft topical device negative pressure therapy Economic craft
89526397|NCT02512159|Active Comparator|Healing|"Patients who were managed with traditional conservative treatment."
89526398|NCT02516839|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning.
89526399|NCT02516839|Experimental|Behavioral Weight Loss (BWL)|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
89526400|NCT02516839|Experimental|BWL+ ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments.
89526401|NCT02516839|Active Comparator|Nutrition Education, Stress Management Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
89526402|NCT02512237|Experimental|Phase 1a: Dose-Escalation|Six cohorts with escalated dose levels of ARX788 at 0.33 mg/kg, 0.66 mg/kg, 1.3 mg/kg, 2.2 mg/kg, 2.9 mg/kg and 3.8 mg/kg will be administered every 3 weeks via intravenous infusion to determine the MTD.
89526403|NCT02512237|Experimental|Phase 1b: Dose-evaluation 1|Breast cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
89526404|NCT02512237|Experimental|Phase 1b: Dose-evaluation 2|Breast cancer subjects with mid/low HER2 expression, categorized as ISH negative AND IHC2+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
89526405|NCT02512237|Experimental|Phase 1b: Dose-evaluation 3|Gastric cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
89526406|NCT01376167|Experimental|Tafenoquine 50mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 50mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
89526407|NCT01376167|Experimental|Tafenoquine 100mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 100mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
89526408|NCT01376167|Experimental|Tafenoquine 300mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
89526409|NCT01376167|Experimental|Tafenoquine 600mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 600mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
89526410|NCT01376167|Active Comparator|Primaquine 15mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15.
89526411|NCT01376167|Placebo Comparator|Chloroquine only|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered.
89526412|NCT01376167|Experimental|Tafenoquine 300mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
89526413|NCT01376167|Active Comparator|Primaquine 15mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15
89526414|NCT01376167|Placebo Comparator|Chloroquine only (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered
89526415|NCT02511769|Experimental|WEB-MAP CBT|Web-MAP Group. Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
89526416|NCT02511769|Active Comparator|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
89526417|NCT02516761|Experimental|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise.
89526418|NCT02516761|Experimental|Low-impact aerobic exercise|Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
89526419|NCT02516761|Active Comparator|Control group|With this group no intervention is done, but they are assessed like the other groups.
89526420|NCT02511613|Placebo Comparator|Placebo|Monthly intravitreal ranibizumab plus Placebo Ophthalmic solution
89526421|NCT02511613|Active Comparator|Active|Monthly intravitreal ranibizumab plus Squalamine Lactate Ophthalmic solution 0.2%
89526422|NCT02516683||Shigella sonnei-exposed cohort|Shigella sonnei infection - A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
89526423|NCT02516683||control cohort|A control cohort of age and sex-matched, non-infected 105 contemporary hospital employees.
89526424|NCT02506699||analgesic effect of rTMS|Observe the analgesic effect of rTMS, reference method of noninvasive stimulation of the motor cortex validated by data from the literature and current practice, after 5 separate sessions a week apart, patients with neuropathic pain chronic, refractory to first and second-line treatments proposed in a multidisciplinary center specializing in chronic pain Lower Normandy.
89526425|NCT02506777|Experimental|FDC x 6 cycles with metformin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with metformin 850 mg BID
89526426|NCT02506777|Experimental|FDC x 6 cycles with melatonin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with melatonin 3 mg before sleep daily
89526427|NCT02506777|Active Comparator|FDC x 6 cycles|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days
89526428|NCT04497571|Experimental|Piezoelectric osteotomy|Implant placement by piezoelectric osteotomy
89526429|NCT04497571|Active Comparator|Conventional drilling|Implant placement by conventional drilling
89526430|NCT02516527|Experimental|Induction Phase:Ipilimumab|Ipilimumab dose as specified
89526431|NCT02516527|Experimental|Maintenance Phase:Ipilimumab|Ipilimumab dose as specified
89526432|NCT02511847|Other|single-arm|"Drug: Afatinib (single group assignment)~First phase: Afatinib montherapy~The following phases: combination with oral afatinib and weekly paclitaxel in a 3-weekly course for total of four courses."
89526433|NCT02511691|Other|18F-PSS232|Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
89526434|NCT02516449|Experimental|Patient decision aids|Participants read and fill a patient decision aid before being provided education on asthma.
89526435|NCT02516449|No Intervention|Usual care|Participants do not read and fill a patient decision aid before being provided education on asthma.
89526436|NCT02511925||ICU Cluster 1|Adult Intensive Care Unit - Royal Brompton Hospital
89526437|NCT02511925||ICU Cluster 2|Paediatric ICU - Royal Brompton Hospital
89526438|NCT02511925||ICU Cluster 3|Adult Intensive Care Unit - Harefield Hospital
89526439|NCT02506621|Experimental|ELR monitoring|"Single arm study. All participants with existing permanent dual chamber pacemakers will be monitored with 5 different Loop recorder devices for a 2 week period to assess there sensitivity and specificity in detecting AF burden. The devices used will be~R test~Nuubo~TECHNOMED pocket ECG~ZIO xt patch~MoMe"
89526440|NCT02506855|Experimental|Group A|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and anesthetic will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight <70kg: Ropivacaine 75mg - 150 mg on each side (20mL ropivacaine 3.75mg/ml each side)~Weight greater than or equal to 70kg: Ropivacaine 100mg - 200mg on each side (20mL ropivacaine 5mg/ml each side"
89526441|NCT02506855|Placebo Comparator|Group B|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and the placebo solution will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight <70kg: 20mL each side~Weight greater than or equal to 70kg: 20mL each side"
89526442|NCT02506543|Experimental|COMPASS intervention|Subjects in this group will be pre-tested at the same time with the subjects in the Wait-list control group. Subjects in this group will receive the intervention immediately after the initial pre-test/baseline assessment, which includes life skills education, access to mentors in safe spaces, and a structured parenting intervention for girls' caregivers. Then, the subjects in this group have completed the intervention (at 12-months post-intervention initiation), the subjects in this group will take the post-test at the same time with the subjects in the Wait-list control group.
89526443|NCT02506543|Active Comparator|Wait-list control|No intervention
89526444|NCT02516371|Other|lymphocytes|To evaluate the subpopulation of lymphocytes in cancer patients
89526445|NCT02516293|Experimental|Intervention group|"Physical exercise intervention~Nutritional counseling~Pharmaceutical counseling"
89526446|NCT02516215||1_Hypertension|Patients with diagnosed hypertension, without other systemic diseases
89526447|NCT02516215||2_Diabetes mellitus|Patients with diagnosed diabetes mellitus, without other systemic diseases
89526448|NCT02516215||3_Hypertension and diabetes mellitus|Patients with both diagnosed hypertension and diabetes mellitus
89526449|NCT02516215||4_end stage renal disease with hemodialysis|Patients with end stage renal disease with hemodialysis
89526450|NCT02516215||5_Peripheral arterial occlusive disease|Patients with disgnosed peripheral arterial occlusive disease
89526451|NCT02516215||6_Coronary artery disease|Patients with diagnosed coronary artery disease
89526452|NCT02516215||7_liver cirrhosis|Patients with diagnosed liver cirrhosis
89526453|NCT02516215||8_Anemia|Patients with diagnosed anemia
89526454|NCT02516137|Experimental|Dry needling group|Subjects with tight hamstrings will receive dry needling to the hamstrings with the needle inserted into the muscle tissue in addition to a standard hamstring stretching exercise program.
89526455|NCT02516137|Sham Comparator|Sham dry needling group|Subjects with tight hamstrings will receive sham dry needling to the hamstrings with the needle inserted into the subcutaneous tissue in addition to a standard hamstring stretching exercise program.
89526456|NCT02516137|Placebo Comparator|No needling group|Subjects with tight hamstrings will receive no needling but have the tip of a blunt needle handle placed on the skin over the hamstrings in addition to a standard hamstring stretching exercise program.
89526457|NCT02511223|Experimental|Single Arm|Only one Arm,All patients will receive Olaparib 300 (mg) milligram bid p.o till disease progression
89526458|NCT02516059|Active Comparator|Oxycodone and naloxone (Targin®)|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
89526459|NCT02516059|Active Comparator|Oxycodone (Oxycontin®)|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
89526460|NCT02516059|Placebo Comparator|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
89526461|NCT02515981|Experimental|Incentives|Participants randomly assigned to the incentive arm, will receive cash incentives for engaging in healthy lifestyle behaviors.
89526462|NCT02515981|Experimental|No Incentives|Participants randomly assigned to the no incentives arm, will not receive cash incentives for engaging in healthy lifestyle behaviors.
89526463|NCT02506231|Experimental|Folinic acid|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
89526464|NCT02506231|Placebo Comparator|Placebo|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
89526465|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia|minizone with Microneedles pretreatment and Metvixia cream application
89526466|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia under occlusion|minizone with Microneedles pretreatment and Metvixia cream application with occlusion
89526467|NCT02511145|Active Comparator|Laser pretreatment and Metvixia|minizone with laser pretreatment and Metvixia cream application
89526468|NCT02511145|Active Comparator|Laser pretreatment and Metvixia under occlusion|minizone with Laser pretreatment and Metvixia cream application with occlusion
89526469|NCT02511145|Active Comparator|Metvixia|minizone with Metvixia cream application, without pretreatment
89526470|NCT02511145|Active Comparator|Metvixia under occlusion|minizone with Metvixia cream application under occlusion, without pretreatment
89526471|NCT02511145|Experimental|Microneedles pretreatment only|minizone with Microneedles pretreatment only
89526472|NCT02511145|Experimental|Laser pretreatment only|minizone with Laser pretreatment only
89526473|NCT02511145|No Intervention|Normal skin|Normal skin control mini-zone
89526474|NCT04499287|Placebo Comparator|Control|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption. One week later the test meal was consumed with fiber (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) added to the apple juice (active) and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption . One week later participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes (experimental). Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption
89526475|NCT04499287|Active Comparator|Fiber|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. 9 grams of soluble viscous fiber from psyllium husk (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) was mixed with the apple juice. Participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption. One week later participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes (experimental). Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption. One week later the test meal was consumed, and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (placebo).
89526476|NCT04499287|Experimental|Walk|Test meal [bagel with butter (20 g) and apple juice (240 ml) with added sugar (24 g)] The meal was a total of 640 kcal (100 g carbohydrate, 21 g fat, 10 g protein. Participants were given 5 minutes to transition to the treadmill following consumption of the test meal and began walking on a motorized treadmill at their calculated preferred walking speed for 15 minutes. Afterwards participants remained seated in the laboratory with minimal activity for the remainder of the four hours following test meal consumption One week later the test meal was consumed, and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (placebo comparator). One week later the test meal was consumed with fiber (36 g, Metamucil powder, Procter&Gamble, Cincinnati, OH) added to the apple juice and participants remained seated in the laboratory with minimal activity for the four hours following test meal consumption (active comparator).
89526477|NCT02511301|Experimental|Cyrcadia CBR™ Device|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.There are no interventions after the CBR™ is removed from the Study Subject
89526478|NCT02505997|Experimental|Midazolam/Delafloxacin|Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.
89526479|NCT02506075|Experimental|Pre-tDCS group|"In Pre-tDCS group, total sessions of the transcranical direct current stimulator stimulation(tDCS) was done for each three subgroups and visual inattention training was followed after that.~Patient had 2 times of tDCS for 13 minutes with 20minutes of resting interval. After that, additional 2 times of Visual inattention training was done with same protocol."
89526480|NCT02506075|Experimental|Simultaneous tDCS group|In Simultaneous transcranical direct current stimulator(tDCS) group, tDCS and visual inattention training was done simultaneously.
89526481|NCT02506075|No Intervention|Sham control group|without transcranical direct current stimulator(tDCS) or without visual training
89526482|NCT02505685||Lung cancer|People that were diagnosed with advanced lung cancer.
89526483|NCT02505841|Active Comparator|Group 1|Curare: Atracurium injection at 0.5 mg/kg
89526484|NCT02505841|Experimental|Group 2|TAP block and curare: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg then atracurium injection at 0.5 mg/kg
89526485|NCT02505841|Experimental|Group 3|TAP block: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
89526486|NCT04500145|Active Comparator|SIB-IMRT|patients received radiotherapy using IMRT or VMAT，60Gy is given to the field of tumor and metastatic lymph nodes and 50Gy given to CR lesion and high-risk area.concurrent or sequential with 4-6 circles of chemotherapy of EP.
89526487|NCT04500145|Other|routine|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
89526488|NCT02510755|Other|PTSD group|PTSD group
89526489|NCT02510755|Other|Healthy Volunteers|Healthy Volunteers, age-matched controls.
89526490|NCT02510677|Other|myocardial perfusion scintigraphy|Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.
89526491|NCT03345745||Periodontally healthy subjects|Salivary samples
89526492|NCT03345745||Chronic periodontitis patients|Salivary samples
89526493|NCT03345745||Gingivitis patients|Salivary samples
89526494|NCT03345667||Anti-Vegf|Use intravitreous anti-vegf
89526495|NCT03345589|Experimental|18-22mg/kg/d Ursodeoxycholic group|
89526496|NCT03345589|Placebo Comparator|13-15mg/kg/d Ursodeoxycholic group|
89526497|NCT04499989|Experimental|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
89526498|NCT04499989|Placebo Comparator|Placebo Comparator|3 vaginal tablet of Placebo Comparator self-inserted by the patient 12 hours before IUD insertion.
89526499|NCT02515903|Experimental|Intra-endoscopy|This intervention arm will receive intra-endoscopic evacuation surgery for ICH.
89526500|NCT02515903|Placebo Comparator|Stereotactic Aspiration|This arm will receive stereotactic aspiration surgery for ICH evacuation.
89526501|NCT04500067|Experimental|Study Group (IVIG)|Patients receive IVIG (trade name - Bioven) with base therapy
89526502|NCT04500067|No Intervention|Control group|Patients receive base therapy only
89526503|NCT03345511|Experimental|Ultrasound Guided Caudal Block|30 minutes before benign canal anal surgery, a 18 G tuohy needle guided with an ultrasound probe to visualize the caudal space, a solution of bupivacaine 0.25%, Lidocaine 1% and dexamethasone 8mg was injected and needle removed.
89526504|NCT02515747|No Intervention|conservative treatment|Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage
89526505|NCT02515747|Active Comparator|percutaneous coronary intervention|2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment
89526506|NCT02515747|Active Comparator|coronary artery bypass grafting|elective surgery myocardial revascularisation on the basement of drugs treatment
89526507|NCT02505763|Experimental|Strategy with thoracic ultrasound|"Use of thoracic ultrasound for the treatment of pleural effusion, treatment and monitoring.~Use of other examinations like chest CT if necessary"
89526508|NCT02505763|No Intervention|Strategy without thoracic ultrasound|"Usual care : without thoracic ultrasound~Use of chest radiography or chest CT scan if necessary, as for treatment and monitoring.~Usual care: without the use of ultrasound Using either chest radiography or TDM if necessary, as for treatment and monitoring."
89526509|NCT04497649|Experimental|Sofosbuvir and Daklatasuvir|Sofosbuvir and Daklatasuvir with standard of care treatment
89526510|NCT04497649|No Intervention|Standard of care treatment|Standard of care treatment
89526511|NCT02505451|Experimental|Type 2 diabetic patients|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with type II diabetes (according to the American Diabetes Association, 2012) free of coronary diseases.
89526512|NCT02505451|Experimental|Metabolic syndrom|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with the Metabolic syndrome (according to Alberti et al 2009) free of diabetes and coronary diseases.
89526513|NCT02505451|Experimental|controls|Regional myocardial function will be assessed during dobutamine stress echocardiography in healthy subjects.
89526514|NCT02505529|Experimental|Resistance Exercise Training|12-weeks of high-intensity, progressive resistance exercise training (3x/wk).
89526515|NCT02505529|Experimental|Mental Imagery|6-weeks of mental imagery of strong muscle contractions and mobility tasks (5x/wk).
89526516|NCT02505529|No Intervention|Control Group|6-weeks of no change in lifestyle.
89526517|NCT02505373|Experimental|Intervention Group ASSIP|Intervention Group ASSIP (Brief Therapy)
89526518|NCT02505373|Active Comparator|Control Group CG|Control Group CG (structured interview)
89526519|NCT02505607|No Intervention|Standard Care Group|In this group, subjects will receive standard counseling regarding Overactive Bladder.
89526520|NCT02505607|Experimental|Care Plan Group|"In this group, subjects will receive counseling regarding Overactive Bladder using a printed Overactive Bladder Plan of Care information sheet."
89526521|NCT02505295|Active Comparator|selenium|vial selenium (selenase 500 microgr ) 2000 microgram stat and 1000 microgram daily for 5 days
89526522|NCT02505295|Placebo Comparator|normal saline|40 cc normal saline stat and 20 cc daily for 5 days( in vials like selenase vial)
89526523|NCT02510833|Experimental|Continuing Intervention Group|
89526524|NCT02510833|Active Comparator|Control Group|
89526525|NCT02510911|Experimental|Caffeine (100 mg)|Verum 1 with 100 mg caffeine
89526526|NCT02510911|Experimental|Caffeine (200 mg)|Verum 2 with 200 mg caffeine
89526527|NCT02510911|Placebo Comparator|corn starch (250 mg approx.)|approx. 250 mg corn starch as placebo
89526528|NCT04499911|Experimental|Neural prolotherapy|Neural prolotherapy using isotonic dextrose 5% in water solution (about 5 ml). The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
89526529|NCT03343951||Shoulder patients|Shoulder patients referred to examination at the shoulder clinic, Silkeborg Regional Hospital.
89532718|NCT06032546|Placebo Comparator|Arm A: Placebo|Participants will receive budigalimab placebo on Day 1, and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo on Day 1 and Weeks 4 and 8.
89526530|NCT03121807|Experimental|Home parenteral nutrition|"Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.~Patients received 85 mg/m2 oxaliplatin and 200 mg/m2 leucovorin as a 2-h intravenous infusion on day 1, followed by 2400 mg/m2 5Fluorouracil as a 46-h continuous infusion. This regimen is repeated every 14 days as a cycle."
89526531|NCT03121729|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
89526532|NCT03343873|Experimental|Midarolam|midarolam sensation group
89526533|NCT03343873|Experimental|Propofol|propofol sensation group
89526534|NCT03343873|Experimental|dexmedetomidine|dexmedetomidine sensation group
89526535|NCT02647281|Experimental|Part 1: GSK3389404 10 mg|Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.
89526536|NCT02647281|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.
89526537|NCT02647281|Experimental|Part 1: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.
89526538|NCT02647281|Experimental|Part 1: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.
89526539|NCT02647281|Experimental|Part 1: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.
89526540|NCT02647281|Experimental|Part 2: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.
89526541|NCT02647281|Placebo Comparator|Part 2: Placebo|Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.
89526542|NCT02647281|Experimental|Part 2: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.
89526543|NCT02647281|Experimental|Part 2: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.
89526544|NCT03343795|Experimental|study group 1|oral progesterone
89526545|NCT03343795|Active Comparator|study group 2|intramuscular progesterone
89526546|NCT03343717|Experimental|rehabilitation|"Phase 1 passive mobilization with 10 repetitions on each joint motion and muscle stretching to the upper.~Phase 2 - ability to respond to 3 of 5 simple verbal commands. Beginning with passive, active-assisted or active exercises with 5 repetitions in each joint movement in the MMSS and MMII, following the sequence of phase 1.~Phase 3 - exercises of MMSS with cycle ergometer - 1 series of 1 minute or passive, active-assisted, active or active-resistidos with 5 repetitions in each joint movement, following the sequence of phase 1."
89526547|NCT03343717|Active Comparator|chest physical therapy|respiratory exercises that include techniques of bronchial hygiene maneuvers with the objective of airway clearance, pulmonary reexpansion techniques for reversal of atelectasis, passive mobilization techniques with the aim of reducing deformities and preserving joint mobility
89526548|NCT02510365|Experimental|Functional collagen scaffold|Functional neural regeneration collagen scaffold transplantation.
89526549|NCT02505139||Study Group|
89526550|NCT04499755|Experimental|Nucleo CMP forte|Nucleo CMP forte twice daily for 6 weeks with supportive treatment.
89526551|NCT04499755|No Intervention|Supportive treatment|Supportive treatment only.
89526552|NCT02515513|Active Comparator|Pancreatic Cancer Patients|During the surgical resection for the pancreatic cancer a muscle tissue biopsy sample will be performed.
89526553|NCT02515513|Active Comparator|Surgical Patients with benign pathology|During surgical resection for patients with benign right upper quadrant pathology, a muscle tissue biopsy sample will be performed.
89526554|NCT03345433|Experimental|interactive group drumming sessions|Participants will be involved in four interactive group drumming sessions (10-30 minutes each) and complete surveys and questionnaires about music and quality of life.
89526555|NCT02510287|Active Comparator|Continuous Epidural Infusion|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~A continuous infusion of 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour) will then be administered.~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered."
89526556|NCT02510287|Experimental|Programmed Intermittent Epidural Bolus|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour.~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered ."
89526557|NCT02510443||BAY1454032|All subjects who give their consent and meet the eligibility criteria will be scheduled for an insert placement procedure
89526558|NCT03345355||patient with axial spondyloarthritis|
89526559|NCT02505061|Experimental|Program|"The participants performance is indicative of the extent to which early power mobility training is feasible for both young infants and up to 3-year-old child with mobility Disabilities.Parents/caregivers and occupational therapists will be responsible for theHospital-based Program and Regular Therapy Program service respectively"
89526560|NCT02510521|Placebo Comparator|in rest situation|No intervention during one week. Daily usual activities are allowed.
89532719|NCT06032546|Experimental|Arm B: Budigalimab|Participants will receive budigalimab on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo Day 1 and Weeks 4 and 8.
89526561|NCT02510521|Experimental|after acute muscle exercise by NMES|"A working session of 20 minutes with three sequences electrostimulation:~warming-up sequence~work sequence (starting at 50% of the intensity achieved during warm-up)~relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
89526562|NCT02510521|Experimental|after a daily workout sequence with NMES in one week|"Working sessions of 20 minutes 7 days in a row, including :~warming-up sequence~work sequence (starting at 50% of the intensity achieved during warm-up)~relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
89526563|NCT03345277||Continuous Temperature monitoring|All residents of a long-term care facility will be considered for the study over the predetermined timeframe. Residents who choose not to participate or are determined, by their care providers, to be inappropriate for inclusion will be excluded.
89526564|NCT02510209|Experimental|Teen Outreach Program|
89526565|NCT02510209|No Intervention|Control|Business as usual.
89526566|NCT02515357|Placebo Comparator|Control group|This arm will receive standard care, i.e. CPAP prescription and brief written healthy lifestyle advice.
89526567|NCT02515357|Experimental|Mediterranean lifestyle group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month lifestyle intervention based on the Mediterranean lifestyle on top of standard care.
89526568|NCT02515357|Experimental|Mediterranean diet group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month dietary intervention based on the Mediterranean dietary pattern on top of standard care.
89526569|NCT02515435|Experimental|apatinib single agent|apatinib, single agent, 500mg or 750mg Qd po, continue until disease progression
89526570|NCT02515201|Active Comparator|Taurolidine|Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.
89526571|NCT02515201|Active Comparator|Heparin|Heparin be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Heparin infusion will be used with heparin solution contain 50 International Unit (UI)/ml.
89526572|NCT02515123|Experimental|E-Motion System|E-motion tube + E-motion EPG 1000
89526573|NCT02515123|Sham Comparator|E-Motion Sham Decive|E-motion tube + SHAM E-motion EPG 1000
89526574|NCT02504983|Active Comparator|GALNT14 TT|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
89526575|NCT02504983|Active Comparator|GALNT14 non-TT TACE alone|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
89526576|NCT02504983|Experimental|GALNT14 non-TT TACE plus sorafenib|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation, plus sorafenib adjuvant therapy. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued. patients will receive sorafenib 400 mg/d between each TACE. Patient will start receiving Sorafenib on Day 4 (up to Day 7) after 1st TACE (Day 1) and will interrupt after evening dose 4 days before each next TACE and re-start Sorafenib on Day 4 (up to Day 7) after each TACE cycle.Additional sorafenib treatment is optional and will be judged by investigator in the subject's best medical interest.
89526577|NCT02504749|Active Comparator|Group A: General anaesthesia group|-Standard rapid sequence induction with pre-oxygenation by 100 % OXYGEN FOR 3 MINUTES FOLLOWED BY 4-5 mg/kg thiopental and 100 mg succinylcholine,cricoid pressure was applied once necessary.After correct placement of tracheal tube was confirmed,anaesthesia was maintained with up to 1.5% isoflurane and oxygen,neuromuscular blockade was maintained with 0.4 mg/kg atracurium.
89526578|NCT02504749|Active Comparator|Group B:Spinal anaesthesia group.|"Prehydration with 500 ml lactated ringer solution intravenous within 15 minutes in the sitting position.Low back was prepared and drapped in a sterile fashion with Betadine solution 10%.~Spinal anaesthesia performed at L 2-3 or L 3-4 intervertebral space using a fine needle size 22 G.Injection of local anaesthetics into the subarachnoid space,Bupivacaine(marcaine) 1.5 -3.5 ml used."
89526579|NCT02509975|Experimental|Prostate Artery Embolization|Transarterial administration of OCL 503 to the arteries feeding the prostate.
89526580|NCT02504593|Other|Community health volunteers|The study subjects are all community health volunteers in community units in Kenya (10 community units in Bungoma East and 6 community units in Kiminini) that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing.
89526581|NCT02504515|Active Comparator|Homeopathy|
89526582|NCT02504515|Active Comparator|Allopathy homeopathy control|
89526583|NCT02504515|Active Comparator|Acupuncture|
89526584|NCT02504515|Active Comparator|Allopathy acupuncture control|
89526585|NCT02504515|Active Comparator|Anthroposophic medicine|
89526586|NCT02504515|Active Comparator|Allopathy anthroposophy control|
89526587|NCT02510053|Other|Patients With IFI in ICU|40 patients receive Caspofungin for an Invasive Fungal Infection(IFI) in the Intensive Car will be recruited
89526588|NCT02504437|Experimental|pre-conditioned BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.
89526589|NCT02504437|Active Comparator|BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.
89526590|NCT02504437|Sham Comparator|Controls|standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion.
89526591|NCT02510131|Active Comparator|Pelvic floor exercise|"Participants randomized to Kegel's exercises will be asked to contract their pelvic floor muscle for 1-10 seconds, followed by 10 seconds' relaxation.~Length of duration of exercise is tailored to individual's ability in contracting her pelvic floor muscle.~Each cycle is equivalent to 1 contraction and 1 relaxation phase. Participants will be asked to perform 3 sessions per day, and to perform their Kegel exercises at home daily.~1 session of Kegel's exercise is consists of 20 cycles of slow twitch fibre contraction and 30 repetitions of fast twitch fibre for 1 minute."
89526592|NCT02510131|Experimental|Hyacinth exercise|"In this arm participants are also taught Kegel's exercises but will be additionally taught extra steps which mirrored Muslim's praying steps.~As well as their Kegel's exercises, participants will be asked to perform the extra steps at least 63 minutes per week.~Participants may choose to perform these at the same time or at a different time from their Kegel's exercises. Participants will be asked to perform 1 cycle (3 minutes and 1 second) for 3 sessions a day for daily.~Each cycle is consists of repetition of 4 positions: standing upright- 90 degree bow- prostration-sitting."
89526593|NCT02504359|Experimental|Treatment (BEAM allogeneic transplant, ixazomib)|"BEAM CONDITIONING REGIMEN: Patients receive carmustine on day -6, cytarabine and etoposide on days -5 to -2, and melphalan on day -1.~PERIPHERAL BLOOD STEM CELL TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO on days -2 to at least 6 months with a taper as early as 3 months post-transplant and methotrexate IV on days 1, 3, 6, and 11.~MAINTENANCE THERAPY: Beginning between days 100 and 180 post-transplant, patients receive ixazomib PO on days 1 and 14 or days 1, 8, and 15 if the principal investigator deems it medically important. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
89526594|NCT02729545|Experimental|Tung's acupuncture|The Tung's acupuncture group received acupuncture treatments twice per week for 12 weeks. The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
89526595|NCT02729545|Active Comparator|CPA/EE|Cyproterone acetate/ethinylestradiol (CPA/EE) was taken orally one tablet per day from the 8th day of menstrual cycle or any day for patients with amenorrhea. The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
89526596|NCT02509819|Experimental|Military Performance Lab testing|Subjects who use IDEOs will come to the Military Performance Lab for one test session during which they will walk in standardized shoes with six different foam heel wedges (Heel Cushion Material Bulk (foam) from Kingsley Manufacturing Company) in random order. Control data will also be collected on able-bodied individuals. Control subjects will also come to the MPL for one test session in which they will walk using the same standardized shoes. For all subjects, biomechanical gait data will be collected as the subjects walk along a walkway in the MPL. This data will be used to calculate roll-over shape, instantaneous radius of curvature, COP velocity, and ankle moment.
89526597|NCT01376089|Other|Arm 1-Iodixanol|
89526598|NCT01376089|Active Comparator|Arm 2-Iopamidol|
89526599|NCT02509741|Experimental|Educational intervention|High-protein and low-GI diet education
89526600|NCT02509741|Experimental|Dietary intervention|High-protein and low-GI diet plus education
89526601|NCT02509741|Experimental|Internet-of-things (IOT) monitoring intervention|Dietary intervention plus IOT monitoring
89526602|NCT02509741|No Intervention|control|Routine diet recommendation
89526603|NCT02514967|Experimental|Blisibimod|
89526604|NCT02514967|Placebo Comparator|Placebo|
89526605|NCT02504125|Experimental|Receving TXA, Study group|Tranexamic acid, Study group tranexamic acid 1g, intravenous injection, pre-operationally
89526606|NCT02504125|Placebo Comparator|Normal saline, Control group|Not receiving tranexamic acid, Control group Normal saline 100mL, intravenous injection, pre-operationally
89526607|NCT02504047|Experimental|T-Cell replete haplo-transplant|Infusion of peripheral blood stem cells from a haploidentical related donor following myeloablative conditioning. Cyclophosphamide, mycophenolate mofetil and tacrolimus will be given for GVHD prophylaxis.
89526608|NCT02503813|Experimental|Experimental|Venous blood gas will be obtained at the same time points as arterial blood gas in the apnea challenge test.
89526609|NCT02503969||Screened|Those who received an adequate screen for colorectal cancer.
89526610|NCT02503969||Not Screened|Those who received an adequate screen for colorectal cancer.
89526611|NCT02514733||Young donor|Kidney transplant recipient > 60 years of age who received organ from donor <=40 years of age
89526612|NCT02514733||Old donor|Kidney transplant recipient >= 60 years of age who received organ from donor >=50 years of age
89526613|NCT02509663|Active Comparator|Sinuplasty balloon|Patients will receive the innovative health technology to treat frontal sinusitis : a balloon sinuplasty
89526614|NCT02509663|Active Comparator|Conventional surgical procedure|Patients will be treated with the conventional procedure : a sinus surgery with rigide instrumentation
89532720|NCT06032546|Experimental|Arm C: ABBV-382 Dose A|Participants will receive budigalimab placebo on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.
89532721|NCT06032546|Experimental|Arm D: Budigalimab + ABBV-382 Dose B|Participants will receive budigalimab on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose B on Day 1 and Weeks 4 and 8.
89532722|NCT06032546|Experimental|Arm E: Budigalimab + ABBV-382 Dose A|Participants will receive budigalimab on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.
89532723|NCT06021158|Active Comparator|AID-count|
89532724|NCT06021158|Experimental|AID-estimate|
89532725|NCT06021158|Experimental|AID-detect|
89532726|NCT06019182||Affected|Individuals who have MEHMO syndrome or eIF2-pathway related conditions 1-week of age or older.
89532727|NCT06019182||Carrier|EIF2S3-variant carrier individuals 1-month of age or older.
89532728|NCT06019182||Unaffected Non-carrier|Unaffected individuals 1 month of age or older who are 1st degree relative of an affected individual
89532729|NCT06016738|Experimental|OP-1250 (palazestrant)|Participants will receive OP-1250
89526615|NCT02514811|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
89526616|NCT02514811|No Intervention|Control Group|Students in the control condition receive a benign intervention called the Community Voices (CV) program, which like TOP, meets in a group setting. The CV students are convened four times during the program year. Sessions are the same length as the TOP sessions. The first and last CV sessions are primarily focused on survey data gathering. At the two other sessions, CV students are convened to discuss current issues among young people in their community. The CV program specifically does not include any sexuality education or community service learning opportunities.
89526617|NCT02503891|Experimental|Polymer on Ceramic|MP-1 Polymer on Ceramic articulation system
89526618|NCT02509429|Experimental|Control-to-Range algorithm and Threshold Low Glucose Suspend|"On this arm, patients will realize two investigational sessions:~the first with Control-to-Range algorithm (CTR),~the second with Threshold Low Glucose Suspend (TLGS)."
89526619|NCT02509429|Experimental|Threshold Low Glucose Suspend and Control-to-Range algorithm|"On this arm, patients will realize two investigational sessions:~the first with Threshold Low Glucose Suspend (TLGS),~the second with Control-to-Range algorithm (CTR)."
89526620|NCT04497181|Experimental|Experimental group|
89526621|NCT04497181|Sham Comparator|Control group|
89526622|NCT02509273|Experimental|CLONIDINE HYDROCHLORIDE|solution for i.v. infusion (maximum 55 μg/kg per day; maximum 7 day treatment)
89526623|NCT02509273|Active Comparator|MIDAZOLAM|solution for i.v. infusion (maximum 5.5 mg/kg per day; maximum 7 day treatment)
89526624|NCT03344653|Active Comparator|Resolute Onyx stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
89526625|NCT03344653|Active Comparator|BioFreedom stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
89526626|NCT02514343|Experimental|Magnesium sulfate|Will administrate 1 ml of magnesium sulfate 10% and 1.5 mL of sterile water
89526627|NCT02514343|Experimental|Bupivacaine|Will administrate 1 ml of magnesium sulfate 10% and 1.5 ml of bupivacaine (5mg/ml)
89526628|NCT03344575|Active Comparator|Conventional defect closure|The defect is sutured with continuous PDS 2-0.
89526629|NCT03344575|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
89526630|NCT03344497|Other|VC (Conventional Consultation/Video) Group|Subjects will receive conventional consultation and watch an animated video.
89526631|NCT03344497|No Intervention|CC (Conventional Consultation) Group|Subjects will receive conventional consultation only. Subjects will cross-over to receive animated video at the end.
89526632|NCT02514265||UCPPS patients|"All participants in this study are men or women who have been diagnosed with Urologic Chronic Pelvic Pain Syndrome (UCPPS). Approximately one-half of the participants will be male, and one-half will be enriched to meet the body map pain location criteria of pelvic pain (PP) only. In addition, enrichment recruitment of 240 UCPPS patients (120 males; 120 females) will also be targeted for those who answer no to questionaire question about specific Bladder pain symptoms."
89526633|NCT02514421|Experimental|Electrochemotherapy with gemcitabine/nab-paclitaxel|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with gemcitabine and abraxane. The schedule of administration of gemcitabine and nab-paclitaxel will be administered as per standard of care. The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
89526634|NCT04499209|Experimental|Period 1- XG005|XG005 capsule in 4 dose level
89526635|NCT04499209|Active Comparator|Period 2- Naproxen and Pregabalin|Combination of Naproxen and Pregabalin
89526636|NCT04499209|Placebo Comparator|Period 1- Placebo|XG005 matching placebo
89526637|NCT02514109||patient|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.
89526638|NCT02514109||control|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.
89526639|NCT04497103|Active Comparator|control|The traditional rehabilitation program conducted for 40-min sessions, three times per week for 8 weeks for all children.
89526640|NCT04497103|Experimental|task oriented training|Task-oriented training TOT group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
89532730|NCT06016738|Active Comparator|Standard of Care Endocrine Therapy|Participants will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
89526641|NCT04497103|Experimental|Xbox kinect|Xbox training group was conducted with an average of 50-min sessions three times a week for 8 weeks. Baseline Canadian Occupational Performance Measure COPM results were used to generate individualized intervention goals for each participant.
89526642|NCT02509351|Experimental|misoprostol|women receiving pre-operative rectally administered 400 microgram misoprostol
89526643|NCT02509351|Active Comparator|placeboo|women receiving placebo
89526644|NCT02513953|Experimental|Endometriosis|Four port laparoscopy by way of intervention was needed for convenience in aspirating the cystic fluid and reversal of the cyst wall taking care not to destroy the normal ovarian tissue to minimize loss of ovarian reserve
89526645|NCT02509195|Experimental|Switch to Triumeq|HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).
89526646|NCT04496791|Experimental|Successor of Phonak Audéo M-90|Phonak Hearing instrument (HI) with modified precalculation.
89526647|NCT04496791|Active Comparator|Phonak Audéo M-90|Phonak Audéo M-90 is the most recent RIC device from Phonak which will be fitted to the participants individual hearing loss.
89526648|NCT02508961|Experimental|Web-based physio|Participants receive an online individualised exercise programme to complete over the internet twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. After this, every 2 weeks online exercise diaries are remotely monitored by a physiotherapist and exercise programmes progressed as appropriate.
89526649|NCT02508961|Active Comparator|Print-out exercise programme|Participants receive printed exercise programme to complete twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. Participants complete a paper exercise diary and after the first 2 weeks if they require a progression to their exercise programme they contact their physiotherapist.
89526650|NCT02503345|Placebo Comparator|Placebo|Placebo capsules (1, 2 or 5) PO TID
89526651|NCT02503345|Experimental|ALLN-177 low dose|ALLN-177 1,500 units/meal PO TID
89526652|NCT02503345|Experimental|ALLN-177 mid dose|ALLN-177 3,000 units/meal PO TID
89526653|NCT02503345|Experimental|ALLN-177 high dose|ALLN-177 7,500 units/meal PO TID
89526654|NCT03345199|Experimental|Inspiratory Muscle Trainer (IMT)|Inspiratory Muscle Trainer (IMT) provides resistance as a person inhales, thereby strengthening respiratory muscles.
89526655|NCT03121651|Experimental|RL-adaptive application|"Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers).~Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications."
89526656|NCT03121495|Active Comparator|Second forward view exam|During withdrawal, the colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed.
89526657|NCT03121495|No Intervention|Conventional withdrawal exam|No intervention additional to the conventional withdrawal examination during withdrawal
89526658|NCT02508805|Experimental|Neuromultivit +Voltaren+Sirdalud|"Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days.~Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days."
89526659|NCT02508805|Active Comparator|Voltaren+Sirdalud alone|Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days
89526660|NCT03121573|Other|intervention|medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
89526661|NCT03121417|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity
89526662|NCT02513797|Experimental|LARIAT + PVI Treatment Group|Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
89526663|NCT02513797|Active Comparator|PVI Catheter Ablation Group|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
89526664|NCT02503267||patients with congenital heart disease|patients with congenital heart disease
89526665|NCT02503033|Experimental|HMPL-523|"Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.~At the Dose-expansion stage, HMPL-523 600mg will be dosed once daily."
89526666|NCT02503189|Experimental|KCT-0809|
89526667|NCT02503189|Placebo Comparator|Placebo|
89526668|NCT02508883||Upper gastrointestinal bleeding|patients with cancer who presented or were admitted in the emergency room, wards or intensive care units of the Cancer Institute of São Paulo (ICESP), with a recent episode of upper gastrointestinal bleeding.
89526669|NCT02508727|Other|Healthy volunteers|Healthy volunteers
89526670|NCT02508727|Other|Subjects with an anterior myocardial infarction sequela|Subjects with an anterior myocardial infarction sequela
89526671|NCT02508727|Other|Subjects with lower myocardial infarction sequelae|Subjects with lower myocardial infarction sequelae
89526672|NCT02502721|Experimental|Part A|To study effect of DWC20151 on DWC20152 PK
89526673|NCT02502721|Experimental|Part B|To study effect of DWC20152 on DWC20151 PK
89526674|NCT04498975||Patients with IHD|No intervention
89526675|NCT02502643|Experimental|OK-432 pleurodesis|Picibanil ( OK-432 ) ,OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci; UKIMA PLANT OF CHUGAI PHARMA MANUFACTURING CO, LTD; JAPAN).
89526676|NCT02502643|Active Comparator|normal saline pleurodesis|(Normal Saline),Isotonic Sodium Chloride Solution
89526677|NCT02502565||Uric Acid Level|
89526678|NCT02508415|Experimental|Non Surgical Periodontal Therapy|Will receive oral hygiene education, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine mouth rinse twice a day
89526679|NCT02508415|No Intervention|No Non Surgical Periodontal Therapy|No treatment received
89526680|NCT02501551|Experimental|Regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
89526681|NCT02501395||Patients with Kennedy disease|Men over 18 years old with confirmed Kennedy disease.
89526682|NCT02501395||Healthy, voluntary controls|Gender and age matched healthy, voluntary controls.
89526683|NCT02501317|Experimental|Active Perineal Rehabilitation protocol|"study group that will be treated with Active Perineal Rehabilitation protocol"
89526684|NCT02501317|Active Comparator|Kari Bo protocol|control group will be treated with the protocol already widely used
89526685|NCT04498897|Active Comparator|Test group|Vortioxetine + Acamprosate
89526686|NCT04498897|Placebo Comparator|Placebo Group|Placebo + Acamprosate
89526687|NCT02502877|Other|Midazolam Group|"In the midazolam group the investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after."
89526688|NCT02502877|Active Comparator|Propofol group|"In the propofol group the investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery."
89526689|NCT02508181|Active Comparator|I-gel intra ocular pressure|supraglottic airway device
89526690|NCT02508181|Active Comparator|LMA Supreme intra ocular pressure|supraglottic airway device
89526691|NCT03343561|No Intervention|Control|Subjects would have subjects' own diet as usual
89526692|NCT03343561|Experimental|Intervention diet 1|Nutrition advice will be given to subjects to consume a healthy diet and select food with Polyunsaturated fatty acids like fish and nuts to replace subjects' own food in high fat
89526693|NCT03343561|Experimental|Intervention diet 2|Nutrition advice will be given to subjects to consume a healthy diet and select food with whole grains to replace subjects own food in carbohydrate
89526694|NCT03343561|Experimental|Intervention diet 3|Nutrition advice will be given to subjects to consume a healthy diet and select food with healthy choices in fat and carbohydrate to replace subjects' own food choice
89526695|NCT04498819|Experimental|Single Arm|Only one arm, one intervention; this is a feasibility study.
89526696|NCT02502331|Experimental|study group|Test Oral Cholera Vaccine
89526697|NCT02502331|Active Comparator|comparator group|Euvichol®
89526698|NCT02501239|Experimental|Accept Yourself! Intervention|Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
89526699|NCT02501239|Active Comparator|Behavioral Weight Loss|Weight Watchers groups
89526700|NCT03121339|Active Comparator|Treatment A - Fasting Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to fasted subjects.
89526701|NCT03121339|Active Comparator|Treatment B - Fed Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to subjects with a small snack.
89526702|NCT03343327|Experimental|Chronocort®, then Cortef®|Single dose of 20mg Chronocort® (oral administration), followed by a single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration).
89526703|NCT03343327|Active Comparator|Cortef®, then Chronocort®|Single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration), followed by a single dose of 20mg Chronocort® (oral administration).
89526704|NCT03343249|Experimental|Study Visits|"The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured.~Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete."
89526705|NCT03121183||Patients who have undergone an extraction of implantable pace|
89526706|NCT02502175|Experimental|Opium|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
89526707|NCT02502175|Active Comparator|methadone|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
89526708|NCT03343405|Experimental|Intervention: Online Mind/Body|Participants randomized to the intervention group (i.e., Online Mind/Body Program for Fertility) were provided the 10 online modules provided weekly (one module per week), intended to be completed over 10 weeks. Additionally, participants received weekly therapeutic feedback.
89526709|NCT03343405|No Intervention|Wait-List|After 10-weeks being in the wait-list group, participants had the potential to participate in the intervention protocol if they desire.
89526710|NCT02501785||patient and caregivers|This is a prospective cohort study. Four questionnaires will be used to collect data from caregivers: demographic and socioeconomic data will be collected from the caregiver before the patient's surgery, and caregiver burden information will be collected 15 (+/- 3) days after surgery.
89526711|NCT04495387||patients with colon cancer|
89526712|NCT04495387||patients with breast cancer|
89526713|NCT02501005|Experimental|Treatment Group 1 (TG1)|Prophylactic VT ablation prior to ICD implantation
89526714|NCT02501005|Other|Treatment Group 2 (TG2)|ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter
89526715|NCT04495075|Experimental|Visuomotor Therapy|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. A target sine wave with a maximum amplitude of 30% MVIC and a minimum amplitude of 5% MVIC and a frequency of 0.128 Hz was visually presented to the patient.31 The patient was instructed to match their torque to the presented target throughout the duration of testing. Each visuomotor therapy trial was 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes.
89526716|NCT04495075|Active Comparator|Passive Motion|Patients were seated in the isokinetic dynamometer with their hips flexed to 85º. The dynamometer then passively moved the patient from 80º to 120º of knee flexion for 60-seconds, followed by 30-seconds of rest for 10 repetitions, totaling 15 minutes. The patient was provided visual feedback of their knee position throughout the trials. The patient was instructed to relax their knee throughout the intervention.
89532731|NCT06015893|Placebo Comparator|Placebo|Weekly subcutaneous (s.c.) injections of placebo.
89526717|NCT02500927|Experimental|ASP8273 group|Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
89526718|NCT04495309|No Intervention|Standard|Standard of care, i. e. no local radiotherapy in addition to standard systemic therapy (exception: palliative local treatment of symptomatic lesions where indicated)
89526719|NCT04495309|Experimental|Experimental|Standard of care (standard systemic therapy) + study intervention
89526720|NCT02507869|Experimental|Affect-Guided Prescription|Intervention: Participants in the affect-guided condition are instructed to exercise while monitoring how they feel, and to adjust the intensity of their exercise to maintain a pleasant affective response.
89526721|NCT02507869|Active Comparator|Heart Rate-Guided Prescription|Intervention: Participants in the heart rate-guided condition are instructed to exercise while monitoring their heart rate, and to adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
89526722|NCT02501863|Experimental|Ropivacaine+fentanyl|"Femoral nerve block with ropivacaine+fentanyl~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
89526723|NCT02501863|Experimental|Ropivacaine|"Femoral nerve block with ropivacaine~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
89526724|NCT02500771|Experimental|children and tutors using V-Motive|"The following intervention will be administered:~ABA therapy enhanced with V-Motive software~Tutors treating children with Applied Behavioral Analysis therapy will use the V-Motive software to enhance therapy sessions. Children will receive therapy as usual, but half of their current behavioral programs (skills/goals) will have been selected for enhanced prompting through video modeling."
89526725|NCT03344185|Experimental|Low GI diet|This diet contained three meals, all with a low GI value. This was the Low Glycaemic Diet intervention.
89526726|NCT03344185|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
89526727|NCT02500615|Experimental|0 PG: 100 VG|
89526728|NCT02500615|Experimental|30 PG: 70 VG|
89526729|NCT02500615|Experimental|50 PG: 50 VG|
89526730|NCT02500615|Experimental|70 PG: 30 VG|
89526731|NCT02500615|Experimental|100 PG: 0 VG|
89526732|NCT04496011|Experimental|Experimental Group|In this group the exercise program will be based on the protocol of Control Group, without the exception of walking training, adding aerobic capacity training using the bicycle ergometer, model CBL11 Classic® from ACT®.
89526733|NCT04496011|No Intervention|Group Control|"In this group the exercise program is based on the standard physiotherapy protocol that is part of the care routines performed at the bone marrow transplant service.~It includes essential components of a rehabilitation program: range of motion, balance training, gait and strength of the upper and lower limbs"
89526734|NCT03344107|Active Comparator|Vortek double-J stent|Vortek double-J stent after RIRS.
89526735|NCT03344107|Active Comparator|Polaris Loop stent|Polaris Loop ureteral stent after RIRS.
89526736|NCT02500459|Experimental|intraparenchymally-administered topotecan|Patients will have topotecan administered directly into the tumor bed using convection-enhanced delivery (CED)
89526737|NCT02500225|Active Comparator|Etomidate|0.2 mg/kg etomidate during anesthesia induction
89526738|NCT02500225|Active Comparator|8% sevoflurane|Sevoflurane 8% concentration during anesthesia induction
89526739|NCT04496557|Experimental|Patients diagnosed with PTSD|7-15 men and women with PTSD will be recruited from the community and from local clinical programs through a multi-modal outreach program.
89526740|NCT02507635|No Intervention|healthy volunteers|healthy volunteers
88814469|NCT04366622|Experimental|Riociguat, control A|Healthy age-, weight-, and gender- matched participants to Child Pugh A group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
89526741|NCT02507635|Active Comparator|Desloratadine|patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
89526742|NCT02507635|Active Comparator|Levocetirizine|patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks
89526743|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|SARS-CoV-2 Sclamp antigen 5 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart.(Cohorts 1 & 4)
89526744|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|SARS-CoV-2 Sclamp antigen 15 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 2 & 5)
89526745|NCT04495933|Experimental|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|SARS-CoV-2 Sclamp antigen 45 mcg mixed with MF59 adjuvant in 0.5 mL suspension, administered in a two dose regimen, at least 28 days apart. (Cohorts 3 & 6)
89526746|NCT04496089|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab
89526747|NCT04495465|Experimental|Experimental group: manual therapy + shock waves|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on neck muscles) and 3 minutes (2000 shocks aproximately) of extracorporeal radial shock waves therapy on painful points of neck muscles at 2 bars and 10 Hetzs.
89526748|NCT04495465|Placebo Comparator|Control group: manual therapy + placebo shock waves|Four sessions (one per week along one month) of manual therapy (25 minutes of massage on neck muscles) and 3 minutes (2000 shocks aproximately) of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
89526749|NCT02500069|Placebo Comparator|Placebo|Tap water infusion in all three locations (duodenum, jejunum and ileum)
89526750|NCT02500069|Experimental|Duodenum|Infusion of casein in duodenum
89526751|NCT02500069|Experimental|Jejunum|Infusion of casein in jejunum
89526752|NCT02500069|Experimental|Ileum|Infusion of casein in ileum
89526753|NCT02499991|Experimental|Treatment|"Treatment group will keep diary of social events according to training instructions.~Memory intervention will be used."
89526754|NCT02499991|No Intervention|Control|Control group will use own memory of social events without training instructions.
89526755|NCT02499913|Active Comparator|breath alcohol monitoring|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use.
89526756|NCT02499913|Experimental|breath monitoring plus prize contingency management|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use. Participants of this group earn opportunities to draw cards from a prize bowl for negative breath samples.
89526757|NCT04498039|Experimental|Active|Electrical stimulation to the tongue is delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Active subjects will be able to feel the sensation.
89526758|NCT04498039|Sham Comparator|Control|Electrical stimulation to the tongue will be delivered via the Portable Neuromodulation Stimulator (PoNS™) device . The PoNS™ device is held in place lightly by the lips and teeth around a rectangular tab that goes into the mouth and rests on the anterior, superior part of the tongue. Control subjects will be informed that while they may not feel the electrotactile stimulation, they are in-fact receiving a low level signal.
89526759|NCT02507557||Before GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record prior to the start of the training curriculum.
89526760|NCT02507557||After GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record after the training program took place
89526761|NCT03343015||Traditional CR establishing|establishing a CR in traditional way with occlusal wax rims during complete dentures therapy
89526762|NCT03343015||Gothic arch method|establishing a CR with gothic arch tracing device during complete dentures therapy
89526763|NCT04498195|Experimental|Increase physical activity and exercise|
89526764|NCT03344029|Experimental|SP Shz TIV|Participants aged 18 to 59 years will receive a single injection of SP Shz TIV.
89526765|NCT03344029|Active Comparator|Hualan TIV|Participants aged 18 to 59 years will receive a single injection of Hualan TIV.
89526766|NCT04494997||Dentists|Practicing Dental Health Professionals who are either General Dentists &/or Specialists Dentists are part of the Cohort. They should have held or currently hold Social Media account for their Professional purpose. They should have used or currently using their Social Media account for Professional purpose. The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media &/Or email to seek responses. The link will be available for single response for a single respondent.
89526767|NCT05460637|Experimental|Intervention Group|Participants receive a Fitbit and access to a 10 week educational course that accessible through the web or app. While participants can complete the program at their own pace, there is a suggested schedule with 1-2 modules/lessons completed per week. Each module has a different topic related to promoting adoption and maintenance of physical activity.
89526768|NCT03120637|Experimental|Methylene Blue|Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours
89526769|NCT03120637|No Intervention|Standard Treatment|
89526770|NCT02496169|Experimental|eucaLimus|Percutaneous Coronary Intervention (PCI)
89526771|NCT02496013|Experimental|68Ga-NEB injection and PET/CT scan|"Patients for blood pool imaging:~The patients were intravenously injected with 68Ga-NEB and underwent PET/CT scan 30~45min after the injection.~Patients for lymph node imaging:~The patients were locally injected 10~20MBq 68Ga-NEB and followed by dynamic regional PET acquisitions."
89526772|NCT02499757|Experimental|flavor and sweetener|E-cigarette with a novel flavor and sweetener added
89526773|NCT02499757|Experimental|flavor and nicotine|E-cigarette with a novel flavor and 12 mg nicotine added
89526774|NCT02499757|Experimental|flavor, nicotine and sweetener|E-cigarette with a novel flavor, sweetener, and 12 mg nicotine added
89526775|NCT02499757|Experimental|flavor|E-cigarette with a novel flavor: without a sweetener and 12 mg nicotine added
89526776|NCT02499601|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
89526777|NCT02499679||Patients diagnosed with CAD by cCTA|All clinically stable, symptomatic patients diagnosed with CAD by coronary computed tomography angiography (cCTA), that meet eligibility criteria, and are able and willing to participate are candidates for the ADVANCE Registry. Those patients that meet all inclusion/exclusion criteria and who sign the ethics committee (EC)/institutional review board (IRB) approved informed consent will be enrolled in the registry. FFRCT shall be used in accordance with the current Instructions for Use (IFU) document.
89526778|NCT02499523|Active Comparator|THR with conventional technique|Use of conventional technique in THR
89526779|NCT02499523|Experimental|THR with ACOG|THR with Acetabular Cup Orientation Guides (ACOG)
89526780|NCT03120559|No Intervention|Control|"The dental consultation was the same for all the groups.~- Examination and diagnosis (15 min).~- Motivation, discussion about desired outcomes and treatment needs followed by instrumentation (scaling, polishing) (30 min).~- Therapeutic goals, therapeutic strategies, teaching skills (brushing and interproximal control with regular waxed floss at the Control group) and scheduling of the follow-up appointment (15 min).~They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback."
89526781|NCT03120559|Other|NFH - New Floss Holder|The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback. New Floss Holder - Gum Chucks
89526782|NCT03120559|Other|New Floss Holder and Short Messages|"The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The Intervention time was 60 minutes and also included behavior change techniques, such as reinforcement, goal-setting, and feedback. Participants in the NFH/SMS group further received a total of 16 messages (SMS).~New Floss Holder - Gum Chucks/SMS"
89526783|NCT00706849|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
89526784|NCT00706849|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection once a week for 26 weeks.
89526785|NCT02499445|Active Comparator|Remifentanil and propofol|remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)
89526786|NCT02499445|Active Comparator|remifentanil and sevoflurane 1|remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)
89526787|NCT02499445|Active Comparator|sevoflurane 2 and sufentanil|sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)
89526788|NCT03336775|Experimental|acupuncture|Patients receive acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks). These patients also received corticosteroid for 4 weeks, methylprednisolone 80mg ivdrip. for 3 days, 60mg ivdrip. for 3 days, 40mg ivdrip. for 3 days, 30mg po. for 7 days, 20mg po. for 7 days, 10mg po. for 5 days and maintain.
89526789|NCT03336775|No Intervention|control|Patients receive no acupuncture. The use of corticosteroid is the same with Arm I.
89526790|NCT04443049|Active Comparator|Lenvatinib +Placebo|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily
89526791|NCT04443049|Experimental|Lenvatinib and mebendazole|Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
89526792|NCT02499133|Other|adult who suffered traumatic brain injury|
89526793|NCT02499133|Other|control group|
89526794|NCT02495935|Experimental|OkuStim®|The OkuStim® group will undergo 30-minute treatments once a week for 12 weeks at 200% threshold level according to their individual phosphene threshold (IPT) readings from the OkuStim® device at the pre-treatment visit (week 1). Rectangular biphasic current pulses (1-ms positive, directly followed by 1-ms negative) will be applied at a frequency of 20 Hz.
89526795|NCT02495935|Sham Comparator|Sham-OkuStim®|Subjects in the Sham-OkuStim® group will wear treatment glasses and corneal electrodes for 30 minutes weekly for 12 weeks, but corneal electrodes will not be activated.
89526796|NCT02495545|Experimental|CSFD with elevation of MAP|Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
89526797|NCT02495545|Active Comparator|Maintenance of MAP|Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.
89526798|NCT03336697||Parkinson's disease subjects|Patients with untreated or treated Parkinson's disease ages 45-75.
89526799|NCT03336697||Healthy control subjects|Healthy control subjects ages 45-75.
89526800|NCT02495155|Active Comparator|Fatigue|Participants who have received treatment for early stage breast cancer and who experience fatigue, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
89526801|NCT02495155|Active Comparator|Treatment-related Pain|Participants who have received treatment for early stage breast cancer and who experience pain, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
89526802|NCT02495155|Active Comparator|Insomnia|Participants who have received treatment for early stage breast cancer and who experience insomnia, assessed as difficulty sleeping over the last week, yes or no, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
89526803|NCT02499211|Experimental|Intervention stores|Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) and Supplemental Nutrition Assistance Program (SNAP) funding. The intervention will last for 2 years, and will consist of in-store marketing of healthier (lower calorie) products through placement and promotion strategies in 6 food and beverage categories: milk; frozen meals; beverages in checkout coolers; bread; salty snacks; and cheese.
89526804|NCT02499211|No Intervention|Non-intervention stores|No intervention administered. Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of WIC and SNAP funding. The non-intervention stores will not receive an intervention.
89526805|NCT02498899|Experimental|Video 1 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
89526806|NCT02498899|Experimental|Video 2 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
89526807|NCT02499055|Experimental|FearFighter|The experimental group will use the program FearFighter™.
89526808|NCT02499055|No Intervention|Control group|The control group receive no intervention for nine weeks.
89526809|NCT03336463||Controls|No intervention
89526810|NCT03336463||Cases|No intervention
89526811|NCT03120793||Esophageal balloon catheter placement|This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions
89526812|NCT02494999|Experimental|13-valent pneumococcal conjugate vaccine|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
89526813|NCT02494999|Active Comparator|Prevnar 13|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
89526814|NCT03341845|Experimental|axitinib and avelumab|axitinib 5MG BID and avelumab 10mg/kg Q2W
89526815|NCT03336385|Placebo Comparator|Placebo|Maltodextrin 12 gram used as placebo
89526816|NCT03336385|Active Comparator|Naxus|Naxus contains the wheat-derived prebiotic fibre Arabinoxylan
89526817|NCT03336385|Active Comparator|Oatwell|Oatwell contains an oat-derived prebiotic beta-glucan fibre
89526818|NCT03336307||Patients with Parkinson's disease|"All participants could walk independently without walking devices. All patients were taking oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13 patients) and were recorded in on phase. Medication was kept constant throughout the trial, and all interventions were performed at the same time of day for each patient during ON phase.~Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS-II and III) and the Hoehn and Yahr staging system.~All patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease"
89526819|NCT02494765|Active Comparator|I-gelTM|I-gel is a supraglottic device made of gel like material. It is used for administration of anesthesia in selected patients.
89526820|NCT02494765|Active Comparator|Ambu® AuraOnceTM|Ambu AuraOnce (AO) is a supraglottic device having different material and its shaft has greater curvature than I-gel. It is also used for administration of anesthesia in selected patients.
89526821|NCT02494843|Active Comparator|Online haemodiafiltration|
89526822|NCT02494843|Active Comparator|Haemodialysis|
89526823|NCT02498743|Experimental|Intervention group with television|Animated cartoons with sound were reproduced during the echocardiography
89526824|NCT02498743|No Intervention|control group with usual care|Echocardiography was performed by using the distractions available at the time of test.
89526825|NCT03336229|Active Comparator|Intervention|
89526826|NCT03336229|No Intervention|Control|
89526827|NCT02494609|Experimental|Treatment A|once daily dosing for 7 days, followed by 7-day washout
89526828|NCT02494609|Experimental|Treatment B|once daily dosing for 28 days
89526829|NCT02494609|Experimental|Treatment C|once daily dosing for 14 days of oral contraceptive, followed by coadministration with sotagliflozin once daily for 7 days
89526830|NCT03336151|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage in the campus cafeteria after a control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
89526831|NCT03341767|Experimental|Clofazimine|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
89526832|NCT03341767|Placebo Comparator|Placebo|Placebo gelatin capsule(s) taken orally every 8 hours for 5 days.
89526833|NCT03341767|Experimental|Clofazimine, no diarrhea|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
89526834|NCT02498353|Experimental|study group|"Preoperative short-course radiotherapy with local boost ,the dose of radiotherapy is PTV-CTV 25Gy/5F with local boost of PTV-GTV 30Gy/5F.~TME surgery after radiotherapy."
89526835|NCT02498353|Active Comparator|control group|"Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F without local boost.~TME surgery after radiotherapy."
89526836|NCT02498431|Experimental|myocardial infraction|Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement
89526837|NCT02498431|Active Comparator|coronary artery disease|Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement
89526838|NCT02498431|Active Comparator|Control|Patients subjected to coronary angiography and found with no presence of coronary artery disease
89526839|NCT02498509|Experimental|Treatment|CKD-342
89526840|NCT02498509|Active Comparator|Control 1|Mometasone furoate
89526841|NCT02498509|Active Comparator|Control 2|Levocabastine HCL
89526842|NCT02498275||Healthy volunteers|Blood samples from healthy volunteers will be collected for ex vivo stimulation and for further sample preparation and analysis.
89526843|NCT02498275||Nucleoside/nucleotide analogue-treated CHB patients|Blood samples from nucleoside/nucleotide analogue-treated CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
89526844|NCT02498275||Treatment-naive CHB patients|Blood samples from treatment-naïve CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
89526845|NCT03341611||Adults 55 and younger|
89526846|NCT03341611||Adults 55 and older|
89526847|NCT03335683|Experimental|Phytoterapy agent|Subjects were allocated to receive 1 h and 12 h after surgery: group 1, Lenidase® (Enfarma SRL, Misterbianco, Italy)
89526848|NCT03335683|Placebo Comparator|Placebo|Subjects were allocated to received 1 h and 12 h after surgery: placebo (Sugar pill, Sucratol - Placebo Capsules).
89526849|NCT03341455|Other|Intervention preschools|"Capacity building to support families affected by IPV & substance misuse will be provided to the intervention preschools.~Specifically, capacity building, training and support will be provided to~selected mothers on the provision of safe, confidential and relevant community-based referral and support services for women affected by IPV.~selected fathers on the provision of safe, confidential and relevant community-based referral and support to men seeking support for substance misuse problems.~intervention preschool teachers on provision of IPV and substance misuse prevention educational messages and referral pathways to services for these issues."
89526850|NCT03341455|No Intervention|Control preschool|No intervention or training will not be provided to the control group in order to assess the impact of the intervention between the control and intervention arms of the study.
89526851|NCT03341377||Lung cancer surgical patients|Patient-reported symptom assessments in patients undergoing lung cancer surgery.
89526852|NCT04494919||Ultrafine Endoscope Assisted|The self-expanding metal stent (SEMS) implantation was conducted using an ultrafine endoscope (UFE) (GIF-XP260NS; Olympus, Tokyo, Japan). The UFE researched the stricture, and a guidewire was inserted into the endoscopic working channel. The guidewire was left. And the endoscope was withdrawn. The normal colonoscope was exchanged under the reverse guidance of the guidewire. Finally, a metal, uncovered SEMS was placed along the guidewire.
89526853|NCT04494685|Experimental|Robotic rehabilitation|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland).
89526854|NCT04494685|Active Comparator|Conventional physiotherapy|The protocol will be based on lower limb exercises, aiming at maintaining and gaining muscle strength through passive, assisted or active mobilization, when possible, on the affected side.
89526855|NCT04494607|Experimental|Test arm|Determination of Glycemic and Insulinemic curves under different alimentary intake
89526856|NCT03342859|Experimental|Vilaprisan group|Vilaprisan 2 mg oral daily over 8-12 weeks
89526857|NCT03342859|Active Comparator|Ulipristal group|Ulipristal 5 mg oral daily over 8-12 weeks
89526858|NCT03342859|No Intervention|Control group|Patients undergoing surgery without any prior treatment, as control group
89526859|NCT03335605||Antibody deficiency (CVID)|Subjects with antibody deficiency (CVID)
89526860|NCT03335605||Healthy controls|Age and gender-matched control subjects
89526861|NCT03341221||One group|Diagnosis of ascites in infants and children by history, examination and investigations
89526862|NCT03342781|Active Comparator|Diffuser-mask group|The patients received oxygen therapy (8-15 L/min) from an OxyMask (Southmedic, Inc., Barrie, ON, Canada) to maintain oxygen saturation (SpO2) > 92%. Oxygen therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h. The oxygen flow rate was then decreased to 2 L/min and the patient was monitored while breathing room air.
89526863|NCT03342781|Active Comparator|HFNC group|The patients received oxygen therapy at a high flow rate from a Precision Flow nasal cannula (Vapotherm, Inc., Stevensville, MD, USA). We selected a 1.9 mm pediatric cannula, which can dispense 1-20 L/min of oxygen. The initial oxygen flow rate was 1 L/kg/min and the FiO2 was 100%. The initial flow rate was increased by 1 L/kg/min until the SpO2 reached 92%. The initial FiO2 was decreased once the SpO2 was greater than 92% and the oxygen flow rate was maintained. HFNC therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h at a FiO2 value of 21%, and the patient was transferred to a ward.
89526864|NCT02494453||Cardiac MRI|
89526865|NCT02493283|Active Comparator|Treatment A|single-dose administration of 100 mg dapsone; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
89526866|NCT02493283|Active Comparator|Treatment B|multiple-dose administration of 100 mg dapsone s.i.d. for 7 days; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
89526867|NCT03342703||Patients with Liver Fibrosis Measurement|Group1: Patients will undergo an Ultrasound to correlate fibrosis measurements obtained using standard-of-care MRI.
89526868|NCT03342703||Patients with Liver Steatosis Measurement|Group 2: Patients will undergo an Ultrasound to correlate steatosis measurements obtained using standard-of-care MRI.
89526869|NCT03335527|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h during mechanical ventilation, for a maximum of 3 days
89526870|NCT03335527|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 3 days
89526871|NCT03342625|Experimental|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI
89526872|NCT03341065|Experimental|exoskeleton type robot|exoskeleton type robot assisted gait training (Lokomat orthosis)
89526873|NCT03341065|Experimental|end-effector type robot|end-effector type robot assisted gait training (G-EO system)
89526874|NCT02493049|Experimental|Domperidone|Add on oral Domperidone 10 mg, three times daily. Target dose:30mg daily. Duration: 16 weeks
89526875|NCT02493049|No Intervention|No add on treatment|No add on treatment. Control group
89526876|NCT03120715|Placebo Comparator|NLMWH-A|non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
89532732|NCT06015893|Experimental|Semaglutide|Weekly subcutaneous (s.c.) injections of semaglutide up to 2.4 mg/week or maximum tolerated dose (MTD). Consistent with current recommendations, the dose will be titrated at minimum every four weeks to maximize tolerability and minimize adverse events.
89526877|NCT03120715|Experimental|LMWH-B|low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
89526878|NCT03120403|Active Comparator|intrathecal morphine 2 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
89526879|NCT03120403|Active Comparator|intrathecal morphine 5 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
89526880|NCT03120403|Active Comparator|intrathecal morphine 10 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
89526881|NCT02497963|Experimental|Foreskin Graft-Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Foreskin Graft Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, graft inner foreskin, and create a new urethra on a urethral catheter.
89526882|NCT02497963|Active Comparator|Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, and create a new urethra on a urethral catheter.
89526883|NCT03342547|Experimental|Intestinal stem cell-derived enteroids|Duodenal biopsy samples and saliva will be collected from participants and then processed in laboratory to generate intestinal stem cell-derived enteroids.
89526884|NCT02492815||Population with condition and without condition|Participating in EAP
89526885|NCT03340987|Experimental|Vista technique with SCTG|vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
89526886|NCT03340987|Active Comparator|coronally advanced flap with SCTG|coronally advanced flap combined with subepithelial connective tissue graft
89526887|NCT02492893|Experimental|Hatha Yoga|A 12-session 90-minute weekly hatha yoga intervention, that includes asanas (physical postures), pranayama (breathing exercises) and dhyana (meditation.
89526888|NCT02492893|No Intervention|Treatment as Usual|
89526889|NCT02492737|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
89526890|NCT03340831||CGM/BGM Group|single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 and G6 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).
89526891|NCT03120481||Normal control|
89526892|NCT02498119||Normal|Patient sample within the normal range of blood results.
89526893|NCT02498119||Abnormal|Patient sample from freshly diagnosed Type 2 Diabetes Mellitus.
89526894|NCT03335449|Experimental|Protective ventilation group|Protective ventilation (PV group) (Vt 6 ml/Kg of ideal body weight, PEEP 8-10 cmH 2 O and repeated recruitment maneuvers.
89526895|NCT03335449|No Intervention|Standard ventilation group|Standard ventilation (SV group) (Tidal Volume, Vt 10 ml/Kg of ideal body weight, Positive End Expiratory Pressure, PEEP 5 cmH 2 O, no recruitment maneuvers)
89526896|NCT03335293|Placebo Comparator|Placebo|normal saline vehicle added to subarachnoid block
89526897|NCT03335293|Experimental|100 mcg epinephrine|100 mcg epinephrine added to subarachnoid block
89526898|NCT03335293|Experimental|200 mcg epinephrine|200 mcg epinephrine added to subarachnoid block
89526899|NCT02498197|Experimental|Participatory Intervention|Participatory intervention with workers and their leaders. Workshops with presentation of work tasks with excessive physical load and subsequently plans to reduce these loads
89526900|NCT02498197|Active Comparator|Control|Receive standard information about correct lifting technics, use of assistive technology, and ergonomics
89526901|NCT02498041|Experimental|Transnasal Endoscopy|Unsedated transnasal endoscopy with biopsies
89526902|NCT02498041|Active Comparator|Standard Gastroscopy|Standard endoscopy with biopsies. Patients will decide whether they prefer to have endoscopy with intrevenous sedation or with local anaesthetic only
89526903|NCT02494531|Other|Positon Emission Tomographic (PET)-scan|2 PET-scan: Fluorodeoxyglucose-PET and florbetapir F 18-PET
89526904|NCT03335215|Experimental|cognitive remediation|The innovative nature of this cognitive remediation program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
89526905|NCT03335215|No Intervention|usual care|
89526906|NCT03340597|Experimental|A1; F901318 (10 days)|F901318 : 10 days dosing orally
89526907|NCT03340597|Experimental|A2; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
89526908|NCT03340597|Experimental|A3; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
89526909|NCT03340597|Experimental|A4; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
89526910|NCT03342391|Other|Treatment Phase|Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis
89526911|NCT03335137||ICU Patients with Severe Burns|Patients suffering from severe burns treated on a burn unit - Drug Level Monitoring Piperacillin/Tazobactam
89526912|NCT03335137||ICU Patients without Burns - Drug Level Monitoring|Patient suffering from disease treated on an ICU - Drug Level Monitoring Piperacillin/Tazobactam
89526913|NCT00707161|Experimental|All participants|
89526914|NCT03120247|Active Comparator|DEX I|OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
89526915|NCT03120247|Active Comparator|DEX II|OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
89526916|NCT03120247|Active Comparator|DEX III|OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
89526917|NCT04443205||no macrosomy|pregnant women whose child is not macrosomal
89526918|NCT04443205||screened macrosomy|pregnant women whose child is macrosomal and have been screened g using ultrasound during the third trimester of pregnancy
89526919|NCT04443205||no screened macrosomy|pregnant women whose child is macrosomal and havenot been screened g using ultrasound during the third trimester of pregnancy
89526920|NCT02497885||healthcare personnel group|healthcare worker who was exposed to confirmed MERS patients, irrespective of adequate personal protective equipment.
89526921|NCT02497651|Experimental|Healthy, heavy smoking men|Twelve healthy, male subjects. Intervention: Will undergo two separate, identical test days. One absent smoking, and one with concomitant smoking.
89526922|NCT02497651|Experimental|Healthy, non-smoking men|Twelve healthy, male subjects. Intervention: Will undergo a liquid mixed meal test and a skin biopsy.
89526923|NCT05465473|Active Comparator|Group I|will include 10 patients undergo distalization according to a standardized protocol
89526924|NCT05465473|Active Comparator|Group II|will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol
89526925|NCT02494375|Experimental|Sleep and glucose assessement.|
89526926|NCT03335059|Experimental|Synergo® RITE + MMC|Bladder radiofrequency-induced hyperthermia will be delivered in combination with each instillation of MMC in accordance with the Sponsor operational guidelines.
89526927|NCT02497729|No Intervention|Sniffing Position, No Checklist|Patient in the sniffing position without the use of a written checklist
89526928|NCT02497729|Active Comparator|Sniffing Position, Checklist|Patient in the sniffing position with the use of a written checklist
89526929|NCT02497729|Active Comparator|Head of Bed Up, No Checklist|Patient with the head of bed up and without the use of a checklist
89526930|NCT02497729|Active Comparator|Head of Bed Up, Checklist|Patient with the head of bed up and with the use of a checklist
89526931|NCT02497495|No Intervention|GC|Control group - CG (n = 21), which suffered no recuperative technique
89526932|NCT02497495|Experimental|G1|G1 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
89526933|NCT02497495|Experimental|G2|G2 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
89526934|NCT02497495|Experimental|G3|G3 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
89526935|NCT02497495|Experimental|G4|G4 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
89526936|NCT03334981||exposed mother and child|mother and child who have been exposed to methadone or to buprenorphine during pregnancy
89526937|NCT03340363|Experimental|environmental change|Shoppers were exposed to modifications to the supermarket environment to encourage selection of low-cost, kid-friendly meals
89526938|NCT03340363|Experimental|environmental change and messaging|Shoppers were exposed to modifications to the supermarket environment and weekly messages via text or email to encourage selection of low-cost, kid-friendly meals
89526939|NCT02492503|Active Comparator|pacli carb 3|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
89526940|NCT02492503|Active Comparator|pacli carb 1|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
89526941|NCT03340285|Experimental|AkP06|first two weeks: Placebo + prescribed Diet then 4 weeks AkP06 two tablet/day before meals + Diet
89526942|NCT03340285|Placebo Comparator|Placebo|first two weeks: Placebo + prescribed Diet then 4 weeks Placebo two tablet/day before meals + Diet
89526943|NCT03334669|Experimental|Intervention|"Sites randomized to the intervention group will receive the following:~Parents Connect for Healthy Living (PConnect)~Enhanced Nutrition Support~Media Resources"
89526944|NCT03334669|No Intervention|Control|Control sites will not receive any intervention components (i.e., standard practice).
89526945|NCT02497339|Experimental|Intervention group|Intervention group (Mindfulness Smoking cessation program): Women in intervention group will be provided 2 sessions mindfulness training within 2 weeks. Each session will last for 2 hours with 8-20 participants. For mindfulness training, it aims to understand women smokers' own life planning, stressors and their correlation with smoking; to help women smokers sit with negative affect and alleviate stress through mindfulness; to educate women smokers gain the self-control and replace the smoking habit; to teach women smokers how to prevent craving and relapse.
89526946|NCT02497339|Experimental|Control group|Control group (Self-help smoking cessation booklet): Only the self-help booklet related to quitting will be provided to the participants.
89526947|NCT02497183|Experimental|first|a repeat abdominal ultrasound exam to patients following the filling of bowel with contrast material per os.
89526948|NCT02497105|Experimental|Epilepsy/Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention.
89526949|NCT02497105|No Intervention|Epilepsy/Non-Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention.
89526950|NCT02497027|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
89526951|NCT02497027|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
89526952|NCT03339973|Experimental|allo-APZ2-PAOD|20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10^6 cells per patient (depending on length of lower leg)
89526953|NCT03339973|Placebo Comparator|Placebo|20-30 intramuscular injections, vehicle solution (depending on length of lower leg)
89526954|NCT03334591|Experimental|Apatinib 5 days' continuous use and 2 days' off|Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
89526955|NCT03334591|Active Comparator|Apatinib 500mg continuous use|Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer
89526956|NCT03339895|Experimental|pvı-guided|pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery
89526957|NCT03339895|Experimental|traditional-guided|4-8 ml/kg/h infusion during surgery
89526958|NCT03339817|Other|Patients with severe MS|polysomnography and functional pulmonary testings.
89526959|NCT03334513||ROP group|children with retinopathy of prematurity received either bevacizumab or ranibizumab
89526960|NCT02496949|Experimental|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
89526961|NCT03339739|Experimental|Isometric exercise Group|Group of participants which perform Isometric mandibular exercises, once a day, for 21 days
89526962|NCT03339739|Active Comparator|Isotonic exercise Group|Group of participants which perform Isotonic mandibular exercises, once a day, for 21 days
89526963|NCT03339739|Placebo Comparator|Counseling Group|Group of participants which receive education brochure and no further interventions.
89526964|NCT02130466|Experimental|Part 1:pembrolizumab 2 mg/kg+dabrafenib150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by intravenous (IV) infusion on Days 1 and 22 of each 6-week cycle (Q6W); 150 mg/day total dabrafenib orally, in a divided dose, twice a day (BID) starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally once a day (QD) starting on Day 1 and continuing up until study treatment discontinuation.
89526965|NCT02130466|Experimental|Part 1:pembrolizumab 2 mg/kg+trametinib 2 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526966|NCT02130466|Experimental|Part 1:pembrolizumab 2 mg/kg+trametinib 1.5 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526967|NCT02130466|Experimental|Part 2:pembrolizumab 2 mg/kg+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526968|NCT02130466|Experimental|Part 2:pembrolizumab 2 mg/kg+trametinib 1.5 mg|Participants with BRAF wild-type melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W and 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526969|NCT02130466|Experimental|Part 3:pembrolizumab 2 mg/kg+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received 2 mg/kg pembrolizumab administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526970|NCT02130466|Placebo Comparator|Part 3:placebo+dabrafenib 150 mg+trametinib 2 mg|Participants with BRAF mutant melanoma received saline placebo administered by IV infusion on Days 1 and 22 Q6W; 150 mg/day total dabrafenib orally, in a divided dose, BID starting on Day 1 and continuing up until study treatment discontinuation; and 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526971|NCT02130466|Experimental|Part 4:trametinib 2 mg for 4 weeks+pembrolizumab 200 mg+trametinib 2 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 4 weeks. Starting with Week 5, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 of each 3-week cycle (Q3W) and a concurrent dosing schedule of 2 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526972|NCT02130466|Experimental|Part 4:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526973|NCT02130466|Experimental|Part 4:trametinib 1.5 mg for 4 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 4 weeks. Starting with Week 5, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526974|NCT02130466|Experimental|Part 4:trametinib 2 mg for 2 weeks+pembrolizumab 200 mg+trametinib 2 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 2 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
89532733|NCT06015308|Experimental|Amlitelimab|Participants will receive amlitelimab and vaccines as per protocol.
89532734|NCT06015308|Placebo Comparator|Placebo|Participants will receive placebo matching amlitelimab and vaccines as per protocol.
88814470|NCT04366622|Experimental|Riociguat, control B|Healthy age-, weight-, and gender- matched participants to Child Pugh B group received a single dose of 1 mg (2 x 0.5 mg IR tablet) of riociguat in the fasted state
88814471|NCT04366778||patients hospitalized for Covid-19|Patients with Covid-19 infection hospitalized in Lyon University Hospitals
89526975|NCT02130466|Experimental|Part 4:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 1.5 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
89526976|NCT02130466|Experimental|Part 5:trametinib 1.5 mg for 2 weeks+pembrolizumab 200 mg+trametinib 1.5 mg concurrent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 1.5 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and a concurrent dosing schedule of 1.5 mg trametinib orally QD starting on Day 1 and continuing up until study treatment discontinuation.
89526977|NCT02130466|Experimental|Part 5:trametinib 2 mg for 2 weeks+pembrolizumab 200 mg+trametinib 2 mg intermittent dosing|Participants with BRAF wild-type melanoma or solid tumors (irrespective of BRAF status) received 2 mg trametinib orally QD for 2 weeks. Starting with Week 3, participants received 200 mg pembrolizumab administered by IV infusion on Day 1 Q3W and an intermittent dose schedule of 2 mg trametinib orally QD with 1 week OFF trametinib and 2 weeks ON trametinib continuing up until study treatment discontinuation.
89526978|NCT03334357|No Intervention|Control|Non-Exercise group. We will provide general advices to control group participants thought an information meeting performed by a graduate in Sport Sciences. It will recommended to follow the physical activity recommendations for adults provided by World Health Organization
89526979|NCT03334357|Experimental|PAR group|"The volume in PAR is based on the minimum physical activity recommended (150min/week at moderate intensity).~Intensity selected for PAR aerobic training is 60-65% HRres. Strength intensity selected was 40-50% of 1 RM.~Frequency. PAR group will train 3 days/week, the minimum frequency recommended. Exercises programmed for the aerobic exercise are treadmill, cycle-ergometer and elliptical ergometer in aerobic training part and weight bearing and guided pneumatic machines (involved major upper and lower body muscle group) in resistance training.~Training load variation. We propose a gradual progression to control the exercise dose Training periodization divided in two phases of 5 weeks each one, starting with a familiarization phase (2 weeks).~Training sessions. Sessions start with a dynamic standardized warm up, which include several muscle activation exercises. Aerobic sessions include compensatory exercises. Training session will be ended with a cooling-down protocol"
89526980|NCT03334357|Experimental|HIIT group.|"The volume in HIIT 40-65 min/week at high intensity. Intensity. Two different protocols: HIIT with long intervals (Type A session), which intensity will be >95% VO2max and HIIT with short intervals (Type B session), >120% VO2max.~Training frequency two times/week. Type of exercise. Type A session are walking in treadmill with personalized slopes. Eight weight-bearing exercises in circuit form, type B session.~Training load variation. Gradual progression to control the exercise dose. Training periodization divided in: familiarization phase, phase I, phase II. Training sessions. Type A: 5 minutes in treadmill at 60% VO2max. After warm-up, participants complete sets corresponding to each training session following the corresponding characteristics. Type B: eight weight-bearing exercises (in circuit form) two times/set with an active rest (walking at 60%VO2max) as many times at as defined. Training session will be ended with a cooling-down protocol"
89526981|NCT03334357|Experimental|WB-EMS group.|"WB-EMS training program will be the same than HIIT intervention related to volume, intensity, frequency, type of exercise, training load variation, training periodization and training session. However, electrical impulse will be included in order to assess if WB-EMS training will produce an added effect compared to HIIT.~Electrical parameters:~We will apply a frequency of 15-33 Hz in type A session. And, we will apply a frequency of 35-75 Hz in type B session.~Intensity will be 80-100 mA. Impulse Width adjusted in relation to body segment: thigh zone (400μsec), glute zone (350μsec), abdominal zone (300μsec), dorsal zone (250μsec), cervical (200μsec), chest zone (200μsec) and arm zone (200μsec).~Duty cycle. We have programmed a duty cycle of 50-67% in type B session, but duty cycle in type A session will be 99%.~RPE impulse: the impulse intensity was individually adapted to generate similar values of rate of perceived exertion (RPE) in Borg CR-10 Scale 5 of 9"
89526982|NCT03339661|Experimental|Group 1_ No proph treatment|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated will depend on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if γδ T cell expansion occurs, no secondary prophylaxis treatment will be introduce, and curative treatment stops.
89526983|NCT03339661|Experimental|Group 2A_Proph treatment and γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
89526984|NCT03339661|Experimental|Group 2B_Proph treatment and no γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
89526985|NCT03334279||non smokers|
89526986|NCT03334279||cigarette smokers|Cigarette smokers to be included in the study must be frequent smokers (at least 10 cigarettes a day) for a period not less than 5 years.
89526987|NCT03334279||simultaneous cigarette and cannabis smokers|frequent cigarette smokers (at least 10 cigarettes a day) and frequent cannabis smoker (at least 3 times/week) for not less than 5 years.
89526988|NCT02492659|Experimental|trial group|the trial group underwent femtosecond laser-assisted cataract surgery
89526989|NCT02492659|Other|control group|the control group underwent conventional phacoemulsification
89526990|NCT02493829|Experimental|AML Cell Vaccine|
89526991|NCT03342313|Experimental|healthy weight|BMI (kg/m2) ≥ 18.5 and < 23
89526992|NCT03342313|Experimental|Overweight|BMI (kg/m2) ≥23 chewing 15 times and 50 times per bite
89532735|NCT06014203||Patients undergoing shoulder arthroscopy surgery|Patients who underwent arthroscopic shoulder surgery by a single surgeon at Gazi Hospital Department of Orthopedics and Traumatology (rotator cuff repair, slap, bankart repair)
89526993|NCT03334123|Experimental|Functional training and cycling|Participants in this group will perform 20 minutes of functional training before dialysis (in the first 8 weeks) and intradialysis cycling exercise during dialysis. Participants will also receive exercise counselling; investigators will teach them how to practice at home by practice and examples given during the 20 minutes of functional training pre-dialysis. In the second phase of additional eight weeks participants will perform the functional training at home on non-dialysis days in addition to intradialysis cycling. Kinesiologist will monitor, advice and motivate them.
89526994|NCT03334123|Active Comparator|Cycling|This active control comparator group will perform intradialytic cycling on an adapted ergometer 3 times per week for 4 months without functional training prior to dialysis procedure and without exercise counselling.
89526995|NCT02496793|Experimental|Peer Facilitator and Support Group|Peer-facilitated community support group is the experimental intervention. The intervention tested in this study involved using trained peer facilitators to create demand for and retention within the ANC/PMTCT program.The peer facilitators were volunteer women from the community, who had recently been through the ANC process themselves and could speak about their experience(s). the support group meetings was to develop skills and generate self-efficacy for the women to be able to take actions such as routine antenatal and postnatal clinic attendance using participatory learning techniques. The peer facilitators were provided with job aids which outlined key points for the various educational sessions.
89526996|NCT02496793|No Intervention|Standard Care|ANC/PMTCT activities as per standard of care in Zimbabwe
89526997|NCT03339427|Active Comparator|vitamin D,capsule|A total of 150 subjects were recruited in the vitamin D supplementation group.
89526998|NCT03339427|Other|control|A total of 150 subjects were recruited in the control group.
89526999|NCT03339193||Patients having LAAC|Patients who meet current clinical criteria for left atrial appendage closure (LAAC), ie have atrial fibrillation, a CHA2DS2-VASc score of 3 or more and a contraindication to long-term oral anticoagulation therapy and who have been approved by the OUH NHS Foundation Trust LAAC Multidisciplinary Team (MDT) as suitable for left atrial appendage occlusion in accordance with National Health Service (NHS) guidelines.
89527000|NCT02163538|Active Comparator|articulating Enseal|This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
89527001|NCT02163538|Active Comparator|Ligasure device|This group of women undergoing hysterectomy is randomized to the Ligasure energy device.
89527002|NCT02496637|Experimental|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
89527003|NCT02496637|Active Comparator|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
89527004|NCT02496637|No Intervention|No Treatment Control|No intervention, assessment only
89527005|NCT02496715|Experimental|Treatment 1|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
89527006|NCT02496715|Experimental|Treatment 2|Advair 100/50 Diskus pMDI containing fluticasone propionate 100mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
89527007|NCT02496715|Placebo Comparator|Treatment 3|Placebo inhalation. Single puff, twice daily (approximately every 12 hr) for 4 weeks
89527008|NCT02496871|Active Comparator|KWMP-GP|Weekly group phone calls for 6 months. Group phone calls will last about 45 minutes each. Phone calls will include groups of 12-18 participants.
89527009|NCT02496871|Experimental|KWMP-SM|Participants interact through a private Facebook group. New activities for participants to complete each week for 6 months.
89527010|NCT02163226|Experimental|Hypofractionated Radiation Therapy|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
89527011|NCT02163226|Active Comparator|One Radiation Therapy Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
89527012|NCT02496481|Experimental|Group1 Baseline+MI+tailored brochure|"Participants randomized to Group 1 will receive the motivational interviewing intervention in the ED and will be mailed a tailored educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
89527013|NCT02496481|Experimental|Group2 Baseline+MI+general info|"Participants randomized to Group 2 will receive the motivational interviewing intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
89527014|NCT02496481|Experimental|Group3 Baseline+tailored brochure|"Participants randomized to Group 3 will receive no intervention in the ED and will be mailed a tailored educational brochure about child passenger safety~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
89527015|NCT02496481|No Intervention|Group4 Baseline+general info|"Control Group. Participants randomized to this arm will receive no intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
89527016|NCT02496559|Active Comparator|Pre-consultation CRP|Every third child included get a CRP-test before the consultation and the doctor have the answer at start of consultation
89527017|NCT02496559|No Intervention|CRP requested|No intervention, the consultation with children as normal, the CRP is used at doctors request.
89527018|NCT02496325|Other|perineal technic|
89527019|NCT02193178|Experimental|comfilcon A toric|Participants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
89527020|NCT03342235|Experimental|Surgical Group|Participants randomized to PRK surgery will be referred to a study surgical center. The participant will have a preoperative exam within 7 days prior to surgery and surgery within 60 days after randomization. Participants will continue prescribed 2 hours per day of patching between randomization and the day of surgery.
89527021|NCT03342235|Active Comparator|Non-surgical Control Group|For participants assigned to the non-surgical control group, patching will be prescribed for 2 hours per day with optical correction, and will continue until the 8-month primary outcome visit.
89527022|NCT03333889|Active Comparator|E-max hybrid crown|E-max hybrid crown Lithium Disilicate based ceramic which is characterized by high strength and optimum esthetics and considered a gold standard in anterior restorations
89527023|NCT03333889|Experimental|Vita Enamic hybrid crown|Vita Enamic hybrid crown polymer infilltrated ceramic network(hybrid ceramic) characterized by low modulus of elasticity that acts as cushion on implants.
89527024|NCT02129608|Active Comparator|LLLT|Low Level Laser Therapy (LLLT) once a week for 12 weeks
89527025|NCT02129608|Active Comparator|Lorcaserin|locarserin monotherapy - 10 mg, twice daily for 12 weeks
89527026|NCT02129608|Active Comparator|LLLT and Lorcaserin|LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
89527027|NCT02496403|Experimental|Standard Medical Management|Standard Medical Management (SMM) is a relatively brief (1.5 hour per week for 9 weeks), medically-focused behavioral intervention for opioid dependence. The experimental arm does not involve an investigational drug, device, or biologic.
89527028|NCT02496403|No Intervention|Intensive Outpatient Treatment|The Intensive Outpatient Treatment (IOT) arm is considered usual care and is a predominant model of care in specialty treatment. It incorporates psychosocial support, education, and relapse-prevention approaches and requires attendance at 12-step program. It is a group-based treatment, with individual counseling available as needed. During the initial, 3-week phase, treatment consists of 4-6 hours a day, 7 days a week. In weeks four through 9, treatment consists of 1.5 hours, four days each week. After 9 weeks, patients attend one-hour weekly group meetings for one year. Services include supportive therapy, psycho-education, relapse prevention, and family-oriented therapy. The program emphasis is on abstinence and is similar to many public and private intensive outpatient programs.
89527029|NCT03338725|Active Comparator|Patients without intervention|Patients without follow-up by clinical pharmacy model
89527030|NCT03338725|Experimental|Patients with intervention|Patients who are being monitored by a clinical pharmacy model
89527031|NCT01631188|Experimental|Aortic Valve Replacement|During surgery your doctor will utilize a new technique using surgical equipment that have already been FDA Approved for other indication. The combination of the equipment and technique will be experimental and will be closely evaluated during and after each case.
89527032|NCT03333733|Experimental|HENRY|Children's Centres within local authorities that have been randomised to the experimental arm, HENRY, will receive staff training to deliver the training and be asked to implement at least two programmes per year. Parents enrolled to attend HENRY programmes will then be invited to take part in the research.
89527033|NCT03333733|No Intervention|Waiting list control|Children's Centres within local authorities that have been randomised to the control arm will continue with usual practice. Parents attending another programme (Stay and Play) will be invited to take part in the research. At the end of the follow-up period, they will be offered training to deliver HENRY programmes although this will not be compulsory.
89527034|NCT02492347|Active Comparator|Neonates exposed to AN SSRI use|A group of newborn babies who have been exposed to SSRIs in pregnancy will receive an Electrocardiogram at 48-72 hours of age.
89527035|NCT02492347|Other|Neonates not exposed to AN SSRI use|A group of newborn babies, who require treatment with intravenous antibiotics for at least 36 hours, having been identified as being at risk of having an infection within 12 hours of being born. They are subsequently confirmed as clinically well and will receive an Electrocardiogram at 48-72 hours of age.
89527036|NCT02129062|Experimental|Treatment (ibrutinib)|Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
89527037|NCT02496247|Experimental|Immediate Herring|Participants in this arm will receive the Canned Herring intervention. Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child), which will be distributed weekly by community health workers. Families will be instructed to feed the study child half a can of herring per day (without reducing usual home food given to the child), and to not share the remaining herring with individuals who are in the Delayed Herring study arm. When families come to collect their weekly distribution they will be asked to bring in at least 7 empty herring cans in order to receive the next ration, and will answer a question about how often the child eats the herring.
89527038|NCT02496247|No Intervention|Delayed Herring (Control)|Families with children in this study arm will not receive any herring during the 8-10 week period when Immediate Herring families receive a weekly ration of herring. After the 8-10 week (end line) measurements, an equal amount of herring will be distributed to the family.
89527039|NCT04494763|Experimental|Propanolol|Dose: 1 to 8 mg/kg/day in 1 to 2 divided doses adjusted to achieve target reduction in resting heart rate by 25% from baseline Frequency: once to Twice daily Route of Administration: Oral Duration: 18 months
89527040|NCT04494763|Placebo Comparator|Placebo|Placebo in a similar manner
89527041|NCT03338491|Experimental|Induction of Implemental Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
89527042|NCT03338491|Experimental|Induction of Deliberative Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
89527043|NCT03338491|No Intervention|Control|Participants will revive no induction of any mindset.
89527044|NCT02162758|Experimental|Dexlansoprazole 60 milligram (mg) QD|Dexlansoprazole 60 mg, delayed-release capsules, orally, QD and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.
89527045|NCT02162758|Experimental|Dexlansoprazole 60 mg BID|Dexlansoprazole 60 mg, delayed-release capsules, orally, BID for up to 12 months.
89527046|NCT03333499|Placebo Comparator|the control group|YanXinShi placebo pills
89527047|NCT03333499|Experimental|YanXinShi group|YanXinShi pills
89527048|NCT03333499|Active Comparator|Trimetazidine group|Trimetazidine pills
89527049|NCT03333499|Other|YangXinShi and Trimetazidine group|YanXinShi and Trimetazidine pills
89527050|NCT02493907||heart failure|heart failure patients with CRT
89527051|NCT03338413|Experimental|Goal Management Training|
89527052|NCT03338413|Experimental|Computerized Cognitive Training|
89527053|NCT04494139|Active Comparator|Canteen Only|Train canteen staff and implement canteen intervention in the canteen space: interventions targeting food quality and quantity, intervention targeting food choice at point of sale, interventions target improved supply, interventions targeting price and promotional material.
89527054|NCT04494139|Experimental|Behavioral and Canteen intervention|The behavioral intervention will be comprised of a combination of intensive education sessions and goal setting and monitoring based on a validated worksite curriculum tailored to local needs. The curriculum includes 24 sessions: 16 core weekly sessions during the first four months of the intervention followed by 8 weekly maintenance sessions (text messages). Each session will be facilitated by a nutritionist/dietitian and a peer educator; and will last one hour. Broadly, the curriculum covers the subject matters of importance of healthy weight, eating a healthy diet, increasing physical activity, stress management, and challenges of lifestyle changes. Participants will be encouraged to keep food and activity diaries throughout the course of the study. During the maintenance period, the focus will be on overcoming declines in motivation and on maintaining long-term healthy behaviors.
89527055|NCT03333187|Experimental|Arm A|Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
89527056|NCT03333187|Active Comparator|Arm B|Treatment with Ruxolitinib continuous therapy
89527057|NCT02191618|Other|WEB Aneurysm Embolization Device|"The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant."
89527058|NCT03331159|Experimental|NanoBone|The participants were treated with anterior lumbar interbody fusion (ALIF) with a new nanocrystalline hydroxyapatite embedded in a silica gel matrix (NH-SiO2)
89527059|NCT03331159|Active Comparator|Homologous bone|The participants were treated with anterior lumbar interbody fusion (ALIF) with homologous bone
89527060|NCT02491957|Experimental|LOFT Therapy|LOFT therapy twice weekly for 4 weeks
89527061|NCT03331081|Experimental|Group Bladder Training|Patients will receive verbal instructions on bladder function (filling and bladder emptying phases), pelvic floor musculature on bladder function; orientation on urinary positioning and habits (urinary frequency); and the definition and major risk factors responsible for urinary incontinence.
89527062|NCT03331081|Active Comparator|Group TMAP|In this group the patients will perform TMAP in isolation. The training protocol aims at the work of strength and muscular hypertrophy, with concentric-isometric muscular action and load of 100% of the maximum voluntary contraction.
89527063|NCT03331081|Active Comparator|Group Bladder Training + TMAP|In this group, the patients should perform the proposed exercises for the Bladder Training Group and the exercises proposed for the TMAP Group. The training protocol of this group will consist of exercises that have as objectives: to improve the control over the urgency and urge-incontinence; increase bladder capacity, and thus prolong the intervals between urinations; to restore confidence in bladder control; and improve MAP strength and hypertrophy.
89527064|NCT02491645|Experimental|Intervention group|"Children would receive both standard therapy and home based sensory interventions as described below,~Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs .~Home based sensory interventions - children would receive home based sensory interventions targeting visual and auditory system, tactile abnormalities, proprioceptive and vestibular abnormalities.These interventions would be carried out daily , at least 5 days a week, for a minimum duration of 1hour/day."
89527065|NCT02491645|No Intervention|Control group|This group of children would receive only standard therapy as described below, Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs.
89527066|NCT02491879|Experimental|Ketoprofen|Ketoprofen gel
89527067|NCT02491879|Placebo Comparator|Placebo|Placebo form of ketoprofen gel
89527068|NCT02493985|Active Comparator|Atmosphere 1 - Ambient air|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and ambient air at sea level, followed by 2 hour exposure of 3% carbon dioxide inhalation.
89527069|NCT02493985|Experimental|Atmosphere 2 - 0.5% CO2|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and air with 0.5% carbon dioxide, followed by 2 hour exposure of 3% carbon dioxide inhalation.
89527070|NCT03332953|Other|E-cigarette|Subjects will be asked to vape various e-cigarettes at three concentrations of nicotine and sweet flavor (9 stimuli per subject). The subject will be asked to make ratings for the overall liking or disliking of the e-cigarette, followed by ratings on perceived intensities of sensations.
89527071|NCT02494219|Experimental|Rapid Immunochromatographic Streptococcal test|Throat swabbing by two port germ Amines agar (copan) swabs,the swabs were randomly labeled as swab A and swab B.Swab A was processed for rapid streptococcal test and swab B was processed for culture in Colombia blood agar.All patients were followed up after 48-72 hours with the final culture results that ultimately determined the need to continue or discontinue treatment.
89527072|NCT03338179|Experimental|Adult Patients|Schizophrenia patients aged between 18 and 45 years old
89527073|NCT03338179|Experimental|Aged Patients|Schizophrenia patients aged 59.5 years and above
89527074|NCT03338179|Active Comparator|Adult Controls|Controls aged between 18 and 45 years old
89527075|NCT03338179|Active Comparator|Aged Controls|Controls aged 59.5 years and above
89527076|NCT02491723|Experimental|Azithromycin group|Patients with non-cystic bronchiectasis were treated with azithromycin. The intervention was 500mg daily for three to five days.
89527077|NCT02491567||Hashimoto Thyroiditis (HT)|Children and adolescents with Hashimoto thyroiditis either hypothyroidic or euthyroidic.
89527078|NCT02491567||Graves Disease (GD)|Children and adolescents with Graves Disease both those on remission and under antihyroid medication.
89527079|NCT02491567||Controls (C)|Healthy individuals matched for gender and age without 1) any autoimmune disease 2) family history of autoimmune disease in the first degree relatives
89527080|NCT02492191|Active Comparator|RAPP, e- assessed follow-up|"A mobile application (app) is installed on each patient's own smartphone. The app includes the Swedish web version of the QoR (SwQoR). After a patient is discharged from the day-surgery department, the patients in the intervention group will answer the RAPP daily for 14 days. His or her smartphone will initiate the postoperative recovery measurements daily through a push function. Each question will appear separately on the mobile phone screen and will disappear from the screen immediately after a response is given. The app also contains a question asking if the patient wants to be contacted by a nurse, which they will answer with a YES or NO. If YES, a nurse at the day surgery department will contact the patient and offer further information and assistance. The number of contacts and the reasons for contact requests will be documented."
89527081|NCT02492191|No Intervention|Control|The control group will receive standard care; i.e., no follow-up
89527082|NCT03332875|Experimental|OurRelationship - 1 Coach Call|OurRelationship online program plus a single call with a coach.
89527083|NCT03332875|Experimental|OurRelationship - 4 Coach Calls|OurRelationship online program plus four calls with a coach.
89527084|NCT02493673|Active Comparator|CPAP therapy|Continuous positive airway pressure therapy
89527085|NCT02493673|Sham Comparator|Sham CPAP|Sham- Continuous positive airway pressure
89527086|NCT02493595||Cancer|Patients attending One-stop Symptomatic Breast Care clinics with suspicion of a breast lesion in one or both breasts.
89527087|NCT04494373|Experimental|HS-20090|Subcutaneously injection of HS-20090 (120mg/1.7mL) once on the first day
88807347|NCT05191524|Active Comparator|Proprioceptive Neuromuscular facilitation therapy|"Different PNF components (such as commands, stretching, timing, and manual resistance) will be used for optimizing patients' output. We will do ten repetitions of each pattern before~Proceeding to the next pattern. The PNF patterns in the set used in the study will be :~Lower extremity:~< Flexion-abduction-external rotation (knee flexed and knee extended) < Extension-adduction-internal rotation (knee flexed and knee extended) < Flexion-adduction-internal rotation (knee flexed and knee extended) < Extension-abduction-external rotation (knee flexed and knee extended"
88807348|NCT05190900|Experimental|Experimental|We will measure the stabilometric variables before and after the performance of a neuromeningeal mobilisation.
89527088|NCT04494373|Active Comparator|Xgeva®|Subcutaneously injection of Xgeva® (120mg/1.7mL) once on the first day
89527089|NCT03332719|Active Comparator|Enbrel®|Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients/Once a week Methotrexate 15 to 25 mg /Once a week
89527090|NCT03332719|Experimental|Enerceptan®.|Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg /Once a week
89527091|NCT03331003|Experimental|low level light therapy|1 group uses the investigational device on the left side, and the subjects will have half part receiving low level light therapy (red light-emitting diode and laser irradiation)
89527092|NCT03331003|Placebo Comparator|non-LLLT wavelength group group|the control device on the right side, other half with non-low-level laser therapy wavelength (white light-emitting diode light bulb coating with red paint to make the irradiating light close to the red).
89527093|NCT03332641|Experimental|Citron peel Extract|Citron peel extract for 12 weeks
89527094|NCT03332641|Placebo Comparator|Placebo|Placebo for 12 weeks
89527095|NCT03337867|Active Comparator|Real-iTBS|
89527096|NCT03337867|Sham Comparator|Sham-iTBS|
89527097|NCT03330925|Experimental|ElastiMed's SACS|Healthy Subjects which the Elastimed's SACS will be tried on
89527098|NCT03332563|Experimental|WebMAP Mobile|Adolescent participants assigned to this arm will receive access to the WebMAP mobile program delivering cognitive-behavioral intervention for chronic pain. Parents of adolescents will receive access to cognitive-behavioral strategies for parents on the WebMAP parent web site.
89527099|NCT03332563|No Intervention|Usual care|Participants assigned to this arm will receive usual care from the pain or specialty clinic during the non-exposure periods in the stepped wedge design.
89527100|NCT03330769||Patients with active Psoriatic Arthritis|Patients with clinically diagnosed PsA with clinically active joint disease starting a new course of treatment.
89527101|NCT03330613|Other|Inhalational anesthesia|Inhalational anesthesia is an anesthesia procedure using by respiratory tract. PAEDS used to for postanesthesia pediatric patients.
89527102|NCT03330613|Active Comparator|Total intravenous anesthesia|Total intravenous anesthesia (TIVA) is an anesthesia procedure using vascular infusion method.PAEDS used to for postanesthesia pediatric patients.
89527103|NCT03332485|Experimental|ECP Colon Prep Kit|
89527104|NCT03332485|Active Comparator|MoviPrep®|
89527105|NCT03330535|Active Comparator|Verbal oral hygiene instructions|Participants will receive verbal oral hygiene instructions during routine orthodontic visits.
89527106|NCT03330535|Experimental|Reminders once a week|Participants will receive active reminders once a week.
88807349|NCT05190354|Experimental|Xtremity Prosthesis|Xtremity Prosthesis fitting
89527107|NCT03330535|Experimental|Reminders three times a week|Participants will receive active reminders three times a week.
89527108|NCT03330535|Experimental|Daily reminders|Participants will receive active reminders daily.
89527109|NCT03332329|Experimental|Sequential combination arm|Drug: Entecavir for 60 weeks Drug: HBV vaccine (60ug/month, every four weeks) for 24 weeks Drug: Granulocyte Macrophage Colony Stimulating Factor (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84 Drug: Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108
89527110|NCT03337633|Active Comparator|Experiment 1 Easy|"For the first experiment, subjects in this arm received the easy menu during the protocol."
89527111|NCT03337633|Active Comparator|Experiment 1 Hard|"For the first experiment, subjects in this arm received the hard menu during the protocol."
89527112|NCT03337633|Active Comparator|Experiment 2 Easy|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the easy menu during the protocol."
89527113|NCT03337633|Active Comparator|Experiment 2 Hard|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the hard menu during the protocol."
89527114|NCT03337555|Active Comparator|Macintosh|intubation using Macintosh direct laryngoscope
89527115|NCT03337555|Experimental|McGrath|intubation using McGrath MAC®
89527116|NCT03337555|Experimental|Pentax|intubation using Pentax-airway scope®
89527117|NCT03330379|Experimental|continuous adjustment strategy|patients assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff
89527118|NCT03330379|No Intervention|usual care|patients with usual care
89527119|NCT03330301||Exposed|"Individuals born between June1983 and May1985 were exposed to the mandatory vitamin D margarine fortification during fetal life.~Cases: individuals defined as having one of the aforementioned diseases of interest from the registers"
89527120|NCT03330301||Non-exposed|"Individuals born between September1986 and August 1988 were not exposed to the mandatory vitamin D margarine fortification during fetal life.~Controls: cohort of matched disease-free individuals"
89527121|NCT02492113|Experimental|Patients with BMI > 35|"ICU patients with a BMI > 35, on pressure support ventilation, scheduled for spontaneous breathing trial for evaluation of extubation~After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs) in randomized order. Either the patient will receive SBT at PEEP = 0-5 cmH2O, with PSV=0 and FiO2 unchanged; or the patient will perform an SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
89527122|NCT03331939|Experimental|No stimulation|All patients will receive three different stimulations
89527123|NCT03331939|Other|Beta (25-30 Hz)|Vagal nerve stimulator will be set to Beta (25-30 Hz)
89527124|NCT03331939|Other|Theta (5 Hz)|Vagal nerve stimulator will be set to Theta (5 Hz)
89527125|NCT03330223||Clopidogrel|clopidogrel 75mg qd;aspirin 100mg qd, n=30
89527126|NCT03330223||Ticagrelor|ticagrelor 90mg bid; aspirin 100mg qd, n=30
89527127|NCT03330145|Experimental|children who lost a parent to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
89527128|NCT03330145|Active Comparator|children who lost a parent not to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
89527129|NCT05232721||Fecal Immunochemical Test|People in this group will detect hemoglobin in stool before colonoscopy by the new instrument
89527130|NCT03329833|Experimental|Motivational Interviewing|Participants will talk to a coach on the phone who will employ Motivational Interviewing as a coaching style.
89527131|NCT03329833|Experimental|Web-Based Application|Participants will use a Web-Based Application to track their daily physical activity.
89527132|NCT03329833|Experimental|Combination MI and App|Participants will have both a coach by phone who will employ Motivational Interviewing as a coaching style and use a Web-Based Application to track their daily physical activity.
89527133|NCT03329833|No Intervention|Educational Program|Participants will get to use a website that contains information relevant to patients with Parkinson's Disease.
89527134|NCT02493439|Experimental|Best Possible Self|Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health. The participants are instructed to practice the BPS intervention for a month, 5 minutes/day.
89527135|NCT02493439|Placebo Comparator|Daily Activities|Participants are asked to think and write about the activities carried out in the last 24 hours. The participants are instructed to practice the Daily Activities exercise for a month, 5 minutes/day.
89527136|NCT03337321||ETvalid|Pregnant women attending maternal care services and having access to computational device
89527137|NCT03337243|Experimental|HAM and HUMCWJ Injections (Group 1)|Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.
89527138|NCT03337243|No Intervention|Control (Group 2)|Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months.
89527139|NCT03331861|Experimental|Metformin|Metformin for 6 months
89527140|NCT03331861|Placebo Comparator|Placebo|Matched placebo for 6 months
89527141|NCT03337165|Experimental|tolerogenic dendritic cells|Each dose of autologous monocyte-derived dendritic cells generated in the presence of IFN-α/GM-CSF and tolerized with Dexamethasone (1x106, 3x106, 5x106, 8x106 and 10x106 cells in 2.0 mL sodium chloride 0.9% solution) will be administered in RA patients through intra-articular injection (into the knee joint).
89527142|NCT03329755|Experimental|Experimental|
89527143|NCT03329755|Other|Standard|
89527144|NCT03329443|Placebo Comparator|placebo|
89527145|NCT03329443|Active Comparator|Spironolactone|
89527146|NCT03329287|Experimental|SCBT + Drug|Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
89527147|NCT03329287|Active Comparator|Psychological Placebo + Drug|Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
89527148|NCT03329287|Active Comparator|Drug|Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.
89527149|NCT03329053|Experimental|Experimental group|Patients randomized into the experimental group will undergo behavioural counselling. During the 30-minute long consultation patients will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support system EXPERT tool.
89527150|NCT03329053|Active Comparator|Control group|Patients randomized into the control group will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, also in the domain of recommendations for physical activities.
89527151|NCT03325075|Experimental|VAL-181388|
89527152|NCT03325075|Placebo Comparator|Placebo|
89527153|NCT03324997|Experimental|Restylane|half the chest to be treated with Restylane Silk
89527154|NCT03324997|Placebo Comparator|Placebo|half-chest injections with saline as a placebo to Restylane Silk.
89527155|NCT02646891|Placebo Comparator|Adults: Placebo|Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
89527156|NCT02646891|Experimental|Adults: 30 µg P2-VP8|Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
89527157|NCT02646891|Experimental|Adults: 90 µg P2-VP8|Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
89527158|NCT02646891|Placebo Comparator|Toddlers: Placebo|Toddlers received one intramuscular injection of placebo on Day 0.
89527159|NCT02646891|Experimental|Toddlers: 30 µg P2-VP8|Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
89527160|NCT02646891|Experimental|Toddlers: 90 µg P2-VP8|Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
89527161|NCT02646891|Placebo Comparator|Infants: Placebo|Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
89527162|NCT02646891|Experimental|Infants: 15 µg P2-VP8|Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
89527163|NCT02646891|Experimental|Infants: 30 µg P2-VP8|Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
89527164|NCT02646891|Experimental|Infants: 90 µg P2-VP8|Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
89527165|NCT03109405|Experimental|stimulation-assisted|All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
89527166|NCT03109405|Other|standard IV cannulation|The subject underwent standard IV cannulation using a 20 gauge cannula into the best available vein. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
89527167|NCT02492035|Experimental|Physical activity|Tailoring intervention with kinesiologist
89527168|NCT02492035|Experimental|Diet|Tailoring intervention with nutritionist
89527169|NCT02492035|Experimental|Physical activity and diet|Tailoring intervention with kinesiologist and nutritionist
89527170|NCT02492035|No Intervention|Standard medical care|Follow with family doctor as usual care.
89527171|NCT03324919||Psoriasis, HRQL|Patients with a medical diagnosis of Psoriasis were enclosed.
89527172|NCT03324919||Urticaria, HRQL|Patients with a medical diagnosis of Urticaria were enclosed.
89527173|NCT03324919||Lupus erythematodes, HRQL|Patients with a medical diagnosis of Lupus were enclosed.
89527174|NCT03324841||MI Profiling|Subjects must have undergone Caris MI Profiling in order to be eligible for the study. No required intervention is dictated by the protocol.
89527175|NCT03328975|Active Comparator|Dexamethasone|Group 1 will receive an injection of 4mg of dexamethasone 4 mL of 1% lidocaine.
89527176|NCT03328975|Placebo Comparator|Placebo|Group 2 will receive an injection of 5 mL of 1% lidocaine (placebo).
89527177|NCT04484415|Experimental|Cevira® treatment|The Cevira® treatment is an integrated combination of drug and device
89527178|NCT04484415|Placebo Comparator|Placebo ointment|The placebo ointment contains only vehicle, and is similar in appearance and consistence as the Cevira® ointment. The placebo device is identical in appearance as the Cevira® device, but does not provide light.
89527179|NCT02491801|Experimental|3.25% M.F. Milk|3.25% M.F. Milk
89527180|NCT02491801|Experimental|Greek Yogurt|Greek Yogurt (2% M.F.)
89527181|NCT02491801|Experimental|Cheddar Cheese|Regular Fat Cheddar Cheese
89527182|NCT02491801|Experimental|Control 1|Skim milk
89527183|NCT02491801|Experimental|Control 2|Filtered water, calorie-free control
89527184|NCT03102957|Experimental|epileptic patients|2 functional MRI (pre and post resective surgery) with memory and language tasks
89527185|NCT03102957|Other|Healthy volunteers|1 functional MRI with memory and language tasks
89527186|NCT03324763||stool sampling|
89527187|NCT05430711|Experimental|Dinoprostone|Participants will receive dinoprostone 10 mg vaginal delivery system for up to 24 hours.
89527188|NCT05430711|No Intervention|Expectant management|Participants will not receive drugs to induce labour, they will be managed expectantly for up to 24 hours.
89527189|NCT03331783|Experimental|Test of new adhesive strips|"On the peristomal skin 4 different patches are applied to the skin (Standard hydrocolloid adhesive patch; LT-2, LT21 and 33-20. There is a bag welded to each patch. Tthe bag contains real output.~The difference between the four patches is that they are made of four different adhesives.~The primary endpoint is measured after 8 hours and 24 hours."
89527190|NCT03102567|Experimental|GLPG1205 50mg q.d.|oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo
89527191|NCT03102567|Placebo Comparator|placebo|oral hard gelatin capsules containing placebo for q.d. administration
89527192|NCT03102567|Experimental|GLPG1205 250 mg loading and 50mg q.d. maintenance|open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration
89527193|NCT03331705||Use of new cystoscope|Patients in which the cystoscope is used.
89527194|NCT03324685|Experimental|BIIB074 150 mg and Oral Contraceptive|Participants will receive BIIB074 in tablet form in 150 mg doses every 8 hours on prescription (TID) on days 1-7 and on days 26-32. OC will be taken in tablet form (ethinyl estradiol 30 micrograms and levonorgestrel 150 micrograms) once daily (QD) on days 12-32.
89527195|NCT03331627|Active Comparator|STR001-IT/STR001-ER|
89527196|NCT03331627|Active Comparator|STR001-IT/STR001-ER Placebo|
89527197|NCT03331627|Placebo Comparator|STR001-IT placebo/STR001- ER placebo|
89527198|NCT03331549||Myocardial infarction|
89527199|NCT03331549||Control group|
89527200|NCT03324295||cortical cataract|patients with age related cortical cataracts who are otherwise healthy
89527201|NCT03324295||ocular problems|systemically healthy subjects with ocular problems other than cataract
89527202|NCT03324295||impaired renal functions|patients with impaired renal functions and are not on dialysis
89527203|NCT03328585|Active Comparator|CBT-I in person|
89527204|NCT03328585|Experimental|CBT-I via telemedicine|
89527205|NCT03328585|Other|Waitlist Control|Patients in this arm will receive in person CBT-I treatment after conclusion of the study.
89527206|NCT03324217|Experimental|Motor Imagery Group|The participants in the motor imagery group were given instructions to perform a daily training composed of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant only had to imagine that he was performing that task, placed in the standard position with the tennis ball in the hand. Once the first set was completed, the participant had to take a 2-minute break before starting the second set, in which they had to complete the set both imagining and actively performing the isometric contractions with the tennis ball.
89527207|NCT03324217|Experimental|Action Observation Group|The participants in the action observation group were given instructions to perform a daily training comprised of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant simply watched a video that showed a forearm performing the task, placed in the standard position and with the tennis ball in the hand. Once that first set was completed, the participant took a 2-minute break before starting the second set, in which they performed the 10 isometric contractions with the tennis ball while they watched the video.
89527208|NCT03324217|Active Comparator|Control Group|The participants in the control group were given instructions to perform a daily training of a single set. The set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions.
89527209|NCT03331471|Active Comparator|alveolar recruitment maneuver|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O and applying alveolar recruitment maneuver (PEEP 10 cmH2O for 3 breath - PEEP 15 cmH2O for 3 breath and PEEP 20 cmH2O for 10 breath) immediate before and after pneumoperitoneum
89527210|NCT03331471|Experimental|conventional ventilation|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O applying during anesthesia
89527211|NCT02491489|Experimental|Painful shoulders|Subjects with shoulder pain undergoing glenohumeral mobilization
89527212|NCT02491489|Active Comparator|Normal shoulders|Subjects without shoulder pain undergoing glenohumeral mobilization
89527213|NCT03331237|Active Comparator|LVS group|interscalene injection
89527214|NCT03331237|Active Comparator|ISO group|in this group all patients will receive ISO block.
89527215|NCT03328429|Other|Marsupialization|Bartholin gland marsupialization will be done to all patients with Bartholin abscess.
89527216|NCT03328429|Other|Excision|Bartholin gland excision will be done to all patients with Bartholin abscess.
89527217|NCT03328351|Experimental|manual group|"The Manual therapy (Mobilization):~Cervical postero-anterior vertebral mobilization glides: the mobilization was grade 3 for 2 min 3 set~Cervical lateral vertebral glides: the mobilization was grade 3 for 1 min 3 set.~Strengthening Exercises for deep neck flexor muscle"
89527218|NCT03328351|Sham Comparator|sham group|"Superficial soft tissue massage~Strengthening Exercises: for deep neck flexor muscles for 10 seconds and repeating it for 10 times ."
89527219|NCT05430633||Pregnant patients who underwent laparoscopic appendectomy|Pregnant patients who underwent laparoscopic appendectomy
89527220|NCT05430633||Pregnant patients who underwent open appendectomy|Pregnant patients who underwent open appendectomy
89527221|NCT03324139|Experimental|Study Group|Treatment with low molecular weight Heparin.
89527222|NCT03324139|Placebo Comparator|Control Group|Treatment with Placebo.
89527223|NCT05430321|Experimental|Effect of facilitated tucking after preterm labor|Implementation of facilitated tucking after preterm labor
89527224|NCT05430321|No Intervention|Supine position after preterm labor|Implementation of supine position after preterm labor
89527225|NCT03324061|Experimental|Fulvestrant for Injectable Suspension|Fulvestrant for Injectable Suspension (500 mg/vial)
89527226|NCT03324061|Active Comparator|Faslodex (R)|Faslodex (250 mg/mL)
89527227|NCT03323983||Normal lung clearance index|
89527228|NCT03323983||Elevated lung clearance index|
89527229|NCT02488603|Experimental|Decision aids|
89527230|NCT02488603|No Intervention|usual care|
89527231|NCT03323827||Aim 2a|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2a. Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) nondiabetics 20 subjects will be enrolled"
89527232|NCT03323827||Aim 2b|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2b (muscle contraction and acetylation) Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 32 subjects will be enrolled"
89527233|NCT03323827||Aim 3|"Specific Aim 3. To determine how acetylation of the mitochondrial inner membrane adenine nucleotide translocase ANT1 regulates protein structure and function.~Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 20 subjects will be enrolled."
89527234|NCT02640105||Patient with Cluster headache|Prospective follow-up of patient with Cluster headache
89527235|NCT03328117|Active Comparator|Intervention|
89527236|NCT03328117|Placebo Comparator|Placebo|
89527237|NCT05430087|Experimental|Vitamin D + Placebo|The first group received 400 IU cholecalciferol (Nature Plus) t.i.d (three times a day) and placebo (Saccharum lactis) t.i.d.
89527238|NCT05430087|Experimental|Curcumin-Piperine + Placebo|The second group received a tablet containing curcumin (632 mg) - piperine (15,800 mg) (Bioglan) one time daily and a placebo (Saccharum lactis) t.i.d.
89527239|NCT05430087|Experimental|Vitamin D + Curcumin-Piperine|The third group received 400 IU cholecalciferol (Nature Plus) t.i.d and curcumin (600 mg) - piperine (15,800 mg) (Bioglan) one time daily
89527240|NCT03327883||1/Patients medical records|Medical records of patients with metastatic bladder cancer
89527241|NCT03327727|Experimental|VL-2397|Investigational agent VL-2397 600 mg IV infusion administered every day for 28 days (4 weeks) followed by 2 weeks of standard treatment
89527242|NCT03327727|Active Comparator|Standard (First-Line) Treatment|Investigator selected standard treatments of voriconazole, isavuconazole, or liposomal amphotericin B administered every day for 42 days (6 weeks) per product package insert
89527243|NCT03337789|Experimental|Polygonatum sibiricum|
89527244|NCT03337789|Placebo Comparator|Placebo|
89527245|NCT03102489|Experimental|BP101|Treatment with BP101
89527246|NCT03102489|Placebo Comparator|Placebo|Treatment with placebo
89527247|NCT02522637|Active Comparator|Exercise training F1|Patients will be treated with a specific rehabilitation in-hospital program consisting of one daily sessions of 30 minutes of exercise (Frequency 1 : Program F1 )
89527248|NCT02522637|Experimental|Exercise training F2|Patients will be treated with a specific rehabilitation in-hospital program consisting of two daily sessions of 30 minutes of exercise (Frequency 2 : Program F2 )
89527249|NCT03323671|Experimental|premenstruation group|preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle
89527250|NCT03323671|Experimental|menstruation group|mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle
89527251|NCT02503527|Other|Diben 1.5 kcal HP|Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
89527252|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)
89527253|NCT03323593|Active Comparator|iv|
89527254|NCT03323593|Active Comparator|drip|
89527255|NCT03323593|Active Comparator|atomizer|
89527256|NCT02499003|Experimental|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
89527257|NCT03320551|Experimental|Nutrition Education Immersion Program|Assessing if a one week lifestyle interventions can lead to long term health benefits.
89527258|NCT04492813|Experimental|Obese patients|Severe and morbidly obese patients (35²≤BMI <55)
89527259|NCT04492813|Active Comparator|Non Obese patients|Patients with normal weight or slightly overweight (19 <BMI <30).
89527260|NCT01236807|Active Comparator|MR Inform|Management guided by the result of the MR perfusion scan. Possible intervention: coronary artery revascularization.
89527261|NCT01236807|Active Comparator|FFR Inform|Management guided by the result of FFR measurement. Possible intervention: coronary artery revascularization.
89527262|NCT03323359|Experimental|Hemopatch 45x90 mm - CE 0297 Class III|Hemopatch + Common surgical techniques
89527263|NCT03323359|Other|Standard Surgery Technique|Common surgical techniques
89527264|NCT02441751||bleeding|intraoperative blood loss > 500 ml
89527265|NCT02441751||no bleeding|intraoperative blood loss < 500 ml
89527266|NCT02491255|Experimental|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
89527267|NCT02488369|Experimental|Patients with non-Hodgkin's lymphoma|
89527268|NCT03320395|Experimental|Small bowel RFA treatment|Five small bowel samples each of the duodenum, jejunum and ileum will be recruited treated.
89527269|NCT03102801|Active Comparator|Type 2 diabetes arm|Both arms will be subjected to Hypoglycaemia and compare results
89527270|NCT03102801|Active Comparator|Non diabetics arm|Both arms will be subjected to Hypoglycaemia and compare results
89527271|NCT03327415||Age groups|Eleven age groups that took into account the previous surveys and the key stages of child development were defined: 15 days to 3 months, 4, 5, 6, 7, 8-9, 10-11, 12- 17, 18-23, 24-29, and 30-35 months.
88814472|NCT04366778||patients hospitalized for Covid-19 who present thrombosis|Patients with Covid-19 infection hospitalized in Lyon University Hospitals who present thrombosis during hospitalization
89527272|NCT02646423|Experimental|Prior CD Decision App (PCDDA)|Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
89527273|NCT02646423|No Intervention|Usual Care - No App|Women randomized to the Usual Care - No App group will simply continue with usual care.
89527274|NCT03327337|Experimental|experimental group|operate with Arthroscopic Assisted Balloon Tibioplasty on this group patients
89527275|NCT03327337|Other|control group|operate with open reduction and internal fixation on this group patients
89527276|NCT03327259|Active Comparator|Activity Planning Only|
89527277|NCT03327259|Experimental|Enhanced Activity Planning|Activity planning with therapist guided activity practice.
89527278|NCT04412577|Experimental|TQB3473 tablets|TQB3473 tablets administered once daily in 28-day cycle .
89527279|NCT02488057|Active Comparator|Diet-induced weight loss|Investigators will randomize subjects to lifestyle change or lifestyle change plus GLP-1 receptor agonist. Lifestyle change will be developed around a meal replacement strategy. The intervention will be weight loss using Slim-Fast®. Participants will be provided Slim-Fast® meal replacement shakes to utilize for two meals daily plus one to two 100 calorie snacks, similar to the Look AHEAD protocol. The subjects will receive specific menus and training on food composition to prepare one healthy 500 calorie meal daily, for a net hypocaloric diet.
89527280|NCT02488057|Active Comparator|Weight loss plus liraglutide|Patients will be randomized to lifestyle change and the GLP-1 agonist, liraglutide. Subjects in this group will be administered 0.6mg liraglutide, sq injection daily for 1 week, increased to 1.2 mg for 1 week, and then 3.0 mg for the next 10 weeks of the acute phase. This gradual escalation of the dose is designed to minimize gastrointestinal side effects. Empty syringes will be monitored for compliance.
89527281|NCT04044495|Experimental|Sample of 100 persons included in AMI / AMImage 2|Sample of 100 persons included in AMI / AMImage 2
89527282|NCT04039347|Experimental|L-CsA 5 mg plus Standard of Care|L-CsA 5 mg twice daily plus Standard of Care for up to 144 weeks for patients post Single Lung Transplant
89527283|NCT04039347|Experimental|L-CsA 10 mg plus Standard of Care|L-CsA 10 mg twice daily plus Standard of Care for up to 144 weeks for patients post Double Lung Transplant
89527284|NCT03327181|Experimental|COPD|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
89527285|NCT03327181|Active Comparator|Healthy older adults|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
89527286|NCT03320239|Experimental|the online-RASSL intervention group|HIV risk assessment and tailored suggestions, free HIV testing link
89527287|NCT03320239|Experimental|intervention group 2|HIV risk behavior investigation and routine education
89527288|NCT03320239|Placebo Comparator|the control group|The placebo control: HIV/AIDS knowledge assessment, routine education
89527289|NCT03327103|No Intervention|Enhanced Usual Care|Receive standard care
89527290|NCT03327103|Experimental|Decision Intervention|Receives decision aid intervention that encompasses balance sheets, navigation, audio files, and interaction -- Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION)
89527291|NCT02488291|Experimental|0.5 sufentanil|0.5µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
89527292|NCT02488291|Experimental|0.25 sufentanil|0.25µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
89527293|NCT03102255|Active Comparator|Conventional|Performed nasotracheal intubation as usual. Sniffing position but doesn't lift a nasal tip.
89527294|NCT03102255|Experimental|Nasal tip lifting|Performed sniffing position and nasal tip lifting while the endotracheal tube insert patient's nasal cavity.
89527295|NCT03327025|Experimental|Intervention|
89527296|NCT05226039|Other|Young adult group|One group will consist of 20 to 30 year olds. Participants will complete all three visits that include both the treatment (exercise visit) and the control (rest) visits. The treatment visit will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike.
89527297|NCT05226039|Other|Older adult group|The other group will consist of 60 to 70 year olds. Participants will complete all three visits that include both the treatment (exercise visit) and the control (rest) visits. The treatment visit will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike.
89527298|NCT03320083|Active Comparator|Educational care derived from POSSUMS|Intervention group were offered a sleep education session using behavioral change counseling communication skills, derived from the POSSUMS approach developed by Douglas P and Whittingham K. However we could not use Acceptance and Commitment Therapy (ACT), because none of the investigators had sufficient training on ACT at the time the study was conducted.
89527299|NCT03320083|No Intervention|Usual Care|General anticipatory guidance given
89527300|NCT03102333|Active Comparator|Constant-rate Infusion|INTERVENTION : Constant-rate Infusion mode : The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
89527301|NCT03102333|Active Comparator|Variable-rate Feedback Infusion|INTERVENTION : Variable-rate Feedback Infusion mode :The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
89527302|NCT03323047|Experimental|Group 1|Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia.
89527303|NCT03323047|Active Comparator|Group 2|Acetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
89527304|NCT03323047|Placebo Comparator|Group 3|Placebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia.
89527305|NCT03102099||contrast-enhanced ultrasound group|The contrast-enhanced ultrasound(CEUS)patients will undergo biopsy with contrast-enhanced ultrasound guidance.
89527306|NCT03102099||conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
89527307|NCT03102177|Experimental|Stable isotope arm|Measurement of blood levels of labelled levothyroxine after administration of single oral dose of stable isotope levothyroxine
89527308|NCT03322969|Experimental|receiving modified chemotherapy|Paclitaxel/DDP
89527309|NCT03322969|Active Comparator|receiving the original chemotherapy|XELOX/SOX
89527310|NCT03320005|Active Comparator|ResistanceTraining Group|The RT program has the following features: 05 classes performing two weekly sessions; day shift; sessions with maximum duration of 1 (one) hour; 02 series; 08 to 12 repetitions; interval between sets of 01 to 02 minutes; exercises: bench press, seated leg press 45°, pull forward, Earth, rowing standing calf standing, power lifting, abdominal and development.
89527311|NCT03320005|No Intervention|Non training group|sedentary elderly
88814473|NCT02245334|Experimental|Povidone-iodine|povidone iodine pill
89527312|NCT05187975|Experimental|Integrated rehabilitation group|This group will include 101 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation .
89527313|NCT05187975|Active Comparator|Standard care group|The patients were recommended to take one oral tablet of paroxetine hydrochloride (20 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.
89527314|NCT05464303||Postoperative cholangitis|Patients who had conducted kasai procedure and suffered from postoperative cholangitis after surgery
89527315|NCT05464303||None postoperative cholangitis|Patients who had conducted kasai procedure and followed up in a clinic，at which time they didn't present signs of cholangitis
89527316|NCT02352129|Experimental|Cardiomyopathy dilated patient|Cardiomyopathy dilated patients wil be evalueted by CMR using T1 mapping technique to evalueted the level myocardial fibrosis
89527317|NCT02352129|Active Comparator|healthy subjects|healthy subject wil be evaluated by CMR using T1 mapping technique to know the baseline of myocardial fibrosis in healthy subjects
89527318|NCT03319771|Experimental|Treadmill Walking Exercise Training|12 weeks of supervised, progressive treadmill walking exercise training
89527319|NCT03319771|Active Comparator|Stretching-and-toning Exercise Training|12 weeks of supervised, stretching-and-toning exercise training
89527320|NCT05042427||primigravida women|Weight management health literacy of primigravida women.
89527321|NCT04443283||LTBI Group|IGRA(+)
89527322|NCT04443283||No LTBI Group|IGRA(+)
89527323|NCT02075697||New drugs|Cohort exposed to biologic therapy, apremilast or fumarates
89527324|NCT02075697||Classic systemic therapy|Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).
89527325|NCT03322891|Experimental|Educational Supplement|Participants diagnosed with prostate cancer will receive education for treatment options and treatment side effects.
89527326|NCT03319693||Mucosal melanoma|Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014
89527327|NCT04435275|Active Comparator|Donning PPE using VA then doffing PPE using HC|Study subjects will receive VA guidance for donning first, then guidance from a human coach (HC) for doffing.
89527328|NCT04435275|Active Comparator|Donning PPE using HC then doffing PPE using VA|Study subjects will receive HC guidance for donning first, then VA guidance for doffing.
89527329|NCT04435275|Active Comparator|Intubation using VA then extubation using HC;|Study subjects will receive VA guidance for the intubation first , then HC guidance for extubation procedure
89527330|NCT04435275|Active Comparator|Intubation using HC then extubation using VA|Study subjects will receive HC guidance for the intubation first , then VA guidance for extubation procedure
89527331|NCT04000269|Experimental|Treatment Group|Treatment with 'Soterix MxN Neuromodulation device (high definition transcranial direct current stimulator) using HD-Targets for optimal neural targeting will be provided to participants and will include 20 minutes of stimulation coupled with conventional OT treatment during and after the intervention. There will be a total of 10 sessions over about a 2 week period.
89527332|NCT04000269|Sham Comparator|Sham group|Sham stimulation will consist of using the devices auto-sham feature. The exact same setup/device will be used during both groups. This is considered a control for the experiment. Both groups will receive similar physical occupational and speech therapy
89527333|NCT02488213|Active Comparator|Usual Diet Guidance|The patients will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed in outpatient patients treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre.
89527334|NCT02488213|Experimental|Nutritional Counseling|The patients will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material.
89527335|NCT02491021|Active Comparator|Treatment Group|Treatment Group (TG) The TG underwent a 7-week outpatient rehabilitation programme comprising both exercise and education sessions under the direct supervision of the physiotherapy team. The exercise intervention was 20 minutes, 3x/week (1 supervised, 2 self directed) titrated to a specific intensity based on risk stratification - highvs low risk). The intervention also included 6 x 1 hour education sessions.
89527336|NCT02491021|No Intervention|Control Group|Control Group (CG) The CG received physiotherapy, exercises and education as per current standards of practice in our institution up until hospital discharge. Following discharge no further specific input or education was provided. Participants were contacted at least once during the study period to check on their general well being and to encourage attendance at the second assessment by the physiotherapy team. In line with the ethical requirements for the study, all control subjects were offered the chance to participate in the rehabilitation programme once their trial participation was completed following second assessment.
89527337|NCT03319615|No Intervention|Habitual dietary intake|Habitual dietary intake
89527338|NCT03319615|Experimental|Energy Restriction|Match period (to comparator) of dietary energy restriction
89527339|NCT02491177|Other|cMM and Text Messaging|Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
89527340|NCT02491177|Other|cMM Only|Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
89532736|NCT06004414|Experimental|SilverCloud|Adolescents who screen positive for significant mental health symptoms and who are enrolled in their school-based health center (SBHC) randomized to receive SilverCloud.
88814474|NCT02245334|No Intervention|no intervention|no intervention
89527341|NCT02491177|Other|Text Messaging Only|Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
89527342|NCT02491177|No Intervention|Neither cMM nor Text Messaging|Participants randomized to this arm will receive standard of care with no interventions.
89527343|NCT03322735|Experimental|anti-tumor response of BCMA CAR-T|"Drug: Cyclophosphamide patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days.~Drug: Fludarabine Fludarabine 25-30mg/m2/day IV for 3 days. Biological: BCMA CAR-T BCMA CAR-T cells will be administered after completion of the chemotherapy."
89527344|NCT03953625|No Intervention|no delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~if the patient is included and depending on the week of inclusion, he will then be randomized to either the no booklet or the booklet group.~If it is randomized to the arm 1 no booklet group, the patient will have classic management.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
89527345|NCT03953625|Experimental|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If the patient is included and depending on the week of inclusion, the patient will then be randomized to either the no booklet or the booklet group.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
89527346|NCT03109327||Urgent Excision|Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
89527347|NCT03109327||Non-urgent Excision|Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
89527348|NCT02487901|Active Comparator|Ultrasonic osteotome|making gutter on the hinge side of lamina with ultrasonic osteotome
89527349|NCT02487901|Sham Comparator|Drill|making gutter on the hinge side of lamina with conventional drill
89527350|NCT02487667|Active Comparator|Intervention Group|Therapeutic exercise
89527351|NCT02487667|No Intervention|Control Group|No treatment
89527352|NCT02490709|Experimental|Local excision|Local excision for rectal cancer with good response
89527353|NCT05418205|Experimental|Intervention Group (IG)|Families with FGP support (families with disabled and/or chronically children under 18 in the greater area of Mainz, Saarbrucken and Munich (Germany)
89527354|NCT05418205|No Intervention|Control Group (CG)|Families without FGP support (standard care) under the same conditions
89527355|NCT03326635||frailty group|frailty score ≤ 3
89527356|NCT03326635||non-frailty group|frailty score >3
89527357|NCT02487823|Experimental|BKM 120 (60 mg)|BKM120 (60 mg) in combination with LH-RH agonists and bicalutamide
89527358|NCT02487823|Experimental|BKM 120 (80 mg)|BKM120 (80 mg) in combination with LH-RH agonists and bicalutamide
89527359|NCT02487823|Experimental|BKM 120 (100 mg)|BKM120 (100 mg) in combination with LH-RH agonists and bicalutamide
89527360|NCT03326557|Active Comparator|Membrane sweeping|Membrane sweeping involves the insertion of a digit past the internal cervical os followed by three circumferential passes of the digit causing separation of the membranes from the lower uterine segment. When the cervix is closed, a massage of the cervical surface for 15 to 30 seconds will be performed instead. Membrane sweeping will be undertaken twice a day at 8 to 10 hours apart.
89527361|NCT03326557|Active Comparator|Transcervical Foley catheter insertion|Transcervical Foley catheter No. 18 F will be inserted under aseptic technique into the endocervical canal surpassed beyond the internal os. The balloon will be inflated with 60 ml of sterile water and the catheter is plastered to patient's thigh with gentle traction. The catheter will be checked for its position and the traction at 6 hours interval. If it were expelled spontaneously, it would not be re-inserted. Otherwise, the catheter will be removed after 24 hours.
89527362|NCT03326479||Retrospective|Subject who have previously had MI Profiling performed prior to 11/11/2016 are eligible for this study. No drug intervention is required for this study.
89527363|NCT03326401||Case (AMD group)|Case group including 100 patients diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
89527364|NCT03326401||Control (Non-AMD group)|Case group including 100 patients not diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The questionaire form, prepared to determine socio-demographic features of individuals participating in the research, was applied by the research with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
89527365|NCT02487511|Active Comparator|14 days|14 days treatment regimen
89527366|NCT02487511|No Intervention|7 days|7 days treatment regimen
89527367|NCT03319381||w/o SOP|Time period 1: 2000-2006, without new SOPs
89527368|NCT03319381||SOP|Time period 2: 2010-2012, after implementation of the new SOPs
89527369|NCT03322579|Experimental|Patients with Eustachian tube dysfunction|
89527370|NCT03322501|Experimental|Intervention|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
89527371|NCT03326089|Active Comparator|High flow oxygen supplementation|Pulmonary rehabilitation with constant high flow supplementary oxygen supply FiO2 50% for 2 months (Group A).
89527372|NCT03326089|Placebo Comparator|Oxygen supplementation upon hypoxemia|Pulmonary rehabilitation without oxygen supply unless upon resting or exercise induced hypoxemia for 2 months (Group B).
89527373|NCT02487589|No Intervention|Control group|"In Italy, medical risks and patients risk behaviour are not systematically registered and addressed by hospital physicians, specialists and general practitioners (GPs).~Patients allocated in control group will receive by the hospital staff tailored recommendations based on their own risk profile. The same information will be sent to their GPs. No restrictions on co-interventions will be placed."
89527374|NCT02487589|Experimental|Treated group|Telephone support, telemonitoring and tele-exercise
89527375|NCT03319225||Tetraplegia|Persons with Tetraplegia
89527376|NCT03319225||Paraplegia|Persons with Paraplegia
89527377|NCT03319225||Neurologically-intact|Neurologically-intact controls
89527378|NCT03319147|Placebo Comparator|Placebo|4g of maltodextrin
89527379|NCT03319147|Active Comparator|Active|4g of essential amino acids
89527380|NCT03322111|Experimental|Cyclofusion|
89527381|NCT03326011|Experimental|Gait training group|Gait training with Samsung Hip Assist v1 All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions.
89527382|NCT03325933|Experimental|Resistance Training 1|Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
89527383|NCT03325933|Experimental|Resistance Training 2|Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
89527384|NCT03325933|No Intervention|Wait-list control|This group will be offered the option of participating in either experimental group after the study is completed.
89527385|NCT02487433|Experimental|Tofacitinib MR 22 mg Fed|Single dose of tofacitinib MR 22 mg administered under fed conditions
89527386|NCT02487433|Experimental|Tofacitinib MR 22 mg Fasted|Single dose of tofacitinib MR 22 mg administered under fasted conditions
89527387|NCT03319069|Experimental|group (1)|Hypofractionated radiotherapy women with T3-4 and /or 4 or more axillary nodes involvement post mastectomy. Hypofractionated radiotherapy 43,5 GY/15 fractions (f) /3w. to chest wall and supraclavicular nodal region.
89527388|NCT03319069|Active Comparator|group(2)|Conventional fractionated radiotherapy breast cancer women with T3-4 and/ or 4 or more axillary nodes involvement post mastectomy. Conventional fractionated radiotherapy 50 Gray(GY)/25 fractions (f)/5w to chest wall and supraclavicular nodal region.
89527389|NCT04493125|Experimental|Mosapride group|Patients receive placebo or mosapride citrate (5mg/T) three times a day from the first day after surgery.
89527390|NCT04493125|Placebo Comparator|Placebo group|Patients receive placebo instead of mosapride citrate (5mg/T) three times a day from the first day after surgery
89527391|NCT03318991|Active Comparator|GreenLight laser|180W Greenlight laser is used for vaporesection of the prostate.
89527392|NCT03318991|Active Comparator|Thulium laser|200W Thulium laser is used for enucleation of the prostate.
89527393|NCT04493983|Other|Investigation|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
89527394|NCT04493593|Experimental|Space for Sleep Group|SilverCloud internet-delivered CBT intervention for Insomnia
89527395|NCT03318913|No Intervention|Health control|Health young subjects free of diabetes mellitus and nutritional intervention
89527396|NCT03318913|Placebo Comparator|DM Placebo|Sucralose
89527397|NCT03318913|Active Comparator|DM FHP|Fish protein hydrolysates
89527398|NCT03318835|Experimental|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
89527399|NCT03318835|Active Comparator|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
89527400|NCT03318757|Experimental|Group 1- Bupivacaine extended release liposome injection|Bupivacaine extended release liposome injection (Exparel TM) is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.
89527401|NCT03318757|Active Comparator|Group 2- Bupivacaine HCl|Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area in which the drug is applied.
89527402|NCT03325699|Experimental|Intervention|Participants assigned to the intervention group will have access to the SMART4MD health application and participate in clinical visits every 6 months
89527403|NCT03325699|No Intervention|Control|Participants assigned to the intervention group will NOT have access to the SMART4MD health application and participate in clinical visits every 6 months
89527404|NCT03325621|Active Comparator|PRS-080#022-DP|Experimental: PRS-080#022-DP Hepcidin antagonist, repeated administrations, ascending doses
89527405|NCT03325621|Placebo Comparator|PRS-080-Placebo#001|Experimental: PRS-080-Placebo#001 Comparator treatment, repeated administrations
89527406|NCT02487355|Active Comparator|group (MG)|Magnesium sulfate 50 mg add to 1 ml/kg of 0.25%of bupivacaine
89527407|NCT02487355|Active Comparator|group (D)|Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
89527408|NCT02487355|Active Comparator|group (MD)|50 mg magnesium sulfate and Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
89527409|NCT02487355|Active Comparator|group (C)|1ml/kg of 0.25%of bupivacaine + 1 ml of normal saline
89527410|NCT02487121|Experimental|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
89527411|NCT02487121|Active Comparator|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
89527412|NCT03325465|Experimental|Pembrolizumab and epacadostat|"Patients will receive neoadjuvant immunotherapy either with anti-PD-1 (pembrolizumab) alone or anti-PD-1 in combination with IDO1 inhibition (epacadostat). Patients will receive Pembrolizumab every 3 weeks over a period of 8 weeks as well as epacadostat starting on day 1 for the duration of pembrolizumab treatment.~All patients will undergo baseline biopsy (mandatory, sampling ≥ 4 areas to represent the tumor), as well as baseline imaging (and for exploratory analysis collection of blood for baseline ctDNA testing and TCR analysis)."
89527413|NCT03325387|Experimental|LY3305677|Escalating doses of LY3305677 administered by subcutaneous (SC) injection
89527414|NCT03325387|Placebo Comparator|Placebo|Saline solution administered by SC injection
89527415|NCT03325309||Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
89527416|NCT01876953|Experimental|Dasatinib 100mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
89527417|NCT01876953|Experimental|Dasatinib 140mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
89527418|NCT04493359|Experimental|Switch therapy|Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.
89527419|NCT04493359|No Intervention|Maintenance therapy|Renin-angiotensin system inhibitors will be kept during in-hospital stay
89527420|NCT03321955|Experimental|Subjects with Painful Neuropathy|All subjects will be implanted with the Medtronic Synchromed II pump, and treated with the same algorithm for dose adjustment for painful neuropathy with Ziconotide 100 micrograms/ml.
89527421|NCT01793805||Metastatic Colorectal Cancer Patients|
89527422|NCT04493437|Experimental|Telerehabilitation group A|Device: Telerehabilitation Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
89527423|NCT04493437|Experimental|Telerehabilitation group B|"Device: Telerehabilitation + rehabilitation at health care center Telerehabilitation: Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire & Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).~Rehabilitation at health care center: The rehabilitation will consist of four closed group sessions focusing on patient education. The groups will consist of both patients and relatives. The program at the health care center will not include any psychological tests or data control. Duration is 4 x 2 hours sessions over a period of 1 month."
89527424|NCT03318601|Experimental|cirrhotic patients with ascites|cirrhotic patients with ascites requiring prolonged hospitalization
89527425|NCT04493281|Experimental|MT-1186|Healthy subjects were administered a single dose of Edaravone oral suspension
89527426|NCT04493281|Active Comparator|MCI-186|Healthy subjects were administered a single dose of Edaravone intravenous formulation
89527427|NCT01764711|Experimental|Low Salt Diet POTS|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
89527428|NCT01764711|Experimental|Low Sodium Diet Controls|Each participant will be asked to sit in a chair for 30 minutes prior to a blood draw. Then a small dose of cosyntropin is administered intravenous. Blood samples will be drawn again at 30 minutes and 60 minutes after the drug has been given.
89527429|NCT04493047|Experimental|Counselling on pneumonia prevention|Recruited caregivers will be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject.
89527430|NCT01737255||TP53 mutation carriers|Carriers of TP53 mutation not known to be low penetrance
89527431|NCT01737255||Population controls|Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years
89527432|NCT04493515|Experimental|Oral Oxytocin|Oxytocin orally (24 IU)
89527433|NCT04493515|Placebo Comparator|Oral Placebo|Placebo orally (24 IU, identical ingredients, except the active agent)
89527434|NCT04493749||atrial fibrillation (AF)|Patients diagnosed with AF during reference ECG
89527435|NCT04493749||sinus rhythm (SR)|Patients diagnosed with SR during reference ECG
89527436|NCT03318445|Experimental|Rucaparib and irinotecan|"Rucaparib will be taken twice daily by mouth for 7-14 days in 21 or 28 day cycles. Irinotecan will be administered by IV for 90 minutes every 14 days, or every 21 days if not tolerated.~During the dose escalation phase, the maximum tolerated dose for combining Rucaparib and irinotecan will be determined. The dose for rucaparib during dose escalation will range from 300 mg to 600 mg, depending on the progression of study. The dose for irinotecan during dose escalation may range from 40 mg/m2 to 150 mg/m2.~During the dose expansion phase, patients who have received prior PARP inhibitors will be given rucaparib and irinotecan at the maximum tolerated dose levels determined during the dose escalation phase."
89532737|NCT06004414|Active Comparator|Treatment as Usual (TAU)|Adolescents who screen positive for significant mental health symptoms and who are enrolled in their school-based health center (SBHC) randomized to receive psychotherapy.
89532738|NCT06003465|Experimental|LY3437943 - Test|A single dose of LY3437943 administered by subcutaneous (SC) injection via a test device (test formulation)
89532739|NCT06003465|Active Comparator|LY3437943 - Reference|A single dose of LY3437943 administered by SC injection via a reference device (reference formulation)
89532740|NCT06002087|Experimental|Experimental group: Unified Protocol (UP)|Participants will receive 14 weekly individual sessions of 50-60 minutes each using the adapted UP treatment.
89527437|NCT03318445|Experimental|Rucaparib only|During the dose expansion phase, patients who have not received prior PARP inhibitor therapy will take 600 mg of rucaparib by mouth daily. Patients who progress on single-agent rucaparib will be given the option to cross-over to the combination treatment arm and receive rucaparib in combination with irinotecan at the maximum tolerated dose levels determined during dose escalation.
89527438|NCT03321877|Experimental|Study group|All included patients underwent dose reduction.
89527439|NCT01556139|Experimental|Spirotiger|Patients belonging to this group perform 20 sessions of usual training (cyclette and calisthenic exercises) and additional 20 sessions of a specific training for respiratory muscles with Spirotiger
89527440|NCT01556139|No Intervention|Control|Control group with a placebo device
89527441|NCT03318367|Experimental|Supportive care (virtual reality education module)|After undergoing a previously planned CT simulation scan, patients complete a virtual reality education module to learn more about radiation therapy for prostate cancer. Patients also complete questionnaires before and after the module.
89527442|NCT02485015|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.Patients undergo Apatinib.
89527443|NCT02485015|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
89527444|NCT01137123|Active Comparator|standard two field +follow-up|
89527445|NCT01137123|Experimental|standard two field +adjuvant chemotherapy|
89527446|NCT01137123|Experimental|total two field+follow-up|
89527447|NCT01137123|Experimental|total two field+adjuvant chemotherapy|
89527448|NCT01137123|Experimental|three field+follow-up|
89527449|NCT01137123|Experimental|three field+adjuvant chemotherapy|
89527450|NCT02484781|Active Comparator|Total Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning total hip arthroplasty on a trendmill
89527451|NCT02484781|Active Comparator|Resurfacing Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning resurfacing hip arthroplasty on a trendmill
89527452|NCT03318289|Experimental|Ving Tsun (VT) group|Participants in the VT group will receive VT exercise intervention for 12 weeks.
89527453|NCT03318289|No Intervention|Control group|No intervention but can continue daily activities.
89527454|NCT03933423|Active Comparator|Intervention|Educational session of pregnant mothers, blood grouping of parents and identifying risk factors for developing jaundice, screening newborns for neonatal jaundice, glucose 6-phosphate dehydrogenase deficiency and illness, Home based phototherapy and referral.
89527455|NCT03933423|No Intervention|Control|No intervention will be deliver
89527456|NCT02486887|Experimental|telemonitoring|telemonitoring of weight, arterial pressure and heart rate at home with connection to a medical platform to monitor the evolution.
89527457|NCT02486887|No Intervention|conventional follow-up|conventional follow-up
89527458|NCT03316339|Experimental|Dexmedetomidine|
89527459|NCT03316339|Active Comparator|Control|
89527460|NCT02484625|Experimental|Potato chips|Commercial potato chips, 180 kcal
89527461|NCT02484625|Experimental|Greek yogurt|Greek yogurt, 180 kcal
89527462|NCT02484625|Experimental|Cookies|Sandwich-type cookies, 180 kcal
89527463|NCT02484625|Experimental|Cheese|Mozzarella cheese, 180 kcal
89527464|NCT02484625|Experimental|Milk (fluid)|Milk, 2% m.f., 180 kcal
89527465|NCT02490865|Experimental|RNS60|Administration of nebulized RNS60 to test for systemic bioactivity
89527466|NCT02490865|Placebo Comparator|Normal Saline|Administration of normal saline used as control
89527467|NCT02486809|Experimental|Treatment 1: Needle and Syringe|Healthy volunteers will receive a single SC injection of lebrikizumab, withdrawn from a vial and administered by a needle and syringe.
89527468|NCT02486809|Experimental|Treatment 2: PFS-NSD|Healthy volunteers will receive a single SC injection of lebrikizumab, administered by PFS-NSD.
89527469|NCT02490787|Experimental|Concizumab|
89527470|NCT02490787|Placebo Comparator|Placebo|
89527471|NCT02490553||Dunkirk area|Representative sample of Dunkirk and the surrounding urban area (of ~200 000inhabitants).Dunkirk area is characterize by high emission of industrial air pollutant
89527472|NCT02490553||Lille area|Representative sample of Lille and the surrounding urban area (of ~1 million inhabitants, the fourth urban area in France)
89527473|NCT02484703|Placebo Comparator|Placebo|Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
89527474|NCT02484703|Experimental|RO5186582 120 mg BID|Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
89527475|NCT02484703|Experimental|RO5186582 40 mg BID|Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
89527476|NCT02484703|Experimental|RO5186582 60 mg BID|Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.
89527477|NCT02484469|Experimental|Exposed|The Virtual Human Project videos and Team-Based learning session about leprosy
89527478|NCT02484469|Placebo Comparator|Unexposed|Standard Team-Based learning session about leprosy
89527479|NCT03316183|Experimental|Intervention Group|"Maintain rSO2 values at or above 75% of the baseline~Midline position~Target CO2 of ≥40 mmHg, target MAP >60 mm Hg~Maintain cerebral perfusion pressure >50 mm Hg~Target pump flow 2.5 L/m2/min~If rSO2 persistently below treatment threshold:~FiO2 is increased~or propofol 50-100 mg bolus is administered~If Hct below 20% packed red blood cells will be transfused~timeline: before induction, after time-out has been performed, and will continue until 24 hours post surgery."
89527480|NCT03316183|No Intervention|Control Group|Patients in the control group will be managed under the attending physician's discretion. Cerebral oximetry data will be collected in the same fashion as in the intervention group, but the measurements will be blinded to the physician. Blood samples will be collected for metabolomic profiling in the same fashion and at identical time points as the intervention group for later analysis.
89527481|NCT02486731||Noonan syndrome|Patients with Noonan syndrome
89527482|NCT02486731||LEOPARD syndrome|Patients with LEOPARD syndromes
89527483|NCT02486731||Controls|Healthy subjects
89527484|NCT02484313|Experimental|Greek yogurt|25 g available carbohydrates
89527485|NCT02484313|Experimental|Cookies|25 g available carbohydrates
89527486|NCT02486497|Active Comparator|5-FU group|Grades of hENT1 immunostaining are 0 or 1.
89527487|NCT02486497|Active Comparator|Gemcitabine group|Grade of hENT1 immunostaining is 2.
89527488|NCT02486575|Other|self-learning|Residents training alone with pre-recorded instructions. No tutor intervention, only self-learning training Intervention Type: Behavioral (video-based and instruction based learning)
89527489|NCT02486575|Other|Mentoring|"Residents training with a mentor, giving tailored instruction to each of them and correction to wrong behaviours.~Intervention Type: Behavioral (tutored learning)"
89527490|NCT03318211|Active Comparator|MgSO4 discontinuation|after delivery , no Extradoses of MgSO4 were given
89527491|NCT03318211|Active Comparator|MgSO4 continuation|After delivery , Mg Sop4 was given at a rate of 1 gram /hour for 24 hours after delivery
89527492|NCT04492579|Experimental|Supplementation of Gentle-UHT donor milk|Supplementation of Gentle-UHT donor milk in addition to mother's own milk, as recommended by the health care providers.
89527493|NCT03318055||Single group study|"The study population will include patients presenting for elective surgery, who fulfil the inclusion criteria of all surgical disciplines undergoing elective surgery period during the period of the study.~Inclusion Criteria:~> 18 years of age Non-cardiac patients Non-obstetric patients Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
89527494|NCT02484235|Experimental|Group HIIT|Only Aerobic Training with HIIT
89527495|NCT02484235|Experimental|Group Strength|Only Strength Training
89527496|NCT02484235|Experimental|HIIT and Strength|Both intervention HIIT and Strength training
89527497|NCT03321487|Experimental|Stage I Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex
89527498|NCT03321487|Experimental|Stage II Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex
89527499|NCT02484157|Experimental|Patient|Patients were checked activated coagulation time by both Hemochron Jr and ACT Plus during cardiac surgery with heparin administration.
89527500|NCT02490397|Experimental|Exposed to Day light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI. A blood draw will be performed before any light therapy. The patients will then receive a light box (Square One Wake Up Light NatureBright 10,000 LUX) that they shall use every morning from 8.30-9.00 AM for the next 2 weeks. At the conclusion of the two weeks another blood sample will be drawn.
89527501|NCT02490397|Sham Comparator|Exposed to Room light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI and will only be exposed to room light. They will have blood drawn on the day of enrollment and then at 2 weeks after the MI.
89527502|NCT02486419||Summer|
89527503|NCT02486419||Winter|
89527504|NCT02483767|Experimental|standard chemotherapy with goserelin|standard chemotherapy with the GnRH agonist goserelin
89527505|NCT02483767|Active Comparator|standard chemotherapy without goserelin|standard chemotherapy without goserelin
89527506|NCT03317665||Standard of care|Mesh for hernia repair: Standard of care products used by the Investigator for open ventral hernia repair procedure
89527507|NCT02483845|Experimental|Natalizumab|Natalizumab therapy will be given at 300mg intravenously every 4 weeks for 24 weeks
89527508|NCT02486341|Experimental|Human Neutral Protamine Hagedorn (NPH)|The inclusion will be stratified into 2 groups according to the type of basal insulin being at baseline (ratio 1: 1): NPH human insulin / Long-acting basal insulin analogues. The type of insulin will not be changed by this protocol.
89527509|NCT02486341|Experimental|Long-acting basal insulin analogues|
89527510|NCT02484001|Experimental|ESL 800 mg|ESL will be administered orally once daily (QD)
89527511|NCT02484001|Experimental|ESL 1200 mg|ESL will be administered orally once daily (QD)
89527512|NCT02484001|Experimental|ESL 1600 mg|ESL will be administered orally once daily (QD)
89527513|NCT02484001|Experimental|ESL 400 mg|ESL will be administered orally once daily (QD)
89527514|NCT02483923|Experimental|Group S|
89527515|NCT02483923|Placebo Comparator|Group C|
89527516|NCT02647359|Experimental|Ataluren|Participants will receive ataluren orally 3 times a day (TID) at a dose of 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 48 weeks in Stage 1 (double-masked period) and for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
89527517|NCT02647359|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren TID orally in the morning, at midday, and in the evening for 48 weeks in Stage 1 (double-masked period) and ataluren orally TID at a dose of 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for additional 96 weeks in Stage 2 (open-label extension period). Participants, who complete Stage 2 and agree to continue in open-label sub-study, will continue to receive ataluren treatment at same dose as mentioned above, for 96 weeks or until commercial availability of ataluren for this indication, whichever is first, or until a positive risk-benefit assessment in this indication is not demonstrated.
89527518|NCT02483689|Placebo Comparator|Saline|Patient will be given saline with a maximum of 30 cc either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
89527519|NCT02483689|Experimental|Local|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
89527520|NCT02490085|Active Comparator|Multiple daily injections|Subjects will use multiple daily injections to regulate glucose levels. Subject's usual insulin analog will be used.
89527521|NCT02490085|Active Comparator|Closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Subject's usual fast-acting insulin analog will be infused using a subcutaneous infusion pumps (Accu-Chek Combo, Roche). The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
89527522|NCT03102021|Active Comparator|1|erythropoeitin
89527523|NCT03102021|Placebo Comparator|2|saline placebo
89527524|NCT03317587|Experimental|INSPIRE|
89527525|NCT04916691|Other|EPSB for rib fractures|EPSB for rib fractures
89527526|NCT02486185|Other|SARC-F|screening test for sarcopenia being studied, the SARC-F
89527527|NCT02490163|Experimental|CMNC|the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
89527528|NCT02490163|Active Comparator|MNC|The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure.
89527529|NCT05117385|Experimental|Acerola|"dietary supplement : acerola extract self administrated by mouth for 28 days~1 capsule per day"
89527530|NCT05117385|Experimental|Panax ginseng extract|"dietary supplement : panax ginseng extract self administrated by mouth for 28 days~1 capsule per day"
89527531|NCT05117385|Experimental|Echinacea extract|"dietary supplement : echinacea extract self administrated by mouth for 28 days~1 capsule per day"
89527532|NCT05117385|Experimental|Quillaja extract|"dietary supplement : quillaja extract self administrated by mouth for 28 days~1 capsule per day"
89527533|NCT05117385|Placebo Comparator|Maltodextrin|"dietary supplement : maltodextrin supplement self administrated by mouth for 28 days~1 capsule per day"
89527534|NCT02483455|Experimental|ALC-919 Topical Solution|ALC-919 Topical Solution will be applied twice daily to study area for the treatment of Common Warts
89527535|NCT02483455|Placebo Comparator|Vehicle-Control Topical Solution|Vehicle-Control Topical Solution will be applied twice daily to study area for the treatment of Common Warts
89527536|NCT05105139||A1: Allantoin / Coal Tar / Clioquinol (Sebryl®)|Pharmaceutical Form: Shampoo Dosage: 0.2 g/ 5.0 g/ 3.0 g Administration way: For scalp use
89527537|NCT05105139||A2: Allantoin/ Coal Tar/ Clioquinol/ Triclosan (Sebryl Plus®)|Pharmaceutical Form: Shampoo Dosage: 0.2 g/ 3.0 g/ 3.0 g/ 0.3 g Administration way: For scalp use
89527538|NCT04492423||Prasugrel|Patients taking prasugrel
89527539|NCT04492423||Ticagrelor|Patients taking ticagrelor
89527540|NCT03317509|Active Comparator|Real rTMS|Each patient received high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days
89527541|NCT03317509|Sham Comparator|Sham rTMS|Each patient received rTMS with the same pulse as the first group but with the coil placed perpendicular to the scalp.
89527542|NCT03317353|Experimental|Vestibular rehabil.: CDP|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
89527543|NCT03317353|Experimental|Vestibular rehabil.: optokinetic stimuli|Group B. Patient has to stand in a dark room, wiht optokinetic stimuli around him/her. Ten sessions (one per day, five per week, two weeks), with progressive increase of stimulus speed (from 30º/sec the first day to 100º/sec the last), duration of session (from 5 minutes the first day to 15 minutes the last), stimulus complexity (horizontal stimuli in the first sessions, progressively adding vertical and rotating stimuli) and support surface difficulty (initially hard surface, last sessions on foam).
89527544|NCT03317353|Experimental|Vestibular rehabil.: home exercises|Group C. The patient is given a list of exercises (and explained how to do them) to stabilise eye position and improve postural control. They are to be performed twice a day for two weeks. Approximate duration of each session: 15 minutes. The exercises must be supervised by a family member to verify adherence to the programme.
89527545|NCT03317353|No Intervention|Control group|Group D. No vestibular rehabilitation is developed.
89527546|NCT02490007||Allergy Cases|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999). Allergy case participants have all attended allergy clinics associated with tertiary teaching hospitals. They have confirmed IgE-mediated food allergy as defined by the case description and as ascertained by their medical records.
89527547|NCT02490007||Controls|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999).
89527548|NCT03315637|Experimental|Fetoscopic repair of spina bifida|This is a single arm study, all patients will receive a fetoscopic repair of the spina bifida
89527549|NCT03843255||Part 1: Dilated Cardiomyopathy patients|Approximately 1200 patients recruited prospectively from participating sites with a diagnosis of Dilated Cardiomyopathy (DCM). Will also include approximately 800 retrospective patients diagnosed with DCM currently biobanked by the lead site.
89527550|NCT03843255||Part 2: Heritable Cardiovascular Disease|Patients may be recruited with other diagnosed heritable cardiovascular disorders. Family members of patients may be invited to take part in the study. Children may also be approached to take part in the study.
89527551|NCT03317275|Experimental|injection based on 18F-Fluoride-PET/MRI|One group will undergo facet injection(s) according to the 18F-Fluoride-PET/MRI result, with standard injections performed under CT-guidance. The Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
88807350|NCT05190198|Experimental|Experimental group|"The experimental group will receive ankle proprioceptive training.~Ankle proprioceptive training includes the following group of exercises:~Training on the floor for 10 minutes (1-8 weeks)~Training on balance pad for 10 minutes (1-4 weeks)~Training on rocked balance board for 10 minutes (5-8 week)"
88814475|NCT04357340|Experimental|Pulmonary Physiotherapy Techniques group|Pulmonary physiotherapy techniques, 6 sessions during 3 days and incentive spirometer.
89527552|NCT03317275|Active Comparator|injection based on clinical practise|The control group will undergo facet injections blinded to the 18F-Fluoride-PET/MRI results, but based on current standard clinical practise (MRI and clinical correlation). Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
89527553|NCT03325543|Experimental|Intervention Group|The treatment program is based on the motor learning concepts of PFMs. The steps of learning a correct muscle contraction will be separate into four levels: 1. Understand 2. Search 3. Find 4. Learn. Feedback from the PF is mandatory. The intervention program will last four weeks, and will contain four outpatient consultations (1 session per week) lasting 60 minutes each session.
89527554|NCT03325543|Active Comparator|Control Group|The control group will receive only verbal instructions about the anatomy and function of the PFM, and to perform the contraction of the PFMs.
89527555|NCT03835689|Experimental|Strongest Families Program Self-Managed (no coaching)|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
89527556|NCT03835689|Experimental|Strongest Families Program with Group Telephone Coaching|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
89527557|NCT03835689|No Intervention|Information Resource Website|They will not receive Strongest Families Intervention during the 10 month study phase, but will receive the usual care services and access to an Information Resource Website.
89527558|NCT02483377||Observational (treatment summaries and plan report)|"Patients receive treatment summaries and plan report that captures patient data through the use of an intake checklist completed during the initial consultation with the breast oncology team and used to guide referrals to existing services and programmed with generic information related to disease and treatment management plan. Additional elements, such as psycho-social services, exercise, and/or nutrition, identified by the patient self-report, will be incorporated. Patients also complete 3 questionnaires at each clinic visit."
89527559|NCT05463445||A|"patients diagnosed with Primary Sclerosing Cholangitis which met the PSC criteria according to The European Association for the Study of the Liver Clinical Practice Guidelines Management of cholestatic liver diseases in 2009."
89527560|NCT05463445||B|patients diagnosed with IgG4-related Sclerosing Cholangitis which met initially using the Japan Pancreas Society criteria and confirmed using HISORt criteria.
89527561|NCT04435353|Active Comparator|Time-day of respiratory fail|Objective data
89527562|NCT04435353|Active Comparator|Oxygen status|Facultative data
89527563|NCT04435353|Active Comparator|Oxugen support|FiO2
89527564|NCT04435353|Active Comparator|Adverse outcomes|Complication
89527565|NCT02645409|Experimental|Partial nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for partial nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
89527566|NCT02645409|Experimental|Radical nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for radical nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
89527567|NCT03321331|Experimental|Lark (JITAI)|"Participants in the intervention arm will use for 12 weeks the pro version of a mHealth app called Lark, developed by Lark Technologies Ltd. Lark is a coach app, which uses several variables to generate smart and empathic conversations. Variables include activity, sleep, meals, weight, and height data, weight goal set by the user/Lark coach, activity goal set by user/Lark coach, starchy food goal set by user/Lark coach. Lark uses all these variables to create a dynamic coaching system, constantly changing and adapting to the user in the moment and over time. For these features, Lark provides a just in time adaptive intervention (JITAI)."
89527568|NCT03321331|Active Comparator|MyFitnessPal (no JITAI)|"Participants in the control arm will be assigned to use MyFitnessPal. Similar to the intervention arm, they will be instructed to use the app for 12 weeks. MyFitnessPal does not include JITAI components, but allows users to keep track of their caloric intake and energy expenditure. MyFitnessPal has features that can be associated with effective behavior change techniques, including: self-monitoring of behavior and outcomes, goal setting and feedback (similar to Lark). In MyFitnessPal, social support is limited to comments and 'likes' from friends of its restricted user community, therefore tackling the techniques of social comparisons and social reward."
89527569|NCT03104829|Active Comparator|DSME|participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
89527570|NCT03104829|Experimental|DSME+MI|participants in this arm will receive standard care for diabetes plus motivation interviewing (MI) sessions at the beginning of the study and 3 months later, will also receive motivation interviewing sessions by phone at 1, 2, 4, 5 month after the beginning of the study
89527571|NCT03317197|Placebo Comparator|Control Group|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only~Control group receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Saline solution~Syringe No. 2 : Saline solution"
89527572|NCT03317197|Active Comparator|Experimental Group 1|"Using Vasopressin [20 IU/CPR cycle] injection until the 5th cycle~Experimental Group 1 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Vasopressin~Syringe No. 2 : Saline solution"
89527573|NCT03317197|Active Comparator|Experimental Group 2|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~Experimental Group 2 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Saline solution~Syringe No. 2 : Steroid"
89532741|NCT06002087|No Intervention|Control group: Waitlist Control|Participants in the control group will be placed on a waitlist and will not receive any treatment until the end of the study.
89532742|NCT05998902|Active Comparator|Full enteral feeding|Patients will receive full enteral feeding through nasogastric tube or nasointestinal tube.
89527574|NCT03317197|Experimental|Experimental Group 3|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~Experimental Group 3 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Vasopressin~Syringe No. 2 : Steroid"
89527575|NCT03317041|Experimental|Tecar treatment group|The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
89527576|NCT03317041|No Intervention|Control group|Participants will test passively in a sitting position for 30-min period
89527577|NCT02483299|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
89527578|NCT02483299|Active Comparator|combined|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
89527579|NCT01597479|No Intervention|No dPNBs group|Patients in this group didn't receive any intervention in the postoperative period.
89527580|NCT01597479|Experimental|dPNBs group|"Patients in this group received ultrasound guided dPNBs on radial and median nerves (target nerves of TRA) in the postoperative period, before discharge.~The procedural objective of dPNBs was to place local anesthetic around the target nerves to achieve a long lasting, sensitive and selective block in the surgical area. dPNBs were performed with 5 ml/nerve of levobupivacaine 0,125%.~Ultrasound guidance allowed us to verify the correct distribution of LA around the target nerves target and optimize needle position if it was necessary, always avoiding the intraneural injection."
89527581|NCT03316963|Experimental|Drug-induced sleep endoscopy (DISE) with Neostigmine|Artificial sleep will be induced by intravenous administration of propofol with micro boluses until clinical sleep is achieved with spontaneous respiration and observed apneas under monitored anesthesia care. Endoscopy will be performed with visualization on a monitor and recording on a digital recorder. After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate.
89527582|NCT03101943|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=68) will receive the Family Spirit Nurture (FSN) home-visiting module, consisting of six 45-minute lessons delivered biweekly by trained local American Indian Family Health Coaches (FHCs), from 3 to 6 months postpartum. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices. Lessons are highly visual and interactive, and will incorporate cultural teachings related to infant feeding and nutrition that support aims. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
89527583|NCT03101943|Other|Control Program|The control group (n=68) will receive three home-based lessons with home safety information (injury prevention is a priority identified by Navajo leadership that does not interfere with study questions). Mothers randomized to the control group will receive 3 educational lessons on home safety and child safety proofing. These meaningful topics were selected so as not to dilute measurement on key FSN outcomes and to provide benefit to all study participants. Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
89527584|NCT03315481|Active Comparator|SAX catheter insertion|Ultrasound guided cather insertion in the short axis (SAX) of the adductor canal. Injection of lidocaine through the catheter
89527585|NCT03315481|Active Comparator|LAX catheter insertion|Ultrasound guided cather insertion in the long axis (LAX) of the adductor canal. Injection of lidocaine through the catheter
89527586|NCT03101865|Experimental|Closed loop with diluted insulin|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using DILUTED insulin aspart over 3 weeks.
89527587|NCT03101865|Active Comparator|Closed loop with standard insulin strength|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using STANDARD strength insulin aspart over 3 weeks.
89527588|NCT02489929|Experimental|patient suffering of MDS or Myeloid leukemia|The patients suffering of MDS or Acute myeloid leukemia will be the object of 8 sampling of blood (on tube EDTA) distributed as this: the first day of the usual treatment (azacytidine) at T0, T30 MIN, T60 MIN, T90 MIN, T120 MIN, then a second series of taking in the 5th day of treatment at T0, T30 MIN, T90 MIN to determine cytidine deaminase (CDA) activities by following its plasmatic dosage
89527589|NCT04548141|Experimental|Active adults|Adults coming for a visit for sports activity participation and submitted the SAPHIR questionnaire
89527590|NCT05154903|Active Comparator|Citicoline|the Citicoline group will receive citicoline in continuous Iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks
89527591|NCT05154903|No Intervention|control|the control group will not receive citicoline
89527592|NCT03315325|Experimental|Adult men|The average age was 25.80±0.37 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
89527593|NCT03315325|Experimental|Middle age men|The average age was 47.00±0.77 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
89527594|NCT03315325|Experimental|Advance age men|The average age was 73.20±0.91 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
89527595|NCT02486107||PECD|percutaneous endoscopic cervical foraminotomy
89527596|NCT02486107||MTPF|microscopic tubular retractor assisted foraminotomy
89527597|NCT02486107||ACDF|anterior cervical discectomy and fusion
88814476|NCT04357340|No Intervention|Control group|Incentive spirometer only
89527598|NCT04888611|Experimental|Neoadjuvant PD-1 inhibitor plus DC vaccine|Patients will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, DC vaccines and further PD-1 inhibitor treatment until toxicity or progression.
89527599|NCT04888611|Active Comparator|Neoadjuvant PD-1 inhibitor plus Placebo|Patients will receive neoadjuvant Camrelizumab (PD-1 antibody), followed by surgical resection, placebo and further PD-1 inhibitor treatment until toxicity or progression.
89527600|NCT02483143|Active Comparator|NAC plus normal saline group|1ml/3mgr NAC+NS preCTPA 3 ml/kg for 1 h, 1 ml/kg/h for post CTPA for 6 h
89527601|NCT02483143|Active Comparator|NaHCO3 plus normal saline group|132 mEq NaHCO3+NS preCTPA 3 ml/kg for 1h, post CTPA 1ml/kg/h for 6 h
89527602|NCT02483143|Placebo Comparator|Normal saline alone|preCTPA 3 ml/kg NS for 1h, postCTPA 1ml/kg/h SF for 6 h
89527603|NCT04828239|Experimental|Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
89527604|NCT04828239|Active Comparator|Manual Acupuncture Group|Acupuncture point: PC-6 and PC-7 Responses elicited: de qi sensation Manual: twirling with lifting-thrusting method stimulation Needles retained for 30 min Needle type: C&G, gauge and size: 0.25x40mm
89527605|NCT04828239|Sham Comparator|Sham Laser Acupuncture Group|Acupuncture point: PC-6 and PC-7 Sham laser pen is vertical to the points and with the pen at a distance of 0.5- cm from the skin., every point is treated for 1 min administrated over 4 weeks (2 sessions/wk)
89527606|NCT02483221|Active Comparator|TCI-PCA|
89527607|NCT02483221|Active Comparator|PCA|
89527608|NCT02489851|Active Comparator|Quadratus Lumborum block group|"Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%"
89527609|NCT02489851|Active Comparator|Transversus abdominis plane block group|"Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.125%"
89527610|NCT04766697|Experimental|Receive Intervention|All 20 couples will receive the 8-session adapted intervention.
89527611|NCT02485951|Active Comparator|Central air injection|The needle was moved radially inside the trephination site and advanced to the central or paracentral cornea.
89527612|NCT02485951|Active Comparator|Peripheral air injection|The needle was inserted into the deep stroma from the trephination site and advanced into the peripheral cornea to approximately 1.5 mm anterior to the limbus.
89527613|NCT02489461|Experimental|VM-1500 20 mg + ART|VM-1500 - 20 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
89527614|NCT02489461|Experimental|VM-1500 40 mg + ART|VM-1500 - 40 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
89527615|NCT02489461|Active Comparator|Efavirenz 600 mg + ART|Efavirenz 600 mg (Stage I and Stage II), ART
89527616|NCT04762095|Experimental|The Effect of mindfulness stress reduction program Quality of Life|mindfulness stress reduction program reduces menopausal complaints.
89527617|NCT04762095|Experimental|The Effect of mindfulness stress reduction program Menopausal Symptoms|mindfulness stress reduction program improves the quality of life of women in the menopausal period.
89527618|NCT03315169|Active Comparator|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity as per normal practice.
89527619|NCT03315169|Experimental|External dressing|External application of a non-adherent dressing to the perianal abscess cavity.
89527620|NCT05048043|Experimental|Computer-assisted Behavior Intervention|A serious game paired with teacher consultation to address common needs related to ADHD in the classroom.
89527621|NCT05048043|Active Comparator|Challenging Horizons Program, School Consultation|An established teacher consultation program to help teachers address ADHD in the classroom.
89527622|NCT02838381|Other|Additional biological samples|"Additional blood samples will be realized at the inclusion of patients. Two optional blood samples could be realized if necessary with at least 3 months apart.~Peripheral Blood Mononuclear Cells (PBMC) will be collected. Tissue tumor will be collected if available."
89527623|NCT03104361|Experimental|Platelet-rich plasma treatment arm|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
89527624|NCT02489305||Participants With Major Depressive Disorder|Participants with major depressive disorder who have responded to oral antidepressant treatment will be observed over time.
89527625|NCT03104751||Infants with Complex Congenital Heart Defect|Infants diagnosed a Complex Congenital Heart Defect
89527626|NCT03104751||Comparison/Healthy Infants|Infants born without genetic syndromes or cardiac condition.
89527627|NCT02485795||Pain patients|Observational; Patients presenting to interventional pain management centers for therapy.
89527628|NCT04923321||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
89527629|NCT04923321||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
89527630|NCT04923321||Non exposure|Non-pharmacological treatment (psychotherapy)
89527631|NCT03104907|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
89527632|NCT02489383|Active Comparator|Continuous Exercise Training|The interventions of active comparator will be education program and exercise training.
89527633|NCT02489383|Active Comparator|Interval Exercise Training|The interventions of active comparator will be education program and exercise training.
89527634|NCT02485873||Rivaroxaban|Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention
89527635|NCT02485873||Vitamin K antagonists (VKA)|NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention
89527636|NCT02483065||inpatients with dementia|
89527637|NCT02483065||inpatients without dementia|
89527638|NCT03104127|Experimental|Alter G Bionic Leg|Participants randomised to a group including normal therapy (physiotherapy) and the use of a Alter G robotic bionic leg. All participants have previously completed normal NHS therapy.
89527639|NCT03104127|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
89527640|NCT03104127|No Intervention|Usual care|Have completed normal NHS therapy and no longer (> 6 months) receive active physiotherapy.
89527641|NCT03316729|Experimental|DS-9231|In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3
89527642|NCT03316729|Placebo Comparator|Placebo|In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator
89527643|NCT04758741|Experimental|Acceptance and commitment treatment|The members of the intervention group receive one session of acceptance and commitment treatment per week according to Hayes (2006) approach in groups of 10 in 8 sessions of 90 minutes by a trained counselor (researcher) in Mashhadalkoubeh Health Center.
89527644|NCT04758741|Sham Comparator|Health Education|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience.
89527645|NCT03315091|Experimental|Treatment sequence 1 (Fasted-Fed)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
89527646|NCT03315091|Experimental|Treatment sequence 2 (Fed-Fasted)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
89527647|NCT02482987|Experimental|Cytoplast|Patients will receive ridge preservation procedure with a Cytoplast barrier membrane
89527648|NCT02482987|Experimental|BioXclude|Patients will receive ridge preservation procedure with a BioXclude barrier membrane
89527649|NCT04519203|Active Comparator|SPI group|Group of patients where opioid consumption will be guided using SPI target
89527650|NCT04519203|Active Comparator|Control Group|Group of patients where only standard monitoring and patient reaction will be used to guide opioid administration during intraoperative period
89527651|NCT02482909|Experimental|Hepatic resection|Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
89527652|NCT02482909|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed as a primary treatment for hepatocellular carcinoma.
89527653|NCT04475055||Community sample|Participants will take part in the DIPS-interview and in an online survey.
89527654|NCT02482831||Diabetes|Diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
89527655|NCT02482831||non-Diabetes|Non-diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
89527656|NCT02489149|Experimental|Multi-sector interventions|"Multi-sector interventions~Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~Helping families to have more knowledge about your citizen rights."
89527657|NCT02489149|Placebo Comparator|Control|Conventional approach of current public food and nutrition policies.
89527658|NCT03321175|Experimental|Subcutaneous irrigaton|Patients will receive 200 cc subcutaneous saline irrigation before skin incision closure.
89527659|NCT03321175|No Intervention|Subcutaneous no irrigation|Patients will not receive subcutaneous saline irrigation before skin incision closure.
89527660|NCT04644003|Experimental|STP1 Low Dose|1 capsule and 1 tablet per intake
89527661|NCT04644003|Experimental|STP1 High Dose|1 capsule and 1 tablet per intake
89527662|NCT04644003|Placebo Comparator|Placebo|1 placebo capsule and 1 placebo tablet per intake
89527663|NCT02488837||DBS subjects|deep brain stimulation (DBS) in patients with Parkinson's disease, tremor, dystonia, and Tourette's syndrome
89527664|NCT03316651|Experimental|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
89527665|NCT03315013|Experimental|SLATE|The SLATE arm will be administered the SLATE II algorithm and initiated on ART immediately if eligible under the algorithm. Patients not eligible under the algorithm will be referred for standard care.
89527666|NCT03315013|No Intervention|Standard|The standard arm will be referred to standard care after study enrollment.
89527667|NCT02485405||stressed|stressed volunteers perform Trier social stress test
89527668|NCT02485405||non-stressed|non-stressed volunteers perform Trier social stress test
89527669|NCT02489071|Experimental|Brain Training|8-session cognitive training program
89527670|NCT02489071|Experimental|Brain Health|8-session cognitive education program
89527671|NCT02489071|No Intervention|Control|Wait-list control group
89527672|NCT02488993||Prospective Phase Rifaximin-α 550mg|Prospective data collection of patients treated with Rifaximin-α 550mg from point of study entry.
89527673|NCT02488993||Prospective Phase No Rifaximin-α 550mg|Prospective data collection of patients NOT treated with Rifaximin-α 550mg from point of study entry.
89527674|NCT02488993||Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received Rifaximin-α 550mg within the previous 12 months.
89527675|NCT03316495|No Intervention|without pamphlet|NOT EXPOSED TO PAMPHLETS
89527676|NCT03316495|Experimental|with pamphlet|EXPOSED TO PAMPHLETS
89527677|NCT03320863|Active Comparator|Active or Enso Group|Active Enso device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
89527678|NCT03320863|No Intervention|Sham Group|Sham device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
89527679|NCT02485327|Experimental|Afrezza®|"Two-period, replicate single dose, euglycemic clamp study. There will be 2 treatment periods with a replicate administration of 1 dose of Afrezza TI (40U) in both periods.~Each patient will be given a replicate administration of 1 dose level of Afrezza TI with washout duration between treatment periods (5-19 days between periods, ie, 7 to 21 days between dosing occasions)."
89527680|NCT03314701|Active Comparator|Group 1|"Biphasic Intermittent Positive Airway Pressure (BIPAP) group:~Following endotracheal intubation BIPAP mode will be started with:~Inspiratory positive airway pressure [IPAP] at 20 cmH2O~Expiratory positive airway pressure [EPAP] at 5 cmH2O~PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]~Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
89527681|NCT03314701|Active Comparator|Group 2|"Airway Pressure Release Ventilation (APRV) group:~high airway pressure (Phigh) will be set at 20 cmH2O~low airway pressure ( Plow) will be set at 5 cmH2O~the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~T high at 4.5-6 seconds~T low at 0.5 to 0.8 second"
89527682|NCT02485249|Experimental|Dexamethasone Phosphate|Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 14
89527683|NCT02482441|Experimental|OMP-131R10 intravenous (in the vein) infusions|OMP-131R10 will be administered IV on the first day of each 14-day cycle.
89527684|NCT02482441|Experimental|FOLFIRI (5-FU, irinotecan, leucovorin).|dosing continues up to the 20 mg/kg dose level
89527685|NCT03320707|Experimental|Daratumumab|Participants will receive a single subcutaneous (SC) dose of daratumumab in each of first 7 dose cohorts. Doses will be escalated based on review of pharmacokinetic, pharmacodynamic, and safety data of previous cohort. Participants in Cohort 8 will receive single SC daratumumab formulation containing recombinant human hyaluronidase (rHuPH20).
89527686|NCT03320707|Placebo Comparator|Placebo|Participants will receive placebo as a single SC dose in each of first 7 cohorts.
89527687|NCT02485093|Active Comparator|No pacing|Ventricular intrinsic conduction enhanced
89527688|NCT02485093|Experimental|Pacing|Septal ventricular pacing with optimized AV delay
89527689|NCT03320629|Experimental|apatinib and S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
89527690|NCT03320629|Active Comparator|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
89527691|NCT02488525|Experimental|Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
89527692|NCT02488525|No Intervention|Control|The control group will receive all treatments according to standard of care which does not include prophylactic administration of Wilfactin®
89527693|NCT02482597|Experimental|WBPA (Whole Body Accleration)|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional."
89527694|NCT02482597|Active Comparator|Active Recovery|Active recovery methods (e.g.walking, biking) have been shown to decrease blood lactate levels more than passive recovery 1,2. This arm requires subjects to walk at a low intensity as recovery.
89527695|NCT02482363|Active Comparator|Active UVA radiation|This arm will receive 20 minutes of UVA to the skin while resting quietly.
89527696|NCT02482363|Sham Comparator|Sham control|This arm will receive 20 minutes of quiet rest and heat but with their skin protected from UVA
89527697|NCT03314545|Other|laminate veneers with coronal posts|anterior endodontically treated teeth restored with laminate veneers with coronal posts
89527698|NCT03314545|Other|post, core and crown|anterior endodontically treated teeth restored with post, core and crown
89527699|NCT03316417||Patients under immunotherapy|All patients with Immune Checkpoints inhibitors treatment (Nivolumab, Pembrolizumab, ipilimumab, Atezolizumab), for dermatologic, pneumologic, or oncologic cancer treated on Centre Hospitalier Lyon Sud are included.
89527700|NCT02482207|Experimental|Rosuvastatin|Rosuvastatin 10 mg qd for 1 year and life style modification
89527701|NCT02482207|Placebo Comparator|Placebo|Life style modification alone
89527702|NCT02485171|Experimental|Experimental|Introduction of a walking aid device SAFEWALKER for elderly patients during rehabilitation after a post-fall syndrome.
89527703|NCT02485171|No Intervention|No intervention|No introduction of a walking aid device for elderly patients during rehabilitation after a post-fall syndrome.
89527704|NCT02480179|Experimental|single arm pilot feasibility study|Hematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.
89527705|NCT05529589||control group|Diabetic macular edema patient with inner limit membrane
89527706|NCT05529589||experimental group|Diabetic macular edema patient with inner limit membrane peeling
89527707|NCT02480101|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine
89527708|NCT02480101|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
89527709|NCT02476981|Experimental|Remifentanil|Remifentanil is commonly used in monitored anesthesia care because of its rapid onset and short duration of action.
89527710|NCT02476981|Experimental|Dexmedetomidine|Dexmedetomidine is a highly selective α 2 adrenergic agonist and has both sedative and analgesic properties, and rarely causes respiratory depression.
89527711|NCT02476981|Other|midazolam|Midazolam is commonly used before induction for its anxiolytic effect.
89527712|NCT02476981|Other|propofol|Propofol is the most commonly used in sedative analgesia for its rapid onset and recovery time.
89527713|NCT02476981|Other|ephedrine|Adrenergic agonist to treat hypotension
89527714|NCT04248465|Experimental|Ravulizumab|Participants will receive ravulizumab for the duration of the study.
89527715|NCT04248465|Placebo Comparator|Placebo|Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.
89527716|NCT02480335|Experimental|Usual care and bosentan|Usual care and also treatment with bosentan.
89527717|NCT02480335|No Intervention|Usual care|Usual care only.
89527718|NCT05245383|Other|Single arm|
89527719|NCT03314467||Cases DR|diabetic patients with diabetic retinopathy (DR)
89527720|NCT03314467||Cases other|diabetic patiens with other/multiple ocular disorder(s)
89527721|NCT03314467||Control|diabetic patients without ocular abnormalities
89527722|NCT05245305|Experimental|MBSR Intervention|The intervention group will take part in mindfulness-based stress reduction (MBSR) program led by a certified MBSR instructor via Zoom. The MBSR program was structured as 11 weeks, taking into account the characteristics of the participants.
89527723|NCT05245305|No Intervention|Control|No intervention was applied to the control group. Data will be collected from the control group simultaneously with the study group.
89527724|NCT02481973|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy, prescribed according to their characteristic symptoms and confirmed my their miasmatic facial features. Although different individualised remedies may be dispensed, each remedy will be homoeopathic and prepared in accordance with the German Homoeopathic Pharmacopoeia. Each prescription will be in a potency of 30CH which will be taken once daily, according to the GBM. Sucrose pillules will used as the vehicle for each remedy.
89527725|NCT02479945|Other|Selective internal iliac vein sampling|
89527726|NCT05245227|Active Comparator|Intravenous Oxytocin only|Patients will receive standard postpartum Oxytocin IV per protocol
89527727|NCT05245227|Experimental|Misoprostol plus intravenous Oxytocin|Patients will receive standard postpartum Oxytocin IV per protocol and also be given Misoprostol 400 mcg sublingual
89527728|NCT02479867|Experimental|A Test|Test drug (Duricef) 1 tablet contains 1 gm Cefadroxil
89527729|NCT02479867|Experimental|B Reference|Reference drug (Biodroxil) 1 tablet contains 1 gm Cefadroxil
89527730|NCT05245149||Prospective Cohort|Patients with a clinical indication for coronary CT angiography will undergo this scan on a photon counting detector CT (PCD-CT).
89527731|NCT05245149||Retrospective Cohort|For comparison, a matched retrospective cohort will be created of patients who had undergone coronary CT angiography on prior CT scanner generations (with energy-integrating detector CT, EID-CT)
89527732|NCT04533399|Experimental|Cohort 1 (HIV negative) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
89527733|NCT04533399|Placebo Comparator|Cohort 1 (HIV negative) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
89527734|NCT04533399|Experimental|Cohort 2 (HIV positive) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
89527735|NCT04533399|Placebo Comparator|Cohort 2 (HIV positive) Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
89527736|NCT03314389|Experimental|Cochet bonnet esthesiometer|To examine sensation
89527737|NCT02476591||Charge transparency|Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
89527738|NCT02476591||Without charge transparency|Providers without access to patient specific charge data
89527739|NCT02476747|Experimental|Cold snare polypectomy|CSP will be performed by closing the snare loop after positioning the open snare at the point of lesion.
89527740|NCT02476747|Active Comparator|Endoscopic mucosal resection|EMR will be performed in the way of drawing the lesion into the loop of the snare and resecting followed by saline injection to the its margin.
89527741|NCT05244837|Experimental|Arm A:Resectable Stage IIB-IIIA Non Small Cell Lung Cancer (NSCLC)|Patients received neoadjuvant treatment with Platinum-based doublet chemotherapy plus tislelizumab(200 mg) on day 1 of each 21-day cycle, for 3-4 cycles before surgical resection, followed by adjuvant intravenous tislelizumab monotherapy for 1 year ( 200 mg every 3 weeks for 2 cycles, followed by 200 mg every 4 weeks for 12 cycles).
89527742|NCT05244837|Experimental|Arm B：Unresectable Stage IIIA/IIIB/IIIC or IV Non Small Cell Lung Cancer (NSCLC)|Patients received neoadjuvant treatment with Platinum-based doublet chemotherapy plus tislelizumab(200 mg) on day 1 of each 21-day cycle, for 4-6 cycles , followed by adjuvant intravenous tislelizumab monotherapy ( 200 mg every 3 weeks )，until disease progression or intolerable toxicity If surgery is not possible；If surgery is possible after assessment, subsequent treatment at the discretion of the investigator
89527743|NCT03103893|Experimental|Rapamycin|Rapamycin
89527744|NCT05497375|Active Comparator|Group Hypocapnia|End-tidal carbon dioxide level will be 30±2 mmHg in the capnography, and the respiratory rate will be 14-20/minutes in the hypocapnia group.
89527745|NCT05497375|Active Comparator|Group Hypercapnia|End-tidal carbon dioxide level will be 40±2 mmHg in the capnography, and the respiratory rate will be 10-14/minutes in the hypercapnia group.
89527746|NCT05244759|Experimental|Arm 1|Single oral dose of [14C]-BLU-5937
89527747|NCT03314311|Experimental|Rehabilitation Programme|12 week multi-disciplinary intervention prescribing exercise, individual dietary counselling and education sessions.
89527748|NCT03314311|No Intervention|Control|Usual care control arm
88814477|NCT02487498|Experimental|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
89527749|NCT04281225|Placebo Comparator|Placebo only condition|Participants in this condition will be told at the time of the initial assessments (T1) that the device they will be testing will improve their hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked if they perceive their hearing to be changed by the device in addition to qualitative descriptions of the audio. This group will allow researchers to investigate the main effect of the placebo hearing aid - without calling participant's attention to variability in their symptoms.
89527750|NCT04281225|Experimental|Placebo and ATV condition|Participants in this condition at the time of the initial assessments (T1) will be told that the device they will be testing will improve their hearing. They will then be told that in-order to receive the maximum benefit from the hearing device, they should focus on instances in which they can hear better and worse. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will asked 1) if they perceive their hearing to be changed by the device; 2) to note any changes in what they heard in the audio focusing on the story in the ballad; and 3) whether their hearing is possibly impacted by activities and behavior and what they were doing.This condition will enable researchers to test the effects of the interaction between attention to variability and the placebo effect.
89527751|NCT04281225|Experimental|ATV only condition|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for design purposes. However, these participants will also be told that their input while wearing the device will help the team in developing the final device and allow the team to focus on how to best improve hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked 1) to note any changes in what they heard in the audio focusing on the story in the ballad and 2) whether their hearing might possibly be impacted by activities and behavior. They will also be asked 3) about their general health and wellness, as compared to the last time they were contacted by email. This condition will enable researchers to test the main effect of attention to variability, without an explicit placebo effect.
89527752|NCT04281225|No Intervention|Control condition- no ATV or Placebo effect.|Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for ergonomic purposes. They will listen to the audio and record volume levels at the start and at the end of the audio and provide feedback on the design. They will be told that each day they will listen to a brief audio (ballad of under 3 minutes) and will be asked a few similar questions twice daily for 6 days. After the 2nd audio of the day, they will be asked for feedback on the hearing device design. They will also be asked about their general health and wellness, as compared to the last time they were contacted.This group will allow researchers to test for the effects of having any device at all.
89527753|NCT02481661|Experimental|segmentectomy|Patients undergo anatomic segmentectomy by minimal incision thoracotomy or thoracoscopy/VATS.
89527754|NCT02481661|Active Comparator|lobectomy|Patients undergo lobectomy by minimal incision thoracotomy or thoracoscopy/VATS.
89527755|NCT05244603|Experimental|Normal Hearing|Listeners with normal hearing
89527756|NCT05244603|Experimental|Hearing Impaired|Listeners with hearing loss
89527757|NCT03103815|Experimental|experimental group|Experimental group will receive Amivita.
89527758|NCT02479789|Experimental|Lidocaine|Subjects in the Lidocaine arm of the randomized trial will receive a bolus of 1 mg /Kg of IV lidocaine followed by 1.5 mg/KG/h of IV lidocaine infusion during the surgery which will be stopped at extubation.
89527759|NCT02479789|Placebo Comparator|Placebo|Subjects in the Placebo arm of the randomized trial will receive a bolus of 1mg/kg Placebo ( 0.9% saline) followed by 1.5 mg/KG/h Placebo ( 0.9% saline) infusion during the surgery which will be stopped at extubation.
89527760|NCT03103737|Experimental|Intervention|Psychological intervention composed by four sessions along 1 week. Participants can interact with virtual environments and a multimedia system for reminiscence purposes.
89527761|NCT03103737|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. After one week, they have the possibility to receive the psychological intervention.
89527762|NCT04266639|Active Comparator|Remote Ischemic Conditioning|"Remote Ischemic Conditioning (RIC) is applied during the in-hospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be 200 mmHg; if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~Initial Remote Ischemic Conditioning: < 2 hours from inclusion~Remote Ischemic Postconditioning: twice daily for 7 days~Usual care with or without acute reperfusion therapy"
89527763|NCT04266639|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham Remote Ischemic Conditioning (Sham-RIC) is applied during the in-hospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be always be 20 mmHg.~Initial Sham Remote Ischemic Conditioning: < 2 hours from inclusion~Sham Remote ischemic Postconditioning: twice daily for 7 days~Usual care with or without acute reperfusion therapy."
89527764|NCT04266639|No Intervention|Controls|The control group will not receive treatment with Remote Ischemic Conditioning.
89527765|NCT02481895|Experimental|Experimental|E-neurocognitive module training.
89527766|NCT02481895|No Intervention|Control|The group will note receive any sort of add-on training, just the recommendations from the therapists.
89527767|NCT02643693|Experimental|P3L Product use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
89527768|NCT02643693|Experimental|VUSE Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
89527769|NCT02643693|Experimental|CC Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
89527770|NCT05361733|Active Comparator|XFB-19|"Part A: XFB-19 SC injection at the following dose levels:~Cohort 1: 5 mg~Cohort 2: 10 mg~Cohort 3: 20 mg~Part B: XFB-19 SC injection at the 2 highest acceptable dose levels from Part A:~Cohort 4: second highest acceptable dose level from Part A~Cohort 5: highest acceptable dose level from Part A"
89527771|NCT05361733|Placebo Comparator|Placebo|10 healthy volunteers will be randomized and assigned to the Placebo arm in Part A (Cohorts 1, 2 and 3) and Part B (Cohorts 4 and 5).
89527772|NCT02726113|Active Comparator|Intervention: Cholecalciferol|vitamin D3 (cholecalciferol) supplementation at 4000 IU daily for approximately two months prior to surgery (prostatectomy).
89527773|NCT02726113|Placebo Comparator|Placebo|softgel (containing no active ingredient) daily for approximately two months prior to surgery (prostatectomy).
89527774|NCT02481583|Experimental|part 1|12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
89527775|NCT02481583|Experimental|part 2|30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
89527776|NCT02480023|Experimental|healthcare|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
89527777|NCT03101397||improved group|defined by two or more of the following: A decrease in symptoms, specifically an increase in the level of exertion required before the patient must stop because of breathlessness or a decline in the frequency or severity of cough Reduction of parenchymal abnormalities on chest CT scan Physiologic improvement defined by > 10% increase in FVC (or at least > 200-ml change) or > 15% increase in single-breath DLCO (or at least > 3 ml/min/mm Hg)
89527778|NCT03101397||deteriorated group|defined by two or more of the following: An increase in symptoms, especially dyspnea or cough; An increase in opacities on chest CT scan, especially the development of honeycombing ; deterioration in lung function with > 10% decrease in FVC ( or > 200ml change) or > 15% decrease in DLCO (or at least > 3ml/min/mm Hg change).
89527779|NCT03101397||stable group|not included in improved group or deteriorated group
89527780|NCT05243589|Experimental|group A/ routine physical therapy and proprioceptive training|Routine physical therapy and proprioceptive training is performed
89527781|NCT05243589|Active Comparator|Group B/ routine physical therapy|Routine physical therapy
89527782|NCT02479633|Other|gingival recession type 1|recession defects without CAL intervention:Coronally advanced flap with connective tissue graft
89527783|NCT02479633|Other|gingival recession type 2|gingival recession with an amount of CAL equal or smaller to the buccal CAL. Intervention: Coronally advanced flap with connective tissue graft
89527784|NCT05243355|Experimental|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w. Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles. Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total.
89527785|NCT02479711|Experimental|composite restoration|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with Tetric EvoCeram Bulk Fill composite
89527786|NCT02479711|Active Comparator|glass ionomer cement|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with the glass ionomer restoration, Equia
89527787|NCT05334511|Experimental|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
89527788|NCT05196945|Experimental|VA-dual|"14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)"
89527789|NCT05196945|Active Comparator|EACP - quadruple|14days(Esomeprazole 20mg/ time, 2 times/day, oral+Amoxicillin 1g/ time, 2 times/day, oral+Clarithromycin 0.5g/ time, 2 times/day, oral+Bismuth potassium citrate 220mg/ time, twice a day, orally)
89527790|NCT02481427|Experimental|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
89527791|NCT02481427|Experimental|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
89527792|NCT03804021||1|Patients who received ADVM-043 in a treatment protocol
89527793|NCT05715151|Experimental|CQI intervention|The proposed CQI cohort consists of three activities carried out iteratively until the improvement objectives are achieved.
89527794|NCT05715151|Active Comparator|Audit and feedback|Clinics in the control group will receive feedback on six key AA indicators, patients reported experience about access and selected AA processes.
89527795|NCT03800979|Experimental|Tofacitinib|All participants will take Tofacitinib 5 mg twice daily for 24 weeks to treat extensive and recalcitrant alopecia areata.
89527796|NCT02476123|Experimental|Mogamulizumab+Nivolumab|"During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals.~Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination.~Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination."
89527797|NCT02481271|No Intervention|Usual care|Does not receive a specific study intervention
89527798|NCT02481271|Experimental|preoperative relaxation program|preoperative relaxation program
89527799|NCT02481271|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
89527800|NCT02481271|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
89527801|NCT03794661|Experimental|Single Arm|Clinician programmer electrode screening mode tool
89527802|NCT02481115||Critically Ill Children|Children in the Pediatric Critical Care Unit regardless of admitting diagnosis aged at least 6 months of age up to 5 years of age.
89527803|NCT02481037|Experimental|Intervention group|Embedding a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate practitioners utilizing best-evidence; training these practices' chronic disease management (CDM) professionals to provide asthma education to children with asthma and their parents; and clinicians receiving an EMR embedded dashboard.
89527804|NCT02481037|No Intervention|Control group|Practice will continue with routine care. Control group will be offered the intervention at study completion, if successful.
89527805|NCT02481193|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
89527806|NCT02481193|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg
89527807|NCT02481193|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg
89527808|NCT03101709|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
89527809|NCT03101631|Experimental|CASE ARM|"This is a three cohorts arm with intervention (CGA):~Nutritional Assessment: Mini Nutritional Assessment (MNA)~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~Psychological status: Geriatric Depression Scale (GDS)~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~Age~Haemoglobin~Creatinine Clearance (CrCl)~Presence of Geriatric Syndromes"
89527810|NCT03101631|No Intervention|CONTROL ARM|This is a three cohorts arm with no intervention
89527811|NCT02480959|Other|Medial plication|Patient undergoing surgical treatment for recurrent patellar instability that includes medial retinacular plication
89527812|NCT02480959|Other|MPFL reconstruction|Patient undergoing surgical treatment for recurrent patellar instability that includes medial patellofemoral ligament reconstruction using a tendon graft
89527813|NCT03101553|Experimental|Interpretation Bias Modification|"Treatment consists of eight brief sessions consisting of two tasks. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive feedback based on their response."
89527814|NCT03101553|Active Comparator|Progressive Muscle Relaxation|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release different muscle groups.
89527815|NCT05452759|Experimental|new type of tracheotomy high-flow oxygen therapy (NTHF)|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
89527816|NCT05452759|Active Comparator|Respiratory Humidification Treatment（ AIRVO TM 2）|Use AIRVOTM2 (Fisher & Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
89527817|NCT02479555|Active Comparator|Treatment Group: Dexamethasone Delivery|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy.~Treatment Group: Standard endovascular revascularization therapy consisting of angioplasty followed by Dexamethasondihydrogenphosphat-dinatrium (Ph.Eur.) 4 mg/mL Injektionslösung and with or without stent placement. The drug is diluted to 3.2 mg/mL and administered to the adventitia per Bullfrog Instructions for Use in a dose of 0.8 mg dexamethasone (0.25 mL) per cm of desired vessel treatment length, up to 30 cm."
89527818|NCT02479555|No Intervention|Control Group|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy. Control Group: Standard endovascular revascularization therapy consisting of angioplasty with or without stent placement. No specific distribution of gender regarding enrollment or randomization is intended. There will also be a separate randomization of patients with Rutherford 6 score to a maximum of 20 enrolled patients."
89527819|NCT03103659|Experimental|Elderly patient with cancer living in a nursing home|
89527820|NCT02476045|Active Comparator|ARM A|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with 5-FU/LV (De Gramont regimen) plus panitumumab given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
89527821|NCT02476045|Experimental|ARM B|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with panitumumab alone given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
89527822|NCT01832181||Metformin|
89527823|NCT01832181||Control|
89527824|NCT02479399||Suglat group|Tablets
89527825|NCT03885921|Experimental|Ezetimibe+Atorvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with atorvastatin 40 mg (starting dose) via oral tablet once daily in the morning (may be titrated up to a maximum daily dose of 80 mg for atorvastatin, if needed) for up to 24 months.
89527826|NCT03885921|Experimental|Ezetimibe+Simvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with simvastatin 40 mg (starting dose) via oral tablet once daily in the evening (may be titrated up to a maximum daily dose of 80 mg for simvastatin, if needed) for up to 24 months.
89527827|NCT02475889||RFA group|patients who received hepatic RFA followed by primary tumor resection were assigned to the RFA group
89527828|NCT02475889||Non-RFA group|patients who received initial primary tumor resection without RFA
89527829|NCT01230879|Experimental|60 - 70 years old|EFR and TDM
89527830|NCT01230879|Experimental|71 - 80 years old|EFR and TDM
89527831|NCT01230879|Experimental|81 - 95 years old|EFR and TDM
89527832|NCT03750747|Experimental|Intervention (Pulse Oximeter)|The intervention facilities will provide IMCI services with PO in addition to following existing IMCI guidelines. The IMCI service providers will classify and treat children presenting with cough and difficult breathing based on history and clinical signs. In addition, they will use PO to measure the SpO2 status of the sick children. Children clinically classified as 'Pneumonia' but having SpO2<90% will be referred to higher-level facilities for in-patient management. Only the children clinically classified 'Pneumonia' and having SpO2>90% will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day).
89527833|NCT03750747|No Intervention|Comparison|The comparison facilities will continue providing routine IMCI services as per the existing guidelines. In routine IMCI services, IMCI service providers classify and treat children presenting with cough and difficult breathing based on history and clinical signs only. In routine IMCI services in Bangladesh, PO has not been introduced. Therefore, in the comparison facilities all children clinically classified as 'Pneumonia' will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day)
89527834|NCT02475967|Experimental|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.
89527835|NCT02475967|Active Comparator|Control group|The control group patients receive conventional cardiac care alone.
89527836|NCT02475577|Experimental|Control|Control: Peripherals with HealthInterlink technology will record and transmit data, without intervention. Subject is able to view graphed data, bring the HealthInterlink tablet/smartphone to the physician's office and share data with family/other caregiver.
89527837|NCT02475577|Experimental|Intervention 1|Intervention 1: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver.
89527838|NCT02475577|Experimental|Intervention 2|Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.
89527839|NCT01361919|Experimental|Feedback During CPR Training and Testing|"A feedback defibrillator (ZOLL R series) will be used at teaching, immediate testing and 12 week (retention) testing. A simulation manikin with an attached accelerometer pad on its sternum will be used to collect CPR performance data. Subjects will be told to perform compressions on top of the accelerometer pad and will be taught to use and follow the audio and visual feedback to optimize their CPR performance. After training, the raw data collected by the accelerometer will be used as a demonstration and training tool, to correct the subjects' performance by visually demonstrating the difference between ideal and suboptimal CPR performance. Testing will be carried out with the use of a feedback defibrillator."
89527840|NCT01361919|Active Comparator|Feedback during CPR Training Not Testing|"A feedback defibrillator will be used for teaching, with a standard no feedback defibrillator used at immediate and 12 week (retention) testing to assess if the techniques the students' learned during training are transferable to devices without feedback. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest."
89527841|NCT01361919|Placebo Comparator|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
89527842|NCT05714917||Confirmed diagnosis of NOS-induced neurological damage|"Any patient first presented with paraesthesia, weakness, ataxia or gait disturbance with a history of NOS use (age limit 16-30) as of 01/04/2023.~Patients who can read and write in English, so that they can complete the questionnaires."
89527843|NCT02480881|Experimental|Single Sequence A, B, C, and D|Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
89527844|NCT02479243||Collateral Circulation|Symptomatic patients with unilateral MCA severe stenosis confirmed ≥ 90% by magnetic resonance angiography or 70-99% by conventional angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI.
89530170|NCT03249805|Experimental|Steenbeek Foot Abduction Brace (SFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The Steenbeek Foot Abduction Brace (SFAB) is a fixed metal bar attached to two leather shoes with laces. The shoes have laces and a strap. The FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
89527845|NCT05713591|Experimental|Transition care model|Patients in the experimental arm will receive the TC intervention which encompasses three main pillars that guided a standardized and structured clinical pathway to ensure an optimal transition from childhood care to adult care. Briefly, the first pillar was designed to improve the understanding of the clinical condition through tailored education. Healthcare providers delivered specific information and education strategies. The second pillar aimed to support the development of functional coping strategies by discussing with a counselor and/or a psychologist. The TC encompassed for this pillar both structured face-to-face discussions and counseling moments. The third pillar hoped to improve the engagement of CHD adolescents and their families.
89527846|NCT05713591|No Intervention|Usual care|Patients in the control arm will receive a usual care approach without the high focus on standardization given by the experimental arm (e.g. without flyers and booklets or standardized moments of face-to-face counseling). Data collection will be performed using a consistent approach with the one described in the experimental arm: every three months in a year (T0, T1, T2, T3, and T4).
89527847|NCT02480647|Experimental|levonorgestrel & etonogestrel|"Levonorgestrel releasing intrauterine system~Other names:~Mirena."
89527848|NCT02480647|Active Comparator|etonogestrel|"Etonogestrel implant:~Other name: Implanon Releasing 20μg/day."
89527849|NCT05072925|Active Comparator|Combustible Cigarette|The usual brand of combustible cigarette smoked by study subjects, with a minimum Federal Trade Commission tar yield of 8mg
89527850|NCT05072925|Experimental|BIDI Stick ENDS Arctic flavor|BIDI Stick ENDS containing 6% nicotine and Arctic flavor
89527851|NCT05072925|Experimental|BIDI Stick ENDS Classic flavor|BIDI Stick ENDS containing 6% nicotine and Classic flavor
89527852|NCT05072925|Experimental|BIDI Stick ENDS Zest flavor|BIDI Stick ENDS containing 6% nicotine and Zest flavor
89527853|NCT05072925|Experimental|BIDI Stick ENDS Regal flavour|BIDI Stick ENDS containing 6% nicotine and Regal flavor
89527854|NCT05072925|Experimental|BIDI Stick ENDS Winter flavour|BIDI Stick ENDS containing 6% nicotine and Winter flavor
89527855|NCT05072925|Experimental|BIDI Stick ENDS Solar flavor|BIDI Stick ENDS containing 6% nicotine and Solar flavor
89527856|NCT05072925|Active Comparator|JUUL ENDS Virginia Tobacco flavor|JUUL ENDS containing 5% nicotine and Virginia Tobacco flavor
89527857|NCT02479477|Experimental|kinesio therapy|"The intervention is one protocol of labour kinesiotherapy that will be realized tree times per week, eatch intervention with fiveteen minutes, during eitgh weeks.~To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase."
89527858|NCT02479477|No Intervention|control|the control group will continue their daily tasks uring eitgh weeks. To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase.
89527859|NCT05384509||Chemotherapy|Cancer Patients underwent chemotherapy
89527860|NCT05384509||Targeted therapy|Patients underwent targeted therapy
89527861|NCT05384509||Immunotherapy|Patients underwent immunotherapy
89527862|NCT05384509||Disease-free|Cancer patients have been disease-free for ≥ 6 months group
89527863|NCT02479165|Active Comparator|Opioid group|"If randomized to the opiod group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Oxycodone (slow-release) 10mg, Twice daily for 1 week Tbl. Paracetamol 1000mg, Four times daily for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed, until discharge. Inj, oxycodone 2.5 mg, Max 4 times daily, as needed, until discharge Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml 10 drops daily, for 1 week"
89527864|NCT02479165|Active Comparator|Ibuprofene group|"If randomized to the ibuprofen group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Ibuprofen (slow-release) 800mg, Twice daily, for 1 week Tbl. Paracetamol 1000mg, Four times daily, for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed. Until discharge. Inj, oxycodone 2.5 mg Max 4 times daily, as needed. Until discharge. Tbl. Lanzoprazole 40 mg, Once daily, for 1 week Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml, 10 drops daily, for 1 week"
89527865|NCT05072769|Experimental|Experimental group|After the fetus and placenta are born, feeding 100 gr (5-6 pieces) dates to the experimental group
89527866|NCT05072769|No Intervention|Control group|The group that was not attempted any intervention in the postpartum period
89527867|NCT02479087|Experimental|Plasma-derived FVIII/VWF concentrate|"The drug will be delivered through intravenous slow infusion/injection. The starting dosage can vary between the minimum dosage of 50 IU/Kg 3 times a week up to a maximum of 200 IU/kg per day.~This starting dosage will be decided by the Principal Investigator according to patient's condition and other variables.~The initial dosage can be then adjusted on the base of response."
89527868|NCT05072691||Patients with Multiple sclerosis and Optic Neuritis|Patients ≥ 18 year-old at the time of enrollment, with newly diagnosed multiple sclerosis according to 2017 McDonald diagnostic criteria Patients ≥ 18 year-old at the time of enrollment with first episode of optic neuritis, fulfilling or not (i.e. CIS, clinically isolated syndrome) 2017 McDonald diagnostic criteria for multiple sclerosis
89527869|NCT05072691||Patients with non-inflammatory neurologic diseases (NIND)|Patients ≥ 18 year-old with suspected non-inflammatory neurologic diseases (such as Alzheimer disease, intracranial hypertension, etc) receiving routine diagnostic lumbar puncture
89527870|NCT05072691||Patients with other inflammatory neurologic diseases (IND)|Patients ≥ 18 year-old with suspected inflammatory neurologic diseases other than multiple sclerosis (such as inflammatory peripheral neuropathies, meningitis, neuromyelitis optica spectrum disorders, etc) receiving routine diagnostic lumbar puncture
89527871|NCT05071989|Experimental|Sleep education group do not supported with social media reminders|Sleep education do not supported with social media reminders
89527872|NCT05071989|Experimental|Sleep education group supported with social media reminders|Sleep education group supported with social media reminders
89527873|NCT05071989|No Intervention|Control group|No intervention was made in the control group.
89530558|NCT03121703|Experimental|lumbar stabilization exercises group|diverse lumbar stabilization exercises
89530559|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
89527874|NCT03103269|Experimental|Challenge! Small Group Intervention only|"This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~This group is in schools that were randomly assigned to NOT receive the Environmental Intervention."
89527875|NCT03103269|Experimental|Challenge! Small Group and Environmental Intervention|"This group consists of participants who receive the Challenge! Small Group Intervention AND attend a school that is randomly assigned to receive an environmental intervention.~This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
89527876|NCT03103269|Experimental|Environmental Intervention Only|"This group consists of participants who do not receive the Challenge! Small Group Intervention but attend a school that is randomly assigned to receive an environmental intervention.~This group does not receive the Challenge! Small Group Intervention.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
89527877|NCT03103269|No Intervention|Control Group|This group does not receive the Challenge! Small Group intervention and is in a school that is randomly assigned to NOT have the Environmental Intervention.
89527878|NCT03719547|Experimental|Robot-assisted radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
89527879|NCT03719547|Active Comparator|Abdominal radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
89527880|NCT02475499||Treated with incretins|Ever-use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) between (and including) base cohort entry and the index day - 365 days.
89527881|NCT02475499||Treated with sulfonylureas|Ever-use of sulfonylureas between (and including) base cohort entry and the index day - 365 days, and never-use of incretin-based drugs.
89527882|NCT02475499||Treated with other antidiabetic agents|Ever-use of other antidiabetic agents (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) between (and including) base cohort entry and the index day - 365 days, with never-use of incretin-based drugs and never use of sulfonylureas.
89527883|NCT05072223|Experimental|Group A|
89527884|NCT05072223|Active Comparator|Group B|
89527885|NCT05071443|Experimental|Negative pressure wound therapy (NPWT)|Negative pressure wound therapy (NPWT): an NPWT device will be applied hermetically from randomization to skin grafting.
89527886|NCT05071443|Active Comparator|Conventional dressing|Conventional dressing will be performed from randomization to skin grafting. The dressings will be performed following usual procedures of investigating centers
89527887|NCT05071521|Active Comparator|Eating disorders prevention|"The Body Project. The Body Project is a dissonance-based eating disorders prevention programme. It is a manualised evidence-based programme that targets eating pathology and body image dissatisfaction in young women. The objective of the programme is to create cognitive dissonance to encourage participants to decrease pursuing ideal-thinness. It includes group discussion, written and behavioural exercises and role-play to achieve cognitive dissonance (Stice, Rohde, & Shaw, 2013). It involves four group sessions for an hour each in consecutive weeks. At the beginning of each meeting, the facilitator reinforces voluntary commitment. Homework is explained and given at the end of each meeting and reviewed at the beginning of the following meeting.~References:~Stice, E., Rohde, P., Shaw, H. (2013). The body project a dissonance-based eating disorders prevention intervention (updated edition). New York: Oxford University Press."
89527888|NCT05071521|Sham Comparator|Healthy eating education|"The control group were asked to read educational material in Arabic about healthy nutrition and active lifestyle from the Saudi branch of the World Obesity Federation (Kayl Association for Combatting Obesity, 2021). The material includes information about body mass index; easy ways to measure food units without a scale; benefits of working out; means to adopt healthier daily habits; and healthier food alternatives. The material was chosen because it was designed to be easy to understand by any individual.~References:~Kayl Association for Combatting Obesity. (2021). Kayl association for combatting obesity. Retrieved from https://www.kayl.org.sa"
89527889|NCT03136809|Experimental|Cu(II)ATSM|Cu(II)ATSM administered once daily
89527890|NCT02475421|Experimental|Healthy, lean subjects|Healthy subjects with BMI < 27 kg/m^2
89527891|NCT02475421|Experimental|Healthy, obese subjects|Healthy subjects with BMI > 33 kg/m^2
89527892|NCT02475421|Experimental|Diabetic, lean subjects|Diabetic subjects with BMI < 27 kg/m^2
89527893|NCT02475421|Experimental|Diabetic, obese subjects|Diabetic subjects with BMI > 33 kg/m^2
89527894|NCT03641859|No Intervention|Local anesthesia|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 1 (usual care): the procedure of care will be the same as usual."
89527895|NCT03641859|Experimental|local anesthesia + virtual reality|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 2 (intervention): local anesthesia + virtual reality"
89530560|NCT02512835||Clinic patients|Aims 1a and 1b: The participants include all unique patients seen at the 12 study practices (approximately 170,000 patients over the past two years).
89527896|NCT02475343|Experimental|Control|People without keratoconus, history of ocular surgery, and other diseases mentioned in exclusion criteria. Normal people will receive treatment or measurement including: Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking, Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination.
89527897|NCT02475343|Experimental|Keratoconic patients|Patients with keratoconus.Keratoconic patients will receive treatment or measurement including:Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking,Ocular morphology measurement,and routine ophthalmic examination.
89527898|NCT02475343|Experimental|Patients received keratoplasty|Patients received keratoplasty. Patients received keratoplasty will receive treatment or measurement including:Schiotz tonometer measurement,Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination..
89527899|NCT05070897||Population A|18 to 64 years old
89527900|NCT05070897||Population B|65 years old and more
89527901|NCT02478619|Active Comparator|IMT group|The volunteers will do the respiratory muscle training through a linear inspiratory pressure resistance device (POWERbreathe®) at 50% of the maximal inspiratory pressure.
89527902|NCT02478619|Placebo Comparator|Control group|Patients will do a placebo respiratory muscle training through a load pressure resistance device (POWERbreathe®) with the minimum load available (10cmH20).
89527903|NCT02088333|Experimental|mCRC intervention|intervention arm
89527904|NCT02088333|Placebo Comparator|Healthy lifestyles education|tablet-based patient education about healthy lifestyles
89527905|NCT02480725||CJD (Creutzfeldt-Jakob disease) patients|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
89527906|NCT02480725||non-CJD patients with a type of dementia|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
89527907|NCT02480725||CSF samples of non-CJD patient used as control|CSF samples : Thrombin activity will be assayed.
89527908|NCT05070507|Experimental|Enzyme containing lozenge|
89527909|NCT05070507|Placebo Comparator|Placebo lozenge|
89527910|NCT02475109|Experimental|PAN-90806 Ophthalmic Solution|PAN-90806 Ophthalmic Solution taken daily for 8 weeks.
89527911|NCT02480569|Experimental|Side-Hole Catheter|2 FFR measurements from an engaged side-hole guide catheter and a disengaged side-hole guide catheter
89527912|NCT02480569|Experimental|Non-Side-Hole Catheter|2 FFR measurements from an engaged non-side-hole guide catheter and a disengaged non-side-hole guide catheter
89527913|NCT04492501|No Intervention|Supportive Arm|As per Institutional COVID-19 Management Guidelines all patients of moderate, severe and critical COVID-19 received standard protocol of aspirin, anticoagulation, ulcer prophylaxis, awake Proning (if PaO2 < 80mmHg) and corticosteroids. All patients of Cytokine release storm (CRS) received either Methylprednisolone 1 mg/kg or Dexamethasone 6-12mg/day irrespective of disease severity.
89527914|NCT04492501|Experimental|TPE arm|addition to standard care TPE will be performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access will be achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume will be calculated as per Nadler's formula. Anticoagulant acid dextrose ratio will be 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation will be monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume will be removed during each procedure. Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures will be performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE will be continued till recovery.
89527915|NCT04492501|Experimental|TPE in combination with other investigational treatments|During TPE, Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively plus 200-400 ml of convalescent plasma. A predefined number of patients will also receive mesenchymal stem cell therapy and/or Remdesivir
89527916|NCT04492501|Experimental|Either alone or combination of MSC, Remdesivir and Tocilizumab|A predefined number of patients will receive either alone Tocilizumab, Remdesivir and Mesenchymal stem cell therapy or their combination
89527917|NCT03101085|Experimental|S-equol|Participants will receive S-equol 50mg twice daily for one month
89527918|NCT03101085|Placebo Comparator|Placebo|Participants will receive matched placebo pill to take twice daily for one month
89527919|NCT02480491||Third day embryos|embryos culture media during third day after fertilization
89527920|NCT02480491||Fifth day embryos|embryos culture media during fifth day after fertilization
89527921|NCT03606759|Experimental|Traitment as usual adjusted on ATI information|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
89527922|NCT03606759|Active Comparator|Traitment as usual|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
89527923|NCT05070195|Experimental|The DDI of SKLB1028 and Midazolam|Eligible subjects received a single dose of Midazolam 15 mg on Day 1, and took a single dose of Midazolam 15 mg and a single dose of SKLB1028 150 mg with dosing interval of 0.5 h on Day 3.
88814478|NCT02487498|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
89527924|NCT04412655||STEMI patients treated in March April 2019|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2019
89527925|NCT04412655||STEMI patients treated in March April 2020|Patients with STEMI undergoing mecahnical revascularization from 1th March to 30th April 2020
89527926|NCT02478307|Active Comparator|Cognitive Therapy|Eight, 2-hours sessions of group delivered cognitive therapy.
89527927|NCT02478307|Active Comparator|Mindfulness Meditation|Eight, 2-hours sessions of group delivered mindfulness meditation.
89527928|NCT02478307|Active Comparator|Mindfulness-Based Cognitive Therapy|Eight, 2-hours sessions of group delivered mindfulness-based cognitive therapy
89527929|NCT05069883|Experimental|Oral Steroid|In this group oral steroids were given after Direct vision internal urethrotomy
89527930|NCT05069883|Placebo Comparator|No Oral Steroids|In this group no oral steroids were given after Direct vision internal urethrotomy
89527931|NCT02478385|Active Comparator|Birth environment labour room|Supportive care of labour room designed with special attention on sound and light effects, covering medical devices and insulation from outside noise
89527932|NCT02478385|Placebo Comparator|Labour in a standard labour room|The woman gives labour in a standard labour room
89527933|NCT03100929|Experimental|Elective cesarean section|Any patient undergoing elective cesarean section. Ultrasound
89527934|NCT02474953|Experimental|Dosing Sequence 1|Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
89527935|NCT02474953|Experimental|Dosing Sequence 2|Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
89527936|NCT05713435|Active Comparator|Mona Lisa Touch CO2 laser|"Power: 30 W.~Dwell time: 1000 μs.~Spacing: 1000 μm.~Depth: SmartStack parameter from 1 to 3 depending on the treatment status.~D-pulse mode.~At the introitus the power will be reduced to 24 W"
89527937|NCT05713435|Active Comparator|Fotona Smooth erbium:YAG laser|"Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm.~Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 10 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm."
89527938|NCT05713435|Sham Comparator|sham treatment|"The blocking device is inserted over the laser outlet before attaching the application speculum. With this device the laser beam is blocked entirely.~Phase I (vaginal) Renovalase™ mode with (a) fluence of 5,5J/cm2, (b) SMOOTHTM mode frequency 1.6 Hz, and (c) spot size 7 mm.~Phase II (vestibulum and introitus) Renovalase™ mode with (a) fluence 1,5 J/cm2, (b) SMOOTHTM mode frequency 1.6Hz, and (c) spot size 7 mm."
89527939|NCT05069025|Experimental|music group|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
89527940|NCT05069025|Other|non-music group|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
89527941|NCT05714371||Immunotherapy (IO)|Patients receiving IO
89527942|NCT05714371||Targeted therapy (TT)|Patients receiving TT
89527943|NCT03103191||Case|"50 subjects with fibrosing interstitial lung disease.~50 subjects with pulmonary fibrosis secondary to collagen diseases."
89527944|NCT03103191||Control|"75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.~75 subjects with collagen disease without pulmonary fibrosis."
89527945|NCT02472613|Experimental|traditional acupuncture & placebo|Apply traditional acupuncture to treat the ischemic post-stroke depression according to TCM theory.
89527946|NCT02472613|Active Comparator|sham-acupoint acupuncture & fluoxetine|Fluoxetine was given at a dose of 20 mg/day. sham-acupoint will be penetrated for treat the ischemic post-stroke depression.
89527947|NCT03100851|Experimental|LcS intervention|Patients with constipation received dietary supplement with Lactobacaiilus casei strain Shirota.
89527948|NCT05047783|Experimental|Masitinib 3.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo (all patients will receive Best Supportive Care)
89527949|NCT05047783|Experimental|Masitinib 4.5 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus corresponding placebo (all patients will receive Best Supportive Care)
89527950|NCT05047783|Experimental|Masitinib 6.0 mg/kg/day|Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day for 6 days versus corresponding placebo (all patients will receive Best Supportive Care)
89527951|NCT05047783|Placebo Comparator|Placebo|Placebo arms associated with the three Experimental arms (all patients will receive Best Supportive Care) which will be pooled for analysis
89527952|NCT03100695|No Intervention|Control|Patients will undergo operative procedure with no additional intervention.
89527953|NCT03100695|Experimental|Study|Patients will undergo usual operative procedure with the addition of an injection of autologous, concentrated PRP-BMA at the site of fixation.
89527954|NCT02472535|Experimental|placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules|
89527955|NCT00783237|Experimental|Mometasone Furoate Nasal Spray|
89527956|NCT00783237|Placebo Comparator|Placebo Nasal Spray|
89527957|NCT02478541|Active Comparator|Sugar Study_low fructose|Consumption of a single test meal that contains fat and a sugary drink made with a low amount of fructose and high amount of glucose
89527958|NCT02478541|Active Comparator|Sugar Study_high fructose|Consumption of a single test meal that contains fat and a sugary drink made with a high amount of fructose and low amount of glucose
89527959|NCT02474875|Active Comparator|Educational program Control Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: talk about medical issues (drugs, nutrition, importance of sleep...)
89527960|NCT02474875|Experimental|Educational program High Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
89527961|NCT02474875|Experimental|Educational program Diluted Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
89527962|NCT02474875|Experimental|Educational program Concentrated Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: educational sessions about the neurophysiology of pain
88814479|NCT04357418||hospital staff|
89527963|NCT03103035|Experimental|Exposition to a healthy eating blog|Participants randomised to this arm are exposed to one blog post each week for a period of 6 months.
89527964|NCT03103035|No Intervention|No exposition to a healthy eating blog|Participants randomised to this arm do not have exposure to the blog.
89527965|NCT03109249|Experimental|SPARC1613|Intravenous administration of SPARC1613
89527966|NCT03109249|Active Comparator|Reference 1613|Intravenous administration of Reference1613
89527967|NCT02478229|Experimental|SOF and LDV|Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.
89527968|NCT04491799||Nosocomial diarrhea|Patients who are hospitalized and develop diarrhea after 72 hours of hospitalization.
89527969|NCT04887025|Experimental|Dose Escalation|Subjects will be treated with RGV004 as a single injection, one time.
89527970|NCT04879615|Experimental|Alteplase with standard therapy|
89527971|NCT04879615|No Intervention|Standard therapy|
89527972|NCT05069103|Experimental|Intervention|"Similar to the original TWIST trial, patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~At least one image of their surgical wound(s).~Patients will receive automated requests via notifications asking to complete the online tool over the 30-day period (every 3 days +/- 1 day), however they may also complete the online form whenever wished."
89527973|NCT05713045||intramuscolar injection|intramuscolar injection of 1 mg vitamin K at birth
89527974|NCT05713045||intramuscolar injection following by oral low dose|intramuscolar injection of 1 mg vitamin K at birth followed by 50 μg/die orally from the second to the fourteenth week of life
89527975|NCT05713045||intramuscolar injection following by oral high dose|intramuscolar injection of 1 mg vitamin K at birth followed by 150 μg/die orally from the second to the fourteenth week of life
89527976|NCT05713045||oral administration|oral dose of 2 mg vitamin K at birth, followed by a second dose at 4 weeks, and a third dose at 12 weeks
89527977|NCT00653835|Experimental|Ezetimibe + Simvastatin|
89527978|NCT00653835|Active Comparator|Simvastatin|
89527979|NCT05068557|Active Comparator|Intervention group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with fish oil (3 capsules daily. Containing EPA+DHA: 1.8 g). (n=40)
89527980|NCT05068557|Placebo Comparator|Control group|Dietary plan with a mild calorie restriction and adjusted in PUFA omega-3/omega-6 ratio (4:1) along with chia/linseed oil (3 capsules daily. Containing ALA 1.6 g). (n=40)
89527981|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units|100,000 units Vitamin D2 one time only.
89527982|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units D2|100,000 units vitamin D2 weekly for three months.
89527983|NCT03099759|Active Comparator|Vitamin Dose Group 50,000/2,000 D2/D3|50,000 units Vitamin D2 for 10 days followed by 2,000 units Vitamin D3 daily the remainder of the three month study period.
89527984|NCT03100773|Experimental|Group control|Caries-free children submitted to four consecutive sessions of oral health educational strategy (once a week).
89527985|NCT03100773|Experimental|Group of strategy + ART|Children with at least one decayed primary molar in dentin submitted to four consecutive sessions of oral health educational strategy (once a week) followed by Atraumatic Restorative Treatment (ART)
89527986|NCT03100773|Experimental|Group of ART|Children with at least one decayed primary molar in dentin submitted to Atraumatic Restorative Treatment (ART)
89527987|NCT05712811|Active Comparator|Group A cryotherapy|Cryotherapy Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
89527988|NCT05712811|Active Comparator|Group B Topical TCA 90%|Topical TCA 90 % Warts in Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline
89527989|NCT05711797|Experimental|ZX-7101A 80mg Mild or moderate liver insufficiency|
89527990|NCT05711797|Experimental|ZX-7101A 80mg Normal liver function|
89527991|NCT05068245|No Intervention|Routine pain control|The routine pain control group will receive instructions to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants.
89527992|NCT05068245|Experimental|Routine pain control plus music|Patients randomized to receive music in addition to routine pain control measures, will be instructed to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants. Preselected classical music will be played for this group throughout the procedure.
89527993|NCT05244577|Experimental|Olanzapine|Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy; Dexamethasone 6mg Po QD, D1-7; Fosaprepitant 150mg IVD D1,4, 60 minutes before chemotherapy; Olanzapine 5mg Po D1-7
89527994|NCT05244577|Placebo Comparator|Placebo|Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy; Dexamethasone 6mg Po QD, D1-7; Fosaprepitant 150mg IVD D1,4, 60 minutes before chemotherapy; Placebo 5mg Po D1-7
89527995|NCT03099837||Pregnant mothers|
88814480|NCT04357418||close relatives.|
89527996|NCT03099837||infants|
89527997|NCT03099837||children|
89527998|NCT05068323|Other|Epilepsy|Newly diagnosed epileptic patients
89527999|NCT05068323|Sham Comparator|Control|healthy subjects
89528000|NCT02472379|Experimental|Writing: Group 1|Subjects will be asked to write about experiences with familiar individuals in their lives.
89528001|NCT02472379|Placebo Comparator|Writing: Group 2|Subjects will be asked to write about experiences with familiar places in their lives.
89528002|NCT04846387||Females with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A urinary pouch will be used to collect the participant's urine while in the scanner."
89528003|NCT04846387||Males with Normal Bladder Function|"Diagnostic Tests: functional MRI and urodynamic studies.~During screening, subject will be asked to come to their appointment with a full bladder. For the uroflow, they will urinate into a special funnel connected to a measuring instrument in a private bathroom followed by measuring Post void residual volume through PVR scanner. This is to ensure that they do not have any urological issue which can disqualify them from the study. At this visit, we will also instruct them about the urine voiding-holding task, our noninvasive fMRI paradigm, which the subjects will be performing during the fMRI portion of the study at visit 2. A 7-Tesla Siemens MAGNETOM scanner will be used. A condom catheter will be used to collect the participant's urine while in the scanner."
89528004|NCT05067699||Patients|recurrent pityriasis versicolor
89528005|NCT05067699||Controls|Healthy age and sex matched
89528006|NCT02474797|Experimental|Diaphragmatic ultrasonography in septic patient|Diaphragmatic Thickening Fraction
89528007|NCT04191993|Experimental|Direct Superior Approach (DSA)|Direct superior incision during surgery
89528008|NCT04191993|Active Comparator|Posterior Approach (PA)|Posterior approach incision during surgery
89528009|NCT02474719|Experimental|conventional scheme followed by alternate schem|"The first day of the study, patients receive an adapted conventional peritoneal dialysis scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²).~The second day, patients receive an adapted and alternate scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once."
89528010|NCT02474719|Experimental|alternate scheme followed by conventional scheme|"The first day of the study, patients receive an adapted and alternate peritoneal dialysis scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once.~The second day, patients receive an adapted conventional scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²)."
89528011|NCT05067153|Experimental|Intervention|Intervention group (n=50, anticipated) receives 30 days postoperative treatment with 5000 IE LMWH daily.
89528012|NCT05067153|Active Comparator|Control|Control group (n=50, anticipated) receives standard 10 days postoperative treatment with 5000 IE LMWH daily.
89528013|NCT02642679|Experimental|Opticell Ag|Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.
89528014|NCT05224921||Very low birth weight infants|Include very low birth weight infants admitted into NICU in Children's hospital of Fudan University, and prospectively observe whether they get late onset sepsis.
89528015|NCT03100461|Active Comparator|HE + HE|Participants receive up to two interventions. Participants receive HE initially and then a second time if not screened after 6 months.
89528016|NCT03100461|Active Comparator|HE + I2|Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
89528017|NCT03100461|Experimental|I2 + I2|Participants receive up to two interventions. Participants receive I2 initially and then a second time if not screened after 6 months.
89528018|NCT03100461|Active Comparator|I2 + HE|Participants receive up to two interventions. Participants receive I2 initially and then HE if not screened after 6 months.
89528019|NCT05338255||Patients who have undergone surgery at the MAZ hospital for knee/hip replacement.|
89528020|NCT02472301|Experimental|Cowpeas|Cowpea supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
89528021|NCT02472301|Experimental|Common bean|Common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
89528022|NCT02472301|Active Comparator|Corn Soy Flour|Corn flour with 10% soy supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
89528023|NCT05067309||Missed abortion received letrozole then misoprostol|
89528024|NCT05067309||Missed abortion received misoprostol alone|
89528025|NCT03099603|Placebo Comparator|0.5g|single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
89528026|NCT03099603|Placebo Comparator|1.0g|single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
89528027|NCT03099603|Placebo Comparator|2.0g|single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
89528028|NCT03099603|Placebo Comparator|4.0g|single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
89528029|NCT02474563||Bortezomib, Melphalan, Prednisone (VMP) Group|Participants will not receive any intervention in this study. Participants receiving VMP therapy for MM that was not eligible for autologous stem cell transplantation will be enrolled in the study.
89528030|NCT04092153|Active Comparator|Mechanically aligned|Neutral limb alignment irrespective of the patient's native knee anatomy and joint mechanics
89528031|NCT04092153|Experimental|Functionally aligned|Restore the patient's own pre-arthritic knee anatomy
89528032|NCT05066841|Experimental|CM group|
89528033|NCT05066841|Placebo Comparator|placebo group|
89528034|NCT04090515|Experimental|Project Health|Project Health has three aims: 1) encourage participants to explore the costs of obesity, an unhealthy diet, and sedentary behavior and the benefits of physical fitness, a healthy diet, and regular exercise; 2) help participants gradually reduce caloric intake and increase physical activity, such that the participant reaches energy balance (i.e., is not eating more calories than they need); and 3) reduce attitudinal and behavioral risk factors for eating disorders and obesity. The intervention will be administered in Spanish.
89528035|NCT04090515|Placebo Comparator|Educational Video Control|The educational video control condition will include an educational video series on obesity in Spanish.
89528036|NCT03099525||RA-ILD|Patients who are diagnosed with ILD. No intervention in this study.
89528037|NCT03099525||RA-non ILD|Patients who are not diagnosed with ILD. No intervention in this study.
89528038|NCT03100227|Active Comparator|PET [18F] FDG|Each subject will have a PET scan at [18F] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
89528039|NCT03100227|Sham Comparator|Review test-retest|Of the 40 volunteers included, 10 will have test-retest exams (2 separate exams every 15 days).
89528040|NCT03099447|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
89528041|NCT03099447|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
89528042|NCT03099447|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
89528043|NCT03098901|Other|no other arm|
89528044|NCT03108781|Active Comparator|Lavender Oil|
89528045|NCT03108781|Placebo Comparator|sunflower oil|
89528046|NCT05419609|Experimental|Office-based limited facelift|Patients will undergo a limited facelift in the office. Patients will receive local anesthesia and optionally may receive an antianxiety medication.
89528047|NCT05419609|Active Comparator|Hospital-based full facelift|Patients will undergo a full facelift in the hospital or ambulatory surgical center. Patients will receive either general anesthesia or intravenous sedation.
89528048|NCT05066763||People with Parkinson's disease|
89528049|NCT02477995|Experimental|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
89528050|NCT02477995|Active Comparator|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B (Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
89528051|NCT03098823|Experimental|RAYOS®|
89528052|NCT03098823|Active Comparator|IR prednisone|
89528053|NCT04788277||Diagnostic (biospecimen collection)|Patients undergo collection of urine samples at baseline during standard of care office/clinic visit.
89528054|NCT04478487|Experimental|Study Participants|all preterm infants ≤ 32 weeks and 0 days gestational age (GA) with a birth weight 700 g to 1500 g at the hospital, who are enterally fed human milk in the neonatal intensive care unit (NICU) for at least 7 days. Various blending ratios of the fortifier with either the mother's expressed milk or donor milk will be used to deliver macro and micronutrients based on established guidelines to be adjusted according to the infant's tolerance for volume and calories. The estimated time for each subject's participation is approximately from 1 week through 8 weeks, depending on the weight and age at enrollment. Historic control cases treated by another human milk based human milk fortifier will be obtained from medical records, matched on birth weight and gender, with sample size twice (n=80) that of the study population.
89528055|NCT03108937|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
89528056|NCT03108937|Placebo Comparator|saline|Same amount of saline will be administrated.
89528057|NCT03098667|Experimental|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated
89528058|NCT03098667|Active Comparator|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
89528059|NCT00705523|Active Comparator|1|
89528060|NCT00705523|Placebo Comparator|2|
89528061|NCT03903939|Experimental|Iloprost|Patients randomized to active treatment (n = 110 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first
89528062|NCT03903939|Placebo Comparator|Placebo|Patients randomized to placebo treatment (n= 110 patients) will receive continuous infusion of isotonic saline (equal volume) for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
89530561|NCT02512835||Clinicians|Aims 2 and 3: The clinicians in this analysis will include 15 participants recruited from the approximately 100 clinicians at the 12 practices
89528063|NCT03718221|Active Comparator|Usual Care FIT Screening Strategy|"Mailed outreach invitation to complete FIT include: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage). Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion. Centralized processes to promote guideline-based follow-up."
89528064|NCT03718221|Experimental|GeoMail FIT Screening Strategy|The experimental arm differs from the active comparator in one way: patients living in treated ZIP codes will receive the mailed outreach at the same time.
89528065|NCT03703323|Experimental|Rotative thromboelastometry analysis|Evaluation of diagnostic properties of coagulation by rotative thromboelastometry in patient with digestive hemorrhage in predictive value of mortality.
89528066|NCT03100305||Extremely preterm infants|
89528067|NCT03100305||Very preterm infants|
89528068|NCT03100305||Moderately preterm infants|
89528069|NCT03100305||Late preterm infants|
89528070|NCT05064969|Experimental|Single-arm non-randomised|This study includes a baseline assessment, a 9-week (with the possibility of extension to 12 weeks) blended intervention period, a post-intervention assessment, and two follow-ups at 3 and 6 months. Informal caregivers of people with dementia (with at least 18-year-old) with no restriction in terms of sex, educational level, or ethnic background will be included.
89528071|NCT04434573||french-speaking digestive surgeons|french-speaking digestive surgeons are visceral and digestive surgeons that have a general surgical activity too. They can have or not an expertise on hernia pathology. They are questioned by survey on decisions about different patient asymptomatic hernia clinical situations.
89528072|NCT05010915|Experimental|dorsolateral prefrontal cortex|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
89528073|NCT05010915|Experimental|ventrolateral prefrontal cortex|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
89528074|NCT05010915|Placebo Comparator|sham comparator|"Age > 50 years.~Major depressive disorder (MDD).~Right handiness~with a score ≥ 12 on the Beck Scale of Suicidal Ideation (BSSI) and a score of at least 3 on Question #3 (Suicide: 3 ideas and gestures of suicide) of the HAMD"
89528075|NCT03439917|Experimental|Carnitine and Meal Replacement Drink|2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
89528076|NCT03439917|Placebo Comparator|Placebo and Meal Replacement Drink|2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.
89528077|NCT05064891||Stroke patients|
89528078|NCT05064891||Participants without stroke|
89528079|NCT05064189|No Intervention|Group 1|15 patients will be included in group 1 (no additional treatment)
89528080|NCT05064189|Experimental|Group 2|15 patients will be in group 2 (treatment directly after cataract surgery in the surgical theatre)
89528081|NCT05064189|Experimental|Group 3|15 patients will receive treatment after local anaesthesia (pre-operatively) and directly after cataract surgery (group 3)
89528082|NCT05064033|Experimental|GROUP A|Pragmatic Set of intervention and posterior capsular stretch
89528083|NCT05064033|Active Comparator|GROUP B|Pragmatic Set of intervention and Sleeper Stretch
89528084|NCT05058183|Experimental|All participants|All participants
89528085|NCT05063799|Experimental|a case included pulmonary rehabilitation program|
89528086|NCT03099993|Other|A: Healthy volunteers|
89528087|NCT03099993|Other|B: Patient with heamiplegia|
89528088|NCT03099993|Other|C: Patient with heamiplegia and constraint induced therapy|arm with constraint induced therapy (done before the protocol)
89528089|NCT02725411|Active Comparator|Celecoxib|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
89528090|NCT02725411|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
89528091|NCT02725411|Experimental|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
89528092|NCT02435511|No Intervention|Control arm|The control group will receive usual care, no HealtheRx.
89528093|NCT02435511|Experimental|Intervention arm|The intervention arm will receive the intervention, a HealtheRx, which includes a list of resources in their community tailored to their health needs.
89528094|NCT05058105|Experimental|FL058 500mg and Meropenem 1000mg|"FL058 500mg and Meropenem 1000mg (8 subjects);~FL058 Placebo and Meropenem 1000mg(2 subjects)"
89528095|NCT05058105|Experimental|FL058 1000mg and Meropenem 1000mg|"D1~FL058 1000mg(8 subjects) and FL058 Placebo(2 subjects);~D4~Meropenem 1000mg(8 subjects) and Meropenem Placebo(2 subjects);~D7~ D15~FL058 1000mg and Meropenem 1000mg (8 subjects);~FL058 Placebo and Meropenem 1000mg(2 subjects)"
89528096|NCT05058105|Experimental|FL058 1000mg and Meropenem 2000mg (IV 120min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
89528097|NCT05058105|Experimental|FL058 1000mg and Meropenem 2000mg (IV 180min)|"FL058 1000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
89528098|NCT05058105|Experimental|FL058 2000mg and Meropenem 2000mg|"FL058 2000mg and Meropenem 2000mg (8 subjects);~FL058 Placebo and Meropenem 2000mg(2 subjects)"
89528099|NCT05058027|Active Comparator|GUARDIX-SG®|Treat GUARDIX-SG 6g prefilled syringe after surgery
89528100|NCT05058027|Experimental|Medicurtain®|Treat Medicurtain® 5ml prefilled syringe after surgery
89528101|NCT05063409|Active Comparator|1:1 Ratio of FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:1 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
89528102|NCT05063409|Active Comparator|1:4 Ratio FFP to PRBC|Randomized treatment to receive blood products at a ratio of 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
89528103|NCT05046405|Experimental|home-based remotely supervised tDCS|The intervention combines home-based tDCS (1 or 2 cycles of 15 daily sessions for 3 weeks/cycle at 2 mA for 30 minutes) with tele-health for remote supervision and e-health for self-monitoring of depressive symptoms.
89528104|NCT02477917|Experimental|Allergovac depot|Allergovac depot with Parietaria judaica pollen extract
89528105|NCT05063253|Experimental|TG103, 15 mg|TG103 (15 mg) will be administered via subcutaneous injection once weekly.
89528106|NCT05063253|Experimental|TG103, 22.5 mg|TG103 (22.5 mg) will be administered via subcutaneous injection once weekly.
89528107|NCT05063253|Experimental|TG103, 30 mg|TG103 (30 mg) will be administered via subcutaneous injection once weekly.
89528108|NCT05063253|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection once weekly.
89528109|NCT02477761|No Intervention|Water preload|"During the Water preload study, each subject consume 500 ml of water 30 minutes before a 75 g glucose ingestion"
89528110|NCT02477761|Experimental|Nutrient preload|"During the Nutrient preload study, each subject consume a small mixed meal 30 minutes before a 75 g glucose ingestion. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
89528111|NCT05062941|Active Comparator|Control group|Conventional therapy (CT) was applied to all participants. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS) in conventional mode, 5 minutes of ultrasound (1.5 W/cm2, 1 MHz), 20 minutes of interference current with vacuum electrodes (80 Hz pulse frequency, 1/1 rectangular spectrum), and exercises (all exercises were applied as 1 set of 10 repetitions in each direction: Codman exercises (3-directions), wand exercises (4-directions), exercises using the shoulder wheel (2-directions), exercises with exercise band (5-directions), exercises on the finger ladder (1 set of 10 repetitions in both directions); and shoulder capsule stretching exercises performed (1 set of 12 repetitions) by asking the subjects to wait 20 seconds where the tension was felt).
89528112|NCT05062941|Active Comparator|Study group|"Same conventional therapy (CT) that was applied to control group was also applied to all participants in this group. CT included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS), 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and the same exercises.~In addition to the CT program, only study group has received HILT (BTL 6000, BTL Industries, Inc., USA) application to the shoulder area (analgesic mode, 25 Hz,10 W, 12 j/cm2) for 2 minutes."
89528113|NCT05057325|Experimental|Wave One Gold|Receporcating single file used for preparation of root canals in primary molars
89528114|NCT05057325|Experimental|One shape|Rotation single file used for preparation of root canals in primary molars
89528115|NCT05045781|Experimental|Eptinezumab 100 mg|
89528116|NCT05045781|Experimental|Eptinezumab 300 mg|
89528117|NCT02472067|No Intervention|Physical Therapy|Usual care of physical therapy and rehabilitation for a musculoskeletal injury. Patients complete self-rated standardized surveys before and following treatment.
89528118|NCT02472067|Experimental|Psychologically-Based Physical Therapy|Psychologically-Based Physical Therapy includes the early identification and management of psychological obstacles to recovery in order to modify maladaptive responses previously found to be associated with chronicity and disability. This is accomplished through patient education, an emphasis on functional goals and encouraging self-care techniques. Patients complete self-rated standardized surveys before and following treatment.
89528119|NCT05045859|Experimental|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning.
89528120|NCT05045859|No Intervention|No Intervention: Wait- List Controls (WL)|Patients in wait- list control arm received no active treatment during their 15-weeks waiting period. At the end of that period received the exact intervention as the study group.
89528121|NCT02471989|Experimental|Low-FODMAP diet|FOS in diet
89528122|NCT02471989|Active Comparator|Classical GERD diet|avoid fatty meals, head of bed elevation...
89528123|NCT05046015|No Intervention|non diabetic|Control Group of 20 non-diabetics. Skin measurements, evaluation of skin dryness and sampling of skin particles will be performed
89528124|NCT05046015|Experimental|moderate dryness-diabetic|"Experimental: Diabetics with moderate dryness. Intervention Group of 20 diabetics with moderate dryness~10% Urea foot lotion During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
89528125|NCT05046015|Experimental|severe dryness- diabetic|"Intervention Group of 20 diabetics with severe dryness 10% Urea foot ointment During the course of the study participants cleanse their feet once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® Fuss Salbe 10% Urea on both feet once daily in the evening by themselves."
89528126|NCT04652557|Experimental|Fampridine SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 82 days depending on the individual scheduling of each subject."
89528127|NCT04652557|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
89528128|NCT05062551|Experimental|intervetion group|50 patients complained of post-menstrual bleeding with confirmed presence of isthmocele. After written consent, the patient will be subjected to three steps hysteroscopic resection of an isthmocele by removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
89528129|NCT05185297|No Intervention|Standard care|Participants will continue with standard care provided by the family physician.
89528130|NCT05185297|Experimental|Recreational Futsal, plus standard care|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
89528131|NCT05045469|Active Comparator|group A (dian dao san group)|Herbal medicine (dian dao san) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
89528132|NCT05045469|Placebo Comparator|group B( topical medicine without therapeutic effects)|Placebo (topical medicine without therapeutic effects) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
89528133|NCT03099213|Experimental|Ramipril|Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily.
89528134|NCT02474485|Active Comparator|BVS - Absorb|"BVS - Absorb scaffold group will be treated by implantation of drug eluting bioresorbable vascular scaffold (Absorb®). In this arm following interventions will be performed:~BVS Absorb implantation. For in stent restenosis treatment during index procedure.~OCT visualization.During index procedure and at 9 month follow-up.~Control coronary angiography. Control angiography will be performed at 9 month follow-up.~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
89528135|NCT02474485|Active Comparator|DEB - Sequent Please|"In DEB - Sequent Please Group, dilatation of drug eluting balloon Sequent Please ® will be used for treatment of the narrowed part of the artery. In this arm following interventions will be performed:~DEB Sequent Please inflation. For in stent restenosis treatment during index procedure.~OCT visualization.During index procedure and at 9 month follow-up.~Control coronary angiography. Control angiography will be performed at 9 month follow-up.~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
89528136|NCT05056935|Experimental|LB1148|active
89528137|NCT05056935|Placebo Comparator|Placebo|placebo
89528138|NCT05056701|Experimental|patient with preeclampsia|Patient meeting preeclampsia criteria according to International Society for the Study of Hypertension in Pregnancy (ISSHP) 2018 definitions
89528139|NCT02190604|Experimental|Part 1 Cohort 1: QBW251|Single dose of QBW251 10 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528140|NCT02190604|Experimental|Part 1 Cohort 2: QBW251|Single dose of QBW251 25 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528141|NCT02190604|Experimental|Part 1 Cohort 3: QBW251|Single dose of QBW251 75 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528142|NCT02190604|Experimental|Part 1 Cohort 4: QBW251|Single dose of QBW251 150 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528143|NCT02190604|Experimental|Part 1 Cohort 5: QBW251|Single dose of QBW251 300 mg in healthy volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528144|NCT02190604|Experimental|Part 1 Cohort 6: QBW251|Single dose of QBW251 500 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528145|NCT02190604|Experimental|Part 1 Cohort 6: QBW251(fed)|Single dose of QBW251 500 mg (fed). single dose with food for a preliminary assessment of the effect of food on the absorption of QBW251 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528146|NCT02190604|Experimental|Part 1 Cohort 7: QBW251|Single dose of QBW251 750 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528147|NCT02190604|Experimental|Part 1 Cohort 8: QBW251|Single dose of QBW251 1000 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528148|NCT02190604|Placebo Comparator|Part 1 Placebo|Placebo to QBW251 in all cohorts of part 1 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
89528149|NCT02190604|Experimental|Part 2 Cohort 1: QBW251|Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
89528150|NCT02190604|Experimental|Part 2 Cohort 2: QBW251|Multiple doses of QBW251 400 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
89528151|NCT02190604|Experimental|Part 2 Cohort 3: QBW251|Multiple doses of QBW251 750 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
89528152|NCT02190604|Experimental|Part 2 Cohort 4: QBW251|Multiple doses of QBW251 450 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
89528153|NCT02190604|Experimental|Part 2 Cohort 5: QBW251|Multiple doses of QBW251 750 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
89528154|NCT02190604|Placebo Comparator|Part 2 Placebo|Placebo to QBW251 in all cohorts of part 2 in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
89528155|NCT02190604|Experimental|Part 3 Cohort 1: QBW251|150 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
89528156|NCT02190604|Experimental|Part 3 Cohort 2: QBW251|450 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
89528157|NCT02190604|Experimental|Part 3 Cohort 3: QBW251|450 mg b.i.d. Multiple doses. Patients who are homozygous for the F508del mutation in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
89528158|NCT02190604|Placebo Comparator|Part 3 Placebo|Placebo to QBW251 in all cohorts of part 3 in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
89528159|NCT05062005|Other|Induction Chemotherapy+Chemoradiotherapy|
89528160|NCT05062005|Other|Chemoradiotherapy|
89528161|NCT05061459||Group1:|28 control
89528162|NCT05061459||Group 2:|68 T2DM patients
89528163|NCT05061615||acne vulgaris patients|
89528164|NCT05061225|Experimental|Intervention|Participants invited to the private Facebook group
89528165|NCT05061225|No Intervention|Waiting list|Waiting list. Will be invited to Facebook group after finalising the study and will receive same intervention.
89528166|NCT05061147|Experimental|Max-40279-01 in combination with Azacitidine (AZA)|"This is an open-label Phase Ib/II clinical study. The study will be conducted in two parts:~Part I: Phase Ib dose escalation. Participants receive Max-40279-01 in combination with azacytidine (AZA), with different dose schedules.~Part II: Phase II dose expansion. Participants divide into positive group and negative group according to whether FLT3 gene mutation occurs, approximately 40 people per group.~All participants receive the recommended dose for Part 2 of Max-40279-01 with azacytidine (AZA)."
89528167|NCT04434651|Experimental|Block group (A)|"26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed using 2 % lidocaine before induction of anesthesia.~The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes."
89528168|NCT04434651|Sham Comparator|control sham group (B)|26 patients who will be subjected to a neurosurgical intervention for removal of supratentorial brain tumor. Supratentorial brain tumors with shift of the mid-line <10 mm evaluated by CT scan [computerized tomography] . SPGB will be performed using normal saline.The anesthesia induced by IV anesthetics and maintained by Isoflurane. ICP, Jugular venous bulb oxygen saturation, and AVDO2 will be assessed every 20 minutes
89528169|NCT02127970|Experimental|Single-Dose Dalbavancin|Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
89528170|NCT02127970|Experimental|Two-Dose Dalbavancin|Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
89528171|NCT03097887|Active Comparator|Anti-reflux sutures|Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device. Biliary reflux measured using Bilitec 2000™.
89528172|NCT03097887|Active Comparator|No anti-reflux sutures|Omega Loop Gastric Bypass without anti-reflux sutures. Biliary reflux measured using Bilitec 2000™.
89528173|NCT02474251|Active Comparator|Group A|25 cognitively normal elderly subjects (age 55-75), newly enrolled or currently participating in R01HL118624-01 (IRB S12-03068), a 2-year longitudinal on-going study that is aimed at examining the longitudinal associations between SDB and cognitive decline in the elderly.
89528174|NCT02474251|Active Comparator|Group B|20 cognitively normal adults (age 30-75) with severe SDB (Apnea Hypopnea index [AHI]-all >30/hour) and good CPAP compliance from Mt. Sinai School of Medicnie (MSSM)
89528175|NCT05056389|Experimental|NIPEX-OXA arm|20 patients treated with NIPEC-OXA after CRS and HIPEC.
89528176|NCT02473861|Experimental|Immediate exercise arm|The length of the intervention for the immediate exercise group will be determined by treatment protocol and could range from 8 to 13 weeks. The intervention can begin up to one week before the first treatment and will continue until 2 weeks after the final taxane-containing treatment. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
89528177|NCT02473861|Experimental|delayed exercise arm|The delayed exercise group will begin an exercise intervention two weeks after completion of their last taxane-containing chemotherapy treatment that will last the length of their taxane chemotherapy plus two weeks. If participants in the delayed exercise group have a surgery planned during the intervention time that will require >1 week off from exercise, the exercise intervention will be delayed until after the surgery. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
89528178|NCT02548299|Experimental|Cooking Lecture|Participants in this arm will receive cooking education through lecture/PowerPoint presentation led by our executive chef. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
89528179|NCT02548299|Experimental|Cooking Demo|Participants in this arm will receive cooking education through observation of our executive chef who will explain cooking techniques and healthy food preparation practices as he cooks a healthy recipe(s) for participants to sample. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
88807351|NCT05190198|Active Comparator|Conventional therapy group|"The control group will receive Traditional physical therapy exercises.~Active range of motion exercises for ankle and subtalar joints for 5 minutes.~Functional balance training for 15 minutes involving~Gait training for 10 minutes."
88814481|NCT04357028|Experimental|MMR vaccine|0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm
89528180|NCT02548299|Experimental|Hands-on Cooking|Participants in this arm will receive cooking education through hands on practical experience with our executive chef in a teaching kitchen. Participants will be able to sample what they prepare. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
89528181|NCT04759612|Experimental|Self-Action Observation (s-AO Group)|Participants will watch their own actions during an upper extremity functionality test.
89528182|NCT04759612|Experimental|Action Observation (AO Group)|Participants will watch another person's actions during an upper extremity functionality test.
89528183|NCT02471677|Active Comparator|Puregon|Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles
89528184|NCT02471677|Experimental|Elonva|Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)
89528185|NCT04755634|Experimental|Single Arm|This is a prospective, single-arm, single-center study
89528186|NCT03097809||Epilepsy Subjects|Subjects will be recruited from the epilepsy-monitoring unit. These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
89528187|NCT02471599|Experimental|tonsillectomy group|The case group will receive tonsillectomy.
89528188|NCT02471599|Active Comparator|non-tonsillectomy group|The controlled group will not receive tonsillectomy.
89528189|NCT05060757|Experimental|colonoscopy|Participants will be patients undergoing colonoscopy
89528190|NCT05405179|Experimental|Simultaneous dental implantation|To perform dental implantation simultaneously in free vascularized flap during jaw reconstruction
89528191|NCT03099135|Other|Odalasvir and AL-335 With or Without Simeprevir|Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.
89528192|NCT05055687|Experimental|Part A：FL058|a single ascending dose (SAD) of intravenous (IV) FL058(2500mg~3000mg)
89528193|NCT05055687|Placebo Comparator|Part A：Placebo|FL058 Placebo
89528194|NCT05055687|Experimental|Part B：FL058|a multiple ascending dose (MAD) of intravenous (IV) FL058(500mg~2000mg)
89528195|NCT05055687|Placebo Comparator|Part B：Placebo|FL058 Placebo
89528196|NCT02473939|Experimental|VR942 Dose 1|VR942 Dose 1
89528197|NCT02473939|Experimental|VR942 Dose 2|VR942 Dose 2
89528198|NCT02473939|Experimental|VR942 Dose 3|VR942 Dose 3
89528199|NCT02473939|Experimental|VR942 Dose 4|VR942 Dose 4
89528200|NCT02473939|Experimental|VR942 Dose 5|VR942 Dose 5
89528201|NCT03097419|Experimental|Intervention|Remote post-ischemic conditioning
89528202|NCT03097419|No Intervention|Control|Standard medical care by the primary treatment team.
89528203|NCT02477449|Experimental|low dose group|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
89528204|NCT02477449|Experimental|mid dose group|12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
89528205|NCT02477449|Experimental|high dose group|12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
89528206|NCT04470843|Active Comparator|Acetazolamide|Group 1 (acetazolamide): Patients undergoing RALP with the peri-operative use of one-time 250 mg dose of acetazolamide
89528207|NCT04470843|Placebo Comparator|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
89528208|NCT03097263||Patients|Patients included for rehabilitation program
89528209|NCT05161741|Experimental|Uncontrolled diabetes requiring Insulin|
89528210|NCT05036889|Experimental|MND|Subject's physician in this group will be using the Mind.Px report as a treatment reference for prescribing the subject's biologic.
89528211|NCT05036889|No Intervention|TAU|Treatment as usual. This group will have the biologic prescribed with results given to the physician at the end of the subject's participation and will not be used as a reference for the subject's treatment.
89528212|NCT02471443||Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
89528213|NCT05044143||Women who remained undelivered after their first episode of threatened preterm labor|Women admitted to the hospital due to their first episode of threatened preterm labor (i.e onset of spontaneous labor < 34 weeks gestation), who did not deliver prematurely as labor stopped (with or without interventions such as tocolysis). Those with a cervical length < 25 mm at the time of hospital discharge are eligible to participate in the study
89528214|NCT02477371|Experimental|Fractional flow reserve-guided CABG|Patients are randomized to an FFR-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan form the heart team meeting are changed by the study investigator according to the FFR-measurements and randomization, so that coronary arteries with FFR ≤ 0,8 receive grafting and coronary arteries with FFR > 0,8 are deferred.
89530592|NCT03397589|No Intervention|Wait-list Control Arm|This arm will receive usual care. After completion of the final data collection at one year, participants and sites allotted to this arm will be offered CHW services.
88812185|NCT05945446||Placenta accreta spectrum pregnancies (study group)|34-36 weeks of gestation. Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.
89528215|NCT02477371|Active Comparator|Angiography-guided CABG|Patients are randomized to an angiography-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan are based on the coronary angiography.
89528216|NCT02477293|Experimental|Hyeonggaeyeongyo-tang|
89528217|NCT05055219||Group 1: Overweight or Obese Group (visits #1-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight. Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
89528218|NCT05055219||Group 2: Overweight or Obese Group (visits #3-4)|Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight, or children and young adults who previously participated in the study (completed visits #1-2 in previous study phase). Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
89528219|NCT05055219||Group 3: Normal Weight Control Group|Children and adolescents who are 8 to 17 years of age, who have do not have risk factors for diabetes such as being overweight or a history of type 2 diabetes in the family. Healthy weight, as defined by a BMI ≥ 5th percentile & < 85th percentile. Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
89528220|NCT02473627|Experimental|Period 1|Period 1 Day 1: single oral dose of 2.5 mg midazolam hydrochloride Day 2: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion
89528221|NCT02473627|Experimental|Period 2|"Period 2 Days 1 through 12 repeated doses of 400 mg DS-1971a administered orally bid .~On the days listed below, each probe substrate(s) will be coadministered with the morning dose of DS 1971a:~Day 8: single oral dose of 2.5 mg midazolam hydrochloride Day 9: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion"
89528222|NCT02477137|Experimental|Intervention group|In combination with usual care according to the routines at the clinic, patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
89528223|NCT02477137|No Intervention|Control group|Usual care according to the routines at the clinic.
89528224|NCT03095703|Experimental|Sirolimus|All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.
89528225|NCT05035953|Experimental|Edaravone|Edaravone Dexborneol injection
89528226|NCT05035953|Placebo Comparator|Placebo|Edaravone Dexborneol matching injection
89528227|NCT05583487|Active Comparator|Control/non-experimental group|The control/nonexperimental group will consist of multidisciplinary teams, who will not be given the nurse-led protocol and will be asked to mobilize the assigned ventilated neurosurgery patient according the facility's standard mobility procedures.
89528228|NCT05583487|Experimental|Experimental/interventional group|The experimental/interventional group will consist of multidisciplinary teams who will use a given nurse-led protocol (intervention) to mobilize the assigned patient.
89528229|NCT02477059|Experimental|tocilizumab|2 infusions four weeks apart
89528230|NCT02477059|Placebo Comparator|saline solution|2 infusions four weeks apart
89528231|NCT05036031||EASL-CLIF ACLF patients|
89528232|NCT05036031||APASL ACLF patients|
89528233|NCT05036031||Non-ACLF patients|
89528234|NCT02471209||Biliary Atresia Infants|Twenty-five infants diagnosed with Biliary Atresia and undergoing surgery were included in the study (age range 1-3 months). Inclusion criteria were persistent yellow skin or sclera, pale stool (in severe cases, clay-like), and hepatomegaly; increased serum bilirubin (progressively or no decline after increase), increased total bilirubin (TBil) dominated by increased direct bilirubin (DBil) (>60%); elevated liver enzymes; ultrasound confirmation of poor gallbladder filling and signs of liver fibrosis; with radionuclide imaging confirmation of obstructed biliary excretion. Infants were excluded if they had concomitant cardiovascular or abdominal organ malformations.
89528235|NCT02470819|Experimental|Targeted Therapy|Those who will receive targeted therapy based on their genetic profiling
89528236|NCT02471131|Experimental|WATCHMAN Implantation|
89528237|NCT02473705|Active Comparator|Fish Oil and Bicarbonate placebo|1280mg of fish oil per day and bicarbonate placebo
89528238|NCT02473705|Active Comparator|Fish Oil Placebo and Bicarbonate|fish oil placebo and 1mg of bicarbonate per Kg of body weight per day
89528239|NCT02473705|Experimental|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
89528240|NCT02473705|Placebo Comparator|Fish Oil placebo and Bicarbonate placebo|Fish oil placebo and Bicarbonate placebo
89528241|NCT02473237|Experimental|indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once time on visit one, with dry powder inhaler device.
89528242|NCT02473237|Active Comparator|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once time a Day, with dry powder inhaler device.
89528243|NCT04347811|Experimental|Death Cafe Arm|Participants undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
89528244|NCT04347811|No Intervention|Control Arm|Participants do not undergo biweekly Death Café sessions hosted by a trained psychotherapist for 3 months.
89528245|NCT02473159|Experimental|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
89528246|NCT02473081|Experimental|Minimal Psychological Intervention|Participants allocated to this group not only received the usual care as given by their family physicians, but also accepted biweekly minimal psychological intervention via telephone during six weeks.
89528247|NCT02473081|Other|Usual care|Participants in this group received usual care only.
89528248|NCT04273243||Subjects who received AT-GTX-501 gene transfer|Subjects with CLN6 Batten disease who previously received AT-GTX-501 in the preceding study (Study AT-GTX-501-01).
89532743|NCT05998902|Experimental|Trophic enteral feeding combined with supplemental parenteral nutrition|Patients will receive trophic enteral feeding combined with supplemental parenteral feeding.
89528249|NCT03549871|Experimental|Fitusiran|Cohort A [inhibitor]: participants with severe hemophilia A/B and inhibitory antibodies to coagulation factor VIII (FVIII)/factor IX (FIX) previously received BPA prophylaxis. Cohort B [non-inhibitor]: participants with severe hemophilia A/B without inhibitory antibodies to FVIII/FIX previously received factor prophylaxis. Participants from both cohorts was enrolled into 6-month factor/BPA prophylaxis period and continued their pre-study, regularly scheduled prophylaxis regimen with factor/BPAs. This period could be skipped by subgroup of Cohort A (hemophilia B with inhibitors to FIX and historical annualized bleeding rate [ABR] >=20) that started directly with fitusiran. Post completing factor/BPA prophylaxis period, participants entered 7-month fitusiran treatment period (1-month onset+6-month efficacy) followed by AT follow-up/roll-over into LTE15174 (NCT03754790). Throughout study, participants could receive on-demand treatment for breakthrough BE with factor/BPAs, as appropriate.
89528250|NCT04220125|Experimental|Ketamine Group|Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
89528251|NCT04220125|Active Comparator|MIdazolam Group|Midazolam 0.045 mg/kg administered via intravenous catheter.
89528252|NCT03108547||Sarcoidosis - fatigued|Men and women with sarcoidosis and a score of ≥ 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
89528253|NCT03108547||Sarcoidosis - non-fatigued|Men and women with sarcoidosis and a score of < 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
89528254|NCT03108547||Healthy controls|Hair steroid values of a previously collected normal values study in adults will be used as healthy controls
89528255|NCT03305185|Experimental|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
89528256|NCT03305185|Active Comparator|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
89528257|NCT02472769|Active Comparator|IBP-9414|IBP-9414 Oral Daily
89528258|NCT02472769|Placebo Comparator|Placebo|Sterile water
89528259|NCT04089943|Experimental|Revascularization group|Participants will be randomized to either an endovascular or an open bypass procedure.
89528260|NCT04089943|Other|Control group|Healthy non-PAD participants will be recruited as control group
89528261|NCT02472691|Experimental|Lenalidomide + Aza + DLI|Patients will be included at the time of relapse after first allo-SCT. As standard of care all patients will receive Azacitidine 75 mg/m2/d for 7 days every 28 days for up to 8 cycles and DLIs given after cycle 4, 6 and 8 at a dose of 0.5-1x106CD3/kg (1st DLI), 1-5x106CD3/kg (2nd DLI) and 5-15x106CD3/kg (3rd DLI). As intervention (investigational drug), Lenalidomide will be also started on day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
89528262|NCT03311035|Experimental|Group A|patients undergoing ligation of intersphincteric fistula tract (LIFT technique)
89528263|NCT03311035|Experimental|Group B|patients undergoing Seton method
89528264|NCT02470663|Experimental|Study group|Children recieving DENSITYTM caplets (marketed as Amorphical) 200 mg BID for 12 months
89528265|NCT02470663|Active Comparator|Control group|Children recieving Calcium carbonate 600 mg once daily for 12 months
89528266|NCT00705367|Placebo Comparator|Placebo|
89528267|NCT00705367|Active Comparator|Abatacept, 30 mg/kg|
89528268|NCT00705367|Other|Abatacept, 10 mg/kg|Open-label long-term extension phase
89528269|NCT03310801||LAAO with DAPT|patients with AF who underwent PCI and treated with LAAO(either ACP or Watchman) and DAPT
89528270|NCT03310801||Conventional antithrombotic therapy|patients with AF who underwent PCI and treated with conventional antithrombotic therapy
89528271|NCT03055429|Experimental|Full Scale Unit|Testing of 6 modules
89528272|NCT03043729|Active Comparator|Arm A|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
89528273|NCT03043729|Experimental|Arm B|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
89528274|NCT03310645|Experimental|Dose 1 of BAY1817080|"Study Part 1:~Oral dose 1 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
89528275|NCT03310645|Experimental|Dose 2 of BAY1817080|"Study Part 1:~Oral dose 2 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
89528276|NCT03310645|Experimental|Dose 3 of BAY1817080|"Study Part 1:~Oral dose 3 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
89528277|NCT03310645|Experimental|Dose 4 of BAY1817080|"Study Part 1:~Oral dose 4 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
89528278|NCT03310645|Placebo Comparator|Placebo|"Study Part 1:~Oral dose of matching placebo twice daily with a loading dose administered three times on Day 1"
89528279|NCT03310645|Experimental|Placebo+BAY1817080|"Study Part 2:~Randomized crossover design in cough patients Placebo+4 different doses of BAY1817080"
89528280|NCT03310645|Experimental|BAY1817080+Placebo|"Study Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1817080+Placebo"
89530593|NCT03243565|Active Comparator|OM-85|OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.
89528281|NCT05306431|Experimental|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant. It is non-corrosive, non-toxic and acts by disrupting cell membrane integrity. PHMB 0.2% has been recently used as a root canal irrigant in vitro and has shown promising results of antimicrobial effectiveness of > 99.9% for both PHMB and Sodium hypochlorite
89528282|NCT05306431|Experimental|Sodium Hypochloride|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter.
89528283|NCT02970955||Inoperable thoracic nodes metastases|Oligometastatic patients with inoperable thoracic nodes metastases from any primary
89528284|NCT03108313|Experimental|aloe vera toothpaste|aloe vera toothpaste isa will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
89528285|NCT03108313|Active Comparator|fluoride toothpaste|fluoride toothpaste isa herbal toothpaste will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
89528286|NCT03108625|Experimental|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
89528287|NCT03310567|Experimental|Epacadostat + pembrolizumab|
89528288|NCT02468791|Experimental|MabionCD20®|A course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
89528289|NCT02468791|Active Comparator|MabThera®|A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
89528290|NCT02470195|Experimental|workshop|workshop of procedural simulation
89528291|NCT02470195|No Intervention|control|no specific workshop of procedural simulation
89528292|NCT02693821|Experimental|Gabapentin|300mg of Gabapentin per day (two doses), orally during 30 days
89528293|NCT02693821|Placebo Comparator|Placebo|300mg of Placebo per day (two doses), orally during 30 days
89528294|NCT02468713|Experimental|Group 1|Combiflex® lipid peri as a reference product (Period 1) -> Winuf® peri as a test product (Period 2)
89528295|NCT02468713|Experimental|Group 2|Winuf® peri as a test product (Period 1) -> Combiflex® lipid peri as a reference product (Period 2)
89528296|NCT02470117|Active Comparator|Alginate-based reflux suppressant|Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks
89528297|NCT02470117|Sham Comparator|magnesium-aluminium antacid gel|magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks
89528298|NCT03310333|Experimental|Cook cervical ripening|the device is introduced by a resident or a doctor. No traction on the probe was done. It is left in place for maximum 12 hours. Oxytocin is added at the end of the first 6 hours even if device is fallen. An epidural analgesia can be started before or after the installation of oxytocin
89528299|NCT03310333|Active Comparator|Dinoprostone vaginal group|"the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.~After 24 hours, it is removed. If they are any contraction, oxytocin is started with or without epidural analgesic."
89528300|NCT03310177||COPD|The smokers who are diagnosed as chronic obstructive pulmonary disease according to GOLD guideline.
89528301|NCT03310177||healthy control|The healthy controls without chronic obstructive pulmonary disease
89528302|NCT00705289||RA Subjects/ Infliximab 3 mg/kg|Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics [SPC] of Remicade®).
89528303|NCT02469805|Active Comparator|stimulated intrauterine insemination (IUI)|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
89528304|NCT02469805|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
89528305|NCT02469805|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
89528306|NCT03310099|Experimental|Dietary Intervention|Dietary intervention aimed at increasing UFA consumption. The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated [MUFA] and polyunsaturated fatty acids [PUFA]), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
89528307|NCT03309865|Experimental|Combined diet and vedolizumab|Intervention: vedolizumab injection (300mg, IV infusions at week 0, 2, 6, 14) and concurrently on structured semi-vegetarian diet; Duration of Therapy: 14 weeks
89528308|NCT02469571|Active Comparator|Probiotic|5 g of Winclove-607 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24 at a concentration of 1.1 x 109 cfu/g twice daily for the 4 weeks
89528309|NCT02469571|Placebo Comparator|Placebo|a similar looking and tasting placebo without bacteria once daily for 4 weeks
89528310|NCT03309709|No Intervention|watch-and-wait patients|patients who receive a watch-and-wait approach
89528311|NCT03309709|Experimental|Progesterone patients|Treatment consists of 7 days of 25 mg subcutaneous progesterone administered from 18° to 25° day of the menstrual cycle and repeated for 3 cycles
89528312|NCT01720147|Experimental|Quercetin - Dietary Supplement|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required) for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
89528313|NCT02469883|Experimental|Sinotecean|
89528314|NCT02468635|Other|without training for upper limb|Receive treatment from traditional pulmonary rehabilitation and without resistive training for upper limb (UL)
89528315|NCT02468635|Other|upper limb exercises|Receive the same treatment control with additional upper limb resistance training.
89528316|NCT02469727|Experimental|Fitbit + Facebook|Participants will use the Fitbit device and join the Facebook group.
89528317|NCT02469727|No Intervention|Usual care control|No intervention provided.
89528318|NCT05190055|Experimental|Minimally invasive spinal fusion surgery|A filler tube with an integrated threaded rod, which can be connected to a surgical drill, was used for rapid and continuous graft filling.
89528319|NCT05190055|Active Comparator|traditional spinal fusion surgery|Bone substitutes were filled in the disc space manually using a bone grafting funnel.
89528320|NCT03304951|Experimental|Synopsis® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
89528321|NCT00806065|Experimental|ENMD-2076|Oral capsules, once daily in 28-day cycles
89528322|NCT03309553|Active Comparator|Current Primary Care Referral Process|In villages randomized to the current primary care process, families will be notified if their children screen positive in exactly the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. The list of referred children is also given to the Norton Sound Audiology Department, who reaches out to families to schedule appointments during the next available audiology clinic.
89528323|NCT03309553|Experimental|Expedited Telemedicine Referral|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
89528324|NCT03304795||Vitamin D deficiency|Serum 25-hydroxyvitamin D level is less than 50 nmol/L.
89528325|NCT03304795||Normal|Serum 25-hydroxyvitamin D level is 50 nmol/L or greater.
89528326|NCT03304561|Experimental|traditional rehabilitation|patients in this groups is going to recieve traditional rehabilitation programme for 3 months after ACL recontsruction
89528327|NCT03304561|Experimental|Cross-over training|patients in this programme is going to recieve isokinetic exercise programme targeting unilvolved limb during rehabilitation. for the first 4 weeks after ACL reconstruction traditional rehabiitation programme is going to applied to the subjects. after 4 weeks, isokinetic strenghtening programme at 60˚/second angular velocity, between 0-90 degree knee flexion until 3 months after ACL reconstructon
89528328|NCT03314077||Standard managed subjects|COPD patients accepted standard COPD management.
89528329|NCT03314077||Controls|COPD patients didn't accepted standard COPD management or quality control, who are from hospital subjects with a retrospective cohort study.
89528330|NCT03304405||Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
89528331|NCT03309319|Experimental|Ros|Rosiglitazone：2 times a day, 4mg each time（4mgBid）
89528332|NCT03304327|Experimental|Mindfullness and Yoga|Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team
89528333|NCT03309241|Experimental|Cohort 1|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
89528334|NCT03309241|Experimental|Cohort 2|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
89528335|NCT03309241|Experimental|Cohort 3 (optional)|Single Ascending Dose administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
89528336|NCT03313921|Experimental|Online Manifest Refraction|All participants will undergo three assessments of refractive error, in random order. All will perform an unsupervised manifest refraction with the use of a computer screen and their smartphone. Next, a regular manifest refraction assessment performed by an optometrist will function as active comparator. An automated refraction assessment will be performed to relate the quality and repeatability of the online refraction to another unsupervised method of refraction assessment.
89528337|NCT02469493|Experimental|Acupuncture 1|In this group, patients separately received twice electroacupuncture at bilateral PC6 acupoint before and after Cisplatin administration on the first day of chemotherapy.
89528338|NCT02469493|Experimental|Acupuncture 2|In this group, patients separately received twice electroacupuncture at bilateral PC6 and RN12 acupoints before and after Cisplatin administration on the first day of chemotherapy.
89528339|NCT02469493|Sham Comparator|Sham acupuncture|In this group, patients separately received twice electroacupuncture at bilateral nonacupuncture point (S1 located at lateral of flexor carpi radialis, 2 cun above the wrist. S2 located at 3 cun right side of RN12) before and after Cisplatin administration on the first day of chemotherapy.
89528340|NCT02469493|No Intervention|Waitinglist control|In this group, patients received no electroacupuncture
89528341|NCT03309163|Active Comparator|Group T|All patients receive the patient-controlled intravenous analgesia with Tramadol.
89528342|NCT03309163|Placebo Comparator|Group H|All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
89528343|NCT03309163|Placebo Comparator|Group E|All patients receive the patient-controlled epidural analgesia with Ropivacaine.
89528344|NCT03309085|Experimental|Single arm|Repeated CT scan
89528345|NCT03308851|Experimental|Piezocorticision and osteoperforation group|All participants in this arm will receive the piezocorticision and osteoperforation procedures on the upper jaw on the left and the right side.
89528346|NCT03308851|No Intervention|Control|The participants in this arm will receive no treatment, but will have the same monitoring as the experimental group.
89528347|NCT03304015|Experimental|Intervention: Behavioral Change Communications|
89528348|NCT03304015|No Intervention|Control: No intervention|
89528349|NCT03174847||Medical Treatment|Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
89528350|NCT03174847||Surgical Treatment|Patients with unilateral PA who underwent adrenalectomy
89528351|NCT03313765|Experimental|Intervention|
89528352|NCT03313765|Active Comparator|Standard-of-care|
89528353|NCT04442035|Experimental|The teatment group|5-element misic therapy
89528354|NCT04442035|Experimental|The control group|health education
89528355|NCT04441723|Active Comparator|lag screw with dynamic mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
89528356|NCT04441723|Active Comparator|lag screw with static mode|Device: Gamma 3 nail whit lag screw on dynamic mode Surgical stabilization of intertrochanteric hip fractures using two different lag screw modes
89528357|NCT04441801|Experimental|15 seconds|Stretching of the hamstring muscles will be performed by the primary researcher. A straight-leg-raising technique will be used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible, each subject's knee will be maintained in extension with the ankle at 90 degrees without medial (internal) or lateral (external) rotation of the lower extremity, and the extremity was raised until the subject reported discomfort. The subject was asked to relax the lower extremity in an effort to prevent contracting muscles from affecting the stretch and to allow for a slow stretch. stretching will continue for 15 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
89528358|NCT04441801|Experimental|30 seconds|the same stretching technique will continue for 30 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
89528359|NCT04441801|Experimental|60 seconds|the same stretching technique will continue for 60 seconds .The patient relaxed for approximately 20s and the procedure was repeated three times.
89528360|NCT04441801|Sham Comparator|control|The control group followed the same procedures except that no stretching force was applied at the end.
89528361|NCT03313531||Study group 1|Patients with severe hemophilia A
89528362|NCT03313531||Study group 2|Healthy volunteers
89528363|NCT03313531||Study group 3|Healthy volunteers ) that at previous measurements have been shown to have a TGC>2SD of the median of the control population.
89528364|NCT03313531||Treated HA person|One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions
88812186|NCT05945433||Patients undergoing gynecological surgical procedure with the anovo Surgical System|
89528365|NCT03308539||myocardial infarction patients|transthoracic echocardiography and cardiac magnetic resonance
89528366|NCT03313453|Experimental|Aircleaner group|PuriCare (HEPA Air Cleaner) in active mode
89528367|NCT03313453|Placebo Comparator|Control comparator|Mock device of PuriCare in active mode
89528368|NCT03303781||BE + CR|Belgian ischemic heart disease patients with cardiac rehabilitation program
89528369|NCT03303781||BE-CR|Belgian ischemic heart disease patients without cardiac rehabilitation program
89528370|NCT03303781||Si + CR|Singapore (Asian) ischemic heart disease patients with cardiac rehabilitation program
89528371|NCT03303781||SI -CR|Singapore (Asian) ischemic heart disease patients without cardiac rehabilitation program
89528372|NCT03308461|Experimental|Fecal microbiota transplantation (FMT)|Patients underwent single FMT in this studyAll patients were assessed before FMT and during 12-week follow-up after FMT.
89528373|NCT05067907||Control|COVID-19 ICU-admitted patients that did not received physiotherapy interventions during ICU stay.
89528374|NCT05067907||Physiotherapy|COVID-19 ICU-admitted patients that received physiotherapy interventions during ICU stay.
89528375|NCT03313375|No Intervention|Control|Subjects will have no intervention. They will be resting in a chair for the entire length of the visit (4-5 hours) where blood pressure will be taken every 10 min, while other non-invasive cardiac measures are taken (I.E. Cardiac output, systemic vascular resistance, heart rate variability).
89528376|NCT03313375|Active Comparator|Continuous exercise|Subjects will be asked to perform a 45 min exercise bout. After a warmup, the exercise will be 30 minutes at a continuous level. After the exercise period subject will remain in the lab and blood pressure will be measured every 10 minutes for the remainder of the visit (4 hours) while other non-invasive cardiac measures are taken continuously as discussed above.
89528377|NCT03313375|Experimental|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. After a warmup period, the subjects will complete a 4x4 protocol in that they will alternate 4, 4 minute higher intensity exercise bouts with 3, 3 minute lower intensity bouts. After the exercise, subjects will remain in the lab and blood pressure will be measured every 10 minutes for 4 hours, while other non-invasive cardiac measures are taken continuously as discussed above.
89528378|NCT03308383|Experimental|TRANSTHORACIC ECHOCARDIOGRAM|Individuals who visit pre-anaesthetic check up (PAC) clinic for minor surgery which includes plastic, rhino-otolaryngeal, ophthalmologic, orthopaedic, abdominal, urological, gynaecological surgeries, who are free of cardiac disease or any known risk factors for the cardiac disease like chronic alcoholism, chronic smoking, metabolic syndrome, morbid obesity
89528379|NCT05289973|Experimental|TruNatomy Files|Newly introduced endodontic file
89528380|NCT05289973|Experimental|Hyflex EDM|Endodontic file
89528381|NCT03303703|No Intervention|Control|Usual cardiac rehabilitation and social phone calls for attention control.
89528382|NCT03303703|Experimental|Intervention|RENEwS intervention is five 60-minute group educational sessions.
89528383|NCT03308227||Experimental Group|septic shock patients;
89528384|NCT03308227||Conrol Group|non-septic shock patients;
89528385|NCT02468167|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
89528386|NCT02468167|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
89528387|NCT03313297|Active Comparator|AZD4017|400mg oral AZD4017 twice daily for 35 days
89528388|NCT03313297|Placebo Comparator|Placebo|A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate to match the active tablets in size, shape and colour.
89528389|NCT03308071|Experimental|Hypnosis Group|Participants will undergo a brief hypnotic assessment, a single hypnosis session with an MD trained in hypnosis, and be given a phone number to listen to a guided self-hypnosis recording for 1 week pre-op until 2 weeks post-op.
89528390|NCT03308071|No Intervention|Usual care|These patients will be enrolled in the study and usual care will be provided.
89528391|NCT03313219|Experimental|Gentuximab Injection|Patients are assigned to a dose level at the time of study entry and scheduled to receive i.v. of a single dose. The patient enter the subsequent multiple dose i.v. in a 7-day cycle if no DLT in 21 days after the first dose. The study period of each subject will be up to 4 cycles until the tumor progression or unacceptable toxicity. The MTD will be determined by assessing DLT in each cohort from cohort 1 to 6, using a 3+3 dose escalation model. Cohort A begin at 4mg/kg IV and the dose escalated in separate cohorts from 8mg/kg IV, 12mg/kg IV，16mg/kg IV and 20mg/kg IV. If there is no DLT observe in any of these 3 patients in 7 weeks, then the trial proceeds to enroll 3 patients into the next higher dose cohort. If one subject develops a DLT at a specific cohort, an additional 3 patients are enrolled into that same dose cohort. Development of DLTs in more than 1 of 6 patients in a specific dose cohort suggests that the MTD has been exceeded, and further dose escalation is not pursued.
89528392|NCT03303313|Experimental|Cemdisiran|
89528393|NCT03303235|Experimental|IV Methergine|"IV methylergonovine group~-IM 0.9% NaCl (1 ml)) + IV methylergonovine (2 mcg/ml) infusion (100 ml)"
89528394|NCT03303235|Active Comparator|Conventional|"IM methylergonovine group~-200 mcg IM methylergonovine (1 ml) + IV 0.9% NaCl infusion (100 ml)"
89528395|NCT03307993|Experimental|Idalopirdine|"Idalopirdine 60 mg once daily for 10 day (up to 14 days possible), adjunct to donezepil (patients individualized maintenance dose)~If high receptor occupancy cannot be verified, the receptor occupancy following a higher dose (up to 60 mg twice daily for 10-14 days) will be assessed in Cohort 2."
89528396|NCT04442113|Active Comparator|Control group|Pulmonary vein isolation alone (by catheter ablation)
89528397|NCT04442113|Experimental|STAR guided ablation group|Pulmonary vein isolation plus ablation guided by STAR MappingTM
89528398|NCT05127499|Experimental|Experimental:|will do progressive relaxation exercises
89528399|NCT05127499|No Intervention|No Intervention|won't do progressive relaxation exercises
89528400|NCT03303001|Experimental|Subacromial high volume infiltration|This group received an subacromial infiltration guided by ultrasound, of 50 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 8 mL of lidocaine simple plus 10 mL of ropivacaine 7.5% plus 30 mL of saline solution.
89528401|NCT03303001|Active Comparator|Subacromial conventional infiltration|This group received an subacromial infiltration guided by ultrasound of 10 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 3 mL of lidocaine simple plus 5 mL of ropivacaine 7.5%
89528402|NCT03302923|Experimental|Brisk walking 1|1 time a week of 9 months brisk walking
89528403|NCT03302923|Experimental|Brisk walking 3|3 times a week of 9 months brisk walking
89528404|NCT03302923|No Intervention|Control group|No brisk walking session
89528405|NCT04490629|Other|DURAFORM|DURAFORM was used in repairing cerebral dura mater.
89528406|NCT04490629|Experimental|Lyoplant Onlay|Lyoplant Onlay was used in repairing cerebral dura mater.
89528407|NCT03302845|Experimental|Omeprazole|Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
89528408|NCT03302845|Experimental|Famotidine|Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
89528409|NCT03313141|Experimental|Subjects|Only one arm is considered
89528410|NCT03313063||PE|Women with a history or preeclampsia, between 18 - 50 years of age, 0.5 - 20 years postpartum
89528411|NCT03313063||Control|Age-matched women without any birth complications, between 18 - 50 years of age, 0.5 - 20 years postpartum
89528412|NCT03312985|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
89528413|NCT03312985|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
89528414|NCT03302689|Experimental|Ropivacaine|TAP-block with Ropivacaine Solution
89528415|NCT03302689|Experimental|Levobupivacaine|TAP-block with Levobupivacaine Solution
89528416|NCT03108235|Experimental|Intervention group A|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP)
89528417|NCT03108235|Experimental|Intervention group B|HOM-HEMP with the smartphone app.
89528418|NCT03108235|Active Comparator|control group|Participants will receive the standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
89528419|NCT03307681|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
89528420|NCT03307681|Experimental|Baked potato with skin|Baked russet potato
89528421|NCT03307681|Experimental|Mashed potato served hot|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
89528422|NCT03307681|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
89528423|NCT03307681|Experimental|Meal skipping|No food given
89528424|NCT03307603|Experimental|Yttrium-90 + Nivolumab|240 mg Nivolumab intravenously, beginning at 2 weeks after Yttrium-90 treatment and given every 2 weeks until progression or toxicity. Additional dose at 2 weeks prior to Y-90 will be given if the first 3 patients do not have toxicity. If any of the first 3 patients have toxicity, the schedule can be relaxed to begin 3 weeks after Y-90 treatment.
89528425|NCT03302533||Primary arthroplasty|All patients who received TEA for an acute trauma with fracture of the distal humerus.
89528426|NCT03302533||Secondary arthroplasty|All patients who received TEA due to a failed reconstruction or non-operative treatment after a distal humerus fracture.
89528427|NCT00703963|Active Comparator|Usual Care|Subjects will be having their INR tested by their Primary Care Provider as often as their Care Provider dictates. This study phase is twelve weeks long beginning at the day of discharge from our hospital.
89528428|NCT00703963|Active Comparator|Patient Self Testing|Subjects will be testing their INR at home using an FDA approved device (INRatio monitor by Hemosense) reporting their results to Quality Assured Services (QAS) via an 800 phone number; their Primary Care Provider will receive a fax with the INR result. We ask this group of patients to test at minimum one time a week, additional testing as requested by their Primary Care Provider. This phase lasts twelve weeks, beginning on the day of discharge from our hospital.
89528429|NCT02468323|Placebo Comparator|Placebo group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of saline 0,9%.
89528430|NCT02468323|Experimental|Ondansetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of ondansetron after cord clamping.
89528431|NCT02468323|Experimental|Palonosetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of palonosetron after cord clamping.
89528432|NCT03307447|Experimental|Treatment arm|Cosentyx (Secukinumab) 300 mg subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks until 16 weeks
89528433|NCT03312673||Asthma population|Patients (men and women) asthmatic smokers and non-smokers followed routinely in the pulmonology department, Croix-Rousse Hospital, Hospices Civils of Lyon.
89528434|NCT02469259|Experimental|Treatment|Subjects will receive either 20IU or 40IU intranasal oxytocin
89528435|NCT02469259|Placebo Comparator|Placebo|Subjects will receive intranasal saline spray
89528436|NCT03302455|Experimental|eCBTI|This group will receive a 1-week of eCBTI treatment and will receive 3 months of follow-up.
89528437|NCT03302455|No Intervention|Control|This group does not receive any interventions during first 3 months of clinical study. If the participants still have no remission from insomnia after 3 months, will be recommended to enter the standardized insomnia treatment (medication and / or non-drug treatment).
89528438|NCT02467933|Placebo Comparator|Placebo|The placebo arm receives a placebo letter unrelated to Seroquel
89528439|NCT02467933|Experimental|Informative Letter|The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.
89528440|NCT03302377|Experimental|Physical activity intervention|Participants will receive an individual counseling session in the clinic to help them set physical activity and step goals. They will then receive a Fitbit wrist monitor and help personalizing the Fitbit app. They will send weekly emails to their physicians reporting their goals and current activity. They will return at 12 weeks to engage in a semi-structured interview to give their overall impressions of the intervention.
89528441|NCT03307213|Experimental|BioFreedom™CoCr|Patients with CAD will receive the BioFreedom™CoCr stent if randomised to this arm.
89528442|NCT03307213|Active Comparator|BioFreedom™ SS|Patients with CAD will receive the BioFreedom™SS stent if randomised to this arm.
89528443|NCT03302221|Other|Group control|In the control group, local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
89528444|NCT03302221|Experimental|Paravertebral Block Group|In Group Paravertebral Block, patients received standardized general anaesthesia supplemented by paravertebral Block. The USG approach for TPVB was used with the patient in the lateral position at the T4-T6 level according to the incision protocol in our centre.
89528445|NCT03302221|Experimental|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
89528446|NCT02469337|Active Comparator|Preoperative carbohydrate drinks|Patients who were randomised to carbohydrate group ingested 800ml PreOp (Nutricia Clinical Care, 12.5g CHO/100 ml) the night before and 400ml in the morning of surgery, about 2-3 hours before the induction of anaesthesia.
89528447|NCT02469337|Active Comparator|Dichloroacetate infusion|The patients in the dichloroacetate group received the CHO drinks as well as an intravenous infusion of DCA (50mg/kg body weight) over 45 min, one- two hours before the induction of anaesthesia.
89528448|NCT02469337|Active Comparator|Moderate intensity exercise|Patients randomised to exercise group, will perform a 30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate(determined by the formula: (220-Age)*0.7 under close supervision and monitoring of their vital parameters.
89528449|NCT02469337|No Intervention|Control|Patients in this group will have surgery as standard practice with none of the above interventions
89528450|NCT03307135|Experimental|Simple Assessment group|Intervention is a single evaluation with the MSPMI by two evaluators.
89528451|NCT03307135|Experimental|Hospitalization group|Evaluation with the MSPMI by two evaluators on two consultations separate by a 7 days interval.
89528452|NCT03307135|Experimental|Treatment group|Evaluation with the MSPMI by two evaluators before and after specific therapies proposed on our usual practices (Selective tibial neurotomy, anesthetic block or botulinum toxin intramuscular injection).
89528453|NCT02469181||FD(Fabry disease) group|28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).
89528454|NCT03306823||aneurysm|For cerebral aneurysm with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
89528455|NCT03306823||arteriovenous malformations|For arteriovenous malformations with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
89528456|NCT02469103|Experimental|C2 & colonoscopy|C2 and colonoscopy
89528457|NCT03312439|Active Comparator|Intervention group|Will be given advice as described above
89528458|NCT03312439|No Intervention|Control group|Consisting of subjects from the general Swedish population.
89528459|NCT03302143|Active Comparator|Control|Guided bone regeneration with Bovine Bone Mineral
89528460|NCT03302143|Experimental|Experimental|Guided bone regeneration with freeze dried bone allograft
89528461|NCT03302065|Experimental|Test Product 1 Tiotropium|4 inhalations
89528462|NCT03302065|Experimental|Test Product 2 Tiotropium|4 inhalations
89528463|NCT03302065|Experimental|Test Product 3 Tiotropium|4 inhalations
89528464|NCT03302065|Active Comparator|Reference Tiotropium|2 inhalations
89528465|NCT03306745|Experimental|Study group|"1 soft capsule/day containing 500mg omega-3 fatty acids~one tablet/day containing 800mg folic acid, 70mg selenium, 30 mg Vitamin E, 4 mg catechin, 12 mg glycyrrhizin, and 30 mg coenzyme Q10"
89528466|NCT03306745|Placebo Comparator|Control group|200µg folic acid - two capsules per day
89528467|NCT03301987|Experimental|Therapeutic exercise|
89528468|NCT02469025|Experimental|Resting position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in a resting position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
89528469|NCT02469025|Experimental|End range position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in an end range position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
89528470|NCT03306667|Experimental|Normal group|Healthy control subjects
89528471|NCT03306667|Experimental|Mild hepatic-insufficient group|Patients with mild hepatic impaired function (Child-Pugh A)
89528472|NCT03306667|Experimental|Moderate hepatic-insufficient group|Patients with moderate hepatic impaired function (Child-Pugh B)
89528473|NCT03306667|Experimental|Severe hepatic-insufficient group|Patients with severe hepatic impaired function (Child-Pugh C)
89528474|NCT03312361|Experimental|15% Oxygen|All participants will breath in 15% oxygen for 2 hours
89528475|NCT03306511||Case|Football players with a previous self-reported hamstring strain injury in the preceding 12 months
89528476|NCT03306511||Control|Football players without a previous self-reported hamstring strain injury in the preceding 12 months
89528477|NCT03312283|Experimental|QL1205|QL1205 injection (0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
89528478|NCT03312283|Active Comparator|Lucentis|Lucentis® injection(0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
89528479|NCT03312205|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells
89528480|NCT03301597|Other|Control Arm|The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
89528481|NCT03301597|Experimental|Low Dose Arm|The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
89528482|NCT03301597|Experimental|Medium Dose Arm|The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
89528483|NCT03301597|Experimental|High Dose Arm|The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.
89528484|NCT02721355|Experimental|Food supplement GastimunHP|The subjects take food supplement containing specific IgY (GastimunHP) during treatment with routine medical regime
89528485|NCT02721355|No Intervention|Control|The subjects undergo the routine treatment regime without taking food supplement
89528486|NCT03312127|Experimental|GORE Excluder|GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'
89528487|NCT02468401|Experimental|Coronary angiography|Patients undergoing coronary angio with or without percutaneous coronary intervention using a new protocol designed to minimize the exposure to contrast medium
89528488|NCT03301285||Children with osteoporosis associated to multiple disabilities|Treated with zoledronic acid
89528489|NCT04491565|No Intervention|standard education|
89528490|NCT04491565|Active Comparator|educational video|
89528491|NCT03249493||HIV Injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
89528492|NCT03249493||HIV Non injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
89528493|NCT02467855||Cross-Sectional Cohort|Participants receiving standard of care for hypertension with well-controlled hypertension will participate in 1 visit.
89528494|NCT02467855||Longitudinal Cohort|Participants receiving standard of care for hypertension with history of hypertension who are uncontrolled on the current antihypertensive medications or participants with newly diagnosed hypertension (diagnosed within the past 4 weeks and uncontrolled on antihypertensive therapy) will be observed over the course of 12-16 weeks.
89528495|NCT03301207|Experimental|Ibrutinib + Oral Contraceptives + Probe Drugs (CYP)|Pre-treatment Phase: Participants will receive a single dose of oral contraceptive (OC) consisting of ethinylestradiol (EE) 30 microgram (mcg) and levonorgestrel (LN) 150 mcg on Study Day 1, and probe drugs (CYP) consisting of bupropion 75 milligram (mg) and midazolam 2 mg on Study Day 3, followed by a washout period from Study Days 4 to 7. Treatment Phase: Participants will receive ibrutinib 560 mg (4*140 mg capsules) once daily (QD) on Days 8 to 26 along with midazolam 2 mg once orally on Study Day 8 (Cycle 1 Day 1), OC once orally on Study Day 22 (Cycle 1 Day 15; EE and LN), and bupropion 75 mg and midazolam 2 mg once orally on Study Day 24 (Cycle 1 Day 17). From Study Day 27 (Cycle 1 Day 20) and onwards participants will continue oral treatment with ibrutinib 420 mg (3*140 mg capsules) or 560 mg QD (depending on the subtype of B-cell malignancy) up to the end of Cycle 6 (each cycle will consist of 28 days).
89528496|NCT03301129|Experimental|Traditional cigarette|smoke one Traditional cigarette (with a mean nicotine content of 0.6 mg according to package label) and in a sub-group smoke a sham cigarette (an traditional cigarette without combustion).
89528497|NCT03301129|Experimental|Electronic cigarette|smoke a tobacco-flavored Electronic cigarette (9 puffs approximately equivalent to 0.6 mg of nicotine content) and in a sub-group smoke a sham cigarette (an electronic cigarette without nicotine).
89528498|NCT03301129|Experimental|Heat-not-burn tobacco products (IQOS)|smoke one IQOS cigarette (with a mean nicotine content of 0.6 mg according to package label).
89528499|NCT03311971|Sham Comparator|Conventional therapy|Patient undergoing conventional analgesic therapy after total knee replacement
89528500|NCT03311971|Experimental|Virtual reality glasses|Patient undergoing conventional analgesic therapy after total knee replacement and treated with virtual glasses
89528501|NCT03311893|Active Comparator|health personnel|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
89528502|NCT03311893|Placebo Comparator|population|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
89528503|NCT03305965|Experimental|Patient navigation|
89528504|NCT03305965|No Intervention|Care as usual|
89528505|NCT03311737|Experimental|general anesthesia group|The patients in this group receive general anesthesia preoperatively, and use patient controlled intravenous analgesia postoperatively.
89528506|NCT03311737|Active Comparator|epidural group|The patients in this group receive general anesthesia combined with epidural anesthesia, and use patient controlled epidural analgesia postoperatively.
89528507|NCT03300973|Active Comparator|urodynamics study group|65 patients with stress urinary incontinence were randomly chosen to have urodynamic study before surgery
89528508|NCT03300973|Active Comparator|surgery only group|60 patients with stress urinary incontinence were randomly chosen to have surgery without urodynamics study
89528509|NCT03300895|Experimental|High-intensity interval training|
89528510|NCT03300895|Active Comparator|Moderate-intensity continuous exercise|
89528511|NCT04491019|Experimental|Balance exercise group|Balance exercises will be carried out with a physiotherapist.
89528512|NCT04491019|Experimental|Strengthening exercise group|Strengthening exercises will be performed with a physiotherapist.
89528513|NCT03300661|Experimental|Mediterranean Style|Educational intervention with personalized suggestions to improve diet and physical activity
89528514|NCT03300583||ILD patients|Patients from all types of ILD who are under the care of the two collaborating hospitals.
89528515|NCT03300583||Family/Carers|Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.
89528516|NCT03300583||Clinicians|Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.
89528517|NCT02467543|Placebo Comparator|20% Ethanol|20% ethanol containing no active ingredients. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
89528518|NCT02467543|Experimental|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
89528519|NCT03311581|Experimental|Propofol group|propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
89528520|NCT03311581|Active Comparator|Sevoflurane group|sevoflurane 2~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
89528521|NCT03311425|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
89528522|NCT03311425|Placebo Comparator|IV dexamethasone|Intraoperative systemic (IV) steroid (dexamethasone) only.
89528523|NCT02468089|Experimental|Carbepenem+albumin+GMCSF.|
89528524|NCT02468089|Active Comparator|Carbepenem+albumin|
89528525|NCT03311347|Experimental|100%O2 breathing|Primary aim, item 1
89528526|NCT03311347|Experimental|Air breathing|Primary aim, item 1
89528527|NCT03300349||axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have developed breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme
89528528|NCT03300349||No axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have not develped breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme.
89528529|NCT03300349||Fulfillment of a preventive programme|Patients who fulfil a preventive programme for axillary lymphadenectomy sequels
89528530|NCT03300349||No fulfillment of a preventive programme|Patients who do not fulfil a preventive programme for axillary lymphadenectomy sequels
89528531|NCT04491097|Experimental|Experimental: Panavia V5 resin cement|Resin cement with non-MDP monomer
89528532|NCT04491097|Active Comparator|Experimental: Panavia F2.0 resin cement|Resin cement with MDP monomer
89528533|NCT02468011|Experimental|Vibration|Whole body vibration with 35 Hz
89528534|NCT03311191||Younger Women|Women ages 20-30 who are not pregnant will be painted with oxygen sensing bandage
89528535|NCT03311191||Younger Men|Men ages 20-30 will be painted with oxygen sensing bandage
89528536|NCT03311191||Older Women|Women ages 55-65 who are not pregnant will be painted with oxygen sensing bandage
89528537|NCT03311191||Older Men|Men ages 55-65 will be painted with oxygen sensing bandage
89528538|NCT02733991|Experimental|Treatment|MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
89528539|NCT02733991|Active Comparator|Control|MiniMed™640G alone
89528540|NCT02468869|Experimental|Information structuring skills training|Physicians received a communication skills training focusing on information structuring with the so-called book metaphor for a structured discharge communication with the patient.
89528541|NCT02468869|Active Comparator|Empathy skills training|Physicians received a communication skills training focusing on empathy skills with the acronym NURSE for an empathetic discharge communication with the patient.
89528542|NCT03311113||Patients with osteoarticular infection|To evaluate drug adherence to oral antibiotic therapy in patients treated for bone and joint infection for a minimum expected duration of 6 weeks.
89528543|NCT03300271|Other|No intervention (Education)|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
89528544|NCT03300271|Experimental|Mobile Application (Self monitoring)|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
89528545|NCT03300271|Experimental|Mobile Application (Personal coaching)|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
89528546|NCT03305263|Experimental|Hydroxychlorochine HCQ|Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
89528547|NCT03305263|Placebo Comparator|Hydroxychlorochine HCQ Placebo|Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
89528548|NCT03300193||Tremor patients|Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)
89528549|NCT03300115|Experimental|AC0010|Each participant will be given AC0010 300mg bid.
89528550|NCT03305107|Experimental|Exercise and Chocolate Milk|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of chocolate milk"
89528551|NCT03305107|Experimental|Exercise and Water|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of water"
89528552|NCT03305107|Experimental|Sitting and Chocolate Milk|Children will quietly sit for 20 minutes Children will then drink 240mL of chocolate milk
89528553|NCT03305107|Experimental|Sitting and Water|Children will quietly sit for 20 minutes Children will then drink 240mL of water
89528554|NCT04442191|Experimental|Convalescent plasma|This study will utilize convalescent plasma from donors recovered from infection with SARS-CoV-2 (which causes COVID-19) with neutralizing antibody titers >1:64.
89528555|NCT04442191|Placebo Comparator|Placebo|Placebo utilized in this study will include Fresh Frozen Plasma collected before the COVID-19 pandemic began. As an extra control, some of this plasma will be saved and tested for COVID-19 antibodies to ensure they are not present.
89528556|NCT03305029|Experimental|SCNT-hES-RPE Cells|Pars plana vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells (SCNT-hES-RPE Cells) in Patients with Advanced Dry Age-related Macular Degeneration(AMD)
89528557|NCT05728021|Experimental|Recovery Record Aftercare|Intervention group (IG)
89528558|NCT05728021|Active Comparator|Treatment as usual (TAU)|Control group (CG)
89528559|NCT00702949|Experimental|Pregabalin75|Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
89528560|NCT00702949|Experimental|Pregabalin150|Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
89528561|NCT00702949|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 6 weeks.
89528562|NCT04791475|Experimental|Dexmedetomidine with 0.5% bupivacaine|1mcg/kg dexmedetomidine as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
89528563|NCT04791475|Active Comparator|Dexamethasone with 0.5% bupivacaine|4mg dexamethasone as an adjuvant to 0.5% bupivacaine 20 ml in USG guided Supraclavicular Brachial Plexus Block
89528564|NCT03299803|Experimental|Men's Healing Pathways|Men with physical disabilities will receive a 15 session weekly peer implemented program
89528565|NCT03299803|No Intervention|Control group|Telephone contact only
89528566|NCT03299725|Experimental|Treatment arm|
89528567|NCT03299647||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
89528568|NCT03299647||TD group|Typically development controls without lifetime diagnosis with ADHD
89528569|NCT04490551|Experimental|Intervention group|This group will be screened with the risk-based model. The input of the model will be gathered with the FIT, a validated questionnaire, and from data of the Dutch general population registry. The threshold of the model will be set at a calculated risk of 0.10. To comply with ethical guidelines, all participants in this group with a FIT result of >=15 mcg Hb/g faeces and a calculated risk of <0.10 will also be offered a colonoscopy.
89528570|NCT04490551|Active Comparator|Control group|This group will be screened with the FIT. The threshold of the FIT will be set at >= 15 mcg Hb/g faeces.
89528571|NCT05727943|Experimental|add - on clioquinol|"Add-on clioquinol to concomitant anti seizure medications.~Clioquinol - magistral suspension preparation (100mg/ml) - oral intake Exposure 2 weeks to low dose: 1 mg/kg/day Exposure 6 weeks to higher dose: 4 mg/kg/day"
89528572|NCT02466997|Experimental|Tacrolimus group|Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
89528573|NCT02466997|Placebo Comparator|Control group|"In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.~Counselling on natural light exposure during the duration of the trial will be given."
89528574|NCT05445427|Experimental|VNS Treatment|Subjects with post COVID syndrome with fatigue and headache will have vagal nerve stimulator applied to the neck for 2 minute intervals with two sets administered three times daily
89528575|NCT05445427|No Intervention|Non-VNS Treatment|Subjects with post COVID syndrome with fatigue and headache will receive current standard of care
89528576|NCT05441683|Experimental|HEI|PAOO with horizontally extending incisions on both sides
89528577|NCT05441683|Active Comparator|VRI|PAOO with vertical releasing incisions on both sides
89528578|NCT02466529||type 1 spinal muscular atrophy|The age of onset of patients with type 1 SMA is below 6 months of age.
89528579|NCT00702715|Experimental|Participants with severe renal impairment|Participants with severe renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Severe renal impairment was defined as creatinine clearance <30mL/min.
89528580|NCT00702715|Active Comparator|Participants with normal renal function|Participants with normal renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Normal renal function was defined as creatinine clearance >=80mL/min.
89528581|NCT05727631|Experimental|gentle human touch|In the study, after the mother in the experimental group was dressed in a clean apron, she was allowed to wash and disinfect her hands. When the temperature of the mother's hand was measured with a non-contact thermometer, it was allowed to warm it under a radiant heater until it reached 34 ºC. The mother, who was informed about the method before, was allowed to place the palm of one hand on the baby's crown, with her fingertips touching the eyebrow line. She placed her other hand on her lower abdomen, encircling the baby's waist and hips. It has been provided to perform sensitive touch operation without pressure and massage. The mother started the gentle touch method 5 minutes before the blood draw, and continued to do the touching during the blood draw and 5 minutes after the blood draw was finished.
89528582|NCT05727631|No Intervention|Control group|"The standard procedure of the clinic was applied to preterm infants in the control group. In the standard procedure of the clinic, the mother was with her baby in the blood collection room and did not perform any procedure.~IN ALL BABIES IN THE CONTROL AND EXPERIMENTAL GROUP., Before the procedure, 5 minutes after the procedure and 20 minutes after the procedure, the mother filled out the STAI-I form. The NIPS scale to measure the infant's pain was scored by two independent observers before, during, and five minutes after the procedure. KTA, SPO2 values of the baby were recorded before, during and five minutes after the procedure. The baby's crying time was started when the crying started, and stopped when the crying stopped."
89528583|NCT03299491|Experimental|MWA+IEC intervention|
89528584|NCT03299491|Experimental|IEC intervention|
89528585|NCT03299491|No Intervention|Control|
89528586|NCT03299413|Experimental|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose
89528587|NCT04939909|Other|Patients treated with Botulinum toxin type A|Patients were treated with Botulinum toxin type A
89528588|NCT02466295|Experimental|Volume-controlled ventilation|The patient's lungs will be mechanically ventilated using the volume-controlled ventilation with tidal volume 8 ml/kg.
89528589|NCT02466295|Experimental|Pressure-controlled ventilation|The patient's lungs will be mechanically ventilated using the pressure-controlled ventilation with tidal volume 8 ml/kg.
89528590|NCT03299257|Active Comparator|donepezil treatment|donepezil with 10 mg will be administered for 30 days.
89528591|NCT03299257|Placebo Comparator|placebo treatment|placebo with 10 mg placebo will be administered for 30 days.
89528592|NCT02466373|No Intervention|No clonidine|No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms
89528593|NCT02466373|Experimental|Clonidine 600mcg|4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.
89528594|NCT02466373|Experimental|Clonidine 1200mcg|"4 patients receive 1200 µg/day of clonidine without loading schedule.~4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h."
89528595|NCT02466373|Experimental|Clonidine 1800mcg|"4 patients receive 1800 µg/day of clonidine without loading schedule.~4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h."
89528596|NCT05728099|Experimental|Expiratory muscle strength training + SpiroGym application|The experimental arm will undergo 24 weeks of expiratory muscle strength training coupled with SpiroGym app.
89528597|NCT05728099|Active Comparator|Expiratory muscle strength training|The experimental arm will undergo 24 weeks of expiratory muscle strength training.
89528598|NCT02466451||Children operated at birth on CDH and EA|Standardized Questionnaires:For not collaborative patients,< 4 years:Standardized questionnaire collecting anamnestic-clinical data;Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents) For collaborative patients, >4 years:Standardized questionnaire collecting anamnestic-clinical data;Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar);Spirometry;6-minutes walk test (WT 6'); Prick tests;Children Quality of life questionnaire (KINDL questionnaire);Psychological test (Raven Matrices);Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents).
89528599|NCT05319535|Active Comparator|Foundational REP|Foundational REP uses the Replicating Effective Program implementation strategy and includes 5 elements that were developed and tested in the investigators' prior Function QUERI work: Stakeholder engagement; Toolkit; SharePoint access for clinical program training materials; Data dashboard to assist sites with tracking their own data; and Diffusion Networks to promote peer-to-peer sharing and implementation support.
89528600|NCT05319535|Experimental|Enhanced REP|Enhanced REP begins with the same activities as Foundational REP. Sites randomized to receive Enhanced REP will continue with Foundational REP and also receive higher intensity support for a period of approximately 4 months. The higher intensity support will consist of facilitation, a process of interactive problem solving and support that occurs in a context of a supportive interpersonal relationship and CONNECT, a complexity science-based bundle of interaction-oriented activities designed to supplement implementation efforts by promoting team function and readiness for change. Facilitation will be provided by Function QUERI team members.
89528601|NCT02466919|Experimental|Levofloxacin-based concomitant|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day10 Metronidazole 500 mg BID day1~day10 Levofloxacin 500 mg QD day1~day10
89528602|NCT02466919|Active Comparator|Sequential|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day5 Metronidazole 500 mg BID day6~day10 Clarithromycin 500 mg BID day6~day10
89528603|NCT05259709|Experimental|Single ascending dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab|"Part A:~Doses of 89Zr˗DFO˗REGN5054 may be reduced based upon assessment."
89528604|NCT05259709|Experimental|Defined dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab|"Part B:~Defined dose of 89Zr˗DFO˗REGN5054 determined in Part A."
89528605|NCT05302531|Experimental|Amoxicillin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
89528606|NCT05302531|Experimental|Ofloxacin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
89528607|NCT05302531|Experimental|Levofloxacin|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
89528608|NCT05302531|Experimental|Sulfamethoxazole trimethoprim|Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
89528609|NCT00702403|Experimental|Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)|"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445.~Treatment continues in the absence of disease progression or unacceptable toxicity."
89528610|NCT05302453|Experimental|Basic Body Awareness Therapy Group|BBAT exercises to the participants in the study group, were performed under the leadership of two physiotherapists with internationally valid training certificates. In the face-to-face training, BBAT exercises were taught to the participants. Then the training went on via Google Meet. The lying exercises were shown on one participant before each group study and participants were asked to do lying exercises at home. Sitting and lying exercises were performed as a hybrid at one hour/in a week for 12 weeks. At the beginning and end of each group training, feedback was received from the participants' own experiences of the effects of the exercises on the body, emotions, and thoughts.
89528611|NCT05302453|No Intervention|Control Group|The Control group was warned to continue with daily routines and not to take any training that includes body-mind approaches such as yoga or Tai chi for 12 weeks.
89528612|NCT04691947|Experimental|Low dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 3 µg/0.5 ml Vaccine Intervention Description:Two applications on Days 0 and 21
89528613|NCT04691947|Experimental|Medium dose vaccine|Type: Biological/Vaccine Name: ERUCOV-VAC 6 µg/0.5 ml Vaccine Intervention Description: Two applications on Days 0 and 21
89528614|NCT04691947|Placebo Comparator|Placebo|Placebo Vaccine, containing 0.9 % saline Intervention Description: Two applications on Days 0 and 21
89528615|NCT00702325|Experimental|1|
89528616|NCT00702325|Active Comparator|2|
89528617|NCT02719171|Placebo Comparator|Placebo|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
89528618|NCT02719171|Experimental|Risankizumab 150 mg Every 4 Weeks|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
89528619|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0, 4, and 16|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
89528620|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0 and 12|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
89528621|NCT02719171|Experimental|Risankizumab 75 mg Week 0|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
89528622|NCT02464813|Active Comparator|Pregabalin|Pregabalin in hard capsule 2mg/kg rounded up to next 25mg twice daily, max 150mg x 2, for 5 days.
89528623|NCT02464813|Placebo Comparator|Sugar pill|Same hard capsule and same amount of tablets twice daily for 5 days.
89528624|NCT05726929|Experimental|Osteopathic treatment (OT)|Osteopathic treatment, 3 sessions of 1h + Treatment As Usual (TAU)
89528625|NCT05726929|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual, Capsaicin Qutenza Patch (Conventionnal Treatment in algology in supportive care)
89528626|NCT04490473|Other|volunteer group|Only volunteer participants will be included in the research. Survey forms will be sent to individuals online. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
89528627|NCT05726695||Heart failure with reduced ejection fraction.|"Patients indicated for biochemical analysis due to a suspected heart disease, with HFrEF diagnosed on echocardiography with left-ventricular ejection fraction lower than 35%.~Diagnostic Test: MicroRNA test. Laboratory analysis for the detection of microRNA in blood samples.~Diagnostic Test: Heart ultrasound examination. Heart ultrasound examination will be performed as a standard cardiology examination."
89528628|NCT05726695||Control group|"Patients with no known heart disease (hypertrophy or dilatation), which has been confirmed on echocardiography.~Diagnostic Test: microRNA test. Laboratory analysis for the detection of microRNA in blood samples.~Diagnostic Test: Heart ultrasound examination. Heart ultrasound examination will be performed as a standard cardiology examination."
89528629|NCT04755907||Group A|colorectal cancer patients at resectable stage II/III who will receive adjuvant chemotherapy after surgery
89528630|NCT04755907||Group B|colorectal cancer patients at locally advanced stage who will receive neoadjuvant chemotherapy before surgery and adjuvant chemotherapy after surgery
89528631|NCT04755907||Group C|colorectal cancer patients with liver metastases
89528632|NCT02466607|Other|RETeval color flicker ERG|Compare implicit times and amplitudes of electroretinograms obtained from series of color flashes to those obtained from white flashes.
89528633|NCT02466607|Other|RETeval dilated versus un-dilated flicker ERG|Compare implicit times and amplitudes of ERGs obtained from cd/m2/sec stimulation (used with dilated pupils) to those obtained from troland stimulation (used with un-dilated pupils).
89528634|NCT04590079|Experimental|First intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment and daily sessions with the medical device - 1 month of wash-out - 3 months of conventional pain treatment.
89528635|NCT04590079|Experimental|Second intervention group|Patients suffering from peripheral osteoarthritis who will have : 3 months of conventional pain treatment - 1 month of wash-out - 3 months of conventional pain treatment and daily sessions with the medical device.
89528636|NCT04740385||Lung cancer patients|Correct position of double lumen endotracheal tube will be assessed using lung sonography, routine chest auscultation and fiberoptic brochoscopy
89528637|NCT02718625|Experimental|Santyl|Santyl collagenase ointment applied topically once per day for up to six weeks
89528638|NCT02718625|Active Comparator|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
89528639|NCT05123911|Experimental|Product Kit: Shampoo, Conditioner and Combining Cream (Investigational Products [IPs])|The parents/legally acceptable representative (LAR) of the participants will receive a product kit containing the 3 investigational products (shampoo, conditioner and combining cream) and will bathe the child participant with shampoo followed by conditioner and then apply combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
89528640|NCT05719987|Experimental|Biodentine Group|study group
89528641|NCT05719987|Other|MTA Group|control group
89528642|NCT05122351|Experimental|Group of Bupivacaine infiltration at the Quadratus Lumborum muscle|Patients will receive Quadratus Lumborum Block by infiltration of Bupivacaine as post operative analgesia in Open Inguinal Hernia surgery
89528643|NCT05122351|Experimental|Group of paracetamol injection|Patients will receive post operative 1 gm paracetamol injection as analgesia in Open Inguinal Hernia surgery
89528644|NCT05118919|Experimental|Active|
89528645|NCT05118919|Placebo Comparator|Placebo|
89528646|NCT02466061|Experimental|Arm A: Telemedicine Group|"Telemedicine Weight Management plus Wi-Fi Scale (Arm A) Participants in the Telemedicine Group will receive a Wi-Fi Scale that measures weight, lean mass, and fat mass. Participants will receive 15-20 minute telephone counseling sessions by phone. Sessions will occur at routine intervals during the six month intervention period.~All Aim 1 participants, including those randomized to Arm A, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 followup weight data also will be collected through medical record abstraction."
89528647|NCT02466061|Experimental|Arm B: Text for Diet (Text4Diet) Group|"Text for Diet (Text4Diet) Group (Arm B) The intervention in this Arm involves delivery of Short Message Service (SMS) text messages to participants each day over the course of a 6 month intervention period. Participants will also receive a digital scale to track weight on a weekly basis. SMS text messages will be sent 2-3 times per day and will provide feedback, support, prompting, and strategies to adhere to behaviors associated with long-term weight management.~All Aim 1 participants, including those randomized to Arm B, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
89528648|NCT02466061|Active Comparator|Arm C: Enhanced Usual Care Group|"Enhanced Usual Care Group (Arm C) Participants will be provided with handouts based on American Cancer Society guidelines on healthy eating and exercise.~All Aim 1 participants, including those randomized to Arm C, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
89528649|NCT05232331|No Intervention|Control|This group will receive non-surgical periodontal treatment, however they will not receive any modification to their diet
89528650|NCT05232331|Experimental|Intervention|This group will receive non-surgical periodontal treatment, and also as a treatment of interest, will receive the indication to consume ~ 350 mg of nitrate from vegetables, as well as an accompaniment to achieve this objective.
89528651|NCT02465671||Patients group|All patients with acute spontaneous basal ganglia hemorrhage admitted to the Jinhua People's Hospital within the first 24 h from stroke during the same period were enrolled.
89528652|NCT02464501|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal lesions. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 4mm to 7mm in diameter. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.
89528653|NCT02465827|Active Comparator|Saphenous and obturator nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.~Ropivacaine 0.75% for nerve blockades for both nerves mentioned."
89528654|NCT02465827|Active Comparator|Saphenous nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block"
89532744|NCT05996003|Experimental|NS-089/NCNP-02|"Experimental: NS-089/NCNP-02~NS-089/NCNP-02 solution for infusion (Cohort 1)~NS-089/NCNP-02 solution for infusion (Cohort 2)"
89528655|NCT02465827|Placebo Comparator|Placebo nerve block|"5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Saline for nerve blockades for both nerves mentioned."
89528656|NCT04368403|Experimental|KHK4827|
89528657|NCT04358185|Experimental|Itacitinib|Itacitinib (INCB039110) - novel and small molecule selective inhibitor of JAK1
89528658|NCT02716987|Experimental|Set A: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally, once on Day 1 and up to 100 megabecquerel (MBq) of Positron Emission Tomography (PET) ligand PGM028299 labeled with [18F] ([18F]PGM299) with a maximal mass up to 12.5 microgram (mcg), injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
89528659|NCT02716987|Experimental|Set A: TAK-831 200 mg|TAK-831 200 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
89528660|NCT02716987|Experimental|Set A: TAK-831 250 mg|TAK-831 250 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
89528661|NCT02716987|Experimental|Set A: TAK-831 500 mg|TAK-831 500 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
89528662|NCT02716987|Experimental|Set B: [18F]PGM299|[18F]PGM299 up to 100 MBq (with a maximal mass up to 12.5 mcg), injection, intravenously, prior to PET imaging on Days 1 and 10.
89528663|NCT04331977|Experimental|Quadhelix Group|
89528664|NCT04331977|Active Comparator|Hyrax Group|
89528665|NCT02464423|No Intervention|Control|"Usual care: WE-ACTx For Hope and CHUK offer a host of services for HIV+ young people, and these will represent the usual care condition for the study. Both clinics provide adolescent-friendly environments with multidisciplinary teams that offer weekly or monthly support groups, peer education, medical services, mental health screenings, sports activities, HIV and health education sessions, and outreach to parents and guardians. The services youth in the usual care condition receive will be carefully tracked."
89528666|NCT02464423|Active Comparator|Treatment|Culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) intervention: The components of the TI-CBT include a) psychosocial health education b) relaxation training c) cognitive restructuring d) adherence barriers e) caregiver psycho-education. The TI-CBTe will be administered in groups of 8-10 weekly for 2 hours for 3 Sundays each month over 2 months. Two IYL will co-lead each intervention, and two IYL will rate fidelity.
89528667|NCT02464189||Children with asthma|
89528668|NCT05686759|Experimental|Undiluted intravenous infusion of I.V.-Hepabig inj|Undiluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit within approximately 30 minutes
89528669|NCT05686759|Active Comparator|Diluted intravenous infusion of I.V.-Hepabig inj|Diluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit into Dextrose 5% in water within approximately 1 hour
89528670|NCT05679895|Experimental|Experimental: CD1a-CAR T|CD1a CAR T cells transduced with a lentiviral vector to express CD1a chimeric receptor domain on T cells administered with a dose-escalation approach.
89528671|NCT05679661|Experimental|Group A (immunonutrition and oral chlorhexidine decontamination, IN&CD)|Patients will receive immunonutrition supplement of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery and oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
89528672|NCT05679661|Experimental|Group B (immunonutrition and routine oral care, IN&RC)|Patients will receive immunonutrition supplement of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery and routine oral care.
89528673|NCT05679661|Experimental|Group C (routine nutrition advice and oral chlorhexidine decontamination, RN&CD)|Patients will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d. Patients will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
89528674|NCT05679661|No Intervention|Group D (routine nutrition advice and routine oral care, RN&RC)|Patients will be advised to follow a standard nutrition advice and routine oral care.
89528675|NCT04813315|Experimental|Kendall exercise|Experimental group 1 got this intervention containing Kendall exercise for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
89528676|NCT04813315|Experimental|Gong's mobilization|Experimental group 1 got this intervention containing Gong's mobilization for 15-20 mins, followed by conventional physiotherapy treatment (hot pack).Participants were treated 3 times per week for 4 weeks. Pre and Post treatment readings were taken in 1st session and 4th week respectively. Assessment was done via Numeric pain rating scale, neck disability index, universal goniometer and modified sphygmomanometer test.
89528677|NCT02466763|Active Comparator|round window|Half of the participants will be randomized to the round window technique of cochlear implant device electrode insertion. Intervention for participants randomized to the round window arm include having the round window technique used for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
89528678|NCT02466763|Active Comparator|cochleostomy|Half of the participants will be randomized to the cochleostomy technique of cochlear implant device electrode insertion. For the participants randomized to the cochleostomy arm, the surgeon will use a cochleostomy technique for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
89528679|NCT02464111|Experimental|Group 1|Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses
89528680|NCT02464111|Experimental|Group 2|Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose
89528681|NCT02464111|Experimental|Group 3|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses
89528682|NCT02464111|Experimental|Group 4|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given
88812187|NCT05945420|Active Comparator|Desmopressin arm|This arm will receive tamsulosin and desmopressin
89528683|NCT02464111|Experimental|Group 5|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given
89528684|NCT02464111|Experimental|Group 6|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose
89528685|NCT02465983|Experimental|CART-meso-19 T cells|A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.
89528686|NCT02465749|Experimental|Continuous Oxygen|Continuous oxygen intake and routine drug treatment .
89528687|NCT02465749|Experimental|Blue Light Deprivation|Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
89528688|NCT02465749|Experimental|Continuous Oxygen Therapy Combined With Blue Light Deprivation|Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
89528689|NCT02465749|Other|control|Routine drug treatment
89528690|NCT00701779|Experimental|Dutasteride|"Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.~Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks."
89528691|NCT02465905|Active Comparator|Raw milk|For raw milk immunotherapy (RMI), fixed dose of raw milk was daily administered at home, determined using tolerated threshold dose during the DBPCFC. Augmentation was made every 5 weeks in the allergy clinic.
89528692|NCT02465905|Active Comparator|Heated milk|For heated milk immunotherapy (HMI), families were asked to weekly increase the daily dose of milk at home using industrial preparations. Milk included in the preparation was less and less heated among time. Passage from heated-milk to half-heated milk and then raw milk was performed in the allergy clinic.
89528693|NCT05599009|Experimental|RIC group|RIC+Standard medical treatment. Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
89528694|NCT05599009|Sham Comparator|control group|Sham RIC+Standard medical treatment. Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg.
89528695|NCT04169815||ED Setting|An acute HF population enrolled at the emergency department. Testing of clinical samples will be performed with the Access natriuretic peptide assay.
89528696|NCT02463565||hospitalized patients|
89528697|NCT05029141|Experimental|Chidamide+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group. Patients whose last induction failure regimen is a demethylated agent combined with priming regimen enter the experimental group directly.
89528698|NCT05029141|Placebo Comparator|Placebo+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group.
89528699|NCT02463643|Experimental|Z-215 10 mg/day|Drug: Z-215 10mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
89528700|NCT02463643|Experimental|Z-215 20 mg/day|Drug: Z-215 20mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
89528701|NCT02463643|Experimental|Z-215 40 mg/day|Drug: Z-215 20mg Drug: Z-215 20mg Drug: Rabeprazole Sodium Placebo
89528702|NCT02463643|Active Comparator|Rabeprazole Sodium 10 mg/day|Drug: Z-215 Placebo Drug: Z-215 Placebo Drug: Rabeprazole Sodium
89528703|NCT02463721|Other|SBP patients|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
89528704|NCT04913467|Experimental|Groningen Anti-Inflammatory Diet (GrAID)|Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups.
89528705|NCT04913467|Experimental|ColoVit capsule|2 times daily intake of a supplement containing 37,5 mg vitamin B2, 2,5 mg vitamin B3 and 250 mg vitamin C in a ColoPulse-coated capsule, a pH-sensitive coating allowing ileocolonic-targeted-delivery
89528706|NCT04913467|Placebo Comparator|Placebo capsule|2 times daily intake of a capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
89528707|NCT02463955|Experimental|Thoracoscopy|"experimental intervention (flexible video endoscope)~reference procedure (video-rigid thoracoscope)"
89528708|NCT04889833|Experimental|Hypnosis Therapy Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & shoulder function. 7 days before surgery, they will receive a pre-recorded video (~19 min) of guided hypnosis to be watched at least 1x/day, until surgery. Before & after the video, they will rate pain/anxiety levels. On the day of surgery, they will watch the video again & answer questions about their average anxiety and pain level. After surgery, they will watch the video each day and report on pain/anxiety, medication use, satisfaction, and sleep disturbance until postoperative day 7. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication & study doctor will be the same as any shoulder arthroplasty patient regardless of study participation.
89530594|NCT03243565|Placebo Comparator|Placebo|Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.
88812188|NCT05945420|Placebo Comparator|Placebo arm|This arm will receive tamsulosin and placepo
88812189|NCT05945407|Experimental|Myometrial invasion group|Pelvic enhanced magnetic resonance imaging or transvaginal color Doppler ultrasound suggests that the tumor invades less than one half of the myometrium.
88812190|NCT05945407|Other|No myometrial invasion group|Pelvic enhanced magnetic resonance imaging or transvaginal color Doppler ultrasound suggests that the tumor is limited to the endometrium.
88812191|NCT05945381|Experimental|GIC on MIH|see below
88814482|NCT04357028|Placebo Comparator|Control|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
89530595|NCT04486105|Placebo Comparator|control|vehicle only for one week
89530596|NCT04486105|Experimental|40g sucrose ingestion|40g sucrose treatment on top of habitual diet for one week
89530597|NCT04486105|Experimental|80g sucrose ingestion|80g sucrose treatment on top of habitual diet for one week
89530598|NCT04486105|Experimental|120g sucrose ingestion|120g sucrose treatment on top of habitual diet for one week
89530599|NCT03369197|Experimental|Intervention: Nasal Mask|Nasal anesthesia mask with positive pressure
89530600|NCT03369197|Active Comparator|Control: Nasal cannula|Nasal Cannula with standard care
89530601|NCT03234673|Experimental|Group A (Tacrolimus group):|fractional CO2 laser therapy and Tacrolimus ointment 1
89530602|NCT03234673|Experimental|Group B (Calcipotriol group):|fractional CO2 laser therapy and Calcipotriol ointment
89530603|NCT03234673|Experimental|Group C (NB-UVB group):|fractional CO2 laser therapy and NB-UVB twice weekly
89530604|NCT03148613|Other|18-49 year old smokers using COBSS|"Younger smokers - Assessment of intended user performance in use scenarios, user documentation assessment, subjective feedback and rating scales.~NOTE: 18-49 year Age Arm intended to evaluate human factors and usability of COBSS in younger smokers"
89530605|NCT03148613|Other|≥50 year old smokers using COBSS|"Older smokers- Assessment of intended user performance in use scenarios, user documentation assessment, subjective feedback and rating scales.~NOTE:≥50 year Age Arm intended to evaluate human factors and usability of COBSS in younger smokers"
89530606|NCT03243643|Experimental|HS-1024+apatinib|"For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.~For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease)."
89530607|NCT03243487|Experimental|PAMS service|"Study participants will be randomly assigned to have their Continuous positive airway pressure therapy (CPAP) or Bilevel Positive Airway Pressure (BiPAP) therapy followed by a structured patient adherence management service (PAMS).~Interventions: Call to patient by sleep coach on days 3,7,14,32,45, 60, and 75 after participants begin PAP treatment. At each time frame sleep coach reviews CPAP adherence data on EncoreAnywhere (EA) a cloud based program collecting adherence data via wireless modem on CPAP units. Calls will not be made at days 7 and 14 if adherence is good. If problems are identified and cannot be handled over the telephone the problems will be escalated to VA MD or CPAP respiratory therapy (RT) providers for direct intervention. All patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment."
89530608|NCT03243487|Active Comparator|Standard Care (SCP)|Study participants will be randomly assigned to have their CPAP or BiPAP therapy followed by the current Sleep Center standard care process. This includes a telephone number that patients can call or problems and review of adherence data on EncoreAnywhere (EA) at 4 to 6 weeks after starting treatment. Patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment.
89530609|NCT03238261|Experimental|Chemotherapy and concomitant radiotherapy|
89530610|NCT03238261|Active Comparator|Radiotherapy|
89530611|NCT03237949|Active Comparator|Phone counseling|The patient will receive standard care inside the hospital. After discharge the active comparator group will receive four phone counseling sessions. The sessions will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The counseling timing, duration, and content will be consistent with guideline-based recommendations.
89530612|NCT03237949|Experimental|Text message|The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
89530613|NCT03234517|Experimental|Vaginal Clindamycin Cream Plus continuous Vaginal Probiotic|Vaginal Clindamycin Cream followed by continuous Vaginal Probiotic use for 60 days
89530614|NCT03234517|Active Comparator|Vaginal Clindamycin Cream Plus interrupted Vaginal Probiotic|Vaginal Clindamycin Cream followed by interrupted Vaginal Probiotic use
89530615|NCT02453815|Experimental|arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to receive an arterial catheter at surgery, then the subject will be placed in the experimental arm of the study.
89530616|NCT02453815|Placebo Comparator|no arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to not receive an arterial catheter at the time of surgery, then the subject will be placed in the placebo comparator arm of the study.
89530617|NCT03238105|Experimental|Intense pulsed light|The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
89530618|NCT03238105|Experimental|Peeling of 10% thioglycolic acid|In the first session the acid will be applied for three minutes, and with each new session the duration time with the product will increase in three minutes, so that in the last session the duration of the application will be 9 minutes. For the application of the product will be used flexible cotton rod, sparing the region just below the eyelids of the lower eyelid 0.5cm, therefore, no other measure is necessary for eye protection. After the given time, the substance will be removed with lint with 0.9% saline solution.
89530619|NCT03243721|Experimental|Gilenya treated MS patients|Multiple sclerosis patients treated with Gilenya for at least six months. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
89530620|NCT03243721|Experimental|Healthy controls|Subjects without multiple sclerosis or other diseases of the central nervous system. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
89532838|NCT05866471|Active Comparator|Group 4: taVNS + Psilocybin + Sham taVNS|Group 4 will receive twice daily taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive twice-daily sham taVNS paired with psychedelic session contextual cues for 7 days.
89533069|NCT05590728|Experimental|T2|Subjects 18 to 45 years of age to receive single 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. 2 h (+/- 5 min) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
89533070|NCT05590728|Experimental|T3|Subjects 18 to 45 years of age to receive single 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. 4 h (+/-10 min) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
88814483|NCT05620316|Experimental|Injection group|In this group, patients will be injected with 10 MU of botulinum toxin type A in the masseter muscle.
88814484|NCT05620316|Placebo Comparator|Placebo group|In this group, patients will prick twice in the masseter muscle.
88814485|NCT04357106|Experimental|Convalescent Plasma|200 ml of convalescent plasma, single dose.
88814486|NCT04360304|Experimental|Study group|
88807352|NCT01658904|Experimental|Cohort 1- CFZ 20 mg/m^2 (Day 1,2)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
88807353|NCT01658904|Experimental|Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
88812192|NCT05945368|Experimental|Eribulin+Trastuzumab + Pertuzumab|"Eribulin mesylate, 1.4 mg/m², days 1 and 8;~trastuzumab, 8 mg/kg loading dose in cycle 1 and 6 mg/kg thereafter on day 1;~pertuzumab with a loading dose of 840 mg in cycle 1 and 420 mg in subsequent cycles on day 1; 21 days in a cycle of 4 cycles"
88812193|NCT05945238|Experimental|Thrower's Ten|
88812194|NCT05945238|No Intervention|Control|
88814558|NCT01607645|Experimental|Arm2: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
88814559|NCT01647581|Experimental|Clip|A clip is been placed at the polypectomy site.
88807354|NCT01658904|Experimental|Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
88807355|NCT04235400||patient with dry eye disease|
88807356|NCT05238948|Experimental|Midazolam with/without CKD-506|Single arm and 1-sequence crossover
88814560|NCT01647581|Placebo Comparator|No Clip|A hemoclip is not placed at the site of the polypectomy.
88807357|NCT05284578|Experimental|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
88814561|NCT01608659||botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
88814562|NCT01608815|Experimental|Study Group|All participants will receive single dose of typhoid Vi polysaccharide vaccine on Day 0.
88814563|NCT01608971||Weight based protamine group|In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)
88814564|NCT01608971||Heparin level based protamine group|In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.
88814565|NCT01647737|Active Comparator|MighTeaFlow|4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks
88814566|NCT01647737|Active Comparator|Xylitol|4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks
88807358|NCT05284578|Experimental|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
88807359|NCT05284578|Active Comparator|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
88807360|NCT00385580|Experimental|1|
88807361|NCT00385580|Experimental|2|
88807362|NCT05187780||Group 1|Adolescents with Idiopathic Scoliosis who have 10⁰-24⁰ Cobb angles
88807363|NCT05187780||Group 2|Adolescents with Idiopathic Scoliosis who have 25⁰-40⁰ Cobb angles
88807364|NCT05187780||Group 3|Healthy adolescents without scoliosis as controls
88812195|NCT05945186|Experimental|Single Arm|Baseline blood flow (hemodynamic) measurements will be obtained via ultrasound for all enrolled subjects. Following baseline measurements, compression will be applied and blood flow (hemodynamic) measurements will be repeated via ultrasound.
88812196|NCT05945173|Experimental|Experimental group 1|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the selective enamel etching strategy.
88812197|NCT05945173|Experimental|Experimental group 2|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the selective enamel etching strategy.
88807365|NCT05185674||COVID-19 survivors subjects|"All patients discharged from the National University Hospital of Colombia (Bogotá, Colombia) who required admission to the Intensive Care Unit of the same institution with a confirmed diagnosis of SARS-CoV-2 disease (COVID-19 disease) between April 1, 2020 and March 31, 2021~Severe Acute Respiratory Syndrome (SARS)~Coronavirus (CoV)"
88812198|NCT05945173|Active Comparator|Control group 1|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the selective enamel etching strategy.
89533071|NCT05590728|Experimental|T4|Subjects 18 to 45 years of age to receive single 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. 8 h (+/- 15 min) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
89533072|NCT05590728|Experimental|T5|Subjects 18 to 45 years of age to receive single 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. Cohort T5 will be enrolled after plasma and lung apramycin concentrations and preliminary PK data analysis are completed in cohorts T1-T4 24 h (+/- 1 h) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
89533073|NCT05586555|Other|Control group (normal hearing in regards of age)|Normal hearing participants according to pure tone hearing levels defined for age and tested frequency (audiometry ISO 7029 and Wang & Puel, 2020 recommendations for hearing loss at the tested frequencies). Total of 32 subjects in this arm.
89533074|NCT05586555|Experimental|CI group (cochlear implanted subjects)|"Cochlear implanted subjects with bilateral, severe-to-profound sensorineural hearing loss, with at least one Oticon Medical cochlear implant system .~Up to 40 subjects in this arm:~20 subjects will perform experiment 1 & 2~20 subjects will perform experiment 3~The subjects of the experiment 3 ore either those taken part to experiment 1 and 2, or subjects who only take port to the experiment 3"
89533075|NCT05585710|Experimental|Pulsed Lavage Washout|This cohort will undergo standard of care bilateral or unilateral mastectomies as determined by breast surgical oncologists and immediate standard of care breast reconstruction with tissue expander placement and pulsed lavage washout.
89533076|NCT05585710|Active Comparator|No Pulsed Lavage|This cohort will undergo standard of care bilateral or unilateral mastectomies as determined by breast surgical oncologists and immediate standard of care breast reconstruction with tissue expander placement.
89533077|NCT05585307|Experimental|Substudy-01: GS-5894|"Participants will receive GS-5894. After assessments on Day 11 or upon early termination (ET), participants will initiate a regimen of Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, BVY)), or other non-nonnucleoside reverse transcriptase inhibitor (NNRTI) based standard of care (SOC) antiretroviral therapy (ART) regimen up to Day 39.~Non-NNRTI SOC ART regimen may include:~abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC), (ABC/DTG/3TC)~DTG plus (tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF) plus (emtricitabine (FTC) or 3TC)~Approximately 5 cohorts may enroll. Participants will be enrolled in Cohort 1 initially and then dosing in subsequent cohorts will proceed after safety review team (SRT) review of emerging data."
89533078|NCT05585307|Experimental|Substudy-02: GS-1720|"Participants will receive GS-1720. After assessments on Day 11 or upon ET, participants will initiate a regimen of Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, BVY)), or an alternative SOC ART regimen up to Day 60.~SOC ART regimen, example INSTIs: DTG/ABC/3TC or DTG/3TC~Approximately 5 cohorts may enroll. Participants will be enrolled in Cohort 1 initially and then dosing in subsequent cohorts will proceed after safety review team (SRT) review of emerging data."
89533079|NCT05585307|Experimental|Substudy-03: GS-6212|"Participants will receive GS-6212. After assessment on Day 11 or upon ET, participants will initiate a regimen of Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, BVY)), or an alternative SOC ART regimen up to Day 25.~Approximately 5 cohorts may enroll. Participants will be enrolled in Cohort 1 initially and then dosing in subsequent cohorts will proceed after safety review team (SRT) review of emerging data."
89533080|NCT05582434|Experimental|One gel treatment|Every participant will be instructed to apply a topical retinoid every day.
89533081|NCT05582434|Experimental|Two gel treatment|One-third of the participants will be instructed to apply adapalene and the clindamycin phosphate/benzoyl peroxide gel every day.
89533082|NCT05582434|Experimental|Three gel treatment|One-third of the participants will be instructed to apply adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.
89533083|NCT05581121|Other|Arm A|Control arm
89533084|NCT05581121|Experimental|Arm B|Experimental arm
89533085|NCT05578976|Experimental|Epcoritamab and R-CHOP|Participants will receive subcutaneous epcoritamab combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) followed by epcoritamab in 21-day cycles.
89533086|NCT05578976|Experimental|R-CHOP and Rituximab|Participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles.
89533087|NCT05570214|Experimental|Virtual Reality Group|Subjects will wear a virtual reality headset during their urological bedside vasectomy.
89533088|NCT05570214|No Intervention|Standard of Care Group|Subjects will undergo standard of care urological bedside vasectomy
89533089|NCT05558696|Experimental|bomedemstat|Participants will receive bomedemstat daily for 36 weeks and may qualify for additional treatment thereafter if deriving clinical benefit.
89533090|NCT05556265|Experimental|Deucravacitinib Dose 1|
89533091|NCT05556265|Experimental|Deucravacitinib Dose 2|
89533092|NCT05556265|Placebo Comparator|Placebo, followed by Deucravacitinib Dose 1 or Dose 2.|
89533093|NCT05552326|Experimental|Olezarsen|Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
89533094|NCT05552326|Placebo Comparator|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
89533095|NCT05552196|Experimental|Treatment A: Ponesimod|Participants will receive up-titrated Ponesimod orally once daily from Day 1 to Day 15.
89533096|NCT05552196|Experimental|Treatment B: Ponesimod + Carbamazepine|Participants will receive up-titrated Carbamazepine from Day 1 to Day 7 and from Day 23 to Day 26. Participants will also receive up-titrated Ponesimod and Carbamazepine from Day 8 to Day 22.
89533097|NCT05548881||Group 1|Women who have submitted clinical samples for prenatal aneuploidy screening test with the finding of X mosaicism
89533098|NCT05548881||Group 2 (Control)|Control group of Female volunteers of appropriate age, ethnicity, BMI, SES and parity
89533099|NCT05546827|Experimental|Surgical resection|Patients will have surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
89530621|NCT03234439|Experimental|myStrength Intervention|The myStrength intervention arm will be encouraged to utilize the chronic pain offering consisting of 6 modules. Each module has 5 activities and can take on average 5-15 minutes to complete. Study participants assigned to the myStrength intervention will have one week to complete each module. In addition to completing the required chronic pain modules, study participants in the myStrength intervention arm will have the option to also select other areas of interest and complete corresponding activities at their own pace. myStrength utilization will be recorded and analyzed.
89530622|NCT03234439|No Intervention|Waitlist Control|The waitlist control group will gain access to the myStrength platform 60 days following the start of the study.
89530623|NCT03238183|Active Comparator|hyaluronic acid combined dextrose group|Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
89530624|NCT03238183|Placebo Comparator|hyaluronic acid group|Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
89530625|NCT02729051|Experimental|FF/UMEC/VI closed triple therapy plus Placebo|Subjects will receive FF/UMEC/VI, 100 mcg/62.5 mcg/25 mcg and placebo inhalation powder via the dry powder inhaler (DPI), once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
89530626|NCT02729051|Active Comparator|FF/VI plus UMEC open triple therapy|Subjects will receive FF/VI, 100 mcg/25 mcg and UMEC, 62.5 mcg inhalation powder via the DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
89530627|NCT03234283|Experimental|Study intervention group|All participants will be intubated with a video-laryngiscope by guiding the tracheal tube according to the highlighted Larynx on the Video Screen.
89530628|NCT03234205|Experimental|MRI scan during free respiration|
89530629|NCT03237637|Active Comparator|Group A- Propranolol|Oral propranolol 1mg/kg/day as crushed tablets, in two divided doses, increased to 2mg/kg/day in two divided doses after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
89530630|NCT03237637|Experimental|Group B- Atenolol|Oral atenolol 0.5mg/kg as a single dose, increased to 1mg/kg as a single dose after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
89530631|NCT03243331|Experimental|Gedatolisb + PTK7-ADC|
89530632|NCT03237715||Breast fed cohort|
89530633|NCT03237715||Formula fed cohort|
89530634|NCT02453035||PTCA - Desolve Scaffold|Patients with coronary artery stenosis who have been treated with a DESolve bioresorbable coronary scaffold
89530635|NCT03237793|Active Comparator|Fluorosed Group|45 patients for the fluorosis groupGROUP 1A: Patients with healthy fluorosed teeth receiving desensitising agent (potassium nitrate- RA Themoseal**) treatment. (n=15) GROUP 1B: Patients with healthy fluorosed teeth receiving diode laser treatment$. (n=15) GROUP 1C: Patients with healthy fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15)
89530636|NCT03237793|Placebo Comparator|Non Flourosed Group|45 patients for the non-fluorosis groupGROUP 2- Non Flourosed Group (n=45) GROUP 2A: Patients with healthy non fluorosed teeth receiving desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15) GROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment. (n=15
89530637|NCT02507453|Other|Influence of Gravity on the Size-mass Illusion|to investigate the interaction between perceived size and perceived mass of objects in 0G and 1.8G compared to 1G using the size-mass illusion (SMI)
89530638|NCT02452957||Device: Simpliciti™ System|"The Simpliciti™ nucleus is a humeral prosthesis intended for total and hemi shoulder arthroplasty in patients with a severely painful and/or disabled joint resulting from osteoarthritis or traumatic arthritis.~The implant is sized to match and replicate the anatomy of the proximal humerus, while maintaining a bone conserving approach. It does not extend beyond the metaphysis, leaving the humeral canal untouched. Fixation is enhanced through a porous coating with a high coefficient of friction; resulting in a solid initial fit and long term fixation.~The Simpliciti™ nucleus is designed to receive a humeral head. The Simpliciti™ system is authorized to bear the CE mark and will be investigated within this clinical study in accordance with its intended use."
89530639|NCT02515565|Experimental|Experimental group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will be included in a physiotherapy program added to the standard medical treatment.
89530640|NCT02515565|Other|Control group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will receive only the standard medical treatment based on cephalosporin with or without erythromycin.
89530641|NCT03234049|No Intervention|Control Arm|In the control arm, teams will not receive a copy of the checklist for use.
89530642|NCT03234049|Experimental|Checklist Arm|In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
89530643|NCT03237559||eligible couples|Eligible couples refers to methods that are adopted by eligible couples for having physically and psychologically healthy conception and pregnancy
89530644|NCT05600075|Active Comparator|Glycolic acid 35% group|will be subjected to microneedling with topical glycolic acid 35%.
89530645|NCT05600075|Active Comparator|topical insulin group|will be subjected to microneedling with topical human insulin solution.
89530646|NCT03234127|Other|Atherosclerosis- resistance|FH Patient without atherosclerosis
89530647|NCT03234127|Other|Control|FH patient with atheroclerosis
89530648|NCT03234127|Other|the related population without familial hypercholesterolemia|No FH patient
89530649|NCT02512601|Experimental|Sulodexide|Compression therapy + Sulodexide (two capsules of Sulodexide 15 mg twice daily).
89530650|NCT03233815||Inhaled anesthesia (Sevoflurane)|Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
89530651|NCT03233815||Total Intravenous Anesthesia (Propofol)|Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
89530652|NCT02507609|Active Comparator|M group|moderate neuromuscular blockade group by intermittent injection of rocuronium bromide
89530653|NCT02507609|Active Comparator|D group|deep neuromuscular blockade group by continuous infusion of rocuronium bromide
89530654|NCT03233971||Older adults|
89530655|NCT03233971||Caregivers|
89530656|NCT02512367|Experimental|Intervention|
89530657|NCT02512367|Placebo Comparator|Surveillance|
89530658|NCT02512523|Experimental|Teneligliptin|Film-coated tablet for oral administration Dosage: 20mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
89530659|NCT02512523|Active Comparator|Sitagliptin|Film-coated tablet for oral administration Dosage: 100mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
89530660|NCT03233893|Experimental|light activated calcium silicate|Apply light activated calcium silicate in deep occlusal caries lesions and taking the base line image for the first group after restoring the cavity with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
89530661|NCT03233893|Active Comparator|light activated calcium hydroxide|Apply the light activated calcium hydroxide in deep occlusal carious lesions and taking the base line image for the second group after restoring with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
89530662|NCT05597813|Active Comparator|Group A|microneedling group
89530663|NCT05597813|Active Comparator|Group B|microneedling plus timolol group
89530664|NCT03233581|Experimental|Fitbit + Facebook + Health Coaching|Participants will use the Fitbit device and join the Facebook group. They will also receive brief weekly health coaching from a research staff. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide them with support.
89530665|NCT03233581|Active Comparator|Usual care control with Fitbit only|Participants will be loaned a Fitbit device only. They will not join the Facebook group nor receive health coaching. They will not select an adult family member or friend to receive a Fitbit device to provide them with support.
89530666|NCT03237247||Benign|cases with benign biliary stricture
89530667|NCT03237247||Calcular OJ|cases with calcular extrahepatic cholestasis
89530668|NCT03237247||Malignant Distal|cases with malignant distal extrahepatic cholestasis
89530669|NCT03237247||Malignant Proximal|cases with malignant proximal extrahepatic cholestasis
89530670|NCT03237247||Intrahepatic|cases with intrahepatic cholestasis
89530671|NCT04499261|Experimental|laparoscopic surgery|The laparoscopic view is caudal to cephalic, which is consistent with the direction of hepatic transection. In addition, the high-definition magnified view and ability to change perspectives with the laparoscope are conducive to subtle manipulation, and compression of the carbon dioxide pneumoperitoneum can reduce venous bleeding. Therefore, laparoscopic surgery may have certain advantages in the treatment of paracaval-originating lesions.
89530672|NCT04499261|Active Comparator|Open surgery|Open surgery is the traditional surgical method for resection of paracaval-originating lesions.
89530673|NCT03237169||Prospective cohort|Prospective cohort of patients with stable or stabilized coronary artery disease and de novo coronary lesions, in whom functional evaluation is performed, according do standard clinical indications.
89530674|NCT02512133|Experimental|MIGS Hydrus Ivantis|opening the anterior chamber (2mm.) injecting visco-material, injecting the Hydrus stent in the Schlemm's canal under gonioscopic control
89530675|NCT02512133|Experimental|SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
89530676|NCT02512289|Active Comparator|Real stimulation|real tDCS associated with robot-assisted therapy (RAT)
89530677|NCT02512289|Sham Comparator|Sham stimulation|Sham tDCS associated with RAT
89530678|NCT03107767|Active Comparator|Prospective Cohort|The prospective cohort following introduction of the evidence based algorithm for ankle fractures.
89530679|NCT03107767|No Intervention|Historical Cohort|Patients treated before introduction of algorithm. Matched to prospective cohort for comparison
89530680|NCT02507063||study subjects|Patients age 0-18 with intracranial monitoring devices in place or requiring a VP shunt revision who receive a ocular ultrasound evaluating ONSD
89530681|NCT03233503||Dutch trained taste panel|The study population consists of a sample of 15 healthy Dutch males and females, recruited in the Wageningen area.
89530682|NCT03233503||Malaysian trained taste panel|The study population consists of a sample of 20 healthy Malaysian males and females, recruited in the Subang Jaya, Selangor area.
89530683|NCT04497623|Experimental|Intervention arm|Patients with indication for volume-controlled mechanical ventilation
89530684|NCT03242785|Experimental|Self-monitoring/Self-titration|The intervention consists of self-monitoring blood pressure at home, and subsequent medication self-titration, based on a medication adjustment plan pre-established by the family physician, in patients with uncontrolled hypertension.
89530685|NCT03242785|No Intervention|Routine care|Patients in this arm will receive routine care for high blood pressure in the primary health care center.
89530686|NCT02512211||Patients adults|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
89530687|NCT02512211||Children with haemophilia|Sign hemophilia patients under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
88812199|NCT05945173|Active Comparator|Control group 2|35 non-carious cervical lesions (NCCL) will receive composite resin restorations in the selective enamel etching strategy.
88812200|NCT05945095|Experimental|Experimental group|Gum chewing group
88812201|NCT05945095|No Intervention|Control group|Routine care
88807366|NCT05236530|Experimental|Cohort 1|Each participant will receive a single oral dose of the 4-probe substrate cocktail consisting of midazolam, repaglinide, dextromethorphan and metformin in the morning of Day 1 of Period 1. In Period 2, participants will receive ganaplacide and lumefantrine combination orally once daily (q.d.) in the morning on Days 1 through 3, with a single oral dose of the 4-probe substrate cocktail co-administered on Day 3.
88807367|NCT05236530|Experimental|Cohort 2|Each participant will receive a single oral dose of the 2 probe substrate cocktail consisting of rosuvastatin and dolutegravir in the morning on Day 1 of Period 1. In Period 2, participants will receive ganaplacide and lumefantrine combination orally q.d. in the morning on Days 1 through 3, with a single oral dose of the 2 probe substrate cocktail co-administered on Day 3.
88807368|NCT00455702|Experimental|D-cycloserine|50 mg d-cycloserine
88807369|NCT00455702|Placebo Comparator|Placebo|50 mg placebo
88807370|NCT04388306||Study Group|Thirty-two participants with undergone arthroscopic Rotator Cuff repair
88807371|NCT04388306||Control Group|Thirty-two healthy participants
88807372|NCT00456014|Experimental|1 - SSRI|Participants will receive standardized pharmacotherapy with the SSRI escitalopram over 8 weeks. Non-remitters after 8 weeks will be offered standardized pharmacotherapy with desipramine
88807373|NCT05235516|Experimental|treatment arm|
88807374|NCT05235516|Placebo Comparator|placebo arm|
88807375|NCT00411398|Experimental|Memantine 5-20mg/d flexible dose|Memantine tablets 5-20mg/d flexible dose
88807376|NCT05234268|Experimental|Manual Cervical Traction|The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion.
88807377|NCT05234268|Experimental|Passive Accessory Intervertebral Movements|Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension. Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra.
88807378|NCT05234268|Experimental|Active Strength Training|The progression of exercises will be done using different colours of Thera-band indicating varied resistance
88807379|NCT05231694|Other|sham EA + placebo group|sham EA + placebo group contain sham EA intervention and placebo injection
88807380|NCT05231694|Other|sham EA + NGF group|sham EA + NGF group contain sham EA intervention and NGF injection
88807381|NCT05231694|Other|EA + placebo group|EA + placebo group contain EA intervention and placebo injection
88807382|NCT05231694|Other|EA + NGF group|EA + NGF group contain EA intervention and NGF injection
88807383|NCT00457730|Experimental|Duloxetine|subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
88807384|NCT00457730|Placebo Comparator|placebo|matched placebo medication
88807385|NCT01965470|Experimental|Combination Prevention|"Scale-up of HTC services during 2 annual HTC campaigns, with a target of >90% of adults having documentation of their HIV-infected status or documentation of an HIV-negative test in the preceding 12 months.~Scale-up of universal ART for all HIV-infected adults, with a target of >93% of HIV positive adults receiving ART.~Scale-up of retention in care and adherence interventions, with a target of ensuring that >95% of HIV-infected adults are virally suppressed with HIV-1 RNA <400 copies per ML..~Scale-up of linkage to MC services, with a target of ensuring >60% of HIV-negative men are circumcised.~Rapid strengthening of PMTCT services, with a target of >90% of women initiated on indefinite ART (Option B+) during pregnancy remaining in care and on treatment at 12 months post-delivery."
88807386|NCT01965470|Active Comparator|Enhanced Care|Enhanced Care Communities will receive guidance and improved technical support for quality management and data systems at all local clinics at which individuals receive HIV care and treatment.
88807387|NCT05181384|Experimental|Transabdominal Sonography-guided Biofeedback group|pelvic floor muscle training with transabdominal sonography-guided Biofeedback
88807388|NCT05181384|Active Comparator|Exercise group|pelvic floor muscle training
88807389|NCT05181384|Placebo Comparator|Control group|pelvic girdle education
88807390|NCT00458822|Experimental|All Patients|All patients treated with Melphalan with Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients with Systemic Light-Chain (AL) Amyloidosis
88807391|NCT00459368|Experimental|I|In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
88807392|NCT00459368|Active Comparator|II|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
88807393|NCT01795040|Experimental|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
88807394|NCT01795040|Placebo Comparator|placebo without PUFAs|Placebo without PUFAs
88807395|NCT05278572|Experimental|Group|Intervention consists of a psychotherapy trial using cognitive-behavioral stress management/expressive supportive therapy to target depression among HIV-positive older women. Dosage: 8 sessions. Frequency: weekly. Duration: 8 weeks.
88807396|NCT00413582|Active Comparator|1|Epidural analgesia
88807397|NCT00413582|Experimental|2|IV narcotic analgesia
88807398|NCT00389168|Experimental|Irbesartan|Irbesartan per os titrated to 300 mg od, 48 weeks
88807399|NCT00389168|Active Comparator|Atenolol|Atenolol per os titrated to 100 mg od, 48 weeks
88807400|NCT00462020|Active Comparator|1|5 days of IV antibiotics after appendectomy
88807401|NCT00462020|Experimental|2|home on oral antibiotics to complete 7 days of treatment when tolerating PO's
88807402|NCT05178576|Experimental|Arm 1|ctDNA positive Gevokizumab for 1 year (maximum of 13 cycles)
88807403|NCT05177718|Other|Treatment Single Arm|SINGLE ARM: 30 patients with multiple sclerosis treated with Natlizumab infusion given monthly at the dose of 300 mg IV
88807404|NCT05177250|Other|Case group|50 cases with type 2 DM.
88807405|NCT05177250|Other|Control group|50 subjects not diabetics.
88807406|NCT00414206|Active Comparator|1% mecamylamine|
88807407|NCT00414206|Active Comparator|0.3% mecamylamine|
88807408|NCT00414206|Placebo Comparator|Placebo|
88807409|NCT04241874|Experimental|Low PEEP and full inspiratory synchronization|PEEP = 5 cmH2O + clinically selected pressure support (PSVclin)
88807410|NCT04241874|Experimental|High PEEP and full inspiratory synchronization|PEEP = 15 cmH2O + clinically selected pressure support (PSVclin)
88807411|NCT04241874|Experimental|Low PEEP and inspiratory desynchronization|PEEP = 5 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
88807412|NCT04241874|Experimental|High PEEP and inspiratory desynchronization|PEEP = 15 cmH2O + bilevel positive airway pressure (Respiratory rate 15 breaths/minute, inspiratory time=1 sec, Inspiratory pressure=PSVclin+PEEP, PS=0 cmH2O)
88807413|NCT04241640|Experimental|Nefopam group[|
88807414|NCT04241640|Placebo Comparator|placebo group|
88807415|NCT00462332|Experimental|High risk patientes|Category of risk will be defined according to biological features.
88807416|NCT00462332|Experimental|Low risk patients|Category of risk will be defined according to biological features.
88807417|NCT04241094|Experimental|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
88807418|NCT05226312|Experimental|Local Warm Compress|They are gauze covers brought to a certain temperature (temperature varies between 26-34°C or 79-93°F in warm applications) as a compress material, or wraps and covers that can be reheated.
88807419|NCT05226312|No Intervention|Not Local Warm Compress|No warm wet application will be made to this group. It will be tracked for only 3 days.
88807420|NCT00462644|Active Comparator|Etomidate|Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications
88807421|NCT00462644|Active Comparator|Fentanyl-Midazolam|Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.
88807422|NCT00462722|Placebo Comparator|Placebo pre and post exercise|placebo before and after musculoskeletal-loading exercise
88807423|NCT00462722|Experimental|Placebo pre and ibuprofen post exercise|placebo before and ibuprofen after musculoskeletal-loading exercise
88807424|NCT00462722|Experimental|Ibuprofen pre and placebo post exercise|ibuprofen before and placebo after musculoskeletal-loading exercise
88807425|NCT05224830||Presence of Hyperventilation Syndrome (HVS+)|Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS +- : Nijmegen questionnaire score > 23/64
88807426|NCT05224830||No presence of Hyperventilation Syndrome (HVS-).|Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS - : Nijmegen questionnaire score < 24/64
88807427|NCT00528398|Experimental|Treatment (idarubicin, cytarabine)|Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.
88807428|NCT05223348|Experimental|Body Scan Meditation|The experimental condition involves participants listening to a 16-minute recording of a body scan meditation. The body scan condition guides participants to focus on their bodily sensations separately, then together as a whole.
88807429|NCT05223348|Active Comparator|Listening Task|The active comparer condition involves participants listening to a 16-minute recording of text that describes the human musculoskeletal system. The text will be narrated by a female voice to match the body scan meditation. In addition, the focus on the body in the text of the active condition matches the focus on the body in the body scan meditation and, as such, controls for demand characteristics.
88807430|NCT00528788|Experimental|Pre and post doxicalciferol|ESRD: all patients with secondary hyperparathyroidism who are vitamin D naive will receive doxercalciferol 2 mcg or 4 mcg 3 times per week fopr 30 days (1 month). Blood work and vascular laboratory studies will be performed pre and post treatment.
88807431|NCT05174520|Active Comparator|Routine Physical Therapy group|"Routine physical therapy group includes thermotherapy for 10 mins, transcutaneous electrical nerve stimulations for 10 mins. Exercises such as: Pelvic tilts, bridging exercise, William flexion exercises and stretching will be performed for 7-10 repetitions.~Treatment duration will be 25 minutes."
88807432|NCT05174520|Experimental|Experimental group|"Experimental group includes 6-7 repetitions of Muscle energy technique on Quadratus Lumborum muscle and Routine physical therapy, i.e Thermotherapy, transcutaneous electrical nerve stimulations, Pelvic tilts, bridging exercise, William flexion exercises and stretching will be performed for 7-10 repetitions.~Treatment duration will be 40 minutes."
88807433|NCT00414518|Experimental|Treatment interruption|Oral Tenofovir disoproxil fumarate/Emtricitabine and Lopinavir/Ritonavir for 12 weeks followed by treatment interruption if CD4 count is 450 mm^3 or higher. When CD4 count is less than 350 mm^3 on two separate, consecutive measurements during treatment interruption, therapy will be resumed.
88807434|NCT00414518|Experimental|CD4 T cell guided therapy|Anti Retroviral Therapy initiated when AIDS-defining illness occurs or if CD4 count is confirmed at less than 350 mm^3 at two separate, consecutive measurements
88807435|NCT01795664|Active Comparator|Seretide Evohaler|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen & Hanburys, UK)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
88807436|NCT01795664|Experimental|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
88807437|NCT05271084|Experimental|Citalopram + Pentoxifylline group|Citalopram (tablet): 20 mg once a day for 12 weeks + Pentoxifylline (tablet): 400 mg twice a day for 12 weeks
88807438|NCT05271084|Placebo Comparator|Control group|Citalopram (tablet): 20 mg once a day for 12 weeks + placebo (tablet) twice a day for 12 weeks
88807439|NCT00531518|No Intervention|Control group|This is the control arm. Participants will be offered only case management. Participants may seek outside treatment, without guidance from study staff.
88807440|NCT00531518|Experimental|Family-aided Assertive Community Treatment|This is the experimental intervention arm for high-risk-for-psychosis participants. The intervention includes psychiatric drugs (aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine), psychoeducational multifamily group treatment and supported employment and education .
88807441|NCT01658514|Experimental|Met DR|One dose of 1000 mg metformin delayed-release
88807442|NCT01658514|Active Comparator|Met XR|One dose of 1000 mg metformin extended-release
88807443|NCT01658514|Placebo Comparator|Placebo|One dose of Placebo
88807444|NCT00533546|Experimental|Tier One|Participants will receive APC by intravenous injection, receiving 50% of dose as a bolus and the remainder as an infusion over one ho.
88807445|NCT00534794|Experimental|Elestat|
88807446|NCT00534794|Active Comparator|Pataday|
88807447|NCT01658436|Experimental|BEZ235 300 mg/400 mg bid (Stage 1)|Stage 1 consisted of a single arm where patients received BEZ235 300mg or 400mg bid. Initially the study started with a dose of 400mg bid. However, following an amendment after the preliminary safety and tolerability data from the first 3 patients treated at the 400mg dose, the dosage was changed to 300mg bid.
88807448|NCT04244604|Experimental|High Sodium Meal (2500 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a high sodium meal (2500 mg sodium).
88807449|NCT04244604|Placebo Comparator|Low Sodium Meal (140 mg sodium)|Participants will have sympathetic nerve activity, vascular function, blood pressure and blood samples (from intravenous catheters) assessed before and after a low sodium meal (140 mg sodium) which will serve as the control condition to demonstrate whether or not observed changes are due to high sodium or occur irrespective of sodium in the postprandial state.
88807450|NCT05170776|Experimental|Pilates and postural correction exercise|pilates and postural correction exercise will be received three times a week for 10 weeks
88807451|NCT05170776|Active Comparator|Pilates exercises|pilates exercise will be received three times a week for 10 weeks
88807452|NCT05170776|Active Comparator|postural correction exercises|postural corrections exercise will be received three times a week for 10 weeks
88807453|NCT05219838|Experimental|Lu AG06466 Low Dose|Participants will receive Lu AG06466 low dose capsule orally once daily for 6 days approximately 30 minutes following a light meal.
88807454|NCT05219838|Experimental|Lu AG06466 High Dose|Participants will receive Lu AG06466 high dose capsule orally once daily for 6 days approximately 30 minutes following a light meal.
88807455|NCT05168280|Active Comparator|DEX group|The DEX group patients will be received dexmedetomidine intraoperatively.
88807456|NCT05168280|Placebo Comparator|Placebo group|The placebo group patients will be received 0.9% saline intraoperatively.
88807457|NCT05219370|Experimental|CBD rich|Cannabis oil oral drops containing 95 mg/ml CBD; 5 mg/ml THC; 15 mg/ml CBDV ; no CBG, once daily Titration from 0.3 to 1.8 ml/day during 21 days
88807458|NCT05219370|Experimental|CBG rich|"Cannabis oil oral drops containing no CBD; 5 mg/ml THC; no CBDV; 95 mg/ml CBG, once daily.~Titration from 0.3 to 1.8 ml/day during 21 days"
88807459|NCT05219370|Experimental|CBD & CBG rich|"Cannabis oil oral drops containing 47.5 mg/ml CBD; 2.5 mg/ml THC; 7.5 mg/ml CBDV; 47.5 mg/ml CBG, once daily.~Titration from 0.3 to 1.8 ml/day during 21 days"
88807460|NCT05219370|Placebo Comparator|placebo|Placebo oil oral drops once daily. Titration from 0.3 to 1.8 ml/day during 21 days
88807461|NCT05170308|Other|Treatment (CO2 fractional laser) arm|CO2 fractional laser will be used to treat dyspigmentation in lichen planus pigmentosus in one half along sagittal midline section in each subject.
88807462|NCT05170308|No Intervention|No treatment (Control) arm|One half along sagittal midline section in each subject will not receive the CO2 fractional laser treatment.
88807463|NCT05170152|Active Comparator|. Group A|Underwent ultrasound guided methyl prednisolone acetate injection, between A1 pulley and tendons
88807464|NCT05170152|Experimental|Group B|Underwent ultrasonography-guided percutaneous A1 pulley needle release
88807465|NCT05168514|Experimental|Massage|"Massage begins with the patting (eflorage) maneuver. Massage is continued with petrissage, bearing, friction and percussion maneuvers.~Maneuvers are performed for 3-5 minutes. A patting motion is performed between maneuvers and at the end of the massage. During the massage, it is observed whether the integrity of the skin is impaired or in terms of redness."
88807466|NCT05108376|Experimental|Intervention Arm|The Visensia Safety Index (VSI) will be used to alert RACE staff of patient deterioration.
88807467|NCT00464204|Experimental|Voluven® Arm|
88807468|NCT00464204|Active Comparator|0.9 % NaCl|
88807469|NCT05107206|Experimental|Envi™-SR Thrombectomy Device|Mechanical Thrombectomy using the Envi™-SR Thrombectomy Device
88807470|NCT05107206|Active Comparator|Solitaire or Trevo Revascularization Device|Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device
88807471|NCT05106816|Experimental|Vibrotactile Continuous stimulation|Continuous stimulation
88807472|NCT05106816|Experimental|Vibrotactile Intermittent stimulation|Intermittent stimulation
88807473|NCT05106816|Sham Comparator|Vibrotactile Sham|Sham stimulation
88807474|NCT00464438|Experimental|1|
88807475|NCT00464438|Active Comparator|2|
88807476|NCT00465530|Experimental|2|Saline plus Gentamycin
88807477|NCT00465530|Placebo Comparator|1|Saline
88807478|NCT04421430|Experimental|Distraction cards group|Distraction cards was applied to the children in this group during the venipuncture procedure.
88807479|NCT04421430|Experimental|Virtual reality group|Virtual reality intervention was applied to the children in this group during the venipuncture procedure.
88807480|NCT04421430|Experimental|Buzzy® group|Buzzy® was applied to the children in this group during the venipuncture procedure.
88807481|NCT04421430|No Intervention|Control group|The control group received the routine venipuncture procedure and did not receive any other non-pharmacological intervention.
88814567|NCT02458092|Experimental|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant given intramuscularly in the deltoid muscle of the non-dominant arm.
88807482|NCT05052762|Experimental|Group A: Elastic resisted training for Gluteus Maximus strength.|bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped and weight-bearing hip extension are added.
88807483|NCT05052762|Experimental|Group B: Weight resisted training for Gluteus Maximus strength|Prone hip extension with knee flexion against weighted resistance
88807484|NCT00466310|Active Comparator|Aripiprazole for 4 weeks|Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
88807485|NCT00466310|Active Comparator|Risperidone for 4 weeks|Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
88807486|NCT00466310|Other|Healthy volunteers|Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.
88807487|NCT05051904||Warfarin|"All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with warfarin. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection)."
88807488|NCT05051904||Dabigatran|"All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with dabigatran. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection)."
88807489|NCT05051904||Rivaroxaban|"All eligible Japanese on-valvular atrial fibrillation (NVAF) patients with concomitant Coronary Artery Disease (CAD), who were prescribed with rivaroxaban. From existing data from the Japan Medical Data Vision Co. Ltd. (MDV) database, which covered all insurance types and a large population size.~The study period started on April 18th, 2011 (start of data collection) to December 31st, 2020 (end of data collection)."
88807490|NCT05106270||Combined procedure|The whole cohort underwent combining procedure of catheter ablation and left atrial appendage closure, atrial pressure was measured before and after pulmonary vein isolation, and after left atrial appendage closure.
88807491|NCT02116322|Experimental|Pancreatic mass|Patients with pancreatic mass presenting for EUS-FNA
88807492|NCT00535652|Experimental|Ertapenem|Administration of 1 gram ertapenem I.V.
88807493|NCT00418028|Active Comparator|A Cint|Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 days,until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
88807494|NCT00418028|Experimental|B Ccont|Capecitabine 800 mg/m2 orally twice-daily (in the morning and in the evening the equivalent of one dose of 1600 mg/m2) for 21 days, in 3 week cycles without resting period, until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
88807495|NCT05160246|Experimental|taping group|Facilitation taping will be applied to the rectus femoris of patients with knee OA in the taping group.
88807496|NCT05160246|Placebo Comparator|placebo group|The patients with knee OA in the placebo group will be placed tape on the rectus femoris without any tension.
88807497|NCT05049954|Experimental|Healthy Ketogenic Diet (HKD)|"Participants in the HKD group will be advised to follow a calorie-restricted healthy ketogenic diet (n=35), with a maximum of 50g net carbohydrate intake daily, with calorie prescriptions calculated based on the Schofield equation, adjusted with a deficit of 500 kcal daily to promote weight loss.~Participants will attend group workshops conducted by dietitians at weeks 1, 3, 5, 7, and thereafter at 6-week intervals over the course of a 6-month period (total of 7 workshops). Participants will also be recommended to use the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, steps count and to aid in their adherence to the diet and physical activity recommendations during the 6 months period. The participants will be recommended to achieve their incremental daily step count goal from 3,000, 7,000 to 10,000 to promote increased physical activity, as per their tolerance."
88807498|NCT05049954|Active Comparator|Low Fat caloric-restricted Diet (LFD)|"Participants in the reference group will be instructed to follow a calorie-restricted low fat diet (LFD) (n=35), with calorie prescriptions calculated based on the Schofield equation, adjusted with a deficit of 500 kcal daily to promote weight loss.~Similar to the experimental group, participants will attend group workshops conducted by dietitians at weeks 1, 3, 5, 7, and thereafter at 6-week intervals over the course of a 6-month period (total of 7 workshops). Participants will also be recommended to use the Nutritionist Buddy (nBuddy) mobile application to facilitate monitoring of diet intake, steps count and to aid in their adherence to the diet and physical activity recommendations during the 6 months period. The participants will be recommended to achieve their incremental daily step count goal from 3,000, 7,000 to 10,000 to promote increased physical activity, as per their tolerance."
88807499|NCT00537290|Experimental|Rituximab|All patients will receive 1000 milligrams of rituximab by intravenous infusion on Days 1 and 15.
88807500|NCT05049720|Experimental|Experimental|Patients will be implanted with an Extravascular ICD and undergo requisite electrical testing.
88807501|NCT05158842|Other|Bubble CPAP Oxygen Therapy|Feasibility of Device
88807502|NCT00538304|Experimental|1|bimatoprost eye drops
88807503|NCT00538304|Placebo Comparator|2|placebo
88807504|NCT00538616|Active Comparator|Precedex-Propofol|Patients received an infusion of precedex for six hours and then a washout and then a propofol infusion for six hours.
88807505|NCT00538616|Active Comparator|Propofol- Precedex|Patients received an infusion of propofol for six hours and then a washout and then a precedex infusion for six hours.
88807506|NCT00469274|Active Comparator|Antibiotic PEP|Subjects who did receive PEP following pertussis exposure
88807507|NCT00469274|No Intervention|No PEP|Subjects who did not receive PEP following pertussis exposure
88807508|NCT05158296|Experimental|Ultevursen 180/60 µg|180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
88807509|NCT05158296|Experimental|Ultevursen 60/60 µg|60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
88807510|NCT05158296|Sham Comparator|Sham-procedure|Sham-procedure (no experimental drug administered) on Day 1, Month 3 and every 6 months thereafter
88807511|NCT05099094|Experimental|BD311 Adults single group|Administered by suprachoroidal injection. Dosage form: injection solution. Dose: 500uL. Frequency of administration: one time injection.
88807512|NCT05099016|Experimental|Joint Effort (mobile application)|The Joint Effort mobile application aims to support young adults into taking action on their cannabis use. Based on the Theory of Planned Behaviour, the content focuses on intention, attitude and perceived behavioral control. Various intervention methods and strategies are used to address these determinants (e.g., personalized feedback, persuasive communication, self-observation and activation of intention). The objectives includes: to allow the individual to become aware (or more aware) of their cannabis use, to support the individual's decision-making process of taking action on their cannabis use, to guide and support the establishment and sustainability of an action plan. An optional logbook-type feature (weekly journal of cannabis use) allows personalized monitoring and data collection throughout the course of the intervention.
88807513|NCT05099016|Active Comparator|Brief normative feedback and standard information|The comparator is composed of a a brief normative feedback regarding last month frequency of cannabis use and basic reliable non personalized information on lower-risk cannabis use (official public websites).
88807514|NCT00469508|Active Comparator|Modafinil|Modafinil 400mg oral dose taken daily for 12 weeks
88807515|NCT00469508|Placebo Comparator|Placebo|Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks
88807516|NCT05096832|Experimental|V-01 COVID-19 Vaccine|1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).
88807517|NCT05096832|Placebo Comparator|Placebo control|1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).
88807518|NCT00470600|Placebo Comparator|Normal Saline|250 milliliters normal saline as a placebo comparator was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
88807519|NCT00470600|Experimental|Intravenous ibuprofen|800 mg of intravenous ibuprofen diluted in 250 milliliters normal saline was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
88807520|NCT00471068|Experimental|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
88807521|NCT00471068|Active Comparator|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
88807522|NCT00471380|Active Comparator|Crossover group ABB|"3 period, 2 treatment cross-over model:~Participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for period 1 for 8 weeks. Then participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)"
88807523|NCT00471380|Active Comparator|Crossover group BAA|"3 period, 2 treatment cross-over model:~Participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 1 (8 weeks). Then participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)."
88807524|NCT00538850|Experimental|Fentanyl sublingual spray|Participants received fentanyl sublingual spray 7 times or placebo 3 times in random order to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.
88807525|NCT00418262|Experimental|Atomoxetine HCL (Strattera)|Teatment of children with fetal alcohol syndrome and ADHD with Atomoxetine HCL (Strattera)
88807526|NCT00418574|Experimental|Abagovomab|
88807527|NCT00418574|Placebo Comparator|Placebo|
88807528|NCT00473642|Experimental|1|Standard Fluence Photodynamic Therapy combined with ranibizumab
88807529|NCT00473642|Experimental|2|Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab
88807530|NCT00473642|Active Comparator|3|Ranibizumab monotherapy
88807531|NCT00418964|Experimental|Single bundle hamstring|
88807532|NCT00418964|Experimental|Double bundle hamstring|
88807533|NCT00418964|Active Comparator|Bone patellar tendon bone|
88807534|NCT00539942|Active Comparator|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
88807535|NCT00539942|Experimental|Arixtra (fondaparinux sodium)|Patients randomized to treatment arm will initiate Arixtra (fondaparinux sodium) treatment on post-operative day 1 and continue treatment until post-operative day 22 (21 consecutive days). Subjects randomized to this arm are to receive the standard prophylactic dose for major abdominal surgery of 2.5 mg/day for a total of 21 consecutive days (including hospitalization time and after hospital discharge).
88807536|NCT00419666|Experimental|Calcitriol 3mcg/g|Participants receive calcitriol 3 micrograms per gram (mcg/g) ointment applied topically twice daily for 56 days.
88814568|NCT02458092|Experimental|Rabies Vaccine Rabipur|Rabies Vaccine Rabipur given intramuscularly in the deltoid muscle of the non-dominant arm.
88807537|NCT00540722|Experimental|Treatment (R-(-)-gossypol acetic acid)|"Patients receive oral R-(-)-gossypol once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Patients undergo tumor tissue and blood sample collection at baseline and periodically during study for biomarker correlative studies. Archived tumor tissue samples, if available, are analyzed for Bcl-2 family protein expression (e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, and BH3 domain for BH3 members only) and MGMT gene methylation status. Blood samples are analyzed for apoptotic protein levels (Bcl-2) by enzyme-linked immunosorbent assay."
88807538|NCT00541190|Experimental|cystic fibrosis|Cystic fibrosis patients
88807539|NCT00541190|Experimental|healthy controls|Healthy control subjects
88807540|NCT00542750|Experimental|N-Acetylcysteine|All participants will receive N-Acetylcysteine 1200 mg twice daily during four weeks of participation. Tolerability, marijuana use, and reactivity to marijuana cues will be investigated.
88807541|NCT00475904|Active Comparator|amitriptyline 4% ketamine 2% cream, placebo capsules|Np-1 cream and placebo gabapentin
88807542|NCT00475904|Active Comparator|gabapentin capsules, placebo cream|gabapentin caps and placebo cream
88807543|NCT00475904|Placebo Comparator|placebo cream and capsules|placebo cream and capsules
88807544|NCT00420992|Experimental|ALO-01|Up to 80 mg twice a day (bid)
88807545|NCT00420992|Placebo Comparator|Placebo|Twice a day (bid)
88807546|NCT00423878|Experimental|1|Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day
88807547|NCT00423878|Active Comparator|2|Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day.
88807548|NCT00478556|Active Comparator|1|Gastroview
88807549|NCT00478556|Experimental|2|Omnipaque
88807550|NCT00480740|Experimental|Cardiac Transplant|diagnostic cardiac catheterization in children with a transplanted heart
88807551|NCT00480740|Experimental|Fontan procedure|diagnostic cardiac catheterization in children with a transplanted ventricle
88807552|NCT00480740|Other|Normal Physiology|diagnostic cardiac catheterization in children with normal cardiac physiology
88807553|NCT00424268|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: tiotropium 18 µg, once daily, inhaled"
88807554|NCT00424268|Placebo Comparator|Placebo|"Placebo~underlying medication: tiotropium 18 µg, once daily, inhaled"
88807555|NCT00424502|Experimental|1|
88807556|NCT00425672|Experimental|Arm I|Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
88807557|NCT00543764||Pre pathway|Pre pathway
88807558|NCT00543764||Post pathway|Post pathway
88807559|NCT00544076|Experimental|Sildenafil Citrate/Mo+Aprostadil/day|Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
88807560|NCT00544076|Active Comparator|Sildenafil Citrate Monthly|Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
88807561|NCT00544076|Experimental|Daily Sildenafil Citrate|Patients receive oral sildenafil citrate once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
88807562|NCT00544778|Experimental|Arm 1|High-dose chemotherapy with doxorubicin at 120 mg/m2 and ifosfamide at 2 g/m2 followed by a prolonged schedule of CPT-11 at 20 mg/m2.
88807563|NCT02122796|Experimental|Acupuncture|Two sessions of acupuncture, at least twelve hours apart, post-mastectomy.
88807564|NCT02122796|No Intervention|Standard of Care|Standard of care post-mastectomy.
88807565|NCT00484874|Experimental|A Single Dose of I-131 Tositumomab|I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.
88807566|NCT01795742|Active Comparator|Electric Nebulizer|Pulmo-Aide Model 5650D
88807567|NCT01795742|Experimental|Human-Powered Nebulizer|Human-Powered
88807568|NCT00486824|Active Comparator|Indomethacin|50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
88807569|NCT00486824|Active Comparator|Nifedipine|30 mg Nifedipine initially followed by 20 mg every 6 hrs for 48 hrs.
88807570|NCT00489086|Other|Tazarotene Cream|Open label
88807571|NCT02119442|Other|Transcatheter Valve Implantation|Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
88807572|NCT00489866|Experimental|Aripiprazole|
88807573|NCT00489866|Placebo Comparator|Placebo|
88807574|NCT00546104|Experimental|Dasatinib|50- 100 mg PO BID
88807575|NCT00546728|Experimental|Exenatide|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
88807576|NCT00546728|Active Comparator|Metformin|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
88807577|NCT00546884|Placebo Comparator|MI|The MI condition will expose participants to the provision of an advance directive and written instructions, roughly mimicking community standards and the requirements of the federal Patient Self Determination Act.
88807578|NCT00546884|Active Comparator|GI|Subjects randomized to the GI group will be invited to meet individually with a health care professional specializing in EOL care
88807579|NCT00547586|Placebo Comparator|Placebo|
88807580|NCT00547586|Experimental|150 mg|
88807581|NCT00547586|Experimental|300 mg|
88807582|NCT00547586|Experimental|450 mg|
88807583|NCT00547586|Experimental|600 mg|
88807584|NCT00547898|Experimental|Placebo|
88807585|NCT00547898|Experimental|Crofelemer 125 mg|
88807586|NCT00547898|Experimental|Crofelemer 250 mg|
88807587|NCT00547898|Experimental|Crofelemer 500 mg|
88807588|NCT00548132|No Intervention|1|Patients in this arm will continue to get routine care
88807589|NCT00548132|Experimental|Chlorhexidine-impregnated foam dressing|Patient's catheters were cleaned with chlorhexidine-alcohol solution at least weekly before application of the Biopatch. These were evaluated daily and if the dressing was bloody, soiled or damaged, the dressing and the Biopatch were replaced prior to the 7-day period.
88807590|NCT00490100|Experimental|Treatment|Treatment
88807591|NCT00490256|No Intervention|Control|Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.
88807592|NCT00490256|Active Comparator|Experimental|This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.
88807593|NCT00490802|Experimental|Intranasal Oxytocin|Subjects were given 24 IU intranasal oxytocin twice daily, in the morning and afternoon for 6 weeks.
88807594|NCT00490802|Placebo Comparator|Placebo|Subjects were given placebo twice daily, in the morning and afternoon for 6 weeks.
88807595|NCT00550394|Active Comparator|Quetiapine and Placebo|Quetiapine and Placebo
88807596|NCT00550394|Experimental|Quetiapine and Topiramate|Quetiapine and Topiramate
88807597|NCT00550862|Experimental|INT-747 10 mg|INT-747 10 mg once daily in combination with URSO for 12 weeks.
88807598|NCT00550862|Experimental|INT-747 25 mg|INT-747 25 mg once daily in combination with URSO for 12 weeks.
88807599|NCT00550862|Experimental|INT-747 50 mg|INT-747 50 mg once daily in combination with URSO for 12 weeks.
88807600|NCT00550862|Placebo Comparator|Placebo|Placebo once daily in combination with URSO for 12 weeks.
88807601|NCT00551174|Experimental|1|
88807602|NCT00551174|Active Comparator|2|
88807603|NCT00492206|Experimental|Cetuximab|"Cetuximab 400 mg/m2 IV week 0 only~External beam radiation weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly thereafter weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly weeks 8 - 26~Carboplatin AUC = 6 IV Paclitaxel 200 mg/m2 IV Every 3 weeks x 3 Cycles"
88807604|NCT00431132|Experimental|Vagifem® 10 mcg|One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks
88807605|NCT00493064|Experimental|Prospective active treatment|Niacin 500mg TID PO for treatment of retinal vein occlusions.
88807606|NCT00552422|Experimental|Domperidone Arm|Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.
88807607|NCT00552812|Experimental|Stent therapy of aortic coarctation|Stenting of aortic coarctation
88807608|NCT00432458|Experimental|Arm I: Thal/ZLD|Thalidomide (Thal) + Zolendronic acid (ZLD)
88807609|NCT00432458|Experimental|Arm II: ZLD|Zoledronic acid (ZLD)
88807610|NCT01656408|Experimental|Panel A: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
88807611|NCT01656408|Experimental|Panel B: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
88807612|NCT01656408|Experimental|Panel C: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
88807613|NCT01656408|Experimental|Panel D: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
88807614|NCT01656408|Experimental|Panel E-Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
88807615|NCT01656408|Experimental|Panel F - Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
88807616|NCT01656408|Experimental|Panel G - Healthy - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
88807617|NCT01656408|Experimental|Panel H - Crossover|MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods
88807618|NCT01656408|Experimental|Panel I - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
88807619|NCT01656408|Experimental|Panel J - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
89530688|NCT02512211||Parents of children with haemophilia|Sample of parents of children with hemophilia under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
88807621|NCT00433550|Experimental|Group 1 (6/6 UGT1A1 genotype)|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 2-15
88807622|NCT00433550|Experimental|Group 2 (6/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride as in group 1. They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
88807623|NCT00433550|Experimental|Group 3 (7/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
88807624|NCT02208037|Experimental|Tacrolimus/Methotrexate/Bortezomib|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Bortezomib.
88807625|NCT02208037|Experimental|Tacrolimus/Methotrexate/Maraviroc|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Maraviroc.
88807626|NCT02208037|Experimental|Tacrolimus/MMF/Cyclophosphamide|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Mycophenolate Mofetil (MMF), and Cyclophosphamide.
88807627|NCT05043402|Experimental|Combination navicixizumab + paclitaxel|Combination navicixizumab + paclitaxel: navicixizumab 3 mg/kg Q2W of a 28 day cycle (i.e., Days 1 and 15); paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28 day cycle
88807628|NCT05043402|Active Comparator|Paclitaxel monotherapy|Paclitaxel monotherapy: paclitaxel 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
88807629|NCT05043402|Experimental|Navicixizumab monotherapy|Navicixizumab monotherapy: navicixizumab 3 mg/kg Q2W of a 28-day cycle (i.e., Days 1 and 15)
88807630|NCT03008161|Experimental|Cohort 1|Participants will receive monthly IV infusions of either low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
88807631|NCT03008161|Experimental|Cohort 2|Participants will receive monthly IV infusions of either mid-low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
88807632|NCT03008161|Experimental|Cohort 3|Participants will receive monthly IV infusions of either mid-high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
88807633|NCT03008161|Experimental|Cohort 4|Participants will receive monthly IV infusions of either high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
88807634|NCT00496262|Experimental|Human Fibrinogen Concentrate|
88807635|NCT05043246||Basic diseases Patients/Healthy People|Hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease,Chronic Liver Diseases, Cancer diseases Patients
88807636|NCT03007927|Experimental|Bupivacaine-Dexamethasone|bupivacaine 1,5 mg/kg + dexamethasone 8 mg 2ml
88807637|NCT03007927|Active Comparator|Bupivacaine- physiological solution|bupivacaine 1,5 mg/kg + physiological solution
88807638|NCT05151900|Experimental|Stakeholder Perspectives and Virtual Parent-Led Peer Support Group|Qualitative interviews regarding the impact of COVID-19 will be conducted with youth who have an eating disorder (ED), parents of youth who have an ED, ED clinicians and ED program administrators, as well as get their perspectives on parent-led peer support groups. Three parent-led peer support groups will be started, including psychoeducation in a virtual group setting for parents who have a child or adolescent with an eating disorder.
88807639|NCT01483807|Experimental|SPT-B then SPT-R|Participants first received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
88807640|NCT01483807|Experimental|SPT-R then SPT-B|Participants first received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
88807641|NCT00434018|Other|Wheelchair Skills Training Program|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs. The WSP is a set of assessment and training protocols related to wheelchair skills. The WSP includes the Wheelchair Skills Test (WST), the Wheelchair Skills Training Program (WSTP) and related materials.
88807642|NCT00434018|Other|Basic Health Education|Basic health educational training sessions: Five sessions are held with subjects to provide them additional information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
88807643|NCT05150496|Experimental|Two doses CoronaVac® + one dose medium-dose CoronaVac®|200 participants who were vaccinated with CoronaVac® will be given one dose booster immunization using medium-dose CoronaVac®3-8 months after their second dose
88807644|NCT05150496|Experimental|Two doses CoronaVac® + one dose high-dose CoronaVac®|200 participants who were vaccinated with CoronaVac® will be given one dose booster immunization using high-dose CoronaVac® 3-8 months after their second dose
88807645|NCT05150496|Experimental|Two doses Comirnaty + one dose medium-dose CoronaVac®|120 participants were vaccinated with Comirnaty will be given one dose booster immunization using medium-dose CoronaVac® 6-8 months after their second dose
88807646|NCT05150496|Experimental|Two doses Comirnaty + one dose high-dose CoronaVac®|120 participants were vaccinated with Comirnaty will be given one dose booster immunization using one dose high-dose CoronaVac® 6-8 months after their second dose
88807647|NCT05090514|Experimental|Reading and Growth Mindset Intervention Group|Parents and students receive a packet of age-appropriate books and educational materials on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
88807648|NCT05090514|Active Comparator|Wait-list Control Group|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read.
88807649|NCT00496340|Experimental|Conditioning Followed by HCT|"Pentostatin/Busulfan/Rituximab/Allogeneic Hematopoietic Cell Transplant (HCT).~Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.~Conditioning:~Patients will receive anti-seizure prophylaxis with lorazepam 0.5 mg every 6 hours beginning day -6.~Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.~Patient will then receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.~Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.~Rituximab: Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
88807650|NCT00496808|Experimental|Herceptin|8 mg/kg intravenously (IV) Over 90 Minutes
88807651|NCT05089812|Experimental|Test-Group|PRF-Group
88807652|NCT05089812|Placebo Comparator|Control-Group|
88807653|NCT05040672||Group I|All volunteer male employees of Libbs Pharmaceuticals residing in all Brazilian regions will participate in this research.An online questionnaire will be applied to assess research subjects understanding of prostate cancer and health habits.
88807654|NCT05039268|Active Comparator|15mg Dose Group|Participants will receive a fixed dose regimen of five doses of 15mg.
88807655|NCT05039268|Active Comparator|30mg Dose Group|Participants will receive a fixed dose regimen of five doses of 30mg.
88807656|NCT05038878|Experimental|GnRH antagonist (Elagolix)|Post-menopausal women with benign appearing adrenal adenomas, absence of clinical features of overt Cushing's signs or symptoms and MACE confirmed on either 24 hr urine free cortisol (UFC), late night salivary cortisol and/or abnormal dexamethasone suppression
88807657|NCT05038566|No Intervention|Comparator Baseline|The subject wears their usual partial hand prosthesis while performing functional outcome measures.
88807658|NCT05038566|Experimental|Pointdexter|The subject wears a modified version of their usual partial hand prosthesis. The modification replaces the usual index finger of the partial hand prosthesis with the investigational Pointdexter device. Subjects will either test out this hand configuration in the lab while performing functional outcome measures or at home in their daily lives for approximately four weeks.
88807659|NCT05037864||Ballet Dancer Group (Adolescent Ballet Dancers)|Adolescent ballet dancer student aged 7-17 years who have been actively attending a ballet dance school for at least 1 year will be form ballet dancer group. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. The assessment form, which includes demographic data such as, ballet duration(min/day), frequency (times/week) and continuity (year) will record by asking the parents. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist. Postural alignment will assess with New York Posture Rating Scale (NYPR). Static and dynamic balance will determine with Romberg's Test, Flamingo Balance Test (FBT) and Star Excursion Balance Test (SEBT). Participants will be evaluate for flexibility outcomes by applying following test: sit up and reach test, Thomas test and straight leg raise test. Quality of life will be assess with SF36.
88807660|NCT05037864||Control Group (Sedentary Adolescents)|The control group (Sedentary Adolescent) of the study, are not ballet dance students who aged 7-17 years and have not experience in competitive sport or activity. The age, body weight (kg) and height (centimeter) of each individual included in the study will record. All measurements will be take before lesson and without warm-up. All measurements will be evaluate by an experienced physiotherapist. Postural alignment will assess with New York Posture Rating Scale (NYPR). Static and dynamic balance will determine with Romberg's Test, Flamingo Balance Test (FBT) and Star Excursion Balance Test (SEBT). Participants will be evaluate for flexibility outcomes by applying following test: sit up and reach test, Thomas test and straight leg raise test. Quality of life will be assess with SF36.
88807661|NCT00554372|Experimental|Low Dose|1e8 pfu (plaque forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
88807662|NCT00554372|Experimental|High Dose|1e9 pfu (plaque-forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
88807663|NCT01795820|Other|Group 1 (no loading)|Patients allocated to this group will not receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start), while ticagrelor 90 mg bis in die will be administered from the day of the pharmacological shift on.
88807664|NCT01795820|Other|Group 2 (loading)|Patients allocated to this group will receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start). On the very day of the pharmacological shift, patients allocated in Group 2 will receive Ticagrelor 180 mg (loading dose) on the morning and Ticagrelor 90 mg on the evening, while ticagrelor 90 mg bis in die will be administered from the day after the pharmacological shift on.
88807665|NCT00554996|Other|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
88807666|NCT05087238|Other|PVC-specific CBT|This novel CBT treatment for symptomatic PVC targets cardiac anxiety and symptom preoccupation related to PVC. Treatment is developed from the research groups treatment for Atrial Fibrillation and may be altered during the treatment period to better meet the needs of the patients. Patients receive 10 weeks of CBT delivered through face to face digital video sessions.
88807667|NCT01483963|Experimental|AA4500 0.29 mg/1 mL|Up to three injections
88807668|NCT01483963|Experimental|AA4500 0.58 mg/2 mL|Up to three injections
88807669|NCT01483963|Experimental|AA4500 0.58 mg/1 mL|Up to three injections
88807670|NCT01483963|Experimental|AA4500 0.58 mg/0.5 mL|Up to three injections
88807671|NCT01483963|Other|Shoulder exercises|Home shoulder exercises for 64 days
88807672|NCT05145660|Experimental|Involved site irradiation|"High-risk CTV1 : GTVnx plus a 10-mm margin to encompass the microscopic extension of the gross tumor, the whole nasopharynx, the high-risk structures recommended for CTVp2 by the contouring consensus* (such as parapharyngeal space, skull base, pterygopalatine fossa and the inferior part of the nasal cavity and maxillary sinus), the VIIa, and the retrostyloid space above the bilateral transverse process of C1.~Low-risk CTV2:~N0/positive RPLN only: Bilateral cervical nodal region with the 3-cm caudal expansion below transverse process of C1, and at least covering the level II.~N1-2 (positive cervical LNs): Ipilateral cervical nodal region with the 3-cm expansion below the positive LN (GTVnd), and at least covering the level II; contralateral cervical nodal region with the 3-cm caudal expansion below the transverse process of C1, and at least covering the level II.~Suspicious LN: 1-cm expansion below the suspicious LN (GTVnd-suspicious)"
88807673|NCT05145660|Active Comparator|Elective region irradiation|"High-risk CTV1 : GTVnx plus a 10-mm margin to encompass the microscopic extension of the gross tumor, the whole nasopharynx, the high-risk structures recommended for CTVp2 by the contouring consensus* (such as parapharyngeal space, skull base, pterygopalatine fossa and the inferior part of the nasal cavity and maxillary sinus), the VIIa, and the retrostyloid space above the bilateral transverse process of C1.~Low-risk CTV2:~N0/positive RPLN only: Bilateral level III + Va N1-2 (positive cervical LNs): At least one subsequent level below CTV1"
88814569|NCT01649609|Active Comparator|Reduction of standard immunosuppression|Low dose Tacrolimus with low dose Mycophenolate acid
88807674|NCT05085132|Experimental|MindFi app: Standard content|Participants will receive full access to the MindFi app, containing learning tracks, practice tracks, and assessments. Participants will be instructed to use a practice track for a minimum of 10 minutes a day, and may use other exercises or tracks if desired. The intervention will last 4 weeks.
88807675|NCT05085132|Sham Comparator|Mindfi app: Standard content without practice|Participants will receive full access to the MindFi app, containing learning tracks, music tracks, and assessments. Participants will be instructed to use a music track for a minimum of 10 minutes a day, and may use other exercises or tracks if desired. The intervention will last 4 weeks.
88807676|NCT05034900|Active Comparator|Chest Physiotherapy Group|Patients in this group will perform comprehensive chest physiotherapy program two times a day, 7 days a week for 8 weeks at their homes.
88807677|NCT05034900|Experimental|OPEP device + Chest Physiotherapy Group|In addition to the same physiotherapy program applied to the controls, patients in this group will also use OPEP device two times a day, 7 days a week for 8 weeks at their homes.
88807678|NCT01484041|Experimental|Dovitinib plus aromatase inhibitors|Dovitinib with aromatase inhibitor
88807679|NCT00555152|Experimental|Arm I (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.
88807680|NCT00555152|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
88807681|NCT01461499|Active Comparator|Direct renin inhibitor|
88807682|NCT01461499|Active Comparator|Angiotensin receptor blockers|
88807683|NCT00555464|Experimental|1|Vincristine is a drug that has been used to treat cancers in children (including infants). It has been effective in treating a small number of infants with hemangiomas, most of whom failed previous therapies including steroids. Vincristine must be administered into a vein. Given the encouraging response data and documented safety record, Vincristine is a good choice for a clinical trial treating infants with complicated hemangiomas.
88807684|NCT00555464|Active Comparator|2|The standard treatment for hemangioma at most centers is oral steroids (Prednisolone). Prednisolone has been used to stop the growth of infantile hemangiomas that are life threatening, that could harm important functions, or are likely to result in severe disfigurement (scarring) without treatment.
88807685|NCT05082948|Experimental|Suture arm|Esophageal stent will be placed in standard of care fashion by the endoscopists using standard gastroscopes. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
88807686|NCT05082948|Placebo Comparator|Non-suture|Esophageal stent will be placed in standard of care fashion by the endoscopists using standard gastroscopes. No sutures will be placed to fixate the stent
88807687|NCT01795976|Experimental|NY-ESO-1 T cells|"NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype A serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg.."
88807688|NCT01461655|Placebo Comparator|Topical retinoid - Placebo|
88807689|NCT01461655|Active Comparator|Topical retinoid-NSAID|
88807690|NCT01461733|Experimental|amiodarone|standard dose amiodarone
88807691|NCT01461733|Placebo Comparator|placebo|
88807692|NCT01462279|Experimental|Thiamine|Open label - 200mg IV
88807693|NCT03839472|Experimental|Continuous Bladder Irrigation (CBI)|"Each subject will have a TURBT procedure performed per standard of care procedure, which will be followed by the study intervention - Continuous Bladder Irrigation (CBI) for up to two hours after procedure.~Six samples of discarded bladder irrigation will be collected from each participant (N=20) immediately after TURBT and after the completion of each liter of normal saline 0.9% irrigation (1 to 5 L) for a total of 120 samples."
88807694|NCT04421898||group 1|group 1 : infants with congenital muscular torticollis
88807695|NCT04421898||group 2|group 2 : healthy , without congenital muscular torticollis
88807696|NCT02207803|Experimental|Intervention|Experimental Transition Assistance Program
88807697|NCT02207803|No Intervention|Control|Control
88807698|NCT00435812|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
88807699|NCT00435812|Active Comparator|Engerix-B|1.0 mL Engerix-B
88807700|NCT05081466||United Kingdom Women's Cohort|United Kingdom Women's Cohort Study. No interventions are to be administered in this observational prospective cohort study.
88807701|NCT01464229|Experimental|Iloperidone addition to SSRI antidepressant|
88807702|NCT01464229|Placebo Comparator|Placebo addition to standard SSRI antidepressant|
88807703|NCT05030688|Active Comparator|Group FICB = Fascia iliaca compartment block|FICB will be performed with a suprainguinal approach under US guidance. The probe will be placed sagittally to view the ilium and iliacus muscle. The probe will be moved medially and inferiorly along the inguinal ligament to view the femoral artery. The probe will then be moved superiorly and laterally along the inguinal ligament towards the anterior superior iliac crest to reach the lateral aspect of the femoral nerve. The deep circumflex artery will be visualized 1-2 cm cephalad to the inguinal ligament and superficial to the iliac fascia. The needle will be inserted with in-plane method 2-4 cm caudal to the inguinal ligament to reach below the fascia ilica. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
88807704|NCT05030688|Active Comparator|Group PENG|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block site is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
88807705|NCT00556478|Active Comparator|Double-Blind Active|Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
88807706|NCT00556478|Placebo Comparator|Double-Blind Placebo|Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
88807707|NCT00556478|Active Comparator|Open Label Phase|Subjects will all receive PSD502 if they wish to continue in the trial.
88807708|NCT01467037||Rotavirus-negative|Patients with a negative result for rotavirus via enzyme immunoassay (EIA). No intervention done.
88807709|NCT01467037||Rotavirus-positive|Patients with a positive result for rotavirus via enzyme immunoassay (EIA). Rotavirus-positives were confirmed via real-time reverse-transcriptase polymerase chain reactions (RT-PCR). RT-PCR results were used in the event of discordant EIA results. Rotavirus genotyping was performed. No intervention done.
88807710|NCT05080998||Single arm - Patients undergoing surveillance for UC recurrence|Subjects previously diagnosed with UC and are undergoing a schedule of surveillance cystoscopies and treatment for the possible recurrence of UC will be recruited. Only intermediate and high-risk group, according to AUA /SUO risk categorisation for non-muscle invasive UC, will be eligible for this study. All subjects will undergo CxBladder urine diagnostic testing.
88807711|NCT01912040||Patients|Administration of 123Iodine MIBG to the patients referred .
88807712|NCT01468675|Experimental|Intervention|The intervention is completion of a validated, web-based risk assessment used to assess personalized risk and generate a risk report
88807713|NCT01468675|No Intervention|Control|Usual Care
88807714|NCT00500240|No Intervention|Conventional Care|Control Group: Conventional care using blood sugar management with regular human insulin.
88807715|NCT00500240|Other|Intensive Insulin|Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine
88807716|NCT01469767|Experimental|Fluocinonide cream|Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.
88807717|NCT03246620|Experimental|Olanzapine|oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
88807718|NCT03246620|Active Comparator|Haloperidol|Haloperidol encapsulated tablet, 2 mg tablet, single dose
88807719|NCT03246620|Active Comparator|Diazepam|Diazepam encapsulated tablet, 2mg tablet, single dose
88807720|NCT05141058|Experimental|Prevention of SARS-CoV-2 infection in immunocompromised adult patients|In this dose escalation trial, donor derive coronavirus-specific T cell (CST) (three doses, 1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and <80 years) HSCT recipients (Arm A)
88807721|NCT05141058|Experimental|Prevention of SARS-CoV-2 infection in immunocompromised pediatric patients|In this dose escalation trial, donor derive coronavirus-specific T cell (CST) (three doses, 1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for pediatric (≥12 years of age and <18 years) HSCT recipients (Arm B).
88807722|NCT01470781|Experimental|Cognitive Remediation|This arm will receive computer-based cognitive remediation treatment 3 times per week for 24 weeks, for a total of 70 hours of treatment
88807723|NCT01470781|Placebo Comparator|Computer Control|Group will receive 70 hours of computer time playing pre-selected computer games administered in a similar format as the Cognitive Remediation condition
88807724|NCT01470859|Active Comparator|pramipexole|0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
88807725|NCT01470859|Active Comparator|Levodopa|Sinemet CR CR， Controlled Release
88807726|NCT00436046|Active Comparator|Group 1: 0.6 ml of IVV|30 subjects to receive 0.6 ml of inactivated influenza virus vaccine (IVV).
88807727|NCT00436046|Experimental|Group 3: 0.7 ml of IVV + 10M units of IFN|30 subjects to receive 0.7 ml of IVV containing 10M units of interferon (IFN).
88807728|NCT00436046|Experimental|Group 2: 0.6 ml of IVV + 1M unit of IFN|30 subjects to receive 0.6 ml of IVV containing 1M units of interferon (IFN).
88807729|NCT01471639|Experimental|Intranasal ketorolac (Sprix)|FDA approved drug used in single arm study
88807730|NCT05622656|Placebo Comparator|Placebo|Intraperitoneal instillation of normal saline
88807731|NCT05622656|Active Comparator|Dexmedetomidines|Intraperitoneal instillation Dexmedetomidine 5ug/ml (10ml,50ug)
88807732|NCT05079126|Experimental|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC.
88807733|NCT05079126|Placebo Comparator|Placebo|Subjects will receive a single IV bolus dose of 7 mL Normal Saline.
88807734|NCT05149872|Other|TOF ratio 0.9 spontaneous recovery|TOF ratio maintained at 0.9, spontaneous recovery
88807735|NCT05149872|Other|TOF ratio 0.7 spontaneous recovery|TOF ratio maintained at 0.7, spontaneous recovery
88807736|NCT05149872|Other|TOF ratio 0.7 low dose sugammadex|TOF ratio maintained at 0.7, reversal with sugammadex 2 mg/kg
88807737|NCT05149872|Other|TOF ratio 0.7 high dose sugammadex|TOF ratio maintained at 0.7, reversal with sugammadex 4 mg/kg
88807738|NCT00436904|Experimental|Alemtuzumab + Rituximab|Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
88807739|NCT05139654||Shoulder pain climbers group|Subjects with shoulder pain will be included to perform scaption and pull-up, and assess shoulder kinematics and muscle activation at the same time.
88807740|NCT05139654||Healthy climbers group|Healthy subjects will be included to compare the differences in shoulder kinematics and muscle activation between healthy subjects and subjects with shoulder pain. Subjects in this group will received the same assessments as the shoulder pain climbers group.
88807741|NCT00438854|Experimental|Dasatinib treatment|All patients were treated with dasatinib pills by mouth as treatment.
88812202|NCT05945056|Experimental|Electrotherapy with Frog Leg Exercise Intervention|Experimental group received Frog leg technique along with transcutaneous electrical nerve stimulation for 10 sessions of duration half hour each on regular basis.
88814570|NCT01649609|Active Comparator|mTOR Arm|Low dose Sirolimus with low dose Mycophenolate acid (mTOR Substitution)
88807742|NCT01485055|Experimental|Infliximab and Basiliximab|"Other Names:~Simulect Remicade Monoclonal antibody~Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
88807743|NCT05028348|Experimental|Selinexor, pomalidomide and dexamethasone (SPd)|"Selinexor will be given as an oral dose:~40 mg (2 20 mg tablets) once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.~Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.~Patients ≤75 years:~o Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion.~Patients > 75 years:~Dexamethasone will be given as an oral 20 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Dose may be divided over 2 days at the Investigator's discretion."
88807744|NCT05028348|Active Comparator|Elotuzumab, Pomalidomide and Dexamethasone (EloPd)|"Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.~Pomalidomide will be given as an oral 4 mg dose once a day (QD) on Days 1 to 21 of each 28-day cycle.~Patients ≤75 years:~Dexamethasone 28 mg PO + 8 mg IV on days of elotuzumab dosing~Dexamethasone 40 mg PO on non-elotuzumab days (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion.~Patients >75 years:~Dexamethasone 8 mg PO + 8 mg IV on days of elotuzumab dosing~Dexamethasone 20 mg PO on non-elotuzumab dosing weeks (e.g., days 8, 15, and 22 of cycle 3 and beyond). Dose may be divided over 2 days at the Investigator's discretion."
88807745|NCT01486615|Placebo Comparator|Melatonin|Premedication with 3 mg melatonin (Meloset) tablet orally 1-2 hour prior to anesthesia
88807746|NCT01486615|Placebo Comparator|melatonin and alprazolam premedication|Premedication with 3 mg melatonin and 0.5 mg alprazolam (Stresnil) tablet orally 1-2 hrs prior to anesthesia
88807747|NCT01486615|Placebo Comparator|alprazolam premedication|Premedication with 0.5 mg alprazolam (Alprax) tablet orally 1-2 hr prior to anesthesia
88807748|NCT01486615|Active Comparator|placebo premedication|Premedication with a similar looking placebo tablet orally 1-2 hr prior to anesthesia
88807749|NCT01797068|Experimental|Patient Navigator|Patients in the experimental group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH).
88807750|NCT01797068|Active Comparator|Standard of Care|Patients in the active comparator group will experience the usual intake process in the ED setting.
88807751|NCT00503750|Active Comparator|Trastuzumab and Abraxane followed Trastuzumab and Vinorelbine|Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta®) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
88807752|NCT05078112|Experimental|Sleep Device intervention|Infants will utilize the sleep device during sleep for 20 days
88807753|NCT00438932|Active Comparator|Lanthanum Carbonate and Low Phosphorus Diet|25% of subjects will receive binders plus a phosphate restricted diet.
88807754|NCT00438932|Active Comparator|Lanthanum Carbonate and Unrestricted Phosphorus Diet|25% binders + unrestricted phosphate diet.
88807755|NCT00438932|Active Comparator|Placebo and Low Phosphorus Diet|25% placebo + phosphate restricted diet.
88807756|NCT00438932|Active Comparator|Placebo and Unrestricted Phosphorus Diet|25% placebo + unrestricted phosphate diet.
88807757|NCT04421274|Experimental|BM-MSCs group|Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )
88807758|NCT04421274|Sham Comparator|Control group|Receive the best medication, percutaneous coronary intervention
88807759|NCT05022498|No Intervention|Control 1|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
88807760|NCT05022498|No Intervention|Control 2|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
88807761|NCT05022498|Experimental|Exercise 1|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
88807762|NCT05022498|Experimental|Exercise 2|Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
88807763|NCT00506714|Experimental|Adult subjects with hip osteoarthritis|Walk with and without a single point cane at baseline and after four weeks
88807764|NCT00506714|No Intervention|Healthy Subjects|Healthy adults walking without a cane at baseline
88807765|NCT00508118|Experimental|1|Nicardipine
88807766|NCT00508118|Placebo Comparator|2|0.9% saline
88807767|NCT05622266|Experimental|Pulpotomy|The removal of a small portion of the vital coronal pulp as a means of preserving the remaining coronal and radicular pulp tissues.
88807768|NCT05622266|Active Comparator|Root Canal Therapy|The complete removal of the vital dental pulp. Any material or combination of materials placed inside a root canal for the purpose of obturating and sealing the canal space.
88807769|NCT05139030|Experimental|Cohort 1: EXPAREL admix arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl
88807770|NCT05139030|Active Comparator|Cohort 1: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline
88807771|NCT05139030|Experimental|Cohort 2: EXPAREL admix arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl
88807772|NCT05139030|Active Comparator|Cohort 2: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline
88807773|NCT00440180|Placebo Comparator|Group B|Placebo
88807774|NCT00440180|Experimental|Group A|Anastrozole
88807775|NCT05021094|Experimental|POI patients who taking Kuntai capsule|Patients in this group will take Kuntai capsule orally, 4 capsules each time, 3 times a day, and take the medicine for 3 courses.
88807776|NCT05021094|Active Comparator|POI patients who accepting hormone therapy|The estrogen and progesterone sequential regimen was adopted. The drug was estradiol tablets/estradiol didroxyprogesterone tablets (Femoston). Red tablets (estradiol, 2mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and 3 courses of treatment were taken.
88807777|NCT05021094|Experimental|POI patients who taking Kuntai capsule combined with hormone therapy|Kuntai capsule was taken at the same dose as Kuntai group on the basis of hormone therapy for 3 courses.
88807778|NCT05021094|Experimental|Subclinical POI patients who taking Kuntai capsule|Subclinical POI patients in this group which with Kuntai capsule intervention. This group is a self-controlled experiment before and after treatment
88807779|NCT02114216|Sham Comparator|control group|Subjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
88807780|NCT02114216|Active Comparator|ERD group|Subjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
88807781|NCT02114216|Active Comparator|NERD group|Subjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
88807782|NCT02982746|Experimental|gPCC-G (Gothenburg Person Centred Care) Group|gPCC-G Patients randomized to the intervention group were contacted and scheduled to attend a meeting at the oncology clinic with the nurse specialist in oncology
88807783|NCT02982746|No Intervention|Control group|Control Group Patients randomized to the control group received usual care and return visits were scheduled according to the treatment procedure described under the previous heading and based on the Regional care program for patients with HNC. CG patients were recruited at the same time and in the same way as those in the intervention group
88807784|NCT01364298|Experimental|Gabapentin/B-complex|
88807785|NCT01364298|Active Comparator|Pregabalin|
88807786|NCT04421742||43 COPD|COPD patients with severe airflow obstruction and 1 moderate exacerbation in the previous year being treated with BDP/FF NEXThaler® 100/6 μg b.i.d. for 12 weeks
88807787|NCT00441350|Active Comparator|OM 40|Olmesartanmedoxomil (OM)40 mg tablets.
88807788|NCT00441350|Experimental|OM/HCTZ 40/12.5|Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.
88807789|NCT05072652|Experimental|Immobilization|Participants in the immobilization groups will undergo one week of unilateral knee joint immobilization of the left leg.
88807790|NCT05072652|No Intervention|Control|The control group will not undergo any intervention.
88807791|NCT01488019|Experimental|Perforomist, nebulization, COPD|Active
88807792|NCT01488019|Placebo Comparator|Perforomist-Placebo|Placebo
88807793|NCT05138796|Experimental|TP-05 SAD|Single dose of TP-05 (lotilaner oral capsules) at 4 dose levels in ascending order
88807794|NCT05138796|Experimental|Placebo SAD|Single dose of Placebo
88807795|NCT05138796|Experimental|TP-05 MAD|Four doses of TP-05 (lotilaner oral capsules) at 3 dose levels in ascending order
88807796|NCT05138796|Experimental|Placebo MAD|Four doses of Placebo
88807797|NCT05138796|Experimental|TP-05 Fasted|Single dose of TP-05 (lotilaner oral capsules) in a fasted state
88807798|NCT05138796|Experimental|Placebo Fasted|Single dose of placebo in a fasted state
88807799|NCT04351321|Experimental|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed for the treatment of patients assigned to this group.
88807800|NCT04351321|Active Comparator|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-assisted total gastrectomy will be performed for the treatment of patients assigned to this group.
88807801|NCT05071248|Active Comparator|patients with robot-assisted early mobilization|All patients will receive a physical examination at various time points to assess physical functionality and muscle strength, as well as a sonographic examination of leg muscles, diaphragm, and lungs. These examinations should be performed on day -1 (preoperatively), on postoperative days 1,2,3, then once a week if the patient remains in the ICU, on day 28, on the day of discharge from the ICU, and on a follow-up examination approximately 3 months after discharge from the ICU.The follow-up examination should only take place if the patients present themselves at the hospital anyway due to medically indicated follow-up examinations (not study-related). Alternatively, patients can be asked about their condition by telephone.
88807802|NCT05071248|No Intervention|patients with conventional early mobilization (historic group)|All patients fulfill the same criteria like the intervention group and receive conventional early mobilization.
88807803|NCT01797146|Active Comparator|CARE|All patients in the intervention wards will receive the Catheter Reminder and Evaluation (CARE) intervention.
88807804|NCT01797146|No Intervention|Control|All patients in the control wards will receive usual care without the CARE intervention.
88807805|NCT01488409|Experimental|Acipimox|Treatment with the study drug Acipimox
88807806|NCT01488409|Placebo Comparator|Placebo|Treatment with Placebo control.
88807807|NCT01488877|Experimental|PF03882845|
88807808|NCT01488877|Active Comparator|Spironolactone|25 mg once daily
88807809|NCT01488877|Placebo Comparator|Placebo|Placebo once daily
88807810|NCT01364922|Experimental|Open-label Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 2 tablets twice daily
88807811|NCT01364922|Experimental|Double-blind Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 1 tablet twice daily
88807812|NCT01364922|Placebo Comparator|Double-blind Placebo|Placebo, 1 tablet twice daily
88807813|NCT01489579|Active Comparator|BST counseling group|The patients in the Brief, structured, telephone tobacco cessation, BST, counseling group, will receive tobacco cessation counseling, intervention, by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources.
88807814|NCT01489579|Placebo Comparator|Usual care group|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
88807815|NCT01489969|Active Comparator|20 mg|Neu-P11 dose of 20 mg
88807816|NCT01489969|Active Comparator|50 mg|Neu-P11 dose of 50 mg
88807817|NCT01489969|Placebo Comparator|placebo|matching placebo
88807818|NCT00509288|Experimental|anti-MART-1 F5 TCR PBL + HD IL-2|Patients treated with peripheral blood lymphocytes (PBL)
88807819|NCT00509288|Experimental|anti-MART-1 F5 TCR TIL + HD IL-2|Patients treated with TIL (tumor infiltrating lymphocytes).
88807820|NCT01490359|Experimental|HIV/STD risk-reduction|Men Making a Difference HIV/STD Risk Reduction Intervention was designed to reduce sexual risk behaviors that increase risk of HIV and other sexually transmitted diseases.
88807821|NCT01490359|Active Comparator|Health Promotion Control|Health Promotion Intervention was designed to increase physical activity, healthful diet, and other behaviors to reduce risk of noncommunicable diseases, including diabetes, hypertension, and cancers.
88807822|NCT00442364|Experimental|1|Polidocanol (1%) Microfoam (Varisolve)
88807823|NCT01492309|Active Comparator|Active Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive active 1 Hz right-sided dorsolateral prefrontal cortex (DLPFC) TMS.
88807824|NCT01492309|Sham Comparator|Sham Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive sham transcranial magnetic stimulation.
88807825|NCT00444080|Active Comparator|Control Arm|Subjects undergoing trabeculectomy with the use of Mitomycin C
88807826|NCT00444080|Experimental|Treatment Arm|Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C
88807827|NCT01493167|Other|limb casting/splinting|Patient age 0-90 years. Patient treatment requires extremity immobilization
88807828|NCT05136300|Experimental|Intervention|An integrated multidisciplinary rehabilitation program on general quality of life (short form 36, SF-36, subdomain general health) in the 12 months postoperative period in patients undergoing elective minimal invasive surgery in lung cancer
88807829|NCT05136300|No Intervention|Control|Standard of care
88807830|NCT00510224|Experimental|1|
88807831|NCT05135208||experimental group|patients positioned with 3D camera
88807832|NCT05135208||control group|patients positioned by experienced radiology assistants
88807833|NCT00511706|Experimental|dexamethasone and ranibizumab|Intravitreal injection of dexamethasone 700 µg at Day 1; ranibizumab 500 µg at Day -30 and Day 7-14.
88807834|NCT00511706|Sham Comparator|sham and ranibizumab|Sham injection at Day 1; ranibizumab 500 µg at day -30 and Day 7-14.
88807835|NCT05015244|Experimental|Von Willebrand Disease Type 2B patient with neurological symptoms|evaluation of patients using 3T (Tesla) Magnetic Resonance Imaging (MRI) and series of neuropsychological tests that cover virtually all cognitive domains.
88807836|NCT00511862|Experimental|TheraSphere|Single arm, TheraSphere Yttrium 90 glass microspheres at 120 Gy +/- 10%; stratified by type of disease (colorectal cancer, neuroendocrine cancer, non-colorectal/non-neuroendocrine cancer
88807837|NCT05067894|Experimental|Adult - Vaccine candidate|50 µg dose, adult group (18-59 years)
88807838|NCT05067894|Active Comparator|Adult - Control|SARS-CoV-2 inactivated vaccine, adult group (18-59 years)
88807839|NCT05067894|Experimental|Elderly - Vaccine candidate|50 µg dose, elderly group (> 60 years)
88807840|NCT05067894|Active Comparator|Elderly - Control|SARS-CoV-2 inactivated vaccine, elderly group (> 60 years)
88807841|NCT01493947|Experimental|Ivermectin 1% cream|
88807842|NCT01493947|Active Comparator|Metronidazole 0.75% cream|
88807843|NCT05621720|Experimental|Intervention group|Subjects in the intervention group will receive a 3-moth community-based health-social partnership program (C-HSPP) led by a nurse case manager, and supported by social workers and community workers.
88807844|NCT05621720|Other|Control group|Subjects in the control group will receive usual community services and a monthly social control call from trained community workers.
88807845|NCT05013372|Other|Dose-escalation|Dose -1：0.1×10E+6/kg Dose 1：0.25×10E+6/kg Dose 2：0.5×10E+6/kg Dose 3：1.0×10E+6/kg Dose 4：2.0×10E+6/kg
88807846|NCT00445484|Experimental|Group 1|Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
88807847|NCT00445484|Experimental|Group 2|Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
88807848|NCT01495585|Placebo Comparator|Placebo|Placebo control
88807849|NCT01495585|Experimental|Group 1|lonafarnib 100mg
88807850|NCT01495585|Experimental|Group 2|lonafarnib 200mg
88807851|NCT04421976|Placebo Comparator|Conventional PEEP|PEEP = 5 cmH2O
88807852|NCT04421976|Experimental|Driving pressure (DP) guided-PEEP|PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively.
88807853|NCT00446264|Experimental|islet transplantation|Each participant received up to three sequential fresh islet infusions within three months.
88807854|NCT01495819|Active Comparator|Nicotine|subjects will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg). At the beginning of each experimental session, subjects will first sample the assigned nicotine dose and placebo (saline) condition that are randomly labeled as A or B. which may be nicotine or saline. This procedure will allow subjects to sample the nicotine and saline that will be available during that session. In addition, subjective and physiological responses to the sample nicotine dose and saline will be assessed.
88807855|NCT01495819|Placebo Comparator|Saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
88807856|NCT04214886|Experimental|CAR 5 x 105 transduced T cells/kg (Dose Level -1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 5 x 105 transduced T cells/kg.
88807857|NCT04214886|Experimental|CAR 1 x 106 transduced T cells/kg (Dose Level 1)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1 x 106 transduced T cells/kg.
88807858|NCT04214886|Experimental|CAR 1.5 x 106 transduced T cells/kg (Dose Level 2)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1.5 x 106 transduced T cells/kg.
88807859|NCT04214886|Experimental|CAR 2 x 106 transduced T cells/kg (Dose Level 3)|Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 2 x 106 transduced T cells/kg.
88807860|NCT05621642|Experimental|Online Group|Trainings will be given to the intervention group patients by the researchers. Respiratory, balance and strengthening exercises suitable for the patients will be applied over an online platform under the supervision of a physiotherapist.
88807861|NCT05621642|Active Comparator|Offline Group|The exercises will be video recorded gradually every two weeks and the exercise program of each week will be sent to the patient. The patient will do respiratory, balance and strengthening exercises accompanied by video.
88807862|NCT00513344|Experimental|dark chocolate containing polyphenols|dark chocolate
88807863|NCT00513344|Experimental|Milk chocolate containing polyphenols|Bespoke milk chocolate
88807864|NCT00513344|Active Comparator|Control chocolate with no polyphenols|cocoa-free chocolate
88807865|NCT00514592||All|All patients enter the same group
88807866|NCT04422054||Open Surgery Repair Group|In the open surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications, in the postoperative period, during follow up.
88807867|NCT04422054||Endovascular Repair Group|In the endovascular surgery repair group, preoperative patient characteristics, comorbid conditions, aneurysm anatomy and diameters will be matched with outcomes and complications in the postoperative period, during follow up.
88807868|NCT05127876|Experimental|Group E|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group E: were administered intravenous ephedrine 10 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
88807869|NCT05127876|Experimental|Group OL|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group OL: were administered intravenous ondansetron 4 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
88807870|NCT05127876|Experimental|Group OH|Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group OH: were administered intravenous ondansetron 8 mg diluted in 10 mL 0.9% saline over 1 minute; Then under aseptic precautions, spinal anesthesia was administered.
88807871|NCT05127876|Placebo Comparator|Group P|"Monitoring with pulse oximetry, noninvasive blood pressure measurement and electrocardiogram was established on arrival to the operating room Group P: was a control group who received 0.9% saline 10 mL over 1 minute as a placebo.~Then under aseptic precautions, spinal anesthesia was administered."
88807872|NCT02522286|No Intervention|Usual Care|Standard clinical care in primary care offices
88807873|NCT02522286|Experimental|Ask 3 Questions|Patients using 3 questions to their physicians when making medical decisions during the office visit.
88807874|NCT02522286|Experimental|Open Communication|This arm has three components: (1) Patients, physicians, and medical assistants watching a video aimed at encouraging open communication; (2) Patients fill out a Visit Companion Booklet about what are the most important issues they want to discuss with their physicians, record their next steps, and teach back on their next steps; (3) physicians receiving communication coaching from a Standardized Patient Instructor on patient-centered communication.
88807875|NCT02522286|Experimental|Ask 3 Questions + Open Communication|A combination of both the Ask 3 and Open Communication arms.
88807876|NCT01496131|Active Comparator|Standard therapy|Radiation therapy in combination with androgen deprivation therapy (ADT).
88807877|NCT01496131|Experimental|Standard therapy plus tecemotide (L-BLP25)|Standard therapy (radiation therapy in combination with ADT) plus tecemotide (L-BLP25).
88807878|NCT02520726|Experimental|Sertraline|Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age >65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
88807879|NCT02520726|Placebo Comparator|Placebo|Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.
88807880|NCT05062434|Experimental|Intervention Arm|VA cardiac electrophysiologists receiving the intervention
88807881|NCT01497613|Active Comparator|PRISM B: Notebook Condition|Telephone check-in calls and a notebook containing similar categories of information as the features on the PRISM C computer system such as a resource guide; games; classroom and information, calendar.
88807882|NCT01497613|Experimental|PRISM C: Computer Condition|A computer-based system designed to support socialization and access to resources; knowledge and prospective memory. The system is placed in the homes of those randomized to the condition for 12 months.
88807883|NCT05126550||Immunogenicity|Group 1 constitutes the immunogenicity group which will be evaluated regarding immunogenicity, safety, and effectiveness of the SARS-CoV-2 vaccine (Vero cell) inactivated produced by Sinopharm
88807884|NCT05126550||Non-Immunogenicity|Group 2 that constitutes the non-immunogenicity group which will be evaluated regarding only safety and effectiveness of the aforementioned vaccine
88807885|NCT02115542|Experimental|Regorafenib Monotherapy|Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
88807886|NCT01540513|Experimental|I124-NM404 brain metastases or GBM imaging|injection of I-124NM404 for imaging
88807887|NCT02519712|Experimental|Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells|This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.
88807888|NCT00450242|Experimental|5% Lidocaine cream|5% topical lidocaine cream.
88807889|NCT00450242|Placebo Comparator|Placebo cream|
88807890|NCT05009238|Experimental|Group (A)|Group (A): will receive lumbar stabilization exercises
88807891|NCT05009238|No Intervention|Group (B)|Group (B): will be control group.
88807892|NCT00515528|Experimental|Vaccine Alone|Subjects received vaccine immunization injected intra-dermally or subcutaneously on day 1. The vaccine was an emulsification consisting of 250 mcg each of the following peptides: Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF 125 mcg and Montanide. A second and third vaccination was given at 2 weeks and 4 weeks after the first. If there was no evidence of cancer progression, additional courses of three vaccinations administered at 2 week intervals were administered until disease progression.
88807893|NCT00515528|Experimental|Vaccine plus Ontak|Subjects in Vaccine plus Ontak received the same vaccination strategy as Vaccine alone group but additionally received a single dose of denileukin diftitox(18 mcg/kg) 4 days prior to the first vaccine administration
88807894|NCT05007444|Placebo Comparator|Placebo comparator|Patients in the placebo group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
88807895|NCT05007444|Active Comparator|Active comparator P2Et|Patients in the P2Et group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
88807896|NCT00517010|Experimental|proton beam with ranibizumab|Intervention is 24Gy proton radiation in 2 fractions given within 6 weeks of first dose of intravitreal ranibizumab (0.5mg) drug combined with four monthly doses of intravitreal lucentis and monthly prn lucentis thereafter.
88807897|NCT00517556|Experimental|study group (CCOCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles
88807898|NCT00517556|Active Comparator|control group (traditional OCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.
88807899|NCT05057988|Experimental|Empowered Relief|
88807900|NCT00519584|Placebo Comparator|Ropivacaine/saline|Ropivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
88807901|NCT00519584|Active Comparator|Ropivacaine/dex|Ropivacaine and local steroid: 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic and 0.9% saline 2ml (systemic placebo) for intravenous injection with sedation for the block;
88807902|NCT00519584|Active Comparator|bupivacaine/dex|bupivacaine and systemic steroid: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block plus dexamethasone 8 mg (2 ml) administered intravenously with sedation administered for the block.
88807903|NCT00519584|Placebo Comparator|bupivacaine/Saline|bupivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
88807904|NCT05122884|Experimental|Milrinone group|The pharmacist prepares milrinone 20 mg with normal saline solution (NSS) 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours. The doctor performs Echocardiogram before start Milrinone, during infusion, and after 12 hours from stop Milrinone. Other medications or interventions were used or not used depending on own doctor.
88807905|NCT05122884|Placebo Comparator|Placebo group|The pharmacist uses 100 ml of NSS, packed out in the same format, dose, and administration of the drug were exactly the same as in the milrinone group. The doctor performs Echocardiogram same time as the milrinone group
88807906|NCT00520286|Active Comparator|Modafinil|Participants will receive a Modafinil 200 mg or 400 mg tablet one time per day for 12 weeks
88807907|NCT00520286|Placebo Comparator|Placebo|Participants will receive a matching Modafinil placebo 200 mg or 400 mg tablet one time per day for 12 weeks
88807908|NCT01540825|Experimental|BI 113608 high dose 1|Powder for oral solution
88807909|NCT01540825|Experimental|BI 113608 low dose 1|Powder for oral solution
88807910|NCT01540825|Experimental|BI 113608 low dose 2|Powder for oral solution
88807911|NCT01540825|Experimental|BI 113608 low dose 4|Powder for oral solution
88807912|NCT01540825|Experimental|BI 113608 low dose 5|Powder for oral solution
88807913|NCT01540825|Experimental|BI 113608 medium dose 1|Powder for oral solution
88807914|NCT01540825|Experimental|BI 113608 medium dose 2|Powder for oral solution
88807915|NCT01540825|Experimental|BI 113608 medium dose 3|Powder for oral solution
88807916|NCT01540825|Experimental|BI 113608 high dose 2|Powder for oral solution
88807917|NCT01540825|Experimental|BI 113608 high dose 3|Powder for oral solution
88807918|NCT01540825|Placebo Comparator|Placebo|Powder for oral solution
88807919|NCT05122416|Experimental|Group 1a: SSD<15mm and with splenomegaly|Patients with a Spleen to Skin Distance less than 15mm and who present a splenomegaly.
88807920|NCT05122416|Experimental|Group 1b: SSD<15mm and without splenomegaly|Patients with a Spleen to Skin Distance less than 15mm and who does not present a splenomegaly.
88807921|NCT05122416|Experimental|Group 2a : 15<SSD<25mm and with splenomegaly|Patients with a Spleen to Skin Distance between 15 and 25 mm and who present a splenomegaly.
88807922|NCT05122416|Experimental|Group 2b : 15<SSD<25mm and without splenomegaly|Patients with a Spleen to Skin Distance between 15 and 25 mm and who does not present a splenomegaly.
88807923|NCT05122416|Experimental|Group 3a: SSD≥25mm and with splenomegaly|Patients with a Spleen to Skin Distance higher than 25 mm and who present a splenomegaly.
88807924|NCT05122416|Experimental|Group 3b: SSD≥25mm and without splenomegaly|Patients with a Spleen to Skin Distance higher than 25 mm and who does not present a splenomegaly.
88807925|NCT01796288|Experimental|Erlotinib & simultaneous radiotherapy|patients started simultaneously radiotherapy for all gross tumors
88807926|NCT01796288|Other|Erlotinib & no radiotherapy|patients received no radiotherapy for all gross tumors
88807927|NCT01395043|Other|TAP-catheter|Each patient receives bilateral TAP-catheters preoperatively.
88807928|NCT05573750|Experimental|Intervention|Singing groups with an instrument
88807929|NCT05573750|Other|Control (delayed intervention)|Delayed comparator
88807930|NCT01542229|Experimental|Arm 1: PE + TAU|Prolonged Exposure Therapy +Treatment As Usual
88807931|NCT01542229|Active Comparator|Arm 2: Usual Treatment|Treatment As Usual
88807932|NCT00520910|Experimental|Polypodium leucotomos extract|Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
88807933|NCT00520910|No Intervention|No intervention|Subject is not given any treatment.
88807934|NCT00521456|Experimental|1|
88807935|NCT00521456|Placebo Comparator|2|
88807936|NCT01542307|Experimental|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
88807937|NCT01542307|Placebo Comparator|Room Air|Medical air inhaled for 30 minutes during migraine attack
88807938|NCT01796366|Experimental|Insulin 338 + placebo|
88807939|NCT01796366|Active Comparator|Insulin glargine + placebo|
88807940|NCT03326180|Experimental|Liposomal bupivacaine (EXPAREL)|266mg/20ml EXPAREL mixed with 80ml 0.9% normal saline and 100mg/20ml 0.5% plain bupivacaine hydrochloride. Administered as a single dose intra-operatively by periarticular infiltration.
88807941|NCT03326180|Active Comparator|Bupivacaine hydrochloride alone|"100ml 0.9% normal saline mixed with 100mg/20ml 0.5% plain bupivacaine hydrochloride.~Administered as a single dose intra-operatively by periarticular infiltration."
88807942|NCT01498549|Active Comparator|Atomoxetine|Atomoxetine compared to the sugar pill
88807943|NCT01498549|Placebo Comparator|Sugar Pill|Sugar pill compared to atomoxetine
88807944|NCT05549102||Treatment Group|Participants undergoing a course of Cognitive Behavioural Therapy (CBT)
88807945|NCT05549102||Waiting List Group|Participants on the Waiting List for CBT
88807946|NCT01499173|Experimental|Stroke preparedness intervention|Youth and adults from predominately African American churches in Flint will be enrolled to undergo a faith-based, scientific theory-driven, peer-led behavioral intervention utilizing a pre-post test design.
88807947|NCT01796444|Active Comparator|Axillary Lymph Node Dissection|After sentinel lymph node biopsy, surgery for standard axillary lymph node dissection. Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
88807948|NCT01796444|Experimental|Non-Axillary Lymph Node Dissection|After sentinel lymph node biopsy, no surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial). Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
88807949|NCT01542541|Experimental|Rifaximin|
88807950|NCT01542541|No Intervention|Control|Randomly-selected matched PET-CT scans performed on same day as intervention group.
88807951|NCT05054946|Active Comparator|Endometrioma|Participants who will have endometrioma after histopathological evaluation.
88807952|NCT05054946|Active Comparator|Mature cystic teratoma (dermoid cyst)|Participants who will have mature cystic teratoma (dermoid cyst) after histopathological evaluation.
88807953|NCT05054946|Active Comparator|Serous or mucinous cystadenoma|Participants who will have serous or mucinous cystadenoma after histopathological evaluation.
88807954|NCT00524264|Experimental|1|
88807955|NCT00524264|Placebo Comparator|2|
88807956|NCT05119218||Stunted subject|The population is all children under five aged 3-5 years in the stunting locus village. Subjects in this study were taken with a sampling quota of 100 stunting toddlers toddlers in each area.
88807957|NCT05119218||Normal subject|The population is all children under five aged 3-5 years in the stunting locus village. Subjects in this study were taken with a sampling quota of 100 non-stunted toddlers in each area.
88814571|NCT01610453||ultrasound|primiparous women with prolonged labours will be eligible for examination
88807958|NCT01395277|Experimental|High Flavanol first then Low Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with high flavanol content and 2) before and 2 hours following consumption of a beverage with low flavanol content."
88807959|NCT01395277|Experimental|Low Flavanol first then High Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with low flavanol content and 2) before and 2 hours following consumption of a beverage with high flavanol content."
88807960|NCT00452426|Experimental|Sedation System|Computer-Assisted Personalized Sedation (CAPS) device used for delivery of sedation
88807961|NCT00452426|Active Comparator|Current Standard of Care|Site's current standard used for delivery of sedation
88807962|NCT01396837|Experimental|RedDress Wound Care System (RD1)|RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit
88807963|NCT05117814|Experimental|Zanubrtuinib|Zanubrutinib 320mg Qd
88807964|NCT01544023||Breast Reconstruction with TilOOP|
88807965|NCT04999254|Experimental|Osteopathic treatment / Usual care|osteopathic treatment will be applied in this intervention group.
88807966|NCT04999254|Active Comparator|Usual care|Classic medical treatment
88807967|NCT00524342|Experimental|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
88807968|NCT01545193||Age 18-50|This is a younger study cohort who is anticipated to have a lower incidence of residual neuromuscular blockade
88807969|NCT01545193||Age 70-90|This is a older study cohort who is anticipated to have a higher incidence of residual neuromuscular blockade
88807970|NCT05117658|Experimental|HA121-28|Patients will receive HA121-28 tablets at 450 mg once daily (QD) for 21 days on a 28-day treatment cycle.
88807971|NCT00524576|Experimental|Engerix 2 Doses + Challenge Dose|Subjects received 2 doses of Engerix™-B (Month 0 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
88807972|NCT00524576|Experimental|Engerix 3 Doses + Challenge Dose|Subjects received 3 doses of Engerix™-B (Month 0, 1 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
88807973|NCT02516202|Active Comparator|Vagifem|"One hundred participants will be randomized into the Vagifem® 'active' arm. These women will receive a bottle of Vagifem® tablets (estradiol 10 mcg). One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.~Vagifem® tablets contain 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. The excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate. Vagifem® comes as a small white film-coated tablet. The coating is made of hypromellose and polyethylene glycol.~A placebo gel visually similar to Replens composed of inert hydroxyethylcellulose gel (pH adjusted) applied every 3 days over entire 12 weeks."
88807974|NCT02516202|Active Comparator|Replens|"One hundred participants will be randomized into the Replens® 'active' arm. These women will receive a tube containing Replens® vaginal gel, with 2.5 gm applied vaginally every 3 days over 12 weeks.~Replens® is a bioadhesive polycarbophil-based moisturizing vaginal gel containing; purified water (vehicle humectant), glycerin (moisturizer), mineral oil (as a moisturizer), polycarbophil and carbomer homopolymer type B (allow the product to stick to the vaginal wall), hydrogenated palm oil glyceride (moisturizer), sorbic acid (preservative, antimicrobial), methylparaben, sodium hydroxide (adjusts pH of product so it is suitable for vaginal use).~A placebo tablet visually identical to Vagifem® is inserted daily for 2 weeks, then 2 days/week for remaining 10 weeks."
88807975|NCT02516202|Placebo Comparator|Placebo|"One hundred participants will be randomized into the 'placebo' arm of the study. This arm is comprised of two placebo preparations; placebo tablet and placebo gel applied on the same schedule as 'active' arms.~The placebo tablet coating and excipient ingredients will be the same as are used for Vagifem®; the coating is made of hypromellose and polyethylene glycol and the excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate.~Placebo gel. The product is an inert hydroxyethylcellulose gel (pH adjusted)."
88807976|NCT00526058|Other|A (Secura then Futura)|The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
88807977|NCT00526058|Other|B (Futura then Secura)|The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.
88807978|NCT00526292|Experimental|natural killer (NK) cells with salvage chemotherapy|This is a Phase II study, designed to determine the efficacy of natural killer (NK) cells isolated from HLA-haploidentical related donors when infused following a salvage chemotherapy regimen into patients who have relapsed or persistent leukemia following an allogeneic HLA-compatible HSCT and who are ineligible for a second HSCT.
88807979|NCT05115396|Experimental|Mirror therapy|"To perform mirror therapy, the participant shall be seated in a chair with a table in front of him/her. On the table there will be a mirror in the sagittal plane between the two upper limbs. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the intervention, participants will be instructed to concentrate on the hand reflected in the mirror.~During MT, they will perform an exercise protocol based on previous studies and the American College of Sports Medicine guidelines. The duration will be 30 minutes."
88807980|NCT05115396|Active Comparator|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
88807981|NCT04949490|Experimental|Group A, BNT162b2s01 30 µg (1 dose)|Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) will receive one booster injection of BNT162b2s01 on Day 1. Day 1 (baseline in this trial) must occur ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
88807982|NCT04949490|Experimental|Group A, BNT162b2 30 µg (1 dose)|Trial participants from BNT162-01 (excluding transplant participants from Cohort 13) who received two injections of 30 μg BNT162b2 (Comirnaty) will receive one booster injection of BNT162b2 (Comirnaty) on Day 1. Day 1 (baseline in this trial) must occur ≥24 weeks after the last BNT162b2 (Comirnaty) injection in the parent BNT162-01 trial.
88814572|NCT02449902|Active Comparator|Treatment 1|Estradiol 10 μg vaginal softgel capsule
88807983|NCT04949490|Experimental|Group B, BNT162b2 30 µg (2 doses)|Trial participants in either the trial BNT162-01 (excluding transplant participants from Cohort 13) or BNT162-04 who did not receive the full two vaccinations of 30 μg BNT162b2 (Comirnaty) will be offered two injections of 30 μg BNT162b2 (Comirnaty) as per the conditional marketing authorization on Day 1 and Day 21. Day 1 (baseline in this trial) must occur ≥12 weeks after receiving the last BNT162 candidate vaccine in the respective parent BNT162-01 or BNT162-04 trial.
88807984|NCT04949490|Experimental|Group B transplant subjects, BNT162b2 30 µg (2 doses)|Transplant trial participants from Cohort 13 of the trial BNT162-01 will receive one injection of 30 μg BNT162b2 (Comirnaty) on Day 1 which will be followed 3 to 7 months afterward by a second injection of BNT162b2 (Comirnaty). Day 1 (baseline in this trial) must occur ≥12 weeks after receiving the last BNT162 candidate vaccine in the parent BNT162-01 trial.
88807985|NCT02121860|Experimental|Chil-Pugh Class A|All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
88807986|NCT02121860|Experimental|Chil-Pugh Class B|All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
88807987|NCT02121860|Experimental|Chil-Pugh Class C|All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
88807988|NCT02121860|Experimental|Normal Hepatic Function|All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
88807989|NCT04203810|Experimental|Ectoin® Mouth and Throat Spray Althaea Honey|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
88807990|NCT04203810|Active Comparator|EMSER® Hals- und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
88807991|NCT02122406||Patients RA-BIO|Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)
88807992|NCT05113446||MCI(Mild Cognitive Impairment) group|"Inclusion criteria : Patients 65 years of age or older who are admitted to a LTC(long-term care) facilities, Patients diagnosed with mild cognitive impairment by doctors, Patients with a score of 18 or more and 23 or less on the Mini-Mental State Examination~Exclusion criteria : Patients unable to measure the delirium assessment tool, The Short Confusion Assessment Methods (S-CAM) (Inouye, 2014) due to severe vision and hearing problems, Patients with serious psychiatric or neurological diagnosis,Patients who died or were transferred on the day of admission, Patients receiving emergency treatment at the time of the delirium assessment or unable to measure or intervene with S-CAM due to hospital circumstances"
88807993|NCT04420806|Active Comparator|HIT-exercise|13 months of high intensity endurance and resistance exercise - 3 months of exercise break
88807994|NCT04420806|Sham Comparator|control|no exercise intervention that affect the present study outcomes
88807995|NCT05298332|Experimental|ATI-2173 50 mg Japanese|Healthy adult Japanese subjects will receive 50 mg of ATI-2173
88807996|NCT05298332|Experimental|ATI-2173 50 mg Chinese|Healthy adult Chinese subjects will receive 50 mg of ATI-2173
88807997|NCT05298332|Experimental|ATI-2173 50 mg Non-Asian|Healthy adult non-Asian subjects will receive 50 mg of ATI-2173
88807998|NCT04211220|Experimental|Type 1 diabetes|
88807999|NCT01545583|Placebo Comparator|Placebo intravenous|Placebo administered once intravenously
88808000|NCT01545583|Experimental|0.1 milligram (mg) LY3016859 intravenous|0.1 mg LY3016859 administered once intravenously
88808001|NCT01545583|Experimental|1 mg LY3016859 intravenous|1 mg LY3016859 administered once intravenously
88808002|NCT01545583|Experimental|10 mg LY3016859 intravenous|10 mg LY3016859 administered once intravenously
88808003|NCT01545583|Experimental|50 mg LY3016859 intravenous|50 mg LY3016859 administered once intravenously
88808004|NCT01545583|Experimental|250 mg LY3016859 intravenous|250 mg LY3016859 administered once intravenously
88808005|NCT01545583|Experimental|750 mg LY3016859 intravenous|750 mg LY3016859 administered once intravenously
88808006|NCT01545583|Placebo Comparator|Placebo subcutaneous|Placebo administered once subcutaneously
88808007|NCT01545583|Experimental|50 mg LY3016859 subcutaneous|50 mg LY3016859 administered once subcutaneously
88808008|NCT04210362|Experimental|Educational intervention for 30 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 30 months.
88808009|NCT04210362|Experimental|Educational intervention for 24 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 24 months.
88808010|NCT04210362|Experimental|Educational intervention for 12 months|Children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca will have been exposed to the Neurobehavioral and Psycho-affective Development Program for 12 months.
88808011|NCT04210362|No Intervention|Comparison group|Group comprised of children aged 31 to 60 months and their caregivers from 20 municipalities of Oaxaca, Mexico. Children and their caregivers will not be exposed to the intervention at the moment of their measurements.
88808012|NCT02124044|Experimental|HIV/HCV GT-1b, 24 wks ASV/DCV|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
88808013|NCT02124044|Experimental|HIV/HCV GT-1a/1b, 12 wks ASV/DCV with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
88808014|NCT01502761|Experimental|Regional Intra-arterial Magnesium 0.75g|Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
88808015|NCT01502761|Experimental|Regional Intra-arterial magnesium 1.5g|Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
88808016|NCT01502761|Experimental|Regional/ Distal (75/25%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
88808017|NCT01502761|Experimental|Regional/ Distal (50/50%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
88808018|NCT05112276|Active Comparator|Control Diet|Average Swedish diet
88808019|NCT05112276|Experimental|Intervention Diet|The intervention diet will be based on food items that have shown a beneficial effect on gut microbiota associated with cardiometabolic risk factors.
88808020|NCT02124122|Experimental|Lactobacillus|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
88808021|NCT02124122|Placebo Comparator|Placebo|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
88808022|NCT01504477|Experimental|Combination of Panitumumab and Bortezomib|IV panitumumab and bortezomib
88808023|NCT02124512|Experimental|Arm 1 Rifaximin SSD|Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
88808024|NCT02124512|Placebo Comparator|Arm 2 Placebo|Placebo
88808025|NCT01504711|Experimental|Treatment (nausea and vomiting prophylaxis)|Receive fosaprepitant dimeglumine IV 30 mins. prior to FOLFIRINOX chemotherapy.
88808026|NCT05148260|Experimental|LTP+|"The LTP+ is divided into two components:~First, underpinned by Piaget's theory of cognitive development (Piaget, 1952; Sidik, 2020) and Bowlby's theory of attachment (Bowlby, 1980; Granqvist & Duschinsky, 2021), the central focus here is a pictorial calendar devised for parents, depicting eight successive stages of child development from birth to 3 years, with illustrations of parent-child play and other activities that promote parental involvement, learning, and mum-baby attachment.~Second, well-grounded in the standard framework of cognitive-behavioural theory (Bernal et al., 2009) and uses techniques of active listening, changing negative thinking, guided discovery, behavioural tasks, and homework (i.e. trying things out between sessions, putting what has been learnt into practice), while educating participating mums about depression/anxiety, correlates and management, social support, and practical advice on using appropriate healthcare (Bernal et al., 2009)."
88808027|NCT05148260|Active Comparator|Psychoeducation|This is the comparative group with a primary aim of monitoring participating mums to ensure their postnatal depression does not degenerate. However, supportive, and postnatal educational components are provided. These psychoeducation sessions are grounded on the theory and philosophy of group psychosocial support (with basic but relevant topics on postnatal mental healthcare advice and discussions).
88808028|NCT05131880|Experimental|Experimental|"The experimental group will participate in a physiotherapy program with the addition of the Fisior Tapestry Method physiotherapy program, three sessions per week, for 12 weeks.~An initial assessment will be made at the beginning of the study, another one at the end of the intervention, and another one at follow-up."
88808029|NCT05131880|Active Comparator|Control|The control group will participate in a physiotherapy program three sessions per week for 12 weeks.
88808030|NCT04993950|Experimental|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
88808031|NCT04993950|Active Comparator|SNAGS with thoracic postural correction techniques|active as well as therapist-facilitated stretches.thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
88808032|NCT02208349|Experimental|Video Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
88808033|NCT02208349|Active Comparator|Direct Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
88808034|NCT04993716||Cohort|Patient present in the SAU after an extra-hospital cardiac arrest
88808035|NCT02209519|Experimental|Metronidazole|Male Partner: metronidazole 500 mg PO BID x 7days Female Partner: metronidazole 500 mg PO BID x 7days
88808036|NCT02209519|Placebo Comparator|Placebo|Male Partner: one tablet PO BID for 7 days Female Partner: metronidazole 500 mg PO BID x 7days
88808037|NCT01546285|Experimental|Blood Pressure Reading|Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
88808038|NCT01397071|Active Comparator|Ground Beef Patty with Avocado|Test burgers with fresh avocado added just prior to consumption
88808039|NCT01397071|Active Comparator|Ground Beef Patty without Avocado|Test burgers
88808040|NCT01546675|Active Comparator|Traditional 1, Skeletal Stabilization 2|Subjects using the Traditional Socket and socket hypothesized to increase skeletal stabilization in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
88808041|NCT01546675|Experimental|Skeletal Stabilization 1, Traditional 2|Subjects using the socket hypothesized to increase skeletal stabilization and Traditional Socket and in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
88808042|NCT01397617|Experimental|NobelActive Internal|NobelActive Internal implant
88808043|NCT01397617|Experimental|NobelActive External|NobelActive External implant
88808044|NCT01397617|Active Comparator|NobelReplace Tapered Groovy|NobelReplace Tapered Groovy implant
88808045|NCT02518620|Experimental|ALX-0061 150 mg q2w (+ MTX)|
88808046|NCT02129660|Experimental|Dose 1 of glycopyrrolate, 2.0% QD|glycopyrrolate Topical Wipes
88808047|NCT02129660|Experimental|Dose 2 of glycopyrrolate, 3.0% QD|glycopyrrolate Topical Wipes
88808048|NCT02129660|Active Comparator|Dose 1 of glycopyrronium, 2.5% QD|glycopyrronium Topical Wipes
88808049|NCT02129660|Active Comparator|Dose 2 of glycopyrronium, 3.75% QD|glycopyrronium Topical Wipes
88808050|NCT02129660|Placebo Comparator|Vehicle|Vehicle Topical Wipes
88808051|NCT01398475|Experimental|LY3009104 Reference Formulation|8 milligrams (mg) LY3009104 (two 4-mg phosphate salt capsules), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
88814573|NCT02449902|Placebo Comparator|Treatment 2|Placebo vaginal softgel capsule
88808052|NCT01398475|Experimental|LY3009104 Test Formulation 1|8 mg LY3009104 (one 8-mg smaller particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
88808053|NCT01398475|Experimental|LY3009104 Test Formulation 2|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
88808054|NCT01398475|Experimental|LY3009104 Test Formulation 2 + Meal|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally with high-fat/high calorie meal, once only. There will be a washout period of 5 to 7 days between doses of study drug.
88808055|NCT04946136|Experimental|Gait modification|In this pilot study, participants modify their gait patterns guided by real-time visual feedback on their medial knee load while walking on an instrumented treadmill.
88808056|NCT04235582|Experimental|Outcomes Group|"During the intervention period, the Outcomes group will receive incentives for abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care and a similar mobile app and debit card as the Inputs group. However, the app will prompt patients in this group to submit saliva drug tests through their mobile phones on a random schedule (averaging three tests per week). Patients will receive immediate financial rewards in exchange for submitting drug-negative samples. Saliva tests typically have a window of detection between 24-48 hr after drug use."
88808057|NCT04235582|Experimental|Inputs Group|"Will receive incentives for behaviors that are inputs to abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care. Additionally, patients will be registered for a mobile phone app provided by DynamiCare Health and provided with a linked debit card. The app will prompt patients to complete actions that are inputs to abstinence an average of three times per week. These actions will be tailored to the patient's individual needs, and may include:~Drug adherence to prescribed SUD pharmacotherapy~Attendance at individual and group psychotherapy sessions"
88808058|NCT04235582|Experimental|Combination Group|"Will receive interventions from both Inputs and Outputs groups, as well as standard of care therapy services and urine drug tests an average of three times per week, total. Interventions include incentives for:~Drug adherence to prescribed SUD pharmacotherapy~Attendance at individual and group psychotherapy sessions~Random saliva tests"
88808059|NCT01549405|No Intervention|Control group|Control group: Group that without intercostal nerve block
88808060|NCT01549405|Experimental|nerve block|Group that performing intercostal block
88808061|NCT04945044|Experimental|Computed adenoma detection system (CADe)|Tis system can detect in the screen suspicion areas of adenomatous polyps. This is an additional help for the endoscopist for the detection of lesions
88808062|NCT04945044|Active Comparator|Control group (absence of CADe)|This is the control group. As in the routine colonoscopy the endoscopist is in charge of the detection of the lesions.
88808063|NCT01797770||Mechanical bowel preperation|mechanical bowel preparation with polyethylene glycol one day prior to surgery
88808064|NCT01505179|Active Comparator|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
88808065|NCT01505179|Placebo Comparator|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
88808066|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Placebo|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 48 weeks~Ribavirin 200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 48 weeks~Placebo 0 mg Tablets, by mouth, Once daily, 24 weeks"
88808067|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Daclatasvir|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 24 or 48 weeks depending on response~Ribavirin 1000-1200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 24 or 48 weeks depending on response~Daclatasvir 60 mg Tablets, by mouth, Once daily, 24 weeks"
88808068|NCT04740632|No Intervention|Mothers of children with food allergy diagnosed by a multidisciplinary team|Mothers of children with food allergy diagnosed by a multidisciplinary team (Group 1) already followed for at least 6 months by the Tertiary Center of Pediatric Allergology..
88808069|NCT04740632|Experimental|Mothers of children with food allergy diagnosed by a non-multidisciplinary team|Mothers of children with food allergy diagnosed by a non-multidisciplinary team who plan to visit for the first time the Tertiary Center of Pediatric Allergology.
88808070|NCT04580810|Experimental|CBT4CBT in the Black Church|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of alcohol use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
88808071|NCT04580810|No Intervention|Community Based Treatment as Usual|Treatment as usual, typically groups, offered by a specialty community based treatment center (MCCA)
88808072|NCT01398943|Experimental|COPD Patients|"Patients with COPD~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
88809725|NCT00752102|Active Comparator|Paricalcitol|"Paricalcitol, USP, the active ingredient in Zemplar® Capsules, is a synthetically manufactured analog of calcitriol, the metabolically active form of vitamin D indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Zemplar is available as soft gelatin capsules for oral administration containing 1 mcg, 2 mcg or 4 mcg of paricalcitol. Each capsule also contains medium chain triglycerides, alcohol, and butylated hydroxytoluene.~Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels."
88808073|NCT01398943|Experimental|Controls|"Healthy age- and sex- matched controls~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
88808074|NCT04372862|Active Comparator|Serratus anterior plane block|Serratus anterior plane block was performed in the supine position placing the ipsilateral upper limb in abduction 90 degrees position. Aiming to find the serratus anterior muscle the investigator identified the fifth rib in the mid-axillary line by the linear probe in the sagittal plane. The latissimus dorsi muscle (superficial and posterior), teres major muscle (superior) and serratus muscles (deep and inferior) were detected using ultrasound. The investigator penetrated the serratus anterior muscle by a 25 GA, 90 mm spinal needle in-plane concerning the ultrasound probe from superoanterior to posteroinferior to inject deep to it.
88808075|NCT04372862|Active Comparator|Erector spinae plane block|Erector spinae plane block was performed at lateral decubitus with the operation site up, the vertebrae were counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe was placed vertically 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle.
88808076|NCT01550341|Active Comparator|Buprenorphine|
88808077|NCT01550341|Placebo Comparator|Placebo|
88808078|NCT02125292|Experimental|Mesalamine (Vanilla Yogurt)|One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
88808079|NCT02125292|Experimental|Mesalamine (Applesauce)|One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
88808080|NCT02125292|Experimental|Mesalamine (Dosing Cup)|One 500mg capsule contents emptied into a dosing cup and taken with water
88808081|NCT01401517|Placebo Comparator|Placebo|Microcrystalline cellulose NF at 60 mg/capsule, BID
88808082|NCT01401517|Experimental|40 mg Sodium Nitrite|40 mg dose, BID
88808083|NCT01401517|Experimental|80 mg Sodium Nitrite|80 mg dose, BID
88808084|NCT05038436|Experimental|Polyglucosamine L112|composed of (beta-1.4 polymer of D-glucosamine and N-acetyl-D-glucosamine)
88808085|NCT05038436|Placebo Comparator|Placebo|Dicalcium phosphate, cellulose
88808086|NCT02214277|Experimental|Test Arm|
88808087|NCT02214277|Active Comparator|Control Arm|
88808088|NCT02214277|Other|Safety Arm|
88808089|NCT02126306|Placebo Comparator|Placebo|Normal saline administered orally daily as a placebo
88808090|NCT02126306|Active Comparator|Beta Glucosylceramide|Beta glucosylceramide administered orally daily
88808091|NCT01550731|Experimental|PREPARE|The intervention group will review the PREPARE advance care planning website and PREPARE materials plus receive an advance directive. The control group will only receive an advance directive.
88808092|NCT01550731|Active Comparator|CONTROL|The control group will only receive an advance directive.
88808093|NCT02127632|Active Comparator|Group ETT (endo tracheal tube)|Group ETT (Endotracheal tube Group). In the ETT group for women no. 7-7.5 tube will use. ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
88808094|NCT02127632|Experimental|Group LM-S(Laryngeal mask supreme Group)|Experimental: Group LM-S Group LM-S (Laryngeal mask supreme Group) For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
88808095|NCT01550809|Active Comparator|tBolus (traditional bolus)|Traditional mealtime insulin bolus based on the individual insulin-to-CHO ratio
88808096|NCT01550809|Experimental|iBolus (CGM-based insulin administration)|This is a CGM-based algorithm for prandial insulin administration. An individual patient's model characterizing a 5-hour postprandial period (0-5h PP) is obtained from a 6-day CGM period. A model with interval parameters accounting for patient's variability is calculated considering 20% uncertainty in insulin sensitivity and 10% in carbohydrates (CHO) estimation. Based on this model, constraints on plasma glucose are posed and a set-inversion problem lead to a set of solutions (the iBolus) that contains a bolus insulin dose, a specific mealtime basal insulin dose and the time for restoration of basal to baseline values.
88808097|NCT01551199|Experimental|Multiple Channel Exposure Therapy|MCET-V is a cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks
88808098|NCT01653912|Experimental|GSK2110183, carboplatin and paclitaxel|Subjects will be treated with a maximum of six doses of carboplatin + paclitaxel in combination with continuous daily GSK2110183 followed by single agent GSK2110183 at the single-agent MTD of 125 mg or above oral daily.
88808099|NCT01551979|Active Comparator|Active rTMS|High frequency rTMS stimulation of the vermis(lobule VII) of the cerebellum.
88808100|NCT01551979|Sham Comparator|Sham rTMS|Sham rTMS to the vermis (lobule VII) of the cerebellum.
88808101|NCT03833258|No Intervention|Rehabilitation with precautions|Patients in this arm will continue with rehabilitation following routine care recommendations after total hip replacement; therefore following precautions.
88808102|NCT03833258|Experimental|Rehabilitation with no precautions|Patients in this arm will continue with rehabilitation after total hip replacement without precautions, being permitted to move within limits of their own pain only.
88808103|NCT04132388|Active Comparator|Standard-of-Care|Subjects will be instructed to take adalimumab according to the labeled dosing regimen. Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit.
88809726|NCT01273922|Placebo Comparator|Low Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo.
88809727|NCT01273922|Placebo Comparator|High Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo
88808104|NCT04132388|Experimental|Electronic Reporting|"Subjects will be instructed to take adalimumab according to the labeled dosing regimen. The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
88808105|NCT04944030|Experimental|SCLC (small cell lung cancer)|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
88808106|NCT04944030|Experimental|NSCLC (no small cell lung lung cancer) without oncogenic addiction:|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
88808107|NCT04944030|Experimental|NSCLC (no small cell lung lung cancer) with oncogenic addiction|"At each disease progression, patient will have specific interventions :~Metastasis biopsy~Biomarkers blood, urine and microbiota samples~Patient Reported Outcome (PRO)"
88808108|NCT01552213|Active Comparator|Treatment for glucose intolerance|Regular visit with dietician, exercise, self blood glucose monitoring, Insulin therapy if determined necessary.
88808109|NCT01552213|Active Comparator|Minimum intervention control group|Single visit with dietician or health educator followed by routine care per provider.
88808110|NCT02982824|Experimental|Magnesium add-on|20 children with drug resistant epilepsy will receive oral magnesium sulfate 6 ml per day which equivalent to 400 mg elemental magnesium (Yuen & Sander, 2012) for 6 months and their regular antiepileptic drugs.
88808111|NCT02982824|Placebo Comparator|Antiepileptic drugs only|20 children with drug resistant epilepsy will receive their regular antiepileptic drugs and placebo for 6 months.
88808112|NCT02982824|No Intervention|Healthy controls|To asses serum magnesium level for comparison with the intervention group.
88808113|NCT04991688|Experimental|BOTOX-A|
88808114|NCT02483520|Experimental|Intervention FamTechCare|This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
88808115|NCT02483520|Placebo Comparator|Control and Delayed FamTechCare|This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).
88808116|NCT01797692|Other|geriatric assessment|geriatric assessment
88808117|NCT04989738|Experimental|THRIVE Condition|Specifically, parents will learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
88808118|NCT04989738|Active Comparator|Care As Usual - Healthy Steps Model|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
88808119|NCT01798160|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
88808120|NCT01798160|Experimental|SIRT|Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres)
88808121|NCT02514174|Experimental|Afatinib|afatinib starting at 30 mg daily dose
88808122|NCT02132468|Experimental|fosbretabulin tromethamine|Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
88808123|NCT01507987||Patients with SJM leads implanted|Patient has at least one market released Riata, Riata ST, QuickSite/QuickFlex, or Durata lead implanted
88808124|NCT03195764|Experimental|T-1101 (Tosylate)|
88808125|NCT01508455|Experimental|Dexmedetomidine|Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
88808126|NCT03127982|Experimental|Group 1|Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
88808127|NCT03127982|Active Comparator|Group 2|Participants randomly assigned to this condition do not receive any active intervention during a six-week wait period after randomization, while completing assessment evaluation at the beginning and end of wait list period, after which they receive the same intervention (Unified Protocol) provided to the treatment condition (Group 1).
88808128|NCT03114254|Experimental|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days"
88808129|NCT04081922|Experimental|Regional analgesia using erector spinae plane block|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. Then, regional analgesia is performed for additional analgesia; ultrasound guided erector spinae plane block is performed using 0.25% ropivacaine (total 1 ml/kg) bilaterally. Plasma concentration of ropivacaine at baseline, and 5, 10, 20, 30, 60, 120 minutes after ropivacaine injection will be measured.
88808130|NCT04081922|No Intervention|Control|After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. No regional block is performed.
88808131|NCT02482428|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
88808132|NCT02482428|Experimental|LLFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
88808133|NCT02482428|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
88808134|NCT02482428|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
88808135|NCT02482428|Active Comparator|Aldara|Aldara 5% cream 3 applications per week for a maximum of 16 weeks
88808136|NCT04054076|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
88808137|NCT04054076|Experimental|Custom-made insoles soft|Custom-made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate.
88808138|NCT04054076|Experimental|Custom-made hard|Custom-made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate.
88808139|NCT04054076|No Intervention|Control group|No intervention with therapeutic insoles and/or shoes.
88808140|NCT03796754|Active Comparator|YoBEKA Intervention|
88808141|NCT03796754|No Intervention|Control group|
88808142|NCT02319824|Experimental|Treatment (radiation and NY-ESO-1-specific T cells)|Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.
88808143|NCT01510327|Experimental|PROMUS Element|Patients who received the PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique. Total loaded dose of everolimus per stent is dependent on stent size and in this study the administered dose ranged from 60.1 µg to 138.6 µg per stent. Note that the total dose of everolimus administered to a patient is based on the number of stents received and the size of the stent(s). The total dose received per patient ranged from 60.1 µg to 197.8 µg.
88808144|NCT01401595|Experimental|Night Eaters|Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
88808145|NCT01401595|No Intervention|Control Subjects|"At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls."
88808146|NCT02480712|Experimental|SOF/VEL|Participants will receive SOF/VEL for 12 weeks
88808147|NCT02678156||LYoplant ONlay|Primary objective of the study is the generation of clinical data in patients receiving Lyoplant® Onlay for dura repair to assess its safety.
88808148|NCT01512667|Experimental|Severe Renal Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with severe renal insufficiency.
88808149|NCT01512667|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
88808150|NCT03916094|Experimental|HLX22 group|HLX22, at four dose levels (3, 10, 25mg/kg), to be intravenously injected once every three weeks; Study drugs given until disease progression, one year of treatment, withdrawal from the study or death
88808151|NCT03628976|Sham Comparator|Sham-tVNS to ear lobe|Sham-tVNS will be applied to the ear lobe.
88808152|NCT03628976|Active Comparator|tVNS to tragus|tVNS will be applied to the tragus.
88808153|NCT00115700|Experimental|Radiotherapy+ Chemotherapy|Involved field Radiotherapy (RT) 30-36 GY plus Cyclophosphamide, Vincristine and Prednisolone (CVP) + rituximab × 6 cycles
88808154|NCT00115700|Active Comparator|Radiotherapy alone|Involved field Radiotherapy (30-36 GY) alone
88808155|NCT01553539|Experimental|Treatment (antiangiogenesis therapy)|Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.
88808156|NCT00557882|Active Comparator|mesh|Vaginal reconstructive surgery with synthetic polypropylene mesh
88808157|NCT00557882|Active Comparator|no mesh|Vaginal reconstructive surgery without mesh
88808158|NCT03848000|Experimental|Exercise Programme and NHS Standard Care|Exercise and NHS standard care.
88808159|NCT03848000|Active Comparator|NHS Standard Care only|Alcohol addiction counselling.
88808160|NCT01555567|Experimental|Electrical stimulation|Subjects placed into this group will undergo electrical stimulation following anterior cruciate ligament reconstruction (ACLr). Subjects will be required to report 2 times per week for 6 weeks following ACLr for electrical stimulation therapy. Electrical stimulation therapy post-reconstruction will commence immediately post-ACLr and end at week 6.
88808161|NCT01555567|No Intervention|Standard of Care|This group will undergo standard ACL rehabilitation
88808162|NCT01555567|Experimental|Eccentric Exercise|Subjects placed into this group will undergo eccentric exercise strength training following ACLr. Subjects will be required to report 2 times per week for 6 weeks following ACLr. Eccentric strengthening will begin at week 6 post-ACLr and will end at week 12 post-ACLr.
88808163|NCT01555567|Experimental|Stimulation and Eccentrics|Subjects placed into this group will undergo a combined electrical stimulation and eccentric exercise intervention following ACLr. The electrical stimulation intervention will be delivered immediately following ACLr and will end at 6 weeks post-ACLr. Subjects will receive the electrical stimulation therapy 2 times per week for the first 6 weeks post-ACLr. At six weeks post-ACLr, subjects will begin the eccentric strengthening protocol. Subjects will eccentrically train 2 times per week for 6 weeks. The eccentric strengthening will end at 12 weeks post-ACLr.
88808164|NCT01555957|Experimental|low dose intravenous lipids|
88808165|NCT01555957|Placebo Comparator|high dose of intravenous lipids|
88808166|NCT03243890|Experimental|Intervention|Study drug. Supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day)
88808167|NCT03243890|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablet is matched to the study drug for taste, color, and size.
88808168|NCT03750500|Experimental|Experimental|Participants included in this arm will benefit from a 12-week exercise program using the novel biofeedback rehabilitation device, under remote monitoring from a physical therapist
88808169|NCT03750500|Placebo Comparator|Standard of Care|Patients included in this arm will benefit from the standard of care currently in place in the Primary Care facility: education on risk factors for falls, medication review, visual and auditory acuity screening.
88808170|NCT00560612|Active Comparator|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
88808171|NCT00560612|Placebo Comparator|Placebo|
88808172|NCT01556347|Experimental|Elimination of Immunologic Memory|A single arm multi-drug regimen is used to delete immunologic memory in order to reduce or eliminate alloreactive anti-HLA antibodies in highly sensitized heart transplant candidates. The intervention includes a protocol of Thymoglobulin, Rituximab, plasmapheresis and Bortezomib.
88808173|NCT00561002|Experimental|Influenza vaccine Naive/Inadequately Primed|Participants had no more than one previous lifetime dose of influenza vaccine and received two doses of Fluzone®, on Days 0 and 14.
88808174|NCT00561002|Experimental|Influenza Vaccine Primed|Participants had previously received 2 injections of Influenza vaccine in the same season and received a single dose of Fluzone® on Day 0.
88808175|NCT03236792|Experimental|Newly Diagnosed AL Amyloidosis|Ixazomib/Cyclophosphamide/Dexamethasone. Treatment cycles will be repeated up to 6 cycles or until disease progression or until development of significant treatment-related toxicities.
88808176|NCT03725384|Experimental|Ferrous Sulfate and Vitamin C every other day|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every other day for 12 weeks
88808177|NCT03725384|Active Comparator|Ferrous Sulfate and Vitamin C daily|Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every day for 12 weeks
88808178|NCT01556425|Experimental|Vivitrol Only|The VIVITROL group will be offered one injection of VIVITROL every 4 weeks. Participants in the VIVITROL group will be required to take their scheduled injections to work and earn wages. If a participant misses a scheduled VIVITROL injection (more than 3 days from the scheduled date of administration), the participant will not be allowed to work until the injection is accepted. Additionally, missing a scheduled injection will result in a base pay reset from $8 per hour to $1 per hour. After the reset, the participant's base pay will increase by $1/hour to the maximum of $8/hour for every day that the participant works at least 5 minutes.
88808179|NCT01556425|Experimental|VIVITROL&Opiate Abstinence Reinforcement|This group will be offered VIVITROL and will be required to take it to attend the workplace and to maintain maximum pay. This group will also receive employment-based opiate abstinence reinforcement. This contingency will require participants to provide opiate-negative urine samples on M,W, and F to maintain their maximum pay. If a participant in this group provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
88808180|NCT01556425|Experimental|Opiate Abstinence Reinforcement Only|This group would receive employment-based opiate abstinence reinforcement, but this group will not receive VIVITROL.
88808181|NCT01556425|Other|Usual Care Control|This group will receive neither abstinence reinforcement nor VIVITROL injections, but they will be invited to attend the workplace and outpatient drug abuse counseling.
88808182|NCT01798628|Experimental|Sequence ABC|
88808183|NCT01798628|Experimental|Sequence ACB|
88808184|NCT01798628|Experimental|Sequence BAC|
88808185|NCT01798628|Experimental|Sequence BCA|
88808186|NCT01798628|Experimental|Sequence CAB|
88808187|NCT01798628|Experimental|Sequence CBA|
88808188|NCT01513447|Active Comparator|Sterile Water Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
88808189|NCT01513447|Placebo Comparator|Normal Saline Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
88808190|NCT00562328|Experimental|Alemtuzumab + Rituximab + GM-CSF|Alemtuzumab + Rituximab + GM-CSF
88808191|NCT01514149|Experimental|Arm 1 - Weekly CJC-1134-PC|
88808192|NCT01514149|Experimental|Arm 2 - Weekly CJC-1134-PC|
88808193|NCT01514149|Experimental|Arm 3 - Weekly CJC-1134-PC|
88808194|NCT01514149|Experimental|Arm 4 - Weekly CJC-1134-PC|
88808195|NCT01514149|Placebo Comparator|Arm 5 - Weekly Placebo|
88808196|NCT01514383|Experimental|Surgical Adhesive|The surgical adhesive (cyanoacrylate) will be used once to close the topical skin surgical incision created during surgical procedures.
88808197|NCT01556581|Active Comparator|Usual Care (UC)|The usual care (UC) group will be managed with stepped care approach, receiving a screening exam, advice, education, activity limitation profile and medications if needed, but no early physical therapy.
88808198|NCT01556581|Active Comparator|Early Physical Therapy (PT)|All subjects in this group will get usual care approach in addition to immediately receiving eight sessions of physical therapy based on a pragmatic treatment based classification system for treating low back pain.
88808199|NCT05566093|Experimental|Nonfunctional pancreatic neuroendocrine tumors|The patients with NF-pNETs will undergo EUS-guided ethanol or lauromacrogol ablation
88808200|NCT05565859|Experimental|Planetary Health Plate Signage|A Planetary Health Plate intervention phase where signage was posted in the dining hall promoting the planetary health diet
88808201|NCT05565859|No Intervention|Control|Control phase with dining hall signage as usual.
88808202|NCT01557595|Experimental|Adults with ADHD|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. Subjects will 19 years or older and have ADHD"
88808203|NCT02127710|Experimental|AZD6094 600 mg daily continuously|All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.
88808204|NCT01558063|Active Comparator|Ketamine Dose 1|0.1 mg/kg, IV (in the vein) of Ketamine and MRI scan
88808205|NCT01558063|Active Comparator|Ketamine Dose 2|0.2 mg/kg, IV (in the vein) of Ketamine and MRI scan
88808206|NCT01558063|Active Comparator|Ketamine Dose 3|0.3 mg/kg, IV (in the vein) of Ketamine and MRI scan
88808207|NCT01558063|Active Comparator|Ketamine Dose 4|0.4 mg/kg, IV (in the vein) of Ketamine and MRI scan
88808208|NCT01558063|Active Comparator|Ketamine Dose 5|0.5 mg/kg, IV (in the vein) of Ketamine and MRI scan
88808209|NCT01558063|Placebo Comparator|Saline Solution|Saline infused over 40 minutes and MRI scan
88808210|NCT01515943|Active Comparator|Computer-based therapy (CBT)|The CBT group will be assigned active home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
88808211|NCT01515943|Active Comparator|Near target push-up (NTP)|The NTP group will be assigned placebo home-based computer vergence/accommodative therapy (5 minutes/day) plus near target push-ups (15 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
88808212|NCT01515943|Placebo Comparator|Placebo|The placebo group will be assigned placebo home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
88808213|NCT03670784||Women_KPNC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Northern California (KPNC).
88808214|NCT03670784||Women_KPSC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Southern California (KPSC).
88808215|NCT01798238|Placebo Comparator|Placebo group|
88808216|NCT01798238|Experimental|MP-513 group|
88808217|NCT02857400|Other|Arm A (standard)|
88808218|NCT02857400|Experimental|Arm B (experimental)|
88808219|NCT05565781|Active Comparator|ECG Smartwatch for up to 1 year|Cardiac monitoring with an ECG Smartwatch over 1 year after the acute phase of cryptogenic stroke. Simultaneously, a continuous cardiac monitoring will be performed using an Insertable Cardiac Monitor (ICM)
88808220|NCT05565781|Active Comparator|Holter monitoring for up to 1 year|Cardiac monitoring with an external holter device for 30 days after the acute phase of cryptogenic stroke and 15 additional days of extended use every 3 months up to 1 year
88808221|NCT05565781|Other|Control group|Regular cardiac monitoring with an external holter device for 30 days after the acute phase of cryptogenic stroke
88808222|NCT03641846|Active Comparator|LiST + 5mg Tadalafil Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks.
88808223|NCT03641846|Placebo Comparator|LiST+Placebo Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily placebo pill. Total treatment period = 4 weeks.
88808224|NCT05560724|Active Comparator|Anodal M1 tDCS|20 minutes of anodal tDCS (C3 or C4 depending on side of lesion) to the ipsilesional M1: 2mA Combined with 45min of structured motor training.
88808225|NCT05560724|Active Comparator|Combined M1 and cerebellar anodal tDCS|20 minutes of anodal tDCS (C3 or C4 depending on side of lesion) to the ipsilesional M1 combined with contralesional cerebellar montage (2cm lateral to Inion): 2mA per anode Combined with 45min of structured motor training.
88808226|NCT05560724|Sham Comparator|Sham tDCS|Sham stimulation. Combined with 45min of structured motor training.
88808227|NCT02490722|Active Comparator|Intervention|Four times two hours interdisciplinary patient education and usual care
88808228|NCT02490722|No Intervention|Control|Usual care
88808229|NCT03590678||1|Subject is scheduled for an invasive procedure and did not have NIPT testing in current pregnancy
88808230|NCT03590678||2|Subject is scheduled for an invasive procedure and has a known positive or no-call result from a targeted NIPT in the current pregnancy
88808231|NCT02241980||Medicare Part D patients|Survey
88808232|NCT02241980||Physician Providers|Survey
88808233|NCT02118662|Experimental|Male Cohort|"Eight Male participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
88808234|NCT02118662|Experimental|Female Cohort|"Eight femalel participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
88808235|NCT03545282|Experimental|ALMA Intervention Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention after baseline assessment.
88808236|NCT03545282|Other|ALMA Delayed Intervention Control Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention five months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
88808237|NCT05560334|Experimental|Pemigatinib|Selective FGFR1-3 inhibitor
88808238|NCT05560178|Experimental|Experimental: Training group|women in the intervention group will be given sexual health education once a week for 4 weeks
88808239|NCT05560178|No Intervention|No Intervention: control group|Women will be monitored without any intervention
88808240|NCT01516957|Experimental|AMG 827 140|140 mg AMG 827
88808241|NCT01516957|Placebo Comparator|Placebo SC|Placebo
88808242|NCT01516957|Experimental|AMG 827 280|280 mg AMG 827
88808243|NCT01516957|Experimental|AMG 827 210|AMG 827 SC 210 mg
88808244|NCT01851434||healthy volunteers|age- and sex-matched to the participants with unilateral optic neuritis and a brain MRI suggestive of MS
88808245|NCT01851434||Patients with unilateral optic neuritis|Recruitment will proceed until 10 participants with a brain MRI suggestive of MS (obtained at any time point during the study) have completed the study.
88809728|NCT01279928||Type 1 Diabetes Paediatric|Paediatric patients aged 8-18 with diagnosed Diabetes Mellitis Type 1 attending paediatric clinic at John Hunter Hospital.
88809729|NCT00723632||Peginterferon alfa-2b and ribavirin|All participants included in the study
88808246|NCT03448250|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
88808247|NCT03448250|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
88808248|NCT01519063|Experimental|Naltrexone and memantine|Treatment with Naltrexone and memantine first
88808249|NCT01519063|Placebo Comparator|Naltrexone and Placebo|Treatment with naltrexone and placebo first
88808250|NCT03397940||Year Round School|Children attending year round school
88808251|NCT03397940||Traditional School|Children attending a traditional school with a traditional calendar school year
88808252|NCT01559857|Active Comparator|Pioglitazone|50% of participants will be allocated to 12 weeks of treatment with 30 mg/day of Pioglitazone.
88808253|NCT01559857|Placebo Comparator|Sugar pill|50% of participants will be randomized to 12 weeks of treatment with placebo pill.
88808254|NCT01814540|Placebo Comparator|Placebo Control, Glucose polymer|Treatment 1: Polycose Glucose Polymer Module powder (Abbott Nutrition, Abbott Park, Illinois 60064), fed as 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.
88808255|NCT01814540|Experimental|Treatment 2: Low-Dose BMO|"Treatment 2: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 25% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
88808256|NCT01814540|Experimental|Treatment 3: High-Dose BMO|"Treatment 3: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 35% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 35% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
88808257|NCT01562041|Experimental|Ranolazine 500 mg|Participants received ranolazine 500 milligrams (mg), orally, twice daily (b.i.d.) up to 14 days.
88808258|NCT01519453|Experimental|Home Based Asthma Education|Families will receive 4 home based and 3 phone based asthma education sessions with a community asthma outreach worker
88808259|NCT01519453|No Intervention|Control|There is no control arm specific intervention
88808260|NCT02210065|Experimental|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
88808261|NCT05565547||Patients with common eye diseases|Patients who have common eye diseases, including common anterior segment eye diseases (conjunctivitis, keratitis, corneal opacity, cataract) and fundus diseases (age-related macular degeneration, diabetic retinopathy) and refractive error (myopia, high myopia, hyperopia, anisometropia and presbyopia).
88808262|NCT00634166|Other|Historical Control|Treated within the last 5 years (if possible) with topical prophylactic therapies that did not include mafenide acetate or mafenide salt forms. These are considered the Topical Antimicrobial/Antifungal Medications
88808263|NCT00634166|Experimental|Prospective Patients/Active Drug|Prospective subjects with thermal injuries of 20-60% TBSA on the chest, abdomen, or proximal upper and lower extremities requiring meshed autografts on these areas will receive SS5% as the initial topical moist dressing over the meshed autograft(s) placed at the initial graft procedure (Day 1). Intervention is Sulfamylon® For 5 % Topical Solution.
88808264|NCT02981251|Experimental|Intervention|Health education with support by trained female health volunteer
88808265|NCT02981251|No Intervention|Control|Extra intervention will not be provided except usual care by their physician of the participant.
88808266|NCT00565370|Experimental|A|XP+sorafenib
88808267|NCT00565370|Placebo Comparator|B|XP
88808268|NCT05559788||Participants With Multiple Myeloma|Participants with MM who are first relapsed and will start treatment with selinexor, daratumumab and dexamethasone in a real-world clinical practice setting will be observed prospectively for approximately up to 1 year.
88808269|NCT05559632|Active Comparator|conventional drilling group|drilling the other contralateral sites of bone using the conventional sequential drilling system according to the manufactural instruction.
88808270|NCT05559632|Experimental|osseodensification drilling group|bone preparation was performed using tapered multifluted burs (Densah Bur; Versah, MI, USA) at 800- 1200 rpm counterclockwise rotation under saline irrigation. Drilling to the desired depth using the tapered densah pilot drill with speed of 800-1200 rpm with copious irrigation without any lateral pressure with clock wise motion.
88808271|NCT03315182|Experimental|Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=2 participants)"
88808272|NCT03315182|Experimental|Cohort 2 (Med Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 2 (Med Dose): 5 X 10E13 vg/kg (n=4-5 participants)"
88808273|NCT03315182|Experimental|Cohort 3 (High Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 3 (High Dose): 1 X 10E14 vg/kg (n=4-8 participants)"
88808274|NCT03303950|Experimental|Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)|Participants receive busulfan IV over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Participants undergo HSCT on day 0. Participants then receive cyclophosphamide IV over 60 minutes on days 3 and 4.
88808275|NCT01563055|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
88808276|NCT00565916|Experimental|estrogen plus progesterone|Hormone replacement therapy (HRT): estrogen plus progesterone
88808277|NCT00565916|Active Comparator|estrogen plus placebo|Hormone replacement therapy (HRT): estrogen plus placebo
88808278|NCT03258320|Experimental|CDMS, Surgery|"Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.~Procedure: radical prostatectomy surgery."
88808279|NCT03258320|No Intervention|Control|No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
88808280|NCT05565469|Experimental|Neurostimulator group|Adjustment of neurostimulator settings to see whether or not abdominal stimulation can be provoked
88808281|NCT05559554|Experimental|AK104 (after the change)|Drug: AK104 (after the change) Dose 1 and dose 2, will be administrated intravenously in 60±10 minutes.
88808282|NCT05559554|Active Comparator|AK104 (before the change)|Drug: AK104 (before the change) Dose 1 and dose 2, will be administrated intravenously in 60±10 minutes.
88808283|NCT01564693||ANOREXIC CANCER PATIENTS|Nine lung cancer patients were diagnosed as anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
88808284|NCT01564693||NON-ANOREXIC CANCER PATIENTS|Four lung cancer patients were diagnosed as non-anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
88808285|NCT01564693||CONTROL GROUP|Two healthy volunteers with normal appetite were studied by fMRI regarding the hypothalamic activity.
88808286|NCT01797926|Experimental|Group 1 (5 mg amlodipine and 50 mg losartan)|Subjects in Group 1 will be randomized to receive a single dose FDC 5/50 mg tablet and also separate single tablets each of reference treatment 5 mg amlodipine and 50 mg losartan. The reference treatment will be replicated in a three sequence, three period design
88808287|NCT01797926|Experimental|Group 2 (5 mg amlodipine and 100 mg losartan)|Subjects in Group 2 will be randomized to receive a single dose FDC 5/100 mg; and also separate single tablets each of reference treatment 5 mg amlodipine and 100 mg losartan. The reference treatment will be replicated in a three sequence, three period design
88808288|NCT03008083|Active Comparator|3 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 3 months.
88808289|NCT03008083|Active Comparator|12 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 12 months.
88808290|NCT05559398|Placebo Comparator|Placebo|
88808291|NCT05559398|Experimental|Glenzocimab|
88808292|NCT04388462||locked plating with predicted distribution of loc|
88808293|NCT04388462||unlocked plating with predicted distribution of loc|
88808294|NCT04388462||Interlocking nail +/- blocking screws|
88808295|NCT01521871|Experimental|Tissue glue wound closure|Skin wound closure by tissue glue
88808296|NCT01521871|Active Comparator|Conventional suture + dressing|Skin wound closure by conventional suture + dressing
88808297|NCT00566150|Active Comparator|Levetiracetam|
88808298|NCT00566150|Placebo Comparator|Placebo|
88808299|NCT01521949|Experimental|Acai Juice|2 ounces of Acai Juice Product by mouth twice daily.
88808300|NCT05559242|Experimental|Anlotinib Hydrochloride Capsules|Anlotinib hydrochloride capsules, 12mg, 1 time in total
88808301|NCT01522339|Experimental|Safety of a Customized NICU MRI System|Device: GE OPTIMA MR430s with HDX/GE Electronics
88808302|NCT00566540|Experimental|Treatment (neoadjuvant, adjuvant chemotherapy and radiation)|"PREOPERATIVE:Patients receive cisplatin IV over 2 hours three times weekly in week 1 once daily(QD),5 days a week, in weeks 1-2.~SURGERY:Patients undergo triple endoscopy and biopsy with submandibular gland transfer in week 3.~INTRAOPERATIVE: Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation.~POSTOPERATIVE: Patients receive paclitaxel IV over 3 hours in weeks 7-10 and cisplatin IV over 1-2 hours three times weekly in weeks 7 and 10. Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation QD, 5 days a week, in weeks 7-10."
88808303|NCT00566930|No Intervention|1|
88808304|NCT00566930|Active Comparator|2|spinal manipulation
88808305|NCT00566930|Experimental|3|Spinal manipulation + exercises
88808306|NCT00567008|Experimental|1|Varenicline (Chantix)
88808307|NCT00567008|Placebo Comparator|2|Placebo
88808308|NCT00567242|Experimental|Word-finding with intention component|Treats word-finding (picture naming, category member generation) with an intention manipulation (complex left-hand movement to initiate word-finding trials)
88808309|NCT00567242|Active Comparator|Word-finding with no intention component|Word-finding trials similar to intention mediated treatment, but without intention manipulation
88808310|NCT00567320|Active Comparator|Varenicline|
88808311|NCT00567320|Active Comparator|Sugar Pill or Placebo|Placebo is compared to active drug varenicline
88808312|NCT01522417|Experimental|Short Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
88808313|NCT01522417|Active Comparator|Eptifibatide (Integrilin)|"Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.~Patients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
88808314|NCT01522417|Experimental|Long Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
88808315|NCT00568022|Experimental|Ixabepilone + Capecitabine|
88808316|NCT05554562||Injured athletes|Athletes suffering a groin injury
88809730|NCT00723788|Experimental|Only one arm|All patients enrolled will receive an MRI of the abdomen with detailed views of the appendix
88808317|NCT01522963|Experimental|Nicotine Lozenge Immediately Prior to Stress task|Subjects will receive the nicotine lozenge immediately prior to the stress task at one laboratory session and after the stress task at the other laboratory session
88808318|NCT01522963|Experimental|Nicotine lozenge 10 Minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and immediately prior to the stress task at the other laboratory session
88808319|NCT01522963|Experimental|Nicotine lozenge 20 minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and 10 minutes prior to the stress task at the other laboratory session
88808320|NCT01522963|Experimental|Nicotine Lozenge 30 minutes prior to stress taks|Subjects will receive the nicotine lozenge 10 minutes prior to the stress task during one laboratory session and after the stress task at the other laboratory session
88808321|NCT03094286|Experimental|Arm 1|Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients
88808322|NCT03071666|Experimental|Vitamin B12|cobalamin, 50 µg per day throughout pregnancy and during the first 6 months postpartum.
88808323|NCT03071666|Placebo Comparator|Placebo|Identical taste and appearance with the Experimental arm. Contains no cobalamin
88808324|NCT01865162|Experimental|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
88808325|NCT05363306||thin crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 2mm below the crestal bone in presence of thin mucosa (< 2.5mm)
88808326|NCT05363306||medium crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 2) 1mm below the crestal bone in presence of medium mucosa (2.5-3.5mm);
88808327|NCT05363306||thick crestal mucosa|Based upon vertical mucosa thickness measured at implant placement, implants were placed: 1) at crestal level in presence of thick mucosa (> 3.5 mm);
88808328|NCT05363228|Experimental|Therapy by Dance and Movement|Participants assigned to this part take part in Dance Movement Therapy twice a week (90 minutes each) for the duration of three months.
88808329|NCT05363228|No Intervention|Control to Dance Movement Therapy|Participants assigned to this arm take part in no particular activity for the three months.
88808330|NCT05363228|Experimental|Movement Therapy by Tai Chi|Participants assigned to this part take part inTai Chi class twice a week (90 minutes each) for the duration of three months.
88808331|NCT05363228|No Intervention|Control to Tai Chi|Participants assigned to this arm take part in no particular activity for the three months.
88808332|NCT05533580|Experimental|Remimazolam group|"Induction of anesthesia Slowly injects remimazolam 0.4-0.6 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional remimazolam (0.05 mg/kg each time) is allowed. After the LoC, intravenous sufentanil 0.3 ~0.5ug/kg and cisatracurium besylate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope.~Maintenance of anesthesia remimazolam 0.4~1.2 mg/kg/h and remifentanil 0.1~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
88808333|NCT05533580|Active Comparator|Propofol group|"Induction of anesthesia Slowly injects propofol 2-4 mg/kg (about 1 min) until loss of consciousness (LoC), allowing additional propofol (0.5 mg/kg each time) if sedation is insufficient. after LoC, intravenous sufentanil 0.3 ~0.5ug/kg and cisatracurium besylate 0.1 mg/kg. after sufficient muscle relaxation and blood circulation stabilization, the tracheal tube was inserted under the sliding scope.~Maintenance of anesthesia propofol 4~10mg/kg/h and remifentanil 0.1~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %."
88808334|NCT02998892|Active Comparator|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
88808335|NCT02998892|Experimental|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
88808336|NCT05362604||prenatal|patients affected by confirmed fetal esophageal, duodenal or intestinal atresia and followed in our high-risk pregnancy unit, and scheduled for delivery between 38 and 39 weeks in our tertiary center, regardless of the patient's place of residence
88808337|NCT05362604||postnatal|patients with unsuspected fetal atresia who delivered in their local hospitals: their newborns were transferred to our tertiary hospital within 24 hours and the mother had the option to be also transferred in order to follow her baby.
88808338|NCT05473286||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
88808339|NCT05362214||Audio (no visual cue)|The condition that a participant has to perform Baduanjin exercise by following the audio guidance/illustration according to the reference of Baduanjin practicing video.
88808340|NCT05362214||Video (2D visual cue)|The condition that a participant has to perform Baduanjin exercise by following the video guidance/illustration according to the reference of Baduanjin practicing video.
88808341|NCT05362214||Drone (3D visual cue)|The condition that a participant has to perform Baduanjin exercise by following the drone guiding system including a guidance from drone and audio illustration regarding the reference of Baduanjin practicing video.
88808342|NCT02129426|Experimental|Dexmedetomidine and Ketamine|Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
88808343|NCT02129426|Active Comparator|Dexmedetomidine and Midazolam|Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
88808344|NCT01523821|Other|Cohort 1 (30 mg/kg)|Alpha 1 anti-trypsin (AAT) will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 30mg/kg (maintenance dose) every other day (QOD) on days 3, 5, 7, 9, 11, 13 & 15.
88808345|NCT01523821|Other|Cohort 2 (60 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 60 mg/kg (maintenance dose) QOD on days 3, 5, 7, 9, 11, 13 & 15.
88808346|NCT01523821|Other|Cohort 3 (90 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg on days 1, 3, 5, 7, 9, 11, 13 & 15.
88808347|NCT01523899|Experimental|Xpert MRSA/SA SSTI|use of the Xpert MRSA/SSTI diagnostic assay
88808348|NCT01523899|Active Comparator|Standard culture|performance of standard bacterial culture of abscess material
88808349|NCT05409716|Experimental|Compressive Elastic dressing|Patients who received compressive elastic dressing as a hemostasis technique after coronary angiography using radial approach.
88808350|NCT05409716|Active Comparator|wristband TR Band|Patients who received wristband TR Band as a hemostasis technique after coronary angiography using radial approach.
88808351|NCT01565551||Early-Presenting TBI: Acute Sites|This cohort of patients are studied after acute presentation within 24 hours of TBI to one of the three TRACK-TBI acute Level I Trauma Centers (SFGH, UPMC, UMCB).
88808352|NCT01565551||Late-Presenting TBI: Rehabilitation Center|This cohort of patients are studied after presentation to the TRACK-TBI rehabilitation site (MSMC).
88808353|NCT05356598|Experimental|Peer-delivered|The arm will receive an intervention in the form of a peer-delivered video promoting help-seeking for musculoskeletal injuries while in ROTC. This video will be presented by a current ROTC cadet.
88808354|NCT05356598|Experimental|Authority-delivered|The arm will receive an intervention in the form of an authority-delivered video promoting help-seeking for musculoskeletal injuries while in ROTC. This video will be presented by a US Army Lieutenant Colonel who is currently a professor of military science for an ROTC battalion.
88808355|NCT05356598|Other|Control|The arm will receive no true intervention. Participants in the control arm will watch a video of a US Army First Lieutenant exercising with no reference to musculoskeletal injuries or help-seeking behavior.
88808356|NCT05395910|Experimental|PIPAC Paclitaxel|"3 patients will be allocated to PIPAC arm at Paclitaxel 15mg/m2. If there is 1 dose limiting toxicity (DLT), an additional 3 patients will be allocated to PIPAC arm at 15mg/m2. If there is 2 - 3 DLT, study had exceeded its Maximum Tolerable Dose (MTD) and we will proceed to stop recruitment.~Should there be no DLT, recruitment at PIPAC 30mg/m2 and ePIPAC 15mg/m2 will occurs concurrently in an alternating fashion. PIPAC/ePIPAC dose escalation will continue until a MTD has been reached. Should there be no DLT at PIPAC 30mg/m2 and ePIPAC 15mg/m2, recruitment at PIPAC 45mg/m2 and ePIPAC 30mg/m2 will occurs concurrently in an alternating fashion. Finally, should there be no DLT, recruitment at ePIPAC 45mg/m2 will occurs."
88808357|NCT05395910|Experimental|ePIPAC Paclitaxel|Should there be no DLT under PIPAC arm at Paclitaxel 15mg/m2, recruitment at ePIPAC 15mg/m2 and PIPAC 30mg/m2 will occurs concurrently in an alternating fashion. PIPAC/ePIPAC dose escalation will continue until a MTD has been reached. Should there be no DLT at PIPAC 30mg/m2 and ePIPAC 15mg/m2, recruitment at PIPAC 45mg/m2 and ePIPAC 30mg/m2 will occurs concurrently in an alternating fashion. Finally, should there be no DLT, recruitment at ePIPAC 45mg/m2 will occurs.
88808358|NCT01566331|Experimental|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet.
88808359|NCT01566331|No Intervention|no intervention|Baby-guardTM system, without inflation
88808360|NCT01566409|Active Comparator|Active maintenance treatment|
88808361|NCT01566409|Placebo Comparator|Placebo maintenance treatment|
88808362|NCT04388696|Experimental|Sisterhood 2.0|"Sisterhood 2.0 used a group format with activities that explore respect, nonviolence, healthy relationships, and sexuality, through 8 sessions (3 hours/session) over an 8 week period.~Sessions focus on gender, consider harmful messages around femininity and their image, healthy sexuality, healthy relationships and connections, understanding sexual abuse and assault, and self care."
88808363|NCT04388696|Active Comparator|Job Skills Training|The curriculum used for this program is an intensive 18-24 hour job readiness training curriculum distributed across 3 weeks, or up to 2 months.
88808364|NCT02184416||Observational Arm|"Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be:~Sutent (prospective) - Inlyta~Sutent (retrospective) - Inlyta~Sutent - not further active treatment (supportive care)~Sutent - other second line treatment (Nexavar (sorafenib), Votrient (pazopanib), Afinitor (everolimus), Torisel (temsirolimus), other))"
88808365|NCT04387838||Anti-SARS-CoV2 serological status|"At Day 0, a blood sample is collected by venipuncture and a questionnaire is being filled. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.~For individuals who are anti-SARS-CoV2 seronegative, the same intervention is made at Day 30 and D60.~For the individuals who are anti-SARS-CoV2 seropositive, the study follow-up is stopped."
88808366|NCT01567891|Experimental|Cohort 1|This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells.
88808367|NCT05354336|Experimental|SHR6390（100mg）|
88808368|NCT05354336|Experimental|SHR6390（125mg）|
88808369|NCT05354336|Experimental|SHR6390（150mg）|
88808370|NCT05564923||group 1|Advanced cancer patients over 65 years of age receiving nivolumab
88808371|NCT05349110||Gastroenterology patients|"Patient receiving a colonoscopy because of regular care will be considered eligible for inclusion if at least one diminutive colorectal polyp is encountered during the colonoscopy. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases.~Colonoscopies will be executed using Fujifilm endoscopy systems (Fujifilm® Corporation, Tokyo, Japan), using Pentax endoscopy systems (Pentax Medical®, Hamburg, Germany), and using Olympus endoscopy systems (Olympus®, Tokyo, Japan)."
88808372|NCT01568827|Experimental|Blackraspberry slurry, washout, water|Blackraspberry slurry daily x 5 days, 2 day washout, 8 oz. water daily x 5 days
88808373|NCT01568827|Experimental|Water, washout, Blackraspberry slurry|8 oz. water daily x 5 days, 2 day washout, Blackraspberry slurry daily x 5 days
88808374|NCT05245370|Active Comparator|Control group 1: Control video|
88808375|NCT05245370|Active Comparator|Control group 2: Rationale video + control video|
88808376|NCT05245370|Experimental|Rationale video + clinician testimonial|
88808377|NCT05245370|Experimental|Rationale video + patient testimonial|
88808378|NCT05245370|Experimental|Rationale video + clinician testimonial + patient testimonial|
88808379|NCT01568905|Experimental|Arm 1 Low Level Nicotine Cigarette|(0.4 mg/g)
88808380|NCT01568905|Experimental|Arm 2 Intermediate Nicotine Level Cigarette|(5.7-5.8 mg/g)
88808381|NCT01568905|Experimental|Arm 3 High Level Nicotine Cigarette|(11.4-12.8 mg/g)
88808382|NCT05322980||Microcephaly|Infants with primary microcephaly.
88808383|NCT05322980||Control|Infants without primary microcephaly.
88808384|NCT01569451|Active Comparator|(Placebo and) Glatiramer Acetate|Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
88808385|NCT01569451|Experimental|Rituximab and Glatiramer Acetate (R-GA)|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.
88808386|NCT01569529||No ad exposure|Young adults, who enroll in the cessation program, one month prior to presenting the online advertisements (intervention).
88808387|NCT01569529||Ad exposure|Young Adults, who register for the cessation program, by clicking through the online advertisements (intervention).
88808388|NCT01569607|Experimental|Hebbian-type Stimulation|Participants will be randomized to receive motor training with Hebbian-type stimulation.
88808389|NCT01569607|Sham Comparator|Sham Stimulation|Participants will be randomized to receive sham stimulation.
88808390|NCT01526629||ICD patients with remote follow-up|Patients implanted with a fully automatic ICD and remotely followed-up.
88808391|NCT05564845||Severe SCD genotypes|Children between 6 and 18 years of age of genotypes HbSS, HbSβº
88808392|NCT05564845||Not severe SCD genotypes|Children between 6 and 18 years of age of genotypes HbSβ+, and HbSC and more
88808393|NCT02132936|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
88808394|NCT02132936|Placebo Comparator|Aerosol foam vehicle|Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
88808395|NCT02132936|Active Comparator|Calcipotriol BDP gel|Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
88808396|NCT02132936|Placebo Comparator|Gel vehicle|Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks
88808397|NCT01528891|Active Comparator|Dexmedetomidine|Dexmedetomidine
88808398|NCT01528891|Placebo Comparator|placebo|Normal saline
89530689|NCT03242707|Experimental|Autologous adipose tissue knee injection|Fat will be removed from the abdomen and processed using the Lipogems device. Approximately 5ml of the microfragmented fat product will be injected into the knee joint.
88808401|NCT05198102|Experimental|Investigational vaccine group|Recombinant novel coronavirus vaccine (CHO cells) injection, Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose.
88808402|NCT01529203|Other|Azzalure and Restylane|All subjects will be injected with Azzalure and Restylane
88808403|NCT01529827|Experimental|Treatment (reduced intensity allogeneic PBSCT)|PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan IV over 30 minutes on day -2. Patients undergo low-dose TBI BID on day -1. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. GvHD PROPHYLAXIS: Patients receive tacrolimus IV or PO BID on days -1 to 100 with taper over 4-6 months, MMF PO or IV every 6-8 hours on days -1 to 60, and methotrexate IV over 15 to 30 minutes on days 1, 3, and 6.
88808404|NCT00569192|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
88808405|NCT00569192|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
88808406|NCT00569192|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
88808407|NCT05289206|Experimental|Intervention - single arm|Oxford/AstraZeneca (ChAdOx1-S/nCoV-19 [recombinant]) - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
88808408|NCT01571557||OZURDEX®|OZURDEX® (dexamethasone 700 ug intravitreal implant) administered according to standard of care.
88808409|NCT00569660|Experimental|Azacitidine|75 mg/m^2 Subcutaneous Daily for 7 days every 4 weeks
88808410|NCT05129228|Experimental|OCT-guided saphenous vein graft coronary artery bypass graft surgery|Optical Coherence Tomography (OCT) provides high quality intravascular images by using infrared light. OCT will assess the harvested saphenous vein conduit in Coronary Bypass Graft Surgery (CABG). Abnormalities found in the harvested conduits via OCT, at the discretion of the surgeon, will not be utilized for CABG.
88808411|NCT05129228|No Intervention|Visual inspection-guided saphenous vein graft coronary artery graft surgery|Harvested saphenous vein conduits will be assessed visually and will undergo a blinded OCT.
88808412|NCT01573273|Experimental|TSST Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
88808413|NCT01573273|Placebo Comparator|TSST Women Placebo|Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
88808414|NCT01573273|Experimental|MRI 1 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
88808415|NCT01573273|Placebo Comparator|MRI 1 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
88808416|NCT01573273|Experimental|MRI 2 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
88808417|NCT01573273|Placebo Comparator|MRI 2 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
88808418|NCT01573273|Experimental|TSST Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
88808419|NCT01573273|Placebo Comparator|TSST Men Placebo|Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
88808420|NCT01573273|Experimental|MRI I Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
88808421|NCT01573273|Placebo Comparator|MRI I Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
88808422|NCT01573273|Experimental|MRI 2 Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
88808423|NCT01573273|Placebo Comparator|MRI 2 Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
88808424|NCT01574287|Experimental|FACBC|
88808425|NCT00572468|Active Comparator|Simvastatin|Twenty-two men will be on the Statin arm and take 40 mg of simvastatin.
88808426|NCT00572468|Placebo Comparator|Placebo|Twenty-two men will be on the placebo arm.
88808427|NCT02339246|Active Comparator|Prograf vs Envarsus XR vs Astagraf XL|Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
88808428|NCT02339246|Active Comparator|Prograf vs Astagraf XL vs Envarsus XR|Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.
88808429|NCT05085626|Experimental|fluzoparib+chidamide|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Chidamide: It is recommended to take 20 mg (4 tablets) twice a week, with an interval of no less than 3 days between doses (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), for 30 minutes. Until disease progression or intolerable to patient."
88808430|NCT05085626|Experimental|fluzoparib+camrelizumab|"Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.~Camrelizumab: 200 mg IV drip over approximately 30 minutes (no less than 20 minutes and no more than 60 minutes) on Day 1 of each 3-week treatment cycle until disease progression or intolerance."
88808431|NCT05041946|Experimental|Methylphenidate|treatment of attention deficit disorder and narcolepsy (sleep disorder)
88808432|NCT05041946|Experimental|Placebo|Sugar pill
88808433|NCT00573872|Experimental|Spinal Radiosurgery|Patients will be fitted in a custom immobilization device. A CT simulation scan will then be performed to pinpoint intended radiosurgery target producing a computer optimized radiation plan to be confirmed by planning radiation physicist. Patient will then be placed in their immobilization device and aligned with the treatment planning position. Patient then receives radiosurgery. Treatment delivery will be divided into components of 3-5Gy with repeat CT based localization in between each of these components. For all patients, a nominal prescription dose of 24Gy will be entered into the tomotherapy cost function. Once the plan that provides maximal spinal sparing has been generated, the plan will be renormalized to produce no more than 8Gy (prior RT) or 10Gy (no prior RT) to 0.5cc of spinal cord by dividing the single fraction treatment into fractions of 3-5Gy.
88808434|NCT00574340|Active Comparator|Control study then antecedent hypoglycemia study group|Day 1 euglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to antecedent hypoglycemia study Day 1 hypoglycemia, Day 2 hypoglycemia
88808435|NCT00574340|Active Comparator|Antecedent Hypoglycemic clamp study|Day 1 hypoglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to control study Day 1 euglycemia, Day 2 hypoglycemia
88808436|NCT05004896|Experimental|Ketamine|Four infusions of ketamine will be administered over two weeks. The first two infusions will be dosed at 0.5mg/kg over a period of 40 minutes. For infusions 3 and 4, patients will be flexibly dosed between 0.5 mg/kg to 0.75 mg/kg, depending on clinical response to first two infusions.
88808437|NCT05004896|Active Comparator|Midazolam|Four infusions of midazolam will be administered over two weeks. The first two infusions will be dosed at 0.02mg/kg over a period of 40 minutes. For infusions 3 and 4, patients will be flexibly dosed between 0.02 mg/kg to 0.03 mg/kg, depending on clinical response to first two infusions.
88808438|NCT05005754|Experimental|Probiotics|Subjects are instructed to take one capsule of probiotics daily for a total of 3 months
88808439|NCT05005754|Placebo Comparator|Placebo Control|Subjects are instructed to take one capsule of placebo daily for a total of 3 months
88808440|NCT01798082|No Intervention|Standard counseling|
88808441|NCT01798082|Experimental|Standard counseling, pelvic organ prolapse decision aid|In addition to standard counseling at the time of the initial new patient visit, the patients randomized to the experimental arm will recieve a pelvic organ prolapse decision aid prior to their initial visit.
88808442|NCT00576680|Experimental|Temozolomide with RAD001|
88808443|NCT04866602|Experimental|Atoguanil|Atovaquone 500 mg + Proguanil 348 mg
88808444|NCT04866602|Active Comparator|Malarone®|Atovaquone 1000 mg + Proguanil HCl 400 mg
88808445|NCT04730648|Experimental|pcsk9 inhibitor group|patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.
88808446|NCT04730648|No Intervention|control group|Patients with comparable age, sex ratio, and BMI, but coronary arteries are relatively normal evaluated by coronary angiography. their blood and urine would be collected as the control group.
88808447|NCT05246540||Patients|
88808448|NCT05246462|Experimental|Experimental group|Gynecological cancer patients in a chemotherapy unit in Trabzon were recruited in the study. Inclusion criteria for the study were volunteering to take part in the study, being able to read and write in Turkish, being 18 years of age or older, having been diagnosed with gynecological cancer, knowing that s/he had been diagnosed with cancer, having received at least one chemotherapy treatment and having cancer stage 2 or 3. Exclusion criteria in the study were having a verbal communication disability, having been diagnosed with psychotic and neurological disorders, having received, or receiving psychotherapy, living outside the city center of Trabzon, and receiving treatment at intervals longer than 21 days. The experimental group received 7 sessions of logotherapy interviews.
88808449|NCT05246462|No Intervention|Control group|Gynecological cancer patients in a chemotherapy unit in Trabzon were recruited in the study. Inclusion criteria for the study were volunteering to take part in the study, being able to read and write in Turkish, being 18 years of age or older, having been diagnosed with gynecological cancer, knowing that s/he had been diagnosed with cancer, having received at least one chemotherapy treatment and having cancer stage 2 or 3. Exclusion criteria in the study were having a verbal communication disability, having been diagnosed with psychotic and neurological disorders, having received, or receiving psychotherapy, living outside the city center of Trabzon, and receiving treatment at intervals longer than 21 days. The control group received standard nursing care.
88808450|NCT00578552|Placebo Comparator|Placebo|Non active placebo pill
88808451|NCT00578552|Active Comparator|Gabapentin - 1800 mg/day|Gabapentin - 1800 mg/day
88808452|NCT00578552|Active Comparator|Gabapentin - 2700 mg/day|Gabapentin - 2700 mg/day
88808453|NCT01532089|Active Comparator|Arm A (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
88808454|NCT01532089|Experimental|Arm B (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride as in Arm A and bevacizumab IV over 30-90 minutes on day 1. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
88808455|NCT04640792|No Intervention|Common Colonoscopy (Group A)|Patients will be examined with Conventional Colonoscopy (CC)
88808456|NCT04640792|Experimental|Magentiq Eye Assisted Colonoscopy (Group B)|Patients will be examined with Magentiq Eye Assisted Colonoscopy (MEAC)
88808457|NCT05563987|Experimental|ACT-DE|The proposed intervention was a six-week acceptance-based diabetes education programme (ACT-DE) programme comprising Acceptance and Commitment Therapy (ACT) and diabetes education (DE). it included one diabetes education session (1st session), three ACT sessions (2nd to 4th), and a booster session in the 6th week conducted by the researcher. Each session lasted about 120 minutes in groups of 6 participants. The sessions were delivered face-to-face.
88808458|NCT05563987|Active Comparator|DE|participants in the control group only received one session of diabetes education with the same session duration.
88808459|NCT05563285|Experimental|Exercise and Mindfulness-Based Intervention|Patients in the intervention group will be provided exercise and mindfulness-based intervention was shown for the 1-8 weeks.
88808460|NCT05563285|Active Comparator|Control Group|Control group will not receive exercise and mindfulness-based intervention however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
88808461|NCT01746056|Active Comparator|Heat Patch Continuous|applied 2 hrs daily for 12 weeks
88808462|NCT01746056|Active Comparator|Heat Patch Noncontinuous|applied 2 hrs daily 2 weeks on and 2 weeks off for 12 weeks
88808463|NCT05246228||Patient with cSCC addressed to adjuvant radiotherapy as per clinical practice|The aim of the study is to evaluate patient's outcome according to the post-radiation lymphocytes count and to the changes induced in the immune cell population by a loco-regional treatment as radiotherapy. The way to objectivate these results is to collect some blood samples and analyze them.
88808464|NCT01533259|Experimental|Stribild|Participants will switch to Stribild for 48 weeks.
88808465|NCT05246072|Active Comparator|Ivermectin + colchicine + standard care|"In addition to the local standard of care for COVID 19 patients, the patient will receive:~Ivermectin + Colchicine"
88808466|NCT05246072|Active Comparator|Colchicine + standard care|"In addition to the local standard of care for COVID 19 patients, the patient will receive:~Colchicine"
88808467|NCT05246072|No Intervention|standard care|Patients will receive Standard care
88808468|NCT02135432|Experimental|Ivacaftor (VX-770)|twice a day administration of Ivacaftor: 150mg
88808469|NCT02135432|Placebo Comparator|Placebo|matching placebo
88808470|NCT01576003|Experimental|Glutamine|Infants randomized to the Glutamine group will receive L-Glutamine (GLN) administered enterally at a dose of 0.6g/kg body weight/day (0.3g/kg/dose) in 2 divided daily doses for 6 months. GLN will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
88808471|NCT01576003|Placebo Comparator|L-alanine|Infants randomized to the placebo group will receive L-alanine (ALA) administered enterally at a dose of 0.6g/kg body weight/day in 2 divided doses (0.3g/kg/day twice a day) for 6 months. ALA will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
88808472|NCT01576003|No Intervention|Healthy Control|Healthy age-matched infants (n=12) will have serial stools collected on 4 occasions, each separated by 60 days.
88808473|NCT05245994|Experimental|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|
88808474|NCT05547529|Active Comparator|Neoadjuvant Chemoradiotherapy|"Carboplatin (AUC 2 mg/mL per min) and Paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. A total radiation dose of 41,4 Gy was given in 23 fractions of 1,8 Gy, 5 days per week.~After neoadjuvant therapy, patients receive Ivor-Lewis or Mckeown Esophagectomy."
88808475|NCT05547529|Experimental|Neoadjuvant Chemotherapy|"4 cycles of DCF regimen (docetaxel 75 mg/m2 day, CDDP 75 mg/m2 and 5FU at 750 mg/m2/ day for 5 days) every 3 weeks. Patients with dysphagia 3 оr with weight loss more then 10% 6 cycles of modified-DCF regimen will be performed (mDCF, docetaxel 50 mg/m2 day, CDDP 50 mg/m2 day and 5-FU at 2400 mg/m2/day for 2 days) every 3 weeks.~After neoadjuvant therapy, patients receive Ivor-Lewis or Mckeown Esophagectomy."
88808476|NCT05245604|Experimental|TJO-087|
88808477|NCT05245604|Active Comparator|Cyclosporine 0.05%|
88808478|NCT01576471|Placebo Comparator|Placebo|
88808479|NCT01576471|Experimental|TSO 7500|
88808480|NCT05245448|Experimental|tetrandrine|tetrandrine administered 40milligram (mg) orally thrice daily through Week 24.
88808481|NCT05245448|Placebo Comparator|placebo|Placebo administered orally thrice daily through Week 12. Starting at Week 12, participants were given tetrandrine 40 milligram (mg) orally thrice daily through Week 24.
88808482|NCT00580502|Experimental|LAGB for low BMI patients|the LAP-BAND® Adjustable Gastric Band (LAGB®) for patients with BMI between 30-40 kg/m2 with co-morbidities
88808483|NCT01576939|Experimental|IMRT Modulation|"All patients will undergo a computed tomography (CT) simulation study +/- a positron emission tomography (PET) scan using ≤ 3mm slices for radiation treatment planning. A standard, non-filling optimized IMRT (Intensity Modulated Radiation Therapy) plan will be generated and patients will be treated with megavoltage radiation over a course of > 6 weeks with a planned tumor dose of > 60 Gy. A medical doctor will perform weekly mucositis evaluation and grading for the measured site once a week during radiation therapy~Modulation of an IMRT plan to reduce the dose to less than 35 Gy delivered to adjacent normal mucosa surrounding the dental filling without compromising normal tissue or tumor doses."
88808484|NCT00581048|Experimental|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
88808485|NCT01577329|Experimental|mindfulness meditation class|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
88808486|NCT01577329|No Intervention|wait list|Subjects assigned to the control group will continue with medical treatment as usual and be allowed to attend the mindfulness meditation class after week eight.
88808487|NCT04391504|Experimental|transesophageal echocardiography guidance|
88808488|NCT04391504|Experimental|intracardiac echocardiography guidance|
88808489|NCT05233280||Group A|Early feeding group
88808490|NCT05233280||Group B|Delayed feeding group
88808491|NCT05222360||female high school athletes|Athletes who identify as female at a local high school who are in an athletic program. There was no control group as the school wanted everyone to have the 3 educational sessions. The athletes underwent 3 educational sessions. No medication was used. Education was the intervention
88808492|NCT01578031|Active Comparator|Obese Patients with Obstructive Sleep Apnea|Obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
88808493|NCT01578031|Active Comparator|Non-obese Patients with Obstructive Sleep Apnea|Non-obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
88808494|NCT01578031|Other|Obese subjects without OSA|Control.
88808495|NCT01578031|Other|Non-obese subjects without OSA|Control.
88808496|NCT01798472|Experimental|uncemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an uncemented hemiarthroplasty
88808497|NCT01798472|Experimental|reverse hybrid total hip arthroplasty|Patients aged between 65 and 79 years treated with an reverse hybrid arthroplasty.
88808498|NCT01798472|Active Comparator|cemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an cemented hemiarthroplasty
88808499|NCT01798472|Active Comparator|cemented total hip arthroplasty|Patients aged between 65 and 79 years treated with an cemented total hip arthroplasty.
88808500|NCT04378166|Experimental|Smart glasses|Application of smart glasses for ultrasound-guided central venous catheterization
88808501|NCT04378166|No Intervention|Control|Conventional ultrasound-guided central venous catheterization
88808502|NCT01578577|No Intervention|Standard Care|This arm will serve as a control group and will not receive any intervention.
88808503|NCT01578577|Experimental|EHMI|Electronic Health Record-based Health Literacy Medication Therapy Management Intervention (EHMI)arm consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
88808504|NCT01578577|Experimental|Nurse Educator + EHMI|
88808505|NCT04361396|Other|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy).
88808506|NCT01579045|Experimental|Sequence 1|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, senofilcon A, Filcon II 3"
88808507|NCT01579045|Experimental|Sequence 2|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, Filcon II 3, senofilcon A"
88808508|NCT01579045|Experimental|Sequence 3|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, senofilcon A, Filcon II 3"
88808509|NCT01579045|Experimental|Sequence 4|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, Filcon II 3, senofilcon A"
88808510|NCT01579045|Experimental|Sequence 5|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, senofilcon A, Filcon II 3"
88808511|NCT01579045|Experimental|Sequence 6|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, Filcon II 3, senofilcon A"
88808512|NCT01579045|Experimental|Sequence 7|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, senofilcon A, Filcon II 3"
88808513|NCT01579045|Experimental|Sequence 8|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, Filcon II 3, senofilcon A"
88808514|NCT01579045|Experimental|Sequence 9|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, senofilcon A, Filcon II 3"
88808515|NCT01579045|Experimental|Sequence 10|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, Filcon II 3, senofilcon A"
88808516|NCT01579045|Experimental|Sequence 11|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, senofilcon A, Filcon II 3"
88808517|NCT01579045|Experimental|Sequence 12|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, Filcon II 3, senofilcon A"
88808518|NCT00582998|Active Comparator|Standard Wound Dressing|Standard post-operative wound dressing
88808519|NCT00582998|Active Comparator|Vacuum Assisted Closure Device|Vacuum Assisted Closure (VAC) device
88808520|NCT05208476|Experimental|Participants|All subjects will be observed for one menstrual cycle then given Osteopathic manipulative treatment during the second menstrual cycle. During the third menstrual cycle, participants will continue to be observed.
88808521|NCT01579513|Active Comparator|Intraoperative Methylprednisone|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass(CPB) in the first month of life that receive one dose of intravenous methylprednisolone (30 mg/kg) during anesthetic induction.
88808522|NCT01579513|Placebo Comparator|Placebo|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass (CPB) in the first month of life that receive one dose of placebo (normal saline) during anesthetic induction.
88808523|NCT05204186||Group A|Patient with (Group A) any Grade 3 (and over) Clavien-Dindo grading complication rate (30dC and 90dC)
88808524|NCT05204186||Group B|Patient without (Group B) any Grade 3 (and over) Clavien-Dindo grading complication rate (30dC and 90dC)
88808525|NCT04266392|Experimental|1|
88808526|NCT01534897|Experimental|GSK2118436|Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
88808527|NCT05121350|Experimental|Arotinib hydrochloride capsule + Epirubicin|Arotinib hydrochloride capsule combined with epirubicin, 21 days as a treatment cycle
88808528|NCT05121350|Active Comparator|Placebo + Epirubicin|Placebo combined with epirubicin, 21 days as a treatment cycle
88808529|NCT01534975|Active Comparator|Iodixanol 320|"group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
88808530|NCT01534975|Active Comparator|iohexol 350|"group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
88808531|NCT01534975|Active Comparator|iopamidol 370|"group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
88808532|NCT01534975|Active Comparator|iodixanol 270|"group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
88808533|NCT00583622|Experimental|Bevacizumab + High-Dose Chemotherapy|Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant
88808534|NCT01535365|Active Comparator|Heat|Application of Heat pad to site of muscle sprain.
88808535|NCT01535365|Active Comparator|Cold|Application of ice pack to muscle sprain.
88808536|NCT00583700|No Intervention|1|Control for study - watchful waiting.
88808537|NCT00583700|Experimental|2|Combined treatment with Pentoxifylline and Vitamin E.
88808538|NCT05540743|Other|JIA associated uveitis|patients diagnosed with Juvenile idiopathic arthritis and uveitis taking immunosuppression including biologics 9of any type according to their rheumatologist recommendations) for control of their autoimmune uveitis.
88808539|NCT00584402|Experimental|Contrast sonography|Contrast-enhanced sonography perflutren lipid microspheres
88808540|NCT01537315|Placebo Comparator|Matching Placebo|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
88808541|NCT01537315|Experimental|Hydroxychloroquine|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
88808542|NCT05094986|Experimental|Intervention group: IMA Intervention|"General practitioners (GP) applied the IMA intervention to all patients receiving a new prescription for pharmacological treatments of cardiovascular disease or diabetes.~Following the IMA intervention, nurses and community pharmacists offered information support in line with the information provided by the GP. Professionals had the intervention support tools available (leaflets, website and dispensing alert in community pharmacies)."
88808543|NCT05094986|Active Comparator|Control group|Healthcare professionals from the control group prescribed medication and provided information as usual.
88808544|NCT04257188||minimally invasive vitrectomy under subtenon anaesthesia|
88808545|NCT04257188||minimally invasive vitrectomy under general anaesthesia|
88808546|NCT01579669|Experimental|Use of Toolkit|All participants will have access to the toolkit
88808547|NCT05039996|Active Comparator|Intervention group|"Educational and training part. The educational part will be done once in the first visit in about 30 minutes Information and skills will be demonstrated and applied in the session through power point presentation, educational brochures, and video lessons and guided home-based practice.~Appropriate relaxation training Program~Relaxation training comprises deep breathing exercises and progressive muscle relaxation, to perform them daily and to keep a record of them.~Group meeting sessions for training will be held every week for the 1st 4 weeks~Video programs will be used as relaxation facilitators.~Patient will try these exercises for the first time in front of the researcher.~Patients will be advised to perform them daily for 8 weeks to achieve 60 sessions and to keep a record of them.~Follow up of the intervention group adherence to instructions will be done weekly by Telephone."
88808548|NCT05039996|Placebo Comparator|Control group|The control group will be advised to be adherent to the prescribed medications only and try not to change the treatment plan during the study period.
88808549|NCT04224428|Placebo Comparator|Control group|
88808550|NCT04224428|Active Comparator|Fexofenadine group|
88808551|NCT01579747|Placebo Comparator|Nerve stimulation sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach using nerve stimulation
88808552|NCT01579747|Active Comparator|Ultrasound guided sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach when using an ultrasound
88808553|NCT00584480|Active Comparator|1|Active Hyperbaric Oxygen Treatment (HBOT)
88808554|NCT03007693|Experimental|JNJ-61393215 (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 once daily for 7 days. 4 sequential cohorts will be enrolled to evaluate escalating doses which will be defined, based on safety, tolerability and pharmacokinetic (PK) data from the preceding cohorts. Dose adjustment/selection (increase/decrease) for the next cohort will be based on the JNJ- 61393215 PK profile up to and including the last day of dosing (24 hours postdose) and the safety and tolerability profile of the current cohort.
88808555|NCT03007693|Placebo Comparator|Placebo (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 matching placebo for 7 days.
88808556|NCT00584558||1|Patients undergoing catheter ablation.
88808557|NCT04224194|Other|Interventional, Single arm to evaluate autoinjector handling|To assess the real-life patient handling experience with the use of an autoinjector in patients with moderate to severe active Rheumatoid Arthritis (RA) who selfinject AVT02 (adalimumab) subcutaneously (SC).
88808558|NCT02215369|Experimental|VenaCure EVLT 400 µm fiber Procedure Kit|Only one limb can be treated and included in this study; however, multiple IPV's within the study limb may be treated. All IPV's treated will be followed according to the study schedule.
88808559|NCT04986176|Experimental|HC-1119 + Usual Care|4 (40mg) soft gel capsule, 160 mg total
88808560|NCT04986176|Placebo Comparator|Placebo + Usual Care|4 soft gel capsule
88808561|NCT00584948|Experimental|Memantine|
88808562|NCT00584948|Placebo Comparator|Placebo|
88808563|NCT00605072|Experimental|Candesartan|Angiotensin Receptor Blocker
88808564|NCT00605072|Experimental|Lisinopril|Angiotensin-Converting Enzyme (ACE) Inhibitor
88808565|NCT00605072|Active Comparator|HCTZ|Hydrochlorothiazide (diuretic)
88808566|NCT00585104|Experimental|1|All randomized patients receive drug.
88808567|NCT00585182|Experimental|1|
88808568|NCT00585494||Preoperative orthopedic|Patients undergoing elective total hip, knee and spinal surgery at University of Wisconsin hospital, having their preoperative visit between December 1, 2007 and November 30, 2008.
88808569|NCT04856228|Other|diagnostic single group|Patients diagnosed with lateral epicondylitis with physical examinations will be evaluated with electrophysiology After electrophysiological evaluations, patients' effected extremity evaluated with ultrasonography for lateral epicondylitis and radial tunnel syndrome and compared with uneffected side 30 minutes after posterior interosseous nerve block with 1 cc 2% lidocaine with USG guide, full examination will be repeated for evaluation of NRS score changing to exact diagnose of radial tunnel syndrome 30 minutes after lateral epicondyle 1 cc 2% lidocaine injection with USG guide, full examination will be repeated for evaluation of NRS score changing to final diagnose of lateral epicondylitis
88808570|NCT03830528|Experimental|Part A-1|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
88808571|NCT03830528|Experimental|Part A-2|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
88808572|NCT03830528|Experimental|Part A-3|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
88808573|NCT03830528|Experimental|Part B|There will be one cohort of Japanese healthy men dosed with multiple doses of KW-6356 or placebo and one potential additional cohort (KW-6356 dose as determined in Part A or placebo)
88808574|NCT03830528|Experimental|Part C-1|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
88808575|NCT03830528|Experimental|Part C-2|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
88808576|NCT03830528|Placebo Comparator|Placebo|
88808577|NCT00605384|Experimental|1|
88808578|NCT00605384|Experimental|2|
88808579|NCT00586196|Active Comparator|1|
88808580|NCT00586196|Placebo Comparator|2|
88808581|NCT00605696|Experimental|1|Participants will receive insulin to target glucose 80-110 mg/dl within 6-12 hours after presenting to ED.
88808582|NCT00605696|Active Comparator|2|Participants will receive insulin to target 150-180 mg/dl for 48 hours after ICU admission followed by usual clinical care.
88808583|NCT04745312|Active Comparator|Ambient light|Fluorescent ambient lighting
88808584|NCT04745312|Experimental|Ambient light plus task lamp|Fluorescent ambient lighting plus task lamp
88808585|NCT00606554|Experimental|Computer-assisted weaning|Group assigned to the computer-assisted weaning program
88808586|NCT00606554|Active Comparator|Standard of care weaning|Group assigned to receive current, evidence-based, standard of care for discontinuation of mechanical ventilation.
88808587|NCT00587132|Experimental|New Onset Diabetes|"Adults diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
88808588|NCT00587132|Experimental|Familial Pancreatic Cancer|"Adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
88808589|NCT00587132|Experimental|Peutz-Jeghers Syndrome|"Adults age 35-99 with Peutz-Jeghers syndrome.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
88808590|NCT00587132|Experimental|Clinical Symptoms of Pancreatic Cancer, Normal CT|"Adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
88808591|NCT00606944|Experimental|ERP group|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
88808592|NCT00606944|No Intervention|control group|traditional, conventional care group
88808593|NCT00587678|Experimental|Randomized|Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years
88808594|NCT00587678|Experimental|Ezetemibe|Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.
88808595|NCT02138006|Experimental|Intensive insulin treatment|Intensive insulin treatment
88808596|NCT02138006|Active Comparator|Standard insulin treatment|Standard insulin treatment
88808597|NCT00587834|Experimental|1|Within-subject design: one side of the mouth receives Gintuit
88808598|NCT00587834|Active Comparator|2|Within-subject control: one side of mouth receives tissue harvested from the palate
88808599|NCT05247476|Active Comparator|L-T4 therapy group|Patients with refractory hypothyroidism still receive L-T4 therapy as usual.
88808600|NCT05247476|Experimental|L-T4+T3 therapy group|Patients with refractory hypothyroidism receive L-T4+T3 therapy
88808601|NCT04565210|Experimental|Oriental music|Infants assigned to this group will be exposed to oriental music.
88808602|NCT04565210|Active Comparator|Western music|Infants assigned to this group will be exposed to western music.
88808603|NCT04565210|Placebo Comparator|Silence / control|Infants assigned to this group will be exposed to the same protocol but using a track of silence.
88808604|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 600 mg three times daily
88808605|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine|N-Acetyl Cysteine 1,200 mg three times daily
88808606|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily
88808607|NCT04545008|Experimental|High Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 1,800 mg three times daily
88808608|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily
88808609|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily
88808610|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily
88808611|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily
88808612|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily
88808613|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily
88808614|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily
88808615|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily
88808616|NCT04527770|Active Comparator|dexamethasone group|sonar guided median nerve hydrodissection by bupivacaine 0.5% and dexamethasone
88808617|NCT04527770|Active Comparator|midazolam group|sonar guided median nerve hydrodissection by bupivacaine 0.5% and midazolam
88808618|NCT02138240|Experimental|Social network intervention|"Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of participant's social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide."
88808619|NCT05247086|No Intervention|Convention closure|Conventional closure of the surgical wound after mesh removal surgery.
88808620|NCT05247086|Experimental|Negative pressure therapy|Negative pressure therapy of the surgical wound after mesh removal surgery.
88808621|NCT05247008|Other|Thyme honey interventional arm in geriatric patients having end-stage renal disease.|Thyme honey used as mouth rinse in treatment of xerostomia in geriatric patients with end-stage renal disease.
88808622|NCT02139176|Active Comparator|Patient referral|Women are given an invitation to give to a male partner inviting them to come to the clinic for important pregnancy information
88808623|NCT02139176|Experimental|contract referral|Same as control. However, if the male partner does not present, a community worker will trace the partner in the community.
88808624|NCT01798784|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive an electronic pill container and are provided with daily reminders to take their medication but are not enrolled in the sweepstakes.
88808625|NCT01798784|Experimental|Sweepstakes Incentive 1|Arm 2 will be a sweepstakes incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
88808626|NCT01798784|Experimental|Sweepstake Incentive 2|Arm 3 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which monetary prizes may be awarded if participants take their medication prior to receiving a reminder.
88808627|NCT01798784|Experimental|Sweepstake Incentive 3|Arm 4 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which each participant maintains an account that will accumulate money based on their medication adherence throughout the study.
88808628|NCT04492436|Experimental|Low Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
88808629|NCT04492436|Experimental|High Dose|Reconstituted lyophilized ART-123 with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
88808630|NCT04492436|Placebo Comparator|Placebo|Reconstituted lyophilized placebo with sterile water for injection administered by intravenous drip infusion over approximately 30 minutes on Day 1 of each chemotherapy cycle.
88808631|NCT00609128|Experimental|Olopatadine|one drop in one eye only two times per day at an interval of 6 to 8 hours for 1 week
88808632|NCT04409054||Patients undergoing the cough and Valsalva protocol|Patients over 18 years old, consulting in neuro urology departement, undergoing ano rectal manometry in order to explore ano rectal disorders
88808633|NCT00668564|Experimental|Intent-to-Treat|All patients treated with study regimen.
88808634|NCT00610688|Placebo Comparator|Prenatal Vitamin D3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a placebo tablet containing 0IU of Vitamin D
88808635|NCT00610688|Experimental|2|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a tablet containing 1600IU of Cholecalciferol (Vitamin D3)
88808636|NCT00610688|Experimental|3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3) along with a tablet containing 3600IU of Cholecalciferol (Vitamin D3).
88808637|NCT00669578|Experimental|CC-4047|
88808638|NCT02135900|Experimental|Heliox|Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
88808639|NCT02137382|Experimental|Creon N, then Creon®|Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
88808640|NCT02137382|Experimental|Creon® , then Creon N|Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
88808641|NCT00611468|Experimental|Intravenous Topotecan and Oral Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
88808642|NCT00670202|Experimental|Drug: Fasudil hydrochloride|Fasudil hydrochloride 40 mg three times a day X 14 days
88808643|NCT00670202|Placebo Comparator|Drug: Placebo oral tablet|Placebo 1 tablet three times daily x 14 days
88808644|NCT00670982|Experimental|First line treatment|Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week
88808645|NCT00670982|Experimental|Second line treatment|Patients with 1 prior line for metastatic breast cancer will receive bevacizumab intravenously every two weeks, vinorelbine intravenously once per week, and trastuzumab intravenously once per week.
88808646|NCT00611624|Experimental|Five Days of Mammosite Therapy|Five Days of Mammosite Therapy (Radiotherapy)
88808647|NCT00612560|Experimental|2|Flaxseed 25 mg per day and 1 placebo pill per day
88808648|NCT00612560|Experimental|3|25 mg flaxseed per day and 1 mg anastrozole pill per day
88808649|NCT00612560|Placebo Comparator|4|Placebo pill 1 per day
88808650|NCT00612560|Experimental|1|Anastrozole 1 mg pill per day
88808651|NCT00671918|Experimental|Lymphoseek, Lymphatic mapping, Injection|
88808652|NCT00612716|Experimental|Allogeneic Transplantation|Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.
88808653|NCT00613028|Experimental|Temo + Avastin|Patients treated with bevacizumab + temozolomide
88808654|NCT00613028|Experimental|VP-16 + Avastin|Patients treated with bevacizumab and VP-16 (etoposide)
88808655|NCT01799798|Experimental|Denosumab subcutaneously|
88808656|NCT00614198|Experimental|Gluten- and casein-free diet|Stage 1: Gluten- and casein-free dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If showed group significant improvements then progressed to stage 2 (continued on a gluten- and casein-free diet for a further 12 months).
88808657|NCT00614198|No Intervention|No dietary intervention|Stage 1: No special dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If gluten- and casein-free dietary group showed group significant improvements then progressed to stage 2 (introduction of a gluten- and casein-free diet for 12 months).
88808658|NCT00616772|Experimental|ABT-335 + Atorvastatin|ABT-335 (135 mg) and atorvastatin (up to 40 mg) once daily for 2 years.
88808659|NCT00616772|Placebo Comparator|Placebo + Atorvastatin|Placebo and atorvastatin (up to 40 mg) once daily for 2 years.
88808660|NCT00672854|Active Comparator|Intralipid 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving Intralipid 20% (soybean-based)
88808661|NCT00672854|Experimental|ClinOleic 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving ClinOleic 20% (olive oil based)
88808662|NCT00672932|Experimental|raltegravir group|The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
88808663|NCT00672932|No Intervention|No augmented treatment|Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.
88808664|NCT02513550|Experimental|80 mg Ixekizumab Q2W|160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
88808665|NCT02513550|Experimental|80 mg Ixekizumab Q4W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
88808666|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
88808667|NCT02513550|Experimental|80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
88808668|NCT02513550|Experimental|80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
88808669|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
88808670|NCT00673400|Other|Stapled transanal rectum resection|patients operated with stapled transanal rectum resection
88808671|NCT00673712|Experimental|Continuous Sternal Block|Continuous Sternal block with infusion of local anesthetic via ON-Q Painbuster Silver Soaker system
88808672|NCT00673712|Active Comparator|Opioid based analgesia|Opioid based analgesia including Patient controlled analgesia plus IM, Oral narcotics and other analgesics
88808673|NCT04062032|Experimental|ASA 81 mg daily|Participants will be given ASA 81 mg orally once daily for a total of 7 days
88808674|NCT04062032|Experimental|ASA 325 mg daily|Participants will be given ASA 325 mg orally once daily for a total of 7 days.
88808675|NCT00617396|Experimental|Quetiapine treatment group|All subjects will receive seroquel treatment for 8 weeks. Seroquel is the intervention.
88808676|NCT03722966|Experimental|Varenicline/Counseling + Med Reminders (VAR+REM)|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and automated medication reminders via their smartphones.
88808677|NCT03722966|Experimental|Varenicline/Counseling (VAR+NREM)|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, and no automated medication reminders.
88808678|NCT03722966|Experimental|Varenicline/Counseling + Oral NRT (VAR+NRT+NREM)|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and no automated medication reminders.
88808679|NCT03722966|Experimental|Varenicline/Counseling + Oral NRT + Med Reminders (VAR+NRT+REM)|Participants will receive behavioral tobacco cessation counseling, a 13-week course of varenicline, 12 weeks of oral nicotine replacement therapy (NRT; gum or lozenge), and automated medication reminders via their smartphones.
88808680|NCT01581541|Experimental|PU-H71|PU-H71 will be administered intravenous (IV) over one hour, once weekly, 2 weeks out of 3, (i.e., on days 1 and 8) every 21 days
88808681|NCT02142608|Experimental|BR55|All patients received BR55 as a single intravenous injection at the dose of 0.03 mL/kg...
88808682|NCT02143310|Experimental|EVP|Subject who use the EVP for up to 2 years
88808683|NCT01582477|Experimental|EXPAREL 20 mL (undiluted)|20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.
88808684|NCT01582477|Active Comparator|EXPAREL 40 mL (diluted)|20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.
88808685|NCT03001687|Experimental|vitamin D +|"Patients in the vitamin D group will receive enteral supplementation with vitamin D, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
88808686|NCT03001687|Placebo Comparator|vitamin D -|"Patients in vitamin D - group do not receive enteral supplementation with vitamin D and represent the control group, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
88808687|NCT03001765|Other|Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac|Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.
88808688|NCT03007771|Experimental|MR-HIFU|"Philips 1.5T MRI scanner equipped with a Sonalleve V2 HIFU system will be used~Will be scanned in the MRI in 1 or more positions to the extremities and/or pelvis while aligned to the HIFU system. The HIFU device will then be used to apply sub-clinical levels (≤ 41°C) of heat to one or more small volumes. Regions will be heated to the desired temperature for variable short durations of time not exceeding 30 minutes.~After the session is complete, the patient will be removed from the MR-HIFU system and, following a 15-30-minute period of monitoring for any adverse events, allowed to leave.~Before the scan, after the scan and 5-10 days following the scan, participants will be asked to rate any pain, discomfort, in the area to be heated, as well as any anxiety or claustrophobia on a scale of 1-10 with 1 being minimal/none and 10 being extreme. The skin area to be treated will also be reviewed for any redness/discoloration."
88808689|NCT01583101|Experimental|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
88808690|NCT01583101|Active Comparator|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
88808691|NCT03001609|Experimental|AC0010|each participant will be given a single dose of 14C-labeled AC0010
88808692|NCT03007381|Experimental|Ketorolac tromethamine|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the ketorolac intervention group, then the participant will receive 30 mg of intravenous (IV) ketorolac tromethamine. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
88808693|NCT03007381|Sham Comparator|Normal Saline|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the control group the patient will be given a sham IV medication. The sham medication will be normal saline at the same volume as ketorolac, which corresponds to 3 ccs. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
88808694|NCT03001921||Hemodialysis patients|End stage renal disease patients receiving hemodialysis treatment
88808695|NCT01585129|Experimental|Postpartum Antibiotics|Patients will receive one additional dose of postpartum antibiotics (Clinda, Gentamicin)
88808696|NCT01585129|Placebo Comparator|No postpartum antibiotics|No further postpartum antibiotics
88808697|NCT01585207|Experimental|Vigabatrin|3 tablets, bid for 8 weeks
88808698|NCT03007303||schizophrenia|"15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT.~The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated."
88808699|NCT03007303||health controls|15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group
88808700|NCT01585441|Experimental|Finasteride 5 mg|Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.
88808701|NCT01585441|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.
88808702|NCT04345315||asymptomatic population at high risk of infection|healthy individuals at high risk of infection, including individuals who have had contact with a patient tested positive for COVID-19, voluntary health workers and oncological patients candidate to immunosuppressive therapy
88808703|NCT04345315||COVID-19 patients|patients with confirmed diagnosis of COVID-19
88808704|NCT03007459||Female Fitness Athletes|Psychological health and physiological health of fitness athletes
88808705|NCT03007459||Female, physically active Controls|Psychological health and physiological health of female controls
88808706|NCT02980861|Experimental|Laparoscopic total gastrectomy|Participants including in the laparoscopic total gastrectomy (LTG) group will undergo LTG with spleen-preserving splenic hilum lymph nodes dissection.
88808707|NCT02980861|Active Comparator|Open total gastrectomy|Participants who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
88808708|NCT03007615|Experimental|Experimental group|
88808709|NCT03006913|Active Comparator|Randomization to counseling: In-person|Behavioral: Comparing genetic counseling modes.
88808710|NCT03006913|Active Comparator|Randomization to counseling: By phone|Behavioral: Comparing genetic counseling modes.
88808711|NCT03006913|Active Comparator|Randomization to counseling: By video|Behavioral: Comparing genetic counseling modes.
88808712|NCT04345237|Experimental|Experimental group 1 (TS + placebo)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.~Daily consumption for 3 months of placebo milk."
88808713|NCT04345237|Experimental|Experimental group 2 (TS + leucine)|"Training twice a week, with wave periodization. Traditional training (TS) in two circuits. Each exercise is separated by a rest period of 3 minutes and 5 minutes between circuits.~Daily consumption for 3 months of milk enriched with leucine."
88808714|NCT04345237|Experimental|Experimental group 3 (HRC + placebo)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.~Daily consumption for 3 months of placebo milk."
88808715|NCT04345237|Experimental|Experimental group 4 (HRC + leucine)|"Training twice a week, with wave periodization. High intensity training (HRC) on two circuits. Each exercise is separated by a rest period of 35 seconds and 5 minutes between circuits.~Daily consumption for 3 months of milk enriched with leucine."
88808716|NCT04345237|Experimental|Experimental group 5 (no physical exercise + leucine)|"The subjects will not carry out any type of physical activity.~Daily consumption for 3 months of milk enriched with leucine."
88808717|NCT04345237|No Intervention|Control (no physical exercise + placebo)|"The subjects will not carry out any type of physical activity.~Daily consumption for 3 months of placebo milk."
88808718|NCT03001531|Active Comparator|HydroSun|application of ultraviolet light for 30 minutes
88808719|NCT03001531|Active Comparator|Hilotherm|application of heat (maximum of 43°C) for 30 minutes
88808720|NCT00617942|Experimental|Neo-adjuvant cohort 1|
88808721|NCT00617942|Experimental|Neo-adjuvant cohort 2|
88808722|NCT00617942|Experimental|Adjuvant cohort 1|
88808723|NCT00617942|Experimental|Adjuvant cohort 2|
88808724|NCT03001375|Active Comparator|Mobilization group|Laparoscopic splenic flexure mobilization will be done.
88808725|NCT03001375|Active Comparator|Non mobilization group|No mobilization of splenic flexure.
88808726|NCT03001297|Experimental|MEDI5884 Dose 1|Participants will receive single dose of MEDI5884 Dose 1 injection SC on Day 1.
88808727|NCT03001297|Placebo Comparator|Placebo|Placebo will be administered subcutaneously (SC).
88808728|NCT03001297|Experimental|MEDI5884 Dose 2|Participants will receive single dose of MEDI5884 Dose 2 injection SC on Day 1.
88808729|NCT03001297|Experimental|MEDI5884 Dose 3|Participants will receive single dose of MEDI5884 Dose 3 injection SC on Day 1.
88808730|NCT03001297|Experimental|MEDI5884 Dose 4|Participants will receive single dose of MEDI5884 Dose 4 injection SC on Day 1.
88808731|NCT03000985|Experimental|Psychoeducation|6 session of a psychoeducation program with the family. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
88808732|NCT03000985|No Intervention|Control|Treatment as usual
88808733|NCT00618332|Active Comparator|1|2 weeks of treatment
88808734|NCT00618332|Placebo Comparator|2|2 weeks of treatment
88808735|NCT03001141||Single group - observational|
88808736|NCT03000907|Experimental|Intervention|"diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls.~physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months."
88808737|NCT03000907|No Intervention|Control|Clinical practise
88808738|NCT01585597|Experimental|Mild Hypothermia|Reduction of body temperature to 34 degrees centigrade. This will be accomplished using the Zoll Coolguard .
88808739|NCT01588561|Active Comparator|Intravenous Nicotine (1.5 mg/70 kg)|Participants are given a siingle infusion of nicotine (1.5 mg/70 kg), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
88808740|NCT01588561|Placebo Comparator|Saline - placebo|Participants are given physiological saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
88808741|NCT00619190|Experimental|open aripipraprazole|Openly provided, flexibly dosed aripiprazole in doses from 1mg to 30mg
88808742|NCT00619190|No Intervention|no medication control|group of children whose parents do not want them to take medications for autism over the year following enrollment in the trial.
88808743|NCT01589263|Active Comparator|ARM 1: onaBoNT-A + placebo|onaBoNT-A 200 U prostate injection and placebo oral capsule daily
88808744|NCT01589263|Active Comparator|ARM 2: Saline + Tamsulosin|Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.
88808745|NCT00674492||Hepatitis C patients|patients who initiated antiviral treatment for hepatitis C
88808746|NCT03700190||Control|Healthy child
88808747|NCT03700190||Experimental|Patients with Autism Spectrum Disorder
88808748|NCT01590979|Active Comparator|Ranolazine|The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
88808749|NCT01590979|Placebo Comparator|Placebo|Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
88808750|NCT01799018||SAH Patients|Patients admitted with the diagnosis of aneurismal subarachnoid hemorrhage (SAH) and cerebral angiogram negative SAH who would need to have the external ventricular drain (EVD) placed for the management of hydrocephalus.
88808751|NCT01799018||Control Patients|Patients with non-hemorrhagic brain pathology such as posterior fossa tumor or stroke who will have the CSF sampling for diagnostic or therapeutic purposes.
88808752|NCT00619970|Active Comparator|Healthy Control|Healthy controls
88808753|NCT00619970|Active Comparator|Children receiving Rifaximin|2/3 Patients with CAP
88808754|NCT00619970|Placebo Comparator|Children receiving Placebo|1/3 patients with CAP
88808755|NCT01591837|Experimental|Adults|Healthy volunteers aged 18 to 59 years received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
88808756|NCT01591837|Experimental|Older Adults|Healthy volunteers aged 60 years or older received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
88808757|NCT01592071|Experimental|Replace reactive w/ non-reactive foods|Test results, individual dietary plan: 'Replace reactive foods with non-reactive foods'
88808758|NCT03531788|Experimental|Armon Ayura (Kinova)|Participants will trial the Armon Ayura dynamic arm support.
88808759|NCT03531788|Experimental|JAECO WREX|Participants will trial the JAECO Wilmington Robotic EXoskeleton (WREX) dynamic arm support.
88808760|NCT03445130|Active Comparator|Lavandula Angustifolia oil (LO)|2 Drops in Oxygen Mask
88808761|NCT03445130|Active Comparator|Michelia Alba Leaf oil (MA)|2 Drops in Oxygen Mask
88808762|NCT03445130|Active Comparator|Almond oil (AO)|2 Drops in Oxygen Mask
88808763|NCT03445130|Active Comparator|Water|2 Drops in Oxygen Mask
88808764|NCT03006991||good efficacy|using therapeutic drug monitoring to adjust the dose of methotrexate. patients can reach effective outcome.
88808765|NCT03006991||poor efficacy|patients can not reach effective outcome.
88808766|NCT01592851|Experimental|Arm 1|Dentifrice containing stannous fluoride
88808767|NCT01592851|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
88808768|NCT00675584|Active Comparator|Placebo Budesonide|Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days.
88808769|NCT00675584|Experimental|Budesonide|Participants will receive 1 mg of ICS (budesonide as Pulmicort Respules®) twice a day for 7 days at the onset of a respiratory tract illness; they will receive placebo ICS once a day at all other times during the study.
88808770|NCT03007069|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and collagen membrane to be used for bone augmentation around exposed threads of inserted dental implants.
88808771|NCT03007069|Active Comparator|MPM Augmentation.|Mineralized plasmatic matrix (MPM) to be used without collagen membrane to augment the defect in the maxillary bone and cover the exposed threads of the dental implants.
88808772|NCT00620126|Experimental|Intervention|UC Home Automated Telemanagement
88808773|NCT00620126|Active Comparator|Control|Best Available Care
88808774|NCT00620828|Placebo Comparator|Block Negative|Subjects receive intra-op saline injection per protocol
88808775|NCT00620828|Experimental|Block Positive|Subjects receive intra-op Ropivicaine 0.5% injection per protocol
88808776|NCT01596283|Active Comparator|Standard fluid management|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
88808777|NCT01596283|Active Comparator|Goal directed fluid therapy|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
88808778|NCT00676364|Active Comparator|4% lidocaine topical anesthetic cream|This group received topical 4% lidocaine anesthetic cream under occlusive dressing for 15 minutes prior to needle stick.
88808779|NCT00676364|Placebo Comparator|Placebo|This group received matching placebo cream under occlusive dressing for 15 minutes prior to needle stick.
88808780|NCT00676676|Active Comparator|Testosterone|Testosterone patch delivering 300mcg daily for 8-weeks.
88808781|NCT01799252||Doxy|Women who are prescribed a seven-day regimen of doxycycline following medical abortion
88808782|NCT01799252||No Doxy|Women who are not prescribed antibiotics following medical abortion
88808783|NCT00677690|Active Comparator|NM+PR|Patients undergone to combination of neuromuscular stimulation and pulmonary rehabilitation (NM+PR)
88808784|NCT00677690|Placebo Comparator|SS+PR|Patients undergone to pulmonary rehabilitation
88808785|NCT00621530|Experimental|Ketorolac|ketorolac 2 mg ketorolac tromethamine opthalmic solution
88808786|NCT00621530|Placebo Comparator|Placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
89530690|NCT03242707|Active Comparator|Hyaluronic Acid knee injection|Hyaluronic Acid - Synvisc-One®: A high molecular weight sodium hyaluronate (HA). HA is an FDA approved, standard of care treatment.
89530691|NCT02511977||overdenture with annual maintenance|Rehabilitation should be: overdenture with at least 2 implants placed in the mandible and 3 implants in the maxilla per person. They were divided into two groups: Group I: Annual maintenance for the past seven years
89530692|NCT02511977||overdenture whitout annual maintenance|Group II: individuals who have not returned for the last seven years. Individuals who said they went to the dentist at least once a year, for whatever treatment, were included in the maintenance group. Individuals who denied any visit to the dentist in the last seven years were included in the no maintenance group.
89530693|NCT03242629|Active Comparator|oral group|
89530694|NCT03242629|Experimental|enema group|
89530695|NCT02452723|Experimental|ISC-hpNSC|
89530696|NCT02512055|Experimental|Group 1|Pediatric patients undergoing repeat radiotherapy session under ketamine sedation
89530697|NCT03242395||Burn patients|Adult survivors of severe burns who have been admitted to Burns ITU for invasive ventilation within 10 years of neurocognitive assessment
89530698|NCT03242395||Controls|Healthy volunteers, controlled for age/sex/IQ
89530699|NCT02514863||Patients undergoing CMR|"Assessment of hemodynamic function using:~CMR~EV with an inter-electrode gap (lower pair) of 5 cm~EV with an inter-electrode gap (lower pair) of 15 cm"
89530700|NCT02514941|Experimental|pre OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed within three days before the scheduled proximal Roux-en-Y gastric bypass surgery. A gastroduodenoscopy with biopsy of the lower duodenum will be performed before the first pharmacokinetic study period.
89530701|NCT02514941|Experimental|post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed 5-7 days after the scheduled proximal Roux-en-Y gastric bypass surgery. A sampling of a tissue specimen from the jejunum will be collected during the operation.
89530702|NCT02514941|Experimental|one year post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period and a gastrojejunoscopy with biopsy of the jejunum will be performed about one year after the scheduled proximal stomach bypass surgery.
89530703|NCT02511743||physicians|physicians taking care of patients with chronic Hepatitis B Virus infection
89530704|NCT02515019|No Intervention|Group Sevo1.8%|Anaesthesia was maintained with a constant inspired concentration of sevoflurane 1.8% (Sevorane; Abbvie, Wiesbaden, Germany) administered via the ventilator. From the beginning of CPB, a constant flow of sevoflurane 1.8% was administered with the oxygenator fresh-gas supply, using a common anaesthetic vaporiser (Draeger Vapor Version 2000; Draeger, Luebeck, Germany). Following successful weaning from CPB, sevoflurane was again administered at an inspired concentration of 1.8% using the ventilator.
89530705|NCT02515019|Experimental|Bispectral index Monitoring|The sevoflurane concentration via the ventilator and the oxygenator fresh gas supply was titrated to maintain a target BIS value between 40 and 60 (BIS-Monitor, Covidien, Boulder, Colorado, USA). However, the concentration of sevoflurane in the oxygenator fresh gas supply was not reduced below 0.3%.
89530706|NCT02511665|Experimental|Metformin|Metformin given , 1g twice a day for 4 weeks until prostatectomy +/- one week
89530707|NCT02511665|Placebo Comparator|Placebo|placebo given , 1g twice a day for 4 weeks until prostatectomy +/- one week
89530708|NCT02511665|Experimental|PET-MRI|5 patients in this arm will all receive metformin and undergo two additional PET- MRI scans, one before and one after treatment
89530709|NCT03233269|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
89530710|NCT03242551|Experimental|Neoadjuvant chemotherapy|Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
89530711|NCT02511821|Experimental|Supportive Care (Vivofit watch, online surveys)|Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery.
89530712|NCT03242473|Experimental|Lactated Ringers (LR)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
89530713|NCT03242473|Experimental|Normal Saline (NS)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
89530714|NCT02514629|Placebo Comparator|Placebo|Placebo for 52 weeks
89530715|NCT02514629|Experimental|Metformin|Metformin 850 mg tablets twice daily for 52 weeks
89530716|NCT02514629|Experimental|Testosterone|Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
89530717|NCT02514629|Experimental|Metformin + Testosterone|Metformin 850 mg tablets twice daily + Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
89530718|NCT03237091|Experimental|bihemispheric transcranial pulsed current stimulation (tPCS)|
89530719|NCT03237091|Experimental|unihemispheric transcranial pulsed current stimulation (tPCS)|
89530720|NCT03237091|Experimental|bihemispheric transcranial direct current stimulation (tDCS)|
89530721|NCT03237091|Experimental|unihemispheric transcranial direct current stimulation (tDCS)|
89530722|NCT03237091|Active Comparator|sham-control|
89530723|NCT02511899|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
89530724|NCT02511899|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
89530725|NCT03233659||BMT patients|All patients undergoing Allogeneic Stem Cell Transplantation are enrolled in the study.
89530726|NCT02511509|Experimental|Bifrontal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
89530727|NCT02511509|Active Comparator|Bitemporal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
89530728|NCT04485715|Experimental|AI-aided group|
89530729|NCT04485715|No Intervention|control group|
89530730|NCT02511353|Placebo Comparator|placebo|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
89530731|NCT02511353|Experimental|ivermectin 300 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
89530732|NCT02511353|Experimental|ivermectin 600 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.
89530733|NCT03242317|Experimental|Mitomycin C + Raindrop Near Vision Inlay|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
89530734|NCT02514317|Experimental|percutaneous treatment|percutaneous treatment of carpal tunnel syndrome under ultrasound guidance in interventional radiology room.
89530735|NCT02453503|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
89530736|NCT02453503|Experimental|Licorice|Licorice mucoadhesive films 1 mg every 6 hours for two weeks.
89530737|NCT04499651|No Intervention|Control|All people who are living with HIV who are currently in custody in the Los Angeles County Jail are provided with Transitional Case Management and may also receive Whole Person Care related services regardless of participation in this study. Participants recruited from clinics who do not enroll in the study will be offered HIV/HCV care that follows the national HIV/HCV care guidelines, as provided by participating study clinics. Participants recruited from non-medical community agencies who do not enroll in the study and do not have a regular provider will receive a referral list of HIV/HCV care facilities that follow the national HIV/HCV care guidelines.
89530738|NCT04499651|Active Comparator|Navigation|"Participants will be paired with a navigator and will complete the following didactic sessions in one-on-one format:~Session 1: Intervention Overview and Basic HIV/HCV Knowledge and Skills Builder~Session 2: Rapport Building~Session 3: Society and Self and the Role of Disclosure~Session 4: Accompaniment 1~Session 5: Goal-Setting, Problem-Solving and a Disclosure Toolkit~Session 6: Accompaniment 2~Session 7: Accompaniment 3 (ONLY if needed)~Weekly check-in calls following Session 2 for six months"
89530739|NCT03242083||Primary atrophic AMD|
89530740|NCT03242083||Secondary atrophic AMD|
89530741|NCT04499885|Active Comparator|Paraffin oil gastric lavafe|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
89530742|NCT04499885|Active Comparator|Saline gastric lavage|Gastric lavage with saline and sodium bicarbonate
89530743|NCT03233113|Active Comparator|Exposure and response prevention|Exposure therapy with response prevention involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to prevent engaging in any safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
89530744|NCT03233113|Experimental|Exposure with judicious safety behaviors|Exposure therapy with judiciously used safety behaviors for spider phobia involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to strategically incorporate safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
89530745|NCT02511275|Other|renal microdialysis|patient with renal microdialysis
89530746|NCT02453425|Active Comparator|60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
89530747|NCT02453425|Active Comparator|75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
89530748|NCT02453425|Active Comparator|90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
89530749|NCT02511197|Experimental|68Ga-NOTA-PRGD2 injection & PET/CT scan|The patients were intravenously injected with 68Ga-NOTA-PRGD2 in one dose in nearly 111 MBq and then underwent PET/CT scan 0.5 h later.
89530750|NCT02453269|Experimental|Transdisciplinary program|"Children in G1 were submitted to a transdisciplinary intervention once a week. Each child received a nutritional education kit including four games (Cool Diet, a board game, a memory game and a word search puzzle) and an interactive booklet containing)."
89530751|NCT02453269|No Intervention|Control group|The children in the control group (G2) were not exposed to interventions.
89530752|NCT04499105|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem cell + Nacl 0.9%
89530753|NCT03236701|No Intervention|Control|usual diet
89530754|NCT03236701|Experimental|Intervention|egg white instead of meat or fish in two meals twice a week for three months
89531411|NCT06066931|Other|Group 2 is plastic surgery with a mesh endoprosthesis n=50|In group 2 patients, a mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
88808787|NCT02513472|Experimental|Eribulin Mesylate + Pembrolizumab|Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
88808788|NCT03109028|Active Comparator|Treatment as Usual|Regular standard psychiatric health care including all feasible interventions including medication, psychotherapy and social work.
88808789|NCT03109028|Experimental|Stepped and Collaborative Care Modell|A stepped and collaborative treatment model with varying stepped psychotherapeutic interventions for adult and adolescent refugees.
88808790|NCT01596595||Medically Indicated for ICD or CRT-D|Medically Indicated for ICD or CRT-D implantation per guidelines
88808791|NCT00621686|Experimental|Sorafenib + Bevacizumab/Group A|"Patients receive oral sorafenib 400 mg (200 mg twice daily) days 1-5 and 8-12 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
88808792|NCT00621686|Experimental|Sorafenib + Bevacizumab /Group B|"Patients receive oral sorafenib 200 mg once daily on days 1-14 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
88808793|NCT02924714|Other|Discontinuation of imatinib|Patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no longer detectable GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or RFA of the metastases are assigned to discontinue imatinib.
88808794|NCT00678470|Experimental|Single Arm|Investigational intervention without random assignment
88808795|NCT00679952|Active Comparator|1|closed suction drainage group (CD group)
88808796|NCT00679952|Active Comparator|2|natural drainage group (ND group)
88808797|NCT00623012|Experimental|1|
88808798|NCT02699060|Experimental|NERD patients|Patients have typical reflux syndrome without esophageal injury.
88808799|NCT02699060|Experimental|EE patients|Patients have erosion(s) or ulcer(s) in esophagus.
88808800|NCT02699060|Experimental|BE patients|Patients have esophageal specialized intestinal metaplasia.
88808801|NCT00623636|Experimental|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks.
88808802|NCT00623636|Other|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks.
88808803|NCT02549222||Control Cohort|During the Control cohort period patients will have study data collected following transfusion with only conventional PCs for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
88808804|NCT02549222||INTERCEPT Cohort|During the INTERCEPT phase, patients will receive only INTERCEPT PCs and will have study data collected following transfusion for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
88808805|NCT01799876|Experimental|Autologous Cell|Regenerative cells obtained from autologous fat are administered in the knee at microfracture site.
88808806|NCT01799876|Sham Comparator|Control|Standard arthroscopy with sham lipoplasty procedure (no fat cells harvested).
88808807|NCT01799954|Other|NYVAC Prime / NYVAC + AIDSVAX® B/E Boost vs. Placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a NYVAC vaccine prime and NYVAC + AIDSVAX® B/E boost. Twenty participants will get vaccines and 4 will get only placebos.
88808808|NCT01799954|Other|NYVAC + AIDSVAX® B/E Prime / Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of priming and boosting with the vaccines NYVAC + AIDSVAX® B/E. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 1 to see if the priming makes a difference in the body's immune response.
88808809|NCT01799954|Other|DNA prime + NYVAC + AIDSVAX® B/E Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 4 to see if the priming makes a difference in the body's immune response.
88808810|NCT01799954|Other|DNA+AIDSVAX® B/E prime / NYVAC+AIDSVAX® B/E boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine + AIDSVAX® B/E priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 3 to see if the priming makes a difference in the body's immune response.
88808811|NCT00623714|Experimental|Arm 1|study medication + Pbo
88808812|NCT00623714|Experimental|Arm 2|Pbo + study medication
88808813|NCT02174822|Experimental|Paroxetine + AVP-786|Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.
88808814|NCT02174822|Experimental|AVP-786 + paroxetine|AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20
88808815|NCT02174822|Experimental|Duloxetine + AVP-786|Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
88808816|NCT02174822|Experimental|AVP-786 + duloxetine|AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.
88808817|NCT02139800|Active Comparator|Control Arm-Standard of care|Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
88808818|NCT02139800|Experimental|Sustained Intervention|Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
88808819|NCT02139878|Experimental|Wild blueberry juice|240 ml wild blueberry juice
88808820|NCT02139878|Placebo Comparator|Placebo wild blueberry juice|240 ml placebo wild blueberry juice
88808821|NCT00624416|Other|Prednisolone and Isoproteronol Together|Beta-adrenergic agonists and corticosteroid
88808822|NCT01894646|Experimental|Young healthy individuals (ages 18-50)|Positron Emission Tomography (PET) Imaging
88808823|NCT01894646|Experimental|Elderly healthy individuals (ages 60-85)|Positron Emission Tomography (PET) Imaging
88808824|NCT01894646|Other|Patients with Alzheimer's disease or mild cognitive impairment|Positron Emission Tomography (PET) Imaging
88808825|NCT00682838|Experimental|Self-Management (SM)|Active Intervention - Self-management: Self-management Educational component focused on sleep apnea and CPAP from a self-management perspective
88808826|NCT00682838|Active Comparator|Telemonitored Care (TC)|Active Comparator - Telemonitored care: Telemonitored care Consists of CPAP therapist actively monitoring care at a distance, and acting on that data per a set protocol
88808827|NCT00682838|Experimental|SM + TC|Self-management and Telemonitored care: Combination of both SM + TC intervention
88808828|NCT00682838|No Intervention|Usual care (UC)|Control Group
88808829|NCT00624806|Experimental|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers
88808830|NCT00624806|Active Comparator|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
88808831|NCT00626210|Experimental|Modafinil|
88808832|NCT00653276|Active Comparator|Treatment A|Treatment A: subjects will be given a single oral dose of cyclosporine 100 mg capsules on Day 1.
88808833|NCT00653276|Active Comparator|Treatment B|Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.
88808834|NCT00683852|Active Comparator|Drug 2mg/Drug 5mg|patients randomly assigned to the drug/drug sequence, the dose of aripiprazole will be 2 mg/day during the first phase of the study, and 5 mg/day in the second phase.
88808835|NCT00683852|Active Comparator|Placebo/Drug 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study.
88808836|NCT00683852|Placebo Comparator|Placebo/Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study.
88808837|NCT01596751|Experimental|Phase Ib: 600 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 600 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8."
88808838|NCT01596751|Experimental|Phase Ib: 800 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 800 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
88808839|NCT01596751|Experimental|Phase Ib: 1000 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 1000 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
88808840|NCT01596751|Experimental|Phase II: 800 mg/Day PLX3397 Lead in +Combined with Eribulin|"Treatment begins with a 7 day Lead-in phase of PLX3397 alone, followed by 21 day cycles of PLX3397 in combination with eribulin.~Lead-in phase treatment:~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest.~Treatment given in each 21 day cycle:~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest, repeated weekly~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
88808841|NCT03000595|Experimental|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
88808842|NCT03000595|Placebo Comparator|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
88808843|NCT03006835|Experimental|Domestic Clopidogrel 300mg|Domestic Clopidogrel 300mg
88808844|NCT03006835|Experimental|Domestic Clopidogrel 600mg|Domestic Clopidogrel 600mg
88808845|NCT03006835|Experimental|Imported Clopidogrel 300mg|Imported Clopidogrel 300mg
88808846|NCT03006835|Active Comparator|Imported Clopidogrel 600mg|Imported Clopidogrel 600mg
88808847|NCT03006757|Experimental|Column titanium dioxide|patient take titanium dioxide denture participants will receive titanium dioxide denture ( made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial.
88808848|NCT03006757|Experimental|column placebo|patient will take denture with conventional acrylic ( 20 minutes cure ) for 1 month in the initial phase
88808849|NCT02247271|Other|Diabetes health coach support|The intervention is that subjects will receive coach support once a week for 30 minutes for six months. Support is provided by a Diabetes Coach who uses self-management support strategies to assist subjects to achieve their personal health goals.
88808850|NCT05566405|Active Comparator|General Anaesthesia|Patients undergoing open retropubic radical prostatectomy under general anaesthesia
88808851|NCT05566405|Active Comparator|Combined (Epidural and Spinal) Anaesthesia|Patients undergoing open retropubic radical prostatectomy under combined (epidural and spinal) anaesthesia
88808852|NCT03000361|Experimental|Motorized Spiral Colonoscopy|Motorized Spiral Colonoscopy (MSC) with the novel motorized spiral endoscope represents a new technology which offers all of the advantageous options of spiral-assisted endoscopy with a faster and less invasive approach
88808853|NCT03000127|Experimental|Single arm crossover|All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient
88808854|NCT02999815|Active Comparator|Human tetanus immunoglobulin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intrathecal 500 IU
88808855|NCT02999815|Sham Comparator|Intramuscular antitoxin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intramuscular 3000 IU OR Equine antiserum - 21,000 units
88808856|NCT02999659||Control group|The control group implies patients with non-acute cerebral disease (e.g. cerebral aneurysm without symptoms). The pupilometer data are once collected during ambulant routine examination. The patients do not undergo any further study related examinations.
88808857|NCT02999659||Treatment group|The treatment group implies patients with an acute cerebral disease ensured by CT, MRI or spinal tap. Pupillometry measurements are done during neurological routine examinations. Generally, during the initial diagnosis examination, followed by daily routine measurements and after 3 and 6 month upon hospital discharge.
88808858|NCT03006523|Active Comparator|Intrauterine Insemination with 200 µl|The sperm sample will be concentrated by centrifugation to a volume of 200 µl
88808859|NCT03006523|Experimental|Intrauterine Insemination with 500 µl|The sperm sample will be concentrated by centrifugation to a volume of 500 µl.
88808860|NCT02247817|Experimental|HYBRID|Hybrid transvenous/epicardial implantation of a CRT-(D) device.
88808861|NCT03006679|Experimental|Meropenem-Vaborbactam HABP|Participants with a clinical diagnosis of HABP will be treated with meropenem 2 grams (g) and vaborbactam 2 g in 250 milliliters (mL) infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
88808862|NCT03006679|Active Comparator|Piperacillin/Tazobactam HABP|Participants with a clinical diagnosis of HABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
88808863|NCT03006679|Experimental|Meropenem-Vaborbactam VABP|Participants with a clinical diagnosis of VABP will be treated with meropenem 2 g and vaborbactam 2 g in 250 mL infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
88808864|NCT03006679|Active Comparator|Piperacillin/Tazobactam VABP|Participants with a clinical diagnosis of VABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
88808865|NCT02998333|Active Comparator|Open surgical ankle stabilization|These patients will receive open surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
88808866|NCT02998333|Active Comparator|Arthroscopic surgical ankle stabilization|These patients will receive arthroscopic surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
88808867|NCT03006601|Placebo Comparator|Placebo group|After enrollment, patients will be randomized into either treatment group or placebo group. Patients will receive placebo procedure which were designed to look like real vergence/accommodative therapy procedures yet not stimulate vergence, accommodation, of fine saccadic eye movement skills beyond normal daily visual activities. Office-based procedures (60 minutes per visit, one time per week, 12 weeks) and home procedures (15 minutes each time, five times per week, 12 weeks) will be provided to patients.
88808868|NCT03006601|Experimental|Treatment group|After enrollment, patients will be randomized into either treatment group or placebo group. Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks) will be provided to patients of treatment group.
88808869|NCT03006445|Experimental|FYU-981|
88808870|NCT02247895|Sham Comparator|Sham Treatment|Sham stimulation twice daily
88808871|NCT02247895|Active Comparator|Active Treatment|The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
88808872|NCT05007847|Active Comparator|Active|Participants randomised to the active arm will be provided with an AW Series 4 on Day 0 for the duration of the study. They shall undergo an education and training session to ensure technical competency of heart rhythm recording and familiarity with the recommended recording schedule for the duration of the study. Participants will also be given the contact details for a dedicated email mailbox for the duration of the study through which they can submit remote transmissions of ECG data.
88808873|NCT05007847|No Intervention|Control|Participants in the control arm will be advised to continue with the standard of care and advised to contact their direct clinical team or primary care physician should they experience any symptoms of concern (palpitations, dizziness, collapse). They will be contacted by the study team at 6 and 12 months for clinical assessment (symptoms, hospitalisation data, further stroke events, mortality).
88808874|NCT05237479|Placebo Comparator|Control Group|DAA THA under spinal anesthesia ( standard of care at Montefiore)
88808875|NCT05237479|Active Comparator|Intervention Group|DAA THA under spinal anesthesia and a preoperative supra-inguinal fascia iliac compartment block (S-FICB)
88808876|NCT03006367|Experimental|NFC-1 100 mg|Single Dose of NFC-1 100 mg
88808877|NCT03006367|Experimental|NFC-1 200 mg|Single Dose of NFC-1 200 mg
88808878|NCT03006367|Experimental|NFC-1 400 mg|Single Dose of NFC-1 400 mg
88808879|NCT03006367|Experimental|NFC-1 800 mg|Single Dose of NFC-1 800 mg
88808880|NCT02980939|Placebo Comparator|Euhydration - no thirst|
88808881|NCT02980939|Experimental|Dehydration - no Thirst|
88808882|NCT03006289||The thyroid cancer group|The postoperative pathology of thyroid is malignant
88808883|NCT03006289||The thyroid nodule group|The postoperative pathology of thyroid is benign
88808884|NCT05673031||68Ga-HA-DOTATATE|68Ga-HA-DOTATATE Intravenous injection of 100-250 MBq 68Ga-HA-DOTATATE
88808885|NCT03006211|Active Comparator|corneal endothal|Evaluate the effects of nitrogen protoxide to corneal endothal and compare with oxygen.
88808886|NCT03006211|Active Comparator|Cell density|Evaluate the effects of nitrogen protoxide to Cell density and compare with oxygen.
88808887|NCT02248051|Experimental|CXA-10|
88808888|NCT05672641|Experimental|Inertial training group|13 young men, physical education students. Inertial training was performed three times a week (Monday, Wednesday, Friday, between 7:00 a.m. and 8:30 a.m.) for 6 weeks using Cyklotren device (Inerion, Poland).
88808889|NCT05672641|Experimental|Body building training group|13 young men, physical education students. Body building training was performed three times a week (Monday, Wednesday, Friday, between 7:00 a.m. and 8:30 a.m.) for 6 weeks using traditional free weights.
88808890|NCT05672563|Experimental|women with previous CSP|experimental: women with previous cesarean scar pregnancy that are invited to our unit for sonographic evaluation.
88808891|NCT03005821|Experimental|pediatric massage|Patients will receive Montmorillonite Powder and racecadotril granules as usual care according to different age or weight. Intravenous infusion, Oral Rehydration Salts (ORS), Zn,and antibiotics will be used if the pediatrician in charge considers necessary. Patients will receive Chinese pediatric massage once per day and for three days continuously. A cloak which can cover the child's hands and upper body will be required to put on, all the manipulations will be done under the cloak. Six acupoints will be adopted,i.e. Neibagua, Dachang,Xiaochang, Banmen, Fu, Tuishang Qijiegu. Each visit, children who are under 2 years old will receive manipulations on Neibagua for 500 times, 300 times for the other 5 acupoints each; if they are from 2-3 years old, the manipulations on Neibagua will be 700 times and 500 times for the other 5 acupoints respectively; while the manipulations on Neibagua will be 1000 times, and 800 times for the other 5 acupoints if the children are from 4-6 years old.
88808892|NCT03005821|Sham Comparator|sham massage|Patients will receive the same usual care as the experimental group. For the sham massage, the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead childrens' hand or childrens' body. Patients will be required to put on the same kind of cloak as that for the the experimental group, all the manipulations will be done under the cloak. The manipulation times for each acupoints will be the same as those for experimental group in accordance with different age. The sham massage will be given once per day for 3 days continuously.
88808893|NCT02247505|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
88808894|NCT02247505|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
88808895|NCT02996929|Experimental|Study group|Subjects who are scheduled for CIED lead extraction with the LC system
88808896|NCT02248129||Hypertensive patients|
88808897|NCT04627675|Experimental|1A: Age 18-50; CORVax|Healthy volunteers age 18-50 will receive CORVax
88808898|NCT04627675|Experimental|1B: Age 18-50; CORVax + pIL-12|Healthy volunteers age 18-50 will receive CORVax + pIL-12
88808899|NCT04627675|Experimental|2A: Age > 50; CORVax|Healthy volunteers age > 50 will receive CORVax
88808900|NCT04627675|Experimental|2B: Age > 50; CORVax + pIL-12|Healthy volunteers age > 50 will receive CORVax + pIL-12
88808901|NCT02248207||Parkinson Disease patients|
88808902|NCT03006055|Experimental|MBC Group|metastatic breast cancer Age：18-75 ECOG:0-2
88808903|NCT03006055|Experimental|Control Group|benign breast tumour Age：18-75 ECOG:0-2
88808904|NCT03005743|Experimental|MR based BT|Magnetic Resonance Image based Brachytherapy
88808905|NCT03005743|Other|Conventional BT|Conventional Radiograph based Brachytherapy
88808906|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
88808907|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
88808908|NCT00683930|Placebo Comparator|Placebo|
88808909|NCT03005587||Cirrhotics with no previous decompensation|
88808910|NCT03005587||Cirrhotics with previous one or more than one decompensation|
88808911|NCT05671939||Training set|The whole cohort is randomly assigned to a training cohort and validation cohort.
88808912|NCT05671939||validation set|The whole cohort is randomly assigned to a training cohort and validation cohort.
88808913|NCT03005509|No Intervention|Pre-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.~The Trauma Quality Improvement Meeting (TQIM) checklist will not be introduced during this phase."
88808914|NCT03005509|Other|Post-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.~The Trauma Quality Improvement Meeting (TQIM) checklist will be used at all Trauma Quality Improvement Meetings (TQIMs)"
88808915|NCT00684242|Experimental|Lenalidomide|10 mg by mouth daily
88808916|NCT00684320|Active Comparator|2 Placebo Condition (PC)|The placebo, group will complete the PC procedure, which is identical to the ADT procedure except that during the presentation of the trials where a disgust or angry face is present, the probe will appear with equal frequency in the position of disgust or angry and neutral face. Thus, disgust, angry nor neutral face will have signal value regarding the position of the probe.
88808917|NCT00684320|Experimental|1 Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
88808918|NCT04492111|Experimental|X-space group|Each patient of the experimental group will receive one X-space implant.
88808919|NCT04492111|Active Comparator|2P group|Each patient of the control group will receive one 2P implant. Bone System Cylindric implants. Surface Ecotek.
88808920|NCT00684554|Active Comparator|Unobserved-at home|Buprenorphine Unobserved at home induction
88808921|NCT00684554|Active Comparator|Observed|Buprenorphine Observed in office induction
88808922|NCT04490395|Experimental|Engage PA|
88808923|NCT04490395|Other|Treatment as usual plus fitness tracker|
88808924|NCT00626912|Active Comparator|1|platinum coils
88808925|NCT00626912|Active Comparator|2|hydrogel coils
88808926|NCT02248441|Experimental|Daily RIC|Daily ischemic conditioning treatment
88808927|NCT00628394|Other|Atomox/CR|Patients are given the drug Atomoxetine and Cognitive Remediation training.
88808928|NCT00628394|Other|Atomox/Control|Patients are given the drug Atomoxetine and Remediation Control training.
88808929|NCT00628394|Other|Placebo/CR|Patients are given a Placebo and Cognitive Remediation training.
88808930|NCT00628394|Other|Placebo/Control|Patients are given Placebo and Remediation Control training.
88808931|NCT02996617|Active Comparator|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF（ruibai 100ug）.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L for total 4 courses.
88808932|NCT02996617|Experimental|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle for total 4 courses.
88808933|NCT04387604||non vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
88808934|NCT04387604||vitrectomized eyes|ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
88808935|NCT03005665|Experimental|Group A - Acetazolamide|Acetazolamide 5 mg/kg diluted in 10 ml normal saline through orogastric Ryle's Tube soon after the induction of anaesthesia followed by 10 ml normal saline flush.
88808936|NCT03005665|Placebo Comparator|Group s - Normal saline|20 ml normal saline total volume.
88808937|NCT00684788|No Intervention|No Intervention|Participants were offered depot naltrexone injections and were not required to take scheduled injections to work.
88808938|NCT00684788|Experimental|Employment-based reinforcement|Participants were offered depot naltrexone injections and were required to take scheduled injections to work.
88808939|NCT04351165|Experimental|Arm 1|"Period 1:~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);~Period 2:~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
88808940|NCT04351165|Experimental|Arm 2|"Period 1:~100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule);~Period 2:~100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule);~Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose."
88808941|NCT00628628|Experimental|Group A|As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
88808942|NCT00628628|Experimental|Group B|Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily
88808943|NCT04366999||LSG|In this group, the bariatric procedure is laparoscopic sleeve gastrectomy (LSG), all operations follow the same standard operating procedure.
88808944|NCT04366999||LRYGB|In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass (LRYGB), all operations follow the same standard operating procedure.
88808945|NCT04366999||OAGB-MGB|In this group, the bariatric procedure is one anastomosis gastric bypass-mini gastric bypass(OAGB-MGB), all operations follow the same standard operating procedure.
88808946|NCT00629018|Experimental|SC Group|"SC therapy,'Bone Marrow Stimulation','CD34+ autologous stem cell transplantation':~In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect"
88808947|NCT00629018|No Intervention|Controls|Patients receiving no cell therapy.
88808948|NCT00199238|Placebo Comparator|Placebo|Once daily/ 28 days
88808949|NCT00199238|Experimental|rupatadine 5mg|Once daily/ 28 days
88808950|NCT00199238|Experimental|rupatadine 10 mg|Once daily/ 28 days
88808951|NCT00199238|Experimental|rupatadine 20 mg|Once daily/ 28 days
89531118|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 5|Participants with COPD will receive 3 administration of MEDI3506 Dose 5 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
88808952|NCT05670067|Active Comparator|immediate implant with bone graft (autogenous)|with immediate implant placement autogenous grafting using maxillary tuberosity will be done
88808953|NCT05670067|Active Comparator|immediate implant with bonegraft (xenograft)|with immediate implant placement grafting with xenograft will be done
88808954|NCT00630734|Experimental|SLCO1B1 Group 1|Participants with the SLCO1B1 *1A/*1A diplotype; Interventions: pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
88808955|NCT00630734|Experimental|SLCO1B1 Group 2|Participants with the SLCO1B1 *1A/*1B or *1B/*1B diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
88808956|NCT00630734|Experimental|SLCO1B1 Group 3|Participants who carry at least one SLCO1B1 *5, *15, or *17 diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
88808957|NCT05666323|No Intervention|Control Group|The control group will not receive any intervention.
88808958|NCT05666323|Experimental|Phase 1: TM1|Patients in the TM1 condition will be randomized to receive either an autonomy supportive message, or a directive motivational message.
88808959|NCT05666323|Experimental|Phase 1: TM+|Patients in the TM+ condition will be randomized to receive 5 text messages in scheduled succession. These messages will be either an autonomy supportive message, or a directive motivational message.
88808960|NCT05666323|Experimental|Phase 2: TM1 and PN|Patients in the TM1 and PN condition will be randomized to receive either an autonomy supportive message, or a directive motivational message. Additionally, they will receive the option to talk with a Patient Navigator to receive MAPS coaching
89531119|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 6|Participants with COPD will receive 3 administration of MEDI3506 Dose 6 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
89531120|NCT03096795|Placebo Comparator|Part 3: Placebo|Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously.
89531121|NCT03096795|Experimental|Part 3: MEDI3506 IV Dose 6|Healthy Japanese participants will receive a single MEDI3506 Dose 6 intravenously.
88808961|NCT05666323|Experimental|Phase 2: TM1 continued|"Patients in the TM1 continued arm have the continued option to reply to the first text message in Phase 1: TM1. They do not receive any additional intervention."
88808962|NCT05666323|Experimental|Phase 2: TM+ and PN|Patients in the TM+ and PN condition will be randomized to receive 3 additional either autonomy supportive messages, or directive motivational messages. Additionally, they will receive the option to talk with a Patient Navigator to receive MAPS coaching
88808963|NCT05666323|Experimental|Phase 2: TM+ continued|Patients in TM+ continued will receive 3 additional either autonomy supportive messages, or directive motivational messages.
88808964|NCT05665933|Experimental|THE EFFECT OF ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|PSYCHOEDUCATION PROGRAM Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
88808965|NCT05665933|No Intervention|THE EFFECT OF ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION ON EXAM ANXIETY IN ADOLESCENTS|Similar training will be provided after the study is completed. Number of People: 30
88808966|NCT01799096|Experimental|Sucrose|Receives sucrose
88808967|NCT01799096|Placebo Comparator|Aspartame|Receives Aspartame sweetened drinks
88808968|NCT03005431|Experimental|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
88808969|NCT03005431|No Intervention|Waitlist control group|These parents will receive regular or typical services
88808970|NCT05516017|Experimental|Vestibular Electrical Stimulation and exercises with pinhole glasses|"For VES, which we will apply in our study, the anode will be placed on the mastoid protrusion on the sick ear and a cathode electrode is placed on the healthy ear.The skin to be treated will be cleaned and dried The electrodes are fixed to the head with the help of an elastic band. VES application per session will be applied for 30 minutes, 2 days a week, for 8 weeks. Patients will be asked to perform a bed exercise program once a day for 20-30 minutes each session, 5 days a week, for 8 weeks, including the above exercises, which they will perform in bed after the first day.These exercises are; fixation of the head and turning the eyes to the right and left, the movement of fixing the eyes and turning the head to the left and right, turning the head and eyes in one direction and focusing, hip flexor and knee extensor strengthening.~Patients in the experimental group will also wear pinhole glasses while applying VES."
88808971|NCT05516017|Active Comparator|VES and exercises without pinhole glasses|"For VES, which we will apply in our study, the anode will be placed on the mastoid protrusion on the sick side and the cathode will be placed on the healthy ear. The skin to be treated will be cleaned and dried. The electrodes are fixed to the head with the help of an elastic band. VES application per session will be applied for 30 minutes, 2 days a week, for 8 weeks.Patients will be asked to perform a bed exercise program once a day for 20-30 minutes each session, 5 days a week, for 8 weeks, including the above exercises, which they will perform in bed after the first day.These exercises are; fixation of the head and turning the eyes to the right and left, the movement of fixing the eyes and turning the head to the left and right, turning the head and eyes in one direction and focusing, hip flexor and knee extensor strengthening.~Patients in the active comparator will not wear pinhole glasses while VES is applied."
88808972|NCT01799174|Active Comparator|UVA-1 Phototherapy|Receive medium dose UVA-1 (70 J/cm2) 3x/week for 10 weeks
88808973|NCT01799174|Sham Comparator|Placebo|"Receive sham UVA1 phototherapy (0 J/cm2) 3x/week for 10 weeks"
88808974|NCT05644249|Experimental|Experimental treatment|Each patient will be scheduled for 3 courses of combined treatment: in total 3 PIPAC with cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 and 6 cycles of FOLFOX systemic chemotherapy.
88808975|NCT00686582|Experimental|Initially Vaccinia Naive, 2 dose primed, 1 booster dose|"Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
88808976|NCT00686582|Experimental|Initially Vaccinia Naive, 1 dose primed, 1 booster dose|"Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
88808977|NCT00686582|Other|Vaccinia Experienced, boosted, blood draw only|"Group 4 Vaccinia Experienced~1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)"
88808978|NCT02223637||Exposure group|"Pregnant women who were exposed to~≥1 dose of Menveo vaccine within 28 days prior to conception or at any time during pregnancy were included."
88808979|NCT00631358|Experimental|Maxidex|Maxidex
88808980|NCT00631358|Sham Comparator|No treatment|Healthy normal control group receiving no treatment
88808981|NCT02248753|Active Comparator|Standard Care|Pharmacological cardioversion and/or electrical cardioversion
88808982|NCT02248753|Experimental|Wait-and-see Approach|Rate control drugs only (metoprolol, verapamil or digoxin)
88808983|NCT00687674|Experimental|Sorafenib + Lenalidomide + Dexamethasone|
88808984|NCT00687830|Active Comparator|Polythylene Glycol (PEG) in the evening|"Bowel preparation with Polyethylene Glycol given in the evening prior to the day of the afternoon colonoscopy.~'Polyethylene Glycol afternoon'"
88808985|NCT00687830|Experimental|Polythylene Glycol (PEG) in the Morning|"Bowel preparation with Polyethylene Glycol given on the morning of the day of the afternoon colonoscopy.~'Polyethylene Glycol morning'"
88808986|NCT02248831|Experimental|Doppler ultrasound|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
88808987|NCT00687908|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel once daily
88808988|NCT00687908|Placebo Comparator|2|Vehicle Gel once daily
88808989|NCT04028011||PSG and novel wearable device|75 patients will wear polysomnography at the same time as the Novel wearable device
88808990|NCT04028011||PG and novel wearable device|75 patients will wear polygraphy at the same time as the novel wearable device
88808991|NCT05626231|Experimental|Gender-Affirming Psychotherapy (GAP)|"The single-arm intervention study will test an online asynchronous gender-affirming training intervention called GAP Training."
88808992|NCT00689078|Active Comparator|Pred acetate 1%|Prednisolone acetate 1.0% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
88808993|NCT00689078|Active Comparator|Pred acetate .12%|Prednisolone acetate 0.12% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
88808994|NCT00689078|Active Comparator|Lot Etab 0.2%|Loteprednol Etabonate 0.2% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
88808995|NCT00689078|Placebo Comparator|Placebo|Tears Naturale (Artificial Tears) in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
88808996|NCT05590819|Experimental|bilateral rTMS|5 hertz(Hz), 1000 pulses, 90% resting motor threshold(RMT) stimulation on bilateral motor cortex of suprahyoid muscle for 15 minutes.
88808997|NCT05590819|Experimental|unilateral rTMS|5 hertz(Hz), 1000 pulses, 90% RMT stimulation on motor cortex of suprahyoid muscle at ipsilateral side as the lesion for 15 minutes; sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
88808998|NCT05590819|Placebo Comparator|control group of rTMS|Sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
88808999|NCT05590819|Experimental|bilateral iTBS|600 pulses iTBS stimulation on bilateral motor cortex of suprahyoid muscle for 15 minutes.
88809000|NCT05590819|Experimental|unilateral iTBS|600 pulses iTBS on motor cortex of suprahyoid muscle at ipsilateral side as the lesion for 15 minutes; sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
88809001|NCT05590819|Placebo Comparator|control group of iTBS|Sham stimulation on motor cortex of suprahyoid muscle at contra-lateral side as the lesion for 15 minutes.
88809002|NCT01795508|Experimental|PMTO|Parent Management Training Oregon
88809003|NCT01795508|Active Comparator|TAU|Other kinds of family treatment
88809004|NCT05568979||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
88809005|NCT05568979||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
88809006|NCT00588380|Experimental|GLP-1|All participants recieved GLP-1 intravenously at 0.75 pmol/kg/min for the first hour and then at 1.5 pmol/kg/min for the next hour
88809007|NCT03991429||Group 1|Patients with BPH and significant improvement in storage symptoms after BOO procedures
88809008|NCT03991429||Group 2|Patients with BPH who have persistent storage symptoms after BOO procedures
88809009|NCT03991429||Group 3 (Control group)|Men without LUTS who are planning to undergo radical prostatectomy
88809010|NCT03005353|Experimental|Cumin seed extract|Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days.
88809011|NCT03005353|Active Comparator|clotrimazole|Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days.
88809012|NCT00588536|Experimental|1|MTX, 6-TG, Leucovorin
88809013|NCT03977233|Experimental|SingleArm: FOLFIRINOX|Subjects will receive FOLFIRINOX as an outpatient every 14 days per community standards of medical care. Protocol-based therapy will continue for 12 cycles (24 weeks) or until disease progression, unacceptable toxicity, study withdrawal, or subject death. Subjects will have the option of surgical resection after 8 cycles of therapy if repeat scans show evidence of resectable disease. The starting doses for mFOLFIRINOX regimen are: oxaliplatin 85 mg/m2, followed by leucovorin 400 mg/m2 given simultaneously with irinotecan 180mg/m2, followed by 5FU 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion.
88809014|NCT00590018|Experimental|1|Subjects in this arm will receive a 5 day tapering course of hydrocortisone.
89531122|NCT03098199|Experimental|AMH<1.5, 300IU Gonal-F + 150 IU Menopur|dosage at 300IU Gonal-F + 150IU Menopur
88809015|NCT00590018|Placebo Comparator|2|Subjects in this arm will receive 5 days of placebo.
88809016|NCT02219503|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks
88809017|NCT02219815|No Intervention|Standard Care|Patients in the standard care group will receive care as is currently delivered to patients awaiting cardiac surgery at each site. At present, patients are advised to rest and participate in very light intensity physical activity while awaiting surgery. At 1-2 weeks prior to their scheduled surgical date, the patient attends a single three hour cardiac pre-assessment with a nurse practitioner and cardiac anesthesiologist. In addition, a cardiac nurse counsels each patient on healthy behaviors (e.g. smoking cessation, diet, exercise).
88809018|NCT02219815|Experimental|Prehab Intervention|Patients in the Prehab group will receive, in addition to the standard of care, an eight-week comprehensive exercise therapy and education program at a community-based CR facility. Patients will be asked to complete at least two sessions of supervised, structured exercise class plus have the option to attend one additional exercise class per week for eight-weeks, with progression to a moderate to high-intensity interval program based on the supervised assessment of the patient's capabilities. Prehab participants will also attend four education sessions on topics such as risk factor reduction, medication use, cardiovascular physiology, smoking cessation, healthy eating, exercise, and stress management and promotion of self-managed care.
88809019|NCT00592124|Experimental|1|Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
88809020|NCT00592124|Experimental|2|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
88809021|NCT00592124|Experimental|3|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
88809022|NCT00592124|Experimental|4|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
89531123|NCT03098199|Experimental|AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur|dosage of 225IU Gonal-F + 75IU Menopur
89531124|NCT03098199|Experimental|AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur|start dosage of 150IU Gonal-F and 75IU Menopur
88809023|NCT00592124|Experimental|5|Oral TDF for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
88809024|NCT00592124|Experimental|6|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
88809025|NCT03005119|Experimental|PTL201|Up to 30 mg/day (30 mg THC, 10 mg CBD), recommended to be administered after meals and if required before bed time. Patients will be instructed not to take more than 10 mg (two capsules) at a single dosing session.
88809026|NCT03005119|Placebo Comparator|Placebo|PTL201 and placebo capsules will be identical in appearance
88809027|NCT00593372|Experimental|I|Drug Plus Behavioral Therapy
88809028|NCT00593372|No Intervention|II|Drug Therapy Only
88809029|NCT02221219|Placebo Comparator|immediate cord clamp & placebo IV solution|This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 12hrs of life.
88809030|NCT02221219|Experimental|delay cord clamp & placebo IV solution|A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.
88809031|NCT02221219|Active Comparator|immediate cord clamp & indomethacin IV|Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 12hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
88809032|NCT02221219|Experimental|indomethacin iv & delayed cord clamp|A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 12hrs of life), 0.1mg/kg every 24 hrs for three total doses.
88809033|NCT02247583||mRCC patients|Patients with metastatic renal cell carcinoma
88809034|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later).~Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU.~Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
88809035|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred."
88809036|NCT00593450|Active Comparator|1|Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.
88809037|NCT00593450|Experimental|2|Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.
88809038|NCT00593450|Experimental|3|Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
88809039|NCT00593450|Experimental|4|Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
88809040|NCT00631670|Experimental|Single Treatment Group|15 Gy dose in one stereotactic body radiation treatment
88809041|NCT00631670|Experimental|25 Treatments Group|25 treatments, given once a day, Monday through Friday for about five weeks; Dose: 70 Gy at 2.8 Gy/treatment
88809042|NCT00631748|Experimental|Study Drug|Subjects randomized to the experimental arm of the study will be initially administered 50mg/day quetiapine fumarate (Seroquel XR) to be titrated up to 400mg/day by the end of the second week. Subjects will be stabilized at a dose of 400mg/day or alternatively 300, 200, 100, or 50mg/day or quetiapine fumarate as tolerated. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
88809043|NCT00631748|Placebo Comparator|Placebo|Subjects randomized to the placebo arm of the study will follow the same titration and dosing procedure as the experimental arm but will receive matched placebo tablets. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
88809044|NCT04387682|Other|OSCC subjects with β-glucan supplement|Oral squamous cell carcinoma subjects with pre-surgical administration of whole glucan particle β-glucan
88809045|NCT04387682|No Intervention|Healthy donors|healthy donors without pre-surgical administration of whole glucan particle β-glucan
88809046|NCT04387682|No Intervention|OSCC subjects without β-glucan supplement|Oral squamous cell carcinoma subjects without pre-surgical administration of whole glucan particle β-glucan
88809047|NCT00594230|Experimental|Panobinostat 20 mg|Treatment with LBH589 (Panobinostat) 20 mg
88809048|NCT00594230|Experimental|Panobinostat 30 mg|Treatment with LBH589 (Panobinostat) 30 mg
89531125|NCT03098199|Experimental|AMH >=7.0, 75IU Gonal-F+75U Menopur|start dosage of 75IU Gonal-F and 75U Menopur
89531126|NCT00707057|Experimental|Ibuprofen 600 mg ER group|One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
88809049|NCT00595088|Experimental|20 mg of BC-819/PEI|Six intravesical instillations of 20 mg of plasmid DNA (BC-819) complexed with PEI into the bladder of patients with intermediate-risk superficial bladder cancer [recurrent stages Ta (low or high grade) and T1 (low grade) TCC] who have failed prior intravesical therapies including BCG and/or chemotherapy.
88809050|NCT02137538|Active Comparator|Letrozole|Letrozole 2.5 mg daily
88809051|NCT02137538|Active Comparator|Anastrozole|Anastrozole 1 mg daily
88809052|NCT01799330|Experimental|Group 1:Active TCEMS|Transcutaneous Electrical Muscle Stimulation (TCEMS): Group 1 will undergo TCEMS using an Omnistim FX-2 with two surface patch electrodes (8 x 6 cm) applied to each quadriceps, hamstring and calf muscles. The knee angle will remain at 90 degrees during simultaneous muscle stimulation to prevent joint movement. Electrical stimulation will be performed for 20 minutes on each limb, 3 days/week for 8 continuous weeks on an outpatient basis. The stimulator will be set to generate brief bursts of electrical impulses at 50Hz lasting 200 ms every 1500 ms. Muscles will be stimulated with an asymmetrical square wave pulse with an initial intensity set to create a visible contraction ranging from 55 mA to 120 mA.
88809053|NCT01799330|Placebo Comparator|Group 2: Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response.
88809054|NCT00595556|Experimental|A|Zonisamide
88809055|NCT00595556|Placebo Comparator|B|placebo
88809056|NCT00595790|Active Comparator|IC51 2 x 6 mcg|2 x 6 mcg (microgram)
88809057|NCT00595790|Active Comparator|IC51 1 x 12 mcg|1 x 12 mcg (microgram)
88809058|NCT00595790|Active Comparator|IC51 1 x 6 mcg|1 x 6 mcg (microgram)
88809059|NCT00595946|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
88809060|NCT00595946|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
88809061|NCT00638924||Exercise Capacity|Individuals from the female gender; age range of 20 to 30 years old; considered healthy (i.e. with no diagnosed health condition; considered sedentary (i.e. performing less than 150 minutes of moderate intensity physical activity per week); will be asked to volunteer in the research and perform a exercise capacity test.
88809062|NCT00597038|Experimental|Phase I Dose Escalation|Dasatinib and Dacarbazine (DTIC). The first cohort was a dasatinib dose of 50 mg by mouth (PO) twice a day (BID) given days 2-19 with DTIC given at a dose of 800 mg/m2 once every 3 weeks. The dose escalation was continued until MTD and a recommended Phase II dose was established.
88809063|NCT00597038|Experimental|Phase II Dose Treatment|Dasatinib and Dacarbazine (DTIC). The recommended phase II dose was dasatinib 70 mg BID with dacarbazine 800 mgm^2.
88809064|NCT00597272|Experimental|1|Vaccine- KLH conjugates with GD2L and GD3L
88809065|NCT00597428|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
88809066|NCT00597428|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
88809067|NCT00597818|Placebo Comparator|Placebo|Participants receive matching placebo capsules for 20 months
88809068|NCT00597818|Experimental|Cobiprostone QD|Participants receive 18 mcg cobiprostone once daily (QD) for 20 months
88809069|NCT00597818|Experimental|Cobiprostone BID|Participants receive 18 mcg cobiprostone twice daily (BID) for 20 months
88809070|NCT00597818|Experimental|Cobiprostone TID|Participants receive 18 mcg cobiprostone three times daily (TID) for 20 months
88809071|NCT00597896|Experimental|Active pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
88809072|NCT00597896|Placebo Comparator|Placebo pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
88809073|NCT00600080|Other|etafilcon A first nelfilcon A second|etafilcon A worn daily during week 1, nelfilcon A worn daily for week 2
88809074|NCT00600080|Other|nelfilcon A first, etafilcon A second|nelfilcon A worn daily during week 1, etafilcon A worn daily for week 2
88809075|NCT00600704|Active Comparator|RESTRICTED FLUIDS|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary Bypass
88809076|NCT00600704|Active Comparator|FREE FLUIDS|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
88809077|NCT01790282|Experimental|estradiole - progesterone arm|Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
88809078|NCT01790282|Active Comparator|Progesterone only arm|Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
88809079|NCT00691808|Experimental|High Dose|
88809080|NCT00691808|Experimental|Low Dose|
88809081|NCT00691808|Placebo Comparator|Placebo|
88809082|NCT03843541|Experimental|Active test treatment-NAC|NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
88809083|NCT03843541|Active Comparator|Active control treatment-Ambroxol hydrochloride|Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
88809084|NCT03843541|Placebo Comparator|Placebo|Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
88809085|NCT00692198|Experimental|Supplemental oxygen therapy|Participants will receive treatment with supplemental oxygen therapy.
88809086|NCT00692198|No Intervention|No supplemental oxygen therapy|Participants will receive no supplemental oxygen therapy, unless the participant becomes severely hypoxemic at rest (e.g., meets conventional Medicare criteria for 24-hour supplemental oxygen due to severe hypoxemia at rest).
88809087|NCT00639158|Active Comparator|ABT-335 + atorvastatin + ezetimibe|
88809088|NCT00639158|Placebo Comparator|Placebo + atorvastatin + ezetimibe|
88809089|NCT03004885|Experimental|Minimal Distension|Tidal volume 4 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R
88809090|NCT03004885|Experimental|Maximal Recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain plateau pressure between 23 - 25 cmH2O + ECCO2R
88809091|NCT03004885|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R
88809092|NCT02248909||Patients with COPD risk factors|Group of subjects with COPD risk factors. This group will include patients aged ≥40 years, with smoking history of ≥10 pack years and long-active (not less than 3 consequent months) respiratory complaints
88809093|NCT02248909||Patients previously diagnosed with COPD|Group of patients who according to the medical records have already been diagnosed with COPD
88809094|NCT02994901||Group 1|Geriatric patient with Sarcopenia
88809095|NCT02994901||Group 2|Geriatric Patient without Sarcopenia
88809096|NCT02994901||Group 3|healthy control group
88809097|NCT02994589|Experimental|OASIS® wound matrix|OASIS wound matrix is a biologic extracellular matrix derived from porcine small intestine submucosa. Some components of OASIS wound matrix are similar to human dermis including types of collagens, elastin, glycoproteins and proteoglycans. In addition, OASIS wound matrix retains some growth factors that have been suggested to aid in the wound healing process. It is a FDA approved wound dressing indicated for use in a variety of ulcers, abrasions and surgical wounds.
88809098|NCT02994589|Active Comparator|Tegaderm™(Absorbant, 3M)|Transparent dressing allows for wound monitoring without changing the dressing Clear design takes the guesswork out of application over the wound Novel acrylic polymer pad technology designed to handle low to moderate wound drainage. No dressing breakdown in the wound. Low friction surface minimizes potential for friction and shear. Allows for gentle removal from skin. Barrier to external contaminants, body fluids, bacteria and viruses.
88809099|NCT02994589|Active Comparator|Xeroform™|Xeroform™ Occlusive Petrolatum Gauze. 3% Bismuth Tribromophenate in a special petrolatum blend on fine mesh gauze. Non-adherent. Clings and conforms to all body contours.
88809100|NCT03498859|Other|Home-based training|10 weeks of home-based training with no supervision of a physiotherapist
88809101|NCT03498859|Other|Physiotherapist-supervised training|Physiotherapist-supervised training once per week during 10 weeks in addition to home-based training
88809102|NCT05424133|Experimental|Active cycle of breathing technique|Group A will receive Active cycle of breathing technique with routine chest physiotherapy.
88809103|NCT05424133|Active Comparator|High frequency chest wall oscillation|Group B will receive High frequency chest wall oscillations with routine chest physiotherapy
88809104|NCT00692276|Experimental|1|Interspinous Process Spacer Device
88809105|NCT00692276|Active Comparator|2|Interspinous Process Spacer Device
88809106|NCT02248987||Clozapine|stable patients treated with clozapine
88809107|NCT02248987||Other antipsychotics|stable patients treated with risperidone or paliperidone or olanzapine
88809108|NCT02248987||Healthy volunteer|healthy controls
88809109|NCT03004963|Active Comparator|clinical group|evaluate the volume status just according to clinical indexes in this group.
88809110|NCT03004963|Experimental|clinical and BCM group|Both body composition monitor (BCM) and clinical indexes are used to evaluate the volume status of patients in this group.
88809111|NCT00639860|Experimental|Placing OSSIX-Plus in Extraction Site|Placement of OSSIX-Plus, a resorbable collagen membrane, and the promotion of bone healing following exodontia.
88809112|NCT05392309|Experimental|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
88809113|NCT05392309|Active Comparator|conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
88809114|NCT00692978|Experimental|Asthma|Asthma patients
88809115|NCT00692978|Active Comparator|Healthy volunters|Healthy participants
88809116|NCT02247661||Direct lateral approach|Total or hemiarthroplasty operated with direct-lateral approach.
88809117|NCT02247661||Postero-lateral approach|Total or hemiarthroplasty operated with postero-lateral approach.
88809118|NCT03004807|Experimental|Multivitamin|Centrum Silver Men's Formula Multivitamin/Multimineral Supplement: 1/day
88809119|NCT03004807|Placebo Comparator|Control|Matching tablet to active multivitamin arm: 1/day
88809120|NCT00601718|Experimental|Treatment (enzyme inhibitor, monoclonal antibody, chemotherapy|Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
88809121|NCT03004729|Other|CoMiSS|Measure of CoMiSS followed by two weeks eviction Cow's milk protein diet and second CoMiSS measurement.
88809122|NCT03275779|Experimental|Low Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
88809123|NCT03275779|Experimental|High Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
88809124|NCT03004651||Obese Patients|Power Doppler ultrasound on obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
88809125|NCT03004651||Non obese patients|Power Doppler ultrasound on non obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
88809126|NCT03004573|Experimental|Deep brain stimulation|
88809127|NCT00640250|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
88809128|NCT00601796|Experimental|Combination Immunotherapy|Vaccine + Cytoxan + ATRA as outlined in Detailed Description
88809129|NCT00601952|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
88809130|NCT00601952|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
88809131|NCT01799408||betamethasone|Patients who had intra-articular injection of betamethasone
88809132|NCT01799408||Hyaluronic acid|Patients who had intra-articular injection of hyaluronic acid
88809133|NCT00693992|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88809134|NCT00693992|Placebo Comparator|Arm II (placebo)|Patients receive placebo 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
88809135|NCT00694070||health care professionals and lay users|h= 8 health care professionals p= 43 lay users
88809136|NCT00645710|Experimental|Arm I|"Patients receive floxuridine as a continuous hepatic arterial infusion on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 9 and 11. Patients also receive yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV over 25 minutes on day 9. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive an additional course of floxuridine in combination with systemic therapy at the discretion of the treating physician."
88809137|NCT00603044|Active Comparator|Fluticasone furoate|55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
88809138|NCT00603044|No Intervention|No treatment|
88809139|NCT00603902|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
88809140|NCT00603902|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
88809141|NCT00603902|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
88809142|NCT00646646|Active Comparator|propofol|active drug
88809143|NCT00646646|Active Comparator|dexmedetomidine|sedative
88809144|NCT00646646|Active Comparator|midazolam|Sedative
88809145|NCT00646646|Placebo Comparator|placebo|placebo control
88809146|NCT02998658|Experimental|Vaginal cuff closure using barbed sutures|Vaginal cuff is closed with barbed sutures
88809147|NCT02998658|Active Comparator|Vaginal cuff closure using conventional sutures|Vaginal cuff is closed with conventional sutures
88809148|NCT02998424|Experimental|Propofol 1 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 1 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
88809149|NCT02998424|Experimental|Propofol 2 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 2 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
88809150|NCT02998424|Experimental|Propofol 3 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 3 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
88809151|NCT00696488|Experimental|Fluorouracil 0.5%|each subject will receive the study medication: Carac® 0.5% Fluorouracil, a standard treatment for actinic keratoses. Carac® will be dispensed to the subjects in the original tube with MEMS electronic monitoring caps attached. Subjects will be asked to apply the medication daily to AK lesions
88809152|NCT00697190|Active Comparator|senofilcon A/galyfilcon A|senofilcon A silicone hydrogel toric contact lenses will be worn first. galyfilcon A silicone hydrogel toric contact lenses will be worn second.
88809153|NCT00697190|Active Comparator|galyfilcon A/senofilcon A|galyfilcon A silicone hydrogel toric contact lenses worn first. senofilcon A silicone hydrogel toric contact lenses worn second.
88809154|NCT02998112|Placebo Comparator|control|5-ASA 4g/day enema through TET for 1 week; 200ml saline infusion through TET for 3 times every other day in one week
88809155|NCT02998112|Experimental|Study group|5-ASA 4g/day enema through TET for 1 week; 200ml fecal microbiota suspension infusion through TET for 3 times every other day in one week
88809156|NCT00650078|Experimental|NP01|Modified Release (MR) prednisone 5 mg
88809157|NCT00650078|Placebo Comparator|Placebo|
88809158|NCT00699140|Experimental|1 treatment group with IGIV3I Grifols|"Open label, non-randomized treatment group with IGIV3I Grifols~Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses."
88809159|NCT01799486|Experimental|Telbivudine|Telbivudine,600mg/d,oral,100patients,2 years.
88809160|NCT01799486|Experimental|Adefovir|Adefovir,10mg/d,oral,100 patients,2years.
88809161|NCT01799486|Experimental|Enecavir|Enecavir,0.5mg/d,oral,100 patients,2 year
88809162|NCT02320838|Experimental|5 KHz|"Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
88809163|NCT02320838|Experimental|TENS|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds"
88809164|NCT02320838|Sham Comparator|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
88809165|NCT00650546|Experimental|A pre treatment NAS score|liver biopsy score pre treatment with exenatide 5 micrograms SQ (sub-cutaneous) twice a day titrated to 10 mcg SQ twice a day as tolerated
88809166|NCT02998190|Experimental|Single oral dose of EB8018|Single ascending doses, sequential group design
88809167|NCT02998190|Placebo Comparator|Single oral dose of placebo|Single doses, matching placebo
88809168|NCT02998190|Experimental|Multiple oral doses of EB8018|Multiple ascending doses, daily for 14 days
88809169|NCT02998190|Placebo Comparator|Multiple oral doses of placebo|Multiple ascending doses, daily for 14 days
88809170|NCT00699218|Experimental|rTMS treatment|Active rTMS treatment. Transcranial magnetic stimulation using a device called MagStim
88809171|NCT00650858|Active Comparator|0.3 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
88809172|NCT00650858|Active Comparator|1.0 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 1.0 mg dose arm or the 0.3 mg dose arm. Subjects in this arm (1.0 mg) received up to 8 doses of 1.0 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
88809173|NCT00650858|Experimental|1.0 mg Rt-PA q8h|In stage 2 of the protocol, dose frequency, subjects received up to 8 doses of 1.0 mg of rt-PA (Cathflo) every 8 hours through the intraventricular catheter to treat intraventricular hemorrhage.
88809174|NCT00650936|Other|AMPLATZER Septal Occluder|Subjects were enrolled if the implant of the AMPLATZER Septal Occluder device was completed or was attempted (delivery system entered the subject's body).
88809175|NCT00651482|Experimental|Bevacizumab + RAD001 (everolimus)|"Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles~Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)~Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)"
88809176|NCT02998034|Experimental|Cemented monoblock hemiarthroplasty|The cemented monoblock hemiarthroplasty is a double tapered polished stem with a hemiarthroplasty head cemented in place (Zimmer incorporated, UK)
88809177|NCT02998034|Experimental|Hyroxyapatite coated prosthesis|the Furlong Hyroxyapatite coated prosthesis (JRI orthopaedics limited UK) is a hydroxyapatite coating uncemented a hip prosthesis with a hemiarthroplasty head. The implant is uncemented.
88809178|NCT00651794|Active Comparator|Control (NRP Curriculum with LFT and no team training)|Standard Neonatal Resuscitation Program (NRP) curriculum with no team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
88809179|NCT00651794|Experimental|NRP with LFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
88809180|NCT00651794|Experimental|NRP with HFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitations using high-fidelity simulators for high-fidelity training (HFT)
88809181|NCT02997956|Experimental|Tocilizumab|"Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.~The first part of the trial will be Phase Ib and will enroll 18 participants. Participants will receive TACE on day 1 and Tocilizumab at dose level 1, 2, or 3 on days 1, 29 and 57. Maximum tolerated dose (MTD) of Tocilizumab will be determined.~The second part of the trial will be a Phase II and will enroll 50 subjects. Participants will receive TACE on day 1 and Tocilizumab at the MTD on days 1, 29 and 57."
88809182|NCT00654836|Experimental|Carboplatin, ABI-007 and Bevacizumab|Participants will receive combination carboplatin, nanoparticle albumin-bound paclitaxel (ABI-007-Abraxane), and bevacizumab (Avastin)
88809183|NCT02997800|Experimental|Esmolol|Esmolol infusion and 1 ml saline infusion
88809184|NCT02997800|Experimental|Labetalol|Labetalol Bolus and saline infusion
88809185|NCT02997800|Active Comparator|Fentanyl|Fentanyl Bolus and saline infusion
88809186|NCT02997644|Experimental|Video Education|Video education delivered on a tablet computer
88809187|NCT02997644|Placebo Comparator|Usual Care Group|Regular information about opioid usage they typically receive from their surgeon.
88809188|NCT00701636|Experimental|Cases|The first 15 subjects enrolled will receive the intervention drug daptomycin as surgical antibiotic prophylaxis.
88809189|NCT00701636|No Intervention|Controls|15 subjects will be enrolled in the standard of care antibiotic group to serve as the controls. Controls will receive no experimental medications or treatments. The purpose of enrolling control patients was to serve as a reference group for intervention patients. Specifically cases and controls will be compared for changes in commonly collected hematologic parameters, creatinine, and CPK. Additionally, parameters collected during anesthesia will be compared. Controls will be matched to the intervention group by age (+/- 10 years), gender, and ethnicity.
88809190|NCT00701714|Experimental|1|HX575, EPO HEXAL
88809191|NCT00701714|Active Comparator|2|ERYPO
88809192|NCT00655538|Experimental|Dalcetrapib|
88809193|NCT00655538|Placebo Comparator|Placebo|
88809194|NCT00656630|Active Comparator|1|Acamprosate
88809195|NCT00656630|Active Comparator|2|Naltrexone
88809196|NCT00656630|Placebo Comparator|3|
88809197|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 200 et 160|According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
88809198|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 159 et 120|According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
88809199|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation inferior to 119|According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
88809200|NCT01362998|Active Comparator|Preservative free morphine|This group will receive 3mg of preservative free morphine epidurally during the procedure.
88809201|NCT01362998|Active Comparator|Fentanyl infusion|This group will receive an epidural infusion of fentanyl (60 micrograms per hour), which will be started during the Cesarean section and which will continue for the next two days.
88809202|NCT04387526|Active Comparator|SOF/DCV|"Easy to treat arm: Participants were treated with a dual therapy (SOF and DCV) for 12 weeks.~This arm included non-cirrhotic treatment-naïve patients"
88809203|NCT04387526|Active Comparator|SOF/DCV/RBV + Cirrhosis|This difficult-to-treat arm included 111 cirrhotic participants who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
88809204|NCT04387526|Active Comparator|SOF/DCV/RBV + Non-Cirrhosis|This difficult-to-treat arm included treatment-experienced non-cirrhotic participants (77 participants) who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
88809205|NCT02997566||Autistic Disorder|Age: 3 to 14 years-old Gender: male and female Autism Spectrum Disorder
88809206|NCT02997566||Typical|Age: 3 to 14 years-old Gender: male and female Typical
88809207|NCT02997488||McGrath|McGrath Videolaryngoscope
88809208|NCT02997488||Pentax|Pentax Airwayscope
88809209|NCT00658112|Experimental|Benzoyl Peroxide 5%|Subjects will be given standard instructions in the use of topical benzoyl peroxide gel and will be provided with a supply of medication fitted with a Medication Event Monitoring System (MEMS) cap. This cap records dates and times the assembly is opened which can be downloaded at the final visit and tabulated with associated software. When the tubes are weighed, data from the MEMS Caps will be collected. Study coordinators will record adherence, while assessors are blinded to adherence rates. All subjects will be assigned to treatment with topical benzoyl peroxide to the entire face.
88809210|NCT02997332|Experimental|Patients with squamous cell carcinoma of the oral cavity,|The aim is to evaluate safety, PK and pharmacodynamics of durvalumab in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx previously untreated, with indication of induction chemotherapy.
88809211|NCT04345094|Experimental|Comparator|Emulsion containing 1% Hexylresourcinol
88809212|NCT04345094|Active Comparator|Intervention|Emulsion containing 2% Hydroquinone
88809213|NCT00702884|Experimental|Sunitinib|Sunitinib 37.5 mg daily for a 4 week cycle
88809214|NCT00703508|Experimental|Metformin|Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
88809215|NCT01284335|Experimental|Gemcitabine plus LY573636|
88809216|NCT01284335|Experimental|Docetaxel plus LY573636|
88809217|NCT01284335|Experimental|Temozolomide plus LY573636|
88809218|NCT01284335|Experimental|Cisplatin plus LY573636|
88809219|NCT01284335|Experimental|Erlotinib plus LY573636|
88809220|NCT01230125|Experimental|Mapracorat|Ophthalmic suspension 3%
88809221|NCT01230125|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
88809222|NCT01194479|Active Comparator|Type 1 Diabetics|The active group were participants with type 1 diabetes.
88809223|NCT01194479|Other|Healthy Volunteers|The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.
88809224|NCT01230593|Active Comparator|Hot Compress|"Hot Compress"
88809225|NCT01230593|Active Comparator|Tobrex|"Hot Compress, Tobrex Drops, Tobrex Ointment"
88809226|NCT01230593|Active Comparator|Tobradex|"Hot Compress, Tobradex Drops, Tobradex Ointment"
88809227|NCT01195025|Other|A.acetatedRingers, B.colloid & C.colloid+acetatedRingers|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by 150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
88809228|NCT01195025|Other|A.colloid, B.colloid+acetatedRinger & C.acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
88809229|NCT01195025|Other|A.acetatedRingers, B.acetatedRingers+colloid & C.colloid|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B.Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples."
88809230|NCT01195025|Other|A.colloid, B.acetatedRingers & C.colloid+acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
88809231|NCT01195025|Other|A.colloid+acetatedRingers, B.colloid & C.acetated Ringers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
88809232|NCT03009695|Experimental|High frequency repetitive dTMS + Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): present."
88809233|NCT03009695|Experimental|High frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): absent."
88809234|NCT03009695|Experimental|Low frequency repetitive dTMS+ Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT) Frequency: 1 Hz Duration of the train: 10 min Inter-train interval: 1 min Trains number: 4 Total pulses: 2400 Total treatment duration: 43 min Cue (sight of food preferred by patient): present"
88809235|NCT03009695|Experimental|Low frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 1 Hz, Duration of the train: 10 min, Inter-train interval: 1 min, Trains number: 4, Total pulses: 2400, Total treatment duration: 43 min, Cue (sight of food preferred by patient): absent."
88809236|NCT03009695|Sham Comparator|Sham|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to sham stimulation.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz (50% of patients) and 1 Hz (50% of patients), Duration of the train: 2 sec or 10 min, Inter-train interval: 20 sec or 1 min, Trains number: 80 or 4, Total pulses: 2880 or 2400, Total treatment duration: 29.3 or 43 min, Cue (sight of food preferred by patient): present."
88809237|NCT01285427||DNA loci (SeCore vs. SSP UniTray platforms)|
88809238|NCT03009851|Experimental|OBCHI|This small group process intervention focuses upon the cultural heritage of the residents in LTC settings measuring quality of life, activity engagement and social participation.
88809239|NCT03009851|No Intervention|Control|The control group only received the typical activities conducted in LTC facilities.
88809240|NCT01286441|Placebo Comparator|Placebo|Placebo for East Indian Sandalwood Oil ointment administered topically twice daily
88809241|NCT01286441|Active Comparator|10% EISO|East Indian Sandalwood Oil ointment, 10% (w/w), applied topically twice daily
88809242|NCT01286441|Active Comparator|20% EISO|East Indian Sandalwood Oil ointment, 20% (w/w), applied topically twice daily
88809243|NCT01286441|Active Comparator|30% EISO|East Indian Sandalwood Oil ointment, 30% (w/w), applied topically twice daily
88809244|NCT01195883|Active Comparator|Crystalloid|Lactated Ringers solution will be used for fluid replacement.
88809245|NCT01195883|Active Comparator|Colloid|Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
88809246|NCT01196117|Placebo Comparator|14 days of Placebo therapy, then CPAP|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
88809247|NCT01196117|Active Comparator|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
88809248|NCT00703664|Experimental|Treatment (vorinostat, bortezomib)|"Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.~Treatment arm consists of 3 cohorts, all receiving the same treatment:~A: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~B: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~C: Diffuse Large B-Cell Lymphoma (DLBCL) - with no prior bortezomib."
88809249|NCT01232465||IVF|those individuals undergoing conventional IVF to inseminate their retrieved eggs
88809250|NCT01232465||ICSI|those individuals whose eggs were fertilized via intracytoplasmic sperm injection (ICSI)
88809251|NCT00658736|Experimental|1|EUS guided celiac block with bupivicaine and triamcinolone. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
88809252|NCT00658736|Placebo Comparator|2|EUS guided celiac block with bupivicaine only. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
88809253|NCT01196819|Active Comparator|Xience V|Implantation of Xience V drug eluting stent
88809254|NCT01196819|Experimental|Firehawk|Implantation of Firehawk drug eluting stent
88809255|NCT04387058|Other|patients with cirrhosis and and portal hypertension|All major patients under 70 years of age with cirrhosis and portal hypertension justifying a treatment with TIPS. These patients must be affiliated to a social security and able to sign a free, informed and written consent.
88809256|NCT01799564|Experimental|Micropulse|Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions
88809257|NCT01799564|No Intervention|Control|The fellow eye does not receive any treatment
88809258|NCT00659360|Experimental|Arm I|Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity.
88809259|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable microfoam 0.125%|Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
88809260|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable micrfoam, 1.0%|Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
88809261|NCT01197833|Active Comparator|endovenous ablation+vehicle (placebo)|endovenous ablation followed by injection of vehicle (placebo) to target vein
88809262|NCT02997098||Patients undergoing hepatectomy|Patients undergoing hepatectomy, or liver resection, for a non-transplant indication.
88809263|NCT04270448|Active Comparator|Control|Practice of a joystick based motor sequence task. Participants receive feedback that they have completed the practice trials in that block of practice.
88809264|NCT04270448|Experimental|Performance Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block.
88809265|NCT04270448|Experimental|Performance plus Positive Feedback|Practice of a joystick based motor sequence task. Participants receive feedback on their response time to complete the trials in the practice block plus positive social comparative feedback.
88809266|NCT04270370|Experimental|LY3478045 (Part A)|LY3478045 administered orally.
88809267|NCT04270370|Placebo Comparator|Placebo (Part A)|Placebo administered orally
88809268|NCT04270370|Experimental|LY3478045 (Part B)|LY3478045 administered orally.
88809269|NCT04270370|Placebo Comparator|Placebo (Part B)|Placebo administered orally
88809270|NCT04270370|Experimental|LY3478045 + Atorvastatin (Part B)|LY3478045 co-administered with atorvastatin orally.
88809271|NCT04270370|Placebo Comparator|Placebo + Atorvastatin|Placebo co-administered with atorvastatin orally.
88809272|NCT01288781|Experimental|Acetazolamide|Arm 1: ACETAZOLAMIDE (250mg) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
88809273|NCT01288781|Placebo Comparator|Placebo|Placebo (LACTOSE MONOHYDRATE) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
88809274|NCT02990078||Acute TBI|Subjects will be recruited from the neurointensive care unit within 72 hours of their injury. At the time of informed consent, the investigators will perform fNIRS testing with a hypercapnia challenge, fNIRS with hypercapnia challenge 60 minutes after a single oral dose of 50mg sildenafil citrate, outcome qustionaires and symptom checklists (including: Glasgow Outcomes Scale-Extended, Rivermead Post-Concussive Symptom Questionnaire, Brief Symptom Inventory, Alcohol Consumption Questionnaire, Patient Health Questionnaire, and Insomnia Severity Index). This will all be administered again at 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, and 4 years after injury.
88809275|NCT02990078||Sub-acute/Chronic TBI|Subjects who suffered a TBI previously and have now entered a subacute or chronic phase of their TBI will be approached by the research team at their clinic visit with a TBI specialist. In those subjects, study timing will be based on the time of their original injury, therefore will start study visits at the next possible time point.
88809276|NCT02990078||Healthy Controls|"The investigators will also enroll healthy peer controls. These control subjects will be family members and friends of TBI subjects. These peer controls are likely to have similar environmental and socioeconomic exposures/support which may impact recovery after TBI and may also impact CVR. These control subjects will meet the same inclusion/exclusion criteria as TBI subjects without the requirement for an injury or acute brain imaging. These subjects will be tested in the same way as both TBI groups, but will only have one visit."
88809277|NCT01288859|Experimental|encapsulated curcumin|
88809278|NCT01288859|Experimental|encapsulated curcumin + PQG|PQG means Piperine, Quercetin and Genistein
88809279|NCT01288859|Active Comparator|free cocoa polyphenol|
88809280|NCT01288859|Placebo Comparator|control|
88809281|NCT01288859|Experimental|encapsulated cocoa polyphenols|
88809282|NCT01288859|Active Comparator|free curcumin|Subjects will consume bread added with free curcumin
88809283|NCT02994134|Active Comparator|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
88809284|NCT02994134|Experimental|High intensity exercise|High intensity aerobic exercise intervention (delivered at 65%-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
88809285|NCT00659828|Experimental|Recombinant Methionyl Human Leptin|Recombinant methionyl human leptin: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss).
88809286|NCT01235195|Active Comparator|Sertraline 50 mg capsules|
88809287|NCT01235195|Active Comparator|Sertraline 50 mg tablet|
88809288|NCT04387214||Veterinary students and researchers|
88809289|NCT01198691|Placebo Comparator|Control Group|This group will receive the standard metallic staples to close their incision.
88809290|NCT01198691|Experimental|Case Group|This group will receive the Insorb absorbable staples to close their incision.
88809291|NCT00660530|Active Comparator|1|One week before the administration of crushed or chewed lanthanum, the subjects were instructed to discontinue their P-binding agents, if prescribed previously. At the end of the 1-week washout period, subjects whose serum P exceeded 5.5 mg/dL were randomized to receive, in a crossover fashion, lanthanum 1000 mg (Fosrenol, Shire US Inc., Wayne, PA, USA) 3 times daily to be chewed with meals (chewed LAN) or lanthanum 1000 mg crushed into a ﬁne powder and taken with meals 3 times daily (crushed LAN), for 4 weeks each. The lanthanum tablets were crushed into a ﬁne powder using a mortar and pestle by the investigators, individually wrapped in powder packets and dispensed to the subjects on a weekly basis. The subjects were instructed to empty the powder into a small plastic cup provided, mix with 2 tablespoonfuls of applesauce and take it with meals. After each treatment (chewed or crushed LAN), there was a 1-week washout period.
88809292|NCT00660530|Experimental|2|After the one-week washout period, the subject received the other lanthanum treatment (chewed or crushed) that they did not receive in the initial treatment period.
88809293|NCT01198769|Experimental|Rotarix Group|subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.
88809294|NCT02996942||Replacement therapy|Hemophilia A receiving replacement therapy (prophylaxis or on demand)
88809295|NCT01199237|Active Comparator|Sevoflurane|Patients receive sevoflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
88809296|NCT01199237|Active Comparator|Desflurane|Patients receive Desflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
88809297|NCT01235897|Experimental|Maximum tolerated dose|
88809298|NCT01236053||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date.
88809299|NCT00703976|Active Comparator|Cetuximab, Pemetrexed and Radiation therapy|"Cetuximab, Pemetrexed and Radiation therapy Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks"
88809300|NCT00703976|Experimental|Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab|"Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy."
88809301|NCT02320214|Experimental|Miami w/ frag Personal lubricant|Healthy subjects use Novel lubricant Miami w/ frag Personal lubricant at least 4 times per week for 2 weeks.
88809302|NCT02994368||Primary Cohort|No intervention
88809303|NCT02994368||Expansion Cohort|No intervention
88809304|NCT02996708||Group with teleconsultation - before period|
88809305|NCT02996708||Group without teleconsultation - before period|
88809306|NCT02996708||Group with teleconsultation - after period|
88809307|NCT02996708||Group without teleconsultation - after period|
88809308|NCT00661544|Experimental|Arsenic Trioxide + Vitamin C + Melphalan|Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)
88809309|NCT02996552|Experimental|M & T Repair Group|Both mitral and tricuspid valves repair
88809310|NCT02996552|Active Comparator|Mitral-Only Group|Only mitral valve repair
88809311|NCT00706394|Experimental|A|Powerlink 34mm cuff stent graft
88809312|NCT00706550|Other|Immediate|"Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
88809313|NCT00706550|Other|Delayed|"Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
88809314|NCT02997878|Experimental|PSC patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
88809315|NCT02997878|Experimental|AIH patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
88809316|NCT02979392|Experimental|Phase I|Part A, Dose escalation TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (Phase I starting dose 75 mg/m2) Part B, Expansion TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (RP2D dose determined in part A)
88809317|NCT01237301|Experimental|CGM Group|Wear an unblinded CGM for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use real time continuous glucose monitoring (rt CGM).
88809318|NCT01237301|Active Comparator|SMBG Group|Use SMBG 4 to 7 times a day for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use structured self monitoring blood glucose (stSMBG) and periodic, blinded continuous glucose monitoring (CGM).
88809319|NCT02999906|Placebo Comparator|Placebo|Matching placebo (sugar pill)
88809320|NCT02999906|Active Comparator|Active|Oral treprostinil sustained release tablet
88809321|NCT02999750|Other|individual therapy|individual therapy
88809322|NCT01238471|Experimental|Propranolol|Oral propranolol for premature infants allocated to this arm by randomization
88809323|NCT01238471|Placebo Comparator|Oral sucrose 5%|Placebo: Oral sucrose 5% for premature infants allocated to control arm by randomization
88809324|NCT00706784|Experimental|A|
88809325|NCT02996786|Experimental|Danggui Buxue Tang group|Danggui Buxue Tang group receive orally supplementation of 7.5 g/day of Danggui Buxue Tang for 10 days
88809326|NCT02996786|Placebo Comparator|Placebo group|Placebo group receive orally supplementation of 7.5 g/day of placebo for 10 days
88809327|NCT00664430|Other|Calcitriol challenge followed by paricalcitol|Participants began a controlled calcitriol therapy period (calcitriol challenge) to confirm calcitriol resistance. After this period, those who failed to reduce PTH (according to parameters in protocol) initiated paricalcitol therapy.
88809328|NCT01292135|Experimental|PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)|
88809329|NCT01292135|Experimental|PCI-32765 plus bendamustine/rituximab (BR)|
88809330|NCT01238549||Spinal Cord Injury|Participants with SCI
88809331|NCT01241435|Experimental|LY2216684|LY2216684: A single dose of 18 milligrams (mg) administered orally in participants with normal hepatic function, mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B), or severe hepatic impairment (Child-Pugh C)
88809332|NCT01292447|Placebo Comparator|Control Group|Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.
88809333|NCT01292447|Experimental|Study Group|Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.
88809334|NCT02194439||hematopoietic stem cell transplant|procedure
88809335|NCT00704912|Active Comparator|Lifestyle intervention|Orlistat/Meal Replacement/Lifestyle Modification
88809336|NCT00704912|Active Comparator|Oral Contraceptives (OCP)|Loestrin 1/20
88809337|NCT00704912|Active Comparator|Lifestyle/OCP Combined|Combination of treatments
88809338|NCT02195921|Experimental|Single point CV12|"choose single point:Zhongwan(CV12).Zhongwan(CV12):On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line.Manipulating until achieving a de Qi sensation,then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
88809339|NCT02195921|Experimental|Single point ST36|"choose another single point Zusanli（ST36）.Zusanli(ST36):On the anterior aspect of the leg, on the line connecting ST35 with ST41, 3 B-cun inferior to ST35，located on the tibialis anterior muscle..Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
88809340|NCT02195921|Experimental|ST36+CV12 acupoints|"Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
88809341|NCT02195921|Active Comparator|only antiemetics|The control group will receive standard antiemetics alone. Standard antiemetics for all groups are based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days. If nausea and/or vomiting is persistent and failed to respond to the antiemetic treatment , based on the experience of each clinician, the other advanced 5-HT3 antagonist or a neurokinin 1 antagonist(NK-1) will be chosen.
88809342|NCT04387292|Experimental|Ophthalmologic exam|
88809343|NCT02189213|Active Comparator|Sertraline|Sertraline will be administered PO to treat anxiety disorders in children and adolescents. he following dosing schedules will be used: Sertraline will be titrated from 25mg once a day orally up to 200mg once a day orally, for 12 weeks. The titration will stop at the dose in which the participant shows a full response to the medication or experiences side effects that will inhibit titration.
88809344|NCT02189213|No Intervention|Control|There will be no intervention in this arm.
88809345|NCT02999828|Experimental|3.0 EU in Children|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
88809346|NCT01241513|Experimental|N-acetyl-L-Cysteine|N-Acetyl-L-Cysteine
88809347|NCT01241513|Placebo Comparator|Placebo|placebo
88809348|NCT00665132|Experimental|StimRouter (SR) for CTS|Percutaneous implantation of StimRouter System
88809349|NCT01799642||Cystic Fibrosis Patients|Participants with Cystic Fibrosis
88809350|NCT01799642||Healthy Controls|Participants who do not have cystic fibrosis and are otherwise healthy.
88809351|NCT01241903|Experimental|Crestor|
88809352|NCT01241903|Placebo Comparator|sugar pill|
88809353|NCT00666848|Placebo Comparator|2 (enalapril 5mg)|Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .
88809354|NCT00666848|Placebo Comparator|1 (placebo)|Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.
88809355|NCT00666848|Placebo Comparator|3 (enalapril 10mg)|Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.
88809356|NCT01287377|Experimental|Pre-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients will be encouraged to start using these patches PRIOR to their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
88809357|NCT01287377|Active Comparator|Post-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients are encouraged to start using their patches ON their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
88809358|NCT01287377|Active Comparator|Telephone Counseling and no patches sent|Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls.
88809359|NCT02996240|Experimental|Omega-3 FFA|Patients will take 12 capsules daily with meals, divided twice daily (example, 6 with breakfast and 6 with dinner).
88809360|NCT01242527|Placebo Comparator|placebo|
88809361|NCT01242527|Experimental|Epanova 2 g|
88809362|NCT01242527|Experimental|Epanova 3 g|
88809363|NCT01242527|Experimental|Epanova 4 g|
88809364|NCT00667004|Experimental|1|ecabet ophthalmic solution
88809365|NCT00667004|Placebo Comparator|2|Placebo comparator
88809366|NCT02991014|Active Comparator|researcher-selected frequency-modulated music|
88809367|NCT02991014|Placebo Comparator|researcher-selected non-modulated music|
88809368|NCT02991014|Experimental|participant-selected non-modulated music|
88809369|NCT02995616|Experimental|Lokomat training|Patients will be tested in 3 Lokomat training sessions on 3 separate days. During the first session patients will walk in the Lokomat according to their regular therapy settings. During the second and third session patients will walk in the Lokomat with 2 different levels of guidance force (100% guidance force and 60% guidance force).
88809370|NCT01204853|Experimental|Sitaxentan treatment|
88809371|NCT01028846|Active Comparator|Diazoxide|1-2 mg/kg total dose given intravenously during pancreatic clamp study
88809372|NCT01028846|Placebo Comparator|Placebo|Intravenous normal saline during pancreatic clamp study
88809373|NCT02998814|Active Comparator|acid-etch only|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid-etch only will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
88809374|NCT02998814|Active Comparator|self-etch adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for self-etch adhesive will be treated with self-etch adhesive (AdperTM EasyBond, 3M ESPE) for 10 seconds followed by light curing for 20 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
88809375|NCT02998814|Active Comparator|etch-and-rinse adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch-and-rinse adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, etch-and-rinse adhesive (Single BondTM, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
88809376|NCT02998814|Active Comparator|self-etch adhesive after acid-etch|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid etch + self-etch adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, self-etch adhesive (AdperTM EasyBond, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
88809377|NCT00714272|Experimental|A|Granulocytapheresis treatment
88809378|NCT00714272|Placebo Comparator|B|Sham device treatment
88809379|NCT01275794||1|Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program
88809380|NCT01205399||AlloMax Surgical Graft Group|
88809381|NCT04386122|Experimental|FABALOFEN 60|Subjects will receive a single dose of 1 FABALOFEN 60 tablet under fed condition
88809382|NCT04386122|Active Comparator|JAPROLOX TABLET|Subjects will receive a single dose of 1 JAPROLOX® TABLETS tablet under fed condition
88809383|NCT03009461|Experimental|Sor-HAIC group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
88809384|NCT03009461|Active Comparator|Sor group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
88809385|NCT02995460|Experimental|interval training|4x4 high intensity interval training was performed on a stationary bicycle with a supervisor twice a week and by one self-training a week.
88809386|NCT02995460|No Intervention|controls|No change in diet and training habits
88809387|NCT02990702|Active Comparator|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block group patients (Group R) will receive 30 cc %0.5 Bupivacaine
88809388|NCT02990702|Active Comparator|Ultrasound guided infraclavicular block|Ultrasound guided coracoid infraclavicular block group patients (Group C) will receive 30 cc %0.5 Bupivacaine
88809389|NCT01243619|Experimental|FLT PET|This is a single arm trial, in which all patients receive three FDG-PET scans and three FLT-PET scans, before, during and after pre-operative chemoradiation for esophageal cancer.
88809390|NCT02995304|Active Comparator|Morphine and Midazolam premedication|30 children will receive 0.025 mg/kg midazolam IV followed by 0.1 mg/kg morphine 20 to 30 min before surgical incision.
88809391|NCT02995304|Active Comparator|Midazolam only premedication|30 children who will receive 0.025 mg/kg midazolam IV followed by saline 20 to 30 min before surgical incision.
88809392|NCT02990858|Experimental|PRO 140|
88809393|NCT02995148|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
88809394|NCT00725504|Experimental|Lidocaine infusion|Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.
88809395|NCT02990624|Active Comparator|High risk group|Patients with psoriasis and atherosclerosis will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
88809396|NCT02990624|Active Comparator|Low risk group|Patients with psoriasis but no atherosclerosis detected, will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
88809397|NCT02990624|No Intervention|Control group|Age-matching apparently normal individuals will receive no interventions but will perform investigational tests.
88809398|NCT01275872|Experimental|Guided Imagery and Progressive Muscle Relaxation|
88809399|NCT02995226|Other|Anorexia nervosa|"Patients with DSM-5 criteria of anorexia nervosa"
88809400|NCT02995226|Other|First degree relatives|First degree relatives (of patients suffering from anorexia nervosa) with no eating disorder
88809401|NCT02995226|Other|Controls (with no eating disorder)|Other
88809402|NCT02995070|Experimental|CTG + LLLT|The irradiation will be performed with a GaAlAs diode laser that will continuously emits a wavelength of 660 nm with a power of 30 milliwatts. The patients allocated for the LLLT group will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 J/cm2 and a time of 20 seconds. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment will be calibrated prior to each application.
88809403|NCT02995070|Sham Comparator|CTG + SHAM|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which will not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications.
88809404|NCT01276028|Experimental|Acupuncture|This group will start acupuncture treatments within 3 weeks of consent and continue to receive up to 20 treatments over a six month period. The number of treatments will be jointly determined by the participant and the acupuncturist.
88809405|NCT01276028|Other|Waitlist|This group of participants will be asked to wait 6 months and will then be allowed to receive acupuncture.
88809406|NCT03830684|Experimental|low-dose group|Baicalein Tablets group
88809407|NCT03830684|Experimental|high-dose group|Baicalein Tablets group
88809408|NCT03830684|Placebo Comparator|placebo group|control group
88809409|NCT00727064|Active Comparator|DVS/VEN|
88809410|NCT00727064|Active Comparator|VEN/DVS|
88809411|NCT00727220||Insulin Pump Therapy|Children starting insulin pump therapy
88809412|NCT00727220||Insulin Injections|Children remaining on insulin injections.
88809413|NCT01294163|Experimental|Xenon|
88809414|NCT01294163|Active Comparator|Sevoflurane|
88809415|NCT01294163|Active Comparator|Total intravenous anaesthesia|
88809416|NCT01294241|Experimental|Oleogel-S10|The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
88809417|NCT01294241|Other|Non-adhesive wound dressing|Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
88809418|NCT01244243|Experimental|Active therapy|All subjects receive the same active robotic therapy, there is no placebo arm, as a key goal of this study is to define predictors of response to active treatment.
88809419|NCT01294319|Experimental|Sedentary young adults, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
88809420|NCT01294319|Experimental|Endurance-trained young athletes, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
88809421|NCT01294319|Experimental|Sedentary young adults, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
88809422|NCT01294319|Experimental|Endurance-trained young athletes, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
88809423|NCT01294319|Experimental|Sedentary young adults, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
88809424|NCT01294319|Experimental|Endurance-trained young athletes, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
88809425|NCT01294319|Experimental|Sedentary young adults,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
88809426|NCT01294319|Experimental|Endurance-trained young athletes,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
88809427|NCT00727298||Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
88809428|NCT02994992|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
88809429|NCT02990312|Experimental|Sirolimus + Maraviroc|Participants will be placed on the combination of Sirolimus and Maraviroc, unless they are already on one of these medications.
88809430|NCT01244477|Experimental|CPT-C|Participants in group CPT-C
88809431|NCT01244477|No Intervention|Treatment-as-Usual|Participants randomly assigned to the Waitlist Control Group (who will participate in CPT-C after 12 weeks).
88809432|NCT02994524|Other|transsphincteric perianal fistula|Rerouting technique done in patients with high transsphincteric fistula or with high internal opening.
88809433|NCT01294709|Experimental|Telcagepant/ Placebo|Participants receive single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 1 and single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
88809434|NCT01294709|Experimental|Placebo/Telcagepant|Participants receive single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 1 and a single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
88809435|NCT01295879|Experimental|Ergocalciferol|Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks
88809436|NCT01244633|Experimental|Ecopipam|Active treatment
88809437|NCT01296191|Active Comparator|VIGAMOX|Subjects undergoing cataract surgery, randomized to the VIGAMOX group Generic name is moxifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
88809438|NCT01296191|Active Comparator|Besivance|Subjects scheduled for cataract surgery, randomized to the Besivance group Generic name is besifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
88809439|NCT01244711|Experimental|Quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
88809440|NCT01245413|Active Comparator|SenSura Adhesive (device)|Sensura is a commercially available adhesive, that is designed to collect output from a stoma.
88809441|NCT01245413|Experimental|Athena adhesive|Athena = new test adhesive. The Athena baseplate is intended for collecting output from a stoma.
88809442|NCT01210079|Experimental|Gabapentin|
88809443|NCT01210079|Placebo Comparator|Placebo|
88809444|NCT01245647|Placebo Comparator|Sugar Pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
88809445|NCT01245647|Active Comparator|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
88809446|NCT00708110|Experimental|Treatment A|GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
88809447|NCT00708110|Experimental|Treatment B|GSK1349572 10 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
88809448|NCT00708110|Experimental|Treatment C|GSK1349572 50 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
88809449|NCT01296815|No Intervention|HAART|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
88809450|NCT01296815|Experimental|HAART+ Bevacizumab injection|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Patients received 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) in the target lesion every 2 weeks. Bevacizumab was injected using an insulin syringe in a submucosal plane. The volume injected was based on the size of the target lesion; the dose was 0.2 mL (5 mg) per cm2.
88809451|NCT01246349|Experimental|Motivational Interviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical psychology doctoral student trained in Motivational Interviewing administered six individual motivational interviewing treatment sessions, each 30 minutes in length.
88809452|NCT01246349|Active Comparator|Control Group|The comparison group received six social skills training sessions instead of Motivational Interviewing (MI).
88809453|NCT01276262|Placebo Comparator|Treatment A|Monophasic oral contraceptive (Microgynon® 30) with placebo tablets
88809454|NCT01276262|Experimental|Treatment B|Monophasic oral contraceptive (Microgynon® 30) and fostamatinib
88809455|NCT01276340||1|women with urinary incontinence
88809456|NCT01276418|Experimental|Treatment|
88809457|NCT01297283|Experimental|Leadless ECG first|Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device
88809458|NCT01297283|Active Comparator|Programmer ECG first|Measurements of pacing thresholds are done first with the support of the programmer ECG
88809459|NCT02995382|Experimental|Anterior Intramuscular Transposition|This is the only arm in our study, patients with cubital tunnel syndrome will undergo anterior intramuscular transposition, one of many surgical techniques utilized on patients with Cubital Tunnel Syndrome to alleviate symptoms.
88809460|NCT02998502|Experimental|Device Group|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with PD. FBS has now received FDA clearance for the treatment of PD adults and is currently commercially available and more than 150 therapist have provided the service nationally. However, FBS has not yet been tested for efficacy in a pediatric populations. Due to its portability, FBS may pose an advantage for use in younger age groups, compared to multiple therapy sessions required for CBT or lower acceptability for long-term medication use for adolescent PD. In this pilot intervention study, the efficacy of the FBS system in youth will be tested.
88809461|NCT02998502|No Intervention|Control Group|The device will be given to those in the control group after 8-week baseline period.
88809462|NCT04351997|Experimental|Early cord clamping|Cord clamping at 60 seconds after birth.
88809463|NCT04351997|Experimental|Delayed cord clamping|Cord clamping at 180 seconds after birth,
88809464|NCT01276496|Experimental|Treatment (cilengitide, paclitaxel)|"Patients receive cilengitide IV over 1 hour on days* 1, 8, and 15 and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Some patients receive cilengitide IV over 1 hour on days 1, 2, 8, 9, 15, and 16."
88809465|NCT01297595|Experimental|crizotinib|
88809466|NCT01297985|Experimental|BRIDGES Intervention|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a 10-week course to an 8-week course, meeting for 2 1/2 hours once a week.
88809467|NCT01297985|No Intervention|Comparison Wait-list Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend the BRIDGES program after their final research interview.
88809468|NCT02992418|Experimental|Concomitant Administration Group|Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine.
88809469|NCT02992418|Experimental|Sequential Administration Group|Participants will be administered the first dose of CYD dengue vaccine 28 days after a dose of Tdap vaccine.
88809470|NCT01276730|Experimental|Group A|Treatment consists of Interferon, given as a sub-cutaneous injection, 3 times per week for 4 weeks, 20 mg Retinoic Acid tablets, 2 times a day for 30 days. starting from the first day of radiation.
88809471|NCT01276730|Active Comparator|Group B|"Treatment consists of radiation and chemotherapy using Cisplatin. Cisplatin, given intravenously, will be administered on the first day of each week, mixed with saline solution, before and after the Cisplatin infusion.~Radiation will be given for a few minutes daily, five days a week, for approximately 5 weeks.~Two weeks after completion of external radiotherapy, subject will receive internal radiation (brachytherapy) once a week for two weeks. For this internal radiation a specially designed instrument will be inserted into the vagina that will be connected to a machine for a few minutes."
88809472|NCT02994212|Experimental|Intervention group|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF. Anthropometric measurements were taken on a weekly basis for 4 weeks to monitor treatment response.
88809473|NCT01298063|Experimental|Afatinib Group A, B (2), D|healthy subjects, mild and moderate liver impaired subjects to receive one single dose treatment containing the highest dose afatinib
88809474|NCT01298063|Experimental|Afatinib Group B (3), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the medium dose of afatinib
88809475|NCT01298063|Experimental|Afatinib Group B (1), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the low dose of afatinib
88809476|NCT04386356|No Intervention|Orotracheal intubation with macintosh laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Macintosh laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
88809477|NCT04386356|Active Comparator|Orotracheal intubation with Airtraq Video Laryngoscope|"Following standard intubation protocol, tracheal intubation will be performed by first year anaesthesia trainee using Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.~Duration of intubation attempt, failed intubation, optimization maneuvers required to perform tracheal intubation, glottic view according to the Cormack and Lehane grading will be evaluated. Similarly, the maximum fall in oxygen saturation during intubation, HR, SBP and DBP will be documented immediately following intubation and then every 5 minutes till the end of surgery. The occurrence of minor complications (visible trauma to lip or oral mucosa, and presence of blood on laryngoscope blade), and the postoperative sore throat and hoarseness will be evaluated at the end of surgery in the postoperative recovery room."
88809478|NCT02999594|Experimental|tramadol|50mg tramadol hydrochloride will be used intramuscularly as an experimental drug for evaluating its safety and efficacy as labor analgesic
88809479|NCT02999594|Placebo Comparator|distilled water|2ml distilled water intramuscularly will be used as a placebo.
88809480|NCT02993744||Case Group|75 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, threatening preterm delivery, application of Betamethasone
88809481|NCT02993744||Control Group|65 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, no threatening preterm delivery
88809482|NCT01298219|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
88809483|NCT01298219|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
88809484|NCT01276808|Experimental|Magnetic navigation PCI|These patients will be treated with magnetically navigated percutaneous coronary intervention
88809485|NCT01276808|Active Comparator|Conventional PCI|These patients will be treated with normal standard percutaneous coronary intervention
88809486|NCT01276886||Acute Diverticulitis|
88809487|NCT01276964||1. Women in the fertile age|Healthy women in the fertile age (between 20-45 years) with apparently normal periods
88809488|NCT02322242|Active Comparator|Perineural Dexamethasone|ISB performed with local anesthetic (ropivacaine 0.5%) and perinerual dexamethasone (4mg)
88809489|NCT02322242|Other|Systemic Dexamethasone|ISB with local anesthetic alone (ropivacaine 0.5%) alone and intravenous dexamethasone (4mg)
88809490|NCT02993666|Experimental|upper body|warming with upper body blankets
88809491|NCT02993666|Experimental|lower body|warming with lower body blankets
88809492|NCT01211873|Experimental|Dotarem (gadoterate meglumine )|Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.
88809493|NCT01211873|Active Comparator|Magnevist (gadopentetate dimeglumine)|Dotarem and Magnevist were randomised as 2:1 ratio
88809494|NCT01211873|Experimental|Dotarem 2 (gadoterate meglumine )|Pediatric patients were assigned to Dotarem group only.
88809495|NCT02993588|Experimental|Melatonin|Melatonin 6 mg tablet once daily.
88809496|NCT02993588|Placebo Comparator|Placebo|Placebo tablet once daily
88809497|NCT01277120||Cohort|
88809498|NCT02991092|Experimental|the experimental group|After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h
88809499|NCT02991092|Other|the control group|"patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
88809500|NCT01270022|Experimental|Implementation|
88809501|NCT01270022|Active Comparator|dissemination|
88809502|NCT01277198||surgery without using a flexible cystoscopy|surgery without using a flexible cystoscopy: patients who did not undergo a flexible cystoscopy during laparoscopic stone surgery
88809503|NCT01277198||surgery with using a flexible cystoscopy|surgery with using a flexible cystoscopy: patients who underwent a flexible cystoscopy during laparoscopic stone surgery
88809504|NCT01277276||Diagnostic tool|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
88809505|NCT04386824||Behçet's disease|Male patients who arediagnosed as Behçet's disease according to International Study Group Classification Criteria
88809506|NCT01270100|Experimental|Recovery management intervention|
88809507|NCT01277432||Psychiatrist interview|"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~MINI~SSI-28 (somatization)"
88809508|NCT01277432||Depression screening|"All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.~All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.~Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;~Patient Health Questionnaire (PHQ-9)~Depression Anxiety and Stress Scale (DASS-21)~Diabetes Distress Scale (DDS-17)~Life events questions (Inter-Heart Study)~Diabetes Empowerment Scale (C-DES 20)~Summary of Diabetes Self Care Activities (SDSCA-15)~Euroqol-5D (EQ-5D)"
88809509|NCT01270178||Entecavir|
88809510|NCT02993276||Treatment Group|All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.
88809511|NCT02993042|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
88809512|NCT01277588||Patient|
88809513|NCT01277588||Physcician|
88809514|NCT01270334||ph above cutoff|
88809515|NCT01270334||PH under cutoff|
88809516|NCT01277900||Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
88809517|NCT02992730||Women Diagnosed with Breast Cancer|Observational - Usual Care
88809518|NCT01270412|Experimental|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml of platelet-derived preparation rich in growth factors
88809519|NCT01270412|Active Comparator|Hyaluronic acid|Drug: hyaluronic acid 20 mg / 2 ml Other Name: Arthrease
88809520|NCT02992496|Active Comparator|Ketamine treatment group|Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.
88809521|NCT02992496|Active Comparator|Control group|Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks
88809522|NCT00729482|Experimental|1|Treatment Arm (RAD001)
88809523|NCT01270490|Experimental|Interferon-gamma|
88809524|NCT01270490|No Intervention|No intervention|No adjunctive treatment
88809525|NCT01278056|Experimental|Exjade|
88809526|NCT02992652|Active Comparator|Study Group|Received 600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
88809527|NCT02992652|No Intervention|Control Group|Underwent ERCP without allopurinol prophylaxis
88809528|NCT01270646|Experimental|Intraventricular Electrical Activation|
88809529|NCT01270724|Experimental|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|Two to four cycles of induction therapy with open label GemPOx followed by consolidation and autologous stem cell transplant (ASCT).
88809530|NCT00709826|Experimental|apricoxib + gemcitabine + erlotinib|400mg apricoxib + 1000mg/m2 gemcitabine + 100mg erlotinib
88809531|NCT00709826|Placebo Comparator|placebo + gemcitabine + erlotinib|placebo + 1000mg/m2 gemcitabine + 100mg erlotinib
88809532|NCT01271114|Experimental|Hypertonic Saline and Terlipressin|
88809533|NCT01271114|Active Comparator|Normal Saline and norepinephrine|
88809534|NCT00710840|Experimental|1|
88809535|NCT00710840|Active Comparator|2|
88809536|NCT02992340|Experimental|Phase 1B|Varlitinib (starting dose at 200 mg BID) Cisplatin Gemcitabine
88809537|NCT00710996||AcrySof Natural Intraocular Lens|"AcrySof Natural Intraocular Lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SN"
88809538|NCT00710996||AcrySof clear intraocular lens|"AcrySof clear intraocular lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SA"
88809539|NCT00710996||Phakic patients|Phakic patients - Age matched patients who have not had cataract surgery
88809540|NCT00711464|Experimental|100 mg|modafinil 100 milligrams oral dose
88809541|NCT00711464|Experimental|200 mg|modafinil 200 mg oral dose
88809542|NCT00711464|Experimental|400 mg|modafinil 400 mg oral dose
88809543|NCT00711464|Placebo Comparator|Placebo|Single oral placebo capsule
88809544|NCT01278290|Active Comparator|Triptorelin test AND LHRH test|Patients undergo two tests with a test interval of at least 15 days
88809545|NCT01278290|Active Comparator|LHRH test AND Triptorelin test|Patients undergo two test with a test interval of al least 15 days.
88809546|NCT00575432||1|
88809547|NCT01278368|Active Comparator|Preoperative chemotherapy (PCHT)|Patients who underwent pancreatic resection after PCHT.
88809548|NCT01278368|Active Comparator|Control|Patient who underwent pancreatic resection without preoperative therapy
88809549|NCT01278446|Experimental|Test Formula|New hydrolyzed whey formula
88809550|NCT01278446|Active Comparator|Control Formula|Commercially available hydrolyzed infant formula
88809551|NCT01271192|Active Comparator|Surgical resection and adjuvant therapy|Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4 weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6 weeks, from 8-12 weeks after operation
88809552|NCT01271192|Experimental|Neoadjuvant followed by operation|Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI for 7 cycles from 2-4 weeks after operation.
88809553|NCT02339558|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
88809554|NCT01278524||Critically ill patients|Patients staying in the ICU on the 25th of January
88809555|NCT00730730|Experimental|Complete SE Iliac Stent|Complete SE Iliac Stent
88809556|NCT00730964|Other|Phase 4|Open Label
88809557|NCT00731198|Experimental|1|Drotaverine hydrochloride
88809558|NCT00731198|Active Comparator|2|Hyoscine-N-butylbromide
88809559|NCT01278602|Experimental|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
88809560|NCT00712244|Active Comparator|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device during cataract surgery.
88809561|NCT00712244|Active Comparator|DuoVisc|Use of DuoVisc Viscoelastic System (Viscoat, Provisc) during cataract surgery.
88809562|NCT00712244|Active Comparator|Healon5|Use of Healon5 ophthalmic viscosurgical device (OVD) during cataract surgery.
88809563|NCT00712244|Active Comparator|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device during cataract surgery.
88809564|NCT02992106|Other|Normal weight during pregnancy|"Offspring of 156 women with a normal weight during their pregnancy recruited by Bogaerts et al, in 3 belgian hospitals. Results of maternal data published in 2013. Now the children will be recruited. This group wil function as a control group.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
88809565|NCT02992106|Other|Obese mothers without intervention|"This subgroup will be compiled of the offspring of women recruited in two different studies. First of all there is the offspring of 65 women from the cohort that was recruited by Guelinckx et al, data published in 2010. This population was recruited in the University hospital of Leuven as control group for women receiving lifestyle interventions during pregnancy. Secondly there are children of 63 women from the cohort of Bogaerts et al of 2013 that had a BMI > 29 kg/m² during their singleton pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
88809566|NCT02992106|Other|Obese mothers & lifestyle intervention|"This one will also be a composition of study subjects of two different study cohorts. Firstly there are children of about 100 Belgian women that were included in the DALI cohort, a European randomized controlled trial. All of them underwent a lifestyle intervention during pregnancy, concerning diet and/ or exercise. Secondly there is the offspring of the other subgroup of the cohort recruited by Guelinckx et al. 130 women were divided into 2 groups which underwent lifestyle interventions during pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
88809567|NCT02992106|Other|History of bariatric surgery|"The PABAS cohort (Pregnancy After Bariatric Surgery) provides children of 49 women who underwent bariatric surgery before their singleton pregnancy. The women were included in five Flemish hospitals before 15 weeks of pregnancy. Furthermore we will recruit the offspring of 200 women that are recruited in the ongoing AURORA cohort (bAriatric sUrgery Registration in women Of Reproductive Age). Women in this cohort are recruited from the start of their process undergoing bariatric surgery and are followed until after their pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
88809568|NCT02991950|Experimental|parnaparin sodium|"Women in LMWH arm are administered with routine ovulation induction protocol and prophylactic dose of parnaparin sodium (LMWH), starting the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until the delivery or the end of pregnancy. Women in the LMWH arm will be tested for blood cell count twice in the first 10 days of therapy.~Parnaparin will be administered at the dose of 100 IU/kg/day from the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until delivery or the end of the pregnancy.~Used dosages Parnaparin 0.4 4250 UI Parnaparin 0.6 6400 UI"
88809569|NCT02991950|No Intervention|no treatment|Women in the control arm are administered with routine ovulation induction protocol, without the addition of parnaparin sodium.
88809570|NCT02991872|Other|V49_24E1 Group|Up to 225 subjects, who completed the full PEP rabies regimens in the parent study V49_24 (NCT01680016), will be invited to participate to this extension study.
88809571|NCT01271582|Experimental|FOLFIRI|Patients with colorectal cancer or gastric cancer will be treated with FOLFIRI(Irinotecan, 5FU, leucovorin) regimen upto 12 cycles. (Single arm study)
88809572|NCT02991638|Other|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
88809573|NCT01271660|Active Comparator|Pregabalin|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with pregabalin.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
88809574|NCT01271660|Placebo Comparator|Placebo|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with placebo.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
88809575|NCT02991560|Experimental|Kinesio tape (KT)|The KT group was taped 2 days a week for 4 weeks using the muscle and fascia correction techniques
88809576|NCT02991560|Experimental|Athletic taping (AT)|An athletic tape with adhesive backing was used (38 mm wide-Muller Protape-The Netherlands).
88809577|NCT00731588|Experimental|PPG1A - Adults|Phase I completed: Healthy male and post-menopausal female volunteers between the ages of 18 and 65. Volunteers must not have donated blood in the previous 8 weeks.
88809578|NCT00731588|Experimental|PPG1B - Infants|Phase II in progress: Newborns >= 24 weeks gestation who are patients in the Neonatal Intensive Care Unit at the University of Iowa Hospitals and Clinics that are being treated with the expectation of survival.
88809579|NCT01271738|Active Comparator|Breast Conserving Surgery (BCS)|
89528709|NCT04889833|No Intervention|Usual Care Group|Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, & shoulder function. 7 days before surgery, they will receive a daily questionnaire about their pain & anxiety over the last 24 hours. On the day of surgery, before they are given any anesthesia, they will answer questions about their average anxiety & pain levels. Starting the next morning on the day following surgery and every day for the subsequent week, they will be given questionnaires about their pain & anxiety levels, medication use, satisfaction, and sleep disturbance due to pain. Their postoperative course will be otherwise completely standard of care, including a first postoperative clinic visit at 10 days after surgery, where the patients will be given these same questionnaires. Finally, patients will answer them one more time on postoperative day 49 and this will constitute a study endpoint. The whole process each day should take approximately 10 minutes.
89528710|NCT04150861|Experimental|Follitropin delta 12 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.
89528711|NCT04150861|Experimental|Follitropin delta 18 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.
89528712|NCT04150861|Experimental|Follitropin delta 24 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.
89528713|NCT04150705|Experimental|FDG PET/MRI|-Patients will undergo FDG-PET/MRI in lieu of the standard pelvic MRI at up to 6 time-points at which it would normally be performed in their care for the period of time extending 30-36 months from the time of enrollment (depending on enrollment point). In the surveillance period, when patients typically undergo pelvic MRI every 3 months, the FDG-PET/MRI will be done in lieu of the standard pelvic MRI on an approximately every-other-scan basis. In other words, the FDG-PET/MRI will occur roughly once every 6 months.
89528714|NCT02465359|Experimental|Immune globulin subcutaneous (Human)|lmmune Globulin Subcutaneous(Human) 20% Liquid (Hizentra) will be given weekly
89528715|NCT02465281||Stroke patients|20 patients who are at least 6 months post stroke. Device: 3T scanner with MRI-compatible robot
89528716|NCT02465281||Healthy volunteers|80 age-matched healthy volunteers
89528717|NCT04857229||All patient|All recruited patient will have their margins assessed with the confocal microscope with comparison of accuracy against gold standard histology.
89528718|NCT02463019|Other|Tenofovir|Tenofovir Disoproxil Fumarate 300mg daily for 3 years
89528719|NCT02462941|Experimental|Adenosine|After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.
89528720|NCT02462707|Experimental|PF-03084014|
89528721|NCT03714451|Experimental|Onyx Group|Patients with T2DM will receive food products containing onyx sorghum (Onyx Group).
89528722|NCT03714451|Active Comparator|Wheat Flour Group|Patients with T2DM will receive food products with wheat flour.
89528723|NCT04096885||InSurg cohort|Patients who undergo elective or emergency surgery at the Department of Visceral Surgery and Medicine, Inselspital, Bern, who gave informed consent.
89528724|NCT02465047|Experimental|Self-help booklet|The intervention consists of a brief A5 self-help stress management booklet with an audio Compact Disk.
89528725|NCT02465047|No Intervention|Delayed Intervention|Participants do not receive the intervention until one month after the initial assessment.
89528726|NCT02463253||Phase 1|"A. OBJECTIVE: The objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. This phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.~B. STUDY DESIGN: Enroll 20 subjects who are post-transplant and are undergoing kidney transplant biopsies at the UC Davis transplant center. Ten subjects will be enrolled who are receiving surveillance protocol biopsies and 10 subjects."
89528727|NCT02463175|Experimental|Intervention group|Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement
89528728|NCT02463175|Experimental|Control group|Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment
89528729|NCT02462395|Experimental|Cefaly tDCS|Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
89528730|NCT03707977|Experimental|Group PK-A: ART + VRC01LS|In the PK Step, participants will continue ART and receive VRC01LS at Weeks 0, 4, and 8 as a single intravenous (IV) dose (30 mg/kg load then 10 mg/kg maintenance).
89528731|NCT03707977|Experimental|Group PK-B: ART + 10-1074|In the PK Step, participants will continue ART and receive 10-1074 at Weeks 0, 4, and 8 as a single IV dose (30 mg/kg).
89528732|NCT03707977|Experimental|Steps 1-3 Participants (ART + 10-1074 + VRC01LS)|In Step 1, eligible participants will continue to receive ART and will receive both 10-1074 and VRC01LS at Weeks 0, 4, and 8. Following a recommendation from the study team and Safety Monitoring Committee (SMC) to increase the maintenance dosing based on the PK Step, a VRC01LS loading dose of 30 mg/kg will be given at the start of Step 1, followed by 15 mg/kg dosing at each 4-weekly visit, and 10-1074 dosing will be at 30 mg/kg at each 4-weekly visit. In Step 2, participants with ongoing viral suppression throughout Step 1 will undergo withdrawal of ART and will continue maintenance 10-1074 (30 mg/kg) and VRC01LS (15 mg/kg) treatment for up to 24 weeks. In Step 3, both 10-1074 and VRC01LS will be discontinued and ART will be re-started.
89528733|NCT02465125|Active Comparator|Low transfusion trigger|Intervention group. Low or restrictive transfusion trigger: hemoglobin < 5 mmol/L (approx. 8 g/dl or a hematocrit of 25%) This trigger is what is recommended by the Danish Health and Medicines Authority for stable patients with chronic heart disease.
89528734|NCT02465125|Active Comparator|High transfusion trigger|Control group. High or liberal transfusion trigger: hemoglobin < 6 mmol/L (approx. 10 g/dl or a hematocrit of 30%) This trigger reflects the practice among Danish vascular anesthesiologists and correspond to the transfusion trigger recommended by the European society for vascular surgery
89528735|NCT02464891|Experimental|CCX168|Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.
89528736|NCT02462551|Experimental|FEAST|Patients with treatment-resistant depression will undergo 3 sessions of focal electrically administered seizure therapy for two to six weeks. The complete parameter range of the stimulus delivered (Freq: 20-120 Hz; PW: 0.2-2 ms; Duration: 0.1 to 8 s; Current: 0.5-0.8A; charge: 1-576 mC) is determined by an initial titration session and the PI (as an expert in neuromodulation treatments).
89528737|NCT03297151|Sham Comparator|CONTROL|"Intervention: Dietary Supplement: Non-essential amino acids A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g non-essential amino acids dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry.~Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
89528738|NCT03297151|Active Comparator|PROTEIN|"Intervention: Dietary Supplement: Whey Protein Concentrate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Concentrate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
89528739|NCT03297151|Active Comparator|HYDROLYSATE|"Intervention: Dietary Supplement: Whey Protein Hydrolysate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Hydrolysate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
89528740|NCT03297073|Experimental|major hepatic surgery|resection greater than or equal to three hepatic segments
89528741|NCT03297073|Experimental|hepatic surgery|resection less than three hepatic segments
89528742|NCT03297073|Experimental|hepatic surgery recovery|
89528743|NCT03296995|Experimental|flash glucose monitoring system|Subjects in the arm measure blood glucose by flash glucose monitoring system.
89528744|NCT03296917|Experimental|IMP - PrEP-001|"In Viral Challenge arm cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~In the Safety arm's first dose cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~Then assuming no significant safety issues with the lower dose (as determined by blinded review by the DSMB team), the Safety arm's second dose cohort will consist of:~A nasal dose of 12800 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)"
89528745|NCT03296917|Placebo Comparator|Placebo - G-004|"In the Viral Challenge arm and each Safety Arm cohort:~A nasal dose of placebo equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)."
89528746|NCT02462317|Active Comparator|botulinum A toxin|Patients are injected with botulinum toxin in a standardized protocol and received placebo baclofen tablets (120 patients)
89528747|NCT02462317|Active Comparator|Baclofen|Patients are injected with placebo in a standardized protocol and received baclofen tablets (120 patients)
89528748|NCT02462317|Placebo Comparator|double Placebo|Patients are injected with placebo in a standardized protocol and received placebo baclofen tablets (60 patients)
89528749|NCT03296761||ESM-1<5ng/ml|
89528750|NCT03296761||ESM-1≥5ng/ml|
89528751|NCT03296683|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
89528752|NCT03402685|No Intervention|NIBP-Group|NIBP will be shown, ClearSight will be covered.
89528753|NCT03402685|Experimental|ClearSight-Group|ClearSight will be shown, NIBP will be covered.
89528754|NCT02462785|Active Comparator|In-Class Instruction|This group of adolescents will receive carbohydrate counting instruction through an in-person, in class session led by a registered dietician. This represents the usual standard of care at the Diabetes Clinic at The Hospital for Sick Children (SickKids).
89528755|NCT02462785|Experimental|Internet-Based Teaching|This group of adolescents will receive carbohydrate counting instruction through an online teaching tutorial.
89528756|NCT02462863|Experimental|Immunonutrient treatment|Administration of arginine and fish oil.
89528757|NCT02461069|Active Comparator|Dimethyl fumarate treatment arm (A)|All patients will receive dimethyl fumarate (Tecfidera®) according to national recommendations (Krankheitsbezogenes Kompetenznetz Multiple Sklerose, KKNMS) from week 0 to week 24 (EOS-1) in the core study.
89528758|NCT02461069|No Intervention|Healthy subject arm (B)|Healthy subjects will not receive any treatment for RRMS during the study.
89528759|NCT03332095|Experimental|Cohort 1: DOR|Participants received a single dose of DOR at study entry (Day 0).
89528760|NCT03332095|Experimental|Cohort 2: DOR/3TC/TDF|Participants received DOR/3TC/TDF from Day 0 through Week 96.
89528761|NCT03296605||Obesity|Patients with obesity already received bariatric surgery
89528762|NCT03296605||Healthy control|Volunteers with normal body weight and already received abdominal surgery
89528763|NCT04489381|Active Comparator|Nitazoxanide|Two nitazoxanide 300 mg tablets orally twice daily for 5 days
89528764|NCT04489381|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
89528765|NCT04489849|Experimental|Apixaban|Apixaban 2.5mg BID
89528766|NCT04489849|Active Comparator|Control|Other treatment except oral anticoagulant
89528767|NCT03296449|No Intervention|One-Lung Ventilation|During one-lung ventilation, when the chest is open, the non-dependent lung is collapsed and manipulated by the surgeon. It is the routine procedure during video-assisted thoracic surgery.
89528768|NCT03296449|Active Comparator|CPAP to non-dependent lung|"The patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-dependent lung at a pressure of 2-3cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
89528769|NCT03296449|Experimental|HFJV to non-dependent lung|"The patient is randomly assigned to the study arm High-frequency jet ventilation (HFJV). HFJV will be applied for 20 minutes to the non-dependent lung with a driving pressure of a 0.6 atm, respiratory rate 100 cycles per minute using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland)."
89528770|NCT04488367|Experimental|Early TXA|Experimental group will receive 10 mg/kg IV TXA while in the Emergency Department, and repeat preoperative and postoperative doses.
89528771|NCT04488367|Other|Control|Control group will receive 100 mL 0.9% normal saline in the Emergency Department, and 10 mg/kg IV TXA before skin incision and again in post anesthesia care unit.
89528772|NCT03296293|Other|Group I:IVPD≤3mmHg|Effect of PEEP at 5cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 10cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 15cmH2O on ICP in Group I:IVPD≤3mmHg
89528773|NCT03296293|Other|Group II:3mmHg<IVPD≤6mmHg|Effect of PEEP at 5cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 10cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 15cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg
89528774|NCT03296293|Other|Group III:IVPD>6mmHg|Effect of PEEP at 5cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 10cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 15cmH2O on ICP in Group III:IVPD>6mmHg
89528775|NCT03296215||Observational|Patterno of admitted cases in Respiratory Intensive Care Unit at Assiut University Hospitals and Outcome
89528776|NCT03108391|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 3 to size 5 based on manufacturer guidelines
89528777|NCT03108391|Active Comparator|LMA Supreme|Subjects will receive the LMA Supreme size 3 to size 5 based on manufacturer guidelines
89528778|NCT04489459|Active Comparator|colistin-tigecycline|this group received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12h
89528779|NCT04489459|Active Comparator|colistin-meropenem|received Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h plus Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
89528780|NCT03296137|Experimental|All participants|
89528781|NCT03295903|Placebo Comparator|Placebo|Sugar pill that will have no effect.
89528782|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (1 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
89528783|NCT03295903|Active Comparator|Cannabidiol (1 dose)|Only cannabidiol supplement.
89528784|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (2 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
89528785|NCT03295903|Active Comparator|Cannabidiol only (2 dose)|Only cannabidiol supplement.
89528786|NCT03290833|Experimental|Robotic|The experimental group will receive 30 minutes robotic training sessions, 3 times per week for a total of 30 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive schedule (1-hour sessions, 3 times/week, 30 total sessions) of conventional therapy from an occupational therapist.
89528787|NCT03290833|Active Comparator|Conventional|In conventional therapy group, participants will receive an one-hour of one-on-one treatment (1-hour sessions, 3 times/week, 30 total sessions) from an occupational therapist, focusing on arm and hand function.
89528788|NCT03290755||MSM co-infected HIV-HCV|
89528789|NCT02460913|Experimental|Acupuncture|patients received a 20 to 30 minutes session of acupuncture
89528790|NCT02460913|Active Comparator|IV Morphine|patients received an intravenous titration of morphine every 5 minutes.
89528791|NCT04444999|Experimental|Endovascular abdominal aortic aneurysm repair|a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA).
89528792|NCT01174225|Active Comparator|I|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Flexi T 380(+) IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
89528793|NCT01174225|Active Comparator|II|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Nova T IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
89528794|NCT01174225|No Intervention|III|"Participants who elect for forms of contraception other than a copper IUD will chose which form of contraception they would like to use and be put into one of the groups specified below based on her contraceptive choice. These participants will be observed throughout the study for overall satisfaction and repeat pregnancy rate.~Groups - Participants will be in one of the five following groups Group A - Oral contraceptive pill 28day supply provided after abortion Group B - Medroxyprogesterone acetate (Depo-provera)150mg IM provided after abortion, lasts for 3 months Group C - Ethinyl estradiol and etonogestrel (Nuva ring) provided at time of abortion, lasts for 28 days Group D - Condoms provided at time of abortion Group E - Other"
89528795|NCT04326049|Experimental|LLETZ with videocolposcopy|The LLETZ procedure will be performed using a videocolposcopy
89528796|NCT04326049|Active Comparator|LLETZ with binocular colposcopy|The LLETZ procedure will be performed using a binocular colposcope
89528797|NCT03290599||No Post operative cognitive dysfunction|Patients who did not have any change or a change less than 4 points between MMT1 and MMT3
89528798|NCT03290599||Post operative cognitive dysfunction|Patients with a difference more than 4 points between MMT1 and MMT3
89528799|NCT03295825|Other|Biomarker|Blood sampling
89528800|NCT03290443|Experimental|Enasidenib (CC-90007) tablet|Subjects will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
89528801|NCT03290365|Active Comparator|Platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.
89528802|NCT03290365|Placebo Comparator|Platelet rich plasma + normal saline|Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.
89531127|NCT00707057|Placebo Comparator|Placebo group|Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
88809580|NCT01271738|Active Comparator|Breast Conserving Surgery with Additional 5 Margins (BCS + M)|
88809581|NCT01271816||Presymptomatic ARVC gene carriers|ARVC gene positive patients without manifest ARVC after standard screening clinical testing.
88809582|NCT01278680|No Intervention|Hold-out control|Hold-out control: participants will be asked to refrain from using the walkstations for the duration of the study (90 days).
88809583|NCT01278680|Active Comparator|Personal incentive|Personal incentive: Participants will receive $3 for each time they use the walkstation.
88809584|NCT01278680|Experimental|Charitable incentive|Charitable incentive: $3 will be donated to charity every time the participant uses the walkstation.
88809585|NCT01271894|Experimental|Reduced dose Efavirenz arm|Participants randomized in main study to receive EFV (400 mg once daily; 2 x 200 mg + 1 x placebo once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
88809586|NCT01271894|Active Comparator|Normal Efavirenz dose arm|Patients randomized in the main study to receive EFV (600 mg once daily; 3 x 200 mg once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
88809587|NCT01271972|Experimental|Cohort 1|Dose 1
88809588|NCT01271972|Experimental|Cohort 2|Dose 2
88809589|NCT01271972|Experimental|Cohort 3|Dose 3
88809590|NCT01271972|Experimental|Cohort 4|Dose 4
88809591|NCT01271972|Experimental|Cohort 5|Dose 5
88809592|NCT01271972|Experimental|Expansion Cohort 1|Dose 4
88809593|NCT01271972|Experimental|Expansion Cohort 2|Dose 5
88809594|NCT01278758|Experimental|ASA404 + standard therpy|
88809595|NCT02991716||Recorded patients|Patients requiring Intracradiac Defibrillator (ICD) implantation, Electrophysiology (EP) study or a holter monitor recording, mainly due to suspected ventricular tachy - arrhythmias
88809596|NCT00717626|Experimental|Daily administration of low dose FVIII|Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)
88809597|NCT04386668|Experimental|LIO-C|Participants receive LIO-C writing intervention
88809598|NCT04386668|Placebo Comparator|Neutral writing control|Participants receive neutral writing control intervention
88809599|NCT00718094|Experimental|Polyphenon E treatment|Polyphenon E® therapy was given for 56 days.
88809600|NCT00718094|Placebo Comparator|Placebo|Oral Placebo
88809601|NCT02991326|Experimental|Test Group (TG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to Osteopathic Manipulative Treatment - OMT.
88809602|NCT02991326|Sham Comparator|Control Group (CG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to sham intervention (Osteopathic Manipulative Treatment simulated).
88809603|NCT02991170|Active Comparator|control group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
88809604|NCT02991170|Experimental|interventional group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
88809605|NCT01278836|Other|fascio-cutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
88809606|NCT00719186|Active Comparator|A|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
88809607|NCT00719186|Active Comparator|B|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
88809608|NCT02991404|Active Comparator|Continuous adductor canal block|"After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time (Initial bolus) 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.~Multimodal peripheral nerve block injection."
88809609|NCT02991404|Sham Comparator|Single injection block with sham cath|Single Shot Adductor Canal Block . Patients will receive single injection adductor canal block (Initial Bolus) with bupivacaine 0.25%, epinephrine, clonidine, buprenorphine and dexamethasone. These patients will have a sham infusion catheter of inert saline placed in the same fashion as the other group.
88809610|NCT00719576|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
88809611|NCT00719576|Active Comparator|Microfracture|Microfracture
88809612|NCT00721136|Experimental|1|Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.
88809613|NCT00721136|Active Comparator|2|Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).
88809614|NCT00721136|Experimental|3|High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.
88809615|NCT00721136|Active Comparator|4|"High risk patients randomized to holding coumadin for 4-5 days and using bridging anticoagulation with heparin while the coumadin is held."
88809616|NCT00736580|Active Comparator|Blunt Needles|Cesarean Delivery Performed with Blunt-tipped surgical Needles
88809617|NCT00736580|Placebo Comparator|Sharp Needles|Cesarean delivery performed with sharp surgical needles.
88809618|NCT01272206|Experimental|A|
88809619|NCT01272206|Experimental|B|
88809620|NCT00737204|Experimental|Armodafinil|Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
88809621|NCT00737204|Placebo Comparator|Placebo|Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.
88809622|NCT04385810|Experimental|Ophthalmologic exam|
88812203|NCT05945056|Active Comparator|Standard Exercise Therapy with Electrotherapy|Control group received standard exercise therapy treatment along with transcutaneous electrical nerve stimulation for 10 sessions of duration half hour each on regular basis.
88812204|NCT05945030||With Xanthelasma|T2DM with Xanthelasma
88812205|NCT05945030||Without Xanthelasma|T2DM without Xanthelasma
88812206|NCT05945004||Experiment|
88812207|NCT05945004||Control|
88812208|NCT05944991|Experimental|Olive oil message|Give olive oil message 2 times per day
88812209|NCT05944627|Experimental|FURESTEM-OA Kit Inj.|"Subjects are slowly administered FURESTEM-OA Kit Inj. once into the knee joint cavity contained in a disposable sterile syringe mixed with Solution 1 and Solution 2 depending on the dose group assigned at the baseline (Visit 2).~The subjects are assigned sequentially to the following 3 dose groups in Phase 1 clinical trial, and in Phase 2a clinical trial, the subjects are randomized to 1-2 dose groups below MTD determined in Phase 1."
88812210|NCT05944627|Placebo Comparator|Placebo|Product name: Placebo of FURESTEM-OA Kit Inj. (placebo administration in Phase 2a clinical trial)
88812211|NCT05944575|Active Comparator|Active Intervention|Participants will self-administer active taVNS for 30 min per day for 7 days.
88812212|NCT05944575|Sham Comparator|Sham Intervention|Participants will self-administer sham-taVNS for 30 min per day for 7 days.
88812213|NCT05944185|Experimental|CAR T cells|
88812214|NCT05944107|Active Comparator|Activated Clotting Time (ACT)|"In this group, only ACT measurements and fixed doses of heparin and protamine are administered.~ACT is measured using the ACT Plus device (Medtronic, MN, USA). Heparin formulation administered is HEPARIN/LEO INJ.SOL 25000IU/5ML. Protamine formulation administered is PROTAMINE SULPHATE/LEO PHARMA 10mg/ml"
88812215|NCT05944107|Active Comparator|Heparin Concentration (HC)|"In this group, the Hepcon HMS Plus (Medtronic, MN, USA) is used to perform heparin concentration calculations and test each patient's individual response to heparin. Specifically tests performed were:~Heparin Dose Response test~Heparin Assay test"
88812216|NCT05943834||Patients with a minor or major neurocognitive disorder|"Every patient will receive one semi-automated phone call, during the call a series of cognitive tasks will be performed.~Each task will be recorded in a secondary audio stream which records the participant responses to allow for deep speech analysis of performance on these tasks"
88812217|NCT05943080|Experimental|PCI + ACB Group|Firstly, perioperative application is performed in the anatomical space between the posterior capsule and the popliteal artery before implantation. In the application, a 22G 10 cm needle is used in the form of 20 ml 0.25% bupivacaine + 2.0 μg/mL of epinephrine.For the adductor canal block, which will be applied by the anesthesiologist at the end of the operation, first of all, the femoral artery and nerve in the inguinal region are visualized while the patient is in the supine position, accompanied by ultrasonography. Afterwards, the artery is followed distally and the adductor canal and the femoralarter inside it and the nerve are visualized. At the level just below the sartorius muscle, a simultaneous needle is visualized by ultrasonography and 7m of 0.5%bupivacaine + 8ml of 0.9% saline solution is injected into the adductor canal. Appropriate drug distribution is confirmed by ultrasonography and the procedure is terminated.
88812218|NCT05943080|Experimental|IPACK block + ACB Group|First of all, for the adductor canal block, which will be applied by the anesthesiologist at the end of the operation, the femoral artery and nerve in the inguinal region are visualized by ultrasonography while the patient is in the supine position. Afterwards, the artery is followed distally and the adductor canal and the femoral arter inside it and the nerve are visualized. At the level just below the sartorius muscle, a simultaneous needle is visualized by ultrasonography and 7m of 0.5%bupivacaine + 8ml of 0.9% saline solution is injected into the adductor canal. Appropriate drug distribution is confirmed by ultrasonography and the procedure is terminated. then ACB is performed with the help of USG in the anatomical space between the posterior capsule and the popliteal artery. In practice, a 22G 10 cm needle is used in the form of 20 ml 0.25% bupivacaine + 2.0 μg/mL of epinephrine.
88812219|NCT05943080|Other|ACB Group (control)|"At the end of the operation by the anesthesiologist only adductor canal block is applied, while the patient is in the supine position, the femoral artery and nerve are visualized in the inguinal region under ultrasound guidance. Afterwards, the artery is followed distally and the adductor canal and the femoralarter inside it and the nerve are visualized. At the level just below the sartorius muscle, a simultaneous needle is visualized by ultrasonography and 7m of 0.5%bupivacaine + 8ml of 0.9% saline solution is injected into the adductor canal. Appropriate drug distribution is confirmed by ultrasonography and the procedure is terminated.~VAS values and opioid consumption will be recorded as the primary outcome of the patients who are taken to the service after the surgical procedure performed under spinal anesthesia without the use of a tourniquet. Post-operative 3. Hour-12. Hour -24. Hours -48th hour and 72nd hour."
88812220|NCT05942625|Experimental|HS-10390|Single or multiple dosing of HS-10390 in a fastingstate
88812221|NCT05942625|Experimental|Placebo|Single or multiple dosing of placebo in a fastingstate
88812222|NCT05941598|Experimental|Electroacupuncture|After skin disinfection, acupuncture needles will be inserted into the acupoints. All needles will be manipulated to achieve deqi. Then, an electroacupuncture apparatus will be connected. The stimulation parameters will be continuous wave, 2 Hz, and the current intensity will be adjusted according to the participant's comfort level.
88812223|NCT05941598|Sham Comparator|Sham acupuncture|After skin disinfection, acupuncture needles will be inserted into acupoints that are unrelated to the treated syndromes. The needles will be inserted to a depth of 3 to 5 mm, without any manipulation or deqi. Then, the electronic acupuncture apparatus will be connected, with a continuous wave of 2 Hz. However, the intensity of electrical stimulation will be set to a minimum level that participants can perceive, and the apparatus will be turned off after 30 seconds of stimulation.
88812224|NCT05940428|Experimental|ASKG712|Multiple doses of ASKG712 by intravitreal injection
88812225|NCT05940194|Experimental|COVIVAC 3 mcg|3 mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
88812226|NCT05940194|Experimental|COVIVAC 6 mcg|6 mcg IVAC COVIVAC vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
88812227|NCT05940194|Active Comparator|AZD1222|AZD1222 (AstraZeneca) vaccine for intramuscular injection administered as two doses (0.5mL each) 28 days apart.
88812228|NCT05939804|Experimental|TENS group|60 minutes of TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher. After the procedure, the amount of analgesic consumed by the experimental group in the first hour will be questioned and recorded.
89528803|NCT02764489|Experimental|Part 1:FEIBA 85±15 U/kg at Regular Volume Then 50% Reduced Volume at 2 U/kg/min Rate or Vice Versa|Participants who were eligible were randomized to receive: 3 infusions (infusions 1, 2 and 3) of factor eight inhibitor bypassing activity (FEIBA) 85 ± 15 U/kg, reconstituted in regular volume sterile water for injection (SWFI) followed by 3 infusions (infusions 4, 5 and 6) of FEIBA 85 ± 15 U/kg reconstituted in 50% reduced volume SWFI (Sequence A) or: 3 infusions (infusions 1, 2 and 3) of FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI, followed by 3 infusions of FEIBA 85 ± 15 U/kg, reconstituted in regular volume SWFI (Sequence B). All infusions in Part 1 were given at the standard infusion rate of 2 U/kg/min.
89528804|NCT02764489|Experimental|Part 2:FEIBA 85±15U/kg 50% Reduced Volume at 4U/kg/min Rate Then at 10U/kg/min Rate|Participants who completed Part 1, received FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI at an increased rate of 4 U/kg/min for infusions 7, 8, and 9, followed by FEIBA 85 ± 15 U/kg, reconstituted in 50% reduced volume SWFI at an increased rate of 10 U/kg/min for infusions 10, 11, and 12.
89528805|NCT04488991||the woman who has just HPV infection|the woman who is between 30-65 years old, who is participate this research, and has just HPV infection in cervix.
89528806|NCT04488991||the woman who has just nabothian cyst|the woman who is between 30-65 years old, who is participate this research, and has just nabothian cyst in cervix.
89528807|NCT04488991||the woman who has both nabothian cyst and HPV infection|the woman who is between 30-65 years old, who is participate this research, and has both nabothian cyst in cervix.
89528808|NCT02462161|Experimental|Insulin Aspart|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of insulin aspart (20 IU) for 12 weeks.
89528809|NCT02462161|Placebo Comparator|Placebo|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of placebo (saline) for 12 weeks.
89528810|NCT03290053|Experimental|CE-5S A: Treatment arm|Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion
89528811|NCT03290053|Sham Comparator|CE-5S A: Control arm|Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion
89528812|NCT03290053|Experimental|CE-5S B: Treatment arm|Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion
89528813|NCT03290053|Sham Comparator|CE-5S B: Control arm|Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion
89528814|NCT04441645|Experimental|the acupoint-on-head group|pressing acupoints only on head
89528815|NCT04441645|Experimental|the acupoint-on-body group|pressing acupoints only on body
89528816|NCT04441645|Experimental|the acupoint-on-head-and-body group|pressing acupoints on head and body
89528817|NCT04441645|No Intervention|the control group|routine care
89528818|NCT03289819|Experimental|Pembrolizumab/Nab-Paclitaxel|"This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.~All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.~After the 25th patient has started trial treatment, all further included patients will receive 1 additional cycle of pembrolizumab i.v. 200 mg q3w monotherapy before starting regular trial treatment.~Clinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent."
89528819|NCT02001623|Experimental|Tisotumab Vedotin (HuMax-TF-ADC)|All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)
89528820|NCT01910051||Generally healthy|Generally healthy
89528821|NCT01910051||Type 2 diabetes mellitus|Type 2 diabetes mellitus
89528822|NCT03373331|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
89528823|NCT03373331|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer.~."
89528824|NCT02713867|Active Comparator|Nivolumab 240 mg|Nivolumab 240 mg Every 2 Weeks
89528825|NCT02713867|Experimental|Nivolumab 480 mg|Nivolumab 480 mg Every 4 Weeks
89528826|NCT03373175|Experimental|Ventilator 1 vs Ventilator 2|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record Pressure Support 10 (PS 10)record Pressure Support 15 (PS 15) record Pressure Support 20 (PS 20) record
89528827|NCT03373175|Experimental|Ventilator 3 vs Ventilator 4|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed.Interventions: Basal record PS10 record PS15 record PS 20 record
89528828|NCT03373175|Experimental|Ventilator 5 vs Ventilator 6|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
89528829|NCT03373175|Experimental|Ventilator 7 vs Ventilator 8|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
89528830|NCT03373019|Experimental|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
89528831|NCT03372863||Cardiac surgery patients|
89528832|NCT03372785||Complete revascularization group|Complete Revascularization of CTO and non-CTO lesions
89528833|NCT03372785||Non-CTO revascularization group|Non-CTO vessel revascularization
89528834|NCT03295513|Active Comparator|veneered zirconia full coverage restorations|InCoris zirconia material (TZI-Densupply sirona)
89528835|NCT03295513|Experimental|Monolithic zirconia full coverage restorations|InCoris (TZI-Densupply sirona)
89528836|NCT00985205|Experimental|Enteral Glutamine|0.5 g/kg/day mixed in water and given via nasogastric or feeding tube as boluses q 4 hrs or TID or QID if po
89528837|NCT00985205|Placebo Comparator|Placebo|Mixed in with water and given via nasogastric or feeding tube as boluses q 4hrs or TID or QID if po
89528838|NCT04526873|No Intervention|Control|No intervention control group
89528839|NCT04526873|Experimental|Postcard: non-telehealth, photo|This group receives a postcard that does not include telehealth information and features a stock photo
88812229|NCT05939804|No Intervention|Control group|The routine treatment and care of the control group will not be interfered with.
88812230|NCT05937217|Experimental|myofascial induction and direct scar release techniques group|They will receive myofascial induction therapy in the form of transverse sliding and cross hand therapy and direct scar release techniques in the form of stroking, circular movement, vertical point lifting , C and S grip techniques, and therapeutic ultrasound, 2 sessions per week for two weeks.
88812231|NCT05937217|Experimental|therapeutic ultrasound group|They will receive a therapeutic ultrasound, 2 sessions per week for two weeks.
88812232|NCT05933330||Danish HHT patient 18-65 years of age|
88812233|NCT05931185|Experimental|Low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound|participant will receive low frequency transcutaneous electrical stimulation and therapeutic Ultrasound as a treatment
88812234|NCT05931185|Active Comparator|Therapeutic Ultrasound|patients will receive therapeutic ultrasound as a treatment
88812235|NCT05931185|Active Comparator|Low frequency transcutaneous electrical stimulation|participant will receive low frequency transcutaneous electrical stimulation
88812236|NCT05929495|Experimental|Metformin|"25 patients with GBM will take 1g/day of Metformin (2 tablets of 500 mg) for two weeks and then take 2g/day of Metformin for a total of 6 weeks. At the end of 6 weeks, treatment with Metformin alone will be continued for 4 weeks.~Thereafter, the second-phase Stupp protocol (adjuvant TMZ) + metformin is resumed continuously until the end of the enrollment period, i.e., 58 weeks from the start of treatment, for each patient."
88812237|NCT05927870|Experimental|pyocele|obstructed gallbladder with infection on top
88812238|NCT05924035|No Intervention|Control Group|Control Group will participate in standardized, prescribed exercise 4 days per week and perform countermovement jumps on a force plate both before and after daily workouts (standard of care summer athletic training)
88812239|NCT05924035|Experimental|HBOT Treatment|HBOT Treatment Group will receive HBOT Treatment in addition to standardized, prescribed exercise 4 days per week and perform countermovement jumps on a force plate both before and after daily workouts (standard of care summer athletic training)
88812240|NCT05921409|Experimental|MED DIET + AOVE|A six-months nutritional intervention with a Mediterranean diet, daily supplemented with 50 ml of extra virgin olive oil. The intake of the oil was divided in the main meals and needed to be consumed without cooking.
88812241|NCT05921409|Placebo Comparator|MED DIET + AO|A six-months nutritional intervention with a Mediterranean diet, daily supplemented with 50 ml of olive oil. The intake of the oil was divided in the main meals and needed to be consumed without cooking.
88812242|NCT05906849|No Intervention|Control Group|Group of participants with a main diagnosis of social anxiety disorder (n≥13) or generalized anxiety disorder (n≥13) not subjected to any psychological intervention within the current trial. They will be asked to fill in the self-report protocol at 2 different time points (12 weeks interval) mimicking the pre- and post-intervention assessment moments; these adolescents will be assessed after the second time point and referred to the school psychology services if the difficulties persist.
88812243|NCT05906849|Experimental|SAD Intervention Group|Group of participants with a main diagnosis of social anxiety disorder (n=26) subjected to individual online delivered 12 sessions ACT psychotherapy. Participants pertaining to this group will be assessed at 4 different time points (pre- and post-treatment and at a 3- and 6- month follow-up).
88812244|NCT05906849|Experimental|GAD Intervention Group|Group of participants with a main diagnosis of generalized anxiety disorder (n=26) subjected to individual online delivered 12 sessions ACT psychotherapy. Participants pertaining to this group will be assessed at 4 different time points (pre- and post-treatment and at a 3- and 6- month follow-up).
88812245|NCT05904769|Experimental|Hospitalized Diabetic Group|Subjects hospitalized and diabetic on insulin, undergoing four times daily blood sugar checks, will wear the LIFELEAF Smartwatch for the duration of their hospital stay.
88812246|NCT05904769|Experimental|Electrophysiologic (EP) Group|Subjects undergoing an EP procedure will wear he LIFELEAF Smartwatch for the duration of the procedure.
88812247|NCT05904665|Experimental|ctDNA dynamic monitoring + routine postoperative follow-up|"Dynamic monitoring of ctDNA + routine postoperative follow-up: ctDNA detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years, a total of 10 times. At the same time, routine postoperative follow-up is given.~Follow-up intervention*: After completion of adjuvant chemotherapy in the patient, if ctDNA detection suggests positive, immediate chest, abdomen, and pelvis CT and other imaging examinations are performed to determine whether there is recurrence or metastasis. If it is not confirmed, repeat imaging examinations are carried out every two months in the follow-up process, and ctDNA detection is continued every three months according to the schedule. If two consecutive ctDNA retests are negative, the above imaging follow-up will resume at the frequency of routine follow-up."
88812248|NCT05904665|No Intervention|Routine postoperative follow-up|Routine postoperative follow-up: Only routine postoperative follow-up is given as follows: Physical examination and CEA were performed every 3-6 months for the first 2 years, every 6 months within the third to fifth year, and then annually. Chest/abdominal/pelvis computed tomography was performed annually for up to 5 years, and colonoscopy was performed for proper patients the first year after treatment and repeated in the third year if no advanced adenoma was found and then every 5 years.
88812249|NCT05895734|Experimental|Powerball|Rehabilitation using the Powerball system
88812250|NCT05895734|Active Comparator|Conventional treatment|Rehabilitation by conventional treatment
88812251|NCT05893043|Experimental|Cohort 1: GSBR-1290 or Placebo|Healthy Japanese participants will receive once daily doses of study drug (GSBR-1290 or placebo oral capsules) for up to 4 weeks.
88812252|NCT05893043|Experimental|Cohort 2: GSBR-1290|Healthy non-Japanese participants (Caucasians or African Americans) will receive once daily doses of study drug (GSBR-1290 oral capsules) for up to 4 weeks.
89528840|NCT04526873|Experimental|Postcard: non-telehealth, salience/humorous cartoon|This group receives a postcard that does not include telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
89528841|NCT04526873|Experimental|Postcard: telehealth, photo|This group receives a postcard that does includes telehealth information and features a stock photo
89528842|NCT04526873|Experimental|Postcard: telehealth, salience/humorous cartoon|This group receives a postcard that includes telehealth information and features a humorous cartoon as well as examples of serious health risks that the visit could help prevent (stroke and heart attack)
89528843|NCT04526873|Experimental|Phone call|This group receives a phone call
89528844|NCT03289663|Active Comparator|Control|The arm will receive bednets treated with conventional insecticide (Pyrethroid)
89528845|NCT03289663|Experimental|Experimental|The arm will receive bednets treated with new generation of insecticides (synergistic combination of insecticides)
89528846|NCT03372629|Experimental|ID-085, single ascending dose (Part A)|ID-085 administered at different single dose levels in a sequential manner, and in a maximum of 6 dose levels starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort)
89528847|NCT03372629|Placebo Comparator|Placebo, single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to ID-085
89528848|NCT03372629|Experimental|ID-085 multiple ascending dose (Part B)|ID-085 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be either 10 or 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A
89528849|NCT03372629|Placebo Comparator|Placebo, multiple ascending dose (Part B)|Matched placebo administered as single ascending doses in parallel to ID-085
89528850|NCT03295357||Patients with extubation while on ECLS|
89528851|NCT03295357||Patients without extubation|
89528852|NCT02519933|Active Comparator|mNT-BBAVF|Patients in Chronic Kidney Disease (CKD) stage 4-5 without previous dysfunctional fistula access
89528853|NCT02519933|Active Comparator|BCAVF|Patients in CKD stage 4-5 without previous dysfunctional fistula access
89528854|NCT04488835|Experimental|TENS Therapy Group|patients in this group received TENS therapy in addition to routine physical therapy
89528855|NCT04488835|Experimental|PEMFT group|patients in this group received PEMFT therapy in addition to routine physical therapy
89528856|NCT03372473|Experimental|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg one dose a day
89528857|NCT03372473|Active Comparator|Montelukast|Montelukast 5mg one dose per day
89528858|NCT03289429|Experimental|Atorvastatin|Atorvastatin and intravenous placebo
89528859|NCT03289429|Experimental|Magnesium sulfate|Magnesium sulfate and tablets placebo
89528860|NCT03289429|Placebo Comparator|Control|intravenous placebo and tablet placebo
89528861|NCT03372395|Other|Group 1|Standard treatment plus short-term (3 months) vaginal Lactobacillus rhamnosus BMX 54 implementation
89528862|NCT03372395|Experimental|Group 2|Standard treatment plus long-lasting (6 months) Lactobacillus rhamnosus BMX 54 administration
89528863|NCT03372239|Experimental|Part 1: Bioavailability and Food Effect|"Subjects will be randomized to receive the following 3 regimens in randomized sequence:~Single dose of Indoximod base formulation under fasting conditions~Single dose of Indoximod HCL (salt) formulation under fed conditions~Single dose of Indoximod HCL (salt) formulation under fasting conditions"
89528864|NCT03372239|Experimental|Part 2: Single Ascending Dose|
89528865|NCT03289117|Experimental|Novel gel installation device procedure|"Catheter change with novel device.~Each subject will undergo catheter change with novel gel instillation device procedure"
89528866|NCT03289117|Active Comparator|Standard procedure|"Catheter change with standard procedure.~Each subject will undergo catheter change with standard procedure"
89528867|NCT03372005|Experimental|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
89528868|NCT03372005|No Intervention|Control|This group functions as a control group, that will continue the normal lifestyle throughout the study.
89528869|NCT03371927|No Intervention|Standard Feeding Method|The control group consisted of prescribed volumes of oral and/or gavage feedings at two or three hour intervals per feeding.
89528870|NCT03371927|Experimental|SINC Feeding Protocol|Safe individualized nipple-feeding competence (SINC) protocol
89528871|NCT03294967|Active Comparator|Caffeine|To determine the effect of caffeine on ocular circulation in high myopes by consuming 200 mg caffeine capsule
89528872|NCT03294967|Placebo Comparator|Vitamin E|To determine the effect of caffeine on ocular circulation in high myopes by consuming and 200 International Unit vitamin E control capsule, as control
89528873|NCT03371849|Experimental|Group 1|Reference Drug → Test Drug
89528874|NCT03371849|Experimental|Group 2|Test Drug → Reference Drug
89528875|NCT03371771|Experimental|Volunteer-delivered Behavioral Activation|
89528876|NCT03371771|Active Comparator|MSW-delivered Behavioral Activation|
89528877|NCT03371693|Experimental|HIPEC|"Patients will undergo a CRS plus HIPEC and IVCT. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the abdominal cavity is bathed in a warm solution of anti-cancer medications for 60 minutes.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
89528878|NCT03371693|Other|Non HIPEC|Patients will undergo only CRS and IVCT. Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS.
89528879|NCT03288883|Active Comparator|Fractional Microablative CO2-laser|
89528880|NCT03288883|Active Comparator|Photothermal Non-ablative Erbium:YAG-laser|
89528881|NCT03371537||Hepatectomy|Patient undergoing laparotomy for liver resection. The aim is to measure the flow rates in the portal vein and the hepatic artery.
89528882|NCT02085421|Active Comparator|Active tDCS|The active tDCS will be applied at a current of 1-2mA via two saline soaked electrode sponges (3 cm x 4.5 cm) for the first 20 minutes of each CRT session in the active condition.
89528883|NCT02085421|Sham Comparator|Sham tDCS|In the sham condition, tDCS will be ramped up to 1-2 mA via two saline soaked electrode sponges (3 cm x 4.5 cm) over the first 30 seconds of each CRT session and then turned off.
89528884|NCT03371303||diabetology|
89528885|NCT03371303||cardiology|
89528886|NCT03371303||rheumatology|
89528887|NCT03371303||geriatrics|
89528888|NCT03294811|Experimental|Telemonitoring group|Recieve a smartphone with an application to coach them, a blood pressure monitor and scale.
89528889|NCT03294811|No Intervention|Control group|Control group (usual care, without telemonitoring)
89528890|NCT03123887||R/r B-precursor ALL|This study selected patients with Relapsed or Refractory (R/r) B-precursor Acute Lymphoblastic Leukemia
89528891|NCT02462005||ALL COMERS|Patients implanted or scheduled for an implant with a Ranger Drug coated balloon.
89528892|NCT03124043|Experimental|Intervention First|Participants in Intervention First were enrolled in the intervention for the first 6 months of study participation followed by a return to usual care for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc.
89528893|NCT03124043|Experimental|Intervention Second|"Participants in the 'Intervention Second received usual care for the first 6 months of study participation followed by enrollment in the intervention for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc."
89528894|NCT03294733|Other|Ultrasound|Ultrasound wrists to determine carpal tunnel size
89528895|NCT04307329|Experimental|Monalizumab + trastuzumab - low TILs (<5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
89528896|NCT04307329|Experimental|Monalizumab + trastuzumab - high TILs (>=5%)|trastuzumab 4 mg/kg and monalizumab 750 mg every two weeks.
89528897|NCT03290209|Experimental|Laparoscopic D1 Lymphadenectomy|Laparoscopic D1 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
89528898|NCT03290209|Active Comparator|Laparoscopic D2 Lymphadenectomy|Laparoscopic D2 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
89528899|NCT04526483|Experimental|laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D|
89528900|NCT04526717|Other|MPT0B640|There is single Arm in this clinical trials.
89528901|NCT04295707|Experimental|Monthly replacement orthokeratology without protein removal|Subjects will be required to perform daily cleaning for the monthly replacement orthokeratology lenses
89528902|NCT04295707|Active Comparator|Monthly replacement lenses with weekly protein removal|Subjects will be required to perform both daily cleaning and weekly protein removal for the monthly replacement orthokeratology lenses
89528903|NCT04295707|Active Comparator|Yearly replacement lenses with weekly protein removal|Subjects will be prescribed with orthokeratology lenses which will be replaced at least every 12 months during the study period. They will be required to perform both daily cleaning and weekly protein removal for their lenses.
89528904|NCT04526327|Other|exercise group|Female and male patients over 70 years of age with osteoporosis and sarcopenia
89528905|NCT03294655|No Intervention|No contact control|the no contact control group will do nothing
89528906|NCT03294655|Experimental|Intervention|the intervention condition will come to the lab for a 1 hour Pilot Resilience Building Intervention including a presentation on resilience and strategies to boost adherence, of which they will chose five to integrate in their daily life over the following 4 weeks
89528907|NCT03371147|Experimental|CancerLife|Arm A will be asked to download a mobile application called CancerLife. CancerLife is a stand-alone application that is NOT integrated into the patient's electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.
89528908|NCT03371147|No Intervention|Usual care|Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.
89528909|NCT03288649||Anorexia nervosa|adolescents with anorexia nervosa (N=20 ?), their parents (N=20), their physicians (N=20)
89528910|NCT03288649||Anxiety based school refusal|adolescents with anxiety based school refusal (N=20 ?), their parents (N=20), their physicians (N=20)
89528911|NCT03288649||Depression|adolescents with depression (N=20 ?), their parents (N=20), their physicians (N=20)
89528912|NCT03371069||users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
89528913|NCT03294577|Active Comparator|TAC + Pegfilgrastim|"Phase 3:TAC + Pegfilgrastim (6 mg)+ D5W placebo~D5W Placebo: 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W"
89528914|NCT03294577|Experimental|TAC + Pegfilgrastim + Plinabulin|Phase 3: TAC+ Plinabulin (40 mg) + Pegfilgrastim (6 mg)
89528915|NCT04526015|Experimental|Ilioinguinal iliohypogastric Block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
89528916|NCT04526015|Other|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
89528917|NCT03370835|Experimental|Sequence 1|"Metoprolol-succinate-ER 25mg daily weeks 0-2, 50mg daily weeks 2-4, 100mg daily weeks 4-6, 200mg daily weeks 6-8, 100mg daily week 9, 50mg daily week 10~Carvedilol 3.125mg twice daily weeks 10-12, 6.25mg twice daily weeks 12-14, 12.5mg twice daily weeks 14-16, 25mg twice daily weeks 16-18"
89528918|NCT03370835|Active Comparator|Sequence 2|"Carvedilol 3.125mg twice daily weeks 0-2, 6.25mg twice daily weeks 2-4, 12.5mg twice daily weeks 4-6, 25mg twice daily weeks 6-8, 12.5mg twice daily week 9, 6.25mg twice daily week 10~Metoprolol-succinate-ER 25mg daily weeks 10-12, 50mg daily weeks 12-14, 100mg daily weeks 14-16, 200mg daily weeks 16-18"
89528919|NCT03288571|Experimental|Wharton Jelly Mesenchymal stem cells|"Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.~Number of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
89528920|NCT04525859|Experimental|Safety|Six patients will be enrolled in the Phase 1 safety cohort. Patients will have an IR guided biopsy and FNA. Up to four core biopsies and FNAs at one site will be performed prior to intratumoral (IT) administration of Poly-ICLC. Pleural fluid will be collected for research analysis if available. Poly-ICLC will be injected in 2 locations within the pleura. Patients will undergo surgery 21±7 days after the biopsy and Poly-ICLC intratumoral (IT) injection. The type of surgery that will be performed is at the discretion of the thoracic surgeon and per the standard of care. This includes pleurectomy/decortication or extrapleural pneumonectomy. Patients will be evaluated per the standard of care post-operatively. On day 7±4 days a final toxicity assessment, physical exam and research blood will be collected. All post-operative care and monitoring thereafter is as per standard of care.
89528921|NCT04525859|Experimental|Expansion Cohort|If at most one (1) patient in the Phase 1 safety cohort experiences a DLT then a total of thirteen (13) additional patients will be enrolled into the Phase 1b Expansion Cohort. Patients in the Expansion Cohort will receive the same dose and schedule of Poly-ICLC as in the Phase 1 safety cohort. Patients will be followed for safety and tolerability, as well as efficacy. If a total of 4 or more patients experience DLTs then the study will be closed due to excessive toxicity.
89528922|NCT03294421|Active Comparator|standard closed tympanomastoidectomy|In this group it will be performed the standard technique for closed tympanomastoidectomy, in which a surgical microscope is used.
89528923|NCT03294421|Experimental|combined access tympanomastoidectomy|In this group a closed tympanomastoidectomy with combined access will be performed. This technique combines the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation.
89528924|NCT04526171|Experimental|Vaparshun|In intervention clusters, two full day events, with a gap of 4 weeks between the two events, were organized at cluster level. Eligible households with a government or contract tor built toilet were invited to enroll for a toilet makeover. Intervention activities, delivered at cluster level, included films on toilet improvement, comfort and convenience of toile use, addressing pit filling anxiety and celebrating proud toilet owners by providing certificates and acknowledging them during the events.
89528925|NCT04526171|No Intervention|Control Arm|No intervention was delivered to clusters in the control arm.
89528926|NCT02460367|Experimental|Phase 1: Dose Escalation|Up to 18 participants will be enrolled and treated at escalating doses of Indoximod with a fixed dose of tergenpumatucel-L and docetaxel. Treatment may continue until definitive disease progression or significant toxicology.
89528927|NCT03370601|Other|Optimisation strategy|increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks
89528928|NCT03370601|Other|Addition strategy|same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine
89528929|NCT03370211|Experimental|experimental intervention|The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums (RM).The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
89528930|NCT03370211|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
89528931|NCT03376529|Experimental|SPR741/Ceftazidime (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + ceftazidime1.0 gram IV over 1 hour, and ceftazidime 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
89528932|NCT03376529|Experimental|SPR741/Piperacillin/tazobactam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + piperacillin/tazobactam 4.5 grams IV over 1 hour, and piperacillin/tazobactam 4.5 grams IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
89528933|NCT03376529|Experimental|SPR741/Aztreonam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + aztreonam 1.0 gram IV over 1 hour, and aztreonam 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
89528934|NCT03370055|Active Comparator|LeucoPatch®|Usual wound care and LeucoPatch® treatment for 8 weeks, with the offer of additional 8 weeks treatment with LeucoPatch®
89528935|NCT03370055|Placebo Comparator|Control|Usual wound care for 8 weeks, with the offer of 8 weeks of LeucoPatch® treatment after the first 8 weeks
89528936|NCT04132661|Experimental|bisacodyl|5 mg bisacodyl, one tablet once
89528937|NCT04132661|Placebo Comparator|placebo|placebo, one tablet once
89528938|NCT03369977|Experimental|BioGlue Surgical Adhesive|Subjects in the BioGlue group will receive BioGlue as an adjunct for traditional surgical repair of the sinus of Valsalva.
89528939|NCT03369977|Other|Traditional Surgical Repair|Subjects in the control group will receive traditional surgical repair of the sinus of Valsalva.
89528940|NCT03376373|Experimental|active|Neurofeedback for FER
89528941|NCT03376373|No Intervention|control|waiting list
89528942|NCT02460211|Active Comparator|Treatment|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
89528943|NCT02460211|Placebo Comparator|Placebo/Control Arm|Those randomized to the control arm will receive three oral placebo doses.
89531128|NCT05034705|Active Comparator|Active comparator: Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
89528944|NCT03294343|Experimental|HBOCS|For carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome), if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy only by laparoscopy and long-term follow-up are provided.
89528945|NCT03294343|Experimental|Lynch syndromes|for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11, , if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy with hysterectomy by laparoscopy and long-term follow-up are provided.
89528946|NCT03294343|Other|Refusal to surgery|For carriers with any mutation genes (BRCA1, BRCA2, ATM, BRIP1, RAD51, RAD51C, RAD51D, STK11, MLH1, MSH2, MSH6, PMS2 and EPCAM) but refusal to any risk-reducing surgeries, counseling, decision-making analysis, and then long-term follow-up are provided.
89528947|NCT03288259|Experimental|Obese patients|Obese patients undergoing Local Anesthetics and Transnasal Endoscopy.
89528948|NCT03288181|Experimental|Muscle Stretch Group|This is the group who applies the splint to stretch the calf muscles as per the described protocol for 4 weeks.
89528949|NCT03288181|No Intervention|Control Arm|This is the group who has undergone no splint for 4 weeks.
89528950|NCT03294265|Experimental|Peer support group|"Patients who accept to participate in the protocol and are randomized to the intervention group will be invited to five sessions, one per bimester, that will be carried out in our facilities until their next appointment to the centre (fifth visit). All of them will be coordinated by a group leader.~Interventions are made each bimester in 2 hours in peer support sessions in which the patients discuss and reinforce the following topics: grief stages, control goals, self-care activities, adequate diet planning and diminish sedentary lifestyle."
89528951|NCT03294265|Active Comparator|Control group|"Patients who accept to participate in the protocol and are randomized to the control group will receive weekly messages and reminders about self-care to their cell phones via WhatsApp.~Interventions are made by sending each week a self-care reminder via WhatsApp and questionnaires about self-care activities and drugs"
89528952|NCT03294031|Experimental|Pilates|The Pilates program covered a 12-week period, two weekly sessions. In one session, exercises were performed on a mat (Mat Pilates), and in the second session in standing and sitting position. The programme included warm-up exercises, the main part of the session and cooling activities.
89528953|NCT03294031|Active Comparator|Conventional Exercise|The conventional exercise programme covered a 12-week period, two weekly sessions. The programme aimed at improving aerobic capacity, muscular resistance, balance and flexibility. The program combined land-based and water-based exercise sessions.
89528954|NCT01203085||Pediatric patients|All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.
89528955|NCT03287713|Active Comparator|Conventional oxygen (EPIDOC)|Patients randomized in conventional oxygen (EPIDOC) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to flow needed to maintain SpO2 ≥ 90% during training with both systems.
89528956|NCT03287713|Active Comparator|Nasal High-Flow oxygen therapy (EPIDOAF)|Patients will be randomized in nasal High-Flow oxygen therapy (EPIDOAF) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to FiO2 needed to maintain SpO2 ≥ 90% during training with both systems.
89528957|NCT02730455|Experimental|natalizumab high dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
89528958|NCT02730455|Experimental|natalizumab low dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
89528959|NCT02730455|Experimental|Placebo|Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
89528960|NCT02460757||Patients with COPD|
89528961|NCT02460757||Patients with interstitial lung disease|
89528962|NCT02460757||Healthy subjects|
89528963|NCT03287479|Experimental|Gavi®|surplus or all fertilized oocytes will be cryoperserved by utilizing the closed, semi-automated Gavi® vitrification system
89528964|NCT03287479|Active Comparator|Cryotop®|surplus or all fertilized oocytes will be cryoperserved by utilizing the open, manual Cryotop® vitrification system
89528965|NCT03287401||Patients with general anesthesia|Patients with general anaesthesia are monitored with electroencephalography and the results will be associated with the risk for PACU delirium
89528966|NCT03376217|No Intervention|Control|IPTp delivered at antenatal clinic
89528967|NCT03376217|Experimental|Intervention|IPTp delivered by HSAs
89528968|NCT02460523|Active Comparator|conservative|"1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen ) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.~Improvement: If the stone spontaneously passes to the duodenum and CBD is clear completely from the stones proved by US, the patient will undergo laparoscopic cholecystectomy (LC) within 3 days.~No improvement: the patient will undergo ERCP and then LC."
89528969|NCT02460523|Active Comparator|ERCP (endoscopic)|"2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.cholecystectomy (LC) within 3 days.~b- No improvement: the patient will undergo ERCP and then LC."
89528970|NCT03376139|Experimental|Zonisamide (up to 400 mg/day)|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
89528971|NCT03376139|Placebo Comparator|Placebo|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
89528972|NCT03369509||hypersensitivity drug reaction|Patient followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction.
89528973|NCT03369275|Experimental|Mesenchymal Stromal Cells (MSCs)|Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells
89528974|NCT03369275|Placebo Comparator|Placebo|Intravenous infusion of Placebo, with excipients
89528975|NCT03293875|Other|HIV testing promoted by members of the social network|Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.
89528976|NCT03293875|Other|Peer network behavioral intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.
89528977|NCT03287323|No Intervention|Usual Care Group|One hundred patients of a control group will receive standard intensive care treatment (Usual Care Group).
89528978|NCT03287323|Other|Proactive Palliative Care|One hundred patients will additionally be offered a palliative care Intervention (Proactive Palliative Care Group).
89528979|NCT03287167|Experimental|1 month DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month， then will be given aspirin and placebo for next 5 months.
89528980|NCT03287167|Active Comparator|6 months DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
89528981|NCT04440449|Experimental|Behavioral Lifestyle Intervention|The participants will receive behavioral lifestyle intervention with a smartphone-based self-monitoring for diet and physical activity. This group also includes a total of 10 Group sessions over 6 months.
89528982|NCT04440449|Other|Group B control arm|Participants use the smart-phone app to record their daily diet and physical activity, with no group sessions.
89528983|NCT03293797|Experimental|Abbreviated Mindfulness-based Therapy|5 week, abbreviated group MBT treatment for depression and anxiety
89528984|NCT04403789|Experimental|Intervention Group|During the intervention period they will receive 2 hours per week of group exercise sessions during working hours for 12 weeks. However, after the intervention period, there will be no change in working hours
89528985|NCT04403789|Active Comparator|Delayed Intervention Group (Control group)|During the intervention period there will be no change in working hours. However, after the intervention period they will receive 2 hours of exercise time during working hours per week for 4 weeks
89528986|NCT03293719||Ceramic|Patients receiving BPK-S Integration UC implant made from BIOLOX delta ceramic
89528987|NCT03293719||CoCr|Patients receiving BPK-S Integration UC implant made from CoCr (metal)
89528988|NCT03369119|Active Comparator|Montelukast|Children received 4 mg oral montelukast granule daily until discharge.
89528989|NCT03369119|Placebo Comparator|Placebo|Children receive 4 mg oral placebo montelukast granule daily until discharge
89528990|NCT03287011|Active Comparator|Control tooth paste|controlled fluoridated toothpaste will be provided for brushing to both the groups initially
89528991|NCT03287011|Experimental|Shoplaque tooth paste|Fluoridated toothpaste with organic plaque disclosing dye will be given to the test group second visit
89528992|NCT04385537|No Intervention|Control|Participants in this group avoid all nuts for 4-weeks
89528993|NCT04385537|Experimental|PECAN|Participants in this group consume 68 g of pecans/d with no other changes to their habitual diet and avoid all other nuts.
89528994|NCT03286933|Experimental|Yoga therapy intervention|Participants will participate in weekly yoga therapy sessions and have the opportunity to use the home video online.
89528995|NCT03293641|Experimental|Zinc Sulfate Tablet|Zinc Sulfate Tablet 10 mg, 3 times a week plus Standard of Care for 6 months
89528996|NCT03293641|Placebo Comparator|Control Arm|Standard of Care for 6 months
89528997|NCT03375905|Experimental|cNEP|cNEP treatment
89528998|NCT02460601|Experimental|Qizhiweitong granule|2.5g/time,tid,oral administration,6 weeks
89528999|NCT02460601|Placebo Comparator|Placebo|2.5g/time,tid,oral administration,6 weeks
89529000|NCT02519543|Placebo Comparator|Placebo|Placebo comparator to be given twice daily, once with breakfast and once with supper
89529001|NCT02519543|Experimental|Metformin|Metformin 2000 mg daily to be given as follows: 1000 mg with breakfast and 1000 mg with supper
89529002|NCT03286855|Experimental|Vibrating Mesh Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Aerogen Ultra (CE 0050) vibrating mesh Nebuliser.
89529003|NCT03286855|Active Comparator|Standard Hospital Care Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Hudson micromist small volume nebuliser which is the standard of care at our institution.
89529004|NCT03293407||BAYQ6256_Ventavis|Patients with pulmonary hypertension who agree to be treated with Ventavis (Iloprost) at the discretion of physician
89529005|NCT02519699|Experimental|Norepinephrine|Noradrenaline continuous infusion IV
89529006|NCT03286777|Placebo Comparator|Placebo|Mannitol and silicon dioxide
89529007|NCT03286777|Experimental|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide
89529008|NCT03286777|Experimental|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant
89529009|NCT02519465|Active Comparator|HEATED FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen heated .
89529010|NCT02519465|Active Comparator|COLD FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen cold
89529011|NCT00701311|Experimental|Study Drug CC-10004|Study drug CC-10004 20mg taken orally twice a day.
89529012|NCT03368885|Experimental|Experimental area PCI|"In this arm, in addition to the standard care for Polio eradication program activities of CGPP project, the following interventions are added:~Maternal dietary diversity; Diet diversity in complementary feeding; Exclusive breast feeding; Community mobilization; Capacity building; Convergence;Use of existing platforms VHSND; Strategic Use of Data"
89529013|NCT03368885|No Intervention|Control area PCI|This arm will receive standard care with respect to Polio eradication program activities of CGPP such as awareness generation around Polio and routine immunization, hand washing and sanitation
89529014|NCT03293329|Experimental|Diaphragm manual therapy|3 diaphragm stretching techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
89529015|NCT03293329|Experimental|Diaphragm hipopressive exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
89529016|NCT03293329|Active Comparator|Shoulder myofascial trigger points treatment|A ischemic compression technique in infraespinatus and supraespinatus myofascial trigger points performed by a physical therapist is employed in this group. 20 people are recruited in order to the inclusion criteria for the study. They had rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
89529017|NCT03375749|Experimental|Standing Desk Intervention|Each participant allocated to the experimental group will receive a low-cost, cardboard, fixed-height standing desk converter (https://oristand.co/) that will be placed in their regular office environment, along with their usual sitting desk. The participants will be instructed on how to use the fixed-height standing desk converter (herein referred to as standing desk) as a way to break up sitting time every 30 minutes. In addition, each participant will be provided with information about the health benefits of breaking up sitting time.
89529018|NCT03375749|Other|Waitlist Control|Control group participants will not encounter any changes to their regular office environment. They will be provided with the standing desk and behaviour change strategies 6-months post-intervention.
89529019|NCT03293251||uveitic/ POAG|Outcomes, success rates, complications of trabeculectomy with MMC in Uveitic glaucoma
89529020|NCT03293251||POAG|Outcomes, success rates, complications of trabeculectomy with MMC and I stent in this groups
89529021|NCT03375671|Experimental|Ketamine|Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM
89529022|NCT03375671|Active Comparator|Midazolam + haloperidol|Single administration of combination of: Midazolam injection (5 mg, IM) and haloperidol injection (5mg, IM)
89529023|NCT03298789|Experimental|Experimental condition|7 series of static stretching will be conducted in the experimental condition. Activation exercises will be performed after 7th series of static stretching.
89529024|NCT03298789|Other|Control|7 series of static stretching will be conducted in the control condition.
89529025|NCT03375593|Experimental|Narcotic|Hydrocodone 5mg/Acetaminophen 500 mg Tab
89529026|NCT03375593|Experimental|Non Narcotic|Ibuprofen 600mg Tab + acetaminophen 500 mg Tab
89529027|NCT04525235|Active Comparator|Rifampicin standard dose|rifampicin standard dose + phenotyping cocktail
89529028|NCT04525235|Experimental|Rifampicin high dose|rifampicin high dose + phenotyping cocktail
89529029|NCT03363815|Experimental|Part1:Omeprazole + Midazolam + Warfarin + Vitamin K + CC-90001|Patient will receive CC-90001, 20mg Omeprazole, 2mg Midazolam 10mg Warfarin and 10mg Vitamin K
89529030|NCT03363815|Experimental|Part 2- Rosuvastatin and CC-90001|Patients will receive CC-90001 and 10mg of Rosuvastatin
89529031|NCT03363815|Experimental|Part 3: Metformin + Digoxin and CC-90001|Patients will receive CC-90001, 500mg Metformin and 0.25mg, Digoxin
89529032|NCT03363815|Experimental|Part 4: Nintedanib and CC-90001|Patients will receive CC-90001 and 100mg of Nintedanib
89529033|NCT03286621||Children with Autism Spectrum Disorder|Children with an Autism Spectrum Disorder according to DSM-5 criteria
89529034|NCT03286621||Typically Developing Children|Typically developing children
89529035|NCT03286621||Children with Delayed Development Disorders|Children with Delayed Developmental Disorders other than ASD
89529036|NCT03363737|Active Comparator|Static|
89529037|NCT03363737|Experimental|Dynamic|
89529038|NCT03293173|Experimental|Group A|Biologically low risk group, R-CHOEP-14
89529039|NCT03293173|Experimental|Group B|Biologically high risk group, DA-EPOCH-R
89529040|NCT03293095||Acute musculoskeletal pathology patients|Musculoskeletal pathology patients that they will perform functional tasks measuring with motion sensors and motion capture.
89529041|NCT03293095||Match control|Healthy people of the same age as the acute musculoskeletal pathology subjects. They will perform functional tasks measuring with motion sensors and motion capture.
89529042|NCT03368651|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
89529043|NCT03368651|No Intervention|control group|no neo-adjuvant treatment before operation
89529044|NCT03368573|No Intervention|Control Arm|Participants in the control arm will undergo standard treatment as usual for ADHD. This will involve the clinician reviewing the child's symptom improvement once on medication and altering the dose according to their clinical judgement which may be informed by rating scales (completed by the parent, teacher and/or young person) and interviews with the parent and young person.
89529045|NCT03368573|Experimental|Experimental Arm|Participants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).
89529046|NCT03292939|Other|vaginal progestrone group|cohort of patients who received 400mg vaginal progestrone .
89529047|NCT03363425|Active Comparator|Lidocaine|
89529048|NCT03363425|Active Comparator|Dexmedetomidine|
89529049|NCT03363425|Placebo Comparator|Normal Saline 0,9%|
89529050|NCT03292783|Experimental|NOV150101 (ABL001)|
89529051|NCT03368495|Experimental|Co-administration of MMR/YF|Participants randomized to this arm will receive both MMR and yellow fever vaccines on Day 0.
89529052|NCT03368495|Active Comparator|MMR followed by YF|Participants randomized to this arm will receive MMR vaccine on Day 0 followed by yellow fever vaccine on Day 28.
89529053|NCT03368495|Active Comparator|YF followed by MMR|Participants randomized to this arm will receive YF vaccine on Day 0 followed by MMR vaccine on Day 28.
89529054|NCT03298555|Experimental|Mobile phone based intervention|This group will receive the smartphone app HealthyMoms between gestational week 14 and 37. The app will contain information and support to achieve a healthy weight gain and lifestyle during pregnancy. This group will also receive standard care.
89529055|NCT03298555|No Intervention|Control|This group will only receive standard care.
89529056|NCT03363347||Radioiodine refractory papillary thyroid cancer|Patients with radioiodine refractory papillary thyroid cancer who received redifferentiation therapy with retinoid acid.
89529057|NCT03363347||Radioiodine sensitive papillary thyroid cancer|Patients who were in remission after one or two radioiodine therapies.
89529058|NCT03286231||Healthy volunteers|Healthy volunteers who will undergo contrast-enhanced CT imaging of the gluteal venous vasculature in the prone and jackknife positions
89529059|NCT03286153|Experimental|Ideal Body Weight First|Randomized to receive factor product based on ideal body weight first
89529060|NCT03286153|Experimental|Actual Body Weight First|Randomized to receive factor product based on actual body weight first
89529061|NCT03368417|Active Comparator|Usual Care|Usual care from SingHealth Polyclinics which includes non-wireless HBPM. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
89529062|NCT03368417|Experimental|Wireless HBPM System|Usual care from SingHealth Polyclinics with wireless HBPM system. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
89529063|NCT03368417|Experimental|Wireless HBPM System and Incentives|Usual care from SingHealth Polyclinics with wireless HBPM system and BP monitoring incentives. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
89529064|NCT03292705|Experimental|PEP+CCI|"PEP: The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains.~CCI. VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention.~Intervention format and fidelity The PEP+CCI group will practice PEP for the first 4 weeks and VSOP for the following 6 weeks."
89529065|NCT03292705|Active Comparator|control+CCI|For the control + CCI group, an inert control condition, consisting of nothing outside of the ordinary, will be implemented for the first 4 weeks, and CCI for 6 more weeks.
89529066|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.045%)|topical Ophthalmic Drops (0.045%)
89529067|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.06%)|topical Ophthalmic Drops (0.06%)
89529068|NCT03368339|Placebo Comparator|Vehicle|Placebo
89529069|NCT03286075|Experimental|Anode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (anode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
89529070|NCT03286075|Experimental|Cathode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (cathode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
89529071|NCT03286075|Placebo Comparator|Placebo tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (placebo).~Subjects will receive a 30-minutes SHAM session of tDCS."
89529072|NCT03363269|Experimental|ID1201 100mg|
89529073|NCT03363269|Experimental|ID1201 200mg|
89529074|NCT03363269|Experimental|ID1201 400mg|
89529075|NCT03363269|Placebo Comparator|Placebo|
89529076|NCT02459977|Experimental|No basiliximab group|The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
89529077|NCT02459977|Active Comparator|Basilixiab group|Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
89529078|NCT02519153|Placebo Comparator|control|patient receive placebo for 4 weeks and followed for passage of stone distal ureter
89529079|NCT02519153|Active Comparator|sildenafil|patient receive sildenafil 50 mg for 4 weeks once per day and followed for passage of stone distal ureter
89529080|NCT03285997|Experimental|GC3110A|One injection: Day 0 Two injection: Day 0 and Day 28
89529081|NCT03285997|Active Comparator|GCFLU Pre-filled syringe inj.|One injection: Day 0 Two injection: Day 0 and Day 28
89529082|NCT04523987|Experimental|gemcitabine and nab-paclitaxel chemotherapy|Patients who are recommended gemcitabine and nab-paclitaxel chemotherapy as a standard-of-care by their treating physician will be offered to participate in this study.
89529083|NCT03292627||mid age|mid age: 50-70 years old
89529084|NCT03292627||old age|old age: age older than 70 years old
89529085|NCT03368261|Other|HTAP/ clinical complications in the sickle cell disease|Supply epidemiological data on this detected HTAP, and allow the characterization of the clinico-biological paintings and the mortality which are associated to them.
89529086|NCT03298399|Experimental|MSC dose level 1|The first three subjects (minimum) will receive four weekly infusions of MSCs.
89529087|NCT03298399|Experimental|MSC dose level 2|If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
89529088|NCT03298399|Experimental|MSC dose level 3|If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
89529089|NCT03363191|Experimental|Subjects received Fluticasone Furoate/Vilanterol|Subjects will receive fluticasone furoate/vilanterol 100/25 mcg inhalation powder via ELLIPTA dry powder inhaler (DPI) once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
89529090|NCT03363191|Active Comparator|Subjects received Fluticasone Furoate|Subjects will receive fluticasone furoate 100 mcg inhalation powder via ELLIPTA DPI once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
89529091|NCT03285919|Experimental|Case - stroke survivor|Stroke survivor, 6mon post stroke resulting in right-sided hemiparesis, 53yrs old, had completed a 2mon rehabilitation program prior to the study. He underwent 30 training sessions with the Balance Assessment Robot (BAR™) within a 10-week period, each consisting of 10-15min of unperturbed treadmill and 30-45min of perturbation training. Perturbations were delivered in the forward, backward, left and right direction, occurring every 6sec, at the left leg initial contact and the right leg initial contact. Two training sessions were spent to determine adequate treadmill speed (0.4m/s) and perturbation amplitude (60N), followed by the first assessment session. After the last training session, assessment was repeated using the same parameters plus 90N perturbation amplitude.
89529092|NCT03285919|Active Comparator|Control - matched healthy subject|Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
89529093|NCT03368105|Experimental|LP299v group|Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.
89529094|NCT03368105|Placebo Comparator|Placebo group|Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.
89529095|NCT03292549||Patients|Robotic partial surgery
89529096|NCT03368027|Experimental|Stress management program|A cognitive-behavioral program of coping with psychological stress for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
89529097|NCT03368027|Active Comparator|Standard intervention|Usual activities performed in the association where they attend (supervised by a psychologist) for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
89529098|NCT03292393|Active Comparator|Group Contingency Management|During the intervention phase, the Group Contingency Management (GCM) arm will continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a home blood pressure monitoring reading using the HBPM. Participants in the GCM arm will receive a payment after each phone call, dependent on their medication adherence assessment. The GCM arm will also receive an additional payment based on their group's medication adherence.The intervention administered is the Financial Reward and Social Norms.
89529099|NCT03292393|Active Comparator|Individual Contingency Management|During the intervention phase, those in the Individual Contingency Management (ICM) arm will also continue to take their hypertensive medication for the four-month period but will receive a payment after each phone call, dependent on their medication adherence assessment.The intervention administered is the Financial Reward.
89529100|NCT03292393|Placebo Comparator|Control Arm|During the intervention phase, those in the control arm will be asked to continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a blood pressure reading using the HBPM. Those in the control arm will only be paid for their participation in the study regardless of medication adherence assessment.
89529101|NCT03367949|No Intervention|Accuracy of surgical guide from Model optical scan|
89529102|NCT03367949|Active Comparator|Accuracy of surgical guide from Impression inversion Technique|
89529103|NCT02518841|Active Comparator|Achilles Tendon Stretching|This is the arm of participants who will first be assigned to perform 6 weeks of achilles tendon stretching as demonstrated in the protocol. As this is a crossover design study, this arm will then switch to 6 weeks of ThermaWedge TM stretching.
89529104|NCT02518841|Experimental|ThermaWedge TM|This is the arm of participants who will first be assigned to perform 6 weeks of ThermaWedge TM stretching as demonstrated in the protocol. As this is a crossover design study this arm will then switch to 6 weeks of Achilles Tendon Stretching
89529105|NCT03108079|Other|Arm 1|"Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (Cystosure Urinary Access Catheter and Foley Catheter). During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.~Interventions are listed in the Interventions Section."
89529106|NCT03367559|Experimental|Rotavirus Vaccine|3 dose, interval for each dose is 4 weeks. The first dose will be received at 6-8 weeks of age.
89529107|NCT03285685|Experimental|tDCS M1|active tDCS Participants will receive active transcranial direct current stimulation.
89529108|NCT03285685|Experimental|tDCS DLPF|active tDCS Participants will receive active transcranial direct current stimulation.
89529109|NCT03285685|Sham Comparator|tDCS sham|tDCS Sham Participants will receive sham transcranial direct current stimulation.
89529110|NCT03367481|Active Comparator|Control toothbrush|The participants will use a toothbrush with soft bristles.
89529111|NCT03367481|Experimental|Test toothbrush|The participants will use a toothbrush with medium bristles.
89529112|NCT03292159|Experimental|RAVANS|
89529113|NCT03292159|Sham Comparator|Sham stimulation|
89529114|NCT03367325|Experimental|CDS-NVAF benefiting group|CDS-NVAF = Clinical decision support (CDS) tool for improving the adequacy of the anticoagulant therapy adequacy in non-valvular atrial fibrillation (NVAF)
89529115|NCT03367325|No Intervention|CDS-NVAF not-benefiting group|
89531129|NCT05034705|Experimental|Experimental: Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
89531130|NCT03096561|Other|Hypothermia related cardiac arrest|blood draw from three different vessels punctured in the emergency room (central vein, peripheral vein, artery) and comparison of potassium rate and other biological values between the different sites of blood draw and two different measuring techniques (laboratory vs. blood gas analyser)
89529116|NCT03285607|Experimental|Dose Level 1:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
89529117|NCT03285607|Experimental|Dose Level 2:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
89529118|NCT03285607|Experimental|Dose Expansion:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
89529119|NCT03298321||Vidaza patients|This study will be performed on adults with Acute Myeloid Leukemia and atrial fibrillation. Only patients treated for the first time with vidaza® within an hospital hematology unit will be included.
89529120|NCT03362723|Experimental|Treatment Sequence 1: ABCD|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
89529121|NCT03362723|Experimental|Treatment Sequence 2: ABDC|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
89529122|NCT03362723|Experimental|Treatment Sequence 3: BACD|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
89529123|NCT03362723|Experimental|Treatment Sequence 4: BADC|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
89529124|NCT03362723|Experimental|Optional Treatment Extension Arm|Following completion of the BE/rBA cycle (Cycle 1), participants who have no clinically defined progressive disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and who recover from any prior treatment toxicity to Grade </=1 may enter the optional treatment extension phase. Participants will receive 200 mg idasanutlin orally (200-mg tablet reference formulation) daily for 5 days, followed by 23 days of rest. This extension phase will continue for additional 28-day cycles or until disease progression or unacceptable toxicity is observed.
89529125|NCT04527055|Active Comparator|The 14-day bismuth-based quadruple therapy group|The patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
89531131|NCT02494349|Experimental|JLP-1207|JLP-1207 dosing in the fed state(high fat meal)
89531132|NCT02494349|Experimental|Solifenacin 5mg+Tamsulosin 0.2mg|Solifenacin 5mg+Tamsulosin 0.2mg in the fed state(high fat meal)
89531133|NCT05034237|Experimental|ND;YAG 1064 NM LASER|monthly sessions of laser hair removal
89529126|NCT04527055|Active Comparator|The 10-day bismuth-based quadruple therapy group|The patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Flagyl 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.
89529127|NCT04527055|No Intervention|The non-H. pylori-infected control|Age- and sex-matched patients who do not have H. pylori infection by endoscopic gastric biopsy are enrolled as the non-H. pylori-infected control.
89529128|NCT04527055|Active Comparator|The probiotic therapy group|"The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the probiotic therapy group ingesting probiotic powder twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of >= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
89529129|NCT04527055|No Intervention|The non-probiotic control group|The patients who still have depletion of gut F. prausnitzii 12 months after H. pylori eradication are enrolled into the probiotic supplement trial. They are randomized to the non-probiotic control therapy and they do not ingest probiotic powder.
89529130|NCT03362645||Fabry cardiomyopathy|
89529131|NCT03362645||Hypertrophic cardiomyopathy|
89529132|NCT03123653|Experimental|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks.
89529133|NCT03292081|Experimental|OFDI-guided PCI|
89529134|NCT03292081|Active Comparator|IVUS-guided PCI|
89529135|NCT02518763|Experimental|Vitamin D3, 100 000 IU weekly, 4 times|
89529136|NCT03362567|Experimental|SNAGS Group|Subjects in SNAGS group were treated with application of sustained natural apophyseal glides, twice weekly for six weeks
89529137|NCT03362567|Experimental|MCT Group|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
89529138|NCT03292003||Journey II BCS Total Knee System|Subjects having TKA with Journey II BCS Total Knee System
89529139|NCT03285217|Experimental|HMB|HMB Group (n=30) will receive received twice a day for 3 months a specialized, nutrient-dense ready-to-drink liquid (Abbott Nutrition) with 350 kcal, 20 g protein, 11 g fat, 44 g carbohydrate, 1.5 g calcium-HMB, 160 IU vitamin D and other essential micronutrients.
89529140|NCT03285217|Active Comparator|Control|Control Group (n=30) will receive twice a day for 3 months another supplement with similar composition in macro- and micro-nutrients but without HMB
89529141|NCT03362411|Experimental|BMS-986205 intact tablet orally then crushed tablet orally|Single, 100 mg dose
89529142|NCT03362411|Experimental|BMS-986205 crushed tablet orally, then intact tablet orally|Single, 100 mg dose
89529143|NCT03362411|Experimental|BMS-986205 intact tablet orally then suspension via NG tube|Single, 100 mg dose
89529144|NCT03362411|Experimental|BMS-986205 suspension via NG tube then intact tablet orally|Single, 100 mg dose
89529145|NCT03291925|Experimental|Selective invasive angiography based on CT/CCTA imaging|Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
89529146|NCT03291925|Active Comparator|Invasive Cardiac Angiography|Patients will undergo systematic invasive angiography.
89529147|NCT03362333|Experimental|pain neuroscience education and exercise|This group received pain neuroscience education and exercise once a week over 4 weeks
89529148|NCT03362333|Active Comparator|Exercise|This group received exercise directed at the neck and shoulder regions once a week over 4 weeks
89529149|NCT03362255|Active Comparator|Rapid speed of injection|Rapid speed of injection (3cc/sec) during thoracic epidurography thoracic epidural catheterization
89529150|NCT03362255|Active Comparator|Slow speed of injection|Slow speed of injection (1cc/sec) during thoracic epidurography thoracic epidural catheterization
89529151|NCT03362021||DEX|Sedation with dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
89529152|NCT03362021||MZM|Sedation with remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min and midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
89529153|NCT03367091|Experimental|Ekso GT gait training|"Participants will be measured during three Ekso GT gait trainings:~20-minute Ekso GT gait training with high swing assistance~20-minute Ekso GT gait training with neutral swing assistance~20-minute Ekso GT gait training with high swing resistance.~Each training will be performed on a separate day in a randomized order (within one week and controlled for time of day)."
89529154|NCT03298165|Experimental|disinfection the cavity with diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
89529155|NCT03298165|Placebo Comparator|no cavity disinfection|placebo is used as no cavity disinfection will be done as after excavation the restoration will be placed .
89529156|NCT02461381||Dr.Tang's research group|This group included diabetic participants with completed both the short-term HRV test and Ewing's test.
89529157|NCT03361787|Experimental|Parentship coaching intervention|
89529158|NCT03284983|Experimental|10 mm suture spacing|The investigators aim to determine how suture spacing affects cosmetic outcome of wound healing. One side (1/2 of the wound length) was sutured with 10 mm suture spacing
89529159|NCT03291457||Glucocorticoids + Tocilizumab|Participants with RA who are receiving glucocorticoid treatment will be observed for up to 52 weeks after starting tocilizumab.
89529160|NCT03361709|Active Comparator|Dexamethasone group|Dexamethasone injected at conclusion of Phacoemulsification
89529161|NCT03361709|Placebo Comparator|Non-dexamethasone group|No dexamethasone will be injected at the conclusion of Phacoemulsification
89529162|NCT03284905|Active Comparator|Probiotics|
89529163|NCT03284905|Placebo Comparator|Placebo|
89529164|NCT03366935|Experimental|EPL and CEI|Those with receive a standard epidural (EPL) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
89529165|NCT03366935|Active Comparator|DPE and CEI|Those with receive a dural puncture labor epidural (DPE) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
89529166|NCT03366935|Active Comparator|DPE and PIEB|Those with receive a dural puncture labor epidural (DPE) and programmed intermittent epidural boluses(PIEB) + patient-controlled epidural analgesia (PCEA)
89529167|NCT03284749|Experimental|Copper impregnated wound dressing|Wound dressing impregnated with 3% copper oxide ions, to be applied for 7 days after caesarean section
89529168|NCT03284749|Placebo Comparator|Normal wound dressing|Wound dressing without copper, to be applied for 7 days after caesarean section
89529169|NCT03284749|Experimental|Copper impregnated maternity pads|Maternity pads impregnated with 3% copper oxide ions, to be used for 14 days after delivery
89529170|NCT03284749|Placebo Comparator|Normal maternity pads|Maternity pads without copper, to be used for 14 days after delivery
89529171|NCT04523675|Experimental|EXP-NAC|Participated in daily training sessions and three games, and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
89529172|NCT04523675|Experimental|EXP-Pla|Participated in daily training sessions and three games, and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
89529173|NCT04523675|Active Comparator|CON-NAC|Participated in daily training sessions only and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
89529174|NCT04523675|Active Comparator|CON-Pla|Participated in daily training sessions only and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
89529175|NCT03298009|Placebo Comparator|Treatment 1|placebo oral capsule will be administered once daily, for 2 weeks
89529176|NCT03298009|Experimental|Treatment 2|Canagliflozine 100mg once daily, for 2 weeks
89529177|NCT03366857|Active Comparator|30%|Participants allocated to these groups will receive a FiO2 of 0.3 during the operation and for two hours postoperatively.
89529178|NCT03366857|Active Comparator|80%|Participants allocated to these groups will receive a FiO2 of 0.8 during the operation and for two hours postoperatively.
89529179|NCT03291301|Experimental|CBT Group|Cognitive Behavioral Therapy for Insomnia
89529180|NCT03291301|Experimental|Combined Group|Cognitive Behavioral Therapy for Insomnia plus Acupressure
89529181|NCT03291301|No Intervention|Wait-list Control Group|
89529182|NCT03284671|Experimental|bifocal stimulation|Transcranial direct current Bifocal stimulation
89529183|NCT03361631|Experimental|arm treated with MSC|"Type 1 diabetic man~Aged from 18 to 50 years~Having a diabetes evolving for at least 10 years~Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot~Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)~IIEF-5 score less than or equal to 10"
89529184|NCT03291145|Experimental|Beta Blockers|With and without Beta Blockers
89529185|NCT03291145|Experimental|Spironolactone|With and without Spironolactone
89529186|NCT03366701||Patient during rehabilitation program|Patient performing a 5 weeks inpatient pulmonary rehabilitation program
89529187|NCT03366701||Patient after the rehabilitation program|Patient in their domicile after the 5 weeks program
89529188|NCT03297931|Active Comparator|Commercial corn chips + Onion dip|Corn chips + onion dip
89529189|NCT03297931|Experimental|Commercial pulse chip + pulse spread|Pinto bean chip + hummus
89529190|NCT03297931|Experimental|Novel pulse chip + pulse spread|Yellow pea chip + hummus
89529191|NCT03297931|Experimental|Commercial pulse chip + non-pulse spread|Pinto bean chip + onion dip
89529192|NCT03297931|Experimental|Novel pulse chip + non-pulse spread|Yellow pea chip + onion dip
89529193|NCT03297931|Experimental|Non-pulse chip + pulse spread|Corn chips + hummus
89529194|NCT03366623|Other|Hospital clown intervention|"The performance of the hospital clown included creating a relation with the child by using different techniques in the venipuncture procedure.~The hospital clown used distraction techniques with music, songs, toys, fake tattoos (a small sticker/label with a picture applied to the skin with water), dream journeys, storytelling and making agreements in collaboration with the child, parents and healthcare personnel."
89529195|NCT03366623|Other|No hospital clown intervention|The clinical staff, defined as pediatric nurses and biomedical laboratory technologists, assisted the child in the venipuncture procedure with conventional communication, comfort and care techniques.
89529196|NCT03366389||Case|patients with irritable bowel syndrome
89529197|NCT03366389||Control|Healthy subjects without any gastrointestinal disorders, chronic diseases and malignancy.
89529198|NCT03361475|Experimental|Intervention school|One school workshop and a small talk were conducted first at the beginning of the programme, which was to promote SME and introduce the function of SME App for students, followed by downloading and using immediately to connect family members, then let them continue to use for one month with system reminder.
89529199|NCT03361475|No Intervention|Waitlist control schools|The intervention won't be provided during evaluation period and will be provided after the evaluation period
89529200|NCT03284593||intensive chemotherapy group|patients treated with intensive chemotherapy
89529201|NCT03284593||Azacitidine group|patients treated with azacitidine
89529202|NCT03366311|Active Comparator|holding position|different holding position of endotracheal tube
89529203|NCT03366311|Active Comparator|stylet shapes|banana shape versus straight-to-cuff shape
89529204|NCT03366311|Active Comparator|epiglottis lift|with epiglottis lift or without
89529205|NCT03284515||All women|Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
89529206|NCT03361397|Active Comparator|Lidocaine nebulization|Inhalation of 10 mL nebulized lidocaine hydrochloride via mask nebulizer 5 min before laryngeal mask insertion.
89529207|NCT03361397|Placebo Comparator|Distilled water nebulization|Inhalation of 10 mL of nebulized distilled water solution via mask nebulizer 5 min before laryngeal mask insertion in the preoperative period.
89529208|NCT03366233|Experimental|Mentally fatiguing task|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task.
89529209|NCT03366233|Placebo Comparator|Control task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial for 90 min.
89529210|NCT03284437|No Intervention|Usual Care|Usual medical care provided to patients in the ICU.
89529211|NCT03284437|Experimental|Early Cognitive Training|Usual medical care provided to patients in the ICU plus additional activities designed to engage the patient's attention and cognition. Activities are chosen by the family member from an activity cart according to the level designated by occupation therapy.
89529212|NCT03123497||Idiopathic Thrombocytopenic Purpura|completion of questionnaire
89529213|NCT03283345|Active Comparator|postmenopausal women|postmenopausal female breast cancer patients who underwent modified radical mastectomy
89529214|NCT03283345|Active Comparator|premenopausal women|premenopausal female breast cancer patients who underwent modified radical mastectomy
89529215|NCT03123419|Other|Vaccine|All patients who consent to be in the study will receive Appointment reminders.
89529216|NCT03284281|Experimental|Interventional arm|Active TVNS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 8 hours daily (4 hours twice daily) for 1-week post discharge.
89529217|NCT03284281|Placebo Comparator|Control arm|No stimulation will be performed.
89529218|NCT03366077|Active Comparator|Active|L reuteri
89529219|NCT03366077|Placebo Comparator|Placebo|Placebo
89529220|NCT03283267|Experimental|ZS 5g, qd|Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
89529221|NCT03283267|Experimental|ZS 10g, qd|Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
89529222|NCT03109379|Experimental|TAR-302-5018 (42-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
89529223|NCT03109379|Experimental|TAR-302-5018 (84-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.
89529224|NCT03361319|Experimental|Part 1: (Phase Ib) Dose Escalation|"A dose-finding study of nintedanib (Vargatef) with nab-paclitaxel (Abraxane) with a standard 3+3 design. In the dose escalation part there will be 3 dose cohorts of nintedanib:~Dose level -1: 100mg po BID d2-7, 9-21, q21 Dose level 1: 150mg po BID d2-7, 9-21, q21 Dose level 2: 200mg po BID d2-7, 9-21, q21"
89529225|NCT03361319|Experimental|Part 1: Dose Expansion|In the dose expansion part, 6 additional patients will be enrolled at the maximum tolerated dose (MTD) of nintedanib (Vargatef) with nab-paclitaxel (Abraxane), prior to proceeding to part 2.
89529226|NCT03361319|Placebo Comparator|Part 2: (Phase II)|"A placebo-controlled, randomised, double-blind, 2-arm, phase 2 multi-centre clinical trial of nab-paclitaxel (Abraxane) with nintedanib (Vargatef) and nab-paclitaxel alone.~Arm A: nab-paclitaxel + placebo Arm B: nab-paclitaxel + nintedanib"
89529227|NCT03365999|Active Comparator|Oral Tranexamic Acid|"Tranexamic acid will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid tablets are 650 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
89529228|NCT03365999|Experimental|Oral Aminocaproic Acid|"Aminocaproic acid will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic acid tablets are 500 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the aminocaproic acid, a total dose of 3 grams (6 tablets) divided between the 3 administrations (1 gram each, ie 2 tablets of 500 mg) will be administered."
89529229|NCT02460055|Active Comparator|Endotracheal tube|Following routine inhalation induction with 8% sevoflurane in oxygen and nitrous oxide, 100% oxygen will be administered and intravenous access will be secured. Intravenous administration of Propofol 3mg/kg and Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation with an age appropriate endotracheal tube. Presence of an audible air leak around the endotracheal tube will be addressed by inflating the cuff with air until the audible leak is no longer appreciated. The endotracheal tube will not be lubricated prior to intubation. Other medications that will be administered during the procedure include Dexamethasone at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg.
89529230|NCT02460055|Active Comparator|No Endotracheal tube|Those not receiving endotracheal intubation will undergo an inhalation induction, have intravenous access secured and intravenous propofol 3mg/kg with Fentanyl 1mcg/kg will be administered prior to placement of the nasal trumpet and connection to the anesthesia circuit.patients will receive a general anesthetic consisting of sevoflurane in oxygen and air at routine concentrations for maintenance of anesthesiaOther medications that will be administered during the procedure to both arms of patients include Dexamethasone which will be administered at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg for post operative nausea and vomiting prophylaxis.
89529231|NCT03361241|Experimental|No Physiotherapeutic Intervention|Virtual reality training without physiotherapeutic intervention
89529232|NCT03361241|Active Comparator|Physiotherapeutic Intervention|Virtual reality training with physiotherapeutic intervention
89529233|NCT03297619|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness by Fleming and Kocovski (2013), a self-help book based on acceptance and commitment therapy.
89529234|NCT03297619|Active Comparator|CBT self-help book condition|Participants in this condition will be assigned to read The Shyness and Social Anxiety Workbook by Antony and Swinson (2008), a self-help book based on cognitive-behavioral therapy for social anxiety.
89531134|NCT02497859|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
89529235|NCT03361163|Experimental|GAS oropharyngeal challenge|"Biological: emm75 Streptococcus pyogenes (GAS M75, strain 611024)~Direct oropharyngeal application using a sterile-tipped Dacron swab after immersion for 10 seconds in a 1mL vial containing 1-3x10^4 to 1-3x10^8 colony forming units (CFU) of the challenge strain (depending on dose group allocation)."
89529236|NCT03284125||Facial paralysis|Patients affected by facial paralysis treated by LTM The aim is to evaluate the improvement of the swallowing disorders after surgery.
89529237|NCT03365921|Experimental|Hepatitis E vaccine lot 1|
89529238|NCT03365921|Experimental|Hepatitis E vaccine lot 2|
89529239|NCT03365921|Experimental|Hepatitis E vaccine lot 3|
89529240|NCT03283189||Group 1|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
89529241|NCT03283189||Group 2|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
89529242|NCT03283189||Group 3|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
89529243|NCT03283189||Group 4|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
89529244|NCT03283189||Group 5|Pregnancy follow-up in a type I maternity and in a rural area (around Saint-Flour)
89529245|NCT03283189||Group 6|Liberal follow-up of pregnancy
89529246|NCT03361085|Experimental|Intervention|nvHAP-Prevention Bundle
89529247|NCT02461147||Validation cohort|All patients of the study (single group, single arm) will undergo initial cholecystectomy with intraoperative cholangiogram, followed if required by ERCP, according to the standard protocol of treatment previously implemented at the investigators institution.
89529248|NCT03365843|Experimental|Montage bone putty|Sternal closure with conventional wire cerclage plus Montage bone putty
89529249|NCT03365843|Active Comparator|Conventional Sternal Closure|Conventional wire cerclage sternal closure only -- standard care.
89529250|NCT03283111|Experimental|autologous stem cell transplantation|Lymphoma patients received autologous stem cell transplantation for the first time
89529251|NCT03361007||Common carotid artery access for TAVI|Patients in whom femoral artery could not be used to deliver the bioprosthesis for any reason.
89529252|NCT03282877|Experimental|iCST web-application|A computerised cognitive stimulation programme consisting of 21 sessions.
89529253|NCT03282877|No Intervention|Treatment as usual (TAU)|The control group will consist of a treatment-as-usual group and will not receive any additional intervention.
89529254|NCT03365765|Experimental|mFOLFOX6 & apatinib|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks. Patients also take apatinib, 1 time daily, 500mg each time, lasting 1 year, from the first chemotherapy of mFOLFOX6.
89529255|NCT03365765|Active Comparator|mFOLFOX6|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks.
89529256|NCT03297463|Experimental|Phase Ib (Dose Escalation)|
89529257|NCT03297463|Experimental|Phase II (Dose Expansion)|
89529258|NCT03365531|Experimental|Alternate Daily Fasting (ADF)|Participants randomized to the ADF group will alternate between a day of ad lib feeding and a day of nearly no energy intake. Participants will be prescribed a core diet for feeding days that meets 110% of their estimated calorie needs within the fixed macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. In accordance with the ad lib feeding protocol, optional modules of similar macronutrient content will be prescribed, each providing an additional 200 kcals. Meal timing will not be restricted on these days. On fasting days, participants will be asked to consume 16 oz. of G2 Gatorade (40 kcal) in the morning and then only water or non-caloric beverages for the rest of the day.
89529259|NCT03365531|Active Comparator|Caloric Restriction|Participants randomized to the CR group will consume a diet of fixed energy designed to yield a 500 kcal/d deficit with a macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. Meal timing and caloric distribution will not be restricted.
89529260|NCT03283891|Experimental|educational intervention|Various pedagogical activities to mobilise Watson's ten Carative Factors
89529261|NCT03283891|No Intervention|control|No intervention during the different times of measurement. Educational intervention will be delivered after the last measure.
89529262|NCT03360851|Experimental|Low-dose CT|A low-dose chest CT-scan will be performed either directly from the ER or from the medical ward as soon as possible but within 24 hours of admission. The CT will be performed with a radiation dose <0.5 mSv for a 70kg patient, as a replacement or in addition to the chest radiograph. Pregnancy will be an exclusion criterion for CT because of unwanted radiation exposure. CT interpretation will be performed by a radiologist. Test results will be communicated to the treating physician. Recommendations based on the CT may be to discontinue antibiotics in case of a noninfectious diagnosis that explains the presented signs and symptoms and to start treatment for the alternative diagnosis if needed, or to re-evaluate the CAP diagnosis if no signs of lobar or bronchopneumonia are detected on the CT.
89529263|NCT03360851|Experimental|PoC-PCR|The FilmArray real-time multiplex PCR (Biofire; bioMérieux) is a Point-of-Care PCR with a panel of respiratory viruses (adenovirus, coronavirus, human metapneumovirus, human rhinovirus/enterovirus, influenza A and B, parainfluenza virus, and respiratory syncytial virus), and three atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis), which will be performed on nasopharyngeal swab samples. Test results will be made available to the treating physician immediately. The treatment recommendation could be adaptation of antibiotic treatment for a documented atypical pathogen, a recommendation to not start or discontinue antibiotics when a virus is the only detected pathogen, or a recommendation to discontinue coverage of atypical pathogens.
89529264|NCT03360851|No Intervention|Standard care|All hospitals will continue the antibiotic stewardship activities employed during the baseline period as part of standard care. A representative of the Antibiotics-team (Team consisting of clinical microbiologists, infectious diseases specialist and clinical pharmacists supervising in-hospital antibiotic use) will monitor the empirical antibiotic treatment of patients hospitalized with CAP to non-ICU wards and provide feedback if indicated.
89529265|NCT03283735|Experimental|Elderly Enablement|The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
89529266|NCT03283735|No Intervention|Control|This will be the control group.
89529267|NCT02459743||Patients with hematological malignancies|Patients with a conclusive diagnosis of haematological malignancies according to WHO criteria referred to the Rete Ematologica Lombarda (REL) clinical network will be enrolled. The investigators will analyse genomic DNA extracted from hematopoietic cells at different time points of patient disease. The study contemplates the use of two optimized molecular platforms aimed at the identification of recurrent mutations in myeloid and lymphoid neoplasms, respectively. Screening of gene mutations by NGS will be prospectively implemented in the context of REL clinical network. Patient samples will be analyzed at diagnosis and sequentially during the course of the disease at specific timepoints.
89529268|NCT03360617|Experimental|Syringe Arm|IV antibiotics will be delivered by syringe IV push over 2-3 minutes
89529269|NCT03360617|Sham Comparator|Piggyback Arm|IV antibiotics will be delivered by IV piggyback over 30 minutes
89529270|NCT03283579||Pregnant women|
89529271|NCT03297385|Experimental|Prostatectomy after enzalutamide|"This is a single-arm study. Patients will have biopsies, after which they will receive enzalutamide for 3 months.~After 3 months they will have a prostatectomy."
89529272|NCT03365297|Experimental|Treatment|apalutamide, 240mg (4x60mg tablets) orally, daily for a max. duration of 90 continuous days.
89529273|NCT02459821|Experimental|Robot-assisted gait training group|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
89529274|NCT02459821|Active Comparator|Conventional training group|The group will be subjected to conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
89529275|NCT03282721||redesigned|the commissure constructions of the cleft side were precised located, include the upper and lower inherent vermilion border, the interior commissure, the outline of commissure, the exterior commissure, the upper skin-mucosa junction and the lower skin-mucosa junction.
89529276|NCT03282721||classical|follows the simple-symmetry rule, the commissure of the healthy side is measured, and then the affected side is located accordingly.
89529277|NCT04479319||COVID-19 Pneumonia|"COVID-19 patients who have pneumonia on thorax CT~either Thorax CT + SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +"
89529278|NCT04479319||COVID-19, without Pneumonia|"COVID-19 patients who have not pneumonia on thorax CT~Thorax CT - SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-"
89529279|NCT04479319||Non COVID-19|"Patients with viral infection symptoms who is not diagnosed with COVID-19~either Thorax CT - SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 -"
89529280|NCT04412941|Experimental|Treatment group|Myofunctional exercises + home oropharyngeal exercises + the rules of sleep hygiene
89529281|NCT04412941|Active Comparator|Control group|the rules of sleep hygiene
89529282|NCT04350541|Experimental|Interval training|Interval training will consist of 10 minutes of warm-up between 40-50% of the peak oxygen consumption (VO2peak), followed by four to six repetitions of three-minute intervals between 80-90% of VO2peak and three minutes between 40-50% VO2peak and finally, five minutes of cooling down between 30-40% of VO2peak.
89529283|NCT04350541|Active Comparator|Continuous training|The continuous aerobic training will consist of 10 minutes of warm-up with intensity between 40 and 50% of VO2peak, 20 minutes of conditioning between 60 and 70% of VO2peak and 5 minutes of cooling down between 30 and 40% of VO2peak.
89529284|NCT03282643|Experimental|Rivaroxaban 10mg daily|orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
89529285|NCT03282643|Experimental|Rivaroxaban 20mg daily|orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
89529286|NCT03282643|Active Comparator|Low-molecular-weight heparin|subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)
89529287|NCT03282487|No Intervention|Conventional immediate release hydrocortisone|
89529288|NCT03282487|Active Comparator|Modified release Hydrocortisone|12 weeks of modified release hydrocortisone (Plenadren)
89529289|NCT03282487|No Intervention|Healthy control group|Same research laboratory measurements performed in a healthy control group for comparison to patient group
89529290|NCT04068805|Active Comparator|Positive affect condition|Participants use Happify and have the option to use a diabetes-specific track that focuses on building skills for greater happiness, reducing stress, and coping better with diabetes. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
89529291|NCT04068805|Sham Comparator|Psychoeducation condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
89529292|NCT02458651||Tier 1 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in northern region of China
89529293|NCT02458651||Tier 1 and South|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in southern region of China
89529294|NCT02458651||Tier 2 and Middle|Site as described by tier level of the city where the site is located and by geographical location: Tier city in middle region of China
89529295|NCT02458651||Tier 2 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in northern region of China
89529296|NCT02458651||Tier 2 and South Eastern|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south eastern region of China
89529297|NCT02458651||Tier 2 and South Western|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south western region of China
89529298|NCT02458729|Placebo Comparator|Placebo Group|Primary total knee replacement with 0.9% normal saline 20ml administration intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
89529299|NCT02458729|Active Comparator|One-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously five minutes before deflation of the tourniquet. and then 0.9% normal saline 20ml administration intravenously 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
89529300|NCT02458729|Active Comparator|Two-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
89529301|NCT04229173|Other|MSA patients|"Patients with multiple system atrophy will be examined at baseline, 6 months and 12 months via the following procedures performed at all 3 visits:~a clinical examination;~blood and cerebrospinal fluid (CSF) (optional) sampling for the assessment of selected fluid biomarkers;~MRI for the assessment of brain volume, white matter integrity and cerebral iron deposition; DAT-SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography) for the assessment of presynaptic dopaminergic function"
89529302|NCT04229173|Other|Healthy volunteers|healthy. Controls will undergo an MRI scan at baseline, 6 months and 12 months, and a DAT-SPECT(Dopamine Transporter, Single Photon Emission Computed Tomography) scan at baseline and 12 months.
89529303|NCT02457715||Prostate Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
89529304|NCT02457715||Renal Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
89529305|NCT02457715||Brain Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
89529306|NCT02457715||Amyotrophic Lateral Sclerosis (ALS)|Subjects will use a Jawbone Up24 for 14 weeks.
89529307|NCT02457871|Experimental|Ecological Nurse Case Managemnt|Ecological Nurse Case Management (ENCM) group receives 6 months of ENCM services in addition to their usual primary care services at the study site.
89529308|NCT02457871|No Intervention|Comparison|Usual Clinical Care - is the usual primary care services delivered at the site of the study, a free clinic.
89529309|NCT03282331|Experimental|standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
89529310|NCT03282331|Other|High flow nasal oxygen therapy|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
89529311|NCT03282331|Other|NonInvasive Ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
89529312|NCT03920527|Active Comparator|Six months|Six months of itraconazole
89529313|NCT03920527|Experimental|12 months|12-months of itraconazole
89529314|NCT03764995|Experimental|Abdominal Massage|
89529315|NCT03764995|Placebo Comparator|Placebo Ultrasound|
89529316|NCT03698539||Down syndrome who stutter|"This group consists of individuals with Down syndrome who stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures and stutter frequency are investigated in this group."
89529317|NCT03698539||Down syndrome who do not stutter|"This group consists of individuals with Down syndrome who do not stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures are investigated in this group"
89529318|NCT03698539||Typically developing children who stutter|This group consists of typically developing children who stutter. They function as a control group to the individuals with Down syndrome.
89529319|NCT03698539||Typically developing children who do not stutter|This group consists of typically developing children who do not stutter. They function as a control group to the individuals with Down syndrome.
89529320|NCT03626311|Experimental|AKBM-3031|4g/day (2 capsules BID)
89529321|NCT03626311|Placebo Comparator|Placebo|4g/day (2 capsules BID)
89529322|NCT03265327|Experimental|Treatment|Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.
89529323|NCT03265327|Placebo Comparator|Placebo|Subjects will receive an oral supplement containing coconut oil and light olive oil.
89529324|NCT03611569|Experimental|Lu AF82422|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
89529325|NCT03611569|Placebo Comparator|Placebo|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
89529326|NCT03107845|Active Comparator|Cognitive Behavior Therapy|Cognitive Behavioral Therapy without psychometric Feedback.
89529327|NCT03107845|Experimental|CBT plus Feedback|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
89529328|NCT03107845|Experimental|CBT plus Feedback plus CST|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
89531441|NCT06066333|Experimental|Participants with Adrenocortical Carcinoma|Participants with histologically proven metastatic Adrenocortical Carcinoma/ACC with both intra-hepatic and extra-hepatic sites of disease.
89529329|NCT03264937|Experimental|Social-software management group|We set up a mini-program based on wechat application. We instruct warfarin therapy via social-software including dose adjustment, answer questions, remind monitoring INR et.al.
89529330|NCT03264937|No Intervention|Routine management group|This is the control group, Warfarin therapy was managed via traditional style without social software intervention.
89529331|NCT03282175|Experimental|Exercise|Participant in this group performed an acute resistance exercise protocol. The exercise protocol consisted of general warm-up of 10 min, followed by 8 exercises with 2 sets of 8 repetition and 1 min between sets.
89529332|NCT03282175|Experimental|Training|Participants allocated to intervention group initiated the progressive resistance training program of moderate intensity, with three weekly sessions throughout the 12-week treatment period.
89529333|NCT03282175|Active Comparator|Control group|Participants allocated to control group did not receive any placebo or treatment.
89529334|NCT03282019|Experimental|Arm A(myAIRVO2® + HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.
89529335|NCT03282019|Active Comparator|Arm B(HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.
89529336|NCT03536455|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89529337|NCT03536455|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
89529338|NCT03529825|Experimental|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
89529339|NCT03529825|No Intervention|Retrospective comparison cohort|Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
89529340|NCT03281941|Other|Patients without BT|
89529341|NCT03281941|Other|Post BT|
89529342|NCT03264703||Participants with RA with cDMARD, but no anti-TNF experience|Male and female participants diagnosed with rheumatoid arthritis (RA), who have no experience with anti-tumor necrosis factor (anti-TNF) and who have experienced two or more Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) of a stable dose for at least 3 months.
89529343|NCT02459509|Active Comparator|Dexmedetomidine 2 mcg/kg|2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
89529344|NCT02459509|Active Comparator|Dexmedetomidine 4 mcg/kg|4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
89529345|NCT03264781|Experimental|Cyclofem group|Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose
89529346|NCT03264781|Placebo Comparator|Placebo group|normal saline 0.5 ml IM single dose
89529347|NCT03272581|No Intervention|Control Group|Control group followed routine basketball training and traditional strength training.
89529348|NCT03272581|Experimental|Training Group|Functional exercises were applied to training group for 20 weeks (2 days/week) with routine basketball training.
89529349|NCT03281785|Active Comparator|Pressure controlled mandatory ventilation mode (P-CMV)|Patients will be ventilated using pressure controlled mandatory ventilation mode
89529350|NCT03281785|Active Comparator|Pressure synchronized intermittent mandatory ventilation|Patients will be ventilated using pressure synchronized intermittent mandatory ventilation mode (P-SIMV)
89529351|NCT03281785|Active Comparator|Pressure support mode (PS)|Patents will be ventilated with pressure support mode (PS)
89529352|NCT03272269|Experimental|Cohort 1, low dose|4 SC injections of IMCY-0098 or Placebo
89529353|NCT03272269|Experimental|Cohort 2, medium dose|4 SC injections of IMCY-0098 or Placebo
89529354|NCT03272269|Experimental|Cohort 3, high dose|4 SC injections of IMCY-0098 or Placebo
89529355|NCT02458495|No Intervention|Standard of Care Control Group|"Participants will be granted access to a generic Diabetes website. Participants will complete the same eligibility and baseline self-report as the intervention group. The 1 month and 3 month self-report survey will omit mention of the Diabetes MAP website and will reference the generic diabetes website.~Participants will be provided with access to a generic Diabetes website. Participants will complete the same eligibility, baseline and self-report surveys as the intervention group."
89529356|NCT02458495|Experimental|Diabetes MAP Intervention Group|Participants will be granted access to the Diabetes MAP website. Participants will complete the same eligibility and baseline self-report as the control group. The 1 month and 3 month self-report will refer to the Diabetes MAP website specifically.
89529357|NCT03264625|Experimental|Treatment group|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
89529358|NCT03264625|Placebo Comparator|Control group|Patients randomized to the placebo group will receive routine therapy for PD.
89529359|NCT03281551|Experimental|PZ01 CAR-T Cells|This is a phase I study. Patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma are eligible for enrollment.
89529360|NCT03271645|Experimental|Space from depression|Space from depression is an 8 module CBT-based intervention.
89529361|NCT03271645|Experimental|Space from Anxiety|Space from anxiety CBT is an 8 module CBT-based intervention.
89529362|NCT03271645|Experimental|Space from stress|Space from stress CBT is an 8 module CBT-based intervention.
89529363|NCT03271645|Active Comparator|Face-to-face counselling|Face-to-face counselling
89529364|NCT03281473|Experimental|Arms A|Strategy 1 - Washout period - Strategy 2
89529365|NCT03281473|Experimental|Arms B|Strategy 2 - Washout period - Strategy 1
89529366|NCT02458573|Experimental|continuous epidural analgesia group|
89529367|NCT02458573|Active Comparator|continuous intravenous analgesia group|
89531135|NCT02497859|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
89531136|NCT05043519|Experimental|FAM-NP41 Fluorescence Imaging|The patients will be injected with FAM-NP41 preoperatively, and fluorescence imaging of cranial nerves will be evaluated after the craniotomy.
89531137|NCT05034315|Experimental|Whole egg consumption|
89531138|NCT05034315|No Intervention|No egg control|
89531139|NCT05430347|Experimental|TCbHPy*6|"Pyrotinib combined with docetaxel, carboplatin and trastuzumab for 6 cycles (Every three weeks).~T (Docetaxel 100 mg/m2, d1) C (Carboplatin, AUC 6, D1) H (Trastuzumab, 8 mg/kg for the first dose, 6 mg/kg for the rest, D1) Py (pyrotinib 400mg, qD, D1-21)"
88812255|NCT05881460|Active Comparator|Active vibrotactile coordinated reset|Participants will receive active Vibrotactile Coordinated Reset stimulation.
88812256|NCT05881460|Sham Comparator|Sham vibrotactile coordinated reset|Participants will receive inactive Vibrotactile Coordinated Reset stimulation.
88812257|NCT05879692|Experimental|study group (Group A)|Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive High Intensity Focused Ultrasound (Cavitation), a dietary regimen that combines Low Caloric Diet (LCD) and low (FODMAPs) diet and aerobic exercises with moderate intensity.
88812258|NCT05879692|Active Comparator|control group (Group B)|Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive only the same dietary regimen and aerobic exercise that prescribed for group A.
88812259|NCT05867147|Experimental|Group 1|Participants will receive VNZ-matching placebo, moxifloxacin-matching placebo and VNZ at different time points.
88812260|NCT05867147|Active Comparator|Group 2A|Participants will receive VNZ-matching placebo, moxifloxacin, and moxifloxacin-matching placebo at different time points.
88812261|NCT05867147|Active Comparator|Group 2B|Participants will receive VNZ-matching placebo, moxifloxacin-matching placebo and moxifloxacin at different time points.
88812262|NCT05867017||Severe COVID-19 Group|Hospitalized in ICU with COVID-19 (PCR positive) and recovered
88812263|NCT05867017||Mild COVID-19 positive Group|COVID-19 positive (by PCR) who recovered from mild COVID-19 and were seen in outpatient clinics or ER with symptoms that did not justify hospitalization.
88812264|NCT05867017||COVID-19 negative Group|COVID-19 negative (by PCR) and seen in outpatient clinics or ER during same time period as Groups I and II.
88812265|NCT05864222|Experimental|Nurses Working in an Academic Health System (AHS)|Nurse participants will receive aromatherapy (AT) after baseline measurements. Each day, the participants will pick up AT stickers to wear throughout the day on their staff badges. Participants will receive monthly emails, reminding them to wear the AT every day that they are working.
88812266|NCT05852548|Experimental|Parent-Mediated Intervention with ASD|In-home intervention (1-2x/week) will occur with families with children with ASD, including direct intervention, parent coaching, and parent training.
88812267|NCT05842278|Active Comparator|4 session rTMS|Four sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
88812268|NCT05842278|Active Comparator|6 session rTMS|Six sessions of active TMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
88812269|NCT05842278|Active Comparator|8 session rTMS|Eight sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
88812270|NCT05842278|Active Comparator|10 session rTMS|Ten sessions of active rTMS would be delivered to the left DLPFC daily, with a session of 1800 pulse.
88812271|NCT05842278|Sham Comparator|sham rTMS|Subjects were randomized to receive 4 sessions or 6 sessions or 8 sessions or 10 sessions of sham rTMS to the left DLPFC daily in a 1:1:1:1 ratio.
88812272|NCT05832983|No Intervention|Control|Participants in the control arm will receive the current standard of nursing care for treating anxiety prior to receiving the intra-articular injection (emotional support, distraction, and/or therapeutic touch as necessary).
88812273|NCT05832983|Experimental|Experimental Group A|Participants in Group A will receive a guided meditation prior to receiving the intra-articular injection.
88812274|NCT05832983|Experimental|Experimental Group B|Participants in Group B will receive an Elequil Aromatab and the same guided meditation delivered to Group A prior to receiving the intra-articular injection.
88812275|NCT05831228|Experimental|Experimental: Ketogenic food products|Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
88812276|NCT05831228|Placebo Comparator|Control: Placebo|Dietary Supplement comparator
88812277|NCT05827484|Active Comparator|10 patients with acute skeletal muscle injury underwent PRP injection|Patients with acute skeletal muscle injury received a single ultrasound guided local PRP injection in the site of injury in day 1 or 2 of the injury.
88812278|NCT05827484|Experimental|10 patients with acute skeletal muscle injury underwent PRP injection and oral LOSARTAN|Patients with acute skeletal muscle injury received a single ultrasound guided local PRP injection in day 1 or 2 of injury in addition to administration of oral (50mg LOSARTAN /day) from day 5 to day 30.
88812279|NCT05820841|Active Comparator|Standard arm|6x R-miniCHOP + 2x Rituximab.
88812280|NCT05820841|Experimental|Experimental arm|6x R-miniCHOP + 2x Rituximab + Acalabrutinib.
88812281|NCT05818514|Experimental|[11C]AZ14132516|Pilot panel: up to 3 participants to complete 1 PET examination each during the course of the study Main panel: up to 6 participants to complete 2 PET examinations each during the course of the study
88812282|NCT05818267|Experimental|Treatment group|The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
89529368|NCT03281395||Cerebral aneurysm surgery with RVP|During surgery patients allocated to this group will undergo RVP. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
89529369|NCT03281395||Craniotomy without RVP|No rapid ventricular pacing is applied during surgery. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
89529370|NCT03269929|Experimental|Music therapy|
89529371|NCT03269929|Active Comparator|Midazolam|
89529372|NCT02457481|Experimental|Embryo Culture medium|Embryos from each patient are randomly allocated to culture in the commercial or experimental embryo culture medium (half of the embryos in commercial and half in experimental medium).
89529373|NCT02730377|Experimental|Liraglutide 1.8 mg|Add-on to metformin
89529374|NCT02730377|Active Comparator|OAD|Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
89529375|NCT03269773|Experimental|FURESTEM-AD Inj.|hUCB-MSC 5.0x10^7 cells
89529376|NCT03269773|Placebo Comparator|Placebo|
89529377|NCT03264547|Active Comparator|Arm A|"Trastuzumab + pertuzumab + Taxane*~*Taxane is chosen from the following; Docetaxel or Paclitaxel"
89529378|NCT03264547|Experimental|Arm B|Trastuzumab+ Pertuzumab + Eribulin
89529379|NCT03360461|Experimental|EMI-137|Ten participants to receive the IMP - EMI-137 1 to 3 hours before laparoscopic colonic resection surgery. Dose range 0.02mg/kg to 0.13mg/kg will be administered.
89529380|NCT03365219|Experimental|Alexis Retractor|This group received an Alexis O-Ring Wound Retractor during cesarean delivery.
89529381|NCT03365219|Active Comparator|Standard Surgical Retractors|This group received routine hand-held metal retractors as needed by the surgical team during cesarean delivery.
89529382|NCT03360383|Experimental|grade 1|percutaneous vertebroplasty
89529383|NCT03360383|Active Comparator|grade 2|conservative treatment
89529384|NCT03360305|No Intervention|Usual care|The ED clinician will perform a standard medical evaluation. This evaluation includes a focused history and exam to identify injuries. Laboratory tests and radiologic imaging may be ordered. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics). The research assistant (RA) will read the CDC STEADI brochure to the patient and provide them with a printed copy at the conclusion of their visit. The RA will solicit feedback from the clinician and the patient at the conclusion of the visit using the post-visit survey.
89529385|NCT03360305|Experimental|Intervention|"ED clinician will perform standard medical evaluation, including focused history and exam to identify injuries. RA will solicit feedback from clinician and patient via post-visit survey at conclusion of visit.~PT will perform services, including integrative mobility training and lower extremity strength training and recommending outpatient services/referrals. Specific assessments and treatments will be tailored to patient.~Pharmacist will perform a medication review using the updated BEERS criteria and CDC's STEADI instrument and recommend changes to potential fall risk increasing medication. Recommendations will be communicated to ED treatment team.~Seniors will return home with standardized checklist containing details of their assessment and action plan. The checklist addresses patient's personal risk factors for the fall and required further actions."
89529386|NCT03365141|Experimental|Experimental group|"All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.~Intervention: Intralesional injection of triamcinolone acetonide (0.4mg/cc) will be performed weekly."
89529387|NCT03365141|Active Comparator|Control group|All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
89529388|NCT03364985|Experimental|Cohort 1: DWP16001 Amg|DWP16001 Amg, tablets, orally, single dose administration
89529389|NCT03364985|Experimental|Cohort 2: DWP16001 Bmg|DWP16001 Bmg, tablets, orally, single dose administration
89529390|NCT03364985|Experimental|Cohort 3: DWP16001 Cmg|DWP16001 Cmg, tablets, orally, single dose administration
89529391|NCT03364985|Experimental|Cohort 4: DWP16001 Dmg|DWP16001 Dmg, tablets, orally, single dose administration
89529392|NCT03364985|Experimental|Cohort 5: DWP16001 Emg|DWP16001 Emg, tablets, orally, single dose administration
89529393|NCT03364985|Experimental|Cohort 6: DWP16001 Fmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
89529394|NCT03364985|Experimental|Cohort 7: DWP16001 Gmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
89529395|NCT03364985|Experimental|Cohort 8: DWP16001 Hmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
89529396|NCT03364985|Experimental|Cohort 9: DWP16001 Img|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
89529397|NCT03364985|Experimental|Cohort 10: DWP16001 Jmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
89529398|NCT04523441||Parents|man or woman
89529399|NCT04523441||Professionals|health professionals in charge of monitoring children
89529400|NCT03364907||HIPEC patients|Patients with a diagnosis of peritoneal carcinomatosis who undergo HIPEC treatment with oxaliplatin.
89529401|NCT03359915|Experimental|Intervention Group|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
89529402|NCT03359915|No Intervention|Control Group|COPD 'standard' care in local setting - Bhaktapur, Nepal; Lima, Peru; Nakaseke, Uganda
89529403|NCT03364829|Experimental|COPD on Indacaterol/Glycopyrronium|COPD on indacaterol/glycopyrronium for 1 month
89529404|NCT03359837|Experimental|Glargine based therapy|Once daily glargine plus prandial oral anti-hyperglycemic drugs
89529405|NCT03359837|Active Comparator|Premixed insulin|Twice daily premixed insulin
89529406|NCT04523285|Experimental|TQB3728 tablets|TQB3728 tablets administered orally, once a week in 28-day cycle.
89529407|NCT04524923||cohort group|Ninety-seven typically developing preschool children of both genders with age ranges from three to five years will be included in this study. Visual motor integration, quality of life and cognitive function were assessed by the Peabody Developmental Motor Scale, the Pediatric Quality of Life Inventory™ and the Pediatric Quality of Life Inventory™ cognitive functioning scale respectively
89529408|NCT03359681|Active Comparator|metformin hydrochloride|metformin, encapsulated tablet, 500mg 3 times a day for 30 days.
89529409|NCT03359681|Placebo Comparator|placebo oral capsule|placebo, encapsulated tablet, 500mg 3 times a day for 30 days.
89529410|NCT03359603|Experimental|Group A|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA 3 sessions per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
89529411|NCT03359603|Experimental|Group B|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA once per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
89529412|NCT04171063|Other|Bracing arm|Patients that will be using the thoracic compressor
89529413|NCT04524845|Experimental|Rebel Reliever|Rebel Reliever (RR) (Thuasne, Levallois Perret, France) with bilateral rigid frames and two hinges. The valgus correction was set by adjusting the medial and lateral frame lengths to a difference of two or three points as dictated by the participant's feeling and comfort. Six straps maintained the brace in place
89529414|NCT04524845|Experimental|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France) made mainly from textile. Upper and lower straps were adjusted to the participant's feeling and comfort.
89529415|NCT04524845|Active Comparator|Unloader One|Unloader One (UO) (Össur, Reykjavik, Iceland), with unilateral frame and one hinge. Upper and lower straps were adjusted to the setting recommended by the fitting instructions and confirmed by the participant's sensation.
89529416|NCT04524845|No Intervention|No orthosis|Control condition without brace
89529417|NCT03364595||Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the radial head fracture will be carried out
89529418|NCT03364595||Replacement|The operating surgeon will determine the positioning of the patient for surgery. During the surgery, they take out the the comminuted radial head and proceed replacement using artificial.
89529419|NCT03364361|Other|Acupuncture|Feasibility Study
89529420|NCT03364205|Experimental|intervention|solution-focused interview techniques
89529421|NCT03364205|No Intervention|control|This group did not apply solution-focused interview techniques.
89529422|NCT03363971|Experimental|Experimental group|Zhi Kang Capsule, 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery,treatment for 6 weeks.
89529423|NCT03363971|Placebo Comparator|Control group|Simulant agent for Zhi Kang Capsule,consistent with the appearance, color, odor, and usage of the Zhi Kang capsule, so that it can not be distinguished.oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery, treatment for 6 weeks.
89529424|NCT04524377|Experimental|DBS for Parkinsons Disease|
89529425|NCT03359525|Experimental|Group A|Group A: Intravenous Tranexamic acid at a dose of 1 gram administered 30 min prior to skin incision and 1 gram 3 hours after the procedure. (Total dose administered is 2 grams)
89529426|NCT03359525|Experimental|Group B|Group B: Topical Tranexamic acid at a dose of 1 gram injected in to the periarticular tissues prior to closure and 1 gram injected into the joint through the drain following wound closure. (Total dose administered is 2 grams)
89529427|NCT03359525|Experimental|Group C|Group C: Combined Intravenous 1 gram given intravenous 30 min prior to skin incision and topical tranexamic acid (1 gram) injected in to the periarticular tissues prior to closure. (Total dose administered is 2 grams)
89529428|NCT03359447|Experimental|Weekly Iron|Weekly ferrous sulfate: one dose (4mg/kg/week).
89529429|NCT03359447|Active Comparator|Daily Iron|Daily ferrous sulfate: one dose (1 mg/kg/day). Maximum daily dose: 40 mg
89529430|NCT04524299|Experimental|Concurrent chemotherapy Twice a Week|During the period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.
89529431|NCT04524299|Active Comparator|Concurrent chemotherapy Once a Week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours.
89529432|NCT03358433|Experimental|Exercise|
89529433|NCT03358433|Active Comparator|Antidepressants|
89529434|NCT03359369||Septic Patients|
89529435|NCT03359369||Non Septic Patients|
89529436|NCT03359291|Experimental|Sequence AB|Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.
89529437|NCT04522583||Troponin-positive ED patients|All patients admitted to the ED at the Hillel Yaffe Medical Center in Hadera, Israel, in the period 2016-2019 with cTn level higher than the 99th percentile of cTn concentration in the normal population (>0.014 nanogram/milliliter).
89529438|NCT03358277|Experimental|ADHD+DMDD Group|The subjects with comorbid ADHD and DMDD received pharmacological intervention with combination treatment of MPH+ APZ with flexible dosage according to clinical judgment for six weeks.
89529439|NCT03359135||group1|hEDS treated with rehabilitation only
89529440|NCT03359135||group 2|hEDS treated with rehabilitation associated to compression garments wearing
89529441|NCT04522193|Experimental|Experimental group|All children born at the Lille University Hospital during the investigation period with esophageal atresia type III or IV
89529442|NCT03359057|Experimental|Estradiol + levonorgestrel + folic acid|Coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days.
89529443|NCT03359057|Placebo Comparator|Folic acid|Coated tablet of placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle.
89529444|NCT04522115|Experimental|aerobic training|Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.
89529445|NCT04522115|Experimental|Resistance training|Resistance exercise training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated.
89529446|NCT03358199||Study group|PCOS women with AMH level (≥ 7 ng/ml) who underwent LOD in the preceding 3 months prior to IVF/ICSI
89529447|NCT03358199||Control group|PCOS women with AMH level (≥ 7 ng/ml) who did not undergo LOD in the preceding 3 months prior to IVF/ICSI
89529448|NCT03358121||Diabetics without hypoglycemia awareness|Diabetic patients without impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
89529449|NCT03358121||Diabetics with hypoglycemia awareness|Diabetic patients with impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
89529450|NCT03358901|Experimental|YC-6|6 volunteers in each level will be infused 100, 200, 400, or 600 mg of YC-6 over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
89529451|NCT03358901|Placebo Comparator|Vehicle|2 volunteers in each level will be infused 2, 4, 8, or 12 g of vehicle over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
89529452|NCT03358823||Angelman syndrome|Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011). all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including maternal deletions involving chromosome 15q11.2-q13;paternal uniparental disomy of 15q11.2-q13;imprinting defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)
89529453|NCT02714569|Experimental|Part A: LY3202328 (LY)|Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.
89529454|NCT02714569|Placebo Comparator|Part A: Placebo|A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
89529455|NCT02714569|Experimental|Part B: LY3202328 (LY)|A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
89529456|NCT02714569|Placebo Comparator|Part B: Placebo|A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
89529457|NCT03358745|Experimental|Standard meal, bread/butter as starter|"Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal and consists of bread and butter, soup, salad and cheese. The participants eat the bread and butter portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).~Blood samples are taken before the lunch and every 30 min postprandial for 4 h."
89529458|NCT03358745|Experimental|Standard meal with soup as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the soup portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
89529459|NCT03358745|Experimental|Standard meal with cheese as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the cheese portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
89529460|NCT03358745|Experimental|Standard meal with salad as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the salad portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
89529461|NCT03358667||group A|single edentulism implant insertion tent screw 2mm augmentation peri-implant soft tissue
89529462|NCT03358667||group B|single edentulism implant insertion cover screw and membrane augmentation peri-implant soft tissue
89529463|NCT04522817|Experimental|CLBS119 Active Treatment|Single administration of CLBS119
89529464|NCT03281161|Experimental|Sun Safe Workplaces Program|A follow up to the previous study that promoted the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers to promote policy adoption, promotional materials for sun safety, and in-person training of outdoor workers by research staff over two years. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of the SSW intervention completed 2 years after the initial intervention.
89529465|NCT03281161|Active Comparator|Attention Control|A follow up to the previous study that promoted occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of SSW completed 2 years after the initial program contact.
89529466|NCT03357809|Experimental|Endoscopic treatment|ENDOSCOPIC MUCOSAL RESECTION AT DAY 1
89529467|NCT03281083|Experimental|Levothyroxine (LT4)|Levothyroxine sodium (LT4) dose titrated at TSH 0.34 - 1.70mIU/L during maximum 12 weeks, followed by a maintenance phase of 16 weeks using the dose necessary for titration.
89529468|NCT04445129||Narcolepsy Type 1 Participants|Participants with NT1 on stable wake-promoting medications and exclusive of any sleep promoting medications will be fitted with the portable electrocardiogram (ECG) device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
89529469|NCT04445129||Healthy Participants|Participants who are healthy sex- and age (plus or minus 5 years)-matched controls will be fitted with the portable ECG device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
89529470|NCT04522037||interventional group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 receiving morphinic treatment for COVID-19 disease dyspnea.
89529471|NCT04522037||control group|patients hospitalized at the hospices civils of Lyon with a level of care 3 or 4 not receiving morphinic treatment for COVID-19 disease dyspnea.
89529472|NCT03357653|Experimental|Losartan group|Losartan 50 mg daily
89529473|NCT03357653|Placebo Comparator|Placebo group|Placebo 1 pill daily which has same size, color and taste with losartan
89529474|NCT02713789|Active Comparator|hMaxi-K|Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
89529475|NCT02713789|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
89529476|NCT04445051|Active Comparator|Intermittent catheter; SpeediCath® Standard male or female|Participants underwent catheterization with standard of care intermittent catheter. The catheterization was performed by a trained nurse.
89529477|NCT04445051|Experimental|New intermittent catheter Variant 1 for male or female|Participants underwent catheterization with the new intermittent catheter Variant 1 for males or females. The catheterization was performed by a trained nurse.
89529478|NCT04445051|Experimental|New intermittent catheter Variant 2 for male or female|Participants underwent catheterization with the new intermittent catheter Variant 2 for males or females. The catheterization was performed by a trained nurse.
89529479|NCT04522349|Active Comparator|Greifer then Axon-Hook|T0 + 2 weeks: evaluation with Greifer. T1 + 2 weeks: evaluation with Axon-Hook
89529480|NCT04522349|Active Comparator|Axon-Hook then Greifer|T0 + 2 weeks: evaluation with Axon-Hook. T1 + 2 weeks: evaluation with Greifer
89529481|NCT03281005||Retinitis pigmentosa in Part 1A|Retinitis pigmentosa patients with severe visual impairment
89529482|NCT03281005||Retinitis pigmentosa in Part 1B|Retinitis pigmentosa patients with severe visual impairment
89529483|NCT03281005||Retinitis pigmentosa in Part 2|Retinitis pigmentosa patients with severe visual impairment
89529484|NCT03281005||Healthy volunteers in Part 3|Healthy volunteers
89529485|NCT03358589|Other|MESTAR|All patients will have the same scans performed
89529486|NCT03264313|Active Comparator|dTMS active|patients undergoing of dTMS real
89529487|NCT03264313|Sham Comparator|dTMS Sham|patients undergoing to placebo dTMS
89529488|NCT03357575|Experimental|Mesenchymal Stem Cells from adipose|Mesenchymal Stem Cells from adipose will be injected.
89529489|NCT03357575|Active Comparator|hyaluronic acid|Hyaluronic acid will be injectied.
89529490|NCT03269461|Experimental|30 days evaluation|Angiography and Optical Coherence Tomography evaluations
89529491|NCT03269461|Experimental|2 months evaluation|Angiography and Optical Coherence Tomography evaluations
89529492|NCT03269461|Experimental|3 months evaluation|Angiography and Optical Coherence Tomography evaluations
89529493|NCT03358511|Experimental|Breast Cancer Patients|All subjects will be given 2-4 weeks of probiotics prior to surgery in operable stage I-III breast adenocarcinoma tumors ≥1.0 cm. Subjects will take the probiotic three times a day.
89529494|NCT03269617|Placebo Comparator|Placebo Comparator|Placebo control: 1 capsule containing rice maltodextrin consumed 1x daily for 28 days.
89529495|NCT03269617|Experimental|Experimental|Bacteriophage mixture: 1 capsule containing rice maltodextrin and a mixture of 4 bacteriophages consumed 1x daily for 28 days.
89529496|NCT03357497|Experimental|Very early mobilization|This group will be mobilized in the post-operative unit by a designated physiotherapist. The intervention will be conducted accordingly with the SOMS protocol.
89529497|NCT03357497|No Intervention|Standard post-operative care|This group will receive standard post-operative care. Mobilization will only take place if the patient request it or to facilitate god post-operative care.
89529498|NCT03280927|Experimental|Jublia®|
89529499|NCT03357263|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
89529500|NCT03357263|Active Comparator|GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
89529501|NCT03269383|Sham Comparator|Saline|Patients will receive a stellate ganglion block but with 10ml of 0.9% saline.
89529502|NCT03269383|Experimental|Treatment|Patients will receive a stellate ganglion block with 10ml of 0.5% bupivacaine
89529503|NCT04522427|Experimental|Multifocal and Extended Depth-of-Focus intraocular lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
89529504|NCT04522427|Active Comparator|Monofocal intraocular Lenses|Patients suffering from cataract getting phacoemulsification and Intraocular lenses(IOLs) implantation
89529505|NCT03280849|Experimental|Patient with bilaminar chitosan implant|A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
89529506|NCT04521491|Experimental|FOLFOX4|Patients who will receive FOLFOX4 chemotherapy after liver resection
89529507|NCT04521491|No Intervention|placebo|No adjuvant therapy after liver resection
89529508|NCT04509635|Experimental|Arm A|Using treatment of cetuximab plus chemotherapy. Cetuximab: 500 mg/m2 IV over 2 hours, day 1, every 2 weeks. Chemotherapy: detailed regimen is determined by a multi-disciplinary team.
89529509|NCT04509635|Active Comparator|Arm B|Using treatment of chemotherapy alone. Chemotherapy: detailed regimen is determined by a multi-disciplinary team
89529510|NCT03280771|Experimental|Hope Soap group|Children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre
89529511|NCT03280771|Active Comparator|Control group|Children in control households received a colourful, translucent bar or soap with the toy alongside it.
89529512|NCT03269539||Headache Patients|Patients Referred for MRI with History of Headaches
89529513|NCT03269539||Motion prone patients|Patients without the ability to remain still for the entire protocol
89529514|NCT04521023|Experimental|A|
89529515|NCT04521023|Active Comparator|B|
89529516|NCT03269071|Experimental|Treatment Cohort A|"See Study Description~TC-A: 0.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
89529517|NCT03269071|Experimental|Treatment Cohort B|"See Study Description~TC-B: 1.4 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
89529518|NCT03269071|Experimental|Treatment Cohort C|"See Study Description~TC-C: 2.8 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
89529519|NCT03269071|Experimental|Treatment Cohort D|"See Study Description~TC-D: 5.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
89529520|NCT04521101|Other|VAST Course|
89529521|NCT02518529|Experimental|250µg dose treatment|Subjects were treated with a 250mcg/0.2ml G17DT injection at weeks 0, 2 and 6.
89529522|NCT02457169|Experimental|Parent Engagement Intervention group|This group of parents will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool.
89529523|NCT02457169|Other|Attention Control|Waitlist Control Group: This group will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool after a 3 month delay.
89529524|NCT04444817||Tacrolimus-based immunosuppression|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started.
89529525|NCT05234827|Experimental|Virtual Reality|VR sessions include a device (XBOX 360) and motion sensor (Kinect) and LED (tv screen) with speakers attached. Height of the device is 1m while tv screen is placed 2.5m away, motion sensor is placed 1.2m away from the patient, play area should be 1.8m wide and long. Instruction to play game is provided to each patient. Before starting each training session, the device was adjusted to correctly follow the movements of each patient. VR session includes games by Kinect Adventures (Microsoft games studios, Washington, US) which include minigames in which patients participated these mini games are 20000 Leaks, Curvy Creek, Rally Ball and Reflux Ridge.
89529526|NCT05234827|Active Comparator|Control|Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing
89529527|NCT04520945|Active Comparator|Active Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
89529528|NCT04520945|Placebo Comparator|Placebo Participant of Phase 2B Clinical Study Chondrogen|50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.
89529529|NCT02459431|Active Comparator|21G needle group|21 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
89529530|NCT02459431|Active Comparator|22G needle group|22 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
89529531|NCT04509089|Experimental|Experimental|Congestive heart failure patients scheduled for pulmonary artery catheterization (Swan-Ganz)
89529532|NCT04509323|Experimental|Experimental：Huperzine A for Injection+Basic treatment|Huperzine A for Injection: Dissolve each bottle with 2ml sterile water for injection and inject into muscle, the course of treatment is 14 days； Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
89529533|NCT04509323|No Intervention|Control：Basic treatment|Basic treatment：Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
89529534|NCT04520789|Sham Comparator|RD control group|Conventional Surgery for Retinal Detachment
89529535|NCT04520789|Experimental|RD treatment group1|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study
89529536|NCT04520789|Active Comparator|RD treatment group2|Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study, postoperative intervention
89529537|NCT03356951||Lateral approach group|TAR through lateral approach and subtalar fusion
89529538|NCT03356951||Anterior approach group|TAR through anterior approach and subtalar fusion
89529539|NCT03280459||Ileal Conduit|Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy
89529540|NCT03280459||Neobladder|Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy
89529541|NCT04443647|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
89529542|NCT04443647|Placebo Comparator|Placebo|Saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
89529543|NCT04443881|Experimental|Anakinra Arm|Standard of care plus Anakinra (100mg) administered as 4-times daily i.v. infusions for a maximun of 15 days
89529544|NCT04443881|No Intervention|Control Arm|Standard of care
89529545|NCT02458339|Experimental|Experimental|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle will be of 4 weeks duration. During the first 3 weeks, methotrexate will be infused twice weekly on days 1 and 4 (+/- 2 days). The 4th week is a rest week.
89529546|NCT03268915|Experimental|patient with idiopathic pulmonary fibrosis|
89529547|NCT03356795|Experimental|Cervical cancer-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.
89529548|NCT03268759||PCE|Emerging adult individuals who were exposed to cocaine in-utero
89529549|NCT03268759||NCE|Emerging adult individuals who were not exposed to cocaine in-utero
89529550|NCT03354533|Other|Treatment with ORL-1F - L-fucose|
89529551|NCT03268525|Active Comparator|Study|Marcaine 0.5 % Injectable Solution will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Marcaine 0.25%will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
89529552|NCT03268525|Placebo Comparator|Control|Sodium Chloride 0.9% will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Sodium Chloride 0.9% will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
89529553|NCT03356717|Experimental|educational intervention - observer tool|"Participants in this arm will be given the observer tool (OT) before the scenario and will be explained how to use it, i.e. observe all details of the scenario on the screen and tick on the OT all actions which are done by active participants.The observer tool will also be used to engage observers during the debriefing session.~The scenario will then be observed in a screen (i.e. the scenario is played by active participants in an adjacent room using direct video-recording and transmission."
89529554|NCT03356717|Active Comparator|without observer tool|Participants in this arm will not be given the observer tool (OT) before the scenario but will be asked to observe all details of the scenario on the screen.The observers will also be asked to participate during the debriefing session.
89529555|NCT04520243|Experimental|English alphabet illiterate group|Individuals with no self-reported understanding of English alphabet and recognition of <6/10 Sloan Letters
89529556|NCT04520243|Active Comparator|English alphabet literate group|Individuals with self-reported understanding of English alphabet and recognition of ≥6/10 Sloan Letters
89529557|NCT02456935|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
89529558|NCT02456935|Active Comparator|Esomeprazole 40 mg QD|Esomeprazole 40 mg, tablet, once daily, oral administration for up to 8 weeks
89529559|NCT03354455|Experimental|REAL TMS|30 minutes of repetitive transcranial magnetic stimulation with 100% of the patients' individual resting motor threshold.
89529560|NCT03354455|Sham Comparator|SHAM TMS|30 minutes of repetitive transcranial magnetic stimulation with 30% of the patients' individual resting motor threshold.
89529561|NCT02457013|Experimental|HFNC treatment|HFNC : High flow nasal canula 24hours Patients will be treated by a High flow nasal canula (HFNC: 2l/kg/min) for the initial management of their bronchiolitis (24 hours)
89529562|NCT02457013|Active Comparator|nCPAP treatment|nCPAP : nasal NCPAP Patients will be treated by a nasal CPAP (n-CPAP: 7 cmH2O) for the initial management of their bronchiolitis (24 hours)
89529563|NCT04520399||violence|
89529564|NCT04520399||non-violence|
89529565|NCT03356639|Experimental|ASP6981 50 mg, then matching Placebo|Participants in Sequence AB will first receive ASP6981 capsules orally (50 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
89529566|NCT03356639|Experimental|Matching Placebo, then ASP6981 50 mg|Participants in Sequence BA will first receive matching placebo capsules orally during period 1. After a 14-day washout period, participants receive ASP6981 capsules (50 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
89529567|NCT03356639|Experimental|ASP6981 135 mg, then matching Placebo|Participants in Sequence CD will first receive ASP6981 capsules orally (135 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
89529568|NCT03356639|Experimental|Matching Placebo, then ASP6981 135 mg|Participants in Sequence DC will first receive matching placebo capsules orally during period 1. After a-14 day washout period, participants receive ASP6981 (135 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
89529569|NCT03263689|Experimental|Intervention|"ITM group were given~Local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia~100 micrograms of preservative-free morphine."
89529570|NCT03263689|Active Comparator|Control|TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.
89529571|NCT03354299|Experimental|Group I|Group I patients received 25 gram of sugar (pudding) and 50 cc of coconut milk as late night snack for a month
89529572|NCT03354299|Active Comparator|Group II|Group II patients received 50 gram of sugar (25 gram pudding and 25 gram syrup) as late night snack for a month
89529573|NCT03264001|Experimental|Diet-induced negative energy balance|For the diet-induced negative energy balance arm, the three trials will include one control trial (isocaloric diet; zero energy balance) and two trials of progressively increasing negative energy balance induced by calorie restriction (20% and 40% reduction of daily energy needs for weight maintenance). With respect to physical activity, all diet trials will be performed under resting conditions.
89529574|NCT03264001|Experimental|Exercise-induced negative energy balance|For the exercise-induced negative energy balance arm, the three trials will include one control trial (rest; zero energy balance) and two trials of progressively increasing negative energy balance induced by aerobic exercise (20% and 40% reduction of daily energy needs for weight maintenance); with respect to caloric intake, all exercise trials will be performed under isocaloric conditions.
89529575|NCT03356561|Experimental|Group 1: Ad26.ZIKV.001 5*10^10 Viral Particles (vp)|Participants will receive Ad26.ZIKV.001 at 5*10^10 viral particles (vp) via intramuscular (IM) route on Days 1 and 57.
89529576|NCT03356561|Experimental|Group 2: Ad26.ZIKV.001 5*10^10 vp and Placebo|Participants will receive Ad26.ZIKV.001 5*10^10 vp on Day 1 and placebo on Day 57 via IM route.
89529577|NCT03356561|Experimental|Group 3: Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at 1*10^11 vp via IM route on Days 1 and 57.
89529578|NCT03356561|Experimental|Group 4: Ad26.ZIKV.001 1*10^11 vp and Placebo|Participants will receive Ad26.ZIKV.001 1*10^11 vp on Day 1 and placebo on Day 57 via IM route.
89529579|NCT03356561|Placebo Comparator|Group 5: Placebo|Participants will receive placebo via IM route on Days 1 and 57.
89529580|NCT03268369|Active Comparator|Control group|
89529581|NCT03268369|Experimental|Non lesional diurnal partial epilepsy|
89529582|NCT03268369|Experimental|Idiopathic generalized epilepsy|
89529583|NCT03268369|Experimental|Nocturnal frontal lobe epilepsy|
89529584|NCT03268369|Experimental|Epileptic patients with Vagus Nerve Stimulation (VNS)|
89529585|NCT03356327|Experimental|Group 1|Group 1 consisting of 30 children treated with Actitan F and standard oral rehydration (SOR)
89529586|NCT03356327|Active Comparator|Group 2|Group 2 consisting of 30 children who received only SOR.
89529587|NCT03268447|Active Comparator|Lactobacillus plantarum P8|Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum P8, administered daily at a fixed dosage of 10 log CFU/sachet/day and continue for 12 weeks.
89529588|NCT03268447|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
89529589|NCT03354221|Experimental|Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale|Patients going through the six food elimination diet (clinically) for EoE will be asked to participate. During the initial 6 week elimination period, participants will return at 2, 4 and 6 weeks to swallow the cytosponge. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the future of the 6 food elimination diet to determine if a period of 6 weeks of initial elimination is necessary. The EEsAI Pro questionnaire measures symptomatic response to the elimination of the foods. The Likert Scoring Scale measures patient experience of the cytosponge and the upper endoscopy.
89529590|NCT02458417|Active Comparator|Full surface CO2 laser 200mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 209 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
89529591|NCT02458417|Experimental|Full surface CO2 laser 150mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
89529592|NCT02458417|Experimental|Fractional CO2 laser 7.5mJ 20% + ReCell|This test region will receive pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
89529593|NCT02458417|No Intervention|Control|No intervention
89529594|NCT03356171|Experimental|Cardiac Coherence|Patients participate to Adapted physical activity sessions and to cardiac coherence sessions
89529595|NCT03356171|Active Comparator|Adapted Physical Activity|Patients only participate to Adapted physical activity sessions
89529596|NCT04508387|Active Comparator|Group HH (heated-humidified) patients|Group HH (heated-humidified) patients were administered 95% humidified CO2 insufflation at 37°C. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
89529597|NCT04508387|Placebo Comparator|Group CD (cold-dry) patients|Group CD (cold-dry) patients were administered dry CO2 via insufflator at room temperature (21°C). All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.
89529598|NCT03280069||Subjects between the ages of 40 - 70|Subjects who present with signs of skin laxity & evaporation dry eye will receive 3 treatments with the THERMIeyes® 20 RF System and monitored for improvements in the conditions for which they have presented.
89529599|NCT03268291|Active Comparator|Standard outpatient observation|Outpatient management according to Ministry of health standards
89529600|NCT03268291|Experimental|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;~service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;~questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
89529601|NCT03356093||Patients with head and neck cancer|No intervention was provided. The patients were only asked to complete a set of questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of postoperative radiotherapy.
89529602|NCT03356015|Experimental|4L Polyethylene Glycol|4L-group received 4 bags of PEG and were instructed to drink 2L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
89529603|NCT03356015|Active Comparator|3L Polyethylene Glycol|3L-group received 3 bags of PEG and were instructed to drink 1L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
89529604|NCT03279679|Experimental|costoclavicular group|patients in this group are assigned to receive ultrasound-guided costoclavicular infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
89529605|NCT03279679|Other|paracoracoid group|patients in this group are assigned to receive ultrasound-guided paracoracoid infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
89529606|NCT03354065|Active Comparator|Early oral feeding|TIME OF FEEDING. 48 hours after pancreatitis general management is started ( liquid diet)
89529607|NCT03354065|Experimental|Immediate oral feeding|TIME OF FEEDING: 8 hours of after pancreatitis general management is started (enteral formula)
89529608|NCT03263377|Active Comparator|2|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.
89529609|NCT03263377|Other|Non Intervention|A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
89529610|NCT02518607|Experimental|Group 1, Session 1, Active|"Lowest dose of SAD:~MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose"
89529611|NCT02518607|Experimental|Group 1, Session 2, Active|"Dose Escalation SAD:~MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose"
89529612|NCT02518607|Experimental|Group 1, Session 3, Active|Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose
89529613|NCT02518607|Experimental|Group 2, Session 1, Active|Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose
89529614|NCT02518607|Experimental|Group 2, Session 2, Active|Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose
89529615|NCT02518607|Experimental|Group 2, Session 3, Active|Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose
89529616|NCT02518607|Experimental|Group 3, Active|Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
89529617|NCT02518607|Experimental|Group 4, Active|Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
89529618|NCT02518607|Experimental|Group 5, Active|Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
89529619|NCT02518607|Placebo Comparator|Group 1, Session 1, Placebo|"Lowest dose of SAD:~Placebo, 1 liquid filled enterically coated capsule, single dose"
89529620|NCT02518607|Placebo Comparator|Group 1, Session 2, Placebo|Placebo, 2 liquid filled enterically coated capsules, single dose
89529621|NCT02518607|Placebo Comparator|Group 1, Session 3, Placebo|Placebo, 3 liquid filled enterically coated capsules, single dose
89529622|NCT02518607|Placebo Comparator|Group 2, Session 1, Placebo|Placebo, 4 liquid filled enterically coated capsules, single dose
89529623|NCT02518607|Placebo Comparator|Group 2, Session 2, Placebo|Placebo, 5 liquid filled enterically coated capsules, single dose
89529624|NCT02518607|Placebo Comparator|Group 2, Session 3, Placebo|Placebo, 6 liquid filled enterically coated capsules, single dose
89529625|NCT02518607|Placebo Comparator|Group 3, Placebo|Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
89529626|NCT02518607|Placebo Comparator|Group 4, Placebo|Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
89529627|NCT02518607|Placebo Comparator|Group 5, Placebo|Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
89529628|NCT03279211|Experimental|Zein protein|Zein protein included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
89529629|NCT03279211|Experimental|Whey protein isolate|Whey protein isolate included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
89529630|NCT03279211|Other|Protein-free|No protein added in the test-meal, only 500 ml of water + flavour/sugar In order to determine the endogenous loss of amino acid in the digesta samples.
89529631|NCT03278353|Experimental|Conservative care|Exercise and manual therapy
89529632|NCT03122873||Myelopathy of any cause|Male or female 18 years or older with myelopathy and detectable finger extension weakness due to 1) prototypic multiple sclerosis (N=50) 2) other etiologies of myelopathy (N=50), including other inflammatory conditions (e.g. idiopathic transverse myelitis, neuromyelitis optica, acute disseminated encephalomyelitis, sarcoidosis) or other etiologies (compression, vascular disorders, degenerative disorders, neoplasms).
89529633|NCT03122873||Peripheral neuropathy|Male or female 18 years or older with C7 radiculopathy, radial neuropathy, plexopathy, peripheral neuropathy, who have detectable finger extension weakness.
89529634|NCT03122873||Healthy Controls|Male and female 18 year or older with no finger extension weakness and no known neurological conditions.
89529635|NCT02518451|Experimental|(Test) Group I|Valsartan 160 mg film-coated caplets of PT Dexa Medica
89529636|NCT02518451|Active Comparator|(Reference) Group II|Valsartan 160 mg film-coated caplets (Diovan® 160)
89529637|NCT03263611|Placebo Comparator|placebo|subject will receive single intradiscal injection of placebo
89529638|NCT03263611|Experimental|AMG0103 low dose|subject will receive single intradiscal injection of AMG0103 low dose
89529639|NCT03263611|Experimental|AMG0103 middle dose|subject will receive single intradiscal injection of AMG0103 middle dose
89529640|NCT03263611|Experimental|AMG0103 high dose|subject will receive single intradiscal injection of AMG0103 high dose
89529641|NCT04516811|Experimental|Arm 1|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
89529642|NCT04516811|Placebo Comparator|Arm 2|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines.
89529643|NCT03263299|Active Comparator|cabergoline group|received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
89529644|NCT03263299|Active Comparator|Aspirin group|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
89529645|NCT03263299|Active Comparator|GnRH Group|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
89529646|NCT03355937|Active Comparator|UEI Sperm Chip (-)|Conventional IVF treatment and using conventional sperm selection
89529647|NCT03355937|Experimental|UEI Sperm Chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
89529648|NCT03355937|Active Comparator|RIF sperm chip (-)|Conventional IVF treatment and using conventional sperm selection
89529649|NCT03355937|Experimental|RIF sperm chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
89529650|NCT02457091|Active Comparator|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
89529651|NCT02457091|Experimental|Resistance exercise|The resistance condition will consist of 1-3 sets, 10-15 repetitions of 12 exercises targeting lower body, upper body, and core muscle groups performed 2 days per week.
89529652|NCT04444271|Experimental|Mesenchymal stem cells|10 patients will be given mesenchymal stem cells at dose 2x10^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care
89529653|NCT04444271|Placebo Comparator|Placebo|Only supportive care will be given to 10 patients
89529654|NCT03263455|Experimental|Kinesio Taping group|The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).
89529655|NCT03263455|Sham Comparator|Sham Taping group|"Patients in the ST group, smaller I-strips of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group"
89529656|NCT04444349|Experimental|Coenzyme Q10 group|Participants in the experimental group will be given 10mg of Coenzyme Q10 each time (3 times a day).
89529657|NCT04444349|Sham Comparator|Control|Participants in the experimental group will be given 10mg of placebo each time (3 times a day).
89529658|NCT03263533|Experimental|Vorinostat Group 1 (P-V-P-P)|"This group will receive this sequence after the 1 initial week washout:~vorinstat (4 weeks) placebo (1 week) placebo (4 weeks)"
89529659|NCT03263533|Experimental|Vorinostat Group 2 (P-P-P-V)|"This group will receive this sequence after the 1 initial week washout:~placebo (4 weeks) placebo (1 week) vorinostat (4 weeks)"
89529660|NCT03355859|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8 CAR+ T cells.
89529661|NCT03267745|Experimental|Amino Acid|Subjects in this arm will receive amino acid supplementation (23.7g) 3 times daily for 28 days. Amino acids will be provided in powder form to be dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
89529662|NCT03267745|Placebo Comparator|Placebo|Subjects in this arm will receive placebo 3 times daily for 28 days. Placebo will consist of 23.7g of excipient-matched placebo in water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
89529663|NCT03122951|Other|ovulation test use|All voluteers will receive device for use according to instructions
89529664|NCT03267823||Heart surgery|Patients undergoing heart surgery will have blood samples tested for INR values
89529665|NCT03123107|Experimental|Ascorbic Acid|4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.
89529666|NCT03267979|Other|Patients have a surgical operation|Patients have a surgical operation and have received analgesic treatment. One hour after the end of surgical patients will have electrocardiogram and video-pupillometer.
89529667|NCT04516655|Experimental|C-R-MTX|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles
89529668|NCT02458183|Experimental|DTaP-IPV combination vaccine|Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of right thigh at the age of 2, 4, and 6 months
89529669|NCT02458183|Active Comparator|DTaP vaccine and IPV vaccine|"Product name: : Boryung DTaP Vaccine Inj. (Prefilled syringe) (Absorbed diphtheria, tetanus toxoid, and purified pertussis combination vaccine) Dosage and administration: A 0.5-mL dose is administered 3 times intramuscularly in the anterolateral aspect of right thigh at the age of 2, 4, and 6 months.~Product name: IPVAX INJ. PREFILLED SYRINGE INJ. Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh at the age of 2, 4, and 6 months."
89529670|NCT04444193|Experimental|Durvalumab and Lenvatinib|Combination therapy of Lenvatinib 80-120mg daily orally and durvalumab 1500mg by IV infusion every 4 weeks
89529671|NCT03267901|Experimental|Walnut-Control|
89529672|NCT03267901|Experimental|Control-Walnut|
89529673|NCT02457949|No Intervention|Treatment As Usual (TAU)|Receipt of social assistance on government cheque issue days for 6 income assistance cycles (approx 26 weeks).
89529674|NCT02457949|Experimental|Staggered Arm|Receipt of social assistance once monthly on a randomly assigned day that does not fall during the week of government cheque issue (Non-synchronized social assistance receipt), for 6 income assistance cycles (approx 26 weeks).
89529675|NCT02457949|Experimental|Staggered and Split Arm|Receipt of social assistance twice monthly on equally spaced randomly assigned days that do not fall during the week of government cheque issue (Non-synchronized social assistance receipt, cheque divided into two equal disbursements), for 6 income assistance cycles (approx 26 weeks).
89529676|NCT04444037||OCT-guided PCI|PCI procedure was done with intra-coronary imaging OCT.
89529677|NCT04444037||Angiography-guided PCI|PCI procedure was done without any intra-coronary imaging assistance, guided by angiography alone
89529678|NCT03984955|Active Comparator|Group A PRP injection|"Platelet-Rich Plasma injection Single therapeutic injection of Platelet-Rich Plasma performed under ultrasound guidance.~This group will also undergo a class-based physiotherapy intervention. This outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and those receiving the sham injection."
89529679|NCT03984955|Active Comparator|Group B Ostenil Tendon|Sodium hyaluronate with mannitol (Ostenil Tendon) Single therapeutic injection of sodium hyaluronate with mannitol (marketed under the device name Ostenil Tendon) under ultrasound guidance. This group will also undergo a class-based physiotherapy intervention.
89529680|NCT03984955|Sham Comparator|Group C control group|Subcutaneous sham injection. This group will also undergo a class-based physiotherapy intervention. The outcomes for this group will be compared to those receiving Sodium hyaluronate with mannitol (Ostenil Tendon) and to those receiving PRP injection.
89529681|NCT03355547||no URI (upper respiratory tract infection) symptoms|Patients without upper respiratory tract infection symptoms
89529682|NCT03355547||URI (upper respiratory tract infection) symptoms|Patients with upper respiratory tract infection symptoms
89529683|NCT03946969|Experimental|Sintilimab + Liposomal Paclitaxel + Cisplatin + S-1|Sintilimab will be administered prior to the chemotherapy in an interval of half an hour.
89529684|NCT03355391||Screening participants|Individuals aged 50 to 65 years who were included in the screening program of Cancer Hospital of Barretos
89529685|NCT03277573|Experimental|Salsalate|Drug: Salsalate 2 tablets twice daily (3,000 mg total daily) by mouth for 12 months
89529686|NCT03277573|Placebo Comparator|Placebo|Drug: Placebo 2 tablets twice daily by mouth for 12 months
89529687|NCT03355313|Experimental|Low level light therapy 1|
89529688|NCT03355313|Experimental|Low level light therapy 2|
89529689|NCT03355313|Experimental|Low level light therapy 3|
89529690|NCT03267667||obstructive sleep apnea patients|number of 90 patients will be investigated by 2D echocardiography and cardiac MRI to determine the right ventricle function
89529691|NCT03267667||healthy volunteers|number of 10 subjects will be investigated by 2D echocardiography and cardiac MRI to determine right ventricular function in healthy persons have risk factors other than cardiac or lung diseases
89529692|NCT03353987|No Intervention|Control|Preoperative counselling will be given upon recruitment Patients will be given instructions to continue their normal routine.
89529693|NCT03353987|Experimental|Cognitive Training|Preoperative counselling will be given upon recruitment Patients are taught cognitive training and are asked to perform a prescribed set of one-hour cognitive training daily for a minimum of 10 days and up to 1 month prior to surgery.
89529694|NCT03355235||Cognitive assessment using standardized tools|cognitive assessment using standardized tools pre and post transplant.
89529695|NCT03262831|Experimental|Arm 1: Yoga|"Prior to start of treatment, a yoga therapist will work with each patient to develop a personalized yoga protocol using Gentle Hatha and Restorative Yoga~Each protocol will consist of 5-10 minutes of centering poses to invite focus and relaxation, then 15-20 minutes of seated and standing active poses, ending with 5-10 minutes of guided relaxation.~The personalized practice will be given to each participant and she will be asked to practice beginning at the start of neoadjuvant treatment at least 3 times a week (but preferably daily) at home for at least 30 minutes each time. Participants will continue their personalized yoga practice during the entirety of treatment. Each participant will be asked to journal when and for how long she practices at home and make any comments as to how the practice might have made her feel~During participation, weekly follow-up calls will be made by a member of the study team to each participant randomized to the yoga arm."
89529696|NCT03262831|Active Comparator|Arm 2: No Yoga|-Patients in this arm will not receive a personalized yoga plan
89529697|NCT03353909|Experimental|Treatment|At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
89529698|NCT03353909|No Intervention|Control|At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
89529699|NCT03267355|Experimental|Gastrointestinal diseases|Endoscopic Ultrasound
89529700|NCT02459353|Experimental|dapagliflozin 10mg|a group which treated with dapagliflozin 10mg plus basal insulin therapy
89529701|NCT02459353|Placebo Comparator|placebo 10mg|a group which treated with dapagliflozin placebo plus basal insulin therapy
89529702|NCT04508231||Hormonal treatment|The University Hospital in Nancy is an academic regional transgender referral center in Lorraine (France) and keeps a register of subjects available from 2004. The register at the time of the present study (February 2020) included 320 subjects who met diagnostic criteria for gender dysphoria and were seen regularly in the out-patient clinic at our department of endocrinology. Our investigation is a part of the regular care of subjects with gender dysphoria.
89529703|NCT04508231||Controls|Data for control subjects are retrieved from medical records of healthy non-obese females and males who underwent an initial assessment for gender dysphoria in our department, but not yet receiving hormonal treatment at the time of the present study.
89529704|NCT04514627|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
89529705|NCT04514627|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during hospitalization.
89529706|NCT03263065|Experimental|Nopal added to test meal|test meal including nopal powder
89529707|NCT03263065|Experimental|Psyllium added to test meal|test meal including psyllium powder
89529708|NCT03263065|Experimental|Bran added to test meal|test meal including bran powder
89529709|NCT03274531|Experimental|Interventional Arm|Immediate referral of hypertensive patients to the attending physician based on automated office blood pressure measurements
89529710|NCT03274531|No Intervention|Observational Arm|Repeated automated office blood pressure measurements and referral of hypertensive patients to the attending physician after completion of the trial
89529711|NCT04513613||Subjects with a clinical indication for PVI|Subjects with a clinical indication for Peripheral Vascular Intervention (PVI).
89529712|NCT02518373|Experimental|G17DT & Omeprazole|"A 14-day washout period~An Omeprazole Treatment Period 1 (Day -15 to Day -1)~A G17DT treatment period (Day 0 to Day 85)~An Omeprazole Treatment Period 2 (Day 86 to Day 100)"
89529713|NCT03263143|No Intervention|Standard of Care|
89529714|NCT03263143|Other|Early Palliative Care Consultation|
89529715|NCT03353597|Experimental|Plasma Transfusion|Plasma Transfusions with 2 units of plasma per dose, for a total of 6 doses
89529716|NCT03266965|Experimental|Histidine Intervention Group|A total of 15 subjects will be recruited in batches of 5 until completed 15 subjects in the trial. If a subject withdraws the trial, the study will continue and enrolling subjects until 15 of them complete the trial. The subject composition (MS patient/Normal subject) 4 MS and 1 normal will be tested on a dose of L-Histidine 250 mg plus Lodosyn 50 mg BID for seven days. If there are no safety concerns, the next 5 patients will be recruited 4 MS and 1 normal to test the dose of 500 mg with Lodosyn 50 mg bid for seven days. If there are no safety concerns, then L-histidine 1,000 mg plus Lodosyn (Carbidopa) 50 mg bid will be tested in the next 5 subjects 4 MS and 1 normal for seven days.
89529717|NCT03353519|Experimental|Primary care model|The new model of care incorporates a multi-factorial package of service aimed at providing a review of patient needs, facilitated self-management of longer-term stroke care needs for survivors and their carers, optimised communication between patients and health and social care services, optimised communication between the different care services, and increased awareness of and access to national and local community and charity provided services.
89529718|NCT03353519|No Intervention|Usual care|The control arm will consist of the usual care currently provided for stroke survivors registered with each general practice.
89529719|NCT04512677|No Intervention|No Interventions: Control|Conventional clinical treatment and using the ventilatory weaning protocol and standard extubation with the spontaneous breathing test (SBT) with the T-piece in 30 minutes.
89529720|NCT04512677|Experimental|Experimental: Intervention|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
89529721|NCT03266731|Experimental|use of aspirin and clopidogrel|
89529722|NCT04507529|Experimental|Peer-mentoring|Peer-mentoring
89529723|NCT02458963|Active Comparator|IVF group|Women will undergo one full IVF cycle
89529724|NCT02458963|Active Comparator|Gonadotropin group|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.
89529725|NCT03262597|Experimental|Beverage Hydration Index of beverages|Subjects will consume 4 different beverages to obtain the beverage hydration index.
89529726|NCT03355079|Experimental|SmofKabiven® E + standard oral nutrition|SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit® will be administered at 5-7 days per week for up to 9 +/-1 weeks in addition to standard of care oral nutrition as per routine dietary counseling, to reach the patient's target energy intake.
89529727|NCT03355079|No Intervention|Standard oral nutrition|The patients will consume standard of care oral nutrition as per routine dietary counseling, to reach their target energy intake. Standard of care tube feeding or parenteral nutrition is allowed to start earliest 3 weeks after baseline visit, if required.
89529728|NCT03262753||surgery|Primary end-to-end surgical treatment of coarctation of the aorta
89529729|NCT03262753||balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
89529730|NCT03262753||stent|Primary stent dilation treatment of coarctation of the aorta
89529731|NCT04507607|Experimental|Pregnant women with CHB|Start taking TAF at 24 weeks of gestation until delivery. The liver function, viral load and antigen status were reviewed monthly and 10 ml peripheral blood was collected.
89529732|NCT04507607|Active Comparator|women with CHB|Nonpregnant women taking TAF for antiviral therapy were regularly rechecked for liver function, viral load, and antigens.
89529733|NCT03353441|Active Comparator|Glycine (MSG)|Microencapsulated Sublingual Glycine (MSG): 1 tablet prior to TSST; 1 tablet after the TSST
89529734|NCT03353441|Placebo Comparator|Placebo|Lactose: 1 tablet prior to TSST; 1 tablet after the TSST
89529735|NCT03353441|No Intervention|No treatment|
89529736|NCT03273205|Experimental|Anodal tDCS|"The first group of patients has the real stimulation and the electrodes are placed in this position:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
89529737|NCT03273205|Sham Comparator|Sham tDCS|"The second group has the sham stimulation, but the electrodes are placed in the same position as in the first group:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
89529738|NCT04511429||Kidney transplant patients|Patients submitted to kidney transplantation.
89529739|NCT04511429||Liver transplant patients|Patients submitted to liver transplantation.
89529740|NCT04511429||Oncological patients|Oncological patients submitted to chemotherapy.
89529741|NCT03353363|Placebo Comparator|Normal Saline|Subject will receive 20ml of normal saline infiltration
89529742|NCT03353363|Experimental|Plain Bupivacaine|Subject will receive 20ml of 0.5% plain bupivacaine infiltration (100mg)
89529743|NCT03353363|Experimental|Liposomal Bupivacaine|Subject will receive 20ml of liposomal bupivacaine infiltration (266mg) non-expanded
89529744|NCT03266185|Experimental|45-minutes|45-minutes post-infusion cooling time
89529745|NCT03266185|Experimental|20-minutes|20-minutes post-infusion cooling time
89529746|NCT03266185|No Intervention|No scalp cooling|Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia
89529747|NCT03354923|Experimental|immediate intervention group|Immediate PEERS intervention
89529748|NCT03354923|Other|delayed intervention|delayed PEERS intervention to begin after experimental group
89529749|NCT03353285||Group I|Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing)
89529750|NCT03353285||Group II|Group II= egg retrieved in the 1st-2nd flush
89529751|NCT03353285||Group III|Group III= egg retrieved in the 3rd-5th flush
89529752|NCT04086121|Experimental|Spesolimab 600 mg|"600 milligrams (mg) solution for subcutaneous (SC) injection of BI 655130 (Spesolimab) were to administered subcutaneously every 4 weeks.~All patients will return 16 weeks post the last treatment for an End of Study (EOS) visit."
89529753|NCT03353207||health Control|"No family history of RBD;~Age- and sex- matched with isolated RSWA subjects~Absence of dream enactment behaviors;~A score of RBDQ-HK less than 19;~Absence of RSWA as measured by v-PSG;~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
89529754|NCT03353207||Case with isolated RSWA|"First degree relatives of patients with iRBD;~Age 45 years or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the cut-off suggestive of a diagnosis of RBD;~Presence of RSWA as measured by v-PSG; RSWA is defined as the percentage of increased EMG activity (phasic or tonic) at least 10% during REM sleep for any channel.~for those individuals with moderate to severe obstructive sleep apnea (apnea-hypopnea index, AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
89529755|NCT03353207||Case without isolated RSWA|"First degree relatives of patients with iRBD;~Age- and sex- matched with isolated RSWA subjects;~Absence of dream enactment behaviors;~A score of RBDQ-HK less than 19;~Absence of RSWA as measured by v-PSG;~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
89529756|NCT03354845|No Intervention|Control (usual care) group|In the control group, doctors maintained the usual practice of medication review, altering and discontinuing medications as necessary, without receiving deprescribing recommendations from pharmacists.
89529757|NCT03354845|Other|Deprescribing intervention group|The five-step patient-centred deprescribing process was utilized in the intervention group.
89529758|NCT05234905|Experimental|Recombinant human adenovirus type 5+ Camrelizumab|"Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×10^12vp (3 injections) on day 1, 1.0×10^12vp (2 injections) on day 4.~② Tumor maximum diameter >5cm but ≤10cm, 3.0×10^12vp (6 injections) on day 1 and 2.0×10^12vp (4 injections) on day 4.~③ Tumor maximum diameter >10cm, 4.5×10^12vp (9 injections) on day 1 and 3.0×10^12vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV."
89529759|NCT03266263|Experimental|automatic computer-led feedback|automated feedback for CPR quality provided by computers
89529760|NCT03266263|Active Comparator|instructor-led feedback|feedback for CPR quality provided by instructors
89529761|NCT03354767||Wasting patients|Patients with >10% loss of skeletal muscle one week after major aortic surgery
89529762|NCT03354767||Non-wasting patients|Patients with <10% loss of skeletal muscle one week after major aortic surgery
89529763|NCT04511195|Experimental|Sphaeralcea angustifolia standardized extract|Patients with diagnosis of knee osteoarthritis will be included in the experimental group and assigned the treatment consisting of a topical administration of a gel elaborated with the pharmaceutical formulation prepared with a standardized extract from S. angustifolia, which will be administered three times a day for four weeks.
89529764|NCT04511195|Active Comparator|Diclofenac 2 %|Patients with diagnosis of knee osteoarthritis will be included in the control group and assigned the treatment consisting of a topical administration of a gel elaborated with 2% diclofenac, which be administered three times a day for four weeks
89529765|NCT05075473|Experimental|Segmental Stabilization|Segmental control over the primary stabilizers (TrA, deep multifidus, pelvic floor and diaphram) is maintained. Weight of body is minimized by using drawing in maneuver. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
89529766|NCT05075473|Active Comparator|General lumber stabilization exercises|It includes exercises in closed chain with low velocity as well as low load. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for about 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
89529767|NCT03353051||Group A: other - observational study|neonates ≥2000-<2500g and born with a gestation age <37 weeks.
89529768|NCT03353051||Group B: other- observational study|Group B will contain neonates >2500g and born with a gestation age <37 weeks.
89529769|NCT03353051||Group C: other - observational study|Group C will contain neonates ≥2000-<2500g but with a gestation age >37 weeks.
89529770|NCT03353051||Group D1:other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.
89529771|NCT03353051||Group D2: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs
89529772|NCT03353051||Group D3: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.
89529773|NCT03262207||testicular tumours|
89529774|NCT03262207||fertile|
89529775|NCT03262207||infertile|
89529776|NCT04443725|Experimental|Hydroxychloroquine plus Sofosbuvir/Daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days, Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days
89529777|NCT04443725|Active Comparator|Standard of care|Hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days
89529778|NCT04507451|Experimental|Trained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle training. This program will be delivered 5 days a week.~Inspiratory muscle training (IMT): using a threshold IMT device with mouthpiece, 5 sets of 6 breaths, intensity is prescribed at 60% of maximal inspiratory pressure for the first set, and then increased to the highest tolerable intensity to allow completion of the 6th breath Expiratory muscle training (EMT): using a bottle filled with water, starting at 5cm and then increased to 8 cm gradually, 5 sets of 6 breaths~Training program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
89529779|NCT04507451|Placebo Comparator|Untrained group|"Patients will benefit from usual respiratory physiotherapy (secretion clearance treatment and recruitment maneuvers), and muscle exercises that are not planned to train muscles. This program will be delivered 5 days a week.~Inspiratory exercises: fractionated inspiration, 5 sets of 6 breaths Expiratory exercises: using a bottle filled with water (1 cm)~Exercises program starts after mechanical ventilation weaning, as soon as the patient is collaborative, and is continued until 1 month after ICU discharge"
89529780|NCT05074927|Other|Cohort|All patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France)
89529781|NCT04510805|Experimental|Intervention Arm|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
89529782|NCT04510805|No Intervention|Control Arm|Usual standard of care. Clinical experience of the treating physician taking into account the covariates, dosing and INR history of each patient, to determine the initial, and subsequent maintenance doses.
89529783|NCT03265951|Active Comparator|Ramelteon|Ramelteon 8 mg po at bedtime
89529784|NCT03265951|Placebo Comparator|Usual care|education brochure about sleep hygiene
89529785|NCT04507295|Active Comparator|volume controlled group|"15 patients in is this group will be ventilated during capnothorax using volume controlled ventilation with the following parameters:~FIO2 of 60 %.~Tidal Volume (TV) of 6-8 ml/kg.~Respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.~inspiratory to expiratory ratio (I: E) 1:2.~using a minimal Positive End Expiratory Pressure (PEEP) of 2 cm H2O."
89529786|NCT04507295|Active Comparator|pressure controlled group|"15 patients in is this group will be ventilated during capnothorax using pressure controlled ventilation with the following parameters:~FIO2 60 %.~inspiratory pressure adjusted to fulfil the required TV according to the weight of the patient (6-8 ml /kg) then the insufflation pressure will be added to the driving pressure.~respiratory rate of 30 breathes/min then the respiratory rate will be modified to maintain the ETCO2 between 30-35 mm Hg.~I:E ratio of 1:1.5 .~Using a minimal PEEP of 2 cm H2O."
89529787|NCT03265717|Experimental|"Group 1: Untreated high risk watch and wait"|Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
89529788|NCT03265717|Experimental|Group 2: Ibrutinib treated patients|Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
89529789|NCT02456779||Erosive Esophagitis|"Patients diagnosed with GERD with erosive esophagitis present on routine endoscopy during the previous 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
89529790|NCT02456779||non erosive reflux disease|"Patients diagnosed with GERD with erosive esophagitis not present on routine endoscopy during the last 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
89529791|NCT02456779||healthy controls|"No GERD symptoms RDQ = 0 RSI = 0-9~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire intervention: questionnaire"
89529792|NCT04510493|Active Comparator|active treatment arm|Treatment with Canakinumab i.v. administered over 2 hours
89529793|NCT04510493|Placebo Comparator|placebo treatment arm|placebo treatment
89529794|NCT04509869|Experimental|pre-operative and postoperative|the patients who will undergo the operation to treat the pain
89529795|NCT03262363|Experimental|Curcumin/NFE2L2 A>G|Patients in Experimental group 1 and 2 will receive 800 mg/day of curcumin (for which a bioavailability of about 90% has been demonstrated and greater than other curcuminoids, administered in two doses of 400 mg each (the presentation will be in capsules containing 400 mg of THC).
89529796|NCT03262363|Placebo Comparator|Placebo/NFE2L2 A>G|Patients in control group 1 and 2, the placebo intervention will consist of administering sucralose capsules (a substance lacking pharmacological action, with no active principle and a lower intake of glucose compared to sucrose). Patients will receive 300 mg/day of sucralose distributed in two doses of 150 mg each.
89529797|NCT04509713||infected/positive group|asymptomatic or mildly symptomatic participants positive for SARS-CoV-2 RNA
89529798|NCT04509713||uninfected/negative group|no evidence of SARS-CoV-2 by real-time RT-PCR
89529799|NCT02459041||Pancreatic cancer|"Consecutively admitted patients with pancreatic cancer confirmed by EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
89529800|NCT02459041||Benign pancreatic masses|"Consecutively admitted patients with benign pancreatic masses with negative EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
89529801|NCT02459041||Malignant lymph nodes|"Consecutively admitted patients with malignant lymphnodes confirmed by EUS-guided FNA.~EG-EUS will be applied in all patients."
89529802|NCT02459041||Benign lymph nodes|"Consecutively admitted patients with benign lymphnodes with negative EUS-guided FNA.~EG-EUS will be applied in all patients."
89529803|NCT03352973|Experimental|active tDCS on the dlPFC|tDCS on the DLPFC Dorsolateral prefrontal cortex (DLPFC) target will be identified by the baseline functional magnetic resonance imaging (fMRI) study for regulation of craving using a separate sample. During the intervention, each participant will receive an active transcranial direct current stimulation (tDCS) intervention on this DLPFC region (1.5 mA for 20 minutes).
89529804|NCT03352973|Sham Comparator|sham tDCS on the dlPFC|Each participant will also receive a sham tDCS intervention as a controlled condition. The sham tDCS only include a 30-s ramp up and a 30-s ramp down.
89529805|NCT04506827|Active Comparator|Control group|patients in the control group received Demineralized Bovine Bone Mineral for the maxillary sinus augmentation
89529806|NCT04506827|Experimental|Test group 1|patients in the test group 1 received TCP with particle size from 250 to 1000 µm
89529807|NCT04506827|Experimental|Test group 2|patients in the test group 2 received TCP as in test group1 plus crosslinked Hyaluronic Acid
89529808|NCT03262285||phacoemulsification|patients undergoing phacoemulsification surgery for senile cataract
89529809|NCT03262285||extracapsular cataract extraction|patients undergoing extracapsular cataract extraction surgery for senile cataract
89529810|NCT03352895|Placebo Comparator|control|Control group will receive placebo medication therapy
89529811|NCT03352895|Experimental|test group|resveratrol group will receive oral resveratrol (100 mg per day)
89529812|NCT03265483|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
89529813|NCT03265483|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
89529814|NCT03265483|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
89529815|NCT03265483|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
89529816|NCT05074147|Experimental|3 weeks antibiotherapy|Patients are treated 3 weeks with appropriate antibiotics after antibiogram evaluation.
89529817|NCT05074147|Experimental|6 weeks antibiotherapy|Patients are treated 6 weeks with appropriate antibiotics after antibiogram evaluation.
89529818|NCT03350633|Experimental|Tocilizumab|Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
89529819|NCT03350633|Active Comparator|Azathioprine|Imuran
89529820|NCT03265795|Experimental|PEEK patient specific implant|this PEEK (poly ether ether ketone) Patient Specific Implant containing autogenous bone graft is used in reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
89529821|NCT03350555|Experimental|ERCP with additioned endoscopy|This arm will include participants undergoing ERCP with assistance of additioned endoscopy.
89529822|NCT03350555|No Intervention|ERCP without additioned endoscopy|This arm will include participants undergoing ERCP without assistance of additioned endoscopy as negative controls.
89529823|NCT03265561|Experimental|Bone allograft group|This participants will receive bone structural allograft management for vertebral reconstruction. All patients undergo surgical procedure to realize debridement of the lesion, and the application of allograft without autograft.
89529824|NCT03265561|Active Comparator|Bone auto and allograft group|This participants will receive bone structural allograft plus spongy autograft management for vertebral reconstruction. All patients undergo surgical procedure.
89529825|NCT03350477|Active Comparator|Cancer ablation|In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89529826|NCT03350477|Active Comparator|Life information rehabilitation therapy|"In this group,the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89529827|NCT03350477|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
89529828|NCT03350477|No Intervention|Control|In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
89529829|NCT03265639|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
89529830|NCT03265639|Experimental|Intervention|This arm is the 8 week p-inulin treatment phase (8 grams twice daily, oral).
89529831|NCT03265639|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
89531140|NCT05430347|Active Comparator|TCbHP*6|"Pertuzumab combined with docetaxel, carboplatin and trastuzumab for 6 cycles (Every three weeks).~T (Docetaxel 100 mg/m2, d1) C (Carboplatin, AUC 6, D1) H (Trastuzumab, 8 mg/kg for the first dose, 6 mg/kg for the rest, D1) P (Pertuzumab, 840mg for the first dose, 420mg for the rest, D1))"
89529832|NCT04504409|Active Comparator|Exercise group (ExG)|The exercise program consisted of; Codman , wand, stretching and strengthening exercises [25] applied twice a day, 5 times a week and duration of 3 weeks in all groups. All exercises were performed for 10 repetitions and 3 sets. Patients performed exercises with under supervision of physiotherapist in the clinic settings. In ExG, patients received only this exercise protocol for 3-weeks.
89529833|NCT04504409|Experimental|KT application combined with exercise (KTG)|Before KT application, their skin was shaved, cleaned with alcohol, and dried. Prior to application, the patient was seated and asked to flex their neck laterally to the contralateral side and to rotate their head to the same side. KTs (Ares®) tape was used. The first strip was a Y-strip representative of the supraspinatus, which was applied from its insertion to origin with paper off tension. A Y-strip refers to a section of tape that has a portion cut down the middle to produce 2 tails. In KTG, patients wore the KT for a 3-week duration (renewed twice a week periodically in this time).
89529834|NCT04504409|Active Comparator|DN combined with exercise (DNG)|The MTrP dry needling procedure employed was similar to the MTrP injection described by Hong. The MTrP was located by palpating the taut band and identifying the point of maximal tenderness. This was then firmly compressed by the index finger or middle finger of the nondominant hand to direct the placement of the needle tip while inserting the needle. The needle was inserted into the skin at a point above the taut band, approximately 1 cm from the MTrP region. After penetration of the needle into the subcutaneous layer, it was kept there and obliquely (about 45 degrees) directed to the MTrP region under the fingertip of the non-dominant hand. Then, the needle was inserted rapidly into the MTrP region and withdrawn rapidly. In DNG, patients received DN for a 3-week duration (twice a week periodically in this time).
89529835|NCT03262051||Patient with acute inflammation (surgery)|patients undergoing hip surgery
89529836|NCT03262051||Patient with chronic inflammation|patients with rheumatoid arthritis
89529837|NCT03262051||Patient with acute inflammation (SARS-CoV-2 infection)|patients with SARS-CoV-2 infection
89529838|NCT03352817||Patients in cardiac rehabilitation|Eligible patients must have reached the age of majority, participate in a CR program at one of the centers cited, and agreed to respond to the study questionnaire voluntarily
89529839|NCT04506749|Experimental|Experimental group|"Consumption of antioxidant boiled ham, 100 grams daily to consume during the day.~Consumption time: 8 weeks."
89529840|NCT04506749|Placebo Comparator|control group Placebo|Consumption of extra boiled ham, 100 grams daily to consume during the day. Consumption time: 8 weeks.
89529841|NCT02458105|Experimental|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
89529842|NCT02458105|Active Comparator|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
89529843|NCT04506671|Experimental|Cryoablation group|Patients with T1b renal tumor and ECOQ>20
89529844|NCT04506671|Active Comparator|Partial nephrectomy group|Patients with T1b renal tumor
89529845|NCT03352739|Experimental|DBS of the fornix, power on|
89529846|NCT03352739|Experimental|DBS of the NbM, power on|
89529847|NCT03352739|Sham Comparator|DBS of the fornix, power off|
89529848|NCT03352739|Sham Comparator|DBS of the NbM, power off|
89529849|NCT03352739|No Intervention|Control group|The patients are going to prescribe stable dosage of donepezil during observation period without surgical interference.
89529850|NCT03350399||level of placenta growth factor in IUGR|
89529851|NCT03265093|Active Comparator|experimental; Corticosteroid|Intralesional corticosteroid administration
89529852|NCT03265093|Experimental|Experimental; Injectable Platelet rich fibrin|Injectable Platelet rich fibrin
89529853|NCT03122483||OSA|Blood biomarker results in subjects with obstructive sleep apnea.
89529854|NCT03122483||Non-OSA|Blood biomarker results in subjects without obstructive sleep apnea
89529855|NCT03261583||Thoracic Surgery|Observational study. It is only a matter of collecting clinical data.
89529856|NCT03352661||Endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
89529857|NCT03352661||No endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
89529858|NCT03261739|Experimental|RYI- 018|The doses of RYI-018 to be evaluated in sequential cohorts will be 0.6 mg/kg, 1.2 mg/kg, and 2.5 mg/kg.
89529859|NCT03261739|Placebo Comparator|Placebo|vehicle control
89529860|NCT03352583|Active Comparator|Day|Group receives casein protein during the day (greater than 6 hours before bed).
89529861|NCT03352583|Experimental|Night|Group receives casein protein immediately before going to bed.
89529862|NCT02456623|Experimental|Intervention|Behavioral intervention that targets the parent of a preschool age child who is overweight. The intervention is 8 sessions in length. Each session is expected to last 1-1.5 hours and will be carried out in the participant's home over 4 months. The sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to these factors. Intervention content for the parent will be based on Motivational Interviewing principles.
89529863|NCT02456623|Active Comparator|Attention Control|The attention control condition includes 1 initial Motivational Interviewing (MI) session conducted in the home. The content of the MI session will be the same as for the intervention participants. Following this session, parents will receive bi-monthly newsletters that will include content similar to what intervention participants receive. AC participants will receive a total of 7 newsletters; 2 on nutrition, 2 on physical activity, 2 on parenting behavior and 1 on community resources. AC participants will also receive a monthly 20-min phone call designed to review newsletter content and answer parent questions.
89529864|NCT03350321|Experimental|Molidustat (BAY85-3934)|Molidustat group
89529865|NCT03350321|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
89529866|NCT04956679||Family members in the study|Community groups that meet the inclusion criteria
89529867|NCT03352505||control|healthy walking control participants
89529868|NCT03352505||wheelchair dancer|wheelchair users, who are performing wheelchair dancing
89529869|NCT03352505||wheelchair marathon participants|wheelchair users, who are participants in wheelchair/ handbike Marathon competitions
89529870|NCT03352505||sedentary wheelchair patients|wheelchair users, who conduct exercise bouts less than 2 times per month
89529871|NCT03261895|Experimental|Intervention group|Nurse-led Integrative health and wellness programme
89529872|NCT03261895|No Intervention|control group|usual diabetes care
89529873|NCT03350165|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
89529874|NCT03350165|Placebo Comparator|Control Group|placebo tablet twice daily.
89529875|NCT03352349|Experimental|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
89529876|NCT04933669|Experimental|Imatinib neoadjuvant|Patients receive oral imatinib mesylate 400mg once daily for 3-12 months in the absence of disease progression or unacceptable toxicity. Within 1 week after completion of preoperative imatinib mesylate, patients with responding or stable disease undergo surgical resection. After complete resection, patients receive oral imatinib mesylate 400mg once daily for 36 months in the absence of disease progression or unacceptable toxicity, and are followed for 5 years.
89529877|NCT03352271|Experimental|Individualized Incremental hemodialysis|ESRD patients starting an individualized (twice/week, once/week, once/10 days or less frequent) incremental hemodialysis program.
89529878|NCT03352271|Active Comparator|Thrice weekly dialysis|ESRD patients initiating a conventional thrice weekly hemodialysis program
89529879|NCT03350087|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
89529880|NCT03350087|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
89529881|NCT03350087|Experimental|iTBS+cTBS group|Continuous theta burst stimulation (cTBS group) at first followed by intermittent theta burst stimulation (iTBS group).
89529882|NCT03350087|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
89529883|NCT03350087|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
89529884|NCT03350087|Experimental|VCT+optimal rTMS group|VCT+optimal rTMS group received the VCT training and optimal rTMS in addition to traditional rehabilitation.
89529885|NCT04669561|Experimental|Single /arm|All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
89529886|NCT03259399||wild genotype|Detection of genotype will be carried out through next generation sequencing, distinguish wild genotype of enalapril
89529887|NCT03259399||mutant genotype|Detection of genotype will be carried out through next generation sequencing, distinguish mutant genotype of enalapril
89529888|NCT02729909|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
89529889|NCT02729909|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
89529890|NCT04615117||Study Group|Patients treated with Superior Capsular Reconstruction with Allomend
89529891|NCT03350009||High and low grade embryos|The distribution for the high and low grade embryos is based on common morphological grading criteria.
89529892|NCT03350009||High and low quality follicles|The distribution for the high and low grade oocytes is based on common morphological grading criteria and on different features of the participants such as age.
89529893|NCT03352193||SOTI group|Wheat spaghetti
89529894|NCT03352193||Historical control group|No intervention
89529895|NCT03252769|Other|Self-sampling|Invitation to self-sample
89529896|NCT03352115|Experimental|Steroid group|Will recieve 5 day course of oral prednisolone post-operatively
89529897|NCT03352115|Placebo Comparator|Control|Will receive placebo syrup for 5 days post-operatively
89529898|NCT02456077|Experimental|Intervention Practices|Intervention offices will adopt a multi-modal vaccine program to increase their patients' vaccine rates.
89529899|NCT02456077|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
89529900|NCT03349931||Hematological patients|Hematological patients at high risk for invasive aspergillosis
89529901|NCT03252457|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take decitabine in combination with dexamethasone at the indicated dose
89529902|NCT03252457|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose
89529903|NCT03259009||Patients with metastatic colorectal cancer|Rechallenge with an anti-EGFR monoclonal antibody in patients with metastatic colorectal cancer
89529904|NCT03258931|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
89529905|NCT03258931|Active Comparator|Midostaurin|Midostaurin following salvage chemotherapy
89529906|NCT04506281|Experimental|Neoadjuvant treatment|"Gemox chemotherapy:~Day1 Oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day 8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 3 courses.~Lenvatinib (8mg/d) for 9 weeks of continuous use.~Toripalimab (240mg, once every 3 weeks), used 3 times. Evaluate the resectability of the operation within 2-4 weeks after the end of the neoadjuvant treatment course, and implement radical resection. All patients after resection use capecitabine 2500mg/m2 twice a day for 2 weeks, stopping for 1 week as a course of treatment, totaling 8 courses"
89529907|NCT04506281|No Intervention|Traditional group|No anti-tumor drug treatment before surgery. All patients undergoing resection use capecitabine 2500mg/m2 twice a day, stopping for 1 week as a course of treatment, totaling 8 courses.
89529908|NCT03261349|Experimental|Anti-HCV (Ledipasvir and sofosbuvir)|Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
89529909|NCT04488211||Prospective survey respondents|Invitations to participate in the survey will be emailed on three occasions to selected fertility specialists worldwide who are affiliated to a public or private fertility clinic.
89529910|NCT02455609|Active Comparator|dexmedetomidine (I)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume.
89529911|NCT02455609|Active Comparator|ketamine (II)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume.
89529912|NCT02455609|Active Comparator|Dexmedetomidine + Ketamine group (III)|intrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume.
89529913|NCT04504019|Experimental|USCTR Procedure|Participants will undergo the USCTR procedure with SX-One MicroKnife®
89529914|NCT04504019|Active Comparator|mOCTR Procedure|Participants will undergo the traditional mOCTR procedure.
89529915|NCT03352037|Other|Single Arm|In this project, there is only one study group which comprises of patients with pancreatic cystic neoplasms who will undergo pancreatic PET/MRI.
89529916|NCT03349697|Experimental|Active Product then Placebo|
89529917|NCT03349697|Experimental|Placebo then Active Product|
89529918|NCT05723627|Experimental|Remimazolam|Patient group who receives remimazolam for sedation during endoscopy
89529919|NCT05723627|Active Comparator|Propofol|Patient group who receives propofol for sedation during endoscopy
89529920|NCT02713243|Experimental|LJN452 followed by placebo|Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
89529921|NCT02713243|Experimental|Placebo followed by LJN452|Randomized patients in this arm will receive single oral dose of placebo daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of LJN452 daily for 14 days.
89529922|NCT03349619|Experimental|Resveratrol plus Carboxymethyl-β-Glucan|
89529923|NCT03349619|Placebo Comparator|Placebo|
89529924|NCT04505657|Experimental|Celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
89529925|NCT04505657|Active Comparator|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
89529926|NCT04505657|Active Comparator|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
89529927|NCT03259243|Placebo Comparator|placebo group|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
89529928|NCT03259243|Experimental|Preincision Bupivacaine|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
89529929|NCT03259243|Experimental|Preclosure bupivacaine|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
89529930|NCT03259243|Experimental|Bupivacaine group|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
89529931|NCT03351959||ypT0 rectal cancers|Rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection and had a final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (pathologic complete response, pCR - ypT0).
89529932|NCT03349541|Experimental|Complex Care Curriculum Intervention|Paediatric residents who are randomized to the intervention group will participate in the complex care curriculum during an academic half-day prior to the Objective Structured Clinical Examination (OSCE).
89529933|NCT03349541|No Intervention|No intervention|Paediatric residents who are randomized to the control group will attend the regular academic half-day unrelated to complex care prior to the Objective Structured Clinical Examination (OSCE).
89529934|NCT03258775|Active Comparator|250ml|
89529935|NCT03258775|Active Comparator|500ml|
89529936|NCT03258697|No Intervention|Patient-Controlled Analgesia|Patient had no local analgesic agent during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
89529937|NCT03258697|Active Comparator|Peri-articular LevoBupivacaine|Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
89529938|NCT03258697|Experimental|Intra-articular LevoBupivacaine|Patient had intra-articular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
89529939|NCT03530891|Experimental|Computer guided lag screw fixation|Patient specific surgical guided will be used for open reduction and internal fixation for anterior mandibular fracture by lag screws.
89529940|NCT03530891|Active Comparator|Conventional lag screw fixation|Open reduction and internal fixation for anterior mandibular fracture using lag screws.
89529941|NCT02456155|Experimental|ultrasound group|using B ultrasound as a instruction technique to place Nasal Jejunal Tube
89529942|NCT02456155|Placebo Comparator|endoscope group|Conventional methods for placing Nasal Jejunal Tube
89529943|NCT03349463|Experimental|18F-Fluciclovine|
89529944|NCT02456467||Cardiac Surgery Patients|Intervention: Procedure: Blood specimen collection
89529945|NCT03530813|Active Comparator|Face-To-Face Group|Asthma First Aid Management in Schools 3 Hour Face to Face Training Group, selected a training session to attend in their local area.
89529946|NCT03530813|Experimental|Ebook Group|Asthma Management in Schools eBook training group were sent a cloudStor link to download and complete training
89529947|NCT02455297|Experimental|Copanlisib|Copanlisib (BAY80-6946) solution for IV infusion
89529948|NCT03351881|Active Comparator|Opt Out|
89529949|NCT03351881|Active Comparator|Opt In|
89529950|NCT03351881|Active Comparator|Opt Neutral|
89529951|NCT02456701|Experimental|Combination of Vemurafenib and KTN3379|Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks
89529952|NCT03252379|Experimental|Group A|Patients undergoing modified hepaticojejunostomy with gastric access loop
89529953|NCT03252379|Experimental|Group B:|Patients undergoing modified hepaticojejunostomy with subcutaneous access loop
89529954|NCT03252379|Experimental|Group C:|Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop
89529955|NCT03122795|Experimental|Microbiome transplant|The only arm of the study. Patients suffering from CRSsNP gets microbiome transplants from donors without any sinonasal health problems.
89529956|NCT03349307|Experimental|No Intervention|
89529957|NCT03258229|Experimental|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
89529958|NCT03258229|Placebo Comparator|Placebo|Placebo for 8 weeks
89529959|NCT02456545||help-seekers at-risk|"persons consulting collaborating Early Recognition Centers presenting with hints for ≥ 1 potential risk factor for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse, ADHD)~anticipated n = 500"
89529960|NCT02456545||patients with depressive syndrome|"in- and outpatients with depressive syndrome (SCID)~anticipated n = 500"
89529961|NCT02456545||patients with ADHD|"in- and outpatients with Attention-Deficit/Hyperactivity-Disorder (ADHD)~anticipated n = 150"
89529962|NCT02456545||representative population cohort|"representative population cohort from the IMAGEN study~anticipated n = 500"
89529963|NCT03252067|Experimental|azithromycin eyedrop|Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.
89529964|NCT04505033|Experimental|50 mg s.c|
89529965|NCT04505033|Placebo Comparator|50 mg placebo|
89529966|NCT04505033|Experimental|150 mg s.c.|
89529967|NCT04505033|Placebo Comparator|150 mg placebo|
89529968|NCT04505033|Experimental|300 mg s.c.|
89529969|NCT04505033|Placebo Comparator|300 mg placebo|
89529970|NCT04505033|Experimental|450 mg s.c.|
89529971|NCT04505033|Placebo Comparator|450 mg placebo|
89529972|NCT03258307|Active Comparator|omentectomy|Preoperative
89529973|NCT03258307|Other|Omentectomy|Postoperative
89529974|NCT03258307|Other|No omentectomy|Preoperative post operative
89529975|NCT05550545||Parents/caregivers of RSV-infected infants|
89529976|NCT03258073|Experimental|Medical simulation using scenarion execution|Study participants will be exposed to medical simulation using scenario execution. In this exercise, participants will be exposed to a scenario that simulates a medical emergency. They will be required to respond. Following their response, the participants will have a chance to share with the investigators their experiences and what they have learnt from the exposure in a debriefing session. The investigator will then provide feedback on their performance.
89529977|NCT03252223|Active Comparator|Women with normal menses|
89529978|NCT03252223|Active Comparator|Women with Polycystic Ovary Syndrome|
89529979|NCT05513807|Experimental|Nicotinamide|
89529980|NCT05513807|Placebo Comparator|Placebo|
89529981|NCT03251833||obese|Body mass index >30 Kilogram/m2
89529982|NCT03251833||non-obese|Body mass index <30 Kilogram/m2
89529983|NCT02518217|Active Comparator|Apps Only|
89529984|NCT02518217|Experimental|ShapeUp Empower|
89529985|NCT02518217|Experimental|ShapeUp Empower + Incentives|
89529986|NCT03258151||wild genotype|Through next generation sequencing, distinguish wild genotype of docetaxel
89529987|NCT03258151||mutant genotype|Through next generation sequencing, distinguish mutant genotype of docetaxel
89529988|NCT03349151|Active Comparator|Early feeding|This group will be served soft meal diet served on postoperative 2nd hour on return to the ward.
89529989|NCT03349151|Placebo Comparator|On- demand feeding|This group will be served soft meal diet served whenever they wanted to eat on return to the ward.
89529990|NCT03813433|Experimental|Enosequence|3-4 mm of Endosequence will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
89529991|NCT03813433|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of Mineral Trioxide Aggregate will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
89529992|NCT03251677|Active Comparator|Total laparo hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by laparoscopy)
89529993|NCT03251677|Active Comparator|Mini-lap hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by mini-laparotomy)
89529994|NCT03791749|Experimental|Breastfeeding Support|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. Mothers will be asked to perform a simple technique while breastfeeding at least once a day.
89529995|NCT03791749|No Intervention|Standard Care|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. No intervention will be administered.
89529996|NCT03351725||Peripheral venous catheter indwell time more than 48 hours|
89529997|NCT03261661|Experimental|Reading Plus Mindset|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency. Participants also complete mindset training and activities.
89529998|NCT03261661|Experimental|Reading Embedded with Mindset|Multicomponent reading intervention (providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency) with mindset instruction specific to reading progress embedded in the intervention Participants also complete mindset training and activities.
89529999|NCT03261661|Active Comparator|Reading|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency.
89530000|NCT03261661|Active Comparator|Business as Usual|Participation in the typical reading instruction and intervention provided within participating schools.
89530001|NCT04504877|Experimental|cannabidiol plus general clinical supportive measures|The participants will receive CBD 300mg/daily plus general measures (supporting motivational videos, fitness videos). All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern, as well as five collections of saliva, in a collecting tube, to assess viral load. They will also be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
89531141|NCT03095469|Experimental|study group|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24 h after PCI.
89530002|NCT04504877|Other|general clinical supportive measures|The participants will receive general measures (supporting motivational videos, fitness videos) alone. All the participants will perform invasive and non-invasive procedures with the nursing team, the invasive being five blood collections, in their workplaces, to evaluate laboratory parameters, detailed in this project. The non-invasive ones refer to the measurement of height, weight, body temperature, and sleep pattern in a collecting tube to assess viral load. Also, they will be monitored through weekly self-assessment scales, applied remotely, electronically (cell phones or computers), with an estimated duration of ten minutes each, which will have their responses recorded in an electronic database by the study coordination team.
89530003|NCT03251755|Experimental|Exercise|Exercise promotion using Dao-in (Chinese Yoga)
89530004|NCT03251755|No Intervention|Control|Usually clinical practice
89530005|NCT02518295|Active Comparator|Positive control|Ultra high temperature (UHT) milk containing 18 g total lactose
89530006|NCT02518295|Active Comparator|Positive control with S. thermophilus|UHT milk containing 18 g total lactose+ S. thermophilus
89530007|NCT02518295|Active Comparator|Positive control with B. longum|UHT milk containing 18 g total lactose+ B. longum
89530008|NCT02518295|Placebo Comparator|Negative control|Lactose free milk
89530009|NCT03261271|Experimental|Weight Loss and Weight Maintenance|Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
89530010|NCT03261271|Active Comparator|Control|Participants will receive a standardized educational flyer about a healthy diet and exercise.
89530011|NCT03260959||Father|Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)
89530012|NCT03257683||Selected group with cardiac ischemia|This selected study group will have a specific echocardiographic imaging protocol performed, which includes the known ischemic regions. All segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE software to derive strain values. Following eight (8) weeks of ranolazine therapy, each subject will be re-interrogated with the same echocardiographic imaging protocol and have identical measurements of regional strain performed. Ranolazine will be added to the patients' usual medical therapy. Each patient will serve as their own control, from baseline to post therapeutic state.
89530013|NCT03251521||spasticity post-stroke|pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale
89530014|NCT03351569|Experimental|Immunoglobulin|Intravenous immunoglobulin 25 grams (five 100 ml bottles, 5g/100ml), in 3 hours, once a month for one year.
89530015|NCT03351569|Placebo Comparator|Saline solution|Intravenous saline solution 500 ml (five 100 ml bottles), in 3 hours, once a month for one year.
89530016|NCT03257839||Asymptomatic women with dense breast tissue|Healthy women presenting to enrollment sites for routine annual mammographic examinations, confirmed to have BI-RADS category c or d breast composition (density).
89530017|NCT03348917|Active Comparator|Treatment sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)"
89530018|NCT03348917|Active Comparator|Treatment sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)"
89530019|NCT03348917|Active Comparator|Treatment sequence Group 3|"Treatment Sequence Group 3 = C -> A ->B~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)"
89530020|NCT05462249||Vaccinated|Patients who have been vaccinated against HPV virus.
89530021|NCT05462249||Not vaccinated|Patients who have not been vaccinated against HPV virus.
89530022|NCT03260803|Experimental|postmenopausal osteopenic women receiveing Oligopin|postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
89530023|NCT03260803|Placebo Comparator|postmenopausal osteopenic women receiving placebo|postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
89530024|NCT03257605||Study group|Participants enrolled in PACE who underwent pharmacogenomics testing as part of their medical care and also consented to the use of their de-identified data for research purposes.
89530025|NCT03348839|Experimental|Cluster 1|NeLLY service is implemented after 8 months.
89530026|NCT03348839|Experimental|Cluster 2|NeLLY service is implemented after 12 months.
89530027|NCT03348839|Experimental|Cluster 3|NeLLY service is implemented after 16 months.
89530028|NCT03348839|Experimental|Cluster 4|NeLLY service is implemented after 20 months.
89530029|NCT03348839|Experimental|Cluster 5|NeLLY service is implemented after 24 months.
89530030|NCT03348839|Experimental|Cluster 6|NeLLY service is implemented after 28 months.
89530031|NCT03348839|Experimental|Cluster 7|NeLLY service is implemented after 32 months.
89530032|NCT03251365|No Intervention|Group I, Normal|Group I. After cytoreductive surgery, R0, and intestinal reconstruction, the patient after multidisciplinary study will receive adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
89530033|NCT03251365|Experimental|Group II,experimental.HIPEC-Gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
89530034|NCT03257527|Experimental|ENHANCE group|The ENHANCE group is comprised of 12 weekly session to be completed in-person and delivered by trained group facilitators.
89530035|NCT03257527|Active Comparator|MBSR group|"The MBSR group will complete a self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook over a 12 week period."
89530036|NCT03251443|Experimental|Apatinib|A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
89530037|NCT03348605|Other|First setting ON|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality ON. The second time the gait analysis is performed in the OFF modality.
89531142|NCT03095469|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h when the operation begin and stopped until 24 h after PCI.
89530038|NCT03348605|Other|First setting OFF|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality OFF. The second time the gait analysis is performed in the ON modality.
89530039|NCT03251287|Active Comparator|Sodium Nitrate|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
89530040|NCT03251287|Placebo Comparator|Placebo|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
89530041|NCT04502303|Experimental|Crohn's disease: patients with intestinal stricture|Patients with intestinal strictures confirmed by other modalities, e.g. CT, MR, ultrasound, and endoscopy, will be recruited in the study.
89530042|NCT05350943|Experimental|HAIC+Toripalimab+Donafenib|HAIC(GEMOX)+Toripalimab+Donafenib
89530043|NCT03351413|Experimental|Intervention|"LIVE-LiFE to Prevent Falls Among Older Fallers Intervention, which is an individually tailored program at the participant's home spaced across 12 weeks including:~Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~Medication review and feedback concerning medications with increased fall risk"
89530044|NCT03351413|No Intervention|Control|- An individualized fall risk assessment provided to participant and their primary care provider
89530045|NCT03251053|Experimental|Electronic cigarette use|Subjects who try to switch to electronic cigarettes (EC) and subjects who successfully switch to EC.
89530046|NCT03251053|Other|Control regular cigarette smokers|Habitual smokers without EC use
89530047|NCT04503785||Dysphagia|Patients with Esophageal dysphagia
89530048|NCT03261427|Experimental|YNP-1807 Tablet(Pregabalin 330mg)|YNP-1807(Pregabalin 330mg), QD
89530049|NCT03261427|Active Comparator|Lyrica Capsule(Pregabalin 150mg)|Lyrica Capsule(Pregabalin 150mg), BID
89530050|NCT05329571|Experimental|Low-FODMAP Diet|Participants will be instructed to maintain their usual diet, while eliminating FODMAPs (A subgroup of carbohydrates are considered fermentable, given the lack of suitable hydrolase enzymes in the colon, required for their digestion and absorption, thus making them available for fermentation).
89530051|NCT05329571|Experimental|Gluten-Free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
89530052|NCT05329571|Other|Control|Patients of this group will be asked to adhere to their regular, daily diet.
89530053|NCT03261115|No Intervention|Control group|Topical Anesthesia
89530054|NCT03261115|Experimental|Study group|No topical anesthesia
89530055|NCT03348527|Experimental|Stage I: Dose = 35% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 35 % of their prostate volume.
89530056|NCT03348527|Experimental|Stage I: Dose = 45% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 45 % of their prostate volume.
89530057|NCT03348527|Experimental|Stage II: Dose = 16mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 16mL
89530058|NCT03348527|Experimental|Stage II: Dose = 20mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 20mL
89530059|NCT03251131|Experimental|Restrictive fluid management|Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
89530060|NCT03251131|No Intervention|Standard therapy|Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.
89530061|NCT05320133|Experimental|JWC group|Jinghua Weikang Capsule containing quadruple therapy.
89530062|NCT05320133|Active Comparator|Control group|Bismuth-containing quadruple therapy.
88812283|NCT05812183|Experimental|Bariatric surgery|Gastric sleeve resection will be performed by experienced surgeons. Postoperative care will follow UCLA's postoperative care pathways for gastric sleeve resection.
89530063|NCT03257293|Active Comparator|Routine Cystoscopy|
89530064|NCT03257293|Experimental|Modified Cystoscopy|
89530065|NCT03347045|Experimental|Trimodal Prehab & ERP|"Trimodal prehab includes:~Guided exercise program at Repsol Place in Calgary, Alberta 2x/week, hosted by the Total Cardiology group. Home-exercise program for another 3x/week.~Nutritional optimization with a high-protein oral supplement, along with nutritional counseling and access to a Registered Dietitian on site.~Anxiety reduction workshop and take-home anxiety reduction program."
89530066|NCT03347045|Active Comparator|No Prehab; ERP Alone|The active comparator group will be given a home exercise program, nutrition education, and a take-home anxiety reduction program.
89530067|NCT03122561|Other|Paracetamol 500 mg tablet at Morning|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning
89530068|NCT03122561|Other|Paracetamol 500 mg tablet at Midday|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday
89530069|NCT03122561|Other|Paracetamol 500 mg tablet at Night|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night
89530070|NCT03260335|Experimental|Biofeedback intervention|Biofeedback prompt in text or graphic form to implement proactive anxiety management strategy, as per standard care plan
89530071|NCT03351179||AMI patients with HFpEF|
89530072|NCT03351179||AMI patients without HF|
89530073|NCT02454829||Adults, gonadotoxic treatment|Women 18 years of age or older who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
89530074|NCT02454829||Girls, gonadotoxic treatment|Girls under 18 years of age who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
89530075|NCT02454829||Adults, ovarian pathology|Women 18 years of age or older who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
89530076|NCT02454829||Girls, ovarian pathology|Girls under 18 years of age who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
89530077|NCT02454829||Adults, genetic disorders|Women 18 years of age or older who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
89530078|NCT02454829||Girls, genetic disorders|Girls under 18 years of age who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
88813134|NCT03836924||Perampanel|Participants receiving perampanel tablets, orally according to prescribing information and the treating physician's clinical judgment will be observed prospectively for up to 6 months or participant withdrawal, whichever occurs first.
88813135|NCT03837002|Experimental|foot care protocol|foot examination at the first interview, foot care and training once a month and weekly follow-up for 3 months, foot examination at the last interview (six month)
88813136|NCT03837002|No Intervention|Control|foot examination at the first interview, foot examination at the last interview (six month)
88814574|NCT02449044|Experimental|Tolvaptan|Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
89530079|NCT04503629|Experimental|Anaprazole Sodium 20mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
89530080|NCT04503629|Experimental|Anaprazole Sodium 40mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
89530081|NCT04503629|Active Comparator|Rabeprazole sodium 10mg QD|administered orally once every 30-60 minutes before breakfast for 4 weeks
89530082|NCT03257059|Experimental|Breakfast|Subject given standardized breakfast (glutinous rice) to test blood glucose response
89530083|NCT03257059|Experimental|No breakfast|Subject not given breakfast to test blood glucose response
89530084|NCT03256903|Experimental|Methoxyflurane|Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
89530085|NCT03256903|Active Comparator|Standard of Care (SoC)|Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.
89530086|NCT03260725|Experimental|Internet-delivered treatment|This treatment arm entails Internet-Delivered PCIT (I-PCIT) remotely delivered in real time using videoconferencing. Families stream live parent-child interactions from their own home to a remote therapist who provides live bug-in-the-ear parent coaching via a parent-worn Bluetooth earpiece.
89530087|NCT03260725|Active Comparator|Clinic-delivered treatment|This treatment arm entails Parent-Child Interaction Therapy (PCIT) delivered in the clinic. For much of the treatment, the therapist observes family interactions from behind a 1-way mirror and provides live bug-in-the-ear parent coaching via a parent-worn earpiece.
89530088|NCT03260413||Pneumonia cases|Children between the ages of 1 month through 5 years of age who are admitted to Chenla Children's Healthcare between opening of the hospital (mid-2017) and early February 2018 for pneumonia and respiratory distress.
89530089|NCT03256747|Experimental|NMES group|NMES will be placed at the knee extensors, with maximal intensity tolerance evaluated by to induce visible contractions.
88810949|NCT04989309|Experimental|Experiment 2. Phonetic precision disrupted by TMS|"Experiment 2 tests the influence of temporary disruption of activity within the left or right temporal cortex on the speed and precision of phonetic decisions compared to vertex stimulation. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Immediately following stimulation pulses, participants will perform a visual analog scale (VAS) phonetic rating task on tokens from the four continua, embedded in speech-shaped noise. To control for the possibility that TMS leads to a generalized deficit in categorization, a control task will involve categorization of visual objects on a morphed dog to cat object continuum. (We expect this task to be unaffected by TMS). The variables of interest are the steepness of the categorization curve, mean reaction time to all items on the continuum, and the difference in reaction time for boundary vs. endpoint tokens."
88810950|NCT04989309|Experimental|Experiment 3. Phonetic ambiguity in continuous speech|"Experiment 3 is designed to test whether left vs. right temporal lobe stimulation selectively disrupts processing of naturally-occurring phonetic ambiguity as compared to vertex stimulation (control). Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). Stimuli will be nonsense sentences produced clearly or in a casual register. By-sentence phonetic ambiguity is estimated by the proximity of each token to other vowels belonging to different categories. Sentences will be embedded in speech-shaped noise to increase difficulty. Participants will listen to each sentence, then respond whether a visually-presented probe word appeared in the sentence (BRASS?). Dependent variables are accuracy and reaction time on this probe verification task."
88810951|NCT04989309|Experimental|Experiment 6: Disruption of talker-specific phonetic learning using TMS.|"Experiment 6 is designed to test whether disruption of activity in left or right temporal regions (vs. vertex control) using TMS interferes with talker-specific learning. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). The study uses a training paradigm where one talker's speech is manipulated to always have relatively short voice onset times (VOTs) for voiceless stops (e.g., /k/ in coal) and another to have relatively long VOTs. Immediately after stimulation, listeners will undergo a training trial where they identify sounds as mapping to Talker 1 or Talker 2's voice, and to the word (e.g. gain vs. cane). At test, listeners hear two VOT variants and are asked which is more typical of that talker's speech. The dependent variable is the accuracy of reporting which variant is typical of the talker."
88810952|NCT04952220||native septic arthritis of the knee|"Describe the ultrasound abnormalities observed at D0, D10 or before surgery, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee:~thickness and vascularity of the synovial membrane, existence and measurement of joint effusion existence of articular partitioning, erosions and adjacent soft tissue involvement (muscle abscess, cellulitis)"
88810953|NCT04948619|Other|Arm A - Single booster vaccines|Those subjects randomized to Arm A, single dose vaccine boosters, will receive non live vaccine boosters at the 3 and 12 month visits. Boosters for live vaccines will be given at the 6 month visit. Boosters will only be given as applicable for low titers tested at the baseline assessment visit. Subjects who have negative/undetectable titers to any vaccine at the 24 month visit will receive boosters to each applicable vaccine.
88810954|NCT04948619|Other|Arm B - Staged revaccination series|Those subjects randomized to Arm B, the full revaccination series, will receive applicable vaccines when titers are low (below normal range) at baseline. When indicated, non-live vaccines will be given at the 3, 6, 9, and 12 month visits, live vaccines will be given at the 6 and 9 month visit. Subjects who have negative/undetectable titers to any vaccine at the 24 month visit will receive boosters to each applicable vaccine.
88810955|NCT04941183|Experimental|NTR-441|Single Ascending Dose; Multiple Ascending Dose.
88810956|NCT04941183|Placebo Comparator|Placebo|Single Ascending Dose; Multiple Ascending Dose.
88810957|NCT04940624|Experimental|Soticlestat|Participants weighing <45kg: Soticlestat, mini-tablets, at the dose of 40mg to 200mg, orally or via gastrostomy tube (G-tube) or low-profile gastric tube (MIC-KEY button) or jejunostomy tube (J-tube), twice daily (BID) based on the body weight up to 4 weeks in Titration Period. Participants will continue to receive dose that they are on at the end of Titration Period, for 12 weeks in Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). The dose will be tapered down if participants decide to discontinue the treatment. Participants weighing ≥45kg: Soticlestat mini-tablets or tablets with a starting dose of 100mg BID followed by 200 mg BID and, then 300mg BID, up to 4 weeks in Titration Period. Participants will continue to receive 300mg BID for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). The dose will be tapered down if participants decide to discontinue the treatment.
88810958|NCT04940624|Placebo Comparator|Placebo|Soticlestat placebo-matching mini-tablets or tablets, orally or via G-tube or MIC-KEY button or J-tube, BID, up to 4 weeks in the Titration Period. Participants will continue to receive the soticlestat placebo-matching mini-tablets or tablets for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks. Soticlestat matching tapering will be done to maintain the blind if participants decide to discontinue the treatment.
88810959|NCT04938141||Acalabrutinib|CLL patients initiating acalabrutinib alone or in combination with an anti-CD20 mAb
88810960|NCT04938141||Ibrutinib|CLL patients receiving ibrutinib alone or in combination with an anti-CD20 mAb
88810961|NCT04930198|Other|Social Incentive|"For the social incentive, the mHealth application will track the participant's individual adherence score (% of doses taken), track the top scorers (leaderboard), and provide a figure highlighting the proportion of their peers with poor (<80%), medium (80-94%), or high (>94%) adherence scores. The display of the individual's adherence score relative to peer scores is considered a descriptive norm and is meant to portray what most people are doing, as young people often inaccurately estimate behaviors for their peer groups. Participants will also receive an injunctive norm, or an indication of what they ought to be doing. This will come in the form of an emoji or congratulatory vs. motivating text for those with high or low adherence scores, respectively. When coupled with descriptive norms, injunctive norms have counteracted regression to the mean for individuals who demonstrate desirable behaviors relative to their peers."
88814624|NCT04355000|Active Comparator|RMGIC restoration|In RMGIC(Vitremer) filling, carious lesion will be completely removed from primary molars using air rotor and local anaesthesia according to need and filled with vitremer rmgic material.
88811614|NCT03008681|Experimental|Andresen functional removable orthodontic appliance|"All the enrolled patients was applied the Andresen Activator (a removable orthodontic appliance) 12-14 hours in a day in total.~Functional appliances helped the movement of the teeth, with the achievement of good facial muscle function. All patients in the cohort were treated with the andresen actovator appliancev for deep bite and class II malocclusion correction.~The appliances were individually manufactured of acrylic resin, with a central screw and a vestibular arch, fabricated through a wax bite registration; the patient was guided to close the mouth in mandibular protrusion with coincidence of the upper and lower midlines. The registration bite was very thin in order to obtain a minimum vertical dimension. The activator was modified every three months increasing its posterior vertical dimension in order to stimulate the mandibular ramus growth thanks to the dislocation of the mandibular condyle."
88811615|NCT01472549|Active Comparator|Iodine-alcohol|8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)
88811616|NCT01472549|Experimental|Chlorhexidine-alcohol|2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)
88811617|NCT00852644|Experimental|56 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
88811618|NCT00852644|Experimental|62 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
88811619|NCT00852644|Experimental|68 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
88811620|NCT00852644|Experimental|56 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
88811621|NCT00852644|Experimental|62 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
88811622|NCT00852644|Experimental|68 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
88811623|NCT01404923|Experimental|meteospasmyl|
88811624|NCT01404923|Active Comparator|standard of care|
88811625|NCT00854594|No Intervention|Control|Control sites will receive the baseline measures pre and post. These sites will receive traditional diabetes education, which includes teleconsultation.
88811626|NCT00854594|Experimental|ReSPECT Intervention|Intervention sites will receive baseline measures pre and post, but also in-depth Shared Medical Appointments (SMA)(The Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT) intervention) and at 15 months SMA video conferences. At the end of the 18 months the randomly selected patients and providers will be asked to take part in a qualitative interview.
88811627|NCT01368263|Experimental|Group 1 (Ki67 <10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Neoadjuvant treatment repeats every 28 days for a total of 16-18 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Recommendations for postsurgical treatment will be based on PEPI score and physician discretion.
88811628|NCT01368263|Experimental|Group 2 (Ki67 >= 10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant chemotherapy in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
88811629|NCT01368263|Experimental|Group 3 (E2 > 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant therapy at the discretion of the physician. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
88811630|NCT03032276|Experimental|Intervention|"'Safe motherhood and newborn health promotion package' will be implemented in the intervention arm which comprise 15 randomly selected unions (lowest level of administrative unit)."
88811631|NCT03032276|No Intervention|Comparison|Another 15 union will be selected where no intervention will be implemented
88811632|NCT01405313|Experimental|Modified ASV|Modified ASV Enhanced ASV algorithm which includes auto-adjusting expiratory pressure.
88811633|NCT01405313|Active Comparator|Conventional ASV|Conventional ASV This is the current (predicate) ASV algorithm.
88811634|NCT00814970|Experimental|Complete SE Vascular Stent System|COMPLETE SE Vascular Stent System - implantation of study device in native SFA and/or PPA for subjects with symptomatic ischemic peripheral arterial disease in the superficial femoral artery or proximal popliteal arteries with an occlusion or lesion greater or equal to 50 percent with lesions located above the knee and amenable to percutaneous treatment with angioplasty and vascular stent implantation.
88811635|NCT00815360|Experimental|Treatment group|"single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)~peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography"
88811636|NCT00815360|Active Comparator|Control Group|"single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)~macular laser per treatment criteria"
88811637|NCT00855842|Experimental|osmotic dilator|osmotic dilator
88811638|NCT00856232|No Intervention|Standard therapy|Standard emergency department evaluation and treatment for headache
88811725|NCT01491113|Experimental|Group E: End-stage renal disease|"Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3.~The 4-h Hemodialysis are scheduled as follows:~Dialysis: 44 h to 48 h after the first dose (Day 3)~Dialysis: 92 h to 96 h after the first dose (Day 5)~Dialysis: 140 h after the first dose (Day 7)~Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44*, 44.25*, 44.5*, 45*, 46*, 47*, 48*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing.~49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis.~*Inflow blood, outflow blood, and dialysate fluid will be collected."
88811726|NCT00816062|Experimental|Treatment|Patients diagnosed with an abdominal aortic or aorto-iliac aneurysm that are considered candidates for endovascular repair, per the FDA approved IFU.
88811727|NCT01415453|Experimental|Retinitis Pigmentosa|Subject will have retinitis pigmentosa and will be legally blind in one or both eyes
88811728|NCT03839498|Experimental|Axitinib (AG-013736)|Subjects with Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma will receive 16 weeks of therapy (Axitinib), and be seen in clinic every 4 weeks to monitor therapy.
88811729|NCT01492673|Experimental|Cyclophosphamide, Topotecan, and Bevacizumab (CTB)|This is a multi-center, open label phase II study evaluating the safety and efficacy of the novel combination of agents consisting of bevacizumab, cyclophosphamide, and topotecan.
88811730|NCT01494545|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks. A new pair was inserted each day.
88811731|NCT00818324|Experimental|OPC-12759 Ophthalmic suspension|Instillation, 4times/day
88811732|NCT01419275|Experimental|Moyamoya|Approximately 60 Moyamoya patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
88811733|NCT01419275|Experimental|Acute stroke|Approximately 60 acute stroke patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
88811734|NCT01419275|Experimental|Healthy participants|Approximately 30 healthy participants will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
88811735|NCT01419275|Experimental|Diagnosis unspecified|Approximately 60 participants with diagnosis unspecified will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
88811736|NCT02155010|Experimental|Dexmedetomidine|IV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
88811737|NCT02155010|Active Comparator|Dexmedetomidine with heavy bupivacaine|IV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine
88811738|NCT01495481|Experimental|Adenosine and Dexmedetomidine|Patients will receive adenosine and then dexmedetomidine for the termination of SVT
88811739|NCT02079584||Warfarin|A study group taken from existing anticoagulant clinics treated with warfarin.
88811740|NCT02079584||Rivaroxaban|A group seen in the rivaroxaban clinic under study.
88811741|NCT01954550|Experimental|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
88811742|NCT01954550|Sham Comparator|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
88811743|NCT00861146|Experimental|1 concurrent smoking cessation|smoking cessation delivered concurrent with intensive alcohol treatment
88811744|NCT00861146|Active Comparator|2 deferred smoking cessation|smoking cessation delivered 12 weeks after intensive alcohol treatment
88811745|NCT00819182|Experimental|Paced respiration|The paced respiration intervention group received a compact disc with paper booklet. The booklet reinforced instructions on the first audio track for how to accomplish a target breath rate of 6-8 breaths per minute, practice twice per day for 15 minutes, and apply the breathing at the onset of each hot flash. Women were instructed to do slow, deep, abdominal breathing in through the nose and out through the mouth as per international recommendations (4). They were also instructed to practice twice per day for 15 minutes as per the small, laboratory-based studies (5, 6). The second and third tracks contained specially composed, digitally recorded music to help entrain the breath rate and structure the length of practice.
88811746|NCT00819182|Sham Comparator|Sham comparator: Fast, shallow breathing|The sham comparator group received a digital videodisc with paper booklet. The booklet reinforced voice-over and video demonstration to practice twice per day and apply the fast shallow breathing at the onset of each flash. A previously published report provides additional details and data indicating this program was a suitable attention control.
88811747|NCT00819182|No Intervention|Control: Usual Care|The usual care group received an investigator-signed letter explaining they were not selected to receive any study materials during the 16-week follow-up. These participants received paced respiration materials by mail after study completion.
88811748|NCT01497665|Experimental|GRN1005 alone|GRN1005 alone
88811749|NCT00819260|Experimental|Harmonic Reduced Breast|harmonic scalpel used to reduce breast on that side
88811750|NCT00819260|Active Comparator|Electrocautery Reduced Breast|Electrocautery (current practice = control) used to reduce breast on that side
88811751|NCT01379183|Active Comparator|Erythromycin|Erythromycin 200 mg i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
88811752|NCT01379183|Placebo Comparator|Placebo|Matching placebo i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
88811753|NCT01333436|Experimental|Diabetic participants|Diabetic participants with normal to moderately high LDL-C
88811754|NCT01333436|Experimental|Nondiabetic participants|Non-diabetic participants with normal to moderately high LDL-C
88811755|NCT04382456|Experimental|acacia gum|
88811756|NCT01379651|Experimental|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of food antigen
88811757|NCT01379651|No Intervention|control|controls were kept on an egg-free diet for 6 months
88811758|NCT01379963||Cohort|
88812161|NCT05945758|Active Comparator|Spacing in the maxillary anterior teeth area treated with conventional layering composite technique.|shade mapping of enamel and dentin, then isolation the teeth with rubber dam. Palatal index will be done on waxing up and applied against the palatal surface to check the adaptation of the index. Then, the enamel shade adapted on the index in the spacing area. index will be placed back on the anterior teeth to build the palatal wall. A brush will be used to adapt the composite to the margin. After removing excess material, light curing will be carried out for 20 seconds. The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
88812162|NCT05945693|Placebo Comparator|Placebo control|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule.
88812163|NCT05945693|Active Comparator|Placebo and aerobic exercise|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule and will perform aerobic type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day.
88812164|NCT05945693|Experimental|Omega-3|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA.
88812165|NCT05945693|Experimental|Omega-3 and aerobic exercise|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA and will perform aerobic type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day.
88812166|NCT05945667|Active Comparator|Monural|3000 mg of fosfomycin trometamol per sachet
88812167|NCT05945667|Experimental|UroNext + Monural|3000 mg of fosfomycin trometamol per sachet 500 mg of Qcran, 2000 mg of D-mannose, 5 mcg of vitamin D3 per sachet
88812168|NCT05945654||Anastomotic leak|Patients who had an Ivor Lewis Oesophagectomy and suffered an anastomotic leak (AL) postoperatively. AL, as defined according to ECCG (Esophagectomy Complication Consensus Group) criteria 1-3.
88812169|NCT05945654||No anastomotic leak|Patients who had an Ivor Lewis Oesophagectomy and had no AL postoperatively, ECCG 0.
88812170|NCT05945628|Experimental|Experiment 1|Subjects with iEEG electrodes implanted will perform an eye-tracking memory task in which they view pictures of naturalistic scenes and later undergo memory testing for these scene pictures. For the memory test, studied scenes will be repeated and presented along with novel (foil) scenes. Subjects will attempt to discriminate studied from novel scenes using button press responses. Eye movements will be remotely (noninvasively) tracked using a camera during both study and test. This memory task will take about 1.5 hours to complete. 20 subjects undergoing iEEG recordings as part of epilepsy treatment will be assigned to this study experiment condition.
88812171|NCT05945628|Experimental|Experiment 2|Subjects with iEEG electrodes implanted will perform an eye-tracking memory task in which they view arrays of everyday objects arranged as a grid and later undergo memory testing for these object image arrays. Half of the object-image arrays are studied actively (subjects view objects in any order they wish) and half are studied passively (viewing patterns are predetermined and subjects must follow along). For the memory test, subjects attempt to pick studied objects from among novel (foil) objects and replace them at studied locations using the computer mouse. Eye movements will be remotely (noninvasively) tracked using a camera during the study phases. This memory task will take about 1.5 hours to complete. 20 subjects undergoing iEEG recordings as part of epilepsy treatment will be assigned to this study experiment condition.
88812172|NCT05945628|Experimental|Experiment 3|The same 20 subjects with iEEG electrodes implanted who perform Study Experiment Condition 2 will perform the same eye-tracking memory task described for Study Experiment Condition 1. For these subjects, high-frequency electrical stimulation will be delivered through the iEEG electrodes on a subset of study trials, with half of stimulated trials receiving stimulation of the hippocampus and the other half receiving stimulation of the amygdala. This memory task will take about 1.5 hours to complete and will be performed on a different day of their inpatient visit than the procedures for Study Experiment Condition 2.
88812173|NCT05945628|Experimental|Experiment 4|The same 20 subjects with iEEG electrodes implanted who perform Study Experiment Condition 1 will perform the same eye-tracking memory task described for Study Experiment Condition 2. For these subjects, high-frequency electrical stimulation will be delivered through the iEEG electrodes on a subset of study trials, with half of stimulated trials receiving stimulation of the hippocampus and the other half receiving stimulation of the amygdala. This memory task will take about 1.5 hours to complete and will be performed on a different day of their inpatient visit than the procedures for Study Experiment Condition 1.
88812174|NCT05945628|Experimental|Experiment 5|Subjects with iEEG electrodes implanted will perform the same eye-tracking memory task as described for Study Experiment Condition 1. This is a different group of iEEG subjects selected based on having iEEG electrodes implanted in the hippocampus as well as in at least one location of the Dorsal Attention Network (DAN), which is a region of interest for the experiment condition. 20 subjects undergoing iEEG recordings as part of epilepsy treatment will be assigned to this study experiment condition.
88812175|NCT05945628|Experimental|Experiment 6|The same group of 20 iEEG subjects that are included in Study Experiment Condition 5 will perform the same eye-tracking memory task as described for Study Experiment Condition 2. This experiment condition will be performed on a different day of the inpatient visit than participation in Study Experiment Condition 5.
88812176|NCT05945589|Experimental|Singapore A-Health Group|A 12-week professionally led participatory art program at the gallery with each week comprising one 2-hour art session, totaling 24 hours of museum tours and participatory art activities.
88812177|NCT05945589|No Intervention|Control Group|No art-based activities offered and advised not to participate in concurrent health and art-based interventions during the 12-week research period.
88812178|NCT05945524|Experimental|Analysis of bone marrow|Analysis of bone marrow in patients initiated treatment by Teclistamab for 18 cycles
88812179|NCT05945511||Kidney transplant patients|KT recipients at Seoul national university hospital from January 2005 to July 2022.
88812180|NCT05945498|Experimental|TB/Flu-05E vaccine|Single dose of 7.7 lg EID50 vector vaccine
88812181|NCT05945498|Placebo Comparator|Placebo|Single dose of placebo
88812182|NCT05945459|Experimental|Intervention arm|High-calorie density formula (1 kcal/ml)
88812183|NCT05945459|Placebo Comparator|Control arm|Standard formula (0.67 kcal/ml)
88813080|NCT01457417|Experimental|600 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
88813081|NCT01457417|Experimental|300 mg DKN-01 Part B|Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
88813082|NCT03217292|Experimental|Group S|"IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.~20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB."
88813083|NCT03217292|Active Comparator|Group T|IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
88813084|NCT03217448|Experimental|Dabigatran etexilate group|Subjects in this group will take Dabigatran etexilate for 6 months after randomization
88813085|NCT03217448|Active Comparator|Warfarin group|Subjects in this group will take Warfarin for 6 months after randomization
88813086|NCT03217370|Other|all haematologists|"There will be only one arm: the haematologists will all be included in the interventional phase.~Interventions are: 1) rewriting guidelines to order blood components; 2) to show the last hemoglobin value on the orders for erytrocytes and the last platelet count on the orders dor thrombocytes and 3)implementation of a clinical decision support system in the electronic rodering of blood components to stimulate restrictive blood transfusion."
88813087|NCT03211754|Experimental|Obese patients|Treatment for 8 weeks
88813088|NCT01457573|Experimental|One (single arm)|All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg (1 tab) and Solifenacin (Vesicare) 5 mg (1 tab) orally at the same time.
88813089|NCT03217526|Active Comparator|Ex Group|"EX: Standard exercise program (EX) (active range-of otion exercises, balance and mobility exercises) and walking training on the overground.~This rehabilitation program physiotherapist will be applied to participants for five days a week. Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be instructed to walk with verbal commands and encourage them to continue their walk at constant speed.The duration of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale."
88813090|NCT03217526|Experimental|Ex +WT Group|Ex: A standard exercise (SE) (active range-of otion exercises, balance and mobility exercises) WT: walking training on the treadmill (WT). This rehabilitation program physiotherapist will be applied to participants for five days a week.Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be trained on the treadmill.The duration of walking training and the speed of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale.
88813091|NCT02474082|Experimental|Secukinumab|Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
88813092|NCT02474082|Active Comparator|Fumaric acid (initial and maintenance therapy)|Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
88813093|NCT01836146|Experimental|Renal Artery Ablation|
88813094|NCT01560143|Other|Tigecycline|All subjects receive a single dose of tigecycline
88813095|NCT03212066|Experimental|Intervention|Master Mind is a 25-lesson elementary school, mindfulness education substance abuse prevention program for 4th and 5th grade classrooms.
88813096|NCT03212066|No Intervention|Wait-List Control|Business as usual
88813097|NCT01836224|Active Comparator|Noradrenaline|Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.
88813098|NCT01836224|Experimental|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
88813099|NCT01560377|Experimental|Subjects Imaged with PINPOINT|Colonic tissue perfusion assessed with PINPOINT for laparoscopic left colectomy in the lower tract.
88813100|NCT03211676|Active Comparator|Theranova-500|
88813101|NCT03211676|Sham Comparator|Elisio-21H|
88813102|NCT03217214||EP-PT|"Existing Procedure EP- Passive Thermography PT (40 patients)~Passive Thermography (PT): 2 thermoscans of the following parts:~Both carotid artery on left and right of the neck.~Both superficial temporal artery on the left and right of forehead.~Left forearm. No relaxation time will be given between the two tests. Each thermoscanning of region will take 60 seconds. The complete procedure will take 10-15 minutes of time."
88813137|NCT03837080|Experimental|Nutrition Education|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care will go through a series of individual and group nutrition educations. Educations are specifically tailored for chronic pain patients, based on our preliminary findings on this group of patients.
88813103|NCT03217214||EP-ATLIC/ATPC|"Existing Procedure EP- Active Thermography ATLIC/ATPC (60 patients)~Active Thermography (AT): Temperature mapping over both carotid arteries will be done with the application of maximum cooling for 45-60 seconds in pulsed or lock-in manner. Pulsed mode is continuous, lock-in cooling will be intermittent. Maximum cooling time is 45-60 seconds, using a cooling pad/ cold air blower. Continuous thermoscanning will be done from the instance of application of cooling to reaching of a fixed temperature during rewarming. Procedure will be done 2 times per subject on both carotid arteries. Relaxation time between procedures is 10 minutes. A warming pad/ hot air blower will be used after the test to bring the skin temperature to normal. The complete procedure will take 60 min."
88813104|NCT01836302||Patients with Cerebral Desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
88813105|NCT01836302||Patients without cerebral desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
88813106|NCT01836380|Experimental|Swimming Training|The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
88813107|NCT01836380|Experimental|Cycling Training|The cycling training will be conducted in the newly-constructed Exercise Training Intervention Core-Laboratory in the Department of Kinesiology and Health Education on the University of Texas campus. In the first 2-3 weeks a cycling instructor will provide personalized skill feedback to the subjects in the cycle training group. Subjects will cycle 15-20 minutes/day at a relatively low intensity of exercise while they receive cycling skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
88813108|NCT03211364|Active Comparator|Angular mobilization|Angular mobilization of the shoulder joint in the frontal plane.
88813109|NCT03211364|Active Comparator|Angular mobilization with soft tissue techniques|Angular mobilization performed in the scapular plane. Additional soft tissue techniques to eliminate limitations created by tensed muscles in order to perform capsular stretch.
88813110|NCT03211364|Placebo Comparator|Scapular mobilization|Scapular mobilization without glenohumeral movement.
88813111|NCT01836536|Other|BEVACIZUMAB|BEVACIZUMAB standard of care
88813112|NCT03216980|Experimental|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
88813113|NCT03216980|Placebo Comparator|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
88813114|NCT03216980|Experimental|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
88813115|NCT03216980|Placebo Comparator|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
88813116|NCT00895232|Experimental|Cohort I|500 mg dose Venofer over 4 hours
88813117|NCT00895232|Experimental|Cohort II|500 mg Venofer infusion over 4-6 hours on Day 0 and repeated on Day 2 to 7
88813118|NCT00895232|Experimental|Cohort III|500 mg Venofer over 6 hours, followed within 24 hours by 500 mg Venofer over 6 hours
88813119|NCT03211130|Experimental|SystemCHANGE™|
88813120|NCT03211130|Active Comparator|Attention-Control|
88813121|NCT04380974|Experimental|OCTA plus OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization, OCTA and OCT in the extension treatment period.
88813122|NCT04380974|Active Comparator|OCT guided 3+PRN regimen|Monthly intravitreal injections of anti-VEGF drug in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization and OCT in the extension treatment period.
88813123|NCT01836692|Experimental|Thoracic radiotherapy|Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
88813124|NCT03211052|Experimental|TAK-700 + LHRH agonist + Prostatectomy|Neoadjuvant TAK-700 for 6 months with LHRH agonists prior to prostatectomy
88813125|NCT03211052|Other|Prostatectomy|Prostatectomy only-Within 28 days of randomisation
88813126|NCT01560923|Experimental|Sipuleucel-T + Oral Indoximod|Oral Indoximod will be self-administered by mouth twice daily (1200 mg) for 6 months starting after the last (3rd) infusion of sipuleucel-T. Indoximod is a sterile tan powder compounded in capsule form of 200 mg.
88813127|NCT01560923|Placebo Comparator|Sipuleucel-T + Placebo|Placebo is identical-looking to Indoximod and provided in the same manner.
88813128|NCT01836770||Transforaminal Epidural Steroid Injection|Patients with a history of lumbosacral radiculopathy or lumbar herniated nucleus pulposus, scheduled for Transforaminal Epidural Steroid Injection.
88813129|NCT03837548|Experimental|Training with Neurofeedback|
88813130|NCT03837548|Experimental|The other Training with Neurofeedback|
88813131|NCT05566145||Patients included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, included in the support program for Return To Home for Heart Failure (PRADO)
88813132|NCT05566145||Patients not included in the PRADO program|Patients hospitalized for global heart failure or left ventricular insufficiency in the Cardiology department of the GHPSJ between January 2016 and September 2018, not included in the Return A DOmicile support program for Heart Failure (PRADO)
88813133|NCT01836848|Experimental|indocyanine green|in this arm we do the Intervention 'measuring cerebral perfusion by NIRS with ICG', the pat. gets before a CT-Scan with perfusion measurement a indocyanine green bolus i.v. and a measurement of cerebral perfusion with near-infrared-spectroscopy
89530090|NCT03256747|Placebo Comparator|NMES-placebo group|NMES-placebo will be placed at the knee extensors, with minimal intensity to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
88813452|NCT01727648|Experimental|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
88813453|NCT01727648|Active Comparator|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
88813454|NCT04205994|Experimental|Tolcapone|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in a single 200mg dosage once in randomized, double-blind, counterbalanced fashion with a placebo.
88813455|NCT04205994|Placebo Comparator|Placebo|Placebo will be administered in a single pill once in randomized, double-blind, counterbalanced fashion with a placebo.
88813456|NCT03007745|Experimental|REVAMP|Veterans randomized to this arm will have access to the Remote Veteran Apnea Management Platform (REVAMP) a personalized, interactive website that allows Veterans to be evaluated for OSA without travelling to the sleep center.
88813457|NCT03007745|Active Comparator|In-person management|Veterans randomized to this arm will receive standard in-person management of their sleep apnea in the sleep center.
88813458|NCT01727804|Experimental|Laser|
88813459|NCT01727882|Experimental|Daily Assessments & Brief Feedback|Daily assessments during 30 days after parole and a feedback intervention based on these daily assessments.
88813460|NCT01727882|Active Comparator|Daily assessments|Daily assessments during 30 days after parole.
88813461|NCT02218307|Active Comparator|Mupirocin|topical antibiotic
88813462|NCT02218307|Placebo Comparator|Placebo|Placebo control for mupirocin
88813463|NCT01727960||Korean Male Adolescents|students from two academic high schools
88813464|NCT03007433|Experimental|healthy volunteers|60 healthy volunteers with no functional dyspepsia as defined by the Rome Questionnaire and no more than mild symptoms on maximum 1 days a week on the GSRS, that meet inclusion and exclusion criteria will be recruited. Eligible subjects will be block randomized by sex and age such that 10 men and women in each age group (<40, 41-60, >60) are recruited.
88813465|NCT03007433|Experimental|Functional dyspeptic patients|20 patients with functional dyspepsia with postprandial distress syndrome as defined by the Rome IV Questionnaire and at least moderate symptom severity on at least 3 days a week that meet the inclusion and exclusion criteria will be recruited to provide pilot data in the local patient population
88813466|NCT01728038|Experimental|Cessation Counseling|Parental smokers will be given a brief cessation intervention consisting of counseling, nicotine replacement therapy and Quitline connection.
88813467|NCT01722032|Experimental|Treatment|"The intervention centers' menus were modified to include more fresh fruit, fresh vegetables, low-fat (1%) or skim milk, water, less juice, and less simple carbohydrate snacks. The centers were also encouraged to incorporate fresh fruits and vegetables as often as possible for snack and meal time.~Physical Activity. Physical activity was promoted for at least 60 minutes per day. TV viewing, watching movies and playing computer games were logged and limited to 30 minutes or less per day. Schools adopted Best-Practice Policies."
88813468|NCT01722032|No Intervention|Control|Those schools randomized to the control arm received a safety curriculum and some child care center locations received an attention control consisting of three visits from the University of Miami Safety Van which provided parents and teachers with home, car and child seat safety information. The control group received all the same pre-post measures as the intervention arms. They also received the same incentives as the intervention arms to foster involvement and ensure retention/reduce loss to follow up.
88813469|NCT01722110|Experimental|Indomethacin Extended-Release Capsules USP 75 mg|Indomethacin Extended-Release Capsules USP 75 mg of Ipca Laboratories Limited, India
88813470|NCT01722110|Active Comparator|Indomethacin Extended Release Capsules USP 75 mg|Indomethacin Extended Release Capsules USP 75 mg of Epic Pharma, USA.
88813471|NCT01573949|Experimental|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
88813472|NCT02496702|Experimental|Training|"The intervention is done in the form of groups of 4-5 participants per set of tiles, with 2-3 set of tiles at a time. As more set can be used it is possible to make groups of more people. The training will consist of 1.5-3 minutes of training (depending on the game) on tiles and the rest while the other 2-3 participants train (4-6 minutes of break). Then the participants will train for 1.5-3 minutes again until each participant have received a total of 13 minutes of training.~The intervention will be done 2 times a week for 12 weeks, each session lasting 1 hour and each participant receiving 13 minutes of training each time (see training plan)."
88813473|NCT02496702|No Intervention|Control|No training.
88813474|NCT01722188||Optim Leads|
88813475|NCT01574105||Heparin Resistant|Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.
88813476|NCT01574105||Heparin Sensitive|Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.
88813477|NCT01574183|Experimental|Vilazodone|Flexible dose up to 40 mg capsule daily
88813478|NCT01574183|Placebo Comparator|Placebo|Flexible dose up to 40 mg capsule daily
88813697|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)|Participants will receive a single 1000-mg/m^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
88813658|NCT03007121|Active Comparator|Bupivacaine + Sufentanil epidural|An epidural catheter will be inserted before induction of anaesthesia in a sitting position between T9 and T10 - T12 and L1 vertebrae. A test dose of 4 ml 0.5 bupivacaine will be administered to rule out intravascular injection or subarachnoid or subdural block. Standard general anaesthesia will be performed. Thirty minutes before the end of the surgery, patients will be administered a bolus of a mixture of bupivacaine 0.5% (3 ml) + sufentanil 10 mcg (2 ml) + NS 5 ml followed by a continuous infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h. At the same time patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
88813659|NCT03007121|Active Comparator|Morphine intravenous|Patients will be administered standard general anaesthesia. After surgery, bolus doses of morphine 2 mg will be administered until level of pain will be < 4 (VAS 0 - 10). Analgesia will be continued by PCA device using morphine, bolus dose 1 mg, lock-out interval 5 min. for 3 days at surgical ICU.
88813660|NCT04959864|Experimental|Isitol® (Food supplement treated group)|"36 eligible males between 20 and 45 yo. (included limits) will take 1 sachet of Isitol® per day during 16 (± 2) weeks. The sachet of powder is to dissolve in a glass of water or directly in mouth.~1 sachet of Isitol® (2,1g) contains 1000 mg of myo-inositol, 300 mg of N-acetyl-cysteine, 150 % of the Nutritional Reference Values (NRV) in zinc and 100 % of the NRV: in vitamins B2, B3, B6, B9 and E."
88813661|NCT04959864|Placebo Comparator|Placebo treated group|"36 eligible males between 20 and 45 yo. (included limits) will take 1 sachet of placebo per day during 16 (± 2) weeks. The sachet of powder is to dissolve in a glass of water or directly in mouth.~1 sachet of placebo (2,1g) contains only excipients used in Isitol® and excipients to get similar organoleptic aspect (maltodextrin, sucralose, silicon dioxide, magnesium carbonate, citric acid and beta-carotene)."
88813662|NCT01725152|Experimental|Ganaxolone then Placebo|Participants first received ganaxolone. They were first titrated up to the 12 milligram per kilogram (mg/kg) three times daily (tid) during a 2-week titration phase, then maintained on that dose for an additional 4 weeks. After a washout period of 2 weeks, participants received placebo for a duration of 6 weeks (from week 8 to 14).
88813663|NCT01725152|Experimental|Placebo then Ganaxolone|Participants first received placebo. They were first titrated up to the 12 mg/kg tid during a 2-week titration phase, then maintained on that dose for an additional 4 weeks. After a washout period of 2 weeks, participants received ganaxolone for a duration of 6 weeks (from week 8 to 14).
88813664|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
88813665|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
88813666|NCT01723982|Experimental|A. FE 200440|Barusiban (FE 200440) Solution for Injection for Subcutaneous use
88813667|NCT01723982|Placebo Comparator|B. Placebo|Placebo Solution for Injection for Subcutaneous use
88813668|NCT02981303|Experimental|Melanoma|Imprime PGG + Pembrolizumab
88813669|NCT02981303|Experimental|Triple Negative Breast Cancer|Imprime PGG + Pembrolizumab
88813670|NCT03834038|Experimental|Open Label Lyophilized Fecal Microbiota Transplantation|Eligible participants with history of recurrent or refractory CDI
88813671|NCT02981459|Experimental|Mirabegron 25 mg or 50 mg|
88813672|NCT01724138|Experimental|Deferasirox|The study will provide PK, safety, tolerability and efficacy data collected during 48 weeks of treatment with deferasirox in Chinese pediatric patients with transfusion dependent -thalassemia major, aged 2 to <6 years at enrollment. The target patient pool consists of 20 patients with evidence of iron overload measured by serum ferritin level at the start of study. Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. Serum ferritin will be monitored every month and the dose of deferasirox will be adjusted if necessary every 3 months based on the trends in serum ferritin. Other possible dose adjustments will be based on the patient's safety assessments.
88813673|NCT02247167|Experimental|adenotonsillectomy (AT)|Children with SDB studied before and after before adenotonsillectomy.
88813674|NCT03001505||Patients with pancreatic cancer|Patients diagnosed with pancreatic cancer evaluated at this institution.
88813675|NCT03006809|Experimental|1|pretreatment antibiotics + FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
88813676|NCT03006809|Experimental|2|no antibiotics, FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
88813677|NCT03006809|Experimental|3|pretreatment antibiotics + FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
88813678|NCT03006809|Experimental|4|no antibiotics, FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
88813679|NCT01580423|Experimental|aprepitant|
88813680|NCT01580423|Placebo Comparator|inert powder|
88813681|NCT01049984|Experimental|Rasagiline 1 mg|Participants took a 1 mg rasagiline tablet orally each day for 18 weeks.
88813682|NCT01049984|Placebo Comparator|Placebo|Participants took a matching placebo tablet once daily for 18 weeks.
88813683|NCT03001271|Experimental|Healthy Subjects|Placebo and Angiotensin-(1-7) acute infusion
88813684|NCT03001271|Experimental|Hypertensive Subjects|Placebo and Angiotensin-(1-7) acute infusion
88813685|NCT03001349|Experimental|Diagnostic (gallium Ga 68-edotreotide, PET/CT)|Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.
88813686|NCT03001115||Participants with Hidradenitis suppurativa (HS)|Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.
88813687|NCT03006575|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose at the initial course: 40-51Gy/10-17f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 15-24 Gy/5-8f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
88813688|NCT03001193|Experimental|DF01 low dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in low dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
88813850|NCT05566457|Experimental|HGWD group|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
88813851|NCT05566457|Placebo Comparator|control group|Patients in the control group and the HGWD group used vitamin E milk and vitamin B12 to smear the limbs three times per day for 14 days.
88813852|NCT03004937|Experimental|Single-Arm, Non-Randomized, Stepped Wedge|All patients who meet the inclusion criteria will receive the same intervention.
88813853|NCT03004781|No Intervention|Waiting-list|8-week period without intervention, N=45
88813854|NCT03004781|Experimental|self-efficacy|8-week group-based parenting program on self-efficacy beliefs, N=19
88813855|NCT03004781|Experimental|self-efficacy/emotion coaching|8-week group-based parenting program on self-efficacy beliefs and emotion coaching practice, N=26
88813856|NCT03004859||Adults ≥ 65 with a positive test result|Adults ≥ 65 that are got a positive test result were asked to visit their general practitioner and are called for an interview two times, 8 weeks and 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacies as well as of the two telephone interviews are compared to the results of the adults ≥ 65 with a negative test result.
88813857|NCT03004859||Adults ≥ 65 with a negative test result|Adults ≥ 65 that are got a negative test result are called for an interview 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacy as well as of the telephone interview are compared to the results of the adults ≥ 65 with a positive test result.
88813858|NCT01041638|Experimental|Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)|Patients receive sargramostim SC or IV over 2 hours on days 0-13 of courses 1, 3, and 5; monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4; and isotretinoin PO BID on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5. Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4. Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88813859|NCT03004625|Experimental|Study Arm|HCV-1b patients without baseline NS5A resistance-associated variants receiving Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks. (daclatasvir, asunaprevir plus ribavirin)
88813860|NCT03004703|Experimental|Active drug|Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
88813861|NCT03004703|Placebo Comparator|Placebo|Sodium chloride 0.9%; 100 ml i.v. once.
88813862|NCT03404102||university clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion~Informed Consent: All participants will give their informed consent prior to enrollment.~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
88813863|NCT03404102||primary healthcare unit clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion~Informed Consent: All participants will give their informed consent prior to enrollment.~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
88813864|NCT03404024|Experimental|Stage 1-Low dose VM202RY|Patients in this group will receive total 1mg of VM202RY. (4 sites of 0.25mg/0.5 mL VM202RY)
88813865|NCT03404024|Experimental|Stage 1-Middle dose VM202RY|Patients in this group will receive total 2mg of VM202RY. (8 sites of 0.25mg/0.5 mL VM202RY)
88813866|NCT03404024|Experimental|Stage 1-High dose VM202RY|Patients in this group will receive total 3mg of VM202RY. (12 sites of 0.25mg/0.5 mL VM202RY)
88813867|NCT03404024|Placebo Comparator|Stage 2-Placebo|Patients in this group will receive 6mL of VM202RY vehicle. (12 sites of 0.5mL 0.9% NaCl, 1.1% sucrose)
88813868|NCT03404024|Experimental|Stage 2-Low dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-0.5mg VM202RY/1mg VM202RY/1.5mg VM202RY based on the tolerated dose result from Stage 1.)
88813869|NCT03404024|Experimental|Stage 2-High dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-1mg VM202RY/2mg VM202RY/3mg VM202RY based on the tolerated dose result from Stage 1.)
88813870|NCT02247713||Retrospective cohort|Participating centers will retrospectively provide demographic, tumor, treatment and follow-up details on at least 25 consecutive patients with stage III NSCLC previously treated with curative intent chemoradiotherapy (concurrent or sequential) in the period between 2010 and 2013.
88813871|NCT02247713||Prospective cohort|Participating centers will provide prospective data on patients with stage III NSCLC treated with curative intent concurrent chemoradiotherapy. Centers will be asked to include at least 25 consecutive cases following the training intervention and the successful local implementation of PET/CT for RTP in NSCLC.
88813872|NCT01725464|Experimental|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
88813873|NCT01725542|Experimental|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|"Lead-in Phase: day 0 to week 4 PegInterferon alpha-2a + Ribavirin~Quadruple therapy: week 4 to week 28 Asunaprevir + Daclatasvir + PegInterferon alpha-2a + Ribavirin"
88813874|NCT02247869|Experimental|dose dense ABVD|1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)
88813875|NCT00914186|Placebo Comparator|Vehicle|
88813876|NCT00914186|Experimental|TS-022 0.005% lotion|
88813877|NCT00914186|Experimental|TS-022 0.010% lotion|
88813878|NCT00914186|Experimental|TS-022 0.020% lotion|
88814056|NCT04347668|Experimental|Virtual Reality|"Virtual Reality (VR) is a scenario that simulates experiences. The immersive environment is similar to the real world, creating an experience. A person using virtual reality equipment is able to look around the artificial world, move around in it, and interact with virtual features or items. VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds that simulate a user's physical presence in a virtual or imaginary environment. A library has been developed, set to music, as well, we will use library items already part of the BroomX. We will attempt to use BroomX in their own room or in a suitable room within the LTC home. The participants still get the immersive experience, and the projection device has automatic controls that conform the visuals to a 360 experience no matter what size the room is, or what chairs, window blinds, are in the room."
88814057|NCT03401528|Experimental|Single Ascending Dose - AVB-S6-500|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
88814058|NCT03401528|Placebo Comparator|Single Ascending Dose - placebo|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
88814059|NCT03401528|Experimental|Repeat Dose - AVB-S6-500|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
88814060|NCT03401528|Placebo Comparator|Repeat Dose - placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
88814061|NCT02516592|Experimental|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. Capsules for inhalation
88814062|NCT02516592|Active Comparator|salmeterol/fluticasone 50/500 micrograms|salmeterol/fluticasone 50/500 micrograms b.i.d. Dry inhalation powder
88814063|NCT03401372|Experimental|Doxycycline/BCD chemotherapy|Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy
88814064|NCT03401372|Active Comparator|BCD chemotherapy|Bortezomib-cyclophosphamide-dexamethasone chemotherapy
88814065|NCT04373096|Active Comparator|Group C (Control)|Will use current IPAC-UHN PPE as described under assigned intervention:
88814066|NCT04373096|Experimental|Group H (enhanced PPE group )|Will use modified IPAC-UHN PPE including the prototype hood as described under assigned intervention:
88814067|NCT04934904|Experimental|Experimental Group|On the basis of the clinical routine treatment of AGI in severe patients, the Experimental Group will receives ultrasound-guided erector spinae plane block with routine treatment of AGI for 7 days or until transferring to the general ward.
88814068|NCT04934904|No Intervention|Controlled Group|the routine clinical treatment of AGI is given to severe patients, such as gastrointestinal dynamic drugs, traditional Chinese drugs and physical rehabilitation therapy
88814069|NCT03401216|Experimental|SYNERGY 48 PCI + 3 month OCT follow-up|Synergy 48 mm stent implantation followed by 3 month OCT imaging
88814070|NCT03401216|Experimental|SYNERGY 48 PCI + 6 month OCT follow-up|Synergy 48 mm stent implantation followed by 6 month OCT imaging
88814071|NCT02219321|Active Comparator|Lidocaine infusion|A continuous intravenous infusion of lidocaine
88814072|NCT02219321|Placebo Comparator|Saline infusion|A continuous intravenous infusion of saline
88814073|NCT02241044|Active Comparator|the Combined group|The Combined group patients received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
88814074|NCT02241044|Placebo Comparator|the Injection group|Injection group patients underwent distilled water alone at index endoscopy. Then patients were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
88814075|NCT04955574|Experimental|Probiotic + Antibiotic Placebo|
88814076|NCT04955574|Experimental|Probiotic + Antibiotic|
88814077|NCT04955574|Placebo Comparator|Probiotic Placebo + Antibiotic Placebo|
88814078|NCT02156258||Diagnostic Cases|Collection of cases that were scheduled for biopsy (BI-RADS 4 or 5) using Full Field Digital Mammography (FFDM) Mammography and Digital Breast Tomosynthesis (DBT) Mammography
88814079|NCT02156258||Recall Cases|Collection of Imaging Recall Cases (were scheduled for additional imaging due an assessment of BI-RADS 0) using FFDM Mammography and DBT Mammography
88814080|NCT02156258||Screening Cases|Collection of cases who underwent routine screening mammography using FFDM Mammography and DBT Mammography
88814081|NCT02492100|Experimental|Multi-modality sexual dysfunction intervention|"- Patients in remission > 6 months after allogeneic bone marrow transplant~Patient Enrollment and Baseline Data Collection~First Intervention Visit:~Comprehensive assessment of sexual dysfunction~Normalization & Education~Therapeutic interventions~Referral to Sexual Health Clinic if applicable~Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable"
88814082|NCT04716335|Experimental|Harmine + DMT|
88814083|NCT04716335|Experimental|Harmine + Placebo(DMT)|
88814084|NCT04716335|Placebo Comparator|Placebo(Harmin & Placebo)|
88814085|NCT04366934||COVID-19 patients|Subject consulting in the Lariboisière hospital (Paris) in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection
88814086|NCT04366934||Control subjects|Subject consulting in the ear, nose and throat department at the Lariboisière hospital (Paris) with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia
88814087|NCT02221349|Other|oxalate liquid & gel plus SnF2 paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied
88814088|NCT02221349|Other|oxalate liquid & gel plus NaF paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied
88814089|NCT02461758|Other|Control Group|A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.
89530091|NCT05278559||Adolescents living with HIV|- ALHIV with a viral load result of less than <1000 copies/mL and aged between 13-19 years
88814294|NCT02243852||Growth Hormone Replacement Therapy (n=16)|"GHD patients, who are eligible for GH replacement therapy as part of their routine clinical care, according to the National Institute for Clinical Excellence (NICE) recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire score (AGHDA score>11) will be recruited. These patients attend the Joint Endocrine clinic at University Hospital Aintree, Liverpool, and those who are about to commence growth hormone replacement will be asked to participate in this observational study.~Anthropometric, biochemical including measurement of FGF21 and MR evaluation will be carried out in patients who are to be treated with GH as part of their routine clinical care immediately prior to GH therapy and after six months of replacement treatment. The type of GH and dose of treatment will be at the discretion of the treating physician. Standard doses will be used and patients will remain under the care of the supervising"
88814295|NCT02243930|Experimental|Cap|Sigmoidoscopy with cap
88814296|NCT02243930|No Intervention|No cap|Sigmoidoscopy without cap
88814297|NCT02244008|Experimental|joint mobilization|Anteroposterior mobilization of the talus (Maitland mobilization grade III)
88814298|NCT02244008|Placebo Comparator|manual contact|
88814299|NCT04347278||Patients receiving treatment for COVID19|
88814300|NCT04369586|Experimental|meplazumab dose 1|0.06mg/kg for single dose
88814301|NCT04369586|Experimental|meplazumab dose 2|0.12mg/kg for single dose
88814302|NCT04369586|Experimental|meplazumab dose 3|0.2mg/kg for single dose
88814303|NCT04369586|Experimental|meplazumab dose 4|0.3mg/kg for single dose
88814304|NCT04369586|Experimental|meplazumab dose 5|0.42mg/kg for single dose
88814305|NCT04369586|Experimental|meplazumab dose 6|0.56mg/kg for single dose
88814306|NCT04369586|Experimental|meplazumab multiple dose|0.3mg/kg for double doses, 1 dose/week
88814307|NCT02231177|Experimental|BI 1744 CL/Tiotropium FDC|
88814308|NCT02231177|Active Comparator|BI 1744 CL|
88814309|NCT02231177|Active Comparator|Tiotropium|
88814310|NCT04368884||Healthcare workers|The healthcare workers who are being tested for COVID-19 would be included in this group
88814311|NCT04368884||OPD patients|Individuals outside from the hospital who are coming for the COVID-19 testing will be included in this group
88814312|NCT04368884||IPD COVID-19 cases|Admitted positive cases of COVID-19 in the hospital will be included in this group
88814313|NCT02223689|Experimental|Skin Affix|Surgical adhesive
88814314|NCT04369118|Experimental|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up and wear the selective chest wall restriction belt in parallel. Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
88814315|NCT04369118|Active Comparator|conventional postoperative follow-up|Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
88814316|NCT03283007|Experimental|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
88814317|NCT03283007|Placebo Comparator|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
88814318|NCT04363190||Cases|
88814319|NCT04363190||Controls|
88814320|NCT00927992||Patients with haemophilia who undergo liver transplantation|Patients with haemophilia who underwent liver transplantation and who have been followed up at any site in Spain.
88814321|NCT02244086|No Intervention|bupivacaine 0.125%|administrate bupivacaine at 0.125% during initiation of effective labor work
88814322|NCT02244086|Experimental|bupivacaine 0.25%|Administrate bupivacaine at 0.25% during initiation of effective labor work One of the researchers selected from a randomized list containing pages in both groups with numbers ranging from 0001 to 0110 with 55 pages for each group and these selected folios prepared in sterile form and start the day in the morning, the amount of 10 10 ml syringes with foil for each mixture. The remaining samples were discarded if 10 analgesics are not achieved during the day, and the day new preparations were made.
88814323|NCT01629797|Other|Acne Vulgaris|Patients with Acne vulgaris will receive educational teaching on Acne
88814324|NCT02249117|Experimental|BIWH 3|single escalating dose
88814325|NCT02249117|Placebo Comparator|Placebo|
88814326|NCT03234023|Active Comparator|INTERVENTION GROUP|The participants of this group will follow recommendations of food, physical exercise, control of consumption of drugs and consumption of alcohol and tobacco.
88814327|NCT03234023|No Intervention|CONTROL GROUP|The participants of this group are submitted to the standard intervention.
88814328|NCT00928304|Experimental|Florbetaben (BAY94-9172)|
88814329|NCT03205709|Active Comparator|Training Group 1|Computerized Cognitive Training
88814330|NCT03205709|Placebo Comparator|Training Group 2|Crossword puzzles
88814331|NCT04363424||Validation cohort|Patients with alcoholic cirrhosis with reliable self-reported alcohol use.
88814332|NCT04363424||Clinical application cohort|Patients with alcoholic cirrhosis who deny moderate or excessive alcohol use in the previous 3 months.
88814333|NCT04362020|Experimental|Group-1|No anticoagulation
88814334|NCT04362020|Active Comparator|Group-2|ACT-guided anticoagulation
88814335|NCT04368572|Experimental|lumbar puncture under hypnosis|Hypnosis is the only act added by protocol to patients receiving a lumbar puncture as part of the etiological assessment of cognitive disorders
88814336|NCT04368572|Active Comparator|lumbar puncture without hypnosis|Lumbar puncture is performed by a physician assisted by a nurse or a psychologist who reassure the patient during the installation and the procedure.
88814337|NCT01630109|Active Comparator|Metoclopramide 5 mg|Pro-motility agent
88814338|NCT01630109|Active Comparator|Metoclopramide 10 mg|Pro-motility agent
88814339|NCT01630109|Placebo Comparator|Placebo control|Placebo to be used as the control group
88814340|NCT04368650|Experimental|Main treatment group|The in situ BMP-2 gel was prepared to a concentration of approximately 0.5 μg/ml and were stored at 4oC. The gel was then dispensed at site of interest in the study.
88814341|NCT04368650|Active Comparator|Control|In patients selected for control group, after degranulation, sticky bone was used to fill the defect. The surgical site was protected and covered using a periodontal dressing.
89530092|NCT03256669|Experimental|umbilical incision|neonates undergone surgery by umbilical incision
88814433|NCT02451930|Experimental|Necitumumab + Pembrolizumab|"Part A Cohort 1: 600 mg Necitumumab + 200 mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 600 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in participants with Stage IV NSCLC (all histologies).~Part A Cohort 2, Part B and Part C: 800mg Necitumumab + 200mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 800 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in Part A cohort 2 participants with any histology, Part B and C participants with Stage IV NSCLC of squamous and nonsquamous histology.~Part C were Japan participants. Part C were Japan participants."
88814434|NCT04358120|Other|Hyaluronic Acid Combined With Chondroitin Sulfate|The treatment consists of 3 intra articular injections of Hyaluronic Acid With Chondroitin Sulfate administered one per week for 3 consecutive weeks: the 1st at Visit 1 (Week 0), the 2nd at Visit 2 (Week 1) and the 3rd at Visit 3 (Week 2)
88814435|NCT00932828|Experimental|Peanut oral immunotherapy|Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.
88814436|NCT04932798||High-Risk group|: Montreal Heart Institute biobank participants with a high specific genome-wide polygenic risk scores for atrial fibrillation G
88814437|NCT04932798||Low-Risk group|Montreal Heart Institute biobank participants with a low specific genome-wide polygenic risk scores for atrial fibrillation G
88814438|NCT00928694|Active Comparator|1|Fenofibrate U.S. Formulation
88814439|NCT00928694|Active Comparator|2|Fenofibrate UK Formulation
88814440|NCT01639157|Experimental|Buspirone|Subjects will be maintained on 30 mg buspirone daily.
88814441|NCT01639157|Placebo Comparator|Placebo|Subjects will be maintained on placebo (i.e., 0 mg buspirone daily).
88814442|NCT02451696|Experimental|Treated Subjects|This group will be treated with everolimus 7-28 days prior to surgery
88814443|NCT02451696|No Intervention|Reference Subjects|This group will be enrolled as reference subjects, and will be undergoing routine surgery as part of standard of care treatment. No intervention will be provided to these subjects as part of the study.
88814444|NCT00928772|Active Comparator|Alpha-Stim intervention|One hour Alpha-Stim intervention with sham midazolam
88814445|NCT00928772|Sham Comparator|Sham Alpha-Stim with midazolam|Sham Alpha-Stim intervention with real midazolam administration
88814446|NCT00928772|Placebo Comparator|Placebo|No Alpha-Stim and only topical anesthetics
88814447|NCT04361084|Active Comparator|traditional training|Participants will undertake the Community simulation using traditional methods, physical items to recreate the community environment. Training will be in pairs and will play the role of their own profession when undertaking simulated scenarios. Medium to low fidelity traditional simulation techniques involving scenarios played out using actors as (standardised patients) to participants. Following a briefing, the participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results and are anonymous. They will also complete their pre-questionnaire which will anonymous. Afterwards participants undertake a post-questionnaire and then asked if they wish to take part in a semi-structured interview.
88814448|NCT04361084|Experimental|mixed reality simulation training|Participants will undertake a mixed reality (MR) simulation training session set in two home situations; involving immersive virtual reality equipment. Participants will be asked a series of questions prior to the simulation to establish their profession, age and level of previous training achieved so this can be compared against the results. The participants will then undertake the simulation watched via live camera by the simulation technician, simulation fellow and a community specialist. Participants will undertake a post simulation questionnaire and then asked if they wish to take part in a semi-structured interview (optional).
88814449|NCT02459418|Experimental|Afolia - US Gonal-f® (Sequence A) Arm|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive treatment sequence: (Sequence A): Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
88814450|NCT02459418|Active Comparator|US Gonal-f® - Afolia (Sequence B) Arm:|During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive treatment sequence (Sequence B): Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
88814451|NCT04361318|Experimental|Hydroxychloroquine plus Nitazoxanide|200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days
88814452|NCT04361318|Active Comparator|Standard care|Standard care delivered in the COVID-19 isolation hospitals.
88814453|NCT04367012||group 1 NAFLD and group 2 Non NAFLD|study from 20-60 years old.Subjects will be evaluated clinically by abdominal examination for evaluation of fatty liver and grades it into 3 grades .evaluation of fatty pancreas and grade it into 3 grades ,measuring blood pressure and physically by calculating body mass index (BMI) weight/height2
88814454|NCT04367012||Group1 NAFLD & Group 2 Non NAFLD|As the study is randomized cross sectional , all subjects whom have fatty liver by abdominal ultrasound included in group 1 NAFLD , and whom do not have fatty liver by abdominal ultrasound included in group 2.both groups was age and sex matched
88814455|NCT04925076|Experimental|Family History Positive|People reporting at least one parent with a history of alcohol problems.
88814456|NCT04925076|Experimental|Family History Negative|People who do not report having a parent with a history of alcohol problems.
88814457|NCT04366700|Active Comparator|Bone replacement substitute and membrane|periapical surgery will be done and defect will be filled with a mixture of autograft and prf and over the defect and denuded root surface collagen membrane will be placed before closure of flap
88814458|NCT04366700|Active Comparator|membrane|periapical surgery will be done and defect will be filled with blood clot and over the defect and denuded root surface collagen membrane will be placed before closure of flap
88814459|NCT01598207|Experimental|Marinol|
88814460|NCT01598207|Placebo Comparator|Placebo|
88814461|NCT00937118||Injury Management|Patients with full thickness duodenal laceration undergoing laparotomy and surviving more then 72 hours at our level 1 trauma center in the years 1989-2009. Patients requiring pancreaticoduodenectomy were excluded.
88814533|NCT02233517|Experimental|Cognitive Behavioral Therapy|"Cognitive-Behavioral Therapy for Anger and Aggression in Combat Veterans with PTSD (CBT-A) is a 12-week manualized group treatment protocol that is grounded in up-to-date research, and that specifically addresses the Energy and Drive Functions, Attention Functions, Emotion Functions, and Thought Functions that are hypothesized to underlie the limitations to Activities and Participation associated with PTSD-related anger and aggression. Each session lasts 90 minutes. The first session orients participants to the structure and philosophy of the program, provides a historical overview of PTSD, and introduces the concept of the survival mode of functioning (Chemtob et al., 1997). The remaining 11 sessions follow a standard format: 1) practice relaxation training (15-20 minutes); 2) review homework, introduce new material, and engage in group activities focused on implementing new skills and behaviors (70-80 minutes); and 3) review problems or concerns of group members."
88814534|NCT02233517|Active Comparator|Present Centered Therapy|"Present Centered Therapy (PCT) is an active, manualized treatment comparison condition for psychotherapy trials. PCT is designed to control for nonspecific factors of therapy such as contact with a trained therapist, rationale for treatment, and instillation of expectancy for therapeutic gains. The therapeutic approach was drawn from Yalom's group therapy model, which utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now. Previous large-scale randomized clinical trials of Veterans with PTSD have found reduced PTSD symptoms in the PCT comparison condition (Schnurr et al., 2003), and a survey of practice patterns within the VA suggests that similar present-focused approaches are routinely employed by VA mental health providers (Rosen et al., 2004). Consistent with recommendations in the PCT manual, training will emphasize the approach rather than specific interventions."
88814535|NCT01605539|Placebo Comparator|Control|Subjects will receive pills that resemble the Cannabidiol capsule but do not have have its properties.
88814536|NCT01605539|Experimental|Cannabidiol 400|Subjects in Arm Cannabidiol 400 will receive 400 mg of cannabidiol
88814537|NCT01605539|Experimental|Cannabidiol 800|Subjects in Arm Cannabidiol 800 will receive 800mg of cannabidiol
88814538|NCT02458638|Experimental|Atezolizumab|The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
88814539|NCT01607255|Experimental|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
88814540|NCT01607255|Experimental|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
88814541|NCT01607255|Active Comparator|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
88814542|NCT01607411|Placebo Comparator|Fluoride free toothpaste|toothpaste with no fluoride
88814543|NCT01607411|Experimental|1426ppm Fluoride Toothpaste|Experimental toothpaste containing 1426 ppm Fluoride
88814544|NCT01607411|Experimental|1000 ppm Fluoride Toothpaste|Experimental toothpaste containing 1000 ppm Fluoride
88814545|NCT01607411|Experimental|500 ppm Toothpaste|Experimental toothpaste containing 500 ppm Fluoride
88814546|NCT01691339|Experimental|Fluzone vaccine (Group 1)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
88814547|NCT01691339|Experimental|Fluzone Intradermal vaccine (Group 2)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone Intradermal vaccine intradermally
88814548|NCT01691339|Experimental|Fluzone vaccine (Group 3)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
88814549|NCT01691339|Active Comparator|Fluzone High-Dose Vaccine (Group 4)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone High-Dose vaccine intramuscularly
88814550|NCT01692743|No Intervention|Standard of Care|Participants undergo usual follow up (routine and as needed office visits and telephone calls) and receive educational fact sheets from the Crohn's and Colitis Foundation of America.
88814551|NCT01692743|Experimental|Weekly Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
88814552|NCT01692743|Experimental|Home Monitoring Every Other Week|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
88814553|NCT02233751|Experimental|Testosterone enanthate auto-injector - 50 mg|Testosterone enanthate auto-injector - 50 mg (SC injection)
88814554|NCT02233751|Experimental|Testosterone enanthate auto-injector - 200 mg|Testosterone enanthate auto-injector- 200 mg (SC injection)
88814555|NCT02233985|Active Comparator|Nebulized 0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
88814556|NCT02233985|Experimental|Nebulized 3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
88814557|NCT01607645|Experimental|Arm1: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
88814577|NCT04942938|Experimental|Neubie Treatment|"Participants in this study will participate in intervention treatment with the Neubie for 6 weeks. Outcome measures objective and subjective will be collected at the beginning and end of the study. The treatments will include:~Manual activations to underactive, spastic or limited in sensory muscles/regions~Neubie Mapping mode scanning process to scan for 1) spots that stimulate movement they couldn't do before per initial assessment, 2) spots that allow movement which is a greater range than available before per initial assessment, 3) spots that lead to decreased spasticity, and 4) diminished sensation areas - drive signal to increase sensory nerves and become metabolically active.~Train using physical therapy exercises with Neubie in training mode and Hz current adjusted for tolerance (perceived 7/10) and ability to work through or decrease spasticity in (500 Hz) in the areas which show spasticity, contraction, are dead/diminished sensation, and hot spots."
88814578|NCT04942470|Experimental|Experimental:Intervention Arm|For the experimental group patients, sponges prepared by impregnating cream containing Aloe Vera and Propolis will be sterilized in the sterilization device. If any contamination occurs in the wound area of the patient (in the presence of feces, discharge), the product is applied to the wound bed after cleaning the wound with 0.9% isotonic sodium chloride washing solution. And the effects of the product on the wound will be monitored. The solution will be applied 2 times a day for the first 10 days. The second 10 days will be applied daily 1x1. Application results will be recorded and wound healing status will be monitored. In order to prevent and maintain pressure injury, the experimental group patients will be given an in-bed position every 2 hours. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure, etc.), necessary treatment and care is performed.
88814579|NCT04942470|No Intervention|No Intervention:Control Arm|In control group patients, if any pollution occurs in the wound area (feces, discharge) in the sterile dressing performed in the morning and evening at 10-22 hours, the wound area will be cleaned with the help of 0.9% isotonic sodium chloride washing solution and the clinical routine application of the pressure injury of the hospital will be carried out according to the physician's order. In patients in the control group, the results of the application will be recorded and wound healing status will be observed. An in-bed position will be given every 2 hours for the prevention and care of pressure injury patients of the control group patients. If there is a deficiency or deterioration in the patient's laboratory findings (hemoglobin, albumin, prealbumin, leukocyte, blood sugar, SaO2, fever, pulse, blood pressure and other), the necessary treatment and care will be performed.
88814580|NCT00942578|Experimental|Single Arm - 4 Drug Combination|A two dose level escalation of Lenalidomide from 15mg to 20mg to 25mg- standard 3+3 dose escalation approach in combination with docetaxel, Bevacizumab and prednisone.
88814581|NCT02229461|Experimental|IR ASA co-administered with naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
88814582|NCT02229461|Experimental|IR ASA 30 min after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
88814583|NCT02229461|Experimental|IR ASA 8 hours after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
88814584|NCT02229461|Active Comparator|IR ASA only|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
88814585|NCT02229461|Experimental|IR ASA 30 min before naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
88814586|NCT02229461|Experimental|IR ASA 30 min after first dose of naproxen sodium bid|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
88814587|NCT04356482|Experimental|single arm|"Determine the convalescent plasma dose to be administered to two groups: one severely ill (not intubated) and one very severely ill (intubated).~Second phase: safety and efficacy of the plasma dose found in the same two types of patients."
88814588|NCT04641104|Experimental|Thiamine|Patients in this arm will receive a solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9%.
88814589|NCT04641104|Placebo Comparator|Placebo|Patients in this arm will receive a solution of 100 ml of NaCl 0.9% alone.
88814590|NCT01695473|Experimental|Neoadjuvant BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in operating room (OR) scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
88814591|NCT02237417|Other|Healthy Control|
88814592|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group A)|
88814593|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group B)|
88814595|NCT04359836||General Population|The general population will have their microbiome sequenced from stool samples provided.
88814596|NCT03833492|Experimental|Underwater EMR|"The patients who are randomized to the  Underwater EMR arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
88814597|NCT03833492|No Intervention|Traditional EMR|"The patients who are randomized to the  Traditional EMR arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
88814598|NCT00942890|Experimental|NMES plus Standard Rehab Protocol|"NMES (EMPI 300PV stimulator) plus standard of care intervention. NMES is to the quadriceps muscle of the residual and intact limb plus rehabilitation. Therapy is 12-wks of NMES home training w/ the EMPI 300PV muscle stimulator. Participants perform training at home for 5days/wk; sessions consisted of 15 to 20 min. of NMES to each leg eliciting15 contractions/leg (10 seconds on:50 seconds off), plus a 5-minute patient treatment log, 5x/wk for 12-wks. Each contraction will be elicited by an electrical impulse generated by a battery-operated device. Two 3 X 5 electrodes are placed over the quadriceps muscle group. Participants will train at 30-40% of MVC during weeks 1-6, and 40-50% of MVC during weeks 7-12; incremental increases will be made at the study visits."
88814599|NCT00942890|Active Comparator|Standard Rehab Protocol|TMARP standard of care intervention: 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1 week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
88814600|NCT02245490|Experimental|Tamsulosin|
88814601|NCT02245490|Placebo Comparator|Placebo|
88814602|NCT04356092|Experimental|Perfusion|Consecutive patients scheduled to undergo infrapopliteal angioplasty or stenting, or both, as part of their standard treatment for Rutherford-Becker class 5 and 6 chronic limb-threatening ischemia, were included in the study. All procedures were performed using local anesthesia. An antegrade access was used in all patients followed by the deployment of a 5 or 6 Fr arterial sheaths. A semi-lateral foot projection was preferred and the pre-revascularization DSA of the foot was performed via a 5 Fr angiographic catheter placed at the distal third of the popliteal artery. Following revascularization of one or more tibial arteries, the catheter was placed at the same popliteal segment and post-procedural DSA of the foot was performed following the exact pre-revascularization injection protocol at the same semi-lateral projection. The 2D-perfusion imaging and analysis of the DICOM files was performed after revascularization.
88814603|NCT04355936|Experimental|TELMISARTAN|Patients in this group will receive 80 mg Telmisartan twice daily plus standard care.
88814604|NCT04355936|No Intervention|CONTROL|Patients in this group will receive standard care.
88814605|NCT00934934|Placebo Comparator|Placebo|Saline will serve as the placebo solution since the active comparator is clear and colourless.
88814606|NCT00934934|Active Comparator|Antifungal|Patient will receive a dose daily for a total of 14 days
88814607|NCT01651793|Active Comparator|Caffeinated cocoa|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
88814608|NCT01651793|Active Comparator|Cocoa|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
88814609|NCT01651793|Active Comparator|Caffeine|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
88814610|NCT01651793|Placebo Comparator|Placebo|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
88814611|NCT01611779|Experimental|Tongue suspension|Tongue-based suspension
88814612|NCT01699373|Experimental|Ultrasound-assisted|Pre-procedural ultrasound scan performed
88814613|NCT01699373|No Intervention|Manual Palpation|
88814614|NCT01652495|Active Comparator|methylprednisolone acetate group|Single intrabursal injection of methylprednisolone acetate
88814615|NCT01652495|Active Comparator|Triamcinolone acetonide group|Single intrabursal injection of Triamcinolone acetonide
88814616|NCT00935792|Experimental|Arm I|Patients receive oral everolimus thrice weekly for 9 weeks and alemtuzumab subcutaneously thrice weekly for 8 weeks.
88814617|NCT01699607|Experimental|amphetamine|There is only one arm to the study. All subjects will receive amphetamine at 0.5mg/kg prior to the second PET scan.
88814618|NCT04355468|Active Comparator|Control group|General anesthesia was induced with midazolam 0.1 mg∙kg-1, propofol 2 mg∙kg-1, and cisatracurium 0.15 mg∙kg-1. The patients were intubated with a left-sided double-lumen tube in adequate size and positioned laterally. Anesthesia was maintained with 1 minimum alveolar concentration (MAC) sevoflurane. The patients awoke from anesthesia in a post-anesthesia care unit, and were extubated after the administration of adequate doses of atropine and neostigmine as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
88814619|NCT04355468|Experimental|Opioid Free Aneasthesia group|General anesthesia was induced with midazolam 0.1 mg∙kg-1, propofol 2 mg∙kg-1, and cisatracurium 0.15 mg∙kg-1. The patients were intubated with a left-sided double-lumen tube in adequate size and positioned laterally. Anesthesia was maintained with 1 minimum alveolar concentration (MAC) sevoflurane. The patients awoke from anesthesia in a post-anesthesia care unit, and were extubated after the administration of adequate doses of atropine and neostigmine as required. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anesthetist before commencing the patient controlled analgesia (PCA). This dose was titrated to achieve adequate analgesia. Each patient then commenced PCA. The PCA solution was oxycodone (1mgml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. Additionally, patients were given 1 g intravenous paracetamol every 6 h and 100mg of intravenous ketoprofen every 12 h.
88814620|NCT04355624||ICU patients|COVID-19 patients admitted in Intensive Care Units
88814621|NCT04355624||Non ICU patients|COVID-19 patients admitted in conventional units
88814622|NCT01699763|Experimental|Subjects with and without Diabetes|All testing and lancing were performed by the study staff; Subjects with and without Diabetes did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using three Blood Glucose Monitoring Systems (BGMS): Contour® NEXT LINK BGMS; OneTouch® UltraLink® BGMS; Nova Max Link® BGMS.
88814623|NCT04355000|Active Comparator|Hall Technique|In Hall Technique, SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
88814699|NCT04355078|Experimental|Strength Training|The rehabilitation program starts two months after surgery, 45 minutes daily session, 3 times a week for 6 weeks that includes straight leg raising exercises, Supine position-isometric quadriceps contraction, Supine position-knee flexion and extension ROM exercises, the heel in contact with the bench during the ROM, Prone position-straight leg raising exercises, Prone position-knee flexion & Extension ROM exercises, Stationary biking-before reaching 100 degrees of flexion(Progression: stair climbing and strength exercises), Standing-full weight-bearing, controlled balance double-limb support during parallel and diagonal stance, controlled knee extension, emphasis on full knee extension in weight-bearing position 3 10 reps Standing heel rising exercises both legs and one leg, 1 leg and 2 leg Wobble board Exercise, Step Up and down low height, Squatting exercises without bars/weight, Hamstrings, hip adductor and abductor strengthening exercises and progress after every two weeks
88814700|NCT01620593|Placebo Comparator|Placebo|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy.
88814701|NCT01620593|Active Comparator|Metformin|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy. In the rare case where a patient may not tolerate 500 mg three times a day, he may remain on the study taking only 500 mg twice a day.
88814702|NCT00939536|Experimental|Torrent's Zolpidem Tartrate Tablets 10 mg|Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg
88814703|NCT00939536|Active Comparator|Sanofi-Synthelabo's Ambien® 10 mg Tablets|Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets
88814704|NCT02982122|Experimental|CPPopt intervention group|Patients are managed according to Brain Trauma Foundation guidelines, except for CPP where the CPPopt is targeted.
88814705|NCT02982122|Active Comparator|CPP control group|"Patients are managed according to Brain Trauma Foundation guidelines with CPP between 60 and 70 mmHg.~CPPopt information is recorded but hidden for the treating clinicians."
88814706|NCT02981810|Active Comparator|control|tonsillectomy
88814707|NCT02981810|Experimental|coblation|coblation of the tonsills
88814708|NCT04358354|Experimental|FOLFOXiri group|Irinotecan 150 mg/m2 iv drip d1; Oxaliplatin 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
88814709|NCT04358354|Active Comparator|FOLFOX group|Oxaliplatin: 85 mg/m2 iv drip d1; LV 200 mg/m2 iv drip d1; 5FU 400mg/m2 iv bolus and 2400 mg/m2 civ 46h; The regimen will be repeated every 2 weeks until disease progression or untolerable toxicity.
88814710|NCT03531086||Ioflupane I123|Participants will receive Ioflupane I123 as an adjunct diagnostic tool in combination with single photon emission computer tomography (SPECT) to evaluate striatal dopamine transporter. Patients will serve as their own control longitudinally.
88814711|NCT03524378|Other|Ergonomic and movement modifications|No group assignment - all participants will self select suitable ergonomic or movement modifications
88814712|NCT03516968|Experimental|Monthly bolus arm|
88814713|NCT03516968|Active Comparator|Daily arm|
88814714|NCT03516968|Other|Control group|Group of obese patients without vitamin D deficiency
88814715|NCT04354766||Convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID + on the temporary sampling platform that was set up at HCL at the start of the epidemic, which notably concerns symptomatic healthcare professionals for whom hospitalization does not was not necessary.
88814716|NCT04354766||Hospitalized convalescent patients diagnosed with COVID +|Five convalescent patients (minimum 12 days after the onset of symptoms), diagnosed COVID +, hospitalized in the infectious diseases department of the Croix-Rousse hospital living in the metropolitan area of Lyon, having presented hypoxaemic pneumonia requiring hospitalization.
88814717|NCT04355156|Experimental|Axitinib|small molecule multi-kinase inhibitor
88814718|NCT04355156|Placebo Comparator|Placebo|
88814719|NCT04358510||COViage|Machine learning intervention
88814720|NCT03032666|Experimental|sofosbuvir/velpatasvir|Epclusa
88814721|NCT03318380|Experimental|Diagnostic Contrast-Enhanced Ultrasound Imaging (CEUS)|Patients receive sulfur hexafluoride IV and undergo CEUS imaging over 10 minutes.
88814722|NCT03199274|Experimental|Group I (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo CEUS over 60 minutes at 1-6 hours and at approximately 7 and 14 days after yttrium Y-90 radioembolization.
88814723|NCT03199274|Active Comparator|Group II (standard of care)|Patients undergo standard of care yttrium Y-90 radioembolization.
88814724|NCT04354610|Other|Patients hospitalized for Covid-19 infection|"Patients hospitalized for Covid-19 infection will undergo the following evaluations:~Clinical examination~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
88814725|NCT04354376||Loop diuretics, thiazides, dihydropyridines|Reference group
88814726|NCT04354376||Telmisartan|Exposure group
88814727|NCT03032588|Experimental|Group 1: sIPV|Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.
88814728|NCT03032588|Active Comparator|Group 2: cIPV|Participants will receive single intramuscular injection of the currently used trivalent inactivated poliovirus vaccine IMOVAX POLIO, based on the conventional Salk poliovirus strains produced on Vero cells (cIPV) on Day 1.
88814729|NCT03032432|Experimental|Dynamic elastic garment and injection|
88814730|NCT03032432|Active Comparator|Corticosteroid injection|
88814731|NCT02939924|Experimental|DCB treatment|Patient treated with Kanshas DCB
88814732|NCT03032354|Experimental|Probiotics arm: Probiotics group|combination of probiotics: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 in the same capsule
88814733|NCT03032354|Placebo Comparator|Placebo arm: Placebo group|Placebo - maltodextrin
88814734|NCT02777372|Experimental|Sertraline|To determine the impact of short term luteal phase treatment with Sertraline 50mg tablets (PMDD group only) on acoustic startle response across the menstrual cycle. Sertraline 50 mg tablets are administered daily from ovulation until menses onset.
88814735|NCT02777372|No Intervention|Control|No intervention.
88814736|NCT04354142|Experimental|iSpy|In addition to usual care, participants in the intervention group will receive the iSpy intervention.
88814827|NCT03030950|Placebo Comparator|Control group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
88814828|NCT02022644|Experimental|Group 1 - 20 mg|Tumor diameter: 1 cm, Tumor volume: ~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 20 mg/ml, Infusion time: 6-24 hours, no more than 48
88814829|NCT02022644|Experimental|Group 2 - 40 mg|Tumor diameter: 2 cm,Tumor volume: ~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
88814830|NCT02022644|Experimental|Group 3 - 140 mg|Tumor diameter: 3 cm, Tumor volume: ~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 140 mg/ml, Infusion Time: 6-24 hours, no more than 48
88814831|NCT02022644|Experimental|Group 4 - 340 mg|Tumor diameter: 4 cm, Tumor volume: ~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 340 mg/ml, Infusion Time: 6-24 hours, no more than 48
88814832|NCT02022644|Experimental|Group 5 - 40 mg|Tumor diameter: 1 cm, Tumor volume: ~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
88814833|NCT02022644|Experimental|Group 6 - 80 mg|Tumor diameter: 2 cm, Tumor volume: ~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 80 mg/ml, Infusion Time: 6-24 hours, no more than 48
88814834|NCT02022644|Experimental|Group 7 - 280 mg|Tumor diameter: 3 cm, Tumor volume: ~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 280 mg/ml, Infusion Time: 6-24 hours, no more than 48
88814835|NCT02022644|Experimental|Group 8 - 680 mg|Tumor diameter: 4 cm, Tumor volume: ~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 680 mg/ml, Infusion Time: 6-24 hours, no more than 48
88814836|NCT01664897|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
88814837|NCT05417906|Active Comparator|Standard care|
88814838|NCT05417906|Experimental|Eosinophil-directed care|
88814839|NCT03034148|Other|Coronary artery disease|blood sampling for biomarkers assessment in a population undergoing coronary angiogram
88814840|NCT01664975|Experimental|GDPT regimen|GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen
88814841|NCT01664975|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
88814842|NCT03030794|Active Comparator|Repetitive TMS|Subjects will receive the repetitive transcranial magnetic stimulation study procedure.
88814843|NCT03030794|Placebo Comparator|No (blocked) repetitive TMS|Subjects will not receive the repetitive transcranial magnetic stimulation study procedure by blocking the stimulation between the coil and the head, but the audiovisual conditions will be mimicked.
88814844|NCT03034070|Other|Diagnostic performance 3D T1|A 3D T1-weighted GE mDixon MR imaging sequence will be added to the routine 3D T1-weighted FSE sequence. mDixon sub-sequences (Fat and In Phase) are compared to 3D T1-weighted FSE in terms of diagnostic accuracy for M and N staging in prostate cancer patients: Fat, In Phase, Fat+In Phase and the routine 3D T1 will be analyzed separately, blindly and randomly.
88814845|NCT03033680|Experimental|Multiple System Atrophy (MSA)|Eight subjects with a probable MSA diagnosis will be recruited for this study. Each subject will undergo a [F-18]PBR06 PET scan at baseline, and at 9 months follow-up.
88814846|NCT00950612|Experimental|Group A|
88814847|NCT00950612|Placebo Comparator|Group B|
88814848|NCT01665053|Active Comparator|Promus Element Plus|PROMUS Element Plus is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
88814849|NCT01665053|Experimental|SYNERGY|SYNERGY is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
88814850|NCT05292638|Experimental|CKDB-501A|
88814851|NCT05292638|Active Comparator|Botox®|
88814852|NCT03030716|Experimental|0.03 mg 95% condensed proanthocyanidin|0.03 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.03 g 95% condensed proanthocyanidins from grape seed extract at week 4
88814853|NCT03030716|Experimental|0.25 g 95% condensed proanthocyanidin|0.25 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.25 g 95% condensed proanthocyanidins from grape seed extract at week 4
88814854|NCT03030716|Experimental|1.5 g 95% condensed proanthocyanidin|1.5 g 95% condensed proanthocyanidins from grape seed extract at week 0 1.5 g 95% condensed proanthocyanidins from grape seed extract at week 4
88814855|NCT05219864|Experimental|Ruxolitinib|Ruxolitinib cream 1.5% twice daily (BID) for 16 weeks followed by ruxolitinib cream 1.5% BID for an additional 16-week treatment extension period.
88814856|NCT05219864|Placebo Comparator|Vehicle|Vehicle cream for 16 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 16-week treatment extension period.
88814857|NCT05282615|Experimental|Treatment Group (Emanate Tray)|Full mouth periodontal debridement + Emanate Tray (treatment group)
88814858|NCT05282615|No Intervention|Control Group|Full mouth periodontal debridement alone (control group)
88814859|NCT04353362|Experimental|Ofloxacin group|
88814860|NCT04353362|Active Comparator|Amoxicillin plus Metronidazole group|
88814861|NCT00946478|Active Comparator|Pimecrolimus|
88814862|NCT00946478|Sham Comparator|Vehicle cream|
88814863|NCT01667471|Experimental|RoActemra/Actemra|
88814864|NCT03030482|Experimental|Touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
88814865|NCT03030482|No Intervention|control|standard care ICU
88814866|NCT03033524|Experimental|Cohort 1|Patients will be treated with 8mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
88814867|NCT03033524|Experimental|Cohort 2|Patients will be treated with 12mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
88815106|NCT03019484|Experimental|Intervention|The intervention consisted on breastfeeding support at three stages: a) week 28-39 pregnancy: women were provided with written information and watch a breastfeeding self-efficacy enhancing video; b) during hospitalization after birth: based on their responses to the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF) questionnaire and the observation of a whole breastfeed, nurses provided specific advice using active listening. All the relevant information was registered; c) within one week after birth: a nurse or midwife made a phone call to follow-up mothers breastfeeding behaviour, addressing issues that during the hospitalization needed reinforcement, solving any question or matter that they had and providing positive reinforcement.
88815107|NCT03019484|No Intervention|Control: Standard Care|"This group received standard antenatal and postnatal care by midwives and nurses caring for them during their regular antenatal visits and after delivery.~The professionals delivering the intervention were the same than those providing the standard care. That was the reason to first collect the data from the control group and after that organising the training of health professionals to deliver de intervention."
88815108|NCT05395676|Experimental|Cognitive dual task training (CDT) Group|The CDT group (n = 20) will participate in games on Xbox one consoles that require a higher cognitive demand compared to those of the BDT group. The training sessions will include five different games that require participants to stand and use their hand reach function to interact with different cognitive (i.e. dual-tasking) skills, such as working memory, problem solving, Stroop effect, planning, attention and response time.
88815109|NCT05395676|Active Comparator|Balance dual task (BDT) training Group|The BDT group (n = 20) will participate in the conventional training programme on Wii consoles that have been used by previous studies (Barcala et al. 2013; Chao et al. 2015; Kannan et al. 2019), to improve balance performance. The training sessions will include five different games that require participants to stand and use their weight shift to control the game while maintaining balance.
88815110|NCT01684007|Experimental|Bilateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
88815111|NCT01684007|Active Comparator|Contralateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] and AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1, contralateral implantation
88815112|NCT02249897|Placebo Comparator|PLACEBO|AFTER COMPLETING THE INITIAL EVALUATION (ANTHROPOMETRY, SERUM BIOCHEMISTRY AND CML LEVELS, FUNDUS, MUTIFOCAL ELECTRORETINOGRAM AND OPTIC NERVE CONDUCTION VELOCITY) PATIENTS WILL RECEIVE ORAL PLACEBO CAPSULES 4 PER EACH MEAL/DAY DURING 12 WEEKS
88815113|NCT02249897|Active Comparator|CHOLESTIRAMINE|AFTER COMPLETING THE CONTROL PERIOD (PLACEBO CAPSULES) PATIENTS WILL BE REASSESSED, AND THEN TREATED WITH ORAL CHOLESTYRAMINE 6 G/DAY (500 MG CAPSULES -> 4 CAPSULES PER EACH MEAL/DAY) DURING 12 WEEKS AND E SAME INITIAL EVALUATION WILL BE REPEATED
88815114|NCT00963872|Experimental|Complement Fragment 3A - Small Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
88815115|NCT00963872|Experimental|Complement Fragment A - Larger Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
88815116|NCT00964496|Active Comparator|Thalidomide Group|
88815117|NCT00964496|Other|Iron-controlled Group|
88815118|NCT02245880|Active Comparator|Glidescope videolaryngoscope|cervical collar was applied to 47 patients then facemask ventilations were recoded intubated with Glidescope and insertion time: handling of the device till the good glottic visualisation intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device after removal heart rate preinduction heart rate postinduction heart rate postinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation wrere recorded. postoperative minor complications were recorded.
88815119|NCT02245880|Active Comparator|Intubating laryngeal mask airway|cervical collar was applied to 47 patients then facemask ventilations through the collar were recorded and intubated with ILMA insertion time: handling of the device till the good glottic visualisation appears intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device heart rate preinduction heart rate postinduction heart rate posinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation
88815120|NCT02981654|Experimental|Femilift treatment|"The Alma Lasers Pixel carbon dioxide laser system delivers fractionated laser energy through a special lens that divides the energy into a 9 x 9 (81) matrix of 1 cm square area. The fractional laser rays cause thermal damage that reaches the vaginal sub - epithelium to stimulate the growth of new collagen.~Intervention: FemiLift vaginal handpiece is inserted into the vagina, to deliver CO2 laser energy. The vaginal epithelium is covered by rotation of vaginal handpiece in 360 degrees, releasing laser energy at 6-8 points, and than withdrawn 1 cm each time to perform the same process, to cover the the total vaginal length."
88815121|NCT01685021|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-optimized Anti-CD19 Antibody
88815122|NCT05691101|Experimental|Continuous interscalene brachial plexus block(CISB) with IV PCA group|Patients in this group received continuous interscalene brachial plexus block(CISB) and intravenous PCA
88815123|NCT05691101|Active Comparator|Continuous interscalene brachial plexus block (CISB) group|Patients in this group received continuous interscalene brachial plexus block (CISB)
88815124|NCT04834193|Experimental|WET-SUCTION|The stylet will be removed and the needle will be pre-flushed with 1-2mL of saline. The lesion will then be punctured, and suction will be applied using a 10-mL pre-vacuum syringe. The sample collected will be pushed into a formalin vial with saline.
88815125|NCT04834193|Active Comparator|SLOW-PULL|After puncturing the lesion, the stylet will be slowly and gradually withdrawn for at least 40cm. The sample will be pushed into formalin using the stylet.
88815126|NCT00966446|Experimental|Unsupervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided.
88815939|NCT03013010|Experimental|Preoperative radiochemotherapy|"1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~5 weeks preoperative chemoradiotherapy.~1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
88815913|NCT01099358|Experimental|Cetuximab and Cisplatin (C)|"Cycle 1 (4 weeks, combination therapy):~100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks combination therapy):~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
88815914|NCT01099358|Experimental|Cetuximab on Cisplatin (B)|"Cycle 1:~400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1.~Cycle 2:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~Cycle 3 + :~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
88815915|NCT01099358|Experimental|Cisplatin on Cetuximab (A)|"Cycle 1:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1.~Cycle 2 +:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on weeks 1-3, day 1.~After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
88815916|NCT03388034||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing"
88815917|NCT03388034||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing~Blood sampling:~A blood sample collected by fingerprick"
88815918|NCT03388034||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
88815919|NCT01118624|Experimental|Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin (Folotyn)|"Intravenous (IV) push administration over 3-5 minutes. Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
88815920|NCT02461563|Experimental|GT1: 200 mg MK-1075|Fasted GT1 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
88815921|NCT02461563|Experimental|GT1: 400 mg MK-1075|Fasted GT1 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
88815922|NCT02461563|Experimental|GT1: 800 mg MK-1075|Fasted GT1 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
88815923|NCT02461563|Experimental|GT3: 200 mg MK-1075|Fasted GT3 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
88815924|NCT02461563|Experimental|GT3: 400 mg MK-1075|Fasted GT3 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
88815925|NCT02461563|Experimental|GT3: 800 mg MK-1075|Fasted GT3 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
88815926|NCT02438475|Active Comparator|Mynx Vascular Closure System|Where subjects will have venous hemostasis attempted to be achieved using the Mynx Vascular Closure system alone
88815927|NCT02438475|Other|Manual Compression|Where patients will have venous hemostasis attempted to be achieved using manual compression alone
88815928|NCT02439879|Active Comparator|alpha lipoic acid treatment|After a decrease in the total symptoms score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
88815929|NCT02439879|No Intervention|alpha lipoic acid withdrawal|After a decrease in the total symptoms Score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment
88815930|NCT03371108|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
88815931|NCT03371108|Active Comparator|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
88815932|NCT02517567|Other|Sequence 1|Delefilcon A, then narafilcon A, then somofilcon A, then no lens wear. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
88815933|NCT02517567|Other|Sequence 2|Narafilcon A, then no lens wear, then delefilcon A, then somofilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
88815934|NCT02517567|Other|Sequence 3|Somofilcon A, then delefilcon A, then no lens wear, then narafilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
88815935|NCT02517567|Other|Sequence 4|No lens wear, then somofilcon A, then narafilcon A, then delefilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
88815936|NCT02980172||Pain triage complaint|Patients admitted at GUH ED triaged with a main complaint requiring a pain evaluation.
88815965|NCT02524977|Active Comparator|Educational Intervention Only|"Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process."
88815966|NCT02524977|Experimental|Educational Intervention plus Decision Support|Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.
88815967|NCT01103414|Experimental|Mitoglitazone 50 mg capsules|Mitoglitazone 50 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
88815968|NCT01103414|Experimental|Mitoglitazone 100 mg capsules|Mitoglitazone 100 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
88815969|NCT01103414|Experimental|Mitoglitazone 150 mg capsules|Mitoglitazone 150 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
88815970|NCT01103414|Active Comparator|Pioglitazone 45 mg capsules|Pioglitazone 45 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
88815971|NCT01103414|Placebo Comparator|Matching placebo|Placebo capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
88815972|NCT01103492|Experimental|Ablation catheter|Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.
88815973|NCT03012932|Other|HPV Self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
88815974|NCT02525055|Experimental|Infectious titre 1|6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10*3 TCID50 of virus
88815975|NCT02525055|Experimental|Infectious titre 2|6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10*4 TCID50 of virus
88815976|NCT02525055|Experimental|Infectious titre 3|6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10*5 TCID50 of virus
88815977|NCT02525055|Experimental|Infectious titre 4|6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10*6 TCID50 of virus
88815978|NCT02525055|Experimental|Infectious titre 5 (age 18 to 45 y)|6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
88815979|NCT02525055|Experimental|Infectious titre 5 (age 46 to 64 y)|16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
88815980|NCT02180828|Experimental|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
88815981|NCT02180828|Active Comparator|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
88815982|NCT02466087|Experimental|Mg Cl|500mg Mg Cl per day for 6 weeks
88815983|NCT02466087|No Intervention|Control|No intervention
88815984|NCT01105754|No Intervention|Standard Care|Parents of children in the standard care group will complete the baseline assessment, but no asthma prompt will be created for either the caregiver or provider, and no information regarding the interview will be shared with the provider. After the baseline assessment, the office visit will proceed according to usual care.
88815985|NCT01105754|Experimental|Multifaceted Prompting Intervention|Multifaceted Prompting Intervention
88815986|NCT02525523|Experimental|Alicaforsen|Alicaforsen enema, 240mg once daily for 6 weeks
88815987|NCT02525523|Placebo Comparator|Placebo|Placebo enema, once daily for 6 weeks
88815988|NCT02528409|Placebo Comparator|Placebo|10 milligrams per day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
88815989|NCT02528409|Experimental|Vortioxetine|10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
88815990|NCT02467179|Active Comparator|Manual Catheter Manipulation|25 subjects will be randomized to this arm. Manual catheter ablation of the cavo-tricuspid isthmus will be performed.
88815991|NCT02467179|Experimental|Amigo™ Robotic Catheter Manipulation|25 subjects will be randomized to this arm. Robotic catheter ablation of the cavo-tricuspid isthmus with the Amigo Catheter System will be performed.
88815992|NCT01122446|Placebo Comparator|Placebo comparator|Two doses of placebo day 1 and 30
88815993|NCT01122446|Active Comparator|Alum-GAD (Diamyd)|20 microgram Diamyd day 1 and 30
88815994|NCT02530281|Experimental|glycopyrronium|glycopyrronium Topical Wipes
88815995|NCT02530281|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
88815996|NCT02236832|Experimental|FTD (frontotemporal dementia) patients|fronto-temporal demential patients
88815997|NCT02236832|Experimental|PSP patients|progressive supra nuclear palsy patients
88815998|NCT02236832|Active Comparator|healthy controls|healthy control education matched, age matched and sex matched with PSP and FTD patients
88815999|NCT02236832|Experimental|healthy participants|healthy participants that will participate to the TMS study.
88816000|NCT02236832|Experimental|healthy young participants|Healthy participants will be included for an EEG study
88816025|NCT02538783|Experimental|Escalating lottery|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. In addition to the incentives for midpoint and end of study surveys, participants who meet their weekly goal (weighing in 6 of 7 days) will be eligible for the weekly lottery during the first 6 months of the study. The expected weekly winning for the lottery is $3.55 in week 1 and this expected value will increase by $0.43 per week for each week the participant achieves their goal of weighing 6/7 days. All incentive earnings will be paid out on a monthly basis.
88816026|NCT00363519|Placebo Comparator|P|
88816027|NCT00363519|Experimental|E|
88816028|NCT02471313|Experimental|[18F] FMISO PET scan|Patients with primary hepatic malignancy who underwent [18F] FMISO PET Scan following transarterial chemoembolization (TACE) procedure
88816029|NCT04743687|Experimental|Zanuburutinib|Oral Zanuburutinib 160mg twice a day
88816030|NCT04341285|Active Comparator|Early ECMO|Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
88816031|NCT04341285|Active Comparator|Late ECMO|Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.
88816032|NCT02542761|Experimental|CFPF first, then FPF|After a 4 week acclimation period, subjects were studied on their current carbon fiber composite foot (CFPF), followed by another 4 week acclimation period, then studied on the study provided fiberglass composite foot (FPF).
88816033|NCT02542761|Experimental|FPF first, then CFPF|After a 4 week acclimation period, subjects were studied on the study provided fiberglass composite foot (FPF), followed by another 4 week acclimation period, then studied on their current carbon fiber composite foot (CFPF).
88816034|NCT02474901|Active Comparator|QLAIV, HIV-infected|QLAIV administered to HIV-infected individuals 2 to 25 yoa
88816035|NCT02474901|Active Comparator|QLAIV, HIV-uninfected|QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
88816036|NCT02475837|Active Comparator|Vorapaxar intervention|"This arm will receive the study drug: Vorapaxar sulfate.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
88816037|NCT02475837|Placebo Comparator|Placebo intervention|"This arm will receive the matching placebo.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
88816038|NCT02477319||Part A|"Cohort 1: Healthy Controls~Cohort 2: Partial CFTR function CF (class IV/V)~Cohort 3: Absent CFTR function CF (Class I/II)"
88816039|NCT02477319||Part B|CF patients who are homozygous for the F508del
88816040|NCT01124786|Experimental|CO-1.01|
88816041|NCT01124786|Active Comparator|gemcitabine|
88816042|NCT02477709|Experimental|Gefapixant|Gefapixant oral tablets (150 mg) administered as a single dose
88816043|NCT01933958||Group 1|Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.
88816044|NCT01108406|Experimental|SoundBite Hearing System|"The objective of this study was to assess the long-term safety and quality of life impact of the SoundBite™ Hearing System.~Safety was measured in terms of dental, audiological and medical adverse events related to device or procedure.~Quality of Life was measured in terms of changes in Abbreviated Profile of Hearing Aid Benefit (APHAB) and as reported in a quality of life survey (SSD Questionnaire).~The duration of the study was 6 months with measures taken at Day 1, 3 months and 6 months."
88816045|NCT01125098||PRO-CT group: Experimental|COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.
88816046|NCT01125098||Standard group: No intervention|COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.
88816047|NCT02179424|Experimental|Health talk + Workshop + Booklet + SMS|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
88816048|NCT02179424|Experimental|Face-to-face counseling + Booklet + SMS|Face to Face counseling (Motivational intervention) + Booklet + SMS
88816049|NCT02179424|Experimental|Phone counseling + Health talk + Booklet + SMS|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
88816050|NCT02179424|Experimental|Phone counseling + Booklet + SMS|Phone counseling (Motivational intervention) + booklet + SMS
88816051|NCT02478489|Experimental|Extended-release injectable naltrexone (XR-NTX)|Monthly XR-NTX (380 mg) Subjects randomized to XR-NTX will receive one intramuscular gluteal injection (in accordance with the FDA approved label/package insert) of 380 mg of NTX for extended-release injectable suspension at study entry (in the hospital) and 1, and 2 months later (outpatient in the primary care clinic), alternating buttocks.
88816052|NCT02478489|Active Comparator|Oral naltrexone (PO-NTX)|Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
88816053|NCT02480439|Experimental|TAK-648 Sequence ABC|Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 3.
88816054|NCT02480439|Experimental|TAK-648 Sequence BCA|Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 3.
88816180|NCT02561481|Active Comparator|Sulforaphane|"Sulforaphane (SF) will be administered once a day orally in an approximate dose of 1 µmol/lb (2.2 kg µmol/kg) body weight. Each SF tablet will contain 125 mg broccoli seed powder (equivalent to ~ 15 µmol SF). The total dose per day will depend on participants' body weight:~30-50 lb: 3 tablets (45 µmol/day) 50-70 lb: 4 tablets (60 µmol/day) 70-90 lb: 6 tablets (90 µmol/day) 90-110 lb: 7 tablets (105 µmol/day) 110-130 lb: 8 tablets (120 µmol/day)~For pilot study, all participants (n=10) will receive SF for 14 days. For main clinical trial, 25 participants will randomly receive SF for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo to sulforaphane arm will take place, and all participants will receive SF from 15-30 weeks."
88816181|NCT02561481|Placebo Comparator|Placebo|"Placebo tablets identical in size and similar in appearance to the active tablets will be used. Number of placebo tablets will be equivalent to the active tablets depending on participants' body weight.~For the main clinical trial, 25 participants will be randomly allocated to receive placebo for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo arm to sulforaphane arm will take place, and all participants will receive sulforaphane from 15-30 weeks."
88816182|NCT01173848|Active Comparator|Vitamin D2|Patients randomized to take vitamin D2
88816183|NCT01173848|Active Comparator|Vitamin D3|Patient's randomized to take Vitamin D3
88816184|NCT02384538|Placebo Comparator|Placebo|Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
88816185|NCT02384538|Experimental|ABT-981|ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
88816186|NCT01174082|Experimental|KLH Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
88816187|NCT01174082|Experimental|KLH-id Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
88816188|NCT01174082|Experimental|KLH Vaccine (Donor)|Donor Group 1: (non-specific vaccination) vaccinated with KLH only vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
88816189|NCT01174082|Experimental|Vaccine KLH-id (Donor)|Donor Group 2: (myeloma specific vaccination) vaccinated with KLH-id vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collections.
88816190|NCT02566083|Active Comparator|non-toric intraocular lens|non-toric approved intraocular lens
88816191|NCT02566083|Active Comparator|toric intraocular lens|approved toric intraocular lens
88816192|NCT02410824|Experimental|stenfilcon A toric lens|Participants were randomized to wear stenfilcon A toric lens for one week during the cross over study.
88816193|NCT02410824|Active Comparator|etafilcon A toric lens|Participants were randomized to wear etafilcon A toric lens for one week during the cross over study.
88816194|NCT05185778||parasitic infected individuals received COVID-19 vaccine|parasitic infected individuals with helminthic or protozoan who received COVID-19 vaccines of any type
88816195|NCT05185778||parasitic infected individuals not received COVID-19 vaccine|parasitic infected individuals with helminthic or protozoan who don't receive COVID-19 vaccines of any type
88816196|NCT02491359|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
88816197|NCT01175798|No Intervention|No treatment (standard of care)|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
88816198|NCT01175798|Experimental|Vitamin D repletion|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
88816199|NCT02246894|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
88816200|NCT03012074|Experimental|Patients with Type II Diabetes|Patients with Type II Diabetes
88816201|NCT02181140|Other|EUS guided FNA and fine needle punction|punction of endosonographically identified space-occupying process with aspirating fine needle and pro core fine needle in a randomized order
88816202|NCT02384460|Experimental|SD-101-6.0 cream|SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
88816203|NCT02384460|Placebo Comparator|Placebo (SD-101-0.0) cream|SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
88816204|NCT02184494|Experimental|Blood Lactate Response in PD|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in a PD population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
88816205|NCT02184494|Experimental|Blood Lactate Response in MS|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in an MS population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
88816206|NCT02184494|Experimental|Blood Lactate Responses in Controls|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in healthy, older adults. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
88816207|NCT03012542|Experimental|Diet 1|Administered for 8 weeks.
88816208|NCT03012542|Experimental|Diet 2|Administered for 8 weeks.
88816209|NCT03011996|Experimental|CJ-12420 100mg|CJ-12420 100mg BID for 5 days
88816210|NCT03011996|Experimental|CJ-12420 50mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days
88816211|NCT03011996|Active Comparator|Pantoprazole 40mg + CLR 500mg + AMX 1g|coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days
88816212|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days
88816213|NCT03011996|Experimental|CLR 500mg/AMX 1g|CLR 500mg/AMX 1g BID for 5 days
88816214|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg/AMX 1g|coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days
88816215|NCT01178216|Experimental|Rituxan|All study patients will receive Rituxan 1g on day 15 from start of desensitization and either 3M or 6M post transplant depending on the presence of DSA.
88816225|NCT02437188|No Intervention|TAU|Current pre-surgery treatment includes a nurse-led patient education class covering the post-operative course and what to expect for pain control and recovery. Patients may be taking analgesia (i.e. opioids and/or non-opioids) preoperatively for a chronic pain condition and are prescribed analgesics, sedatives and/ or anxiolytics immediately prior to surgery. Intraoperatively, regional (i.e., spinal and femoral) anesthesia and analgesia is given and patients receive opioids, non-opioids, anticonvulsants and/or anxiolytics during the immediate postoperative period. Other pain treatments may be used, such as cryotherapy, music therapy, relaxation, imagery, etc. Patients are sent home with analgesia (often a combination medication of an opioid and acetaminophen) for breakthrough pain.
88816226|NCT02980250|Experimental|low dose|The premature infant in this group will be feed with 0.2mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
88816227|NCT02980250|Experimental|normal dose|The premature infant in this group will be feed with 0.4mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
88816228|NCT02980250|Experimental|over dose|The premature infant in this group will be feed with 0.6mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
88816229|NCT02980250|Placebo Comparator|placebo|The premature infant in this group will be feed with some vitamin which will dilute into the 5% glucose and have the same appearance and taste with the experimental team for 7 days and will be tested the residual percentage everyday.
88816230|NCT02491437|Experimental|Dydrogesterone tablets 3x10 mg|Dydrogesterone tablets 3x10 mg
88816231|NCT02491437|Experimental|Crinone 8% intravaginal progesterone gel 90 mg|Crinone 8% intravaginal progesterone gel 90 mg
88816232|NCT04919772||Stroke survivors|Chronic stroke, generally speaking chronic stroke refers to the period of recovery that takes place at least six months after the initial stroke event
88816233|NCT05071196|Experimental|Facilitated Vegan Diet|The facilitated vegan participants will self-prepare and consume 2 vegan meal kits per day for 4 weeks
88816234|NCT05071196|Active Comparator|Standard Omnivorous Diet|The standard omnivorous arm will self-prepare and consume 2 non-vegan meal kits per day for 4 weeks
88816235|NCT02383758|Experimental|Treatment Program|Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
88816236|NCT02383758|Active Comparator|Waitlist Control|Pediatric subjects with autistic spectrum disorder will wait for 8 weeks and then be offered treatment at that time.The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, participants will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
88816237|NCT02492451|Active Comparator|Endometrial Injury|Endometrial injury in luteal phase of preceding IUI cycle
88816238|NCT02492451|Active Comparator|Luteal Phase Support|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
88816239|NCT02492451|No Intervention|Control group|Only IUI
88816240|NCT02493621||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management.
88816241|NCT02493621||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
88816242|NCT01180478|Other|Narrow Band Imaging|Narrow Band Imaging (NBI)
88816243|NCT01180478|Other|White Light Trans Urethral Resection|White Light Trans Urethral Resection
88816244|NCT02566239|Experimental|Shared Data|"Share activity data with care team.~Participants will have sensor technology installed in their home and caregivers will be provided with the data via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
88816245|NCT02566239|No Intervention|Non-shared Data|"Participants will have sensor technology installed in their home and caregivers will NOT have data provided via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
88816246|NCT02410278|Experimental|DMF plus montelukast|DMF as described in the United States Prescribing Information (USPI) plus 10mg montelukast tablet once daily according to the prevailing product label (Singulair)
88816247|NCT02410278|Experimental|DMF plus placebo|DMF as described in the USPI plus matched placebo
88816248|NCT02566317|Active Comparator|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace.
88816249|NCT02566317|Experimental|Stand & Move|Move intervention (A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace) plus the installation of a sit-stand workstation.
88816250|NCT01181258|Experimental|Patients Receiving NK Cell Infusion|Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
88816316|NCT02501265|Experimental|Varenicline Adaptive Protocol|Participant chooses Varenicline treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Varenicline. Two weeks prior to TQD, cigarettes smoked per day is assessed. If the number of cigarettes smoked per day is reduced by >50%, the participant is considered a Varenicline responder, and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Varenicline non-responder and starts active Bupropion 1 week prior to TQD. Varenicline responders will continue active Varenicline and placebo Bupropion to 12 weeks post TQD. Varenicline non-responders will continue active Varenicline and active Bupropion to 12 weeks post TQD.
88816317|NCT02501265|Experimental|Nicotine Patch Adaptive Protocol|Participant choses Nicotine treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Nicotine Patches. Two weeks prior to TQD, cigarettes smoked per day is assessed. If cigarettes smoked per day is reduced by >50%, the participant is considered a Nicotine Patch responder and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Nicotine Patch non-responder and starts active Bupropion 1 week prior to the TQD. Nicotine Patch responders will continue active Nicotine Patches and placebo Bupropion to 12 weeks post TQD. Nicotine Patch non-responders will continue active Nicotine Patches and Bupropion to 12 weeks post TQD.
88816318|NCT01181492||*1/*1|Grouped by CYP3A4*1G polymorphism, wild-type homozygote
88816319|NCT01181492||*1/*1G|Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote
88816320|NCT01181492||*1G/*1G|Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote
88816321|NCT02408016|Experimental|Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
88816322|NCT02408016|Experimental|Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)|Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
88816323|NCT02408016|Experimental|Arm II (T lymphocytes, IL-2, surgery)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
88816324|NCT02579421|Active Comparator|Males - Progesterone|200 mg progesterone BID
88816325|NCT02579421|Placebo Comparator|Males - Placebo|placebo BID
88816326|NCT02579421|Active Comparator|Females - Progesterone|200 mg progesterone BID
88816327|NCT02579421|Placebo Comparator|Females - Placebo|placebo BID
88816328|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fed)|Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition.
88816329|NCT01181804|Experimental|Boceprevir Capsules then tablets (fed)|Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition.
88816330|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fasted)|Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast.
88816331|NCT01181804|Experimental|Boceprevir Capsules then Tablets (fasted)|Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast.
88816332|NCT00363987|Experimental|1|
88816333|NCT00363987|Other|2|
88816334|NCT04352114|Experimental|LY3461767 - Subcutaneous (SC)|LY3461767 administered SC.
88816335|NCT04352114|Placebo Comparator|Placebo - SC|Placebo administered SC.
88816336|NCT04352114|Experimental|LY3461767 - Intravenous (IV)|LY3461767 administered IV.
88816337|NCT01186250|Active Comparator|Pioglitazone|Pioglitazone
88816338|NCT01186250|Placebo Comparator|Placebo|Placebo
88816339|NCT01186406|Experimental|Gliadel, Radiation Therapy, Avastin, Temodar|Single arm study where patients with newly diagnosed Grade IV malignant glioma will receive Gliadel at the time of resection, followed by radiation therapy (XRT), Avastin, and Temodar for approximately 6 1/2 weeks, followed by Avastin and Temodar post-radiation
88816340|NCT02504073||PT's working in stroke in NW-Switzerland|"54 Physiotherapists (PT's) working in north-west Switzerland (at Bruderholzspital, RehaB Basel, Klinik Tschugg, Reha Rheinfelden, RehaClinic Zurzach) are asked to analyse videos of 6 hemiplegic patients when walking. They are asked to write down their main observations, the major problem and hypotheses about how this major problem is produced.~There is no intervention."
88816341|NCT04743375|Experimental|Sericin dressing with collagen|Sericin dressing with collagen
88816342|NCT04743375|Active Comparator|Bactigras|Commercial dressing
88816343|NCT02407704|Experimental|Aerobic Exercise + Venlafaxine XR|"Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Exercise will include walking on a treadmill 1 hour 3 times/week for 12 weeks. Heart rate will be closely monitored during sessions. The intensity of the exercise will start at 50% of the age-based maximum for the first week and then increase and be maintained at 60-70% of the age-based maximum for the remainder of the intervention.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
88816344|NCT02407704|Active Comparator|Venlafaxine XR Only|"Venlafaxine (Effexor) XR comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
88816345|NCT02504619|Experimental|CordIn|Transplantation of CordIn
88816346|NCT04431843|Experimental|Spirulina maxima extract|Spirulina maxima extract for 1.5 g/day
88816629|NCT05858476|Experimental|Chef V's 21-Day Starter Challenge Detox & Green Drink Supplement|"The detox program provides the three primary macronutrients alongside antioxidants to promote detoxification. The 21-Day Detox schedule is below:~Days 1-7: Healthy Routine- The Healthy Routine involves drinking a 16oz Green Drink and Protein Shake for breakfast and then choosing their lunch, snack, and dinner from the Meal Planner that will be provided.~Days 8-10: 3-Day Cleanse- Each day during the three-day cleanse, participants will consume 4 16oz Green Drinks, 2 Protein Shakes, and a Soup designed explicitly to detox the body.~Days 11-21: Healthy Routine- The last period of the 21 days will mimic the Healthy Routine from Days 1-7.~Days 21-28 Participants will follow up this program by using the Green Drink supplement provided for an additional 7 days."
88816630|NCT05858424|Experimental|Group A : former patients with multidisciplinary day hospitalization|In this group, a multidisciplinary day hospitalization will be programmed after the end-of-treatment evaluation and 2 months after the end of treatment at the latest. This day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview.
88816631|NCT05858424|No Intervention|Group B : former patients without multidisciplinary day hospitalization|In this group, the former patients will experiment the standard of care, with an oncological follow-up.
88816632|NCT05858411|Experimental|SRP+rhPDGF|After SRP the infrabony defect will be filled with a collagen sponge soaked in rhPDGF.
88816633|NCT05858411|Active Comparator|SRP+ collagen sponge|After SRP the infrabony defect will be filled with a collagen sponge soaked in saline solution.
88816634|NCT05858411|Active Comparator|SRP alone|SRP alone will be performed.
88816635|NCT05858398|Experimental|Pharmocokinetics blood sample assessment|during first administration of docetaxel several pharmacokinetics samples will be assessed
88816636|NCT05858372|Experimental|Chios Mastiha essential oil|1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
88816637|NCT05858372|Placebo Comparator|Placebo|1 soft gel capsule only 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
88816638|NCT05858346|Experimental|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
88816639|NCT05858346|Active Comparator|Cognitive Behavioral Therapy for Social Anxiety Disorder|To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
88816640|NCT05858333|No Intervention|Group 1: (day 5 group)|Women will undergo ICSI, and verification-thawed blastocysts will be transferred after 5 days of ovulation (60cases).
88816641|NCT05858333|Experimental|Group 2: (day 3-5 group)|Women will undergo ICSI, who had cryopreserved embryos on day 3 then thawed and embryos will be allowed for extended cultured for 2 additional days and then will be transferred as blastocysts after 5 days of ovulation (60 cases).
88816642|NCT05858294|Experimental|Cognitive Behavioral Therapy program|"Access to the Alena CBT-based therapy programme for 4 weeks. Each of the four therapy modules gradually became available on a weekly basis until all four were available in the final intervention week. Participants were instructed to complete one module per week. Each therapy module consisted of psychoeducational content, guided psychological reflection and perspective-taking exercises, and, where appropriate, skills training exercises such as attention training, public speaking, and exposure experiments to be completed in real life."
88816643|NCT05858294|No Intervention|Waitlist control|Waitlist control. Participants in this arm were given access to the CBT content at the end of the 4-week trial period.
88816644|NCT05858255|Experimental|Exergaming|A 12-weeks, twice a week exergaming program, consisting of a combined high-intensity interval training and flash-reflex pods gaming condition, each session lasting 45 minutes, conducted one-on-one with a designated personal trainer (experienced and authorized health personnel with additional competence in exercise/sports and/or physical therapy).
88816645|NCT05858242||Early and mid-stage breast cancer patients awaiting radical surgery|To explore the predictive effect of plasma ctDNA methylation on postoperative prognosis of breast cancer and the application value of monitoring postoperative recurrence risk through regular postoperative follow-up of stage I-III breast cancer patients undergoing radical surgery.
89530093|NCT03256825|Other|Rapid diagnostics|patients admitted to medical and surgical wards with urinary tract infections at Ålesund Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics alone will be implemented.
88816647|NCT05858190|Experimental|DEB group|paclitaxel-coated balloon (Orchid, Acotec Scientific Holdings Limited, Beijing, China)
88816648|NCT05858190|Placebo Comparator|POB group|
88816649|NCT05858177|Other|Temozolomide|TMZ was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
88816650|NCT05858138|Experimental|Jing-Si Herbal Tea group|Each patient will receive Jing-Si Herbal Tea two times (after breakfast and lunch) in a day for 24 weeks.
88816651|NCT05858138|Placebo Comparator|Placebo group|Each patient will receive placebo two times (after breakfast and lunch) in a day for 24 weeks.
88816652|NCT05858047|Placebo Comparator|Group I (Placebo)|Placebo will be administered orally (PO) for 12 weeks.
88816653|NCT05858047|Experimental|Group Ⅱ (SYHX1901 60 mg)|SYHX1901 will be administered orally (PO) for 12 weeks.
88816654|NCT05858047|Experimental|Group III (SYHX1901 90 mg)|SYHX1901 will be administered orally (PO) for 12 weeks.
88816655|NCT05858047|Experimental|Group Ⅳ (SYHX1901 180 mg)|SYHX1901 will be administered orally (PO) for 12 weeks.
88816656|NCT05858021||Anal HSIL|Participants must have histologically proven diagnosis of Anal HSIL.
89530094|NCT03256825|Other|Rapid diagnostics and RADS|patients admitted to medical and surgical wards with urinary tract infections at Molde Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics will be implemented in conjunction with Real-time antimicrobial stewardship decision support : rapid diagnostics and RADS.
88816671|NCT05857813|Experimental|ASD teens and their caregiver|"Teens: (1) aged 11-20 years, currently enrolled in school between the sixth grade of elementary school and the third year of high school; (2) with a clinical diagnosis of ASD from a licensed mental health or medical professional based on DSM-5; (3) experiencing social difficulties as reported by parents in a structured intake interview; (4) scored ≧ 26 on the caregiver-reported Autism Spectrum Quotient (AQ), indicating clinical impairment associated with ASD (5) demonstrating verbal fluency in Chinese (6) with a full-scale IQ > 70 on WAIS-IV; (7) with motivation to participate in the intervention; (8) with a caregiver who was fluent in Chinese and willing to participate as a social coach in the study.~Parents: (1) demonstrating verbal fluency in Chinese (2) with motivation to participate in the intervention and assist their children to do the homework assignments."
88816672|NCT05857722|Experimental|Entrepreneurship and Jóvenes Capibara group|Participants in the experimental arm will receive a 10-day intervention, which consists of an entrepreneurship program, plus Jóvenes Capibara, an intervention that aims to improve emotion regulation and mental health symptoms among youth impacted by violence.
88816673|NCT05857722|Other|Control waitlist condition|Participants in the control waitlist condition will will be eligible to receive the intervention after 6-month follow-up data collection, which will take place approximately 10 to 12 months after the Entrepreneurship and Jóvenes Capibara group receives the intervention.
88816674|NCT05858073|Other|Kinesio Taping.|
88816675|NCT05858073|Placebo Comparator|Placebo Kinesio Taping.|
88816676|NCT05853913|No Intervention|Rest|Individuals will rest for about 1 hour in the seated position to mimic time exercising.
88816677|NCT05853913|Experimental|Exercise|Individuals will exercise for at medium to hard intensity for 1 hour.
88816678|NCT05850247|Experimental|[18F]DPA-714 PET|
88816679|NCT05843552||patients with GD|
88816680|NCT05843552||obligate carriers|
88816681|NCT05843552||healthy volunteers|
88816682|NCT05843513||Monitoring|"From every participant the following information was recorded for further analysis:~State Trait Anxiety Inventory (STAI) questionnaire.~A questionnaire is carried out to assess:~Endogenous abrasion: presence or absence of wear facets; carrier of occlusal splint; presence of harmful oral habits; day and/or night grinding.~Exogenous abrasion: whether they bite hard or soft things.~Exogenous erosion: - Environmental factors: frequent swimming. - Ingestion of acidic drinks or substances: fizzy drinks, juices, alcohol, dressings, etc.~Endogenous erosion: reflux, vomiting, heartburn, nighttime drooling, etc.~An examination of the temporomandibular joint (TMJ) is carried out; palpation of the muscles most frequently related to bruxism and/or alterations of the TMJ.~2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (over 100 microns) using Geomagic software."
88816683|NCT05836025|Experimental|Rapamycin|Participants randomized to the treatment arm will receive 5mg/week of rapamycin orally, for 12 weeks (3 months).
88816684|NCT05836025|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive placebo orally, for 12 weeks (3 months).
88816685|NCT05833633||Group of DMD patients with different type of small mutations (Group 1)|Group of DMD patients with different type of small mutations (15 ambulant or not-ambulant patients)
88816686|NCT05833633||Group of DMD patients with non sense mutations in treatment with Traslarna (Group 2)|Group of 10 ambulant DMD patients with non sense mutations in treatment with Traslarna (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid).
88816687|NCT05818254|Experimental|Routine Care Providers|Care Providers in this arm will continue seeing patients as normal in clinic.
88816688|NCT05818254|Experimental|HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Providers|HOP-STEP providers will inquire and document their patients about contraceptive usage and pregnancy interest, then provide personalized guidance on family planning.
88816689|NCT05816187|Experimental|supervised without chemotherapy, radiotherapy or hormone treatment|Therapeutic exercise program based on aerobic work, strength-endurance and self-stretching of 6 weeks duration, in addition to a reinforcement of the usual self-care recommendations.
88816690|NCT05816187|Experimental|supervised with chemotherapy, radiotherapy or hormone treatment|Therapeutic exercise program based on aerobic work, strength-endurance and self-stretching of 6 weeks duration, in addition to a reinforcement of the usual self-care recommendations.
88816691|NCT05816187|Active Comparator|Not Supervised exercise group|Unsupervised intervention group: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking.
88816692|NCT05805657|Experimental|Standard TranS-C|Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation.
88816693|NCT05805657|Experimental|Adapted TranS-C|The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions.
88816694|NCT05805657|Active Comparator|UC-DT|Usual Care Delayed Treatment. Usual care in the partner CMHCs starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
88816695|NCT05794971|Experimental|Irinotecan Drug-Eluting Beads combined with regorafenib|
88816696|NCT05794971|Active Comparator|regorafenib|
88816697|NCT05785195|Experimental|Inhaled Nitric Oxide (iNO)|iNO 20ppm，≥8 hours/day for 3 days
88816698|NCT05774496||Congenital toxoplasmosis women|Women older than 21 suffering from congenital toxoplasmosis, with or without children.
88816734|NCT05598008||Liraglutide Group|"Liraglutide Group: receiving Liraglutide for weight management in addition to conventional weight management (= lifestyle intervention plus liraglutide).~Conventional weight management is conducted according to clinical guidelines (in both groups) and includes nutritional and exercise counselling, counselling by motivational coaches and/ or psychological support.~Participants in the Liraglutide group will inject the medication themselves."
88816735|NCT05598008||Lifestyle group|"Lifestyle group: using conventional weight management (= lifestyle intervention only).~Conventional weight management is conducted according to clinical guidelines (in both groups) and includes nutritional and exercise counselling, counselling by motivational coaches and/ or psychological support."
88816699|NCT05738720|Experimental|Homespirometer Group (HsGr)|"Patients will be taught to use the homespirometer device, download the phone application, use the application, use the video call feature, measure saturation and heart rate with the same device, and daily symptom scoring in the device's system.~Patients will be asked to perform pulmonary function tests with a spirometer device, measure saturation and heart rate, score symptoms, and write down any problems related to their illness twice a week on days without exercise. The evaluations made after 2 tests. They will be sent to the researchers via the device.andthe video containing the exercises after the first training will be sent to them via whatsapp for the exercise compliance of the patients. In the first exercise week, the first 2 exercise sessions will be done one-on-one via video call, and the exercises will be done correctly."
88816700|NCT05738720|Active Comparator|Control Group (CGr)|The same exercise training will be taught to the study group and the same exercise video will be sent to the patients via WhatsApp. The first 2 exercise sessions will be done one-on-one via video call (via whatsapp), and the exercises will be done correctly. Patients will be given an exercise diary and asked to take notes on their weekly exercises.
88816701|NCT05737810||People with Type 2 Diabetes|Participants are recruited via email through online panel companies
88816702|NCT05713500||PD patients with chronic pain|Parkinsonian patient with pain
88816703|NCT05713500||PD patients without pain|Parkinsonian patient without pain
88816704|NCT05713500||non-PD patients with chronic pain|Non-PD with fibromyalgia and non-PD with chronic headache
88816705|NCT05704426||Retrospective|Patients with available data for 6 months before the implantation of the Optimizer implantation and at least 8 months after the implantation of the optimizer at the time the study is initiated and patients with available data for 6 months before the implantation of the Optimizer implantation, but less than 8 months of follow up after Optimizer implantation at the time of the study initiation.
88816706|NCT05704426||Prospective|Patients prior to the implantation of the Optimizer that will take place as per standard of care.
88816707|NCT05693675|Experimental|Postoperative methadone|
88816708|NCT05693675|Placebo Comparator|Postoperative placebo|
88816709|NCT05688410|Experimental|Assisted Exercise and I-STOP|"Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted exercise bike). Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP)."
88816710|NCT05688410|Experimental|Voluntary Exercise and I-STOP|"Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP)."
88816711|NCT05688410|Experimental|Assisted Exercise and No I-STOP|"Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted exercise bike). Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
88816712|NCT05688410|Experimental|Voluntary Exercise and No I-STOP|"Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
88816713|NCT05688410|Experimental|No Exercise and I-STOP|"Participants randomized to receive No Exercise will not receive structured assisted or voluntary rate cycling exercise. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
88816714|NCT05688410|No Intervention|No Exercise and No I-STOP|"Participants randomized to receive No Exercise will not receive structured assisted or voluntary rate cycling exercise. Participants randomized to No I-STOP will not receive the psychotherapy for pain and addiction but will receive their standard behavioral treatment as usual (TAU)."
88816715|NCT05674981|Experimental|Probiotic group|Subjects received two probiotic sachets per day
88816716|NCT05674981|Placebo Comparator|Placebo group|Subjects received two placebo sachets per day
88816717|NCT05655273|Active Comparator|Post-liver transplant patients receiving Prograf|
88816718|NCT05655273|Active Comparator|Post-liver transplant patients receiving Envarsus|
88816719|NCT05653414|Experimental|"short early psychological care group"|Women with short early psychological care associated with encouragement of early support consultation with generalist practitioner or midwife
88816720|NCT05653414|Active Comparator|"control group"|Women with encouragement of early support consultation with generalist practitioner or midwife
88816721|NCT05645068|Experimental|Optical Coherence Tomography Angiography|
88816722|NCT05641402|Other|Experienced acceptability study|The final study in this research will involve people with type 2 diabetes receiving the text messages
88816723|NCT05624151|Active Comparator|general anesthesia+ infraorbital nerve block by dexmedetomidine plus bupivacaine|
88816724|NCT05624151|Active Comparator|general anesthesia+ infraorbital nerve block by magnesium sulphate plus bupivacaine|
88816725|NCT05624151|Active Comparator|general anesthesia+infraorbital nerve block by bupivacaine only|
88816726|NCT05623527||Ischemic stroke group|"Ischemic stroke secondary to patients receiving cardiac electronic implants~Ischemic stroke met the diagnostic criteria of the 2018 edition of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and was confirmed by cranial CT/MRI scan."
88816727|NCT05623527||Transient ischemic attack group|"Transient ischemic attack secondary to patients receiving cardiac electronic implants~Ischemic stroke met the diagnostic criteria of the 2018 edition of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and was confirmed negative of new onset of infarction by cranial CT/MRI scan."
88816728|NCT05623527||Cerebral hemorrhage group|"Cerebral hemorrhage secondary to patients receiving cardiac electronic implants~Cerebral hemorrhage met the diagnostic criteria of the 2021 Chinese Guidelines for the Diagnosis and Treatment of cerebral hemorrhage and was confirmed by head CT/MRI."
88816729|NCT05612477|Experimental|Autotransfusion|patients in this arm will receive their salvaged and washed RBCs via transfusion
88816847|NCT04866264|Active Comparator|Outpatient Group|"After signing the informed consent, outpatients will be invited for a clinical baseline visit at the Center on Aging and Mobility (CAM), where they will complete the dietary assessment with the eNutrition optimizer at the CAM guided by the study physicians, who will also interpret the immediate results and recommendations produced by the tool to the study participant.~For validating the eNutrition-Optimizer tool, participants will be asked to report their dietary intake in the past 24h during a 24-h diet recall phone call conducted by a trained interviewer on random days (weekday and weekend), so the participant cannot prepare or alter their habits. This 24h diet recall phone calls will be performed 4 times during the second half of the follow-up (month 4 to 6). In addition participants will complete the System Usability Scale at baseline and the subjective effectiveness questionnaire at month 6."
88816848|NCT04866264|Active Comparator|Inpatient Group|After signing the informed consent, inpatients (Senior trauma center/heart surgery) will do the dietary assessment with the eNutrition optimizer with supervision of a trained study physician to assess user feasibility in the inpatient setting. In addition they will have a follow-up phone call at month 3 to 6 to assess the subjective effectiveness of the eNO.
88816849|NCT04845503|Experimental|MR-guided Radiotherapy (5 x 7,5 Gy)|5 x 7,5 Gy prescribed on the PTV
88816850|NCT04829955|No Intervention|Observation phase|After screening and randomization for either the eccentric orientated intervention group or the concentric orientated intervention group, all measurements will be made for the first time by investigators at point A1. An observational phase for six weeks will follow to achieve an intern acceptance sampling for the measurements which will be used.
88816851|NCT04829955|Active Comparator|Eccentric training group|"Subjects in the eccentric training group (GEC) will attend six weeks of eccentric orientated training. The eccentric orientated training will use the cadence 3-0-1 for eccentric - break - concentric.~3 sessions/week~60 minutes per session including a warming up and cool down phase~6 exercises~total of 18 sessions"
88816852|NCT04829955|Active Comparator|Concentric training group|"The concentric training group (GCO) will attend six weeks of concentric orientated training. Each group will perform a manual resistance/bodyweight resistance training accentuating the concentric phase of the movement. The concentric orientated training will use the cadence 1-0-3 for eccentric - break - concentric.~3 sessions/week~60 minutes per session including a warming up and cool down phase~6 exercises~total of 18 sessions"
88816853|NCT04813354|Experimental|ELLIPTA/ BREEZHALER/Questionnaire version 1|Participants received placebo ELLIPTA Dry Powder Inhaler (DPI) followed by placebo BREEZHALER DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and visual analogue scale (VAS) on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 1 on Day 1.
88816854|NCT04813354|Experimental|ELLIPTA/ BREEZHALER/Questionnaire version 2|Participants received placebo ELLIPTA DPI followed by placebo BREEZHALER DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and VAS on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 2 on Day 1.
88816855|NCT04813354|Experimental|BREEZHALER/ ELLIPTA/Questionnaire version 1|Participants received placebo BREEZHALER DPI followed by placebo ELLIPTA DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and VAS on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 1 on Day 1.
88816856|NCT04813354|Experimental|BREEZHALER/ ELLIPTA/Questionnaire version 2|Participants received placebo BREEZHALER DPI followed by placebo ELLIPTA DPI on Day 1. Participants were asked to complete the ease-of-use questionnaire and VAS on their willingness to continue with the inhaler after using each device. Participants also completed the preference questionnaire version 2 on Day 1.
88816857|NCT04803422|Active Comparator|Arm 1- Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.~Last 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim."
88816858|NCT04803422|Active Comparator|Arm 2 - Postoperative Course|"Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.~First 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.~Last 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin."
88816859|NCT04795973|Experimental|time-restricted fasting for 4 weeks|
88816860|NCT04795973|Experimental|5:2 regimen for 4 weeks|
88816861|NCT04786223|Other|C-11 ER176 PET/CT|C-11 ER176 is an investigational radiopharmaceutical that will be produced under cGMP in the Mayo Clinic Cyclotron Facility. The imaging agent (C-11 ER176) will be administered on an outpatient basis. It will be administered at a single time IV prior to the PET imaging.
88816862|NCT04785677|Experimental|Comprehensive Trauma-Based Reentry Program|Participants will complete up to19 session comprehensive trauma-based reentry program.
88816863|NCT04785677|No Intervention|Treatment as usual (TAU)|Participants will be receive all reentry services normally eligible to receive by the state or the community to which they are released.
88816864|NCT04779957|Experimental|Tocilizumab|Evaluation of the use of Tocilizumab after allograft nephrectomy.
88816865|NCT04770532|Experimental|Insulin icodec|Insulin icodec + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.
88816866|NCT04770532|Active Comparator|Insulin degludec|Insulin degludec + non-insulin anti-diabetic drugs. Pre-trial non-insulin anti-diabetic background medication throughout the entire trial except from sulfonylureas and glinides, which must be discontinued at randomisation. The background medication should be maintained at the stable, pre-trial dose and at the same frequency during the entire treatment period.
88816949|NCT04252677|Active Comparator|Vaping and Obesity Prevention Only|"Obesity prevention and vaping~Vaping:~Factual information about vaping devices and vaping~Beliefs and attitudes about nicotine products~Refusing and avoiding vaping~Recognizing addiction and getting help~Health information:~• Factual information about healthy eating and activity (PA)~Motivation:~Personal: Create positive attitudes toward engagement in healthy eating and PA~Social: Enlisting social support to increase healthy eating and PA~Social: Identification of community resources that promote and support healthy eating and PA~Behavioral Skills~Tips for engaging in prevention behaviors and avoiding risk behaviors in the context of existing barriers~Skills for social situations around behaviors~Skills for making behavior part of routine~Build autonomy, self-efficacy and model good health decision-making for health behaviors"
88816950|NCT04252677|Experimental|Health Literacy and Obesity Prevention|"Obesity prevention and health literacy (HL).~Health Literacy~Functional HL: skills for reading/understanding nutrition labels and medication instructions.~Interactive HL: verbal skills for interacting with others on health issues.~Critical HL: connections between advocacy and health~Media HL: skills for accessing and identifying reliable source of media.~Health information:~• Factual information about healthy eating and activity (PA)~Motivation:~Create positive attitudes toward engagement in healthy eating and PA~Enlisting social support to increase healthy eating and PA~Identification of community resources that promote and support healthy eating and PA~Behavioral Skills~Tips for engaging in prevention behaviors and avoiding risk behaviors~Skills for social situations around behaviors~Skills for making behavior part of routine~Build autonomy, self-efficacy and good health decision-making for health behaviors"
88816951|NCT04250051|Experimental|Treatment (combination chemotherapy, ivosidenib)|"INDUCTION: Patients receive filgrastim SC QD on days 0-6, fludarabine phosphate IV QD over 30 minutes on days 1-5, cytarabine IV QD over 4 hours on days 1-5, and ivosidenib PO QD on days 7-28. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
88816952|NCT04246879|Experimental|MRI|
88816953|NCT04243915|Experimental|PNMES plus exercise|6-week intervention program with 3 treatment sessions of PNMES and motor control exercise program.
88816954|NCT04243915|Sham Comparator|Sham PNMES (introducing the needle) plus exercise|Sham PNMES (introducing the needle) plus motor control exercise program
88816955|NCT04243915|Active Comparator|TENS plus exercise|6-week intervention program with 3 treatment sessions of TENS plus motor control exercise program.
88816956|NCT04243915|Placebo Comparator|Placebo PNMES (without inserting the needle) plus exercise|6-week intervention program with 3 treatment sessions of placebo PNMES (without inserting the needle) and exercise
88816957|NCT04240327||GG2+ Prostate Cancer Risk|Participants at risk for Grade Group 2 (GG2+) prostate cancer. Participants will be followed for up to two years to rule out the presence of GG2+ prostate cancer
88816958|NCT04236271|Experimental|patient|interventional group
88816959|NCT04206124|Experimental|Single Arm Study Group|Includes all consented patients, male and female, undergoing anterior cervical spine surgery, parathyroidectomy or thyroidectomy (18-60 years old), without history of diabetes mellitus and not pregnant or incarcerated.
88816960|NCT04165824|Experimental|MT-1186|
88816961|NCT04116476|Experimental|Moderate Hepatic Impairment|
88816962|NCT04116476|Experimental|Normal Healthy Matches|
88816963|NCT04116476|Experimental|Mild Hepatic Impairment|
88816964|NCT04108039|Active Comparator|GnRH antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles >14mm or E2 levels >400 pg/ml and continuing until ovulation triggering.
88816965|NCT04108039|Experimental|Micronized progesterone|In the progesterone cycle, endogenous LH suppression will be accomplished by oral administration of micronized progesterone (200 mg) once a day at bed time, from stimulation day 1 and continuing until ovulation triggering.
88816966|NCT04096950|Experimental|MT-3921|Intravenous, single dose
88816967|NCT04069169|Experimental|Intravenous lidocaine|1% preservative free lidocaine 10 mg/ml in 0.9% NaCl
88816968|NCT04069169|Placebo Comparator|Intravenous saline control|0.9% sodium chloride, also known as normal saline
88816969|NCT04065880|Active Comparator|TachoSil®|TachoSil® is a collagen sponge coated with the human coagulation factors fibrinogen and thrombin.
88816970|NCT04065880|Active Comparator|Neoveil®|Neoveil® sheet made of polyglycolic acid (PGA). It is a biodegradable, thermoplastic and non-antigenic polymer.
88816971|NCT04038229|No Intervention|Standard of care|Prospective derived data from children and adolescents undergoing spinal fusion due to idiopathic scoliosis
88816972|NCT04038229|Experimental|Enhanced recovery pathway|Children and adolescents undergoing spinal fusion due to idiopathic scoliosis using the pre -per and postoperative enhanced recovery protocol
88816973|NCT04002674|Placebo Comparator|Placebo|"Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
88816974|NCT04002674|Active Comparator|200 mg Nilotinib|Sixty (60) participants will be recruited and randomized into 2 arms (1:1). Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
88816975|NCT03997097|Experimental|sildenafil|• Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day (t.i.d.), as defined in the marketing authorization indicated for PAH in adolescent and adult patients, and for a period of 6 months.
88816976|NCT03997097|Placebo Comparator|placebo|• Patients in the group 2 will receive a placebo (t.i.d.), for the same period of 6 months. To guarantee the double blind, capsules will be similar in size and colour and will be differentiated only by a vial number regarding to the randomization list
88816977|NCT03991065|Experimental|with endoscopy|high digestive endoscopy
88816978|NCT03991065|No Intervention|without endoscopy|no endoscopy
88816979|NCT03988036|Experimental|HER2-enriched|"Trial treatment is defined as neoadjuvant therapy only. The Investigational Medicinal Products (IMPs) are pembrolizumab, trastuzumab biosimilar and pertuzumab.~Trastuzumab Biosimilar (Trazimera®) - Investigational Medicinal Product~Loading dose: 8 mg/kg bodyweight at initial administration infusion over 90 min; monitor patient for at least 6 h afterwards.~Maintenance dose: 6 mg/kg bodyweight, over 30-90 min; monitor patient for 2 h afterwards.~Route: Intravenous infusion.~Schedule: Every 3 weeks during the neoadjuvant phase.~Pertuzumab (Perjeta®) - Investigational Medicinal Product~Loading dose: 840 mg, initial administration.~Maintenance dose: 420 mg.~Route: Intravenous infusion.~Schedule: Every 3 weeks during the neoadjuvant phase.~Pembrolizumab (Keytruda®) - Investigational Medicinal Product~Dose: 200 mg.~Route: Intravenous infusion.~Schedule: Every 3 weeks during the neoadjuvant phase."
88816980|NCT03965897|Active Comparator|Attention Control (AC)|The primary purpose of this workshop is to provide attention and education to participants. Topics of discussion will include: a) the pathophysiology of postoperative pain and how it differs from preoperative pain, b) the role of contextual factors (e.g., depressive or anxiety symptoms, expectation) on the experience of pain, d) the role of inflammation in pain and healing, e) types of pain medications and other pain relief strategies provided following surgery, and f) goals of pain medications. Additionally, deep (diaphragmatic) breathing strategies will be taught and a progressive muscle relaxation exercise will be performed in the workshop at strategic times to maintain Veteran engagement.
88816981|NCT03965897|Experimental|Acceptance and Commitment Therapy (ACT)|"The ACT intervention will include: 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts such as I can't take this pain anymore or This is unfair) and learning how to willingly face experiences that cannot be changed; and 2) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise. The workshop will also include information on pain and pain control post-TKA."
88816982|NCT03932214|Experimental|Infrared illumination group|The nurse uses the Accuvein® device to identify the veins before puncture.
88816983|NCT03932214|No Intervention|Control group|The nurse proceeds as usual (visual identification in the light of the room and palpation)
88816984|NCT03885739|Other|Patients with hip fracture|15 consecutive HF patients who were admitted to a single level 3 center and who report severe pain despite a standardized analgesia protocol. Patients were assessed by the Pain Service as part of a multidisciplinary care pathway and a Continuous Pericapsular Nerve Group blocks was offered as a component of a multimodal analgesic regimen.
88816985|NCT03876314|Experimental|Physical Activity Condition (PAC)|Subjects will be asked to attend virtual exercise sessions 3 times a week for 1 year.
88816986|NCT03876314|No Intervention|Usual Care Control (UCC)|Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.
88816987|NCT03857061||COPD Patients|This is a prospective cohort study enrolling patients with COPD to 1) wear a smartwatch that passively senses heart rate, motion, audio, 2) use a smartphone that can obtain oxygen saturation upon demand, 3) use a self-management app on the smartwatch, smartphone and a webapp.
88816988|NCT03850028|Other|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.
88816989|NCT03840993|Experimental|MT-2990|MT-2990, IV, over 16 weeks
88816990|NCT03840993|Placebo Comparator|Placebo|Placebo, IV, over 16 weeks
88816991|NCT03809039|Experimental|Single Ascending Dose: MT-6345 & Placebo|
88816992|NCT03809039|Experimental|Multiple Ascending Dose: MT-6345 & Placebo|
88816993|NCT03801954||RC Patients|Patients at the University of Kansas Medical Center who have not yet had their radical cystectomy, after their radical cystectomy, or between the completion of chemotherapy and the radical cystectomy.
88816994|NCT03767530|Experimental|Mibo Thermoflo (thermal device)|3 sessions at 2 weeks interval (basal, week 2, week 4)of 11 minutes per eye of thermal therapy with Mibo Thermoflo.
88816995|NCT03767530|Active Comparator|Warm compresses and eyelid massage|2 times per day, 11 minutes per eye.
88816996|NCT03688022|Experimental|MT-7117 BA and DDI (fasted)|MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)
88816997|NCT03688022|Experimental|MT-7117 food effect and DDI (fed)|MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)
88816998|NCT03681210||Patients implanted with HVAD System|Patients intended to be implanted with a HVAD for use as destination therapy are eligible for enrollment into the DT PAS and must be consented for the study prior to the HVAD implant.
88816999|NCT03655912|Active Comparator|Patch|Eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc)
88817000|NCT03655912|Experimental|Electronic Devices|Eye patch on the fellow eye and a electronic tablet
88817001|NCT03655912|Experimental|Red/Green Glasses|Red/green glasses and a electronic tablet
88817002|NCT03614481||AMD patient|"During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.~After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent."
88819279|NCT03008330|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88817003|NCT03614481||control without AMD|"898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.~The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years."
88817004|NCT03610763|Active Comparator|Transplantation/Replantation Patients|Can plateaued hand function in hand transplantation patients/hand replantation patients in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
88817005|NCT03610763|Active Comparator|Nerve Injury Patients active|Can plateaued hand function in peripheral nervous system injuries in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
88817006|NCT03610763|No Intervention|Actigraphy Testing|We will acquire a set of actigraphy data from a group of hand transplant/replant patients and unilateral, adult amputees in order to evaluate typical patterns of limb use prior to hand transplantation and to investigate prosthesis utilization.
88817007|NCT03576937||Cohort 1|Patients with advanced (incurable stage IIIB or IV), histologically proven, non-squamous NSCLC who are never- or light-smokers (≤10 pack year smoking history) and are being considered for systemic therapy in the first line setting are eligible. Blood will be collected prior to first line treatment for testing cfDNA with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
88817008|NCT03576937||Cohort 2|Patients with advanced non-squamous NSCLC with known oncogenic drivers (such as EGFR, ALK, ROS-1, BRAF) that have failed tyrosine kinase inhibitor (TKI) therapy, and are being considered for subsequent therapy. Blood will be collected from patients at time of progression on TKI therapy for cfDNA testing with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
88817009|NCT03573973|Experimental|Fresh fruit and vegetable placement intervention|The intervention is a store refurbishment programme that includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the availability and position of fresh fruit and vegetables.
88817010|NCT03573973|Sham Comparator|Control|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
88817011|NCT03554044|Experimental|Cohort I (talimogene laherparepvec, chemotherapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with one of the following chemotherapies: paclitaxel (IV), nab-paclitaxel IV, or gemcitabine / carboplatin IV.~Cycles repeat every 21 days until disease progression or unacceptable toxicity"
88817012|NCT03554044|Experimental|Cohort II (talimogene laherparepvec, endocrine therapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with letrozole PO, anastrazole PO, exemestane PO, tamoxifen PO on days 1-21 or fulvestrant IM every 2 weeks for 3 doses then every 4 weeks for the subsequent courses.~Cycles repeat every 28 days until disease progression or unacceptable toxicity"
88817013|NCT03542097||Temozolomide and Irinotecan treatment|The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done
88817014|NCT03541200|Experimental|Open Label|MT-8554
88817015|NCT03524937|Experimental|MELATONIN (LOW DOSE)|Daily administration of melatonin by enteral route at 0.3 mg/day (low dose arm), up to 14 days.
88817016|NCT03524937|Experimental|MELATONIN (HIGH DOSE)|Daily administration of melatonin by enteral route at 3 mg/day (high dose arm), up to 14 days.
88817017|NCT03524937|Placebo Comparator|PLACEBO|Daily administration of identical placebo up to 14 days.
88817018|NCT03505710|Experimental|Cohort 1: HER2 Overexpressing|Participants with HER2-overexpressing(immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
88817019|NCT03505710|Experimental|Cohort 1a: HER2 Overexpressing|Participants with HER2-overexpressing (immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
88817020|NCT03505710|Experimental|Cohort 2: HER2 Mutated|Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
88817021|NCT03503266|Experimental|[14C] MT-7117|14-C MT-7117
88817022|NCT03473145|Active Comparator|Health Living Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention. This group will receive one in-person health coaching sessions and 6 phone counseling sessions.
88817023|NCT03473145|Experimental|Reduce Sitting|Participants in the Reduce Sitting condition will receive an intervention aimed at reducing daily sitting time. This group will receive five in-person health coaching sessions and two phone counseling sessions.
88817024|NCT03473145|Experimental|Sit-to-Stand Transition|Participants in the Sit-to-Stand Transition condition will receive an intervention aimed at increasing the daily number of brief sit-to-stand transitions. This group will receive five in-person health coaching sessions and two phone counseling sessions.
88817025|NCT03471130|Experimental|Low dose MT-8554 or placebo to match|Low dose MT-8554
88817026|NCT03471130|Experimental|High dose MT-8554 or placebo to match|High dose MT-8554
88817027|NCT03435458|Experimental|Balloon catheter + oral misoprostol|
88817028|NCT03435458|Active Comparator|Oral misoprostol alone|
88817029|NCT03381404|Experimental|[14C] MT-8554|
88817030|NCT03364621||Metastatic Colorectal Cancer with Isolated Liver Metastasis|Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery.
88817031|NCT03291067|Experimental|MT-8554 1mg|
88817095|NCT02418572|Experimental|Transdermal testosterone gel|"Patients will receive once daily application of 0.55 gr TTG (Testosterone gel 1%; Laboratories Besins International,Paris,France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
88817096|NCT02418572|Placebo Comparator|Placebo transdermal gel|"Patients will receive once daily application of 0.55 gr identical placebo gel starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
88817097|NCT02411409|Experimental|Intervention group|This group of patients receives the HealtheRx.
88817098|NCT02411409|No Intervention|Control group|This group of patients does not receive the HealtheRx
88817099|NCT02351141|Other|Asthma Patients|All enrolled asthma patients will undergo hyperpolarized noble gas MRI with Helium-3 and/or Xenon-129, Pulmonary Function Tests, Quality of Life Questionnaires, dyspnea scales in two visits over three years.
88817100|NCT02345330|Experimental|Tavokinogene Telseplasmid (tavo) Electroporation (EP)|Participants received tavo intratumorally followed immediately by electroporation (EP) on Days 1, 8, and 15 in a 6-week cycle for up to 9 cycles.
88817101|NCT02320955||Reimplantation of cryoconserved bone flap|All patients who receive reimplantation of a cryoconserved autologous bone flap
88817102|NCT02272491|Experimental|ZrO2|"Straumann CARES Variobase Abutment RN~Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
88817103|NCT02272491|Active Comparator|PFM crown|Straumann Gold Abutment RN Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
88817104|NCT02054689|Other|Fractionated Stereotactic Radiosurgery|24 to 36 Gy in 3 fractions (8-12 Gy/fx).
88817105|NCT02050113|Experimental|Endovascular repair|Endovascular repair of Complex Aortic Aneurysm using a physician modified stent graft. custom made device or arch branch device.
88817106|NCT01938677|Experimental|Initial Gamma knife|Patients with VS and preserved hearing, randomized to initial gamma knife radiosurgery will receive this treatment within a few months after enrollment
88817107|NCT01938677|No Intervention|Initial conservative|Patients with VS and preserved hearing, randomized to initial conservative treatment will initially be followed with repeated MRI and audiometry. If MRI show progression of VS requiring intervention, patients will receive treatment but still belong to the initial treatment arm, according to intention to treat.
88817108|NCT01705119|Experimental|Mechanically Ventilated|
88817109|NCT01665677|Experimental|Atorvastatin calcium (Lipitor)|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
88817110|NCT01665677|Experimental|Unrelated Donor|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
88817111|NCT01649531|Active Comparator|Test group|1 Implant, to be placed in the position with greater vertical bone height with a mesial or distal cantilever.
88817112|NCT01649531|Active Comparator|Control group|2 Implants
88817113|NCT01530373|Experimental|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
88817114|NCT01530373|Active Comparator|clonidine|oral clonidine 0.1 mg daily for 3 weeks
88817115|NCT01513343|Experimental|Parent and child classes (prevention group)|Parent and child groups focused on self-regulation of eating
88817116|NCT01513343|No Intervention|Treatment as usual (control group)|Treatment as usual
88817117|NCT01499953|Experimental|Rivaroxaban|Rivaroxaban for 45 days oral dose: 10 mg OD
88817118|NCT01499953|Active Comparator|Fondaparinux|Fondaparinux for 45 days subcutaneous application: 2,5 mg OD
88817119|NCT01487603||confirmed or suspected lung cancer|
88817120|NCT01461226|Experimental|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
88817121|NCT01461226|Other|Usual Care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
88817122|NCT01440816|Experimental|Cohort A: Tavo-EP|Patients in Cohort A received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, after which they proceeded to definitive treatment (surgery and/or radiation therapy) which started between 2 and 4 weeks after the first injection.
88817123|NCT01440816|Experimental|Cohort B: Tavo-EP|Patients in Cohort B received up to 4 cycles (3 daily treatments on Days 1, 5, and 8, per cycle) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, with 12 planned weeks between each cycle, lasting up to 12 months.
89531143|NCT02497703|Experimental|Knee robot|This robotic system has been developed to facilitate functional motor recovery by practices walking with a one joint motor powered exoskeleton
88817553|NCT05371431|Experimental|BFR groups|Patients in the BFR group underwent the same traditional rehabilitation training protocol with non-BFR utilizing a medical grade tourniquet system (ATS 4000 TS，Zimmer Surgical, Inc. Dover). The ATS 4000 tourniquet system tailors the individualized tourniquet pressure to each patient following determination of the limb occlusion pressure (LOP), and studies have shown that 50% LOP is safe and effective in the rehabilitation of DRF. When the tourniquet system was used, LOPs were reassessed for every session before training, and pressures were continually monitored. Participants were to perform the entirety of each training (including intra-set rest periods) under 50% LOP with the tourniquets released during the 2-minute rest periods between sets. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks.
88817554|NCT01307930|Experimental|Anidulafungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
88817555|NCT02974179||Subjects who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
88817556|NCT05371197|Experimental|PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab)
88817557|NCT01309646|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
88817558|NCT01309646|Active Comparator|Infanrix IPV Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
88817559|NCT01746095|Experimental|Vancomycin hydrochloride inhalation powder|32 or 64 mg twice daily (BID)
88817560|NCT01746095|Placebo Comparator|Placebo inhalation powder|Matching placebo inhalation powder BID
88817561|NCT05371119|Experimental|Blood Flow Restriction|Use of the BFR cuff during the training intervention
88817562|NCT05371119|Active Comparator|control|No use of inflated cuff
88817563|NCT05730777|Experimental|Bifidobacterium Bifidum Oral Capsule in addition to conventional treatment|Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
88817564|NCT05730777|Active Comparator|conventional antitumor treatment|Patients in the control group will receive conventional antitumor treatment only.
88817565|NCT04425239|Active Comparator|CONTINUOUS ARM:|Patients will receive Panitumumab plus FOLFIRI until progressive disease, unacceptable toxicity or informed consent withdrawal.
88817566|NCT04425239|Experimental|INTERMITTENT ARM:|Patients will have a treatment free interval until progressive disease (PD), when they will receive up to 8 cycles of Panitumumab plus FOLFIRI. In the presence of complete or partial response, or stable disease, non-progressing patients will undergo again to treatment free interval until PD, when they will restart treatment. Treatment cycling will continue till any PD on treatment.
88817567|NCT01309802|No Intervention|placebo|no intervention
88817568|NCT01309802|Active Comparator|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
88817569|NCT00366093|Experimental|1|eszopiclone 3 mg
88817570|NCT00366093|Placebo Comparator|2|Placebo tablet
88817571|NCT04379999|Active Comparator|Atorvastatin|Atorvastatin (LIPITOR) 20 milligram tablet daily for 6 weeks
88817572|NCT04379999|Active Comparator|Atorvastatin and Aspirin|Atorvastatin (LIPITOR) 20 milligram tablet and Aspirin 325 mg tablet daily for 6 weeks
88817573|NCT01309880|Active Comparator|Air Optix Aqua|Ciba Vision daily wear contact lens
88817574|NCT01309880|Experimental|Test Lens|Investigational silicone hydrogel contact lens
88817575|NCT03009422|Experimental|Treatment|CO2 fractional laser with local application of Pentostam
88817576|NCT03009422|Active Comparator|control|Intra-lesinal Pentostam injedction
88817577|NCT05730621|Experimental|Sarpogrelate Sustained Release/Aspirin|Sarpogrelate Sustained Release/Aspirin Combination Therapy for 12 weeks
88817578|NCT05730621|Active Comparator|Aspirin|Aspirin Monotherapy qd for 12 weeks
88817579|NCT01346072|Other|Tolvaptan|Single arm study
88817580|NCT04313231||MDS|"Female and male patients aged 18 years and older~MDS, MDS/MPN diagnosis based on current WHO classification. CCUS and CHIP defined by Valent (Valent, Oncotarget, 2018) and by Stauder (Stauder, Blood, 2018)"
88817581|NCT04313231||control|age-matched healthy persons
88817582|NCT03008720|Active Comparator|tDCS active|Transcranial stimulation ( tDCS ) active will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle.
88817583|NCT03008720|Placebo Comparator|tDCS sham|Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
88817584|NCT03008720|Active Comparator|FES active|Functional electrical stimulation (FES) active will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 μs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold.
88817585|NCT03008720|Placebo Comparator|FES sham|Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA.
88817586|NCT01346852||Pediatric participants|Pediatric participants (age 4 to 17) with a diagnosis of asthma
88817587|NCT01346852||Adult participants|Adult participants (age 18 and older) with a diagnosis of asthma
88817588|NCT01721837||Atrial fibrillation and mild to moderate renal impairment|
89531144|NCT05034549|No Intervention|Control|
89531145|NCT05034549|Experimental|Noninvasive ventilation|
88818374|NCT01801241|Active Comparator|Anatomic TSA using SOC Instrumentation|During Anatomic Total Shoulder Arthroplasty, the surgeon will use the pre operative CT scan at least two weeks prior to surgery to define the glenoid pathology, select the implant of choice and plan the placement of that implant in the desired position. This information will be available to the surgeon at the time of surgery but the SmartBone models and the IRI will not be available. The surgeon will have pre operative x-rays and the pre operative CT scan provided by the radiology department for intra - use. The surgeon will perform the surgery using any of the instruments provided for guide pin placement operative the. These include a wide variety of free hand and adjustable guides that assist the surgeon for placement of the guide pin for location and trajectory.
88818375|NCT01801241|Experimental|Anatomic TSA Using IRI Instrumentation|During Anatomic Total Shoulder Arthroplasty, the surgeon will have use of the SmartBone model of the patient's anatomy and glenoid guide-pin location, and the Intelligent Reuseable Instrument for placement of the glenoid implant.
88818376|NCT02686437|Experimental|Increasing Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the lesser tubercle of the humerus. Over the course of the 4 weeks of care, the tension of the Intervention Group's tape will systemically increase based on the following timelines:~Week 1: 0% tension Week 2: 25% tension Week 3: 50% tension Week 4: 75% tension"
88818377|NCT02686437|Sham Comparator|Control Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the greater tuberosity of the humerus. Over the course of the 4 weeks of care, the tension of the Control Group's tape will remain at 0% tension"
88818378|NCT04351139||gynecological cancer|Patients over 18 with gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned during the period of COVID-19 pandemic during 2020
88818379|NCT04351139||control group|Patients over 18 with gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer) and whose therapeutic management was planned outside the period of COVID-19 pandemic, on the end of the year 2019
88818380|NCT02687139|Experimental|18F-DCFPyL PET/CT|
88818381|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Abdomen)|Participants ≤55 years of age will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
88818382|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Upper Arm)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
88818383|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Thigh)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
88818384|NCT01818245|Experimental|LY2605541: Cohort B (Injection site: Abdomen)|Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.
88818385|NCT02687217|No Intervention|Group A: Control|Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
88818386|NCT02687217|Experimental|Group B: Test|Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
88818387|NCT01386632|Active Comparator|DCA (dichloroacetate) Treatment|DCA orally 12.5mg/kg or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
88818388|NCT01386632|Placebo Comparator|Placebo|Placebo orally or per G-tube BID for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
88818389|NCT02266277|Active Comparator|Arm 1: E-portal message with IVR call|Patients identified as e-portal users will receive an e-portal message with IVR call
88818390|NCT02266277|Active Comparator|Arm 2: E-portal message with no IVR call|Patients identified as e-portal users will receive an e-portal message only
88818391|NCT02266277|Active Comparator|Arm 3: No e-portal message with IVR call|Patients identified as e-portal users will receive an IVR call only
88818392|NCT02266277|No Intervention|Arm 4: No E-portal message with no IVR call|Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
88818393|NCT02266277|Active Comparator|Arm 5: IVR call|Patients identified as non e-portal users will receive an IVR call only
88818394|NCT02266277|No Intervention|Arm 6: No IVR call|Patients identified as non e-portal users will not receive any outreach
88818395|NCT02687529||Low Risk|Tested with CST001
88818396|NCT02687529||Known Risk|Tested with CST001
88818397|NCT01387178||COPD patients - risk analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. Patient records for the risk analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 3 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and June 30, 2008).
88818398|NCT01387178||COPD patients - cost analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. The cost analysis population is a subset of the risk analysis population. Patient records for the cost analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 12 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and September 30, 2007).
88818399|NCT05587335|Experimental|In person|Couples will be assigned into in person relationship intervention.
88818599|NCT01420016|Active Comparator|Prioritized Clinical Decision Support|The Prioritized Clinical Decision Support (CDS) intervention is a protocol driven CDS system linked within the EMR that identifies patients with high cardiovascular risk and provides tailored, prioritized decision support to the provider and patient at the point of care. The CDS was printed at intervention sites. It i) compiled most recent lab data (A1c, SBP, and LDL), BMI, smoking status, and aspirin use, (ii) calculated a 10-year risk for stroke or heart attack, (iii) prioritized clinical domains based on the absolute risk reduction for each component, (iv) compiled information related to renal and liver function, creatine kinase level, and previous diagnoses (CHF, CVD, DM), and (v) provided recommendations for intensification of therapy for A1c, SBP and/or LDL if not at goal.
88818600|NCT01420016|No Intervention|Usual Care|Providers in the usual care arm did not have access to the prioritized clinical decision support tool.
88818601|NCT02701101|Other|Daily Skin Assessments (SoC and SEM Scanner Readings)|"The SEM Scanner 200 measures sub-epidermal moisture (SEM), which has been studied as an indicator of localized edema characteristic of pressure-induced tissue damage. Daily assessments were performed at the sacrum and both heels unless the anatomical location(s) were not assessable. Daily assessments included:~Risk Assessment (standard of care; Braden, Waterlow, or Norton)~Skin Assessment (standard of care visual skin assessments utilizing tactile and visual cues)~SEM Scanner readings (test variable in this study). Standard of care evaluations were conducted by individuals meeting the definition of Specialist specified in the study protocol whereas separate individuals meeting the definition of Generalist performed SEM Scanner 200 measurements. Specialists were blinded to the assessment by the Generalists, and vice versa."
88818602|NCT01398566|Experimental|SuperBetter Play|members of this group will play SuperBetter for 6 weeks (averaging 10 min per day of play for 6 week period)
88818603|NCT01399268|Experimental|Steroid|Hydrocortisone 100 mg IV Q 8hrs x3
88818604|NCT01399268|Placebo Comparator|Control|Saline IV Q8hr x3
88818605|NCT05459493|Experimental|TJAOA101|Once enrolled, participants will be administrated TJAOA101 and followed by a 3-month medication cycle. The usage of this herbal compound is to take orally twice a day(two sacks per). Add it to about 200ml warm water and take it half an hour before breakfast in the morning and half an hour before bedtime in the evening except menstrual period.
88818606|NCT03008876|Experimental|acetaminophen|Group of patients randomized to receive acetaminophen to treat their PDA
88818607|NCT03008876|Active Comparator|ibuprofen|Group of patients randomized to receive ibuprofen to treat their PDA
88818608|NCT05414487||Ofatumumab|17 RMS patients and 17 NMOSD patients prescribed with Ofatumumab will be enrolled after informed consent.
88818609|NCT01483352|Experimental|Single Arm|Participants were implanted with Accu-Chek DiaPort with Infusion Set connected to an Accu-Chek Insulin Pump to perform continuous intraperitoneal insulin delivery.
88818610|NCT02701257|Active Comparator|iPhone bionic pancreas - Lilly glucagon|iPhone based bionic pancreas using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
88818611|NCT02701257|Experimental|iLet bionic pancreas - Lilly glucagon|iLet Bionic Pancreas using using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
88818612|NCT02701257|Experimental|iLet bionic pancreas - Xerisol glucagon|iLet Bionic Pancreas using using insulin lispro and Xeris Xerisol glucagon. These visits will be conducted separately from the infusion set sub-study visits.
88818613|NCT02701257|Experimental|iLet infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
88818614|NCT02701257|Active Comparator|Contact Detach infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
88818615|NCT01836029|Experimental|chemotherapy and cetuximab plus VTX-2337|"VTX-2337 (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
88818616|NCT01836029|Active Comparator|chemotherapy and cetuximab plus placebo|"Placebo (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
88818617|NCT02701647|Experimental|25Hz-TT|Participants will receive 4s train of 25-Hz rTMS pulses with 50s inter-train interval, with an intensity of 80% resting motor threshold (RMT). Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
88818618|NCT02701647|Experimental|1Hz-TT|Participants will receive a total of 600 1-Hz rTMS pulses in 10 minutes for each hemisphere and a total of 1200 pulses ,with an intensity of 80% RMT, followed by 30 minutes of treadmill training.
88818619|NCT02701647|Sham Comparator|Sham-TT|Sham rTMS will be applied over the same site as for real rTMS, however, with the cable of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as per 25Hz-TT group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect. Sham rTMS will be followed by 30 minutes of treadmill training.
88818620|NCT05209139|Experimental|Beetroot supplementation|Acute beetroot juice supplementation
88818621|NCT05209139|Placebo Comparator|Placebo supplementation|Acute placebo supplementation
88818622|NCT05114213|Experimental|Arm A: SBRT|mPDAC patients not progressing after 8 weeks of standard of care systemic therapy (SoC-CT: minimum doublet chemotherapy). The primary tumor is treated with SBRT (6.6Gy x 5) on a MR-LINAC in breath-hold technique. For this purpose, daily adaptive planning is performed aiming to maintain stringent dose constraints for organs at risk (duodenum / stomach / bowel / kidney). Chemotherapy will be continued after SBRT.
88818695|NCT02835807|Experimental|Health Chat including Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image) with 25% of all of the content being about indoor tanning. Indoor tanning-related content was developed by the investigators and a social media marketing expert using information from published literature on IT risk factors, evidence-based intervention content from published trials targeting IT reduction, public health campaigns from major non-profit organizations (e.g., CDC, Skin Cancer Foundation, etc.), and investigator-developed video-recorded interviews of local mothers and professionals about the risks of indoor tanning, experiences with skin cancer, and mother-daughter communication role modeling.
88818696|NCT02835807|Active Comparator|Health Chat excluding Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image), but does not include any content about indoor tanning. The designated number of posts (25%) assigned to the indoor tanning content in the intervention group will be assigned to prescription drug use in the control arm. In order to keep number and frequency of posts standardized between the two groups, prescription drug use was selected to replace the indoor tanning content for the control arm.
88818697|NCT02658669|Experimental|Cognitive-Behavioral Therapy for Insomnia|6-week manualized treatment designed to improve symptoms of chronic insomnia.
88818698|NCT02658669|Active Comparator|Sleep Education|6-week manualized treatment designed to provide information regarding traumatic brain injury and its relationship to sleep disturbance, which incorporates training in sleep hygiene to help improve nighttime sleep and daytime functioning.
88818699|NCT02722239|Experimental|T/R|Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)
88818700|NCT02722239|Experimental|R/T|Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.
88818701|NCT02581917||Ancillary-Correlative (metabolic changes)|Patients undergo collection of PBMC samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.
88818702|NCT01845155|Experimental|Music Therapy|Neuro-Music-Therapy according to the Heidelberg Model
88818703|NCT01845155|Active Comparator|Counselling|Counselling
88818704|NCT02578641|Experimental|Arm A|"4 cycles* of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T cells every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle.~*Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon discretion of Investigator, if EBV-specific CTL infusions are not available in time for the 1st scheduled infusion.~As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs, will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000 mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days"
88818705|NCT02578641|Active Comparator|Arm B|6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.
88818706|NCT05746715||genetic Creutzfeldt-Jakob Disease (CJD) patients|A group of patients diagnosed with CJD, who are carriers of E200K mutation in the PRNP gene (gCJD)
88818707|NCT05746715||Healthy first degree relatives|A group of first-degree healthy relatives (HR) (both carriers and non-carriers of the E200K mutation in the PRNP gene) of patients diagnosed with gCJD.
88818708|NCT05084859|Experimental|CRPC (Castration Resistant Prostate Cancer) - SM08502 + Abiraterone/Prednisone|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC.~Subjects will receive increasing doses of SM08502 with fixed doses of Abiraterone/Prednisone to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM08502 in subjects with advanced CRPC. Approximately 20 subjects will be enrolled."
88818709|NCT05084859|Experimental|NSCLC (Non-Small Cell Lung Cancer) - SM08502 + Docetaxel|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced NSCLC.~Subjects will receive increasing doses of SM08502 with fixed doses of docetaxel to determine the MTD and recommended Part 2 dose and schedule.~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM0850 in subjects with advanced NSCLC. Approximately 20 subjects will be enrolled."
88818710|NCT05084859|Experimental|CRC (Colorectal Cancer) - SM08502 + FOLFIRI/Panitumumab|"Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRC.~Subjects will receive increasing doses of SM08502 with fixed doses of FOLFIRI plus panitumumab ( RAS wild type tumors) or with fixed doses of FOLFIRI (RAS mutant tumors)~Escalation will follow a 3+3+3 design within each cohort.~Part 2 will further evaluate the recommended dose and schedule of SM08502. Subjects that have RAS wild type tumors will receive FOLFIRI and panitumumab with SM08502 (n=15). Subjects that have RAS mutant tumors will receive FOLFIRI with SM08502 (n=15)."
88818711|NCT01846871|Experimental|Tivozanib|1.5 mg daily for 3 weeks, with 1 week off.
88818712|NCT05746637||Study population|The entire study population
88818713|NCT02431260|Experimental|INCB054329 Monotherapy|
88818714|NCT05745545|Experimental|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|
88818715|NCT05745545|Placebo Comparator|Placebo|
88818716|NCT01847027|Active Comparator|Active supplement|NutraStem, 2 tablets daily, Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg).
88818717|NCT01847027|Placebo Comparator|Sugar pill|"The placebo is identical in appearance to the NutraStem® supplement and contains the following ingredients in a Vegi Capsule:~MCC200 DICALCIUM PHOSPHATE BROWN LAKE BLEND (SENSIENT # 09127 ) RED DYE DB-088 (COLORCON) MAGNESIUM STEARATE BLUE #1 ALUM LAKE (POWDER)"
88819280|NCT03008330|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
88818750|NCT04575155|Experimental|TEAM Strategy|Patients randomized to the TEAM intervention arm will receive at least one call from a Walgreens pharmacist to help them with their complex Rx regimens. Pharmacists will have read/write EHR access with established Epic security points. Through shared access to patients' medical records, pharmacists can perform comprehensive medication therapy management services, document and communicate patients' Rx challenges for review and action by primary care providers. After the pharmacist calls the patient for a Comprehensive Medication Review, they will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit.
88818751|NCT04575155|No Intervention|Enhanced Usual Care|Patients randomized to enhanced usual care will have the medical record available to a Walgreens pharmacist with 'read only' access. All patients at the five targeted health centers already have read-only access in place. This means the Walgreens pharmacist will have the capability to review a patient's record as necessary. The pharmacist may refer to the EHR as needed and in a reactive manner; such as if a patient were to request a medication requiring review for billing purposes (i.e. verify insurance, prior authorizations), or if a patient safety concern was raised (e.g. potential drug-drug or drug- disease interaction, therapeutic duplication, etc.). Similarly, read only EHR access means pharmacists must continue to use existing communication channels (e.g. phone, fax) to contact prescribers.
88818752|NCT01469247|Experimental|Radiation Therapy|Starting dose of 24 Gray (Gy) in 2 Gy fractions.
88818753|NCT01848899|Experimental|Ioxaglate Arm|
88818754|NCT01848899|Experimental|Iodixanol arm|
88818755|NCT01848977|Experimental|vascular occlusion test|"The pediatric SomaSensor™ probe of INVOS® and the 15-mm sensor of InSpectra™ are placed on each thenar muscle in the same subject. The side on which the probe will be placed is randomly determined. INVOS® updates data every 5 s and data (SrO2) will be manually recorded. The data of InSpectra™ (StO2) are automatically collected and sampled every 2 s.~Vascular occlusion test (VOT) is done as follows:Adult-size blood pressure cuffs are placed around each upper arm. The both cuffs are simultaneously inflated to 30 mmHg above the initial systolic blood pressure and kept inflated until the SrO2 or StO2 decreased to 40%. When the value reaches 40% or just below it, the cuff on the same side is deflated rapidly. The data will be collected until the SrO2 and StO2 values returned to the baseline."
88818756|NCT02731833|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute
88818757|NCT02731833|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush whole mouth thoroughly for at least 1 minute
88818758|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) post infusion|Cangrelor IV + Oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation
88818759|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (5 doses)|Prasugrel discontinued 48h (n=6) prior to initiation of cangrelor infusion (2h)
88818760|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) at 1.5h|Cangrelor IV + oral prasugrel (60mg) administered at 1.5h after the cangrelor infusion start time.
88818761|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) a 1.0h|Cangrelor IV + oral prasugrel (60mg) administered at 1.0h after the cangrelor infusion start time.
88818762|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (6 doses)|Prasugrel discontinued 24h prior to initiation of cangrelor infusion (2h)
88818763|NCT00422487|Experimental|MBX-2044 1.5 mg|
88818764|NCT00422487|Experimental|MBX-2044 4.5 mg|
88818765|NCT00422487|Experimental|MBX-2044 15 mg|
88818766|NCT00422487|Experimental|MBX-2044 30 mg|
88818767|NCT00422487|Experimental|MBX-2044 60 mg|
88818768|NCT00422487|Experimental|MBX-2044 90 mg|
88818769|NCT00422487|Placebo Comparator|Placebo|
88818770|NCT02430870|Experimental|Part 1 Cohort 1: TAK-648 0.35 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 1 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
88818771|NCT02430870|Experimental|Part 1 Cohort 2: TAK-648 0.80 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 2 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
88818772|NCT02430870|Placebo Comparator|Part 1: Placebo Cohort 1-2|Participants with T2DM on a stable dose of metformin in study Part 1 received placebo-matching TAK-648, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
88818773|NCT02430870|Experimental|Part 2 Cohort 1: TAK-648 0.05 mg|Healthy participants of Japanese descent in study Part 2, Cohort 1 received TAK-648 0.05 mg, solution , orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
88818774|NCT02430870|Experimental|Part 2 Cohort 2: TAK-648 0.15 mg|Healthy participants of Japanese descent in study Part 2, Cohort 2 received TAK-648 0.15 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
88818775|NCT02430870|Experimental|Part 2 Cohort 3: TAK-648 0.35 mg|Healthy participants of Japanese descent in study Part 2, Cohort 3 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
88818776|NCT02430870|Experimental|Part 2 Cohort 4: TAK-648 0.80 mg|Healthy participants of Japanese descent in study Part 2, Cohort 4 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
88818777|NCT02430870|Placebo Comparator|Part 2: Placebo Cohort 1-4|Healthy participants of Japanese descent in study Part 2, received TAK-648 placebo-matching solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
88818856|NCT01421186|Experimental|Phase 2a confirmatory cohorts|"Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.~Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.~Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.~For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment."
88818857|NCT05675969|Experimental|Pre-eclamptic women|The intervention consists of the collection of 2 additional tubes of 4.5mL of citrate blood. The sample will be collected as close as possible to the diagnosis of pre-eclampsia during a routine care assessment
88818858|NCT05675969|Active Comparator|Non pre-eclamptic women|The intervention consists of the collection of 2 additional tubes of 4.5mL of citrate blood. sampling will be performed during routine care according to the matching.
88818859|NCT03697967|Experimental|Supine|Infant placed supine for 120 seconds before cord clamping
88818860|NCT03697967|Experimental|Prone|Infant placed prone for 120 seconds before cord clamping
88818861|NCT02645253|Experimental|Cohort 1|AZD7594 inhalation powder (200 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
88818862|NCT02645253|Experimental|Cohort 2|AZD7594 inhalation powder (400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
88818863|NCT02645253|Experimental|Cohort 3|1600 μg AZD7594 inhalation powder (4 x 400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
88818864|NCT02645253|Experimental|Cohort 4|400 μg AZD7594 pressurized inhalation suspension (2 x 200 μg inhalations) or placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
88818865|NCT03636347|Placebo Comparator|Placebo oral tablet|
88818866|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
88818867|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
88818868|NCT01484288|Experimental|Device group|Barostim Neo system
88818869|NCT01860287|Placebo Comparator|Placebo group|Healthy volunteers receive placebo during session (within-subjects design).
88818870|NCT01860287|Experimental|buprenorphine (0.2 mg) group|Healthy volunteers receive buprenorphine (0.2 mg) during session (within-subjects design).
88818871|NCT01860287|Experimental|buprenorphine (0.4 mg) group|Healthy volunteers receive buprenorphine (0.4 mg) during session (within-subjects design).
88818872|NCT01421498|Experimental|5.0% Lifitegrast|Lifitegrast
88818873|NCT01421498|Placebo Comparator|Placebo|Placebo
88818874|NCT04677621|Experimental|Nurse Telehealth Intervention|Allocated to tele-intervention
88818875|NCT04677621|Active Comparator|Standard Deep Brain Stimulation (DBS)|Allocated to conventional approach
88818876|NCT01421654|Experimental|Fixed Mode + Acclimate|S9 Elite flow generator with Acclimate feature activated.
88818877|NCT01421654|Active Comparator|Fixed Mode only|S9 Elite Flow Generator with Fixed Mode only
88818878|NCT05446311||DS group|Subjects going to receive dinalbuphine sebacate for post-cesarean section pain.
88818879|NCT04739085||Defocus curve group|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to the distances of 30 cm, 40 cm, 60 cm, and 80 cm, respectively.
88818880|NCT04739085||wDDART group|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
88818881|NCT01422200|Experimental|Subcutaneous|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once
88818882|NCT01422200|Active Comparator|Intramuscular|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via intramuscular route once
88818883|NCT05445765|Experimental|anti-CD33 CAR T cells|Dose escalation phase: anti-CD33 CAR T cells will be transduced with a lentiviral vector to express anti-CD33 CARs
88818884|NCT01860521|Active Comparator|Programmed Intermittent Epidural Bolus|
88818885|NCT01860521|Active Comparator|Continuous Epidural Infusion|
88818886|NCT02648919|Experimental|Noni 6,000 mg/day|Noni extract 6,000 mg/day (4 capsules with breakfast, 4 capsules with lunch and 4 capsules with dinner)
88818887|NCT04566861|Experimental|Anxious pregnant women - intervention group|100 pregnant women who have at least mild anxiety will be randomized to the intervention group where they will receive six one-on-one core sessions of Cognitive Behavioral Therapy during pregnancy (plus possible booster sessions)
88818888|NCT04566861|No Intervention|Anxious pregnant women - enhanced usual care group|100 pregnant women who have at least mild anxiety will be randomized to the enhanced usual care group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
88818889|NCT04566861|No Intervention|Non-anxious pregnant women - healthy control|100 pregnant women who do not have symptoms of anxiety or depression be followed in the healthy control group. They will not receive intervention sessions but will receive transportation vouchers to come to the hospital and facilitation by study staff to attend to their regular antenatal care visits.
88818890|NCT01400906|Placebo Comparator|3 periods cross-over study|Each subject will receive each intervention BID during a 7 days period. The treatment periods are separated by 14 days washout. The sequence in which the interventions are administered are at random and double blind.
88818891|NCT00367653|Experimental|1|
88818892|NCT00367653|Experimental|2|
88818893|NCT01861301|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
88818894|NCT05445531|Active Comparator|Control|Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to STIKO, German vaccination committee)
88818895|NCT05445531|Active Comparator|Recovered|Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline not fulfilled.
88819094|NCT05111691|Experimental|Dry needling|"Two needles will be inserted on or near the most tender point of the low back. Two additional needles will be inserted on the opposite side at the level of the most tender point regardless of unilateral or bilateral low back pain (LBP). After piercing the skin, the needle will be directed toward the spinous process in a slight inferior-medial angle (approximately 20-30°). Once the needle is inserted, the treating investigator will use a ultrasound scanner to visualize the needle placement and to confirm that needle has reached the deeper layer of the lumbar multifidus (LM) muscle.~Once the needle placement is confirmed, it will be pulled slightly in and out within the muscle and redirected in small angles for 10 seconds after insertion. The needles will stay (in situ) in the LM for approximately 10 minutes after the insertion and then will be withdrawn."
88819095|NCT04739241|Experimental|Group A (experimental arm)|Premixed insulin therapy
88819096|NCT04739241|Active Comparator|Group B (active comparator)|Basal bolus insulin therapy
88819097|NCT03024437|Experimental|Phase I - Dose Escalation|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and ANY or NO prior treatments.~Three dose levels of entinostat will be tested in 3-patient cohorts according to the 3 + 3 standard design (1 mg, 3 mg and 5 mg). The starting dose level of entinostat will be 1 mg orally every 7 days. The Phase II dose will be recommended phase II dose of entinostat (i.e., the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)."
88819098|NCT03024437|Experimental|Phase II - Cohort A|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and NO prior treatments.~Patients in Cohort A will be treated with atezolizumab, bevaciuzmab, and the recommended phase II dose of entinostat. During Phase II, the study will have a run-in period with entinostat for one cycle followed by atezolizumab and bevacizumab for the second cycle, and then the combination phase (i.e., atezolizumab + bevacizumab + entinostat for all cycles thereafter)."
88819099|NCT03024437|Experimental|Phase II - Cohort B|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and at least one prior treatment with a PD1 or PDL1 inhibitor.~Patients in Cohort B will be treated with the same combination therapy as in Cohort A."
88819100|NCT04707807||Nightshift workers|
88819101|NCT04707807||Non-nightshift workers|
88819102|NCT04707963|Experimental|Immediate Intervention Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder (72g/day) will be provided for daily consumption during the study period
88819103|NCT04707963|Active Comparator|Wait-list Control Group|Participants will complete 10 weeks of twice-weekly whole body resistance training. Peanut protein powder will be provided after the study period
88819104|NCT03475173|Experimental|Laser Speckle Blood Flow Group|
88819105|NCT01489826|Experimental|Dexanabinol 2 mg/kg|Dexanabinol 2 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819106|NCT01489826|Experimental|Dexanabinol 3 mg/kg|Dexanabinol 3 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819107|NCT01489826|Experimental|Dexanabinol 6 mg/kg|Dexanabinol 6 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819108|NCT01489826|Experimental|Dexanabinol 12 mg/kg|Dexanabinol 12 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819109|NCT01489826|Experimental|Dexanabinol 15 mg/kg|Dexanabinol 15 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819110|NCT01489826|Experimental|Dexanabinol 22 mg/kg|Dexanabinol 22 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819111|NCT01489826|Experimental|Dexanabinol 30 mg/kg|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819112|NCT01489826|Experimental|Dexanabinol 36 mg/kg|Dexanabinol 36 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819113|NCT01489826|Experimental|Dexanabinol Expansion Phase|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
88819114|NCT05070975||Twins|Twins identified from the birth cohort (Hospices Civils de Lyon) with at least one twin hospitalized for an acute RSV-infection
88819115|NCT02677623|Experimental|A- Pyridium|"Method of administration: oral~Dose: 200 mg PO with small sip of water~Known adverse events: yellow discoloration of skin or sclera, 1-10% central nervous system effects including headache and dizziness, GI effect of cramping, < 1% acute renal failure, methemoglobinemia, hemolytic anemia, hepatitis, rash, skin pigmentation, vertigo, stomach cramps~Contraindications: to be used in caution in patients with renal impairment Cr Cl < 50ml/minute and in patients who are receiving nitric oxide, prilocaine and sodium nitrite as it can cause methemoglobinemia"
88819116|NCT02677623|Experimental|B- Sodium Fluorescein|"Method of administration: intravenous~Dose: 25 mg~Known adverse events: nausea, vomiting, flushing or rash, hypersensitivity and anaphylactic reactions can occur following injection and immediate treatment with epinephrine should be available, skin and urine discoloration (urine may appear bright yellow for 24-36 hours), extravasation may cause skin sloughing, toxic neuritis and phlebitis, nausea, rare cardiac arrest and seizure,~Contraindications: use with caution in patients with history of hypersensitivity, allergies or asthma"
88819117|NCT02677623|Experimental|C- Mannitol|"Method of administration: irrigant during cystoscopy~Dose: 300cc during cystoscopy to visualize the ureters~Known adverse events: dysuria, polyuria, hyponatremia with excess absorption, potential increased risk of urinary tract infection~Contraindications when used as a genitourinary irrigation solution: anuria"
88819118|NCT02677623|Experimental|Control- Normal saline|"Method of administration: irrigant during cystoscopy~Dose: 300cc~Known adverse events: no known significant adverse events~Contraindications: none"
88819119|NCT02677701|Active Comparator|azithromycin|azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
88819120|NCT02677701|Placebo Comparator|placebo|encapsulated placebo taken by mouth thrice weekly for 6 weeks
88819121|NCT03375255|Experimental|SRP-5051|"Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051 on Day 1.~Patients who complete the study and continue to meet safety eligibility criteria will have the opportunity to enroll in an open-label extension study to continue to receive SRP-5051."
88819281|NCT01546454|Experimental|Non-steroidal effects|Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.
88819247|NCT05451459|Other|Wait-list home-based group|The wait-list home-based group will serve as the control group (during intervention). This group will be instructed to continue their typical routines and activities for the duration of the 12-week intervention. At the end of the 12 weeks, they will be asked to complete the post-test surveys (same as questionnaires completed prior to randomization). Their participation in the research will be complete at this time. However, because the intervention has been shown to potentially benefit families, immediately following the post-test, participants in the wait-list home-based group will be offered the chance to complete the home-based intervention program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) as described for the intervention group). No data will be collected for research from them during this time.
88819248|NCT05451147|Experimental|Group A|DRUG: Chhinnavahni Kashaya Vati FORM: Tablet DOSE: 1 g TDS (2 Tab. of 500 mg each), Before Meals MODE OF ADMINISTRATION: Oral ANUPAAN: 20 ml of Agnimantha Kwatha DURATION: 3 Months
88819249|NCT05451147|Active Comparator|GROUP B|DRUG: Metformin FORM: Tablet DOSE: 500mg BID/TDS, Before Meals MODE OF ADMINISTRATION: Oral ANUPAAN:: Plain Water DURATION 3 Months
88819250|NCT01429064|Experimental|ODM-201|
88819251|NCT02204150|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
88819252|NCT04553367|Placebo Comparator|Group A|patients of group A Continue on the conventional way of ventilation and . Microbiological results collected from patients of group A through qualitative sputum.
88819253|NCT04553367|Active Comparator|Group B|had three times bronchoscopy one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period to confirm both clinical and bacteriological cure. Bronchoscopy done with the following precautions: we used flexible bronchoscopy Olympus BF-160 adult size, patients kept sedated with both midazolam and fentanyl, 4 syringe of normal isotonic saline used for wash every one 10 ml and suction done immediately after injection, suction of the fluid and small airway secretion after only the first injection of isotonic saline syringe used for BAL and sent for qualitative culture
88819254|NCT00369759||1|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
88819255|NCT00369759||2|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
88819256|NCT00369759||3|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
88819257|NCT00369837|Experimental|clevidipine|A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.
88819258|NCT05450445|Experimental|Intervention: myHealthHub|
88819259|NCT05450445|Active Comparator|Active control: TV-only|
88819260|NCT05450367||patients with a haematological malignancy treated with immunotherapy|
88819261|NCT05450289|Active Comparator|Control Group|Control group will receive allergen specific immunotherapy and standard pharmacotherapy
88819262|NCT05450289|Experimental|Experimental Group|Experimental group will receive allergen specific immunotherapy, standard pharmacotherapy, and nigella sativa oil
88819263|NCT01493024|Placebo Comparator|Placebo|Placebo (silicified microcrystalline cellulose) randomized to mimic escalating doses of experimental drug administered three times daily (TID) with meals.
88819264|NCT01493024|Experimental|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated, microporous zirconium silicate, an oral sorbent) administered 3 times daily (tid) with meals.
88819265|NCT05443815||HaemoCer-PLUS|Patients who had receive HaemoCer-PLUS
88819266|NCT05449899|Experimental|G-CSF+DAC+BF|For patients with sAML undergoing allo-HSCT, Granulocyte Colony-Stimulating Factor (G-CSF)+Decitabine+BF conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -6 to -3, Fludarabine (FLU) 30mg/m2/ day on days -7 to -3.
88819267|NCT05449899|Active Comparator|G-CSF+DAC+BUCY|For patients with sAML undergoing allo-HSCT, Granulocyte Colony -Stimulating Factor (G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5ug/kg/day on days -17 to -10 (when white blood cell is more than 20G/L, stop using G-CSF), Decitabine 20mg/m2/day on days -14 to -10, Busulfan (BU) 3.2 mg/kg/day on days -7 to -4, Cyclophosphamide (CY) 60 mg/kg/day on days -3, -2.
88819268|NCT04338789|Experimental|Group 1|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed immediately before molar protraction on the left or right side of the patient.
88819269|NCT04338789|Experimental|Group 2|It consisted of 20 subjects with bilateral first molar extraction space where piezocesion was performed 3 months after molar protraction with no piezocision on the left or right side of the patient.
88819270|NCT04338789|No Intervention|Group 3|It consisted of 20 subjects (40 molars) where molar protraction was performed with no piezocesion.
88819271|NCT01429454|Placebo Comparator|Soybean-Corn Blend Capsule|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
88819272|NCT01429454|Experimental|Omega 3 long chain fatty acid|The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
88819273|NCT05441631|Active Comparator|Intensive insulin therapy|
88819274|NCT05441631|Active Comparator|Conventional insulin therapy|
88819275|NCT05449353|Experimental|Trauma-infomed Cognitive Behavioural Therapy|Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
88819276|NCT01429532||Group I|1.8-mm-incision-size phacoemulsification system
88819277|NCT01429532||Group II|2.2-mm-incision-size phacoemulsification system
88819278|NCT01429532||Group III|3.0-mm-incision-size phacoemulsification system
88819546|NCT03497871|No Intervention|Standard care (control) group|"40 patients are in the no-intervention group (20 in Belgium and 20 in Italy).~They receive standard care, which consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year."
88819547|NCT01553708|Experimental|Epidermal growth factor with silver sulfadiazine cream|Epidermal growth factor with silver sulfadiazine cream was applied to the experimental wounds completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
88819548|NCT01553708|Active Comparator|Silver zinc sulfadiazine cream|Silver sulfadiazine cream was applied to cover the controlled-wound completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
88819549|NCT02370498|Experimental|Pembrolizumab|Participants receive 200 mg intravenous (IV) pembrolizumab on Day 1 of each 21-day cycle, for up to 35 administrations (approximately 2 years).
88819550|NCT02370498|Active Comparator|Paclitaxel|Participants receive 80 mg/m^2 IV paclitaxel on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
88819551|NCT01554488|Experimental|Arm 1|High dose inhaled fluticasone (1760mcg/day)
88819552|NCT01554488|Active Comparator|Arm 2|Low dose inhaled fluticasone (88mcg/day)
88819553|NCT03440853|Experimental|TASCCI|Patients randomized to TASCCI will receive a stepped-care approach of pharmaco and/or behavioral therapy for 12 weeks. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference.
88819554|NCT03440853|Other|Technology Delivered Health Education|Patients randomized to the Technology Delivered Health Education Intervention health education group will receive technology delivered health education material on topics relevant to dialysis.
88819555|NCT05453331||Awake MER-guided surgical procedure under local anesthesia with intraoperative testing|Awake micro-electrode recording-guided surgical procedure under local anesthesia with intraoperative testing
88819556|NCT05453331||Asleep MRI-guided and CT-verified surgical procedure|Asleep MRI-guided and CT-verified surgical procedure
88819557|NCT01437488|Experimental|Cabazitaxel|Cabazitaxel following platinum-based chemotherapy
88819558|NCT02347332|Experimental|Vinflunine plus methotrexate|vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
88819559|NCT02347332|Active Comparator|Methotrexate|methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks
88819560|NCT01502306|Experimental|Telephone counseling|One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling begins immediately after intake, if the client is available for a 30-minute session or by appointment at the clients' convenience. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls. The follow-up calls (about 10 minutes) will be scheduled as follows: a reminder call if the quit date is more than one week out for the initial counseling, on the quit date, 4-7 days after the quit date, and 10-14 days after the quit date.
88819561|NCT01502306|Experimental|Phone counseling & nicotine patches|"One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients the day after the screening intake. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day."
88819562|NCT01502306|Experimental|Phone counseling, NRT and incentives|"One-on-one, proactive telephone counseling to quit smoking; The counseling addresses behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day.~Gift cards (to one of 4 major chains) are $20 for the first counseling session and $10 for each additional one (up to five sessions total)."
88819563|NCT03325959|Active Comparator|Hyperbaric oxygen therapy|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group.
88819564|NCT03325959|Active Comparator|Pharmacotherapy|"patients will be offered pharmacological treatment with one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg at bedtime while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 6 weeks patients will be evaluated and dose will be adjusted as necessary. Patients may also be switched from one medication to the other based according to clinical judgment.~Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group."
88819565|NCT04337463|Experimental|ATG-008 and Toripalimab|Toripalimab will be combined with ATG-008.
88819566|NCT02347176|Placebo Comparator|Placebo|Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
88819567|NCT02347176|Experimental|Tralokinumab Dose 1|Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
88819568|NCT02347176|Experimental|Tralokinumab Dose 2|Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
88819569|NCT02347176|Experimental|Tralokinumab Dose 3|Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
88819745|NCT02346240|Experimental|CZP 400 mg|"Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
88819746|NCT02346240|Active Comparator|Etanercept|"Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
88819747|NCT02346240|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
88819748|NCT01511978|Active Comparator|Continuous 3,4-DAP|Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
88819749|NCT01511978|Placebo Comparator|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
88819750|NCT02772783|Experimental|high GI meal, euglycemic insulin clamp|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
88819751|NCT02772783|Experimental|high GI meal, fixed insulin infusion|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
88819752|NCT02772783|Active Comparator|low GI meal, euglycemic insulin clamp|A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
88819753|NCT02774343|Experimental|Pioglitazone + Therapy + Contingency Management|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
88819754|NCT02774343|Placebo Comparator|Placebo + Therapy + Contingency Management|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
88819755|NCT05349045||an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor group|
88819756|NCT02392104|Experimental|Intervention Arm|All patients in the study will be in the intervention arm.
88819757|NCT04336605||Young-HUNT|The young-HUNT study is a renowned, representative, population-based study where all adolescents living in the Nord-Trøndelag county have been invited to participate in four subsequent waves, from 1995 to 2019. Information about the study can be found here: https://www.ntnu.edu/hunt/young-hunt. In this study data from the Young-HUNT1-4 studies (1995-2019) will be linked to longitudinal, individual data from the Norwegian prescription Database (NorPD) (2004-2020), providing a unique, longitudinal dataset in which research questions will be explored. To obtain good, reliable follow-up data and outcome measures for the young-HUNT3 participants (2006-2008) the investigators will additionally include longitudinal data from the HUNT4 study of young adults (2017-2019); applicable for those participating in both the YoungHUNT3 and the YoungHUNT4.
88819758|NCT04737915|Experimental|Virtual Reality Exposure|Participants completed a single session of exposure administered via a virtual reality headset. The exposure exercise involved looking over virtual railings into an atrium at various floor levels (the virtual environment was designed to look like the atrium in the in vivo exposure condition). Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
88819759|NCT04737915|Experimental|In Vivo Exposure|Participants completed a single session of exposure administered in vivo. The exposure exercise involved looking over actual railings into an atrium at various floor levels. Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
88819760|NCT04737915|No Intervention|Waitlist Control|Participants watched a neutral video during the time participants in other conditions were completing the exposure exercise. Participants received no exposure-based intervention.
88819761|NCT01450826|Active Comparator|aprepitant+ondansetron|On day 1, patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide). Additionally, On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
88819762|NCT01450826|Active Comparator|ondansetron|On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
88819763|NCT04335357|Placebo Comparator|placebo|The appearance and fill of placebo syringes will be identical to the active comparator.
88819764|NCT04335357|Active Comparator|TBR-760|TBR-760 is supplied as a ready-to-use solution in pre-filled syringes at a concentration of 5 mg/ml.
88819810|NCT05450055|Experimental|intraperitoneal analgesic group|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump. At the same time, patients in both groups were connected with intravenous controlled intravenous controlled analgesia (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.
88819811|NCT05450055|Placebo Comparator|control group|Before the end of surgery, patients in the control group (C group) were extensively sprayed with 20mL normal saline intraperitoneally before the peritoneum was sutured. The surgeon placed an intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. In the control group, 0.9% normal saline was injected intraperitoneally with 10mL/h, and the total volume in the pump was 720mL. At the same time, patients in both groups were connected with intravenous controlled analgesia pump (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.
88819812|NCT02743377|Experimental|Subjects with McCune-Albright syndrome (MAS)|Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans
88819813|NCT02743377|Experimental|Healthy control|Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans
88819814|NCT05437965||isolated coronary arteritis|
88819815|NCT05437965||coronary artery disease|
88819816|NCT01512758|Experimental|Alisertib 30 mg|Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
88819817|NCT01512758|Experimental|Alisertib 40 mg|Alisertib 40 mg ECT, orally, BID for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 7 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
88819818|NCT02746107|Experimental|risk presented on 1 diagram|decision aid with risk of stroke presented on 1 diagram (risk under OAC treatment)
88819819|NCT02746107|Active Comparator|risk presented on 2 diagrams|decision aid with risk of stroke presented on 2 diagrams (one presenting risk without and one presenting risk with treatment)
88819820|NCT02746107|Active Comparator|1year risk estimate|risk of stroke presented over a timeframe of 1 year
88819821|NCT02746107|Experimental|5year risk estimate|risk of stroke presented over a timeframe of 5 years
88819822|NCT02746107|Other|CHA2DS2-VASC risk score 1|CHA2DS2-VASC risk score =1
88819823|NCT02746107|Other|CHA2DS2-VASC risk score 2|CHA2DS2-VASC risk score =2
88819824|NCT02746107|Other|CHA2DS2-VASC risk score 3|CHA2DS2-VASC risk score =3
88819825|NCT02746107|Other|CHA2DS2-VASC risk score 4|CHA2DS2-VASC risk score =4
88819826|NCT02746107|Other|CHA2DS2-VASC risk score 5|CHA2DS2-VASC risk score =5
88819827|NCT02746107|Active Comparator|prescription to virtual patient|prescription is done for a virtual patient
88819828|NCT02746107|Experimental|prescription to physician himself|prescription is done to physician himself
88819829|NCT01513538||TherapyGuide|Patients implanted with a dual chamber pacemaker featuring the TherapyGuide function
88819830|NCT05303571||Monodof|monofocal and EDOF lens
88819831|NCT05303571||Bidof|Bifocal and EDOF lens
88819832|NCT01453166|Experimental|Group 1|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
88819833|NCT01453166|Experimental|Group 2|Group B received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
88819834|NCT01453166|Experimental|Group 3|Group C received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
88819835|NCT04334733|Experimental|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography.
88819836|NCT04334733|Experimental|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
88819837|NCT04334733|Experimental|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography and the children in the groups were distracted by kaleidoscope during the echocardiography process, until the process was over.
88819838|NCT04334733|Experimental|Control group|No intervention was made to children in the control group
88819839|NCT01514162|Experimental|Trifecta Valve Group|Subjects implanted with a Trifecta valve.
88819840|NCT05244135|Experimental|Pulmonary rehabilitation in VR (VR group)|"The VR group will perform the endurance exercise training using the Virtual Park, developed by CNR-STIIMA. The system includes a COSMED cycle-ergometer, a virtual environment and a physiological sensor-either a HR band or a pulse-oximeter depending on the target patient's needs. The virtual environment represents a ride in a park, enriched with realistic elements and sound effects, in order to simulate a daily life situation.~In the VR group, the VR Tier One device (Stolgraf®) will be used as a VR source. Thanks to using a head mounted display and the phenomenon of total immersion, VR therapy provides an intense visual, auditory and kinaesthetic stimulation. The aim of the software was to calm and improve the mood, while motivating and cognitively activating the patient."
88819841|NCT05244135|Active Comparator|Traditional Pulmonary Rehabilitation (TPR)|"In the TPR group, exercise training will be performed on the bicycle. The training will be conducted on cycle ergometers with the use of the Peloton™ system, which ensures the monitoring of performance parameters.~In the TPR group, Schultz Autogenous Training will be performed. Schultz Autogenic Training has been shown to be effective in treating these pathologies. In both groups the relaxation training will be carried out once a day and will last about 20 minutes."
88819842|NCT02748525|Experimental|CCK then Milk|CCK administered and HIDA scan performed. Results analyzed, if ejection fraction is low, patient is given milk to drink, and HIDA scan performed again. Results are analyzed to determine if ejection fraction is still low.
88819843|NCT01454414|Experimental|Permethrin Impregnated Uniforms|Uniforms (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin.
88819844|NCT01454414|No Intervention|Placebo|Uniforms sent to Insect Shield, washed and refolded (no permethrin applied).
88819845|NCT04335513|Experimental|Intervention|Early diabetes management and education including focused education based on pathophysiology of type 1 diabetes, factors which impact blood glucose, and effects of insulin using data from continuous glucose monitoring device (CGM) worn unblinded at least 20 days per month with interpretation and education on results. Early initiation of insulin therapy, when warranted based on a pattern of prolonged or repeated high blood glucose values.
88819846|NCT04335513|Active Comparator|Control|Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK (ongoing studies at BDC). This includes: blood glucose checks 2-3 times per month, participant-led contact with study personnel when abnormalities are noted and transition to clinical care when criteria for clinical type 1 diabetes are met.
88819847|NCT05219019||PD patients who have elected DBS|Ten individuals with moderate to advanced Parkinson's disease who have elected to undergo deep brain stimulation (DBS) of the subthalamic nucleus (STN) or internal globus pallidus (GPi) as standard of care for management of Parkinson's disease tremor and/or motor complications
88819848|NCT01514318||Revelation|Subjects who received the Revelation Hip Stem prior to 2002 and have agreed to come into the office for a single visit.
88819849|NCT01514396|Experimental|Surgical Glue|Surgiseal
88819850|NCT01514630|Experimental|Creatine monohydrate|14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.
88819851|NCT04140669||Fetal Surgery Procedures|All pregnant women with a fetus diagnosed with a fetal abnormality and planning to undergo a fetal surgical procedure will be included in this single arm of the study.
88819852|NCT01568528|Experimental|Oxytocin|The intranasal oxytocin intervention will be the administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. Each puff is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
88819853|NCT01568528|Placebo Comparator|Placebo|"Intranasal placebo The PBO/control will consist of the OT vehicle administered as three puffs in each nostril. Each puff is is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally.~Treatment assignment will be by random allocation in blocks of six. Both experimenters and subjects will be blind to the treatment they are receiving."
88819854|NCT01568528|Other|Healthy Controls|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will not receive oxytocin or placebo. They will only receive psychiatric screening interview, MATRICS Consensus Cognitive Battery (MCCB) assessment, urine drug screen, vision testing, and the three social cognition tasks.
88819855|NCT05199207|Experimental|Sarcopenic patient|Patient with sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)
88819856|NCT05199207|Active Comparator|Non sarcopenic patient|Patient without sarcopenic criteria (SARC-F Score, muscle strengh value, appendicular lean mass value)
88819857|NCT05065359|Experimental|Rodatristat Ethyl 300 mg BID - Japanese subjects|
88819858|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects|
88819859|NCT05065359|Experimental|Rodatristat Ethyl 300 mg BID - Caucasian subjects|
88819860|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects|
88819861|NCT05065359|Experimental|Rodatristat Ethyl 600 mg BID - Japanese subjects|
88819862|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects|
88819863|NCT05065359|Experimental|Rodatristat Ethyl 600 mg BID - Caucasian subjects|
88819864|NCT05065359|Placebo Comparator|Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects|
88819865|NCT01568606|Experimental|Body Composition Analysis InBody Scale|
88819866|NCT01460732|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
88819867|NCT05013255|Active Comparator|Pioglitazone 15mg Dose|Subjects will be given PIO 15mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
88819868|NCT05013255|Active Comparator|Pioglitazone 30mg Dose|Subjects will be given PIO 30mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
88819869|NCT05013255|No Intervention|No Drug|Subjects will be assigned to a no drug control group based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
88819994|NCT02780661|Experimental|Denture Cleanser Weekly Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
88819995|NCT05440968|Other|A - Intervention|A - After randomization, participants will be offered information on healthy lifestyles according to their score on the FINDRISC questionnaire and subsequently a POC-A1c measurement + a confirmatory test order (Oral Glucose Tolerance Test)
88819996|NCT05440968|Other|B - Control|B - After randomization, will be offered the same information on healthy lifestyles according to their FINDRISC score, and will receive an order to an Oral Glucose Tolerance Test.
88819997|NCT02781051|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.
88819998|NCT01516424|Experimental|Blonanserin|Antipsychotics
88819999|NCT01516424|Active Comparator|Risperidone|Antipsychotics
88820000|NCT02782065||Pediatric patients with Asthma|165 patients aged 7 to 18 years, and 30 patients aged 2 to 6 years
88820001|NCT02368314|Experimental|BCD-080|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
88820002|NCT02368314|Active Comparator|Clexane|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
88820003|NCT04492839|Experimental|Intestial adsorbent arm|This is a single arm study, all participants will receive the class IIa intestinal adsorbent medical device
88820004|NCT01518530|Experimental|Passive Mobilization Cervical Spine|Patients with chronic neck pain according to the International Association of the Study of Pain criteria of the following types: facet joint disorder, post-whiplash injury, myofascial pain syndrome.
88820005|NCT02366910|Experimental|omafilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
88820006|NCT02366910|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
88820007|NCT02783469||Diabetic neuropathic pain|Those with type 2 diabetes and painful neuropathy
88820008|NCT02783469||Controls|Type 2 diabetics with non-painful neuropathy, or pain without neuropathy
88820009|NCT01463384|Active Comparator|Minocycline|Subjects will be administered 50mg minocycline twice daily.
88820010|NCT01519466|Other|Intervention|Subjects will use a FreeStyle InsuLinx blood glucose meter during the study
88820011|NCT01519466|Other|Control|Subjects will use a FreeStyle Freedom Lite blood glucose meter during the study.
88820012|NCT02785185|Experimental|IDP-122 Lotion|Lotion
88820013|NCT02785185|Active Comparator|Ultravate Cream|Cream
88820014|NCT02785185|Active Comparator|IDP-122 Vehicle Lotion|Lotion
88820015|NCT02785185|Active Comparator|IDP-122 Vehicle Cream|Cream
88820016|NCT02786355|Other|Maximum bimanual compression|Squeeze through Frova bougie with maximum bimanual compression
88820017|NCT02786355|Other|Normal bimanual compression|Squeeze through Frova bougie with normal bimanual compression
88820018|NCT02787057|Experimental|Control group|IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.
88820019|NCT02787057|Active Comparator|study group|IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
88820020|NCT01466972|Experimental|Pazopanib in combination with a NSAI|Non-randomized, open label
88820021|NCT02787291|Other|Ellipse VR ICD and Durata/Optisure lead|Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region
88820022|NCT02787681|Experimental|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
88820023|NCT04440501|No Intervention|Standard education (Control)|Standard education regarding the gluten free diet by the nutritionist will be provided.
88820024|NCT04440501|Experimental|Virtual Reality Program to teach gluten free diet|"Virtual Reality Goggles and education regarding the gluten free diet will be provided.~This group will receive VIRTUE, and watch a VR educational video, and play Chaos Café, which will be administered by a research team member. This group will be prescribed to take home the VIRTUE headset and play modules for 15 minutes per week until the 6-8 month follow up.~The VIRTUE technology will track frequency of game playing to control for adherence to the prescription."
88820025|NCT02792049|Experimental|Modified Ambu Spur II bag valve mask|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
88820026|NCT02792049|Active Comparator|Conventional Ambu Spur II bag valve mask|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
88820027|NCT04420845|Other|Intervention|
88820028|NCT05106309|Experimental|Part A: Single doses of CVL-231 IR/MR formulations in healthy participants under fasted conditions|Oral Dose
88820029|NCT05106309|Experimental|Part B: Single doses of CVL-231 target release formulation under fasted and fed conditions|Oral Dose
88820030|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 1|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the lowest of these three doses (dose 1) is 3×10^5 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
89530095|NCT03351023||Nurses' Health Study II|Nurses' Health Study II, an ongoing cohort study of 116,430 female registered nurses in the US, aged 25-42 at enrollment in 1989. Participants have been followed by biennial mailed questionnaires that elicit updated information on diet, lifestyle, and various health outcomes; the follow-up rate over 26 years exceeds 90% of the eligible person-time.
89530096|NCT03260179|Experimental|gastric carcinoma|20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
88820240|NCT06191172|Experimental|EXPERIMENT I|Reminiscence therapy intervention group
88820241|NCT06191172|Experimental|EXPERIMENT II|Montessori application initiative group
88820242|NCT06191172|Experimental|EXPERIMENT III|Environmental initiative group
88820243|NCT06191172|Experimental|EXPERIMENT IV|Application of contrast ergonomic special equipment initiative group
88820244|NCT06191172|No Intervention|CONTROL GROUP|ORDINARY CARE
88820245|NCT06191133|Experimental|Excisional procedure + Fenofibrate|Participants with high-grade dysplasia will receive 200mg of Fenofibrate starting on the day of enrollment and will continue the drug administration daily for 2-4 weeks +/- 7 days until their excisional procedure
88820246|NCT06191133|Experimental|Hysterectomy or chemoradiation + fenofibrate|Participants with invasive cervical cancer will receive 200mg of Fenofibrate starting on the day of enrollment and will continue the drug administration daily for 2-4 weeks +/- 7 days until their definitive hysterectomy or chemoradiation
88820247|NCT06191107|Experimental|PEEK-RPDs|Participants with removable partial dentures made of PEEK
88820248|NCT06191055|Experimental|Beta Alanine high dose|Consumption for 28 days.
88820249|NCT06191055|Experimental|Beta Alanine low dose|Consumption for 28 days.
88820250|NCT06191055|Placebo Comparator|Control group|Consumption for 28 days.
88820251|NCT06191029||Healthy adults|
88820252|NCT06190990|Other|additional effects of exer gaming with otago exercises|"Strengthening training~Sitting knee extension~Standing hip abduction~Standing knee flexion~Tip toe~Heel tiptoe Balance training~Knee bends~Backward walking~Walk in figure 8~Sideways walking~Tandem stands~Tandem walking~1-leg stand~Heel walking~Toe walking~Heel-toe walking backward~Sit to stand After Otago exercises, the participants will receive the following exer-gaming based exercises.~Football player~Boat~Volleyball beach"
88820253|NCT06190990|Other|exer gaming based exercises|"The participants will receive the following exer-gaming based exercises.~Football player~Boat~Volleyball beach"
88820254|NCT06190977|Experimental|Otago Exercise Program|"Warm-up activities for 5 min head movement, neck movement, back stretching, trunk movement, and ankle movement.~strength and balance training for 30 mins Strengthening training include sitting knee extension, standing hip abduction, standing knee flexion, tiptoe and heel tiptoe Balance training include standing on one foot, walking in the shape of the number eight, walking sideways, walking backward, standing to sit position training, knee bending, toe to heel standing, heel walking, toe to heel walking, toe to heel walking, toe to heel walking, toe to heel walking backward, and climbing stairs Walking training for 10 min"
88820255|NCT06190977|Other|General TKR ptotocol|Ankle pumps Straight leg raises Heel slides Seated knee extensions Standing knee flexion Calf raises Quadriceps contraction Stationary bike
88820256|NCT06190951|Active Comparator|Arm A|Randomized 1:1:1
88820257|NCT06190951|Experimental|Arm B|Randomized 1:1:1
88820258|NCT06190951|Experimental|Arm C|Randomized 1:1:1
88820259|NCT06190938||The relation between diabetes, its neurological and optical complications with hearing loss|
88820260|NCT06190912|Experimental|Bryostatin 1|Participants in this arm will receive treatment with Bryostatin 1
88820261|NCT06190899|Experimental|Phase 1 Arm 1|Arm 1 - 120 mg of gedatolisib (administered once weekly for 3 weeks on/1 week off) in combination with darolutamide 600 mg (two 300 mg tablets) orally administered twice daily (equivalent to a total daily dose of 1200 mg on Days 1-28 of each cycle)
88820262|NCT06190899|Experimental|Phase 1 Arm 2|Arm 2 - 180 mg of gedatolisib (administered once weekly for 3 weeks on/1 week off) in combination with darolutamide 600 mg (two 300 mg tablets) orally administered twice daily (equivalent to a total daily dose of 1200 mg on Days 1-28 of each cycle)
88820263|NCT06190899|Experimental|Phase 2|The recommended Phase 2 dose (RP2D) of gedatolisib (administered once weekly for 3 weeks on/1 week off) in combination with darolutamide 600 mg (two 300 mg tablets) orally administered twice daily (equivalent to a total daily dose of 1200 mg on Days 1-28 of each cycle)
88820264|NCT06190873|Experimental|group to be trained over the phone|This group will be trained by phone for 6 weeks after discharge.
88820265|NCT06190873|No Intervention|Group without telephone training|This group will be given training during their stay in the hospital. There will be no training over the phone after discharge.
88820266|NCT06190860|Other|Control|"Post-extraction sockets will be sutured and left to heal spontaneously with physiological blood clot.~First intervention: intraoral scan and intraoral scan and Cone Beam Computed Tomography in the treated zone. Clinicians will make a post-surgical control to evaluate how healing will be performed Four months after the first Intervention, participants will recall getting a second scan and Cone Beam Computed Tomography in the treated zone. Images will be used for implant treatment planification. Before implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections."
88820306|NCT06190431|Active Comparator|Only physiotherapist guidance|The aim of this study is to test whether the use of a coaching module (playful visual stimulation) in addition to guidance by a physiotherapist improves the learning and effectiveness of the technique compared to guidance alone.
88820307|NCT06190431|Active Comparator|Physiotherapist guidance + coaching module|The aim of this study is to test whether the use of a coaching module (playful visual stimulation) in addition to guidance by a physiotherapist improves the learning and effectiveness of the technique compared to guidance alone.
89530097|NCT03260179|Experimental|hepatocellular carcinoma|20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
89530098|NCT03260179|Experimental|Nasopharyngeal carcinoma|20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
89530099|NCT04504565|Experimental|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTC-3PRGD2, patients underwent single-photon emission computed tomography/COMPUTED tomography (SPECT/CT) examination.
89530100|NCT03250819||Corticosteroid responders|Patients who develop an increase in eye pressure after the use of corticosteroids
88820267|NCT06190860|Experimental|L-PRF Treatment|Post-extraction sockets will be treated with L-PRF plugs and membranes. First intervention: intraoral scan and intraoral scan and Cone Beam Computed Tomography in the treated zone. Clinicians will make a post-surgical control to evaluate how healing will be performed Four months after the first Intervention, participants will recall getting a second scan and Cone Beam Computed Tomography in the treated zone. Images will be used for implant treatment planification. Before implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
88820268|NCT06190847||Experimental|cancer
88820269|NCT06190834||The patients with coronary heart disease diagnosed by coronary angiography|The patients with coronary heart disease diagnosed by coronary angiography in the department of cardiology of Beijing Tsinghua Changgeng Hospital. Except patients with severe valvular disease, severe myocarditis, severe hepatic and renal insufficiency, thyroid insufficiency, severe infectious or systemic inflammatory diseases, severe blood diseases, malignant tumors, etc.
88820270|NCT06190808|Experimental|Single Arm|All members of the arm will have a CGM place and glucose concentration downloaded.
88820271|NCT06190782|Experimental|PD-1 inhibitor+/- chemotherapy combined with local therapy|Patients randomized to this arm will receive local treatment combined with systemic treatment (immunotherapy or chemo-immunotherapy)
88820272|NCT06190782|Active Comparator|PD-1 inhibitor +/- chemotherapy alone|Patients randomized to this arm will receive only systemic treatment (immunotherapy or chemo-immunotherapy)
88820273|NCT06190756|Experimental|T1 Diabetic group|Group with diabetic patients
88820274|NCT06190756|Other|Healthy Control Group|Control group with healthy participants
88820275|NCT06190743||Study Group|Adult individuals who voluntarily wish to participate in prevention events organized by participating centers
88820276|NCT06190730|No Intervention|Control|Besides the consent process, subjects in this arm will have no other research-specific activities until after 40 days after the surgery for an exit interview.
88820277|NCT06190730|Experimental|Voice-Assisted Remote Symptom Monitoring System (VARSMS) group|Subjects in this group will be issued the device, to be activated 1 day after discharge. The device will administer a set of questions daily.
88820278|NCT06190704||CMD|Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR>25U, in line with prior research.
88820279|NCT06190704||non-CMD|Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR≤25U, in line with prior research.
88820280|NCT06190691|Experimental|Pirtobrutinib (Mild Hepatic Impairment)|Pirtobrutinib administered orally.
88820281|NCT06190691|Experimental|Pirtobrutinib (Moderate Hepatic Impairment)|Pirtobrutinib administered orally.
88820282|NCT06190691|Experimental|Pirtobrutinib (Severe Hepatic Impairment)|Pirtobrutinib administered orally.
88820283|NCT06190691|Experimental|Pirtobrutinib (Normal Hepatic Function)|Pirtobrutinib administered orally.
88820284|NCT06190678|Experimental|Pirtobrutinib (Severe Renal Impairment)|Pirtobrutinib administered orally
88820285|NCT06190678|Experimental|Pirtobrutinib (Normal Renal Function)|Pirtobrutinib administered orally
88820286|NCT06190639|Experimental|Experimental group|
88820287|NCT06190613|Other|Combination peer navigation and mHealth Intervention|Peer navigation and SMS text message medication reminders
88820288|NCT06190613|No Intervention|Control|standard of care
88820289|NCT06190600|Active Comparator|Neoadjuvant chemotherapy with Standard Supportive Care|Patients aged 18 to 40 in good physical condition Eastern Cooperative Oncology Group (ECOG) scale 0-1, who are set to receive neoadjuvant chemotherapy will be selected. Criteria for entry into the study include proper liver, kidney and bone marrow function as well as heart ejection fraction of ≥ 50%. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).
88820290|NCT06190600|Experimental|High Intensity Interval Training (HIIT)|"The group in which, concurrently with chemotherapy,IPA will be ordered, by means of supervised high intensity interval training twice a week.~During the course of chemotherapy, the intensity of physical activity will be increasing."
88820291|NCT06190587|No Intervention|Control Group|In control group participants had 8-weeks follow-up without any intervention.
88820292|NCT06190587|Experimental|Interventional Group|In interventional group participants had 8-weeks follow-up with 20 g/day goji berry consumption intervention.
88820293|NCT06190548||cCRKP|Patients with classic CRKP infection
88820294|NCT06190548||hvCRKP|Patients with hypervirulent CRKP infection
88820295|NCT06190535|Experimental|Etamsylate +|Arm in which etamsylate (Dicynone injectable 250mg/2ml) is administrated through the nasogastric tube (NT) 2 ampules twice (X2)/day for 48 hours.
88820296|NCT06190535|No Intervention|the standard postoperative treatment|Arm in which patients have the standard postoperative treatment
88820297|NCT06190522||Patients with acute renal failure|Patients receiving a clinical ultrasound by the on-site emergency physician trained in the technique
88820298|NCT06190509|Active Comparator|Candi5V half dose|
88820299|NCT06190509|Active Comparator|Candi5V half dose + adjuvant|
88820300|NCT06190509|Active Comparator|Candi5V target dose|
88820301|NCT06190509|Active Comparator|Candi5V target dose + adjuvant|
88820302|NCT06190509|Placebo Comparator|Placebo|
88820303|NCT06190483|Experimental|Diazepam/Placebo|Participant&#39;s receive diazepam on 1st MRI scan, and placebo (ascorbic acid) on 2nd MRI scan
88820304|NCT06190483|Experimental|Placebo/Diazepam|Participant&#39;s receive placebo (ascorbic acid) on 1st MRI scan, and diazepam on 2nd MRI scan
88820305|NCT06190457||Experimental group|"From May 2015 to December 2020, 16 children with NHL who were diagnosed in the Department of Pediatric Oncology of Sun Yat-sen Memorial Hospital of Sun Yat-sen University agreed to receive RTX intrathecal therapy and signed an informed consent form. Among them, there were 13 males and 3 females, with a male-to-female ratio of 4.33:1.00, an age of 5.1-13.1 years, and an average age of onset of 8.5 years.~1.2 Diagnosis All children are diagnosed according to WHO lymphoma typing criteria by pathomorphological classification and immunotyping of tissue or bone marrow .~Exclusion Criteria Patients with severe organic diseases such as heart, liver and kidney, allergic to rituximab."
88820327|NCT06190262|Experimental|Psychoeducation|"The experimental condition consists of a psychoeducation program with six sessions. Two of the sessions are online. A teacher and a volunteer will lead the sessions. The topic of the sessions are diverse and cover topics such as mental illness, the diathesis-stress model, treatment of mental illness, caregiver coping mechanisms and caregiver rights.~Before the first session, participants are asked to fill in an online questionnaire with background information and well-being indicators. After the last session, participants are asked to fill in another short questionnaire with the same well-being indicators and also a measure of their satisfaction with the program."
88820328|NCT06190223||PPTB Group|Patients will undergo anterior cruciate ligament reconstruction with the novel PPTB graft and a tibial press-fit technique.
88820329|NCT06190210||Congenital heart disease|Neonates with congenital heart disease necessitating treatment before the age of 6 months, either surgical or through cardiac catheterization
88820330|NCT06190184|Placebo Comparator|Placebo|Participants who have mental health issues are randomized into this study arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
88820331|NCT06190184|Experimental|Viome's Precision Nutrition Program (VPNP)|Participants who have mental health issues are randomized into this study arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.
88820332|NCT06190171|Experimental|Active respiratory muscle strength training|Enrolled heart transplant patients will undergo active preoperative respiratory strength training using two respiratory strength training devices from enrollment until they receive a heart transplant.
88820333|NCT06190171|Sham Comparator|Sham respiratory muscle strength training|Enrolled heart transplant patients will undergo sham preoperative respiratory strength training using two respiratory strength training devices from enrollment until they receive a heart transplant. For individuals completing sham respiratory strength training, the spring will be removed from the devices as has been done in prior sham-controlled trials.
88820334|NCT06190158||type 2 diabetes at risk for chronic kidney disease|type 2 diabetes at risk for chronic kidney disease
88820335|NCT06190145|Experimental|Teriflunomide|Oral Teriflunomide is given at a dose of 7 mg once daily with dose adjustments for 24 weeks. Treatment was discontinued if a dose-limiting toxic effect occurred, rescue medication was used, or concomitant medication for immune thrombocytopenia was changed beyond the 10% level as defined above.
88820336|NCT06190132|Active Comparator|Group A|Group A allocated to treatment with omega 3 fatty acids for 4 weeks then after 6 weeks washout period, the patients received gabapentin for 4 weeks
88820337|NCT06190132|Active Comparator|Group B|Group B allocated to treatment with gabapentin for 4 weeks then after 6 weeks washout period, the patients received omega 3 fatty acids for 4 weeks
88820338|NCT06190119||POAG Group|POAG patients who underwent filtering surgery, cataract surgery or MIGS.
88820339|NCT06190119||Control Group|Healthy patients who underwent cataract surgery.
88820340|NCT06190106|Experimental|Experimental treatment group|Participants had received 8-10 cognitive behavior therapy-based therapeutic sessions and their feedback was taken to check the positive and negative effects of Psychotherapeutic Intervention (cognitive-behavioral intervention).
88820341|NCT06190015|Active Comparator|Advanced platelet rich fibrin (APRF) group;|After surgical removal of one of the impacted mandibular third molar, APRF clots will be placed in the alveolus
88820342|NCT06190015|No Intervention|Control group 1;|Standard surgical removal of the other impacted mandibular third molar will be performed without placing APRF in the wound
88820343|NCT06190015|Active Comparator|Enamel matrix derivative (EMD) group;|After surgical removal of one impacted mandibular third molar, EMD with collagen sponges will be placed in the extraction alveolus
88820344|NCT06190015|No Intervention|Control group 2;|Standard surgical removal of the other impacted mandibular third molar will be performed without placing EMD in the wound
88820345|NCT06190002||invasive fungal infection group and non-invasive fungal infection group|According to the presence or absence of invasive fungal infection, the patients were divided into invasive fungal infection group and non-invasive fungal infection group
88820346|NCT06189989|Experimental|Intervention Group|In addition to the clinical routine care, the newborn temporary tachypnea care package that we created was applied to the babies in the intervention group. Physiological parameters and blood gas results were recorded.
88820347|NCT06189989|No Intervention|Control group|Only clinical routine care practices were applied to the babies in the control group. Physiological parameters and blood gas results were recorded.
88820348|NCT06189963|Experimental|SNK01|SNK01 will be administered as an IV infusion Q3W for up to 1 year.
88820349|NCT06189963|Placebo Comparator|Placebo|Placebo will be administered as an IV infusion Q3W for up to 1 year.
88820350|NCT06189950|Experimental|Experimental group|Microport NeuroTech Intracranial Visualized Stent
88820351|NCT06189950|Active Comparator|Control group|LVIS™ and LVIS™ Jr
88820352|NCT06189924||Mechanically ventilated patients with primary or secondary lung injury|Mechanically ventilated patients with primary or secondary lung injury due to various pathologies. Patients will be treated at intensive care units (ICU).
88820353|NCT06189924||Mechanically ventilated patients without lung injury|Mechanically ventilated patients without lung injury, with various pathologies. Patients will be treated at intensive care units (ICU).
88820354|NCT06189911||transfused|Group of patients who received perioperative blood transfusions which was defined as the transfusion of packed red cells during the operation and 48 hours after surgery.
88820355|NCT06189911||non-transfused|Group of patients who did not received perioperative blood transfusions
88820356|NCT06189885|Experimental|Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty|
88820357|NCT06189885|Experimental|Preoperative Vancomycin Prophylaxis in Two-Stage Exchange Arthroplasty|
88820358|NCT06189872|Other|Attune Cementless, Fixed Bearing, Cruciate Retaining TKA System|Attune Cruciate Retaining TKA System
88820359|NCT06189794|Experimental|Rosa damascena oil group|
88820360|NCT06189794|Experimental|Frankincense oil group|
88820361|NCT06189794|Active Comparator|Solution group|
89530101|NCT03250819||Non-corticosteroid responders|Patients who use/used corticosteroids but didn't develop an increase in eye pressure
88820455|NCT06145373|Experimental|fitusiran|"The pre-fitusiran treatment period is defined as the transition period up to the first fitusiran administration. Participants will receive on demand or prophylactic treatment with intravenous clotting factor concentrates (IV CFCs) or bypassing agents (BPAs) from Month-2 until Day 1.~Fitusiran treatment period: Participants will receive subcutaneous (SC) fitusiran prophylaxis once every 2 months (Q2M) or once monthly (QM) from Day 1 until Month18.~Participants may receive IV antithrombin concentrate (ATIIIC) upon investigator's judgement.~AT FU period: Participants will be followed up until AT activity levels recover to at least 60% (per central laboratory).~In case of bleeding events participants will receive IV CFCs or BPAs. Participants may receive IV ATIIIC upon investigator's judgement."
88820456|NCT06145334|Experimental|Veterans Social|Peer-led weekly community-based social groups (16 weeks)
88820457|NCT06144086|Experimental|Foscenvivint|Foscenvivint 280 mg/m2, twice a week for 24 weeks
88820458|NCT06143488|Experimental|EVT group|In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice.
88820459|NCT06143488|Active Comparator|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
88820460|NCT06139094||CMD negative|Participants in this group exhibit no signs of Coronary Microvascular Disease (CMD), as evidenced by a CFR measurement equal to or greater than 2.5. This group serves as the comparative reference, representing individuals without CMD-related myocardial ischemia.
88820461|NCT06139094||CMD positive|This group comprises participants demonstrating signs of Coronary Microvascular Disease (CMD), defined by a coronary flow reserve (CFR) measurement of less than 2.5. Participants in this category are experiencing myocardial ischemia without significant blockages in their coronary arteries.
88820462|NCT06137482|Experimental|IV Cohort 1 Low Dose|Randomized (6:2) to REGN13335 or placebo
88820463|NCT06137482|Experimental|IV Cohort 2 Mid Dose|Randomized (6:2) to REGN13335 or placebo
88820464|NCT06137482|Experimental|IV Cohort 3 High Dose|Randomized (6:2) to REGN13335 or placebo
88820465|NCT06137482|Experimental|IV Cohort 4 Higher Dose|Randomized (6:2) to REGN13335 or placebo
88820466|NCT06137482|Experimental|SC Cohort 1 Low Dose|Randomized (6:2) to REGN13335 or placebo
88820467|NCT06137482|Experimental|SC Cohort 2 High Dose|Randomized (6:2) to REGN13335 or placebo
88820468|NCT06137482|Experimental|IV or SC Optional Cohort 1|Randomized (6:2) to REGN13335 or placebo
88820469|NCT06137482|Experimental|IV or SC Optional Cohort 2|Randomized (6:2) to REGN13335 or placebo
88820470|NCT06136507|Experimental|The main test period and the extension period|Group 1:≥6 years old and <12 years old; Group 2: <6 years old pediatric patients Preventive treatment: 25~50 is recommendedlU/kg, Q3D, can adjust the dose to 65 IU/kg based on the patient's response, and if necessary, the investigator can adjust the frequency of administration based on the clinical outcome of the subject (the occurrence of bleeding and its clinical manifestations) and the FVIII valley concentration.PK intensive blood collection will be performed for the PK subgroup at V1 (DO) and appropriate PK blood collection will be performed at other specified visit time points. After completion of ∠50EDs and 26 months of treatment, the original prophylactic regimen can be continued until 100EDs
88820471|NCT06132685|Experimental|Arm I (NDS)|Patients receive tapering doses of dexamethasone on days 1-15. Patients also undergo blood sample collection at time of surgery, at follow up visits and optionally at wound check visit 10-14 days post operative at investigator availability. Patients additionally undergo MRI and CT scan during inpatient stay as part of standard of care.
88820472|NCT06132685|Experimental|Arm II (RDS)|Patients receive tapering doses of dexamethasone on days 1-4. Patients may receive dexamethasone IV and restart the taper if clinically indicated. Patients also undergo blood sample collection at time of surgery, follow up visits and optionally at wound check visit 10-14 days post operative at investigator availability. Patients additionally undergo MRI and CT scan during inpatient stay as part of standard of care.
88820473|NCT06123663|Experimental|Tetanus Vaccine, Adsorbed (TTVA)|1 dose of (TTVA) (0.5ml)
88820474|NCT06123663|Active Comparator|Tetanus Vaccine, Adsorbed (TT)|1 dose of (TT) (0.5ml)
88820475|NCT06119503|Experimental|Elongating Time HOrizons for Reentry (ETHoR)|Episodic Future Thinking (EFT) utilizes participant-generated descriptions of future events to elongate an individual's temporal horizon. In EFT paradigms, the participant is asked to create and envision vivid descriptions of specific, positively valanced, events that could happen in the future. Recent research suggests that directing EFTs to focus on specific goals (i.e. evoking images of oneself engaging in activities consistent with a desired future outcome) are associated with stronger decreases in undesirable health behaviors. Thus, as part of the ETHoR condition, participants will be asked to verbally describe and imagine four specific events reflecting positive activities in which the participant engages in substance and incarceration-free activities, corresponding to predetermined future timepoints. The PRC will encourage participants to include as many contextual and emotional details as possible.
88820476|NCT06119503|Active Comparator|Standardized Recent Thinking (ERT)|Individuals in the control group utilizes SET; an approach that controls for activation of episodic thinking but does not engage prospection (the hypothesized mechanism of episodic future thinking, future outcome) are associated with stronger decreases in undesirable health behaviors. Thus, as part of the SET condition, participants will be asked to verbally describe and imagine four current events reflecting positive activities in which the participant engages in substance and incarceration-free activities, corresponding to current experiences. The PRC will encourage participants to include as many contextual and emotional details as possible.
88820477|NCT06116981|Experimental|Experimental Group|The experimental group consists of individuals who received high-induction magnetic field therapy in addition to conservative treatment (routine rehabilitation sessions including stretching, transcutaneous electrical nerve stimulation, and exercises.).
88820478|NCT06116981|Active Comparator|Comparison Group|Conservative Treatment Group: Group with routine rehabilitation sessions including stretching, transcutaneous electrical nerve stimulation, and exercises.
88820479|NCT06113913|Experimental|Interventional (SC infliximab, weekly)|Participants will switch from an optimized dose of intravenous infliximab to an optimized dose of subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every week.
88820574|NCT05964699|Experimental|Periodontal regeneration|Regeneration will be attempted during root scaling and planing with the application of Emdogain and the use of a Videoscope.
88820575|NCT05964699|Placebo Comparator|Control|The control group will receive standard-of-care root scaling and planing without the application of Emdogain and the use of a Videoscope.
88820576|NCT05963633|Experimental|Episodic Future Thinking (EFT)|Parents who are receiving residential substance use disorder (SUD) treatment will receive an adapted episodic future thinking focused condition. Parents will meet with peer recovery coaches (PRCs) who will administer the intervention, focused on generating future, pleasant milestones with their children. The participant will also be allowed to draw or write about the scene, to help them envision it, which they will keep to refer to if they choose. After the intervention session, PRCs will check-in with parents daily over the course of two weeks to practice episodic future thinking (EFT) intervention by asking participants to further elaborate on the milestones they identified in the intervention to prompt these episodes in vivid detail.
88820577|NCT05963633|Active Comparator|Episodic Recent Thinking (ERT)|Parents who are receiving residential substance use disorder (SUD) treatment will receive an adapted episodic recent thinking intervention. Parents will meet with peer recovery coaches (PRCs) who will administer the intervention. During the intervention, the participant will be asked to describe in detail two things they struggled with and two things that went well that occurred during the last few days. The participant will also be allowed to draw or write about the scene, to help them envision it, which they will keep to refer to if they choose. After the intervention session, or present-oriented thinking (in the comparison condition, by asking participants to discuss an event that happened that day PRCs will check-in with parents daily over the course of two weeks to practice episodic future thinking (EFT) intervention by asking participants to further elaborate on the milestones they identified in the intervention to prompt these episodes in vivid detail.
88820578|NCT05962736|No Intervention|Control group|The control group consisted of patients who underwent thoracotomy and underwent routine rehabilitation in the post-surgical period. routine respiratory rehabilitation program; It consists of a) positioning, b) general body exercises, c) airway clearance techniques, d) breathing exercises, e) incentive spirometry and f) mobilization applications.
88820579|NCT05962736|Experimental|Study group|The study group consisted of patients who would receive mirror therapy in addition to the routine rehabilitation program described above and applied to the control group in the post-thoracotomy period.
88820580|NCT05958199|Experimental|NPX267 Treatment|
88820581|NCT05953831|Experimental|CDR132L 4.52 mg|Six times CDR132L 4.52 mg/kg body weight intravenous in single dose.
88820582|NCT05953831|Placebo Comparator|Placebo|Six times Placebo intravenous in single dose.
88820583|NCT05950945|Experimental|Cohort 1: HR-negative, HER2-low|Participants with HR-negative HER2-low unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd.
88820584|NCT05950945|Experimental|Cohort 2: HR-negative, HER2 IHC 0|Participants with HR-negative HER2 IHC 0 unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd.
88820585|NCT05950945|Experimental|Cohort 3: HR-positive, HER2-low|"Participants with HR-positive HER2-low unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd.~Participants must also have recurrent disease <2 years from the initiation of adjuvant ET or have disease progression on CDK4/6 inhibitor-based regimen within 12 months of completion of adjuvant therapy with a CDK4/6 inhibitor or have disease progression within the first 12 months of CDK4/6 in the first line metastatic setting."
88820586|NCT05950945|Experimental|Cohort 4: HR-positive, HER2 IHC 0|Participants with HR-positive HER2 IHC 0 unresectable and/or metastatic breast cancer who have received at least one and at most two prior lines of therapy in the metastatic setting will receive T-DXd.
88820587|NCT05948709|Experimental|Treatment|Fitabase collects data from Fitbits worn by the participants. Under the treatment functionality, participants earn a meal donation for each day that they meet the step goal and a monetary incentive for each day they meet the step goal (for upto 5 days a week). The investigators identified 7,500 steps as an appropriate goal as studies show older adults walk 4,000 steps on average. Meals are donated by the investigators on behalf of participants.
88820588|NCT05948709|No Intervention|Control|The control group will not have the functionality to earn meal donations or monetary incentives by walking, and will only be asked to wear their Fitbit so that step count data can be collected.
88820591|NCT05947448||AZL-M single drug group|Azilsartan Medoxomil Potassium Tablet，80mg，tablet，QD，six months
88820592|NCT05947448||CCB single drug group|Nifedipine Controller-release Tablets，clinical maximum tolerated dose，tablet，QD，six months；or Levoamlodipine Maleate Table，clinical maximum tolerated dose，tablet，QD，six months； Doctor choose a medication that is more suitable for patient treatment.
88820686|NCT05788601|Active Comparator|6 mg dapiglutide|Abdominal s.c. self-administration of 6 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks to 4 mg and again to 6 mg after six weeks until the remaining six weeks of treatment (12 weeks in total)
88820628|NCT05878990|Active Comparator|Preference-Driven Culturally-tailored Tobacco Treatment Intervention|Upon consent, participants will complete a baseline survey, receive the home Carbon monoxide monitor and instructions on how to use, and be scheduled for weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences. Participants will complete the one-item Control Preference Scale and receive either an Active Content Newsletter or Passive Content Newsletter emailed after their weekly cessation counseling session.
88820629|NCT05871736||Parents of children with cerebral palsy|Parents of children with CP 1.5-11 years of age who applied to the Physical Medicine and Rehabilitation Clinic of Ankara City Hospital
88820630|NCT05871736||Parents of children without cerebral palsy|Parents of healthy children without cerebral palsy 1.5-11 years of age who applied to the Physical Medicine and Rehabilitation Clinic of Ankara City Hospital
88820631|NCT05871372|Experimental|Depression Cohort|
88820632|NCT05871372|Experimental|Epilepsy Cohort|
88820637|NCT05868070|No Intervention|Conventional rehabilitation|Conventional rehabilitation corresponds to general rehabilitation for critically ill patients and is mainly performed according to functional mobility with a range of motion. This includes Lying without contractures, turning self, sitting balance, sitting at the edge, standing and transfer, assisted gait, and gait endurance.
88820638|NCT05868070|Experimental|Conventional rehabilitation plus multimodal exercise|Conventional rehabilitation corresponds to general rehabilitation for critically ill patients and is mainly performed according to functional mobility with a range of motion. This includes Lying without contractures, turning self, sitting balance, sitting at the edge, standing and transfer, assisted gait, and gait endurance. Patients in the intervention group additionally receive multimodal exercise using the in-bed cycle/stepper.
88820639|NCT05861336|Experimental|Chemotherapy+Losartan+Stereotactic Radiation|"Chemotherapy will be administered for six cycles as per clinical practice (nab-paclitaxel and gemcitabine: nab-paclitaxel 125 mg/m2 on days 1, 8, and 15, Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days) Losartan will be administered per os every day during induction chemotherapy and maintained until starting SBRT.~SBRT will be administered in 7 consecutive fractions for a total dose of 35-42 Gy if no progression will be observed after induction therapy."
88820640|NCT05855525|Experimental|Real-time fMRI|Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
88820641|NCT05854017|Active Comparator|Active|Dietary Supplement: Theanine for stress relief formulation
88820642|NCT05854017|Placebo Comparator|Placebo|Placebo tablet
88820643|NCT05850130|Experimental|Arm A|6 weeks of acupuncture once a week. At week 7, patients will be assessed for the primary endpoint Then ,the patient may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist.
88820644|NCT05850130|Active Comparator|Arm B|"6 weeks without acupuncture. At week 7, patients will be assessed for the primary endpoint.~Then, the patient will receive or not acupuncture intervention:~A mandatory acupuncture once a week if the patient' NRS global score at week 7 is ≥ 4 .~No acupuncture if the patient' NRS global score at week 7 is <4,"
88820645|NCT05847270|Experimental|Anterior and posterior treatment strategy|Anterior transoral release and reduction + posterior internal fixation and bone graft fusion
88820646|NCT05847270|Experimental|Simple Posterior Approach Treatment Strategy|posterior reduction and internal fixation
88820647|NCT05844943|Experimental|Soft tissue hand injury|
88820648|NCT05843045|No Intervention|Pre-mitigation|Information will be collected from participants about their health status and asthma symptoms. Information about the air quality inside the participants' homes will also be collected.
88820649|NCT05843045|Experimental|Indoor Air Quality Mitigation|Indoor air quality mitigation strategies of a smart home thermostat, smart bath fan switch, and a high-quality furnace filter will be employed within the participants' homes. Information will continue to be collected about participants' health status and asthma symptoms as well as the air quality inside their homes.
88820650|NCT05841524||AAA patients, without intraluminal thrombus|patients diagnosed with an abdominal aneurysm, with a diameter below the treatment threshold of 5.5 cm and without intraluminal thrombus.
88820651|NCT05841524||AAA patients, with intraluminal thrombus|patients diagnosed with an abdominal aneurysm, with a diameter below the treatment threshold of 5.5 cm and with intraluminal thrombus.
88820652|NCT05835323|Experimental|Robotic-assisted mini-Percutaneous Nephrolithotomy (PCNL)|Participants with kidney stones will be enrolled for robotic-assisted mini-percutaneous nephrolithotomy procedure using the MONARCH Platform, Urology for removal of kidney stones. The MONARCH Platform, Urology enables electro-mechanical articulation and precise control of a flexible ureteroscope and/or a flexible mini-PCNL suction catheter for visualization and access to the urinary tract for diagnostic and therapeutic procedures.
88820653|NCT05835206|Experimental|microbiome therapeutic|The study intervention is manufactured from a healthy screened donor as an investigational product (IP) and delivered via swallowed capsule after room reset of the patient's hospital room.
88820654|NCT05835206|Placebo Comparator|Placebo|The control arm will remain in routine contact precautions per standard of care, take placebo capsules, and have a room reset.
88820687|NCT05786508|Experimental|Partners4Pain program|adults with chronic neck or back pain from populations that experience health disparities due to race/ethnicity or socioeconomic status
88820655|NCT05833763|Experimental|Study Treatment|"This study design involves 3 phases:~Treatment Ramp-Up~Pre-Phase (7 days): Obinutuzumab (1000mg) will be administered intravenously (IV) on D-7 and a second dose administered between Day 6 and Day 1.~Cycle 1: An initial dose level of Glofitamab will evaluate step-up dosing. If excessive dose-limiting toxicity is observed, including cytokine release syndrome (CRS), a lower initial dose of 1.25mg of glofitamab will be evaluated at dose level -1.~i. Dose level 1 (14 days):~2.5mg Glofitamab by IV on Day 1~10mg Glofitamab by IV on Day 8 ii. Dose level -1 (21 days):~1.25mg Glofitamab by IV on Day 2~2.5mg Glofitamab by IV on Day 8~10mg Glofitamab by IV on Day 15 c. Cycle 2 (21 days): 30mg Glofitamab by IV on Day 1~Fixed course combination phase: Cycles 3-12 (21 days per cycle): 30mg of Glofitamab by IV on day 1~Maintenance phase: Cycles 13+ (21 days per cycle): Glofitamab discontinued. 200mg oral daily"
88820656|NCT05831709|Experimental|Supervised training + immediate hormone substitution therapy|
88820657|NCT05831709|Experimental|Supervised training + delayed hormone substitution therapy|
88820658|NCT05831709|Active Comparator|Delayed supervised training + immediate hormone substitution therapy|
88820659|NCT05829694||Parents|Individuals diagnosed with cystic fibrosis who became a first-time parent between January 1, 2012 and December 31, 2022.
88820660|NCT05829694||Non-parents|Individuals diagnosed with cystic fibrosis who have never been a parent.
88820661|NCT05827224||Air Optix Aqua Sphere|Lotrafilcon B spherical soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
88820662|NCT05827224||Air Optix plus HydraGlyde Sphere|Lotrafilcon B spherical soft contact lenses with comfort additive worn in both eyes and removed daily for cleaning and disinfection
88820663|NCT05827224||Air Optix plus HydraGlyde Toric|Lotrafilcon B toric soft contact lenses with comfort additive worn in both eyes and removed daily for cleaning and disinfection
88820664|NCT05827224||Biofinity Sphere|Comfilcon A spherical soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
88820665|NCT05827224||Biofinity Toric|Comfilcon A toric soft contact lenses worn in both eyes and removed daily for cleaning and disinfection
88820666|NCT05824273|Experimental|Tailored health communication intervention (LungTalk)|"Participants will receive the tailored health intervention LungTalk. LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool that is theoretically grounded in the Conceptual Model on Lung Cancer Screening Participation."
88820667|NCT05824273|Active Comparator|Non-tailored Intervention|Participants will receive non-tailored American Cancer Society (ACS) Lung Screening Informational Video as per standard of care. ACS Lung Screening Informational Video (ACS LSIV) is a non-tailored 5-minute video from the American Cancer Society about lung cancer screening designed for the lay individual.
88820668|NCT05820100||Normally Sighted|Participants with clinically normal ocular findings and BCVA better than logMAR 0.3 in each eye.
88820669|NCT05820100||Severely Sight Impaired|Participants with BCVA no better than logMAR 1.6 in better seeing eye, and worse than logMAR 1.9 in the worse seeing eye, and a clinical diagnosis of advanced RP
88820670|NCT05819619|Active Comparator|Standard of care|Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
88820671|NCT05819619|Experimental|Prophylactic use|Administration of ibuprofen and ondansetron at the time of misoprostol administration.
88820672|NCT05817851|Active Comparator|Control group|- Control group (standard treatment): post-cardiac arrest care will be provided, including temperature control, according to current international guidelines and local procedures. Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
88820673|NCT05817851|Experimental|Experimental group|- Experimental group (IV high-dose vit-C): in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
88820674|NCT05799105|Experimental|Open-capsule|Subjects in this arm will be treated with omeprazole 40 milligrams twice daily (or alternative medication if not covered by the subject's insurance) taken as an open-capsule until confirmed ulcer healing.
88820675|NCT05799105|Active Comparator|Intact-capsule|Subjects in this arm will be treated with omeprazole 40 milligrams twice daily (or alternative medication if not covered by the subject's insurance) taken as an intact-capsule until confirmed ulcer healing or potential cross-over.
88820676|NCT05797155|Experimental|CoQuit App - Cognitive Dissonance Based Smoking Cessation|This group will receive daily smoking cessation tips and will be asked to complete activities within the app that are designed to induce cognitive dissonance, create and share videos related to the activities with an online group, and provide support to other group members
88820677|NCT05797155|Active Comparator|Comparison App - Smoking Cessation Support without Cognitive Dissonance Activities|This group will use an app that consists of tips for quitting cigarettes but does not include the cognitive dissonance component.
88820678|NCT05796180|Experimental|Behavioral: sexual health counseling based on the BETTER model|"Sexual health counseling based on the BETTER model~The content of the research will be discussed by face-to-face interviews with women who gave birth vaginally and applied to the hospital for birth control 8-10 weeks after delivery. Pre-evaluation forms will be applied to women who have agreed to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method.~An appointment will be made for interviews with the women in the experimental group. It is planned that these meetings will be held in the form of online video calls and will last an average of 45 minutes. The final tests will be held 8 weeks after the online meetings are over."
88820679|NCT05796180|No Intervention|Control group: Routine postpartum care|"Routine postpartum care~Women who gave birth vaginally and applied to the hospital for postpartum controls 8-10 weeks after delivery will be interviewed face-to-face with the women and the content of the research will be mentioned. Pre-evaluation forms will be applied to the women who accepted to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method. Women in the control group will receive routine postpartum care administered in the hospital. Women in the control group will receive routine postpartum care administered in the hospital. Post-tests will be administered 8 weeks after the first interview."
88820699|NCT05766267|Experimental|2 BMZD/2 BMD|"Eight weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), plus delamanid (D or DLM) followed by nine weeks of daily treatment with bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM)~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily.~Study drug doses: Bedaquiline (B): 200 mg once daily x 56 days, then 100 mg daily; Moxifloxacin (M): 400 mg once daily; Pyrazinamide (Z) 1500 mg (weight <75kg) or 2000mg(> 75kg) once daily x 56 days; Delamanid (D):300 mg once daily"
88820700|NCT05766267|Active Comparator|2RHZE/4RH|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered once daily~study drug doses: Rifampin (R), 600 mg daily; Isoniazid (H), 300 mg daily; Pyrazinamide (Z) 1500 mg (weight <75kg) or 2000mg(> 75kg) once daily ; Ethambutol, 15 mg/kg once daily rounded up to nearest 400 mg dose"
88820701|NCT05765266|Experimental|ACP Max™|Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
88820702|NCT05765266|Active Comparator|40 mg of methylprednisolone acetate|Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
88820703|NCT05765201||High IOP|Eyes in this arm will maintain an IOP of 65mmHg throughout the cataract surgery.
88820704|NCT05765201||Low IOP|Eyes in this arm will maintain an IOP of 28mmHg throughout the cataract surgery.
88820705|NCT05762822|Placebo Comparator|Placebo|60 ml water (same taste as active comparator) at 10 pm the night before and 6 am on the day for blood sampling (8 am).
88820706|NCT05762822|Active Comparator|3-OHB|60 ml 3-OHB (30 g) at 10 pm the night before and 6 am on the day for blood sampling (8 am).
89530102|NCT03350945|Active Comparator|Device:Titanium Clips|Device: Tumor localization. Preoperative endoscopic localization with titanium clips
88820708|NCT05757102|Experimental|Participants receiving FF/UMEC/VI|
88820709|NCT05757102|Active Comparator|Participants receiving FF/VI|
88820710|NCT05754346|Active Comparator|Control Group|"Patients in this group will receive Complete Decongestive Therapy for 6 weeks. 1 session each week will be supervised in a clinic. Rest of the sessions will be performed at home."
88820711|NCT05754346|Experimental|Study Group|"Patients in this group will receive Complete Decongestive Therapy combined with diaphragmatic breathing exercises for 6 weeks. 1 session each week will be supervised in a clinic. Rest of the sessions will be performed at home."
88820712|NCT05744583|Active Comparator|Packed red blood cell|control
88820713|NCT05744583|Experimental|Low titer whole blood|case
88820714|NCT05741359|Experimental|Treatment group|2.0 - 10.0×105/kgBW,
88820715|NCT05735431|Experimental|Formoterol 6 mcg/fluticasone 125 mcg|Formoterol 6 mcg/fluticasone 125 mcg Eurofarma.
88820716|NCT05735431|Active Comparator|Alenia® 6 mcg/200 mcg|Alenia® 6 mcg/200 mcg.
88820717|NCT05732038|Experimental|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to practice 10 minutes per day for 12 weeks. The first four weeks will be prescribed. Weeks 5-12 will allow full access to the app's library.
88820718|NCT05732038|Experimental|Wellness App (WA)|Participants in the WA group will be asked to listen to the app content for 10 minutes per day for the entire 12 weeks.
88820719|NCT05730920|Active Comparator|Intravenous (IV) Methadone|Subjects will receive IV methadone 0.2 mg/kg (maximum dose 20mg) via an infusion pump over 15 minutes while undergoing continuous monitoring. Additional IV methadone may be given during the case per the anesthesiologist's discretion, but the total dose may not exceed 20mg.
88820720|NCT05730920|Experimental|Liposomal Bupivacaine (LB, Exparel)|Subjects will receive four-point ESPB with an admixture of LB and 0.25% bupivacaine hydrochloride. The total LB dose will be 4mg/kg, max dose of 266mg, while the total dose of bupivacaine hydrochloride will be 2mg/kg.
88820721|NCT05726916|Experimental|Experimental group|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
88820722|NCT05726916|Active Comparator|Control group|Blood pressure control with renin angiotensin system blockers
88820723|NCT05725772||Parkinson's disease|People with Parkinson's disease living in medically underserved areas
88820724|NCT05723081||Native Americans|Native Americans / American Indians
88820725|NCT05721235|Experimental|Open Label|13.1 mg/2.6 mg SDX/d-MPH, 26.1/5.2 mg SDX/d-MPH, or 39.2 mg/7.8 mg SDX/d-MPH
88820726|NCT05715736|Experimental|SAD cohort|SAD cohorts 1-5. Randomised participants in each cohort will receive a single IV dose of APB-R3.
88820727|NCT05715736|Placebo Comparator|Placebo|SAD cohorts 1-5. 2 randomised participants of each cohort will receive a placebo.
88820728|NCT05715502|Experimental|Experimental|Experimental: All recruited participants will be treated with salvage partial (focal) prostate brachytherapy for the lesion of recurrent prostate cancer with appropriate margin.
88820729|NCT05715125|Placebo Comparator|Placebo|
88820730|NCT05715125|Experimental|VTX958 Dose A|
88820731|NCT05715125|Experimental|VTX958 Dose B|
88820732|NCT05714254|Active Comparator|MEDI0618|A human immunoglobulin antibody to the Protease Activated Receptor 2 (PAR2)
88820733|NCT05714254|Placebo Comparator|Placebo|Histidine/histidine HCl, sucrose and polysorbate
88820734|NCT05712590||Vegans|In this group women aged 30-45 years that follow vegan diet for at least 3 years will be included.
88820735|NCT05712590||Vegetarians|In this group women aged 30-45 years that follow vegetarian (lacto-ovo/lacto/ovo) diet for at least 3 years will be included.
88820736|NCT05712590||Omnivores|In this group women aged 30-45 years that follow omnivorous diet for at least 3 years will be included.
88820737|NCT05710627|No Intervention|Control|Standard of care
88820738|NCT05710627|Experimental|Treatment|TENEX device will be used
88820739|NCT05703672|Experimental|Varenicline and electronic cigarette|At the end of the 6-week open label phase, dual users of cigarettes and e-cigarettes will receive 1mg varenicline to take twice daily for 12 weeks. They will also receive an additional 12 weeks of the nicotine salt-based pod system e-cigarette.
88820763|NCT05683028|Experimental|Cognitive control training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
88820764|NCT05683028|Active Comparator|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
88820765|NCT05682963|Active Comparator|Square-Stepping Exercise Program Group|Square stepping exercise is performed on a thin exercise mat divided into 40 small squares of 250 cm x 100 cm. Participants practice a set of step patterns on the mat. Square step exercises are a low-cost, highly accessible and fun exercise method. It is known that it improves motor performance and muscle strength in healthy young individuals, and has positive effects on functional fitness and gait parameters in individuals with osteoarthritis. It is known to have positive effects on balance, fall risk, walking ability, physical and cognitive function in elderly individuals. It will be applied to examine the effects on mobility, balance and position sense in individuals with multiple sclerosis.
88820766|NCT05682963|Active Comparator|Home Exercise Program Group|The home exercise program group will implement a protocol of frenkel's coordination exercises developed for balance and coordination therapy. The exercise protocol, which includes frenkel's coordination exercises, will be delivered to the patient in the form of a brochure and in the form of a Compact Disc (CD) with video images.
88820767|NCT05681299|Active Comparator|Growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects. Injections will be performed from the night of day 0 to the night of day 20.
88820768|NCT05681299|Active Comparator|Liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly. Injections will be performed from the night of day 0 to the night of day 20.
88820769|NCT05681299|Active Comparator|Growth hormone and liraglutide|"GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects. Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.~Injections will be performed from the night of day 0 to the night of day 20."
88820770|NCT05681299|Placebo Comparator|Placebo|Placebo will be administered as one nightly subcutaneous self-injection at 9-11pm from the night of day 0 to the night of day 20.
88820771|NCT05679505|Experimental|Left ear transcutaneous vagus nerve stimulation|"Left ear transcutaneous vagus nerve stimulation will be applied to the participants in this group.A continuous electrical stimulation with a current frequency of 10 Heartz (Hz) with a current transit time of 300 μs was applied to the participants in both groups. The participants included in both groups were treated with taVNS with the Vagustim device for 20 minutes once a day and for a total of 10 sessions application was made."
88820772|NCT05679505|Experimental|Bilateral double ear transcutaneous vagus nerve stimulation|"Bilateral double ear transcutaneous vagus nerve stimulation will be applied to the participants in this group.A continuous electrical stimulation with a current frequency of 10 Heartz (Hz) with a current transit time of 300 μs was applied to the participants in both groups. The participants included in both groups were treated with taVNS with the Vagustim device for 20 minutes once a day and for a total of 10 sessions application was made."
88820773|NCT05675813|Experimental|T1: CHOP+selinexor+5-Azacitidine (CHOPX2) vs CHOP|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
88820774|NCT05675813|Experimental|T2: CHOP+duvelisib+5-Azacitidine vs CHOP|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
88820775|NCT05675813|Experimental|T3: CHOP+chidamide+tislelizumab （CHOPX2）vs CHOP|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
88820776|NCT05673967||Cohort 1|Real-world (RW) patients with RRMM who have either at least three prior lines of therapy (LOT) and are triple-class exposed (3L+/TCE), or are triple-class refractory (TCR), meet similar inclusion/exclusion criteria used to establish phase 2 cohort 2 of the R5458-ONC-1826 trial, and are initiating currently available therapies.
88820805|NCT05620433|Experimental|Joint Effort mobile application|The Joint Effort mobile application aims to support young adults in taking action on their cannabis use. Based on the Theory of Planned Behaviour, the content focuses on intention, attitude, and perceived behavioral control. Various intervention methods and strategies are used to address these determinants (e.g., personalized feedback, persuasive communication, self-observation, and activation of intention). The objectives include: to allow the individual to become aware (or more aware) of their cannabis use, to support the individual's decision-making process of taking action on their cannabis use, and to guide and support the establishment and sustainability of an action plan. An optional logbook-type feature (weekly journal of cannabis use) allows personalized monitoring and data collection throughout the course of the intervention.
88820806|NCT05620433|Active Comparator|Brief normative feedback and standard information|The comparator is composed of a brief normative feedback regarding last month's frequency of cannabis use and basic reliable non-personalized information on lower-risk cannabis use (official public websites).
88820807|NCT05619783|Experimental|Active|All participants will be treated with oral (or feeding tube) AMX0035 (a fixed-dose combination of Sodium Phenylbutyrate (PB) and taurursodiol). All participants will take 2 sachets daily (one morning dose and one evening dose) starting on Day 1, for the duration of the study (if twice a day dosing is poorly tolerated, dosing interruptions and reductions are further discussed in section 6.3) AMX0035 will be supplied by Amylyx as a carton box containing approximately 1 month supply of single use sachets. Each AMX0035 sachet contains active ingredients in a powder formulation with 3 g PB and 1 g taurursodiol. AMX0035 powder is mixed with water and taken orally (or via feeding tube).
88820808|NCT05617755|Experimental|AB-1015|Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-1015 intravenously on day 0.
88820809|NCT05616026|Experimental|Intervention|The intervention (INT) will include 6 months of DM management support via SMS texts including reminders for medication adherence, appointments, and DM self-care activities as well as education, and support.
88820810|NCT05616026|Placebo Comparator|Control|The control (CL) will receive 6 months of texts for general health promotion.
88820811|NCT05614492|Experimental|Individual Arm (IDM)|Self-administration of the intervention
88820812|NCT05614492|Experimental|Shared Arm (SDM)|Advocate-administration of the intervention
88820813|NCT05614492|Active Comparator|Control Arm (Time and Attention Matched Control)|Self-administration of standard PrEP information from Centers for Disease Control (CDC).
88820814|NCT05613608|Active Comparator|Full-Spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
88820815|NCT05613608|Active Comparator|Broad-Spectrum Cannabidiol|210mg/day of full-spectrum cannabidiol, containing 0.0% THC.
88820816|NCT05613608|Placebo Comparator|Placebo|210mg/day of hemp seed oil with no cannabinoids present.
88820817|NCT05612802|Other|IGF|Creatinine and NGAL have been used successfully in the follow-up of acute kidney injury. In our study, in order to show the effect of pneumoperitoneum on acute kidney injury in patients scheduled for laparoscopic surgery, NGAL and IGF-1 values will be measured before, after and 24 hours after pneumoperitoneum, and these values will be compared.
88820818|NCT05611619|No Intervention|Control|Single study night with no noise exposure, to determine normal baseline sleep
88820819|NCT05611619|Experimental|Study 1: High level continuous flow tyre noise (A1)|Single study night in first experimental study arm, with traffic noise to determine consequences of sleep disturbance by high level, continuous flow traffic noise. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
88820820|NCT05611619|Experimental|Study 1: Medium level continuous flow tyre noise (B1)|Single study night in first experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level, continuous flow traffic noise. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
88820821|NCT05611619|Experimental|Study 1: High level, discrete traffic tyre noise (A2)|Single study night in first experimental study arm, with traffic noise events to determine consequences of sleep disturbance by high level traffic noise comprised of single, discrete traffic events. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
88820822|NCT05611619|Experimental|Study 1: Medium level, discrete traffic tyre noise (B2)|Single study night in first experimental study arm, with traffic noise events to determine consequences of sleep disturbance by moderate level traffic noise comprised of single, discrete traffic events. Noise will include mix of different acoustical characteristics of tyre noise throughout the night.
88820823|NCT05611619|Experimental|Study 2: Medium level composite wheel tyre noise (A1)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level traffic noise comprised of composite wheel types.
88820824|NCT05611619|Experimental|Study 2: Low level composite wheel tyre noise (B1)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by low level traffic noise comprised of composite wheel types.
88820825|NCT05611619|Experimental|Study 2: Medium level air-filled tyre noise (A2)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by medium level traffic noise comprised of traditional air-filled wheel types.
88820826|NCT05611619|Experimental|Study 2: Low level air-filled tyre noise (B2)|Single study night in second experimental study arm, with traffic noise to determine consequences of sleep disturbance by low level traffic noise comprised of traditional air-filled wheel types.
88820827|NCT05610085|Experimental|Dose escalation with LEV|Additional LEV at a higher dose (30 mg/kg, 60 mg/kg, or 90 mg/kg depending on the stage of the study).
88820828|NCT05610085|Active Comparator|Standard of care Phenobarbital|Treatment with Phenobarbital 20mg/kg IV and if needed a further 20mg/kg totalling 40mg/kg
88820829|NCT05608863|Active Comparator|Combined intervention|The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting
88820830|NCT05608863|Active Comparator|individual intervention|The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting
89530103|NCT03350945|Active Comparator|Device:Intra-operative Endoscopy|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using intra-operative endoscopy detection.
89530104|NCT03350945|Experimental|Device:Carbon Nanoparticles|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using carbon nanoparticles.
89530105|NCT03256513|Experimental|model controlling|an statistical model for periprocedural blood pressure control
88820885|NCT05512156|Experimental|Intervention Group|All children in the intervention arm of the study will be receiving daily supervised toothbrushing in kindergartens for two years. All children are exposed to background water fluoridation.
88820886|NCT05512156|No Intervention|Control Group|All children in the control arm of the study will be receiving TAU which is awareness sessions in the school about importance of the daily brushing, healthy diet and demonstrating how to brush correctly and efficiently. All children are exposed to background water fluoridation.
88820887|NCT05508464|Active Comparator|Standard of Care|Standard or care palliative radiotherapy (includes the option for no treatment)
88820888|NCT05508464|Active Comparator|SABR|SABR to all tumors 6Gy x 5 over 3 weeks
88820889|NCT05500716|Experimental|Auricular Non-Invasive Vagus Nerve Stimulation+Traditional Rehabilitation Program|"Auricular Non-Invasive Vagus Nerve Stimulation~Deep Friction Massage~Myofascial Trigger Point Compression Therapy~Temporomandibular Joint Mobilization~Rocabado Exercises~Muscle-Energy Techniques"
88820890|NCT05500716|Active Comparator|Traditional Rehabilitation Program|"Deep Friction Massage~Myofascial Trigger Point Compression Therapy~Temporomandibular Joint Mobilization~Rocabado Exercises~Muscle-Energy Techniques"
88820891|NCT05498272|Experimental|Investigational Group|"300 mg of olaparib taken orally twice a day for 6 cycles (approximately 6 months). There are 30 days in a cycle.~Olaparib will be taken with an LHRH agonist (leuprolide, triptorelin, or goserlin). This choice of therapy will be taken for a total of 180 days per institutional standards.~After 6 cycles of neoadjuvant therapy, patients will undergo a radical prostatectomy (RP). After RP, patients will be followed for testosterone recovery and PSA progression."
88820892|NCT05497115|Experimental|Trauma Resilience and Recovery Program|TRRP is a stepped model of care that delivers education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), fosters symptom monitoring and continued education (Step 2), screens for PTSD and depression 30 days post-injury (Step 3), and provides a referral and warm handoff to mental health services if needed (Step 4)
88820893|NCT05497115|No Intervention|Enhanced Usual Care Condition|Patients in the EUC arm will be given education about mental health after traumatic injury, educational materials about mental health recovery, and local referral information to assist treatment-seeking patients in seeking care.
88820894|NCT05494840|Experimental|Haptonomy- first experimental Group|Haptonomy Group Pregnant school will made to the experimental group, and haptonomy will be applied for at least 30 minutes, once a week for 6 weeks (with the researcher).
88820895|NCT05494840|Experimental|Haptonomy- second experimental Group|Haptonomy Group Pregnant school will made to the experimental group, and haptonomy will be applied for at least 30 minutes, once a week for 3 weeks (with the researcher).
88820896|NCT05494840|No Intervention|Haptonomy- Control Group|Standard of care Group The control group will not be interfered with.
88820897|NCT05494762|Experimental|Phase 1a: Dose Escalation|Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)
88820898|NCT05494762|Experimental|Phase 1b: Dose Expansion|BGB-B167 alone or in combination with tislelizumab (BGB-A317)
88820899|NCT05492123|Active Comparator|Standard Chemoradiation|Traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week or carboplatin AUC 2/week
88820900|NCT05492123|Experimental|Immunotherapy|4 cycles of induction therapy with nivolumab 1mg/kg and ipilimumab 3mg/kg every 3 weeks followed by traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week (or carboplatin AUC 2/week) with concurrent nivolumab 240mg every 2 weeks.
88820901|NCT05489614|Experimental|Single Dose Olpasiran Renal Impairment|Participants will be enrolled in 1 of 5 renal function groups based on their renal impairment status, as determined by estimated glomerular filtration rate (eGFR). All participants will receive a single dose of olpasiran on Day 1.
88820902|NCT05489614|Experimental|Single Dose Olpasiran Normal Renal Function|Participants with normal renal function will be enrolled and will receive a single dose of olpasiran on Day 1.
88820903|NCT05466656|Experimental|Quasi-experimental uncontrolled, before-and-after.|The intervention will consist of the use of a continuous quality improvement cycle model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.
88820904|NCT05466422|Experimental|MK-2214|Participants will receive MK-2214 administered in escalating doses as an intravenous (IV) infusion on Days 1, 29, and 57.
88820905|NCT05466422|Placebo Comparator|Placebo|Participants will receive placebo as an IV infusion on Days 1, 29, and 57.
88820906|NCT05461482|No Intervention|Control group|The physician requesting the intervention will be responsible for informing the patient, explaining the purpose of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention.
88820928|NCT05426070|No Intervention|No contact, wait-list control|Participants in the no contact, wait-list control intervention will participate in assessments at baseline and three months. Following the six month assessment, participants will have the option of receiving the strength training-based intervention as described above.
89530106|NCT03256513|Active Comparator|conventional controlling|an conventional strategy for periprocedural blood pressure control
89530107|NCT03348371|Experimental|Oral day|Participant receive ethanol orally
89530108|NCT03348371|Experimental|i.v. infusion day|Participant receive ethanol in an i.v. infusion
89530109|NCT03251209|Experimental|Group 1|Post-stroke participants receive the mental practice before the physical practice. The activities will be presented in a videotherapy way.
89530110|NCT03251209|Experimental|Group 2|Post-stroke participants receive the mental practice after the physical practice. The activities will be presented in a videotherapy way.
89530111|NCT03251209|Active Comparator|Group 3|Post-stroke participants receive only physical practice. The activities will be presented in a videotherapy way.
89530112|NCT05231603|Active Comparator|Treatment group:|Ivermectin 0.4 mg/kg/day (maximum 24 mg)
89530113|NCT05231603|Placebo Comparator|Control group|Placebo-inactive substance
88820907|NCT05461482|Experimental|Experimental group|In addition to the information provided by the referring physician, an interventional radiologist will assist the patient in a consultation before the intervention to inform him, explaining the objective of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention. In this group, educational videos will be used, one for each type of intervention, which will complement the explanations of the physician. The videos will aim to present in an understandable way the preparation for the intervention, its objective, the benefits and risks that derive from it and what you can expect once it has been carried out. Patients will have access to the videos before attending the consultation and will view them before being seen by the interventional radiologist.
88820908|NCT05461053|No Intervention|Warm Compress application|The control group will receive instructions on applying warm compresses, the current standard of care. The patient or parent/guardian will be directed to apply a warm compress to the abscess or soak the area in warm water for 15 minutes. The application/soak will be done 4 times during the day.
88820909|NCT05461053|Experimental|LMX4-A topical anesthetic application|The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
88820910|NCT05455697|Experimental|Treatment (TRR, CHOP)|"PREPHASE THERAPY: Patients receive tafasitamab IV over 30 minutes on days 1, 8, and 15 of each cycle, rituximab and hyaluronidase human SC on day 1 of each cycle, and retifanlimab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~COMBINATION THERAPY: After completion of prephase therapy or if patients progress during prephase therapy, patients receive tafasitamab IV over 30 minutes, retifanlimab IV over 30 minutes, rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 of each cycle. Patients also receive prednisone PO on days 1-5 of each cycle. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity."
88820911|NCT05444543|No Intervention|Control|Participants in this arm will continue with their normal standard of care regimen of daily topical steroids
88820912|NCT05444543|Experimental|Intervention|Participants in this arm will cycle their topical steroid therapy in a three-months on three-months off fashion
88820913|NCT05443971|Experimental|Treatment (durvalumab, grid therapy)|Patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo grid therapy on day 1. Beginning 7-14 days after grid therapy, patients also undergo palliative radiation therapy for 5 fractions. Additionally, patients undergo blood sample collection at baseline and throughout study.
88820914|NCT05442424|Experimental|Produce Vouchers|Half of parent-child dyads will receive $60 per month for 6 months, to purchase fresh fruits and vegetables from a local farmers' market.
88820915|NCT05442424|Active Comparator|Wait-List Control|Half of parent-child dyads will be placed on a 6 month wait list and will receive $60 per month for 6 months, to purchase fresh fruits and vegetables from a local farmers' market, after completing the 6 month waiting period and follow up data collection.
88820916|NCT05438862|Experimental|Early surgery|Early surgical treatment, state of art aortic valve surgery.
88820917|NCT05438862|No Intervention|Watchful waiting|Watchful waiting strategy, regular follow-up of patients with severe valve disease. Guideline-based indication for surgery only during the follow-up.
88820918|NCT05438290|Experimental|DPCP|0.4% ointment
88820919|NCT05436951|Experimental|No-nap, then brief 45-minute nap|Participants will be monitored for a total of 48 hours, including a 12-hour simulated night shift. At baseline (consent), participants are randomized to a crossover study design with two study arms (no nap, brief 45-minute nap). In this sequence, participants will perform the 12-hour simulated night shift with no nap first, undergo a minimum of 1-week washout, then return complete the 48-hour protocol again with the brief 45-minute nap.
88820920|NCT05436951|Experimental|The brief 45-minute nap, then no-nap|Participants will be monitored for a total of 48 hours, including a 12-hour simulated night shift. At baseline (consent), participants are randomized to a crossover study design with two study arms (no nap, brief 45-minute nap). In this sequence, participants will perform the 12-hour simulated night shift with the brief 45-minute nap, undergo a 1-week minimum washout, then return to complete the 48-hour protocol again with the no-nap
88820921|NCT05436379|Other|TBS|"In this open-label trial, all participants will undergo 2 continuous TBS (cTBS) sessions per visit over 10 days (weekdays, over 2 weeks; total = 20 TBS sessions in 10 visits). The total time of each pair of sessions (including pause between sessions) will be approximately 1 hour, with each session lasting approximately 100 seconds.~There is only 1 group and 1 arm of the study. All participants will receive the treatment."
88820922|NCT05426928||HIPEC|"Adults undergoing cytoreductive surgery and who are deemed eligible for HIPEC after surgical exploration in the operating theatre.~The patients will receive HIPEC according to routine practice, as defined by the surgical oncologist."
88820923|NCT05426460|Experimental|AAT + tDCS|Approach Avoidance Task + Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex
88820924|NCT05426460|Sham Comparator|AAT + sham tDCS|Approach Avoidance Task with Sham Transcranial Direct Current Stimulation.
88820925|NCT05426460|Active Comparator|AC + tDCS|Active Control Task with Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex
88820926|NCT05426460|Sham Comparator|AC + sham tDCS|Active Control Task with sham Transcranial Direct Current Stimulation
88820927|NCT05426070|Experimental|Strength training-based exercise|The strength training-based exercise intervention will be delivered via group-based Zoom sessions, motivational text messages, and a website. Participants will take part in two group-based Zoom exercise sessions (40-minute exercise sessions and 20 minutes of motivational counseling) and two individual exercise sessions per week for three months. Exercise sessions will include a combination of various aerobic and muscle strengthening exercises designed to keep heart rate in the 60-85% range of maximum heart rate. Motivational counseling will be focused on increasing motivation to exercise and habit formation. Strength training-based participants will also receive access to a mobile phone-friendly study website and will receive email messages. Both the website and email messages will contain motivational content to complete the exercise sessions.
88820949|NCT05406583|Experimental|Cohort 1|"Cohort 1 will be opened first to accrual, with Strata 1A and 1B being opened concurrently, to evaluate the PK and safety of two single DTG liquid suspension doses for the relevant stratum. Stratum 1C will only be opened to accrual if PK and safety data from Strata 1A and 1B infants support administration of DTG 5 mg DT across all neonates, or only in neonates with a minimum birth weight.~Stratum 1A (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)~Stratum 1B (DTG-exposed): Infants with in utero exposure to maternal DTG (mothers who receive at least one dose of DTG within 72 hours prior to delivery)~Stratum 1C (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)."
88820950|NCT05406583|Experimental|Cohort 2|"Cohort 2, Strata 2A and 2B, will be opened to accrual when the DTG dose and formulation to be administered for each stratum are established based on the PK and safety data from all Cohort 1 strata (Strata 1A and 1B, and 1C if applicable) and available data from other studies.~Stratum 2A (DTG-naïve): Infants with no in utero exposure to maternal DTG (no exposure to DTG during the two weeks prior to delivery)~Stratum 2B (DTG-exposed): Infants with in utero exposure to maternal DTG (mothers who receive at least one dose of DTG within 72 hours prior to delivery)"
88820951|NCT05405803|Experimental|Intervention Group|Participants will be asked to visit WPAPP-K at least two times a week for 12 months.
88820952|NCT05405803|Active Comparator|Control group|Participants will have access to a link of the CDC website from baseline and during the duration of the study (12 months).
88820953|NCT05403541|Experimental|Batoclimab Induction Dose 1 (Period 1)|
88820954|NCT05403541|Experimental|Batoclimab Induction Dose 2 (Period 1)|
88820955|NCT05403541|Placebo Comparator|Placebo Induction Dose (Period 1)|
88820956|NCT05403541|Experimental|Batoclimab Maintenance Dose 1 (Period 2)|
88820957|NCT05403541|Experimental|Batoclimab Maintenance Dose 2 (Period 2)|
88820958|NCT05403541|Placebo Comparator|Placebo Maintenance Dose (Period 2)|
88820959|NCT05403398|Experimental|BSCU1|B. subtilis CU1 at 2 billion CFUs daily for 4 weeks
88820960|NCT05403242|Experimental|RC48-ADC Combined With S-1|
88820961|NCT05397197|Other|Longitudinal follow-up|Follow-up of children at 40 weeks of corrected age for all children and then regularly until 24 months
88820962|NCT05397145|Active Comparator|Group IPB = Iliopsoas plane block|While the patient is in the supine position, the probe will be placed in the transversal plane distal to the anterior superior iliac spine. Then, the probe will be rotated approximately 30° counterclockwise and slid along the inguinal ligament until the femoral head enters the edge of the acetabulum. The block needle will be passed through the sartorius and iliopsoas muscles and the iliopsoas plane between the iliopsoas muscle and the iliofemoral ligament will be reached. After the block site is confirmed with 5 ml of saline, 10 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
88820963|NCT05397145|Active Comparator|Group PENG = PENG block|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block site is confirmed with 5 ml of saline, 20 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
88820964|NCT05393583|Experimental|Outpatient|Discharge on the day of hysterectomy
88820965|NCT05393583|Active Comparator|Inpatient|Discharge after 1 night stay in the hospital
88820966|NCT05383898|Experimental|Phase 1a Dose escalation of D-1553|Phase 1a will evaluate up to sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation
88820967|NCT05383898|Experimental|Phase 1b Dose expansion of D-1553|Phase 1b will evaluate more subjects with up to 2 different doses of D-1553 to confirm the recommended phase 2 dose.
88820968|NCT05383898|Experimental|Phase 2 of D-1553 monotherapy|Phase 1b will evaluate more subjects at the recommended phase 2 dose of D-1553 to evaluate the efficacy.
88820969|NCT05383872|Experimental|Exablate BBBD|Using Exablate Model 4000 Type 2 for liquid biopsy in subjects with Glioblastoma
88820970|NCT05382559|Experimental|ASP3082 Dose Escalation (Monotherapy Part 1)|Participants will receive ASP3082 in a 21-day cycle.
88820971|NCT05382559|Experimental|ASP3082 Dose Expansion (Monotherapy Part 2)|Participants will receive ASP3082 with dose level(s) selected from dose escalation (part 1) in a 21-day cycle.
88820972|NCT05382559|Experimental|ASP3082 + Cetuximab Dose Escalation (Combination Therapy Part 1)|Participants will receive ASP3082 in a 21-day cycle. Cetuximab will be administered weekly.
88820973|NCT05382559|Experimental|ASP3082 + Cetuximab Dose Expansion (Combination Therapy Part 2)|Participants with locally advanced or metastatic colorectal cancer will receive ASP3082 or ASP3082 + Cetuximab with dose level(s) selected from dose escalation (part 1) in a 21-day cycle. Cetuximab will be administered weekly.
88820974|NCT05382559|Experimental|ASP3082 China Safety Cohort|Participants will receive ASP3082 with dose level selected from dose escalation (Monotherapy part 1) in a 21-day cycle.
88820975|NCT05381480|Active Comparator|In-home Preventive Health Visits by Advanced Practice Nurse|APRNs will perform in-home multidimensional health assessment with quarterly follow up visits to provide individualized patient education, negotiation of recommendations to maintain/improve health and wellness. All participants continue to receive care from their primary care provider and other community-based providers, although use might be modified. Throughout the intervention, participants are encouraged to take a primary role in the management of their own health. APRNs coach and guide the participant in navigating existing service providers as well as accessing and establishing new services. Having the program in-home promotes an atmosphere of shared decision-making, while allowing the nurse to observe the physical and social environment. Key to this model is identification of individual profiles of health strengths and health risks; recommendations and negotiation over priority health behavior change; and quarterly follow up.
88821030|NCT05251948|Active Comparator|Atezo + CAPOX (capecitabine + oxaliplatin)|Participants in the atezolizumab plus capecitabine plus oxaliplatin in Stage 1 will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
88821031|NCT05251948|Experimental|Atezo + CAPOX +Tira|Participants in the atezolizumab plus capecitabine plus oxaliplatin plus tiragolumab arm in Stage 1 will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
88820976|NCT05381480|Active Comparator|On-site Evidence-based Physical Activity, Health and Wellness Classes|Curriculum. There will be three categories of classes offered at sites randomized into this intervention. A physical activity class will be offered three times weekly, and will include elements of Tai Chi, fall prevention, and arthritis exercises. Class content/activity will be modified for all levels of ability. A class focused on mental health and functioning will be offered weekly, and include activities targeting depression prevention, memory enhancement, and engagement (e.g., life review, agile mind). There will also be offered a weekly multi-topic class with a repeating cycle of topics and instructors including medication management, computer literacy and electronic health records, etc.. Tenants will be engaged in choosing topics that reflect the group consensus on importance. Altogether, at each location there will be five scheduled class opportunities each week for tenants to choose among.
88820977|NCT05377242|Experimental|Gulf War Veterans, Curcumin|"All GWI Veterans will undergo the same screening and experimental procedures. Participants must meet both the Kansas and CDC (Centers for Disease Control and Prevention) Case Definitions of GWI. Participants must have been deployed to the Persian Gulf Region during the 1990-1991 Gulf War, meet symptom domain criteria, and not have exclusionary medical conditions. The case definitions will be used for inclusionary screening purposes. This trial tests three interventions, which are all tested independently. Participants will receive only one of the three interventions. The curcumin, resveratrol, and stinging nettle trials all follow the same design and procedures.~Participants will complete one month of baseline, eight months of capsules, and one month of endline measurements."
88820978|NCT05377242|Experimental|Gulf War Veterans, Resveratrol|"All GWI Veterans will undergo the same screening and experimental procedures. Participants must meet both the Kansas and CDC (Centers for Disease Control and Prevention) Case Definitions of GWI. Participants must have been deployed to the Persian Gulf Region during the 1990-1991 Gulf War, meet symptom domain criteria, and not have exclusionary medical conditions. The case definitions will be used for inclusionary screening purposes. This trial tests three interventions, which are all tested independently. Participants will receive only one of the three interventions. The curcumin, resveratrol, and stinging nettle trials all follow the same design and procedures.~Participants will complete one month of baseline, eight months of capsules, and one month of endline measurements."
88820979|NCT05377242|Experimental|Gulf War Veterans, Stinging Nettle|"All GWI Veterans will undergo the same screening and experimental procedures. Participants must meet both the Kansas and CDC (Centers for Disease Control and Prevention) Case Definitions of GWI. Participants must have been deployed to the Persian Gulf Region during the 1990-1991 Gulf War, meet symptom domain criteria, and not have exclusionary medical conditions. The case definitions will be used for inclusionary screening purposes. This trial tests three interventions, which are all tested independently. Participants will receive only one of the three interventions. The curcumin, resveratrol, and stinging nettle trials all follow the same design and procedures.~Participants will complete one month of baseline, eight months of capsules, and one month of endline measurements."
88820980|NCT05371665|Experimental|Culturally Adapted Compass for Courage|All youth will receive the culturally adapted Compass for Courage from Native American providers in the school setting.
88820981|NCT05359211|Experimental|Treatment (lymphodepletion, liso-cel, NKTR-255)|Patients receive standard of care lymphodepletion therapy consisting of cyclophosphamide and fludarabine on days -5 to -3 followed by liso-cel CAR-T cell infusion on day 0. Patients then receive NKTR-255 IV over 30 minutes every 3 weeks starting on day 10 or 14 for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray and ECHO or MUGA during screening. Patients undergo bone marrow biopsy and aspiration, LP for CSF sample collection during screening, on the study and during follow-up as clinically indicated. Patients also undergo PET/CT throughout the trial. Additionally, patients undergo blood sample collection and may optionally undergo tissue biopsy throughout the trial.
88820982|NCT05357677|Experimental|SR419-Placebo sequence|30 mg of SR419 administered TID for 4 weeks followed by placebo administered TID for 4 weeks
88820983|NCT05357677|Experimental|Placebo-SR419 sequence|placebo administered TID for 4 weeks followed by 30 mg of SR419 administered TID for 4 weeks
88820984|NCT05352763|Experimental|Simufilam 100 mg|simufilam 100 mg oral tablets, b.i.d.
88820985|NCT05351541|Experimental|Psilocybin in combination with Zolpidem and Modafinil|Single dose of Psilocybin (1mg-30mg) in combination with zolpidem and modafinil
88820986|NCT05351541|Experimental|Psilocybin in combination with Zolpidem|Single dose of Psilocybin (1mg-30mg) in combination with zolpidem
88820987|NCT05351541|Experimental|Psilocybin in combination with Modafinil|Single dose of Psilocybin (1mg-30mg) in combination with modafinil
88820988|NCT05351541|Experimental|Psilocybin in combination with Placebo|Single dose of Psilocybin (1mg-30mg) in combination with placebo
88820989|NCT05336136|Experimental|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
88820990|NCT05336136|Active Comparator|Current commercial mask|Current commercial mask used by the participant for administration of non-invasive ventilation
88820991|NCT05330247|Experimental|Therapeutic Diet: CRHP Diet|Carbohydrate-reduced high-protein (CRHP) dietary intervention. Intervention: Therapeutic Diet: CRHP Diet.
88820992|NCT05330247|Active Comparator|Therapeutic Diet: CD Diet|Conventional diabetes (CD) dietary intervention. Intervention: Therapeutic Diet: CD Diet.
88820993|NCT05328167|Experimental|Diagnostic (perflutren protein-type A microspheres, CEUS)|Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo ultrasound at 1 month before TARE, 1-4 hours, 1 week, and 2 weeks post-TARE.
88820994|NCT05327699|Experimental|Major depressive disorder (MDD) Ketamine|Participants randomized to the ketamine arm will receive a single intravenous (IV) infusion of ketamine at 0.5mg/kg through an indwelling catheter over a 40-100min period.
88820995|NCT05327699|Placebo Comparator|Major depressive disorder (MDD) Placebo|Participants randomized to the placebo arm will receive a single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
88820996|NCT05327699|No Intervention|Healthy Controls|The subjects in this group will not receive any intervention.
88821032|NCT05250310|Active Comparator|Yoga|Patients randomized to Yoga arm will practice chair yoga for 30 minutes at least three days a week for 16 weeks
88821033|NCT05250310|No Intervention|Standard of Care|Control group patients will follow standard of care (SOC) treatment.
88821034|NCT05249465|Experimental|Condition 1|Core Only
88821035|NCT05249465|Experimental|Condition 2|Core + Track Weight
88820997|NCT05320250||Parkinson's disease|"60 patients. People with Parkinson's disease (pwPD) will be recruited for the study at Fondazione Don Gnocchi.~PwPD will be assigned to a rehabilitation program that will last for 6 consecutive weeks. Two possible rehabilitation plans are included:~Rehabilitation treatment at the IRCCS S. Maria Nascente: 30 sessions / 5 days a week including motor rehabilitation, cognitive rehabilitation and speech therapy rehabilitation.~Self-treatment program consisting of stretching and active mobilization exercises at home. Before starting the program, the subjects will undergo an educational and training session with the physiotherapist to learn the correct way of carrying out the proposed exercises."
88820998|NCT05320250||Atypical Parkinsonism|Progressive supranuclear palsy: 20 patients; Corticobasal syndrome: 20 patients; Multisystemic atrophy: 20 patients.
88820999|NCT05320250||REM sleep Behavior Disorder|30 patients
88821000|NCT05320250||Healthy controls|30 patients
88821001|NCT05315414|Experimental|Single tooth restorations|A single, open-label group with patients in need of single tooth restorations will receive PrimeTaper EV implant system with diameters 3.6, 4.2, 4.8, 5.4 mm, and lengths 6.5, 8, 9, 11, 13, 15 and 17 mm.
88821002|NCT05307939|Experimental|Screening, active surveillance, and treatment (Arm A)|Participants who meet criteria for the treatment phase (a post-operative HPV ctDNA which rose from initial undetectable to meet HPV16 ctDNA criteria and have no clinical or radiographic evidence of gross disease) will undergo delayed standard of care adjuvant radiation (50-60 Gy administered in 1.8-2 Gy fractions) based on the patient's initial pathology. Treatment will be initiated within 4 weeks of a NavDx result. Subjects will undergo FDG PET/CT simulation and standard radiation treatment planning and this FDG PET/CT will also be utilized to rule out distant metastases. Diagnostic FDG PET/CT fusion is also allowed for treatment planning and to rule out distant metastases. Non-therapeutic assessments will be completed.
88821003|NCT05307939|Experimental|Screening and deescalated treatment (Arm B)|"Participants who meet criteria for the de-escalated treatment phase (Arm B) will undergo adjuvant radiation (30 Gy administered in 2 Gy fractions) with concurrent chemotherapy.~They will undergo FDG PET/CT simulation and standard radiation treatment planning and this FDG PET/CT will also be utilized to rule out distant metastases. Diagnostic FDG PET/CT fusion is also allowed for treatment planning and to rule out distant metastases. Non-therapeutic assessments will be completed and the Study calendar."
88821004|NCT05305612|Experimental|Early UFH administration|The iv. bolus of UFH (100Units/kg) will be given after obtained femoral vein access and at least 5 minutes prior to the start of the TSP.
88821005|NCT05305612|Active Comparator|Late UFH administration|The iv. bolus of UFH (100Units/kg) will be given immediately after TSP, defined as the introduction of transseptal sheath into the left atrium.
88821006|NCT05304780|Experimental|experimental group|Needs-tailored nurse-led recovery program
88821007|NCT05304780|No Intervention|Control group|existing community homecare services
88821008|NCT05298592|Experimental|Part 1A: BMS-986406 (Monotherapy Dose Escalation)|
88821009|NCT05298592|Experimental|Part 1B: BMS-986406 + Nivolumab (Combination Dose Escalation)|
88821010|NCT05298592|Experimental|Part 1C: BMS-986406 + Nivolumab (Indication-Specific Dose Expansion)|
88821011|NCT05298592|Experimental|Part 2: BMS-986406 + Nivolumab (Expansion Cohorts)|
88821012|NCT05298592|Experimental|Part 1D: BMS-986406 + Nivolumab + Carboplatin with Pemetrexed or Paclitaxel|
88821013|NCT05281523|Experimental|Participants receiving depemokimab (GSK3511294)|
88821014|NCT05281523|Placebo Comparator|Participants receiving Placebo|
88821015|NCT05280418|Active Comparator|Tezepelumab|"Tezepelumab 210 mg subcutaneous injections every 4 weeks as an investigational drug.~Sterile tezepelumab will be provided 110 mg/mL pre-filled vial, with a dose of 210 mg delivered by pre-filled syringe."
88821016|NCT05280418|Placebo Comparator|Matched placebo|Sterile placebo for tezepelumab will be provided in identically matched pre-filled syringes.
88821017|NCT05280158|Active Comparator|Standard-dose|mRNA-1273 (Moderna COVID-19 vaccine) 50 ug
88821018|NCT05280158|Experimental|Mid-Dose|mRNA-1273 (Moderna COVID-19 vaccine) 100 ug
88821019|NCT05280158|Experimental|High-Dose|mRNA-1273 (Moderna COVID-19 vaccine) 200 ug
88821020|NCT05268796|Active Comparator|In-person treatment|
88821021|NCT05268796|Active Comparator|Telehealth-enabled treatment|
88821022|NCT05268796|Placebo Comparator|Psychoeducation|
88821023|NCT05259566|No Intervention|no menthol ban|usual menthol cigarettes and menthol flavored e-cigarette available
88821024|NCT05259566|Experimental|menthol ban in cigarettes only|non-menthol cigarettes and menthol flavored e-cigarette available
88821025|NCT05259566|Experimental|menthol ban in both cigarettes and e-cigarettes|non-menthol cigarettes and tobacco flavored e-cigarette available,
88821026|NCT05257824|Active Comparator|short-term dual antiplatelet group|Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU < 550 and PRU 85 ~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 6 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling
88821027|NCT05257824|Experimental|long-term dual antiplatelet group|Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU < 550 and PRU 85 ~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 12 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling.
88821028|NCT05256940|Experimental|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, and is delivered in three sessions in person, virtually, or by telephone.
88821029|NCT05256940|Active Comparator|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
88821036|NCT05249465|Experimental|Condition 3|Core + Track Steps
88821075|NCT05202756|Experimental|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
88821076|NCT05202756|Active Comparator|EMA Monitoring Only (EMO)|Participants in this condition will receive the Safety Planning Intervention (SPI) and will receive ecological momentary assessment prompts on the same schedule as the MAPS condition. However, they will not have access to any other MAPS features.
88821077|NCT05199545|Experimental|Dietary supplement group|2 tablets / day for 6 weeks of the dietary supplement (Rhodiola rosea L. and Crocus sativus L.), to be taken every day in the morning with a large glass of water, from D1 to D42.
88821078|NCT05199545|Placebo Comparator|Placebo group|2 tablets / day for 6 weeks of the placebo, to be taken every day in the morning with a large glass of water, from D1 to D42.
88821079|NCT05187884|Experimental|Intervention|Darovasertib 300mg bd
88821080|NCT05186818|Experimental|CK-3773274 up to 20 mg|Patients will receive doses of 5 mg, 10 mg, 15 mg or 20 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 24 weeks
88821081|NCT05186818|Placebo Comparator|Placebo to match CK-3773274|Patients will receive placebo for up to 24 weeks
88821082|NCT05185531|Experimental|Neoadjuvant|PD-1(Tislelizumab) plus stereotactic body radiotherapy
88821083|NCT05184712|Experimental|Ivonescimab (SMT112 or AK112) in combination with Pemetrexed and Carboplatin|Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
88821084|NCT05184712|Placebo Comparator|Placebo in combination with Pemetrexed and Carboplatin|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
88821085|NCT05183971||(1) Degenerative Cervical Myelopathy|Chinese subjects aged 50 or above who have radiological evidence of Degenerative Cervical Myelopathy, symptomatic with Nurick Grade less than 3 will be included.
88821086|NCT05183971||(2) Healthy Controls|Chinese healthy controls aged 50 or above who have no myelopathic signs of Degenerative Cervical Myelopathy with Nurick Grade less than 3 will be included.
88821087|NCT05180721|Experimental|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
88821088|NCT05180500|Active Comparator|Q-GRFT Nasal Spray|Q-Griffithsin (Q-GRFT) nasal spray (7.5mg/mL). Two metered doses of 100μL into each nostril, total of 3mg Q-GRFT per administration, administered once daily for 14 consecutive days.
88821089|NCT05180500|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray. Two metered doses of 100μL into each nostril, administered once daily for 14 consecutive days.
88821090|NCT05180383|Experimental|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
88821091|NCT05180331|Experimental|Mobile Application to Prevent Suicide (MAPS)|"Participants receiving MAPS will receive the Safety Planning Intervention (SPI) which will be uploaded into the smartphone app. They will be prompted four times per day to complete a brief ecological momentary assessment check-in inquiring about their cognitions, affect, and behavior, including suicidal thoughts and behaviors. Based on these responses, they will be provided with coping strategies from their safety plans and from a database of coping strategies created by study staff. They will also have access to emergency phone numbers, the coping strategies database, and can communicate with their study clinician through a text-like interface in the app. They will receive this intervention for one month."
88821092|NCT05178316|Experimental|JZP150 0.3 mg|Participants who will be randomized to receive JZP150 0.3 mg orally once daily for up to 12 weeks.
88821093|NCT05178316|Experimental|JZP150 4.0 mg|Participants who will be randomized to receive JZP150 4.0 mg orally once daily for up to 12 weeks.
88821094|NCT05178316|Placebo Comparator|Placebo|Participants who will be randomized to receive placebo orally once daily for up to 12 weeks.
88821095|NCT05173818|Experimental|HBO at 1.5 Atmosphere absolute|Participants in this group will be exposed to hyperbaric oxygen at 1.5 atmosphere absolute (ATA) for 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
88821096|NCT05173818|Sham Comparator|Sham control initially at 1.2 then changed to 1.0 ATA|Participants in this group will be exposed to hyperbaric oxygen at 1.2 atmosphere absolute (ATA) during the first 5 to 7 minutes and the chamber pressure will be reduced to 1.0 ATA for the remaining 53 - 57 minutes for a total of 60 minutes per session. Each participant will complete 40 sessions, five sessions per week within 3 months from randomization
88821097|NCT05172986|Experimental|RAAC (Program Arm)|Patient under RAAC Program
88821098|NCT05172986|No Intervention|Standard Arm|Standard patient procedure
88821099|NCT05171686|Experimental|Diuretic augmentation|The participant's blood pressure medication regimen will be altered to initiate a thiazide-type or loop diuretic in those not already prescribed a diuretic, or to increase the dose if one is already prescribed.
88821100|NCT05168202|Experimental|CC-95251 monotherapy|
88821101|NCT05168202|Experimental|CC-95251 + azacitidine|
88821102|NCT05168202|Experimental|CC-95251 + azacitidine + venetoclax|
88821103|NCT05163938|Experimental|REThink therapeutic game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
88821104|NCT05163938|Active Comparator|Treatment as usual|In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
88821105|NCT05160636||Study cohort positive for COVID-19|Cohort will be those that are COVID-19 positive by RT-PCR from a SOC nasopharyngeal swab.
88821106|NCT05160272|Experimental|AP-325 Treatment|AP-325, film-coated tablet, 50mg once daily
88821107|NCT05160272|Placebo Comparator|Placebo Treatment|Placebo matching AP-325 film-coated tablet, once daily
88821108|NCT05160129|Experimental|Circuit-selective DBS|People suffering from severe obsessive-compulsive disorder (OCD)
88821109|NCT05152173|Experimental|EN3835 Group|Participant will receive a maximum dose of up to 1.8mg of EN3835 injection
88821110|NCT05152173|Placebo Comparator|Placebo Group|Participant will receive a maximum dose of up to 1.8mg of Placebo injection
88821111|NCT05146661|Experimental|Treatment|The NEURESCUE device will be used as an adjunct to ALS.
88821112|NCT05146297|Active Comparator|Patient Participants|Patients with invasive breast, prostate or liver cancer, who face a treatment decision
88821113|NCT05146297|Active Comparator|Physician Participants|Oncologists, and advanced practitioners caring for patients with breast, prostate, liver cancer including medical, surgical, radiation oncologists, interventional radiologists, urologists & hepatologists
88821114|NCT05145361|Experimental|B001 injection|Subjects randomized to this arm will receive B001 twice, at day 1 and day 15, up to the end of the study.
88821115|NCT05145361|Placebo Comparator|Placebo|Subjects randomized to this arm will receive Placebo twice, at day 1 and day 15, up to the end of the study.
88821116|NCT05139420|Experimental|lifestyle intervention plus phentermine-topiramate|Participants will be enrolled in a weight loss program based on lifestyle changes and the use of phentermine-topiramate to aid with weight loss
88821117|NCT05139420|Experimental|lifestyle intervention|Participants will be enrolled in a weight loss program based on lifestyle changes. They will be given a 6-month subscription to a calorie-reduced meal replacement program that also offers lifestyle coaching.
88821118|NCT05135260|Experimental|Virtual Reality Therapy|Participants will watch videos for 11 minutes that will allow them to view nature, dinosaurs, animals, and human interactions in three dimension.
88821119|NCT05135260|Active Comparator|Control Group|This group will not watch videos, but will continue with their normal routine as if nothing has changed.
88821120|NCT05133492|Experimental|Interventional|Use of the EAST System for the stabilization treatment of AAA. The device is delivered endovascularly and placed in the AAA sac to deliver the Stabilizer Infusion Solution.
88821121|NCT05124769|Experimental|Pain Allow|Pain is allowed up to 5/10 during exercises, monitored by NPRS. Depending on tissue irritability and other factors such as ROM, the exercises may be performed in an isometric way, or dynamic.
88821122|NCT05124769|Active Comparator|Pain Avoid|Pain is not allowed during the exercises, and should be <2/10, monitored by NPRS.
88821123|NCT05106608|Experimental|Group PBM_1|Energy density 7.5 J / cm2 for group PBM_1
88821124|NCT05106608|Experimental|Group PBM_2|Energy density 3 J / cm2 for group PBM_2
88821125|NCT05106608|Placebo Comparator|Placebo Control|The placebo control group will carry out the same protocol used in irradiated patients (including the use of protective glasses) using the same laser device to imitate a real irradiation; however, the device will be turned off and a recording of the emission sounds will be used to give the patient the hearing sensation of the laser therapy.
88821126|NCT05102019|Experimental|Arm 1 (treatment arm):Implantation of the Reducer device|
88821127|NCT05102019|Sham Comparator|Arm 2 (sham-control arm): Control (no device implantation)|
88821128|NCT05102019|Other|Arm 3 (unblinded, non-randomized): Single Arm Registry|
88821129|NCT05100017|Active Comparator|Methocarbamol|Patients will receive oral Methocarbamol 750mg every six hours after ureteroscopy as needed for pain in addition to the standard postoperative pain regimen (Tylenol 1000mg every six hours, Tamsulosin 0.4mg daily, phenazopyridine 200mg every eight hours, and diclofenac 50mg every eight hours).
88821130|NCT05100017|Active Comparator|Oxybutynin|Patients will receive oral Oxybutynin XL 10mg daily after ureteroscopy as needed for pain in addition to the standard postoperative pain regimen (Tylenol 1000mg every six hours, Tamsulosin 0.4mg daily, phenazopyridine 200mg every eight hours, and diclofenac 50mg every eight hours).
88821131|NCT05085990|Experimental|TARA-002|TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.
88821132|NCT05081492|Experimental|Treatment (CF33-hNIS-antiPDL1)|Patients receive CF33-hNIS-antiPDL1 IT on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
88821133|NCT05081102|Experimental|Group 1: FDC oxycodone 5 mg/ibuprofen 400 mg from Eurofarma Laboratórios SA (experimental drug)|Participants randomized to this group will receive one (01) tablet of the experimental drug + one (01) tablet of Tylex® placebo when post-surgical pain intensity reaches moderate to intense intensity (≥ 40 mm on a 0-100 mm VAS). Participants will be instructed to, from then on, use this same treatment whenever needed for pain relief, observing a minimum interval of six (06) hours between two intakes, for up to 3 days (72 hours after the initial dose).
88821185|NCT04960397|Experimental|Cohort 3|Once, there is sufficient evidence of safety and tolerability in Cohorts 1 and 2,and enrollment has completed of all 45 in each of these cohorts. Cohort 3 will begin enrollment. A cohort of influenza non-naïve 25 healthy children, 2-8 years old, will receive a single dose of 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=15) or placebo (N=10) at Day 1. N=25.
88821152|NCT05022862|Experimental|Video Directly Observed Therapy plus Financial Incentives|Participants in this group will receive the same treatments and education provided to Usual Care Control participants, as well as treatment viewed by video DOT. This arm will also earn financial contingent incentives. Participants will receive incentive payments when a submitted video is monitored by a staff member and deemed valid. If a participant fails to submit a video on a medication day or if a submitted video is deemed invalid (i.e., not the correct person or no appropriate ingestion of medication), the participant will not receive the scheduled incentive amount that day and the daily incentive value will be decreased.The participant will have opportunities the next day to again resume adherence. After taking the medication again for one week, participants will earn a reduced incentive until they adhere to the medication schedule for a week.
88821153|NCT05012410|Experimental|Immediate treatment group with High-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive telephone and email prompts.
88821154|NCT05012410|Experimental|Immediate treatment group with Low-Intensity Prompts|Caregivers will use the WeCareAdvisor tool for six months and receive email prompts only.
88821155|NCT05012410|Experimental|Waitlist Control after three months with high-Intensity prompts|After three months, caregivers will receive WeCareAdvisor and telephone and email prompts.
88821156|NCT05012410|Experimental|Waitlist Control after three months with Low-Intensity Prompts|After three months, caregivers will receive WeCareAdvisor and email prompts only.
88821157|NCT05011305|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.
88821158|NCT05011305|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.
88821159|NCT05011305|Placebo Comparator|Placebo|Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment.
88821160|NCT05009719|Experimental|Prophylactic|The patients with high risk of relapse of disease and full donor chimerism after allo-HSCT without signs of the disease will be include in this group.
88821161|NCT05009719|Experimental|Preventive|The patients with persisted minimal residual disease or cytogenetic relapse after allo-HSCT will be include in this group.
88821162|NCT05009602||Participating Centre|To complete all index tests and reference scan
88821163|NCT05006937|Active Comparator|laser dusting|"In the dusting arm, the ureteroscope will be advanced into the kidney or ureter over an access wire without an access sheath in place. The identified stone will be dusted using a 200 micron Moses laser fiber at a setting of 0.3-0.6 J and 50-120 Hz using the Moses 2.0 laser system. Stone dusting will continue until the surgeon feels the fragments are all negligible in size and would be able to pass. One small piece will be extracted for analysis and the remainder will be left to pass spontaneously. If there is no evidence of injury or swelling of the ureter at the conclusion of the case a stent will be omitted."
88821164|NCT05006937|Active Comparator|basketing|In the Basketing arm, a ureteral access sheath (UAS) will be placed per standard fashion. The ureteroscope will be introduced into the kidney and the stone fragmented at a setting of 0.8-1.0 J and 6-15 Hz. The resultant fragments will be basket extracted through the sheath for analysis. All fragments will be removed until no residual stone remains. At the time of UAS removal the ureter will be inspected. If there is no evidence of ureteral injury or swelling then a stent will be omitted.
88821165|NCT05001945|Placebo Comparator|Placebo (Part I)|Placebo tablet(s) by mouth once or twice daily.
88821166|NCT05001945|Experimental|Dose 1 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
88821167|NCT05001945|Experimental|Dose 2 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
88821168|NCT05001945|Experimental|Dose 3 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
88821169|NCT05001945|Placebo Comparator|Placebo (Part II)|Placebo tablet(s) by mouth once daily.
88821170|NCT05001945|Experimental|Dose (Part II)|MLS-101 tablet(s) by mouth once daily.
88821171|NCT05000320||Vigabatrin-naive|Adults 18 - 80 years of age suffering from post anoxic status epilepticus (PASE) who have not received vigabatrin.
88821172|NCT04999605|Experimental|AK112|AK112 injection
88821173|NCT04998123|Sham Comparator|Sham Stimulation|
88821174|NCT04998123|Experimental|ISP Stimulation|
88821175|NCT04998123|No Intervention|Perpheral Stimulation|
88821176|NCT04982965|Experimental|Active THC|Participants will be administered 400mg of vaporized cannabis (5.1%) before pain testing and fMRI.
88821177|NCT04982965|Placebo Comparator|Placebo THC|Participants will be administered 400mg of vaporized cannabis (<.1%) before pain testing and fMRI.
88821178|NCT04975230|Experimental|Sleep Self-Management|The Sleep Self-Management Intervention involves an initial 50-minute face-to-face interactive session in a private location. Participants are asked to extend time in bed by 1 hour and consistently maintain the extension on both weekends and weekdays. Bedtimes and waketimes will be assessed to ascertain which time is most modifiable for the participant's lifestyle and routine. There will be weekly follow-ups and in-person 3-week booster sessions. Sleep reports generated by the actigraphy will be shared with participants with brief action planning and goal setting to address progress towards goal achievement. A need to revise plans for future weeks will be the booster sessions' major goal.
88821179|NCT04975230|No Intervention|Diabetes Self-Management Education|The Attention Control arm will receive Diabetes Self-Management Education at the initial consultation visit via in-person contact at T1. There will be weekly follow-ups and in-person 3-week sessions. A Diabetes Self-Management Tracking Form will be used to monitor the weekly acquisition of information and plans for the 6-week intervention and at the 3-month and 6-month data points.
88821180|NCT04965025|Experimental|Multi-stage urethroplasty with graft inlay in first stage|
88821181|NCT04965025|Active Comparator|Multi-stage urethroplasty with graft inlay in second stage|
88821182|NCT04961619||dabrafenib and trametinib|patients on adjuvant treatment with dabrafenib + trametinib
88821183|NCT04960397|Experimental|Cohort 1|A cohort of influenza non-naïve 45 healthy children, 9-17 years old, will receive a single dose of 10^9 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1. N=45.
88821184|NCT04960397|Experimental|Cohort 2|A cohort of influenza non-naïve 45 healthy children, 2-8 years old, will receive a single dose of 10^8 TCID50 of intranasal Sing2016 M2SR H3N2 vaccine (N=30) or placebo (N=15) at Day 1 intranasally. N= 45
88821210|NCT04894864|Active Comparator|Opioid-Based Anesthesia Analgesia|Premedication: IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Propofol 2-3mg/kg, Fentanyl 1-2mcg/kg and Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/kg. Anesthesia maintenance: Desflurane set at approximately 1 MAC, Morphine 0.1-0.12mg/kg, Fentanyl 1-2mcg/kg during induction and 50-100mcg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, along with Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. ICU stay sedation: Remifentanil infusion, until removal of the endotracheal tube. Surgical ward: PCA pump with Morphine for the first 3 postoperative days. Additional postoperative analgesia: Paracetamol 1g x3 +/- Dexketoprofen trometamol 50mg x2. Rescue therapy only: Tramadol 50-100mg.
88821211|NCT04894864|Active Comparator|Opioid-Free Anesthesia Analgesia|Premedication: Pregabalin 50-150mg x2, IM Midazolam 0.05-0.07mg/kg. Anesthesia induction: Midazolam 0.03mg/kg, Dexdmedetomidine 0.5-1mcg/kg, Lidocaine 1mg/kg, Propofol 2-3mg/kg, Ketamine 1-1.5mg/kg, Hyoscine 10mg, Cisatracurium 0.2mg/kg or alternatively Rocuronium 0.6-1.2mg/kg, Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg. Anesthesia maintenance: Desflurane set at ~1 MAC, Dexmedetomidine 0.2-1.2mcg/kg/h, Lidocaine 0.5-1mg/kg/h, Ketamine 0.3-0.5mg/kg prn, Paracetamol 1g +/- Dexketoprofen trometamol 50mg, and Ondansetron 4mg or Droperidol 0.625mg. Wound infiltration: Ropivacaine 75-150mg. ICU sedation: Dexmedetomidine + Lidocaine infusions, until removal of the ETT. Surgical ward: PCA pump with Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam for the first 3 postoperative days. Additionally, Pregabalin 50mg per os x1 and 25mg x1, up to x2, Paracetamol 1g x3 +/- Dexketoprofen trometamol 50mg x2. Rescue therapy only: Tramadol 50-100mg.
88821212|NCT04893434|Experimental|DCE-MR images with Gadobutrol (GBCA)|10 volunteers will undergo a single DCE-MRI of the normal cervix to fine-tune parameters and test the performance of reconstruction and quantification algorithms. Goldenangled radial LAVA data will be continuously acquired for 5 minutes and the contrast agent will be injected intravenously after 1 minute (same contrast agent and injection rate. 60 gynecologic cancer patients will be enrolled (inclusion criterion: newly diagnosed gynecologic cancer scheduled for standard of care pelvic MRI for staging). Data from 30 of the patients will be used to assess repeatability; DCE-MRI will be acquired at baseline and repeated 48 hours (+/- 24 h) later (no therapy between the 2 scans). Data from the other 30 patients will be used to document treatment induced changes in DCE-MRI; patients in this group will undergo DCE-MRI at baseline and repeated after 2 weeks (+/- 3 days) of completion of chemoradiation treatment.
88821213|NCT04889040|Placebo Comparator|Placebo|The dose and regimen of the placebo will match that of AT-527.
88821214|NCT04889040|Experimental|RO7496998 (AT-527)|Orally administered, 550 mg twice daily (BID) for 5 days
88821215|NCT04886726|Experimental|PTCY and uhCG/EGF|PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
88821216|NCT04885829|Experimental|DRL_TC|Subcutaneous injection of DRL's Tocilizumab
88821217|NCT04885829|Active Comparator|RP and RMP|Subcutaneous injection of Actemra and RoActemra (Commercially available Tocilizumab)
88821218|NCT04868682|Experimental|Behavioral Education Intervention I|Manual-based education program provided in individual sessions
88821219|NCT04868682|Active Comparator|Behavioral Education Intervention II|Manual-based education program provided in individual sessions
88821220|NCT04860843|Experimental|Local anesthetic TPVB + Local anesthetic Pecs block|Patients will receive a thoracic paravertebral with pecs block, both with local anesthetic infiltrate.
88821221|NCT04860843|Sham Comparator|Local anesthetic TPVB + Sham Pecs block|Patients will receive a thoracic paravertebral with local anesthetic infiltrate and a pecs block with saline infiltrate.
88821222|NCT04858412|Active Comparator|HMB enriched amino acid arm|The patients randomized to the HMB enriched amino acid (HMB/EAA) arm will be given HMB/EAA for 90 days.
88821223|NCT04858412|Placebo Comparator|Balanced amino acid arm|The patients randomized to the Balanced amino acid (BAA) arm will be given BAA for 90 days.
88821224|NCT04855383|Experimental|The group of frozen embryo transfer with intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
88821225|NCT04855383|No Intervention|The group of frozen embryo transfer without intramuscular injection of human chorionic gonadotropin.|In this group, endometrial preparation for embryo transfer will be through the standard protocol using a gonadotropin-releasing hormone agonist. Embryo transfer will be done without human chorionic gonadotropin intramuscular injection.
88821226|NCT04853225||Main cohort|COPD, chronic bronchitis and healthy participants (never smoker) from Type A and Type B hospitals will be included.
88821227|NCT04853225||Sub-cohort|COPD, chronic bronchitis and healthy participants (never smoker) from selected Type A hospitals will be included.
88821228|NCT04844593||Participants With CD|Participants with CD diagnosed with or without CPF will be identified from EMRs through medical language application program interface (API) software. The AI will apply NLP and machine learning to identify and analyse text information in EMRs and thereby, extract medical information. The data will be collected retrospectively from January 1st 2015 and December 31st 2021.
88821229|NCT04831320|Experimental|nab-Paclitaxel + Nivolumab|"nab-Paclitaxel 125 mg/m^2 intravenous (IV) on days 1, 8 & 15 of each 28-day cycle.~Nivolumab 480 mg IV Day 1 of each 28-day cycle."
88821230|NCT04827914|Experimental|Enhanced Care Condition|
88821231|NCT04827914|Active Comparator|Basic Care Condition|
88821232|NCT04816006|Experimental|Aerobic Exercise Training|Breast cancer survivors randomized to the intervention group will participate in a moderate-intensity aerobic exercise program for 24 weeks.
88821233|NCT04816006|Active Comparator|Health Education (Control)|Individuals randomized to Health Education will receive individual education and counseling related to general cancer-related health and support across 24 weeks.
88821234|NCT04813172|Experimental|Head and neck cancer patients|Patients from the Eye and Ear Institute Survivorship Clinic who are diagnosed with head and neck cancer.
88821235|NCT04808310|Active Comparator|Angiography|The indication to further coronary intervention will be based on angiographic diameter stenosis.
88821236|NCT04808310|Experimental|Quantitative flow ratio (QFR)|The indication to further coronary intervention will be based on QFR.
88821237|NCT04805333|Experimental|Dose 1 - 450mg Artemisia annua|Participants in this group will consume 1 cup of decaffeinated coffee (450 mg Artemisia annua).
88821255|NCT04776018|Experimental|Phase 1b, Part 1 - Dose Escalation: Arm A - TAK-981 Twice Weekly (BIW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg subcutaneous (SC) injection once weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by once every 2 weeks in Cycle 3 through 6, then every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: Escalating doses of TAK-981 BIW intravenous (IV) infusion on Days 1, 4, 8, 11 and 15 in Cycle 1 and 2 (each Cycle is of 28 days) followed by every 2 weeks in Cycles 3 through 6, followed by once every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
88821256|NCT04776018|Experimental|Phase 1b, Part 1 - Dose Escalation: Arm B - TAK-981 Weekly (QW) + Mezagitamab|"Mezagitamab: A fixed dose of 600 mg SC injection once weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by once every 2 weeks from Cycle 3 through 6, then every 4 weeks up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: Escalating doses of TAK-981 QW IV infusion on Days 1, 8, 15, and 22 in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycles 3 through 6, followed by once every 4 weeks. up to Cycle 24 or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first."
88821257|NCT04776018|Experimental|Phase 1b, Part 2 - Lead-in Cohort: TAK-981 + Daratumumab and Hyaluronidase-fihj|"Daratumumab and hyaluronidase-fihj: 1800 mg SC injection QW once weekly in Cycles 1 and 2 , (each cycle is of 28 days) followed by every 2 weeks in Cycle 3 through 6 , followed by every 4 weeks up to Cycle 24 until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.~TAK-981: As per dose and schedule of TAK-981 defined in Phase 1b Part 1."
88821258|NCT04776018|Experimental|Phase 2 - Dose Expansion: TAK-981 + Daratumumab and Hyaluronidase-fihj or Mezagitamab|TAK-981 at RP2D as determined in Phase 1b. Mezagitamab at a fixed dose of 600 mg SC injection or Daratumumab and Hyaluronidase-fihj at a fixed dose of 1800 mg weekly in Cycles 1 and 2 (each cycle is of 28 days), followed by every 2 weeks in Cycle 3 through 6, followed by every 4 weeks up to Cycle 24 or until disease progression unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first.
88821259|NCT04772157||Cohort|Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
88821260|NCT04770844||premature child|300 premature child will be included. They will have three acquisitions during hospitalization.
88821261|NCT04763759|Experimental|Dose Level 1- 6mg/kg|Randomized 3:1 (TRL1068:placebo) via IV infusion
88821262|NCT04763759|Experimental|Dose Level 2- 15mg/kg|Randomized 5:2 (TRL1068:placebo) via IV infusion
88821263|NCT04763759|Experimental|Dose Level 3- 30 mg/kg|Randomized 5:2 (TRL1068:placebo) via IV infusion
88821264|NCT04760548||Train dataset|This group is dedicated to developing an automated algorithm
88821265|NCT04760548||Test dataset|This group is dedicated to testing the semantic performance of an automated algorithm
88821266|NCT04760548||Clinical Validations|Patients groups are dedicated to assessing the clinical validity of the measurement in independent validation cohorts, with or without longitudinal evaluations such as monitoring of a treatment effect
88821267|NCT04760353|Experimental|Probiotic|one powder portion bag of the probiotic mixture (OMNi-BiOTiC STRESS) containing 9 human bacterial strains [Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51 Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)] and vitamin B (B2, B6, B12), self-administered orally twice a day for 8 weeks
88821268|NCT04760353|Placebo Comparator|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~Powder portion bags are suitable for participants with intolerance to yeasts or lactose~Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
88821269|NCT04738708||Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients attending genetic counselling for Hereditary Breast and Ovarian Cancer (HBOC) and Lynch Syndrome in Clinical Genetic Services (CGS) at National Cancer Centre Singapore (NCCS)
88821270|NCT04734821|Experimental|NIR Fluorescence guided lymphadenectomy and anastomosis|
88821271|NCT04733378|Experimental|Peri-operative neurological monitoring|
88821272|NCT04730739|Experimental|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The patient must have been treated with either Knee Spanning or Damage Control FastFrame External Fixation System.
88821273|NCT04729803|Experimental|Attention Guidance + Exposure|Participants will complete teleconferencing-based exposure trials with an attention guidance component.
88821274|NCT04729803|Active Comparator|Exposure Alone|Participants will complete teleconferencing-based exposure trials.
88821275|NCT04729803|Experimental|Attention Control + Exposure|Participants will complete teleconferencing-based exposure trials with an attention control component.
88821276|NCT04723823|Experimental|fMRI w/ motor or sensory imagery|Individuals will be asked to imagine movements or sensations while fMRI is used to measure brain activity.
88821277|NCT04720768|Experimental|Dose escalation phase|"Encorafenib (tablet) 450mg PO daily~Binimetinib (tablet) 45mg PO BD~Palbociclib (tablet) variable dose PO daily for 21 consecutive days on treatment, followed by 7 consecutive days off treatment in a 28 day cycle"
88821278|NCT04692818|Experimental|Clinically indicated breast tumor biopsy|Subjects with breast lesion and are scheduled for clinically-indicated biopsy will have 3D Multimodal Ultrasound Imaging performed
88821279|NCT04683549|Other|One-Arm HPV serum level and FDG PET CT|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy
88821280|NCT04678752|Active Comparator|Standard of Care|Each primary care provider will administer weight loss care per their standard practice.
88821281|NCT04678752|Experimental|PATHWEIGH|A weight management care path that support primary care both through the EHR and training for the clinicians.
88821282|NCT04678401|Experimental|IS-FREE TREG CRAFT_ENGINEERED HaploHCT for relapsed/refractory AML or MDS EB-2|"After meeting eligibility criteria and being enrolled, patients will receive:~Day -15 to -6 prior to hematopoietic stem cell transplant (HSCT), preparatory regimen of radiation and chemotherapy: Total Myeloid and Lymphoid Irradiation (TMLI): Days -15 to -11 prior to HSCT; - Chemotherapy (infusion): Day -10 to day -6 prior to HSCT: Fludarabine (all days), Thiotepa (days -10 and -9) and Cyclophosphamide and Mesna (days -8 and -7)~Day -4 prior to (HSCT), a Treg-enriched donor cell infusion and graft vs host disease (GVHD) assessment~Day -1 prior to (HSCT), a unmodified donor T Cell infusion and (GVHD) assessment~Day of (day 0) (HSCT), CD34+ Haplo Peripheral Blood Stem Cell Infusion/Transplant and (GVHD) assessment~Days 30, 60,100, 180, 365 post hematopoietic stem cell transplant (HSCT), participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD)"
88821283|NCT04678401|Experimental|IS-FREE TREG CRAFT_ENGINEERED HaploHCT for Ultra high-risk AML or MDS with mutated TP53|"After meeting eligibility criteria and being enrolled, patients will receive:~Day -15 to -6 prior to hematopoietic stem cell transplant (HSCT), preparatory regimen of radiation and chemotherapy: Total Myeloid and Lymphoid Irradiation (TMLI): Days -15 to -11 prior to HSCT; - Chemotherapy (infusion): Day -10 to day -6 prior to HSCT: Fludarabine (all days), Thiotepa (days -10 and -9) and Cyclophosphamide and Mesna (days -8 and -7)~Day -4 prior to (HSCT), a Treg-enriched donor cell infusion and graft vs host disease (GVHD) assessment~Day -1 prior to (HSCT), a unmodified donor T Cell infusion and (GVHD) assessment~Day of (day 0) (HSCT), CD34+ Haplo Peripheral Blood Stem Cell Infusion/Transplant and (GVHD) assessment~Days 30, 60,100, 180, 365 post hematopoietic stem cell transplant (HSCT), participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD)"
88821284|NCT04676152|Experimental|Test subjects|All subjects enrolled had blood pressure measurements taken using the noninvasive blood pressure device.
88821285|NCT04673630|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
88821286|NCT04665596|Experimental|Ultrasound treatment|Ultrasound treatment of patients with symptomatic aortic valve stenosis who are not eligible for valve replacement
88821287|NCT04659044|Experimental|Treatment (rituximab, polatuzumab vedotin, venetoclax)|"INDUCTION: Patients receive rituximab IV on day 1 of cycle 1 and rituximab and hyaluronidase human SC over 5 minutes on day 1 of cycles 2-6. Patients also receive polatuzumab vedotin IV over 30-90 minutes on day 1 and venetoclax PO daily on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive venetoclax PO daily on days 1-21 and rituximab and hyaluronidase human SC over 5 minutes every 60 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
88821288|NCT04657081|Experimental|Oral administration of ASTX727 and Venetoclax combination|"Cycle 1: ASTX727 according to a prescribed dosing regimen and venetoclax on day 1 (100 mg daily), day 2 (200 mg daily), and days 3-28 (400 mg daily) of a 28-day cycle.~Cycle 2 and beyond: ASTX727 according to a prescribed dosing regimen and venetoclax on days 1-28 (400 mg daily) of a 28-day cycle."
88821289|NCT04653246|Experimental|Isa-RVD|"The main study consists of 4 phases a) 28-day screening phase; b) an induction phase inclusive of two 42-day induction treatment cycles: Isatuximab (IV), Bortezomib (SQ). Lenalidomide (PO), Dexamethasone; c) Followed by stem cell mobilization (at the discretion of the Principal Investigator [PI]);d) Participants will proceed with either autologous stem cell transplant or two additional induction cycles.~- Induction will be followed by a maintenance phase that continues until disease progression."
88821290|NCT04640545|Experimental|LBL-007+Toripalimab+Axitinib Tablets|"Study Part A： LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv；~Study Part B： LBL-007 Dose A/Dose B/Dose C/Dose D Q2W iv+Toripalimab 3mg/kg Q2W iv+Axitinib Tablets 5mg + Axitinib Tablets 1mg"
88821291|NCT04638998||Healthy Control|The healthy control group are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. This cohort do not experience any Gulf War Illness symptoms.
88821292|NCT04638998||Gulf War Illness|The GWI cohort are men ages 46-70 who were present in the Persian Gulf War between 1990 and August 1991. The men in this cohort will also meet the Kansas Inclusion Criteria for GWI.
88821293|NCT04626687|Experimental|test DCB group|use the DCB made by Acotec Scientific
88821294|NCT04626687|Active Comparator|RESTORE DCB group|use the DCB made by CARDIONOVUM GmbH
88821295|NCT04620603|Experimental|LDR + SOC Immunotherapy|Participants will receive one treatment of brachytherapy on treatment day 1 (LDRD1). After a minimum of 7 days but no more than 30 days to allow antigenic release, participants will then begin immunotherapy treatment with SOC immunotherapy at the standard FDA-approved dose. Standard immunotherapy will be administered on D1 of every standard of care cycle (either 14, 21, 28, or 42 day cycle) at the standard dose. Participants can receive up to 1 year of SOC immunotherapy.
88821296|NCT04612140|Experimental|Radiosurgery|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
88821297|NCT04612140|Active Comparator|Repeated catheter ablation|Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
88821300|NCT04592861|Experimental|Carbon ion radiotherapy|Carbon ion radiotherapy will be administered 5 days each week (Monday-Friday). The prescription dose will be 60 GyE in 20 fractions, to be delivered over four weeks.
88821301|NCT04592861|Active Comparator|Routine standard of care|Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.
88821302|NCT04564560||Patients treated with Zenith Alpha Spiral-Z®|Patients that from January 2017 until December 2019 received endovascular aortic repair with the Zenith Alpha Spiral-Z® at St. Olavs Hospital
88821337|NCT04447703|Experimental|Aim I (Interview)|Providers attend an interview over 1 hour to discuss how they would use the tool, then receive the tool to test in their clinic for 2 weeks. After 2 weeks, providers discuss their experience using the tool over 10-15 minutes. Providers have the option to use the tool for up to 6 months and complete a brief survey about the benefits and limitations of the tool for patient identification in Arm II.
88821304|NCT04556045|Experimental|Radiation Therapy + Exercise Therapy|This group will receive exercise intervention in addition to their standard of care radiation treatment. At the baseline visit, they will meet with the certified exercise trainer (CET) and will be provided with a personalized exercise prescription and log to record what they do in between daily radiation treatment visits. The participant will also undergo an in-person exercise session prior to radiation therapy, which will take place either on the same day that the physical function tests are preformed or on a separate day. Participants will exercise between 1 and 7 times/week depending on the patient's tolerance to the exercise prescription. The CET will meet with the participant at every radiation treatment visit for an exercise counseling check-in. After five radiation treatments, the CET will follow-up with the participants via phone call once per week for 4 weeks during the follow-up period.
88821305|NCT04556045|No Intervention|Radiation Therapy|The observational group will continue with their usual standard of care of radiation therapy. The study team will provide patients with an educational pamphlet at the end of their baseline visit. They will also be provided with a self-directed exercise program framework. Additionally, the participant's medical record will be reviewed for serious adverse events during their time on study. Baseline and final measurements will be obtained.
88821306|NCT04551144||Transmen|Subjects starting testosterone therapy as part of standard of care for gender incongruence
88821307|NCT04551144||transwomen|Subjects starting estradiol therapy as part of standard of care for gender incongruence
88821308|NCT04547712|Experimental|aDBS Single Threshold|Adaptive DBS Single Threshold Mode
88821309|NCT04547712|Experimental|aDBS Dual Threshold|Adaptive DBS DualThreshold Mode
88821310|NCT04546425|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
88821311|NCT04546425|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
88821312|NCT04542551|Active Comparator|Without stricture - dilation with 60-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 60-Fr dilator
88821313|NCT04542551|Sham Comparator|Without stricture - dilation with 15-Fr|Patients without stricture on upper endoscopy will receive empiric dilation with 15-Fr dilator (sham)
88821314|NCT04542551|Active Comparator|Non severe stricture - dilation with 60-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 60-Fr dilator
88821315|NCT04542551|Active Comparator|Non severe stricture - dilation with 46-Fr|Patients with non-severe stricture on upper endoscopy will receive dilation with 46-Fr dilator
88821316|NCT04542551|Active Comparator|Severe stricture - dilation with 51-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 51-Fr dilator
88821317|NCT04542551|Active Comparator|Severe stricture - dilation with 42-Fr|Patients with severe stricture on upper endoscopy will receive dilation with 42-Fr dilator
88821318|NCT04537949|Experimental|Part A participants aged 18 to 55 years|Escalating dose levels
88821319|NCT04537949|Experimental|Part A participants aged 56 to 85 years (optional)|Escalating dose levels
89530114|NCT03256591|Experimental|HBB plus simulation training|Participants receive training from facilitators for HBB training with simulation skills
89530115|NCT03256591|No Intervention|Control|Participants receive training from facilitators for HBB training without simulation skills
88821322|NCT04523922|Experimental|Oxytocin Treatment Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin.~40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session."
88821323|NCT04523922|Active Comparator|Placebo Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus placebo (intranasal saline spray).~Intranasal dose of saline spray self-administered 30 minutes prior to the start of each weekly COPE session."
88821324|NCT04515810|Experimental|Arm I (PACT)|Participants use PACT mHealth app.
88821325|NCT04515810|Active Comparator|Arm II (standard care)|Participants engage in standard care with no modifications.
88821326|NCT04505007|No Intervention|Usual clinical care|In this arm, patients with devices and heart failure will undergo usual clinical care. This consists of follow-up as deemed necessary by their primary care providers.
88821327|NCT04505007|Experimental|Specialized clinic|"In this arm, patients with devices and heart failure will be enrolled in a specialized clinic with the following aims:~Referral to a heart failure nurse practitioner to undergo optimization of medical therapy.~Optimization of device programming with reduction of ventricular pacing where possible, rate responsiveness when indicated.~For those patients with CRT - ECG optimization using a previously tested protocol will be performed. This will consist of attempts to achieve the shortest QRS duration with the following guidelines:~Two BV fusion patterns in leads V1 and V2: QRS normalization or a new or an increased R wave.~QRS difference ≤-25 ms. Remodelling probability increases as QRS difference takes on larger negative values (QRS difference = BV paced QRS - LBBB QRS duration, in ms)."
88821328|NCT04493034|Experimental|Art Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
88821329|NCT04493034|Experimental|Music Therapy|Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
88821330|NCT04493034|No Intervention|Standard Of Care|A list of support services is provided. No requirement to attend sessions and no home assignments
88821331|NCT04463641|Experimental|Axone 4LV Lead|Subjects implanted with the Axone 4LV Lead
88821332|NCT04457336|Experimental|Tildacerfont Group 1|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1
88821333|NCT04457336|Experimental|Tildacerfont Group 2|Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2
88821334|NCT04457336|Experimental|Tildacerfont Group 3|Tildacerfont administered daily via oral tablet for 70 weeks at dose level 3
88821335|NCT04457336|Placebo Comparator|Placebo|Placebo administered daily via oral tablet for 12 weeks.
88821336|NCT04452357|Experimental|PLDR Chemoradiation|"Patients will receive pulse-low-dose rate radiation, along with gemcitabine chemotherapy.~6 patients each will be accrued at two dose levels. PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows: Dose level 1: 56 Gy; Dose level 2: 66 Gy"
89530116|NCT03250429||CRS subjects|CRS subjects who have sinus surgery
88821403|NCT04269213|Experimental|Treatment (CPX-351)|"INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Patients who do not achieve remission receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Beginning 5-8 weeks after the start of the last induction, patients who achieve CR receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 45 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity."
88821404|NCT04263584|Experimental|Copanlisib and R-CHOP chemotherapy|All patients will receive 6 cycles of R-CHOP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/ m², vincristine 1.4 mg/m² (dose capped at 2 mg or 1 mg for individuals above 60 years of age), prednisolone 500 mg. In addition, copanlisib at a dose of 60 mg will be administered on days 1 and 8 of each 21-day cycle of R-CHOP in the first 6 patients. If dose limiting toxicity (DLT) occurs in no more than one out of these 6 patients during cycle 1, additional 6 patients at 60 mg will be enrolled and treated for at least 1 cycle before opening the phase II portion of the study. If a DLT is observed in 2 or more of the first 6 patients during cycle 1 the dose of copanlisib will be reduced to 45 mg on days 1 and 8 for the next 6 patients. The data of the safety run-in analysis (first 12 patients) will be presented to the Data Safety Monitoring Board and the recommended phase 2 dose will be determined.
88821405|NCT04249362|Experimental|Cohort A|Patients received standard radiotherapy [60 gray (Gy) ± 10% or hypofractionated BED] prior to study entry.
88821406|NCT04249362|Experimental|Cohort B|Patients received palliative radiotherapy [40 to < 54 Gy or hypofractionated BED] prior to study entry.
88821407|NCT04241627|Experimental|Cell Phone Support|An adherence facilitator will deliver Cell Phone Support by daily phone calls Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
88821408|NCT04241627|Experimental|Live Text Support|An adherence facilitator will deliver Live Text Support, Monday through Friday for 12 weeks, to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services.
88821409|NCT04241627|Active Comparator|Automated Text Reminders|"The comparison condition will include automated text message reminders, using this template: Take [name of medication] at [set time]. To confirm intake, press REPLY, type CARE 1, and press SEND."
88821410|NCT04238728|Experimental|Silverlon arm|Silverlon is a silver-nylon dressing approved for treatment of burns and wounds. In this study, the Silverlon dressing will be applied to the whole breast area receiving radiation therapy throughout the prescribed course of radiation therapy starting the first day of radiation therapy and until two weeks post-radiation. The Silverlon dressing will be held in place by a bra and worn daily except when bathing/showering, received radiation therapy, or swimming. Subject document when they remove the dressing and apply the dressing every day.
88821411|NCT04236804|Experimental|TMC-CP01 Intervention|Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines.
88821412|NCT04236804|No Intervention|Standard of Care|Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
88821413|NCT04231877|Experimental|Treatment (polatuzumab vedotin, combination chemotherapy)|Patients receive rituximab IV on day 1, polatuzumab vedotin IV on day 1, prednisone PO BID on days 1-5, etoposide IV on days 1-4, doxorubicin IV on days 1-4, and cyclophosphamide IV on day 5. Patients also receive filgrastim SC 24-72 hours after the last dose of each treatment cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
88821414|NCT04228172||Parkinson's disease (PD) glucocerebrosidase (GBA) carriers|Parkinson's disease subjects with GBA mutation
88821415|NCT04228172||Parkinson's disease (PD) non glucocerebrosidase (GBA) carriers|Parkinson's disease subjects without GBA mutation
88821416|NCT04227379|Experimental|DD-TXT|Participants in this group will be signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol will consist of: Core Messaging: Customizable core modules on medication management, blood sugar and blood pressure monitoring, preventive care, problem solving, appointment reminders, administrative messages; and Optional Messaging: A library of patient-selected modules (e.g. nutrition, physical activity, weight management, emotional coping, goal setting) designed to motivate and educate.
88821417|NCT04227379|Active Comparator|DSE|"The comparison condition will be signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE contains only one-way educational content consisting only of content from the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, which was created in alignment with VA/DoD diabetes guidelines and is recommended for patients as part of usual care. Everyone in the DSE arm will receive the same daily text messages taken verbatim or almost verbatim from the content of the workbook but shortened to fit the 160-character limit of a text message. There will be no customizable or interactive content for the DSE arm."
88821418|NCT04224636|Experimental|Up-front Atezo/Bev, then TACE|Patients will receive atezolizumab and bevacizumab iv every three weeks for up to 24 months. Upon detection of at least one unequivocal progressive hepatic lesion, selective TACE directed against progressive lesion(s) (sdTACE) will be performed. RFA or MWA are permitted as alternative to TACE to treat one or more lesion that cannot be reasonably selectively targeted by TACE
88821419|NCT04224636|Experimental|Atezo/Bev combined with TACE|First TACE will be performed as selectively as possible against all viable tumor lesions. Atezo/Bev will be initiated within three days from TACE. Upon detection of at least one unequivocal progressive hepatic lesion, treatment with Atezo/Bev will be continued if RFA or MWA can be used to treat this/these progressive lesion.
88821420|NCT04200352|Experimental|TEV-50717|The dose of the TEV-50717 should be increased on a weekly basis to reach a clinically meaningful reduction in dyskinesia, as indicated by a reduction in the Clinical Global Impression of Improvement;(CGI-I).
88821421|NCT04194840|Experimental|Transplant Wellness Clinic|"Physical therapy consult~Intake vitals~CARG online survey, mental status exam~Medication review~Nutrition survey~Social work: available on prn basis (as-needed)~Exit survey~Recommendations made and given to the participant and sent to the referring MD. Participant receives post clinic phone call before transplant. Referring MD receives questionnaires. Data collected depending on if participant moved forward with transplant"
88821672|NCT02992782|Experimental|Exercise and Compression Garment|Intervention will include having participants wear a compression sleeve during exercise. They will wear the sleeve while carrying out the decongestive progressive resistance exercise program and will continue wearing their day-time compression garment for at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 Weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness center or at home.
88821673|NCT02992782|Experimental|Exercise and Adjustable Compression Wrap|Intervention will include having participants will be fitted for an adjustable compression wrap. They will be required to wear the adjustable compression wrap during the decongestive progressive resistance exercise program and will continue wearing their compression sleeve at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness centre or at home.
88821674|NCT02959021|Active Comparator|Self-directed treatment|Participants randomly assigned to this arm will receive written and pre-recorded behavioral weight loss intervention materials (i.e., DVDs, online videos), and they will be instructed to work through the materials independently at their own pace. They will have continued physician contact as needed for routine medical care.
88821675|NCT02959021|Experimental|Peer coach treatment|Participants randomly assigned to this arm will receive a combination of in-person, group-based behavioral weight loss sessions plus individual, telephone contacts. Groups and phone calls will be facilitated by a peer coach interventionist. Similar to the self-directed condition, participants will receive written and pre-recorded intervention materials (i.e., DVDs, online videos). They will also have continued contact with their physician for routine medical care.
88821676|NCT02948621||Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
88821677|NCT02915198|Experimental|Metformin|Participants receive initial treatment with metformin XR 500 mg 1 tablet daily, with stepwise titration to a maximum dose of 2000 mg (4 tablets) daily.
88821678|NCT02915198|Placebo Comparator|Placebo|Participants receive initial treatment with 1 tablet daily of placebo (for metformin XR), with stepwise titration to a maximum of 4 tablets daily.
88821679|NCT02913482|Experimental|Part 1 (Dose Finding): Risdiplam (RO7034067)|Participants will receive multiple ascending doses of risdiplam (RO7034067), administered orally once daily for a minimum of 4 weeks to select the dose for Part 2. During the first year of treatment, most participants will switch to the Part 2 dose. During the second year of treatment, all Part 1 participants will be receiving the Part 2 dose. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
88821680|NCT02913482|Experimental|Part 2 (Confirmatory): Risdiplam (RO7034067)|Participants will receive risdiplam (RO7034067), administered orally once daily at the dose defined in Part 1 of the study, for a duration of 24 months. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
88821681|NCT02838420|Experimental|Alectinib|Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.
88821682|NCT02838420|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.
88821683|NCT02802553|Experimental|Integrated Imaging Goggles|Cardio-GreenTM (indocyanine green) peritumorally injected to breast tumor with 1 cycle. Viewed by Smart Googles and compare lesions detected by commercial FDA approved near infrared camera device (SPY Elite/Quest/PDE) in addition to those detected by gamma probe and blue dyes.
88821684|NCT02757859|Active Comparator|Arm I (EIPL-S)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive EIPL-S lavage 10 times over 15 minutes.
88821685|NCT02757859|Active Comparator|Arm II (EIPL-D)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive EIPL-D lavage 10 times over 15 minutes.
88821686|NCT02757859|Sham Comparator|ARM III (NO LAVAGE)|Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy with no extensive lavage after removal of tumor.
88821687|NCT02744677|Experimental|TPVR - Main Cohort|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
88821688|NCT02744677|Experimental|TPVR - THV Registry|Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.
88821689|NCT02744677|Experimental|TPVR- S3UR Registry|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
88821690|NCT02736669|Active Comparator|Fixed Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to reduce their food intake by a moderate amount and stay at this level of moderate reduction until their weight loss goal is achieved.
88821691|NCT02736669|Experimental|Variable Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to alternate between two levels of calorie reduction. One level will be a small amount of calorie reduction, while the other will be a more significant amount of calorie reduction. At the instruction of the research team, participants will periodically alternate back and forth between these two goals until their weight loss goal is achieved.
88821692|NCT02728076|Experimental|Radiation Therapy followed by Lumpectomy|Phase II-Preoperative MRI-BasedRadiation followed by Lumpectomy
88821693|NCT02719613|Experimental|Elotuzumab|This is a continuation roll-over study for patients receiving benefit from prior elotuzumab protocols. All participants will receive elotuzumab and/or other study drugs as per previous protocol.
88821760|NCT01815749|Experimental|Treatment (genetically modified T cell infusion)|Patients undergo mobilization for autologous stem cell collection with cytoreductive chemotherapy and filgrastim and/or plerixafor per current standard operating policies. Patients undergo myeloablative conditioning regimen per institutional standards beginning day -7 followed by hematopoietic stem cell transplantation on day 0. Patients receive CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells IV on day 2 or 3 (may be delayed up to day 45 if the patient is not yet eligible). Patients who experience disease progression and have not experienced DLTs at greater than or equal to 100 days post HSCT will be allowed to receive an optional second T cell infusion.
89530117|NCT04503083||Migraine patients|"Excellent responder, a patient who experiences a >75% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;~Responder, a patient who experiences a >50% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline;~Non responder, a patient who experiences a decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days ranging from 26 to 49% during the last 4 weeks of treatment as compared to baseline;~Full non responder, a patient who experiences a <25% decrease of either the monthly number of migraine days or the monthly number of moderate/severe headache days during the last 4 weeks of treatment as compared to baseline."
89530118|NCT03256279|Experimental|Heat-activated archwire|".014 NiTi heat-activated archwire in the lower arch during the first three months of the orthodonci treatment"
89530119|NCT03256279|Active Comparator|superelasticwire|"This arm are going to receive .014 NiTi Superelastic archwire in the lower arch during the first three months of the orthodonci treatment"
89530120|NCT02914483|Other|Enhanced Usual Care (EUC)|
89530121|NCT02914483|Other|Stress Management|
89530122|NCT03256123|Experimental|red palm shortening group|A group receiving the supplementation of red palm shortening biscuits. The subjects are expected to receive 630 µg RE of vitamin A/day by consuming the biscuits four days a week.
89530123|NCT03256123|Placebo Comparator|palm shortening group|A group receiving supplementation of palm shortening biscuits with corresponding fatty acids as red palm shortening group.
89530124|NCT03350867|Experimental|Personalized Insole Group|The participants will use insole with personalized support directed to your biomechanics necessities.
89530125|NCT03350867|Placebo Comparator|Placebo Group|The participants will use plane insoles.
89530126|NCT03256357|Active Comparator|CIMT + AOT|"In a 2-week day camp model children receive constraint-induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Action observation training consists of 15 sessions of 1 hour. Children watch video sequences showing goal-directed actions and subsequently execute the observed actions with the affected upper limb."
89530127|NCT03256357|Placebo Comparator|CIMT + POT|"In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Placebo observation training consists of 15 sessions of 1 hour.This group performs the same actions after watching computer games without biological movements."
89530128|NCT03350789|Experimental|Real acupuncture|manual acupuncture + electroacupuncuture on acupoints, twice a week, for 4 weeks
89530129|NCT03350789|Sham Comparator|Sham acupuncture|sham acupuncture (no skin penetration) + placebo electroacupuncture without electrical stimulation on acupoints, twice a week, for 4 weeks
89530130|NCT02517983||Chronic respiratory disease|
89530131|NCT03438331|Experimental|CBT-I|
89530132|NCT03438331|Active Comparator|CBT-D|
89530133|NCT03438331|No Intervention|Waiting-list control|
89530134|NCT05585489|Experimental|Persons with moderate idiopathic Parkinson's disease|
89530135|NCT03346967|Experimental|Stem cell Administration for female patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients
89530136|NCT03346967|Experimental|Stem cell Administration for male patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients
89530137|NCT03348293|Experimental|3D printing patient|Immediate breast reconstruction using 3D printing personalized scaffold
89530138|NCT03036683|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.
89530139|NCT03036683|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
89530140|NCT02888249|Experimental|Cigarette W|"Altered composition cigarettes~moisture = 12.20 %, tar = 10.40 mg/cigarette, total particulate matter = 12.0 mg/cigarette, high sugar content"
89530141|NCT02888249|Experimental|Cigarette X|"Altered composition cigarettes~moisture = 12.10 %, tar = 8.60 mg/cigarette, total particulate matter = 9.60 mg/cigarette, low sugar content"
89530142|NCT02888249|Experimental|Cigarette Y|"Altered composition cigarettes~moisture = 13.20 %, tar = 9.10 mg/cigarette, total particulate matter = 10.10 mg/cigarette, low sugar content"
89530143|NCT02888249|Experimental|Cigarette Z|"Altered composition cigarettes~moisture = 13.60 %, tar = 8.10 mg/cigarette, total particulate matter = 9.10 mg/cigarette, low sugar content"
89530144|NCT03348137||Ancillary-Correlative (questionnaire)|Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation.
89530538|NCT03246763|Experimental|Richmond/Montgomery Counties|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
89530539|NCT03246763|Experimental|TBD|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
89530540|NCT03246763|Experimental|To be determined|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
89530541|NCT02512991||HEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Helicopter Emergency Medical Service (HEMS) in a 36-month period (May 1st 2010 - April 30th 2013).
89530542|NCT02512991||GEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Ground Emergency Medical Service in a 40-month period (January 1st 2010 - April 30th 2013).
89530543|NCT02513147|Experimental|2 NRTI+ Dolutegravir|22 patients will be treated with 2 NRTI+Dolutegravir 50 mg during 24 weeks
89530544|NCT02513147|Active Comparator|2 NRTI + PI|22 patients will be treated with 2 NRTI + PI during 24 weeks
89530545|NCT03121781|Active Comparator|CPAP with binasal prongs|Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.
89530546|NCT03121781|Active Comparator|CPAP with RAM cannula|Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours.
89530547|NCT03246685|Experimental|Pembrolizumab Failures|Imprime PGG + Pembrolizumab
89530548|NCT03246685|Experimental|Active Stable Disease on Pembrolizumab|Imprime PGG + Pembrolizumab
89530549|NCT03121625|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells.
89530550|NCT02453893|Experimental|oral iloperidone|2~12mg/day for 2 weeks,12~24mg/day for 6 weeks.
89530551|NCT02453893|Active Comparator|oral risperidone|1~3mg/day for 2 weeks,3~6mg/day for 6 weeks.
89530552|NCT03707093|Experimental|ADG106 Dose escalation|
89530553|NCT03238885||LARC-CRT|LARC patients who will receive neoadjuvant CRT before surgical resection.
89530554|NCT02513069|Experimental|Mobile Contingency Management (mCM)|"The mCM arm represents a proactive tele-health intervention that combines guideline based cognitive-behavioral smoking cessation telephone counseling, a tele-medicine clinic for access to nicotine replacement therapy (NRT), and intensive behavioral therapy administered via a smart phone (with carbon monoxide monitor) based application. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
89530555|NCT02513069|Active Comparator|Tele-Health for Smoking Ccessation|"TELE-HEALTH FOR SMOKING CESSATION is a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same guideline based cognitive-behavioral smoking cessation telephone counseling, and tele-medicine clinic for access to NRT as in the mCM intervention. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
89530556|NCT03244111|Active Comparator|Healthy Cognition|The intervention will be carried out as described in the study details using the simple memory tool. The group with healthy cognition may perform better on tasks since they have a higher level of cognition.
89530557|NCT03244111|Active Comparator|MCI|The intervention will be carried out as described in the study details using the simple memory tool. The group with MCI may have a lower level of performance on tasks since they have a lower level of cognition. Some tasks may take longer for the participant or need more explanation from the researcher (e.g., explanation of a question).
89530562|NCT02454205|Active Comparator|Conventional treatment 21-24 months|"Participants will receive a 6-8 month intensive phase of: Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily,Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~The continuation phase will start after 2 consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone.~In 2016 the WHO revised the treatment guidelines for MDR-TB. The South African National Tuberculosis Program adopted these recommendations and it was integrated into the study in September 2016: SA NTP recommended shorter regimen(9-12 months):Intensive phase (4-6 months): kanamycin, levofloxacin, clofazimine, pyrazinamide, high-dose isoniazid/ethionamide, ethambutol. Continuation phase (5 months): levofloxacin, clofazimine, pyrazinamide, ethambutol."
89530563|NCT02454205|Experimental|Interventional treatment 6-9 months|"Participants will receive six to nine months of oral:~Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (<50kg) or 1000mg (>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures."
89530564|NCT03243877||Breast Cancer Positive|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were positive.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
89530565|NCT03243877||Breast Cancer Negative|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were negative.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
89530566|NCT02515721|Experimental|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
89530567|NCT02515721|Experimental|Virtual Chromoendoscopy -SB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
89530568|NCT03238729|Experimental|CHF App|Patients will be provided with a mobile app on a smartphone for education and management of heart failure.
89530569|NCT03238729|Active Comparator|Standard of Care|Patients will be provided standard literature on heart failure management.
89530570|NCT03238339||The Portable Home Noninvasive Ventilator treatment group|The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
89530571|NCT03238339||Routine home oxygen therapy group|The patient maintained a stable COPD regimen and conventional home oxygen therapy.
89530572|NCT02515409||CPAP|CPAP, as a first line treatment to OSAS.
89530573|NCT02515409||HHHFNC|Treatment with HHHFNC after CPAP treatment fails.
89530574|NCT03238573||optical enhancment endoscopy|
89530575|NCT02512757||Group 1|Patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer will contribute a fasting blood sample.
89530576|NCT02512757||Group 2|Patients whose most recent screening imaging is within 60 days who have lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for >2 years by repeat CT imaging will contribute a fasting blood sample.
89530577|NCT02512757||Group 3|Patients who have undergone low-dose computed tomography (LDCT) or standard computed tomography (CT) or X-ray testing to screen for lung cancer with no nodules suspicious for lung cancer within 1 year prior to signing informed consent will contribute a fasting blood sample.
89530578|NCT02515487|Experimental|Breast cancer patients receiving chemotherapy treatment|
89530579|NCT04486339|Experimental|stereotactic body radiotherapy (SBRT)|Noninvasive SBRT will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.
89530580|NCT03345329||Periodontal patient|
89530581|NCT03345329||Healthy person|
89530582|NCT03345329||Peri-implantitis patient|
89530583|NCT03243799|Experimental|Intervention Group|"The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms.~Group psychoeducation."
89530584|NCT03243799|No Intervention|Control Group|Usual clinical care
89530585|NCT03345251|Experimental|manipulation of endometrium|The arm is physical manipulation to the endometrium prior to ICSI By one of these interventions )Hydrotubation , Sonohysterography or endometrial scratching
89530586|NCT03345251|Placebo Comparator|no manipulation to endometrium in ICSI|This is the control group , with no manipulation to endometrium prior to ICSI No intervention to this group
89530587|NCT03235141|Experimental|azithromycin eye drops by essex|In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.
89530588|NCT03235141|Active Comparator|AzaSite|In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.
89530589|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel A|IV nesiritide 3 pmol/kg/min or placebo for nesiritide
89530590|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel B|IV nesiritide 2 pmol/kg/min or placebo for nesiritide
89530591|NCT03397589|Experimental|CHW Arm|The intervention is community health worker (CHW) services. CHWs trained in oral health will be assigned to half of the sites. Participants in these sites will be offered four in-person visits and follow-up phone calls over 12-months. These visits can occur at the location of the family's preference (recruitment site, home, or mutually-agreed upon other location). A core curriculum of oral health topics will be covered during visits, with an emphasis on developing and sustaining healthy oral health management routines for the entire family.
89530873|NCT02501057|Active Comparator|Enhanced Motivational Interviewing|Participants meet with a counselor to discuss their alcohol use, the impact it has on their health, and the possibility of reducing their drinking. The first counseling session is intended to help participants reduce their alcohol use. They are asked to describe the pros and cons of their alcohol use and whether it might be important to reduce or quit drinking. After, they are given a study smartphone and asked to use HealthCall-S daily to help keep track of their drinking. At 30 days, participants review a graph showing the results of HealthCall-S use and discuss it with the counselor. They also have a brief discussion about drinking patterns and goals for reduction. They are then asked to continue using HealthCall-S for the next 30 days, after which the counselor meets with the participant for another brief interview to go over the updated graph, and to discuss their experience with HealthCall-S. They will also have a brief discussion about drinking patterns and goals for reduction.
89530874|NCT02501057|Experimental|Enhanced Clinician's Guide|Participants in this group receive the Clinician's Guide intervention paired with daily use of HealthCall-S, which includes two cycles of daily use of HealthCall for 30 days, followed by personalized feedback in the form of a graph with a clinic staff member.
89530875|NCT02509091|Experimental|The experimental group|fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)
89530876|NCT02509091|No Intervention|The controlled group|fundamental treatment(including anti-infection,eliminating phlegm,oxygen therapy etc.)
89530877|NCT04495361|Experimental|Online learning portal|Final year medical students will use an online learning portal in which three case scenarios of under five pneumonia patients will be displayed each month. Based on history and examination, the user will diagnose and manage the patient.
89530878|NCT03343223|Experimental|Intervention Group|"Public health personnel identify PrEP-eligible clients.~PrEP-eligible clients are given a list of PrEP providers in Iowa and a brochure with info on getting PrEP. Clients are referred to a PrEP navigator, who facilitates linkage to clients' choice of TelePrEP or to community PreP providers.~Public health clients choosing TelePrEP complete a video visit with the tele-pharmacist and obtain PrEP relevant lab tests.~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
89530879|NCT03343223|No Intervention|Control Group|"Public health personnel identify PrEP-eligible.~Public health personnel give PrEP-eligible clients a list of PrEP providers in Iowa, and a brochure with information on getting PrEP.~The client initiates contact with a PrEP provider in Iowa and schedules an appointment.~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
89530880|NCT03343145|Experimental|Test Drug Group|Leucostim 5µg/kg/day
89530881|NCT03343145|Active Comparator|Reference Drug Group|Neupogen 5µg/kg/day
89530882|NCT02508857|Active Comparator|ketorolac|intravenous ketorolac (30 mg) is injected in bolus, followed by continuous infusion of saline solution (Group K) during the surgical procedure
89530883|NCT02508857|Experimental|magnesium|intravenous magnesium sulfate (20 mg/kg) is injected in bolus, followed by continuous infusion of magnesium sulfate (2 mg/kg/h) (Group M) during the surgical procedure
89530884|NCT02508857|Placebo Comparator|saline|intravenous saline solution (20 ml) is injected in bolus, followed by continuous infusion of saline infusion during the entire procedure (Group S).
89530885|NCT02509169|Experimental|TAE plus p53 gene|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
89530886|NCT02509169|Active Comparator|TAE|Trans-catheter embolization (TAE) will be given once per month
89530887|NCT02508779|Experimental|Bump2Be|Blood Glucose Awareness Training for pregnancy or preconception
89530888|NCT02508779|Active Comparator|Routine Care|Routine care provided by subject's medical team
89530889|NCT02500823||CHD group|200 consecutive patients were recruited, who have diagnosed with coronary heart disease(CHD) by coronary angiography.
89530890|NCT02500823||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
89530891|NCT02508623|Experimental|Rifaximin|Rifaximin 550 mg 1 tablet BID for 60 days
89530892|NCT02508623|Placebo Comparator|Placebo|Placebo 1 tablet BID for +60 days
89530893|NCT02508545|Other|perceived egocentric distance measurements - parabolic flight|perceived egocentric distance (PED) measurements during parabolic flight
89530894|NCT02500745||Transesophageal echocardiography|Patients referred for transesophageal echocardiography for a clinical indication
89530895|NCT04498637||Physiotherapy students|Students enrolled in the Physiotherapy Bachelor´s Degree of the University of Cadiz, Spain
89530896|NCT04498637||Nursing students|Students enrolled in the Nursing Bachelor´s Degree of the University of Cadiz, Spain
89530897|NCT02500667|Experimental|N91115 + Rifampin|N91115 200 mg twice daily (BID) from Study Day 1- 13, Rifampin 600 mg once daily (QD) from Study Day 8 - 12
89530898|NCT02500355|Active Comparator|Group A|Carpal Tunnel Release via limited approaches with 2 years follow-up.
89530899|NCT02500355|Active Comparator|Group B|Carpal Tunnel Release via standard approach with 2 years follow-up.
89530900|NCT02500355|Placebo Comparator|Group C|Endoscopic Carpal Tunnel Release with 2 years follow-up.
89531146|NCT02497625|Experimental|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
89531088|NCT05043909|Experimental|Experimental Group (EG)|The students in EG received VR-based training for elderly oral health care at 2-week (Time 2), 4-week (Time 3), and 6-week (Time 4) follow-ups. The learning module was divided into three sessions according to the physical condition (1) Mild disability, (2) Semi-disability, (3) Total disability and oral condition, (1) wearing dentures, (2) missing teeth of the elderly. Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
89531089|NCT05043909|No Intervention|Control Group (CG)|The students in CG do not receive any of the interventions. However, the same VR-based curriculum of oral health care on dependency elderly were provided at the end of the study.
89531090|NCT05035563|No Intervention|Traditional communication management (Pre-intervention)|"Traditional communication practices are maintained, which consists of reporting the patient's medical conditions or specific requirements of the case, between the health team and the family.~According to the social and administrative conditions of each centers, medical telephone information is provided on the conditions of the patients."
89531091|NCT05035563|Experimental|Early and integral communication strategy (EICS) (Post-intervention)|"EICS that includes a bundle of various strategies that allow to favor communication and contact between family members, patients and health team.~That considers the delivery of: (1) Receive timely and understandable information; (2) Receive visits, companionship, and spiritual assistance"
89531092|NCT03342443|Experimental|memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
89531093|NCT03342443|Placebo Comparator|placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
89531094|NCT02498093|Experimental|Maximal strength training|Maximal strength training supervised by a physiotherapist
89531095|NCT02498093|Active Comparator|Control|Conventional rehabilitation supervised by a physiotherapist
89531096|NCT02498015|Experimental|"3D regimen"|"The 3D regimen contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, and one dasabuvir tablet (250 mg) twice daily for genotype 1b without cirrhosis. Treatment will be 12 weeks."
89531097|NCT02498015|Experimental|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, one dasabuvir tablet (250 mg) twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a (with/without) and genotype 1b with cirrhosis. Treatment will be for 12 weeks."
89531098|NCT05043753|No Intervention|Control group: Symphysis fundal height measurement|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNMs) using symphysis fundal height (SFH)
89531099|NCT05043753|Experimental|intervention group: Symphysis fundal height measurement and point of care ultrasound.|Screening for fetal growth abnormalities is performed by certified nurse midwives (CNM) using symphysis fundal height (SFH) and point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)
89531100|NCT05043597|Experimental|Thrombus aspiration|
89531101|NCT05043597|No Intervention|control group|
89531102|NCT03340571||Alzheimer's Patients|
89531103|NCT03340571||Healthy Volunteers|
89531104|NCT02494505|Experimental|mycophenolate mofetil|
89531105|NCT02494505|Placebo Comparator|placebo|placebo pills
89531106|NCT03340493|Active Comparator|Assigned Interventions|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
89531107|NCT03340493|Experimental|Tenecteplase|Patients will receive intravenous tenecteplase (0.4mg/kg, maximum 40mg, administered as a bolus over ~10 seconds).
89531108|NCT03096795|Placebo Comparator|Part 1: Placebo|Healthy participants with a history of mild atopy and proven sensitivity to house dust mite (HDM) will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously.
89531109|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 1|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 subcutaneously.
89531110|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 2|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 2 subcutaneously.
89531111|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 3|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 3 subcutaneously.
89531112|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 4|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 4 subcutaneously.
89531113|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 5|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 5 subcutaneously.
89531114|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 subcutaneously.
89531115|NCT03096795|Experimental|Part 1: MEDI3506 IV Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 intravenously.
89531116|NCT03096795|Placebo Comparator|Part 2: Placebo|Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
89531117|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 4|Participants with COPD will receive 3 administration of MEDI3506 Dose 4 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
89531381|NCT05051319||Elderly participants living at home|Participants over the age of 65, living at home, not having mental and communication problems that would prevent the evaluations, and volunteering to participate in the study. The sociodemographic information of the participants such as gender, duration of education, living environment and people with whom they live were recorded. In addition, information about the medical condition of geriatric individuals, such as body mass indexes and the number of drugs used, was also recorded in the form. In order to evaluate the cognitive status of the participants, the Standardized or Standardized Mini-Mental Test for the Uneducated was used according to their educational status. The Center for Disease Control Health-Related Quality of Life-4 Scale (CDC HRQoL-4) was used to assess quality of life, and the Geriatric Depression Scale was used to assess emotional status. In addition, the presence of pain and pain levels according to body regions were determined with a 6-point Likert-type scale.
89531382|NCT03336125|Experimental|Vitamin D group|Intervention is vitamin D supplement
89531383|NCT03336125|Placebo Comparator|Control group|Placebo capsule contains olive oil
89531384|NCT05051163|Experimental|Ceftriaxone|Ceftriaxone will be administered intravenously at a dose of 50 - 75mg/kg once daily
89531385|NCT05051163|Active Comparator|Ampicillin and Gentamicin|"Ampicillin will be administered intravenously at a dose of 50mg/kg 6hourly~Gentamicin will be administered intravenously at a dose 5mg/kg once daily"
89531386|NCT03337295||Low-MGD|
89531387|NCT03337295||High-MGD|
89531388|NCT06067412|Active Comparator|levetiracetam|"levetiracetam at a dose of 30 mg/kg diluted in 50 ml of normal saline in 15 minutes followed by a maintenance dose of 30mg/kg/day divided in two doses 12 hours apart after initial loading dose.~if seizures recurred after the first loading dose an additional 10mg/kg of the same drug was given over 10 minutes. If seizures recurred, the patients were loaded with sodium valporate 30 mg/kg diluted in 50 ml normal saline in 15 minutes."
89531389|NCT06067412|Active Comparator|phenytoin|"I/V phenytoin at 20 mg/kg diluted in 50ml normal saline in 15 minutes followed by maintenance dose of 5 mg/kg/day divided in two doses 12 hours apart.~if seizures recurred after the first loading dose an additional 10mg/kg of the same drug was given over 10 minutes. If seizures recurred, the patients were loaded with sodium valporate 30 mg/kg diluted in 50 ml normal saline in 15 minutes."
89531390|NCT06067386|Experimental|Intervention arm|For each E. coli positive urine culture analyzed by LabOuest, GPs will receive an antibiotic susceptibility testing report, with the list of antibiotics restricted according to four E. coli susceptibility profiles, with an emphasis on narrower-spectrum antibiotics. The selected antibiotic susceptibility testing was developed following a targeted literature review and consultation with a steering committee including GPs, biologists and infectiologists. At the GP's request, a full antibiogram can be provided.
89531391|NCT06067386|Active Comparator|Control arm|GPs will receive a standard antibiotic susceptibility testing report for each E. coli positive urine culture.
89531392|NCT06067373||patients with postponed surgery|patients with postponed surgery
89531393|NCT06067360|Experimental|sleeve|Evaluation of IFIS sleeve performance
89531394|NCT06067334|Active Comparator|Conventional (Open tray impression technique)|After osseointegration, a conventional open tray splinted impression technique will be made for each patient on the implant/abutment level.
89531395|NCT06067334|Active Comparator|Digital impression|Scan bodies implant level/abutment level will be tightened for each patient, and a digital intraoral scanner will be used to scan the scan bodies for making implant level/abutment level digital impressions.
89531396|NCT06067321|Active Comparator|4 hours formula feed|Parents asked to offer formula feed 4 hours prior to anticipated procedure start
89531397|NCT06067321|Active Comparator|6 hour formula feed|Parents asked to offer formula 6 hours prior to anticipated procedure start
89531398|NCT06067308|Experimental|to assess the sensitivity and accuracy of YEARS score in the diagnosis of PE.|50 patients with suspected PE were evaluated in Chest Department at faculty of medicine, Kasr Al-Ainy Hospital. At the beginning, clinical evaluation using YEARS score was done; subsequently for definitive diagnosis, computed tomography pulmonary angiography was performed in all cases as a reference method.
89531399|NCT06067152|Active Comparator|T0= Enrollment|mechanical ventilation will be set according to the standard of care criteria
89531400|NCT06067152|Active Comparator|T1= guided MV at the end of SRM trial|EIT guided mechanical ventilation will be set
89531401|NCT06067152|Active Comparator|T2= 24 hours with EIT guided MV|evaluation of mechanical ventilation after 24h EIT-guided ventilation
89531402|NCT06067139|Experimental|Digital cognitive behavioral therapy (dCBT-I)|CBT-I is designed to change sleep habits and scheduling factors that affect sleep, and to address misconceptions about sleep and insomnia that perpetuate sleep difficulties. The investigators will employ SHUTi, which is an extensively studied dCBT-I program. SHUTi is intended to improve insomnia symptoms by providing neurobehavioral intervention (cognitive behavioral therapy for insomnia - CBT-I) in adults with chronic insomnia. It is a six-core internet-delivered CBT-I web-based app that is run through a browser. It is accessible via iPhone/iPad, Android phone/tablet, computer or laptop (any device with a browser). SHUTi follows evidence-based CBT-I principles.
89531403|NCT06067139|Active Comparator|Patient Education (PE)|Participants will be given access to a patient education website. It will provide nontailored material about insomnia symptoms; the impact, prevalence, and causes of insomnia; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
89531404|NCT06067074|Experimental|Volar Locking Plate|Surgery with a Volar Locking Plate due to displaced distal radius fracture
89531405|NCT06067074|Experimental|Non-operative treatment group|Patients allocated to non-operative treatment received a plaster cast for 4-5 weeks.
89531406|NCT06067061|Experimental|Atezolizumab plus RP1 (Immulytic™) oncolytic immunotherapy|Atezolizumab IV q2w RP1 (Immulytic™) by imaging-guided intra-tumor (IT) route.
89531407|NCT06067048|Experimental|Treatment arm|Zanubrutinib, 320 mg per day (four 80 mg capsules)
89531408|NCT06067022||Study Group|"42 patients with diabetic foot ulcers were included. For patients in this group, regarding diabetic foot; Sensory assessment, ulcer area and depth measurement, and diabetes management information were measured.~Apart from these evaluations, quality of life, pain, mandibular function and oropharyngeal swallowing problems were evaluated."
89531409|NCT06067022||Control Group|42 patients without diabetes were included. Patients in this group were evaluated for general health and quality of life, pain, mandibular function and oropharyngeal swallowing problems.
89531412|NCT06066931|Experimental|Group 3 is a new method of plastic surgery n=50|In group 3 the plastic stage is performed: on one side of the perineal wound, a cutaneous-subcutaneous-fascial flap on the leg is cut out and deepithelized, along the entire length of the wound, thereby forming a diamond-shaped perineal wound, plunging it into the pelvic aperture, fixing it with single sutures to the remnants of the muscle lifting the anus of the opposite side, and the flap width is 3-4 cm to fill the pelvic aperture. On the opposite side of the wound, a triangular skin-subcutaneous fascial flap is cut out on a leg equal to the width of the previously formed diamond-shaped wound at an angle of 60-80 degrees from the middle of the wound edge, and the sides of the triangular flap should be equal to half the length of the edge of the diamond-shaped wound, then it is moved and additionally fill the wound cavity with it, in condition of displacement of the apex of the triangle flap with the top of the rhombus-wounds. The flap is fixed with separate skin nodular sutures.
89531413|NCT06066892|Experimental|Digital impression|Digital impression using intraoral scanner
89531414|NCT06066892|Experimental|One stage open impression technique|Splinting impression long transfer and open tray impression technique
89531415|NCT06066892|Experimental|Two stage closed tray and open tray|Primary impression with closed tray impression techniques then secondary impression by open tray technique
89531416|NCT06066879|Experimental|Ketamine Infusion|ketamine infusion at 0.5 mg/kg over one hour two weeks (14 days) prior to their scheduled surgical date
89531417|NCT06066879|No Intervention|Standard Of Care|No use of ketamine pre, intra, or post-operatively
89531418|NCT06066840|Experimental|vedolizumab+basiliximab|Patients with steroid-refractory aGVHD with gastrointestinal involvement receive combined therapy of vedolizumab and basiliximab.
89531419|NCT06066658|No Intervention|Standard care|Standard care for Help with Breathlessness including medication, cognitive and behavioural strategies
89531420|NCT06066658|Experimental|CES|8 weeks of 60 minutes a day 100microA a day with four week follow-up with standard care for help with breathlessness
89531421|NCT06066645|Experimental|iDose TR|Travoprost Intraocular Implant in subjects who had successful iStent infinite placement
89531422|NCT06066645|Sham Comparator|sham procedure|Sham surgical procedure in subjects who had successful iStent infinite placement
89531423|NCT06066632||"Group 1 - Dual Pathology"|"Age >65 years~Severe aortic stenosis at echocardiographic examination~TAVI o SAVR planned or already undergone TAVI/SAVR~ECG-gated cardiac CT and echocardiographic examinations available before TAVI/SAVR~Cardiac uptake at bone tracer scintigraphy with a Perugini score of 2 or 3."
89531424|NCT06066632||"Group 2- Control Group"|"Age >65 years~Severe aortic stenosis at echocardiographic examination~TAVI o SAVR planned or already undergone TAVI/SAVR~ECG-gated cardiac CT and echocardiographic examinations available before TAVI/SAVR~Patients with no cardiac uptake at scintigraphy with bone tracer."
89531425|NCT06066606|Experimental|Vilanterol + fluticasone furoate|Participants are administered Vilanterol + fluticasone furoate from an inhaler device testing
89531426|NCT06066606|Placebo Comparator|Placebo|Participants are administered placebo from an inhaler device testing
89531427|NCT06066593||Ischemic Stroke|MRI suggests a new cerebral infarction.
89531428|NCT06066593||Hemorrhagic Stroke|CT suggests a new cerebral hemorrhage.
89531429|NCT06066593||Asymptomatic Group|Without new infarction or hemorrhage
89531430|NCT06066541|Active Comparator|Scorecard|"Participants randomized to this arm will receive a scorecard from Humana reporting patients' medication adherence using a refill score. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score."
89531431|NCT06066541|Experimental|Scorecard + Social norms|Participants randomized to this arm will receive the Arm 1 scorecard plus dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores). Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
89531432|NCT06066541|Experimental|Scorecard + Messenger effects|Participants randomized to this arm will receive the Arm 1 scorecard, coming from the trusted messenger of a Humana-identified pharmacist taking the same medication. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
89531433|NCT06066541|Experimental|Processing fluency|"Participants randomized to this arm will receive a modified scorecard increasing processing fluency through a visual metaphor of closing the ring. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score."
89531434|NCT06066541|Experimental|Processing fluency + Social norms|Participants randomized to this arm will receive the Arm 4 processing fluency scorecard plus dynamic social norms messaging. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
89531435|NCT06066541|Experimental|Processing fluency + Messenger effects|Participants randomized to this arm will receive the Arm 4 processing fluency scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication. Two messages will be sent during the intervention: The first message will contain the baseline refill score. The second message will note any changes in the refill score.
89531436|NCT06066541|No Intervention|Usual care|Participants randomized to this arm will not receive any mailed message.
89531437|NCT06066398|Other|medical thoracoscope|medical thoracoscope will be done during which pleural brush, pleural forceps biopsy and pleural lavage will be taken to compare yield of diagnosis and safety between them
89531438|NCT06066385|Experimental|Small bites suturing technique of the abdominal wall during midline laparotomy|In the experimental group of 288 patients the small bites technique was applied with bite widths of 0,5 cm and inter suture spacing of 0,5 cm with the use of PDS plus ll 2-0 single suture material with a 31 mm needle placed in the linea alba. In the small bites technique, twice as many stitches will be placed per sutured cm, with a smaller needle and thinner suture material.
89531439|NCT06066385|Active Comparator|Large bites suturing technique of the abdominal wall during midline laparotomy|As control the conventional large bites technique (mass closure) was applied with bites widths of 1 cm and inter-suture spacing of 1 cm with the use of PDS plus ll 1-0 double loop suture material with a 48 mm needle.
89531440|NCT06066346|Experimental|Talquetamab|Subcutaneous Talquetamab
89531488|NCT06065852||APRT Deficiency Rare Disease Group|"Aims:~To collect clinical data on patients with APRT Deficiency in a Registry. This will allow us to:~study the causes, natural history and outcome of the condition develop patient cohorts for future studies~To collect biological samples for future studies in a Biobank. This will allow us to:~identify factors influencing the course of APRT Deficiency determine the role of various genes~To develop new methods to measure urinary purine excretion. This will improve tools that allow us to:~study the effectiveness of pharmacological and dietary interventions identify factors influencing the course of the condition~To work with patient organisations, health care professionals and researchers:~to enhance the education and training aspect of this project to develop strategies to increase the awareness and early detection of APRT Deficiency and improve patient outcomes."
89531489|NCT06065852||ARPKD & NPHP Rare Disease Group|"Aims:~The Autosomal Recessive Polycystic Kidney Disease (ARPKD)/Nephronophthisis (NPHP) Rare Disease Group (RDG) aims to:~Develop and advocate best practice guidelines for the treatment of ARPKD and NPHP Provide up-to-date, best practice patient information and group support Support research into basic science, genetic, translational, psychosocial and clinical aspects of ARPKD and NPHP Foster collaborations with European and international groups and partner"
89531490|NCT06065852||Atypical Haemolytic Uraemic Syndrome Rare Disease Group|"Aims:~To establish and maintain a registry of all individuals affected by aHUS in the UK To provide information to clinicians on the investigation and management of aHUS To provide information to affected individuals and their families on aHUS To facilitate collaborative research into all aspects of aHUS"
89531491|NCT06065852||Autosomal Dominant Polycystic Kidney Disease Rare Disease Group|"Aims:~To develop the ADPKD RaDaR registry To develop best practice guidelines in regards to the treatment of ADPKD To provide better patient information and support To develop international collaborations to enable the above aims To support research, in collaboration with international groups, into basic science, disease progression models and clinical trials"
89531492|NCT06065852||Autosomal Dominant Tubulointerstitial Kidney Disease Rare Disease Group|The group was established as part of the RaDaR initiative, in light of the increasing numbers of families being identified with this syndrome and following the pioneering work undertaken by Dr Anne Simmonds and others in the Purine Laboratory at Guy's Hospital, London.
89531493|NCT06065852||BK Nephropathy Rare Disease Group|"The BK Nephropathy (BKN) Rare Disease Group aims to:~collate contemporary information from UK kidney transplant recipients with BK Nephropathy use this information to develop current and relevant information for patients disseminate this information to the renal and transplant communities establish a national consensus to identify recipients at high risk of developing BK Nephropathy develop a recommendation for the optimal screening frequency for the presence of BK viraemia by PCR of peripheral blood produce guidance on the modification of immunosuppressive regimens and use of additional agents to treat BK Nephropathy develop a strategy for patient recruitment to observational and interventional clinical trials"
89531494|NCT06065852||Calciphylaxis rare Disease Group|"The Calciphylaxis Rare Disease Group aims to:~Develop a comprehensive clinical database of Calciphylaxis patients via the RaDaR Rare Disease Registry Collaborate with international registries, particularly the German registry Form an expert panel of interested clinicians to review future clinical trials and research programmes Develop diagnostic and treatment algorithms"
89531495|NCT06065852||CKD due to Genetic Factors in people of African ancestry Rare Disease Group|"People of African or Afro-Caribbean ancestry are five times more likely to have kidney disease. They also develop kidney failure when they are about ten years younger than white people. The connection between ethnicity and kidney disease is complex. There have been some new scientific discoveries which may help us to begin to understand the cause of this problem and develop treatments, but much more work is needed.~This group will allow us to find lots of people with African or Afro-Caribbean ancestry with CKD living in the UK that can take part in research."
89531496|NCT06065852||Cystinosis Rare Disease Group|"Aims:~To improve the care for all patients with cystinosis in the UK To collaborate with the National Designation Centres for Cystinosis To work together with Cystinosis Foundation UK and other patient groups To register every willing patient with cystinosis onto RaDaR To promote research for the benefit of patients with cystinosis, and their families To promote educational resources for patients with cystinosis, and their families"
89531497|NCT06065852||Cystinuria Rare Disease Group|To improve our understanding of kidney stone formation in Cystinuria, develop best practice in the care of patients with this condition and to develop new ways to prevent and treat Cystinuria.
89531498|NCT06065852||Dent Disease & Lowe Syndrome Rare Disease Group|"The group aims to advance our knowledge of Dent Disease and Lowe Syndrome by:~establishing a registry of patients developing clinical guidelines regarding diagnosis and treatment providing a platform for clinical and molecular research into these disorders empowering affected patients and their families by facilitating contacts between patient/families and by the development of educational material"
89531499|NCT06065852||Fabry Disease Rare Disease Group|"The main objectives of the Fabry Disease Rare Disease Group are to:~Provide reliable information for patients and relatives regarding the condition Provide referral information for clinicians, including details about where to send samples Improve referral pathways between the relevant specialties in each geographical area e.g. cardiology and nephrology Design and implement studies to determine the burden of undiagnosed disease and make testing for Fabry more accessible nationwide Organise patient information days to promote face-to-face contact between clinicians and patients/families"
89531500|NCT06065852||Fibromuscular Dysplasia Rare Disease Group|"The main objectives of the Fibromuscular Dysplasia Rare Disease Group are to:~Raise awareness and provide advice about the best strategy for the diagnosis and management of this still underdiagnosed disease.~Study the presentation of the disease and baseline patient demographics. Study the prevalence of different subtypes of Fibromuscular Dysplasia, the incidence and determinants of disease progression/extension and complications Develop a Register of long term impact of intervention, as part of RaDaR"
89531501|NCT06065852||Haemolytic Uraemic Syndrome Rare Disease Group|"To identify key issues and challenges facing the field of Haemolytic Uraemic Syndrome, specifically in the development of an informatics framework within the UK~To stimulate and encourage industry partnerships.~To identify the needs and priorities for basic, clinical, translational and social research~To identify suitable funding opportunities and help support appropriate strategies for successful applications."
89531503|NCT06065852||Hyperoxaluria Rare Disease Group|"The Hyperoxaluria Rare Disease Group aims to:~The Hyperoxaluria Rare Disease Group aims to:~Provide up to date support for patients and their families. Increase the knowledge and understanding of Primary Hyperoxaluria and Oxalosis to improve its clinical management.~Provide clinical information on dialysis and transplantation. Increase the knowledge of clinical presentation and outcome of Primary Hyperoxaluria.~Foster national and international partnerships to promote scientific innovation and research in Primary Hyperoxaluria and facilitate applications for funding for research collaboration.~Create a forum for UK clinical studies on Primary Hyperoxaluria, including trials with orphan drugs.~Foster genotype studies on Primary Hyperoxaluria. Co-operate in order to obtain funding for research activities through industrial or public partners in order to facilitate the dissemination of the results deriving from scientific research.'"
89531504|NCT06065852||IgA Nephropathy Rare Disease Group|"The IgA Nephropathy (IgAN) Rare Disease Group aims to:~collate avaliable information on IgAN and develop new information for both patients and carers implement a communications strategy for the wider renal community about all aspects of the RDG's work programme develop a strategy for patient recruitment to clinical trials in IgAN"
89531505|NCT06065852||Inherited Renal Cancer Syndromes Rare Disease Group|"The development of evidence based clinical care pathways in inherited RCC has been identified as a priority owing to the lack of fully commissioned screening programmes nationally. Several published expert led disease management guidelines are being evaluated. Therefore the familial RCC RDG will set as a priority the development and validation of evidence based care pathways that reflect both national and international opinion and can be adopted by NHS commissioning groups.~The familial RDG will work closely with other RDGs, the Renal Registry and the Renal Association to produce advice for commissioners that relate to specific aspects of these diseases as well as more general advice that relates to rare diseases, CKD and renal replacement therapy."
89531506|NCT06065852||Lupus Nephritis Rare Disease Group|
89531507|NCT06065852||Membranous Nephropathy Rare Disease Group|"Aims:~To develop evidence based clinical care pathways. Current treatment for Membranous Nephropathy (MN) is based on knowledge and drugs available in the 1990's.~To empower and inform patients and families.~To audit clinical outcomes:~Establish a registry of biopsy proven prevalent cases and new incident cases of both primary and secondary MN starting from Jan 2013. In total we seek to capture data on 2000 patients during the next 5 years with a minimum of one complete data return per patient per year.~To promote and develop research."
89531508|NCT06065852||Mitochondrial disease affecting the kidney Rare Disease Group|This group is to promote the recognition of patients with mitochondrial disease affecting the kidney.
89531509|NCT06065852||Monoclonal Gammopathy of Renal Significance Rare Disease Group|To promote the RaDaR registration of patients affected by Monoclonal Gammopathy of Renal Significance (MGRS) To develop standard operating procedures in regards to the treatment of Paraprotein Associated Kidney Diseases To provide better patient information and support To support research, in collaboration with international groups, into basic science, disease progression models and clinical trials
89531510|NCT06065852||MPGN, DDD & C3 Glomerulopathy Rare Disease Group|"To bring together clinicians, scientists and consumers for the purposes of:~Undertaking clinical research into the causes of and treatment for MPGN and C3 glomerulopathies Promoting best clinical practice for patients with MPGN and C3 glomerulopathies Facilitating support for patients and families affected by MPGN and C3 glomerulopathies"
89531511|NCT06065852||Nephrotic Syndrome Rare Disease Group|"To compile a comprehensive UK registry of childhood and adult Nephrotic Syndrome, which includes detailed clinical information, laboratory results and genetic testing information where available. The information will be available to the patients/parents, their clinicians, and, in an anonymised form, to the Nephrotic Syndrome Rare Disease Group for research purposes.~To investigate the underlying cause of Nephrotic Syndrome by comprehensive genetic testing of all patients (with full informed consent), and the study of patient plasma for biomarkers of disease To inform patients about the latest research and educational advances regarding the disease To put patients in touch with recognised support groups and charities To develop treatment and investigation guidelines for clinicians and patients To enable clinical trials to be designed and carried out to further management of the disease"
89531512|NCT06065852||Pregnancy and Chronic Kidney Disease Rare Disease Group|"Increasing numbers of women with chronic kidney disease (CKD) are thinking about pregnancy. It has been known for over 50 years that CKD can affect how a pregnancy progresses and that a pregnancy can have a negative effect on damaged kidneys. However, outcomes have been improving decade by decade.~The group will develop care pathways for women with CKD throughout pregnancy.~Specific areas of research interest include:~What is the best blood pressure target during pregnancy for women with CKD? Is preconception counselling for women with CKD useful? How should we prevent blood clots during pregnancy in women with CKD? What is the effect of protein loss in the urine on pregnancies? Which women with CKD are most likely to develop pre-eclampsia? What is the best way to measure kidney function in pregnant women with CKD? What happens to mothers with CKD and their babies after pregnancy?"
89531513|NCT06065852||Pure Red Cell Aplasia Rare Disease Group|To increase awareness of Pure Red Cell Aplasia (PRCA). To streamline the diagnostic process. To investigate and implement measures to reduce the incidence of the disease. To empower affected patients in seeking help and support. To establish international collaborations to promote research into the causes and management of the disease.
89531514|NCT06065852||Retroperitoneal Fibrosis Rare Disease Group|"The Retroperitoneal Fibrosis (RPF) Rare Disease Group aims to:~establish a registry of patient data and biological samples (plasma, urine, biopsy tissue) collate available information on RPF and develop new information for both patients and carers improve upon observational data in terms of the presentation, natural history and outcomes in RPF patients nationally develop multi-disciplinary consensus care pathways and clinical guidelines for RPF develop a strategy for patient recruitment to trials"
89531692|NCT05708742|Experimental|ESP group|The ESP group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%. After skin sterilization, ESP block was administered in a sitting position. A linear US transducer was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between. Next, 2-3 ml of 2% lidocaine was infiltrated. Hydro dissection of the interfascial plane between the erector spinae muscle and TP was confirmed by visualizing the local anesthetic spreading in a linear pattern between the muscle and the bony acoustic shadows of the TP.
89531515|NCT06065852||Tuberous Sclerosis Rare Disease Group|"There are a number of unanswered questions relating to Tuberous Sclerosis Complex (TSC), which the RDG hopes to be able to address:~What is the frequency and severity of renal involvement in patients with TSC, particularly as they grow older? What is the frequency of multiple renal AMLs in individuals without other features of TSC? What is the frequency of renal impairment or renal haemorrhage in patients with renal AMLs, and how does this relate the lesion size, number and distribution? What is the frequency of bleeding or renal impairment in patients with multiple renal AMLS treated with mTOR inhibitors or other interventions? What is the frequency of impaired GFR (CKD stage 2 or higher), and what are the causes? What is the efficacy of treatment of renal AMLs in preventing bleeding and preserving GFR? What are the optional treatment regimes with mTOR inhibitors?"
89531516|NCT06065852||Tubulopathy Rare Disease Group|The newly renamed Tubulopathy Rare Disease Group, previously known as Hypokalaemic Alkaloses, has recently expanded it's inclusion criteria for RaDaR to include a large number of conditions.
89531517|NCT06065852||Vasculitis Rare Disease Group|"The Vasculitis Rare Disease Group has developed from the UK and Ireland Vasculitis registry initiative UKIVAS. The group members represent Vasculitis units across the UK and participate in Vasculitis research and care.~We have a number of aims:~To promote collaboration and sharing of expertise and resources in clinical research~To develop guidelines for the management of Vasculitis~To develop a nationwide registry of anonymized demographic, treatment and outcome data for patients with Vasculitis in the UK and Ireland~To develop high quality patient and clinician information via the Rare Renal and Vasculitis UK websites~To link with interested patient groups, research collaborations and industry."
89531518|NCT06065839|No Intervention|Control group|non-nutritive sucking was not given before feeding
89531519|NCT06065839|Active Comparator|Experimental group A|Give pacifier non-nutritive sucking for 5 minutes before feeding
89531520|NCT06065839|Placebo Comparator|Experimental group B|Give pacifier non-nutritive sucking for 15 minutes before feeding
89531521|NCT06065813|Experimental|Toripalimab|
89531522|NCT06065787|Experimental|NeuroGlove Treatment Arm|Subjects will receive treatment using the NeuroGlove. The treatment regimen at home will include 1 hour of therapy per day (two 30-minute sessions, one using each hand) for 4 weeks.
89531523|NCT06065722|Active Comparator|AKYNZEO for patient receiving MEC|Add Akynzeo to 5HT3 And dexamethasone
89531524|NCT06065722|Active Comparator|oLANZAPINE and Akynzeo to patients receiving highly emetogenic|olANZAPINE plus Akynzeo
89531525|NCT06065696||Early mobilization|Patients who achieved early mobilization after colorectal surgery
89531526|NCT06065696||No early mobilization|Patients who did not achieve early mobilization after colorectal surgery
89531527|NCT06065683||T2 hour|
89531528|NCT06065683||T12 hour|
89531529|NCT06065683||T24 hour|
89531530|NCT06065683||T48 hour|
89531531|NCT06065683||T72 hour|
89531532|NCT06065644|Experimental|Long fixation|CT in a neutral and then by provocation (anterior straight leg raise and figure-of-four).
89531533|NCT06065644|Active Comparator|One segment fixation|CT in a neutral and then by provocation (anterior straight leg raise and figure-of-four).
89531534|NCT06065605||Fabry patients without clinical evidence of nephropathy|No deterioration of kidney function.
89531535|NCT06065605||Fabry patients with clinical evidence of nephropathy|Deterioration of kidney function.
89531536|NCT06065605||Naïve Fabry patients|These patients have no received treatment.
89531537|NCT06065605||Healthy controls|Not diagnosed with Fabry disease.
89531538|NCT06065579|Experimental|Intervention Group|Intervention group will receive intervention
89531539|NCT06065579|No Intervention|Control Group|Control group will not receive intervention
89531540|NCT06065566|Experimental|Patients on bypass with cardiopulmonary bypass +gluta|Patients operated on bypass with cardiopulmonary bypass + glutamine
89531541|NCT06065566|Placebo Comparator|Patients on bypass + cardiopulmonary bypass + glutamine|Patients operated on bypass with cardiopulmonary bypass + glutamine
89531542|NCT06065566|Experimental|patients without bypass + cardiopulmonary bypass +glutamine|Patients operated without bypass with cardiopulmonary bypass + glutamine
89531543|NCT06065566|Placebo Comparator|Patients without bypass + cardiopulmonary bypass +placebo|Patients operated without bypass with cardiopulmonary bypass + placebo
89531544|NCT06065436|Experimental|Collagenase Clostridium Histolyticum with Low Intensity Shockwave Therapy|Subjects will receive Collagenase Clostridium Histolyticum (CCH) intralesional injection with low-intensity shockwave therapy (LiSWT).
89531545|NCT06065436|Active Comparator|Collagenase Clostridium Histolyticum|Subjects will receive Collagenase Clostridium Histolyticum (CCH) intralesional injection per standard of care.
89531546|NCT06063239|Experimental|Test Group|Subjects who will receive orally administred probiotics based on L. rhamnosus and L. plantarum for 90 days in adjunction to the instruction of their care-giver regarding oral hygiene procedures.
89531547|NCT06063239|Active Comparator|Positive Control|Subjects who will receive orally administred probiotics based on placebo for 90 days in adjunction to the instruction of their care-giver regarding oral hygiene procedures.
89531548|NCT06063239|Other|Negative Control|Subjects who will receive esclusively the instruction of their care-giver regarding oral hygiene procedures.
89531549|NCT06063226|Experimental|Probiotics|Patients who will be assigned to oral consumption of one stick of probiotics with L. plantarum and L. rhamnosus for 30 days, in adjucntion to routinary oral hygiene procedures.
89531550|NCT06063226|Placebo Comparator|Positive Control|Patients who will be assigned to oral consumption of one stick of placebo for 30 days, in adjucntion to routinary oral hygiene procedures.
89531551|NCT06063226|Other|Negative control|Patients who will be assigned to routinary oral hygiene procedures esclusively.
89531552|NCT06062550|Active Comparator|Low-dose group|Patient-controlled analgesia is established with esketamine 50 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
89531553|NCT06062550|Experimental|Medium-dose group|Patient-controlled analgesia is established with esketamine 100 mg, dexmedetomidine 200 microgram, and sufentanil 4 microgram/kg (maximum 250 microgram), diluted with normal saline to 200 ml, and programmed to administer 2-ml boluses with a lockout interval of 8 minutes and a background infusion rate at 1 ml/h.
89531589|NCT06011863||Grup ESP ( Erector spinae plane block)|Group ESP: Before induction of anaesthesia, the patient is placed on the operating table and placed in a forward tilted position. Asepsis and antisepsis conditions are provided. The linear USG probe is moved approximately 2-3 cm lateral to the spinous process T5 - T6 level on the side to be operated. The trapezius, rhomboid major and erector spinae muscles will be identified to find the correct probe position. A 22 gauge , 50 mm or 22 gauge 80 mm single shot nerve blocks needle will be inserted through the skin in a cranio-caudal direction. With the needle resting on the transverse process, the plane between the erector spinae muscle and the transverse process will be verified by hydrodissection with 5 ml saline solution. Then 20 ml of 0.25% bupivacaine will be injected. The ESP block will be considered successful if the local anaesthetic spreads linearly up to the T8 - T9 level. The patient will then be placed in the supine position and general anaesthesia will be administered.
89531590|NCT06011824||Biopsy Negative|Female age 18 and above with negative breast biopsy
89531591|NCT06011824||Biopsy positive for carcinoma in situ (ductal, lobular, or other)|Females age 18 and above with any subtype of breast cancer (ductal, lobular, or other)
89531592|NCT06011824||Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)|Females age 18 and above with any subtype of breast cancer (HER2+, ER/PR, TNBC, BRCA1 +/-, other).
89531593|NCT06011824||Metastatic Stage IV|Females age 18 and above with any subtype of breast cancer, including metastases
89531594|NCT06006130|Active Comparator|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered at 10 Hz, 1500 pulses targeting the hand representation of the left primary motor cortex. rTMS delivery will require ~11 min to complete. In Experiment 1, this intervention will be performed for 1 session (~11min). In Experiment 2, this intervention will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
89531595|NCT06006130|Sham Comparator|Sham rTMS|Sham rTMS will be delivered at as a placebo control. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active rTMS. In Experiment 2, this intervention will be performed approximately 5 days per week for 2 weeks. In addition, participants will experience their standard medical care.
89531596|NCT05999084||Anti-amyloid Monoclonal Antibodies (mAbs)|Patients with Mild Cognitive Impairment (MCI) or mild AD dementia who are receiving treatment with anti-amyloid mAbs, per standard of care. Patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.
89531597|NCT05999084||Historical Comparator Group|Available historical data from biomarker-confirmed patients with MCI or mild dementia due to AD who have been followed in the Emory Cognitive Neurology Clinic will serve as a comparator group. Patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.
89531598|NCT05999084||Caregivers of Patients Receiving Anti-amyloid Monoclonal Antibodies (mAbs)|Caregivers of patients with Mild Cognitive Impairment (MCI) or mild AD dementia who are receiving treatment with anti-amyloid mAbs, per standard of care. Caregivers of patients seen in the Emory and GMN MACs are evaluated with standard instruments for cognitive and functional abilities.
89531599|NCT05990010||Patients with AF|
89531600|NCT05990010||Patients without AF|
89531601|NCT05985083|Experimental|Dose escalation|"It's a dose escalation to identify the Maximum Tolerated dose (MTD) , recommended Phase II dose (RP2D) of IMM47, an accelerated titration method and the traditional 3+3 design method will be adopted. IMM47 will be sequentially escalated at the dose of 5 μg/kg，50 μg/kg, 250 μg/kg，1.0 mg/kg，3.0 mg/kg and 5.0 mg/kg or higher dose levels, administered via intravenous infusion every 2 weeks in 28-day treatment cycles.~The duration of the infusion is 120 min (± 10 min) for the 1st infusion and 60 min (± 5 min) for subsequent infusions."
89531602|NCT05980234||Longevity IT Oblique Liners|The Longevity IT Oblique liner was designed to provide variable joint anteversion and abduction.
89531603|NCT05980234||Longevity IT Offset Liners|The Longevity IT Offset liner was designed to lateralize the center of rotation of the cup.
89531604|NCT05966805|Experimental|Exercise Training Group|Exercise intervention group will undergo a 12-week exercise program.
89531605|NCT05966805|Other|Wait-List Control Group|Wait-List control group will participate in visits every 4 weeks for data collection and periodic phone calls for monitoring. They will be offered the exercise training intervention option at conclusion.
89531606|NCT05962801|Active Comparator|Lumoral users|Use of Lumoral device and Lumorinse mouthwash once per day for 6 months and performance of oral hygiene twice per day for 6 months.
89531607|NCT05962801|No Intervention|Lumoral non-users|No use of Lumoral device and Lumorinse mouthwash. Performance of oral hygiene twice per day for 6 months.
89531608|NCT05954819|Experimental|Planned patient education|"Pre-test data will be obtained by using the Healthy Lifestyle Behaviors Scale and Diabetes Self-Management Scale. The participants will be individual education on myocardial infarction and diabetes by researcher. One month later, the posttest data will be obtained using Healthy Lifestyle Behaviors Scale and Diabetes Self-Management Scale."
89531609|NCT05954819|No Intervention|Routine patient education|"Pre-test data will be obtained by using Healthy Lifestyle Behaviors Scale and Diabetes Self-Management Scale. No attempt will be made to participants by the researcher. Participants will undergo discharge training routinely administered by bedside nurses at the hospital. One month later, the posttest data will be obtained using Healthy Lifestyle Behaviors Scale and Diabetes Self-Management Scale."
89531610|NCT05937646|Experimental|EHR (Control), then AWARE|In this hour-long task, participants in this arm will first review and complete tasks using the institutional EHR. Then after an approximate 5 minute rest, participants will then review and complete tasks using AWARE.
89531611|NCT05937646|Experimental|AWARE Intervention, then EHR (Control)|In this hour-long task, participants in this arm will first review and complete tasks using the AWARE intervention. Then after an approximate 5 minute rest, participants will then review and complete tasks using the institutional EHR.
89531612|NCT05929469|Experimental|Fully Automated Kick-Off + App|"This arm includes participants who respond to the Fully Automated Kick-Off + App in stage 1.~In stage 1, participants will receive a Fully Automated Kick-Off and an mHealth program.~In stage 2, responders to the Fully Automated Kick-Off + App will continue with the mHealth program, alone, for the remainder of the study."
89531641|NCT05865067|Experimental|Yoga Therapy|Participation will consist of 1) a telephone survey to screen for exclusion factors; 2) filling out two questionnaires and consent at the first visit; 3) filling out four questionnaires on orientation day (day 2); 4) receiving an orientation for you and your child and receive an educational pamphlet on the 2nd and 15th (closing); 5) participate in the 12 Yoga sessions with your child (Saturdays) with a weekly call to remind you of your appointment; 6) fill out a questionnaire on day 8 (6th yoga class); 7) fill out five questionnaires on the 15th (closing); 8) a possible assessment of your child's heartbeat at the 12 intervention sessions (will be randomly selected); 9) an evaluation of your child's sweating at the first visit (orientation) and at visit 15 (closing); 10) a last visit to finish and offer additional information (day 15; closing); 11) a telephone survey three months (day 16) after completing the study.
89531642|NCT05865067|Active Comparator|Wait-List with Exercise|Participation consists of 1) a telephone survey to screen for exclusion factors; 2) filling out two questionnaires and informed consent at the first visit; 3) filling out four questionnaires in the second meeting (day 2 of orientation); 4) filling out six questionnaires in the last meeting (day 15; closure); 4) receive a 30-45 minute video orientation and psychoeducation (where you will also receive an educational brochure) and a series of exercise recommendations for you and your child on day 2 (orientation); 5) 12 phone calls (once a week); 6) an evaluation of your child's sweating at the first visit (orientation) and last visit (day 15; closure); 7) an evaluation of your child's heart rhythm at the first visit (orientation) and last visit (day 15; closure); 8) a telephone survey (day 16; follow-up) 3 months after completing the study; 9) a call at the end of the study to coordinate the Yoga sessions for you and your child once the first group has finished.
89531643|NCT05864157|Active Comparator|Control|Participants will perform walking practice on a treadmill and overground without the use of a metronome.
89531644|NCT05864157|Experimental|Targeted Rhythmic Auditory Cueing (TRAC)|Participants will perform walking practice on a treadmill (with a metronome set to 85% of typical cadence) and overground (with a metronome set to 115% of typical cadence).
89531645|NCT05864157|Experimental|Distorted Targeted Rhythmic Auditory Cueing (dTRAC)|Participants will perform walking practice on a treadmill (with a metronome set around 85% of typical cadence) and overground (with a metronome set around 115% of typical cadence).
89531646|NCT05854550|Experimental|Apreo Implant Group|This group will undergo up to 2 procedures and will receive up to 3 implants during in each lung.
89531647|NCT05850611|Experimental|Methylene Blue|The first intervention group (group A) includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention (70 mg in 200 ml of milk) for 4 weeks.
89531648|NCT05850611|Experimental|Milk (control)|Patients with non-healing Diabetic Foot Ulcers only will receive 200 ml of milk for 4 weeks.
89531649|NCT05850611|Experimental|Methylene Blue and Platelet-Rich Plasma-Fibrin Glue|Patients with non-healing Diabetic Foot Ulcers will treat with PRP-Fibrin-Glue plus oral methylene blue (70 mg in 200 ml of milk) for 4 weeks.
89531650|NCT05850611|Experimental|Milk and Platelet-Rich Plasma-Fibrin Glue (control)|Patients with non-healing Diabetic Foot Ulcers will be treated with PRP-Fibrin-Glue and 200 ml of milk for 4 weeks.
89531651|NCT05839769||carpal tunnel syndrome in third trimester pregnant women|pregnant women who has CTS
89531652|NCT05839769||healthy pregnant women in third trimester|
89531653|NCT05838339|Experimental|Co-creation School|An existing healthy sleep intervention will be scaled up using a shortened co-creation process. An effect- and process evaluation will be performed.
89531654|NCT05838339|Active Comparator|Standard Implementation School|The existing healthy sleep intervention will be implemented without using a co-creation approach. An effect- and process evaluation will be performed.
89531655|NCT05838339|No Intervention|Control School|No intervention will be implemented. An effect evaluation will be performed.
89531656|NCT05831098|Experimental|Experimental Diagnostic: Reveal TP (Syphilis) Antibody Test|Participants are tested with investigational devices and conventional syphilis serology tests.
89531657|NCT05830279||Anti-depressants|Patients who have been prescribed either 1) the selective serotonin reuptake inhibitors (SSRI) citalopram or escitalopram, or 2) the selective norepinephrine reuptake inhibitors (SNRI) venlafaxine or desvenlafaxine
89531658|NCT05830279||Opioid pain medications|Patients who have been prescribed opioid pain medications including codeine, oxycodone, hydrocodone, or tramadol.
89531659|NCT05830279||Anti-metics|Patients who have been prescribed the antiemetic agent ondansetron
89531660|NCT05827757|Experimental|MSC transplantation|Transplant 100 million MSCs
89531661|NCT05824832|Experimental|Interscalene block with the addition of buprenorphine, clonidine, dexamethasone|Interscalene brachial plexus blocks (ISB) is performed with a 22g x 50 mm PAJUNK SonoPlexⓇ II Facet S echogenic needle. Once adequate needle visualization is achieved within the correct anatomic position and plane, 30mL of 0.5% bupivacaine with 100 mcg clonidine, 0.3 mg buprenorphine, and 4 mg dexamethasone will be injected.
89531662|NCT05824832|Active Comparator|Interscalene block with buprenorphine alone|Interscalene brachial plexus blocks (ISB) is performed with a 22g x 50 mm PAJUNK SonoPlexⓇ II Facet S echogenic needle. Once adequate needle visualization is achieved within the correct anatomic position and plane 30mL of 0.5% bupivacaine will be injected.
89531663|NCT05812157|Experimental|Experimental group|Patients with aSp receiving fiber supplements in the form of Fibruline® Instant (Fagron laboratories)
89531664|NCT05812157|Placebo Comparator|Control group|Patients with aSp receiving fake fiber supplements (placebo) in the form of Maltodextrine (laboratoire Fagron).
89531665|NCT05810428|Experimental|GKRS-VR training|GKRS-VR group will undergo GKRS and neuromodulation based on Virtual Reality sensorimotor rehabilitation using an immersive system
89531666|NCT05810428|Active Comparator|Control Group|Control group (CT) will undergo only GKRS
89531667|NCT05810428|No Intervention|Healthy subjects|Age- and sex-matched healthy subjects recruited to compare neuropsychological,clinical and structural/functional magnetic resonance imaging characteristics at baseline.
89531668|NCT05809609|Experimental|Ketamine|Participants in this arm will receive a single intravenous injection, antidepressant dose of Ketamine hydrochloride (0.5mg/kg)
89531669|NCT05809609|Placebo Comparator|Placebo|Participants in this arm will receive a single intravenous injection of an inactive placebo (0.9% sodium chloride)
89531727|NCT05622136|Experimental|Regorafenib|"Cycles 1 and 2:~Week 1: 80mg/day~Week 2: 120mg/day~Week 3: 160mg/day~Week 4: off-treatment Cycles 3 on (up to treatment discontinuation)~Weeks 1 to 3: Maximum dose tolerated daily, defined as the highest dose at which the patient had no adverse events grade ≥3 by CTCAE version 5.0 during cycles 1 and 2.~Week 4: off treatment~Dose adjustments may be required. Appendix 11.1 guide dose adjustments. Individual decisions at the occurrence of particular adverse events may be discussed individually within the study team and investigators.~Treatment will be administered until any of the following events occur:~Both radiological and clinical progression according to definition of mRECIST or clinical deterioration that prevents treatment continuation according to the judgment of the attending physician~Limiting toxicity as defined by a grade 3 adverse event that does not resolve to grade < 3 within 7 days; adverse event grade 4 or 5.~Subject decision."
89531728|NCT05621954|Experimental|Telehealth monitoring|"Telehealth remote monitoring provided by a specialised service with a monitoring and patient education app featuring:~Symptom, blood pressure, weight, heart rate and oxygen saturation monitoring with optional step counters~Customised algorithms with patient feedback for prehabilitation (e.g. patient self-reporting of symptoms, activities and health-related activities with positive feedback loops and recommendations for self-directed management)~Centralised weekly review and escalation to expedited surgery if deteriorations noted~Post-operative monitoring with symptom, blood pressure, weight, heart rate, oxygen saturation and photographic wound review with optional step counters"
89531729|NCT05621954|No Intervention|Standard of Care|Standard of care will be no remote monitoring for patients whilst on the waiting list or after discharge from hospital. Access to tertiary services for advice, information or to report deteriorations will be through conventional existing modes such as printed or online literature provided at the time of outpatient review, telephone access to administrative staff allowing clinical information to be conveyed to the usual care team, and local primary care and emergency services for acute deteriorations. Existing standard of care remote services (e.g. wound monitoring by digital photograph reviews) will continue.
89531730|NCT05621759|Experimental|Reduced-Dose Post-Transplant Cyclophosphamide, Abatacept, and Short-Duration Tacrolimus|"Participants to receive:~Cyclophosphamide 25 mg/kg IV over 1 hour on Day 3 and Day 4 following transplant~Abatacept 10 mg/kg IV on Day 5, Day 14, Day 28, and Day 56 following transplant~Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on Day 5 following transplant. May switch to oral administration when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Tacrolimus treatment is continued until Day 60 and then tapered over a period of 4 weeks in the absence of GvHD."
89531731|NCT05617716|Experimental|Standard dose SBRT|Participants will undergo standard dose Stereotactic Body Radiation Therapy
89531732|NCT05617716|Experimental|High dose SBRT|Participants will undergo high dose Stereotactic Body Radiation Therapy
89531733|NCT05617716|Experimental|Conventional EBRT|Participants will undergo External Beam Radiation Therapy
89531734|NCT05606328|Experimental|Implementation Period|ED leadership at each site will identify 5-10 delirium champions (nurse educators and managers, bedside nurses) based on their interest in delirium and commitment to program participation, including training of nurses by champions. The implementation period will take place over a period of 3 months. No data analysis will take place during the implementation period.
89531735|NCT05606328|No Intervention|Intervention Period|The intervention period will take place 3-9 months after implementation of the ED-DDP program over a 15 month period, depending on when a site is randomized to receive the ED-DDP intervention.
89531736|NCT05606159|Experimental|Bacillus velezensis DSM 33864|"This arm will receive a single strain probiotic capsule containing Bacillus velezensis DSM 33864.~The probiotic will be taken orally, once a day, for 8 weeks."
89531737|NCT05606159|Placebo Comparator|Placebo control group|A placebo capsule containing microcrystalline cellulose will be taken orally, once a day, for 8 weeks.
89531738|NCT05600270|Active Comparator|Angled wire|Angled guidewire intervention arm
89531739|NCT05600270|Active Comparator|Straight wire|Straight guidewire intervention arm
89531740|NCT05598996|Experimental|COT-Based Intervention|The COT-based intervention will include the following to improve both steps/day (move more), and improving minutes/week of MVPA (exercise): adaptive daily steps/day goal-setting plus feedback; positive reinforcement (i.e., points, which translate to gift cards), self-monitoring of both steps/day and min/week MVPA; education about MVPA sent via text message in both conditions; planning support for scheduling bouts of MVPA via SMS in both conditions; and motivational messages sent via SMS in both conditions, and the use of a self-experimentation tool (REFLECT), developed based on prior successful pilot efforts, focused on fostering effective self-regulatory capacities of individuals.
89531741|NCT05598996|No Intervention|Control|The non-COT approach was designed to be an equivalent to emerging standard of care options for digital health worksite wellness programs to increase PA (control) for a 12-month study period. Participants assigned to the non-COT-based (control) group will receive the latest Fitbit Versa smartwatch and will download the Fitbit smartphone app. Unlike the intervention group, the daily step goal and the accompanying number of points will be static (10,000 steps/day; 150 points/day, respectively). The goal will be delivered to participants via the standard Fitbit app features and points will be communicated via email. Participants will also receive a weekly PA goal (150 minutes of MVPA/per week) and the same accompanying motivational and informative texts that the intervention group receives. Control participants will not complete the physical activity and exercise reflection and planning exercise (Reflect).
89531742|NCT05580276||Study group|Adolescent with headache, 10-18 ages
89531743|NCT05580276||Control group|Adolescent without headache
89531744|NCT05572021|Experimental|Prospective|Participants enrolled to ventral hernia repair with Fortiva mesh
89531745|NCT05572021|Active Comparator|Retrospective|Retrospective participants with ventral hernia repair using Strattice mesh
89531746|NCT05569798|No Intervention|Standard care|Thirty patients will receive standard care (regular ICU treatment without any restriction to usual medical care). INSIGHT scans will not be performed on these patients. However, other forms of ultrasound scanning will be permitted in this group. For example, departmental ultrasound scans (full echocardiography, liver, or vascular ultrasound assessment); transoesophageal echocardiography; transcranial doppler; any form of PoCUS other than the INSIGHT scan.
89531893|NCT04914793|Experimental|Intervention phase|"Antimicrobial Prescribing guidelines mobile phone application (MicroGuide) Both paediatric and adult antimicrobial prescribing guidelines are transferred to MicroGuide; which is a medical guideline application. MicroGuide is an offline application, free-of-charge for the individual users. The app can monitor the number of users and which guidelines are being accessed. The app is installed to the personal smart phones of local physicians by the PI. Both mobile app and paper guidelines will be available in Lao languages.~Antimicrobial stewardship (AMS) training AMS training sessions are given to prescribers in participating hospitals when they firstly enter to the intervention phase. This session is given alongside an introduction of mobile phone app prescribing guideline. The training focus on good practices of antimicrobial prescription. Providing training after introducing treatment guidelines is not routine practice in many hospitals in Laos."
89531894|NCT04902391|Experimental|Acute Mental Health Care Bundle|We developed an evidence-based bundle of care to address current gaps in care. The bundle: 1) brings together multiple evidence-based assessment tools (ASQ, HEADS-ED) to ensure efficient, high-value ED-based care; 2) removes barriers to assessment and builds connections to care: Assessments are conducted by a mental health care provider and families have access to urgent follow-up care; and 3) prioritizes family engagement: A shared decision-making framework (Choice and Partnership) is used to promote children and youth as stewards of their care and support partnership between EDs and follow-up services with the duration of care determined collaboratively by the patient and their provider.
89531895|NCT04902391|No Intervention|Usual ED-Based Mental Health Care|Local standards of ED-based mental health care will be delivered at control sites. Site leads have determined that this care does not involve the 3 specific core innovations in the bundle. Local care standards are similar across study sites and include use of CTAS score at triage (but no mental health risk assessment tool), ED physician medical clearance and assessment of consultation need, and no consistent mental health follow-up plan. Sites that are randomized to the control arm will not adopt core bundle elements.
89531896|NCT04889898||ALS Patients|All ALS patients will be enrolled in this arm, which involves a combination of clinical and home-based assessments of speech and swallowing.
89531897|NCT04889898||Listeners|Healthy listeners will be recruited to listen to the audio recordings of patients in the study in order to judge the intelligibility of their speech.
89531898|NCT04877990|Experimental|Long-Term Extension Rollover Study: Deucravacitinib|
89531899|NCT04862897||Patient-controlled admissions|Patients who have been granted access to patient-controlled admissions and agreed to its use with inpatient care and outpatient care
89531900|NCT04856488|Experimental|Iodine Potassium Iodide solution|Participants receive Iodine Potassium Iodide solution oral drops 3 times per day for 10 Days prior to thyroidectomy in addition to standard preoperative treatment
89531901|NCT04856488|No Intervention|No intervention|Participants continue with standard preoperative treatment
89531902|NCT04836988||Digitally delivered osteoarthritis treatment|Participants enrolled in the digitally delivered osteoarthritis managament program (Joint Academy register)
89531903|NCT04836988||Face-to-face delivered osteoarthritis treatment|Participants enrolled in the face-to-face delivered osteoarthritis managament program (BOA-register)
89531904|NCT04832607|Experimental|Multivirus (CMV, EBV, AdV)-specific T cells|"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of Cytomegalovirus, Adenovirus and Epstein-Barr Virus~Max dose:~HLA-matched (8/8) donors: 1.0 x 10e5 T cells/kg recipient BW~HLA-mismatched donors: 2.5 x 10e4 T cells/kg recipient BW~Min. dose:~- 10 T cells/kg recipient BW"
89531905|NCT04832607|Placebo Comparator|Sodium chloride|Suspension of multivirus-specific T cells in 20 mL of 0.9% NaCl + 0.5% HSA
89531906|NCT04827680|Experimental|All subjects|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.
89531907|NCT04817020|Experimental|Klorheksidin|
89531908|NCT04817020|Experimental|Alchol|
89531909|NCT04812522|Other|Clean Cut intervention - Cluster 1|"Cluster 1 will receive the Clean Cut infection prevention intervention at random time point A"
89531910|NCT04812522|Other|Clean Cut intervention - Cluster 2|"Cluster 2 will receive the Clean Cut infection prevention intervention at random time point B"
89531911|NCT04812522|Other|Clean Cut intervention - Cluster 3|"Cluster 3 will receive the Clean Cut infection prevention intervention at random time point C"
89531912|NCT04812522|Other|Clean Cut intervention - Cluster 4|"Cluster 4 will receive the Clean Cut infection prevention intervention at random time point D"
89531913|NCT04812522|Other|Clean Cut intervention - Cluster 5|"Cluster 5 will receive the Clean Cut infection prevention intervention at random time point E"
89531914|NCT04808973|Experimental|Lamivudine plus Dolutegravir in FDC|Single arm of 3TC+DTG for treatment of pregnant women with HIV infection
89531915|NCT04807842|Other|Active product|
89531916|NCT04807842|Placebo Comparator|Placebo|
89531917|NCT04806854|Experimental|LUM-201 (1.6 mg/kg/day)|
89531918|NCT04806854|Experimental|LUM-201 (3.2 mg/kg/day)|
89531919|NCT04800159|Active Comparator|THC Cannabis|11.86% THC/ 1.12% CBD
89531920|NCT04800159|Active Comparator|CBD Cannabis|0.35% THC/ 11.27% CBD
89531921|NCT04800159|Placebo Comparator|Placebo|≤ 0.01% THC/ ≤ 0.01% CBD
89531922|NCT04776161|No Intervention|Control|Patients in the control arm will not receive any intervention (but will receive electronic pill bottles to monitor their adherence).
89531923|NCT04776161|Experimental|Cue-Reward Intervention|Patients in this intervention arm will choose an event-based cue and receive reminder text messages reminding them of their cue. Additionally, a donation will be made to a local charity every time they take their medication.
89531924|NCT04776161|Experimental|Cue-Reward Intervention with possible intensification.|Patients in this intervention arm will choose an event-based cue. Additionally, a donation will be made to a local charity every time they take their medication. Those who show no improvement in adherence after 6 weeks will start receiving reminder text messages reminding them of their cue.
89531925|NCT04775069|Active Comparator|mRNA Group|The subjects will be vaccinated with the mRNA vaccine (Pfizer-Biontech).
89531926|NCT04775069|Active Comparator|Inactivated Virus Group|The subjects will be vaccinated with inactivated SARS Cov-2 (Sinovac).
89531947|NCT04627415|Experimental|Face to Face Treatment|The F2F version of PEAK contains 10 BPE sessions (1.5 hours each). Session content includes: 1) Introduction to ADHD, 2) Attending, Rewards and Ignoring, 3) General Behavior Management Strategies, 4) Problem-Solving Approach, 5) Preventive Intervention, 6) Instructive Interventions, 7) Response Strategies, 8) Extending What Works to Community Settings, 9) Promoting Early Reading and Math Skills, and 10) Effective Communication Strategies. Each session contains didactic instruction and activities designed to enhance engagement. Sessions include video examples and interactive activities. Weekly homework is assigned for strategy practice. At the start of the following session, the leader checks in with families on the use of the chosen strategy. The session leader praises successes and troubleshoots challenges. The intervention also includes optimistic training which aims to identify/improve pessimistic thinking patterns that parents have about their parenting and child's behaviors.
89531948|NCT04627415|Experimental|Online Treatment|For the online version of the program, in addition to content regarding an overview of ADHD, the initial session consists of brief video clips demonstrating how to access PEAK sessions on the Internet, and an orientation to online content (e.g., handouts, interactive chat sessions, research team contact links). Prior to the session, parents are provided with password-protected individual access codes. Similar to the F2F program, check-ins are provided weekly via each parent's preferred mode of communication (i.e., text, internet, phone) to query strategies implemented, praise success, and troubleshoot alternative strategies. Parents in the online condition will also receive supplemental optimistic training to improve pessimistic thinking patterns about their child and parenting.
89531949|NCT04627415|Other|Waitlist Control|The comparison condition is a waitlist control group that will receive no intervention throughout the intervention timeframe. Instead, participants will receive wellness information about typical child development and constructs unrelated to the intervention content. Subsequent to the 12-month follow-up assessment, they will be provided access to the online version of the program. To encourage ongoing participation in the absence of services, parents will be informed that, at the end of the intervention timeframe, they will receive support (i.e., weekly contact to answer questions) while they complete the online program.
89531950|NCT04603859|Experimental|Elective induction of labour|Elective induction of labour at 39 gestational weeks and 0 to 3 days.
89531951|NCT04603859|No Intervention|Expectant management|Awaiting spontaneous labor.
89531952|NCT04559490||Standard formula|Participants receiving intact protein lactose-based formula, exclusively for at least 3 months.
89531953|NCT04559490||Sensitive|Participants receiving intact protein glucose/sucrose- based formula, exclusively for at least 3 months.
89531954|NCT04542148|Experimental|Sliding Scale Insulin|Addition of supplemental sliding scale insulin to home insulin regimen for maximum of 5 days after antenatal corticosteroids
89531955|NCT04542148|Experimental|Up-Titration of Home Insulin|Increase in home insulin regimen based on standardized algorithm for maximum of 5 days after antenatal corticosteroids
89531956|NCT04542148|Experimental|Continuous Insulin Infusion|Discontinuation of home insulin regimen and receipt of continuous insulin infusion for maximum of 5 days after antenatal corticosteroids
89531957|NCT04521946|Experimental|Treatment (chemotherapy, HCT)|Patients receive thiotepa IV over 2-4 hours and etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3. Patients receiving umbilical cord transplant only also receive lapine T-lymphocyte immune globulin IV over 4-12 hours on days -4 and -3. Patients then undergo HCT on day 0. Patients also receive tacrolimus IV or cyclosporine IV beginning on day -2 to and mycophenolate mofetil PO every 8 hours or IV from days 0-40 and tapered to day 90.
89531958|NCT04505774|Other|Therapeutic Dose Anticoagulation|"increased dose of heparin above standard of care.~1.0 - This arm was stopped in severe patients in December 2020 and results are published in PMID: 34351722 (NEJM, August, 2021) (see reference section for citation). This arm was stopped for moderate patients in January 2021."
89531959|NCT04505774|Other|Prophylactic Dose Anticoagulation|"Heparin standard of care~1.0 - this arm was stopped for all patients in January, 2021 and results are published in PMID: 34351721 (NEJM, August, 2021) (see reference section for citation)"
89531960|NCT04505774|Other|Therapeutic Dose Anticoagulation + P2Y12 inhibitor|"increased dose of heparin above standard of care with an added P2Y12 inhibitor~This Arm enrolled moderate illness patients only. Enrollment of moderate illness patients in the trial was ended per DSMB on June 19, 2021 and results are published in PMID: PMID: 35040887 (JAMA, January, 2022) (see reference section for citation)"
89531961|NCT04505774|Other|Prophylactic Dose Anticoagulation + P2Y12 inhibitor|"Heparin standard of care with an added P2Y12 inhibitor~This Arm enrolled severe illness patients only. Enrollment of severe illness patients in the trial was ended per DSMB in June 2022."
89531962|NCT04505774|Other|Standard of Care + Crizanlizumab|"Standard of care plus crizanlizumab infusion~This arm will enroll moderate and severe illness patients~This arm was ended for all patients per the DSMB in September 2022."
89531963|NCT04505774|Other|Standard of Care + SGLT2 inhibitor|"Standard of care plus SGLT2 inhibitor~This arm will enroll moderate and severe illness patients~This arm was ended in March 2023"
89531964|NCT04490824|Active Comparator|Treated Then Control Water|This Arm includes half of the total randomly allocated participants in the study. Participants will initially inhale KELEA Excellerated Water for 2 days followed by inhaling water without an elevated level of KELEA for 2 days, with Covid-19 testing and symptom assessments performed at the ends of both of the 2 days periods.
89531965|NCT04490824|Placebo Comparator|Control Than Treated Water|This Arm includes half of the total randomly allocated participants in the study. Participants will initially inhale water without an elevated level of KELEA for 2 days followed by inhaling KELEA Excellerated water for 2 days, with Covid-19 testing and symptom assessments performed at the ends of both of the 2 days periods.
89531966|NCT04472299|Experimental|Experimental|Participants in this group will receive the intervention.
89531967|NCT04472299|No Intervention|Control|Participants in this group will receive no intervention.
89531968|NCT04464798|Experimental|Cohort A- Monotherapy in R/R lymphoma subjects|Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
89532010|NCT06338592|Experimental|Study 1 (Study of Patients with Uncertain LCS Eligibility) Intervention Arm|Patients allocated to the intervention arm of Study 1 will be exposed to the MyLungHealth intervention in addition to usual care. The Study 1 MyLungHealth eligibility questionnaires will consist of pre-visit smoking history questions asked through the EHR patient portal to increase the identification of screening-eligible patients (Figure 2). Patients will be prompted to engage in the intervention through pre-visit questionnaires for primary care visits administered up to 7 days prior to the visits. These questions will ask about the patients' smoking history and determine whether patients meet LCS eligibility criteria. Study 1 patients who meet LCS eligibility criteria will be offered the intervention provided to patients in the intervention arm of Study 2 immediately after confirming eligibility but will not be considered participants in Study 2.
89532011|NCT06338592|Active Comparator|Study 2 (Study of Patients with Documented LCS Eligibility) Control Arm|In Study 2 (Study of Patients with Documented LCS Eligibility), patients allocated to the control arm will be exposed to the DecisionPrecision+ intervention because DecisionPrecision+ intervention automatically identifies patients with documented LCS eligibility in the EHR. The DecisionPrecision+ intervention is designed to promote LCS and LCS SDM; the intervention consists of provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders (only available at UUH). Simple patient-facing preventive care reminders will be available at UUH, but not NYU, because NYU does not use this type of reminders.
89532012|NCT06338592|Experimental|Study 2 (Study of Patients with Documented LCS Eligibility) Intervention Arm|Patients allocated to the intervention arm will be offered the MyLungHealth education tool in addition to the DecisionPrecision+ intervention. The pre-visit questionnaire will directly invite patients to use the MyLungHealth education app, rather than first asking about smoking history to confirm eligibility. When patients affirm in the patient portal that they were able to successfully open the MyLungHealth education tool, their providers will be notified of their potential interest in LCS through a passive (non-interruptive) prompt in the EHR.
89532013|NCT06338553|Placebo Comparator|Participants receiving placebo|Participants receive a placebo orally once before the pre-TZIELD® MMTT. Participants also receive a placebo orally once before one of the post-TZIELD® MMTTs.
89532014|NCT06338553|Experimental|Participants receiving a semaglutide (Rybelsus®)|Participants receive 7mg of semaglutide (Rybelsus®) orally once before one of the post-TZIELD® MMTTs. Rybelsus is only given one time.
89532015|NCT06338540|Experimental|Group 1|Black caries color
89532016|NCT06338540|Experimental|Group 2|Dark brown caries color
89532017|NCT06338540|Experimental|Group 3|Light brown caries color
89532018|NCT06338540|Experimental|Group 4|Yellow caries color
89532019|NCT06338527|Active Comparator|Experimental group|The researchers placed 2 drops of lavender oil on gauze in a box each night 30 minutes before the patient went to bed and placed it 15 to 20 centimeters from the pillow.
89532020|NCT06338527|Active Comparator|Control group|The control group had no aromatherapy intervention during the study period.
89532021|NCT06338514|Active Comparator|Dry needling group (study group)|Real dry needling into the muscle under ultrasound guidance.
89532022|NCT06338514|Sham Comparator|Sham dry needling group (control group)|Sham dry needling into the subcutaneous fatty tissue under ultrasound guidance.
89532023|NCT06338501|Experimental|Group Exercise|30 functional specific exercises for muaythai athletes. Nutrition Control HRV quantify.
89532024|NCT06338488|Active Comparator|Dry needling group (study group)|Real dry needling into the muscle under ultrasound guidance.
89532025|NCT06338488|Sham Comparator|Sham dry needling group (control group)|Sham dry needling into the subcutaneous fatty tissue under ultrasound guidance.
89532026|NCT06338475|Experimental|Goal-Focused Emotion-Regulation Therapy (GET)|A novel behavioral intervention to enhance self-regulation through improved goal navigation skills, improved sense of purpose, and better ability to regulate emotional responses in young adults with testicular cancer.
89532027|NCT06338475|Active Comparator|Individual Supportive Listening (ISL)|Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience.
89532028|NCT06338462|Experimental|Mobile Health and Oral Testing|to adapt an automated conversation agent (Chatbot) and oral testing as a novel multi-component strategy for implementing TB contact investigation over three phases of participatory co-design
89532029|NCT06338449|Active Comparator|Aerobic training (AT)|Aerobic exercise can include activities like swimming, running, or cycling. Scientifically, aerobic exercise is defined as any activity that uses large muscle groups, can be maintained continuously, and is rhythmic in nature. It improves the efficiency of the cardiovascular, respiratory, and circulatory systems by delivering oxygen more efficiently to the body. According to reports, aerobic exercise can help reduce fat and improve liver function.
89532030|NCT06338449|Active Comparator|Resistance training (RT)|Resistance exercise is a form of physical activity that is designed to improve muscular fitness by exercising a muscle or a muscle group against external resistance. This includes traditional weightlifting, using weight machines, resistance band exercises, bodyweight exercises, and other activities designed to build muscle strength, endurance, and size. The key principle is the muscle's ability to contract against resistance: using weights, resistance bands, or one's own body weight, the muscle is challenged, leading to muscular adaptation and growth, enhancing strength and endurance. According to reports, resistance exercise can also help improve liver function.
89532031|NCT06338449|Active Comparator|Combined aerobic and resistance training (AT + RT)|The combination of aerobic exercise and resistance exercise.
89532032|NCT06338436|Experimental|single-arm objective performance criteria, OPC|According to the NMPA Guidance on Proton and Carbon Ion treatment system clinical evaluation andclinical trial, the objective performance criteria for the validity of medical device treatment for trial use should be at least 80%, with an expected target of 95% in which the validity is defined as: Complete Response + Partial Response + Stable Disease (CR+PR+SD), and the definition of tumor disease control rate in this clinical trial is basically identical. Therefore, the clinical trial did not have a control group, but using single-arm objective performance criteria, when evaluating ProBeam radiotherapy for tumor patients, the main validity evaluation index of tumor disease control rate; the main safety evaluation by incident of acute radiation injury and adverse event.
89532092|NCT06337994|Experimental|interventional|"- number of participant: >/= 60. This open-label clinical trial consisted of 24 weeks of memantine intake period, followed by 4-week (or more) post-trial observation period to monitor the drug adverse effects (e.g. sleep problems, sleepiness, sedation, anxiety, weight change and hypotension). Clinic visits will be scheduled at baseline and follow-ups after 6, 12, 18, 24 weeks of treatment initiation. Concomitant medications were essentially kept unchanged during the trial, i.e. the intake of antidepressant or antianxiologic psychotropic medications, psychotherapy to treat depressive or anxiety symptoms does not exclude participation in the study.~Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient."
89532093|NCT06337994|No Intervention|No intervention|number of participants: >/= 40
89532094|NCT06337981|Experimental|Test group 1|(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
89532095|NCT06337981|Experimental|Test group 2|(AJU-S56 5%), 1drop/1times, 6times in a day
89532096|NCT06337981|Placebo Comparator|Comparator group|Placebo(Vehicle), 1drop/1times, 6times in a day
89532097|NCT06337968|Active Comparator|Ultrasound guided circum-psoas block|Injection of 20ml 0.2% ropivacaine around the antero-lateral margin of psoas major muscle at the level of iliac crest with an in-plane approach under ultrasound guidance. Then the transducer was placed at the level of Lumbar vertebra 5 to obtain the paramedian transverse plane of the intertransverse ligament and lumbosacral ligament. An additional 20ml 0.2% ropivacaine was injected when the needle punctured the lumbosacral ligament.
89532098|NCT06337968|Placebo Comparator|Sham block|Ultrasound-guided injection of equal volume of normal saline in the same location as would for a circum-psoas block.
89532099|NCT06337942|Experimental|Bladder Transplantation|Patients with terminal bladders who do not have kidney failure and who qualify for the study may undergo bladder transplantation.
89532100|NCT06337942|Experimental|Combined Kidney and Bladder Transplantation|Patients with terminal bladders who also have kidney failure and who qualify for the study may undergo combined kidney and bladder transplantation.
89532101|NCT06337929|Experimental|CAPOEIRA GROUP|The training program will be conducted over 12 weeks with two weekly sessions. Each session will last 60 minutes and will be divided into three parts: 1) initial part: execution of stretches and low-intensity actions with specific movements of capoeira; 2) main part: realization of the training program the schedule present in Table 1 for the learning of attacks, dodges and acrobatic movements or flourishes and; 3) Final part: in a self-selected way in the capoeira roda, the participant will develop the previously learned movements.
89532102|NCT06337929|Active Comparator|CONTROL GROUP|The CONTROL GROUP will be conducted over 12 weeks with two weekly sessions. Each session will last 60 minutes and will be divided into three parts: 1) initial part: execution of stretches and low-intensity actions with specific movements of capoeira; 2) main part: continuation with execution of stretches and low-intensity actions with specific movements of capoeira and; 3) Final part: in a self-selected way in the capoeira roda, the participant will develop the previously learned movements.
89532103|NCT06337916|Active Comparator|Cervical Stabilization Exercise Group|"The patients age is between the ages of 18-55~Being literate and with good cognitive function,~Having neck pain longer than 3 months~Not taking painkillers and nsaii drugs in the last 1 week"
89532104|NCT06337916|Active Comparator|Cervical Standard Exercise Group|"The patients age is between the ages of 18-55~Being literate and with good cognitive function,~Having neck pain longer than 3 months~Not taking painkillers and nsaii drugs in the last 1 week"
89532105|NCT06337903|Experimental|Self-compassion intervention|8-week manualized online Mindful Self-Compassion course
89532106|NCT06337890||CO2 FEVAR|Use of automated CO2 angiographies combined with Fusion Imaging in patients with complex aortic aneurysms to obtain zero- or near zero- contrast FEVAR
89532107|NCT06337864|Experimental|LNAA supplementation, Then no intervention|"Phase 1: No intervention (1 Week):~Each participant will stop taking any LNAA therapy or amino acid formula.~Phase 2: LNAA Treatment Period (8 Weeks):~Each participant will be prescribed a specific dosage of LNAA tablets to be taken three times daily.~During the entire study period, participants will follow a semi-restricted diet with the goal of maintaining blood phenylalanine levels within a target range of 600 and 1500 µmol/L."
89532108|NCT06337864|Experimental|No intervention, Then LNAA supplementation|"Phase 1: LNAA Treatment Period (8 Weeks):~Each participant will be prescribed a specific dosage of LNAA tablets to be taken three times daily.~Phase 2: No intervention (1 Week) Each participant will stop taking any LNAA therapy or amino acid formula.~During the entire study period, participants will follow a semi-restricted diet with the goal of maintaining blood phenylalanine levels within a target range of 600 and 1500 µmol/L."
89532109|NCT06337864|Experimental|LNAA supplementation, Then Low-Phe diet|"Phase 1: LNAA Treatment Period (8 Weeks) Each participant will be prescribed a specific dosage of LNAA tablets to be taken three times daily.~Phase 2: Low-Phe diet (8 weeks) Each participant will follow a low-phenylalanine diet. LNAA therapy will not be administered during this phase."
89532110|NCT06337864|Experimental|Low-Phe diet, Then LNAA supplementation|"Phase 1: Low-Phe diet (8 weeks) Each participant will follow a low-phenylalanine diet. LNAA therapy will not be administered during this phase.~Phase 2: LNAA Treatment Period (8 Weeks) Each participant will be prescribed a specific dosage of LNAA tablets to be taken three times daily."
89532111|NCT06337864|Other|Healthy controls|LNAA treatment (1 week)
89532112|NCT06337851|Active Comparator|Simultaneous burr hole craniostomy (Group-1)|Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
89532113|NCT06337851|Active Comparator|Consecutive burr hole craniostomy (Group-2)|In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated.
89532688|NCT06058377|Experimental|Step 2, Arm 2 (chemotherapy, durvalumab)|"Patients receive paclitaxel IV over 30-60 minutes on days 1 and 8 of every cycle and durvalumab IV over 60 minutes on day 1 of every other cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1 of each cycle, and durvalumab IV over 60 minutes on day 1 of every other cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at SOC surgery, and undergo collection of blood samples prior to STEP 2 treatment, after cycle one of chemotherapy, and one month post-SOC surgery."
89532689|NCT06054854||Patients with lung nodule or lung cancer|Patients suspected of or suffering from early stage (supracentimetric nodule) or advanced thoracic cancer
89532690|NCT06053762|Experimental|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes.
89532691|NCT06053762|Other|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
89532692|NCT06053593||Testing of Ketostix by Persons with Diabetes.|Each PWD will test Ketostix in their self-collected urine, complete a labeling evaluation, and test four urine control solutions.
89532693|NCT06053593||Testing of Keto-Diastix by Persons with Diabetes.|Each PWD will test Keto-Diastix in their self-collected urine, complete a labeling evaluation, and test four urine control solutions.
89532694|NCT06052631||Healthy controls|Healthy participants
89532695|NCT06052631||PIEZO2 Deficiency Syndrome (PDS)|Participants with a diagnosis of PIEZO2 Deficiency Syndrome; an inherited mutation in the PIEZO2 gene
89532696|NCT06052618|Experimental|Arm 1|Treatment with pacritinib
89532697|NCT06051890|Experimental|Transition to Extended-Release Buprenorphine (XRB)|Participants randomized to transition to treatment with XRB.
89532698|NCT06051890|Active Comparator|Sublingual Buprenorphine (SLB) Maintenance|Participants randomized to remain on-treatment with SLB.
89532699|NCT06051695|Experimental|A2B694|Patients receive Preconditioning Lymphodepletion (PCLD) Regimen followed by a single dose of A2B694 intravenously on day 0
89532700|NCT06050135|Experimental|Web-based decision support (Roadmap to Parenthood)|Patients will receive access to the Roadmap to Parenthood tool (website). The goal of the Roadmap tool is to encourage young adult females (YA-Fs) to be informed about family-building options, set realistic expectations about potential difficulties, and plan ahead to avoid or mitigate barriers, while also inspiring hope and confidence that parenthood may be achieved, despite their cancer histories.
89532701|NCT06050135|Active Comparator|Informational booklet|Patients will receive the web-based Livestrong 'Planning for Life After Cancer: A Guide to Survivorship for Teens and Young Adults' informational booklet, covering many topics (e.g., physical symptoms, emotional concerns, day-to-day needs).
89532702|NCT06049719||Patients group|Patients with low back pain (18-65 years)
89532703|NCT06049693|Experimental|Iron supplementation|Iron supplementation will be provided in the form of ferrous gluconate 300mg twice a day for a period of 1 month
89532704|NCT06049693|No Intervention|Control|Control patients will be recruited on the ground of no form of iron prehabilitation
89532705|NCT06041516|Experimental|1/Arm1|ADCT-701 given as an IV infusion
89532706|NCT06041503|Experimental|Arm 1|Treatment with enfortumab vedotin
89532707|NCT06041503|Experimental|Arm 2|Treatment with enfortumab vedotin and pembrolizumab
89532708|NCT06038201|Experimental|EUS-GBD with stone clearance|Patients >18-year-old with a diagnosis of gallstones by abdominal ultrasound, will be randomly allocated to EUS-guided GBD with electrocautery-enhanced lumen-apposing metal stent (LAMS) (Boston Scientific, Marlborough, MA, EEUU) with stone clearance.
89532709|NCT06038201|Active Comparator|Elective laparoscopic cholecystectomy|Patients >18-year-old with a diagnosis of gallstones by abdominal ultrasound are randomly allocated to elective laparoscopic cholecystectomy and laparoscopic biliary exploration.
89532710|NCT06036849|Experimental|Neck pain participants: spinal manipulation first|Spinal manipulation will be delivered first (followed by spinal mobilization at 72 hours).
89532711|NCT06036849|Experimental|Neck pain participants: spinal mobilization first|Spinal mobilization will be delivered first (followed by spinal manipulation at 72 hours).
89532712|NCT06036849|No Intervention|Healthy controls|Participants will attend a single session and no intervention will be performed but all experimental procedures will be identical to those occurring in the neck pain cohort. Measurements in individuals without neck pain are necessary for the assessment of potential baseline differences in the outcomes of interest between the patient cohort (with neck pain) and those without neck pain. Without this information, it is not possible to determine if the measured responses to spinal manipulation are due to the intervention or, systematic differences in the baseline outcomes of interest in the symptomatic cohort.
89532713|NCT06035939|Experimental|Intervention|Study participants randomized to receive the intervention.
89532714|NCT06035939|Active Comparator|Control|Study participants randomized to receive enhanced usual care (control).
89532715|NCT06033521||Women with menopausal hormone therapy|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
89532716|NCT06033131|Active Comparator|Metformin ER|Metformin ER oral tablet 500 mg three times daily and increased to one gram (two tablets) three times daily as tolerated.
89532717|NCT06033131|Placebo Comparator|Placebo|1 placebo tablet three times daily and increased to 2 placebo tablets three times daily as tolerated.
89532797|NCT05914324|Experimental|LB-01|LB-01 arm participants will be managed by the clinic staff, including the triage and clinical examination pathway through the facility, treatment and referral decisions, all of which can include the LB-01 device. After the child has been given a primary diagnosis and decision on onward care (i.e. referral or home-based management), the study data collector will conduct an exit interview. This interview will include the following topics: the clinical examination conducted by the healthcare worker; current intentions for onward care (e.g. are if planning to go to hospital, how is the healthcare worker travelling); extracting clinical information from the patient medical record - including oxygen saturation measurement. Finally, the study data collector will conduct oxygen saturation measurements using the LB-01 device and a reference device.
89532798|NCT05910827|Experimental|Arm A|All participants receive HMBD-001 with docetaxel
89532799|NCT05910827|Experimental|Arm B|All participants receive HMBD-001 with docetaxel plus cetuximab
89532800|NCT05909202|Experimental|Active VR Group|Nature-based immersive VR program, completion of questionnaires, and saliva and blood sample submission.
89532801|NCT05909202|Sham Comparator|Sham VR Group|Nature-based non-immersive VR program, completion of questionnaires, and saliva and blood sample submission.
89532802|NCT05909046|Active Comparator|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
89532803|NCT05909046|Other|Standard of care|Standard of care is 4-12 week outpatient postpartum OGTT
89532804|NCT05907759|Experimental|Arm 1|Treatment with daratumumab SC
89532805|NCT05904093|Experimental|Fostamatinib in participants with Sickle Cell Disease|Participants with Sickle Cell Disease will receive Fostamatinib which will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, taken orally, twice a day for 28 days (total 42 days).
89532806|NCT05898828|Experimental|1/ Phase I|H1299 cell lysate vaccine with Montanide(R) ISA-51 VG, entinostat, and nivolumab (Phase I component to determine lysate dose)
89532807|NCT05898828|Experimental|2/ Phase II|H1299 cell lysate vaccine with Montanide(R) ISA-51 VG, entinostat, and nivolumab (lysate at dose determined in Phase I)
89532808|NCT05896839|Experimental|Treatment (nivolumab and ipilimumab)|See detailed description
89532809|NCT05890729|Experimental|Part A - XTMAB-16: 2 mg/kg every 4 weeks (Q4W) for 12 weeks or Placebo|
89532810|NCT05890729|Experimental|Part A - XTMAB-16: 4 mg/kg every 4 weeks (Q4W) for 12 weeks or Placebo|
89532811|NCT05890729|Experimental|Part A - XTMAB-16: 2 mg/kg every 2 weeks (Q2W) for 12 weeks or Placebo|
89532812|NCT05890729|Experimental|Part A - XTMAB-16: 4 mg/kg every 2 weeks (Q2W) for 12 weeks or Placebo|
89532813|NCT05890729|Experimental|Part B - XTMAB-16 (dose established in Part A) for 24 weeks or Placebo|
89532814|NCT05888025|Experimental|MBCT-T|Participants with high pain catastrophizing who are scheduled for spine surgery will receive four weekly sessions of preoperative telephone-delivered mindfulness-based cognitive therapy (MBCT-T). They will then be followed for two weeks postoperatively.
89532815|NCT05884658|Active Comparator|laparoscopic hysterectomy|Laparoscopic Hysterectomy will be performed in a standardized manner
89532816|NCT05884658|Experimental|natural vaginal orifice transluminal endoscopic system for hysterectomies (vNOTES)|Vaginal hysterectomy will be performed in a standardized manner using transluminal endoscopic system
89532817|NCT05883644|Experimental|Durvalumab plus Tremelimumab|Participants will receive a single priming dose of Tremelimumab plus Durvalumab at Day 1 (Week 0), followed by Durvalumab monotherapy starting at Week 4 and continuing until clinical progression, confirmed RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or any intervention discontinuation criteria.
89532818|NCT05879484|Experimental|Arm 1|Pembrolizumab + de-escalating doses of valemetostat
89532819|NCT05879484|Experimental|Arm 2|RP2D of valemetostat in combination with pembrolizumab
89532820|NCT05874063|Experimental|Experimental for high-risk patients|Thromboprophylaxis in addition of the standard chemotherapy
89532821|NCT05874063|No Intervention|Control for high-risk patients|No thromboprophylaxis in addition of the standard chemotherapy
89532822|NCT05874063|No Intervention|Low-risk patients|No thromboprophylaxis in addition of the standard chemotherapy
89532823|NCT05870865|Experimental|ASN008 1.25%|ASN008 1.25% twice daily topical application applied as a thin layer (approximately 2 mg/cm^2) for 4 weeks (28 days)
89532824|NCT05870865|Experimental|ASN008 2.5%|ASN008 2.5% twice daily topical application applied as a thin layer (approximately 2 mg/cm^2) for 4 weeks (28 days)
89532825|NCT05870865|Experimental|ASN008 5%|ASN008 5% twice daily topical application applied as a thin layer (approximately 2 mg/cm^2) for 4 weeks (28 days)
89532826|NCT05870865|Placebo Comparator|ASN008 Matching Vehicle|ASN008 matching vehicle twice daily topical application applied as a thin layer (approximately 2 mg/cm^2) for 4 weeks (28 days)
89532827|NCT05869032||Cohort 1 (n=10)|Gender: Male Age: 20-29
89532828|NCT05869032||Cohort 2 (n=10)|Gender: Female Age: 20-29
89532829|NCT05869032||Cohort 3 (n=10)|Gender: Male Age: 30-39
89532830|NCT05869032||Cohort 4 (n=10)|Gender: Female Age: 30-39
89532831|NCT05869032||Cohort 5 (n=10)|Gender: Male Age: 40-49
89532832|NCT05869032||Cohort 6 (n=10)|Gender: Female Age: 40-49
89532833|NCT05869032||Cohort 7 (n=10)|Gender: Male Age: 50-59
89532834|NCT05869032||Cohort 8 (n=10)|Gender: Female Age: 50-59
89532835|NCT05866471|Experimental|Group 1: Sham taVNS + Psilocybin + taVNS|Group 1 will receive twice daily sham taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive twice-daily taVNS paired with psychedelic session contextual cues for 7 days.
89532836|NCT05866471|Sham Comparator|Group 2: Sham taVNS + Psilocybin + Sham taVNS|Group 2 will receive twice daily sham taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive twice-daily sham taVNS paired with psychedelic session contextual cues for 7 days.
89532837|NCT05866471|Active Comparator|Group 3: Sham taVNS + Psilocybin + Treatment as Usual|Group 3 will receive twice daily sham taVNS for 7 days immediately prior to psilocybin dosing. Post-psilocybin dosing, they will receive treatment as usual (TAU), comprised of an integration session 1 day and 1-week post-psilocybin dosing.
89533045|NCT05642208|Experimental|Experimental Group|"Injections will be spaced as :~Every 3 weeks between M0 and M4,~Every 4 weeks between M4 and M8 (if ADCT<7 and IGA ≤ 2, AD assessed as controlled by the investigator and stable amount of local treatment used),~Then every 5 weeks until the end of the clinical trial (M12) (if ADCT<7 and IGA ≤ 2, AD assessed as controlled by the investigator and stable amount of local treatment used).~In case of ADCT≥7 or IGA > 2 or disease assessed as uncontrolled by the investigator, the injection interval treatment will be step up to the previous interval.~The treatment is administered subcutaneously and can be delivered in pen or syringe for subcutaneous injection.~The dosage is usually :~300 mg per injection for adults and adolescents (12-17 years) weighing more than 60 kg~200 mg per injection for adolescents (12-17 years) weighing less than 60 kg."
89533046|NCT05642208|No Intervention|Control group|"in this group the interval between injections is maintained every 2 weeks (14 days) throughout the clinical trial.~The treatment is administered subcutaneously and can be delivered in pen or syringe for subcutaneous injection.~Treatment will be prescribed in the control group according to the marketing authorization dosage (see paragraph 5.1). The dosage is usually :~300 mg every 14 days for adults and adolescents (12-17 years) weighing more than 60 kg~200 mg every 14 days for adolescents (12-17 years) weighing less than 60 kg."
89533047|NCT05642195|Experimental|1/ Vaccine with Montanide Adjuvant|H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant without or with N-803 (Phase I component to determine H1299 cell lysate dose)
89533048|NCT05642195|Experimental|2/ Vaccine with Montanide Adjuvant and N-803|H1299 cell lysate vaccine administered with Montanide (Registered Trademark) ISA-51 VG adjuvant with N-803 (H1299 cell lysate at dose determined in Phase I)
89533049|NCT05628415|Active Comparator|Procedure: non-powered AEON™ Endostapler|Bilateral or unilateral lung-volume-reduction-surgery (LVRS) by video-assisted thoracic surgery (VATS) or open method with use of the non-powered AEON™ Endostapler for left and/or right side of the lung. By randomization it is specified on which side and with which method the lung tissue will be closed. If bilateral surgery is planned, the other side is automatically closured using the other method. In cases of a unilateral surgery a random stapler as stated in the envelop would be allocated for that side in question.
89533050|NCT05628415|Active Comparator|Procedure: Echelon FLEX™ Powered plus Stapler|Bilateral or unilateral lung-volume-reduction-surgery (LVRS) by video-assisted thoracic surgery (VATS) or open method with use of the Echelon FLEX™ Powered plus Stapler for left and/or right side of the lung. By randomization it is specified on which side and with which method the lung tissue will be closed. If bilateral surgery is planned, the other side is automatically closured using the other method. In cases of a unilateral surgery a random stapler as stated in the envelop would be allocated for that side in question.
89533051|NCT05625412|Experimental|BMS-986360|
89533052|NCT05625412|Experimental|BMS-986360 + Docetaxel|
89533053|NCT05625412|Experimental|BMS-986360 + Nivolumab|
89533054|NCT05625412|Experimental|BMS-986360 + Capecitabine|
89533055|NCT05621291|Experimental|1/Intervention|Systematic, frequent monitoring intervention to risk stratify pts for risk of relapse postCART
89533056|NCT05617014||Cognitively Normal (CN)|700 participants with no apparent memory problems, which is anticipated to include 250 newly enrolled participants and 450 rollover participants from the prior ADNI3 study without apparent memory problems.
89533057|NCT05617014||Mild Cognitive Impairment (MCI)|450 participants with mild cognitive impairment (MCI), which is anticipated to include 250 newly enrolled participants and 200 rollover participants from the prior ADNI3 study with MCI.
89533058|NCT05617014||Dementia (DEM)|350 participants with mild dementia (DEM), which is anticipated to include 250 newly enrolled participants and 100 participants followed from the prior ADNI3 study with dementia.
89533059|NCT05616975||reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests
89533060|NCT05616975||validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests
89533061|NCT05616975||normative|Collection of normative SWAY Balance, Functional, and Cognitive data
89533062|NCT05616871||Upadacitinib Alone or In Combination with Methotrexate|Participants will receive upadacitinib alone or in combination with methotrexate as prescribed by their physician according to local label in real- world practice.
89533063|NCT05616780|Other|Obtaining lung volume measurements in patients with airflow obstruction|"All patients involved in this study will be attending a pulmonary function test as part of their routine patient treatment pathway, requested by their consultant. Potential participants will be sent a patient information sheet prior to their lung function test.~The pulmonary function test begins routinely, with the pre-test questions. Spirometry will then be performed. If the patient's results are variable and the repeatability criteria are not met, the patient will not be asked to take part in the study, and no additional tests (not requested by the consultant routinely) will be carried out. If the patient has normal or obstructive results (FEV1/FVC <70%) the patient will sign the consent form and both lung volume tests will be conducted. They must be able to follow the instructions for both nitrogen washout and body plethysmography, and the results must also meet the acceptability and repeatability criteria."
89533064|NCT05601492|Active Comparator|Arm 1 - Standard of Care|Participant will be given the medication with an electronic monitoring cap attached and a return appointment for a standard of care regular visit
89533065|NCT05601492|Experimental|Arm 2 - Reminder text|Participant will be given the medication with an electronic monitoring cap attached and receive weekly electronic text/email-based reporting intervention that is designed to promote better adherence to treatment (to help assure that the study have subjects who have excellent adherence. Having patients report their progress on a regular basis promotes better treatment adherence, perhaps by creating the same sense of accountability promoted by regular office visits
89533066|NCT05601492|Experimental|Arm 3 - Initial patient consult|Participant will be given the medication with an electronic monitoring cap attached and will receive an initial patient consultation intervention, which will focus on the prescribed medication education and setting expectations of what to anticipate with usage of the medication
89533067|NCT05600920|Experimental|Single Cohort|Patients with ICL who are enrolled in 09-I-0102.
89533068|NCT05590728|Experimental|T1|Subjects 18 to 45 years of age to receive 30 mg/kg apramycin dose administered intravenously (IV) in a forearm vein over 30 min (+/- 5 min) using a syringe or infusion pump. 0.5 h (+/- 5 min) after dosing a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed to analyze concentration of apramycin in BAL. N=4
